

THE LANCET

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2015; published online June 8. [http://dx.doi.org/10.1016/S0140-6736\(15\)60692-4](http://dx.doi.org/10.1016/S0140-6736(15)60692-4).

Appendix to Global, regional, and national incidence, prevalence, and YLDs for 301 acute and chronic diseases and injuries for 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013

This appendix provides further methodological detail, supplemental figures, and more detailed results for incidence, prevalence, and years of life lived with disability. The appendix is organised in broad sections following the structure of the main paper.

Table of Contents

Appendix A: Methods	2
Appendix B: DisMod-MR 2.0	3
Appendix C: Non-fatal Cancer Outcomes	7
Appendix D: Injuries	9
Appendix E: Impairments	15
Appendix F: Differences in estimates for the year 2010 between GBD 2010 and GBD 2013 studies	33
Supplemental Appendix Materials and Detailed Results for Non-fatal Health Outcomes	55
References	56

Appendix A: Methods

Comorbidity Simulation

A.1. Simulation inputs

The two components necessary for the computation of YLDs, prevalence of each disease sequelae and disability weights, are the two inputs into COMO. The prevalence values are primarily produced using DisMod-MR. The process for computing disability weights is described in Solomon et al.¹

A.2. Methods

The micro-simulation, as performed for a single estimation of an age-sex-country-year, can best be represented as a four-step process. First, simulants are exposed to independent probabilities of having each sequelae, where the probability is equal to the prevalence estimate. For each simulant, the probability of having a disease sequela is equal to the estimated prevalence from that draw from the uncertainty distribution. Each simulant is determined to have or not have the disease sequelae based on a draw from the binomial distribution. From this simulation, simulants end up having from none to multiple disease sequelae. Second, the disability weight for each simulant is estimated based on the disease sequelae that they have acquired. The formula for the cumulative disability weight for a simulant is one minus the multiplicative sum of one minus each disability weight present:

$$\text{Simulant } DW_l = 1 - \prod_{k=i}^j (1 - DW_k)$$

where the DW_k is the disability weight for the k^{th} disease sequelae that the simulant l has acquired. Once the simulant disability weight is computed, the disability weight attributable to each sequela for the simulant is calculated using the following formula:

$$ADW_{lk} = \frac{DW_k}{\sum_{k=i}^j DW_k} * \text{Simulant } DW_l$$

Where ADW_{lk} is the attributable DW for disease sequelae k in simulant l ; DW_k is the disability weight for disease sequelae k , and simulant DW_l is the disability weight for simulant l from the combination of all sequelae that they have acquired. This formula apportions the overall simulant disability weight to each condition in proportion to the disability weight of each condition in isolation.

Finally, YLDs per capita in an age-sex-country-year are computed by taking the sum of the attributable disability weights for a disease sequela across simulants.

$$\text{YLD Rate}_k = \frac{\sum_{l=1}^n ADW_{lk}}{n}$$

The actual number of YLDs from disease sequela k in an age-sex-country-year is then computed as the YLD rate k times the appropriate age-sex-country-year population.

A.3. Comorbidity Simulation

The final stage in the estimation of YLDs is a micro-simulation, which adjusts for comorbidity. We refer to this micro-simulation process as “COMO”. The purpose of COMO is to take into account comorbidity in the computation of disease-sequelae specific YLDs. COMO is performed separately for each age-sex-country-year, exposes a synthetic population of 40,000 individuals to the risk of contracting each disease sequelae. This process is summarised below and is described in more detail in Vos et al.²

Appendix B: DisMod-MR 2.0

B.1. Changes between DisMod-MR 1.0 and 2.0

DisMod-MR was developed for the GBD 2010 study to address the challenges in estimating the prevalence of non-fatal health outcomes and risk factor exposures. The information gathered by systematic reviews of published studies, grey literature sources, and survey data varied tremendously for each outcome of interest in terms of the volume of data, methods used to collect the data, geographical and temporal coverage, and the type of epidemiological parameter. The goal was to find the true variation in the occurrence of diseases and risk factors for every country and over time.

Estimates of prevalence (or any of the other epidemiological parameters of interest: incidence, remission, duration and risk of mortality) for the same populations often varied by much more than would be expected based on sampling error. Differences in data collection methods such as sampling design, case definitions, measurement instruments, and implementation issues contributed to large non-sampling error. There are two approaches to deal with this heterogeneity. One could set criteria for the optimal measurement of each disease parameter of interest and include only those studies that meet that high standard. This would make measurements comparable but would leave out the vast majority of information available. In GBD, the preferred approach is to make use of all available data that meets a minimum standard of acceptable quality and address major differences in measurement methods by adjusting data for any systematic bias introduced by a study quality characteristic relative to a chosen reference value. This was done by identifying for each disease or risk factor exposure the important study characteristics that can help explain the variation in measurements and flag data points that deviate from the chosen, optimal, reference value with a covariate. DisMod-MR then estimated a coefficient for each chosen study covariate and adjusted the data accordingly.

To help make estimates for countries and time periods for which little or no data were available, DisMod-MR would predict based on country characteristics and random effects on super-region, region and country. For this purpose a database of country covariates for 93 topic areas and 242 variants thereof was created. Missing data were filled in using Gaussian process or space-time regression methods to ensure a complete set of values for each covariate for every country and every year from 1980 to present. If no country covariates were specified and no data were available, a country estimate would revert to the average of a region, super-region or the world.

DisMod-MR dealt with any specification of age ranges by which data were available to produce estimates by the 20 standard GBD age groups. It also allowed the user to add strong prior knowledge on the age at onset or age pattern of prevalence or incidence such as restricting the occurrence of pre-menstrual syndrome to fertile ages or stipulating that there are no cases of Parkinson's disease before age 30. All these functions were new in DisMod-MR compared to earlier DisMod version used in previous GBD studies which required an analyst to choose one particular data source for a given disease parameter rather than being able to evaluate all available data. Hence the tool was renamed DisMod-MR, the suffix indicating the important meta-regression component. DisMod-MR also accommodated the main functionality of the earlier DisMod tools, i.e. confronting the data from different disease parameters and forcing consistency between these based on differential equations that determine the flow of cases in a stable population between those disease-free and prevalent cases of disease (through incidence or remission) and those in either category that die from other causes (other-cause mortality) and the disease of interest (cause-specific mortality).

To accommodate all functions, DisMod-MR was designed as a Bayesian meta-regression tool using a generalised negative binomial model with fixed effects on age, study and country level covariates as well as random intercepts for country, region and super-region. Greater detail on DisMod-MR has been published in a web-appendix to the paper on non-fatal health outcomes in the GBD 2010.

While DisMod-MR successfully addressed many of the major challenges in the estimation of non-fatal health outcomes and risk factor exposures it had a number of drawbacks which we have tried to solve for GBD 2013 by creating an updated version of the tool, DisMod-MR 2.0. The biggest drawback was the computing time required. Each disease model needed to run between 4 and 24 hours on a large computer cluster to produce results for all countries and three time periods (1990, 2005, and 2010). Moreover because of computational constraints a decision

had to be made to restrict the consistency checks at the level of 21 regions only. To make country estimates, the relevant fixed effects on study and country covariates and the random effects for each country were applied. While this produced defensible estimates of prevalence it did not guarantee coherence between prevalence and other disease parameters such as incidence and excess mortality rates at the country level.

The code for DisMod-MR 2.0 was rewritten and optimised to run up to 50 times faster than DisMod-MR. We decided to shift to an offset log-normal rather than a negative binomial model as this is easier to implement and predictive validity tests carried out in DisMod-MR indicated that the statistical properties of the two types of models were at least equivalent.

The much faster running time of the core computational engine in DisMod-MR 2.0 allowed us to better evaluate all the data through a geographical cascade of four levels. At first, all the available global data are evaluated to estimate the fixed effects on age, sex, study level, and country level covariates as well as a first pass at estimating the random effects for countries, regions and super-regions. The outputs of the global level analysis are then used as priors for the next super-region level of the cascade. A single age pattern for both sexes and all years of interest is created with uncertainty bounds. All data points that are marked as pertaining to both sexes or flagged with a covariate for a study characteristic (e.g. a less than optimal case definition or a low response rate) are adjusted at this stage to reflect what the likely value would have been if the study had specified sex and/or used the reference study characteristic. The data are also split up between super-regions and, optionally, by time period and sex. Using the global prior and the adjusted data, values for each super-region are re-estimated using the same core computational engine. While there is flexibility to re-assess fixed effects on sex or study level covariates at this level, the default option is to adjust the data by the sex and study-level covariates after the global level fit only. At each successive level of the cascade the fixed effects on country-level covariates are re-evaluated and centered on the average of values for the countries that make up a super-region or region. Similarly, random effects are re-evaluated for just the countries in a given geography. It logically follows that no fixed or random effects are re-evaluated at the country level. After fitting the model to each of the super-regions, the results are fed as priors to the region-specific fits and, finally, region fits are used as a prior when modelling a country's results for a particular time period.

A new interface was created to draw relevant data for each disease, sequela, or risk factor to be modelled, to apply all the default and optional settings, and to visualise results. The analyst has a lot of choice to set model parameters to suit any given disease or risk factor of interest. There is a setting to define the age mesh point at which DisMod-MR 2.0 does its calculations. The default setting is to use 21 age mesh points that define the 20 GBD standard age groups. For each study-level and country-level covariate the analyst can set a reference value and upper and lower values for the coefficients. The inclusion of cause-specific mortality rates by age and sex from GBD's mortality estimates is optional. An alternative method of informing a model with mortality data is by using the log of the age-standardised mortality rate as a country-level covariate. Other examples of the basic settings include a value for the parameter that determines the amount of smoothing over the age curve and is denoted by Greek letter 'xi' (ξ); the value of the offset for the lognormal ('eta' or η) for which the default setting is at one per cent of the median of available data values for a parameter or 0.0001 in case there are no data for that parameter; and a range of values for the parameter 'zeta' (ζ) that determines how much 'noise' the analyst allows DisMod-MR 2.0 to estimate for a parameter. The latter function is useful to the analyst. When DisMod-MR 2.0 estimates zeta close to the upper threshold it indicates there is a lot of noise in the data or it may be an indication that there are data entry errors that deserve attention.

B.2 DisMod-MR 2.0 likelihood estimation

Analysts have the choice of using a Gaussian, log-Gaussian, Laplace or Log-Laplace likelihood function in DisMod-MR 2.0. The default log-Gaussian equation for the data likelihood is:

$$-\log[p(y_j|\Phi)] = \log(\sqrt{2\pi}) + \log(\delta_j + s_j) + \frac{1}{2} \left(\frac{\log(a_j + \eta_j) - \log(m_j + \eta_j)}{\delta_j + s_j} \right)^2$$

where, y_j is a 'measurement value' (i.e. data point); Φ denotes all model random variables; η_j is the offset value, eta, for a particular 'integrand' (prevalence, incidence, remission, excess mortality rate, with-condition mortality rate,

cause-specific mortality rate, relative risk or standardised mortality ratio) and a_j is the adjusted measurement for data point j , defined by:

$$a_j = e^{(-u_j - c_j)} y_j$$

where u_j is the total ‘area effect’ (i.e. the sum of the random effects at three levels of the cascade: super-region, region and country) and c_j is the total covariate effect (i.e. the mean combined fixed effects for sex, study level and country level covariates), defined by:

$$c_j = \sum_{k=0}^{K[I(j)]-1} \beta_{I(j),k} \hat{X}_{k,j}$$

with standard deviation

$$s_j = \sum_{l=0}^{L[I(j)]-1} \zeta_{I(j),l} \hat{Z}_{l,j}$$

where k denotes the mean value of each data point in relation to a covariate (also called x-covariate); $I(j)$ denotes a data point for a particular integrand, j ; $\beta_{I(j),k}$ is the multiplier of the k^{th} x-covariate for the i^{th} integrand; $\hat{X}_{k,j}$ is the covariate value corresponding to the data point j for covariate k ; l denotes the standard deviation of each data point in relation to a covariate (also called z-covariate); $\zeta_{I(j),l}$ is the multiplier of the l^{th} z-covariate for the i^{th} integrand; and δ_j is the standard deviation for adjusted measurement j , defined by:

$$\delta_j = \log[y_j + e^{(-u_j - c_j)} \eta_j + c_j] - \log[y_j + e^{(-u_j - c_j)} \eta_j]$$

Where m_j denotes the model for the j^{th} measurement, not counting effects or measurement noise and defined by:

$$m_j = \frac{1}{B(j) - A(j)} \int_{A(j)}^{B(j)} I_j(a) da$$

where $A(j)$ is the lower bound of the age range for a data point; $B(j)$ is the upper bound of the age range for a data point; and $I(j)$ denotes the function of age corresponding to the integrand for data point j .

B.3 Model fit metrics: R^2

A variant of the coefficient of determination (R^2) has been computed for each of the sequelae prevalence models to measure how closely each model fits its input data. This metric compares the variance of the model’s errors with the total variance of the input data. It is formulated such that as a model’s errors approach zero (i.e. as the model approaches a perfect fit to the data), the R^2 metric approaches 1.

As described in the main text, the prevalence modelling process accounts for the uncertainty of the input data. The models are expected to be better predictors of more certain data. To account for this uncertainty in computing R^2 , the errors are weighted by the inverse of the standard error of the input data. Further, as the prevalence modelling is conducted in log space, the R^2 metric is also computed in log space. The formulation of R^2 used in this analysis is:

$$1 - \frac{\sum_i \frac{1/s}{\|1/s\|_i} \times (\ln(y_i) - \ln(\hat{y}_i))^2}{\sum_i \frac{1/s}{\|1/s\|_i} \times (\ln(y_i) - \overline{\ln(\mathbf{y})})^2}$$

Where:

- \mathbf{y} is the data vector, of length N
- y_i is the i^{th} data point
- \hat{y}_i is the predicted value for the i^{th} data point
- \mathbf{s} is the vector of standard errors of the data points (transformed into log space using the delta method)
- $\frac{1/s}{\|1/s\|_i}$ is the inverse of the standard error of the i^{th} data point, normalised

Appendix Table A.4 includes results for R^2 as well as descriptions of model strategy by cause and sequela.

B.4 DisMod-MR 2.0 validation and RMSE calculation

Model validity is assessed by performing cross-validation. In this procedure, a DisMod-MR 2.0 model is estimated with 30% of the incidence data and 30% of the prevalence data excluded at random. The data, both the excluded data and the data left in, are cross-walked for inter-study consistency between estimates. Then, the resulting model fit is compared to the adjusted (by study level covariate effects in the analysis) excluded data and the out-of-sample correlation, root mean squared error (RMSE), the standard deviation of the residuals, and coverage for incidence and prevalence separately. The equation for calculating RMSE is below:

$$\sqrt{\frac{\sum_{i=1}^n (\ln(\hat{y}_i) - \ln(\hat{y}_i))^2}{n}}$$

Where n is the total number of excluded data points, \hat{y}_i is the adjusted data point, and \hat{y}_i is the prediction for the same country, year, age, and sex as adjusted data \hat{y}_i . Coverage was assessed as the proportion of data that lie within the 95% uncertainty interval for data predictions. For out-of-sample data, a coverage of 95% would be expected. A coverage larger than this would indicate that a model's uncertainty intervals are too large, while an out-of-sample coverage less than 95% would indicate uncertainty intervals that are too small.

Due to computational time required for the analysis, we chose 10 models at random to assess external validity. Appendix Table 7 contains the RMSE and the uncertainty interval coverage both in and out of sample for the ten DisMod-MR 2.0 models. For all cases, the RMSE out-of-sample was quite comparable to the in-sample RMSE. Uncertainty interval coverage was over 90% for nearly all cases; uncertainty interval coverage for the COPD model was somewhat lower in the 80% range.

Appendix C: Non-fatal Cancer Outcomes

C.1 Survival curve boundaries

In both the GBD 2010 and the GBD 2013, we used the access to care variable to scale survival for each cancer by country and sex between an upper and a lower boundary in order to calculate the cohort survival for each cancer. For the upper boundary (best case survival), we used SEER 2006 data in the GBD 2010; whereas in the GBD 2013, we used SEER 2010 survival data for the upper boundary.³ For the lower boundary (worst case survival), we used US Mortality Files from 1950 in the GBD 2010; whereas in the GBD 2013 we compared survival from the 1950 US Mortality Files to SurvCan data and used whichever survival was the lowest.⁴ We based our rationale for changing the lower boundary in the GBD 2013 on the premise that survival in the US in 1950 is unlikely to reflect the global worst case survival.

In contrast to the GBD 2010, we included mesothelioma in our estimations for GBD 2013. For the lower boundary, we used SEER 1975 survival data, as the US Mortality Files from 1950 do not include mesothelioma. For the upper boundary we used SEER 2010 data.

Survival for non-melanoma skin cancer (NMSC) is usually not reported in cancer registries. In the GBD 2010 we used melanoma survival data as a substitution for NMSC survival. In the GBD 2013, since NMSC is a much less aggressive disease compared to melanoma, we decided to use a survival of 100% as best case scenario.

The SEER publication used to generate survival curves in the GBD 2013 did not report yearly survival patterns for gallbladder cancer. Therefore, we used SEER 1973 data as worst case survival and SEER 2010 data as best case survival in the GBD 2013 estimates.

C.2 Timeframe for estimation of cohort survival

In the GBD 2010 we estimated survival up to 5 years and assumed that everyone who did not die of cancer within 5 years was a survivor. In the GBD 2013, we extended the timeframe for survival to 10 years since relative survival for most cancers continues to decline after 5 years and truncation of the survival curves at 5 years leads to an underestimation of disability due to disseminated and terminal cancer.

C.3 Duration of sequelae

To calculate YLDs for different cancers, we estimated the duration of time that the cancer population spends in four different sequelae: 1) diagnosis and treatment; 2) remission; 3) disseminated; 4) terminal. In the GBD 2010, only the population who dies within 5 years experiences all four sequelae. In the GBD 2013, we increased this number to the population who dies within 10 years. In the GBD 2010 the population that survived 5 years only experienced sequela 1; however, in the GBD 2013 we estimated duration of sequelae 1 and 2 for the 'survivor' group and only applied a disability weight to the remission for the first 5 years.

In the GBD 2010, we based duration of sequelae on expert opinion. In the GBD 2013, we estimated duration of sequela 1 (diagnosis and treatment) based on Neal et al. for esophageal, stomach, larynx, cervical, uterine, oral cavity, pancreas, testicular, kidney, bladder, nasopharyngeal cancer, cancer of other part of the pharynx, multiple myeloma, and leukemia.⁵ Since the duration described in this analysis did not include duration of treatment we added 2 months to account for the average treatment time. For lung, breast, prostate, colorectal, ovarian cancer, Hodgkin, and Non-Hodgkin lymphoma we used the durations described in Allgar et al. and added 2 months to account for the average treatment duration.⁶ For melanoma we used the duration until diagnosis described in Neal et al. and also added 2 months to account for treatment.⁷ For NMSC we used the duration of sequela 1 for melanoma.⁸ For liver, gallbladder, brain, thyroid cancer, and mesothelioma we based duration of sequela 1 on expert opinion.⁹

In the GBD 2013, we based duration of sequela 2 (remission) on the time until death or 5 years for the survivors minus the duration of the other sequelae.

In the GBD 2013, we based duration of sequela 3 (disseminated phase) on SEER analysis of median survival for patients with stage IV disease for melanoma, mesothelioma, esophageal, stomach, liver, lung, breast, cervical,

uterine, prostate, colorectal, gallbladder, ovarian, kidney, bladder, and pancreas cancer. For thyroid, larynx, oral cavity, nasopharyngeal cancer, and cancer of other part of the pharynx we used the SEER median survival of patients with stage IVc. For testicular cancer, we used the SEER median survival of patients with stage III. For NMSC, we based the duration of sequela 3 on Nolen et al. For Hodgkin and Non-Hodgkin lymphoma we based the duration of disseminated phase on Kewalramani et al. For multiple myeloma, leukemia, and other cancers we used SEER median overall survival of all patients regardless of stage.

C.4 Procedure sequelae

In the GBD 2010 we estimated disability due to procedure sequelae (mastectomy, laryngectomy, stoma for colorectal cancer, incontinence and impotence for prostate cancer, and incontinence for bladder cancer) only for the survivor population. Since these procedures do not ensure cure and lead to additional disability even in cancer patients who ultimately die of their disease, in the GBD 2013 we decided to estimate disability due to procedures for the whole cancer population.

Appendix D: Injuries

D.1 Overview of the calculation of YLDs due to injuries


For the GBD 2013 study, we estimate the burden due to 26 external cause-of-injury categories and 47 nature-of-injury categories, for both short-term outcomes and lasting disability. Permuting each of these groups results in over 2400 unique sequelae; we wish to provide you with an overview of the process through which we derive morbidity estimates for each of these sequelae. What follows is a brief description of the various steps involved in this process, a list of the most significant departures from the GBD 2010 data and methodology, and finally a more detailed description of several of the more complex steps.

To estimate the morbidity from injuries, we use data from hospital and emergency department records and surveys to produce years lost to disability (YLDs) by country, year, sex, age, external cause-of-injury (E-code), and nature-of-injury (N-code). There are several interdependent steps in the process (see flowchart below):

- 1) We calculate a nature-of-injuries severity hierarchy used to assign a particular N-code to a patient that may have been coded with numerous N-codes. See additional documentation for more description of the reasoning and methodology behind this hierarchy.
- 2) We calculate incidence of “injuries warranting inpatient admission” and “injuries warranting other health care” by E-code. Multiple hospital, emergency department and survey datasets feed into these incidence models.
- 3) Because injury disability is linked to nature-of-injury (N-code) rather than cause-of-injury, we generate transition matrices to map the proportion of each E-code that results in a particular N-code. These matrices are based on a collection of dual-coded (e.g. both E- and N-codes) patient-level or aggregated hospital and emergency department datasets. We develop separate matrices for inpatient and outpatient injuries.
- 4) Next, we separate the concepts of short-term and long-term injury outcomes. We assume that all who suffer from an injury experience short-term outcomes (pain, motor impairment, etc.) but that a percentage of these people experience lasting disability from their injury. Furthermore, we assume that this percentage varies by nature-of-injury and whether the injury was treated or not. We develop empirical estimates of the probability of experiencing long-term outcomes for treated injuries based on the results of a combined analysis of unit record data from follow-up studies that have assessed an injured person’s health status for a year using SF-12 or EQ5D as generic health status instruments. Additionally, due to the lack of data regarding long-term outcomes of untreated injuries, we use expert opinion-driven estimates of the probability of developing long-term outcomes for untreated injuries relative to treated injuries. Using an IHME-developed proxy covariate, *Health System Access*, we assign a weighted average of the treated and untreated probabilities to each country-year to come up with country-year-N-code-specific estimates of the probability of developing long-term outcomes
- 5) We assume that long-term outcomes are lasting (i.e. no remission), but for short-term outcomes, we must come up with estimates for duration. This calculation is performed using patient responses to the Dutch Injury Surveillance System follow-up study, the details of which are in the additional documentation below. We supplement the empirically derived estimate of the duration treated injuries for each N-code with expert-opinion estimates of the duration for untreated injuries. For each country and year we take a weighted average of these treated and untreated duration using a linear interpolation on the scale of the health system access covariate. This process is identical to that performed in the calculation of the probability of long-term outcomes above. The incidence of short-term injury outcomes by unique E-code/N-code combination is multiplied by the N-code-specific duration to arrive at prevalence. Prevalence is then multiplied by the corresponding disability weights for short-term injury outcomes to estimate YLDs. Because of the computational strain we would incur with the addition of >1200 short-term injury sequelae, these outcomes are not included in our all-cause comorbidity correction micro-simulation tool. As their prevalence is small (due to the short duration) it would have little bearing on comorbidity in any case.

- 6) In the case of long-term outcomes, we must determine the probability that a patient will develop long-term disability following an injury of a given N-code. To do this we rely on the same datasets used to develop our injury hierarchy – a collection of follow-up studies with measurements of health status >1 year post-injury. The details of this calculation are included in the additional documentation below. These probabilities are then multiplied by the short-term incidence to get incidence of “injuries developing long-term outcomes” for each unique E-code/N-code combination.
- 7) In order to calculate YLDs, we must first arrive at prevalence. We utilize the DisMod modelling software developed at IHME to estimate prevalence given our incidence inputs, an assumption of zero remission (i.e. disability at one-year past-injury reflects lifetime disability) and, where applicable data on the excess risk of mortality associated with each N-code category. We found evidence for an increased risk of dying for long-term disability associated with spinal cord injury, burns, moderate to severe traumatic brain injury and hip fracture. Where we had multiple studies with SMR or RR data we used inverse variance meta-analysis to pool the data. We assumed the highest value SMR to apply to long-term disability from N-code “multiple significant injuries,” as we had no literature for this category and it tended to incorporate many severe injuries. For all other types of long-term disability we assume no excess mortality. Once the prevalence has been calculated, it is used as input for COMO, our comorbidity-correction microsimulation, which gives us final estimates of YLDs.

Appendix Figure D.1. Injuries Modeling Cascade



D.2 Significant differences from the GBD 2010

- We have incorporated additional data. In addition to receiving new inpatient and outpatient datasets from a variety of countries, we have incorporated new follow-up studies from the Netherlands and China and recent years of the Medical Expenditures Panel Survey from the U.S. A list of the new studies can be seen in attached spreadsheets. Please let us know if you are aware of additional available data that may be of use in our analysis.

- We use a more detailed list of nature-of-injury codes used, outlining 47 categories instead of the 23 used in the GBD 2010
- We report short-term outcomes by unique E-code/N-code category, rather than only by E-code
- We use a hierarchy to estimate the most severe N-code for patients with multiple natures-of-injury. We chose to do this as our GBD 2010 regression methods assigned a large number of cases of long-term disability to seemingly less severe N-code categories. With the hierarchy we aim to better assign the long-term disability to more severe injuries. Please see the documentation below for additional information on reasoning and methodology for this process.
- We allow for differing durations of short-term outcomes and probabilities of long-term disability depending on whether an injury was treated or not.

D.3 Detailed descriptions of specific steps in the calculation of YLDs from injuries

- A nature-of-injury hierarchy
- The duration of short-term outcomes of various nature of injury categories (N-codes) when untreated; and
- The probability of developing long-term outcomes of various nature of injury categories when left untreated.

These three aspects of the process will be explained in detail below. Due to the limited availability of data to inform these numbers, there have been varying degrees of expert-driven estimation for each aspect.

Nature-of-injury hierarchy

We decided to account for the co-occurrence of multiple natures of injury by assigning each injured individual in our hospital, survey, and literature-based datasets a single nature of injury that is estimated to account for the largest burden for that individual. In this way, we avoid overestimating the burden of minor injuries that frequently appear together with more severe injuries. In the GBD 2010, we used a regression-based approach with dummies for each nature of injury category and found an undue proportion of burden being assigned to seemingly less severe nature of injury categories. A hierarchy has been used in the previous GBD and some national burden studies but was fully expert-driven. We have sought a more empirically driven approach to setting a hierarchy for the GBD 2013.

The hierarchy aims to establish a one-to-one relationship between individual and nature of injury by selecting the nature of injury responsible for the largest burden when an individual experiences multiple injuries. Because the burden from long-term outcomes dwarfs that of short-term outcomes (due to the much longer duration), we sought to construct our hierarchy based on the mean long-term disability experienced by individuals experiencing a particular nature of injury.

To form an empirical basis for this hierarchy, we have relied on an analysis of follow-up surveys that contain information on long-term health status following specific natures of injury. This follows similar methods as we have described in our GBD 2010 paper on non-fatal outcomes.² For the GBD 2013, we have been able to add three more Dutch datasets (a follow-up of the first study that was used in the GBD 2010 and two other datasets following up burns and multi-trauma patients). We also have added a follow-up study carried out in one of the sites of the Chinese Injury Surveillance System run by China CDC. Briefly, our process consisted of mapping the health status measurements used by these studies (SF-12, SF-36 and EQ5D) into disability weight (DW) space, then running a regression of logit-transformed DW on nature of injury sustained and several individual characteristics. These characteristics included interactions between age, sex, and whether a patient was injured at some point in the dataset. This last characteristic related to the U.S. Medical Expenditures Panel Survey. In this survey only, we had multiple observations for patients that may have been injury-free during one observation but sustained an injury prior to a subsequent observation. We found that at certain ages and sexes, the self-reported uninjured health status differed between those that would eventually get injured and those that were never injured. This interesting finding led us to include that final term in the interaction. We also included a random effect on country, believing that self-reported health status may depend on the country a patient is from. Finally, several nature of injury categories, including

amputations, were assumed to have 100% probability of developing long-term outcomes and thus were automatically ascribed the GBD DW corresponding to the long-term treated sequela for that nature of injury.

We ran the regression process separately for “injuries warranting inpatient care” and “injuries warranting outpatient care” and created two separate hierarchies. We also ran the regression on the pooled data. Nature of injury categories that resulted in no long-term disability according to the analysis (i.e. after accounting for other sources of health loss no health loss remained to attribute to the injury of interest), were ranked below those that resulted in a positive long-term disability. These categories were then ranked by their GBD short-term outcome disability weights. If we observed a higher long-term disability in the outpatient regression than we did in the inpatient regression, we considered this implausible and used the mean disability from the pooled regression for both hierarchies.

Certain nature of injury categories were rare in our data set with mean values estimated from small sample sizes. In these cases especially, we feel expert opinion may be warranted to refine the position of specific nature of injury categories within the hierarchies.

Duration of short-term sequelae of untreated injuries

In the GBD 2010, the estimates of short-term duration were based on limited expert opinion. In the GBD 2013, we tried to find a more empirical basis for these estimates. In the Dutch Injury Surveillance System follow-up studies of 2007-2008 and 2001-2002, injured patients were asked at 2.5, 5 and 9 or 12 months post-injury whether they were still experiencing problems due to their injury.^{10,11} If not, they were asked how many days of problems they had experienced. To estimate the average duration of ‘experiencing problems’ after each nature of injury we took the average number of days reported by those who during the follow-up periods reported that they no longer had problems from the injury. Those who still reported having problems at one year we assumed to be captured as long-term disability cases by our separate analyses. The short-term duration estimates were estimated for those hospitalised for their injury and for outpatients, separately. The results of the Dutch study analyses are supplemented by expert-driven estimates of short-term duration for nature of injury categories that did not appear in the Dutch dataset. Our expert-driven estimates of the expected duration of short-term outcomes from “untreated” injuries are expressed as a multiplier of the “treated” duration estimates.

Probability of long-term disability from injuries


We generally follow the same strategy of determining the proportion of long-term disabling outcomes as in the GBD 2010 with a few differences:

- 1) We use an expanded list of nature of injury categories.
- 2) We use a hierarchy of nature of injury categories (see above).
- 3) We utilize an expanded dataset of injury follow-up studies as described above.
- 4) We allow for a difference in probability of long-term outcomes from treated and untreated injuries

The probability of treated long-term outcomes is estimated via the ratio of the average level of disability one year after an injury relative to the long-term disability weight for each nature of injury category. This is the same strategy used to calculate probability of long-term outcomes in the GBD 2010. Because this ratio incorporates the disability weights assigned to each N-code, the probabilities at which we arrive depend strongly on the choice of these disability weights. We have incorporated a new round of disability weights for the GBD 2013 study based on further data collection in 4 European countries, Hungary, Italy, Sweden and the Netherlands. The European DW study was initiated by ECDC (Europe’s equivalent of CDC).¹² IHME contributed additional funds to expand the sample size to a total of 30,000 respondents. The same method of pair-wise comparisons as in the GBD 2010 study was used. A large proportion of the GBD health states with their lay descriptions were repeated in the European surveys. We also added new health states for conditions that had not yet been covered (of interest for injuries: inclusion of a health state for concussion) and added re-written lay descriptions for the GBD 2010 health states that were found lacking in consistency or in content (of interest for injuries: we added incontinence in the description of the health states for spinal cord injury and made the descriptions of several amputation descriptions more consistent). We have decided to analyze the GBD 2010 and European surveys in a combined dataset. That means all DWs in the GBD 2013 are

different. Most are only different marginally, but some have changed quite a bit. For instance, the inclusion of incontinence in spinal cord injury led to higher DWs. Without change in the lay descriptions many of the fracture DWs got lower values in the European surveys and hence the GBD 2013 DWs are also lower. Appendix Figure D2 shows a scatterplot of the old vs. the new DWs marking those health states for which we have found the greater changes.

Appendix Figure D.2: Comparison of disability weights for GBD 2010 and GBD 2013



ST – short-term; LT – long-term; Rx – treated; un-Rx – untreated; UL – upper limb

In the GBD 2010 it was assumed that the probabilities of long-term outcomes derived from follow-up of treated injury patients equally applied to untreated cases. In the GBD 2013, we’ve made separate estimates for nature of injury categories where we expect a significantly higher probability of long-term disability in untreated cases. The difficulty with this approach is that, as one would expect, there are no follow-up data available for untreated patients. In the attached spreadsheet, the columns in blue show a first pass of expert-driven estimates of the ratio of the probability of long-term outcomes among treated persons to the probability of long-term outcomes among untreated persons.

For two long-term probabilities we had to employ different estimation methods. First, there were only 20 cases of “adverse effects of medical treatment” in our follow-up dataset, and all reported extremely high disability weights. This gave us 100% probability of permanent health-loss from this “cause-of-injury, which is problematic given that our initial incidence data for this cause-of-injury category is quite high, thus making YLDs attributed to this cause implausibly large. We decided that we have inadequate data to estimate the probability of permanent health-loss. Second, our long-term probability estimates for spinal cord lesions were implausibly low due to a much higher GBD 2013 disability weight than that used in the GBD 2010. Instead, we used a large USA study of spinal injuries followed for more than 1 year with data classified by the 5 category ASIA Impairment Scale (AIS A-E) of the American Spinal Injury Association (ASIA) International Classification of Spinal Cord Injury.¹³ We matched the descriptions of AIS A-E with appropriate GBD health states as follows: attributing a different proportion, disability weight and long-term probability to each according to a large study of spinal injuries (Appendix Table D1). Given we have two spinal lesion categories (at and below neck level), we used the same A-E proportions to split both.

Despite applying the N-code hierarchy to our follow-up dataset, we still observed implausibly high estimates of long-term disability for several outpatient N-codes. We made the decision to not allow any long-term disability from outpatient injuries in the following categories: open wound, poisoning, and contusion.

Appendix Table D.3. – ASIA impairment scale for spinal cord injury with matched health states, disability weights, and proportions at the one-year follow up mark

AIS Category	AIS Description of Impairment	Matched GBD Health State	Long-term		Proportion Attributed
			Disability Weight - Treated	Disability Weight - Untreated	
A	Complete – No motor or sensory function is preserved in the sacral segments S4-S5.	Spinal cord lesion at neck level (GBD 2013)	0.589	0.732	0.50
		Spinal cord lesion below neck level (GBD 2013)	0.296	0.623	0.50
B	Incomplete – Sensory but not motor function is preserved below the neurologic level and includes the sacral segments S4-S5.	Spinal cord lesion at neck level (GBD 2010)	0.463	0.682	0.07
		Spinal cord lesion below neck level (GBD 2010)	0.057	0.46	0.07
C	Incomplete – Motor function is preserved below the neurologic level, and more than half of key muscles below the neurologic levels have a muscle grade less than 3.	Spinal cord lesion at neck level (GBD 2010)	0.463	0.682	0.14
		Spinal cord lesion below neck level (GBD 2010)	0.057	0.460	0.14
D	Incomplete – Motor function is preserved below the neurologic level, and at least half of key muscles below the neurologic level have a muscle grade of 3 or more.	Motor impairment, moderate	0.061	0.610	0.27
		Motor impairment, moderate	0.061	0.610	0.27
E	Normal – Motor sensory function is normal.	No long-term disability	-	-	0.01

Data from Marino et al. (1999). Neurological recovery after traumatic spinal cord injury: Data from the Model Spinal Cord Injury Systems. Arch Phys Med Rehabil; 80: 1391-6.

Appendix E: Impairments

E.1 Anemia

To estimate anemia in the GBD 2013, we employed largely the same method as we did in the GBD 2010. Despite broad similarity in methods, several key changes affected magnitude and age patterns of anemia burden, as well as magnitude and severity-distribution of aetiology-specific estimates. Our GBD 2013 strategy began with the calculation of an anemia envelope – a determination of mean hemoglobin as well as sum total of anemia prevalence by severity for each country, age group, and both sexes for each year from 1980 through 2010. The envelope approach avoided double counting while capturing potentially different disease profiles within each population group. We defined a population group as a specific country, sex, age-group, and year.

Our dataset for estimating the anemia envelope contained more than four times as many data points as it did in the GBD 2010 (9899 versus 2425), and notably included data from Turkey and India as well as subnational data from the United Kingdom, China, and Mexico.¹⁴ We predicted mean hemoglobin levels for all missing population groups using a mixed-effects regression with fixed effects on prevalence of severe underweight (<2SD below mean; same as the GBD 2010) and age group and nested random effects on super-region, region, and country/subnational site. We again separated each population into five groups: male and female children under 5 years, pregnant females, non-pregnant females, and males over 5 years. The net effect of this new data was most pronounced in populations under age 10, where predicted mean hemoglobin levels in this analysis were consistently higher (and anemia prevalence therefore lower) than were predicted in the GBD 2010. Second, in recognizing the limitations of predicting anemia prevalence—especially severe anemia—directly from mean hemoglobin using multiple steps, we instead pooled survey microdata for each population group separately and fitted the pooled data with Weibull distributions. We then performed OLS regression of the shape and scale parameters versus all predicted mean hemoglobins predicted above. The net effect of this change was quantitatively minimal, but greatly improved the efficiency of envelope calculation.

Appendix Table E.1 - Severity definitions and corresponding disability weights used to calculate GBD 2010 anemia envelope			
	Severity of anemia		
	Mild	Moderate	Severe
Age < 5 years			
Males	110 - 119 g/L	80 - 109 g/L	50 - 79 g/L
Females	110 - 119 g/L	80 - 109 g/L	50 - 79 g/L
Age 5+ years			
Males	120 - 129 g/L	90 - 119 g/L	60 - 89 g/L
Females, non-pregnant	110 - 119 g/L	80 - 109 g/L	50 - 79 g/L
Females, pregnant	100 - 109 g/L	70 - 99 g/L	40 - 69 g/L

We adopted different thresholds for defining anemia by age than were used in the GBD 2010 as they do not reflect the hematologic realities of early life. The GBD 2010 and the GBD 2013 thresholds are in Appendix Tables C1 and C2. Since the GBD 2000, likely in recognition of this same phenomenon, WHO recommendations have changed. Our current thresholds match those published by WHO with the exception of those under 1 month of age, where there is no internationally recommended cutoff for diagnosing anemia. The net effect of these changes was substantial, as expected. In the GBD 2013, anemia estimates were greatly reduced amongst 1-9 year olds, though they still remained the age groups most afflicted by anemia, and estimates were higher than the GBD 2010 amongst those less than 1 year of age. We estimated anemia to be nearly zero in the GBD 2010 for most population groups under 1 year old.

Appendix Table E.2 - Severity definitions and corresponding disability weights used to calculate GBD 2013 anemia envelope

	Severity of anemia		
	Mild	Moderate	Severe
Age < 1 month			
Males	130 - 149 g/L	90 - 129 g/L	< 90 g/L
Females	130 - 149 g/L	90 - 129 g/L	< 90 g/L
Age 1 month - 5 years			
Males	100 - 109 g/L	70 - 99 g/L	< 70 g/L
Females	100 - 109 g/L	70 - 99 g/L	< 70 g/L
Age 5 - 14 years			
Males	110 - 114 g/L	70 - 99 g/L	< 70 g/L
Females	110 - 114 g/L	70 - 99 g/L	< 70 g/L
Age 5+ years			
Males	110 - 129 g/L	80 - 109 g/L	< 80 g/L
Females, non-pregnant	110 - 119 g/L	80 - 109 g/L	< 80 g/L
Females, pregnant	100 - 109 g/L	70 - 99 g/L	< 70 g/L

We performed cause-specific attribution on the anemia envelope using information on cause-specific prevalence and hemoglobin shift using the same method as in the GBD 2010. Total “hemoglobin shift” was determined as the difference between the normal and predicted mean hemoglobin levels for each population group. We denoted the normal hemoglobin level as the global 95th percentile of the distribution of mean-hemoglobin within each age-group, sex, and year. We then determined a total shift for each country in the corresponding age-group, sex, and year by finding the difference between the global “normal” and the country-specific predicted mean hemoglobin. Our model of attribution followed that, because the shift is a disease state experienced by 100% of the population, then the sum of cause-specific hemoglobin shifts times the prevalence of each contributing cause should add up to the total. We summed shift times prevalence estimates from all causes, compared to the total predicted hemoglobin shift, and proportionally assigned. We distributed the residual envelope among seven remaining causes. Of note, our iron-deficiency anemia (IDA) estimates include acute and chronic hemorrhagic states for which supplementation may be helpful, but poor nutritional intake is not the only underlying problem. A few causes in this category – hookworm, schistosomiasis, upper gastrointestinal bleeding, and gynecologic diseases – were considered separately from IDA because there was enough data from the GBD 2010 to do so. Distribution of anemia burden to IDA only after assignment to “known” causes avoided double counting of these cases. Most other causes of anemia not specifically considered were included in the “other” categories.

Two changes in the GBD 2013 analysis affected the aetiology-specific anemia estimates. First, and most importantly, we identified an inconsistency in this cause-specific attribution method where the total number of cases of anemia due to a condition was not bounded to be less than the total number of cases of the condition itself. We have introduced a method in this analysis to ensure that bounds are included. Second, inherent in our method of determining “normal” hemoglobin is the fact that 5% of population groups will have zero, or negative, total shift. In these cases, or when the sum of all causes’ shift-times-prevalence estimates exceeded the total shift, we assigned the denominator to be equal to the sum of the numerators. Subsequent review of findings from National Health and Nutrition Examination Survey (NHANES) suggested that the implicit assumption of zero residual—and therefore zero IDA—in the GBD 2010 approach was implausible.^{15,16} Based on the published rates of IDA seen in these analyses, we therefore introduced a minimum of 10% of all anemia to be assigned to residual causes in the GBD 2013.

In order to disaggregate marginal estimates of anemia severity and aetiology into a complete set of prevalence estimates for aetiology/severity pairs, we developed a new method for the GBD 2013 that employed techniques from Bayesian contingency table modelling.^{17,18} The model combined marginal estimates on the row sums (total aetiology prevalence for each cause) and column sums (total anemia prevalence by severity [mild, moderate, severe]) with priors on the mean hemoglobin shift for each aetiology and priors on the rank order of variation of severity (i.e. anemia due to malaria is expected to vary most between cases of all aetiologies, whereas anemia due to sickle cell disorders are expected to be some of the least variable in severity). We used nonlinear optimization to find the maximum a posteriori (MAP) point estimate for 50 samples from estimated posterior distributions on the marginal values (aetiology and severity estimates) independently for each country/year/sex/age-group, and then scaled and shifted these estimates to ensure that updated marginal row sums were all non-zero and the updated column sums matched the original draws exactly.

E.2 Epilepsy


In the GBD 2013, we used the following definitions from the “Guidelines for Epidemiologic Studies on Epilepsy:”¹⁹

Epilepsy. A condition characterised by recurrent (two or more) epileptic seizures, unprovoked by any immediate identified cause.

“Active” epilepsy. A prevalent case of active epilepsy is defined as a person with epilepsy who has had at least one epileptic seizure in the previous 5 years, regardless of antiepileptic drug (AED) treatment.

We divided epilepsy parent (epilepsy impairment envelope) to primary (or idiopathic) and secondary epilepsies. Each of these were subdivided into “severe” (on average 1 or more fits per month) and “non-severe.” Non-severe cases were sub-divided into “treated” and “un-treated.” Finally, “treated” cases were divided into “treated cases with fits” (between 1 and 11 fits on average in preceding year) and “treated cases without fits” (no fits reported in preceding year) (Appendix Figure C1).

Appendix Figure E.1: Epilepsy classification for the GBD 2013



Epidemiological data sources: mortality and morbidity

We conducted a systematic review to update the GBD 2010 dataset. Inclusion criteria were:

- Representative, population-based surveys
- Reporting of prevalence, incidence, remission rate, excess mortality rate, relative risk of mortality, standardised mortality ratio or with-condition mortality rate.

We excluded the studies with no clearly defined sample, for example, among clinic attenders or patient organization members with not-specific or non-representative catchment area. The count of prevalence data points dropped from 1885 in GBD 2010 to 1464 in GBD 2013 as we dropped 712 lifetime prevalence data points and added 291 new data points.

Proportions of idiopathic (vs. secondary) and severe epilepsy

We used a mixed-effects generalised linear model (binomial family) to predict the proportion of idiopathic epilepsy. We used a fixed effect on LDI, a lagged transformation of GDP per capita and super-region random effects in the final model. We also tested health system access as well as region and country effects in different models, but they did not improve the model (Appendix Tables C3 and C4). We used a similar model to predict the proportion of severe epilepsy and treatment gap based on the reported proportions extracted from the systematic review. We used fixed effects on health system access and LDI and super-region random effects in the final model for severe epilepsy. We also tested region and country effects in different models, but they did not improve the model. For estimating the treatment gap, we used fixed effects on LDI and health system access and super-region random effects in the final model. We tested region and country effects in different models, but they did not improve the model. We generated 1,000 draws of country-specific estimates for each year between 1980 and 2013 for each of the models.

Appendix Table E.3. - Coefficients of mixed effect generalised linear model (binomial family) for proportions of idiopathic and severe epilepsy in the countries

Dependent	LDI	HSA	Super-region	Constant
	β	β	β	β
Idiopathic proportion	-0.000025 (-0.000033, -0.000018)	removed	0.7124 (0.2478, 2.0475)	0.3217 (-0.3094, 0.9528)
Severe, proportion	-0.000017 (-0.000025, -0.000008)	-0.1742 (-0.2446, -0.1038)	0.0645 (0.0165, 0.2514)	-0.1569 (-0.3718, 0.0581)
Treatment gap	-0.000044 (-0.000059, -0.000029)	-0.162 (-0.2057, -0.1183)	0.5801 (0.1934, 1.74)	0.7259 (0.1423, 1.3095)


Appendix Table E.4. - Random effect (with its standard error) of GBD super-regions for proportion of severe epilepsy and treatment gap

Super-regions	Idiopathic, proportion		Severe, proportion		Treatment gap	
	Random effect	SE for RE	Random effect	SE for RE	Random effect	SE for RE
Central/ Eastern Europe, and Central Asia	-0.2772	0.041	0.3276	0.0768	0.2361	0.2346
High-income	0.5839	0.0214	-0.023	0.0263	-1.4558	0.0896
Latin America and Caribbean	-0.3527	0.0527	0.1353	0.1083	0.0962	0.0698
North Africa and Middle East	1.1317	0.0567	-0.2332	0.1518	0.3063	0.1267
South Asia	0.4426	0.1176	-0.2748	0.1003	-0.5866	0.0492
Southeast Asia, East Asia, and Oceania	0.1783	0.0309	0.2902	0.0707	0.2832	0.1124
Sub-Saharan Africa	-1.7066	0.0289	-0.2221	0.0729	1.1206	0.0605

Seizure-free treated epilepsy

There were too few data points (only 7 studies) to use a mixed effects model. Instead, we used meta-analysis to generate two different pooled estimates for proportion of seizure free treated epilepsy in developing and developed countries (Appendix Figure E.2.)

Appendix Figure E.2: Pooled estimated for proportion of seizure-free treated epilepsy



Modelling Specifications

We used the DisMod-MR 2.0 tool for the epilepsy impairment envelope to model a consistent fit between incidence, prevalence, remission, and SMR data while using meta-regression to correct data points with non-reference study quality characteristics. We assumed a non-zero prevalence at birth to account for neonatal and congenital causes of epilepsy. We found no systematic bias for the covariate “non-standard case definition” indicating studies that did not define ‘active epilepsy’ and added this covariate as a ‘z-cov’ to the model which means a multiplier is applied to the standard error and thus is given less weight in the analysis than the ‘reference’ data points. We also tested ‘life-time prevalence’ and ‘sampling strategy’ as covariates. In the GBD 2013, we excluded data of life-time prevalence and did not use sampling strategy as a z-cov because it did not have a significant effect. We used the log of age-standardised death rates of epilepsy (from the cause of death model of epilepsy) as a country level covariate for prevalence (Appendix Table C5).

Appendix Table E.5. - The fixed effect values of covariates in epilepsy impairment envelope model

Parameter	Covariates	Type	Value	Exponentiated
Prevalence	Nonstandard case definition	Study-level (z-cov)	0.030 (0.009 — 0.062)	1.03 (1.01 — 1.06)
Incidence	Nonstandard case definition	Study-level (z-cov)	0.45 (0.062 — 1.81)	1.57 (1.06 — 6.10)
Prevalence	Epilepsy	lnASDR	0.008 (-0.008 — 0.026)	1.01 (0.99 — 1.03)

We split the epilepsy impairment envelope according to the proportions generated by the generalised linear models and meta-analysis. Of the results, we combined the non-severe untreated and non-severe treated with fits groups into the “Epilepsy, seizures 1-11 per year” category. We categorised the severe epilepsy category as “Epilepsy, seizures \geq once a month.” For treated epilepsy without recent seizures we decided to use a more generic health state for other conditions without symptoms requiring daily medication (e.g. uncomplicated diabetes).

Disease Severity

In the GBD 2010, we wrote the lay descriptions for epilepsy health states before the systematic reviews of epidemiological surveys. The information on seizure frequency in the lay descriptions of severe (‘seizures once a week’), untreated (seizures once every 2 weeks’), and ‘treated with seizures’ (‘seizures once a month’) epilepsy health states were consistent with the categorisation in epidemiological studies where severe is one seizure a month or more and as the untreated and treated with seizure categories refer to non-severe cases. We collected information on average seizure frequency from 35 studies and fit a curve through the heterogeneous data in order to infer the average DW in each severity category.

In the GBD 2013, a new opportunity to derive DWs was provided by a study in 4 European countries replicating the GBD 2010 methods of pair-wise comparisons.¹² We collaborated with the European researchers allowing us to field alternative formulations of our lay descriptions. Appendix Table C6 shows the health states, lay descriptions, and disability weight values from the GBD 2010 and the GBD 2013 studies. The average DW per prevalent case of epilepsy globally has risen from 0.31 to 0.34.

Appendix Table E.6. - Comparison of disability weights for epilepsy in the GBD 2010 and the GBD 2013				
GBD 2010 health states	GBD 2010 lay descriptions	GBD 2010 DW		
		Mean	Lower limit	Upper limit
Epilepsy, treated, seizure free	had sudden seizures in the past, but they have stopped now with medicines. The person has some drowsiness, difficulty concentrating, and some anxiety about future episodes.	0.072	0.047	0.106
Epilepsy, treated, with recent seizures	has sudden seizures once a month, with violent muscle contractions and stiffness and loss of consciousness. Between seizures the person has some drowsiness, difficulty concentrating, and anxiety about future episodes.	0.319	0.211	0.445
Epilepsy, untreated	has sudden seizures twice a month, with violent muscle contractions and stiffness, loss of consciousness, and loss of urine or stool control. Between seizures the person has anxiety about future episodes.	0.42	0.279	0.572
Epilepsy, severe	has sudden, prolonged seizures once a week, with violent muscle contractions and stiffness, loss of consciousness, and loss of urine or stool control. Between seizures the person has drowsiness, memory loss, difficulty concentrating, and anxiety	0.657	0.464	0.827
GBD 2013 health states	GBD 2013 lay descriptions	GBD 2013 DW		
		Mean	Lower limit	Upper limit
Epilepsy, seizures \geq once a month	has sudden seizures one or more times each month, with violent muscle contractions and stiffness, loss of consciousness, and loss of urine or bowel control. Between seizures the person has memory loss and difficulty concentrating.	0.552	0.375	0.71
Epilepsy, seizures 1-11 per year	has sudden seizures two to five times a year, with violent muscle contractions and stiffness, loss of consciousness, and loss of urine or bowel control.	0.263	0.173	0.367
Generic uncomplicated disease: worry and daily medication	has a chronic disease that requires medication every day and causes some worry but minimal interference with daily activities.	0.049	0.031	0.072

Appendix Table E.7. shows that there are 42.4 million individuals suffering from primary and various causes of secondary epilepsy in 2013 up from 30.4 million in 1990 – over half of which are due to epilepsy without a clear underlying cause and presumed to be largely genetically determined.⁸⁸ Three neonatal causes (preterm birth, neonatal encephalopathy, and hemolytic disease of the newborn) account for a fifth of epilepsy cases but the evidence base for the long-term outcomes of neonatal disorders including epilepsy remains small. The remaining primary causes of epilepsy come from ten other infectious disease causes. Cases with severe epilepsy (seizures more than once a month) account for almost half (46.3%), 41.4% are untreated or despite treatment continue to experience at least one seizure per year and the remaining 12.3% is seizure-free on treatment. Prevalence and YLD by underlying cause for 1990 and 2013 and the prevalence by severity are shown in Appendix table E.7.

Appendix Table E.7. Prevalence and YLDs, with percent of total, for epilepsy by cause, 1990 and 2013, and prevalence by severity in 2013

	Total Prevalence (in thousands)		Total YLDs (in thousands)		Prevalence 2013 (in thousands)		
	1990	2013	1990	2013	Treated, seizure-free	Less severe	Severe
Primary epilepsy	16,512.8 (54.37%)	21,717.9 (51.18%)	5,364.9 (67.52%)	7,544.2 (61.43%)	2,506.0 (5.91%)	8,955.2 (21.10%)	10,256.5 (24.07%)
Unassigned secondary epilepsy	7,992.0 (26.31%)	10,863.9 (25.60%)	-	-	1,508.0 (3.55%)	4,579.3 (10.79%)	4,776.4 (11.25%)
Preterm birth complications	1,693.9 (5.58%)	4,506.3 (10.62%)	836.3 (10.53%)	2,246.4 (18.29%)	519.9 (1.23%)	1,786.4 (4.21%)	2,200.1 (5.42%)
Neonatal encephalopathy due to birth asphyxia and trauma	1,324.1 (4.36%)	2,046.6 (4.82%)	697.0 (8.77%)	1,095.6 (8.92%)	248.7 (0.59%)	847.9 (2.00%)	999.9 (2.38%)
Hemolytic disease and other neonatal jaundice	876.3 (2.88%)	1,573.2 (3.71%)	463.0 (5.83%)	842.7 (6.86%)	195.5 (0.46%)	656.6 (1.55%)	790.6 (1.90%)
Cysticercosis	1,390.2 (4.58%)	1,031.2 (2.43%)	391.3 (4.93%)	310.4 (2.53%)	146.1 (0.34%)	446.9 (1.05%)	438.2 (1.07%)
Pneumococcal meningitis	136.7 (0.45%)	187.3 (0.44%)	39.9 (0.50%)	59.1 (0.48%)	25.4 (0.06%)	83.2 (0.20%)	70.1 (0.17%)
H influenzae type B meningitis	89.5 (0.29%)	112.0 (0.26%)	26.6 (0.33%)	35.6 (0.29%)	15.7 (0.04%)	50.6 (0.12%)	46.3 (0.11%)
Food-borne trematodiasis	112.1 (0.37%)	108.1 (0.25%)	32.7 (0.41%)	33.9 (0.28%)	14.7 (0.03%)	44.7 (0.11%)	46.3 (0.11%)
Other meningitis	70.2 (0.23%)	86.2 (0.20%)	21.5 (0.27%)	28.2 (0.23%)	11.5 (0.03%)	38.1 (0.09%)	36.6 (0.09%)
Encephalitis	67.5 (0.22%)	83.9 (0.20%)	21.0 (0.26%)	28.4 (0.23%)	10.5 (0.02%)	35.2 (0.08%)	33.2 (0.08%)
Malaria	52.2 (0.17%)	75.9 (0.18%)	27.5 (0.35%)	40.8 (0.33%)	11.9 (0.03%)	35.3 (0.08%)	23.0 (0.06%)
Meningococcal meningitis	20.1 (0.07%)	29.2 (0.07%)	6.0 (0.08%)	9.2 (0.08%)	4.4 (0.01%)	13.3 (0.03%)	11.5 (0.03%)
Tetanus	27.8 (0.09%)	7.4 (0.02%)	15.0 (0.19%)	4.2 (0.03%)	0.8 (0.00%)	3.1 (0.01%)	3.3 (0.01%)
Cystic echinococcosis	8.3 (0.03%)	6.8 (0.02%)	2.6 (0.03%)	2.3 (0.02%)	0.9 (0.00%)	2.8 (0.01%)	3.2 (0.01%)
Total Prevalence	30,373.6 (100.00%)	42,436.0 (100.00%)	-	-	5,220.0 (12.30%)	17,578.5 (41.42%)	19,637.5 (46.28%)
Total YLDs	-	-	7,945.3 (100.00%)	12,280.8 (100.00%)	200.0 (1.63%)	3,616.4 (29.45%)	8,464.4 (68.92%)

E.3 Hearing impairment

We modelled the prevalence of hearing loss over five steps. First, we ran three DisMod-MR 2.0 models to estimate the total prevalence estimates of hearing loss: normal hearing (0- 19dB), mild hearing loss (20-34dB), and moderate hearing loss and above (35+ dB). We squeezed the prevalence estimates from these DisMod-MR 2.0 models to fit within the entire population of each country. We estimated prevalence of normal hearing for this squeezing purpose only, and hence did not form part of further analysis. Appendix Figure C3 provides an example of the DisMod-MR 2.0 model showing the data points in gray and prevalence estimates at regional level in purple.


Second, we ran five additional DisMod-MR 2.0 models for each severity levels of hearing loss above mild: moderate (35-49dB), moderately severe (50-64dB), severe (65-79dB), profound (80-94dB), and complete (95+). We then squeezed the prevalence estimates from these models to fit within the prevalence that were estimated for 35+dB in the first step. By the end of the second step, we had estimated prevalence of six severity levels of hearing loss, including mild (20-34dB).

Third, we adjusted the prevalence of each severity level by accounting for hearing aids. We assumed the use of hearing aids reduced the severity by one level. Data obtained from a survey in Norway provided detailed information on people with hearing aids, which was used to estimate the proportion of hearing aids for each severity level.²⁰ We ran a log-linear regression with binary indicator for severity levels. We used the estimated coefficients to transform the prevalence of each severity level and proportionally squeeze to determine the proportion of hearing aids in each severity level. We shifted the identified fraction of people in each severity level a level below, except for complete hearing loss, which we assumed was not correctable by hearing aids. This provided the adjusted prevalence of six severity levels of all-cause hearing loss.

Fourth, we estimated the prevalence of hearing loss due to multiple causes: otitis media, congenital, meningitis (pneumococcal, H influenza type B meningitis, meningococcal, and other bacterial), and age-related and other causes not classified elsewhere. For congenital hearing loss, we assumed that all hearing losses occurring at the time of birth are of congenital nature. We implemented proportional squeezes to scale cause-specific hearing loss prevalence to the total prevalence of each severity level.

Finally, we estimated the percent of people experiencing tinnitus for at least 5 minutes per day by severity level using data from the US National Health and Examination Survey (NHANES) from 1999-2004 and two datasets from the United Kingdom. We calculated confidence intervals assuming a binomial distribution. We assumed the same distribution of tinnitus across all types of hearing loss.

Appendix Figure E.3: Prevalence of 35+ dB in Andean Latin America for males in 2013



E.4 Heart failure

We modeled a heart failure envelope and estimated aetiologic fractions to generate prevalence and burden of heart failure due to each GBD cause. We estimated the aetiologic fractions using data from a literature review, causes of death data, results of modelling causes of death data, and hospital discharge data. We attributed each heart failure case to one of the 20 conditions that might lead to heart failure: ischemic heart disease; cardiomyopathy and myocarditis; hypertensive heart disease; Chagas; chronic obstructive pulmonary disease; other interstitial lung disease; rheumatic heart disease; other circulatory diseases (non-rheumatic cardiac valve disease and pericarditis); endocarditis; thalassemia; iron deficiency anemia; iodine deficiency; G6PD deficiency; other endocrine, nutritional, blood, and immune disorders; other hemolytic anemia; congenital heart anomalies; coal worker's pneumoconiosis, asbestosis; silicosis; and other pneumoconiosis.

We calculated the estimates for heart failure attributable to the 20 causes in a three-step process. First, we grouped the 20 causes into seven more general major cause groups, including: ischemic heart disease; cardiomyopathy and myocarditis; hypertensive heart disease; Chagas; cardiopulmonary; valvular heart disease; and other causes. For these major cause groups, we conducted a systematic review of the literature and extracted individual hospital discharge data. We also analysed cause of death data and assessed distribution of the heart failure death and each major cause group death. As a conceptual basis for this analysis, if we observed an increase in deaths coded as heart failure and a concurrent decrease in deaths coded to one of the seven major cause groupings (adjusted by the total number of deaths from these seven causes), we concluded that the death was misclassified as heart failure, a garbage code, and used this to inform our allocation of heart failure to that cause. For this analysis, we used available data in ten years in either direction, created ten-year age groups, and incorporated nested region and super-region random effects in order to better-inform our estimates for redistribution, especially in low-data areas.


We used the DisMod-MR 2.0 Bayesian meta-regression tool to model the cause fraction for each of the seven major cause groupings using the three data inputs mentioned above. We also used relevant country-level covariates to inform the level if the coefficient of the covariate was plausible. After modelling each major cause separately, we rescaled the results to add to one. The rescaling process was based on the assumption of one patient-one cause.

Second, we disaggregated the seven major cause groupings into the more detailed 17 causes of heart failure. The split was proportional to the number of deaths due to the component cause in each major cause. We split cardiopulmonary into chronic obstructive pulmonary disease (COPD), other interstitial lung disease, and pneumoconiosis; we split valvular heart disease into rheumatic heart disease and non-rheumatic heart valve disease; and we split other into endocarditis, pericarditis, thalassemia, iron deficiency anemia, G6PD deficiency, other endocrine, nutritional, blood and immune disorders, other hemolytic anemia, and congenital heart anomalies. We summed pericarditis and non-rheumatic heart valve diseases fractions were summed to make "other circulatory diseases" aetiologic fraction.

Third, we split pneumoconiosis into coal worker's pneumoconiosis, asbestosis, silicosis, and other pneumoconiosis. This split is illustrated in Appendix Figure C4.

One difference between the GBD 2010 and the GBD 2013 is that we modeled heart failure due to Chagas separately. Data on the proportion of heart failure due to Chagas is very limited and the resulting estimates did not well match the known trends and the spatial distribution of Chagas; moreover, this approach produced implausible estimates among some groups (e.g. the estimated prevalence of heart failure due to Chagas among the elderly in Brazil exceeded the prevalence of Chagas among the same group). We revised our approach to address these concerns. Rather than estimating the proportion of heart failure due to Chagas, our new approach is to estimate the attributable risk of heart failure among those with Chagas. Using age-sex specific data from a Brazilian cohort study (unpublished data from Sabino et al. "Ten-Year Incidence of Chagas Cardiomyopathy Among Asymptomatic *Trypanosoma cruzi*-Seropositive Former Blood Donors." *Circulation*. 2013; 127: 1105-1115.),²¹ we estimated the Chagas attributable risk of heart as the prevalence of heart failure among those with Chagas, minus the prevalence of heart failure among those without Chagas. We then multiplied these age-sex specific estimates times our estimates of the prevalence of Chagas to determine the prevalence of heart failure due to Chagas.

Appendix Figure E.4.: Three-step process for estimating heart failure



We estimated the prevalence of the heart failure envelope in DisMod-MR 2.0 using incidence, prevalence, and case fatality of heart failure. We used mean body mass index as a country-level fixed effect covariate to inform estimation for the regions without data. We used hospital discharge rate in developed and developing countries and adjusted the level by age and developing/developed country source to be comparable with prevalence of heart failure.

Data

Step 1: Modelling the seven major cause groups

We used three types of data in the first step of estimating the aetiologic fraction for the 7 major causes.

1 – Modelling heart failure-specific death: The input database used for the analysis of causes of death data was comprised of 1,720 country-years of vital statistics, which were primarily gathered for use in the World Health Organization (WHO) Mortality Database.²² 1,113 country-years of these vital statistics were reported according to International Classification of Disease (ICD) 10 standards, and 607 country-years were reported according to ICD9 standards. Overall, the database encompassed 117 countries in 18 different GBD regions from 1980-2010.

2 – Extractions from individual hospital admissions: We analysed admissions from 29 countries in Europe, North America, and Central Latin America. Brazil's hospital data was outliered due to smaller observed prevalence of

heart failure compared to other hospital areas and other systematic data. The hospital admission data spanned from 1989 to 2012. We used all hospital admissions where the primary ICD code was for heart failure, and a secondary ICD code mapped to one of our 7 causes. We then estimated relative proportions of each of the 7 causes based off of this data.

3 – Literature review: In the GBD 2010, we conducted a systematic review to find the studies that reported patients with heart failure attributable to the seven major cause groupings. We updated this systematic review with studies after 2010 and incorporated additional papers that were suggested to us by expert groups. Overall, we used 57 studies in the analysis.

Step 2: Modelling the 17 individual causes

The three causes disaggregated in step two included cardio-pulmonary, valvular heart disease, and other. For the cardiopulmonary and other causes, we used Cause of Death estimates to estimate the proportions attributable to each cause. Because the Cause of Death estimates do not produce disease-specific results for the valvular heart disease causes, we used vital registration data and redistributed proportionally. For the vital registration data, we used ICD9 detailed and ICD10 detailed data and extracted the proportion of each detailed cause within the major cause grouping. We used five-year bounds for year in either direction and 10-year age groups.

Step 3: Splitting pneumoconiosis

Finally, we split the proportion of heart failure attributable to pneumoconiosis into four sub-causes: asbestosis; silicosis; coal worker’s lung; and other pneumoconiosis. We split them proportionally according to the total prevalence of the total causes.

Heart failure envelope

To model the total number of heart failure cases that were subsequently allocated to the 17 detailed causes, we conducted a systematic review of the literature and extracted data on prevalence, incidence, and case fatality of heart failure. By definition, a case of a heart failure was a patient diagnosed with a reduced systolic ejection fraction, as diagnosed by a physician. We assumed it be equivalent to Grade II or higher on the New York Heart Association Functional Scale.²³ We also added age-specific hospital discharge rate due to heart failure and prevalence of heart failure in the analysis to inform prevalence estimation. We modeled all types of data in DisMod-MR 2.0.

Results

We estimated the aetiological fraction of the 17 final GBD causes by year, sex, age, and country for 1990, 2005, 2010, and 2013.

Appendix Table E.8. - Aetiological fraction (percent) of different causes in both genders in all years combined for all ages combined (relative proportion of each cause, collapsed)			
Cause	Aetiological fraction	Cause	Aetiological fraction
Chagas	0.7	Hypertensive Heart Disease	15.8
Cardiomyopathy and myocarditis	11.8	Ischemic Heart Disease	30.4
COPD	9.5	Iodine deficiency	0.01
Congenital heart anomalies	1.1	Iron deficiency anemia	0.8
Endocarditis	0.4	Other circulatory	14.4
G6PD deficiency	0.03	Other endocrine, nutritional, blood, and immune disorders	1.2
Other hemolytic	0.3	Other interstitial lung disease	1.3
Rheumatic Heart Disease	11.1	Thalassemia	0.2

Pneumoconiosis	0.5	
Pneumoconiosis aetiological fractions, all years and ages combined		
Cause	Aetiological Fraction	
Other pneumoconiosis	56.7	
Asbestosis	1.9	
Silicosis	32.3	
Coal worker's pneumoconiosis	9.1	
Region comparison of prevalence of HF in different regions: males, 2013 Prevalence of HF in high income NA, males, 2013, with adjusted datapoints		

E.5 Infertility

We used DisMod-MR 2.0 and individual-level survey data to estimate the prevalence of primary, secondary, and all infertility among couples. Primary infertility is defined in a couple who have not had a live birth, who wish a child, and have been in a union for more than five years without using contraceptives. Secondary infertility is defined in a couple who wish a child and have been in a union for more than five years without using contraceptives since the last live birth. We included data were included for women in five-year age groups between 15 and 49 from surveys including the Demographic and Health Surveys (DHS), World Fertility Surveys (WFS), Reproductive Health Surveys (RHS), Family and Fertility Survey (FFS), and others (EUR, NSF, PCD, PFM). We extracted an additional 265 prevalence data points for primary infertility and 255 data points for secondary infertility from new surveys identified after the GBD 2010, bringing the total number of data points available for the GBD 2013 analyses to 1621 for primary infertility and 1575 for secondary infertility. Although these surveys only interviewed women, the resultant estimate of prevalence is an indicator of couples' infertility, as it is not possible to determine in a survey which partner is the cause of the infertility. Because some surveys ask questions of only ever-married women, we separately estimated the prevalence of four parameters, two each for primary and secondary infertility: 1) prevalence of exposure to infertility of that type; and 2) prevalence of infertility of that type among exposed women. We estimated primary and secondary couples' infertility from DisMod-MR 2.0 models by multiplying the estimates for prevalence of infertility among exposed women by the prevalence of exposure to infertility to obtain prevalence of infertility among all women and all men.

We expanded the GBD 2010 data set of 15 studies by adding 5 more on the proportion of infertile couples where the impairment is identified in the man and/or the woman.

We used DisMod-MR 2.0 to produce estimates of the proportion of primary and secondary infertility in men and women by region, age, and sex for 1990, 1995, 2000, 2005, 2010 and 2013. Because infertility in some couples is attributable to both partners rather than just one, the sum of the proportion of couples' prevalence due to male factor infertility and due to female factor infertility is greater than 1.

There are 7 identified causes of female infertility in the GBD 2013 cause list: chlamydia, gonorrhoea, other sexually transmitted diseases, maternal sepsis, polycystic ovarian syndrome, endometriosis, and Turner syndrome. For each of these diseases, we determined the prevalence of infertility by a literature review of the probability of becoming infertile due to that disease. For sexually transmitted diseases we applied a proportion with infertility derived from Westrom et al. (1992, Sex Transm Dis) to incident cases of pelvic inflammatory disease and streamed out prevalence over the fertile age range using DisMod-MR 2.0.²⁴ We added all the disease-specific estimates of prevalence and assigned the remaining proportion to categories of "female primary infertility due to other causes" and "female secondary infertility due to other causes." We assumed all infertility from Turner syndrome is primary infertility and all infertility following maternal sepsis is secondary infertility. The only recognised cause of male

infertility in the GBD 2013 cause list is Klinefelter syndrome. We assigned all other male infertility to “male infertility due to other causes”.

Prevalence and YLD by underlying cause for 1990 and 2013 and the prevalence of primary and secondary infertility are shown in Appendix table E.9. Appendix Table C9 provides our results of primary and secondary infertility: 63.4 million women in 2013 were infertile and 39.3 million men were infertile. In women less than a third is primary infertility and the majority is secondary infertility while in men primary infertility is about twice as common as secondary infertility. In women, the leading cause is the unexplained category but a major cause is polycystic ovarian syndrome affecting 22.4 million women. Collectively sexually transmitted diseases account for a further 3.7 million cases. Rates of infertility have remained stable between 1990 and 2013 but due to demographic changes, the number of infertile people in the world has increased by over 40%.

Appendix Table E.9: Prevalence and YLDs, with percent of total, for infertility by cause, 1990 and 2013, and prevalence of primary and secondary infertility by cause in 2013


	Sex	Total Prevalence (in thousands)		Total YLDs (in thousands)		Prevalence 2013 (in thousands)	
		1990	2013	1990	2013	Primary	Secondary
Male infertility due to other causes	Male	27,295.3 (39.04%)	39,265.7 (38.23%)	180.0 (30.23%)	258.6 (29.27%)	25,427.1 (24.76%)	13,838.5 (13.47%)
Klinefelter syndrome	Male	50.5 (0.07%)	76.7 (0.07%)	0.4 (0.06%)	0.6 (0.07%)	76.7 (0.07%)	-
Female infertility due to other causes	Female	21,992.4 (31.45%)	34,747.5 (33.83%)	122.3 (20.54%)	191.9 (21.72%)	7,214.4 (7.02%)	27,533.1 (26.81%)
Polycystic ovarian syndrome	Female	14,552.2 (20.81%)	22,376.7 (21.79%)	212.3 (35.66%)	327.0 (37.01%)	9,751.6 (9.49%)	12,625.0 (12.29%)
Maternal sepsis and other maternal infections	Female	1,921.0 (2.75%)	1,677.6 (1.63%)	9.6 (1.61%)	8.4 (0.95%)	-	1,677.6 (1.63%)
Gonococcal infection	Female	1,342.5 (1.92%)	1,517.4 (1.48%)	8.0 (1.35%)	9.1 (1.03%)	655.2 (0.64%)	862.3 (0.84%)
Chlamydial infection	Female	1,098.0 (1.57%)	1,090.3 (1.06%)	6.5 (1.10%)	6.5 (0.74%)	447.8 (0.44%)	642.4 (0.63%)
Other sexually transmitted diseases	Female	1,098.0 (1.57%)	1,090.3 (1.06%)	6.5 (1.10%)	6.5 (0.74%)	447.8 (0.44%)	642.4 (0.63%)
Endometriosis	Female	490.6 (0.70%)	736.9 (0.72%)	49.1 (8.25%)	74.0 (8.38%)	316.5 (0.31%)	420.4 (0.41%)
Turner syndrome	Female	80.8 (0.12%)	127.3 (0.12%)	0.6 (0.10%)	0.9 (0.11%)	127.3 (0.12%)	-
Total Prevalence	Both	69,921.2 (100.00%)	102,706.2 (100.00%)	-	-	44,464.5 (43.29%)	58,241.7 (56.71%)
Total YLDs	Both	-	-	595.4 (100.00%)	883.5 (100.00%)	443.1 (50.15%)	440.5 (49.85%)

E.6 Intellectual disability

We modelled the prevalence estimates of intellectual disability (ID), both aetiology-specific IDs and idiopathic ID, over multiple steps. First, we ran a DisMod-MR 2.0 model to estimate the total prevalence estimates of all aetiology IDs defined as anyone with IQ below 70 (envelope ID). As data points were rather sparse, we used two country-level fixed effect covariates to inform DisMod-MR 2.0 to extrapolate estimates to missing country-years: log-

transformed lag distributed income per capita, and year. Appendix Figure C5 provides an example of DisMod-MR 2.0 model showing the data points in gray and prevalence estimates at regional level in purple.

Appendix Figure E.1.: Prevalence of intellectual disability in East Asia for females in 2005



We estimated prevalence of each aetiology-specific ID by models from the parent causes provided in Appendix Table C10. We calculated prevalence of idiopathic ID by subtracting all aetiology-specific IDs from the envelope and assuming the residuals to represent idiopathic. The issue arises here when this subtraction leaves no residual or even becomes negative (i.e. total prevalence of aetiology-specific ID exceeds the envelope ID). In order to have a plausible set of prevalence estimates between the envelope ID, idiopathic ID, and all aetiology-specific IDs, we made an assumption that idiopathic ID should be no less than 5% of total prevalence of envelope ID for any country-year-sex-age, at the 1000 draws level. When a subtraction left less than 5% of the envelope, the prevalence of all aetiology-specific IDs were proportionally squeezed to fit within 95% of the envelope, leaving 5% for idiopathic ID.

As we estimated the prevalence of individual aetiology-specific IDs by models from the respective parent causes, the squeezing may result in a distorted balance of prevalence estimates within their parent causes. With the aim to maintain consistencies of prevalence within each of the parent causes, we added the difference between the original and the squeezed prevalence estimates to the ‘motor impairment’ sequela if the squeezed sequela represented ‘motor and cognitive impairment.’ For autism, we obtained the fraction of cases that result in ID from literature (0.29; 0.27-0.30 CI 95%) and applied to the subtraction and squeezing processes.

We further split the total prevalence of idiopathic ID estimated in the previous step into four severity levels: mild (IQ 50-69), moderate (IQ 35-49), severe (IQ 20-34), and profound (IQ below 20). In calculating the fractions of these four severity levels, we pooled a subset of data used for estimating the ID envelope if the source distinguished cases by these severity levels. We did this by pooling fractions of three cumulative severity levels (i.e. IQ <50, IQ<35, IQ<20) to maximize the number of sources. We extrapolated the prevalence of the fifth category of borderline (IQ 70-84) from the envelope (IQ below 70) prevalence by applying pooled ratios between the two obtained from a subset of sources that provided both of these prevalent cases. In splitting or extrapolating these five severity levels, we separately pooled fractions or ratios for high-income countries and low and middle-income countries. The uncertainty of the pooled fractions and ratios were propagated throughout our calculations using 1000 draws assuming beta distributions parameterised by 95% confidence intervals provided during the pooling process.

Appendix Table E.10. - Causes that include intellectual disability as sequelae

Neonatal preterm birth complications (<28w, 28-32w, 32-36w)
Neonatal encephalopathy due to birth asphyxia and trauma
Hemolytic disease and other neonatal jaundice
Meningitis (pneumococcal, H influenza type B, meningococcal, other bacterial)
Encephalitis
Malaria
Neonatal tetanus
Iodine deficiency
African trypanosomiasis
Stroke (hemorrhagic, ischemic)
Down syndrome
Klinefelter syndrome
Chromosomal unbalanced rearrangements
Neural tube defects
Hypertensive disorders of pregnancy (eclampsia, preeclampsia)
Autism
Fetal alcohol syndrome

Before splitting the idiopathic ID prevalence into four severity levels using the fractions, we adjusted the severity distributions to account for some aetiology-specific IDs that have skewed distributions. We assumed all ID cases due to iodine deficiency (cretinism) to result in either severe or profound level, and Klinefelter syndrome cases that result in ID will have either borderline or mild level. While we estimated the prevalence of Klinefelter syndrome for each severity level by the parent model, we split prevalence of cretinism into two severity levels assuming the ratio between the two fractions estimated above. We first multiplied the 1000 draws from the envelope ID by the 1000 draws of each severity fraction to obtain the envelope ID prevalence in four levels of severities. We then subtracted the prevalence of cretinism and Klinefelter syndrome from the corresponding severity levels of the envelop ID, and recalculated the fractions of each severity at the draw level. After these adjustments, we applied those fractions to the 1000 draws of idiopathic ID to obtain the prevalence in four severity levels.


E.7 Vision impairment

We modelled the prevalence of vision loss in three steps. In the first step, we ran four DisMod MR 2.0 models to estimate the total prevalence estimates of vision impairment and blindness: moderate vision impairment, severe vision impairment, blindness, and near vision impairment (presbyopia). Appendix Figure C6 provides an example of DisMod-MR 2.0 models showing the data points in gray and prevalence estimates at regional level in purple. We directly derived prevalence of presbyopia from DisMod MR 2.0, whereas the remaining three models that reflect different severity levels of distance vision loss continued to the next step.

In the second step, we removed the uncorrected refractive error from the prevalence estimates obtained from DisMod-MR 2.0 models in the preceding step. We first identified what proportion of distance vision loss was due to under-correction of refractive error. Refractive error results in blurry vision and can cause vision loss. The blurriness caused by refractive error can be addressed through the use of contact lenses, glasses, or refractive surgery.

However, a large proportion of people with vision loss due to refractive error do not have these corrective devices or procedures.

Appendix Figure E.2: Prevalence of blindness in South Asia for females in 2013



We identified studies that reported both presenting and best-corrected estimates of vision loss. We used these data to estimate region and age-specific coefficients that capture the relationship between presenting vision loss and best-corrected. We ran a logit transformed regression by using the ratio of best-corrected over presenting as the dependent variable. After testing various sets of covariates, only age and South Asia region covariates provided statistically significant coefficients, and hence were included in the model. We deemed data points with best-corrected ratios of less than 0.3 to be outliers and we excluded them from the analysis. We then used those estimated coefficients to split the prevalence of vision impairment and blindness into uncorrected refractive error and best-corrected. We obtained the prevalence estimates of uncorrected refractive error for three severity levels from this step. The best-corrected prevalence of distance vision loss was subject for further analysis.

In the third step, we estimated the prevalence of vision loss due to multiple causes: cataract, glaucoma, macular degeneration, diabetic retinopathy, retinopathy due to prematurity, trachoma, vitamin A deficiency, onchocerciasis, and other causes not classified elsewhere. For blindness, we also accounted for other causes such as meningitis, neonatal tetanus, neonatal preterm birth complications, neonatal encephalopathy, hemolytic disease, etc. We implemented proportional squeezes to scale cause-specific vision loss prevalence to the total prevalence of best-corrected vision loss for each of the three severity levels.

Although total prevalence estimates for vision impairment changed little from the GBD 2010 to the GBD 2013, specific prevalence estimates for cataract and for macular degeneration both decreased by 36% and 34%, respectively, from the GBD 2010 to the GBD 2013. These decreases resulted from a change in strategy for estimating the prevalence of each major underlying cause of vision impairment. In the GBD 2013, we modelled the major underlying causes of vision impairment using DisMod-MR 2.0 as prevalence rates rather than proportions of the total of vision impairment as we did in the GBD 2010. This allowed for better use of survey data that did not specify all major causes of vision impairment. This change revealed a potential underestimation of vision impairment due to uncorrected refractive error in the GBD 2010. To amend this underestimation, we increased the share of uncorrected refractive error in the total vision impairment burden in the GBD 2013 which resulted in decreased prevalence for all other vision impairment causes, including cataract and macular degeneration, in the GBD 2013.

E.8 Guillain-Barré syndrome

Guillain-Barré syndrome is a rare condition that usually occurs as a complication of respiratory or gastro-intestinal infection. It is considered an immune-mediated nerve dysfunction with rapid onset of weakness in feet and hands ascending towards the trunk. In the acute phase about a quarter of cases required mechanical ventilation for survival. The majority of cases fully recover within months to a year. In the GBD 2013, in DisMod-MR 2.0 we used 156 incidence data points from 26 countries representing 9 of 21 GBD regions and four remission data points from 4 countries in 3 GBD regions. We estimate a global incidence of just under 1 per 100,000 and global prevalence of just over 0.5 per 100,000, consistent with remission of 1.8 or an average duration of 6.7 months.

There were 35 studies that provided information on the underlying cause: 31 mentioning all of the identified underlying infectious diseases; 26 providing a proportion for upper respiratory infections, 3 for influenza, 25 for diarrheal disease and 14 for other infectious diseases. We used random effects meta-analysis to pool these proportions (Appendix Table E.11.) and stream out 1,000 draws assuming a binomial distribution around the pooled mean. At the draw level we assign the complement to one of the proportion with any underlying infectious disease to a rest category of 'idiopathic Guillain-Barré syndrome' that is classified under neurological disorders. Also, at the draw level we squeeze the proportions for influenza, diarrheal diseases, upper respiratory infections and other infectious diseases to add to the proportion for all identified infectious underlying diseases.

Appendix Table E.11. - Pooled proportions of Guillain-Barré syndrome by underlying cause			
	Mean (%)	Lower limit (%)	Upper limit (%)
All specified causes	61.70	56.50	66.90
Upper respiratory infections	39.90	33.70	46.20
Influenza	14.60	7.90	22.70
Diarrheal diseases	13.80	11.00	16.90
Other infections	8.90	6.50	11.50

Appendix Table E.12. shows prevalence and YLDs for Guillain-Barré syndrome by cause.

Appendix Table E.12. Prevalence and YLDs for Guillain-Barré syndrome by cause, 1990 and 2013				
	Total Prevalence (in thousands)		Total YLDs (in thousands)	
	1990	2013	1990	2013
Upper respiratory infections	8.4 (34.70%)	12.2 (34.63%)	2.5 (34.71%)	3.6 (34.64%)
Other neurological disorders	8.0 (32.76%)	11.6 (32.90%)	2.4 (32.76%)	3.4 (32.90%)
Lower respiratory infections	3.1 (12.76%)	4.5 (12.73%)	0.9 (12.76%)	1.3 (12.73%)
Diarrheal diseases	2.9 (12.02%)	4.2 (12.00%)	0.9 (12.02%)	1.3 (12.00%)
Other infectious diseases	1.9 (7.76%)	2.7 (7.74%)	0.6 (7.75%)	0.8 (7.74%)
Total Prevalence	24.3 (100.00%)	35.3 (100.00%)	-	-

Total YLDs	-	-	7.2 (100.00%)	10.4 (100.00%)
------------	---	---	------------------	-------------------

E.9 Pelvic inflammatory disease

In the GBD 2013, we estimated incidence of pelvic inflammatory disease (PID) using inpatient and outpatient hospital data, assuming the ratio of hospital visits to persons not presenting for care is consistent. We also used this ratio to guide the assignment of PID as either moderate or severe. Disability weights for these health states did not appreciably change. In the GBD 2013, in order to estimate the proportion of all PID due to chlamydia, gonorrhea, and other STI, we improved on the GBD 2010 method by modelling all available PID aetiology data as proportions in DisMod-MR 2.0. This approach resulted in estimates for each aetiology of PID having greater geographic variation than was present previously in the GBD 2010.

Appendix Table E.13. shows prevalence and YLDs for PID by cause in 1990 and 2013 and 2013 prevalence by severity.

Appendix Table E.13. Prevalence and YLDs for pelvic inflammatory disease by cause, 1990 and 2013, and prevalence by severity in 2013						
	Total Prevalence (in thousands)		Total YLDs (in thousands)		Prevalence 2013 (in thousands)	
	1990	2013	1990	2013	Moderate	Severe
Other sexually transmitted diseases	125.5 (47.18%)	160.0 (54.07%)	16.8 (46.95%)	21.4 (53.83%)	142.3 (48.09%)	17.7 (5.98%)
Gonococcal infection	78.0 (29.33%)	79.8 (26.97%)	10.4 (29.20%)	10.7 (26.96%)	71.1 (24.01%)	8.8 (2.97%)
Chlamydial infection	62.5 (23.49%)	56.1 (18.96%)	8.5 (23.85%)	7.6 (19.21%)	49.9 (16.87%)	6.2 (2.09%)
Total Prevalence	266.1 (100.00%)	296.0 (100.00%)	-	-	263.3 (88.96%)	32.7 (11.04%)
Total YLDs	-	-	35.7 (100.00%)	39.7 (100.00%)	29.1 (73.34%)	10.6 (26.66%)

Appendix F: Differences in estimates for the year 2010 between GBD 2010 and GBD 2013 studies

1. Tuberculosis

YLD estimates for tuberculosis decreased by 47% (from 6,777,400 to 3,545,343 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

In the GBD 2010, we estimated tuberculosis mortality and then estimated population incidence through mixed effects regression as a function of tuberculosis mortality, case-notifications, and an indicator variable for health system access used as a proxy for completeness of registration.

In the GBD 2013, we shifted to using all available data for different outcomes and simultaneously estimating incidence, remission, excess mortality, prevalence, and cause-specific mortality using the GBD Bayesian meta-regression tool, DisMod-MR 2.0. To estimate national levels and trends for tuberculosis in a country, we included four sources of information: annual case notifications, expert judgment on the case-detection rate, prevalence surveys, and cause of death data. Additionally, to facilitate convergence of the meta-regression, we used estimated excess mortality and remission rates. Given that incidence, prevalence, and mortality might be measured imperfectly, this new approach is predicated on the theory that a statistical triangulation of all sources for a country will provide a more robust assessment. We performed our meta-regression analysis for all forms of tuberculosis. As a final step, we estimated incidence, prevalence, and death in individuals who are HIV-positive and those who are HIV-negative. This is further described in Murray et al.²⁵

YLD estimates decreased by 47% between the GBD 2010 and the GBD 2013 largely due to changes in the estimation of incidence and prevalence in the South Asia and East Asia GBD regions. In the GBD 2010, we only included notification data by age and sex for Bangladesh and China in a single year. All other data sources were for all ages combined. In the GBD 2013, however, we incorporated age-sex specific data for all countries in the regions which led to a halving of modelled incidence and which, in turn, led to a halving of the prevalence estimates. As the South Asia and East Asia regions contribute close to half of global cases, it led to a substantial reduction in global estimates. The volume of incidence data points in just these two regions increased from 73 in the GBD 2010 to 2,750 in the GBD 2013 and the number of prevalence data points in the two regions increased from 6 to 2,855.

2. HIV/AIDS resulting in mycobacterial infection

YLD estimates for HIV/AIDS resulting in mycobacterial infection decreased by 76% (from 1,224,026 to 289,898 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

For the GBD 2010, we primarily used estimates of prevalence and mortality developed by UNAIDS. The main modification was the requirement that the sum of cause-specific mortality from each cause in a country, age, sex, and year group equaled the estimate of all-cause mortality for that country, age, and sex group generated through the analysis of demographic sources. Modifications of HIV deaths through this internal consistency process did not lead to revisions of incidence or prevalence for HIV in a particular age-sex-country-year. For the GBD 2013, however, we sought to develop a set of estimates of incidence, prevalence, and mortality from HIV that are internally consistent with each other and also meet the GBD requirement that the sum of each cause of death equals all-cause mortality. Internally consistent means the incidence, prevalence, and death figures are mathematically possible given that prevalence is a function of past incidence, remission, and death rates for any age cohort.

3. Upper respiratory infections

YLD estimates for upper respiratory infections (URI) increased by 60% (from 1,730,273 to 2,724,690 YLDs) from the GBD 2010 to the GBD 2013 due to changes in classifications and proportions of mild and moderate URI. This change is not significant.

In the GBD 2010, we used pharyngitis as a proxy for moderate URI, epiglottitis as a proxy for severe URI, and the remaining proportion was considered mild URI. In the GBD 2013, we classified nasopharyngitis, or common cold, as mild URI and acute pharyngitis, tonsillitis, laryngitis, sinusitis, and epiglottitis as moderate URI. We no longer kept severe URI as a separate category as we did in the GBD 2010 since the proportion of epiglottitis was very small. Overall, these changes contributed to a lower proportion of mild URI and a higher proportion of moderate URI. For example, the severity distribution of URI for children aged 0 to 4 years in the GBD 2010 were: mild URI (90.97%), moderate URI (9.00%) and severe URI (0.03%). The severity distribution for children aged 0 to 4 years for the GBD 2013 were: mild URI (84.75%) and moderate URI (15.25%) respectively. These changes resulted in higher YLD estimates for URI in the GBD 2013.

4. Otitis media

YLD estimates for otitis media decreased by 62% (from 4,440,092 to 1,666,540 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

In the GBD 2010, hearing loss due to otitis media was assumed to have the same distribution as other causes of hearing loss on literature²⁶ suggesting a distribution of hearing loss at mild and moderate levels only. This led to much lower estimates. We also added two new health states which has an opposite effect of adding some YLD: vertigo and the rarer occurrence of serious infectious complications, brain abscess, meningitis and mastoiditis, but the latter have limited duration and therefore contribute less to changes in YLD, despite their severity.

4. Meningitis

Meningococcal meningitis

Other meningitis

YLD estimates for meningitis decreased from the GBD 2010 to the GBD 2013. Specifically, YLD estimates for meningococcal meningitis decreased by 61% (from 406,159 to 158,594 YLDs) and YLD estimates for other meningitis decreased by 53% (from 933,524 to 435,391 YLDs). These changes are significant.

In the GBD 2010, we estimated hearing loss due to bacterial meningitis using data from hearing loss studies that also reported meningitis as one of the underlying aetiologies. Using the same data in the GBD 2013 revealed that the estimated prevalence became implausibly high compared to the meningitis incidence. Therefore, in the GBD 2013, we modelled hearing loss due to meningitis using data from a meta-analysis study that investigated the long-term sequelae of meningitis, including hearing loss.²⁷ The decline in YLDs between the GBD 2010 and the GBD 2013 can also be attributed to the case fatality data we used for modelling long-term sequelae. In the GBD 2010, we used from a meta-analysis a single pooled estimate for all regions/ year/ age/ sex. In the GBD 2013, we estimated excess mortality from case fatality rates specific to regions/ year/ age/ sex. This led to a lower estimation of long-term prevalence in meningitis-endemic regions in the GBD 2010.

5. Dengue

YLD estimates for dengue increased by 3203% (from 12,183 to 439,329 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

The addition of post-acute chronic fatigue as a sequela, with an associated health state of “infectious disease, post-acute consequences (fatigue, emotional lability, insomnia)” explains most of the large increase in dengue YLD since the GBD 2010.

The other reason is a change in the method of correcting for underreporting. In the GBD 2010, we accounted for underreporting by assuming complete dengue reporting in high income countries with good access to care and increasing underreporting in countries with less access based on our composite indicator of health system access. In the GBD 2013, we adopted a new approach of benchmarking country-level deviations from expected values (based on new dengue risk maps from Bhatt et al [2013]) against published estimates of empirical correction factors for underreporting.²⁸

6. Yellow fever

YLD estimates for yellow fever increased by 5231% (from 4 to 81 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

A recent analysis by Johansson, Vasconcelos and Staples (2014) provided compelling evidence that reported cases underestimate true cases of yellow fever.²⁹ However, little recent data exists on the degree of underreporting of yellow fever. Therefore, for GBD 2013, we used data on underreporting of dengue as a proxy for underreporting of yellow fever and inflated reported cases accordingly. Based on the same analysis we also estimated a proportion of cases to be asymptomatic cases which has the opposite effect of lowering estimates.

7. Hookworm disease

YLD estimates for hookworm disease decreased by 34% (from 3,232,065 to 2,098,711 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

Changes in burden estimates for anemia due to hookworm disease resulted in changes in the burden of hookworm disease from the GBD 2010 to the GBD 2013. For details regarding hookworm disease modelling changes, please refer to the description of methods for calculating the burden of anemia on page 6.

8. Food-borne trematodiasis

YLD estimates for food-borne trematodiasis (FBT) increased by 93% (from 1,875,473 to 3,539,950 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

This increase can be attributed to the following modifications to the modelling strategy.

Firstly, in the GBD 2013, we increased the disability weights for paragonimiasis and cerebral paragonimiasis. In the GBD 2010, we applied the disability weight for moderate abdominal pain (0.11) to all FBT cases. In the GBD 2013, however, since symptoms of paragonimiasis and cerebral paragonimiasis do not match moderate abdominal pain, we used more appropriate weights for TB and epilepsy, respectively. As a result, YLD estimates for paragonimiasis and cerebral paragonimiasis are three times higher.

Secondly, we used different input data for DisMod-MR between the GBD 2010 and the GBD 2013. In the GBD 2010, following a literature review and an in-depth analysis, the GBD experts provided the input data. We then pre-modelled the data (e.g. applying standardised age and sex profiles and using DisMod-MR). In the GBD 2013, however, we used raw data from studies that reported national prevalence rates of FBT as the input for DisMod-MR 2.0.

Thirdly, we modified how we applied prevalence rates across countries within the same GBD region. In the GBD 2010 study, we assumed the prevalence rate for all countries in a particular GBD region was the same. For example, we applied the prevalence rate of *Clonorchiasis sinensis* in Russia to all other countries in the Eastern Europe region (Belarus, Estonia, Latvia, Lithuania, Moldova, and Ukraine) as their national prevalence rates were unavailable. For the GBD 2013, however, we did not adopt the same rate across all countries in a region, but rather limited estimates to only those countries for which national prevalence rates were available. We chose not to include countries in close geographic proximity because infection is highly dependent on the ingestion of certain types of food and close geographic proximity does not infer similar food habits.

Fourthly, we modified how we calculated the rates of high infection. In the GBD 2010, we applied one rate, based on literature, to assess the number of persons with high infection. In the GBD 2013, however, we expected rates of high infection to increase with age. Therefore, we included age-dependent rates of high infection for clonorchiasis, opisthorchiasis, and intestinal fluke infection (but not for [cerebral] paragonimiasis and fascioliasis, as there were insufficient data on high intensity infection by age or sex category for these diseases). This change in approach resulted in higher percentages of cases with high intensity infection, particularly for clonorchiasis and opisthorchiasis.

9. Chagas disease

YLD estimates for Chagas disease decreased by 70% (from 306,778 to 89,982 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

In the GBD 2010, the prevalence of sequelae were not constrained to add up to estimates of the total Chagas prevalence. In the GBD 2013, we revised our approach by using age-specific relative risks for each sequela, rather than the GBD 2010 approach which assigned a defined proportion of cases to each age group regardless of the underlying population structure. We also re-evaluated our approach to estimating cardiovascular sequelae. We no longer assign disability to common but asymptomatic electrocardiography (ECG) abnormalities but restrict our cardiovascular estimates to heart failure and atrial fibrillation. Moreover, based on the results of a recent study by Ribeiro et al (2014), in the GBD 2013, we reduced our estimate of the prevalence of atrial fibrillation among those with Chagas.³⁰

10. Leishmaniasis

YLD estimates for leishmaniasis decreased by 62% (from 124,306 to 45,670 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

The majority of YLD from leishmaniasis are due to cutaneous rather than visceral leishmaniasis. The main difference is that in the GBD 2013, we excluded seroincidence and seroprevalence data used in the GBD 2010 which resulted in lower incidence and prevalence estimates.

11. Cysticercosis

YLD estimates for cysticercosis decreased by 32% (from 456,627 to 313,146 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

In the GBD 2010 estimates of epilepsy arising from various diseases in the GBD schedule were left unconstrained. In GBD 2013, we constrained these estimates not to exceed the estimated burden of secondary epilepsy which is derived from the prevalence estimates of the epilepsy ‘envelope’ model multiplied by output from a second DisMod-MR 2.0 model of the proportions of epilepsy that are ‘idiopathic’ or secondary.

12. Onchocerciasis

YLD estimates for onchocerciasis increased by 149% (from 493,801 to 1,254,856 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

In the GBD 2010 and the GBD 2013, we based the burden estimates for onchocerciasis on the same prevalence estimates. However, in the GBD 2010, the disability weights for the skin manifestations failed to account for itch (one of the most prevalent manifestations of onchocerciasis). Based upon consultation with collaborating experts, we switched to using higher disability weights for the disfigurement of skin lesions that are accompanied by itch in the GBD 2013. Also, unlike in the GBD 2010, we included the most severe level skin sequelae for hanging groin, lichenified onchodermatitis with confluent plaques, and chronic papular onchodermatitis with scratch marks, further contributing to increases in YLDs.

13. Maternal sepsis and other maternal infections

YLD estimates for maternal sepsis and other maternal infections decreased by 45% (from 41,298 to 22,865 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

While we adopted a similar strategy for estimating maternal sepsis and other maternal infections between the GBD 2010 and the GBD 2013, two differences contributed to the decrease in YLD estimates. First, for all maternal conditions we have a mix of hospital inpatient data for high income and Latin American countries from which we generally derive population rates. Another source is data from the literature which typically reports cases per 1,000 live births. To be able to include both sets of data we converted the hospital rates to a ratio per 1,000 live births and ran DisMod-MR 2.0 with all data in this format. The results from DisMod-MR 2.0 are afterwards back-transformed to population rates using data on age-specific fertility rates by country, year and age. In the GBD 2010 this last back-transformation to population rates was not done and that led to overestimation.

The second change concerns a disaggregation into two types of maternal infections. ICD-10 includes a range of infections temporally associated with pregnancy, but not traditionally thought of as puerperal in nature. Examples include wound infections, vaginal tract infections, cystitis/ pyelonephritis and mastitis. In the GBD 2013, split the two into separate models: puerperal sepsis and “other maternal infections”. The GBD 2013 disability weight for severe infection used for puerperal sepsis is 0.133 while in the GBD 2010 the disability weight for severe abdominal pain was used with a much higher value of 0.326. The cases of ‘other maternal infections’ were given the disability weight for moderate infection, at about half the value of the severe infection disability weight. Unlike in the GBD 2010, we did include secondary infertility after maternal sepsis as a sequela assuming the same proportion of cases develops infertility as reported for pelvic inflammatory disease by Weström et al (1992).²⁴

14. Maternal hypertensive disorders

YLD estimates for maternal hypertensive disorders decreased by 32% (from 92,524 to 63,634 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

While we adopted a similar strategy for estimating maternal hypertensive disorders between the GBD 2010 and the GBD 2013, one key difference contributed to the change in estimates. For all maternal conditions we have a mix of hospital inpatient data for high income and Latin American countries from which we generally derive population rates. Another source is data from the literature which typically reports cases per 1,000 live births. To be able to include both sets of data we converted the hospital rates to a ratio per 1,000 live births and ran DisMod-MR 2.0 with all data in this format. The results from DisMod-MR 2.0 are afterwards back-transformed to population rates using data on age-specific fertility rates by country, year and age. In the GBD 2010 this last back-transformation to population rates was not done and that led to overestimation.

15. Complications of abortion

YLD estimates for complications of abortion decreased by 93% (from 32,371 to 2,312 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

We estimated complications of abortive outcome of pregnancy, which includes ectopic pregnancy and induced abortions, using hospital datasets as the primary input. In the GBD 2010, this category also included spontaneous miscarriages, but due to inconsistent reporting of this phenomenon and that it would not be expected to result in disability of the nature seen in other maternal complications, we excluded it from the GBD 2013 analysis. In the GBD 2013, we also did not include Demographic and Health Survey data sources due to a lack of differentiation of spontaneous from induced abortion. We modeled the number of abortions per live birth in DisMod-MR 2.0. We then used three study-level covariates to crosswalk systematic differences in the datasets: 1) those data that only included induced abortions (i.e. excluded ectopic), 2) those data collected in hospitals which are not likely representative of the entire population, and 3) data from those countries where abortion is considered illegal under all circumstances and therefore any induced abortions that may occur are not reported. We used age-standardised abortive outcome mortality rate from the GBD 2013 cause-of-death analysis and whether or not on-demand abortion is legal (*Abortion On-Demand Illegal [binary]*), as country-level covariates to predict incident cases. After standardization to the population level, we calculated prevalent cases and disability from abortion, assuming 3 days (2 – 4 days) duration of moderate abdominopelvic problem. Similar to what is noted for maternal sepsis and hypertensive disorders in pregnancy, in the GBD 2010 a back-transformation between rates per live births was left out and this led to overestimation.

16. Preterm birth complications

YLD estimates for preterm birth complications increased by 102% (from 2,980,505 to 6,009,271 YLDs) from the GBD 2010 to the GBD 2013, a significant increase. This change is significant.

We calculated preterm birth complications by starting with birth prevalence by three gestational age categories (<28 weeks; 28-31.9 weeks; and 32-36.9 weeks). We subtracted the proportion of cases dying in the first month and multiply by a probability of long-term mild motor and cognitive impairment and those with more severe long-term motor and/or cognitive impairments with or without blindness or seizures.

In the GBD 2010, we derived these probabilities from a meta-analysis within three strata of countries based on their neonatal mortality rate (<5; 5-14 and 15+ per 1,000 live births). In the GBD 2013 we ran mixed effect models by the same gestational age categories to pool birth prevalence, case fatality proportion and probabilities of mild or more severe long term impairments using the log of countries' neonatal mortality rate and year as fixed effects and random effects on three levels of geography (super-region, region, and country). In sparser data sets we dropped country and/or region random effects. In the sparsest models we resorted to meta-analysis. This change in modelling strategy led to 121% higher estimates of 2010 prevalence in the GBD 2013 as changes over time were inadequately picked up using the coarse binning of countries into three categories, rather than using neonatal mortality rate as a continuous variable. As birth prevalence of preterm births has been increasing and case fatality has been dropping over time and the probability of long term impairments has not changed much, prevalence estimates increased a lot, particularly in latter years compared to the GBD 2010 estimates. YLDs increased by a lower proportion (102%) than prevalence estimates as we forced estimates of epilepsy and intellectual disability, as sequelae of preterm birth complications, to fit within the 'envelope' of the total impairments. In the GBD 2010, we did not include this step. As intellectual disability and epilepsy occur together with motor impairment we decided to recategorise cases that exceeded the envelope of either impairment as having motor impairment only. The disability weights for moderate and severe motor impairment only are quite a bit lower than those for moderate and severe motor plus intellectual impairments or the combined states of motor impairments and epilepsy.

17. Neonatal encephalopathy due to birth asphyxia and trauma

YLD estimates for neonatal encephalopathy due to birth asphyxia and trauma decreased by 62% (from 6,146,716 to 2,318,108 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

The GBD 2010 estimates for neonatal encephalopathy were hindered by not having access to the primary data. As a result, we based estimates on a regression equation provided by GBD experts. In the GBD 2013, we used the same strategy as for preterm birth complications: mixed effects models predicting country values of birth prevalence, 28-day case fatality proportion and probabilities of long term impairments with the log of countries' neonatal mortality rate and year as fixed effects and random effects on geography. The prevalence estimates for the year 2010 decreased by 31% compared to the GBD 2010 estimates. YLDs dropped further (by 62%) after we implemented the same 'squeeze' on intellectual disability and epilepsy as mentioned above for preterm birth complications.

18. Neonatal sepsis and other neonatal infections

YLD estimates for neonatal sepsis and other neonatal infections decreased by 76% (from 22,900 to 5,877 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

We estimated prevalence of neonatal sepsis from deaths and a mixed-effects models predicting case fatality proportions based on data for neonatal meningitis (note: we modelled neonatal meningitis separately as part of the meningitis model for all ages). Compared to the GBD 2010, birth prevalence dropped by 67%, partly because deaths from neonatal sepsis dropped by 36% and partly because we assumed a shorter duration (2 vs 4 weeks) based on expert advice.

19. Iodine deficiency

YLD estimates for iodine deficiency decreased by 46% (from 3,891,254 to 2,063,276 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

Despite universal iodization of salt in many countries, the GBD 2010 results did not reflect a decreasing trend in the prevalence of iodine deficiency over time. In the GBD 2013, we addressed this issue by setting the "Proportion of households using iodised salt (adjusted)" covariate to be negatively associated with iodine deficiency and also by adding a year covariate. This change resulted in lower prevalence and YLD estimates for iodine deficiency in the GBD 2013.

20. Vitamin A deficiency

YLD estimates for vision loss due to vitamin A deficiency decreased by 80% (from 806,779 to 161,690 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

Given a massive global scale up of vitamin A supplementation in recent years, this decline seems realistic. To take into account the intervention coverage, in the GBD 2013, we added a country-level covariate, “Vitamin A supplementation coverage rate,” not previously included in the GBD 2010. We used additional covariates including: *Vitamin A Deficiency Prevalence (age-standardised)*, (serum retinol < 70 µmol/L), and a year covariate. In the GBD 2010, we assumed zero prevalence of corneal ulceration and corneal scar due to vitamin A deficiency in high income countries. In the GBD 2013, however, we assumed zero prevalence of these conditions for countries in the Eastern Europe and Central Europe GBD regions in addition to high income countries. These changes combined resulted in the lower prevalence and YLD of vision loss due to vitamin A deficiency in the GBD 2013.

21. Syphilis

YLD estimates for syphilis decreased by 35% (from 93,863 to 57,979 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

In the GBD 2010 and the GBD 2013, we estimated disability due to tertiary syphilis only. This includes combined disability of cardiovascular syphilis, neurosyphilis, and late benign syphilis. We assumed disability associated with primary and secondary syphilis was insignificant as both disease phases are generally subtle and asymptomatic.

We used similar data sources in the GBD 2010 and the GBD 2013. We primarily used hospital data to estimate prevalence of tertiary syphilis in countries where reliable inpatient data is available. We made a few key changes to model specifications since the GBD 2010, which had an impact on the magnitude of prevalence and YLD estimates in the GBD 2013. 010, we defined the duration of syphilis as 15 years. In the GBD 2013, we set remission and excess-mortality each to have a maximum value of 0.1 per person-year. This functionally set the minimum duration at 5 years but did not specify an upper bound. Additionally, in the GBD 2013, updates to cause-specific mortality data and the syphilis seroprevalence covariate were marginally lower than estimated in the GBD 2010, which decreased the magnitude of our adult tertiary syphilis prevalence estimates.

22. Acute hepatitis B

YLD estimates for acute hepatitis B decreased by 30% (from 246,679 to 160,452 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

Our overall estimates of the number of acute hepatitis B cases did not change substantially from the GBD 2010 to the GBD 2013; however, our YLD estimates in the GBD 2013 were notably lower than those from the GBD 2010. The decline in YLDs was driven by changes in our method for assigning cases to symptomatic and asymptomatic states: we improved our approach in this regard and in the GBD 2013 used age-specific estimates for the proportion of cases that were symptomatic, rather than a fixed proportion for all ages. This reduced the proportion of cases that were symptomatic in younger age groups and, consequently, reduced our overall YLD estimates.

23. Acute hepatitis C

YLD estimates for acute hepatitis C decreased by 57% (from 39,208 to 16,444 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

This change is driven completely by a change in the estimates of prevalence. In the GBD 2010 and the GBD 2013, we estimated the incidence of hepatitis C infection using DisMod, based on anti-HCV (hepatitis C virus) seroprevalence data. This compartmental model estimated incidence as a function of duration and changes in prevalence. We set priors on excess mortality due to hepatitis C which influenced duration and, in turn, our estimates of incidence. In the GBD 2013, we conducted a literature review and found the previous prior used in the GBD 2010 was based on sources that disproportionately included individuals with advanced and symptomatic hepatitis C infections. Therefore, we reduced our prior for excess mortality in the GBD 2013 based on data published by El-Kamary, Jhaveri and Shardell (2011) that we believe are based on a more representative sample of people infected with hepatitis C.³¹ This reduction in the prior for excess mortality in the GBD 2013 yielded lower incidence estimates than in the GBD 2010.

24. Leprosy

YLD estimates for leprosy increased by 560% (from 6,046 to 37,922 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

This increase in YLDs can be attributed to an increase in the prevalence of leprosy as well as to the assignment of disability weights according to the age and sex distribution of grade 1 and grade 2 leprosy disabilities.

Firstly, prevalence estimates for leprosy increased by 99% (from 319,087 to 628,190 cases) from the GBD 2010 to the GBD 2013. In the GBD 2010, we relied on WHO prevalence data which represented cases under treatment. We assumed no excess mortality and assigned the value of the prior for duration in DisMod-MR to be 2 years. In the GBD 2013, we similarly assumed no excess mortality, however we considered the prevalence estimates to represent individuals that ever had leprosy, given that actual treatment duration is longer than 2 years.

Secondly, regarding disability weights, in the GBD 2010, we assigned all prevalent cases of leprosy a disability (grade 1 or 2) based on a super-region-specific proportion for disfigurement with itch (level 1) versus disfigurement with itch (level 2) that was the same for all years, ages, and sexes. We determined the fraction of leprosy cases with level 2 disability based on data on grade 2 disability (G2D) reported to the WHO, aggregated to the super-region level. We assigned all other cases a level 1 disability

In the GBD 2013, however, we calculated incidence of grade 1 and 2 disability (G1D and G2D) as a proportion of incident leprosy cases, based on the estimated incidence of leprosy, G2D proportions reported to the WHO (new G2D cases / all new leprosy cases, aggregated over sex and age), and the age and sex distribution of G1D and G2D among new leprosy cases (using data from Brazil).

We modeled the age and sex distribution of G1D and G2D jointly in a generalised ordinal logistic regression model which relaxed the proportional odds assumptions (i.e. we allowed that the proportions of G1D and G2D were not always proportional over different ages and sexes). For each country-year, we scaled the estimated age/sex distribution for G2D such that the overall G2D proportion equaled the reported proportion (taking into account uncertainty in the reported G2D proportion). To constrain the proportion e

25. Ischemic heart disease

YLD estimates for ischemic heart disease (IHD) decreased by 41% (from 8,770,304 to 5,190,172 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

This main reason for this decrease in YLDs is a 49% decrease in the prevalence of angina. In the GBD 2013, we altered our strategy such that all prevalence estimates from the World Health Survey Rose Angina Questionnaire were crosswalked downward towards more reliable non-WHS survey data. In the GBD 2010, we only performed this crosswalk for WHS surveys from sub-Saharan Africa. Therefore the lower prevalence fit was an intended outcome. A modern study in Helsinki used linked medical records and suggested that the Rose Angina Questionnaire significantly overestimates angina prevalence (Lallukka, Tea, Kristiina Manderbacka, Ilmo Keskimäki, Harry Hemingway, Ossi Rahkonen, Eero Lahelma, and Reunanen Antti. "Angina Pectoris: Relation of Epidemiological Survey to Registry Data." *European Journal of Cardiovascular Prevention & Rehabilitation* 18, no. 4 (August 1, 2011): 621–26. doi:10.1097/HJR.0b013e32833bfc73.).³² This study supports the lower angina prevalence estimates in the GBD 2013 as an improvement to the GBD 2010 results.

26. Hypertensive heart disease

YLD estimates for hypertensive heart disease increased by 124% (from 464,123 to 1,038,033 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

YLD for hypertensive heart disease come from the envelope of all heart failure. A big change in strategy between GBD 2010 and GBD 2013 was the use of age-specific hospital data instead of the age-standardised HF discharge data used in the GBD 2010. This led to lower rates in the young but higher rates in the elderly where most cases occur.

We calculated the prevalence of hypertensive heart failure by applying estimated proportion of heart failure due to hypertension and prevalence of heart failure. The aetiological fraction of hypertension in the GBD 2013 was higher than in the GBD 2010. For additional details, please refer to the description of methods for calculating the burden of heart failure on page 15.

27. Cardiomyopathy and myocarditis

YLD estimates for cardiomyopathy and myocarditis increased by 99% (from 395,345 to 780,880 YLDs) from the GBD 2010 to the GBD 2013 due to a 120% increase in the prevalence of heart failure due to cardiomyopathy. This change is significant.

A big change in the modelling strategy of heart failure between GBD 2010 and GBD 2013 was the use of age-specific hospital data instead of the age-standardised HF discharge data used in the GBD 2010. This led to lower rates in the young but higher rates in the elderly where most cases occur.

28. Atrial fibrillation and flutter

YLD estimates for atrial fibrillation and flutter decreased by 64% (from 2,428,072 to 881,463 YLDs) from the GBD 2010 to the GBD 2013 due to a 63% decrease in prevalence. This change is significant.

In the GBD 2013, we selected a different modelling strategy than in the GBD 2010. In the GBD 2010 prevalence in regions without data was informed by adding data on CSMR due to atrial fibrillation. We re-evaluated the CSMR data used in the GBD 2010 and find that it is implausibly low, in particular for East and South Asia. There was likely significant misclassification bias with CoD data for atrial fibrillation. In the GBD 2013, in addition to data on incidence, prevalence, and excess mortality, we used only INASDR due to atrial fibrillation as a covariate fixed effect. This informs regions without data in a way that reflects relative differences in atrial fibrillation death rates rather than their absolute magnitude.

29. Peripheral vascular disease

YLD estimates for peripheral vascular disease (PVD) decreased by 67% (from 419,514 to 128,972 YLDs) from the GBD 2010 to the GBD 2013 due to a significant decrease in estimated prevalence. This change is significant.

The model we used in the GBD 2010 had no age restriction for peripheral vascular disease whereas in the GBD 2013, we allowed prevalence to increase after age 30 as there were no data points at younger ages. This led to a prevalence estimate at ages 40-50 which was quite a bit lower than in the GBD 2010 and hence the large drop in prevalence. We think this is an improved model.

30. Endocarditis

YLD estimates for endocarditis decreased by 50% (from 61,668 to 30,923 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

This change can be attributed to a decrease in endocarditis prevalence resulting from the addition of new data to the GBD 2013 model, specifically new hospital data with lower admission rates of endocarditis.³³

31. Pneumoconiosis

YLD estimates for pneumoconiosis decreased by 87% (from 445,941 to 46,678 YLDs) from the GBD 2010 to the GBD 2013 due to changes to the modelling approach. This change is significant.

First, in the GBD 2013, for the coal workers pneumoconiosis and silicosis analyses, we dropped all data collected among occupational workers rather than attempting to crosswalk them to population-level data as we did in the GBD 2010. The GBD 2010 coal workers pneumoconiosis model estimated that data among coal workers was 22 times higher on average than population-level data. In the GBD 2013, however, we thought that correction to be implausibly low, thereby overestimating prevalence of this condition in countries where those data were present and in countries affected by those data. The GBD 2010 silicosis model estimated that data among miners was more than 400,000 times higher than population-level data. This could be plausible in some countries but is difficult to validate.

Second, in the GBD 2010 model, we did not use any country-level covariates; however, in the GBD 2013, we included the log of the age-standardised cause-specific death rate (ASDR) obtained from CODEm output as a country-level covariate on the prevalence of these diseases. ASDR was able to inform geographical variation in areas with little or no data.

Finally, in the GBD 2013, we imposed narrow bounds on the coefficient on sex to inform the split of aggregated data into sex-specific data points in an attempt to better capture the difference across sex. We estimated the male-to-female ratios from country-years of inpatient data and the ratios are shown in Appendix Table 19 below, alongside the sex ratios observed in cause of death results for comparison. The difference in male-to-female ratios between prevalence and mortality suggest at this aggregate level that mortality rates among males are higher than that among females for asbestosis, coal workers pneumoconiosis, and silicosis, and the opposite is suggested for other pneumoconiosis.

	Prevalence	Mortality
Asbestosis	5.5	7.1
Coal workers pneumoconiosis	3.3	8.5
Silicosis	8.2	13.0
Other pneumoconiosis	1.8	0.7

32. Interstitial lung disease and pulmonary sarcoidosis

YLD estimates for interstitial lung disease and pulmonary sarcoidosis increased by 53% (from 162,415 to 75,012 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

In the GBD 2010, the DisMod-MR tool used did not allow specification of individual parameters for country covariates so we applied the natural logarithm of the age-standardised death rate (LnASDR) for this cause to all epidemiological parameters. However, the updated DisMod-MR 2.0 tool used in the GBD 2013 allowed us to apply the LnASDR for this cause only to incidence as a country-level covariate to inform variation over space and time. Also in the GBD 2013, we included the estimated excess mortality rates obtained from an analysis of chronic obstructive pulmonary disease among countries with reliable prevalence and cause-specific mortality rate data to inform this model under the assumption that excess mortality rates are similar for the two causes. Finally, we included more data points of inpatient hospital data. Doing so caused the data adjustments to be slightly smaller for studies that reported only sarcoidosis cases, only idiopathic pulmonary fibrosis, or only both. GBD regions with the most drastic changes in prevalence in the GBD 2013, such as the South Asia region, lack data and were dependent on the country covariate on incidence and inclusion of excess mortality estimates from chronic obstructive pulmonary disease to better inform the disease compartmental model.

33. Peptic ulcer disease

YLD estimates for peptic ulcer disease (PUD) increased by 309% (from 311,428 to 1,244,936 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

Prevalence estimates for symptomatic peptic ulcer disease episodes increased by 105% (from 1.4 million to 2.8 million cases) from the GBD 2010 to the GBD 2013. In GBD 2013, we added data of symptomatic cases of PUD from surveys as well as outpatient and inpatient data; these surveys have much higher estimates than outpatient and inpatient data and used Norwegian data to adjust outpatient estimates for multiple visits of each patient. This led to the two-fold increase of the estimates of peptic ulcer episodes. However, the largest change in terms of YLD has come from the attribution of anemia to peptic ulcer disease. The higher estimate of peptic ulcer disease incidence has contributed to a higher fraction of anemia being attributed to this cause but another important reason is that the strategy changed to use incidence of underlying causes for anemia rather than prevalence to determine the fraction of total anemia by cause. As the duration for peptic ulcer disease is short relative to many other causes of anemia this would lead to a greater attribution.

34. Gastritis and duodenitis

YLD estimates for gastritis and duodenitis increased by 182% (from 855,406 to 2,340,849 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

Prevalence of episodes of gastritis and duodenitis increased marginally by 5.8% compared to the GBD 2010. In the GBD 2013, we used outpatient and inpatient data; for outpatient visits, we adjusted the number of cases based on Norway on multiple visits of each patient. The global results were close to the GBD 2010.

Additionally, the increase in YLDs for gastritis and duodenitis in the GBD 2013 can be attributed to a large increase in anemia due to a change in strategy to use incidence of underlying causes for anemia rather than prevalence (as we did in the GBD 2010) to determine the fraction of total anemia by cause. As the duration for gastritis and duodenitis is short relative to many other causes of anemia this led to a greater attribution.

35. Paralytic ileus and intestinal obstruction

YLD estimates for paralytic ileus and intestinal obstruction increased by 184% (from 12,586 to 32,506 YLDs) from the GBD 2010 to the GBD 2013 due to changes to covariates. This change is significant.

In the GBD 2013, we did not use *Health System Access* as a covariate.

In the previous version of DisMod-MR used in the GBD 2010, a very large negative coefficient (around -4) was estimated for health system access to model as a study level covariate. This led to significant, implausible, downward adjustment of incidence data from high income countries.

36. Inguinal, femoral, and abdominal hernia

YLD estimates for inguinal, femoral, and abdominal hernia decreased by 43% (from 441,373 to 252,738 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

In the GBD 2013, we scaled remission rates to reflect different waiting times for surgery by the health system access covariate. These changes increased the duration of the disease and therefore, also the prevalence calculated from incidence in low income countries and shortened the duration in high income countries compared to the GBD 2010 model. The net effect is that the lower prevalence in high and middle income countries was greater than the increase in low income countries and hence a lower prevalence in the GBD 2013. However, with wide uncertainty around these estimates this is not a significant change.

37. Gallbladder and biliary diseases

YLD estimates for gallbladder and biliary diseases increased by 34% (from 453,589 to 604,460 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

In the GBD 2013, we used more points of prevalence data from surveys on the prevalence of gallbladder and biliary diseases and outpatient data. We crosswalked the survey data to the outpatient data to have a more realistic estimate of symptomatic cases. These changes prompted an increase in the prevalence estimates in the GBD 2013 as compared to the GBD 2010.

38. Pancreatitis

YLD estimates for pancreatitis increased by 180% (from 206,140 to 570,179 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

In the GBD 2010, we ran models separately for men and women; however, in the GBD 2013, we did not run different models for each sex as DisMod-MR 2.0, the updated tool used in the GBD 2013 could better detect different patterns of age distribution for male and female than previous version of DisMod-MR used in the GBD 2010. This led to a sex distribution which is more compatible with input data. In the GBD 2010, we used *Health System Access* as a covariate and did not use a covariate to differentiate acute and chronic pancreatitis. *Health System Access* had a positive fixed effect on incidence and pushed the estimates to unrealistically low estimates in countries with low health system access. So, we did not use it in the recent round. Additionally, we used a study-level covariate, “acute vs. chronic,” to differentiate acute and chronic pancreatitis. As a result, these changes led to higher estimates of prevalence for pancreatitis in the GBD 2013.

39. Multiple sclerosis

YLD estimates for multiple sclerosis increased by 34% (from 525,528 to 703,495 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

We used significantly more data points (1,453 versus 968) in the GBD 2013 than in the GBD 2010. DisMod-MR 2.0 estimated a non-significant coefficient on the covariate for case ascertainment method (marking studies that did not have a confirmation of diagnosis by a physician or neurologist) while in the GBD 2010 those data points were adjusted downwards by 40%. A different value on the covariate for latitude contributed further to the 20% increase in prevalence estimates for the year 2010 between the two studies. A further contribution to higher YLD estimates was a change in strategy in determining severity distributions. In the GBD 2010 a separate meta-analysis was carried out for high income and low and middle income countries. As the confidence intervals for the proportions mild, moderate and severe were largely overlapping we decided to use globally pooled estimates for GBD 2013.

40. Idiopathic intellectual disability

YLD estimates for idiopathic intellectual disability increased by 348% (from 1,042,801 to 4,601,807 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

We increased data points from the GBD 2010 to the GBD 2013 (from 176 to 284) with better geographic coverage (from 25 to 30 countries). Relative risk was the main parameter that informed the mortality pattern for different age-groups in both GBD 2010 and GBD 2013. However, DisMod-MR estimates of relative risk in the GBD 2010 showed a plateau over a broad age range from 20 to 60 with values around 10 while the raw data had a peak of 10 at around age 20 and then sharply declined with age to close to one by age 60. The high relative risk values until age 60 resulted in a sharp decline of prevalence with virtually no cases left by age 60 and low prevalence overall. In the GBD 2013, the relative risk estimates followed the data neatly translating into a much higher prevalence at older age-groups and overall that seems more plausible.

41. Alcohol use disorders

YLD estimates for alcohol use disorders decreased by 45% (from 13,838,202 to 7,549,307 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

Prevalence estimates for alcohol use disorders decreased by 21% (from 96,456,983 to 75,796,379 cases) between the GBD 2010 and the GBD 2013 largely because DisMod-MR 2.0 produced an age pattern with a single peak at ages 20-40 rather than a peak at age 20 and another peak at age 45 as estimated in the GBD 2010 using the previous version of DisMod-MR. YLD estimates for alcohol use disorders decreased by a greater margin (45%) due to the inclusion of a milder health state (very mild alcohol dependence DW=0.123). There were small differences in the DWs for mild (0.235 in the GBD 2013 vs. 0.259 in the GBD 2010), moderate (0.373 vs. 0.388) and severe (0.570 vs. 0.549). Using the same survey data from NESARC and the Australian NSMHWB we get similar proportions asymptomatic (42% in the GBD 2013 vs. 44% in the GBD 2010), a large proportion in very mild (47% vs. not estimated), a much smaller proportion in mild (4% vs. 49%) and small proportions in the moderate (3% vs. 4%) and severe (4% vs. 2%) categories. The net effect is an average DW of 0.102 per prevalent case in the GBD 2013 (before comorbidity correction) as compared to 0.153 in the GBD 2010.

42. Cannabis use disorders

YLD estimates for cannabis use disorders decreased by 81% (from 2,058,989 to 394,871 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

As prevalence estimates for cannabis use disorders did not change significantly (a 4% increase from 13,091,176 to 13,577,895 cases), this decrease in YLDs can be attributed to changes to severity splits and disability weights. In the GBD 2010, we applied only one disability weight of 0.329 (0.233-0.455) to all symptomatic cases of cannabis use disorders. In the GBD 2013, however, we introduced a new “mild” disability weight of 0.039 (0.024-0.06) and then we split symptomatic cases between this mild disability weight and the original GBD 2010 disability weight, summarily renamed “moderate/severe” and updated to 0.266 (0.178-0.364) to reflect existing GBD 2010 data and additional data captured in new surveys conducted in four European countries). Severity splits also changed between the GBD 2010 and the GBD 2013 to accommodate this change. In the GBD 2010, we identified 51% of cases as

asymptomatic and 49% as symptomatic. In the GBD 2013, we identified 58% of cases as asymptomatic and 42% as symptomatic. Thirty-six percent of symptomatic cases were allocated to the mild category with the lower disability weight rather than to the moderate/severe category. These changes resulted in a lower YLD estimate for cannabis use disorders in the GBD 2013.

43. Acute glomerulonephritis

YLD estimates for acute glomerulonephritis increased by 149% (from 785 to 1,900 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

The prevalence increased by 45% but it was not a significant change. The increase is largely due to higher estimates for East and Southeast Asia, regions without any data. The estimates for the high income regions and Latin America for which there are data follow similar pattern as in the GBD 2010. The GBD 2013 estimates used the disability weight for moderate infectious disease (0.051). In the GBD 2010 the seemingly less appropriate disability weight for “generic disease without symptoms and worry” was used (0.029).

44. Chronic kidney disease

Chronic kidney disease due to diabetes mellitus

Chronic kidney disease due to hypertension

YLD estimates for chronic kidney disease increased from the GBD 2010 to the GBD 2013. Specifically, YLD estimates for chronic kidney disease due to diabetes mellitus increased by 121% (from 1,003,995 to 2,204,733 YLDs) and YLD estimates for chronic kidney disease due to hypertension increased by 185% (from 872,594 to 2,468,691 YLDs). These changes are significant.

Several factors contribute to the large increase in YLD for chronic kidney disease due to diabetes, hypertension and other causes (the latter in GBD2013 was split into an explicit category for glomerulonephritis and a smaller rest category of other chronic kidney disease). First, we used the log of the age-standardised mortality rate as a covariate in the model for CKD stages III, IV and V. This led to much greater differentials in disease occurrence than was estimated before where all regions closely followed the estimates for high income regions for which the vast majority of data were available. Second, in GBD2010, anemia was estimated for chronic kidney disease stage III only, assuming that the disability weights for stage IV and V incorporated the symptoms associated with anemia. In GBD2013 we made explicit estimates of anemia for stage IV. Third, we assumed a longer duration for survival (96-24 months) based on a systematic review of survival of stage V patients who do not receive dialysis or transplant (ref O'Connor J of Palliative Medicine 2011, 5:228). As these patients get a high disability weight for a longer duration this has caused quite an increase in YLDs.

45. Interstitial nephritis and urinary tract infections

YLD estimates for interstitial nephritis and urinary tract infections decreased by 73% (from 206,876 to 55,106 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

In the GBD 2013, we got access to Norway outpatient data to inform the data adjustment for inpatient hospital data to outpatient levels in addition to the data from the USA only used in the GBD 2010. Norway outpatient levels are much lower than USA rates resulting in a smaller upward data adjustment of hospital admission numbers than was used in the GBD 2010.

46. Benign prostatic hyperplasia

YLD estimates for benign prostatic hyperplasia decreased by 38% (from 5,094,065 to 3,156,254 YLDs) from the GBD 2010 to the GBD 2013 due to the addition of new data points. This change is not significant.

In the GBD 2010, estimates of benign prostatic hyperplasia relied on 184 survey data points from 21 countries; whereas in the GBD 2013, we added a substantial amount of hospital data from 68 sites (28 countries), bringing the total data points to 6828 from 78 sites (37 countries). We used study level covariates on inpatient and outpatient data to crosswalk between survey data. The increased number and improved geographic coverage of data points allowed

DisMod-MR 2.0 to account for wider and more accurate regional variations and resulted in lower prevalence estimates for regions which lacked data points in the GBD 2010.

47. Uterine fibroids

YLD estimates for uterine fibroids decreased by 31% (from 3,034,792 to 2,084,102 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

We added nine prevalence data points to this sparse data set that contained 26 incidence and 21 prevalence data points in the GBD 2010. The drop in prevalence estimates by 38% is partially due to lower prevalence of the new studies and partially due to differences in the covariate values estimated in DisMod-MR 2.0. Despite the scarcity of data four covariates had to be used to deal with variations in case definition and coefficient values varied between 2010 and 2013. YLDs dropped by a lesser proportion, 31%, due to a greater attribution of anemia envelope to fibroids.

48. Polycystic ovarian syndrome

YLD estimates for polycystic ovarian syndrome (PCOS) decreased by 59% (from 2,757,156 to 1,150,789 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

While prevalence estimates for PCOS decreased minimally (by 6%) between the GBD 2010 and the GBD 2013, YLD estimates decreased by a greater margin due to decreased disability weights for mild disfigurement (from 0.013 to 0.011) due to hirsutism and primary infertility (from 0.011 to 0.008).

49. Endometriosis

YLD estimates for endometriosis increased by 147% (from 555,576 to 1,334,574 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

The GBD 2010 data set contained just 28 data points for endometriosis. We added an additional 39 data points from the GBD 2013 systematic review. The coefficient for incidence data points without pathology confirmation decreased from 0.94 to 0.53 (in log space) and therefore these data points were adjusted upwards by a lesser amount. This resulted in a decrease in prevalence of 23%.

50. Genital prolapse

YLD estimates for genital prolapse decreased by 39% (from 1,809,270 to 1,045,092 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

Prevalence estimates for genital prolapse increased marginally by 4% between the GBD 2010 and GBD 2013. YLDs decreased by 39% as the new disability weight for stress incontinence (estimated to be present in 12.1% of cases) has lower value (0.02 vs. 0.142) than that for urinary incontinence that was used as a placeholder in the GBD 2010.

51. Hemoglobinopathies and hemolytic anemias

G6PD deficiency

YLD estimates for G6PD deficiency decreased by 76% (from 146,531 to 34,601 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

The modelling strategy for non-fatal health burden due to hemoglobinopathies was consistent from GBD 2010 to GBD 2013. Hemoglobinopathies are divided into four main causes: thalassemias, sickle cell disorders, glucose-6-phosphate dehydrogenase (G6PD) deficiency, and other hemoglobinopathies and hemolytic anemias. We modeled sub-types of each hemoglobinopathy separately. We estimated thalassemia burden in three separate models: 1) beta thalassemia major, 2) hemoglobin E-Beta thalassemia disease, and 3) hemoglobin H disease. We likewise estimated sickle cell burden in three separate models: 1) homozygous sickle cell and “severe” sickle cell-Beta thalassemia, 2) “mild” sickle cell-beta thalassemia, and 3) hemoglobin SC disease. We estimated the burden of glucose-6-phosphate dehydrogenase (G6PD) deficiency as a single model. Finally, we attributed a portion of the anemia not-otherwise-specified (NOS) burden, which was calculated in the analysis of the overall morbidity from anemia, to other hemoglobinopathies and hemolytic anemias.

Two important changes have occurred between GBD 2010 and GBD 2013. First, while we estimated anemia-related disability from heterozygotes, we did not report them separately. Second, while we estimated the disability associated with many different acute and chronic complications that can occur to those with hemoglobinopathies, we had not fully implemented a framework to ensure each of the health states is mutually exclusive and collectively exhaustive. As both of these details are, we believe, of great interest to clinicians and policymakers, they have been implemented for GBD 2013. Heterozygote frequencies, including the breakdown of which proportion of each are estimated to be symptomatic from anemia, are now explicitly reported. Those heterozygote states now included are the following: Beta-thalassemia trait, hemoglobin E trait, sickle cell trait, and hemizygous G6PD (a phenomenon to which only females are susceptible). Outcomes of homozygous and compound heterozygous disease states are now mutually exclusive and collectively exhaustive, which will improve the ease with which these figures can be interpreted at the country level.

We used the same specifications for DisMod-MR 2.0 models as we used in the GBD 2010. We constrained both remission and incidence to be zero. Case-fatality data used in models of non-fatal health outcomes again did not include the results of our mortality analysis based on the observation in many settings that all hemoglobinopathy-related mortality is not ascribed to it. With-condition mortality data from primary literature, as in the GBD 2010, thus was a primary informer of estimates of prevalence at older ages. Changes in DisMod-MR 2.0 from GBD 2010 were notable in the case of hemoglobinopathies, specifically in the ability for prevalence to be non-zero at birth. This change resulted in a modest increase in estimated initial number of cases for many of the hemoglobinopathies. The only significantly different result was for the thalassemias, which are known to all have high geographic heterogeneity, were estimated to be lower than previously in central and eastern Europe, a finding that is more in line with the primary data used in the models. To estimate carrier prevalence for thalassemias and sickle cell diseases—hemoglobin S, hemoglobin E, hemoglobin beta, and hemizygous G6PD (females only)—we assumed Hardy-Weinberg equilibrium.

We used the same method as previously to estimate the number of YLDs associated with each of the subtypes of hemoglobinopathies as guided by personal correspondence with Sir David Weatherall, an internationally-recognised hemoglobinopathologist, who completed an extensive literature review and country correspondence for GBD 2010. With the exception of anemia, only homozygous persons were considered to experience disability. The only disabling outcome associated with carrier status is anemia. Likewise, disability estimates for “other hemoglobinopathies and hemolytic anemias” was limited to that associated with anemia. Heart failure is an important non-fatal outcome of thalassemias and G6PD deficiency. To model the number of patients with heart failure attributable to each condition, we first estimated the total number of heart failure cases, then the aetiological fraction of heart failure cases that were due to thalassemias and G6PD deficiency. G6PD deficiency is otherwise considered to be asymptomatic for a vast majority of those with the condition (Class III-V). The only disability estimated, therefore, was that associated with anemia from chronic hemolysis (Class I) and hemolytic crises (Class II). Females heterozygous for G6PD deficiency exhibit chimerism, as one X chromosome becomes dominant in each of the red blood cells. We therefore estimated half as many heterozygous females will be symptomatic as homozygous females. YLDs due to thalassemias were estimated for anemia, heart failure, and infection individually. Six other sequelae—splenomegaly, skeletal deformity, delayed growth/puberty, diabetes, hypothyroidism, and leg ulcers—were combined into a single outcome called “other combined sequelae of thalassemia” as they are significant, but uncommon, with very little data to inform their frequency in populations. This functionally means that we estimate no persons with thalassemia are asymptomatic. Sickle cell-related YLDs were estimated in similar fashion—for anemia, heart failure, pain crises/splenic sequestration, stroke, and “other combined sequelae of sickle cell disorders,” though the proportion in each health state varied by subtype of sickle cell disorder.

52. Endocrine, metabolic, blood, and immune disorders

YLD estimates for endocrine, metabolic, blood, and immune disorders decreased by 32% (from 3,724,891 to 2,520,411 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

In the GBD 2010, endocrine, metabolic, blood and immune disorders included obesity which was no longer included under this sequela in the GBD 2013 as we consider it a risk factor, not a cause of disability per se. This resulted in a 32% decline in YLDs.

53. Osteoarthritis

YLD estimates for osteoarthritis (OA) decreased by 31% (from 17,148,545 to 11,856,790 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

This was caused by a decrease in prevalence due to revisions to incidence age patterns. In the GBD 2010, a zero incidence was assumed for the terminal age-group, which resulted in an age pattern where almost all incidence occurred around the age of 40-50 and then continued to decline till the terminal age-group of 100. This incidence pattern produced a sharp increase in prevalence around the age of 40) and resulted in an overestimation of prevalence at ages 40-60. In the GBD 2013, we assumed incidence has an increasing pattern with age. Although not as prominent a pattern as in knee OA, the hip OA model in the GBD 2010 also had an inconsistent incidence pattern with age that we revised in the GBD 2013. These corrections resulted in lower prevalence of osteoarthritis in the GBD 2013 estimates.

54. Gout

YLD estimates for gout increased by 53% (from 114,104 to 172,307 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

In the GBD 2013, we added new data sources with higher prevalence values (an increase from 607 to 684 data points) and, due to the inclusion of an additional study on the frequency of gout attacks, the proportion of time a patient is considered symptomatic by pooling average duration and number of attacks per year from literature increased from 7.2% to 9.4%.³⁴ These changes led to higher prevalence and YLD estimates for gout in the GBD 2013.

55. Congenital anomalies

Congenital heart anomalies

Cleft lip and cleft palate

Down syndrome

YLD estimates for congenital heart anomalies increased by 96% (from 563,703 to 1,136,663 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

YLD estimates for cleft lip and cleft palate decreased by 75% (from 254,288 to 64,883 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

YLD estimates for Down syndrome increased by 73% (from 627,314 to 1,073,994 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

The cause list for GBD 2013 included neural tube defects, cleft lip and palate, congenital heart disease, Down syndrome, Klinefelter syndrome, Turner syndrome, unbalanced and other chromosomal syndromes, and other congenital anomalies. Turner and Klinefelter syndrome were previously contained within the estimates for other chromosomal syndromes. As in the GBD 2010, we again subdivided congenital heart disease in the GBD 2013 into critical, severe, and less severe groups; we again modeled moderate and severe neural tube defects separately.

We modified several details of this estimation strategy in the GBD 2013, but generally maintained the same principles used in the GBD 2010 analysis. In the GBD 2010, in most cases, we assumed a constant baseline risk of congenital anomalies. In other words, in the absence of external influences, congenital conditions would arise at an identical rate everywhere for each condition. Estimation of birth prevalence for GBD 2010 involved adjusting the presumed constant risk for a number of proximate factors such as legality of abortion, maternal age, probability of stillbirth, and folic acid fortification. The specifics of adjustment were particular for each cause. We applied an additional uniform adjustment factor to those anomalies commonly associated with chromosomal abnormalities—congenital heart disease, neural tube defects, and cleft lip and palate—to exclude them from the non-chromosomal models. We then applied male-to-female ratios at the global level for neural tube defects and cleft lip and palate where sex differences have been consistently described. We then split final live birth prevalence into treated and untreated groups. We assumed treatment availability, and therefore live birth prevalence in each group, tracked with

the neonatal mortality rate (NMR). We converted data that described each condition's natural history as a function of treatment availability to standardised mortality ratios (SMR) based on the origin of each study.³⁵⁻⁴³ We then converted SMR data into excess mortality rates for each country, year, and age-group based on national mortality rates calculated from the GBD 2010 mortality analysis.⁴⁴ We paired these excess mortality rate data with treated and untreated live birth prevalence and modeled each group separately in DisMod-MR. We did not use study-level or country-level covariates in any of the models in the GBD 2010.

Our GBD 2013 estimation strategy involved five methodological updates. First, rather than *a priori* assuming constant risk, we analyzed primary data from all available congenital registries. We were able to identify 1,291 site-years of data from 48 countries and 31 of 33 provinces of China. Data came from the European Surveillance of Congenital Anomalies (EUROCAT), the International Clearinghouse for Birth Defects Monitoring System (ICBDMS), and the National Center of Birth Defects Monitoring of China which is run by the National Office of Maternal and Child Health Surveillance System (MCH). We extracted all data and entered it into a central database.

Second, our estimates focused on calculating live births, without additional quantification of numbers of stillbirths or terminations. We elected this approach largely because there is substantial variation in reported rates of termination, even when controlling for its legality, as well as in reliability of stillbirth reporting. We applied male-to-female ratios to the primary data for neural tube defects and cleft lip and palate and we calculated live birth prevalence for each dataset entry as the number of live births divided by the total number of births in that entry.

Third, we analyzed the primary data to inform the proportion of anomalies associated with chromosomal abnormalities. EUROCAT presents isolated *and* chromosomally-associated anomaly counts, so we extracted both and identified the latter with a binary study-level covariate. We then carefully reviewed underlying documentation of all other sources and likewise identified each datum using the same binary covariate. Study-level covariates function like empirical correction factors, identifying systematic differences between types of data (e.g. different diagnostic criteria or sample populations) to facilitate quantitative cross-walking by DisMod-MR 2.0. We included an additional study-level covariate for all congenital models to identify those data where live births and stillbirths were aggregated in the numerator.

Fourth, we estimated birth prevalence for each condition using DisMod-MR 2.0. We combined the study-covariates above with country-level covariates (from the GBD Covariates Database) that corresponded to proximate factors affecting live birth prevalence. Many were the same as used in the GBD 2010 (e.g. legality of abortion and maternal age), but others were different. For example, instead of folic acid fortification for neural tube defects and cleft lip and palate, our analysis of the compiled primary data suggested the logit-transformed *Percent of total calories consumed as vegetables* covariate was a better predictor of live birth prevalence. Using this approach we were also able to fully integrate the GBD 2013 specific cause-of-death results by including natural log-transformed age-standardised mortality rates as country-level covariates.⁴⁵

Finally, in the GBD 2013, we paired the birth prevalence results above with country, age, sex, and year-specific excess mortality rates to estimate prevalence in all age groups using DisMod-MR 2.0. We utilised the same assumptions about treatment access—including its relationship to national NMR—as were employed in the GBD 2010. As before, we generated excess mortality rate data for each country, age-group, sex and year from pooled SMR data. DisMod-MR 2.0 thus estimated age-specific prevalence as a single model for each condition.

Our approach to calculating the disability associated with each of the congenital conditions was largely unchanged in the GBD 2013. From a UK study, 70% (95% UI 61.6-78.4%) of those with neural tube defects were considered to have severe mobility impairment, often with urinary incontinence, while the remainder was continent and had more moderate mobility impairment.⁴⁶ The disability weight (DW) for moderate motor impairment in the GBD 2013 was 0.061 which is somewhat lower than the GBD 2010 when it was 0.076; for severe motor impairment the GBD 2013 DW was 0.402, a slightly higher value than the 0.377 used in the GBD 2010; the DW for incontinence was relatively unchanged at 0.139.

For congenital heart disease, a UK-based cross-sectional short form (36) functional health survey analyzed cohort physical and mental functional limitations, which we converted to a corresponding DW using the same functional

form as described in our severity analysis.^{47,48} We assumed this DW to be experienced by 100% of those surviving with critical and severe congenital heart disease, and 55% of those with less severe congenital heart defects. We based this latter proportion on observation that nearly 75% of those in this category do not require an operation⁴⁹ and at least 60% of those are asymptomatic.^{50,51} We estimated the subset of those with mild, moderate, or severe heart failure due to congenital heart disease separately as part of the overall GBD 2013 heart failure analysis.

As in the GBD 2010, we assumed disability associated with cleft lip and palate to be dependent on the level of care available in a given country-year. We calculated the proportion of the population in each of three tiers—modern care including surgery and supportive care, basic surgery, and no care—using national NMR in the same way that SMR were interpolated for prevalence models. This led to different proportions between the three tiers compared to the GBD 2010 which used Smiletrain data to estimate access to surgical corrections in a range of low and middle income countries (including China, Pakistan, Bangladesh, Philippines, India, and Ethiopia) and assumed that all surgery in low and middle income countries was ‘basic’. We estimated unoperated clefts to be universally associated with moderate disfigurement and speech problems. The GBD 2013 DW were 0.067 for moderate disfigurement and 0.051 for speech problems, both of which are slightly lower than the GBD 2010 values of 0.072 and 0.054, respectively. As in the GBD 2010, we estimated that 15% of those with access to modern care would have residual disability with two thirds having mild disfigurement, two thirds with speech problems, and the remainder with moderate disfigurement.⁵²⁻⁵⁴ We estimated the proportion with disability to be twice as high in those with access to only basic surgery. We assumed all successfully repaired clefts to have no disability.

We combined the category of other chromosomal syndromes with that of unbalanced chromosomal arrangements (defined by ICD-10 codes Q90-99 except Down, Klinefelter, and Turner syndromes) and renamed it “unbalanced and other chromosomal syndromes”. This is the reason for the increased burden estimates. Like in the GBD 2010, we again estimated disability to be of similar nature in each of Down syndrome and unbalanced and other chromosomal disorders. We estimated disability associated with a combined 95% probability of intellectual disability,⁵⁵ 42% likelihood of congenital heart disease⁵⁶ most of which are severe⁵⁷ and/or warrant early intervention, and early-onset dementia⁵⁸ ranging from 8% in 45-49 year-olds up to 75% in those 55 years and older. We estimated that 100% of adult males with Klinefelter syndrome would be infertile and a subset have borderline or mild intellectual disability in all age groups.⁵⁹ We likewise assumed Turner syndrome to be associated with universal primary infertility in adult females and congenital heart disease in a subset at all ages.⁶⁰ DWs for all tiers of intellectual disability were at least 25% higher in the GBD 2013 than previously. Those for moderate and severe dementia were also somewhat higher, while that for infertility was slightly lower. On aggregate, DW changes conferred a moderate increase in estimated severity of chromosomal syndromes.

56. Psoriasis

YLD estimates for psoriasis increased by 332% (from 1,050,679 to 4,519,006 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

Psoriasis prevalence increased by 184% between the GBD 2010 and the GBD 2013. In the GBD 2013, the psoriasis epidemiological dataset approximately doubled in size from the GBD 2010 as we added data from an additional 30 prevalence studies and 5 incidence studies and these tended to be higher than data points used in the GBD 2010. This was also the case for other regions. Additionally, we modelled psoriasis with a longer duration in the GBD 2013 than in the GBD 2010. A comparison of incidence and prevalence data points (e.g. from the USA and UK) showed between an 8- to 10-fold difference in level of incidence from that of prevalence in the same country, suggesting a more chronic disease pattern, and a long duration. Based on this and consultations with experts, in the GBD 2013 we modelled psoriasis with remission set between 0.05 and 0.15 as opposed to the GBD 2010 remission assumption varying between 1 and 4 which translates to an average duration of less than one year.

YLDs for psoriasis increased by a greater proportion than prevalence as we did not use a proportion of cases without symptoms as was done in the GBD 2010, arguing that most data come from surveys that include examination and therefore picks up cases who are symptomatic only. The disability weights and the severity distribution changed marginally only.

57. Cellulitis

YLD estimates for cellulitis decreased by 68% (from 378,097 to 114,741 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

Cellulitis prevalence decreased by 84% between the GBD 2010 and the GBD 2013. The GBD 2010 dataset included 36 data points from the MEPS dataset, 12 data points from a published survey of cellulitis in a US sample,⁶¹ and 4,590 data points from a combination of both in-patient and out-patient cases. The GBD 2013 literature update expanded considerably on data sources, culminating in a dataset made up of the same MEPS and survey data points but 13,191 data points from in-patient samples or in-patient and out-patient samples. We modelled MEPS data points as prevalence in the GBD 2010 but experts advised that the survey's sampling methodology was more likely to capture estimates equivalent to the incidence of cellulitis, meaning that in the GBD 2013 model we did not use any prevalence data points. In both the GBD 2010 and the GBD 2013, we used a study-level covariate to adjust incidence data points derived from in-patient samples upwards towards data points derived from in-patient and out-patient samples combined which were more representative of the general population. Due to additional data, this covariate had a lower coefficient in the GBD 2010 (-3.1) compared to the GBD 2013 (-2.7) translating into 50% lower crosswalk in the GBD 2013. The average disability weight per case increased from 0.035 to 0.071 as we no longer make an assumption that there is a proportion asymptomatic.

58. Pyoderma

YLD estimates for pyoderma decreased by 98% (from 1,322,170 to 32,759 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

In the GBD 2013, we estimated only a small fraction of the prevalence of impetigo, abscesses and other bacterial skin conditions estimated in the GBD 2010. This large difference was due to a change in assumptions on remission. For impetigo in the GBD 2010, remission was defined as "bound between 1 and 13 treated cases per patient-year (which corresponds to a duration between 4 weeks and 1 year)" allowing DisMod-MR to make estimates close to 1 corresponding to an average duration of almost one year. In the GBD 2013, however, we consulted with experts who agreed that duration should be much shorter: between 2 (treated) to 4 (untreated) weeks. This significant change in duration produced substantially lower prevalence in the GBD 2013 estimates.

59. Fungal skin diseases

YLD estimates for fungal skin diseases increased by 70% (from 2,309,877 to 3,692,288 YLDs) between the GBD 2010 and the GBD 2013. This change is not significant.

Prevalence estimates for fungal skin diseases decreased by 34% from the GBD 2010 to the GBD 2013. In the GBD 2010, we estimated prevalence for all fungal skin diseases combined; however, in the GBD 2013, we estimated prevalence separately for tinea capitis and a combined group of 'any' other fungal skin disease. Although this makes it difficult to directly compare prevalence output between the GBD 2010 and the GBD 2013 for fungal skin diseases, some differences in covariates used may explain the decrease in prevalence. In the GBD 2013, a study-level covariate was included in the "any other fungal skin disease" model to adjust data points derived from MEPS towards the level of other prevalence data points. As MEPS is aimed at collecting data on health expenditure, its sampling strategy is biased towards those seeking health care which only represents part of the distribution of fungal skin diseases in the population. This covariate had a smaller upwards adjustment by a factor 5.6 than the equivalent MEPS covariate used in the GBD 2010 for the all fungal skin diseases model (a factor 8.5). In the GBD 2010 model, also a mean temperature country level covariate was used which had a statistically significant effect on prevalence (1.25, 1.02-1.55) but due to changes in the dataset, this covariate effect was not statistically significant in the GBD 2013. YLDs, however, increased by 70% because in the GBD 2013 we did not take into account a proportion of asymptomatic cases as we did in the GBD 2010, given that data are from surveys with examination of skin problems and therefore, by definition, are symptomatic. This led to an average disability weight per case that was 2.4 times higher than in the GBD 2010 (0.0056 vs 0.0023).

60. Viral skin diseases

YLD estimates for viral skin diseases increased by 42% (from 2,777,357 to 3,869,719 million YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

Viral skin diseases prevalence decreased by 40% between the GBD 2010 and the GBD 2013. We modelled prevalence separately for viral warts and molluscum contagiosum and the majority of the decrease in prevalence between the GBD 2010 and the GBD 2013 can be explained by changes related to molluscum contagiosum. A re-evaluation of the GBD 2010 data points for inclusion in the GBD 2013 showed that the wrong parameter unit had been captured for a number of incidence data points in the GBD 2010 dataset causing them to be ten times higher in the dataset than what was reported in the study.⁶² This artificially inflated the incidence (and therefore prevalence) of molluscum contagiosum in the GBD 2010. In the GBD 2010, a country-level covariate was used which made use of levels of sanitation between countries to improve the predictive power of the model. This covariate had an upward adjustment of 0.32 (0.23-0.43) on incidence. The association between sanitation and the incidence of molluscum contagiosum is not entirely defined and when tested in the GBD 2013 this covariate derived levels and global variations in prevalence that were inconsistent to available data points. As a result, we did not include the covariate in the final GBD 2013 model. YLD estimates for viral skin diseases increased by 42% between the GBD 2010 and the GBD 2013 because we did not take into account a proportion of asymptomatic cases as we did in the GBD 2010, given that data were from surveys with examination of skin problems and therefore, by definition, are symptomatic. This led to an average disability weight per case of 0.031 compared to 0.013 in the GBD 2010.

61. Acne vulgaris

YLD estimates for acne vulgaris increased by 81% (from 4,011,597 to 7,260,747 YLDs) between the GBD 2010 and the GBD 2013. This change is not significant.

Prevalence estimates for acne vulgaris showed little change (an increase of 3%) between the GBD 2010 and the GBD 2013. YLDs increased by 81% between the GBD 2010 and the GBD 2013 because we did not take into account a proportion of asymptomatic cases, given that most data points are from examination surveys and hence finding symptomatic cases. This led to an average disability weight per case of 0.011 compared to 0.006 in the GBD 2010.

62. Alopecia areata

YLD estimates for alopecia areata decreased by 78% (from 1,332,849 to 277,109 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

Prevalence estimates for alopecia areata decreased by 78% (from 38,337,044 to 83,113,737 cases) between the GBD 2010 and the GBD 2013. In contrast to the GBD 2010, in the GBD 2013, we used lower estimates from the outpatient data for the USA.^{63,64} As the largest source of data, this led to a different age pattern and overall level of estimation. YLDs also decreased concomitantly by 78% between the GBD 2010 and the GBD 2013 as the severity distribution and disability weights did not change.

63. Pruritus

YLD estimates for pruritus decreased by 99% (from 2,108,655 to 10,434 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

In the GBD 2013, we estimated just under one million cases of pruritus, a small fraction of the 280 million estimated in the GBD 2010. In the GBD 2010, studies of ‘itch’ were used as prevalence of pruritus and thus included cases of itchy skin and non-skin conditions for which separate estimates are being made. Restricting data to outpatient data from Norway and the USA and a few data points from the literature of people diagnosed with pruritus (i.e. excluding known causes of itch) in general practice produced much lower, but more plausible, prevalence, and therefore, YLD estimates.

64. Urticaria

YLD estimates for urticaria increased by 69% (from 2,586,597 to 4,320,516 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

This change can be attributed to our decision not to include a proportion asymptomatic in the GBD 2013 as we did in the GBD 2010, given that most data points were from examination surveys and hence finding symptomatic cases. This led to an average disability weight per case of 0.059 compared to 0.031 in the GBD 2010.

65. Decubitus ulcer

YLD estimates for decubitus ulcer decreased by 48% (from 479,638 to 246,583 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

Prevalence estimates for decubitus ulcer decreased by 61% between the GBD 2010 and the GBD 2013, largely due to a change in the remission assumption. In the GBD 2010, bounds on remission were set between 0 and 12. The estimates of remission were quite a bit smaller than one, particularly at older ages which led to implausible implied durations ranging from 1 to almost 20 years. This meant that we overestimated the prevalence estimated from the incidence data points. In the GBD 2013, however, we set bounds on remission (0.5 to 6) but estimates were between 4 and 5, corresponding to more realistic duration of around 3 months. YLDs decreased by a smaller proportion than prevalence as the average disability weight per case across three levels of severity increased from 0.108 to 0.146.

66. Cataract

YLD estimates for cataract decreased by 43% (from 4,737,827 to 2,747,365 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

For details regarding cataract modelling changes, please refer to the description of methods for calculating the burden of vision impairment on page 21.

67. Macular degeneration

YLD estimates for macular degeneration decreased by 52% (from 1,331,841 to 647,065 YLDs) from the GBD 2010 to the GBD 2013. This change is significant.

For details regarding macular degeneration modelling changes, please refer to the description of methods for calculating the burden of vision impairment on page 21.

68. Periodontal diseases

YLD estimates for periodontal diseases decreased by 43% (from 5,412,999 to 3,060,236 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

In the GBD 2013, severe chronic periodontitis (SCP) was also estimated using the same framework as the GBD 2010.⁶⁵ We included three definitions of SCP commonly found in the updated systematic literature review: 1) Community Periodontal Index of Treatment Needs (CPITN) - Class 4 only, 2) Clinical Attachment Loss (AL) > 6mm, and 3) Gingival Pocket Depth (PD) > 5mm. If more than one type of data was included in a study, our first preference was AL followed by PD, with CPITN considered the least accurate representation of the GBD case definition. The purpose of taking this approach rather than crosswalking the data in DisMod-MR 2.0 is that the relationships between the three values are not constant with respect to age and potentially vary by gender. Indeed, the age variability is likely part of the reason that multiple definition of SCP have been developed. Naturally, all the input data for SCP and permanent caries excludes those in the population that have already lost all their teeth. So, while 100% of those with periodontal disease are symptomatic, the parent model needs to have the denominator reduced because the input data already excludes those that are edentulous. In the GBD 2010, we only had the capability of subtracting the edentulism rate for each super-region (average for 1990 and 2010) from the predicted prevalence of SCP, but for this analysis have corrected for edentulism in each country, age-group, sex, and year independently. The net result of this is a drop in prevalence by 37%. The slightly higher drop in YLDs is due to a small change downwards in the value of the disability weight from 0.008 to 0.007.

69. Edentulism and severe tooth loss

YLD estimates for edentulism and severe tooth loss increased by 39% (from 4,668,474 to 6,429,342 YLDs) from the GBD 2010 to the GBD 2013. This change is not significant.

Prevalence of edentulism and severe tooth loss increased by 49%. Quantitatively, most changes in the levels and trends of edentulism can be traced back to two small changes in the estimation strategy. First, we eliminated the country-covariate for year. The effect of this covariate is to project the same temporal pattern—*increase or decrease*—to every location. However, with the addition of additional prevalence data, there emerged some geographic heterogeneity in time trends so we eliminated the covariate. While DisMod-MR 2.0 still did predict time

trends, these trends were limited to a subset of locations where it is supported by data. Second, after further review we elected to exclude the only prevalence data available from >65 year olds in sub-Saharan Africa. In addition to having lower prevalence than any other study in this age group by nearly an order of magnitude, this lone study was strongly influencing model predictions. As a result of this exclusion, edentulism prevalence estimates for sub-Saharan Africa are still among the lowest in the world, but are nearly twice the GBD 2010 estimate. Symptomatic toothlessness leads to “great difficulty in eating meat, fruits, and vegetables”. As in the GBD 2010, the global proportion of those with symptoms was determined via pooled analysis and estimated to be 0.444 (0.438 – 0.451).⁶⁶⁻⁶⁸

Supplemental Appendix Materials and Detailed Results for Non-fatal Health Outcomes

- Appendix Table A.1 – GBD 2013 cause and sequelae list
- Appendix Table A.2 – List of International Classification of Diseases codes mapped to the Global Burden of Disease cause list for causes of disability
- Appendix Table A.3 – Citation list by country
- Appendix Table A.4 – Model type and fit metrics: R-squared
- Appendix Table A.5 – ICD 9-CM mapped to MEPS data by GBD 2013 cause list
- Appendix Table A.6 – Disability weight lay descriptions
- Appendix Table A.7 – Sequelae severity distribution descriptions
- Appendix Figure B.1 – GBD 2010 DisMod 1.0 Cascade
- Appendix Figure B.2 – GBD 2013 DisMod-MR 2.0 Cascade
- Appendix Table B.1 – DisMod-MR 2.0 statistical output by cause
- Appendix Table G.1 – Sequelae-level prevalence results
- Appendix Table G.2 – Sequelae-level YLDs results
- Appendix Table G.3 – Age-specific global results – YLDs and prevalence (cause-level)
- Appendix Table G.4 – Country-specific, all age results – YLDs and prevalence (cause-level)

References

- 1 Salomon JA, Vos T, Hogan DR, *et al.* Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. *Lancet* 2012; **380**: 2129–43.
- 2 Vos T, Flaxman AD, Naghavi M, *et al.* Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *The Lancet* 2012; **380**: 2163–96.
- 3 National Cancer Institute (United States). United States - SEER Cancer Statistics Review (CSR) 1975-2011. Bethesda, United States: National Cancer Institute, 2014 <http://ghdx.healthdata.org/record/united-states-seer-cancer-statistics-review-csr-1975-2011> (accessed Nov 19, 2014).
- 4 Sankaranarayanan R, Swaminathan R, Lucas E. Cancer survival in Africa, Asia, the Caribbean and Central America (SurvCan). Lyon, France: International Agency for Research on Cancer: IARC Scientific Publication, 2011.
- 5 Neal RD, Din NU, Hamilton W, *et al.* Comparison of cancer diagnostic intervals before and after implementation of NICE guidelines: analysis of data from the UK General Practice Research Database. *Br J Cancer* 2014; **110**: 584–92.
- 6 Allgar VL, Neal RD. Delays in the diagnosis of six cancers: analysis of data from the National Survey of NHS Patients: Cancer. *Br J Cancer* 2005; **92**: 1959–70.
- 7 Neal RD, Cannings-John R, Hood K, *et al.* Excision of malignant melanomas in North Wales: effect of location and surgeon on time to diagnosis and quality of excision. *Fam Pract* 2008; **25**: 221–7.
- 8 Nolan RC, Chan MT-L, Heenan PJ. A clinicopathologic review of lethal nonmelanoma skin cancers in Western Australia. *J Am Acad Dermatol* 2005; **52**: 101–8.
- 9 Kewalramani T, Nimer SD, Zelenetz AD, *et al.* Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. *Bone Marrow Transplant* 2003; **32**: 673–9.
- 10 Haagsma JA, van Beeck EF, Toet H, Polinder S. Posttraumatic Stress Disorder Following Injury: Trajectories and Impact on Health-Related Quality of Life. *J Depress Anxiety* 2013; **S 4**: 2167–1044.
- 11 Polinder S, van Beeck EF, Essink-Bot ML, *et al.* Functional outcome at 2.5, 5, 9, and 24 months after injury in the Netherlands. *J Trauma* 2007; **62**: 133–41.
- 12 Haagsma JA, Noordhout C, Polinder S, *et al.* The European disability weights study: assessing disability weights based on the responses of 30,660 people from four European countries. *Popul Health Metr* 2014; published online Forthcoming.
- 13 Marino RJ, Ditunno JF, Donovan WH, Maynard F. Neurologic recovery after traumatic spinal cord injury: data from the Model Spinal Cord Injury Systems. *Arch Phys Med Rehabil* 1999; **80**: 1391–6.
- 14 Kassebaum NJ, Jasrasaria R, Naghavi M, *et al.* A systematic analysis of global anemia burden from 1990 to 2010. *Blood* 2014; **123**: 615–24.
- 15 Centers for Disease Control and Prevention (CDC). Iron deficiency--United States, 1999-2000. *MMWR Morb Mortal Wkly Rep* 2002; **51**: 897–9.
- 16 Looker AC, Dallman PR, Carroll MD, Gunter EW, Johnson CL. Prevalence of iron deficiency in the united states. *JAMA* 1997; **277**: 973–6.

- 17 Bishop YM, Fienberg SE, Holland PW. Discrete Multivariate Analysis - Theory and Practice. Springer, 2007 <http://www.springer.com/mathematics/probability/book/978-0-387-72805-6> (accessed Nov 24, 2014).
- 18 Pearson K. Mathematical Contributions to the Theory of Evolution. VII. On the Correlation of Characters not Quantitatively Measurable. *Philos Trans R Soc Lond Ser Contain Pap Math Phys Character* 1900; **195**: 1–405.
- 19 Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology and Prognosis, International League Against Epilepsy. *Epilepsia* 1993; **34**: 592–6.
- 20 Molvaer OI, Vårdal L, Gundersen T, Halmrast T. Hearing acuity in a Norwegian standard population. *Scand Audiol* 1983; **12**: 229–36.
- 21 Sabino EC, Ribeiro AL, Salemi VMC, *et al*. Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors. *Circulation* 2013; **127**: 1105–15.
- 22 WHO | WHO Mortality Database. WHO. 2014; published online Nov 24. http://www.who.int/healthinfo/mortality_data/en/ (accessed Nov 24, 2014).
- 23 Classes of Heart Failure. Am. Heart Assoc. 2014; published online Sept 29. http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-Heart-Failure_UCM_306328_Article.jsp.
- 24 Weström L, Joesoef R, Reynolds G, Hagdu A, Thompson SE. Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. *Sex Transm Dis* 1992; **19**: 185–92.
- 25 Murray CJL, Ortblad KF, Guinovart C, *et al*. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2014; **384**: 1005–70.
- 26 Fria TJ, Cantekin EI, Eichler JA. Hearing acuity of children with otitis media with effusion. *Arch Otolaryngol Chic Ill 1960* 1985; **111**: 10–6.
- 27 Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis* 2010; **10**: 317–28.
- 28 Bhatt S, Gething PW, Brady OJ, *et al*. The global distribution and burden of dengue. *Nature* 2013; **496**: 504–7.
- 29 Johansson MA, Vasconcelos PFC, Staples JE. The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases. *Trans R Soc Trop Med Hyg* 2014; **108**: 482–7.
- 30 Ribeiro ALP, Marcolino MS, Prineas RJ, Lima-Costa MF. Electrocardiographic abnormalities in elderly Chagas disease patients: 10-year follow-up of the Bambui Cohort Study of Aging. *J Am Heart Assoc* 2014; **3**: e000632.
- 31 El-Kamary SS, Jhaveri R, Shardell MD. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. *Clin Infect Dis Off Publ Infect Dis Soc Am* 2011; **53**: 150–7.
- 32 Lallukka T, Manderbacka K, Keskimäki I, *et al*. Angina pectoris: relation of epidemiological survey to registry data. *Eur J Cardiovasc Prev Rehabil Off J Eur Soc Cardiol Work Groups Epidemiol Prev Card Rehabil Exerc Physiol* 2011; **18**: 621–6.
- 33 Ministry of Health (Mexico). Mexico Ministry of Health Hospital Discharges 2013. Mexico City, Mexico: Ministry of Health (Mexico), 2014.

- 34 Edwards NL, Sundy JS, Forsythe A, Blume S, Pan F, Becker MA. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. *J Med Econ* 2011; **14**: 10–5.
- 35 Acharya SR, Rao S. A study of antimuscarinic agents on skeletal muscle of frog. *J Postgrad Med* 1977; **23**: 168–71.
- 36 Bleker J. [Chemiatic ideas and analogic thinking in Leonhart Thurneisser's urine diagnosis (1971 and 1976)]. *Sudhoffs Arch* 1976; **60**: 66–75.
- 37 Fork FT. [Double-blind study of a new gallbladder contrast medium]. *Läkartidningen* 1977; **74**: 915–7.
- 38 Grechikhin EI, Mel'nikov VS. [Experience in decreasing industrial Injuries in Tula enterprises]. *Zdr Ross Fed Minist Zdr RSFSR* 1978; **6**: 27–9.
- 39 Hundahl S. Acupuncture and Osler. *JAMA* 1978; **240**: 737.
- 40 Marković M. [The value of human-genetic studies for the evaluation of the etiology of malocclusions and bite irregularities]. *Zahn Mund Kieferheilkd Zentralbl* 1977; **66**: 28–37.
- 41 Savinov VA. [Experience in organizing specialized help for bronchial asthma patients in a district hospital]. *Zdr Ross Fed Minist Zdr RSFSR* 1978; **7**: 35–7.
- 42 Schuster E. [Epidemiology of alcohol abuse]. *Öffentliche Gesundheitswesen* 1977; **39**: 2–11.
- 43 Woodward W, Rainer U. [Appointment correspondence of Rudolph Hermann Lotze to Rudolph Wagner (13 letters: 1 December 1842-11 April 1844)]. *Sudhoffs Arch* 1975; **59**: 356–86.
- 44 Wang H, Dwyer-Lindgren L, Lofgren KT, *et al.* Age-specific and sex-specific mortality in 187 countries, 1970–2010: a systematic analysis for the Global Burden of Disease Study 2010. *The Lancet* 2012; **380**: 2071–94.
- 45 Wang H, Liddell CA, Coates MM, *et al.* Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *The Lancet* 2014; **384**: 957–79.
- 46 Hunt GM, Oakeshott P. Outcome in people with open spina bifida at age 35: prospective community based cohort study. *BMJ* 2003; **326**: 1365–6.
- 47 Burstein R, Flemming T, Salomon J, Haagsma J, Vos T, Murray C. Estimating Distributions of Health State Severity for the Global Burden of Disease Study. *Popul Health Metr* 2014; published online Forthcoming.
- 48 Lane DA, Lip GYH, Millane TA. Quality of life in adults with congenital heart disease. *Heart* 2002; **88**: 71–5.
- 49 Wren C, O'Sullivan J. Survival with congenital heart disease and need for follow up in adult life. *Heart* 2001; **85**: 438–43.
- 50 Gabriel HM, Heger M, Innerhofer P, *et al.* Long-term outcome of patients with ventricular septal defect considered not to require surgical closure during childhood. *J Am Coll Cardiol* 2002; **39**: 1066–71.
- 51 Neumayer U, Stone S, Somerville J. Small ventricular septal defects in adults. *Eur Heart J* 1998; **19**: 1573–82.
- 52 Bearn D, Mildinhal S, Murphy T, *et al.* Cleft lip and palate care in the United Kingdom--the Clinical Standards Advisory Group (CSAG) Study. Part 4: outcome comparisons, training, and conclusions. *Cleft Palate-Craniofacial J Off Publ Am Cleft Palate-Craniofacial Assoc* 2001; **38**: 38–43.

- 53 Sell D, Grunwell P, Mildinhall S, *et al.* Cleft lip and palate care in the United Kingdom--the Clinical Standards Advisory Group (CSAG) Study. Part 3: speech outcomes. *Cleft Palate-Craniofacial J Off Publ Am Cleft Palate-Craniofacial Assoc* 2001; **38**: 30–7.
- 54 Williams AC, Beam D, Mildinhall S, *et al.* Cleft lip and palate care in the United Kingdom--the Clinical Standards Advisory Group (CSAG) Study. Part 2: dentofacial outcomes and patient satisfaction. *Cleft Palate-Craniofacial J Off Publ Am Cleft Palate-Craniofacial Assoc* 2001; **38**: 24–9.
- 55 Epstein C. Down syndrome (trisomy 21). In: In Sciver Cr, Beaudet Al, Sly WS, Valle D. (Eds). *The metabolic basis of inherited disease*. McGraw-Hill Inc, New York, 1995.
- 56 Baird PA, Sadovnick AD. Life expectancy in Down syndrome. *J Pediatr* 1987; **110**: 849–54.
- 57 Freeman SB, Taft LF, Dooley KJ, *et al.* Population-based study of congenital heart defects in Down syndrome. *Am J Med Genet* 1998; **80**: 213–7.
- 58 Henderson A, Lynch SA, Wilkinson S, Hunter M. Adults with Down's syndrome: the prevalence of complications and health care in the community. *Br J Gen Pract* 2007; **57**: 50–5.
- 59 Boada R, Janusz J, Hutaff-Lee C, Tartaglia N. The cognitive phenotype in Klinefelter syndrome: A review of the literature including genetic and hormonal factors. *Dev Disabil Res Rev* 2009; **15**: 284–94.
- 60 Mazzanti L, Cacciari E. Congenital heart disease in patients with Turner's syndrome. Italian Study Group for Turner Syndrome (ISGTS). *J Pediatr* 1998; **133**: 688–92.
- 61 Ellis Simonsen SM, van Orman ER, Hatch BE, *et al.* Cellulitis incidence in a defined population. *Epidemiol Infect* 2006; **134**: 293–9.
- 62 Koning S, Bruijnzeels MA, van Suijlekom-Smit LW, van der Wouden JC. Molluscum contagiosum in Dutch general practice. *Br J Gen Pract J R Coll Gen Pract* 1994; **44**: 417–9.
- 63 National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), SRA International, Inc., US Census Bureau. United States National Ambulatory Medical Care Survey 2010. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).
- 64 National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), SRA International, Inc., US Census Bureau. United States National Hospital Ambulatory Medical Care Survey 2010. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).
- 65 Kassebaum NJ, Bernabé E, Dahiya M, Bhandari B, Murray CJL, Marcenes W. Global Burden of Severe Periodontitis in 1990-2010: A Systematic Review and Meta-regression. *J Dent Res* 2014; **93**: 1045–53.
- 66 Bradbury J, Thomason JM, Jepson NJA, *et al.* Perceived Chewing Ability and Intake of Fruit and Vegetables. *J Dent Res* 2008; **87**: 720–5.
- 67 Sheiham A, Steele J. Does the condition of the mouth and teeth affect the ability to eat certain foods, nutrient and dietary intake and nutritional status amongst older people? *Public Health Nutr* 2001; **4**: 797–803.
- 68 Tsakos G, Herrick K, Sheiham A, Watt RG. Edentulism and fruit and vegetable intake in low-income adults. *J Dent Res* 2010; **89**: 462–7.

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Communicable, maternal, neonatal, and nutritional diseases	1
HIV/AIDS and tuberculosis	2
Tuberculosis	3
HIV/AIDS	3
HIV/AIDS resulting in mycobacterial infection	4
HIV/AIDS resulting in other diseases	4
Early HIV	5
Symptomatic HIV	5
AIDS with antiretroviral treatment	5
AIDS without antiretroviral treatment	5
Diarrhea, lower respiratory, and other common infectious diseases	2
Diarrheal diseases	3
Mild diarrheal diseases	4
Moderate diarrheal diseases	4
Severe diarrheal diseases	4
Guillain-Barré syndrome due to diarrheal diseases	4
Intestinal infectious diseases	3
Typhoid fever	4
Acute typhoid infection	5
Severe typhoid fever	5
Intestinal perforation due to typhoid	5
Gastrointestinal bleeding due to typhoid	5
Paratyphoid fever	4
Acute paratyphoid infection	5
Moderate paratyphoid fever	5
Severe paratyphoid fever	5
Intestinal perforation due to paratyphoid	5
Other intestinal infectious diseases	4
Lower respiratory infections	3
Moderate lower respiratory infections	4
Severe lower respiratory infections	4
Guillain-Barré syndrome due to lower respiratory infections	4
Upper respiratory infections	3
Mild upper respiratory infections	4
Moderate upper respiratory infections	4
Guillain-Barré syndrome due to upper respiratory infections	4
Otitis media	3
Acute otitis media	4
Severe infectious complications due to chronic otitis media	4
Vertigo with mild hearing loss due to chronic otitis media	4
Vertigo with mild hearing loss and ringing due to chronic otitis media	4
Mild hearing loss due to chronic otitis media	4
Mild hearing loss with ringing due to chronic otitis media	4
Vertigo with moderate hearing loss due to chronic otitis media	4
Vertigo with moderate hearing loss and ringing due to chronic otitis media	4
Moderate hearing loss due to chronic otitis media	4
Moderate hearing loss with ringing due to chronic otitis media	4
Meningitis	3
Pneumococcal meningitis	4
Acute pneumococcal meningitis	5
Mild behavioral problems due to pneumococcal meningitis	5
Mild motor impairment due to long term due to pneumococcal meningitis	5
Mild motor plus cognitive impairments due to pneumococcal meningitis	5

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Borderline intellectual disability due to pneumococcal meningitis	5
Monocular distance vision loss due to pneumococcal meningitis	5
Mild intellectual disability due to pneumococcal meningitis	5
Moderate motor impairment due to pneumococcal meningitis	5
Severe motor impairment due to pneumococcal meningitis	5
Moderate motor plus cognitive impairments due to pneumococcal meningitis	5
Severe motor plus cognitive impairments due to pneumococcal meningitis	5
Epilepsy due to pneumococcal meningitis	5
Blindness due to pneumococcal meningitis	5
Mild hearing loss due to pneumococcal meningitis	5
Mild hearing loss with ringing due to pneumococcal meningitis	5
Moderate hearing loss due to pneumococcal meningitis	5
Moderate hearing loss with ringing due to pneumococcal meningitis	5
Moderately severe hearing loss due to pneumococcal meningitis	5
Moderately severe hearing loss with ringing due to pneumococcal meningitis	5
Severe hearing loss due to pneumococcal meningitis	5
Severe hearing loss with ringing due to pneumococcal meningitis	5
Profound hearing loss due to pneumococcal meningitis	5
Profound hearing loss with ringing due to pneumococcal meningitis	5
Complete hearing loss due to pneumococcal meningitis	5
Complete hearing loss with ringing due to pneumococcal meningitis	5
H influenzae type B meningitis	4
Acute H influenzae type B meningitis	5
Mild behavioral problems due to H influenzae type B meningitis	5
Mild motor impairment due to long term due to H influenzae type B meningitis	5
Mild motor plus cognitive impairments due to H influenzae type B meningitis	5
Borderline intellectual disability due to H influenzae type B meningitis	5
Monocular distance vision loss due to H influenzae type B meningitis	5
Mild intellectual disability due to H influenzae type B meningitis	5
Moderate motor impairment due to H influenzae type B meningitis	5
Severe motor impairment due to H influenzae type B meningitis	5
Moderate motor plus cognitive impairments due to H influenzae type B meningitis	5
Severe motor plus cognitive impairments due to H influenzae type B meningitis	5
Epilepsy due to H influenzae type B meningitis	5
Blindness due to H influenzae type B meningitis	5
Mild hearing loss due to H influenzae type B meningitis	5
Mild hearing loss with ringing due to H influenzae type B meningitis	5
Moderate hearing loss due to H influenzae type B meningitis	5
Moderate hearing loss with ringing due to H influenzae type B meningitis	5
Moderately severe hearing loss due to H influenzae type B meningitis	5
Moderately severe hearing loss with ringing due to H influenzae type B meningitis	5
Severe hearing loss due to H influenzae type B meningitis	5
Severe hearing loss with ringing due to H influenzae type B meningitis	5
Profound hearing loss due to H influenzae type B meningitis	5
Profound hearing loss with ringing due to H influenzae type B meningitis	5
Complete hearing loss due to H influenzae type B meningitis	5
Complete hearing loss with ringing due to H influenzae type B meningitis	5
Meningococcal meningitis	4
Acute meningococcal meningitis	5
Mild behavioral problems due to meningococcal meningitis	5
Mild motor impairment due to long term due to meningococcal meningitis	5
Mild motor plus cognitive impairments due to meningococcal meningitis	5
Borderline intellectual disability due to meningococcal meningitis	5

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Monocular distance vision loss due to meningococcal meningitis	5
Mild intellectual disability due to meningococcal meningitis	5
Moderate motor impairment due to meningococcal meningitis	5
Severe motor impairment due to meningococcal meningitis	5
Moderate motor plus cognitive impairments due to meningococcal meningitis	5
Severe motor plus cognitive impairments due to meningococcal meningitis	5
Epilepsy due to meningococcal meningitis	5
Blindness due to meningococcal meningitis	5
Mild hearing loss due to meningococcal meningitis	5
Mild hearing loss with ringing due to meningococcal meningitis	5
Moderate hearing loss due to meningococcal meningitis	5
Moderate hearing loss with ringing due to meningococcal meningitis	5
Moderately severe hearing loss due to meningococcal meningitis	5
Moderately severe hearing loss with ringing due to meningococcal meningitis	5
Severe hearing loss due to meningococcal meningitis	5
Severe hearing loss with ringing due to meningococcal meningitis	5
Profound hearing loss due to meningococcal meningitis	5
Profound hearing loss with ringing due to meningococcal meningitis	5
Complete hearing loss due to meningococcal meningitis	5
Complete hearing loss with ringing due to meningococcal meningitis	5
Other meningitis	4
Acute viral meningitis	5
Other acute bacterial meningitis	5
Mild behavioral problems due to other bacterial meningitis	5
Mild motor impairment due to long term due to other bacterial meningitis	5
Mild motor plus cognitive impairments due to other bacterial meningitis	5
Borderline intellectual disability due to other bacterial meningitis	5
Monocular distance vision loss due to other bacterial meningitis	5
Mild intellectual disability due to other bacterial meningitis	5
Moderate motor impairment due to other bacterial meningitis	5
Severe motor impairment due to other bacterial meningitis	5
Moderate motor plus cognitive impairments due to other bacterial meningitis	5
Severe motor plus cognitive impairments due to other bacterial meningitis	5
Epilepsy due to other meningitis	5
Blindness due to other bacterial meningitis	5
Mild hearing loss due to other bacterial meningitis	5
Mild hearing loss due with ringing to other bacterial meningitis	5
Moderate hearing loss due to other bacterial meningitis	5
Moderate hearing loss with ringing due to other bacterial meningitis	5
Moderately severe hearing loss due to other bacterial meningitis	5
Moderately severe hearing loss with ringing due to other bacterial meningitis	5
Severe hearing loss due to other bacterial meningitis	5
Severe hearing loss with ringing due to other bacterial meningitis	5
Profound hearing loss due to other bacterial meningitis	5
Profound hearing loss with ringing due to other bacterial meningitis	5
Complete hearing loss due to other bacterial meningitis	5
Complete hearing loss with ringing due to other bacterial meningitis	5
Encephalitis	3
Acute encephalitis	4
Mild behavioral problems due to encephalitis	4
Mild motor impairment due to long term due to encephalitis	4
Mild motor plus cognitive impairments due to encephalitis	4
Borderline intellectual disability due to encephalitis	4

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Monocular distance vision loss due to encephalitis	4
Mild intellectual disability due to encephalitis	4
Moderate motor impairment due to encephalitis	4
Severe motor impairment due to encephalitis	4
Moderate motor plus cognitive impairments due to encephalitis	4
Severe motor plus cognitive impairments due to encephalitis	4
Epilepsy due to encephalitis	4
Blindness due to encephalitis	4
Diphtheria	3
Moderate diphtheria	4
Severe diphtheria	4
Whooping cough	3
Tetanus	3
Severe tetanus	4
Mild motor impairment due to neonatal tetanus	4
Mild motor plus cognitive impairments due to neonatal tetanus	4
Moderate motor impairment due to neonatal tetanus	4
Moderate motor impairment with blindness due to neonatal tetanus	4
Moderate motor impairment with epilepsy due to neonatal tetanus	4
Moderate motor impairment with blindness and epilepsy due to neonatal tetanus	4
Moderate motor plus cognitive impairment with blindness due to neonatal tetanus	4
Moderate motor plus cognitive impairment with epilepsy due to neonatal tetanus	4
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal tetanus	4
Severe motor impairment due to neonatal tetanus	4
Severe motor impairment with blindness due to neonatal tetanus	4
Severe motor impairment with epilepsy due to neonatal tetanus	4
Severe motor impairment with blindness and epilepsy due to neonatal tetanus	4
Severe motor plus cognitive impairment with blindness due to neonatal tetanus	4
Severe motor plus cognitive impairment with epilepsy due to neonatal tetanus	4
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal tetanus	4
Measles	3
Moderate measles	4
Severe measles	4
Varicella and herpes zoster	3
Chickenpox	4
Herpes zoster	4
Neglected tropical diseases and malaria	2
Malaria	3
Asymptomatic malaria parasitemia (PfPR)	4
Mild malaria	4
Moderate malaria	4
Severe malaria	4
Moderate motor impairment due to malaria	4
Moderate motor impairment with blindness due to malaria	4
Moderate motor impairment with epilepsy due to malaria	4
Moderate motor impairment with blindness and epilepsy due to malaria	4
Moderate motor plus cognitive impairment with blindness due to malaria	4
Moderate motor plus cognitive impairment with epilepsy due to malaria	4
Moderate motor plus cognitive impairment with blindness and epilepsy due to malaria	4
Severe motor impairment due to malaria	4
Severe motor impairment with blindness due to malaria	4
Severe motor impairment with epilepsy due to malaria	4
Severe motor impairment with blindness and epilepsy due to malaria	4

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Severe motor plus cognitive impairment with blindness due to malaria	4
Severe motor plus cognitive impairment with epilepsy due to malaria	4
Severe motor plus cognitive impairment with blindness and epilepsy due to malaria	4
Mild anemia due to malaria parasitemia (PfPR)	4
Moderate anemia due to malaria parasitemia (PfPR)	4
Severe anemia due to malaria parasitemia (PfPR)	4
Chagas disease	3
Acute Chagas disease	4
Mild chronic digestive disease due to Chagas disease	4
Moderate chronic digestive disease due to Chagas disease	4
Asymptomatic Chagas disease	4
Atrial fibrillation and flutter due to Chagas disease	4
Mild heart failure due to Chagas disease	4
Moderate heart failure due to Chagas disease	4
Severe heart failure due to Chagas disease	4
Leishmaniasis	3
Visceral leishmaniasis	4
Moderate visceral leishmaniasis	5
Severe visceral leishmaniasis	5
Cutaneous and mucocutaneous leishmaniasis	4
African trypanosomiasis	3
Disfigurement due to African trypanosomiasis	4
Severe motor plus cognitive impairments due to African trypanosomiasis	4
Schistosomiasis	3
Mild schistosomiasis	4
Mild diarrhea due to schistosomiasis	4
Hematemesis due to schistosomiasis	4
Hepatomegaly due to schistosomiasis	4
Ascites due to schistosomiasis	4
Dysuria due to schistosomiasis	4
Bladder pathology due to schistosomiasis	4
Hydronephrosis due to schistosomiasis	4
Mild anemia due to schistosomiasis	4
Moderate anemia due to schistosomiasis	4
Severe anemia due to schistosomiasis	4
Cysticercosis	3
Cystic echinococcosis	3
Abdominal problems due to cystic echinococcosis	4
Chronic respiratory disease due to cystic echinococcosis	4
Epilepsy due to echinococcosis	4
Lymphatic filariasis	3
Prevalence of detectable microfilaria due to lymphatic filariasis	4
Lymphedema due to lymphatic filariasis	4
Hydrocele due to lymphatic filariasis	4
Onchocerciasis	3
Asymptomatic onchocerciasis	4
Mild skin disease due to onchocerciasis	4
Mild skin disease without itch due to onchocerciasis	4
Moderate skin disease due to onchocerciasis	4
Severe skin disease due to onchocerciasis	4
Severe skin disease without itch due to onchocerciasis	4
Moderate vision impairment due to onchocerciasis	4
Severe vision impairment due to onchocerciasis	4

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Blindness due to onchocerciasis	4
Trachoma	3
Moderate vision impairment due to trachoma	4
Severe vision impairment due to trachoma	4
Blindness due to trachoma	4
Dengue	3
Moderate dengue	4
Severe dengue	4
Post-dengue chronic fatigue syndrome	4
Yellow fever	3
Asymptomatic yellow fever	4
Moderate yellow fever	4
Severe yellow fever	4
Rabies	3
Intestinal nematode infections	3
Ascariasis	4
Heavy infestation of ascariasis	5
Mild abdominopelvic problems due to ascariasis	5
Severe wasting due to ascariasis	5
Asymptomatic ascariasis	5
Trichuriasis	4
Heavy infestation of trichuriasis	5
Mild abdominopelvic problems due to trichuriasis	5
Severe wasting due to trichuriasis	5
Asymptomatic trichuriasis	5
Hookworm disease	4
Heavy infestation of hookworm	5
Mild abdominopelvic problems due to hookworm disease	5
Severe wasting due to hookworm disease	5
Mild anemia due to hookworm disease	5
Moderate anemia due to hookworm disease	5
Severe anemia due to hookworm disease	5
Asymptomatic hookworm disease	5
Food-borne trematodiasis	3
Asymptomatic clonorchiasis	4
Asymptomatic fascioliasis	4
Asymptomatic intestinal fluke infection	4
Asymptomatic opisthorchiasis	4
Asymptomatic paragonimiasis	4
Heavy opisthorchiasis due to food-borne trematodiasis	4
Heavy clonorchiasis due to food-borne trematodiasis	4
Heavy intestinal fluke infection due to food-borne trematodiasis	4
Heavy fascioliasis due to food-borne trematodiasis	4
Heavy paragonimiasis due to food-borne trematodiasis	4
Cerebral paragonimiasis	4
Other neglected tropical diseases	3
Acute infection due to other neglected tropical diseases	4
Mild anemia due to other neglected tropical diseases	4
Moderate anemia due to other neglected tropical diseases	4
Severe anemia due to other neglected tropical diseases	4
Maternal disorders	2
Maternal hemorrhage	3
Maternal hemorrhage (< 1L blood lost)	4

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Maternal hemorrhage (> 1L blood lost)	4
Mild anemia due to maternal hemorrhage	4
Moderate anemia due to maternal hemorrhage	4
Severe anemia due to maternal hemorrhage	4
Maternal sepsis and other maternal infections	3
Puerperal sepsis	4
Other maternal infections	4
Infertility due to puerperal sepsis	4
Maternal hypertensive disorders	3
Other hypertensive disorders of pregnancy	4
Severe pre-eclampsia	4
Long term sequelae of severe pre-eclampsia	4
Eclampsia	4
Long term sequelae of eclampsia	4
Obstructed labor	3
Obstructed labor, acute event	4
Rectovaginal fistula	4
Vesicovaginal fistula	4
Complications of abortion	3
Other maternal disorders	3
Neonatal disorders	2
Preterm birth complications	3
Asymptomatic retinopathy of prematurity	4
Mild vision impairment due to retinopathy of prematurity	4
Moderate vision impairment due to retinopathy of prematurity	4
Severe vision impairment due to retinopathy of prematurity	4
Blindness due to retinopathy of prematurity	4
Mild motor impairment due to neonatal preterm birth complications <28wks	4
Mild motor plus cognitive impairments due to neonatal preterm birth complications <28wks	4
Mild motor impairment due to neonatal preterm birth complications 28-32wks	4
Mild motor plus cognitive impairments due to neonatal preterm birth complications 28-32wks	4
Mild motor impairment due to neonatal preterm birth complications 32-36wks	4
Mild motor plus cognitive impairments due to neonatal preterm birth complications 32-36wks	4
Moderate motor impairment due to neonatal preterm birth complications <28wks	4
Moderate motor impairment with blindness due to neonatal preterm birth complications <28wks	4
Moderate motor impairment with epilepsy due to neonatal preterm birth complications <28wks	4
Moderate motor impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks	4
Moderate motor plus cognitive impairment with blindness due to neonatal preterm birth complications <28wks	4
Moderate motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications <28wks	4
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks	4
Severe motor impairment due to neonatal preterm birth complications <28wks	4
Severe motor impairment with blindness due to neonatal preterm birth complications <28wks	4
Severe motor impairment with epilepsy due to neonatal preterm birth complications <28wks	4
Severe motor impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks	4
Severe motor plus cognitive impairment with blindness due to neonatal preterm birth complications <28wks	4
Severe motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications <28wks	4
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks	4
Moderate motor impairment due to neonatal preterm birth complications 28-32wks	4
Moderate motor impairment with blindness due to neonatal preterm birth complications 28-32wks	4
Moderate motor impairment with epilepsy due to neonatal preterm birth complications 28-32wks	4
Moderate motor impairment with blindness and epilepsy due to neonatal preterm birth complications 28-32wks	4
Moderate motor plus cognitive impairment with blindness due to neonatal preterm birth complications 28-32wks	4
Moderate motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications 28-32wks	4

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications 28-32wks	4
Severe motor impairment due to neonatal preterm birth complications 28-32wks	4
Severe motor impairment with blindness due to neonatal preterm birth complications 28-32wks	4
Severe motor impairment with epilepsy due to neonatal preterm birth complications 28-32wks	4
Severe motor impairment with blindness and epilepsy due to neonatal preterm birth complications 28-32wks	4
Severe motor plus cognitive impairment with blindness due to neonatal preterm birth complications 28-32wks	4
Severe motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications 28-32wks	4
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications 28-32wks	4
Moderate motor impairment due to neonatal preterm birth complications 32-36wks	4
Moderate motor impairment with blindness due to neonatal preterm birth complications 32-36wks	4
Moderate motor impairment with epilepsy due to neonatal preterm birth complications 32-36wks	4
Moderate motor impairment with blindness and epilepsy due to neonatal preterm birth complications 32-36wks	4
Moderate motor plus cognitive impairment with blindness due to neonatal preterm birth complications 32-36wks	4
Moderate motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications 32-36wks	4
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications 32-36wks	4
Severe motor impairment due to neonatal preterm birth complications 32-36wks	4
Severe motor impairment with blindness due to neonatal preterm birth complications 32-36wks	4
Severe motor impairment with epilepsy due to neonatal preterm birth complications 32-36wks	4
Severe motor impairment with blindness and epilepsy due to neonatal preterm birth complications 32-36wks	4
Severe motor plus cognitive impairment with blindness due to neonatal preterm birth complications 32-36wks	4
Severe motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications 32-36wks	4
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications 32-36wks	4
Neonatal encephalopathy due to birth asphyxia and trauma	3
Mild motor plus cognitive impairments due to neonatal encephalopathy due to birth asphyxia and trauma	4
Mild motor impairment due to neonatal encephalopathy due to birth asphyxia and trauma	4
Moderate motor impairment due to neonatal encephalopathy due to birth asphyxia and trauma	4
Moderate motor impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma	4
Moderate motor impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	4
Moderate motor impairment with blindness and epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	4
Moderate motor plus cognitive impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma	4
Moderate motor plus cognitive impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	4
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	4
Severe motor impairment due to neonatal encephalopathy due to birth asphyxia and trauma	4
Severe motor impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma	4
Severe motor impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	4
Severe motor impairment with blindness and epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	4
Severe motor plus cognitive impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma	4
Severe motor plus cognitive impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	4
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	4
Neonatal sepsis and other neonatal infections	3
Hemolytic disease and other neonatal jaundice	3
Moderate motor impairment due to hemolytic disease and other neonatal jaundice	4
Moderate motor impairment with blindness due to hemolytic disease and other neonatal jaundice	4
Moderate motor impairment with epilepsy due to hemolytic disease and other neonatal jaundice	4
Moderate motor impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice	4
Moderate motor plus cognitive impairment with blindness due to hemolytic disease and other neonatal jaundice	4
Moderate motor plus cognitive impairment with epilepsy due to hemolytic disease and other neonatal jaundice	4
Moderate motor plus cognitive impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice	4
Severe motor impairment severe due to hemolytic disease and other neonatal jaundice	4
Severe motor impairment with blindness due to hemolytic disease and other neonatal jaundice	4
Severe motor impairment with epilepsy due to hemolytic disease and other neonatal jaundice	4
Severe motor impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice	4
Severe motor plus cognitive impairment with blindness due to hemolytic disease and other neonatal jaundice	4

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Severe motor plus cognitive impairment with epilepsy due to hemolytic disease and other neonatal jaundice	4
Severe motor plus cognitive impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice	4
Other neonatal disorders	3
Nutritional deficiencies	2
Protein-energy malnutrition	3
Kwashiorkor due to protein-energy malnutrition	4
Marasmus due to protein-energy malnutrition	4
Severe wasting due to protein-energy malnutrition	4
Iodine deficiency	3
Visible goiter without symptoms	4
Visible goiter without heart failure due to iodine deficiency	4
Visible goiter with mild heart failure due to iodine deficiency	4
Visible goiter with moderate heart failure due to iodine deficiency	4
Visible goiter with severe heart failure due to iodine deficiency	4
Visible goiter with signs and symptoms	4
Severe intellectual disability due to iodine deficiency	4
Profound intellectual disability due to iodine deficiency	4
Vitamin A deficiency	3
Moderate vision impairment loss due to vitamin A deficiency	4
Severe vision impairment loss due to vitamin A deficiency	4
Blindness due to vitamin A deficiency	4
Iron-deficiency anemia	3
Mild iron-deficiency anemia	4
Moderate iron-deficiency anemia	4
Severe iron-deficiency anemia	4
Mild heart failure due to iron-deficiency anemia	4
Moderate heart failure due to iron-deficiency anemia	4
Severe heart failure due to iron-deficiency anemia	4
Other nutritional deficiencies	3
Other communicable, maternal, neonatal, and nutritional diseases	2
Sexually transmitted diseases excluding HIV	3
Syphilis	4
Chlamydial infection	4
Asymptomatic chlamydial infection	5
Mild chlamydial infection	5
Epididymo-orchitis due to chlamydial infection	5
Moderate pelvic inflammatory diseases due to chlamydial infection	5
Severe pelvic inflammatory diseases due to chlamydial infection	5
Primary infertility due to chlamydial infection	5
Secondary infertility due to chlamydial infection	5
Gonococcal infection	4
Asymptomatic gonococcal infection	5
Mild gonococcal infection	5
Epididymo-orchitis due to gonococcal infection	5
Moderate pelvic inflammatory diseases due to gonococcal infection	5
Severe pelvic inflammatory diseases due to gonococcal infection	5
Primary infertility due to gonococcal infection	5
Secondary infertility due to gonococcal infection	5
Trichomoniasis	4
Asymptomatic trichomoniasis infection	5
Acute trichomoniasis infection	5
Genital herpes	4
Asymptomatic genital herpes	5

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Symptomatic genital herpes	5
Moderate infection due to initial genital herpes episode	5
Other sexually transmitted diseases	4
Other sexually transmitted diseases	5
Moderate pelvic inflammatory diseases due to other sexually transmitted diseases	5
Severe pelvic inflammatory diseases due to other sexually transmitted diseases	5
Primary infertility due to other sexually transmitted diseases	5
Secondary infertility due to other sexually transmitted diseases	5
Hepatitis	3
Hepatitis A	4
Asymptomatic acute hepatitis A	5
Mild acute hepatitis A	5
Moderate acute hepatitis A	5
Severe acute hepatitis A	5
Hepatitis B	4
Asymptomatic acute hepatitis B	5
Moderate acute hepatitis B	5
Severe acute hepatitis B	5
Chronic Hepatitis B	5
Hepatitis C	4
Asymptomatic acute hepatitis C	5
Moderate acute hepatitis C	5
Severe acute hepatitis C	5
Chronic Hepatitis C	5
Hepatitis E	4
Asymptomatic acute hepatitis E	5
Moderate acute hepatitis E	5
Severe acute hepatitis E	5
Leprosy	3
Disfigurement level 1 due to leprosy	4
Disfigurement level 2 due to leprosy	4
Other infectious diseases	3
Acute other infectious diseases	4
Mild anemia due to other infectious diseases	4
Moderate anemia due to other infectious diseases	4
Severe anemia due to other infectious diseases	4
Guillain-Barré syndrome due to other infectious diseases	4
Non-communicable diseases	1
Neoplasms	2
Esophageal cancer	3
Diagnosis and primary therapy phase of esophageal cancer	4
Controlled phase of esophageal cancer	4
Metastatic phase of esophageal cancer	4
Terminal phase of esophageal cancer	4
Stomach cancer	3
Diagnosis and primary therapy phase of stomach cancer	4
Controlled phase of stomach cancer	4
Metastatic phase of stomach cancer	4
Terminal phase of stomach cancer	4
Liver cancer	3
Liver cancer due to hepatitis B	4
Diagnosis and primary therapy phase of liver cancer due to hepatitis B	5
Controlled phase of liver cancer due to hepatitis B	5

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Metastatic phase of liver cancer due to hepatitis B	5
Terminal phase of liver cancer due to hepatitis B	5
Liver cancer due to hepatitis C	4
Diagnosis and primary therapy phase of liver cancer due to hepatitis C	5
Controlled phase of liver cancer due to hepatitis C	5
Metastatic phase of liver cancer due to hepatitis C	5
Terminal phase of liver cancer due to hepatitis C	5
Liver cancer due to alcohol use	4
Diagnosis and primary therapy phase of liver cancer due to alcohol use	5
Controlled phase of liver cancer due to alcohol use	5
Metastatic phase of liver cancer due to alcohol use	5
Terminal phase of liver cancer due to alcohol use	5
Liver cancer due to other causes	4
Diagnosis and primary therapy phase of liver cancer due to other causes	5
Controlled phase of liver cancer due to other causes	5
Metastatic phase of liver cancer due to other causes	5
Terminal phase of liver cancer due to other causes	5
Larynx cancer	3
Diagnosis and primary therapy phase of larynx cancer	4
Controlled phase of larynx cancer	4
Metastatic phase of larynx cancer	4
Terminal phase of larynx cancer	4
Laryngectomy due to larynx cancer	4
Tracheal, bronchus and lung cancer	3
Diagnosis and primary therapy phase of lung, bronchus, and trachea cancer	4
Controlled phase of lung, bronchus, and trachea cancer	4
Metastatic phase of lung, bronchus, and trachea cancer	4
Terminal phase of lung, bronchus, and trachea cancer	4
Breast cancer	3
Diagnosis and primary therapy phase of breast cancer	4
Controlled phase of breast cancer	4
Metastatic phase of breast cancer	4
Terminal phase of breast cancer	4
Mastectomy due to breast cancer	4
Cervical cancer	3
Diagnosis and primary therapy phase of cervical cancer	4
Controlled phase of cervical cancer	4
Metastatic phase of cervical cancer	4
Terminal phase of cervical cancer	4
Uterine cancer	3
Diagnosis and primary therapy phase of uterine cancer	4
Controlled phase of uterine cancer	4
Metastatic phase of uterine cancer	4
Terminal phase of uterine cancer	4
Prostate cancer	3
Diagnosis and primary therapy phase of prostate cancer	4
Controlled phase of prostate cancer	4
Metastatic phase of prostate cancer	4
Terminal phase of prostate cancer	4
Impotence due to prostate cancer	4
Incontinence due to prostate cancer	4
Colon and rectum cancer	3
Diagnosis and primary therapy phase of colon and rectum cancers	4

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Controlled phase of colon and rectum cancers	4
Metastatic phase of colon and rectum cancers	4
Terminal phase of colon and rectum cancers	4
Stoma due to colon and rectum cancer	4
Lip and oral cavity cancer	3
Diagnosis and primary therapy phase of mouth cancer	4
Controlled phase of mouth cancer	4
Metastatic phase of mouth cancer	4
Terminal phase of mouth cancer	4
Nasopharynx cancer	3
Diagnosis and primary therapy phase of nasopharynx cancer	4
Controlled phase of nasopharynx cancer	4
Metastatic phase of nasopharynx cancer	4
Terminal phase of nasopharynx cancer	4
Other pharynx cancer	3
Diagnosis and primary therapy phase of other pharynx cancer	4
Controlled phase of other pharynx cancer	4
Metastatic phase of other pharynx cancer	4
Terminal phase of other pharynx cancer	4
Gallbladder and biliary tract cancer	3
Diagnosis and primary therapy phase of gallbladder and biliary tract cancer	4
Controlled phase of gallbladder and biliary tract cancer	4
Metastatic phase of gallbladder and biliary tract cancer	4
Terminal phase of gallbladder and biliary tract cancer	4
Pancreatic cancer	3
Diagnosis and primary therapy phase of pancreatic cancer	4
Controlled phase of pancreatic cancer	4
Metastatic phase of pancreatic cancer	4
Terminal phase of pancreatic cancer	4
Malignant skin melanoma	3
Diagnosis and primary therapy phase of malignant skin melanoma	4
Controlled phase of malignant skin melanoma	4
Metastatic phase of malignant skin melanoma	4
Terminal phase of malignant skin melanoma	4
Non-melanoma skin cancer	3
Diagnosis and primary therapy phase of cutaneous squamous cell carcinoma	4
Control phase of cutaneous squamous cell carcinoma	4
Metastatic phase of cutaneous squamous cell carcinoma	4
Terminal phase of cutaneous squamous cell carcinoma	4
Disfigurement due to basal cell carcinoma	4
Ovarian cancer	3
Diagnosis and primary therapy phase of ovarian cancer	4
Controlled phase of ovarian cancer	4
Metastatic phase of ovarian cancer	4
Terminal phase of ovarian cancer	4
Testicular cancer	3
Diagnosis and primary therapy phase of testicular cancer	4
Controlled phase of testicular cancer	4
Metastatic phase of testicular cancer	4
Terminal phase of testicular cancer	4
Kidney cancer	3
Diagnosis and primary therapy phase of kidney cancer	4
Controlled phase of kidney cancer	4

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Metastatic phase of kidney cancer	4
Terminal phase of kidney cancer	4
Bladder cancer	3
Diagnosis and primary therapy phase of bladder cancer	4
Controlled phase of bladder cancer	4
Metastatic phase of bladder cancer	4
Terminal phase of bladder cancer	4
Urinary incontinence due to bladder cancer	4
Brain and nervous system cancer	3
Diagnosis and primary therapy phase of brain and nervous system cancers	4
Controlled phase of brain and nervous system cancers	4
Metastatic phase of brain and nervous system cancers	4
Terminal phase of brain and nervous system cancers	4
Thyroid cancer	3
Diagnosis and primary therapy phase of thyroid cancer	4
Controlled phase of thyroid cancer	4
Metastatic phase of thyroid cancer	4
Terminal phase of thyroid cancer	4
Mesothelioma	3
Diagnosis and primary therapy phase of mesothelioma	4
Controlled phase of mesothelioma	4
Metastatic phase of mesothelioma	4
Terminal phase of mesothelioma	4
Hodgkin lymphoma	3
Diagnosis and primary therapy phase of Hodgkin disease	4
Controlled phase of Hodgkin disease	4
Metastatic phase of Hodgkin disease	4
Terminal phase of Hodgkin disease	4
Non-Hodgkin lymphoma	3
Diagnosis and primary therapy phase of non-Hodgkin lymphoma	4
Controlled phase of non-Hodgkin lymphoma	4
Metastatic phase of non-Hodgkin lymphoma	4
Terminal phase of non-Hodgkin lymphoma	4
Multiple myeloma	3
Diagnosis and primary therapy phase of multiple myeloma	4
Controlled phase of multiple myeloma	4
Metastatic phase of multiple myeloma	4
Terminal phase of multiple myeloma	4
Leukemia	3
Diagnosis and primary therapy phase of leukemia	4
Controlled phase of leukemia	4
Metastatic phase of leukemia	4
Terminal phase of leukemia	4
Other neoplasms	3
Diagnosis and primary therapy phase of other neoplasms	4
Controlled phase of other neoplasms	4
Metastatic phase of other neoplasms	4
Terminal phase of other neoplasms	4
Cardiovascular diseases	2
Rheumatic heart disease	3
Rheumatic heart disease, without heart failure	4
Mild heart failure due to rheumatic heart disease	4
Moderate heart failure due to rheumatic heart disease	4

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Severe heart failure due to rheumatic heart disease	4
Ischemic heart disease	3
Asymptomatic ischemic heart disease following myocardial infarction	4
Acute myocardial infarction first 2 days	4
Acute myocardial infarction 3 to 28 days	4
Asymptomatic angina due to ischemic heart disease	4
Mild angina due to ischemic heart disease	4
Moderate angina due to ischemic heart disease	4
Severe angina due to ischemic heart disease	4
Mild heart failure due to ischemic heart disease	4
Moderate heart failure due to ischemic heart disease	4
Severe heart failure due to ischemic heart disease	4
Cerebrovascular disease	3
Ischemic stroke	4
Asymptomatic chronic ischemic stroke	5
Chronic ischemic stroke severity level 1	5
Chronic ischemic stroke severity level 2	5
Chronic ischemic stroke severity level 4	5
Chronic ischemic stroke severity level 3	5
Chronic ischemic stroke severity level 5	5
Acute ischemic stroke severity level 1	5
Acute ischemic stroke severity level 2	5
Acute ischemic stroke severity level 4	5
Acute ischemic stroke severity level 3	5
Acute ischemic stroke severity level 5	5
Hemorrhagic stroke	4
Asymptomatic chronic hemorrhagic stroke	5
Chronic hemorrhagic stroke severity level 1	5
Chronic hemorrhagic stroke severity level 2	5
Chronic hemorrhagic stroke severity level 4	5
Chronic hemorrhagic stroke severity level 3	5
Chronic hemorrhagic stroke severity level 5	5
Acute hemorrhagic stroke severity level 1	5
Acute hemorrhagic stroke severity level 2	5
Acute hemorrhagic stroke severity level 4	5
Acute hemorrhagic stroke severity level 3	5
Acute hemorrhagic stroke severity level 5	5
Hypertensive heart disease	3
Mild heart failure due to hypertensive heart disease	4
Moderate heart failure due to hypertensive heart disease	4
Severe heart failure due to hypertensive heart disease	4
Cardiomyopathy and myocarditis	3
Acute myocarditis	4
Mild heart failure due to cardiomyopathy and myocarditis	4
Moderate heart failure due to cardiomyopathy and myocarditis	4
Severe heart failure due to cardiomyopathy and myocarditis	4
Atrial fibrillation and flutter	3
Asymptomatic atrial fibrillation and flutter	4
Symptomatic atrial fibrillation and flutter	4
Peripheral vascular disease	3
Asymptomatic peripheral vascular disease	4
Symptomatic claudication due to peripheral vascular disease	4
Endocarditis	3

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Moderate endocarditis	4
Severe endocarditis	4
Mild heart failure due to endocarditis	4
Moderate heart failure due to endocarditis	4
Severe heart failure due to endocarditis	4
Other cardiovascular and circulatory diseases	3
Mild heart failure due to other cardiovascular diseases	4
Moderate heart failure due to other cardiovascular diseases	4
Severe heart failure due to other cardiovascular diseases	4
Asymptomatic other cardiovascular diseases	4
Mild other cardiovascular diseases	4
Moderate other cardiovascular diseases	4
Severe other cardiovascular diseases	4
Chronic respiratory diseases	2
Chronic obstructive pulmonary disease	3
Asymptomatic chronic obstructive pulmonary disease	4
Mild chronic obstructive pulmonary disease	4
Moderate chronic obstructive pulmonary disease	4
Severe chronic obstructive pulmonary disease without heart failure	4
Mild heart failure due to severe chronic obstructive pulmonary disease	4
Moderate heart failure due to severe chronic obstructive pulmonary disease	4
Severe heart failure due to severe chronic obstructive pulmonary disease	4
Pneumoconiosis	3
Silicosis	4
Asymptomatic silicosis	5
Mild silicosis	5
Moderate silicosis	5
Severe silicosis without heart failure	5
Mild heart failure due to severe silicosis	5
Moderate heart failure due to severe silicosis	5
Severe heart failure due to severe silicosis	5
Asbestosis	4
Asymptomatic asbestosis	5
Mild asbestosis	5
Moderate asbestosis	5
Severe asbestosis without heart failure	5
Mild heart failure due to severe asbestosis	5
Moderate heart failure due to severe asbestosis	5
Severe heart failure due to severe asbestosis	5
Coal workers pneumoconiosis	4
Asymptomatic coal workers pneumoconiosis	5
Mild coal workers pneumoconiosis	5
Moderate coal workers pneumoconiosis	5
Severe coal workers pneumoconiosis without heart failure	5
Mild heart failure due to severe coal workers pneumoconiosis	5
Moderate heart failure due to severe coal workers pneumoconiosis	5
Severe heart failure due to severe coal workers pneumoconiosis	5
Other pneumoconiosis	4
Asymptomatic other pneumoconiosis	5
Mild other pneumoconiosis	5
Moderate other pneumoconiosis	5
Severe other pneumoconiosis without heart failure	5
Mild heart failure due to severe other pneumoconiosis	5

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Moderate heart failure due to severe other pneumoconiosis	5
Severe heart failure due to severe other pneumoconiosis	5
Asthma	3
Asymptomatic asthma	4
Controlled asthma	4
Partially controlled asthma	4
Uncontrolled asthma	4
Interstitial lung disease and pulmonary sarcoidosis	3
Asymptomatic interstitial lung disease and pulmonary sarcoidosis	4
Mild interstitial lung disease and pulmonary sarcoidosis	4
Moderate interstitial lung disease and pulmonary sarcoidosis	4
Severe interstitial lung disease and pulmonary sarcoidosis without heart failure	4
Mild heart failure due to severe interstitial lung disease and pulmonary sarcoidosis	4
Moderate heart failure due to severe interstitial lung disease and pulmonary sarcoidosis	4
Severe heart failure due to severe interstitial lung disease and pulmonary sarcoidosis	4
Other chronic respiratory diseases	3
Cirrhosis	2
Cirrhosis due to hepatitis B	3
Cirrhosis due to hepatitis C	3
Cirrhosis due to alcohol use	3
Cirrhosis due to other causes	3
Digestive diseases	2
Peptic ulcer disease	3
Peptic ulcer disease, symptomatic episodes	4
Mild anemia due to peptic ulcer disease	4
Moderate anemia due to peptic ulcer disease	4
Severe anemia due to peptic ulcer disease	4
Gastritis and duodenitis	3
Gastritis and duodenitis, symptomatic episodes	4
Mild anemia due to gastritis and duodenitis	4
Moderate anemia due to gastritis and duodenitis	4
Severe anemia due to gastritis and duodenitis	4
Appendicitis	3
Paralytic ileus and intestinal obstruction	3
Inguinal, femoral, and abdominal hernia	3
Inflammatory bowel disease	3
Ulcerative colitis	4
Crohn's disease	4
Vascular intestinal disorders	3
Gallbladder and biliary diseases	3
Pancreatitis	3
Other digestive diseases	3
Neurological disorders	2
Alzheimer disease and other dementias	3
Mild Alzheimer disease and other dementias	4
Moderate Alzheimer disease and other dementias	4
Severe Alzheimer disease and other dementias	4
Parkinson disease	3
Mild Parkinson disease	4
Moderate Parkinson disease	4
Severe Parkinson disease	4
Epilepsy	3
Seizure-free, treated epilepsy	4

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Less severe epilepsy	4
Severe epilepsy	4
Multiple sclerosis	3
Mild multiple sclerosis	4
Moderate multiple sclerosis	4
Severe multiple sclerosis	4
Migraine	3
Asymptomatic migraine	4
Symptomatic migraine	4
Tension-type headache	3
Asymptomatic tension-type headache	4
Symptomatic tension-type headache	4
Medication overuse headache	3
Asymptomatic medication overuse headache	4
Symptomatic medication overuse headache	4
Other neurological disorders	3
Other neurological disorders	4
Guillain-Barré syndrome due to other neurological disorders	4
Mental and substance use disorders	2
Schizophrenia	3
Schizophrenia residual state	4
Schizophrenia acute state	4
Alcohol use disorders	3
Asymptomatic alcohol dependence	4
Very mild alcohol dependence	4
Mild alcohol dependence	4
Moderate alcohol dependence	4
Severe alcohol dependence	4
Asymptomatic fetal alcohol syndrome	4
Mild fetal alcohol syndrome	4
Moderate fetal alcohol syndrome	4
Severe fetal alcohol syndrome	4
Drug use disorders	3
Opioid use disorders	4
Asymptomatic opioid dependence	5
Mild opioid dependence	5
Severe opioid dependence	5
Cocaine use disorders	4
Asymptomatic cocaine dependence	5
Mild cocaine dependence	5
Severe cocaine dependence	5
Amphetamine use disorders	4
Asymptomatic amphetamine dependence	5
Mild amphetamine dependence	5
Severe amphetamine dependence	5
Cannabis use disorders	4
Asymptomatic cannabis dependence	5
Mild cannabis dependence	5
Severe cannabis dependence	5
Other drug use disorders	4
Depressive disorders	3
Major depressive disorder	4
Major depressive disorder, currently without symptoms	5

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Mild major depressive disorder	5
Moderate major depressive disorder	5
Severe major depressive disorder	5
Dysthymia	4
Dysthymia, currently without symptoms	5
Symptomatic dysthymia	5
Bipolar disorder	3
Bipolar disorder residual state	4
Bipolar disorder depressive state	4
Bipolar disorder manic state	4
Anxiety disorders	3
Anxiety disorders, currently without symptoms	4
Mild anxiety disorders	4
Moderate anxiety disorders	4
Severe anxiety disorders	4
Eating disorders	3
Anorexia nervosa	4
Bulimia nervosa	4
Autistic spectrum disorders	3
Autism	4
Asperger syndrome	4
Attention-deficit/hyperactivity disorder	3
Attention-deficit/hyperactivity disorder, currently without symptoms	4
Symptomatic attention-deficit/hyperactivity disorder	4
Conduct disorder	3
Conduct disorder, currently without symptoms	4
Symptomatic conduct disorder	4
Idiopathic intellectual disability	3
Borderline idiopathic intellectual disability	4
Mild idiopathic intellectual disability	4
Moderate idiopathic intellectual disability	4
Severe idiopathic intellectual disability	4
Profound idiopathic intellectual disability	4
Other mental and substance use disorders	3
Other mental disorders, currently without symptoms	4
Mild other mental disorders	4
Moderate other mental disorders	4
Severe other mental disorders	4
Diabetes, urogenital, blood, and endocrine diseases	2
Diabetes mellitus	3
Uncomplicated diabetes mellitus	4
Diabetic neuropathy	4
Diabetic foot due to neuropathy	4
Diabetic neuropathy and amputation with treatment	4
Diabetic neuropathy and amputation without treatment	4
Moderate vision impairment due to diabetes mellitus	4
Severe vision impairment due to diabetes mellitus	4
Blindness due to diabetes mellitus	4
Acute glomerulonephritis	3
Chronic kidney disease	3
Chronic kidney disease due to diabetes mellitus	4
Stage III chronic kidney disease without anemia due to diabetes mellitus	5
Stage III chronic kidney disease and mild anemia due to diabetes mellitus	5

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Stage III chronic kidney disease and moderate anemia due to diabetes mellitus	5
Stage III chronic kidney disease and severe anemia due to diabetes mellitus	5
Stage IV chronic kidney disease without anemia due to diabetes mellitus	5
Stage IV chronic kidney disease and mild anemia due to diabetes mellitus	5
Stage IV chronic kidney disease and moderate anemia due to diabetes mellitus	5
Stage IV chronic kidney disease and severe anemia due to diabetes mellitus	5
Stage V chronic kidney disease untreated due to diabetes mellitus	5
End-stage renal disease after transplant due to diabetes mellitus	5
End-stage renal disease on dialysis due to diabetes mellitus	5
Chronic kidney disease due to hypertension	4
Stage III chronic kidney disease without anemia due to hypertension	5
Stage III chronic kidney disease and mild anemia due to hypertension	5
Stage III chronic kidney disease and moderate anemia due to hypertension	5
Stage III chronic kidney disease and severe anemia due to hypertension	5
Stage IV chronic kidney disease without anemia due to hypertension	5
Stage IV chronic kidney disease and mild anemia due to hypertension	5
Stage IV chronic kidney disease and moderate anemia due to hypertension	5
Stage IV chronic kidney disease and severe anemia due to hypertension	5
Stage V chronic kidney disease untreated due to hypertension	5
End-stage renal disease after transplant due to hypertension	5
End-stage renal disease on dialysis due to hypertension	5
Chronic kidney disease due to glomerulonephritis	4
Stage III chronic kidney disease without anemia due to glomerulonephritis	5
Stage III chronic kidney disease and mild anemia due to glomerulonephritis	5
Stage III chronic kidney disease and moderate anemia due to glomerulonephritis	5
Stage III chronic kidney disease and severe anemia due to glomerulonephritis	5
Stage IV chronic kidney disease without anemia due to glomerulonephritis	5
Stage IV chronic kidney disease and mild anemia due to glomerulonephritis	5
Stage IV chronic kidney disease and moderate anemia due to glomerulonephritis	5
Stage IV chronic kidney disease and severe anemia due to glomerulonephritis	5
Stage V chronic kidney disease untreated due to glomerulonephritis	5
End-stage renal disease after transplant due to glomerulonephritis	5
End-stage renal disease on dialysis due to glomerulonephritis	5
Chronic kidney disease due to other causes	4
Stage III chronic kidney disease without anemia due to other causes	5
Stage III chronic kidney disease and mild anemia due to other causes	5
Stage III chronic kidney disease and moderate anemia due to other causes	5
Stage III chronic kidney disease and severe anemia due to other causes	5
Stage IV chronic kidney disease without anemia due to other causes	5
Stage IV chronic kidney disease and mild anemia due to other causes	5
Stage IV chronic kidney disease and moderate anemia due to other causes	5
Stage IV chronic kidney disease and severe anemia due to other causes	5
Stage V chronic kidney disease untreated due to other causes	5
End-stage renal disease after transplant due to other causes	5
End-stage renal disease on dialysis due to other causes	5
Urinary diseases and male infertility	3
Interstitial nephritis and urinary tract infections	4
Mild interstitial nephritis and urinary tract infections	5
Moderate interstitial nephritis and urinary tract infections	5
Urolithiasis	4
Acute urolithiasis	5
Chronic urolithiasis	5
Benign prostatic hyperplasia	4

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Asymptomatic benign prostatic hyperplasia	5
Symptomatic benign prostatic hyperplasia	5
Male infertility due to other causes	4
Primary male infertility	5
Secondary male infertility	5
Other urinary diseases	4
Gynecological diseases	3
Uterine fibroids	4
Asymptomatic uterine fibroids	5
Mild abdominal pain due to uterine fibroids, without anemia	5
Mild abdominal pain due to uterine fibroids, with mild anemia	5
Mild abdominal pain due to uterine fibroids, with moderate anemia	5
Mild abdominal pain due to uterine fibroids, with severe anemia	5
Polycystic ovarian syndrome	4
Asymptomatic polycystic ovarian syndrome	5
Hirsutism due to polycystic ovarian syndrome	5
Hirsutism and primary infertility due to polycystic ovarian syndrome	5
Primary infertility due to polycystic ovarian syndrome	5
Hirsutism and secondary infertility due to polycystic ovarian syndrome	5
Secondary infertility due to polycystic ovarian syndrome	5
Female infertility due to other causes	4
Idiopathic primary female infertility	5
Idiopathic secondary female infertility	5
Endometriosis	4
Asymptomatic endometriosis	5
Mild abdominal pain due to endometriosis	5
Moderate abdominal pain due to endometriosis	5
Severe endometriosis	5
Primary infertility due to endometriosis	5
Mild abdominal pain and primary infertility due to endometriosis	5
Moderate abdominal pain and primary infertility due to endometriosis	5
Severe abdominal pain and primary infertility due to endometriosis	5
Secondary infertility due to endometriosis	5
Mild abdominal pain and secondary infertility due to endometriosis	5
Moderate abdominal pain and secondary infertility due to endometriosis	5
Severe abdominal pain and secondary infertility due to endometriosis	5
Genital prolapse	4
Asymptomatic genital prolapse	5
Abdominal pain due to genital prolapse	5
Stress incontinence due to genital prolapse	5
Abdominal pain and stress incontinence due to genital prolapse	5
Premenstrual syndrome	4
Asymptomatic premenstrual syndrome	5
Abdominal pain and depression due to premenstrual syndrome	5
Abdominal pain due to premenstrual syndrome	5
Depression due to premenstrual syndrome	5
Other gynecological diseases	4
Asymptomatic other gynecological disorders	5
Mild other gynecological disorders	5
Moderate other gynecological disorders	5
Severe other gynecological disorders	5
Mild anemia due to other gynecological diseases	5
Moderate anemia due to other gynecological diseases	5

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Severe anemia due to other gynecological diseases	5
Hemoglobinopathies and hemolytic anemias	3
Thalassemias	4
Beta-thalassemia major, with mild anemia	5
Beta-thalassemia major, with moderate anemia	5
Beta-thalassemia major, with severe anemia	5
Beta-thalassemia major, severe infection with severe anemia	5
Hemoglobin E/beta-thalassemia, with mild anemia	5
Hemoglobin E/beta-thalassemia, with moderate anemia	5
Hemoglobin E/beta-thalassemia, with severe anemia	5
Hemoglobin E/beta-thalassemia, severe infection with severe anemia	5
Hemoglobin H disease, with mild anemia	5
Hemoglobin H disease, with moderate anemia	5
Hemoglobin H disease, with severe anemia	5
Hemoglobin H disease, severe infection with severe anemia	5
Mild heart failure due to thalassemias	5
Moderate heart failure due to thalassemias	5
Severe heart failure due to thalassemias	5
Hemoglobin H disease, without anemia	5
Beta-thalassemia major, without anemia	5
Hemoglobin E/Beta-thalassemia, without anemia	5
Thalassemia trait	4
Asymptomatic B-thalassemia trait	5
Mild anemia due to B-thalassemia trait	5
Moderate anemia due to B-thalassemia trait	5
Severe anemia due to B-thalassemia trait	5
Asymptomatic hemoglobin E trait	5
Mild anemia due to hemoglobin E trait	5
Moderate anemia due to hemoglobin E trait	5
Severe anemia due to hemoglobin E trait	5
Sickle cell disorders	4
Homozygous sickle cell and severe sickle cell/beta-thalassemia, without anemia	5
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with vaso-occlusive crisis, without anemia	5
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with stroke, without anemia	5
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with vaso-occlusive crisis and stroke, without anemia	5
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with mild anemia	5
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with moderate anemia	5
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with severe anemia	5
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with vaso-occlusive crisis and severe anemia	5
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with stroke and severe anemia	5
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with vaso-occlusive crisis, stroke, and severe anemia	5
Hemoglobin SC disease, without anemia	5
Hemoglobin SC disease, with vaso-occlusive crisis, without anemia	5
Hemoglobin SC disease, with stroke, without anemia	5
Hemoglobin SC disease, with vaso-occlusive crisis and stroke, without anemia	5
Hemoglobin SC disease, with mild anemia	5
Hemoglobin SC disease, with moderate anemia	5
Hemoglobin SC disease, with severe anemia	5
Hemoglobin SC disease, with vaso-occlusive crisis and severe anemia	5
Hemoglobin SC disease, with stroke and severe anemia	5
Hemoglobin SC disease, with vaso-occlusive crisis, stroke, and severe anemia	5
Mild sickle cell/beta-thalassemia, without anemia	5
Mild sickle cell/beta-thalassemia, with vaso-occlusive crisis, without anemia	5

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Mild sickle cell/beta-thalassemia, with stroke, without anemia	5
Mild sickle cell/beta-thalassemia, with vaso-occlusive crisis and stroke, without anemia	5
Mild sickle cell/beta-thalassemia, with mild anemia	5
Mild sickle cell/beta-thalassemia, with moderate anemia	5
Mild sickle cell/beta-thalassemia, with severe anemia	5
Mild sickle cell/beta-thalassemia, with vaso-occlusive crisis and severe anemia	5
Mild sickle cell/beta-thalassemia, with stroke and severe anemia	5
Mild sickle cell/beta-thalassemia, with vaso-occlusive crisis, stroke, and severe anemia	5
Sickle cell trait	4
Asymptomatic sickle cell trait	5
Mild anemia due to sickle cell trait	5
Moderate anemia due to sickle cell trait	5
Severe anemia due to sickle cell trait	5
G6PD deficiency	4
Mild anemia due to G6PD deficiency	5
Moderate anemia due to G6PD deficiency	5
Severe anemia due to G6PD deficiency	5
Mild heart failure due to G6PD deficiency	5
Moderate heart failure due to G6PD deficiency	5
Severe heart failure due to G6PD deficiency	5
Asymptomatic G6PD deficiency	5
G6PD trait	4
Asymptomatic hemizygous G6PD deficiency	5
Mild anemia due to hemizygous G6PD deficiency	5
Moderate anemia due to hemizygous G6PD deficiency	5
Severe anemia due to hemizygous G6PD deficiency	5
Other hemoglobinopathies and hemolytic anemias	4
Other hemoglobinopathies and hemolytic anemias	5
Mild anemia due to other hemoglobinopathies and hemolytic anemias	5
Moderate anemia due to other hemoglobinopathies and hemolytic anemias	5
Severe anemia due to other hemoglobinopathies and hemolytic anemias	5
Mild heart failure due to other hemoglobinopathies and hemolytic anemias	5
Moderate heart failure due to other hemoglobinopathies and hemolytic anemias	5
Severe heart failure due to other hemoglobinopathies and hemolytic anemias	5
Endocrine, metabolic, blood, and immune disorders	3
Asymptomatic endocrine, metabolic, blood, and immune disorders	4
Mild endocrine, metabolic, blood, and immune disorders	4
Moderate endocrine, metabolic, blood, and immune disorders	4
Severe endocrine, metabolic, blood, and immune disorders	4
Mild anemia due to endocrine, metabolic, blood, and immune disorders	4
Moderate anemia due to endocrine, metabolic, blood, and immune disorders	4
Severe anemia due to endocrine, metabolic, blood, and immune disorders	4
Mild heart failure due to endocrine, metabolic, blood, and immune disorders	4
Moderate heart failure due to endocrine, metabolic, blood, and immune disorders	4
Severe heart failure due to endocrine, metabolic, blood, and immune disorders	4
Musculoskeletal disorders	2
Rheumatoid arthritis	3
Mild rheumatoid arthritis	4
Moderate rheumatoid arthritis	4
Severe rheumatoid arthritis	4
Osteoarthritis	3
Mild osteoarthritis of the hip	4
Moderate osteoarthritis of the hip	4

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Severe osteoarthritis of the hip	4
Mild osteoarthritis of the knee	4
Moderate osteoarthritis of the knee	4
Severe osteoarthritis of the knee	4
Low back and neck pain	3
Low back pain	4
Mild low back pain without leg pain	5
Mild low back pain with leg pain	5
Moderate low back pain without leg pain	5
Moderate low back pain with leg pain	5
Severe low back pain without leg pain	5
Severe low back pain with leg pain	5
Most severe low back pain without leg pain	5
Most severe low back pain with leg pain	5
Neck pain	4
Mild neck pain	5
Moderate neck pain	5
Severe neck pain	5
Most severe neck pain	5
Gout	3
Asymptomatic gout	4
Symptomatic episodes of gout	4
Polyarticular gout	4
Other musculoskeletal disorders	3
Asymptomatic other musculoskeletal disorders	4
Other musculoskeletal disorders severity level 2	4
Other musculoskeletal disorders severity level 3	4
Other musculoskeletal disorders severity level 5	4
Other musculoskeletal disorders severity level 6	4
Other musculoskeletal disorders severity level 1	4
Other musculoskeletal disorders severity level 4	4
Other non-communicable diseases	2
Congenital anomalies	3
Neural tube defects	4
Moderate motor impairment due to moderate neural tube defects	5
Severe motor impairment due to severe neural tube defects	5
Severe motor plus cognitive impairments due to severe neural tube defects	5
Severe motor impairment with incontinence due to severe neural tube defects	5
Congenital heart anomalies	4
Asymptomatic less severe congenital heart anomalies	5
Symptomatic less severe congenital heart anomalies	5
Severe congenital heart anomalies	5
Critical congenital heart anomalies	5
Mild heart failure due to congenital heart anomalies	5
Moderate heart failure due to congenital heart anomalies	5
Severe heart failure due to congenital heart anomalies	5
Orofacial clefts	4
Asymptomatic orofacial clefts	5
Disfigurement level 1 due to orofacial clefts	5
Disfigurement level 2 due to orofacial clefts	5
Disfigurement level 2 and speech problems due to orofacial clefts	5
Down syndrome	4
Asymptomatic Down syndrome	5

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Intellectual disability due to Down syndrome	5
Intellectual disability with congenital heart disease due to Down syndrome	5
Intellectual disability with dementia due to Down syndrome	5
Intellectual disability with congenital heart disease and dementia due to Down syndrome	5
Isolated congenital heart disease due to Down syndrome	5
Turner syndrome	4
Asymptomatic Turner syndrome	5
Congenital heart disease due to Turner syndrome	5
Primary infertility due to Turner syndrome	5
Congenital heart disease with infertility due to Turner syndrome	5
Klinefelter syndrome	4
Asymptomatic Klinefelter syndrome	5
Borderline intellectual disability due to Klinefelter syndrome	5
Borderline intellectual disability with infertility due to Klinefelter syndrome	5
Mild intellectual disability due to Klinefelter syndrome	5
Mild intellectual disability with infertility due to Klinefelter syndrome	5
Primary infertility due to Klinefelter syndrome	5
Chromosomal unbalanced rearrangements	4
Asymptomatic chromosomal unbalanced rearrangements	5
Intellectual disability due to chromosomal unbalanced rearrangements	5
Intellectual disability with congenital heart disease due to chromosomal unbalanced rearrangements	5
Intellectual disability with dementia due to chromosomal unbalanced rearrangements	5
Intellectual disability with congenital heart disease and dementia due to chromosomal unbalanced rearrangements	5
Isolated congenital heart disease due to chromosomal unbalanced rearrangements	5
Other congenital anomalies	4
Mild hearing loss due to other congenital anomalies	5
Mild hearing loss with ringing due to other congenital anomalies	5
Moderate hearing loss due to other congenital anomalies	5
Moderate hearing loss with ringing due to other congenital anomalies	5
Moderately severe hearing loss due to other congenital anomalies	5
Moderately severe hearing loss with ringing due to other congenital anomalies	5
Severe hearing loss with ringing due to other congenital anomalies	5
Severe hearing loss due to other congenital anomalies	5
Profound hearing loss due to other congenital anomalies	5
Profound hearing loss with ringing due to other congenital anomalies	5
Complete hearing loss due to other congenital anomalies	5
Complete hearing loss with ringing due to other congenital anomalies	5
Other congenital anomalies	5
Skin and subcutaneous diseases	3
Dermatitis	4
Mild eczema	5
Moderate eczema	5
Severe eczema	5
Asymptomatic contact dermatitis	5
Mild contact dermatitis	5
Severe contact dermatitis	5
Asymptomatic seborrhoeic dermatitis	5
Symptomatic seborrhoeic dermatitis	5
Psoriasis	4
Mild psoriasis	5
Moderate psoriasis	5
Severe psoriasis	5
Cellulitis	4

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Mild cellulitis	5
Severe cellulitis	5
Pyoderma	4
Impetigo	5
Abscess and other bacterial skin diseases	5
Scabies	4
Fungal skin diseases	4
Tinea capitis	5
Other fungal skin diseases	5
Viral skin diseases	4
Mild molluscum contagiosum	5
Severe molluscum contagiosum	5
Mild viral warts	5
Severe viral warts	5
Acne vulgaris	4
Alopecia areata	4
Mild alopecia areata	5
Severe alopecia areata	5
Pruritus	4
Urticaria	4
Mild urticaria	5
Severe urticaria	5
Decubitus ulcer	4
Mild decubitus ulcer	5
Moderate decubitus ulcer	5
Severe decubitus ulcer	5
Other skin and subcutaneous diseases	4
Asymptomatic other skin and subcutaneous diseases	5
Symptomatic other skin and subcutaneous diseases	5
Sense organ diseases	3
Glaucoma	4
Moderate vision impairment due to glaucoma	5
Severe vision impairment due to glaucoma	5
Blindness due to glaucoma	5
Cataract	4
Moderate vision impairment due to cataract	5
Severe vision impairment due to cataract	5
Blindness due to cataract	5
Macular degeneration	4
Moderate vision impairment due to macular degeneration	5
Severe vision impairment due to macular degeneration	5
Blindness due to macular degeneration	5
Uncorrected refractive error	4
Moderate vision impairment due to uncorrected refractive error	5
Severe vision impairment due to uncorrected refractive error	5
Blindness due to uncorrected refractive error	5
Near vision impairment due to presbyopia due to uncorrected refractive error	5
Age-related and other hearing loss	4
Mild hearing loss due to age-related and other hearing loss	5
Mild hearing loss with ringing due to age-related and other hearing loss	5
Moderate hearing loss due to age-related and other hearing loss	5
Moderate hearing loss with ringing due to age-related and other hearing loss	5
Moderately severe hearing loss due to age-related and other hearing loss	5

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Moderately severe hearing loss with ringing due to age-related and other hearing loss	5
Severe hearing loss with ringing due to age-related and other hearing loss	5
Severe hearing loss due to age-related and other hearing loss	5
Profound hearing loss due to age-related and other hearing loss	5
Profound hearing loss with ringing due to age-related and other hearing loss	5
Complete hearing loss due to age-related and other hearing loss	5
Complete hearing loss with ringing due to age-related and other hearing loss	5
Other vision loss	4
Moderate vision impairment due to other vision loss	5
Severe vision impairment due to other vision loss	5
Blindness due to other vision loss	5
Other sense organ diseases	4
Asymptomatic other sense organ diseases	5
Mild other sense organ diseases	5
Moderate other sense organ diseases	5
Severe other sense organ diseases	5
Oral disorders	3
Deciduous caries	4
Asymptomatic deciduous caries	5
Tooth pain due to deciduous caries	5
Permanent caries	4
Asymptomatic permanent caries	5
Tooth pain due to permanent caries	5
Periodontal diseases	4
Edentulism and severe tooth loss	4
Asymptomatic edentulism and severe tooth loss	5
Difficulty eating due to edentulism and severe tooth loss	5
Other oral disorders	4
Mild other oral disorders	5
Severe other oral disorders	5
Injuries	1
Transport injuries	2
Road injuries	3
Pedestrian road injuries	4
Cyclist road injuries	4
Amputations	5
Burns	5
Fractures	5
Head Injury	5
Minor Injury	5
Other Injury	5
Spinal Lesions	5
Motorcyclist road injuries	4
Amputations	5
Burns	5
Fractures	5
Head Injury	5
Minor Injury	5
Other Injury	5
Spinal Lesions	5
Motor vehicle road injuries	4
Amputations	5
Burns	5

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Fractures	5
Head Injury	5
Minor Injury	5
Other Injury	5
Spinal Lesions	5
Other road injuries	4
Amputations	5
Burns	5
Fractures	5
Head Injury	5
Minor Injury	5
Other Injury	5
Spinal Lesions	5
Other transport injuries	3
Amputations	4
Burns	4
Fractures	4
Head Injury	4
Minor Injury	4
Other Injury	4
Spinal Lesions	4
Unintentional injuries	2
Falls	3
Amputations	4
Burns	4
Fractures	4
Head Injury	4
Minor Injury	4
Other Injury	4
Spinal Lesions	4
Drowning	3
Amputations	4
Burns	4
Fractures	4
Head Injury	4
Minor Injury	4
Other Injury	4
Spinal Lesions	4
Fire, heat, and hot substances	3
Amputations	4
Burns	4
Fractures	4
Head Injury	4
Minor Injury	4
Other Injury	4
Spinal Lesions	4
Poisonings	3
Amputations	4
Burns	4
Fractures	4
Head Injury	4
Minor Injury	4
Other Injury	4

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Spinal Lesions	4
Exposure to mechanical forces	3
Unintentional firearm injuries	4
Amputations	5
Burns	5
Fractures	5
Head Injury	5
Minor Injury	5
Other Injury	5
Spinal Lesions	5
Unintentional suffocation	4
Amputations	5
Burns	5
Fractures	5
Head Injury	5
Minor Injury	5
Other Injury	5
Spinal Lesions	5
Other exposure to mechanical forces	4
Amputations	5
Burns	5
Fractures	5
Head Injury	5
Minor Injury	5
Other Injury	5
Spinal Lesions	5
Adverse effects of medical treatment	3
Animal contact	3
Venomous animal contact	4
Amputations	5
Burns	5
Fractures	5
Head Injury	5
Minor Injury	5
Other Injury	5
Spinal Lesions	5
Non-venomous animal contact	4
Amputations	5
Burns	5
Fractures	5
Head Injury	5
Minor Injury	5
Other Injury	5
Spinal Lesions	5
Foreign body	3
Pulmonary aspiration and foreign body in airway	4
Amputations	5
Burns	5
Fractures	5
Head Injury	5
Minor Injury	5
Other Injury	5
Spinal Lesions	5

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Foreign body in eyes	4
Minor Injury	5
Other Injury	5
Foreign body in other body part	4
Amputations	5
Burns	5
Fractures	5
Head Injury	5
Minor Injury	5
Other Injury	5
Spinal Lesions	5
Other unintentional injuries	3
Amputations	4
Burns	4
Fractures	4
Head Injury	4
Minor Injury	4
Other Injury	4
Spinal Lesions	4
Self-harm and interpersonal violence	2
Self-harm	3
Amputations	4
Burns	4
Fractures	4
Head Injury	4
Minor Injury	4
Other Injury	4
Spinal Lesions	4
Interpersonal violence	3
Assault by firearm	4
Amputations	5
Burns	5
Fractures	5
Head Injury	5
Minor Injury	5
Other Injury	5
Spinal Lesions	5
Assault by sharp object	4
Amputations	5
Burns	5
Fractures	5
Head Injury	5
Minor Injury	5
Other Injury	5
Spinal Lesions	5
Assault by other means	4
Amputations	5
Burns	5
Fractures	5
Head Injury	5
Minor Injury	5
Other Injury	5
Spinal Lesions	5

Appendix Table A.1: GBD 2013 cause and sequelae list

All causes	Cause level
Forces of nature, war, and legal intervention	2
Exposure to forces of nature	3
Amputations	4
Burns	4
Fractures	4
Head Injury	4
Minor Injury	4
Other Injury	4
Spinal Lesions	4
Collective violence and legal intervention	3
Amputations	4
Burns	4
Fractures	4
Head Injury	4
Minor Injury	4
Other Injury	4
Spinal Lesions	4

Appendix Table A.2: List of International Classification of Diseases codes mapped to the Global Burden of Disease cause list for causes of disability

Cause Name	ICD-10 Code	ICD-9 Code
	A00-A00.9, A01.0-A14, A15-A28.9, A30-A31.0, A31.8-A39.9, A42-A44.9, A48.1, A48.2, A48.4-A48.52, A49.1, A50-A60.9, A63-A63.8, A65-A71.9, A74-A75.9, A77-A96.9, A98-A98.8, B00-B06.9, B10-B10.89, B15-B17.2, B19.1-B19.21, B20-B27.99, B29.4, B33-B33.8, B37-B37.2, B37.5-B54.0, B55.0-B55.2, B56-B60.8, B63, B65-B81.8, B83-B83.8, B90-B92, B94.0-B94.2, B95-B95.5, D50-D52.0, D52.8-D53.9, D62-D63.8, D64.1-D64.3, D64.8-D64.9, D69.9, D84, D84.9, E00-E02, E40-E46.9, E50-E61.9, E63-E64.9, F07.1, G00.0-G00.8, G03-G03.8, G04-G05.8, G14, G14.6, H65-H75.83, I00, I02, I02.9, I00-106.9, I09-J15.8, I16, I16.9, I20-I21.9, I36, I36.0, K67.0-K67.8, K74.7, K74.8, K93.0, M03.1, M12.1, M12.19, M49.0, M49.1, M73.0, M73.1, M89.6-M89.69, N70-N71.9, N73-N74.8, N96, O00-O07.9, O10-O16.9, O20-O20.9, O23-O23.93, O43.2-O43.239, O44-O46.93, O64-O67.9, O71-O72.3, O85-O86.89, O91-O91.23, P00-P03.1, P03.6-P05.9, P07-P15.9, P19-P29.9, P35-P39.9, P50-P61.9, P70, P70.3-P72.9, P74-P78.9, P80-P81.9, P83-P84, P90-P94.9, P96, P96.3, P96.4, P96.8-P96.89, R19.7, Z03.0, Z03.7-Z03.79, Z11-Z11.9, Z13.2-Z13.3, Z16-Z16.39, Z20-Z21, Z22-Z23.0, Z23.2-Z23.7, Z24.0-Z24.6, Z25.0, Z25.1, Z26.0, Z83.0, Z83.1, Z87.5-Z87.6	001-001.9, 002.0-034.9, 036-036.40, 036.5, 036.8-037.9, 039-039.4, 039.8-040, 040.1-041.89, 042-066.9, 070.0-070.21, 070.3-070.31, 070.41-070.43, 070.51-070.53, 070.7-070.71, 071-076.9, 078.5-084.9, 085.0-085.5, 086-088.9, 090-104.9, 112, 112.0, 112.3-118.9, 120-131.9, 136-136.5, 137-139.1, 139.9, 244.2, 260-269.9, 279.2, 279.3, 279.8-281.9, 285-285.9, 320.0-320.89, 321-323.9, 357.0, 381-384.9, 390-390.9, 391.4, 392, 392.9, 460-469, 470.0, 475-475.9, 476.9, 480-482.89, 483.0-483.9, 484.0-484.7, 487-489, 614-614.9, 630-636.92, 638-638.92, 640-642.94, 646.3-646.33, 659.3-659.33, 660-660.93, 665-665.34, 666-666.9, 670-670.9, 716.0-716.09, 730.4-730.99, 760-760.70, 760.72-768, 768.2-770, 770.1-775, 775.4-779.34, 779.6-779.89, 787.91, V01-V02.9, V03.0-V03.82, V03.9-V06, V07, V07.0, V07.2, V07.3, V08-V09.91, V12.00-V12.1, V12.61, V13.7, V15.87, V18.2, V18.3, V18.8, V58.62, V73.0-V73.99, V74.0-V74.3, V74.5-V74.9, V75.0-V75.9, V77.2, V78.0, V78.1
Communicable, maternal, neonatal, and nutritional diseases		
HIV/AIDS and tuberculosis	A10-A14, A15-A19.9, B20-B24.9, B90-B90.9, D84, D84.9, K67.3, K93.0, M49.0, P37.0, Z03.0, Z11.1, Z11.4, Z20.1, Z20.6, Z21, Z22.6, Z23.2, Z83.0	010-019.9, 042-044.9, 112.4-118.9, 136.3-136.5, 137-137.9, 138.0, 138.9, 139.9, 279.2, 279.3, 279.8, 279.9, 320.4, 730.4-730.6, V01.1, V03.2, V08, V12.01, V74.1
Tuberculosis	A10-A14, A15-A19.9, B90-B90.9, K67.3, K93.0, M49.0, P37.0, Z03.0, Z11.1, Z20.1, Z23.2	010-019.9, 137-137.9, 138.0, 138.9, 139.9, 320.4, 730.4-730.6, V01.1, V03.2, V12.01, V74.1
HIV/AIDS	B20-B24.9, D84, D84.9, Z11.4, Z20.6, Z21, Z22.6, Z83.0	042-044.9, 112.4-118.9, 136.3-136.5, 279.2, 279.3, 279.8, 279.9, V08
HIV/AIDS resulting in mycobacterial infection	B20.0	
HIV/AIDS resulting in other diseases	B20.1-B23.9	042.0-042.9, 043.0-043.9, 044.1-044.9
Diarrhea, lower respiratory, and other common infectious diseases		
Diarrheal diseases	A00-A00.9, A01.0-A09.9, A33-A37.91, A39-A39.9, A83-A87.9, B01-B02.9, B05-B05.9, B94.1, F07.1, G00.0, G00.8, G03-G03.8, G04-G05.8, H65-H75.83, J00-J02, J02.8-J03, J03.8-J06.9, J09-J15.8, J16-J16.9, J20-J21.9, J36, J36.0, P23-P23.9, P35.8, R19.7, Z11.0, Z20.0-Z20.09, Z20.811, Z20.820, Z22.0-Z22.2, Z22.31, Z23.0, Z23.5-Z23.7, Z24.1, Z24.4, Z25.1	001-001.9, 002.0-009.9, 032-033.9, 036-036.40, 036.5, 036.8-037.9, 047-049.9, 052-053.9, 055-055.9, 062-064.9, 139.0, 320.0-320.3, 320.5-320.89, 321-321.4, 321.6-323.9, 381-384.9, 460-469, 470.0, 475-475.9, 476.9, 480-482.89, 483.0-483.9, 484.0-484.3, 484.6, 484.7, 487-489, 771.3, 787.91, V01.0, V01.71, V01.79, V01.82-V01.84, V02.0-V02.4, V03.0, V03.1, V03.5-V03.7, V03.81, V03.82, V04.2, V04.7, V04.81, V04.82, V05.0, V05.1, V05.4, V12.61, V73.2, V74.0, V74.3
Cholera	A00-A00.9, Z23.0	001-001.9, 003-006.9, 007.4-007.8, 008.01, 008.02, 008.04, 008.2-009.9, 787.91, V01.0, V01.83, V02.0, V02.2, V02.3, V03.0, V74.0
Other salmonella infections	A02-A02.9	001-001.9, V01.0, V02.0, V03.0, V74.0
Shigellosis	A03-A03.9	003-003.9
Enteropathogenic E coli infection	A04.0	004-004.9
Enterotoxigenic E coli infection	A04.1	008.01
Campylobacter enteritis	A04.5	008.02, 008.04, V01.83
Amoebiasis	A06-A06.9	008.43
Cryptosporidiosis	A07.2	006-006.9, V02.2
Rotaviral enteritis	A08.0	007.4-007.7
Aeromonas		008.61
Clostridium difficile	A04.7	008.2
Norovirus	A08.1-A08.19	008.45
Adenovirus	A08.2	008.63
Other bacterial foodborne diarrhea	A05-A05.9	008.62
Other diarrheal diseases	A04, A04.3, A04.6, A04.8, A04.9, A07, A07.3, A07.4, A08, A08.3-A09.9, R19.7, Z22.1	005-005.9
Intestinal infectious diseases	A01.0-A01.4, A04.2, A04.4, A07.0, A07.1, A07.8, A07.9, Z11.0, Z20.0-Z20.09, Z22.0	007.8, 008.3-008.42, 008.44, 008.46-008.6, 008.64-009.9, 787.91, V02.3
Typhoid fever	A01.0-A01.09, Z22.0	002.0-002.9, 007-007.3, 007.9-008.00, 008.03, 008.09, 008.1, V02.1, V03.1
Paratyphoid fever	A01.1-A01.4	002.0, V02.1, V03.1
Other intestinal infectious diseases	A04.2, A04.4, A07.0, A07.1, A07.8, A07.9, Z11.0, Z20.0-Z20.09	002.1-002.9
Lower respiratory infections	J09-J15.8, J16-J16.9, J20-J21.9, P23-P23.9, Z25.1	007-007.3, 007.9-008.00, 008.03, 008.09, 008.1
Influenza	J09-J11.89, Z25.1	466-469, 470.0, 480-482.89, 483.0-483.9, 484.1, 484.2, 484.6, 484.7, 487-489, V01.82, V03.81, V03.82, V04.7, V04.81, V04.82, V12.61
Pneumococcal pneumonia	J13, J13.0, J15.3, J15.4, J15.6	487-489, V04.7, V04.81
H influenzae type B pneumonia	J14, J14.0	481-481.9, V03.82
Respiratory syncytial virus pneumonia	J12.1	482.2, V03.81
Other lower respiratory infections	J12, J12.0, J12.2-J12.9, J15-J15.29, J15.5, J15.7, J15.8, J16-J16.9, J20-J21.9, P23-P23.9	480.1, V04.82
Upper respiratory infections	J00-J02, J02.8-J03, J03.8-J06.9, J36, J36.0	466-469, 470.0, 480, 480.0, 480.2-480.9, 482-482.1, 482.3-482.89, 483.0-483.9, 484.1, 484.2, 484.6, 484.7
Otitis media	H65-H75.83	460-465.9, 475-475.9, 476.9
Meningitis	A39-A39.9, A87-A87.9, G00.0-G00.8, G03-G03.8, Z20.811, Z22.31	381-384.9
Pneumococcal meningitis	G00.1	036-036.40, 036.5, 036.8-036.9, 047-049.9, 320.0-320.3, 320.5-320.89, 321-321.4, 321.6-322.9, V01.84
H influenzae type B meningitis	G00.0	047-049.9, 320.2, 320.3, 320.7-320.89, 321-321.4, 321.6-322.9
Meningococcal meningitis	A39-A39.9, Z20.811, Z22.31	062-064.9, 139.0, 323-323.9, V05.0, V05.1
Other meningitis	A87-A87.9, G00.2-G00.8, G03-G03.8	032-032.9, V02.4, V03.5, V74.3
Encephalitis	A83-A86.4, B94.1, F07.1, G04-G05.8, Z24.1	033-033.9, 484.3, V03.6
Diphtheria	A36-A36.9, Z22.2, Z23.6	037-037.9, 771.3, V03.7
Whooping cough	A37-A37.91, Z23.7	055-055.9, 484.0, V04.2, V73.2
Tetanus	A33-A35.0, Z23.5	052-053.9, V01.71, V01.79, V05.4
Measles	B05-B05.9, Z24.4	060-061.8, 065-066.9, 071-071.9, 076-076.1, 076.6, 076.9, 080, 080.2-084.9, 085.0-085.5, 086-088.9, 120-130.9, 139.1, V01.5, V04.4, V04.5, V05.2, V12.03, V73.4-V73.6, V75.1-V75.5, V75.5-V75.8
Varicella and herpes zoster	B01-B02.9, P35.8, Z20.820	
Neglected tropical diseases and malaria	A68-A68.9, A69.2-A69.5, A71-A71.9, A74.0, A75-A75.9, A77-A79.9, A82-A82.9, A90-A96.9, A98-A98.8, B50-B54.0, B55.0-B55.2, B56-B60.8, B65-B81.8, B83-B83.8, B94.0, P37.1, P37.3, P37.4, Z11.6, Z20.3, Z24.2, Z24.3, Z26.0	
Malaria	B50-B54.0, P37.3, P37.4	084-084.9, V12.03, V75.1
Chagas disease	B57-B57.5	086-086.2, 086.9, V75.3
Leishmaniasis	B55.0-B55.2, Z26.0	085.0-085.5, V05.2, V75.2
Visceral leishmaniasis	B55.0	085.0
Cutaneous and mucocutaneous leishmaniasis	B55.1, B55.2, Z26.0	085.1-085.5
African trypanosomiasis	B56-B56.9	086.3-086.5
Schistosomiasis	B65-B65.9	120-120.9, V75.5
Cysticercosis	B69-B69.9	123.1
Cystic echinococcosis	B67-B67.99	122-122.9
Lymphatic filariasis	B74-B74.2	125.0-125.2, V75.6
Onchocerciasis	B73-B73.1	125.3
Trachoma	A71-A71.9, A74.0, B94.0	076-076.1, 076.6, 076.9, 139.1, V73.6
Dengue	A90-A91.9	061-061.8
Yellow fever	A95-A95.9, Z24.3	060-060.9, V04.4, V73.4
Rabies	A82-A82.9, Z20.3, Z24.2	071-071.9, V01.5, V04.5
Intestinal nematode infections	B76-B77.9, B79, Z11.6	126-126.9, 127.0, 127.3, V75.7
Ascariasis	B77-B77.9	127.0
Trichuriasis	B79	127.3
Hookworm disease	B76-B76.9	126-126.9
Food-borne trematodiasis	B66-B66.9	121-121.9
Other neglected tropical diseases	A68-A68.9, A69.2-A69.5, A75-A75.9, A77-A79.9, A92-A94.0, A96-A96.9, A98-A98.8, B58-B60.8, B68-B68.9, B70-B72.0, B74.3-B75, B78-B78.9, B80-B81.8, B83-B83.8, P37.1	065-066.9, 080, 080.2-083.9, 087-088.9, 123, 123.0, 123.2-125, 125.4-125.9, 127, 127.1, 127.2, 127.4-130.9, V73.5
Maternal disorders	N96, O00-O07.9, O10-O16.9, O20-O20.9, O23-O23.93, O43.2-O43.239, O44-O46.93, O64-O67.9, O71-O72.3, O85-O86.89, O91-O91.23, Z03.7-Z03.79, Z87.5-Z87.6	630-636.92, 638-638.92, 640-642.94, 646.3-646.33, 659.3-659.33, 660-660.93, 665-665.34, 666-666.9, 670-670.9
Maternal hemorrhage	O20-O20.9, O43.2-O43.239, O44-O46.93, O67-O67.9, O71-O71.4, O72-O72.3	640-641.93, 665-665.34, 666-666.9
Maternal sepsis and other maternal infections	O23-O23.93, O85-O86.89, O91-O91.23	659.3-659.33, 670-670.9

Appendix Table A.2: List of International Classification of Diseases codes mapped to the Global Burden of Disease cause list for causes of disability			
Cause Name	ICD-10 Code	ICD-9 Code	
Maternal hypertensive disorders	O10-O16.9	642-642.94	
Obstructed labor	O64-O66.9, O71.5-O71.9	660-660.93	
Complications of abortion	N96, O00-O07.9	630-636.92, 638-638.92, 646.3-646.33	
Indirect maternal deaths			
Late maternal deaths			
Maternal deaths aggravated by HIV/AIDS			
Other maternal disorders	P00-P03.1, P03.6-P05.9, P07-P15.9, P19-P22.9, P24-P29.9, P36-P36.9, P38-P39.9, P50-P61.9, P70, P70.3-P72.9, P74-P78.9, P80-P81.9, P83-P84, P90-P94.9, P96, P96.3, P96.4, P96.8-P96.89	760-760.70, 760.72-768, 768.2-770, 770.1-771, 771.4-775, 775.4-779.34, 779.6-779.89, V13.7, V15.87	
Neonatal disorders			
Preterm birth complications	P01.0, P01.1, P07-P07.39, P22-P22.9, P25-P28.9, P61.2, P77-P77.9	761.0, 761.1, 765-765.9, 769-769.9, 770.2-770.9, 776.6, 777.5-777.6	
Neonatal encephalopathy due to birth asphyxia and trauma	P01.7-P03.1, P03.6-P03.9, P10-P15.9, P20, P21, P24-P24.9, P90-P91.9	761.7-763.9, 767-768, 768.2-768.9, 770.1-770.18, 772.1-772.9, 779.0-779.2	
Neonatal sepsis and other neonatal infections	P36-P36.9, P38-P39.9	771.4-771.9	
Hemolytic disease and other neonatal jaundice	P55-P59.9	773-774.9	
Other neonatal disorders	P00-P01, P01.2-P01.6, P04-P05.9, P08-P09, P19-P19.9, P20-P20.9, P21.0-P21.9, P29-P29.9, P50-P54.9, P60-P61.1, P61.3-P61.9, P70, P70.3-P72.9, P74-P76.9, P78-P78.9, P80-P81.9, P83-P84, P92-P94.9, P96, P96.3, P96.4, P96.8-P96.89	760-760.70, 760.72-761, 761.2-761.6, 764-764.99, 766-766.9, 770, 771, 772, 772.0, 775, 775.4-776.5, 776.7-777.4, 777.7-779, 779.3-779.34, 779.6-779.89	
Nutritional deficiencies	D50-D52.0, D52.8-D53.9, D62-D63.8, D64.1-D64.3, D64.8-D64.9, D69.9, E00-E02, E40-E46.9, E50-E61.9, E63-E64.9, M12.1-M12.19, Z13.2-Z13.3	244.2, 260-269.9, 280-281.9, 285-285.9, 716.0-716.09, V12.1, V18.2, V18.3, V77.2, V78.0, V78.1	
Protein-energy malnutrition	E40-E46.9, E64.0	260-263.9	
Iodine deficiency	E00-E02	244.2	
Vitamin A deficiency	E50-E50.9, E64.1	264-264.9	
Iron-deficiency anemia	D50-D50.9, D62-D63.8, D64.1-D64.3, D64.8-D64.9, D69.9	280-281, 285-285.9, V18.2, V18.3, V78.0, V78.1	
Other nutritional deficiencies	D51-D52.0, D52.8-D53.9, E51-E61.9, E63-E64, E64.2, E64.3, M12.1-M12.19, Z13.2-Z13.3	265-269.9, 281.0-281.9, 716.0-716.09	
Other communicable, maternal, neonatal, and nutritional diseases	A20-A28.9, A30-A31.0, A31.8-A32.9, A38-A38.9, A42-A44.9, A48.1, A48.2, A48.4-A48.52, A49.1, A50-A60.9, A63-A63.8, A65-A67.9, A69-A69.1, A69.8-A70, A74, A74.8-A74.9, A80-A81.9, A88-A89.9, B00-B00.9, B03, B04, B06-B06.9, B10-B10.89, B15-B17.2, B19.1-B19.21, B25-B27.99, B29.4, B33-B33.8, B37-B37.2, B37.5-B49.9, B63, B91, B92, B94.2, B95-B95.5, G14, G14.6, I00, I02, I02.9, J02.0, J03.0-J03.01, K67.0, K67.2, K67.8, K74.7, K74.8, M03.1, M49.1, M73.0, M73.1, M89.6-M89.69, N70-N71.9, N73-N74.8, P35-P35.3, P35.9, P37, P37.2, P37.5-P37.9, Z11.3, Z20.2, Z20.4, Z20.5, Z20.810, Z22.4-Z22.59, Z22.8, Z22.9, Z23.3, Z23.4, Z24.0, Z24.5, Z24.6, Z25.0	020-031.9, 034-034.9, 039-039.4, 039.8-040, 040.1-041.89, 045-046.9, 050-051.9, 054-054.9, 056-059.9, 070-070.21, 070.3-070.31, 070.41-070.43, 070.51-070.53, 070.7-070.71, 072-075.9, 075.0, 076.8, 078.5-079.9, 080.0, 090-104.9, 112, 112.0, 112.3, 131-131.9, 136-136.29, 138, 139, 321.5, 357.0, 390-390.9, 379.4, 392, 392.9, 484.4, 484.5, 614-614.9, 730.7-730.99, 771.0-771.2, V01.2-V01.4, V01.6, V01.7, V01.8, V01.81, V01.89, V02.51-V02.9, V03.3, V03.4, V03.8, V03.9-V04.1, V04.3, V04.6, V04.8, V04.89, V05, V05.3, V05.8-V06, V12.00, V12.02, V12.09, V73.0, V73.1, V73.3, V73.8, V73.88, V73.9, V73.98, V74.2, V74.5, V74.6	
Sexually transmitted diseases excluding HIV	A50-A60.9, A63-A63.8, B63, K67.0-K67.2, M03.1, M73.0, M73.1, N70-N71.9, N73-N74.8, Z11.3, Z20.2, Z24	054.1, 090-099.9, 131-131.9, 614-614.9, V01.6, V02.7-V02.9, V73.8, V73.88, V73.9, V73.98, V74.5, V74.6	
Syphilis	A50-A53.9, K67.2, M03.1, M73.1	090-097.9	
Chlamydial infection	A55-A56.8, K67.0	099, 099.1, 099.3-099.6, V73.8, V73.88, V73.9, V73.98	
Gonococcal infection	A54-A54.9, K67.1, M73.0	098-098.9, V02.7	
Trichomoniasis	A59-A59.9	131-131.9	
Genital herpes	A60-A60.9	054.1	
Other sexually transmitted diseases	A57-A58, A63-A63.8	099.0, 099.2, 099.8, 099.9	
Hepatitis	B15-B17.2, B19.1-B19.21, B94.2, P35.3, Z20.5, Z22.5-Z22.59, Z24.6	070.0-070.21, 070.3-070.31, 070.41-070.43, 070.51-070.53, 070.7-070.71, V02.6-V02.69, V05.3	
Acute hepatitis A	B15-B15.9	070.0, 070.1	
Acute hepatitis B	B16-B17.0, B19.1-B19.11, P35.3	070.2-070.21, 070.3-070.31, 070.42, 070.52, V02.61	
Acute hepatitis C	B17.1-B17.11, B19.2-B19.21	070.41, 070.51, 070.7-070.71, V02.62	
Acute hepatitis E	B17.2	070.43, 070.53	
Leptosy	A30-A30.9, B92	030-030.9, V74.2	
Other infectious diseases	A20-A28.9, A31, A31.0, A31.8-A32.9, A38-A38.9, A42-A44.9, A48.1, A48.2, A48.4-A48.52, A49.1, A65-A67.9, A69-A69.1, A69.8-A70, A74, A74.8-A74.9, A80-A81.9, A88-A89.9, B00-B00.9, B03, B04, B06-B06.9, B10-B10.89, B25-B27.99, B29.4, B33-B33.8, B37-B37.2, B37.5-B49.9, B91, B95-B95.5, G14, G14.6, I00, I02, I02.9, J02.0, J03.0-J03.01, K67.8, K74.7, K74.8, M49.1, M89.6-M89.69, P35-P35.2, P35.9, P37, P37.2, P37.5-P37.9, Z20.4, Z20.810, Z22.8, Z22.9, Z23.3, Z23.4, Z24.0, Z24.5, Z25.0	020-029, 031-031.9, 034-034.9, 039-039.4, 039.8-040, 040.1-041.89, 045-046.9, 050-051.9, 054, 054.0, 054.10-054.9, 056-059.9, 072-075.9, 076.5, 076.8, 078.5-079.9, 080.0, 100-104.9, 112, 112.0, 112.3, 136-136.29, 138, 139, 321.5, 357.0, 390-390.9, 391.4, 392, 392.9, 484.4, 484.5, 730.7-730.99, 771.0-771.2, V01.2-V01.4, V01.7, V01.8, V01.81, V01.89, V02.51-V02.59, V03.3, V03.4, V03.8, V03.9-V04.1, V04.3, V04.6, V04.8, V04.89, V05, V05.8-V06, V12.00, V12.02, V12.09, V73.0, V73.1, V73.3, V73.8, V73.88, V73.9, V73.98, V74.2, V74.5, V74.6	
	A31.1, A31.2, A46, A46.0, B07-B09, B18-B18.9, B30-B30.9, B31.9, B32.3, B32.4, B35-B36.9, B37.3-B37.49, B85-B88.9, C00-C13.9, C15-C25.9, C30-C34.92, C37-C38.8, C40-C41.9, C43-C45.9, C47-C54.9, C56-C57.8, C58, C58.0, C60-C63.8, C64-C67.9, C68.0-C68.8, C69-C75.8, C81-C86.6, C88-C97.9, D00.0-D00.2, D01.0-D01.3, D02.0-D02.3, D03-D06.9, D07.0-D07.2, D07.4, D07.5, D09.0, D09.2-D09.8, D10.0-D10.7, D11-D12.9, D13.0-D13.7, D14.0-D14.32, D15-D25.9, D26.0, D26.1, D27-D27.9, D28.0-D28.7, D29.0-D29.8, D30.0-D30.8, D31-D36.7, D37.0-D37.5, D38.0-D38.5, D39.1-D39.8, D40.0-D40.8, D41.0-D41.8, D42-D43.9, D44.0-D44.8, D45-D47.9, D48.0-D48.7, D49.2-D49.4, D49.6, D49.81, D52.1, D55-D58.9, D59.0-D59.9, D59.5, D59.6, D60-D61.9, D64.0, D64.4, D66-D69.8, D70-D75.89, D76-D78.89, D80-D83.9, D84.0-D84.8, D86-D86.9, D89-D89.9, E03-E07.1, E09-E19.9, E20-E34.8, E36-E36.8, E65-E68, E70-E85.29, E87.1, E88-E89.9, F00-F03.91, F06.2-F06.7, F10-F14.8, F40-F49, F50.0-F50.5, F51-F52.9, F54-F83, F84.0-F84.8, F89.0-F98.6, F99.0, G10-G13.8, G20-G26.0, G30-G31.9, G35-G37.9, G40-G41.9, G43-G44.229, G44.4-G47.9, G50-G52.9, G54-G54.5, G54.8, G54.9, G56-G58.7, G60-G62.2, G64, G64.0, G70-G73.7, G90-G90.9, G93.7, G95-G95.9, G97-G97.9, H00-H02.8, H02.82-H02.9, H04-H05.429, H05.4-H06.3, H10-H11.9, H13-H13.8, H15-H22.8, H25-H26.09, H26.2-H28.8, H30-H36.8, H40-H40.9, H42-H44.539, H44.8-H55.89, H57-H62.8, H80-H83.9, H90-H91.93, H93-H95.9, I01-I01.9, I02.0, I05-I09.9, I11-H13.9, I20-I25.9, I27.1, I28-I28.8, I30-I31.1, I31.8, I31.9, I33-I42.9, I47-I48.92, I51.0-I51.6, I60-I61.9, I62.0-I62.03, I63-I63.9, I64.0-I66.9, I67-167.3, I67.5-I67.7, I69.0-I69.198, I69.20-I69.398, I70.2-I70.8, I72-I78.9, I80-I89.9, I91.9, I95.2, I95.3, I97-198.9, I30-I35.9, I37-I47.9, I60-I63.8, I65-I66.9, I70-I70.9, I82, I84-I84.9, I91-I92.9, I95-I95.9, I98-I98.09, I98.4-I98.6, K00-K15.9, K20-K22.9, K25-K29.91, K31-K31.89, K35-K38.9, K40-K46.9, K50-K52.9, K55-K57.93, K58.0-K62.9, K63.5, K64-K64.9, K66.8, K67, K68-K68.9, K70-K70.9, K71.3-K71.51, K71.7, K72.1-K74.69, K74.9, K75.2-K77.8, K80-K83.9, K85-K86.9, K90-K92, K92.8-K92.89, K94-K95.89, L00-L05.92, L08-L08.9, L10-L14.0, L20-L30.9, L40-L45, L49-L60.9, L62-L68.9, L70-L76.82, L80-L95.9, L97-L98.6, M00-M03.0, M03.2, M03.6, M05-M12, M12.2-M12.49, M12.8-M19.079, M22-M25.879, M26-M27.9, M30-M36.8, M40-M43.9, M45-M49, M49.2-M51.9, M53-M54.9, M60-M60.19, M60.8-M63.89, M65-M68.8, M70-M73, M73.8, M75-M77.9, M79-M87.19, M87.3-M89.59, M89.7-M96.9, M99-N08.8, N10-N12.9, N14-N16.8, N18-N18.9, N20-N23.0, N25-N32.0, N32.3, N32.4, N34-N37.8, N39-N39.8, N40-N53.9, N60-N65.1, N72, N72.0, N75-N77.8, N80-N81.9, N83-N83.9, N84.0-N84.8, N85-N91.5, N94.3, N95, N95.1-N95.9, N97-N97.9, N99-N99.9, P03.2-P03.5, P70.0-P70.2, P96.0-P96.2, P96.5, Q00-Q07.9, Q10-Q18.9, Q20-Q28.9, Q30-Q45.9, Q50-Q87.89, Q89-Q89.8, Q90-Q93.9, Q95-Q99.8, R12-R13.3, R43.0, R43.1, R50.2, R50.82, R50.83, R73-R73.9, R78.0-R78.5, X45-X45.9, X49-X49.9, Z01.0-Z01.7, Z01.3-Z03.5, Z04.6-Z04.72, Z08-Z09.9, Z12-Z13.1, Z13.4-Z13.85, Z13.858-Z15.89, Z21.0, Z31-Z31.9, Z41.1, Z41.3, Z42-Z43.9, Z48-Z49.32, Z51-Z51.9, Z52.4-Z52.7, Z64, Z80-Z81.8, Z82.0-Z83, Z83.2-Z83.79, Z84.0-Z84.2, Z85-Z85.9, Z86.0-Z87.448, Z87.7, Z87.798, Z88-Z88.9, Z92-Z97.4	035-035.9, 036.41-036.43, 036.6, 070.22, 070.23, 070.32, 070.33, 070.44, 070.54, 077-078.4, 110-111.9, 112.1, 112.2, 132-135.9, 136.6, 140-148.9, 150-158.9, 160-164.9, 170-175.9, 180-183.8, 184.0-184.4, 184.8, 185-186.9, 187.1-187.8, 188-188.9, 189.0-189.8, 190-194.8, 200-208.92, 209.0-209.17, 209.21-209.27, 209.31-209.57, 209.61, 209.63-209.67, 210.0-210.9, 211.0-211.8, 212.0-212.8, 213-218.9, 219.0, 219.1, 220-220.9, 221.0-221.8, 222.0-222.8, 223.0-223.89, 224-228.9, 229.0, 229.8, 230.1-230.8, 231.0-231.2, 232-232.9, 233.0-233.2, 233.31, 233.32, 233.4, 233.5, 233.7, 234.0-234.8, 235.0, 235.4, 235.6-235.8, 236.1, 236.2, 236.4, 236.5, 236.7, 236.91-237.9, 238.0-238.8, 239.2-239.4, 239.6, 240-243.9, 244.0, 244.1, 244.3, 244.8, 245-246.9, 250-259.9, 270-276, 277-277.2, 277.30-277.9, 278.0-279.19, 279.4-279.6, 282-284.9, 286-286.5, 286.7-292.9, 294.1-296.99, 298-298.4, 299-300.15, 300.2-300.89, 301-301.89, 302-303.93, 304.0-304.83, 305-306.9, 307.0-307.49, 307.51, 307.54, 307.6, 307.7, 307.81, 308-309.9, 311-313.83, 314-314.2, 315-315.5, 317-319.9, 327-327.09, 327.3-327.8, 330-331.2, 331.5-339.12, 339.20-341.9, 345-347.9, 349-349.8, 350-356.9, 357.1-357.7, 358-360.44, 360.8-366.19, 366.3-374.85, 374.87-376.52, 376.8-380.9, 385-385.82, 385.89-389.9, 391-391.2, 391.8, 391.9, 392.0, 393-398.99, 402-404.93, 410-414.9, 416.1, 416.2, 417-417.9, 420-423, 423.1-425.9, 427-427.32, 427.4-427.89, 429.0, 429.1, 430-435.9, 437.0-437.2, 437.5-437.8, 442-457.9, 459, 459.1-459.39, 470, 470.9-474.9, 476-476.1, 477-479, 490-504.9, 506-506.9, 508-509.515, 516-517.8, 518.6, 518.7, 518.9, 519.0-519.8, 520-526.1, 536.4-536.49, 537-537.6, 537.8-537.84, 538-539.4, 550-553.5, 555-558.9, 560-560.39, 560.8-560.9, 562-562.13, 564-564.7, 565-566.9, 569.0-569.44, 569.5-569.71, 569.84, 569.85, 571-571.9, 572.3-572.29, 573.0-573.4, 573.8-577.9, 579-583.9, 585-585.9, 588-590.9, 592-593.89, 594-599.6, 599.8-599.89, 600-608.89, 610-612.1, 615-618.9, 620-620.9, 621.0-622.7, 623-624.9, 625.4, 627-629.81, 680-709.3, 709.8-712.99, 713.0-713.5, 714-714.33, 714.8-715.98, 716.2-716.39, 717-718.99, 719.2-719.39, 719.8-719.89, 720-721.6, 721.8-728.11, 728.13-728.81, 728.83-729.5, 729.7-729.99, 729.92-730.39, 731-734.2, 737-737.9, 739-758.9, 759.0-759.89, 760.71, 775.0-775.3, 779.4, 779.5, 780.5-780.52, 780.57, 780.59, 780.62, 780.63, 786.03, 787.1, 788.0, 788.3-788.39, 790.2-790.22, 790.3, 885.0, 885.029, 885.09, 885.439, 886.0-E86.019, V07.1, V07.31-V07.59, V10-V12.0, V12.2-V12.6, V12.69, V12.79, V13.0-V13.09, V13.2, V13.22-V13.69, V13.81, V14-V15.1, V15.8-V15.86, V16-V16.19, V18.4-V18.7, V19.9, V19.0-V19.8, V26-V26.9, V40-V41.9, V42.0-V42.9, V42.81, V42.83, V43.0-V43.83, V44-V45.4, V45.6-V45.89, V47.2-V47.5, V48.4, V48.5, V49.81, V50.3, V56-V56.8, V58.5, V58.61, V58.63-V58.67, V58.71, V58.78, V59.1-V59.74, V72, V72.2, V73.2, V74.4, V76-V76.9, V77.0, V77.1, V77.3-V77.8, V77.91, V78, V78.2, V80.0, V80.09-V81.6, V82.0-V82.3, V85-V85.54	
Non-communicable diseases	C00-C13.9, C15-C25.9, C30-C34.92, C37-C38.8, C40-C41.9, C43-C45.9, C47-C54.9, C56-C57.8, C58, C58.0, C60-C63.8, C64-C67.9, C68.0-C68.8, C69-C75.8, C81-C86.6, C88-C97.9, D00.0-D00.2, D01.0-D01.3, D02.0, D03-D06.9, D07.0-D07.2, D07.4, D07.5, D09.0, D09.2-D09.8, D10.0-D10.7, D11-D12.9, D13.0, D13.1, D14.0-D14.32, D15-D25.9, D26.0, D26.1, D27-D27.9, D28.0-D28.7, D29.0-D29.8, D30.0-D30.8, D31-D36.7, D37.0-D37.5, D38.0-D38.5, D39.1-D39.8, D40.0-D40.8, D41.0-D41.8, D42-D43.9, D44.0-D44.8, D45-D47.9, D48.0-D48.7, D49.2-D49.4, D49.6, D49.81, K31.7, K62.0, K62.1, K63.5, N60-N60.99, N84.0-N84.8, N87-N87.9, Z03.1, Z08-Z09.9, Z12-Z12.9, Z80-Z80.9, Z85-Z85.9, Z86.0-Z86.03	140-148.9, 150-158.9, 160-164.9, 170-175.9, 180-183.8, 184.0-184.4, 184.8, 185-186.9, 187.1-187.8, 188-188.9, 189.0-189.8, 190-194.8, 200-208.92, 209.0-209.17, 209.31-209.57, 209.61, 209.63-209.67, 210.0-210.9, 211.0-211.8, 212.0-212.8, 213-218.9, 219.0, 219.1, 221.0-221.8, 222.0-222.8, 223.0-223.89, 224-228.9, 229.0, 229.8, 230.1-230.8, 231.0-231.2, 232-232.9, 233.0-233.2, 233.31, 233.32, 233.4, 233.5, 233.7, 234.0-234.8, 235.0, 235.4, 235.6-235.8, 236.1, 236.2, 236.4, 236.5, 236.7, 236.91-237.9, 238.0-238.8, 239.2-239.4, 239.6, 240-243.9, 244.0, 244.1, 244.3, 244.8, 245-246.9, 250-259.9, 270-276, 277-277.2, 277.30-277.9, 278.0-279.19, 279.4-279.6, 282-284.9, 286-286.5, 286.7-292.9, 294.1-296.99, 298-298.4, 299-300.15, 300.2-300.89, 301-301.89, 302-303.93, 304.0-304.83, 305-306.9, 307.0-3	

Appendix Table A.2: List of International Classification of Diseases codes mapped to the Global Burden of Disease cause list for causes of disability

Cause Name	ICD-10 Code	ICD-9 Code
Breast cancer	C50-C50.119, C50.2-C50.929, Z12.3-Z12.39, Z80.3, Z85.3	174-175.9, V10.3, V16.3, V76.1-V76.19
Cervical cancer	C53-C53.9, Z12.4, Z85.41	180-180.9, V10.4.1, V72.32, V76.2
Uterine cancer	C54-C54.9, Z85.42	182-182.8, V10.4.2
Prostate cancer	C61-C61.9, Z12.5, Z80.42, Z85.46	185-185.9, V10.4.6, V16.4.2, V76.4.4
Colon and rectum cancer	C18-C20.0, C20.9-C21.8, K63.5, Z12.1-Z12.13, Z85.03-Z85.04.8, Z86.010	153-154.9, 155.5, 155.9, 209.1-209.17, V10.05, V10.06, V76.41, V76.5-V76.52
Lip and oral cavity cancer	C00-C08.9, Z85.81, Z85.810	140-145.9, V10.01, V10.02, V76.4.2
Nasopharynx cancer	C11-C11.9	147-147.9
Other pharynx cancer	C09-C10.9, C12-C13.9	146-146.9, 148-148.9
Gallbladder and biliary tract cancer	C20.8, C23-C24.9	156-156.9, 209.25-209.27
Pancreatic cancer	C25-C25.9, Z85.07	157-157.9
Malignant skin melanoma	C43-C43.9, C44, Z85.72, Z85.82-Z85.82.8	172-172.9
Non-melanoma skin cancer	C44-C44.99	173-173.99, 209.31-209.36, V76.4.3
Ovarian cancer	C56-C56.9, Z80.41, Z85.43	183, 183.0, V10.4.3, V16.4.1, V76.4.6
Testicular cancer	C62-C62.92, Z80.43, Z85.47, Z85.48	186-186.9, V10.4.7, V10.4.8, V16.4.3, V76.4.5
Kidney cancer	C64-C65.9, Z80.51, Z85.52-Z85.54	189.0, 189.1, 209.24, V10.5.2, V10.5.3, V16.5.1
Bladder cancer	C67-C67.9, Z12.6-Z12.7.9, Z80.52, Z85.51	188-188.9, V10.5.1, V16.5.2, V76.3
Brain and nervous system cancer	C70-C72.9, Z85.84.1, Z85.84.8	191-192.9, V10.8.5, V10.8.6
Thyroid cancer	C73-C73.9, Z85.85.0	193-193.9, V10.8.7
Mesotheliom	C45-C45.9	163-163.3, 163.8, 163.9
Hodgkin lymphoma	C81-C81.99, Z85.71	201-201.98, V10.7.2
Non-Hodgkin lymphoma	C82-C86.6, C96-C97.9, D36.0, D47.0-D47.2, D47.9	200-200.9, 202-202.98, V10.7, V10.7.1, V10.7.9, V16.7
Multiple myeloma	C88-C90.32	203-203.9
Leukemia	C91-C95.92, Z80.6, Z85.6	204-208.92, V10.59-V10.69, V16.6
Other neoplasms	C17-C17.9, C30-C31.9, C37-C38.8, C40-C41.9, C47-C49.9, C50.12-C50.12.9, C51-C52.9, C57-C57.8, C58, C58.0, C60-C60.9, C63-C63.8, C66-C66.9, C68.0-C68.8, C69-C69.92, C74-C75.8, D00.00-D00.2, D01.0-D01.3, D02.0-D02.3, D03-D06.9, D07.0-D07.2, D07.4, D07.5, D09.0, D09.2-D09.8, D10.0-D10.7, D11-D12.9, D13.0-D13.7, D14.0-D14.32, D15-D25.9, D26.0, D26.1, D27-D27.9, D28.0-D28.7, D29.0-D29.8, D30.0-D30.8, D31-D36, D36.1-D36.7, D37.01-D37.5, D38.0-D38.5, D39.1-D39.8, D40.0-D40.8, D41.0-D41.8, D42-D43.9, D44.0-D44.8, D45-D47, D47.3-D47.7, D48.0-D48.7, D49.2-D49.4, D49.6, D49.8.1, K31.7, K62.0, K62.1, N60-N60.99, N84.0-N84.8, N87-N87.9, Z12.8-Z12.9, Z85.06-Z85.06.8, Z85.22-Z85.29, Z85.83-Z85.84.0, Z86.00.0, Z86.01.1, Z86.01.1	036.41-036.43, 036.6, 391-391.2, 391.8, 391.9, 392.0, 393-398.99, 402-402.91, 410-414.9, 417-417.9, 420-423, 423.1-425.9, 427-427.32, 427.6-427.89, 429.0, 429.1, 430-435.9, 437.0-437.2, 437.5-437.8, 442-445.89, 447-454.9, 456, 456.3-457.9, 459, 459.1-459.39, V12.5-V12.5.9, V15.1, V17.1, V17.3-V17.49, V42.1, V42.2, V43.2-V43.5, V45.0-V45.0.9, V45.81, V45.82, V47.2, V58.61, V58.63, V58.66, V58.73, V81.3, V81.2
Cardiovascular diseases		
Rheumatic heart disease	I01-I01.9, I02.0, I05-I09.9	391-391.2, 391.8, 391.9, 392.0, 393-398.99
Ischemic heart disease	I20-I25.9, Z82.4-Z82.4.9	410-414.9, V17.3
Cerebrovascular disease	G45-G46.8, I60-I61.9, I62.0-I62.03, I63-I63.9, I64.0-I66.9, I67.0-I67.3, I67.5-I67.7, I69.0-I69.198, I69.20-I69.398, Z82.3	430-435.9, 437.0-437.2, 437.5-437.8, V12.54, V17.1
Ischemic stroke	G45-G46.8, I63-I63.9, I64.0-I66.9, I67.2, I67.3, I67.5, I67.6, I69.3-I69.398	433-435.9, 437.0, 437.1, 437.5-437.8
Hemorrhagic stroke	I60-I61.9, I62.0-I62.03, I67.0, I67.1, I67.7, I69.0-I69.198, I69.20-I69.298	430-432.9, 437.2
Hypertensive heart disease	I11-I11.9	402-402.91
Cardiomyopathy and myocarditis	I40-I42.9, I51.4-I51.6	036.43, 036.6, 422-422.99, 425-425.9, 429.0, 429.1
Atrial fibrillation and flutter	I48-I48.92	427.3-427.32
Aortic aneurysm		
Peripheral vascular disease	I70.2-I70.799, I73-I73.9	443.0-443.9
Endocarditis	I33-I33.9, I39-I39.9	036.42, 421-421.9, 424.9-424.91
Other cardiovascular and circulatory diseases	I28-I28.8, I30-I31.1, I31.8, I31.9, I34-I38.9, I47-I47.9, I51.0-I51.3, I70.8, I72-I72.9, I74-I78.9, I80-I83.93, I86-I89.9, I91.9	036.41, 417-417.9, 420-420.99, 423, 423.1-424.8, 424.99, 427-427.2, 427.6-427.89, 442-443, 444-445.89, 447-454.9, 456, 456.3-457.9, 459, 459.1-459.39
Chronic respiratory diseases	D86-D86.2, D86.89, D86.9, G47.3-G47.39, J30-J35.9, J37-I47.9, J60-J63.8, J65-J68.9, J70-J70.1, J70.8, J70.9, J82, J84-I84.9, J91-J92.9, J98-J98.09, J98.4-J98.6, Z82.5, Z83.6, Z87.0-Z87.0.9, Z94.2	490-492.9, 494-494.9, 496-499
Chronic obstructive pulmonary disease	J40-J44.9, J47-I47.9	490-492.9, 494-494.9, 496-499
Pneumoconiosis	J60-J63.8, J65, J65.0, J92.0	500-504.9, V15.84
Silicosis	J62-J62.9	502-502.9, 503.0, 503.9
Asbestosis	J61, J61.0, J92.0	501, V15.84
Coal workers pneumoconiosis	J60, J60.0	500-500.9, 501.0, 501.9
Other pneumoconiosis	J63-J63.8, J65, J65.0	503, 503.1, 504-504.9
Asthma	J45-J46.9, Z82.5	493-493.92, V17.5
Interstitial lung disease and pulmonary sarcoidosis	D86-D86.2, D86.89, D86.9, J84-I84.9	135-135.9, 136.6, 515, 516-516.9
Other chronic respiratory diseases	G47.3-G47.39, J30-J35.9, J37-I39.9, J66-J68.9, J70-J70.1, J70.8, J70.9, J82, J91-J92.9, J98-J98.09, J98.4-J98.6	327.2-327.8, 470, 470.9-474.9, 476-476.1, 477-479, 495-495.9, 506-506.9, 508-509, 517-517.8, 518.6, 518.9, 519.1-519.8, 713.4, 780.57, 786.03, V07.1, V13.81, V14-V15.09, V19.6
Cirrhosis	B18-B18.9, I85-I85.9, K70-K70.9, K71.3-K71.5.1, K71.7, K72.1-K74.69, K74.9, K75.8-K76.0, K76.6, K76.7, K76.9, Z52.6, Z94.4	070.22, 070.23, 070.32, 070.33, 070.44, 070.54, 456.0-456.21, 571-571.9, 572.3-572.9, 573.0-573.3, 573.8, 573.9, V42.7, V59.6
Cirrhosis due to hepatitis B		
Cirrhosis due to hepatitis C		
Cirrhosis due to alcohol use		
Cirrhosis due to other causes		
Digestive diseases		
Peptic ulcer disease	K25-K28.9, K31, K31.1-K31.6, K31.8, K31.82-K31.89	531-534.91, V12.71
Gastritis and duodenitis	K29-K29.91	535-535.9
Appendicitis	K35-K37.9, K38.3	540-542.9
Paralytic ileus and intestinal obstruction	K56-K56.9	560-560.39, 560.8-560.9
Inguinal, femoral, and abdominal hernia	K40-K42.9, K44-K46.9	550-551.1, 551.3-552.1, 552.3-553.03, 553.6, 555.3
Inflammatory bowel disease	K50-K52.9, K58.0, M09.1	555-555.2, 555.9-556.9, 558-558.9, 569.5, V12.72
Vascular intestinal disorders	K55-K55.9	557-557.9
Gallbladder and biliary diseases	K80-K83.9	574-576.9
Pancreatitis	K85-K86.9	577-577.9, 579.4
Other digestive diseases	I84-I84.9, K00-K01.1, K03-K04.99, K06-K15.9, K20-K22.9, K25-K29.91, K31-K31.6, K31.8-K31.89, K35-K38.9, K40-K42.9, K44-K46.9, K50-K52.9, K55-K57.93, K58.0-K62, K62.2-K62.6, K62.8-K62.9, K64-K64.9, K66.8, K67, K68-K68.9, K75.2-K75.4, K76.1-K76.5, K76.8-K76.8.9, K77-K77.8, K80-K83.9, K85-K86.9, K90-K90.9, K92.8-K92.89, M09.1, R12-R14.3, Z13.81-Z13.81.8, Z43.1-Z43.4, Z83.7-Z83.7.9, Z87.1-Z87.1.9	455-455.9, 530-536.1, 537-537.6, 537.8-537.8.4, 538, 540-543.9, 550-551.1, 551.3-552.1, 552.3-553.6, 555-558.9, 560-560.39, 560.8-560.9, 562-562.13, 564-564.1, 564.5-564.7, 565-566.9, 569.1-569.42, 569.5, 569.7, 569.7.1, 573.4, 574-577.9, 579-579.2, 579.4-579.9, 713.1, 787.1, V12.7-V12.7.9, V18.5-V18.5.9, V45.72, V45.75, V47.3, V58.75
Neurological disorders		
Alzheimer disease and other dementias	F00-F03.91, G30-G31.9	290-290.9, 294.1-294.9, 331-331.2
Parkinson disease	G20-G21.0, G21.2-G22.0	332-332.9
Epilepsy	G40-G41.9, Z82.0	345-345.91
Multiple sclerosis	G35-G35.9	340-340.9
Migraine	G43-G43.919	346-346.93
Tension-type headache	G44-G44.229, G44.8-G44.8.9	307.81, 339-339.12, 339.20-339.89

Appendix Table A.2: List of International Classification of Diseases codes mapped to the Global Burden of Disease cause list for causes of disability

Cause Name	ICD-10 Code	ICD-9 Code
Medication overuse headache	G44.4-G44.59	
Other neurological disorders	G10-G13.8, G23-G24, G24.1-G25.0, G25.2, G25.3, G25.5, G25.8-G26.0, G36-G37.9, G50-G52.9, G54, G54.0, G54.5, G54.8, G54.9, G56-G57, G57.2-G58.7, G60-G62, G62.2, G64, G64.0, G70-G72, G72.2-G73.7, G90-G92.9, G95-G95.9, M33-M33.99, M60-M60.19, M60.8-M63.89, M79-M79.9	330-330.9, 331.5-331.9, 333-338.4, 341-341.9, 349, 349.2-349.8, 350-353.0, 353.5-355, 355.1-356.9, 357.1, 357.3, 357.4, 357.7, 358-359.9, 713.5, 725-725.9, 728-728.11, 728.13-728.81, 728.83-729.5, 729.7-729.90, 729.92, 729.99, 775.2
Mental and substance use disorders	F06.2-F06.7, F10-F13.8, F40-F49, F50.0-F50.5, F51-F52.9, F54-F83, F84.0-F84.8, F89.0-F89.6, F99.0, G47-G47.29, G47.4-G47.9, G62.1, G72.1, P96.1, Q86.0, R43.0, R43.1, R78.0-R78.5, X45-X45.9, X49-X49.9, Z03.2, Z04.6-Z04.72, Z13.4, Z64, Z81.8, Z86.5-Z86.59	291-292.9, 295-296.99, 298-298.4, 299-300.15, 300.2-300.89, 301-301.89, 302-303.93, 304.0-304.83, 305-306.9, 307.0-307.49, 307.51, 307.54, 307.6, 307.7, 308-309.9, 311-313.83, 314-314.2, 315-315.5, 317-319.9, 327-327.09, 347-347.9, 357.5, 760.71, 780.5-780.52, 780.59, 790.3, E85.0-E85.029, E85.09-E85.439, E86.0-E86.019, V11.0-V12.0, V15.8-V15.83, V15.85, V15.86, V17, V17.0, V18.4, V40-V41.9, V79-V79.9
Schizophrenia	F06.2, F20-F23.9, F25-F29.9	295-295.95, 301.0, 301.2-301.22, V11.0
Alcohol use disorders	F10-F10.99, G62.1, G72.1, Q86.0, R78.0, X45-X45.9, Z81.1	291-291.9, 303-303.93, 305.0-305.03, 357.5, 760.71, 790.3, E86.0-E86.019, V11.3
Drug use disorders	F11-F16.99, F18-F19.99, P96.1, R78.1-R78.5, X49-X49.9, Z81.2-Z81.4	292-292.9, 304.0-304.83, 305, 305.1-305.93, E85.0-E85.029, E85.09-E85.439, V15.8-V15.83, V15.85, V15.86
Opioid use disorders	F11-F11.99, P96.1, R78.1	304.0-304.03, 305.5-305.53, E85.00-E85.029
Cocaine use disorders	F14-F14.99, R78.2	304.2-304.23, 305.6-305.63
Amphetamine use disorders	F15-F15.99	304.4-304.43, 305.7-305.73
Cannabis use disorders	F12-F12.99	304.3-304.33, 305.2-305.23
Other drug use disorders	F13-F13.99, F16-F16.99, F18-F19.99, R78.3-R78.5, X49-X49.9	292-292.9, 304.1-304.13, 304.5-304.83, 305, 305.1-305.13, 305.3-305.43, 305.8-305.93, V15.8-V15.83, V15.85, V15.86
Depressive disorders	F32-F33.9, F34.1	296.2-296.36, 300.4, 311-311.9, V11.1, V11.2
Major depressive disorder	F32-F33.9	296.2-296.36, 311-311.9, V11.1, V11.2
Dysthymia	F34.1	300.4
Bipolar disorder	F06.3-F06.34, F30-F31.9, F34.0	296-296.16, 296.4-296.99, 301.1-301.13
Anxiety disorders	F06.4-F06.7, F40-F44.9	300.0-300.09, 300.2-300.3, 301.4, 308-309.9, 313.0
Eating disorders	F50.0-F50.5	307.1, 307.51, 307.54
Anorexia nervosa	F50.0-F50.1	307.1, 307.54
Bulimia nervosa	F50.2-F50.5	307.51
Autistic spectrum disorders	F84.0-F84.8	299.0-299.01, 299.8-299.81
Autism	F84.0-F84.4	299.0-299.01
Asperger syndrome	F84.5, F84.8	299.8-299.81
Attention-deficit/hyperactivity disorder	F90-F90.9	314.0-314.01
Conduct disorder	F91-F94.9	301, 301.3, 301.5-301.89, 312-312.9
Idiopathic intellectual disability	F70-F79.9, Z81.0	317-319.9, V18.4
Other mental and substance use disorders	F17-F17.9, F24, F34, F34.8, F45-F49, F51-F52.9, F54-F69.0, F80-F83, F89.0, F95-F98.6, P99.0, G47-G47.29, G47.4-G47.9, R43.0, R43.1	298-298.4, 299, 299.1-299.11, 299.9-300, 300.1-300.15, 300.5-300.89, 302-302.9, 306-306.9, 307.0, 307.2-307.49, 307.6, 307.7, 313, 313.1-313.83, 314, 314.1, 314.2, 315-315.5, 327-327.09, 347-347.9, 780.5-780.52, 780.59
Diabetes, urogenital, blood, and endocrine diseases	B37.3-B37.49, D52.1, D55-D58.9, D59.0-D59.3, D59.5, D59.6, D60-D61.9, D64.0, D64.4, D66-D69.8, D70-D75.89, D76-D78.89, D80-D83.9, D84.0-D84.8, D86.3-D86.87, D89-D89.9, E03-E07.1, E09-E16.9, E20-E20.8, E36-E36.8, E65-E68, E70-E85.29, E87.71, E88-E89.9, G21.1-G21.19, G24.0-G24.09, G25.1, G25.4, G25.6-G25.79, G62.0, G72.0, G93.7, G97-G97.9, H59-H59.89, H95-H95.9, I12-I13.9, I95.2, I95.3, I97-198.9, J70.2-J70.5, J95-J95.9, K43-K43.9, K62.7, K91-K92, K94-K95.89, L23.3, L24.4, L25.1, L27.0, L27.1, L56, L56.0, L58-L58.9, M10.2-M10.29, M83.5, M87.1-M87.19, M96-M96.9, N00-N08.8, N10-N12.9, N14-N16.8, N18-N18.9, N20-N23.0, N25-N32.0, N32.3, N32.4, N34-N37.8, N39-N39.8, N40-N53.9, N61-N65.1, N72, N72.0, N75-N77.8, N80-N81.9, N83-N83.9, N85-N86, N88-N91.5, N94.3, N95, N95.1-N95.9, N97-N97.9, N99-N99.9, P03.2-P03.5, P70.0-P70.2, P96.2, P96.5, R50.2, R50.82, R50.83, R73-R73.9, Z01.4-Z01.7, Z13.1, Z13.10, Z31-Z31.9, Z42-Z43.0, Z43.5-Z43.9, Z48-Z49.32, Z51-Z51.9, Z52.4, Z83.3-Z83.49, Z84.1, Z84.2, Z86.1-Z86.19, Z87.4-Z87.448, Z88-Z88.9, Z92-Z94.0, Z94.6, Z94.8-Z94.9, Z96-Z96.49, Z96.6-Z97.2	250-250.39, 250.5-250.99, 357.2, 362.0-362.07, 366.41, 775.0, 775.1, 790.2-790.22, V18, V18.0, V42.83, V45.85, V58.67, V77.1
Diabetes mellitus	E10-E10.11, E10.3-E11.1, E11.3-E12.1, E12.3-E13.11, E13.3-E14.1, E14.3-E14.9, P70.0-P70.2, R73-R73.9, Z13.1, Z83.3	250-250.39, 250.5-250.99, 357.2, 362.0-362.07, 366.41, 775.0, 775.1, 790.2-790.22, V18, V18.0, V42.83, V45.85, V58.67, V77.1
Acute glomerulonephritis	N00-N01.9	580-580.9
Chronic kidney disease	E10.2-E10.29, E11.2-E11.29, E12.2, E13.2-E13.29, E14.2, I12-I13.9, N02-N08.8, N15.0, N18-N18.9, Z49-Z49.32, Z52.4, Z99.2	250.4-250.49, 403-404.93, 581-583.9, 585-585.9, 589-589.9, V13.03, V13.09, V18.6, V18.69, V42.0, V45.1-V45.12, V45.73, V56-V56.8, V59.4, V81.5, V81.6
Chronic kidney disease due to diabetes mellitus	E10.2-E10.29, E11.2-E11.29, E12.2, E13.2-E13.29, E14.2	250.4-250.49
Chronic kidney disease due to hypertension	I12-I13.9	403-404.93
Chronic kidney disease due to glomerulonephritis	N03-N06.9	581-583.9
Chronic kidney disease due to other causes	N02-N02.9, N07-N08.8, N15.0	589-589.9
Urinary diseases and male infertility	N10-N12.9, N15, N15.1-N16.8, N20-N23.0, N25-N32.0, N32.3, N32.4, N34-N37.8, N39-N39.8, N40-N53.9, Z43.5-Z43.7, Z84.1, Z84.2	588-588.9, 590-590.9, 592-593.89, 594-596.81, 596.89-598.1, 598.8-599.6, 599.8-599.89, 600-608.89, 788.0, 788.3-788.39, V13.0-V13.02, V26.5, V26.52, V45.74, V47.4, V58.76
Interstitial nephritis and urinary tract infections	N10-N12.9, N15, N15.1-N16.8, N30-N30.91, N34-N34.3, N39.0-N39.2	590-590.9, 595-595.9, 597-597.9, 599.0, V13.02
Urolithiasis	N20-N23.0	592-592.9, 594-594.9, 788.0, V13.01
Benign prostatic hyperplasia	N40-N40.9	600-600.91
Male infertility due to other causes	N46-N46.9, Z43.7	606-606.9, V26.5, V26.52
Other urinary diseases	N25-N29.8, N31-N32.0, N32.3, N32.4, N35-N37.8, N39, N39.3-N39.8, N41-N45.9, N47-N53.9	588-588.9, 593-593.89, 596-596.81, 596.89, 596.9, 598-598.1, 598.8-599, 599.1-599.6, 599.8-599.89, 601-605.9, 607-608.89, 788.3-788.39
Gynecological diseases	B37.3-B37.49, E28.2, N61-N64.9, N72, N72.0, N75-N77.8, N80-N81.9, N83-N83.9, N85-N86, N88-N88.9, N91.5, N94.3, N95, N95.1-N95.9, N97-N97.9, Z01.4-Z01.7, Z31-Z31.9, Z86.1-Z86.19, Z87.4-Z87.448	112.1, 112.2, 220-220.9, 256.4, 611-612.1, 615-616.9, 620-620.9, 621.4-621.9, 622.3-622.7, 623, 623.2-623.6, 623.8-624.9, 625.4, 627-629.81, V07.4-V07.59, V13.2, V13.29, V18.7, V26-V26.49, V26.51, V26.8, V26.9, V43.82, V45.71, V45.83, V47.5, V49.81, V59.7-V59.74, V72.3, V72.31
Uterine fibroids		
Polycystic ovarian syndrome	E28.2	256.4
Female infertility due to other causes	N97-N97.9, Z31-Z31.9	628-628.9, V26-V26.49, V26.51, V26.8-V26.9, V59.7-V59.74
Endometriosis	N80-N80.9	617-617.9
Genital prolapse	N81-N81.9	618-618.9
Premenstrual syndrome	N94.3	625.4
Other gynecological diseases	B37.3-B37.49, N61-N64.9, N72, N72.0, N75-N77.8, N83-N83.9, N85-N86, N88-N91.5, N95, N95.1-N95.9	112.1, 112.2, 220-220.9, 611-612.1, 615-616.9, 620-620.9, 621.4-621.9, 622.3-622.7, 623, 623.2-623.6, 623.8-624.9, 625.4, 627-629.81, V07.4-V07.59
Hemoglobinopathies and hemolytic anemias	D55-D58.9, D59.1, D59.3, D59.5, D60-D61.09, D61.2-D61.9, D64.0, D64.4	282-284.9, 713.2, V78, V78.2-V78.9
Thalassemias	D56-D56.9	282.4-282.49
Thalassemia trait	D57-D57.819	282.5-282.68, V78.2
Sickle cell disorders	D55-D55.9	282.2, 282.3
Sickle cell trait	D58-D58.9, D59.1, D59.3, D59.5, D60-D61.09, D61.2-D61.9, D64.0, D64.4	282-282.1, 282.69-284.9, 713.2
G6PD deficiency		
G6PD trait		
Other hemoglobinopathies and hemolytic anemias	D52.1, D59.0, D59.2, D59.6, D61.1, D66-D69.8, D70-D75.89, D76-D78.89, D80-D83.9, D84.0-D84.8, D86.3, D86.87, D89-D89.9, E03-E07.1, E09-E09.9, E15-E16.9, E20-E28.1, E28.3-E34.8, E36-E36.8, E65-E68, E70-E85.29, E87.71, E88-E89.9, G21.1-G21.19, G24.0-G24.09, G25.1, G25.4, G25.6-G25.79, G62.0, G72.0, G93.7, G97-G97.9, H59-H59.89, H95-H95.9, I95.2, I95.3, I97-198.9, J70.2-J70.5, J95-J95.9, K43-K43.9, K62.7, K91-K92, K94-K95.89, L23.3, L24.4, L25.1, L27.0, L27.1, L56, L56.0, L58-L58.9, M10.2-M10.29, M83.5, M87.1-M87.19, M96-M96.9, N14-N14.4, N65-N65.1, N99-N99.9, P03.2-P03.5, P96.2, P96.5, R50.2, R50.82, R50.83, Z21.0, Z42-Z43.0, Z43.8, Z43.9, Z48-Z48.9, Z51-Z51.9, Z83.4-Z83.49, Z88-Z88.9, Z92-Z94.0, Z94.6, Z94.8-Z94.9, Z96-Z96.49, Z96.6-Z97.2, Z97.8-Z99.12	240-243.9, 244.0, 244.1, 244.3, 244.8, 245-246.9, 251-256.39, 256.8-259.9, 270-273.9, 275-276, 277-277.2, 277.30-277.9, 278.0-279.19, 279.4-279.6, 286-286.5, 286.7-289.9, 349.0, 349.1, 357.6, 518.7, 519.0-519.09, 536.4-536.49, 539-539.9, 551.2-551.29, 552.2-552.29, 564.2-564.4, 569.6-569.69, 579.3, 596.82, 596.83, 598.2, 598.3, 598.4, 598.5, 598.6, 598.7, 598.8, 598.9, 599.0, 599.1, 599.2, 599.3, 599.4, 599.5, 599.6, 599.7, 599.8, 599.9, 600, 600.1, 600.2, 600.3, 600.4, 600.5, 600.6, 600.7, 600.8, 600.9, 601, 601.1, 601.2, 601.3, 601.4, 601.5, 601.6, 601.7, 601.8, 601.9, 602, 602.1, 602.2, 602.3, 602.4, 602.5, 602.6, 602.7, 602.8, 602.9, 603, 603.1, 603.2, 603.3, 603.4, 603.5, 603.6, 603.7, 603.8, 603.9, 604, 604.1, 604.2, 604.3, 604.4, 604.5, 604.6, 604.7, 604.8, 604.9, 605, 605.1, 605.2, 605.3, 605.4, 605.5, 605.6, 605.7, 605.8, 605.9, 606, 606.1, 606.2, 606.3, 606.4, 606.5, 606.6, 606.7, 606.8, 606.9, 607, 607.1, 607.2, 607.3, 607.4, 607.5, 607.6, 607.7, 607.8, 607.9, 608, 608.1, 608.2, 608.3, 608.4, 608.5, 608.6, 608.7, 608.8, 608.9, 609, 609.1, 609.2, 609.3, 609.4, 609.5, 609.6, 609.7, 609.8, 609.9, 610, 610.1, 610.2, 610.3, 610.4, 610.5, 610.6, 610.7, 610.8, 610.9, 611, 611.1, 611.2, 611.3, 611.4, 611.5, 611.6, 611.7, 611.8, 611.9, 612, 612.1, 612.2, 612.3, 612.4, 612.5, 612.6, 612.7, 612.8, 612.9, 613, 613.1, 613.2, 613.3, 613.4, 613.5, 613.6, 613.7, 613.8, 613.9, 614, 614.1, 614.2, 614.3, 614.4, 614.5, 614.6, 614.7, 614.8, 614.9, 615, 615.1, 615.2, 615.3, 615.4, 615.5, 615.6, 615.7, 615.8, 615.9, 616, 616.1, 616.2, 616.3, 616.4, 616.5, 616.6, 616.7, 616.8, 616.9, 617, 617.1, 617.2, 617.3, 617.4, 617.5, 617.6, 617.7, 617.8, 617.9, 618, 618.1, 618.2, 618.3, 618.4, 618.5, 618.6, 618.7, 618.8, 618.9, 619, 619.1, 619.2, 619.3, 619.4, 619.5, 619.6, 619.7, 619.8, 619.9, 620, 620.1, 620.2, 620.3, 620.4, 620.5, 620.6, 620.7, 620.8, 620.9, 621, 621.1, 621.2, 621.3, 621.4, 621.5, 621.6, 621.7, 621.8, 621.9, 622, 622.1, 622.2, 622.3, 622.4, 622.5, 622.6, 622.7, 622.8, 622.9, 623, 623.1, 623.2, 623.3, 623.4, 623.5, 623.6, 623.7, 623.8, 623.9, 624, 624.1, 624.2, 624.3, 624.4, 624.5, 624.6, 624.7, 624.8, 624.9, 625, 625.1, 625.2, 625.3, 625.4, 625.5, 625.6, 625.7, 625.8, 625.9, 626, 626.1, 626.2, 626.3, 626.4, 626.5, 626.6, 626.7, 626.8, 626.9, 627, 627.1, 627.2, 627.3, 627.4, 627.5, 627.6, 627.7, 627.8, 627.9, 628, 628.1, 628.2, 628.3, 628.4, 628.5, 628.6, 628.7, 628.8, 628.9, 629, 629.1, 629.2, 629.3, 629.4, 629.5, 629.6, 629.7, 629.8, 629.9, 630, 630.1, 630.2, 630.3, 630.4, 630.5, 630.6, 630.7, 630.8, 630.9, 631, 631.1, 631.2, 631.3, 631.4, 631.5, 631.6, 631.7, 631.8, 631.9, 632, 632.1, 632.2, 632.3, 632.4, 632.5, 632.6, 632.7, 632.8, 632.9, 633, 633.1, 633.2, 633.3, 633.4, 633.5, 633.6, 633.7, 633.8, 633.9, 634, 634.1, 634.2, 634.3, 634.4, 634.5, 634.6, 634.7, 634.8, 634.9, 635, 635.1, 635.2, 635.3, 635.4, 635.5, 635.6, 635.7, 635.8, 635.9, 636, 636.1, 636.2, 636.3, 636.4, 636.5, 636.6, 636.7, 636.8, 636.9, 637, 637.1, 637.2, 637.3, 637.4, 637.5, 637.6, 637.7, 637.8, 637.9, 638, 638.1, 638.2, 638.3, 638.4, 638.5, 638.6, 638.7, 638.8, 638.9, 639, 639.1, 639.2, 639.3, 639.4, 639.5, 639.6, 639.7, 639.8, 639.9, 640, 640.1, 640.2, 640.3, 640.4, 640.5, 640.6, 640.7, 640.8, 640.9, 641, 641.1, 641.2, 641.3, 641.4, 641.5, 641.6, 641.7, 641.8, 641.9, 642, 642.1, 642.2, 642.3, 642.4, 642.5, 642.6, 642.7, 642.8, 642.9, 643, 643.1, 643.2, 643.3, 643.4, 643.5, 643.6, 643.7, 643.8, 643.9, 644, 644.1, 644.2, 644.3, 644.4, 644.5, 644.6, 644.7, 644.8, 644.9, 645, 645.1, 645.2, 645.3, 645.4, 645.5, 645.6, 645.7, 645.8, 645.9, 646, 646.1, 646.2, 646.3, 646.4, 646.5, 646.6, 646.7, 646.8, 646.9, 647, 647.1, 647.2, 647.3, 647.4, 647.5, 647.6, 647.7, 647.8, 647.9, 648, 648.1, 648.2, 648.3, 648.4, 648.5, 648.6, 648.7, 648.8, 648.9, 649, 649.1, 649.2, 649.3, 649.4, 649.5, 649.6, 649.7, 649.8, 649.9, 650, 650.1, 650.2, 650.3, 650.4, 650.5, 650.6, 650.7, 650.8, 650.9, 651, 651.1, 651.2, 651.3, 651.4, 651.5, 651.6, 651.7, 651.8, 651.9, 652, 652.1, 652.2, 652.3, 652.4, 652.5, 652.6, 652.7, 652.8, 652.9, 653, 653.1, 653.2, 653.3, 653.4, 653.5, 653.6, 653.7, 653.8, 653.9, 654, 654.1, 654.2, 654.3, 654.4,

Appendix Table A.2: List of International Classification of Diseases codes mapped to the Global Burden of Disease cause list for causes of disability

Cause Name	ICD-10 Code	ICD-9 Code
Low back and neck pain	G54.1-G54.4, G57.0-G57.12, M43.2-M43.9, M45-M49, M49.2-M51.9, M53-M54.9, M99, M99.1-M99.9	353.1-353.4, 355.0, 720-721.1, 721.3, 721.5, 721.6, 721.8-724.9, 737-737.9
Low back pain	G54.1, G54.3, G54.4, G57.0-G57.12, M43.2-M43.5, M43.8, M43.9, M45-M49, M49.2-M49.89, M51-M51.9, M53, M53.2-M54, M54.1-M54.18, M54.3-M54.9, M99, M99.1-M99.9	353.1, 353.3, 353.4, 355.0, 720-721, 721.3, 721.5, 721.6, 721.8-722, 722.1-722.39, 722.5-722.70, 722.72-722.80, 722.82-722.90, 722.92, 722.93, 724-724.9, 737-737.9
Neck pain	G54.2, M50-M50.93, M53.0, M53.1, M54.0-M54.09, M54.2	353.2, 721.0, 721.1, 722.0, 722.4, 722.71, 722.81, 722.91, 723-723.9
Gout	M10-M10.19, M10.3-M10.9	274-274.9
	I27.1, I93-L93.2, M00-M03.0, M03.2, M03.6, M07-M08, M08.9-M09.0, M09.2, M09.8, M11-M12, M12.2, M12.49, M12.8-M12.9, M14-M14.89, M22-M25.879, M30-M32.9, M34-M36.8, M40-M43.19, M65-M68.8, M70-M73, M73.8, M75-M77.9, M80-M83.4, M83.8-M87.09, M87.3-M89.59, M89.7-M95.9, M99.0-M99.09	416.1, 416.2, 446-446.9, 695.4-695.59, 710-712.99, 716.2-716.39, 719.2-719.39, 719.8-719.89, 721.2, 721.4-721.42, 726-727.9, 730-730.39, 732-734.2, 739-739.9
Other musculoskeletal disorders	A31.1, A31.2, A46, A46.0, B07-B09, B30-B30.9, B31.9, B32.3, B32.4, B35-B36.9, B85-B88.9, H00-H02.8, H02.82, H02.9, H04-H05.429, H05.8-H06.3, H10-H11.9, H13-H13.8, H15-H22.8, H25-H26.09, H26.2, H28.8, H30-H36.8, H40-H40.9, H42-H44.539, H44.8-H45.89, H57-H58.9, H60-H62.8, H80-H83.93, H90-H91.93, H93-H94.83, K02-K02.9, K05-K05.6, L00-L05.92, L08-L08.9, L10-L14.0, L20-L23.2, L23.4-L24.3, L24.5-L25.0, L25.2-L27, L27.2-L30.9, L40-L45, L49-L55.9, L56.1-L57.9, L59-L60.9, L62-L68.9, L70-L76.82, L80-L92.9, L94-L95.9, L97-L98.6, M26-M27.9, P96.0, Q00-Q07.9, Q10-Q18.9, Q20-Q28.9, Q30-Q45.9, Q50-Q86, Q86.1-Q87.89, Q89-Q89.8, Q90-Q93.9, Q95-Q99.8, Z01.0-Z01.12, Z13.5, Z13.7-Z13.79, Z13.84, Z14-Z15.89, Z41.1, Z41.3, Z52.5, Z82.1, Z82.2, Z82.7-Z82.79, Z83.5-Z83.52, Z84.0, Z87.2, Z87.7-Z87.798, Z94.5, Z94.7, Z96.5, Z97.3, Z97.4	035-035.9, 077-078.4, 110-111.9, 132-134.9, 360-360.44, 360.8-362, 362.1-366.19, 366.3-366.4, 366.42-374.85, 374.87-376.52, 376.8-380.9, 385-385.82, 385.89-389.9, 520-529.9, 680-695.3, 695.8-709.3, 709.8, 709.9, 713.3, 740-758.9, 759.0-759.89, 707.31, V13.3, V13.6-V13.69, V18.61, V18.9, V19.0-V19.5, V19.7, V19.8, V42.3, V42.5, V43.0, V43.1, V43.83, V45.6-V45.69, V45.78, V45.84, V48.4, V48.5, V50.3, V58.5, V58.71, V58.77, V59.1, V59.5, V72.2, V74.4, V80, V80.0, V80.09-V80.3, V82.0, V82.3
Other non-communicable diseases	P96.0, Q00-Q07.9, Q10-Q18.9, Q20-Q28.9, Q30-Q45.9, Q50-Q86, Q86.1-Q87.89, Q89-Q89.8, Q90-Q93.9, Q95-Q99.8, Z13.7-Z13.79, Z14-Z15.89, Z82.7-Z82.79, Z87.7-Z87.798	740-758.9, 759.0-759.89, V13.6-V13.69, V18.61, V18.9, V19.5, V19.7, V19.8, V82.3
Congenital anomalies		
Neural tube defects	Q00-Q01.9, Q05-Q05.9	740-741.93, 742.0, V13.63
Congenital heart anomalies	Q20-Q28.9	745-747.9, V13.65, V18.61
Orofacial clefts	Q35-Q37.9	749-749.9
Down syndrome	Q90-Q90.9	758.0
Turner syndrome	Q96-Q96.9	
Klinefelter syndrome	Q98-Q98.9	
Chromosomal unbalanced rearrangements	Q91-Q93.9, Q95-Q95.9, Q97-Q97.9, Q99-Q99.8	758, 758.1-758.9
Other congenital anomalies	P96.0, Q02-Q04.9, Q06-Q07.9, Q10-Q18.9, Q30-Q34.9, Q38-Q45.9, Q50-Q86, Q86.1-Q87.89, Q89-Q89.8	742, 742.1-744.9, 748-748.9, 750-757.9, 759.0-759.89, V13.61, V13.62, V13.64, V13.66-V13.69
Skin and subcutaneous diseases	A31.1, A31.2, A46, A46.0, B07-B09, B35-B36.9, B85-B88.9, L00-L05.92, L08-L08.9, L10-L14.0, L20-L23.2, L23.4-L24.3, L24.5-L25.0, L25.2-L27, L27.2-L30.9, L40-L45, L49-L55.9, L56.1-L57.9, L59-L60.9, L62-L68.9, L70-L76.82, L80-L92.9, L94-L95.9, L97-L98.6, Z41.1, Z84.0, Z87.2, Z94.5	035-035.9, 078-078.4, 110-111.9, 132-134.9, 680-695.3, 695.8-709.3, 709.8, 709.9, 713.3, V13.3, V19.4, V42.3, V43.83, V58.77, V59.1, V82.0
Dermatitis	L20-L23.2, L23.4-L24.3, L24.5-L25.0, L25.2-L27, L27.2-L27.9	690-693.9
Psoriasis	L40-L41.9	696-696.9
Cellulitis	L03-L04	681-682.9
Pyoderma	A31.1, A31.2, A46, A46.0, L00-L02.93, L04.0-L05.92, L08-L08.9, L88, L97-L98.499	035-035.9, 680-680.9, 683-686.9
Scabies	B86	133-133.6
Fungal skin diseases	B35-B36.9	110-111.9
Viral skin diseases	B07-B09	078-078.4
Acne vulgaris	L70-L70.3, L70.8, L70.9, L73.0	706.1, 706.2
Alopecia areata	L63-L63.1, L63.8, L63.9	704.0-704.09
Pruritus	L29-L29.9	698-698.9
Urticaria	L50-L50.9	708-708.9
Decubitus ulcer	L89-L89.95	707-707.9
Other skin and subcutaneous diseases	B85-B85.4, B87-B88.9, L10-L14.0, L28-L28.2, L30-L30.9, L42-L45, L49-L49.9, L51-L55.9, L56.1-L57.9, L59-L60.9, L62-L62.8, L63.2, L64-L68.9, L70.4, L70.5, L71-L73, L73.1-L76.82, L80-L87.9, L90-L92.9, L94-L95.9, L98.5, L98.6	132-132.9, 133.8-134.9, 694-695.3, 695.8-695.9, 697-697.9, 700-704, 704.1-706.0, 706.3-706.9, 709-709.3, 709.8, 709.9, 713.3
Sense organ diseases	B30-B30.9, B31.9, B32.3, B32.4, H00-H02.8, H02.82, H02.9, H04-H05.429, H05.8-H06.3, H10-H11.9, H13-H13.8, H15-H22.8, H25-H26.09, H26.2-H28.8, H30-H36.8, H40-H40.9, H42-H44.539, H44.8-H45.89, H57-H58.9, H60-H62.8, H80-H83.93, H90-H91.93, H93-H94.83, Z01.0-Z01.12, Z13.5, Z41.3, Z52.5, Z82.1, Z82.2, Z83.5-Z83.52, Z94.7, Z97.3, Z97.4	077-077.99, 360-360.44, 360.8-362, 362.1-366.19, 366.3-366.4, 366.42-374.85, 374.87-376.52, 376.8-380.9, 385-385.82, 385.89-389.9, V19.0-V19.3, V42.5, V43.0, V43.1, V45.6-V45.69, V45.78, V48.4, V48.5, V50.3, V58.71, V59.5, V74.4, V80, V80.0, V80.09-V80.3
Glaucoma	H36, H36.0, H40-H40.9, H42-H42.8	365-365.9, V19.11
Cataract	H25-H26.09, H26.2-H26.9, H28-H28.2	366-366.19, 366.3-366.4, 366.42-366.9
Macular degeneration	H35.3-H35.389	362.50-362.57
Uncorrected refractive error	H49-H51.9	367-368.9, 378-378.9
Age-related and other hearing loss	H80-H80.93, H90-H91.93, H93-H94.83	385-385.82, 385.89, 385.9, 387-387.9, 389-389.9, V19.2
Age-related and other vision loss	H30-H32.0, H33-H35.23, H35.4-H35.9, H43-H43.9, H46-H48.1, H52-H54.9	361-362, 362.1-362.5, 362.6-363.9, 364.5-364.9, 369-369.9
Other sense organ diseases	B30-B30.9, B31.9, B32.3, B32.4, H00-H02.8, H02.82, H02.9, H04-H05.429, H05.8-H06.3, H10-H11.9, H13-H13.8, H15-H22.8, H27-H27.9, H28.8, H32.8, H36.8, H44-H44.539, H44.8-H45.8, H48.8, H55-H55.89, H57-H58.9, H60-H62.8, H81-H83.93	077-077.99, 360-360.44, 360.8-360.9, 364-364.42, 370-374.85, 374.87-376.52, 376.8-377.9, 379-380.9, 386-386.9, 388-388.9, V74.4
Oral disorders	K02-K02.9, K05-K05.6, M26-M27.9, Z01.2-Z01.21, Z13.84, Z96.5	520-529.9, V07.31, V45.84, V58.5, V72.2
Deciduous caries		
Permanent caries	K02-K02.9	521.0-522.9, V07.31
Periodontal diseases	K05-K05.6	523-523.9
Edentulism and severe tooth loss		525.0-525.19, 525.4-525.54
Other oral disorders	M26-M27.9	520-521, 524-525, 525.2-525.3, 525.6-529.9
Sudden infant death syndrome		
	H02.81, H02.819, H05.5-H05.53, H44.6-H44.799, M60.2-M60.28, V00-V86.99, V87.2, V87.3, V88.2, V88.3, V90, V90.0, V90.01-V98.8, W00-W46.2, W49-W62.9, W64-W70.9, W73-W81.9, W83-W94.9, W97.9, W99-X06.9, X08-X40.9, X43-X43.9, X46-X48.9, X50-X54.9, X57-X58.9, X60-X08.9, Y35-Y84.9, Y87.1-Y88.3, Y89.0, Y89.1, Z03.6, Z04.1-Z04.5, Z13.850, Z18-Z18.9	360.5-360.69, 374.86, 376.6, 385.83, 709.4, 728.82, 729.6, E00.0-E03.0, E80.0-E80.03, E80.1-E80.13, E80.2-E80.23, E80.3-E80.33, E80.4-E80.43, E80.5-E80.53, E80.6-E80.63, E80.7-E80.73, E81.00-E81.07, E81.10-E81.17, E81.20-E81.27, E81.30-E81.37, E81.40-E81.47, E81.50-E81.57, E81.60-E81.67, E81.70-E81.77, E81.80-E81.87, E81.90-E81.97, E82.00-E82.07, E82.10-E82.17, E82.20-E82.27, E82.30-E82.37, E82.40-E82.47, E82.50-E82.57, E82.60-E82.67, E82.70-E82.74, E82.80-E82.84, E82.90, E82.94, E83.0-E83.89, E84.0-E84.99, E85.03-E85.089, E85.48-E85.899, E86.02-E86.999, E87.0-E87.69, E87.8-E88.699, E88.8-E92.889, E92.91-E92.94, E93.0-E97.99, E99.0-E99.91, V15.4-V15.5, V15.53-V15.6, V15.88, V90-V90.9
Injuries	V00-V86.99, V87.2, V87.3, V88.2, V88.3, V91-V91.9, V93-V98.8, Z04.1	E80.0-E80.03, E80.1-E80.13, E80.2-E80.23, E80.3-E80.33, E80.4-E80.43, E80.5-E80.53, E80.6-E80.63, E80.7-E80.73, E81.00-E81.07, E81.10-E81.17, E81.20-E81.27, E81.30-E81.37, E81.40-E81.47, E81.50-E81.57, E81.60-E81.67, E81.70-E81.77, E81.80-E81.87, E81.90-E81.97, E82.00-E82.07, E82.10-E82.17, E82.20-E82.27, E82.30-E82.37, E82.40-E82.47, E82.50-E82.57, E82.60, E82.61, E82.63, E82.64, E82.70, E82.73, E82.74, E82.80, E82.84, E82.90, E82.94
Transport injuries	V01-V04.99, V06-V80.929, V82-V82.9, V87.2, V87.3	E80.03, E80.13, E80.23, E80.33, E80.43, E80.53, E80.63, E80.73, E81.00-E81.06, E81.10-E81.17, E81.20-E81.27, E81.30-E81.37, E81.40-E81.47, E81.50-E81.57, E81.60-E81.67, E81.70-E81.77, E81.80-E81.87, E81.90-E81.97, E82.00-E82.06, E82.10-E82.16, E82.20-E82.27, E82.30-E82.37, E82.40-E82.47, E82.50-E82.57, E82.60, E82.61, E82.63, E82.64, E82.70, E82.73, E82.74, E82.80, E82.84, E82.90, E82.94
Road injuries	V01-V04.99, V06-V09.9	E81.17, E81.27, E81.37, E81.47, E81.57, E81.67, E81.77, E81.87, E81.97, E82.27, E82.37, E82.47, E82.57, E82.60, E82.70, E82.80, E82.90
Pedestrian road injuries	V10-V19.9	E80.03, E80.13, E80.23, E80.33, E80.43, E80.53, E80.63, E80.73, E81.06, E81.16, E81.26, E81.36, E81.46, E81.56, E81.66, E81.76, E81.86, E81.96, E82.06, E82.16, E82.26, E82.36, E82.46, E82.56, E82.61
Cyclist road injuries	V20-V29.9	E81.02, E81.03, E81.12, E81.13, E81.22, E81.23, E81.32, E81.33, E81.42, E81.43, E81.52, E81.53, E81.62, E81.63, E81.72, E81.73, E81.82, E81.83, E81.92, E81.93, E82.02, E82.03, E82.12, E82.13, E82.22, E82.23, E82.32, E82.33, E82.42, E82.43, E82.52, E82.53
Motorcyclist road injuries	V30-V79.9, V87.2, V87.3	E81.00, E81.01, E81.10, E81.11, E81.20, E81.21, E81.30, E81.31, E81.40, E81.41, E81.50, E81.51, E81.60, E81.61, E81.70, E81.71, E81.80, E81.81, E81.90, E81.91, E82.00, E82.01, E82.10, E82.11, E82.20, E82.21, E82.30, E82.31, E82.40, E82.41, E82.50, E82.51
Motor vehicle road injuries		

Appendix Table A.2: List of International Classification of Diseases codes mapped to the Global Burden of Disease cause list for causes of disability

Cause Name	ICD-10 Code	ICD-9 Code
	V80-V80.929, V82-V82.9	E81.04, E81.05, E81.14, E81.15, E81.24, E81.25, E81.34, E81.35, E81.44, E81.45, E81.54, E81.55, E81.64, E81.65, E81.74, E81.75, E81.84, E81.85, E81.94, E81.95, E82.04, E82.05, E82.14, E82.15, E82.24, E82.25, E82.34, E82.35, E82.44, E82.45, E82.54, E82.55, E82.63, E82.64, E82.73, E82.74, E82.84, E82.94
Other road injuries	V00-V00.898, V05-V05.99, V81-V81.9, V83-V86.99, V88.2, V88.3, V91-V91.9, V93-V98.8	E80.0-E80.02, E80.1-E80.12, E80.2-E80.22, E80.3-E80.32, E80.4-E80.42, E80.5-E80.52, E80.6-E80.62, E80.7-E80.72, E81.07, E82.07, E82.17, E82.22, E82.27, E82.32, E83.1-E83.19, E83.3-E83.89, E84.0-E84.99, E92.91
Other transport injuries	H02.81-H02.819, H05.5-H05.53, H44.6-H44.799, M60.2-M60.28, V90, V90.0, V90.01-V90.9, V92-V92.9, W00-W46.2, W49-W62.9, W64-W70.9, W73-W81.9, W83-W94.9, W97.9, W99-X06.9, X08-X29.9, X40-X40.9, X43-X43.9, X46-X48.9, X50-X54.9, X57-X58.9, Y38.9-Y84.9, Y88-Y88.3, Z03.6, Z04.2, Z04.3, Z18-Z18.9	360.5-360.69, 374.86, 376.6, 385.83, 709.4, 728.82, 729.6, E00.0-E03.0, E83.0-E83.09, E83.2-E83.29, E85.03-E85.089, E85.48-E85.899, E86.02-E86.999, E87.0-E87.69, E87.8-E88.699, E88.8-E89.909, E90.01-E90.019, E90.11-E90.119, E90.2-E90.4, E90.41-E90.699, E91.0-E92.889, E92.92-E92.94, E93.0-E94.99, V15.53, V15.6, V15.88, V90-V90.9
Unintentional injuries	W00-W19.9	E88.0-E88.699, E88.8-E88.89, E92.93, V15.88
Falls	V90, V90.0, V90.01-V90.9, V92-V92.9, W65-W70.9, W73-W74.9	E83.0-E83.09, E83.2-E83.29, E91.0-E91.099
Drowning	X00-X06.9, X08-X19.9, X20.5	E89.0-E89.909, E92.4-E92.499, E92.94
Fire, heat, and hot substances	X40-X40.9, X43-X43.9, X46-X48.9, Z03.6	E85.03-E85.089, E85.48-E85.899, E86.02-E86.999, E92.92, V15.6
Poisonings	W20-W38.9, W40-W43.9, W45.0-W45.2, W46-W46.1, W49-W52, W52.3, W75-W76.9, Z04.2	E91.3-E91.319, E91.6-E92.299, E92.81-E92.87
Exposure to mechanical forces	W32-W34.9	E92.2-E92.299, E92.87
Unintentional firearm injuries	W75-W76.9	E91.3-E91.319
Unintentional suffocation	W20-W31.9, W35-W38.9, W40-W43.9, W45.0-W45.2, W46-W46.1, W49-W52, W52.3	E91.6-E92.199, E92.81-E92.86
Other exposure to mechanical forces	Y38.9-Y84.9, Y88-Y88.3	E87.0-E87.69, E87.8-E87.99, E93.0-E94.99
Adverse effects of medical treatment	W52.0-W52.2, W52.4-W62.9, W64-W64.9, X20-X20.4, X20.6-X29.9	E90.5-E90.699
Animal contact	X20-X20.4, X20.6-X29.9	E90.5-E90.599
Venomous animal contact	W52.0-W52.2, W52.4-W62.9, W64-W64.9	E90.6-E90.699
Non-venomous animal contact	H02.81-H02.819, H05.5-H05.53, H44.6-H44.799, M60.2-M60.28, W44-W45, W45.3-W45.9, W46.2, W78-W80.9, W83-W84.9, Z18-Z18.9	360.5-360.69, 374.86, 376.6, 385.83, 709.4, 728.82, 729.6, E91.1-E91.209, E91.38-E91.509, V15.53, V90-V90.9
Foreign body	W78-W80.9, W83-W84.9	E91.1-E91.209, E91.38-E91.399
Pulmonary aspiration and foreign body in airway	H02.81-H02.819, H05.5-H05.53, H44.6-H44.799	360.5-360.69, 374.86, 376.6, 385.83, 709.4, 728.82, 729.6, E91.4-E91.409, V15.53
Foreign body in eyes	M60.2-M60.28, W44-W45, W45.3-W45.9, W46.2	E91.5-E91.509
Foreign body in other body part	W39-W39.9, W77-W77.9, W81-W81.9, W85-W94.9, W97.9, W99-W99.9, X50-X54.9, X57-X58.9, Z04.3	E00.0-E03.0, E90.01-E90.019, E90.11-E90.119, E90.2-E90.4, E90.41-E90.499, E91.32-E91.339, E92.3-E92.399, E92.5-E92.809, E92.88-E92.889, E90.40-E90.409, E95.0-E96.9, V15.41
Other unintentional injuries	X60-Y08.9, Y87.1, Y87.2, Z04.4-Z04.5	E95.0-E95.9
Self-harm and interpersonal violence	X60-X84.9	E90.40-E90.409, E96.0-E96.9, V15.41
Self-harm	X85-Y08.9, Y87.1, Y87.2, Z04.4-Z04.5	E96.5-E96.54
Interpersonal violence	X93-X94.0, X94.3-X94.7, X94.9-X95.9, X96.5	E96.6
Assault by firearm	X99-X99.9	E90.40-E90.409, E96.0-E96.4, E96.55-E96.59, E96.7-E96.9
Assault by sharp object	X85-X92.9, X94.1, X94.2, X94.8, X96-X96.4, X96.6-X98.9, Y00-Y08.9, Y87.1, Y87.2	E90.0-E90.009, E90.09-E90.109, E90.18-E90.199, E90.7-E90.999, E97.0-E97.999, E99.0-E99.91
Assault by other means	X30-X39.9, Y35-Y38.893, Y89.0, Y89.1	E90.0-E90.009, E90.09-E90.109, E90.18-E90.199, E90.7-E90.999
Forces of nature, war, and legal intervention	X30-X39.9	E97.0-E97.999, E99.0-E99.91
Exposure to forces of nature	Y35-Y38.893, Y89.0, Y89.1	None
Collective violence and legal intervention	None	T05.3, T05.5
None	T05.3, T05.5	896.2, 896.3, 897.6, 897.7
Amputation of lower limbs, bilateral	T27-T27.7	947.0-947.2
Lower airway burns	S73-S73.046	835-835.13
Dislocation of hip	S83-S83.1, S83.7-S83.9	836-836.69
Dislocation of knee	S43-S43.396	831-831.19
Dislocation of shoulder	S03-S03.9, S13-S13.9, S16-S16.9, S23-S23.9, S29-S29.099, S33-S33.9, S39.0-S39.6, S43.4-S43.92, S46-S46.999, S49.8-S49.92, S53-S53.7, S56-S56.9, S59.7-S59.919, S63-S63.9, S66-S66.9, S69-S69.92, S73.1-S73.199, S76-S76.999, S83.2-S83.6, S86-S86.999, S93-S93.699, S96-S96.999, S99-S99.929, T03-T03.9, T09.2, T09.5, T11.2, T13.2, T14.3, T92.3, T93.3, T93.5	830-830.1, 832-834.12, 837-849, 905.6-905.8
Muscle and tendon injuries, including sprains and strains lesser dislocations	S42-S42.9, S49-S49.7, T92.1	810-812.59
Fracture of clavicle, scapula, or humerus	S02.2-S02.7	802-802.9
Fracture of face bones	S92-S92.9	825-826.6
Fracture of foot bones except ankle	S62-S62.9, T92.2	814-816.13
Fracture of hand (wrist and other distal part of hand)	S72.0-S72.2	820-820.9, 905.3
Fracture of hip	S68.4-S68.429, S68.7-S68.9, T05.0, T05.2, T05.6	887.6-888.9
Amputation of upper limbs, bilateral	S82-S82.9, S89.0-S89.7	822-824.9, 905.4
Fracture of patella, tibia or fibula, or ankle	S32.3-S32.9	808-808.9
Fracture of pelvis	S52-S52.9, S59-S59.299	813-813.93, 905.2
Fracture of radius and/or ulna	S02-S02.19, S02.8-S02.92	800-801.99, 803-804.99, 905.0
Fracture of skull	S22.2-S22.9	807-807.04, 807.07-807.6
Fracture of sternum and/or fracture of one or more ribs	S12-S12.9, S22-S22.1, S32-S32.2, T08, T08.0, T91.1	310.2, 805-805.9, 905.1
Fracture of vertebral column	S72, S72.3-S72.9, S79-S79.199, T93.1	821-821.39
Fracture of femur, other than femoral neck	G44.31-G44.319, S06.0	850-850.9
Minor TBI	S06, S06.1, S06.3-S06.6, S06.9, S07, T90.2	852-852.59, 907, 907.0, V15.52
Moderate TBI	S06.2, S06.7, S06.8, T90.5	851-851.99, 853-854.19
Severe TBI	S68.1-S68.3, S68.6-S68.629	886-886.1
Amputation of fingers (excluding thumb)	T16-T16.9	931
Foreign body in ear	T17-T17.998	932-934.9
Foreign body in respiratory system	T18-T19.9	935-939.9
Foreign body in GI and urogenital system	S14-S14.159, T91.3	806-806.19, 952-952.09
Spinal cord lesion at neck level	S24-S24.159, S34-S34.139	806.2-806.9, 952.1-952.9
Spinal cord lesion below neck level	T75.1	994.1
Drowning and nonfatal submersion	T71-T71.9	994.7
Asphyxiation	S07.0-S07.9, S17-S18, S38-S38.3, S47-S47.9, S57-S57.9, S67-S67.92, S77-S77.22, S87-S87.82, S97-S97.82, T92.6, T93.6	906.4, 925-928.9, 929.9
Crush injury	S04-S04.9, S14.2-S14.9, S24.2-S24.9, S34.2-S34.9, S44-S44.92, S54-S54.92, S64-S64.92, S74-S74.92, S84-S84.92, S94-S94.92, T1.3, T1.3.3, T90.3, T92.4, T93.4	907.1, 907.3-907.9, 950-951.9, 953-957.9
Nerve injury	H26.1-H26.139, S01.1-S01.159, S05-S05.92, T14.4, T15-T15.92, T26-T26.92, T90.4	366.2-366.23, 870-871.9, 918-918.9, 921-921.9, 930-930.9, 940-940.9
Injury to eyes	S78-S78.929, S88-S88.929, S98-S98.029, S98.3-S98.929	896-896.1, 897-897.5
Amputation of lower limb, unilateral	S01-S01.05, S01.2-S01.95, S08-S09.399, S10, S10.7, S11, S11.1-S11.15, S11.8-S11.95, S15-S15.9, S21-S21.95, S31-S31.8, S39, S39.7, S41-S41.8, S45-S45.999, S51-S51.9, S55-S55.999, S61-S61.9, S65-S65.999, S71-S71.8, S75-S75.999, S81-S81.9, S85-S85.999, S91-S91.7, S95-S95.999, T01-T01.9, T09.1, T11.1, T11.4, T11.5, T13.1, T13.4, T13.5, T14.1, T14.5, T14.6, T90.1, T92.0, T92.5, T93.0	872-873.9, 874.2-884.2, 890-894.2, 900-900.9, 903-904.9, 906-906.2
Open wound(s)	T36-T65.94, T96-T97.0	960-989.9
Poisoning requiring urgent care	S11.0-S11.039, S11.2-S11.7, S25-S28.229, S29.7-S29.9, T91.4	807.05, 807.06, 860-862.9, 874-874.12, 901-901.9, 908.0
Severe chest injury	S35-S37.99, S39.8-S39.848, T79-T79.9, T91.5	863-869.1, 902-902.9, 908.1-908.3
Internal hemorrhage in abdomen and pelvis	S20-S20.02, S20.2-S20.229, S30-S30.3, S40-S40.2, S50-S50.12, S60-S60.9, S70-S70.2, S80-S80.7, S90-S90.4	906.3, 920, 922-924.9
Contusion in any part of the body	T33-T35.7, T66-T70.9, T75-T75.09, T75.2-T75.89, T95.8, T95.9	990-994.0, 994.2-994.6, 994.8, 994.9
Effect of different environmental factors	T80-T88.9	995.4, 996-996.99, 998-999.39, 999.6-999.9
Complications following therapeutic procedures	S00-S00.97, S10.0-S10.17, S10.8-S10.97, S20.1-S20.179, S20.3-S20.97, S30.7-S30.98, S40.21-S40.929, S50.3-S50.919, S70.21-S70.929, S80.8-S80.929, S90.41-S90.936, T00-T00.9, T09.0, T1.0, T13.0, T14.0, T90.0	910-917.9, 919-919.9
Superficial injury of any part of the body	T02-T02.9, T04-T04.9, T06-T07.0	817-819.1, 827-828.1, 929.0
Multiple fractures, dislocations, crashes, wounds, lacerations, and strains	F07.2-F08, G44.3-G44.309, G44.32-G44.329, G91.3	339.2
Long term sequelae for TBI		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Afghanistan	Central Statistics Office (Afghanistan), UNICEF Afghanistan Country Office, German Technical Cooperation Agency (GTZ). Afghanistan Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Afghanistan	Central Statistics Organization (Afghanistan), United Nations Children's Fund (UNICEF). Afghanistan Multiple Indicator Cluster Survey 2003.	2003	*	
Afghanistan	Afghanistan Malaria Indicators Survey 2008 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008	*	†
Afghanistan	Central Statistics Organization (Afghanistan), United Nations Children's Fund (UNICEF). Afghanistan Multiple Indicator Cluster Survey 2010-2011. New York, United States: United Nations Children's Fund (UNICEF), 2013.	2010-2011	*	
Afghanistan	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Afghanistan	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Afghanistan	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998-1999		
Afghanistan	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Afghanistan	Ventevogel P, Vries GD, Scholte WF, Shirwari NR, Faiz H, Nassery R, Briuk W van den, Olff M. Properties of the Hopkins Symptom Checklist-25 (HSCL-25) and the Self-Reporting Questionnaire (SRQ-20) as screening instruments used in primary care in Afghanistan. Soc Psychiatry Psychiatr Epidemiol. 2007; 42(4): 328-35.	2004		
Afghanistan	Scholte WF, Olff M, Ventevogel P, de Vries G-J, Jansveld E, Cardoso BL, Crawford CAG. Mental health symptoms following war and repression in eastern Afghanistan. JAMA. 2004; 292(5): 585-93.	2003		
Afghanistan	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2001, 2004, 2007, 2010, 2012		
Afghanistan	Cardozo BL, Bilukha OO, Gotway CA, Wolfe MI, Gerber ML, Anderson M. Report from the CDC: mental health of women in postwar Afghanistan. J Womens Health (Larchmt). 2005; 14(4): 285-93.	2002		
Afghanistan	World Health Organization (WHO). Afghanistan WHO Leishmaniasis Country Profile.	2003-2010	*	
Afghanistan	Ministry of Counter Narcotics (Afghanistan), Ministry of Public Health (Afghanistan), United Nations Office on Drugs and Crime (UNODC). Afghanistan Drug Use Survey 2009.	2009	*	
Afghanistan	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
Afghanistan	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	
Afghanistan	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Afghanistan	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Afghanistan	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
Afghanistan	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Afghanistan	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Afghanistan	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Afghanistan	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Afghanistan	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Afghanistan	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Afghanistan	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Afghanistan	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Afghanistan	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Afghanistan	Singh M, Saidali A, Bakhtiar A, Arya LS. Diphtheria in Afghanistan - review of 155 cases. J Trop Med Hyg. 1985; 88(6): 373-6.	1978-1981		
Afghanistan	Mazières S, Temory SA, Vasseur H, Gallian P, Di Cristofaro J, Chironi J. Blood group typing in five Afghan populations in the North Hindu-Kush region: implications for blood transfusion practice. Transfus Med. 2013; 23(3): 167-74.	2009-2011	*	†
Afghanistan	Cattand P, Desjeux P, Guzmán MG, Jannin J, Kroeger A, Medici A, Musgrove P, Nathan MB, Shaw A, Schofield CJ. Tropical Diseases Lacking Adequate Control Measures: Dengue, Leishmaniasis, and African Trypanosomiasis. In: Jamison DT, Breman JG, Measham AR, et al., editors. Disease Control Priorities in Developing Countries. New York, United States: Oxford University Press; 2006. 451-66.	1994, 2002		
Afghanistan	Cottler L, Ruktanonchai C, Ghani MA, Gold M, Martin D. The Prevalence of Drug and Alcohol Use in Urban Afghanistan: Data from the Afghanistan National Urban Drug Use Study (ANUDUS). Lancet Glob Health. 2014; 2(10): e592-600.	2012	*	
Afghanistan	Social and Health Development Program (Afghanistan), United Nations Population Fund (UNFPA). Afghanistan Prevalence of Obstetric Fistula Among Women of Reproductive Age in Six Provinces 2010.	2008-2010	*	
Afghanistan	Abdur Rab M, Freeman TW, Rahim S, Durrani N, Simon-Taha A, Rowland M. High altitude epidemic malaria in Bamian province, central Afghanistan. East Mediterr Health J. 2003; 9(3): 232-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000	*	†
Afghanistan	Kolaczinski J, Graham K, Fahim A, Brooker S, Rowland M. Malaria control in Afghanistan: progress and challenges. Lancet. 2005; 365(9469): 1506-12 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Afghanistan	Rowland M, Hewitt S, Durrani N. Prevalence of malaria in Afghan refugee villages in Pakistan sprayed with lambda-cyhalothrin or malathion. Trans R Soc Trop Med Hyg. 1994; 88(4): 378-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†
Afghanistan	Rowland M, Webster J, Saleh P, Chandramohan D, Freeman T, Pearce B, Durrani N, Rab A, Mohammed N. Prevention of malaria in Afghanistan through social marketing of insecticide-treated nets: evaluation of coverage and effectiveness by cross-sectional surveys and passive surveillance. Trop Med Int Health. 2002; 7(10): 813-22 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Albania	National Institute of Statistics (Albania), United Nations Children's Fund (UNICEF). Albania Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Albania	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2005		
Albania	ICF Macro, Institute of Public Health (Albania), Institute of Statistics (Albania). Albania Demographic and Health Survey 2008-2009. Calverton, United States: ICF Macro, 2009.	2008-2009		†
Albania	Albania Institute of Public Health (IPH), Ministry of Health (Albania), National Institute of Statistics (Albania), and Centers for Disease Control and Prevention. (2005) Albania Reproductive Health Survey 2001. Atlanta, United States: Centers for Disease Control and Prevention (CDC).	2001		
Albania	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. Scand J Clin Lab Invest. 2007; 67(1): 39-69.	1990-2006		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Albania	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2006		
Albania	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Albania	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol.</i> 2008; 121(4): 947-954.	1995, 2000-2001		
Albania	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001-2008		
Albania	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Albania	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2001		
Albania	Franzelli F, Hyska J, Bushi E, Fanolla A, Luisi L, Bonetti L, Morosetti G, Radetti G. A national study of iodine status in Albania. <i>J Endocrinol Invest.</i> 2009; 32(6): 533-7.	2006	*	
Albania	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Albania	Vrbic V, Vulovi M, Raji Z, Topi B, Tati E, Mali M, Mili D, Aurer-Kozelj J, Neceva L, Redzepagi S. Oral health in SFR Yugoslavia in 1986. <i>Community Dent Oral Epidemiol.</i> 1988; 16(5): 286-8.	1986		
Albania	Kruja J, Beghi E, Zerbi D, Dobi D, Kuqo A, Zekja I, Mijo S, Kapiszyz M, Messina P. High prevalence of major neurological disorders in two Albanian communities: results of a door-to-door survey. <i>Neuroepidemiology.</i> 2012; 38(3): 138-47.	2006-2008	*	
Albania	Manaj A, Rrugia A, Manoku N. The impact of preeclampsia in pregnancy. <i>J Prenat Med.</i> 2011; 5(1): 19-22.	2008-2009	*	
Albania	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 2001, 2004, 2007, 2010, 2012		
Albania	Fraser GR, Defaranas B, Kattamis CA, Race RR, Sanger R, Stamatoyannopoulos G. Glucose-6-phosphate dehydrogenase, colour vision and XG blood groups in Greece: linkage and population data. <i>Ann Hum Genet.</i> 1964; 395-403.	1962		
Albania	Pilaca AS, Beqiri AI, Ndreu AH, Puca ES, Pepa AK, Elezi FM. Factors affecting the prognosis of Albanian adult patients with generalized tetanus. <i>G Chir.</i> 2012; 33(4): 105-9.	1984-2002	*	
Albania	World Health Organization (WHO). Albania WHO Leishmaniasis Country Profile.	1994-2008	*	
Albania	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Albania	Zimmermann MB, Bridson J, Bozo M, Grimci L, Selimaj V, Tanner MS. Severe iodine deficiency in southern Albania. <i>Int J Vitam Nutr Res.</i> 2003; 73(5): 347-50.	2003		†
Albania	Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, Büchele G, Clausen M, Cookson WOC, von Mutius E, Strachan DP, Williams HC, ISAAC Phase Two Study Group. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. <i>J Allergy Clin Immunol.</i> 2008; 121(1): 141-147.	2005-2007	*	
Albania	Adhami JE, Angoni R. [Hepatitis E virus infection in Albania]. <i>Sante.</i> 2001; 11(1): 13-5.	1998-2000	*	
Albania	Malamitsi-Puchner A, Papacharitonos S, Sotos D, Tzala L, Psychogiou M, Hatzakis A, Evangelopoulou A, Michalakis S. Prevalence study of different hepatitis markers among pregnant Albanian refugees in Greece. <i>Eur J Epidemiol.</i> 1996; 12(3): 297-301.	1995		
Albania	Flohr C, Weinmayr G, Weiland SK, Addo-Yobo E, Annesi-Maesano I, Björkstén B, Bråbäck L, Büchele G, Chico M, Cooper P, Clausen M, El Sharif N, Martinez Gimeno A, Mathur RS, von Mutius E, Morales Suarez-Varela M, Pearce N, Svabe V, Wong GWK, Yu M, Zhong NS, Williams HC, ISAAC Phase Two Study Group. How well do questionnaires perform compared with physical examination in detecting flexural eczema? Findings from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. <i>Br J Dermatol.</i> 2009; 161(4): 846-53.	2005-2007	*	
Albania	Albania Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Albania	Albania Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Algeria	National Office of Statistics (Algeria), Ministry of Health, Population and Hospital Reform (Algeria), League of Arab States. Algeria Family Health Survey 2002-2003.	2002-2003		†
Algeria	National Office of Statistics (Algeria), League of Arab States. Algeria Maternal and Child Health Survey 1992.	1992		†
Algeria	Ministry of Health, Population and Hospital Reform (Algeria), World Health Organization (WHO). Algeria - Sétif and Mostaganem STEPS Noncommunicable Disease Risk Factors Survey 2003.	2003		
Algeria	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Algeria	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Algeria	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol.</i> 2008; 121(4): 947-954.	1996, 2002		
Algeria	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1991-1994, 1997, 2000, 2008-2009		
Algeria	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Algeria	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2002		
Algeria	Khelafi R, Aissanou A, Tarsift S, Skander F. Epidemiology of chronic obstructive pulmonary disease in Algiers. <i>Rev Mal Respir.</i> 2011; 28(1): 32-40.	2008-2010	*	
Algeria	Forman D, Bray F, Brewster DH, Gomb Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version). Lyon, IARC. http://ci5.iarc.fr	2003-2007	*	
Algeria	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Algeria	Barsoun RS. Burden of chronic kidney disease: North Africa. <i>Kidney Int Suppl.</i> 2013; 3: 164-6.	2000-2010		
Algeria	Kermani S, Berah H. La situation épidémiologique du RAA en Algérie depuis 1990 [Algeria Epidemiological Situation on Rheumatic Fever Since 1990]. Algiers, Algeria: Ministry of Health, Population and Hospital Reform (Algeria), 2001.	1989-1990		
Algeria	Bahri O, Erzikouri S, Alaya-Bouafif NB, Iguer F, Feydi AEE, Mestiri H, Benazzouz M, Khalfallah T, Afifi R, Elkhilal L, Berkane S, Marchio A, Dehzi N, Dejean A, Fineau P, Triki H, Benjeloun S. First multicenter study for risk factors for hepatocellular carcinoma development in North Africa. <i>World J Hepatol.</i> 2011; 3(1): 24-30.	2002-2005		
Algeria	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2001, 2004, 2007, 2010, 2012		
Algeria	Richard F, Belhani M, Colonna P. G-6PD deficiency in newborns in Algiers (author's transl). <i>Nouv Rev Fr Hematol.</i> 1974; 14(4): 453-9.	1972-1973		
Algeria	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant.</i> 1988; 3(6): 714-27.	1985-1986		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Algeria	Barsoum RS. End-stage renal disease in North Africa. <i>Kidney Int Suppl.</i> 2003; 83: S111-4.	1993-2002		
Algeria	Ministry of Health, Population and Hospital Reform (Algeria), University Hospital of Batna. Algeria - Batna Cancer Registry Report 2000-2006. Batna, Algeria: University Hospital of Batna.	2000-2006	*	
Algeria	Oran Cancer Registry (Algeria). Algeria - Oran Cancer Registry Report 2005. Oran, Algeria: Oran Cancer Registry (Algeria), 2006.	2005-2006	*	
Algeria	Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M and Boyle P, eds (2007). <i>Cancer Incidence in Five Continents, Vol. IX Periodic Data (electronic version)</i> . Lyon, IARC. http://ci5.iarc.fr	1998-2002	*	
Algeria	Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. <i>Cancer Incidence in Five Continents, Vol. 1 to VIII</i> . Lyon, France, IARC Press, 2005.	1986-1997	*	
Algeria	World Health Organization (WHO). Algeria WHO Leishmaniasis Country Profile.	1997-2008	*	
Algeria	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec.</i> 2006; 81(32): 309-16.	2005	*	
Algeria	World Health Organization (WHO). Global leprosy situation, 2007 (additional information). <i>Wkly Epidemiol Rec.</i> 2007; 82(44): 388.	2006	*	
Algeria	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Algeria	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Algeria	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Algeria	Galazka AM, Robertson SE. Diphtheria: changing patterns in the developing world and the industrialized world. <i>Eur J Epidemiol.</i> 1995; 11(1): 107-17.	1993-1994		
Algeria	Smahi M-C, Rahmoun L, Ghomari SM, Benmansour S, Sendani H, Bendeddouche AS, Gendrel D. Séroprévalence et facteurs de risque de l'hépatite virale A, Tiemcen, Algérie. <i>Arch Pediatr.</i> 2009; 16(6): 844-6.	2006	*	
Algeria	Slimani S, Ladjouze-Rezig A. Prevalence of rheumatoid arthritis in an urban population of Algeria: a prospective study. <i>Rheumatology.</i> 2014; 53(3): 571-3.	2010	*	
Algeria	Hamdi-Cherif M, Touabti A, Belabbes EH. [Prevalence of hepatitis virus A in the city of Sétif]. <i>Arch Inst Pasteur Alger.</i> 1986; 285-7.	1983-1985		
Algeria	Khalifa S, Ardjoun H. [Epidemiology of viral hepatitis in Algeria]. <i>Med Trop (Mars).</i> 1984; 44(3): 247-52.	1997		
Algeria	World Health Organization (WHO). Report of the Consultative Meeting on Cutaneous Leishmaniasis. Geneva, Switzerland: World Health Organization (WHO), 2008.	2007		
Algeria	Algeria Vital Registration Birth Data 1986 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1986		
Andorra	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2005		
Andorra	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Andorra	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1999-2009		
Andorra	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. <i>Community Dent Oral Epidemiol.</i> 1991; 19(2): 72-3.	1987		
Andorra	De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology.</i> 2000; 54(11 Suppl 5): S21-23.	1997		
Andorra	Berger K BM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology.</i> 2000; 54(11): 24-7.	1997		
Andorra	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Andorra	Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. <i>J Clin Endocrinol Metab.</i> 2008; 93(4): 1408-11.	2005		
Andorra	Trichopoulos D, Bania C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nüthlings U, Overved K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PHM, Lund E, Quirós JR, González CA, Sánchez Pérez M-J, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu I, Chuang S-C, Murphy N, Boffetta P, Trichopoulos A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. <i>J Natl Cancer Inst.</i> 2011; 103(22): 1686-95.	1992-2006	*	
Angola	Angola Malaria Indicator Survey 2006-2007 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006-2007	*	†
Angola	Living Conditions Monitoring Office (Angola), National Statistics Office (Angola), United Nations Children's Fund (UNICEF), Angola Multiple Indicator Cluster Survey 1996. New York, United States: United Nations Children's Fund (UNICEF).	1996	*	†
Angola	National Institute of Statistics (Angola), United Nations Children's Fund (UNICEF). Angola Multiple Indicator Cluster Survey 2001. New York, United States: United Nations Children's Fund (UNICEF).	2001	*	†
Angola	Angola Malaria Indicator Survey 2011 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2011	*	†
Angola	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Angola	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Angola	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1988		
Angola	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1989-1991, 1997, 2000-2007		
Angola	Berrang-Ford L, Lundine J, Breau S. Conflict and human African trypanosomiasis. <i>Soc Sci Med.</i> 2011; 72(3): 398-407.	1996-2002	*	
Angola	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Angola	Bastos I, Reimer A, Lundgren K. Chronic otitis media and hearing loss in otitis in urban schoolchildren in Angola: a prevalence study. <i>Audiol Med.</i> 1993; 129-40.	1981-1982		
Angola	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Angola	Evaristo-Neto AD, Foss-Freitas MC, Foss MC. Prevalence of diabetes mellitus and impaired glucose tolerance in a rural community of Angola. <i>Diabetol Metab Syndr.</i> 2010; 63.	2007-2009		
Angola	Strand RT, Da Silva F, Jangsten E, Bergström S. Postpartum hemorrhage: a prospective, comparative study in Angola using a new disposable device for oxytocin administration. <i>Acta Obstet Gynecol Scand.</i> 2005; 84(3): 260-5.	1998	*	
Angola	Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. <i>Int J Health Geogr.</i> 2010; 9: 57.	1980-2010		
Angola	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec.</i> 2005; 80(13): 118-24.	2003	*	
Angola	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec.</i> 2006; 81(32): 309-16.	2005	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Angola	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Angola	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Angola	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Angola	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Angola	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Angola	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Angola	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Angola	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Angola	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Angola	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Angola	Pelkonen T, Roine I, Monteiro L, Joao Simoes M, Anjos E, Pelerito A, Pitkaranta A, Bernardino L, Peltola H. Acute childhood bacterial meningitis in Luanda, Angola. Scand J Infect Dis. 2008; 40(11-12): 859-66.	2004		
Angola	The MENTOR Initiative Malaria Survey as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005-2006	*	†
Angola	RBM Complex Emergency Malaria Database: Angola as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Antigua and Barbuda	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-1992, 1995-2005		
Antigua and Barbuda	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Antigua and Barbuda	Smadja D, Cabre P, May F, Fanon J-L, René-Coraïl P, Riocreux C, Charpentier J-C, Fournier P, Saint-Vil M, Ketterlé J. ERMANCIA: Epidemiology of Stroke in Martinique, French West Indies. Stroke. 2001; 32(12): 2741-7.	1998-1999		
Antigua and Barbuda	McSwain M, Martin TC, Amarawamy R. The prevalence, aetiology and treatment of congestive cardiac failure in Antigua and Barbuda. West Indian Med J. 1999; 48(3): 137-40.	1995-1996		
Antigua and Barbuda	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998, 2000-2002, 2004-2009		
Antigua and Barbuda	Vignarajah S, Williams GA. Prevalence of dental caries and enamel defects in the primary dentition of Antiguan pre-school children aged 3-4 years including an assessment of their habits. Community Dent Health. 1992; 9(4): 349-60.	1989		
Antigua and Barbuda	Canino G, Shrout PE, Rubio-Stipec M, et al. The DSM-IV rates of child and adolescent disorders in Puerto Rico: Prevalence, correlates, service use, and the effects of impairment. Arch Gen Psychiatry. 2004; 61(1): 85-93.	1999-2000		
Antigua and Barbuda	Rubio-Stipec M, Canino GJ, Shrout P, Dulcan M, Freeman D, Bravo M. Psychometric properties of parents and children as informants in child psychiatry epidemiology with the Spanish Diagnostic Interview Schedule for Children (DISC.2). J Abnorm Child Psychol. 1994; 22(6): 703-20.	1992	*	
Antigua and Barbuda	Canino GJ, Bird HR, Shrout PE, Rubio-Stipec M, Bravo M, Martinez R, Sesman M, Guevara LM. The prevalence of specific psychiatric disorders in Puerto Rico. Arch Gen Psychiatry. 1987; 44(8): 727-35.	1984		
Antigua and Barbuda	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Antigua and Barbuda Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2005		
Antigua and Barbuda	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2001, 2007, 2010, 2012		
Antigua and Barbuda	Bird HR, Canino G, Rubio-Stipec M, Gould MS, Ribera J, Sesman M, Woodbury M, Huertas-Goldman S, Pagan A, Sanchez-Lacay A. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico. The use of combined measures. Arch Gen Psychiatry. 1988; 45(12): 1120-6.	1985-1986	*	
Antigua and Barbuda	Vignarajah S. Periodontal treatment needs in 12 and 15 to 19-year-old school children in the Caribbean Island of Antigua, 1990. J Periodont Res. 1994; 29(5): 324-7.	1990		
Antigua and Barbuda	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Antigua and Barbuda	Merikangas KR, Conway KP, Swendsen J, Febo V, Dierker L, Brunetto W, Stolar M, Canino G. Substance use and behaviour disorders in Puerto Rican youth: a migrant family study. J Epidemiol Community Health. 2009; 63(4): 310-6.	1990		
Antigua and Barbuda	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Antigua and Barbuda	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Antigua and Barbuda	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Antigua and Barbuda	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Antigua and Barbuda	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Antigua and Barbuda	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Antigua and Barbuda	Oilindo S, Cabre P, Deschamps R, Chatot-Henry C, René-Coraïl P, Fournier P, Saint-Vil M, May F, Smadja D. Acute stroke in the very elderly: epidemiological features, stroke subtypes, management, and outcome in Martinique, French West Indies. Stroke. 2003; 34(7): 1593-7.	1998-1999		
Antigua and Barbuda	Fassio E, Diaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L, Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. Ann Hepatol. 2010; 9(1): 63-9.	2006-2008	*	
Argentina	Argentina Vital Registration - Deaths 1980 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1980	*	
Argentina	Argentina Vital Registration - Deaths 2002 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2002	*	
Argentina	Argentina Vital Registration - Deaths 2008 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2008	*	
Argentina	Directorate of Epidemiology, Ministry of Health (Argentina). Argentina Annual Epidemiological Bulletin 2003-2005. Buenos Aires, Argentina: Ministry of Health (Argentina).	2004-2005	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Argentina	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1999-2002		
Argentina	Argentina Vital Registration - Deaths 2010 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2010	*	
Argentina	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Argentina	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Argentina	Moreno L, Krishnan JA, Duran P, Ferrero F. Development and validation of a clinical prediction rule to distinguish bacterial from viral pneumonia in children. <i>Pediatr Pulmonol.</i> 2006; 41(4): 331-7.	2002-2003		
Argentina	Perna ER, Barbagelata A, Grinfeld L, García Ben M, Cimbaro Canella JP, Bayol PA, Sosa Liprandi A. Overview of acute decompensated heart failure in Argentina: lessons learned from 5 registries during the last decade. <i>Am Heart J.</i> 2006; 151(1): 84-91.	1993, 1999, 2003-2004		
Argentina	Segura EL, Cura EN, Estani SA, Andrade J, Lansetti JC, De Rissio AM, Campanini A, Blanco SB, Gürtler RE, Alvarez M. Long-term effects of a nationwide control program on the seropositivity for Trypanosoma cruzi infection in young men from Argentina. <i>Am J Trop Med Hyg.</i> 2000; 62(3): 353-62.	1981-1993		
Argentina	Pan American Health Organization (PAHO), Southern Cone Initiative (INCOSUR). Xth Meeting of the Intergovernmental Committee for the Elimination of Triatoma Infestans and the Interruption of American Trypanosomiasis by Transfusion. Washington, D.C., United States: Pan American Health Organization (PAHO), 2002.	2001		
Argentina	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol.</i> 2008; 121(4): 947-954.	1993, 1997, 2002		
Argentina	Espul C, Cuello H, Navarra LM, Mamani N, O'Ryan M, O'Ryan M. Characterization of antigenic types of circulating rotaviruses in Mendoza, Argentina based on typing of the external VP7 capsid protein. <i>Acta Gastroenterol Latinoam.</i> 1995; 23(4): 211-6.	1991-1992		
Argentina	Gómez J. Diarrea por rotavirus: estudio prospectivo de 49 familias del partido de Avellaneda, provincia de Buenos Aires. <i>Arch Argent Pediatr.</i> 1986; 85: 139.	1983-1986		
Argentina	Gómez JA, Biscotti EL, Bercovich JA, Grinstein S. Epidemiology of human rotaviruses in Argentina as determined by RNA genome electrophoresis. <i>Intervirology.</i> 1987; 26(3): 174-80.	1983-1985		
Argentina	Komaid JA, de Caillou SL, Suárez AM, de Castagnaro NR. Electrophoretic types of rotavirus RNA during a 4-yr study of gastroenteritis in Tucumán. <i>Rev Argent Microbiol.</i> 1990; 22(3): 123-9.	1986-1989		
Argentina	Lombardi GH, Roseto AM, Stamboulian D, Oro JG. Letter: Virus of infantile gastroenteritis in Argentina. <i>Lancet.</i> 1975; 2(7948): 1311.	1975		
Argentina	Muchnik GR, Grinstein S, Plaza A. Rotavirus infection in children hospitalized for diarrhoea in Argentina. <i>Ann Trop Paediatr.</i> 1981; 1(3): 167-73.	1978-1980		
Argentina	O'Ryan M, Pérez-Schael I, Mamani N, Peña A, Salinas B, González G, González F, Matson DO, Gómez J. Rotavirus-associated medical visits and hospitalizations in South America: a prospective study at three large sentinel hospitals. <i>Pediatr Infect Dis J.</i> 2001; 20(7): 685-93.	1997-1999		
Argentina	Souza JP, Cecatti JG, Faundes A, Morais SS, Villar J, Carroli G, Gulmezoglu M, Wojdyla D, Zavaleta N, Donner A, Velazco A, Bataglia V, Valladares E, Kublickas M, Acosta A. Maternal near miss and maternal death in the World Health Organization's 2005 global survey on maternal and perinatal health. <i>Bull World Health Organ.</i> 2010; 88(2): 113-9.	2005		
Argentina	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1999, 2001, 2004-2009		
Argentina	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Argentina	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2002		
Argentina	Moro P, Schantz PM. Cystic echinococcosis in the Americas. <i>Parasitol Int.</i> 2006; 55(1): S181-6.	1996		
Argentina	Secretariat for Programming Drug Abuse Prevention and the Fight against Drug Trafficking (SEDRONAR). Argentina National Survey on Consumption Prevalence of Psychoactive Substances 1999.	1999		
Argentina	Bianchi ME, Fariás EF, Bolaño J, Massari PU. Epidemiology of renal and cardiovascular risk factors in Toba Aborigines. <i>Ren Fail.</i> 2006; 28(8): 665-70.	2003		
Argentina	Morillo LE, Alarcon F, Aramaga N, Aulet S, Chapman E, Conterro L, Estevez E, Garcia-Pedroza F, Garrido J, Macías-Isas M, Monzillo P, Nunez L, Plascencia N, Rodriguez C, Takeuchi Y, Latin American Migraine Study Group. Prevalence of migraine in Latin America. <i>Headache.</i> 2005; 45(2): 106-17.	1999		
Argentina	Sosa-Estani S, Gamba-León MR, Del Cid-Lemus J, Althabe F, Alger J, Almendares O, Cafferata ML, Chippaux J-P, Dumontell E, Gibbons L, Padilla-Raygoza N, Schneider D, Belizán JM, Buekens P, Working Group. Use of a rapid test on umbilical cord blood to screen for Trypanosoma cruzi infection in pregnant women in Argentina, Bolivia, Honduras, and Mexico. <i>Am J Trop Med Hyg.</i> 2008; 79(5): 755-9.	2006-2007		
Argentina	Bar ME, Oscherov EB, Pieri Damborsky M, Borda M. Epidemiology of American trypanosomiasis in the North of Corrientes province, Argentina. <i>Medicina (B Aires).</i> 2010; 70(2): 133-8.	2007-2008		
Argentina	Sosa-Estani S, Dri L, Touris C, Abalde S, Dell'arciprete A, Braunstein J. Vectorial and congenital transmission of Trypanosoma cruzi in Las Lomitas, Formosa. <i>Medicina (B Aires).</i> 2009; 69(4): 424-30.	2005-2006		
Argentina	Mallol J, Solé D, Baeza-Bacab M, Aguirre-Camposano V, Soto-Quiros M, Baena-Cagnani C, Latin American ISAAC Group. Regional variation in asthma symptom prevalence in Latin American children. <i>J Asthma.</i> 2010; 47(6): 644-50.	2001-2003	*	
Argentina	Llompart G, Marin GH, Silberman M, Merlo I, Zurriaga O, GIS (Grupo Interdisciplinario para Salud). Oral health in 6-year-old schoolchildren from Berisso, Argentina: falling far short of WHO goals. <i>Med Oral Patol Oral Cir Bucal.</i> 2010; 15(1): e101-105.	2007		†
Argentina	Romanelli H, Gonzalez y Rivas M, Chiappe V, Gómez M, Macchi R. Periodontal treatment needs in Argentine adult subjects. <i>Acta Odontol Latinoam.</i> 2007; 20(1): 39-47.	1999-2000	*	
Argentina	Larrieu E, Del Carpio M, Mercapide CH, Salvitti JC, Sustercic J, Moguilensky J, Panomarenko H, Uchiumi L, Herrero E, Talmon G, Volpe M, Araya D, Mujica G, Mancini S, Labanchi JL, Odriozola M. Programme for ultrasound diagnoses and treatment with albendazole of cystic echinococcosis in asymptomatic carriers: 10 years of follow-up of cases. <i>Acta Trop.</i> 2011; 117(1): 1-5.	1997-1998	*	
Argentina	Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version). Lyon, IARC. http://ci5.iarc.fr	2003-2007	*	
Argentina	Castello AA, Argiuelles MH, Rota RP, Humphrey CD, Olthoff A, Gentsch JR, Glass RI, Glikmann G, Jiang B. Detection and characterization of group C rotavirus in Buenos Aires, Argentina, 1997-2003. <i>J Med Virol.</i> 2009; 81(6): 1109-16.	1997-2003	*	
Argentina	De Muñiz BR. Epidemiologic oral health survey of Argentine children. <i>Community Dent Oral Epidemiol.</i> 1985; 13(6): 328-33.	1983		
Argentina	Pinduli I, Spivacow R, del Valle E, Vidal S, Negri AL, Previgliano H, Fariás E dos R, Andrade JH, Negri GM, Boffi-Boggero HJ. Prevalence of urolithiasis in the autonomous city of Buenos Aires, Argentina. <i>Urol Res.</i> 2006; 34(1): 8-11.	1998		
Argentina	Melcon CM, Melcon MO. Prevalence of stroke in an Argentine community. <i>Neuroepidemiology.</i> 2006; 27(2): 81-8.	1991		
Argentina	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2004-2008		
Argentina	Melcon MO, Anderson DW, Vergara RH, Rocca WA. Prevalence of Parkinson's disease in Junín, Buenos Aires province, Argentina. <i>Mov Disord.</i> 1997; 12(2): 197-205.	1991		
Argentina	Nano ME, Nano HD, Mugica JM, Silva JC, Montaña G, Limburg H. Rapid assessment of visual impairment due to cataract and cataract surgical services in urban Argentina. <i>Ophthalmic Epidemiol.</i> 2006; 13(3): 191-7, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2005		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Argentina	Dayan GH, Panero MS, Debbag R, Urquiza A, Molina M, Prieto S, Del Carmen Perego M, Scagliotti G, Galimberti D, Carroli G, Wolff C, Schmid DS, Loparev V, Guris D, Seward J. Varicella seroprevalence and molecular epidemiology of varicella-zoster virus in Argentina, 2002. <i>J Clin Microbiol.</i> 2004; 42(12): 5698-704.	2002		
Argentina	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Argentina Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2005-2006		
Argentina	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), United Nations Office on Drugs and Crime (UNODC). Youth and Drugs in South American Countries: A Public Policy Challenge 2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2006.	2005		
Argentina	Rios FG, Riso-Vázquez A, Alvarez J, Vinzio M, Falbo P, Rondinelli N, Bienzobas DH. Clinical characteristics and outcomes of obstetric patients admitted to the intensive care unit. <i>Int J Gynaecol Obstet.</i> 2012; 119(2): 136-40.	2008-2010	*	
Argentina	Kochen S, Melcon MO. Prognosis of epilepsy in a community-based study: 8 years of follow-up in an Argentine community. <i>Acta Neurol Scand.</i> 2005; 112(6): 370-4.	1991-1993	*	†
Argentina	Fassio E, Miguez C, Soria S, Palazzo F, Gadano A, Adrover R, Landeira G, Fernández N, García D, Barbero R, Perelstein G, Ríos B, Isla R, Civetta E, Pérez Ravier R, Barzola S, Curciarello J, Colombato LA, Jmenitzky A. Etiology of hepatocellular carcinoma in Argentina: results of a multicenter retrospective study. <i>Acta Gastroenterol Latinoam.</i> 2009; 39(1): 47-52.	2006-2008		
Argentina	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Argentina	Perazzi BE, Menghi CI, Coppolillo EF, Gatta C, Eliseth MC, de Torres RA, Vay CA, Famiglietti AMR. Prevalence and comparison of diagnostic methods for Trichomonas vaginalis infection in pregnant women in Argentina. <i>Korean J Parasitol.</i> 2010; 48(1): 61-5.	2005-2007		
Argentina	Fernández-Cean J, González-Martínez F, Schwedt E, Mazzuchi N. Renal replacement therapy in Latin America. <i>Kidney Int.</i> 2000; 57(s74): 55-59.	1997		
Argentina	Lugon JR, Strogoff de Matos JP. Disparities in end-stage renal disease care in South America. <i>Clin Nephrol.</i> 2010; 74(Suppl 1): S66-71.	2006		
Argentina	Cusumano A, García-García G, Di Gioia C, Hermida O, Lavorato C, Carreño CA, Torrico MP, Batista PB, Romão JE, Badal HP, Miranda SE, Gomez R, Calderon MC, Sanchez SH, Lopez MA, Moscoso J, Merino RL, Polo JV, Lopez A, Romero NJ, Garcia R, Acosta BV, Lopez AS, Delpin ES, Mena E, González C, Milanés CL, Achiardo S. End-stage renal disease and its treatment in Latin America in the twenty-first century. <i>Ren Fail.</i> 2006; 28(8): 631-7.	2004		
Argentina	Santiago-Delpin EA, García VD. Latin American Transplant Registry VIIIth Report: 1998. <i>Transplant Proc.</i> 1999; 31(1-2): 214-6.	1995, 1997		
Argentina	Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M and Boyle P, eds (2007). Cancer Incidence in Five Continents, Vol. IX Periodic Data (electronic version). Lyon, IARC. http://ci5.iarc.fr	1998-2002	*	
Argentina	Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. Cancer Incidence in Five Continents. Vol. 1 to VIII. Lyon, France, IARC Press, 2005.	1990-1997		
Argentina	Bauso DJ, Tartari JP, Stefani CV, Rojas JI, Giunta DH, Cristiano E. Incidence and prevalence of Parkinson's disease in Buenos Aires City, Argentina. <i>Eur J Neurol.</i> 2012; 19(8): 1108-13.	2003-2008		
Argentina	World Health Organization (WHO). Argentina WHO Leishmaniasis Country Profile.	1994-2010	*	
Argentina	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Argentina	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Argentina	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Argentina	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Argentina	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Argentina	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Argentina	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Argentina	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Argentina	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2003. Pan American Health Organization (PAHO).	2003		†
Argentina	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2004. Pan American Health Organization (PAHO).	2004		†
Argentina	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2005. Pan American Health Organization (PAHO).	2005		†
Argentina	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2006. Pan American Health Organization (PAHO).	2006		†
Argentina	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2007. Pan American Health Organization (PAHO).	2007		†
Argentina	Tregnaghi MW, Sáez-Llorens X, López P, Abate H, Smith E, Póseman A, et al. Evaluating the efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PH10-CV) against community-acquired pneumonia in Latin America [abstract]. In: Abstracts of the 29th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2011 June 7-11; The Hague, The Netherlands.	1997-2000	*	
Argentina	Lomuto CC, Galina L, Brussa M, Quiroga A, Alda E, Benítez AM, Bouzas L, Dinerstein NA, Erpen N, Falbo J, Manzitti J, Marinaro S, Nieto R, Sepúlveda T, Visintín P. [Epidemiology of retinopathy of prematurity in public services from Argentina during 2008]. <i>Arch Argent Pediatr.</i> 2010; 108(1): 24-30.	2008	*	†
Argentina	Melcon MO, Kochen S, Vergara RH. Prevalence and clinical features of epilepsy in Argentina. A community-based study. <i>Neuroepidemiology.</i> 2007; 28(1): 8-15.	1991-1993	*	
Argentina	Sosa Liprandi MI, González MA, Liprandi AS. [Heart failure in Argentina]. <i>Medicina (B Aires).</i> 1999; 59(6): 787-92.	1992		
Argentina	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Argentina	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Argentina	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Argentina	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Argentina	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Argentina	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Argentina	Degiusseppe JI, Giovoacchini C, Stupka JA, Red Nacional de Vigilancia de Gastroenteritis Virales. [Rotavirus epidemiology and surveillance in Argentina: 2009-2011]. Arch Argent Pediatr. 2013; 111(2): 148-54.	2009-2011	*	
Argentina	Yanez LA, Lucero NS, Barri PA, Diaz M del P, Tenaglia MM, Spinsanti LI, Nates SV, Isa MB, Ré VE. Evidence of Hepatitis A virus circulation in central Argentina: Seroprevalence and environmental surveillance. J Clin Virol. 2014; 59(1): 38-43.	2009-2010	*	
Argentina	Brasca AP, Pezzotto SM, Berli D, Villavicencio R, Fay O, Gianguzzo MP, Poletto L. Epidemiology of gallstone disease in Argentina: prevalences in the general population and European descendants. Dig Dis Sci. 2000; 45(12): 2392-8.	1998		
Argentina	López H, Zitto T, Baré P, Vidal G, Vukasovic J, Gómez R. Prevalence of anti-hepatitis A antibodies in an urban middle class area of Argentina: some associated factors. Int J Infect Dis. 2000; 4(1): 34-7.	1995-1996		
Argentina	Gonzalez J, Fay O, Canero-Velasco MC, Fernandez E, Carchio E, Moreiro R, Weller C, Taborda M, Mutti J, Degaetano S, Flores I, Auveux C, Cavo M, Sosa A, Nucifora S, Marchesini N, Castro R, Cisaruk E. [Hepatitis A virus infection in children in Argentina: a pilot study]. Acta Gastroenterol Latinoam. 1997; 27(5): 331-4.	1996		
Argentina	Tapia-Conyer R, Santos JI, Cavalcanti AM, Urdaneta E, Rivera L, Manterola A, Potin M, Ruttiman R, Tanaka Kido J. Hepatitis A in Latin America: A Changing Epidemiologic Pattern. Am J Trop Med Hyg. 1999; 61(5): 825-9.	1996-1997		
Argentina	Foussal MD, Picón C, Sorrentino A. [Hepatitis A in childhood. The tip of an infectious disease iceberg]. Acta Gastroenterol Latinoam. 2002; 32(2): 101-5.	2001		
Argentina	Soria SM, Katz SL, Alvarez DF, Rodríguez RR, González MG, D'Angelo PJ, Bulacio PA, Sixto MI, Abdelnur IGI, Garay ME, Bianchi AM, Leguina MI, Véliz MA, Villamil FG. [Prevalence of liver diseases in a small rural community isolated in the mountain heights: clinical, biochemical and ultrasonographic study]. Acta Gastroenterol Latinoam. 2006; 36(4): 174-81.	2002		
Argentina	Caccavo A, Álvarez A, Bello FH, Ferrari AE, Carrique AM, Lasdica SA, Esandi ME. Incidencia poblacional del infarto con elevación del ST o bloque de rama izquierda a lo largo de 11 años en una comunidad de la provincia de Buenos Aires. Rev Argent Cardiol. 2007; 75(3): 185-8.	1995-2005		
Argentina	Mule MF, Szajowicz D, Kevorkian R, Cohen G, Principato MB, Higa CC. Eventos clínicos en pacientes que consultan a la guardia por dolor precordial. Rev Argent Cardiol. 1997; 65(1): 1.	1995		
Argentina	Del Pino N, Martínez Peralta L, Pampuro S, Pimentel E, Libonatti O. HTLV-III seroprevalence and coinfection with other pathogens in blood donors in Buenos Aires. J Acquir Immune Defic Syndr. 1994; 7(2): 206-7.	1991-1992		
Argentina	Ferrer JF, Del Pino N, Esteban E, Sherman MP, Dube S, Dube DK, Basombrio MA, Pimentel E, Segovia A, Quirulas S, Poiesz BJ. High Rate of Infection with the Human T-Cell Leukemia Retrovirus Type II in Four Indian Populations of Argentina. Virology. 1993; 197(2): 576-84.	1991		
Argentina	Rey JA, Findor JA, Daruich JR, Velazco CC, Igartua EB, Schmee E, Kohan AI. Prevalence of IgG Anti-HEV in Buenos Aires, a Nonendemic Area for Hepatitis E. J Travel Med. 1997; 4(2): 100-1.	1994-1995	*	
Argentina	Pan American Health Organization (PAHO), World Health Organization (WHO). Quantitative Estimation of Chagas in the Americas.	2005	*	
Argentina	Bar ME, Damborsky MP, Oscherov EB, Alvarez BM, Mizdraji G, Avalos G. [Household infestation by triatomines and human seroprevalence in Empedrado Department, Corrientes, Argentina]. Cad Saude Publica. 1997; 13(2): 305-12.	1994-1995	*	
Argentina	Gürtler RE, Chuit R, Cécere MC, Castañera MB, Cohen JE, Segura EL. Household prevalence of seropositivity for Trypanosoma cruzi in three rural villages in northwest Argentina: environmental, demographic, and entomologic associations. Am J Trop Med Hyg. 1998; 59(5): 741-9.	1992	*	
Argentina	Blejer JL, Saguer MC, Salamone HJ. Antibodies to Trypanosoma cruzi among blood donors in Buenos Aires, Argentina. Int J Infect Dis. 2001; 5(2): 89-93.	1995-1999	*	
Argentina	Diosque P, Padilla AM, Cimino RO, Cardozo RM, Negrette OS, Marco JD, Zacca R, Meza C, Juarez A, Rojo H, Rey R, Corrales RM, Nasser JR, Basombrio MA. Chagas disease in rural areas of Chaco Province, Argentina: epidemiologic survey in humans, reservoirs, and vectors. Am J Trop Med Hyg. 2004; 71(5): 590-3.	1999-2002	*	
Argentina	Moreno ML, Moretti E, Basso B, Céspedes MF, Catalá SS, Gorla DE. Seroprevalence of Trypanosoma cruzi infection and vector control activities in rural communities of the southern Gran Chaco (Argentina). Acta Trop. 2010; 113(3): 257-62.	1997-2007	*	
Argentina	Tortora C, Bejarano I, Dipietri J, Alfaro E, García T. [Chagas diseases seroepidemiology in schoolchildren of Jujuy]. Medicina (B Aires). 2000; 60(4): 469-73.	1992-1998	*	
Argentina	Bar ME, Damborsky MP, Oscherov EB, Wisnivesky-Colli C. [Epidemiology of Chagas disease in San Roque, Corrientes. Triatomine infestation and human seroprevalence]. Medicina (B Aires). 2005; 65(2): 97-102.	1998-1999	*	
Argentina	Biancardi MA, Conca Moreno M, Torres N, Pepe C, Althech J, Freilij H. [Seroprevalence of Chagas disease in 17 rural communities of "Monte Impenetrable", Chaco Province]. Medicina (B Aires). 2003; 63(2): 125-129.	1999-2000	*	
Argentina	Chuit R, Subias E, Pérez AC, Paulone I, Wisnivesky-Colli C, Segura EL. Usefulness of serology for the evaluation of Trypanosoma cruzi transmission in endemic areas of Chagas' disease. Rev Soc Bras Med Trop. 1989; 22(3): 119-124.	1983-1985	*	
Argentina	Mallimaci MC, Sijvarger C, Dates A, Alvarez M, Sosa-Estani S. [Seroprevalence of Chagas disease in Ushuaia, Argentina, an area without Triatominae]. Rev Panam Salud Publica. 2001; 9(3): 169-171.	1995-1996	*	
Argentina	Argentina Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Argentina	Argentina National Registry of Congenital Anomalies Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
Argentina	Argentina Latin American Collaborative Study of Congenital Malformations Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT). International Centre on Birth Defects. World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Armenia	Ministry of Health (Armenia), National Statistical Service (NSS), ORC Macro. Armenia Demographic and Health Survey 2000. Calverton, United States: Macro International, Inc.	2000		†
Armenia	MOH Center for Health Information and Statistics, Macro International, Inc, National Statistical Service (NSS). Armenia Demographic and Health Survey 2005. Calverton, United States: Macro International, Inc.	2005		†
Armenia	ICF Macro, Ministry of Health (Armenia), National Statistical Service of the Republic of Armenia. Armenia Demographic and Health Survey 2010. Calverton, United States: ICF Macro.	2010	*	†
Armenia	Ministry of Health (Armenia), National Statistical Service of the Republic of Armenia. Armenia Health and Health Care 2009. Yerevan, Armenia: National Health Information Analytic Center, National Institute of Health (Armenia), 2010.	1990, 1995, 2000, 2002-2009	*	
Armenia	Centre for Health Informatics and Multiprofessional Education, University College London. Model's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Armenia	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1999, 2001-2005		
Armenia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Armenia	Knapp CJ. Dialysis in Armenia. Nephrol News Issues. 1992; 6(6): 5, 11.	1990		
Armenia	World Health Organization (WHO). Armenia WHO Leishmaniasis Country Profile.	1999-2008	*	
Armenia	Rossi L, Branca F. Salt iodisation and public health campaigns to eradicate iodine deficiency disorders in Armenia. Public Health Nutr. 2003; 6(5): 463-9.	1997		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Armenia	Asratian AA, Melik-Andreasian GG, Mkhitarian IL, Aleksanian IT, Shmavonian MV, Kazarian SM, Mkhitarian RG, Kozhevnikova LK. [Seroprevalence and epidemiological characterization of virus hepatitis in the Republic of Armenia]. Zh Mikrobiol Epidemiol Immunobiol. 2005; 93-6.	1997-2002		
Armenia	USSR - Armenian SSR Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD), United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Australia	International Diabetes Institute (IDI). Australia Diabetes, Obesity and Lifestyle Study 1999-2000. Melbourne, Australia: International Diabetes Institute (IDI).	1999-2000		
Australia	Australian Bureau of Statistics. Australia National Health Survey 1995-1996. Canberra, Australia: Australian Bureau of Statistics.	1995-1996		
Australia	Department of Health and Ageing (Australia), World Health Organization (WHO). Australia World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		
Australia	Australian Bureau of Statistics. Australia National Health Survey 2001. Canberra, Australia: Australian Bureau of Statistics.	2001		
Australia	Australian Bureau of Statistics. Australia National Health Survey 2004-2005.	2004-2005		
Australia	Australian Bureau of Statistics. Australia National Health Survey 2007-2008. Canberra, Australia: Australian Bureau of Statistics.	2007-2008		
Australia	Australian Bureau of Statistics. Australia Survey of Disability, Ageing, and Carers 2003.	2003		
Australia	Australian Bureau of Statistics. Australia Survey of Disability, Ageing, and Carers 2009.	2009		
Australia	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1991-1999		
Australia	Lake FR, Cullen KJ, de Klerk NH, McCall MG, Rosman DL. Atrial fibrillation and mortality in an elderly population. Aust N Z J Med. 1989; 19(4): 321-6.	1980-1981		
Australia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Australia	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	2009		†
Australia	Homma Y, Kawabe K, Tsukamoto T, Yamanaka H, Okada K, Okajima E, Yoshida O, Kumazawa J, Gu FL, Lee C, Hsu TC, Dela Cruz RC, Tantiwang A, Lim PH, Sheikh MA, Bapat SD, Marshall VR, Tajima K, Aso Y. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score. Int J Urol. 1997; 4(1): 40-6.	1995		
Australia	Charles PGP, Grayson ML, Pierce RJP, Mayall BC, Fuller AJ, Stirling R, Hooy M, Korman TM, Holmes PW, Wright AA, Catton MG, Whitty B, Johnson B, Armstrong JG, Nimmo GR, Christiansen KJ, Waterer GW, Grayson L, Johnson P, Munchhof W, Looke D, Garske L, Playford G, Spelman D, Kotsimbo T, Holmes P, Korman T, Bardin P, Heath C, Birch C, Druce J, Ryan N, Irving L, Hart D. The etiology of community-acquired pneumonia in Australia: Why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis. 2008; 46(10): 1513-21.	2004-2005		
Australia	Kilkenny M, Stathakis V, Jolley D, Marks R. Maryborough skin health survey: prevalence and sources of advice for skin conditions. Australas J Dermatol. 1998; 39(4): 233-7.	1996		
Australia	Plunkett A, Merlin K, Gill D, Zuo Y, Jolley D, Marks R. The frequency of common nonmalignant skin conditions in adults in central Victoria, Australia. Int J Dermatol. 1999; 38(12): 901-8.	1997-1998		
Australia	Thrift AG, Dewey HM, Sturm JW, Srikanth VK, Gilligan AK, Gall SL, Macdonell RAL, McNeil JJ, Donnan GA. Incidence of stroke subtypes in the North East Melbourne Stroke Incidence Study (NEMESIS): differences between men and women. Neuroepidemiology. 2009; 32(1): 11-8.	1997-1999		
Australia	Islam MS, Anderson CS, Hankey GJ, Hardie K, Carter K, Broadhurst R, Jamrozik K. Trends in Incidence and Outcome of Stroke in Perth, Western Australia During 1989 to 2001. Stroke. 2008; 39(3): 776-82.	1989-1990, 1995-1996, 2000-2001		
Australia	Thrift AG, Dewey HM, Macdonell RAL, McNeil JJ, Donnan GA. Incidence of the Major Stroke Subtypes: Initial Findings From the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke. 2001; 32(8): 1732-8.	1996-1997		
Australia	Thrift AG, Dewey HM, Macdonell RAL, McNeil JJ, Donnan GA. Stroke Incidence on the East Coast of Australia: The North East Melbourne Stroke Incidence Study (NEMESIS). Stroke. 2000; 31(9): 2087-92.	1996-1997		
Australia	McLean AS, Eslick GD, Coats AJS. The epidemiology of heart failure in Australia. Int J Cardiol. 2007; 118(3): 370-4.	1990, 2002		
Australia	Wilkinson T. Haemoglobinopathies in Australia and New Zealand. Hemoglobin. 1981; 5(5): 525-30.	1977-1980		
Australia	Raasch BA, Buettner PG. Multiple nonmelanoma skin cancer in an exposed Australian population. Int J Dermatol. 2002; 41(10): 652-8.	1997-1999		
Australia	Richmond-Sinclair NM, Pandeya N, Ware RS, Neale RE, Williams GM, van der Pols JC, Green AC. Incidence of basal cell carcinoma multiplicity and detailed anatomic distribution: longitudinal study of an Australian population. J Invest Dermatol. 2009; 129(2): 323-8.	1997-2006		
Australia	Staples MP, Elwood M, Burton RC, Williams JL, Marks R, Giles GG. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust. 2006; 184(1): 6-10.	2002		
Australia	Cowan J, Kerr C. Incidence of homozygous beta-thalassaemia in New South Wales, 1961-1976. Med J Aust. 1982; 1(13): 554-6.	1961-1976		
Australia	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001-2005, 2007-2009		
Australia	South Australian Department of Health, University of Adelaide, University of South Australia. Australia - Adelaide Musculoskeletal Conditions: Arthritis 2004-2006. Adelaide, Australia: University of Adelaide, 2007.	2004-2006		
Australia	Minaur N, Sawyers S, Parker J, Darmawan J. Rheumatic disease in an Australian Aboriginal community in North Queensland, Australia. A WHO-ILAR COPCORD survey. J Rheumatol. 2004; 31(5): 965-72.	2002		
Australia	Gillman A, Steinfurt C. Sarcoidosis in Australia. Intern Med J. 2007; 37(6): 356-9.	2005		
Australia	Jg M, Sr H, Jf H. Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results. Med J Aust. 1994; 160(3): 117-22.	1971-1981		
Australia	Hammond SR, de Wyt C, Maxwell IC, Landy PJ, English D, McLeod JG, McCall MG. The epidemiology of multiple sclerosis in Queensland, Australia. J Neurol Sci. 1987; 80(2-3): 185-204.	1981		
Australia	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J. 1998; 12(2): 315-35.	1993-1995		
Australia	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2002		
Australia	Burgess JA, Matheson MC, Gurrin LC, Byrnes GB, Adams KS, Wharton CL, Giles GG, Jenkins MA, Hopper JL, Abramson MJ, Walters EH, Dharmage SC. Factors influencing asthma remission: a longitudinal study from childhood to middle age. Thorax. 2011; 66(6): 508-13.	1968-2007		
Australia	Wilson DH, Adams RJ, Tucker G, Appleton S, Taylor AW, Ruffin RE. Trends in asthma prevalence and population changes in South Australia, 1990-2003. Med J Aust. 2006; 184(5): 226-9.	1990, 1992, 2002-2003		
Australia	James AL, Knuiam MW, Divitini ML, Hui J, Hunter M, Palmer LJ, Maier G, Musk AW. Changes in the prevalence of asthma in adults since 1966: the Busselton health study. Eur Respir J. 2010; 35(2): 273-278.	2005-2007		
Australia	Fapp RJ, Shaw JE, de Courten MP, Dunstan DW, Welborn TA, Zimmet PZ. AusDiab Study Group. Type 2 diabetes: an Australian population-based study. Diabet Med. 2003; 20(2): 105-13.	1999-2000		
Australia	Davis TM, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia. 2008; 51(4): 562-6.	1993-1996		
Australia	Australian Institute of Health and Welfare, Roy Morgan Research. Australia National Drug Strategy Household Survey 1998.	1998		
Australia	Badawi N, Kurinczuk JJ, Keogh JM, Alessandri LM, O'Sullivan F, Burton PR, Pemberton PJ, Stanley FJ. Antepartum risk factors for newborn encephalopathy: the Western Australian case-control study. BMJ. 1998; 317(7172): 1549-53.	1993-1995		†
Australia	Busselton Population Medical Research Institute (Australia). Australia - Busselton Health Study 1981.	1981		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Australia	Jaross N, Ryan P, Newland H. Prevalence of diabetic retinopathy in an Aboriginal Australian population: results from the Katherine Region Diabetic Retinopathy Study (KRDRS). Report no. 1. Clin Experiment Ophthalmol. 2003; 31(1): 32-9.	1993, 1996		
Australia	Tapp RJ, Shaw JE, Harper CA, de Courten MP, Ballau B, McCarty DJ, Taylor HR, Welborn TA, Zimmet PZ, AusDiab Study Group. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care. 2003; 26(6): 1731-7.	2002		
Australia	Adams RJ, Appleton S, Wilson DH, Taylor AW, Dal Grande E, Chittleborough C, Gill T, Ruffin R. Population comparison of two clinical approaches to the metabolic syndrome: implications of the new International Diabetes Federation consensus definition. Diabetes Care. 2005; 28(11): 2777-9.	2000		
Australia	Simmons D, McKenzie A, Eaton S, Shaw J, Zimmet P. Prevalence of diabetes in rural Victoria. Diabetes Res Clin Pract. 2005; 70(3): 287-90.	2002		
Australia	Mitchell P, Wang JJ, Currie J, Cumming RG, Smith W. Prevalence and vascular associations with migraine in older Australians. Aust N Z J Med. 1998; 28(5): 627-32.	1992-1994		
Australia	March LM, Schwarz JM, Carfrae BH, Bagge E. Clinical validation of self-reported osteoarthritis. Osteoarthritis Cartilage. 1998; 6(2): 87-93.	1995		
Australia	Cumming RG, Klineberg RJ. Epidemiological study of the relation between arthritis of the hip and hip fractures. Ann Rheum Dis. 1993; 52(10): 707-10.	1990-1991		
Australia	Chittleborough CR, Taylor AW, Dal Grande E, Gill TK, Grant JF, Adams RJ, Wilson DH, Ruffin RE, North West Adelaide Health Study Team. Gender differences in asthma prevalence: variations with socioeconomic disadvantage. Respirology. 2010; 15(1): 107-14.	2007-2009	*	
Australia	Ackerman IN, Osborne RH. Obesity and increased burden of hip and knee joint disease in Australia: results from a national survey. BMC Musculoskelet Disord. 2012; 13(1): 254.	2009	*	
Australia	Tai A, Volkmer R, Burton A. Association between asthma symptoms and obesity in preschool (4-5 year old) children. J Asthma. 2009; 46(4): 362-5.	2006	*	
Australia	Tai A, Volkmer R, Burton A. Prevalence of asthma symptoms and atopic disorders in preschool children and the trend over a decade. J Asthma. 2009; 46(4): 343-6.	2006	*	
Australia	Dogar F, Kruger E, Dyson K, Tennant M. Oral health of pre-school children in rural and remote Western Australia. Rural Remote Health. 2011; 11(4): 1869.	2009	*	
Australia	Arora A, Evans RW. Dental caries in children: a comparison of one non-fluoridated and two fluoridated communities in NSW. N S W Public Health Bull. 2010; 21(11-12): 257-62.	2006		
Australia	Powell RN, McEnery TM. The Brisbane Statistical Division Survey of Adult Dental Health 1984. 3. Dental health status and treatment needs. Aust Dent J. 1988; 33(2): 109-15.	1984	*	
Australia	Heywood AE, Newall AT, Gao Z, Wood JG, Breschkin A, Nicholson S, Gidding HF, Dwyer DE, Gilbert GL, Macintyre CR. Changes in seroprevalence of hepatitis A in Victoria, Australia: a comparison of three time points. Vaccine. 2012; 30(42): 6020-6.	1988-1989, 1997-1998, 2008		
Australia	Rees CS, Smith AJ, O'Sullivan PB, Kendall GE, Straker LM. Back and neck pain are related to mental health problems in adolescence. BMC Public Health. 2011; 11: 382.	1989-1992	*	
Australia	Broom AF, Kirby ER, Sibbritt DW, Adams J, Refshauge KM. Back pain amongst mid-age Australian women: A longitudinal analysis of provider use and self-prescribed treatments. Complement Ther Med. 2012; 20(5): 275-82.	2004-2007	*	
Australia	O'Sullivan PB, Beales DJ, Smith AJ, Straker LM. Low back pain in 17 year olds has substantial impact and represents an important public health disorder: a cross-sectional study. BMC Public Health. 2012; 12(1): 100.	2008	*	
Australia	Barnes GL, Uren E, Stevens KB, Bishop RF. Etiology of acute gastroenteritis in hospitalized children in Melbourne, Australia, from April 1980 to March 1993. J Clin Microbiol. 1998; 36(1): 133-8.	1980-1993	*	
Australia	Burke V, Gracey M, Robinson J, Peck D, Beaman J, Bundell C. The microbiology of childhood gastroenteritis: Aeromonas species and other infective agents. J Infect Dis. 1983; 148(1): 68-74.	1980	*	
Australia	Katzellenbogen JM, Sanfilippo FM, Hobbs MST, Briffa TG, Ridout SC, Knuiman MW, Dimer L, Taylor KP, Thompson PL, Thompson SC. Incidence of and case fatality following acute myocardial infarction in Aboriginal and non-Aboriginal Western Australians (2000-2004): a linked data study. Heart Lung Circ. 2010; 19(12): 717-25.	2000-2004	*	
Australia	Gopinath B, Rochtchina E, Wang JJ, Schneider J, Leeder SR, Mitchell P. Prevalence of age-related hearing loss in older adults: Blue Mountains Study. Arch Intern Med. 2009; 169(4): 415-6.	2000		
Australia	Wilson DH, Walsh PG, Sanchez L, Davis AC, Taylor AW, Tucker G, Meagher I. The epidemiology of hearing impairment in an Australian adult population. Int J Epidemiol. 1999; 28(2): 247-52.	1995		
Australia	Australian Institute of Health and Welfare, University of Adelaide. Australia Child Dental Health Survey 1990.	1990		
Australia	Australian Institute of Health and Welfare, University of Adelaide. Australia Child Dental Health Survey 1998.	1998		
Australia	Australian Institute of Health and Welfare, University of Adelaide. Australia Child Dental Health Survey 2007: Report on 30 Year Trends in Child Oral Health 1977-2007. Canberra, Australia: Australian Institute of Health and Welfare, 2012.	2004-2007		
Australia	Armfield JM, Spencer AJ, Slade GD. Changing inequalities in the distribution of caries associated with improving child oral health in Australia. J Public Health Dent. 2009; 69(2): 125-34.	1977-2002		
Australia	Crocombe LA, Mejia GC, Koster CR, Slade GD. Comparison of adult oral health in Australia, the USA, Germany and the UK. Aust Dent J. 2009; 54(2): 147-53.	2004-2006		
Australia	Armfield JM, Spencer AJ. Quarter of a century of change: caries experience in Australian children, 1977-2002. Aust Dent J. 2008; 53(2): 151-9.	2002		
Australia	Chalmers JM, Carter KD, Spencer AJ. Caries incidence and increments in community-living older adults with and without dementia. Gerodontology. 2002; 19(2): 80-94.	1999-2000		
Australia	Slade GD, Gansky SA, Spencer AJ. Two-year incidence of tooth loss among South Australians aged 60+ years. Community Dent Oral Epidemiol. 1997; 25(6): 429-37.	1991-1993		
Australia	Roberts-Thomson K, Stewart JF. Risk indicators of caries experience among young adults. Aust Dent J. 2008; 53(2): 122-127.	2005		
Australia	Hallett KB, O'Rourke PK. Dental caries experience of preschool children from the North Brisbane region. Aust Dent J. 2002; 47(4): 331-8.	2000		
Australia	Kruger E, Dyson K, Tennant M. Pre-school child oral health in rural Western Australia. Aust Dent J. 2005; 50(4): 258-62.	2003		
Australia	Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). Australia and New Zealand Dialysis and Transplant Registry Annual Report 2009. Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), 2009.	2009		
Australia	Mitchell PB, Slade T, Andrews G. Twelve-month prevalence and disability of DSM-IV bipolar disorder in an Australian general population survey. Psychol Med. 2004; 34(05): 777-85.	1997		
Australia	Ben-Tovim DI, Walker K, Gilchrist P, Freeman R, Esterman A. Outcome in patients with eating disorders: a 5-year study. Lancet. 2001; 357(9264): 1254-7.	1994-1999		
Australia	Sawyer MG, Arney FM, Baghurst PA, Clark JJ, Graetz BW, Kosky RJ, Nurcombe B, Patton GC, Prior MR, Raphael B, Rey JM, Whites LC, Zubrick SR. The mental health of young people in Australia: key findings from the child and adolescent component of the national survey of mental health and well-being. Aust N Z J Psychiatry. 2001; 35(6): 806-14.	1998		
Australia	Weintraub RG, Nugent AW, Daubeney PEF. Pediatric cardiomyopathy: The Australian experience. Prog Pediatr Cardiol. 2007; 23(1-2): 17-24.	1987-1996		
Australia	Nugent AW, Daubeney PEF, Chondros P, Carlin JB, Cheung M, Wilkinson LC, Davis AM, Kahler SG, Chow CW, Wilkinson JL, Weintraub RG. National Australian Childhood Cardiomyopathy Study. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med. 2003; 348(17): 1639-46.	1987-1996		
Australia	Norman PE, Flicker L, Almeida OP, Hankey GJ, Hyde Z, Jamrozik K. Cohort Profile: The Health In Men Study (HIMS). Int J Epidemiol. 2009; 38(1): 48-52.	1996-1999		
Australia	Holman CDJ, Wisniewski ZS, Semmens JB, Bass AJ. Changing treatments for primary urolithiasis: impact on services and renal preservation in 16,679 patients in Western Australia. BJU Int. 2002; 90(1): 7-15.	1981-1997		
Australia	Swift W, Hall W, Teesson M. Cannabis use and dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. Addiction. 2001; 96(5): 737-48.	1997, 2003		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Australia	Coffey C, Carlin JB, Degenhardt L, Lynskey M, Sancl L, Patton GC. Cannabis dependence in young adults: an Australian population study. <i>Addiction</i> . 2002; 97(2): 187-94.	1998		
Australia	Swift W, Coffey C, Carlin JB, Degenhardt L, Patton GC. Adolescent cannabis users at 24 years: trajectories to regular weekly use and dependence in young adulthood. <i>Addiction</i> . 2008; 103(8): 1361-70.	2003		
Australia	Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. <i>BMJ</i> . 2002; 325(7374): 1195-8.	1997		
Australia	Andrews G, Henderson S, Hall W. Prevalence, comorbidity, disability and service utilisation Overview of the Australian National Mental Health Survey. <i>Br J Psychiatry</i> . 2001; 178(2): 145-53.	1997		
Australia	Cheng A, Athan E, Appelbe A, McDonald M. The changing profile of bacterial endocarditis as seen at an Australian provincial centre. <i>Heart Lung Circ</i> . 2002; 11(1): 26-31.	1994-1999		
Australia	de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Künzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P, European Community Respiratory Health Survey Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. <i>Thorax</i> . 2004; 59(2): 120-125.	1991-1993		
Australia	Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E, BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. <i>Lancet</i> . 2007; 9589(9589): 741-50.	2005-2006		
Australia	Williams K, Helmer M, Mellis CM, Tuck M, Glasson EJ, Bower CL, Wray J. Incidence of autism spectrum disorders in children in two Australian states. <i>Med J Aust</i> . 2005; 182(3): 108-11.	1999-2000		
Australia	Grover SR, Quinn MA. Is there any value in bimanual pelvic examination as a screening test. <i>Med J Aust</i> . 1995; 162(8): 408-10.	1992		
Australia	Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). Australia and New Zealand Dialysis and Transplant Registry Annual Report 2005. Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), 2005.	2005		
Australia	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2005		
Australia	Panaretto KS, Lee HM, Mitchell MR, Larkins SL, Manassis V, Buettner PG, Watson D. Prevalence of sexually transmitted infections in pregnant urban Aboriginal and Torres Strait Islander women in northern Australia. <i>Aust N Z J Obstet Gynaecol</i> . 2006; 46(3): 217-24.	2002-2003		
Australia	Cheney K, Chen MY, Donovan B. Chlamydia trachomatis infection among antenatal women in Sydney. <i>Aust N Z J Public Health</i> . 2006; 30(1): 85-7.	2004		
Australia	Bateson DJ, Weisberg E, Lota H. Chlamydia trachomatis infection in the family planning clinical setting across New South Wales. <i>Sex Health</i> . 2006; 3(1): 15-20.	2004		
Australia	Lenton J-A, Freedman E, Hoskin K, Knight V, Turley D, Balding B, Kennedy C, Chen MY, McNulty A. Chlamydia trachomatis infection among antenatal women in remote far west New South Wales, Australia. <i>Sex Health</i> . 2007; 4(2): 139-40.	2005		
Australia	Chen MY, Fairley CK, De Guingand D, Hocking J, Tabrizi S, Wallace EM, Grover S, Gurrin L, Carter R, Pirota M, Garland S. Screening pregnant women for chlamydia: what are the predictors of infection? <i>Sex Transm Infect</i> . 2009; 85(1): 31-5.	2006		
Australia	Walker J, Fairley CK, Bradshaw CS, Tabrizi SN, Chen MY, Twin J, Taylor N, Donovan B, Kaldor JK, McNamee K, Urban E, Walker S, Currie M, Birden H, Bowden F, Gunn J, Pirota M, Gurrin L, Harindra V, Garland S, Hocking JS. The difference in determinants of Chlamydia trachomatis and Mycoplasma genitalium in a sample of young Australian women. <i>BMC Infect Dis</i> . 2011; 35.	2007-2008		
Australia	Chan DKY, Cordato D, Karr M, Ong B, Lei H, Liu J, Hung WT. Prevalence of Parkinson's disease in Sydney. <i>Acta Neurol Scand</i> . 2005; 111(1): 7-11.	2005		
Australia	Waite LM, Broe GA, Creasey H, Grayson DA, Cullen JS, O'Toole B, Edelbrock D, Dobson M. Neurodegenerative and other chronic disorders among people aged 75 years and over in the community. <i>Med J Aust</i> . 1997; 167(8): 429-33.	1991-1994		
Australia	McCann SJ, LeCouteur DG, Green AC, Brayne C, Johnson AG, Chan D, McManus ME, Pond SM. The Epidemiology of Parkinson's Disease in an Australian Population. <i>Neuroepidemiology</i> . 1998; 17(6): 310-7.	1995		
Australia	Lawrence D, Jablensky AV, Holman CD, Pinder TJ. Mortality in Western Australian psychiatric patients. <i>Soc Psychiatry Psychiatr Epidemiol</i> . 2000; 35(8): 341-7.	1980-1995		
Australia	Ruschena D, Mullen PE, Burgess P, Cordner SM, Barry-Walsh J, Drummer OH, Palmer S, Browne C, Wallace C. Sudden death in psychiatric patients. <i>Br J Psychiatry</i> . 1998; 172(4): 331-6.	1995		
Australia	University of Western Australia. Australia National Study of Low Prevalence (Psychotic) Disorders 1997-1998.	1997-1998		
Australia	Bartu A, Freeman NC, Gawthorne GS, Codde JP, Holman CDJ. Mortality in a cohort of opiate and amphetamine users in Perth, Western Australia. <i>Addiction</i> . 2004; 99(1): 53-60.	1985-1998		
Australia	Australia - Blue Mountains Eye Study 1992-1994 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1992-1994		
Australia	Walker BF, Muller R, Grant WD. Low back pain in Australian adults: prevalence and associated disability. <i>J Manipulative Physiol Ther</i> . 2004; 27(4): 238-44.	2001		
Australia	March LM, Brnabic AJ, Skinner JC, Schwarz JM, Finnegan T, Druce J, Brooks PM. Musculoskeletal disability among elderly people in the community. <i>Med J Aust</i> . 1998; 168(9): 439-42.	1991		
Australia	Grimmer K, Nyland L, Milanese S. Longitudinal investigation of low back pain in Australian adolescents: a five-year study. <i>Physiother Res Int</i> . 2006; 11(3): 161-72.	1999		
Australia	Dimitrov PN, Mukesh BN, McCarty CA, Taylor HR. Five-year incidence of bilateral cause-specific visual impairment in the Melbourne Visual Impairment Project. <i>Invest Ophthalmol Vis Sci</i> . 2003; 44(12): 5075-81. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1992-1999		
Australia	Casson R, Giles L, Newland HS. Prevalence of blindness and visual impairment in an elderly urban population. <i>Aust N Z J Ophthalmol</i> . 1996; 24(3): 239-43. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1992		
Australia	Robaei D, Huynh SC, Kiley A, Mitchell P. Correctable and non-correctable visual impairment in a population-based sample of 12-year-old Australian children. <i>Am J Ophthalmol</i> . 2006; 142(1): 112-8. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2004-2005		
Australia	Gidding HF, MacIntyre CR, Burgess MA, Gilbert GL. The seroepidemiology and transmission dynamics of varicella in Australia. <i>Epidemiol Infect</i> . 2003; 131(3): 1085-9.	1997-1999		
Australia	Gilbert GL, Gidding HF, Backhouse J, MacIntyre PB. Varicella seroprevalence and vaccine uptake in preschool children. <i>Med J Aust</i> . 2005; 182(1): 42.	2002		
Australia	O'Grady KA, Merianos A, Patel M, Gilbert L. High seroprevalence of antibodies to varicella zoster virus in adult women in a tropical climate. <i>Trop Med Int Health</i> . 2000; 5(10): 732-6.	1998		
Australia	Vally H, Dowse GK, Eastwood K, Cameron S. An outbreak of chickenpox at a child care centre in Western Australia. Costs to the community and implications for vaccination policy. <i>Aust N Z J Public Health</i> . 2007; 31(2): 113-9.	2002		
Australia	Chant KG, Sullivan EA, Burgess MA, Ferson MJ, Forrest JM, Baird LM, Tudehope DI, Tilse M. Varicella-zoster virus infection in Australia. <i>Aust N Z J Public Health</i> . 1998; 22(4): 413-8.	1971-1995		
Australia	Leonard H, Peterson B, Bower C, Sanders R. Prevalence of intellectual disability in Western Australia. <i>Paediatr Perinat Epidemiol</i> . 2003; 17(1): 58-67.	1992-1999		
Australia	Peterson B, Bourke J, Leonard H, Jacoby P, Bower C. Co-occurrence of birth defects and intellectual disability. <i>Paediatr Perinat Epidemiol</i> . 2007; 21(1): 65-75.	1990		
Australia	Wellesley D, Hockey A, Stanley F. The aetiology of intellectual disability in Western Australia: a community-based study. <i>Dev Med Child Neurol</i> . 1991; 33(11): 963-73.	1991		
Australia	Beange H, Taplin JE. Prevalence of intellectual disability in northern Sydney adults. <i>J Intellect Disabil Res</i> . 1996; 40 (Pt 3): 191-7.	1953, 1958, 1963, 1968		
Australia	Bittles AH, Peterson BA, Sullivan SG, Hussain R, Glasson EJ, Montgomery PD. The influence of intellectual disability on life expectancy. <i>J Gerontol A Biol Sci Med Sci</i> . 2002; 57(7): M470-472.	1953-2000		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Australia	Ponsonby A-L, Catto-Smith AG, Pezie A, Dupuis S, Halliday J, Cameron D, Morley R, Carlin J, Dwyer T. Association between early-life factors and risk of child-onset Crohn's disease among Victorian children born 1983-1998: a birth cohort study. <i>Inflamm Bowel Dis</i> . 2009; 15(6): 858-66.	1983-2006	*	
Australia	Wilson J, Hair C, Knight R, Catto-Smith A, Bell S, Kamm M, Desmond P, McNeil J, Connell W. High incidence of inflammatory bowel disease in Australia: a prospective population-based Australian incidence study. <i>Inflamm Bowel Dis</i> . 2010; 16(9): 1550-6.	2007-2008	*	†
Australia	Zutshi A, Eckert KA, Hawthorne G, Taylor AW, Goldney RD. Changes in the prevalence of bipolar disorders between 1998 and 2008 in an Australian population. <i>Bipolar Disord</i> . 2011; 13(2): 182-8.	1998, 2004, 2008	*	
Australia	Williams L, Jacka F, Pasco J, Henry M, Dodd S, Nicholson G, Kotowicz M, Berk M. The prevalence of mood and anxiety disorders in Australian women. <i>Australas Psychiatry</i> . 2010; 18(3): 250-5.	1994-2008	*	
Australia	Carapetis JR, Wolff DR, Currie BJ. Acute rheumatic fever and rheumatic heart disease in the top end of Australia's Northern Territory. <i>Med J Aust</i> . 1996; 164(3): 146-9.	1985-1995		
Australia	Carapetis JR, Currie BJ, Mathews JD. Cumulative incidence of rheumatic fever in an endemic region: a guide to the susceptibility of the population? <i>Epidemiol Infect</i> . 2000; 124(2): 239-44.	1997		
Australia	Cancer Council Victoria (Australia), Department of Health and Ageing (Australia). Australia Secondary Students' Alcohol and Drug Survey 2005.	2005		
Australia	Coomber K, Toumbourou JW, Miller P, Staiger PK, Hemphill SA, Catalano RF. Rural adolescent alcohol, tobacco, and illicit drug use: a comparison of students in Victoria, Australia, and Washington State, United States. <i>J Rural Health</i> . 2011; 27(4): 409-15.	2002	*	
Australia	Hall W, Teesson M, Lynskey M, Degenhardt L. The 12-month prevalence of substance use and ICD-10 substance use disorders in Australian adults: findings from the National Survey of Mental Health and Well-Being. <i>Addiction</i> . 1999; 94(10): 1541-50.	1997		
Australia	Lynskey M, White V, Hill D, Letcher T, Hall W. Prevalence of illicit drug use among youth: results from the Australian School Students' Alcohol and Drugs Survey. <i>Aust N Z J Public Health</i> . 1999; 23(5): 519-24.	1996		
Australia	Patton GC, HM, Rosier MJ, Carlin JB, Caust J, Bowes G. Patterns of common drug use in teenagers. <i>Aust J Public Health</i> . 1995; 19(4): 393-9.	1992		
Australia	Carolan MC, Davey M-A, Biro M, Kealy M. Very advanced maternal age and morbidity in Victoria, Australia: a population based study. <i>BMC Pregnancy Childbirth</i> . 2013; 13(1): 80.	2005-2006	*	
Australia	Hammond G, Langridge A, Leonard H, Hagan R, Jacoby P, Deklerk N, Pennell C, Stanley F. Changes in risk factors for preterm birth in Western Australia 1984-2006. <i>BJOG</i> . 2013; 120(9): 1051-60.	1984-2006	*	
Australia	Anderson NH, McCowan LME, Fyfe EM, Chan EHY, Taylor RS, Stewart AW, Dekker GA, North RA, SCOPE Consortium. The impact of maternal body mass index on the phenotype of pre-eclampsia: a prospective cohort study. <i>BJOG</i> . 2012; 119(5): 589-95.	2004-2008	*	
Australia	Chen JS, Ford JB, Roberts CL, Simpson JM, March LM. Pregnancy outcomes in women with juvenile idiopathic arthritis: a population-based study. <i>Rheumatology</i> . 2013; 52(6): 1119-25.	2000-2010	*	
Australia	Chen JS, Roberts CL, Simpson JM, Ford JB. Prevalence of pre-eclampsia, pregnancy hypertension and gestational diabetes in population-based data: impact of different ascertainment methods on outcomes. <i>Aust N Z J Obstet Gynaecol</i> . 2012; 52(1): 91-5.	2007-2008	*	
Australia	North RA, McCowan LME, Dekker GA, Poston L, Chan EHY, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. <i>BMJ</i> . 2011; d1875.	2004-2008	*	
Australia	Pereira G, Hagger F, Shand AW, Bower C, Cook A, Nassar N. Association between pre-eclampsia and locally derived traffic-related air pollution: a retrospective cohort study. <i>J Epidemiol Community Health</i> . 2013; 67(2): 147-52.	2000-2006	*	
Australia	Roberts CL, Ford JB, Algert CS, Antonsen S, Chalmers J, Cnattingius S, Gokhale M, Kotelchuck M, Melve KK, Langridge A, Morris C, Morris JM, Nassar N, Norman JE, Norrie J, Sorensen HT, Walker R, Weir CJ. Population-based trends in pregnancy hypertension and pre-eclampsia: an international comparative study. <i>BMJ Open</i> . 2011; 1(1): e000101.	1998-2006	*	
Australia	Smits LJM, North RA, Kenny LC, Myers J, Dekker GA, McCowan LME. Patterns of vaginal bleeding during the first 20 weeks of pregnancy and risk of pre-eclampsia in nulliparous women: results from the SCOPE study. <i>Acta Obstet Gynecol Scand</i> . 2012; 91(11): 1331-8.	2004-2008	*	
Australia	Thornton C, Dahlen H, Korda A, Hennessy A. The incidence of preeclampsia and eclampsia and associated maternal mortality in Australia from population-linked datasets: 2000-2008. <i>Am J Obstet Gynecol</i> . 2013; 208(6): 476e1-5.	2000-2008	*	
Australia	Von Katterfeld B, Li J, McNamara B, Langridge AT. Maternal and neonatal outcomes associated with gestational diabetes in women from culturally and linguistically diverse backgrounds in Western Australia. <i>Diabet Med</i> . 2012; 29(3): 372-7.	1998-2006	*	
Australia	Schildkraut V, Alex G, Cameron DIS, Hardikar W, Lipschitz B, Oliver MR, Simpson DM, Catto-Smith AG. Sixty-year study of incidence of childhood ulcerative colitis finds eleven-fold increase beginning in 1990s. <i>Inflamm Bowel Dis</i> . 2013; 19(1): 1-6.	1980-1990, 1992-2009		†
Australia	Leyden JM, Kleimig TJ, Newbury J, Castle S, Cranefield J, Anderson CS, Crotty M, Whitford D, Janes J, Lee A, Greenhill J. Adelaide stroke incidence study: declining stroke rates but many preventable cardioembolic strokes. <i>Stroke</i> . 2013; 44(5): 1226-31.	2009-2010	*	
Australia	Simpson S Jr, Pittas F, van der Mei I, Blizard L, Ponsonby A-L, Taylor B. Trends in the epidemiology of multiple sclerosis in Greater Hobart, Tasmania: 1951 to 2009. <i>J Neurol Neurosurg Psychiatry</i> . 2011; 82(2): 180-7.	1961, 1981, 2001-2009	*	
Australia	Hawthorne G, Goldney R, Taylor AW. Depression prevalence: is it really increasing Aust N Z J Psychiatry. 2008; 42(7): 606-16.	1998, 2004		
Australia	Jorm AF, Henderson AS, Kay DWK, Jacomb PA. Mortality in relation to dementia, depression and social integration in an elderly community sample. <i>Int J Geriatr Psychiatry</i> . 1991; 6(1): 11-15.	1982-1988		
Australia	Sawyer MG, Guidolin M, Schulz KL, McGinnes B, Zubrick SR, Baghurst PA. The mental health and wellbeing of adolescents on remand in Australia. <i>Aust N Z J Psychiatry</i> . 2010; 44(6): 551-9.	1997		
Australia	Wilhelm K, Mitchell P, Slade T, Brownhill S, Andrews G. Prevalence and correlates of DSM-IV major depression in an Australian national survey. <i>J Affect Disord</i> . 2003; 75(2): 155-62.	1997		
Australia	Roberts SK, Kemp W. Hepatocellular carcinoma in an Australian tertiary referral hospital 1975-2002: change in epidemiology and clinical presentation. <i>J Gastroenterol Hepatol</i> . 2007; 22(2): 191-6.	1995-2002		
Australia	Goldney RD, Eckert KA, Hawthorne G, Taylor AW. Changes in the prevalence of major depression in an Australian community sample between 1998 and 2008. <i>Aust N Z J Psychiatry</i> . 2010; 44(10): 901-10.	2008	*	
Australia	Chadban SJ, Braganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, Atkins RC. Prevalence of kidney damage in Australian adults: The AusDiab kidney study. <i>J Am Soc Nephrol</i> . 2003; 14(7 Suppl 2): S131-8.	1999-2000		
Australia	Parner ET, Thorsen P, Dixon G, de Klerk N, Leonard H, Nassar N, Bourke J, Bower C, Glasson EJ. A comparison of autism prevalence trends in Denmark and Western Australia. <i>J Autism Dev Disord</i> . 2011; 41(12): 1601-8.	2004	*	
Australia	Australian Institute of Health and Welfare, Roy Morgan Research. Australia National Drug Strategy Household Survey 2010.	2010	*	
Australia	McEvoy PM, Grove R, Slade T. Epidemiology of anxiety disorders in the Australian general population: findings of the 2007 Australian National Survey of Mental Health and Wellbeing. <i>Aust N Z J Psychiatry</i> . 2011; 45(11): 957-67.	2007		
Australia	National Drug and Alcohol Research Centre, University of New South Wales. Australia Estimating the Number of Current Regular Heroin Users in NSW and Australia 1997-2002. Randwick, Australia: National Drug and Alcohol Research Centre, University of New South Wales, 2004.	1997-2002	*	
Australia	Degenhardt L, Randall D, Hall W, Butler T, Law M, Burns L. Mortality among persons receiving opioid pharmacotherapy in New South Wales, Australia, 1985-2006: risk factors for elevated mortality and estimated mortality reductions of a statewide programme across 20 years.	1985-2006	*	
Australia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Australia	Graetz BW, Sawyer MG, Hazell PL, Arney F, Baghurst P. Validity of DSM-IVADHD subtypes in a nationally representative sample of Australian children and adolescents. <i>J Am Acad Child Adolesc Psychiatry</i> . 2001; 40(12): 1410-7.	1997	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Australia	Mein J, Bowden FJ. A profile of inpatient STD-related pelvic inflammatory disease in the Top End of the Northern Territory of Australia. <i>Med J Aust.</i> 1997; 166(9): 464-7.	1991-1994	*	†
Australia	Kwan KSH, Giele CM, Combs B, Mak DB. Improvement in antenatal testing for sexually transmissible infections and blood-borne viruses in Western Australian hospitals, 2007 to 2010. <i>Sex Health.</i> 2012; 9(4): 349-54.	2007-2010	*	
Australia	Robaei D, Rose K, Ojaimi E, Kifley A, Huynh S, Mitchell P. Visual acuity and the causes of visual loss in a population-based sample of 6-year-old Australian children. <i>Ophthalmology.</i> 2005; 112(7): 1275-82. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2003-2005		
Australia	Chia E-M, Mitchell P, Rochtchina E, Foran S, Golding M, Wang JJ. Association between vision and hearing impairments and their combined effects on quality of life. <i>Arch Ophthalmol.</i> 2006; 124(10): 1465-70. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	1997-1999		
Australia	Foran S, Wang JJ, Mitchell P. Causes of visual impairment in two older population cross-sections: the Blue Mountains Eye Study. <i>Ophthalmic Epidemiol.</i> 2003; 10(4): 215-25. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	1992-1994		
Australia	Wang JJ, Foran S, Mitchell P. Age-specific prevalence and causes of bilateral and unilateral visual impairment in older Australians: the Blue Mountains Eye Study. <i>Clin Experiment Ophthalmol.</i> 2000; 28(4): 268-73. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	1992-1994		
Australia	Robaei D, Kifley A, Rose KA, Mitchell P. Refractive error and patterns of spectacle use in 12-year-old Australian children. <i>Ophthalmology.</i> 2006; 113(9): 1567-73. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2004-2005		
Australia	VanNewkirk MR, Weih L, McCarty CA, Taylor HR. Cause-specific prevalence of bilateral visual impairment in Victoria, Australia: the Visual Impairment Project. <i>Ophthalmology.</i> 2001; 108(5): 960-7. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	1992-1996		
Australia	Roberts CL, Ford JB, Algert CS, Bell JC, Simpson JM, Morris JM. Trends in adverse maternal outcomes during childbirth: a population-based study of severe maternal morbidity. <i>BMC Pregnancy Childbirth.</i> 2009; 7.	1999, 2004	*	
Australia	Carmody C, Garland S, Kent HE, Denham I. Prevalence of type-specific herpes simplex virus antibodies in partners of patients with recurrent genital herpes. <i>Venerology.</i> 2001; 14(4): 160.	1995-1996	*	
Australia	Song B, Dwyer DE, Mindel A. HSV type specific serology in sexual health clinics: use, benefits, and who gets tested. <i>Sex Transm Infect.</i> 2004; 80(2): 113-7.	1993-2001	*	
Australia	Mindel A, Taylor J, Tideman RL, Seifert C, Berry G, Wagner K, Page J, Marks C, Trudinger B, Cunningham A. Neonatal herpes prevention: a minor public health problem in some communities. <i>Sex Transm Infect.</i> 2000; 76(4): 287-91.	1995-1998	*	
Australia	Taylor HR, Livingston PM, Stanislavsky YL, McCarty CA. Visual impairment in Australia: distance visual acuity, near vision, and visual field findings of the Melbourne Visual Impairment Project. <i>Am J Ophthalmol.</i> 1997; 123(3): 328-37. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	1992-1996		
Australia	Pai AS-I, Wang JJ, Samarawickrama C, Burlutsky G, Rose KA, Varma R, Wong TY, Mitchell P. Prevalence and risk factors for visual impairment in preschool children the Sydney Paediatric Eye Disease Study. <i>Ophthalmology.</i> 2011; 118(8): 1495-500. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2007-2009		
Australia	Carli G, Reiger I, Evans N. One-year neurodevelopmental outcome after moderate newborn hypoxic ischaemic encephalopathy. <i>J Paediatr Child Health.</i> 2004; 40(4): 217-20.	1988-2000	*	†
Australia	Yeo CL, Tudehope DI. Outcome of resuscitated apparently stillborn infants: a ten year review. <i>J Paediatr Child Health.</i> 1994; 30(2): 129-33.	1981-1991	*	†
Australia	Downie E, Craig ME, Hing S, Cusumano J, Chan AKF, Donaghue KC. Continued reduction in the prevalence of retinopathy in adolescents with type 1 diabetes: role of insulin therapy and glycemic control. <i>Diabetes Care.</i> 2011; 34(11): 2368-73.	1990-2009		
Australia	Sillars BA, Davis WA, Kamber N, Davis TME. The epidemiology and characteristics of type 2 diabetes in urban, community-based young people. <i>Intern Med J.</i> 2010; 40(12): 850-4.	2005-2006		
Australia	Sutton DL, Lyle DM, Pierce JP. Incidence and prevalence of insulin-dependent diabetes mellitus in the zero- to 19-years' age-group in Sydney. <i>Med J Aust.</i> 1989; 151(3): 140-6.	1984-1987		
Australia	Allen KL, Byrne SM, Forbes D, Oddy WH. Risk factors for full- and partial-syndrome early adolescent eating disorders: a population-based pregnancy cohort study. <i>J Am Acad Child Adolesc Psychiatry.</i> 2009; 48(8): 800-9.	2004	*	
Australia	Byrne A. Nine-year follow-up of 86 consecutive patients treated with methadone in general practice, Sydney, Australia. <i>Drug Alcohol Rev.</i> 2000; 19(2): 153-8.	1987-1996	*	
Australia	Diguisto E, Shakeshaft A, Ritter A, O'Brien S, Mattick RP, NEPOD Research Group. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). <i>Addiction.</i> 2004; 99(4): 450-60.	1998-2002	*	
Australia	Hall WD, Ross JE, Lynskey MT, Law MG, Degenhardt LJ. How many dependent heroin users are there in Australia? <i>Med J Aust.</i> 2000; 173(10): 528-31.	1990, 1997-1998	*	
Australia	Law MG, Lynskey M, Ross J, Hall W. Back-projection estimates of the number of dependent heroin users in Australia. <i>Addiction.</i> 2001; 96(3): 433-43.	1997	*	
Australia	Tait RJ, Ngo HTT, Hulse GK. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment. <i>J Subst Abuse Treat.</i> 2008; 35(2): 116-24.	2001-2006	*	
Australia	Teesson M, Baillie A, Lynskey M, Manor B, Degenhardt L. Substance use, dependence and treatment seeking in the United States and Australia: a cross-national comparison. <i>Drug Alcohol Depend.</i> 2006; 81(2): 149-55.	1997	*	
Australia	Teesson M, Mills K, Ross J, Darke S, Williamson A, Havard A. The impact of treatment on 3 years' outcome for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). <i>Addiction.</i> 2008; 103(1): 80-88.	2001-2005	*	
Australia	Budtz-Olsen O, Kidson C. Absence of red cell enzyme deficiency in Australian Aborigines. <i>Nature.</i> 1961; 192: 765.	1959-1961		
Australia	Smith MB. The incidence of glucose-6-phosphate dehydrogenase deficiency in a population of Greek, Italian and Yugoslav origin in Australia. <i>Med J Aust.</i> 1976; 2(13): 485-6.	1972-1976		
Australia	Lowe P, Kovacs G, Howlett D. Incidence of polycystic ovaries and polycystic ovary syndrome amongst women in Melbourne, Australia. <i>Aust N Z J Obstet Gynaecol.</i> 2005; 45(1): 17-9.	1994-2000		
Australia	March WA, Moore VM, Willson KJ, Phillips DIW, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. <i>Hum Reprod.</i> 2010; 25(2): 544-51.	2007		
Australia	Australian Institute of Health and Welfare, School of Population Health, University of Queensland (Australia). <i>Australia Burden of Disease and Injury Report 2003.</i> Canberra, Australia: Australian Institute of Health and Welfare, 2007.	1996-2003		
Australia	Brennan D, Spencer A, Slade G. Prevalence of periodontal conditions among public-funded dental patients in Australia. <i>Aust Dent J.</i> 2001; 46(2): 114-21.	1995-1996		
Australia	Wright FA, Hammond RH, Lewis JM. Changes in periodontal conditions of adults from Melbourne, Australia. <i>Int Dent J.</i> 1994; 44(3): 207-14.	1985, 1990		
Australia	Flinders Centre for Ageing Studies, Flinders University. <i>Australia - Adelaide Longitudinal Study of Aging Report.</i>	1993, 2007		
Australia	Proudfoot H, Baillie AJ, Teesson M. The structure of alcohol dependence in the community. <i>Drug Alcohol Depend.</i> 2006; 81(1): 21-6.	1997		
Australia	Mehta P, Kifley A, Wang JJ, Rochtchina E, Mitchell P, Sue CM. Population prevalence and incidence of Parkinson's disease in an Australian community. <i>Intern Med J.</i> 2007; 37(12): 812-4.	1992-2004	*	
Australia	Allen K, Rife M, Goldfield S, Halliday J. Estimating the prevalence of fetal alcohol syndrome in Victoria using routinely collected administrative data. <i>Aust N Z J Public Health.</i> 2007; 31(1): 62-6.	1995-2002		
Australia	Bell R, Lumley J. Alcohol consumption, cigarette smoking and fetal outcome in Victoria, 1985. <i>Community Health Stud.</i> 1989; 13(4): 484-91.	1985	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Australia	Bower C, Silva D, Henderson TR, Ryan A, Rudy E. Ascertainment of birth defects: the effect on completeness of adding a new source of data. <i>J Paediatr Child Health</i> . 2000; 36(6): 574-6.	1980-1997	*	
Australia	Durvasula S, Beange H, Baker W. Mortality of people with intellectual disability in northern Sydney. <i>J Intellect Dev Disabil</i> . 2002; 27(4): 255-64.	1989-1999	*	
Australia	Elliot EJ, Payne J, Morris A, Haan E, Bower C. Fetal alcohol syndrome: a prospective national surveillance study. <i>Arch Dis Child</i> . 2008; 93(9): 732-7.	2001-2004	*	
Australia	Harris KR, Bucens IK. Prevalence of fetal alcohol syndrome in the Top End of the Northern Territory. <i>J Paediatr Child Health</i> . 2003; 39(7): 528-33.	1990-2000	*	
Australia	Slade T, Johnston A, Oakley Browne MA, Andrews G, Whiteford H. 2007 National Survey of Mental Health and Wellbeing: methods and key findings. <i>Aust N Z J Psychiatry</i> . 2009; 43(7): 594-605.	2007	*	
Australia	Hankey GJ. Guillain-Barré syndrome in Western Australia, 1980-1985. <i>Med J Aust</i> . 1987; 146(3): 130-3.	1980-1985		
Australia	Storey E, Cook M, Peppard R, Newton-John H, Byrne E. Guillain-Barré syndrome and related conditions in Victorian teaching hospitals 1980-84. <i>Aust N Z J Med</i> . 1989; 19(6): 687-93.	1980-1984		†
Australia	OzFoodNet Working Group. Monitoring the incidence and causes of diseases potentially transmitted by food in Australia: annual report of the OzFoodNet Network, 2009. <i>Commun Dis Intell J Q Rep</i> . 2010; 34(4): 396-426.	2009		
Australia	Stein AN, Britt H, Harrison C, Conway EL, Cunningham A, Macintyre CR. Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. <i>Vaccine</i> . 2009; 27(4): 520-9.	2000-2006		
Australia	Herbert D, Lucke J, Dobson A. Agreement between self-reported use of in vitro fertilization or ovulation induction, and medical insurance claims in Australian women aged 28-36 years. <i>Hum Reprod</i> . 2012; 27(9): 2823-8.	1996, 2000, 2003, 2006		
Australia	Weichbold V, Nekahm-Heis D, Welzl-Mueller K. Universal newborn hearing screening and postnatal hearing loss. <i>Pediatrics</i> . 2006; 117(4): e631-636.	1995-2005	*	
Australia	Marshall CS, Cheng AC, Markey PG, Towers RJ, Richardson LJ, Fagan PK, Scott L, Krause VL, Currie BJ. Acute Post-Streptococcal Glomerulonephritis in the Northern Territory of Australia: A Review of 16 Years Data and Comparison with the Literature. <i>Am J Trop Med Hyg</i> . 2011; 85(4): 703-10.	1991-2008	*	
Australia	Waite LM, Broe GA, Grayson DA, Creasey H. The incidence of dementia in an Australian community population: the Sydney Older Persons Study. <i>Int J Geriatr Psychiatry</i> . 2001; 16(7): 680-9.	1991-1994		
Australia	Alexander PMA, Daubeney PEF, Nugent AW, Lee KJ, Turner C, Colan SD, Robertson T, Davis AM, Ramsay J, Justo R, Sholler GF, King I, Weintraub RG. National Australian Childhood Cardiomyopathy Study. Long-term outcomes of dilated cardiomyopathy diagnosed during childhood: results from a national population-based study of childhood cardiomyopathy. <i>Circulation</i> . 2013; 128(18): 2039-46.	1987-1996	*	
Australia	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec</i> . 2005; 80(13): 118-24.	2003	*	
Australia	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec</i> . 2005; 80(34): 289-95.	2004	*	
Australia	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec</i> . 2007; 82(25): 225-32.	2006	*	
Australia	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec</i> . 2009; 84(33): 333-40.	2008	*	
Australia	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec</i> . 2010; 85(35): 337-48.	2009	*	
Australia	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec</i> . 2012; 87(34): 317-28.	2011	*	
Australia	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec</i> . 2013; 88(35): 365-79.	2012	*	
Australia	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec</i> . 2011; 86(36): 389-99.	2010	*	
Australia	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1994; 69(20): 145-51.	1993	*	
Australia	Tideman RL, Taylor J, Marks C, Seifert C, Berry G, Trudinger B, Cunningham A, Mindel A. Sexual and demographic risk factors for herpes simplex type 1 and 2 in women attending an antenatal clinic. <i>Sex Transm Infect</i> . 2001; 77(6): 413-5.	1995-1998	*	
Australia	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland: World Health Organization (WHO).	2000-2012	*	
Australia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2000.	2000		
Australia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2001.	2001		
Australia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2002.	2002		
Australia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2003.	2003		
Australia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2004.	2004		
Australia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2005.	2005		
Australia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2006.	2006		
Australia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2007.	2007		
Australia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2008.	2008		
Australia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2009.	2009		
Australia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2010.	2010		
Australia	Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). Australia and New Zealand Dialysis and Transplant Registry 1990. [Unpublished].	1990		
Australia	Hebbandi S, Bowen J, Hipwell G, Ma P, Leslie G, Arnold J. Ocular sequelae in extremely premature infants at 5 years of age. <i>J Paediatr Child Health</i> . 1997; 33(4): 339-42.	1987	*	†
Australia	Keith CG, Doyle LW. Retinopathy of Prematurity in Extremely Low Birth Weight Infants. <i>Pediatrics</i> . 1995; 95(1): 42-5.	1981, 1989	*	†
Australia	May M, Daley A, Donath S, Isaacs D, on b. Early onset neonatal meningitis in Australia and New Zealand, 1992-2002. <i>Arch Dis Child Fetal Neonatal Ed</i> . 2005; 90(4): F324-F327.	1992-2000		†
Australia	Francis BM, Gilbert GL. Survey of neonatal meningitis in Australia: 1987-1989. <i>Med J Aust</i> . 1992; 156(4): 240-3.	1987-1989		
Australia	Hanna JN, Wild BE. Bacterial meningitis in children under five years of age in Western Australia. <i>Med J Aust</i> . 1991; 155(3): 160-4.	1984-1988		
Australia	McDonnell CM, Harris M, Zacharin MR. Iodine deficiency and goitre in schoolchildren in Melbourne, 2001. <i>Med J Aust</i> . 2003; 178(4): 159-62.	2001		
Australia	Australian Institute of Health and Welfare. Australia National Oral Health Survey 1987-1988.	1987-1988		
Australia	Teede HJ, Joham AE, Paul E, Moran LJ, Loxton D, Jolley D, Lombard C. Longitudinal weight gain in women identified with polycystic ovary syndrome: Results of an observational study in young women. <i>Obesity (Silver Spring)</i> . 2013; 21(8): 1526-32.	2004-2006		
Australia	Medcalf GW. Busselton dental survey 1978. <i>Aust Dent J</i> . 1981; 26(5): 304-8.	1969, 1978		
Australia	Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). Australia and New Zealand Dialysis and Transplant Registry Annual Report 2011. Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), 2011.	2010	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Australia	Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). Australia and New Zealand Dialysis and Transplant Registry Annual Report 2012. Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), 2012.	2010-2011	*	
Australia	Australian Institute of Health and Welfare. Australia Child Dental Health Survey 2005.	2005		
Australia	Huppertz C, Durrheim DN, Levi C, Dalton C, Williams D, Clements MS, Kelly PM. Etiology of Encephalitis in Australia, 1990-2007. <i>Emerg Infect Dis.</i> 2009; 15(9): 1359-65.	1990-2007		
Australia	Biggs BA, Megna R, Wickremesinghe S, Dwyer B. Human infection with <i>Cryptosporidium</i> spp.: results of a 24-month survey. <i>Med J Aust.</i> 1987; 147(4): 175-7.	1984-1986	*	
Australia	Sinclair MI, Hellard ME, Wolfe R, Mitakakis TZ, Leder K, Fairley CK. Pathogens causing community gastroenteritis in Australia. <i>J Gastroenterol Hepatol.</i> 2005; 20(11): 1685-90.	1997-1999	*	
Australia	Tzipori S, Smith M, Birch C, Barnes G, Bishop R. Cryptosporidiosis in hospital patients with gastroenteritis. <i>Am J Trop Med Hyg.</i> 1983; 32(5): 931-4.	1981-1982	*	
Australia	Clucas DB, Carville KS, Connors C, Currie BJ, Carapetis JR, Andrews RM. Disease burden and health-care clinic attendances for young children in remote aboriginal communities of northern Australia. <i>Bull World Health Organ.</i> 2008; 86(4): 275-81.	2002-2005	*	
Australia	Rhomberg HP, Judmair G, Lochs A. How common are gallstones Br <i>Med J (Clin Res Ed).</i> 1984; 289(6450): 1002.	1982		
Australia	Williams H, Robertson C, Stewart A, Ait-Khaled N, Anabwani G, Anderson R, Asher I, Beasley R, Björkstén B, Burr M, Clayton T, Crane J, Ellwood P, Keil U, Lai C, Mallol J, Martinez F, Mitchell E, Montefort S, Pearce N, Shah J, Sibbald B, Strachan D, von Mutius E, Weiland SK. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. <i>J Allergy Clin Immunol.</i> 1999; 103(1 Pt 1): 125-38.	1997-1999	*	
Australia	Boughton CR, Hawkes RA, Ferguson V. Viral hepatitis A and B: a seroepidemiological study of a non-hepatic Sydney population. <i>Med J Aust.</i> 1980; 1(4): 177-80.	1971-1974		
Australia	Crofts N, Cooper G, Stewart T, Kiely P, Coghlan P, Hearne P, Hocking J. Exposure to hepatitis A virus among blood donors, injecting drug users and prison entrants in Victoria. <i>J Viral Hepat.</i> 1997; 4(5): 333-8.	1995		
Australia	Amin J, Gilbert GL, Escott RG, Heath TC, Burgess MA. Hepatitis A epidemiology in Australia: national seroprevalence and notifications. <i>Med J Aust.</i> 2001; 174(7): 338-41.	1998		
Australia	Beaglehole R, Stewart AW, Jackson R, Dobson AJ, McElduff P, D'Este K, Heller RF, Jamrozik KD, Hobbs MS, Parsons R, Broadhurst R. Declining Rates of Coronary Heart Disease in New Zealand and Australia, 1983-1993. <i>Am J Epidemiol.</i> 1997; 145(8): 707-13.	1993		
Australia	Dobson AJ, McElduff P, Heller R, Alexander H, Colley P, D'Este K. Changing Patterns of Coronary Heart Disease in the Hunter Region of New South Wales, Australia. <i>J Clin Epidemiol.</i> 1999; 52(8): 761-71.	1984-1985		
Australia	Tunstall-Pedoe H, Kuulasmaa K, Mahönen M, Tolonen H, Ruokokoski E. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. <i>Lancet.</i> 1999; 353(9164): 1547-57.	1984-1993		
Australia	National Public Health Institute (Finland), World Health Organization (WHO). MONICA Coronary Event Registration Data Book 1980-1995. Geneva, Switzerland: World Health Organization (WHO), 2000.	1980-1995		
Australia	Australian Institute of Health and Welfare. The Burden of Disease and Injury in Australia 1996. Canberra, Australia: Australian Institute of Health and Welfare, 1999.	1996-1997		
Australia	Amin J, Gidding H, Gilbert G, Backhouse J, Kaldor J, Dore G, Burgess M. Hepatitis C prevalence - a nationwide survey. <i>Commun Dis Intell.</i> 2004; 28(4): 517-21.	1995-1998		
Australia	Ashwell MJ, Cossart YE. An autopsy survey of hepatitis B in Sydney. <i>Pathology.</i> 1995; 27(1): 43-7.	1984		
Australia	Campbell DH, Plant AJ, Sargent JW, Mock PA, Barrett ER, Archer KH. Hepatitis B infection of children in a mixed-race community in western New South Wales. <i>Med J Aust.</i> 1991; 154(4): 253-6.	1991		
Australia	Campbell DH, Sargent JW, Plant AJ. The prevalence of markers of infection with hepatitis B virus in a mixed-race Australian community. <i>Med J Aust.</i> 1989; 150(9): 489-92.	1989		
Australia	Garner JJ, Goughwin M, Dodding J, Wilson K. Prevalence of hepatitis C infection in pregnant women in South Australia. <i>Med J Aust.</i> 1997; 167(9): 470-2.	1996-1998		
Australia	Gidding HF, Warlow M, MacIntyre CR, Backhouse J, Gilbert GL, Quinn HE, McIntyre PB. The impact of a new universal infant and school-based adolescent hepatitis B vaccination program in Australia. <i>Vaccine.</i> 2007; 25(51): 8637-41.	2002		
Australia	Hanna JN, Faoagali JL, Buda PJ, Sheridan JW. Further observations on the immune response to recombinant hepatitis B vaccine after administration to aboriginal and Torres Strait Island children. <i>J Paediatr Child Health.</i> 1997; 33(1): 67-70.	1980-1999		
Australia	Moore DJ, Bucens MR, Holman CD, Ott AK, Wells JI. Prenatal screening for markers of hepatitis B in aboriginal mothers resident in non-metropolitan Western Australia. <i>Med J Aust.</i> 1987; 147(11-12): 557-8.	1983-1985		
Australia	O'Sullivan BG, Gidding HF, Law M, Kaldor JM, Gilbert GL, Dore GJ. Estimates of chronic hepatitis B virus infection in Australia, 2000. <i>Aust N Z J Public Health.</i> 2004; 28(3): 212-6.	1996-1999	*	
Australia	Paterson F, Bumak J, Batey R. Changing prevalence of hepatitis B virus in urbanized Australian Aborigines. <i>J Gastroenterol Hepatol.</i> 1993; 8(5): 410-3.	1987-1988		
Australia	Sturrock CJ, Currie MJ, Vally H, O'Keefe EJ, Primrose R, Habel P, Schamburg K, Bowden FJ. Community-based sexual health care works: a review of the ACT outreach program. <i>Sex Health.</i> 2007; 4(3): 201-4.	2002-2005		
Australia	Tawk HM, Vickery K, Bisset L, Selby W, Cossart YE. Infection in Endoscopy Study Group. The impact of hepatitis B vaccination in a Western country: recall of vaccination and serological status in Australian adults. <i>Vaccine.</i> 2006; 24(8): 1095-106.	1999-2001		
Australia	Justice F, Carlin J, Bines J. Changing epidemiology of intussusception in Australia. <i>J Paediatr Child Health.</i> 2005; 41(9-10): 475-8.	1994-2000		
Australia	English DR, Krickler A, Heenan PJ, Randell PL, Winter MG, Armstrong BK. Incidence of non-melanocytic skin cancer in Geraldton, Western Australia. <i>Int J Cancer.</i> 1997; 73(5): 629-33.	1987-1992	*	
Australia	Kay DWK, Henderson AS, Scott R, Wilson J, Rickwood D, Grayson DA. Dementia and depression among the elderly living in the Hobart community: the effect of the diagnostic criteria on the prevalence rates. <i>Psychol Med.</i> 1985; 15(04): 771-88.	1982-1983		†
Australia	Aithal S, Aithal V, Kei J, Driscoll C. Conductive hearing loss and middle ear pathology in young infants referred through a newborn universal hearing screening program in Australia. <i>J Am Acad Audiol.</i> 2012; 23(9): 673-85.	2004-2009	*	
Australia	Katzenellenbogen JM, Vos T, Somerford P, Begg S, Semmens JB, Codde JP. Excess Mortality Rates for Estimating the Non-Fatal Burden of Stroke in Western Australia: A Data Linkage Study. <i>Cerebrovasc Dis.</i> 2010; 30(1): 57-64.	1997-2002	*	
Australia	The ACROSS Group. Epidemiology of Aneurysmal Subarachnoid Hemorrhage in Australia and New Zealand Incidence and Case Fatality From the Australasian Cooperative Research on Subarachnoid Hemorrhage Study (ACROSS). <i>Stroke.</i> 2000; 31(8): 1843-1850.	1995-1998	*	
Australia	Cobiac LJ, Magnus A, Lim S, Barendregt JJ, Carter R, Vos T. Which interventions offer best value for money in primary prevention of cardiovascular disease <i>PLoS One.</i> 2012; 7(7): e41842.	2008	*	
Australia	Bowen JR, Gibson FL, Hand PJ. Educational outcome at 8 years for children who were born extremely prematurely: A controlled study. <i>J Paediatr Child Health.</i> 2002; 38(5): 438-44.	1987		†
Australia	Stanley FJ, Watson L. Trends in perinatal mortality and cerebral palsy in Western Australia, 1967 to 1985. <i>BMJ.</i> 1992; 304(6843): 1658-63.	1976, 1980, 1984		†
Australia	Improved outcome into the 1990s for infants weighing 500-999 g at birth. The Victorian Infant Collaborative Study Group. <i>Arch Dis Child Fetal Neonatal Ed.</i> 1997; 77(2):F91-94.	1991		†
Australia	Roberts G, Anderson PJ, De Luca C, Doyle LW, Victorian Infant Collaborative Study Group. Changes in neurodevelopmental outcome at age eight in geographic cohorts of children born at 22-27 weeks gestational age during the 1990s. <i>Arch Dis Child Fetal Neonatal Ed.</i> 2010; 95(2):F90-94.	1997		†
Australia	Doyle LW, Roberts G, Anderson PJ, Victorian Infant Collaborative Study Group. Changing long-term outcomes for infants 500-999 g birth weight in Victoria, 1979-2005. <i>Arch Dis Child Fetal Neonatal Ed.</i> 2011 Nov; 96(6):F443-447.	1986-1987, 2005		†
Australia	Zeitlin J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT; 2008. Available from: http://www.perinataleudit.nl/downloads/bestand/649/peristat-ii-2008-	2004		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Australia	Australia Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD), United Nations Demographic Yearbook - Historical Supplement 1997, New York City, United States: United Nations Statistics Division (UNSD).	1990		
Australia	Australia - Victoria Birth Defects Registry Data 2001 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems, International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003, Rome, Italy: International Centre on Birth Defects.	2001	*	
Australia	Australia - Victoria Birth Defects Registry Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research, International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005, Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
Australia	Australia - Western Australian Birth Defects Registry Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research, International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005, Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
Australia	Australian Congenital Malformation Monitoring System Data 1981 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems, Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems, Amsterdam, Netherlands: Elsevier, 1991.	1981	*	
Australia	Australian Congenital Malformation Monitoring System Data 1984 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems, Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems, Amsterdam, Netherlands: Elsevier, 1991.	1984	*	
Australia	Australian Congenital Malformation Monitoring System Data 1987 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems, Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems, Amsterdam, Netherlands: Elsevier, 1991.	1987	*	
Australia	Australia - Western Australian Register of Developmental Anomalies Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research, International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010, Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
Australia	Australian Congenital Malformation Monitoring System Data 1988 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems, Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems, Amsterdam, Netherlands: Elsevier, 1991.	1988	*	
Australia	Australian Congenital Malformation Monitoring System Data 1985 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems, Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems, Amsterdam, Netherlands: Elsevier, 1991.	1985	*	
Australia	Australia - Western Australian Birth Defects Registry Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research, International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009, Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Australia	Australia - Victoria Birth Defects Registry Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research, International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009, Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Australia	Australian Congenital Malformation Monitoring System Data 1982 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems, Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems, Amsterdam, Netherlands: Elsevier, 1991.	1982	*	
Australia	Australia - Western Australian Register of Developmental Anomalies Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research, International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011, Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Australia	Australia - Western Australian Register of Developmental Anomalies Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research, International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012, Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
Australia	Australia - Western Australian Birth Defects Registry Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research, International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006, Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
Australia	Australia - Victoria Birth Defects Registry Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research, International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006, Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
Australia	Australian Congenital Malformation Monitoring System Data 1983 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems, Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems, Amsterdam, Netherlands: Elsevier, 1991.	1983	*	
Australia	Australian Congenital Malformation Monitoring System Data 1986 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems, Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems, Amsterdam, Netherlands: Elsevier, 1991.	1986	*	
Australia	Australian Congenital Malformation Monitoring System Data 1993-1997 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO), World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1997	*	
Australia	Astbury J, Orgill AA, Bajuk B, Yu VY. Neurodevelopmental outcome, growth and health of extremely low-birthweight survivors: how soon can we tell Dev Med Child Neurol. 1990; 32(7): 582-9.	1980		‡
Austria	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	1999-2010		
Austria	Austria Vital Registration - Deaths 1982 ICD9 as it appears in World Health Organization (WHO), World Health Organization (WHO), WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1982		
Austria	Austria Vital Registration - Deaths 1989 ICD9 as it appears in World Health Organization (WHO), World Health Organization (WHO), WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1989		
Austria	World Health Organization (WHO). Austria World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 1989. Vienna, Austria: Statistics Austria.	1989		
Austria	Austrian Institute for Health Studies (ÖIF), European Centre for Social Welfare Policy and Research, United Nations Economic Commission for Europe (UNECE), Austria Fertility and Family Survey 1995-1996. Geneva, Switzerland: United Nations Economic Commission for Europe (UNECE).	1995-1996		
Austria	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. Scand J Clin Lab Invest. 2007; 67(1): 39-69.	1988, 2006		
Austria	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists' Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2006		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Austria	Madersbacher S, Haidinger G, Temml C, Schmidbauer CP. Prevalence of lower urinary tract symptoms in Austria as assessed by an open survey of 2,096 men. <i>Eur Urol.</i> 1998; 34(2): 136-41.	1996		
Austria	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol.</i> 2008; 121(4): 947-954.	1995, 2002-2003		
Austria	Friedrich M, Rustler T, Hahne J. Prevalence of self-reported musculoskeletal pain in the Austrian population. <i>Wien Klin Wochenschr.</i> 2006; 118(3-4): 82-9.	2003		
Austria	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001, 2003-2005, 2007-2009		
Austria	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Austria	Lai CK, Beasley A, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2003		
Austria	Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. <i>Diabetologia.</i> 1996; 39(11): 1377-84.	1993-1995		
Austria	Ziegler D, Gries FA, Spiller M, Lessmann F. The epidemiology of diabetic neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. <i>J Diabet Complications.</i> 1992; 6(1): 49-57.	1989-1991		
Austria	Derfler K, Waldhäusl W, Zyman HJ, Howorka K, Holler C, Freyler H. Diabetes care in rural area: clinical and metabolic evaluation. <i>Diabetes Care.</i> 1986; 9(5): 509-17.	1985		
Austria	Lampf C, Buzath A, Baumhackl U, Klingler D. One-year prevalence of migraine in Austria: a nation-wide survey. <i>Cephalalgia.</i> 2003; 23(4): 280-6.	2001		†
Austria	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. <i>Community Dent Oral Epidemiol.</i> 1991; 19(2): 72-3.	1987		
Austria	Pieber K, Stein K, Herceg M, Rieder A, Fialka-Moser V, Dorner T. Determinants of satisfaction with individual health in male and female patients with chronic low back pain. <i>J Rehabil Med.</i> 2012; 44(8): 658-63.	2006-2007	*	
Austria	Huhulescu S, Kiss R, Brettlecker M, Cerny RJ, Hess C, Wewalka G, Allerberger F. Etiology of acute gastroenteritis in three sentinel general practices, Austria 2007. <i>Infection.</i> 2009; 37(2): 103-8.	2007	*	
Austria	Mangweh-Matekz B, Rupp CI, Hausmann A, Assmayr K, Mariacher E, Kemmler G, Whitworth AB, Biebl W. Never too old for eating disorders or body dissatisfaction: A community study of elderly women. <i>Int J Eat Disord.</i> 2006; 39(7): 583-6.	2004-2005		
Austria	Fruhwald FM, Dusleag J, Eber B, Fruhwald S, Zweiker R, Klein W. Long-term outcome and prognostic factors in dilated cardiomyopathy. Preliminary results. <i>Angiology.</i> 1994; 45(9): 763-70.	1974-1988		
Austria	Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E. BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. <i>Lancet.</i> 2007; 9589(9589): 741-50.	2005-2006		
Austria	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2004-2005		
Austria	Heinemann LAJ, Minh TD, Filonenko A, Uhl-Hochgräber K. Explorative evaluation of the impact of severe premenstrual disorders on work absenteeism and productivity. <i>Womens Health Issues.</i> 2010; 20(1): 58-65.	2007		
Austria	United States Renal Data System Coordinating Center. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2000-2003		
Austria	De Rijk MC, Launer LJ, Berger K, Breteler MM, Darigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology.</i> 2000; 54(11 Suppl 5): S21-23.	1997		
Austria	Berger K BM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology.</i> 2000; 54(11): 24-7.	1997		
Austria	Munoz M, Boutros-Toni F, Preux PM, Chartier JP, Ndzanga E, Boa F, Cruz ME, Vallat JM, Dumas M. Prevalence of neurological disorders in Haute-Vienne department (Limousin region-France). <i>Neuroepidemiology.</i> 1995; 14(4): 193-8.	1986		†
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 2001. Vienna, Austria: Statistics Austria.	2001		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 1990. Vienna, Austria: Statistics Austria.	1990		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 1991. Vienna, Austria: Statistics Austria.	1991		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 1992. Vienna, Austria: Statistics Austria.	1992		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 1993. Vienna, Austria: Statistics Austria.	1993		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 1994. Vienna, Austria: Statistics Austria.	1994		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 1995. Vienna, Austria: Statistics Austria.	1995		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 1996. Vienna, Austria: Statistics Austria.	1996		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 1997. Vienna, Austria: Statistics Austria.	1997		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 1998. Vienna, Austria: Statistics Austria.	1998		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 1999. Vienna, Austria: Statistics Austria.	1999		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 2000. Vienna, Austria: Statistics Austria.	2000		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 2002. Vienna, Austria: Statistics Austria.	2002		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 2003. Vienna, Austria: Statistics Austria.	2003		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 2004. Vienna, Austria: Statistics Austria.	2004		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 2005. Vienna, Austria: Statistics Austria.	2005		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 2006. Vienna, Austria: Statistics Austria.	2006		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 2007. Vienna, Austria: Statistics Austria.	2007		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 2008. Vienna, Austria: Statistics Austria.	2008		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 2009. Vienna, Austria: Statistics Austria.	2009		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 2010. Vienna, Austria: Statistics Austria.	2010		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Austria	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Austria	Federal Ministry of Health (Austria), Statistics Austria. Austria Hospital Inpatient Discharges 1989. Vienna, Austria: Statistics Austria.	1989		
Austria	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	2004		
Austria	Walch C, Anderhuber W, Ksle W, Berghold A. Bilateral sensorineural hearing disorders in children: etiology of deafness and evaluation of hearing tests. <i>Int J Pediatr Otorhinolaryngol</i> . 2000; 53(1): 31-8.	1980-1996		
Austria	Petritsch W, Fuchs S, Berghold A, Bachmaier G, Högenauer C, Hauer AC, Weiglhofer U, Wenzl HH. Incidence of inflammatory bowel disease in the province of Styria, Austria, from 1997 to 2007: a population-based study. <i>J Crohns Colitis</i> . 2013; 7(1): 58-69.	1997-2007	*	†
Austria	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2005-2006		
Austria	Bodner K, Wierani F, Grünberger W, Bodner-Adler B. Influence of the mode of delivery on maternal and neonatal outcomes: a comparison between elective cesarean section and planned vaginal delivery in a low-risk obstetric population. <i>Arch Gynecol Obstet</i> . 2011; 283(6): 1193-8.	2005-2009	*	
Austria	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2001, 2004, 2007, 2010, 2012		
Austria	Schober E, Frisch H. Incidence of childhood diabetes mellitus in Austria 1979-1984. <i>Acta Paediatr Scand</i> . 1988; 77(2): 299-302.	1979-1984		
Austria	Schober E, Schneider U, Waldhör T, Tuomilehto J. Increasing incidence of IDDM in Austrian children. A nationwide study 1979-1993. Austrian Diabetes Incidence Study Group. <i>Diabetes Care</i> . 1995; 18(9): 1280-3.	1986-1993		
Austria	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Austria National Report to the EMCDDA 2006.	2000-2004	*	
Austria	Bargagli AM, Hickman M, Davoli M, Perucci CA, Schifano P, Buser M, Brugal T, Vicente J, COSMO European Group. Drug-related mortality and its impact on adult mortality in eight European countries. <i>Eur J Public Health</i> . 2006; 16(2): 198-202.	1990-1998	*	
Austria	Bauer SM, Lajpl R, Jagsch R, Gruber D, Rissler D, Thau K, Fischer G. Mortality in opioid-maintained patients after release from an addiction clinic. <i>Eur Addict Res</i> . 2008; 14(2): 82-91.	1998-2004	*	
Austria	Kraus L, Augustin R, Frischer M, Kümmler P, Uhl A, Wiessing L. Estimating prevalence of problem drug use at national level in countries of the European Union and Norway. <i>Addiction</i> . 2003; 98(4): 471-85.	1995	*	
Austria	Rissler D, Hönigschnabl S, Stichenwirth M, Pfudl S, Sebal D, Kaff A, Bauer G. Mortality of opiate users in Vienna, Austria. <i>Drug Alcohol Depend</i> . 2001; 64(3): 251-6.	1995-1997	*	
Austria	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant</i> . 1988; 3(6): 714-27.	1985		
Austria	Van Dijk PC, Jager KJ, Stengel B, Grönhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). <i>Kidney Int</i> . 2005; 67(4): 1489-99.	1991-1992, 1999-2000		
Austria	Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. <i>Nephrol Dial Transplant</i> . 2003; 18(9): 1824-33.	1990-1991, 1998-1999		
Austria	Mueller A, Gooren LJ, Naton-Schütz S, Cupisti S, Beckmann MW, Dittlich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. <i>J Clin Endocrinol Metab</i> . 2008; 93(4): 1408-11.	2005		
Austria	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguiar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Gilst WH van, Widimsky J, Freeman N, Eastaugh J, Mason J. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J</i> . 2003; 24(5): 442-63.	2000-2001		
Austria	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2012. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	2008	*	
Austria	Weichbold V, Rohrer M, Winkler C, Weitz-Müller K. [Hearing screening at nursery schools: results of an evaluation study]. <i>Wien Klin Wochenschr</i> . 2004; 116(14): 478-83.	2001-2003	*	
Austria	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland: World Health Organization (WHO).	2001-2005	*	
Austria	Trichopoulos D, Bania C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overved K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PHM, Lund E, Quirós JR, González CA, Sánchez Pérez M-J, Navarro C, Dorransoro M, Barriarte A, Lindkvist B, Regné S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu L, Chuang S-C, Murphy N, Boffetta P, Trichopoulou A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. <i>J Natl Cancer Inst</i> . 2011; 103(22): 1686-95.	1992-2006	*	
Austria	Prodinger WM, Larcher C, Sölder BM, Geissler D, Dierich MP. Hepatitis A in Western Austria—the epidemiological situation before the introduction of active immunisation. <i>Infection</i> . 1994; 22(1): 53-5.	1991		
Austria	Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Barré J, André C. The impact of headache in Europe: principal results of the Eurolight project. <i>J Headache Pain</i> . 2014; 15(31). [Unpublished data].	2008	*	
Austria	Zeitlan J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT; 2008. Available from: http://www.perinataleaudit.nl/downloads/bestand/649/peristat-ii-2008-	2004		†
Austria	Austrian Dialysis and Transplant Registry Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Austria	Austrian Dialysis and Transplant Registry Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Austria	Austrian Dialysis and Transplant Registry Renal Replacement Therapy Data 1997 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 1998. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2003.	1997	*	
Austria	Austria Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Austria	European Surveillance of Congenital Anomalies (EUROCAT). Austria EUROCAT Prevalence Tables. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	1985-2009		
Austria	Austria - Styrian Malformation Registry Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT). International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Azerbaijan	State Statistics Committee of Azerbaijan, United Nations Children's Fund (UNICEF). Azerbaijan Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Azerbaijan	Macro International, Inc. State Statistical Committee of Azerbaijan. Azerbaijan Demographic and Health Survey 2006. Calverton, United States: Macro International, Inc.	2006		†
Azerbaijan	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Azerbaijan	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Azerbaijan	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001-2005, 2007-2008		
Azerbaijan	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Azerbaijan	Fatullayev N. Paid and Free Dialysis. Radioazadlyg [Internet]. 2011 Aug 11; Region; [about 3 screens]. http://www.radioazadlyg.org/content/article/24287872 .	2010		
Azerbaijan	Magalov SI, Hasanov NF, Azizova NX, Novruzov AN, Mustafayev ZB, Kazimov SA, Sultanov SS, Hasanov EN, Alev G. The prevalence of epilepsy in the Nakhichevan Autonomous Republic of Azerbaijan. CNS Neurol Disord Drug Targets. 2012; 11(2): 102-9.	2003	*	
Azerbaijan	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2004, 2010, 2012		
Azerbaijan	World Health Organization (WHO). Azerbaijan WHO Leishmaniasis Country Profile.	1994-2010	*	
Azerbaijan	Vitek CR, Velibekov AS. Epidemic diphtheria in the 1990s: Azerbaijan. J Infect Dis. 2000; S73-79.	1990-1996		
Azerbaijan	Markou KB, Georgopoulos NA, Makri M, Anastasiou E, Vlasopoulou B, Lazarou N, Deville L, Megreli C, Vagenakis GA, Sakellaropoulos GC, Jabbarov R, Kerimova MG, Mamedgasanov RM, Vagenakis AG. Iodine deficiency in Azerbaijan after the discontinuation of an iodine prophylaxis program: reassessment of iodine intake and goiter prevalence in schoolchildren. Thyroid. 2001; 11(12): 1141-6.	2001		
Azerbaijan	Tsoi RM, Pak IV, Bobrova IA. [Distribution of blood types of four systems and ABO incompatibility in migration population of a northern town]. <i>Fiziol Cheloveka</i> . 2003; 29(3): 125-8.	1997-1998	*	†
Azerbaijan	USSR - Azerbaijan SSR Vital Registration Birth Data 1989 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1989		
Bahrain	Angastiniotis M, Modell B, Englezos P, Boulyjenkov V. Prevention and control of haemoglobinopathies. Bull World Health Organ. 1995; 73(3): 375-86.	1991-1993		
Bahrain	Thalassaemia International Federation, World Health Organization (WHO). Management of Haemoglobin Disorders: Report of a Joint WHO-TIF Meeting, Nicosia, Cyprus, 16-18 November 2007. Geneva, Switzerland: World Health Organization (WHO), 2008.	1985, 2002, 2007		
Bahrain	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Bahrain	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Bahrain	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998-2002, 2004, 2006-2009		
Bahrain	Al-Mahroos F, Al-Roomi K. Diabetic neuropathy, foot ulceration, peripheral vascular disease and potential risk factors among patients with diabetes in Bahrain: a nationwide primary care diabetes clinic-based study. Ann Saudi Med. 2007; 27(1): 25-31.	2005		
Bahrain	al-Mahroos F, McKeigue PM. High prevalence of diabetes in Bahrainis. Associations with ethnicity and raised plasma cholesterol. Diabetes Care. 1998; 21(6): 936-42.	1996		
Bahrain	Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version). Lyon, IARC. http://ci5.iarc.fr	2003-2007	*	
Bahrain	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Bahrain	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2007, 2010, 2012		
Bahrain	Dash S. Hemoglobinopathies, G6PD deficiency, and hereditary elliptocytosis in Bahrain. Hum Biol. 2004; 76(5): 779-83.	2002-2004		
Bahrain	Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M and Boyle P, eds (2007). Cancer Incidence in Five Continents, Vol. IX Periodic Data (electronic version). Lyon, IARC. http://ci5.iarc.fr	1998-2002	*	
Bahrain	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Bahrain	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Bahrain	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Bahrain	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
Bahrain	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Bahrain	Al Arrayed S. Campaign to control genetic blood diseases in Bahrain. Community Genet. 2005; 8(1): 52-5.	2002	*	
Bahrain	Al-Hilli F. The ABO and Rh blood groups in Bahrain, Arabian Gulf. Hum Biol. 1985; 57(3): 441-7.	1982	*	†
Bahrain	Bahrain Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Bangladesh	Bangladesh Bureau of Statistics, Mitra and Associates, United Nations Children's Fund (UNICEF). Bangladesh Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006	*	
Bangladesh	Macro International, Inc. Mitra and Associates, National Institute of Population Research and Training (NIPORT). Bangladesh Demographic and Health Survey 1996-1997. Calverton, United States: Macro International, Inc.	1996-1997		†
Bangladesh	Macro International, Inc. Mitra and Associates, National Institute of Population Research and Training (NIPORT). Bangladesh Demographic and Health Survey 1993-1994. Calverton, United States: Macro International, Inc.	1993-1994		
Bangladesh	Mitra and Associates, ORC Macro. Bangladesh Demographic and Health Survey 2004. Calverton, United States: ORC Macro.	2004		†
Bangladesh	Macro International, Inc. Mitra and Associates, National Institute of Population Research and Training (NIPORT). Bangladesh Demographic and Health Survey 2007. Calverton, United States: Macro International, Inc. 2009.	2007		†
Bangladesh	World Health Organization (WHO). Bangladesh World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Bangladesh	Macro Systems, Inc. Mitra and Associates, National Institute of Population Research and Training (NIPORT). Bangladesh Demographic and Health Survey 1999-2000. Calverton, United States: Macro International, Inc.	1999-2000		†
Bangladesh	National Institute of Population Research and Training (Bangladesh), International Statistical Institute. Bangladesh World Fertility Survey 1975-1976. Voorburg, Netherlands: International Statistical Institute.	1975-1976		
Bangladesh	ICF Macro, Mitra and Associates, National Institute of Population Research and Training (NIPORT). Bangladesh Demographic and Health Survey 2011-2012. Calverton, United States: ICF Macro.	2011-2012	*	†
Bangladesh	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988, 1997-2005		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Bangladesh	Haque R, Mondal D, Kirkpatrick BD, Akther S, Farr BM, Sack RB, Petri WA Jr. Epidemiologic and clinical characteristics of acute diarrhoea with emphasis on Entamoeba histolytica infections in preschool children in an urban slum of Dhaka, Bangladesh. <i>Am J Trop Med Hyg.</i> 2003; 69(4): 398-405.	1999-2002		
Bangladesh	Shahid NS, Greenough WB 3rd, Samadi AR, Haq MI, Rahman N. Hand washing with soap reduces diarrhoea and spread of bacterial pathogens in a Bangladeshi village. <i>J Diarrhoeal Dis Res.</i> 1996; 14(2): 85-9.	1983		
Bangladesh	Qadri F, Saha A, Ahmed T, Al Tarique A, Begum YA, Svennerholm AM. Disease burden due to enterotoxigenic Escherichia coli in the first 2 years of life in an urban community in Bangladesh. <i>Infect Immun.</i> 2007; 75(8): 3961-8.	2002-2004		
Bangladesh	Mahalanabis D, Alam AN, Rahman N, Hasnat A. Prognostic indicators and risk factors for increased duration of acute diarrhoea and for persistent diarrhoea in children. <i>Int J Epidemiol.</i> 1991; 20(4): 1064-72.	1983-1985		
Bangladesh	Baqi AH, Sack RB, Black RE, Haider K, Hossain A, Alim AR, Yunus M, Chowdhury HR, Siddique AK. Enteropathogens associated with acute and persistent diarrhea in Bangladeshi children less than 5 years of age. <i>J Infect Dis.</i> 1992; 166(4): 792-6.	1988-1989		
Bangladesh	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Bangladesh	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Bangladesh	Hasan K, Jolly P, Marquis G, Roy E, Podder G, Alam K, Huq F, Sack R. Viral etiology of pneumonia in a cohort of newborns till 24 months of age in Rural Mirzapur, Bangladesh. <i>Scand J Infect Dis.</i> 2006; 38(8): 690-5.	1993-1994		
Bangladesh	Rahman M, Huq F, Sack DA, Butler T, Azad AK, Alam A, Nahar N, Islam M. Acute lower respiratory tract infections in hospitalized patients with diarrhea in Dhaka, Bangladesh. <i>Rev Infect Dis.</i> 1990; 12(Suppl 8): S899-906.	1986-1988		
Bangladesh	Black RE, Merson MH, Rahman AS, Yunus M, Alim AR, Haq I, Yolken RH, Curlin GT. A two-year study of bacterial, viral, and parasitic agents associated with diarrhea in rural Bangladesh. <i>J Infect Dis.</i> 1980; 142(5): 660-4.	1977-1979		
Bangladesh	Henry FJ, Udoy AS, Wanke CA, Aziz KM. Epidemiology of persistent diarrhea and etiologic agents in Mirzapur, Bangladesh. <i>Acta Paediatr Suppl.</i> 1992; 381: 27-31.	1987-1989		
Bangladesh	Baqi AH, Yunus MD, Zaman K, Mitra AK, Hossain KM. Surveillance of patients attending a rural diarrhoea treatment centre in Bangladesh. <i>Trop Geogr Med.</i> 1991; 43(1-2): 17-22.	1983-1984		
Bangladesh	Begum S, Salahuddin AK. Study on quality assessment of neonatal tetanus cases admitted in the Infectious Diseases Hospital, Dhaka. <i>J Acad Hosp Adm.</i> 1991; 3(2): 25-8.	1988		
Bangladesh	Roy E, Hasan KZ, Haque F, Siddique AKM, Sack RB. Acute otitis media during the first two years of life in a rural community in Bangladesh: a prospective cohort study. <i>J Health Popul Nutr.</i> 2007; 25(4): 414-21.	1993-1996		
Bangladesh	Biswas AC, Joarder AH, Siddiquee BH. Prevalence of CSOM among rural school going children. <i>Mymensingh Med J.</i> 2005; 14(2): 152-5.	2001-2002		
Bangladesh	Kamal N, Joarder AH, Chowdhury AA, Khan AW. Prevalence of chronic suppurative otitis media among the children living in two selected slums of Dhaka City. <i>Bangladesh Med Res Counc Bull.</i> 2004; 30(3): 95-104.	2001		
Bangladesh	Arifeen SE, Rahman S, Rahman KM, Rahman SM, Bari S, Naheed A, Mannan I, Seraji MHR, Hassan MS, Huda N, Siddik AU, Quasem I, Brooks WA, Sack D, Luby SP, Saha SK, Islam M, Fatima K, Al-Emran H, Ahmed NU, Baqui AH, Breiman RF. Invasive pneumococcal disease among children in rural Bangladesh: Results from a population-based surveillance. <i>Clin Infect Dis.</i> 2009; 48(Suppl 2): S103-S113.	2004-2007		
Bangladesh	Zaman K, Baqui AH, Yunus M, Sack RB, Bateman OM, Chowdhury HR, Black RE. Acute respiratory infections in children: a community-based longitudinal study in rural Bangladesh. <i>J Trop Pediatr.</i> 1997; 3(43): 133-7.	1988-1989		
Bangladesh	Rahman M, Shahid NS, Rahman H, Sack DA, Rahman N, Hossain S. Cryptosporidiosis: a cause of diarrhea in Bangladesh. <i>Am J Trop Med Hyg.</i> 1990; 42(2): 127-30.	1985		
Bangladesh	Moisi JC, Saha SK, Falade AG, Njanpop-Lafourcade B-M, Oundo J, Zaidi AKM, Afroj S, Bakare RA, Buss JK, Lasi R, Mueller J, Odekanmi AA, Sangare L, Scott JAG, Knoll MD, Levine OS, Gessner BD. Enhanced diagnosis of pneumococcal meningitis with use of the binax NOW immunochromatographic test of Streptococcus pneumoniae antigen: A multisite study. <i>Clin Infect Dis.</i> 2009; 48(Suppl 2): S49-S56.	2006-2007		
Bangladesh	Saha SK, Rikitiom N, Ruhulamin M, Watanabe K, Ahmed K, Biswas D, Hanif M, Khan WA, Islam M, Matsumoto K. The increasing burden of disease in Bangladeshi children due to Haemophilus influenzae type b meningitis. <i>Ann Trop Paediatr.</i> 1997; 17(1): 5-8.	1987-1994		
Bangladesh	Oberle MW, Merson MH, Islam MS, Rahman AS, Huber DH, Curlin G. Diarrhoeal disease in Bangladesh: epidemiology, mortality averted and costs at a rural treatment centre. <i>Int J Epidemiol.</i> 1980; 9(4): 341-8.	1975-1976		
Bangladesh	Islam SS, Shahid NS. Morbidity and mortality in a diarrhoeal diseases hospital in Bangladesh. <i>Trans R Soc Trop Med Hyg.</i> 1986; 80(5): 748-52.	1980-1981		
Bangladesh	Tanaka G, Faruque ASG, Luby SP, Malek MA, Glass RI, Parashar UD. Deaths from rotavirus disease in Bangladeshi children: estimates from hospital-based surveillance. <i>Pediatr Infect Dis J.</i> 2007; 26(11): 1014-8.	1993-2004		
Bangladesh	Hossain MA, Albert MJ, Hasan KZ. Epidemiology of shigellosis in Teknaf, a coastal area of Bangladesh: a 10-year survey. <i>Epidemiol Infect.</i> 1990; 105(1): 41-9.	1975-1984		
Bangladesh	Von Seidlein L, Kim DR, Ali M, Lee H, Wang X, Thiem VD, Canh DG, Chaicumpa W, Agtini MD, Hossain A, Bhutta ZA, Mason C, Sethabutr O, Talukder K, Nair GB, Deen JL, Kotloff K, Clemens J. A Multicentre Study of Shigella Diarrhoea in Six Asian Countries: Disease Burden, Clinical Manifestations, and Microbiology. <i>PLoS Med.</i> 2006; 3(9): e353.	2002-2004		
Bangladesh	Haq SA, Darmawan J, Islam MN, Uddin MZ, Das BB, Rahman F, Chowdhury MAJ, Alam MN, Mahmud TAK, Chowdhury MR, Tahir M. Prevalence of rheumatic diseases and associated outcomes in rural and urban communities in Bangladesh: a COPCORD study. <i>J Rheumatol.</i> 2005; 32(2): 348-53.	2000-2001		
Bangladesh	Hussain A, Vaaler S, Sayeed MA, Mahtab H, Ali SM, Khan AK. Type 2 diabetes and impaired fasting blood glucose in rural Bangladesh: a population-based study. <i>Eur J Public Health.</i> 2007; 17(3): 291-6.	1999		
Bangladesh	Sayeed MA, Mahtab H, Akter Khanam P, Abdul Latif Z, Keramat Ali SM, Banu A, Ahren B, Azad Khan AK. Diabetes and impaired fasting glycaemia in a rural population of Bangladesh. <i>Diabetes Care.</i> 2003; 26(4): 1034-9.	2000		
Bangladesh	Hussain A, Rahim MA, Azad Khan AK, Ali SM, Vaaler S. Type 2 diabetes in rural and urban population: diverse prevalence and associated risk factors in Bangladesh. <i>Diabet Med.</i> 2005; 22(7): 931-6.	2002		
Bangladesh	Abu Sayeed M, Mahtab H, Akter Khanam P, Abul Ahsan K, Banu A, Rashid AN, Azad Khan AK. Diabetes and impaired fasting glycaemia in the tribes of Khagrachari hill tracts of Bangladesh. <i>Diabetes Care.</i> 2004; 27(5): 1054-9.	2002		
Bangladesh	Dewan AM, Corner R, Hashizume M, Onge ET. Typhoid Fever and its association with environmental factors in the Dhaka Metropolitan Area of Bangladesh: a spatial and time-series approach. <i>PLoS Negl Trop Dis.</i> 2013; 7(1): e1998.	2005-2009	*	
Bangladesh	Saha SK, Saha S, Shakur S, Hanif M, Habib MA, Datta SK, Bock HL. Community-based cross-sectional seroprevalence study of hepatitis A in Bangladesh. <i>World J Gastroenterol.</i> 2009; 15(39): 4932-7.	2005-2006		
Bangladesh	Ahmed M, Munshi SU, Nessa A, Ullah MS, Tabassum S, Islam MN. High prevalence of hepatitis A virus antibody among Bangladeshi children and young adults warrants pre-immunization screening of antibody in HAV vaccination strategy. <i>Indian J Med Microbiol.</i> 2009; 27(1): 48-50.	2005		
Bangladesh	Labrique AB, Zaman K, Hossain Z, Saha P, Yunus M, Hossain A, Tietchurst J, Nelson KE. Population seroprevalence of hepatitis E virus antibodies in rural Bangladesh. <i>Am J Trop Med Hyg.</i> 2009; 81(5): 875-81.	2003-2004		
Bangladesh	Shahen MM, Raquib A, Ahmad SM. Prevalence and associated socio-demographic factors of chronic suppurative otitis media among rural primary school children of Bangladesh. <i>Int J Pediatr Otorhinolaryngol.</i> 2012; 76(8): 1201-4.	2007-2009	*	
Bangladesh	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Bangladesh	Chowdhury F, Rahman MA, Begum YA, Khan AI, Faruque ASG, Saha NC, Baby NI, Malek MA, Kumar AR, Svennerholm A-M, Pietroni M, Cravioto A, Qadri F. Impact of rapid urbanization on the rates of infection by Vibrio cholerae O1 and enterotoxigenic Escherichia coli in Dhaka, Bangladesh. <i>PLoS Negl Trop Dis</i> . 2011; 5(4): e999.	2008-2010	*	
Bangladesh	Faruque AS, Mahalanabis D, Islam A, Hoque SS, Hasnat A. Common diarrhoea pathogens and the risk of dehydration in young children with acute watery diarrhoea: a case-control study. <i>Am J Trop Med Hyg</i> . 1993; 49(1): 93-100.	1988-1989	*	
Bangladesh	Faruque ASG, Malek MA, Khan AI, Huq S, Salam MA, Sack DA. Diarrhoea in elderly people: aetiology, and clinical characteristics. <i>Scand J Infect Dis</i> . 2004; 36(3): 204-8.	1996-2001	*	
Bangladesh	Fun BN, Unicomb L, Rahim Z, Banu NN, Podder G, Clemens J, Van Loon FP, Rao MR, Malek A, Tzipori S. Rotavirus-associated diarrhoea in rural Bangladesh: two-year study of incidence and serotype distribution. <i>J Clin Microbiol</i> . 1991; 29(7): 1359-63.	1987-1989	*	
Bangladesh	Unicomb LE, Kilgore PE, Faruque SG, Hamadani JD, Fuchs GJ, Albert MJ, Glass RI. Anticipating rotavirus vaccines: hospital-based surveillance for rotavirus diarrhoea and estimates of disease burden in Bangladesh. <i>Pediatr Infect Dis J</i> . 1997; 16(10): 947-51.	1990-1993	*	
Bangladesh	Black RE, Merson MH, Huq I, Alim AR, Yunus M. Incidence and severity of rotavirus and Escherichia coli diarrhoea in rural Bangladesh. Implications for vaccine development. <i>Lancet</i> . 1981; 1(8212): 141-3.	1977-1978	*	
Bangladesh	CHOICE Study Group. Multicenter, randomized, double-blind clinical trial to evaluate the efficacy and safety of a reduced osmolarity oral rehydration salts solution in children with acute watery diarrhoea. <i>Pediatrics</i> . 2001; 107(4): 613-8.	1995-1997	*	
Bangladesh	Black RE, Brown KH, Becker S, Alim AR, Huq I. Longitudinal studies of infectious diseases and physical growth of children in rural Bangladesh. II. Incidence of diarrhoea and association with known pathogens. <i>Am J Epidemiol</i> . 1982; 115(3): 315-24.	1978-1979	*	
Bangladesh	Albert MJ, Faruque AS, Faruque SM, Sack RB, Mahalanabis D. Case-control study of enteropathogens associated with childhood diarrhoea in Dhaka, Bangladesh. <i>J Clin Microbiol</i> . 1999; 37(11): 3458-64.	1993-1994	*	
Bangladesh	Stoll BJ, Glass RI, Huq MI, Khan MU, Holt JE, Banu H. Surveillance of patients attending a diarrhoeal disease hospital in Bangladesh. <i>Br Med J (Clin Res Ed)</i> . 1982; 285(6349): 1185-8.	1979-1980	*	
Bangladesh	Khan AM, Hossain MS, Khan AI, Chisti MJ, Chowdhury F, Faruque ASG, Salam MA. Bacterial enteropathogens of neonates admitted to an urban diarrhoeal hospital in Bangladesh. <i>J Trop Pediatr</i> . 2009; 55(2): 122-4.	1991-2004	*	
Bangladesh	Ahmed S, Hussain M, Akhter S, Islam T, Ahmed SU, Kabir ML. Genotypes of rotavirus diarrhoea in a children hospital of Bangladesh. <i>Mymensingh Med J</i> . 2012; 21(3): 497-502.	2006-2007	*	
Bangladesh	Hoque BA, Juncker T, Sack RB, Ali M, Aziz KM. Sustainability of a water, sanitation and hygiene education project in rural Bangladesh: a 5-year follow-up. <i>Bull World Health Organ</i> . 1996; 74(4): 431-7.	1993	*	
Bangladesh	Aziz KM, Hoque BA, Hasan KZ, Patwary MY, Huttly SR, Rahaman MM, Feachem RG. Reduction in diarrhoeal diseases in children in rural Bangladesh by environmental and behavioural modifications. <i>Trans R Soc Trop Med Hyg</i> . 1990; 84(3): 433-8.	1986-1987	*	
Bangladesh	Nasrin D, Wu Y, Blackwelder WC, Farag TH, Saha D, Sow SO, Alonso PL, Breiman RF, Sur D, Faruque ASG, Zaidi AKM, Biswas K, Van Eijk AM, Walker DG, Levine MM, Kotloff KL. Health care seeking for childhood diarrhoea in developing countries: evidence from seven sites in Africa and Asia. <i>Am J Trop Med Hyg</i> . 2013; 89(1 Suppl): 3-12.	2009-2011	*	
Bangladesh	Haq SA, Darmawan J, Islam MN, Ahmed M, Banik SK, Fazlur Rahman AKM, Alam MN, Tahir M, Rasker JJ. Incidence of musculoskeletal pain and rheumatic disorders in a Bangladeshi rural community: a WHO-APLAR-COPCORD study. <i>Int J Rheum Dis</i> . 2008; 11(3): 216-23.	2001-2002		
Bangladesh	Begum J, Barman A, Bhuiyan SA, Rahman AJ. Dental caries in primary school children in rural areas of Dhaka, Bangladesh. <i>Med Res Counc Bull</i> . 1987; 13(2): 80-4.	1984		
Bangladesh	Kidney Foundation (Bangladesh). Situation of Kidney Disease in Bangladesh. Kidney Foundation [Internet]. Dhaka, Bangladesh: Kidney Foundation (Bangladesh); [updated 2011].	1988-2009		
Bangladesh	Mullick MSI, Goodman R. The prevalence of psychiatric disorders among 5-10 year olds in rural, urban and slum areas in Bangladesh: an exploratory study. <i>Soc Psychiatry Psychiatr Epidemiol</i> . 2005; 40(8): 663-71.	2004		
Bangladesh	Monawar Hosain GM, Chatterjee N, Ara N, Islam T. Prevalence, pattern and determinants of mental disorders in rural Bangladesh. <i>Public Health</i> . 2007; 121(1): 18-24.	2000		
Bangladesh	Islam MM, Ali M, Ferroni P, Underwood P, Alam MF. Prevalence of psychiatric disorders in an urban community in Bangladesh. <i>Gen Hosp Psychiatry</i> . 2003; 25(5): 353-7.	1996-1997		
Bangladesh	Razzaque A, Da Vanzo J, Rahman M, Gausia K, Hale L, Khan MA, Mustafa AHMG. Pregnancy spacing and maternal morbidity in Matlab, Bangladesh. <i>Int J Gynaecol Obstet</i> . 2005; 89(Suppl 1): S41-49.	1996-2002		
Bangladesh	United States Renal Data System Coordinating Center. <i>USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States</i> . Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2004-2008		
Bangladesh	International Society of Nephrology (ISN). <i>International Society of Nephrology Kidney Disease Data Center 2006-2009</i> .	2009		
Bangladesh	United States Renal Data System Coordinating Center. <i>USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States</i> . Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2000-2003		
Bangladesh	United States Renal Data System Coordinating Center. <i>USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States</i> . Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2003.	1998-1999		
Bangladesh	Bangladesh National Blindness and Low Vision Prevalence Survey 1999-2000 [Unpublished] as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	1999-2000		
Bangladesh	Wadud Z, Kuper H, Polack S, Lindfield R, Akm MR, Choudhury KA, Lindfield T, Limburg H, Foster A. Rapid assessment of avoidable blindness and needs assessment of cataract surgical services in Satkhira District, Bangladesh. <i>Br J Ophthalmol</i> . 2006; 90(10): 1225-9. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2005		
Bangladesh	Saha SK, Darmstadt GL, Hanif M, Khan R. Seroepidemiology of varicella-zoster virus in Bangladesh. <i>Ann Trop Paediatr</i> . 2002; 22(4): 341-5.	1999-2000		
Bangladesh	Islam S, Durkin MS, Zaman SS. Socioeconomic status and the prevalence of mental retardation in Bangladesh. <i>Ment Retard</i> . 1993; 31(6): 412-7.	1993		
Bangladesh	Stein Z, Belmont L, Durkin M. Mild mental retardation and severe mental retardation compared: experiences in eight less developed countries. <i>Ups J Med Sci Suppl</i> . 1987; 89-96.	1987		
Bangladesh	Ahmed J, Mostafa Zaman M, Monzur Hassan MM. Prevalence of rheumatic fever and rheumatic heart disease in rural Bangladesh. <i>Trop Doct</i> . 2005; 35(3): 160-1.	1991		
Bangladesh	Mohammad QD, Habib M, Hoque A, Alam B, Haque B, Hossain S, Rahman KM, Khan SU. Prevalence of stroke above forty years. <i>Mymensingh Med J</i> . 2011; 20(4): 640-4.	2001-2003	*	
Bangladesh	Durkin MS, Davidson LL, Hasan ZM, Hasan Z, Hauser WA, Khan N, Paul TJ, Shrout PE, Thorburn MJ, Zaman S. Estimates of the prevalence of childhood seizure disorders in communities where professional resources are scarce: results from Bangladesh, Jamaica and Pakistan. <i>Paediatr Perinat Epidemiol</i> . 1992; 6(2): 166-80.	1991	*	†
Bangladesh	Zaman S, Khan M, Alam K, Williams R. Primary hepatocellular carcinoma and viral hepatitis B and C infection in Bangladeshi subjects. <i>J Trop Med Hyg</i> . 1995; 98(1): 64-8.	1992		
Bangladesh	Zaman K, Yunus M, Arifeen SE, Baqui AH, Sack DA, Hossain S, Rahim Z, Ali M, Banu S, Islam MA, Begum N, Begum V, Breiman RF, Black RE. Prevalence of sputum smear-positive tuberculosis in a rural area in Bangladesh. <i>Epidemiol Infect</i> . 2006; 134(5): 1052-9.	2001		
Bangladesh	World Health Organization (WHO). <i>WHO Tuberculosis Case Notifications</i> . Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Bangladesh	Bangladesh Rural Advancement Committee (BRAC), Damien Foundation, International Centre for Diarrhoeal Disease Research (Bangladesh), KNCV Tuberculosis Foundation, World Health Organization (WHO). <i>Bangladesh Tuberculosis Disease-Cum-Infection Prevalence Survey 2007-2009</i> .	2007-2009		
Bangladesh	United Nations Children's Fund (UNICEF). <i>Child Mortality and Injury in Asia</i> . New York, United States: United Nations Children's Fund (UNICEF), 2008. (Innocenti Working Papers: Special Series on Child Injuries Nos. 1-4).	2003	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Bangladesh	Ministry of Health and Family Welfare (Bangladesh), The Alliance for Safe Children (TASC), United Nations Children's Fund (UNICEF). Bangladesh Health and Injury Survey 2003.	2003	*	
Bangladesh	Qutub M, Akhter J. Epidemiology of genital herpes (HSV-2) among brothel based female sex workers in Bangladesh. <i>Eur J Epidemiol.</i> 2003; 18(9): 903-5.	2000-2002		
Bangladesh	Nessa K, Waris S-A, Sultan Z, Monira S, Hossain M, Nahar S, Rahman H, Alam M, Baatsen P, Rahman M. Epidemiology and etiology of sexually transmitted infection among hotel-based sex workers in Dhaka, Bangladesh. <i>J Clin Microbiol.</i> 2004; 42(2): 618-21.	2002	*	
Bangladesh	Bogaerts J, Ahmed J, Akhter N, Begum N, Rahman M, Nahar S, Van Ranst M, Verhaegen J. Sexually transmitted infections among married women in Dhaka, Bangladesh: unexpected high prevalence of herpes simplex type 2 infection. <i>Sex Transm Infect.</i> 2001; 77(2): 114-9.	1996-1998		
Bangladesh	Akhter A, Fatema K, Ahmed SF, Afroz A, Ali L, Hussain A. Prevalence and associated risk indicators of retinopathy in a rural Bangladeshi population with and without diabetes. <i>Ophthalmic Epidemiol.</i> 2013; 20(4): 220-7.	2011		
Bangladesh	Bhowmik B, Afana F, My Diep L, Binte Munir S, Wright E, Mahmood S, Khan AKA, Hussain A. Increasing prevalence of type 2 diabetes in a rural bangladeshi population: a population based study for 10 years. <i>Diabetes Metab J.</i> 2013; 37(1): 46-53.	1999, 2004, 2009		
Bangladesh	Asghar S, Khan AKA, Ali SMK, Sayeed MA, Bhowmik B, Diep ML, Shi Z, Hussain A. Incidence of diabetes in Asian-Indian subjects: a five year follow-up study from Bangladesh. <i>Prim Care Diabetes.</i> 2011; 5(2): 117-24.	1999-2004		
Bangladesh	Nizam S, Khalequzzaman M, Yatsuya H, Khanam PA, Sayeed MA, Naito H, Nakajima T. Incidence of young onset insulin-requiring diabetes mellitus among 18- to 30-year-olds in Dhaka, Bangladesh (1994-2003). <i>Nagoya J Med Sci.</i> 2012; 74(1-2): 149-56.	1994-2003		
Bangladesh	Azim T, Chowdhury EI, Reza M, Faruque MO, Ahmed G, Khan R, Rahman M, Pervez MM, Jana S, Strathdee SA. Prevalence of infections, HIV risk behaviors and factors associated with HIV infection among male injecting drug users attending a needle/syringe exchange program in Dhaka, Bangladesh. <i>Subst Use Misuse.</i> 2008; 43(14): 2124-44.	2002-2007	*	
Bangladesh	Papiha SS, Roberts DF, Ali SG, Islam MM. Some hereditary blood factors of the Bengali Muslim of Bangladesh (red cell enzymes, haemoglobins, and serum proteins). <i>Humangenetik.</i> 1975; 28(4): 285-93.	1973-1975		
Bangladesh	Rashid, H. 1986-1996: Bangladesh Renal Registry Report. <i>Bangladesh Renal J.</i> 2002; 21: 25-28.	1996-1998		
Bangladesh	Brooks WA, Hossain A, Goswami D, Sharmeen AT, Nahar K, Alam K, Ahmed N, Naheed A, Nair GB, Luby S, Breiman RF. Bacteremic Typhoid Fever in Children in an Urban Slum, Bangladesh. <i>Emerg Infect Dis.</i> 2005; 11(2): 326-9.	2000-2001		
Bangladesh	Naheed A, Ram PK, Brooks WA, Hossain MA, Parsons MB, Talukder KA, Mintz E, Luby S, Breiman RF. Burden of typhoid and paratyphoid fever in a densely populated urban community, Dhaka, Bangladesh. <i>Int J Infect Dis.</i> 2010; e93-e99.	2003-2004	*	
Bangladesh	Fatema K, Abedin Z, Mansur A, Rahman F, Khatun T, Sumi N, Kobura K, Akter S, Ali L. Screening for chronic kidney diseases among an adult population. <i>Saudi J Kidney Dis Transpl.</i> 2013; 24(3): 534-41.	2010-2012	*	
Bangladesh	Ryan ET, Dhar U, Khan WA, Salam MA, Faruque AS, Fuchs GJ, Calderwood SB, Bennis ML. Mortality, morbidity, and microbiology of endemic cholera among hospitalized patients in Dhaka, Bangladesh. <i>Am J Trop Med Hyg.</i> 2000; 63(1-2): 12-20.	1986-1996	*	
Bangladesh	World Health Organization (WHO). Bangladesh WHO Leishmaniasis Country Profile.	1999-2010	*	
Bangladesh	Wu J. Diarrheal diseases in rural Bangladesh: spatial-temporal patterns, risk factors and pathogen detection. <i>Diss Abstr Int.</i> 2011; 73(1).	2000-2006	*	
Bangladesh	International Council for the Control of Iodine Deficiency Disorders (ICCID), United Nations Children's Fund (UNICEF), University of Dhaka. Bangladesh National Iodine Deficiency Disorders Survey 1993.	1993		
Bangladesh	Institute of Public Health Nutrition (Bangladesh). Bangladesh National Iodine Deficiency Disorders Survey 1999.	1999		†
Bangladesh	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Bangladesh	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec.</i> 2007; 82(25): 225-32.	2006	*	
Bangladesh	World Health Organization (WHO). Global leprosy situation, 2008 (additional information). <i>Wkly Epidemiol Rec.</i> 2008; 83(50): 459.	2007	*	
Bangladesh	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Bangladesh	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Bangladesh	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Bangladesh	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Bangladesh	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Bangladesh	Bangladesh National Vitamin A Survey 1997-1998 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1997-1998		
Bangladesh	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Bangladesh	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Bangladesh	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Bangladesh	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Bangladesh	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Bangladesh	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1993; 68(25): 181-6.	1992	*	
Bangladesh	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Bangladesh	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Bangladesh	Filteau SM, Sullivan KR, Anwar US, Anwar ZR, Tomkins AM. Iodine deficiency alone cannot account for goitre prevalence among pregnant women in Modhupur, Bangladesh. <i>Eur J Clin Nutr.</i> 1994; 48(4): 293-302.	1994		†
Bangladesh	World Health Organization Regional Office for South-East Asia (SEARO). Situation Update of Dengue in the SEA Region, 2010. New Delhi, India: World Health Organization Regional Office for South-East Asia (SEARO).	2006-2009		
Bangladesh	WHO Regional Office for South-East Asia (SEARO). WHO South-East Asia Region: Reported Cases and Deaths of Dengue from 2003 to 2012. New Delhi, India: WHO Regional Office for South-East Asia (SEARO), 2013.	2003-2012	*	
Bangladesh	Ashraf H, Alam NH, Rothermundt C, Brooks A, Bardhan P, Hossain L, Salam MA, Hassan MS, Beglinger C, Gyr N. Prevalence and risk factors of hepatitis B and C virus infections in an impoverished urban community in Dhaka, Bangladesh. <i>BMC Infect Dis.</i> 2010; 10(1): 208.	2005-2006		
Bangladesh	Khan M, Mustafa MG, Ahmad N, Alam MS, Baig RH, Chowdhry ZR, Ahmed M. Seroprevalence of hepatitis C virus in rural population of Bangladesh. <i>Indian J Gastroenterol.</i> 2010; 29(1): 38-9.	2007-2008		
Bangladesh	Dhar SC, Ansari S, Saha M, Ahmad MM, Rahman MT, Hasan M, Khan AK. Gallstone disease in a rural Bangladeshi community. <i>Indian J Gastroenterol.</i> 2001; 20(6): 223-6.	1994-1995		
Bangladesh	Rahman M. Incidence of important blood groups in Bangladesh. <i>Bangladesh Med Res Counc Bull.</i> 1975; 1(1): 60-3.	1972-1974	*	†
Bangladesh	Rasul CH, Hasan MA, Yasmin F. Outcome of neonatal hyperbilirubinemia in a tertiary care hospital in bangladesh. <i>Malays J Med Sci.</i> 2010; 17(2): 40-4.	2005-2008	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Bangladesh	Mollah AH, Nahar N, Siddique MA, Anwar KS, Hassan T, Azam MG. Common transfusion-transmitted infectious agents among thalassaemic children in Bangladesh. <i>J Health Popul Nutr.</i> 2003; 21(1): 67-71.	2000-2001		
Bangladesh	Sheikh A, Sugitani M, Kimkawa N, Moriyama M, Arakawa Y, Komiyama K, Li T-C, Takeda N, Ishaque SM, Hasan M, Suzuki K. Hepatitis e virus infection in fulminant hepatitis patients and an apparently healthy population in Bangladesh. <i>Am J Trop Med Hyg.</i> 2002; 66(6): 721-4.	1995-1996		
Bangladesh	Zaki H, Darmstadt GL, Baten A, Ahsan CR, Saha SK. Seroepidemiology of hepatitis B and delta virus infections in Bangladesh. <i>J Trop Pediatr.</i> 2003; 49(6): 371-4.	1997-1998		
Bangladesh	Khan NZ, Muslima H, Parveen M, Bhattacharya M, Begum N, Chowdhury S, Jahan M, Darmstadt GL. Neurodevelopmental outcomes of preterm infants in Bangladesh. <i>Pediatrics.</i> 2006; 118(1): 280-9.	2001		†
Bangladesh	Bangladesh Programme to Eliminate Lymphatic Filariasis Country Report 2004 as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2001-2004	*	
Bangladesh	Ferdous J, Ahmed A, Dasgupta SK, Jahan M, Huda FA, Ronsmans C, Kobliński M, Chowdhury ME. Occurrence and determinants of postpartum maternal morbidities and disabilities among women in Matlab, Bangladesh. <i>J Health Popul Nutr.</i> 2012; 30(2): 143-158.	2007-2008	*	
Bangladesh	Fronczak N, Antelman G, Moran AC, Caulfield LE, Baqui AH. Delivery-related complications and early postpartum morbidity in Dhaka, Bangladesh. <i>Int J Gynaecol Obstet.</i> 2005; 91(3): 271-278.	1993-1995	*	
Bangladesh	United Nations Population Fund (UNFPA). South Asia Conference for the Prevention and Treatment of Obstetric Fistula. New York City, United States: United Nations Population Fund (UNFPA), 2004.	2003	*	
Bangladesh	Haque U, Ahmed SM, Hossain S, Huda M, Hossain A, Alam MS, Mondal D, Khan WA, Khalequzzaman M, Haque R. Malaria Prevalence in Endemic Districts of Bangladesh. <i>PLoS One.</i> 2009; 4(8): e6737 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2007	*	†
Bangladesh	Bangladesh Vital Registration Birth Data 1988 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1988		
Bangladesh	Cohen N, Rahman H, Sprague J, Jalil MA, Leemhuis de Regt E, Mitra M. Prevalence and determinants of nutritional blindness in Bangladeshi children. <i>World Health Stat Q.</i> 1985; 38(3): 317-30. as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1982-1983		
Bangladesh	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-2005		
Barbados	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Barbados	Smadja D, Cabre P, May F, Fanon J-L, René-Coraïl P, Riocreux C, Charpentier J-C, Fourmerie P, Saint-Vil M, Ketterlé J. ERMANCIA: Epidemiology of Stroke in Martinique, French West Indies. <i>Stroke.</i> 2001; 32(12): 2741-7.	1998-1999		
Barbados	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol.</i> 2008; 121(4): 947-954.	1994-1996, 2001, 2003		
Barbados	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000-2001, 2004, 2006-2009		
Barbados	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Barbados	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2001		
Barbados	Hennis A, Wu SY, Nemesure B, Li X, Leske MC, Barbados Eye Study Group. Diabetes in a Caribbean population: epidemiological profile and implications. <i>Int J Epidemiol.</i> 2002; 31(1): 234-9.	1990		
Barbados	Foster C, Rotimi C, Fraser H, Sundarum C, Liao Y, Gibson E, Holder Y, Hoyos M, Mellanson-King R. Hypertension, diabetes, and obesity in Barbados: findings from a recent population-based survey. <i>Ethn Dis.</i> 1993; 3(4): 404-12.	1992		
Barbados	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Barbados	Canino G, Shrout PE, Rubio-Stipec M, et al. The DSM-IV rates of child and adolescent disorders in Puerto Rico: Prevalence, correlates, service use, and the effects of impairment. <i>Arch Gen Psychiatry.</i> 2004; 61(1): 85-93.	1999-2000		
Barbados	Rubio-Stipec M, Canino GJ, Shrout P, Dulcan M, Freeman D, Bravo M. Psychometric properties of parents and children as informants in child psychiatry epidemiology with the Spanish Diagnostic Interview Schedule for Children (DISC.2). <i>J Abnorm Child Psychol.</i> 1994; 22(6): 703-20.	1992	*	
Barbados	Adams OP, Carter AO, Prussia P, McIntyre G, Branch SL. Risk behaviour, healthcare access and prevalence of infection with Chlamydia trachomatis and Neisseria gonorrhoeae in a population-based sample of adults in Barbados. <i>Sex Transm Infect.</i> 2008; 84(3): 192-4.	2003		
Barbados	Canino GJ, Bird HR, Shrout PE, Rubio-Stipec M, Bravo M, Martinez R, Sesman M, Guevara LM. The prevalence of specific psychiatric disorders in Puerto Rico. <i>Arch Gen Psychiatry.</i> 1987; 44(8): 727-35.	1984		
Barbados	Mahy GE, Mallett R, Left J, Bhugra D. First-contact incidence rate of schizophrenia on Barbados. <i>Br J Psychiatry.</i> 1999; 28-33.	1995		
Barbados	Hyman L, Wu SY, Connell AM, Schachat A, Nemesure B, Hennis A, Leske MC. Prevalence and causes of visual impairment in The Barbados Eye Study. <i>Ophthalmology.</i> 2001; 108(10): 1751-6. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1988-1992		
Barbados	Inter-American Drug Abuse Control Commission (CICAD). Organization of American States (OAS), National Council on Substance Abuse (Barbados). Barbados National Household Survey 2006.	2006		
Barbados	Inter-American Drug Abuse Control Commission (CICAD). Organization of American States (OAS). Barbados Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2006		
Barbados	Soyibo AK, Barton EN. Report from the Caribbean renal registry, 2006. <i>West Indian Med J.</i> 2007; 56(4): 355-63.	2006		
Barbados	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2001, 2007, 2010		
Barbados	Bird HR, Canino G, Rubio-Stipec M, Gould MS, Ribera J, Sesman M, Woodbury M, Huertas-Goldman S, Pagan A, Sanchez-Lacay A. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico. The use of combined measures. <i>Arch Gen Psychiatry.</i> 1988; 45(12): 1120-6.	1985-1986	*	
Barbados	Barbados Eye Study 1987-1992 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1987-1992		
Barbados	Jordan OW, Lipton RB, Stupnicka E, Cruickshank JK, Fraser HS. Incidence of type I diabetes in people under 30 years of age in Barbados, West Indies, 1982-1991. <i>Diabetes Care.</i> 1994; 17(5): 428-31.	1982-1991		
Barbados	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Barbados	Merikangas KR, Conway KP, Swendsen J, Febo V, Dierker L, Brunetto W, Stolar M, Canino G. Substance use and behaviour disorders in Puerto Rican youth: a migrant family study. <i>J Epidemiol Community Health.</i> 2009; 63(4): 310-6.	1990		
Barbados	Ministry of Health (Barbados). Barbados Annual Communicable Disease Surveillance Report 2009. St. Michael, Barbados: Ministry of Health (Barbados), 2011.	2000-2009	*	
Barbados	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Barbados	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Barbados	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Barbados	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Barbados	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Barbados	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Barbados	Olindo S, Cabre P, Deschamps R, Chatot-Henry C, René-Corail P, Fournerie P, Saint-Vil M, May F, Smadja D. Acute stroke in the very elderly: epidemiological features, stroke subtypes, management, and outcome in Martinique, French West Indies. <i>Stroke</i> . 2003; 34(7): 1593-7.	1998-1999		
Barbados	Edwards CN, Griffith SG, Hennis AJ, Hambleton IR. Inflammatory bowel disease: Incidence, prevalence, and disease characteristics in Barbados, West Indies. <i>Inflamm Bowel Dis</i> . 2008; 14(10): 1419-24.	1980-2004		
Barbados	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L. Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Ann Hepatol</i> . 2010; 9(1): 63-9.	2006-2008	*	
Barbados	Leske MC, Nemesure BB, He Q, Mendell N, Polednak A. Open-angle glaucoma and blood groups. The Barbados Eye Study. <i>Arch Ophthalmol</i> . 1996; 114(2): 205-10.	1988-1992	*	†
Barbados	Barbados Vital Registration Birth Data 1988 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1988		
Belarus	Ministry of Statistics and Analysis of the Republic of Belarus, United Nations Children's Fund (UNICEF). Belarus Multiple Indicator Cluster Survey 2005. New York, United States: United Nations Children's Fund (UNICEF).	2005	*	†
Belarus	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2005		
Belarus	National Statistical Committee of the Republic of Belarus, United Nations Children's Fund (UNICEF). Belarus Multiple Indicator Cluster Survey 2012. New York, United States: United Nations Children's Fund (UNICEF), 2013.	2012	*	
Belarus	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Belarus	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000-2002, 2005, 2007-2009		
Belarus	Shpakou A, Brožek G, Stryzhak A, Neviartovich T, Zejda J. Allergic diseases and respiratory symptoms in urban and rural children in Grodno Region (Belarus). <i>Pediatr Allergy Immunol</i> . 2012; 23(4): 339-46.	2010	*	
Belarus	Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version). Lyon, IARC. http://ci5.iarc.fr	2003-2007	*	
Belarus	Kulesh SD, Filina NA, Frantava NM, Zhytko NL, Kastinevich TM, Kliatskova LA, Shumskas MS, Hilz MJ, Schwab S, Kolominsky-Rabas PL. Incidence and Case-Fatality of Stroke on the East Border of the European Union The Grodno Stroke Study. <i>Stroke</i> . 2010; 41(12): 2726-30.	2001-2003		
Belarus	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2007, 2010, 2012		
Belarus	Martinucci ME, Curradi G, Fasulo A, Medici A, Toni S, Osovik G, Lapishtskaya E, Sherbitskaya E. Incidence of childhood type 1 diabetes mellitus in Gomel, Belarus. <i>J Pediatr Endocrinol Metab</i> . 2002; 15(1): 53-7.	1976-1999		
Belarus	Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M and Boyle P, eds (2007). Cancer Incidence in Five Continents, Vol. IX Periodic Data (electronic version). Lyon, IARC. http://ci5.iarc.fr	1998-2002	*	
Belarus	Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. Cancer Incidence in Five Continents. Vol. I to VIII. Lyon, France, IARC Press, 2005.	1983-1997	*	
Belarus	Gudkov VG, Tomal' LS, Rytik PG, Shket VA, Moroz AG. [Status of collective immunity to hepatitis A virus in urban residents in Byelorussia]. <i>Zh Mikrobiol Epidemiol Immunobiol</i> . 1992; 60-2.	1986-1990		
Belarus	Fisenka EG, Germanovich FA, Glinskaya IN, Lyabis OI, Rasuli AM. Effectiveness of universal hepatitis A immunization of children in Minsk City, Belarus: four-year follow-up. <i>J Viral Hepat</i> . 2008; 57-61.	2007		
Belarus	USSR - Byelorussian SSR Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Belgium	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2003-2009		
Belgium	Scientific Institute of Public Health (IPH) (Belgium), Statistics Belgium. Belgium Health Interview Survey 2004.	2004		
Belgium	World Health Organization (WHO). Belgium World Health Survey 2002. Geneva, Switzerland: World Health Organization (WHO), 2005.	2002		
Belgium	Center for Population and Family Studies (CBGS) (Belgium), United Nations Economic Commission for Europe (UNECE). Belgium Fertility and Family Survey 1991-1992. Geneva, Switzerland: United Nations Economic Commission for Europe (UNECE).	1991-1992		
Belgium	Eurostat, Statistics Belgium. Belgium European Union Statistics on Income and Living Conditions 2007.	2007		
Belgium	De Baquer D, De Backer G, Kornitzer M. Prevalences of ECG findings in large population based samples of men and women. <i>Heart</i> . 2000; 84(6): 625-33.	1998		
Belgium	Gulbis B, Cotton F, Ferster A, Ketelslegers O, Dresse MF, Rongé-Collard E, Minon JM, Lé PQ, Vertongen F. Neonatal haemoglobinopathy screening in Belgium. <i>J Clin Pathol</i> . 2009; 62(1): 49-52.	1994-2007		
Belgium	Gulbis B, Ferster A, Cotton F, Leboucard M, Cochaux P, Vertongen F. Neonatal haemoglobinopathy screening: review of a 10-year programme in Brussels. <i>J Med Screen</i> . 2006; 13(2): 76-78.	1994-2004		
Belgium	Thalassaemia International Federation, World Health Organization (WHO). Management of Haemoglobin Disorders: Report of a Joint WHO-TIF Meeting, Nicosia, Cyprus, 16-18 November 2007. Geneva, Switzerland: World Health Organization (WHO), 2008.	2004, 2006		
Belgium	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. <i>Scand J Clin Lab Invest</i> . 2007; 67(1): 39-69.	1988, 2006		
Belgium	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2006		
Belgium	De Schutter I, De Wachter E, Malfroot A, Soetens O, Pierard D, Crockaert F, Verhaegen J. Microbiology of bronchoalveolar lavage fluid in children with acute nonresponding or recurrent community-acquired pneumonia: Identification of nontypeable haemophilus influenzae as a major pathogen. <i>Clin Infect Dis</i> . 2011; 52(12): 1437-44.	2005		
Belgium	Nijsten T, Rombouts S, Lambert J. Acne is prevalent but use of its treatments is infrequent among adolescents from the general population. <i>J Eur Acad Dermatol Venerol</i> . 2007; 21(2): 163-8.	2004-2005		
Belgium	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol</i> . 2008; 121(4): 947-954.	1995, 2002		
Belgium	Van Hoeck KJ, Mahieu LM, Vaerenberg MH, van Acker KJ. A retrospective epidemiological study of bacterial meningitis in an urban area in Belgium. <i>Eur J Pediatr</i> . 1997; 156(4): 288-91.	1988-1993		
Belgium	Van Damme P, Giaquinto C, Huet F, Gotheffors L, Maxwell M, Van der Wielen M. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. <i>J Infect Dis</i> . 2007; 195 Suppl 1: 4-16.	2004-2005		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Belgium	Demyttenaere K, Bruffaerts R, Lee S, Posada-Villa J, Kovess V, Angermeyer MC, Levinson D, de Girolamo G, Nakane H, Mueinneh Z, Lara C, de Graaf R, Scott KM, Gureje O, Stein DJ, Haro JM, Bromet EJ, Kessler RC, Alonso J, Von Korff M. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. <i>Pain</i> . 2007; 129(3): 332-42.	2001-2002		
Belgium	Cardon G, De Bourdeaudhuij I, De Clercq D, Philippaerts RM, Verstraete S, Geldhof E. Physical Fitness, Physical Activity, and Self-Reported Back and Neck Pain in Elementary Schoolchildren. <i>Pediatr Exerc Sci</i> . 2004; 16(2): 147-157.	2001		
Belgium	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001-2009		
Belgium	Thomeer M, Demeds M, Vandeurzen K. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. <i>Acta Clin Belg</i> . 2001; 56(3): 163-72.	1992-1996		
Belgium	Van Ooteghem P, DHooghe MB, Vlietinck R, Carton H. Prevalence of multiple sclerosis in Flanders, Belgium. <i>Neuroepidemiology</i> . 1994; 13(5): 220-5.	1991		
Belgium	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J</i> . 1998; 12(2): 315-35.	1993-1995		
Belgium	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	2002		
Belgium	Scientific Institute of Public Health (IPH) (Belgium), Statistics Belgium. Belgium Health Interview Survey 2001.	2001		
Belgium	Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. <i>Diabetologia</i> . 1996; 39(11): 1377-84.	1993-1995		
Belgium	Van Acker K, Bouhassira D, De Bacquer D, Weiss S, Matthys K, Raemen H, Mathieu C, Colin IM. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. <i>Diabetes Metab</i> . 2009; 35(3): 206-13.	2006		
Belgium	Belgian Cancer Registry. Belgium Cancer Registry - Incidence. Brussels, Belgium: Belgian Cancer Registry.	2003-2010	*	
Belgium	Jarvis D, Newson R, Lovall J, Hastan D, Tomassen P, Keil T, Gjormarkaj M, Forsberg B, Gunnbjornsdottir M, Minov J, Brozek G, Dahlen SE, Toskala E, Kowalski ML, Olze H, Howarth P, Krämer U, Baelum J, Loureiro C, Kasper L, Bousquet PJ, Bousquet J, Bachert C, Fokkens W, Burney P. Asthma in adults and its association with chronic rhinosinusitis: the GALZEN survey in Europe. <i>Allergy</i> . 2012; 67(1): 91-8.	2008-2009	*	
Belgium	Claes N, Van Laethem C, Goethals M, Goethals P, Mairesse G, Schwagten B, Nuyens D, Schrooten W, Vijgen J. Prevalence of atrial fibrillation in adults participating in a large-scale voluntary screening programme in Belgium. <i>Acta Cardiol</i> . 2012; 67(3): 273-8.	2010	*	
Belgium	Govaere E, Van Gysel D, Verhamme KMC, Doli E, Oranje AP, De Baets F. The prevalence, characteristics of and risk factors for eczema in Belgian schoolchildren. <i>Pediatr Dermatol</i> . 2009; 26(2): 129-38.	2004-2005	*	
Belgium	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. <i>Community Dent Oral Epidemiol</i> . 1991; 19(2): 72-3.	1987		
Belgium	Dolphens M, Cagnie B, Coorevits P, Vanderstraeten G, Cardon G, Dhooghe R, Danneels L. Sagittal standing posture and its association with spinal pain: a school-based epidemiological study of 1196 Flemish adolescents before age at peak height velocity. <i>Spine</i> . 2012; 37(19): 1657-66.	2008-2009	*	
Belgium	Giaquinto C, van Damme P, REVEAL Study Group. Age distribution of paediatric rotavirus gastroenteritis cases in Europe: the REVEAL study. <i>Scand J Infect Dis</i> . 2010; 42(2): 142-7.	2004-2005	*	
Belgium	Roelands M, Wostyn P, Dom H, Baro F. The prevalence of dementia in Belgium: a population-based door-to-door survey in a rural community. <i>Neuroepidemiology</i> . 1994; 13(4): 155-61.	1990-1992		
Belgium	Vanobbergen J, Declercq D, Mwalili S, Martens L. The effectiveness of a 6-year oral health education programme for primary schoolchildren. <i>Community Dent Oral Epidemiol</i> . 2004; 32(3): 173-82.	1996-2001		
Belgium	Bolin AK, Bolin A, Koch G. Children's dental health in Europe: caries experience of 5- and 12-year-old children from eight EU countries. <i>Int J Paediatr Dent</i> . 1996; 6(3): 155-62.	1994		
Belgium	Carvalho JC, Declercq D, Vinckier F. Oral health status in Belgian 3- to 5-year-old children. <i>Clin Oral Investig</i> . 1998; 2(1): 26-30.	1995		
Belgium	Declercq D, Leroy R, Martens L, Lesaffre E, Garcia-Zattera M-J, Vanden Broucke S, Debyser M, Hoppenbrouwers K. Factors associated with prevalence and severity of caries experience in preschool children. <i>Community Dent Oral Epidemiol</i> . 2008; 36(2): 168-78.	2006		
Belgium	de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Künzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P. European Community Respiratory Health Survey Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. <i>Thorax</i> . 2004; 59(2): 120-125.	1991-1993		
Belgium	Bartholomeussen S, Vandenbroucke J, Truyers C, Truyers C, Buntinx F. Time trends in the incidence of peptic ulcers and oesophagitis between 1994 and 2003. <i>Br J Gen Pract</i> . 2007; 57(539): 497-9.	1994-1995, 2002-2003		
Belgium	Knight M, Callaghan WM, Berg C, Alexander S, Bouvier-Colle MH, Ford JB, Joseph KS, Lewis G, Liston RM, Roberts CL, Oats J, Walker J. Trends in postpartum hemorrhage in high resource countries: a review and recommendations from the International Postpartum Hemorrhage . <i>BMC Pregnancy Childbirth</i> . 2009; 9(55).	2002-2007		
Belgium	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2005		
Belgium	United States Renal Data System Coordinating Center. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2005.	2001-2003		
Belgium	De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology</i> . 2000; 54(11 Suppl 5): S21-23.	1997		
Belgium	Berger K BM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology</i> . 2000; 54(11): 24-7.	1997		
Belgium	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Belgium	Goubert L, Crombez G, De Bourdeaudhuij I. Low back pain, disability and back pain myths in a community sample: prevalence and interrelationships. <i>Eur J Pain</i> . 2004; 8(4): 385-94.	2001		
Belgium	Skovron ML, Szpalski M, Nordin M, Melot C, Cukier D. Sociocultural factors and back pain. A population-based study in Belgian adults. <i>Spine</i> . 1994; 19(2): 129-37.	1991		
Belgium	Nardone A, de Ory F, Carton M, Cohen D, van Damme P, Davidkin I, Rota MC, de Melker H, Mossong J, Slacikova M, Tischer A, Andrews N, Berbers G, Gabutti G, Gay N, Jones L, Jokinen S, Kafatos G, de Aragón MVM, Schneider F, Smetana Z, Vargova B, Vranckx R, Miller E. The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. <i>Vaccine</i> . 2007; 25(45): 7866-72.	2002		
Belgium	Thiry N, Beutels P, Shkedy Z, Vranckx R, Vandermeulen C, Wielen MVD, Damme PV. The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium). <i>Eur J Pediatr</i> . 2002; 161(11): 588-93.	1999-2000		
Belgium	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	2001		
Belgium	Deben K, Janssens de Varebeke S, Cox T, Van de Heyning P. Epidemiology of hearing impairment at three Flemish Institutes for Deaf and Speech Defective Children. <i>Int J Pediatr Otorhinolaryngol</i> . 2003; 67(9): 969-75.	1999-2000		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Belgium	McDowell RD, Ryan A, Bunting BP, O'Neill SM, Alonso J, Bruñaerts R, de Graaf R, Florescu S, Vilagut G, de Almeida JMC, de Girolamo G, Haro JM, Hinkov H, Kovess-Masfety V, Matschinger H, Tomov T. Mood and anxiety disorders across the adult lifespan: a European perspective. <i>Psychol Med.</i> 2013; 1-16.	2001-2002	*	
Belgium	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2005-2006		
Belgium	Boon P, De Deyn P, Hauman E, Mol L, Schmedding E, Vlietinck R, Willaert B. Epidemiology of Epilepsy in Flanders (Belgium). <i>Epilepsia.</i> 1995; 36(Suppl 3): S17-S17.	1993	*	
Belgium	Bracke P. Sex differences in the course of depression: evidence from a longitudinal study of a representative sample of the Belgian population. <i>Soc Psychiatry Psychiatr Epidemiol.</i> 1998; 33(9): 420-9.	1992		
Belgium	Lépine JP, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). <i>Int Clin Psychopharmacol.</i> 1997; 12(1): 19-29.	1995		
Belgium	Henrion J, Libon E, De Maeght S, Schapira M, Ghilain JM, Maisin JM, Heller FR. Surveillance for hepatocellular carcinoma: compliance and results according to the aetiology of cirrhosis in a cohort of 141 patients. <i>Acta Gastroenterol Belg.</i> 2000; 63(1): 5-9.	1995		
Belgium	Van Biesen W, De Bacquer D, Verbeke F, Delanghe J, Lameire N, Vanholder R. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. <i>Eur Heart J.</i> 2007; 28(4): 478-83.	1980-1984		
Belgium	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Belgium	Depuydt CE, Leuridan E, Van Damme P, Bogers J, Vereecken AJ, Donders GGG. Epidemiology of Trichomonas vaginalis and human papillomavirus infection detected by real-time PCR in flanders. <i>Gynecol Obstet Invest.</i> 2010; 70(4): 273-80.	2008	*	
Belgium	Noël J-C, Fayt I, Romero Munoz MR, Simon P, Engohan-Aloghe C. High prevalence of high-risk human papillomavirus infection among women with Trichomonas vaginalis infection on monolayer cytology. <i>Arch Gynecol Obstet.</i> 2010; 282(5): 503-5.	2005-2008	*	
Belgium	Bodéus M, Laffineur K, Kabamba-Mukadi B, Hubinont C, Bernard P, Goubau P. Seroepidemiology of herpes simplex type 2 in pregnant women in Belgium. <i>Sex Transm Dis.</i> 2004; 31(5): 297-300.	2001-2002	*	
Belgium	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant.</i> 1988; 3(6): 714-27.	1985		
Belgium	Van Dijk PC, Jager KJ, Stengel B, Grönhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). <i>Kidney Int.</i> 2005; 67(4): 1489-99.	1991-1992, 1999-2000		
Belgium	Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. <i>Nephrol Dial Transplant.</i> 2003; 18(9): 1824-33.	1990-1991, 1998-1999		
Belgium	De Sutter P, Dutré T, Vanden Meerschaut F, Stuyver I, Van Maele G, Dhont M. PCOS in lesbian and heterosexual women treated with artificial donor insemination. <i>Reprod Biomed Online.</i> 2008; 17(3): 398-402.	2002-2006		
Belgium	Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. <i>J Clin Endocrinol Metab.</i> 2008; 93(4): 1408-11.	2005		
Belgium	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Gilst WH van, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J.</i> 2003; 24(5): 442-63.	2000-2001		
Belgium	Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M and Boyle P, eds (2007). Cancer Incidence in Five Continents, Vol. IX Periodic Data (electronic version). Lyon, IARC. http://ci5.iarc.fr	1998-2002	*	
Belgium	Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. Cancer Incidence in Five Continents. Vol. I to VIII. Lyon, France, IARC Press, 2005.	1997-1998	*	
Belgium	Aertgeerts B, Buntinx F, Ansoms S, Fevery J. Screening properties of questionnaires and laboratory tests for the detection of alcohol abuse or dependence in a general practice population. <i>Br J Gen Pract.</i> 2001; 51(464): 206-17.	1998		
Belgium	Aertgeerts B, Buntinx F, Vandermeulen C, Roelants M, Fevery J, Ansoms S. [Prevalence of alcohol abuse and alcohol dependence according to DSM-IV criteria in first year university students]. <i>Ned Tijdschr Geneesk.</i> 1999; 143(52): 2621-4.	1995-1996		
Belgium	Avonts D, Seru M, Heyerick P, Vandermeeren I, Piot P. Sexually transmitted diseases and Chlamydia trachomatis in women consulting for contraception. <i>J R Coll Gen Pract.</i> 1989; 39(327): 418-20.	1989		
Belgium	Pebody RG, Andrews N, Brown D, Gopal R, De Melker H, François G, Gatcheva N, Hellenbrand W, Jokinen S, Klavs I, Kojouharova M, Kortbeek T, Kriz B, Proscenc K, Roubalova K, Teocharov P, Thierfelder W, Valle M, Van Damme P, Vranckx R. The seroepidemiology of herpes simplex virus type 1 and 2 in Europe. <i>Sex Transm Infect.</i> 2004; 80(3): 185-91.	1999-2000	*	
Belgium	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland: World Health Organization (WHO).	2004-2005	*	
Belgium	Annenmans L, Bresse X, Gobbo C, Papageorgiou M. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. <i>J Med Econ.</i> 2010; 13(3): 537-51.	2006		
Belgium	Avonts D, Piot P. Genital infections in women undergoing therapeutic abortion. <i>Eur J Obstet Gynecol Reprod Biol.</i> 1985; 20(1): 53-9.	1985		
Belgium	Van Hoecke F, Van Maerken T, De Boule M, Geerts A, Vlierbergh V, Colle I, Padalok HE. Hepatitis E seroprevalence in east and west Flanders, Belgium. <i>Acta Gastroenterol Belg.</i> 2012; 75(3): 322-4.	2011	*	
Belgium	Lapeere H, Naeyaert J-M, De Weert J, De Maeseneer J, Brochez L. Incidence of scabies in Belgium. <i>Epidemiol Infect.</i> 2008; 136(3): 395-8.	2004	*	
Belgium	Boemer F, Vanbellingen J-F, Bours V, Schoors R. Screening for sickle cell disease on dried blood: a new approach evaluated on 27,000 Belgian newborns. <i>J Med Screen.</i> 2006; 13(3): 132-6.	2003-2005	*	
Belgium	Tshilolo L, Gulbis B, Barlow P, Damis E, Denis-Song R, Ferster A, Haumont D, Vanderpas JB, Pardou A, Schwes J, Vokaer A, Vertongen F. [Neonatal screening for hemoglobinopathies in the Brussels region]. <i>Rev Med Brux.</i> 1997; 18(2): 70-3.	1994-1996	*	
Belgium	Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overved K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PHM, Lund E, Quiros JR, González CA, Sanchez Perez M-J, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu L, Chuang S-C, Murphy N, Boffetta P, Trichopoulos A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. <i>J Natl Cancer Inst.</i> 2011; 103(22): 1686-95.	1992-2006	*	
Belgium	Coester CH, Avonts D, Colaert J, Desmyter J, Piot P. Syphilis, hepatitis A, hepatitis B, and cytomegalovirus infection in homosexual men in Antwerp. <i>Br J Vener Dis.</i> 1984; 60(1): 48-51.	1981-1982		
Belgium	Vranckx R, Muyile L, Cole J. In Belgium, viral hepatitis A is predominantly childhood disease. <i>Rev Epidemiol Sante Publique.</i> 1984; 32(6): 366-9.	1982		
Belgium	Vranckx R. Hepatitis A virus infections in Belgian children. <i>Infection.</i> 1993; 21(3): 168-70.	1990-1992		
Belgium	Jacques P, Moens G, Van Damme P, Goubau P, Vranckx R, Steeno J, Muyile L, Desmyter J. Increased risk for hepatitis A among female day nursery workers in Belgium. <i>Occup Med (Lond).</i> 1994; 44(5): 259-61.	1991		
Belgium	Beutels M, Van Damme P, Vranckx R, Meheus A. The shift in prevalence of hepatitis A immunity in Flanders, Belgium. <i>Acta Gastroenterol Belg.</i> 1998; 4-7.	1993-1994		
Belgium	Vranckx R, Jacques P, Moens G. Prevalence of hepatitis A antibodies in a large sample of Belgian health care workers. <i>Infection.</i> 1999; 27(4-5): 256-8.	1996-1997		
Belgium	Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, Tolonen H, Ruokokoski E. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. <i>Lancet.</i> 1999; 353(9164): 1547-57.	1980-1995		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Belgium	Beutels M, Van Damme P, Aelvoet W, Desmyter J, Dondeyne F, Gollay C, Mak R, Muylle L, Pierard D, Stroobant A, Van Look F, Waumans P, Vranckx R. Prevalence of hepatitis A, B and C in the Flemish population. <i>Eur J Epidemiol.</i> 1997; 13(3): 275-80.	1993-1994		
Belgium	De Schrijver K, Maes I, Van Damme P, Tersago J, Moës E, Van Ranst M. An outbreak of nosocomial hepatitis B virus infection in a nursing home for the elderly in Antwerp (Belgium). <i>Acta Clin Belg.</i> 2005; 60(2): 63-9.	2002-2003		
Belgium	Quoilin S, Hutse V, Vandenberghe H, Claeys F, Verhaegen E, De Cock L, Van Look F, Top G, Van Damme P, Vranckx R, Van Oyen H. A population-based prevalence study of hepatitis A, B and C virus using oral fluid in Flanders, Belgium. <i>Eur J Epidemiol.</i> 2007; 22(3): 195-202.	2003		
Belgium	Van Damme P, Thyssen A, Van Look F. Epidemiology of hepatitis C in Belgium: present and future. <i>Acta Gastroenterol Belg.</i> 2002; 65(2): 78-9.	1993-1994		
Belgium	Castillo Taucher S. [Services for the care and prevention of birth defects. Reduced report of a World Health Organization and March of Dimes Foundation meeting]. <i>Rev Med Chil.</i> 2007; 135(6): 806-13.	1990-2006		
Belgium	Belgium - Ghent Coronary Event Registry Data 1983-1992, 1996-2006, provided by Global Burden of Disease 2010 Ischemic Heart Disease Expert Group. [Unpublished].	1983-1992, 1996-2006		
Belgium	Van Kerschaver E, Boudevyns AN, Declau F, Van de Heyning PH, Wuyts FL. Socio-demographic determinants of hearing impairment studied in 103,835 term babies. <i>Eur J Public Health.</i> 2013; 23(1): 55-60.	2003-2004	*	
Belgium	Zaitan J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT; 2008. Available from: http://www.perinataleaudit.nl/downloads/bestand/649/peristat-ii-2008-	2004		†
Belgium	Belgium Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Belgium	Belgium Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Belgium	Belgium Renal Replacement Therapy Data 1997 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 1998. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2003.	1997	*	
Belgium	Belgium Vital Registration Birth Data 1992 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1992		
Belgium	European Surveillance of Congenital Anomalies (EUROCAT), University of Ulster. Belgium EUROCAT Prevalence Tables. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	1980-2011		
Belgium	Belgium - Hainaut-Namur Congenital Anomaly Registry Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Belgium	Belgium - Antwerp Congenital Anomaly Data 1993-1998 - EUROCAT as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Belize	Statistical Institute of Belize, United Nations Children's Fund (UNICEF). Belize Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006	*	†
Belize	Belize Central Statistical Office (CSO), Belize Family Life Association, Division of Reproductive Health-Centers for Disease Control and Prevention (CDC), Ministry of Health (Belize). Belize Family Health Survey 1991. Atlanta, United States: Centers for Disease Control and Prevention (CDC).	1991		
Belize	Statistical Institute of Belize, United Nations Children's Fund (UNICEF). Belize Multiple Indicator Cluster Survey 2011. New York, United States: United Nations Children's Fund (UNICEF), 2013.	2011	*	†
Belize	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-1992, 1995-2005		
Belize	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Belize	Smadja D, Cabre P, May F, Fanon J-L, René-Corail P, Riocreux C, Charpentier J-C, Fourmerie P, Saint-Vil M, Ketterlé J. ERMANCIA: Epidemiology of Stroke in Martinique, French West Indies. <i>Stroke.</i> 2001; 32(12): 2741-7.	1998-1999		
Belize	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998, 2002-2009		
Belize	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Belize	Canino G, Shrout PE, Rubio-Stipec M, et al. The DSM-IV rates of child and adolescent disorders in Puerto Rico: Prevalence, correlates, service use, and the effects of impairment. <i>Arch Gen Psychiatry.</i> 2004; 61(1): 85-93.	1999-2000		
Belize	Rubio-Stipec M, Canino GJ, Shrout P, Dulcan M, Freeman D, Bravo M. Psychometric properties of parents and children as informants in child psychiatry epidemiology with the Spanish Diagnostic Interview Schedule for Children (DISC.2). <i>J Abnorm Child Psychol.</i> 1994; 22(6): 703-20.	1992	*	
Belize	Canino GJ, Bird HR, Shrout PE, Rubio-Stipec M, Bravo M, Martinez R, Sesman M, Guevara LM. The prevalence of specific psychiatric disorders in Puerto Rico. <i>Arch Gen Psychiatry.</i> 1987; 44(8): 727-35.	1984		
Belize	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Belize Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2005		
Belize	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 2001, 2004, 2007, 2010, 2012		
Belize	Bird HR, Canino G, Rubio-Stipec M, Gould MS, Ribera J, Sesman M, Woodbury M, Huertas-Goldman S, Pagan A, Sanchez-Lacay A. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico. The use of combined measures. <i>Arch Gen Psychiatry.</i> 1988; 45(12): 1120-6.	1985-1986	*	
Belize	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Belize	Merikangas KR, Conway KP, Swendsen J, Febo V, Dierker L, Brunetto W, Stolar M, Canino G. Substance use and behaviour disorders in Puerto Rican youth: a migrant family study. <i>J Epidemiol Community Health.</i> 2009; 63(4): 310-6.	1990		
Belize	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Belize	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Belize	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Belize	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Belize	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Belize	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Belize	Olando S, Cabre P, Deschamps R, Chatot-Henry C, René-Corail P, Fournier P, Saint-Vil M, May F, Smadja D. Acute stroke in the very elderly: epidemiological features, stroke subtypes, management, and outcome in Martinique, French West Indies. Stroke. 2003; 34(7): 1593-7.	1998-1999		
Belize	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artoya Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L, Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. Ann Hepatol. 2010; 9(1): 63-9.	2006-2008	*	
Belize	Craig PG, Bryan JP, Miller RE, Reyes L, Hakre S, Jaramillo R, Krieg RE. The prevalence of hepatitis A, B and C infection among different ethnic groups in Belize. Am J Trop Med Hyg. 1993; 49(4): 430-4.	1992		
Belize	Chamberlin J, Bryan JP, Jones DL, Reyes L, Hakre S. Seroprevalence of hepatitis B virus among school-age children in the Stann Creek District of Belize, Central America. Am J Trop Med Hyg. 1996; 55(4): 452-5.	1995		
Belize	Pan American Health Organization (PAHO), World Health Organization (WHO). Quantitative Estimation of Chagas in the Americas.	2005	*	
Belize	Belize Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Benin	National Institute of Statistics and Economic Analysis (INSAE) (Benin), International Statistical Institute. Benin World Fertility Survey 1981-1982. Voorburg, Netherlands: International Statistical Institute.	1981-1982		
Benin	Macro International, Inc, National Institute of Statistics and Economic Analysis (INSAE) (Benin), Benin Demographic and Health Survey 1996. Calverton, United States: Macro International, Inc.	1996		†
Benin	National Institute of Statistics and Economic Analysis (INSAE) (Benin), ORC Macro. Benin Demographic and Health Survey 2001. Calverton, United States: ORC Macro.	2001		†
Benin	Macro International, Inc, National Institute of Statistics and Economic Analysis (INSAE) (Benin), National Program Against AIDS (PNLS) (Benin), Benin Demographic and Health Survey 2006. Calverton, United States: Macro International, Inc.	2006		†
Benin	Ministry of Health (Benin), World Health Organization (WHO). Benin - Littoral STEPS Noncommunicable Disease Risk Factors Survey 2007.	2007		
Benin	Ministry of Health (Benin), World Health Organization (WHO). Benin STEPS Noncommunicable Disease Risk Factors Survey 2008.	2008		
Benin	ICF International, National Institute of Statistics and Economic Analysis (INSAE) (Benin), National Program Against AIDS (PNLS) (Benin), Benin Demographic and Health Survey 2011-2012. Fairfax, United States: ICF International, 2014.	2011-2012	*	†
Benin	Benin Demographic and Health Survey 2011-2012 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2011-2012	*	†
Benin	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Benin	Rahimy MC, Gangbo A, Ahouignan G, Alihonou E. Newborn screening for sickle cell disease in the Republic of Benin. J Clin Pathol. 2009; 62(1): 46-8.	1993-1996		
Benin	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	2009		†
Benin	Filippi V, Ronsmans C, Gohou V, Goufodji S, Lardi M, Sahel A, Saizonou J, De Brouwere V. Maternity wards or emergency obstetric rooms? Incidence of near-miss events in African hospitals. Acta Obstet Gynecol Scand. 2005; 84(1): 11-6.	1999-2001		
Benin	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1996-1998		
Benin	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1995-1997, 1999-2009		
Benin	Mutebi J-P, Barrett ADT. The epidemiology of yellow fever in Africa. Microbes Infect. 2002; 4(14): 1459-68.	1996		
Benin	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Benin	Guerchet M, Houinato D, Paraiso MN, von Ahnen N, Nubukpo P, Otto M, Clément J-P, Preux P-M, Dartigues J-F. Cognitive impairment and dementia in elderly people living in rural Benin, west Africa. Dement Geriatr Cogn Disord. 2009; 27(1): 34-41.	2007		
Benin	Paraiso MN, Guerchet M, Saizonou J, Cowppli-Bony P, Mouanga AM, Nubukpo P, Preux P-M, Houinato DS. Prevalence of dementia among elderly people living in Cotonou, an urban area of Benin (West Africa). Neuroepidemiology. 2011; 36(4): 245-51.	2008		
Benin	Filippi V, Ronsmans C, Gohou V, Goufodji S, Lardi M, Sahel A, Saizonou J, De Brouwere V. Maternity wards or emergency obstetric rooms? Incidence of near-miss events in African hospitals. Acta Obstet Gynecol Scand. 2005; 84(1): 11-16.	1999-2000		
Benin	Filippi V, Alihonou E, Mukantaganda S, Graham WJ, Ronsmans C. Near misses: maternal morbidity and mortality. Lancet. 1998; 351(9096): 145-6.	1995-1996		
Benin	Houinato D, Yemadjé L-P, Gliho G, Adjien C, Avode G, Druet-Cabanac M, Preux P-M. Epidemiology of epilepsy in rural Benin: prevalence, incidence, mortality, and follow-up. Epilepsia. 2013; 54(4): 757-63.	2005	*	
Benin	Yemadjé L-P, Houinato D, Boumédjène F, Ngoungou EB, Preux P-M, Druet-Cabanac M. Prevalence of epilepsy in the 15 years and older in Benin: a door-to-door nationwide survey. Epilepsy Res. 2012; 99(3): 318-26.	2010	*	
Benin	Cossi M-J, Gobron C, Preux P-M, Niama D, Chabriat H, Houinato D. Stroke: prevalence and disability in Cotonou, Benin. Cerebrovasc Dis. 2012; 33(2): 166-72.	2008-2009	*	
Benin	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Benin	Béhanzin L, Diabaté S, Minani I, Lowndes CM, Boily M-C, Labbé A-C, Anagonou S, Zannou DM, Buvé A, Alary M. Decline in HIV prevalence among young men in the general population of Cotonou, Benin, 1998-2008. PLoS One. 2012; 7(8): e43818.	1998, 2008	*	
Benin	Négrel AD, Avognon Z, Minassian DC, Babagbeto M, Oussa G, Bassabi S. [Blindness in Benin]. Med Trop (Mars). 1995; 55(4 Pt 2): 409-14, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1990		
Benin	Dovonou A, Adoukonou T, Sanni A, Gandaho P. [Major salmonellosis in Benin]. Med Trop (Mars). 2011; 71(6): 634-5.	2005-2007	*	
Benin	Houinato D, Adoukonou T, Nisiba F, Adjien C, Avode D-G, Preux P-M. Prevalence of migraine in a rural community in south Benin. Cephalalgia. 2010; 30(1): 62-7.	2003	*	†
Benin	Damien GB, Djénontin A, Rogier C, Corbel V, Bangana SB, Chandre F, Akogbeto M, Kindé-Gazard D, Massougboji A, Henry M-C. Malaria infection and disease in an area with pyrethroid-resistant vectors in southern Benin. Malar J. 2010; 9(1): 380 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2007	*	†
Benin	Nahum A, Erhart A, Mayé A, Ahounou D, van Overmeir C, Menten J, van Loen H, Akogbeto M, Coosemans M, Massougboji A, D'Alessandro U. Malaria incidence and prevalence among children living in a peri-urban area on the coast of Benin, west Africa: a longitudinal study. Am J Trop Med Hyg. 2010; 83(3): 465-73, as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003-2004	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Benin	Myung K, Massougbdji A, Ekoue S, Atchade P, Kiki-Fagla V, Klion AD. Lymphatic filariasis in a hyperendemic region: a ten-year, follow-up panel survey. <i>Am J Trop Med Hyg.</i> 1998; 59(2): 222-6. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1983, 1993	*	
Benin	Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jamin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. <i>Int J Health Geogr.</i> 2010; 9: 57.	1980-2010		
Benin	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec.</i> 2005; 80(13): 118-24.	2003	*	
Benin	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec.</i> 2006; 81(32): 309-16.	2005	*	
Benin	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Benin	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Benin	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Benin	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Benin	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Benin	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Benin	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Benin	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Benin	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Benin	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Benin	Weiss HA, Buvé A, Robinson NJ, Van Dyck E, Kahindo M, Anagonou S, Musonda R, Zekeng L, Morison L, Caraël M, Laga M, Hayes RJ. Study Group on Heterogeneity of HIV Epidemics in African Cities. The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. <i>AIDS.</i> 2001; 15(9): 977-108.	1997-1998	*	
Benin	Cresta M, Avoundgoba N. Risultati dello studio longitudinale dalla nascita a 5 anni in un gruppo di bambini di Porto Novo (Repubblica Popolare del Benin). <i>Riv Antropol.</i> 1980; 43-132.	1975-1976	*	
Benin	Akogbeto M, Modiano D, Bosman A. Malaria transmission in the lagoon area of Cotonou, Benin. <i>Parassitologia.</i> 1992; 34(1-3): 147-54 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1989-1990	*	†
Benin	Djivoh C, Massougbdji A, Turk P, Fayomi E, Gay F, Danis M. [Low levels of chloroquine resistance of Plasmodium falciparum in the province of Zou in Benin]. <i>Bull Soc Pathol Exot.</i> 1988; 81(3): 332-7 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Benin	Migot-Nabias F, Noupko JM, Guillard E, Doritchamou J, Garcia A, Dugoujon J-M. Imbalanced Distribution of GM Immunoglobulin Allotypes According to the Clinical Presentation of Plasmodium falciparum Malaria in Beninese Children. <i>J Infect Dis.</i> 2008; 198(12): 1892-5 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Benin	Raccurt CP, Arouko H, Djossou F, Macaigne F, Massougbdji A, Zohoun T, Sadeler BC, Ripert C. [In vivo amodiaquine sensitivity of Plasmodium falciparum the town of Cotonou and in the vicinity (Bénin)]. <i>Med Trop (Mars).</i> 1990; 50(1): 21-6 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Benin	Wang SJ, Lengeler C, Smith TA, Vounatsou P, Akogbeto M, Tanner M. Rapid Urban Malaria Appraisal (RUMA) IV: epidemiology of urban malaria in Cotonou (Benin). <i>Malar J.</i> 2006; 5: 45 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Benin	Monitoring the Chemosensitivity of Plasmodium Falciparum to Antimalarials in West Africa as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Bhutan	Ministry of Health (Bhutan), World Health Organization (WHO). Bhutan - Thimphu STEPS Noncommunicable Disease Risk Factors Survey 2007.	2007		
Bhutan	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Bhutan	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000, 2009		
Bhutan	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Bhutan	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Bhutan	Giri BR, Sharma KP, Chapagai RN, Palzom D. Diabetes and hypertension in urban bhutanesen men and women. <i>Indian J Community Med.</i> 2013; 38(3): 138-43.	2008		
Bhutan	World Health Organization (WHO). Bhutan WHO Leishmaniasis Country Profile.	2005-2010	*	
Bhutan	Bhutan National Nutrition Survey 1986-1988 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1986-1988		
Bhutan	Bhutan Vitamin A Deficiency Survey 1999 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1999		
Bhutan	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Bhutan	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec.</i> 2007; 82(25): 225-32.	2006	*	
Bhutan	World Health Organization (WHO). Global leprosy situation, 2008 (additional information). <i>Wkly Epidemiol Rec.</i> 2008; 83(50): 459.	2007	*	
Bhutan	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Bhutan	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Bhutan	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Bhutan	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Bhutan	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Bhutan	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Bhutan	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Bhutan	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Bhutan	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Bhutan	Bhutan Iodine Deficiency Disorders 1992 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1991-1992		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Bhutan	Bhutan Tracking Progress Towards Sustainable Elimination of Iodine Deficiency Disorders 1996 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1996		
Bhutan	Bhutan Cyclic Monitoring Survey Report 2000 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2000		
Bhutan	Bhutan Cyclic Monitoring Survey Report 1998 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1998		
Bhutan	Bhutan Cyclic Monitoring Survey Report 1999 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1999		
Bhutan	World Health Organization Regional Office for South-East Asia (SEARO). Reported Cases of DF/DHF in Selected Countries in SEA Region. New Delhi, India: World Health Organization Regional Office for South-East Asia (SEARO).	2004-2006		
Bhutan	World Health Organization Regional Office for South-East Asia (SEARO). Situation Update of Dengue in the SEA Region, 2010. New Delhi, India: World Health Organization Regional Office for South-East Asia (SEARO).	2007-2009		
Bhutan	WHO Regional Office for South-East Asia (SEARO). WHO South-East Asia Region: Reported Cases and Deaths of Dengue from 2003 to 2012. New Delhi, India: WHO Regional Office for South-East Asia (SEARO), 2013.	2003-2012	*	
Bhutan	Da Villa G, Andjaparidze A, Cautelli M, Franco E, Roggendorf M, Sepe A, Zaratti L. Viral hepatitis in the Bhutanese population: preliminary results of a seroepidemiological investigation. Res Virol. 1997; 148(2): 115-7.	1995-1997		
Bolivia	Population Development and Environment (PODEMA), National Directorate of Epidemiology (Bolivia), United Nations Children's Fund (UNICEF). Bolivia Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	
Bolivia	Macro International, Inc, National Institute of Statistics (Bolivia). Bolivia Demographic and Health Survey 1998. Calverton, United States: Macro International, Inc.	1998		†
Bolivia	Macro Systems, Inc.; Institute for Resource Development, National Institute of Statistics (Bolivia). Bolivia Demographic and Health Survey 1989. Columbia, United States: Macro Systems, Inc.	1989		†
Bolivia	Macro International, Inc, National Institute of Statistics (Bolivia). Bolivia Demographic and Health Survey 1993-1994. Calverton, United States: Macro International, Inc.	1993-1994		†
Bolivia	Macro International, Inc, Ministry of Health and Sports (Bolivia), National Institute of Statistics (Bolivia). Bolivia Demographic and Health Survey 2003-2004. Calverton, United States: Macro International, Inc.	2003-2004		†
Bolivia	Macro International, Inc, Ministry of Health and Sports (Bolivia), National Institute of Statistics (Bolivia). Bolivia Demographic and Health Survey 2008. Calverton, United States: Macro International, Inc.	2008		†
Bolivia	World Health Organization (WHO). Control of Foodborne Trematode Infections 1995. Geneva, Switzerland: World Health Organization (WHO), 1995.	1995	*	
Bolivia	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1993-1994, 1996-2002		
Bolivia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Bolivia	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Bolivia	Pan American Health Organization (PAHO), Southern Cone Initiative (INCOSUR). XIth Meeting of the Intergovernmental Committee for the Elimination of Triatoma Infestans and the Interruption of American Trypanosomiasis by Transfusion. Washington, D.C., United States: Pan American Health Organization (PAHO), 2002.	2001		
Bolivia	De Oliveira LH, Danovaro-Holliday MC, Andrus JK, de Fillipsis AMB, Gentsch J, Matus CR, Widdowson M-A. Sentinel hospital surveillance for rotavirus in Latin American and Caribbean countries. J Infect Dis. 2009; 200 Suppl 1: 131-139.	2006-2007		
Bolivia	Róost M, Altamirano V, Liljestrand J, Essén B. Priorities in emergency obstetric care in Bolivia – maternal mortality and near-miss morbidity in metropolitan La Paz. BJOG. 2009; 116(9): 1210-7.	2006-2007		
Bolivia	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1980-1998		
Bolivia	Pan American Health Organization (PAHO). Update on yellow fever in the Americas. Epidemiol Bull. 2000; 21(2):13.	1985-1995		
Bolivia	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1985-1986, 2004-2005, 2008-2009		
Bolivia	Vasconcelos PF da C. Febre amarela. Rev Soc Bras Med Trop. 2003; 36(2): 275-93.	1980-2001		
Bolivia	Pan American Health Organization (PAHO). Yellow Fever: Number of Cases and Deaths, 1960-2007. Washington, D.C., United States: Pan American Health Organization (PAHO), 2007.	2007		
Bolivia	Sylvatic yellow fever outbreak in Bolivia. EPI Newsl. 1999; 1(21): 1-3.	1999		
Bolivia	World Health Organization (WHO). Yellow fever in Africa and South America, 2006. Wkly Epidemiol Rec. 2008; 83(8): 60-76.	2006		
Bolivia	World Health Organization (WHO). Yellow fever in Africa and South America, 2007. Wkly Epidemiol Rec. 2009; 84(13): 97-104.	2007		
Bolivia	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2003		
Bolivia	Salas Clavijo NA, Postigo JR, Schneider D, Santalla JA, Brutus L, Chippaux J-P. Prevalence of Chagas disease in pregnant women and incidence of congenital transmission in Santa Cruz de la Sierra, Bolivia. Acta Trop. 2012; 124(1): 87-91.	2006-2008		
Bolivia	Sosa-Estani S, Gamboa-León MR, Del Cid-Lemus J, Althabe F, Alger J, Almendares O, Cafferata ML, Chippaux J-P, Dumontel E, Gibbons L, Padilla-Raygoza N, Schneider D, Belizán JM, Buekens P, Working Group. Use of a rapid test on umbilical cord blood to screen for Trypanosoma cruzi infection in pregnant women in Argentina, Bolivia, Honduras, and Mexico. Am J Trop Med Hyg. 2008; 79(5): 755-9.	2006-2007		
Bolivia	Medrano-Mercado N, Ugarte-Fernandez R, Butrón V, Uber-Busek S, Guerra HL, Araújo-Jorge TC de, Correa-Oliveira R. Urban transmission of Chagas disease in Cochabamba, Bolivia. Mem Inst Oswaldo Cruz. 2008; 103(5): 423-30.	1995-1999		
Bolivia	Brutus L, Schneider D, Postigo J, Romero M, Santalla J, Chippaux JP. Congenital Chagas disease: diagnostic and clinical aspects in an area without vectorial transmission, Bermejo, Bolivia. Acta Trop. 2008; 106(3): 195-9.	2002-2004		
Bolivia	Chippaux J-P, Postigo JR, Santalla JA, Schneider D, Brutus L. Epidemiological evaluation of Chagas disease in a rural area of southern Bolivia. Trans R Soc Trop Med Hyg. 2008; 102(6): 578-84.	2007		
Bolivia	Mallol J, Solé D, Baeza-Bacab M, Aguirre-Camposano V, Soto-Quiros M, Baena-Cagnani C, Latin American ISAAC Group. Regional variation in asthma symptom prevalence in Latin American children. J Asthma. 2010; 47(6): 644-50.	2001-2003	*	
Bolivia	Gonzales L, Sanchez S, Zambrana S, Iniguez V, Wiklund G, Svennerholm A-M, Sjöling A. Molecular characterization of enterotoxigenic Escherichia coli isolates recovered from children with diarrhea during a 4-year period (2007 to 2010) in Bolivia. J Clin Microbiol. 2013; 51(4): 1219-25.	2007-2010	*	
Bolivia	Rodas C, Mamani R, Blanco J, Blanco JE, Wiklund G, Svennerholm A-M, Sjöling A, Iniguez V. Enterotoxins, colonization factors, serotypes and antimicrobial resistance of enterotoxigenic Escherichia coli (ETEC) strains isolated from hospitalized children with diarrhea in Bolivia. Braz J Infect Dis. 2011; 15(2): 132-7.	2002-2006	*	
Bolivia	Nicoletti A, Sofia V, Giuffrida S, Bartoloni A, Bartalesi F, Bartolo MLL, Ferno SL, Cocuzza V, Gamboa H, Salazar E, Reggio A. Prevalence of Stroke: A Door-to-Door Survey in Rural Bolivia. Stroke. 2000; 31(4): 882-5.	1994		
Bolivia	Nicoletti A, Sofia V, Bartoloni A, Bartalesi F, Gamboa Barahon H, Giuffrida S, Reggio A. Prevalence of Parkinson's disease: a door-to-door survey in rural Bolivia. Parkinsonism Relat Disord. 2003; 10(1): 19-21.	1994		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Bolivia	Bartoloni A, Bartalesi F, Roselli M, Mantella A, Dini F, Carballo ES, Barron VP, Paradisi F. Seroprevalence of varicella zoster and rubella antibodies among rural populations of the Chaco region, south-eastern Bolivia. <i>Trop Med Int Health</i> . 2002; 7(6): 512-7.	1997		
Bolivia	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Bolivia Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2004-2005		
Bolivia	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), United Nations Office on Drugs and Crime (UNODC). Youth and Drugs in South American Countries: A Public Policy Challenge 2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2006.	2005		
Bolivia	Nicoletti A, Bartoloni A, Sofia V, Bartalesi F, Chavez JR, Osinaga R, Paradisi F, Dumas JL, Tsang VCW, Reggio A, others. Epilepsy and Neurocysticercosis in Rural Bolivia: A Population-based Survey. <i>Epilepsia</i> . 2005; 46(7): 1127-32.	1994		†
Bolivia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Bolivia	Vergnes H, Larrouy G. G6PD deficiency in populations of the Bolivian Andes. <i>Nouv Rev Fr Hematol</i> . 1967; 7(1): 124-8.	1965-1967		
Bolivia	Fernández-Cean J, González-Martínez F, Schwedt E, Mazzuchi N. Renal replacement therapy in Latin America. <i>Kidney Int</i> . 2000; 57(s74): 55-59.	1997		
Bolivia	Cusumano A, García-García G, Di Gioia C, Hermida O, Lavorato C, Carreño CA, Torrico MP, Batista PB, Romão JE, Badal HP, Miranda SE, Gomez R, Calderon MC, Sanchez SH, Lopez MA, Moscoso J, Merino RL, Polo JV, Lopez A, Romero NJ, García R, Acosta BV, Lopez AS, Delpin ES, Mena E, González C, Milanés CL, Acchiardo S. End-stage renal disease and its treatment in Latin America in the twenty-first century. <i>Ren Fail</i> . 2006; 28(8): 631-7.	1999		
Bolivia	Masuet-Aumatell C, Ramon-Torrell JM, Casanova-Rituerto A, Banqué-Navarro M, Dávalos-Gamboa MDR, Montaña-Rodríguez SL. Seroprevalence of varicella-zoster virus infection in children from Cochabamba: tropical or temperate pattern <i>Trop Med Int Health</i> . 2013; 18(3): 296-302.	2010	*	
Bolivia	Villazón-Vargas N, Conde-Glez CJ, Juárez-Figueroa L, Uribe-Salas F. [Evaluation of a rapid diagnostic test to assess the prevalence of maternal syphilis in Bolivia]. <i>Rev Med Chil</i> . 2009; 137(4): 515-21.	2003		
Bolivia	Tinajeros F, Grossman D, Richmond K, Steele M, García SG, Zegarra L, Revollo R. Diagnostic accuracy of a point-of-care syphilis test when used among pregnant women in Bolivia. <i>Sex Transm Infect</i> . 2006; v17-21.	2004		
Bolivia	Revollo R, Tinajeros F, Hilarí C, García SG, Zegarra L, Díaz-Olivarrieta C, Conde-González CJ. [Maternal and congenital syphilis in four provinces in Bolivia]. <i>Salud Publica Mex</i> . 2007; 49(6): 422-8.	2004		
Bolivia	World Health Organization (WHO). Bolivia WHO Leishmaniasis Country Profile.	1997-2010	*	
Bolivia	Bolivia Meeting the Challenge of Iodine Deficiency as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1989		
Bolivia	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec</i> . 1999; 74(38): 313-6.	1998	*	
Bolivia	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec</i> . 2001; 76(23): 173-9.	2000	*	
Bolivia	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec</i> . 2000; 75(28): 226-31.	1999	*	
Bolivia	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1994; 69(20): 145-51.	1993	*	
Bolivia	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec</i> . 1997; 72(23): 165-72.	1996	*	
Bolivia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec</i> . 1996; 71(20): 149-56.	1995	*	
Bolivia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1995; 70(25): 177-82.	1994	*	
Bolivia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2003. Pan American Health Organization (PAHO).	2003		†
Bolivia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2004. Pan American Health Organization (PAHO).	2004		†
Bolivia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2005. Pan American Health Organization (PAHO).	2005		†
Bolivia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2006. Pan American Health Organization (PAHO).	2006		†
Bolivia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2007. Pan American Health Organization (PAHO).	2007		†
Bolivia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Bolivia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Bolivia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Bolivia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Bolivia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Bolivia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Bolivia	Tapia PJ, Suarez EI, Lanza VHZ, Balderrama MH. Contribution to the Epidemiological Study of Rheumatic Fever / Rheumatic Heart Disease (RF/RHD). Review of School District V. Villa Fatima, La Paz, Bolivia. La Paz, Bolivia: Ministry of Health (Bolivia), 1990.	1989-1990		
Bolivia	Masuet-Aumatell C, Ramon-Torrell JM, Casanova-Rituerto A, Banqué Navarro M, Dávalos Gamboa M, Montaña Rodríguez SL. Prevalence of hepatitis A antibodies in Eastern Bolivia: a population-based study. <i>J Med Virol</i> . 2013; 85(10): 1692-7.	2010	*	
Bolivia	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L. Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Ann Hepatol</i> . 2010; 9(1): 63-9.	2006-2008	*	
Bolivia	Konomi N, Miyoshi C, La Fuente Zerain C, Li TC, Arakawa Y, Abe K. Epidemiology of hepatitis B, C, E, and G virus infections and molecular analysis of hepatitis G virus isolates in Bolivia. <i>J Clin Microbiol</i> . 1999; 37(10): 3291-5.	1992-1998	*	
Bolivia	Bartoloni A, Bartalesi F, Roselli M, Mantella A, Caceres Arce C, Paradisi F, Hall AJ. Prevalence of antibodies against hepatitis A and E viruses among rural populations of the Chaco region, south-eastern Bolivia. <i>Trop Med Int Health</i> . 1999; 4(9): 596-601.	1997		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Bolivia	Gandolfo GM, Ferri GM, Conti L, Antenucci A, Marrone R, Frasca AM, Vitelli G. Prevalence of infections by hepatitis A, B, C and E viruses in two different socioeconomic groups of children from Santa Cruz, Bolivia. <i>Med Clin (Barc)</i> . 2003; 120(19): 725-7.	1988		
Bolivia	Bartoloni A, Aquilini D, Roselli M, Parri F, de Majo E, Nunez LE, Nicoletti P, Corti G, Paradisi F. Prevalence of antibody to hepatitis A virus in the Santa Cruz region of Bolivia. <i>J Trop Med Hyg</i> . 1989; 92(4): 279-81.	1987		
Bolivia	Salas AA, Mazzi E. Exchange transfusion in infants with extreme hyperbilirubinemia: an experience from a developing country. <i>Acta Paediatr</i> . 2008; 97(6): 754-8.	2000-2004	*	†
Bolivia	Pan American Health Organization (PAHO), World Health Organization (WHO). Quantitative Estimation of Chagas in the Americas.	2005	*	
Bolivia	Albarracín-Veizaga H, de Carvalho ME, Nascimento EM, Rodrigues VL, Casanova C, Barata JM. Chagas disease in an area of recent occupation in Cochabamba, Bolivia. <i>Rev Saude Publica</i> . 1999; 33(3): 230-6.	1996	*	
Bolivia	Salas NA, Cot M, Schneider D, Mendoza B, Santalla JA, Postigo J, Chippaux JP, Brutus L. Risk factors and consequences of congenital Chagas disease in Yacuiba, south Bolivia. <i>Trop Med Int Health</i> . 2007; 12(12): 1498-505.	2003-2005	*	
Bolivia	Depickère S, Durán P, López R, Chávez T. Presence of intradomicile colonies of the tritomatine bug <i>Panstrongylus rufituberculatus</i> in Muñecas, La Paz, Bolivia. <i>Acta Trop</i> . 2011; 117(2): 97-100.	2008	*	
Bolivia	Brenière SF, Bosseno MF, Noireau F, Yacsik N, Liegeard P, Aznar C, Hontebeyrie M. Integrate study of a Bolivian population infected by <i>Trypanosoma cruzi</i> , the agent of Chagas disease. <i>Mem Inst Oswaldo Cruz</i> . 2002; 97(3): 289-95.	1994-1995	*	
Bolivia	Brutus L, Schneider D, Postigo J, Delgado W, Mollinedo S, Chippaux J-P. Evidence of congenital transmission of <i>Trypanosoma cruzi</i> in a vector-free area of Bolivia. <i>Trans R Soc Trop Med Hyg</i> . 2007; 101(11): 1159-60.	2001	*	
Bolivia	Cancrini G, Bartoloni A, Guglielmetti P, Roselli M, Pereira L. Malaria parasitological indices in the Cordillera Province. <i>Ann Trop Med Parasitol</i> . 1992; 86(3): 217-23 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988-1989	*	†
Bolivia	Hill N, Lenglet A, Arnéz AM, Carneiro I. Plant based insect repellent and insecticide treated bed nets to protect against malaria in areas of early evening biting vectors: double blind randomised placebo controlled clinical trial in the Bolivian Amazon. <i>BMJ</i> . 2007; 335(7628): 1023 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Bolivia	Bolivia Vital Registration Birth Data 1977 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1977		
Bolivia	Bolivia Latin American Collaborative Study of Congenital Malformations Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT). International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Bosnia and Herzegovina	Directorate for Economic Planning (Bosnia and Herzegovina), Federal Office of Statistics (Federation of Bosnia and Herzegovina), Institute of Statistics (Republic of Srpska), Ministry of Health (Federation of Bosnia and Herzegovina), Ministry of Health and Social Welfare (Republic of Srpska), Public Health Institute of Federation of Bosnia and Herzegovina, United Nations Children's Fund (UNICEF). Bosnia and Herzegovina Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006	*	†
Bosnia and Herzegovina	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2005		
Bosnia and Herzegovina	World Health Organization (WHO). Bosnia and Herzegovina World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Bosnia and Herzegovina	Agency for Statistics (Bosnia and Herzegovina), Ministry of Health (Federation of Bosnia and Herzegovina), Ministry of Health and Social Welfare (Republic of Srpska), United Nations Children's Fund (UNICEF). Bosnia and Herzegovina Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Bosnia and Herzegovina	Agency for Statistics (Bosnia and Herzegovina), Federal Ministry of Health (Bosnia and Herzegovina), Ministry of Health and Social Welfare (Republic of Srpska), Public Health Institute of Federation of Bosnia and Herzegovina, United Nations Children's Fund (UNICEF), United Nations Entity for Gender Equality and the Empowerment of Women (UN Women). Bosnia and Herzegovina Multiple Indicator Cluster Survey 2011-2012.	2011-2012	*	†
Bosnia and Herzegovina	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Bosnia and Herzegovina	Zvizdi S, Telabasi S, Beslagi E, Cavaljuga S, Maglaji J, Zvizdi A, Hamzi S. Clinical characteristics of rotaviruses disease. <i>Bosn J Basic Med Sci</i> . 2004; 4(2): 22-4.	1988-1991		
Bosnia and Herzegovina	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998-1999, 2002, 2007-2008		
Bosnia and Herzegovina	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Bosnia and Herzegovina	Dedić-Ljubović A, Hukić M, Bekić D, Zvizdić A. Frequency and distribution of diarrhoeagenic <i>Escherichia coli</i> strains isolated from pediatric patients with diarrhoea in Bosnia and Herzegovina. <i>Bosn J Basic Med Sci</i> . 2009; 9(2): 148-55.	2007-2008	*	
Bosnia and Herzegovina	Damjanović V, Vasilij I, Vlak T, Zelenika D. Prevalence and risk factors of the rheumatoid arthritis in Herzegovina region in 2003-2005. <i>Coll Antropol</i> . 2009; 73-7.	2003-2005		
Bosnia and Herzegovina	Ivanković A, Lukić IK, Ivanković Z, Radi A, Vukić I, Šimić A. Dental caries in postwar Bosnia and Herzegovina. <i>Community Dent Oral Epidemiol</i> . 2003; 31(2): 100-4.	1997		
Bosnia and Herzegovina	Vrbic V, Vulović M, Rajić Z, Topić B, Tatić E, Malić M, Milić D, Aurer-Kozelj J, Neveća L, Redžepagić S. Oral health in SFR Yugoslavia in 1986. <i>Community Dent Oral Epidemiol</i> . 1988; 16(5): 286-8.	1986		
Bosnia and Herzegovina	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2005		
Bosnia and Herzegovina	Pavlović-Calić N, Salkić NN, Gegić A, Smajić M, Alibegović E. Crohn's disease in Tuzla region of Bosnia and Herzegovina: a 12-year study (1995-2006). <i>Int J Colorectal Dis</i> . 2008; 23(10): 957-64.	1995-2006	*	
Bosnia and Herzegovina	Salkić NN, Pavlović-Calić N, Gegić A, Jovanović P, Basic M. Ulcerative colitis in the Tuzla region of Bosnia and Herzegovina between 1995 and 2006: epidemiological and clinical characteristics. <i>Eur J Gastroenterol Hepatol</i> . 2010; 22(3): 346-53.	1995-2006	*	
Bosnia and Herzegovina	Klupka-Sarić I, Galić M. Epidemiology of multiple sclerosis in western Herzegovina and Herzegovina – Neretva Canton, Bosnia and Herzegovina. <i>Coll Antropol</i> . 2010; 189-93.	1997-2006	*	
Bosnia and Herzegovina	Başoğlu M, Livanou M, Crnobarčić C, Francisković T, Suljić E, Durić D, Vranesić M. Psychiatric and cognitive effects of war in former Yugoslavia: association of lack of redress for trauma and posttraumatic stress reactions. <i>JAMA</i> . 2005; 294(5): 580-90.	2000-2002	*	
Bosnia and Herzegovina	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2010, 2012		
Bosnia and Herzegovina	Radosević B, Bukara-Radujković G, Mijljković V, Pejić S, Bratina N, Battelino T. The incidence of type 1 diabetes in Republic of Srpska (Bosnia and Herzegovina) and Slovenia in the period 1998-2010. <i>Pediatr Diabetes</i> . 2013; 14(4): 273-9.	1998-2010		
Bosnia and Herzegovina	Fraser GR, Defarinas B, Kartamis CA, Race RR, Sanger R, Stamatoyannopoulos G. Glucose-6-phosphate dehydrogenase, colour vision and XG blood groups in Greece: linkage and population data. <i>Ann Hum Genet</i> . 1964; 395-403.	1962		
Bosnia and Herzegovina	World Health Organization (WHO). Bosnia and Herzegovina WHO Leishmaniasis Country Profile.	2002-2005	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Bosnia and Herzegovina	Bosnia and Herzegovina Iodine Status of the Population 2005 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2005		
Bosnia and Herzegovina	Bosnia and Herzegovina Iodine Deficiency 1999 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1999		
Bosnia and Herzegovina	Eric J, Stančić I, Tihček-Šojić L, Kulić L, Popovac A, Tsakos G. Prevalence, severity, and clinical determinants of oral impacts in older people in Bosnia and Herzegovina. Eur J Oral Sci. 2012; 120(5): 438-43.	2009-2010	*	
Bosnia and Herzegovina	Skobić H, Sinanović O, Skobić Bovan N, Ivanković A, Pejanović Skobić N. Prevalence of alcohol abuse and alcoholism in general population of Mostar region, Bosnia and Herzegovina. Coll Antropol. 2010; 29-31.	2002		
Bosnia and Herzegovina	Bosnia and Herzegovina Renal Register Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Bosnia and Herzegovina	Bosnia and Herzegovina Renal Register Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Botswana	Central Statistics Office (Botswana), Macro Systems, Inc.; Institute for Resource Development, Ministry of Health (Botswana). Botswana Demographic and Health Survey 1988. Columbia, United States: Macro Systems, Inc.; Institute for Resource Development.	1988	*	†
Botswana	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Botswana	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Botswana	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1996-1997, 2002, 2005, 2007		
Botswana	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Botswana	Basu G, Roussow J, Sebunya TK, Gashe BA, de Beer M, Dewar JB, Steele AD. Prevalence of rotavirus, adenovirus and astrovirus infection in young children with gastroenteritis in Gaborone, Botswana. East Afr Med J. 2003; 80(12): 652-5.	2001-2002	*	
Botswana	Kebaabetswe LP, Sebunya TK, Matsheka MI, Ndung'u T. Detection and molecular characterisation of group A rotavirus from children in northern Botswana. East Afr Med J. 2005; 82(4): 203-8.	2003-2004	*	
Botswana	Kasule M, Sebunya TK, Gashe BA, Armah G, Steele AD. Detection and characterization of human rotavirus among children with diarrhoea in Botswana. Trop Med Int Health. 2003; 8(12): 1137-42.	1999-2001	*	
Botswana	Ben-Tovim DI, Cushnie JM. The prevalence of schizophrenia in a remote area of Botswana. Br J Psychiatry. 1986; 576-80.	1981-1982		
Botswana	Clausen T, Romøren TI, Ferreira M, Kristensen P, Ingstad B, Holmboe-Ottesen G. Chronic diseases and health inequalities in older persons in Botswana (southern Africa): a national survey. J Nutr Health Aging. 2005; 9(6): 455-61. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1998		
Botswana	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2010, 2012		
Botswana	Botswana Micronutrient Malnutrition Survey 1994 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1994		
Botswana	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Botswana	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Botswana	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Botswana	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Botswana	Romoren M, Sundby J, Velauthapillai M, Rahman M, Klouman E, Hjortdahl P, Chlamydia and gonorrhoea in pregnant Batswana women: time to discard the syndromic approach BMC Infect Dis. 2007; 7.	2000-2001	*	
Botswana	Paz-Bailey G, Rahman M, Chen C, Ballard R, Moffat HJ, Kenyon T, Kilmarx PH, Totten PA, Astete S, Boily MC, Ryan C. Changes in the Etiology of Sexually Transmitted Diseases in Botswana between 1993 and 2002: Implications for the Clinical Management of Genital Ulcer Disease. Clin Infect Dis. 2005; 41(9): 1304-12.	2001-2002	*	
Botswana	Ministry of Health (Botswana). Botswana Microbiological Survey of Sexually Transmitted Infections 2007-2008.	2007-2008		
Brazil	Brazil Vital Registration - Deaths 1996 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1996	*	
Brazil	Brazil Vital Registration - Deaths 1997 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1997	*	
Brazil	Brazil Vital Registration - Deaths 1998 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1998	*	
Brazil	Brazil Vital Registration - Deaths 1999 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1999	*	
Brazil	Brazil Vital Registration - Deaths 2000 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2000	*	
Brazil	Brazil Vital Registration - Deaths 2001 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2001	*	
Brazil	Brazil Vital Registration - Deaths 2002 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2002	*	
Brazil	Brazil Vital Registration - Deaths 2003 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2003	*	
Brazil	Brazil Vital Registration - Deaths 2004 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2004	*	
Brazil	Brazil Vital Registration - Deaths 2005 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2005	*	
Brazil	Brazilian Society for Family Welfare (BEMFAM), Westinghouse; Institute for Resource Development. Brazil Demographic and Health Survey 1986. Columbia, United States: Westinghouse; Institute for Resource Development.	1986		†
Brazil	Brazilian Society for Family Welfare (BEMFAM), Macro International, Inc. Brazil Demographic and Health Survey 1991. Calverton, United States: Macro International, Inc.	1991		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Brazil	Brazilian Society for Family Welfare (BEMFAM), Macro International, Inc. Brazil Demographic and Health Survey 1996. Calverton, United States: Macro International, Inc.	1996		†
Brazil	Center for Scientific and Technological Information, Oswaldo Cruz Foundation and World Health Organization (WHO). Brazil World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Brazil	Ministry of Health (Brazil). Brazil Hospital Information System 2009. Rio de Janeiro, Brazil: Ministry of Health (Brazil).	2009		
Brazil	Brazil Vital Registration - Deaths 2007 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2007	*	
Brazil	Brazil Vital Registration - Deaths 2006 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2006	*	
Brazil	Ministry of Health (Brazil). Brazil Hospital Information System 2008. Rio de Janeiro, Brazil: Ministry of Health (Brazil).	2008		
Brazil	Ministry of Health (Brazil). Brazil Hospital Information System 2007. Rio de Janeiro, Brazil: Ministry of Health (Brazil).	2007		
Brazil	Ministry of Health (Brazil). Brazil Hospital Information System 2006. Rio de Janeiro, Brazil: Ministry of Health (Brazil).	2006		
Brazil	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-2002		
Brazil	Barreto ML, Santos LM, Assis AM, Araujo MP, Farenzena GG, Santos PA, Fiaccone RL. Effect of vitamin A supplementation on diarrhoea and acute lower-respiratory-tract infections in young children in Brazil. <i>Lancet</i> . 1994; 344(8917): 228-31.	1990-1991		
Brazil	Lima AA, Moore SR, Barboza MS Jr, Soares AM, Schlepner MA, Newman RD, Sears CL, Nataro JP, Fedorko DP, Wuhib T, Schorling JB, Guerrant RL. Persistent diarrhea signals a critical period of increased diarrhea burdens and nutritional shortfalls: a prospective cohort study among children in northeastern Brazil. <i>J Infect Dis</i> . 2000; 181(5): 1643-51.	1989-1993		
Brazil	Newman RD, Sears CL, Moore SR, Nataro JP, Wuhib T, Agnew DA, Guerrant RL, Lima AA. Longitudinal study of Cryptosporidium infection in children in northeastern Brazil. <i>J Infect Dis</i> . 1999; 180(1): 167-75.	1989-1993		
Brazil	Schorling JB, Wanke CA, Schorling SK, McAuliffe JF, De Souza MA, Guerrant RL. A prospective study of persistent diarrhea among children in an urban Brazilian slum. Patterns of occurrence and etiologic agents. <i>Am J Epidemiol</i> . 1990; 132(1): 144-56.	1985-1986		
Brazil	Brazil Vital Registration - Deaths 2010 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2010	*	
Brazil	Fornari LS, Calderaro D, Nassar IB, Lauretti C, Nakamura L, Bagnatori R, Ageno W, Caramelli B. Misuse of antithrombotic therapy in atrial fibrillation patients: frequent, pervasive and persistent. <i>J Thromb Thrombolysis</i> . 2006; 23(1): 65-71.	2002		
Brazil	Fernandes APCC, Januário JN, Cangussu CB, Macedo DL de, Viana MB. Mortality of children with sickle cell disease: a population study. <i>J Pediatr (Rio J)</i> . 2010; 86(4): 279-84.	1998-2005		
Brazil	Lobo CL de C, Bueno LM, Moura P, Ogeda LL, Castilho S, de Carvalho SMF. Neonatal screening for hemoglobinopathies in Rio de Janeiro, Brazil. <i>Rev Panam Salud Publica</i> . 2003; 13(2-3): 154-9.	2000-2001		
Brazil	Thalassaemia International Federation, World Health Organization (WHO). Management of Haemoglobin Disorders: Report of a Joint WHO-TIF Meeting, Nicosia, Cyprus, 16-18 November 2007. Geneva, Switzerland: World Health Organization (WHO), 2008.	1998		
Brazil	Centre for Health Informatics and Multiprofessional Education, University College London. Model's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Brazil	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Brazil	Martins-Leite P, Gazzinelli G, Alves-Oliveira LF, Gazzinelli A, Malaquias LCC, Correa-Oliveira R, Teixeira-Carvalho A, Silveira AMS. Effect of chemotherapy with praziquantel on the production of cytokines and morbidity associated with schistosomiasis mansoni. <i>Antimicrob Agents Chemother</i> . 2008; 52(8): 2780-6.	2006		
Brazil	Assis AM, Barreto ML, Prado MS, Reis MG, Parraga IM, Blanton RE. Schistosoma mansoni infection and nutritional status in schoolchildren: a randomized, double-blind trial in northeastern Brazil. <i>Am J Clin Nutr</i> . 1998; 68(6): 1247-53.	1992-1993		
Brazil	Assis AMO, Prado MS, Barreto ML, Reis MG, Conceição Pinheiro SM, Parraga IM, Blanton RE. Childhood stunting in Northeast Brazil: the role of Schistosoma mansoni infection and inadequate dietary intake. <i>Eur J Clin Nutr</i> . 2004; 58(7): 1022-9.	2004		
Brazil	Coutinho E, Barbosa FS, Barbosa JM, Pessoa P, Pinto RF, Oliveira PA, Rodrigues BA. Inquérito clínico-nutricional e antropométrico preliminar, em áreas endêmicas de esquistossomose mansônica, no Nordeste do Brasil. <i>Rev Soc Bras Med Trop</i> . 1972; 6: 211-36.	1965-1967		
Brazil	Coutinho EM, Abath FG, Barbosa CS, Domingues AL, Melo MC, Montenegro SM, Lucena MA, Romani SA, Souza WV, Coutinho AD. Factors involved in Schistosoma mansoni infection in rural areas of northeast Brazil. <i>Mem Inst Oswaldo Cruz</i> . 1997; 92(5): 707-15.	1994-1995		
Brazil	De Lima e Costa MF, Leite ML, Rocha RS, de Almeida Magalhães MH, Katz N. Anthropometric measures in relation to Schistosomiasis mansoni and socioeconomic variables. <i>Int J Epidemiol</i> . 1988; 17(4): 880-6.	1981		
Brazil	Kloetzel K, Chieffo PP, de Siqueira JG. Repeated mass treatment of schistosomiasis mansoni: experience in hyperendemic areas of Brazil. 3. Techniques for assessment and surveillance. <i>Trans R Soc Trop Med Hyg</i> . 1990; 84(1): 74-9.	1987-1990		
Brazil	Lehman JS Jr, Mott KE, Morrow RH Jr, Muniz TM, Boyer MH. The intensity and effects of infection with Schistosoma mansoni in a rural community in northeast Brazil. <i>Am J Trop Med Hyg</i> . 1976; 25(2): 285-94.	1972		†
Brazil	Parraga IM, Assis AM, Prado MS, Barreto ML, Reis MG, King CH, Blanton RE. Gender differences in growth of school-aged children with schistosomiasis and geohelminth infection. <i>Am J Trop Med Hyg</i> . 1996; 55(2): 150-6.	1992		
Brazil	Nascimento-Carvalho CM, Ribeiro CT, Viriato D, Souza AL, Cardoso MRA, Barral A, Araujo-Neto CA, Oliveira JR, Sobral LS, Saukkoripi A, Paldanius M, Leinonen M, Väinönpää R, Ruuskanen O. The role of respiratory viral infections among children hospitalized for community-acquired pneumonia in a developing country. <i>Pediatr Infect Dis J</i> . 2008; 27(10): 939-41.	2003-2005		
Brazil	Barretto AC, Nobre MR, Wajngarten M, Canesin MF, Ballas D, Serro-Azul JB. Heart failure at a large tertiary hospital of São Paulo. <i>Arq Bras Cardiol</i> . 1998; 71(1): 15-20.	1995		
Brazil	Barretto AC, Wajngarten M, Serro-Azul JB, Pierri H, Nussbacher A, Gebara OC. Medical treatment of heart failure at a tertiary hospital of São Paulo. <i>Arq Bras Cardiol</i> . 1997; 69(6): 375-9.	1995-1996		
Brazil	Cabral NL, Gonçalves ARR, Longo AL, Moro CHC, Costa G, Amaral CH, Fonseca L a M, Eluf-Neto J. Incidence of stroke subtypes and prevalence of risk factors in Joinville, Brazil: a 2 year community based study. <i>J Neurol Neurosurg Psychiatry</i> . 2009; 80(7): 755-61.	2005-2006		
Brazil	Godinho RN, Gonçalves TM, Nunes FB, Becker CG, Becker HM, Guimarães RE, Sanfins F, Colosimo EA, Oliveira RG, Lamounier JA. Prevalence and impact of chronic otitis media in school age children in Brazil First epidemiologic study concerning chronic otitis media in Latin America. <i>Int J Pediatr Otorhinolaryngol</i> . 2001; 61(3): 223-32.	1999-2001		
Brazil	Bechelli LM, Haddad N, Pimenta WP, Pagnano PM, Melchior E Jr, Fregnan RC, Zanin LC, Arenas A. Epidemiological survey of skin diseases in schoolchildren living in the Purus Valley (Acre State, Amazonia, Brazil). <i>Dermatologica</i> . 1981; 163(1): 78-93.	1974-1975		
Brazil	Figuerêdo-Silva J, Kaneda Y, Tachibana H, Furushima R, Tatenos S, Correia-Lima FG, Bento DN. Epidemiological survey of Trypanosoma cruzi infection in north-eastern Brazil using different diagnostic methods. <i>Rev Inst Med Trop Sao Paulo</i> . 1991; 33(3): 193-8.	1991		
Brazil	Costa M, Barbosa R, Sousa M. Contribuições do sertoão do pajé - Pernambuco/Brasil, para o quadro nacional da doença de chagas. <i>SaBios</i> . 2011; 6(2): 66-71.	1999		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Brazil	Pan American Health Organization (PAHO), Southern Cone Initiative (INCOSUR). XIth Meeting of the Intergovernmental Committee for the Elimination of Triatoma Infestans and the Interruption of American Trypanosomiasis by Transfusion. Washington, D.C., United States: Pan American Health Organization (PAHO), 2002.	2001		
Brazil	Aras R, Veiga M, Gomes I, Mota G, Rodrigues B, Rabelo R, Guzman-Bracho C, Melo A. Prevalence of Chagas disease in Mulungu do Morro northeastern Brazil. Arq Bras Cardiol. 2001; 78(5): 441-3.	1998-1999		
Brazil	Silveira A, Vinhaes M. Elimination of vector-borne transmission of Chagas disease. Mem Inst Oswaldo Cruz. 1999; 94: 405-11.	1989-1997		
Brazil	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. J Allergy Clin Immunol. 2008; 121(4): 947-954.	1994-1995, 2001-2003		
Brazil	Cunha A. Relationship between acute respiratory infection and malnutrition in children under 5 years of age. Acta Paediatr. 2000; 5(89): 608-609.	1991		†
Brazil	Robertson SE, Roca A, Alonso P, Simoes EAF, Kartasasmita CB, Olaleye DO, Odaibo GN, Collinson M, Venter M, Yuwei Zhu, Wright PF. Respiratory syncytial virus infection: denominator-based studies in Indonesia, Mozambique, Nigeria and South Africa. Bull World Health Organ. 2004; 12(82): 914-22.	1987-2001		
Brazil	Victoria CG, Barros FC, Kirkwood BR, Vaughan JP. Pneumonia, diarrhea, and growth in the first 4 years of life: a longitudinal study of 5914 urban Brazilian children. Am J Clin Nutr. 1990; 2(52): 391-6.	1984-1986		
Brazil	Fang GD, Lima AA, Martins CV, Nataro JP, Guerrant RL. Etiology and epidemiology of persistent diarrhea in northeastern Brazil: a hospital-based, prospective, case-control study. J Pediatr Gastroenterol Nutr. 1995; 21(2): 137-44.	1988-1991		
Brazil	Gusmão RH, Mascarenhas JD, Gabbay YB, Lins-Lainson Z, Ramos FL, Monteiro TA, Valente SA, Fagundes-Neto U, Linhares AC. Rotavirus subgroups, G serotypes, and electrophoretotypes in cases of nosocomial infantile diarrhoea in Belém, Brazil. J Trop Pediatr. 1999; 45(2): 81-6.	1992-1994		
Brazil	Lucena R, Gomes I, Ferreira A, Góes J, Araújo L, Veiga M, Melo A. Características clínicas e laboratoriais de meningites bacterianas em crianças. Arq Neuropsiquiatr. 1996; 54(4): 571-6.	1990-1992		
Brazil	Nascimento-Carvalho CM, Moreno-Carvalho OA. [Etiology of bacterial meningitis in a cohort from Salvador, Bahia]. Arq Neuropsiquiatr. 1998; 56(1): 83-7.	1988-1995		
Brazil	Weiss DP, Coplan P, Guess H. Epidemiology of bacterial meningitis among children in Brazil, 1997-1998. Rev Saude Publica. 2001; 35(3): 249-55.	1997-1998		
Brazil	Araújo IT, Fialho AM, de Assis RMS, Rocha M, Galvão M, Cruz CM, Ferreira MSR, Leite JPG. Rotavirus strain diversity in Rio de Janeiro, Brazil: characterization of VP4 and VP7 genotypes in hospitalized children. J Trop Pediatr. 2002; 48(4): 214-8.	1996-1999		
Brazil	Bittencourt JA, Arbo E, Malysz AS, Gravee R, Dias C. Seasonal and age distribution of rotavirus infection in Porto Alegre--Brazil. Braz J Infect Dis. 2000; 4(6): 279-83.	1996-1998		
Brazil	Da Silva Domingues AL, da Silva Vaz MG, Moreno M, Câmara FP. Molecular epidemiology of group A rotavirus causing acute diarrhea in infants and young children hospitalized in Rio de Janeiro, Brazil, 1995-1996. Braz J Infect Dis. 2000; 4(3): 119-25.	1995-1996		
Brazil	Fernandes JV, Fonseca SM, Azevedo JC, Maranhão H de S, Fonseca MH, Dantas MT, Meissner R de V. Rotavirus detection in feces of children with acute diarrhea. J Pediatr (Rio J). 2000; 76(4): 300-4.	1996-1998		
Brazil	Lima AA, Guerrant RL. Persistent diarrhea in children: epidemiology, risk factors, pathophysiology, nutritional impact, and management. Epidemiol Rev. 1992; 14: 222-42.	1989-1991		
Brazil	Luz CRNE de, Mascarenhas JDP, Gabbay YB, Motta ARB, Lima TVR, Soares L da S, Linhares AC. Rotavirus serotypes and electrophoretotypes identified among hospitalized children in São Luís, Maranhão, Brazil. Rev Inst Med Trop Sao Paulo. 2005; 47(5): 287-93.	1997-1999		
Brazil	Cardoso D das D de P, Soares CMA, Dias e Souza MB de L, de Azevedo M da SP, Martins RMB, Queiróz DA de O, de Brito WMED, Munford V, Rácz ML. Epidemiological features of rotavirus infection in Goiânia, Goiás, Brazil, from 1986 to 2000. Mem Inst Oswaldo Cruz. 2003; 98(1): 25-9.	1986-2000		
Brazil	Rosa E Silva ML, Pires De Carvalho I, Gouvea V. 1998-1999 rotavirus seasons in Juiz de Fora, Minas Gerais, Brazil: detection of an unusual G3P4 epidemic strain. J Clin Microbiol. 2002; 40(8): 2837-42.	1998-1999		
Brazil	Santos N, Volotão EM, Soares CC, Campos GS, Sardi SL, Hoshino Y. Predominance of rotavirus genotype G9 during the 1999, 2000, and 2002 seasons among hospitalized children in the city of Salvador, Bahia, Brazil: implications for future vaccine strategies. J Clin Microbiol. 2005; 43(8): 4064-9.	1999-2000, 2002		
Brazil	Soares CC, Volotão EM, Albuquerque MCM, da Silva FM, de Carvalho TRB, Nozawa CM, Linhares RE, Santos N. Prevalence of enteric adenoviruses among children with diarrhea in four Brazilian cities. J Clin Virol. 2002; 23(3): 171-7.	1998-2000		
Brazil	Volotão EM, Soares CC, Maranhão AG, Rocha LN, Hoshino Y, Santos N. Rotavirus surveillance in the city of Rio de Janeiro-Brazil during 2000-2004: detection of unusual strains with G8P4 or G10P9 specificities. J Med Virol. 2006; 78(2): 263-72.	2000-2004		
Brazil	Alves L, Cesar JA, Hortá BL. Prevalence of angina pectoris in Pelotas, south of Brazil. Arq Bras Cardiol. 2010; 95(2): 179-85.	2007		
Brazil	Souza JP, Cecatti JG, Faundes A, Moraes SS, Villar J, Carroli G, Gulmezoglu M, Wojdyla D, Zavaleta N, Donner A, Velazco A, Bataglia V, Valladares E, Kublickas M, Acosta A. Maternal near miss and maternal death in the World Health Organization's 2005 global survey on maternal and perinatal health. Bull World Health Organ. 2010; 88(2): 113-9.	2003-2005		
Brazil	Moraes APP, Barreto SM, Passos VMA, Golino PS, Costa JA, Vasconcelos MX. Incidence and main causes of severe maternal morbidity in São Luís, Maranhão, Brazil: a longitudinal study. Sao Paulo Med J. 2011; 129(3): 146-52.	2009-2010		
Brazil	De Araújo MCPE, Serafim ESS, de Castro Jr WAP, de Medeiros TMD. Prevalence of abnormal hemoglobins in newborns in Natal, Rio Grande do Norte, Brazil. Cad Saude Publica. 2004; 1(20): 123-8.	2001		
Brazil	Diniz D, Guedes C, Barbosa L, Tauil PL, Magalhães I. Prevalence of sickle cell trait and sickle cell anemia among newborns in the Federal District, Brazil, 2004 to 2006. Cad Saude Publica. 2009; 1(25): 188-94.	2004-2006		
Brazil	Salzano FM. Incidence, effects, and management of sickle cell disease in Brazil. Am J Pediatr Hematol Oncol. 1985; 3(7): 240-4.	1964-1968		
Brazil	Brandelise S, Pinheiro V, Gabetta CS, Hambleton I, Serjeant B, Serjeant G. Newborn screening for sickle cell disease in Brazil: the Campinas experience. Clin Lab Haematol. 2004; 1(26): 15-9.	1992-2000		
Brazil	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1980-1981		
Brazil	Pan American Health Organization (PAHO). Update on yellow fever in the Americas. Epidemiol Bull. 2000; 21(2):13.	1985-1995		
Brazil	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1990, 1999, 2003-2005, 2008-2009		
Brazil	Vasconcelos PF da C. Febre amarela. Rev Soc Bras Med Trop. 2003; 36(2): 275-93.	1980-2001		
Brazil	Secretariat of Health Surveillance, Ministry of Health (Brazil). Emergências em Saúde Pública de Importância Nacional (ESPIN) de Febre Amarela Silvestre em São Paulo e no Rio Grande do Sul e a Situação Epidemiológica Atual no Brasil (2008/2009). [Public Health Emergencies of National Importance, Sylvatic Yellow Fever in Sao Paulo and Rio Grande do Sul and the Current Epidemiological Situation in Brazil 2008-2009]. Rio de Janeiro, Brazil: Ministry of Health (Brazil).	2009		
Brazil	De Filippis AMB, Nogueira RMR, Schatzmayr HG, Tavares DS, Jabor AV, Diniz SCM, Oliveira JC, Moreira E, Miagostovich MP, Costa EV, Galler R. Outbreak of jaundice and hemorrhagic fever in the Southeast of Brazil in 2001: detection and molecular characterization of yellow fever virus. J Med Virol. 2002; 68(4): 620-7.	2001		
Brazil	Pan American Health Organization (PAHO). Yellow Fever: Number of Cases and Deaths, 1960-2007. Washington, D.C., United States: Pan American Health Organization (PAHO), 2007.	2007		
Brazil	Vasconcelos PF, Rodrigues SG, Degallier N, Moraes MA, Da Rosa JF, Da Rosa ES, Mondet B, Barros VL, Da Rosa AP. An epidemic of sylvatic yellow fever in the southeast region of Maranhao State, Brazil, 1993-1994: epidemiologic and entomologic findings. Am J Trop Med Hyg. 1997; 57(2): 132-7.	1993		†
Brazil	Ribeiro M, Antunes CM de F. Yellow fever: study of an outbreak. Rev Soc Bras Med Trop. 2009; 42(5): 523-31.	2002-2003		
Brazil	Sylvatic yellow fever outbreak in Bolivia. EPI NewsL. 1999; 1(21): 1-3.	1988, 1993-1994		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Brazil	Vasconcelos PF, Costa ZG, Travassos Da Rosa ES, Luna E, Rodrigues SG, Barros VL, Dias JP, Monteiro HA, Oliva OF, Vasconcelos HB, Oliveira RC, Sousa MR, Barbosa Da Silva J, Cruz AC, Martins EC, Travassos Da Rosa JF. Epidemic of jungle yellow fever in Brazil, 2000: implications of climatic alterations in disease spread. <i>J Med Virol.</i> 2001; 598-604.	1980-2000		
Brazil	World Health Organization (WHO). Yellow fever in Africa and South America, 2006. <i>Wkly Epidemiol Rec.</i> 2008; 83(8): 60-76.	2006		
Brazil	World Health Organization (WHO). Yellow fever in Africa and South America, 2007. <i>Wkly Epidemiol Rec.</i> 2009; 84(13): 97-104.	2007		
Brazil	World Health Organization (WHO). Yellow fever, Brazil. <i>Wkly Epidemiol Rec.</i> 2008; 83(7): 61-2.	2008		
Brazil	Bennett K, Cardiel MH, Ferraz MB, Riedemann P, Goldsmith CH, Tugwell P. Community screening for rheumatic disorder: cross cultural adaptation and screening characteristics of the COPCORD Core Questionnaire in Brazil, Chile, and Mexico. <i>J Rheumatol.</i> 1997; 24(1): 160-8.	1994		
Brazil	Brito LL, Barreto ML, Silva RDCR, Assis AMO, Reis MG, Parraga IM, Blanton RE. Moderate- and low-intensity co-infections by intestinal helminths and <i>Schistosoma mansoni</i> , dietary iron intake, and anemia in Brazilian children. <i>Am J Trop Med Hyg.</i> 2006; 75(5): 939-44.	1997		
Brazil	De Lima e Costa MF, Rocha RS, Katz N. Schistosomiasis morbidity and its relation to the <i>Schistosoma mansoni</i> egg count in an hyperendemic area in the State of Minas Gerais. <i>Rev Inst Med Trop Sao Paulo.</i> 1985; 27(2): 66-75.	1984-1985		†
Brazil	De Lima e Costa MF, Rocha RS, Colley D, Gazzinelli G, Katz N. Validity of selected clinical signs and symptoms in diagnosis of <i>Schistosoma mansoni</i> infection. <i>Rev Inst Med Trop Sao Paulo.</i> 1991; 33(1): 12-7.	1986		
Brazil	Firino JO, Lima Costa MF, Guerra HL, Rocha RS. Urban schistosomiasis: morbidity, sociodemographic characteristics and water contact patterns predictive of infection. <i>Int J Epidemiol.</i> 1996; 25(6): 1292-300.	1991-1992		
Brazil	Guimarães MD, de Barros HL, Katz N. A clinical epidemiologic study in a schistosomiasis mansoni endemic area (Tuparecê, Minas Gerais). <i>Rev Inst Med Trop Sao Paulo.</i> 1985; 27(3): 123-31.	1984-1985		†
Brazil	Proietti FA, Paulino UH, Chiari CA, Proietti AB, Antunes CM. Epidemiology of <i>Schistosoma mansoni</i> infection in a low-endemic area in Brazil: clinical and nutritional characteristics. <i>Rev Inst Med Trop Sao Paulo.</i> 1992; 34(5): 409-19.	1990-1992		
Brazil	Callegaro D, de Lolio CA, Radvany J, Tilbery CP, Mendonça RA, Melo AC. Prevalence of multiple sclerosis in the city of São Paulo, Brazil, in 1990. <i>Neuroepidemiology.</i> 1992; 11(1): 11-4.	1990		
Brazil	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Brazil	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2003		
Brazil	Muniz EC, Rocha RM, Reis ML, Santos VL, Grossi SA. Neuropathic and ischemic changes of the foot in Brazilian patients with diabetes. <i>Ostomy Wound Manage.</i> 2003; 49(8): 60-70.	2000-2002		
Brazil	Tres GS, Lisboa HR, Syllos R, Canani LH, Gross JL. Prevalence and characteristics of diabetic polyneuropathy in Passo Fundo, South of Brazil. <i>Arq Bras Endocrinol Metabol.</i> 2007; 51(6): 987-92.	2001-2002		
Brazil	Vieira-Santos K, Souza WV, Carvalho EF, Medeiros MC, Nóbrega MG, Lima PM. Prevalence of diabetic foot and associated factors in the family health units of the city of Recife, Pernambuco State, Brazil, in 2005. <i>Cad Saude Publica.</i> 2008; 24(12): 2861-70.	2006		
Brazil	K G Santos, B Tschiedel, J R Schneider, K E P Souto, I Roisenberg. Prevalence of retinopathy in Caucasian type 2 diabetic patients from the South of Brazil and relationship with clinical and metabolic factors. <i>Braz J Med Biol Res.</i> 2005; 38(2): 221-6.	2004		
Brazil	Heukelbach J, Wilcke T, Winter B, Feldmeier H. Epidemiology and morbidity of scabies and pediculosis capitis in resource-poor communities in Brazil. <i>Br J Dermatol.</i> 2005; 153(1): 150-6.	2001		
Brazil	Marqueze GF, Oliveira CM, Pereira AC, Krieger JE, Mill JG. Metabolic syndrome determinants in an urban population from Brazil: social class and gender-specific interaction. <i>Int J Cardiol.</i> 2008; 129(2): 259-65.	2003		
Brazil	Queiroz LP, Barea LM, Blank N. An epidemiological study of headache in Florianópolis, Brazil. <i>Cephalalgia.</i> 2006; 26(2): 122-7.	2000		
Brazil	Wiehe M, Fuchs SC, Moreira LB, Moraes RS, Fuchs FD. Migraine is more frequent in individuals with optimal and normal blood pressure: a population-based study. <i>J Hypertens.</i> 2002; 20(7): 1303-6.	1996-1998		
Brazil	Morillo LE, Alarcon F, Aranaga N, Aulet S, Chapman E, Conterno L, Estevez E, Garcia-Pedroza F, Garrido J, Macias-Islas M, Monzillo P, Nunez L, Plascencia N, Rodriguez C, Takeuchi Y, Latin American Migraine Study Group. Prevalence of migraine in Latin America. <i>Headache.</i> 2005; 45(2): 106-17.	1999		
Brazil	Benseñor IM, Lotufo PA, Goulart AC, Menezes PR, Scazufica M. The prevalence of headache among elderly in a low-income area of São Paulo, Brazil. <i>Cephalalgia.</i> 2008; 28(4): 329-33.	2003-2005		
Brazil	Lima LM de, Alves NP, Barbosa V de F, Pimenta GA, Moraes-Souza H, Martins PRJ. Prevalence of Chagas disease in blood donors at the Uberaba Regional Blood Center, Brazil, from 1995 to 2009. <i>Rev Soc Bras Med Trop.</i> 2012; 45(6): 723-6.	1995-2009		
Brazil	Carvalho EOC de, Rosa JA da, de Carvalho AA, Chaves HCO, Souza EA de, Ostermayer AL, Camargo LMA de. Study on Chagas disease occurrence in the municipality of Monte Negro, State of Rondônia, Brazilian Amazon. <i>Rev Soc Bras Med Trop.</i> 2011; 44(6): 703-7.	2007-2010		
Brazil	Ostermayer AL, Passos ADC, Silveira AC, Ferreira AW, Macedo V, Prata AR. The national survey of seroprevalence for evaluation of the control of Chagas disease in Brazil (2001-2008). <i>Rev Soc Bras Med Trop.</i> 2011; 108-21.	2001-2008		
Brazil	Lima-Costa MF, Matos DL, Ribeiro ALP. Chagas disease predicts 10-year stroke mortality in community-dwelling elderly: the Bambuí cohort study of aging. <i>Stroke.</i> 2010; 41(11): 2477-82.	1997		
Brazil	Sabino EC, Salles NA, Sarr M, Barreto AM, Oikawa M, Oliveira CD, Leao SC, Carneiro-Proietti AB, Custer B, Busch MP, NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II), International Component. Enhanced classification of Chagas serologic results and epidemiologic characteristics of seropositive donors at three large blood centers in Brazil. <i>Transfusion.</i> 2010; 50(12): 2628-37.	2007-2008		
Brazil	Silva EM da, Rocha MO da C, Silva RC, Paixão G do C, Buzzati H, Santos AN, Nunes M do CP. Clinic and epidemiological study on Chagas disease in the Serra Azul district of Mateus Leme, central-western region of the State of Minas Gerais, Brazil. <i>Rev Soc Bras Med Trop.</i> 2010; 43(2): 178-81.	2007		
Brazil	Araújo AB, Castagno VD, Gallina T, Berne MEA. Prevalence of Chagas disease among pregnant women in the southern region of Rio Grande do Sul. <i>Rev Soc Bras Med Trop.</i> 2009; 42(6): 732-3.	2004		
Brazil	Silva RA da, Goldenberg P. Chagas' disease in Porto Letícia, São Paulo: a comparative study in the Pontal do Paranapanema. <i>Rev Soc Bras Med Trop.</i> 2008; 41(6): 621-7.	2003-2005		
Brazil	Do Amaral RP, do Amaral RP, de Saidneuy AEKT, Ribeiro WL, de Andrade J. Serological profile of potential solid organ donors in Santa Catarina, Brazil. <i>Transplant Proc.</i> 2008; 40(3): 665-7.	2006-2007		
Brazil	Castro LKK de, Cerci Neto A, Ferreira Filho OF. Prevalence of symptoms of asthma, rhinitis and atopic eczema among students between 6 and 7 years of age in the city of Londrina, Brazil. <i>J Bras Pneumol.</i> 2010; 36(3): 286-92.	2008	*	
Brazil	De Farias MR de C, Rosa AM, Hacon S de S, de Castro HA, Ignotti E. Prevalence of asthma in schoolchildren in Alta Floresta - a municipality in the southeast of the Brazilian Amazon. <i>Rev Bras Epidemiol.</i> 2010; 13(1): 49-57.	2007	*	
Brazil	Feitosa CA, Santos DN, Barreto do Carmo MB, Santos LM, Teles CAS, Rodrigues LC, Barreto ML. Behavior problems and prevalence of asthma symptoms among Brazilian children. <i>J Psychosom Res.</i> 2011; 71(3): 160-5.	2006	*	
Brazil	Fiori NS, Gonçalves H, Dumith SC, Cesar MADC, Menezes AMB, Macedo SEC. Ten-year trends in prevalence of asthma in adults in southern Brazil: comparison of two population-based studies. <i>Cad Saude Publica.</i> 2012; 28(1): 135-44.	2010	*	
Brazil	Freitas MS, Monteiro JCS, Camelo-Nunes IC, Solé D. Prevalence of asthma symptoms and associated factors in schoolchildren from Brazilian Amazon islands. <i>J Asthma.</i> 2012; 49(6): 600-5.	2007-2009	*	
Brazil	Garcia-Marcos L, Mallol J, Solé D, Brand PLP, EISL Study Group. International study of wheezing in infants: risk factors in affluent and non-affluent countries during the first year of life. <i>Pediatr Allergy Immunol.</i> 2010; 21(5): 878-88.	2005-2007	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Brazil	Lukrafka JL, Fuchs SC, Moreira LB, Picon RV, Fischer GB, Fuchs FD. Performance of the ISAAC questionnaire to establish the prevalence of asthma in adolescents: a population-based study. <i>J Asthma</i> . 2010; 47(2): 166-9.	2005-2007	*	
Brazil	Mallol J, Solé D, Baeza-Bacab M, Aguirre-Camposano V, Soto-Quiros M, Baena-Cagnani C. Latin American ISAAC Group. Regional variation in asthma symptom prevalence in Latin American children. <i>J Asthma</i> . 2010; 47(6): 644-50.	2001-2003	*	
Brazil	Matos SMA, Jesus SR, Saldiva SRDM, Prado MS, D'Innocenzo S, Assis AMO, Rodrigues LC, Alcantara-Neves NM, Cruz AA, Simões S de M, Barreto ML, SCAALA (Social Change, Asthma and Allergy in Latin America) Study Group. Overweight, asthma symptoms, atopy and pulmonary function in children of 4-12 years of age: findings from the SCAALA cohort in Salvador, Bahia, Brazil. <i>Public Health Nutr</i> . 2011; 14(7): 1270-8.	2005	*	
Brazil	Roelofs R, Gurgel RQ, Wendte J, Polderman J, Barreto-Filho JAS, Solé D, Motta-Franco J, De Munter J, Agyemang C. Relationship between asthma and high blood pressure among adolescents in Aracaju, Brazil. <i>J Asthma</i> . 2010; 47(6): 639-43.	2008	*	
Brazil	Silva AA, Barbieri MA, Cardoso VC, Batista RF, Simões VM, Vianna EO, Gutierrez MR, Figueiredo ML, Silva NA, Pereira TS, Rodriguez JD, Loureiro SR, Ribeiro VS, Bettiol H. Prevalence of non-communicable diseases in Brazilian children: follow-up at school age of two Brazilian birth cohorts of the 1990s. <i>BMC Public Health</i> . 2011; 11: 486.	2004-2006	*	
Brazil	Silva R de CR, Assis AMO, Gonçalves MS, Fiaccone RL, Matos SMA, Barreto ML, Pinto E de J, Silva LA da, Rodrigues LC, Alcantara-Neves NM. The prevalence of wheezing and its association with body mass index and abdominal obesity in children. <i>J Asthma</i> . 2013; 50(3): 267-73.	2010	*	
Brazil	Souza da Cunha S, Barreto ML, Fiaccone RL, Cooper PJ, Alcantara-Neves NM, Simões S de M, Cruz AA, Rodrigues LC. Asthma cases in childhood attributed to atopy in tropical area in Brazil. <i>Rev Panam Salud Publica</i> . 2010; 28(6): 405-11.	2005-2006	*	
Brazil	Toledo MF, Rozov T, Leone C. Prevalence of asthma and allergies in 13- to 14-year-old adolescents and the frequency of risk factors in carriers of current asthma in Taubaté, São Paulo, Brazil. <i>Allergol Immunopathol (Madr)</i> . 2011; 39(5): 284-90.	2008-2010	*	
Brazil	Chong Neto HJ, Rosário NA, Grasselli EA, Silva FC e, Bojarski L de FM, Rosário CS, Rosário BA, Chong FH. Recurrent wheezing in infants: epidemiological changes. <i>J Pediatr (Rio J)</i> . 2011; 87(6): 547-50.	2005-2006, 2009-2010	*	
Brazil	Jucá SCBMP, Takano OA, Moraes LSL, Guimarães LV. Asthma prevalence and risk factors in adolescents 13 to 14 years of age in Curitiba, Mato Grosso State, Brazil. <i>Cad Saude Publica</i> . 2012; 28(4): 689-97.	2008	*	
Brazil	Lima WL, Lima EVNCL, Costa M do R da SR, Santos AM dos, Silva AAM da, Costa ES. Asthma and associated factors in students 13 and 14 years of age in São Luís, Maranhão State, Brazil. <i>Cad Saude Publica</i> . 2012; 28(6): 1046-56.	2008-2009	*	
Brazil	Luna M de FG de, Almeida PC de, Silva MGC da. Asthma and rhinitis prevalence and co-morbidity in 13-14-year-old schoolchildren in the city of Fortaleza, Ceará State, Brazil. <i>Cad Saude Publica</i> . 2011; 27(1): 103-12.	2006-2007	*	
Brazil	Medeiros D, Silva AR, Rizzo JÁ, Sarinho E, Mallol J, Solé D. Prevalence of wheezing and associated risk factors among infants in Recife, Pernambuco State, Brazil. <i>Cad Saude Publica</i> . 2011; 27(8): 1551-9.	2007	*	
Brazil	Wehrmeister FC, Peres KG de A. Regional inequalities in the prevalence of asthma diagnosis in children: an analysis of the Brazilian National Household Sample Survey, 2003. <i>Cad Saude Publica</i> . 2010; 26(9): 1839-52.	2003	*	
Brazil	Feldmeier H, Jackson A, Ariza L, Calheiros CML, Soares V de L, Oliveira FA, Hengge UR, Heukelbach J. The epidemiology of scabies in an impoverished community in rural Brazil: presence and severity of disease are associated with poor living conditions and illiteracy. <i>J Am Acad Dermatol</i> . 2009; 60(3): 436-43.	2003	*	
Brazil	Laczynski CMM, Cestari S da CP. Prevalence of dermatosis in scholars in the region of ABC paulista. <i>An Bras Dermatol</i> . 2011; 86(3): 469-76.	2006	*	
Brazil	Medeiros A, Biagi DG, Sobreira TIP, de Oliveira PSL, Negrão CE, Mansur AJ, Krieger JE, Brum PC, Pereira AC. Mutations in the human phospholamban gene in patients with heart failure. <i>Am Heart J</i> . 2011; 162(6): 1088-1095.	1995-2004		
Brazil	Mendes DC, Silva TF, Barros L de O, de Oliveira MVM, Vieira LT, Haikal DS, Guimarães ALS, De Paula AMB. Analysis of the normative conditions of oral health, depression and serotonin-transporter-linked promoter region polymorphisms in an elderly population. <i>Geriatr Gerontol Int</i> . 2013; 13(1): 98-106.	2011	*	
Brazil	Rodrigues SM, Oliveira AC, Vargas AMD, Moreira AN, E Ferreira EF. Implications of edentulism on quality of life among elderly. <i>Int J Environ Res Public Health</i> . 2012; 9(1): 100-9.	2010	*	
Brazil	Miranda L de P, Silveira MF, Oliveira TL, Alves SFF, Júnior HM, Batista AUD, Bonan PRF. Cognitive impairment, the Mini-Mental State Examination and socio-demographic and dental variables in the elderly in Brazil. <i>Gerodontology</i> . 2012; 29(2): e34-40.	2008-2009	*	
Brazil	Cyrino RM, Miranda Cota LO, Pereira Lages EJ, Bastos Lages EM, Costa FO. Evaluation of self-reported measures for prediction of periodontitis in a sample of Brazilians. <i>J Periodontol</i> . 2011; 82(12): 1693-704.	2009-2010	*	
Brazil	Ribeiro MTF, Rosa MAC da, Lima RMN de, Vargas AMD, Haddad JPA, Ferreira E Ferreira E. Edentulism and shortened dental arch in Brazilian elderly from the National Survey of Oral Health 2003. <i>Rev Saude Publica</i> . 2011; 45(5): 817-23.	2002-2003	*	
Brazil	Boeira GF, Correa MB, Peres KG, Peres MA, Santos IS, Matijasevich A, Barros AJD, Demarco FF. Caries is the main cause for dental pain in childhood: findings from a birth cohort. <i>Caries Res</i> . 2012; 46(5): 488-95.	2009	*	
Brazil	Bönecker M, Ardenghi TM, Oliveira LB, Sheiham A, Marcenes W. Trends in dental caries in 1- to 4-year-old children in a Brazilian city between 1997 and 2008. <i>Int J Paediatr Dent</i> . 2010; 20(2): 125-31.	1997, 1999, 2002, 2004, 2006, 2008	*	
Brazil	Borges HC, Garbín CAS, Saliba O, Saliba NA, Moimaz SAS. Socio-behavioral factors influence prevalence and severity of dental caries in children with primary dentition. <i>Braz Oral Res</i> . 2012; 26(6): 564-70.	2010	*	
Brazil	Carvalho JC, Silva EF, Gomes RR, Fonseca JAC, Mestrinho HD. Impact of enamel defects on early caries development in preschool children. <i>Caries Res</i> . 2011; 45(4): 353-60.	2009	*	
Brazil	De Andrade FB, Lebrão ML, Santos JLF, Duarte YA de O. Relationship between oral health and frailty in community-dwelling elderly individuals in Brazil. <i>J Am Geriatr Soc</i> . 2013; 61(5): 809-14.	2006	*	
Brazil	França-Pinto CC, Cenci MS, Correa MB, Romano AR, Peres MA, Peres KG, Matijasevich A, Santos IS, Barros AJD, Demarco FF. Association between black stains and dental caries in primary teeth: findings from a Brazilian population-based birth cohort. <i>Caries Res</i> . 2012; 46(2): 170-6.	2009	*	
Brazil	Gaio EJ, Haas AN, Carrard VC, Oppermann RV, Albandar J, Susin C. Oral health status in elders from South Brazil: a population-based study. <i>Gerodontology</i> . 2012; 29(3): 214-23.	2001	*	
Brazil	Gradella CMF, Bernabé E, Bönecker M, Oliveira LB. Caries prevalence and severity, and quality of life in Brazilian 2- to 4-year-old children. <i>Community Dent Oral Epidemiol</i> . 2011; 39(6): 498-504.	2008-2009		†
Brazil	Silva-Boghossian CM, Luiz R, Colombo AP. Risk indicators for increased periodontal probing depth in subjects attending a public dental school in Brazil. <i>Oral Health Prev Dent</i> . 2011; 9(3): 289-99.	2005-2008	*	
Brazil	Bandéa MC, Nadin MR, Calixto LR, Saad JRC, da Silva SRC. Correlation between oral health perception and clinical factors in a Brazilian community. <i>Community Dent Health</i> . 2011; 28(1): 64-8.	2006-2007	*	
Brazil	Jamelli SR, Rodrigues CS, de Lira PI. Nutritional status and prevalence of dental caries among 12-year-old children at public schools: a case-control study. <i>Oral Health Prev Dent</i> . 2010; 8(1): 77-84.	2001	*	
Brazil	Marquezan M, Marquezan M, Faraco-Junior IM, Feldens CA, Kramer PF, Ferreira SH. Association between occlusal anomalies and dental caries in 3- to 5-year-old Brazilian children. <i>J Orthod</i> . 2011; 38(1): 8-14.	2009	*	
Brazil	Moure-Leite FR, Ramos-Jorge J, Ramos-Jorge ML, Paiva SM, Vale MP, Pordeus LA. Impact of dental pain on daily living of five-year-old Brazilian preschool children: prevalence and associated factors. <i>Eur Arch Paediatr Dent</i> . 2011; 12(6): 293-7.	2009	*	
Brazil	Parisotto TM, Steiner-Oliveira C, De Souza-E-Silva CM, Peres RCR, Rodrigues LKA, Nobre-Dos-Santos M. Assessment of cavitated and active non-cavitated caries lesions in 3- to 4-year-old preschool children: a field study. <i>Int J Paediatr Dent</i> . 2012; 22(2): 92-9.	2009	*	
Brazil	Piovesan C, Mendes FM, Antunes JLF, Ardenghi TM. Inequalities in the distribution of dental caries among 12-year-old Brazilian schoolchildren. <i>Braz Oral Res</i> . 2011; 25(1): 69-75.	2009	*	
Brazil	Piovesan C, Mendes FM, Ferreira FV, Guedes RS, Ardenghi TM. Socioeconomic inequalities in the distribution of dental caries in Brazilian preschool children. <i>J Public Health Dent</i> . 2010; 70(4): 319-26.	2008-2009		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Brazil	Frias AC, Antunes JLF, Fratucci MVB, Zilbovicius C, Junqueira SR, de Souza SF, Yassui EM. [Population based study on periodontal conditions and socioeconomic determinants in adults in the city of Guarulhos (SP), Brazil, 2006]. <i>Rev Bras Epidemiol.</i> 2011; 14(3): 495-507.	2006	*	
Brazil	Tóres LH do N, da Silva DD, Neri AL, Hilgert JB, Hugo FN, Sousa M da LR de. Association between underweight and overweight/obesity with oral health among independently living Brazilian elderly. <i>Nutrition.</i> 2013; 29(1): 152-7.	2008-2009	*	
Brazil	Traebert J, Jinbo Y, de Lacerda JT. Association between maternal schooling and caries prevalence: a cross-sectional study in southern Brazil. <i>Oral Health Prev Dent.</i> 2011; 9(1): 47-52.	2006	*	
Brazil	Miotto MHM de B, Barcellos LA, Velten DB. [Evaluation of the impact on quality of life caused by oral health problems in adults and the elderly in a southeastern Brazilian city]. <i>Cien Saude Colet.</i> 2012; 17(2): 397-406.	2008	*	
Brazil	Moreira R da S, Nico LS, Tomita NE. [Spatial risk and factors associated with edentulism among elderly persons in Southeast Brazil]. <i>Cad Saude Publica.</i> 2011; 27(10): 2041-54.	2005	*	
Brazil	Susin C, Valle P, Oppermann RV, Haugejorden O, Albandar JM. Occurrence and risk indicators of increased probing depth in an adult Brazilian population. <i>J Clin Periodontol.</i> 2005; 32(2): 123-9.	2001		
Brazil	Markus JR, Cruz CR, Maluf EMCP, Tahan TT, Hoffmann MM. Seroprevalence of hepatitis A in children and adolescents. <i>J Pediatr (Rio J).</i> 2011; 87(5): 419-24.	2006		
Brazil	Braga WSM, Castilho M da C, Borges FG, Martinho AC de S, Rodrigues IS, Azevedo EP de, Scazufca M, Menezes PR. Prevalence of hepatitis B virus infection and carriage after nineteen years of vaccination program in the Western Brazilian Amazon. <i>Rev Soc Bras Med Trop.</i> 2012; 45(1): 13-7.	2005-2007		
Brazil	Scaravelli NG, Passos AM, Voigt AR, Livramento A do, Toniai G, Treitinger A, Spada C. Seroprevalence of hepatitis B and hepatitis C markers in adolescents in Southern Brazil. <i>Cad Saude Publica.</i> 2011; 27(4): 753-8.	2008		
Brazil	Toniai GC, Passos AM, Livramento A do, Scaravelli NG, Batschauer AP de B, Bueno EC, Largura A, Spada C, Treitinger A. Hepatitis B marker seroprevalence and vaccination coverage in adolescents in the City of Itajaí, State of Santa Catarina, Southern Brazil, in 2008. <i>Rev Soc Bras Med Trop.</i> 2011; 44(4): 416-9.	2008		
Brazil	Pereira LMMB, Martelli CMT, Moreira RC, Merchan-Hamman E, Stein AT, Cardoso MRA, Figueiredo GM, Montarroyos UR, Braga C, Turchi MD, Coral G, Crespo D, Lima MLC, Alencar LCA, Costa M, dos Santos AA, Ximenes RAA. Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study. <i>BMC Infect Dis.</i> 2013; 60.	2005-2009		
Brazil	Cardoso MA, Scopel KKG, Muniz PT, Villamor E, Ferreira MU. Underlying factors associated with anemia in Amazonian children: a population-based, cross-sectional study. <i>PLoS One.</i> 2012; 7(5): e36341.	2007	*	
Brazil	Lobo CL de C, Pinto JFC, Nascimento EM, Moura PG, Cardoso GP, Hankins JS. The effect of hydroxycarbamide therapy on survival of children with sickle cell disease. <i>Br J Haematol.</i> 2013; 161(6): 852-60.	2000-2009	*	
Brazil	Wagner SC, de Castro SM, Gonzalez TP, Santin AP, Zaleski CF, Azevedo LA, Dreau H, Henderson S, Old J, Hutz MH. Neonatal screening for hemoglobinopathies: results of a public health system in South Brazil. <i>Genet Test Mol Biomarkers.</i> 2010; 14(4): 565-9.	2004-2007	*	
Brazil	Fonseca GH, Souza R, Salemi VMC, Jardim CVP, Gualandro SFM. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. <i>Eur Respir J.</i> 2012; 39(1): 112-8.	2006-2009		
Brazil	Zimmermann A, Bernuit D, Gerlinger C, Schaefer M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. <i>BMC Womens Health.</i> 2012; 6.	2009	*	
Brazil	Onofrio AC, da Silva MC, Domingues MR, Rombaldi AJ. Acute low back pain in high school adolescents in Southern Brazil: prevalence and associated factors. <i>Eur Spine J.</i> 2012; 21(7): 1234-40.	2009	*	
Brazil	De Vitta A, Martinez MG, Piza NT, Simeão SF de AP, Ferreira NP. [Prevalence of lower back pain and associated factors in students]. <i>Cad Saude Publica.</i> 2011; 27(8): 1520-8.	2007	*	
Brazil	Ferreira GD, Silva MC, Rombaldi AJ, Wrege ED, Siqueira FV, Hallal PC. Prevalence and associated factors of back pain in adults from southern Brazil: a population-based study. <i>Rev Bras Fisioter.</i> 2011; 15(1): 31-6.	2007	*	
Brazil	Souza SF de, Costa M da CN, Paim JS, Natividade MS da, Pereira SM, Andrade AM de S, Teixeira MG. Bacterial meningitis and living conditions. <i>Rev Soc Bras Med Trop.</i> 2012; 45(3): 323-8.	2004-2009		
Brazil	Sobel J, Gomes TAT, Ramos RTS, Hoekstra M, Rodrigue D, Rassi V, Griffin PM. Pathogen-specific risk factors and protective factors for acute diarrheal illness in children aged 12-59 months in São Paulo, Brazil. <i>Clin Infect Dis.</i> 2004; 38(11): 1545-51.	1989-1990	*	
Brazil	Munford V, Gilio AE, de Souza EC, Cardoso DM, Cardoso D da D de P, Borges AMT, Costa PSS da, Melgaço IAM, Rosa H, Carvalho PRA, Goldani MZ, Moreira ED Jr, Santana C, El Khoury A, Ikedo F, Rácz ML. Rotavirus gastroenteritis in children in 4 regions in Brazil: a hospital-based surveillance study. <i>J Infect Dis.</i> 2009; 200(Suppl 1): S106-113.	2005-2006	*	
Brazil	Stewien KE, da Cunha LC, Alvim A de C, dos Reis Filho SA, Alvim MA, Brandão AA, Neiva MN. Rotavirus associated diarrhoea during infancy in the city of São Luís (MA), Brazil: a two-year longitudinal study. <i>Rev Inst Med Trop Sao Paulo.</i> 1991; 33(6): 459-64.	1986-1988		
Brazil	CHOICE Study Group. Multicenter, randomized, double-blind clinical trial to evaluate the efficacy and safety of a reduced osmolarity oral rehydration salts solution in children with acute watery diarrhea. <i>Pediatrics.</i> 2001; 107(4): 613-8.	1995-1997	*	
Brazil	Guerrant RL, Kirchhoff LV, Shields DS, Nations MK, Leslie J, de Sousa MA, Araujo JG, Correia LL, Sauer KT, McClelland KE. Prospective study of diarrheal illnesses in northeastern Brazil: patterns of disease, nutritional impact, etiologies, and risk factors. <i>J Infect Dis.</i> 1983; 148(6): 986-97.	1978-1980	*	
Brazil	Linhares AC, Monção HC, Gabbay YB, de Araújo VL, Serruya AC, Loureiro EC. Acute diarrhoea associated with rotavirus among children living in Belém, Brazil. <i>Trans R Soc Trop Med Hyg.</i> 1983; 77(3): 384-90.	1979-1980	*	
Brazil	Rácz ML, Candéias JA, Trabsulsi JR, Murahowski J. Diarrheal diseases in Brazil: clinical features of rotavirus-associated gastroenteritis in children. <i>Eur J Epidemiol.</i> 1988; 4(3): 382-5.	1986-1987	*	
Brazil	Nunes MRMC, Magalhães PP, Penna FJ, Nunes JMM, Mendes EN. Diarrhea associated with Shigella in children and susceptibility to antimicrobials. <i>J Pediatr (Rio J).</i> 2012; 88(2): 125-8.	2004-2007	*	
Brazil	Nunes AA, de Mello LM, Parrode RN, Bittar JPM, Domingues AL da S. Prevalence of rotavirus in acute diarrhea and its association with clinical signs and symptoms. <i>J Trop Pediatr.</i> 2010; 56(3): 212-3.	2005-2007	*	
Brazil	Sáfadi MAP, Berezin EN, Munford V, Almeida FJ, de Moraes JC, Pinheiro CF, Rácz ML. Hospital-based surveillance to evaluate the impact of rotavirus vaccination in São Paulo, Brazil. <i>Pediatr Infect Dis J.</i> 2010; 29(11): 1019-22.	2004-2008	*	
Brazil	Lopes MA, Ferrioli E, Nakano EY, Litvov J, Bottino CMC. High prevalence of dementia in a community-based survey of older people from Brazil: association with intellectual activity rather than education. <i>J Alzheimers Dis.</i> 2012; 32(2): 307-16.	2009-2011		
Brazil	Bottino CMC, Azevedo D Jr, Tatsch M, Hototian SR, Moscoso MA, Folquitto J, Scalco AZ, Bazzarella MC, Lopes MA, Litvov J. Estimate of dementia prevalence in a community sample from São Paulo, Brazil. <i>Dement Geriatr Cogn Disord.</i> 2008; 26(4): 291-9.	2002-2003		
Brazil	Scazufca M, Menezes PR, Vallada HP, Crepaldi AL, Pastor-Valero M, Coutinho LMS, Di Rienzo VD, Almeida OP. High prevalence of dementia among older adults from poor socioeconomic backgrounds in São Paulo, Brazil. <i>Int Psychogeriatr.</i> 2008; 20(2): 394-405.	2003-2005		
Brazil	Herrera E Jr, Caramelli P, Silveira ASB, Nitrini R. Epidemiologic survey of dementia in a community-dwelling Brazilian population. <i>Alzheimer Dis Assoc Disord.</i> 2002; 16(2): 103-8.	1997-1998		
Brazil	Nitrini R, Caramelli P, Herrera E Jr, Bahia VS, Caixeta LF, Radanovic M, Anghinah R, Charchat-Fichman H, Porto CS, Carthey MT, Hartmann API, Huang N, Smid J, Lima EP, Takada LT, Takahashi DY. Incidence of dementia in a community-dwelling Brazilian population. <i>Alzheimer Dis Assoc Disord.</i> 2004; 18(4): 241-6.	1997-2000		
Brazil	Senna ER, De Barros ALP, Silva EO, Costa IF, Pereira LVB, Ciconelli RM, Ferraz MB. Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. <i>J Rheumatol.</i> 2004; 31(3): 594-7.	2001		
Brazil	Bevilacqua MC, Banhara MR, Oliveira AN, Moret AL, Alvarenga Kde F, Caldana Mde L, Camargo LM, Costa OA, Bastos JR. Survey of hearing disorders in an urban population in Rondonia, Brazil. <i>Rev Saude Publica.</i> 2013; 47(2): 309-15.	2006		
Brazil	Béria JU, Raymann BCW, Gigante LP, Figueiredo ACL, Jotz G, Roithman R, Selaimen da Costa S, Garcez V, Scherer C, Smith A. Hearing impairment and socioeconomic factors: a population-based survey of an urban locality in southern Brazil. <i>Rev Panam Salud Publica.</i> 2007; 21(6): 381-7.	2003		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Brazil	Maltz M, Schoenardie AB, Carvalho JC. Dental caries and gingivitis in schoolchildren from the municipality of Porto Alegre, Brazil in 1975 and 1996. <i>Clin Oral Investig.</i> 2001; 5(3): 199-204.	1975, 1996		
Brazil	Narvai PC, Castellanos RA, Frazão P. Dental caries prevalence in permanent teeth of schoolchildren in Brazil, 1970-1996. <i>Rev Saude Publica.</i> 2000; 34(2): 196-200.	1996		
Brazil	Rihs LB, de Sousa M da LR, Wada RS. Root caries in areas with and without fluoridated water at the Southeast region of São Paulo State, Brazil. <i>J Appl Oral Sci.</i> 2008; 16(1): 70-4.	1998		
Brazil	Mendes LGA, Biazevic MGH, Michael-Crosato E, Mendes MOA. Dental caries and associated factors among Brazilian adolescents: a longitudinal study. <i>Braz J Oral Sci.</i> 2008; 7(26): 1614-9.	2001-2005		
Brazil	Bönecker M, Marcenes W, Sheiham A. Caries reductions between 1995, 1997 and 1999 in preschool children in Diadema, Brazil. <i>Int J Paediatr Dent.</i> 2002; 12(3): 183-8.	1995-1999		
Brazil	Mattos-Graner R de O, Rontani RM, Gavião MB, Bocatto HA. Caries prevalence in 6-36-month-old Brazilian children. <i>Community Dent Health.</i> 1996; 13(2): 96-8.	1993		
Brazil	Leite IC, Ribeiro RA. Dental caries in the primary dentition in public nursery school children in Juiz de Fora, Minas Gerais, Brazil. <i>Cad Saude Publica.</i> 2000; 16(3): 717-22.	1998		
Brazil	Ferreira SH, Béria JU, Kramer PF, Feldens EG, Feldens CA. Dental caries in 0- to 5-year-old Brazilian children: prevalence, severity, and associated factors. <i>Int J Paediatr Dent.</i> 2007; 17(4): 289-96.	2005		
Brazil	Bastos RS, Silva RPR, Maia-Junior AF, Carvalho FS, Merlini S, Caldana ML, Lauris JRP, Bastos JRM. Dental caries profile in Monte Negro, Amazonian state of Rondônia, Brazil, in 2008. <i>J Appl Oral Sci.</i> 2010; 18(5): 437-41.	2008		
Brazil	Maciel SM, Marcenes W, Sheiham A. The relationship between sweetness preference, levels of salivary mutans streptococci and caries experience in Brazilian pre-school children. <i>Int J Paediatr Dent.</i> 2001; 11(2): 123-30.	1999		
Brazil	Dini EL, Holt RD, Bedi R. Caries and its association with infant feeding and oral health-related behaviours in 3-4-year-old Brazilian children. <i>Community Dent Oral Epidemiol.</i> 2000; 28(4): 241-8.	1998		
Brazil	Carvalho JC, Figueiredo MJ, Vieira EO, Mestrinho HD. Caries trends in Brazilian non-privileged preschool children in 1996 and 2006. <i>Caries Res.</i> 2009; 43(1): 2-9.	2006		
Brazil	Forte FDS, Martins RJ, Saliba Moimaz SA, das Saliba Garbin CA, das Saliba NA. Dental caries in preschool children in Bilac, Brazil. <i>Public Health.</i> 2005; 119(6): 556-7.	2002		
Brazil	Antoniuk SA, Zanon França M, Tannous Tahan T, Oliveira Rossoni AM, Dal-Ri Moreira S, Rodrigues Cruz C, Dal-Pra Dueci R, Hamdar F, Tiekou Frare Kira A. Study of 312 children with meningitis treated at a University Hospital in the South of Brazil. <i>Medicina (B Aires).</i> 2009; 69(1 Pt 1): 127-32.	2003-2007		
Brazil	Escosteguy CC, Medronho R de A, Madruga R, Dias HG, Braga RC, Azevedo OP. Epidemiologic surveillance and evaluation of meningitis hospital care. <i>Rev Saude Publica.</i> 2004; 38(5): 657-63.	1986-2002		
Brazil	Simões LLP, Andrade ALSS, Laval CA, Oliveira RM, Silva SA, Martelli CMT, Alves SL de A, Almeida RM, Andrade JG. Impact of Haemophilus influenzae b (Hib) vaccination on meningitis in Central Brazil. <i>Rev Saude Publica.</i> 2004; 38(5): 664-70.	1995-1999		
Brazil	Andrade L, Walters EE, Gentil V, Laurenti R. Prevalence of ICD-10 mental disorders in a catchment area in the city of São Paulo, Brazil. <i>Soc Psychiatry Psychiatr Epidemiol.</i> 2002; 37(7): 316-25.	1994-1996		
Brazil	Fleitch-Bilyk B, Goodman R. Prevalence of child and adolescent psychiatric disorders in southeast Brazil. <i>J Am Acad Child Adolesc Psychiatry.</i> 2004; 43(6): 727-34.	2000-2002		
Brazil	Costa E, Barreto SM, Uchoa E, Firmo JOA, Lima-Costa MF, Prince M. Prevalence of International Classification of Diseases, 10th Revision Common Mental Disorders in the Elderly in a Brazilian Community: The Bambui Health Ageing Study. <i>Am J Geriatr Psychiatry.</i> 2007; 15(1): 17-27.	1997-2001		
Brazil	Azevedo VMP, Santos MA, Albanesi Filho FM, Castier MB, Tura BR, Amino JGC. Outcome factors of idiopathic dilated cardiomyopathy in children - a long-term follow-up review. <i>Cardiol Young.</i> 2007; 17(2): 175-84.	1982-2004		
Brazil	Souza JP, Cecatti JG, Parpinelli MA, Serruya SJ, Amaral E. Appropriate criteria for identification of near-miss maternal morbidity in tertiary care facilities: a cross sectional study. <i>BMC Pregnancy Childbirth.</i> 2007; 7(20): 1-8.	2003-2004		
Brazil	Menezes AM, Perez-Padilla R, Jardim JR, Muiño A, Lopez MV, Valdivia G, Montes de Oca M, Talamo C, Hallal PC, Victora CG, PLATINO Team. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. <i>Lancet.</i> 2005; 366(9500): 1875-81.	2002-2004		
Brazil	Menezes A, Macedo SC, Gigante DP, da Costa JD, Olinto MT, Fiss E, Chatkin M, Hallal PC, Victora CG. Prevalence and Risk Factors for Chronic Obstructive Pulmonary Disease According to Symptoms and Spirometry. <i>COPD.</i> 2004; 1(2): 173-9.	2001		
Brazil	Queiroz LP, Peres MFP, Piovesan EJ, Kowacs F, Ciciarelli MC, Souza JA, Zukerman E. A nationwide population-based study of tension-type headache in Brazil. <i>Headache.</i> 2009; 49(1): 71-8.	2006-2007		
Brazil	Araujo MP, Girão, Manoel João Batista Castello, Girão, Manoel João Batista Castello, Sartori, Marair Gracio Ferreira. Pelvic floor disorders among indigenous women living in Xingu Indian Park, Brazil. <i>Int Urogynecol J.</i> 2009; 20(9): 1079-84.	2006		
Brazil	Goodman R, Neves dos Santos D, Robatto Nunes AP, Pereira de Miranda D, Fleitch-Bilyk B, Almeida Filho N. The Ilha de Maré study: a survey of child mental health problems in a predominantly African-Brazilian rural community. <i>Soc Psychiatry Psychiatr Epidemiol.</i> 2005; 40(1): 11-7.	2003		
Brazil	Rohde LA, Biederman J, Busnelo EA, Zimmermann H, Schmitz M, Martins S, Tramontina S. ADHD in a School Sample of Brazilian Adolescents: A Study of Prevalence, Comorbid Conditions, and Impairments. <i>J Am Acad Child Adolesc Psychiatry.</i> 1999; 38(6): 716-22.	1997		
Brazil	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2003-2008		
Brazil	Heinemann LAJ, Minh TD, Filonenko A, Uhl-Hochgräber K. Explorative evaluation of the impact of severe premenstrual disorders on work absenteeism and productivity. <i>Womens Health Issues.</i> 2010; 20(1): 58-65.	2007		
Brazil	Silva CML da, Gigante DP, Minten GC. Premenstrual symptoms and syndrome according to age at menarche in a 1982 birth cohort in southern Brazil. <i>Cad Saude Publica.</i> 2008; 24(4): 835-44.	2004-2005		
Brazil	Silva CML da, Gigante DP, Carret MLV, Fassa AG. Population study of premenstrual syndrome. <i>Rev Saude Publica.</i> 2006; 40(1): 47-56.	2003		
Brazil	Guimarães EMB, Guimarães MDC, Vieira MAS, Bontempo NM, Seixas MSS, Garcia MSD, Daud LES, Côrtes RLM, Alves M de FC. Lack of utility of risk score and gynecological examination for screening for sexually transmitted infections in sexually active adolescents. <i>BMC Med.</i> 2009; 8.	2002		
Brazil	Galduróz JCF, Noto AR, Nappo SA, Carlini EA. Trends in drug use among students in Brazil: analysis of four surveys in 1987, 1989, 1993 and 1997. <i>Braz J Med Biol Res.</i> 2004; 37(4): 523-31.	1993, 1997		
Brazil	Blay SL, Andreoli SB, Dewey ME, Gastal FL. Co-occurrence of chronic physical pain and psychiatric morbidity in a community sample of older people. <i>Int J Geriatr Psychiatry.</i> 2007; 22(9): 902-8.	2004		
Brazil	Mendoza-Sassi R, Béria JU, Fiori N, Bortolotto A. Prevalence of signs and symptoms, associated sociodemographic factors and resulting actions in an urban center in southern Brazil. <i>Rev Panam Salud Publica.</i> 2006; 20(1): 22-8.	2000		
Brazil	Arieta CEL, de Oliveira DF, Lupinacci AP de C, Novaes P, Paccola M, Jose NK, Limburg H. Cataract remains an important cause of blindness in Campinas, Brazil. <i>Ophthalmic Epidemiol.</i> 2009; 16(1): 58-63. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2003		
Brazil	Araújo Filho A, Salomão SR, Berezovsky A, Cinoto RW, Morales PHA, Santos FRG, Belfort R Jr. Prevalence of visual impairment, blindness, ocular disorders and cataract surgery outcomes in low-income elderly from a metropolitan region of São Paulo-Brazil. <i>Arq Bras Oftalmol.</i> 2008; 71(2): 246-53. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2002		
Brazil	Yu AL, Amaku M, Burattini MN, Massad E, Azevedo RS. Varicella transmission in two samples of children with different social behaviour in the State of São Paulo, Brazil. <i>Epidemiol Infect.</i> 2001; 127(3): 493-500.	1992, 1998		
Brazil	Yu AL, Costa JM, Amaku M, Panutti CS, Souza VA, Zanetta DM, Burattini MN, Massad E, Azevedo RS. Three year seroepidemiological study of varicella-zoster virus in São Paulo, Brazil. <i>Rev Inst Med Trop São Paulo.</i> 2000; 42(3): 125-8.	1992-1994		
Brazil	Correia JB, Patel MM, Nakagomi O, Montenegro FMU, Germano EM, Correia NB, Cuevas LE, Parashar UD, Cunliffe NA, Nakagomi T. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. <i>J Infect Dis.</i> 2010; 201(3): 363-9.	2006-2008		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Brazil	Gurgel RG, Bohland AK, Vieira SCF, Oliveira DMP, Fontes PB, Barros VF, Ramos MF, Dove W, Nakagomi T, Nakagomi O, Correia JB, Cunliffe N, Cuevas LE. Incidence of rotavirus and all-cause diarrhea in northeast Brazil following the introduction of a national vaccination program. <i>Gastroenterology</i> . 2009; 137(6): 1970-5.	2006-2008		
Brazil	Dias AC, Ribeiro M, Dunn J, Sesso R, Laranjeira R. Follow-up study of crack cocaine users: situation of the patients after 2, 5, and 12 years. <i>Subst Abus</i> . 2008; 29(3): 71-9.	1995-2006		
Brazil	Galduróz JCF, Noto AR, Nappo SA, Carlini EA. Household survey on drug abuse in Brazil: study involving the 107 major cities of the country – 2001. <i>Addict Behav</i> . 2005; 30(3): 545-56.	2001		
Brazil	De Micheli D, Formigoni MLOS. Drug use by Brazilian students: associations with family, psychosocial, health, demographic and behavioral characteristics. <i>Addiction</i> . 2004; 99(5): 570-8.	2001		
Brazil	Sartori AMC, Valentim J, de Soárez PC, Novaes HMD. Rotavirus morbidity and mortality in children in Brazil. <i>Rev Panam Salud Publica</i> . 2008; 23(2): 92-100.	1986-2006		
Brazil	De Nobrega M, Weckx LLM, Juliano Y. Study of the hearing loss in children and adolescents, comparing the periods of 1990-1994 and 1994-2000. <i>Int J Pediatr Otorhinolaryngol</i> . 2005; 69(6): 829-38.	1990-2000		
Brazil	Stein Z, Belmont L, Durkin M. Mild mental retardation and severe mental retardation compared: experiences in eight less developed countries. <i>Ups J Med Sci Suppl</i> . 1987; 89-96.	1987		
Brazil	Nitrini R, Caramelli P, Herrera E Jr, de Castro I, Bahia VS, Anghinah R, Caixeta LF, Radanovic M, Charchat-Fichman H, Porto CS, Teresa Carbery M, Hartmann API, Huang N, Smid J, Lima EP, Takahashi DY, Takada LT. Mortality from dementia in a community-dwelling Brazilian population. <i>Int J Geriatr Psychiatry</i> . 2005; 20(3): 247-53.	1997-2000		
Brazil	Victoria CR, Sassak LY, Nunes HR de C. Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of São Paulo State, Brazil. <i>Arq Gastroenterol</i> . 2009; 46(1): 20-5.	1986-2005	*	†
Brazil	Merikangas KR, Jin R, He J-P, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Ladea M, Medina-Mora ME, Ono Y, Posada-Villa J, Sagar R, Wells JE, Zarkov Z. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. <i>Arch Gen Psychiatry</i> . 2011; 68(3): 241-51.	2005-2007	*	
Brazil	Andrade LH, Wang Y-P, Andreoni S, Silveira CM, Alexandrino-Silva C, Siu ER, Nishimura R, Anthony JC, Gattaz WF, Kessler RC, Viana MC. Mental disorders in megacities: findings from the São Paulo megacity mental health survey. <i>Brazil. PLoS One</i> . 2012; 7(2): e31879.	2005-2007		
Brazil	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), United Nations Office on Drugs and Crime (UNODC). <i>Youth and Drugs in South American Countries: A Public Policy Challenge 2006</i> . Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS); 2006.	2005		
Brazil	Alves Meira ZM, de Castilho SR, Lins Barros MV, Maria Vitarelli A, Diniz Capanema F, Moreira NS, Moreira Camargos PA, Coelho Mota CC. Prevalence of rheumatic fever in children from a public high school in Belo Horizonte. <i>Arq Bras Cardiol</i> . 1995; 65(4): 331-4.	1992		
Brazil	Jungerman FS, Menezes PR, Pinsky L, Zaleski M, Caetano R, Laranjeira R. Prevalence of cannabis use in Brazil: data from the I Brazilian National Alcohol Survey (BNAS). <i>Addict Behav</i> . 2010; 35(3): 190-3.	2005-2006	*	
Brazil	Nunes ML, Geib LTC, Grupo Apego. Incidence of epilepsy and seizure disorders in childhood and association with social determinants: a birth cohort study. <i>J Pediatr (Rio J)</i> . 2011; 87(1): 50-6.	2003-2007		
Brazil	Nogueira PR, Rassi S, Corrêa K de S. Epidemiological, clinical e therapeutic profile of heart failure in a tertiary hospital. <i>Arq Bras Cardiol</i> . 2010; 95(3): 392-8.	2008		
Brazil	Amaral E, Souza JP, Surtta F, Luz AG, Sousa MH, Cecatti JG, Campbell O. A population-based surveillance study on severe acute maternal morbidity (near-miss) and adverse perinatal outcomes in Campinas, Brazil: the Vigimoma Project. <i>BMC Pregnancy Childbirth</i> . 2011; 11: 9.	2005	*	
Brazil	Morse ML, Fonseca SC, Gottroy CL, Waldmann CS, Gueller E. Severe maternal morbidity and near misses in a regional reference hospital. <i>Rev Bras Epidemiol</i> . 2011; 14(2): 310-22.	2009	*	
Brazil	Santos EMF, Amorim LP de, Costa OLN, Oliveira N, Guimarães AC. [Profile of gestational and metabolic risk in the prenatal care service of a public maternity in the Brazilian Northeast]. <i>Rev Bras Ginecol Obstet</i> . 2012; 34(3): 102-6.	2007-2008	*	
Brazil	Carvalho JFF de, Alves MB, Viana GÁA, Machado CB, Santos BFC dos, Kanamura AH, Lottenberg CL, Neto MC, Silva GS. Stroke Epidemiology, Patterns of Management, and Outcomes in Fortaleza, Brazil: A Hospital-Based Multicenter Prospective Study. <i>Stroke</i> . 2011; 42(12): 3341-6.	2009-2010		
Brazil	Lana-Peixoto MA, Frota ERC, Campos GB, Monteiro LP. Brazilian Committee for Treatment and Research in Multiple Sclerosis. The prevalence of multiple sclerosis in Belo Horizonte, Brazil. <i>Arq Neuropsiquiatr</i> . 2012; 70(2): 102-7.	2001	*	†
Brazil	Callegaro D, Goldbaum M, Morais L, Tilbery CP, Moreira MA, Gabbai AA, Scaff M. The prevalence of multiple sclerosis in the city of São Paulo, Brazil, 1997. <i>Acta Neurol Scand</i> . 2001; 104(4): 208-13.	1997	*	
Brazil	Ministry of Health (Brazil), National Regulatory Agency for Private Health Insurance and Plans (ANS) (Brazil). <i>Brazil Private Health Insurance Reimbursements to Unified Health System 2005</i> . Rio de Janeiro, Brazil: National Regulatory Agency for Private Health Insurance and Plans (ANS) (Brazil); 2005.	2005		
Brazil	Fernandes J, Schmidt M, Monte T, Tozzi S, Sander J. Prevalence of epilepsy: the Porto Alegre Study. <i>Epilepsia</i> . 1992; 33(Suppl 3): 132.	1991	*	
Brazil	Noronha ALA, Borges MA, Marques LHN, Zanetta DMT, Fernandes PT, de Boer H, Espíndola J, Miranda CT, Prilipko L, Bell GS, Sander JW, Li LM. Prevalence and pattern of epilepsy treatment in different socioeconomic classes in Brazil. <i>Epilepsia</i> . 2007; 48(5): 880-5.	2002	*	†
Brazil	Borges MA, Barros EP de, Zanetta DMT, Borges APP. [Prevalence of epilepsy in Bakairi Indians from Mato Grosso State, Brazil]. <i>Arq Neuropsiquiatr</i> . 2002; 60(1): 80-5.	2000	*	†
Brazil	Li LM, Fernandes PT, Noronha ALA, Marques LHN, Borges MA, Cendes F, Guerreiro CAM, Zanetta DMT, de Boer HM, Espíndola J, Miranda CT, Prilipko L, Sander JW. Demonstration Project on Epilepsy in Brazil: situation assessment. <i>Arq Neuropsiquiatr</i> . 2007; 5-13.	2007	*	
Brazil	Carrilho FJ, Kikuchi L, Branco F, Goncalves CS, Mattos AA de, Brazilian HCC Study Group. Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. <i>Clinics (Sao Paulo)</i> . 2010; 65(12): 1285-90.	2004-2009		
Brazil	Gonçalves CS, Pereira FE, Gayotto LC. Hepatocellular carcinoma in Brazil: report of a national survey (Florianópolis, SC, 1995). <i>Rev Inst Med Trop Sao Paulo</i> . 1997; 39(3): 165-70.	1992-1994		
Brazil	Miranda ECBM, Moia L de JP, Amaral I do SA, Barbosa MS de B, Conde SRS da S, de Araújo MTF, da Cruz E do RM, Demachki S, Bensabath G, Soares M do CP. [Hepatitis B and C virus infection and the hepatocellular carcinoma in the East Amazon, Brazil]. <i>Rev Soc Bras Med Trop</i> . 2004; 47-51.	1992-1999		
Brazil	Anselmi L, Fletlich-Bilyk B, Menezes AMB, Araújo CL, Rohde LA. Prevalence of psychiatric disorders in a Brazilian birth cohort of 11-year-olds. <i>Soc Psychiatry Psychiatr Epidemiol</i> . 2010; 45(1): 135-42.	2004-2006	*	
Brazil	World Health Organization (WHO). <i>WHO Tuberculosis Case Notifications</i> . Geneva, Switzerland: World Health Organization (WHO); 2001, 2004, 2007, 2010, 2012.	2001, 2004, 2007, 2010, 2012		
Brazil	Da Silva A Jr, Costa EC, Gomes JB, Leite FM, Gomez RS, Vasconcelos LP, Krynczantowski A, Moreira P, Teixeira AL. Chronic headache and comorbidities: a two-phase, population-based, cross-sectional study. <i>Headache</i> . 2010; 50(8): 1306-12.	2005-2006	*	†
Brazil	Mascarenhas REM, Machado MSC, Costa e Silva BFB da, Pimentel RFW, Ferreira TT, Leoni FMS, Grassi MFR. Prevalence and risk factors for bacterial vaginosis and other vulvovaginitis in a population of sexually active adolescents from Salvador, Bahia, Brazil. <i>Infect Dis Obstet Gynecol</i> . 2012; 378640.	2008-2010	*	
Brazil	Pinto VM, Szwarcwald CL, Baroni C, Stringari LL, Inocêncio LA, Miranda AE. Chlamydia trachomatis prevalence and risk behaviors in parturient women aged 15 to 24 in Brazil. <i>Sex Transm Dis</i> . 2011; 38(10): 957-61.	2009	*	
Brazil	Duarte WR, Barros AJD, Dias-da-Costa JS, Cattán JM. [Prevalence of near vision deficiency and related factors: a population-based study]. <i>Cad Saude Publica</i> . 2003; 19(2): 551-9.	1999-2000		
Brazil	Salomao SR, Cinoto RW, Berezovsky A, Araujo-Filho A, Mitsuhiro MRKH, Mendieta L, Moraes PHA, Pokharel GP, Belfort R Jr, Ellwein LB. Prevalence and causes of vision impairment and blindness in older adults in Brazil: the Sao Paulo Eye Study. <i>Ophthalmic Epidemiol</i> . 2008; 15(3): 167-75. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2004		
Brazil	Cowan FM, French RS, Mayaud P, Gopal R, Robinson NJ, de Oliveira SA, Faillace T, Uusküla A, Nygård-Kibur M, Ramalingam S, Sridharan G, El Aouad R, Alami K, Rbai M, Sunil-Chandra NP, Brown DW. Seroepidemiological study of herpes simplex virus types 1 and 2 in Brazil, Estonia, India, Morocco, and Sri Lanka. <i>Sex Transm Infect</i> . 2003; 79(4): 286-90.	2000	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Brazil	Schellini SA, Durkin SR, Hoyama E, Hirai F, Cordeiro R, Casson RJ, Selva D, Padovani CR. Prevalence and causes of visual impairment in a Brazilian population: the Botucatu Eye Study. <i>BMC Ophthalmol.</i> 2009; 9: 8. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2006-2007		
Brazil	Salgado PPC de A, Silva IN, Vieira EC, Simões e Silva AC. Risk factors for early onset of diabetic nephropathy in pediatric type 1 diabetes. <i>J Pediatr Endocrinol Metab.</i> 2010; 23(12): 1311-20.	1999-2005		
Brazil	Negrato CA, Dias JPL, Teixeira MF, Dias A, Salgado MH, Lauris JR, Montenegro RM Jr, Gomes MB, Jovanovic L. Temporal trends in incidence of Type 1 diabetes between 1986 and 2006 in Brazil. <i>J Endocrinol Invest.</i> 2010; 33(6): 373-7.	1986-2001, 2003-2006		
Brazil	Palvo F, Toledo EC, Menin AM, Jorge PP, Godoy MF, Solé D. Risk factors of childhood asthma in Sao Jose do Rio Preto, Sao Paulo, Brazil. <i>J Trop Pediatr.</i> 2008; 54(4): 253-7.	2003-2004	*	
Brazil	Saldanha PH, Nóbrega FG, Maia JC. Distribution and heredity of erythrocyte G6PD activity and electrophoretic variants among different racial groups at São Paulo, Brazil. <i>J Med Genet.</i> 1969; 6(1): 48-54.	1967-1969		
Brazil	Barreto OCO. Erythrocyte glucose-6-phosphate dehydrogenase deficiency in São Paulo, Brazil. <i>Braz J Med Biol Res.</i> 1970; 3(12): 61-5.	1968-1970		
Brazil	Compri MB, Saad ST, Ramalho AS. Genetico-epidemiological and molecular investigation of G-6-PD deficiency in a Brazilian community. <i>Cad Saude Publica.</i> 2000; 16(2): 335-42.	1995-1998		
Brazil	Castro S, Weber R, Dadalt V, Tavares V, Giugliani R. Prevalence of G6PD deficiency in newborns in the south of Brazil. <i>J Med Screen.</i> 2006; 13(2): 85-6.	2003		
Brazil	Sesso R, Anção MS, Draibe SA, Sigulem D, Ramos OL. Survival analysis of 1563 renal transplants in Brazil: report of the Brazilian Registry of Renal Transplantation. <i>Nephrol Dial Transplant.</i> 1990; 5(11): 956-61.	1987-1989		
Brazil	Passos VM, Barreto SM, Lima-Costa MF, Bambuí Health and Ageing Study (BHAS) Group. Detection of renal dysfunction based on serum creatinine levels in a Brazilian community: the Bambuí Health and Ageing Study. <i>Braz J Med Biol Res.</i> 2003; 36(3): 393-401.	1997		
Brazil	Fernández-Cean J, González-Martínez F, Schwedt E, Mazzuchi N. Renal replacement therapy in Latin America. <i>Kidney Int.</i> 2000; 57(s74): 55-59.	1997		
Brazil	Lugon JR, Strogoff de Matos JP. Disparities in end-stage renal disease care in South America. <i>Clin Nephrol.</i> 2010; 74(Suppl 1): S66-71.	2008-2010		
Brazil	Cisumano A, Garcia-Garcia G, Di Gioia C, Hermida O, Lavorato C, Carreño CA, Torrico MP, Batista PB, Romão JE, Badal HP, Miranda SE, Gomez R, Calderon MC, Sanchez SH, Lopez MA, Moscoso J, Merino RL, Polo JV, Lopez A, Romero NJ, Garcia R, Acosta BV, Lopez AS, Delpin ES, Mena E, González C, Milanés CL, Acchiardo S. End-stage renal disease and its treatment in Latin America in the twenty-first century. <i>Ren Fail.</i> 2006; 28(8): 631-7.	2004		
Brazil	Oliveira MB, Romão JE Jr, Zatz R. End-stage renal disease in Brazil: epidemiology, prevention, and treatment. <i>Kidney Int Suppl.</i> 2005; 97: S82-6.	2005		
Brazil	Santiago-Delplán EA, García VD. Latin American Transplant Registry VIIIth Report: 1998. <i>Transplant Proc.</i> 1999; 31(1-2): 214-6.	1995, 1997		
Brazil	Zatz R, Romão JE Jr. End-stage renal failure and national resources: the Brazilian experience. <i>Ren Fail.</i> 2006; 28(8): 627-9.	2005		
Brazil	Melo AS, Vieira CS, Barbieri MA, Rosa-E-Silva ACJS, Silva AAM, Cardoso VC, Reis RM, Ferriani RA, Silva-de-Sá MF, Bettiol H. High prevalence of polycystic ovary syndrome in women born small for gestational age. <i>Hum Reprod.</i> 2010; 25(8): 2124-31.	2007-2008		
Brazil	Oliveira MT de Jr, Canesin MF, Munhoz RT, del Carlo CH, Scipioni A, Ramires JAF, Barreto ACP. [Major clinical characteristics of patients surviving 24 months or more after hospitalization due to decompensated heart failure]. <i>Arq Bras Cardiol.</i> 2005; 84(2): 161-6.	1993-1995		
Brazil	Dini EL, Guimarães LO. Periodontal conditions and treatment needs (CPTIN) in a worker population in Araraquara, SP, Brazil. <i>Int Dent J.</i> 1994; 44(4): 309-11.	1992		
Brazil	Flores-de-Jacoby L, Bruchmann S, Mengel R, Zafiroopoulos GG. Periodontal conditions in Rio de Janeiro City (Brazil) using the CPTIN. <i>Community Dent Oral Epidemiol.</i> 1991; 19(2): 127-8.	1988		
Brazil	Susin C, Haas AN, Valle PM, Oppermann RV, Albandar JM. Prevalence and risk indicators for chronic periodontitis in adolescents and young adults in south Brazil. <i>J Clin Periodontol.</i> 2011; 38(4): 326-33.	2006		
Brazil	Susin C, Vecchia CFD, Oppermann RV, Haugejorden O, Albandar JM. Periodontal Attachment Loss in an Urban Population of Brazilian Adults: Effect of Demographic, Behavioral, and Environmental Risk Indicators. <i>J Periodontol.</i> 2004; 75(7): 1033-41.	2002		
Brazil	Ministry of Health (Brazil). Brazil Information System for Notifiable Diseases - Typhoid Fever.	2002-2006, 2008-2011	*	
Brazil	Barros MB de A, Botega NJ, Dalgalarondo P, Marín-León L, de Oliveira HB. Prevalence of alcohol abuse and associated factors in a population-based study. <i>Rev Saude Publica.</i> 2007; 41(4): 502-9.	2003		
Brazil	Grinfeld H, Goldenberg S, Segre CA, Chadi G. Fetal alcohol syndrome in São Paulo, Brazil. <i>Paediatr Perinat Epidemiol.</i> 1999; 13(4): 496-7.	1997	*	
Brazil	Joinville Stroke Registry. Brazil - Joinville Stroke Registry Tables 2010-2011. [Unpublished].	2010-2011	*	
Brazil	Arruda MA, Guidetti V, Galli F, Albuquerque RCAP, Bigal ME. Primary headaches in childhood – a population-based study. <i>Cephalalgia.</i> 2010; 30(9): 1056-64.	2009	*	
Brazil	Arruda MA, Bigal ME. Behavioral and emotional symptoms and primary headaches in children: a population-based study. <i>Cephalalgia.</i> 2012; 32(15): 1093-100.	2009	*	
Brazil	Benseñor IM, Goulart AC, Lofu PA, Menezes PR, Scazufca M. Cardiovascular risk factors associated with migraine among the elderly with a low income: the Sao Paulo Ageing and Health Study (SPAHS). <i>Cephalalgia.</i> 2011; 31(3): 331-7.	2003-2005	*	
Brazil	Falavigna A, Teles AR, Velho MC, Vedana VM, Silva RC da, Mazzocchin T, Basso M, Braga GL de. Prevalence and impact of headache in undergraduate students in Southern Brazil. <i>Arq Neuropsiquiatr.</i> 2010; 68(6): 873-7.	2009	*	†
Brazil	Dias-Tosta E, Küchelhaus CS. Guillain Barré syndrome in a population less than 15 years old in Brazil. <i>Arq Neuropsiquiatr.</i> 2002; 60(2-B): 367-73.	1990-1996		
Brazil	Rocha MSG, Brucki SMD, Carvalho AA de S, Lima UWP. Epidemiologic features of Guillain-Barré syndrome in São Paulo, Brazil. <i>Arq Neuropsiquiatr.</i> 2004; 62(1): 33-7.	1995-2002		†
Brazil	Da Silva LPA, Queiros F, Lima I. Etiology of hearing impairment in children and adolescents of a reference center APADA in the city of Salvador, state of Bahia. <i>Braz J Otorhinolaryngol.</i> 2006; 72(1): 33-6.	2002-2004	*	
Brazil	Gondim LMA, Balen SA, Zimmermann KJ, Pagnossin DF, Fialho I de M, Roggia SM. Study of the prevalence of impaired hearing and its determinants in the city of Itajaí, Santa Catarina State, Brazil. <i>Braz J Otorhinolaryngol.</i> 2012; 78(2): 27-34.	2008-2011	*	
Brazil	Baraky LR, Bento RF, Raposo NRB, Tibiriçá SHC, Ribeiro LC, Barone MMVB, Vasconcelos NB. Disabling hearing loss prevalence in Juiz de Fora, Brazil. <i>Braz J Otorhinolaryngol.</i> 2012; 78(4): 52-8.	2009	*	
Brazil	Camargo LM, Ferreira MU, Krieger H, De Camargo EP, Da Silva LP. Unstable hypoendemic malaria in Rondonia (western Amazon region, Brazil): epidemic outbreaks and work-associated incidence in an agro-industrial rural settlement. <i>Am J Trop Med Hyg.</i> 1994; 51(1): 16-25 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991-1992	*	†
Brazil	Alves FP, Durlacher RR, Menezes MJ, Krieger H, Silva LHP, Camargo EP. High prevalence of asymptomatic Plasmodium vivax and Plasmodium falciparum infections in native Amazonian populations. <i>Am J Trop Med Hyg.</i> 2002; 66(6): 641-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998-2000	*	†
Brazil	Duarte EC, Gyorkos TW, Pang L, Abrahamowicz M. Epidemiology of malaria in a hypoendemic Brazilian Amazon migrant population: a cohort study. <i>Am J Trop Med Hyg.</i> 2004; 70(3): 229-37 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996-1997	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Brazil	Tada MS, Marques RP, Mesquita E, Dalla Martha RC, Rodrigues JA, Costa JDN, Peleascov RR, Katsuragawa TH, Pereira-da-Silva LH. Urban malaria in the Brazilian Western Amazon Region I: high prevalence of asymptomatic carriers in an urban riverside district is associated with a high level of clinical malaria. Mem Inst Oswaldo Cruz. 2007; 102(3): 263-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001-2002	*	†
Brazil	World Health Organization (WHO). Brazil WHO Leishmaniasis Country Profile.	1984-2010	*	
Brazil	Albuquerque MF, Marzochi MC, Sabroza PC, Braga MC, Padilha T, Silva MC, Silva MR, Schindler HC, Maciel MA, Souza W. Bancroftian filariasis in two urban areas of Recife, Brazil: pre-control observations on infection and disease. Trans R Soc Trop Med Hyg. 1995; 89(4): 373-7, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1990-1991	*	
Brazil	Braga C, de Albuquerque MF, Schindler H, Rezende A, Maciel A, Silva MC, Furtado A, de Carvalho AB, Lapa T, Ximenes RA. [Epidemiological pattern of lymphatic filariasis in children living in endemic areas]. J Pediatr (Rio J). 1997; 73(2): 95-100.	1991	*	
Brazil	Braga C, Dourado I, Ximenes R, Miranda J, Alexander N. Bancroftian filariasis in an endemic area of Brazil: differences between genders during puberty. Rev Soc Bras Med Trop. 2005; 38(3): 224-8, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1999-2000	*	
Brazil	Maciel MA, Marzochi KB, Silva EC, Rocha A, Furtado AF. [Comparative studies on endemic areas of bancroftian filariasis in Greater Recife, Brazil]. Cad Saude Publica. 1994; 10(Suppl 2): 301-9, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1991	*	
Brazil	Medeiros Z, Oliveira C, Quaresma J, Barbosa E, Aguiar-Santos AM, Bonfim C, Almeida J, Lessa F. Lymphatic filariasis in Moreno, Northeast Brazil. Rev Bras Epidemiol. 2004; 7(1): 73-9.	2001-2003	*	
Brazil	Brandão E, Bonfim C, Cabral D, Lima JL, Aguiar-Santos AM, Maciel A, Medeiros Z. Mapping of Wuchereria bancrofti infection in children and adolescents in an endemic area of Brazil. Acta Trop. 2011; 120(1-2): 151-4, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2000-2002	*	
Brazil	Medeiros Z, Bonfim C, Alves A, Oliveira C, Netto MJE, Aguiar-Santos AM. The epidemiological delimitation of lymphatic filariasis in an endemic area of Brazil, 41 years after the first recorded case. Ann Trop Med Parasitol. 2008; 102(6): 509-19.	2000	*	
Brazil	Bonfim C, Lessa F, Oliveira C, Evangelista MJ, do Espírito Santo M, Meireles E, Pereira JC, Medeiros Z. [The occurrence and distribution of lymphatic filariasis in Greater Metropolitan Recife: the case of an endemic area in Jaboatão dos Guararapes, Pernambuco, Brazil]. Cad Saude Publica. 2003; 19(5): 1497-505, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2000-2002	*	
Brazil	Braga C, Dourado ML, Ximenes RA de A, Alves L, Brayner F, Rocha A, Alexander N. Field evaluation of the whole blood immunochromatographic test for rapid bancroftian filariasis diagnosis in the northeast of Brazil. Rev Inst Med Trop Sao Paulo. 2003; 45(3): 125-9, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1999	*	
Brazil	Anosike JC. The status of human filariasis in north-western zone of Bauchi State, Nigeria. Appl Parasitol. 1994; 35(2): 133-40, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1996-2001	*	
Brazil	Fontes G, Braun RF, Fraiha Neto H, Vieira JBF, Padilha SS, Rocha RC, da Rocha EMM. [Lymphatic filariasis in Belém, Pará State, North of Brazil and the perspective of elimination]. Rev Soc Bras Med Trop. 2005; 38(2): 131-6, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1980-1986	*	
Brazil	Kawabata-Yoshihara LA, Benseñor IM, Kawabata VS, Menezes PR, Scazufca M, Lotufo PA. Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging & health study. Arq Bras Cardiol. 2009; 93(6): 602-7.	2003-2005	*	
Brazil	Makdisse M, Pereira A da C, Brasil D de P, Borges JL, Machado-Coelho GLL, Krieger JE, Nascimento Neto RM, Chagas ACP. Hearts of Brazil Study and Peripheral Arterial Disease Committee of the Brazilian Society of Cardiology/Funacor. Prevalence and risk factors associated with peripheral arterial disease in the Hearts of Brazil Project. Arq Bras Cardiol. 2008; 91(6): 370-82.	2004		
Brazil	Lamario LM, Ramos FL, Mello WA, Santos MC, Barbagelata LS, Justino MCA, da Silva AF, Quaresma AJPG, da Silva VB, Burbano RR, Linhares AC. Prevalence and clinical features of respiratory syncytial virus in children hospitalized for community-acquired pneumonia in northern Brazil. BMC Infect Dis. 2012; 119.	2006-2007	*	
Brazil	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Brazil	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Brazil	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Brazil	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Brazil	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Brazil	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1993; 68(25): 181-6.	1992	*	
Brazil	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Brazil	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Brazil	Clinical, Subclinical, and Epidemiological Aspects of Vitamin A Deficiency in the State of Paraíba as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1992		
Brazil	Smith JS, Herrero R, Muñoz N, Eluf-Neto J, Ngelangel C, Bosch FX, Ashley RL. Prevalence and risk factors for herpes simplex virus type 2 infection among middle-age women in Brazil and the Philippines. Sex Transm Dis. 2001; 28(4): 187-94.	1990-1991	*	
Brazil	Weinberg A, Canto CL, Pamuti CS, Kwang WN, Garcia SA, Zugaib M. Herpes simplex virus type 2 infection in pregnancy: asymptomatic viral excretion at delivery and seroepidemiologic survey of two socioeconomically distinct populations in São Paulo, Brazil. Rev Inst Med Trop Sao Paulo. 1993; 35(3): 285-90.	1988-1989	*	
Brazil	Morales Ibrahim F, Moraes Ibrahim M, Pompeo de Camargo JR, Veronese Rodrigues M de L, Scott IU, Silva Paula J. Visual impairment and myopia in Brazilian children: a population-based study. Optom Vis Sci. 2013; 90(3): 223-7.	2007	*	
Brazil	Secretariat of Health Surveillance, Ministry of Health (Brazil). Brazil Dengue Incidence Rate--Indicators and Basic Data 2008. Rio de Janeiro, Brazil: Ministry of Health (Brazil), 2008.	2003-2007		
Brazil	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2003. Pan American Health Organization (PAHO).	2003		†
Brazil	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2004. Pan American Health Organization (PAHO).	2004		†
Brazil	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2005. Pan American Health Organization (PAHO).	2005		†
Brazil	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2006. Pan American Health Organization (PAHO).	2006		†
Brazil	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2007. Pan American Health Organization (PAHO).	2007		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Brazil	Brazilian Society of Nephrology. Brazilian Society of Nephrology Dialysis Census 2006. São Paulo, Brazil: Brazilian Society of Nephrology.	2005		
Brazil	Brazilian Society of Nephrology. Brazilian Society of Nephrology Dialysis Census 2007.	2003-2006		
Brazil	Brazilian Society of Nephrology. Brazilian Society of Nephrology Dialysis Census 2008. São Paulo, Brazil: Brazilian Society of Nephrology.	2002, 2005, 2007		
Brazil	Brazilian Society of Nephrology. Brazilian Society of Nephrology Dialysis Census 2009. São Paulo, Brazil: Brazilian Society of Nephrology.	1993-1999, 2002, 2004-2009		
Brazil	Afonso ET, Minamisava R, Bierenbach AL, Escalante JJC, Alencar AP, Domingues CM, Morais-Neto OL, Toscano CM, Andrade AL. Effect of 10-Valent Pneumococcal Vaccine on Pneumonia among Children, Brazil. <i>Emerg Infect Dis.</i> 2013; 19(4): 589-97.	2010-2011	*	
Brazil	Zin AA, Moreira MEL, Bunce C, Darlow BA, Gilbert CE. Retinopathy of Prematurity in 7 Neonatal Units in Rio de Janeiro: Screening Criteria and Workload Implications. <i>Pediatrics.</i> 2010; 126(2): e410-e417.	2005	*	†
Brazil	Filho JBF, Eckert GU, Procianny L, Barros CK, Procianny RS. Incidence and risk factors for retinopathy of prematurity in very low and in extremely low birth weight infants in a unit-based approach in southern Brazil. <i>Eye (Lond).</i> 2007; 23(1): 25-30.	2004	*	†
Brazil	Graziano RM, Leone CR, Cunha SL, Pinheiro AC. [Prevalence of retinopathy of prematurity in very low birth weight infants]. <i>J Pediatr (Rio J).</i> 1996; 73(6): 377-82.	1993	*	†
Brazil	Berezin EN, Carvalho ES, Casagrande S, Brandileone MC, Mimica IM, Farhat CK. Streptococcus pneumoniae penicillin-nonsusceptible strains in invasive infections in Sao Paulo, Brazil. <i>Pediatr Infect Dis J.</i> 1996; 15(11): 1051-3.	1989-1993		
Brazil	Reis JN, Cordeiro SM, Coppola SJ, Salgado K, Carvalho MGS, Teixeira LM, Thompson TA, Facklam RR, Reis MG, Ko AL. Population-based survey of antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae from meningitis patients in Salvador, Brazil. <i>J Clin Microbiol.</i> 2002; 40(1): 275-7.	1995-1999		
Brazil	Brito LL, Barreto ML, Silva Rde C, Assis AM, Reis MG, Parraga I, Blanton RE. [Risk factors for iron-deficiency anemia in children and adolescents with intestinal helminthic infections]. <i>Rev Panam Salud Publica.</i> 2003; 14(6): 422-31.	2002		
Brazil	Santos L, Dricot J, Ascutti L, Benigna M, Dricot-d'Ans C. [Epidemiologic Survey of serophthalmia in the State of Paraíba]. <i>Rev Bras Med.</i> 1983; 419-25 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1981-1983		
Brazil	Corrainsi P, Baelum V, Panuti CM, Pustiglioni AN, Romito GA, Pastiglioni FE. Periodontal attachment loss in an untreated isolated population of Brazil. <i>J Periodontol.</i> 2008; 79(4): 610-20.	2005-2006		
Brazil	Ministry of Health (Brazil). Brazil National Oral Health Survey 2010.	2010	*	
Brazil	Ministry of Health (Brazil). Prevenção e Atenção às IST/AIDS na Saúde Mental no Brasil: Análises, Desafios e Perspectivas [Prevention and Attention to STI/AIDS in Mental Health in Brazil: Analysis, Challenges and Prospects]. Rio de Janeiro, Brazil: Ministry of Health (Brazil), 2008.	2004		
Brazil	Campos JADB, Melanda EA, Antunes J da S, Foschini ALR. Dental caries and the nutritional status of preschool children: a spatial analysis. <i>Cien Saude Colet.</i> 2011; 16(10): 4161-8.	2006-2007	*	
Brazil	Costa SM, Vasconcelos M, Haddad JPA, Abreu MHNG. The severity of dental caries in adults aged 35 to 44 years residing in the metropolitan area of a large city in Brazil: a cross-sectional study. <i>BMC Oral Health.</i> 2012; 25.	2010	*	
Brazil	Jeremias F, de Souza JF, Silva CM da C, Cordeiro R de CL, Zuanon ACC, Santos-Pinto L. Dental caries experience and Molar-Incisor Hypomineralization. <i>Acta Odontol Scand.</i> 2013; 71(3-4): 870-6.	2011	*	
Brazil	Benazzi AS, da Silva RP, de Meneghim M, Ambrosano GM, Pereira AC. Dental caries and fluorosis prevalence and their relationship with socioeconomic and behavioural variables among 12-year-old schoolchildren. <i>Oral Health Prev Dent.</i> 2012; 10(1): 65-73.	2007	*	
Brazil	De Marchi RJ, Hugo FN, Hilgert JB, Padilha DMP. Association between number of teeth, edentulism and use of dentures with percentage body fat in south Brazilian community-dwelling older people. <i>Gerodontology.</i> 2012; 29(2): e69-76.	2006	*	
Brazil	World Health Organization (WHO). Mental Illness in General Health Care: An International Study. Geneva, Switzerland: World Health Organization (WHO), 1995.	1991-1992		
Brazil	Madrugá CS, Laranjeira R, Caetano R, Ribeiro W, Zaleski M, Pinsky I, Ferri CP. Early life exposure to violence and substance misuse in adulthood-The first Brazilian national survey. <i>Addict Behav.</i> 2011; 36(3): 251-5.	2005-2006		
Brazil	De Campos Lopes CB, Yamada AT, Aratijo F, Pereira Barreto AC, Mansur AJ. Socioeconomic factors in the prognosis of heart failure in a Brazilian cohort. <i>Int J Cardiol.</i> 2006; 113(2): 181-7.	1998-2000		
Brazil	Almeida TF de, Vianna MIP, Cabral MBB de S, Cangussu MCT, Floriano FR. Family context and incidence of dental caries in preschool children living in areas covered by the Family Health Strategy in Salvador, Bahia State, Brazil. <i>Cad Saude Publica.</i> 2012; 28(6): 1183-95.	2007-2008	*	
Brazil	Bonanato K, Pordues IA, Moura-Leite FR, Ramos-Jorge ML, Vale MP, Paiva SM. Oral disease and social class in a random sample of five-year-old preschool children in a Brazilian city. <i>Oral Health Prev Dent.</i> 2010; 8(2): 125-32.	2005	*	
Brazil	Pardi V, Kopycka-Kedzierawski DT, Billings RJ, Pereira SM, de Meneghim M, Pereira AC. Assessment of caries experience in 12-year-old adolescents in Piracicaba, Sao Paulo, Brazil. <i>Oral Health Prev Dent.</i> 2010; 8(4): 361-7.	2007-2008	*	
Brazil	Pitanga Fernandes ET, Duarte Vargas AM, Oliveira AC, Camargo da Rosa MA, Dutra Lucas S, Ferreira E, Ferreira E. Factors related to dental caries in adolescents in southeastern Brazil. <i>Eur J Paediatr Dent.</i> 2010; 11(4): 165-70.	2008	*	
Brazil	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Brazil	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Brazil	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Brazil	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Brazil	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Brazil	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Brazil	Cordeiro MT, Schatzmayr HG, Nogueira RMR, Oliveira VF de, Melo WT de, Carvalho EF de. Dengue and dengue hemorrhagic fever in the State of Pernambuco, 1995-2006. <i>Rev Soc Bras Med Trop.</i> 2007; 40(6): 605-11.	1995-2006	*	
Brazil	Garofolo L, Barros N Jr, Miranda F Jr, D'Almeida V, Cardien LC, Ferreira SR. Association of increased levels of homocysteine and peripheral arterial disease in a Japanese-Brazilian population. <i>Eur J Vasc Endovasc Surg.</i> 2007; 34(1): 23-8.	2000		
Brazil	El Khouri M, Cordeiro Q, Luz DABP da, Duarte LS, Gama MEA, Corbett CEP. Endemic hepatitis B and C virus infection in a Brazilian Eastern Amazon region. <i>Arq Gastroenterol.</i> 2010; 47(1): 35-41.	2007-2008		
Brazil	Livramento A do, Cordova CMM de, Spada C, Treitinger A. Seroprevalence of hepatitis B and C infection markers among children and adolescents in the southern Brazilian region. <i>Rev Inst Med Trop Sao Paulo.</i> 2011; 53(1): 13-7.	2007-2008		
Brazil	Aquino JA, Pegado KA, Barros LP, Machado LFA. Soroprevalência de infecções por vírus da hepatite B e vírus da hepatite C em indivíduos do Estado do Pará. <i>Rev Soc Bras Med Trop.</i> 2008; 334-7.	2002-2005		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Brazil	Voigt AR, Strazer Neto M, Spada C, Treitinger A. Seroprevalence of hepatitis B and hepatitis C markers among children and adolescents in the south Brazilian region: metropolitan area of Florianópolis, Santa Catarina. <i>Braz J Infect Dis.</i> 2010; 14(1): 60-5.	2007-2008		
Brazil	De Paula VS, Arruda ME, Vitral CL, Gaspar AM. Seroprevalence of viral hepatitis in riverine communities from the Western Region of the Brazilian Amazon Basin. <i>Mem Inst Oswaldo Cruz.</i> 2001; 96(8): 1123-8.	1997-1999		
Brazil	Tavares-Neto J, Almeida D, Soares MC, Uchoa R, Viana S, Darub R, Farias E, Rocha G, Vitvitski L, Paraná R. Seroprevalence of hepatitis B and C in the Western Brazilian Amazon region (Rio Branco, Acre): a pilot study carried out during a hepatitis B vaccination program. <i>Braz J Infect Dis.</i> 2004; 8(2): 133-9.	2000	*	
Brazil	Braga Wornei Silva Miranda SEB da. Soroprevalência da infecção pelo vírus da hepatite B e pelo plasmódio em Lábrea, Amazonas: estimativa da ocorrência de prováveis coinfeções. <i>Rev Soc Bras Med Trop.</i> 2005; 38(3): 218-23.	2000	*	
Brazil	Neto M, De JP, Dourado MV, Reis MG dos, Gonçalves MS. A novel c.197T -> A variant among Brazilian neonates with glucose-6-phosphate dehydrogenase deficiency. <i>Genet Mol Biol.</i> 2008; 31(1): 33-5.	2000	*	
Brazil	Almeida D, Tavares-Neto J, Queiroz-Andrade M, Dias C, Ribeiro T, Silva F, Silva-Araújo J, Tatsch F, Paraná R. [Sociodemographic aspects of seroprevalence of hepatitis A virus in the settlement of Cavunge, a semi-arid region of Bahia State]. <i>Rev Soc Bras Med Trop.</i> 2006; 39(1): 76-8.	2000	*	
Brazil	Gomes MAC, Ferreira A de SP, da Silva AAM, de Souza ER. Hepatitis A: seroprevalence and associated factors among schoolchildren of São Luís (MA), Brazil. <i>Rev Bras Epidemiol.</i> 2011; 14(4): 548-55.	2002-2004	*	
Brazil	Gonçalves AAS, Oliveira LCM de. Seroprevalence of hepatitis A immunity among children and adolescents in two cities of the Triângulo Mineiro region, state of Minas Gerais, Brazil. <i>Braz J Infect Dis.</i> 2012; 16(5): 496-7.	2010-2011	*	
Brazil	Assis SB, Souto FJ, Fontes CJ, Gaspar AM. Prevalência da infecção pelos vírus das hepatites A e E em escolas de município da Amazônia Matogrossense. <i>Rev Soc Bras Med Trop.</i> 2002; 35(2): 155-8.	1998		
Brazil	Bortolero AL, Bonametti AM, Morimoto HK, Matsuo T, Reiche EMV. Seroprevalence for hepatitis E virus (HEV) infection among volunteer blood donors of the Regional Blood Bank of Londrina, State of Paraná, Brazil. <i>Rev Inst Med Trop Sao Paulo.</i> 2006; 48(2): 87-92.	1999		
Brazil	Trinta KS, Liberto MI, de Paula VS, Yoshida CF, Gaspar AM. Hepatitis E virus infection in selected Brazilian populations. <i>Mem Inst Oswaldo Cruz.</i> 2001; 96(1): 25-9.	1994-1998		
Brazil	Daudt LE, Zechmeister D, Portal L, Neto EC, Silla LM da R, Giugliani R. [Neonatal screening for hemoglobinopathies: a pilot study in Porto Alegre, Rio Grande do Sul, Brazil]. <i>Cad Saude Publica.</i> 2002; 18(3): 833-41.	1999	*	
Brazil	Pinheiro LS, Gonçalves RP, Tomé CAS, Alcântara AEE, Marques ARC, Silva MM da. Prevalência de hemoglobina S em recém-nascidos de Fortaleza: importância da investigação neonatal. <i>Rev Bras Ginecol Obstet.</i> 2006; 28(2): 122-5.	2001-2002	*	
Brazil	Zago MA, Costa FF, Tone LG, Bottura C. Hereditary hemoglobin disorders in a Brazilian population. <i>Hum Hered.</i> 1983; 33(2): 125-9.	1978-1982	*	
Brazil	Ministry of Health (Brazil). Brazil Information System for Notifiable Diseases - Leprosy. [Unpublished].	2001-2012	*	
Brazil	Osório FMF, Lauer GM, Lima AS, Vidigal PVT, Ferrari TCA, Couto CA. Epidemiological aspects of hepatocellular carcinoma in a referral center of Minas Gerais, Brazil. <i>Arq Gastroenterol.</i> 2013; 50(2): 97-100.	1998-2010	*	
Brazil	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L, Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Ann Hepatol.</i> 2010; 9(1): 63-9.	2006-2008	*	
Brazil	Tapia-Conyer R, Santos JI, Cavalcanti AM, Urdaneta E, Rivera L, Manterola A, Potin M, Ruttiman R, Tanaka Kido J. Hepatitis A in Latin America: A Changing Epidemiologic Pattern. <i>Am J Trop Med Hyg.</i> 1999; 61(5): 825-9.	1996-1997		
Brazil	Vital CL, Yoshida CF, Lemos ER, Teixeira CS, Gaspar AM. Age-specific prevalence of antibodies to hepatitis A in children and adolescents from Rio de Janeiro, Brazil, 1978 and 1995. Relationship of prevalence to environmental factors. <i>Mem Inst Oswaldo Cruz.</i> 1998; 93(1): 1-5.	1978, 1995		
Brazil	Sutmoller F, Gaspar AM, Cynamon SE, Richa N, Mercadante LA, Schatzmayr HG. A water-borne hepatitis A outbreak in Rio de Janeiro. <i>Mem Inst Oswaldo Cruz.</i> 1982; 77(1): 9-17.	1980		
Brazil	Black FL, Jacobson DL. Hepatitis A antibody in an isolated Amerindian tribe fifty years after exposure. <i>J Med Virol.</i> 1986; 19(1): 19-21.	1983-1984		
Brazil	Abuzwaida AR, Sidoni M, Yoshida CF, Schatzmayr HG. Seroepidemiology of hepatitis A and B in two urban communities of Rio de Janeiro, Brazil. <i>Rev Inst Med Trop Sao Paulo.</i> 1987; 29(4): 219-23.	1986		
Brazil	Queiroz DA, Cardoso DD, Martelli CM, Martins RM, Porto SO, Borges AM, Azevedo MS, Daher RR. Risk factors and prevalence of antibodies against hepatitis A virus (HAV) in children from day-care centers, in Goiania, Brazil. <i>Rev Inst Med Trop Sao Paulo.</i> 1995; 37(5): 427-33.	1991-1992		
Brazil	Pinho JR, Sumita LM, Moreira RC, de Souza VA, Saraceni CP, Oba IT, Carvalho MC, Pannuti CS. Duality of patterns in hepatitis A epidemiology: a study involving two socioeconomically distinct populations in Campinas, São Paulo State, Brazil. <i>Rev Inst Med Trop Sao Paulo.</i> 1998; 40(2): 105-6.	1995-1996		
Brazil	Ferreira CT, Pereira-Lima J, Barros FC. Hepatitis A antibodies in two socioeconomically distinct populations of Porto Alegre, Southern Brazil. <i>J Trop Pediatr.</i> 1998; 44(3): 184-5.	1997		
Brazil	Luiz RR, Almeida RM, Almeida RT, de Almeida LM. The relation between anti-hepatitis A virus antibodies and residence water access in Rio de Janeiro, Brazil. <i>Int J Hyg Environ Health.</i> 2003; 206(6): 575-82.	1997		
Brazil	Almeida LM, Wernick GL, Caimcross S, Coeli CM, Costa MC, Colety PE. The epidemiology of hepatitis A in Rio de Janeiro: environmental and domestic risk factors. <i>Epidemiol Infect.</i> 2001; 127(2): 327-33.	1997		
Brazil	Saback FL, Gomes SA, de Paula VS, da Silva RR, Lewis-Ximenez LL, Niel C. Age-specific prevalence and transmission of TT virus. <i>J Med Virol.</i> 1999; 59(3): 318-22.	1997-1998		
Brazil	Gaze R, Carvalho DM de, Wernick GL. [Hepatitis A and B seroprevalence in Macaé, Rio de Janeiro State, Brazil]. <i>Cad Saude Publica.</i> 2002; 18(5): 1251-9.	1998		
Brazil	Lewis-Ximenez LL, Gaspar AMC, D'Oro ACC, Mercadante LAC, Ginuino CF, Yoshida CFT. Viral hepatitis markers in antepartum and postpartum women in Rio de Janeiro, Brazil. <i>Mem Inst Oswaldo Cruz.</i> 2002; 97(2): 203-4.	1998		
Brazil	Morais LM, de Paula VS, Arantes MR, Oliveira MLA, Gaspar AMC. Early infection and asymptomatic spread of hepatitis A virus in a public child care center in Rio de Janeiro, Brazil: should attending children under two years of age be vaccinated? <i>Mem Inst Oswaldo Cruz.</i> 2006; 101(4): 401-5.	1999		
Brazil	Almeida D, Tavares-Neto J, Vitvitski L, Almeida A, Mello C, Santana D, Tatsch F, Paraná R. Serological markers of hepatitis A, B and C viruses in rural communities of the semi-arid Brazilian northeast. <i>Braz J Infect Dis.</i> 2006; 10(5): 317-21.	1999		
Brazil	Santos DCM dos, Souto FJD, Santos DRL dos, Vitral CL, Gaspar AMC. Seroepidemiological markers of enterically transmitted viral hepatitis A and E in individuals living in a community located in the North Area of Rio de Janeiro, RJ, Brazil. <i>Mem Inst Oswaldo Cruz.</i> 2002; 97(5): 637-40.	1999		
Brazil	Saback FL, Palmer TE, Sabino RR, Carvalho SM, Amorim LM, Gaspar AM, Oliveira ML, Yoshida CF, Niel C. Infection with hepatitis A and TT viruses and socioeconomic status in Rio de Janeiro, Brazil. <i>Scand J Infect Dis.</i> 2001; 33(2): 121-5.	1999		
Brazil	Ferreira CT, Leite JC, Tanaguchi ANR, Vieira SMG, Pereira-Lima J, da Silveira TR. Seroprevalence of hepatitis A antibodies in a group of normal and Down syndrome children in Porto Alegre, southern Brazil. <i>Braz J Infect Dis.</i> 2002; 6(5): 225-31.	1999-2000		
Brazil	Niel C, Lampe E. High detection rates of TTV-like mini virus sequences in sera from Brazilian blood donors. <i>J Med Virol.</i> 2001; 65(1): 199-205.	2000		
Brazil	Lafer MM, de Moraes-Pinto MI, Weckx LY. Prevalence of antibodies against hepatitis A virus among the Kuikuro and Kaiabi Indians of Xingu National Park, Brazil. <i>Rev Inst Med Trop Sao Paulo.</i> 2007; 49(3): 155-7.	2001		
Brazil	Dinelli MIS, Fisberg M, Moraes-Pinto MI de. Anti-hepatitis A virus frequency in adolescents at an outpatient clinic in São Paulo, Brazil. <i>Rev Inst Med Trop Sao Paulo.</i> 2006; 48(1): 43-4.	2001		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Brazil	Moreira ED Jr, Nassri VB, Santos RS, Matos JF, de Carvalho WA, Silvani CS, Santana e Sant'ana C. Association of Helicobacter pylori infection and giardiasis: results from a study of surrogate markers for fecal exposure among children. World J Gastroenterol. 2005; 11(18): 2759-63.	2001-2002		
Brazil	Kozłowski AG, Motta-Castro ARC, Nascimento LB, Silva AMC, Teles SA, Villar LM, Gaspar AMC, Martins RMB. Prevalence of hepatitis A virus infection in Afro-Brazilian isolated communities in Central Brazil. Mem Inst Oswaldo Cruz. 2007; 102(1): 121-3.	2002-2003		
Brazil	De Souza VAUF, Sumita LM, Nascimento M-C, Oliveira J, Mascheretti M, Quiroga M, Freire WS, Tateno A, Boulos M, Mayaud P, Pannuti CS. Human herpesvirus-8 infection and oral shedding in Amerindian and non-Amerindian populations in the Brazilian Amazon region. J Infect Dis. 2007; 196(6): 844-52.	2003-2004		
Brazil	Matos MAD, Reis NRS, Kozłowski AG, Teles SA, Motta-Castro ARC, Mello FCA, Gomes SA, Martins RMB. Epidemiological study of hepatitis A, B and C in the largest Afro-Brazilian isolated community. Trans R Soc Trop Med Hyg. 2009; 103(9): 899-905.	2004		
Brazil	Zago-Gomes MP, Stantolin GC, Perazzo S, Aikawa KH, Gonçalves CS, Pereira FEL. Prevalence of anti-hepatitis A antibodies in children of different socioeconomic conditions in Vila Velha, ES. Rev Soc Bras Med Trop. 2005; 38(4): 285-9.	2004		
Brazil	De Alencar Ximenes RA, Martelli CMT, Merchán-Hamann E, Montarroyos UR, Braga MC, de Lima MLC, Cardoso MRA, Turchi MD, Costa MA, de Alencar LCA, Moreira RC, Figueiredo GM, Pereira LMMB. Multilevel analysis of hepatitis A infection in children and adolescents: a household survey in the Northeast and Central-west regions of Brazil. Int J Epidemiol. 2008; 37(4): 852-61.	2004-2005		
Brazil	Cruz BR, Chiba AK, Moritz E, Bordin JO. RHD alleles in Brazilian blood donors with weak D or D-negative phenotypes. Transfus Med. 2012; 22(2): 84-9.	2008-2010	*	†
Brazil	Lessa I, Cortes E, Souza JA, Souza Filho J, Netto JP, Almeida FA. Epidemiology of acute myocardial infarction in Salvador, Brazil: I. Incidence, lethality, and mortality. Bull Pan Am Health Organ. 1987; 21(1): 28-37.	1982		
Brazil	Aguiar JI, de Souza JA, Aguiar ES, Oliveira JM, de Lemos ERS, Yoshida CFT. Low prevalence of hepatitis B and C markers in non-Amazonian indigenous population. Braz J Infect Dis. 2002; 6(5): 269-70.	1999		
Brazil	Andrade AFB, Oliveira-Silva M, Silva SGC, Motta JF, Bonvicino CR. Seroprevalence of hepatitis B and C virus markers among blood donors in Rio de Janeiro, Brazil, 1998-2005. Mem Inst Oswaldo Cruz. 2006; 101(6): 673-6.	1998-2005		
Brazil	Bertolini DA, Pinho JRR, Saraceni CP, Moreira RC, Granato CFH, Carrilho FJ. Prevalence of serological markers of hepatitis B virus in pregnant women from Paraná State, Brazil. Braz J Med Biol Res. 2006; 39(8): 1083-90.	1998-2002		
Brazil	Carvalho MB, Hamerschlak N, Vaz RS, Ferreira OC Jr. Risk factor analysis and serological diagnosis of HIV-1/HIV-2 infection in a Brazilian blood donor population: validation of the World Health Organization strategy for HIV testing. AIDS. 1996; 10(10): 1135-40.	1992-1993		
Brazil	Catalan-Souares BC, Almeida RT, Carneiro-Proietti AB. Prevalence of HIV-1/2, HTLV-I/II, hepatitis B virus (HBV), hepatitis C virus (HCV), Treponema pallidum and Trypanosoma cruzi among prison inmates at Manaus, Minas Gerais State, Brazil. Rev Soc Bras Med Trop. 2000; 33(1): 27-30.	1998		
Brazil	Coimbra Júnior CE, Santos RV, Yoshida CF, Baptista ML, Flowers NM, do Valle AC. Hepatitis B epidemiology and cultural practices in Amerindian populations of Amazonia: the Tupi-Mondé and the Xavante from Brazil. Soc Sci Med. 1996; 42(12): 1735-43.	1990		
Brazil	Cotrim H, Mota E, Leite L, Silva L, Lyra L. A case-control study on the association of hepatitis B virus infection and hepatocellular carcinoma in northeast Brazil. Rev Saude Publica. 1992; 26(5): 301-5.	1982-1987		
Brazil	De Nishioka SA, Gyorkos TW, Joseph L, Collet JP, MacLean JD. Tattooing and transfusion-transmitted diseases in Brazil: a hospital-based cross-sectional matched study. Eur J Epidemiol. 2003; 18(5): 441-9.	1998-2000		
Brazil	De Souza NCN, Botelho CAO, Honer MR. Retrospective study of a pioneer antenatal screening program with 8,477 pregnant women in Brazil. Clin Exp Obstet Gynecol. 2004; 31(3): 217-20.	2002-2003		
Brazil	Dos Santos JI, Lopes MA, Delêge-Vasconcelos E, Couto-Fernandez JC, Patel BN, Barreto ML, Ferreira Júnior OC, Galvão-Castro B. Seroprevalence of HIV, HTLV-I/II and other perinatally-transmitted pathogens in Salvador, Bahia. Rev Inst Med Trop Sao Paulo. 1995; 37(4): 343-8.	1990-1991		
Brazil	El Khouri M, Duarte LS, Ribeiro RB, da Silva LFF, Camargo LMA, dos Santos VA, Burattini MN, Corbett CEP. Seroprevalence of hepatitis B virus and hepatitis C virus in Monte Negro in the Brazilian western Amazon region. Clinics (Sao Paulo). 2005; 60(1): 29-36.	2001		
Brazil	Gonzalez TT, Sabino EC, Murphy EL, Chen S, Chamone DAF, McFarland W. Human immunodeficiency virus test-seeking motivation in blood donors, São Paulo, Brazil. Vox Sang. 2006; 90(3): 170-6.	2004		
Brazil	Lima MP, Pedro RJ, Rocha MD. Prevalence and risk factors for hepatitis C virus (HCV) infection among pregnant Brazilian women. Int J Gynaecol Obstet. 2000; 70(3): 319-26.	1994-1998		
Brazil	Martins RM, Porto SO, Vanderborght BO, Rouzeur CD, Queiroz DA, Cardoso DD, Yoshida CF. Short report: prevalence of hepatitis C viral antibody among Brazilian children, adolescents, and street youths. Am J Trop Med Hyg. 1995; 53(6): 654-5.	1990-1993		
Brazil	Martins RM, Vanderborght BO, Rouzeur C, Cardoso DD, Azevedo MS, Yoshida CF. Anti-HCV prevalence and risk factors analysis in pregnant women in central Brazil. Mem Inst Oswaldo Cruz. 1995; 90(1): 11.	1990-1992		
Brazil	Miranda AE, Alves MC, Neto RL, Areal KR, Gerbase AC. Seroprevalence of HIV, hepatitis B virus, and syphilis in women at their first visit to public antenatal clinics in Vitória, Brazil. Sex Transm Dis. 2001; 28(12): 710-3.	1999		
Brazil	Motta-Castro ARC, Yoshida CFT, Lemos ERS, Oliveira JM, Cunha RV, Lewis-Ximenez LL, Cabello PH, Lima KMB, Martins RMB. Seroprevalence of Hepatitis B virus infection among an Afro-descendant community in Brazil. Mem Inst Oswaldo Cruz. 2003; 98(1): 13-7.	1999-2000		
Brazil	Oliveira MD da S, Martins RMB, Matos MA, Ferreira RC, Dias MA, Carneiro MAS, Junqueira ALN, Teles SA. Seroepidemiology of hepatitis B virus infection and high rate of response to hepatitis B virus Butang vaccine in adolescents from low income families in Central Brazil. Mem Inst Oswaldo Cruz. 2006; 101(3): 251-6.	2003-2004		
Brazil	Rosini N, Mousse D, Spada C, Treitinger A. Seroprevalence of HbsAg, Anti-HBc and anti-HCV in Southern Brazil, 1999-2001. Braz J Infect Dis. 2003; 7(4): 262-7.	1999-2001		
Brazil	Santos AK, Ishak MO, Santos SE, Guerreiro JF, Ishak R. A possible correlation between the host genetic background in the epidemiology of hepatitis B virus in the Amazon region of Brazil. Mem Inst Oswaldo Cruz. 1995; 90(4): 435-42.	1983-1991		
Brazil	Zarife MAS, Silva LK, Silva MBS, Lopes GB, Barreto ML, Teixeira M da G, Dourado I, Reis MG. Prevalence of hepatitis C virus infection in north-eastern Brazil: a population-based study. Trans R Soc Trop Med Hyg. 2006; 100(7): 663-8.	1998		
Brazil	Da Rocha EM, Fontes G, Brito AC, Silva TR, Medeiros Z, Antunes CM. [Bancroftian filariasis in urban areas of Alagoas State, Northeast Brazil: study in the general population]. Rev Soc Bras Med Trop. 2000; 33(6): 545-51. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1995-2000	*	
Brazil	Medeiros Z, Alves A, Brito JA, Borba L, Santos Z, Costa JP, do Espírito Santo ME, Netto MJE. The present situation regarding lymphatic filariasis in Cabo de Santo Agostinho, Pernambuco, Northeast Brazil. Rev Inst Med Trop Sao Paulo. 2006; 48(5): 263-7. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2000	*	
Brazil	Rihs LB, Silva DD da, Sousa M da LR de. Dental caries and tooth loss in adults in a Brazilian southeastern state. J Appl Oral Sci. 2009; 17(5): 392-6.	2007		
Brazil	Cardoso EM, Parente RCP, Vettore MV, Rebelo MAB. Oral health conditions of elderly residents in the city of Manaus, Amazonas: estimates by sex. Rev Bras Epidemiol. 2011; 14(1): 131-40.	2007		
Brazil	Valença MM, Valença LP. [Etiology of the epileptic seizures in Recife city, Brazil: study of 249 patients]. Arq Neuropsiquiatr. 2000; 58(4): 1064-72.	1987-1990		†
Brazil	Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol. 1996; 14(5): 417-23.	1980, 1993		
Brazil	Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis. 2004; 27(5): 305-18.	1998, 2002		
Brazil	Kiesslich D, Rocha Júnior JE, Crispim MA. Prevalence of hepatitis E virus antibodies among different groups in the Amazonian basin. Trans R Soc Trop Med Hyg. 2002; 96(2): 215.	2000	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Brazil	Parana R, Cortim HV, Cortey-Boenne ML, Trepo C, Lyra L. Prevalence of hepatitis E virus IgG antibodies in patients from a referral unit of liver diseases in Salvador, Bahia, Brazil. <i>J Trop Med Hyg.</i> 1997; 57(1): 60-1.	1992-1994	*	
Brazil	Souto FI, Fontes CJ. Prevalence of IgG-class antibodies against hepatitis E virus in a community of the southern Amazon: a randomized survey. <i>Ann Trop Med Parasitol.</i> 1998; 92(5): 623-5.	1996	*	
Brazil	Bevilacqua MC, Alvarenga K de F, Costa OA, Moret ALM. The universal newborn hearing screening in Brazil: from identification to intervention. <i>Int J Pediatr Otorhinolaryngol.</i> 2010; 74(5): 510-5.	2005-2008	*	
Brazil	Botelho MS e N, Silva VB da, Arruda L da S, Kuniyoshi IC, Oliveira LLR de, Oliveira AS de. Newborn hearing screening in the Limiar Clinic in Porto Velho - Rondônia. <i>Braz J Otorhinolaryngol.</i> 2010; 76(5): 605-10.	2004-2006	*	
Brazil	Pan American Health Organization (PAHO), World Health Organization (WHO). Quantitative Estimation of Chagas in the Americas.	2005	*	
Brazil	Carvalho ME de, da Silva RA, Barata JMS, Domingos M de F, Ciaravolo RM de C, Zacharias F. [Chagas' disease in the southern coastal region of Brazil]. <i>Rev Saude Publica.</i> 2003; 37(1): 49-58.	1984-1999	*	
Brazil	De Andrade AL, Zicker F, Luquetti AO, Oliveira RM, Silva SA, Souza JM, Martelli CM. Surveillance of Trypanosoma cruzi transmission by serological screening of schoolchildren. <i>Bull World Health Organ.</i> 1992; 70(5): 625-9.	1991	*	
Brazil	Coutinho CF de S, Souza-Santos R, Teixeira NFD, Georg I, Gomes TF, Boia MN, dos Reis NB, Maia A de O, Lima MM. An entomoepidemiological investigation of Chagas disease in the state of Ceará, Northeast Region of Brazil. <i>Cad Saude Publica.</i> 2014; 30(4): 785-93.	2008-2009	*	
Brazil	Brito CR do N, Sampaio GHF, Câmara ACJ da, Nunes DF, Azevedo PRM de, Chiari E, Galvão LM da C. Seroepidemiology of Trypanosoma cruzi infection in the semi-arid rural zone of the State of Rio Grande do Norte, Brazil. <i>Rev Soc Bras Med Trop.</i> 2012; 45(3): 346-52.	2007-2009	*	
Brazil	Magalhães BML, Coelho LIARC, Maciel MG, Ferreira JMBB, Umezawa ES, Coura JR, Guerra JA de O, Barbosa M das GV. Serological survey for Chagas disease in the rural areas of Manaus, Coari, and Tefé in the Western Brazilian Amazon. <i>Rev Soc Bras Med Trop.</i> 2011; 44(5): 697-702.	2007-2008	*	
Brazil	Lima MM, Sarquis O, de Oliveira TG, Gomes TF, Coutinho C, Daflon-Teixeira NF, Toma HK, Britto C, Teixeira BR, D'Andrea PS, Jansen AM, Boia MN, Carvalho-Costa FA. Investigation of Chagas disease in four periurban areas in northeastern Brazil: epidemiologic survey in man, vectors, non-human hosts and reservoirs. <i>Trans R Soc Trop Med Hyg.</i> 2012; 106(3): 143-9.	2004-2006	*	
Brazil	Borges-Pereira J, Sarquis O, Zauza PL, Britto C, Lima MM. [Epidemiology of Chagas disease in four rural localities in Jaguaruana, State of Ceará: seroprevalence of infection, parasitemia and clinical characteristics]. <i>Rev Soc Bras Med Trop.</i> 2008; 41(4): 345-51.	2000-2002	*	
Brazil	Coura JR, Naranjo MA, Willcox HP. Chagas' disease in the Brazilian Amazon. II. A serological survey. <i>Rev Inst Med Trop Sao Paulo.</i> 1995; 37(2): 103-7.	1992-1994	*	
Brazil	De Andrade AL, Martelli CM, Luquetti AO, de Oliveira OS, Almeida e Silva S, Zicker F. Serologic screening for Trypanosoma cruzi among blood donors in central Brazil. <i>Bull Pan Am Health Organ.</i> 1996; 22(2): 157-164.	1988-1989	*	
Brazil	Reiche EM, Inouye MM, Pontello R, Morimoto HK, Ito Jankevicius S, Matsuo T, Jankevicius JV. Seropositivity for anti-trypanosoma cruzi antibodies among blood donors of the "Hospital Universitário Regional do Norte do Paraná", Londrina, Brazil. <i>Rev Inst Med Trop Sao Paulo.</i> 1996; 38(3): 233-240.	1991-1994	*	
Brazil	Parasitological Survey of the Population of Guariba-Colniza for Identification of Individuals with Asymptomatic Infection by Plasmodium, Colniza, Mato Grosso as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Brazil	Straughn HK, Goldenberg RL, Tolosa JE, Daly S, de Codes J, Festin MR, Limpongsanurak S, Lumbiganon P, Paul VK, Peedicyal A, Purwar M, Sabogal JC, Shenoy S. Birthweight-specific neonatal mortality in developing countries and obstetric practices. <i>Int J Gynaecol Obstet.</i> 2003 Jan; 80(1): 71-8.	2003		†
Brazil	Alexandre CO, Camargo LM, Mattei D, Ferreira MU, Katzin AM, Camargo EP, da Silva LH. Humoral immune response to the 72 kDa heat shock protein from Plasmodium falciparum in populations at hypoendemic areas of malaria in western Brazilian Amazon. <i>Acta Trop.</i> 1997; 64(3-4): 155-66 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Brazil	Arruda ME, Zimmerman RH, Souza RM, Oliveira-Ferreira J. Prevalence and level of antibodies to the circumsporozoite protein of human malaria parasites in five states of the Amazon region of Brazil. <i>Mem Inst Oswaldo Cruz.</i> 2007; 102(3): 367-72 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Brazil	Burattini MN, Massad E, Coutinho FA, Baruzzi RG. Malaria prevalence amongst Brazilian Indians assessed by a new mathematical model. <i>Epidemiol Infect.</i> 1993; 111(3): 525-37 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Brazil	Callegari-Jacques SM, Salzano FM, Weimer TA, Franco MH, Mestriner MA, Hutz MH, Schiller L. The Wai Wai Indians of South America: history and genetics. <i>Ann Hum Biol.</i> 1996; 23(3): 189-201 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Brazil	Camargo LM, Noronha E, Salcedo JM, Dutra AP, Krieger H, Pereira da Silva LH, Camargo EP. The epidemiology of malaria in Rondonia (Western Amazon region, Brazil): study of a riverine population. <i>Acta Trop.</i> 1999; 72(1): 1-11 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994-1995	*	†
Brazil	Camargo LM, dal Colletto GM, Ferreira MU, Gurgel S de M, Escobar AL, Marques A, Krieger H, Camargo EP, da Silva LH. Hypoendemic malaria in Rondonia (Brazil, western Amazon region): seasonal variation and risk groups in an urban locality. <i>Am J Trop Med Hyg.</i> 1996; 55(1): 32-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Brazil	Carvalho TA, Queiroz MG, Cardoso GL, Diniz IG, Silva AN, Pinto AY, Guerreiro JF. Plasmodium vivax infection in Anajás, State of Pará: no differential resistance profile among Duffy-negative and Duffy-positive individuals. <i>Malar J.</i> 2012; 11(1): 430 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2009	*	†
Brazil	Junior CC, Boulos M, Coutinho AF, Hatab M do CL, Falqueto A, Rezende HR, Duarte AMR, Collins W, Malafrente RS. Epidemiologic aspects of the malaria transmission cycle in an area of very low incidence in Brazil. <i>Malar J.</i> 2007; 6(1): 1-12 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002-2003	*	†
Brazil	Crompton P, Ventura AM, de Souza JM, Santos E, Strickland GT, Silbergeld E. Assessment of Mercury Exposure and Malaria in a Brazilian Amazon Riverine Community. <i>Environ Res.</i> 2002; 90(2): 69-75 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
Brazil	Carvalho ME de, Ferreira MU, Souza MRD de, Ninomia RT, Matos GF, Camargo LMA, Ferreira CS, Carvalho ME de, Ferreira MU, Souza MRD de, Ninomia RT, Matos GF, Camargo LMA, Ferreira CS. Malaria seroepidemiology: comparison between indirect fluorescent antibody test and enzyme immunoassay using bloodspot eluates. <i>Mem Inst Oswaldo Cruz.</i> 1992; 87(2): 205-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†
Brazil	Gomes A de C, Paula MB de, Duarte AMR de C, Lima MA, Malafrente R dos S, Mucci LF, Gottlieb SLD, Natal D. Epidemiological and ecological aspects related to malaria in the area of influence of the lake at Porto Primavera dam, in western Sao Paulo State, Brazil. <i>Rev Inst Med Trop Sao Paulo.</i> 2008; 50(5): 287-95 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Brazil	Kano FS, Sanchez BA, Sousa TN, Tang ML, Saliba J, Oliveira FM, Nogueira PA, Gonçalves AQ, Fontes CJ, Soares IS, Brito CF, Rocha RS, Carvalho LH. Plasmodium vivax Duffy binding protein: baseline antibody responses and parasite polymorphisms in a well-consolidated settlement of the Amazon Region. <i>Trop Med Int Health</i> . 2012; 17(8): 989-1000 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008	*	†
Brazil	Katsuragawa TH, Cunha RP, de Souza DC, Gil LH, Cruz RB, Silva A, Tada MS, da Silva LH. [Malaria and hematological aspects among residents to be impacted by reservoirs for the Santo Antônio and Jirau Hydroelectric Power Stations, Rondônia State, Brazil]. <i>Cad Saude Publica</i> . 2009; 25(7): 1486-92 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004-2005	*	†
Brazil	Kremsner PG, Neifer S, Zotter GM, Bienzle U, Rocha RM, Maracic M, Clavijo P, Nussenzweig RS, Cochrane AH. Prevalence and level of antibodies to the circumsporozoite proteins of human malaria parasites, including a variant of Plasmodium vivax, in the population of two epidemiologically distinct areas in the state of Acre, Brazil. <i>Trans R Soc Trop Med Hyg</i> . 1992; 86(1): 23-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Brazil	Ladeia-Andrade S, Ferreira MU, de Carvalho ME, Curado I, Coura J. Age-dependent acquisition of protective immunity to malaria in riverine populations of the Amazon Basin of Brazil. <i>Am J Trop Med Hyg</i> . 2009; 80(3): 452-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002-2003	*	†
Brazil	Malafrente RS, Valdivia JL, Nakaie CR, Kloetzel JK. Seasonal variation of anti-RESA/PI55 Plasmodium falciparum antibodies in three localities from the state of Amapá, Brazil. <i>Rev Inst Med Trop Sao Paulo</i> . 1994; 36(3): 237-43 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Brazil	Marrelli MT, Malafrente RS, Kloetzel JK. Seasonal variation of anti-Plasmodium falciparum antibodies directed against a repetitive peptide of gametocyte antigen pfs2400 in the State of Amapá, Brazil. <i>Acta Trop</i> . 1997; 63(2-3): 167-77 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Brazil	McGreedy PB, Dietze R, Prata A, Hembree SC. Effects of immigration on the prevalence of malaria in rural areas of the Amazon basin of Brazil. <i>Mem Inst Oswaldo Cruz</i> . 1989; 84(4): 485-91 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985-1986	*	†
Brazil	Santos JB, dos Santos F, Marsden P, Tosta CE, Andrade AL, Macêdo V. [Effect of bed nets impregnated with deltamethrin on malaria morbidity in an area of the Brazilian Amazonas]. <i>Rev Soc Bras Med Trop</i> . 1998; 31(1): 1-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†
Brazil	Silbergeld E, Nash D, Trevant C, Strickland G, de Souza J, da Silva R. Mercury exposure and malaria prevalence among gold miners in Pará, Brazil. <i>Rev Soc Bras Med Trop</i> . 2002; 35(5): 421-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
Brazil	Silva-Nunes M da, Malafrente R dos S, Luz B de A, Souza EA de, Martins LC, Rodrigues SG, Chiang JO, Vasconcelos PF da C, Muniz PT, Ferreira MU. The Acre Project: the epidemiology of malaria and arthropod-borne virus infections in a rural Amazonian population. <i>Cad Saude Publica</i> . 2006; 22(6): 1325-34 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004-2006	*	†
Brazil	Soares IS, Oliveira SG, Souza JM, Rodrigues MM. Antibody response to the N and C-terminal regions of the Plasmodium vivax Merozoite Surface Protein 1 in individuals living in an area of exclusive transmission of P. vivax malaria in the north of Brazil. <i>Acta Trop</i> . 1999; 72(1): 13-24 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996-1997	*	†
Brazil	Suárez-Mutis MC, Coura JR. [Evaluation of the thick smear in a field condition in a malaria endemic area in the Middle Region of Rio Negro, Amazon]. <i>Rev Soc Bras Med Trop</i> . 2006; 39(5): 495-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Brazil	Suarez-Mutis MC, Cuervo P, Leoratti FMS, Moraes-Avila SL, Ferreira AW, Fernandes O, Coura JR. Cross sectional study reveals a high percentage of asymptomatic Plasmodium vivax infection in the Amazon Rio Negro area, Brazil. <i>Rev Inst Med Trop Sao Paulo</i> . 2005; 49(3): 159-64 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002-2004	*	†
Brazil	Tada MS, Mattos Ferreira RDG, Katsuragawa TH, Dalla Marthia RC, Costa JDA, Albrecht L, Wunderlich G, Pereira da Silva, LH. Asymptomatic infection with Plasmodium falciparum and Plasmodium vivax in the Brazilian Amazon basin: to treat or not to treat? <i>Mem Inst Oswaldo Cruz</i> . 2012; 107: 621-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Brazil	Urdaneta M, Prata A, Struchiner CJ, Tosta CE, Tauli P, Boulos M. SPI66 vaccine trial in Brazil: conceptual framework study design and analytical approach. <i>Rev Soc Bras Med Trop</i> . 1996; 29(3): 259-69 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†
Brazil	Vitor-Silva S, Reyes-Lecca RC, Pinheiro TR, Lacerda MV. Malaria is associated with poor school performance in an endemic area of the Brazilian Amazon. <i>Malar J</i> . 2009; 8: 230 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008	*	†
Brazil	De Arruda ME, Aragaki C, Gagliardi F, Haile RW. A seroprevalence and descriptive epidemiological study of malaria among Indian tribes of the Amazon basin of Brazil. <i>Ann Trop Med Parasitol</i> . 1996; 90(2): 135-43 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Brazil	Carvalho ME de, Glasser CM, Ciaravolo RM de C, Etzel A, Santos LA dos, Ferreira CS. Sorologia da malaria vivax no foco Aldeia dos Indios, Município de Perube, Estado de São Paulo, 1984 a 1986. <i>Cad Saude Publica</i> . 1988; 4(3): 276-92 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985-1986	*	†
Brazil	Brazil Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Brazil	Brazil Latin American Collaborative Study of Congenital Malformations Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Brunei	Centre for Health Informatics and Multiprofessional Education, University College London. Model's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Brunei	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Brunei	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998-2000, 2003-2005, 2008-2009		
Brunei	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Brunei	United States Renal Data System Coordinating Center. United States Renal Data System Annual Data Report 2004. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2004.	1998-2001		
Brunei	Aditama TY. Prevalence of tuberculosis in Indonesia, Singapore, Brunei Darussalam and the Philippines. <i>Tubercle</i> . 1991; 72(4): 255-60.	1986		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Brunei	Lie-Injo LE, Chin J, Ti TS. Glucose-6-phosphate dehydrogenase deficiency in Brunei, Sabah and Sarawak. Ann Hum Genet. 1964; 173-6.	1962-1964		
Brunei	Lee G. End-stage renal disease in the Asian-Pacific region. Semin Nephrol. 2003; 23(1): 107-14.	1998-2000		
Brunei	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Brunei	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	
Brunei	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Brunei	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Brunei	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
Brunei	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Brunei	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Brunei	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Brunei	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland; World Health Organization (WHO).	2011	*	
Brunei	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2000.	2000		
Brunei	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2001.	2001		
Brunei	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2002.	2002		
Brunei	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2003.	2003		
Brunei	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2004.	2004		
Brunei	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2005.	2005		
Brunei	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2006.	2006		
Brunei	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2007.	2007		
Brunei	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2008.	2008		
Brunei	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2009.	2009		
Brunei	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2010.	2010		
Brunei	Brunei Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD), United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Bulgaria	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2005		
Bulgaria	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. Scand J Clin Lab Invest. 2007; 67(1): 39-69.	1990-2006		
Bulgaria	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2006		
Bulgaria	Tasheva ES, Toshkov SA, Dobрева AM. Hemoglobinopathies in Bulgaria. Hemoglobin. 1987; 11(5): 523-9.	1985		
Bulgaria	Kojouharova M, Gatcheva N, Setchanova L, Robertson SE, Wenger JD. Epidemiology of meningitis due to Haemophilus influenzae type b in children in Bulgaria: a prospective, population-based surveillance study. Bull World Health Organ. 2002; 80(9): 690-5.	1997-1999		
Bulgaria	Mladenova Z, Korsun N, Geonova T, Iturriza-Gómara M, Rotavirus Study Group. Molecular epidemiology of rotaviruses in Bulgaria: annual shift of the predominant genotype. Eur J Clin Microbiol Infect Dis. 2010; 29(5): 555-62.	2005-2008		
Bulgaria	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000, 2002-2009		
Bulgaria	Kalafatova O. Geographic and Climatic Factors and Multiple Sclerosis in Some Districts of Bulgaria. Neuroepidemiology. 1987; 6(3): 116-9.	1979		
Bulgaria	Milanov I, Georgiev D, Kmetzka K, Jordanova L, Topalov N. Prevalence of Multiple Sclerosis in Bulgaria. Neuroepidemiology. 1997; 16(6): 304-7.	1995		
Bulgaria	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2002		
Bulgaria	Todorov T, Boeva V. Human echinococcosis in Bulgaria: a comparative epidemiological analysis V. Bull World Health Organ. 1999; 77(2): 110-8.	1995		
Bulgaria	Gatseva P, Vladeva S, Argirova M. Evaluation of endemic goiter prevalence in Bulgarian schoolchildren: results from national strategies for prevention and control of iodine-deficiency disorders. Biol Trace Elem Res. 2007; 116(3): 273-8.	2004-2006	*	
Bulgaria	Pakhomov GN, Moller J, Atanasov NP, Kabackchieva RI, Sharkov NI. Effect of an amine fluoride dentifrice on dental caries used in a community-based oral health education program. J Public Health Dent. 1997; 57(3): 181-3.	1989-1992		
Bulgaria	Vrbic V, Vulovi M, Raji Z, Topi B, Tati E, Mali M, Mili D, Aurer-Kozelj J, Neceva L, Redzepagi S. Oral health in SFR Yugoslavia in 1986. Community Dent Oral Epidemiol. 1988; 16(5): 286-8.	1986		
Bulgaria	United States Renal Data System Coordinating Center. United States Renal Data System Annual Data Report 2004. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2004.	1998-2001		
Bulgaria	Milanov I, Kmetzka K, Karakolev B, Nedialkov E. Prevalence of Parkinson's Disease in Bulgaria. Neuroepidemiology. 2001; 20(3): 212-4.	1997, 1999		
Bulgaria	Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganey K, Giel R, an der Heiden W, Holmberg SK, Janca A, Lee PW, León CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirikin SI, Varma VK, Walsh D, Wiersma D. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry. 2001; 178: 506-17.	1978-1993		
Bulgaria	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN), ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Bulgaria	Vassileva P, Gieser SC, Vitale S, Cholakova T, Katz J, West S. Blindness and visual impairment in western Bulgaria. Ophthalmic Epidemiol. 1996; 3(3): 143-9. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1993		
Bulgaria	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1999, 2005		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Bulgaria	Merikangas KR, Jin R, He J-P, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Ladea M, Medina-Mora ME, Ono Y, Posada-Villa J, Sagar R, Wells JE, Zarkov Z. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry. 2011; 68(3): 241-51.	2003-2007	*	
Bulgaria	McDowell RD, Ryan A, Bunting BP, O'Neill SM, Alonso J, Bruffaerts R, de Graaf R, Florescu S, Vilagut G, de Almeida JMC, de Girolamo G, Haro JM, Hinkov H, Kovess-Masfety V, Matschinger H, Tomov T. Mood and anxiety disorders across the adult lifespan: a European perspective. Psychol Med. 2013; 1-16.	2003-2007	*	
Bulgaria	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Bulgaria	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2004, 2007, 2010, 2012		
Bulgaria	Kamenov ZA, Parapunova RA, Georgieva RT. Earlier development of diabetic neuropathy in men than in women with type 2 diabetes mellitus. Gend Med. 2010; 7(6): 600-15.	1990-2007		
Bulgaria	Tzaneva V, Iotova V, Yotov Y. Significant urban/rural differences in the incidence of type 1 (insulin-dependent) diabetes mellitus among Bulgarian children (1982-1998). Pediatr Diabetes. 2001; 2(3): 103-8.	1982-1998		
Bulgaria	Fraser GR, Defarinas B, Kattamis CA, Race RR, Sanger R, Stamatoyannopoulos G. Glucose-6-phosphate dehydrogenase, colour vision and XG blood groups in Greece: linkage and population data. Ann Hum Genet. 1964; 395-403.	1962		
Bulgaria	Tzoneva M, Mavrudieva M, Toncheva D, Lalchev S. Glucose-6-phosphate dehydrogenase deficiency and Rh factor. Haematologia (Budap). 1984; 17(3): 399-403.	2004-2006		
Bulgaria	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. Nephrol Dial Transplant. 1988; 3(6): 714-27.	1985-1986		
Bulgaria	Mircescu G, Capsa D, Covic M, Caprioara MG, Gluhovschi G, Golea O, Ursea N, Gârmeata L, Cepoi V, Constantinovici N, Covic A. Nephrology and renal replacement therapy in Romania – transition still continues (Cinderella story revisited). Nephrol Dial Transplant. 2004; 19(12): 2971-80.	1995, 2001		
Bulgaria	Rutkowski B. Changing pattern of end-stage renal disease in central and eastern Europe. Nephrol Dial Transplant. 2000; 15(2): 156-60.	1998		
Bulgaria	Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M and Boyle P, eds (2007). Cancer Incidence in Five Continents, Vol. IX Periodic Data (electronic version). Lyon, IARC. http://g5.iarc.fr	1998-2002	*	
Bulgaria	Bulgarian National Cancer Registry. Bulgaria Cancer Incidence Report 2006. Sofia, Bulgaria: "Avis 24" Ltd, 2008.	2006	*	
Bulgaria	Yolov T. Periodontal condition and treatment needs (CPITN) in the Bulgarian population aged over 60 years. Int Dent J. 2002; 52(4): 255-60.	2000		
Bulgaria	Hristova D, Zachariev Z, Mateva N, Grozdev I. Incidence of Parkinson's disease in Bulgaria. Neuroepidemiology. 2010; 34(2): 76-82.	2002-2004	*	
Bulgaria	Eurostat, Ministry of Health (Bulgaria), National Statistical Institute of Bulgaria. Bulgaria European Health Interview Survey 2008.	2008	*	
Bulgaria	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2012. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	2008	*	
Bulgaria	World Health Organization (WHO). Bulgaria WHO Leishmaniasis Country Profile.	1996-2008	*	
Bulgaria	Bulgaria Monitoring of the Efficiency of the Iodine Deficiency Program 1994 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1994		
Bulgaria	Pebody RG, Andrews N, Brown D, Gopal R, De Melker H, François G, Gatcheva N, Hellenbrand W, Jokinen S, Klavs I, Kojouharova M, Kortbeek T, Kriz B, Prosenk K, Roubalova K, Teocharov P, Thierfelder W, Valle M, Van Damme P, Vranckx R. The seroepidemiology of herpes simplex virus type 1 and 2 in Europe. Sex Transm Infect. 2004; 80(3): 185-91.	1999	*	
Bulgaria	Petrova E, Tsaveva N, Marinova B. Pneumoconioses in Bulgaria: prevalence, development, prognosis and prevention. Cent Eur J Public Health. 2014; 2(1): 47-8.	1990-1991		
Bulgaria	Lozanov B, Hubaveshki S, Kovatcheva R, Ivanova R, Kirilov G, Apostolova E. The early effects of adequate iodine supplementation on the indicators of iodine deficiency in Smoljan's endemic area (south Bulgaria) [in Bulgarian]. Endocrinologia. 39-45 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1995		
Bulgaria	Vatev NT, Atanasova MV, Stoilova YD, Chervenayakova TP, Troyancheva MG. Seroprevalence of hepatitis A viral infection in Plovdiv, Bulgaria. Folia Med (Plovdiv). 2009; 51(1): 70-3.	2008	*	
Bulgaria	Atanasova MV, Haydouchka IA, Zlatev SP, Stoilova YD, Iliev YT, Mateva NG. Prevalence of antibodies against hepatitis C virus and hepatitis B coinfection in healthy population in Bulgaria. A seroepidemiological study. Minerva Gastroenterol Dietol. 2004; 50(1): 89-96.	1999-2000		
Bulgaria	Vakrilova L, Kalaidzhieva M, Slincheva B, Popivanova A, Metodieva V, Garnizov T. [Resuscitation in very low birth weight and extremely low birth weight newborns in the delivery room]. Akush Ginekol (Sofia). 2002; 41(2): 18-23.	1998		†
Bulgaria	Bulgaria Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Bulgaria	European Surveillance of Congenital Anomalies (EUROCAT). Bulgaria EUROCAT Prevalence Tables. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	1996-1999		
Bulgaria	Bulgaria - Sofia Registry of Congenital Anomalies Data 1996-1997 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1996-1997	*	
Burkina Faso	United Nations Children's Fund (UNICEF), National Institute of Statistics and Demography (INSD) (Burkina Faso). Burkina Faso Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006	*	†
Burkina Faso	Macro International, Inc, National Institute of Statistics and Demography (Burkina Faso). Burkina Faso Demographic and Health Survey 1992-1993. Calverton, United States: Macro International, Inc.	1992-1993		†
Burkina Faso	Macro International, Inc, National Institute of Statistics and Demography (Burkina Faso). Burkina Faso Demographic and Health Survey 1998-1999. Calverton, United States: Macro International, Inc.	1998-1999		†
Burkina Faso	Macro International, Inc, National Institute of Statistics and Demography (Burkina Faso). Burkina Faso Demographic and Health Survey 2003. Calverton, United States: Macro International, Inc.	2003		†
Burkina Faso	ICF Macro, Ministry of Health (Burkina Faso), National Institute of Statistics and Demography (Burkina Faso). Burkina Faso Demographic and Health Survey 2010-2011. Calverton, United States: ICF Macro.	2010-2011	*	†
Burkina Faso	Burkina Faso Demographic and Health Survey 2010-2011 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2010-2011	*	†
Burkina Faso	World Health Organization (WHO). Burkina Faso World Health Survey 2002-2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2002-2003		†
Burkina Faso	Ministry of Health (Burkina Faso). Burkina Faso Health Statistical Yearbook 2004. Ouagadougou, Burkina Faso: Ministry of Health (Burkina Faso), 2005.	2004	*	
Burkina Faso	Millogo A, Nitiéma P, Carabin H, Boncoeur-Martel MP, Rajshakar V, Tamagda Z, Praet N, Dorny P, Cowan L, Ganaba R, Hounton S, Preux PM, Cissé R. Prevalence of neurocysticercosis among people with epilepsy in rural areas of Burkina Faso. Epilepsia. 2012; 53(12): 2194-2202.	2007		
Burkina Faso	Kafando E, Sawadogo M, Cotton F, Vertongen F, Gulbis B. Neonatal screening for sickle cell disorders in Ouagadougou, Burkina Faso: a pilot study. J Med Screen. 2005; 12(3): 112-4.	1990-2004		
Burkina Faso	Centre for Health Informatics and Multiprofessional Education, University College London. Model's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Burkina Faso	Simpore J, Ibouido D, Damintoti K, Sawadogo L, Maria E, Binet S, Nitiema H, Ouedraogo P, Pignatelli S, Nikiema J-B. Glucose-6-phosphate dehydrogenase deficiency and sickle cell disease in Burkina Faso. <i>Pak J Biol Sci.</i> 2007; 10(3): 409-14.	1999-2005		
Burkina Faso	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Burkina Faso	Parent du Châtelet I, Traore Y, Gessner BD, Antignac A, Nacro B, Njanpop-Lafourcade BM, Ouedraogo MS, Tiendrebeogo SR, Varon E, Taha MK. Bacterial meningitis in Burkina Faso: surveillance using field-based polymerase chain reaction testing. <i>Clin Infect Dis.</i> 2005; 40(1): 17-25.	2002-2003		
Burkina Faso	Moisi JC, Saha SK, Falade AG, Njanpop-Lafourcade B-M, Oundo J, Zaidi AKM, Afroj S, Bakare RA, Buss JK, Lasi R, Mueller J, Odekanni AA, Sangare L, Scott JAG, Knoll MD, Levine OS, Gessner BD. Enhanced diagnosis of pneumococcal meningitis with use of the binax NOW immunochromatographic test of <i>Streptococcus pneumoniae</i> antigen: A multisite study. <i>Clin Infect Dis.</i> 2009; 48(Suppl 2): S49-S56.	2006-2007		
Burkina Faso	Yaro S, Lourd M, Nacro B, Njanpop-Lafourcade BM, Hien A, Ouedraogo MS, Traore Y, Schouls LM, Parent du Châtelet I, Gessner BD, Clinical Group, Laboratory Group. The epidemiology of Haemophilus influenzae type b meningitis in Burkina Faso. <i>Pediatr Infect Dis J.</i> 2006; 25(5): 415-9.	2002-2005		
Burkina Faso	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1983-1985		
Burkina Faso	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1995-1997, 1999-2006, 2008-2009		
Burkina Faso	Mutebi J-P, Barrett ADT. The epidemiology of yellow fever in Africa. <i>Microbes Infect.</i> 2002; 4(14): 1459-68.	1998		
Burkina Faso	Baudon D, Robert V, Roux J, Lhuillier M, Saluzzo JF, Sarthou JL, Cornet M, Stanghellini A, Gazin P, Molez JF. The 1983 yellow fever epidemic in Burkina Faso. <i>Bull World Health Organ.</i> 1986; 64(6): 873-82.	1983		
Burkina Faso	Tomori O. Yellow fever in Africa: public health impact and prospects for control in the 21st century. <i>Biomedica.</i> 2002; 22(2): 178-210.	1983		
Burkina Faso	World Health Organization (WHO). Yellow fever in Africa and South America, 2007. <i>Wkly Epidemiol Rec.</i> 2009; 84(13): 97-104.	2007		
Burkina Faso	Koukounari A, Gabrielli AF, Toure S, Bosque-Oliva E, Zhang Y, Sellin B, Donnelly CA, Fenwick A, Webster JP. Schistosoma haematobium infection and morbidity before and after large-scale administration of praziquantel in Burkina Faso. <i>J Infect Dis.</i> 2007; 196(5): 659-69.	2004		
Burkina Faso	Miszurka M, Haddad S, Langlois ÉV, Freeman EE, Kouanda S, Zanzunegui MV. Heavy burden of non-communicable diseases at early age and gender disparities in an adult population of Burkina Faso: World Health Survey. <i>BMC Public Health.</i> 2012; 12(1): 24.	2001	*	
Burkina Faso	Varenne B, Fournet F, Cadot E, Msellati P, Ouedraogo HZ, Meyer PE, Cornu J-F, Salem G, Petersen PE. [Family environment and dental health disparities among urban children in Burkina Faso]. <i>Rev Epidemiol Sante Publique.</i> 2011; 59(6): 385-92.	2009	*	
Burkina Faso	Simpore J, Pignatelli S, Barlati S, Musumeci S. Modification in the frequency of Hb C and Hb S in Burkina Faso: an influence of migratory fluxes and improvement of patient health care. <i>Hemoglobin.</i> 2002; 26(2): 113-20.	1999-2001	*	
Burkina Faso	Labie D, Richin C, Pagnier J, Gentilini M, Nagel RL. Hemoglobins S and C in Upper Volta. <i>Hum Genet.</i> 1984; 65(3): 300-2.	1981-1983	*	
Burkina Faso	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Burkina Faso	Mueller JE, Yaro S, Ouedraogo MS, Levina N, Njanpop-Lafourcade B-M, Tall H, Idohou RS, Sanou O, Kroman SS, Drabo A, Nacro B, Millogo A, van der Linden M, Gessner BD. Pneumococci in the African meningitis belt: meningitis incidence and carriage prevalence in children and adults. <i>PLoS One.</i> 2012; 7(12): e52464.	2007-2009		
Burkina Faso	Novak RT, Kambou JL, Diomandé FV, Tarbango TF, Ouedraogo-Traore R, Sangaré L, Lingani C, Martin SW, Hatcher C, Mayer LW, Laforce FM, Avokey F, Djingarey MH, Messonnier NE, Tiendrebeogo SR, Clark TA. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. <i>Lancet Infect Dis.</i> 2012; 12(10): 757-64.	2007-2011		
Burkina Faso	Tall H, Hugonnet S, Donnen P, Dranaix-Wilmet M, Kambou L, Drabo F, Mueller JE. Definition and characterization of localised meningitis epidemics in Burkina Faso: a longitudinal retrospective study. <i>BMC Infect Dis.</i> 2012; 12: 2.	2004-2008		
Burkina Faso	Simpore J, Ouermi D, Ibouido D, Kabre A, Zeba B, Pietra V, Pignatelli S, Nikiema JB, Kabre GB, Caligaris S, Schumacher F, Castelli F. Aetiology of acute gastro-enteritis in children at Saint Camille Medical Centre, Ouagadougou, Burkina Faso. <i>Pak J Biol Sci.</i> 2009; 12(3): 258-63.	2006-2008	*	
Burkina Faso	Bonkougou IJO, Sanou I, Bon F, Benon B, Coulibaly SO, Haukka K, Traoré AS, Barro N. Epidemiology of rotavirus infection among young children with acute diarrhoea in Burkina Faso. <i>BMC Pediatr.</i> 2010; 94.	2008-2010	*	
Burkina Faso	Bonkougou IJO, Haukka K, Österblad M, Hakanen AJ, Traoré AS, Barro N, Siitonen A. Bacterial and viral etiology of childhood diarrhea in Ouagadougou, Burkina Faso. <i>BMC Pediatr.</i> 2013; 13: 36.	2009-2010	*	
Burkina Faso	Tapsoba H, Bakayoko-Ly R. Oral health status of 12-year-old schoolchildren in the province of Kadiogo, Burkina Faso. <i>Community Dent Health.</i> 2000; 17(1): 38-40.	1996-1998		
Burkina Faso	Varenne B, Petersen PE, Ouattara S. Oral health status of children and adults in urban and rural areas of Burkina Faso, Africa. <i>Int Dent J.</i> 2004; 54(2): 83-9.	1999		
Burkina Faso	Müller O, Becher H, van Zweeken AB, Ye Y, Diallo DA, Konate AT, Gbangou A, Kouyate B, Garenne M. Effect of zinc supplementation on malaria and other causes of morbidity in west African children: randomised double blind placebo controlled trial. <i>BMJ.</i> 2001; 322(7302): 1567 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999-2000	*	†
Burkina Faso	Nitiéma P, Carabin H, Houtson S, Praet N, Cowan LD, Ganaba R, Kompaoré C, Tarnagda Z, Dorny P, Millogo A, Efécab. Prevalence case-control study of epilepsy in three Burkina Faso villages. <i>Acta Neurol Scand.</i> 2012; 126(4): 270-8.	2007	*	
Burkina Faso	Debouverie M, Kabore J, Dumas M, Weber M, Duboz P, Vaugelade J. Epidémiologie des épilepsies au Burkina Faso [Epidemiology of Epilepsy in Burkina Faso]. In: Dumas M, Giordano C, Gentilini M, Chieze F, editors. <i>Neurologie Tropicale</i> . Paris, France: John Libbey Eurotext, 1993. 57-61.	1989	*	†
Burkina Faso	Kabore JK, Cabore JW, Melaku Z, Druet-Cabanac M, Preux PM. Epilepsy in a focus of onchocerciasis in Burkina Faso. <i>Lancet.</i> 1996; 347(9004): 836.	1996	*	
Burkina Faso	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Burkina Faso	Lagarde E, Congo Z, Meda N, Baya B, Yaro S, Sangli G, Traoré Y, Van Renthergem H, Caraël M, Study Group on HIV Dynamic Among Young Adults in Burkina Faso. Epidemiology of HIV infection in urban Burkina Faso. <i>Int J STD AIDS.</i> 2004; 15(6): 395-402.	2000	*	
Burkina Faso	Modiano D, Luoni G, Sirima BS, Lanfrancotti A, Petrarca V, Cruciani F, Simporé J, Ciminelli BM, Foglietta E, Grisanti P, Bianco I, Modiano G, Coluzzi M. The lower susceptibility to Plasmodium falciparum malaria of Fulani of Burkina Faso (west Africa) is associated with low frequencies of classic malaria-resistance genes. <i>Trans R Soc Trop Med Hyg.</i> 2001; 95(2): 149-52.	1993-1994		
Burkina Faso	Meissner PE, Coulibaly B, Mandi G, Mansmann U, Witte S, Schiek W, Müller O, Schirmer RH, Mockenhaupt FP, Bienzle U. Diagnosis of red cell G6PD deficiency in rural Burkina Faso: comparison of a rapid fluorescent enzyme test on filter paper with polymerase chain reaction based genotyping. <i>Br J Haematol.</i> 2005; 131(3): 395-9.	2003		
Burkina Faso	Meda N, Sangaré L, Lankoandé S, Sanou PT, Compaoré PI, Catraye J, Cartoux M, Soudré RB. Pattern of sexually transmitted diseases among pregnant women in Burkina Faso, west Africa: potential for a clinical management based on simple approaches. <i>Genitourin Med.</i> 1997; 73(3): 188-93.	1994		
Burkina Faso	World Health Organization (WHO). Burkina Faso WHO Leishmaniasis Country Profile.	1996-2005, 2008	*	
Burkina Faso	Kyelem D, Sanou S, Boatin B, Medlock J, Coulibaly S, Molyneux DH. Impact of long-term ivermectin (Mectizan) on Wuchereria bancrofti and Mansonella perstans infections in Burkina Faso: strategic and policy implications. <i>Ann Trop Med Parasitol.</i> 2003; 97(8): 827-38.	2001	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Burkina Faso	Sinarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. <i>Int J Health Geogr.</i> 2010; 9: 57.	1980-2010		
Burkina Faso	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec.</i> 2005; 80(13): 118-24.	2003	*	
Burkina Faso	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec.</i> 2006; 81(32): 309-16.	2005	*	
Burkina Faso	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Burkina Faso	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Burkina Faso	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Burkina Faso	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Burkina Faso	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Burkina Faso	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Burkina Faso	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Burkina Faso	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Burkina Faso	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Burkina Faso	Burkina Faso - Centre Sud Situational Analysis of the Health Status of Students in Formal Area and Sapone Ipelece Schools as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1999		
Burkina Faso	Burkina Faso - Situational Analysis of the Health Status of Students in Formal Schools in Boukmiende, Oudalan, Sanguie, Sammatenga, and Zoundweogo as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2001		
Burkina Faso	Mueller JE, Sangaré L, Njanpop-Lafourcade B-M, Tarnagda Z, Traoré Y, Yaro S, Borrow R, Gessner BD, Nicolas P. Molecular Characteristics and Epidemiology of Meningococcal Carriage, Burkina Faso, 2003. <i>Emerg Infect Dis.</i> 2007; 13(6): 847-54.	2002		
Burkina Faso	Traore Y, Tameklo TA, Njanpop-Lafourcade B-M, Lourd M, Yaro S, Niamba D, Drabo A, Mueller JE, Koeck J-L, Gessner BD. Incidence, seasonality, age distribution, and mortality of pneumococcal meningitis in Burkina Faso and Togo. <i>Clin Infect Dis.</i> 2009; S181-189.	2002-2006		†
Burkina Faso	Sié A, Pflüger V, Coulibaly B, Dangy JP, Kapaun A, Junghans T, Pluschke G, Leimkugel J. ST2859 serogroup A meningococcal meningitis outbreak in Nouna Health District, Burkina Faso: a prospective study. <i>Trop Med Int Health.</i> 2008; 13(6): 861-8.	2006		
Burkina Faso	Gessner BD, Mueller JE, Yaro S. African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adults. <i>BMC Infect Dis.</i> 2010; 10(1): 22.	2002-2005		
Burkina Faso	National Center for Scientific and Technological Research (Burkina Faso). Burkina Faso School Health Survey 2006.	2006		
Burkina Faso	Delange FM, Kibambo TN, Ouedraogo A, Acakpo A, Salami M, Jooste PL. Standardized evaluation of iodine nutrition in West Africa: the African phase of the thyromobil program. <i>Food Nutr Bull.</i> 2002; 23(4): 395-401 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1999		
Burkina Faso	AIDSTECH. AIDSTECH Final Report 1993. Durham, North Carolina: Family Health International, 1993.	1991		
Burkina Faso	Gouagna LC, Bancone G, Yao F, Yameogo B, Dabiré KR, Costantini C, Simpore J, Ouedraogo JB, Modiano D. Genetic variation in human HBB is associated with Plasmodium falciparum transmission. <i>Natl Genet.</i> 2010; 42(4): 328-31.	2001, 2007	*	
Burkina Faso	Keita MF, Prost A, Balique H, Ranque P. Associations in filarial infections in man in the savanna zones of Mali and Upper Volta. <i>Am J Trop Med Hyg.</i> 1981; 30(3): 590-2. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1980-2000	*	
Burkina Faso	Kyelem D, Medlock J, Sanou S, Bonkougou M, Boatin B, Molyneux DH. Short communication: impact of long-term (14 years) bi-annual ivermectin treatment on Wuchereria bancrofti microfilaraemia. <i>Trop Med Int Health.</i> 2005; 10(10): 1002-4. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2002	*	
Burkina Faso	Desjeux P. Leishmaniasis: current situation and new perspectives. <i>Comp Immunol Microbiol Infect Dis.</i> 2004; 27(5): 305-18.	1995, 2000		
Burkina Faso	Filippi V, Goufodji S, Sismanidis C, Kanhonou L, Fottrell E, Ronsmans C, Alithonou E, Patel V. Effects of severe obstetric complications on women's health and infant mortality in Benin. <i>Trop Med Int Health.</i> 2010; 15(6): 733-742.	2004-2006	*	
Burkina Faso	Malaria in Burkina Faso: Epidemiological Study of Transmission, Parasitological Indices, Morbidity, and Lethality [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Burkina Faso	Baragatti M, Fournet F, Henry M-C, Assi S, Ouedraogo H, Rogier C, Salem G. Social and environmental malaria risk factors in urban areas of Ouagadougou, Burkina Faso. <i>Malar J.</i> 2009; 8(1): 13 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Burkina Faso	Boudin C, Olivier M, Molez J, Chiron J, Ambroise-Thomas P. High human malarial infectivity to laboratory-bred Anopheles gambiae in a village in Burkina Faso. <i>Am J Trop Med Hyg.</i> 1993; 48(5): 700-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Burkina Faso	Boudin C, Robert V, Carnevale P, Ambroise-Thomas P. Epidemiology of Plasmodium falciparum in a rice field and a savanna area in Burkina Faso. Comparative study on the acquired immunoprotection in native populations. <i>Acta Trop.</i> 1992; 51(2): 103-11 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985-1986	*	†
Burkina Faso	Boudin C, Robert V, Verhave JP, Carnevale P, Ambroise-Thomas P. Plasmodium falciparum and P. malariae epidemiology in a West African village. <i>Bull World Health Organ.</i> 1991; 69(2): 199-205 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Burkina Faso	Carnevale P, Robert V, Boudin C, Halna JM, Pazart L, Gazin P, Richard A, Mouchet J. [Control of malaria using mosquito nets impregnated with pyrethroids in Burkina Faso]. <i>Bull Soc Pathol Exot.</i> 1988; 81(5): 832-46 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Burkina Faso	Chumputazi BFF, Peyron F, Simon J, Boudin C, Sheick-Zakiuddin I, Picot S, Ambroise-Thomas P. Longitudinal survey in an endemic region of plasma soluble interleukin-2 receptor and antibody levels in Plasmodium falciparum malaria. <i>J Clin Microbiol.</i> 1990; 28(7): 1545-50 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987-1988	*	†
Burkina Faso	Del Nero L, Lamizana L, Nebie I, Sare S, Bougouma L, Pietra V. In vivo sensitivity of Plasmodium falciparum to halofantrine hydrochloride in Burkina Faso. <i>Am J Trop Med Hyg.</i> 1994; 50(1): 102-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Burkina Faso	Del Nero L, Lamizana L, Pietra V, Nebi I. Sensitivity to antimalarial drugs by Plasmodium falciparum in Goundry, Ouhitenga province, Burkina Faso. <i>Parassitologia.</i> 1994; 36(3): 287-93 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Burkina Faso	Deloron P, Cot M. Antibodies to the ring-infected erythrocyte surface antigen and the circumsporozoite protein of <i>Plasmodium falciparum</i> in a rural community from Burkina Faso. <i>Trans R Soc Trop Med Hyg.</i> 1990; 84(2): 191-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Burkina Faso	Esposito F, Lombardi S, Modiano D, Zavala F, Reeme J, Lamizana L, Coluzzi M, Nussenzweig RS. Prevalence and levels of antibodies to the circumsporozoite protein of <i>Plasmodium falciparum</i> in an endemic area and their relationship to resistance against malaria infection. <i>Trans R Soc Trop Med Hyg.</i> 1988; 82(6): 827-32 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Burkina Faso	Gardella F, Assi S, Simon F, Bogreau H, Eggele T, Ba F, Founmane V, Henry M-C, Kientega PT, Basco L, Trape J-F, Lalou R, Martelloni M, Desbordes M, Baragatti M, Briolant S, Almeras L, Pradines B, Fusai T, Rogier C. Antimalarial drug use in general populations of tropical Africa. <i>Malar J.</i> 2008; 7(1): 124 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Burkina Faso	Gazin P, Freier C, Turk P, Gineste B, Carnevale P. [Malaria in employees of an African industrial enterprise (Bobo Dioulasso, Burkina Faso)]. <i>Ann Soc Belg Med Trop.</i> 1988; 68(4): 285-92 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Burkina Faso	Gazin P, Robert V, Carnevale P. Le paludisme urbain à Bobo-Dioulasso (Burkina Faso) / 2 : Les indices paludologiques. <i>Cahiers ORSTOM Entomol Medicale Parasitol.</i> 1987; 25(1): 27-31 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985-1986	*	†
Burkina Faso	Gazin P, Robert V, Cot M, Carnevale P. <i>Plasmodium falciparum</i> incidence and patency in a high seasonal transmission area of Burkina Faso. <i>Trans R Soc Trop Med Hyg.</i> 1988; 82(1): 50-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Burkina Faso	Gazin P, Robert V, Cot M, Simon J, Halna JM, Darriet F, Legrand D, Carnevale P, Ambrose-Thomas P. [Malaria in Oudalan, a Sahelian region of Burkina Faso]. <i>Ann Soc Belg Med Trop.</i> 1988; 68(3): 255-64 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985-1986	*	†
Burkina Faso	Geiger C, Agustar HK, Compaoré G, Coulibaly B, Sié A, Becher H, Lanzer M, Jänisch T. Declining malaria parasite prevalence and trends of asymptomatic parasitaemia in a seasonal transmission setting in north-western Burkina Faso between 2000 and 2009-2012. <i>Malar J.</i> 2013; 12(1): 27 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000	*	†
Burkina Faso	Gnémé A, Guelbéogo WM, Riehle MM, Tiono AB, Diarra A, Kabré GB, Sagnon N, Vernick KD. <i>Plasmodium</i> species occurrence, temporal distribution and interaction in a child-aged population in rural Burkina Faso. <i>Malar J.</i> 2013; 12(1): 67 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2007-2011	*	†
Burkina Faso	Meraldi V, Nebi I, Tiono AB, Diallo D, Sanogo E, Theisen M, Druilhe P, Corradin G, Moret R, Sirima BS. Natural antibody response to <i>Plasmodium falciparum</i> Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection. <i>Parasite Immunol.</i> 2004; 26(6-7): 265-72 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Burkina Faso	Modiano D, Petrarca V, Sirima BS, Bosman A, Nebi I, Diallo D, Lamizana L, Esposito F, Coluzzi M. <i>Plasmodium falciparum</i> malaria in sympatric ethnic groups of Burkina Faso, west Africa. <i>Parassitologia.</i> 1995; 37(2-3): 255-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†
Burkina Faso	Modiano D, Petrarca V, Sirima BS, Nebi I, Luoni G, Esposito F, Coluzzi M. Baseline immunity of the population and impact of insecticide-treated curtains on malaria infection. <i>Am J Trop Med Hyg.</i> 1998; 59(2): 336-40 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994-1996	*	†
Burkina Faso	Nebie I, Diarra A, Ouedraogo A, Soulama I, Bougouma EC, Tiono AB, Konaté AT, Chilengi R, Theisen M, Dodo D, Remarque E, Bosomprah S, Milligan P, Sirima SB. Humoral responses to <i>Plasmodium falciparum</i> blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. <i>Infect Immun.</i> 2008; 76(2): 759-66 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Burkina Faso	Nebie I, Tiono AB, Diallo DA, Samandoulougou S, Diarra A, Konaté AT, Cuzin-Ouattara N, Theisen M, Corradin G, Couzens S, Ouattara AS, Ilibouo-Sanogo E, Sirima BS. Do antibody responses to malaria vaccine candidates influenced by the level of malaria transmission protect from malaria? <i>Trop Med Int Health.</i> 2008; 13(2): 229-37 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Burkina Faso	Paganotti GM, Palladino C, Modiano D, Sirima BS, Raberg L, Diarra A, Konaté A, Coluzzi M, Walliker D, Babiker HA. Genetic complexity and gametocyte production of <i>Plasmodium falciparum</i> in Fulani and Mossi communities in Burkina Faso. <i>Parasitology.</i> 2006; 132(5): 607-14 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Burkina Faso	Paganotti GM, Babiker HA, Modiano D, Sirima BS, Verra F, Konaté A, Ouedraogo AL, Diarra A, Mackinnon MJ, Coluzzi M, Walliker D. Genetic complexity of <i>Plasmodium falciparum</i> in two ethnic groups of Burkina Faso with marked differences in susceptibility to malaria. <i>Am J Trop Med Hyg.</i> 2004; 71(2): 173-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
Burkina Faso	Pietra Y, Procacci P, Sabatinelli G, Kumlien S, Lamizana L, Rotigliano G. [Impact of utilization of permethrin impregnated curtains on malaria in a rural zone of high transmission in Burkina Faso]. <i>Bull Soc Pathol Exot.</i> 1991; 84(4): 375-85 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987-1988	*	†
Burkina Faso	Procacci PG, Lamizana L, Kumlien S, Habluetzel A, Rotigliano G. Permethrin-impregnated curtains in malaria control. <i>Trans R Soc Trop Med Hyg.</i> 1991; 85(2): 181-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Burkina Faso	Sabatinelli G, Bosman A, Lamizana L, Rossi P. [Prevalence of malaria in Ouagadougou and the surrounding rural environment during the period of maximal transmission]. <i>Parassitologia.</i> 1986; 28(1): 17-31 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Burkina Faso	Sanou D, Turgeon-O'Brien H, Desrosiers T. Prevalence and nondietary predictors of anaemia and iron deficiency among preschool orphans and vulnerable children from Burkina-Faso. <i>Nutrition Clinique et Metabolisme.</i> 2008; 22(1): 10-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Burkina Faso	Stich A, Oster N, Abdel-Aziz Z, Stieglbauer G, Coulibaly B, Wickert H, McLean J, Kouyat BA, Becher H, Lanzer M. Malaria in a holoendemic area of Burkina Faso: a cross-sectional study. <i>Parasitol Res.</i> 2006; 98(6): 596-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000	*	†
Burkina Faso	Wang SJ, Lengeler C, Smith TA, Vounatsou P, Diadie DA, Pritroipa X, Convelbo N, Kientga M, Tanner M. Rapid urban malaria appraisal (RUMA) I: epidemiology of urban malaria in Ouagadougou. <i>Malar J.</i> 2005; 4: 43 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Burkina Faso	Ye Y, Hoshen M, Louis V, Seraphin S, Traore I, Sauerborn R. Housing conditions and <i>Plasmodium falciparum</i> infection: protective effect of iron-sheet roofed houses. <i>Malar J.</i> 2006; 5: 8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003-2004	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Burkina Faso	Zeba AN, Sorgho H, Rouamba N, Zongo I, Rouamba J, Guiguemde RT, Hamer DH, Mokhtar N, Ouedraogo JB. Major reduction of malaria morbidity with combined vitamin A and zinc supplementation in young children in Burkina Faso: a randomized double blind trial. <i>Nutr J</i> . 2008; 7: 7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Burundi	United Nations Children's Fund (UNICEF), Burundi Institute of Statistics and Economic Studies, United Nations Population Fund (UNFPA). Burundi Multiple Indicator Cluster Survey 2005. New York, United States: United Nations Children's Fund (UNICEF).	2005	*	
Burundi	Burundi Institute of Statistics and Economic Studies, United Nations Children's Fund (UNICEF). Burundi Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Burundi	Population Department, Ministry of the Interior (Burundi), Westinghouse; Institute for Resource Development. Burundi Demographic and Health Survey 1987. Columbia, United States: Westinghouse; Institute for Resource Development.	1987		†
Burundi	Burundi Institute of Statistics and Economic Studies, ICF International, Ministry of Public Health and the Fight against AIDS (Burundi). Burundi Demographic and Health Survey 2010-2011. Fairfax, United States: ICF International, 2012.	2010-2011	*	†
Burundi	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Burundi	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Burundi	Gibbs, S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. <i>Int J Dermatol</i> . 1996; 35(9): 633-9.	1994		
Burundi	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1995, 1997-1999, 2004, 2006-2009		
Burundi	Gryseels B, Nkuliqiyinka L. The morbidity of schistosomiasis mansoni in the highland focus of Lake Cohoba, Burundi. <i>Trans R Soc Trop Med Hyg</i> . 1990; 84(4): 542-7.	1987-1990		†
Burundi	Gryseels B. The morbidity of schistosomiasis mansoni in the Rusizi Plain (Burundi). <i>Trans R Soc Trop Med Hyg</i> . 1988; 82(4): 582-7.	1985-1988		†
Burundi	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Burundi	Newell E, Vyungimana F, Geerts S, Van Kerckhoven I, Tsang VCW, Engels D. Prevalence of cysticercosis in epileptics and members of their families in Burundi. <i>Trans R Soc Trop Med Hyg</i> . 1997; 91(4): 389-91.	1997	*	
Burundi	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Burundi	Burundi Survey on Disorders due to Iodine Deficiency 1991 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1991		
Burundi	Burundi Survey of Endemic Goitre in Primary Schools 1990 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1990		
Burundi	Burundi National Nutrition Survey 2005 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2005		
Burundi	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec</i> . 2005; 80(13): 118-24.	2003	*	
Burundi	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec</i> . 2006; 81(32): 309-16.	2005	*	
Burundi	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec</i> . 2010; 85(35): 337-48.	2009	*	
Burundi	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec</i> . 2012; 87(34): 317-28.	2011	*	
Burundi	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec</i> . 2011; 86(36): 389-99.	2010	*	
Burundi	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec</i> . 2001; 76(23): 173-9.	2000	*	
Burundi	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part 1. <i>Wkly Epidemiol Rec</i> . 1995; 70(25): 177-82.	1994	*	
Burundi	Kandeke L, Mathenge W, Giramahoro C, Undendere F-PA, Ruhagaze P, Habyakare C, Courtright P, Lewallen S. Rapid assessment of avoidable blindness in two northern provinces of Burundi without eye services. <i>Ophthalmic Epidemiol</i> . 2012; 19(4): 211-5.	2009-2010	*	
Burundi	Mutesa L, Boemer F, Ngenadahayo L, Rulisa S, Rusingiza EK, Cwinya-Ay N, Mazina D, Kariyo PC, Bours V, Schoos R. Neonatal screening for sickle cell disease in Central Africa: a study of 1825 newborns with a new enzyme-linked immunosorbent assay test. <i>J Med Screen</i> . 2007; 14(3): 113-6.	2004-2006		
Burundi	Moreno JL, Baribwira C. The epidemiology of neonatal sickle cell anemia in Bujumbura (Burundi). <i>Ann Pediatr (Paris)</i> . 1994; 41(4): 215.	1992-1993	*	
Burundi	Aubry P, Niel L, Niyongabo T, Kerguelen S, Larouze B. Seroprevalence of hepatitis E virus in an adult urban population from Burundi. <i>Am J Trop Med Hyg</i> . 1997; 57(3): 272-3.	1992-1993		
Burundi	Ndihokubwayo H. The in-vitro sensitivity of Plasmodium Falciparum to Chloroquine and Sulfadoxine-Pyrimethamine (Fansidar) in Burundi (Nyanza-Lac). <i>Malar Infect Dis Afr</i> . 1995; 3: 23-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Burundi	Bartra C, Mittal P, Adak T, Sharma V. Malaria investigation in District Jodhpur, Rajasthan, during the summer season. <i>Indian J Malariol</i> . 1998; 36(3-4): 75-80 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985-1986	*	†
Burundi	Delacollette C, Barutwanayo M, Mpitabakana P. Epidémiologie du paludisme au Burundi. <i>Med Afr Noire</i> . 1990; 37(12): 718-21 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Burundi	Protopopoff N, Van Herp M, Maes P, Reid T, Baza D, D'Alessandro U, Van Bortel W, Coosemans M. Vector control in a malaria epidemic occurring within a complex emergency situation in Burundi: a case study. <i>Malar J</i> . 2007; 6: 93 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002-2006	*	†
Burundi	Smits A, Coosemans M, Van Bortel W, Barutwanayo M, Delacollette C. Readjustment of the malaria vector control strategy in the Rusizi Valley, Burundi. <i>Bulletin of Entomological Research</i> . 1995; 85(4): 541-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Cambodia	Macro International, Inc, Ministry of Health (Cambodia), National Institute of Statistics (Cambodia). Cambodia Demographic and Health Survey 2000. Calverton, United States: Macro International, Inc.	2000		†
Cambodia	Macro International, Inc, National Institute of Public Health (Cambodia), National Institute of Statistics (Cambodia). Cambodia Demographic and Health Survey 2005-2006. Calverton, United States: Macro International, Inc.	2005-2006		†
Cambodia	ICF Macro, Ministry of Health (Cambodia), National Institute of Statistics (Cambodia). Cambodia Demographic and Health Survey 2010-2011. Calverton, United States: ICF Macro, 2011.	2010-2011		†
Cambodia	Ministry of Health (Cambodia). Cambodia National Health Statistics 2008. Phnom Penh, Cambodia: Ministry of Health (Cambodia), 2008.	2008	*	
Cambodia	Ministry of Health (Cambodia). Cambodia National Health Statistics 2007. Phnom Penh, Cambodia: Ministry of Health (Cambodia), 2007.	2007	*	
Cambodia	Ministry of Health (Cambodia). Cambodia National Health Statistics 2006. Phnom Penh, Cambodia: Ministry of Health (Cambodia), 2007.	2006	*	
Cambodia	Ministry of Health (Cambodia). Cambodia National Health Statistics 2009. Phnom Penh, Cambodia: Ministry of Health (Cambodia), 2009.	2009	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Cambodia	Ministry of Health (Cambodia). Cambodia National Health Statistics 2010. Phnom Penh, Cambodia: Ministry of Health (Cambodia).	2010	*	
Cambodia	Ministry of Health (Cambodia). Cambodia National Health Statistics 2011. Phnom Penh, Cambodia: Ministry of Health (Cambodia).	2011	*	
Cambodia	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-1999		
Cambodia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Cambodia	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		i
Cambodia	Ministry of Health (Cambodia), University of Health Sciences (Cambodia), World Health Organization (WHO). Cambodia STEPS Noncommunicable Disease Risk Factors Survey 2010.	2010		
Cambodia	Nyambat B, Meng CY, Vansith K, Vuthy U, Rin E, Kirkwood C, Bogdanovic-Sakan N, Kilgore PE. Hospital-based surveillance for rotavirus diarrhoea in Phnom Penh, Cambodia, March 2005 through February 2007. Vaccine. 2009; 27(Suppl 5): 81-84.	2005-2007		
Cambodia	Lumbiganon P, Laopaiboon M, Gülmezoglu AM, Souza JP, Taneepanichkul S, Ruyan P, Aitygalle DE, Shrestha N, Mori R, Hinh ND, Bang HT, Rathavy T, Chuyun K, Cheang K, Festin M, Udonprasertgul V, Gernar MJV, Yanqu G, Roy M, Carroli G, Ba-Thike K. Method of delivery and pregnancy outcomes in Asia: the WHO global survey on maternal and perinatal health 2007-08. Lancet. 2010; 375(9713): 490-9.	2007-2008		
Cambodia	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998, 2002		
Cambodia	Amarasena N, Ikeda N, Win KKS, Yamaguchi Y, Takehara T, Miyazaki H. Periodontal status of rural inhabitants in Prek Russey, Cambodia. Asia Pac J Public Health. 2002; 14(2): 105-9.	1993-1994	*	
Cambodia	Soeung SC, Rani M, Huong V, Sarath S, Kimly C, Kohei T. Results from nationwide hepatitis B serosurvey in Cambodia using simple and rapid laboratory test: implications for National Immunization Program. Am J Trop Med Hyg. 2009; 81(2): 252-7.	2006		
Cambodia	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Cambodia	Meng CY, Smith BL, Bodhidatta L, Richard SA, Vansith K, Thy B, Srijan A, Serichantalergs O, Mason CJ. Etiology of diarrhea in young children and patterns of antibiotic resistance in Cambodia. Pediatr Infect Dis J. 2011; 30(4): 331-5.	2004-2006	*	
Cambodia	Chu CH, Wong AWY, Lo ECM, Courtel F. Oral health status and behaviours of children in rural districts of Cambodia. Int Dent J. 2008; 58(1): 15-22.	2003-2007		
Cambodia	Cambodia Rapid Assessment for Avoidable Blindness 2007 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2007		
Cambodia	Cambodia - Battambang Rapid Assessment of Cataract Surgical Services 2002 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2002		
Cambodia	Rutzen AR, Elish NJ, Schwab L, Graham PJ, Pizzarello LD, Hemady RK, Maldonado MJ. Blindness and eye disease in Cambodia. Ophthalmic Epidemiol. 2007; 14(6): 360-6. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1996		
Cambodia	Preux P-M, Chea K, Chamroun H, Bhalla D, Vannareth M, Huc P, Samleng C, Cayreire M, Gérard D, Dumas M, Oum S. First-ever, door-to-door cross-sectional representative study in Prey Veng province (Cambodia). Epilepsia. 2011; 52(8): 1382-7.	2008-2010	*	
Cambodia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Cambodia	National Center for Tuberculosis and Leprosy Control (CENAT) (Cambodia). Cambodia National Tuberculosis Prevalence Survey 2002.	2002		
Cambodia	Japan International Cooperation Agency, Ministry of Health (Cambodia), National Center for Tuberculosis and Leprosy Control (CENAT) (Cambodia). Cambodia National Tuberculosis Prevalence Survey 2010-2011.	2010-2011		
Cambodia	Cambodia - Kampong Cham Rapid Assessment of Cataract Surgical Services 2002 as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2002		
Cambodia	Cambodia - Kampong Rapid Assessment of Cataract Surgical Services 2002 as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2002		
Cambodia	Monchy D, Babin FX, Srey CT, Ing PN, von Xylander S, Ly V, Busch Hallen J. Frequency of G6PD deficiency in a group of preschool-aged children in a centrally located area of Cambodia. Med Trop (Mars). 2004; 64(4): 355-8.	2002		
Cambodia	Louichareon C, Nuchprayoon I. G6PD Viangchan (871G>A) is the most common G6PD-deficient variant in the Cambodian population. J Hum Genet. 2005; 50(9): 448-52.	2002-2003		
Cambodia	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Cambodia	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
Cambodia	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	
Cambodia	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Cambodia	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Cambodia	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Cambodia	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
Cambodia	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Cambodia	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Cambodia	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Cambodia	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Cambodia	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Cambodia	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Cambodia	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Cambodia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Cambodia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2000.	2000		
Cambodia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2001.	2001		
Cambodia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2002.	2002		
Cambodia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2003.	2003		
Cambodia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2004.	2004		
Cambodia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2005.	2005		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Cambodia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2006.	2006		
Cambodia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2007.	2007		
Cambodia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2008.	2008		
Cambodia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2009.	2009		
Cambodia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2010.	2010		
Cambodia	Ng KP, Ngeow YF, K R, M R. Hepatitis B seroprevalence among University of Malaya Students in the Post-universal Infant Vaccination Era. <i>Med J Malaysia</i> . 2013; 68(2): 144-7.	2005-2011	*	
Cambodia	Thiring EG, Joller-Jemelka HI, Sareth H, Sokhan U, Reth C, Grob P. Prevalence of markers of hepatitis viruses A, B, C and of HIV in healthy individuals and patients of a Cambodian province. <i>Southeast Asian J Trop Med Public Health</i> . 1993; 24(2): 239-49.	1990-1991		
Cambodia	Remote Sensing as a Tool for Malaria Stratification in Cambodia: A Feasibility Study in Ratanakiri as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Cambodia	A Survey of Plasmodium Falciparum Prevalence Among Phnom Villagers in Mondulakiri, Cambodia [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
Cambodia	Dysosley L, Kaneko A, Eto H, Mita T, Socheat D, Björkman A, Kobayakawa T. Changing patterns of forest malaria among the mobile adult male population in Chumkiri District, Cambodia. <i>Acta Trop</i> . 2008; 106(3): 207-12 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Cambodia	Hoyer S, Nguon S, Kim S, Habib N, Khim N, Sum S, Christophe E-M, Bjorge S, Thomson A, Kheng S, Chea N, Yok S, Top S, Ros S, Sophal U, Thompson MM, Mellor S, Arley F, Witkowski B, Yeang C, Yeung S, Duong S, Newman RD, Menard D. Focused Screening and Treatment (FSAT): A PCR-Based Strategy to Detect Malaria Parasite Carriers and Contain Drug Resistant P. falciparum, Pailin, Cambodia. <i>PLoS One</i> . 2012; 7(10): e45797 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2010	*	†
Cambodia	Incardona S, Vong S, Chiv L, Lim P, Nhem S, Sem R, Khim N, Doung S, Mercereau-Pujalon O, Fandeur T. Large-scale malaria survey in Cambodia: novel insights on species distribution and risk factors. <i>Malar J</i> . 2007; 6: 37 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001-2003	*	†
Cambodia	Cambodia Plasmodium Falciparum Parasite Rate Data. Personal Communication with SMRU MSF-B, Médecins Sans Frontières 2008 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003-2005	*	†
Cambodia	Cambodia Plasmodium Falciparum Parasite Rate Data. Personal Communication with SMRU MSF-H, Médecins Sans Frontières 2005 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999-2002	*	†
Cambodia	Cambodia Vitamin A Deficiency Survey 1993 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1993		
Cambodia	Department of Statistics and Accounting, Ministry of the Economy and Finance (Cameroon) and United Nations Children's Fund (UNICEF). Cameroon Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	
Cameroon	United Nations Children's Fund (UNICEF), National Institute of Statistics (Cameroon). Cameroon Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006	*	†
Cameroon	Minister of the Economy and Planning (Cameroon), International Statistical Institute. Cameroon World Fertility Survey 1978. Voorburg, Netherlands: International Statistical Institute.	1978		
Cameroon	Macro International, Inc, Ministry of Economy, Planning and Regional Development (Cameroon), Cameroon Demographic and Health Survey 1991. Calverton, United States: Macro International, Inc.	1991		†
Cameroon	Central Bureau of the Census and Population Studies (Cameroon), Macro International, Inc. Cameroon Demographic and Health Survey 1998. Calverton, United States: Macro International, Inc.	1998		†
Cameroon	Macro International, Inc, National Institute of Statistics (Cameroon), Cameroon Demographic and Health Survey 2004. Calverton, United States: Macro International, Inc.	2004		†
Cameroon	ICF International, Ministry of Economy, Planning and Regional Development (Cameroon), Ministry of Public Health (Cameroon), National Institute of Statistics (Cameroon), Pasteur Center of Cameroon. Cameroon Demographic and Health Survey 2011. Fairfax, United States: ICF International.	2011	*	†
Cameroon	Cameroon Demographic and Health Survey 2011 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2011	*	†
Cameroon	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Cameroon	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Cameroon	Mayosi BM. Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa. <i>Heart</i> . 2007; 93(10): 1176-1183.	1957-2005		
Cameroon	Mwenda JM, Noto KM, Abebe A, Enweronu-Laryea C, Amina I, Mchomvu J, Kisakye A, Mpabalwani EM, Pazvakambwa I, Amah GE, Seheri LM, Kiulia NM, Page N, Widdowson M-A, Steele AD. Burden and epidemiology of rotavirus diarrhea in selected African countries: preliminary results from the African Rotavirus Surveillance Network. <i>J Infect Dis</i> . 2010; 202(Suppl): S5-S11.	2007-2008		
Cameroon	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1980, 1984, 1990, 1994		
Cameroon	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1988-1989, 1991, 1997, 2001-2004, 2007-2009		
Cameroon	Tomori O. Yellow fever in Africa: public health impact and prospects for control in the 21st century. <i>Biomedica</i> . 2002; 22(2): 178-210.	1981		
Cameroon	Wisongse CS, Nomo E, Mawo J, Ofal J, Mimbouga J, Ticha J, Ndumbe PM. Yellow fever epidemic in the extreme North of Cameroon in 1990: first yellow fever virus isolation in Cameroon. <i>BMC Med</i> . 2008; 6: 3.	1990		
Cameroon	Wisongse CS, Nomo E, Mawo J, Ofal J, Mimbouga J, Ticha J, Ndumbe PM. Yellow fever control in Cameroon: where are we now and where are we going? <i>BMC Med</i> . 2008; 6: 3.	2003-2006		
Cameroon	World Health Organization (WHO). Yellow fever in Africa and South America, 2007. <i>Wkly Epidemiol Rec</i> . 2009; 84(13): 97-104.	2007		
Cameroon	Befidi-Mengue RN, Ratard RC, Beltran G, D'Alessandro A, Rice J, Befidi-Mengue R, Kouemeni LE, Cline BL. Impact of Schistosoma haematobium infection and of praziquantel treatment on anaemia of primary school children in Bertoua, Cameroon. <i>J Trop Med Hyg</i> . 1993; 9(8): 225-30.	1993		†
Cameroon	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	2002		
Cameroon	Ndip EA, Tchakonte B, Mbanya JC. A study of the prevalence and risk factors of foot problems in a population of diabetic patients in cameroon. <i>Int J Low Extrem Wounds</i> . 2006; 5(2): 83-8.	2002-2003		
Cameroon	Sobngwi E, Mbanya JC, Moukouri EN, Ngu KB. Microalbuminuria and retinopathy in a diabetic population of Cameroon. <i>Diabetes Res Clin Pract</i> . 1999; 44(3): 191-6.	1998		
Cameroon	Jivraj I, Ng M, Rudnisky CJ, Dimla B, Tambe E, Nathoo N, Tennant MT. Prevalence and severity of diabetic retinopathy in Northwest Cameroon as identified by teleophthalmology. <i>Telemed J E Health</i> . 2011; 17(4): 294-8.	2007-2008		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Cameroon	Bissek A-CZ-K, Tabah EN, Kouotou E, Sini V, Yepnjo FN, Nditanchou R, Nchufor RN, Defo D, Dema F, Fonsah JY, Njamshi AK, Muna WFT. The spectrum of skin diseases in a rural setting in Cameroon (sub-Saharan Africa). <i>BMC Dermatol.</i> 2012; 7.	2010	*	
Cameroon	Bernstein SC, Bowman JE, Kaptue Noche L. Population studies in Cameroon: hemoglobin S, glucose-6-phosphate dehydrogenase deficiency and falciparum malaria. <i>Hum Hered.</i> 1980; 30(4): 251-8.	1977-1979	*	
Cameroon	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Cameroon	Esona MD, Armah GE, Steele AD. Molecular epidemiology of rotavirus infection in Western Cameroon. <i>J Trop Pediatr.</i> 2003; 49(3): 160-3.	1999-2000	*	
Cameroon	Wilson MR, Mansour M, Ross-Degnan D, Moukouri E, Fobi G, Alemayehu W, Martone JF, Casey R, Bazargan M. Prevalence and causes of low vision and blindness in the Extreme North Province of Cameroon, West Africa. <i>Ophthalmic Epidemiol.</i> 1996; 3(1): 23-33, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1992		
Cameroon	Oye JE, Kuper H, Dineen B, Befidi-Mengue R, Foster A. Prevalence and causes of blindness and visual impairment in Muyuka: a rural health district in South West Province, Cameroon. <i>Br J Ophthalmol.</i> 2006; 90(5): 538-42, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2003-2004		
Cameroon	Oye JE, Kuper H. Prevalence and causes of blindness and visual impairment in Limbe urban area, South West Province, Cameroon. <i>Br J Ophthalmol.</i> 2007; 91(11): 1435-9, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2004-2005		
Cameroon	Ngowa JDK, Ngassam A-N, Dohbit JS, Nzejdjom C, Kasia JM. Pregnancy outcome at advanced maternal age in a group of African women in two teaching Hospitals in Yaounde, Cameroon. <i>Pan Afr Med J.</i> 2013; 134.	2007-2011	*	
Cameroon	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Cameroon	Kingue S, Dzudie A, Menanga A, Akono M, Ouankou M, Muna W. Nouveau regard sur l'insuffisance cardiaque chronique de l'adulte en Afrique à l'ère de l'échocardiographie Doppler : expérience du service de médecine de l'Hôpital Général de Yaoundé. <i>Ann Cardiol Angeiol (Paris).</i> 2005; 54(5): 276-83.	1998-2001		
Cameroon	Wonkam A, Noubiap JN, Djomou F, Fieggen K, Njock R, Toure GB. Aetiology of childhood hearing loss in Cameroon (sub-Saharan Africa). <i>Eur J Med Genet.</i> 2013; 56(1): 20-5.	2009-2011	*	
Cameroon	World Health Organization (WHO). Cameroon WHO Leishmaniasis Country Profile.	2008	*	
Cameroon	Cho-Ngwa F, Amambua AN, Ambe MA, Titanji VPK. Evidence for the exacerbation of lymphedema of geochemical origin, podoconiosis, by onchocerciasis. <i>J Infect Public Health.</i> 2009; 2(4): 198-203.	2002-2003		
Cameroon	Damascono A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D, Dzudie A, Kouam CK, Suliman A, Schrueder N, Yonga G, Ba SA, Maru F, Alemayehu B, Edwards C, Davison BA, Cotter G, Sliva K. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. <i>Arch Intern Med.</i> 2012; 172(18): 1386-94.	2007-2010		
Cameroon	Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. <i>Int J Health Geogr.</i> 2010; 9: 57.	1980-2010		
Cameroon	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec.</i> 2005; 80(13): 118-24.	2003	*	
Cameroon	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec.</i> 2006; 81(32): 309-16.	2005	*	
Cameroon	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Cameroon	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Cameroon	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Cameroon	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Cameroon	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Cameroon	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Cameroon	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Cameroon	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Cameroon	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Cameroon	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Cameroon	Ngandjio A, Clerc M, Fonkoua MC, Thonnon J, Njock F, Pouillot R, Lunel F, Bebear C, De Barbeyrac B, Bianchi A. Screening of volunteer students in Yaounde (Cameroon, Central Africa) for Chlamydia trachomatis infection and genotyping of isolated C. trachomatis strains. <i>J Clin Microbiol.</i> 2003; 41(9): 4404-7.	2001	*	
Cameroon	Suligoi B, Tchamgema O, Samati L, Bugarini R, Toma L, Bakary DK, Glikoutou M, Rezza G. Prevalence and risk factors for herpes simplex virus type 2 infection among adolescents and adults in northern Cameroon. <i>Sex Transm Dis.</i> 2001; 28(12): 690-3.	1997-1998	*	
Cameroon	Weiss HA, Buvé A, Robinson NJ, Van Dyck E, Kahindo M, Anagonou S, Musonda R, Zekeng L, Morison L, Caraël M, Laga M, Hayes RJ, Study Group on Heterogeneity of HIV Epidemics in African Cities. The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. <i>AIDS.</i> 2001; 15(7): 997-108.	1997-1998	*	
Cameroon	Bernstein SC, Bowman JE, Noche LK. Interaction of sickle cell trait and glucose-6-phosphate dehydrogenase deficiency in Cameroon. <i>Hum Hered.</i> 1980; 30(1): 7-11.	1977-1979	*	
Cameroon	Ndumbe PM, Njije TK. Hepatitis A and B infections in Yaoundé, Cameroon. <i>Res Virol.</i> 1989; 140(3): 253-61.	1988		
Cameroon	Skalsky JA, Joller-Jemelka HI, Bianchi L, Knoblauch M. Liver pathology in rural south-west Cameroon. <i>Trans R Soc Trop Med Hyg.</i> 1995; 89(4): 411-4.	1990-1992		
Cameroon	Ndumbe PM, Skalsky J, Joller-Jemelka HI. Seroprevalence of hepatitis and HIV infection among rural pregnant women in Cameroon. <i>APMIS.</i> 1994; 102(9): 662-6.	1991-1992		
Cameroon	Belinga S, Ngo Sack F, Bilong C, Manga J, Mengue M-A, Tchendjou P. High prevalence of anti-D antibodies among women of childbearing age at Centre Pasteur de Cameroon. <i>Afr J Reprod Health.</i> 2009; 13(3): 47-52.	2006-2007	*	†
Cameroon	Mencarini P, De Luca A, Antinori A, Maiuro G, Spedini G, Bailly C, Tamburrini E. Prevalence of anti-HCV antibodies in Cameroon. <i>Trans R Soc Trop Med Hyg.</i> 1991; 85(5): 654-5.	1987-1990		
Cameroon	Ngatchu T, Stroffolini T, Rapietta M, Chionne P, Lantum D, Chiaramonte M. Seroprevalence of anti-HCV in an urban child population: a pilot survey in a developing area, Cameroon. <i>J Trop Med Hyg.</i> 1992; 95(1): 57-61.	1992		
Cameroon	Rapietta M, Stroffolini T, Ngatchu T, Chionne P, Ciccaglione AR, Lantum D, Chiaramonte M. Age- and sex-related study of HBV-DNA in HBsAg asymptomatic children from an endemic area (Cameroon). <i>Ann Trop Paediatr.</i> 1991; 11(4): 325-9.	1989		
Cameroon	Stroffolini T, Chiaramonte M, Ngatchu T, Rapietta M, Sarrecchia B, Chionne P, Lantum D, Naccarato R. A high degree of exposure to hepatitis A virus infection in urban children in Cameroon. <i>Microbiologica.</i> 1991; 14(3): 199-203.	1989		
Cameroon	Ivoko N. Rural bancroftian filariasis in north-western Cameroon: parasitological and clinical studies. <i>J Commun Dis.</i> 2000; 32(4): 254-63, as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1995-2000	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Cameroon	Marceau C, Couprie B, Combe A, Same-Ekobo A, Tribouley J, Puel V, Piquemal A, Ripert C. [Epidemiology of filariasis (onchocerciasis and bancroftosis) in the Tala-Mokolo region (Mandara Mountains of North Cameroon)]. Bull Soc Pathol Exot Filiales. 1986; 79(5 Pt 2): 755-65. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1984	*	
Cameroon	Moyou-Somo R, Ouambe MA, Fon E, Bema J. [Prevalence of Bancroftian filariasis in seven villages of the Bonassama Health District in the Wouri Estuary, littoral province of Cameroon]. Med Trop (Mars). 2003; 63(6): 583-6. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2002	*	
Cameroon	Ripert C, Eono P, Eono D, Tribouley J, Appriou M, Issoufa H. [Epidemiological study of bancroftian filariasis in the Logone Valley (North Cameroon) (author's transl)]. Med Trop (Mars). 1982; 42(1): 59-66. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1980	*	
Cameroon	Results of the Malariometric Surveys Conducted in Djoum and Ngaoundere in Cameroon [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Cameroon	The Epidemiology and Consequences of Malaria Infection in Primary School Children in the Muea Area and its Environs as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Cameroon	Comparative Malariometric Study in Areas Rural (Bandoumka and Bapoudeu) and Urban (Ville de Bafang) in the Department of Haut-Kam as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Cameroon	Study of Seasonal Malaria Morbidity in the Urban Emonbo Quarter of Yaounde as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Cameroon	Evaluation In Vivo of the Chemical Sensitivity of Plasmodium Falciparum to Chloroquine in a School in Dschang as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Cameroon	Prevalence of Malaria in Two Villages in the Southwest Province in Cameroon as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Cameroon	Parasitological Study of Malaria Transmission in the Nkolbison and Nkolbikok Neighborhoods as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Cameroon	Study of the Behavior of the An Gambiae Complex and the Transmission of Malaria in Two Ecological Aspects of Mali and Cameroon [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Cameroon	Evaluation In Vivo of the Chemical Sensitivity of Plasmodium Falciparum to Chloroquine in the Region of Yaounde-School of Ntui as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Cameroon	Epidemiological and Immunological Aspects of Malaria Among Ngaoundere Children 0-10 Years [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Cameroon	Malaria Survey in Bilalang (Edea, Cameroon) as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Cameroon	Malaria Parasitaemia and Helminthic Infections in Asymptomatic School-pupils from Fako Division, South Western Cameroon as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Cameroon	Report on the Malariometric Sample Survey in Maroua in the Republic of Cameroon as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Cameroon	Malaria in Ntouessong Primary and Nursery School Children: An Epidemiological Survey as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Cameroon	Malaria and Helminthic Infections Alongside Haemoglobin Levels Amongst School Children in Bello Sub-division Cameroon as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008	*	†
Cameroon	Epidemiological Aspects of Malaria in the city of Kumba, South-West Province, Cameroon [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Cameroon	Study of the Current Endemic Malaria Situation in Children from 3 Months to 14 Years in the City of Bafoussam as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Cameroon	Étude épidémiologique du paludisme dans la région du futur lac de retenue de la Birni (Adamaoua) Cameroun. Bulletin de Liaison et de la Documentation de l'OCEAC. 1991; 97: 40-4. as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Cameroon	Enquête paludométrique dans trois villages de la Vallée de la Kadei (Cameroon) as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†
Cameroon	Achidi EA, Apinjah TO, Mbuwne E, Besingi R, Yafi C, Wenjighe Awah N, Ajua A, Anchang JK. Febrile status, malarial parasitaemia and gastro-intestinal helminthiasis in schoolchildren resident at different altitudes, in south-western Cameroon. Ann Trop Med Parasitol. 2008; 102(2): 103-18 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004-2005	*	†
Cameroon	Agnamey PP, Leroy G, Kouamou J, Brasseur P. [Sensitivity in vivo and in vitro of Plasmodium falciparum to chloroquine and amodiaquine in Bangangte (west Cameroon)]. Bull Soc Pathol Exot. 1995; 88(4): 149-51 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Cameroon	Akenji TN, Ntonfor NN, Kimbi HK, Abongwa EL, Ching JK, Ndukum MB, Anong DN, Nkweschu A, Songmbe M, Boyo MG, Ndamikong KN, Titanji VPK. The epidemiology of malaria in Bolifamba, a rural community on the eastern slopes of Mount Cameroon: seasonal variation in the parasitological indices of transmission. Ann Trop Med Parasitol. 2005; 99(3): 221-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Cameroon	Atangana J, Fomena A, Tamesse J, Fondjo E. [Agricultural activities and epidemiology of malaria in Soudano-Sahelian zone in Cameroon]. Bull Soc Pathol Exot. 2012; 105(1): 23-29 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Cameroon	Audibert M, Josserean R, Josse R, Adjidji A. Irrigation, schistosomiasis, and malaria in the Logone Valley, Cameroon. Am J Trop Med Hyg. 1990; 42(6): 550-60 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Cameroon	Bigoga JD, Manga L, Titanji VP, Coetzee M, Leke RG. Malaria vectors and transmission dynamics in coastal south-western Cameroon. Malar J. 2007; 6(1): 5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Cameroon	Chambon R, Lemaudeley P, Boudin C, Ringwald P, Chandener J. [Surveillance of the in vivo sensitivity of Plasmodium falciparum to antimalarial agents: the results of initial tests of the OCEAC Malaria Network]. Med Trop (Mars). 1997; 57(4): 357-60 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Cameroon	Eiang J, Chouabou M, Toto JC, Faye O, Manga L, Sam-Ekoko A, Awono-Ambene P, Simard F. A preliminary test of the protective efficacy of permethrin-treated bed nets in an area of Anopheles gambiae metabolic resistance to pyrethroids in north Cameroon. <i>Trans R Soc Trop Med Hyg.</i> 2007; 101(9): 881-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Cameroon	Gardella F, Assi S, Simon F, Bogreau H, Eggelte T, Ba F, Founmane V, Henry M-C, Kientega PT, Basco L, Trape J-F, Lalou R, Martelloni M, Desbordes M, Baragatti M, Briolant S, Almeras L, Pradines B, Fusai T, Rogier C. Antimalarial drug use in general populations of tropical Africa. <i>Malar J.</i> 2008; 7(1): 124 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Cameroon	Gazin P, Louis JP, Mulder L, Eberle F, Jambou R, Moyroud, Hengy C. [Evaluation of Plasmodium falciparum susceptibility to chloroquine and amodiaquine using a simplified vivo, 7-day test in southern Cameroon]. <i>Med Trop (Mars).</i> 1990; 50(1): 27-31 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Cameroon	Gardon J, Eberle F, Louis JP, Cheringou H, Trebuq A, Hengy C. Evaluation de la chloroquine-sensibilite de Plasmodium falciparum au Cameroun. <i>Med Afr Noire.</i> 1991; 38(4): 270-2 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Cameroon	Josse R, Hengy C, Bailly C, Calvez T, Ambassa P, Wandji R, Gabon H, Koua-Bemba D, Merlin M. Etude épidémiologique du paludisme dans la ville de Nkongsamba (Province du Littoral, République du Cameroun). <i>Med Afr Noire.</i> 1988; 35(1): 17-24 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Cameroon	Josse R, Merlin M, Combe A, Jossieran R, Le Hesran JY, Avnec F, Ngnintedem B, Nkongsto AM, Kamwa M, Eboumbou JT. [Comparative study of the malaria indices in Nanga-Eboko, Yaounde and Edea (Cameroon)]. <i>Med Trop (Mars).</i> 1988; 48(3): 201-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986-1987	*	†
Cameroon	Josse R, Trebuq A, Jaureguiberry G, Ghogomou A, Nzinda O, Founmane V, Combourieu I, Tribouley J, Ripert C. [Evaluation of malarial indices in the forest region of Djoum (southern Cameroon)]. <i>Med Trop (Mars).</i> 1990; 50(1): 47-51 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Cameroon	Kimbi HK, Nformi D, Patchong AM, Ndamukong KJ. Influence of urbanisation on asymptomatic malaria in school children in Molyko, South West Cameroon. <i>East Afr Med J.</i> 2006; 83(11): 602-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000	*	†
Cameroon	Macaigne F, Combe A, Vincendeau P, Eboumbou J, Garnier T, Michel R, Ripert C. [In vivo sensitivity of Plasmodium falciparum to amodiaquine in the town of Edea (Cameroon)]. <i>Bull Soc Pathol Exot.</i> 1989; 82(2): 208-16 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Cameroon	Manga L, Traore O, Cot M, Mooh E, Camevale P. [Malaria in the village of Yaounde (Cameroon). 3. Parasitological study in 2 central districts]. <i>Bull Soc Pathol Exot.</i> 1993; 86(1): 56-61 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Cameroon	Mathews GA, Dobson HM, Nkot PB, Wiles TL, Birchmore M. Preliminary examination of integrated vector management in a tropical rainforest area of Cameroon. <i>Trans R Soc Trop Med Hyg.</i> 2009; 103(11): 1098-104 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Cameroon	Merlin M, Le Hesran JY, Josse R, Jossieran R, Sicard JM, Le Mao G, Eteki D, Combe A, Tribouley J, Ripert C. [Evaluation of the clinical, parasitological and immunological indices of malaria in the Bonny's Bay area of Central Africa]. <i>Bull Soc Pathol Exot.</i> 1986; 79(5): 707-20 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Cameroon	Moyou-Somo R, Lehman LG, Awahmukalah S, Ayuk Enyong P. Deltamethrin impregnated bednets for the control of urban malaria in Kumba Town, South-West Province of Cameroon. <i>J Trop Med Hyg.</i> 1995; 98(5): 319-24 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Cameroon	Ndamukong KJ, Dinga JS, Ayuk MA, Akenji TN, Ndiforchu VA, Titanji VP. Microscopy is more reliable than questionnaire-based methods in the diagnosis of malaria in school children. <i>Afr J Health Sci.</i> 2002; 9(3-4): 147-52 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998-1999	*	†
Cameroon	Nkoo-Akenji TK, Chi PC, Cho JF, Ndamukong KK, Sumbele I. Malaria and helminth co-infection in children living in a malaria endemic setting of mount Cameroon and predictors of anemia. <i>J Parasitol.</i> 2006; 92(6): 1191-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Cameroon	Oduola AM, Moyou-Somo RS, Kyle DE, Martin SK, Gerena L, Milhous WK. Chloroquine resistant Plasmodium falciparum in indigenous residents of Cameroon. <i>Trans R Soc Trop Med Hyg.</i> 1989; 83(3): 308-10 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Cameroon	Quakyi IA, Leke RG, Befidi-Mengue R, Tsafack M, Bomba-Nkolo D, Manga L, Tchinda V, Njeunge E, Kouontchou S, Fogako J, Nyongloma P, Harun LT, Djokam R, Sama G, Eno A, Megnekou R, Metenou S, Ndountse L, Same-Ekobo A, Alake G, Meli J, Ngu J, Tietche F, Lohoue J, Mvondo JL, Wansi E, Leke R, Folefack A, Bigoga J, Bomba-Nkolo C, Titanji V, Walker-Abbey A, Hickey MA, Johnson AH, Taylor DW, Ndoutse L. The epidemiology of Plasmodium falciparum malaria in two Cameroonian villages: Simbok and Etoa. <i>Am J Trop Med Hyg.</i> 2000; 63(5-6): 222-30 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Cameroon	Raccurt CP, Bourianne C, Lambert MT, Tribouley J, Mandji O, Amadou A, Bouloumie J, Ripert C. [Malaria indices, larval ecology and trophic activity of Anopheles mosquitoes in Djohong (Adamoua, Cameroon) in the rainy season]. <i>Med Trop (Mars).</i> 1993; 53(3): 355-62 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Cameroon	Van der Kolk M, Tebo AE, Nimpaye H, Ndongbol DN, Sauerwein RW, Eling WM. Transmission of Plasmodium falciparum in urban Yaoundé, Cameroon, is seasonal and age-dependent. <i>Trans R Soc Trop Med Hyg.</i> 2003; 97(4): 375-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
Canada	Statistics Canada. Canada Community Health Survey 2000-2001. Ottawa, Canada: Statistics Canada, 2003.	2000-2001		
Canada	Canadian Institute for Health Information (CIHI). Canada Discharge Abstract Database 1994-1995. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	1994		
Canada	Canadian Institute for Health Information (CIHI). Canada Discharge Abstract Database 1995-1996. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	1995		
Canada	Canadian Institute for Health Information (CIHI). Canada Discharge Abstract Database 1996-1997. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	1996		
Canada	Canadian Institute for Health Information (CIHI). Canada Discharge Abstract Database 1997-1998. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	1997		
Canada	Canadian Institute for Health Information (CIHI). Canada Discharge Abstract Database 1998-1999. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	1998		
Canada	Canadian Institute for Health Information (CIHI). Canada Discharge Abstract Database 1999-2000. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	1999		
Canada	Canadian Institute for Health Information (CIHI). Canada Discharge Abstract Database 2000-2001. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	2000		
Canada	Canadian Institute for Health Information (CIHI). Canada Discharge Abstract Database 2001-2002. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	2001		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Canada	Canadian Institute for Health Information (CIHI). Canada Discharge Abstract Database 2002-2003. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	2002		
Canada	Canadian Institute for Health Information (CIHI). Canada Discharge Abstract Database 2003-2004. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	2003		
Canada	Canadian Institute for Health Information (CIHI). Canada Discharge Abstract Database 2004-2005. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	2004		
Canada	Canadian Institute for Health Information (CIHI). Canada Discharge Abstract Database 2005-2006. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	2005		
Canada	Canadian Institute for Health Information (CIHI). Canada Discharge Abstract Database 2006-2007. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	2006-2007		
Canada	Canadian Institute for Health Information (CIHI). Canada Discharge Abstract Database 2007-2008. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	2007		
Canada	Canadian Institute for Health Information (CIHI). Canada Discharge Abstract Database 2008-2009. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	2008		
Canada	Canadian Institute for Health Information (CIHI). Canada Discharge Abstract Database 2009-2010. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	2009		
Canada	Canadian Institute for Health Information (CIHI). Canada National Ambulatory Care Reporting System 2002-2003. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	2002		†
Canada	Canadian Institute for Health Information (CIHI). Canada National Ambulatory Care Reporting System 2003-2004. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	2003		†
Canada	Canadian Institute for Health Information (CIHI). Canada National Ambulatory Care Reporting System 2004-2005. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	2004		†
Canada	Canadian Institute for Health Information (CIHI). Canada National Ambulatory Care Reporting System 2005-2006. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	2005		†
Canada	Canadian Institute for Health Information (CIHI). Canada National Ambulatory Care Reporting System 2006-2007. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	2006		†
Canada	Canadian Institute for Health Information (CIHI). Canada National Ambulatory Care Reporting System 2007-2008. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	2007		†
Canada	Canadian Institute for Health Information (CIHI). Canada National Ambulatory Care Reporting System 2008-2009. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	2008		†
Canada	Canadian Institute for Health Information (CIHI). Canada National Ambulatory Care Reporting System 2009-2010. Ottawa, Canada: Canadian Institute for Health Information (CIHI).	2009		†
Canada	Krahn AD, Manfreda J, Tate RB, Mathewson FAL, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the manitoba follow-up study. <i>Am J Med.</i> 1995; 98(5): 476-84.	1980-1992		
Canada	Ceresine L, Upshur RE. Atrial fibrillation in a primary care practice: prevalence and management. <i>BMC Fam Pract.</i> 2002; 3: 11.	1999-2000		
Canada	Centre for Health Informatics and Multiprofessional Education, University College London. <i>Modell's Haemoglobinopathists Almanac.</i> London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	2003		
Canada	Robitaille N, Delvin EE, Hume HA. Newborn screening for sickle cell disease: A 1988-2003 Quebec experience. <i>Paediatr Child Health.</i> 2006; 11(4): 223-7.	1988-2003		
Canada	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	2009		†
Canada	Wong SC, Ali MA. Hemoglobinopathies in Canada. <i>Hemoglobin.</i> 1982; 6(3): 235-41.	1981		
Canada	Yorke D, Mitchell J, Clow C, Nuguid E, Cadogan R, Sinclair D, Luscombe S, Rozen R, Meredith P, Esseltine D. Newborn screening for sickle cell and other hemoglobinopathies: a Canadian pilot study. <i>Clin Invest Med.</i> 1992; 15(4): 376-83.	1990-1992		
Canada	Nickel JC, Downey J, Bénard F, Chetner M, Grantmyre J, So A, Whelan P. The Canadian Benign Prostatic Hyperplasia Audit Study (CanBas). <i>Can Urol Assoc J.</i> 2008; 2(4): 367-73.	2007		
Canada	Norman RW, Nickel JC, Fish D, Pickett SN. Prostate-related symptoms' in Canadian men 50 years of age or older: prevalence and relationships among symptoms. <i>Br J Urol.</i> 1994; 74(5): 542-50.	1991		
Canada	Bourassa MG, Gurné O, Bangdiwala SI, Ghali JK, Young JB, Rousseau M, Johnstone DE, Yusuf S. Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. <i>J Am Coll Cardiol.</i> 1993; 22(4 Suppl A): 14A-19A.	1988-1989		
Canada	Health Canada, Public Health Agency of Canada, Statistics Canada. <i>Canada Health Measures Survey 2007-2009.</i> Ottawa, Canada: Statistics Canada.	2007-2009		
Canada	Ko DT, Alter DA, Austin PC, You JJ, Lee DS, Qiu F, Stukel TA, Tu JV. Life expectancy after an index hospitalization for patients with heart failure: A population-based study. <i>Am Heart J.</i> 2008; 155(2): 324-31.	1999-2001		
Canada	Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting Mortality Among Patients Hospitalized for Heart Failure. <i>JAMA.</i> 2003; 290(19): 2581-7.	1999-2002		
Canada	Côté P, Cassidy JD, Carroll L. The Saskatchewan Health and Back Pain Survey. The prevalence of neck pain and related disability in Saskatchewan adults. <i>Spine.</i> 1998; 23(15): 1689-98.	1995-1996		
Canada	Wen SW, Huang L, Liston R, Heaman M, et al. Severe maternal morbidity in Canada, 1991-2001. <i>Can Med Assoc J.</i> 2005; 173(7): 759-64.	1991-2001		
Canada	Robitaille N, Delvin EE, Hume HA. A 1988-2003 Quebec experience. <i>Paediatr Child Health.</i> 2006; 4(11): 223-7.	1988-2003		
Canada	Gallagher RP, Ma B, McLean DI, Yang CP, Ho V, Carruthers JA, Warshawski LM. Trends in basal cell carcinoma, squamous cell carcinoma, and melanoma of the skin from 1973 through 1987. <i>J Am Acad Dermatol.</i> 1990; 23(3 Pt 1): 413-21.	1980-1987		
Canada	World Health Organization (WHO). <i>Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System.</i> Geneva, Switzerland: World Health Organization (WHO).	2000, 2002-2009		
Canada	De Vera M, Rahman MM, Rankin J, Kopec J, Gao X, Choi H. Gout and the risk of Parkinson's disease: a cohort study. <i>Arthritis Rheum.</i> 2008; 59(11): 1549-54.	1991-2004		
Canada	De Vera MA, Rahman MM, Bhole V, Kopec JA, Choi HK. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. <i>Ann Rheum Dis.</i> 2010; 69(6): 1162-4.	1994-2004		
Canada	Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. <i>Circulation.</i> 2007; 116(8): 894-900.	1986-2000		
Canada	Klein GM, Rose MS, Seland TP. A prevalence study of multiple sclerosis in the Crowsnest Pass region of southern Alberta. <i>Can J Neurol Sci.</i> 1994; 21(3): 262-5.	1989		
Canada	Hader WJ, Elliot M, Ebers GC. Epidemiology of multiple sclerosis in London and Middlesex County, Ontario, Canada. <i>Neurology.</i> 1988; 38(4): 617-617.	1984		
Canada	Sloka JS, Pryse-Phillips WEM, Stefanelli M. Incidence and Prevalence of Multiple Sclerosis in Newfoundland and Labrador. <i>Can J Neurol Sci.</i> 2005; 32(1): 37-42.	2001		
Canada	Beck CA, Metz LM, Svenson LW, Patten SB. Regional variation of multiple sclerosis prevalence in Canada. <i>Mult Scler.</i> 2005; 11(5): 516-9.	2000-2001		
Canada	Hader WJ, Seland TP, Hader MB, Harris CJ, Dietrich DW. The occurrence of multiple sclerosis in the Hutterites of North America. <i>Can J Neurol Sci.</i> 1996; 23(4): 291-5.	1990		
Canada	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Canada	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2003		
Canada	Ghosh S, Pahwa P, Rennie D, McDuffie HH. Opposing trends in the prevalence of health professional-diagnosed asthma by sex: A Canadian National Population Health Survey study. <i>Can Respir J.</i> 2008; 15(3): 146.	1994-2001		
Canada	To T, Gershon A, Wang C, Dell S, Cicutto L. Persistence and remission in childhood asthma: a population-based asthma birth cohort study. <i>Arch Pediatr Adolesc Med.</i> 2007; 161(12): 1197.	2000-2005		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Canada	Reid KS, Martin BD, Duerksen F, Nicolle LE, Garrett M, Simonsen JN, Trepanier E, Embil JM. Diabetic foot complications in a northern Canadian Aboriginal community. <i>Foot Ankle Int.</i> 2006; 27(12): 1065-73.	2005		
Canada	Ross SA, McKenna A, Mozejko S, Fick GH. Diabetic retinopathy in native and nonnative Canadians. <i>Exp Diabetes Res.</i> 2007; 76271.	2006		
Canada	Pryse-Phillips W, Findlay H, Tugwell P, Edmeads J, Murray TJ, Nelson RF. A Canadian population survey on the clinical, epidemiologic and societal impact of migraine and tension-type headache. <i>Can J Neurol Sci.</i> 1992; 19(3): 333-9.	1989-1990		
Canada	O'Brien B, Goeree R, Streiner D. Prevalence of migraine headache in Canada: a population-based survey. <i>Int J Epidemiol.</i> 1994; 23(5): 1020-6.	1992		
Canada	Chen Y, Mai X-M. Smoking and asthma in men and women with normal weight, overweight, and obesity. <i>J Asthma.</i> 2011; 48(5): 490-4.	2007-2008	*	
Canada	Dell SD, Foy RG, Gilbert NL, Jerret M, To T, Walter SD, Stieb DM. Asthma and allergic disease prevalence in a diverse sample of Toronto school children: results from the Toronto Child Health Evaluation Questionnaire (T-CHEQ) Study. <i>Can Respir J.</i> 2010; 17(1): e1-6.	2006	*	
Canada	Lawson JA, Janssen I, Bruner MW, Madani K, Pickett W. Urban-rural differences in asthma prevalence among young people in Canada: the roles of health behaviors and obesity. <i>Ann Allergy Asthma Immunol.</i> 2011; 107(3): 220-8.	2001-2002	*	
Canada	Muggah E, Graves E, Bennett C, Manuel DG. Ascertainment of chronic diseases using population health data: a comparison of health administrative data and patient self-report. <i>BMC Public Health.</i> 2013; 13: 16.	2001-2005	*	
Canada	Wang H-Y, Pizzichini MMM, Becker AB, Duncan JM, Ferguson AC, Greene JM, Rennie DC, Senthilselvan A, Taylor BW, Sears MR. Disparate geographic prevalences of asthma, allergic rhinoconjunctivitis and atopic eczema among adolescents in five Canadian cities. <i>Pediatr Allergy Immunol.</i> 2010; 21(5): 867-77.	2003	*	
Canada	Yang CL, To T, Foy RG, Stieb DM, Dell SD. Verifying a questionnaire diagnosis of asthma in children using health claims data. <i>BMC Pulm Med.</i> 2011; 11: 52.	1997-2006	*	
Canada	Vozoris NT, O'Donnell DE. Prevalence, risk factors, activity limitation and health care utilization of an obese, population-based sample with chronic obstructive pulmonary disease. <i>Can Respir J.</i> 2012; 19(3): e18-24.	2005	*	
Canada	Gershon AS, Wang C, Wilton AS, Raut R, To T. Trends in chronic obstructive pulmonary disease prevalence, incidence, and mortality in Ontario, Canada, 1996 to 2007: a population-based study. <i>Arch Intern Med.</i> 2010; 170(6): 560-5.	1996, 2002, 2007	*	
Canada	Sandhu RK, Bakal JA, Ezekowitz JA, McAlister FA. The epidemiology of atrial fibrillation in adults depends on locale of diagnosis. <i>Am Heart J.</i> 2011; 161(5): 986-992.	2000-2005	*	
Canada	Benigeri M, Brodeur JM, Payette M, Charbonneau A, Ismail AI. Community periodontal index of treatment needs and prevalence of periodontal conditions. <i>J Clin Periodontol.</i> 2000; 27(5): 308-12.	1994-1995	*	
Canada	O'Leary JD, Odame I, Pehora C, Chakraborty P, Crawford MW. Effectiveness of preoperative screening for sickle cell disease in a population with a newborn screening program: a cohort study. <i>Can J Anaesth.</i> 2013; 60(1): 54-9.	2006-2010	*	
Canada	Zimmermann A, Bernuit D, Gerlinger C, Schaeffers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. <i>BMC Womens Health.</i> 2012; 6.	2009	*	
Canada	Gurwith M, Wenman W, Hinde D, Feltham S, Greenberg H. A prospective study of rotavirus infection in infants and young children. <i>J Infect Dis.</i> 1981; 144(3): 218-24.	1976-1977	*	
Canada	Sapostnik G, Redelmeier DA, Lu H, Fuller-Thomson E, Lonn E, Ray JG. Myocardial infarction associated with recency of immigration to Ontario. <i>QJM.</i> 2010; 103(4): 253-8.	1995-2007	*	
Canada	Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, Spitz PW, Hoga M, Kleinheksel SM, Cathey MA. The mortality of rheumatoid arthritis. <i>Arthritis Rheum.</i> 1994; 37(4): 481-94.	1966-1990		
Canada	Uddin J, Kraus Fapha ASS, Garfield Kelly H. Survivorship and Death in Rheumatoid Arthritis. <i>Arthritis Rheum.</i> 1970; 13(2): 125-30.	1954-1966		
Canada	Locker D, Ford J, Leake JL. Incidence of and risk factors for tooth loss in a population of older Canadians. <i>J Dent Res.</i> 1996; 75(2): 783-9.	1989-1992		
Canada	Hawkins RJ, Jutai DK, Brothwell DJ, Locker D. Three-year coronal caries incidence in older Canadian adults. <i>Caries Res.</i> 1997; 31(6): 405-10.	1989-1992		
Canada	Hawkins RJ, Main PA, Locker D. Oral health status and treatment needs of Canadian adults aged 85 years and over. <i>Spec Care Dentist.</i> 1998; 18(4): 164-9.	1996		
Canada	Kandelman D, Gagnon G. Clinical results after 12 months from a study of the incidence and progression of dental caries in relation to consumption of chewing-gum containing xylitol in school preventive programs. <i>J Dent Res.</i> 1987; 66(8): 1407-11.	1982-1983		
Canada	Stamm JW, Dixter CT, Langlais RP. Principal dental health indices for 13-14 year old Quebec children. <i>J Can Dent Assoc.</i> 1980; 46(2): 125-37.	1978		
Canada	Ismail AI, Sohn W. The impact of universal access to dental care on disparities in caries experience in children. <i>J Am Dent Assoc.</i> 2001; 132(3): 295-303.	1995-1996		
Canada	Bretton JJ, Bergeron L, Valla J-P, Berthiaume C, Gaudet N, Lambert J, St-Georges M, Houde L, Lépine S. Quebec Child Mental Health Survey: Prevalence of DSM-III-R Mental Health Disorders. <i>J Child Psychol Psychiatry.</i> 1999; 40(3): 375-84.	1992		
Canada	Romano E, Tremblay RE, Vitaro F, Zoccolillo M, Pagani L. Prevalence of Psychiatric Diagnoses and the Role of Perceived Impairment: Findings from an Adolescent Community Sample. <i>J Child Psychol Psychiatry.</i> 2001; 42(4): 451-61.	1995-1997		
Canada	Offord DR, Boyle MH, Racine YA, Fleming JE, Cadman DT, Blum HM, Byrne C, Links PS, Lipman EL, MacMillan HL. Outcome, prognosis, and risk in a longitudinal follow-up study. <i>J Am Acad Child Adolesc Psychiatry.</i> 1992; 31(5): 916-23.	1983-1987		
Canada	Cross-national comparisons of the prevalences and correlates of mental disorders. WHO International Consortium in Psychiatric Epidemiology.	1990-1991		
Canada	Nguyen CT, Fournier L, Bergeron L, Roberge P, Barrette G. Correlates of depressive and anxiety disorders among young Canadians. <i>Can J Psychiatry.</i> 2005; 50(10): 620-8.	2002		
Canada	Bland RC, Newman SC, Orn H. Period Prevalence of Psychiatric Disorders in Edmonton. <i>Acta Psychiatr Scand.</i> 1988; 77(S338): 33-42.	1983-1986		
Canada	Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E, BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. <i>Lancet.</i> 2007; 9589(9589): 741-50.	2005-2006		
Canada	Al-Hazmi M, Wooldrage K, Anthonisen NR, Becklake MR, Bowie D, Chan-Yeung M, Dimich-Ward H, Ernst P, Manfreda J, Sears MR, Siersted HC, Sweet L, Van Til L. Airflow obstruction in young adults in Canada. <i>Can Respir J.</i> 2007; 14(4): 221-227.	1993-1994		
Canada	Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D. Pervasive Developmental Disorders in Montreal, Quebec, Canada: Prevalence and Links With Immunizations. <i>Pediatrics.</i> 2006; 118(1): e139-e150.	2003-2004		
Canada	Claude D, Firestone P. The development of ADHD boys: A 12-year follow-up. <i>Can J Behav Sci.</i> 1995; 27(2): 226-49.	1981-1993		
Canada	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2001-2005		
Canada	Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. <i>Arch Womens Ment Health.</i> 2003; 6(3): 203-9.	1999-2001		†
Canada	United States Renal Data System Coordinating Center. USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2002.	2000		
Canada	Snow B, Wiens M, Hertzman C, Calne D. A community survey of Parkinson's disease. <i>CMAJ.</i> 1989; 141(5): 418-22.	1986		
Canada	Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Rudolph A, Lang AE. Survival in Parkinson disease Thirteen-year follow-up of the DATATOP cohort. <i>Neurology.</i> 2005; 64(1): 87-93.	1987-2000		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Canada	Iacono WG, Beiser M. Are males more likely than females to develop schizophrenia. <i>Am J Psychiatry</i> . 1992; 149(8): 1070-4.	1982-1984		
Canada	Curkendall SM, Mo J, Glasser DB, Rose Stang M, Jones JK. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. <i>J Clin Psychiatry</i> . 2004; 65(5): 715-20.	1996-1999		
Canada	Liira JP, Shannon HS, Chambers LW, Haines TA. Long-term back problems and physical work exposures in the 1990 Ontario Health Survey. <i>Am J Public Health</i> . 1996; 86(3): 382-7.	1990		
Canada	Currie SR, Wang J. Chronic back pain and major depression in the general Canadian population. <i>Pain</i> . 2004; 107(1-2): 54-60.	2000-2001		
Canada	Cassidy JD, Carroll LJ, Côté P. The Saskatchewan health and back pain survey. The prevalence of low back pain and related disability in Saskatchewan adults. <i>Spine</i> . 1998; 23(17): 1860-67.	1995		
Canada	Bradley EA, Thompson A, Bryson SE. Mental retardation in teenagers: prevalence data from the Niagara region, Ontario. <i>Can J Psychiatry</i> . 2002; 47(7): 652-9.	1994		
Canada	Baird PA, Sadovnick AD. Mental retardation in over half-a-million consecutive livebirths: an epidemiological study. <i>Am J Ment Defic</i> . 1985; 89(4): 323-30.	1959		
Canada	Lowe A-M, Roy P-O, B-Poulin M, Michel P, Bitton A, St-Onge L, Brassard P. Epidemiology of Crohn's disease in Québec, Canada. <i>Inflamm Bowel Dis</i> . 2009; 15(3): 429-35.	1993-2002	*	
Canada	Grieci T, Blüter A. The incidence of inflammatory bowel disease in the pediatric population of Southwestern Ontario. <i>J Pediatr Surg</i> . 2009; 44(5): 977-80.	1997-2006	*	†
Canada	Centre for Addiction and Mental Health (Canada). Canada - Ontario Drug Use Among Students 1977-2007. Toronto, Canada: Centre for Addiction and Mental Health (Canada), 2007.	1999, 2001, 2003, 2005, 2007		
Canada	Dalhousie University, Statistics Canada. Canada Alcohol and Other Drugs Survey 1994. Ottawa, Canada: Statistics Canada.	1994		
Canada	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2005-2006		
Canada	Health Canada. Canada Alcohol and Drug Use Monitoring, Summary Results 2011.	2004, 2008-2011	*	
Canada	Tu JV, Nardi L, Fang J, Liu J, Khalid L, Johansen H. National trends in rates of death and hospital admissions related to acute myocardial infarction, heart failure and stroke, 1994-2004. <i>CMAJ</i> . 2009; 180(13): E118-25.	1994, 2004		
Canada	Yeung DF, Boom NK, Guo H, Lee DS, Schultz SE, Tu JV. Trends in the incidence and outcomes of heart failure in Ontario, Canada: 1997 to 2007. <i>CMAJ</i> . 2012; 184(14): E765-73.	1997, 1999, 2001, 2003, 2005, 2007		
Canada	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Canada Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2004		
Canada	Adlaf EM, Ivis FJ, Smart RG, Walsh GW. Enduring resurgence or statistical blip? Recent trends from the Ontario Student Drug Use Survey. <i>Can J Public Health</i> . 1996; 87(3): 189-92.	1991, 1993, 1995		
Canada	Cunningham JA, Bondy SJ, Walsh GW. The risks of cannabis use: evidence of a dose-response relationship. <i>Violence Abuse Abstr</i> . 2000; 6(4).	1990-1991		
Canada	Liu S, Joseph KS, Hutcheon JA, Bartholomew S, León JA, Walker M, Kramer MS, Liston RM. Maternal Health Study Group of Canadian Perinatal Surveillance System. Gestational age-specific severe maternal morbidity associated with labor induction. <i>Am J Obstet Gynecol</i> . 2013; 209(3): 209e1-8.	2003-2010	*	
Canada	Bonnet M-P, Basso O, Bouvier-Colle M-H, Dupont C, Rudigoz R-C, Fuhrer R, Deneux-Tharaux C. Postpartum haemorrhage in Canada and France: a population-based comparison. <i>PLoS One</i> . 2013; 8(6): e66882.	2004-2006	*	
Canada	Fleming N, Ng N, Osborne C, Biederman S, Yasseen AS 3rd, Dy J, Rennicks White R, Walker M. Adolescent pregnancy outcomes in the province of Ontario: a cohort study. <i>J Obstet Gynaecol Can</i> . 2013; 35(3): 234-45.	2006-2010	*	
Canada	Mehrabadi A, Hutcheon JA, Lee L, Kramer MS, Liston RM, Joseph KS. Epidemiological investigation of a temporal increase in atonic postpartum haemorrhage: a population-based retrospective cohort study. <i>BJOG</i> . 2013; 120(7): 853-62.	2001, 2009	*	
Canada	Mehrabadi A, Hutcheon JA, Lee L, Liston RM, Joseph KS. Trends in postpartum hemorrhage from 2000 to 2009: a population-based study. <i>BMC Pregnancy Childbirth</i> . 2012; 108.	2000-2009	*	
Canada	Nili F, McLeod L, O'Connell C, Sutton E, McMillan D. Maternal and neonatal outcomes in pregnancies complicated by systemic lupus erythematosus: a population-based study. <i>J Obstet Gynaecol Can</i> . 2013; 35(4): 323-8.	1988-2008	*	
Canada	Van Wagner V, Osephook C, Harney E, Crosbie C, Tulugak M. Remote midwifery in Nunavik, Québec, Canada: outcomes of perinatal care for the Inuitsivik health centre, 2000-2007. <i>Birth</i> . 2012; 39(3): 230-7.	2000-2007	*	
Canada	Wilson-Mitchell K, Rummens JA. Perinatal outcomes of uninsured immigrant, refugee and migrant mothers and newborns living in Toronto, Canada. <i>Int J Environ Res Public Health</i> . 2013; 10(6): 2198-213.	2007-2010	*	
Canada	Barnabe C, Faris PD, Quan H. Canadian pregnancy outcomes in rheumatoid arthritis and systemic lupus erythematosus. <i>Int J Rheumatol</i> . 2011; 2011(345727).	1998-2009	*	
Canada	Bodmer-Roy S, Morin L, Cousineau J, Rey E. Pregnancy outcomes in women with and without gestational diabetes mellitus according to the International Association of the Diabetes and Pregnancy Study Groups criteria. <i>Obstet Gynecol</i> . 2012; 120(4): 746-52.	2008-2010	*	
Canada	Boivin A, Luo Z-C, Audibert F, Mâsse B, Lefebvre F, Tessier R, Nuyt AM. Pregnancy complications among women born preterm. <i>CMAJ</i> . 2012; 184(16): 1777-84.	1987-2008	*	
Canada	Boyajian T, Shah PS, Murphy KE. Risk of preeclampsia in HIV-positive pregnant women receiving HAART: a matched cohort study. <i>J Obstet Gynaecol Can</i> . 2012; 34(2): 136-41.	2003-2010	*	
Canada	Liu S, Joseph KS, Liston RM, Bartholomew S, Walker M, León JA, Kirby RS, Sauve R, Kramer MS. Maternal Health Study Group of Canadian Perinatal Surveillance System (Public Health Agency of Canada). Incidence, risk factors, and associated complications of eclampsia. <i>Obstet Gynecol</i> . 2011; 118(5): 987-94.	2003-2009	*	
Canada	Roberts CL, Ford JB, Algert CS, Antonsen S, Chalmers J, Cnattingius S, Gokhale M, Kotelchuck M, Melve KK, Langridge A, Morris C, Morris JM, Nassar N, Norman JE, Norrie J, Sørensen HT, Walker R, Weir CJ. Population-based trends in pregnancy hypertension and pre-eclampsia: an international comparative study. <i>BMJ Open</i> . 2011; 1(1): e000101.	2002-2007	*	
Canada	Urquia ML, Ying I, Glazier RH, Berger H, De Souza LR, Ray JG. Serious preeclampsia among different immigrant groups. <i>J Obstet Gynaecol Can</i> . 2012; 34(4): 348-52.	2002-2009	*	
Canada	Kingwell E, van der Kop M, Zhao Y, Shirani A, Zhu F, Oger J, Tremlett H. Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada. <i>J Neurol Neurosurg Psychiatry</i> . 2012; 83(1): 61-6.	1980-2004	*	
Canada	Camfield CS, Camfield PR, Gordon K, Wirrell E, Dooley JM. Incidence of epilepsy in childhood and adolescence: a population-based study in Nova Scotia from 1977 to 1985. <i>Epilepsia</i> . 1996; 37(1): 19-23.	1977-1985	*	
Canada	Kirby S, Sadler RM. Injury and death as a result of seizures. <i>Epilepsia</i> . 1995; 36(1): 25-8.	1990-1991	*	
Canada	Gao S, Manns BJ, Culleton BF, Tonelli M, Quan H, Crowshoe L, Ghali WA, Svenson LW, Hemmelgarn BR. Alberta Kidney Disease Network. Prevalence of chronic kidney disease and survival among aboriginal people. <i>J Am Soc Nephrol</i> . 2007; 18(11): 2953-9.	2003-2004		
Canada	Hemmelgarn BR, Zhang J, Manns BJ, Tonelli M, Larsen E, Ghali WA, Southern DA, McLaughlin K, Mortis G, Culleton BF. Progression of kidney dysfunction in the community-dwelling elderly. <i>Kidney Int</i> . 2006; 69(12): 2155-61.	2001-2003		
Canada	Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl RV, De Graaf R, Vollebergh W, Dragomirecka E, Kohn R, Keller M, Kessler RC, Kawakami N, Kiliç C, Offord D, Ustun TB, Wittchen H-U. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. <i>Int J Methods Psychiatr Res</i> . 2003; 12(1): 3-21.	1990-1991		
Canada	Bland RC, Newman SC, Orn H. Age and remission of psychiatric disorders. <i>Can J Psychiatry</i> . 1997; 42(7): 722-9.	1983-1986		
Canada	Fleming JE, Offord DR, Boyle MH. Prevalence of childhood and adolescent depression in the community. <i>Ontario Child Health Study</i> . <i>Br J Psychiatry</i> . 1989; 155: 647-54.	1983		
Canada	Murphy JM, Monson RR, Olivier DC, Sobol AM, Leighton AH. Affective disorders and mortality. A general population study. <i>Arch Gen Psychiatry</i> . 1987; 44(5): 473-80.	1952-1968		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Canada	Newman SC, Bland RC, Orn HT. The prevalence of mental disorders in the elderly in Edmonton: a community survey using GMS-AGECAT. Geriatric Mental State-Automated Geriatric Examination for Computer Assisted Taxonomy. <i>Can J Psychiatry</i> . 1998; 43(9): 910-4.	1996		
Canada	Newman SC, Sheldon CT, Bland RC. Prevalence of depression in an elderly community sample: a comparison of GMS-AGECAT and DSM-IV diagnostic criteria. <i>Psychol Med</i> . 1998; 28(6): 1339-45.	1994		
Canada	Offord DR, Boyle MH, Campbell D, Goering P, Lin E, Wong M, Racine YA. One-year prevalence of psychiatric disorder in Ontarians 15 to 64 years of age. <i>Can J Psychiatry</i> . 1996; 41(9): 559-63.	1994		
Canada	Patten SC. The duration of major depressive episodes in the Canadian general population. <i>Chronic Dis Can</i> . 2001; 22(1): 6-11.	1996-1997		
Canada	Patten SB, Stuart HL, Russell ML, Maxwell CJ, Arboleda-Flórez J. Epidemiology of major depression in a predominantly rural health region. <i>Soc Psychiatry Psychiatr Epidemiol</i> . 2003; 38(7): 360-5.	1999-2000		
Canada	Patten SB, Williams JVA, Lavorato D, Li Wang J, Khaled S, Bulloch AGM. Mortality associated with major depression in a Canadian community cohort. <i>Can J Psychiatry</i> . 2011; 56(11): 658-66.	1994-2006	*	
Canada	Statistics Canada. Canada Community Health Survey, Cycle 1.2, Mental Health and Well-Being 2002. Ottawa, Canada: Statistics Canada.	2002		
Canada	Garg AX, Papaioannou A, Ferko N, Campbell G, Clarke JA, Ray JG. Estimating the prevalence of renal insufficiency in seniors requiring long-term care. <i>Kidney Int</i> . 2004; 65(2): 649-53.	2001-2002		
Canada	Lazoff T, Zhong L, Piperni T, Fombonne E. Prevalence of pervasive developmental disorders among children at the English Montreal School Board. <i>Can J Psychiatry</i> . 2010; 55(11): 715-20.	2007-2008	*	
Canada	Bryson SE, Clark BS, Smith IM. First report of a Canadian epidemiological study of autistic syndromes. <i>J Child Psychol Psychiatry</i> . 1988; 29(4): 433-45.	1986		
Canada	Offord DR, Boyle MH, Szatmari P, Rae-Grant NI, Links PS, Cadman DT, Byles JA, Crawford JW, Blum HM, Byrne C. Ontario Child Health Study. II. Six-month prevalence of disorder and rates of service utilization. <i>Arch Gen Psychiatry</i> . 1987; 44(9): 832-6.	1983	*	
Canada	El-Gabalawy R, Mackenzie CS, Shoostari S, Sareen J. Comorbid physical health conditions and anxiety disorders: a population-based exploration of prevalence and health outcomes among older adults. <i>Gen Hosp Psychiatry</i> . 2011; 33(6): 556-64.	2002	*	
Canada	Mosier KE, Vasilias H-M, Lepnum M, Puchala C, Pekrul C, Tempier R. Prevalence of mental disorders and service utilization in seniors: results from the Canadian community health survey cycle 1.2. <i>Int J Geriatr Psychiatry</i> . 2010; 25(10): 960-7.	2002	*	
Canada	Nicole L, Lesage A, Lalonde P. Lower incidence and increased male:female ratio in schizophrenia. <i>Br J Psychiatry</i> . 1992; 556-7.	1983-1987	*	
Canada	Vanasse A, Courteau J, Fleury M-J, Grégoire J-P, Lesage A, Moisan J. Treatment prevalence and incidence of schizophrenia in Quebec using a population health services perspective: different algorithms, different estimates. <i>Soc Psychiatry Psychiatr Epidemiol</i> . 2012; 47(4): 533-43.	2006	*	
Canada	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1990, 1995, 1998, 2001, 2004, 2007, 2010, 2012		
Canada	Howard M, Sellors JW, Jang D, Robinson NJ, Fearon M, Kaczorowski J, Chernesky M. Regional distribution of antibodies to herpes simplex virus type 1 (HSV-1) and HSV-2 in men and women in Ontario, Canada. <i>J Clin Microbiol</i> . 2003; 41(1): 84-9.	2000-2001	*	
Canada	Singh AE, Romanowski B, Wong T, Gourishankar S, Myziuk L, Fenton J, Preiksaitis JK. Herpes simplex virus seroprevalence and risk factors in 2 Canadian sexually transmitted disease clinics. <i>Sex Transm Dis</i> . 2005; 32(2): 95-100.	1994-1995	*	
Canada	Finer NN, Robertson CM, Richards RT, Pinnell LE, Peters KL. Hypoxic-ischemic encephalopathy in term neonates: perinatal factors and outcome. <i>J Pediatr</i> . 1981; 98(1): 112-7.	1974-1978	*	†
Canada	Muttitt SC, Taylor MJ, Kobayashi JS, MacMillan L, Whyte HE. Serial visual evoked potentials and outcome in term birth asphyxia. <i>Pediatr Neurol</i> . 1991; 7(2): 86-90.	1988-1990	*	†
Canada	Newhook LA, Penney S, Fiander J, Dowden J. Recent incidence of type 1 diabetes mellitus in children 0-14 years in Newfoundland and Labrador, Canada climbs to over 45/100,000: a retrospective time trend study. <i>BMC Res Notes</i> . 2012; 628.	1987-2010		
Canada	Birmingham CL, Su J, Hlynsky JA, Goldner EM, Gao M. The mortality rate from anorexia nervosa. <i>Int J Eat Disord</i> . 2005; 38(2): 143-6.	1981-2000	*	
Canada	Popova S, Rehm J, Fischer B. An overview of illegal opioid use and health services utilization in Canada. <i>Public Health</i> . 2006; 120(4): 320-8.	2003	*	
Canada	Fenton S, Desmeules M, Copleston P, Arbus G, Froment D, Jeffery J, Kjellstrand C. Renal replacement therapy in Canada: a report from the Canadian Organ Replacement Register. <i>Am J Kidney Dis</i> . 1995; 25(1): 134-50.	1988-1992		
Canada	Brodeur J-M, Payette M, Benigeri M, Charbonneau A, Olivier M, Chabot D. Periodontal diseases among Quebec adults aged 35 to 44 years. <i>J Can Dent Assoc</i> . 2001; 67(1): 34-5.	1994-1995		
Canada	Morrison HL, Ellison LF, Taylor GW. Periodontal disease and risk of fatal coronary heart and cerebrovascular diseases. <i>J Cardiovasc Risk</i> . 1999; 6(1): 7-11.	1970-1980		
Canada	Giffen PJ, Oki G, Lambert S. Ages and Causes of Death of the Chronic Drunkenness Offender Population (Chapter 13). In: <i>The Chronic Drunkenness Offender</i> . Toronto, Canada: Addiction Research Foundation; 1971.	1953-1964		
Canada	De Lint J, Levinson T. Mortality among patients treated for alcoholism: a 5-year follow-up. <i>Can Med Assoc J</i> . 1975; 113(5): 385-7.	1969-1974		
Canada	Schmidt W, De Lint J. Causes of death of alcoholics. <i>Q J Stud Alcohol</i> . 1972; 33(1): 171-85.	1951-1963		
Canada	Allison Jones C, Wayne Martin WR, Wieler M, King-Jesso P, Voaklander DC. Incidence and mortality of Parkinson's disease in older Canadians. <i>Parkinsonism Relat Disord</i> . 2012; 18(4): 327-31.	1992-2001	*	
Canada	Lix LM, Hobson DE, Azimae M, Leslie WD, Burchill C, Hobson S. Socioeconomic variations in the prevalence and incidence of Parkinson's disease: a population-based analysis. <i>J Epidemiol Community Health</i> . 2010; 64(4): 335-40.	1987-1988, 1990-1991, 2006-2007	*	
Canada	Williams RJ, Odaibo FS, McGee JM. Incidence of fetal alcohol syndrome in northeastern Manitoba. <i>Can J Public Health</i> . 1999; 90(3): 192-4.	1994	*	
Canada	Cooke LJ, Becker WJ. Migraine prevalence, treatment and impact: the Canadian Women and Migraine Study. <i>Can J Neurol Sci</i> . 2010; 37(5): 580-7.	2005	*	
Canada	Deceuninck G, Boucher R-M, De Wals P, Ouakki M. Epidemiology of Guillain-Barré syndrome in the province of Quebec. <i>Can J Neurol Sci</i> . 2008; 35(4): 472-5.	2000-2002		
Canada	Hauck LJ, White C, Feasby TE, Zochodne DW, Svenson LW, Hill MD. Incidence of Guillain-Barré syndrome in Alberta, Canada: an administrative data study. <i>J Neurol Neurosurg Psychiatry</i> . 2008; 79(3): 318-20.	1994-2004		
Canada	McLean M, Ducloux P, Jacob P, Humphreys P. Incidence of Guillain-Barré syndrome in Ontario and Quebec, 1983-1989, using hospital service databases. <i>Epidemiology</i> . 1994; 5(4): 443-8.	1983-1989		
Canada	Paris K, Aris A. Endometriosis-associated infertility: a decade's trend study of women from the Estrie Region of Quebec, Canada. <i>Gynecol Endocrinol</i> . 2010; 26(11): 1-5.	1997-2008		
Canada	The Canadian Study of Health and Aging Working Group. The incidence of dementia in Canada. <i>Neurology</i> . 2000; 55(1): 66-73.	1991-1999		
Canada	Tyas SL, Tate RB, Wooldrage K, Manfreda J, Strain LA. Estimating the incidence of dementia: the impact of adjusting for subject attrition using health care utilization data. <i>Ann Epidemiol</i> . 2006; 16(6): 477-84.	1991-1997		
Canada	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1994; 69(20): 145-51.	1993	*	
Canada	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1995; 70(25): 177-82.	1994	*	
Canada	WorkSafeBC (Canada). Occupational Diseases in British Columbia, 1984-2008. Vancouver, Canada: WorkSafeBC (Canada).	1984-2008		
Canada	Rotermann M, Langlois KA, Severini A, Totten S. Prevalence of Chlamydia trachomatis and herpes simplex virus type 2: Results from the 2009 to 2011 Canadian Health Measures Survey. <i>Health Rep</i> . 2013; 24(4): 10-5.	2009-2011	*	
Canada	Patrick DM, Dawar M, Cook DA, Krajden M, Ng HC, Rekart ML. Antenatal seroprevalence of herpes simplex virus type 2 (HSV-2) in Canadian women: HSV-2 prevalence increases throughout the reproductive years. <i>Sex Transm Dis</i> . 2001; 28(7): 424-8.	1999	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Canada	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland: World Health Organization (WHO).	2000-2011	*	
Canada	Lee SK, McMillan DD, Ohlsson A, Pendray M, Synnes A, Whyte R, Chien L-Y, Sale J. Variations in Practice and Outcomes in the Canadian NICU Network. 1996-1997. <i>Pediatrics</i> . 2000; 106(5): 1070-9.	1997	*	†
Canada	Lefebvre F, Glorieux J, St-Laurent-Gagnon T. Neonatal survival and disability rate at age 18 months for infants born between 23 and 28 weeks of gestation. <i>Am J Obstet Gynecol</i> . 1996; 174(3): 833-8.	1989	*	†
Canada	Grégoire M-C, Lefebvre F, Glorieux J. Health and Developmental Outcomes at 18 Months in Very Preterm Infants With Bronchopulmonary Dysplasia. <i>Pediatrics</i> . 1998; 101(5): 856-60.	1989	*	†
Canada	Saigal S, Rosenbaum P, Stoskopf B, Sinclair JC. Outcome in infants 501 to 1000 gm birth weight delivered to residents of the McMaster Health Region. <i>J Pediatr</i> . 1984; 105(6): 969-76.	1978	*	†
Canada	King SM, Law B, Langley JM, Heurter H, Bremner D, Wang EE, Gold R. Dexamethasone therapy for bacterial meningitis: Better never than late <i>Can J Infect Dis</i> . 1994; 5(5): 210-5.	1989-1991		
Canada	Jadavji T, Biggar WD, Gold R, Prober CG. Sequelae of acute bacterial meningitis in children treated for seven days. <i>Pediatrics</i> . 1986; 78(1): 21-5.	1979-1983		†
Canada	Edgar BL, Galanis E, Kay C, Skowronski D, Naus M, Patrick D. The burden of varicella and zoster in British Columbia 1994-2003: Baseline assessment prior to universal vaccination. <i>Can Commun Dis Rep</i> . 2007; 33(12).	1994-2003		
Canada	Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, Roos L, De Serres G. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. <i>Epidemiol Infect</i> . 2001; 127(2): 305-14.	1979-1997		
Canada	Hunt AM, Lewis DW, Banting D, Foster MK. Ontario dental health survey-1978. <i>J Can Dent Assoc</i> . 1980; 46(2): 117-24.	1978		
Canada	Wang D, Bortolussi R. Acute viral infection of the central nervous system in children: an 8-year review. <i>Can Med Assoc J</i> . 1981; 125(6): 585-9.	1972-1980		
Canada	Ross HE. DSM-III-R alcohol abuse and dependence and psychiatric comorbidity in Ontario: results from the Mental Health Supplement to the Ontario Health Survey. <i>Drug Alcohol Depend</i> . 1995; 39(2): 111-28.	1990		
Canada	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Canada	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Canada	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Canada	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Canada	Lambert PJ, Dyck M, Thompson LH, Hammond GW. Population-Based Surveillance of Clostridium difficile Infection in Manitoba, Canada, by Using Interim Surveillance Definitions. <i>Infect Control Hosp Epidemiol</i> . 2009; 30(10): 945-51.	2005-2006	*	
Canada	Pépin J, Valiquette L, Alary M-E, Villemure P, Pelletier A, Forget K, Pépin K, Chouinard D. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. <i>CMAJ</i> . 2004; 171(5): 466-72.	1991-2003	*	
Canada	Scheifele DW, De Serres G, Gilca V, Duval B, Milner R, Ho M, Ochnio JJ. A nationwide Survey: unspecified of past hepatitis A infections among Canadian adults. <i>Vaccine</i> . 2010; 28(32): 5174-8.	2007-2008	*	
Canada	Widdifield J, Paterson JM, Bernatsky S, Tu K, Tomlinson G, Kuriya B, Thorne JC, Bombardier C. The epidemiology of rheumatoid arthritis (RA) in Ontario, Canada. <i>Arthritis Rheum</i> . 2014; 66(4): 786-93.	1996-2010	*	
Canada	Al-Omran M, Mandani M, McLeod RS. Epidemiologic features of acute appendicitis in Ontario, Canada. <i>Can J Surg</i> . 2003; 46(4): 263-8.	1991-1998		
Canada	Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. Epidemiology of Crohn's Disease and Ulcerative Colitis in a Central Canadian Province: A Population-based Study. <i>Am J Epidemiol</i> . 1999; 149(10): 916-24.	1989-1994		
Canada	McFarlane ES, Embil JA, Manuel FR, Gorelick M. Prevalence of antibodies to hepatitis A antigen in patients attending a clinic for treatment of sexually transmitted diseases. <i>Sex Transm Dis</i> . 1980; 7(2): 87-9.	1979		
Canada	Crewe MD, Embil JA, Garner JB. Prevalence of antibodies to hepatitis A virus in Nova Scotia children. <i>Can Med Assoc J</i> . 1983; 128(10): 1195-7.	1981-1982		
Canada	Embil JA, Manley K, White LA. Hepatitis A: a serological study in the Canadian Armed Forces. <i>Mil Med</i> . 1989; 154(9): 461-5.	1981-1983		
Canada	Kocupchyk FR, Lightfoot PJ, Stout I, Devine RD. Seroprevalence of hepatitis A antibodies in travellers at the Edmonton Travellers Health Clinic--Alberta. <i>Can Commun Dis Rep</i> . 1995; 21(8): 65-71.	1991-1992		
Canada	Ochnio JJ, Scheifele DW, Ho M. Hepatitis A virus infections in urban children--are preventive opportunities being missed <i>J Infect Dis</i> . 1997; 176(6): 1610-3.	1995-1996		
Canada	Roy E, Haley N, Leclerc P, Cédras L, Bédard L, Allard R. Seroprevalence and risk factors for hepatitis A among Montreal street youth. <i>Can J Public Health</i> . 2002; 93(1): 52-3.	1995-1996		
Canada	Levy I, Chen D, Sherman M, Smith D, Kraiden M. Hepatitis A virus seroprevalence in 1,000 university students in Toronto. <i>Can Commun Dis Rep</i> . 2001; 27(11): 93-6.	1997		
Canada	Ochnio JJ, Scheifele DW, Fyfe M, Bigham M, Bowering D, Martiquet P, Ho M, Talling DN. The prevalence of hepatitis A in children in British Columbia. <i>Can J Infect Dis Med Microbiol</i> . 2005; 16(3): 175-9.	2000		
Canada	Duval B, De Serres G, Ochnio JJ, Scheifele D, Gilca V. Nationwide Canadian study of hepatitis A antibody prevalence among children eight to thirteen years old. <i>Pediatr Infect Dis J</i> . 2005; 24(6): 514-9.	2003		
Canada	Ochnio JJ, Scheifele DW, Marion SA, Bigham M, Patrick DM, Ho M, Mozel M. Participant-collected, mail-delivered oral fluid specimens can replace traditional serosurveys: a demonstration-of-feasibility survey of hepatitis A virus-specific antibodies in adults. <i>Can J Public Health</i> . 2007; 98(1): 37-40.	2006		
Canada	Sgro M, Campbell D, Barozzino T, Shah V. Acute neurological findings in a national cohort of neonates with severe neonatal hyperbilirubinemia. <i>J Perinatol</i> . 2011; 31(6): 392-6.	2002-2004	*	†
Canada	Bata IR, Gregor RD, Eastwood BJ, Wolf HK. Trends in the incidence of acute myocardial infarction between 1984 and 1993 - The Halifax County MONICA Project. <i>Can J Cardiol</i> . 2000; 16(5): 589-95.	1984, 1993		
Canada	Brophy JM. The epidemiology of acute myocardial infarction and ischemic heart disease in Canada: data from 1976 to 1991. <i>Can J Cardiol</i> . 1997; 13(5): 474-8.	1991-1992		
Canada	Cox JL, Bata IR, Gregor RD, Johnstone DE, Wolf HK. Trends in event rate and case fatality of patients hospitalized with myocardial infarction between 1984 and 2001. <i>Can J Physiol Pharmacol</i> . 2006; 84(1): 121-7.	1984-1993		
Canada	Armstrong SA, Gangam N, Chipman ML, Rootman DS. The prevalence of positive hepatitis B, hepatitis C, and HIV serology in cornea donors prescreened by medical and social history in Ontario, Canada. <i>Cornea</i> . 1997; 16(5): 512-6.	1993-1996		
Canada	Dawar M, Patrick DM, Bigham M, Cook D, Kraiden M, Ng H. Impact of universal preadolescent vaccination against hepatitis B on antenatal seroprevalence of hepatitis B markers in British Columbia women. <i>CMAJ</i> . 2003; 168(6): 703-4.	1999		
Canada	Glasgow KW, Schabas R, Williams DC, Wallace E, Nalezty LA. A population-based hepatitis B seroprevalence and risk factor study in a northern Ontario town. <i>Can J Public Health</i> . 1997; 88(2): 87-90.	1993		
Canada	Grossman DW, Hans LM, Glazier R. Geographic origin and risk for congenital infection in a Canadian inner city: findings and implications for policy. <i>Can J Public Health</i> . 1999; 90(6): 385-8.	1996-1997		
Canada	Houston S, Rowe BH, Mashinter L, Preiksaitis J, Joffe M, Mackey D, Galbraith J, Wiebe N. Sentinel surveillance of HIV and hepatitis C virus in two urban emergency departments. <i>CJEM</i> . 2004; 6(2): 89-96.	1998		
Canada	Larke RP, Froese GJ, Devine RD, Petruk MW. Extension of the epidemiology of hepatitis B in circumpolar regions through a comprehensive serologic study in the Northwest Territories of Canada. <i>J Med Virol</i> . 1987; 22(3): 269-76.	1983-1985		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Canada	Louie M, Low DE, Feinman SV, McLaughlin B, Simor AE. Prevalence of bloodborne infective agents among people admitted to a Canadian hospital. CMAJ. 1992; 146(8): 1331-4.	1990		
Canada	Marion SA, Tomm Pastore M, Pi DW, Mathias RG. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol. 1994; 140(8): 734-46.	1984-1989		
Canada	Minuk GY, Zhang M, Wong SGM, Uhanova J, Bernstein CN, Martin B, Dawood MR, Vardy L, Giulvi A. Viral hepatitis in a Canadian First Nations community. Can J Gastroenterol. 2003; 17(10): 593-6.	1999		
Canada	Morris BA, Sabetti L. Prenatal screening for hepatitis B surface antigen. Is universal screening necessary? Can Fam Physician. 1993; 61-4.	1990		
Canada	Zahariadis G, Plitt SS, O'Brien S, Yi Q-L, Fan W, Preiksaitis JK. Prevalence and estimated incidence of blood-borne viral pathogen infection in organ and tissue donors from northern Alberta. Am J Transplant. 2007; 7(1): 226-34.	1998-2004		
Canada	U.S. Renal Data System. USRDS 1998 Annual Data Report. Bethesda (MD), United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 1998.	1995-1996		
Canada	United States Renal Data System Coordinating Center. USRDS 1997 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 1997.	1994		
Canada	U.S. Renal Data System. USRDS 1996 Annual Data Report. Bethesda (MD), United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 1996.	1992-1993		
Canada	U.S. Renal Data System. USRDS 1994 Annual Data Report. Bethesda (MD), United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 1994.	1989-1991		
Canada	Canadian Neonatal Network. Canadian Neonatal Network Annual Report 2009.	2005, 2009		†
Canada	Canada Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Canada	Canada - Alberta Congenital Anomalies Surveillance System Data 2001 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
Canada	Canada - Alberta Congenital Anomalies Surveillance System Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
Canada	Canada - British Columbia Health Status Registry Congenital Anomalies Surveillance Program Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
Canada	Canadian Congenital Anomalies Surveillance Network Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
Canada	Canadian Congenital Anomalies Surveillance System Data 1993-1997 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1997	*	
Canada	Canada - Alberta Congenital Anomalies Surveillance System Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Canada	Canadian Congenital Anomalies Surveillance System Data 1980 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1980	*	
Canada	Canadian Congenital Anomalies Surveillance System Data 1983 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1983	*	
Canada	Canadian Congenital Anomalies Surveillance System Data 1986 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1986	*	
Canada	Canada - British Columbia Health Status Registry Congenital Anomalies Surveillance Program Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Canada	Canadian Congenital Anomalies Surveillance System Data 1982 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1982	*	
Canada	Canada - British Columbia Health Status Registry Congenital Anomalies Surveillance Program Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
Canada	Canada - Alberta Congenital Anomalies Surveillance System Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
Canada	Canada - Alberta Congenital Anomalies Surveillance System Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Canada	Canadian Congenital Anomalies Surveillance Network Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Canada	Canada - Alberta Congenital Anomalies Surveillance System Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Canada	Canada - Alberta Congenital Anomalies Surveillance System Data 2010 - ICBDSR as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	2010	*	
Canada	Canadian Congenital Anomalies Surveillance System Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
Canada	Canada - Alberta Congenital Anomalies Surveillance System Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Canada	Canada - British Columbia Health Status Registry Congenital Anomalies Surveillance Program Data 2007 - ICBDSP as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Canada	Canada - British Columbia Health Status Registry Congenital Anomalies Surveillance Program Data 2008 - ICBDSP as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
Canada	Canadian Congenital Anomalies Surveillance Network Data 2007 - ICBDSP as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2007	*	
Canada	Canadian Congenital Anomalies Surveillance Network Data 2006 - ICBDSP as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2006	*	
Canada	Canadian Congenital Anomalies Surveillance System Data 1988 - ICBDMS as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1988	*	
Canada	Canadian Congenital Anomalies Surveillance System Data 1985 - ICBDMS as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1985	*	
Canada	Canadian Congenital Anomalies Surveillance System Data 1981 - ICBDMS as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1981	*	
Canada	Canadian Congenital Anomalies Surveillance System Data 1984 - ICBDMS as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1984	*	
Canada	Canadian Congenital Anomalies Surveillance System Data 1987 - ICBDMS as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1987	*	
Cape Verde	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Cape Verde	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Cape Verde	World Health Organization (WHO). Cape Verde STEPS Noncommunicable Disease Risk Factors Survey 2007.	2007		
Cape Verde	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997-1998, 2000-2009		
Cape Verde	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Cape Verde	Schémann JF, Inocencio F, de Lourdes Monteiro M, Andrade J, Auzemery A, Guelfi Y. Blindness and low vision in Cape Verde Islands: results of a national eye survey. Ophthalmic Epidemiol. 2006; 13(4): 219-26. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1998		
Cape Verde	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2004, 2007, 2012		
Cape Verde	Cape Verde National Survey on Iodine Deficiency and Salt Consumption 1996 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1996		
Cape Verde	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Cape Verde	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Cape Verde	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Cape Verde	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Cape Verde	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Cape Verde	Franco L, Di Caro A, Carletti F, Vapalahti O, Renaudat C, Zeller H, Tenorio A. Recent expansion of dengue virus serotype 3 in West Africa. Euro Surveill [Internet]. 2010 Feb 18; 15(7): 19490.	2009		
Cape Verde	Alves J, Machado P, Silva J, Gonçalves N, Ribeiro L, Faustino P, do Rosário VE, Manco L, Gusmão L, Amorim A, Arez AP. Analysis of malaria associated genetic traits in Cabo Verde, a melting pot of European and sub Saharan settlers. Blood Cells Mol Dis. 2010; 44(1): 62-8.	1995-2003	*	
Cape Verde	Alves J, Roque AL, Cravo P, Valdez T, Jelinek T, do Rosário VE, Arez AP. Epidemiological characterization of Plasmodium falciparum in the Republic of Cabo Verde: implications for potential large-scale re-emergence of malaria. Malar J. 2006; 5(1): 1-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998-2000	*	†
Cape Verde	Cape Verde Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Central African Republic	United Nations Children's Fund (UNICEF). Central African Republic Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Central African Republic	United Nations Children's Fund (UNICEF). Central African Republic Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006	*	†
Central African Republic	Division of Statistics and Economic Studies (Central African Republic), Macro International, Inc. Central African Republic Demographic and Health Survey 1994-1995. Calverton, United States: Macro International, Inc.	1994-1995		†
Central African Republic	Central African Institute of Statistics, Economic and Social Studies (ICASEES) (Central African Republic), ICF International. Central African Republic Multiple Indicator Cluster Survey 2010-2011. Fairfax, United States: ICF International, 2013.	2010-2011	*	†
Central African Republic	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Central African Republic	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Central African Republic	Georges MC, Roure C, Tauxe RV, Meunier DM, Merlin M, Testa J, Baya C, Limbassa J, Georges AJ. Diarrheal morbidity and mortality in children in the Central African Republic. Am J Trop Med Hyg. 1987; 36(3): 598-602.	1983		
Central African Republic	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997-2005, 2007-2009		
Central African Republic	World Health Organization (WHO). Yellow fever in Africa and South America, 2006. Wkly Epidemiol Rec. 2008; 83(8): 60-76.	2006		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Central African Republic	Berrang-Ford L, Lindine J, Breau S. Conflict and human African trypanosomiasis. <i>Soc Sci Med.</i> 2011; 72(3): 398-407.	1995-2001	*	
Central African Republic	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Central African Republic	Georges-Courbot MC, Monges J, Beraud-Cassel AM, Gouandjika I, Georges AJ. Prospective longitudinal study of rotavirus infections in children from birth to two years of age in Central Africa. <i>Ann Inst Pasteur Virol.</i> 1988; 139(4): 421-8.	1983-1985	*	
Central African Republic	Georges MC, Wachsmuth IK, Meunier DM, Nebout N, Didier F, Siopathis MR, Georges AJ. Parasitic, bacterial, and viral enteric pathogens associated with diarrhea in the Central African Republic. <i>J Clin Microbiol.</i> 1984; 19(5): 571-5.	1981-1982	*	
Central African Republic	Guerchet M, Mbelesso P, Mouanga AM, Bandzouzi B, Tabo A, Houinato DS, Paraiso MN, Cowppli-Bony P, Nubukpo P, Abovans V, Clément J-P, Dartigues J-F, Preux P-M. Prevalence of dementia in elderly living in two cities of Central Africa: the EDAC survey. <i>Dement Geriatr Cogn Disord.</i> 2010; 30(3): 261-8.	2008-2009		
Central African Republic	Mbelesso P, Tabo A, Guerchet M, Mouanga AM, Bandzouzi B, Houinato D, Paraiso MN, Cowppli-Bony P, Abovans V, Nubukpo P, Preux PM, Dartigues JF, Clément JP. Epidemiology of dementia in elderly living in the 3rd borough of Bangui (Central African Republic). <i>Bull Soc Pathol Exot.</i> 2012; 105(5): 388-95.	2008-2009		
Central African Republic	Vinck P, Pham PN. Association of exposure to violence and potential traumatic events with self-reported physical and mental health status in the Central African Republic. <i>JAMA.</i> 2010; 304(5): 544-52.	2009	*	
Central African Republic	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2010, 2012		
Central African Republic	Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. <i>Int J Health Geogr.</i> 2010; 9: 57.	1980-2010		
Central African Republic	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec.</i> 2005; 80(13): 118-24.	2003	*	
Central African Republic	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec.</i> 2006; 81(32): 309-16.	2005	*	
Central African Republic	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Central African Republic	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Central African Republic	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Central African Republic	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Central African Republic	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Central African Republic	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Central African Republic	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Central African Republic	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Central African Republic	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Central African Republic	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Central African Republic	Mbopi-Kéou FX, Grésenguet G, Mayaud P, Weiss HA, Gopal R, Matta M, Paul JL, Brown DW, Hayes RJ, Mabey DC, Bélec L. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. <i>J Infect Dis.</i> 2000; 182(4): 1090-6.	1997-1999	*	
Central African Republic	Biassoni P, Schenone F, Bertocchi J, Green J, Mela G, Balestra V, Ouham-Pendé: a new endemic goiter area in Centro-African Republic (C.A.R.). Preliminary observations on school children. <i>Thyroidology.</i> 1990; 2(1): 35-40 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1990		
Central African Republic	Yazipo D, Ngairindro LF, Barrière-Constantin L, Namboua L, Pichard E, Ndojo J, Bourdoux P. [Effectiveness of a water iodination system for preventing iodine deficiency diseases in Central Africa]. <i>Sante.</i> 1995; 5(1): 9-17 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1993		
Central African Republic	Bekondi C, Mobima T, Ouavèné JO, Koffi B, Konama X, Béré A, Le Faou A. Étiopathologie du carcinome hépatoocellulaire à Bangui, République centrafricaine : caractéristiques cliniques, biologiques et aspects virologiques des patients. <i>Pathol Biol.</i> 2010; 58(2): 152-5.	2006-2009	*	
Central African Republic	Pawlotsky JM, Bêc L, Grésenguet G, Deforges L, Bouvier M, Duval J, Dhumeaux D. High prevalence of hepatitis B, C, and E markers in young sexually active adults from the Central African Republic. <i>J Med Virol.</i> 1995; 46(3): 269-72.	1993, 1995		
Central African Republic	Monitoring the Chemoresistance of Plasmodium Falciparum to Amino-4 Quinolones as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Central African Republic	Prospective Study of Malarionometric Indices in Children from a Village in the Region of Bambari as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Central African Republic	Monges P. Evaluation des indices paludométriques à Bangui. <i>Med Afr Noire.</i> 1987; 34: 3 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Central African Republic	Nguembi E, Yanza MC, Sepou A, Youssouf A, Ngbale R, Vohito MD. Lutte antipaludique en zones rurale et semi-urbaine de Centrafrique : Rôle des moustiquaires imprégnées. <i>Med Afr Noire.</i> 2004; 51(4): 231-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
Chad	United Nations Children's Fund (UNICEF), Census Bureau (Chad), National Institute of Statistical, Economic and Demographic Studies (Chad). Chad Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Chad	Census Bureau (Chad), Macro International, Inc, National Institute of Statistical, Economic and Demographic Studies (Chad). Chad Demographic and Health Survey 1996-1997. Calverton, United States: Macro International, Inc.	1996-1997		†
Chad	Macro International, Inc, National Institute of Statistical, Economic and Demographic Studies (Chad). Chad Demographic and Health Survey 2004. Calverton, United States: Macro International, Inc.	2004		†
Chad	World Health Organization (WHO). Chad World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Chad	Ministry of Planning, Economy, and International Cooperation (Chad), National Institute of Statistical, Economic and Demographic Studies (Chad), United Nations Children's Fund (UNICEF). Chad Multiple Indicator Cluster Survey 2010. New York, United States: United Nations Children's Fund (UNICEF), 2014.	2010	*	†
Chad	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Chad	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Chad	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997, 1999, 2001, 2003-2006, 2008-2009		
Chad	Buck AA, Anderson RI, MacRae AA. Epidemiology of poly-parasitism IV Combined effects on the state of health. <i>Trop Med Parasitol.</i> 1978; 29(3): 253-68.	1977-1978		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Chad	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Chad	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2004, 2010, 2012		
Chad	Dionadji M, Boy B, Mouanodji M, Batakao G. [Prevalence of diabetes mellitus in rural areas in Chad]. Med Trop (Mars). 2010; 70(4): 414-5.	2004		
Chad	Chad National Survey on Iodine Deficiency Disorder Prevalence 1993-1994 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1993		
Chad	Chad Evaluation Report on the Fight Against IDD 2003 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2003		
Chad	Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J Health Geogr. 2010; 9: 57.	1980-2010		
Chad	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Chad	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Chad	World Health Organization (WHO). Global leprosy situation, 2007 (additional information). Wkly Epidemiol Rec. 2007; 82(44): 388.	2006	*	
Chad	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Chad	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Chad	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Chad	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Chad	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Chad	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Chad	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1993; 68(25): 181-6.	1992	*	
Chad	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Chad	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Chad	Resnikoff S. [Epidemiological aspects of xerophthalmia in Chad]. Med Trop (Mars). 1988; 48(1): 27-32 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1984-1985		
Chad	Evaluation of Endemic Malaria in the Sahelian Zone and Savanna in Chad as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Chad	Clinical and Hematological Survey Among 117 Children 0-9 Years in a Rice-growing Region in Southern Chad (Ninga-La') as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Chad	Evaluation of Endemic Malaria and Vector Control Practices in the Bongor Prefecture of Mayo-Kebbi (Republic of Chad) as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Chad	Monthly Activity Report on the Treated Mosquito Nets Project in Milezi as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Chad	Epidemiological Study of Malaria in the Dry Season in the City of NDjamena (Republic of Chad) as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Chad	Evaluation in vivo de la chimiosensibilité de Plasmodium falciparum à la chloroquine dans la région de Moundou as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Chad	Othnigüé N, Wyss K, Tanner M, Genton B. Urban malaria in the Sahel: prevalence and seasonality of presumptive malaria and parasitaemia at primary care level in Chad. Trop Med Int Health. 2006; 11(2): 204-10 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Chad	Xerophthalmia and Trachoma in Burkina Faso, Chad, Mali and Niger 1986 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1986		
Chile	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	2002-2005		
Chile	Ferreccio C, Prado V, Ojeda A, Cayazo M, Abrego P, Guers L, Levine MM. Epidemiologic patterns of acute diarrheal and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am J Epidemiol. 1991; 134(6): 614-27.	1986-1989		
Chile	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Chile	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Chile	Díaz A, Barria P, Niederman M, Restrepo MI, Dreys J, Fuentes G, Couble B, Saldias F. Etiology of community-acquired pneumonia in hospitalized patients in Chile: the increasing prevalence of respiratory viruses among classic pathogens. Chest. 2007; 131(3): 779-87.	2003-2005		
Chile	Levine OS, Lagos R, Muñoz A, Villaroel J, Alvarez AM, Abrego P, Levine MM. Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J. 1999; 18(12): 1060-4.	1992-1995		
Chile	Castro GP, Vukasovic R JL, Garcés S E, Sepúlveda M L, Ferrada K M, Alvarado O S. Insuficiencia cardíaca en hospitales chilenos: resultados del Registro Nacional de Insuficiencia Cardíaca, Grupo ICARO. Rev Med Chil. 2004; 132(6): 655-62.	2002		
Chile	Lavados PM, Sacks C, Prina L, Escobar A, Tossi C, Araya F, Feuerhake W, Galvez M, Salinas R, Alvarez G. Incidence, 30-day case-fatality rate, and prognosis of stroke in Iquique, Chile: a 2-year community-based prospective study (PISCIS project). Lancet. 2005; 365(9478): 2206-15.	2000-2002		
Chile	Lorca M, García A, Bahamonde MI, Fritz A, Tassara R. Serological certification of the interruption of the vectorial transmission of Chagas disease in Chile. Rev Med Chil. 2001; 129(3): 264-9.	1982, 1994, 1999		
Chile	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. J Allergy Clin Immunol. 2008; 121(4): 947-954.	1994-1995, 2001		
Chile	Chavez P A, Rojas A C, Rakela R S, Chadid S J, Fischer S C. Meningitis bacteriana aguda: experiencia de 10 años. Rev Chil Infectol. 1994; 11(2): 92-8.	1983-1992		
Chile	De Oliveira LH, Danovaro-Holliday MC, Andrus JK, de Filipis AMB, Gentsch J, Matus CR, Widdowson M-A. Sentinel hospital surveillance for rotavirus in Latin American and Caribbean countries. J Infect Dis. 2009; 200 Suppl 1: 131-139.	2007		
Chile	O'Ryan M, Pérez-Schael I, Mamani N, Peña A, Salinas B, González G, González F, Matson DO, Gómez J. Rotavirus-associated medical visits and hospitalizations in South America: a prospective study at three large sentinel hospitals. Pediatr Infect Dis J. 2001; 20(7): 685-93.	1997-1999		
Chile	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997-2001, 2003-2009		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Chile	Bennett K, Cardiel MH, Ferraz MB, Riedemann P, Goldsmith CH, Tugwell P. Community screening for rheumatic disorder: cross cultural adaptation and screening characteristics of the COPCORD Core Questionnaire in Brazil, Chile, and Mexico. <i>J Rheumatol</i> . 1997; 24(1): 160-8.	1994		
Chile	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J</i> . 1998; 12(2): 315-35.	1993-1995		
Chile	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	2001		
Chile	Moro P, Schantz PM. Cystic echinococcosis in the Americas. <i>Parasitol Int</i> . 2006; 55(1): S181-6.	2003		
Chile	Jadue L, Vega J, Escobar MC, Delgado I, Garrido C, Lastra P, Espejo F, Peruga A. Risk factors for non communicable diseases: methods and global results of the CARMEN program basal survey. <i>Rev Med Chil</i> . 1999; 127(8): 1004-13.	1997		
Chile	Ministry of Health (Chile). Chile First Report of Population Cancer Registries 2003-2007. Santiago, Chile: Ministry of Health (Chile), 2012.	2003-2007	*	
Chile	Lavados PM, Tenhamm E. Epidemiology of migraine headache in Santiago, Chile: a prevalence study. <i>Cephalalgia</i> . 1997; 17(7): 770-7.	1993		
Chile	Apt W, Zulantay I, Arnelo M, Oddó D, González S, Rodríguez J, Kemmerling U, Truyens C, Carlier Y. Congenital infection by Trypanosoma cruzi in an endemic area of Chile: a multidisciplinary study. <i>Trans R Soc Trop Med Hyg</i> . 2013; 107(2): 98-104.	2005-2009		
Chile	Apt W, Zulantay I, Solari A, Ortiz S, Oddo D, Corral G, Truyens C, Carlier Y. Vertical transmission of Trypanosoma cruzi in the Province of Choapa, IV Region, Chile: Preliminary Report (2005-2008). <i>Biol Res</i> . 2010; 43(3): 269-74.	2006-2008		
Chile	García-Marcos L, Mallol J, Solé D, Brand PLP. EISL Study Group. International study of wheezing in infants: risk factors in affluent and non-affluent countries during the first year of life. <i>Pediatr Allergy Immunol</i> . 2010; 21(5): 878-88.	2005-2007	*	
Chile	Mallol J, Solé D, Baeza-Bacab M, Aguirre-Camposano V, Soto-Quiros M, Baena-Cagnani C. Latin American ISAAC Group. Regional variation in asthma symptom prevalence in Latin American children. <i>J Asthma</i> . 2010; 47(6): 644-50.	2001-2003	*	
Chile	Gamonal J, Mendoza C, Espinoza I, Muñoz A, Urrutia I, Aranda W, Carvajal P, Arteaga O. Clinical attachment loss in Chilean adult population: First Chilean National Dental Examination Survey. <i>J Periodontol</i> . 2010; 81(10): 1403-10.	2007		
Chile	Gamonal JA, Lopez NJ, Aranda W. Periodontal conditions and treatment needs, by CPTN, in the 35-44 and 65-74 year-old population in Santiago, Chile. <i>Int Dent J</i> . 1998; 48(2): 96-103.	1995	*	
Chile	Acosta-Jamett G, Cleaveland S, Cunningham AA, Bronsvort BM deC, Craig PS. Echinococcus granulosus infection in humans and livestock in the Coquimbo region, north-central Chile. <i>Vet Parasitol</i> . 2010; 169(1-2): 102-10.	1995-2006	*	
Chile	Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version). Lyon, IARC. http://cis.iarc.fr	2003-2007	*	
Chile	O'Ryan ML, Peña A, Vergara R, Díaz J, Mamani N, Cortés H, Lucero Y, Vidal R, Osorio G, Santolaya ME, Hermosilla G, Prado VJ. Prospective characterization of norovirus compared with rotavirus acute diarrhea episodes in Chilean children. <i>Pediatr Infect Dis J</i> . 2010; 29(9): 855-9.	2006-2008	*	
Chile	Mariño RJ, Onetto JE. Caries experience in urban and rural Chilean 3-year-olds. <i>Community Dent Oral Epidemiol</i> . 1995; 23(1): 60-1.	1990, 1992		
Chile	Díaz JM, Catalán L, Urrutia MT, Prado V, Ledermann W, Mendoza C, Topelberg S. Trends of etiology of acute bacterial meningitis in Chilean children from 1989 to 1998. Impact of the anti-H influenzae type b vaccine. <i>Rev Med Chil</i> . 2001; 129(7): 719-26.	1989-1998		
Chile	Vicente B, Riosoco P, Saldivia S, Kohn R, Torres S. [Chilean study on the prevalence of psychiatric disorders (DSM-III-R/CID) (ECPPI)]. <i>Rev Med Chil</i> . 2002; 130(5): 527-36.	1992-1999		
Chile	Vicente B, Kohn R, Riosoco P, Saldivia S, Baker C, Torres S. Population prevalence of psychiatric disorders in Chile: 6-month and 1-month rates. <i>Br J Psychiatry</i> . 2004; 184(4): 299-305.	1992-1999, 2002		
Chile	Vicente B, Kohn R, Riosoco P, Saldivia S, Levav I, Torres S. Lifetime and 12-month prevalence of DSM-III-R disorders in the Chile psychiatric prevalence study. <i>Am J Psychiatry</i> . 2006; 163(8): 1362-70.	1992-1999		
Chile	Menezes AM, Perez-Padilla R, Jardim JR, Muiño A, Lopez MV, Valdivia G, Montes de Oca M, Talamo C, Hallal PC, Victora CG, PLATINO Team. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. <i>Lancet</i> . 2005; 366(9500): 1875-81.	2002-2004		
Chile	Lavados PM, Tenhamm E. Epidemiology of tension-type headache in Santiago, Chile: a prevalence study. <i>Cephalalgia</i> . 1998; 18(8): 552-8.	1993		
Chile	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2004-2008		
Chile	United States Renal Data System Coordinating Center. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2000-2003		
Chile	United States Renal Data System Coordinating Center. USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2003.	1998-1999		
Chile	Florenzano R, Pino P, Marchandón A. Risk behavior in adolescent students in Santiago de Chile. <i>Rev Med Chil</i> . 1993; 121(4): 462-9.	1991		
Chile	Gilbert CE, Ellwein LB. Prevalence and causes of functional low vision in school-age children: results from standardized population surveys in Asia, Africa, and Latin America. <i>Invest Ophthalmol Vis Sci</i> . 2008; 49(3): 877-81. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1998		
Chile	Barria von-Bischhoffhausen F, Silva JC, Limburg H, Castillo DL, Martínez RL, Muñoz RD, Salinas AE, Vegas IF, Werner SM, Riquelme LA. Analysis of barriers, coverage and postoperative outcomes of cataract surgery determined by quick survey avoidable blindness in the VIII region, Chile. <i>Arch Ophthalmol</i> . 2007; 64(1/2): 69-87. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2006-2007		
Chile	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Chile Evaluation of Progress in Drug Control 2005-2006.	2005-2006		
Chile	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), United Nations Office on Drugs and Crime (UNODC). Youth and Drugs in South American Countries: A Public Policy Challenge 2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2006.	2005		
Chile	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Chile Evaluation of Progress in Drug Control 2007-2009.	2008	*	
Chile	Parra-Cordero M, Rodrigo R, Barja P, Bosco C, Rencoret G, Sepúlveda-Martínez A, Quezada S. Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy. <i>Ultrasound Obstet Gynecol</i> . 2013; 41(5): 538-44.	2002-2010	*	
Chile	Lavados J, Germain L, Morales A, Campero M, Lavados P. A descriptive study of epilepsy in the district of El Salvador, Chile, 1984-1988. <i>Acta Neurol Scand</i> . 1992; 85(4): 249-56.	1988	*	
Chile	Chiofalo N, Kirschbaum A, Schoenberg B, Olivares O, Valenzuela B, Soto E, Alvarez G. [Epidemiological study of neurological diseases in metropolitan Santiago, Chile]. <i>Rev Chil Neuropsiquiatr</i> . 1992; 30(4): 335-41.	1989, 1991		
Chile	Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl RV, De Graaf R, Vollebergh W, Dragomirecka E, Kohn R, Keller M, Kessler RC, Kawakami N, Kiliç C, Offord D, Ustun TB, Wittchen H-U. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. <i>Int J Methods Psychiatr Res</i> . 2003; 12(1): 3-21.	1992-1999		
Chile	Araya R, Rojas G, Fritsch R, Acuña J, Lewis G. Common mental disorders in Santiago, Chile: prevalence and socio-demographic correlates. <i>Br J Psychiatry</i> . 2001; 228-33.	1996-1998		
Chile	Escobar C, Arce I, Jara A, Mezzano S, Ardiles L. Renal health in Chile. <i>Ren Fail</i> . 2006; 28(8): 639-41.	2003		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Chile	Vicente B, Saldivia S, de la Barra F, Kohn R, Pihan R, Valdivia M, Riosco P, Melipillan R. Prevalence of child and adolescent mental disorders in Chile: a community epidemiological study. <i>J Child Psychol Psychiatry</i> . 2012; 53(10): 1026-35.	2007-2009	*	
Chile	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 2001, 2004, 2007, 2010, 2012		
Chile	Maul E, Barroso S, Muñoz SR, Sperduto RD, Ellwein LB. Refractive Error Study in Children: results from La Florida, Chile. <i>Am J Ophthalmol</i> . 2000; 129(4): 445-54.	1998		
Chile	Santos J, Carrasco E, Moore A, Pérez-Bravo F, Albala C. Incidence rate and spatio-temporal clustering of type 1 diabetes in Santiago, Chile, from 1997 to 1998. <i>Rev Saude Publica</i> . 2001; 35(1): 96-100.	1997-1998		
Chile	Lagomarsino E, Valenzuela A, Cavagnaro F, Solar E. Chronic renal failure in pediatrics 1996. Chilean survey. <i>Pediatr Nephrol</i> . 1999; 13(4): 288-91.	1996		
Chile	Fernández-Cean J, González-Martínez F, Schwedt E, Mazzuchi N. Renal replacement therapy in Latin America. <i>Kidney Int</i> . 2000; 57(s74): 55-59.	1997		
Chile	Lagun JR, Strogoff de Matos JP. Disparities in end-stage renal disease care in South America. <i>Clin Nephrol</i> . 2010; 74(Suppl 1): S66-71.	2006		
Chile	Cusumano A, García-García G, Di Gioia C, Hermida O, Lavorato C, Carreño CA, Torrico MP, Batista PB, Romão JE, Badal HP, Miranda SE, Gomez R, Calderon MC, Sanchez SH, Lopez MA, Moscoso J, Merino RL, Polo JV, Lopez A, Romero NJ, Garcia R, Acosta BV, Lopez AS, Delpin ES, Mena E, González C, Milanés CL, Achiardo S. End-stage renal disease and its treatment in Latin America in the twenty-first century. <i>Ren Fail</i> . 2006; 28(8): 631-7.	2004		
Chile	Santiago-Delpin EA, García VD. Latin American Transplant Registry VIIIth Report: 1998. <i>Transplant Proc</i> . 1999; 31(1-2): 214-6.	1995, 1997		
Chile	Cusumano A, García GG, Di Gioia C, Hermida O, Lavorato C. Latin American Registry of Dialysis and Transplantation. The Latin American Dialysis and Transplantation Registry (RLDT) annual report 2004. <i>Ethn Dis</i> . 2006; 16(2 Suppl 2): 10-3.	2003		
Chile	Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M and Boyle P, eds (2007). <i>Cancer Incidence in Five Continents, Vol. IX Periodic Data (electronic version)</i> . Lyon, IARC. http://ci5.iarc.fr	1998-2002	*	
Chile	López NJ, Ríos V, Fernández O. Periodontal conditions in 15-19-year-old Chileans. <i>Int Dent J</i> . 1996; 46(3): 161-4.	1994		
Chile	Black RE, Levine MM, Ferreccio C, Clements ML, Lanata C, Rooney J, Germanier R, Chilean Typhoid Committee. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. <i>Vaccine</i> . 1990; 8(1): 81-4.	1982-1987		
Chile	Levine MM, Ferreccio C, Black RE, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. <i>Lancet</i> . 1987; 1(8541): 1049-52.	1983-1985		
Chile	Berrios X, Lagomarsino E, Solar E, Sandoval G, Guzmán B, Riedel I. Post-streptococcal acute glomerulonephritis in Chile—20 years of experience. <i>Pediatr Nephrol</i> . 2004; 19(3): 306-12.	1980-1999	*	
Chile	Luchsinger V, Piedra PA, Ruiz M, Zunino E, Martínez MA, Machado C, Fasce R, Ulloa MT, Fink MC, Lara P, Avendaño LF. Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus. <i>Clin Infect Dis</i> . 2012; 54(7): 905-12.	2005-2007	*	
Chile	Luchsinger V, Ruiz M, Zunino E, Martínez MA, Machado C, Piedra PA, Fasce R, Ulloa MT, Fink MC, Lara P, Gebauer M, Chávez F, Avendaño LF. Community-acquired pneumonia in Chile: the clinical relevance in the detection of viruses and atypical bacteria. <i>Thorax</i> . 2013; 68(11): 1000-6.	2005-2007	*	
Chile	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec</i> . 2012; 87(34): 317-28.	2011	*	
Chile	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland: World Health Organization (WHO).	2011	*	
Chile	Lagos R, Muñoz A, Valenzuela MT, Heitmann I, Levine MM. Population-based surveillance for hospitalized and ambulatory pediatric invasive pneumococcal disease in Santiago, Chile. <i>Pediatr Infect Dis J</i> . 2002; 21(12): 1115-23.	1998-2001		
Chile	Téllez R, Michaud P. [Prevalence of goiter in school-age children in the Pirque Zone. Effects of salt iodination]. <i>Rev Med Chil</i> . 1996; 124(10): 1207-10 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1995		
Chile	Pozo M, Rodewald AM, Biolley E, Zvaighaft A, Leiva L, Muzzo S. [Prevalence of endemic goiter among school children of central and southern Chile]. <i>Rev Chil Pediatr</i> . 1989; 60(6): 359-62 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1986		
Chile	Muzzo S, Burgueño M, Carvajal F, Moreno R, Leiva L. [Endemic goiter in three census areas of Chile]. <i>Arch Latinoam Nutr</i> . 1994; 44(2): 82-6 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1991		
Chile	Muzzo S, Burgueño M, Carvajal F, Biolley E, Avendaño M, Vargas S, Leiva L. [Iodine nutrition in school children of four census areas of Chile]. <i>Rev Med Chil</i> . 1997; 125(11): 1299-304 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1994		
Chile	Muzzo S, Ramírez I, Carvajal F, Biolley E, Leiva L. [Iodine nutrition in school children of four areas of Chile during the year 2001]. <i>Rev Med Chil</i> . 2003; 131(12): 1391-8 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2001		
Chile	World Health Organization (WHO). Mental Illness in General Health Care: An International Study. Geneva, Switzerland: World Health Organization (WHO), 1995.	1991-1992		
Chile	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Chile	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Chile	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Chile	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Chile	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Chile	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Chile	Tapia-Conyer R, Santos JI, Cavalcanti AM, Urdaneta E, Rivera L, Manterola A, Potin M, Ruttiman R, Tanaka Kido J. Hepatitis A in Latin America: A Changing Epidemiologic Pattern. <i>Am J Trop Med Hyg</i> . 1999; 61(5): 825-9.	1996-1997		
Chile	Zacarias J, Rakela J, Riveros C, Brinck P. [Anti hepatitis A antibodies in healthy children and in patients with hepatitis]. <i>Rev Med Chil</i> . 1981; 109(9): 833-6.	1980		
Chile	Riedemann S, Hochstein-Mintzel V, Reinhardt G. [Prevalence of hepatitis A and B in the population of Valdivia: a seroepidemiological study]. <i>Rev Med Chil</i> . 1984; 112(7): 672-4.	1983		
Chile	Riedemann S, Ibarra H, Hochstein-Mintzel V, Reinhardt G, Niedda M, Foesner G. [Viral hepatitis in a rural area in Chile]. <i>Rev Med Chil</i> . 1987; 115(1): 16-8.	1984-1985		
Chile	Riedemann GS, Ibarra VH, Reinhardt VG, Frosner G, Safary A. Prevalencia de anticuerpos anti-hepatitis A en escolares en la década actual. <i>Rev Med Chil</i> . 1998; 126(10): 1161-4.	1991-1992		
Chile	Lagos R, Potin M, Muñoz A, Abrego P, San Martín OS, Ureta AM, Bustamante C. [Serum antibodies against hepatitis A virus among subjects of middle and low socioeconomic levels in urban area of Santiago, Chile]. <i>Rev Med Chil</i> . 1999; 127(4): 429-36.	1996		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Chile	Ibarra H, Riedemann S, Prado V, Reinhardt G, Vega I, Potin M, Frick P. [Current status of immunity to hepatitis A virus in various adult groups]. Rev Med Chil. 1999; 127(10): 1165-8.	1996-1997		
Chile	Ibarra H, Riedemann S, Reinhardt G, Hochsteinmintzel V, Froesner G. Prevalence of anti hepatitis A antibody in 2 areas with different ruralism in Chile. Rev Med Chil. 1988; 116(11): 1115-8.	1997		
Chile	Fix AD, Martin OS, Gallicchio L, Vial PA, Lagos R. Age-specific prevalence of antibodies to hepatitis A in Santiago, Chile: risk factors and shift in age of infection among children and young adults. Am J Trop Med Hyg. 2002; 66(5): 628-32.	1998		
Chile	Ibarra H, Riedemann S, Toledo C. [Hepatitis A and E virus antibodies in Chilean children of low socioeconomic status: a one year follow-up study]. Rev Med Chil. 2006; 134(2): 139-44.	1999-2000		
Chile	Gonzalez R, Soza A, Hemández V, Pérez RM, Alvarez M, Morales A, Arellano M, Riquelme A, Viviani P, Covarrubias C, Arrese M, Miquel JF, Nervi F. Incidence and prevalence of hepatitis C virus infection in Chile. Ann Hepatol. 2005; 4(2): 127-30.	2000		
Chile	Quiroga P. Dementia Prevalence in Concepción Chile. Dementia Project-WHO-Chile. In: World Congress of Geriatrics and Gerontology; 1997: Adelaide, Australia.	1991-1994		
Chile	Brahm J, Hurtado C, Moraga M, Gil LC, Velasco M, Alegria S, Pagliero B. [Hepatitis E virus infection in Chile: preliminary report]. Rev Med Chil. 1996; 124(8): 947-9.	1993-1994	*	
Chile	Ibarra H, Riedemann S, Reinhardt G, Frick P, Siegel F, Toledo C, Calvo M, Frösner G. [Prevalence of hepatitis E virus antibodies in blood donors and other population groups in southern Chile]. Rev Med Chil. 1997; 125(3): 275-8.	1994	*	
Chile	Ibarra HV, Riedemann SG, Siegel FG, Reinhardt GV, Toledo CA, Frösner G. Hepatitis E virus in Chile. Lancet. 1994; 344(8935): 1501.	1992	*	
Chile	Pan American Health Organization (PAHO), World Health Organization (WHO). Quantitative Estimation of Chagas in the Americas.	2005	*	
Chile	Schenone H, del C Contreras M, Salinas P, Sandoval L, Rojas A, Villarroel F. [Epidemiology of Chagas disease in Chile. Frequency of human Trypanosoma cruzi infection by age groups and regions]. Bol Chil Parasitol. 1995; 50(3-4): 84-86.	1982-1990	*	
Chile	Burchard L, Cáceres J, Sagua H, Inés Bahamonde M, Neira I, Araya J, Goycolea M. [Current human and canine seroprevalence of Chagasic infection in San Pedro de Atacama County, II Region of Antofagasta, Chile, 1995]. Bol Chil Parasitol. 1996; 51(3-4): 76-9.	1995	*	
Chile	Contreras MC, Schenone H, Borgoño JM, Salinas P, Sandoval L, Rojas A, Solís F. [Chagasic infection in blood donors from hospitals in endemic regions of Chile (1982-1987). Epidemiological impact of the problem]. Bol Chil Parasitol. 1992; 47(1-2): 10-5.	1982-1987	*	
Chile	Arancibia AM, Sagua H, Neira I, González J, Varela H. [Chagas disease in northern Chile. Serological prevalence in pregnant women of the city of Antofagasta, 1991-1993]. Bol Chil Parasitol. 1995; 50(1-2): 45-7.	1991-1993	*	
Chile	Valdés J, Contreras MC, Mercado R, Rojas A, Correa V, Schenone H. [Epidemiology of Chagas' disease in Chile. Serological follow-up of 1,906 inhabitants from an endemic rural area, IV Region, 1991-1993]. Bol Chil Parasitol. 1994; 49(3-4): 75-78.	1991-1993	*	
Chile	Lorca M, Schenone H, del C Contreras M, García A, Bahamonde MI, Correa V, Valdés J, Rojas A, Jofré A. [Evaluation of a triatomina infestans eradication program in rural dwellings from the IV region, Chile, by means of serology for Chagas disease in 0-10 years old children]. Bol Chil Parasitol. 1995; 50(3-4): 87-91.	1994	*	
Chile	Lorca M, Schenone H, Contreras MC, García A, Rojas A, Valdés J. [Evaluation of vectors of Chagas' disease eradication programs in Chile by serological study of children under 10 years old]. Bol Chil Parasitol. 1996; 51(3-4): 80-85.	1994-1996	*	
Chile	Cáceres J, Burchard L, Bahamonde MI, Contreras MC, García A, Rojas A, Schenone H, Lorca M. [Epidemiological status of Chagas disease in the endemic area from Region II of Antofagasta]. Bol Chil Parasitol. 1999; 54(1-2): 25-29.	1997	*	
Chile	Chile Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Chile	Chile - Maule Registry of Congenital Malformations, Maule Health Service Data 2003 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
Chile	Chile - Maule Registry of Congenital Malformations, Maule Health Service Data 2007 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Chile	Chile - Maule Registry of Congenital Malformations, Maule Health Service Data 2010 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
Chile	Chile Latin American Collaborative Study of Congenital Malformations Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT). International Centre on Birth Defects. World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Chile	Chile - Maule Registry of Congenital Malformations, Maule Health Service Data 2009 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Chile	Chile - Maule Registry of Congenital Malformations, Maule Health Service Data 2004 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
Chile	Chile - Maule Registry of Congenital Malformations, Maule Health Service Data 2008 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
China	National Bureau of Statistics of China. China Population Information Center (CIPC). China In-depth Fertility Sample Survey 1985. Hong Kong, China: Chinese University of Hong Kong.	1985		
China	China Population Information and Research Center, National Bureau of Statistics of China. China In-Depth Fertility Sample Survey 1987.	1987		
China	World Health Organization (WHO). China World Health Survey 2002. Geneva, Switzerland: World Health Organization (WHO), 2005.	2002		i
China	Ministry of Health (China), National Center for Chronic and Noncommunicable Disease Control and Prevention (China), World Health Organization (WHO). China WHO Study on Global AGEing and Adult Health 2008-2010.	2008-2010		
China	World Health Organization (WHO). Control of Foodborne Trematode Infections 1995. Geneva, Switzerland: World Health Organization (WHO), 1995.	1995	*	
China	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-1999, 2004-2006, 2009		
China	Institute of Social Medicine and Health Policy, Shandong University, Shandong University School of Medicine. World Health Organization (WHO). China WHO Multi-country Survey Study on Health and Health System Responsiveness 2000-2001.	2000-2001		
China	Chien K-L, Su T-C, Hsu H-C, Chang W-T, Chen P-C, Chen M-F, Lee Y-T. Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese. Int J Cardiol. 2010; 139(2): 173-80.	1990-2005		
China	Zhou Z, Hu D. An Epidemiological Study on the Prevalence of Atrial Fibrillation in the Chinese Population of Mainland China. J Epidemiol. 2008; 18(5): 209-16.	2000		
China	Lok N-S, Lau C-P. Prevalence of palpitations, cardiac arrhythmias and their associated risk factors in ambulant elderly. Int J Cardiol. 1996; 54(3): 231-6.	1994		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
China	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
China	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
China	Jia T-W, Zhou X-N, Wang X-H, Utzinger J, Steinmann P, Wu X-H. Assessment of the age-specific disability weight of chronic schistosomiasis japonica. Bull World Health Organ. 2007; 85(6): 458-65.	2004-2005		
China	Nokes C, McGarvey ST, Shiue L, Wu G, Wu H, Bundy DA, Olds GR. Evidence for an improvement in cognitive function following treatment of Schistosoma japonicum infection in Chinese primary schoolchildren. Am J Trop Med Hyg. 1999; 60(4): 556-65.	1992-1993		
China	Zhou H, Ohtsuka R, He Y, Yuan L, Yamauchi T, Sleight AC. Impact of Parasitic Infections and Dietary Intake on Child Growth in the Schistosomiasis-Endemic Dongting Lake Region, China. Am J Trop Med Hyg. 2005; 72(5): 534-9.	2001		
China	Dong Q, Yang Y, Wei Q, Shen H. [A survey of prostate symptoms in old male population]. J West Chin Univ Med Sci. 1998; 29(2): 213-5.	1997		
China	Cao B, Song S-F, Bai L, Yin YD, Zhang Y-Y, Liu Y-M, Guo P, Wang C, Ren L-L, Wang J-W, Zhao F, Zhang J-Z, Gonzalez R. Viral and Mycoplasma pneumoniae community-acquired pneumonia and novel clinical outcome evaluation in ambulatory adult patients in China. Eur J Clin Microbiol Infect Dis. 2010; 29(11): 1443-8.	2008-2009		
China	Sung RYT, Cheng AFB, Chan RCK, Tam JS, Oppenheimer SJ. Epidemiology and Etiology of Pneumonia in Children in Hong Kong. Clin Infect Dis. 1993; 17(5): 894-6.	1986-1988		
China	Zhang Q, MacDonald NE, Guo Z. Vaccinable preventable community-acquired pneumonia in hospitalized children in Northwest China. Pediatr Infect Dis J. 2011; 30(1): 7-10.	2004-2005		
China	Fung WK, Lo KK. Prevalence of skin disease among school children and adolescents in a Student Health Service Center in Hong Kong. Pediatr Dermatol. 2000; 17(6): 440-6.	1996-1997		
China	National Public Health Institute (Finland), World Health Organization (WHO). WHO MONICA Cerebrovascular Event Data 1982-1997, as provided by the Global Burden of Disease 2010 Cerebrovascular Disease Expert Group. [Unpublished].	1984-1993		
China	Sun KO, Chan YW, Cheung RT, So PC, Yu YL, Li PC. Management of tetanus: a review of 18 cases. J R Soc Med. 1994; 87(3): 135-7.	1984-1991		
China	Hong Y, Bots ML, Pan X, Hofman A, Grobbee DE, Chen H. Stroke Incidence and Mortality in Rural and Urban Shanghai From 1984 Through 1991: Findings From a Community-Based Registry. Stroke. 1994; 25(6): 1165-9.	1984-1991		
China	Mallick AA, O'Callaghan FJK. The epidemiology of childhood stroke. Eur J Paediatr Neurol. 2010; 14(3): 197-205.	1998-2001		
China	Zhao D, Liu J, Wang W, Zeng Z, Cheng J, Liu J, Sun J, Wu Z. Epidemiological Transition of Stroke in China Twenty-One-Year Observational Study From the Sino-MONICA-Beijing Project. Stroke. 2008; 39(6): 1668-74.	1984-2004		
China	Chinese Center for Disease Control and Prevention (CCDC). China Chronic Disease and Risk Factor Surveillance 2010. [Unpublished].	2010	*	
China	Shen Y, Wang T, Zhou C, Wang X, Ding X, Tian S, Liu Y, Peng G, Xue S, Zhou J, Wang R, Meng X, Pei G, Bai Y, Liu Q, Li H, Zhang J. Prevalence of acne vulgaris in Chinese adolescents and adults: a community-based study of 17,345 subjects in six cities. Acta Derm Venereol. 2012; 92(1): 40-4.	2009-2011		
China	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. J Allergy Clin Immunol. 2008; 121(4): 947-954.	1994-1995, 2001-2002		
China	Chinese Center for Disease Control and Prevention (CCDC). China Notifiable Infectious Diseases 2004. [Unpublished].	2004	*	
China	Chinese Center for Disease Control and Prevention (CCDC). China Notifiable Infectious Diseases 2007. [Unpublished].	2007	*	
China	Chinese Center for Disease Control and Prevention (CCDC). China Notifiable Infectious Diseases 2010. [Unpublished].	2010	*	
China	Zeng DL, Zhang ZJ, Wang ZL, Zhang JN, Yang ML. Surveillance of acute respiratory infections in three kindergartens in Beijing. Chin Med J (Engl). 1988; 11(101): 787-92.	1984-1985		†
China	Zhang ZJ, Gao LM, Wang ZL, Cao YP, Wu GC, Zhu ZH. Acute respiratory infections in Beijing children Epidemiological studies at Dongguan Brigade. Chin Med J (Engl). 1986; 7(99): 561-8.	1981-1983		
China	Hung YT, Cheung NT, Ip S, Fung H. Epidemiology of heart failure in Hong Kong. 1997. Hong Kong Med J. 2000; 6(2): 159-62.	1997		
China	Sanderson JE, Chan SKW, Chan WWM, Hung YT, Woo KS. The aetiology of heart failure in the Chinese population of Hong Kong - a prospective study of 730 consecutive patients. Int J Cardiol. 1995; 51(1): 29-35.	1992		
China	Hui AC, Ng K, Tong P, Mok V, Chow K, Wu A, Wong LK. Bacterial meningitis in Hong Kong: 10-years experience. Clin Neurol Neurosurg. 2005; 107(5): 366-70.	1992-2001		
China	Sung RY, Senok AC, Ho A, Oppenheimer SJ, Davies DP. Meningitis in Hong Kong children, with special reference to the infrequency of haemophilus and meningococcal infection. J Paediatr Child Health. 1997; 33(4): 296-9.	1984-1993		
China	Xu J, Yang Y, Sun J, Ding Y, Su L, Fang Z, Glass RL. Molecular epidemiology of rotavirus infections among children hospitalized for acute gastroenteritis in Shanghai, China, 2001 through 2005. J Clin Virol. 2009; 44(1): 58-61.	2001-2005		
China	Jin Y, Ye X-H, Fang Z-Y, Li Y-N, Yang X-M, Dong Q-L, Huang X. Molecular epidemic features and variation of rotavirus among children with diarrhea in Lanzhou, China, 2001-2006. World J Pediatr. 2008; 4(3): 197-201.	2001-2006		
China	Von Seidlein L, Kim DR, Ali M, Lee H, Wang X, Thiem VD, Canh DG, Chaicumpa W, Agtini MD, Hossain A, Bhutta ZA, Mason C, Sethabutr O, Talukder K, Nair GB, Deen JL, Kotloff K, Clemens J. A Multicentre Study of Shigella Diarrhoea in Six Asian Countries: Disease Burden, Clinical Manifestations, and Microbiology. PLoS Med. 2006; 3(9): e353.	2002		
China	Chiu TTW, Leung ASL. Neck pain in Hong Kong: a telephone survey on prevalence, consequences, and risk groups. Spine. 2006; 31(16): E540-544.	2003		
China	Demyttenaere K, Bruffaerts R, Lee S, Posada-Villa J, Kovess V, Angermeyer MC, Levinson D, de Girolamo G, Nakane H, Mneimneh Z, Lara C, de Graaf R, Scott KM, Gureje O, Stein DJ, Haro JM, Bromet EJ, Kessler RC, Alonso J, Von Korff M. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. Pain. 2007; 129(3): 332-42.	2002-2003		
China	Lau EM, Sham A, Wong KC. The prevalence of and risk factors for neck pain in Hong Kong Chinese. J Public Health Med. 1996; 18(4): 396-9.	1993		
China	He Y, Lam TH, Jiang B, Wang J, Sai X, Fan L, Li X, Qin Y, Hu FB. Passive smoking and risk of peripheral arterial disease and ischemic stroke in Chinese women who never smoked. Circulation. 2008; 118(15): 1535-40.	2001-2002		
China	Lumbiganon P, Laopaboon M, Gülmezoglu AM, Souza JP, Taneepanichskul S, Ruyan P, Attygalle DE, Shrestha N, Mori R, Hinh ND, Bang HT, Rathay T, Chuyun K, Cheang K, Festin M, Udomprasertgul V, Germar MJV, Yanqiu G, Roy M, Carroll G, Ba-Thike K. Method of delivery and pregnancy outcomes in Asia: the WHO global survey on maternal and perinatal health 2007-08. Lancet. 2010; 375(9713): 490-9.	2007-2008		
China	Yang TY, Yang XY, Chen WC, Qi SL, Jin YJ, Gan WJ, Qu Q. Thalassemia in China. Ann N Y Acad Sci. 1985; 445: 92-105.	1980-1981		
China	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2004		
China	Zeng Q, Huang S, Chen R. 10-year epidemiological study on rheumatic diseases in Shantou area. Chin J Intern Med. 1997; 36(3): 193-7.	1985-1995		
China	Dai S-M, Han X-H, Zhao D-B, Shi Y-Q, Liu Y, Meng J-M. Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis, and gout in Shanghai, China: a COPCORD study. J Rheumatol. 2003; 30(10): 2245-51.	1997-1998		
China	Chen S, Du H, Wang Y, Xu L. The epidemiology study of hyperuricemia and gout in a community population of Huangpu District in Shanghai. Chin Med J (Engl). 1998; 111(3): 228-30.	1995		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
China	Miao Z, Li C, Chen Y, Zhao S, Wang Y, Wang Z, Chen X, Xu F, Wang F, Sun R, Hu J, Song W, Yan S, Wang C-Y. Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. <i>J Rheumatol</i> . 2008; 35(9): 1859-64.	2004		
China	Shi F, Gu K, Lu W, Weng W, Zhu M, Peng Y, Fu D, Fu H. Study on the prevalence of arthritis and relevant factors in Shanghai. <i>Chin J Epidemiol</i> . 2003; 24(12): 1136-40.	2001-2002		
China	Wang Q, Chen R, Du L, Zeng Q. An epidemiological and clinical study of primary gout. <i>Chin J Intern Med</i> . 2001; 40(5): 313-5.	1992, 1995, 1999		
China	Zhang QH, Jiang ZX, Sun Y, Xia AX, Lin H, Tian L. Investigation and analysis of disease prevalence among 20 500 urban middle-aged and elderly women in five communities of Beijing. <i>Chin J Clin Rehab</i> . 2005; 9(39): 20-22.	2004		
China	Nan H, Qiao Q, Dong Y, Gao W, Tang B, Qian R, Tuomilehto J. The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China. <i>J Rheumatol</i> . 2006; 33(7): 1346-50.	2002		
China	Li Y, Li Y, Yu D, Xia M, Hu S, Xiang Y, Zhong Z. A multivariate analysis of the relationship between work ability and S japonicum infection in Dongting Lake region, in China. <i>Rev Inst Med Trop Sao Paulo</i> . 1993; 35(4): 347-53.	1992-1993		
China	Wu X-H, Wang T-P, Lu D-B, Hu H-T, Gao Z-B, Zhu C-G, Fang G-R, He Y-C, Mei Q-J, Wu W-D, Ge J-H, Zheng J. Studies of impact on physical fitness and working capacity of patients with advanced Schistosomiasis japonica in Susong County, Anhui Province. <i>Acta Trop</i> . 2002; 82(2): 247-52.	1998-1999		†
China	Zhou H, Ross AG, Hartel GF, Sleight AC, Williams GM, McManus DP, Luo XS, He Y, Li YS. Diagnosis of schistosomiasis japonica in Chinese schoolchildren by administration of a questionnaire. <i>Trans R Soc Trop Med Hyg</i> . 1998; 92(3): 245-50.	1997-1998		
China	Hou JB, Zhang ZX. Prevalence of multiple sclerosis: a door-to-door survey in Lan Cang La Hu Zu Autonomous County, Yunnan Province of China. <i>Neuroepidemiology</i> . 1992; 11(1): 52.	1986, 1989		
China	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J</i> . 1998; 12(2): 315-35.	1993-1995		
China	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	2001-2002		
China	Han W, Xie Y, Zhou XL, Yin LM, Shu-Ying R. Prognosis of 212 children with asthma: a 5-year follow-up study. <i>Chin J Contemp Pediatr</i> . 2011; 13(11): 870.	2002-2006		
China	Zhang ZJ, Gao LM, Wang ZL, Cao YP, Wu GC, Zhu ZH. Epidemiological studies at Dongguan Brigade. <i>Chin Med J (Engl)</i> . 1986; 99(7): 561-8.	1981-1983		†
China	Dong Y, Gao W, Nan H, Yu H, Li F, Duan W, Wang Y, Sun B, Qian R, Tuomilehto J, Qiao Q. Prevalence of Type 2 diabetes in urban and rural Chinese populations in Qingdao, China. <i>Diabet Med</i> . 2005; 22(10): 1427-33.	2002		
China	Liu DP, Molyneux L, Chua E, Wang YZ, Wu CR, Jing H, Hu LN, Liu YJ, Xu ZR, Yue DK. Retinopathy in a Chinese population with type 2 diabetes: factors affecting the presence of this complication at diagnosis of diabetes. <i>Diabetes Res Clin Pract</i> . 2002; 56(2): 125-31.	1995-1999		
China	Wang N, Xu X, Zou H, Zhu J, Wang W, Ho PC. The status of diabetic retinopathy and diabetic macular edema in patients with type 2 diabetes: a survey from Beixinjing District of Shanghai city in China. <i>Ophthalmologica</i> . 2008; 222(1): 32-6.	2003-2005		
China	A mass survey of diabetes mellitus in a population of 300,000 in 14 provinces and municipalities in China (author's transl). <i>Zhonghua Nei Ke Za Zhi</i> . 1981; 20(11): 678-83.	1980		
China	Pan X, Yang W, Liu J. Prevalence of diabetes and its risk factors in China 1994. National Diabetes Prevention and Control Cooperative Group. <i>Chin J Intern Med</i> . 1997; 36(6): 384-9.	1995		
China	Wang W, Zhao D, Sun JY, Liu J, Qin LP, Wu ZS. Impact of new criterion of glucose level on the prevalence of impaired fasting glucose and risk of ischemic cardiovascular diseases. <i>Chin J Intern Med</i> . 2007; 46(1): 20-4.	1997		
China	Gu D, Reynolds K, Duan X, Xin X, Chen J, Wu X, Mo J, Whelton PK, He J; InterASIA Collaborative Group. Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). <i>Diabetologia</i> . 2003; 46(9): 1190-8.	2001		
China	Tian H, Song G, Xie H, Zhang H, Tuomilehto J, Hu G. Prevalence of diabetes and impaired fasting glucose among 769,792 rural Chinese adults. <i>Diabetes Res Clin Pract</i> . 2009; 84(3): 273-8.	2004		
China	Zhi XY, Wang JH. Prevalence of impaired glucose regulation in the population of Tianjin. <i>Chin Med Sci J</i> . 2008; 23(4): 249-52.	2005		
China	Wu Y, Li H, Loos RJ, Yu Z, Ye X, Chen L, Pan A, Hu FB, Lin X. Common variants in CDKAL1, CDKN2A/B, IGF2BP2, SLC30A8, and HHEX/IDE genes are associated with type 2 diabetes and impaired fasting glucose in a Chinese Han population. <i>Diabetes</i> . 2008; 57(10): 2834-42.	2005		
China	Yang W, Lu J, Wang J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J; China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. <i>N Engl J Med</i> . 2010; 362(12): 1090-101.	2008		
China	Kong CK, Cheng WW, Wong LY. Epidemiology of headache in Hong Kong primary-level schoolchildren: questionnaire study. <i>Hong Kong Med J</i> . 2001; 7(1): 29-33.	1999		
China	Wang S-J, Fuh J-L, Lu S-R, Juang K-D, Wang P-H. Migraine prevalence during menopausal transition. <i>Headache</i> . 2003; 43(5): 470-8.	2000		
China	Wang SJ, Liu HC, Fuh JL, Liu CY, Lin KP, Chen HM, Lin CH, Wang PN, Hsu LC, Wang HC, Lin KN. Prevalence of headaches in a Chinese elderly population in Kinmen: age and gender effect and cross-cultural comparisons. <i>Neurology</i> . 1997; 49(1): 195-200.	1993-1994		
China	Wong TW, Wong KS, Yu TS, Kay R. Prevalence of migraine and other headaches in Hong Kong. <i>Neuroepidemiology</i> . 1995; 14(2): 82-91.	1992-1993		
China	Yu S, Liu R, Zhao G, Yang X, Qiao X, Feng J, Fang Y, Cao X, He M, Steiner T. The prevalence and burden of primary headaches in China: a population-based door-to-door survey. <i>Headache</i> . 2012; 52(4): 582-91.	2008-2009		
China	Zeng QY, Chen R, Xiao ZY, Huang S-B, Liu Y, Xu JC, Chen SL, Darmawan J, Couchman KG, Wigley RD, Muirden KD. Low prevalence of knee and back pain in southeast China: the Shantou COPCORD study. <i>J Rheumatol</i> . 2004; 31(12): 2439-43.	1995		
China	Nevitt MC, Xu L, Zhang Y, Lui L-Y, Yu W, Lane NE, Qin M, Hochberg MC, Cummings SR, Felson DT. Very low prevalence of hip osteoarthritis among Chinese elderly in Beijing, China, compared with whites in the United States: the Beijing osteoarthritis study. <i>Arthritis Rheum</i> . 2002; 46(7): 1773-9.	1998-2000		
China	Bai J, Zhao J, Shen K-L, Xiang L, Chen A-H, Huang S, Huang Y, Wang J-S, Ye R-W. Current trends of the prevalence of childhood asthma in three Chinese cities: a multicenter epidemiological survey. <i>Biomed Environ Sci</i> . 2010; 23(6): 453-7.	2008	*	
China	Li F, Zhou Y, Li S, Jiang F, Jin X, Yan C, Tian Y, Zhang Y, Tong S, Shen X. Prevalence and risk factors of childhood allergic diseases in eight metropolitan cities in China: a multicenter study. <i>BMC Public Health</i> . 2011; 437.	2005	*	
China	Zhao J, Bai J, Shen K, Xiang L, Huang S, Chen A, Huang Y, Wang J, Ye R. Self-reported prevalence of childhood allergic diseases in three cities of China: a multicenter study. <i>BMC Public Health</i> . 2010; 551.	2008-2009	*	
China	Li R, Sun J, Ren L-M, Wang H-Y, Liu W-H, Zhang X-W, Chen S, Mu R, He J, Zhao Y, Long L, Liu Y-Y, Liu X, Lu X-L, Li Y-H, Wang S-Y, Pan S-S, Li C, Wang H-Y, Li Z-G. Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. <i>Rheumatology</i> . 2012; 51(4): 721-9.	2008-2011	*	
China	Jiang L, Rong J, Zhang Q, Hu F, Zhang S, Li X, Zhao Y, Tao T. Prevalence and associated factors of knee osteoarthritis in a community-based population in Heilongjiang, Northeast China. <i>Rheumatol Int</i> . 2012; 32(5): 1189-95.	2005	*	
China	Lam KBH, Yin P, Jiang CQ, Zhang WS, Adab P, Miller MR, Thomas GN, Ayres JG, Lam TH, Cheng KK. Past dust and GAS/FUME exposure and COPD in Chinese: the Guangzhou Biobank Cohort Study. <i>Respir Med</i> . 2012; 106(10): 1421-8.	2003-2006	*	
China	Yin P, Zhang M, Li Y, Jiang Y, Zhao W. Prevalence of COPD and its association with socioeconomic status in China: findings from China Chronic Disease Risk Factor Surveillance 2007. <i>BMC Public Health</i> . 2011; 586.	2007	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
China	Lu M, Yao W, Zhong N, Zhou Y, Wang C, Chen P, Kang J, Huang S, Chen B, Wang C, Ni D, Wang X, Wang D, Liu S, Li J, Shen N, Ding Y, Ran P. Asymptomatic patients of chronic obstructive pulmonary disease in China. <i>Chin Med J (Engl)</i> . 2010; 123(12): 1494-9.	2003	*	
China	Luo Y, Li X, Li J, Wang X, Xu Y, Qiao Y, Hu D, Ma Y. Peripheral arterial disease, chronic kidney disease, and mortality: the Chinese Ankle Brachial Index Cohort Study. <i>Vasc Med</i> . 2010; 15(2): 107-12.	2004		
China	Wang Y, Li J, Zhao D, Wei Y, Hou L, Hu D, Xu Y. Prevalence and characteristics of atherosclerosis and peripheral arterial disease in a Chinese population of Inner Mongolia. <i>VASA</i> . 2011; 40(1): 49-56.	2009		
China	Awuti G, Younusi K, Li L, Upur H, Ren J. Epidemiological survey on the prevalence of periodontitis and diabetes mellitus in Uyghur adults from rural Hotan area in Xinjiang. <i>Exp Diabetes Res</i> . 2012; 758921.	2010	*	
China	Corbet EF, Wong MC, Lin HC. Periodontal conditions in adult Southern Chinese. <i>J Dent Res</i> . 2001; 80(5): 1480-5.	1999	*	
China	Petersen P-E, Peng B, Bao Jun Tai. Oral health status and oral health behaviour of middle-aged and elderly people in PR China. <i>Int Dent J</i> . 1997; 47(6): 305.	1995		
China	Dai S, Shen Z, Zha Z, Leng R, Qin W, Wang C, Chen L, Tian M, Huang Z, Chen G, Cen H, Xue L, Wang J, Lu Y, Cao B, Ye D. Seroprevalence of HIV, syphilis, and hepatitis C virus in the general population of the Liangshan Prefecture, Sichuan Province, China. <i>J Med Virol</i> . 2012; 84(1): 1-5.	1998-2004, 2009-2010		
China	Ding X, Wang T, Shen Y, Wang X, Zhou C, Tian S, Liu Y, Peng G, Zhou J, Xue S, Wang R, Tang Y, Meng X, Pei G, Bai Y, Liu Q, Li H, Zhang J. Prevalence of psoriasis in China: a population-based study in six cities. <i>Eur J Dermatol</i> . 2012; 22(5): 663-7.	2009-2011	*	
China	Qiao M, Zhang H, Liu H, Luo S, Wang T, Zhang J, Ji L. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample in China. <i>Eur J Obstet Gynecol Reprod Biol</i> . 2012; 162(1): 83-6.	2009-2011	*	
China	Wu L, Qiu Z, Wong D, Hernandez LW, Zhao Q. The research on the status, rehabilitation, education, vocational development, social integration and support services related to intellectual disability in China. <i>Res Dev Disabil</i> . 2010; 31(6): 1216-22.	2006	*	
China	Xie Z-H, Bo S-Y, Zhang X-T, Liu M, Zhang Z-X, Yang X-L, Ji S-R, Yan H, Sui X-L, Na X, Guo S-H, Wu Z-L. Sampling survey on intellectual disability in 0 approximately 6-year-old children in China. <i>J Intellect Disabil Res</i> . 2008; 52(12): 1029-38.	2005-2007	*	
China	Chen X, Cheng HG, Huang Y, Liu Z, Luo X. Depression symptoms and chronic pain in the community population in Beijing, China. <i>Psychiatry Res</i> . 2012; 200(2-3): 313-7.	2010	*	
China	Yao W, Mai X, Luo C, Ai F, Chen Q. A cross-sectional survey of nonspecific low back pain among 2083 schoolchildren in China. <i>Spine</i> . 2011; 36(22): 1885-90.	2009	*	
China	Duan Z-L, Liu N, Yang S-H, Zhang J, Sun L-W, Tang J-Y, Jin Y, Du Z-Q, Xu J, Wu Q-B, Tong Z-L, Gong S-T, Qian Y, Ma J-M, Liao X-C, Widdowson M-A, Jiang B, Fang Z-Y. Hospital-Based Surveillance of Rotavirus Diarrhea in the People's Republic of China, August 2003-July 2007. <i>J Infect Dis</i> . 2009; 200(Suppl 1): S167-173.	2003-2007	*	
China	Huilan S, Zhen LG, Mathan MM, Mathew MM, Olarte J, Espejo R, Khin Maung U, Ghafoor MA, Khan MA, Sami Z. Etiology of acute diarrhoea among children in developing countries: a multicentre study in five countries. <i>Bull World Health Organ</i> . 1991; 69(5): 549-55.	1982-1984	*	
China	Wu H, Taniguchi K, Urasawa T, Urasawa S. Serological and genomic characterization of human rotaviruses detected in China. <i>J Med Virol</i> . 1998; 55(2): 168-76.	1994-1995	*	
China	Tam JS, Kum WW, Lam B, Yeung CY, Ng MH. Molecular epidemiology of human rotavirus infection in children in Hong Kong. <i>J Clin Microbiol</i> . 1986; 23(3): 660-4.	1983-1984	*	
China	Lau C-S, Wong DA, Tong LKL, Lo JYC, Ma AMC, Cheng PKC, Lim WWL. High rate and changing molecular epidemiology pattern of norovirus infections in sporadic cases and outbreaks of gastroenteritis in Hong Kong. <i>J Med Virol</i> . 2004; 73(1): 113-7.	2001-2002	*	
China	Guo L, Song J, Xu X, Ren L, Li J, Zhou H, Wang M, Qu J, Wang J, Hung T. Genetic analysis of norovirus in children affected with acute gastroenteritis in Beijing, 2004-2007. <i>J Clin Virol</i> . 2009; 44(1): 94-8.	2004-2007	*	
China	Jin Y, Cheng W, Yang X, Jin M, Zhang Q, Xu Z, Yu J, Zhu L, Yang S, Liu N, Cui S, Fang Z, Duan Z. Viral agents associated with acute gastroenteritis in children hospitalized with diarrhea in Lanzhou, China. <i>J Clin Virol</i> . 2009; 44(3): 238-41.	2005-2007	*	
China	Gao Y, Jin M, Cong X, Duan Z, Li H-Y, Guo X, Zuo Y, Zhang Y, Zhang Y, Wei L. Clinical and molecular epidemiologic analyses of norovirus-associated sporadic gastroenteritis in adults from Beijing, China. <i>J Med Virol</i> . 2011; 83(6): 1078-85.	2007-2008	*	
China	Lou J-T, Xu X-J, Wu Y-D, Tao R, Tong M-Q. Epidemiology and burden of rotavirus infection among children in Hangzhou, China. <i>J Clin Virol</i> . 2011; 50(1): 84-7.	2007-2008	*	
China	Ouyang Y, Ma H, Jin M, Wang X, Wang J, Xu L, Lin S, Shen Z, Chen Z, Qiu Z, Gao Z, Peng L, Li J. Etiology and epidemiology of viral diarrhea in children under the age of five hospitalized in Tianjin, China. <i>Arch Virol</i> . 2012; 157(5): 881-7.	2008-2009	*	
China	Qu M, Deng Y, Zhang X, Liu G, Huang Y, Lin C, Li J, Yan H, Li X, Jia L, Kan B, Huang F, Wang Q. Etiology of acute diarrhea due to enteropathogenic bacteria in Beijing, China. <i>J Infect</i> . 2012; 65(3): 214-22.	2010-2011	*	
China	Prince M, Acosta D, Ferri CP, Guerra M, Huang Y, Llibre Rodriguez JJ, Salas A, Sosa AL, Williams JD, Dewey ME, Acosta I, Jotheeswaran AT, Liu Z. Dementia incidence and mortality in middle-income countries, and associations with indicators of cognitive reserve: a 10/66 Dementia Research Group population-based cohort study. <i>Lancet</i> . 2012; 380(9836): 50-8.	2003-2010		
China	Zhao Q, Zhou B, Ding D, Guo Q, Hong Z. Prevalence, mortality, and predictive factors on survival of dementia in Shanghai, China. <i>Alzheimer Dis Assoc Disord</i> . 2010; 24(2): 151-8.	1997-2001		
China	Sousa RM, Ferri CP, Acosta D, Albanese E, Guerra M, Huang Y, Jacob KS, Jotheeswaran AT, Rodriguez JLL, Pichardo GR, Rodriguez MC, Salas A, Sosa AL, Williams J, Zuniga T, Prince M. Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population-based survey. <i>Lancet</i> . 2009; 374(9704): 1821-30.	2003-2005		
China	By Gao ZX, Xie B, Fang YS, Pan JX. The Prevalence of Dementia Among Elderly in Shanghai Area, China- A Survey in City, Town and Countryside. <i>Hong Kong J Psychiatry</i> . 1999; 9(1): 12-4.	1990		
China	Li G, Shen YC, Chen CH, Zhao YW, Li SR, Lu M. An epidemiological survey of age-related dementia in an urban area of Beijing. <i>Acta Psychiatr Scand</i> . 1989; 79(6): 557-63.	1986		
China	Li S, Yan F, Li G, Chen C, Zhang W, Liu J, Jia X, Shen Y. Is the dementia rate increasing in Beijing? Prevalence and incidence of dementia 10 years later in an urban elderly population. <i>Acta Psychiatr Scand</i> . 2007; 115(1): 73-9.	1997-1999		
China	Shen YC, Li G, Li YT, Chen CH, Li SR, Zhao YW, Zhang WX. Epidemiology of age-related dementia in China. <i>Chin Med J (Engl)</i> . 1994; 107(1): 60-4.	1986-1989		
China	Zhang MY, Katzman R, Salmon D, Jin H, Cai GJ, Wang ZY, Qu GY, Grant I, Yu E, Levy P. The prevalence of dementia and Alzheimer's disease in Shanghai, China: impact of age, gender, and education. <i>Ann Neurol</i> . 1990; 27(4): 428-37.	1987-1988		
China	Wang W, Wu S, Cheng X, Dai H, Ross K, Du X, Yin W. Prevalence of Alzheimer's disease and other dementing disorders in an urban community of Beijing, China. <i>Neuroepidemiology</i> . 2000; 19(4): 194-200.	1994-1995		
China	Li Z, Zou D, Ma X, Chen J, Shi X, Gong Y, Man X, Gao L, Zhao Y, Wang R, Yan X, Dent J, Sung JJ, Wernerson B, Johansson S, Liu W, He J. Epidemiology of peptic ulcer disease: endoscopic results of the systematic investigation of gastrointestinal disease in China. <i>Am J Gastroenterol</i> . 2010; 105(12): 2570-7.	2007-2009	*	
China	Zeng Q, Zang C, Li X, Dong H, Zhang A, Lin L. Associated risk factors of knee osteoarthritis: a population survey in Taiyuan, China. <i>Chin Med J (Engl)</i> . 2006; 119(18): 1522-7.	2005		
China	Du H, Chen S-L, Bao C-D, Wang X-D, Lu Y, Gu Y-Y, Xu J-R, Chai W-M, Chen J, Nakamura H, Nishioka K. Prevalence and risk factors of knee osteoarthritis in Huang-Pu District, Shanghai, China. <i>Rheumatol Int</i> . 2005; 25(8): 585-90.	2002		
China	Kang X, Fransen M, Zhang Y, Li H, Ke Y, Lu M, Su S, Song X, Guo Y, Chen J, Niu J, Felson D, Lin J. The high prevalence of knee osteoarthritis in a rural Chinese population: the Wuchuan osteoarthritis study. <i>Arthritis Rheum</i> . 2009; 61(5): 641-7.	2005		
China	Zhang Y, Xu L, Nevitt MC, Aliabadi P, Yu W, Qin M, Lui LY, Felson DT. Comparison of the prevalence of knee osteoarthritis between the elderly Chinese population in Beijing and whites in the United States: The Beijing Osteoarthritis Study. <i>Arthritis Rheum</i> . 2001; 44(9): 2065-71.	1998		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
China	Zeng QY, Darmawan J, Xiao ZY, Chen SB, Chen R, Lin K, Wigley R, Chen SL, Zhang NZ. Risk factors associated with rheumatic complaints: a WHO-ILAR COPCORD study in Shantou, Southeast China. <i>J Rheumatol</i> . 2005; 32(5): 920-7.	1995		
China	Wigley RD, Zhang NZ, Zeng QY, Shi CS, Hu DW, Couchman K, Duff IF, Bennett PH. Rheumatic diseases in China: ILAR-China study comparing the prevalence of rheumatic symptoms in northern and southern rural populations. <i>J Rheumatol</i> . 1994; 21(8): 1484-90.	1987		
China	Lau E, Symmons D, Bankhead C, MacGregor A, Donnan S, Silman A. Low prevalence of rheumatoid arthritis in the urbanized Chinese of Hong Kong. <i>J Rheumatol</i> . 1993; 20(7): 1133-7.	1990		
China	Jiangsu Province Hospital, Nanjing Medical University. China - Jiangsu, Sichuan, Guizhou, and Jilin WHO Ear and Hearing Disorders Survey 2005-2006, as provided by the Global Burden of Disease 2010 Hearing Disorders Expert Group. [Unpublished].	2006		
China	Lo EC, Evans RW, Lind OP. Dental caries status and treatment needs of the permanent dentition of 6-12-year-olds in Hong Kong. <i>Community Dent Oral Epidemiol</i> . 1990; 1(18): 9-11.	1986		
China	Lind OP, Holmgren CJ, Evans RW, Corbet EF, Lim LP, Davies WI. Part 1: Clinical findings <i>Community Dent Health</i> . 1984; 1(4): 351-66.	1984		
China	Jiang H, Tai B, Du M, Peng B. Effect of professional application of APF foam on caries reduction in permanent first molars in 6-7-year-old children: 24-month clinical trial. <i>J Dent</i> . 2005; 33(6): 469-73.	2000-2002		
China	Hu D, Liu D. Trends of caries prevalence and experience in children in Chengdu City, West China, 1982-1990. <i>Community Dent Oral Epidemiol</i> . 1992; 20(5): 308-9.	1982-1983, 1986, 1990-1991		
China	Wang ZJ, Shen Y, Schwartz E. Dental caries prevalence of 6-14-year-old children in Guangdong, China. <i>Community Dent Oral Epidemiol</i> . 1994; 22(5): 340-1.	1987		
China	King NM, Ling JY, Ng BV, Wei SH. The dental caries status and dental treatment patterns of 12-year-old children in Hong Kong. <i>J Dent Res</i> . 1986; 65(11): 1371-4.	1984		
China	Li G, Wang C, Li J, Ai Y, Zhang Y. Dental caries in Yanan schoolchildren aged 12 years: China. <i>Community Dent Oral Epidemiol</i> . 1994; 22(3): 208.	1992		
China	Douglass JM, Wei Y, Zhang BX, Tinanoff N. Caries prevalence and patterns in 3-6-year-old Beijing children. <i>Community Dent Oral Epidemiol</i> . 1995; 23(6): 340-3.	1991, 1993		
China	Wang H-Y, Petersen PE, Bian J-Y, Zhang B-X. The second national survey of oral health status of children and adults in China. <i>Int Dent J</i> . 2002; 52(4): 283-90.	1995-1996		
China	Wong MC, Lo EC, Schwarz E, Zhang HG. Oral health status and oral health behaviors in Chinese Children. <i>J Dent Res</i> . 2001; 80(5): 1459-65.	1999		
China	Rong WS, Bian JY, Wang WJ, Wang JD. Effectiveness of an oral health education and caries prevention program in kindergartens in China. <i>Community Dent Oral Epidemiol</i> . 2003; 31(6): 412-6.	1998-2000		
China	Bian JY, Li RY, Wang WJ. Feasibility of milk fluoridation and trends in dental caries of children in China. <i>Adv Dent Res</i> . 1995; 9(2): 112-5.	1990		
China	Bian JY, Wang WH, Wang WJ, Rong WS, Lo ECM. Effect of fluoridated milk on caries in primary teeth: 21-month results. <i>Community Dent Oral Epidemiol</i> . 2003; 31(4): 241-5.	1997-1999		
China	Petersen PE, Guang LX. Dental caries prevalence in a group of schoolchildren in Wuhan City, PR China, 1993. <i>Community Dent Oral Epidemiol</i> . 1994; 22(6): 465-6.	1993		
China	Evans RW, Lo EC. Effects of School Dental Care Service in Hong Kong—primary teeth. <i>Community Dent Oral Epidemiol</i> . 1992; 20(4): 193-5.	1990		
China	Tang J, Yu Y, Ma Y. The epidemic tendency of dental caries prevalence of school students from 1991 to 2005 in China. <i>J Huazhong Univ Sci Technol Med Sci</i> . 2010; 30(1): 132-7.	1991, 1995, 2000, 2005		
China	Du M, Luo Y, Zeng X, Alkhatib N, Bedi R. Caries in preschool children and its risk factors in 2 provinces in China. <i>Quintessence Int</i> . 2007; 38(2): 143-51.	2001-2002		
China	Keqing L, Ze C, Lijun C, Qipu J, Guang S, Haoran W, Jing H, Wuwen Z, Jianguo X, Yanping Z, Ben Z, Jianxun J, Xueyi W, Jun T, Yufu Z, Haishan H, Jianping G, Enyi Z. Epidemiological survey of mental disorders in the people aged 18 and older in Hebei Province. <i>Asian J Psychiatr</i> . 2008; 1(2): 51-5.	2004-2005		
China	Lee S, Ng KL, Tsang A. A community survey of the twelve-month prevalence and correlates of bipolar spectrum disorder in Hong Kong. <i>J Affect Disord</i> . 2009; 117(1-2): 79-86.	2007		
China	Phillips MR, Zhang J, Shi Q, Song Z, Ding Z, Pang S, Li X, Zhang Y, Wang Z. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001-05: an epidemiological survey. <i>Lancet</i> . 2009; 373(9680): 2041-53.	2001-2005		
China	Huon GF, Mingyi Q, Oliver K, Xiao G. A large-scale survey of eating disorder symptomatology among female adolescents in the People's Republic of China. <i>Int J Eat Disord</i> . 2002; 32(2): 192-205.	2000		
China	Lee S, Chan YYL, Hsu LKG. The intermediate-term outcome of Chinese patients with anorexia nervosa in Hong Kong. <i>Am J Psychiatry</i> . 2003; 160(5): 967-72.	1984-2000		
China	Chen W, Liu Y, Huang X, Rong Y. Respiratory Diseases Among Dust Exposed Workers. <i>InTech</i> . 2012.	2003, 2005, 2007		
China	Leung P, Hung S, Ho T, Lee C, Liu W, Tang C, Kwong S. Prevalence of DSM-IV disorders in Chinese adolescents and the effects of an impairment criterion: a pilot community study in Hong Kong. <i>Eur Child Adolesc Psychiatry</i> . 2008; 17(7): 452-61.	2001, 2006		
China	Pan Y. A population-based study on incidence of idiopathic cardiomyopathy in Nanjing, 1985-1989. <i>Chin J Epidemiol</i> . 1992; 13(4): 193-6.	1985-1989		
China	Ho H-H, Lee KLF, Lau C-P, Tse H-F. Clinical characteristics of and long-term outcome in Chinese patients with hypertrophic cardiomyopathy. <i>Am J Med</i> . 2004; 116(1): 19-23.	1973-2002		
China	Zou Y, Song L, Wang Z, Ma A, Liu T, Gu H, Lu S, Wu P, Zhang dagger Y, Shen dagger L, Cai Y, Zhen double dagger Y, Liu Y, Hui R. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. <i>Am J Med</i> . 2004; 116(1): 14-8.	2001-2002		
China	Wu Z, Yao C, Zhao D, Wu G, Wang W, Liu J, Zeng Z, Wu Y. Sino-MONICA project: a collaborative study on trends and determinants in cardiovascular diseases in China. Part I: morbidity and mortality monitoring. <i>Circulation</i> . 2001; 103(3): 462-8.	1987-1993		
China	Shen YC ZM, Huang YQ, He YL, Liu ZR, Cheng H, Tsang A, Lee S, Kessler RC. Twelve-month prevalence, severity, and unmet need for treatment of mental disorders in metropolitan China. <i>Psychol Med</i> . 2006; 36(2): 257-67.	2001-2002		
China	He Y, Jiang Y, Wang J, Fan L, Li X, Hu FB. Prevalence of peripheral arterial disease and its association with smoking in a population-based study in Beijing, China. <i>J Vasc Surg</i> . 2006; 44(2): 333-8.	2001-2002		
China	National Central Cancer Registry (China). China Cancer Registry Incidence and Mortality 1990-2009. [Unpublished].	1990-2009	*	
China	Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E. BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. <i>Lancet</i> . 2007; 9589(9589): 741-50.	2003-2004		
China	Jiang RG, Luo DS, Huang CP, Li WM. Study on the prevalence rate and risk factors of chronic obstructive pulmonary disease in rural community population in Hubei province. <i>Chin J Epidemiol</i> . 2007; 28(10): 976-9.	2003-2004		
China	Liu S, Zhou Y, Wang X, Wang D, Lu J, Zheng J, Zhong N, Ran P. Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China. <i>Thorax</i> . 2007; 62(10): 889-97.	2002-2003		
China	Yao WZ, Zhu H, Shen N, Han X, Liang YJ, Zhang LQ, Sun YC, Hao ZT, Zhao MW. Epidemiological data of chronic obstructive pulmonary disease in Yanqing County in Beijing. <i>J Peking Univ Health Sci</i> . 2005; 37(2): 121.	1991-1992		
China	Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S, Chen B, Wang C, Ni D, Zhou Y, Liu S, Wang X, Wang D, Lu J, Zheng J, Ran P. Prevalence of chronic obstructive pulmonary disease in China A large, population-based survey. <i>Am J Respir Crit Care Med</i> . 2007; 176(8): 753-60.	2002-2004		
China	Ko FW, Woo J, Tam W, Lai CK, Ngai J, Kwok T, Hui DS. Prevalence and risk factors of airflow obstruction in an elderly Chinese population. <i>Eur Respir J</i> . 2008; 32(6): 1472-8.	2004-2005		
China	Tian F, Yang D, Zhang X, Zhao Q, Zhan X, Li R, Mu L, Jiang X, Li J. Survey of health status and healthcare service demand of perimenopausal women in Guangdong. <i>Acad J First Med Coll PLA</i> . 2004; 24(8): 928-32.	2001		
China	Shen YC, Wang YF, Yang XL. An epidemiological investigation of minimal brain dysfunction in six elementary schools in Beijing. <i>J Child Psychol Psychiatry</i> . 1985; 26(5): 777-87.	1983		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2005		
China	Chau JP, Chang AM, Chang AM. Relationship between premenstrual tension syndrome and anxiety in Chinese adolescents. <i>J Adolesc Health</i> . 1998; 22(3): 247-9.	1995		
China	Chang AM, Holroyd E, Chau JP. Premenstrual syndrome in employed Chinese women in Hong Kong. <i>Health Care Women Int</i> . 1995; 16(6): 551-61.	1992		
China	Zhao G, Wang L, Qu C. Prevalence of premenstrual syndrome in reproductive women and its influential factors. <i>Chin J Obstet Gynecol</i> . 1998; 33(4): 222-4.	1996-1997		
China	International Society of Nephrology (ISN). International Society of Nephrology Kidney Disease Data Center 2006-2009.	2007-2008		
	United States Renal Data System Coordinating Center. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	1999-2007		
China	Yongjun T, Samuelson J, Qingsheng D, Ali MM, Li X, Yanjian M, Xiaqing C, Jun L, Jian C, Bi L. The prevalence of sexually transmitted and other lower reproductive tract infections among rural women in Sichuan Province, China. <i>Southeast Asian J Trop Med Public Health</i> . 2009; 40(5): 1038-47.	1990, 2003		
China	Detels R, Wu Z, Rotheram MJ, Li L, Guan J, Yin Y, Liang G, Lee M, Hu L, National Institute of Mental Health (NIMH) Collaborative HIV Prevention Trial Group. Sexually transmitted disease prevalence and characteristics of market vendors in eastern China. <i>Sex Transm Dis</i> . 2003; 30(11): 803-8.	2003-2004		
China	Franceschi S, Smith JS, van den Brule A, Herrero R, Arslan A, Anh P-T-H, Bosch FX, Hieu N-T, Matos E, Posso H, Qiao Y-L, Shin H-R, Sukvirach S, Thomas JO, Snijders PJF, Muñoz N, Mejer CLM. Cervical infection with Chlamydia trachomatis and Neisseria gonorrhoeae in women from ten areas in four continents. A cross-sectional study. <i>Sex Transm Dis</i> . 2007; 34(8): 563-9.	2004-2005		
China	He N, Detels R, Zhu J, Jiang Q, Chen Z, Fang Y, Zhang X, Wu M, Zhao Q. Characteristics and sexually transmitted diseases of male rural migrants in a metropolitan area of Eastern China. <i>Sex Transm Dis</i> . 2005; 32(5): 286-92.	2003-2005		
China	Wu Z, Rotheram-Borus MJ, Li L, Guan J, Detels R, Yin Y, Wu S, Liu Z, Lin C, Hsieh J, NIMH Collaborative HIV/STD Prevention Trial Group. Sexually transmitted diseases and risk behaviors among market vendors in China. <i>Sex Transm Dis</i> . 2007; 34(12): 1030-4.	2007		
China	Gao ZY, Li YL, Chai DF. Investigation of cervical Chlamydia trachomatis infection in gynecologic outpatients. <i>Chin J Epidemiol</i> . 1995; 16(4): 211-2.	1995		
China	Chen P, Yu ES, Zhang M, Liu WT, Hill R, Katzman R. ADL dependence and medical conditions in Chinese older persons: a population-based survey in Shanghai, China. <i>J Am Geriatr Soc</i> . 1995; 43(4): 378-83.	1987		
China	Chen RC, Chang SF, Su CL, Chen THH, Yen MF, Wu HM, Chen ZY, Liu HH. Prevalence, incidence, and mortality of PD: A door-to-door survey in Ilan County, Taiwan. <i>Neurology</i> . 2001; 57(9): 1679-86.	1986, 1993-1995		†
China	Wang SJ, Fuh JL, Teng EL, Liu CY, Lin KP, Chen HM, Lin CH, Wang PN, Ting YC, Wang HC, Lin KN, Chou P, Larson EB, Liu HC. A door-to-door survey of Parkinson's disease in a Chinese population in Kinmen. <i>Arch Neurol</i> . 1996; 53(1): 66-71.	1993-1994		†
China	Wang SJ, Fuh JL, Liu CY, Lin KP, Chang R, Yih JS, Chou P, Lin KN, Teng EL, Larson EB. Parkinson's disease in Kin-Hu, Kinmen: a community survey by neurologists. <i>Neuroepidemiology</i> . 1994; 13(1-2): 69-74.	1992		
China	Zhang Z-X, Roman GC, Hong Z, Wu C-B, Qu Q-M, Huang J-B, Zhou B, Geng Z-P, Wu J-X, Wen H-B, Zhao H, Zahner GEP. Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai. <i>Lancet</i> . 2005; 365(9459): 595-7.	1996-2002		†
China	Shi YM. [Study on the prevalence of Parkinson's disease in Hongkou District, Shanghai]. <i>Chin J Epidemiol</i> . 1987; 8(4): 205-7.	1980		
China	Chen C, Shen Y, Zhang W. Epidemiological survey on schizophrenia in 7 areas of China. <i>Chin J Psychiatry</i> . 1998; 31(2): 72-4.	1993		
China	Phillips MR, Yang G, Li S, Li Y. Suicide and the unique prevalence pattern of schizophrenia in mainland China: a retrospective observational study. <i>Lancet</i> . 2004; 364(9439): 1062-8.	1995-1999	*	
China	Ran M-S, Xiang M-Z, Li S-X, Shan Y-H, Huang M-S, Li S-G, Liu Z-R, Chen EY-H, Chan CL-W. Prevalence and course of schizophrenia in a Chinese rural area. <i>Aust N Z J Psychiatry</i> . 2003; 37(4): 452-7.	1994		
China	Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganey K, Giel R, an der Heiden W, Holmberg SK, Janca A, Lee PW, Leon CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin SJ, Varma VK, Walsh D, Wiersma D. Recovery from psychotic illness: a 15- and 25-year international follow-up study. <i>Br J Psychiatry</i> . 2001; 178: 506-17.	1978-1993		
China	Chinese Center for Disease Control and Prevention (CCDC). China National Tuberculosis Prevalence Survey 2000.	2000		
China	Chinese Center for Disease Control and Prevention (CCDC). China National Tuberculosis Prevalence Survey 2010.	2010		
China	Zhimin L, Weihua Z, Zhi L, Yue M, Zhiji C, Jiaqi C. The use of psychoactive substances among adolescent students in an area in the south-west of China. <i>Addiction</i> . 2001; 96(2): 247-50.	1999		
China	China - Beijing Eye Study 2001 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2001		
China	Chinese Center for Disease Control and Prevention (CCDC). China Notifiable Infectious Diseases 2004-2012. [Unpublished].	2004-2012		
China	Zhang S, Lu Z, Liu H, Xiao X, Zhao Z, Bao G, Han J, Jing T, Chen G. Incidence of Japanese encephalitis, visceral leishmaniasis and malaria before and after the Wenchuan earthquake, in China. <i>Acta Trop</i> . 2013; 128(1): 85-9.	2005-2011	*	
China	Lau EM, Egger P, Coggon D, Cooper C, Valenti L, O'Connell D. Low back pain in Hong Kong: prevalence and characteristics compared with Britain. <i>J Epidemiol Community Health</i> . 1995; 49(5): 492-4.	1992		
China	Woo J, Ho SC, Lau J, Leung PC. Musculoskeletal complaints and associated consequences in elderly Chinese aged 70 years and over. <i>J Rheumatol</i> . 1994; 21(10): 1927-31.	1991		
China	China - Luliang County Rapid Assessment for Avoidable Blindness 2008 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2008		
China	Liang YB, Friedman DS, Wong TY, Zhan SY, Sun LP, Wang JJ, Duan XR, Yang XH, Wang FH, Zhou Q, Wang NL. Prevalence and causes of low vision and blindness in a rural Chinese adult population: the Handan Eye Study. <i>Ophthalmology</i> . 2008; 115(11): 1965-72. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2006-2007		
China	Xiao B, Kuper H, Guan C, Bailey K, Limburg H. Rapid assessment of avoidable blindness in three counties, Jiangxi Province, China. <i>Br J Ophthalmol</i> . 2010; 94(11): 1437-42. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2007		
China	Gilbert CE, Ellwein LB. Prevalence and causes of functional low vision in school-age children: results from standardized population surveys in Asia, Africa, and Latin America. <i>Invest Ophthalmol Vis Sci</i> . 2008; 49(3): 877-81. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1998, 2002-2003		
China	Zhao J, Ellwein LB, Cui H, Ge J, Guan H, Lv J, Ma X, Yin J, Yin ZQ, Yuan Y, Liu H. Prevalence of vision impairment in older adults in rural China: the China Nine-Province Survey. <i>Ophthalmology</i> . 2010; 117(3): 409-16. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2006-2007		
China	Li L, Guan H, Xun P, Zhou J, Gu H. Prevalence and causes of visual impairment among the elderly in Nantong, China. <i>Eye (Lond)</i> . 2008; 22(8): 1069-75. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2003		
China	Zhang SY, Zou LH, Gao YQ, Di Y, Wang XD. National epidemiological survey of blindness and low vision in China. <i>Chin Med J (Engl)</i> . 1992; 105(7): 603-8. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1987		
China	Li Z, Cui H, Liu P, Zhang L, Yang H, Zhang L. Prevalence and causes of blindness and visual impairment among the elderly in rural southern Harbin, China. <i>Ophthalmic Epidemiol</i> . 2008; 15(5): 334-8. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2006-2007		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
China	Li S, Xu J, He M, Wu K, Munoz SR, Ellwein LB. A survey of blindness and cataract surgery in Doumen County, China. <i>Ophthalmology</i> . 1999; 106(8): 1602-8. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1997		
China	University of Hong Kong. China - Hong Kong Drug Market 2000.	1996-1998, 2000		
China	Hon KL, Leung E, Hung E, Tang J, Chow CM, Leung TF, Cheung KL, Ng PC. Premorbid factors and outcome associated with respiratory virus infections in a pediatric intensive care unit. <i>Pediatr Pulmonol</i> . 2008; 43(3): 275-80.	2004-2007	*	
China	Sung RYT, Chan PKS, Tsen T, Li AM, Lam WY, Yeung ACM, Nelson EAS. Identification of viral and atypical bacterial pathogens in children hospitalized with acute respiratory infections in Hong Kong by multiplex PCR assays. <i>J Med Virol</i> . 2009; 81(1): 153-9.	2005-2006	*	
China	Liu XZ, Xu LR, Hu Y, Nance WE, Sismanis A, Zhang SL, Xu Y. Epidemiological studies on hearing impairment with reference to genetic factors in Sichuan, China. <i>Ann Otol Rhinol Laryngol</i> . 2001; 110(4): 356-63.	1998-2000		
China	Chen C-Y, Liu C-Y, Su W-C, Huang S-L, Lin K-M. Factors associated with the diagnosis of neurodevelopmental disorders: a population-based longitudinal study. <i>Pediatrics</i> . 2007; 119(2): e435-443.	1998-2001		
China	Hou JW, Wang TR, Chuang SM. An epidemiological and aetiological study of children with intellectual disability in Taiwan. <i>J Intellect Disabil Res</i> . 1998; 42 (Pt 2): 137-43.	1982		
China	Wen H, Zhang Z, Huang J, Duan L, Wang Q. Mortality of dementia and its major subtypes in urban and rural communities of Beijing. <i>Biomed Environ Sci</i> . 2011; 24(5): 483-90.	1997-2001		
China	Fu S, Chen G, Dong J, Zhang L. Prevalence and etiology of hearing loss in primary and middle school students in the Hubei Province of China. <i>Audiol Neurootol</i> . 2010; 15(6): 394-8.	2007-2009		
China	Merikangas KR, Jin R, He J-P, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Ladea M, Medina-Mora ME, Ono Y, Posada-Villa J, Sagar R, Wells JE, Zarkov Z. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. <i>Arch Gen Psychiatry</i> . 2011; 68(3): 241-51.	2006-2007	*	
China	Zhong B, Ding J, Chen H, Li Y, Xu H, Tong J, Wang A, Tang G, Zhu J, Yang D, Liu B, Wang Q, Cheng W, Yin E, Xu M, Zhang T, Hu T, Feng X, Li H, Dan T, Cheng G, Zhang J, Li H, Zhu J. Depressive disorders among children in the transforming China: an epidemiological survey of prevalence, correlates, and service use. <i>Depress Anxiety</i> . 2013; 30(9): 881-92.	2009-2010	*	
China	Chen X, Zhang M, Huang D, Huang M, Xiong Y, Xie M, Shou Y, Li M, Wu C, Zeng H, Li X, Zheng M. An epidemiologic investigation of acute rheumatic fever and rheumatic heart disease among students aged 5-18 in west area of Sichuan Province. <i>J Sichuan Univ Med Sci Ed</i> . 2003; 34(3): 533-5.	1993-1994		
China	Zhimin W, Yubao Z, Lei S, Xianliang Z, Wei Z, Li S, Hao W, Jianjun L, Detrano R, Rutai H. Prevalence of chronic rheumatic heart disease in Chinese adults. <i>Int J Cardiol</i> . 2006; 107(3): 356-9.	2001-2002		
China	Pi X, Cui L, Liu A, Zhang J, Ma Y, Liu B, Cai C, Zhu C, Zhou T, Chen J, Zhou Z, Wang C, Li L, Li S, Wu J, Xiao B. Investigation of prevalence, clinical characteristics and management of epilepsy in Yueyang city of China by a door-to-door survey. <i>Epilepsy Res</i> . 2012; 101(1-2): 129-34.	2010	*	†
China	Zhao Y-H, Zhang Q, Long N, Yang C, Hong J, Mu L, Zhou D. Prevalence of epilepsy and alcohol-related risk in Zayul County, Tibet Autonomous Region in China: an initial survey. <i>Epilepsy Behav</i> . 2010; 19(4): 635-8.	2008	*	
China	Lao TT, Sahota DS, Cheng YKY, Law LW, Leung TY. Advanced maternal age and postpartum hemorrhage - risk factor or red herring? <i>J Matern Fetal Neonatal Med</i> . 2014 Feb;27(3):243-6. doi: 10.3109/14767058.2013.807240. Epub 2013 Jul 23.PMID: 23713943.	1998-2008	*	
China	Liu X, Du J, Wang G, Chen Z, Wang W, Xi Q. Effect of pre-pregnancy body mass index on adverse pregnancy outcome in north of China. <i>Arch Gynecol Obstet</i> . 2011; 283(1): 65-70.	2007-2009	*	
China	Lao TT, Sahota DS, Cheng YKY, Law LW, Leung TY. Maternal hepatitis B surface antigen status and incidence of pre-eclampsia. <i>J Viral Hepat</i> . 2013; 20(5): 343-9.	1995-2009	*	
China	Li Z, Ye R, Zhang L, Li H, Liu J, Ren A. Folic acid supplementation during early pregnancy and the risk of gestational hypertension and preeclampsia. <i>Hypertension</i> . 2013; 61(4): 873-9.	1993-1996	*	
China	Shen J, Yang Z, Wang J. [Study on clinical risk of maternal underlying medical conditions and onset of preeclampsia]. <i>Chin J Obstet Gynecol</i> . 2012; 47(6): 405-11.	2008-2011	*	
China	Zhang J, Li H, Wang X, Hou H. [Comparative study of pregnancy outcomes between spontaneous twin pregnancies and twin pregnancies after fetal reduction in the second trimester]. <i>Chin J Obstet Gynecol</i> . 2011; 46(12): 901-4.	2007-2010	*	
China	Chow DKL, Leong RWL, Tsoi KKF, Ng SSM, Leung W, Wu JCY, Wong VWS, Chan FKL, Sung JYJ. Long-term follow-up of ulcerative colitis in the Chinese population. <i>Am J Gastroenterol</i> . 2009; 104(3): 647-54.	1986-2006	*	
China	Li LL, Ma Y, Chen R, Liu ZM, Qin X, et al. Prevalence of dementia among the elderly in rural community of Anhui. <i>Chin J Dis Control Prev</i> . 2011; 15(4): 292-4.	2008		
China	Zhe, Tang, Chen, Meng, Donghui Qing. [Beijing urban and rural senile dementia prevalence study 1]. <i>Chin J Gerontol</i> . 2002; 22(04): 244-8.	1997		
China	Zhenxin Zhang, Jing Wei, Xia Hong. Prevalence of dementia and major subtypes in urban and rural communities of Beijing. <i>Chin J Neurol</i> . 2001; 34(4): 199-203.	1998-1999		
China	Shen Y, Tang M. The epidemiologic survey of mild cognitive impairment and dementia among residents aged 65 years and over in the urban and the rural areas in Guangzhou [dissertation]. [Guangzhou, China]: Guangzhou Medical University; 2011. 72 p.	2011		
China	Huang W, Yang X, Yang JY. Investigation on prevalence of dementia among elderly in urban communities of Guiyang city. <i>Chin J Public Health</i> . 2007; 23(8): 983-6.	2005		
China	Kang M, Gao YM, Huo HQ. Prevalence of Alzheimer's disease and its related factors among elderly people in Hebei province. <i>Chin J Public Health</i> . 2011; 27(9): 1123-5.	2010		
China	Xiu-Shan He. Analysis of the Status and Influence of Alzheimer's Disease in Rural Communities. <i>J Jiujiang Univ Natural Sci</i> . 2012; 29-32.	2011		
China	Wang Feng, Xu Pin, Zhu Sihui. Survey on the awareness rate and prevalence of Alzheimer's disease in the urban area of Zaozhuang City. <i>Chin J Practical Nerv Dis</i> . 2010; 13(23): 9-11.	2010		
China	Qing-Hua Fan. Study and Analysis of Impact Factors and Health Service of Dementia in Shanxi Province [dissertation]. Shanxi, China:Shanxi Medical University;2012. 115 p.	2008		
China	Guo-ying Ye, Jian-er Chen, Kai-Zhong Shen. Dementia in people over 60 years old and related risk factors. <i>Chin Rural Health Serv Adm</i> . 2011; 31(2): 152.	2011		
China	Guo-Chuan Zhang, Bao-Long Zhao. [A survey of prevalence of senile dementia and parkinson disease]. <i>J Clin Psychol Med</i> . 2001; 143-5.	1986, 1999		
China	Fang X-H, Wang W-H, Zhang X-Q, Liu H-J, Zhang H-M, Qin X-M, Wang Z-C, Ji X-M, Li L-M. Incidence and survival of symptomatic lacunar infarction in a Beijing population: a 6-year prospective study. <i>Eur J Neurol</i> . 2012; 19(8): 1114-20.	2003-2008	*	
China	Ferri CP, Schoenborn C, Kalra L, Acosta D, Guerra M, Huang Y, Jacob KS, Rodriguez JLL, Salas A, Sosa AL, Williams JD, Liu Z, Moriyama T, Valhuerdi A, Prince MJ. Prevalence of stroke and related burden among older people living in Latin America, India and China. <i>J Neurol Neurosurg Psychiatry</i> . 2011; 82(10): 1074-82.	2007-2009	*	
China	Zhao Y, Yao Z, D'Souza W, Zhu C, Chun H, Zhuoga C, Zhang Q, Hu X, Zhou D. An Epidemiological Survey of Stroke in Lhasa, Tibet, China. <i>Stroke</i> . 2010; 41(12): 2739-43.	2006-2008	*	
China	Li SZ. [Epidemiologic study of epilepsy in six cities in China]. <i>Chin J Neurol Psychiatry</i> . 1986; 19(4): 193-6.	1983	*	
China	Yang L, Li S, Wang W, Fang X. Epidemiologic survey of epilepsy in rural area and minority nationality in China. <i>Chin J Neurosurg</i> . 1989; 22-7.	1985	*	
China	Liu X, Guo Q, Zhang Y, Su W, Li Z, Yu Y. Epidemiologic survey of epilepsy in 160,000 population in Shanxi province. <i>J Fourth Mil Med Uni</i> . 1990; 338-41.	1986	*	
China	Li F, Gao C, Qi M. The epidemiologic survey of epilepsy of 100,000 population in Qinghai province. <i>Qinghai Med J</i> . 1997; 1-3.	1987	*	
China	Chen C-C, Chen T-F, Hwang Y-C, Wen Y-R, Chiu Y-H, Wu C-Y, Chen R-C, Chen TH-H, Liou H-H. Population-based survey on prevalence of adult patients with epilepsy in Taiwan (Keelung community-based integrated screening no. 12). <i>Epilepsy Res</i> . 2006; 72(1): 67-74.	2001	*	
China	Fong GCY, Kwan P, Hui ACF, Lui CHT, Fong JKY, Wong V. An epidemiological study of epilepsy in Hong Kong SAR, China. <i>Seizure</i> . 2008; 17(5): 457-64.	2003	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
China	Su C, Chang S, Chen Z, Lee C, Chen R. Neuroepidemiological survey in Ilan, Taiwan (NESTT): (4) Prevalence of epilepsy. <i>Acta Neurol Taiwan</i> . 1998; 7(2): 75-84.	1993-1995	*	†
China	Wang W, Wu J, Wang D, Chen G, Wang T, Yuan C, Yang B, Zhao D. [Epidemiological survey on epilepsy among rural populations in five provinces in China]. <i>Nat Med J Chin</i> . 2002; 82(7): 449-52.	1999-2000	*	†
China	Zhao Y, Zhang Q, Tsering T, Sangwan, Hu X, Liu L, Shang H, Chen Q, Liu Y, Yang X, Wang W, Li S, Wu J, Sander JW, Zhou D. Prevalence of convulsive epilepsy and health-related quality of life of the population with convulsive epilepsy in rural areas of Tibet Autonomous Region in China: an initial survey. <i>Epilepsy Behav</i> . 2008; 12(3): 373-81.	2006		†
China	Liu XH. [An epidemiological survey of epilepsy in 42 thousand population in Sichuan Province (author's transl)]. <i>Chin J Neurol Psychiatry</i> . 1981; 14(3): 135-8.	1973-1975	*	
China	Xu G, Huang Y, Chen Y, Du F. Treatment gap of epilepsy in a rural Chinese community: A population based study. <i>Epilepsia</i> . 2003; 44(Suppl 8): 194.	2002	*	
China	Xue JT. [An investigation of the prevalence of epilepsy in three northwestern provinces of China]. <i>Chin J Epidemiol</i> . 1987; 8(3): 165-7.	1984	*	
China	Zhang X. Investigate report of epilepsy incidence in 600,000 population. <i>J Pract Internal Med</i> . 1986; 602-4.	1983-1985	*	
China	Hsieh L-P, Huang C-Y. Prevalence of treated epilepsy in western medicine among the adult population in Taiwan: a study conducted using antiepileptic drug prescription data. <i>Epilepsy Res</i> . 2008; 80(2-3): 114-8.	2004	*	
China	Huang M, Hong Z, Zeng J, Rong X, Sheng Y, Lu C. [The prevalence of epilepsy in rural Jinshan in Shanghai]. <i>Chin J Epidemiol</i> . 2002; 23(5): 345-6.	2000	*	
China	Wong V. Study of seizure and epilepsy in Chinese children in Hong Kong: period prevalence and patterns. <i>J Child Neurol</i> . 2004; 19(1): 19-25.	1997	*	
China	Fong GCY, Mak W, Cheng TS, Chan KH, Fong JKY, Ho SL. A prevalence study of epilepsy in Hong Kong. <i>Hong Kong Med J</i> . 2003; 9(4): 252-7.	2002	*	
China	Chen N, Wang W, Huang Y, Shen P, Pei D, Yu H, Shi H, Zhang Q, Xu J, Lv Y, Fan Q. Community-based study on CKD subjects and the associated risk factors. <i>Nephrol Dial Transplant</i> . 2009; 24(7): 2117-23.	1992, 1999, 2002, 2006		
China	Chen J, Wildman RP, Gu D, Kusek JW, Spruill M, Reynolds K, Liu D, Hamm LL, Whelton PK, He J. Prevalence of decreased kidney function in Chinese adults aged 35 to 74 years. <i>Kidney Int</i> . 2005; 68(6): 2837-45.	1999-2001		
China	Zhang L, Zhang P, Wang F, Zuo L, Zhou Y, Shi Y, Li G, Jiao S, Liu Z, Liang W, Wang H. Prevalence and factors associated with CKD: a population study from Beijing. <i>Am J Kidney Dis</i> . 2008; 51(4): 373-84.	2006-2008		
China	Chen R, Hu Z, Qin X, Xu X, Copeland JRM. A community-based study of depression in older people in Hefei, China – the GMS-AGECAT prevalence, case validation and socio-economic correlates. <i>Int J Geriatr Psychiatry</i> . 2004; 19(5): 407-13.	2001		
China	Lu J, Ruan Y, Huang Y, Yao J, Dang W, Gao C. Major depression in Kunming: prevalence, correlates and co-morbidity in a south-western city of China. <i>J Affect Disord</i> . 2008; 111(2-3): 221-6.	2005-2006		
China	Chen Y-D, Liu M-Y, Yu W-L, Li J-Q, Peng M, Dai Q, Liu X, Zhou Z-Q. Hepatitis C virus infections and genotypes in China. <i>HBPD Int</i> . 2002; 1(2): 194-201.	2002		
China	Shi J, Zhu L, Liu S, Xie W-F. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. <i>Br J Cancer</i> . 2005; 92(3): 607-12.	1995-2004		
China	Wang B-E, Ma W-M, Sulaiman A, Noer S, Sumoharjo S, Sumarsidi D, Tandon BN, Nakao K, Mishihiro S, Miyakawa Y, Akahane Y, Suzuki H. Demographic, clinical, and virological characteristics of hepatocellular carcinoma in Asia: survey of 414 patients from four countries. <i>J Med Virol</i> . 2002; 67(3): 394-400.	2002		
China	Bromet E, Andrade LH, Huang I, Sampson NA, Alonso J, de Girolamo G, de Graaf R, Demyttenaere K, Hu C, Iwata N, Karam AN, Kaur J, Kostyuchenko S, Lépine J-P, Levinson D, Matschinger H, Mora MEM, Browne MO, Posada-Villa J, Viana MC, Williams DR, Kessler RC. Cross-national epidemiology of DSM-IV major depressive episode. <i>BMC Med</i> . 2011; 9: 90.	2006-2007	*	
China	Lee S, Tsang A, Huang Y-Q, He Y-L, Liu ZR, Zhang M-Y, Shen Y-C, Kessler RC. The epidemiology of depression in metropolitan China. <i>Psychol Med</i> . 2009; 39(5): 735-47.	2001-2002	*	
China	Reynolds K, Gu D, Munter P, Kusek JW, Chen J, Wu X, Duan X, Chen CS, Klag MJ, Whelton PK, He J. A population-based, prospective study of blood pressure and risk for end-stage renal disease in China. <i>J Am Soc Nephrol</i> . 2007; 18(6): 1928-35.	1991-2000		
China	Yao Q, Zhang W, Qian J. Dialysis status in China: a report from the Shanghai Dialysis Registry (2000-2005). <i>Ethn Dis</i> . 2009; 19(1 Suppl 1): S23-6.	1999-2005		
China	Li N, Chen G, Song X, Du W, Zheng X. Prevalence of autism-caused disability among Chinese children: a national population-based survey. <i>Epilepsy Behav</i> . 2011; 22(4): 786-9.	2006	*	
China	Guan B-Q, Luo X-R, Deng Y-L, Wei Z, Ye H-S, Yuan X-H, Ning Z-J, Yang W, Ding J. [Prevalence of psychiatric disorders in primary and middle school students in Hunan Province]. <i>Chin J Contemp Pediatr</i> . 2010; 12(2): 123-7.	2008	*	
China	Tang W, Wen X-J, Liu Q-J, Zhang ZZ, Yanli X, Zhang B, Sha B, Ye TM, Lin CC, Tu X, Chen S, Chen G, Ye JG, Sun H. Epidemiological Investigation on Schizophrenia in Wenzhou Areas. <i>Chin Prev Med</i> . 2005; 6(4): 301-2.	2002-2003		
China	Cui L, Li K, Cui Z, Jiang Q, Gao L, Zhang Y, Li J. Prevalence, demographic characteristics and function status of the schizophrenia in Hebei province. <i>Chin J Nerv Ment Dis</i> . 2007; 33(3).	2003-2004		
China	Tao L, Huang F, Zhou Y, Li Q, Liang H, Li G, Wei H, Zhou L, Feng Q. Epidemiological survey of schizophrenia in urban and rural in Guilin, China. <i>J Guangxi Med Univ</i> . 2011.	2007		
China	Li X, Zhu Z, Zhu J, Lu W, Zhu J. An Epidemiological Survey on schizophrenia in Yancheng of Jiangsu Province. <i>Nerv Dis Mental Hyg</i> . 2003; 3(5): 356-57.	1999		
China	Xiaoyong L, Helong C, Bin H. Epidemiological survey on prevalence of schizophrenia in Jiangxi province. <i>Shanghai Arch Psychiatry</i> . 2004; 16(4): 014.	2002		
China	Onozaki I. Prevalence Survey Global Overview: Background, Survey results since 2007, Lessons and Implications to the Program. Presented at: WHO Multi-country Global Workshop on TB Prevalence Surveys and TB Surveillance; 2013 April 29 - May 3; Accra, Ghana. PowerPoint presentation.	2010		
China	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
China	Chinese Center for Disease Control and Prevention (CCDC). China National Tuberculosis Survey 1984-1985.	1984-1985		
China	Chinese Center for Disease Control and Prevention (CCDC). China National Tuberculosis Prevalence Survey 1990.	1990		
China	Leung PW, Luk SL, Ho TP, Taylor E, Mak FL, Bacon-Shone J. The diagnosis and prevalence of hyperactivity in Chinese schoolboys. <i>Br J Psychiatry</i> . 1996; 168(4): 486-96.	1994	*	
China	Hong S, Xin C, Qianhong Y, Yanan W, Wenyan X, Peeling RW, Mabey D. Pelvic inflammatory disease in the People's Republic of China: aetiology and management. <i>Int J STD AIDS</i> . 2002; 13(8): 568-72.	2000-2001	*	†
China	Department of Health (Hong Kong). China - Hong Kong Injury Survey 2008.	2008		
China	United Nations Children's Fund (UNICEF). Child Mortality and Injury in Asia. New York, United States: United Nations Children's Fund (UNICEF). 2008. (Innocenti Working Papers: Special Series on Child Injuries Nos. 1-4).	2003, 2005	*	
China	Li C, Wu M, Wang J, Zhang S, Zhu L, Pan J, Zhang W. A population-based study on the risks of cervical lesion and human papillomavirus infection among women in Beijing, People's Republic of China. <i>Cancer Epidemiol Biomarkers Prev</i> . 2010; 19(10): 2655-64.	2006-2009	*	
China	Congdon N, Wang Y, Song Y, Choi K, Zhang M, Zhou Z, Xie Z, Li L, Liu X, Sharma A, Wu B, Lam DSC. Visual disability, visual function, and myopia among rural Chinese secondary school children: the Xichang Pediatric Refractive Error Study (X-PRES)-Report 1. <i>Invest Ophthalmol Vis Sci</i> . 2008; 49(7): 2888-94.	2007		
China	Dunzhu S, Wang FS, Courtright P, Liu L, Tenzing C, Noertojo K, Wilkie A, Santangelo M, Bassett KL. Blindness and eye diseases in Tibet: findings from a randomised, population based survey. <i>Br J Ophthalmol</i> . 2003; 87(12): 1443-8. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	1999-2000		
China	Wu M, Yip JLY, Kuper H. Rapid assessment of avoidable blindness in Kunming, China. <i>Ophthalmology</i> . 2008; 115(6): 969-74. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2006		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
China	Zhao J, Jia L, Sui R, Ellwein LB. Prevalence of blindness and cataract surgery in Shunyi County, China. <i>Am J Ophthalmol</i> . 1998; 126(4): 506-14. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	1996		
China	He M, Zeng J, Liu Y, Xu J, Pokharel GP, Ellwein LB. Refractive error and visual impairment in urban children in southern China. <i>Invest Ophthalmol Vis Sci</i> . 2004; 45(3): 793-9.	2002-2003		
China	He M, Huang W, Zheng Y, Huang L, Ellwein LB. Refractive error and visual impairment in school children in rural southern China. <i>Ophthalmology</i> . 2007; 114(2): 374-82. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2005		
China	Sun Y, Pei W, Wu Y, Wang G. [Association of herpes simplex virus type2 infection with dyslipidemia in Chinese]. <i>Nat Med J Chin</i> . 2003; 83(20): 1774-7.	2000-2002	*	
China	Lu Q, Zheng Y, Sun B, Cui T, Congdon N, Hu A, Chen J, Shi J. A population-based study of visual impairment among pre-school children in Beijing: the Beijing study of visual impairment in children. <i>Am J Ophthalmol</i> . 2009; 147(6): 1075-81. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2004		
China	Xiao B, Fan J, Deng Y, Ding Y, Muht M, Kuper H. Using key informant method to assess the prevalence and causes of childhood blindness in Xiushui County, Jiangxi Province, Southeast China. <i>Ophthalmic Epidemiol</i> . 2011; 18(1): 30-5. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2009		
China	Song W, Sun X, Shao Z, Zhou X, Kang Y, Sui H, Yuan H. Prevalence and causes of visual impairment in a rural North-east China adult population: a population-based survey in Bin County, Harbin. <i>Acta Ophthalmol</i> . 2010; 88(6): 669-74. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2007		
China	China - Inner Mongolia Shanguo Rapid Assessment of Avoidable Blindness 2010 [Unpublished] as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2010		
China	China - Inner Mongolia Tuoketuo Rapid Assessment of Avoidable Blindness 2010 [Unpublished] as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2010		
China	China - Sichuan Dechang Rapid Assessment of Avoidable Blindness 2011 [Unpublished] as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2011		
China	China - Sichuan Mianning Rapid Assessment of Avoidable Blindness 2011 [Unpublished] as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2011		
China	Chinese Center for Disease Control and Prevention (CCDC). <i>China Disease Surveillance Points 2007 - China CDC</i> . [Unpublished].	2007	*	†
China	Lam BC, Yeung CY. Perinatal features of birth asphyxia and neurologic outcome. <i>Acta Paediatr Jpn</i> . 1992; 34(1): 17-22.	1985-1987	*	†
China	Liu L, Zheng C-X, Peng S-F, Zhou H-Y, Su Z-Y, He L, Ai T. Evaluation of urinary S100B protein level and lactate/creatinine ratio for early diagnosis and prognostic prediction of neonatal hypoxic-ischemic encephalopathy. <i>Neonatology</i> . 2010; 97(1): 41-4.	2003-2005	*	†
China	Le C, Jun D, Zhankun S, Yichun L, Jie T. Socioeconomic differences in diabetes prevalence, awareness, and treatment in rural southwest China. <i>Trop Med Int Health</i> . 2011; 16(9): 1070-6.	2008-2010		
China	Lee KMC, Sum WMR. Prevalence of diabetic retinopathy in patients with recently diagnosed diabetes mellitus. <i>Clin Exp Optom</i> . 2011; 94(4): 371-5.	2006-2009		
China	Lu B, Yang Z, Wang M, Yang Z, Gong W, Yang Y, Wen J, Zhang Z, Zhao N, Zhu X, Hu R. High prevalence of diabetic neuropathy in population-based patients diagnosed with type 2 diabetes in the Shanghai downtown. <i>Diabetes Res Clin Pract</i> . 2010; 88(3): 289-94.	2006		
China	Ruan Y, Mo M, Joss-Moore L, Li YY, Yang QD, Shi L, Zhang H, Li R, Xu WH. Increased waist circumference and prevalence of type 2 diabetes and hypertension in Chinese adults: two population-based cross-sectional surveys in Shanghai, China. <i>BMJ Open</i> . 2013; 3(10): e003408.	2002-2003, 2009		
China	Wei W, Liu S-Y, Zeng F-F, Yao S-P, Zhang H-T, Wan G, Zhong M, Yang Z, Wang B-Y. Type 2 diabetes and impaired glucose tolerance in North-China-based rural community adults. <i>Public Health</i> . 2010; 124(10): 593-601.	2005		
China	Xia Z, Wang Z, Cai Q, Yang J, Zhang X, Yang T. Prevalence and risk factors of type 2 diabetes in the adults in haikou city, hainan island, china. <i>Iran J Public Health</i> . 2013; 42(3): 222-30.	2010-2011		
China	Zhou X, Pang Z, Gao W, Wang S, Zhang L, Ning F, Qiao Q. Performance of an A1C and fasting capillary blood glucose test for screening newly diagnosed diabetes and pre-diabetes defined by an oral glucose tolerance test in Qingdao, China. <i>Diabetes Care</i> . 2010; 33(3): 545-50.	2006		
China	Fu H, Shen SX, Chen ZW, Wang JJ, Ye TT, LaPorte RE, Tajima N. Shanghai, China, has the lowest confirmed incidence of childhood diabetes in the world. <i>Diabetes Care</i> . 1994; 17(10): 1206-8.	1980-1991		
China	Li XH, Li TL, Yang Z, Liu ZY, Wei YD, Jin SX, Hong C, Qin RL, Li YQ, Dorman JS, Laporte RE, Wang KA. A nine-year prospective study on the incidence of childhood type 1 diabetes mellitus in China. <i>Biomed Environ Sci</i> . 2000; 13(4): 263-70.	1988-1996		
China	Li R, Lu W, Jiang QW, Li YY, Zhao GM, Shi L, Yang QD, Ruan Y, Jiang J, Zhang SN, Xu WH, Zhong WJ. Increasing prevalence of type 2 diabetes in Chinese adults in Shanghai. <i>Diabetes Care</i> . 2012; 35(5): 1028-30.	2002-2003, 2009		
China	Liu M, Wang Z, Sun X, Chen Y, Zhang Q. Rapid increase in the incidence of clinically diagnosed type 2 diabetes in Chinese in Harbin between 1999 and 2005. <i>Prim Care Diabetes</i> . 2007; 1(3): 123-8.	1999-2005		
China	Shen SX, Wang HB, Chen ZW, Shen YE, Fu H, Wu CE, Ye TT, Wang JJ, Wang KA, Li TL, Yang Z, LaPorte RE, Dorman JS. The incidence of insulin-dependent diabetes mellitus in urban districts of Shanghai (1989-1993). <i>J Pediatr Endocrinol Metab</i> . 1996; 9(4): 469-73.	1989-1993		
China	Tam VHK, Lam EPK, Chu BCY, Tse KK, Fung LM. Incidence and progression of diabetic retinopathy in Hong Kong Chinese with type 2 diabetes mellitus. <i>J Diabetes Complicat</i> . 2009; 23(3): 185-93.	2001-2005		
China	Zhang H, Xia W, Yu Q, Wang B, Chen S, Wang Z, Love EJ. Increasing incidence of type 1 diabetes in children aged 0-14 years in Harbin, China (1990-2000). <i>Prim Care Diabetes</i> . 2008; 2(3): 121-6.	1990-2000		
China	Zhang L, Ruan Y, Jiang Z, Yang Z, Liu S, Zhou F, He Y, Yin L, Qin G, Shao Y. [An 1-year prospective cohort study on mortality of injecting drug users]. <i>Chin J Epidemiol</i> . 2005; 26(3): 190-3.	2002-2003	*	
China	Yue PC, Strickland M. Glucose-6-phosphate-dehydrogenase deficiency and neonatal jaundice in Chinese male infants in Hong Kong. <i>Lancet</i> . 1965; 1(7381): 350-1.	1963-1965		
China	Fung RH, Keung YK, Chung GS. Screening of pyruvate kinase deficiency and G6PD deficiency in Chinese newborn in Hong Kong. <i>Arch Dis Child</i> . 1969; 44(235): 373-6.	1968		
China	Xu Y. Investigation of RBC-G6PD deficiency gene frequency in 9 nationality populations in 7 provinces (autonomous regions). <i>Heredity Dis</i> . 1985; 2: 67-71.	1983		
China	Lam STS, Cheng ML. Neonatal screening in Hong Kong and Macau. <i>Southeast Asian J Trop Med Public Health</i> . 2003; 73: 5.	1984-2000		
China	Jiang W, Yu G, Liu P, Geng Q, Chen L, Lin Q, Ren X, Ye W, He Y, Guo Y, Duan S, Wen J, Li H, Qi Y, Jiang C, Zheng Y, Liu C, Si E, Zhang Q, Tian Q, Du C. Structure and function of glucose-6-phosphate dehydrogenase-deficient variants in Chinese population. <i>Hum Genet</i> . 2006; 119(5): 463-78.	1993-2004		
China	Xiu J, Qi X-L, Shan K-R, Xie Y, He Y, Wu C-X, Li Y, Wu X-L, Ren X-L. G6PD Gene Mutations in Shui people in Sandu of Guizhou. <i>J Experiment Hematol</i> . 2005; 13(1): 147-50.	1999-2001		
China	Au W-Y, Ma ESK, Lam VMS, Chan JLC, Pang A, Kwong Y-L. Glucose 6-phosphate dehydrogenase (G6PD) deficiency in elderly Chinese women heterozygous for G6PD variants. <i>Am J Med Genet A</i> . 2004; 129A(2): 208-11.	2002-2004		
China	Yan T, Cai R, Mo O, Zhu D, Ouyang H, Huang L, Zhao M, Huang F, Li L, Liang X, Xu X. Incidence and complete molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Guangxi Zhuang autonomous region of southern China: description of four novel mutations. <i>Haematologica</i> . 2006; 91(10): 1321-8.	2002-2003		
China	Lui P. Glucose-6-phosphate dehydrogenase gene mutations in She nationality, Fujian province. <i>Chin J Hematol</i> . 2005; 26(10): 612-5.	2003-2005		
China	Yang Y, Zhu Y, Li D, Li Z, Lü H, Wu J, Tang J, Tong S. Characterization of glucose-6-phosphate dehydrogenase deficiency and identification of a novel haplotype 487G>A/IVS5-612(G>C) in the Achang population of Southwestern China. <i>Sci China C Life Sci</i> . 2007; 50(4): 479-85.	2005-2007		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
China	Li PK, Kwan BC, Leung CB, Kwan TH, Wong KM, Lui SL, Tsang WK, Mak CC, Mak SK, Yu AW, Tang S; Hong Kong Society of Nephrology. Prevalence of silent kidney disease in Hong Kong: the screening for Hong Kong Asymptomatic Renal Population and Evaluation (SHARE) program. <i>Kidney Int Suppl.</i> 2005; 94: S36-40.	1996		
China	Lee G. End-stage renal disease in the Asian-Pacific region. <i>Semin Nephrol.</i> 2003; 23(1): 107-14.	1998		
China	Chinese Center for Disease Control and Prevention (CCDC). China Disease Surveillance Points 1994 - China CDC. [Unpublished].	1994	*	†
China	Chinese Center for Disease Control and Prevention (CCDC). China Disease Surveillance Points 1995 - China CDC. [Unpublished].	1995	*	†
China	Chinese Center for Disease Control and Prevention (CCDC). China Disease Surveillance Points 1997 - China CDC. [Unpublished].	1997	*	†
China	Zuo L, Wang M. Beijing Hemodialysis Quality Control and Improvement Center. Current status of hemodialysis treatment in Beijing, China. <i>Ethn Dis.</i> 2006; 16(2 Suppl 2): 31-4.	2003-2004		
China	Yen TS. Regular dialysis in the Republic of China. <i>Dialysis Surveillance Group. Contrib Nephrol.</i> 1990; 82: 15-24.	1988		
China	Chen X, Yang D, Mo Y, Li L, Chen Y, Huang Y. Prevalence of polycystic ovary syndrome in unselected women from southern China. <i>Eur J Obstet Gynecol Reprod Biol.</i> 2008; 139(1): 59-64.	2005-2006		
China	Association S of CCM, Cheng K. Retrospective investigation of hospitalized patients with heart failure in some parts of China, in 1980, 1990 and 2000. <i>Chin J Cardiol.</i> 2002; 30(8): 450-4.	1980, 1990, 2000		
China	Parkin DM. International Agency for Research on Cancer, International Association of Cancer Registries. <i>Cancer Incidence in Five Continents. Vol. 1 to VIII.</i> Lyon, France, IARC Press, 2005.	1978-1987	*	
China	Holmgren CJ, Corbet EF, Lim LP. Periodontal conditions among the middle-aged and the elderly in Hong Kong. <i>Community Dent Oral Epidemiol.</i> 1994; 22(5 Pt 2): 396-402.	1991		
China	Hu CZ, Huang CR, Rong S, Zhang W, Wu J, Pilot T. Periodontal conditions in elderly people of Shanghai, People's Republic of China, in 1986. <i>Community Dent Health.</i> 1990; 7(1): 69-71.	1986		
China	Okamoto H, Yoneyama T, Lindhe J, Haffajee A, Socransky S. Methods of evaluating periodontal disease data in epidemiological research. <i>J Clin Periodontol.</i> 1988; 15(7): 430-9.	1986		
China	Ochiai RL, Wang X, von Seidlein L, Yang J, Bhutta ZA, Bhattacharya SK, Agtini M, Deen JL, Wain J, Kim DR, Ali M, Acosta CJ, Jodar L, Clemens JD. <i>Salmonella Paratyphi A Rates, Asia. Emerg Infect Dis.</i> 2005; 11(11): 1764-6.	2001-2002	*	
China	Chen W, Liu Q, Wang H, Chen W, Johnson RJ, Dong X, Li H, Ba S, Tan J, Luo N, Liu T, He H, Yu X. Prevalence and risk factors of chronic kidney disease: a population study in the Tibetan population. <i>Nephrol Dial Transplant.</i> 2011; 26(5): 1592-9.	2007-2009	*	
China	Liu Q, Li Z, Wang H, Chen X, Dong X, Mao H, Tan J, Luo N, Johnson RJ, Chen W, Yu X, Chen W. High prevalence and associated risk factors for impaired renal function and urinary abnormalities in a rural adult population from southern China. <i>PLoS One.</i> 2012; 7(10): e47100.	2006-2007	*	
China	Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, Chen M, He Q, Liao Y, Yu X, Chen N, Zhang J, Hu Z, Liu F, Hong D, Ma L, Liu H, Zhou X, Chen J, Pan L, Chen W, Wang W, Li X, Wang H. Prevalence of chronic kidney disease in China: a cross-sectional survey. <i>Lancet.</i> 2012; 379(9818): 815-22.	2009-2010	*	
China	Shan Y, Zhang Q, Liu Z, Hu X, Liu D. Prevalence and risk factors associated with chronic kidney disease in adults over 40 years: a population study from Central China. <i>Nephrology (Carlton).</i> 2010; 15(3): 354-61.	2007-2008	*	
China	GUO Chaobin, GAO Xian, PANG Zengchang. Analyses on hearing loss and its related factors in middle and old aged persons in Jiaonan of Qingdao. <i>Med J Qilu.</i> 2012; 27(5): 426-29.	2009-2011	*	
China	LI Zong-hua, XU Zhan, CHEN Yang, et al. Hearing status among middle school students in Xi'an - an epidemiological survey. <i>Chin J Otol.</i> 2009; 7(1): 30-34.	2006-2008	*	
China	ZHU Yu-hua, JI Fei, YU Ning, et al. The Distribution of Hearing Levels and the Self-cognitive Abilities of the Elderly People in a Community in Beijing. <i>Chin Sci J Hear Speech Rehabil.</i> 2013; 58: 185-87.	2006-2008	*	
China	Chinese Center for Disease Control and Prevention (CCDC), Ministry of Health (China). China National Injury Surveillance System 2006 - China CDC. [Unpublished].	2006	*	
China	Chinese Center for Disease Control and Prevention (CCDC), Ministry of Health (China). China National Injury Surveillance System 2007 - China CDC. [Unpublished].	2007	*	
China	Chinese Center for Disease Control and Prevention (CCDC), Ministry of Health (China). China National Injury Surveillance System 2008 - China CDC. [Unpublished].	2008	*	
China	Chinese Center for Disease Control and Prevention (CCDC), Ministry of Health (China). China National Injury Surveillance System 2009 - China CDC. [Unpublished].	2009	*	
China	Chinese Center for Disease Control and Prevention (CCDC), Ministry of Health (China). China National Injury Surveillance System 2010 - China CDC. [Unpublished].	2010	*	
China	Chinese Center for Disease Control and Prevention (CCDC), Ministry of Health (China). China National Injury Surveillance System 2011 - China CDC. [Unpublished].	2011	*	
China	Chinese Center for Disease Control and Prevention (CCDC), Ministry of Health (China). China National Injury Surveillance System 2012 - China CDC. [Unpublished].	2012	*	
China	Hao W, Su Z, Liu B, Zhang K, Yang H, Chen S, Biao M, Cui C. Drinking and drinking patterns and health status in the general population of five areas of China. <i>Alcohol Alcohol.</i> 2004; 39(1): 43-52.	2002, 2004		
China	Liu S-M, Wei G, Zhang W, Xiang Y, Huang X-Q, Yang C, Huang W-J, Xie W-J, He X, Su X-F, Wang J, Ciren P, Bima Z, Ci P, Za S, Liu X-H. [Epidemiological survey on neuropsychiatric disorders in Tibet of China: neuroses, alcohol-related disorders, mental retardation and epilepsy]. <i>J Sichuan Univ Med Sci Ed.</i> 2012; 43(2): 210-3.	2003		
China	Zhou L, Conner KR, Phillips MR, Caine ED, Xiao S, Zhang R, Gong Y. Epidemiology of alcohol abuse and dependence in rural Chinese men. <i>Alcohol Clin Exp Res.</i> 2009; 33(10): 1770-6.	2007		
China	Chinese Center for Disease Control and Prevention (CCDC). China Injury Comprehensive Surveillance Study 2009-2011 - China CDC. [Unpublished].	2010-2011	*	
China	Jin Z, Shi L, Wang Y-J, Yang L-G, Shi Y-H, Shen L-W, Ren C-C. Prevalence of headache among children and adolescents in Shanghai, China. <i>J Clin Neurosci.</i> 2013; 20(1): 117-21.	2012	*	
China	Xiu-Xiang Li, Yan Yang. Epidemiology survey of epilepsy in Chengde. <i>Hebei Med.</i> 2012; 18(11): 1676-8.	2008-2010	*	
China	Tao Tao, Si-Ming Chang, Shu-Huai Su. Epidemiological survey of Chengguan Townm Dushan District, Guizhou Province. <i>Guizhou Med J.</i> 1994; 120-1.	1987		
China	Ziao-Rong Pi, Ai-Zhong Liu, Jie Zhang. Epidemiological survey of epilepsy in Yueyang of Hunan Province. <i>J Int Neurol Neurosurg.</i> 2012; 39(2): 103-7.	2010	*	
China	Hao T, Min-Tian D, Liang C. Five provinces of East China adult epilepsy epidemiological survey. <i>J Clin Neurol.</i> 1991.	1986	*	
China	Meng H-M, Li Na CL. A survey on the epidemiology of epilepsy in partial rural areas of Jilin Province. <i>J Apoplexy Nerv Dis.</i> 2010.	2008	*	
China	Shan X, Chen R, Deng J. An epidemiological investigation on epilepsy among children 0-14 age in Jiangsu Province. <i>Acta Univ Med Nanjing.</i> 1992; (2): 170-2.	1987-1988		
China	Da G-W. Tibetan farmers epidemiology of epilepsy of Lhasa. <i>Tibet J Med.</i> 1997; 23-4.	1987	*	
China	Ying Lei. Epidemiology and drug treatment of epilepsy research in Qingtongxia, Ningxia. <i>Shanxi Med J.</i> 2008; 37(8): 1068-70.	2003	*	
China	Yan-hui D, Chen G-S, Xiu-Ying D. Epidemiological Survey on Epilepsy in Rural Residents of Ningxia and on Tentative Effectiveness with Single Antiepileptic Drug-Luminal. <i>J Ningxia Med Coll.</i> 2002; 5(24): 316-22.	2000	*	
China	Yan C, Zhang R-L, Wu M-X. Epidemiology of epilepsy in rural Panzhihua City. <i>Sichuan Med J.</i> 1999.	1993	*	
China	Li FB, Gao CL, Qi MW. [Epidemiological study of epilepsy among 100,000 population in Qinghai Province]. <i>Qinghai Med J.</i> 1997; 27: 1-3.	1987	*	
China	En-Gao Liang, Shu-su Guo. Epidemiological survey of epilepsy in Shandong Province. <i>Shandong Med J.</i> 1993; 11(33): 7.	1987	*	
China	Tai-Ping Wang, Mei-Hua Han, Fen-Xia Li. [Twice Epilepsy Epidemiology Survey Report of Shanxi]. <i>Chin J Integr Med Cardio Cerebrovas Dis.</i> 2009; 7(1): 111-2.	2000, 2004	*	
China	Xu Z-G, Wang T-P, Sun Y-P. Epidemiological survey on epilepsy in rural population of Zezhou Shanxi. <i>Proc Clin Med.</i> 2002.	2000	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
China	Liu X-H, Guo Q-T, Zhang Y-D. Epidemiological survey of epilepsy among 160,000 in Shaanxi, China. <i>J Fourth Mil Med Uni.</i> 1990; 338-41.	1987	*	
China	Wei G. The Epidemiology Survey and Study of Preventative and Curative Strategies on Mental Disorders at Tibet in China [dissertation]. [Chengdu]: Sichuan University; 2004. 91 p.	2003	*	
China	Ying Tang, Guo-Zhong Li. Epidemiological survey of epilepsy in Dongning county, a rural area in Heilongjiang Province of China. <i>Chin J Clin Rehab.</i> 2004; 8(4): 770-1.	2000	*	
China	Hui Ren, Zhi-Peng Yu. Epidemiological survey on epilepsy in Jinuo ethnic minority group in Yunnan Province. <i>J Int Neurol Neurosurg.</i> 2007; 2007(1): 10-12.	2005	*	
China	Yu Z-P, Tang Y-X, Wang W-M. [Epidemiological survey on epilepsy in Kawa ethnic minority group in Yunnan province]. <i>Chin J Epidemiol.</i> 2009; 30(1): 95-6.	2007-2008	*	
China	Bin Z, Zhen H, Mao-Sheng H. Prevalence of Parkinson's Disease in Shanghai urban and rural area. <i>J Brain Nerv Dis.</i> 2001; 9(6): 330-2.	1997	*	
China	Jin Q, Qiu-Min Q, Jian-Feng H. The epidemiology of Parkinson Disease among Elderly people in Xi'an, China. <i>Chin J Neuroimmunol Neurol.</i> 2001.	1997-1998	*	
China	Jian-Long Z, Yu-Ling W, Ya-Ni Y. Analysis of prevalence and related factors in different national Parkinson's disease in Yili of Xinjiang area. <i>J Xinjiang Med Univ.</i> 2013; 36(3): 278-281.	2012	*	
China	Lu-Ning W, Tai-Fang Z, Yu-Ling W. Study on the prevalence and risk factors of the Parkinson's disease in residents aged 35 years or older in Urumqi city. <i>J Xinjiang Med Univ.</i> 2013.	2012	*	
China	Yan L, Xiao-Ying Z, Ying HE. Investigation on prevalence rate of Parkinson's disease in population aged 55 years old and above in Kashi, Xinjiang between 2008 and 2009. <i>Chin J Neurol.</i> 2010; 12(43): 863-5.	2008-2009	*	
China	Cheng Q, Wang D-S, Jiang G-X, Han H, Zhang Y, Wang W-Z, Fredrikson S. Distinct pattern of age-specific incidence of Guillain-Barre syndrome in Harbin, China. <i>J Neurol.</i> 2002; 249(1): 25-32.	1997-1998		†
China	Hui ACF, Chow KM, Tang ASY, Fu M, Kay R, Wong KS. Electrophysiological, clinical and epidemiological study of Guillain-Barre Syndrome in Hong Kong Chinese. <i>J Clin Neurosci.</i> 2005; 12(2): 134-6.	1993-1998		†
China	Zhang Y, Wang D, Han H, Li F, Sheng L, Link H. Epidemiological survey of the incidence of Guillain-Barre syndrome in Harbin from 1997 to 1999. <i>Chin J Clin Rehab.</i> 2004; 7812-5.	1997-1999		†
China	Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agrini MD, Bhutta ZA, Canh DG, Ali M, Shin S, Wain J, Page A-L, Albert MJ, Farrar J, Abu-Elyazed R, Pang T, Galindo CM, von Seidlein L, Clemens JD, Domi Typhoid Study Group. A study of typhoid fever in five Asian countries: disease burden and implications for controls. <i>Bull World Health Organ.</i> 2008; 86(4): 260-8.	2001-2002		
China	Cheng Q, Miao L, Zhang J, Ding SJ, Liu ZG, Wang X, Sun XJ, Zhao ZX, Song YJ, Ding XY, Guo ZL, Yang Y, Chen SD, Jiang GX, Fredrikson S. A population-based survey of multiple sclerosis in Shanghai, China. <i>Neurology.</i> 2007; 68(18): 1495-500.	2004	*	
China	Lau KK, Wong LKS, Li LSW, Chan YW, Li HL, Wong V. Epidemiological study of multiple sclerosis in Hong Kong Chinese: questionnaire survey. <i>Hong Kong Med J.</i> 2002; 8(2): 77-80.	1999	*	
China	Xueqiang Fang YZ. Prevalence and risk factors of trichomoniasis, bacterial vaginosis, and candidiasis for married women of child-bearing age in rural Shandong. <i>Jpn J Infect Dis.</i> 2007; 60(5): 257-61.	2007		
China	Dai Q, Hu L, Jiang Y, Shi H, Liu J, Zhou W, Shen C, Yang H. An epidemiological survey of bacterial vaginosis, vulvovaginal candidiasis and trichomoniasis in the Tibetan area of Sichuan Province, China. <i>Eur J Obstet Gynecol Reprod Biol.</i> 2010; 150(2): 207-9.	2007		
China	Zhang X-J, Shen Q, Wang G-Y, Yu Y-L, Sun Y-H, Yu G-B, Zhao D, Ye D-Q. Risk factors for reproductive tract infections among married women in rural areas of Anhui Province, China. <i>Eur J Obstet Gynecol Reprod Biol.</i> 2009; 147(2): 187-91.	2009		
China	China National Maternal and Child Health Surveillance System Congenital Anomalies 1996-2012 - MCHS.	1996-2012	*	
China	Cao Y, Yi Z-W, Zhang H, Dang X-Q, Wu X-C, Huang A-W. Etiology and outcomes of acute kidney injury in Chinese children: a prospective multicentre investigation. <i>BMC Urol.</i> 2013; 41.	2005	*	
China	Yuen PM, Chan NS, Yim SF, Chang AM. A randomised double blind comparison of Syntometrine and Syntocinon in the management of the third stage of labour. <i>Br J Obstet Gynaecol.</i> 1995; 102(5): 377-80.	1993	*	
China	Llibre Rodriguez JJ, Ferri CP, Acosta D, Guerra M, Huang Y, Jacob KS, Krishnamoorthy ES, Salas A, Sosa AL, Acosta I, Dewey ME, Gaona C, Jotheeswaran AT, Li S, Rodriguez D, Rodriguez G, Kumar PS, Valhuerdi A, Prince M, 10/66 Dementia Research Group. Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey. <i>Lancet.</i> 2008; 372(9637): 464-74.	2004		†
China	Li G, Shen YC, Chen CH, Zhou YW, Li SR, Lu M. A three-year follow-up study of age-related dementia in an urban area of Beijing. <i>Acta Psychiatr Scand.</i> 1991; 83(2): 99-104.	1985-1989		
China	Li Y, Yin Z, Shao Z, Li M, Liang X, Sandhu HS, Hadler SC, Li J, Sun Y, Li J, Zou W, Lin M, Zuo S, Mayer LW, Novak RT, Zhu B, Xu L, Luo H. Acute Meningitis and Encephalitis Syndrome Study Group. Population-based surveillance for bacterial meningitis in China, September 2006-December 2009. <i>Emerg Infect Dis.</i> 2014; 20(1): 61-9.	2006-2009		
China	Lu X, Li X, Zhao Y, Zheng Z, Guan S, Chan P. Contemporary epidemiology of gout and hyperuricemia in community elderly in Beijing. <i>Int J Rheum Dis.</i> 2013.	2009	*	
China	China National Iodine Deficiency Disorders Surveillance 1995 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1995		
China	Lu G, Li J, Xie Z, Liu C, Guo L, Vernet G, Shen K, Wang J. Human metapneumovirus associated with community-acquired pneumonia in children in Beijing, China. <i>J Med Virol.</i> 2013; 85(1): 138-43.	2008-2010	*	
China	China National Iodine Deficiency Disorders Surveillance 2005 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2005		
China	China National Iodine Deficiency Disorders Surveillance 1997 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1997		
China	China National Iodine Deficiency Disorders Surveillance 1999 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1999		
China	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec.</i> 2005; 80(13): 118-24.	2003	*	
China	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
China	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec.</i> 2006; 81(32): 309-16.	2005	*	
China	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec.</i> 2007; 82(25): 225-32.	2006	*	
China	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
China	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
China	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
China	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec.</i> 2008; 83(33): 293-300.	2007	*	
China	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
China	World Health Organization (WHO). Leprosy control in China: trends in detection of new cases, 1987-2008. <i>Wkly Epidemiol Rec.</i> 2010; 85(17): 149-56.	1987-2003	*	
China	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
China	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
China	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
China	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
China	Lo JY, Lim WW, Ho DW, Field PR, Cunningham AL. Difference in seroprevalence of herpes simplex virus type 2 infection among antenatal women in Hong Kong and southern China. Sex Transm Infect. 1999; 75(2): 123.	1995	*	
China	Zhang Y, Wang H, Liu J, Wang T, Cao S, Zhou D, Du L, Li Z, Liu P. Prevalence of blindness and low vision: a study in the rural Heilongjiang Province of China. Clin Experiment Ophthalmol. 2012; 40(5): 484-9.	2008-2009	*	
China	Chen H, Wu X, Wei M, Eichner JE, Fan Y, Zhang Z, Lei C, Stone DU, Yang J. Changes in the prevalence of visual impairment due to blinding trachoma in Sichuan province, China: a comparative study between 1987 and 2006. Ophthalmic Epidemiol. 2012; 19(1): 29-37.	1987, 2006	*	
China	Zhu M, Tong X, Zhao R, He X, Zhao H, Liu M, Zhu J. Visual impairment and spectacle coverage rate in Baoshan district, China: population-based study. BMC Public Health. 2013; 13(1): 311.	2009	*	
China	Wang G-Q, Bai Z-X, Shi J, Luo S, Chang H-F, Sai X-Y. Prevalence and risk factors for eye diseases, blindness, and low vision in Lhasa, Tibet. Int J Ophthalmol. 2013; 6(2): 237-41.	2010	*	
China	Wei M, Chen H, Fan Y-C, Pathai S. Prevalence and causes of visual impairment and blindness in Sichuan province of China. Int J Ophthalmol. 2010; 3(1): 83-8.	2000	*	
China	Li J, Zhong H, Cai N, Luo T, Li J, Su X, Li X, Qiu X, Yang Y, Yuan Y, Yu M. The prevalence and causes of visual impairment in an elderly Chinese Bai ethnic rural population: the Yunnan minority eye study. Invest Ophthalmol Vis Sci. 2012; 53(8): 4498-504.	2010	*	
China	Huang S, Zheng Y, Foster PJ, Huang W, He M. Prevalence and causes of visual impairment in Chinese adults in urban southern China. Arch Ophthalmol. 2009; 127(10): 1362-7.	2003-2004	*	
China	Li X, Zhou Q, Sun L, Wang Z, Han S, Wu S, Wang N. Prevalence of blindness and low vision in a rural population in northern China: preliminary results from a population-based survey. Ophthalmic Epidemiol. 2012; 19(5): 272-7.	2010	*	
China	Xu L, Jonas JB, Cui TT, You QS, Wang YX, Yang H, Li JJ, Wei WB, Liang QF, Wang S, Yang XH, Zhang L. Beijing Eye Public Health Care Project. Ophthalmology. 2012; 119(6): 1167-74.	2008-2009	*	
China	Wang H, Zhang Y, Li Z, Wang T, Liu P. Prevalence and causes of corneal blindness. Clin Experiment Ophthalmol. 2013.	2009	*	
China	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2000.	2000		
China	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2001.	2001		
China	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2002.	2002		
China	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2003.	2003		
China	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2004.	2004		
China	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2005.	2005		
China	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2006.	2006		
China	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2007.	2007		
China	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2008.	2008		
China	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2009.	2009		
China	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2010.	2010		
China	Youwang Y, Jianming D, Yong X, Pong Z. Epidemiological features of an outbreak of diphtheria and its control with diphtheria toxoid immunization. Int J Epidemiol. 1992; 21(4): 807-11.	1988-1989		
China	Chen Y, Li XX, Yin H, Gilbert C, Liang JH, Jiang YR, Zhao MW. Beijing ROP Survey Group. Risk factors for retinopathy of prematurity in six neonatal intensive care units in Beijing, China. Br J Ophthalmol. 2008; 92(3): 326-30.	2005	*	†
China	Tsao PN, Teng RJ, Wu TJ, Tang JR, Yau KI. Early outcome of extremely low birth weight infants in Taiwan. J Formos Med Assoc. 1998; 97(7): 471-6.	1995	*	†
China	Lin Y. Guangxi monitoring network of acute encephalitis, meningitis epidemiological surveillance studies. Dis Surveill. 2010; 25(3).	2007-2008		
China	Dong B, Tang Z, Lin M, Li C, Tan D, Liang D, Liao H, Liu X, Qian Y, Fang J, Wu X, Qin W, Kilgore PE, Kennedy WA, Xu Z, Clemens JD. [Epidemiologic surveillance for bacterial meningitis in 140 000 children under 5 years of age in Nanning district, Guangxi province]. Chin J Epidemiol. 2004; 25(5): 391-5.	2000-2002		
China	Yang Y, Leng Z, Shen X, Lu D, Jiang Z, Rao J, Fan X, Liu J, Shen Y. Acute bacterial meningitis in children in Hefei, China 1990-1992. Chin Med J (Engl). 1996; 109(5): 385-8.	1990-1992		
China	Wang YS, Shi YM, Wu ZY, He YX, Zhang BZ. Parkinson's disease in China. Coordinational Group of Neuroepidemiology. PLA. Chin Med J (Engl). 1991; 104(11): 960-4.	1986, 1991		
China	Li SC, Schoenberg BS, Wang CC, Cheng XM, Rui DY, Bolis CL, Schoenberg DG. A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch Neurol. 1985; 42(7): 655-7.	1983		
China	Zhang ZX1, Anderson DW, Huang JB, Li H, Hong X, Wei J, Yang EL, Maraganore DM. Prevalence of Parkinson's disease and related disorders in the elderly population of greater Beijing, China. Mov Disord. 2003; 18(7): 764-72.	1996-2001		
China	Yan YQ, Chen ZP, Yang XM, Liu H, Zhang JX, Zhong W, Yao W, Zhao JK, Zhang ZZ, Hua JL, Li JS, Yu XQ, Wang FR. Attention to the hiding iodine deficiency in pregnant and lactating women after universal salt iodization: A multi-community study in China. J Endocrinol Invest. 2005; 28(6): 547-53 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2002		
China	Wang W, Xu W, Ding S, Zhou B. Population-based case-control study on risk factors of uterine myomas. Chin J Cancer Prev Treatment. 2007; 14(11): 821-3.	2004		
China	Baelum V, Luan WM, Chen X, Fejerskov O. Predictors of tooth loss over 10 years in adult and elderly Chinese. Community Dent Oral Epidemiol. 1997; 25(3): 204-10.	1984-1994		
China	Baelum V, Wen-Min L, Fejerskov O, Xia C. Tooth mortality and periodontal conditions in 60-80-year-old Chinese. Scand J Dent Res. 1988; 96(2): 99-107.	1986		
China	Lin HC, Corbet EF, Lo EC, Zhang HG. Tooth loss, occluding pairs, and prosthetic status of Chinese adults. J Dent Res. 2001; 80(5): 1491-5.	1997		
China	Lo EC, Schwarz E. Tooth and root conditions in the middle-aged and the elderly in Hong Kong. Community Dent Oral Epidemiol. 1994; 22(5 Pt 2): 381-5.	1984		
China	Hodgson JE, Shi YF, Gao YL, Wu KJ, Jiang BY, Chen YL. Chlamydial infection in a Chinese gynecologic outpatient clinic. Obstet Gynecol. 1988; 71(1): 96-100.	1988		
China	Dong Y. Female simple gonorrhoea. J Pract Obstet Gynaecol. 1991; 172-4.	1988		
China	Chu C-H, Ho P-L, Lo ECM. Oral health status and behaviours of preschool children in Hong Kong. BMC Public Health. 2012; 767.	2009	*	
China	Wong MCM, Lu HX, Lo ECM. Caries increment over 2 years in preschool children: a life course approach. Int J Paediatr Dent. 2012; 22(2): 77-84.	2007-2009	*	
China	Li Z, Zhu L, Zhang B, Si Y, Liu M. [Periodontal health status assessed by community periodontal index and related factors of adult population of Beijing urban community]. J Peking Univ Health Sci. 2012; 44(1): 130-4.	2009-2010	*	
China	Xiang Y-T, Ma X, Lu J-Y, Cai Z-J, Li S-R, Xiang Y-Q, Guo H-L, Hou Y-Z, Li Z-B, Li Z-J, Tao Y-F, Dang W-M, Wu X-M, Deng J, Lai KYC, Ungvari GS. Alcohol-related disorders in Beijing, China: prevalence, socio-demographic correlates, and unmet need for treatment. Alcohol Clin Exp Res. 2009; 33(6): 1111-8.	2002		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
China	World Health Organization (WHO). Mental Illness in General Health Care: An International Study. Geneva, Switzerland: World Health Organization (WHO), 1995.	1991-1992		
China	Society of Cardiology, Chinese Medical Association. Retrospective investigation of hospitalized patients with heart failure in some parts of China in 1980, 1990, and 2000. <i>Chin J Cardiol.</i> 2002; 450-454.	1980, 1990, 2000		
China	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
China	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
China	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
China	Chuang S-Y, Chen C-H, Cheng C-M, Chou P. Combined use of brachial-ankle pulse wave velocity and ankle-brachial index for fast assessment of arteriosclerosis and atherosclerosis in a community. <i>Int J Cardiol.</i> 2005; 98(1): 99-105.	2002		
China	Wong SYS, Kwok T, Woo J, Lynn H, Griffith JF, Leung J, Tang YYN, Leung PC. Bone mineral density and the risk of peripheral arterial disease in men and women: results from Mr. and Ms Os, Hong Kong. <i>Osteoporos Int.</i> 2005; 16(12): 1933-8.	2004		
China	World Health Organization (WHO). WHO Global Programme for the Prevention of Rheumatic Fever and Rheumatic Heart Disease: Report of a Consultation to Review Progress and Develop Future Activities. Geneva, Switzerland: World Health Organization (WHO), 2000.	1998		
China	Dong C, Dai X, Liang J, Dong M, Meng J. Seroprevalence of Hepatitis E virus varies considerably among Chinese provinces. <i>Hepat Mon.</i> 2012; 12(6): 386-90.	2006-2008	*	
China	Lu W-P, Lin G-X, Shi S, Dong J-H. Simultaneously high prevalences of hepatitis B and C virus infections in a population in Putian County, China. <i>J Clin Microbiol.</i> 2012; 50(6): 2142-4.	2009-2010		
China	Li D, Long Y, Wang T, Xiao D, Zhang J, Guo Z, Wang B, Yan Y. Epidemiology of Hepatitis C Virus Infection in Highly Endemic HBV Areas in China. <i>PLoS One.</i> 2013; 8(1): e54815.	2011		
China	Liu S, Wang X, Wang D, Zhou Y, Li J, Zheng J, Zhong N, Ran P. [Epidemiologic analysis of COPD in Guangdong province]. <i>Nat Med J Chin.</i> 2005; 85(11): 747-52.	2002	*	
China	Zhou Y, Wang D, Liu S, Lu J, Zheng J, Zhong N, Ran P. The association between BMI and COPD: the results of two population-based studies in Guangzhou, China. <i>COPD.</i> 2013; 10(5): 567-72.	2002-2007	*	
China	Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y. Reprint of: Epidemiological serosurvey of Hepatitis B in China—declining HBV prevalence due to Hepatitis B vaccination. <i>Vaccine.</i> 2013; 31: 21-28.	2005-2007	*	
China	Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, Büchele G, Clausen M, Cookson WOC, von Mutius E, Strachan DP, Williams HC, ISAAC Phase Two Study Group. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. <i>J Allergy Clin Immunol.</i> 2008; 121(1): 141-147.	2005-2007	*	
China	Zhu Y, Yuan Z, Zhao Q, Chen G, Xu B. Seroprevalence of hepatitis A virus antibody in a population aged 0-30 years in Shanghai, China: implications for hepatitis A immunization. <i>Epidemiol Infect.</i> 2013; 141(3): 556-62.	2009	*	
China	Zhao Y, Zhang R, Hu Y, Li R, Liang L, Gang Y. [An epidemiological survey of gallstones with gray-scale ultrasound]. <i>J West Chin Univ Med Sci.</i> 1990; 21(2): 217-20.	1990		
China	Leong RWL, Lau JY, Sung JY. The epidemiology and phenotype of Crohn's disease in the Chinese population. <i>Inflamm Bowel Dis.</i> 2004; 10(5): 646-51.	1985-2001		
China	Sun L, Yue H, Sun B, Han L, Qi M, Tian Z, Lu S, Shan C, Luo J, Fan Y, Li S, Dong M, Zuo X, Zhang Y, Lin W, Xu J, Heng Y, Hua'an Perinatal-Neonatal Study Group. Estimation of birth population-based perinatal-neonatal mortality and preterm rate in China from a regional survey in 2010. <i>J Matern Fetal Neonatal Med.</i> 2013; 26(16): 1641-8.	2010	*	†
China	Sun YD. [A sero-epidemiological study of viral hepatitis A in a village]. <i>Chin J Prev Med.</i> 1985; 19(3): 140-2.	1980		
China	Hu M, Schenzle D, Deinhardt F, Scheid R. Prevalence of markers of hepatitis A and B in the Shanghai area. <i>J Infect Dis.</i> 1983; 147(2): 360.	1980		
China	Hu MD, Schenzle D, Deinhardt F, Scheid R. Epidemiology of hepatitis A and B in the Shanghai area: prevalence of serum markers. <i>Am J Epidemiol.</i> 1984; 120(3): 404-13.	1980		
China	Xu DZ. [Epidemiologic study of viral hepatitis A in kindergartens and nurseries]. <i>Nat Med J Chin.</i> 1985; 65(3): 148-50.	1981-1982		
China	Wang HT. [An epidemiological study of viral hepatitis A in Beijing suburb]. <i>Chin J Prev Med.</i> 1985; 19(1): 8-10.	1982-1983		
China	Zou QH. [A seroepidemiological study of hepatitis A viral infection]. <i>Chin J Epidemiol.</i> 1984; 5(6): 329-31.	1983		
China	Li L. [The relationship between changing of anti-HAV in population and prevalence of hepatitis A]. <i>Chin J Prev Med.</i> 1989; 23(3): 139-40.	1986		
China	Song Y. [The investigation of anti-hepatitis A virus antibody rate in Guangzhou population]. <i>Chin J Epidemiol.</i> 1991; 12(5): 265-8.	1988		
China	Geng J, Xu D, Gong J, Li W. Assessing hepatitis A virus epidemic stochastic process in eight cities in China in 1990. <i>Int J Epidemiol.</i> 1998; 27(2): 320-2.	1990		
China	Li L, He J, Zhao L. [Epidemiologic features of viral hepatitis in Fujian]. <i>Chin J Epidemiol.</i> 1998; 19(2): 89-92.	1992, 1995-1997		
China	Hazell SL, Mitchell HM, Hedges M, Shi X, Hu PJ, Li YY, Lee A, Reiss-Levy E. Hepatitis A and evidence against the community dissemination of <i>Helicobacter pylori</i> via feces. <i>J Infect Dis.</i> 1994; 170(3): 686-9.	1993		
China	Chen Q, Li M, Li M, Lu X, Li R, Sun J, Liu Z. Molecular basis of weak D and DEL in Han population in Anhui Province, China. <i>Chin Med J (Engl.)</i> 2012; 125(18): 3251-5.	2008-2009	*	†
China	Li Q, Hou L, Guo Z-H, Ye L-Y, Yue D-Q, Zhu Z-Y. Molecular basis of the RHD gene in blood donors with DEL phenotypes in Shanghai. <i>Vox Sang.</i> 2009; 97(2): 139-46.	2006-2008	*	†
China	Bernhardt R, Feng Z, Deng Y, Dai G, Cremer P, Stehle G, Seidel D, Schettler G. Incidence and mortality rates of myocardial infarction in Chinese workers aged 40-59 in relation to coronary risk factors. <i>Klin Wochenschr.</i> 1991; 69(5): 201-12.	1982-1988		
China	Wu Y, Yao C, Wu Z, Zhang R, Zhang M, Wu G, Zhao D, Hong Z. Interim report of Sino-Monica-Beijing for the years 1985-1989. <i>Chin Med Sci J.</i> 1992; 7(3): 125-9.	1985-1989		
China	Wu Z, Yao C, Zhao D. Multiprovincial monitoring of the trends and determinants in cardiovascular diseases (Sino-MONICA project): morbidity and mortality monitoring. <i>Chin J Cardiol.</i> 1997; 25(1): 6-11.	1986		
China	National Public Health Institute (Finland), World Health Organization (WHO). MONICA Coronary Event Registration Data Book 1980-1995. Geneva, Switzerland: World Health Organization (WHO), 2000.	1980-1995		
China	Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study. <i>Int J Epidemiol.</i> 2005; 34(1): 132-7.	1992-1993		
China	Chen H-F, Li C-Y, Chen P, See T-T, Lee H-Y. Seroprevalence of hepatitis B and C in type 2 diabetic patients. <i>J Chin Med Assoc.</i> 2006; 69(4): 146-52.	2003		
China	Clift A, Morgan C, Anderson D, Toole M. Alarming levels of hepatitis B virus detected among rural Tibetans. <i>Trop Doct.</i> 2004; 34(3): 156-7.	1999		
China	Ito S, Yao DF, Nii C, Hibino S, Kamamura M, Nisikado T, Honda H, Shimizu I, Meng XY. Epidemiological characteristics of the incidence of hepatitis C virus (C100-3) antibodies in patients with liver diseases in the inshore area of the Yangtze River. <i>J Gastroenterol Hepatol.</i> 1993; 8(3): 232-7.	1991-1992		
China	Jiang Y, Lu J, Zhang L, Tian R, Liu Q, Bi S. [Antibody detection and sequencing analysis of hepatitis E virus in human population, swine and chicken in Sichuan region in China]. <i>Chin J Exper Clin Virol.</i> 2008; 22(6): 468-71.	2005-2007		
China	Liu P, Shi ZX, Zhang YC, Xu ZC, Shu HS, Zhang XY. A prospective study of a serum-pooling strategy in screening blood donors for antibody to hepatitis C virus. <i>Transfusion.</i> 1997; 37(7): 732-6.	1995		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
China	Lu J, Li H, Tian R, Jiang Y, Xu Y, Yu D, Jiang J, Bi S. [Hepatitis viruses infection situation in human population of the Gansu province]. <i>Chin J Exper Clin Virol</i> . 2009; 23(5): 349-51.	2008		
China	Ma Z, Feng R, Zhao C, Harrison TI, Li M, Qiao Z, Feng Y, Wang Y. Seroprevalence and distribution of hepatitis E virus in various ethnic groups in Gansu province, China. <i>Infect Genet Evol</i> . 2010; 10(5): 614-9.	2008		
China	Mizuki N, Inoko H, Ando H, Kiyosawa K, Seki T, Geng Z, Geng L, Li G, Ishihara M, Shindo Y, Onishi H, Onoe K, Ohno S. Seroepidemiological studies on Silk Road ethnic groups. <i>Tokai J Exp Clin Med</i> . 1996; 21(3): 117-20.	1994		
China	Seiji K, Inoue O, Liu SJ, Xu XP, Jin C, Cai SX, Nakatsuka H, Watanabe T, Uchida Y, Ikeda M. Prevalence of hepatitis B virus infection markers among factory workers in Beijing, China. <i>Asia Pac J Public Health</i> . 1991; 5(4): 345-9.	1988-1989		
China	Shimbo S, Zhang ZW, Qu JB, Wang JJ, Zhang CL, Song LH, Watanabe T, Higashikawa K, Ikeda M. Urban-rural comparison of HBV and HCV infection prevalence among adult women in Shandong Province, China. <i>Southeast Asian J Trop Med Public Health</i> . 1997; 28(3): 500-6.	1996		
China	Taniguchi M, Kim SR, Mishiro S, Takahashi K, Shin MH, Yun H, Park MS, Li ZM, Kim MK, Fang J, Hayashi Y. Epidemiology of hepatitis E in Northeastern China, South Korea and Japan. <i>J Infect</i> . 2009; 58(3): 232-7.	2005-2008		
China	Tao QM, Wang Y, Wang H, Chen WR, Sun Y, Meng Q, Watanabe J, Nishioka K. Seroepidemiology of HCV and HBV infection in northern China. <i>Gastroenterol Jpn</i> . 1991; 156-8.	1988-1990		
China	Tian R-G, Lu J, Zhang B-C, Jiang Y-Z, Bi S-L. [Antibody detection of hepatitis E virus in some human population, swine and chicken in Beijing in China]. <i>Chin J Exper Clin Virol</i> . 2009; 23(1): 14-6.	2006-2007		
China	Tong D-Y, Wang X-H, Xu C-F, Yang Y-Z, Xiong S-D. Hepatitis B virus infection and coronary atherosclerosis: results from a population with relatively high prevalence of hepatitis B virus. <i>World J Gastroenterol</i> . 2005; 11(9): 1292-6.	2002-2004		
China	Wang Y, Tao QM, Zhao HY, Tsuda F, Nagayama R, Yamamoto K, Tanaka T, Tokita H, Okamoto H, Miyakawa Y. Hepatitis C virus RNA and antibodies among blood donors in Beijing. <i>J Hepatol</i> . 1994; 21(4): 634-40.	1992		
China	Zhang M, Sun X-D, Mark SD, Chen W, Wong L, Dawsey SM, Qiao Y-L, Fraumeni JF Jr, Taylor PR, O'Brien TR. Hepatitis C virus infection, Linxian, China. <i>Emerg Infect Dis</i> . 2005; 11(1): 17-21.	2000		
China	Zhang ZW, Shimbo S, Qu JB, Liu ZM, Cai XC, Wang LQ, Watanabe T, Nakatsuka H, Matsuda-Inoguchi N, Higashikawa K, Ikeda M. Hepatitis B and C virus infection among adult women in Jilin Province, China: an urban-rural comparison in prevalence of infection markers. <i>Southeast Asian J Trop Med Public Health</i> . 2000; 31(3): 530-6.	1999		
China	Zhao SM, Jiang TL, Gao FX, Lu L, Zheng HQ, Hu J, Fan YH, Li B, Xiao RR, Yury K. Analysis of true voluntary blood donors with anti-HCV prevalence and implications for donor management in Chongqing, China. <i>Transfus Med</i> . 2007; 17(3): 210-1.	2007		
China	Zhu G, Qu Y, Jin N, Sun Z, Liu T, Lee H, Tian M, Wang T. Seroepidemiology and molecular characterization of hepatitis E virus in Jilin, China. <i>Infection</i> . 2008; 36(2): 140-6.	2003-2006		
China	Zhuo J, Tao G, Ebrahim SH, Wang S, Luo Z, Wang H. The relationship of hepatitis B virus infection between adults and their children in Guangxi Province, China. <i>J Hepatol</i> . 2000; 33(4): 628-31.	1992		
China	Yu SH, Xu LQ, Jiang ZX, Xu SH, Han JJ, Zhu YG, Chang J, Lin JX, Xu FN. Nationwide survey of human parasite in China. <i>Southeast Asian J Trop Med Public Health</i> . 1994; 25(1): 4-10.	1988-1992	*	
China	Food and Agriculture Organization of the United Nations (FAO), World Health Organization (WHO). Joint WHO/FAO Workshop on Foodborne Trematode Infections in Asia. WHO Regional Office for the Western Pacific, 2004.	2004	*	
China	Ministry of Health (China). Report on the National Survey of Current Situation of Major Human Parasitic Diseases in China. Beijing, China: Chinese Center for Disease Control and Prevention (CCDC), 2005.	2001-2004	*	
China	Flohr C, Weimayr G, Weiland SK, Addo-Yobo E, Annesi-Maesano I, Björkstén B, Bråbäck L, Büchele G, Chico M, Cooper P, Clausen M, El Sharif N, Martinez Gimeno A, Mathur RS, von Mutius E, Morales Suarez-Varela M, Pearce N, Svabe V, Wong GWK, Yu M, Zhong NS, Williams HC. ISAAC Phase Two Study Group. How well do questionnaires perform compared with physical examination in detecting flexural eczema? Findings from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. <i>Br J Dermatol</i> . 2009; 161(4): 846-53.	2005-2007	*	
China	Pilot T, Barnes DE, Leclercq MH, McCombie BJ, Sardo Infirri J. Periodontal conditions in adolescents, 15-19 years of age: an overview of CPITN data in the WHO Global Oral Data Bank. <i>Community Dent Oral Epidemiol</i> . 1987; 15(6): 336-8.	1984		
China	Chiu HFK, Lam LCW, Chi I, Leung T, Li SW, Law WT, Chung DWS, Fung HHL, Kan PS, Lum CM, Ng J, Lau J. Prevalence of dementia in Chinese elderly in Hong Kong. <i>Neurology</i> . 1998; 50(4): 1002-9.	1995		
China	China - Beijing Coronary Event Registry Data 1990-2004, provided by Global Burden of Disease 2010 Ischemic Heart Disease Expert Group. [Unpublished].	1990-2004		
China	Pilot T, Lu ZY, Lin ZQ, Yen WP, Cao GR. Periodontal conditions in 35-44-year-old factory workers in Shanghai. <i>Community Dent Oral Epidemiol</i> . 1989; 17(4): 216.	1985		
China	Chen G, Yi X, Chen P, Dong J, Yang G, Fu S. A large-scale newborn hearing screening in rural areas in China. <i>Int J Pediatr Otorhinolaryngol</i> . 2012; 76(12): 1771-4.	2008-2010	*	
China	Liu Z, Liu L. Hearing screening and diagnosis in a large sample of infants in Central China. <i>J Med Screen</i> . 2013; 20(1): 21-6.	2006-2008	*	
China	Wang Q-J, Zhao Y-L, Rao S-Q, Guo Y-F, He Y, Lan L, Yang W-Y, Zheng Q-Y, Ruben RJ, Han D-Y, Shen Y. Newborn hearing concurrent gene screening can improve care for hearing loss: a study on 14,913 Chinese newborns. <i>Int J Pediatr Otorhinolaryngol</i> . 2011; 75(4): 535-42.	2007-2009	*	
China	Chen S, Chen S, Wu F, Chen S, Ke S, Chen S, Pan Z. Epidemiological survey on Clonorchiasis sinensis in Yangxin county of Hubei Province of PR China. <i>Southeast Asian J Trop Med Public Health</i> . 1997; 28(Suppl 1): 51-3.	1993	*	
China	Guo J-D, Li Q-Y, Yin X-M. Geographical distribution of clonorchiasis in Anhui province. <i>Chin J Zoonoses</i> . 2008; 24(2): 182-84.	2002-2003	*	
China	Tan Z, Zeng B-Q, Ma J-Q, Cao F-P, Wu Y-X. Current situation of intestinal parasite infection and its prevention and treatment in Shunde district. <i>J Trop Med Guangzhou</i> . 2004; 4(4): 435-37.	2002	*	
China	Xu JT, Li FH, Sun T et al. An investigation of Clonorchis sinensis in Liaoning. <i>Chinese Journal of Parasitic Disease Control</i> . 1998; 11: 75.	1995-1996	*	
China	Li SL, He G, Wei MB, Tan YG, Zhu QY, Shang SM, Zhang LT, Huang KL, Zhu FZ. Epidemiological investigation of clonorchiasis in Guangxi province. <i>Chinese Journal of Parasitic Disease Control</i> . 2002; 15: 214-16.	1990-1997	*	
China	Guo Y-L, Ou Y, Gao X-X, Li W-W, Li W, Z S-E. Investigation on the Clonorchiasis sinensis infection in Zhaoqing City. <i>J Trop Med Guangzhou</i> . 2007; 7(12): 1221-23.	2006	*	
China	Chen ZZ. Survey on Clonorchis sinensis infection in 22 counties and municipalities of Guangdong Province. <i>Chin J Epidemiol</i> . 1982; 3(1): 38-41.	1980	*	
China	Chen XQ. [Epidemiology of clonorchiasis sinensis in Guangdong Province]. <i>Chin J Epidemiol</i> . 1985; 19(2): 68-71.	1982	*	
China	Huang TR, Yu JH, Li JL, Zhang ZQ, Deng W, Zhang CY, Zhao SF. A cross-sectional study on liver diseases in the rural residents in southern Guangxi, China. <i>Chin J Prev Med</i> . 2007; 41: 123-26.	2007	*	
China	Liu W-J, Yu D-N, Luo W-Q, Liang Q-R, Pan H-Z. Analysis of the results of a baseline survey of clonorchiasis in Taishan City, Guangdong, China. <i>China Tropical Medicine</i> . 2007; 7(4): 602-03.	2006	*	
China	Ou Z-Y. [The general situation of clonorchiasis sinensis in Guangdong Province]. <i>Annual Bulletin of the Society of Parasitology Guangdong Province</i> . 1997; 19: 52-62.	1986	*	
China	Fan S-Y, Huang C-L, Liu Y, Li L-L, Shi X-H. [Epidemiology study of clonorchiasis in Futian district of Shenzhen]. <i>J Trop Med Guangzhou</i> . 2008; 1: 75-76.	2006	*	
China	Yu S-H, Masanori K, Li X-M, Xu L-Q, Lan C-G, Lin R. [Epidemiological investigation on Clonorchiasis sinensis in a human population in an area of South China]. <i>Jpn J Infect Dis</i> . 2003; 56(4): 168-71.	2003	*	
China	Li MG. [Epidemiological survey on paragonimiasis in Kaiyang, Wansan, Jiangkou Counties, Guizhou]. <i>Chin J Parasitol Parasit Dis</i> . 1984; 2(1): 55.	1981	*	
China	Lin CX, Li YS, Zhang RY, Cheng Y, Li L. [Investigation on Paragonimiasis infection in 6 counties of Fujian Province]. <i>Chin J Parasitol Parasit Dis</i> . 2003; 23(3): 191.	2001-2003	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
China	Song CC. [A survey of paragonimiasis control in the Lanting People's Commune of Shaoxing County, Zhejiang Province, China]. Chin J Prev Med. 1982; 16(4): 213-15.	1978-1979	*	
China	Wang CQ. [Epidemiological study of paragonimiasis in Xingshan County, Hubei Province]. Chin J Epidemiol. 1986; 7(1): 45-7.	1977-1984	*	
China	Feng ML, Li SG, Wu ZY, Yin CH, Zhang XJ, Zhai JG, Chen J, Han SF, Zhang XX, Shang YL, Yan XC. [An epidemiological survey on paragonimiasis in Jin Miaoou township in Shanxi province]. Chin J Prev Med. 2007; 41(Suppl): 131-33.	2007	*	
China	Li YS, Lin JX. [Epidemiological survey of paragonimiasis in Fujian Province]. Chin J Prev Med. 1987; 21(6): 331-4.	1985	*	
China	Pan LX. [Recovery of paragonimiasis in an endemic area in Meixian District, Guangdong Province]. Chin J Epidemiol. 1986; 7(1): 42-44.	1982-1984	*	
China	Zeng Z, Zhu Z, Yang Y, Ruan W, Peng X, Su Y, Peng L, Chen J, Yin Q, Zhao C, Zhou H, Yuan S, Hao Y, Qian J, Ng SC, Chen M, Hu P. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. J Gastroenterol Hepatol. 2013; 28(7): 1148-53.	2011-2012	*	
China	Zhao J, Ng SC, Lei Y, Yi F, Li J, Yu L, Zou K, Dan Z, Dai M, Ding Y, Song M, Mei Q, Fang X, Liu H, Shi Z, Zhou R, Xia M, Wu Q, Xiong Z, Zhu W, Deng L, Kamn MA, Xia B. First prospective, population-based inflammatory bowel disease incidence study in mainland of China: the emergence of western" disease. Inflamm Bowel Dis. 2013; 19(9): 1839-45.	2010	*	
China	Tsou K-L, Tsao P-N, Taiwan Infant Development Collaborative Study Group. The morbidity and survival of very-low-birth-weight infants in Taiwan. Acta Paediatr Taiwan. 2003 Dec; 44(6):349-55.	1996		†
China	Zhang Y, Fan ML. [Investigation of rising malaria prevalence in local areas of Fuyang City]. Anhui J Prev Med. 2002; 8(6): 373-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
China	Wang CC, Cheng XM, Li SC, Wang WZ, Wu SP, Wang KX, et al. [Epidemiological survey of neurological disorders in six urban areas of People's Republic of China]. Zhong-Hua Shen-Jing Wai-ke Za-Zhi. 1985; 1: 2-7.	1983	*	
China	Li ZS, Yang QD, Chen SM, Shu Q, Fu YG. [Epidemiological survey of cerebrovascular disease in rural areas of China]. Zhong-Hua Shen-Jing Wai-ke Za-Zhi. 1989; 5: 7-11.	1984	*	
China	Wu GX, Wu ZS, He BL. [Epidemiological characteristics of stroke in 16 provinces of China]. Zhonghua Yi Xue Za Zhi. 1994; 74: 281-283.	1986-1989	*	
China	Tan Y, Yin F, Ya K, Are Z, Pei Z. [Epidemiological study on cerebrovascular disease in Xinjiang]. Zhongguo Man Xing Bing Yu Fang Yu Kong Zhi. 1998; 6: 56-64.	1989-1991	*	
China	China Plasmodium Falciparum Parasite Rate Data, Personal Communication with L. Carneiro and N. Hill 2009 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2007	*	†
China	He R. The reason of Plasmodium vivax outbreaks and its prevention at the later anti-malarial stage. Chinese Journal of Pest Control. 1995; 11(4): 394-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
China	Hu L, Jin X. [Epidemiology of Malaria in Jiangsu, Shandong, Henan, Anhui and Hebei Provinces in 2004 and 2005]. Chinese Journal of Public Health and Preventive Medicine. 2006; 17(6): 54-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004-2005	*	†
China	Huang G, Gu Z, Huang X, Zheng X, Xia Z, Yang Q, Ye Z, S T, Li H, Tang L. Study on the transmission threshold of malaria by Anopheles anthropophagus in hilly land of Hubei Province. Chin J Parasit Dis Cont. 2003; 16(3): 131-3 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
China	Jin X, Gao Q. [Analysis of baseline survey of malaria prevalent status in Sihong Town, Jiangsu Province]. China Tropical Medicine. 2004; 4(5): 714-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
China	Li C, Liu H. [Epidemiologic report of malaria at Nuozha Power Station area]. Chin J Parasit Dis Cont. 2003; 16(5): 7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
China	Li C, Zhang Z. [Malaria surveillance in newly developed areas in Jinghong County]. Chin J Parasit Dis Cont. 2006; 15(3): 140 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000	*	†
China	Li C, Ce L, Yang T. Malaria survey of children in Beihe Village, Mengla County. Practical Journal of Parasitic Diseases. 1998; 6(2): 71 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
China	Li G. [Characteristics of endogenic point endemic malaria in Wandien Township, Changning County]. Chin J Parasit Dis Cont. 2004; 17(6): 3 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
China	Liu J, Meng F, Hua D. [Malaria survey in Nangiao Township of Hainan Province]. Chin J Parasit Dis Cont. 2002; 20(2): 128-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
China	Luo D, Lu D, Yao R, Li P, Huo X, Li A, Wen L, Ge C, Zhang S, Huo H. Alphamethrin-impregnated bed nets for malaria and mosquito control in China. Trans R Soc Trop Med Hyg. 1994; 88(6): 625-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
China	Luo MZ, Zheng X, Shang LY, Chen JF, Zhu WD, Tang LH. [Practicability of IFAT using Plasmodium cynomolgi and Plasmodium falciparum antigens in different malarious areas]. Chin J Parasit Dis Cont. 2000; 18(1): 49-51 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
China	Ou C, Wang X. Children infected with malaria parasites detected by PRC method in the epidemic area of malaria in Hainan. Hainan Medicine. 1998; 2(13): 73-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
China	Zhang Z-X, Zhou H-N, Zhao X-T, Chang F-X, Wang H-J, Li X-J, Zhuoma Y-J, Ciren Q, Bianma Z, Sangdan L, Zhang W, Yong J, Xu H-M, Bian J, Wang L-Y. [Epidemiological survey on malaria situation in Motuo County of Tibet, China]. Chin J Parasit Dis Cont. 2008; 26(5): 343-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
China	China Vital Registration Birth Data 1989 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1989		
China	Hong Kong Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
China	Macao Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
China	China Beijing Birth Defect Surveillance System in Thirty Counties of Four Provinces Data 2001 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
China	China - Sichuan Province Birth Defects Monitoring Program Data 1985 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1985	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
China	China - Sichuan Province Birth Defects Monitoring Program Data 1988 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1988	*	
China	China Beijing Birth Defect Surveillance System in Thirty Counties of Four Provinces Data 1997-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1997-1998	*	
China	Chinese Birth Defects Monitoring Network Data 2001 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
China	Chinese Birth Defects Monitoring Network Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
China	China Beijing Birth Defect Surveillance System in Thirty Counties of Four Provinces Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
China	Chinese Birth Defects Monitoring Network Data 1997-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1997-1998	*	
China	Chinese Birth Defects Monitoring Network Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
China	China - Sichuan Province Birth Defects Monitoring Program Data 1986 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1986	*	
China	China - Sichuan Province Birth Defects Monitoring Program Data 1987 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1987	*	
China	China Beijing Birth Defect Surveillance System in Thirty Counties of Four Provinces Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
China	China Plasmodium Falci-parum Parasite Rate Data, Personal Communication with H. Zhang 2006 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falci-parum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985-1992	*	†
Colombia	Regional Population Center Corporation (Colombia), International Statistical Institute. Colombia World Fertility Survey 1976. Voorburg, Netherlands: International Statistical Institute.	1976		
Colombia	Administrative Department of Science, Technology, and Innovation (Colombia), Center for Development Projects, Pontifical Xavierian University, Ministry of Social Protection (Colombia), Specialized Information Systems. Colombia National Health Survey 2007-2008.	2007-2008		
Colombia	Colombia Vital Registration - Deaths 1998 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1998	*	
Colombia	Colombia Vital Registration - Deaths 1999 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1999	*	
Colombia	Colombia Vital Registration - Deaths 2000 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2000	*	
Colombia	Colombia Vital Registration - Deaths 2001 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2001	*	
Colombia	Colombia Vital Registration - Deaths 2002 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2002	*	
Colombia	Colombia Vital Registration - Deaths 2004 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2004	*	
Colombia	Colombia Vital Registration - Deaths 2006 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2006	*	
Colombia	Macro International, Inc. Profamilia. Colombia Demographic and Health Survey 2004-2005. Calverton, United States: Macro International, Inc.	2004-2005		†
Colombia	Ministry of Health (Colombia), Regional Population Center (Colombia), Westinghouse; Institute for Resource Development. Colombia Demographic and Health Survey 1986. Columbia, United States: Westinghouse; Institute for Resource Development.	1986		†
Colombia	Macro International, Inc.; Institute for Resource Development, Profamilia. Colombia Demographic and Health Survey 1990. Columbia, United States: Macro International, Inc.; Institute for Resource Development.	1990		
Colombia	Macro International, Inc. Profamilia. Colombia Demographic and Health Survey 1995. Calverton, United States: Macro International, Inc.	1995		†
Colombia	Macro International, Inc. Profamilia. Colombia Demographic and Health Survey 2000. Calverton, United States: Macro International, Inc.	2000		†
Colombia	ICF Macro, Profamilia. Colombia Demographic and Health Survey 2009-2010. Calverton, United States: ICF Macro, 2011.	2009-2010		†
Colombia	Colombia Vital Registration - Deaths 2007 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2007	*	
Colombia	National Administrative Department of Statistics (Colombia). Colombia Vital Statistics - Deaths 2008. Bogotá, Colombia: National Administrative Department of Statistics (Colombia).	2008	*	†
Colombia	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-2002		
Colombia	Pontificia Universidad Javeriana (Colombia), World Health Organization (WHO). Colombia WHO Multi-country Survey Study on Health and Health System Responsiveness 2000-2001. Geneva, Switzerland: World Health Organization (WHO).	2000-2001		
Colombia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Colombia	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Colombia	Estrada Castañón R, Torres Bibiano B, Alarcón Hernández H, Villegas Arrizón A, Martínez Sandoval E, Chávez López G, Andersson N. Epidemiología cutánea en dos sectores de atención médica en Guerrero, México; Cutaneous epidemiology in two sectors of Guerrero, Mexico. Dermatol rev mex. 1992; 36(1): 29-34.	1989-1991		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Colombia	Borrero I, Fajardo L, Bedoya A, Zea A, Carmona F, de Borrero MF. Acute respiratory tract infections among a birth cohort of children from Cali, Colombia, who were studied through 17 months of age. <i>Rev Infect Dis.</i> 1990; 12(Suppl 8): S950-6.	1986-1988		†
Colombia	Robertson SE, Roca A, Alonso P, Simoes EAF, Kartasasmita CB, Olaleye DO, Odaibo GN, Collinson M, Venter M, Yuwei Zhu, Wright PF. Respiratory syncytial virus infection: denominator-based studies in Indonesia, Mozambique, Nigeria and South Africa. <i>Bull World Health Organ.</i> 2004; 12(82): 914-22.	1987-2001		
Colombia	Selwyn BJ. The Epidemiology of Acute Respiratory Tract Infection in Young Children: Comparison of Findings from Several Developing Countries. <i>Rev Infect Dis.</i> 1990; 12(12): S870-S888.	1987-1989		†
Colombia	Demyntenaere K, Bruffaerts R, Lee S, Posada-Villa J, Kovess V, Angermeyer MC, Levinson D, de Girolamo G, Nakane H, Mneimneh Z, Lara C, de Graaf R, Scott KM, Gureje O, Stein DJ, Haro JM, Bromet EJ, Kessler RC, Alonso J, Von Korff M. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. <i>Pain.</i> 2007; 129(3): 332-42.	2003		
Colombia	Conde-Agudelo A, Kafury-Goeta AC. Epidemiology of eclampsia in Colombia. <i>Int J Gynaecol Obstet.</i> 1998; 61(1): 1-8.	1993-1995		
Colombia	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1980-1998		
Colombia	Pan American Health Organization (PAHO). Update on yellow fever in the Americas. <i>Epidemiol Bull.</i> 2000; 21(2):13.	1985-1995		
Colombia	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2002-2005, 2007-2009		
Colombia	Vasconcelos PF da C. Febre amarela. <i>Rev Soc Bras Med Trop.</i> 2003; 36(2): 275-93.	1980-2001		
Colombia	World Health Organization (WHO). Yellow fever in Africa and South America, 2006. <i>Wkly Epidemiol Rec.</i> 2008; 83(8): 60-76.	2006		
Colombia	World Health Organization (WHO). Yellow fever in Africa and South America, 2007. <i>Wkly Epidemiol Rec.</i> 2009; 84(13): 97-104.	2007		
Colombia	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2002		
Colombia	Aschner P, King H, Triana de Torrado M, Rodriguez BM. Glucose intolerance in Colombia. A population-based survey in an urban community. <i>Diabetes Care.</i> 1993; 16(1): 90-3.	1989		
Colombia	Morillo LE, Alarcon F, Arana N, Aulet S, Chapman E, Conterno L, Estevez E, Garcia-Pedroza F, Garrido J, Macias-Islas M, Monzillo P, Nunez L, Plascencia N, Rodriguez C, Takeuchi Y, Latin American Migraine Study Group. Prevalence of migraine in Latin America. <i>Headache.</i> 2005; 45(2): 106-17.	1999		
Colombia	Cucunubá ZM, Flórez AC, Cárdenas A, Pavia P, Montilla M, Aldana R, Villamizar K, Ríos LC, Nicholls RS, Puerta CJ. Prevalence and risk factors for Chagas disease in pregnant women in Casanare, Colombia. <i>Am J Trop Med Hyg.</i> 2012; 87(5): 837-42.	2010		
Colombia	Dennis RJ, Caraballo L, García E, Rojas MX, Rondon MA, Pérez A, Aristizabal G, Peñaranda A, Barragan AM, Ahumada V, Jimenez S. Prevalence of asthma and other allergic conditions in Colombia 2009-2010: a cross-sectional study. <i>BMC Pulm Med.</i> 2012; 17.	2009-2010	*	
Colombia	García-Marcos L, Mallol J, Solé D, Brand PLP. EISL Study Group. International study of wheezing in infants: risk factors in affluent and non-affluent countries during the first year of life. <i>Pediatr Allergy Immunol.</i> 2010; 21(5): 878-88.	2005-2007	*	
Colombia	Mallol J, Solé D, Baeza-Bacab M, Aguirre-Camposano V, Soto-Quiros M, Baena-Cagnani C. Latin American ISAAC Group. Regional variation in asthma symptom prevalence in Latin American children. <i>J Asthma.</i> 2010; 47(6): 644-50.	2001-2003	*	
Colombia	Pulido-Rozo M, Gonzalez-Martínez F, Rivas-Muñoz F. [Prevalence of periodontal disease and oral hygiene indicators in high school students from Cartagena, Colombia]. <i>Rev Salud Publica (Bogota).</i> 2011; 13(5): 844-52.	2009	*	
Colombia	Tellez M, Santamaria RM, Gomez J, Martignon S. Dental fluorosis, dental caries, and quality of life factors among schoolchildren in a Colombian fluorotic area. <i>Community Dent Health.</i> 2012; 29(1): 95-9.	2010	*	
Colombia	Cadavid AS, Lince CMA, Jaramillo MC. Dental caries in the primary dentition of a Colombian population according to the ICDA criteria. <i>Braz Oral Res.</i> 2010; 24(2): 211-6.	2007		
Colombia	Caballero A, Torres-Duque CA, Jaramillo C, Bolívar F, Sanabria F, Osorio P, Orduz C, Guevara DP, Maldonado D. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). <i>Chest.</i> 2008; 133(2): 343-9.	2003-2004		
Colombia	Sánchez JL, Burticó O, Pineda D, Santiago Uribe C, Guillermo Palacio L. Prevalence of Parkinson's disease and Parkinsonism in a Colombian population using the capture-recapture method. <i>Int J Neurosci.</i> 2004; 114(2): 175-82.	1996-2000		
Colombia	Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganey K, Giel R, an der Heiden W, Holmberg SK, Janca A, Lee PW, León CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin SJ, Varma VK, Walsh D, Wiersma D. Recovery from psychotic illness: a 15- and 25-year international follow-up study. <i>Br J Psychiatry.</i> 2001; 178: 506-17.	1978-2003		
Colombia	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Colombia Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2004		
Colombia	Merikangas KR, Jin R, He J-P, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Ladea M, Medina-Mora ME, Ono Y, Posada-Villa J, Sagar R, Wells JE, Zarkov Z. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. <i>Arch Gen Psychiatry.</i> 2011; 68(3): 241-51.	2003	*	
Colombia	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), United Nations Office on Drugs and Crime (UNODC). Youth and Drugs in South American Countries: A Public Policy Challenge 2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2006.	2005		
Colombia	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Colombia Evaluation of Progress in Drug Control 2007-2009. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2011.	2008	*	
Colombia	Velez A, Eslava-Cobos J. Epilepsy in Colombia: epidemiologic profile and classification of epileptic seizures and syndromes. <i>Epilepsia.</i> 2006; 47(1): 193-201.	1995-1996	*	
Colombia	Navas M-C, Suarez I, Carreño A, Uribe D, Rios WA, Cortes-Mancera F, Martel G, Vieco B, Lozano D, Jimenez C, Gouas D, Osorio G, Hoyos S, Restrepo JC, Correa G, Jaramillo S, Lopez R, Bravo LE, Arbelaez MP, Scaozec J-Y, Abedi-Ardekani B, Santella RM, Chemin I, Hainaut P. Hepatitis B and Hepatitis C Infection Biomarkers and TP53 Mutations in Hepatocellular Carcinomas from Colombia. <i>Hepat Res Treat.</i> 2011; 1-10.	2000-2007		
Colombia	Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, de Graaf R, Demyntenaere K, Hu C, Iwata N, Karam AN, Kaur J, Kostyuchenko S, Lépine J-P, Levinson D, Matschinger H, Mora MEM, Browne MO, Posada-Villa J, Viana MC, Williams DR, Kessler RC. Cross-national epidemiology of DSM-IV major depressive episode. <i>BMC Med.</i> 2011; 9: 90.	2003	*	
Colombia	Pineda DA, Puerta IC. [Prevalence of dissociated conduct disorder in adolescents using an epidemiological diagnostic questionnaire]. <i>Rev Neurol.</i> 2001; 32(7): 612-8.	1999	*	
Colombia	Zuluaga L, Betancur C, Abanza M, Londoño J. Prevalences of tuberculosis and other respiratory diseases among people over age 15 in the northeast sector of Medellín, Colombia. <i>Bull Pan Am Health Organ.</i> 1992; 26(3): 247-55.	1988		
Colombia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2007, 2010, 2012		
Colombia	Cornejo JW, Osío O, Sánchez Y, Carrizosa J, Sánchez G, Grisales H, Castillo-Parra H, Holguín J. [Prevalence of attention deficit hyperactivity disorder in Colombian children and teenagers]. <i>Rev Neurol.</i> 2005; 40(12): 716-22.	2001	*	
Colombia	Rueda-Sánchez M, Díaz-Martínez LA. Prevalence and associated factors for episodic and chronic daily headache in the Colombian population. <i>Cephalalgia.</i> 2008; 28(3): 216-25.	2005-2007	*	
Colombia	Alberto Restrepo M, Gutierrez E. The frequency of glucose-6-phosphate dehydrogenase deficiency in Colombia. <i>Am J Hum Genet.</i> 1968; 20(1): 82-5.	1966-1968		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Colombia	Moyano M, Méndez F. Erythrocyte defects and parasitemia density in patients with Plasmodium falciparum malaria in Buenaventura, Colombia. <i>Rev Panam Salud Publica</i> . 2005; 18(1): 25-32.	2001		
Colombia	Fernández-Cean J, González-Martínez F, Schwedt E, Mazzuchi N. Renal replacement therapy in Latin America. <i>Kidney Int</i> . 2000; 57(574): 55-59.	1997		
Colombia	Lugon JR, Strogoff de Matos JP. Disparities in end-stage renal disease care in South America. <i>Clin Nephrol</i> . 2010; 74(Suppl 1): S66-71.	2006		
Colombia	Cusumano A, García-García G, Di Gioia C, Hermida O, Lavorato C, Carreño CA, Torrico MP, Batista PB, Romão JE, Badal HP, Miranda SE, Gomez R, Calderon MC, Sanchez SH, Lopez MA, Moscoso J, Merino RL, Polo JV, Lopez A, Romero NJ, García R, Acosta BV, Lopez AS, Delpin ES, Mena E, González C, Milanés CL, Acchiardo S. End-stage renal disease and its treatment in Latin America in the twenty-first century. <i>Ren Fail</i> . 2006; 28(8): 631-7.	2004		
Colombia	Santiago-Delpin EA, García VD. Latin American Transplant Registry VIIIth Report: 1998. <i>Transplant Proc</i> . 1999; 31(1-2): 214-6.	1995, 1997		
Colombia	Gómez RA. Renal disease in Colombia. <i>Ren Fail</i> . 2006; 28(8): 643-7.	2004		
Colombia	World Health Organization (WHO). Colombia WHO Leishmaniasis Country Profile.	2000-2010	*	
Colombia	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec</i> . 2009; 84(33): 333-40.	2008	*	
Colombia	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec</i> . 2012; 87(34): 317-28.	2011	*	
Colombia	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec</i> . 1999; 74(38): 313-6.	1998	*	
Colombia	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec</i> . 2001; 76(23): 173-9.	2000	*	
Colombia	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec</i> . 2000; 75(28): 226-31.	1999	*	
Colombia	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1994; 69(20): 145-51.	1993	*	
Colombia	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec</i> . 1997; 72(23): 165-72.	1996	*	
Colombia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec</i> . 1993; 68(25): 181-6.	1992	*	
Colombia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec</i> . 1996; 71(20): 149-56.	1995	*	
Colombia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1995; 70(25): 177-82.	1994	*	
Colombia	Pattanak P, Herrero R, Morrow RA, Munoz N, Bosch FX, Bayo S, El Gueddari B, Caceres E, Chichareon SB, Castellsague X, Mejer CHLM, Snijders PFF, Smith JS. Type-specific seroprevalence of herpes simplex virus type 2 and associated risk factors in middle-aged women from 6 countries: the IARC multicentric study. <i>Sex Transm Dis</i> . 2007; 34(12): 1019-24.	1985-1997	*	
Colombia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2003. Pan American Health Organization (PAHO).	2003		†
Colombia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2004. Pan American Health Organization (PAHO).	2004		†
Colombia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2005. Pan American Health Organization (PAHO).	2005		†
Colombia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2006. Pan American Health Organization (PAHO).	2006		†
Colombia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2007. Pan American Health Organization (PAHO).	2007		†
Colombia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Colombia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Colombia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Colombia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Colombia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Colombia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Colombia	Restrepo BN, Piedrahita LD, Agudelo IY, Parra-Henao G, Osorio JE. Frequency and clinical features of dengue infection in a schoolchildren cohort from Medellín, Colombia. <i>J Trop Med</i> . 2012; 120496.	2010-2011	*	
Colombia	Alvarado-Mora MV, Gutierrez Fernandez MF, Gomes-Gouveia MS, de Azevedo Neto RS, Carrilho JRR, Hepatitis B (HBV), Hepatitis C (HCV) and Hepatitis Delta (HDV) Viruses in the Colombian Population-How Is the Epidemiological Situation <i>PLoS One</i> . 2011; 6(4): e18888.	2008-2009		
Colombia	Sánchez MC, Villegas VE, Fonseca D. Glucose-6-phosphate dehydrogenase deficiency: enzymatic and molecular analysis in a Bogotá population. <i>Colomb Med</i> . 2008; 39(2): 14-23.	2005-2007	*	
Colombia	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Miguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L, Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Ann Hepatol</i> . 2010; 9(1): 63-9.	2006-2008	*	
Colombia	Ljunggren KE, Patarroyo ME, Engle R, Purcell RH, Gerin JL. Viral hepatitis in Colombia: a study of the hepatitis of the Sierra Nevada de Santa Marta. <i>Hepatology</i> . 1985; 5(2): 299-304.	1984		
Colombia	Carmona-Fonseca J. Frecuencia de los grupos sanguíneos ABO y Rh en la población laboral del valle de Aburrá y del cercano oriente de Antioquia (Colombia). <i>Acta Med Colomb</i> . 2006; 31(1): 20-30.	2003-2005	*	†
Colombia	Palacio LG, Jiménez I, García HH, Jiménez ME, Sánchez JL, Nob J, Ahn IL, Mora O, Giraldo M, Tsang VCV. Neurocysticercosis in persons with epilepsy in Medellín, Colombia. <i>Epilepsia</i> . 1998; 39(12): 1334-9.	1995		
Colombia	Peters W, Killick-Kendrick R, editors. <i>The Leishmaniases in Biology and Medicine</i> . London, United Kingdom: Academic Press; 1987. 941 p. 2 vol. V.1. Biology and Epidemiology. V. 2. Clinical Aspects and Control.	1981-1986		
Colombia	Pan American Health Organization (PAHO), World Health Organization (WHO). Quantitative Estimation of Chagas in the Americas.	2005	*	
Colombia	Straughn HK, Goldenberg RL, Tolosa JE, Daly S, de Codes J, Festin MR, Limpongsanurak S, Lumbiganon P, Paul VK, Peediyail A, Purwar M, Sabogal JC, Shenoy S. Birthweight-specific neonatal mortality in developing countries and obstetric practices. <i>Int J Gynaecol Obstet</i> . 2003 Jan; 80(1): 71-8.	2003		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Colombia	Sevilla-Casas E. Human mobility and malaria risk in the Naya river basin of Colombia. Soc Sci Med. 1993; 37(9): 1155-67 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Colombia	Torrientes ZI, Kramer K, Herrera MA, Chang SP. Naturally acquired antibodies against the major merozoite surface coat protein (MSP-1) of Plasmodium falciparum acquired by residents in an endemic area of Colombia. Mem Inst Oswaldo Cruz. 1994; 89(Suppl 2): 55-61 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†
Colombia	Colombia Integrated National Adaptation Plan. Colombia Plasmodium Falciparum Parasite Rate Data, Personal Communication with Colombia Integrated National Adaptation Plan 2008 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2007	*	†
Colombia	Correa AM, Carmona Fonseca J, Alcaraz Lopez GM. Malaria entre la población Tule (Kuna) del resguardo Caimán Nuevo (Turbo y Necolí; Antioquia, Colombia), 2003-2004. Investigación y Educación en Enfermería. 2005; 23(2): 16-33 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003-2004	*	†
Colombia	Cucunubá ZM, Guerra AP, Rahirant SI, Rivera JA, Cortés LJ, Nicholls RS asymptomatic Plasmodium spp. infection in Tierralta, Colombia. Mem Inst Oswaldo Cruz. 2008; 103(7): 668-73 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Colombia	Gautret P, Barreto M, Méndez F, Zorrilla G, Carrasquilla G. High prevalence of malaria in a village of the Colombian Pacific Coast. Mem Inst Oswaldo Cruz. 1995; 90(5): 559-60 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Colombia	González JM, Olano V, Vergara J, Aryalo-Herrera M, Carrasquilla G, Herrera S, López JA. Unstable, low-level transmission of malaria on the Colombian Pacific Coast. Ann Trop Med Parasitol. 1997; 91(4): 349-58 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Colombia	Herrera S, Perla BL, Sanchez CA, Herrera MA. Malaria crisis activity in sera from individuals of different ethnic groups of Colombia. Immunology Letters. 1990; 25(1-3): 251-3 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Colombia	Mendez F, Carrasquilla G, Muñoz A. Risk factors associated with malaria infection in an urban setting. Trans R Soc Trop Med Hyg. 2000; 94(4): 367-71 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993-1994	*	†
Colombia	Osoorio L, Todd J, Bradley D. [Absence of asymptomatic malaria in schoolchildren of Quibdó, Chocó]. Biomedica. 2004; 24(1): 13-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Colombia	Rojas W, Northup J, Gallo O, Montoya AE, Montoya F, Restrepo M, Nimmich G, Arango M, Echavarría M. Reduction of malaria prevalence after introduction of Romanomermis culicivorax (Mermithidae: Nematoda) in larval Anopheles habitats in Colombia. Bull World Health Organ. 1987; 65(3): 331-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985-1986	*	†
Colombia	Tada MS, Mattos Ferreira RDG, Katsuragawa TH, Dalla Martha RC, Costa JDA, Albrecht L, Wunderlich G, Pereira da Silva, LH asymptomatic infection with Plasmodium falciparum and Plasmodium vivax in the Brazilian Amazon basin: to treat or not to treat? Mem Inst Oswaldo Cruz. 2012; 107: 621-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Colombia	Valero MV, Amador LR, Galindo C, Figueroa J, Bello MS, Murillo LA, Mora AL, Patarroyo G, Rocha CL, Rojas M. Vaccination with SP166, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet. 1993; 341(8847): 705-10 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Colombia	Colombia Vital Registration Birth Data 1986 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1986		
Colombia	Colombia - Bogota Congenital Malformations Surveillance Program Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Colombia	Colombia Latin American Collaborative Study of Congenital Malformations Data 1993-1994 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1994	*	
Colombia	Colombia - Bogota Congenital Malformations Surveillance Program Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
Comoros	United Nations Development Programme (UNDP), United Nations Children's Fund (UNICEF). Comoros Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Comoros	Macro International, Inc, National Centre of Documentation and Scientific Research (Comoros). Comoros Demographic and Health Survey 1996. Calverton, United States: Macro International, Inc.	1996		†
Comoros	World Health Organization (WHO). Comoros World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Comoros	Centre for Health Informatics and Multiprofessional Education, University College London. Model's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Comoros	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Comoros	Gibbs, S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int J Dermatol. 1996; 35(9): 633-9.	1994		
Comoros	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997, 1999, 2003-2009		
Comoros	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Comoros	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2012		
Comoros	Comoros Survey on the Prevalence of Goiter and Vitamin A Deficiency 1994 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1994		
Comoros	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Comoros	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Comoros	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Comoros	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Comoros	Boisier P, Morvan JM, Laventure S, Charrier N, Martin E, Ouledi A, Roux J. [Dengue 1 epidemic in the Grand Comoro Island (Federal Islamic Republic of the Comores). March-May 1993]. Ann Soc Belg Med Trop. 1994; 74(3): 217-29.	1993		
Comoros	Charafouline H, Pesson B. [Bancroft's filariasis in Anjouan (Comoro Islands)]. Bull Soc Pathol Exot Filiales. 1986; 79(2): 229-36. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1982	*	
Comoros	Comoros Plasmodium Falciparum Parasite Rate Data, Personal Communication with G. Li 2009 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Congo	National Center for Statistics and Economic Studies (Congo, Rep.). Congo, Rep. Household Survey for Poverty Assessment 2005.	2005		
Congo	Macro International, Inc, National Center for Statistics and Economic Studies (Congo, Rep.). Congo, Rep. Demographic and Health Survey 2005. Calverton, United States: Macro International, Inc.	2005		†
Congo	World Health Organization (WHO). Congo, Rep. World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Congo	ICF International, Ministry of Health (Congo, Rep.), National Center for Statistics and Economic Studies (Congo, Rep.), Congo, Rep. Demographic and Health Survey 2011-2012. Fairfax, United States: ICF International, 2013.	2011-2012	*	†
Congo	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Congo	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Congo	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1996-1997, 1999, 2001, 2003-2009		
Congo	World Health Organization (WHO). Yellow fever, Republic of the Congo. Wkly Epidemiol Rec. 2009; 84(19): 161.	2009		
Congo	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2002-2003		
Congo	Berrang-Ford L, Lundine J, Breau S. Conflict and human African trypanosomiasis. Soc Sci Med. 2011; 72(3): 398-407.	1976-2004	*	
Congo	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Congo	Guerchet M, Mbelesso P, Mouanga AM, Bandzouzi B, Tabo A, Houinato DS, Paraiso MN, Cowppli-Bony P, Nubukpo P, Abovans V, Clément J-P, Dartigues J-F, Preux P-M. Prevalence of dementia in elderly living in two cities of Central Africa: the EDAC survey. Dement Geriatr Cogn Disord. 2010; 30(3): 261-8.	2008-2009		
Congo	Blindness prevention: prevalence and causes of blindness and visual loss - Weekly Epidemiological Record 1990 as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1988		
Congo	Kimball-Kaky G, Gombet T, Voumbo Y, Ikama-Méou S, Elenga-Mbola B, Mbika-Cardorelle A, Dilou L, Ekoba J, Nkoua JL, Moyon G, Bouramoué C. Rheumatic heart disease in schoolchildren in Brazzaville. Med Trop (Mars). 2008; 68(6): 603-5.	2005		
Congo	Longo-Mbenza B, Bayekula M, Ngyulu R, Kintoki VE, Bikangi NF, Seghers KV, Lukoki LE, Mandundu MF, Manzanza M, Nlandu Y. Survey of rheumatic heart disease in school children of Kinshasa town. Int J Cardiol. 1998; 63(3): 287-94.	1996		
Congo	Vogel JP, Betrán AP, Widmer M, Souza JP, Gülmezoglu AM, Seuc A, Torloni MR, Mengestu TK, Merialdi M. Role of faith-based and nongovernment organizations in the provision of obstetric services in 3 African countries. Am J Obstet Gynecol. 2012; 207(6): 495e1-7.	2004-2005	*	
Congo	Petitjeans F, Gandin C, Sturtz F. Epilepsie dans les pays en voie de développement: recensement et description de cas dans deux villages congolais. Epilepsies. 1995; 167-78.	1992	*	
Congo	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 2001, 2004, 2007, 2010, 2012		
Congo	Congo - Likouala Fight Against Endemic Diseases, Including Iodine Deficiency Mission Report 1987 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1987		
Congo	Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J Health Geogr. 2010; 9: 57.	1980-2010		
Congo	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Congo	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Congo	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Congo	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Congo	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Congo	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Congo	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Congo	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Congo	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Congo	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Congo	Guerchet M, Abovans V, Mbelesso P, Mouanga AM, Salazar J, Bandzouzi B, Tabo A, Clément JP, Preux PM, Lacroix P. Epidemiology of Peripheral Artery Disease in Elder General Population of Two Cities of Central Africa: Bangui and Brazzaville. Eur J Vasc Endovasc Surg. 2012; 44(2): 164-9.	2008-2009		
Congo	Lallemant M, Galacteros F, Lallemand-Lecoq S, Feingold J, Carnevale P, Boukila V, Mouchet J, Rosa J. Hemoglobin abnormalities. An evaluation on new-born infants and their mothers in a maternity unit close to Brazzaville (P.R. Congo). Hum Genet. 1986; 74(1): 54-8.	1983-1985	*	
Congo	Jäger H, Nseka K, Goussard B, Kabeya C-M, Rauhaus G, Peyerl G, Salaun J-J, Korte R. Voluntary blood donor recruitment: a strategy to reduce transmission of HIV-1, hepatitis-B and syphilis in Kinshasa, Zaïre. Infusionstherapie. 1990; 17(4): 224-6.	1989		
Congo	Brandicourt O, Carne B, Gay F, Turk P, Getiniini M. Widespread in vitro resistance to chloroquine of Plasmodium falciparum in the Congo, 1987. Trop Med Parasitol. 1991; 42(1): 55-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Congo	Carne B, Ndounga M, Kissila AM, Mbtsi A, Samba G, Baya T. Resultats de l'enquete menee en 1996 a Brazzaville de la chimiorésistance du Plasmodium falciparum. Malaria and Infectious Diseases in Africa. 1997; 7: 53-60 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Congo	Chandenier J, Ndounga M, Carne B, Gay F, Mbtsi A, Hayette MP, Stanghellini A, Ossoh JO, Baudon D, Zitsamélé RC. [Drug sensitivity of Plasmodium falciparum in vivo and in vitro in Brazzaville (Congo)]. Sante. 1995; 5(1): 25-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Congo	Ibara-Okabande R, Koukoukila-Koussounda F, Ndongma M, Vouvougui J, Malonga V, Sidibe A, Ntouni F, Ibara JR, Ndongma M, Casimiro PN. Reduction of multiplicity of infections but no change in msp2 genetic diversity in Plasmodium falciparum isolates from Congolese children after introduction of artemisinin-combination therapy. <i>Malar J</i> . 2012; 11: 410 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2010	*	†
Congo	Koukoukila-Koussounda F, Malonga V, Mayengue PI, Ndongma M, Vouvougui CJ, Ntouni F. Genetic polymorphism of mezozoite surface protein 2 and prevalence of K76T pfert mutation in Plasmodium falciparum field isolates from Congolese children with asymptomatic infections. <i>Malar J</i> . 2012; 11: 105 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2010	*	†
Congo	Trape JF. Rapid evaluation of malaria parasite density and standardization of thick smear examination for epidemiological investigations. <i>Trans R Soc Trop Med Hyg</i> . 1985; 79(2): 181-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Congo	Trape JF. Malaria and urbanization in central Africa: the example of Brazzaville. Part IV. Parasitological and serological surveys in urban and surrounding rural areas. <i>Trans R Soc Trop Med Hyg</i> . 1987; 81(2): 26-33 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Congo	Trape JF, Fribourg-Blanc A. Ahaetoglobinemia in African populations and its relation to malaria endemicity. <i>Am J Epidemiol</i> . 1988; 127(6): 1282-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Costa Rica	Department of Statistics and Censuses (Costa Rica), International Statistical Institute. Costa Rica World Fertility Survey 1976. Voorburg, Netherlands: International Statistical Institute.	1976		
Costa Rica	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-1991, 1993-2002		
Costa Rica	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Costa Rica	Estrada Castañón R, Torres Bibiano B, Alarcón Hernández H, Villegas Arrizón A, Martínez Sandoval E, Chávez López G, Andersson N. Epidemiología cutánea en dos sectores de atención médica en Guerrero, México; Cutaneous epidemiology in two sectors of Guerrero, Mexico. <i>Dermatol rev mex</i> . 1992; 36(1): 29-34.	1989-1991		
Costa Rica	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol</i> . 2008; 121(4): 947-954.	1994, 2002		
Costa Rica	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997-2001, 2003-2009		
Costa Rica	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J</i> . 1998; 12(2): 315-35.	1993-1995		
Costa Rica	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	2002		
Costa Rica	Mallol J, Solé D, Baeza-Bacab M, Aguirre-Camposano V, Soto-Quiros M, Baena-Cagnani C, Latin American ISAAC Group. Regional variation in asthma symptom prevalence in Latin American children. <i>J Asthma</i> . 2010; 47(6): 644-50.	2001-2003	*	
Costa Rica	Abarca G, Navarrete M, Trejos R, de Céspedes C, Saborío M. Abnormal haemoglobins in the newborn human population of Costa Rica. <i>Rev Biol Trop</i> . 2008; 56(3): 995-1001.	2005-2006	*	
Costa Rica	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Costa Rica Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2006		
Costa Rica	Costa Rican Demographic Association, Ministry of Health (Costa Rica), United Nations Children's Fund (UNICEF). Costa Rica Multiple Indicator Cluster Survey 2011. New York, United States: United Nations Children's Fund (UNICEF), 2013.	2011	*	
Costa Rica	Cerdas M. Chronic kidney disease in Costa Rica. <i>Kidney Int Suppl</i> . 2005; 97(Suppl): S31-3.	2000		
Costa Rica	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Costa Rica	Rodríguez AC, Castle PE, Smith JS, Bratti C, Hildesheim A, Schiffman M, Viscidi R, Burk RD, Ashley RL, Castellsagué X, Herrero R. A population based study of herpes simplex virus 2 seroprevalence in rural Costa Rica. <i>Sex Transm Infect</i> . 2003; 79(6): 460-5.	1993-1994	*	
Costa Rica	Laclé A, Valero-Juan LF. Diabetes-related lower-extremity amputation incidence and risk factors: a prospective seven-year study in Costa Rica. <i>Rev Panam Salud Publica</i> . 2012; 32(3): 192-8.	2001-2007		
Costa Rica	Chaves M, Sáenz GF, Quintana E, Montero A, Jiménez J. Polymorphism of erythrocytic glucose-6-phosphate dehydrogenase in Costa Rica. <i>Sangre (Barc)</i> . 1988; 33(1): 12-4.	1986-1988		
Costa Rica	Fernández-Cean J, González-Martínez F, Schwedt E, Mazzuchi N. Renal replacement therapy in Latin America. <i>Kidney Int</i> . 2000; 57(s74): 55-59.	1997		
Costa Rica	Cusumano A, García-García G, Di Gioia C, Hermida O, Lavorato C, Carreño CA, Torrico MP, Batista PB, Romão JE, Badal HP, Miranda SE, Gomez R, Calderon MC, Sanchez SH, Lopez MA, Moscoso J, Merino RL, Polo JV, Lopez A, Romero NJ, Garcia R, Acosta BV, Lopez AS, Delpin ES, Mena E, González C, Milanés CL, Acchiardo S. End-stage renal disease and its treatment in Latin America in the twenty-first century. <i>Ren Fail</i> . 2006; 28(8): 631-7.	2002, 2004		
Costa Rica	Santiago-Delpin EA, García VD. Latin American Transplant Registry VIIIth Report: 1998. <i>Transplant Proc</i> . 1999; 31(1-2): 214-6.	1995, 1997		
Costa Rica	Cusumano A, García GG, Di Gioia C, Hermida O, Lavorato C. Latin American Registry of Dialysis and Transplantation. The Latin American Dialysis and Transplantation Registry (RLDT) annual report 2004. <i>Ethn Dis</i> . 2006; 16(2 Suppl 2): 10-3.	2003		
Costa Rica	World Health Organization (WHO). Costa Rica WHO Leishmaniasis Country Profile.	2002-2010	*	
Costa Rica	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec</i> . 2009; 84(33): 333-40.	2008	*	
Costa Rica	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec</i> . 2012; 87(34): 317-28.	2011	*	
Costa Rica	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec</i> . 1999; 74(38): 313-6.	1998	*	
Costa Rica	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec</i> . 2001; 76(23): 173-9.	2000	*	
Costa Rica	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec</i> . 2000; 75(28): 226-31.	1999	*	
Costa Rica	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1994; 69(20): 145-51.	1993	*	
Costa Rica	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec</i> . 1997; 72(23): 165-72.	1996	*	
Costa Rica	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec</i> . 1996; 71(20): 149-56.	1995	*	
Costa Rica	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1995; 70(25): 177-82.	1994	*	
Costa Rica	Oberle MW, Rosero-Bixby L, Lee FK, Sanchez-Braverman M, Nahmias AJ, Guinan ME. Herpes simplex virus type 2 antibodies: high prevalence in monogamous women in Costa Rica. <i>Am J Trop Med Hyg</i> . 1989; 41(2): 224-9.	1984-1985	*	
Costa Rica	Ministry of Health (Costa Rica). Costa Rica Ministry of Health Dengue Surveillance 2007-2008.	2007-2008		
Costa Rica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2003. Pan American Health Organization (PAHO).	2003		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Costa Rica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2004. Pan American Health Organization (PAHO).	2004		†
Costa Rica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2005. Pan American Health Organization (PAHO).	2005		†
Costa Rica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2006. Pan American Health Organization (PAHO).	2006		†
Costa Rica	Odió CM, Faingezicht I, Paris M, Nassar M, Baltodano A, Rogers J, Sáez-Llorens X, Olsen KD, McCraggen GH. The Beneficial Effects of Early Dexamethasone Administration in Infants and Children with Bacterial Meningitis. <i>N Engl J Med.</i> 1991; 324(22): 1525-31.	1988		
Costa Rica	Ulloa-Gutierrez R, Avila-Aguero ML, Herrera ML, Herrera JF, Arguedas A. Invasive pneumococcal disease in Costa Rican children: a seven year survey. <i>Pediatr Infect Dis J.</i> 2003; 22(12): 1069-74.	1995-2001		
Costa Rica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Costa Rica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Costa Rica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Costa Rica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Costa Rica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Costa Rica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Costa Rica	Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezziati M, Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. <i>Lancet.</i> 2011; 378(9785): 31-40.	2000		
Costa Rica	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L, Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Ann Hepatol.</i> 2010; 9(1): 63-9.	2006-2008	*	
Costa Rica	Villarejos VM, Serra J, Anderson-Visona K, Mosley JW. Hepatitis A virus infection in households. <i>Am J Epidemiol.</i> 1982; 115(4): 577-86.	1976-1978		
Costa Rica	Pan American Health Organization (PAHO), World Health Organization (WHO). Quantitative Estimation of Chagas in the Americas.	2005	*	
Costa Rica	Diaz T, Achi R. Infectious diseases in a Nicaraguan refugee camp in Costa Rica. <i>Trop Doct.</i> 1989; 19(1): 14-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Costa Rica	Costa Rica Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Costa Rica	Costa Rican Birth Defects Register Center Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
Costa Rica	Costa Rican Birth Defects Register Center Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
Costa Rica	Costa Rican Birth Defects Register Center Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Costa Rica	Costa Rican Register of Congenital Malformation Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
Côte d'Ivoire	Macro International, Inc, National Institute of Statistics (Côte d'Ivoire). Côte d'Ivoire Demographic and Health Survey 1994. Calverton, United States: Macro International, Inc.	1994		†
Côte d'Ivoire	Macro International, Inc, National Institute of Statistics (Côte d'Ivoire). Côte d'Ivoire Demographic and Health Survey 1998-1999. Calverton, United States: Macro International, Inc.	1998-1999		†
Côte d'Ivoire	ICF International, Ministry of the Fight Against AIDS (Côte d'Ivoire), National Institute of Statistics (Côte d'Ivoire). Côte d'Ivoire Demographic and Health Survey 2011-2012. Fairfax, United States: ICF International, 2013.	2011-2012	*	†
Côte d'Ivoire	World Health Organization (WHO). Côte d'Ivoire World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Côte d'Ivoire	United Nations Children's Fund (UNICEF), National Institute of Statistics (Côte d'Ivoire). Côte d'Ivoire Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006	*	†
Côte d'Ivoire	National School for Statistics and Economics Applied (ENSEA), United Nations Children's Fund (UNICEF), United Nations Educational, Scientific and Cultural Organization (UNESCO). Côte d'Ivoire Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	
Côte d'Ivoire	Department of Statistics (Côte d'Ivoire), International Statistical Institute. Côte d'Ivoire World Fertility Survey 1980-1981. Voorburg, Netherlands: International Statistical Institute.	1980-1981		
Côte d'Ivoire	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Côte d'Ivoire	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Côte d'Ivoire	Filippi V, Ronsmans C, Gohou V, Goufodji S, Lardi M, Sahel A, Saizonou J, De Brouwere V. Maternity wards or emergency obstetric rooms? Incidence of near-miss events in African hospitals. <i>Acta Obstet Gynecol Scand.</i> 2005; 84(1): 11-6.	1999-2001		
Côte d'Ivoire	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1982, 1997		
Côte d'Ivoire	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1996, 1998-1999, 2001-2009		
Côte d'Ivoire	Mutebi J-P, Barrett ADT. The epidemiology of yellow fever in Africa. <i>Microbes Infect.</i> 2002; 4(14): 1459-68.	2001		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Côte d'Ivoire	Lhuillier M, Sarthou JL, Cordellier R, Gershy-Damet GM, M'onteny N, Bouchite B, Calen P. Rural epidemic of yellow fever with interhuman transmission in the Ivory Coast in 1982. <i>Bull World Health Organ.</i> 1985; 63(3): 527-36.	1982		
Côte d'Ivoire	World Health Organization (WHO). Yellow fever in Africa and South America, 2006. <i>Wkly Epidemiol Rec.</i> 2008; 83(8): 60-76.	2006		
Côte d'Ivoire	World Health Organization (WHO). Yellow fever, Côte d'Ivoire. <i>Wkly Epidemiol Rec.</i> 2006; 81(43): 410.	2006		
Côte d'Ivoire	Utzingier J, NGoran EK, Esse Aya CM, Acka Adjoua C, Lohourignon KL, Tanner M, Lengeler C. Schistosoma mansoni, intestinal parasites and perceived morbidity indicators in schoolchildren in a rural endemic area of western Côte d'Ivoire. <i>Trop Med Int Health.</i> 1998; 3(9): 711-20.	1997-1998		
Côte d'Ivoire	Utzingier J, NGoran EK, Tanner M, Lengeler C. Simple anamnestic questions and recalled water-contact patterns for self-diagnosis of Schistosoma mansoni infection among schoolchildren in western Côte d'Ivoire. <i>Am J Trop Med Hyg.</i> 2000; 62(5): 649-55.	1998		
Côte d'Ivoire	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2001		
Côte d'Ivoire	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Côte d'Ivoire	Akran V, Peenze I, Akoua-Koffi C, Kette H, de Beer MC, Dosso M, Steele AD. Molecular characterization and genotyping of human rotavirus strains in Abidjan, Côte d'Ivoire. <i>J Infect Dis.</i> 2010; S220-224.	2000-2002, 2004	*	
Côte d'Ivoire	Filippi V, Ronsmans C, Gohou V, Goufodji S, Lardi M, Sahel A, Saizonou J, De Brouwere V. Maternity wards or emergency obstetric rooms? Incidence of near-miss events in African hospitals. <i>Acta Obstet Gynecol Scand.</i> 2005; 84(1): 11-16.	2000-2001		
Côte d'Ivoire	Kaudjhis P. Les agrégats de l'épilepsie de M'brou: approche électroclinique et étiologique [medical thesis]. Abidjan, Côte-d'Ivoire; 1995.	1995	*	
Côte d'Ivoire	Kouassi B, Koffi J, Diarra J, Delorme H, Akani A, Yapi P, Sonant, Boa Y, Piquemal M, Fadiga D, Guessennd G, Giordano C. Prévalence de l'épilepsie en milieu rural ivoirien étude pilote. <i>Publ Med Africaines.</i> 1988; 25-30.	1987	*	
Côte d'Ivoire	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Côte d'Ivoire	Coulibaly FH, Koffi G, Touré HA, Bouanga JC, Allangba O, Tolo A, Sawadogo D, Sanogo I, Konaté S, Préhu C, Sangaré A, Galacteros F. Molecular genetics of glucose-6-phosphate dehydrogenase deficiency in a population of newborns from Ivory Coast. <i>Clin Biochem.</i> 2000; 33(5): 411-3.	1998-2000		
Côte d'Ivoire	Echimane AK, Ahnoux AA, Adoubi I, Hien S, M'Bra K, D'Horpock A, Diomande M, Anongba D, Mensah-Adoh I, Parkin DM. Cancer incidence in Abidjan, Ivory Coast 1995-1997. <i>Cancer.</i> 2000; 89(3): 653-63.	1995-1997	*	
Côte d'Ivoire	Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. <i>Int J Health Geogr.</i> 2010; 9: 57.	1980-2010		
Côte d'Ivoire	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec.</i> 2005; 80(13): 118-24.	2003	*	
Côte d'Ivoire	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Côte d'Ivoire	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Côte d'Ivoire	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Côte d'Ivoire	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Côte d'Ivoire	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Côte d'Ivoire	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Côte d'Ivoire	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Côte d'Ivoire	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1993; 68(25): 181-6.	1992	*	
Côte d'Ivoire	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Côte d'Ivoire	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Côte d'Ivoire	Lafort Y, Sawadogo Y, Delvaux T, Vuylsteke B, Laga M. Should family planning clinics provide clinical services for sexually transmitted infections? A case study from Côte d'Ivoire. <i>Trop Med Int Health.</i> 2003; 8(6): 552-60.	2000	*	
Côte d'Ivoire	Kouamé P, Bellis G, Tebbi A, Gaimard M, Dilumbu I, Assouan A, Roux F, Mayer G, Chastin I, Diarra N, Chaventré A. The prevalence of goitre and cretinism in a population of the west Ivory Coast. <i>Coll Antropol.</i> 1998; 22(1): 31-41 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1994		
Côte d'Ivoire	Zimmermann M, Adou P, Torresani T, Zeder C, Hurrell R. Persistence of goiter despite oral iodine supplementation in goitrous children with iron deficiency anemia in Côte d'Ivoire. <i>Am J Clin Nutr.</i> 2000; 71(1): 88-93 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1997		
Côte d'Ivoire	Hess SY, Zimmermann MB, Adou P, Torresani T, Hurrell RF. Treatment of iron deficiency in goitrous children improves the efficacy of iodized salt in Côte d'Ivoire. <i>Am J Clin Nutr.</i> 2002; 75(4): 743-8 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1999-2000		
Côte d'Ivoire	Diallo MO, Ackah AN, Lafontaine MF, Doorly R, Roux R, Kanga JM, Heroin P, De Cock KM. HIV-1 and HIV-2 infections in men attending sexually transmitted disease clinics in Abidjan, Côte d'Ivoire. <i>AIDS.</i> 1992; 6(6): 581-5.	1992		
Côte d'Ivoire	Fulgence KK, Abibatou K, Vincent D, Henriette V, Etienne AK, Kiki-Barro PC, Yavo W, Koné M, Hervé Menan EI. Tinea capitis in schoolchildren in southern Ivory Coast. <i>Int J Dermatol.</i> 2013; 52(4): 456-60.	2008-2009	*	
Côte d'Ivoire	Tanon-Anoh MJ, Sanogo-Gone D, Kouassi KB. Newborn hearing screening in a developing country: results of a pilot study in Abidjan, Côte d'Ivoire. <i>Int J Pediatr Otorhinolaryngol.</i> 2010; 74(2): 188-91.	2007-2008	*	
Côte d'Ivoire	Memmi-Montezzo: A Malaria Observatory in a Rural Area of Ivory Coast. Results of the Feasibility Study as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†
Côte d'Ivoire	Mission Report of the Entomological and Parasitological Survey from July 2002 in Soubre, Southwest of Côte d'Ivoire as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Côte d'Ivoire	Contribution to the Evaluation of the Sensitivity of Plasmodium falciparum to Chloroquine in Greater Abidjan (Côte d'Ivoire) as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†
Côte d'Ivoire	Malaria in the Forest Area of Tai (Côte d'Ivoire): Entomological Transmission Indices and Parasite Prevalence Among Children in the Villages of Zapobly and Gahably as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Côte d'Ivoire	Identifying Mosquito Species and the Dynamics of Malaria Transmission Around Small Dams in the North of Côte d'Ivoire as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Côte d'Ivoire	Activity Reports on Entomological and Parasitological Surveys Conducted in February, May and August 2005 in Zatta (Yamoussoukro) and Tiémélékro (Dimbokro), Côte d'Ivoire as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Côte d'Ivoire	Côte d'Ivoire National Malaria Control Program Annual Report 2005 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Côte d'Ivoire	Contribution to the Study of Coastal Lagoon Malaria in the Region of Grand Bassam in Côte d'Ivoire as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Côte d'Ivoire	Djaman JA, Kauffy PC, Yavo W, Basco LK, Kone M. [In vivo evaluation of sulfadoxine-pyrimethamine efficacy during uncomplicated falciparum malaria in children of Yopougon (Abidjan, Côte d'Ivoire)]. Bull Soc Pathol Exot. 2004; 97(3): 180-2 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999-2000	*	†
Côte d'Ivoire	Dossou-Yovo J, Ouattara A, Doannio JM, Diarrassouba S, Chauvancy G. [Malaria surveys in a humid savannah region in Côte d'Ivoire]. Med Trop (Mars). 1998; 58(1): 51-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†
Côte d'Ivoire	Girardin O, Dao D, Koudou BG, Essé C, Cissé G, Yao T, N'Goran EK, Tschannen AB, Bordmann G, Lehmann B, Nsabimana C, Keiser J, Killeen GF, Singer BH, Tanner M, Utzinger J. Opportunities and limiting factors of intensive vegetable farming in malaria endemic Côte d'Ivoire. Acta Trop. 2004; 89(2): 109-23 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000	*	†
Côte d'Ivoire	Henry MC, Doannio JM, Darriet F, Nzeyimana I, Carnevale P. [Efficacy of permethrin-impregnated Olyset Net mosquito nets in a zone with pyrethroid resistance vectors. II. Parasitic and clinical evaluation]. Med Trop (Mars). 1999; 59(4): 355-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Côte d'Ivoire	Henry MC, Rogier C, Nzeyimana I, Assi SB, Dossou-Yovo J, Audibert M, Mathonnat J, Keundjian A, Akodo E, Teuscher T, Carnevale P. Inland valley rice production systems and malaria infection and disease in the savannah of Côte d'Ivoire. Trop Med Int Health. 2003; 8(5): 449-58 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
Côte d'Ivoire	Koudou BG, Ghattas H, Essé C, Nsanabana C, Rohrer F, Utzinger J, Faragher BE, Tschannen AB. The use of insecticide-treated nets for reducing malaria morbidity among children aged 6-59 months, in an area of high malaria transmission in central Côte d'Ivoire. Parasit Vectors. 2010; 3: 91 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2007	*	†
Côte d'Ivoire	Koudou BG, Tano Y, Keiser J, Vounatsou P, Girardin O, Klero K, Koné M, N'goran EK, Cissé G, Tanner M, Utzinger J. Effect of agricultural activities on prevalence rates, and clinical and presumptive malaria episodes in central Côte d'Ivoire. Acta Trop. 2009; 111(3): 268-74 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002-2003	*	†
Côte d'Ivoire	Matthys B, Vounatsou P, Raso G, Tschannen AB, Becket EG, Gosoni L, Cissé G, Tanner M, N'goran EK, Utzinger J. Urban farming and malaria risk factors in a medium-sized town in Côte d'Ivoire. Am J Trop Med Hyg. 2006; 75(6): 1223-31 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Côte d'Ivoire	Müller I, Coulibaly JT, Fürst T, Knopp S, Hattendorf J, Krauth SJ, Stele K, Righetti AA, Glinz D, Yao AK, Püschel U, N'goran EK, Utzinger J. Effect of schistosomiasis and soil-transmitted helminth infections on physical fitness of school children in Côte d'Ivoire. PLoS Negl Trop Dis. 2011; 5(7): 1239 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2010	*	†
Côte d'Ivoire	Nzeyimana I, Henry MC, Dossou-Yovo J, Doannio JM, Diawara L, Carnevale P. [The epidemiology of malaria in the southwestern forests of the Ivory Coast (Tai region)]. Bull Soc Pathol Exot. 2002; 95(2): 89-94 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Côte d'Ivoire	Penali LK, Assi-Coulibaly L, Kaptu B, Konan D, Ehouman A. [Parasitological and clinical response to amodiaquine versus chloroquine in the treatment of Plasmodium falciparum malaria in children in an endemic area]. Bull Soc Pathol Exot. 1994; 87(4): 244-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†
Côte d'Ivoire	Raso G, Lugimbizi A, Adjoua CA, Tian-Bi NT, Silué KD, Matthys B, Vounatsou P, Wang Y, Dumas ME, Holmes E, Singer BH, Tanner M, N'goran EK, Utzinger J. Multiple parasite infections and their relationship to self-reported morbidity in a community of rural Côte d'Ivoire. Int J Epidemiol. 2004; 33(5): 1092-102 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Côte d'Ivoire	Rey JL, Houdier R, Soro B, Coulibaly A. Efficacité parasitologique d'une dose unique de différents antimalariques chez des enfants de la région d'Abidjan. Med Afr Noire. 1986; 33(8): 643-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Côte d'Ivoire	Righetti AA, Wegmüller R, Glinz D, Ouattara M, Adiosan LG, N'Goran EK, Utzinger J, Hurrell RF. Effects of inflammation and Plasmodium falciparum infection on soluble transferrin receptor and plasma ferritin concentration in different age groups: a prospective longitudinal study in Côte d'Ivoire. Am J Clin Nutr. 2013; 97(6): 1364-74 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2010	*	†
Côte d'Ivoire	Rohrer F, Zimmermann MB, Wegmüller R, Tschannen AB, Hurrell RF. Mild riboflavin deficiency is highly prevalent in school-age children but does not increase risk for anaemia in Côte d'Ivoire. Br J Nutr. 2007; 97(5): 970-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Côte d'Ivoire	Silue KD, Felger I, Utzinger J, Beck HP, Smith TA, Tanner M, N'Goran EK. [Prevalence, genetic diversity and multiplicity of Plasmodium falciparum infection in school children in central Côte d'Ivoire]. Med Trop (Mars). 2006; 66(2): 149-56 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Côte d'Ivoire	Utzinger J, N'Goran EK, N'Dri A, Lengeler C, Xiao S, Tanner M. Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial. Lancet. 2000; 355(9212): 1320-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
Côte d'Ivoire	Yavo W, Menan EI, Adjete TA, Barro-Kiki PC, Nigué L, Konan YJ, Nebavi NG, Koné M. [In vivo sensitivity of Plasmodium falciparum to amino-4-quinolines and sulfadoxine pyrimethamine in Agou (Ivory Coast)]. Pathol Biol. 2002; 50(3): 184-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Croatia	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2002-2011		
Croatia	Croatia Vital Registration - Deaths 1996 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1996	*	
Croatia	Croatia Vital Registration - Deaths 1999 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1999	*	
Croatia	Croatia Vital Registration - Deaths 2003 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2003	*	
Croatia	World Health Organization (WHO). Croatia World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Croatia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Croatia	Galčić J, Simunović D. Prostate disease prevalence with epidemiological and hormonal analysis in randomly selected male population in Croatia. <i>Coll Antropol.</i> 2008; 32(4): 1195-202.	2006		
Croatia	Lepur D, Baršić B. Community-acquired bacterial meningitis in adults: antibiotic timing in disease course and outcome. <i>Infection.</i> 2007; 35(4): 225-31.	1990-2004		
Croatia	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1999-2009		
Croatia	Alilović M, Peros-Golubičić T, Tekavec-Trkanjec J, Ivčević A. Prevalence of hospitalized patients with sarcoidosis in Croatia. <i>Coll Antropol.</i> 2004; 28(1): 423-8.	1997-2002		
Croatia	Materljan E, Sepčić J, Antonelli L, Sepčić-Grahovac D. Multiple sclerosis in Istria, Yugoslavia. <i>Neurologija.</i> 1989; 38(3): 201-12.	1961-1972, 1981		
Croatia	Pekmezović T, Jarebinski M, Druлович J, Stojasavljević N, Levic Z. Prevalence of multiple sclerosis in Belgrade, Yugoslavia. <i>Acta Neurol Scand.</i> 2001; 104(6): 353-7.	1985-1996		
Croatia	Lai CK, Beasley R, Crane J, Folitaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2002		
Croatia	Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. <i>Diabetologia.</i> 1996; 39(11): 1377-84.	1993-1995		
Croatia	Gudelj I, Mrkić Kobal I, Munivrana Škvorc H, Miše K, Vrbica Z, Plavec D, Tudorić N. Intraregional differences in asthma prevalence and risk factors for asthma among adolescents in Split-Dalmatia County, Croatia. <i>Med Sci Monit.</i> 2012; 18(4): PH43-50.	2009-2011	*	
Croatia	Dukić W, Delija B, Lučić Dukić O. Caries prevalence among schoolchildren in Zagreb, Croatia. <i>Croat Med J.</i> 2011; 52(6): 665-71.	2009-2010	*	
Croatia	Jokić NI, Bakarić D, Janković S, Malatestinić G, Dabo J, Majstorović M, Vuksan V. Dental caries experience in Croatian school children in Primorsko-Goranska county. <i>Cent Eur J Public Health.</i> 2013; 21(1): 39-42.	2008-2009	*	
Croatia	Vrbic V, Vulović M, Raji Z, Topić B, Tati E, Mali M, Mili D, Aurer-Kozelj J, Neceva L, Redzepagi S. Oral health in SFR Yugoslavia in 1986. <i>Community Dent Oral Epidemiol.</i> 1988; 16(5): 286-8.	1986		
Croatia	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2004-2006		
Croatia	United States Renal Data System Coordinating Center. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2001-2003		
Croatia	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pampidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Croatia	Jajić I, Sućur A. [Backache in the population]. <i>Reumatizam.</i> 1985; 32(1-2): 5-9.	1982		
Croatia	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1995, 1999		
Croatia	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Croatia	Josipović-Jelić Z, Sonicki Z, Soljan I, Demarin V, Collaborative Group for Study of Epilepsy Epidemiology in Sibenik-Knin County, Croatia. Prevalence and socioeconomic aspects of epilepsy in the Croatian county of Sibenik-Knin: community-based survey. <i>Epilepsy Behav.</i> 2011; 20(4): 686-90.	1995-2005	*	†
Croatia	Pikija S, Cvetko D, Malojčić B, Trkanjec Z, Pavlicek I, Lukic A, Kopjar A, Hajduk M, Andrović A, Bilic-Gener M, Trkulja V. A population-based prospective 24-month study of stroke: incidence and 30-day case-fatality rates of first-ever strokes in Croatia. <i>Neuroepidemiology.</i> 2012; 38(3): 164-71.	2007-2009	*	
Croatia	Bielen I, Cvitanović-Sojat L, Bergman-Marković B, Kosicek M, Planjar-Prvan M, Vuksic L, Miketek G, Matek P. Prevalence of epilepsy in Croatia: a population-based survey. <i>Acta Neurol Scand.</i> 2007; 116(6): 361-7.	2005	*	
Croatia	Başoğlu M, Livanou M, Crnobarac C, Francisković T, Suljić E, Durić D, Vranesić M. Psychiatric and cognitive effects of war in former Yugoslavia: association of lack of redress for trauma and posttraumatic stress reactions. <i>JAMA.</i> 2005; 294(5): 580-90.	2000-2002	*	
Croatia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2010		
Croatia	Božičević I, Grgić I, Židovec-Lepelj S, Čakalo J, Belak-Kovačević S, Štulhofer A, Begovac J. Urine-based testing for Chlamydia trachomatis among young adults in a population-based survey in Croatia: feasibility and prevalence. <i>BMC Public Health.</i> 2011; 230.	2010	*	
Croatia	Stipančić G, La Grasta Sabolic L, Malenica M, Radica A, Skrabec V, Tiljak MK. Incidence and trends of childhood Type 1 diabetes in Croatia from 1995 to 2003. <i>Diabetes Res Clin Pract.</i> 2008; 80(1): 122-7.	1995-2003		
Croatia	Fraser GR, Defarinas B, Kattamis CA, Race RR, Sanger R, Stamatoyannopoulos G. Glucose-6-phosphate dehydrogenase, colour vision and XG blood groups in Greece: linkage and population data. <i>Ann Hum Genet.</i> 1964; 395-403.	1962		
Croatia	Krzelj V, Zlodre S, Terzić J, Mestrovic M, Jaksic J, Pavlov N. Prevalence of G-6-PD deficiency in the Croatian Adriatic Coast population. <i>Arch Med Res.</i> 2001; 32(5): 454-7.	1999-2001		
Croatia	Markić J, Krzelj V, Markotić A, Marusić E, Striečević L, Zanchi J, Bosnjak N, Sapunar A. High incidence of glucose-6-phosphate dehydrogenase deficiency in Croatian island isolate: example from Vis island, Croatia. <i>Croat Med J.</i> 2006; 47(4): 556-70.	2002-2003		
Croatia	Cala S. Peritoneal dialysis in Croatia. <i>Perit Dial Int.</i> 2007; 27(3): 238-44.	2000-2004		
Croatia	Artuković D, Spalj S, Knezević A, Plančak D, Pandurić V, Anić-Milošević S, Lauc T. Prevalence of periodontal diseases in Zagreb population, Croatia, 14 years ago and today. <i>Coll Antropol.</i> 2007; 31(2): 471-4.	1986, 2000		
Croatia	Plančak D, Aurer-Kozelj J. CPITN assessment of periodontal treatment needs in the population of Zagreb, Croatia. <i>Int Dent J.</i> 1992; 42(6): 441-4.	1991		
Croatia	Petković G, Barišić I. FAS prevalence in a sample of urban schoolchildren in Croatia. <i>Reprod Toxicol.</i> 2010; 29(2): 237-41.	2008, 2010	*	
Croatia	Vuković V, Plavec D, Pavelin S, Janculjak D, Ivanković M, Demarin V. Prevalence of migraine, probable migraine and tension-type headache in the Croatian population. <i>Neuroepidemiology.</i> 2010; 35(1): 59-65.	2006	*	
Croatia	World Health Organization (WHO). Croatia WHO Leishmaniasis Country Profile.	2000-2009	*	
Croatia	Vilbić-Cavlek T, Kucinar J, Ljubić-Sternak S, Kolaric B. Seroepidemiology of Hepatitis A in the Croatian Population. <i>Hepat Mon.</i> 2011; 11(12): 997-9.	2008-2009	*	
Croatia	Šinčić BM, Vučelić B, Persić M, Brnčić N, Erzen DJ, Radaković B, Mičević V, Stimac D. Incidence of inflammatory bowel disease in Primorsko-goranska County, Croatia, 2000-2004: A prospective population-based study. <i>Scand J Gastroenterol.</i> 2006; 41(4): 437-44.	2000-2004		
Croatia	Barek V, Baće A, Kacić M, Belosević D, Mravunac B. Prevalence of antibodies to hepatitis A virus among urban children aged 0-7 years in Yugoslavia. <i>J Infect.</i> 1985; 10(1): 71-5.	1979		
Croatia	Puntarić D, Vodopija I, Baklačić Z, Ljubčić M. [Immunity against hepatitis A in younger age groups and the basis for an immunization program]. <i>Liječ Vjesn.</i> 1995; 117(7-8): 167-72.	1989		
Croatia	Ivić I, Banović I, Bradarić N. Hepatitis B virus infection among pregnant women in Split region. <i>Eur J Epidemiol.</i> 1999; 15(6): 589-90.	1995		
Croatia	Jelić O, Jelić D, Balen I, Jelić A, Jelić N, Mihaljević I. Prevalence of markers of hepatitis B virus infection among the general population of the municipality of Slavonski Brod. <i>Acta Med Croatica.</i> 1993; 48(3): 111-6.	1990-1991		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Croatia	Croatian Registry of Renal Replacement Therapy (CRRRT) Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Croatia	Croatian Registry of Renal Replacement Therapy (CRRRT) Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Croatia	European Surveillance of Congenital Anomalies (EUROCAT). Croatia EUROCAT Prevalence Tables. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	1983-2010		
Croatia	Croatia - Zagreb Congenital Anomaly Data 1993-1997 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1997	*	
Cuba	Cuba Vital Registration - Deaths 2006 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2006	*	
Cuba	National Office of Statistics (Cuba). Cuba Statistical Yearbook 2002. Havana, Cuba: National Office of Statistics (Cuba), 2003	1970, 1980, 1990, 2000-2002	*	
Cuba	Ministry of Public Health (Cuba), United Nations Children's Fund (UNICEF). Cuba Multiple Indicator Cluster Survey 2010-2011. New York, United States: United Nations Children's Fund (UNICEF).	2010-2011	*	
Cuba	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1993-1994, 1997, 1999-2000, 2002-2005		
Cuba	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Cuba	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Cuba	Smadja D, Cabre P, May F, Fanon J-L, René-Corail P, Riocreux C, Charpentier J-C, Fourmerie P, Saint-Vil M, Ketterlé J. ERMANCIA: Epidemiology of Stroke in Martinique, French West Indies. Stroke. 2001; 32(12): 2741-7.	1998-1999		
Cuba	Souza JP, Cecatti JG, Faundes A, Morais SS, Villar J, Carroli G, Gulmezoglu M, Wojdyla D, Zavaleta N, Donner A, Velazco A, Bataglia V, Valladares E, Kubickas M, Acosta A. Maternal near miss and maternal death in the World Health Organization's 2005 global survey on maternal and perinatal health. Bull World Health Organ. 2010; 88(2): 113-9.	2005		
Cuba	Herederó-Baute L. Community-based program for the diagnosis and prevention of genetic disorders in Cuba Twenty years of experience. Community Genet. 2004; 2-3(7): 130-6.	1981, 2002		
Cuba	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997-2009		
Cuba	Reyes-Llerena GA, Guibert-Toledano M, Penedo-Coello A, Pérez-Rodríguez A, Baez-Dueñas RM, Charnicharo-Vidal R, Cardiel MH. Community-based study to estimate prevalence and burden of illness of rheumatic diseases in Cuba: a COPCORD study. J Clin Rheumatol. 2009; 15(2): 51-5.	2006		
Cuba	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2002		
Cuba	Jorge Luis Perez Rivero, Jesus Lazaro Regueira Naranjo, Roberto Hernandez Hernandez. Characterization of diabetes mellitus in a health area. Rev Cubana Med General Integral. 2002; 18(4).	1998		
Cuba	Mallol J, Solé D, Baeza-Bacab M, Aguirre-Camosano V, Soto-Quiros M, Baena-Cagnani C, Latin American ISAAC Group. Regional variation in asthma symptom prevalence in Latin American children. J Asthma. 2010; 47(6): 644-50.	2001-2003	*	
Cuba	Villalba MC, Guan M, Pérez A, Corredor MB, Frometa SS, Moreno AG, Hu WP, Howard T, Lay LA, Anderson D. Seroprevalence of antibodies to hepatitis E virus in two large communities in Havana, Cuba. Trans R Soc Trop Med Hyg. 2010; 104(12): 772-6.	2003		
Cuba	Pérez AE, Dickinson FO, Rodríguez M. Community acquired bacterial meningitis in Cuba: a follow up of a decade. BMC Infect Dis. 2010; 130.	1998-2007		
Cuba	Llibre Rodríguez J, Valhuerdi A, Sanchez II, Reyna C, Guerra MA, Copeland JRM, McKeigue P, Ferri CP, Prince MJ. The prevalence, correlates and impact of dementia in Cuba. A 10/66 group population-based survey. Neuroepidemiology. 2008; 31(4): 243-51.	2005-2007		
Cuba	Prince M, Acosta D, Ferri CP, Guerra M, Huang Y, Llibre Rodríguez JJ, Salas A, Sosa AL, Williams JD, Dewey ME, Acosta I, Jotheeswaran AT, Liu Z. Dementia incidence and mortality in middle-income countries, and associations with indicators of cognitive reserve: a 10/66 Dementia Research Group population-based cohort study. Lancet. 2012; 380(9836): 50-8.	2003-2010		
Cuba	Sousa RM, Ferri CP, Acosta D, Albanese E, Guerra M, Huang Y, Jacob KS, Jotheeswaran AT, Rodriguez JLL, Pichardo GR, Rodriguez MC, Salas A, Sosa AL, Williams J, Zuniga T, Prince M. Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population-based survey. Lancet. 2009; 374(9704): 1821-30.	2003-2005		
Cuba	Morales A, Madrazo Y, Ramirez JI, Castañeda L, Machín W, Álvarez L, Angulo R, Dueñas R, Bermúdez R. Acute myocardial infarction incidence, mortality and case fatality in Santa Clara, Cuba, 2007-2008. MEDICC Rev. 2011; 13(4): 23-9.	2007-2008	*	
Cuba	Canino G, Shrout PE, Rubio-Stipec M, et al. The DSM-IV rates of child and adolescent disorders in Puerto Rico: Prevalence, correlates, service use, and the effects of impairment. Arch Gen Psychiatry. 2004; 61(1): 85-93.	1999-2000		
Cuba	De Jesús Llibre J, Valhuerdi A, Fernández O, Llibre JC, Porto R, López AM, Marcheco B, Moreno C. Prevalence of stroke and associated risk factors in older adults in Havana City and Matanzas Provinces, Cuba (10/66 population-based study). MEDICC Rev. 2010; 12(3): 20-6.	2003-2006		
Cuba	Rubio-Stipec M, Canino GJ, Shrout P, Dulcan M, Freeman D, Bravo M. Psychometric properties of parents and children as informants in child psychiatry epidemiology with the Spanish Diagnostic Interview Schedule for Children (DISC.2). J Abnorm Child Psychol. 1994; 22(6): 703-20.	1992	*	
Cuba	Giroud Benitez JL, Collado-Mesa F, Esteban EM. [Prevalence of Parkinson disease in an urban area of the Ciudad de La Habana province, Cuba. Door-to-door population study]. Neurologia. 2000; 15(7): 269-73.	1997		
Cuba	Canino GJ, Bird HR, Shrout PE, Rubio-Stipec M, Bravo M, Martinez R, Sesman M, Guevara LM. The prevalence of specific psychiatric disorders in Puerto Rico. Arch Gen Psychiatry. 1987; 44(8): 727-35.	1984		
Cuba	Hernández Silva JR, Río Torres M, Padilla González CM. Resultados del RACSS en Ciudad de La Habana, Cuba, 2005. Rev Cubana Oftalmol. 2006; 19(1): 0-0. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2004-2005		
Cuba	Israel López J, Valdespino Pineda LM, Lugones Botell M. Retraso mental y calidad de vida. Rev Cubana Med General Integral. 2005; 21(5-6).	1957, 1967, 1977, 1984, 1989, 1994, 1999		
Cuba	Nordet P, Lopez R, Dueñas A, Sarmiento L. Prevention and control of rheumatic fever and rheumatic heart disease: the Cuban experience (1986-1996-2002). Cardiovasc J Afr. 2008; 19(3): 135-40.	1996		
Cuba	Ferri CP, Schoenborn C, Kalra L, Acosta D, Guerra M, Huang Y, Jacob KS, Rodríguez JLL, Salas A, Sosa AL, Williams JD, Liu Z, Moriyama T, Valhuerdi A, Prince MJ. Prevalence of stroke and related burden among older people living in Latin America, India and China. J Neurol Neurosurg Psychiatry. 2011; 82(10): 1074-82.	2007-2009	*	
Cuba	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2010, 2012		
Cuba	Bird HR, Canino G, Rubio-Stipec M, Gould MS, Ribera J, Sesman M, Woodbury M, Huertas-Goldman S, Pagan A, Sanchez-Lacay A. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico. The use of combined measures. Arch Gen Psychiatry. 1988; 45(12): 1120-6.	1985-1986	*	
Cuba	Kano M, Opolsky AF. Distribution and frequency of glucose-6-phosphate deficiency in the central region of Cuba. Genetika. 1984; 20: 864-7.	1982-1984		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Cuba	Fernández-Cean J, González-Martínez F, Schwedt E, Mazzuchi N. Renal replacement therapy in Latin America. <i>Kidney Int.</i> 2000; 57(s74): 55-59.	1997		
Cuba	Pérez-Oliva JF. Current status of renal replacement therapy in Cuba 2006. <i>Ethn Dis.</i> 2009; 19(1 Suppl 1): 10-12.	2000, 2006		
Cuba	Almaguer M, Herrera R, Alfonso J, Magrans C, Mañalich R, Martínez A, Davalos J, Perez-Oliva J, Landrove O. Chronic kidney disease in Cuba: epidemiological studies, integral medical care, and strategies for prevention. <i>Ren Fail.</i> 2006; 28(8): 671-6.	1994, 2002, 2004		
Cuba	Cusumano A, García-García G, Di Gioia C, Hermida O, Lavorato C, Carreño CA, Torrico MP, Batista PB, Romão JE, Badal HP, Miranda SE, Gomez R, Calderon MC, Sanchez SH, Lopez MA, Moscoso J, Merino RL, Polo JV, Lopez A, Romero NJ, García R, Acosta BV, Lopez AS, Delpin ES, Mena E, González C, Milanés CL, Acchiardo S. End-stage renal disease and its treatment in Latin America in the twenty-first century. <i>Ren Fail.</i> 2006; 28(8): 631-7.	2004		
Cuba	Santiago-Delpin EA, García VD. Latin American Transplant Registry VIIIth Report: 1998. <i>Transplant Proc.</i> 1999; 31(1-2): 214-6.	1995, 1997		
Cuba	Cusumano A, García GG, Di Gioia C, Hermida O, Lavorato C. Latin American Registry of Dialysis and Transplantation. The Latin American Dialysis and Transplantation Registry (RLDT) annual report 2004. <i>Ethn Dis.</i> 2006; 16(2 Suppl 2): 10-3.	2003		
Cuba	Llibre Rodríguez JJ, Ferri CP, Acosta D, Guerra M, Huang Y, Jacob KS, Krishnamoorthy ES, Salas A, Sosa AL, Acosta I, Dewey ME, Gason C, Jotheeswaran AT, Li S, Rodríguez D, Rodríguez G, Kumar PS, Valhuerdi A, Prince M. 10/66 Dementia Research Group. Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey. <i>Lancet.</i> 2008; 372(9637): 464-74.	2003-2004		†
Cuba	World Health Organization (WHO). Global leprosy situation, 2008 (additional information). <i>Wkly Epidemiol Rec.</i> 2008; 83(50): 459.	2007	*	
Cuba	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Cuba	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Cuba	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Cuba	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Cuba	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Cuba	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Cuba	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Cuba	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Cuba	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Cuba	Guzmán MG, Kouri G, Valdes L, Bravo J, Alvarez M, Vazques S, Delgado I, Halstead SB. Epidemiologic studies on Dengue in Santiago de Cuba, 1997. <i>Am J Epidemiol.</i> 2000; 152(9): 793-799.	1997		
Cuba	Peláez O, Guzmán MG, Kouri G, Pérez R, San Martín JL, Vázquez S, Rosario D, Mora R, Quintana I, Bisset J, Cancio R, Masa AM, Castro O, González D, Avila LC, Rodríguez R, Alvarez M, Pelegrino JL, Bernardo L, Prado I. Dengue 3 epidemic, Havana, 2001. <i>Emerg Infect Dis.</i> 2004; 10(4): 719-22.	2001		
Cuba	Merikangas KR, Conway KP, Swendsen J, Febo V, Dierker L, Brunetto W, Stolar M, Canino G. Substance use and behaviour disorders in Puerto Rican youth: a migrant family study. <i>J Epidemiol Community Health.</i> 2009; 63(4): 310-6.	1990		
Cuba	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Cuba	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Cuba	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Cuba	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Cuba	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Cuba	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Cuba	Olindo S, Cabre P, Deschamps R, Chatot-Henry C, René-Corail P, Fournier P, Saint-Vil M, May F, Smadja D. Acute stroke in the very elderly: epidemiological features, stroke subtypes, management, and outcome in Martinique, French West Indies. <i>Stroke.</i> 2003; 34(7): 1593-7.	1998-1999		
Cuba	Estrada M, González R. [Neonatal jaundice and glucose-6-phosphate dehydrogenase deficiency in Havana]. <i>Rev Invest Clin.</i> 1983; 35(4): 297-9.	1980-1982	*	
Cuba	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Finchuk L. Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Ann Hepatol.</i> 2010; 9(1): 63-9.	2006-2008	*	
Cuba	Quintana A, Sanchez L, Larraide O, Anderson D. Prevalence of antibodies to hepatitis E virus in residents of a district in Havana, Cuba. <i>J Med Virol.</i> 2005; 76(1): 69-70.	2002-2004		
Cuba	Llibre J de J, Fernández Y, Marcheco B, Contreras N, López AM, Otero M, Gil I, Guerra M, García M, Bayarre H. Prevalence of Dementia and Alzheimer's Disease in a Havana Municipality: A Community-Based Study among Elderly Residents. <i>MEDICC Rev.</i> 2009; 11(2): 29-35.	2003		
Cuba	Cuba Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Cuba	Cuban Register of Congenital Malformation Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
Cuba	Cuban Register of Congenital Malformation Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Cuba	Cuban Register of Congenital Malformation Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
Cuba	Cuban Register of Congenital Malformation Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Cuba	Cuban Register of Congenital Malformation Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Cuba	Cuban Register of Congenital Malformation Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
Cuba	Cuban Register of Congenital Malformation Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
Cyprus	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2002-2010		
Cyprus	Angastiniotis M, Modell B, Englezos P, Boulyjenvov V. Prevention and control of haemoglobinopathies. Bull World Health Organ. 1995; 73(3): 375-86.	1991		
Cyprus	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. Scand J Clin Lab Invest. 2007; 67(1): 39-69.	1990-2006		
Cyprus	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003, 2006		
Cyprus	World Health Orgn. Community control of hereditary anaemias: memorandum from a WHO meeting. Bull World Health Organ. 1983; 61(1): 63-80.	1974-1979		
Cyprus	Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, Pavlides N, Psiloines M, Simamonian K, Skordos G, Sitarou M, Angastiniotis M. Survival of medically treated thalassaemia patients in Cyprus. Haematologica. 2006; 91(9): 1187-92.	1974-2004		
Cyprus	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000, 2002-2009		
Cyprus	Middleton LT, Dean G. Multiple sclerosis in Cyprus. J Neurol Sci. 1991; 103(1): 29-36.	1988		
Cyprus	Dean G, Aksoy H, Akalin T, Middleton L, Kyriallis K. Multiple sclerosis in the Turkish- and Greek-speaking communities of Cyprus. A United Nations (UNHCR) Bicomunal Project. J Neurol Sci. 1997; 145(2): 163-8.	1993		
Cyprus	Kolokotroni O, Middleton N, Nicolaou N, Pipis S, Priftis KN, Milton DK, Yiallourou PK. Temporal changes in the prevalence of childhood asthma and allergies in urban and rural areas of Cyprus: results from two cross sectional studies. BMC Public Health. 2011; 858.	1999-2000, 2007-2008	*	
Cyprus	Zachariades AG, Zachariadou T, Adamide T, Anagnostopoulou U, Georgiou A, Gourgoulanis KI. Prevalence of chronic obstructive pulmonary disease in Cyprus: a population-based study. COPD. 2012; 9(3): 259-67.	2008	*	
Cyprus	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. Community Dent Oral Epidemiol. 1991; 19(2): 72-3.	1987		
Cyprus	De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000; 54(11 Suppl 5): S21-23.	1997		
Cyprus	Berger K BM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000; 54(11): 24-7.	1997		
Cyprus	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Cyprus	Kurugol Z, Koturoglu G, Aksit S, Ozacar T. Varicella seroprevalence in Turkish population in Cyprus. Acta Paediatr. 2007; 96(6): 861-3.	2006		
Cyprus	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1995, 1999, 2006		
Cyprus	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2004, 2007, 2010, 2012		
Cyprus	Plato CC, Rucknagel DL, Gershowitz H. Studies on the distribution of Glucose-6-phosphate dehydrogenase deficiency, thalassaemia, and other genetic traits in the coastal and mountain villages of Cyprus. Am J Hum Genet. 1964; 267-83.	1962-1964		
Cyprus	Cin S, Akar N, Arcasoy A, Dedeoğlu S, Cavdar AO. Prevalence of thalassaemia and G6PD deficiency in North Cyprus. Acta Haematol. 1984; 71(1): 69-70.	1982-1984		
Cyprus	Drousiotou A, Touma EH, Andreou N, Loiselet J, Angastiniotis M, Verrelli BC, Tishkoff SA. Molecular characterization of G6PD deficiency in Cyprus. Blood Cells Mol Dis. 2004; 33(1): 25-30.	2002-2004		
Cyprus	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. Nephrol Dial Transplant. 1988; 3(6): 714-27.	1985-1986		
Cyprus	Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. J Clin Endocrinol Metab. 2008; 93(4): 1408-11.	2005		
Cyprus	Statistical Service of Cyprus (CYSTAT). Cyprus European Health Interview Survey 2008.	2008	*	
Cyprus	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2012. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	2009	*	
Cyprus	Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overvad K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Dorronsoro M, Barricarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu J, Chuang S-C, Murphy N, Boffetta P, Trichopoulos A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J Natl Cancer Inst. 2011; 103(22): 1686-95.	1992-2006	*	
Cyprus	Hadjipanayis A, Hadjichristodoulou C, Kallias M, Sava K, Petsa A, Demetriadou K, Christodoulou C, Constantinou A, Sidera M. Prevalence of antibodies to hepatitis A among children and adolescents in Larnaca area, Cyprus. Eur J Epidemiol. 1999; 15(10): 903-5.	1998		
Cyprus	Eleftheriou A, Teloni F, Ioannou P. HDV infection in Cyprus. Prog Clin Biol Res. 1992; 277-85.	1986-1992		
Cyprus	Papaevangelou G, Róumeliotou A, Chatziminas M, Kotsianopoulou M, Ioannou P, Trichopoulos E, Nestoridou A. Epidemiological characteristics of hepatitis B virus infection in cyprus. Eur J Epidemiol. 1988; 4(2): 150-3.	1987		
Cyprus	Cyprus Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Czech Republic	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2000-2010		
Czech Republic	World Health Organization (WHO). Czech Republic World Health Survey 2002-2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2002-2003		
Czech Republic	Czech Statistical Office, United Nations Economic Commission for Europe (UNECE). Czech Republic Fertility and Family Survey 1997. Geneva, Switzerland: United Nations Economic Commission for Europe (UNECE).	1997		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Czech Republic	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Czech Republic	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001-2009		
Czech Republic	Hanova P, Pavelka K, Dostal C, Holcatova I, Pikhart H. Epidemiology of rheumatoid arthritis, juvenile idiopathic arthritis and gout in two regions of the Czech Republic in a descriptive population-based survey in 2002-2003. Clin Exp Rheumatol. 2006; 24(5): 499-507.	2002-2003		
Czech Republic	Jedlicka P, Hanzal F. Epidemiology of multiple sclerosis in Czechoslovakia. Cesk Neurol Neurochir. 1986; 49(6): 390-6.	1985		
Czech Republic	Perusicová J, Neuwirt K. The Prague Diabetes Registry. 3. Retinopathies, nephropathies and neuropathies in type 1 diabetics. The Prague Diabetes Collective. Cas Lek Cesk. 1993; 132(16): 489-93.	1992		
Czech Republic	Máchova L, Janout V, Cizek L, Beska F, Lorenc J, Koutná J. Risk factors for tumors, cardiovascular and metabolic diseases in the population of the Šumperk District. Cas Lek Cesk. 2004; 143(2): 90-3.	1981		
Czech Republic	Vrbic V, Vulovic M, Raji Z, Topi B, Tati E, Mali M, Mili D, Aurer-Kozelj J, Neceva L, Redzepagi S. Oral health in SFR Yugoslavia in 1986. Community Dent Oral Epidemiol. 1988; 16(5): 286-8.	1986		
Czech Republic	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2004-2008		
Czech Republic	United States Renal Data System Coordinating Center. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2000-2003		
Czech Republic	United States Renal Data System Coordinating Center. USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2003.	1998-1999		
Czech Republic	Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganev K, Giel R, an der Heiden W, Holmberg SK, Janca A, Lee PW, León CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin SJ, Varma VK, Walsh D, Wiersma D. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry. 2001; 178: 506-17.	1978-2003		
Czech Republic	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Czech Republic	Lejcková P, Mravčík V. Mortality of Hospitalized Drug Users in the Czech Republic. J Drug Issues. 2007; 37(1): 103-18.	1997-2002		
Czech Republic	Malek J, Prikazsk V, Kurziva A, Kozak J, Lengalova E. Prevalence of pain in the Czech Republic – A pilot study. Bolest. 2003; 6(2): 113-22.	2000		
Czech Republic	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1995, 1999, 2004		
Czech Republic	Institute of Health Information and Statistics of the Czech Republic. Czech Republic Health Status Sample Survey 2004.	2004		
Czech Republic	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Czech Republic	Csémy L, Sovinová H, Procházková B. Alcohol consumption and marijuana use in young adult Czechs. Cent Eur J Public Health. 2012; 20(4): 244-7.	2009	*	
Czech Republic	Bouvier-Colle M-H, Mohangoo AD, Gissler M, Novak-Antolic Z, Vutuc C, Szamotulska K, Zeitlin J, Euro-Peristat Scientific Committee. What about the mothers? An analysis of maternal mortality and morbidity in perinatal health surveillance systems in Europe. BJOG. 2012; 119(7): 880-90.	2003-2004	*	
Czech Republic	Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl RV, De Graaf R, Vollebergh W, Dragomirecka E, Kohn R, Keller M, Kessler RC, Kawakami N, Kilić C, Offord D, Ustun TB, Wittchen H-U. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res. 2003; 12(1): 3-21.	1998-1999		
Czech Republic	Stránský J, Horejsová M, Chlumská A, Honzáková E, Vandasová J, Němeček V. Prevalence of anti-HCV antibodies in chronic liver disease in the Czech Republic. Infection. 1997; 25(1): 49-50.	1991-1993		
Czech Republic	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Czech Republic	Lejcková P, Mravčík V. [Mortality of drug users. Summary of cohort study results]. Epidemiol Mikrobiol Imunol. 2005; 54(4): 154-60.	1997-2002	*	
Czech Republic	Fraser GR, Defaranas B, Kattamis CA, Race RR, Sanger R, Stamatiyannopoulos G. Glucose-6-phosphate dehydrogenase, colour vision and XG blood groups in Greece: linkage and population data. Ann Hum Genet. 1964; 395-403.	1962		
Czech Republic	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. Nephrol Dial Transplant. 1988; 3(6): 714-27.	1985-1986		
Czech Republic	Mircescu G, Capsa D, Covic M, Caprioara MG, Gluhovschi G, Golea O, Ursea N, Gârneata L, Cepoi V, Constantinovici N, Covic A. Nephrology and renal replacement therapy in Romania – transition still continues (Cinderella story revisited). Nephrol Dial Transplant. 2004; 19(12): 2971-80.	1995, 2003		
Czech Republic	European Surveillance of Congenital Anomalies (EUROCAT). Czech Republic EUROCAT Prevalence Tables 2000-2010. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	2000-2010		
Czech Republic	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Gilst WH van, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. Eur Heart J. 2003; 24(5): 442-63.	2000-2001		
Czech Republic	Eurostat, Institute of Health Information and Statistics of the Czech Republic. Czech Republic European Health Interview Survey 2008.	2008	*	
Czech Republic	Pebody RG, Andrews N, Brown D, Gopal R, De Melker H, François G, Gatcheva N, Hellenbrand W, Jokinen S, Klavs I, Kojouharova M, Kortbeek T, Kriz B, Prosenec K, Roubalova K, Teocharov P, Thierfelder W, Valle M, Van Damme P, Vranckx R. The seroepidemiology of herpes simplex virus type 1 and 2 in Europe. Sex Transm Infect. 2004; 80(3): 185-91.	1989	*	
Czech Republic	Cerovská J, Hromádková M, Pohanková D, Simonovský V, Bednár J, Tomiska F. Urinary iodine and the state of the thyroid gland in Czech children. Czech Med. 1991; 14(4): 193-204 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1988		
Czech Republic	Džirůvá D, Smolová E, Dragomirecká E. Mental Health in the Sociodemographic Context: Results of a Sample Survey in the Czech Republic. Prague, Czech Republic: Charles University, 2000.	1998-1999		
Czech Republic	Pozler O, Maly J, Bonova O, Dedek P, Frihauf P, Havlickova A, Janatova T, Jimramovsky F, Klimova L, Klusacek D, Kocourkova D, Kolek A, Kotalova R, Marx D, Nevoral J, Petro R, Petru O, Plasilova I, Seidl Z, Sekyrova I, Semendak N, Schreierova I, Stanek J, Sjkora J, Sulakova A, Toukalkova L, Travnickova R, Volf V, Zahradnick L, Zeniskova I. Incidence of Crohn disease in the Czech Republic in the years 1990 to 2001 and assessment of pediatric population with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2006; 42(2): 186-9.	1991, 1993-2001		
Czech Republic	Chlíbek R, Cecetková B, Smetana J, Prymula R, Kohl I. [Seroprevalence of antibodies against hepatitis A virus and hepatitis B virus in nonvaccinated adult population over 40 years of age]. Epidemiol Mikrobiol Imunol. 2006; 55(3): 99-104.	2003-2004		
Czech Republic	Máchova L, Janout V. The incidence of acute myocardial infarction in the district Olomouc in 1994—descriptive study. Cent Eur J Public Health. 1997; 5(3): 122-6.	1984, 1994		
Czech Republic	Skodová Z, Písa Z, Berka L, Čícha Z, Cerovská J, Emrová R, Hejl Z, Hrdlicková K, Hoke M, Pikhartová J. Myocardial Infarction Register in MONICA-Czechoslovakia Centre. Acta Med Scand Suppl. 1988; 79-83.	1984		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Czech Republic	Skodová Z, Písa Z, Hejl Z, Wiesner E, Cícha Z, Píkhartová J, Berka L, Vorlíček J, Emrová R, Vojtíšek P. Coronary events in the population of six districts of the Czech Socialist Republic. Cor Vasa. 1988; 30(5): 324-30.	1984		
Czech Republic	Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, Tolonen H, Ruokokoski E. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet. 1999; 353(9164): 1547-57.	1986, 1993		
Czech Republic	National Public Health Institute (Finland), World Health Organization (WHO). MONICA Coronary Event Registration Data Book 1980-1995. Geneva, Switzerland: World Health Organization (WHO), 2000.	1980-1995		
Czech Republic	Zeitlan J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT; 2008. Available from: http://www.perinataleaudit.nl/downloads/bestand/649/peristat-ii-2008-	2004		†
Czech Republic	Chvojková E, Dort J, Hejčlová A. [What is the fate of our smallest patients? Follow-up of children with a birth weight less than 1000 g]. Cas Lek Cesk 2001 Nov 22; 140(23):729-31.	1996		†
Czech Republic	Czech Republic Registry of Dialysis Patients (RDP) Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Czech Republic	Czech Republic Registry of Dialysis Patients (RDP) Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Czech Republic	Czech Republic Vital Registration Birth Data 1991 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1991		
Czech Republic	Czech Republic Congenital Malformations Monitoring Program Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Czech Republic	Czech Republic - Bohemia and Moravia Czechoslovakian Registry and Monitor of Congenital Malformations Data 1980 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1980	*	
Czech Republic	Czech Republic - Bohemia and Moravia Czechoslovakian Registry and Monitor of Congenital Malformations Data 1983 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1983	*	
Czech Republic	Czech Republic - Bohemia and Moravia Czechoslovakian Registry and Monitor of Congenital Malformations Data 1986 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1986	*	
Czech Republic	Czech Republic Congenital Malformations Monitoring Program Data 2001 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
Czech Republic	Czech Republic National Registry of Congenital Anomalies Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Czech Republic	Czech Republic Congenital Malformations Monitoring Program Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
Czech Republic	Czech Republic National Registry of Congenital Anomalies Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
Czech Republic	Czech Republic Congenital Malformations Monitoring Program Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
Czech Republic	Czech Republic - Bohemia and Moravia Czechoslovakian Registry and Monitor of Congenital Malformations Data 1988 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1988	*	
Czech Republic	Czech Republic - Bohemia and Moravia Czechoslovakian Registry and Monitor of Congenital Malformations Data 1984 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1984	*	
Czech Republic	Czech Republic - Bohemia and Moravia Czechoslovakian Registry and Monitor of Congenital Malformations Data 1981 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1981	*	
Czech Republic	Czech Republic Congenital Malformations Monitoring Program Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
Czech Republic	Czech Republic Congenital Malformations Monitoring Program Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Czech Republic	Czech Republic - Bohemia and Moravia Czechoslovakian Registry and Monitor of Congenital Malformations Data 1987 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1987	*	
Czech Republic	Czech Republic - Bohemia and Moravia Czechoslovakian Registry and Monitor of Congenital Malformations Data 1985 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1985	*	
Czech Republic	Czech Republic - Bohemia and Moravia Czechoslovakian Registry and Monitor of Congenital Malformations Data 1982 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1982	*	
Democratic Republic of the Congo	Ministry of Planning and Reconstruction (Congo, DR), United Nations Children's Fund (UNICEF). Congo, DR Multiple Indicator Cluster Survey 2001. New York, United States: United Nations Children's Fund (UNICEF).	2001		†
Democratic Republic of the Congo	Macro International, Inc, Ministry of Planning (Congo, DR), Congo, DR Demographic and Health Survey 2007. Calverton, United States: Macro International, Inc.	2007		†
Democratic Republic of the Congo	Congo, DR Demographic and Health Survey 2007 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2007	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Democratic Republic of the Congo	Thalassaemia International Federation, World Health Organization (WHO). Management of Haemoglobin Disorders: Report of a Joint WHO-TIF Meeting, Nicosia, Cyprus, 16-18 November 2007. Geneva, Switzerland: World Health Organization (WHO), 2008.	1990-2006		
Democratic Republic of the Congo	Centre for Health Informatics and Multiprofessional Education, University College London. Model's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Democratic Republic of the Congo	Tshilolo L, Aissi LM, Lukusa D, Kinsiyama C, Wembonyama S, Gulbis B, Vertongen F. Neonatal screening for sickle cell anaemia in the Democratic Republic of the Congo: experience from a pioneer project on 31,204 newborns. J Clin Pathol. 2009; 62(1): 35-8.	1990-2008		
Democratic Republic of the Congo	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Democratic Republic of the Congo	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997-1999, 2001, 2003-2009		
Democratic Republic of the Congo	Lutumba P, Makieya E, Shaw A, Meheus F, Boelaert M. Human African trypanosomiasis in a rural community, Democratic Republic of Congo. Emerg Infect Dis. 2007; 13(2): 248-54.	2004		
Democratic Republic of the Congo	Berrang-Ford L, Lundine J, Breau S. Conflict and human African trypanosomiasis. Soc Sci Med. 2011; 72(3): 398-407.	1994-2000	*	
Democratic Republic of the Congo	Malemba JJ, Mbuyi-Muamba JM, Mukaya J, Bossuyt X, Verschueren P, Westhovens R. The epidemiology of rheumatoid arthritis in Kinshasa, Democratic Republic of Congo—a population-based study. Rheumatology. 2012; 51(9): 1644-7.	2010	*	
Democratic Republic of the Congo	Agasa B, Bosunga K, Opara A, Tshilumba K, Dupont E, Vertongen F, Cotton F, Gulbis B. Prevalence of sickle cell disease in a northeastern region of the Democratic Republic of Congo: what impact on transfusion policy Transfus Med. 2010; 20(1): 62-5.	1990-2007		
Democratic Republic of the Congo	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Democratic Republic of the Congo	Kinoshita-Moleka R, Smith JS, Atibu J, Tshetu A, Hemingway-Foday J, Hobbs M, Bartz J, Koch MA, Rimoin AW, Ryder RW. Low prevalence of HIV and other selected sexually transmitted infections in 2004 in pregnant women from Kinshasa, the Democratic Republic of the Congo. Epidemiol Infect. 2008; 136(9): 1290-6.	2004		
Democratic Republic of the Congo	Elongi J-P, Tandu B, Spitz B, Verdonek F. [Influence of the seasonal variation on the prevalence of pre-eclampsia in Kinshasa]. Gynecol Obstet Fertil. 2011; 39(3): 132-5.	2003-2007	*	
Democratic Republic of the Congo	Sumaili EK, Krzesinski JM, Zinga CV, Cohen EP, Delanaye P, Munyanga SM, Nseka NM. Prevalence of chronic kidney disease in Kinshasa: results of a pilot study from the Democratic Republic of Congo. Nephrol Dial Transplant. 2009; 24(1): 117-22.	2006		
Democratic Republic of the Congo	Sumaili EK, Krzesinski JM, Cohen EP, Nseka NM. Epidemiology of chronic kidney disease in the Democratic Republic of Congo: review of cross-sectional studies from Kinshasa, the capital. Nephrol Ther. 2010; 6(4): 232-9.	2001-2004		
Democratic Republic of the Congo	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Democratic Republic of the Congo	Biselele T, Naulaers G, Bunga Muntu P, Nkidiaka E, Kapela M, Mavinga L, Tady B. A descriptive study of perinatal asphyxia at the University Hospital of Kinshasa (Democratic Republic of Congo). J Trop Pediatr. 2013; 59(4): 274-9.	2009-2011	*	†
Democratic Republic of the Congo	Longo-Mbenza B, On'kin JBKL, Okwe AN, Kabangu NK, Fuele SM. Metabolic syndrome, aging, physical inactivity, and incidence of type 2 diabetes in general African population. Diab Vasc Dis Res. 2010; 7(1): 28-39.	2004-2008		
Democratic Republic of the Congo	Sonnet J, Michaux JL. Glucose-6-Phosphate Dehydrogenase Deficiency, Haptoglobin Groups, Blood Groups and Sickle Cell Trait in the Bantus of West Belgian Congo. Nature. 1960; 188(5): 504-5.	1958-1960		
Democratic Republic of the Congo	Motulsky AG, Vandepitte J, Fraser GR. Population genetic studies in the Congo. I. Glucose-6-phosphate dehydrogenase deficiency, hemoglobin S, and malaria. Am J Hum Genet. 1966; 18(6): 514-37.	1964-1966		
Democratic Republic of the Congo	Van Ros G. The African variant of glucose-6-phosphate dehydrogenase deficiency as a factor favoring anemia: comparative study of 157 deficient adults and 300 non-deficient adults. Ann Soc Belg Med Trop. 1977; 57(1): 39-49.	1975-1977		
Democratic Republic of the Congo	Bukabau JB, Makulo J-RR, Pakasa NM, Cohen EP, Lepira FB, Kayembe PK, Nseka NM, Sumaili EK. Chronic kidney disease among high school students of Kinshasa. BMC Nephrol. 2012; 24.	2009-2011	*	
Democratic Republic of the Congo	Tshiswaka MT, Tshimbadi K, Sabua M, Muyunga K. Etudes baseses sur la population pour evaluer la prevalence des alterations de l'ouie chez les ecolier de 5 a 16 ans dans la ville de Kinshasa (Zaire). Report. Kinshasa (Zaire): Service d'oto-rhino-laryngologie (ORL), Cliniques Universitaires de Kinshasa; 1995.	1995		
Democratic Republic of the Congo	Grout L, Minetti A, Hurtado N, François G, Fermon F, Chatelain A, Harczí G, Ngoie J de DI, N'Goran A, Luquero FJ, Grais RF, Porten K. Measles in Democratic Republic of Congo: an outbreak description from Katanga, 2010-2011. BMC Infect Dis. 2013; 13(1): 232.	2010-2011	*	
Democratic Republic of the Congo	N'Goran AA, Ilunga N, Coldiron ME, Graís RF, Porten K. Community-based measles mortality surveillance in two districts of Katanga Province, Democratic Republic of Congo. BMC Res Notes. 2013; 6(1): 537.	2011	*	
Democratic Republic of the Congo	Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J Health Geogr. 2010; 9: 57.	1980-2010		
Democratic Republic of the Congo	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Democratic Republic of the Congo	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Democratic Republic of the Congo	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Democratic Republic of the Congo	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Democratic Republic of the Congo	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Democratic Republic of the Congo	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Democratic Republic of the Congo	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Democratic Republic of the Congo	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Democratic Republic of the Congo	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Democratic Republic of the Congo	Congo, DR National Survey on the Fight Against Iodine Deficiency Disorders 2000 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2000		
Democratic Republic of the Congo	Phillips DI, Lusty TD, Osmond C, Church D. Iodine supplementation: comparison of oral or intramuscular iodized oil with oral potassium iodide. A controlled trial in Zaire. Int J Epidemiol. 1988; 17(1): 142-7 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1985-1986		
Democratic Republic of the Congo	Dormitzer PR, Ellison PT, Bode HH. Anomalous low endemic goiter prevalence among Efe pygmies. Am J Phys Anthropol. 1989; 78(4): 527-31 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1989		
Democratic Republic of the Congo	Mutesa L, Boemer F, Ngendahayo L, Rulisa S, Rusingiza EK, Cwinya-Ay N, Mazina D, Kariyo PC, Bours V, Schoos R. Neonatal screening for sickle cell disease in Central Africa: a study of 1825 newborns with a new enzyme-linked immunosorbent assay test. J Med Screen. 2007; 14(3): 113-6.	2004-2006	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Democratic Republic of the Congo	Kalenga M-K, Nyembo M-K, Nshimba M, Foidart J-M. [Anemia prevalence in pregnant and breast-feeding women in Lubumbashi (Democratic Republic of the Congo). Impact of malaria and intestinal helminthiasis]. J Gynecol Obstet Biol Reprod (Paris). 2003; 32(7): 647-53 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Democratic Republic of the Congo	Werner GT, Frösner GG, Fresenius K. Prevalence of serological hepatitis A and B markers in a rural area of northern Zaire. Am J Trop Med Hyg. 1985; 34(3): 620-4.	1983		
Democratic Republic of the Congo	Epidemiology of Malaria and Prevalence of Parasitic Infections in a Rural Area of D. R. Congo [master's thesis] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Democratic Republic of the Congo	Boivin MJ, Giordani B, Ndanga K, Maky MM, Manzeki KM, Ngunu N, Muamba K. Effects of treatment for intestinal parasites and malaria on the cognitive abilities of schoolchildren in Zaire, Africa. Health Psychology. 1993; 12(3): 220-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Democratic Republic of the Congo	Delacollette C, Van der Stuyft P, Molima K, Hendrix L, Wéry M. [Malaria index according to age and seasons in the health region of Katana, in mountainous Kivu, Zaire]. Ann Soc Belg Med Trop. 1990; 70(4): 263-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Democratic Republic of the Congo	Karch S, Garin B, Asidi N, Manzambi Z, Salaun JJ, Mouchet J. [Mosquito nets impregnated against malaria in Zaire]. Ann Soc Belg Med Trop. 1993; 73(1): 37-53 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Democratic Republic of the Congo	Kazadi W, Sexton JD, Bigonsa M, WOkanga B, Way M. Malaria in primary school children and infants in Kinshasa, Democratic Republic of the Congo: surveys from the 1980s and 2000. Am J Trop Med Hyg. 2004; 71(2): 97-102 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000	*	†
Democratic Republic of the Congo	Mbudi PK, Pela NN, Kalonji MW, Disu MM. [Comparative efficacy of alternative treatments in Plasmodium falciparum infections in Zaire]. Ann Soc Belg Med Trop. 1989; 69(1): 25-33 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986-1987	*	†
Democratic Republic of the Congo	Mulumba MP, Wery M, Ngimbi NN, Paluku K, Van der Stuyft P, De Muynck A. [Childhood malaria in Kinshasa (Zaire). Influence of seasons, age, environment, and family social conditions]. Med Trop (Mars). 1990; 50(1): 53-64 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Democratic Republic of the Congo	Mulumba PM, Wéry M, Ngimbi NN, Paluku K, De Muynck A, van der Stuyft P. [Relationship between Plasmodium parasitemia and febrile episodes in various population groups in Kinshasa, Zaire]. Ann Soc Belg Med Trop. 1994; 74(4): 275-89 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Democratic Republic of the Congo	Paluku KM, Breman JG, Moore M, Ngimbi NP, Sexton JD, Roy J, Steketee RW, Weinman JM, Kalisa-Ruti, ma-Disu M. Response of children with Plasmodium falciparum to chloroquine and development of a national malaria treatment policy in Zaire. Trans R Soc Trop Med Hyg. 1988; 82(3): 353-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Democratic Republic of the Congo	Tshikuka JG, Gray-Donald K, Scott M, Olela KN. Relationship of childhood protein-energy malnutrition and parasite infections in an urban African setting. Trop Med Int Health. 1997; 2(4): 374-82 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Denmark	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2003-2006		
Denmark	World Health Organization (WHO). Denmark World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		
Denmark	Friberg J, Scharling H, Gadsbøll N, Truelsen T, Jensen GB. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol. 2004; 94(7): 889-94.	1980-1994		
Denmark	Friberg J, Scharling H, Gadsbøll N, Jensen GB. Sex-specific increase in the prevalence of atrial fibrillation (The Copenhagen City Heart Study). Am J Cardiol. 2003; 92(12): 1419-23.	1980-1994		
Denmark	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. Scand J Clin Lab Invest. 2007; 67(1): 39-69.	1988, 2006		
Denmark	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	2003, 2006		
Denmark	National Public Health Institute (Finland), World Health Organization (WHO). WHO MONICA Cerebrovascular Event Data 1982-1997, as provided by the Global Burden of Disease 2010 Cerebrovascular Disease Expert Group. [Unpublished].	1982-1991		
Denmark	Jørgensen HS, Plesner AM, Hubbe P, Larsen K. Marked increase of stroke incidence in men between 1972 and 1990 in Frederiksberg, Denmark. Stroke. 1992; 23(12): 1701-4.	1989-1990		
Denmark	Hartvigsen J, Frederiksen H, Christensen K. Back and neck pain in seniors-prevalence and impact. Eur Spine J. 2006; 15(6): 802-6.	2003		
Denmark	Fejer R, Jordan A, Hartvigsen J. Categorising the severity of neck pain: establishment of cut-points for use in clinical and epidemiological research. Pain. 2005; 119(1-3): 176-82.	2003		
Denmark	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2002-2003		
Denmark	Byg KE, Milman N, Hansen S. Sarcoidosis in Denmark 1980-1994. A registry-based incidence study comprising 5536 patients. Respirology. 2003; 20(1): 46-52.	1980-1994		
Denmark	Hoffmann AL, Milman N, Byg KE. Childhood sarcoidosis in Denmark 1979-1994: incidence, clinical features and laboratory results at presentation in 48 children. Acta Paediatr. 2004; 93(1): 30-6.	1979-1994		
Denmark	Kornum JB, Christensen S, Grijota M, Pedersen L, Wogelius P, Beiderbeck A, Sørensen HT. The incidence of interstitial lung disease 1995-2005: a Danish nationwide population-based study. BMC Pulm Med. 2008; 8(24): 24.	1995-2005		
Denmark	Milman N, Hoffmann AL, Byg KE. Sarcoidosis in children. Epidemiology in Danes, clinical features, diagnosis, treatment and prognosis. Acta Paediatr. 1998; 87(8): 871-8.	1980-1992		
Denmark	Koch-Henriksen N, Brønnum-Hansen H, Hyllested K. Incidence of Multiple Sclerosis in Denmark 1948-1982: A Descriptive Nationwide Study. Neuroepidemiology. 1992; 11(1): 1-10.	1950-1982		
Denmark	Koch-Henriksen N. Multiple sclerosis in Scandinavia and Finland. Acta Neurol Scand. 1995; 91(S161): 55-9.	1950-1985		
Denmark	Koch-Henriksen N. The Danish Multiple Sclerosis Registry: a 50-year follow-up. Mult Scler. 1999; 5(4): 293-6.	1950-1990		
Denmark	Koch-Henriksen N, Brønnum-Hansen H, Stenager E. Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry. J Neurol Neurosurg Psychiatry. 1998; 65(1): 56-9.	1951-1993		
Denmark	Schnohr P, Jensen G, Lange P, Scharling H, Appleyard M. The Copenhagen City Heart Study Østerbrounderøgelser: tables with data from the third examination 1991-1994. Eur Heart J. 2001; 3(Suppl H): H1-H83.	1991-1994		
Denmark	Holm M, Omenaas E, Gislason T, Svanes C, Jøgi R, Normann E, Janson C, Torén K. Remission of asthma: a prospective longitudinal study from northern Europe (RHINE study). Eur Respir J. 2007; 30(1): 62-65.	1989-2001		
Denmark	de Fine Olivarius N, Nielsen NV, Andreassen AH. Diabetic retinopathy in newly diagnosed middle-aged and elderly diabetic patients. Prevalence and interrelationship with microalbuminuria and triglycerides. Graefes Arch Clin Exp Ophthalmol. 2001; 239(9): 664-72.	2000		
Denmark	Knudsen LL, Lervang HH, Lundbye-Christensen S, Gorst-Rasmussen A. The North Jutland County Diabetic Retinopathy Study (NCDERS). Acta Ophthalmol. 2010; 88(4): 443-8.	2000-2004		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Denmark	Hove MN, Kristensen JK, Lauritzen T, Bek T. The prevalence of retinopathy in an unselected population of type 2 diabetes patients from Arhus County, Denmark. <i>Acta Ophthalmol Scand.</i> 2004; 82(4): 443-8.	2000		
Denmark	Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population—a prevalence study. <i>J Clin Epidemiol.</i> 1991; 44(11): 1147-57.	1989		
Denmark	Jacobsen S, Sonne-Holm S. Hip dysplasia: a significant risk factor for the development of hip osteoarthritis. A cross-sectional survey. <i>Rheumatology.</i> 2005; 44(2): 211-8.	1991-1994		
Denmark	Jarvis D, Newson R, Lovvall J, Hastan D, Tomassen P, Keil T, Gjomarkaj M, Forsberg B, Gunnbjornsdottir M, Minov J, Brozek G, Dahlen SE, Toskala E, Kowalski ML, Olze H, Howarth P, Krämer U, Baelum J, Loureiro C, Kasper L, Bousquet PJ, Bousquet J, Bachert C, Fokkens W, Burney P. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. <i>Allergy.</i> 2012; 67(1): 91-8.	2008-2009	*	
Denmark	Zilmer M, Steen NP, Zachariassen G, Daus T, Kristiansen B, Halken S. Prevalence of asthma and bronchial hyperreactivity in Danish schoolchildren: no change over 10 years. <i>Acta Paediatr.</i> 2011; 100(3): 385-9.	2001	*	
Denmark	Hansen S, Strøm M, Maslova E, Mortensen EL, Granström C, Olsen SF. A comparison of three methods to measure asthma in epidemiologic studies: results from the Danish National Birth Cohort. <i>PLoS One.</i> 2012; 7(5): e36328.	2003-2010	*	
Denmark	Laxafoss E, Jacobsen S, Gosvig KK, Sonne-Holm S. Case definitions of knee osteoarthritis in 4,151 unselected subjects: relevance for epidemiological studies: the Copenhagen Osteoarthritis Study. <i>Skeletal Radiol.</i> 2010; 39(9): 859-66.	2007-2009	*	
Denmark	Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Nateson JH, Svendsen JH, Torp-Pedersen C, Hansen PR. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. <i>BMJ.</i> 2012; e1257.	1997-2009	*	
Denmark	Nielsen JB, Graff C, Pietersen A, Lind B, Struijk JJ, Olesen MS, Haunso S, Gerds TA, Svendsen JH, Køber L, Holst AG. J-shaped association between QTc interval duration and the risk of atrial fibrillation: results from the Copenhagen ECG study. <i>J Am Coll Cardiol.</i> 2013; 61(25): 2557-64.	2001-2010	*	
Denmark	Oyen N, Ranthe MF, Carstensen L, Boyd HA, Olesen MS, Olesen S-P, Wohlfahrt J, Melbye M. Familial aggregation of lone atrial fibrillation in young persons. <i>J Am Coll Cardiol.</i> 2012; 60(10): 917-21.	1977-2008	*	
Denmark	Li K-Y, Wong MCM, Lam K-F, Schwarz E. Age, period, and cohort analysis of regular dental care behavior and edentulism: a marginal approach. <i>BMC Oral Health.</i> 2011; 11: 9.	1975, 1985, 1995, 2005	*	
Denmark	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. <i>Community Dent Oral Epidemiol.</i> 1991; 19(2): 72-3.	1987		
Denmark	Kjaer P, Wedderkopp N, Korsholm L, Leboeuf-Yde C. Prevalence and tracking of back pain from childhood to adolescence. <i>BMC Musculoskelet Disord.</i> 2011; 98.	1997-1998, 2001, 2003-2004	*	
Denmark	Hoffmann T, Iurriza M, Fauborg-Andersen J, Kraer C, Nielsen CP, Gray J, Høgh B. Prospective study of the burden of rotavirus gastroenteritis in Danish children and their families. <i>Eur J Pediatr.</i> 2011; 170(12): 1535-9.	2008-2009	*	
Denmark	Andersen K, Lolk A, Nielsen H, Andersen J, Olsen C, Kragh-Sørensen P. Prevalence of very mild to severe dementia in Denmark. <i>Acta Neurol Scand.</i> 1997; 96(2): 82-7.	1991-1995		†
Denmark	Andersen K, Nielsen H, Lolk A, Andersen J, Becker I, Kragh-Sørensen P. Incidence of very mild to severe dementia and Alzheimer's disease in Denmark: the Odense Study. <i>Neurology.</i> 1999; 52(1): 85-90.	1995-1998		
Denmark	Andersen-Ranberg K, Vasegaard L, Jeune B. Dementia is not inevitable: a population-based study of Danish centenarians. <i>J Gerontol B Psychol Sci Soc Sci.</i> 2001; 56(3): P152-159.	1995-1996		
Denmark	Schmidt M, Jacobsen JB, Lash TL, Botker HE, Sorensen HT. 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. <i>BMJ.</i> 2012; 344: e356.	1984-2008	*	
Denmark	Pedersen JK, Svendsen AJ, Hørslev-Petersen K. Incidence of Rheumatoid Arthritis in the Southern part of Denmark from 1995 to 2001. <i>Open Rheumatol J.</i> 2007; 18-23.	1995-2001		
Denmark	Poulsen S, Amarantunge A, Risager J. Changes in the epidemiologic pattern of dental caries in a Danish rural community over a 10-year period. <i>Community Dent Oral Epidemiol.</i> 1982; 10(6): 345-57.	1969-1979		
Denmark	Poulsen S, Malling Pedersen M. Dental caries in Danish children: 1988-2001. <i>Eur J Paediatr Dent.</i> 2002; 3(4): 195-8.	1998-2001		
Denmark	Dragheim E, Petersen PE, Kalo I, Saag M. Dental caries in schoolchildren of an Estonian and a Danish municipality. <i>Int J Paediatr Dent.</i> 2000; 10(4): 271-7.	1996-1998		
Denmark	Poulsen S, Scheutz F. Dental caries in Danish children and adolescents 1988-1997. <i>Community Dent Health.</i> 1999; 16(3): 166-70.	1988-1997		
Denmark	Christensen LB, Twetman S, Sundby A. Oral health in children and adolescents with different socio-cultural and socio-economic backgrounds. <i>Acta Odontol Scand.</i> 2010; 68(1): 34-42.	2006		
Denmark	Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. <i>J Clin Psychiatry.</i> 2007; 68(6): 899-907.	1973-2001		
Denmark	Eldrup N, Sillesen H, Prescott E, Nordestgaard BG. Ankle brachial index, C-reactive protein, and central augmentation index to identify individuals with severe atherosclerosis. <i>Eur Heart J.</i> 2006; 27(3): 316-322.	2001-2003		
Denmark	Benn M, Hagelskjaer LH, Tvede M. Infective endocarditis, 1984 through 1993: a clinical and microbiological survey. <i>J Intern Med.</i> 1997; 242(1): 15-22.	1984-1993		
Denmark	Fonager K, Lindberg J, Thulstrup AM, Pedersen L, Schonheyder HC, Sorensen HT. Incidence and short-term prognosis of infective endocarditis in Denmark, 1980-1997. <i>Scand J Infect Dis.</i> 2003; 35(1): 27-30.	1980-1997		
Denmark	Nolse C, Jensen LT, Hartzner K, Godtfredsen J. Occurrence of infectious endocarditis in Denmark. <i>Ugeskr Laeger.</i> 1987; 149(51): 3458-9.	1981-1983		
Denmark	Foghsgaard J, Pedersen SA, Launbjerg J. Incidence and diagnosis of infectious endocarditis in Frederiksborg county, 1990-2000. <i>Ugeskr Laeger.</i> 2004; 166(25): 2446-50.	1990-2000		
Denmark	de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Künzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P. European Community Respiratory Health Survey Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. <i>Thorax.</i> 2004; 59(2): 120-125.	1991-1993		
Denmark	Jensen TK, Grandjean P, Andersen HR, Nielsen F, Eriksen L, Curtis T. KRAM-undersøgelsen. <i>Scand J Public Health.</i> 2011; 39(2): 203-11.	2007		
Denmark	Lassen A, Hallas J, Schaffalitzky de Muckadell OB. Complicated and uncomplicated peptic ulcers in a Danish county 1993-2002: a population-based cohort study. <i>Am J Gastroenterol.</i> 2006; 101(5): 945-53.	1993-2002		
Denmark	Ellefsen A, Kampmann H, Billstedt E, Gillberg IC, Gillberg C. Autism in the Faroe Islands. An Epidemiological Study. <i>J Autism Dev Disord.</i> 2007; 37(3): 437-44.	2002		
Denmark	Lauritsen MB PC, Mortensen PB. The incidence and prevalence of pervasive developmental disorders: a Danish population-based study. <i>Psychol Med.</i> 2004; 34(7): 1339-46.	1990-2001		
Denmark	Mouridsen SE, Bronnum-Hansen H, Rich B, Isager T. Mortality and causes of death in autism spectrum disorders An update. <i>Autism.</i> 2008; 12(4): 403-14.	1972-2006		
Denmark	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2004-2005		
Denmark	United States Renal Data System Coordinating Center. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2001-2003		
Denmark	Sørensen JL, Thranov IR, Hoff GE. Presence of genital Chlamydia trachomatis in abortion seekers—correlates with young age and nulliparity but not with previous genital infection. <i>Ugeskr Laeger.</i> 1992; 154(44): 3053-6.	1989, 1992		
Denmark	Prien-Larsen JC, Kjer JJ. Prevalence of positive gonococcal and chlamydial findings in women applying for termination of pregnancy. A screening evaluation. <i>Ugeskr Laeger.</i> 1989; 151(26): 1671-2.	1989		
Denmark	De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology.</i> 2000; 54(11 Suppl 5): S21-23.	1997		
Denmark	Wermuth L, Stenager EN, Stenager E, Boldsen J. Mortality in patients with Parkinson's disease. <i>Acta Neurol Scand.</i> 1995; 92(1): 55-8.	1973-1991		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Denmark	Berger K BM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. <i>Neurology</i> . 2000; 54(11): 24-7.	1997		
Denmark	Wermuth L, Joensen P, Blünger N, Jeune B. High prevalence of Parkinson's disease in the Faroe Islands. <i>Neurology</i> . 1997; 49(2): 426-32.	1995		†
Denmark	Wermuth L. Epidemiologisk undersøgelse af Parkinson-patienter fra et ambulatorium. <i>Ugeskr Laeger</i> . 1986; 148(27): 1702-4.	1976-1978		
Denmark	Wermuth L, von Weizel-Mudersbach P, Jeune B. A two-fold difference in the age-adjusted prevalences of Parkinson's disease between the island of Als and the Faroe Islands. <i>Eur J Neurol</i> . 2000; 7(6): 655-60.	1997		
Denmark	Munk-Jørgensen P, Weeke A, Jensen EB, Dupont A, Strömgen E. Changes in utilization of Danish psychiatric institutions. II. Census studies 1977 and 1982. <i>Compr Psychiatry</i> . 1986; 27(5): 416-29.	1982		
Denmark	Bajholm S, Strömgen E. Prevalence of schizophrenia on the island of Bornholm in 1935 and in 1983. <i>Acta Psychiatr Scand Suppl</i> . 1989; 157-78.	1983		
Denmark	Thorup A, Waltoft BL, Pedersen CB, Mortensen PB, Nordentoft M. Young males have a higher risk of developing schizophrenia: a Danish register study. <i>Psychol Med</i> . 2007; 37(4): 479-84.	1970-2005		
Denmark	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Denmark	Bredkjaer SR. Musculoskeletal disease in Denmark. The Danish Health and Morbidity Survey 1986-87. <i>Acta Orthop Scand Suppl</i> . 1991; 62(S241): 10-2.	1986-1987		
Denmark	Biering-Sørensen F. Low back trouble in a general population of 30-, 40-, 50-, and 60-year-old men and women. Study design, representativeness and basic results. <i>Dan Med Bull</i> . 1982; 29(6): 289-99.	1977-1978		
Denmark	Hartvigsen J, Christensen K, Frederiksen H. Back pain remains a common symptom in old age: a population-based study of 4486 Danish twins aged 70-102. <i>Eur Spine J</i> . 2003; 12(5): 528-34.	1991, 1995-2001		
Denmark	Skofter B, Foldspang A. Physical activity and low-back pain in schoolchildren. <i>Eur Spine J</i> . 2008; 17(3): 373-9.	2002		
Denmark	Leboeuf-Yde C, Kyvik KO. At what age does low back pain become a common problem? A study of 29,424 individuals aged 12-41 years. <i>Spine</i> . 1998; 23(2): 228-34.	1994-1995		
Denmark	Buch H, Vinding T, Nielsen NV. Prevalence and causes of visual impairment according to World Health Organization and United States criteria in an aged, urban Scandinavian population: the Copenhagen City Eye Study. <i>Ophthalmology</i> . 2001; 108(12): 2347-57. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1986-1988		
Denmark	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2008.	1995, 1999-2000, 2005		
Denmark	Andersen E, Fedelius HC, Føns M, Haugsted R. An epidemiological study of disability in 4-year-old children from a birth cohort in Frederiksborg County, Denmark. <i>Dan Med Bull</i> . 1990; 37(2): 182-5.	1978-1982, 1990		
Denmark	Jakobsen C, Wewer V, Urne F, Andersen J, Faerk J, Kramer I, Stagegaard B, Pilgaard B, Weile B, Pærrgaard A. Incidence of ulcerative colitis and Crohn's disease in Danish children: Still rising or levelling out? <i>J Crohns Colitis</i> . 2008; 2(2): 152-7.	1998-2000, 2002-2004	*	†
Denmark	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Denmark	Bouvier-Colle M-H, Mohangoo AD, Gissler M, Novak-Antolic Z, Vutuc C, Szamotulska K, Zeitlin J, Euro-Peristat Scientific Committee. What about the mothers? An analysis of maternal mortality and morbidity in perinatal health surveillance systems in Europe. <i>BJOG</i> . 2012; 119(7): 880-90.	2003-2004	*	
Denmark	Kjer MM, Lauenborg J, Breum BM, Nilas L. The risk of adverse pregnancy outcome after bariatric surgery: a nationwide register-based matched cohort study. <i>Am J Obstet Gynecol</i> . 2013; 208(6): 464e1-5.	2004-2010	*	
Denmark	Ovesen P, Rasmussen S, Kesmodel U. Effect of prepregnancy maternal overweight and obesity on pregnancy outcome. <i>Obstet Gynecol</i> . 2011; 118(2 Pt 1): 305-12.	2004-2010	*	
Denmark	Bonnesen B, Secher NJ, Møller LK, Rasmussen S, Andreassen KR, Renault K. Pregnancy outcomes in a cohort of women with a preconception body mass index >50 kg/m ² . <i>Acta Obstet Gynecol Scand</i> . 2013; 92(9): 1111-4.	2004-2007	*	
Denmark	Borgen I, Aamodt G, Harsen N, Haugen M, Meltzer HM, Bratsæter AL. Maternal sugar consumption and risk of preeclampsia in nulliparous Norwegian women. <i>Eur J Clin Nutr</i> . 2012; 66(8): 920-5.	1999-2008	*	
Denmark	Chavarro JE, Halldorsson TL, Leth T, Bysted A, Olsen SF. A prospective study of trans fat intake and risk of preeclampsia in Denmark. <i>Eur J Clin Nutr</i> . 2011; 65(8): 944-51.	1998-2003	*	
Denmark	Øvergaard C, Møller AM, Fenger-Gron M, Knudsen LB, Sandall J. Freestanding midwifery unit versus obstetric unit: a matched cohort study of outcomes in low-risk women. <i>BMJ Open</i> . 2011; 1(2): e000262.	2004-2008	*	
Denmark	Roberts CL, Ford JB, Algeter CS, Antonsen S, Chalmers J, Chantingius S, Gokhale M, Kotelchuck M, Melve KK, Langridge A, Morris C, Morris JM, Nassar N, Norman JE, Norrie J, Sørensen HT, Walker R, Weir CJ. Population-based trends in pregnancy hypertension and pre-eclampsia: an international comparative study. <i>BMJ Open</i> . 2011; 1(1): e000101.	1997-2006	*	
Denmark	Gosvig KK, Jacobsen S, Sonne-Holm S, Palm H, Troelsen A. Prevalence of Malformations of the Hip Joint and Their Relationship to Sex, Groin Pain, and Risk of Osteoarthritis: A Population-Based Survey. <i>J Bone Joint Surg Am</i> . 2010; 92(5): 1162-9.	1991-1994	*	
Denmark	Joensen P. Prevalence, incidence, and classification of epilepsy in the Faroes. <i>Acta Neurol Scand</i> . 1986; 74(2): 150-5.	1970-1980	*	
Denmark	Christensen J, Vestergaard M, Pedersen MG, Pedersen CB, Olsen J, Sidenius P. Incidence and prevalence of epilepsy in Denmark. <i>Epilepsy Res</i> . 2007; 76(1): 60-5.	1977-2002	*	
Denmark	Juul-Jensen P, Foldspang A. Natural history of epileptic seizures. <i>Epilepsia</i> . 1983; 24(3): 297-312.	1963-1977	*	
Denmark	Lühdorf K, Jensen LK, Plesner AM. Epilepsy in the elderly: life expectancy and causes of death. <i>Acta Neurol Scand</i> . 1987; 76(3): 183-90.	1979-1983	*	
Denmark	Kočovská E, Biskupstø R, Carina Gillberg I, Ellefsen A, Kampmann H, Stóra T, Billstedt E, Gillberg C. The rising prevalence of autism: a prospective longitudinal study in the Faroe Islands. <i>J Autism Dev Disord</i> . 2012; 42(9): 1959-66.	2009	*	
Denmark	Parner ET, Thorsen P, Dixon G, de Klerk N, Leonard H, Nassar N, Bourke J, Bower C, Glasson EJ. A comparison of autism prevalence trends in Denmark and Western Australia. <i>J Autism Dev Disord</i> . 2011; 41(12): 1601-8.	2004	*	
Denmark	Høye A, Jacobsen BK, Hansen V. Increasing mortality in schizophrenia: are women at particular risk? A follow-up of 1111 patients admitted during 1980-2006 in Northern Norway. <i>Schizophr Res</i> . 2011; 132(2-3): 228-32.	1980-2006	*	
Denmark	Økkels N, Vernal DL, Jensen SOW, McGrath JJ, Nielsen RE. Changes in the diagnosed incidence of early onset schizophrenia over four decades. <i>Acta Psychiatr Scand</i> . 2013; 127(1): 62-8.	1994-2010	*	
Denmark	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO), 1995, 1998, 2001, 2004, 2007, 2010.	1995, 1998, 2001, 2004, 2007, 2010		
Denmark	Faber MT, Nielsen A, Nygård M, Sparén P, Tryggvadottir L, Hansen BT, Liaw K-L, Kjaer SK. Genital chlamydia, genital herpes, Trichomonas vaginalis and gonorrhoea prevalence, and risk factors among nearly 70,000 randomly selected women in 4 Nordic countries. <i>Sex Transm Dis</i> . 2011; 38(8): 727-34.	2004-2005	*	
Denmark	Buch H, Vinding T, La Cour M, Nielsen NV. The prevalence and causes of bilateral and unilateral blindness in an elderly urban Danish population. The Copenhagen City Eye Study. <i>Acta Ophthalmol Scand</i> . 2001; 79(5): 441-9. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1986-1988		
Denmark	Christensen PB, Engle RE, Jacobsen SEH, Krarup HB, Georgsen J, Purcell RH. High prevalence of hepatitis E antibodies among Danish prisoners and drug users. <i>J Med Virol</i> . 2002; 66(1): 49-55.	1999-2001	*	
Denmark	Buch H, Vinding T, La Cour M, Appleyard M, Jensen GB, Nielsen NV. Prevalence and causes of visual impairment and blindness among 9980 Scandinavian adults: the Copenhagen City Eye Study. <i>Ophthalmology</i> . 2004; 111(1): 53-61. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1991-1994	*	
Denmark	Grauslund J. Long-term mortality and retinopathy in type 1 diabetes. <i>Acta Ophthalmol</i> . 2010; 1-14.	1973-2008		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Denmark	Holstein P, Ellitsgaard N, Olsen BB, Ellitsgaard V. Decreasing incidence of major amputations in people with diabetes. <i>Diabetologia</i> . 2000; 43(7): 844-7.	1981-1983, 1995-1997		
Denmark	Mølbak AG, Christau B, Mamer B, Borch-Johnsen K, Nerup J. Incidence of insulin-dependent diabetes mellitus in age groups over 30 years in Denmark. <i>Diabet Med</i> . 1994; 11(7): 650-5.	1973-1977		
Denmark	Clausen L. Time to remission for eating disorder patients: a 2(1/2)-year follow-up study of outcome and predictors. <i>Nord J Psychiatry</i> . 2008; 62(2): 151-9.	1997-2001	*	
Denmark	Helverskov JL, Clausen L, Mors O, Frydenberg M, Thomsen PH, Rokkedal K. Trans-diagnostic outcome of eating disorders: A 30-month follow-up study of 629 patients. <i>Eur Eat Disord Rev</i> . 2010; 18(6): 453-63.	2001-2007	*	
Denmark	Stoving RK, Andries A, Brixen K, Bilenberg N, Hørdér K. Gender differences in outcome of eating disorders: a retrospective cohort study. <i>Psychiatry Res</i> . 2011; 186(2-3): 362-6.	1994-2004	*	
Denmark	Bargagli AM, Hickman M, Davoli M, Perucci CA, Schifano P, Buster M, Brugal T, Vicente J, COSMO European Group. Drug-related mortality and its impact on adult mortality in eight European countries. <i>Eur J Public Health</i> . 2006; 16(2): 198-202.	1996-2002	*	
Denmark	Isbyoy T, Hastrup L, Hay G. Estimating the prevalence of problem opioid use in Copenhagen 1997-1998. <i>Dan Med Bull</i> . 2004; 51(1): 114-6.	1997-1998	*	
Denmark	Sørensen HJ, Jepsen PW, Hastrup S, Juel K. Drug-use pattern, comorbid psychosis and mortality in people with a history of opioid addiction. <i>Acta Psychiatr Scand</i> . 2005; 111(3): 244-9.	1984-1999	*	
Denmark	Arendt M, Munk-Jørgensen P, Sher L, Jensen SOW. Mortality among individuals with cannabis, cocaine, amphetamine, MDMA, and opioid use disorders: a nationwide follow-up study of Danish substance users in treatment. <i>Drug Alcohol Depend</i> . 2011; 114(2-3): 134-9.	1996-2006	*	
Denmark	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant</i> . 1988; 3(6): 714-27.	1985		
Denmark	Van Dijk PC, Jager KJ, Stengel B, Grönhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). <i>Kidney Int</i> . 2005; 67(4): 1489-99.	1991-1992, 1999-2000		
Denmark	Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. <i>Nephrol Dial Transplant</i> . 2003; 18(9): 1824-33.	1990-1991, 1998-1999		
Denmark	Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. <i>J Clin Endocrinol Metab</i> . 2008; 93(4): 1408-11.	2005		
Denmark	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguiar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Gilst WH van, Widimsky J, Freemanle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J</i> . 2003; 24(5): 442-63.	2000-2001		
Denmark	Hoover JN, Ellegaard B, Atttström R. Periodontal status of 14-16 year-old Danish schoolchildren. <i>Scand J Dent Res</i> . 1981; 89(2): 175-9.	1981		
Denmark	Bronnum-Hansen H, Koch-Henriksen N and Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. <i>Brain</i> . 2004; 844-50.	1950-1996	*	
Denmark	Joergensen M, Brusgaard K, Crüger DG, Gerdes A-M, de Muckadell OBS. Incidence, prevalence, etiology, and prognosis of first-time chronic pancreatitis in young patients: a nationwide cohort study. <i>Dig Dis Sci</i> . 2010; 55(10): 2988-98.	1980-2008	*	
Denmark	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2012. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	2010	*	
Denmark	Bak P. Guillain-Barré syndrome in a Danish county. <i>Neurology</i> . 1985; 35(2): 207-11.	1965-1982		†
Denmark	Halls J, Breckjaer C, Friis ML. Guillain-Barré syndrome: diagnostic criteria, epidemiology, clinical course and prognosis. <i>Acta Neurol Scand</i> . 1988; 78(2): 118-22.	1977-1984		
Denmark	Parving A, Hauch AM. The causes of profound hearing impairment in a school for the deaf – a longitudinal study. <i>Br J Audiol</i> . 1994; 28(2): 63-9.	1993-1994	*	
Denmark	Davis A, Parving A. Towards appropriate epidemiological data on childhood hearing disability: A comparative European study of birth cohorts 1982-88. <i>J Audiol Med</i> . 1994; 3(1).	1992	*	
Denmark	Holten A, Parving A. Aetiology of hearing disorders in children at the schools for the deaf. <i>Int J Pediatr Otorhinolaryngol</i> . 1985; 10(3): 229-36.	1984	*	
Denmark	Parving A. Epidemiology of hearing loss and aetiological diagnosis of hearing impairment in childhood. <i>Int J Pediatr Otorhinolaryngol</i> . 1983; 5(2): 151-65.	1982	*	
Denmark	Parving A, Stephens D. Profound permanent hearing impairment in childhood: causative factors in two European countries. <i>Acta Otolaryngol</i> . 1997; 117(2): 158-60.	1975-1980	*	
Denmark	Parving A, Hauch A-M. Permanent childhood hearing impairment – some cross-sectional characteristics from a surveillance program. <i>Int Pediatr</i> . 2001; 16(1).	2000	*	
Denmark	Kjaer SK, de Villiers EM, Caglayan H, Svare E, Haugaard BJ, Engholm G, Christensen RB, Møller KA, Poll P, Jensen H. Human papillomavirus, herpes simplex virus and other potential risk factors for cervical cancer in a high-risk area (Greenland) and a low-risk area (Denmark) – a second look. <i>Br J Cancer</i> . 1993; 67(4): 830-7.	1986, 1988	*	
Denmark	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland: World Health Organization (WHO).	2004-2008	*	
Denmark	Kamper J, Feilberg Jørgensen N, Jonso F, Pedersen-Bjergaard L, Pryds O, Danish ETFOL Study Group. The Danish national study in infants with extremely low gestational age and birthweight (the ETFOL study): respiratory morbidity and outcome. <i>Acta Paediatr</i> . 2004; 93(2): 225-32.	1995	*	†
Denmark	Jensen K, Raneck L, Rosdahl N. Bacterial meningitis: a review of 356 cases with special reference to corticosteroid and antiserum treatment. <i>Scand J Infect Dis</i> . 1969; 1(1): 21-30.	1960-1965		
Denmark	Alanee SRJ, McGee L, Jackson D, Chiou CC, Feldman C, Morris AJ, Orqvist A, Rello J, Luna CM, Baddour LM, Ip M, Yu VL, Klugman KP. International Pneumococcal Study Group. Association of serotypes of <i>Streptococcus pneumoniae</i> with disease severity and outcome in adults: an international study. <i>Clin Infect Dis</i> . 2007; 45(1): 46-51.	1997-2007		
Denmark	Laurberg P, Pedersen KM, Hreidarsson A, Sigfusson N, Iversen E, Knudsen PR. Iodine intake and the pattern of thyroid disorders: a comparative epidemiological study of thyroid abnormalities in the elderly in Iceland and in Jutland, Denmark. <i>J Clin Endocrinol Metab</i> . 1998; 83(3): 765-9 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1988		
Denmark	Osterberg T, Era P, Gause-Nilsson I, Steen B. Dental state and functional capacity in 75-year-olds in three Nordic localities. <i>J Oral Rehabil</i> . 1995; 22(8): 653-60.	1993		†
Denmark	Holm-Pedersen P, Schultz-Larsen K, Christiansen N, Avlund K. Tooth loss and subsequent disability and mortality in old age. <i>J Am Geriatr Soc</i> . 2008; 56(3): 429-35.	1984-2006		
Denmark	Pedersen E. Epidemic encephalitis in Jutland; a clinical survey for the years 1952-54. <i>Dan Med Bull</i> . 1956; 3(3): 65-75.	1952-1954		
Denmark	Parry GJ, Ogston SA. EUROMAC. A European concerted action: maternal alcohol consumption and its relation to the outcome of pregnancy and child development at 18 months. Results—child development at age 18 months. <i>Int J Epidemiol</i> . 1992; 21: 72-78.	1992, 2000-2008	*	
Denmark	Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJA, Wasserman SM, Baker N, Rosser D, Cleland JGF, Ponikowski P. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. <i>Eur Heart J</i> . 2007; 28(18): 2208-16.	1992-1995		
Denmark	Jørgensen T. Prevalence of gallstones in a Danish population. <i>Am J Epidemiol</i> . 1987; 126(5): 912-21.	1982-1984		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Denmark	Trichopoulos D, Bania C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overved K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PHM, Lund E, Quirós JR, González CA, Sánchez Pérez M-J, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu I, Chuang S-C, Murphy N, Boffetta P, Trichopoulou A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. <i>J Natl Cancer Inst.</i> 2011; 103(22): 1686-95.	1992-2006	*	
Denmark	Skinhøj P, Aldershvile J, Black F, Kjersem H, Kryger P, Mathiesen L. Viral hepatitis in southeast Asian refugees. <i>J Med Virol.</i> 1981; 7(2): 149-55.	1976		
Denmark	Mathiesen LR, Skinhøj P, Balstrup F. Antibody to hepatitis A virus in plasma of Danish blood donors and in immune serum globulin produced in Denmark. <i>Scand J Infect Dis.</i> 1980; 12(2): 81-3.	1977		
Denmark	Skinhøj P, Vinterberg H, Aldershvile J, Kryger P. Hepatitis A, B, and non-A, non-B in Danish hospital nursing staff. <i>J Clin Pathol.</i> 1984; 37(7): 763-6.	1983		
Denmark	Linneberg A, Ostergaard C, Tvede M, Andersen LP, Nielsen NH, Madsen F, Frølund L, Dirksen A, Jørgensen T. IgG antibodies against microorganisms and atopic disease in Danish adults: the Copenhagen Allergy Study. <i>J Allergy Clin Immunol.</i> 2003; 111(4): 847-53.	1990-1991		
Denmark	Christensen PB, Homburg KM, Sørensen LT, Georgsen J. Hepatitis A infection and vaccination among Danish blood donors. <i>Scand J Infect Dis.</i> 2005; 37(2): 127-30.	2003		
Denmark	Bjerre JV, Petersen JR, Ebbesen F. Surveillance of extreme hyperbilirubinaemia in Denmark. A method to identify the newborn infants. <i>Acta Paediatr.</i> 2008; 97(8): 1030-4.	2002-2005	*	†
Denmark	Ebbesen F, Andersson C, Verder H, Grytter C, Pedersen-Bjergaard L, Petersen JR, Schaarup J. Extreme hyperbilirubinaemia in term and near-term infants in Denmark. <i>Acta Paediatr.</i> 2005; 94(1): 59-64.	2000-2001	*	†
Denmark	Tunstall-Pedoe H, Kuusmaa K, Mähönen M, Tolonen H, Ruokoski E. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. <i>Lancet.</i> 1999; 353(9164): 1547-57.	1980-1995		
Denmark	National Public Health Institute (Finland), World Health Organization (WHO). MONICA Coronary Event Registration Data Book 1980-1995. Geneva, Switzerland: World Health Organization (WHO), 2000.	1980-1995		
Denmark	Fisker N, Georgsen J, Stolborg T, Khalil MR, Christensen PB. Low hepatitis B prevalence among pre-school children in Denmark: saliva anti-HBc screening in day care centres. <i>J Med Virol.</i> 2002; 68(4): 500-4.	2000		
Denmark	Jensen L, Heilmann C, Smith E, Wantzin P, Peitersen B, Weber T, Krosgaard K. Efficacy of selective antenatal screening for hepatitis B among pregnant women in Denmark: is selective screening still an acceptable strategy in a low-endemicity country? <i>Scand J Infect Dis.</i> 2003; 35(6-7): 378-82.	2000-2001		
Denmark	Competence Centre for Clinical Quality and Health Informatics West (Denmark). Danish Stroke Registry Data 2009. [Unpublished].	2009	*	
Denmark	Andersen-Ranberg K, Schroll M, Jeune B. Healthy centenarians do not exist, but autonomous centenarians do: a population-based study of morbidity among Danish centenarians. <i>J Am Geriatr Soc.</i> 2001; 49(7): 900-8.	1992-1995		
Denmark	Österlind A, Hou-Jensen K, Møller Jensen O. Incidence of cutaneous malignant melanoma in Denmark 1978-1982. Anatomic site distribution, histologic types, and comparison with non-melanoma skin cancer. <i>Br J Cancer.</i> 1988; 58(3): 385-91.	1978-1982		
Denmark	Ringbaek T, Seersholm N, Viskum K. Standardised mortality rates in females and males with COPD and asthma. <i>Eur Respir J.</i> 2005; 25(5): 891-5.	1977-1997	*	
Denmark	Ali Z, Dirks CG, Ulrik CS. Long-term mortality among adults with asthma: a 25-year follow-up of 1,075 outpatients with asthma. <i>Chest.</i> 2013; 143(6): 1649-55.	1974-1990	*	
Denmark	Lange P, Ulrik CS, Vestbo J. Mortality in adults with self-reported asthma. Copenhagen City Heart Study Group. <i>Lancet.</i> 1996; 347(9011): 1285-9.	1976-1993	*	
Denmark	Ulrik CS, Frederiksen J. Mortality and markers of risk of asthma death among 1,075 outpatients with asthma. <i>Chest.</i> 1995; 108(1): 10-5.	1974-1990	*	
Denmark	Buch P, Rasmussen S, Gislason GH, Rasmussen JN, Køber L, Gadsbøl N, Stender S, Madsen M, Torp-Pedersen C, Abildstrom SZ. Temporal decline in the prognostic impact of a recurrent acute myocardial infarction 1985 to 2002. <i>Heart.</i> 2007; 93(2): 210-215.	1985-1989, 2000-2002	*	
Denmark	Bronnum-Hansen H, Jørgensen T, Davidsen M, Madsen M, Osler M, Gerdes LU, Schroll M. Survival and cause of death after myocardial infarction: the Danish MONICA study. <i>J Clin Epidemiol.</i> 2001; 54(12): 1244-1250.	1982-1991	*	
Denmark	Zeitlan J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT; 2008. Available from: http://www.perinataleaudit.nl/downloads/bestand/649/peristat-ii-2008-	2004		†
Denmark	Mathiasen R, Hansen BM, Andersen A-MNN, Forman JL, Greisen G. Gestational age and basic school achievements: a national follow-up study in Denmark. <i>Pediatrics.</i> 2010 Dec;126(6):e1553-1561.	1989		†
Denmark	Danish Society of Nephrology National Registry (DNSL) Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Denmark	Danish Society of Nephrology National Registry (DNSL) Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Denmark	Denmark Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Denmark	European Surveillance of Congenital Anomalies (EUROCAT). Denmark EUROCAT Prevalence Tables. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	1980-2011		
Denmark	Denmark - Funen Registry of Funen County Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Denmark	Danish Registry of Congenital Malformations and Medical Birth Registry Data 1986 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1986	*	
Denmark	Danish Registry of Congenital Malformations and Medical Birth Registry Data 1987 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1987	*	
Denmark	Danish Registry of Congenital Malformations and Medical Birth Registry Data 1985 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1985	*	
Denmark	Danish Registry of Congenital Malformations and Medical Birth Registry Data 1988 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1988	*	
Denmark	Danish Registry of Congenital Malformations and Medical Birth Registry Data 1984 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1984	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Denmark	Danish Registry of Congenital Malformations and Medical Birth Registry Data 1983 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1983	*	
Djibouti	Department of Statistics and Demographic Studies (Djibouti), League of Arab States, Ministry of Health (Djibouti), Pan Arab Project for Family Health (PAPFAM), Djibouti Family Health Survey 2002.	2002		†
Djibouti	Ministry of Economy, Finance, and Planning in charge of Privatization (Djibouti), Ministry of Health (Djibouti), United Nations Children's Fund (UNICEF). Djibouti Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006	*	†
Djibouti	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Djibouti	Gibbs, S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int J Dermatol. 1996; 35(9): 633-9.	1994		
Djibouti	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2007-2009		
Djibouti	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group, [Unpublished].	1990, 2005, 2010		
Djibouti	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2010, 2012		
Djibouti	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
Djibouti	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Djibouti	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Djibouti	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Djibouti	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Djibouti	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Djibouti	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Djibouti	Marcelin AG, Grandadam M, Flandre P, Koeck JL, Philippon M, Nicand E, Teysou R, Agut H, Huraux JM, Dupin N. Comparative Study of Heterosexual Transmission of HIV-1, HSV-2 and KSHV in Djibouti. Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; 2001 Feb 4-8; Chicago (IL), United States. 2001.	1998-2000	*	
Djibouti	Fox E, Abbatte EA, Said-Salah, Constantine NT, Wassef HH, Woody JN. Viral hepatitis markers in Djibouti: an epidemiological survey. Trans R Soc Trop Med Hyg. 1988; 82(5): 750-2.	1987		
Djibouti	Malaria in the Republic of Djibouti: Historical and Epidemiological Aspects [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Dominica	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-2002, 2005		
Dominica	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Dominica	Smadja D, Cabre P, May F, Fanon J-L, René-Corail P, Riocœur C, Charpentier J-C, Fournier P, Saint-Vil M, Ketterlé J. ERMANCIA: Epidemiology of Stroke in Martinique, French West Indies. Stroke. 2001; 32(12): 2741-7.	1998-1999		
Dominica	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000-2001, 2004, 2006-2009		
Dominica	Canino G, Shrout PE, Rubio-Stipec M, et al. The DSM-IV rates of child and adolescent disorders in Puerto Rico: Prevalence, correlates, service use, and the effects of impairment. Arch Gen Psychiatry. 2004; 61(1): 85-93.	1999-2000		
Dominica	Rubio-Stipec M, Canino GJ, Shrout P, Dulcan M, Freeman D, Bravo M. Psychometric properties of parents and children as informants in child psychiatry epidemiology with the Spanish Diagnostic Interview Schedule for Children (DISC-2). J Abnorm Child Psychol. 1994; 22(6): 703-20.	1992	*	
Dominica	Canino GJ, Bird HR, Shrout PE, Rubio-Stipec M, Bravo M, Martinez R, Sesman M, Guevara LM. The prevalence of specific psychiatric disorders in Puerto Rico. Arch Gen Psychiatry. 1987; 44(8): 727-35.	1984		
Dominica	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Dominica Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2006		
Dominica	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), Ministry of Health (Dominica). Dominica Drug Prevalence in Secondary Schools Survey 2006.	2006		
Dominica	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2007, 2010, 2012		
Dominica	Bird HR, Canino G, Rubio-Stipec M, Gould MS, Ribera J, Sesman M, Woodbury M, Huertas-Goldman S, Pagan A, Sanchez-Lacay A. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico. The use of combined measures. Arch Gen Psychiatry. 1988; 45(12): 1120-6.	1985-1986	*	
Dominica	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Dominica	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Dominica	Merikangas KR, Conway KP, Swendsen J, Febo V, Dierker L, Brunetto W, Stolar M, Canino G. Substance use and behaviour disorders in Puerto Rican youth: a migrant family study. J Epidemiol Community Health. 2009; 63(4): 310-6.	1990		
Dominica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Dominica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Dominica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Dominica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Dominica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Dominica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Dominica	Olindo S, Cabre P, Deschamps R, Chatot-Henry C, René-Corail P, Fournier P, Saint-Vil M, May F, Smadja D. Acute stroke in the very elderly: epidemiological features, stroke subtypes, management, and outcome in Martinique, French West Indies. Stroke. 2003; 34(7): 1593-7.	1998-1999		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Dominica	Fassio E, Diaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L. Multicenter Group for Study of Hepatocarcinoma in Latin America. Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Ann Hepatol</i> . 2010; 9(1): 63-9.	2006-2008	*	
Dominica	Robinson MT, Wilson TW, Nicholson GA, Grell GAC, Etienne C, Grim CM, Wilson D, Grim CE. AGT and RH blood group polymorphisms affect blood pressure and lipids in Afro-Caribbeans. <i>J Hum Hypertens</i> . 2004; 18(5): 351-63.	2001-2003	*	†
Dominican Republic	National Council for Population and Family (CONAPOFA) (Dominican Republic), International Statistical Institute. Dominican Republic World Fertility Survey 1975. Voorburg, Netherlands: International Statistical Institute.	1975		
Dominican Republic	National Council for Population and Family (Dominican Republic), Westinghouse; Institute for Resource Development. Dominican Republic Demographic and Health Survey 1986. Columbia, United States: Westinghouse; Institute for Resource Development.	1986		†
Dominican Republic	Macro International, Inc.; Institute for Resource Development, National Planning Office (Dominican Republic), Profamilia. Dominican Republic Demographic and Health Survey 1991. Calverton, United States: Macro International, Inc.	1991		†
Dominican Republic	Center for Social and Demographic Studies (CESDEM), Macro International, Inc, National Planning Office (Dominican Republic), Profamilia. Dominican Republic Demographic and Health Survey 1996. Calverton, United States: Macro International, Inc.	1996		†
Dominican Republic	Center for Social and Demographic Studies (CESDEM), Macro International, Inc. Dominican Republic Demographic and Health Survey 1999. Calverton, United States: Macro International, Inc.	1999		†
Dominican Republic	Center for Social and Demographic Studies (CESDEM), Macro International, Inc. Dominican Republic Demographic and Health Survey 2002. Calverton, United States: Macro International, Inc.	2002		†
Dominican Republic	Center for Social and Demographic Studies (CESDEM), Macro International, Inc. Dominican Republic Demographic and Health Survey 2007. Calverton, United States: Macro International, Inc.	2007		†
Dominican Republic	Center for Social and Demographic Studies (CESDEM), Macro International, Inc. Dominican Republic Special Demographic and Health Survey 2007. Calverton, United States: Macro International, Inc.	2007		†
Dominican Republic	World Health Organization (WHO). Dominican Republic World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Dominican Republic	Center for Social and Demographic Studies (CESDEM), United Nations Children's Fund (UNICEF). Dominican Republic Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Dominican Republic	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-2002		
Dominican Republic	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Dominican Republic	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Dominican Republic	Smadja D, Cabre P, May F, Fanon J-L, René-Corail P, Riocreux C, Charpentier J-C, Fournier P, Saint-Vil M, Ketterlé J. ERMANCIA: Epidemiology of Stroke in Martinique, French West Indies. <i>Stroke</i> . 2001; 32(12): 2741-7.	1998-1999		
Dominican Republic	Gomez E, Peguero M, Sanchez J, Castellanos PL, Feris J, Peña C, Brudzinski-Laclair L, Levine OS. Population-Based Surveillance for Bacterial Meningitis in the Dominican Republic: Implications for Control by Vaccination. <i>Environ Res</i> . 2000; 125(3): 549-54.	1998		
Dominican Republic	Lee EH, Flannery B, Corcino M, Moore A, Garib Z, Pena C, Sanchez J, Fernandez J, Feris-Iglesias JM. Impact of Haemophilus influenzae type b conjugate vaccine on bacterial meningitis in the Dominican Republic. <i>Rev Panam Salud Publica</i> . 2008; 24(3): 161-8.	1998-2004		
Dominican Republic	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1999-2000, 2002-2004, 2007-2009		
Dominican Republic	Acosta D, Rothbeck R, Rodríguez JG, González LM, Almánzar MR, Minaya SN, Ortiz M del C, Ferri CP, Prince MJ. The prevalence and social patterning of chronic diseases among older people in a population undergoing health transition. A 10/66 Group cross-sectional population-based survey in the Dominican Republic. <i>BMC Public Health</i> . 2010; 344.	2007-2009		
Dominican Republic	Prince M, Acosta D, Ferri CP, Guerra M, Huang Y, Llibre Rodríguez JJ, Salas A, Sosa AL, Williams JD, Dewey ME, Acosta I, Jotheeswaran AT, Liu Z. Dementia incidence and mortality in middle-income countries, and associations with indicators of cognitive reserve: a 10/66 Dementia Research Group population-based cohort study. <i>Lancet</i> . 2012; 380(9836): 50-8.	2003-2010		
Dominican Republic	Sousa RM, Ferri CP, Acosta D, Albanese E, Guerra M, Huang Y, Jacob KS, Jotheeswaran AT, Rodríguez JIL, Pichardo GR, Rodríguez MC, Salas A, Sosa AL, Williams J, Zuniga T, Prince M. Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population-based survey. <i>Lancet</i> . 2009; 374(9704): 1821-30.	2003-2005		
Dominican Republic	Canino G, Shrout PE, Rubio-Stipec M, et al. The DSM-IV rates of child and adolescent disorders in Puerto Rico: Prevalence, correlates, service use, and the effects of impairment. <i>Arch Gen Psychiatry</i> . 2004; 61(1): 85-93.	1999-2000		
Dominican Republic	Rubio-Stipec M, Canino GJ, Shrout P, Dulcan M, Freeman D, Bravo M. Psychometric properties of parents and children as informants in child psychiatry epidemiology with the Spanish Diagnostic Interview Schedule for Children (DISC-2). <i>J Abnorm Child Psychol</i> . 1994; 22(6): 703-20.	1992	*	
Dominican Republic	Canino GJ, Bird HR, Shrout PE, Rubio-Stipec M, Bravo M, Martinez R, Sesman M, Guevara LM. The prevalence of specific psychiatric disorders in Puerto Rico. <i>Arch Gen Psychiatry</i> . 1987; 44(8): 727-35.	1984		
Dominican Republic	Dominican Republic Rapid Assessment for Avoidable Blindness Survey 2008 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2008		
Dominican Republic	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). CICAD Comparative Report on Nationwide School Surveys in Seven Countries: El Salvador, Guatemala, Nicaragua, Panama, Paraguay, Dominican Republic, and Uruguay 2003. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2004.	2003	*	
Dominican Republic	Ferri CP, Schoenborn C, Kalra L, Acosta D, Guerra M, Huang Y, Jacob KS, Rodríguez JIL, Salas A, Sosa AL, Williams JD, Liu Z, Moriyan T, Valhuerdi A, Prince MJ. Prevalence of stroke and related burden among older people living in Latin America, India and China. <i>J Neurol Neurosurg Psychiatry</i> . 2011; 82(10): 1074-82.	2007-2009	*	
Dominican Republic	Kay RW. Prevalence of psychotic mental disorders in the Commonwealth of Dominica -- abstract. <i>West Indian Med J</i> . 1990; 39(Suppl 1): 30-1.	1987-1989		
Dominican Republic	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2004, 2007, 2010, 2012		
Dominican Republic	Bird HR, Canino G, Rubio-Stipec M, Gould MS, Ribera J, Sesman M, Woodbury M, Huertas-Goldman S, Pagan A, Sanchez-Lacay A. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico. The use of combined measures. <i>Arch Gen Psychiatry</i> . 1988; 45(12): 1120-6.	1985-1986	*	
Dominican Republic	Fernández-Cean J, González-Martínez F, Schwedt E, Mazzuchi N. Renal replacement therapy in Latin America. <i>Kidney Int</i> . 2000; 57(574): 55-59.	1997		
Dominican Republic	Cusumano A, García-García G, Di Gioia C, Hermida O, Lavorato C, Carreño CA, Torrico MP, Batista PB, Romão JE, Badal HP, Miranda SE, Gomez R, Calderon MC, Sanchez SH, Lopez MA, Moscoso J, Merino RL, Polo JV, Lopez A, Romero NJ, Garcia R, Acosta BV, Lopez AS, Delpin ES, Mena E, González C, Milanés CL, Acchiardo S. End-stage renal disease and its treatment in Latin America in the twenty-first century. <i>Ren Fail</i> . 2006; 28(8): 631-7.	2004		
Dominican Republic	Llibre Rodríguez JJ, Ferri CP, Acosta D, Guerra M, Huang Y, Jacob KS, Krishnamoorthy ES, Salas A, Sosa AL, Acosta I, Dewey ME, Gaona C, Jotheeswaran AT, Li S, Rodríguez D, Rodríguez G, Kumar PS, Valhuerdi A, Prince M, 10/66 Dementia Research Group. Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey. <i>Lancet</i> . 2008; 372(9637): 464-74.	2003-2004		†
Dominican Republic	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec</i> . 2009; 84(33): 333-40.	2008	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Dominican Republic	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Dominican Republic	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Dominican Republic	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Dominican Republic	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Dominican Republic	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Dominican Republic	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Dominican Republic	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Dominican Republic	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Dominican Republic	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Dominican Republic	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2003. Pan American Health Organization (PAHO).	2003		†
Dominican Republic	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2004. Pan American Health Organization (PAHO).	2004		†
Dominican Republic	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2005. Pan American Health Organization (PAHO).	2005		†
Dominican Republic	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2006. Pan American Health Organization (PAHO).	2006		†
Dominican Republic	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2007. Pan American Health Organization (PAHO).	2007		†
Dominican Republic	Merikangas KR, Conway KP, Swendsen J, Febo V, Dierker L, Brunetto W, Stolar M, Canino G. Substance use and behaviour disorders in Puerto Rican youth: a migrant family study. J Epidemiol Community Health. 2009; 63(4): 310-6.	1990		
Dominican Republic	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Dominican Republic	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Dominican Republic	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Dominican Republic	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Dominican Republic	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Dominican Republic	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Dominican Republic	Cabrera-Batista B, Skewes-Ramm R, Fermin CD, Garry RF. Dengue in the Dominican Republic: epidemiology for 2004. Microsc Res Tech. 2005; 68(3-4): 250-4.	2003-2004	*	
Dominican Republic	Olando S, Cabre P, Deschamps R, Chatot-Henry C, René-Corail P, Fournier P, Saint-Vil M, May F, Smadja D. Acute stroke in the very elderly: epidemiological features, stroke subtypes, management, and outcome in Martinique, French West Indies. Stroke. 2003; 34(7): 1593-7.	1998-1999		
Dominican Republic	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L, Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. Ann Hepatol. 2010; 9(1): 63-9.	2006-2008	*	
Dominican Republic	Tapia-Conyer R, Santos JI, Cavalanti AM, Urdaneta E, Rivera L, Manterola A, Potin M, Ruttiman R, Tanaka Kido J. Hepatitis A in Latin America: A Changing Epidemiologic Pattern. Am J Trop Med Hyg. 1999; 61(5): 825-9.	1996-1997		
Dominican Republic	Stafford JL, Hill KR, Arneaud JD. Rhesus factor distribution in the Caribbean; preliminary communication. West Indian Med J. 1955; 4(2): 119-25.	1952-1954	*	†
Dominican Republic	Vargas M, Abreu E, Vargas Matos N. [Prevalence and periodicity of Bancroft's filaria in diurnal blood from the population of Batey Ocho (Central Barahona), Dominican Republic]. Bol Asoc Med P.R. 1981; 73(10): 497-502. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1980	*	
Dominican Republic	Vincent AL, Gonzalvo A, Cowell BC, Nayar JK, Uribe L. A survey of Bancroftian filariasis in the Dominican Republic. J Parasitol. 1987; 73(4): 839-40. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1981-1985	*	
Dominican Republic	Lymphatic Filariasis in the Americas: An Epidemiologic History as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1988-1989, 1991	*	
Dominican Republic	Dominican Republic Vital Registration Birth Data 1981 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1981		
Ecuador	Center for Studies of Population and Social Development (CEPAR), Ecuador Ministry of Health (MSP), Division of Reproductive Health-Centers for Disease Control and Prevention (CDC). English Language Report (1992) Ecuador Family Planning/Maternal and Child Health Survey 1989. Atlanta, United States: Centers for Disease Control and Prevention (CDC).	1989		
Ecuador	Ecuador Vital Registration - Deaths 2002 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2002	*	
Ecuador	Center for Population Studies and Responsible Parenthood (CEPAR) (El Salvador), Westinghouse; Institute for Resource Development. Ecuador Demographic and Health Survey 1987. Columbia, United States: Westinghouse; Institute for Resource Development.	1987		†
Ecuador	World Health Organization (WHO). Ecuador World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Ecuador	Center for Studies of Population and Social Development (CEPAR) (Ecuador), Division of Reproductive Health-Centers for Disease Control and Prevention (CDC). Ecuador Reproductive Health Survey 1999. Atlanta, United States: Centers for Disease Control and Prevention (CDC), 2001.	1999		
Ecuador	Center for Studies of Population and Social Development (CEPAR) (Ecuador) and Division of Reproductive Health-Centers for Disease Control and Prevention (CDC). (2005) Ecuador Reproductive Health Survey 2004. Quito, Ecuador: CEPAR.	2004		†
Ecuador	World Health Organization (WHO). Control of Foodborne Trematode Infections 1995. Geneva, Switzerland: World Health Organization (WHO), 1995.	1995	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Ecuador	National Institute of Statistics and Censuses (Ecuador). Ecuador Hospital Inpatient Discharges 1997. Quito, Ecuador: National Institute of Statistics and Censuses (Ecuador).	1997		†
Ecuador	National Institute of Statistics and Censuses (Ecuador). Ecuador Hospital Inpatient Discharges 1998. Quito, Ecuador: National Institute of Statistics and Censuses (Ecuador).	1998		†
Ecuador	National Institute of Statistics and Censuses (Ecuador). Ecuador Hospital Inpatient Discharges 1999. Quito, Ecuador: National Institute of Statistics and Censuses (Ecuador).	1999		
Ecuador	National Institute of Statistics and Censuses (Ecuador). Ecuador Hospital Inpatient Discharges 2000. Quito, Ecuador: National Institute of Statistics and Censuses (Ecuador).	2000		
Ecuador	National Institute of Statistics and Censuses (Ecuador). Ecuador Hospital Inpatient Discharges 2001. Quito, Ecuador: National Institute of Statistics and Censuses (Ecuador).	2001		
Ecuador	National Institute of Statistics and Censuses (Ecuador). Ecuador Hospital Inpatient Discharges 2002. Quito, Ecuador: National Institute of Statistics and Censuses (Ecuador).	2002		†
Ecuador	National Institute of Statistics and Censuses (Ecuador). Ecuador Hospital Inpatient Discharges 2003. Quito, Ecuador: National Institute of Statistics and Censuses (Ecuador).	2003		†
Ecuador	National Institute of Statistics and Censuses (Ecuador). Ecuador Hospital Inpatient Discharges 2004. Quito, Ecuador: National Institute of Statistics and Censuses (Ecuador).	2004		†
Ecuador	National Institute of Statistics and Censuses (Ecuador). Ecuador Hospital Inpatient Discharges 2005. Quito, Ecuador: National Institute of Statistics and Censuses (Ecuador).	2005		†
Ecuador	National Institute of Statistics and Censuses (Ecuador). Ecuador Hospital Inpatient Discharges 2006. Quito, Ecuador: National Institute of Statistics and Censuses (Ecuador).	2006		†
Ecuador	National Institute of Statistics and Censuses (Ecuador). Ecuador Hospital Inpatient Discharges 2007. Quito, Ecuador: National Institute of Statistics and Censuses (Ecuador).	2007		†
Ecuador	National Institute of Statistics and Censuses (Ecuador). Ecuador Hospital Inpatient Discharges 2008. Quito, Ecuador: National Institute of Statistics and Censuses (Ecuador).	2008		†
Ecuador	National Institute of Statistics and Censuses (Ecuador). Ecuador Hospital Inpatient Discharges 2009. Quito, Ecuador: National Institute of Statistics and Censuses (Ecuador).	2009		
Ecuador	National Institute of Statistics and Censuses (Ecuador). Ecuador Hospital Inpatient Discharges 2010. Quito, Ecuador: National Institute of Statistics and Censuses (Ecuador).	2010		
Ecuador	National Institute of Statistics and Censuses (Ecuador). Ecuador Hospital Inpatient Discharges 2011. Quito, Ecuador: National Institute of Statistics and Censuses (Ecuador).	2011		
Ecuador	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-2002		
Ecuador	Centre for Health Informatics and Multiprofessional Education, University College London. Model's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Ecuador	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Ecuador	Aguilar V HM, Abad-Franch F, Racines V J, Paucar C A. Epidemiology of Chagas disease in Ecuador. A brief review. Mem Inst Oswaldo Cruz. 1999; 94(Suppl 1): 387-93.	1986, 1994, 1997, 1999		
Ecuador	Sempéregui F, Estrella B, Camaniero V, Betancourt V, Izurieta R, Ortiz W, Fiallo E, Troya S, Rodríguez A, Griffiths JK. The beneficial effects of weekly low-dose vitamin A supplementation on acute lower respiratory infections and diarrhea in Ecuadorian children. Pediatrics. 1999; 1(104): e1.	1996-1997		
Ecuador	Souza JP, Cecatti JG, Faundes A, Morais SS, Villar J, Carroli G, Gulmezoglu M, Wojdyla D, Zavaleta N, Donner A, Velazco A, Bataglia V, Valladares E, Kublickas M, Acosta A. Maternal near miss and maternal death in the World Health Organization's 2005 global survey on maternal and perinatal health. Bull World Health Organ. 2010; 88(2): 113-9.	2005		
Ecuador	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1980-1981, 1983-1986, 1990-1993, 1995-1998		
Ecuador	Pan American Health Organization (PAHO). Update on yellow fever in the Americas. Epidemiol Bull. 2000; 21(2):13.	1985-1995		
Ecuador	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1986-1989, 1994, 1998-2003, 2005-2009		
Ecuador	Vasconcelos PF da C. Febre amarela. Rev Soc Bras Med Trop. 2003; 36(2): 275-93.	1980-2001		
Ecuador	Izurieta RO, Macaluso M, Watts DM, Tesh RB, Guerra B, Cruz LM, Galwankar S, Vermund SH. Assessing yellow fever risk in the Ecuadorian Amazon. J Glob Infect Dis. 2009; 1(1): 7-13.	1997		
Ecuador	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2003		
Ecuador	Cruz ME, Cruz I, Preux PM, Schantz P, Dumas M. Headache and cysticercosis in Ecuador, South America. Headache. 1995; 35(2): 93-7.	1992		
Ecuador	Morillo LE, Alarcon F, Aramaga N, Aulet S, Chapman E, Conterno L, Estevez E, Garcia-Pedroza F, Garrido J, Macias-Islas M, Monzillo P, Nunez L, Plascencia N, Rodriguez C, Takeuchi Y, Latin American Migraine Study Group. Prevalence of migraine in Latin America. Headache. 2005; 45(2): 106-17.	1999		
Ecuador	Mallol J, Solé D, Baeza-Bacab M, Aguirre-Camposano V, Soto-Quiros M, Baena-Cagnani C, Latin American ISAAC Group. Regional variation in asthma symptom prevalence in Latin American children. J Asthma. 2010; 47(6): 644-50.	2001-2003	*	
Ecuador	Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version). Lyon, IARC. http://cis.iarc.fr	2003-2007	*	
Ecuador	Suzuki H, Sato T, Kitaoka S, Tazawa F, Konno T, Amano Y, Alava Alprecht A, Gutiérrez Vera E, Lopez Villalta J, Numazaki Y. Epidemiology of rotavirus in Guayaquil, Ecuador. Am J Trop Med Hyg. 1986; 35(2): 372-5.	1978-1981	*	
Ecuador	Ullauri A, et al. WHO Ear and Hearing Survey - Ecuador 2009. Poster session SP421, American Academy of Otolaryngology - Head and Neck Surgery.	2010		
Ecuador	Medina W, Hurtig A-K, San Sebastián M, Quizhpe E, Romero C. Dental caries in 6-12-year-old indigenous and non-indigenous schoolchildren in the Amazon basin of Ecuador. Braz Dent J. 2008; 19(1): 83-6.	1998		
Ecuador	Narváez M, López Jaramillo P, Guevara A, Izurieta A, Guderian R. Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae in 3 groups of Ecuadorian women with different sexual behaviors. Bol Oficina Sanit Panam. 1989; 107(3): 220-5.	1989		
Ecuador	Ecuador Rapid Assessment for Avoidable Blindness Survey 2009 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2009		
Ecuador	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Ecuador Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2005		
Ecuador	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), United Nations Office on Drugs and Crime (UNODC), Youth and Drugs in South American Countries: A Public Policy Challenge 2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2006.	2005		
Ecuador	Plascencia M, Shorvon SD, Paredes V, Bimos C, Sander JW, Suarez J, Cascante SM. Epileptic seizures in an Andean region of Ecuador. Incidence and prevalence and regional variation. Brain. 1992; 115 (Pt 3): 771-82.	1984-1989	*	†
Ecuador	Carpio R. Prevalencia de epilepsia en la parroquia cumbe de la provincia del azuay, ecuador 1983. Rev Inst Investig Cienc Salud. 1986; 10-31.	1983	*	
Ecuador	Del Brutto OH, Santibáñez R, Idrovo L, Rodríguez S, Díaz-Calderón E, Navas C, Gilman RH, Cuesta F, Mosquera A, Gonzalez AE, Tsang VCV, García HH. Epilepsy and neurocysticercosis in Atahualpa: a door-to-door survey in rural coastal Ecuador. Epilepsia. 2005; 46(4): 583-7.	2003	*	†
Ecuador	Cruz ME, Schantz PM, Cruz I, Espinosa P, Preux PM, Cruz A, Benítez W, Tsang VC, Fermojo J, Dumas M. Epilepsy and neurocysticercosis in an Andean community. Int J Epidemiol. 1999; 28(4): 799-803.	1992	*	
Ecuador	Basch EM, Cruz ME, Tapia D, Cruz A. Prevalence of epilepsy in a migrant population near Quito, Ecuador. Neuroepidemiology. 1997; 16(2): 94-8.	1995	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Ecuador	Cruz ME, Schoenberg BS, Ruales J, Barberis P, Proano J, Bossano F, Sevilla F, Bolis CL. Pilot study to detect neurologic disease in Ecuador among a population with a high prevalence of endemic goiter. <i>Neuroepidemiology</i> . 1985; 4(2): 108-16.	1982	*	
Ecuador	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Ecuador	Fernández-Cean J, González-Martínez F, Schwedt E, Mazzuchi N. Renal replacement therapy in Latin America. <i>Kidney Int.</i> 2000; 57(s74): 55-59.	1997		
Ecuador	Lugon JR, Strogoff de Matos JP. Disparities in end-stage renal disease care in South America. <i>Clin Nephrol.</i> 2010; 74(Suppl 1): S66-71.	2006		
Ecuador	Cusumano A, García-García G, Di Gioia C, Hermida O, Lavorato C, Carreño CA, Torrico MP, Batista PB, Romão JE, Badal HP, Miranda SE, Gomez R, Calderon MC, Sanchez SH, Lopez MA, Moscoso J, Merino RL, Polo JV, Lopez A, Romero NJ, García R, Acosta BV, Lopez AS, Delpin ES, Mena E, González C, Milanés CL, Acchiardo S. End-stage renal disease and its treatment in Latin America in the twenty-first century. <i>Ren Fail.</i> 2006; 28(8): 631-7.	2003		
Ecuador	World Health Organization (WHO). Ecuador WHO Leishmaniasis Country Profile.	1999-2010	*	
Ecuador	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Ecuador	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Ecuador	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Ecuador	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Ecuador	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Ecuador	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Ecuador	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Ecuador	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Ecuador	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Ecuador	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Ecuador	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Ecuador	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2003. Pan American Health Organization (PAHO).	2003		†
Ecuador	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2004. Pan American Health Organization (PAHO).	2004		†
Ecuador	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2005. Pan American Health Organization (PAHO).	2005		†
Ecuador	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2006. Pan American Health Organization (PAHO).	2006		†
Ecuador	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2007. Pan American Health Organization (PAHO).	2007		†
Ecuador	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Ecuador	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Ecuador	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Ecuador	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Ecuador	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Ecuador	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Ecuador	Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, Büchele G, Clausen M, Cookson WOC, von Mutius E, Strachan DP, Williams HC, ISAAC Phase Two Study Group. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. <i>J Allergy Clin Immunol.</i> 2008; 121(1): 141-147.	2005-2007	*	
Ecuador	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L, Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Ann Hepatol.</i> 2010; 9(1): 63-9.	2006-2008	*	
Ecuador	Flohr C, Weinmayr G, Weiland SK, Addo-Yobo E, Annesi-Maesano I, Björkstén B, Bråbäck L, Büchele G, Chico M, Cooper P, Clausen M, El Sharif N, Martínez Gimeno A, Mathur RS, von Mutius E, Morales Suarez-Varela M, Pearce N, Svabe V, Wong GWK, Yu M, Zhong NS, Williams HC, ISAAC Phase Two Study Group. How well do questionnaires perform compared with physical examination in detecting flexural eczema? Findings from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. <i>Br J Dermatol.</i> 2009; 161(4): 846-53.	2005-2007	*	
Ecuador	Del Bruto OH, Noboa CA. Late-onset epilepsy in Ecuador: aetiology and clinical features in 225 patients. <i>Trop Geogr Neurol.</i> 1991; 1: 31-4.	1986-1990		†
Ecuador	Hashiguchi Y, Gómez Landries EA. A review of leishmaniasis in Ecuador. <i>Bull Pan Am Health Organ.</i> 1991; 25(1): 64-76.	1983-1986		
Ecuador	Pan American Health Organization (PAHO), World Health Organization (WHO). Quantitative Estimation of Chagas in the Americas.	2005	*	
Ecuador	Malaria y leishmaniasis cutánea en Ecuador: Un estudio interdisciplinario, aspectos históricos, epidemiológicos, antropológicos, entomológicos y métodos de control as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989-1990	*	†
Ecuador	Ecuador Vital Registration Birth Data 1989 as it appears in United Nations Statistics Division (UNSD), United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1989		
Ecuador	Ecuador Congenital Anomaly Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Ecuador	Ecuador Plasmodium Falciparum Parasite Rate Data, Personal Communication with M. Espinel 2008 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008	*	†
Egypt	Central Agency for Public Mobilization and Statistics (Egypt), League of Arab States. Egypt Maternal and Child Health Survey 1991.	1991		†
Egypt	Central Agency for Public Mobilization and Statistics (CAPMAS) (Egypt), International Statistical Institute. Egypt World Fertility Survey 1980. Voorburg, Netherlands: International Statistical Institute.	1980		
Egypt	Egypt Vital Registration - Deaths 1991 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1991	*	
Egypt	Egypt Vital Registration - Deaths 1992 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1992	*	
Egypt	Macro Systems, Inc.; Institute for Resource Development, National Population Council (Egypt). Egypt Demographic and Health Survey 1988-1989. Columbia, United States: Macro Systems, Inc.	1988-1989		†
Egypt	Macro International, Inc, National Population Council (Egypt). Egypt Demographic and Health Survey 1992-1993. Calverton, United States: Macro International, Inc.	1992-1993		†
Egypt	Macro International, Inc, National Population Council (Egypt). Egypt Demographic and Health Survey 1995-1996. Calverton, United States: Macro International, Inc.	1995-1996		†
Egypt	Macro International, Inc, National Population Council (Egypt). Egypt Demographic and Health Survey 2000. Calverton, United States: Macro International, Inc.	2000		†
Egypt	El-Zanaty and Associates, Macro International, Inc, Ministry of Health and Population (Egypt), National Population Council (Egypt). Egypt Demographic and Health Survey 2005. Calverton, United States: Macro International, Inc.	2005		†
Egypt	El-Zanaty and Associates, Macro International, Inc, Ministry of Health and Population (Egypt), National Population Council (Egypt). Egypt Interim Demographic and Health Survey 2003. Calverton, United States: Macro International, Inc.	2003		†
Egypt	El-Zanaty and Associates, Macro International, Inc, Ministry of Health and Population (Egypt). Egypt Demographic and Health Survey 2008. Calverton, United States: Macro International, Inc, 2009.	2008		†
Egypt	World Health Organization (WHO). Control of Foodborne Trematode Infections 1995. Geneva, Switzerland: World Health Organization (WHO), 1995.	1995	*	
Egypt	Health Care International, World Health Organization (WHO). Egypt WHO Multi-country Survey Study on Health and Health System Responsiveness 2000-2001. Geneva, Switzerland: World Health Organization (WHO).	2000-2001		
Egypt	Naficy AB, Rao MR, Holmes JL, Abu-Elyazeed R, Savarino SJ, Wierzb TF, Frenck RW, Monroe SS, Glass RL, Clemens JD. Astrovirus diarrhea in Egyptian children. J Infect Dis. 2000; 182(3): 685-90.	1995-1998		
Egypt	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Egypt	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Egypt	Mustacchi P, Shimkin M. Cancer of the bladder and infestation with Schistosoma hematobium. J Natl Cancer Inst. 1958; 20(4): 825-42.	1955		
Egypt	Abdel-Wahab MF, Esmat G, Ramzy I, Naroos S, Medhat E, Ibrahim M, El-Boraey Y, Strickland GT. The epidemiology of schistosomiasis in Egypt: Fayoum Governorate. Am J Trop Med Hyg. 2000; 62 Suppl 2: 55-64.	1992		†
Egypt	Habib M, Abdel Aziz F, Gamil F, Cline BL. The epidemiology of schistosomiasis in Egypt: Qalyubia Governorate. Am J Trop Med Hyg. 2000; 62 Suppl 2(2): 49-54.	1992		†
Egypt	De Lorenzo A, Bedogni G, Andreoli A, Kandil S, el-Hefni S, Brancati A. Assessment of body hydration in subjects with schistosomiasis. Ann Hum Biol. 1997; 24(4): 315-2.	1996-1997		
Egypt	Abdel-Hafez K, Abdel-Aty MA, Hofny ERM. Prevalence of skin diseases in rural areas of Assiut Governorate, Upper Egypt. Int J Dermatol. 2003; 42(11): 887-92.	1994-1996, 2001		
Egypt	Matson DO, Abdel-Messih IA, Schlett CD, Bok K, Wienkopff T, Wierzb TF, Sanders JW, Frenck RW Jr. Rotavirus genotypes among hospitalized children in Egypt, 2000-2002. J Infect Dis. 2010; 202 Suppl: 263-265.	2000-2002		
Egypt	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998-1999		
Egypt	Abdel-Wahab MF, Esmat G, Naroos SI, Yosery A, Struening JP, Strickland GT. Sonographic studies of schoolchildren in a village endemic for Schistosoma mansoni. Trans R Soc Trop Med Hyg. 1990; 84(1): 69-73.	1989-1990		†
Egypt	Curtale F, Nabil M, el Wakeel A, Shamy MY. Anaemia and intestinal parasitic infections among school age children in Behera Governorate, Egypt Behera Survey Team. J Trop Pediatr. 1998; 44(6): 323-8.	1996		†
Egypt	El-Khoby T, Galal N, Fenwick A, Barakat R, El-Hawey A, Noonan Z, Habib M, Abdel-Wahab F, Gabr NS, Hammam HM, Hussein MH, Mikhail NN, Cline BL, Strickland GT. The epidemiology of schistosomiasis in Egypt: summary findings in nine governorates. Am J Trop Med Hyg. 2000; 62 Suppl 2: 88-99.	1999-2000		
Egypt	Farooq M, Samaan SA, Nielsen J. Assessment of severity of disease caused by Schistosoma haematobium and S. Bull World Health Organ. 1966; 35(3): 389-404.	1963		
Egypt	Hassan EO, el-Hussinie M, el-Nahal N. The prevalence of anemia among clients of family planning clinics in Egypt. Contraception. 1999; 60(2): 93-9.	1993-1994		
Egypt	Mansour MM, Francis WM, Farid Z. Prevalence of latent iron deficiency in patients with chronic S mansoni infection. Trop Geogr Med. 1985; 37(2): 124-8.	1983-1985		†
Egypt	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2002		
Egypt	Macky TA, Khater N, Al-Zamil MA, El Fishawy H, Soliman MM. Epidemiology of diabetic retinopathy in Egypt: a hospital-based study. Ophthalmic Res. 2011; 45(2): 73-8.	2007-2008		
Egypt	Marzouk D, Sassi J, Bakr I, El Hosseiny M, Abdel-Hamid M, Rekaewicz C, Chaturvedi N, Mohamed MK, Fontanet A. Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut. 2007; 56(8): 1105-10.	2004		
Egypt	Yamamah GA, Emam HM, Abdelhamid MF, Elsaie ML, Shehata H, Farid T, Kamel MI, Taalat AA. Epidemiologic study of dermatologic disorders among children in South Sinai, Egypt. Int J Dermatol. 2012; 51(10): 1180-5.	2008-2009	*	
Egypt	Mobarak EH, Shabayek MM, Mulder J, Reda AH, Frencken JE. Caries experience of Egyptian adolescents: does the atraumatic restorative treatment approach offer a solution Med Princ Pract. 2011; 20(6): 545-9.	2009	*	
Egypt	Barakat SH, El-Bashir N. Hepatitis C virus infection among healthy Egyptian children: prevalence and risk factors. J Viral Hepat. 2011; 18(11): 779-84.	2005		
Egypt	Barsoum RS. Burden of chronic kidney disease: North Africa. Kidney Int Suppl. 2013; 3: 164-6.	2000-2010		
Egypt	Wierzb TF, Abdel-Messih IA, Abu-Elyazeed R, Putnam SD, Kamal KA, Rozmajzl P, Ahmed SF, Fatah A, Zabedy K, Shaheen HI, Sanders J, Frenck R. Clinic-based surveillance for bacterial- and rotavirus-associated diarrhea in Egyptian children. Am J Trop Med Hyg. 2006; 74(1): 148-53.	2000-2002	*	
Egypt	El-Mohamady H, Mansour A, Shaheen HI, Henien NH, Motawea MS, Raafat I, Moustafa M, Adib-Messih IA, Sebeny PJ, Young SYN, Klena JD. Increase in the detection rate of viral and parasitic enteric pathogens among Egyptian children with acute diarrhea. J Infect Dev Ctries. 2012; 6(11): 774-81.	2005-2007	*	
Egypt	Shukry S, Zaki AM, DuPont HL, Shoukry I, el Tagi M, Hamed Z. Detection of enteropathogens in fatal and potentially fatal diarrhea in Cairo, Egypt. J Clin Microbiol. 1986; 24(6): 959-62.	1982-1983		†
Egypt	Wasfy MO, Oyofo BA, David JC, Ismail TF, el-Gendy AM, Mohran ZS, Sultan Y, Peruski LF Jr. Isolation and antibiotic susceptibility of Salmonella, Shigella, and Campylobacter from acute enteric infections in Egypt. J Health Popul Nutr. 2000; 18(1): 33-8.	1986-1993	*	
Egypt	Zaki AM, DuPont HL, el Alamy MA, Arafat RR, Amin K, Awad MM, Bassiouni L, Imam IZ, el Malih GS, el Marsafie A. The detection of enteropathogens in acute diarrhea in a family cohort population in rural Egypt. Am J Trop Med Hyg. 1986; 35(5): 1013-22.	1981-1983	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Egypt	Pazzaglia G, Bourgeois AL, Arby I, Mikhail I, Podgore JK, Mourad A, Riad S, Gaffar T, Ramadan AM. Campylobacter-associated diarrhoea in Egyptian infants: epidemiology and clinical manifestations of disease and high frequency of concomitant infections. <i>J Diarrhoeal Dis Res.</i> 1993; 11(1): 6-13.	1983-1984	*	
Egypt	el-Mougi M, Amer A, el-Abhar A, Hughes J, el-Shafie A. Epidemiological and clinical features of rotavirus associated acute infantile diarrhoea in Cairo, Egypt. <i>J Trop Pediatr.</i> 1989; 35(5): 230-3.	1986	*	
Egypt	Behiry IK, Abada EA, Ahmed EA, Labeed RS. Enteropathogenic Escherichia coli associated with diarrhea in children in Cairo, Egypt. <i>ScientificWorldJournal.</i> 2011; 2613-9.	2009	*	
Egypt	Al Jarousha AMK, El Jarou MA, El Qouqa IA. Bacterial enteropathogens and risk factors associated with childhood diarrhea. <i>Indian J Pediatr.</i> 2011; 78(2): 165-70.	2006-2007	*	
Egypt	Naficy AB, Abu-Elyazeed R, Holmes JL, Rao MR, Savarino SJ, Kim Y, Wierzb TF, Peruski L, Lee YJ, Gentsch JR, Glass RI, Clemens JD. Epidemiology of rotavirus diarrhea in Egyptian children and implications for disease control. <i>Am J Epidemiol.</i> 1999; 150(7): 770-7.	1995-1996	*	
Egypt	El Tallawy HN, Farghly WMA, Shehata GA, Rageh TA, Hakeem NA, Abo-Elfeto N, Hegazy AM, Rayan I, El-Moselhy EA. Prevalence of dementia in Al Kharga District, New Valley Governorate, Egypt. <i>Neuroepidemiology.</i> 2012; 38(3): 130-7.	2005-2008		
Egypt	Farrag A, Farwiz HM, Khedr EH, Mahfouz RM, Omran SM. Prevalence of Alzheimer's disease and other dementing disorders: Assiut-Upper Egypt study. <i>Dement Geriatr Cogn Disord.</i> 1998; 9(6): 323-8.	1993-1994		
Egypt	Egyptian Society of Nephrology and Transplantation. <i>Egypt Renal Registry Annual Report 1996.</i>	1996		
Egypt	Egyptian Society of Nephrology and Transplantation. <i>Egypt Renal Registry Annual Report 1998.</i>	1996, 1998		
Egypt	Egyptian Society of Nephrology and Transplantation. <i>Egypt Renal Registry Annual Report 2000.</i>	2000		
Egypt	Egyptian Society of Nephrology and Transplantation. <i>Egypt Renal Registry Annual Report 2001.</i>	2001		
Egypt	Egyptian Society of Nephrology and Transplantation. <i>Egypt Renal Registry Annual Report 2003.</i>	2003		
Egypt	Egyptian Society of Nephrology and Transplantation. <i>Egypt Renal Registry Annual Report 2004.</i>	2004		
Egypt	Ghanem M, Gadallah M, Meki FA, Mourad S, El-Kholy G. National Survey of Prevalence of Mental Disorders in Egypt: preliminary survey. <i>East Mediterr Health J.</i> 2009; 15(1): 65-75.	2003		
Egypt	Zurayk H, Khattab H, Younis N, Kamal O, El-Helw M. Comparing Women's Reports with Medical Diagnoses of Reproductive Morbidity Conditions in Rural Egypt. <i>Stud Fam Plann.</i> 1995; 26(1): 14-21.	1989-1990		
Egypt	International Society of Nephrology (ISN). <i>International Society of Nephrology Kidney Disease Data Center 2006-2009.</i>	2007-2008		
Egypt	Galal SB, Hamad S, Hassan N. Self-reported adolescents' health and gender: an Egyptian study. <i>East Mediterr Health J.</i> 2001; 7(4-5): 625-34.	1998		
Egypt	El-Bayoumy BM, Saad A, Choudhury AH. Prevalence of refractive error and low vision among schoolchildren in Cairo. <i>East Mediterr Health J.</i> 2007; 13(3): 575-9.	1994		
Egypt	Temtamy SA, Kandil MR, Demerdash AM, Hassan WA, Meguid NA, Afifi HH. An epidemiological/genetic study of mental subnormality in Assiut Governorate, Egypt. <i>Clin Genet.</i> 1994; 46(5): 347-51.	1994		
Egypt	Tantawy AZ, Sobhy O, Al-Farag M, Shafik M. Studying the etiology of deafness in the "deaf" schools of Alexandria. <i>J Egypt Public Health Assoc.</i> 1998; 73(1-2): 125-36.	1995-1997		
Egypt	Abdel-Moula AM, Sherif AA, Sallam SA, Mandil AM, Kassem AS, Zaher SR. Prevalence of rheumatic heart disease among school children in Alexandria, Egypt: a prospective epidemiological study. <i>J Egypt Public Health Assoc.</i> 1998; 73(3-4): 233-54.	1993-1994		
Egypt	El Tallawy HNA, Farghly WMA, Rageh TA, Shehata GA, Metwaly NA, Abo Elfeto N, Hegazy AM, El Moselhy EA, Rayan I, Al Fawal BMA, Abd Elhamed MA. Epidemiology of major neurological disorders project in Al Kharga district, New Valley, Egypt. <i>Neuroepidemiology.</i> 2010; 35(4): 291-7.	2007-2008	*	
Egypt	Rasheed S, Abdelmonem A, Amin M. Adolescent pregnancy in Upper Egypt. <i>Int J Gynaecol Obstet.</i> 2011; 112(1): 21-4.	2005-2009	*	
Egypt	Darwish MA, Faris R, Darwish N, Shouman A, Gadallah M, El-Sharkawy MS, Edelman R, Grumbach K, Rao MR, Clemens JD. Hepatitis C and cirrhotic liver disease in the Nile delta of Egypt: a community-based study. <i>Am J Trop Med Hyg.</i> 2001; 64(3-4): 147-53.	1994-1995		
Egypt	Waked IA, Saleh SM, Moustafa MS, Raouf AA, Thomas DL, Strickland GT. High prevalence of hepatitis C in Egyptian patients with chronic liver disease. <i>Gut.</i> 1995; 37(1): 105-7.	1992		
Egypt	el-Zayadi A-R, Badran HM, Barakat EMF, Attia M el-D, Shawky S, Mohamed MK, Selim O, Saied A. Hepatocellular carcinoma in Egypt: a single center study over a decade. <i>World J Gastroenterol.</i> 2005; 11(33): 5193-8.	1993-2002		
Egypt	Hassan MM, Zaghloul AS, El-Serag HB, Soliman O, Patt YZ, Chappell CL, Beasley RP, Hwang LY. The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. <i>J Clin Gastroenterol.</i> 2001; 33(2): 123-6.	1995-1996		
Egypt	Mabrouk GM. Prevalence of hepatitis C infection and schistosomiasis in Egyptian patients with hepatocellular carcinoma. <i>Dis Markers.</i> 1997; 13(3): 177-82.	1995-1996		
Egypt	World Health Organization (WHO). <i>WHO Tuberculosis Case Notifications.</i> Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Egypt	Fouad D, Mousa A, Courtright P. Sociodemographic characteristics associated with blindness in a Nile Delta governorate of Egypt. <i>Br J Ophthalmol.</i> 2004; 88(5): 614-8. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2001-2002		
Egypt	Egypt - Banisweill Mazora Rapid Assessment of Avoidable Blindness 2010 [Unpublished] as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2010		
Egypt	Egypt - Fayoum Kar Baseal Rapid Assessment of Avoidable Blindness 2009 [Unpublished] as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2009		
Egypt	Egypt - Kafarehshshabas Rapid Assessment of Avoidable Blindness 2009 [Unpublished] as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2009		
Egypt	Egypt - Menya Qalta Rapid Assessment of Avoidable Blindness 2010 [Unpublished] as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2010		
Egypt	Egypt - Sohag Baga Rapid Assessment of Avoidable Blindness 2010 [Unpublished] as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2010		
Egypt	Jambart S, Ammache Z, Haddad F, Younes A, Hassoun A, Abdalla K, Selwan CA, Sunna N, Wajsbrot D, Youseif E. Prevalence of painful diabetic peripheral neuropathy among patients with diabetes mellitus in the Middle East region. <i>J Int Med Res.</i> 2011; 39(2): 366-77.	2009		
Egypt	Ragab AH, el-Afifi OS, Abboud MA. Incidence of glucose-6-phosphate dehydrogenase deficiency in Egypt. <i>Am J Hum Genet.</i> 1966; 18(1): 21-5.	1964-1966		
Egypt	Hussein L, Yamamah G, Saleh A. Glucose-6-phosphate dehydrogenase deficiency and sulfamidin acetylation phenotypes in Egyptian oases. <i>Biochem Genet.</i> 1992; 30(3-4): 113-21.	1990-1992		
Egypt	Usanga EA, Ameen R. Glucose-6-phosphate dehydrogenase deficiency in Kuwait, Syria, Egypt, Iran, Jordan and Lebanon. <i>Hum Hered.</i> 2000; 50(3): 158-61.	1996-1997		
Egypt	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant.</i> 1988; 3(6): 714-27.	1985-1986		
Egypt	Van Dijk PC, Jager KJ, Stengel B, Grönhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). <i>Kidney Int.</i> 2005; 67(4): 1489-99.	1995-1996		
Egypt	Barsoum RS. End-stage renal disease in North Africa. <i>Kidney Int Suppl.</i> 2003; 83: S111-4.	1993-2002		
Egypt	Naicker S. Burden of end-stage renal disease in sub-Saharan Africa. <i>Clin Nephrol.</i> 2010; 74(Suppl 1): S13-6.	2008-2010		
Egypt	Afifi A, Karim MA. Renal replacement therapy in Egypt: first annual report of the Egyptian Society of Nephrology. <i>East Mediterr Health J.</i> 1999; 5(5): 1023-9.	1995-1996		
Egypt	Crump JA, Yousef FG, Luby SP, Wasfy MO, Rangel JM, Taalat M, Oun SA, Mahoney FJ. Estimating the Incidence of Typhoid Fever and Other Febrile Illnesses in Developing Countries. <i>Emerg Infect Dis.</i> 2003; 9(5): 539-44.	2000-2001	*	
Egypt	Khedr EM, Al Attar GS, Kandil MR, Kamel NF, Abo Elfeto N, Ahmed MA. Epidemiological study and clinical profile of Parkinson's disease in the Assiut Governorate, Egypt: a community-based study. <i>Neuroepidemiology.</i> 2012; 38(3): 154-63.	2010	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Egypt	El-Tallawy HN, Farghaly WM, Shehata GA, Rageh TA, Hakeem NMA, Hamed MAA, Badry R. Prevalence of Parkinson's disease and other types of Parkinsonism in Al Kharga district, Egypt. <i>Neuropsychiatr Dis Treat.</i> 2013; 1821-6.	2005-2009	*	
Egypt	Wahdan MH, Sérié C, Cerisier Y, Sallam S, Germainier R. A controlled field trial of live <i>Salmonella typhi</i> strain Ty 21a oral vaccine against typhoid: three-year results. <i>J Infect Dis.</i> 1982; 145(3): 292-5.	1978-1981		
Egypt	Abdel-Hamid O, Khatib OMM, Aly A, Morad M, Kamel S. Prevalence and patterns of hearing impairment in Egypt: a national household survey. <i>East Mediterr Health J.</i> 2007; 13(5): 1170-80.	2004-2006	*	
Egypt	World Health Organization (WHO). Egypt WHO Leishmaniasis Country Profile.	2005-2010	*	
Egypt	Faris R, Ramzy RM, Gad AM, Weil GJ, Buck AA. Community diagnosis of Bancroftian filariasis. <i>Trans R Soc Trop Med Hyg.</i> 1993; 87(6): 659-61. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1993	*	
Egypt	Ramzy RMR, El Setouhy M, Helmy H, Ahmed ES, Abd Elaziz KM, Farid HA, Shannon WD, Weil GJ. Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment. <i>Lancet.</i> 2006; 367(9515): 992-9. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2005	*	
Egypt	Weil GJ, Ramzy RM, El Setouhy M, Kandil AM, Ahmed ES, Faris R. A longitudinal study of Bancroftian filariasis in the Nile Delta of Egypt: baseline data and one-year follow-up. <i>Am J Trop Med Hyg.</i> 1999; 61(1): 53-8. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1995-1999	*	
Egypt	Egypt National Survey for Assessment of Vitamin A Status 1995 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1995		
Egypt	Egypt Nutritional Deficiencies Among Primary School Children 1998 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1998		
Egypt	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Egypt	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec.</i> 2007; 82(25): 225-32.	2006	*	
Egypt	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Egypt	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Egypt	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Egypt	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec.</i> 2008; 83(33): 293-300.	2007	*	
Egypt	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Egypt	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Egypt	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Egypt	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Egypt	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Egypt	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Egypt	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Egypt	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1993; 68(25): 181-6.	1992	*	
Egypt	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Egypt	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Egypt	Sullam SA, Mahfouz AA, Dabbous NI, el-Barrawy M, el-Said MM. Reproductive tract infections among married women in Upper Egypt. <i>East Mediterr Health J.</i> 2001; 7(1-2): 139-46.	1998-1999	*	
Egypt	El Tallawy HN, Farghaly WM, Badry R, Rageh TA, Shehata GA, Hakeem N MA, Abd El Hamed M, Sayd MAM, Hamed Y, Kandil MR. Prevalence of dementia in Al-Quseir city, Red Sea Governorate, Egypt. <i>Clin Interv Aging.</i> 2014; 9:14.	2009-2012	*	
Egypt	Girgis NI, Farid Z, Mikhail IA, Farrag I, Sultan Y, Kilpatrick ME. Dexamethasone treatment for bacterial meningitis in children and adults. <i>Pediatr Infect Dis J.</i> 1989; 8(12): 848-51.	1983-1986		†
Egypt	Farag HPM, Abdel-Fattah MM, Youssri AM. Epidemiological, clinical and prognostic profile of acute bacterial meningitis among children in Alexandria, Egypt. <i>Indian J Med Microbiol.</i> 2005; 23(2): 95-101.	2002-2003		†
Egypt	Girgis NI, Sultan Y, Farid Z, Mansour MM, Erian MW, Hanna LS, Mateczun AJ. Tuberculosis meningitis, Abbassia Fever Hospital-Naval Medical Research Unit No. 3-Cairo, Egypt, from 1976 to 1996. <i>Am J Trop Med Hyg.</i> 1998; 58(1): 28-34.	1982-1987		
Egypt	Shoheib S, Madkour S and El Din RS Younis. Egypt Evaluation of RF/RHD Control Program Impact among Egyptian Schoolchildren 1998.	1998		
Egypt	el-Sadawy M, Ragab H, el-Toukhy H, el-Mor A el-L, Mangoud AM, Eissa MH, Afefy AF, el-Shorbagy E, Ibrahim IA, Mahrous S, Abdel-Monem A, Sabee EI, Ismail A, Morsy TA, Etewa S, Nor Edin E, Mostafa Y, Abouel-Magd Y, Hassan MI, Lakouk K, Abdel-Aziz K, el-Hady G, Saber M. Hepatitis C virus infection at Sharkia Governorate, Egypt: seroprevalence and associated risk factors. <i>J Egypt Soc Parasitol.</i> 2004; 34(1 Suppl): 367-84.	2001-2002		
Egypt	Abdel Hady SI, El-Din MS, El-Din ME. A high hepatitis E virus (HEV) seroprevalence among unpaid blood donors and haemodialysis patients in Egypt. <i>J Egypt Public Health Assoc.</i> 1998; 73(3-4): 165-79.	1995-1997	*	
Egypt	Kamel MA, Troonen H, Kapprell HP, el-Ayady A, Miller FD. Seroprevalence of hepatitis E virus in the Egyptian Nile Delta. <i>J Med Virol.</i> 1995; 47(4): 399-403.	1992		
Egypt	Darwish MA, Faris R, Clemens JD, Rao MR, Edelman R. High seroprevalence of hepatitis A, B, C, and E viruses in residents in an Egyptian village in The Nile Delta: a pilot study. <i>Am J Trop Med Hyg.</i> 1996; 54(6): 554-8.	1994-1995		
Egypt	Omar AA, Hashish MH. Screening for hepatitis A virus antibodies among a disadvantaged group of preschool children in Alexandria. <i>J Egypt Public Health Assoc.</i> 2000; 75(5-6): 529-39.	1997		
Egypt	Al-Aziz AMA, Awad MAM. Seroprevalence of hepatitis A virus antibodies among a sample of Egyptian children. <i>East Mediterr Health J.</i> 2008; 14(5): 1028-35.	2002-2003		
Egypt	Salama II, Samy SM, Shaaban FA, Hassanin AI, Abou Ismail LA. Seroprevalence of hepatitis A among children of different socioeconomic status in Cairo. <i>East Mediterr Health J.</i> 2007; 13(6): 1256-64.	2003-2004		
Egypt	Gamaleldin R, Iskander I, Seoud I, Aboraya H, Aravkin A, Sampson PD, Wennberg RP. Risk factors for neurotoxicity in newborns with severe neonatal hyperbilirubinemia. <i>Pediatrics.</i> 2011; 128(4): e925-931.	2008	*	†
Egypt	Agha S, El-Mashad N, El-Malky M, El-Shony H, El-Sherif MZ, El-Hasan MA, Tanaka Y, Mizokami M. Prevalence of low positive anti-HCV antibodies in blood donors: Schistosoma mansoni co-infection and possible role of autoantibodies. <i>Microbiol Immunol.</i> 2006; 50(6): 447-52.	2006		
Egypt	Fix AD, Abdel-Hamid M, Purcell RH, Shehata MH, Abdel-Aziz F, Mikhail N, el Sebai H, Nafeh M, Habib M, Arthur RR, Emerson SU, Strickland GT. Prevalence of antibodies to hepatitis E in two rural Egyptian communities. <i>Am J Trop Med Hyg.</i> 2000; 62(4): 519-23.	1997		
Egypt	Habib M, Mohamed MK, Abdel-Aziz F, Magder LS, Abdel-Hamid M, Gamil F, Madkour S, Mikhail NN, Anwar W, Strickland GT, Fix AD, Sallam I. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. <i>Hepatology.</i> 2001; 33(1): 248-53.	1997		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Egypt	Nafeh MA, Medhat A, Shehata M, Mikhail NN, Swifee Y, Abdel-Hamid M, Watts S, Fix AD, Strickland GT, Anwar W, Sallam I. Hepatitis C in a community in Upper Egypt: I. Cross-sectional survey. <i>Am J Trop Med Hyg.</i> 2000; 63(5-6): 236-41.	2000		
Egypt	Quinti I, Hassan NF, El Salman D, Shalaby H, El Zimatty D, Monier MK, Arthur RR. Hepatitis C virus-specific B cell activation: IgG and IgM detection in acute and chronic hepatitis C. <i>J Hepatol.</i> 1995; 23(6): 640-7.	1992-1994		
Egypt	Reda AA, Arafa MA, Youssry AA, Wandan EH, Ati MA de, Daebees H. Epidemiologic evaluation of the immunity against hepatitis B in Alexandria, Egypt. <i>Eur J Epidemiol.</i> 2003; 18(10): 1007-11.	2001		
Egypt	Sayed HA, El Ayyat A, El Dusoki H, Zoheiry M, Mohamed S, Hassan M, El Assaly N, Awad A, El Ansary M, Saad A, El Karim AA. A cross sectional study of hepatitis B, C, some trace elements, heavy metals, aflatoxin B1 and schistosomiasis in a rural population, Egypt. <i>J Egypt Public Health Assoc.</i> 2005; 80(3-4): 355-88.	2003		
Egypt	Stoszek SK, Abdel-Hamid M, Narooz S, El Daly M, Saleh DA, Mikhail N, Kassem E, Hawash Y, El Kafrawy S, Said A, El Batany M, Shebl FM, Sayed M, Sharaf S, Fix AD, Strickland GT. Prevalence of and risk factors for hepatitis C in rural pregnant Egyptian women. <i>Trans R Soc Trop Med Hyg.</i> 2006; 100(2): 102-7.	1997-2003		
Egypt	Yates SC, Hafez M, Beld M, Lukashov VV, Hassan Z, Carboni G, Khaled H, McMorrow M, Atia M, Goudsmit J. Hepatocellular carcinoma in Egyptians with and without a history of hepatitis B virus infection: association with hepatitis C virus (HCV) infection but not with (HCV) RNA level. <i>Am J Trop Med Hyg.</i> 1999; 60(4): 714-20.	1999		
Egypt	Atta A, Atia MM, Mostafa AM. Prevalence of microfilaria versus intradermal test in El-Koren, Sharkia G., Egypt. <i>J Egypt Soc Parasitol.</i> 1984; 14(1): 251-7. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1980-1984	*	
Egypt	Feinsod FM, Faris R, Gad A, el Said S, Soliman BA, Abd-el Azem IS, Saah AJ. Clinical manifestations of Wuchereria bancrofti filariasis in an endemic village in the Nile Delta. <i>Ann Soc Belg Med Trop.</i> 1987; 67(3): 259-65. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1984-1985	*	
Egypt	Ramzy RM, Helmy H, el-Lethy AS, Kandil AM, Ahmed ES, Weil GJ, Faris R. Field evaluation of a rapid-format kit for the diagnosis of bancroftian filariasis in Egypt. <i>East Mediterr Health J.</i> 1999; 5(5): 880-7. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1995-1999	*	
Egypt	Serour GI, El Ghar M, Mansour RT. Infertility: a health problem in the Muslim world. <i>Popul Sci.</i> 1991; 41-58.	1980-1989	*	
Egypt	Amer AF, Zaki SA, Nagati AM, Darwish MA. Hepatitis E antibodies in Egyptian adolescent females: their prevalence and possible relevance. <i>J Egypt Public Health Assoc.</i> 1996; 71(3-4): 273-84.	1995		
Egypt	Younis N, Khattab H, Zurayk H, el-Mouelhy M, Amin MF, Farag AM. A community study of gynecological and related morbidities in rural Egypt. <i>Stud Fam Plann.</i> 1993; 24(3): 175-186.	1989-1990	*	
Egypt	Egypt Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
El Salvador	Salvadoran Demographic Association (ADS), Westinghouse; Institute for Resource Development. El Salvador Demographic and Health Survey 1985. Columbia, United States: Westinghouse; Institute for Resource Development.	1985		†
El Salvador	El Salvador Demographic Association (ADS), Division of Reproductive Health-Centers for Disease Control and Prevention (CDC). El Salvador Reproductive Health Survey 1998. Atlanta, United States: Centers for Disease Control and Prevention (CDC).	1998		†
El Salvador	Asociación Demográfica Salvadoreña (ADS), Division of Reproductive Health-Centers for Disease Control and Prevention (CDC). (2009) El Salvador Reproductive Health Survey 2008. San Salvador, El Salvador: ADS.	2008		†
El Salvador	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-2007		
El Salvador	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
El Salvador	Spencer HC, Wells JG, Gary GW, Sondy J, Puhr ND, Feldman RA. Diarrhea in a non-hospitalized rural Salvadoran population: the role of enterotoxigenic Escherichia coli and rotavirus. <i>Am J Trop Med Hyg.</i> 1980; 29(2): 246-53.	1977		
El Salvador	Estrada Castañón R, Torres Bibiano B, Alarcón Hernández H, Villegas Arrizón A, Martínez Sandoval E, Chávez López G, Andersson N. Epidemiología cutánea en dos sectores de atención médica en Guerrero, México; Cutaneous epidemiology in two sectors of Guerrero, Mexico. <i>Dermatol rev mex.</i> 1992; 36(1): 29-34.	1989-1991		
El Salvador	De Oliveira LH, Danovaro-Holliday MC, Andrus JK, de Fillipsis AMB, Gentsch J, Matus CR, Widdowson M-A. Sentinel hospital surveillance for rotavirus in Latin American and Caribbean countries. <i>J Infect Dis.</i> 2009; 200 Suppl 1: 131-139.	2006-2007		
El Salvador	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997-2001, 2003-2009		
El Salvador	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2003		
El Salvador	Mallol J, Solé D, Baeza-Bacab M, Aguirre-Camposano V, Soto-Quiros M, Baena-Cagnani C. Latin American ISAAC Group. Regional variation in asthma symptom prevalence in Latin American children. <i>J Asthma.</i> 2010; 47(6): 644-50.	2001-2003	*	
El Salvador	Özel B, Borchelt AM, Cimino FM, Cremer M. Prevalence and risk factors for pelvic floor symptoms in women in rural El Salvador. <i>Int Urogynecol J.</i> 2007; 18(9): 1065-9.	2005		
El Salvador	Posada AB, Jonasson J, de Linares L, Bygdeman S. Prevalence of urogenital Chlamydia trachomatis infection in El Salvador. I. Infection during pregnancy and perinatal transmission. <i>Int J STD AIDS.</i> 1992; 3(1): 33-7.	1989		
El Salvador	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). El Salvador Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2005		
El Salvador	Yen C, Armero Guardado JA, Alberto P, Rodriguez Araujo DS, Mena C, Cuellar E, Nolasco JB, De Oliveira LH, Pastor D, Tate JE, Parashar UD, Patel MM. Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador. <i>Pediatr Infect Dis J.</i> 2011; 30(1 Suppl): S6-S10.	2005-2006		
El Salvador	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). CICAD Comparative Report on Nationwide School Surveys in Seven Countries: El Salvador, Guatemala, Nicaragua, Panama, Paraguay, Dominican Republic, and Uruguay 2003. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2004.	2003		
El Salvador	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
El Salvador	El Salvador Rapid Assessment of Avoidable Blindness 2011 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2011		
El Salvador	Fernández-Ceán J, González-Martínez F, Schwedt E, Mazzuchi N. Renal replacement therapy in Latin America. <i>Kidney Int.</i> 2000; 57(s74): 55-59.	1997		
El Salvador	Cusumano A, García-García G, Di Gioia C, Hermida O, Lavorato C, Carreño CA, Torrico MP, Batista PB, Romão JE, Badal HP, Miranda SE, Gomez R, Calderon MC, Sanchez SH, Lopez MA, Moscoso J, Merino RL, Polo JV, Lopez A, Romero NJ, García R, Acosta BV, Lopez AS, Delpin ES, Mena E, González C, Milanés CL, Achiardo S. End-stage renal disease and its treatment in Latin America in the twenty-first century. <i>Ren Fail.</i> 2006; 28(8): 631-7.	2004		
El Salvador	Olivé JM, Castillo C, Castro RG, de Quadros CA. Epidemiologic study of Guillain-Barré syndrome in children <15 years of age in Latin America. <i>J Infect Dis.</i> 1997; 160-4.	1989-1992		†
El Salvador	World Health Organization (WHO). El Salvador WHO Leishmaniasis Country Profile.	2003-2010	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
El Salvador	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
El Salvador	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
El Salvador	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
El Salvador	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
El Salvador	Ministry of Health (El Salvador). El Salvador Ministry of Health Dengue Statistics 2001-2009. San Salvador, El Salvador: Ministry of Health (El Salvador).	2001-2009		
El Salvador	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
El Salvador	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
El Salvador	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
El Salvador	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
El Salvador	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
El Salvador	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
El Salvador	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Finchuk L. Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. Ann Hepatol. 2010; 9(1): 63-9.	2006-2008	*	
El Salvador	Pan American Health Organization (PAHO), World Health Organization (WHO). Quantitative Estimation of Chagas in the Americas.	2005	*	
El Salvador	El Salvador Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
El Salvador	Sommer A, Quesada J, Doty M, Faich G. Xerophthalmia and anterior segment blindness among preschool-age children in El Salvador. Am J Ophthalmol. 1975; 80(6): 1066-72, as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1973		
Equatorial Guinea	Ministry of Planning, Economic Development and Public Investment (Equatorial Guinea), United Nations Children's Fund (UNICEF). Equatorial Guinea Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Equatorial Guinea	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Equatorial Guinea	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Equatorial Guinea	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997, 2001-2005, 2008-2009		
Equatorial Guinea	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Equatorial Guinea	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2004, 2010		
Equatorial Guinea	Sinarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J Health Geogr. 2010; 9: 57.	1980-2010		
Equatorial Guinea	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Equatorial Guinea	World Health Organization (WHO). Global leprosy situation, 2007 (additional information). Wkly Epidemiol Rec. 2007; 82(44): 388.	2006	*	
Equatorial Guinea	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Equatorial Guinea	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Equatorial Guinea	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Equatorial Guinea	Moser CL, Martín-Baranera M, Vega F, Draper V, Gutiérrez J, Mas J. Survey of blindness and visual impairment in Bioko, Equatorial Guinea. Br J Ophthalmol. 2002; 86(3): 257-60.	1999	*	
Equatorial Guinea	Ropero P, Molina L, González FA, Villegas A. [Incidence of sickle cell disease in Equatorial Guinea]. Med Clin (Barc). 2011; 136(7): 309-10.	2007-2008	*	
Equatorial Guinea	Epidemiological Bases of Malaria in Equatorial Guinea as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Equatorial Guinea	Évaluation des indices paludométriques dans le District de Nsoek Region Continentale (Guinée Equatoriale) as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Equatorial Guinea	Cano J, Berzosa P, Lucio A de, Descalzo MA, Bobuakasi L, Nzambo S, Ondo M, Buatiche JN, Nseng G, Benito A. Transmission of malaria and genotypic variability of Plasmodium falciparum on the Island of Annobon (Equatorial Guinea). Malar J. 2007; 6(1): 141 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Equatorial Guinea	Guerra-Neira A, Rubio JM, Royo JR, Ortega JC, Auñón AS, Díaz PB, LLanes AB. Plasmodium diversity in non-malaria individuals from the Bioko Island in Equatorial Guinea (West Central-Africa). Int J Health Geogr. 2006; 5(1): 27 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Equatorial Guinea	Prevalence of Malaria in the Village of Ela Nguema as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Equatorial Guinea	Equatorial Guinea National Malaria Control Program Mission Report 1990 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990-1991	*	†
Equatorial Guinea	Equatorial Guinea National Malaria Control Program Prevalence of Malaria Reports 1990 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989-1990	*	†
Equatorial Guinea	Equatorial Guinea National Malaria Control Program Prevalence of Malaria Reports 1991 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991-1992	*	†
Equatorial Guinea	Prevalence of Malaria in the Village of Campo Yaoundé 1992 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Equatorial Guinea	Prevalence of Malaria in the Village of Campo Yaoundé 1993 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†
Eritrea	Macro International, Inc, National Statistics and Evaluation Office (Eritrea). Eritrea Demographic and Health Survey 2002. Calverton, United States: Macro International, Inc.	2002		†
Eritrea	Macro International, Inc, National Statistics Office (Eritrea). Eritrea Demographic and Health Survey 1995-1996. Calverton, United States: Macro International, Inc.	1995-1996		†
Eritrea	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Eritrea	Gibbs, S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int J Dermatol. 1996; 35(9): 633-9.	1994		
Eritrea	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1995-1997, 2004		
Eritrea	Seyum B, Mebratu G, Usman A, Mufunda J, Tewolde B, Haile S, Kosia A, Negassi E. Profile of patients with diabetes in Eritrea: results of first phase registry analyses. Acta Diabetol. 2010; 47(1): 23-7.	2009		
Eritrea	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Eritrea	Eritrea Rapid Assessment for Avoidable Blindness Survey 2008 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2008		
Eritrea	Sebhatu M, Kiflom B, Seyoum M, Kassim N, Negash T, Tesfazion A, Borgdorff MW, van der Werf MJ. Determining the burden of tuberculosis in Eritrea: a new approach. Bull World Health Organ. 2007; 85(8): 593-9.	2005		
Eritrea	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2001, 2004, 2007, 2010, 2012		
Eritrea	Eritrea National Iodine Deficiency Disorders Survey 1998 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1998		
Eritrea	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Eritrea	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Eritrea	World Health Organization (WHO). Global leprosy situation, 2008 (additional information). Wkly Epidemiol Rec. 2008; 83(50): 459.	2007	*	
Eritrea	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Eritrea	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Eritrea	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Eritrea	Ghebrekidan H, Rudén U, Cox S, Wahren B, Grandien M. Prevalence of herpes simplex virus types 1 and 2, cytomegalovirus, and varicella-zoster virus infections in Eritrea. J Clin Virol. 1999; 12(1): 53-64.	1995	*	
Eritrea	Waka M, Hopkins RJ, Akinpelu O, Curtis C. Transmission of malaria in the Tesseney area of Eritrea: parasite prevalence in children, and vector density, host preferences, and sporozoite rate. J Vector Ecol. 2005; 30(1): 27-32 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Estonia	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2005		
Estonia	World Health Organization (WHO). Estonia World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Estonia	National Institute for Health Development (Estonia). Estonia New Cases of Malignant Neoplasms by Specified Site, Gender, and Age Group - Health Statistics and Health Research Database.	2003-2004, 2006-2008	*	
Estonia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Estonia	Vibo R, Kõrv J, Roose M. The Third Stroke Registry in Tartu, Estonia: Decline of Stroke Incidence and 28-Day Case-Fatality Rate Since 1991. Stroke. 2005; 36(12): 2544-8.	1991-1993, 2001-2003		
Estonia	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. J Allergy Clin Immunol. 2008; 121(4): 947-954.	1994, 2001		
Estonia	Ginevskaya VA, Amõtina NN, Ereemeeva TP, Shirman GA, Priimägi LS, Drozdov SG. Electropherotypes and serotypes of human rotavirus in Estonia in 1989-1992. Arch Virol. 1994; 137(1-2): 199-207.	1989-1992		
Estonia	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000-2009		
Estonia	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J. 1998; 12(2): 315-35.	1993-1995		
Estonia	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2001		
Estonia	Holm M, Omenaas E, Gislason T, Svanes C, Jõgi R, Norrman E, Janson C, Torén K. Remission of asthma: a prospective longitudinal study from northern Europe (RHINE study). Eur Respir J. 2007; 30(1): 62-65.	1989-2001		
Estonia	Vasar M, Julge K, Kivivare M, Otter K. Regional differences in diagnosing asthma and other allergic diseases in Estonian schoolchildren. Medicina (Kaunas). 2011; 47(12): 661-6.	2003	*	
Estonia	Forman D, Bray F, Brewster DH, Gomb Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version). Lyon, IARC. http://cis.iarc.fr	2003-2007	*	
Estonia	Laks T, Jõeste E, Pullisaar O, Mäets E, Lapidus I, Pietilä A, Salomaa V. Trends in incidence, attack rate, and mortality of acute myocardial infarction in Estonia: The Tallinn AMI Registry 1991-2005. Ann Med. 2013; 45(2): 107-11.	1991-1993, 2003-2005	*	
Estonia	Tamm A, Lintrop M, Veske K, Hansen U, Tamm A. Prevalence of patello- and tibiofemoral osteoarthritis in Elva, Southern Estonia. J Rheumatol. 2008; 35(3): 543-4.	2005		
Estonia	Dragheim E, Petersen PE, Kalo I, Saag M. Dental caries in schoolchildren of an Estonian and a Danish municipality. Int J Paediatr Dent. 2000; 10(4): 271-7.	1996-1998		
Estonia	Kõrv J, Roose M, Kaasik A-E. Changed Incidence and Case-Fatality Rates of First-Ever Stroke Between 1970 and 1993 in Tartu, Estonia. Stroke. 1996; 27(2): 199-203.	1991-1993, 2001-2003		
Estonia	Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E, BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007; 9589(9589): 741-50.	2005-2006		
Estonia	United States Renal Data System Coordinating Center. USRDS 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2001.	1999		
Estonia	Taba P, Asser T. Prevalence of Parkinson's disease in Estonia. Acta Neurol Scand. 2002; 106(5): 276-81.	1996		
Estonia	Taba P, Asser T. Incidence of Parkinson's Disease in Estonia. Neuroepidemiology. 2003; 22(1): 41-5.	1990-1998		
Estonia	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Estonia	Seland JH, Vingerling JR, Aougoud CA, Bentham G, Chakravarthy U, deJong PTVM, Rahu M, Soubrane G, Tomazzoli L, Topouzis F, Fleischer AE. Visual impairment and quality of life in the older European population, the EUREYE study. Acta Ophthalmol. 2011; 89(7): 608-13. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2006-2007		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Estonia	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1998-1999, 2002-2003		
Estonia	Üus K, Davis AC. Epidemiology of permanent childhood hearing impairment in Estonia, 1985-1990. <i>Audiology</i> . 2000; 39(4): 192-7.	1985-1990		
Estonia	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Estonia	Rakitin A, Liik M, Oun A, Haldre S. Mortality risk in adults with newly diagnosed and chronic epilepsy: a population-based study. <i>Eur J Neurol</i> . 2011; 18(3): 465-70.	1994-2007	*	†
Estonia	Bouvier-Colle M-H, Mohangoo AD, Gissler M, Novak-Antolic Z, Vutuc C, Szamotulska K, Zeitlin J, Euro-Peristat Scientific Committee. What about the mothers? An analysis of maternal mortality and morbidity in perinatal health surveillance systems in Europe. <i>BJOG</i> . 2012; 119(7): 880-90.	2003-2004	*	
Estonia	Beilmann A, Napa A, Sõõt A, Talvik I, Talvik T. Prevalence of childhood epilepsy in Estonia. <i>Epilepsia</i> . 1999; 40(7): 1011-9.	1997	*	
Estonia	Beilmann A, Napa A, Hämarik M, Sõõt A, Talvik I, Talvik T. Incidence of childhood epilepsy in Estonia. <i>Brain Dev</i> . 1999; 21(3): 166-74.	1995-1997	*	†
Estonia	Oun A, Haldre S, Mägi M. Incidence of adult epilepsy in Estonia. <i>Acta Neurol Scand</i> . 2003; 108(4): 245-51.	1994-1997	*	
Estonia	Oun A, Haldre S, Mägi M. Prevalence of adult epilepsy in Estonia. <i>Epilepsy Res</i> . 2003; 52(3): 233-42.	1997	*	
Estonia	Aluoja A, Leinsalu M, Shlik J, Vasar V, Luuk K. Symptoms of depression in the Estonian population: prevalence, sociodemographic correlates and social adjustment. <i>J Affect Disord</i> . 2004; 78(1): 27-35.	1996-1997		
Estonia	Kleinberg A, Aluoja A, Vasar V. Point prevalence of major depression in Estonia. Results from the 2006 Estonian Health Survey. <i>Eur Psychiatry</i> . 2010; 25(8): 485-90.	2006	*	
Estonia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Estonia	Uusküla A, Nygard-Kibur M, Cowan FM, Mayaud P, French RS, Robinson JNR, Brown DWG. The burden of infection with herpes simplex virus type 1 and type 2: seroprevalence study in Estonia. <i>Scand J Infect Dis</i> . 2004; 36(10): 727-32.	2000		
Estonia	Eglit T, Rajasalu T, Lember M. Prevalence of diabetes and impaired glucose regulation in Estonia. <i>Diabet Med</i> . 2011; 28(4): 504-5.	2008-2009		
Estonia	Rutkowski B. Changing pattern of end-stage renal disease in central and eastern Europe. <i>Nephrol Dial Transplant</i> . 2000; 15(2): 156-60.	1997-1998		
Estonia	Locatelli F, D'Amico M, Cerjevski H, Dainys B, Miglinas M, Luman M, Ots M, Ritz E. The epidemiology of end-stage renal disease in the Baltic countries: an evolving picture. <i>Nephrol Dial Transplant</i> . 2001; 16(7): 1338-42.	1999		
Estonia	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2012. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	2008	*	
Estonia	Runnel R, Honkala S, Honkala E, Olak J, Nõmmela R, Vahlberg T, Mäkinen KK, Saag M. Caries experience in the permanent dentition among first- and second-grade schoolchildren in southeastern Estonia. <i>Acta Odontol Scand</i> . 2013; 71(3-4): 410-5.	2008	*	
Estonia	Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, Büchele G, Clausen M, Cookson WOC, von Mutius E, Strachan DP, Williams HC, ISAAC Phase Two Study Group. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. <i>J Allergy Clin Immunol</i> . 2008; 121(1): 141-147.	2005-2007	*	
Estonia	Bakler T, Baburin A, Teesalu R, Rahu M. Comparison of management and 30-day mortality of acute myocardial infarction in men versus women in Estonia. <i>Acta Cardiol</i> . 2004; 59(3): 275-81.	2001-2002		
Estonia	Flohr C, Weinmayr G, Weiland SK, Addo-Yobo E, Annesi-Maesano I, Björkstén B, Bråbäck L, Büchele G, Chico M, Cooper P, Clausen M, El Sharif N, Martinez Gimeno A, Mathur RS, von Mutius E, Morales Suarez-Varela M, Pearce N, Svabe V, Wong GWK, Yu M, Zhong NS, Williams HC, ISAAC Phase Two Study Group. How well do questionnaires perform compared with physical examination in detecting flexural eczema? Findings from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. <i>Br J Dermatol</i> . 2009; 161(4): 846-53.	2005-2007	*	
Estonia	Zeitlan J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT; 2008. Available from: http://www.perinataleaudit.nl/downloads/bestand/649/peristat-ii-2008-	2004		†
Estonia	Estonian Society of Nephrology Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Estonia	Estonian Society of Nephrology Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Estonia	Estonian Society of Nephrology Renal Replacement Therapy Data 1997 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 1998. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2003.	1997	*	
Estonia	Estonia Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Ethiopia	Macro International, Inc, Population and Housing Census Commissions Office (PHCCO). Ethiopia Demographic and Health Survey 2005. Calverton, United States: Macro International, Inc.	2005		†
Ethiopia	Central Statistical Agency (Ethiopia), ORC Macro. Ethiopia Demographic and Health Survey 2000. Calverton, United States: ORC Macro, 2001.	2000		†
Ethiopia	Central Statistical Agency (Ethiopia), ICF Macro, Ministry of Health (Ethiopia). Ethiopia Demographic and Health Survey 2010-2011. Calverton, United States: ICF Macro.	2010-2011		†
Ethiopia	World Health Organization (WHO). Ethiopia World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Ethiopia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists' Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Ethiopia	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Ethiopia	Berhe N, Gundersen SG, Abebe F, Birrie H, Medhin G, Gemetchu T. Praziquantel side effects and efficacy related to Schistosoma mansoni egg loads and morbidity in primary school children in north-east Ethiopia. <i>Acta Trop</i> . 1999; 72(1): 53-63.	1995		
Ethiopia	Gibbs, S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. <i>Int J Dermatol</i> . 1996; 35(9): 633-9.	1994		
Ethiopia	Murgia V, Bilcha KD, Shibeshi D. Community dermatology in Debre Markos: an attempt to define children's dermatological needs in a rural area of Ethiopia. <i>Int J Dermatol</i> . 2010; 49(6): 666-71.	2009		
Ethiopia	Figuerola JI, Fuller LC, Abraha A, Hay RJ. Dermatology in southwestern Ethiopia: rationale for a community approach. <i>Int J Dermatol</i> . 1998; 37(10): 752-8.	1994		
Ethiopia	Amsalu S, Lulseged S. Tetanus in a children's hospital in Addis Ababa: review of 113 cases. <i>Ethiop Med J</i> . 2005; 43(4): 233-40.	1989-1998		
Ethiopia	Nida H. Neonatal tetanus in Awassa: retrospective analysis of patients admitted over 5 years. <i>Ethiop Med J</i> . 2001; 39(3): 241-6.	1994-1998		
Ethiopia	Tadesse A, Gebre-Selassie S. Five years review of cases of adult tetanus managed at Gondar University Hospital, North West Ethiopia (Gondar, Sep. 2003-Aug. 2008). <i>Ethiop Med J</i> . 2009; 47(4): 291-7.	2003-2008		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Ethiopia	Leekassa R, Bizuneh E, Alem A, Fekadu A, Shibre T. Community diagnosis of common skin diseases in the Zay community of the Zeway Islands, Ethiopia. <i>Ethiop Med J</i> . 2005; 43(3): 189-95.	1998		
Ethiopia	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol</i> . 2008; 121(4): 947-954.	1995, 2003		
Ethiopia	Ali J, Yifru S, Woldeamanuel Y. Prevalence of tinea capitis and the causative agent among school children in Gondar, North West Ethiopia. <i>Ethiop Med J</i> . 2011; 47(4): 261-9.	2007-2008		
Ethiopia	Woldeamanuel Y, Leekassa R, Chrissyanthou E, Menghistu Y, Petri B. Prevalence of tinea capitis in Ethiopian schoolchildren. <i>Mycoses</i> . 2005; 48(2): 137-41.	2003-2005		
Ethiopia	Gedlu E, Rahlenbeck SL. Pyogenic meningitis in children in north-western Ethiopia. <i>Ann Trop Paediatr</i> . 1995; 15(3): 243-7.	1990-1994		
Ethiopia	Muhe L, Klugman KP. Pneumococcal and Haemophilus influenzae meningitis in a children's hospital in Ethiopia: serotypes and susceptibility patterns. <i>Trop Med Int Health</i> . 1999; 4(6): 421-7.	1993-1995		
Ethiopia	Mwenda JM, Noto KM, Abebe A, Enweronu-Laryea C, Amina I, Mchomvu J, Kisakye A, Mpabawani EM, Pazvakavambwa I, Amah GE, Seheri LM, Kiulia NM, Page N, Widdowson M-A, Steele AD. Burden and epidemiology of rotavirus diarrhea in selected African countries: preliminary results from the African Rotavirus Surveillance Network. <i>J Infect Dis</i> . 2010; 202(Suppl): S5-11.	2007-2008		
Ethiopia	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1995, 1997-2003, 2005-2008		
Ethiopia	Hiatt RA. Morbidity from Schistosoma mansoni infections: an epidemiologic study based on quantitative analysis of egg excretion in two highland Ethiopian villages. <i>Am J Trop Med Hyg</i> . 1976; 25(6): 808-17.	1973, 1975		†
Ethiopia	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J</i> . 1998; 12(2): 315-35.	1993-1995		
Ethiopia	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	2003		
Ethiopia	Lester FT. Clinical status of Ethiopian diabetic patients after 20 years of diabetes. <i>Diabet Med</i> . 1991; 8(3): 272-6.	1976-1990		
Ethiopia	Dagne MB, Günther E. Epidemiology of communicable skin diseases in school children of a rural area in North Ethiopia. <i>Dermatol Monatsschr</i> . 1990; 176(176): 219-23.	1989		
Ethiopia	Tekle Haimanot R, Seraw B, Forsgren L, Ekbohm K, Ekstedt J. Migraine, chronic tension-type headache, and cluster headache in an Ethiopian rural community. <i>Cephalalgia</i> . 1995; 15(6): 482-8.	1992-1993		
Ethiopia	Woldeamanuel Y, Mengistu Y, Chrissyanthou E, Petri B. Dermatophytosis in Tulugudu Island, Ethiopia. <i>Med Mycol</i> . 2005; 43(1): 79-82.	2001		
Ethiopia	Belyhun Y, Amberbir A, Medhin G, Erko B, Hanlon C, Venn A, Britton J, Davey G. Prevalence and risk factors of wheeze and eczema in 1-year-old children: the Butajira birth cohort, Ethiopia. <i>Clin Exp Allergy</i> . 2010; 40(4): 619-26.	2006	*	
Ethiopia	Abuye C, Berhane Y, Akalu G, Getahun Z, Ersumo T. Prevalence of goiter in children 6 to 12 years of age in Ethiopia. <i>Food Nutr Bull</i> . 2007; 28(4): 391-8.	2005	*	
Ethiopia	Abuye C, Berhane Y. The goitre rate, its association with reproductive failure, and the knowledge of iodine deficiency disorders (IDD) among women in Ethiopia: cross-section community based study. <i>BMC Public Health</i> . 2007; 316.	2005	*	
Ethiopia	Demissie T, Ali A, Mekonen Y, Haider J, Umetsu M. Magnitude and distribution of vitamin A deficiency in Ethiopia. <i>Food Nutr Bull</i> . 2010; 31(2): 234-41.	2006		
Ethiopia	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Ethiopia	Stintzing G, Bäck E, Tufvesson B, Johnson T, Wadström T, Habte D. Seasonal fluctuations in the occurrence of enterotoxigenic bacteria and rotavirus in paediatric diarrhoea in Addis Ababa. <i>Bull World Health Organ</i> . 1981; 59(1): 67-73.	1977-1978	*	
Ethiopia	Adamu H, Petros B, Hailu A, Petry F. Molecular characterization of Cryptosporidium isolates from humans in Ethiopia. <i>Acta Trop</i> . 2010; 115(1-2): 77-83.	2007-2008	*	
Ethiopia	Muhe L, Fredrikzon B, Habte D. Clinical profile of rotavirus enteritis in Ethiopian children. <i>Ethiop Med J</i> . 1986; 24(1): 1-6.	1983-1984	*	
Ethiopia	Kebede D, Alem A. Major mental disorders in Addis Ababa, Ethiopia. II. Affective disorders. <i>Acta Psychiatr Scand Suppl</i> . 1999; 397: 18-23.	1994		
Ethiopia	Awas M KD, Alem A. Major mental disorders in Butajira, southern Ethiopia. <i>Acta Psychiatr Scand Suppl</i> . 1999; 56-64.	1995-1996		
Ethiopia	Gessew A. Maternal complications – in a zonal hospital. <i>Ethiop Med J</i> . 2007; 45(1): 47-54.	1993-2003		
Ethiopia	Tekle-Haimanot R, Abebe M, Gebre-Mariam A, Forsgren L, Heijbel J, Holmgren G, Ekstedt J. Community-based study of neurological disorders in rural central Ethiopia. <i>Neuroepidemiology</i> . 1990; 9(5): 263-77.	1986-1988		†
Ethiopia	Zegeye DT, Megabiab B, Mulu A. Age at menarche and the menstrual pattern of secondary school adolescents in northwest Ethiopia. <i>BMC Womens Health</i> . 2009; 9: 29.	2007		
Ethiopia	Tenkir A, Fisseha N, Ayele B. Premenstrual syndrome: prevalence and effect on academic and social performances of students in Jimma University, Ethiopia. <i>Ethiop J Health Dev</i> . 2004; 17(3): 181-8.	1996-1997		
Ethiopia	Kebede D, Alem A. Major mental disorders in Addis Ababa, Ethiopia. I. Schizophrenia, schizoaffective and cognitive disorders. <i>Acta Psychiatr Scand Suppl</i> . 1999; 11-7.	1994		
Ethiopia	Ethiopian Health and Nutrition Research Center, Ministry of Health (Ethiopia), World Health Organization (WHO). Ethiopia Tuberculosis Prevalence Survey 2010-2011.	2010-2011		
Ethiopia	Ethiopia National Blindness and Low Vision Survey 2005-2006 as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2005-2006		
Ethiopia	Cerulli L, Cedrone C, Assefa C, Scuderi GL. Assessment of visual status of the population in seven regions of Ethiopia. <i>Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique</i> . 1984; 2-4: 127-42, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1981-1982		
Ethiopia	Zerihun N, Mabey D. Blindness and low vision in Jimma Zone, Ethiopia: results of a population-based survey. <i>Ophthalmic Epidemiol</i> . 1997; 4(1): 19-26, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1994-1995		
Ethiopia	Melese M, Alemayehu W, Bayu S, Girma T, Haileselassie T, Khandekar R, Worku A, Courtright P. Low vision and blindness in adults in Gurage Zone, central Ethiopia. <i>Br J Ophthalmol</i> . 2003; 87(6): 677-80, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1998		
Ethiopia	Oli K, Porteous J. Prevalence of rheumatic heart disease among school children in Addis Ababa. <i>East Afr Med J</i> . 1999; 76(11): 601-5.	1995		
Ethiopia	Oli K, Porteous J. Rheumatic heart disease among school children in Addis Ababa City: awareness and adequacy of its prophylaxis. <i>Ethiop Med J</i> . 1999; 37(3): 155-61.	1995		
Ethiopia	Gaym A, Bailey P, Pearson L, Admasu K, Gebrehiwot Y, Ethiopian National EmONC Assessment Team. Disease burden due to pre-eclampsia/eclampsia and the Ethiopian health system's response. <i>Int J Gynaecol Obstet</i> . 2011; 115(1): 112-6.	2008-2009	*	
Ethiopia	Biadgilign S, Lakew Y, Reda AA, Deribe K. A population based survey in Ethiopia using questionnaire as proxy to estimate obstetric fistula prevalence: results from demographic and health survey. <i>Reprod Health</i> . 2013; 10: 14.	2005	*	
Ethiopia	Wolde Z, Segni H, Woldie M. Hypertensive disorders of pregnancy in jimma university specialized hospital. <i>Ethiop J Health Sci</i> . 2011; 21(3): 147-54.	2009-2010	*	
Ethiopia	Almu S, Tadesse Z, Cooper P, Hackett R. The prevalence of epilepsy in the Zay Society, Ethiopia – an area of high prevalence. <i>Seizure</i> . 2006; 15(3): 211-3.	2005		†
Ethiopia	Mogga S, Prince M, Alem A, Kebede D, Stewart R, Glozier N, Hotopf M. Outcome of major depression in Ethiopia: population-based study. <i>Br J Psychiatry</i> . 2006; 189: 241-6.	1998-2002		
Ethiopia	Tsega E, Nordenfelt E, Hansson BG. Hepatitis C virus infection and chronic liver disease in Ethiopia where hepatitis B infection is hyperendemic. <i>Trans R Soc Trop Med Hyg</i> . 1995; 89(2): 171-4.	1992-1994		
Ethiopia	Hailmariam S, Tessema F, Asefa M, Tadesse H, Tenkolu G. The prevalence of depression and associated factors in Ethiopia: findings from the National Health Survey. <i>Int J Ment Health Syst</i> . 2012; 6(1): 23.	2003	*	
Ethiopia	Tefera S, Shibre T, Fekadu A, Medhin G, Wakwoya A, Alem A, Kullgren G, Jacobsson L. Five-year mortality in a cohort of people with schizophrenia in Ethiopia. <i>BMC Psychiatry</i> . 2011; 165.	1998-2001	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Ethiopia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010		
Ethiopia	Tadesse, Takele, Demissie, Meaza, Berhane, Yemane, Kebede, Yizgaw, Abebe, Markos. Two-Thirds of Smear-Positive Tuberculosis Cases in the Community Were Undiagnosed in Northwest Ethiopia: Population Based Cross-Sectional Study. PLoS One. 2011; 6(12): e28258.	2010		
Ethiopia	Berhe, Gebretsadik, Enquesselassie, Fikre, Hailu, Elena, Mekonnen, Wondate, Teklu, Tsigemariam, Gebretsadik, Atakti, Berhe, Rezene, Haile, Tseodros, Aseffa, Abraham. Population-based prevalence survey of tuberculosis in the Tigray region of Ethiopia. BMC Infect Dis. 2013; 448.	2011		
Ethiopia	Ashenafi Y, Kebede D, Desta M, Alem A. Prevalence of mental and behavioural disorders in Ethiopian children. East Afr Med J. 2001; 78(6): 308-11.	1998	*	
Ethiopia	Duncan ME, Tibaux G, Pelzer A, Mehari L, Peutherer J, Young H, Jamil Y, Darougar S, Piot P, Rogg�n E. Teenage obstetric and gynaecological problems in an African city. Cent Afr J Med. 1994; 40(9): 234-44.	1991-1993	*	
Ethiopia	Ramos JM, Toro C, Reyes F, Amor A, Guti�rrez F. Seroprevalence of HIV-1, HBV, HTLV-1 and Treponema pallidum among pregnant women in a rural hospital in Southern Ethiopia. J Clin Virol. 2011; 51(1): 83-5.	2008	*	
Ethiopia	Jimma University, World Health Organization (WHO). Ethiopia Jimma Community Injury Survey 2006. [Unpublished].	2006	*	
Ethiopia	Mihret W, Rinke de Wit TF, Petros B, Mekonnen Y, Tsegaye A, Wolday D, Beyene A, Aklilu M, Sanders E, Fontanet AL. Herpes simplex virus type 2 seropositivity among urban adults in Africa: results from two cross-sectional surveys in Addis Ababa, Ethiopia. Sex Transm Dis. 2002; 29(3): 175-81.	1996	*	
Ethiopia	Kebede Y, Dorigo-Zetsma W, Mengistu Y, Mekonnen Y, Schaap A, Wolday D, Sanders EJ, Messele T, Coutinho RA, Dukers NHTM. Transmission of herpes simplex virus Type 2 among factory workers in Ethiopia. J Infect Dis. 2004; 190(2): 365-72.	1990-1999	*	
Ethiopia	Demissie BS, Solomon AW. Magnitude and causes of childhood blindness and severe visual impairment in Sekoru District, Southwest Ethiopia: a survey using the key informant method. Trans R Soc Trop Med Hyg. 2011; 105(9): 507-11. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2009		
Ethiopia	Sheba C, Adam A, Bat-Miriam M. A survey of some genetical characters in Ethiopian tribes. Introduction. Purpose of expedition. Survey of glutathione-instability in red blood cells. Am J Phys Anthropol. 1962; 20: 168-71.	1960-1962		
Ethiopia	Frischer H, Bowman JE, Carson PE, Rieckmann KH, Willerson D Jr, Colwell EJ. Erythrocytic glutathione reductase, glucose-6-phosphate dehydrogenase, and 6-phosphogluconic dehydrogenase deficiencies in populations of the United States, South Vietnam, Iran, and Ethiopia. J Lab Clin Med. 1973; 81(4): 603-12.	1971-1973		
Ethiopia	Muleta M, Fantahun M, Tafesse B, Hamlin EC, Kennedy RC. Obstetric fistula in rural Ethiopia. East Afr Med J. 2007; 84(11): 525-33.	2005	*	
Ethiopia	Mengistu G, Alemayehu S. Prevalence and burden of primary headache disorders among a local community in Addis Ababa, Ethiopia. J Headache Pain. 2013; 14(1): 30.	2011	*	
Ethiopia	Amare A, Yami A. Case-fatality of adult tetanus at Jimma University Teaching Hospital, Southwest Ethiopia. Afr Health Sci. 2011; 11(1): 36-40.	1996-2009	*	
Ethiopia	Amare A, Melkamu Y, Mekonnen D. Tetanus in adults: clinical presentation, treatment and predictors of mortality in a tertiary hospital in Ethiopia. J Neurol Sci. 2012; 317(1-2): 62-5.	2001-2009	*	
Ethiopia	Bartels SA, Greenough PG, Tamar M, VanRooyen MJ. Investigation of a cholera outbreak in Ethiopia's Oromiya Region. Disaster Med Public Health Prep. 2010; 4(4): 312-7.	2006	*	
Ethiopia	World Health Organization (WHO). Ethiopia WHO Leishmaniasis Country Profile.	2004-2010	*	
Ethiopia	Jemaneh L, Kebede D. Clinico-epidemiological study of lymphatic filariasis southwestern Ethiopia. Ethiop Med J. 1995; 33(3): 143-53.	1993	*	
Ethiopia	Mezgebu Y, Mossie A, Rajesh P, Beyene G. Prevalence and severity of iodine deficiency disorder among children 6-12 years of age in shebe senbo district, jimma zone, southwest ethiopia. Ethiop J Health Sci. 2012; 22(3): 196-204.	2011	*	
Ethiopia	Ethiopia - Western Ethiopia Survey on Iodine Deficiency Disorders 2002 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2002		
Ethiopia	Damasceno A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D, Dzudie A, Kouam CK, Suliman A, Schrueder N, Yonga G, Ba SA, Maru F, Alemayehu B, Edwards C, Davison BA, Cotter G, Sliwa K. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med. 2012; 172(18): 1386-94.	2007-2010		
Ethiopia	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Ethiopia	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Ethiopia	World Health Organization (WHO). Global leprosy situation, 2007 (additional information). Wkly Epidemiol Rec. 2007; 82(44): 388.	2006	*	
Ethiopia	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Ethiopia	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Ethiopia	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Ethiopia	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Ethiopia	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Ethiopia	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Ethiopia	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Ethiopia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1993; 68(25): 181-6.	1992	*	
Ethiopia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Ethiopia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Ethiopia	Vitamin A, Iron and Iodine Status in Children with Severe Vitamin A Deficiency in a Rural Village in Hararge Region of Ethiopia as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1988-1989		
Ethiopia	Mitke G, Genetu A, Kassu A, Aseffa A, Woldemichael K, Kebede Y, Melesse T, Dubisso B, Admassu R, Debebe A. A community based study of urogenital chlamydia trachomatis in males aged fifteen years and above, Dembia District, northwest Ethiopia. Ethiop Med J. 2002; 40(3): 251-7.	1999-2000	*	
Ethiopia	Taffa N, Bjune G, Sundby J, Gaustad P, Alestrom A. Prevalence of gonococcal and chlamydial infections and sexual risk behavior among youth in Addis Ababa, Ethiopia. Sex Transm Dis. 2002; 29(12): 828-33.	2000	*	
Ethiopia	Berhane Y, Worku A, Bejiga A, Adamu L, Alemayehu W, Bedri A, Haile Z, Ayalew A, Adamu Y, Gebre T, Kebede TD, West E, West S. Prevalence and causes of blindness and Low Vision in Ethiopia. Ethiop J Health Dev. 2008; 21(3): 204-10.	2005-2006	*	
Ethiopia	Mehari ZA, Yimer AW. Prevalence of refractive errors among schoolchildren in rural central Ethiopia. Clin Exp Optom. 2013; 96(1): 65-9.	2010-2011	*	
Ethiopia	Yared AW, Belaynew WT, Destaye S, Ayanaw T, Zelalem E. Prevalence of refractive errors among school children in gondar town, northwest ethiopia. Middle East Afr J Ophthalmol. 2012; 19(4): 372-6.	2009-2011	*	
Ethiopia	Mekonen E. Prevalence of goitre in Sekota district, Ethiopia. East Afr Med J. 1996; 73(4): 264-7 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1995		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Ethiopia	Tibeb HN, Aboye C, Gebre P, Hailegiorgis B. Patterns of goitre in Sidama Awraja in Ethiopia and its relationship to piped water supply. <i>East Afr Med J</i> . 1993; 70(3): 163-7 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1987		
Ethiopia	Zhao Y-F, Guo X-J, Zhang Z-S, Ma X-Q, Wang R, Yan X-Y, He J. Epidemiology of functional diarrhea and comparison with diarrhea-predominant irritable bowel syndrome: a population-based survey in China. <i>PLoS One</i> . 2012; 7(8): e43749.	2007-2012	*	
Ethiopia	Tsega E, Mengesha B, Nordenfelt E, Hansson BG, Lindberg J. Prevalence of hepatitis B virus markers among Ethiopian blood donors: is HBsAg screening necessary? <i>Trop Geogr Med</i> . 1987; 39(4): 336-40.	1984-1985		
Ethiopia	Gebreselassie L. Prevalence of specific markers of viral hepatitis A and B among an Ethiopian population. <i>Bull World Health Organ</i> . 1983; 61(6): 991-6.	1982		
Ethiopia	Tsega E, Mengesha B, Hansson BG, Lindberg J, Nordenfelt E. Hepatitis A, B, and delta infection in Ethiopia: a serologic survey with demographic data. <i>Am J Epidemiol</i> . 1986; 123(2): 344-51.	1984		
Ethiopia	Tsega E, Nordenfelt E, Mengesha B, Hansson BG, Tsega M, Lindberg J. Age-specific prevalence of hepatitis A virus antibody in Ethiopian children. <i>Scand J Infect Dis</i> . 1990; 22(2): 145-8.	1989		
Ethiopia	Scriver S, Yemaneberhan H, Zebeignis M, Tilahun D, Girma S, Ali S, McElroy P, Custovic A, Woodcock A, Pritchard D, Venn A, Britton J. Independent effects of intestinal parasite infection and domestic allergen exposure on risk of wheeze in Ethiopia: a nested case-control study. <i>Lancet</i> . 2001; 358(9292): 1493-9.	1996		
Ethiopia	Alkan ML, Maayan S, Belmaker I, Arbeli Y, Mani N, Ben-Yshai F. Serological markers for hepatitis B and treponemal infection among HIV carriers from Ethiopia. <i>Isr J Med Sci</i> . 1993; 29(6-7): 390-2.	1991		
Ethiopia	Ayele W, Nokes DJ, Abebe A, Messele T, Dejene A, Enquessele F, Rinke de Wit TF, Fontanet AL. Higher prevalence of anti-HCV antibodies among HIV-positive compared to HIV-negative inhabitants of Addis Ababa, Ethiopia. <i>J Med Virol</i> . 2002; 68(1): 12-7.	1994		
Ethiopia	Kefene H, Rapicetta M, Rossi GB, Bisanti L, Bekura D, Morace G, Palladino P, Di Rienzo A, Conti S, Bassani F, Bertolaso G, Pasquini P. Ethiopian national hepatitis B study. <i>J Med Virol</i> . 1988; 24(1): 75-84.	1985-1986		
Ethiopia	Rahlenbeck SI, Yohannes G, Molla K, Reifen R, Assefa A. Infection with HIV, syphilis and hepatitis B in Ethiopia: a survey in blood donors. <i>Int J STD AIDS</i> . 1997; 8(4): 261-4.	1994-1995		
Ethiopia	Iron Supplementation and Malaria: A Randomised, Placebo-controlled Field Trial in Rural Ethiopia [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Ethiopia	The Behavior and Biology of Anopheles Arabiensis in Relation to Epidemiology and Control of Malaria in Ethiopia [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Ethiopia	Studies on the Bionomics and Molecular Insecticide Resistance of Anophelines in Gorgora, North-west Ethiopia [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Ethiopia	Re-orientation and Definition of the Role of Malaria Vector-control in Ethiopia as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Ethiopia	A Malaria Assessment in Damot Gale Woreda, Wolayita Zone, Ethiopia as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Ethiopia	Micronutrient Nutrition Survey: Fugnido and Kebribeya Refugee Camps, Ethiopia, 2001 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Ethiopia	Annual Report for Koraro, Ethiopia: Millennium Research Village July 2005 to June 2006 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Ethiopia	Prevalence of P. Falciparum and P. Vivax and its Associated Risk Factors in Harar, Eastern Ethiopia as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008	*	†
Ethiopia	Abate A, Degarege A, Erko B. Community knowledge, attitude and practice about malaria in a low endemic setting of Shewa Robit Town, northeastern Ethiopia. <i>BMC Public Health</i> . 2013; 13(1): 312 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2011	*	†
Ethiopia	Adish AA, Esrey SA, Gyorkos TW, Johns T. Risk factors for iron deficiency anaemia in preschool children in northern Ethiopia. <i>Public Health Nutr</i> . 1999; 2(3): 243-52 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†
Ethiopia	Alemayehu T, Ye-ebiyo Y, Ghebreyesus TA, Witten KH, Bosman A, Teklehaimanot A. Malaria, schistosomiasis, and intestinal helminths in relation to microdams in Tigray, northern Ethiopia. <i>Parasitology</i> . 1998; 40(3): 259-67 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Ethiopia	Alemu A, Tsegaye W, Golassa L, Abebe G. Urban malaria and associated risk factors in Jimma town, south-west Ethiopia. <i>Malar J</i> . 2011; 10(1): 173 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2010	*	†
Ethiopia	Ashton RA, Kefayalew T, Tesfaye G, Pullan RL, Yadeta D, Reithinger R, Kolaczinski JH, Brooker S. School-based surveys of malaria in Oromia Regional State, Ethiopia: a rapid survey method for malaria in low transmission settings. <i>Malar J</i> . 2011; 10(1): 25 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2009	*	†
Ethiopia	Ghebreyesus TA, Haile M, Getachew A, Alemayehu T, Witten KH, Medhin A, Yohannes M, Asgedom Y, Ye-ebiyo Y, Lindsay SW, Byass P. Pilot studies on the possible effects on malaria of small-scale irrigation dams in Tigray regional state, Ethiopia. <i>J Public Health</i> . 1998; 20(2): 238-40 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Ethiopia	Kibret S, Alemu Y, Boelee E, Tekie H, Alemu D, Petros B. The impact of a small-scale irrigation scheme on malaria transmission in Ziway area, Central Ethiopia. <i>Trop Med Int Health</i> . 2010; 15(1): 41-50 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005-2006	*	†
Ethiopia	Kloos H, Kello AB, Addus A. Onchocerciasis, malaria and trypanosomiasis in three resettlement schemes in western Ethiopia. <i>Parasitology</i> . 1991; 33(2-3): 187-97 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988-1989	*	†
Ethiopia	Legesse M, Erko B. Prevalence of intestinal parasites among school children in a rural area close to the southeast of Lake Langano, Ethiopia. <i>Ethiop J Health Dev</i> . 2004; 18(2): 116-20 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Ethiopia	Nigatu W, Abebe M, Dejene A. Plasmodium vivax and P. falciparum epidemiology in Gambella, south-west Ethiopia. <i>Trop Med Parasitol</i> . 1992; 43(3): 181-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Ethiopia	Nigatu W, Petros B, Lulu M, Adugna N, Wirtz R, Tilahun D. Some aspects of malaria prevalence, vector infectivity and DDT resistance studies in Gambella Region, Southern Western Ethiopia. <i>Ethiop J Health Dev</i> . 1994; 8(1): 1-10 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Ethiopia	Seboxa T, Snow RW. Epidemiological features of severe paediatric malaria in north western Ethiopia. <i>East Afr Med J</i> . 1997; 74(12): 780-3 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Ethiopia	Seyoum A, Balcha F, Balkew M, Ali A, Gebre-Michael T. Impact of cattle keeping on human biting rate of anopheline mosquitoes and malaria transmission around Ziway, Ethiopia. East Afr Med J. 2002; 79(9): 485-90 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
Ethiopia	Tilaye T, Deressa W. Prevalence of urban malaria and associated factors in Gondar Town, Northwest Ethiopia. Ethiop Med J. 2007; 45(2): 151-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Ethiopia	Wezam A. Malaria survey at Humera, northwestern Ethiopia. Ethiop Med J. 1994; 32(1): 41-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†
Ethiopia	Wolde B, Pickering J, Wotton K. Chloroquine chemoprophylaxis in children during peak transmission period in Ethiopia. J Trop Med Hyg. 1994; 97(4): 215-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Ethiopia	Woyessa A, Gebre-Michael T, Ali A. An indigenous malaria transmission in the outskirts of Addis Ababa, Akaki Town and its environs. Ethiop J Health Dev. 2004; 18(1): 2-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
Ethiopia	Yewhalaw D, Legesse W, Van Bortel W, Gebre-Selassie S, Kloos H, Duchateau L, Speybroeck N. Malaria and water resource development: the case of Gilgel-Gibe hydroelectric dam in Ethiopia. Malar J. 2009; 8: 21 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Ethiopia	Yohannes M, Haile M, Ghebreyesus TA, Witten KH, Getachew A, Byass P, Lindsay SW. Can source reduction of mosquito larval habitat reduce malaria transmission in Tigray, Ethiopia? Trop Med Int Health. 2005; 10(12): 1274-85 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Ethiopia	Yohannes M, Petros B. Urban malaria in Nazareth, Ethiopia: parasitological studies. Ethiop Med J. 1996; 34(2): 83-91 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
Ethiopia	Zein ZA. Haematocrit levels and anaemia in Ethiopian children. East Afr Med J. 1991; 68(6): 412-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Federated States of Micronesia	Centre for Physical Activity and Health, University of Sydney (Australia), Department of Health and Social Affairs (Micronesia), Fiji School of Medicine, Micronesia Human Resources Development Center, Pohnpei State Department of Health Services, World Health Organization (WHO), Micronesia - Pohnpei STEPS Noncommunicable Disease Risk Factors Survey 2002.	2002		
Federated States of Micronesia	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1995-1996, 1998-2010		
Federated States of Micronesia	Centre for Health Informatics and Multiprofessional Education, University College London. Model's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Federated States of Micronesia	Hill AV, Bowden DK, OShaughnessy DF, Weatherall DJ, Clegg JB. Beta thalassaemia in Melanesia: association with malaria and characterization of a common variant (IVS-1 nt 5 G—C). Blood. 1988; 72(1): 9-14.	1985-1987		
Federated States of Micronesia	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998-2001, 2003, 2006-2007, 2009		
Federated States of Micronesia	Fischer GE, Thompson N, Chaves SS, Bower W, Goldstein S, Armstrong G, Williams I, Bialek S. The epidemiology of hepatitis A virus infections in four Pacific Island nations, 1995-2008. Trans R Soc Trop Med Hyg. 2009; 103(9): 906-10.	2000, 2005		
Federated States of Micronesia	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Federated States of Micronesia	Yanagihara RT, Garruto RM, Gajusek DC. Epidemiological surveillance of amyotrophic lateral sclerosis and parkinsonism-dementia in the commonwealth of the Northern Mariana Islands. Ann Neurol. 1983; 13(1): 79-86.	1980-1981		
Federated States of Micronesia	Waldo MC. Schizophrenia in Kosrae, Micronesia: prevalence, gender ratios, and clinical symptomatology. Schizophr Res. 1999; 35(2): 175-81.	1997		
Federated States of Micronesia	Jim R, Johnson E, Pavlin BI. Role of GIS technology during leprosy elimination efforts in Pohnpei. Pac Health Dialog. 2010; 16(1): 109-14.	2008	*	
Federated States of Micronesia	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Federated States of Micronesia	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
Federated States of Micronesia	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Federated States of Micronesia	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	
Federated States of Micronesia	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Federated States of Micronesia	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Federated States of Micronesia	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Federated States of Micronesia	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
Federated States of Micronesia	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Federated States of Micronesia	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Federated States of Micronesia	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Federated States of Micronesia	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Federated States of Micronesia	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Federated States of Micronesia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Federated States of Micronesia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Federated States of Micronesia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2000.	2000		
Federated States of Micronesia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2001.	2001		
Federated States of Micronesia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2002.	2002		
Federated States of Micronesia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2003.	2003		
Federated States of Micronesia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2004.	2004		
Federated States of Micronesia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2007.	2007		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Federated States of Micronesia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2008.	2008		
Federated States of Micronesia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2009.	2009		
Federated States of Micronesia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2010.	2010		
Federated States of Micronesia	Kimura E, Remit K, Fujiwara M, Aniol K, Siren N. Parasitological and clinical studies on Wuchereria bancrofti infection in Chuuk (formerly Truk) State, Federated States of Micronesia. Trop Med Parasitol. 1994; 45(4): 344-6. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1992	*	
Fiji	Fiji Bureau of Statistics, International Statistical Institute. Fiji World Fertility Survey 1974. Voorburg, Netherlands: International Statistical Institute.	1974		
Fiji	Australian Agency for International Development (AusAID), Fiji School of Medicine, Menzies Center for Population Health Research, University of Tasmania (Australia), Ministry of Health (Fiji), World Health Organization (WHO). Fiji STEPS Noncommunicable Disease Risk Factors Survey 2002.	2002		
Fiji	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-1996, 1998-1999		
Fiji	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Fiji	Foliaki S, Annesi-Measano I, Daniel R, Fakakovikaetau T, Magatongia M, Tuuau-Potoi N, Waqatakirewa L, Cheng S, Pearce N. Prevalence of symptoms of childhood asthma, allergic rhinoconjunctivitis and eczema in the Pacific: the International Study of Asthma and Allergies in Childhood (ISAAC). Allergy. 2007; 62(3): 259-64.	1998-2003		
Fiji	Jenney A, Tikoduadua L, Buadromo E, Barnes G, Kirkwood CD, Boniface K, Bines J, Mulholland K, Russell F. The burden of hospitalised rotavirus infections in Fiji. Vaccine. 2009; 27 Suppl 5: 108-11.	2006-2007		
Fiji	Hill AV, Bowden DK, O'Shaughnessy DF, Weatherall DJ, Clegg JB. Beta thalassaemia in Melanesia: association with malaria and characterization of a common variant (IVS-1 nt 5 G→C). Blood. 1988; 72(1): 9-14.	1985-1987		
Fiji	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001-2004, 2006-2009		
Fiji	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2002		
Fiji	Brooks B, Chong R, Ho I, Capstick F, Molyneaux L, Oo TT, Tester M, Yue D. Diabetic retinopathy and nephropathy in Fiji: comparison with data from an Australian diabetes centre. Aust N Z J Ophthalmol. 1999; 27(1): 9-13.	1998		
Fiji	Steer AC, Jenney AWJ, Kado J, Batzloff MR, La Vincente S, Waqatakirewa L, Mulholland EK, Carapetis JR. High burden of impetigo and scabies in a tropical country. PLoS Negl Trop Dis. 2009; 3(6): e467.	2006-2007		
Fiji	Zimmet P, Taylor R, Ram P, King H, Sloman G, Raper LR, Hunt D. Prevalence of diabetes and impaired glucose tolerance in the biracial (Melanesian and Indian) population of Fiji: a rural-urban comparison. Am J Epidemiol. 1983; 118(5): 673-88.	1980		
Fiji	Steer AC, Tikoduadua LV, Manalac EM, Colquhoun S, Carapetis JR, MacLennan C. Validation of an Integrated Management of Childhood Illness algorithm for managing common skin conditions in Fiji. Bull World Health Organ. 2009; 87(3): 173-9.	2007	*	
Fiji	Biaukula VL, Tikoduadua L, Azzopardi K, Seduadua A, Temple B, Richmond P, Robins-Browne R, Mulholland EK, Russell FM. Meningitis in children in Fiji: etiology, epidemiology, and neurological sequelae. Int J Infect Dis. 2012; 16(4): e289-295.	2004-2007		
Fiji	Jamieson LM, Thomson WM, McGee R. Caries prevalence and severity in urban Fijian school children. Int J Paediatr Dent. 2004; 14(1): 34-40.	2002		
Fiji	Secretariat of the Pacific Community (SPC), World Health Organization Regional Office for the Western Pacific (WPRO-WHO). Second Generation Surveillance Surveys of HIV, Other STIs and Risk Behaviours in 6 Pacific Island Countries 2004-2005. Geneva, Switzerland: World Health Organization (WHO), 2006.	2004		
Fiji	Gyaneshwar R, Nsanze H, Singh KP, Pillay S, Seruvatu I. The prevalence of sexually transmitted disease agents in pregnant women in Suva. Aust N Z J Obstet Gynaecol. 1987; 27(3): 213-5.	1985-1986		
Fiji	Yanagihara RT, Garruto RM, Gajusek DC. Epidemiological surveillance of amyotrophic lateral sclerosis and parkinsonism-dementia in the commonwealth of the Northern Mariana Islands. Ann Neurol. 1983; 13(1): 79-86.	1980-1981		
Fiji	Brennan RE, Patel MS. Acute rheumatic fever and rheumatic heart disease in a rural central Australian aboriginal community. Med J Aust. 1990; 153(6): 335-9.	1978-1987		
Fiji	Carapetis JR, Currie BJ. Clinical epidemiology of rheumatic fever and rheumatic heart disease in tropical Australia. Adv Exp Med Biol. 1997; 233-6.	1994-1996		
Fiji	Carapetis JR, Wolff DR, Currie BJ. Acute rheumatic fever and rheumatic heart disease in the top end of Australia's Northern Territory. Med J Aust. 1996; 164(3): 146-9.	1985-1995		
Fiji	Cuboni HD, Finau SA, Cuboni G. Rheumatic fever and rheumatic heart diseases in Fiji: a review from the surveillance system (1996-2000). Pac Health Dialog. 2006; 13(2): 39-47.	1996-2000		
Fiji	Carapetis JR, Currie BJ, Mathews JD. Cumulative incidence of rheumatic fever in an endemic region: a guide to the susceptibility of the population. Epidemiol Infect. 2000; 124(2): 239-44.	1997		
Fiji	Neilson G, Streetfield RW, West M, Johnson S, Glavin W, Baird S. Rheumatic fever and chronic rheumatic heart disease in Yarrabah aboriginal community, north Queensland. Establishment of a prophylactic program. Med J Aust. 1993; 158(5): 316-8.	1985		
Fiji	Steer AC, Kado J, Wilson N, Tuiketeti T, Batzloff M, Waqatakirewa L, Mulholland EK, Carapetis JR. High prevalence of rheumatic heart disease by clinical and echocardiographic screening among children in Fiji. J Heart Valve Dis. 2009; 18(3): 327-36.	2006		
Fiji	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Fiji	Cama AT, Sikivou BT, Keeffe JE. Childhood visual impairment in Fiji. Arch Ophthalmol. 2010; 128(5): 608-12. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2006-2007		
Fiji	Brian G, Ramke J, Szetu J, Qoqonokana MQ. Cataract and its surgery in Fiji. Clin Experiment Ophthalmol. 2011; 39(5): 449-55. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2009		
Fiji	Brian G, Ramke J, Maher L, Page A, Szetu J. The prevalence of diabetes among adults aged 40 years and over in Fiji. N Z Med J. 2010; 123(1327): 68-75.	2009		
Fiji	Thomas M, Woodfield G, Moses C, Amos G. Soil-transmitted helminth infection, skin infection, anaemia, and growth retardation in schoolchildren of Taveuni Island, Fiji. N Z Med J. 2005; 118(1216): 1492.	2004		
Fiji	Buchanan JG, Wilson FS, Nixon AD. Survey for erythrocyte glucose-6-phosphate dehydrogenase deficiency in Fiji. Am J Hum Genet. 1973; 25(1): 36-41.	1971-1973		
Fiji	Davies GN, Hedrick P, Luveni J, Pal V, Singh D. Dental caries and periodontal disease in Fiji. Aust Dent J. 1992; 37(5): 386-93.	1985-1986		
Fiji	Mermond S, Berlioz-Arthaud A, Estivals M, Baumann F, Levenes H, Martin PMV. Aetiology of community-acquired pneumonia in hospitalized adult patients in New Caledonia. Trop Med Int Health. 2010; 15(12): 1517-24.	2006-2007	*	
Fiji	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Fiji	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
Fiji	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Fiji	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Fiji	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Fiji	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Fiji	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
Fiji	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Fiji	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Fiji	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Fiji	Ranke J, Brian G, Maher L, Qalo Oqonokana M, Szetu J. Prevalence and causes of blindness and low vision among adults in Fiji. Clin Experiment Ophthalmol. 2012; 40(5): 490-6.	2005, 2009-2010	*	
Fiji	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2000.	2000		
Fiji	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2001.	2001		
Fiji	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2002.	2002		
Fiji	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2003.	2003		
Fiji	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2004.	2004		
Fiji	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2005.	2005		
Fiji	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2006.	2006		
Fiji	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2007.	2007		
Fiji	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2008.	2008		
Fiji	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2009.	2009		
Fiji	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2010.	2010		
Fiji	Wilson N, Ruff TA, Rana BJ, Leydon J, Locarnini S. The effectiveness of the infant hepatitis B immunisation program in Fiji, Kiribati, Tonga and Vanuatu. Vaccine. 2000; 18(26): 3059-66.	1998		
Fiji	Kimura E. The Global Programme to Eliminate Lymphatic Filariasis: History and achievements with special reference to annual single-dose treatment with diethylcarbamazine in Samoa and Fiji. Trop Med Health. 2011; 39(1): 17-30. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1983-1984	*	
Fiji	Mataika JU, Kimura E, Koroiueta J, Shimada M. Efficacy of five annual single doses of diethylcarbamazine for treatment of lymphatic filariasis in Fiji. Bull World Health Organ. 1998; 76(6): 575-9.	1985, 1987-1991	*	
Fiji	Fiji - Pacific Programme to Eliminate Lymphatic Filariasis: National activities carried out to date as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2007	*	
Fiji	Fiji Vital Registration Birth Data 1987 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1987		
Finland	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2002-2010		
Finland	World Health Organization (WHO). Finland World Health Survey 2004. Geneva, Switzerland: World Health Organization (WHO), 2005.	2004		
Finland	Statistics Finland, United Nations Economic Commission for Europe (UNECE). Finland Fertility and Family Survey 1989-1992. Geneva, Switzerland: United Nations Economic Commission for Europe (UNECE).	1989-1992		
Finland	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. Scand J Clin Lab Invest. 2007; 67(1): 39-69.	1988, 2006		
Finland	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1988, 2003, 2006		
Finland	National Public Health Institute (Finland), World Health Organization (WHO). WHO MONICA Cerebrovascular Event Data 1982-1997, as provided by the Global Burden of Disease 2010 Cerebrovascular Disease Expert Group. [Unpublished].	1983-1991		
Finland	Joki-Erkkilä VP, Laipala P, Pukander J. Increase in paediatric acute otitis media diagnosed by primary care in two Finnish municipalities—1994-5 versus 1978-9. Epidemiol Infect. 1998; 121(3): 529-34.	1978-1979, 1994-1995		
Finland	Pukander J, Luotonen J, Sipilä M, Timonen M, Karma P. Incidence of acute otitis media. Acta Otolaryngol. 1982; 93(6-May): 447-53.	1978-1979		
Finland	Sipilä M, Pukander J, Karma P. Incidence of acute otitis media up to the age of 1 1/2 years in urban infants. Acta Otolaryngol. 1987; 104(2-Jan): 138-45.	1978-1980		
Finland	Sorri M, Jounio-Ervasi K. Otitis media in a cross-sectional population from northern Finland. Arctic Med Res. 1988; 47(Suppl 1): 653-6.	1986-1988		
Finland	Numminen H, Kotila M, Waltimo O, Aho K, Kaste M. Declining Incidence and Mortality Rates of Stroke in Finland From 1972 to 1991: Results of Three Population-Based Stroke Registers. Stroke. 1996; 27(9): 1487-91.	1972-1973, 1978-1980, 1989-1991		
Finland	Immonen-Riihinen P, Mähönen M, Tuomilehto J, Salomaa V, Kaarsalo E, Narva EV, Salmi K, Sarti C, Sivenius J, Alhainen K, Torppa J. Trends in Case-Fatality of Stroke in Finland During 1983 to 1992. Stroke. 1997; 28(12): 2493-9.	1990-1992		
Finland	Alho OP, Lääriä E, Oja H. What is the natural history of recurrent acute otitis media in infancy? J Fam Pract. 1996; 43(3): 258-64.	1985-1986		
Finland	Viirolainen E, Puhakka H, Aantaa E, Tuohimaa P, Ruuskanen O, Meurman OH. Prevalence of secretory otitis media in seven to eight year old school children. Ann Otol Rhinol Laryngol Suppl. 1980; 89(3 Pt 2): 7-10.	1978		
Finland	Hugg T, Ruotsalainen R, Jaakkola MS, Pushkarev V, Jaakkola JJK. Comparison of allergic diseases, symptoms and respiratory infections between Finnish and Russian school children. Eur J Epidemiol. 2008; 23(2): 123-33.	2003		
Finland	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. J Allergy Clin Immunol. 2008; 121(4): 947-954.	1994, 2001		
Finland	Mäkelä M, Heliövaara M, Sievers K, Impivaara O, Knekt P, Aromaa A. Prevalence, determinants, and consequences of chronic neck pain in Finland. Am J Epidemiol. 1991; 134(11): 1356-67.	1977-1980		
Finland	Hakala PT, Rimpelä AH, Saarni LA, Salminen JJ. Frequent computer-related activities increase the risk of neck-shoulder and low back pain in adolescents. Eur J Public Health. 2006; 16(5): 536-41.	2003		
Finland	Ståhl M, Kautiainen H, El-Metwally A, Häkkinen A, Ylinen J, Salminen JJ, Mikkelsen M. Non-specific neck pain in schoolchildren: prognosis and risk factors for occurrence and persistence. A 4-year follow-up study. Pain. 2008; 137(2): 316-22.	1995		
Finland	Sivola SM, Levoska S, Latvala K, Hoskio E, Vanharanta H, Keinänen-Kiukkaanniemi S. Predictive factors for neck and shoulder pain: a longitudinal study in young adults. Spine. 2004; 29(15): 1662-9.	1989		
Finland	Niemeläinen R, Videman T, Battie MC. Prevalence and characteristics of upper or mid-back pain in Finnish men. Spine. 2006; 31(16): 1846-9.	2003		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Finland	Auvinen J, Tammelin T, Taimela S, Zitting P, Karppinen J. Neck and shoulder pains in relation to physical activity and sedentary activities in adolescence. <i>Spine</i> . 2007; 32(9): 1038-44.	2001-2002		
Finland	Vikari A, Rimpelä M, Salminen JJ, Rimpelä A, Savolainen A, Virtanen SM. Neck or shoulder pain and low back pain in Finnish adolescents. <i>Scand J Public Health</i> . 2000; 28(3): 164-73.	1991		
Finland	Hemingway H, McCallum A, Shipley M, Manderbacka K, Martikainen P, Keskimäki I. Incidence and Prognostic Implications of Stable Angina Pectoris Among Women and Men. <i>JAMA</i> . 2006; 295(12): 1404-11.	1980-1998		
Finland	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001-2003, 2005-2009		
Finland	Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. <i>Thorax</i> . 2002; 57(4): 338-42.	1997-1998		
Finland	Samelahti ML, Tienari PJ, Wikström J, Palo J, Hakama M. Increasing prevalence of multiple sclerosis in Finland. <i>Acta Neurol Scand</i> . 2001; 103(3): 153-8.	1993		
Finland	Koch-Henriksen N. Multiple sclerosis in Scandinavia and Finland. <i>Acta Neurol Scand</i> . 1995; 91(S161): 55-9.	1950-1985		
Finland	Sarasoja T, Wikström J, Paltamaa J, Hakama M, Samelahti M-L. Occurrence of multiple sclerosis in central Finland: a regional and temporal comparison during 30 years. <i>Acta Neurol Scand</i> . 2004; 110(5): 331-6.	1979-1998, 2000		
Finland	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J</i> . 1998; 12(2): 315-55.	1993-1995		
Finland	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	2001		
Finland	Pallasaho P, Juusela M, Lindqvist A, Sovijärvi A, Lundbäck B, Rönmark E. Allergic rhinoconjunctivitis doubles the risk for incident asthma-Results from a population study in Helsinki, Finland. <i>Respir Med</i> . 2011; 105(10): 1449-1456.	1996-2007		
Finland	Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. <i>Diabetologia</i> . 1996; 39(11): 1377-84.	1993-1995		
Finland	Voutilainen-Kaunisto RM, Teräsvirta ME, Uusitupa MI, Niskanen LK. Occurrence and predictors of retinopathy and visual acuity in Type 2 diabetic patients and control subjects. 10-year follow-up from the diagnosis. <i>J Diabet Complications</i> . 2001; 15(1): 24-33.	1979-1981, 1985-1986, 1991-1992		
Finland	Fialk AA, Kärr ML, Laatikainen LT. Prevalence and risk factors of retinopathy in children with diabetes. A population-based study on Finnish children. <i>Acta Ophthalmol (Copenh)</i> . 1993; 71(6): 801-9.	1989-1990		
Finland	Harjutsalo V, Forsblom C, Groop PH. Time trends in mortality in patients with type 1 diabetes: nationwide population based cohort study. <i>BMJ</i> . 2011; 343(7824): d5364.	1970-2007		
Finland	Tuomilehto J, Korhonen HJ, Kartovaara L, Salomaa V, Stengård JH, Pitkänen M, Aro A, Javela K, Uusitupa M, Pitkaniemi J. Prevalence of diabetes mellitus and impaired glucose tolerance in the middle-aged population of three areas in Finland. <i>Int J Epidemiol</i> . 1991; 20(4): 1010-7.	1987		
Finland	Kuusisto J, Mykkanen L, Pyörälä K, Laakso M. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. <i>Stroke</i> . 1994; 25(6): 1157-64.	1987		
Finland	Yliharsila H, Lindström J, Eriksson JG, Jousilahti P, Valle TT, Sundvall J, Tuomilehto J. Prevalence of diabetes and impaired glucose regulation in 45- to 64-year-old individuals in three areas of Finland. <i>Diabet Med</i> . 2005; 22(1): 88-91.	1992		
Finland	Saaristo TE, Barengo NC, Korpi-Hyövähti E, Oksa H, Puolijoki H, Saltevo JT, Vanhala M, Sundvall J, Saarikoski L, Peltonen M, Tuomilehto J. High prevalence of obesity, central obesity and abnormal glucose tolerance in the middle-aged Finnish population. <i>BMC Public Health</i> . 2008; 8(1): 423.	2005		
Finland	Heliövaara M, Mäkelä M, Impivaara O, Knekt P, Aromaa A, Sievers K. Association of overweight, trauma and workload with coxarthrosis. A health survey of 7,217 persons. <i>Acta Orthop Scand</i> . 1993; 64(5): 513-8.	1977-1980		
Finland	Juhakoski R, Heliövaara M, Impivaara O, Kröger H, Knekt P, Lauren H, Arokoski JPA. Risk factors for the development of hip osteoarthritis: a population-based prospective study. <i>Rheumatology</i> . 2009; 48(1): 83-7.	1978-2001		
Finland	Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, Gjomarkaj M, Forsberg B, Gunnbjornsdottir M, Minov J, Brozek G, Dahlen SE, Toskala E, Kowalski ML, Olze H, Howarth P, Krämer U, Baelum J, Loureiro C, Kasper L, Bousquet PJ, Bousquet J, Bachert C, Fokkens W, Burney P. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. <i>Allergy</i> . 2012; 67(1): 91-8.	2008-2009	*	
Finland	Rantalaiho VM, Kautiainen H, Järvenpää S, Virta L, Pohjolainen T, Korpela M, Möttönen T, Puolakka K. Decline in work disability caused by early rheumatoid arthritis: results from a nationwide Finnish register, 2000-8. <i>Ann Rheum Dis</i> . 2013; 72(5): 672-7.	2000-2007	*	
Finland	Oksala NKJ, Viljamaa J, Saimanen E, Venermo M. ATTAC study group. Modified ankle-brachial index detects more patients at risk in a Finnish primary health care. <i>Eur J Vasc Endovasc Surg</i> . 2010; 39(2): 227-33.	2008-2009		
Finland	Mattila PT, Niskanen MC, Vehkalahti MM, Nordblad A, Knuutila MLE. Prevalence and simultaneous occurrence of periodontitis and dental caries. <i>J Clin Periodontol</i> . 2010; 37(11): 962-7.	2000-2001		
Finland	Ainamo J, Tervonen T, Ainamo A. CPITN-assessment of periodontal treatment needs among adults in Ostrobothnia, Finland. <i>Community Dent Health</i> . 1986; 3(2): 153-61.	1982-1983	*	
Finland	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. <i>Community Dent Oral Epidemiol</i> . 1991; 19(2): 72-3.	1987		
Finland	Lallukka T, Manderbacka K, Keskimäki I, Hemingway H, Rahkonen O, Lahelma E, Antti R. Angina pectoris: relation of epidemiological survey to registry data. <i>Eur J Cardiovasc Prev Rehabil</i> . 2011; 18(4): 621-6.	2000-2002	*	
Finland	Westerinen H, Kaski M, Virta L, Almqvist F, Ivanainen M. Prevalence of intellectual disability: a comprehensive study based on national registers. <i>J Intellect Disabil Res</i> . 2007; 51(Pt 9): 715-25.	2000, 2007		
Finland	Puustinen L, Blazevic V, Salminen M, Hämäläinen M, Räsänen S, Vesikari T. Noroviruses as a major cause of acute gastroenteritis in children in Finland, 2009-2010. <i>Scand J Infect Dis</i> . 2011; 43(10): 804-8.	2009-2010	*	
Finland	Juva K, Sulkava R, Erkinjuntti T, Valanne J, Tilvis R. Prevalence of dementia in the city of Helsinki. <i>Acta Neurol Scand</i> . 1993; 87(2): 106-10.	1989-1990		
Finland	Toivanen AT, Heliövaara M, Impivaara O, Arokoski JPA, Knekt P, Lauren H, Kröger H. Obesity, physically demanding work and traumatic knee injury are major risk factors for knee osteoarthritis—a population-based study with a follow-up of 22 years. <i>Rheumatology</i> . 2010; 49(2): 308-14.	1979-2001		
Finland	Mutru O, Laakso M, Isomäki H, Koota K. Ten year mortality and causes of death in patients with rheumatoid arthritis. <i>Br Med J (Clin Res Ed)</i> . 1985; 290(6484): 1797-9.	1972-1982		
Finland	Kaipiainen-Seppänen O, Aho K, Nikkarinen M. Regional differences in the incidence of rheumatoid arthritis in Finland in 1995. <i>Ann Rheum Dis</i> . 2001; 60(2): 128-32.	1995		
Finland	Kaipiainen-Seppänen O, Aho K, Isomäki H, Laakso M. Incidence of rheumatoid arthritis in Finland during 1980-1990. <i>Ann Rheum Dis</i> . 1996; 55(9): 608-11.	1980, 1985, 1990		
Finland	Savolainen E, Kaipiainen-Seppänen O, Kröger L, Luosjärvi R. Total incidence and distribution of inflammatory joint diseases in a defined population: results from the Kuopio 2000 arthritis survey. <i>J Rheumatol</i> . 2003; 30(11): 2460-8.	2000		
Finland	Luoma AR, Rönberg K. Twelve-year follow-up of caries prevalence and incidence in children and young adults in Espoo, Finland. <i>Community Dent Oral Epidemiol</i> . 1987; 15(1): 29-32.	1972-1984		
Finland	Downer MC, Nordling V, Blinkhorn AS, Koistinen A. The Edinburgh-Helsinki study: a comparison of dental care for children. <i>Int Dent J</i> . 1985; 35(3): 226-31.	1983		
Finland	Kerosuo H, Honkala E. Caries experience in the primary dentition of Tanzanian and Finnish 3-7-year-old children. <i>Community Dent Oral Epidemiol</i> . 1991; 19(5): 272-6.	1987		
Finland	Milen A, Hausen H, Heinonen OP, Puumio I. Caries in primary dentition related to age, sex, social status, and county of residence in Finland. <i>Community Dent Oral Epidemiol</i> . 1981; 9(2): 83-6.	1978		
Finland	Aalto-Setälä T, Marttunen M, Tuulio-Henriksson A, Poikolainen K, Lönnqvist J. One-month prevalence of depression and other DSM-IV disorders among young adults. <i>Psychol Med</i> . 2001; 31(05): 791-801.	1995		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Finland	Puura K, Almqvist F, Tamminen T, Piha J, Räsänen E, Kumpulainen K, Moilanen I, Koivisto AM. Psychiatric disturbances among prepubertal children in southern Finland. <i>Soc Psychiatry Psychiatr Epidemiol.</i> 1998; 33(7): 310-8.	1989-1990		
Finland	Arola A, Jokinen E, Ruuskanen O, Saraste M, Pesonen E, Kuusela AL, Tikanoja T, Paavilainen T, Simell O. Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland. <i>Am J Epidemiol.</i> 1997; 146(5): 385-93.	1980-1991		
Finland	Almqvist F, Puura K, Kumpulainen K, Tuompo-Johansson E, Henttonen I, Huikko E, Linna S, Ikäheimo K, Aronen E, Katainen S, Piha J, Moilanen I, Räsänen E, Tamminen T. Psychiatric disorders in 8-9-year-old children based on a diagnostic interview with the parents. <i>Eur Child Adolesc Psychiatry.</i> 1999; 8(4): 17-28.	1989		
Finland	Pirkola SP, Isometsä E, Suvisaari J, Aro H, Joukamaa M, Poikolainen K, Koskinen S, Aromaa A, Lönnqvist JK. DSM-IV mood-, anxiety- and alcohol use disorders and their comorbidity in the Finnish general population. <i>Soc Psychiatry Psychiatr Epidemiol.</i> 2005; 40(1): 1-10.	2000-2001		
Finland	Nikkilä MT, Pasternack A. Prevalence of urolithiasis in a Finnish district. An epidemiologic study of adults in Tampere. <i>Scand J Urol Nephrol.</i> 1988; 22(4): 293-7.	1980-1982		
Finland	Ayuso-Mateos JL, Vázquez-Barquero JL, Dowrick C, Lehtinen V, Dalgard OS, Casey P, Wilkinson C, Lasa L, Page H, Dunn G, Wilkinson G. Depressive disorders in Europe: prevalence figures from the ODIN study. <i>Br J Psychiatry.</i> 2001; 179(4): 308-16.	1999-2001		
Finland	Kiveli S-L, Köngäs-Savio P, Pakkala K, Kesti E, Laippala P. Five-Year Prognosis for Dysthymic Disorder in Old Age. <i>Int J Geriatr Psychiatry.</i> 1993; 8(11): 939-47.	1984-1990		
Finland	Arola A, Tuominen J, Ruuskanen O, Jokinen E. Idiopathic Dilated Cardiomyopathy in Children: Prognostic Indicators and Outcome. <i>Pediatrics.</i> 1998; 101(3): 369-376.	1980-1991		
Finland	Jyrki-Tapani K, Sovijärvi A, Lundbäck B. Chronic obstructive pulmonary disease in Finland: prevalence and risk factors. <i>COPD.</i> 2000; 2(3): 331-9.	1995-1997		
Finland	Tuomi T, Heliovaara M, Palosuo T, Aho K. Smoking, lung function, and rheumatoid factors. <i>Ann Rheum Dis.</i> 1990; 49(10): 753-6.	1978-1980		
Finland	Mattila M-L, Kielenen M, Jussila K, Linna S-L, Bloigu R, Ebeling H, Moilanen I. An Epidemiological and Diagnostic Study of Asperger Syndrome According to Four Sets of Diagnostic Criteria. <i>J Am Acad Child Adolesc Psychiatry.</i> 2007; 46(5): 636-46.	2000-2002		
Finland	United States Renal Data System Coordinating Center. <i>USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States.</i> Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2004-2005		
Finland	United States Renal Data System Coordinating Center. <i>USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States.</i> Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2000-2003		
Finland	De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology.</i> 2000; 54(11 Suppl 5): S21-23.	1997		
Finland	Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Changing epidemiology of Parkinson's disease in southwestern Finland. <i>Neurology.</i> 1999; 52(2): 302-8.	1992		
Finland	Berger K, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology.</i> 2000; 54(11): 24-7.	1997		
Finland	Salokangas RK. First-contact rate for schizophrenia in community psychiatric care. Consideration of the oestrogen hypothesis. <i>Eur Arch Psychiatry Clin Neurosci.</i> 1993; 242(6): 337-46.	1983-1988		
Finland	Lauronen E, Koskinen J, Veijola J, Miettunen J, Jones PB, Fenton WS, Isohanni M. Recovery from schizophrenic psychoses within the northern Finland 1966 Birth Cohort. <i>J Clin Psychiatry.</i> 2005; 66(3): 375-83.	1997-2001		
Finland	Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Mental disorders and cause-specific mortality. <i>Br J Psychiatry.</i> 2001; 498-502.	1977-1980		
Finland	Räsänen S, Hakko H, Vilho K, Meyer-Rochow VB, Moring J. Excess mortality among long-stay psychiatric patients in Northern Finland. <i>Soc Psychiatry Psychiatr Epidemiol.</i> 2003; 38(6): 297-304.	1992-2000		
Finland	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). <i>ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries.</i> Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Finland	Turpeinen P. Outcome of drug abuse in a 20-year follow-up study of drug-experimenting schoolchildren in Finland. <i>Nord J Psychiatry.</i> 2001; 55(4): 263-70.	1971-1992		
Finland	Häkälä P, Rimpelä A, Salmiinen JJ, Virtanen SM, Rimpelä M. Back, neck, and shoulder pain in Finnish adolescents: national cross sectional surveys. <i>BMJ.</i> 2002; 325(7367): 743.	1991, 1996, 1999, 2001		
Finland	Heistaro S, Vartiainen E, Heliovaara M, Puska P. Trends of back pain in eastern Finland, 1972-1992, in relation to socioeconomic status and behavioral risk factors. <i>Am J Epidemiol.</i> 1998; 148(7): 671-82.	1982, 1987, 1992		
Finland	Leino PI, Berg MA, Puska P. Is back pain increasing? Results from national surveys in Finland during 1978/9-1992. <i>Scand J Rheumatol.</i> 1994; 23(5): 269-76.	1979-1992		
Finland	Shiri R, Solovieva S, Hugašvel-Pursiainen K, Taimela S, Saarikoski LA, Huupponen R, Viikari J, Raitakari OT, Viikari-Juntura E. The association between obesity and the prevalence of low back pain in young adults: the Cardiovascular Risk in Young Finns Study. <i>Am J Epidemiol.</i> 2008; 167(9): 1110-9.	2001		
Finland	Taimela S, Kujala UM, Salmiinen JJ, Viljanen T. The prevalence of low back pain among children and adolescents. A nationwide, cohort-based questionnaire survey in Finland. <i>Spine.</i> 1997; 22(10): 1132-6.	1993		
Finland	Nardone A, de Ory F, Carton M, Cohen D, van Damme P, Davidkin I, Rota MC, de Melker H, Mossong J, Slacikova M, Tischer A, Andrews N, Berbers G, Gabutti G, Gay N, Jones L, Jokinen S, Kafatos G, de Aragón MVM, Schneider F, Smetana Z, Vargova B, Vranckx R, Miller E. The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. <i>Vaccine.</i> 2007; 25(45): 7866-72.	1997-1998		
Finland	Koskineniemi M, Lappalainen M, Schmid DS, Rubtcova E, Loparev VN. Genotypic analysis of varicella-zoster virus and its seroprevalence in Finland. <i>Clin Vaccine Immunol.</i> 2007; 14(9): 1057-61.	1995-1996		
Finland	Aarnisalo J, Ilonen J, Vainionpää R, Volanen I, Kaitosaari T, Simell O. Development of antibodies against cytomegalovirus, varicella-zoster virus and herpes simplex virus in Finland during the first eight years of life: a prospective study. <i>Scand J Infect Dis.</i> 2003; 35(10): 750-3.	1989-1998		
Finland	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1995, 1997-2002, 2004, 2006		
Finland	Lahti E, Peltola V, Waris M, Virkki R, Rantakokko-Jalava K, Jalava J, Eerola E, Ruuskanen O. Induced sputum in the diagnosis of childhood community-acquired pneumonia. <i>Thorax.</i> 2009; 64(3): 252-7.	2006-2007	*	
Finland	Mäki-Torkko EM, Lindholm PK, Väyrynen MR, Leisti JT, Sorri MJ. Epidemiology of moderate to profound childhood hearing impairments in northern Finland. Any changes in ten years <i>Scand Audiol.</i> 1998; 27(2): 95-103.	1973-1992		
Finland	Vartiainen E, Kempinen P, Karjalainen S. Prevalence and etiology of bilateral sensorineural hearing impairment in a Finnish childhood population. <i>Int J Pediatr Otorhinolaryngol.</i> 1997; 41(2): 175-85.	1974-1987		
Finland	Gissler M, Järvelin MR, Louniala P, Hemminki E. Boys have more health problems in childhood than girls: follow-up of the 1987 Finnish birth cohort. <i>Acta Paediatr.</i> 1999; 88(3): 310-4.	1987-1994		
Finland	Heikura U, Taanila A, Olsen P, Hartikainen A-L, von Wendt L, Järvelin M-R. Temporal changes in incidence and prevalence of intellectual disability between two birth cohorts in Northern Finland. <i>Am J Ment Retard.</i> 2003; 108(1): 19-31.	1966, 1986		
Finland	Patja K, Iivanainen M, Vesala H, Oksanen H, Ruoppila I. Life expectancy of people with intellectual disability: a 35-year follow-up study. <i>J Intellect Disabil Res.</i> 2000; 44 (Pt 5): 591-9.	1957		
Finland	Käiriäinen R. Screening and prevalence of mental retardation in four Finnish birth cohorts. <i>Ups J Med Sci Suppl.</i> 1987; 41-6.	1970		
Finland	Rantakallio P, von Wendt L. Mental retardation and subnormality in a birth cohort of 12,000 children in Northern Finland. <i>Am J Ment Defic.</i> 1986; 90(4): 380-7.	1966		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Finland	Patja K, Mölsä P, Iivanainen M. Cause-specific mortality of people with intellectual disability in a population-based, 35-year follow-up study. <i>J Intellect Disabil Res.</i> 2001; 45(Pt 1): 30-40.	1962-1997		
Finland	Similä S, von Wendt L, Rantakallio P. Mortality of mentally retarded children to 17 years of age assessed in a prospective one-year birth cohort. <i>J Ment Defic Res.</i> 1986; 30(Pt 4): 401-5.	1967-1980		
Finland	Manninen P, Karvonen A-L, Huhtala H, Rasmussen M, Collin P. The epidemiology of inflammatory bowel diseases in Finland. <i>Scand J Gastroenterol.</i> 2010; 45(9): 1063-7.	1986-1999	*	†
Finland	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Finland	Löfgren E, Pouta A, von Wendt L, Tapanainen J, Isojärvi JTT, Järvelin M-R. Epilepsy in the northern Finland birth cohort 1966 with special reference to fertility. <i>Epilepsy Behav.</i> 2009; 14(1): 102-7.	1966-2004	*	†
Finland	Bouvier-Colle M-H, Mohangoo AD, Gissler M, Novak-Antolic Z, Vutuc C, Szamotulska K, Zeitlin J, Euro-Peristat Scientific Committee. What about the mothers? An analysis of maternal mortality and morbidity in perinatal health surveillance systems in Europe. <i>BJOG.</i> 2012; 119(7): 880-90.	2003-2004	*	
Finland	Lamminpää R, Vehviläinen-Julkunen K, Gissler M, Heinonen S. Preeclampsia complicated by advanced maternal age: a registry-based study on primiparous women in Finland 1997-2008. <i>BMC Pregnancy Childbirth.</i> 2012; 47.	1997-2008	*	
Finland	Krökki O, Bloigu R, Reunanen M, Remes AM. Increasing incidence of multiple sclerosis in women in Northern Finland. <i>Mult Scler.</i> 2011; 17(2): 133-8.	1992-2007	*	
Finland	Sillanpää M, Jalava M, Kaleva O, Shinnar S. Long-term prognosis of seizures with onset in childhood. <i>N Engl J Med.</i> 1998; 338(24): 1715-22.	1961-1964	*	†
Finland	Keränen T, Riekkinen PJ, Sillanpää M. Incidence and prevalence of epilepsy in adults in eastern Finland. <i>Epilepsia.</i> 1989; 30(4): 413-21.	1975-1979	*	
Finland	Wendt L, Rantakallio P, Saukkonen A, Mäkinen H. Epilepsy and associated handicaps in a 1 year birth cohort in Northern Finland. <i>Eur J Pediatr.</i> 1985; 144(2): 149-51.	1966-1980	*	
Finland	Eriksson KJ, Koivikko MJ. Prevalence, classification, and severity of epilepsy and epileptic syndromes in children. <i>Epilepsia.</i> 1997; 38(12): 1275-82.	1992	*	†
Finland	Sillanpää M. Epilepsy in children: prevalence, disability, and handicap. <i>Epilepsia.</i> 1992; 33(3): 444-9.	1980	*	
Finland	Fröjd S, Marttunen M, Pelkonen M, von der Pahlen B, Kaltiala-Heino R. Adult and peer involvement in help-seeking for depression in adolescent population: a two-year follow-up in Finland. <i>Soc Psychiatry Psychiatr Epidemiol.</i> 2007; 42(12): 945-52.	2003, 2005		
Finland	Jylhä P, Isometsä E. The relationship of neuroticism and extraversion to symptoms of anxiety and depression in the general population. <i>Depress Anxiety.</i> 2006; 23(5): 281-9.	2003		
Finland	Pahkala K, Kesti E, Königäs-Saviaro P, Laipalla P, Kiveli SL. Prevalence of depression in an aged population in Finland. <i>Soc Psychiatry Psychiatr Epidemiol.</i> 1995; 30(3): 99-106.	1989-1990		
Finland	Pulka T, Pahkala K, Laipalla P, Kiveli SL. Major depression as a predictor of premature deaths in elderly people in Finland: a community study. <i>Acta Psychiatr Scand.</i> 1998; 97(6): 408-11.	1984-1990		
Finland	Wasén E, Isoaho R, Mattila K, Vahlberg T, Kiveli SL, Irjala K. Estimation of glomerular filtration rate in the elderly: a comparison of creatinine-based formulae with serum cystatin C. <i>J Intern Med.</i> 2004; 256(1): 70-8.	1998-1999		
Finland	Keski-Rahkonen A, Hoek HW, Susser ES, Linna MS, Sihvola E, Raevuori A, Bulik CM, Kaprio J, Rissanen A. Epidemiology and course of anorexia nervosa in the community. <i>Am J Psychiatry.</i> 2007; 164(8): 1259-65.	1993-2002	*	
Finland	Kielinen M, Linna S-L, Moilanen I. Autism in Northern Finland. <i>Eur Child Adolesc Psychiatry.</i> 2000; 9(3): 162-7.	1996		
Finland	Kiviniemi M, Suvisaari J, Pirkola S, Häkkinen U, Isohanni M, Hakko H. Regional differences in five-year mortality after a first episode of schizophrenia in Finland. <i>Psychiatr Serv.</i> 2010; 61(3): 272-9.	1995-2001	*	
Finland	Talasilahti T, Alanen H-M, Hakko H, Isohanni M, Häkkinen U, Leinonen E. Mortality and causes of death in older patients with schizophrenia. <i>Int J Geriatr Psychiatry.</i> 2012; 27(11): 1131-7.	1999-2008	*	
Finland	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Finland	Heinonen PK, Miettinen A. Laparoscopic study on the microbiology and severity of acute pelvic inflammatory disease. <i>Eur J Obstet Gynecol Reprod Biol.</i> 1994; 57(2): 85-9.	1983-1988	*	†
Finland	Laitinen A, Koskinen S, Härkinen T, Reunanen A, Laatikainen L, Aromaa A. A nationwide population-based survey on visual acuity, near vision, and self-reported visual function in the adult population in Finland. <i>Ophthalmology.</i> 2005; 112(12): 2227-37. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2000-2001		
Finland	Korodi Z, Wang X, Tedeschi R, Knekt P, Dillner J. No serological evidence of association between prostate cancer and infection with herpes simplex virus type 2 or human herpesvirus type 8: a nested case-control study. <i>J Infect Dis.</i> 2005; 191(12): 2008-11.	1968-1972	*	
Finland	Alanen A, Kahala K, Vahlberg T, Koskela P, Vainionpää R. Seroprevalence, incidence of prenatal infections and reliability of maternal history of varicella zoster virus, cytomegalovirus, herpes simplex virus and parvovirus B19 infection in South-Western Finland. <i>BJOG.</i> 2005; 112(1): 50-6.	2000	*	
Finland	Arvaja M, Lehtinen M, Koskela P, Lappalainen M, Paavonen J, Vesikari T. Serological evaluation of herpes simplex virus type 1 and type 2 infections in pregnancy. <i>Sex Transm Infect.</i> 1999; 75(3): 168-71.	1993-1997	*	
Finland	Azzopardi DV, Stroh B, Edwards AD, Dyet L, Halliday HL, Juszczak E, Kapellou O, Levene M, Marlow N, Porter E, Thoresen M, Whitelaw A, Brocklehurst P, TOBY Study Group. Moderate hypothermia to treat perinatal asphyxial encephalopathy. <i>N Engl J Med.</i> 2009; 361(14): 1349-58.	2002-2006	*	†
Finland	Kubin M, Tossavainen P, Hannula V, Lahti S, Hautala N, Falck A. Prevalence of retinopathy in Finnish children and adolescents with type 1 diabetes: a cross-sectional population-based retrospective study. <i>Arch Dis Child.</i> 2011; 96(10): 963-8.	2006-2008		
Finland	Bäckström J, Saarijärvi S, Helenius H. The prognosis of Finnish female anorexia patients. <i>Nord J Psychiatry.</i> 1997; 51: 59-60.	1980-1995	*	
Finland	Isomaa R, Isomaa A-L, Marttunen M, Kaltiala-Heino R, Björkqvist K. The prevalence, incidence and development of eating disorders in Finnish adolescents: a two-step 3-year follow-up study. <i>Eur Eat Disord Rev.</i> 2009; 17(3): 199-207.	2005	*	
Finland	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), National Research and Development Centre for Welfare and Health (STAKES) (Finland). Finland National Report to the EMCDDA 2006. National Research and Development Centre for Welfare and Health (STAKES) (Finland), 2006.	1997-1999, 2001-2002, 2005	*	
Finland	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant.</i> 1988; 3(6): 714-27.	1985		
Finland	Van Dijk PC, Jager KJ, Stengel B, Grönhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). <i>Kidney Int.</i> 2005; 67(4): 1489-99.	1991-1992, 1999-2000		
Finland	Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. <i>Nephrol Dial Transplant.</i> 2003; 18(9): 1824-33.	1990-1991, 1998-1999		
Finland	European Surveillance of Congenital Anomalies (EUROCAT). Finland EUROCAT Prevalence Tables. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	1994-2010		
Finland	Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. <i>J Clin Endocrinol Metab.</i> 2008; 93(4): 1408-11.	2005		
Finland	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Gilst WH van, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J.</i> 2003; 24(5): 442-63.	2000-2001		
Finland	Ajwani S, Ainamo A. Periodontal conditions among the old elderly: five-year longitudinal study. <i>Spec Care Dentist.</i> 2001; 21(2): 45-51.	1991-1996		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Finland	Tuominen R, Reunanen A, Paunio M, Paunio I, Aromaa A. Oral Health Indicators Poorly Predict Coronary Heart Disease Deaths. <i>J Dent Res</i> . 2003; 82(9): 713-8.	1978-1990		
Finland	Hietanen A, Era P, Sorri M, Eino Heikkinen E. Changes in hearing in 80-year-old people: a 10-year follow-up study. <i>Int J Audiol</i> . 2004; 43(3): 126-35.	1990		
Finland	Uimonen S, Huttunen K, Jounio-Ervasi K, Sorri M. Do we know the real need for hearing rehabilitation at the population level? Hearing impairments in the 5- to 75-year-old cross-sectional Finnish population. <i>Br J Audiol</i> . 1999; 33(1): 53-9.	1997		
Finland	Uimonen S, Mäki-Torkko E, Jounio-Ervasi K, Sorri M. Hearing in 55 to 75 year old people in northern Finland – a comparison of two classifications of hearing impairment. <i>Acta Otolaryngol Suppl</i> . 1997; 69-70.	1997		
Finland	Halme JT, Seppä K, Alho H, Pirkola S, Poikolainen K, Lönnqvist J, Aalto M. Hazardous drinking: prevalence and associations in the Finnish general population. <i>Alcohol Clin Exp Res</i> . 2008; 32(9): 1615-22.	2000-2001		
Finland	Pirkola SP, Poikolainen K, Lönnqvist JK. Currently active and remitted alcohol dependence in a nationwide adult general population – results from the Finnish Health 2000 study. <i>Alcohol Alcohol</i> . 2006; 41(3): 315-20.	2000-2001		
Finland	Pirkola S, Saarni S, Suvisaari J, Elovainio M, Partonen T, Aalto A-M, Honkonen T, Perälä J, Lönnqvist J. General health and quality-of-life measures in active, recent, and comorbid mental disorders: a population-based health 2000 study. <i>Compr Psychiatry</i> . 2009; 50(2): 108-14.	2000-2001		
Finland	Poikolainen K. Risk factors for alcohol dependence: a questionnaire survey. <i>Alcohol Clin Exp Res</i> . 1997; 21(6): 957-61.	1996		
Finland	Sumelahti ML, Hakama M, Elovaara I, Pukkala E. Causes of death among patients with multiple sclerosis. <i>Mult Scler</i> . 2010; 16(2): 1437-42.	1964-1993	*	
Finland	Kinnunen E, Junntila O, Haukka J, Hovi T. Nationwide oral poliovirus vaccination campaign and the incidence of Guillain-Barré Syndrome. <i>Am J Epidemiol</i> . 1998; 147(1): 69-73.	1981-1986		
Finland	Rantala H, Uhari M, Niemelä M. Occurrence, clinical manifestations, and prognosis of Guillain-Barré syndrome. <i>Arch Dis Child</i> . 1991; 66(6): 706-9.	1980-1986		†
Finland	Dietz A, Löppönen T, Valtonen H, Hyvärinen A, Löppönen H. Prevalence and etiology of congenital or early acquired hearing impairment in Eastern Finland. <i>Int J Pediatr Otorhinolaryngol</i> . 2009; 73(10): 1353-7.	1988-2002	*	
Finland	Hannula S, Mäki-Torkko E, Majamaa K, Sorri M. Hearing in a 54- to 66-year-old population in northern Finland. <i>Int J Audiol</i> . 2010; 49(12): 920-7.	2003-2004	*	
Finland	Pohvikoski T, Sulkava R, Rastas S, Sutela A, Niinistö L, Notkola IL, Verkkoniemi A, Viramo P, Juva K, Haltia M. Incidence of dementia in very elderly individuals: a clinical, neuropathological and molecular genetic study. <i>Neuroepidemiology</i> . 2006; 26(2): 76-82.	1991-2001		
Finland	Honkinen M, Lahti E, Österback R, Ruuskanen O, Waris M. Viruses and bacteria in sputum samples of children with community-acquired pneumonia. <i>Clin Microbiol Infect</i> . 2012; 18(3): 300-7.	2006-2007	*	
Finland	Wang Y, Tuomilehto J, Jousilahti P, Antikainen R, Mähönen M, Männistö S, Katzmarzyk PT, Hu G. Coffee consumption and the risk of heart failure in Finnish men and women. <i>Heart</i> . 2011; 97(1): 44-8.	1980-2010		
Finland	Lehtinen M, Dillner J, Knekt P, Luostarinen T, Aromaa A, Kirnbauer R, Koskela P, Paavonen J, Peto R, Schiller JT, Hakama M. Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. <i>BMJ</i> . 1996; 312(7030): 537-9.	1991	*	
Finland	Pebody RG, Andrews N, Brown D, Gopal R, De Melker H, François G, Gatcheva N, Hellenbrand W, Jokinen S, Klavs I, Kojouharova M, Kortbeek T, Kriz B, Prose NC, Roubalova K, Teocharov P, Thierfelder W, Valle M, Van Damme P, Vranckx R. The seroprevalence of herpes simplex virus type 1 and 2 in Europe. <i>Sex Transm Infect</i> . 2004; 80(3): 185-91.	1997-1998	*	
Finland	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland: World Health Organization (WHO).	2005-2008	*	
Finland	Tommiska V, Heinonen K, Lehtonen L, Renlund M, Saarela T, Tammela O, Virtanen M, Fellman V. No Improvement in Outcome of Nationwide Extremely Low Birth Weight Infant Populations Between 1996-1997 and 1999-2000. <i>Pediatrics</i> . 2007; 119(1): 29-36.	1997, 2000	*	†
Finland	Kilpi T, Peltola H, Jauhiainen T, Kallio MJ. Oral glycerol and intravenous dexamethasone in preventing neurologic and audiologic sequelae of childhood bacterial meningitis. <i>Pediatr Infect Dis J</i> . 1995; 14(4): 270-8.	1987-1991		†
Finland	Valmari P, Kataja M, Peltola H. Invasive haemophilus influenzae and meningococcal infections in Finland. A climatic, epidemiologic and clinical approach. <i>Scand J Infect Dis</i> . 1987; 19(1): 19-27.	1978		
Finland	Osterberg T, Era P, Gause-Nilsson I, Steen B. Dental state and functional capacity in 75-year-olds in three Nordic localities. <i>J Oral Rehabil</i> . 1995; 22(8): 653-60.	1993		†
Finland	Hämäläinen P, Meurman JH, Keskinen M, Heikkinen E. Relationship between dental health and 10-year mortality in a cohort of community-dwelling elderly people. <i>Eur J Oral Sci</i> . 2003; 111(4): 291-6.	1990-2000		
Finland	Ajwani S, Mattila KJ, Tilvis RS, Ainamo A. Periodontal disease and mortality in an aged population. <i>Spec Care Dentist</i> . 2003; 23(4): 125-30.	1990-1999		
Finland	Koskineniemi M, Vaheiri A. Effect of measles, mumps, rubella vaccination on pattern of encephalitis in children. <i>Lancet</i> . 1989; 1(8628): 31-4.	1968-1987		
Finland	Ponka A, Pettersson T. The incidence and aetiology of central nervous system infections in Helsinki in 1980. <i>Acta Neurol Scand</i> . 1982; 66(5): 529-35.	1980		
Finland	Koskineniemi M, Korppi M, Mustonen K, Rantala H, Muttillainen M, Herrgård E, Ukkonen P, Vaheiri A. Epidemiology of encephalitis in children. A prospective multicentre study. <i>Eur J Pediatr</i> . 1997; 156(7): 541-5.	1993-1994		
Finland	Kupila L, Vuorinen T, Vainionpää R, Hukkanen V, Marttila RJ, Kotilainen P. Etiology of aseptic meningitis and encephalitis in an adult population. <i>Neurology</i> . 2006; 66(1): 75-80.	1999-2003		
Finland	Salminen JJ, Pentti J, Terho P. Low back pain and disability in 14-year-old schoolchildren. <i>Acta Paediatr</i> . 1992; 81(12): 1035-9.	1989-1991	*	
Finland	Alla F, Zannad F, Filippatos G. Epidemiology of acute heart failure syndromes. <i>Heart Fail Rev</i> . 2007; 12(2): 91-5.	2004		
Finland	Kotila SM, Virolainen A, Snellman M, Ibrahim S, Jalava J, Lyytikäinen O. Incidence, case fatality and genotypes causing <i>Clostridium difficile</i> infections, Finland, 2008. <i>Clin Microbiol Infect</i> . 2011; 17(6): 888-93.	2008	*	
Finland	Turunen P, Kolho K-L, Auvinen A, Iltanen S, Huhtala H, Ashorn M. Incidence of inflammatory bowel disease in Finnish children, 1987-2003. <i>Inflamm Bowel Dis</i> . 2006; 12(8): 677-83.	1987-2003		
Finland	Hannuksela-Svahn A, Pukkala E, Karvonen J. Basal cell skin carcinoma and other non-melanoma skin cancers in Finland from 1956 through 1995. <i>Arch Dermatol</i> . 1999; 135(7): 781-6.	1991-1995		
Finland	Trichopoulos D, Bania C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overvad K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PHM, Lund E, Quirós JR, González CA, Sanchez Perez M-J, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu L, Chuang S-C, Murphy N, Boffetta P, Trichopoulou A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. <i>J Natl Cancer Inst</i> . 2011; 103(22): 1686-95.	1992-2006	*	
Finland	Pohjanpelto P, Lahdensivu R. Rapid decline of hepatitis A in Finland. <i>Scand J Infect Dis</i> . 1984; 16(3): 229-33.	1970, 1982-1983		
Finland	Von Hertzen LC, Laatikainen T, Mäkelä MJ, Jousilahti P, Kosunen TU, Petays T, Pussinen PJ, Haahela T, Vartiainen E. Infectious burden as a determinant of atopy – a comparison between adults in Finnish and Russian Karelia. <i>Int Arch Allergy Immunol</i> . 2006; 140(2): 89-95.	1997		
Finland	Havulinna AS, Pääkkönen R, Karvonen M, Salomaa V. Geographic Patterns of Incidence of Ischemic Stroke and Acute Myocardial Infarction in Finland During 1991-2003. <i>Ann Epidemiol</i> . 2008; 18(3): 206-13.	1991-2003		
Finland	Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, Tolonen H, Ruokokoski E. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. <i>Lancet</i> . 1999; 353(9164): 1547-57.	1980-1995		
Finland	National Institute for Health and Welfare (Finland). Finland National Cardiovascular Diseases Register.	1991, 2005		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Finland	Rantala ML. Causes and outcome of infertility in previously unexamined couples. <i>Acta Obstet Gynecol Scand.</i> 1988; 67(5): 429-32.	1986-1988	*	
Finland	Meretoja A. PERFECT Stroke: PERformance, Effectiveness, and Costs of Treatment Episodes in Stroke [dissertation]. Helsinki, Finland: University of Helsinki; 2011.	1999, 2008	*	
Finland	Jussila A, Virta LJ, Salomaa V, Maki J, Jula A, Färkkilä MA. High and increasing prevalence of inflammatory bowel disease in Finland with a clear North-South difference. <i>J Crohns Colitis.</i> 2013; 7(7): e256-62.	1993	*	
Finland	Manderbacka K, Hetemaa T, Keskimäki I, Luukkainen P, Koskinen S, Reunanen A. Are there socioeconomic differences in myocardial infarction event rates and fatality among patients with angina pectoris? <i>J Epidemiol Community Health.</i> 2006; 60(5): 442-447.	1995-1998	*	
Finland	Zeitlan J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT; 2008. Available from: http://www.perinataleaudit.nl/downloads/bestand/649/peristat-ii-2008-	2004		†
Finland	Tommsika V, Heinonen K, Kero P, Pokela M-L, Tammela O, Järvenpää A-L, Salokorpi T, Virtanen M, Fellman V. A national two year follow up study of extremely low birthweight infants born in 1996-1997. <i>Arch. Dis. Child. Fetal Neonatal Ed.</i> 2003 Jan;88(1):F29-35.	1996, 1999, 2004		†
Finland	Finnish Registry for Kidney Diseases Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA); 2012.	2010	*	
Finland	Finnish Registry for Kidney Diseases Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA); 2013.	2011	*	
Finland	Mikkola K, Ritari N, Tommsika V, Salokorpi T, Lehtonen L, Tammela O, Pääkkönen L, Olsen P, Korkman M, Fellman V. Neurodevelopmental outcome at 5 years of age of a national cohort of extremely low birth weight infants who were born in 1996-1997. <i>Pediatrics.</i> 2005; 116(6): 1391-400.	1996		†
Finland	Finland Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Finland	Finnish Congenital Anomaly Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). <i>World Atlas of Birth Defects.</i> 2nd ed. Geneva, Switzerland: World Health Organization (WHO); 2003.	1993-1998	*	
Finland	Finnish Register of Congenital Malformations Data 1980 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. <i>Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems.</i> Amsterdam, Netherlands: Elsevier; 1991.	1980	*	
Finland	Finnish Register of Congenital Malformations Data 1983 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. <i>Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems.</i> Amsterdam, Netherlands: Elsevier; 1991.	1983	*	
Finland	Finnish Register of Congenital Malformations Data 1986 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. <i>Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems.</i> Amsterdam, Netherlands: Elsevier; 1991.	1986	*	
Finland	Finnish Register of Congenital Malformations Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. <i>International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009.</i> Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Finland	Finnish Register of Congenital Malformations Data 2001 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. <i>International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003.</i> Rome, Italy: International Centre on Birth Defects.	2001	*	
Finland	Finnish Register of Congenital Malformations Data 1984 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. <i>Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems.</i> Amsterdam, Netherlands: Elsevier; 1991.	1984	*	
Finland	Finnish Register of Congenital Malformations Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. <i>International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010.</i> Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research; 2011.	2008	*	
Finland	Finnish Register of Congenital Malformations Data 1982 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. <i>Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems.</i> Amsterdam, Netherlands: Elsevier; 1991.	1982	*	
Finland	Finnish Register of Congenital Malformations Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. <i>International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011.</i> Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research; 2012.	2009	*	
Finland	Finnish Register of Congenital Malformations Data 1981 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. <i>Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems.</i> Amsterdam, Netherlands: Elsevier; 1991.	1981	*	
Finland	Finnish Register of Congenital Malformations Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. <i>International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006.</i> Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research; 2007.	2004	*	
Finland	Finnish Register of Congenital Malformations Data 1987 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. <i>Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems.</i> Amsterdam, Netherlands: Elsevier; 1991.	1987	*	
Finland	Finnish Register of Congenital Malformations Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. <i>International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012.</i> Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research; 2013.	2010	*	
Finland	Finnish Register of Congenital Malformations Data 1985 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. <i>Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems.</i> Amsterdam, Netherlands: Elsevier; 1991.	1985	*	
Finland	Finnish Register of Congenital Malformations Data 1988 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. <i>Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems.</i> Amsterdam, Netherlands: Elsevier; 1991.	1988	*	
Finland	Finnish Register of Congenital Malformations Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. <i>International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005.</i> Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research; 2007.	2003	*	
France	WHO Regional Office for Europe (EURO-WHO). <i>European Hospital Morbidity Database.</i> Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2005		
France	France Vital Registration - Deaths 1980 ICD9 as it appears in World Health Organization (WHO). <i>World Health Organization (WHO). WHO Mortality Database Version July 2012.</i> Geneva, Switzerland: World Health Organization (WHO); 2012.	1980		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
France	France Vital Registration - Deaths 1982 ICD9 as it appears in World Health Organization (WHO). World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1982		
France	France Vital Registration - Deaths 1983 ICD9 as it appears in World Health Organization (WHO). World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1983		
France	France Vital Registration - Deaths 1984 ICD9 as it appears in World Health Organization (WHO). World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1984		
France	France Vital Registration - Deaths 1985 ICD9 as it appears in World Health Organization (WHO). World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1985		
France	France Vital Registration - Deaths 1992 ICD9 as it appears in World Health Organization (WHO). World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1992		
France	France Vital Registration - Deaths 1994 ICD9 as it appears in World Health Organization (WHO). World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1994		
France	France Vital Registration - Deaths 1996 ICD9 as it appears in World Health Organization (WHO). World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1996		
France	France Vital Registration - Deaths 1997 ICD9 as it appears in World Health Organization (WHO). World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1997		
France	France Vital Registration - Deaths 1999 ICD9 as it appears in World Health Organization (WHO). World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1999		
France	France Vital Registration - Deaths 2002 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2002	*	
France	France Vital Registration - Deaths 2003 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2003	*	
France	World Health Organization (WHO). France World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		
France	National Institute for Demographic Studies (France), National Institute of Statistics and Economic Studies (INSEE) (France), United Nations Economic Commission for Europe (UNECE). France Fertility and Family Survey 1994. Geneva, Switzerland: United Nations Economic Commission for Europe (UNECE).	1994		
France	Bardakjian-Michau J, Bahuuu M, Hurtrel D, Godart C, Riou J, Mathis M, Goossens M, Badens C, Ducrocq R, Elion J, Perini JM. Neonatal screening for sickle cell disease in France. <i>J Clin Pathol.</i> 2009; 62(1): 31-3.	1996-2007		
France	Thalassaemia International Federation, World Health Organization (WHO). Management of Haemoglobin Disorders: Report of a Joint WHO-TIF Meeting, Nicosia, Cyprus, 16-18 November 2007. Geneva, Switzerland: World Health Organization (WHO), 2008.	2004		
France	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. <i>Scand J Clin Lab Invest.</i> 2007; 67(1): 39-69.	1988, 2006		
France	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1988, 2003, 2006		
France	Orsini A, Vovan L, Lena-Russo D, Maarouf I, Merono F, Jaujou M, Nebbia D, Fruite B. School screening of hemoglobinopathies in the Marseilles area An analytic study of 35,289 tests. <i>Arch Fr Pediatr.</i> 1987; 44(6): 455-9.	1977-1985		
France	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	2009		†
France	Misery L, Rahhali N, Duhamel A, Taieb C. Epidemiology of pruritus in France. <i>Acta Derm Venereol.</i> 2012; 92(5): 421-2.	2010		
France	Bejot Y, Rouaud O, Durier J, Caillier M, Marie C, Freysz M, Yeguayan J-M, Chantegret A, Osseby G, Moreau T, Giroud M. Decrease in the Stroke Case Fatality Rates in a French Population-Based Twenty-Year Study. <i>Cerebrovasc Dis.</i> 2007; 24(5): 439-44.	1985-2004		
France	Giroud M, Lemesle M, Gouyon JB, Nivelon JL, Milan C, Dumas R. Cerebrovascular disease in children under 16 years of age in the city of Dijon, France: a study of incidence and clinical features from 1985 to 1993. <i>J Clin Epidemiol.</i> 1995; 48(11): 1343-8.	1985-1993		
France	Wolfe CDA, Giroud M, Kolominsky-Rabas P, Dundas R, Lemesle M, Heuschmann P, Rudd A. Variations in Stroke Incidence and Survival in 3 Areas of Europe. <i>Stroke.</i> 2000; 31(9): 2074-9.	1995-1997		
France	Poli F, Dreno B, Verschoore M. An epidemiological study of acne in female adults: results of a survey conducted in France. <i>J Eur Acad Dermatol Venereol.</i> 2001; 15(6): 541-5.	1998		
France	Zannad F, Briancon S, Juilliere Y, Mertes P-M, Villemot J-P, Alla F, Virion J-M. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL study. <i>J Am Coll Cardiol.</i> 1999; 33(3): 734-42.	1993-1995		
France	Forster J, Guarino A, Parez N, Moraga F, Román E, Mory O, Tozzi AE, de Aguilera AL, Wahn U, Graham C, Berner R, Ninan T, Barberousse C, Meyer N, Soriano-Gabarró M. Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of age. <i>Pediatrics.</i> 2009; 123(3): e393-400.	2005-2006		
France	Demyttenaere K, Bruffaerts R, Lee S, Posada-Villa J, Kovess V, Angermeyer MC, Levinson D, de Girolamo G, Nakane H, Mneimneh Z, Lara C, de Graaf R, Scott KM, Gureje O, Stein DJ, Haro JM, Bromet EJ, Kessler RC, Alonso J, Von Korff M. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. <i>Pain.</i> 2007; 129(3): 332-42.	2001-2002		
France	Bouvier-Colle MH, Ancel PY, Varnoux N, Salanave B, Fernandez H, Papiernik E, Bréart G. Intensive care of pregnant and puerperal women. Characteristics of patients and health management structures. <i>J Gynecol Obstet Biol Reprod (Paris).</i> 1997; 26(1): 47-56.	1991-1992		
France	Girard F, Burlot G, Bayoumeu F, Fresson J, Bouvier-Colle MH, Boutroy JL. Severe complications of pregnancy and delivery: the situation in Lorraine based on the European investigation. <i>J Gynecol Obstet Biol Reprod (Paris).</i> 2001; 30(6 Suppl): S10-17.	1995		
France	Chantry AA, Deneux-Tharaux C, Cans C, Ego A, Quantin C, Bouvier-Colle M-H. Hospital discharge data can be used for monitoring procedures and intensive care related to severe maternal morbidity. <i>J Clin Epidemiol.</i> 2011; 64(9): 1014-22.	2006-2007		
France	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2002-2003, 2005-2009		
France	Moreau T, Manceau E, Lucas B, Lemesle M, Urbinelli R, Giroud M. Incidence of multiple sclerosis in Dijon, France: a population-based ascertainment. <i>Neurol Res.</i> 2000; 22(2): 156-9.	1993-1997		
France	Berr C, Puel J, Claret M, Ruidavets JB, Mas JL, Alperovitch A. Risk factors in multiple sclerosis: a population-based case-control study in Hautes-Pyrénées, France. <i>Acta Neurol Scand.</i> 1989; 80(1): 46-50.	1983		
France	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
France	Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. <i>Diabetologia.</i> 1996; 39(11): 1377-84.	1993-1995		
France	Delcourt C, Vauzelle-Kervroedan F, Cathelineau G, Papoz L. Low prevalence of long-term complications in non-insulin-dependent diabetes mellitus in France: a multicenter study. CODIAB-INSERM-ZENECA Pharma Study Group. <i>J Diabetes Complicat.</i> 1998; 12(2): 88-95.	1989-1992		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
France	Gourdy P, Ruidavets JB, Ferrieres J, Ducimetiere P, Amouyel P, Arveiler D, Cottel D, Lamamy N, Bingham A, Hanaire-Broustin H. MONICA Study. Prevalence of type 2 diabetes and impaired fasting glucose in the middle-aged population of three French regions - the MONICA study 1995-97. <i>Diabetes Metab.</i> 2001; 27(3): 347-58.	1996		
France	Pierrat V, Haouari N, Liska A, Thomas D, Subtil D, Truffert P, on b. Prevalence, causes, and outcome at 2 years of age of newborn encephalopathy: population based study. <i>Arch Dis Child Fetal Neonatal Ed.</i> 2005; 90(3): F257-F261.	2000		†
France	Rubino A, Rousculp MD, Davis K, Wang J, Girach A. Diagnosed diabetic retinopathy in France, Italy, Spain, and the United Kingdom. <i>Prim Care Diabetes.</i> 2007; 1(2): 75-80.	2006		
France	Krankimel N, Soussan V, Beauchet A, Duhamel A, Saïag P, Chevallier B, Mahé E. High frequency, diversity and severity of skin diseases in a paediatric emergency department. <i>J Eur Acad Dermatol Venereol.</i> 2010; 24(12): 1468-75.	2006		
France	Defay R, Delcourt C, Ranvier M, Lacroux A, Papoz L. Relationships between physical activity, obesity and diabetes mellitus in a French elderly population: the POLA study. <i>Pathologies Oculaires liées à l'Age. Int J Obes Relat Metab Disord.</i> 2001; 25(4): 512-8.	1996		
France	Bourdrel-Marchasson I, Helmer C, Barberger-Gateau P, Peuchant E, Février B, Ritchie K, Dartigues JF. Characteristics of undiagnosed diabetes in community-dwelling French elderly: the 3C study. <i>Diabetes Res Clin Pract.</i> 2007; 76(2): 257-64.	2000		
France	Henry P, Michel P, Brochet B, Dartigues JF, Tison S, Salamon R, GRIM R. A nationwide survey of migraine in France: prevalence and clinical features in adults. <i>Cephalalgia.</i> 1992; 12(4): 229-237.	1990		
France	Lantéri-Minet M, Valade D, Géraud G, Chautard MH, Lucas C. Migraine and probable migraine—results of FRAMIG 3, a French nationwide survey carried out according to the 2004 IHS classification. <i>Cephalalgia.</i> 2005; 25(12): 1146-58.	2003		
France	Henry P, Auray JP, Gaudin AF, Dartigues JF, Duru G, Lantéri-Minet M, Lucas C, Pradalier A, Chazot G, El Hasnaoui A. Prevalence and clinical characteristics of migraine in France. <i>Neurology.</i> 2002; 59(2): 232-7.	1999		
France	Lantéri-Minet M, Auray JP, El Hasnaoui A, Dartigues JF, Duru G, Henry P, Lucas C, Pradalier A, Chazot G, Gaudin AF. Prevalence and description of chronic daily headache in the general population in France. <i>Pain.</i> 2003; 102(1-2): 143-9.	1999		
France	Guillemin F, Rat AC, Mazieres B, Pouchot J, Fautrel B, Euler-Ziegler L, Fardellone P, Morvan J, Roux CH, Verrouli E, Saraux A, Coste J. 3000 Osteoarthritis group. Prevalence of symptomatic hip and knee osteoarthritis: a two-phase population-based survey. <i>Osteoarthritis Cartilage.</i> 2011; 19(11): 1314-22.	2007-2009		
France	Roux CH, Saraux A, Mazieres B, Pouchot J, Morvan J, Fautrel B, Testa J, Fardellone P, Rat AC, Coste J, Guillemin F, Euler-Ziegler L. KHOALA Osteoarthritis Group. Screening for hip and knee osteoarthritis in the general population: predictive value of a questionnaire and prevalence estimates. <i>Ann Rheum Dis.</i> 2008; 67(10): 1406-11.	2005		
France	Annesi-Maesano I, Hulín M, Lavaud F, Raherison C, Kopferschmitt C, de Blay F, Charpin DA, Denis C. Poor air quality in classrooms related to asthma and rhinitis in primary schoolchildren of the French 6 Cities Study. <i>Thorax.</i> 2012; 67(8): 682-8.	2010-2012	*	
France	Delmas M-C, Guignon N, Chee CC, Fuhrman C, Herbet J-B, Gonzalez L. Asthma and major depressive episode in adolescents in France. <i>J Asthma.</i> 2011; 48(6): 640-6.	2003-2004	*	
France	Delmas M-C, Guignon N, Leynaert B, Annesi-Maesano I, Com-Ruelle L, Gonzalez L, Fuhrman C. Prevalence and control of asthma in young children in France. <i>Rev Mal Respir.</i> 2012; 29(5): 688-96.	2005-2006	*	
France	Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, Gjornmark M, Forsberg B, Gunnbjornsdottir M, Minov J, Brozek G, Dahlen SE, Toskala E, Kowalski ML, Olze H, Howarth P, Krämer U, Baelum J, Loureiro C, Kasper L, Bousquet PJ, Bousquet J, Bachert C, Fokkens W, Burney P. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. <i>Allergy.</i> 2012; 67(10): 91-8.	2008-2009	*	
France	Annesi-Maesano I, Mourad C, Daurès J-P, Kalaboka S, Godard P. Time trends in prevalence and severity of childhood asthma and allergies from 1995 to 2002 in France. <i>Allergy.</i> 2009; 64(5): 798-800.	1995, 2002	*	
France	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. <i>Community Dent Oral Epidemiol.</i> 1991; 19(2): 72-3.	1987		
France	Bercy P, Meurisse JB, Lambert ML, Bertrand F, Tonglet R. [Periodontal health and care needs in a sample of the Belgian population]. <i>Rev Belge Med Dent (1984).</i> 2002; 57(3): 206-14.	1997	*	
France	Berthet S, Monpoux F, Soummer A-M, Bérard E, Sarles J, Badens C. Neonatal screening for sickle cell disease at the Nice University Hospital: the last 8 years. <i>Arch Pediatr.</i> 2010; 17(12): 1652-6.	2000-2008	*	
France	Wolkenstein P, Revuz J, Roujeau JC, Bonnelye G, Grob JJ, Bastuji-Garin S. French Society of Dermatology. Psoriasis in France and associated risk factors: results of a case-control study based on a large community survey. <i>Dermatology (Basel).</i> 2009; 218(2): 103-9.	2005	*	
France	Zimmermann A, Bernuit D, Gerlinger C, Schaeffers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. <i>BMC Womens Health.</i> 2012; 6.	2009	*	
France	Giaquinto C, van Damme P, REVEAL Study Group. Age distribution of paediatric rotavirus gastroenteritis cases in Europe: the REVEAL study. <i>Scand J Infect Dis.</i> 2010; 42(2): 142-7.	2004-2005	*	
France	Larrot M, Bon F, El Hajje MJ, Aho S, Wolfier M, Girardon H, Kaplan J, Marc E, Raymond J, Lebon P, Pothier P, Cendrel D. Epidemiology and clinical features of gastroenteritis in hospitalised children: prospective survey during a 2-year period in a Parisian hospital, France. <i>Eur J Clin Microbiol Infect Dis.</i> 2011; 30(3): 361-8.	2001-2004	*	
France	Letenneur L, Gilleron V, Commenges D, Helmer C, Orgogozo J, Dartigues J. Are sex and educational level independent predictors of dementia and Alzheimer's disease? Incidence data from the PAQUID project. <i>J Neurol Neurosurg Psychiatry.</i> 1999; 66(2): 177-83.	1989-1995		
France	Obadia Y, Rotily M, Degrand-Guillaud A, Guelain J, Ceccaldi M, Severo C, Poncet M, Alperovitch A. The PREMAP Study: prevalence and risk factors of dementia and clinically diagnosed Alzheimer's disease in Provence, France. Prevalence of Alzheimer's Disease in Provence. <i>Eur J Epidemiol.</i> 1997; 13(3): 247-53.	1988-1989, 1991		
France	Béjot Y, Benzenine E, Lorgis L, Zeller M, Aubé H, Giroud M, Cottin Y, Quantin C. Comparative analysis of patients with acute coronary and cerebrovascular syndromes from the national French hospitalization health care system database. <i>Neuroepidemiology.</i> 2011; 37(3-4): 143-52.	2005-2008	*	
France	Duval X, Delahaye F, Alla F, Tattevin P, Obadia J-F, Le Moing V, Doco-Lecompte T, Celard M, Poyart C, Strady C, Chirouze C, Bes M, Cambau E, Lung B, Selson-Suty C, Hoen B. Temporal Trends in Infective Endocarditis in the Context of Prophylaxis Guideline Modifications: Three Successive Population-Based Surveys. <i>J Am Coll Cardiol.</i> 2012; 59(22): 1968-76.	1991, 1999, 2008	*	
France	Guillemin F, Saraux A, Guggenbuhl P, Roux CH, Fardellone P, Le Bihan E, Cantagrel A, Chary-Valckenaere I, Euler-Ziegler L, Flipo R-M, Juvin R, Behier J-M, Fautrel B, Masson C, Coste J. Prevalence of rheumatoid arthritis in France: 2001. <i>Ann Rheum Dis.</i> 2005; 64(10): 1427-30.	2001		
France	Cahen PM, Turtot JC, Frank RM, Clement G, Seckler G. Comparative study of oral conditions in schoolchildren of Strasbourg, France, 1974-85. <i>Community Dent Oral Epidemiol.</i> 1987; 15(4): 211-5.	1974, 1985		
France	Cahen PM, Turtot JC, Frank RM, Obry-Musset AM. National survey of caries prevalence in 6-15-year-old children in France. <i>J Dent Res.</i> 1989; 68(1): 64-8.	1987		
France	Hescot P, Bourgeois D, Doury J. Oral health in 35-44 year old adults in France. <i>Int Dent J.</i> 1997; 47(2): 94-9.	1994		
France	Adam C, Eid A, Riordan PJ, Wolikow M, Cohen F. Caries experience in the primary dentition among French 6-year-olds between 1991 and 2000. <i>Community Dent Oral Epidemiol.</i> 2005; 33(5): 333-40.	1991, 1995, 2000		
France	Tubert-Jeannin S, Riordan PJ, Manevy R, Lecuyer MM, Pegon-Machet E. Caries prevalence and fluoride use in low SES children in Clermont-Ferrand (France). <i>Community Dent Health.</i> 2009; 26(1): 23-8.	2005		
France	Enjary C, Tubert-Jeannin S, Manevy R, Roger-Leroi V, Riordan PJ. Dental status and measures of deprivation in Clermont-Ferrand, France. <i>Community Dent Oral Epidemiol.</i> 2006; 34(5): 363-71.	2004		
France	Gaschnigard J, Levy C, Romain O, Cohen R, Bingen E, Aujard Y, Boileau P. Neonatal Bacterial Meningitis: 444 Cases in 7 Years. <i>Pediatr Infect Dis J.</i> 2011; 30(3): 212-7.	2001-2007		
France	Ritchie K, Artero S, Beluche I, Ancelin M-L, Mann A, Dupuy A-M, Malafosse A, Boulenger J-P. Prevalence of DSM-IV psychiatric disorder in the French elderly population. <i>Br J Psychiatry.</i> 2004; 184(2): 147-52.	1999-2001		
France	Ledoux S, Choquet M, Flament M. Eating disorders among adolescents in an unselected French population. <i>Int J Eat Disord.</i> 1991; 10(1): 81-9.	1988		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
France	Carta MG, Kovess V, Hardoy MC, Morosini P, Murgia S, Carpinello B. Psychiatric disorders in Sardinian immigrants to Paris: a comparison with Parisians and Sardinians resident in Sardinia. <i>Soc Psychiatry Psychiatr Epidemiol.</i> 2002; 37(3): 112-7.	1994-1996		
France	Fauchier L, Babuty D, Poret P, Casset-Senon D, Autret ML, Cosnay P, Fauchier JP. Comparison of long-term outcome of alcoholic and idiopathic dilated cardiomyopathy. <i>Eur Heart J.</i> 2000; 21(4): 306-14.	1986-1997		
France	Hoen B, Alla F, Selton-Suty C, Béguinot I, Bouvet A, Briancon S, Casalta JP, Danchin N, Delahaye F, Etienne J, Le Moing V, Lepout C, Mainardi JL, Ruimy R, Vandenesch F; Association pour l'Etude et la Prvention de l'Endocardite Infectieuse (AEPEI) Study Group. Changing profile of infective endocarditis: results of a 1-year survey in France. <i>JAMA.</i> 2002; 288(1): 75-81.	1999		
France	Delahaye F, Goulet V, Lacassin F, Ecochard R, Selton-Suty C, Hoen B, Etienne J, Briancon S, Lepout C. Characteristics of infective endocarditis in France in 1991. A 1-year survey. <i>Eur Heart J.</i> 1995; 16(3): 394-401.	1990-1991		
France	Goulet V, Etienne J, Fleurette J, Netter R. Infectious endocarditis in France. Epidemiological characteristics. <i>Presse Med.</i> 1986; 15(37): 1855-8.	1982-1983		
France	de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Knzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P. European Community Respiratory Health Survey Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. <i>Thorax.</i> 2004; 59(2): 120-125.	1991-1993		
France	Roche N, Dalmy F, Perez T, Kuntz C, Vergnengre A, Neukirch F, Giordanela JP, Huchon G. FEV1/FVC and FEV1 for the assessment of chronic airflow obstruction in prevalence studies: Do prediction equations need revision. <i>Respir Med.</i> 2008; 102(11): 1568-74.	1998-2000		
France	Downes E, Sikirica V, Gilabert-Estelles J, Bolge SC, Dodd SL, Maroulis C, Subramanian D. The burden of uterine fibroids in five European countries. <i>Eur J Obstet Gynecol Reprod Biol.</i> 2010; 152(1): 96-102.	2007		
France	Fombonne E. The Chartres Study: I. Prevalence of psychiatric disorders among French school-age children. <i>Br J Psychiatry.</i> 1994; 164(1): 69-79.	1987		
France	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2005		
France	Potter J, Bouyer J, Trussell J, Moreau C. Premenstrual syndrome prevalence and fluctuation over time: results from a French population-based survey. <i>J Womens Health (Larchmt).</i> 2009; 18(1): 31-9.	2003-2004		
France	De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology.</i> 2000; 54(11 Suppl 5): S21-23.	1997		
France	Rijk MC de, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alperovitch A, Rocca WA. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. <i>J Neurol Neurosurg Psychiatry.</i> 1997; 62(1): 10-5.	1988-1989		
France	Tison F, Letenneur L, Djossou F, Dartigues JF. Further evidence of increased risk of mortality of Parkinson's disease. <i>J Neurol Neurosurg Psychiatry.</i> 1996; 60(5): 592-3.	1988-1993		
France	Berger K BM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology.</i> 2000; 54(11): 24-7.	1997		
France	Tison F, Dartigues JF, Dubes L, Zuber M, Alperovitch A, Henry P. Prevalence of Parkinson's disease in the elderly: a population study in Gironde, France. <i>Acta Neurol Scand.</i> 1994; 90(2): 111-5.	1989-1998		
France	Bralet MC, Yon V, Loas G, Noisette C. Mortality in schizophrenia: a 8-year follow-up study in 150 chronic schizophrenics. <i>Encephale.</i> 2000; 26(6): 32-41.	1991-1999		
France	Casadebaig F, Philippe A. [Mortality in schizophrenic patients. 3 years follow-up of a cohort]. <i>Encephale.</i> 1999; 25(4): 329-37.	1993-1996		
France	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
France	Gourmelon J, Chastang J-F, Ozguler A, Lano J-L, Ravaud J-F, Leclerc A. Frequency of low back pain among men and women aged 30 to 64 years in France. Results of two national surveys. <i>Ann Readapt Med Phys.</i> 2007; 50(8): 633-44.	2002-2003		
France	Seland JH, Vingerling JR, Aungou CA, Bentham G, Chakravarthy U, deJong PTVM, Rahu M, Soubrane G, Tomazzoli L, Topouzis F, Fletcher AE. Visual impairment and quality of life in the older European population, the EUREYE study. <i>Acta Ophthalmol.</i> 2011; 89(7): 608-13. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2006-2007		
France	Khoshnood B, Debruyne M, Lanon F, Emery C, Fagnani F, Durand I, Floret D. Seroprevalence of varicella in the French population. <i>Pediatr Infect Dis J.</i> 2006; 25(1): 41-4.	2003-2004		
France	Saadatian-Elahi M, Mekki Y, Del Signore C, Lina B, Derrough T, Cautin E, Thierry J, Vanhems P. Seroprevalence of varicella antibodies among pregnant women in Lyon-France. <i>Eur J Epidemiol.</i> 2007; 22(6): 405-9.	2005		
France	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1999-2000, 2005		
France	Lopez D, Martineau H, Palle C. Mortality of individuals arrested for heroin, cocaine or crack use. <i>Tendances.</i> 2004; 1-8.	1992-1999		
France	Helmer C, Joly P, Letenneur L, Commenges D, Dartigues JF. Mortality with dementia: results from a French prospective community-based cohort. <i>Am J Epidemiol.</i> 2001; 154(7): 642-8.	1988-1998		
France	Chouraki V, Savoye G, Dauchet L, Vernier-Massouille G, Dupas J-L, Merle V, Laberrenne J-E, Salomez J-L, Lerebours E, Turck D, Cortot A, Gower-Rousseau C, Colombel J-F. The changing pattern of Crohn's disease incidence in northern France: a continuing increase in the 10- to 19-year-old age bracket (1988-2007). <i>Aliment Pharmacol Ther.</i> 2011; 33(10): 1133-42.	1988-2007	*	†
France	McDowell RD, Ryan A, Bunting BP, O'Neill SM, Alonso J, Bruffaerts R, de Graaf R, Florescu S, Vilagut G, de Almeida JMC, de Girolamo G, Haro JM, Hinkov H, Kovess-Masfety V, Matschinger H, Tomov T. Mood and anxiety disorders across the adult lifespan: a European perspective. <i>Psychol Med.</i> 2013; 1-16.	2001-2002	*	
France	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
France	Melchior M, Chastang J-F, Goldberg P, Fombonne E. High prevalence rates of tobacco, alcohol and drug use in adolescents and young adults in France: results from the GAZEL Youth Study. <i>Addict Behav.</i> 2008; 33(1): 122-33.	1999	*	
France	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). Alcohol and Drug Use Among European 17-18 Year Old Students: Data from the ESPAD Project. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2007.	2003		
France	Tribouilloy C, Buicuc O, Rusinaru D, Malaquin D, Lvy F, Peltier M. Long-term outcome after a first episode of heart failure. A prospective 7-year study. <i>Int J Cardiol.</i> 2010; 140(3): 309-14.	2000-2007		
France	Bonnet M-P, Basso O, Bouvier-Colle M-H, Dupont C, Rudigoz R-C, Fuhrer R, Deneux-Tharaux C. Postpartum haemorrhage in Canada and France: a population-based comparison. <i>PLoS One.</i> 2013; 8(6): e66882.	2004-2006	*	
France	Bouvier-Colle M-H, Mohangoo AD, Gissler M, Novak-Antolic Z, Vutuc C, Szamotulska K, Zeitlin J, Euro-Peristat Scientific Committee. What about the mothers? An analysis of maternal mortality and morbidity in perinatal health surveillance systems in Europe. <i>BJOG.</i> 2012; 119(7): 880-90.	2003-2004	*	
France	Vincent-Rohrfrisch A, Le Ray C, Anselem O, Cabrol D, Goffinet F. [Pregnancy in women aged 43 years or older: maternal and perinatal risks]. <i>J Gynecol Obstet Biol Reprod (Paris).</i> 2012; 41(5): 468-75.	2008-2010	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
France	Béjot Y, Cordonnier C, Durier J, Aboa-Eboulé C, Rouaud O, Giroud M. Intracerebral haemorrhage profiles are changing: results from the Dijon population-based study. <i>Brain</i> . 2013; 136(Pt 2): 658-64.	1985-2008	*	
France	Beaussart M, Faou R, Défaye J. [Epidemiology of epilepsy in the North Pas-de-Calais region (apropos of 12290 cases)]. <i>Lille Med</i> . 1980; 25(5): 183-91.	1976-1977	*	
France	Loiseau J, Loiseau P, Guyot M, Duche B, Dartigues JF, Aublet B. Survey of seizure disorders in the French southwest. I. Incidence of epileptic syndromes. <i>Epilepsia</i> . 1990; 31(4): 391-6.	1984-1985	*	
France	Picot M-C, Baldy-Moulimier M, Daurès J-P, Dujols P, Crespel A. The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country. <i>Epilepsia</i> . 2008; 49(7): 1230-8.	1995	*	
France	Munoz M, Dumas M, Boutros-Toni F, Coquelle D, Vallat JM, Jauberteau MO, Ndzanga E, Boa F, Ndo D. [A neuro-epidemiologic survey in a Limousin town]. <i>Rev Neurol (Paris)</i> . 1988; 144(4): 266-71.	1984	*	
France	Jallon P. [Evaluation of the prevalence of epilepsy in a military selection centre]. <i>Rev Neurol (Paris)</i> . 1991; 147(4): 319-22.	1987-1988	*	†
France	Godin O, Dufouil C, Ritchie K, Dartigues J-F, Tzourio C, Pérès K, Artero S, Alperovitch A. Depressive symptoms, major depressive episode and cognition in the elderly: the three-city study. <i>Neuroepidemiology</i> . 2007; 28(2): 101-8.	1999-2001		
France	Lépine JP, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). <i>Int Clin Psychopharmacol</i> . 1997; 12(1): 19-29.	1995		
France	Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, Joyce PR, Karam EG, Lee CK, Lellouch J, Lépine JP, Newman SC, Rubio-Stipec M, Wells JE, Wickramaratne PJ, Wittchen H, Yeh EK. Cross-national epidemiology of major depression and bipolar disorder. <i>JAMA</i> . 1996; 276(4): 293-9.	1987-1988		
France	Kovess-Masfety V, Briffault X, Sapinho D. Prevalence, risk factors, and use of health care in depression: a survey in a large region of France between 1991 and 2005. <i>Can J Psychiatry</i> . 2009; 54(10): 701-9.	1991, 2005	*	
France	Stengel B, Jausseut I, Guiserix J, Bourgeon B, Papoz L, Favier F; REDIA Study Group. High prevalence of chronic kidney disease in La Réunion island and its association with the metabolic syndrome in the non-diabetic population: La Réunion Diabetes (REDIA) Study. <i>Diabetes Metab</i> . 2007; 33(6): 444-52.	1999-2001		
France	Zmirou D, Benhamou PY, Cordonnier D, Borgel F, Balducci F, Papoz L, Halimi S. Diabetes mellitus prevalence among dialysed patients in France (UREMIDIAB study). <i>Nephrol Dial Transplant</i> . 1992; 7(11): 1092-7.	1989		
France	Fombonne E, Du Mazaubrun C, Cans C, Grandjean H. Autism and associated medical disorders in a French epidemiological survey. <i>J Am Acad Child Adolesc Psychiatry</i> . 1997; 36(11): 1561-9.	1992-1993		
France	Fombonne E, du Mazaubrun C. Prevalence of infantile autism in four French regions. <i>Soc Psychiatry Psychiatr Epidemiol</i> . 1992; 27(4): 203D10.	1982		
France	Mathet F, Martin-Guehl C, Maurice-Tison S, Bouvard M-P. [Prevalence of depressive disorders in children and adolescents attending primary care. A survey with the Aquitaine Sentinelle Network]. <i>Encephale</i> . 2003; 29(5): 391-400.	1999		
France	Loas G, Von V, Maréchal V, Dècle P. Relationships between subjective or objective symptoms and mortality in schizophrenia: a prospective study on 310 schizophrenic patients with a median follow-up of 8.4 years. <i>Psychiatry Res</i> . 2011; 185(1-2): 49-53.	2008	*	
France	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 2001, 2004, 2007, 2010		
France	Malkin JE, Morand P, Malvy D, Ly TD, Chanzy B, de Labareyre C, El Hasnaoui A, Hercberg S. Seroprevalence of HSV-1 and HSV-2 infection in the general French population. <i>Sex Transm Infect</i> . 2002; 78(3): 201-3.	1996	*	
France	Jaffiol C, Thomas F, Bean K, Jégo B, Danchin N. Impact of socioeconomic status on diabetes and cardiovascular risk factors: results of a large French survey. <i>Diabetes Metab</i> . 2013; 39(1): 56-62.	2003-2006		
France	Salet J-L, Baroux N, Pochet M, Benoit-Cattin T, De Montera A-M, Sissoko D, Favier F, Fagot-Campagna A. Prevalence of type 2 diabetes and other cardiovascular risk factors in Mayotte in 2008: the MAYDIA study. <i>Diabetes Metab</i> . 2011; 37(3): 201-7.	2008		
France	De Beaufort CE, Cecchi-Tenerini R, Clerc R, Hilaire M, Schwartz F, Mancieux M. [Incidence of insulin-dependent diabetes in six to sixteen year old school children in Lorraine]. <i>Arch Fr Pediatr</i> . 1991; 48(3): 228.	1989		
France	Doutreix J, Lévy-Marchal C. [Diagnosis of insulin-dependent diabetes in children: data from the incidence registry]. <i>Rev Epidemiol Sante Publique</i> . 1996; 590-96.	1988-1990		
France	Gueguen J, Godart N, Chambry J, Brun-Eberentz A, Foulon C, Divac Phd SM, Gueffé J-D, Rouillon F, Falissard B, Huas C. Severe anorexia nervosa in men: comparison with severe AN in women and analysis of mortality. <i>Int J Eat Disord</i> . 2012; 45(4): 537-45.	1996-2008	*	
France	Huas C, Caille A, Godart N, Foulon C, Pham-Scottez A, Divac S, Dechartres A, Lavoisy G, Gueffé JD, Rouillon F, Falissard B. Factors predictive of ten-year mortality in severe anorexia nervosa patients. <i>Acta Psychiatr Scand</i> . 2011; 123(1): 62-70.	1996-2008	*	
France	Huas C, Godart N, Caille A, Pham-Scottez A, Foulon C, Divac SM, Lavoisy G, Gueffé J-D, Falissard B, Rouillon F. Mortality and its predictors in severe bulimia nervosa patients. <i>Eur Eat Disord Rev</i> . 2013; 21(1): 15-9.	1996-2008	*	
France	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), French Monitoring Centre for Drugs and Drug Addiction. France National Report to the EMCDDA 2006. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2006.	2006	*	
France	Marzo J-N, Rotily M, Meroueh F, Varastet M, Hunault C, Zin A, RECAMs Group, French Monitoring Centre for Drugs and Drug Addiction. Reincarceration and Mortality Among Opioid-Dependent Prisoners: A Prospective Cohort Study Report (2003-2006). Paris, France: French Monitoring Centre for Drugs and Drug Addiction, 2008.	2003-2006	*	
France	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant</i> . 1988; 3(6): 714-27.	1985-1986		
France	Junegers P, Chauveau P, Descamps-Latscha B, Labrunie M, Giraud E, Man NK, Grünfeld JP, Jacobs C. Age and gender-related incidence of chronic renal failure in a French urban area: a prospective epidemiologic study. <i>Nephrol Dial Transplant</i> . 1996; 11(8): 1542-6.	1991-1992		
France	Couchoud C, Stengel B, Landais P, Aldigier JC, de Cornelissen F, Dabot C, Maheut H, Joyeux V, Kessler M, Labeuux M, Isnard H, Jacquelinet C. The renal epidemiology and information network (REIN): a new registry for end-stage renal disease in France. <i>Nephrol Dial Transplant</i> . 2006; 21(2): 411-8.	2003		
France	Berthoux F, Jones E, Gellert R, Mendel S, Saker L, Briggs D. Epidemiological data of treated end-stage renal failure in the European Union (EU) during the year 1995: report of the European Renal Association Registry and the National Registries. <i>Nephrol Dial Transplant</i> . 1999; 14(10): 2332-42.	1995		
France	Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. <i>J Clin Endocrinol Metab</i> . 2008; 93(4): 1408-11.	2005		
France	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Gilst WH van, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J</i> . 2003; 24(5): 442-63.	2000-2001		
France	Bourgeois D, Hescot P, Doury J. Periodontal conditions in 35-44-yr-old adults in France, 1993. <i>J Periodont Res</i> . 1997; 32(7): 570-4.	1993		
France	Bourgeois DM, Doury J, Hescot P. Periodontal conditions in 65-74 year old adults in France, 1995. <i>Int Dent J</i> . 1999; 49(3): 182-6.	1995		
France	Miller NA, Benanghar L, Roland E, Martin J, Abt F. An analysis of the CPITN periodontal treatment needs in France. <i>Community Dent Health</i> . 1987; 4(4): 415-23.	1985		
France	Stengel B, Metzger M, Froissart M, Rainfray M, Berr C, Tzourio C, Helmer C. Epidemiology and prognostic significance of chronic kidney disease in the elderly – the Three-City prospective cohort study. <i>Nephrol Dial Transplant</i> . 2011; 26(10): 3286-95.	1999-2001	*	
France	Leray E, Morrissey S, Yaouanq J, et al. Long-term survival of patients with multiple sclerosis in West France. <i>Mult Scler</i> . 2007; 13(7): 865-74.	1976-2004	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
France	Lefèvre JC, Averous S, Bauriaud R, Blanc C, Bertrand MA, Lareng MB. Lower genital tract infections in women: comparison of clinical and epidemiologic findings with microbiology. <i>Sex Transm Dis.</i> 1988; 15(2): 110-3.	1988		
France	Avettand-Fenoël V, Marlin S, Vauloup-Fellous C, Loudon N, François M, Couloigner V, Rouillon I, Drouin-Garraud V, Laccourreye L, Denoyelle F, Guillemot T, Grabur S, Lerez-Ville M. Congenital cytomegalovirus is the second most frequent cause of bilateral hearing loss in young French children. <i>J Pediatr.</i> 2013; 162(3): 593-9.	2007-2009	*	
France	Simon P, Raméé MP, Autuly V, Laruelle E, Charasse C, Cam G, Ang KS. Epidemiology of primary glomerular diseases in a French region. Variations according to period and age. <i>Kidney Int.</i> 1994; 46(4): 1192-8.	1976-1990	*	
France	World Health Organization (WHO). France WHO Leishmaniasis Country Profile.	1999-2010	*	
France	Letenneur L, Commenges D, Dartigues JF, Barberger-Gateau P. Incidence of dementia and Alzheimer's disease in elderly community residents of south-western France. <i>Int J Epidemiol.</i> 1994; 23(6): 1256-61.	1991-1993		
France	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland: World Health Organization (WHO).	2000-2011	*	
France	Thomas R, Le Tulzo Y, Bouget J, Camus C, Michelet C, Le Corre P, Bellissant E. Trial of dexamethasone treatment for severe bacterial meningitis in adults. <i>Intensive Care Med.</i> 1999; 25(5): 475-80.	1996		
France	Chidiac C, Bruxelles J, Daures J-P, Hoang-Xuan T, Morel P, Leplège A, Hasnaoui AE, Labareyre C de. Characteristics of Patients with Herpes Zoster on Presentation to Practitioners in France. <i>Clin Infect Dis.</i> 2001; 33(1): 62-9.	1997-1998		
France	Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJM, Stalman WAB, van Essen GA. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. <i>Fam Pract.</i> 2002; 19(5): 471-5.	1998-1999		†
France	Mailles A, Vaillant V, Stahl J-P. [Infectious encephalitis in France from 2000 to 2002: the hospital database is a valuable but limited source of information for epidemiological studies]. <i>Med Mal Infect.</i> 2007; 37(2): 95-102.	2000-2002		
France	European Centre for Disease Prevention and Control. Review of Chlamydia Control Activities in EU Countries. Stockholm, Sweden: European Centre for Disease Prevention and Control, 2008.	2007		
France	World Health Organization (WHO). Mental Illness in General Health Care: An International Study. Geneva, Switzerland: World Health Organization (WHO), 1995.	1991-1992		
France	Dehaene P, Samaille-Villette C, Boulanger-Fasquelle P, Subtil D, Delahousse G, Crepin G. [Diagnosis and prevalence of fetal alcoholism in maternity]. <i>Presse Med.</i> 1991; 20(21): 1002.	1975-1996	*	
France	Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJA, Wasserman SM, Baker N, Rosser D, Cleland JGF, Ponikowski P. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. <i>Eur Heart J.</i> 2007; 28(18): 2208-16.	1992-1995		
France	Alla F, Zannad F, Filippatos G. Epidemiology of acute heart failure syndromes. <i>Heart Fail Rev.</i> 2007; 12(2): 91-5.	2001		
France	Pradat P, Caillat-Vallet E, Sahajian F, Bailly F, Excler G, Sepetjan M, Trépo C, Fabry J. Prevalence of hepatitis C infection among general practice patients in the Lyon area, France. <i>Eur J Epidemiol.</i> 2001; 17(1): 47-51.	1997		
France	Lelong M, Kaddari F, Hanichi A, Porte P. Intérêt du dépistage néonatal systématique des hémoglobinopathies à l'hôpital des Saint-Denis. <i>Rev Fr Lab.</i> 2001; 19-21.	1995-1998	*	
France	Monplaisir N, Casius de Linval JC, Sellaye M, Galacteros F, Braconnier F, Beuzard Y, Hilbert J, Mézin R, Quist C, Duville S, Rosa J. Dépistage des hémoglobinopathies à la naissance par isoélectroforesis. Etude de la population de la Martinique. <i>Nouv Presse Med.</i> 1981; 10(38): 3127-30.	1979-1980	*	
France	Caroli-Bosc FX, Deveau C, Harris A, Delabre B, Peten EP, Hastier P, Sgro E, Caroli-Bosc C, Stoia M, Demarquet JF, Dumas R, Coussseau A, Delmont JP. Prevalence of cholelithiasis: results of an epidemiologic investigation in Vidauban, southeast France. General Practitioner's Group of Vidauban. <i>Dig Dis Sci.</i> 1999; 44(7): 1322-9.	1994		
France	Trichopoulos D, Bania C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overved K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PHM, Lund E, Quirós JR, González CA, Sanchez Perez M-J, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu L, Chuang S-C, Murphy N, Boffetta P, Trichopoulou A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. <i>J Natl Cancer Inst.</i> 2011; 103(22): 1686-95.	1992-2006	*	
France	Boutrouille A, Bakkali-Kassimi L, Crucière C, Pavio N. Prevalence of anti-hepatitis E virus antibodies in French blood donors. <i>J Clin Microbiol.</i> 2007; 45(6): 2009-10.	2004-2006	*	
France	Lemaire JM, Brunel D, Rieu D, Lepeu G, Bertrand A. [Antivirus antibodies in hepatitis A (anti-HAV) in southern France]. <i>Nouv Presse Med.</i> 1980; 9(6): 380.	1979		
France	Dubois F, Thevenas C, Caces E, Vol S, Doctoriarena A, Ecault JL, Goudeau A, Tichet J. [Seroepidemiology of hepatitis A in six departments in West-Central France in 1991]. <i>Gastroenterol Clin Biol.</i> 1992; 16(8-9): 674-9.	1991		
France	Germanaud J, Barthez JP, Causse X. [Prevalence of hepatitis A virus antibodies in the personnel of a hospital]. <i>Gastroenterol Clin Biol.</i> 1992; 16(10): 816-7.	1991		
France	Cadilhac P, Roudot-Thoraval F. Seroprevalence of hepatitis A virus infection among sewage workers in the Parisian area, France. <i>Eur J Epidemiol.</i> 1996; 12(3): 237-40.	1993		
France	Djeriri K, Fontana L, Laurichesse H, Peigue-Lafaille H, Henquell C, Chamoux A, Beytout J, Catilina P, Rey M. [Seroprevalence of markers of viral hepatitis A, B and C in hospital personnel at the Clermont-Ferrand University Hospital Center]. <i>Presse Med.</i> 1996; 25(4): 145-50.	1993-1994		
France	Nguyen-Khac E, Delenserie R, Capron D, Duverlie G, Liénard J, Capron JP. [Seroprevalence of viral hepatitis A in at the Amiens University Hospital]. <i>Gastroenterol Clin Biol.</i> 1996; 20(1): 36-41.	1994		
France	Nalpas B, Zylberberg H, Dubois F, Presles MA, Gillant JC, Liénard M, Delemotte B, Bréchet C. [Prevalence of infection by hepatitis viruses in a rural area. Analysis according to risk factors and alcohol consumption]. <i>Gastroenterol Clin Biol.</i> 2000; 24(5): 536-40.	1994-1996		
France	Denis F, Delpyroux C, Debrock C, Rogez S, Alain S. [Seroprevalence of hepatitis A in hospitalized patients in Limoges University Hospital]. <i>Gastroenterol Clin Biol.</i> 2003; 27(8-9): 727-31.	1994-2002		
France	Lucht F, Berthelot P, Job P, Bonneval L, Digonnet C, Fresard A, Chabert B, Cabal C, Pozzetto B. [Seroprevalence of viral hepatitis A in France in homosexuals and intravenous drug users]. <i>Presse Med.</i> 1996; 25(25): 1141-3.	1995		
France	Domart M, Miika-Cabanne N, Henzel D, Pouliquen A, Florentin A, Marande JL, Xerri B, Aufreze A, Larouzé B. Hepatitis A among health workers in Paris hospitals. <i>Occupational Health Physicians of Paris Hospital (AP-HP). J Med Virol.</i> 1999; 58(4): 321-4.	1998		
France	Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, Tolonen H, Raokoski E. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. <i>Lancet.</i> 1999; 353(9164): 1547-57.	1980-1995		
France	National Public Health Institute (Finland), World Health Organization (WHO). MONICA Coronary Event Registration Data Book 1980-1995. Geneva, Switzerland: World Health Organization (WHO), 2000.	1980-1995		
France	Alemy-Carreau M, Durbec JP, Giordanela J, Rousseau S, Blanc G, Monges D, Perreard M, Harle JR, Weiller PJ, Gerolami A. Lack of interaction between hepatitis C virus and alcohol in the pathogenesis of cirrhosis. A statistical study. <i>J Hepatol.</i> 1996; 25(5): 627-32.	1996		
France	Denis F, Ranger-Rogez S, Alain S, Mounier M, Debrock C, Wagner A, Delpyroux C, Tabaste JL, Aubard Y, Preux P-M. Screening of pregnant women for hepatitis B markers in a French Provincial University Hospital (Limoges) during 15 years. <i>Eur J Epidemiol.</i> 2004; 19(10): 973-8.	1984-1998		
France	Dubois F, Desenclos JC, Mariotte N, Goudeau A. Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotypic distribution, and risk factors. The Collaborative Study Group. <i>Hepatology.</i> 1997; 25(6): 1490-6.	1994		†
France	Miédoûgé M, Chatelut M, Mansuy J-M, Rostaing L, Malecize F, Sandres-Sauné K, Boudet F, Puel J, Abbal M, Izopet J. Screening of blood from potential organ and cornea donors for viruses. <i>J Med Virol.</i> 2002; 66(4): 571-5.	1999-2001		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
France	Castillo Taucher S. [Services for the care and prevention of birth defects. Reduced report of a World Health Organization and March of Dimes Foundation meeting]. Rev Med Chil. 2007; 135(6): 806-13.	2006		
France	Ducot B, Spira A, Thonneau P, Toulemon L, Leridon H. [Difficulties in conceiving. Discussion about methodology concerning the INED-INSERM survey carried out in France in 1988 on 3,181 women aged between 18 and 49]. J Gynecol Obstet Biol Reprod (Paris). 1991; 20(5): 643-50.	1988	*	
France	Flohr C, Weimayr G, Weiland SK, Addo-Yobo E, Annesi-Maesano I, Björkstén B, Bråbäck L, Büchele G, Chico M, Cooper P, Clausen M, El Sharif N, Martínez Gimeno A, Mathur RS, von Mutius E, Morales Suarez-Varela M, Pearce N, Svabe V, Wong GWK, Yu M, Zhong NS, Williams HC, ISAAC Phase Two Study Group. How well do questionnaires perform compared with physical examination in detecting flexural eczema? Findings from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. Br J Dermatol. 2009; 161(4): 846-53.	2005-2007	*	
France	U.S. Renal Data System. USRDS 1998 Annual Data Report. Bethesda (MD), United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health. 1998.	1995-1996		
France	United States Renal Data System Coordinating Center. USRDS 1997 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health. 1997.	1994		
France	U.S. Renal Data System. USRDS 1996 Annual Data Report. Bethesda (MD), United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health. 1996.	1992-1993		
France	U.S. Renal Data System. USRDS 1994 Annual Data Report. Bethesda (MD), United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health. 1994.	1989-1991		
France	French Institute of Health and Medical Research (INSERM), Pasteur Institute of Lille, University of Strasbourg. France Coronary Event Registry Data 2000-2007, provided by Global Burden of Disease 2010 Ischemic Heart Disease Expert Group. [Unpublished].	2000-2007		†
France	Dantzer C, Tessier JF, Nejari C, Barberger-Gateau P, Dartigues JF. Mortality of elderly subjects with self-reported asthma in a French cohort, 1991-1996. Eur J Epidemiol. 2001; 17(1): 57-63.	1991-1999	*	
France	Vandendorren S, Baldi I, Annesi Maesano I, Charpin D, Neukirch F, Filleul L, Cantagrel A, Tessier JF. Long-term mortality among adults with or without asthma in the PAARC study. Eur Respir J. 2003; 21(3): 462-7.	1974-1998	*	
France	Steiner TJ, Stovner LJ, Katsarava Z, Láinez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Barré J, André C. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain. 2014; 15(31). [Unpublished data].	2008	*	
France	Autret F, Kieffer F, Tasseau A, Rigourd V, Valleur D, Voyer M, Magny J-F. [Extreme prematurity: comparison of outcome at 5 years depending on gestational age below or above 26 weeks]. Arch Pediatr. 2009 Jul;16(7):976-83.	1990, 1999		†
France	Ayoubi JM, Audibert F, Boithias C, Zupan V, Taylor S, Bosson JL, Frydman R. Perinatal factors affecting survival and survival without disability of extreme premature infants at two years of age. Eur. J. Obstet. Gynecol. Reprod. Biol. 2002 Nov 15;105(2):124-31.	1994		†
France	Larroque B, Bréart G, Kaminski M, Dehan M, André M, Burguet A, Grandjean H, Ledéret B, Lévêque C, Maillard F, Matis J, Rozé JC, Truffert P. Epigage study group. Survival of very preterm infants: Epigage, a population based cohort study. Arch. Dis. Child. Fetal Neonatal Ed. 2004 Mar;89(2):F139-144.	1997		†
France	Brévaut-Malaty V, Busuttill M, Einaudi M-A, Monnier A-S, D'Ercole C, Gire C. Longitudinal follow-up of a cohort of 350 singleton infants born at less than 32 weeks of amenorrhea: neurocognitive screening, academic outcome, and perinatal factors. Eur. J. Obstet. Gynecol. Reprod. Biol. 2010 May;150(1):13-8.	1999		†
France	France Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
France	France Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
France	France Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
France	France - Strasbourg Prospective Study of Congenital Malformations Data 2001 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
France	France - Strasbourg Prospective Study of Congenital Malformations Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
France	France - Central-East France Register of Congenital Malformations Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
France	France - Paris Congenital Anomaly Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
France	France - Strasbourg Prospective Study of Congenital Malformations Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
France	France - Rhone Alps Registry of Malformations Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
France	France - Paris Congenital Anomaly Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
France	France - Strasbourg Registry of Congenital Malformations Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
France	France - Rhone Alps Registry of Malformations Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
France	France - Paris Congenital Anomaly Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
France	European Surveillance of Congenital Anomalies (EUROCAT). France EUROCAT Prevalence Tables. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	1980-2011		
France	France - Paris Congenital Anomaly Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT). International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
France	France - Paris Register of Congenital Malformations Data 1982 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1982	*	
France	France - Paris Register of Congenital Malformations Data 1983 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1983	*	
France	France - Paris Register of Congenital Malformations Data 1984 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1984	*	
France	France - Paris Register of Congenital Malformations Data 1985 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1985	*	
France	France - Paris Register of Congenital Malformations Data 1986 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1986	*	
France	France - Paris Register of Congenital Malformations Data 1987 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1987	*	
France	France - Paris Register of Congenital Malformations Data 1988 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1988	*	
Gabon	General Directorate of Statistics and Economic Studies (Gabon), Macro International, Inc. Gabon Demographic and Health Survey 2000-2001. Calverton, United States: Macro International, Inc.	2000-2001		†
Gabon	General Directorate of Statistics (Gabon), ICF International, Ministry of Economy, Employment and Sustainable Development (Gabon), Ministry of Health (Gabon). Gabon Demographic and Health Survey 2012. Fairfax, United States: ICF International, 2013.	2012	*	†
Gabon	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Gabon	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Gabon	Koko J, Batsiellili S, Duffillot D, Kani F, Gahouma D, Moussavou A. Les méningites bactériennes de l'enfant à Libreville, Gabon. Med Mal Infect. 2000; 30(1): 50-6.	1989-1993		
Gabon	Mayi-Tsonga S, Meyé J-F, Tagne A, Ndongbi I, Diallo T, Oksana L, Mendome G, Mounanga M. Audit de la morbidité obstétricale grave (near miss) au Gabon. Sante. 2007; 17(2): 111-5.	2006		
Gabon	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1994-1995		
Gabon	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1992-1993, 1996, 2001-2002, 2005-2009		
Gabon	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2003		
Gabon	Ngoungou EB, Abovans V, Koua P, Makandja R, Eke Nzengue JE, Allogho CN, Laskar M, Preux P-M, Lacroix P. Prevalence of cardiovascular disease in Gabon: a population study. Arch Cardiovasc Dis. 2012; 105(2): 77-83.	2009-2011		
Gabon	Hogewoning AA, Adegnik AA, Bouwes Bavinck JN, Yazdanbakhsh M, Krensman PG, van der Raaij-Helmer EMH, Staats CCG, Willemze R, Lavrijsen APM. Prevalence and causative fungal species of tinea capitis among schoolchildren in Gabon. Mycoses. 2011; 54(5): e354-359.	2005		
Gabon	Njoum R, Caron M, Besson G, Ndong-Atome G-R, Makuwa M, Pouillot R, Nkoghé D, Leroy E, Kazanji M. Phylogeography, risk factors and genetic history of hepatitis C virus in Gabon, central Africa. PLoS One. 2012; 7(8): e42002.	2005-2008		
Gabon	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Gabon	Sitbon M, Lecerc A, Garin Y, Ivanoff B. Rotavirus prevalence and relationships with climatological factors in Gabon, Africa. J Med Virol. 1985; 16(2): 177-82.	1980-1981	*	
Gabon	Perret J-L, Moussavou-Kombila J-B, Delaporte E, Pemba L-F, Boguikouma J-B, Matton T, Larouze B. [HBs Ag and antibodies to hepatitis C virus in complicated chronic liver disease in Gabon. A case control study]. Gastroenterol Clin Biol. 2002; 26(2): 131-5.	1990-1998		
Gabon	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2010, 2012		
Gabon	Ndjoyi-Mbiguino A, Ozouaki F, Legoff J, Mbopi-Kéou F-X, Si-Mohamed A, Onas IN, Avoune E, Bélec L. Comparison of washing and swabbing procedures for collecting genital fluids to assess cervicovaginal shedding of herpes simplex virus type 2 DNA. J Clin Microbiol. 2003; 41(6): 2662-4.	2000-2002	*	
Gabon	Domarle O, Migot-Nabias F, Mvoukani JL, Lu CY, Nabias R, Mayombo J, Tiga H, Deloron P. Factors influencing resistance to reinfection with Plasmodium falciparum. Am J Trop Med Hyg. 1999; 61(6): 926-31.	1998		†
Gabon	Domarle O, Migot-Nabias F, Mvoukani JL, Lu CY, Nabias R, Mayombo J, Tiga H, Deloron P. Factors influencing resistance to reinfection with Plasmodium falciparum. Am J Trop Med Hyg. 1999; 61(6): 926-31 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Gabon	Migot-Nabias F, Mombo LE, Luty AJ, Dubois B, Nabias R, Bisseye C, Millet P, Lu CY, Deloron P. Human genetic factors related to susceptibility to mild malaria in Gabon. Genes Immun. 2000; 1(7): 435-41.	1995-1996		
Gabon	Mombo L-E, Nioumi F, Bisseye C, Ossari S, Lu CY, Nagel RL, Krishnamoorthy R. Human genetic polymorphisms and asymptomatic Plasmodium falciparum malaria in Gabonese schoolchildren. Am J Trop Med Hyg. 2003; 68(2): 186-90.	1995		
Gabon	Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J Health Geogr. 2010; 9: 57.	1980-2010		
Gabon	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Gabon	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Gabon	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Gabon	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Gabon	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Gabon	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Gabon	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Gabon	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Gabon	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Gabon	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Gabon	Gabon National Study on the Prevalence of Iodine Deficiency Disorders 2001 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2001		
Gabon	Ntyonga-Pono M. Données d'une pré-enquête sur la prévalence du goitre dans une localité du sud-est du Gabon. <i>Med Afr Noire.</i> 1993; 543-5 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1989		
Gabon	Richard-Lenoble D, Traore O, Kombila M, Roingard P, Dubois F, Goudeau A. Hepatitis B, C, D, and E markers in rural equatorial African villages (Gabon). <i>Am J Trop Med Hyg.</i> 1995; 53(4): 338-41.	1991-1992		
Gabon	Hogewoning A, Amoah A, Bavnick JNB, Boakye D, Yazdanbakhsh M, Adegnika A, De Smedt S, Fonteyne Y, Willemze R, Lavrijsen A. Skin diseases among schoolchildren in Ghana, Gabon, and Rwanda. <i>Int J Dermatol.</i> 2013; 52(5): 589-600.	2005	*	
Gabon	Hogewoning AA, Bouwes Bavnick JN, Amoah AS, Boakye DA, Yazdanbakhsh M, Kremsner PG, Adegnika AA, De Smedt SKAD, Willemze R, Lavrijsen APM. Point and period prevalences of eczema in rural and urban schoolchildren in Ghana, Gabon and Rwanda. <i>J Eur Acad Dermatol Venerol.</i> 2012; 26(4): 488-94.	2005	*	
Gabon	Bertherat E, Georges-Courbot MC, Nabias R, Georges AJ, Renaut A. Seroprevalence of four sexually transmitted diseases in a semi-urban population of Gabon. <i>Int J STD AIDS.</i> 1998; 9(1): 31-6.	1996		
Gabon	Caron M, Kazanji M. Hepatitis E virus is highly prevalent among pregnant women in Gabon, central Africa, with different patterns between rural and urban areas. <i>Virology.</i> 2008; 381(2): 157-8.	2005-2007		
Gabon	Dupont A, Delaporte E, Jago JM, Schrijvers D, Merlin M, Josse R. Prevalence of hepatitis B antigen among randomized representative urban and rural populations in Gabon. <i>Ann Soc Belg Med Trop.</i> 1988; 68(2): 157-8.	1986-1987		
Gabon	Makuwa M, Souquire S, Telfer P, Apetrei C, Vray M, Bedjabaga I, Mouinga-Ondeme A, Onanga R, Marx PA, Kazanji M, Roques P, Simon F. Identification of hepatitis B virus subgenotype A3 in rural Gabon. <i>J Med Virol.</i> 2006; 78(9): 1175-84.	2001		
Gabon	Malariaometric Survey of Children Aged 0-14 Years and Evaluation of Family Practices of Malaria Vector Control as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Gabon	Blampain-Azzibrouck G, Lekoulou F, Snounou G, Ravollet JC, Ntouni F. Short communication: Plasmodium falciparum and P. malariae infections in isolates from sickle cell gene carriers living in a hyperendemic area of Gabon. <i>Trop Med Int Health.</i> 1999; 4(12): 872-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Gabon	Chambon R, Lemaire P, Boudin C, Ringwald P, Chandener J. [Surveillance of the in vivo sensitivity of Plasmodium falciparum to antimalarial agents: the results of initial tests of the OCEAC Malaria Network]. <i>Med Trop (Mars).</i> 1997; 57(4): 357-60 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
Gabon	Chizzolini C, Dupont A, Akue JP, Kaufmann MH, Verdini AS, Pessi A, Del Giudice G. Natural antibodies against three distinct and defined antigens of Plasmodium falciparum in residents of a mesoendemic area in Gabon. <i>Am J Trop Med Hyg.</i> 1988; 39(2): 150-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Gabon	Elissa N, Migot-Nabias F, Luty A, Renaut A, Touré F, Vaillant M, Lawoko M, Yangari P, Mayombo J, Lekoulou F, Tshipamba P, Moukagni R, Millet P, Deloron P. Relationship between entomological inoculation rate, Plasmodium falciparum prevalence rate, and incidence of malaria attack in rural Gabon. <i>Acta Trop.</i> 2003; 85(3): 355-61 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998-1999	*	†
Gabon	Luty AJ, Mayombo J, Lekoulou F, Mshana R. Immunologic responses to soluble exoantigens of Plasmodium falciparum in Gabonese children exposed to continuous intense infection. <i>Am J Trop Med Hyg.</i> 1994; 51(6): 720-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Gabon	Martin-Prével Y, Berteau F, Bouyssou M, Ripert C, Pinder M. An epidemiological study of a Schistosoma intercalatum focus in south-east Gabon. <i>Trans R Soc Trop Med Hyg.</i> 1992; 86(4): 401-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Gabon	Merlin M, Dupont A, Josse R, Delaporte E, Cheringou H, Garin D, Abandja J, Hamono B, Hengy C, Lebras J. [Epidemiologic aspects of malaria in Gabon]. <i>Med Trop (Mars).</i> 1990; 50(1): 39-46 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Gabon	Mshana RN, Boulouadi J, Mayombo J, Mendome G. In vitro lymphoproliferative responses to malaria antigens: a prospective study of residents of a holoendemic area with perennial malaria transmission. <i>Parasite Immunol.</i> 1993; 15(1): 35-45 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Gabon	Ntouni F, Rogier C, Dieye A, Trape JF, Millet P, Mercereau-Puijalon O. Imbalanced distribution of Plasmodium falciparum MSP-1 genotypes related to sickle-cell trait. <i>Molecular Medicine.</i> 1997; 3(9): 581-92 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Gabon	Ollomo B, Karch S, Bureau P, Elissa N, Georges AJ, Millet P. Lack of malaria parasite transmission between apes and humans in Gabon. <i>Am J Trop Med Hyg.</i> 1997; 56(4): 440-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993-1994	*	†
Gabon	Richard-Lenoble D, Kombila M, Chandener J, Gay F, Billiault X, Ngouri C, Martz M, Boyer F, Bauzou M. [Malaria in Gabon. 2. Evaluation of the qualitative and quantitative prevalence of parasites in the total school and preschool population of the country]. <i>Bull Soc Pathol Exot.</i> 1987; 80(3): 532-42 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Gabon	Wildling E, Winkler S, Kremsner PG, Brands C, Jenne L, Wernsdorfer WH. Malaria epidemiology in the province of Moyen Ogoov, Gabon. <i>Trop Med Parasitol.</i> 1995; 46(2): 77-82 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Gabon	Van den Biggelaar AH, Lopuhaa C, van Ree R, van der Zee JS, Jans J, Hoek A, Migombet B, Borrmann S, Luckner D, Kremsner PG, Yazdanbakhsh M. The prevalence of parasite infestation and house dust mite sensitization in Gabonese schoolchildren. <i>International Archives of Allergy and Immunology.</i> 2001; 126(3): 231-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
Gabon	National Center for Disease Control (Georgia), State Department of Statistics of Georgia, United Nations Children's Fund (UNICEF). Georgia Multiple Indicator Cluster Survey 2005. New York, United States: United Nations Children's Fund (UNICEF).	2005	*	†
Georgia	World Health Organization (WHO). Georgia World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Georgia	Institute for Polling and Marketing (Georgia), World Health Organization (WHO). Georgia WHO Multi-country Survey Study on Health and Health System Responsiveness 2000-2001.	2000-2001		
Georgia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Georgia	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Georgia	Tsiskaridze A, Djibuti M, van Melle G, Lomidze G, Apridonidze S, Gaurarshvili I, Piechowski-Józwiak B, Shkarishvili R, Bogousslavsky J. Stroke Incidence and 30-Day Case-Fatality in a Suburb of Tbilisi: Results of the First Prospective Population-Based Study in Georgia. <i>Stroke</i> . 2004; 35(11): 2523-8.	2000-2003		
Georgia	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol</i> . 2008; 121(4): 947-954.	1996, 2003		
Georgia	Ginevskaya VA, Eremeva TP, Zangaladze ED, Shirman GA, Kazantseva VA, Sakvarelidze LA, Drozdov SG. Analysis of rotaviral gastroenteritis in Tbilisi. <i>Acta Virol</i> . 1991; 35(3): 232-7.	1984-1986		
Georgia	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001-2009		
Georgia	Tsitlanadze VG, Kartvelishvili EI, Shakulashvili NA, Shalamberidze LP. Incidence and various risk factors for gout in the Georgian SSR. <i>Ter Arkh</i> . 1987; 59(4): 18-20.	1984		
Georgia	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J</i> . 1998; 12(2): 315-35.	1993-1995		
Georgia	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	2003		
Georgia	International Society of Nephrology (ISN). International Society of Nephrology Kidney Disease Data Center 2006-2009.	2008-2009		
Georgia	Lomidze G, Kasradze S, Kvernadze D, Okujava N, Toidze O, de Boer HM, Dua T, Sander JW. The prevalence and treatment gap of epilepsy in Tbilisi, Georgia. <i>Epilepsy Res</i> . 2012; 98(2-3): 123-9.	2008	*	†
Georgia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Georgia	Katsarava Z, Dzagnidze A, Kukava M, Mirvelashvili E, Djibuti M, Janelidze M, Jensen R, Stovner LJ, Steiner TJ. Lifting The Burden: The Global Campaign to Reduce the Burden of Headache Worldwide and the Russian Linguistic Subcommittee of the International Headache Society. Primary headache disorders in the Republic of Georgia: prevalence and risk factors. <i>Neurology</i> . 2009; 73(21): 1796-803.	2006-2008	*	
Georgia	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Gilst WH van, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J</i> . 2003; 24(5): 442-63.	2000-2001		
Georgia	World Health Organization (WHO). Georgia WHO Leishmaniasis Country Profile.	1994-2008	*	
Georgia	Quick ML, Sutter RW, Kobaidze K, Malakmadze N, Strebel PM, Nakashidze R, Murvanidze S. Epidemic diphtheria in the Republic of Georgia, 1993-1996: risk factors for fatal outcome among hospitalized patients. <i>J Infect Dis</i> . 2000; 181(3): 130-137.	1993-1995		
Georgia	Khetsuriani N, Inmadze P, Dekanosidze N. Diphtheria epidemic in the Republic of Georgia, 1993-1997. <i>J Infect Dis</i> . 2000; 180: 80-85.	1993-1997		
Georgia	Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, Büchele G, Clausen M, Cookson WOC, von Mutius E, Strachan DP, Williams HC. ISAAC Phase Two Study Group. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. <i>J Allergy Clin Immunol</i> . 2008; 121(1): 141-147.	2005-2007	*	
Georgia	Nagervadze M, Diasamidze A, Khukhunaishvili R, Akhvediani L, Koridze M, Dumbadze G, Tskvitinidze S. Composition of erythrocytic (ABO, Rh-Hr, Kell, MN) group antigens characteristic of the Ozurgeti district's population. <i>Georgian Med News</i> . 2010; 51-5.	2007-2009	*	†
Georgia	USSR - Georgian SSR Vital Registration Birth Data 1989 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1989		
Germany	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2005		
Germany	Germany Vital Registration - Deaths 1991 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1991	*	
Germany	Germany Vital Registration - Deaths 1992 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1992	*	
Germany	Germany Vital Registration - Deaths 1993 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1993	*	
Germany	Germany Vital Registration - Deaths 1999 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1999	*	
Germany	Germany Vital Registration - Deaths 2003 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2003	*	
Germany	World Health Organization (WHO). Germany World Health Survey 2004. Geneva, Switzerland: World Health Organization (WHO), 2005.	2004		
Germany	Federal Environment Agency (Germany), Federal Institute for Drugs and Medical Devices (Germany), Max Planck Institute of Psychiatry, Robert Koch Institute. Germany National Health Interview and Examination Survey 1997-1999. Berlin, Germany: Robert Koch Institute, 2000.	1997-1999		
Germany	Robert Koch Institute. Germany Epidemiological Infection Yearbook for Notifiable Diseases 2001. Berlin, Germany: Robert Koch Institute, 2002.	2001	*	
Germany	Robert Koch Institute. Germany Epidemiological Infection Yearbook for Notifiable Diseases 2002. Berlin, Germany: Robert Koch Institute, 2003.	2002	*	
Germany	Robert Koch Institute. Germany Epidemiological Infection Yearbook for Notifiable Diseases 2003. Berlin, Germany: Robert Koch Institute, 2004.	2003	*	
Germany	Robert Koch Institute. Germany Epidemiological Infection Yearbook for Notifiable Diseases 2004. Berlin, Germany: Robert Koch Institute, 2005.	2004	*	
Germany	Robert Koch Institute. Germany Epidemiological Infection Yearbook for Notifiable Diseases 2005. Berlin, Germany: Robert Koch Institute, 2006.	2005	*	
Germany	Robert Koch Institute. Germany Epidemiological Infection Yearbook for Notifiable Diseases 2007. Berlin, Germany: Robert Koch Institute, 2008.	2007	*	
Germany	Robert Koch Institute. Germany Epidemiological Infection Yearbook for Notifiable Diseases 2008. Berlin, Germany: Robert Koch Institute, 2009.	2008	*	
Germany	Robert Koch Institute. Germany Epidemiological Infection Yearbook for Notifiable Diseases 2009. Berlin, Germany: Robert Koch Institute, 2010.	2009	*	
Germany	Robert Koch Institute. Germany Epidemiological Infection Yearbook for Notifiable Diseases 2010. Berlin, Germany: Robert Koch Institute, 2011.	2010	*	
Germany	Robert Koch Institute. Germany Epidemiological Infection Yearbook for Notifiable Diseases 2011. Berlin, Germany: Robert Koch Institute, 2012.	2011	*	
Germany	Germany Vital Registration - Deaths 2010 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2010	*	
Germany	Gehring J, Perz S, Stieber J, Kufner R, Keil U. Cardiovascular risk factors, ECG abnormalities and quality of life in subjects with atrial fibrillation. <i>Soz Präventivmed</i> . 1996; 41(3): 185-93.	1984-1988		
Germany	Thalassaemia International Federation, World Health Organization (WHO). Management of Haemoglobin Disorders: Report of a Joint WHO-TIF Meeting, Nicosia, Cyprus, 16-18 November 2007. Geneva, Switzerland: World Health Organization (WHO), 2008.	2004		
Germany	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. <i>Scand J Clin Lab Invest</i> . 2007; 67(1): 39-69.	1988, 2006		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Germany	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1988, 2003, 2006		
Germany	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	2009		†
Germany	Frese T, Herrmann K, Sandholzer H. Pruritus as Reason for Encounter in General Practice. <i>J Clin Med Res.</i> 2011; 3(5): 223-9.	1999-2000		
Germany	Zuberbier T, Balke M, Worm M, Edenharter G, Maurer M. Epidemiology of urticaria: a representative cross-sectional population survey. <i>Clin Exp Dermatol.</i> 2010; 35(8): 869-73.	2009-2010		
Germany	Ständer S, Schäfer I, Phan NQ, Blome C, Herberger K, Heigel H, Augustin M. Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730. <i>Dermatology (Basel).</i> 2010; 221(3): 229-35.	2008		
Germany	Matterne U, Apfelbacher CJ, Loerbroks A, Schwarzer T, Büttner M, Ofenloch R, Diepgen TL, Weisshaar E. Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study. <i>Acta Derm Venereol.</i> 2011; 91(6): 674-9.	2008-2009		
Germany	Augustin M, Herberger K, Hintzen S, Heigel H, Franke N, Schäfer I. Prevalence of skin lesions and need for treatment in a cohort of 90,880 workers. <i>Br J Dermatol.</i> 2011; 165(4): 865-73.	2002-2009		
Germany	Kolominsky-Rabas PL, Sarti C, Heuschmann PU, Graf C, Siemonsen S, Neundoerfer B, Katalinic A, Lang E, Gassmann K-G, von Stockert TR. A Prospective Community-Based Study of Stroke in Germany-The Erlangen Stroke Project (ESPro): Incidence and Case Fatality at 1, 3, and 12 Months. <i>Stroke.</i> 1998; 29(12): 2501-6.	1994-1996		
Germany	Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of Ischemic Stroke Subtypes According to TOAST Criteria. <i>Stroke.</i> 2001; 32(12): 2735-40.	1994-1998		
Germany	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol.</i> 2008; 121(4): 947-954.	1994, 1999		
Germany	Forster J, Ihorst G, Rieger CH, Stephan V, Frank HD, Gurth H, Berner R, Rohwedder A, Werchau H, Schumacher M, Tsai T, Petersen G. Prospective population-based study of viral lower respiratory tract infections in children under 3 years of age (the PRIDE study). <i>Eur J Pediatr.</i> 2004; 12(163): 709-16.	1999-2001		
Germany	Forster J, Guarino A, Parez N, Moraga F, Román E, Mory O, Tozzi AE, de Aguilera AL, Wahn U, Graham C, Berner R, Ninan T, Barberousse C, Meyer N, Soriano-Gabarró M. Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of age. <i>Pediatrics.</i> 2009; 123(3): e393-400.	2005-2006		
Germany	Demytinaere K, Bruhaerts R, Lee S, Posada-Villa J, Kovess V, Angermeyer MC, Levinson D, de Girolamo G, Nakane H, Muehlenberg Z, Lara C, de Graaf R, Scott KM, Gureje O, Stein DJ, Haro JM, Bromet EJ, Kessler RC, Alonso J, Von Korff M. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. <i>Pain.</i> 2007; 129(3): 332-42.	2002-2003		
Germany	Dickerhoff R, Genzel-Boroviczeny O, Kohne E. Haemoglobinopathies and newborn haemoglobinopathy screening in Germany. <i>J Clin Pathol.</i> 2009; 1(62): 34.	2008		
Germany	Stang A, Ziegler S, Büchner U, Ziegler B, Jöckel K-H, Ziegler V. Malignant melanoma and nonmelanoma skin cancers in Northrhine-Westphalia, Germany: a patient- vs diagnosis-based incidence approach. <i>Int J Dermatol.</i> 2007; 46(6): 564-70.	1998-2003		
Germany	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000-2004, 2006-2008		
Germany	Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. <i>Ann Rheum Dis.</i> 2008; 67(7): 960-6.	2000-2005		
Germany	Buddenhagen F, Pantović MM. Comparative epidemiologic analysis of multiple sclerosis in areas of Central and Southern Europe. <i>Psychiatr Neurol Med Psychol (Leipz).</i> 1985; 37(10): 565-72.	1982, 1984		
Germany	Poser S, Kurtzke JF, Poser W, Schlaf G. Survival in multiple sclerosis. <i>J Clin Epidemiol.</i> 1989; 42(2): 159-68.	1973-1981		
Germany	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Germany	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	1999		
Germany	Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. <i>Diabetologia.</i> 1996; 39(11): 1377-84.	1993-1995		
Germany	Ziegler D, Gries FA, Spiller M, Lessmann F. The epidemiology of diabetic neuropathy. <i>Diabet Cardiovascular Autonomic Neuropathy Multicenter Study Group. J Diabet Complications.</i> 1992; 6(1): 49-57.	1989-1991		
Germany	Federal Ministry of Health (Germany), Institute for Therapy and Health Research (IFT). Germany Population Survey on the Consumption of Psychoactive Substances in the German Adult Population 1997.	1997		
Germany	Sämann A, Tajjyeva O, Müller N, Tschauer T, Hoyer H, Wolf G, Müller UA. Prevalence of the diabetic foot syndrome at the primary care level in Germany: a cross-sectional study. <i>Diabet Med.</i> 2008; 25(5): 557-63.	2000-2004		
Germany	Lauterbach S, Kostev K, Köhlmann T. Prevalence of diabetic foot syndrome and its risk factors in the UK. <i>J Wound Care.</i> 2010; 19(8): 333-7.	2008		
Germany	Icks A, Kruse J, Dragano N, Broecker-Preuss M, Slomiany U, Mann K, Jöckel KH, Erbel R, Giani G, Moebus S; Heinz Nixdorf Recall Study Investigator Group. Are symptoms of depression more common in diabetes? Results from the Heinz Nixdorf Recall study. <i>Diabet Med.</i> 2008; 25(11): 1330-6.	2000		
Germany	Rathmann W, Haastert S, Icks A, Löwel H, Meisinger C, Holle R, Giani G. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. <i>Diabetologia.</i> 2003; 46(2): 182-9.	2000		
Germany	H Müller, E Raum, D Rothenbacher, C Stegmaier, H Brenner. Association of diabetes and body mass index with levels of prostate-specific antigen: implications for correction of prostate-specific antigen cutoff values <i>Cancer Epidemiol Biomarkers Prev.</i> 2009; 18(5): 1350-6.	2001		
Germany	Pothmann R, Frankenberg SV, Müller B, Sartory G, Hellmeier W. Epidemiology of headache in children and adolescents: evidence of high prevalence of migraine. <i>Int J Behav Med.</i> 1994; 1(1): 76-89.	1989-1992		
Germany	Fendrich K, Vennemann M, Pfaffenrath V, Evers S, May A, Berger K, Hoffmann W. Headache prevalence among adolescents--the German DMKG headache study. <i>Cephalalgia.</i> 2007; 27(4): 347-54.	2003-2004		
Germany	Radtke A, Neuhauser H. Prevalence and burden of headache and migraine in Germany. <i>Headache.</i> 2009; 49(1): 79-89.	2004		
Germany	Göbel H, Petersen-Braun M, Soyka D. The epidemiology of headache in Germany: a nationwide survey of a representative sample on the basis of the headache classification of the International Headache Society. <i>Cephalalgia.</i> 1994; 14(2): 97-106.	1993		
Germany	Hasford J, Uricher J, Tauscher M, Bramlage P, Virchow JC. Persistence with asthma treatment is low in Germany especially for controller medication - a population based study of 483,051 patients. <i>Allergy.</i> 2010; 65(3): 347-54.	2005-2006	*	
Germany	Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, Gjomarkaj M, Forsberg B, Gunnbjornsdottir M, Minov J, Brozek G, Dahlén SE, Toskala E, Kowalski ML, Olze H, Howarth P, Krämer U, Baelum J, Loureiro C, Kasper L, Bousquet PJ, Bousquet J, Bachert C, Folkens W, Burney P. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. <i>Allergy.</i> 2012; 67(1): 91-8.	2008-2009	*	
Germany	Schäper C, Gläser S, Obst A, Schmidt CO, Völzke H, Felix SB, Ewert R, Koch B. Symptoms and diagnosis of asthma in a general population – longitudinal results from the SHIP database. <i>J Asthma.</i> 2010; 47(8): 860-4.	1997-2006	*	
Germany	Laussmann D, Haftenberger M, Langen U, Eis D. Determinants of asthma among children and adolescents in Germany. Results of the German Health and Examination Survey for Children and Adolescents (KiGGS). <i>Bundesgesundheitsblatt.</i> 2012; 55(3): 308-17.	2003-2006	*	
Germany	Schäfer I, Rustenbach SJ, Zimmer L, Augustin M. Prevalence of skin diseases in a cohort of 48,665 employees in Germany. <i>Dermatology (Basel).</i> 2008; 217(2): 169-72.	2001-2005	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Germany	Glaser S, Schäper C, Obst A, Itermann T, Völzke H, Felix SB, Vogelmeier C, Dörr M, Ewert R, Koch B. Impact of different definitions of airflow limitation on the prevalence of chronic obstructive pulmonary disease in the general population. <i>Respiration</i> . 2010; 80(4): 292-300.	2003-2006	*	
Germany	Cramer C, Link E, Bauer C-P, Hoffmann U, von Berg A, Lehmann I, Herbarth O, Borte M, Schaab B, Sausenthaler S, Wichmann H-E, Heinrich J, Krämer U. LISApplus study group. Association between attendance of day care centres and increased prevalence of eczema in the German birth cohort study LISApplus. <i>Allergy</i> . 2011; 66(1): 68-75.	1997-1999	*	
Germany	Romanos M, Gerlach M, Warnke A, Schmitt J. Association of attention-deficit/hyperactivity disorder and atopic eczema modified by sleep disturbance in a large population-based sample. <i>J Epidemiol Community Health</i> . 2010; 64(3): 269-73.	2003-2006	*	
Germany	Holtfreter B, Demmer RT, Bernhardt O, Papapanou PN, Schwahn C, Kocher T, Desvarieux M. A comparison of periodontal status in the two regional, population-based studies of SHIP and INVEST. <i>J Clin Periodontol</i> . 2012; 39(12): 1115-24.	1997-2001	*	
Germany	Pieper K, Dressler S, Heinzl-Gutenbrunner M, Neuhäuser A, Kreecker M, Wunderlich K, Jablonski-Momeni A. The influence of social status on pre-school children's eating habits, caries experience and caries prevention behavior. <i>Int J Public Health</i> . 2012; 57(1): 207-15.	2006	*	
Germany	Mengel R, Koch H, Pfeifer C, Florès-de-Jacoby L. Periodontal health of the population in eastern Germany (former GDR). <i>J Clin Periodontol</i> . 1993; 20(10): 752-5.	1991-1992	*	
Germany	Flores-de-Jacoby L, Schoop S, Weichsler C, Zafirooulos GG. Periodontal conditions in Hesse, Federal Republic of Germany, measured by CPITN. <i>Community Dent Oral Epidemiol</i> . 1989; 17(6): 307-9.	1987	*	
Germany	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. <i>Community Dent Oral Epidemiol</i> . 1991; 19(2): 72-3.	1987		
Germany	Flores-de-Jacoby L, Mengel R, Joannou U, Zafirooulos GG. CPITN application in regular dental practice. <i>Dtsch Zahn Mund Kieferheilkd Zentralbl</i> . 1992; 80(1): 13-20.	1987-1989	*	
Germany	Holtfreter B, Schwahn C, Biffar R, Kocher T. Epidemiology of periodontal diseases in the Study of Health in Pomerania. <i>J Clin Periodontol</i> . 2009; 36(2): 114-23.	1997-2001	*	
Germany	Ertle J, Dechêne A, Sowa J-P, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn W-K, Canbay A. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. <i>Int J Cancer</i> . 2011; 128(10): 2436-43.	2007-2008	*	
Germany	Abbas S, Ihle P, Köster I, Schubert I. Prevalence and incidence of diagnosed endometriosis and risk of endometriosis in patients with endometriosis-related symptoms: findings from a statutory health insurance-based cohort in Germany. <i>Eur J Obstet Gynecol Reprod Biol</i> . 2012; 160(1): 79-83.	2007	*	
Germany	Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I. Epidemiology and comorbidity of psoriasis in children. <i>Br J Dermatol</i> . 2010; 162(3): 633-6.	2005	*	
Germany	Troitzsch P, Paulista Markus MR, Dörr M, Felix SB, Jünger M, Schminke U, Schmidt C-O, Völzke H, Baumsteier SE, Arnold A. Psoriasis is associated with increased intima-media thickness—the Study of Health in Pomerania (SHIP). <i>Atherosclerosis</i> . 2012; 225(2): 486-90.	2002-2006	*	
Germany	Schnabel E, Sausenthaler S, Brockow I, Liese J, Herbarth O, Michael B, Schaab B, Krämer U, von Berg A, Wichmann H-E, Heinrich J, LISApplus Study Group. Burden of otitis media and pneumonia in children up to 6 years of age: results of the LISApplus birth cohort. <i>Eur J Pediatr</i> . 2009; 188(10): 1251-7.	1997-2005	*	
Germany	Zimmermann A, Bernuit D, Gerlinger C, Schaefers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. <i>BMC Womens Health</i> . 2012; 6.	2009	*	
Germany	Van Gessel H, Gaßmann J, Kröner-Herwig B. Children in Pain: Recurrent Back Pain, Abdominal Pain, and Headache in Children and Adolescents in a Four-Year-Period. <i>J Pediatr</i> . 2011; 158(6): 977-983.e2.	2003-2007	*	
Germany	Schmidt CO, Raspe H, Pflingsten M, Hasenbring M, Basler HD, Eich W, Kohlmann T. Does attrition bias longitudinal population-based studies on back pain? <i>Eur J Pain</i> . 2011; 15(1): 84-91.	2003	*	
Germany	Karsten C, Baumgarte S, Friedrich AW, von Eiff C, Becker K, Wosniok W, Ammon A, Bockemuhl J, Karch H, Huppertz H-I. Incidence and risk factors for community-acquired acute gastroenteritis in north-west Germany in 2004. <i>Eur J Clin Microbiol Infect Dis</i> . 2009; 28(8): 935-43.	2004	*	
Germany	Giaquinto C, van Damme P, REVEAL Study Group. Age distribution of paediatric rotavirus gastroenteritis cases in Europe: the REVEAL study. <i>Scand J Infect Dis</i> . 2010; 42(2): 142-7.	2004-2005	*	
Germany	Jansen A, Stark K, Kunkel J, Schreier E, Ignatius R, Liesenfeld O, Werber D, Göbel UB, Zeitz M, Schneider T. Aetiology of community-acquired, acute gastroenteritis in hospitalised adults: a prospective cohort study. <i>BMC Infect Dis</i> . 2008; 8: 143.	2005-2007	*	
Germany	Riedel-Heller SG, Busse A, Aurich C, Matschinger H, Angermeyer MC. Incidence of dementia according to DSM-III-R and ICD-10: results of the Leipzig Longitudinal Study of the Aged (LEILA75+), Part 2. <i>Br J Psychiatry</i> . 2001; 255-60.	1997-1999		†
Germany	Wernicke TF, Reichsiehs FM. Prevalence of dementia in old age: clinical diagnoses in subjects aged 95 years and older. <i>Neurology</i> . 1994; 44(2): 250-3.	1988-1992		
Germany	Meller I, Fichter M, Schröppel H, Beck-Eichinger M. Mental and somatic health and need for care in octo- and nonagenarians. An epidemiological community study. <i>Eur Arch Psychiatry Clin Neurosci</i> . 1993; 242(5): 286-92.	1990		†
Germany	Riedel-Heller SG, Busse A, Aurich C, Matschinger H, Angermeyer MC. Prevalence of dementia according to DSM-III-R and ICD-10: results of the Leipzig Longitudinal Study of the Aged (LEILA75+) Part 1. <i>Br J Psychiatry</i> . 2001; 250-4.	1997-1998		
Germany	Crocobbe LA, Mejia GC, Koster CR, Slade GD. Comparison of adult oral health in Australia, the USA, Germany and the UK. <i>Aust Dent J</i> . 2009; 54(2): 147-53.	2005		
Germany	Bolin AK, Bolin A, Koch G. Children's dental health in Europe: caries experience of 5- and 12-year-old children from eight EU countries. <i>Int J Paediatr Dent</i> . 1996; 6(3): 155-62.	1994		
Germany	Borutta A, Brauner K, Hufnagl S, Márton S, Mavrodzis K, Tarján I. Oral health in 8-9 year-old children in Saxony-Anhalt (Germany) and in two Hungarian cities (Budapest and Debrecen). <i>Community Dent Health</i> . 2006; 23(1): 26-30.	2001		
Germany	Franz FE, Götz W. Oral health survey in Haitian and Hamburg children aged 12-15. <i>Community Dent Oral Epidemiol</i> . 1983; 11(5): 302-7.	1981		
Germany	Zerfowski M, Koch MI, Niekusch U, Staehle HJ. Caries prevalence and treatment needs of 7- to 10-year-old schoolchildren in southwestern Germany. <i>Community Dent Oral Epidemiol</i> . 1997; 25(5): 348-51.	1995		
Germany	Sünju Clasen AB, von der Fehr FR, Kant van Daal JM. Caries prevalence of kindergarten children in Salzgitter and Oslo. <i>Caries Res</i> . 1992; 26(3): 201-4.	1989		
Germany	Robke FJ. Effects of nursing bottle misuse on oral health. Prevalence of caries, tooth malalignments and malocclusions in North-German preschool children. <i>J Orofac Orthop</i> . 2008; 69(1): 5-19.	2004-2005		
Germany	Jacobi F, Wittchen H-U, Höftling C, Höfler M, Pfister H, Müller N, Lieb R. Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS). <i>Psychol Med</i> . 2004; 34(04): 597-611.	1998-1999		
Germany	Wittchen HU, Nelson CB, Lachner G. Prevalence of mental disorders and psychosocial impairments in adolescents and young adults. <i>Psychol Med</i> . 1998; 28(1): 109-26.	1995		
Germany	Zipfel S, Löwe B, Reas DL, Deter H-C, Herzog W. Long-term prognosis in anorexia nervosa: lessons from a 21-year follow-up study. <i>Lancet</i> . 2000; 355(9205): 721-2.	1976-1997		
Germany	Fichter MM, Quadflieg N, Hedlund S. Twelve-year course and outcome predictors of anorexia nervosa. <i>Int J Eat Disord</i> . 2006; 39(2): 87-100.	1987-1999		
Germany	Meyer C, Rumpf HJ, Hapke U, John U. Prevalence of DSM-IV psychiatric disorders including nicotine dependence in the general population: results from the Northern Germany TACOS study. <i>Neurol Psych Brain Res</i> . 2001; 9(2): 75-80.	1996-1997		
Germany	Hesse A, Brändle E, Wilbert D, Köhrmann K-U, Alken P. Study on the prevalence and incidence of urolithiasis in Germany comparing the years 1979 vs. 2000. <i>Eur Urol</i> . 2003; 44(6): 709-13.	2000-2001		
Germany	Bogh EH, Rokkedal K, Valbak K. A 4-year follow-up on bulimia nervosa. <i>Eur Eat Disord Rev</i> . 2005; 13(1): 48-53.	1993-1999		
Germany	Perkonig A, Goodwin RD, Fiedler A, Behrendt S, Beesdo K, Lieb R, Wittchen H-U. The natural course of cannabis use, abuse and dependence during the first decades of life. <i>Addiction</i> . 2008; 103(3): 439-451.	1997, 1999, 2005		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Germany	Palm F, Urbanek C, Rose S, Bugge F, Bode B, Hennerici MG, Schmieder K, Inselmann G, Reiter R, Fleischer R, Piplack K-O, Safer A, Becher H, Grau AJ. Stroke Incidence and Survival in Ludwigshafen am Rhein, Germany: the Ludwigshafen Stroke Study (LuSS). <i>Stroke</i> . 2010; 41(9): 1865-70.	2006-2007		
Germany	Oldehinkel AJ WH, Schuster P. Prevalence, 20-month incidence and outcome of unipolar depressive disorders in a community sample of adolescents. <i>Psychol Med</i> . 1999; 29(3): 655-68.	1995-1997		
Germany	de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Künzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P. European Community Respiratory Health Survey Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. <i>Thorax</i> . 2004; 59(2): 120-125.	1991-1993		
Germany	Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E, BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. <i>Lancet</i> . 2007; 9589(9589): 741-50.	2005-2006		
Germany	Heinemann K, Thiel C, Möhner S, Lewis MA, Raff T, Kühl-Habich D, Heinemann LA. Benign gynecological tumors: estimated incidence: Results of the German Cohort Study on Women's Health. <i>Eur J Obstet Gynecol Reprod Biol</i> . 2003; 107(1): 78-80.	1998-2000		
Germany	Downes E, Sikirica V, Gilabert-Estelles J, Bolge SC, Dodd SL, Maroulis C, Subramanian D. The burden of uterine fibroids in five European countries. <i>Eur J Obstet Gynecol Reprod Biol</i> . 2010; 152(1): 96-102.	2007		
Germany	Jungehülsing GJ, Müller-Nordhorn J, Nolte CH, Roll S, Rossnagel K, Reich A, Wagner A, Einhäupl KM, Willich SN, Villringer A. Prevalence of stroke and stroke symptoms: a population-based survey of 28,090 participants. <i>Neuroepidemiology</i> . 2008; 30(1): 51-7.	2006-2008		
Germany	Essau CA, Groen G, Conradt J, Turbanisch U, Petermann F. Frequency, comorbidity and psychosocial correlates of attention-deficit/hyperactivity disorder. Results of a Bremen adolescent study. <i>Fortschr Neurol Psychiatr</i> . 1999; 67(7): 296-305.	1997		
Germany	Weyerer S, Castell R, Biener A, Artner K, Dilling H. Prevalence and treatment of psychiatric disorders in 3 to 14-year-old children: results of a representative field study in the small town rural region of Traunstein, upper Bavaria. <i>Acta Psychiatr Scand</i> . 1988; 77(3): 290-6.	1986		
Germany	Heinemann LAJ, Minh TD, Filonenko A, Uhl-Hochgräber K. Explorative evaluation of the impact of severe premenstrual disorders on work absenteeism and productivity. <i>Womens Health Issues</i> . 2010; 20(1): 58-65.	2007		
Germany	Gaulrapp K, Backe J, Steck T. Assessment of the prevalence of pre- and perimenstrual symptoms in female personnel of a university clinic. <i>Gynakol Geburtshilfliche Rundsch</i> . 1995; 35(4): 199-208.	1996-1997		
Germany	United States Renal Data System Coordinating Center. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2000-2007		
Germany	United States Renal Data System Coordinating Center. USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2003.	1998-1999		
Germany	Desai S, Meyer T, Thamm M, Hamouda O, Bremer V. Prevalence of Chlamydia trachomatis among young German adolescents, 2005-06. <i>Sex Health</i> . 2011; 8(1): 120-2.	2005-2006		
Germany	Griesinger G, Gille G, Klapp C, von Otte S, Diedrich K. Sexual behaviour and Chlamydia trachomatis infections in German female urban adolescents, 2004. <i>Clin Microbiol Infect</i> . 2007; 13(4): 436-9.	2007		
Germany	Berg D, Siefker C, Ruprecht-Dörfler P, Becker G. Relationship of substantia nigra echogenicity and motor function in elderly subjects. <i>Neurology</i> . 2001; 56(1): 13-7.	1998		
Germany	De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology</i> . 2000; 54(11 Suppl 5): S21-23.	1997		
Germany	Oertel WH. Parkinson's disease: epidemiology, (differential) diagnosis, therapy, relation to dementia. <i>Arzneimittelforschung</i> . 1995; 45(3A): 386-9.	1992		
Germany	Trenkwalder C, Schwarz J, Gebhard J, Ruland D, Trenkwalder P, Hense HW, Oertel WH. Starnberg trial on epidemiology of Parkinsonism and hypertension in the elderly. Prevalence of Parkinson's disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. <i>Arch Neurol</i> . 1995; 52(10): 1017-22.	1992		
Germany	Tüchsen F, Jensen AA. Agricultural work and the risk of Parkinson's disease in Denmark, 1981-1993. <i>Scand J Work Environ Health</i> . 2000; 26(4): 359-62.	1981-1993		
Germany	Berger K BM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology</i> . 2000; 54(11): 24-7.	1997		
Germany	Cooper B, Sosna U. [Psychiatric disease in an elderly population. An epidemiologic field study in Mannheim]. <i>Nervenarzt</i> . 1983; 54(5): 239-49.	1981		
Germany	Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganey K, Giel R, an der Heiden W, Holmberg SK, Janca A, Lee PW, Lecin CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Tham R, Tsirkin SJ, Varma VK, Walsh D, Wiersma D. Recovery from psychotic illness: a 15- and 25-year international follow-up study. <i>Br J Psychiatry</i> . 2001; 178: 506-17.	1978-1993		
Germany	Hewer W, Rössler W. [Mortality of patients with functional psychiatric illnesses during inpatient treatment]. <i>Fortschr Neurol Psychiatr</i> . 1997; 65(4): 171-81.	1984-1986		
Germany	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Germany	Roth-Isigkeit A, Thyen U, Raspe HH, Stöven H, Schmucker P. Reports of pain among German children and adolescents: an epidemiological study. <i>Acta Paediatr</i> . 2004; 93(2): 258-63.	2001		
Germany	Kohlmann T, Deck R, Raspe H. Prevalence and severity of back pain in Lubeck. <i>Aktuelle Rheumatol</i> . 1995; 20(3): 99-104.	1991-1992		
Germany	Spahn G, Schiele R, Langlotz A, Jung R. Prevalence of functional pain of the back, the hip and the knee in adolescents. Results of a cross-sectional study. <i>Dtsch Med Wochenschr</i> . 2004; 129(43): 2285-90.	2001		
Germany	Hüppe A, Müller K, Raspe H. Is the occurrence of back pain in Germany decreasing? Two regional postal surveys a decade apart. <i>Eur J Public Health</i> . 2007; 17(3): 318-22.	1991-1992, 2003		
Germany	Neuhauser H, Ellert U, Ziese T. Chronic back pain in the general population in Germany 2002/2003: prevalence and highly affected population groups. <i>Gesundheitswesen</i> . 2005; 67(10): 685-93.	2002-2003		
Germany	Schmidt CO, Raspe H, Pflingsten M, Hasenbring M, Basler HD, Eich W, Kohlmann T. Back pain in the German adult population: prevalence, severity, and sociodemographic correlates in a multiregional survey. <i>Spine</i> . 2007; 32(18): 2005-11.	2003-2006		
Germany	Buxbaum S, Doerr HW, Allwinn R. Epidemiological analysis of immunity against vaccine-preventable diseases: rubella, measles, mumps and chickenpox. <i>Dtsch Med Wochenschr</i> . 2001; 126(46): 1289-93.	1999-2000		
Germany	Liedtke W, Opalka B, Zimmermann CW, Lignitz E. Age distribution of latent herpes simplex virus 1 and varicella-zoster virus genome in human nervous tissue. <i>J Neurol Sci</i> . 1993; 116(1): 6-11.	1990		
Germany	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1995, 1997, 2000, 2003, 2006		
Germany	Streppel M, Richling F, Roth B, Walger M, von Wedel H, Eckel HE. Epidemiology and etiology of acquired hearing disorders in childhood in the Cologne area. <i>Int J Pediatr Otorhinolaryngol</i> . 1998; 44(3): 235-43.	1992-1993		
Germany	Cooper B. Mental handicap in school age children of Mannheim. An epidemiologic contribution. <i>Nervenarzt</i> . 1990; 61(9): 550-60.	1990		
Germany	Gulne U, Matschinger H, Angermeyer MC, Riedel-Heller SG. Incident dementia cases and mortality. Results of the Leipzig Longitudinal Study of the Aged (LEILA75+). <i>Dement Geriatr Cogn Disord</i> . 2006; 22(3): 185-93.	1998-1999		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Germany	Ort C, Obermeier F, Thielser S, Kemptner D, Bauer A, Schölmerich J, Rogler G, Timmer A. The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study. <i>Eur J Gastroenterol Hepatol.</i> 2008; 20(9): 917-23.	2004-2006	*	†
Germany	McDowell RD, Ryan A, Bunting BP, O'Neill SM, Alonso J, Bruffaerts R, de Graaf R, Florescu S, Vilagut G, de Almeida JMC, de Girolamo G, Haro JM, Hinkov H, Kovess-Masfety V, Matschinger H, Tomov T. Mood and anxiety disorders across the adult lifespan: a European perspective. <i>Psychol Med.</i> 2013; 1-16.	2002-2003	*	
Germany	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Germany	Bouvier-Colle M-H, Mohangoo AD, Gissler M, Novak-Antolic Z, Vutuc C, Szamotulska K, Zeitlin J, Euro-Peristat Scientific Committee. What about the mothers? An analysis of maternal mortality and morbidity in perinatal health surveillance systems in Europe. <i>BJOG.</i> 2012; 119(7): 880-90.	2003-2004	*	
Germany	Beyerlein A, Schiessl B, Lack N, von Kries R. Associations of gestational weight loss with birth-related outcome: a retrospective cohort study. <i>BJOG.</i> 2011; 118(1): 55-61.	2000-2007	*	
Germany	Voigt M, Neudecker K, Schneider KTM, Olbertz D, Briese V, Straube W, Straube S. Effects of smoking specified as cigarettes per day and maternal body mass index on hypertensive disorders of pregnancy. <i>Z Geburtshilfe Neonatol.</i> 2013; 217(1): 24-7.	1998-2000	*	
Germany	Palm F, Dos Santos M, Urbanek C, Greulich M, Zimmer K, Safer A, Grau AJ, Becher H. Stroke seasonality associations with subtype, etiology and laboratory results in the Ludwigshafen Stroke Study (LaSS). <i>Eur J Epidemiol.</i> 2013; 28(5): 373-81.	2006-2007	*	
Germany	Freitag CM, May TW, Pfäfflin M, König S, Rating D. Incidence of epilepsies and epileptic syndromes in children and adolescents: a population-based prospective study in Germany. <i>Epilepsia.</i> 2001; 42(8): 979-85.	1999-2000	*	
Germany	Doose H, Sitepu B. Childhood epilepsy in a German city. <i>Neuropediatrics.</i> 1983; 14(4): 220-4.	1957-1966	*	
Germany	Doerfer J, Wässer S. An epidemiologic study of febrile seizures and epilepsy in children. <i>Epilepsy Res.</i> 1987; 1(2): 149-51.	1982	*	
Germany	Andrade L, Caraveo-Andujaga JJ, Berglund P, Bijl RV, De Graaf R, Vollebergh W, Dragomirecka E, Kohn R, Keller M, Kessler RC, Kawakami N, Kiliç C, Offord D, Ustun TB, Wittchen H-U. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. <i>Int J Methods Psychiatr Res.</i> 2003; 12(1): 3-21.	1995		
Germany	Copeland JR, Beekman AT, Dewey ME, Hooijer C, Jordan A, Lawlor BA, Lobo A, Magnusson H, Mann AH, Meller I, Prince MJ, Reischies F, Turina C, deVries MW, Wilson KC. Depression in Europe. Geographical distribution among older people. <i>Br J Psychiatry.</i> 1999; 174: 312-21.	1990-1994		
Germany	Lépine JP, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). <i>Int Clin Psychopharmacol.</i> 1997; 12(1): 19-29.	1995		
Germany	Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, Joyce PR, Karam EG, Lee CK, Lellouch J, Lépine JP, Newman SC, Rubio-Stipec M, Wells JE, Wickramaratne PJ, Wittchen H, Yeh EK. Cross-national epidemiology of major depression and bipolar disorder. <i>JAMA.</i> 1996; 276(4): 293-9.	1981		
Germany	Petry W, Heintges T, Hensel F, Erhardt A, Wenning M, Niederer C, Häussinger D. [Hepatocellular carcinoma in Germany. Epidemiology, etiology, clinical aspects and prognosis in 100 consecutive patients of a university clinic]. <i>Z Gastroenterol.</i> 1997; 35(12): 1059-67.	1990-1995		
Germany	Hellerbrand C, Hartmann A, Richter G, Knöll A, Wiest R, Schölmerich J, Lock G. Hepatocellular carcinoma in southern Germany: epidemiological and clinicopathological characteristics and risk factors. <i>Dig Dis.</i> 2001; 19(4): 345-51.	1994-2000		
Germany	Kirchner G, Kirovski G, Hebestreit A, Schölmerich J, Schlitt HJ, Stoeltzing O, Hellerbrand C. Epidemiology and survival of patients with hepatocellular carcinoma in Southern Germany. <i>Int J Clin Exp Med.</i> 2010; 3(2): 169-79.	1994-2008		
Germany	Kubicka S, Rudolph KL, Hanke M, Tietze MK, Tillmann HL, Trautwein C, Manns M. Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area. <i>Liver.</i> 2000; 20(4): 312-8.	1993-1997		
Germany	Rabe C, Pilz T, Klostermann C, Berna M, Schild HH, Sauerbruch T, Caselmann WH. Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. <i>World J Gastroenterol.</i> 2001; 7(2): 208-15.	1997-1999		
Germany	Ravens-Sieberer U, Wille N, Erhart M, Bettge S, Wittchen H-U, Rothenberger A, Herpertz-Dahlmann B, Resch F, Hölling H, Bullinger M, Barkmann C, Schulte-Markwort M, Döpfner M, BELLA study group. Prevalence of mental health problems among children and adolescents in Germany: results of the BELLA study within the National Health Interview and Examination Survey. <i>Eur Child Adolesc Psychiatry.</i> 2008; 22-33.	2003-2006	*	
Germany	Zhang QL, Koenig W, Raun E, Stegmaier C, Brenner H, Rothenbacher D. Epidemiology of chronic kidney disease: results from a population of older adults in Germany. <i>Prev Med.</i> 2009; 48(2): 122-7.	2000-2002		
Germany	Bommer J. Prevalence and socio-economic aspects of chronic kidney disease. <i>Nephrol Dial Transplant.</i> 2002; 17(Suppl 11): 8-12.	1997-2000		
Germany	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2004, 2007, 2010, 2012		
Germany	Kratzer W, Walcher T, Arnold F, Akinli AS, Mason RA, Denzer C, Böhm B, Imhof A, Hainle MM. Gallstone prevalence and risk factors for gallstone disease in an urban population of children and adolescents. <i>Z Gastroenterol.</i> 2010; 48(6): 683-7.	2002-2003	*	
Germany	Walcher T, Haentle MM, Mason RA, Koenig W, Imhof A, Kratzer W, EMIL Study Group. The effect of alcohol, tobacco and caffeine consumption and vegetarian diet on gallstone prevalence. <i>Eur J Gastroenterol Hepatol.</i> 2010; 22(11): 1345-51.	2002-2003		
Germany	Döpfner M, Breuer D, Wille N, Erhart M, Ravens-Sieberer U, BELLA study group. How often do children meet ICD-10/DSM-IV criteria of attention deficit-hyperactivity disorder and hyperkinetic disorder? Parent-based prevalence rates in a national sample--results of the BELLA study. <i>Eur Child Adolesc Psychiatry.</i> 2008; 59-70.	2003-2006	*	
Germany	Fieser N, Sinnacher U, Tausch Y, Werner-Belak S, Ladenburger-Strauss S, von Baum H, Reischl U, Essig A. Chlamydia trachomatis prevalence, genotype distribution and identification of the new Swedish variant in Southern Germany. <i>Infection.</i> 2013; 41(1): 159-66.	2008-2009	*	
Germany	Weissenbacher TM, Kupka MS, Kainer F, Friese K, Mylonas I. Screening for Chlamydia trachomatis in pregnancy: a retrospective analysis in a German urban area. <i>Arch Gynecol Obstet.</i> 2011; 283(6): 1343-7.	2001-2007	*	
Germany	Hellenbrand W, Thierfelder W, Müller-Pebody B, Hamouda O, Breuer T. Seroprevalence of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in former East and West Germany, 1997-1998. <i>Eur J Clin Microbiol Infect Dis.</i> 2005; 24(2): 131-5.	1997-1998	*	
Germany	Galler A, Stange T, Müller G, Näge A, Vogel C, Kapellen T, Bartelt H, Kunath H, Koch R, Kiess W, Rothe U. Childhood Diabetes Registry in Saxony, Germany. Incidence of childhood diabetes in children aged less than 15 years and its clinical and metabolic characteristics at the time of diagnosis: data from the Childhood Diabetes Registry of Saxony, Germany. <i>Horm Res Paediatr.</i> 2010; 74(4): 285-91.	1999-2008		
Germany	Rathmann W, Strassburger K, Heier M, Holle R, Thorand B, Giani G, Meisinger C. Incidence of Type 2 diabetes in the elderly German population and the effect of clinical and lifestyle risk factors: KORA S4/F4 cohort study. <i>Diabet Med.</i> 2009; 26(12): 1212-9.	1999-2008		
Germany	Trautner C, Haastert B, Giani G, Berger M. Incidence of lower limb amputations and diabetes. <i>Diabetes Care.</i> 1996; 19(9): 1006-9.	1990-1991		
Germany	Fichter MM, Quadflieg N. Twelve-year course and outcome of bulimia nervosa. <i>Psychol Med.</i> 2004; 34(8): 1395-406.	1985-2000	*	
Germany	Augustin R, Kraus L. Changes in prevalence of problem opiate use in Germany between 1990 and 2000. <i>Eur Addict Res.</i> 2004; 10(2): 61-7.	1991, 1995, 2000	*	
Germany	Kraus L, Augustin R, Frischer M, Kümmler P, Uhl A, Wiessing L. Estimating prevalence of problem drug use at national level in countries of the European Union and Norway. <i>Addiction.</i> 2003; 98(4): 471-85.	2000	*	
Germany	Scherbaum N, Specka M, Hauptmann G, Gastpar M. [Does maintenance treatment reduce the mortality rate of opioid addicts?]. <i>Fortschr Neurol Psychiatr.</i> 2002; 70(9): 455-61.	1988-1996	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Germany	Soyka M, Apelt SM, Lieb M, Wittchen H-U. One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients. <i>J Clin Psychopharmacol</i> . 2006; 26(6): 657-60.	1993-1994	*	
Germany	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant</i> . 1988; 3(6): 714-27.	1985-1986		
Germany	Berthouf F, Jones E, Gellert R, Mendel S, Saker L, Briggs D. Epidemiological data of treated end-stage renal failure in the European Union (EU) during the year 1995: report of the European Renal Association Registry and the National Registries. <i>Nephrol Dial Transplant</i> . 1999; 14(10): 2332-42.	1995		
Germany	Brodohl J, Offner G, Hoyer PF, Pichlmayr R. Outcome in children with endstage renal disease. <i>Acta Paediatr Jpn</i> . 1990; 32(6): 598-609.	1970-1989		
Germany	Trautner C, Haastert B, Mauckner P, Gätcke L-M, Giani G. Reduced incidence of lower-limb amputations in the diabetic population of a German city, 1990-2005: results of the Leverkusen Amputation Reduction Study (LARS). <i>Diabetes Care</i> . 2007; 30(10): 2633-7.	1990-2005		
Germany	Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. <i>J Clin Endocrinol Metab</i> . 2008; 93(4): 1408-11.	2005		
Germany	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Gilst WH van, Widimsky J, Freemanle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J</i> . 2003; 24(5): 442-63.	2000-2001		
Germany	Gaengler P, Goebel G, Kurbad A, Kosa W. Assessment of periodontal disease and dental caries in a population survey using the CPITN, GPM/T and DMF/T indices. <i>Community Dent Oral Epidemiol</i> . 1988; 16(4): 236-9.	1986		
Germany	Hohlfeld M, Bernimoulin JP. Application of the community periodontal index of treatment needs (CPITN) in a group of 45-54-year-old German factory workers. <i>J Clin Periodontol</i> . 1993; 20(8): 551-6.	1991		
Germany	Micheelis W, Bauch J. Oral health of representative samples of Germans examined in 1989 and 1992. <i>Community Dent Oral Epidemiol</i> . 1996; 24(1): 62-7.	1989-1992		
Germany	Schiffner U, Hoffmann T, Kerschbaum T, Micheelis W. Oral health in German children, adolescents, adults and senior citizens in 2005. <i>Community Dent Health</i> . 2009; 26(1): 18-22.	1997, 2005		
Germany	Rothenbacher D, Klenk J, Denkinger M, Karakas M, Nikolaus T, Peter R, Koenig W, ActiFe Study Group. Prevalence and determinants of chronic kidney disease in community-dwelling elderly by various estimating equations. <i>BMC Public Health</i> . 2012; 343.	2009-2010	*	
Germany	Jacobi F, Wittchen H-U, Höfling C, Sommer S, Lieb R, Höfler M, Pfister H. Estimating the prevalence of mental and somatic disorders in the community: aims and methods of the German National Health Interview and Examination Survey. <i>Int J Methods Psychiatr Res</i> . 2002; 11(1): 1-18.	1997-1999		
Germany	Nelson CB, Wittchen HU. DSM-IV alcohol disorders in a general population sample of adolescents and young adults. <i>Addiction</i> . 1998; 93(7): 1065-77.	1995		
Germany	Pabst A, Kraus L, Piontek D, Baumeister SE. Age differences in diagnostic criteria of DSM-IV alcohol dependence among adults with similar drinking behaviour. <i>Addiction</i> . 2012; 107(2): 331-8.	2006		
Germany	Lehmann S, Milde-Busch A, Straube A, von Kries R, Heinen F. How specific are risk factors for headache in adolescents? Results from a cross-sectional study in Germany. <i>Neuropediatrics</i> . 2013; 44(1): 46-54.	2008-2009	*	
Germany	Milde-Busch A, Blaschek A, Borggräfe I, Heinen F, Straube A, von Kries R. Associations of diet and lifestyle with headache in high-school students: results from a cross-sectional study. <i>Headache</i> . 2010; 50(7): 1104-14.	2007-2009	*	
Germany	Milde-Busch A, Boneberger A, Heinrich S, Thomas S, Kühnlein A, Radon K, Straube A, von Kries R. Higher prevalence of psychopathological symptoms in adolescents with headache. A population-based cross-sectional study. <i>Headache</i> . 2010; 50(5): 738-48.	2007-2009	*	
Germany	Straube A, Pfaffenrath V, Ladwig K-H, Meisinger C, Hoffmann W, Fendrich K, Vennemann M, Berger K. Prevalence of chronic migraine and medication overuse headache in Germany – the German DMKG Headache Study. <i>Cephalalgia</i> . 2010; 30(2): 207-13.	2007-2009	*	
Germany	Yoon M-S, Katsarova Z, Obermann M, Fritsche G, Oezzyurt M, Kaesewinkel K, Katsarova A, Santowski I, Diener H, Moebus S. Prevalence of primary headaches in Germany: results of the German Headache Consortium Study. <i>J Headache Pain</i> . 2012; 13(3): 215-23.	2003-2005	*	
Germany	Lehmann HC, Köhne A, Meyer zu Hörste G, Kieseier BC. Incidence of Guillain-Barré syndrome in Germany. <i>J Peripher Nerv Syst</i> . 2007; 12(4): 285.	2003		
Germany	Schiffner-Rohr J, Jow S, Lilie HM, Köster I, Schubert I. [Herpes zoster in Germany. A retrospective analysis of SHL data]. <i>Fortschr Med</i> . 2010; 193-7.	2004		
Germany	Wagner KS, White JM, Lucenko I, Mercer D, Crowcroft NS, Neal S, Efstratiou A. Diphtheria Surveillance Network. Diphtheria in the postepidemic period, Europe, 2000-2009. <i>Emerg Infect Dis</i> . 2012; 18(2): 217-25.	2000-2009	*	
Germany	Kiese-Himmel C, Schrott J, Kruse E. Identification and diagnostic evaluation of hearing impairments in early childhood in German-speaking infants. <i>Eur Arch Otorhinolaryngol</i> . 1997; 254(3): 133-9.	1994-1995	*	
Germany	Braun N, Schweisfurth A, Lohöfener C, Lange C, Gröndemann C, Kundt G, Gröne H-J. Epidemiology of glomerulonephritis in Northern Germany. <i>Int Urol Nephrol</i> . 2011; 43(4): 1117-26.	2003-2008	*	
Germany	Fichter MM, Schröppel H, Meller I. Incidence of dementia in a Munich community sample of the oldest old. <i>Eur Arch Psychiatry Clin Neurosci</i> . 1996; 246(6): 320-8.	1990-1991		
Germany	Enders G, Risse B, Zauke M, Bolley I, Knotek F. Seroprevalence study of herpes simplex virus type 2 among pregnant women in Germany using a type-specific enzyme immunoassay. <i>Eur J Clin Microbiol Infect Dis</i> . 1998; 17(12): 870-2.	1988-1991, 1996-1997	*	
Germany	Pebody RG, Andrews N, Brown D, Gopal R, De Melker H, François G, Gatcheva N, Hellenbrand W, Jokinen S, Klavs I, Kojouharova M, Kortbeek T, Kriz B, Prosenc K, Roubalova K, Teocharov P, Thierfelder W, Valle M, Van Damme P, Vranckx R. The seroepidemiology of herpes simplex virus type 1 and 2 in Europe. <i>Sex Transm Infect</i> . 2004; 80(3): 185-91.	1997	*	
Germany	Wutzler P, Doerr HW, Färber I, Eichhorn U, Helbig B, Sauerbrei A, Brandstädt A, Rabenau HF. Seroprevalence of herpes simplex virus type 1 and type 2 in selected German populations-relevance for the incidence of genital herpes. <i>J Med Virol</i> . 2000; 61(2): 201-7.	1996-1997	*	
Germany	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland: World Health Organization (WHO).	2000-2011	*	
Germany	Adam D, Fehle K. Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations. <i>Vaccine</i> . 2008; 26(47): 5944-51.	2001-2004	*	
Germany	Rückinger S, von Kries R, Siedler A, van der Linden M. Association of serotype of <i>Streptococcus pneumoniae</i> with risk of severe and fatal outcome. <i>Pediatr Infect Dis J</i> . 2009; 28(2): 118-22.	1997-2003		
Germany	Paul E, Thiel T. [Epidemiology of varicella zoster infection. Results of a prospective study in the Ansbach area]. <i>Hautarzt</i> . 1996; 47(8): 604-9.	1992-1993		
Germany	Bankel M, Robertson A, Köhler B. Carious lesions and caries risk predictors in a group of Swedish children 2 to 3 years of age. One year observation. <i>Eur J Paediatr Dent</i> . 2011; 12(4): 215-9.	2001-2002	*	
Germany	World Health Organization (WHO). Mental Illness in General Health Care: An International Study. Geneva, Switzerland: World Health Organization (WHO), 1995.	1991-1992		
Germany	Parry GI, Ogston SA. EUROMAC. A European concerted action: maternal alcohol consumption and its relation to the outcome of pregnancy and child development at 18 months. Results—child development at age 18 months. <i>Int J Epidemiol</i> . 1992; 21: 772-78.	1992, 2000-2008	*	
Germany	Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJA, Wasserman SM, Baker N, Rosser D, Cleland JGF, Ponikowski P. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. <i>Eur Heart J</i> . 2007; 28(18): 2208-16.	1992-1995		
Germany	Krüger K, Stang A, Kondratieva J, Moebus S, Beck E, Schmermund A, Möhlenkamp S, Dragano N, Siegrist J, Jöckel K-H, Erbel R, Heinz Nixdorf Recall Study Group. Prevalence of peripheral arterial disease – results of the Heinz Nixdorf recall study. <i>Eur J Epidemiol</i> . 2006; 21(4): 279-85.	2000-2003		
Germany	Faber MS, Wenzel JJ, Jilg W, Thamm M, Höhle M, Stark K. Hepatitis E Virus Seroprevalence among Adults, Germany. <i>Emerg Infect Dis</i> . 2012; 18(10): 1654-7.	2008-2011	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Germany	Straube A, Pfaffenrath V, Ladwig KH, Meisinger C, Hoffmann W, Fendrich K, Vennemann M, Berger K. Prevalence of chronic migraine and medication overuse headache in Germany—the German DMKG headache study. <i>Cephalalgia</i> . 2010; 30(3): 207-13.	2002-2006	*	
Germany	Poethko-Müller C, Zimmermann R, Hamouda O, Faber M, Stark K, Ross RS, Thamm M. [Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. <i>Bundesgesundheitsblatt</i> . 2013; 56(5-6): 707-15.	2008-2011		
Germany	Langen U, Schmitz R, Steppuhn H. [Prevalence of allergic diseases in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. <i>Bundesgesundheitsblatt</i> . 2013; 56(5-6): 698-706.	2008-2011	*	
Germany	Krumbholz A, Neubert A, Girschick H, Huppertz HI, Kaiser P, Liese J, Streng A, Niehues T, Peters J, Sauerbrey A, Schrotten H, Tenenbaum T, Wirth S, Sauerbrey A. Prevalence of antibodies against hepatitis A virus among children and adolescents in Germany. <i>Med Microbiol Immunol</i> . 2013; 202(6): 417-24.	1999-2011	*	
Germany	Kratzer W, Kächele V, Mason RA, Hill V, Hay B, Haug C, Adler G, Beckh K, Muche R. Gallstone prevalence in Germany: the Ulm Gallbladder Stone Study. <i>Dig Dis Sci</i> . 1998; 43(6): 1285-91.	1986-1987		
Germany	Völzke H, Baumeister SE, Alte D, Hoffmann W, Schwahn C, Simon P, John U, Lerch MM. Independent risk factors for gallstone formation in a region with high cholelithiasis prevalence. <i>Digestion</i> . 2005; 71(2): 97-105.	2002		
Germany	Walcher T, Haenle MM, Kron M, Hay B, Mason RA, von Schmiesing AFA, Imhof A, Koenig W, Kern P, Boehm BO, Kratzer W. Pregnancy is not a risk factor for gallstone disease: results of a randomly selected population sample. <i>World J Gastroenterol</i> . 2005; 11(43): 6800-6.	2003		
Germany	Trichopoulos D, Bania C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overvad K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Buono-De-Mesquita HB, Van Kranen HJ, Peeters PHM, Lund E, Quiros JR, González CA, Sanchez Perez M-J, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu L, Chuang S-C, Murphy N, Boffetta P, Trichopoulou A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. <i>J Natl Cancer Inst</i> . 2011; 103(22): 1686-95.	1992-2006	*	
Germany	Schäfer T, Nienhaus A, Vieluf D, Berger J, Ring J. Epidemiology of acne in the general population: the risk of smoking. <i>Br J Dermatol</i> . 2001; 145(1): 100-4.	1998-2000	*	
Germany	Frösner GG, Weiss M, Scheid R, Deinhardt F, Gathof GA, Bäcker U, Gosrau E, Bär A. [Prevalence of serological hepatitis A and B markers in Bavarian blood donors]. <i>MMW Munch Med Wochenschr</i> . 1980; 122(7): 231-3.	1977		
Germany	Bölke E, Flehmig B. New epidemiological patterns of hepatitis A and B infections in Germany. <i>Zentralbl Hyg Umweltmed</i> . 1995; 196(6): 511-4.	1987-1988		
Germany	Lasius D, Lange W, Stück B. [Seroepidemiologic studies on hepatitis A infections in German and foreign children living in Berlin (West)]. <i>Monatsschr Kinderheilkd</i> . 1983; 131(2): 93-5.	1989		
Germany	Ebell H, Schaf W. [Hepatitis antibodies in anesthesiologists and anesthesia personnel in a University clinic]. <i>Anasth Intensivther Notfallmed</i> . 1983; 18(3): 111-5.	1989		
Germany	Hofmann F, Wehrle G, Berthold H, Köster D. Hepatitis A as an occupational hazard. <i>Vaccine</i> . 1992; 10 (Suppl 1): S82-S84.	1990		
Germany	Bienle U, Bock H, Meister W, Clemens R, Kruppenbacher J. Anti-HAV seroprevalence in German travellers and hepatitis A vaccination in immune subjects. <i>Lancet</i> . 1993.	1991		
Germany	Abb J. [Prevalence of hepatitis A virus antibodies in hospital personnel]. <i>Gesundheitswesen</i> . 1994; 56(7): 377-9.	1993		
Germany	Rudi J, Töppe H, Marx N, Zuna I, Theilmann L, Stremmel W, Raedsch R. Risk of infection with <i>Helicobacter pylori</i> and hepatitis A virus in different groups of hospital workers. <i>Am J Gastroenterol</i> . 1997; 92(2): 258-62.	1996		
Germany	Thierfelder W, Hellenbrand W, Meisel H, Schreier E, Dortsch R. Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998. <i>Eur J Epidemiol</i> . 2001; 17(5): 429-35.	1998		
Germany	Ongey M, Brenner H, Thefeld W, Rothenbacher D. <i>Helicobacter pylori</i> and hepatitis A virus infections and the cardiovascular risk profile in patients with diabetes mellitus: results of a population-based study. <i>Eur J Cardiovasc Prev Rehabil</i> . 2004; 11(6): 471-6.	1998		
Germany	Hafner S, Timmer A, Herfarth H, Rogler G, Schölmerich J, Schäffler A, Ehrenstein B, Jilg W, Ott C, Strauch UG, Obermeier F. The role of domestic hygiene in inflammatory bowel diseases: hepatitis A and worm infestations. <i>Eur J Gastroenterol Hepatol</i> . 2008; 20(6): 561-6.	1999-2003		
Germany	Nübling M, Hofmann F, Tiller FW. Occupational risk for hepatitis A and hepatitis E among health care professionals? <i>Infection</i> . 2002; 30(2): 94-7.	2001		
Germany	Kuch B, Heier M, von Scheidt W, Kling B, Hoermann A, Meisinger C. 20-year trends in clinical characteristics, therapy and short-term prognosis in acute myocardial infarction according to presenting electrocardiogram: the MONICA/KORA AMI Registry (1985-2004). <i>J Intern Med</i> . 2008; 264(3): 254-64.	1985-1999		
Germany	Tunstall-Pedoe H, Kuulasmaa K, Mahönen M, Tolonen H, Raokoski E. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. <i>Lancet</i> . 1999; 353(9164): 1547-57.	1980-1995		
Germany	Jilg W, Hottenträger B, Weinberger K, Schlottmann K, Frick E, Holstege A, Schölmerich J, Palitzsch KD. Prevalence of markers of hepatitis B in the adult German population. <i>J Med Virol</i> . 2001; 63(2): 96-102.	1999		
Germany	op den Winkel M, Nagel D, Sappl J, op den Winkel P, Lamerz R, Zech CJ, Straub G, Nickel T, Rentsch M, Stieber P, Göke B, Kolligs FT. Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. <i>PLoS One</i> . 2012; 7(10): e45066.	1998-2009	*	
Germany	Stang A, Stegmaier C, Jöckel KH. Non-melanoma skin cancer in the Federal State of Saarland, Germany, 1995-1999. <i>Br J Cancer</i> . 2003; 89(7): 1205-8.	1995-1999	*	
Germany	Flohr C, Weinmayr G, Weiland SK, Addo-Yobo E, Annesi-Maesano I, Björkstén B, Bråbäck L, Büchele G, Chico M, Cooper P, Clausen M, El Sharif N, Martínez Gimeno A, Mathur RS, von Mutius E, Morales Suarez-Varela M, Pearce N, Svabe V, Wong GWK, Yu M, Zhong NS, Williams HC, ISAAC Phase Two Study Group. How well do questionnaires perform compared with physical examination in detecting flexural eczema? Findings from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. <i>Br J Dermatol</i> . 2009; 161(4): 846-53.	2005-2007	*	
Germany	Cebulla M, Shehata-Dieler W. ABR-based newborn hearing screening with MB11 BERaPhone® using an optimized chirp for acoustical stimulation. <i>Int J Pediatr Otorhinolaryngol</i> . 2012; 76(4): 536-43.	2006-2011	*	
Germany	Steiner TJ, Stovner LJ, Katsarava Z, Láinez JM, Lampl C, Lanteri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Barré J, André C. The impact of headache in Europe: principal results of the Eurolight project. <i>J Headache Pain</i> . 2014; 15(31). [Unpublished data].	2008	*	
Germany	Beck JA, Meisinger C, Heier M, Kuch B, Hörmann A, Greschik C, Koenig W. Effect of blood glucose concentrations on admission in non-diabetic versus diabetic patients with first acute myocardial infarction on short- and long-term mortality (from the MONICA/KORA Augsburg Myocardial Infarction Registry). <i>Am J Cardiol</i> . 2009; 104(12): 1607-1612.	1998-2005	*	
Germany	Neubauer A-P, Voss W, Kattner E. Outcome of extremely low birth weight survivors at school age: the influence of perinatal parameters on neurodevelopment. <i>Eur J Pediatr</i> . 2008 Jan;167(1):87-95.	1995		†
Germany	Damm G, Sens B, Harms K, Voss W, Wenzlaff P. [State-wide follow-up of extremely preterm infants: a model of cross-sectoral quality analysis]. <i>Z Evid Fortbild Qual Gesundheitswes</i> . 2011;105(8):597-605.	2004		†
Germany	Germany Renal Replacement Therapy Data 1997 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 1998. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2003.	1997	*	
Germany	Germany Vital Registration Birth Data 1991 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1991		
Germany	International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Germany	European Surveillance of Congenital Anomalies (EUROCAT). Germany EUROCAT Prevalence Tables. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	1987-2011		
Germany	Germany - Saxony-Anhalt Malformation Monitoring Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Germany	Germany - Saxony-Anhalt Malformation Monitoring Data 2001 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
Germany	Germany - Saxony-Anhalt Malformation Monitoring Center Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Germany	Germany - Saxony-Anhalt Malformation Monitoring Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
Germany	Germany - Saxony-Anhalt Malformation Monitoring Center Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
Germany	Germany - Saxony-Anhalt Malformation Monitoring Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
Germany	Germany - Saxony-Anhalt Malformation Monitoring Center Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Ghana	World Health Organization (2005). Study on Global Ageing and Adult Health (SAGE), Pilot Study, 2005 (Data Set 27-28, Cunningham, Shyama.) [machine-readable data file and documentation]. Geneva, Switzerland: World Health Organization (Producer). Los Altos, CA: Sociometrics Corporation, Data Archive of Social Research on Aging (Producer & Distributor).	2005		
Ghana	Ministry of Health (MOH) (Ghana), Ghana Statistical Service and United Nations Children's Fund (UNICEF). Ghana Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006	*	†
Ghana	Ghana Statistical Service, Macro Systems, Inc.; Institute for Resource Development. Ghana Demographic and Health Survey 1988. Columbia, United States: Macro Systems, Inc.	1988		†
Ghana	Ghana Statistical Service, Macro International, Inc. Ghana Demographic and Health Survey 1993-1994. Calverton, United States: Macro International, Inc.	1993-1994		†
Ghana	Ghana Statistical Service, Macro International, Inc. Ghana Demographic and Health Survey 1998-1999. Calverton, United States: Macro International, Inc.	1998-1999		†
Ghana	Ghana Statistical Service, Macro International, Inc. Ghana Demographic and Health Survey 2003. Calverton, United States: Macro International, Inc.	2003		†
Ghana	Ghana Statistical Service, Macro International, Inc, Ministry of Health (Ghana). Ghana Demographic and Health Survey 2008. Calverton, United States: Macro International, Inc.	2008		†
Ghana	World Health Organization (WHO). Ghana World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Ghana	Institute of Statistical, Social and Economic Research, University of Ghana, United Nations Children's Fund (UNICEF), Ghana - Accra Multiple Indicator Cluster Survey 2010-2011. New York, United States: United Nations Children's Fund (UNICEF), 2014.	2010-2011	*	
Ghana	Centers for Disease Control and Prevention (CDC), Ghana Statistical Service, Government of Japan, Ministry of Health (Ghana), Navrogo Health Research Centre, USAID, United Nations Children's Fund (UNICEF), United Nations Population Fund (UNFPA), Ghana Multiple Indicator Cluster Survey 2011. New York, United States: United Nations Children's Fund (UNICEF), 2013.	2011	*	†
Ghana	Thalassaemia International Federation, World Health Organization (WHO). Management of Haemoglobin Disorders: Report of a Joint WHO-TIF Meeting, Nicosia, Cyprus, 16-18 November 2007. Geneva, Switzerland: World Health Organization (WHO), 2008.	1995-2006		
Ghana	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Ghana	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Ghana	Amoah AG, Kallen C. Aetiology of heart failure as seen from a National Cardiac Referral Centre in Africa. <i>Cardiology</i> . 2000; 93(1-2): 11-8.	1992-1995		
Ghana	Hesse IF, Mensah A, Asante DK, Lartey M, Neequaye A. Characteristics of adult tetanus in Accra. <i>West Afr J Med</i> . 2003; 22(4): 291-4.	1994-2001		
Ghana	Hogewoning AA, Koelemij J, Amoah AS, Bouwes Bavinck JN, Aryeetey Y, Hartgers F, Yazdanbakhsh M, Willemze R, Boakye DA, Lavrijsen APM. Prevalence and risk factors of inflammatory acne vulgaris in rural and urban Ghanaian schoolchildren. <i>Br J Dermatol</i> . 2009; 161(2): 475-7.	2007		
Ghana	Mwenda JM, Noto KM, Abebe A, Enweronu-Laryea C, Amina I, Mchomvu J, Kisakye A, Mpabalwani EM, Pazvakambwa I, Amah GE, Seheri LM, Kiulia NM, Page N, Widdowson M-A, Steele AD. Burden and epidemiology of rotavirus diarrhea in selected African countries: preliminary results from the African Rotavirus Surveillance Network. <i>J Infect Dis</i> . 2010; 202(Suppl): S5-11.	2006-2008		
Ghana	Pobee JO. Study of cardiovascular diseases in developing countries supported by the World Health Organization Experience in Ghana 1972-1982. <i>Cas Lek Cesk</i> . 1986; 125(10): 289-92.	1980-1982		
Ghana	Edington GM, Lehmann H. Expression of the sickle-cell gene in Africa. <i>Br Med J</i> . 1955; 4925(1): 1308-11.	1953		
Ghana	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1980-1983, 1993-1994, 1997		
Ghana	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1988-1992, 1995-1996, 1998-2009		
Ghana	Agadzi VK, Boatib BA, Appawu MA, Mingle JA, Addy PA. Yellow fever in Ghana, 1977-80. <i>Bull World Health Organ</i> . 1984; 62(4): 577-83.	1977-1980		
Ghana	Mutebi J-P, Barrett ADT. The epidemiology of yellow fever in Africa. <i>Microbes Infect</i> . 2002; 4(14): 1459-68.	1996		
Ghana	Addy PA, Minami K, Agadzi VK. Recent yellow fever epidemics in Ghana (1969-1983). <i>East Afr Med J</i> . 1986; 63(6): 422-34.	1977-1980, 1983		
Ghana	Tomori O. Yellow fever in Africa: public health impact and prospects for control in the 21st century. <i>Biomedica</i> . 2002; 22(2): 178-210.	1983		
Ghana	World Health Organization (WHO). Yellow fever in Africa and South America, 2006. <i>Wkly Epidemiol Rec</i> . 2008; 83(8): 60-76.	2006		
Ghana	Bosompem KM, Bentum IA, Otcchere J, Anyan WK, Brown CA, Osada Y, Takeo S, Kojima S, Ohta N. Infant schistosomiasis in Ghana: a survey in an irrigation community. <i>Trop Med Int Health</i> . 2004; 9(8): 917-22.	2004		
Ghana	Danso-Appiah A, De Vlas SJ, Bosompem KM, Habbema JDF. Determinants of health-seeking behaviour for schistosomiasis-related symptoms in the context of integrating schistosomiasis control within the regular health services in Ghana. <i>Trop Med Int Health</i> . 2004; 9(7): 784-94.	2000		
Ghana	Ghana Health Service, Ministry of Health (Ghana), University of Ghana, World Health Organization (WHO). Ghana WHO Study on Global AGEing and Adult Health 2007-2008.	2007-2008		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Ghana	Amoah AGB, Owusu SK, Adjei S. Diabetes in Ghana: a community based prevalence study in Greater Accra. <i>Diabetes Res Clin Pract.</i> 2002; 56(3): 197-205.	1997		
Ghana	Marks F, Adu-Sarkodie Y, Hüniger F, Sarpong N, Ekuban S, Agyekum A, Nkrumah B, Schwarz NG, Favorov MO, Meyer CG, May J. Typhoid fever among children, Ghana. <i>Emerg Infect Dis.</i> 2010; 16(11): 1796-7.	2007-2008	*	
Ghana	Danquah I, Zimiel P, Eggelte TA, Ehrhardt S, Mockenhaupt FP. Influence of haemoglobins S and C on predominantly asymptomatic Plasmodium infections in northern Ghana. <i>Trans R Soc Trop Med Hyg.</i> 2010; 104(11): 713-9.	2002	*	
Ghana	Ohene-Frempong K, Odoro J, Tetteh H, Nkrumah F. Screening newborns for sickle cell disease in Ghana. <i>Pediatrics.</i> 2008; 121(Supplement): S120-S121.	1995-2005	*	
Ghana	Kreuels B, Kreuzberg C, Kobbe R, Ayim-Akonor M, Apiah-Thompson P, Thompson B, Ehmen C, Adjei S, Langefeld I, Adjei O, May J. Differing effects of HbS and HbC traits on uncomplicated falciparum malaria, anemia, and child growth. <i>Blood.</i> 2010; 115(22): 4551-8.	2003-2005	*	
Ghana	Binka FN, Anto FK, Odoro AR, Awini EA, Nazzari AK, Armah GE, Asmah RH, Hall AJ, Cutts F, Alexander N, Brown D, Green J, Gray J, Iltis-Gómara M, Navrongo Rotavirus Research Group. Incidence and risk factors of paediatric rotavirus diarrhoea in northern Ghana. <i>Trop Med Int Health.</i> 2003; 8(9): 840-6.	1998-1999	*	
Ghana	Nakano T, Binka FN, Afari EA, Agbodaze D, Aryeetey ME, Mingle JA, Kamiya H, Sakurai M. Survey of enteropathogenic agents in children with and without diarrhoea in Ghana. <i>J Trop Med Hyg.</i> 1990; 93(6): 408-12.	1987-1988	*	
Ghana	Reither K, Ignatius R, Weitzel T, Seidu-Korkor A, Anyidoho L, Saad E, Djie-Maletz A, Zimiel P, Amoo-Sakyi F, Danikuu F, Danour S, Ochwemah RN, Schreier E, Bienzle U, Stark K, Mockenhaupt FP. Acute childhood diarrhoea in northern Ghana: epidemiological, clinical and microbiological characteristics. <i>BMC Infect Dis.</i> 2007; 7: 104.	2005-2006	*	
Ghana	Armah GE, Steele AD, Binka FN, Esona MD, Asmah RH, Anto F, Brown D, Green J, Cutts F, Hall A. Changing patterns of rotavirus genotypes in Ghana: emergence of human rotavirus G9 as a major cause of diarrhea in children. <i>J Clin Microbiol.</i> 2003; 41(6): 2317-22.	1998-2000	*	
Ghana	Armah GE, Mingle JA, Dodo AK, Anyanful A, Antwi R, Comney J, Nkrumah FK. Seasonality of rotavirus infection in Ghana. <i>Ann Trop Paediatr.</i> 1994; 14(3): 223-9.	1991-1992	*	
Ghana	Addo-Yobo C, Williams SA, Curzon ME. Dental caries experience in Ghana among 12-year-old urban and rural schoolchildren. <i>Caries Res.</i> 1991; 25(4): 311-4.	1989		
Ghana	Wusu-Ansah OK, Opare-Addo HS. Pelvic organ prolapse in rural Ghana. <i>Int J Gynaecol Obstet.</i> 2008; 103(2): 121-4.	2005		
Ghana	Guzek JP, Anyomi FK, Fiadovor S, Nyonator F. Prevalence of blindness in people over 40 years in the Volta region of Ghana. <i>Ghana Med J.</i> 2005; 39(2): 55-62, as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2001		
Ghana	Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN, Steele AD, Laserson KF, Ansah NA, Levine MM, Lewis K, Coia ML, Attah-Poku M, Ojwando J, Rivers SB, Victor JC, Nyambane G, Hodgson A, Schödel F, Claret M, Neuzil KM. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. <i>Lancet.</i> 2010; 376(9741): 606-14.	2007-2009		
Ghana	Ngugi AK, Bottomley C, Kleinschmidt I, Wagner RG, Kakooza-Mwesige A, Ae-Ngibise K, Owusu-Agyei S, Masanja H, Kamuyu G, Odhiambo R, Chengo E, Sander JW, Newton CR, SEEDS group. Prevalence of active convulsive epilepsy in sub-Saharan Africa and associated risk factors: cross-sectional and case-control studies. <i>Lancet Neurol.</i> 2013; 12(3): 253-63.	2010-2011	*	
Ghana	Wilson NO, Ceasay FK, Hibbert JM, Driss A, Obed SA, Adjei AA, Gyasi RK, Anderson WA, Stiles JK. Pregnancy outcomes among patients with sickle cell disease at Korle-Bu Teaching Hospital, Accra, Ghana: retrospective cohort study. <i>Am J Trop Med Hyg.</i> 2012; 86(6): 936-42.	2007-2008	*	
Ghana	World Health Organization (2005). <i>Study on Global Ageing and Adult Health (SAGE), Pilot Study, 2005 (Data Set 27-28, Cunningham, Shyama.)</i> [machine-readable data file and documentation]. Geneva, Switzerland: World Health Organization (Producer). Los Altos, CA: Sociometrics Corporation, Data Archive of Social Research on Aging (Producer & Distributor).	2005		
Ghana	World Health Organization (WHO). <i>WHO Tuberculosis Case Notifications.</i> Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Ghana	Mock CN, Forjuoh SN, Rivara FP. Epidemiology of transport-related injuries in Ghana. <i>Accid Anal Prev.</i> 1999; 31(4): 359-70.	1995	*	
Ghana	Cook-Huynh M, Ansong D, Steckelberg RC, Boakye I, Seligman K, Appiah L, Kumar N, Amuasi JH. Prevalence of hypertension and diabetes mellitus in adults from a rural community in Ghana. <i>Ethn Dis.</i> 2012; 22(3): 347-52.	2009-2011		
Ghana	Allison AC, Charles LJ, McGregor IA. Erythrocyte Glucose-6-Phosphate Dehydrogenase Deficiency in West Africa. <i>Nature.</i> 1961; 190(4782): 1198-9.	1959-1961		
Ghana	Lewis RA, Hathorn M. Correlation of S hemoglobin with glucose-6-phosphate dehydrogenase deficiency and its significance. <i>Blood.</i> 1965; 26: 176-80.	1963-1965		
Ghana	Acquaye CT, Oldham JH. Variants of haemoglobin and glucose-6-phosphate dehydrogenase-I. distribution in Southern Ghana. <i>Ghana Med J.</i> 1973; 12(4): 412-8.	1971-1973		
Ghana	Burchard GD, Browne EN, Sievertsen J, May J, Meyer CG. Spleen size determined by ultrasound in patients with sickle cell trait, HbAC trait and glucose-6-phosphate-dehydrogenase deficiency in a malaria hyperendemic area (Ashanti Region, Ghana). <i>Acta Trop.</i> 2001; 80(2): 103-9.	1998		
Ghana	Baird JK, Owusu Agyei S, Utz GC, Koram K, Barcus MJ, Jones TR, Fryauff DJ, Binka FN, Hoffman SL, Nkrumah FN. Seasonal malaria attack rates in infants and young children in northern Ghana. <i>Am J Trop Med Hyg.</i> 2002; 66(3): 280-6.	1996-1997		†
Ghana	Naicker S. Burden of end-stage renal disease in sub-Saharan Africa. <i>Clin Nephrol.</i> 2010; 74(Suppl 1): S13-6.	2008-2010		
Ghana	Mockenhaupt FP, Reither K, Zanger P, Roepecke F, Danquah I, Saad E, Zimiel P, Dzisi SY, Frempong M, Agana-Nsire P, Amoo-Sakyi F, Ochwemah R, Cramer JP, Anemana SD, Dietz E, Bienzle U. Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana. <i>Antimicrob Agents Chemother.</i> 2007; 51(9): 3273-81 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Ghana	World Health Organization (WHO). <i>Ghana WHO Leishmaniasis Country Profile.</i>	1999-2008	*	
Ghana	Dunyo SK, Appawu M, Nkrumah FK, Baffoe-Wilmot A, Pedersen EM, Simonsen PE. Lymphatic filariasis on the coast of Ghana. <i>Trans R Soc Trop Med Hyg.</i> 1996; 90(6): 634-8, as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1994-1995	*	
Ghana	Gyapong JO, Badu JK, Adjei S, Binka F. Bancroftian filariasis in the Kassena Nankana District of the upper east region of Ghana: a preliminary study. <i>J Trop Med Hyg.</i> 1993; 96(5): 317-22, as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1992	*	
Ghana	Gyapong JO, Adjei S, Sackey SO. Descriptive epidemiology of lymphatic filariasis in Ghana. <i>Trans R Soc Trop Med Hyg.</i> 1996; 90(1): 26-30, as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1994	*	
Ghana	Gyapong JO, Gyapong M, Adjei S. The epidemiology of acute adenolymphangitis due to lymphatic filariasis in northern Ghana. <i>Am J Trop Med Hyg.</i> 1996; 54(6): 591-5.	1993-1994	*	
Ghana	Gyapong JO, Webber RH, Morris J, Bennett S. Prevalence of hydrocoele as a rapid diagnostic index for lymphatic filariasis. <i>Trans R Soc Trop Med Hyg.</i> 1998; 92(1): 40-3, as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1995-1996	*	
Ghana	Gyapong JO. The relationship between infection and disease in Wuchereria bancrofti infection in Ghana. <i>Trans R Soc Trop Med Hyg.</i> 1998; 92(4): 390-2.	1995-1996	*	
Ghana	Gyapong JO. Impact of single-dose ivermectin on community microfilaria load in bancroftian filariasis infection: two years post treatment. <i>Trans R Soc Trop Med Hyg.</i> 2000; 94(4): 434-6, as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1999	*	
Ghana	Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Janin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. <i>Int J Health Geogr.</i> 2010; 9: 57.	1980-2010		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Ghana	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec.</i> 2005; 80(13): 118-24.	2003	*	
Ghana	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec.</i> 2006; 81(32): 309-16.	2005	*	
Ghana	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Ghana	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Ghana	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Ghana	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Ghana	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Ghana	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Ghana	Apea-Kubi KA, Yamaguchi S, Sakyi B, Kishimoto T, Ofori-Adjei D, Hagiwara T. Neisseria gonorrhoea, Chlamydia trachomatis, and Treponema pallidum infection in antenatal and gynecological patients at Korle-Bu Teaching Hospital, Ghana. <i>Jpn J Infect Dis.</i> 2004; 57(6): 253-6.	2000-2001	*	
Ghana	Budenz DL, Bandi JR, Barton K, Nolan W, Herndon L, Whiteside-de Vos J, Hay-Smith G, Kim H, Tielisch J. Blindness and Visual Impairment in an Urban West African Population: The Tema Eye Survey. <i>Ophthalmology.</i> 2012; 119(9): 1744-53.	2009-2011	*	
Ghana	Leimkugel J, Adams Forgor A, Gagneux S, Pflüger V, Flierl C, Awine E, Naegeli M, Dangy J-P, Smith T, Hodgson A, Pluschke G. An outbreak of serotype 1 Streptococcus pneumoniae meningitis in northern Ghana with features that are characteristic of Neisseria meningitidis meningitis epidemics. <i>J Infect Dis.</i> 2005; 192(2): 192-9.	1998-2003		
Ghana	Hogewoning A, Amoah A, Bavnick JNB, Boakye D, Yazdanbakhsh M, Adegniko A, De Smedt S, Fonteyne Y, Willemze R, Lavrijsen A. Skin diseases among schoolchildren in Ghana, Gabon, and Rwanda. <i>Int J Dermatol.</i> 2013; 52(5): 589-600.	2004, 2007	*	
Ghana	Hogewoning AA, Bouwes Bavnick JN, Amoah AS, Boakye DA, Yazdanbakhsh M, Krensner PG, Adegniko AA, De Smedt SKAD, Willemze R, Lavrijsen APM. Point and period prevalences of eczema in rural and urban schoolchildren in Ghana, Gabon and Rwanda. <i>J Eur Acad Dermatol Venerol.</i> 2012; 26(4): 488-94.	2004, 2007	*	
Ghana	Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, Büchele G, Clausen M, Cookson WOC, von Mutius E, Strachan DP, Williams HC, ISAAC Phase Two Study Group. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. <i>J Allergy Clin Immunol.</i> 2008; 121(1): 141-147.	2005-2007	*	
Ghana	Mockenhaupt FP, Rong B, Günther M, Beck S, Till H, Kohne E, Thompson WN, Bienze U. Anaemia in pregnant Ghanaian women: importance of malaria, iron deficiency, and haemoglobinopathies. <i>Trans R Soc Trop Med Hyg.</i> 2000; 94(5): 477-83.	1998	*	†
Ghana	Aequaye JK, Mingle JA. Hepatitis B viral markers in Ghanaian pregnant women. <i>West Afr J Med.</i> 1994; 13(3): 134-7.	1992		
Ghana	Adjei AA, Tettey Y, Aviyase JT, Adu-Gyamfi C, Obed S, Mingle JAA, Ayeh-Kumi PF, Adiku TK. Hepatitis E virus infection is highly prevalent among pregnant women in Accra, Ghana. <i>Virology.</i> 2009; 108.	2008		
Ghana	Apea-Kubi KA, Yamaguchi S, Sakyi B, Ofori-Adjei D. HTLV-1 and other viral sexually transmitted infections in antenatal and gynaecological patients in Ghana. <i>West Afr J Med.</i> 2006; 25(1): 17-21.	2000-2001		
Ghana	Damale NKR, Lassey AT, Bekoe V. Hepatitis B virus seroprevalence among parturients in Accra, Ghana. <i>Int J Gynaecol Obstet.</i> 2005; 90(3): 240-1.	2003		
Ghana	Lassey AT, Damale NK, Bekoe V, Klufio CA. Hepatitis C virus seroprevalence among mothers delivering at the Korle-Bu Teaching Hospital, Ghana. <i>East Afr Med J.</i> 2004; 81(4): 198-201.	2001		
Ghana	Martinson FE, Marfo VY, Degraaf J. Hepatitis E virus seroprevalence in children living in rural Ghana. <i>West Afr J Med.</i> 1999; 18(2): 76-9.	1993		
Ghana	Martinson FE, Weigle KA, Mushahwar IK, Weber DJ, Royce R, Lemon SM. Seroepidemiological survey of hepatitis B and C virus infections in Ghanaian children. <i>J Med Virol.</i> 1996; 48(3): 278-83.	1993-1995		
Ghana	Dzodzomenyo M, Dunyo SK, Ahorlu CK, Coker WZ, Appawu MA, Pedersen EM, Simonsen PE. Bancroftian filariasis in an irrigation project community in southern Ghana. <i>Trop Med Int Health.</i> 1999; 4(1): 13-8. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1995-1996	*	
Ghana	Gyapong JO, Magnusson P, Binka FN. Parasitological and clinical aspects of bancroftian filariasis in Kassena-Nankana District, upper east region, Ghana. <i>Trans R Soc Trop Med Hyg.</i> 1994; 88(5): 555-7. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1992	*	
Ghana	Gyapong JO, Omame-Badu K, Webber RH. Evaluation of the filter paper blood collection method for detecting Og4C3 circulating antigen in bancroftian filariasis. <i>Trans R Soc Trop Med Hyg.</i> 1998; 92(4): 407-10. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1997		
Ghana	Fiander A. Causes of infertility among 1000 patients in Ghana. <i>Trop Doct.</i> 1990; 20(3): 137-8.	1988-1990	*	
Ghana	Flohr C, Weinmayr G, Weiland SK, Addo-Yobo E, Annessi-Maesano I, Björkstén B, Bråbäck L, Büchele G, Chico M, Cooper P, Clausen M, El Sharif N, Martinez Gimeno A, Mathur RS, von Mutius E, Morales Suarez-Varela M, Pearce N, Svabe V, Wong GWK, Yu M, Zhong NS, Williams HC, ISAAC Phase Two Study Group. How well do questionnaires perform compared with physical examination in detecting flexural eczema? Findings from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. <i>Br J Dermatol.</i> 2009; 161(4): 846-53.	2005-2007	*	
Ghana	Guldener PH. Hemisektion, Zahnseparation, Wurzelamputation. <i>Schweizerische Monatsschrift für Zahnheilkunde = Revue mensuelle suisse d'odonto-stomatologie / SSO.</i> 1976;86(8):795-811.	1988		†
Ghana	In Vivo and In Vitro Plasmodium Falciparum Sensitivity to Chloroquine and In Vitro Response of Plasmodium Falciparum to Amodiaquine, Quinine and Sulfadoxine/pyrimethamine as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Ghana	Ghana Plasmodium Falciparum Parasite Rate Data, Personal Communication with K.A. Koram and B. Abuaku 2007 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Ghana	Afari EA, Akanmori BD, Nakano T, Ofori-Adjei D. Plasmodium falciparum: sensitivity to chloroquine in vivo in three ecological zones in Ghana. <i>Trans R Soc Trop Med Hyg.</i> 1992; 86(3): 231-2 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1988-1990	*	†
Ghana	Afari EA, Appawu M, Dunyo S, Baffoe-Wilmot A, Nkrumah FK. Malaria infection, morbidity and transmission in two ecological zones Southern Ghana. <i>Afr J Health Sci.</i> 1995; 2(2): 312-5 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Ghana	Afari EA, Dunyo S, Appawu M, Nkrumah FK. In vivo seasonal assessment of Plasmodium falciparum sensitivity to chloroquine in two different malaria endemic communities in Southern Ghana. <i>Afr J Health Sci.</i> 1994; 1(3): 112-5 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†
Ghana	Dadzile S, Boakye D, Asoala V, Koram K, Kiszewski A, Appawu M. A community-wide study of malaria reduction: evaluating efficacy and user-acceptance of a low-cost repellent in northern Ghana. <i>Am J Trop Med Hyg.</i> 2013; 88(2): 309-14 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	2010-2011	*	†
Ghana	Dodoo D, Aikins A, Kusi KA, Lamptey H, Remarque E, Milligan P, Bosomprah S, Chilengi R, Osei YD, Akanmori BD, Theisen M. Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children. <i>Malar J.</i> 2008; 7(1): 142 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Ghana	Dodoo D, Omer FM, Todd J, Akanmori BD, Koram KA, Riley EM. Absolute Levels and Ratios of Proinflammatory and Anti-inflammatory Cytokine Production In Vitro Predict Clinical Immunity to Plasmodium falciparum Malaria. <i>J Infect Dis.</i> 2002; 185(7): 971-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000	*	†
Ghana	Ehrhardt S, Burchard GD, Mantel C, Cramer JP, Kaiser S, Kubo M, Ochwenah RN, Bienzele U, Mockenhaupt FP. Malaria, Anemia, and Malnutrition in African Children-Defining Intervention Priorities. <i>J Infect Dis.</i> 2006; 194(1): 108-14 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Ghana	Klinkenberg E, McCall PJ, Hastings IM, Wilson MD, Amerasinghe FP, Donnelly MJ. Malaria and Irrigated Crops, Accra, Ghana. <i>Emerg Infect Dis.</i> 2005; 11(8): 1290-3 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002-2003	*	†
Ghana	Klinkenberg E, McCall PJ, Wilson MD, Akoto AO, Amerasinghe FP, Bates I, Verhoeff FH, Barnish G, Donnelly MJ. Urban malaria and anaemia in children: a cross-sectional survey in two cities of Ghana. <i>Trop Med Int Health.</i> 2006; 11(5): 578-88 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002-2003	*	†
Ghana	Landgraf B, Kollaritsch H, Wiedermann G, Wernsdorfer WH. Plasmodium falciparum: susceptibility in vitro and in vivo to chloroquine and sulfadoxine-pyrimethamine in Ghanaian schoolchildren. <i>Trans R Soc Trop Med Hyg.</i> 1994; 88(4): 440-2 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†
Ghana	Ofose-Okyere A, Mackinnon MJ, Sowa MP, Koram KA, Nkrumah F, Osei YD, Hill WG, Wilson MD, Arnot DE. Novel Plasmodium falciparum clones and rising clone multiplicities are associated with the increase in malaria morbidity in Ghanaian children during the transition into the high transmission season. <i>Parasitology.</i> 2001; 123(Pt 2): 113-23 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Ghana	Ronald LA, Kenny SL, Klinkenberg E, Akoto AO, Boakye I, Barnish G, Donnelly MJ. Malaria and anaemia among children in two communities of Kumasi, Ghana: a cross-sectional survey. <i>Malar J.</i> 2006; 5(1): 105 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Greece	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2005		
Greece	Greece Vital Registration - Deaths 1983 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1983	*	
Greece	Greece Vital Registration - Deaths 1984 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1984	*	
Greece	Greece Vital Registration - Deaths 1988 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1988		
Greece	Greece Vital Registration - Deaths 1996 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1996		
Greece	Greece Vital Registration - Deaths 1999 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1999		
Greece	Greece Vital Registration - Deaths 2001 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	2001		
Greece	Greece Vital Registration - Deaths 2004 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	2004		
Greece	Greece Vital Registration - Deaths 2006 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	2006		
Greece	Greece Vital Registration - Deaths 2007 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2007	*	
Greece	World Health Organization (WHO). Greece World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		
Greece	Samonis G, Maraki S, Christidou A, Georgiladakis A, Tselentis Y. Bacterial pathogens associated with diarrhoea on the island of Crete. <i>Eur J Epidemiol.</i> 1997; 13(7): 831-6.	1992-1994		
Greece	Greece Vital Registration - Deaths 2010 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2010		
Greece	Greece Vital Registration - Deaths 2011 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2011		
Greece	Goudevenos JA, Vakaliakos JN, Giogiakas V, Lathridou P, Katsouras C, Michalis LK, Sideris DA. An epidemiological study of symptomatic paroxysmal atrial fibrillation in northwest Greece. <i>Europace.</i> 1999; 1(4): 226-33.	1992-1995		
Greece	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. <i>Scand J Clin Lab Invest.</i> 2007; 67(1): 39-69.	1988, 2006		
Greece	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1988, 2003, 2006		
Greece	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	2009		†
Greece	Vemmos KN, Bots ML, Tsiouris PK, Zis VP, Grobbee DE, Stranjalis GS, Stamatiopoulos S. Stroke Incidence and Case Fatality in Southern Greece: The Arcadia Stroke Registry. <i>Stroke.</i> 1999; 30(2): 363-70.	1994-1995		
Greece	Vasilopoulos VA, Karanika M, Theodoridou K, Katsioulis AT, Theodoridou MN, Hadjichristodoulou CS. Prognostic factors related to sequelae in childhood bacterial meningitis: data from a Greek meningitis registry. <i>BMC Infect Dis.</i> 2011; 11: 214.	1974-2005		
Greece	Levidiotou S, Gartzonika C, Papaventsis D, Christaki C, Priavali E, Zotos N, Kapsali E, Vrioni G. Viral agents of acute gastroenteritis in hospitalized children in Greece. <i>Clin Microbiol Infect.</i> 2009; 15(6): 596-8.	2000-2006		
Greece	Ladis V, Chouliaras G, Berdousi H, Kanavakis E, Kattamis C. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. <i>Ann N Y Acad Sci.</i> 2005; 1054: 445-50.	1958-1996, 1998-2004		
Greece	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000-2002, 2005, 2008-2009		
Greece	Andrianakos A, Trontzas P, Christoyannis F, Dantis P, Voudouris C, Georgountzos A, Kaziolas G, Vafiadou E, Pantelidou K, Karamitros D, Komitelli L, Krachtis P, Nikolia Z, Kaskani E, Tavaniotou E, Antoniadou C, Karamikolas G, Kontoyanni A, ESORDIG Study. Prevalence of rheumatic diseases in Greece: a cross-sectional population based epidemiological study. <i>The ESORDIG Study. J Rheumatol.</i> 2003; 30(7): 1589-601.	1996-1999		
Greece	Karakatsani A, Papakosta D, Rapti A, Antoniou KM, Dimadi M, Markopoulou A, Latsi P, Polychronopoulos V, Birba G, Ch L, Bouros D. Epidemiology of interstitial lung diseases in Greece. <i>Respir Med.</i> 2009; 103(8): 1122-9.	2004		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Greece	Piperidou HN, Heliopoulos IN, Maltezos ES, Milonas IA. Epidemiological data of multiple sclerosis in the province of Evros, Greece. <i>Eur Neurol.</i> 2003; 49(1): 8-12.	1974-1978, 1994-1999		
Greece	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Greece	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2002		
Greece	Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. <i>Diabetologia.</i> 1996; 39(11): 1377-84.	1993-1995		
Greece	Mavromichalis I, Anagnostopoulos D, Metaxas N, Papanastassiou E. Prevalence of migraine in schoolchildren and some clinical comparisons between migraine with and without aura. <i>Headache.</i> 1999; 39(10): 728-36.	1997		
Greece	Andrianakos AA, Kontelis LK, Karamitos DG, Aslanidis SI, Georgountzos AI, Kaziolas GO, Pantelidou KV, Vafiadou EV, Dantis PC, ESORDIG Study Group. Prevalence of symptomatic knee, hand, and hip osteoarthritis in Greece. The ESORDIG study. <i>J Rheumatol.</i> 2006; 33(12): 2507-13.	1996-1999		
Greece	Konstantinou GN, Papadopoulos NG, Tavladaki T, Tselikouri T, Tselimigaki A, Grattan CEH. Childhood acute urticaria in northern and southern Europe shows a similar epidemiological pattern and significant meteorological influences. <i>Pediatr Allergy Immunol.</i> 2011; 22(1 Pt 1): 36-42.	2005-2007	*	
Greece	Anthracopoulos MB, Fouzas S, Pandiora A, Panagiotopoulou E, Liolios E, Priftis KN. Prevalence trends of rhinoconjunctivitis, eczema, and atopic asthma in Greek schoolchildren: four surveys during 1991-2008. <i>Allergy Asthma Proc.</i> 2011; 32(6): 56-62.	2008	*	
Greece	Kosti RI, Priftis KN, Anthracopoulos MB, Papadimitriou A, Grigoropoulou D, Lentzas Y, Yfanti K, Panagiotakos DB. The association between leisure-time physical activities and asthma symptoms among 10- to 12-year-old children: the effect of living environment in the PANACEA study. <i>J Asthma.</i> 2012; 49(4): 342-8.	2005-2009	*	
Greece	Papadopoulou A, Hatzigorou E, Matziou VN, Grigoropoulou DD, Panagiotakos DB, Tsanakas JN, Gratzou C, Priftis KN. Comparison in asthma and allergy prevalence in the two major cities in Greece: the ISAAC phase II survey. <i>Allergol Immunopathol (Madr).</i> 2011; 39(6): 347-55.	2000-2001	*	
Greece	Anagnostopoulos I, Zinzaras E, Alexiou I, Papanastassiou AA, Davas E, Koutroumpas A, Barouta G, Sakkas LI. The prevalence of rheumatic diseases in central Greece: a population survey. <i>BMC Musculoskelet Disord.</i> 2010; 98.	2007-2008		
Greece	Ntaios G, Manios E, Synetos M, Savvari P, Venmou A, Koromboki E, Saliaris M, Blanas K, Venmos K. Prevalence of atrial fibrillation in Greece: the Arcadia Rural Study on Atrial Fibrillation. <i>Acta Cardiol.</i> 2012; 67(1): 65-9.	2002-2003	*	
Greece	Anthracopoulos MB, Antonogeorgos G, Liolios E, Triga M, Panagiotopoulou E, Priftis KN. Increase in chronic or recurrent rhinitis, rhinoconjunctivitis and eczema among schoolchildren in Greece: three surveys during 1991-2003. <i>Pediatr Allergy Immunol.</i> 2009; 20(2): 180-6.	1991, 1998, 2003	*	
Greece	Mamai-Homata E, Margaritis V, Koletsis-Kounari H, Oulis C, Polychronopoulou A, Topitsoglou V. Tooth loss and oral rehabilitation in Greek middle-aged adults and senior citizens. <i>Int J Prosthodont.</i> 2012; 25(2): 173-9.	2010	*	
Greece	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. <i>Community Dent Oral Epidemiol.</i> 1991; 19(2): 72-3.	1987		
Greece	Mamai-Homata E, Polychronopoulou A, Topitsoglou V, Oulis C, Athanassouli T. Periodontal diseases in Greek adults between 1985 and 2005—risk indicators. <i>Int Dent J.</i> 2010; 60(4): 293-9.	2005	*	
Greece	Gatou T, Koletsis Kounari H, Mamai-Homata E. Dental caries prevalence and treatment needs of 5- to 12-year-old children in relation to area-based income and immigrant background in Greece. <i>Int Dent J.</i> 2011; 61(3): 144-51.	2006-2007		
Greece	Zacharakis G, Kotsiou S, Papoutselis M, Vafiadis N, Tzara F, Pouliou E, Maltezos E, Koskinas J, Papoutselis K. Changes in the epidemiology of hepatitis B virus infection following the implementation of immunisation programmes in northeastern Greece. <i>Euro Surveill.</i> 2009; 14(32).	1992-1994, 1998-2006		
Greece	Ladomenou F, Kafatos A, Tselentis Y, Galanakis E. Predisposing factors for acute otitis media in infancy. <i>J Infect.</i> 2010; 61(1): 49-53.	2004-2006	*	
Greece	Stranjalis G, Kalamatanos T, Stavrinou LC, Tsamandouraki K, Alamanos Y. Neck pain in a sample of Greek urban population (fifteen to sixty-five years): analysis according to personal and socioeconomic characteristics. <i>Spine.</i> 2011; 36(16): E1098-1104.	2008	*	
Greece	Korovessis P, Repantis T, Zacharatos S, Baikousis A. Low back pain and sciatica prevalence and intensity reported in a Mediterranean country: ordinal logistic regression analysis. <i>Orthopedics.</i> 2012; 35(12): e1775-1784.	2005-2006	*	
Greece	Papavasileiou K, Papavasileiou E, Tzanakaki G, Voyatzis A, Kremastinou J, Chatzipanagiotou S. Acute bacterial meningitis cases diagnosed by culture and PCR in a children's hospital throughout a 9-Year period (2000-2008) in Athens, Greece. <i>Mol Diagn Ther.</i> 2011; 15(2): 109-13.	2000-2008		
Greece	Koukou D, Grivea I, Roma E, Tsoni H, Trimis G, Galanakis E, Farmaki E, Iosifidis E, Michos A, Siamopoulou-Mavridou A, Kalmanti M, Papadopoulou H, Roilides E, Theodoridou M, Syrogiannopoulos GA, Syriopoulou V, Greek Rotascor Extension Study Group. Frequency, clinical characteristics, and genotype distribution of rotavirus gastroenteritis in Greece (2007-2008). <i>J Med Virol.</i> 2011; 83(1): 165-9.	2007-2008	*	
Greece	Bolin AK, Bolin A, Koch G. Children's dental health in Europe: caries experience of 5- and 12-year-old children from eight EU countries. <i>Int J Paediatr Dent.</i> 1996; 6(3): 155-62.	1994		
Greece	Athanassouli T, Koletsis-Kounari H, Mamai-Homata H, Panagopoulos H. Oral health status of adult population in Athens, Greece. <i>Community Dent Oral Epidemiol.</i> 1990; 18(2): 82-4.	1988		
Greece	Megas BF, Athanassouli TN. Dental caries prevalence in the permanent teeth in Greek schoolchildren related to age, sex, urbanization and social status. <i>Community Dent Health.</i> 1989; 6(2): 131-7.	1987		
Greece	Salapata J, Blinkhorn AS, Atwood D. Dental health of 12-year-old children in Athens. <i>Community Dent Oral Epidemiol.</i> 1990; 18(2): 80-1.	1988		
Greece	Petridou E, Athanassouli T, Panagopoulos H, Revinthi K. Sociodemographic and dietary factors in relation to dental health among Greek adolescents. <i>Community Dent Oral Epidemiol.</i> 1996; 24(5): 307-11.	1992		
Greece	Athanassouli I, Mamai-Homata E, Panagopoulos H, Koletsis-Kounari H, Apostolopoulos A. Dental caries changes between 1982 and 1991 in children aged 6-12 in Athens, Greece. <i>Caries Res.</i> 1994; 28(5): 378-82.	1982, 1991		
Greece	Maragakis GM, Kapetanidou DN, Manios Y. Caries prevalence and location and dental treatment needs in preschoolers in Athens—GENESIS project. <i>Community Dent Health.</i> 2007; 24(4): 264-7.	2005		
Greece	Zoitopoulos L, Athanassouli T, Gelbier S, Apostolopoulos A. Caries prevalence of 5-year-old children in Athens and in South London. <i>Int J Paediatr Dent.</i> 1996; 6(1): 3-6.	1994		
Greece	Kalyvas DL, Taylor CM, Michas V, Lygidakis NA. Dental health of 5-year-old children and parents' perceptions for oral health in the prefectures of Athens and Piraeus in the Attica County of Greece. <i>Int J Paediatr Dent.</i> 2006; 16(5): 352-7.	2001		
Greece	Fichter MM, Quadflieg N, Georgopoulou E, Xepapadakis F, Ftbenakis EW. Time trends in eating disturbances in young Greek migrants. <i>Int J Eat Disord.</i> 2005; 38(4): 310-22.	1998		
Greece	Giannitsioti E, Skiadas I, Antoniadou A, Tsiodras S, Kanavos K, Triantafyllidi H, Giamarellou H; Hellenic Endocarditis Study Group. Nosocomial vs. community-acquired infective endocarditis in Greece: changing epidemiological profile and mortality risk. <i>Clin Microbiol Infect.</i> 2007; 13(8): 763-9.	2000-2004		
Greece	Mitsikostas DD, Tsaklakidou D, Athanasiadis N, Thomas A. The prevalence of headache in Greece: correlations to latitude and climatological factors. <i>Headache.</i> 1996; 36(3): 168-73.	1993		
Greece	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2001-2005		
Greece	Karaoulanis SE, Mouzas OD, Rizoulis AA, Angelopoulos NV. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in Greek nursery students. <i>Eur Psychiatry.</i> 2010; 1394.	1996-1997		
Greece	United States Renal Data System Coordinating Center. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2000		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Greece	Levidiotou S, Vrioni G, Papadogeorgaki H, Avdeliodi K, Kada H, Kaparos G, Kouskouni E, Fragouli E, Legakis NJ. Chlamydia trachomatis infections in Greece: first prevalence study using nucleic acid amplification tests. <i>Eur J Clin Microbiol Infect Dis</i> . 2005; 24(3): 207-13.	2005		
Greece	De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology</i> . 2000; 54(11 Suppl 5): S21-23.	1997		
Greece	Berger K BM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology</i> . 2000; 54(11): 24-7.	1997		
Greece	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Greece	Stranjalis G, Tsamandouraki K, Sakas DE, Alamanos Y. Low back pain in a representative sample of Greek population: analysis according to personal and socioeconomic characteristics. <i>Spine</i> . 2004; 29(12): 1355-61.	2000		
Greece	Seland JH, Vingerling JR, Aungood CA, Bentham G, Chakravarthy U, deJong PTVM, Rahu M, Soubrane G, Tomazzoli L, Topouzis F, Fletcher AE. Visual impairment and quality of life in the older European population, the EUREYE study. <i>Acta Ophthalmol</i> . 2011; 89(7): 608-13. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2006-2007		
Greece	Kavaliotis J, Petridou S, Karabaxoglou D. How reliable is the history of chickenpox? Varicella serology among children up to 14 years of age. <i>Int J Infect Dis</i> . 2003; 7(4): 274-7.	1999-2001		
Greece	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1995, 1998-1999, 2004		
Greece	Riga M, Psarommatas I, Lyra C, Douniaki D, Tsakanikos M, Neou P, Apostolopoulos N. Etiological diagnosis of bilateral, sensorineural hearing impairment in a pediatric Greek population. <i>Int J Pediatr Otorhinolaryngol</i> . 2005; 69(4): 449-55.	2000-2003		
Greece	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Greece	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). Alcohol and Drug Use Among European 17-18 Year Old Students: Data from the ESPAD Project. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2007.	2003		
Greece	Kokkevi A, Fotiou A, Richardson C. Drug use in the general population of Greece over the last 20 years: results from nationwide household surveys. <i>Eur Addict Res</i> . 2007; 13(3): 167-76.	1998, 2004		
Greece	Alexandra P, Vassiliou B, Alexandra V, George K, Vassiliou L, Chryssa B. Population-based trends of pregnancy outcome in obese mothers: what has changed over 15 years. <i>Obesity (Silver Spring)</i> . 2011; 19(9): 1861-5.	1983-1998	*	
Greece	Raptis I, Koskinas J, Emmanouil T, Hadziyannis S. Changing relative roles of hepatitis B and C viruses in the aetiology of hepatocellular carcinoma in Greece. <i>Epidemiological and clinical observations</i> . <i>J Viral Hepat</i> . 2003; 10(6): 450-4.	1996-2000		
Greece	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010		
Greece	Skounti M, Giannoukas S, Dimitriou E, Nikolopoulou S, Linardakis E, Philalithis A. Prevalence of attention deficit hyperactivity disorder in schoolchildren in Athens, Greece. Association of ADHD subtypes with social and academic impairment. <i>Atten Defic Hyperact Disord</i> . 2010; 2(3): 127-32.	2009	*	
Greece	Piperaki E-T, Theodora M, Mendris M, Barbits L, Pitiriga V, Antsaklis A, Tsakris A. Prevalence of Trichomonas vaginalis infection in women attending a major gynaecological hospital in Greece: a cross-sectional study. <i>J Clin Pathol</i> . 2010; 63(3): 249-53.	2006-2007	*	
Greece	Skordis N, Efstathiou E, Kyriakides TC, Savvidou A, Savva SC, Pylactou LA, Shammis C, Neocleous V. Epidemiology of type 1 diabetes mellitus in Cyprus: rising incidence at the dawn of the 21st century. <i>Hormones (Athens)</i> . 2012; 11(1): 86-93.	1990-2009		
Greece	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Greece National Report to the EMCDDA 2006.	2002-2006	*	
Greece	Petridou E, Dessypris N, Frangakis CE, Belechri M, Mavrou A, Trichopoulos D. Estimating the population burden of injuries: a comparison of household surveys and emergency department surveillance. <i>Epidemiology</i> . 2004; 15(4): 428-32.	2001	*	
Greece	Choremis C, Fessas P, Kattamis C, Stamatoyannopoulos G, Zannos-Mariolea L, Karaklis A, Belios G. Three inherited red-cell abnormalities in a district of Greece. Thalassaemia, sickling, and glucose-6-phosphate-dehydrogenase deficiency. <i>Lancet</i> . 1963; 1(7287): 907-9.	1952-1962		
Greece	Allison AC, Askonas BA, Barnicot NA, Blumberg BS, Krimbas C. Deficiency of erythrocyte glucose-6-phosphate dehydrogenase in Greek populations. <i>Ann Hum Genet</i> . 1963; 26(3): 237-42.	1961-1963		
Greece	Fraser GR, Grunwald P, Stamatoyannopoulos G. Glucose-6-phosphate dehydrogenase (G6PD) deficiency, abnormal haemoglobins, and thalassaemia in Yugoslavia. <i>J Med Genet</i> . 1966; 3(1): 35-41.	1962		
Greece	Valaes T, Karaklis A, Stravarakis D, Bavela-Stravarakis K, Perakis A, Doxiadis SA. Incidence and mechanism of neonatal jaundice related to glucose-6-phosphate dehydrogenase deficiency. <i>Pediatr Res</i> . 1969; 3(5): 448-58.	1962-1966		
Greece	Kirimlidis S, Politis E, Drossos C, Scaloubakas N, Papaioannou M. Glucose-6-phosphate-dehydrogenase deficiency in Greece. Study by using a modification of Beutler and Fair-banks spot test. <i>Helv Paediatr Acta</i> . 1965; 20(5): 490.	1963-1965		
Greece	Missiou-Tsararakis S. Screening for glucose-6-phosphate dehydrogenase deficiency as a preventive measure: prevalence among 1,286,000 Greek newborn infants. <i>J Pediatr</i> . 1991; 119(2): 293-9.	1977-1989		
Greece	Menounos P, Zervas C, Garinis G, Doukas C, Kolokithopoulos D, Tegos C, Patrinos GP. Molecular heterogeneity of the glucose-6-phosphate dehydrogenase deficiency in the Hellenic population. <i>Hum Hered</i> . 2000; 50(4): 237-41.	1998-2000		
Greece	Reclos GJ, Schulpis KH, Gavriil S, Vlachos G. Evaluation of glucose-6-phosphate dehydrogenase activity in two different ethnic groups using a kit employing the haemoglobin normalization procedure. <i>Clin Biochem</i> . 2003; 36(5): 393-5.	2001-2003		
Greece	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant</i> . 1988; 3(6): 714-27.	1985		
Greece	Van Dijk PC, Jager KJ, Stengel B, Grönhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). <i>Kidney Int</i> . 2005; 67(4): 1489-99.	1991-1992, 1999-2000		
Greece	Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. <i>Nephrol Dial Transplant</i> . 2003; 18(9): 1824-33.	1990-1991, 1998-1999		
Greece	Diamanti-Kandaraki E, Kouli CR, Bergiele AT, Filandra FA, Tsianeteli TC, Spina GG, Zapanti ED, Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. <i>J Clin Endocrinol Metab</i> . 1999; 84(11): 4006-11.	1996		
Greece	Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. <i>J Clin Endocrinol Metab</i> . 2008; 93(4): 1408-11.	2005		
Greece	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguiar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Gilst WH van, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J</i> . 2003; 24(5): 442-63.	2000-2001		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Greece	Greek Cancer Registry, Ministry of Health and Welfare (Greece). Greece Cancer Morbidity Report 1990-1991. Ministry of Health and Welfare (Greece), 1997.	1990-1991	*	
Greece	Anagnostou-Vareltzides A, Diamanti-Kipioti A, Afentoulidis N, Moraitaki-Tsami A, Lindhe J, Mitsis F, Papapanou PN. A clinical survey of periodontal conditions in Greece. <i>J Clin Periodontol</i> . 1996; 23(8): 758-63.	1994		
Greece	Chroni E, Papapetropoulos S, Gioldasis G, Ellul J, Diamadopoulos N, Papapetropoulos T. Guillain-Barré syndrome in Greece: seasonality and other clinico-epidemiological features. <i>Eur J Neurol</i> . 2004; 11(6): 383-8.	1989-2001		†
Greece	Markoula S, Giannopoulos S, Sarmas I, Tzavidi S, Kyritsis AP, Lagos G. Guillain-Barré syndrome in northwest Greece. <i>Acta Neurol Scand</i> . 2007; 115(3): 167-73.	1996-2005		†
Greece	Lionis CD, Vardavas CI, Symvoulakis EK, Papadakis MG, Anastasiou FS, Antonopoulou MD, Apostolakis CM, Dimitrakopoulos SA, Fountakis GI, Grammatikopoulos IA, Komninos JD, Kounalakis DK, Ladoukaki ES, Makri KV, Petraki CS, Plomiris NG, Prokopiadou DP, Stefanaki IN, Tsakountakis NA, Tsiglianni IG, Tzortzis EN, Vasilaki AA, Vasilopoulos TK, Vrentzos GE. Measuring the burden of herpes zoster and post herpetic neuralgia within primary care in rural Crete, Greece. <i>BMC Fam Pract</i> . 2011; 136.	2007-2009	*	
Greece	Apostolopoulos K, Xenelis J, Tzagaroulakis A, Kandiloros D, Yiotakis J, Papafragou K. The point prevalence of otitis media with effusion among school children in Greece. <i>Int J Pediatr Otorhinolaryngol</i> . 1998; 44(3): 207-14.	1996	*	
Greece	World Health Organization (WHO). Greece WHO Leishmaniasis Country Profile.	2004-2008	*	
Greece	Ninios I, Bogossian H, Zarse M, Lazaridou F, Dimitriadis K, Ninios V, Lemke B, Louridas G. Prevalence, clinical correlates and treatment of permanent atrial fibrillation among the elderly: insights from the first prospective population-based study in rural Greece. <i>J Thromb Thrombolysis</i> . 2010; 30(1): 90-6.	2002-2004	*	
Greece	Kyriakis KP. Active leprosy in Greece: a 20-year survey (1988-2007). <i>Scand J Infect Dis</i> . 2010; 42(8): 594-7.	1988-2007	*	
Greece	Syrgiannopoulos GA, Lourida AN, Theodoridou MC, Pappas IG, Babilis GC, Economidis JJ, Zouboulakis DJ, Beratis NG, Matsaniotis NS. Dexamethasone therapy for bacterial meningitis in children: 2- versus 4-day regimen. <i>J Infect Dis</i> . 1994; 169(4): 853-8.	1988-1992		
Greece	Giannakopoulos I, Leotsinidis M, Diamantopoulos S, Makrakis K, Ellina A, Giannakopoulos A, Papanastasiou DA. Rarity of bacterial and viral meningitis in areas of Western Greece with fewer than 2,000 inhabitants. <i>Jpn J Infect Dis</i> . 2008; 61(1): 54-7.	1991-2005		
Greece	Theodoridou MN, Vasilopoulou VA, Atsali EE, Pangalis AM, Mostrou GI, Syriopoulou VP, Hadjichristodoulou CS. Meningitis registry of hospitalized cases in children: epidemiological patterns of acute bacterial meningitis throughout a 32-year period. <i>BMC Infect Dis</i> . 2007; 101.	1974-2005		
Greece	Tsatsoulis A, Johnson E, Sacharis K, Soucacos P, Soucacos P. An epidemiological survey on the prevalence of goiter among schoolchildren in northwestern Greece. <i>Eur J Intern Med</i> . 1996; 35-9 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1994		
Greece	Galanakis E, Tzoufi M, Katragkou A, Nakou I, Roilides E. A prospective multicenter study of childhood encephalitis in Greece. <i>Pediatr Infect Dis J</i> . 2009; 28(8): 740-2.	2000-2007		
Greece	World Health Organization (WHO). Mental Illness in General Health Care: An International Study. Geneva, Switzerland: World Health Organization (WHO), 1995.	1991-1992		
Greece	Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, Büchele G, Clausen M, Cookson WOC, von Mutius E, Strachan DP, Williams HC, ISAAC Phase Two Study Group. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. <i>J Allergy Clin Immunol</i> . 2008; 121(1): 141-147.	2005-2007	*	
Greece	Tsianos EV, Masalas CN, Merkouropoulos M, Dalekos GN, Logan RF. Incidence of inflammatory bowel disease in north west Greece: rarity of Crohn's disease in an area where ulcerative colitis is common. <i>Gut</i> . 1994; 35(3): 369-72.	1982-1991		
Greece	Ladas SD, Mallas E, Giorgiotis K, Karamanolis G, Trigonis D, Markadas A, Sipsa V, Raptis SA. Incidence of ulcerative colitis in Central Greece: a prospective study. <i>World J Gastroenterol</i> . 2005; 11(12): 1785-7.	1990-1994		
Greece	Manousos ON, Koutroubakis I, Potamianos S, Roussomoustakaki M, Gourtsoyiannis N, Vlachonikolis IG. A prospective epidemiologic study of Crohn's disease in Heraklion, Crete. Incidence over a 5-year period. <i>Scand J Gastroenterol</i> . 1996; 31(6): 599-603.	1990-1994		
Greece	Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overvad K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PHM, Lund E, Quirós JR, González CA, Sanchez Perez M-J, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu I, Chuang S-C, Murphy N, Boffetta P, Trichopoulos A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. <i>J Natl Cancer Inst</i> . 2011; 103(22): 1686-95.	1992-2006	*	
Greece	Psychogiou M, Vaindirli E, Tzala E, Voucliaris S, Boletis J, Vosnidis G, Moutafis S, Skoutelis G, Hadjicostantinou V, Trooneh H, Hatzakis A. Hepatitis E virus (HEV) infection in haemodialysis patients. The Multicentre Haemodialysis Cohort Study on Viral Hepatitis. <i>Nephrol Dial Transplant</i> . 1996; 11(6): 1093-5.	1993-1995	*	
Greece	Dalekos GN, Zervou E, Elisaf M, Germanos N, Galanakis E, Bourantas K, Siamopoulos KC, Tsianos EV. Antibodies to hepatitis E virus among several populations in Greece: increased prevalence in an hemodialysis unit. <i>Transfusion</i> . 1998; 38(6): 589-95.	1994-1996	*	
Greece	Kremastinou J, Kalapothaki V, Trichopoulos D. The changing epidemiologic pattern of hepatitis A infection in urban Greece. <i>Am J Epidemiol</i> . 1984; 120(5): 703-6.	1980-1982		
Greece	Lionis C, Koulentaki M, Biziagos E, Kouroumalis E. Current prevalence of hepatitis A, B and C in a well-defined area in rural Crete, Greece. <i>J Viral Hepat</i> . 1997; 4(1): 55-61.	1993-1995		
Greece	Lionis C, Frangoulis E, Koulentaki M, Biziagos E, Kouroumalis E. Prevalence of hepatitis A, B, and C markers in school children of a rural area of Crete, Greece. <i>Eur J Epidemiol</i> . 1997; 13(4): 417-20.	1993-1995		
Greece	Mazokopakis EE, Ganotakis ES, Lionis CD. The Greek armed forces are vulnerable to HAV infection. <i>Mil Med</i> . 2003; 168(5): v.	1998		
Greece	Michos A, Terzidis A, Kalampoki V, Pantelakis K, Spanos T, Petridou ET. Seroprevalence and risk factors for hepatitis A, B, and C among Roma and non-Roma children in a deprived area of Athens, Greece. <i>J Med Virol</i> . 2008; 80(5): 791-7.	2002		
Greece	Kyrka A, Tragiannidis A, Cassimos D, Pantelaki K, Tzoufi M, Mavrokosta M, Pedeli X, Athanassiadou F, Hatzimichael A, Konstantopoulos A, Kafetzis D, Papaevangelou V. Seroepidemiology of hepatitis A among Greek children indicates that the virus is still prevalent: Implications for universal vaccination. <i>J Med Virol</i> . 2009; 81(4): 582-7.	2006-2007		
Greece	Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. <i>Br J Cancer</i> . 1999; 81(1): 69-74.	1986-1995		
Greece	Dalekos GN, Zervou E, Merkouropoulos MH, Tsianos EV. Prevalence of hepatitis B and C viruses infection in chronic alcoholics with or without liver disease in Ioannina, Greece: low incidence of HCV infection. <i>Eur J Epidemiol</i> . 1996; 12(1): 21-5.	1993-1995		
Greece	Dounias G, Kypraios E, Rachiotis G, Tsovili E, Kostopoulos S. Prevalence of hepatitis B virus markers in municipal solid waste workers in Keratsini (Greece). <i>Occup Med (Lond)</i> . 2005; 55(1): 60-3.	1999-2001		
Greece	Elefsiniotis IS, Glynou I, Brokalaki H, Magaziotou I, Pantazis KD, Fotiou A, Liosis G, Kada H, Saroglou G. Serological and virological profile of chronic HBV infected women at reproductive age in Greece. A two-year single center study. <i>Eur J Obstet Gynecol Reprod Biol</i> . 2007; 132(2): 200-3.	2003-2005		
Greece	Elefsiniotis IS, Glynou I, Pantazis KD, Fotos NV, Magaziotou I, Kada H. Prevalence of chronic HBV infection among 13,581 women at reproductive age in Greece. A prospective single center study. <i>J Clin Virol</i> . 2005; 32(2): 179-80.	2003-2004		
Greece	Gogos CA, Fotka KP, Nikiforidis G, Avgeridis K, Sakellariopoulos G, Bassaris H, Maniatis A, Skoutelis A. Prevalence of hepatitis B and C virus infection in the general population and selected groups in South-Western Greece. <i>Eur J Epidemiol</i> . 2003; 18(6): 551-7.	1997-1998		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Greece	Goritsas C, Plerou I, Agalotis S, Spithaki R, Mimidis K, Velissaris D, Lazarou N, Labropoulou-Karatzis C. HCV infection in the general population of a Greek island: prevalence and risk factors. <i>Hepatology</i> . 2000; 47(3): 782-5.	1997		
Greece	Kyriakis KP, Foudoulaki LE, Papouli EI, Sofroniadou KE. Seroprevalence of hepatitis B surface antigen (HBsAg) among first-time and sporadic blood donors in Greece: 1991-1996. <i>Transfus Med</i> . 2000; 10(3): 175-80.	1991-1996		
Greece	Flohr C, Weimayr G, Weiland SK, Addo-Yobo E, Annesi-Maesano I, Björkstén B, Bråbäck L, Büchele G, Chico M, Cooper P, Clausen M, El Sharif N, Martínez Gimeno A, Mathur RS, von Mutius E, Morales Suarez-Varela M, Pearce N, Svabe V, Wong GWK, Yu M, Zhong NS, Williams HC, ISAAC Phase Two Study Group. How well do questionnaires perform compared with physical examination in detecting flexural eczema? Findings from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. <i>Br J Dermatol</i> . 2009; 161(4): 846-53.	2005-2007	*	
Greece	Dalekos GN, Zervou E, Karabini F, Tsianos EV. Prevalence of viral markers among refugees from southern Albania: increased incidence of infection with hepatitis A, B and D viruses. <i>Eur J Gastroenterol Hepatol</i> . 1995; 7(6): 553-8.	1994		
Greece	Vemmos KN, Bots ML, Tsiouris PK, Zis VP, Takis CE, Grobbee DE, Stamatiopoulos S. Prognosis of stroke in the south of Greece: 1 year mortality, functional outcome and its determinants: the Arcadia Stroke Registry. <i>J Neurol Neurosurg Psychiatry</i> . 2000; 69(5): 595-600.	1993-1995		
Greece	Greece Hellenic Renal Registry Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Greece	Greece Hellenic Renal Registry Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Greece	Greece Hellenic Renal Registry Renal Replacement Therapy Data 1997 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), European Renal Association-European Dialysis and Transplant Association Registry Annual Report 1998. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2003.	1997	*	
Greece	Greece Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD), United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Grenada	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-1997, 1999-2005		
Grenada	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Grenada	Smadja D, Cabre P, May F, Fanon J-L, René-Corail P, Riocreux C, Charpentier J-C, Fournier P, Saint-Vil M, Ketterlé J. ERMANCIA: Epidemiology of Stroke in Martinique, French West Indies. <i>Stroke</i> . 2001; 32(12): 2741-7.	1998-1999		
Grenada	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000-2009		
Grenada	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Grenada	Canino G, Shrout PE, Rubio-Stipec M, et al. The DSM-IV rates of child and adolescent disorders in Puerto Rico: Prevalence, correlates, service use, and the effects of impairment. <i>Arch Gen Psychiatry</i> . 2004; 61(1): 85-93.	1999-2000		
Grenada	Rubio-Stipec M, Canino GJ, Shrout P, Dulcan R, Freeman D, Bravo M. Psychometric properties of parents and children as informants in child psychiatry epidemiology with the Spanish Diagnostic Interview Schedule for Children (DISC.2). <i>J Abnorm Child Psychol</i> . 1994; 22(6): 703-20.	1992	*	
Grenada	Canino GJ, Bird HR, Shrout PE, Rubio-Stipec M, Bravo M, Martinez R, Sesman M, Guevara LM. The prevalence of specific psychiatric disorders in Puerto Rico. <i>Arch Gen Psychiatry</i> . 1987; 44(8): 727-35.	1984		
Grenada	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Grenada Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2005		
Grenada	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2004, 2007, 2010		
Grenada	Bird HR, Canino G, Rubio-Stipec M, Gould MS, Ribera J, Sesman M, Woodbury M, Huertas-Goldman S, Pagan A, Sanchez-Lacay A. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico. The use of combined measures. <i>Arch Gen Psychiatry</i> . 1988; 45(12): 1120-6.	1985-1986	*	
Grenada	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec</i> . 2010; 85(35): 337-48.	2009	*	
Grenada	Merikangas KR, Conway KP, Swendsen J, Febo V, Dierker L, Brunetto W, Stolar M, Canino G. Substance use and behaviour disorders in Puerto Rican youth: a migrant family study. <i>J Epidemiol Community Health</i> . 2009; 63(4): 310-6.	1990		
Grenada	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Grenada	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Grenada	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Grenada	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Grenada	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Grenada	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Grenada	Olindo S, Cabre P, Deschamps R, Chatot-Henry C, René-Corail P, Fournier P, Saint-Vil M, May F, Smadja D. Acute stroke in the very elderly: epidemiological features, stroke subtypes, management, and outcome in Martinique, French West Indies. <i>Stroke</i> . 2003; 34(7): 1593-7.	1998-1999		
Grenada	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L, Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Ann Hepatol</i> . 2010; 9(1): 63-9.	2006-2008	*	
Grenada	Grenada Vital Registration Birth Data 1978 as it appears in United Nations Statistics Division (UNSD), United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1978		
Guatemala	Macro International, Inc, National Statistics Institute (Guatemala). Guatemala Demographic and Health Survey 1995. Calverton, United States: Macro International, Inc.	1995		†
Guatemala	Institute of Nutrition of Central America and Panama, Westinghouse; Institute for Resource Development. Guatemala Demographic and Health Survey 1987. Columbia, United States: Westinghouse; Institute for Resource Development.	1987		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Guatemala	Macro International, Inc. National Statistics Institute (Guatemala). Guatemala Interim Demographic and Health Survey 1998-1999. Calverton, United States: Macro International, Inc.	1998-1999		†
Guatemala	World Health Organization (WHO). Guatemala World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Guatemala	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-2002		
Guatemala	Bartlett AV, Torun B, Morales C, Cano F, Cruz JR. Oral gentamicin is not effective treatment for persistent diarrhea. <i>Acta Paediatr Suppl.</i> 1992; 381: 149-54.	1988-1990		
Guatemala	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Guatemala	Estrada Castañón R, Torres Bibiano B, Alarcón Hernández H, Villegas Arrizón A, Martínez Sandoval E, Chávez López G, Andersson N. Epidemiología cutánea en dos sectores de atención médica en Guerrero, México: Cutaneous epidemiology in two sectors of Guerrero, Mexico. <i>Dermatol rev mex.</i> 1992; 36(1): 29-34.	1989-1991		
Guatemala	Bruce N, Weber M, Arana B, Diaz A, Jenny A, Thompson L, McCracken J, Dherani M, Juarez D, Ordóñez S, Klein R, Smith KR. Pneumonia case-finding in the RESPIRE Guatemala indoor air pollution trial: standardizing methods for resource-poor settings. <i>Bull World Health Organ.</i> 2007; 7(85): 535-544.	2002-2004		
Guatemala	Bern C, Hernandez B, Lopez MB, Arrowood MJ, De Merida AM, Klein RE. The contrasting epidemiology of Cyclospora and Cryptosporidium among outpatients in Guatemala. <i>Am J Trop Med Hyg.</i> 2000; 63(5-6): 231-5.	1997-1998		
Guatemala	De Oliveira LH, Danovaro-Holliday MC, Andrus JK, de Fillipsis AMB, Gentsch J, Matus CR, Widdowson M-A. Sentinel hospital surveillance for rotavirus in Latin American and Caribbean countries. <i>J Infect Dis.</i> 2009; 200 Suppl 1: 131-139.	2006-2007		
Guatemala	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001-2005, 2008-2009		
Guatemala	Cruz JR, Cáceres P, Cano F, Flores J, Bartlett A, Torin B. Adenovirus types 40 and 41 and rotaviruses associated with diarrhea in children from Guatemala. <i>J Clin Microbiol.</i> 1990; 28(8): 1780-4.	1986-1988	*	
Guatemala	Cortes J, Arvelo W, Lopez B, Reyes L, Kerin T, Gautam R, Patel M, Parashar U, Lindblade KA. Rotavirus disease burden among children <5 years of age—Santa Rosa, Guatemala, 2007-2009. <i>Trop Med Int Health.</i> 2012; 17(2): 254-9.	2007-2009	*	
Guatemala	Beltranena F, Cassola K, Silva JC, Limburg H. Cataract blindness in 4 regions of Guatemala: results of a population-based survey. <i>Ophthalmology.</i> 2007; 114(8): 1558-63, as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2004		
Guatemala	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Guatemala Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2005		
Guatemala	Lindblade KA, Arvelo W, Gray J, Estevez A, Frenkel G, Reyes L, Moscoso F, Moir JC, Fry AM, Olsen SJ. A comparison of the epidemiology and clinical presentation of seasonal influenza A and 2009 pandemic influenza A (H1N1) in Guatemala. <i>PLoS One.</i> 2010; 5(12): e15826.	2008-2009	*	
Guatemala	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). CICAD Comparative Report on Nationwide School Surveys in Seven Countries: El Salvador, Guatemala, Nicaragua, Panama, Paraguay, Dominican Republic, and Uruguay 2003. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2004.	2003	2	
Guatemala	García-Naval J, Allan JC, Fletes C, Moreno E, de Mata F, Alvarez R-T, de Alfaro HS, Yurrita P, Higuero-Morales H, Mencos F, Craig PS. Epidemiology of Taenia solium taeniasis and cysticercosis in two rural Guatemalan communities. <i>Am J Trop Med Hyg.</i> 1996; 55(3): 282.	1991-1992		
Guatemala	Mendizabal JE, Salguero LF. Prevalence of epilepsy in a rural community of Guatemala. <i>Epilepsia.</i> 1996; 37(4): 373-6.	1995	*	
Guatemala	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2010		
Guatemala	Fernández-Cean J, González-Martínez F, Schwedt E, Mazzuchi N. Renal replacement therapy in Latin America. <i>Kidney Int.</i> 2000; 57(s74): 55-59.	1997		
Guatemala	Cusumano A, García-García G, Di Gioia C, Hermida O, Lavorato C, Carreño CA, Torrico MP, Batista PB, Romão JE, Badal HP, Miranda SE, Gomez R, Calderon MC, Sanchez SH, Lopez MA, Moscoso J, Merino RL, Polo JV, Lopez A, Romero NJ, Garcia R, Acosta BV, Lopez AS, Delpin ES, Mena E, González C, Milanés CL, Acchiardo S. End-stage renal disease and its treatment in Latin America in the twenty-first century. <i>Ren Fail.</i> 2006; 28(8): 631-7.	2004		
Guatemala	Cusumano A, García GG, Di Gioia C, Hermida O, Lavorato C. Latin American Registry of Dialysis and Transplantation. The Latin American Dialysis and Transplantation Registry (RLDT) annual report 2004. <i>Ethn Dis.</i> 2006; 16(2 Suppl 2): 10-3.	2003		
Guatemala	Asturias EJ, Soto M, Menendez R, Ramirez PL, Recinos F, Gordillo R, Holt E, Halsey NA. Meningitis and pneumonia in Guatemalan children: the importance of Haemophilus influenzae type b and Streptococcus pneumoniae. <i>Rev Panam Salud Publica.</i> 2003; 14(6): 377-84.	1996-1999		
Guatemala	World Health Organization (WHO). Guatemala WHO Leishmaniasis Country Profile.	2002-2010	*	
Guatemala	Guatemala Vital Registration - Deaths 2009 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2009	*	
Guatemala	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Guatemala	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Guatemala	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Guatemala	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Guatemala	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Guatemala	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Guatemala	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Guatemala	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2003. Pan American Health Organization (PAHO).	2003		†
Guatemala	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2004. Pan American Health Organization (PAHO).	2004		†
Guatemala	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2005. Pan American Health Organization (PAHO).	2005		†
Guatemala	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2006. Pan American Health Organization (PAHO).	2006		†
Guatemala	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2007. Pan American Health Organization (PAHO).	2007		†
Guatemala	AIDSTECH AIDSTECH Final Report 1993. Durham, North Carolina: Family Health International, 1993.	1992		
Guatemala	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Guatemala	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Guatemala	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Guatemala	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Guatemala	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Guatemala	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Guatemala	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artoia Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L. Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Ann Hepatol.</i> 2010; 9(1): 63-9.	2006-2008	*	
Guatemala	Steinberg EB, Mendoza CE, Glass R, Arana B, Lopez MB, Mejia M, Gold BD, Priest JW, Bibb W, Monroe SS, Bern C, Bell BP, Hoekstra RM, Klein R, Mintz ED, Luby S. Prevalence of infection with waterborne pathogens: a seroepidemiologic study in children 6-36 months old in San Juan Sacatepequez, Guatemala. <i>Am J Trop Med Hyg.</i> 2004; 70(1): 83-8.	1999		
Guatemala	Pan American Health Organization (PAHO), World Health Organization (WHO). Quantitative Estimation of Chagas in the Americas.	2005	*	
Guatemala	Guatemala Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Guinea	Macro International, Inc, National Statistics Directorate (Guinea). Guinea Demographic and Health Survey 1999. Calverton, United States: Macro International, Inc.	1999		†
Guinea	Macro International, Inc, National Statistics Directorate (Guinea). Guinea Demographic and Health Survey 2005. Calverton, United States: Macro International, Inc.	2005		†
Guinea	ICF Macro, Ministry of Health and Public Hygiene (Guinea), National Institute of Statistics (Guinea). Guinea Demographic and Health Survey 2012. Calverton, United States: ICF Macro, 2014.	2012	*	†
Guinea	Guinea Demographic and Health Survey 2012 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2012	*	†
Guinea	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Guinea	Fofana M, Touré S, Dadi Balde M, Sow T, Yassima Camara A, Damby Balde O, Toure A, Conde A. Etiologic and nosologic considerations apropos of 574 cases of cardiac decompensation in Conakry. <i>Ann Cardiol Angeiol (Paris).</i> 1988; 37(8): 419-24.	1981-1985		
Guinea	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1987		
Guinea	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1996-2009		
Guinea	Nathan N, Barry M, Van Herp M, Zeller H. Shortage of vaccines during a yellow fever outbreak in Guinea. <i>Lancet.</i> 2001; 358(9299): 2129-30.	2000-2001		
Guinea	Mutebi J-P, Barrett ADT. The epidemiology of yellow fever in Africa. <i>Microbes Infect.</i> 2002; 4(14): 1459-68.	2000-2001		
Guinea	World Health Organization (WHO). Yellow fever in Africa and South America, 2006. <i>Wkly Epidemiol Rec.</i> 2008; 83(8): 60-76.	2006		
Guinea	World Health Organization (WHO). Yellow fever, Guinea. <i>Wkly Epidemiol Rec.</i> 2008; 83(40): 358-9.	2008		
Guinea	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2002		
Guinea	Millimono TS, Loua KM, Rath SL, Relvas L, Bento C, Diakite M, Jarvis M, Daries N, Ribeiro LM, Manco L, Kaeda JS. High prevalence of hemoglobin disorders and glucose-6-phosphate dehydrogenase (G6PD) deficiency in the Republic of Guinea (West Africa). <i>Hemoglobin.</i> 2012; 36(1): 25-37.	2008-2010	*	
Guinea	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Guinea	Toure S, Balde MD, Balde OD, Sow T, Toure A, Conde A, Diallo MC, Traore O, Fofana M. Enquête sur les cardiopathies en milieu scolaire et universitaire à Conakry (R. Guinée). <i>Cardiol Trop.</i> 1992; 18(72): 205-10.	1987-1988		
Guinea	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Guinea	Guinea Iodine Deficiency Disorders Survey 1999 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1999		
Guinea	Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. <i>Int J Health Geogr.</i> 2010; 9: 57.	1980-2010		
Guinea	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec.</i> 2005; 80(13): 118-24.	2003	*	
Guinea	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec.</i> 2006; 81(32): 309-16.	2005	*	
Guinea	World Health Organization (WHO). Global leprosy situation, 2007 (additional information). <i>Wkly Epidemiol Rec.</i> 2007; 82(44): 388.	2006	*	
Guinea	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Guinea	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Guinea	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Guinea	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Guinea	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Guinea	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Guinea	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Guinea	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Guinea	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1993; 68(25): 181-6.	1992	*	
Guinea	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Guinea	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Guinea	Guinea Iodine Deficiency Disorders Survey 1994 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1994		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Guinea	Jentes ES, Robinson J, Johnson BW, Conde I, Sakouyougui Y, Iverson J, Beecher S, Bah MA, Diakite F, Coulibaly M, Bausch DG, Bryan J. Acute arboviral infections in Guinea, West Africa, 2006. <i>Am J Trop Med Hyg.</i> 2010; 83(2): 388-94.	2006		
Guinea	Loua A, Lamah MR, Haba NY, Camara M. [Frequency of blood groups ABO and rhesus D in the Guinean population]. <i>Transfus Clin Biol.</i> 2007; 14(5): 435-9.	1997-2004	*	†
Guinea	Baldé MC, Camara M, Barry AO, Sow S, Sidibb CT, Lamah O, Lodi OE, Camara SK, Condé N, Bah H. [Malaria prevalence survey in 24 Guinean villages in the Kindia area]. <i>Bull Soc Pathol Exot.</i> 2001; 94(2): 192-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Guinea	Bosman A, Modiano D, Voglino M, Pizzi L, Bartoloni P, Kandia Diallo I, De Giorgi F. Malaria transmission in a central area of Futa Djallon (Guinea): results of a parasitological survey during the 1989 rainy season. <i>Parassitologia.</i> 1992; 34(1-3): 135-42 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Guinea-Bissau	Secretary State of Planning, National Institute of Statistics and Census (INEC), United Nations Children's Fund (UNICEF). Guinea-Bissau Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Guinea-Bissau	United Nations Children's Fund (UNICEF), Government of Guinea-Bissau. Guinea-Bissau Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006	*	†
Guinea-Bissau	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Guinea-Bissau	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Guinea-Bissau	Masmas TN, Garly M-L, Lisse IM, Rodrigues A, Petersen PT, Birgens H. Inherited hemoglobin disorders in Guinea-Bissau, West Africa: a population study. <i>Hemoglobin.</i> 2006; 3(30): 355-64.	2002-2003		
Guinea-Bissau	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1996-1997, 1999, 2001-2009		
Guinea-Bissau	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Guinea-Bissau	Molbak K, Wested N, Højlyng N, Scheutz F, Gottschau A, Aaby P, da Silva AP. The etiology of early childhood diarrhea: a community study from Guinea-Bissau. <i>J Infect Dis.</i> 1994; 169(3): 581-7.	1987-1988	*	
Guinea-Bissau	Matthesen M, Baelum V, Aarstev J, Fejerskov O. Dental health of children and adults in Guinea-Bissau, West Africa, in 1986. <i>Community Dent Health.</i> 1990; 7(2): 123-33.	1986		
Guinea-Bissau	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2004, 2010, 2012		
Guinea-Bissau	Bjerregaard-Andersen M, Hansen L, da Silva LI, Joaquim LC, Hennild DE, Christiansen L, Aaby P, Benn CS, Christensen K, Sodemann M, Jensen DM, Beck-Nielsen H. Risk of metabolic syndrome and diabetes among young twins and singletons in Guinea-Bissau. <i>Diabetes Care.</i> 2013; 36(11): 3549-56.	2009-2011		
Guinea-Bissau	Høj L, Cardoso P, Nielsen BB, Hvidman L, Nielsen J, Aaby P. Effect of sublingual misoprostol on severe postpartum haemorrhage in a primary health centre in Guinea-Bissau: randomised double blind clinical trial. <i>BMJ.</i> 2005; 331(7519): 723.	2003-2004	*	
Guinea-Bissau	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec.</i> 2005; 80(13): 118-24.	2003	*	
Guinea-Bissau	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec.</i> 2006; 81(32): 309-16.	2005	*	
Guinea-Bissau	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Guinea-Bissau	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Guinea-Bissau	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Guinea-Bissau	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Guinea-Bissau	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Guinea-Bissau	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Guinea-Bissau	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Guinea-Bissau	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Guinea-Bissau	Oliveira AL, Batista JL, Silva AP, Sobrinho LG, Rocha LC. Endemic goitre in Guinea-Bissau. <i>Bull World Health Organ.</i> 1991; 69(3): 347-8 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1989		
Guinea-Bissau	Arez AP, Pinto J, Pålsson K, Snounou G, Jaenson TG, do Rosário VE. Transmission of Mixed Plasmodium Species and Plasmodium Genotypes. <i>Am J Trop Med Hyg.</i> 2003; 68(2): 161-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995-1996	*	†
Guinea-Bissau	Goncalves A, Ferrinho P, Dias F. The epidemiology of malaria in Prabis, Guinea-Bissau. <i>Mem Inst Oswaldo Cruz.</i> 1996; 91(1): 11-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991-1992		†
Guinea-Bissau	Jaenson TG, Gomes MJ, Barreto dos Santos RC, Petrarca V, Fortini D, Evora J, Crato J. Control of endophagic Anopheles mosquitoes and human malaria in Guinea Bissau, West Africa by permethrin-treated bed nets. <i>Trans R Soc Trop Med Hyg.</i> 1994; 88(6): 620-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990-1991	*	†
Guinea-Bissau	Lisse IM, Aaby P, Whittle H, Knudsen K. A community study of T lymphocyte subsets and malaria parasitaemia. <i>Trans R Soc Trop Med Hyg.</i> 1994; 88(6): 709-10 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Guinea-Bissau	Rodrigues A, Schellenberg JA, Kofoed PE, Aaby P, Greenwood B. Changing pattern of malaria in Bissau, Guinea Bissau. <i>Trop Med Int Health.</i> 2008; 13(3): 410-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Guinea-Bissau	Satoguina J, Walther B, Drakeley C, Nwakanma D, Oriero E, Correa S, Corran P, Conway D, Walther M. Comparison of surveillance methods applied to a situation of low malaria prevalence at rural sites in The Gambia and Guinea Bissau. <i>Malar J.</i> 2009; 8: 274 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008	*	†
Guinea-Bissau	Snounou G, Pinheiro L, Gonçalves A, Fonseca L, Dias F, Brown KN, do Rosario VE. The importance of sensitive detection of malaria parasites in the human and insect hosts in epidemiological studies, as shown by the analysis of field samples from Guinea Bissau. <i>Trans R Soc Trop Med Hyg.</i> 1993; 87(6): 649-53 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Guinea-Bissau	Sodemann M, Jakobsen MS, Mølbaek K, Alvarenga IC, Martins C, Aaby P. Malaria parasitemia and childhood diarrhea in a peri-urban area of Guinea-Bissau. <i>Am J Trop Med Hyg.</i> 1999; 61(2): 336-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993-1994	*	†
Guyana	Bureau of Statistics (Guyana), United Nations Children's Fund (UNICEF). Guyana Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF)	2000	*	†
Guyana	United Nations Children's Fund (UNICEF), Bureau of Statistics (Guyana). Guyana Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006-2007	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Guyana	Bureau of Statistics (Guyana), International Statistical Institute. Guyana World Fertility Survey 1975. Voorburg, Netherlands: International Statistical Institute.	1975		
Guyana	Guyana Vital Registration - Deaths 1991 ICD9 as it appears in World Health Organization (WHO), World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1991		
Guyana	Bureau of Statistics (Guyana), ICF Macro, Ministry of Health (Guyana). Guyana Demographic and Health Survey 2009. Calverton, United States: ICF Macro, 2011.	2009		†
Guyana	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-2005		
Guyana	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Guyana	Smadja D, Cabre P, May F, Fanon J-L, René-Corail P, Riocreux C, Charpentier J-C, Fournier P, Saint-Vil M, Ketterlé J. ERMANCIA: Epidemiology of Stroke in Martinique, French West Indies. Stroke. 2001; 32(12): 2741-7.	1998-1999		
Guyana	De Oliveira LH, Danovaro-Holliday MC, Andrus JK, de Fillipsis AMB, Gentsch J, Matus CR, Widdowson M-A. Sentinel hospital surveillance for rotavirus in Latin American and Caribbean countries. J Infect Dis. 2009; 200 Suppl 1: 131-139.	2007		
Guyana	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997-1998, 2000-2001, 2003-2009		
Guyana	Bwititi PT, Browne J. Seroprevalence of Trypanosoma cruzi in blood donors at the National Blood Transfusion Services—Guyana. West Indian Med J. 2012; 61(6): 559-63.	2007-2008		
Guyana	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Guyana	Nathan MB, Stroom V. Prevalence of Wuchereria bancrofti in Georgetown, Guyana. Bull Pan Am Health Organ. 1990; 24(3): 301-6. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1981, 1984		
Guyana	Canino G, Shrout PE, Rubio-Stipec M, et al. The DSM-IV rates of child and adolescent disorders in Puerto Rico: Prevalence, correlates, service use, and the effects of impairment. Arch Gen Psychiatry. 2004; 61(1): 85-93.	1999-2000		
Guyana	Rubio-Stipec M, Canino GI, Shrout P, Dulcan M, Freeman D, Bravo M. Psychometric properties of parents and children as informants in child psychiatry epidemiology with the Spanish Diagnostic Interview Schedule for Children (DISC.2). J Abnorm Child Psychol. 1994; 22(6): 703-20.	1992	*	
Guyana	Canino GI, Bird HR, Shrout PE, Rubio-Stipec M, Bravo M, Martinez R, Sesman M, Guevara LM. The prevalence of specific psychiatric disorders in Puerto Rico. Arch Gen Psychiatry. 1987; 44(8): 727-35.	1984		
Guyana	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Guyana Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2002		
Guyana	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 2001, 2004, 2007, 2010, 2012		
Guyana	Bird HR, Canino G, Rubio-Stipec M, Gould MS, Ribera J, Sesman M, Woodbury M, Huertas-Goldman S, Pagan A, Sanchez-Lacay A. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico. The use of combined measures. Arch Gen Psychiatry. 1988; 45(12): 1120-6.	1985-1986	*	
Guyana	World Health Organization (WHO). Guyana WHO Leishmaniasis Country Profile.	2006-2008	*	
Guyana	Rawlins SC, Lammie P, Tiwari T, Pons P, Chadee DD, Oostburg BF, Baboolal S. Lymphatic filariasis in the Caribbean region: the opportunity for its elimination and certification. Rev Panam Salud Publica. 2000; 7(5): 319-24.	1998	*	
Guyana	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Guyana	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Guyana	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Guyana	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Guyana	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Guyana	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Guyana	Merikangas KR, Conway KP, Swendsen J, Febo V, Dierker L, Brunetto W, Stolar M, Canino G. Substance use and behaviour disorders in Puerto Rican youth: a migrant family study. J Epidemiol Community Health. 2009; 63(4): 310-6.	1990		
Guyana	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Guyana	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Guyana	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Guyana	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Guyana	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Guyana	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Guyana	Olindo S, Cabre P, Deschamps R, Chatot-Henry C, René-Corail P, Fournier P, Saint-Vil M, May F, Smadja D. Acute stroke in the very elderly: epidemiological features, stroke subtypes, management, and outcome in Martinique, French West Indies. Stroke. 2003; 34(7): 1593-7.	1998-1999		
Guyana	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L. Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. Ann Hepatol. 2010; 9(1): 63-9.	2006-2008	*	
Guyana	Pan American Health Organization (PAHO), World Health Organization (WHO). Quantitative Estimation of Chagas in the Americas.	2005	*	
Guyana	Guyana Vital Registration Birth Data 1972 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1972		
Haiti	Haitian Institute of Statistics and Informatics, International Statistical Institute. Haiti World Fertility Survey 1977. Voorburg, Netherlands: International Statistical Institute.	1977		
Haiti	Haiti Child Health Institute (CHI), Macro International, Inc. Haiti Demographic and Health Survey 1994-1995. Calverton, United States: Macro International, Inc.	1994-1995		†
Haiti	Haiti Child Health Institute (CHI), Macro International, Inc. Haiti Demographic and Health Survey 2000. Calverton, United States: Macro International, Inc.	2000		†
Haiti	Haiti Child Health Institute (CHI), Haitian Institute of Statistics and Informatics, Macro International, Inc. Haiti Demographic and Health Survey 2005-2006. Calverton, United States: Macro International, Inc.	2005-2006		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Haiti	Centers for Disease Control and Prevention (CDC), Haiti Child Health Institute (CHI), Haitian Institute of Statistics and Informatics, Macro International, Inc. Haiti Demographic and Health Survey 2012. Fairfax, United States: ICF International, 2013.	2012	*	†
Haiti	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1994-1996, 2000		
Haiti	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Haiti	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Haiti	Smadja D, Cabre P, May F, Fanon J-L, René-Corail P, Riocreux C, Charpentier J-C, Fournier P, Saint-Vil M, Ketterlé J. ERMANCIA: Epidemiology of Stroke in Martinique, French West Indies. Stroke. 2001; 32(12): 2741-7.	1998-1999		
Haiti	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2002, 2009		
Haiti	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Haiti	Franz FE, Götzte W. Oral health survey in Haitian and Hamburg children aged 12-15. Community Dent Oral Epidemiol. 1983; 11(5): 302-7.	1981		
Haiti	Canino G, Shrout PE, Rubio-Stipec M, et al. The DSM-IV rates of child and adolescent disorders in Puerto Rico: Prevalence, correlates, service use, and the effects of impairment. Arch Gen Psychiatry. 2004; 61(1): 85-93.	1999-2000		
Haiti	Rubio-Stipec M, Canino GJ, Shrout P, Dulcan M, Freeman D, Bravo M. Psychometric properties of parents and children as informants in child psychiatry epidemiology with the Spanish Diagnostic Interview Schedule for Children (DISC.2). J Abnorm Child Psychol. 1994; 22(6): 703-20.	1992	*	
Haiti	Canino GJ, Bird HR, Shrout PE, Rubio-Stipec M, Bravo M, Martinez R, Sesman M, Guevara LM. The prevalence of specific psychiatric disorders in Puerto Rico. Arch Gen Psychiatry. 1987; 44(8): 727-35.	1984		
Haiti	National Commission on the Fight Against Drugs (Haiti). Haiti Drug Prevalence Survey of Secondary Students 2005.	2005		
Haiti	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Haiti Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2005		
Haiti	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Haiti	Bird HR, Canino G, Rubio-Stipec M, Gould MS, Ribera J, Sesman M, Woodbury M, Huertas-Goldman S, Pagan A, Sanchez-Lacay A. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico. The use of combined measures. Arch Gen Psychiatry. 1988; 45(12): 1120-6.	1985-1986	*	
Haiti	Jackson BR, Fouche B, Lafosse E, Nygren B, Roddly AW, Dahourou G, Copeland J, Mahon B, O'Reilly C, Boney J, Mintz E. Evaluation of cholera severity in a highly affected Haitian population. Am J Trop Med Hyg. 2011; 85(6 Suppl): 288.	2011	*	
Haiti	Boyd A, Won KY, McClintock SK, Donovan CV, Laney SJ, Williams SA, Pilote N, Streit TG, Beau de Rochars MVE, Lammie PJ. A community-based study of factors associated with continuing transmission of lymphatic filariasis in Leogane, Haiti. PLoS Negl Trop Dis. 2010; 4(3): e640. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1996-2001, 2008		
Haiti	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Haiti	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Haiti	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Haiti	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Haiti	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Haiti	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Haiti	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Haiti	Boulos R, Ruff AJ, Nahmias A, Holt E, Harrison L, Magder L, Wiktor SZ, Quinn TC, Margolis H, Halsey NA. Herpes simplex virus type 2 infection, syphilis, and hepatitis B virus infection in Haitian women with human immunodeficiency virus type 1 and human T lymphotropic virus type 1 infections. J Infect Dis. 1992; 166(2): 418-20.	1989-1991	*	
Haiti	Merikangas KR, Conway KP, Swendsen J, Febo V, Dierker L, Brunetto W, Stolar M, Canino G. Substance use and behaviour disorders in Puerto Rican youth: a migrant family study. J Epidemiol Community Health. 2009; 63(4): 310-6.	1990		
Haiti	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Haiti	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Haiti	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Haiti	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Haiti	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Haiti	Olando S, Cabre P, Deschamps R, Chatot-Henry C, René-Corail P, Fournier P, Saint-Vil M, May F, Smadja D. Acute stroke in the very elderly: epidemiological features, stroke subtypes, management, and outcome in Martinique, French West Indies. Stroke. 2003; 34(7): 1593-7.	1998-1999		
Haiti	Hepburn MJ, Lawitz EJ. Seroprevalence of hepatitis C and associated risk factors among an urban population in Haiti. BMC Gastroenterol. 2004; 4: 31.	2000		
Haiti	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artoia Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L. Multicenter Group for Hepatocarcinoma in Latin America. Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. Ann Hepatol. 2010; 9(1): 63-9.	2006-2008	*	
Haiti	Allain JP, Hodges W, Einstein MH, Geisler J, Neilly C, Delaney S, Hodges B, Lee H. Antibody to HIV-1, HTLV-I, and HCV in three populations of rural Haitians. J Acquir Immune Defic Syndr. 1992; 5(12): 1230-6.	1988-1990		
Haiti	De Rochars MB, Kanjilal S, Direny AN, Radday J, Lafontant JG, Mathieu E, Rheingans RD, Haddix AC, Streit TG, Beach MJ, Admiss DG, Lammie PJ. The Leogane, Haiti demonstration project: decreased microfilaremia and program costs after three years of mass drug administration. Am J Trop Med Hyg. 2005; 73(5): 888-94. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2000	*	
Haiti	Raccurt CP, Lowrie RC Jr, Katz SP, Diverseau YT. Epidemiology of Wuchereria bancrofti in Leogane, Haiti. Trans R Soc Trop Med Hyg. 1988; 82(5): 721-5. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1980-1981	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Haiti	One-time Study of Malaria Morbidity in Bellevue as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Haiti	Deloron P, Duverseau Y, Zavallos-Ipenza A, Magloire R, Stanfill P, Nguyen-Dinh P. Antibodies to Pf155, a major antigen of Plasmodium falciparum: seroepidemiological studies in Haiti. Bull World Health Organ. 1987; 65(3): 339-44 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Haiti	Eisele TP, Keating J, Bennett A, Londono B, Johnson D, Lafontant C, Krogstad DJ. Prevalence of Plasmodium falciparum Infection in Rainy Season, Artibonite Valley, Haiti, 2006. Emerg Infect Dis. 2007; 13(10): 1494-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Haiti	Assessment of the prevalence xerophthalmia in Haiti as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1974-1975		
Honduras	Honduras Vital Registration - Deaths 1988 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1988	*	
Honduras	Macro International, Inc, National Institute of Statistics (Honduras), Secretary of Health (Honduras), Honduras Demographic and Health Survey 2005-2006. Calverton, United States: Macro International, Inc.	2005-2006		†
Honduras	Ministry of Health (Honduras), Honduras Family Planning Association (ASHONPLAFA) and Division of Reproductive Health-Centers for Disease Control and Prevention (CDC). (1997) Honduras Reproductive Health Survey 1996. Tegucigalpa, Honduras: ASHONPLAFA.	1996		
Honduras	Honduras Family Planning Association (ASHONPLAFA), Ministry of Health (Honduras), and Division of Reproductive Health-Centers for Disease Control and Prevention (CDC). Honduras Reproductive Health Survey 2001. Tegucigalpa, Honduras: Honduras Family Planning Association (ASHONPLAFA).	2001		†
Honduras	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-2002		
Honduras	ICF International, National Institute of Statistics (Honduras), Honduras Demographic and Health Survey 2011-2012. Calverton, United States: ICF Macro, 2013.	2011-2012	*	†
Honduras	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Honduras	Estrada Castañón R, Torres Bibiano B, Alarcón Hernández H, Villegas Arrizón A, Martínez Sandoval E, Chávez López G, Andersson N. Epidemiología cutánea en dos sectores de atención médica en Guerrero, México; Cutaneous epidemiology in two sectors of Guerrero, Mexico. Dermatol rev mex. 1992; 36(1): 29-34.	1989-1991		
Honduras	De Oliveira LH, Danovaro-Holliday MC, Andrus JK, de Fillipsis AMB, Gentsch J, Matus CR, Widdowson M-A. Sentinel hospital surveillance for rotavirus in Latin American and Caribbean countries. J Infect Dis. 2009; 200 Suppl 1: 131-139.	2006-2007		
Honduras	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997-2009		
Honduras	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2002		
Honduras	Sosa-Estani S, Gamboa-León MR, Del Cid-Lemus J, Althabe F, Alger J, Almendares O, Cafferata ML, Chipaux J-P, Dumonteil E, Gibbons L, Padilla-Raygoza N, Schneider D, Belizán JM, Buekens P, Working Group. Use of a rapid test on umbilical cord blood to screen for Trypanosoma cruzi infection in pregnant women in Argentina, Bolivia, Honduras, and Mexico. Am J Trop Med Hyg. 2008; 79(5): 755-9.	2006-2007		
Honduras	Mallol J, Solé D, Baeza-Bacab M, Aguirre-Camposano V, Soto-Quiros M, Baena-Cagnani C. Latin American ISAAC Group. Regional variation in asthma symptom prevalence in Latin American children. J Asthma. 2010; 47(6): 644-50.	2001-2003	*	
Honduras	Kaminsky RG. Parasitism and diarrhoea in children from two rural communities and marginal barrio in Honduras. Trans R Soc Trop Med Hyg. 1991; 85(1): 70-3.	1990	*	
Honduras	Grimaldi G Jr, Tesh RB, McMahon-Pratt D. A review of the geographic distribution and epidemiology of leishmaniasis in the New World. Am J Trop Med Hyg. 1989; 41(6): 687-725.	1975-1983		
Honduras	Paz-Bailey G, Morales-Miranda S, Jacobson JO, Gupta SK, Sabin K, Mendoza S, Paredes M, Alvarez B, Monteroso E. High rates of STD and sexual risk behaviors among Garifunas in Honduras. J Acquir Immune Defic Syndr. 2009; 826-34.	2006		
Honduras	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Honduras Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2005		
Honduras	Medina MT, Durón RM, Martínez L, Osorio JR, Estrada AL, Zúñiga C, Cartagena D, Collins JS, Holden KR. Prevalence, incidence, and etiology of epilepsies in rural Honduras: the Salama Study. Epilepsia. 2005; 46(1): 124-31.	1996-1997, 2005		†
Honduras	Kohn R, Levav I, García ID, Machuca ME, Tamashiro R. Prevalence, risk factors and aging vulnerability for psychopathology following a natural disaster in a developing country. Int J Geriatr Psychiatry. 2005; 20(9): 835-41.	1998-1999		
Honduras	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Honduras	Fernández-Cean J, González-Martínez F, Schwedt E, Mazzuchi N. Renal replacement therapy in Latin America. Kidney Int. 2000; 57(4): 55-59.	1997		
Honduras	Cusumano A, García-García G, Di Gioia C, Hermida O, Lavorato C, Carreño CA, Torrico MP, Batista PB, Romão JE, Badal HP, Miranda SE, Gomez R, Calderon MC, Sanchez SH, Lopez MA, Moscoso J, Merino RL, Polo JV, Lopez A, Romero NJ, Garcia R, Acosta BV, Lopez AS, Delpin ES, Mena E, González C, Milanés CL, Acchiardo S. End-stage renal disease and its treatment in Latin America in the twenty-first century. Ren Fail. 2006; 28(8): 631-7.	2004		
Honduras	Cusumano A, García GG, Di Gioia C, Hermida O, Lavorato C. Latin American Registry of Dialysis and Transplantation. The Latin American Dialysis and Transplantation Registry (RLDT) annual report 2004. Ethn Dis. 2006; 16(2 Suppl 2): 10-3.	2003		
Honduras	Molinero MR, Varon D, Holden KR, Sladky JT, Molina IB, Cleaves F. Epidemiology of childhood Guillain-Barré syndrome as a cause of acute flaccid paralysis in Honduras: 1989-1999. J Child Neurol. 2003; 18(11): 741-7.	1989-1999		
Honduras	World Health Organization (WHO). Honduras WHO Leishmaniasis Country Profile.	2001-2010	*	
Honduras	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
Honduras	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Honduras	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Honduras	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Honduras	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Honduras	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Honduras	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Honduras	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2003. Pan American Health Organization (PAHO).	2003		†
Honduras	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2004. Pan American Health Organization (PAHO).	2004		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Honduras	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2005. Pan American Health Organization (PAHO).	2005		†
Honduras	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2006. Pan American Health Organization (PAHO).	2006		†
Honduras	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2007. Pan American Health Organization (PAHO).	2007		†
Honduras	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Honduras	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Honduras	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Honduras	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Honduras	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Honduras	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Honduras	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L, Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. Ann Hepatol. 2010; 9(1): 63-9.	2006-2008		
Honduras	Pan American Health Organization (PAHO), World Health Organization (WHO). Quantitative Estimation of Chagas in the Americas.	2005	*	
Honduras	Recurrent Malaria Infection in Honduras as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Honduras	Quintana M, Piper R, Boling HL, Makler M, Sherman C, Gill E, Fernandez E, Martin S. Malaria diagnosis by dipstick assay in a Honduran population with coendemic Plasmodium falciparum and Plasmodium vivax. Am J Trop Med Hyg. 1998; 59(6): 868-71 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Honduras	Honduras Vital Registration Birth Data 1983 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1983		
Hungary	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2005		
Hungary	Hungary Vital Registration - Deaths 1999 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1999	*	
Hungary	World Health Organization (WHO). Hungary World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Hungary	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Hungary	National Public Health Institute (Finland), World Health Organization (WHO). WHO MONICA Cerebrovascular Event Data 1982-1997, as provided by the Global Burden of Disease 2010 Cerebrovascular Disease Expert Group. [Unpublished].	1983-1989		
Hungary	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001, 2003-2009		
Hungary	Prange AJ, Lauer K, Poser S, Palfy G, Minderhoud JM, Firmhaber W, Dassel H, Bauer H. Epidemiological aspects of multiple sclerosis: a comparative study of four centres in Europe. Neuroepidemiology. 1986; 5(2): 71-9.	1981-1982		
Hungary	Bencsik K, Rajda C, Klivényi P, Járđánházy T, Vécsei L. The prevalence of multiple sclerosis in the Hungarian city of Szeged. Acta Neurol Scand. 1998; 97(5): 315-9.	1993-1996		†
Hungary	Bencsik K, Rajda C, Fűvesi J, Klivényi P, Járđánházy T, Török M, Vécsei L. The prevalence of multiple sclerosis, distribution of clinical forms of the disease and functional status of patients in Csongrád County, Hungary. Eur Neurol. 2001; 46(4): 206-9.	1997-1999		†
Hungary	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2003		
Hungary	Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia. 1996; 39(11): 1377-84.	1993-1995		
Hungary	National Cancer Registry (Hungary). Hungary National Cancer Registry - Incidence 2001.	2001	*	
Hungary	National Cancer Registry (Hungary). Hungary National Cancer Registry - Incidence 2004.	2004	*	
Hungary	National Cancer Registry (Hungary). Hungary National Cancer Registry - Incidence 2007.	2007	*	
Hungary	National Cancer Registry (Hungary). Hungary National Cancer Registry - Incidence 2010.	2010	*	
Hungary	National Cancer Registry (Hungary). Hungary National Cancer Registry - Incidence 2002.	2002	*	
Hungary	National Cancer Registry (Hungary). Hungary National Cancer Registry - Incidence 2005.	2005	*	
Hungary	National Cancer Registry (Hungary). Hungary National Cancer Registry - Incidence 2003.	2003	*	
Hungary	National Cancer Registry (Hungary). Hungary National Cancer Registry - Incidence 2006.	2006	*	
Hungary	National Cancer Registry (Hungary). Hungary National Cancer Registry - Incidence 2008.	2008	*	
Hungary	National Cancer Registry (Hungary). Hungary National Cancer Registry - Incidence 2009.	2009	*	
Hungary	National Cancer Registry (Hungary). Hungary National Cancer Registry - Incidence 2011.	2011	*	
Hungary	Szűcs G, Uj M, Mihályi L, Deák J. Burden of human rotavirus-associated hospitalizations in three geographic regions of Hungary. Acta Paediatr Suppl. 1999; 88(426): 61-5.	1993-1996	*	
Hungary	Kiss CG, Lóvei C, Sütő G, Varjú C, Nagy Z, Fűzesi Z, Illés T, Czirják L. Prevalence of rheumatoid arthritis in the South-Transdanubian region of Hungary based on a representative survey of 10,000 inhabitants. J Rheumatol. 2005; 32(9): 1688-90.	2002		
Hungary	Borutta A, Brauner K, Hufnagl S, Márton S, Mavrodisz K, Tarján I. Oral health in 8-9 year-old children in Saxony-Anhalt (Germany) and in two Hungarian cities (Budapest and Debrecen). Community Dent Health. 2006; 23(1): 26-30.	2001		
Hungary	Szőke J, Petersen PE. Evidence for dental caries decline among children in an East European country (Hungary). Community Dent Oral Epidemiol. 2000; 28(2): 155-60.	1980-1996		
Hungary	Bánóczy J, Boross E, Nemes J, Ember G, Pados R. Changes in caries prevalence among adolescents in Budapest, Hungary, from 1975 to 1982. Caries Res. 1985; 19(1): 76-82.	1975, 1982		
Hungary	Vrbic V, Vulovi M, Raji Z, Topi B, Tati E, Mali M, Mili D, Aurer-Kozelj J, Neceva L, Redzepagi S. Oral health in SFR Yugoslavia in 1986. Community Dent Oral Epidemiol. 1988; 16(5): 286-8.	1986		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Hungary	Szumska I, Túry F, Csoboth CT, Réthelyi J, Purebl G, Hajnal Á. The prevalence of eating disorders and weight-control methods among young women: a Hungarian representative study. <i>Eur Eat Disord Rev.</i> 2005; 13(4): 278-84.	1998		
Hungary	Tálgies T, Nemessary J. Epidemiological studies on adverse dieting behaviours and eating disorders among young people in Hungary. <i>Soc Psychiatry Psychiatr Epidemiol.</i> 2004; 39(8): 647-54.	1996-1997		
Hungary	Szádczky E, Rózsa S, Zámberi J, Fűredi J. Anxiety and mood disorders in primary care practice. <i>Int J Psychiatry Clin Pract.</i> 2004; 8(2): 77-84.	1998-1999		
Hungary	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2004-2008		
Hungary	United States Renal Data System Coordinating Center. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2000-2003		
Hungary	United States Renal Data System Coordinating Center. USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2003.	1998-1999		
Hungary	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN), ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Hungary	Pikó B. Epidemiology of psychosomatic symptoms and subjective health evaluation among secondary school students. <i>Orv Hetil.</i> 1999; 140(23): 1297-304.	1996, 2001		
Hungary	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1995, 1999, 2001, 2003		
Hungary	Lakatos L, Kiss LS, David G, Pandur T, Erdelyi Z, Mester G, Balogh M, Szipocs I, Molnar C, Komaromi E, Lakatos PL. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006. <i>Inflamm Bowel Dis.</i> 2011; 17(12): 2558-65.	2002-2006	*	†
Hungary	Lakatos PL, David G, Pandur T, Erdelyi Z, Mester G, Balogh M, Szipocs I, Molnar C, Komaromi E, Kiss LS, Lakatos L. IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008. <i>J Crohns Colitis.</i> 2011; 5(1): 5-13.	1977-2001	*	
Hungary	WHO Regional Office for Europe (EURO-WHO). Young People's Health in Context. Health Behaviour in School-aged Children (HBSC) Study: International Report from the 2001-2002 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2004.	2002		
Hungary	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Hungary	Bouvier-Colle M-H, Mohango AD, Gissler M, Novak-Antolic Z, Vutuc C, Szamotulska K, Zeitlin J, Euro-Peristat Scientific Committee. What about the mothers? An analysis of maternal mortality and morbidity in perinatal health surveillance systems in Europe. <i>BJOG.</i> 2012; 119(7): 880-90.	2003-2004	*	
Hungary	Kun A. Insulin resistance is associated with gestational hypertension and not with preeclampsia: a population-based screening study. <i>Gynecol Obstet Invest.</i> 2011; 71(4): 256-61.	2001-2007	*	
Hungary	Szádczky E, Papp Z s, Vitrai J, Rihmer Z, Fűredi J. The prevalence of major depressive and bipolar disorders in Hungary. Results from a national epidemiologic survey. <i>J Affect Disord.</i> 1998; 50(2-3): 153-62.	1995-1996		
Hungary	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Hungary	Bitter I, Simon V, Bálint S, Mészáros A, Czobor P. How do different diagnostic criteria, age and gender affect the prevalence of attention deficit hyperactivity disorder in adults? An epidemiological study in a Hungarian community sample. <i>Eur Arch Psychiatry Clin Neurosci.</i> 2010; 260(4): 287-96.	2006-2007	*	
Hungary	Fraser GR, Defarinas B, Kattamis CA, Race RR, Sanger R, Stamatoyannopoulos G. Glucose-6-phosphate dehydrogenase, colour vision and XG blood groups in Greece: linkage and population data. <i>Ann Hum Genet.</i> 1964; 395-403.	1962		
Hungary	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant.</i> 1988; 3(6): 714-27.	1985-1986		
Hungary	Mircescu G, Capsa D, Covic M, Caprioara MG, Gluhovschi G, Golea O, Ursea N, Gârneața L, Cepoi V, Constantinovici N, Covic A. Nephrology and renal replacement therapy in Romania – transition still continues (Cinderella story revisited). <i>Nephrol Dial Transplant.</i> 2004; 19(12): 2971-80.	1995, 2001		
Hungary	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Gilst WH van, Widimsky J, Freemanle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J.</i> 2003; 24(5): 442-63.	2000-2001		
Hungary	Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. Cancer Incidence in Five Continents. Vol. I to VIII. Lyon, France, IARC Press, 2005.	1978-1987	*	
Hungary	Farkas I, Sajó K. Goiter Frequency Among Boys of I-V Class of Primary Schools Reports to the Ministry of Health 1994-1995, 1995-1996, 1996, 1997. Public Health Budapest. 1997; 1: 15-19 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1994-1997		
Hungary	Madlén M, Hermann P, Jahn M, Fejérdy P. Caries prevalence and tooth loss in Hungarian adult population: results of a national survey. <i>BMC Public Health.</i> 2008; 364.	2000-2004		
Hungary	Eurostat, Hungarian Central Statistical Office (HCSO). Hungary European Health Interview Survey 2009.	2009	*	
Hungary	Lakatos L, Mester G, Erdelyi Z, Balogh M, Szipocs I, Kamaras G, Lakatos PL. Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001. <i>World J Gastroenterol.</i> 2004; 10(3): 404-9.	2001		
Hungary	Pohl O, Brojnás J, Rusvai E, Ordög K, Siska I, Faludi G, Kapusinszky B, Csohán A, Lendvai K, Lengyel A, Mezey I, Berencsi G. Retrospective detection of a subclinical hepatitis A virus (HAV) epidemic affecting juvenile cohorts of the Hungarian population. <i>FEMS Immunol Med Microbiol.</i> 2003; 38(1): 85-91.	1982, 1987, 1994, 1999		
Hungary	Kassas AL, Mihály I. Seroepidemiologic study of anti-HAV IgG in health-care workers. <i>Acta Microbiol Immunol Hung.</i> 1995; 42(4): 351-4.	1986-1993		
Hungary	National Public Health Institute (Finland), World Health Organization (WHO). MONICA Coronary Event Registration Data Book 1980-1995. Geneva, Switzerland: World Health Organization (WHO), 2000.	1980-1995		
Hungary	Hungary Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD), United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Hungary	European Surveillance of Congenital Anomalies (EUROCAT). Hungary EUROCAT Prevalence Tables. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	1998-2011		
Hungary	Hungarian Congenital Abnormality Registry Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Hungary	Hungarian Congenital Malformation Registry Data 1980 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1980	*	
Hungary	Hungarian Congenital Malformation Registry Data 1983 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1983	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Hungary	Hungarian Congenital Malformation Registry Data 1986 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1986	*	
Hungary	Hungarian Congenital Abnormality Registry Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Hungary	Hungarian Congenital Abnormality Registry Data 2001 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
Hungary	Hungarian Congenital Abnormality Registry Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Hungary	Hungarian Congenital Malformation Registry Data 1982 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1982	*	
Hungary	Hungarian Congenital Malformation Registry Data 1981 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1981	*	
Hungary	Hungarian Congenital Abnormality Registry Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
Hungary	Hungarian Congenital Abnormality Registry Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
Hungary	Hungarian Congenital Malformation Registry Data 1984 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1984	*	
Hungary	Hungarian Congenital Abnormality Registry Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
Hungary	Hungarian Congenital Malformation Registry Data 1988 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1988	*	
Hungary	Hungarian Congenital Abnormality Registry Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
Hungary	Hungarian Congenital Malformation Registry Data 1985 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1985	*	
Hungary	Hungarian Congenital Malformation Registry Data 1987 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1987	*	
Iceland	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2000-2009		
Iceland	Óundarson PT, Thorgeirsson G, Jónmundsson E, Sigfusson N, Hardarson T. Chronic atrial fibrillation- epidemiologic features and 14 year follow-up: A case control study. Eur Heart J. 1987; 8(5): 521-527.	1984		
Iceland	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Iceland	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000-2001, 2003-2009		
Iceland	Haraldsdóttir SO, Jónundsdóttir KB, Yngvason F, Björnsson J, Gíslason T. Sarcoidosis in Iceland 1981-2003. Laeknabladid. 2007; 93(2): 105-9.	1981-2003		
Iceland	Benediktz J, Magnússon H, Guthmundsson G. Multiple sclerosis in Iceland, with observations on the alleged epidemic in the Faroe Islands. Ann Neurol. 1994; 35(2): 175-179.	1985-1990		
Iceland	Benediktz J, Stefánsson M, Guomundsson J, Jónasdóttir A, Fossdal R, Gulcher J, Stefánsson K. The natural history of untreated multiple sclerosis in Iceland. A total population-based 50 year prospective study. Clin Neurol Neurosurg. 2002; 104(3): 208-10.	1954, 1964, 1974, 1996-2000		†
Iceland	Holm M, Omenaas E, Gíslason T, Svanes C, Jögi R, Norrman E, Janson C, Torén K. Remission of asthma: a prospective longitudinal study from northern Europe (RHINE study). Eur Respir J. 2007; 30(1): 62-65.	1989-2001		
Iceland	Danielsen R, Jónsson F, Helgason T. Prevalence of retinopathy and proteinuria in type 1 diabetics in Iceland. Acta Med Scand. 1982; 212(5): 277-80.	1981		
Iceland	Association of Nordic Cancer Registries (ANCR). Iceland NORDCAN Cancer Incidence Data Tables, Age-Specific by Countries. Copenhagen, Denmark: Association of Nordic Cancer Registries (ANCR).	2003-2008	*	
Iceland	Ingvarsson T. Prevalence and inheritance of hip osteoarthritis in Iceland. Acta Orthop Scand Suppl. 2000; 1-46.	1990-1996		
Iceland	Finnbogadóttir AF, Árdal B, Eiríksson H, Hrafnkelsson B, Valdimarsson H, Lúðvíksson BR, Haraldsson Á. A long-term follow-up of allergic diseases in Iceland. Pediatr Allergy Immunol. 2012; 23(2): 181-5.	1987-2008	*	
Iceland	Baldursdóttir TR, Bergmann OM, Jonasson JG, Ludvíksson BR, Axelsson TA, Björnsson ES. The epidemiology and natural history of primary biliary cirrhosis: a nationwide population-based study. Eur J Gastroenterol Hepatol. 2012; 24(7): 824-30.	1991-2010		
Iceland	Stefansdóttir H, Aspelund T, Gudnason V, Amar DO. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace. 2011; 13(8): 1110-7.	1991-2008	*	
Iceland	Arnadóttir IB, Holbrook WP, Agústsóttir H, Saemundsson SR. A 6-year longitudinal study of caries in teenagers and the effect of "dropouts" on the findings. Community Dent Health. 2010; 27(3): 172-7.	1994-2000	*	
Iceland	Agústsóttir H, Gudmundsdóttir H, Eggertsson H, Jonsson SH, Gudlaugsson JO, Saemundsson SR, Eliasson ST, Arnadóttir IB, Holbrook WP. Caries prevalence of permanent teeth: a national survey of children in Iceland using ICDAS. Community Dent Oral Epidemiol. 2010; 38(4): 299-309.	2004-2005		
Iceland	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. Community Dent Oral Epidemiol. 1991; 19(2): 72-3.	1987		
Iceland	Gylfason JT, Kristjánsson KA, Sverrisdóttir G, Jónsdóttir K, Rafnsson V, Geirsson RT. Pelvic endometriosis diagnosed in an entire nation over 20 years. Am J Epidemiol. 2010; 172(3): 237-43.	1981-2000		
Iceland	Björnsdóttir S, Jónsson S, Valdimarsdóttir U. Functional limitations and physical symptoms of individuals with chronic pain. Scand J Rheumatol. 2013; 42(1): 59-70.	2007	*	
Iceland	Hilmarsdóttir I, Baldvinsdóttir GE, Harðardóttir H, Briem H, Sigurðsson SI. Enteropathogens in acute diarrhea: a general practice-based study in a Nordic country. Eur J Clin Microbiol Infect Dis. 2012; 31(7): 1501-9.	2003-2007	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Iceland	Moller P. Caries prevalence in Icelandic children in 1970 and 1983. <i>Community Dent Oral Epidemiol.</i> 1985; 13(4): 230-4.	1970, 1983		
Iceland	Bjarnason S, Koch G. Dental health in Icelandic urban children aged 11 and 12 years. <i>Community Dent Oral Epidemiol.</i> 1987; 15(5): 289-92.	1984		
Iceland	Stefánsson JG, Lindal E, Björnsson JK, Guðmundsdóttir A. Period prevalence rates of specific mental disorders in an Icelandic cohort. <i>Soc Psychiatry Psychiatr Epidemiol.</i> 1994; 29(3): 119-25.	1987-1988		
Iceland	Helgason L. Epidemiology of Mental Disorders in Iceland: A Psychiatric and Demographic Investigation of 5,395 Icelanders. <i>Acta Psychiatr Scand.</i> 1964; 40(Suppl 173): 1-180.	1950		
Iceland	Indridason OS, Birgisson S, Edvardsson VO, Sigvaldason H, Sigfusson N, Pálsson R. Epidemiology of kidney stones in Iceland: a population-based study. <i>Scand J Urol Nephrol.</i> 2006; 40(3): 215-20.	1967-1996		
Iceland	Edvardsson V, Elidóttir H, Indridason OS, Pálsson R. High incidence of kidney stones in Icelandic children. <i>Pediatr Nephrol.</i> 2005; 20(7): 940-4.	1995-2000		
Iceland	de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Künzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P, European Community Respiratory Health Survey Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. <i>Thorax.</i> 2004; 59(2): 120-125.	1991-1993		
Iceland	Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E, BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. <i>Lancet.</i> 2007; 9589(9589): 741-50.	2004-2005		
Iceland	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2004-2005		
Iceland	United States Renal Data System Coordinating Center. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2002		
Iceland	De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology.</i> 2000; 54(11 Suppl 5): S21-23.	1997		
Iceland	Berger K BM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. <i>Neurologic Diseases in the Elderly Research Group. Neurology.</i> 2000; 54(11): 24-7.	1997		
Iceland	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Iceland	Kristjánisdóttir G. Prevalence of pain combinations and overall pain: a study of headache, stomach pain and back pain among school-children. <i>Scand J Soc Med.</i> 1997; 25(1): 58-63.	1989		
Iceland	Helgason S, Petursson G, Guðmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. <i>BMJ.</i> 2000; 321(7264): 794-6.	1990-1999		
Iceland	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Iceland	Hilmarrsson A, Kjartansson O, Olafsson E. Incidence of First Stroke A Population Study in Iceland. <i>Stroke.</i> 2013; 44(6): 1714-6.	2007-2008	*	
Iceland	Eliasdóttir OJ, Olafsson E, Kjartansson O. Incidence of multiple sclerosis in Iceland, 2002-2007: a population-based study. <i>Mult Scler.</i> 2011; 17(8): 909-13.	2002-2007	*	
Iceland	Olafsson E, Hauser WA, Ludvigsson P, Guðmundsson G. Incidence of epilepsy in rural Iceland: a population-based study. <i>Epilepsia.</i> 1996; 37(10): 951-5.	1993	*	
Iceland	Olafsson E, Hauser WA. Prevalence of epilepsy in rural Iceland: a population-based study. <i>Epilepsia.</i> 1999; 40(11): 1529-34.	1993	*	
Iceland	Rafnsson V, Olafsson E, Hauser WA, Guðmundsson G. Cause-specific mortality in adults with unprovoked seizures. A population-based incidence cohort study. <i>Neuroepidemiology.</i> 2001; 20(4): 232-6.	1960-1996	*	
Iceland	Copeland JR, Beekman AT, Dewey ME, Hooger C, Jordan A, Lawlor BA, Lobo A, Magnusson H, Mann AH, Meller I, Prince MJ, Reischies F, Turrina C, deVries MW, Wilson KC. Depression in Europe. Geographical distribution among older people. <i>Br J Psychiatry.</i> 1999; 174: 312-21.	1983		
Iceland	Viktorsdóttir O, Pálsson R, Andresdóttir MB, Aspelund T, Guðnason V, Indridason OS. Prevalence of chronic kidney disease based on estimated glomerular filtration rate and proteinuria in Icelandic adults. <i>Nephrol Dial Transplant.</i> 2005; 20(9): 1799-807.	1967-1996		
Iceland	Magnússon P, Saemundsen E. Prevalence of Autism in Iceland. <i>J Autism Dev Disord.</i> 2001; 31(2): 153D63.	1998		
Iceland	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2004, 2007, 2010, 2012		
Iceland	Faber MT, Nielsen A, Nygård M, Sparén P, Tryggvadóttir L, Hansen BT, Liaw K-L, Kjaer SK. Genital chlamydia, genital herpes, Trichomonas vaginalis and gonorrhoea prevalence, and risk factors among nearly 70,000 randomly selected women in 4 Nordic countries. <i>Sex Transm Dis.</i> 2011; 38(8): 727-34.	2004-2005	*	
Iceland	Guðnauksdóttir E, Arnarsson A, Jonasson F. Prevalence and causes of visual impairment and blindness in Icelanders aged 50 years and older: the Reykjavik Eye Study. <i>Acta Ophthalmol.</i> 2008; 86(7): 778-85. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1996		
Iceland	Pálsdóttir K, Dagbjartsson A, Thorkelsson T, Hardardóttir H. [Birth asphyxia and hypoxic ischemic encephalopathy, incidence and obstetric risk factors]. <i>Laeknabladid.</i> 2007; 93(9): 595-601.	1997-2001	*	†
Iceland	Helgason T, Danielsen R, Thorsson AV. Incidence and prevalence of type 1 (insulin-dependent) diabetes mellitus in Icelandic children 1970-1989. <i>Diabetologia.</i> 1992; 35(9): 880-3.	1980-1989		
Iceland	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant.</i> 1988; 3(6): 714-27.	1985-1986		
Iceland	Tryggvason G, Indridason OS, Thorsson AV, Hreidarsson AB, Pálsson R. Unchanged incidence of diabetic nephropathy in Type 1 diabetes: a nation-wide study in Iceland. <i>Diabet Med.</i> 2005; 22(2): 182-7.	1988-1997		
Iceland	Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. <i>J Clin Endocrinol Metab.</i> 2008; 93(4): 1408-11.	2005		
Iceland	Thorarinnsson AA. Mortality among men alcoholics in Iceland, 1951-74. <i>J Stud Alcohol.</i> 1979; 40(7): 704-18.	1951-1974		
Iceland	Laurberg P, Pedersen KM, Hreidarsson A, Sigfusson N, Iversen E, Knudsen PR. Iodine intake and the pattern of thyroid disorders: a comparative epidemiological study of thyroid abnormalities in the elderly in Iceland and in Jutland, Denmark. <i>J Clin Endocrinol Metab.</i> 1998; 83(3): 765-9 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1988		
Iceland	Helgason S, Sigurdsson JA, Guðmundsson S. The clinical course of herpes zoster: A prospective study in primary care. <i>Eur J Gen Pract.</i> 1996; 2(1): 12-16.	1990-1995		
Iceland	Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, Büchele G, Clausen M, Cookson WOC, von Mutius E, Strachan DP, Williams HC, ISAAC Phase Two Study Group. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. <i>J Allergy Clin Immunol.</i> 2008; 121(1): 141-147.	2005-2007	*	
Iceland	Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overved K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PHM, Lund E, Quirós JR, González CA, Sanchez Perez M-J, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regné S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu I, Chuang S-C, Murphy N, Boffetta P, Trichopoulos A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. <i>J Natl Cancer Inst.</i> 2011; 103(22): 1686-95.	1992-2006	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Iceland	Briem H. Declining prevalence of antibodies to hepatitis A virus infection in Iceland. <i>Scand J Infect Dis.</i> 1991; 23(2): 135-8.	1979, 1987		
Iceland	Briem H, Weiland O, Fridriksson I, Berg R. Prevalence of antibody to hepatitis A in Iceland in relation to age, sex, and number of notified cases of hepatitis. <i>Am J Epidemiol.</i> 1982; 116(3): 451-5.	1979		
Iceland	Asbjørnsdóttir H, Sigurjónsdóttir RB, Sveinsdóttir SV, Birgisdóttir A, Cook E, Gíslason D, Jansson C, Ólafsson I, Gíslason T, Thormjóðleifsson B. [Foodborne infections in Iceland. Relationship to allergy and lung function]. <i>Læknablaðið.</i> 2006; 92(6): 437-44.	1999-2001		
Iceland	Sigfusson N, Sigurdsson G, Agnarsson U, Gudmundsdóttir II, Stefánsdóttir I, Sigvaldason H, Gudnason V. Declining coronary heart disease mortality in Iceland: contribution by incidence, recurrence and case fatality rate. <i>Scand Cardiovasc J.</i> 2002; 36(6): 337-41.	1990, 1999		
Iceland	Tunstall-Pedoe H, Kuulasmaa K, Mahönen M, Tolonen H, Ruokokoski E. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. <i>Lancet.</i> 1999; 353(9164): 1547-57.	1980-1995		
Iceland	Flohr C, Weinmayr G, Weiland SK, Addo-Yobo E, Annesi-Maesano I, Björkstén B, Bråbäck L, Büchele G, Chico M, Cooper P, Clausen M, El Sharif N, Martínez Gimeno A, Mathur RS, von Mutius E, Morales Suarez-Varela M, Pearce N, Svabe V, Wong GWK, Yu M, Zhong NS, Williams HC, ISAAC Phase Two Study Group. How well do questionnaires perform compared with physical examination in detecting flexural eczema? Findings from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. <i>Br J Dermatol.</i> 2009; 161(4): 846-53.	2005-2007	*	
Iceland	Benediktsdóttir B, Gudmundsson G, Jörundsdóttir KB, Völlmer W, Gíslason T. [Prevalence of COPD in Iceland—the BOLD study]. <i>Icelandic Med J.</i> 2007; 93(6): 471-7.	2004-2005	*	
Iceland	Iceland Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Iceland	Iceland Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Iceland	Iceland Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD), United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
India	United Nations Statistical Division, World Health Organization (WHO), United Nations Educational, Scientific, and Cultural Organization (UNESCO), United Nations Population Fund (UNFPA), World Bank (WB), London School of Hygiene and Tropical Medicine, United Nations Children's Fund (UNICEF). India Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	
India	International Institute for Population Sciences (India). India Demographic and Health Survey 1992-1993. Mumbai, India: International Institute for Population Sciences (India).	1992-1993		†
India	International Institute for Population Sciences (India), Macro International, Inc. India Demographic and Health Survey 1998-1999. Calverton, United States: Macro International, Inc.	1998-1999		†
India	International Institute for Population Sciences (India), Macro International, Inc. India Demographic and Health Survey 2005-2006. Calverton, United States: Macro International, Inc.	2005-2006		†
India	International Institute for Population Sciences (India), World Health Organization (WHO). India World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
India	International Institute for Population Sciences (IIPS) (India), Ministry of Health and Family Welfare (India). India District Level Household Survey 1998-1999 (DLHS). Mumbai, India: International Institute for Population Sciences (IIPS) (India).	1998-1999	*	
India	International Institute for Population Sciences (India). India District Level Household Survey 2002-2005. Mumbai, India: International Institute for Population Sciences (India).	2002-2005	*	
India	International Institute for Population Sciences (India). India District Level Household Survey 2007-2008. Mumbai, India: International Institute for Population Sciences (India), 2010.	2007-2008	*	
India	International Institute for Population Sciences (India), World Health Organization (WHO). India WHO Study on Global Ageing and Adult Health 2007. Geneva, Switzerland: World Health Organization (WHO), 2007.	2007		
India	Gubler DJ, Meltzer M. Impact of dengue/dengue hemorrhagic fever on the developing world. <i>Adv Virus Res.</i> 1999; 53: 35-70.	1991-1996		
India	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	2002		
India	Institute of Health Systems (India), World Health Organization (WHO). India - Andhra Pradesh WHO Multi-country Survey Study on Health and Health System Responsiveness 2000-2001.	2000-2001		
India	Nath G, Choudhury A, Shukla BN, Singh TB, Reddy DC. Significance of Cryptosporidium in acute diarrhoea in North-Eastern India. <i>J Med Microbiol.</i> 1999; 48(6): 523-6.	1994-1996		
India	Kaushal SS, DasGupta DJ, Prashar BS, Bhardwaj AK. Electrocardiographic manifestations of healthy residents of a tribal Himalayan village. <i>J Assoc Physicians India.</i> 1995; 43(1): 15-6.	1995		
India	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
India	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
India	Approaches to Increasing the Use of Insecticide Treated Mosquito Nets in Orissa, India as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995		
India	Joshi PP, Mohanan CJ, Sengupta SP, Sarkar RG. Factors precipitating congestive heart failure – role of patient non-compliance. <i>J Assoc Physicians India.</i> 1999; 47(3): 294-5.	1995-1996		
India	Grover S, Ranyal RK, Bedi MK. A cross section of skin diseases in rural Allahabad. <i>Indian J Dermatol.</i> 2008; 53(4): 179-81.	2005		
India	Sridharan SE, Unnikrishnan JP, Sukumaran S, Sylaja PN, Nayak SD, Sarma PS, Radhakrishnan K. Incidence, Types, Risk Factors, and Outcome of Stroke in a Developing Country. <i>Stroke.</i> 2009; 40(4): 1212-8.	2005		
India	Dalal PM, Malik S, Bhattacharjee M, Trivedi ND, Vairale J, Bhat P, Deshmukh S, Khandelwal K, Mathur VD. Population-based stroke survey in Mumbai, India: incidence and 28-day case fatality. <i>Neuroepidemiology.</i> 2008; 31(4): 254-61.	2005-2006		
India	India Chronic Periodontal Disease Data 2008 from Global Burden of Disease 2010. [Primary source undocumentd].	2008		
India	Bandyopadhyay R, Sengupta A, Dasgupta A, Biswas R, Mukherjee S, Biswas AB. A comparative study of common ear morbidity pattern among the primary school children of an urban slum of Kolkata and rural area of Hooghly. <i>J Indian Med Assoc.</i> 2005; 103(8): 428, 430-2.	2004		
India	Jacob A, Rupa V, Job A, Joseph A. Hearing impairment and otitis media in a rural primary school in south India. <i>Int J Pediatr Otorhinolaryngol.</i> 1997; 39(2): 133-8.	1994-1997		
India	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol.</i> 2008; 121(4): 947-954.	1994-1995, 2001-2003		
India	Dogra S, Kumar B. Epidemiology of skin diseases in school children: a study from northern India. <i>Pediatr Dermatol.</i> 2003; 20(6): 470-3.	2001		
India	Rahmathullah L, Underwood BA, Thulasiraj RD, Milton RC, Ramaswamy K, Rahmathullah R, Babu G. Reduced mortality among children in southern India receiving a small weekly dose of vitamin A. <i>N Engl J Med.</i> 1990; 323(14): 929-35 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1988-1989		
India	Broor S, Parveen S, Bharaj P, Prasad VS, Srinivasulu KN, Sumanth KM, Kapoor SK, Fowler K, Sullender WM. A prospective three-year cohort study of the epidemiology and virology of acute respiratory infections of children in rural India. <i>PLoS One.</i> 2007; 6(2): e491.	2001-2004		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
India	Chhabra P, Garg S, Mittal SK, Satyanarayan L, Mehra M, Sharma N. Magnitude of acute respiratory infections in under five. <i>Indian Pediatr.</i> 1993; 11(30): 1315-9.	1989		†
India	Singh MP, Nayar S. Magnitude of acute respiratory infections in under five children. <i>J Commun Dis.</i> 1996; 4(28): 273-8.	1991		†
India	Nagamani K, Pavuluri PRR, Gyaneshwari M, Prasanthi K, Rao MIS, Saxena NK. Molecular characterisation of <i>Cryptosporidium</i> : an emerging parasite. <i>Indian J Med Microbiol.</i> 2007; 25(2): 133-6.	2003-2006		
India	Kang G, Arora R, Chitambar SD, Deshpande J, Gupte MD, Kulkarni M, Naik TN, Mukherji D, Venkatasubramanian S, Gentsch JR, Glass RI, Parashar UD. Multicenter, hospital-based surveillance of rotavirus disease and strains among Indian children aged <5 years. <i>J Infect Dis.</i> 2009; 200 Suppl 1: 147-153.	2005-2007		
India	Mishra OP, Dhawan T, Singla PN, Dixit VK, Arya NC, Nath G. Endoscopic and histopathological evaluation of preschool children with chronic diarrhoea. <i>J Trop Pediatr.</i> 2001; 47(2): 77-80.	1998-1999		
India	Chopra A, Patil J, Billempey V, Relwani J, Tandle HS, et al. Prevalence of rheumatic diseases in a rural population in western India: a WHO-ILAR COPCORD Study. <i>J Assoc Physicians India.</i> 2001; 240-6.	1996		
India	Chow C, Cardona M, Raju PK, Iyengar S, Sukumar A, Raju R, Colman S, Madhav P, Raju R, Reddy KS, Celemajer D, Neal B. Cardiovascular disease and risk factors among 345 adults in rural India—the Andhra Pradesh Rural Health Initiative. <i>Int J Cardiol.</i> 2007; 116(2): 180-5.	1980-2004		
India	Kamili M, Dar I, Ali G, Wazir H, Hussain S. Prevalence of coronary heart disease in Kashmir. <i>Indian Heart J.</i> 2007; 59(1): 44-9.	1980-2006		
India	Singh RB, Sharma JP, Rastogi V, Raghuvanshi RS, Moshiri M, Verma SP, Janus ED. Prevalence of coronary artery disease and coronary risk factors in rural and urban populations of north India. <i>Eur Heart J.</i> 1997; 18(11): 1728-35.	1991		
India	Stein CE, Fall CH, Kumaran K, Osmond C, Cox V, Barker DJ. Fetal growth and coronary heart disease in south India. <i>Lancet.</i> 1996; 348(9037): 1269-73.	1980-1995		
India	Lumbiganon P, Laopaiboon M, Gülmezoglu AM, Souza JP, Taneepanichskul S, Ruyan P, Attygalle DE, Shrestha N, Mori R, Hinh ND, Bang HT, Rathavy T, Chuyun K, Cheang K, Festin M, Udomprasertgul V, Germar MJV, Yanqui G, Roy M, Carroli G, Ba-Thike K. Method of delivery and pregnancy outcomes in Asia: the WHO global survey on maternal and perinatal health 2007-08. <i>Lancet.</i> 2010; 375(9713): 490-9.	2007-2008		
India	Verma IC. Burden of genetic disorders in India. <i>Indian Pediatr.</i> 2000; 67(12): 893-8.	1992-1995		
India	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1992-1993		
India	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001		
India	Mahajan A, Jasrotia DS, Manhas AS, Jamwal SS. Prevalence of Major Rheumatic Disorders in Jammu. <i>JK Science.</i> 2003; 5(2): 63-66.	2000		
India	Joshi VL, Chopra A. Is there an urban-rural divide? Population surveys of rheumatic musculoskeletal disorders in the Pune region of India using the COPCORD Bhigwan model. <i>J Rheumatol.</i> 2009; 36(3): 614-22.	2004		
India	Wadia NH, Bhatia K. Multiple sclerosis is prevalent in the Zoroastrians (Parsis) of India. <i>Ann Neurol.</i> 1990; 28(2): 177-9.	1988		
India	Razdan S, Kaul RL, Motta A, Kaul S, Bhatt RK. Prevalence and pattern of major neurological disorders in rural Kashmir (India) in 1986. <i>Neuroepidemiology.</i> 1994; 13(3): 113-9.	1986		
India	Bharucha NE, Bharucha EP, Wadia NH, Singhal BS, Bharucha AE, Bhise AV, Kurtzke JF, Schoenberg BS. Prevalence of multiple sclerosis in the Parsis of Bombay. <i>Neurology.</i> 1988; 38(5): 727-9.	1985		
India	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
India	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2002		
India	Viswanathan V, Thomas N, Tandon N, Asirvatham A, Rajasekar S, Ramachandran A, Senthilvasan K, Murugan VS, Muthulakshmi. Profile of diabetic foot complications and its associated complications—a multicentric study from India. <i>J Assoc Physicians India.</i> 2005; 53: 933-6.	2002		
India	Gupta R, Sarma M, Thanvi J, Rastogi P, Kaul V, Gupta VP. High prevalence of multiple coronary risk factors in Punjabi Bhatia community: Jaipur Heart Watch-3. <i>Indian Heart J.</i> 2004; 56(6): 646-52.	2003		
India	Jayaprakash P, Bhanjali S, Bhanjali A, Dutta P, Anantharaman R. Magnitude of foot problems in diabetes in the developing world: a study of 1044 patients. <i>Diabet Med.</i> 2009; 26(9): 939-42.	2007-2008		
India	Viswanathan V, Thomas N, Tandon N, Asirvatham A, Rajasekar S, Ramachandran A, Senthilvasan K, Murugan VS, Muthulakshmi. Profile of diabetic foot complications and its associated complications – a multicentric study from India. <i>J Assoc Physicians India.</i> 2005; 53: 933-6.	2002		
India	Narendran V, John RK, Raghuram A, Ravindran RD, Nirmalan PK, Thulasiraj RD. Diabetic retinopathy among self reported diabetics in southern India: a population based assessment. <i>Br J Ophthalmol.</i> 2002; 86(9): 1014-8.	2001		
India	Vyas U, Khandekar R, Trivedi N, Desai T, Danayak P. Magnitude and determinants of ocular morbidities among persons with diabetes in a project in Ahmedabad, India. <i>Diabetes Technol Ther.</i> 2009; 11(9): 601-7.	2007-2008		
India	Rema M, Premkumar S, Anitha B, Deepa R, Pradeepa R, Mohan V. Prevalence of diabetic retinopathy in urban India: the Chennai Urban Rural Epidemiology Study (CURES) eye study. <i>Invest Ophthalmol Vis Sci.</i> 2005; 46(7): 2328-33.	2003-2004		
India	Rema M, Ponnaiya M, Mohan V. Prevalence of retinopathy in non insulin dependent diabetes mellitus at a diabetes centre in southern India. <i>Diabetes Res Clin Pract.</i> 1996; 34(1): 29-36.	1994-1995		
India	Pradeepa R, Prabu AV, Jebarani S, Subhashini S, Mohan V. Use of a large diabetes electronic medical record system in India: clinical and research applications. <i>J Diabetes Sci Technol.</i> 2011; 5(3): 543-52.	1991-2010		
India	Patel JK, Vyas AP, Berman B, Vierra M. Incidence of childhood dermatosis in India. <i>Skinmed.</i> 2010; 8(3): 136-42.	2000-2002		
India	Libu GK, Bina T, Raphael L, Balakrishnan SE, Biju G, Samson JF, Bindu V. Prevalence and socio-demographic determinants of skin disease among lower primary school children in Calicut, Kerala. <i>IMAKMJ.</i> 2010; 185-90.	2006		
India	Singh RB, Bajaj S, Niaz MA, Rastogi SS, Moshiri M. Prevalence of type 2 diabetes mellitus and risk of hypertension and coronary artery disease in rural and urban population with low rates of obesity. <i>Int J Cardiol.</i> 1998; 66(1): 65-72.	1993		
India	Gupta A, Gupta R, Sarma M, Rastogi S, Gupta VP, Kothari K. Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population. <i>Diabetes Res Clin Pract.</i> 2003; 61(1): 69-76.	2001		
India	Shivpuri D, Rajesh MS, Jain D. Prevalence and characteristics of migraine among adolescents: a questionnaire survey. <i>Indian Pediatr.</i> 2003; 40(7): 665-9.	2000		
India	Rao GN, Kulkarni GB, Gururaj G, Rajesh K, Subbakrishna DK, Steiner TJ, Stovner LJ. The burden of headache disorders in India: methodology and questionnaire validation for a community-based survey in Karnataka State. <i>J Headache Pain.</i> 2012; 13(7): 543-50.	2008		
India	Agrawal S. Effect of indoor air pollution from biomass and solid fuel combustion on prevalence of self-reported asthma among adult men and women in India: findings from a nationwide large-scale cross-sectional survey. <i>J Asthma.</i> 2012; 49(4): 355-65.	2005-2006	*	
India	Behl RK, Kashyap S, Sarkar M. Prevalence of bronchial asthma in school children of 6-13 years of age in Shimla city. <i>Indian J Chest Dis Allied Sci.</i> 2010; 52(3): 145-8.	2007-2009	*	
India	Dhabadi BB, Athavale A, Meundi A, Rekha R, Suruliraman M, Shreeranga A, Gururaj S. Prevalence of asthma and associated factors among schoolchildren in rural South India. <i>Int J Tuberc Lung Dis.</i> 2012; 16(1): 120-5.	2009	*	
India	Guddattu V, Swathi A, Nair NS. Household and environment factors associated with asthma among Indian women: a multilevel approach. <i>J Asthma.</i> 2010; 47(4): 407-11.	2005-2006	*	
India	Jain A, Vinod Bhat H, Acharya D. Prevalence of bronchial asthma in rural Indian children: a cross sectional study from South India. <i>Indian J Pediatr.</i> 2010; 77(1): 31-5.	2007-2009	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
India	Jindal SK, Aggarwal AN, Gupta D, Agarwal R, Kumar R, Kaur T, Chaudhry K, Shah B. Indian study on epidemiology of asthma, respiratory symptoms and chronic bronchitis in adults (INSEARCH). <i>Int J Tuberc Lung Dis.</i> 2012; 16(9): 1270-7.	2007-2009	*	
India	Parasuramulu BG, Huiraj N, Rudraprasad BM, Prashanth Kumar SP, Gangabaraiah, Ramesh Masthi NR. Prevalence of bronchial asthma and its association with smoking habits among adult population in rural area. <i>Indian J Public Health.</i> 2010; 54(3): 165-8.	2008	*	
India	Sharma BS, Kumar MG, Chandel R. Prevalence of asthma in urban school children in Jaipur, Rajasthan. <i>Indian Pediatr.</i> 2012; 49(10): 835-6.	2008-2009	*	
India	Grills N, Grills C, Spelman T, Stoope M, Hellard M, El-Hayek C, Singh R. Prevalence survey of dermatological conditions in mountainous north India. <i>Int J Dermatol.</i> 2012; 51(5): 579-87.	2010	*	
India	Salve H, Gupta V, Palanivel C, Yadav K, Singh B. Prevalence of knee osteoarthritis amongst perimenopausal women in an urban resettlement colony in South Delhi. <i>Indian J Public Health.</i> 2010; 54(3): 155-7.	2009	*	
India	Pazhanivel M, Jayanthi V. Diabetes mellitus and cirrhosis liver. <i>Minerva Gastroenterol Dietol.</i> 2010; 56(1): 7-11.	2003-2007		
India	Grewal H, Verma M, Kumar A. Prevalence of dental caries and treatment needs amongst the school children of three educational zones of urban Delhi, India. <i>Indian J Dent Res.</i> 2011; 22(4): 517-9.	2008	*	
India	Shekar C, Cheluviah MB, Namile D. Prevalence of dental caries and dental fluorosis among 12 and 15 years old school children in relation to fluoride concentration in drinking water in an endemic fluoride belt of Andhra Pradesh. <i>Indian J Public Health.</i> 2012; 56(2): 122-8.	2008	*	
India	Chandra AK, Debnath A, Tripathy S. Iodine nutritional status among school children in selected areas of Howrah District in West Bengal, India. <i>J Trop Pediatr.</i> 2008; 54(1): 54-7.	2006	*	
India	Chudasama RK, Verma PB, Mahajan RG. Iodine nutritional status and goiter prevalence in 6-12 years primary school children of Saurashtra region, India. <i>World J Pediatr.</i> 2010; 6(3): 233-7.	2009	*	
India	Das DK, Chakraborty I, Biswas AB, Saha I, Mazumder P, Saha S. Goitre prevalence, urinary iodine and salt iodisation level in a district of West Bengal, India. <i>J Am Coll Nutr.</i> 2008; 27(3): 401-5.	2006	*	
India	Kapil U, Sharma TD, Singh P. Iodine status and goiter prevalence after 40 years of salt iodisation in the Kangra District, India. <i>Indian J Pediatr.</i> 2007; 74(2): 135-7.	2004	*	
India	Misra S, Kantharia SL, Damor JR. Prevalence of goitre in 6-12 years school-going children of Panchmahal district in Gujarat, India. <i>Indian J Med Res.</i> 2007; 126(5): 475-9.	2005	*	
India	Pandav CS, Krishnamurthy P, Sankar R, Yadav K, Palanivel C, Karmarkar MG. A review of tracking progress towards elimination of iodine deficiency disorders in Tamil Nadu, India. <i>Indian J Public Health.</i> 2010; 54(3): 120-5.	2002-2003	*	
India	Sarkar S, Mohanty B, Basu S. Iodine deficiency in school going children of Pondicherry. <i>Indian J Pediatr.</i> 2007; 74(8): 731-4.	2005	*	
India	Biswas AB, Chakraborty I, Das DK, Chakraborty A, Ray D, Mitra K. Elimination of iodine deficiency disorders-current status in Purb Medinipur district of West Bengal, India. <i>Indian J Public Health.</i> 2008; 52(5): 130-5.	2006-2007	*	
India	International Council for the Control of Iodine Deficiency Disorders (ICCID). India - Orissa Tracking Progress Towards Sustainable Elimination of Iodine Deficiency Disorders 2003-2004.	2003-2004	*	
India	Usha Menon V, Sundaram KR, Unnikrishnan AG, Jayakumar RV, Nair V, Kumar H. High prevalence of undetected thyroid disorders in an iodine sufficient adult south Indian population. <i>J Indian Med Assoc.</i> 2009; 107(2): 72-7.	2002-2005	*	
India	Vivek R, Chandu GM, Brown DW, Kang G. Seroprevalence of IgG antibodies to hepatitis E in urban and rural southern India. <i>Trans R Soc Trop Med Hyg.</i> 2010; 104(4): 307-9.	1999-2000		
India	Sachdeva S, Alam S, Beig FK, Khan Z, Khalique N. Determinants of vitamin A deficiency amongst children in Aligarh District, Uttar Pradesh. <i>Indian Pediatr.</i> 2011; 48(11): 861-6.	2009	*	
India	Adamson PC, Krupp K, Freeman AH, Klausner JD, Reingold AL, Madhivanan P. Prevalence & correlates of primary infertility among young women in Mysore, India. <i>Indian J Med Res.</i> 2011; 440-6.	2005-2006	*	
India	Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). <i>Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version)</i> . Lyon, IARC. http://cis.iarc.fr	2003-2007	*	
India	Chadha SK, Sayal A, Malhotra V, Agarwal AK. Prevalence of preventable ear disorders in over 15,000 schoolchildren in northern India. <i>J Laryngol Otol.</i> 2013; 127(1): 28-32.	2008-2011	*	
India	Sophia A, Isaac R, Rebekah G, Brahmamathan K, Rupa V. Risk factors for otitis media among preschool, rural Indian children. <i>Int J Pediatr Otorhinolaryngol.</i> 2010; 74(6): 677-83.	2006-2007	*	
India	Anita GDR. Prevalence Of Psychiatric Morbidity Among 6 To 14 Years Old Children. <i>Indian J Community Med.</i> 2003.	2001-2002	*	
India	Srinath S, Girimaji SC, Gurruraj G, Seshadri S, Subbakrishna DK, Bhola P, Kumar N. Epidemiological study of child and adolescent psychiatric disorders in urban and rural areas of Bangalore, India. <i>Indian J Med Res.</i> 2005; 122(1): 67-79.	1995-2000		
India	Nidhi R, Padmalatha V, Nagarathna R, Amritanshu R. Prevalence of polycystic ovarian syndrome in Indian adolescents. <i>J Pediatr Adolesc Gynecol.</i> 2011; 24(4): 223-7.	2008-2010	*	
India	Vethanayagam RR, Ananda Babu M, Nagalaxmi KS, Maiya PP, Venkatesh HA, Purohit S, Behl R, Bhan MK, Ward RL, Greenberg HB, Durga Rao C. Possible role of neonatal infection with the asymptomatic reassortant rotavirus (RV) strain 1321 in the decrease in hospital admissions for RV diarrhea, Bangalore, India, 1988-1999. <i>J Infect Dis.</i> 2004; 189(12): 2282-9.	1988-1999	*	
India	Nair GB, Ramamurthy T, Bhattacharya MK, Krishnan T, Ganguly S, Saha DR, Rajendran K, Manna B, Ghosh M, Okamoto K, Takeda Y. Emerging trends in the etiology of enteric pathogens as evidenced from an active surveillance of hospitalized diarrhoeal patients in Kolkata, India. <i>Gut Pathog.</i> 2010; 2(1): 4.	2007-2009	*	
India	Huilan S, Zhen LG, Mathan MM, Mathew MM, Olarte J, Espejo R, Khin Maung U, Ghafoor MA, Khan MA, Sami Z. Etiology of acute diarrhoea among children in developing countries: a multicentre study in five countries. <i>Bull World Health Organ.</i> 1991; 69(5): 549-55.	1982-1984	*	
India	Samal SK, Khuntia HK, Nanda PK, Satapathy CS, Nayak SR, Sarangi AK, Sahoo N, Pattnaik SK, Chhotray GP, Pal BB. Incidence of bacterial enteropathogens among hospitalized diarrhoea patients from Orissa, India. <i>Jpn J Infect Dis.</i> 2008; 61(5): 350-5.	2004-2006	*	
India	Bahl R, Ray P, Subodh S, Shambharkar P, Saxena M, Parashar U, Gentsch J, Glass R, Bhan MK. Delhi Rotavirus Study Group. Incidence of severe rotavirus diarrhoea in New Delhi, India, and G and P types of the infecting rotavirus strains. <i>J Infect Dis.</i> 2005; S114-119.	2000-2001	*	
India	Gambhir IS, Jaiswal JP, Nath G. Significance of Cryptosporidium as an aetiology of acute infectious diarrhoea in elderly Indians. <i>Trop Med Int Health.</i> 2003; 8(5): 415-9.	1997-2000	*	
India	Keikar SD, Purohit SG, Boralkar AN, Verma SP. Prevalence of rotavirus diarrhoea among outpatients and hospitalized patients: a comparison. <i>Southeast Asian J Trop Med Public Health.</i> 2001; 32(3): 494-9.	1993-1996	*	
India	CHOICE Study Group. Multicenter, randomized, double-blind clinical trial to evaluate the efficacy and safety of a reduced osmolality oral rehydration salts solution in children with acute watery diarrhea. <i>Pediatrics.</i> 2001; 107(4): 613-8.	1995-1997	*	
India	Paniker CK, Mathew S, Mathan M. Rotavirus and acute diarrhoeal disease in children in a southern Indian coastal town. <i>Bull World Health Organ.</i> 1982; 60(1): 123-7.	1976-1978	*	
India	Saha MR, Sen D, Datta P, Datta D, Pal SC. Role of rotavirus as the cause of acute paediatric diarrhoea in Calcutta. <i>Trans R Soc Trop Med Hyg.</i> 1984; 78(6): 818-20.	1979-1981	*	
India	Babji S, Arunugam R, Peters A, Ramani S, Kang G. Detection and characterisation of rotaviruses from children less than 5 years hospitalised with acute gastroenteritis in Nagercoil. <i>Indian J Med Microbiol.</i> 2013; 31(1): 69-71.	2007-2010	*	
India	Panigrahi D, Agarwal KC, Kaur T, Ayyagari A, Walla BN. A study of rotavirus diarrhoea in children in a north Indian community. <i>J Diarrhoeal Dis Res.</i> 1985; 3(1): 20-3.	1982-1983	*	
India	Ajjampur SSR, Liakath FB, Kannan A, Rajendran P, Sarkar R, Moses PD, Simon A, Agarwal I, Mathew A, O'Connor R, Ward H, Kang G. Multisite study of cryptosporidiosis in children with diarrhea in India. <i>J Clin Microbiol.</i> 2010; 48(6): 2075-81.	2005-2008	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
India	Nasrin D, Wu Y, Blackwelder WC, Farag TH, Saha D, Sow SO, Alonso PL, Breiman RF, Sur D, Faruque ASG, Zaidi AKM, Biswas K, Van Eijk AM, Walker DG, Levine MM, Kotloff KL. Health care seeking for childhood diarrhea in developing countries: evidence from seven sites in Africa and Asia. <i>Am J Trop Med Hyg.</i> 2013; 89(1 Suppl): 3-12.	2010	*	
India	Mathuranath PS, Cherian PJ, Mathew R, Kumar S, George A, Alexander A, Ranjith N, Sarma PS. Dementia in Kerala, South India: prevalence and influence of age, education and gender. <i>Int J Geriatr Psychiatry.</i> 2010; 25(3): 290-7.	2001-2004		
India	Prince M, Acosta D, Ferri CP, Guerra M, Huang Y, Llibre Rodriguez JJ, Salas A, Sosa AL, Williams JD, Dewey ME, Acosta I, Jotheeswaran AT, Liu Z. Dementia incidence and mortality in middle-income countries, and associations with indicators of cognitive reserve: a 10/66 Dementia Research Group population-based cohort study. <i>Lancet.</i> 2012; 380(9836): 50-8.	2003-2007		
India	Banerjee TK, Mukherjee CS, Dutt A, Shekhar A, Hazra A. Cognitive dysfunction in an urban Indian population – some observations. <i>Neuroepidemiology.</i> 2008; 31(2): 109-14.	2002-2003		
India	Mackenzie I. Hearing Impairment in Asia - final report of four country survey, as provided by the Global Burden of Disease 2010 hearing impairment expert group. [Unpublished].	1997		
India	Bhowate RR, Borle SR, Chinchkhede DH, Gondhalekar RV. Dental health amongst 11-15-year-old children in Sevagram, Maharashtra. <i>Indian J Dent Res.</i> 1994; 5(2): 65-8.	1992		
India	Christensen LB, Petersen PE, Bhamhal A. Oral health and oral health behaviour among 11-13-year-olds in Bhopal, India. <i>Community Dent Health.</i> 2003; 20(3): 153-8.	2001		
India	Pandit K, Kannan AT, Sarma A, Aggarwal K. Prevalence of dental caries and associated teeth cleaning habits among children in four primary schools. <i>Int J Epidemiol.</i> 1986; 15(4): 581-3.	1984		
India	Saravanan S, Kalyani V, Vijayarani MP, Jayakodi P, Felix J, Arunmozhi P, Krishnan V, Sampath Kumar P. Caries prevalence and treatment needs of rural school children in Chidambaram Taluk, Tamil Nadu, South India. <i>Indian J Dent Res.</i> 2008; 19(3): 186-90.	2003-2004		
India	Damle SC, Patel AR. Caries prevalence and treatment need amongst children of Dharavi, Bombay, India. <i>Community Dent Oral Epidemiol.</i> 1994; 22(1): 62-3.	1992		
India	Mahejabeen R, Sudha P, Kulkarni SS, Anegundi R. Dental caries prevalence among preschool children of Hubli: Dharwad city. <i>J Indian Soc Pedod Prev Dent.</i> 2006; 24(1): 19-22.	2004		
India	Dhar V, Bhatnagar M. Dental caries and treatment needs of children (6-10 years) in rural Udaipur, Rajasthan. <i>Indian J Dent Res.</i> 2009; 20(3): 256-60.	2007-2008		
India	Sinratvir M, Moghe GA, Thomas AM, Singh N, Chopra S. Evaluation of caries experience in 3-6-year-old children, and dental attitudes amongst the caregivers in the Ludhiana city. <i>J Indian Soc Pedod Prev Dent.</i> 2009; 27(3): 164-9.	2006		
India	Goyal A, Gauba K, Chawla HS, Kaur M, Kapur A. Epidemiology of dental caries in Chandigarh school children and trends over the last 25 years. <i>J Indian Soc Pedod Prev Dent.</i> 2007; 25(3): 115-8.	2002		
India	Sudha P, Bhasin S, Anegundi RT. Prevalence of dental caries among 5-13-year-old children of Mangalore city. <i>J Indian Soc Pedod Prev Dent.</i> 2005; 23(2): 74-9.	2003		
India	Joshi N, Rajesh R, Sunitha M. Prevalence of dental caries among school children in Kulasekharam village: a correlated prevalence survey. <i>J Indian Soc Pedod Prev Dent.</i> 2005; 23(3): 138-40.	2003		
India	Indian Society of Nephrology. India Chronic Kidney Disease Registry Report 2006.	2006		
India	Pillai A, Patel V, Cardozo P, Goodman R, Weiss HA, Andrew G. Non-traditional lifestyles and prevalence of mental disorders in adolescents in Goa, India. <i>Br J Psychiatry.</i> 2008; 192(1): 45-51.	2002-2003		
India	Hackett R, Hackett, Latha, Bhakta, Preetta, Gowers, Simon. The Prevalence and Associations of Psychiatric Disorder in Children in Kerala, South India. <i>J Child Psychol Psychiatry.</i> 1999; 40(5): 801-7.	1992-1993		
India	Premarajan KC, Danabalan M, Chandrasekar R, Srinivasa DK. Prevalence of psychiatric morbidity in an urban community of Pondicherry. <i>Indian J Psychiatry.</i> 1993; 35(2): 99-102.	1998-1999		
India	Joshi K, Kumar R, Avasthi A. Morbidity profile and its relationship with disability and psychological distress among elderly people in Northern India. <i>Int J Epidemiol.</i> 2003; 32(6): 978-87.	1999-2000		
India	Mohan D, Chopra A, Sethi H. Incidence estimates of substance use disorders in a cohort from Delhi, India. <i>Indian J Med Res.</i> 2002; 128-35.	1992-1993, 2000		
India	Das SK, Banerjee TK, Biswas A, Roy T, Raut DK, Mukherjee CS, Chaudhuri A, Hazra A, Roy J. A Prospective Community-Based Study of Stroke in Kolkata, India. <i>Stroke.</i> 2007; 38(3): 906-10.	2003-2005		
India	Kothari S, Dhopeshwarkar R, Saxena A, Juneja R. Dilated cardiomyopathy in Indian children. <i>Indian Heart J.</i> 2003; 55(2): 147-51.	2000-2002		
India	Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E, BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. <i>Lancet.</i> 2007; 9589(9589): 741-50.	2005-2006		
India	Khosla AH, Dahija K, Sangwan K. Maternal mortality and 'near-miss' in rural north India. <i>Int J Gynaecol Obstet.</i> 2000; 68(2): 163-4.	1998		
India	Patra S, Singh B, Reddaiah V. Maternal morbidity during postpartum period in a village in North India. <i>Trop Doct.</i> 2008; 38(4): 204-8.	2002-2003		
India	Derman RJ, Kodkany BS, Goudar SS, Geller SE, Naik VA, Bellad MB, Patted SS, Patel A, Edlavitch SA, Hartwell T, Chakraborty H, Moss N. Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trial. <i>Lancet.</i> 2006; 368(9543): 1248-53.	2002-2005		
India	Raisler J, Kumari S, Walia I, Singh A. Self-Reported Uterine Prolapse in a Resettlement Colony of North India. <i>J Midwifery Womens Health.</i> 2000; 45(4): 343-50.	1996		
India	Banerjee TK, Mukherjee CS, Sarkhel A. Stroke in the urban population of Calcutta – an epidemiological study. <i>Neuroepidemiology.</i> 2001; 20(3): 201-7.	1998-1999		
India	Das SK, Biswas A, Roy T, Banerjee TK, Mukherjee CS, Raut DK, Chaudhuri A. A random sample survey for prevalence of major neurological disorders in Kolkata. <i>Indian J Med Res.</i> 2006; 124(2): 163-72.	2003-2004		
India	Dhamija RK, Dhamija SB. Prevalence of stroke in rural community – an overview of Indian experience. <i>J Assoc Physicians India.</i> 1998; 46(4): 351-4.	1996		
India	Koul R, Motta A, Razdan S. Epidemiology of young strokes in rural Kashmir, India. <i>Acta Neurol Scand.</i> 1990; 82(1): 1-3.	1986		
India	Saha SP, Bhattacharya S, Das SK, Maity B, Roy T, Raut DK. Epidemiological study of neurological disorders in a rural population of Eastern India. <i>J Indian Med Assoc.</i> 2003; 101(5): 299-304.	1992-1993		
India	Devisagamani TR. Psychiatric morbidity in primary school children – an epidemiological study. <i>Indian J Psychiatry.</i> 1990; 32(3): 235-40.	1988		
India	Malhotra S, Kohli A, Arun P. Prevalence of psychiatric disorders in school children in Chandigarh, India. <i>Indian J Med Res.</i> 2002; 21-8.	2000		
India	Sharma P, Malhotra C, Taneja DK, Saha R. Problems related to menstruation amongst adolescent girls. <i>Indian J Pediatr.</i> 2008; 75(2): 125-9.	2005		
India	International Society of Nephrology (ISN). International Society of Nephrology Kidney Disease Data Center 2006-2009.	2008-2009		
India	Ray K, Bala M, Bhattacharya M, Muralidhar S, Kumari M, Sathan S. Prevalence of RTI/STI agents and HIV infection in symptomatic and asymptomatic women attending peripheral health set-ups in Delhi, India. <i>Epidemiol Infect.</i> 2008; 136(10): 1432-40.	2003		
India	Joyee AG, Thyagarajan SP, Rajendran P, Hari R, Balakrishnan P, Jayaseelan L, Kurien T, STD Study Group. Chlamydia trachomatis genital infection in apparently healthy adult population of Tamil Nadu, India: a population-based study. <i>Int J STD AIDS.</i> 2004; 15(1): 51-5.	2004		
India	Munro HL, Pradeep BS, Jayachandran AA, Lowndes CM, Mahapatra B, Ramesh BM, Washington R, Jagannathan L, Mendonca K, Moses S, Blanchard JF, Alary M. Prevalence and determinants of HIV and sexually transmitted infections in a general population-based sample in Mysore district, Karnataka state, southern India. <i>AIDS.</i> 2008; S117-125.	1992, 2005		
India	Bharucha NE, Bharucha EP, Bharucha AE, Bhise AV, Schoenberg BS. Prevalence of parkinson's disease in the Parsi community of Bombay, India. <i>Arch Neurol.</i> 1988; 45(12): 1321-3.	1985		
India	Mehta P, Joseph A, Verghese A. An epidemiologic study of psychiatric disorders in a rural area in Tamilnadu. <i>Indian J Psychiatry.</i> 1985; 27(2): 153-8.	1981-1982		
India	Padmavathi R, Rajkumar S, Kumar N, Manoharan A, Kamath S. Prevalence of schizophrenia in an urban community in madras. <i>Indian J Psychiatry.</i> 1988; 30(3): 233-9.	1986		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
India	Sachdeva JS, Singh S, Sidhu BS, Goyal RK, Singh J. An epidemiological study of psychiatric disorders in rural Faridkot (Punjab). <i>Indian J Psychiatry</i> . 1986; 28(4): 317-23.	1984		
India	Thara R. Twenty-year course of schizophrenia: the Madras Longitudinal Study. <i>Can J Psychiatry</i> . 2004; 49(8): 564-9.	1981-2002		
India	Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganey K, Giel R, an der Heiden W, Holmberg SK, Janca A, Lee PW, León CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin SJ, Varma VK, Walsh D, Wiersma D. Recovery from psychotic illness: a 15- and 25-year international follow-up study. <i>Br J Psychiatry</i> . 2001; 178: 506-17.	1978-2003		
India	Hasker E, Singh SP, Malaviya P, Picado A, Gidwani K, Singh RP, Menten J, Boelaert M, Sundar S. Visceral leishmaniasis in rural Bihar, India. <i>Emerg Infect Dis</i> . 2012; 18(10): 1662-4.	2008-2010	*	
India	Chopra A, Saluja M, Patil J, Tandale HS. Pain and disability, perceptions and beliefs of a rural Indian population: A WHO-ILAR COPCORD study. <i>WHO-International League of Associations for Rheumatology. Community Oriented Program for Control of Rheumatic Diseases. J Rheumatol</i> . 2002; 29(3): 614-21.	1996		
India	Gilbert CE, Ellwein LB. Prevalence and causes of functional low vision in school-age children: results from standardized population surveys in Asia, Africa, and Latin America. <i>Invest Ophthalmol Vis Sci</i> . 2008; 49(3): 877-81. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2000-2001		
India	Murthy GVS, Gupta SK, Bachani D, Jose R, John N. Current estimates of blindness in India. <i>Br J Ophthalmol</i> . 2005; 89(3): 257-60. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	1999-2001		
India	Thulasiraj RD, Nirmalan PK, Ramakrishnan R, Krishnadas R, Manimekalai TK, Baburajan NP, Katz J, Tielsch JM, Robin AL. Blindness and vision impairment in a rural south Indian population: the Aravind Comprehensive Eye Survey. <i>Ophthalmology</i> . 2003; 110(8): 1491-8. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	1995-1997		
India	Dandona R, Dandona L, Srinivas M, Giridhar P, Prasad MN, Vilas K, McCarty CA, Rao GN. Moderate visual impairment in India: the Andhra Pradesh Eye Disease Study. <i>Br J Ophthalmol</i> . 2002; 86(4): 373-7. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	1996-2000		
India	Neena J, Rachel J, Praveen V, Murthy GVS. Rapid Assessment of Avoidable Blindness in India. <i>PLoS One</i> . 2008; 3(8): e2867. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2007		
India	Vijaya L, George R, Arvind H, Baskaran M, Raju P, Ramesh SV, Paul PG, Kumaramanickavel G, McCarty C. Prevalence and causes of blindness in the rural population of the Chennai Glaucoma Study. <i>Br J Ophthalmol</i> . 2006; 90(4): 407-10. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2001-2003		
India	Dandona L, Dandona R, Naduvilath TJ, McCarty CA, Srinivas M, Mandal P, Nanda A, Rao GN. Burden of moderate visual impairment in an urban population in southern India. <i>Ophthalmology</i> . 1999; 106(3): 497-504. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	1996		
India	Thulasiraj RD, Rahamathulla R, Saraswati A, Selvaraj S, Ellwein LB. The Sivaganga eye survey: I. Blindness and cataract surgery. <i>Ophthalmic Epidemiol</i> . 2002; 9(5): 299-312. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	1999		
India	Nirmalan PK, Vijayalakshmi P, Sheeladevi S, Kothari MB, Sundaresan K, Rahmattullah L. The Kariapatti pediatric eye evaluation project: baseline ophthalmic data of children aged 15 years or younger in Southern India. <i>Am J Ophthalmol</i> . 2003; 136(4): 703-9. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2002		
India	Kalivayal V, Naduvilath TJ, Bansal AK, Dandona L. Visual impairment in school children in southern India. <i>Indian J Ophthalmol</i> . 1997; 45(2): 129-34. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	1993-1995		
India	Venkitaraman AR, Seigneurin JM, Lenoir GM, John TJ. Infections due to the human herpesviruses in southern India: a seroepidemiological survey. <i>Int J Epidemiol</i> . 1986; 15(4): 561-6.	1983		
India	Venkitaraman AR, Seigneurin JM, Baccard M, Lenoir GM, John TJ. Measurement of antibodies to varicella-zoster virus in a tropical population by enzyme-linked immunosorbent assay. <i>J Clin Microbiol</i> . 1984; 20(3): 582-3.	1981		
India	Mandal BK, Mukherjee PP, Murphy C, Mukherjee R, Naik T. Adult susceptibility to varicella in the tropics is a rural phenomenon due to the lack of previous exposure. <i>J Infect Dis</i> . 1998; 178(Suppl 1): S52-54.	1995		
India	Lokeshwar MR, Agrawal A, Subbarao SD, Chakraborty MS, Ram Prasad AV, Weil J, Bock HL, Kanwal S, Shah RC, Shah N. Age related seroprevalence of antibodies to varicella in India. <i>Indian Pediatr</i> . 2000; 37(7): 714-9.	1998		
India	Gray RF. Causes of deafness in schools for the deaf in Madras. <i>Int J Pediatr Otorhinolaryngol</i> . 1989; 18(2): 97-106.	1987		
India	Singh AP, Chandra MR, Dayal D, Chandra R, Bhushan V. Prevalence of deafness in a rural population of Lucknow district. <i>Indian J Public Health</i> . 1980; 24(1): 23-31.	1975-1976		
India	Stein Z, Belmont L, Durkin M. Mild mental retardation and severe mental retardation compared: experiences in eight less developed countries. <i>Ups J Med Sci Suppl</i> . 1987; 89-96.	1987		
India	Dave U, Shetty N, Mehta L. A community genetics approach to population screening in India for mental retardation—a model for developing countries. <i>Ann Hum Biol</i> . 2005; 32(2): 195-203.	2005		
India	Merikangas KR, Jin R, He J-P, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Ladea M, Medina-Mora ME, Ono Y, Posada-Villa J, Sagar R, Wells JE, Zarkov Z. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. <i>Arch Gen Psychiatry</i> . 2011; 68(3): 241-51.	2003-2005	*	
India	Agarwal AK, Yunus M, Ahmad J, Khan A. Rheumatic heart disease in India. <i>J R Soc Promot Health</i> . 1995; 115(5): 303-9.	1991-1992		
India	Bhaya M, Panwar S, Beniwal R, Panwar RB. High prevalence of rheumatic heart disease detected by echocardiography in school children. <i>Echocardiography</i> . 2010; 27(4): 448-53.	2007-2008		
India	Gupta I, Gupta ML, Parihar A, Gupta CD. Epidemiology of rheumatic and congenital heart diseases in school children. <i>J Indian Med Assoc</i> . 1992; 90(3): 57-9.	1991		
India	Jose VJ, Gomathi M. Declining prevalence of rheumatic heart disease in rural schoolchildren in India: 2001-2002. <i>Indian Heart J</i> . 2003; 55(2): 158-60.	2000-2001		
India	Kumar P, Garhwal S, Chaudhary V. Rheumatic heart disease: a school survey in a rural area of Rajasthan. <i>Indian Heart J</i> . 1992; 44(4): 245-6.	1988-1990		
India	Lalchandani A, Kumar HRP, Alam SM. Prevalence of rheumatic fever and rheumatic heart disease in rural and urban school children of district Kanpur. <i>Indian Heart J</i> . 2000; 672.	1997-2000		
India	Misra M, Mittal M, Singh R, Verma A, Rai R, Chandra G, Singh D, Chauhan R, Chowdhary V, Singh R, Mall A, Khan MJ, Khare S, Yadav K. Prevalence of rheumatic heart disease in school-going children of Eastern Uttar Pradesh. <i>Indian Heart J</i> . 2007; 59(1): 42-3.	2003-2006		
India	Periwai KL, Gupta BK, Panwar RB, Khatri PC, Raja S, Gupta R. Prevalence of rheumatic heart disease in school children in Bikaner: an echocardiographic study. <i>J Assoc Physicians India</i> . 2006; 279-82.	2002-2004		
India	Thakur JS, Negi PC, Ahluwalia SK, Vaidya NK. Epidemiological survey of rheumatic heart disease among school children in the Shimla Hills of northern India: prevalence and risk factors. <i>J Epidemiol Community Health</i> . 1996; 50(1): 62-7.	1992-1993		
India	Vashistha VM, Kalra A, Kalra K, Jain VK. Prevalence of rheumatic heart disease in school children. <i>Indian Pediatr</i> . 1993; 30(1): 53-6.	1989-1990		
India	Ningombam S, Hutin Y, Murhekar MV. Prevalence and pattern of substance use among the higher secondary school students of Imphal, Manipur, India. <i>Natl Med J India</i> . 2011; 24(1): 11-5.	2007	*	
India	Banerjee TK, Hazra A, Biswas A, Ray J, Roy T, Raut DK, Chaudhuri A, Das SK. Neurological disorders in children and adolescents. <i>Indian J Pediatr</i> . 2009; 76(2): 139-46.	2003-2004	*	†
India	Banerjee TK, Ray BK, Das SK, Hazra A, Ghosal MK, Chaudhuri A, Roy T, Raut DK. A longitudinal study of epilepsy in Kolkata, India. <i>Epilepsia</i> . 2010; 51(12): 2384-91.	2003-2004	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
India	Goel D, Dhanal JS, Agarwal A, Mehlotra V, Saxena V. Neurocysticercosis and its impact on crude prevalence rate of epilepsy in an Indian community. <i>Neurol India</i> . 2011; 59(1): 37-40.	2007-2009	*	†
India	Kumar R, Bhawe A, Bhargava R, Agarwal GG. Prevalence and risk factors for neurological disorders in children aged 6 months to 2 years in northern India. <i>Dev Med Child Neurol</i> . 2013; 55(4): 348-56.	2009-2011	*	
India	Prasad KN, Prasad A, Gupta RK, Nath K, Pradhan S, Tripathi M, Pandey CM. Neurocysticercosis in patients with active epilepsy from the pig farming community of Lucknow district, north India. <i>Trans R Soc Trop Med Hyg</i> . 2009; 103(2): 144-50.	2004-2005	*	
India	Shah PA, Shapoo SF, Koul RK, Khan MA. Prevalence of epilepsy in school-going children (6-18 years) in Kashmir Valley of North-west India. <i>J Indian Med Assoc</i> . 2009; 107(4): 216-8.	2006-2008	*	
India	Singh G, Bawa J, Chinna D, Chaudhary A, Saggarr K, Modi M, Sander JW. Association between epilepsy and cysticercosis and toxocarosis: a population-based case-control study in a slum in India. <i>Epilepsia</i> . 2012; 53(12): 2203-8.	2010-2011	*	
India	Verma A, Shrimali L. Maternal body mass index and pregnancy outcome. <i>J Clin Diagn Res</i> . 2012; 6(9): 1531-3.	2011	*	
India	Gupta SK, Pal DK, Tiwari R, Garg R, Shrivastava AK, Sarawagi R, Patil R, Agarwal L, Gupta P, Lahariya C. Impact of Janani Suraksha Yojana on institutional delivery rate and maternal morbidity and mortality: an observational study in India. <i>J Health Popul Nutr</i> . 2012; 30(4): 464-71.	2003-2007	*	
India	Ramachandra Bhat PB, Navada MH, Rao SV, Nagarathna G. Evaluation of obstetric admissions to intensive care unit of a tertiary referral center in coastal India. <i>Indian J Crit Care Med</i> . 2013; 17(1): 34-7.	2005-2011	*	
India	Chhabra S, Tyagi S, Bhavani M, Gosawi M. Late postpartum eclampsia. <i>J Obstet Gynaecol</i> . 2012; 32(3): 264-6.	1998-2009	*	
India	Mandal D, Manda S, Rakshi A, Dey RP, Biswas SC, Banerjee A. Maternal obesity and pregnancy outcome: a prospective analysis. <i>J Assoc Physicians India</i> . 2011; 486-9.	2006-2008	*	
India	Nanjundan P, Bagga R, Kalra JK, Thakur JS, Raveendran A. Risk factors for early onset severe pre-eclampsia and eclampsia among north Indian women. <i>J Obstet Gynaecol</i> . 2011; 31(5): 384-9.	2007-2008	*	
India	Patil S, Bhosale R, Sambarey P, Gupte N, Suryavanshi N, Sastry J, Bollinger RC, Gupta A, Shankar A. Impact of maternal human immunodeficiency virus infection on pregnancy and birth outcomes in Pune, India. <i>AIDS Care</i> . 2011; 23(12): 1562-9.	2002-2004	*	
India	Pal A, Bhattacharyya R, Adhikari S, Roy A, Chakrabarty D, Ghosh P, Banerjee C. Eclampsia-scenario in a hospital—a ten years study. <i>Bangladesh Med Res Counc Bull</i> . 2011; 37(2): 66-70.	1999-2008	*	
India	Sagili H, Pramy N, Prabhu K, Mascarenhas M, Reddi Rani P. Are teenage pregnancies at high risk? A comparison study in a developing country. <i>Arch Gynecol Obstet</i> . 2012; 285(3): 573-7.	2008-2009	*	
India	Ferri CP, Schoenborn C, Kalra L, Acosta D, Guerra M, Huang Y, Jacob KS, Rodriguez JLL, Salas A, Sosa AL, Williams JD, Liu Z, Moriyma T, Valluerdi A, Prince MJ. Prevalence of stroke and related burden among older people living in Latin America, India and China. <i>J Neurol Neurosurg Psychiatry</i> . 2011; 82(10): 1074-82.	2007-2009	*	
India	Mukhopadhyay A, Sundar U, Adwani S, Pandit D. Prevalence of stroke and post-stroke cognitive impairment in the elderly in Dharavi, Mumbai. <i>J Assoc Physicians India</i> . 2012; 29-32.	2006-2008	*	
India	Mani KS, Rangan G, Srinivas HV, Kalyanasundaram S, Narendran S, Reddy AK. The Yelandur study: a community-based approach to epilepsy in rural South India – epidemiological aspects. <i>Seizure</i> . 1998; 7(4): 281-8.	1990-1991	*	†
India	Pal DK, Carpio A, Sander JWAS. Neurocysticercosis and epilepsy in developing countries. <i>J Neurol Neurosurg Psychiatry</i> . 2000; 68(2): 137-43.	1995-1996	*	†
India	Hackett RJ, Hackett L, Bhakta P. The prevalence and associated factors of epilepsy in children in Calicut District, Kerala, India. <i>Acta Paediatr</i> . 1997; 86(11): 1257-60.	1996	*	†
India	Koul R, Razdan S, Motta A. Prevalence and pattern of epilepsy (Lath/Mirgi/Laran) in rural Kashmir, India. <i>Epilepsia</i> . 1988; 29(2): 116-22.	1986	*	†
India	Das S, S. Neuroepidemiology of major neurological disorders in rural Bengal. <i>Neurol India</i> . 1996; 47-58.	1989	*	
India	Radhakrishnan K, Pandian JD, Santhoshkumar T, Thomas SV, Deetha TD, Sarma PS, Jayachandran D, Mohamed E. Prevalence, knowledge, attitude, and practice of epilepsy in Kerala, South India. <i>Epilepsia</i> . 2000; 41(8): 1027-35.	1996	*	†
India	Gourie-Devi M, Gururaj G, Satishchandra P, Subbakrishna DK. Prevalence of neurological disorders in Bangalore, India: a community-based study with a comparison between urban and rural areas. <i>Neuroepidemiology</i> . 2004; 23(6): 261-8.	1993-1995	*	
India	Rajshekhkar V, Raghava MV, Prabhakaran V, Oommen A, Muliyl J. Active epilepsy as an index of burden of neurocysticercosis in Vellore district, India. <i>Neurology</i> . 2006; 67(12): 2135-9.	2003-2004	*	
India	Sohi D, Walia I, Singh A. Prevalence and treatment of epilepsy in a Chandigarh slum. <i>Bull PGL</i> 1993; 43-5.	1993	*	
India	Bharucha NE, Bharucha EP, Bharucha AE, Bhise AV, Schoenberg BS. Prevalence of epilepsy in the Parsi community of Bombay. <i>Epilepsia</i> . 1988; 29(2): 111-5.	1985	*	†
India	Gourie-Devi M, Gururaj G, Satishchandra P, Subbakrishna DK. Neuro-epidemiological pilot survey of an urban population in a developing country. A study in Bangalore, south India. <i>Neuroepidemiology</i> . 1996; 15(6): 313-20.	1995	*	
India	Singh NP, Ingle GK, Saini VK, Jami A, Beniwal P, Lal M, Meena GS. Prevalence of low glomerular filtration rate, proteinuria and associated risk factors in North India using Cockcroft-Gault and Modification of Diet in Renal Disease equation: an observational, cross-sectional study. <i>BMC Nephrol</i> . 2009; 10: 4.	2005-2007	*	
India	Agarwal N, Naik S, Aggarwal R, Singh H, Somani SK, Kini D, Pandey R, Choudhuri G, Saraswat VA, Naik SR. Occult hepatitis B virus infection as a cause of cirrhosis of liver in a region with intermediate endemicity. <i>Indian J Gastroenterol</i> . 2003; 22(4): 127-31.	1997-1999	*	
India	Berry N, Chakravarti A, Kar P, Das BC, Santhanam, Mathur MD. Association of Hepatitis C virus and Hepatitis B virus in chronic liver disease. <i>Indian J Med Res</i> . 1998; 108(6): 255-9.	1994-1995	*	
India	Saravanan S, Velu V, Nandakumar S, Madhavan V, Shanmugasundaram U, Murugavel KG, Balakrishnan P, Kumarasamy N, Solomon S, Thyagarajan SP. Hepatitis B virus and hepatitis C virus dual infection among patients with chronic liver disease. <i>J Microbiol Immunol Infect</i> . 2009; 42(2): 122-8.	2006	*	
India	Sawant P, Rathi PM, Upadhyaya A. Hepatitis B subtypes and hepatitis C genotypes in cirrhosis in western India: results of a pilot study. <i>J Assoc Physicians India</i> . 1999; 47(6): 580-3.	1994-1995	*	
India	Kumar M, Kumar R, Hissar SS, Saraswat MK, Sharma BC, Sakhuja P, Sarin SK. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from India. <i>J Gastroenterol Hepatol</i> . 2007; 22(7): 1104-11.	1994-2005	*	
India	Kumar R, Saraswat MK, Sharma BC, Sakhuja P, Sarin SK. Characteristics of hepatocellular carcinoma in India: a retrospective analysis of 191 cases. <i>QJM</i> . 2008; 101(6): 479-85.	1991-2003	*	
India	Sarin SK, Thakur V, Gupta RC, Saigal S, Malhotra V, Thyagarajan SP, Das BC. Profile of hepatocellular carcinoma in India: an insight into the possible etiologic associations. <i>J Gastroenterol Hepatol</i> . 2001; 16(6): 666-73.	1993-1999	*	
India	Wang B-E, Ma W-M, Sulaiman A, Noer S, Sumoharjo S, Sumarsidi D, Tandon BN, Nakao K, Mishiyo S, Miyakawa Y, Akahane Y, Suzuki H. Demographic, clinical, and virological characteristics of hepatocellular carcinoma in Asia: survey of 414 patients from four countries. <i>J Med Virol</i> . 2002; 67(3): 394-400.	2002	*	
India	Ahmad A, Khalique N, Khan Z, Amir A. Prevalence of psychosocial problems among school going male adolescents. <i>Indian J Community Med</i> . 2007; 32(3): 219-21.	2002-2003	*	
India	Bansal PD, Barman R. Psychopathology of school going children in the age group of 10-15 years. <i>Int J Appl Basic Med Res</i> . 2011; 1(1): 43-7.	2010	*	
India	Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, de Graaf R, Demyttenaere K, Hu C, Iwata N, Karam AN, Kaur J, Kostyuchenko S, Lépine J-P, Levinson D, Matschinger H, Mora MEM, Browne MO, Posada-Villa J, Viana MC, Williams DR, Kessler RC. Cross-national epidemiology of DSM-IV major depressive episode. <i>BMC Med</i> . 2011; 9: 90.	2003-2005	*	
India	Patil RN, Nagaonkar SN, Shah NB, Bhat TS. A Cross-sectional Study of Common Psychiatric Morbidity in Children Aged 5 to 14 Years in an Urban Slum. <i>J Family Med Prim Care</i> . 2013; 2(2): 164-8.	2011	*	
India	Poongothai S, Pradeepa R, Ganesan A, Mohan V. Prevalence of depression in a large urban South Indian population – the Chennai Urban Rural Epidemiology Study (CURES-70). <i>PLoS One</i> . 2009; 4(9): e7185.	2001-2002	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
India	Rajkumar AP, Thangadurai P, Senthilkumar P, Gayathri K, Prince M, Jacob KS. Nature, prevalence and factors associated with depression among the elderly in a rural south Indian community. <i>Int Psychogeriatr</i> . 2009; 21(2): 372-8.	2004-2005	*	
India	Sarkar S, Sinha VK, Prharaj SK. Depressive disorders in school children of suburban India: an epidemiological study. <i>Soc Psychiatry Psychiatr Epidemiol</i> . 2012; 47(5): 783-8.	2010	*	
India	Silvanus V, Subramanian P. Epidemiological study of mental morbidity in an urban slum community in India for the development of a community mental health programme. <i>Nepal Med Coll J</i> . 2012; 14(1): 13-7.	1995	*	
India	Sarkhel S, Sinha VK, Arora M, Desarkar P. Prevalence of conduct disorder in schoolchildren of Kanke. <i>Indian J Psychiatry</i> . 2006; 48(3): 159-64.	2004	*	
India	World Health Organization (2005). Study on Global Ageing and Adult Health (SAGE), Pilot Study, 2005 (Data Set 27-28, Cunningham, Shayna.) [machine-readable data file and documentation]. Geneva, Switzerland: World Health Organization (Producer). Los Altos, CA: Sociometrics Corporation, Data Archive of Social Research on Aging (Producer & Distributor).	2005		
India	Rajkumar S, Padmavathi R, Thara R, Menon MS. Incidence of schizophrenia in an urban community in Madras. <i>Indian J Psychiatry</i> . 1993; 35(1): 18-21.	1987-1988	*	
India	Seby K, Chaudhury S, Chakraborty R. Prevalence of psychiatric and physical morbidity in an urban geriatric population. <i>Indian J Psychiatry</i> . 2011; 53(2): 121-7.	2002-2003	*	
India	Chadha VK. Tuberculosis epidemiology in India: a review. <i>Int J Tuberc Lung Dis</i> . 2005; 9(10): 1072-82.	1986, 1991-1992, 2000-2001		
India	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2004, 2007, 2010, 2012		
India	Unisa S, Jagannath P, Dhir V, Khandelwal C, Sarangi L, Roy TK. Population-based study to estimate prevalence and determine risk factors of gallbladder diseases in the rural Gangetic basin of North India. <i>HPB (Oxford)</i> . 2011; 13(2): 117-25.	2008-2010	*	
India	Suvarna BS, Kamath A. Prevalence of attention deficit disorder among preschool age children. <i>Nepal Med Coll J</i> . 2009; 11(1): 1-4.	2007-2008	*	
India	Chowdhary A, Malhotra VL, Deb M, Rai U. Screening for chlamydial infections in women with pelvic inflammatory diseases. <i>J Commun Dis</i> . 1998; 30(3): 163-6.	1994-1995	*	†
India	Shrikhande SN, Joshi SG, Zodpey SP, Saoji AM. Chlamydia trachomatis in pelvic inflammatory disease. <i>Indian J Pathol Microbiol</i> . 1995; 38(2): 181-4.	1992-1994	*	†
India	Verma PK, Tewari KN. Epidemiology of Road Traffic Injuries in Delhi Result of a Survey. <i>Regional Health Forum</i> . 2004; 8(1): 1-10.	2002	*	
India	India Survey of Blindness 1986-1989 as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	1986-1989		
India	Vidwan NK, Regi A, Steinhoff M, Huppert JS, Staat MA, Dodd C, Nongrum R, Anandan S, Verghese V. Low prevalence of Chlamydia trachomatis infection in non-urban pregnant women in Vellore, S. India. <i>PLoS One</i> . 2012; 7(5): e34794.	2009-2010	*	
India	Ramakrishnan R, Nirmalan PK, Krishnas R, Thulasiraj RD, Tielsch JM, Katz J, Friedman DS, Robin AL. Glaucoma in a rural population of southern India: the Aravind comprehensive eye survey. <i>Ophthalmology</i> . 2003; 110(8): 1484-90. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	1995-1997		
India	Nirmalan PK, Katz J, Robin AL, Tielsch JM, Namperumalsamy P, Kim R, Narendran V, Ramakrishnan R, Krishnas R, Thulasiraj RD, Suan E. Prevalence of vitreoretinal disorders in a rural population of southern India: the Aravind Comprehensive Eye Study. <i>Arch Ophthalmol</i> . 2004; 122(4): 581-6. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	1995-1997		
India	Nirmalan PK, Thulasiraj RD, Maneksha V, Rahmathullah R, Ramakrishnan R, Padmavathi A, Munoz SR, Ellwein LB. A population based eye survey of older adults in Tirunelveli district of south India: blindness, cataract surgery, and visual outcomes. <i>Br J Ophthalmol</i> . 2002; 86(5): 505-12. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2000		
India	Palimkar A, Khandekar R, Venkataraman V. Prevalence and distribution of glaucoma in central India (Glaucoma Survey 2001). <i>Indian J Ophthalmol</i> . 2008; 56(1): 57-62. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2001		
India	Murthy GV, Gupta S, Ellwein LB, Munoz SR, Bachani D, Dada VK. A population-based eye survey of older adults in a rural district of Rajasthan: I. Central vision impairment, blindness, and cataract surgery. <i>Ophthalmology</i> . 2001; 108(4): 679-85. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	1998-1999		
India	Dorairaj SK, Bandrakalli P, Shetty C, R V, Misquith D, Ritch R. Childhood blindness in a rural population of southern India: prevalence and etiology. <i>Ophthalmic Epidemiol</i> . 2008; 15(3): 176-82. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2005-2006		
India	Chandrashekar TS, Bhat HV, Pai RP, Nair SK. Prevalence of blindness and its causes among those aged 50 years and above in rural Karnataka, South India. <i>Trop Doct</i> . 2007; 37(1): 18-21. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2002		
India	Dandona L, Dandona R, Srinivas M, Giridhar P, Vilas K, Prasad MN, John RK, McCarty CA, Rao GN. Blindness in the Indian state of Andhra Pradesh. <i>Invest Ophthalmol Vis Sci</i> . 2001; 42(5): 908-16. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	1996		
India	Rajapure V, Tirwa R, Poudyal H, Thakur N. Prevalence and risk factors associated with sexually transmitted diseases (STDs) in Sikkim. <i>J Community Health</i> . 2013; 38(1): 156-62.	2010-2011	*	
India	Shivaswamy KN, Thappa DM, Jaisankar TJ, Sujatha S. High seroprevalence of HSV-1 and HSV-2 in STD clinic attendees and non-high risk controls: a case control study at a referral hospital in south India. <i>Indian J Dermatol Venereol Leprol</i> . 2005; 71(1): 26-30.	2001-2003	*	
India	Reynolds SJ, Rishbud AR, Shepherd ME, Zenilman JM, Brookmeyer RS, Paranjape RS, Divekar AD, Gangakhedkar RR, Ghate MV, Bollinger RC, Mehendale SM. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. <i>J Infect Dis</i> . 2003; 187(10): 1513-21.	1993-2003	*	
India	Madhavan HN, Priya K. The diagnostic significance of enzyme linked immuno-sorbent assay for herpes simplex, varicella zoster and cytomegalovirus retinitis. <i>Indian J Ophthalmol</i> . 2003; 51(1): 71-5.	1997-2002	*	
India	Thomas K, Thyagarajan SP, Jayaseelan L, Varghese JC, Krishnamurthy P, Bai L, Hira S, Sudhakar K, Peedicyal A, George S, George R, Rajendran P, Joyee AG, Hari D, Balakrishnan, Sethuraman N, Gharpure H, Srinivasan V. Community prevalence of sexually transmitted diseases and human immunodeficiency virus infection in Tamil Nadu, India: a probability proportional to size cluster survey. <i>Natl Med J India</i> . 2002; 15(3): 135-40.	1991-2002	*	
India	India - Kolar Rapid Assessment of Avoidable Blindness 2011 [Unpublished] as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2011		
India	George B, Padman MSR, Nair MKC, Indira MS, Syamalan K, Padmanohan J. Hypoxic ischemic encephalopathy developmental outcome at 12 years. <i>Indian Pediatr</i> . 2009; s67-70.	2006-2008	*	†
India	Katellaris PH, Tippet GH, Norbu P, Lowe DG, Brennan R, Farthing MJ. Dyspepsia, <i>Helicobacter pylori</i> , and peptic ulcer in a randomly selected population in India. <i>Gut</i> . 1992; 33(11): 1462-6.	1989-1991	*	
India	Balogopal P, Kamalamma N, Patel TG, Misra R. A community-based participatory diabetes prevention and management intervention in rural India using community health workers. <i>Diabetes Educ</i> . 2012; 38(6): 822-34.	2007-2008		
India	Bharati DR, Pal R, Kar S, Rekha R, Yamuna TV, Basu M. Prevalence and determinants of diabetes mellitus in Pudukcherry, South India. <i>J Pharm Bioallied Sci</i> . 2011; 3(4): 513-8.	2007		
India	Bharati DR, Pal R, Rekha R, Yamuna TV. Evaluation of the burden of type 2 diabetes mellitus in population of Pudukcherry, South India. <i>Diabetes Metab Syndr</i> . 2011; 5(1): 12-6.	2007-2008		
India	Gupta SK, Singh Z, Purty AJ, Kar M, Vedapriya D, Mahajan P, Cherian J. Diabetes prevalence and its risk factors in rural area of Tamil Nadu. <i>Indian J Community Med</i> . 2010; 35(3): 396-9.	2008		
India	Kalra S, Kalra B, Sharma A. Prevalence of type 1 diabetes mellitus in Karmal district, Haryana state, India. <i>Diabetol Metab Syndr</i> . 2010; 14.	2008		
India	Muninarayana C, Balachandra G, Hiremth SG, lyengar K, Anil NS. Prevalence and awareness regarding diabetes mellitus in rural Tamaka, Kolar. <i>Int J Diabetes Dev Ctries</i> . 2010; 30(1): 18-21.	2007-2009		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
India	Rajput R, Rajput M, Singh J, Bairwa M. Prevalence of diabetes mellitus among the adult population in rural blocks of Haryana, India: a community-based study. <i>Metab Syndr Relat Disord</i> . 2012; 10(6): 443-6.	2009-2011		
India	Rani PK, Raman R, Gella L, Kulothungan V, Sharma T. Prevalence of Visual Impairment and Associated Risk Factors in Subjects with Type II Diabetes Mellitus: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study (SN-DREAMS, Report 16). <i>Middle East Afr J Ophthalmol</i> . 2012; 19(1): 129-34.	2003-2006		
India	Rao CR, Kamath VG, Shetty A, Kamath A. A study on the prevalence of type 2 diabetes in coastal Karnataka. <i>Int J Diabetes Dev Ctries</i> . 2010; 30(2): 80-5.	2006-2007		
India	Ravikumar P, Bhansali A, Ravikiran M, Bhansali S, Walia R, Shanmugasundar G, Thakur JS, Kumar Bhadada S, Dutta P. Prevalence and risk factors of diabetes in a community-based study in North India: the Chandigarh Urban Diabetes Study (CUDS). <i>Diabetes Metab</i> . 2011; 37(3): 216-21.	2008-2009		
India	Safraj S, Anish T, Vijayakumar K, Kutty VR, Soman CR. Socioeconomic position and prevalence of self-reported diabetes in rural Kerala, India: results from the PROLIFE study. <i>Asia Pac J Public Health</i> . 2012; 24(3): 480-6.	2001		
India	Singh AK, Mani K, Krishnan A, Aggarwal P, Gupta SK. Prevalence, awareness, treatment and control of diabetes among elderly persons in an urban slum of Delhi. <i>Indian J Community Med</i> . 2012; 37(4): 236-9.	2009-2010		
India	Sinharay K, Paul UK, Bhattacharya AK, Pal SK. Prevalence of diabetic foot ulcers in newly diagnosed diabetes mellitus patients. <i>J Indian Med Assoc</i> . 2012; 110(9): 608-11.	2010-2011		
India	Vaz NC, Ferreira AM, Kulkarni MS, Vaz FS. Prevalence of diabetes mellitus in a rural population of Goa, India. <i>Natl Med J India</i> . 2011; 24(1): 16-8.	2008-2010		
India	Mohan V, Deepa M, Anjana RM, Lanthorn H, Deepa R. Incidence of diabetes and pre-diabetes in a selected urban south Indian population (CUPS-19). <i>J Assoc Physicians India</i> . 2008; 152-7.	1997-2006		
India	Mohan D, Chopra A, Sethi H. A rapid assessment study on prevalence of substance abuse disorders in metropolis Delhi. <i>Indian J Med Res</i> . 2001; 114: 107-14.	1992-1993	*	
India	National Cancer Registry Programme (India). India Population Based Cancer Registries 2009-2011. New Delhi, India: Indian Council of Medical Research (ICMR), 2013.	2008-2011	*	
India	Kumar R, Vohra H, Chakraborty A, Sharma YP, Bandhopadhyay S, Dhanda V, Sagar V, Sharma M, Shah B, Ganguly NK. Epidemiology of group A streptococcal pharyngitis and impetigo: a cross-sectional and follow up study in a rural community of northern India. <i>Indian J Med Res</i> . 2009; 130(6): 765-771.	2000-2002		
India	Chatterjee JB. Haemoglobinopathies, glucose-6-phosphate dehydrogenase deficiency and allied problems in the Indian subcontinent. <i>Bull World Health Organ</i> . 1966; 35(6): 837-56.	1964-1966		
India	Deshmukh VV, Sharma KD. Deficiency of erythrocyte glucose-6-phosphate dehydrogenase and sickle cell trait: a survey of Mahar students at Aurangabad, Maharashtra. <i>Indian J Med Res</i> . 1968; 56(6): 821-5.	1966-1968		
India	Kate SL, Mukherjee BN, Malhotra KC, Phadke MA, Mutalik GS, Sainani GS. Red cell glucose-6-phosphate dehydrogenase deficiency and haemoglobin variants among ten endogenous groups of Maharashtra and West Bengal. <i>Hum Genet</i> . 1978; 44(3): 339-43.	1974-1975		
India	Balgir RS. Do tribal communities show an inverse relationship between sickle cell disorders and glucose-6-phosphate dehydrogenase deficiency in malaria endemic areas of Central-Eastern India? <i>Homo</i> . 2006; 57(2): 163-76.	1997-2003		
India	Joshi SR, Patel RZ, Patel HR, Sukumar S, Colah RB. High prevalence of G6PD deficiency in Vataliya Prajapati community in western India. <i>Haematologia (Budap)</i> . 2001; 31(1): 57-60.	1999-2001		
India	Murhekar KM, Murhekar MV, Mukherjee MB, Gorakshakar AC, Surve R, Wadia M, Phanasaogankar S, Shrivdevi S, Colah RB, Mohanty D. Red cell genetic abnormalities, beta-globin gene haplotypes, and APOB polymorphism in the Great Andamanese, a primitive Negrito tribe of Andaman and Nicobar Islands, India. <i>Hum Biol</i> . 2001; 73(5): 739-44.	1999-2001		
India	Gupte SC, Patel PU, Ranat JM. G6PD deficiency in Vataliya Prajapati community settled in Surat. <i>Indian J Med Sci</i> . 2005; 59(2): 51-6.	1999-2004		
India	Sukumar S, Mukherjee MB, Colah RB, Mohanty D. Molecular basis of G6PD deficiency in India. <i>Blood Cells Mol Dis</i> . 2004; 33(2): 141-5.	2002-2004		
India	Nishank SS, Chhotray GP, Kar SK, Ranjit MR. Molecular variants of G6PD deficiency among certain tribal communities of Orissa, India. <i>Ann Hum Biol</i> . 2008; 35(3): 355-61.	2006-2008		
India	Modi GK, Jha V. The incidence of end-stage renal disease in India: a population-based study. <i>Kidney Int</i> . 2006; 70(12): 2131-33.	2002-2005		
India	National Cancer Registry Programme (India). India Consolidated Report of Population Based Cancer Registries 2004-2005. New Delhi, India: Indian Council of Medical Research (ICMR), 2008.	2005	*	
India	Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M and Boyle P, eds (2007). <i>Cancer Incidence in Five Continents, Vol. IX Periodic Data (electronic version)</i> . Lyon, IARC. http://ci5.iarc.fr	1998-2002	*	
India	Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. <i>Cancer Incidence in Five Continents. Vol. I to VIII</i> . Lyon, France, IARC Press, 2005.	1978-1997	*	
India	National Cancer Registry Programme (India). India - North East Population Based Cancer Registries Report 2005-2006. New Delhi, India: Indian Council of Medical Research (ICMR), 2008.	2005-2006	*	
India	National Cancer Registry Programme (India). India Three-Year Report of Population Based Cancer Registries 2006-2008. New Delhi, India: Indian Council of Medical Research (ICMR), 2010.	2005-2008	*	
India	Anil S, Hari S, Vijayakumar T. Periodontal conditions of a selected population in Trivandrum District, Kerala, India. <i>Community Dent Oral Epidemiol</i> . 1990; 18(6): 325.	1988		
India	Bhattacharya SS, Das U, Choudhury BK. Occurrence and antibiogram of <i>Salmonella</i> Typhi and <i>S. Paratyphi A</i> isolated from Rourkela, Orissa. <i>Indian J Med Res</i> . 2011; 431-3.	2005-2008	*	
India	Gupta V, Kaur J, Chander J. An increase in enteric fever cases due to <i>Salmonella</i> Paratyphi A in and around Chandigarh. <i>Indian J Med Res</i> . 2009; 129(1): 95-8.	2003-2006	*	
India	Jog S, Soman R, Singhal T, Rodrigues C, Mehta A, Dastur FD. Enteric fever in Mumbai - clinical profile, sensitivity patterns and response to antimicrobials. <i>J Assoc Physicians India</i> . 2008; 237-40.	2003-2005	*	
India	Ochiai RL, Wang X, von Seidlein L, Yang J, Bhutta ZA, Bhattacharya SK, Agtini M, Deen JL, Wain J, Kim DR, Ali M, Acosta CJ, Jodar L, Clemens JD. <i>Salmonella</i> Paratyphi A Rates, Asia. <i>Emerg Infect Dis</i> . 2005; 11(11): 1764-6.	2003-2004	*	
India	Vidyalakshmi K, Yashavanth R, Chakrapani M, Shrikala B, Bharathi B, Suchitra U, Dhanashree B, Dominic RMS. Epidemiological shift, seasonal variation and antimicrobial susceptibility patterns among enteric fever pathogens in South India. <i>Trop Doct</i> . 2008; 38(2): 89-91.	2005-2006	*	
India	Das SK, Misra AK, Ray BK, Hazra A, Ghosal MK, Chaudhuri A, Roy T, Banerjee TK, Raut DK. Epidemiology of Parkinson disease in the city of Kolkata, India: a community-based study. <i>Neurology</i> . 2010; 75(15): 1362-9.	2003-2007	*	
India	Murhekar MV, Hutin YJ, Ramakrishnan R, Ramachandran V, Biswas AK, Das PK, Gupta SN, Maji D, Martolia HCS, Mohan A, Gupte MD. The heterogeneity of measles epidemiology in India: implications for improving control measures. <i>J Infect Dis</i> . 2011; S421-426.	2004-2006		
India	John S, Sanghi S, Prasad S, Bose A, George K. Two doses of measles vaccine: are some states in India ready for it? <i>J Trop Pediatr</i> . 2009; 55(4): 253-6.	1999, 2006	*	
India	Christian Medical College and Hospital Ludhiana. India - Ludhiana Population-Based Stroke Registry Tables 2010-2013. [Unpublished].	2010-2013	*	
India	Rao GN, Kulkarni GB, Gururaj G, Rajesh K, Subbakrishna DK, Steiner TJ, Stovner LJ. National Institute of Mental Health and Neuro Sciences. India - Karnataka Burden of Headache Disorders Study 2008. [Unpublished].	2008	*	
India	Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baijng D, Bhattacharya SK, Agtini MD, Bhutta ZA, Canh DG, Ali M, Shin S, Wain J, Page A-L, Albert MJ, Farrar J, Abu-Elyazed R, Pang T, Galindo CM, von Seidlein L, Clemens JD. <i>Doni Typhoid Study Group</i> . A study of typhoid fever in five Asian countries: disease burden and implications for controls. <i>Bull World Health Organ</i> . 2008; 86(4): 260-8.	2003-2004		
India	Sinha A, Sazawal S, Kumar R, Sood S, Reddaiah VP, Singh B, Rao M, Naficy A, Clemens JD, Bhan MK. Typhoid fever in children aged less than 5 years. <i>Lancet</i> . 1999; 354(9180): 734-7.	1995-1996		
India	Sur D, Ali M, von Seidlein L, Manna B, Deen JL, Acosta CJ, Clemens JD, Bhattacharya SK. Comparisons of predictors for typhoid and paratyphoid fever in Kolkata, India. <i>BMC Public Health</i> . 2007; 7: 289.	2003-2004		
India	Sur D, Ochiai RL, Bhattacharya SK, Ganguly NK, Ali M, Manna B, Dutta S, Donner A, Kanungo S, Park JK, Puri MK, Kim DR, Dutta D, Bhaduri B, Acosta CJ, Clemens JD. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. <i>N Engl J Med</i> . 2009; 361(4): 335-44.	2004-2006		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
India	Ferlay J, Parkin DM, Curado MP, Bray F, Edwards B, Shin HR and Forman D. Cancer Incidence in Five Continents, Volumes I to IX: IARC CancerBase No. 9 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://cis.iarc.fr	1980-2002	*	
India	Saikia L, Nath R, Saikia NJ, Choudhury G, Sarkar M. A diphtheria outbreak in Assam, India. Southeast Asian J Trop Med Public Health. 2010; 41(3): 647-52.	2009		
India	Madhivanan P, Bartman MT, Pasutti L, Krupp K, Arun A, Reingold AL, Klausner JD. Prevalence of Trichomonas vaginalis infection among young reproductive age women in India: implications for treatment and prevention. Sex Health. 2009; 6(4): 339-44.	2005		
India	Rao RSP, Subramanyam MA, Nair NS, Rajashekar B. Hearing impairment and ear diseases among children of school entry age in rural South India. Int J Pediatr Otorhinolaryngol. 2002; 64(2): 105-10.	1999-2001	*	
India	Bansal R, Raj A. Hearing loss in rural population?: the etiology. Indian J Otolaryngol Head Neck Surg. 1998; 50(2): 147-55.	1992	*	
India	Rao VG, Bhat J, Yadav R, Gopalan GP, Nagamiah S, Bhoneley MK, Anjinappa SM, Ramchandra J, Chadha VK, Wares F. Prevalence of Pulmonary Tuberculosis - A Baseline Survey in Central India. PLoS One. 2012; 7(8): e43225.	2009-2010	*	
India	Datta M, Gopi PG, Appegowda BN, Bhima Rao KR, Gopalan BN. Tuberculosis in North Arcot District of Tamil Nadu - a sample survey. Indian J Tuberc. 2000; 47(3): 147-54.	1989-1990	*	
India	New Delhi Tuberculosis Centre. Study of Epidemiology of Tuberculosis in an Urban Population of Delhi: Report on 30 year Follow-Up. Indian J Tuberc. 1999; 113.	1991	*	
India	Bhat J, Rao VG, Gopi PG, Yadav R, Selvakumar N, Tiwari B, Gadge V, Bhoneley MK, Wares F. Prevalence of pulmonary tuberculosis amongst the tribal population of Madhya Pradesh, central India. Int J Epidemiol. 2009; 38(4): 1026-32.	2007-2008	*	
India	Gopi PG, Subramani R, Radhakrishna S, Kolappan C, Sadacharam K, Devi TS, Frieden TR, Narayanan PR. A baseline survey of the prevalence of tuberculosis in a community in south India at the commencement of a DOTS programme. Int J Tuberc Lung Dis. 2003; 7(12): 1154-62.	1999-2001	*	
India	Das U, Dakshinamurthy KV, Prayaga A. Pattern of biopsy-proven renal disease in a single center of south India: 19 years experience. Indian J Nephrol. 2011; 21(4): 250-7.	1990-2008	*	
India	National Vector Borne Disease Control Programme, Ministry of Health and Family Welfare (India). India Visceral Leishmaniasis Cases and Deaths. Delhi, India: National Vector Borne Disease Control Programme, Ministry of Health and Family Welfare (India).	2011-2012	*	
India	National Vector Borne Disease Control Programme, Ministry of Health and Family Welfare (India). India Dengue Cases and Deaths. Delhi, India: National Vector Borne Disease Control Programme, Ministry of Health and Family Welfare (India).	2009-2013	*	
India	Sugunan AP, Ghosh AR, Roy S, Gupte MD, Sehgal SC. A cholera epidemic among the Nicobarese tribe of Nancowry, Andaman, and Nicobar, India. Am J Trop Med Hyg. 2004; 71(6): 822-7.	2002	*	
India	Sreehari U, Razdan RK, Mittal PK, Ansari MA, Rizvi MMA, Dash AP. Impact of Olyset nets on malaria transmission in India. J Vector Borne Dis. 2007; 44(2): 137-44 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004-2006	*	†
India	Sharma SK, Upadhyay AK, Haque MA, Padhan K, Tyagi PK, Batra CP, Adak T, Dash AP, Subbarao SK. Effectiveness of mosquito nets treated with a tablet formulation of deltamethrin for malaria control in a hyperendemic tribal area of Sundargarh District, Orissa, India. J Am Mosq Control Assoc. 2006; 22(1): 111-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002-2003	*	†
India	Sharma SK, Chattopadhyay R, Chakrabarti K, Pati SS, Srivastava VK, Tyagi PK, Mahanty S, Misra SK, Adak T, Das BS, Chitnis CE. Epidemiology of malaria transmission and development of natural immunity in a malaria-endemic village, San Dulakudar, in Orissa state, India. Am J Trop Med Hyg. 2004; 71(4): 457-65 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001-2005	*	†
India	Sahu SS, Jambulingam P, Vijayakumar T, Subramanian S, Kalyanasundaram M. Impact of alphacypermethrin treated bed nets on malaria in villages of Malkangiri district, Orissa, India. Acta Trop. 2003; 89(1): 55-66 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
India	Sahu SS, Vijayakumar T, Kalyanasundaram M, Subramanian S, Jambulingam P. Impact of lambdacyhalothrin capsule suspension treated bed nets on malaria in tribal villages of Malkangiri district, Orissa, India. Indian J Med Res. 2008; 128(3): 262-70 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
India	Morris SK, Awasthi S, Kumar R, Shet A, Khera A, Nakhaee F, Ram U, Brandao JRM, Jha P. Measles mortality in high and low burden districts of India: Estimates from a nationally representative study of over 12,000 child deaths. Vaccine. 2013; 31(41): 4655-61.	2001-2003, 2005	*	
India	World Health Organization (WHO). India WHO Leishmaniasis Country Profile.	1990-2010	*	
India	Chakma T, Rao PV, Pall S, Kaushal LS, Datta M, Tiwary RS. Survey of pulmonary tuberculosis in a primitive tribe of Madhya Pradesh. Indian J Tuberc. 1996; 43: 85-89.	1991-1992	*	
India	Chadha VK, Kumar P, Anjinappa SM, Singh S, Narasimhaiah S, Joshi MV, Gupta J, Lakshminarayana, Ramchandra J, Velu M, Papkianathan S, Babu S, Krishna H. Prevalence of pulmonary tuberculosis among adults in a rural sub-district of South India. PLoS One. 2012; 7(8): e42625.	2008-2010	*	
India	Kolappan C, Subramani R, Radhakrishna S, Santha T, Wares F, Baskaran D, Selvakumar N, Narayanan PR. Trends in the prevalence of pulmonary tuberculosis over a period of seven and half years in a rural community in south India with DOTS. Indian J Tuberc. 2013; 60(3): 168-76.	2001-2008	*	
India	Yadav R, Rao VG, Bhat J, Gopi PG, Selvakumar N, Wares DF. Prevalence of pulmonary tuberculosis amongst the Baigas--a primitive tribe of Madhya Pradesh, Central India. Indian J Tuberc. 2010; 57(2): 114-6.	2008	*	
India	Gupta B, Jain V, Aggarwal N. Rectal misoprostol versus oxytocin in the prevention of postpartum hemorrhage - A pilot study. Int J Gynaecol Obstet. 2006; S139-S140.	2003-2005	*	
India	Zachariah ES, Naidu M, Seshadri L. Oral misoprostol in the third stage of labor. Int J Gynaecol Obstet. 2006; 92(1): 23-6.	2002-2004	*	
India	Adhikari P, Haldar JP. Prevalence of bancroftian filariasis in Burdwan district, West Bengal: II. Vector and microfilariae density in colliery and non-colliery areas. J Commun Dis. 1995; 27(3): 181-5, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1984	*	
India	Chand G, Barde PV, Singh N. Emergence of new foci of filariasis in Madhya Pradesh, India. Trans R Soc Trop Med Hyg. 2013; 107(7): 462-4, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2010	*	
India	Chandra G, Hati AK. Filariasis survey in a rural area of West Bengal. J Commun Dis. 1996; 28(3): 206-8.	1993-1995	*	
India	Kar SK, Mania J, Kar PK. Prevalence of lymphatic nodule in a bancroftian endemic population. Acta Trop. 1993; 55(1-2): 53-60, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1980-2000	*	
India	Kumar A. Human filariasis: infection rate as the uniform measurable criterion for filarial endemicity. J Commun Dis. 1996; 28(3): 163-7.	1992-1994	*	
India	Ramaiah KD, Vanamail P. Surveillance of lymphatic filariasis after stopping ten years of mass drug administration in rural communities in south India. Trans R Soc Trop Med Hyg. 2013; 107(5): 293-300, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2010	*	
India	Surendran K, Pani SP, Soudarasan MB, Srinivasa DK, Bordolai PC, Subramanian S. Natural history, trend of prevalence and spectrum of manifestations of Bancroftian filarial disease in Pondicherry (South India). Acta Trop. 1996; 61(1): 9-18.	1986, 1992	*	
India	Swaminathan S, Perumal V, Adinarayanan S, Kaliannagounder K, Rengachari R, Purushothaman J. Epidemiological assessment of eight rounds of mass drug administration for lymphatic filariasis in India: implications for monitoring and evaluation. PLoS Negl Trop Dis. 2012; 6(11): e1926, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2008-2009	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
India	Upadhyaya SM, Mutheneeni SR, Kumaraswamy S, Kadiri MR, Pabbisetty SK, Yellepeddi VSM. Filaria monitoring visualization system: a geographical information system-based application to manage lymphatic filariasis in Andhra Pradesh, India. <i>Vector Borne Zoonotic Dis.</i> 2012; 12(5): 418-27. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2004-2007	*	
India	Shriram AN, Murhekar MV, Ramaiah KD, Sehgal SC. Prevalence of diurnally subperiodic bancroftian filariasis among the Nicobarese in Andaman and Nicobar Islands, India: effect of age and gender. <i>Trop Med Int Health.</i> 2002; 7(11): 949-54. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1999	*	
India	Mandal NN, Bal MS, Das MK, Achary KG, Kar SK. Lymphatic filariasis in children: age dependent prevalence in an area of India endemic for Wuchereria bancrofti infection. <i>Trop Biomed.</i> 2010; 27(1): 41-6. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2005-2006	*	
India	Singh S, Bora D, Lal S. Lymphatic filariasis in East District, Sikkim. <i>J Commun Dis.</i> 2010; 42(1): 33-7, as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2008	*	
India	Yuvaraj J, Pani SP, Vanamai P, Ramaiah KD, Das PK. Impact of seven rounds of mass administration of diethylcarbamazine and ivermectin on prevalence of chronic filarial filariasis in south India. <i>Trop Med Int Health.</i> 2008; 13(5): 737-42.	1993-1994, 2001	*	
India	Chandra G, Chatterjee SN, Das S, Sarkar N. Lymphatic filariasis in the coastal areas of Digha, West Bengal, India. <i>Trop Doct.</i> 2007; 37(3): 136-9. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2003-2004	*	
India	Mukhopadhyay AK, Patnaik SK, Babu PS. Status of lymphatic filariasis in parts of east Godavari district of Andhra Pradesh, India. <i>J Vector Borne Dis.</i> 2007; 44(1): 72-4. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2004-2005	*	
India	Singh S, Bora D, Dhariwal AC, Singh R, Lal S. Lymphatic filariasis in rural areas of Patna District, Bihar. A challenge ahead. <i>J Commun Dis.</i> 2006; 38(2): 160-3. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2004	*	
India	Chhotray GP, Ranjit MR, Khuntia HK, Acharya AS. Precontrol observations on lymphatic filariasis and geo-helminthiases in two coastal districts of rural Orissa. <i>Indian J Med Res.</i> 2005; 122(5): 388-94. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2001	*	
India	Das D, Kumar S, Sahoo PK, Dash AP. A survey of bancroftian filariasis for microfilariae & circulating antigenaemia in two villages of Madhya Pradesh. <i>Indian J Med Res.</i> 2005; 121(6): 771-5. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2002	*	
India	Sahoo PK, Geddam JJ, Satapathy AK, Mohanty MC, Ravindran B. Bancroftian filariasis: prevalence of antigenaemia and endemic normals in Orissa, India. <i>Trans R Soc Trop Med Hyg.</i> 2000; 94(5): 515-7.	1999-2000	*	
India	Chhotray GP, Mohapatra M, Acharya AS, Ranjit MR. A clinico-epidemiological perspective of lymphatic filariasis in Satyabadi block of Puri district, Orissa. <i>Indian J Med Res.</i> 2001; 114: 65-71.	1996-1997	*	
India	Khan AM, Dutta P, Khan SA, Baruah NK, Sarma CK, Mahanta J. Prevalence of bancroftian filariasis in a foot-hill tea garden of upper Assam. <i>J Commun Dis.</i> 1999; 31(2): 145-6.	1993	*	
India	Kumar A, Chand SK. Prevalence of Wuchereria bancrofti infection in some coastal villages of Ganjam, Orissa. <i>J Commun Dis.</i> 1990; 22(3): 209-12.	1987-1988	*	
India	Kumar A, Dash AP, Mansing GD. Prevalence of filariasis in rural Puri, Orissa. <i>J Commun Dis.</i> 1994; 26(4): 215-20.	1993	*	
India	Medhi GK, Hazarika NC, Shah B, Mahanta J. Study of health problems and nutritional status of tea garden population of Assam. <i>Indian J Med Sci.</i> 2006; 60(12): 496-505. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2002-2003	*	
India	Pani SP, Krishnamoorthy K, Rao AS, Prathiba J. Clinical manifestations in malayan filariasis infection with special reference to lymphoedema grading. <i>Indian J Med Res.</i> 1990; 200-7.	1988-1989	*	
India	Babu BV, Acharya AS, Mallick G, Jangid PK, Nayak AN, Satyanarayana K. Lymphatic filariasis in Khurda district of Orissa, India: an epidemiological study. <i>Southeast Asian J Trop Med Public Health.</i> 2001; 32(2): 240-3.	1999	*	
India	Arunachalam N, Mariappan T, Vijayakumar KN, Sabesan S, Panicker KN. Mattancherry urban agglomeration, a diminishing focus of lymphatic filariasis in Kerala. <i>J Commun Dis.</i> 1996; 28(3): 168-70. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1992-1994	*	
India	Pani SP, Balakrishnan N, Srividya A, Bundy DA, Grenfell BT. Clinical epidemiology of bancroftian filariasis: effect of age and gender. <i>Trans R Soc Trop Med Hyg.</i> 1991; 85(2): 260-4. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1986	*	
India	Raina VK, Joshi MC, Joshi RD, Singh S, Yadava RL, Kumar A. Filaria situation in the Union Territory of Dadra & Nagar Haveli. <i>J Commun Dis.</i> 1991; 23(3): 182-4.	1990	*	
India	Regu K, Rajendran R, Ali MKS, Koya SM, Dhariwal AC, Lal S. Decline of brugian filariasis in Cherthala taluk, Alappuzha district, Kerala. <i>J Commun Dis.</i> 2005; 37(3): 209-18.	1998-1999	*	
India	Sunish IP, Rajendran R, Satyanarayana K, Munirathinam A, Gajanana A. Immunochromatographic test (ICT) for estimation of true prevalence of bancroftian filariasis in an endemic area in southern India. <i>Trans R Soc Trop Med Hyg.</i> 2001; 95(6): 607-9. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1999	*	
India	Sukhvir S, Bora D, Dhariwal AC, Pawan D, Shiv L. Epidemiological, clinical and entomological observations on lymphatic filariasis in urban Puri, Orissa. <i>J Commun Dis.</i> 2008; 40(2): 161-5. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2006	*	
India	Sharma S, Sharma M, Rathaur S. Bancroftian filariasis in the Varanasi region of north India: an epidemiological study. <i>Ann Trop Med Parasitol.</i> 1999; 93(4): 379-87.	1995-1996	*	
India	Shenoy RK, Suma TK, Kumaraswami V, Rahmah N, Dhananjayan G, Padma S, Abhilash G, Ramesh C. Preliminary findings from a cross-sectional study on lymphatic filariasis in children, in an area of India endemic for Brugia malayi infection. <i>Ann Trop Med Parasitol.</i> 2007; 101(3): 205-13. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2004	*	
India	Libre Rodriguez JJ, Ferri CP, Acosta D, Guerra M, Huang Y, Jacob KS, Krishnamoorthy ES, Salas A, Sosa AL, Acosta I, Dewey ME, Gaona C, Jotheeswaran AT, Li S, Rodriguez D, Rodriguez G, Kumar PS, Valhuerdi A, Prince M, 10/66 Dementia Research Group. Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey. <i>Lancet.</i> 2008; 372(9637): 464-74.	2003-2005		†
India	Chandra AK, Tripathy S, Lahari D, Mukhopadhyay S. Iodine nutritional status of school children in a rural area of Howrah district in the Gangetic West Bengal. <i>Indian J Physiol Pharmacol.</i> 2004; 48(2): 219-24.	2001-2003	*	
India	Chandra AK, Tripathy S, Lahari D, Mukhopadhyay S. Iodine nutritional status of school children in a rural area of Howrah district in the Gangetic West Bengal. <i>Indian J Physiol Pharmacol.</i> 2004; 48(2): 219-24 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2001-2003		
India	Laxmaiah A, Arlappa N, Balakrishna N, Mallikarjuna Rao K, Galreddy C, Kumar S, Ravindranath M, Brahmam GNV. Prevalence and determinants of micronutrient deficiencies among rural children of eight states in India. <i>Ann Nutr Metab.</i> 2013; 62(3): 231-41.	2002-2005	*	
India	Sankar R, Pulger T, Rai TB, Gomathi S, Pandav CS. Iodine deficiency disorders in school children of Sikkim. <i>Indian J Pediatr.</i> 1994; 61(4): 407-14.	1991-1993	*	
India	Sankar R, Pulger T, Rai TB, Gomathi S, Pandav CS. Iodine deficiency disorders in school children of Sikkim. <i>Indian J Pediatr.</i> 1994; 61(4): 407-14 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1991-1993		
India	Saxena A, Ramakrishnan S, Roy A, Seth S, Krishnan A, Misra P, Kalaivani M, Bhargava B, Flather MD, Poole-Wilson PPA. Prevalence and outcome of subclinical rheumatic heart disease in India: the RHEUMATIC (Rheumatic Heart Echo Utilisation and Monitoring Actuarial Trends in Indian Children) study. <i>Heart.</i> 2011; 97(24): 2018-22.	2008-2010		
India	Singh S, Raina VK, Bora D, Dhariwal AC, Lal S. Lymphatic filariasis in Bilaspur district, Chhattisgarh. <i>J Commun Dis.</i> 2005; 37(2): 125-30. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2000	*	
India	India - Kerala Tracking Progress Towards Sustaining Elimination of Iodine Deficiency Disorders 2001 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2001		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
India	India Monitoring of Quality of Iodised Salt to Prevent Iodine Deficiency Disorders and Increase Production of Iodised Salt Through Networking of Medical Colleges in Andhra Pradesh, Karnataka, Kerala, Tamil Nadu and Pondicherry States as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2001		
India	India National Institute of Nutrition Annual Report 2000-2001 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2000-2001		
India	India - Orissa Towards Elimination of Iodine Deficiency Disorder 2003-2004 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2003-2004		
India	India - Bihar Tracking Progress Towards Sustainable Elimination of Iodine Deficiency Disorders 2003-2004 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2003-2004		
India	India - Rajasthan Tracking Progress Towards Sustainable Elimination of Iodine Deficiency Disorders 2004 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2004		
India	Kumar A, Husain S. The Burden of New Leprosy Cases in India: A Population-Based Survey in Two States. ISRN Trop Med. 2013; 329283.	2009-2010	*	
India	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
India	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	
India	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
India	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
India	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
India	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
India	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
India	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
India	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
India	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
India	World Health Organization (WHO). Leprosy. Global situation. Wkly Epidemiol Rec. 2002; 77(1): 1-8.	2001	*	
India	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
India	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
India	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
India	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1993; 68(25): 181-6.	1992	*	
India	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
India	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
India	Vijaya L, George R, Baskaran M, Arvind H, Raju P, Ramesh SV, Kumaramanicavel G, McCarty C. Prevalence of primary open-angle glaucoma in an urban south Indian population and comparison with a rural population. The Chennai Glaucoma Study. Ophthalmology. 2008; 115(4): 648-654.	2002-2004	*	
India	Nangia V, Jonas JB, Kulkarni M, Matin A. Prevalence of age-related macular degeneration in rural central India: the Central India Eye and Medical Study. Retina. 2011; 31(6): 1179-85.	2006-2008	*	
India	Nangia V, Jonas JB, Sinha A, Bhojwani K, Matin A. Visual impairment among school children in urban Central India: The Central India Children Eye Study. Acta Ophthalmol (Copenh). 2012; 90(4): e329-e331.	2006-2008	*	
India	Vijaya L, George R, Asokan R, Velumuri L, Ramesh SV. Prevalence and causes of low vision and blindness in an urban population: The Chennai Glaucoma Study. Indian J Ophthalmol. 2014.	2002-2004	*	
India	Betadapura GS, Donthi K, Datti NP, Ranganath BG, Ramaswamy SB, Jayaram TS. Assessment of avoidable blindness using the rapid assessment of avoidable blindness methodology. N Am J Med Sci. 2012; 4(9): 389-93.	2011	*	
India	Ganuruprasad BS, Krishnamurthy D, Narendra DP, Ranganath BG, Shamanna RB. Changing scenario of cataract blindness in Kolar District, Karnataka, South India. The utility of rapid assessment of avoidable blindness in reviewing programs. Ophthalmic Epidemiol. 2013; 20(2): 89-95.	1995	*	
India	Rustagi N, Uppal Y, Taneja DK. Screening for visual impairment: outcome among schoolchildren in a rural area of Delhi. Indian J Ophthalmol. 2012; 60(3): 203-6.	2009-2011	*	
India	Krishnaiah S, Das T, Nirmalan PK, Nutheti R, Shamanna BR, Rao GN, Thomas R. Risk factors for age-related macular degeneration: findings from the Andhra Pradesh eye disease study in South India. Invest Ophthalmol Vis Sci. 2005; 46(12): 4442-9.	1996-2000	*	
India	Goitre in School Girls of the Mewat Area of Haryana as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1989		
India	Singh J, Harit AK, Jain DC, Panda RC, Panda RC, Tewari KN, Bhatia R, Sokhey J. Diphtheria is declining but continues to kill many children: analysis of data from a sentinel centre in Delhi, 1997. Epidemiol Infect. 1999; 123(2): 209-15.	1997		
India	Havaldar PV. Diphtheria in the eighties: experience in a south Indian district hospital. J Indian Med Assoc. 1992; 90(6): 155-6.	1980-1989		
India	Sharma NC, Banavali IN, Ranjan R, Kumar R. Bacteriological and epidemiological characteristics of diphtheria cases in and around Delhi - a retrospective study. Indian J Med Res. 2007; 126(6): 545-52.	1998-2004		
India	Anima H, Malay M, Santanu H, Rajashree R, Sita C, Baran SA. A study on determinants of occurrence of complications and fatality among diphtheria cases admitted to ID and BG Hospital of Kolkata. J Commun Dis. 2008; 40(1): 53-8.	2004-2005		†
India	Sehgal A, Telang S, Passah SM, Jyothi MC. Maternal and Neonatal Profile and Immediate Outcome in Extremely Low Birth Weight Babies in Delhi. Trop Doct. 2004; 34(3): 165-8.	2001	*	†
India	Charan R, Dogra MR, Gupta A, Narang A. The incidence of retinopathy of prematurity in a neonatal care unit. Indian J Ophthalmol. 1995; 43(3): 123-6.	1993	*	†
India	Roy KK, Baruah J, Kumar S, Malhotra N, Deorari AK, Sharma JB. Maternal antenatal profile and immediate neonatal outcome in VLBW and ELBW babies. Indian J Pediatr. 2006; 73(8): 669-73.	2003	*	†
India	Goitre Survey in a North Indian Village as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1988		
India	Minz S, Balraj V, Lalitha MK, Murali N, Cherian T, Manoharan G, Kadirvan S, Joseph A, Steinhoff MC. Incidence of Haemophilus influenzae type b meningitis in India. Indian J Med Res. 2008; 128(1): 57-64.	1997-1999		
India	Sankar J, Singhi P, Bansal A, Ray P, Singhi S. Role of dexamethasone and oral glycerol in reducing hearing and neurological sequelae in children with bacterial meningitis. Indian Pediatr. 2007; 44(9): 649-56.	2002-2003		
India	Ahsan T, Shahid M, Mahmood T, Jabeen R, Jehangir U, Saleem M, Ahmed N, Shaheer A. Role of dexamethasone in acute bacterial meningitis in adults. J Pak Med Assoc. 2002; 52(6): 233-9.	1995		
India	Feldon K, Bahl S, Bhatnagar P, Wenger J. Severe vitamin A deficiency in India during pulse polio immunization. Indian J Med Res. 2005; 122(3): 265-7 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2003-2004		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
India	Fakhr S, Srivastava I, Ahmad P, Hasan SS. Prevalence of xerophthalmia in pre-school children in an urban slum, Indian Pediatr. 1993; 30(5): 668-70 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1988-1989		
India	Chakraborty B, Bhattacharya AR. Xerophthalmia in under-five children in West Bengal, Indian Pediatr. 1987; 24(7): 600-2 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1985		
India	Zargar AH, Shah JA, Mir MM, Laway BA, Masoodi SR, Shah NA. Prevalence of goitre in schoolchildren in Kashmir Valley, India. Am J Clin Nutr. 1995; 62(5): 1020-1 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1995		
India	Bhardwaj AK, Nayar D, Ramachandran S, Kapil U assessment of iodine deficiency in district Bikaner, Rajasthan. Indian J Matern Child Health. 1997; 8(1): 18-20 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1995		
India	Kapil U, Saxena N, Ramachandran S, Sharma TD, Nayar D. Status of iodine deficiency in selected blocks of Kangra District, Himachal Pradesh, Indian Pediatr. 1997; 34(4): 338-40 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1995		
India	Mittal M, Tandon M, Raghuvanshi RS. Iodine status of children and use of iodized salt in Tarai region of North India. J Trop Pediatr. 2000; 46(5): 300-2 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2000		
India	Brahmbhatt S, Brahmbhatt RM, Boyages SC. Thyroid ultrasound is the best prevalence indicator for assessment of iodine deficiency disorders: a study in rural/tribal schoolchildren from Gujarat (Western India). Eur J Endocrinol. 2000; 143(1): 37-46 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2000		
India	Sen S, Sen S, Mondal A, Dasgupta A, Chakraborty I. Prevalence of iodine deficiency disorders among schoolchildren in three blocks of Bardhaman District and Bardhaman Municipal area of West Bengal, India: a comparative study. Southeast Asian J Trop Med Public Health. 2005; 36(5): 1321-4 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2005		
India	Biswas AB, Chakraborty I, Das DK, Roy RN, Ray S, Kunti SK assessment of iodine deficiency disorders in Purulia district, West Bengal, India. J Trop Pediatr. 2006; 52(4): 288-92 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2005		
India	Joshi DC, Mishra VN, Bhatnagar M, Singh RB, Garg SK, Chopra H. Socioeconomic factors and prevalence of endemic goitre. Indian J Public Health. 1993; 37(2): 48-53 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1989-1990		
India	Mallik AK, Pandav CS, Achar DP, Anand K, Lobo J, Karmarkar MG, Nath LM. Iodine deficiency disorders in Car Nicobar (Andaman and Nicobar Islands). Nat Med J India. 1998; 11(1): 9-11 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1992-1993		
India	Patowary AC, Kumar S, Patowary S, Dhar P. Iodine deficiency disorders (IDD) and iodised salt in Assam: a few observations. Indian J Public Health. 1995; 39(4): 135-40 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1992-1993		
India	Zargar AH, Shah JA, Masoodi SR, Laway BA, Shah NA, Mir MM. Prevalence of goitre in school children in Baramulla (Kashmir valley). Indian J Pediatr. 1997; 64(2): 225-30 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1993		
India	Dodd NS, Samuel AM. Iodine deficiency in adolescents from Bombay slums. Nat Med J India. 1993; 6(3): 110-3 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1993		
India	Pandav CS, Mallik A, Anand K, Pandav S, Karmarkar MG. Prevalence of iodine deficiency disorders among school children of Delhi. Nat Med J India. 1997; 10(3): 112-4 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1994		
India	Kapil U, Saxena N, Ramachandran S, Balamurugan A, Nayar D, Prakash S assessment of iodine deficiency disorders using the 30 cluster approach in the National Capital Territory of Delhi. Indian Pediatr. 1996; 33(12): 1013-7 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1996		
India	Sohal KS, Sharma TD, Kapil U, Tandon M assessment of iodine deficiency disorders in district Hamirpur, Himachal Pradesh, Indian Pediatr. 1998; 35(10): 1008-11 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1996		
India	Kapil U, Sharma NC, Ramachandran S, Nayar D, Vashisht M. Iodine deficiency in district Kinnaur, Himachal Pradesh. Indian J Pediatr. 1998; 65(3): 451-3 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1996		
India	Sohal KS, Sharma TD, Kapil U, Tandon M. Current status of prevalence of goitre and iodine content of salt consumed in District Solan, Himachal Pradesh. Indian Pediatr. 1999; 36(12): 1253-6 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1997		
India	Kapil U, Ramachandran S, Tandon M assessment of iodine deficiency in Andaman district of Union Territory of Andaman and Nicobar. Indian J Matern Child Health. 1998; 19-20 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1997		
India	Kapil U, Ramachandran S, Tandon M assessment of iodine deficiency in Pondicherry. Indian Pediatr. 1998; 35(4): 357-9 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1997		
India	Kapil U, Singh JV, Tandon M, Pathak P, Singh C, Yadav R assessment of iodine deficiency disorders in Meerut district, Uttar Pradesh. Indian J Clin Nutr. 2000; 9(2): 99-101 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1997		
India	Kapil U, Saxena N, Ramachandran S, Nayar D. Iodine status of pregnant mothers residing in a district of endemic iodine deficiency in the state of Himachal Pradesh, India. Indian J Clin Nutr. 1997; 6(3): 224-5 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1997		
India	Toteja GS, Singh P, Dhillon BS, Saxena BN. Iodine deficiency disorders in 15 districts of India. Indian J Pediatr. 2004; 71(1): 25-8 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1997-2000		
India	Rao RSP, Kamath R, Das A, Nair NS, Keshavamurthy. Prevalence of goitre among school children in coastal Karnataka. Indian J Pediatr. 2002; 69(6): 477-9 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1998-1999		
India	Kapil U, Tandon M, Pradhan R, Pathak P. Status of iodine deficiency in selected hill districts of Uttar Pradesh- a pilot study. Indian J Matern Child Health. 1999; 24-7 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1998		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
India	Kapil U, Pathak P, Tandon M, Singh C, Pradhan R, Dwivedi SN. Micronutrient deficiency disorders amongst pregnant women in three urban slum communities of Delhi. Indian Pediatr. 1999; 36(10): 983-9 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1998		
India	Kapil U, Sohal KS, Sharma TD, Tandon M, Pathak P assessment of iodine deficiency disorders using the 30 cluster approach in district Kangra, Himachal Pradesh, India. J Trop Pediatr. 2000; 46(5): 264-6 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1999		
India	Kapil U, Jayakumar PR, Singh P, Aneja B, Pathak P assessment of iodine deficiency in Kottayam district, Kerala State: a pilot study Asia Pac J Clin Nutr. 2002; 11(1): 33-5 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1999		
India	Chandra AK, Ray I. Dietary supplies of iodine and thiocyanate in the etiology of endemic goiter in Tripura. Indian J Pediatr. 2001; 68(5): 399-404 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2001		
India	Bhasin SK, Kumar P, Dubey KK. Comparison of urinary iodine excretion and goiter survey to determine the prevalence of iodine deficiency. Indian Pediatr. 2001; 38(8): 901-5 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2001		
India	Biswas AB, Chakraborty I, Das DK, Biswas S, Nandy S, Mitra J. Iodine deficiency disorders among school children of Malda, West Bengal, India. J Health Popul Nutr. 2002; 20(2): 180-3 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2001		
India	Kapil U, Singh P, Pathak P, Singh C assessment of iodine deficiency disorders in district Bharatpur, Rajasthan. Indian Pediatr. 2003; 40(2): 147-9 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2002		
India	Kapil U, Sethi V, Goidind G, Pathak P, Singh P. Elimination of iodine deficiency disorders in Delhi. Indian J Pediatr. 2004; 71(3): 211-2 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2002		
India	Kapil U, Sharma TD, Singh P, Dwivedi SN, Kaur S. Thirty years of a ban on the sale of noniodized salt: impact on iodine nutrition in children in Himachal Pradesh, India. Food Nutr Bull. 2005; 26(3): 255-8 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2003		
India	Pradhan R, Choudhry M assessment of iodine deficiency disorders in urban areas of Udaipur District, Rajasthan. Indian Pediatr. 2003; 40(5): 406-9 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2003		
India	Biswas A, Chakraborty I, Das D, Roy R, Mukhopadhyay S, Chatterjee S. Iodine deficiency disorders among children of Birbhum, West Bengal. Curr Sci. 2004; 78-80 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2003		
India	Das DK, Chakraborty I, Biswas AB, Sarkar GN, Shrivastava P, Sen S. Iodine deficiency disorders among school children of Dakshin Dinajpur District, West Bengal. Indian J Public Health. 2005; 49(2): 68-72 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2003		
India	Pathak P, Singh P, Kapil U, Raghuvarshi RS. Prevalence of iron, vitamin A, and iodine deficiencies amongst adolescent pregnant mothers. Indian J Pediatr. 2003; 70(4): 299-301 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2003		
India	Chakraborty I, Chatterjee S, Bhadra D, Mukhopadhyaya BB, Dasgupta A, Purkait B. Iodine deficiency disorders among the pregnant women in a rural hospital of West Bengal. Indian J Med Res. 2006; 123(6): 825-9 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2003-2004		
India	World Health Organization Regional Office for South-East Asia (SEARO). Reported Cases of DF/DHF in Selected Countries in SEA Region. New Delhi, India: World Health Organization Regional Office for South-East Asia (SEARO).	1997-2001, 2003-2005		
India	World Health Organization Regional Office for South-East Asia (SEARO). Situation Update of Dengue in the SEA Region, 2010. New Delhi, India: World Health Organization Regional Office for South-East Asia (SEARO).	2006-2009		
India	Dhall K, Sarkar A, Sokhey C, Dhall GI, Ganguly NK. Incidence of gonococcal infection and its clinicopathological correlation in patients attending gynaecological outpatients department. J Obstet Gynaecol India. 1991; 40(3): 410-13.	1990		
India	Sharma VK, Khandpur S. Changing patterns of sexually transmitted infections in India. Natl Med J India. 2004; 17(6): 310-9.	2004		
India	Basavaraj P, Sunil MK, Nagarajappa R, Ashish S, Ramesh G. Correlation Between Oral Health and Child-OIDP Index in 12- and 15-Year-Old Children From Modinagar, India. Asia Pac J Public Health. 2013.	2011	*	
India	Das D, Misra J, Mitra M, Bhattacharya B, Bagchi A. Prevalence of dental caries and treatment needs in children in coastal areas of West Bengal. Contemp Clin Dent. 2013; 4(4): 482-7.	2010-2011	*	
India	Joshi N, Sujan S, Joshi K, Parekh H, Dave B. Prevalence, severity and related factors of dental caries in school going children of Vadodara City – an epidemiological study. J Int Oral Health. 2013; 5(4): 35-9.	2011	*	
India	Maru AM, Narendran S. Epidemiology of dental caries among adults in a rural area in India. J Contemp Dent Pract. 2012; 13(3): 382-8.	2010	*	
India	Shailee F, Girish MS, Kapil RS, Nidhi P. Oral health status and treatment needs among 12- and 15-year-old government and private school children in Shimla city, Himachal Pradesh, India. J Int Soc Prev Community Dent. 2013; 3(1): 44-50.	2009	*	
India	Sharda AJ, Sharda J, Mathur LK. Oral Health Behavior and its Relationship with Dental Caries Status and Periodontal Status among 12-13 Year Old School Children in Udaipur, India. Oral Health Dent Manag. 2013; 12(4): 237-42.	2011	*	
India	Srivastava R, Gupta SK, Mathur VP, Goswami A, Nongkynrih B. Prevalence of dental caries and periodontal diseases, and their association with socio-demographic risk factors among older persons in Delhi, India: a community-based study. Southeast Asian J Trop Med Public Health. 2013; 44(3): 523-33.	2009	*	
India	Suprabha BS, Rao A, Shenoy R, Khanal S. Utility of knowledge, attitude, and practice survey, and prevalence of dental caries among 11- to 13-year-old children in an urban community in India. Glob Health Action. 2013; 20750.	2011	*	
India	Murthy AK, Pramila M, Ranganath S. Prevalence of clinical consequences of untreated dental caries and its relation to dental fear among 12-15-year-old schoolchildren in Bangalore city, India. Eur Arch Paediatr Dent. 2014; 15(1): 45-9.	2012	*	
India	World Health Organization (WHO). Mental Illness in General Health Care: An International Study. Geneva, Switzerland: World Health Organization (WHO), 1995.	1991-1992		
India	WHO Regional Office for South-East Asia (SEARO). WHO South-East Asia Region: Reported Cases and Deaths of Dengue from 2003 to 2012. New Delhi, India: WHO Regional Office for South-East Asia (SEARO), 2013.	2003-2012	*	
India	Premalatha G, Shanthirani S, Deepa R, Markovitz J, Mohan V. Prevalence and risk factors of peripheral vascular disease in a selected South Indian population: the Chennai Urban Population Study. Diabetes Care. 2000; 23(9): 1295-300.	1996-2000		
India	Dandona R, Kumar GA, Ameer MA, Ahmed GM, Dandona L. Incidence and burden of road traffic injuries in urban India. Inj Prev. 2008; 14(6): 354-9.	2005-2006	*	
India	Dandona R, Kumar GA, Ameratunga S, Dandona L. Road use pattern and risk factors for non-fatal road traffic injuries among children in urban India. Injury. 2011; 42(1): 97-103.	2005-2006	*	
India	Mirkazemi R, Kar A. A population-based study on road traffic injuries in Pune City, India. Traffic Inj Prev. 2014; 15(4): 379-85.	2008-2009	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
India	Central TB Division, Directorate General of Health Services (India). India Revised National Tuberculosis Control Program Annual Report 2013. Central TB Division, Directorate General of Health Services (India), 2013.	2011-2012	*	
India	Flohr C, Weiland SK, Weinmayer G, Björkstén B, Bråbäck L, Brunekreef B, Bütchele G, Clausen M, Cookson WOC, von Mutius E, Strachan DP, Williams HC, ISAAC Phase Two Study Group. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. <i>J Allergy Clin Immunol.</i> 2008; 121(1): 141-147.	2005-2007	*	
India	Pao M, Kulkarni A, Gupta V, Kaul S, Balan S. Neonatal screening for glucose-6-phosphate dehydrogenase deficiency. <i>Indian J Pediatr.</i> 2005; 72(10): 835-7.	1998-2003	*	
India	Rath CP, Akki A, Patil SV, Kalyanshetkar SS. Seroprevalence of hepatitis A virus antibody in Bijapur, Karnataka. <i>Indian Pediatr.</i> 2011; 48(1): 71-3.	2006-2008	*	
India	Kumar SG, Premarajan KC, Subitha L, Suguna E, Vinayagamoorthy, Kumar V. Prevalence and Pattern of Alcohol Consumption using Alcohol Use Disorders Identification Test (AUDIT) in Rural Tamil Nadu, India. <i>J Clin Diagn Res.</i> 2013; 7(8): 1637-9.	2012	*	
India	Khuroo MS, Mahajan R, Zargar SA, Javid G, Sapru S. Prevalence of biliary tract disease in India: a sonographic study in adult population in Kashmir. <i>Gut.</i> 1989; 30(2): 201-5.	1987		
India	Sood A, Midha V, Sood N, Bhatia AS, Avasthi G. Incidence and prevalence of ulcerative colitis in Punjab, North India. <i>Gut.</i> 2003; 52(11): 1587-90.	2000		
India	Ghosh SK, Yadav RS, Das BS, Sharma VP. Influence of nutritional and haemoglobin status on malaria infection in children. <i>Indian J Pediatr.</i> 1995; 62(3): 321-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†
India	Arankalle VA, Tsarev SA, Chadha MS, Ailing DW, Emerson SU, Banerjee K, Purcell RH. Age-specific prevalence of antibodies to hepatitis A and E viruses in Pune, India, 1982 and 1992. <i>J Infect Dis.</i> 1995; 171(2): 447-50.	1982, 1992		
India	Chitambar SD, Chadha MS, Joshi MS, Arankalle VA. Prevalence of hepatitis A antibodies in western Indian population: changing pattern. <i>Southeast Asian J Trop Med Public Health.</i> 1999; 30(2): 273-6.	1983, 1987, 1995		
India	Werner GT, Frosner GG, Sareen DK. Prevalence of hepatitis A, B and HIV markers in Punjab. <i>J Indian Med Assoc.</i> 1990; 88(10): 293-4.	1986-1988		
India	Graham DY, Adam E, Reddy GT, Agarwal JP, Agarwal R, Evans DJ Jr, Malaty HM, Evans DG. Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. <i>Dig Dis Sci.</i> 1991; 36(8): 1084-8.	1988-1990		
India	Chadha MS, Chitambar SD, Shaikh NJ, Arankalle VA. Exposure of Indian children to hepatitis A virus & vaccination age. <i>Indian J Med Res.</i> 1999; 11-5.	1991-1995		
India	Thapa BR, Singh K, Singh V, Broor S, Singh V, Nain CK. Pattern of hepatitis A and hepatitis B virus markers in cases of acute sporadic hepatitis and in healthy school children from north west India. <i>J Trop Pediatr.</i> 1995; 41(6): 328-9.	1995		
India	Dhawan PS, Shah SS, Alvares JF, Kher A, Shankaran, Kandoth PW, Sheth PN, Kamath H, Kamath A, Koppikar GV, Kalro RH. Seroprevalence of hepatitis A virus in Mumbai, and immunogenicity and safety of hepatitis A vaccine. <i>Indian J Gastroenterol.</i> 1998; 17(1): 16-8.	1995-1996		
India	Das K, Kar P, Chakraborty A, Gupta S, Das BC. Is a vaccination program against hepatitis A needed in India? <i>Indian J Gastroenterol.</i> 1998; 17(4): 158.	1995-1996		
India	Mittal SK, Rastogi A, Rastogi A, Kumar N, Talukdar B, Kar P. Seroprevalence of hepatitis A in children—implications for hepatitis A vaccine. <i>Trop Gastroenterol.</i> 1998; 19(3): 120-1.	1997		
India	Acharya SK, Batra Y, Bhatkal B, Ojha B, Kaur K, Hazari S, Saraya A, Panda SK. Seroepidemiology of hepatitis A virus infection among school children in Delhi and north Indian patients with chronic liver disease: implications for HAV vaccination. <i>J Gastroenterol Hepatol.</i> 2003; 18(7): 822-7.	1997-2001		
India	Aggarwal R, Naik S, Yachha SK, Naik SR. Seroprevalence of antibodies to hepatitis A virus among children in Northern India. <i>Indian Pediatr.</i> 1999; 36(12): 1248-50.	1998		
India	Mall ML, Rai RR, Philip M, Naik G, Parekh P, Bhawanani SC, Olowokure B, Shamanna M, Weil J. Seroepidemiology of hepatitis A infection in India: changing pattern. <i>Indian J Gastroenterol.</i> 2001; 20(4): 132-5.	1998		
India	Arankalle VA, Chadha MS, Chitambar SD, Walimbe AM, Chobe LP, Gandhe SS. Changing epidemiology of hepatitis A and hepatitis E in urban and rural India (1982-98). <i>J Viral Hepat.</i> 2001; 8(4): 293-303.	1998		
India	Das PK, Harris VK, Shoma B, Bose YN, Annie S. Trend of hepatitis B virus infection in southern Indian blood donors. <i>Indian J Gastroenterol.</i> 1999; 18(4): 182.	1986-1999		
India	Anand AC, Nagpal AK, Seth AK, Dhot PS. Should one vaccinate patients with chronic liver disease for hepatitis A virus in India? <i>J Assoc Physicians India.</i> 2004; 785-7.	1998		
India	Dutta AK, Aggarwal A, Kapoor AK, Ray GN, Batra S. Seroepidemiology of hepatitis A in Delhi. <i>Indian J Pediatr.</i> 2000; 67(2): 77-9.	1999		
India	Joshi N, Yr NK, Kumar A. Age related seroprevalence of antibodies to hepatitis A virus in Hyderabad, India. <i>Trop Gastroenterol.</i> 2000; 21(2): 63-5.	1999		
India	Batra Y, Bhatkal B, Ojha B, Kaur K, Saraya A, Panda SK, Acharya SK. Vaccination against hepatitis A virus may not be required for schoolchildren in northern India: results of a seroepidemiological survey. <i>Bull World Health Organ.</i> 2002; 80(9): 728-31.	2001		
India	Ramachandran J, Eapen CE, Kang G, Abraham P, Hubert DDD, Kurian G, Hepzibah J, Mukhopadhyaya A, Chandy GM. Hepatitis E superinfection produces severe decompensation in patients with chronic liver disease. <i>J Gastroenterol Hepatol.</i> 2004; 19(2): 134-8.	2001-2002		
India	Gadgil PS, Fadnis RS, Joshi MS, Rao PS, Chitambar SD. Seroepidemiology of hepatitis A in voluntary blood donors from Pune, western India (2002 and 2004-2005). <i>Epidemiol Infect.</i> 2008; 136(3): 406-9.	2002, 2004-2005		
India	Xavier S, Anish K. Is hepatitis A vaccination necessary in Indian patients with cirrhosis of liver? <i>Indian J Gastroenterol.</i> 2003; 22(2): 54-5.	2002		
India	Pattanayak, Ipsa. Distribution of A1A2B0 and Rh Blood Groups Among the Rajputs of Uttaranchal. <i>Anthropologist.</i> 2006; 8(2): 139-40.	2003-2005	*	†
India	Das PK, Nair SC, Harris VK, Rose D, Mammen JJ, Bose YN, Sudarsanam A. Distribution of ABO and Rh-D blood groups among blood donors in a tertiary care centre in South India. <i>Trop Doct.</i> 2001; 31(1): 47-8.	1988-1999	*	†
India	Chaudhuri S, Mukherjee B, Roy Choudhury AK, Ghosh J. Study of blood groups and haemoglobin variants of the sikhs in Calcutta. <i>J Hered.</i> 1967; 58(5): 213-4.	1963-1965	*	†
India	Lattoo JA, Masoodi NA, Bhat NA, Khan GQ, Kadla SA. The ABO and Rh Blood groups in Kashmiri Population. <i>Indian J Pract Dr.</i> 2006; 3(2).	1988-2000	*	†
India	Bhat AW, Churoo BA, Iqbal Q, Sheikh MA, Iqbal J, Aziz R. Complication of exchange transfusion at a tertiary care hospital. <i>Curr Pediatr Res.</i> 2011; 15(2): 97-9.	2008	*	†
India	Girish G, Chawla D, Agarwal R, Paul VK, Deorari AK. Efficacy of two dose regimes of intravenous immunoglobulin in Rh hemolytic disease of newborn—a randomized controlled trial. <i>Indian Pediatr.</i> 2008; 45(8): 653-9.	2005-2006	*	†
India	Shekeeb Shahab M, Kumar P, Sharma N, Narang A, Prasad R. Evaluation of oxidant and antioxidant status in term neonates: a plausible protective role of bilirubin. <i>Mol Cell Biochem.</i> 2008; 317(1-2): 51-9.	2005-2007	*	†
India	Mehta S, Kumar P, Narang A. A randomized controlled trial of fluid supplementation in term neonates with severe hyperbilirubinemia. <i>J Pediatr.</i> 2005; 147(6): 781-5.	2002-2004	*	†
India	Ahmad N, Bhopal R. Is coronary heart disease rising in India? A systematic review based on ECG defined coronary heart disease. <i>Heart.</i> 2005; 91(6): 719-725.	1990-1991		
India	Gupta SP, Khetrapsul NK. Incidence of acute myocardial infarction and sudden coronary death in Rohtak City. <i>J Assoc Physicians India.</i> 1981; 29(5): 365-72.	1977-1980		
India	Banerjee A, Chakravarty R, Mondal PN, Chakraborty MS. Hepatitis B virus genotype D infection among antenatal patients attending a maternity hospital in Calcutta, India: assessment of infectivity status. <i>Southeast Asian J Trop Med Public Health.</i> 2005; 36(1): 203-6.	1998		
India	Bhalla P, Garg S, Kakkar M, Sharma VK. Community-based study of hepatitis B markers in women of reproductive age. <i>Indian J Gastroenterol.</i> 2003; 22(1): 33-4.	1996-2000		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
India	Bhattacharya P, Chandra P-K, Datta S, Banerjee A, Chakraborty S, Rajendran K, Basu S-K, Bhattacharya S-K, Chakravarty R. Significant increase in HBV, HCV, HIV and syphilis infections among blood donors in West Bengal, Eastern India 2004-2005: exploratory screening reveals high frequency of occult HBV infection. <i>World J Gastroenterol.</i> 2007; 13(27): 3730-3.	2004-2005		
India	Chaudhuri V, Namu A, Panda SK, Chand P. Evaluation of serologic screening of blood donors in India reveals a lack of correlation between anti-HBc titer and PCR-amplified HBV DNA. <i>Transfusion.</i> 2003; 43(10): 1442-8.	2001		
India	Choudhury N, Ramesh V, Saraswat S, Naik S. Effectiveness of mandatory transmissible diseases screening in Indian blood donors. <i>Indian J Med Res.</i> 1995; 229-32.	1993		
India	Chowdhury A, Santra A, Chakravorty R, Banerji A, Pal S, Dhali GK, Datta S, Banerji S, Manna B, Chowdhury SR, Bhattacharya SK, Mazumder DG. Community-based epidemiology of hepatitis B virus infection in West Bengal, India: prevalence of hepatitis B e antigen-negative infection and associated viral variants. <i>J Gastroenterol Hepatol.</i> 2005; 20(11): 1712-20.	2001-2002		
India	Ganju SA, Goel A. Sero-surveillance of HIV, HBV and HCV infections in antenatal and STD clinic attendees. <i>J Commun Dis.</i> 2004; 36(1): 60-2.	1998-1999		
India	Garg S, Mathur DR, Garg DK. Comparison of seropositivity of HIV, HBV, HCV and syphilis in replacement and voluntary blood donors in western India. <i>Indian J Pathol Microbiol.</i> 2001; 44(4): 409-12.	1994-1999		
India	Gupta N, Kumar V, Kaur A. Seroprevalence of HIV, HBV, HCV and syphilis in voluntary blood donors. <i>Indian J Med Sci.</i> 2004; 58(6): 255-7.	2001-2003		
India	Jain DC, Jain RK, Ichhpujani RL, Sharma RS. Prevalence of hepatitis B virus in pregnant women. <i>J Commun Dis.</i> 1994; 26(4): 233-4.	1992		
India	Jain RC, Soni SB. Detection of HBsAg and HIV carriage among blood donors or rural population of Loni areas. <i>J Assoc Physicians India.</i> 1995; 43(5): 378.	1993-1994		
India	Kakkar N, Kaur R, Dhanoo J. Voluntary donors-need for a second look. <i>Indian J Pathol Microbiol.</i> 2004; 47(3): 381-3.	2001-2003		
India	Kapur S, Mittal A. Incidence of HIV infection & its predictors in blood donors in Delhi. <i>Indian J Med Res.</i> 1998; 45-50.	1989-1997		
India	Kothari A, Ramachandran VG, Gupta P, Singh B, Talwar V. Seroprevalence of cytomegalovirus among voluntary blood donors in Delhi, India. <i>J Health Popul Nutr.</i> 2002; 20(4): 348-51.	2000		
India	Kumar D, Arora A, Singh NP, Kohli R, Kar P, Das BC. Hepatitis G virus infection in hemodialysis patients from urban Delhi. <i>Ren Fail.</i> 2005; 27(1): 87-93.	2003		
India	Kumar H, Gupta PK, Jaiprakash M. The Role of anti-HBc IgM in Screening of Blood Donors. <i>Med J Armed Forces India.</i> 2007; 63(4): 350-2.	2005		
India	Kurien T, Thyagarajan SP, Jeyaseelan L, Peedicayil A, Rajendran P, Sivaram S, Hansdak SG, Renu G, Krishnamurthy P, Sudhakar K, Varghese JC, STD Study Group. Community prevalence of hepatitis B infection and modes of transmission in Tamil Nadu, India. <i>Indian J Med Res.</i> 2005; 121(5): 670-5.	1998		
India	Makroo RN, Hassain G, Koul A, Shah GN. Prevalence of hepatitis B surface antigen in Kashmiri blood donors. <i>Indian J Med Res.</i> 1989; 310-3.	1985-1989		
India	Murhekar MV, Murhekar KM, Das D, Arankalle VA, Sehgal SC. Prevalence of hepatitis B infection among the primitive tribes of Andaman & Nicobar Islands. <i>Indian J Med Res.</i> 2000; 199-203.	1998-1999		
India	Murhekar MV, Murhekar KM, Sehgal SC. Age-specific prevalence of hepatitis B infection among the Karen in the Andaman and Nicobar Islands, India. <i>Trop Doct.</i> 2004; 34(2): 117-8.	2002		
India	Murhekar MV, Murhekar KM, Sehgal SC. Seroepidemiology of hepatitis B infection among tribal school children in Andaman and Nicobar Islands, India. <i>Ann Trop Paediatr.</i> 2004; 24(1): 85-8.	2002		
India	Nandi J, Bhawalkar V, Mody H, Elavia A, Desai PK, Banerjee K. Detection of HIV-1, HBV and HCV antibodies in blood donors from Surat, western India. <i>Vox Sang.</i> 1994; 67(4): 406-7.	1992		
India	Pahuja S, Sharma M, Baita B, Jain M. Prevalence and trends of markers of hepatitis C virus, hepatitis B virus and human immunodeficiency virus in Delhi blood donors: a hospital based study. <i>Jpn J Infect Dis.</i> 2007; 60(6): 389-91.	2002-2005		
India	Qamer S, Shahab T, Alam S, Malik A, Afzal K. Age-specific prevalence of hepatitis B surface antigen in pediatric population of Aligarh, North India. <i>Indian J Pediatr.</i> 2004; 71(11): 965-7.	2002-2003		
India	Sandesh K, Varghese T, Harikumar R, Beena P, Sasidharan VP, Bindu CS, Tony J, Harish K, Sunilkumar K, Ramachandran TM. Prevalence of Hepatitis B and C in the normal population and high risk groups in north Kerala. <i>Trop Gastroenterol.</i> 2006; 27(2): 80-3.	2002-2004		
India	Satoskar A, Ray V. Prevalence of hepatitis B surface antigen (HBsAg) in blood donors from Bombay. <i>Trop Geogr Med.</i> 1992; 44(1-2): 119-21.	1990		
India	Sawaithul VK, Ukey PM, Bobhate SK. Prevalence of HIV infection among persons attending voluntary counseling and testing center, Nagpur. <i>Biomed Res.</i> 2006; 201-4.	2004		
India	Sharma RR, Cheema R, Vajpayee M, Rao U, Kumar S, Marwaha N, Agnihotri SK. Prevalence of markers of transfusion transmissible diseases in voluntary and replacement blood donors. <i>Natl Med J India.</i> 2004; 17(1): 19-21.	1996-2002		
India	Singh H, Aggarwal R, Singh RL, Naik SR, Naik S. Frequency of infection by hepatitis B virus and its surface mutants in a northern Indian population. <i>Indian J Gastroenterol.</i> 2003; 22(4): 132-7.	2002		
India	Singhvi A, Pulmood RB, John TJ, Babu PG, Samuel BU, Padankatti T, Carman RH. The prevalence of markers for hepatitis B and human immunodeficiency viruses, malarial parasites and microfilaria in blood donors in a large hospital in south India. <i>J Trop Med Hyg.</i> 1990; 93(3): 178-82.	1986-1988		
India	Sonwane BR, Birare SD, Kulkarni PV. Prevalence of seroreactivity among blood donors in rural population. <i>Indian J Med Sci.</i> 2003; 57(9): 405-7.	1996-2001		
India	Thakur TS, Goyal A, Sharma V, Gupta ML, Singh S. Incidence of australian antigen (HBs Ag) in Himachal Pradesh. <i>J Commun Dis.</i> 1990; 22(3): 173-7.	1987-1989		
India	Thakur TS, Sharma V, Goyal A, Gupta ML. Seroprevalence of HIV antibodies, Australia antigen and VDRL reactivity in Himachal Pradesh. <i>Indian J Med Sci.</i> 1991; 45(12): 332-5.	1987-1990		
India	Beuria MK, Bal MS, Mandal NN, Das MK. Age-dependent prevalence of asymptomatic amicrofilaraemic individuals in a Wuchereria bancrofti-endemic region of India. <i>Trans R Soc Trop Med Hyg.</i> 2003; 97(3): 297-8. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2001	*	
India	Chand G, Pandey GD, Tiwary RS. Prevalence of Wuchereria bancrofti infection among the tribals of Panna district of Madhya Pradesh. <i>J Commun Dis.</i> 1996; 28(4): 304-7. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1992-1993	*	
India	Das VNR, Siddiqui NA, Kumar N, Verma N, Verma RB, Dinesh DS, Kar SK, Das P. A pilot study on the status of lymphatic filariasis in a rural community of Bihar. <i>J Commun Dis.</i> 2006; 38(2): 169-75. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2000-2012	*	
India	Dixit V, Kurup AV, Gupta AK, Kataria OM, Prasad GB. Bancroftian filariasis in south east Madhya Pradesh: Pre-control epidemiological observations. <i>Indian J Clin Biochem.</i> 1997; 12(Suppl 1): 39-43. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1980-2000	*	
India	Mukhopadhyay AK, Patnaik SK. Effect of mass drug administration programme on microfilaria carriers in East Godavari district of Andhra Pradesh. <i>J Vector Borne Dis.</i> 2007; 44(4): 277-80. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2006	*	
India	Mukhopadhyay AK. Lymphatic filariasis in Andhra Pradesh Paper Mill Colony, Rajahmundry, India after nine rounds of MDA programme. <i>J Vector Borne Dis.</i> 2010; 47(1): 55-7. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2009	*	
India	Murty US, Praveen B, Kumar DVRS, Sriram K, Rao KM, Sai KSK. A baseline study of rural Bancroftian filariasis in southern India. <i>Southeast Asian J Trop Med Public Health.</i> 2004; 35(3): 583-6. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1999-2001	*	
India	Rajagopalan PK, Das PK, Subramanian S, Vanamail P, Ramaiah KD. Bancroftian filariasis in Pondicherry, south India: 1. Pre-control epidemiological observations. <i>Epidemiol Infect.</i> 1989; 103(3): 685-92. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1981	*	
India	Ramaiah KD, Ramu K, Kumar KNV, Guyatt H. Epidemiology of acute filarial episodes caused by Wuchereria bancrofti infection in two rural villages in Tamil Nadu, south India. <i>Trans R Soc Trop Med Hyg.</i> 1996; 90(6): 639-43. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1980-2000	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
India	Ramaiah KD, Vanamail P, Das PK. Changes in Wuchereria bancrofti infection in a highly endemic community following 10 rounds of mass administration of diethylcarbamazine. <i>Trans R Soc Trop Med Hyg.</i> 2007; 101(3): 250-5. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1994, 1996, 1998, 2000, 2002, 2004	*	
India	Ravindran B, Sahoo PK, Dash AP. Lymphatic filariasis and malaria: concomitant parasitism in Orissa, India. <i>Trans R Soc Trop Med Hyg.</i> 1998; 92(1): 21-3. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1994	*	†
India	Ravindran B, Sahoo PK, Dash AP. Lymphatic filariasis and malaria: concomitant parasitism in Orissa, India. <i>Trans R Soc Trop Med Hyg.</i> 1998; 92(1): 21-3 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
India	Sarma RV, Vallishayee RS, Mayurmath S, Narayanan PR, Radhamani MP, Tripathy SP. Prevalence survey of filariasis in two villages in Chingleput district of Tamil Nadu. <i>Indian J Med Res.</i> 1987; 522-30. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1982-1983	*	
India	Shriram AN, Sugunan AP, Murhekar MV, Sehgal SC. Little Andaman Island, a new focus of infection with nocturnally periodic Wuchereria bancrofti. <i>Indian J Med Res.</i> 1996; 166-70. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1994	*	
India	Subramanian S, Pani SP, Das PK, Rajagopalan PK. Bancroftian filariasis in Pondicherry, south India: 2. Epidemiological evaluation of the effect of vector control. <i>Epidemiol Infect.</i> 1989; 103(3): 693-702. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1986	*	
India	Tewari SC, Hiriyani J, Reuben R. Epidemiology of subperiodic Wuchereria bancrofti infection in the Nicobar Islands, India. <i>Trans R Soc Trop Med Hyg.</i> 1995; 89(2): 163-6. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1993	*	
India	Zargar AH, Wani AI, Masoodi SR, Laway BA, Salahuddin M. Epidemiologic and etiologic aspects of primary infertility in the Kashmir region of India. <i>Fertil Steril.</i> 1997; 68(4): 637-43.	1995-1997	*	
India	India Programme to Eliminate Lymphatic Filariasis Country Report 2004 as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2004	*	
India	Flohr C, Weimayr G, Weiland SK, Addo-Yobo E, Annesi-Maesano I, Björkstén B, Bräbäck L, Büchele G, Chico M, Cooper P, Clausen M, El Sharif N, Martinez Gimeno A, Mathur RS, von Mutius E, Morales Suarez-Varela M, Pearce N, Svabe V, Wong GWK, Yu M, Zhong NS, Williams HC, ISAAC Phase Two Study Group. How well do questionnaires perform compared with physical examination in detecting flexural eczema? Findings from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. <i>Br J Dermatol.</i> 2009; 161(4): 846-53.	2005-2007	*	
India	Singh G, Singh P, Singh I, Rani A, Kaushal S, Avasthi G. Epidemiologic classification of seizures associated with neurocysticercosis: observations from a sample of seizure disorders in neurologic care in India. <i>Acta Neurol Scand.</i> 2006; 113(4): 233-40.	1995-2001		
India	India - Mumbai Contributory Health Service Scheme Stroke Dataset 2013, as provided Global Burden of Disease 2013 Stroke Experts. [Unpublished].	2013	*	
India	Vas CJ, Pinto C, Panikker D, Noronha S, Deshpande N, Kulkarni L, Sachdeva S. Prevalence of Dementia in an Urban Indian Population. <i>Int Psychogeriatr.</i> 2001; 13(04): 439-50.	1988-1991		
India	Bhatia JC, Cleland J, Bhagavan L, Rao N. Levels and determinants of gynecological morbidity in a district of south India. <i>Stud Fam Plann.</i> 1997; 28(2): 95-103.	1994	*	
India	Indian Council of Medical Research (ICMR). India - National Institute for Research in Reproductive Health Annual Technical Report 2007-2008.	2006-2007	*	
India	Straughn HK, Goldenberg RL, Tolosa JE, Daly S, de Codes J, Festin MR, Limpongsanurak S, Lumbiganon P, Paul VK, Peedicyail A, Purwar M, Sabogal JC, Shenoy S. Birthweight-specific neonatal mortality in developing countries and obstetric practices. <i>Int J Gynaecol Obstet.</i> 2003 Jan;80(1):71-8.	2003		†
India	Ansari M, Sharma Y, Roy A, Biswas S, Sharma P. Epidemiologic investigations of a malaria outbreak in northern Delhi area. <i>J Am Mosq Control Assoc.</i> 2001; 17(4): 216-20 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
India	Barutwanayo M, Coosemans M, Delacollette C, Bisore S, Mpitabakana P, Seruzingo D. [Campaign against malaria vectors in the framework of a rural development project in Burundi]. <i>Ann Soc Belg Med Trop.</i> 1990; 71(Suppl 1): 113-25 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
India	Biswas S, Seth RK, Tyagi PK, Sharma SK, Dash AP. Naturally Acquired Immunity and Reduced Susceptibility to falciparum Malaria in Two Subpopulations of Endemic Eastern India. <i>Scand J Immunol.</i> 2008; 67(2): 177-84 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	2002-2003	*	†
India	Chand G, Roy SK, Tiwary RS. Malaria epidemic in Lamta PHC of Balaghat district – a rice cultivating ecosystem. <i>J Commun Dis.</i> 1997; 29(2): 179-81 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
India	Das NG, Bhuyan M, Das SC. Entomological and epidemiological studies on malaria in Rajmahal range, Bihar. <i>Indian J Malariol.</i> 2000; 37(3/4): 88-96 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
India	Das PK, Das LK, Parida SK, Patra KP, Jambulingam P. Lambda-deltacyhalothrin treated bed nets as an alternative method of malaria control in tribal villages of Koraput District, Orissa State, India. <i>Southeast Asian J Trop Med Public Health.</i> 1993; 24(3): 513-21 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1989-1991		†
India	Dev V. Malaria survey in Tarajuli tea estate and adjoining hamlets in Sonitpur District, Assam. <i>Indian J Malariol.</i> 1996; 33(1): 21-9 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
India	Dev V, Phookan S, Sharma VP, Dash AP, Anand SP. Malaria parasite burden and treatment seeking behavior in ethnic communities of Assam, Northeastern India. <i>J Infect.</i> 2006; 52(2): 131-9 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1991-1993	*	†
India	Dev V, Raghavendra K, Barman K, Phookan S, Dash AP. Wash-resistance and field efficacy of Olyset net, a permethrin-incorporated long-lasting insecticidal netting, against Anopheles minimus-transmitted malaria in Assam, Northeastern India. <i>Vector Borne Zoonotic Dis.</i> 2010; 10(4): 403-10 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
India	Dubey ML, Sharma SK, Ganguly NK, Mahajan RC. Seroepidemiological study of malaria in a rural population of Chandigarh. <i>Indian J Malariol.</i> 1989; 26(4): 187-90 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1987-1988	*	†
India	Joshi H, Subbarao SK, Valecha N, Sharma VP. Ahaptoglobinemia (HpO) and malaria in India. <i>Indian J Malariol.</i> 2002; 39(1-2): 1-12 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
India	Khan MM, Kareem MA, Rao GK. Laboratory diagnosis of malaria infection and its natural history in an urban pocket of Hyderabad City. <i>Indian J Malariol.</i> 1989; 26(4): 215-8 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
India	Mohapatra PK, Narain K, Prakash A, Bhattacharyya DR, Mahanta J. Risk factors of malaria in the fringes of an evergreen monsoon forest of Arunachal Pradesh. <i>Natl Med J India.</i> 2001; 14(3): 139-42 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
India	Mohapatra PK, Prakash A, Bhattacharyya DR, Mahanta J. Epidemiological importance of younger age group during malaria epidemic in PHC Tamulpur, Assam. <i>J Commun Dis.</i> 1998; 30(4): 229-32 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
India	Mukhopadhyay AK, Hati AK, Dey P. Malarionogenic situations in areas of Aiodhya hills of the district Purulia West Bengal and its present status. Indian J Public Health. 2001; 45(1): 31-2 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
India	Pasricha S-R, Black J, Muthayya S, Shet A, Bhat V, Nagaraj S, Prashanth NS, Sudarshan H, Biggs B-A, Shet AS. Determinants of anemia among young children in rural India. Pediatrics. 2010; 126(1): e140-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008	*	†
India	Prakash A, Mohapatra PK, Bhattacharyya DR, Doloi P, Mahanta J. Changing malaria endemicity – a village based study in Sonitpur, Assam. J Commun Dis. 1997; 29(2): 175-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
India	Roy A, Ansari MA, Kabilan L. A longitudinal study of sero-reactivity to Plasmodium falciparum antigen in children and adult living in an endemic area of U.P.. Indian J Malariol. 1998; 35(2): 48-56 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
India	Roy A, Ansari MA, Biswas S, Kabilan L. Comparison of parasitological and serological data in evaluating malaria. J Commun Dis. 1997; 29(1): 63-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992-1993	*	†
India	Roy A, Tyagi P, Sharma SK. Serological appraisal of malaria status in tribal area of Orissa, India. Indian J Malariol. 2001; 38(3-4): 84-90 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
India	Shukla RP, Sharma SN, Bhat SK. Malaria outbreak in Bhojpur PHC of district Moradabad, Uttar Pradesh, India. J Commun Dis. 2002; 34(2): 118-23 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000	*	†
India	Srivastava HC, Yadav RS. Malaria outbreak in a tribal area of Gujarat state, India. Southeast Asian J Trop Med Public Health. 2000; 31(2): 219-24 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
India	Subbarao SK, Vasantha K, Raghavendra K, Sharma VP, Sharma GK. Anopheles culicifacies: siblings species composition and its relationship to malaria incidence. J Am Mosq Control Assoc. 1988; 4(1): 29-33 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
India	India Birth Defects Registry Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
India	India Birth Defects Registry Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
India	India Birth Defects Registry Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
India	India Plasmodium Falciparum Parasite Rate Data, Personal Communication with S.K. Sharma 2006 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
India	India Plasmodium Falciparum Parasite Rate Data, Personal Communication with S.K. Sharma 2008 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006-2007	*	†
Indonesia	Indonesia National Socioeconomic Survey 1964-1965 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1964		
Indonesia	Central Bureau of Statistics (Indonesia), International Statistical Institute. Indonesia World Fertility Survey 1976. Voorburg, Netherlands: International Statistical Institute.	1976		
Indonesia	Central Bureau of Statistics (Indonesia), National Family Planning Coordinating Board (Indonesia), Westinghouse; Institute for Resource Development. Indonesia Demographic and Health Survey 1987. Columbia, United States: Westinghouse; Institute for Resource Development.	1987		
Indonesia	Central Bureau of Statistics (Indonesia), Macro International, Inc, Ministry of Health (Indonesia), National Family Planning Coordinating Board (Indonesia). Indonesia Demographic and Health Survey 1991. Calverton, United States: Macro International, Inc.	1991		†
Indonesia	Central Bureau of Statistics (Indonesia), Macro International, Inc, Ministry of Health (Indonesia), National Family Planning Coordinating Board (Indonesia). Indonesia Demographic and Health Survey 1994. Calverton, United States: Macro International, Inc.	1994		†
Indonesia	Central Bureau of Statistics (Indonesia), Macro International, Inc, Ministry of Health (Indonesia), National Family Planning Coordinating Board (Indonesia). Indonesia Demographic and Health Survey 1997. Calverton, United States: Macro International, Inc.	1997		†
Indonesia	Macro International, Inc, Ministry of Health (Indonesia), National Family Planning Coordinating Board (Indonesia), Statistics Indonesia. Indonesia Demographic and Health Survey 2002-2003. Calverton, United States: Macro International, Inc.	2002-2003		†
Indonesia	Macro International, Inc, Ministry of Health (Indonesia), National Family Planning Coordinating Board (Indonesia), Statistics Indonesia. Indonesia Demographic and Health Survey 2007. Calverton, United States: Macro International, Inc.	2007		†
Indonesia	Statistics Indonesia, Ministry of Health (Indonesia), United Nations Children's Fund (UNICEF). Indonesia Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	
Indonesia	Minnesota Population Center, Statistics Indonesia. Indonesia Intercensal Population Survey 2005 from the Integrated Public Use Microdata Series, International. [Machine-readable database]. Minneapolis: University of Minnesota, 2012.	2005	*	
Indonesia	ICF International, Ministry of Health (Indonesia), National Population and Family Planning Board (Indonesia), Statistics Indonesia. Indonesia Demographic and Health Survey 2012. Fairfax, United States: ICF International, 2013.	2012	*	†
Indonesia	National Institute of Health Research and Development (NIHRD), Ministry of Health (Indonesia), World Health Organization (WHO). Indonesia WHO Multi-country Survey Study on Health and Health System Responsiveness 2001.	2000-2001		
Indonesia	Humphrey JH, Agoestina T, Wu L, Usman A, Nurachim M, Subardja D, Hidayat S, Tielsch J, West KP Jr, Sommer A. Impact of neonatal vitamin A supplementation on infant morbidity and mortality. J Pediatr. 1996; 128(4): 489-96.	1992-1993	*	
Indonesia	Dibley MJ, Sadjimin T, Kjolhede CL, Moulton LH. Vitamin A supplementation fails to reduce incidence of acute respiratory illness and diarrhea in preschool-age Indonesian children. J Nutr. 1996; 126(2): 434-42.	1989-1990		
Indonesia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Indonesia	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Indonesia	Gessner BD, Sutanto A, Linehan M, Djelantik IG, Fletcher T, Gerudug IK, Ingerani, Mercer D, Moniaga V, Moulton LH, Moulton LH, Mulholland K, Nelson C, Soemohardjo S, Steinhoff M, Widjaya A, Stoeckel P, Maynard J, Arjoso S. Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Lancet. 2005; 365(9453): 43-52.	1998-2002		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Indonesia	Saw SM, Koh D, Adjani MR, Wong ML, Hong CY, Lee J, Chia SE, Munoz CP, Ong CN. A population-based prevalence survey of skin diseases in adolescents and adults in rural Sumatra, Indonesia, 1999. <i>Trans R Soc Trop Med Hyg.</i> 2001; 95(4): 384-8.	1999		
Indonesia	Aceh Epidemiology Group. Outbreak of tetanus cases following the tsunami in Aceh Province, Indonesia. <i>Glob Public Health.</i> 2006; 1(2): 173-7.	2004-2005		
Indonesia	Lee J, Koh D, Adjani M, Saw SM, Munoz C, Chia SE, Wong ML, Hong CY, Ong CN. Effluents from a pulp and paper mill: a skin and health survey of children living in upstream and downstream villages. <i>Occup Environ Med.</i> 2002; 59(6): 373-9.	1999		
Indonesia	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol.</i> 2008; 121(4): 947-954.	1996, 2002		
Indonesia	Robertson SE, Roca A, Alonso P, Simoes EAF, Kartasasmita CB, Olalaye DO, Odaibo GN, Collinson M, Venter M, Yuwei Zhu, Wright PF. Respiratory syncytial virus infection: denominator-based studies in Indonesia, Mozambique, Nigeria and South Africa. <i>Bull World Health Organ.</i> 2004; 12(82): 914-22.	1987-2001		
Indonesia	Putnam SD, Sedyaningsih ER, Listiyaningsih E, Palungsih SP, Komalarini, Soenarto Y, Salim OC, Subekti D, Riddle MS, Burgess TH, Blair PJ. Group A rotavirus-associated diarrhoea in children seeking treatment in Indonesia. <i>J Clin Virol.</i> 2007; 40(4): 289-94.	2004-2005		
Indonesia	Soenarto Y, Aman AT, Bakri A, Waluya H, Firmansyah A, Kadim M, Martiza I, Prasetyo D, Mulyani NS, Widowati T, Soetjningsih, Karyana IPG, Sukardi W, Bressee J, Widdowson M-A. Burden of severe rotavirus diarrhoea in Indonesia. <i>J Infect Dis.</i> 2009; 200 Suppl 1: 188-194.	2006		
Indonesia	Von Seidlein L, Kim DR, Ali M, Lee H, Wang X, Thiem VD, Canh DG, Chaicumpa W, Agtini MD, Hossain A, Bhutta ZA, Mason C, Sethabou O, Talukder K, Nair GB, Deen JL, Kotloff K, Clemens J. A Multicentre Study of Shigella Diarrhoea in Six Asian Countries: Disease Burden, Clinical Manifestations, and Microbiology. <i>PLoS Med.</i> 2006; 3(9): e353.	2001-2003		
Indonesia	Adisasmita A, Deviany PE, Nandiati F, Stanton C, Ronsmans C. Obstetric near miss and deaths in public and private hospitals in Indonesia. <i>BMC Pregnancy Childbirth.</i> 2008; 8(10): 10.	2003-2004		
Indonesia	Ronsmans C, Scott S, Adisasmita A, Deviany P, Nandiati F. Estimation of population-based incidence of pregnancy-related illness and mortality (PRIAM) in two districts in West Java, Indonesia. <i>BJOG.</i> 2009; 116(1): 82-90.	2005-2006		
Indonesia	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998, 2006-2009		
Indonesia	Darmawan J, Valkenburg HA, Muirden KD, Wigley RD. The epidemiology of gout and hyperuricemia in a rural population of Java. <i>J Rheumatol.</i> 1992; 19(10): 1595-9.	1989		
Indonesia	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Indonesia	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2002		
Indonesia	Waspadji S, Ranakusuma AB, Suyono S, Suparonto S, Sukatou U. Diabetes mellitus in an urban population in Jakarta, Indonesia. <i>Tohoku J Exp Med.</i> 1983; 141(Suppl): 219-28.	1982		
Indonesia	Simadibrata M, Tytgat GNJ, Yuwono V, Daldiyono, Lesmana LA, Syam AF, Ariawan I, Rani A. Microorganisms and parasites in chronic infective diarrhea. <i>Acta Med Indones.</i> 2004; 36(4): 211-4.	1995-2000	*	
Indonesia	Soenarto Y, Sebodo T, Ridho R, Alrasjid H, Rohde JE, Bugg HC, Barnes GL, Bishop RF. Acute diarrhea and rotavirus infection in newborn babies and children in Yogyakarta, Indonesia, from June 1978 to June 1979. <i>J Clin Microbiol.</i> 1981; 14(2): 123-9.	1978-1979	*	
Indonesia	Mackenzie I. Hearing Impairment in Asia - final report of four country survey, as provided by the Global Burden of Disease 2010 hearing impairment expert group. [Unpublished].	1998		
Indonesia	Darmawan J, Muirden KD, Valkenburg HA, Wigley RD. The epidemiology of rheumatoid arthritis in Indonesia. <i>Br J Rheumatol.</i> 1993; 32(7): 537-40.	1990		
Indonesia	Morgan MV, Wright FA, Matran ZN, Sundoro E, Chesters RK. The oral health status and health behaviour of 12 and 15 year-old adolescents in Jakarta, Indonesia. <i>Community Dent Health.</i> 1992; 9(2): 171-9.	1990		
Indonesia	Koloway B, Kailis DG. Caries, gingivitis and oral hygiene in urban and rural pre-school children in Indonesia. <i>Community Dent Oral Epidemiol.</i> 1992; 20(3): 157-8.	1990		
Indonesia	Darmawan J, Valkenburg HA, Muirden KD, Wigley RD. Epidemiology of rheumatic diseases in rural and urban populations in Indonesia: a World Health Organisation International League Against Rheumatism COPCORD study, stage I, phase 2. <i>Ann Rheum Dis.</i> 1992; 51(4): 525-8.	1989		
Indonesia	Indonesia - Lombok Rapid Assessment of Cataract Surgical Services 2004 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2004		
Indonesia	Saw S-M, Husain R, Gazzard GM, Koh D, Widjaja D, Tan DTH. Causes of low vision and blindness in rural Indonesia. <i>Br J Ophthalmol.</i> 2003; 87(9): 1075-8. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2001-2002		
Indonesia	Juffrie M, Graham RR, Tan RI, Widjaja S, Mulyadi S, Weil J, Bock HL. Seroprevalence of hepatitis A virus and varicella zoster antibodies in a Javanese community (Yogyakarta, Indonesia). <i>Southeast Asian J Trop Med Public Health.</i> 2000; 31(1): 21-4.	1995-1996		
Indonesia	Katsumata T, Hosea D, Wasito EB, Kolno S, Hara K, Soeparto P, Ranuh IG. Cryptosporidiosis in Indonesia: a hospital-based study and a community-based survey. <i>Am J Trop Med Hyg.</i> 1998; 59(4): 628-32.	1992-1993		
Indonesia	Robertson SE, Roca A, Alonso P, Simoes EAF, Kartasasmita CB, Olalaye DO, Odaibo GN, Collinson M, Venter M, Zhu Y, Wright PF. Respiratory syncytial virus infection: denominator-based studies in Indonesia, Mozambique, Nigeria and South Africa. <i>Bull World Health Organ.</i> 2004; 82(12): 914-22.	1999-2001	*	
Indonesia	Djelantik IG, Gessner BD, Soewignjo S, Steinhoff M, Sutanto A, Widjaya A, Linehan M, Moniaga V, Ingerani. Incidence and clinical features of hospitalization because of respiratory syncytial virus lower respiratory illness among children less than two years of age in a rural Asian setting. <i>Pediatr Infect Dis J.</i> 2003; 22(2): 150-7.	2000-2001	*	
Indonesia	National Narcotics Board (Indonesia), University of Indonesia. Indonesia National Survey on Drug Abuse and Illicit Drugs 2005.	2005		
Indonesia	Wandra T, Subahar R, Simanjuntak GM, Margono SS, Suroso T, Okamoto M, Nakao M, Sako Y, Nakaya K, Schantz PM, Ito A. Resurgence of cases of epileptic seizures and burns associated with cysticercosis in Assologaima, Jayawijaya, Irian Jaya, Indonesia, 1991-95. <i>Trans R Soc Trop Med Hyg.</i> 2000; 94(1): 46-50.	1991-1995	*	
Indonesia	Amirudin R, Akil H, Akahane Y, Suzuki H. Hepatitis B and C virus infection in Ujung Pandang, Indonesia. <i>Gastroenterol Jpn.</i> 1991; 184-8.	1990		
Indonesia	Hadiwandowo S, Tsuda F, Okamoto H, Tokita H, Wang Y, Tanaka T, Miyakawa Y, Mayumi M. Hepatitis B virus subtypes and hepatitis C virus genotypes in patients with chronic liver disease or on maintenance hemodialysis in Indonesia. <i>J Med Virol.</i> 1994; 43(2): 182-6.	1994		
Indonesia	Wang B-E, Ma W-M, Sulaiman A, Noer S, Sumoharjo S, Sumarsidi D, Tandon BN, Nakao K, Mishiuro S, Miyakawa Y, Akahane Y, Suzuki H. Demographic, clinical, and virological characteristics of hepatocellular carcinoma in Asia: survey of 414 patients from four countries. <i>J Med Virol.</i> 2002; 67(3): 394-400.	2002		
Indonesia	Wignjosumarto S, Mukhlas M, Shiratki S. Epidemiological and clinical study of autistic children in Yogyakarta, Indonesia. <i>Kobe J Med Sci.</i> 1992; 38(1): 1-19.	1990		
Indonesia	Kurihara T, Kato M, Reverger R, Tirta IGR. Seventeen-year clinical outcome of schizophrenia in Bali. <i>Eur Psychiatry.</i> 2011; 26(5): 333-8.	1990-2007	*	
Indonesia	Soemantri S, Senewe FP, Tjandrarini DH, Day R, Basri C, Manissero D, Mehta F, Dye C. Three-fold reduction in the prevalence of tuberculosis over 25 years in Indonesia. <i>Int J Tuberc Lung Dis.</i> 2007; 11(4): 398-404.	2004		
Indonesia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2001, 2004, 2007, 2010, 2012		
Indonesia	Soemantri AG, Saha S, Saha N, Tay JS. Molecular variants of red cell glucose-6-phosphate dehydrogenase deficiency in Central Java, Indonesia. <i>Hum Hered.</i> 1995; 45(6): 346-50.	1993-1995		
Indonesia	Suryantoro P. Glucose-6-phosphate dehydrogenase (G6PD) deficiency in Yogyakarta and its surrounding areas. <i>Southeast Asian J Trop Med Public Health.</i> 2003; 138-9.	1996		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Indonesia	Iwai K, Hirono A, Matsuoka H, Kawamoto F, Horie T, Lin K, Tantular IS, Dachlan YP, Notopuro H, Hidayah NI, Salim AM, Fujii H, Miwa S, Ishii A. Distribution of glucose-6-phosphate dehydrogenase mutations in Southeast Asia. <i>Hum Genet.</i> 2001; 108(6): 445-9.	1997-1998		
Indonesia	Matsuoka H, Arai M, Yoshida S, Tantular IS, Pusarawati S, Kerong H, Kawamoto F. Five different glucose-6-phosphate (correction phosphate)dehydrogenase (G6PD) variants found among 11 G6PD-deficient persons in Flores Island, Indonesia. <i>J Hum Genet.</i> 2003; 48(10): 541-4.	2001-2003		
Indonesia	Jalloh A, Tantular IS, Pusarawati S, Kawilarang AP, Kerong H, Lin K, Ferreira MU, Matsuoka H, Arai M, Kita K, Kawamoto F. Rapid epidemiologic assessment of glucose-6-phosphate dehydrogenase deficiency in malaria-endemic areas in Southeast Asia using a novel diagnostic kit. <i>Trop Med Int Health.</i> 2004; 9(5): 615-23.	2002-2003		†
Indonesia	Jalloh A, Tantular IS, Pusarawati S, Kawilarang AP, Kerong H, Lin K, Ferreira MU, Matsuoka H, Arai M, Kita K, Kawamoto F. Rapid epidemiologic assessment of glucose-6-phosphate dehydrogenase deficiency in malaria-endemic areas in Southeast Asia using a novel diagnostic kit. <i>Trop Med Int Health.</i> 2004; 9(5): 615-23 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002-2003	*	†
Indonesia	Shimizu H, Tamam M, Soenatri A, Ishida T. Glucose-6-phosphate dehydrogenase deficiency and Southeast Asian ovalocytosis in asymptomatic Plasmodium carriers in Sumba island, Indonesia. <i>J Hum Genet.</i> 2005; 50(8): 420-4.	2003-2005		
Indonesia	Kawamoto F, Matsuoka H, Kanbe T, Tantular IS, Pusarawati S, Kerong HI, Damianus W, Mere D, Dachlan YP. Further investigations of glucose-6-phosphate dehydrogenase variants in Flores Island, eastern Indonesia. <i>J Hum Genet.</i> 2006; 51(11): 952-7.	2004-2005		
Indonesia	Timmerman MF, Van der Weijden GA, Armand S, Abbas F, Winkel EG, Van Winkelhoff AJ, Van der Velden U. Untreated periodontal disease in Indonesian adolescents. Clinical and microbiological baseline data. <i>J Clin Periodontol.</i> 1998; 25(3): 215-24.	1987		
Indonesia	Ochiai RL, Wang X, von Seidlein L, Yang J, Bhutta ZA, Bhattacharya SK, Agtini M, Deen JL, Wain J, Kim DR, Ali M, Acosta CJ, Jodar L, Clemens JD. Salmonella Paratyphi A Rates, Asia. <i>Emerg Infect Dis.</i> 2005; 11(11): 1764-6.	2002-2003	*	
Indonesia	Simanjuntak CH, Totosudirjo H, Haryanto P, Suprijanto E, Paleologo FP, Punjabi NH, Witham ND, Darmowigoto R, Soeprawoto, Hoffman SL. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. <i>Lancet.</i> 1991; 338(8774): 1055-9.	1986	*	
Indonesia	Vollaard AM, Ali S, Widjaja S, Asten HAGH van, Visser LG, Surjadi C, Dissel JT van. Identification of typhoid fever and paratyphoid fever cases at presentation in outpatient clinics in Jakarta, Indonesia. <i>Trans R Soc Trop Med Hyg.</i> 2005; 99(6): 440-50.	2001-2003	*	
Indonesia	Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agtini MD, Bhutta ZA, Canh DG, Ali M, Shin S, Wain J, Page A-L, Albert MJ, Farrar J, Abu-Elyazeed R, Pang T, Galindo CM, von Seidlein L, Clemens JD, Domi Typhoid Study Group. A study of typhoid fever in five Asian countries: disease burden and implications for controls. <i>Bull World Health Organ.</i> 2008; 86(4): 260-8.	2002-2003		
Indonesia	Supali T, Wibowo H, Rückert P, Fischer K, Ismiid IS, Purnomo, Djuardi Y, Fischer P. High prevalence of Brugia timori infection in the highland of Alor Island, Indonesia. <i>Am J Trop Med Hyg.</i> 2002; 66(5): 560-5, as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2001	*	
Indonesia	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec.</i> 2007; 82(25): 225-32.	2006	*	
Indonesia	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Indonesia	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Indonesia	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Indonesia	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Indonesia	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Indonesia	World Health Organization (WHO). Progress in leprosy control: Indonesia, 1991-2008. <i>Wkly Epidemiol Rec.</i> 2010; 85(26): 249-62.	1991-2007	*	
Indonesia	Kardjati S. Xerophthalmia prevalence in East Java and assessment of contributory factors: a comparison with the situation in 1975-77. <i>Gizi Indon.</i> 1993; 18(1-2): 65-89 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1975-1992		
Indonesia	Kusin JA, Sinaga HS, Marpaung AM. Xerophthalmia in North Sumatra. <i>Trop Geogr Med.</i> 1977; 29(1): 41-6 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1974		
Indonesia	World Health Organization Regional Office for South-East Asia (SEARO). Reported Cases of DF/DHF in Selected Countries in SEA Region. New Delhi, India: World Health Organization Regional Office for South-East Asia (SEARO).	1988-2006		
Indonesia	World Health Organization Regional Office for South-East Asia (SEARO). Situation Update of Dengue in the SEA Region, 2010. New Delhi, India: World Health Organization Regional Office for South-East Asia (SEARO).	2007-2009		
Indonesia	WHO Regional Office for South-East Asia (SEARO). WHO South-East Asia Region: Reported Cases and Deaths of Dengue from 2003 to 2012. New Delhi, India: WHO Regional Office for South-East Asia (SEARO), 2013.	2003-2012	*	
Indonesia	Ng KP, Ngeow YF, K R M R. Hepatitis B seroprevalence among University of Malaya Students in the Post-universal Infant Vaccination Era. <i>Med J Malaysia.</i> 2013; 68(2): 144-7.	2005-2011	*	
Indonesia	Syailiyuni R. Glucose-6-Phosphate Deficiency in School-Age Children in Malaria-Endemic Areas [Master's thesis]. Semarang, Indonesia: Diponegoro University (Indonesia);2003.	2003	*	
Indonesia	Brown P, Breguet G, Smallwood L, Ney R, Moerdowo RM, Gerety RJ. Serologic markers of hepatitis A and B in the population of Bali, Indonesia. <i>Am J Trop Med Hyg.</i> 1985; 34(3): 616-9.	1978-1981		
Indonesia	Corwin A, Putri MP, Winarno J, Lubis I, Suparmanto S, Sumardiati A, Laras K, Tan R, Master J, Warner G, Wignall FS, Graham R, Hyams KC. Epidemic and sporadic hepatitis E virus transmission in West Kalimantan (Borneo), Indonesia. <i>Am J Trop Med Hyg.</i> 1997; 57(1): 62-5.	1994		
Indonesia	Achwan WA, Muttaqin Z, Zakaria E, Depamede SA, Mulyanto, Sumoharjo S, Tsuda F, Takahashi K, Abe N, Mishiro S. Epidemiology of hepatitis B, C, and E viruses and human immunodeficiency virus infections in Tahuna, Sangihe-Talaud Archipelago, Indonesia. <i>Intervirology.</i> 2007; 50(6): 408-11.	2005		
Indonesia	Akbar N, Basuki B, Mulyanto, Garabrant DH, Sulaiman A, Noer HM. Ethnicity, socioeconomic status, transfusions and risk of hepatitis B and hepatitis C infection. <i>J Gastroenterol Hepatol.</i> 1997; 12(11): 752-7.	1994		
Indonesia	Boland GI, Cnossen N, van Bonmel T, Rulos-van den Berg A, van den Berg JPB, van Loon AM, van Hattum J. Molecular diversity of hepatitis C virus in the Batam region. <i>Adv Exp Med Biol.</i> 2003; 211-7.	1995-1997		
Indonesia	Van Hattum J, Boland GI, Jansen KGJJ, Kleinpenning AS, van Bonmel T, van Loon AM, Abdurachman SA, Yusuf H, Rulos-van den Berg A, van den Berg J. Transmission profile of hepatitis B virus infection in the Batam region, Indonesia. Evidence for a predominantly horizontal transmission profile. <i>Adv Exp Med Biol.</i> 2003; 177-83.	1997		
Indonesia	Wibawa IDN, Muljono DH, Mulyanto, Suryadarma IGA, Tsuda F, Takahashi M, Nishizawa T, Okamoto H. Prevalence of antibodies to hepatitis E virus among apparently healthy humans and pigs in Bali, Indonesia: Identification of a pig infected with a genotype 4 hepatitis E virus. <i>J Med Virol.</i> 2004; 73(1): 38-44.	1996		
Indonesia	Wolff AP, Ruys AH, Dolmans WM, Van Loon AM, Pangalila PF. Hepatitis B virus infection in patients with chronic liver disease and healthy controls in north-Sulawesi, Indonesia. <i>Trop Geogr Med.</i> 1990; 42(3): 221-5.	1988		
Indonesia	Castillo Taucher S. [Services for the care and prevention of birth defects. Reduced report of a World Health Organization and March of Dimes Foundation meeting]. <i>Rev Med Chil.</i> 2007; 135(6): 806-13.	1988-2005		
Indonesia	Chang MS, Chan KL, Ho BC. Control of Mansonia mosquitos, vectors of brugian filariasis in Sarawak, Malaysia. Southeast Asian J Trop Med Public Health. 1993; 93-104, as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1984-1986, 1988	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Indonesia	Fischer P, Djuardi Y, Ismid IS, Rückert P, Bradley M, Supali T. Long-lasting reduction of <i>Brugia timori</i> microfilariae following a single dose of diethylcarbamazine combined with albendazole. <i>Trans R Soc Trop Med Hyg.</i> 2003; 97(4): 446-8. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2001	*	
Indonesia	Fischer P, Supali T, Wibowo H, Bonow I, Williams SA. Detection of DNA of nocturnally periodic <i>Brugia malayi</i> in night and day blood samples by a polymerase chain reaction-ELISA-based method using an internal control DNA. <i>Am J Trop Med Hyg.</i> 2000; 62(2): 291-6. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2002	*	
Indonesia	Haarbrink M, Terhell AJ, Abadi K, Asri M, de Medeiros F, Yazdanbakhsh M. Anti-filarial IgG4 in men and women living in <i>Brugia malayi</i> -endemic areas. <i>Trop Med Int Health.</i> 1999; 4(2): 93-7. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1980-2000	*	
Indonesia	Joeseof A, Cross JH. Human filariae in Indonesia. <i>Southeast Asian J Trop Med Public Health.</i> 1978; 9(1): 15-9. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1980-2000	*	
Indonesia	Oqueka T, Supali T, Ismid IS, Purnomo, Rückert P, Bradley M, Fischer P. Impact of two rounds of mass drug administration using diethylcarbamazine combined with albendazole on the prevalence of <i>Brugia timori</i> and of intestinal helminths on Alor Island, Indonesia. <i>Filaria J.</i> 2005; 5. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2002-2004	*	
Indonesia	Partono F, Maizels RM, Purnomo. Towards a filariasis-free community: evaluation of filariasis control over an eleven year period in Flores, Indonesia. <i>Trans R Soc Trop Med Hyg.</i> 1989; 83(6): 821-6. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1980, 1982	*	
Indonesia	Rubis P, Chang MS, Nagum AJ, Jau JL. Parasitological and entomological studies on filariasis in seven villages, Serian District, Sarawak, East Malaysia. <i>Southeast Asian J Trop Med Public Health.</i> 1981; 12(1): 30-5. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1980-2000	*	
Indonesia	Stafford EE, Dennis DT, Masri S, Sudomo M. Intestinal and blood parasites in the Torro Valley, Central Sulawesi, Indonesia. <i>Southeast Asian J Trop Med Public Health.</i> 1980; 11(4): 468-72. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1980-2000	*	
Indonesia	Sudjadi FA, Soeyoko, Noerhaji S. Diurnally subperiodic and non-periodic <i>Brugia</i> type in Balikpapan, East Kalimantan, Indonesia. <i>Southeast Asian J Trop Med Public Health.</i> 1984; 15(3): 425-6. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1982	*	
Indonesia	Sudomo M, Hanifah A, Mak JW, Lim BL. A study of malayan filariasis in Lubuk Mumpo and Datar Lebar villages in Lais Regency, North Bengkulu, Sumatera, Indonesia. <i>Southeast Asian J Trop Med Public Health.</i> 1982; 13(4): 584-9. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1981-1982	*	
Indonesia	Sudomo M, Liat LB, Sustiaryu N, Bang YH. A survey of filariasis at Waru village and Babulu Darat Transmigration Scheme, East Kalimantan. <i>Southeast Asian J Trop Med Public Health.</i> 1980; 11(4): 451-60. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1980	*	
Indonesia	Supali T, Ismid IS, Wibowo H, Djuardi Y, Majawati E, Ginanjar P, Fischer P. Estimation of the prevalence of lymphatic filariasis by a pool screen PCR assay using blood spots collected on filter paper. <i>Trans R Soc Trop Med Hyg.</i> 2006; 100(8): 753-9. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2002	*	
Indonesia	Terhell AJ, Haarbrink M, Abadi K, Bronneberg DC, Tieleman MC, Asri M, Yazdanbakhsh M. A filter paper technique for the detection of anti-filarial IgG4 in lymphatic filariasis. <i>Trans R Soc Trop Med Hyg.</i> 1996; 90(2): 196-8. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1994	*	
Indonesia	Wahyuni S, Houwing-Duistermaat JJ, Syafruddin, Supali T, Yazdanbakhsh M, Sartono E. Clustering of filarial infection in an age-graded study: genetic, household and environmental influences. <i>Parasitology.</i> 2004; 128(Pt 3): 315-21. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2000-2012	*	
Indonesia	Wahyuni S, Van Ree R, Mangali A, Supali T, Yazdanbakhsh M, Sartono E. Comparison of an enzyme linked immunosorbent assay (ELISA) and a radioallergosorbent test (RAST) for detection of IgE antibodies to <i>Brugia malayi</i> . <i>Parasite Immunol.</i> 2003; 25(11-12): 609-14. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2000-2012	*	
Indonesia	Barten J. Screening for infertility in Indonesia. Results of examination of 863 infertile couples. <i>Andrologia.</i> 1978; 10(5): 405-12.	1972-1977	*	
Indonesia	Indonesia - Prevalence study of re-emerging lymphatic filariasis in West Java, Indonesia as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2007	*	
Indonesia	Indonesia Programme to Eliminate Lymphatic Filariasis Country Report 2004 as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2004	*	
Indonesia	Corwin A, Jarot K, Lubis I, Nasution K, Suparmawo S, Sumardiati A, Widodo S, Nazir S, Orndorff G, Choi Y. Two years' investigation of epidemic hepatitis E virus transmission in West Kalimantan (Borneo), Indonesia. <i>Trans R Soc Trop Med Hyg.</i> 1995; 89(3): 262-5.	1993	*	
Indonesia	Study to Determine the Risk Factors for Transmission (Transmission Dynamics) of Malaria in Palolo Subdistrict, Donggala Regency, Central Sulawesi Province as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Indonesia	Jodjana H, Eblen JE. Malnutrition, malaria and intestinal worms in young children. <i>World Health Forum.</i> 1997; 18(1): 21-3 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Indonesia	Malaria in Coastal Asahan: Its Prevalence in Community and Current Approaches to Malaria Chemotherapy as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1985-1986	*	†
Indonesia	Malaria Transmission Research in North Sulawesi as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Indonesia	Passive Case Detection (PCD) as an Indicator of the Magnitude of the Malaria Problem in the Regency of Banjarmasin as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1999-2000	*	†
Indonesia	Development of Malaria Control with Intensification of the Discovery and Treatment of Patients to Prevent the Occurrence of Outbreaks in the Region of South Lampung, Phase-I as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	2003-2004	*	†
Indonesia	Sunaryo S. Dinamika penularan malaria di Kabupaten Biak Numfor Provinsi Papua. <i>Balaba.</i> 2006; 2(1): 7-10 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Indonesia	Improving the Diagnosis and Treatment of Malaria in Eastern Indonesia [dissertation] as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1997-1998	*	†
Indonesia	Habitat dan potensi menularkan malaria dari <i>Anopheles sudaicus</i> di P. Batam Kodya Batam Propinsi Riau as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†
Indonesia	Sudomo M, Idris NS, Peneliti S. Prevalensi malaria di Desa Siheng dan Aek Badak Jae. <i>Media Litbangkes.</i> 1997; 7(3/4):2-5. as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†
Indonesia	Indonesia Plasmodium Falciparum Parasite Rate Data, Personal Communication with R. Allan 2009 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Indonesia	Tanzania Plasmodium Falciparum Parasite Rate Data, Personal Communication with M. Bangs 2009 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	2000	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Indonesia	Indonesia Plasmodium Falciparum Parasite Rate Data, Personal Communication with M.J. Barcus 2001 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000-2001	*	†
Indonesia	Indonesia Plasmodium Falciparum Parasite Rate Data, Personal Communication with I.R.F.E. Elyazar and J.K. Baird 2006 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000	*	†
Indonesia	Ompusunggu S, Marwoto HA, Sulaksono ST, Dewi RM, Sumawinata I, Masbar S. Endemisitas malaria di beberapa daerah pariwisata Jawa Barat. Media Litbangkes. 2002; 12(1): 26-33. as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997-1998	*	†
Indonesia	Malariometric survey in Sindue and Ampibabo subdistricts, Donggala regency, Central Sulawesi province as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Indonesia	Penggunaan Kelambu yang Dicelup Insektisida oleh Petani Se Lahir, Flores Timur as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Indonesia	Chloroquine sensitivity of Plasmodium falciparum in Berakit, Bintan Island, Sumatra, after mass chemoprophylaxis through community participation, and its sociological studies as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†
Indonesia	Utami BS, Supriyanto S, Sururi M, Ekowatiningsih R. Efektifitas diagnosis mikroskopis malaria di puskesmas di tiga puskesmas di kabupaten Purworejo, Jawa Tengah. Media Litbangkes. 2002; 12(2): 1-9. as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Indonesia	Kejadian luar biasa malaria di Kecamatan Kalibawang, Kabupaten Kulon Progo, Provinsi Daerah Istimewa Yogyakarta as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Indonesia	Penapisan kasus malaria di Desa Krandegan, Kecamatan Paninggaran, Kabupaten Pekalongan, Jawa Tengah, tahun 2000 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000	*	†
Indonesia	Malaria di Pulau Samosir, Kabupaten Toba Samosir, Propinsi Sumatera, Tahun 2003 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Indonesia	Efektivitas diagnosis mikroskopis malaria di puskesmas Donggala, puskesmas Lembasada, dan puskesmas Kulawai, Provinsi Sulawesi Tengah as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Indonesia	Indonesia Plasmodium Falciparum Parasite Rate Data, Personal Communication with Litbangkes 1992 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Indonesia	Indonesia Plasmodium Falciparum Parasite Rate Data, Personal Communication with J.D. Maguire 2005 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000-2005	*	†
Indonesia	Indonesia Plasmodium Falciparum Parasite Rate Data, Personal Communication with W.O. Rogers and I.R.F. Elyazar 2005 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Indonesia	Muriuki D, Hahn S, Hexom B, Allan R. Cross-sectional survey of malaria prevalence in tsunami-affected districts of Aceh Province, Indonesia. International Journal of Emergency Medicine. 2012; 5(1): 11 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005-2006	*	†
Indonesia	Andersen E, Jones T, Purnomo, Masbar S, Wiady I, Tirtolusumo S, Bangs M, Charoenvit Y, Gunawan S, Hoffwan S assessment of age-dependent immunity to malaria in transmigrants. Am J Trop Med Hyg. 1997; 56(6): 647-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991-1992	*	†
Indonesia	Asih PB, Rozi IE, Herdiana H, Pratama NR, Hidayati AP, Marantina SS, Kosasih S, Chand K, Wangsamuda S, Rusdy FA, Sumiwi ME, Inran A, Yuniarti T, Sianturi T, Nur J, Asnita A, Bukhari B, Barussanah C, Yani M, Ainun C, Jamil K, Mariam C, Sengkerji SP, Laihah FJ, Hawley W, Syafruddin D. The baseline distribution of malaria in the initial phase of elimination in Sabang Municipality, Aceh Province, Indonesia. Malar J. 2012; 11(1): 291 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2010	*	†
Indonesia	Baird J, Jones T, Danudirjo E, Annis B, Bangs M, Basri H, Punomo, Masbar S. Age-dependent acquired protection against Plasmodium falciparum in people having two years exposure to hyperendemic malaria. Am J Trop Med Hyg. 1991; 45(1): 65-76 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Indonesia	Baird J, Punomo, Masbar S. Plasmodium ovale in Indonesia. Southeast Asian J Trop Med Public Health. 1990; 21(4): 541-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Indonesia	Baird JK, Punomo, Basri H, Bangs MJ, Andersen EM, Jones TR, Masbar S, Harjosuwarno S, Subianto B, Arbani PR. Age-Specific Prevalence of Plasmodium falciparum Among Six Populations with Limited Histories of Exposure to Endemic Malaria. Am J Trop Med Hyg. 1993; 49(6): 707-19 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Indonesia	Baird J, Wiady I, Fryauff D, Sutanihardja M, Leksana B, Widjaya H, Kysdarmanto, Subianto B. In vivo resistance to chloroquine by Plasmodium vivax and Plasmodium falciparum at Nabire, Irian Jaya, Indonesia. Am J Trop Med Hyg. 1997; 56(6): 627-31 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Indonesia	Barcus MJ, Elyazar IRF, Marwoto H, Richie TL, Basri H, Wiady I, Fryauff DJ, Maguire JD, Bangs MJ, Baird JK. Primary infection by Plasmodium falciparum or P. vivax in a cohort of Javanese migrants to Indonesian Papua. Ann Trop Med Parasitol. 2003; 97(6): 565-74 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Indonesia	Barodji W, Nurisa I, Sumardi S, Sutopo T. Kepadatan vektor dan penderita malaria di Desa Waikibang, Kecamatan Tanjung Bunga, Flores Timur Sebelum dan Sesudah Gempa Bumi. Cermin Dunia Kedokteran. 1996; 106: 15-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992-1993	*	†
Indonesia	Dachlan YP, Yotopranoto S, Sutanto BV, Santoso SHB, Widodo AS, Kusmartisnawati, Sutanto A, Gerudug IKK, Takagi M, Tsuda Y, Tanabe K, Kawamoto F, Yoshinaga K, Kanbara H. Malaria Endemic Patterns on Lombok and Sumbawa Islands, Indonesia. Trop Med Health. 2005; 33(2): 105-13 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992-1993	*	†
Indonesia	Dewi R, Marwoto A, Nalim S, Sekartuti E, Tijitra E. Penelitian malaria di Kecamatan Teluk Dalam, Nias, Sumatera Utara. Cermin Dunia Kedokteran. 1996; 106: 5-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994-1995	*	†
Indonesia	Doi H, Kaneko A, Panjaitan W, Ishii A. Chemotherapeutic malaria control operation by single dose of Fansidar plus primaquine in North Sumatra, Indonesia. Southeast Asian J Trop Med Public Health. 1989; 20(3): 341-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987-1988	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Indonesia	Fryauff DJ, Baird JK, Candraikusuma D, Masbar S, Sutarnihardja MA, Leksana B, Tuti S, Marwoto H, Richie T, Romzan A. Survey of in Vivo Sensitivity to Chloroquine by Plasmodium falciparum and P. vivax in Lombok, Indonesia. Am J Trop Med Hyg. 1997; 56(2): 241-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Indonesia	Fryauff D, Gomez-Saladin E, Purnomo, Sumawinata I, Sutarnihardja MA, Tuti S, Subianto B, Richie TL. Comparative performance of the ParaSight F test for detection of Plasmodium falciparum in malaria-immune and nonimmune populations in Irian Jaya, Indonesia. Bull World Health Organ. 1997; 75(6): 547-52 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Indonesia	Fryauff DJ, Leksana B, Masbar S, Wiady I, Sismadi P, Susanti AI, Nagesha HS, Atmosoedjono S, Bangs MJ, Baird JK. The drug sensitivity and transmission dynamics of human malaria on Nias Island, North Sumatra, Indonesia. Ann Trop Med Parasitol. 2002; 96(5): 447-62 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Indonesia	Fryauff DJ, Purnomo S, Sutarnihardja MA, Elyazar IRS, Susanti I, Krisin, Subianto B, Marwoto H. Performance of the OptiMAL assay for detection and identification of malaria infections in asymptomatic residents of Irian Jaya. Am J Trop Med Hyg. 2000; 63(3-4): 139-45 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
Indonesia	Fryauff DJ, Sumawinata I, Purnomo, Richie TL, Tjitra E, Bangs MJ, Kadir A, Ingkokusumo G. In vivo responses to antimalarials by Plasmodium falciparum and Plasmodium vivax from isolated Gag Island off northwest Irian Jaya, Indonesia. Am J Trop Med Hyg. 1999; 60(4): 542-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
Indonesia	Fryauff DJ, Tuti S, Mardi A, Masbar S, Patipelohi R, Leksana B, Kain KC, Bangs MJ, Richie TL, Baird JK. Chloroquine-resistant Plasmodium vivax in transmigrating settlements of West Kalimantan, Indonesia. Am J Trop Med Hyg. 1998; 59(4): 513-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Indonesia	Kaisar MM, Supali T, Wiria AE, Hamid F, Wamnes LJ, Sartono E, Luty AJ, Brienen EA, Yazdanbakhsh M, Lieshout L van, Verweij JJ. Epidemiology of Plasmodium infections in Flores Island, Indonesia using real-time PCR. Malar J. 2013; 12(1): 169 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008	*	†
Indonesia	Kameko A, Kamei K, Suzuki T, Ishii A, Siagian R, Panjaitan W. Gametocytocidal effect of primaquine in a chemotherapeutic malaria control trial in North Sumatra, Indonesia. Southeast Asian J Trop Med Public Health. 1989; 20(3): 351-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Indonesia	Kinwardoyo S, Panut B, Basri H, Waluyo A. Evaluasi pemakaian kelambu dipoles Permethrin untuk Penanggulangan malaria dengan vektor An. sundaicus di Lampung. Cermin Dunia Kedokteran. 1993; 82: 49-52 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986-1987	*	†
Indonesia	Krisin, Basri H, Fryauff DJ, Barcus MJ, Bangs MJ, Ayomi E, Marwoto H, Elyazar IRF, Richie TL, Baird JK. Malaria in a cohort of Javanese migrants to Indonesian Papua. Ann Trop Med Parasitol. 2003; 97(6): 543-56 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997-1999	*	†
Indonesia	Ling J, Baird JK, Fryauff DJ, Sismadi P, Bangs MJ, Lacy M, Barcus MJ, Gramzinski R, Maguire JD, Kumsumangsh M, Miller GB, Jones TR, Chhlay JD, Hoffman SL. Randomized, placebo-controlled trial of atovaquone-proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clin Infect Dis. 2002; 35(7): 825-33 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
Indonesia	Maguire JD, Tuti S, Sismadi P, Wiady I, Basri H, Krisin, Masbar S, Projoedipuro P, Elyazar IRF, Corwin A, Bangs MJ. Endemic coastal malaria in the Thousand Islands District, near Jakarta, Indonesia. Trop Med Int Health. 2005; 10(5): 489-96 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Indonesia	Marwoto HA, Martono. Malaria di kabupaten Sikka, Flores. Cermin Dunia Kedokteran. 1991; 70: 35-41 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Indonesia	Marwoto HA, Purnomo. Penelitian Pemberantasan malaria di Kabupaten Sikka, Flores. Cermin Dunia Kedokteran. 1992; 74: 55-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Indonesia	Nalim S, Barodji W, Widiarti, Widiyastuti U. A field trial with etofenprox (OMS 3002) as a residual insecticide against malaria vectors, in Tanjung Bunga district, east Flores, Indonesia. Southeast Asian J Trop Med Public Health. 1997; 28(4): 851-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993-1994	*	†
Indonesia	Ompusunggu S, Sekartuti M, HA, Dewi RM. Situasi Kepekaan Plasmodium falciparum terhadap oba dan mobilitas penduduk di Nunukan, Kalimantan Timur. Cermin Dunia Kedokteran. 1989; 55: 8-11 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Indonesia	Ompusunggu SM, Hasan M, Kulla RK, Akal JG. Dinamika penularan malaria di kawasan perkubitan kabupaten Sumba Barat, Nusa Tenggara Timur. Media Litbangkes. 2006; 16(2): 43-51 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Indonesia	Ompusunggu SM, Marwoto HA, Sulaksono ST, Nurhayati, Dewi RM. Pengembangan peran serta masyarakat melalui kader dan Dasa Wisma dalam penemuan dan pengobatan penderita malaria di Kecamatan Pituruh, Kabupaten Purworejo. Buletin Penelitian Kesehatan. 2005; 33(3): 140-51 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Indonesia	Pribadi W, Rasidi R, Kiswani D, Rukmono B. Penurunan angka morbiditas malaria dengan Peran Serta Masyarakat di Desa Pablengan, Jawa Tengah. Majalah Parasitologi Indonesia. 1988; 2(1/2): 51-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985-1987	*	†
Indonesia	Pribadi W, Rukmono B, Santoso SS, Soeripto N, Lokollo DM, Soeharyo. Decrease of malaria morbidity with community participation in central Java. Southeast Asian J Trop Med Public Health. 1992; 23(3): 389-96 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Indonesia	Pribadi W, Sutanto I, Atmosoedjono S, Rasidi R, Surya LK, Susanto L. Malaria situation in several villages around Timika, south central Irian Jaya, Indonesia. Southeast Asian J Trop Med Public Health. 1998; 29(2): 228-35 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Indonesia	Purnomo SA, Gomez-Saladin E, Bangs MJ. Rare quadruple malaria infection in Irian Jaya Indonesia. J Parasitol. 1999; 85(3): 574-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
Indonesia	Renny M, Arbani P, Tuti S, Harijani A, Ompusunggu S, Tjitra E. Situasi malaria di Pulau Batam dan Sekitarnya. Majalah Parasitologi Indonesia. 1989; 2(3/4): 65-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986-1987	*	†
Indonesia	Soekirno M, Santijo K, Nadjib AA, Suyinto M, Hasyimi M. Fauna Anopheles dan status, pola penularan serta endemisitas malaria di Halmahera, Maluku Utara. Cermin Dunia Kedokteran. 1997; 118: 15-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Indonesia	Sudomo M, Arianti Y, Wahid I, Safruddin D, Pedersen EM, Charlwood JD. Towards eradication: three years after the tsunami of 2004, has malaria transmission been eliminated from the island of Simeulue? <i>Trans R Soc Trop Med Hyg.</i> 2010; 104(12): 777-81 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005-2007	*	†
Indonesia	Sutanto I, Freisleben HJ, Pribadi W, Atmosoedjono S, Bandi R, Purnomo. Efficacy of permethrin-impregnated bed nets on malaria control in a hyperendemic area in Irian Jaya, Indonesia: influence of seasonal rainfall fluctuations. <i>Southeast Asian J Trop Med Public Health.</i> 1999; 30(3): 432-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993-1995	*	†
Indonesia	Syafruddin D, Ashi P, Coutrier F, Trianty L, Noviyanti R, Luase Y, Sumarto W, Caley M, van der Ven A, Sauerwein R. Malaria in Wanokaka and Loli sub-districts, West Sumba District, East Nusa Tenggara Province, Indonesia. <i>Am J Trop Med Hyg.</i> 2006; 74(5): 733-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Indonesia	Syafruddin D, Ashi PB, Wahid I, Dewi RM, Tuti S, Laowo I, Hulu W, Zendrato P, Laihah F, Shankar AH. Malaria prevalence in Nias District, North Sumatra Province, Indonesia. <i>Malar J.</i> 2007; 6: 116 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Indonesia	Syafruddin, Kamimura K, Hasegawa H, Toma T, Miyagi I, Kawamoto F, Nainggolan JJ, Tumewu-Wagey M, Mandagi-Waworuntu H, Kapojos FX. Epidemiological study of malaria in north Sulawesi, Indonesia by fluorescence and Giemsa staining. <i>Japanese Journal of Medical Science & Biology.</i> 1992; 45(4): 175-84 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†
Indonesia	Tijitra E, Sekartuti R, Arbani P, Marwoto H. Sensitivitas Plasmodium falciparum terhadap beberapa obat anti malaria di desa Pekandangan, Jawa Tengah. <i>Conferencia Dunia Kedokteran.</i> 1993; 82: 53-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Indonesia	Yoshinaga K, Gerudug IK, Herman B, Suryanatha A, Suarsana N, Iskandarsyah, Zainudin, Handomi, Dachlan YP, Maekawa Y, Kanbara H. Malaria epidemiology and control methods in specific geographical foci in Lombok and Sumbawa islands of Indonesia: (I) epidemiology. <i>Trop Med Health.</i> 2008; 36(2): 81-92 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002-2003	*	†
Indonesia	Indonesia Plasmodium Falciparum Parasite Rate Data, Personal Communication with SurfAid 2008 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2007-2008	*	†
Indonesia	Indonesia Plasmodium Falciparum Parasite Rate Data, Personal Communication with D. Syafruddin 2007 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2007	*	†
Indonesia	Indonesia Plasmodium Falciparum Parasite Rate Data, Personal Communication with D. Syafruddin 2010 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005-2006	*	†
Indonesia	Indonesia Plasmodium Falciparum Parasite Rate Data, Personal Communication with United States Naval Medical Research Unit No. 2 2010 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Indonesia	Indonesia Plasmodium Falciparum Parasite Rate Data, Sekartuti 1996 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Indonesia	Indonesia Plasmodium Falciparum Parasite Rate Data, Sekartuti 1999 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Indonesia	Indonesia Plasmodium Falciparum Parasite Rate Data, SurfAid 2006 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Indonesia	Muhilal, Tarwojo I, Kodyat B, Herman S, Permaesih D, Karyadi D, Wilbur S, Tielsch JM. Changing prevalence of xerophthalmia in Indonesia, 1977-1992. <i>Eur J Clin Nutr.</i> 1994; 48(10): 708-714. as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1977-1978, 1992		
Iran	Ministry of Health and Medical Education (Iran), Statistical Centre of Iran. Iran Demographic and Health Survey 2000.	2000	*	
Iran	World Health Organization (WHO), Ministry of Health and Medical Education (Iran), Center for Non-Communicable Diseases Control (Iran). Iran STEPS Noncommunicable Disease Risk Factors Survey 2005.	2005		
Iran	World Health Organization (WHO), Control of Foodborne Trematode Infections 1995. Geneva, Switzerland: World Health Organization (WHO), 1995.	1995	*	
Iran	Ministry of Health and Medical Education (Iran), World Health Organization (WHO). Iran WHO Multi-country Survey Study on Health and Health System Responsiveness 2000-2001. Geneva, Switzerland: World Health Organization (WHO).	2000-2001		
Iran	Ministry of Health and Medical Education (Iran). Iran Vital Statistics - Deaths 2000-2006. [Unpublished].	2000-2006	*	†
Iran	Habibzadeh F, Yadollahie M, Roshanipoor M, Haghghi AB. Prevalence of atrial fibrillation in a primary health care centre in Fars Province, Islamic Republic of Iran. <i>East Mediterr Health J.</i> 2004; 10(1-2): 147-51.	2001		
Iran	Centre for Health Informatics and Multiprofessional Education, University College London. Model's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Iran	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Iran	Safarinejad MR. Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older. <i>Int Urol Nephrol.</i> 2008; 40(4): 921-31.	2003-2006		
Iran	Azarbazhooh MR, Etemadi MM, Donnan GA, Mokher N, Majidi MR, Ghayour-Mobarhan M, Ghandehary K, Farzadfar MT, Kiani R, Panahandeh M, Thrift AG. Excessive Incidence of Stroke in Iran. <i>Stroke.</i> 2010; 41(1): e3-e10.	2006-2007		
Iran	Ghandehari K, Moud ZI. Incidence and etiology of ischemic stroke in Persian young adults. <i>Acta Neurol Scand.</i> 2006; 113(2): 121-4.	2000-2005		
Iran	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol.</i> 2008; 121(4): 947-954.	1995, 2001-2002		
Iran	Ministry of Health and Medical Education (Iran). Iran Vital Registration - Deaths 2007. [Unpublished].	2007	*	†
Iran	Ministry of Health and Medical Education (Iran). Iran Vital Registration - Deaths 2008. [Unpublished].	2008	*	†
Iran	Ministry of Health and Medical Education (Iran). Iran Vital Registration - Deaths 2009. [Unpublished].	2009	*	†
Iran	Ministry of Health and Medical Education (Iran). Iran Vital Registration - Deaths 2010. [Unpublished].	2010	*	†
Iran	Hamed Y, Safa O, Haidari M. Cryptosporidium infection in diarrheic children in southeastern Iran. <i>Pediatr Infect Dis J.</i> 2005; 24(1): 86-8.	2003		
Iran	Eesteghamati A, Gouya M, Keshkar A, Najafi L, Zali MR, Sanaei M, Yaghini F, El Mohamady H, Patel M, Klena JD, Teleb N. Sentinel hospital-based surveillance of rotavirus diarrhea in Iran. <i>J Infect Dis.</i> 2009; 200 Suppl 1: 244-247.	2006-2007		
Iran	Modarres S, Rahbarmanesh AA, Edalat R, Sobrabi A, Modarres S, Gomari H, Motamedirad M, Sayari AA. Human rotavirus genotypes detection among hospitalized children, a study in Tehran, Iran. <i>Arch Iran Med.</i> 2011; 14(1): 39-45.	2004-2008		
Iran	MoezArdalan K, Zali MR, Dallal MMS, Hemami MR, Salmazadeh-Ahrabi S. Prevalence and pattern of antimicrobial resistance of Shigella species among patients with acute diarrhoea in Karaj, Tehran, Iran. <i>J Health Popul Nutr.</i> 2003; 21(2): 96-102.	2001-2002		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Iran	Davatchi F, Jamshidi A-R, Banihashemi AT, Gholami J, Forouzanfar MH, Akhlaghi M, Barghamdi M, Noorolabzadeh E, Khabazi A-R, Salehi M, Salari A-H, Karimifar M, Essalat-Manesh K, Hajjaliloo M, Soroosh M, Farzad F, Mousavi H-R, Samadi F, Ghazvini K, Asgharifard H, Zangabadi A-H, Shahram F, Nadji A, Akbarian M, Gharibdoost F. WHO-ILAR COPCORD Study (Stage 1, Urban Study) in Iran. <i>J Rheumatol</i> . 2008; 35(7): 1384.	2004-2006		
Iran	Fakhrzadeh H, Bandarian F, Adibi H, Samavat T, Malekafzali H, Hodjatzadeh E, Larjani B. Coronary heart disease and associated risk factors in Qazvin: a population-based study. <i>East Mediterr Health J</i> . 2008; 14(1): 33-41.	1980-2000		
Iran	Hadaegh F, Harati H, Ghanbarian A, Azizi F. Prevalence of coronary heart disease among Tehran adults: Tehran Lipid and Glucose Study. <i>East Mediterr Health J</i> . 2009; 15(1): 157-66.	1999-2001		
Iran	Sarraf-Zadegan N, Sayed-Tabatabaei FA, Bashardoost N, Maleki A, Totonchi M, Habibi HR, Sotodehmaran E, Tafazoli F, Karimi A. The prevalence of coronary artery disease in an urban population in Isfahan, Iran. <i>Acta Cardiol</i> . 1999; 54(5): 257-63.	1980-1995		
Iran	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998, 2000-2002		
Iran	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J</i> . 1998; 12(2): 315-35.	1993-1995		
Iran	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	1999		
Iran	Alavi A, Sanjari M, Haghdooost A, Sibbald RG. Common foot examination features of 247 Iranian patients with diabetes. <i>Int Wound J</i> . 2009; 6(2): 117-22.	2005		
Iran	Vatankhah N, Noudeh YJ, Khamseh ME, Baradaran HR. Screening people with type 2 diabetes at risk for foot ulceration in Iran. <i>Diabetes Technol Ther</i> . 2010; 12(9): 731-6.	2010		
Iran	Abdollahi A, Malekmadani MH, Mansoori MR, Bostak A, Abbaszadeh MR, Mirshahi A. Prevalence of diabetic retinopathy in patients with newly diagnosed type II diabetes mellitus. <i>Acta Med Iran</i> . 2006; 44(6): 415-19.	2005		
Iran	Javadi MA, Katibeh M, Rafati N, Dehghan MH, Zayeri F, Yaseri M, Sehat M, Ahmadi H. Prevalence of diabetic retinopathy in Tehran province: a population-based study. <i>BMC Ophthalmol</i> . 2009; 9(1): 12.	2007		
Iran	Amini M, Afshin-Nia F, Bashardoost N, Aminoroaya A, Shahparian M, Kazemi M. Prevalence and risk factors of diabetes mellitus in the Isfahan city population (aged 40 or over) in 1993. <i>Diabetes Res Clin Pract</i> . 1997; 38(3): 185-90.	1993		
Iran	Ayatollahi SMT, Moradi F, Ayatollahi SAR. Prevalences of migraine and tension-type headache in adolescent girls of Shiraz (southern Iran). <i>Headache</i> . 2002; 42(4): 287-90.	1998		
Iran	Kajbaf TZ, Asar S, Alipoor MR. Relationship between obesity and asthma symptoms among children in Ahvaz, Iran: a cross sectional study. <i>Ital J Pediatr</i> . 2011; 1.	2009	*	
Iran	Shakurnia AH, Assar S, Afra M, Latifi M. Prevalence of asthma among schoolchildren in Ahvaz, Islamic Republic of Iran. <i>East Mediterr Health J</i> . 2010; 16(6): 651-6.	2007	*	
Iran	Rad MHR, Hamzezhadeh A. Allergic disease in 6-7-year-old schoolchildren in Urmia, Islamic Republic of Iran. <i>East Mediterr Health J</i> . 2008; 14(5): 1044-53.	2002-2003		
Iran	Bayat-Movahed S, Samadzadeh H, Ziyarati L, Memary N, Khosravi R, Sadr-Eshkevari PS. Oral health of Iranian children in 2004: a national pathfinder survey of dental caries and treatment needs. <i>East Mediterr Health J</i> . 2011; 17(3): 243-9.	2004		
Iran	Eslampour F, Borzabadi-Farahani A, Asgari I. The relationship between aging and oral health inequalities assessed by the DMFT index. <i>Eur J Paediatr Dent</i> . 2010; 11(4): 193-9.	2008	*	
Iran	Hamiissi J, Hamiissi H. Prevalence of dental caries among elementary school attendees in Iran. <i>East Afr J Public Health</i> . 2010; 7(4): 338-41.	2005-2006	*	
Iran	Kazemnejad A, Zayeri F, Rokn AR, Kharzifard MJ. Prevalence and risk indicators of periodontal disease among high-school students in Tehran. <i>East Mediterr Health J</i> . 2008; 14(1): 119-25.	2004	*	
Iran	Hessari H, Vehkalahi M, Eghbal MJ, Murtomaa H. Lifelong exposure to smoking and oral health among 35- to 44-year-old Iranians. <i>Oral Health Prev Dent</i> . 2009; 7(1): 61-8.	2002	*	
Iran	Khalili D, Hadaegh F, Fahimfar N, Shafiee G, Sheikhholeslami F, Ghanbarian A, Azizi F. Does an electrocardiogram add predictive value to the rose angina questionnaire for future coronary heart disease? 10-year follow-up in a Middle East population. <i>J Epidemiol Community Health</i> . 2012; 66(12): 1104-9.	1999-2001	*	
Iran	Talaie M, Sarrafzadegan N, Sadeghi M, Oveisgharan S, Marshall T, Thomas GN, Iranpour R. Incidence of cardiovascular diseases in an Iranian population: the Isfahan Cohort Study. <i>Arch Iran Med</i> . 2013; 16(3): 138-44.	2001-2011	*	
Iran	Mohebbi SR, Rostami Nejad M, Tahaei SME, Pourhoseingholi MA, Habibi M, Azimzadeh P, Naghoosi H, Karayiannis P, Zali MR. Seroepidemiology of hepatitis A and E virus infections in Tehran, Iran: a population based study. <i>Trans R Soc Trop Med Hyg</i> . 2012; 106(9): 528-31.	2006-2007		
Iran	Alian S, Ajami A, Ghasseman R, Yadegarinia D. Age-specific seroprevalence of hepatitis A in Sari, northern Islamic Republic of Iran. <i>East Mediterr Health J</i> . 2011; 17(10): 754-8.	2007		
Iran	Sofian M, Aghakhani A, Farazi A-A, Banifazl M, Etemadi G, Azad-Armaki S, Ziazarifi A, Abhari Z, Eslamifar A, Khadem-Sadegh A, Izadi N, Ramezani A. Seroepidemiology of hepatitis A virus in children of different age groups in Tehran, Iran: implications for health policy. <i>Travel Med Infect Dis</i> . 2010; 8(3): 176-9.	2009		
Iran	Azizi F, Mehran L, Sheikhholeslam R, Ordookhani A, Naghavi M, Hedayati M, Padyab M, Mirmiran P. Sustainability of a well-monitored salt iodization program in Iran: marked reduction in goiter prevalence and eventual normalization of urinary iodine concentrations without alteration in iodine content of salt. <i>J Endocrinol Invest</i> . 2008; 31(5): 422-31.	2000-2001	*	
Iran	Dabbaghmanesh M-H, Sadegholvaad A, Eftehadi F, Ranjbar-Omrani G. The role of iron deficiency in persistent goiter. <i>Arch Iran Med</i> . 2008; 11(2): 157-61.	2005	*	
Iran	Monajemzadeh SM, Moghadam AZ. Prevalence of goiter among children aged 11-16 years in Ahvaz, Iran. <i>Med Princ Pract</i> . 2008; 17(4): 331-3.	2001	*	
Iran	Sivash M, Hassanzadeh Keshтели A, Hashemipour M, Amini M. Increased goiter prevalence in schoolchildren of Isfahan despite long-term iodine sufficiency. <i>Hormones (Athens)</i> . 2009; 8(1): 47-51.	2005	*	
Iran	Abedi F, Madani H, Asadi A, Nejatizadeh A. Significance of blood-related high-risk behaviors and horizontal transmission of hepatitis B virus in Iran. <i>Arch Virol</i> . 2011; 156(4): 629-35.	2008-2009		
Iran	Ataei B, Nokhodian Z, Javadi AA, Kassaian N, Shoaie P, Farajzadegan Z, Adibi P. Hepatitis E virus in Isfahan Province: a population-based study. <i>Int J Infect Dis</i> . 2009; 13(1): 67-71.	2005		
Iran	Saffar MJ, Farhadi R, Ajami A, Khalilian AR, Babamahmudi F, Saffar H. Seroepidemiology of hepatitis E virus infection in 2-25-year-olds in Sari district, Islamic Republic of Iran. <i>East Mediterr Health J</i> . 2009; 15(1): 136-42.	2003		
Iran	Merat S, Rezvan H, Nouraei M, Jafari E, Abolghasemi H, Radmard AR, Zaer-rezaei H, Amini-Kafabad S, Maghsudlu M, Poursahms A, Malekzadeh R, Esmaili S. Seroprevalence of hepatitis C virus: the first population-based study from Iran. <i>Int J Infect Dis</i> . 2010; e113-116.	2006		
Iran	Esmailzadeh S, Delavar MA, Zeinalzadeh M, Mir M-RA. Epidemiology of infertility: a population-based study in Babol, Iran. <i>Women Health</i> . 2012; 52(8): 744-54.	2009-2011	*	
Iran	Safarinejad MR. Infertility among couples in a population-based study in Iran: prevalence and associated risk factors. <i>Int J Androl</i> . 2008; 31(3): 303-14.	2005-2007	*	
Iran	Vahidi S, Ardalan A, Mohammad K. Prevalence of primary infertility in the Islamic Republic of Iran in 2004-2005. <i>Asia Pac J Public Health</i> . 2009; 21(3): 287-93.	2004-2005	*	
Iran	Tehrani FR, Simbar M, Tohidi M, Hosseinpah F, Azizi F. The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. <i>Reprod Biol Endocrinol</i> . 2011; 39.	2008-2010	*	†
Iran	Jafari F, Garcia-Gil LJ, Salmanzadeh-Ahrabi S, Shokrzadeh L, Aslani MM, Pourhoseingholi MA, Derakhshan F, Zali MR. Diagnosis and prevalence of enteropathogenic bacteria in children less than 5 years of age with acute diarrhea in Tehran children's hospitals. <i>J Infect</i> . 2009; 58(1): 21-7.	2003-2005	*	
Iran	Hamiissi J, Ramezani GH, Ghodousi A. Prevalence of dental caries among high school attendees in Qazvin, Iran. <i>J Indian Soc Pedod Prev Dent</i> . 2008; 26 Suppl: S53-55.	2007		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Iran	Meyer-Lueckel H, Paris S, Shirkhani B, Hopfenmuller W, Kielbassa AM. Caries and fluorosis in 6- and 9-year-old children residing in three communities in Iran. <i>Community Dent Oral Epidemiol.</i> 2006; 34(1): 63-70.	2004		
Iran	Safarinejad MR. Adult urolithiasis in a population-based study in Iran: prevalence, incidence, and associated risk factors. <i>Urol Res.</i> 2007; 35(2): 73-82.	2005		
Iran	Basiri A, Shakhssalim N, Khoshdel AR, Naghavi M. Regional and seasonal variation in the incidence of urolithiasis in Iran: a place for obsession in case finding and statistical approach. <i>Urol Res.</i> 2009; 37(4): 197-204.	2007-2008		
Iran	Janghorbani M, Hamzehie MA, Kachoeie H. Epidemiology of non-fatal stroke in Kerman, Iran. <i>Hamdard Medicus.</i> 1997; 89-98.	1992-1994		
Iran	Ahangar AA, Ashraf Vaghefi SB, Ramezani M. Epidemiological Evaluation of Stroke in Babol, Northern Iran (2001-2003). <i>Eur Neurol.</i> 2005; 54(2): 93-7.	2001-2003		
Iran	Bakhsiani NM, Mousavi MN, Khodabandeh G. Prevalence and severity of premenstrual symptoms among Iranian female university students. <i>J Pak Med Assoc.</i> 2009; 59(4): 205-8.	2005		
Iran	Chamani-Tabriz L, Tehrani MJ, Akhondi MMA, Mosavi-Jarrahi A, Zeraati H, Ghasemi J, Asgari S, Kokab A, Eley AR. Chlamydia trachomatis prevalence in Iranian women attending obstetrics and gynaecology clinics. <i>Pak J Biol Sci.</i> 2007; 10(24): 4490-4.	2003		
Iran	Mohseni-Bandpei MA, Bagheri-Nesami M, Shayesteh-Azar M. Nonspecific low back pain in 5000 Iranian school-age children. <i>J Pediatr Orthop.</i> 2007; 27(2): 126-9.	2005		
Iran	Fotouhi A, Hashemi H, Mohammad K, Jalali KH. The prevalence and causes of visual impairment in Tehran: the Tehran Eye Study. <i>Br J Ophthalmol.</i> 2004; 88(6): 740-5. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2002		
Iran	Sharifi Z, Emadi Ghanjin S. The Seroprevalence of Varicella Zoster Virus (VZV) in Different Age Groups in Tehran, Iran. <i>Iran J Allergy Asthma Immunol.</i> 2005; 4(2): 95-8.	2003-2005		
Iran	Ahmadi J, Sharifi M, Mohagheghzadeh S, Dehbozorgi GR, Farrashbandi H, Moosavinasab M, Firoozabadi A, Pridmore S, Evren C, Busch S. Pattern of cocaine and heroin abuse in a sample of Iranian population. <i>German J Psychiatry.</i> 2005; 1-4.	2004		
Iran	Ahmadi J, Hasani M. Prevalence of substance use among Iranian high school students. <i>Addict Behav.</i> 2003; 28(2): 375-9.	2000		
Iran	Ebrahimi H, Shafa M, Hakimzadeh Asl S. Prevalence of active epilepsy in Kerman, Iran: a house based survey. <i>Acta Neurol Taiwan.</i> 2012; 21(3): 115-24.	2010-2011	*	†
Iran	Yazdani S, Yosofniyapasha Y, Nasab BH, Mojaveri MH, Bouzari Z. Effect of maternal body mass index on pregnancy outcome and newborn weight. <i>BMC Res Notes.</i> 2012; 34.	2008-2009	*	
Iran	Bahasadri S, Kashanian M, Khosravi Z. Comparison of pregnancy outcome among nulliparas with and without microalbuminuria at the end of the second trimester. <i>Int J Gynaecol Obstet.</i> 2011; 115(1): 34-6.	2007-2008	*	
Iran	Tabatabaei M. Gestational weight gain, prepregnancy body mass index related to pregnancy outcomes in KAZERUN, FARS, IRAN. <i>J Prenat Med.</i> 2011; 5(2): 35-40.	2007-2010	*	
Iran	Delbari A, Salman Roghani R, Tabatabaei SS, Rahgozar M, Lökk J. Stroke epidemiology and one-month fatality among an urban population in Iran. <i>Int J Stroke.</i> 2011; 6(3): 195-200.	2001	*	
Iran	Delbari A, Salman Roghani R, Tabatabaei SS, Lökk J. A Stroke Study of an Urban Area of Iran: Risk Factors, Length of Stay, Case Fatality, and Discharge Destination. <i>J Stroke Cerebrovasc Dis.</i> 2010; 19(2): 104-9.	2006-2008	*	
Iran	Fahimfar N, Khalili D, Mohebi R, Azizi F, Hadaegh F. Risk factors for ischemic stroke; results from 9 years of follow-up in a population based cohort of Iran. <i>BMC Neurol.</i> 2012; 117.	1999-2009	*	
Iran	Moghtaderi A, Rakhshanzadeh F, Shahraki-Ibrahimi S. Incidence and prevalence of multiple sclerosis in southeastern Iran. <i>Clin Neurol Neurosurg.</i> 2013; 115(3): 304-8.	2006-2009	*	
Iran	Safarinejad MR. The epidemiology of adult chronic kidney disease in a population-based study in Iran: prevalence and associated risk factors. <i>J Nephrol.</i> 2009; 22(1): 99-108.	2002-2005		
Iran	Hajiani E, Masjedizadeh R, Hashemi J, Azmi M, Rajabi T. Risk factors for hepatocellular carcinoma in Southern Iran. <i>Saudi Med J.</i> 2005; 26(6): 974-7.	1999-2004		
Iran	Aghighi M, Mahdavi-Mazdeh M, Zamyadi M, Heidary Rouchi A, Rajolani H, Nourozi S. Changing epidemiology of end-stage renal disease in last 10 years in Iran. <i>Iran J Kidney Dis.</i> 2009; 3(4): 192-6.	1997-2006		
Iran	Monfared A, Safaei A, Panahandeh Z, Nemati L. Incidence of end-stage renal disease in Guilan Province, Iran, 2005 to 2007. <i>Iran J Kidney Dis.</i> 2009; 3(4): 239-41.	2005-2007		
Iran	Samadi SA, Mahmoodzadeh A, McConkey R. A national study of the prevalence of autism among five-year-old children in Iran. <i>Autism.</i> 2012; 16(1): 5-14.	2006-2009	*	
Iran	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Iran	Amiri S, Fakhari A, Maheri M, Mohammadpour Asl A. Attention deficit/hyperactivity disorder in primary school children of Tabriz, North-West Iran. <i>Paediatr Perinat Epidemiol.</i> 2010; 24(6): 597-601.	2007-2008	*	
Iran	Talaei A, Mokhter N, Abdollahian E, Bordbar MRF, Salari E. Attention deficit/hyperactivity disorder: a survey on prevalence rate among male subjects in elementary school (7 to 9 years old) in Iran. <i>J Atten Disord.</i> 2010; 13(4): 386-90.	2008	*	
Iran	Shahbeigi S, Ferestehnejad S-M, Mohammadi N, Golmakani MM, Tadayyon S, Jalilzadeh G, Pakdaman H. Epidemiology of headaches in Tehran urban area: a population-based cross-sectional study in district 8, year 2010. <i>Neurol Sci.</i> 2013; 34(7): 1157-66.	2010	*	
Iran	Fotouhi A, Hashemi H, Khabazkhoob M, Mohammad K. The prevalence of refractive errors among schoolchildren in Dezful, Iran. <i>Br J Ophthalmol.</i> 2007; 91(3): 287-92. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2005		
Iran	Emamian MH, Zeraati H, Majdzadeh R, Shariati M, Hashemi H, Fotouhi A. The gap of visual impairment between economic groups in Shahrood, Iran: a Blinder-Oaxaca decomposition. <i>Am J Epidemiol.</i> 2011; 173(12): 1463-7. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2008-2009		
Iran	Razavi H, Kuper H, Rezvan F, Amelie K, Mahboobi-Par H, Oladi MR, Muhit M, Hashemi H. Prevalence and causes of severe visual impairment and blindness among children in the Lorestan province of Iran, using the key informant method. <i>Ophthalmic Epidemiol.</i> 2010; 17(2): 95-102. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2007-2008		
Iran	Rajavi Z, Katibeh M, Ziaei H, Fardesmaeilpour N, Sehat M, Ahmadi H, Javadi MA. Rapid assessment of avoidable blindness in Iran. <i>Ophthalmology.</i> 2011; 118(9): 1812-8. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2009		
Iran	Hasani N, Khosravi S, Hashemipour M, Haghghatiyan M, Javdan Z, Taheri MH, Kelishadi R, Amini M, Barekatein R. Prevalence and related risk-factors of peripheral neuropathy in children with insulin-dependent diabetes mellitus. <i>J Res Med Sci.</i> 2013; 18(2): 132-6.	2008-2009		
Iran	Pishdad GR. Low incidence of type 1 diabetes in Iran. <i>Diabetes Care.</i> 2005; 28(4): 927-8.	1991-1996		
Iran	Frischer H, Bowman JE, Carson PE, Rieckmann KH, Willerson D Jr, Colwell EJ. Erythrocytic glutathione reductase, glucose-6-phosphate dehydrogenase, and 6-phosphogluconic dehydrogenase deficiencies in populations of the United States, South Vietnam, Iran, and Ethiopia. <i>J Lab Clin Med.</i> 1973; 81(4): 603-12.	1971-1973		
Iran	Bowman JE, Walker DG. Virtual Absence of Glutathione Instability of the Erythrocytes among Armenians in Iran. <i>Nature.</i> 1961; 191(4785): 221-2.	1959-1961		
Iran	Haghighi B, Suzangar M, Yazdani A, Mehnat M. A genetic variant of human erythrocyte glucose 6-phosphate dehydrogenase. <i>Biochem Biophys Res Commun.</i> 1985; 132(3): 1151-9.	1983-1985		
Iran	Usanga EA, Ameen R. Glucose-6-phosphate dehydrogenase deficiency in Kuwait, Syria, Egypt, Iran, Jordan and Lebanon. <i>Hum Hered.</i> 2000; 50(3): 158-61.	1996-1997		
Iran	Abolghasemi H, Mehrani H, Amid A. An update on the prevalence of glucose-6-phosphate dehydrogenase deficiency and neonatal jaundice in Tehran neonates. <i>Clin Biochem.</i> 2004; 37(3): 241-4.	1999		
Iran	Karimi M, Yavarian M, Afrasiabi A, Dehbozorgian J, Rachmilewitz E. Prevalence of beta-thalassemia trait and glucose-6-phosphate dehydrogenase deficiency in Iranian Jews. <i>Arch Med Res.</i> 2008; 39(2): 212-4.	2005		
Iran	Iranpour R, Hashemipour M, Talaei S-M, Soroshnia M, Amini A. Newborn screening for glucose-6-phosphate dehydrogenase deficiency in Isfahan, Iran: a quantitative assay. <i>J Med Screen.</i> 2008; 15(2): 62-4.	2006		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Iran	Haghighi AN, Broumand B, D'Amico M, Locatelli F, Ritz E. The epidemiology of end-stage renal disease in Iran in an international perspective. <i>Nephrol Dial Transplant.</i> 2002; 17(1): 28-32.	2000		
Iran	Mahdavi-Mazdeh M, Heidary Rouchi A, Norouzi S, Aghighi M, Rajolani H, Ahrabi S. Renal replacement therapy in Iran. <i>Urol J.</i> 2007; 4(2): 66-70.	1985-1987, 2006		
Iran	Hashemipour M, Faghilimani S, Zolfaghary B, Hovsepian S, Ahmadi F, Haghighi S. Prevalence of polycystic ovary syndrome in girls aged 14-18 years in Isfahan, Iran. <i>Horm Res.</i> 2004; 62(6): 278-82.	2001		
Iran	Yousefi-Mashouf R, Moshaghi AA. Frequency of Typhoidal and Non-Typhoidal Salmonella Species and Detection of Their Drugs Resistance Patterns. <i>J Res Health Sci.</i> 2007; 7(1): 49-56.	2001-2004	*	
Iran	Najafi I, Shakeri R, Islami F, Malekzadeh F, Salahi R, Yapan-Gharavi M, Hosseini M, Hakemi M, Alatab S, Rahmati A, Broumand B, Nobakht-Haghighi A, Larjani B, Malekzadeh R. Prevalence of chronic kidney disease and its associated risk factors: the first report from Iran using both microalbuminuria and urine sediment. <i>Arch Iran Med.</i> 2012; 15(2): 70-5.	2007-2009	*	
Iran	Najafi I, Attari F, Islami F, Shakeri R, Malekzadeh F, Salahi R, Gharavi MY, Hosseini M, Broumand B, Haghighi AN, Larjani B, Malekzadeh R. Renal function and risk factors of moderate to severe chronic kidney disease in Golestan Province, northeast of Iran. <i>PLoS One.</i> 2010; 5(12): e14216.	2007-2009	*	
Iran	Arami MA, Yazdchi M, Khandaghi R. Epidemiology and characteristics of Guillain-Barré syndrome in the northwest of Iran. <i>Ann Saudi Med.</i> 2006; 26(1): 22-7.	2003		†
Iran	Barzegar M, Dastgiri S, Karegarmaher MH, Varshochiani A. Epidemiology of childhood Guillain-Barre syndrome in the north west of Iran. <i>BMC Neurol.</i> 2007; 22.	2001-2006		†
Iran	Ghandehari K, Riasi HR, Nourian A, Boroumand AR. Prevalence of multiple sclerosis in north east of Iran. <i>Mult Scler.</i> 2010; 16(12): 1525-6.	2009	*	
Iran	Etemadifar M, Maghzi AH. Sharp increase in the incidence and prevalence of multiple sclerosis in Isfahan, Iran. <i>Mult Scler.</i> 2011; 17(8): 1022-7.	2003-2010	*	
Iran	Heydarpor P, Mohammad K, Yekaninejad MS, Elhami SR, Khoshkish S, Sahraian MA. Multiple sclerosis in Tehran, Iran: a jointpoint trend analysis. <i>Mult Scler.</i> 2013.	1991-2011	*	
Iran	Elhami SR, Mohammad K, Sahraian MA, Effekhar H. A 20-year incidence trend (1989-2008) and point prevalence (March 20, 2009) of multiple sclerosis in Tehran, Iran: a population-based study. <i>Neuroepidemiology.</i> 2011; 36(3): 141-720.	1989-2009	*	
Iran	Sahraian MA, Khorramnia S, Ebrahim MM, Moinfar Z, Lotfi J, Pakdaman H. Multiple sclerosis in Iran: a demographic study of 8,000 patients and changes over time. <i>Eur Neurol.</i> 2010; 64(6): 331-6.	1999-2008	*	
Iran	Hashemifar M, Savadi Ouskui D, Farhoudi M, Ayromlou H, Asadolahi A. Multiple sclerosis in East Azerbaijan, North West Iran. <i>Neurology Asia.</i> 2011; 16(2): 127-131.	2005-2009	*	
Iran	Ebrahimi HA, Sedighi B. Prevalence of multiple sclerosis and environmental factors in Kerman province, Iran. <i>Neurology Asia.</i> 2013; 18(4): 385-389.	2011	*	
Iran	Sharafaddinzadeh N, Moghtaderi A, Majdinasab N, Dahmardeh M, Kashipazha D, Shalbafan B. The influence of ethnicity on the characteristics of multiple sclerosis: a local population study between Persians and Arabs. <i>Clin Neuro Neurosurg.</i> 2013; 115(8): 1271-5.	1997-2009	*	
Iran	Sepahi MA, Shajari A, Shakiba M, Shoostary FK, Salimi MH. Acute glomerulonephritis: a 7 years follow up of children in center of Iran. <i>Acta Med Iran.</i> 2011; 49(6): 375-8.	2000-2006	*	
Iran	Ranjbar M, Rahmani E, Nooriamiri A, Gholami H, Golmohamadi A, Barati H, Rajabifar D, Barati S, Sabat MS, Zamiri A, Haghighi S, Taftehashemi P, Nojomi M. High prevalence of multidrug-resistant strains of <i>Vibrio cholerae</i> , in a cholera outbreak in Tehran-Iran, during June-September 2008. <i>Trop Doct.</i> 2010; 40(4): 214-6.	2008	*	
Iran	World Health Organization (WHO). Iran WHO Leishmaniasis Country Profile.	1994-2010	*	
Iran	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Iran	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec.</i> 2007; 82(25): 225-32.	2006	*	
Iran	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Iran	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Iran	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Iran	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec.</i> 2008; 83(33): 293-300.	2007	*	
Iran	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Iran	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Iran	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Iran	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Iran	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Iran	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Iran	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Iran	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1993; 68(25): 181-6.	1992	*	
Iran	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Iran	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Iran	Ziyaeyan M, Japoni A, Roostaee MH, Salehi S, Soleimanjahi H. A serological survey of Herpes Simplex Virus type 1 and 2 immunity in pregnant women at labor stage in Tehran, Iran. <i>Pak J Biol Sci.</i> 2007; 10(1): 148-51.	2003-2006	*	
Iran	Tayyebi D, Tabatabaee M, Rahsaz M. Seroepidemiology of infection with Herpes Simplex Virus type 2 (HSV2) among asymptomatic students attending Islamic Azad University of Kazeroun, southwest of Iran. <i>Retrovirology.</i> 2010; 7(Suppl 1): P88.	2007-2009	*	
Iran	Hashemi H, Khabakzhoob M, Emamian MH, Shariati M, Fotouhi A. Visual impairment in the 40- to 64-year-old population of Shahroud, Iran. <i>Eye (Lond).</i> 2012; 26(8): 1071-7.	2009-2010		
Iran	Shahriari H-A, Izadi S, Rouhani M-R, Ghaseemzadeh F, Maleki A-R. Prevalence and causes of visual impairment and blindness in Sistan-va-Baluchestan Province, Iran: Zahedan Eye Study. <i>Br J Ophthalmol.</i> 2007; 91(5): 579-84.	2004-2005	*	
Iran	Feghhi M, Khataminia G, Ziaei H, Latifi M. Prevalence and causes of blindness and low vision in Khuzestan province, Iran. <i>J Ophthalmic Vis Res.</i> 2009; 4(1): 29-34.	2006	*	
Iran	Haghighi Hasanabad M, Mohammadzadeh M, Bahador A, Fazel N, Rakhshani H, Majnooni A. Prevalence of Chlamydia trachomatis and Mycoplasma genitalium in pregnant women of Sabzevar-Iran. <i>Iran J Microbiol.</i> 2011; 3(3): 123-8.	2010-2011	*	
Iran	Hasanabad MH, Bahador A, Mohammadzadeh M, Haghighi F. P3.272 Prevalence of Chlamydia Trachomatis, Neisseria Gonorrhoeae and Ureaplasma Urealyticum in Pregnant Women of Sabzevar - Iran. <i>Sex Transm Infect.</i> 2013; 89(Suppl 1): A233-A234.	2010-2011	*	
Iran	Dezfulmanesh M, Tehranian N. Endocervical gonorrhea in pregnant and non pregnant women and follow up of the infected cases in Kermanshah Iran 2004. <i>Pak J Med Sci.</i> 2005; 21(3).	2002-2003	*	
Iran	Hassanzadeh P, Mardaneh J, Motamedifar M. Conventional Agar-Based Culture Method, and Nucleic Acid Amplification Test (NAAT) of the cfpB Gene for Detection of Neisseria gonorrhoea in Pregnant Women Endocervical Swab Specimens. <i>Iran Red Crescent Med J.</i> 2013; 15(3): 207-11.	2009-2011	*	
Iran	Nazer M, Nourouzi J, Mirsalehian A, Kazemi B, Mousavi T, Mahdizadeh AAF. Determination of Asymptomatic Chlamydia Trachomatis Infections By Omp1 Gene Based-PCR. <i>Cell J.</i> 2008; 10(1): 41-6.	2006	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Iran	Rashidi BH, Chamani-Tabriz L, Haghollahi F, Jeddi-Tehrani M, Naghizadeh MM, Shariat M, Akhondi MM, Bagheri R, Asgari S, Wylie K. Effects of Chlamydia trachomatis infection on Fertility: A Case-Control Study. <i>J Reprod Infertil.</i> 2013; 14(2): 67-72.	2007-2008	*	
Iran	WHO Regional Office for the Eastern Mediterranean. Operational Research in Tropical and Other Communicable Diseases: Final Report Summaries 2003-2004. Cairo, Egypt: WHO Regional Office for the Eastern Mediterranean.	2003	*	
Iran	Ebrahim M, Ahmad RS, Mohammad M. Incidence and Risk Factors of Retinopathy of Prematurity in Babol, North of Iran. <i>Ophthalmic Epidemiol.</i> 2010; 17(3): 166-70.	2006	*	†
Iran	Fereshtehnejad S-M, Shafeisabet M, Rahimi A, Delbari A. Screening of Parkinsonism in Tehran urban area, Iran: a community-based door-to-door prevalence study in the year 2012.	2012	*	
Iran	Hessari H, Vehkalahi MM, Eghbal MJ, Murtomaa H. Tooth loss and prosthodontic rehabilitation among 35- to 44-year-old Iranians. <i>J Oral Rehabil.</i> 2008; 35(4): 245-51.	2002		
Iran	Bakhtiari A, Hajian-Tilaki K, Pasha H. Genital infection by Trichomonas Vaginalis in women referring to Babol health centers: prevalence and risk factors. <i>Iran Red Crescent Med J.</i> 2008; 10(1): 16-21.	2004-2005		
Iran	Pakpor AH, Hidarnia A, Hajizadeh E, Kumar S, Harrison A-P. The status of dental caries and related factors in a sample of Iranian adolescents. <i>Med Oral Patol Oral Cir Bucal.</i> 2011; 16(6): e822-827.	2009	*	
Iran	Khazaei S, Keshteli AH, Feizi A, Savabi O, Adibi P. Epidemiology and risk factors of tooth loss among Iranian adults: findings from a large community-based study. <i>Biomed Res Int.</i> 2013; 786462.	2010-2011	*	
Iran	Barzandeh F, Yazdambod A, Pourfarzi F, Sepanlou SG, Derakhshan MH, Malekzadeh R. Epidemiology of Peptic Ulcer Disease: Endoscopic Results of a Systematic Investigation in Iran. <i>Middle East J Dig Dis.</i> 2012; 4(2): 90-96.	2000-2001	*	
Iran	Abolhassani F, Moayyeri A, Naghavi M, Soltani A, Larjani B, Shalmani HT. Incidence and characteristics of falls leading to hip fracture in Iranian population. <i>Bone.</i> 2006; 39(2): 408-13.	2003	*	
Iran	Saadat S, Mafi M, Sharif-Alhoseini M. Population based estimates of non-fatal injuries in the capital of Iran. <i>BMC Public Health.</i> 2011; 608.	2008	*	
Iran	Rezapour-Shahkolai F, Naghavi M, Vaez M, Shokouhi M, Laflamme L. Injury incidence, healthcare consumption and avenues for prevention: a household survey on injury in rural Twisarkan, Iran. <i>Public Health.</i> 2009; 123(5): 384-9.	2006	*	
Iran	Panjshahin MR, Lari AR, Talei A, Shamsnia J, Alaghebandan R. Epidemiology and mortality of burns in the South West of Iran. <i>Burns.</i> 2001; 27(3): 219-26.	1994-1998	*	
Iran	Saadat S, Soori H. Epidemiology of traffic injuries and motor vehicles utilization in the capital of Iran: a population based study. <i>BMC Public Health.</i> 2011; 488.	2008	*	
Iran	Soori H. Epidemiology of children's cycling injuries in Ahwaz, Islamic Republic of Iran. <i>East Mediterr Health J.</i> 2002; 8(2-3): 308-14.	1999-2000	*	
Iran	Shakeri MT, Noman H, Ghayour Mobarhan M, Sima HR, Gerayli S, Shahbazi S, Rostami S, Meshkat Z. The prevalence of hepatitis C virus in mashhad, Iran: a population-based study. <i>Hepat Mon.</i> 2013; 13(3): e7723.	2010-2011		
Iran	Ansari-Moghaddam A, Ostovaneh MR, Sharifi Mood B, Sanei-Moghaddam E, Modabbernia A, Poustchi H. Seroprevalence of hepatitis B surface antigen and anti hepatitis C antibody in zahedan city, Iran: a population-based study. <i>Hepat Mon.</i> 2012; 12(9): e6618.	2008-2009		
Iran	Alavian SM, Tabatabaee SV, Nourizad S, Mansouri F, Khademi N, Amini Kafi-abad S, Gharehbaghian A, Abolghasemi H. Seroepidemiology of HBV Infection in Kermanshah- West of Iran: a Population Based Study. <i>Jundishapur J Microbiol.</i> 2012; 5(4): 564-9.	2009-2010	*	
Iran	Gakidou E, Mallinger L, Abbott-Klafter J, Guerrero R, Villalpando S, Ridaura RL, Aekplakorn W, Naghavi M, Lim S, Lozano R, Murray CJ. Management of diabetes and associated cardiovascular risk factors in seven countries: a comparison of data from national health examination surveys. <i>Bull World Health Organ.</i> 2011; 89(3): 172-83.	2004		
Iran	Amoozegar H, Mirshekari M, Pishva N. Does the history before blood transfusion identify donors who are glucose-6-phosphate dehydrogenase (G-6-PD) deficient Turk J Haematol. 2006; 23(3): 147-50.	2003-2005	*	
Iran	Mortazavi Y, Mirzomohammadi F, Ardestani MT, Miri-Moghaddam E, Vulliamy TJ. Glucose 6-phosphate dehydrogenase deficiency in Tehran, Zanjan and Sistan-Balouchestan provinces: prevalence and frequency of Mediterranean variant of G6PD. <i>Iran J Biotechnol.</i> 2010; 8(4): 229-33.	2002-2004	*	
Iran	Nezhad SK, Mashayekhi A, Khatami SR, Daneshmand S, Fahmi F, Ghaderigandmani M, Jalali-Far MA. Prevalence and Molecular Identification of Mediterranean Glucose-6-Phosphate Dehydrogenase Deficiency in Khuzestan Province, Iran. <i>Iran J Public Health.</i> 2009; 38(3): 127-131.	2008	*	
Iran	Ohkura K, Miyashita T, Nakajima H, Matsumoto H, Matsutomo K, Rahabar S, Hedayat S. Distribution of polymorphic traits in Mazandaranian and Guilanian in Iran. <i>Hum Hered.</i> 1984; 34(1): 27-39.	1972		
Iran	Rahimi Z, Raygani AV, Siabani S, Mozafari H, Nagel RL, Muniz A. Prevalence of glucose-6-phosphate dehydrogenase deficiency among schoolboys in Kermanshah, Islamic Republic of Iran. <i>East Mediterr Health J.</i> 2008; 14(4): 978-9.	2005-2007	*	
Iran	Merat S, Rezvan H, Nouraei M, Abolghasemi H, Jamali R, Amini-Kafiabad S, Maghsudlu M, Poursahms A, Malekzadeh R. Seroprevalence and risk factors of hepatitis A virus infection in Iran: a population based study. <i>Arch Iran Med.</i> 2010; 13(2): 99-104.	2006	*	
Iran	Saffar MJ, Abedian O, Ajami A, Abedian F, Mirabi AM, Khalilian A-R, Saffar H. Age-specific seroprevalence of anti-hepatitis A antibody among 1-30 years old population of savadkuh, mazandaran, Iran with literature review. <i>Hepat Mon.</i> 2012; 12(5): 326-32.	2010	*	
Iran	Rahgozar S, Poorfathollah AA, Moafi AR, Old JM. Beta s gene in Central Iran is in linkage disequilibrium with the Indian-Arab haplotype. <i>Am J Hematol.</i> 2000; 65(3): 192-5.	1997-1999	*	
Iran	Farzadegan H, Shamszad M, Noori-Arya K. Epidemiology of viral hepatitis among Iranian population—a viral marker study. <i>Ann Acad Med Singapore.</i> 1980; 9(2): 144-8.	1979		
Iran	Mehr AJ, Ardakani MJE, Hedayati M, Shahraz S, Mehr EJ, Zali MR. Age-specific seroprevalence of hepatitis A infection among children visited in pediatric hospitals of Tehran, Iran. <i>Eur J Epidemiol.</i> 2004; 19(3): 275-8.	2002		
Iran	Ataei B, Javadi AA, Nokhodian Z, Kassaiean N, Shoaei P, Farajzadegan Z, Adibi P. HAV in Isfahan province: a population-based study. <i>Trop Gastroenterol.</i> 2008; 29(3): 160-2.	2006		
Iran	Farhud DD, Eftekhari A. Blood groups distribution in Iran. <i>Iran J Public Health.</i> 1994; 23(1-4): 1-10.	1991-1993	*	†
Iran	Badiee Z. Exchange transfusion in neonatal hyperbilirubinaemia: experience in Isfahan, Iran. <i>Singapore Med J.</i> 2007; 48(5): 421-3.	2001-2004	*	†
Iran	Ardakani SB, Dana VG, Ziaee V, Ashtiani M-TH, Djavid GE, Alijani M. Bilirubin/Albumin Ratio for Predicting Acute Bilirubin-induced Neurologic Dysfunction. <i>Iran J Pediatr.</i> 2011; 21(1): 28-32.	2007-2008		†
Iran	Alizadeh AHM, Ranjbar M, Ansari S, MirArab A, Alavian SM, Mohammad K, Adibi P, Sadri GH, Keramat F, Ardalan A, Arabi M, Gharekhani S, Ataei A, Amraei GR, Hosseinzadeh M, Hatami S, Zali M. Seroprevalence of hepatitis B in Nahavand, Islamic Republic of Iran. <i>East Mediterr Health J.</i> 2006; 12(5): 528-37.	2003		
Iran	Amini S, Mahmoodi MF, Andalibi S, Solati AA. Seroepidemiology of hepatitis B, delta and human immunodeficiency virus infections in Hamadan province, Iran: a population based study. <i>J Trop Med Hyg.</i> 1993; 96(5): 277-87.	1989		
Iran	Karimi M, Ghavanini AA. Seroprevalence of HBsAg, anti-HCV, and anti-HIV among haemophilic patients in Shiraz, Iran. <i>Haematologia (Budap).</i> 2001; 31(3): 251-5.	1999-2000		
Iran	Sanaei-Zadeh H, Amoei M, Taghadosinejad F. Seroprevalence of HIV, HBV and HCV in forensic autopsies, of presumed low risk, in Tehran, the capital of Iran. <i>J Clin Forensic Med.</i> 2002; 9(4): 179-81.	2000-2001		
Iran	Taremi M, Mohammad Alizadeh AH, Ardalan A, Ansari S, Zali MR. Seroprevalence of hepatitis E in Nahavand, Islamic Republic of Iran: a population-based study. <i>East Mediterr Health J.</i> 2008; 14(1): 157-62.	2003		
Iran	Zali MR, Mohammad K, Noorbala AA, Noorimayer B, Shahraz S, Sahraz S. Rate of hepatitis B seropositivity following mass vaccination in the Islamic Republic of Iran. <i>East Mediterr Health J.</i> 2005; 11(1-2): 62-7.	1991, 1999		
Iran	Ketabchi AA, Aziziolahi GA. Prevalence of symptomatic urinary calculi in Kerman, Iran. <i>Urol J.</i> 2008; 5(3): 156-60.	2005-2006	*	
Iran	Basiri A, Shakhssalim N, Khoshdel AR, Ghahestani SM, Basiri H. The demographic profile of urolithiasis in Iran: a nationwide epidemiologic study. <i>Int Urol Nephrol.</i> 2010; 42(1): 119-26.	2007-2008	*	
Iran	Mokri A. Brief overview of the status of drug abuse in Iran. <i>Arch Iran Med.</i> 2002; 5(3): 184-90.	1998-1999	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Iran	Tehrani FR, Simbar M, Abedini M. Reproductive morbidity among Iranian women; issues often inappropriately addressed in health seeking behaviors. <i>BMC Public Health</i> . 2011; 11: 863.	2008-2010	*	
Iran	Iran Vital Registration Birth Data 1991 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1991		
Iran	Iran - Tabriz Registry of Congenital Anomalies Data 2010 - ICBDNR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
Iran	Iran - Tabriz Registry of Congenital Anomalies Data 2007 - ICBDNR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Iran	Iran - Tabriz Registry of Congenital Anomalies Data 2009 - ICBDNR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Iran	Iran - Tabriz Registry of Congenital Anomalies Data 2004 - ICBDNR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
Iran	Iran - Tabriz Registry of Congenital Anomalies Data 2008 - ICBDNR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
Iraq	United Nations Children's Fund (UNICEF), Central Organization for Statistics and Information Technology (Iraq), Kurdistan Regional Statistics Office. Iraq Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006	*	†
Iraq	Central Statistical Organization (Iraq), United Nations Children's Fund (UNICEF). Iraq Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Iraq	Central Organization for Statistics and Information Technology (Iraq), Ministry of Health (Iraq), World Health Organization (WHO). Iraq STEPS Noncommunicable Disease Risk Factors Survey 2006.	2006		
Iraq	Central Organization for Statistics and Information Technology (Iraq), Kurdistan Regional Statistics Office, Ministry of Health (Iraq), United Nations Children's Fund (UNICEF). Iraq Multiple Indicator Cluster Survey 2011. New York, United States: United Nations Children's Fund (UNICEF), 2013.	2011	*	†
Iraq	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Iraq	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Iraq	Al-Rubaiy KK, Al-Rubaiy LK. Dermatoepidemiology: A Household Survey Among Two Urban Areas In Basrah City, Iraq. <i>Internet J Dermatol</i> . 2006; 4(2): 10.	2005		
Iraq	Hassan MK, Taha JY, Al-Naama LM, Widad NM, Jasim SN. Frequency of haemoglobinopathies and glucose-6-phosphate dehydrogenase deficiency in Basra. <i>East Mediterr Health J</i> . 2003; 1-2(9): 45-54.	1990-2001		
Iraq	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001, 2005, 2007-2008		
Iraq	Al-Allawi NA, Al-Dousky AA. Frequency of haemoglobinopathies at premarital health screening in Dohuk, Iraq: implications for a regional prevention programme. <i>East Mediterr Health J</i> . 2010; 16(4): 381-5.	2006	*	
Iraq	Baghdady VS, Ghose LJ. Dental caries prevalence in schoolchildren of Baghdad province, Iraq. <i>Community Dent Oral Epidemiol</i> . 1982; 10(3): 148-51.	1980		
Iraq	Alhasnawi S, Sadiq S, Rasheed M, Baban A, Al-Alak MM, Othman AY, Othman Y, Ismet N, Shawani O, Murthy S, Aljadiry M, Chatterji S, Al-Gaseer N, Streel E, Naidoo N, Mahomoud Ali M, Gruber MJ, Petukhova M, Sampson NA, Kessler RC, Iraq Mental Health Survey Study Group. The prevalence and correlates of DSM-IV disorders in the Iraq Mental Health Survey (IMHS). <i>World Psychiatry</i> . 2009; 8(2): 97-109.	2006-2007		
Iraq	Al-Jawadi AA, Abdul-Rhman S. Prevalence of childhood and early adolescence mental disorders among children attending primary health care centers in Mosul, Iraq: a cross-sectional study. <i>BMC Public Health</i> . 2007; 7: 274.	2003-2004		
Iraq	Hehrani P, Abdolabian E, Behdani F, Vosough I, Javanbakht A. The prevalence of attention deficit hyperactivity disorder in preschool-age children in Mashhad, north-East of Iran. <i>Arch Iran Med</i> . 2007; 10(2): 147-51.	2004		
Iraq	Jabir M, Abdul-Salam I, Sufeil DM, Al-Hilli W, Abul-Hassan S, Al-Zubeiri A, Al-Ba'aj R, Dekan A, Tunçalp O, Souza JP. Maternal near miss and quality of maternal health care in Baghdad, Iraq. <i>BMC Pregnancy Childbirth</i> . 2013; 11.	2010	*	
Iraq	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2001, 2004, 2007, 2010, 2012		
Iraq	Amin-Zaki L, el-Din ST, Kubba K. Glucose-6-phosphate dehydrogenase deficiency among ethnic groups in Iraq. <i>Bull World Health Organ</i> . 1972; 47(1): 1-5.	1970-1972		
Iraq	Hilmi FA, Al-Allawi NA, Rassam M, Al-Shamma G, Al-Hashimi A. Red cell glucose-6-phosphate dehydrogenase phenotypes in Iraq. <i>East Mediterr Health J</i> . 2002; 8(1): 42-8.	2000-2004		
Iraq	Khamroo TY. Assessment of periodontal disease using the CPITN index in a rural population in Ninevah, Iraq. <i>East Mediterr Health J</i> . 1999; 5(3): 549-55.	1997		
Iraq	Al-Abbassi AM, Ahmed S, Al-Hadithi T. Cholera epidemic in Baghdad during 1999: clinical and bacteriological profile of hospitalized cases. <i>East Mediterr Health J</i> . 2005; 11(1-2): 6-13.	1999	*	
Iraq	Khwaif JM, Hayyawi AH, Yousif TI. Cholera outbreak in Baghdad in 2007: an epidemiological study. <i>East Mediterr Health J</i> . 2010; 16(6): 584-9.	2007	*	
Iraq	World Health Organization (WHO). Iraq WHO Leishmaniasis Country Profile.	1989-2008	*	
Iraq	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec</i> . 2007; 82(25): 225-32.	2006	*	
Iraq	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec</i> . 2009; 84(33): 333-40.	2008	*	
Iraq	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec</i> . 2010; 85(35): 337-48.	2009	*	
Iraq	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec</i> . 2012; 87(34): 317-28.	2011	*	
Iraq	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec</i> . 2008; 83(33): 293-300.	2007	*	
Iraq	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec</i> . 2013; 88(35): 365-79.	2012	*	
Iraq	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec</i> . 2011; 86(36): 389-99.	2010	*	
Iraq	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1994; 69(20): 145-51.	1993	*	
Iraq	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1995; 70(25): 177-82.	1994	*	
Iraq	Hameed NN, Na' Ma AM, Vilms R, Bhatani VK. Severe neonatal hyperbilirubinemia and adverse short-term consequences in Baghdad, Iraq. <i>Neonatology</i> . 2011; 100(1): 57-63.	2007-2008	*	†
Iraq	Al-Kubaisy WA, Niazi AD, Kubba K. History of miscarriage as a risk factor for hepatitis C virus infection in pregnant Iraqi women. <i>East Mediterr Health J</i> . 2002; 8(2-3): 239-44.	2002		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Iraq	Shibab K, Ali N, Dorky N, Jawad A, Abdul Latif Y, Habeen R. Immunological and parasitological survey in areas of Iraq where malaria transmission has been interrupted since several years. Bull Endem Dis (Baghdad). 1988; 28(1-4): 17-28 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Iraq	Iraq Vital Registration Birth Data 1977 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1977		
Ireland	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2005		
Ireland	World Health Organization (WHO). Ireland World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		
Ireland	Economic and Social Research Institute (ESRI) (Ireland), Health Promotion Unit, Department of Health and Children (Ireland), National University of Ireland, Galway, Royal College of Surgeons in Ireland (RCSI), University College Cork. Ireland Survey of Lifestyle Attitudes and Nutrition 2007. Dublin, Ireland: Health Promotion Unit, Department of Health and Children (Ireland).	2007		
Ireland	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Ireland	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. J Allergy Clin Immunol. 2008; 121(4): 947-954.	1995, 2003		
Ireland	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001-2009		
Ireland	McGuigan C, McCarthy A, Quigley C, Bannan L, Hawkins SA, Hutchinson M. Latitudinal variation in the prevalence of multiple sclerosis in Ireland, an effect of genetic diversity. J Neurol Neurosurg Psychiatry. 2004; 75(4): 572-6.	2001		
Ireland	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J. 1998; 12(2): 315-35.	1993-1995		
Ireland	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2003		
Ireland	Duggan EM, Sturley J, Fitzgerald AP, Perry JJ, Hourihane JO. The 2002-2007 trends of prevalence of asthma, allergic rhinitis and eczema in Irish schoolchildren. Pediatr Allergy Immunol. 2012; 23(5): 464-71.	2002, 2007	*	
Ireland	Kelly I, Fitzpatrick P. Sub-optimal asthma control in teenagers in the midland region of Ireland. Ir J Med Sci. 2011; 180(4): 851-4.	2006-2007	*	
Ireland	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. Community Dent Oral Epidemiol. 1991; 19(2): 72-3.	1987		
Ireland	Power D, Codd M, Ivers L, Sant S, Barry M. Prevalence of rheumatoid arthritis in Dublin, Ireland: a population based survey. Ir J Med Sci. 1999; 168(3): 197-200.	1995		
Ireland	Bolin AK, Bolin A, Koch G. Children's dental health in Europe: caries experience of 5- and 12-year-old children from eight EU countries. Int J Paediatr Dent. 1996; 6(3): 155-62.	1994		
Ireland	McCabe M, Kinirons MJ. Dental caries and dental registration status in nursery school children in Newry, Northern Ireland. Community Dent Oral Epidemiol. 1995; 23(2): 69-71.	1993		
Ireland	Scully PJ, Owens JM, Kinsella A, Waddington JL. Schizophrenia, schizoaffective and bipolar disorder within an epidemiologically complete, homogeneous population in rural Ireland: small area variation in rate. Schizophr Res. 2004; 67(2-3): 143-55.	1996		
Ireland	Lynch F, Mills C, Daly I, Fitzpatrick C. Challenging times: Prevalence of psychiatric disorders and suicidal behaviours in Irish adolescents. J Adolesc. 2006; 29(4): 555-73.	2003-2004		
Ireland	Ayuso-Mateos JL, Vázquez-Barquero JL, Dowrick C, Lehtinen V, Dalgard OS, Casey P, Wilkinson C, Lasa L, Page H, Dunn G, Wilkinson G. Depressive disorders in Europe: prevalence figures from the ODIN study. Br J Psychiatry. 2001; 179(4): 308-16.	1999-2001		
Ireland	Ryan M, Hamilton V, Bowen M, McKenna P. The role of a high-dependency unit in a regional obstetric hospital. Anaesthesia. 2000; 55(12): 1155-8.	1996-1998		
Ireland	de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Künzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P. European Community Respiratory Health Survey Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax. 2004; 59(2): 120-125.	1991-1993		
Ireland	Lutomski JE, Morrison JJ, Greene RA, Lydon-Rochelle MT. Maternal morbidity during hospitalization for delivery. Obstet Gynecol. 2011; 117(3): 596-602.	2005-2008		
Ireland	Johnson S, Khalid S, Varadkar S, Fleming J, Fanning R, Flynn C. Quality of care in the management of major obstetric hemorrhage. Ir Med J. 2011; 104(4): 119-21.	2009		
Ireland	McMillan HM, O'Carroll H, Lambert JS, Grundy KB, O'Reilly M, Lennon B, Collins C, Walsh TA, Geary MP, Cafferkey MT. Screening for Chlamydia trachomatis in asymptomatic women attending outpatient clinics in a large maternity hospital in Dublin, Ireland. Sex Transm Infect. 2006; 82(6): 503-5.	2003		
Ireland	De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000; 54(11 Suppl 5): S21-23.	1997		
Ireland	Berger K, BM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000; 54(11): 24-7.	1997		
Ireland	Youssef HA, Kinsella A, Waddington JL. Evidence for geographical variations in the prevalence of schizophrenia in rural Ireland. Arch Gen Psychiatry. 1991; 48(3): 254-8.	1987-1988		
Ireland	Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganey K, Giel R, an der Heiden W, Holmberg SK, Janca A, Lee PW, León CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirikis SJ, Varma VK, Walsh D, Wiersma D. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry. 2001; 178: 506-17.	1978-1993		
Ireland	Morgan MG, Scully PJ, Youssef HA, Kinsella A, Owens JM, Waddington JL. Prospective analysis of premature mortality in schizophrenia in relation to health service engagement: a 7.5-year study within an epidemiologically complete, homogeneous population in rural Ireland. Psychiatry Res. 2003; 117(2): 127-35.	1992-1999		
Ireland	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Ireland	Nardone A, de Ory F, Carton M, Cohen D, van Damme P, Davidkin I, Rota MC, de Melker H, Mossong J, Slacikova M, Tischer A, Andrews N, Berbers G, Gabutti G, Gay N, Jones L, Jokinen S, Kafatos G, de Aragón MVM, Schneider F, Smetana Z, Vargova B, Vranckx R, Miller E. The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine. 2007; 25(45): 7866-72.	2003		
Ireland	Knowles SJ, Grundy K, Cahill I, Cafferkey MT. Susceptibility to infectious rash illness in pregnant women from diverse geographical regions. Commun Dis Public Health. 2004; 7(4): 344-8.	2002		
Ireland	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1995, 1999, 2002-2003, 2006-2007		
Ireland	Department of Health, Social Services and Public Safety (Northern Ireland), National Advisory Committee on Drugs (Ireland). Ireland and Northern Ireland Drug Prevalence Survey 2002-2003.	2002-2003		
Ireland	Health Research Board (Ireland). Ireland Annual Report of the National Intellectual Disability Database Committee 2008. Dublin, Ireland: Health Research Board (Ireland), 2009.	1964, 1981, 2006		
Ireland	Hope B, Shahdadpuri R, Dunne C, Broderick AM, Grant T, Hamzawi M, O'Driscoll K, Quinn S, Hussey S, Bourke B. Rapid rise in incidence of Irish paediatric inflammatory bowel disease. Arch Dis Child. 2012; 97(7): 590-4.	2000-2010	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Ireland	Bunting B, Murphy S, O'Neill S, Ferry F. Prevalence and treatment of 12-month DSM-IV disorders in the Northern Ireland study of health and stress. <i>Soc Psychiatry Psychiatr Epidemiol.</i> 2013; 48(1): 81-93.	2004-2008	*	
Ireland	McDowell RD, Ryan A, Bunting BP, O'Neill SM, Alonso J, Bruffaerts R, de Graaf R, Florescu S, Vilagut G, de Almeida JMC, de Girolamo G, Haro JM, Hinkov H, Kovess-Masfety V, Matschinger H, Tomov T. Mood and anxiety disorders across the adult lifespan: a European perspective. <i>Psychol Med.</i> 2013; 1-16.	2004-2007	*	
Ireland	Department of Health, Social Services and Public Safety (Northern Ireland), National Advisory Committee on Drugs (Ireland). Ireland and Northern Ireland Drug Prevalence Survey 2006-2007.	2006-2007		
Ireland	WHO Regional Office for Europe (EURO-WHO). Young People's Health in Context. Health Behaviour in School-aged Children (HBSC) Study: International Report from the 2001-2002 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2004.	2002		
Ireland	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Ireland	Centre for Health Promotion Studies, National University of Ireland, Galway, Department of Public Health Medicine and Epidemiology, University College Dublin, Health Promotion Unit, Department of Health and Children (Ireland). Ireland National Health and Lifestyle Surveys Report 1998-2002. Dublin, Ireland: Health Promotion Unit, Department of Health and Children (Ireland), 2003.	1998, 2002		
Ireland	Scott-Pillai R, Spence D, Cardwell C, Hunter A, Holmes V. The impact of body mass index on maternal and neonatal outcomes: a retrospective study in a UK obstetric population. 2004-2011. <i>BJOG.</i> 2013; 120(8): 932-9.	2004-2011	*	
Ireland	Upton K, Silver RM, Greene R, Lutomski J, Holt VL. Placenta accreta and maternal morbidity in the Republic of Ireland, 2005-2010. <i>J Matern Fetal Neonatal Med.</i> 2014; 27(1): 24-9.	2005-2010	*	
Ireland	North RA, McCowan LME, Dekker GA, Poston L, Chan EHY, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. <i>BMJ.</i> 2011; d1875.	2004-2008	*	
Ireland	O'Connor HD, Hehir MP, Kent EM, Foley ME, Fitzpatrick C, Geary MP, Malone FD. Eclampsia: trends in incidence and outcomes over 30 years. <i>Am J Perinatol.</i> 2013; 30(8): 661-4.	1977-2006	*	
Ireland	Smits LJM, North RA, Kenny LC, Myers J, Dekker GA, McCowan LME. Patterns of vaginal bleeding during the first 20 weeks of pregnancy and risk of pre-eclampsia in nulliparous women: results from the SCOPE study. <i>Acta Obstet Gynecol Scand.</i> 2012; 91(11): 1331-8.	2004-2008	*	
Ireland	Glynn LG, Anderson J, Reddan D, Murphy AW. Chronic kidney disease in general practice: prevalence, diagnosis, and standards of care. <i>Ir Med J.</i> 2009; 102(9): 285-8.	2006		
Ireland	Youssef HA, Scully PJ, Kinella A, Waddington JL. Geographical variation in rate of schizophrenia in rural Ireland by place at birth vs place at onset. <i>Schizophr Res.</i> 1999; 37(3): 233-43.	1992		
Ireland	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2010, 2012		
Ireland	Impey LWM, Greenwood CEL, Black RS, Yeh PS-Y, Sheil O, Doyle P. The relationship between intrapartum maternal fever and neonatal acidosis as risk factors for neonatal encephalopathy. <i>Am J Obstet Gynecol.</i> 2008; 198(1): 49.	1998-2001	*	†
Ireland	McShane M, Maguire S, McClure G, Halliday H, McC Reid M. Birth asphyxia, encephalopathy and outcome. <i>Ir Med J.</i> 1987; 80(12): 421-2.	1979-1984	*	†
Ireland	Azzopardi DV, Strohm B, Edwards AD, Dyet L, Halliday HL, Juscak E, Kapellou O, Levene M, Marlow N, Porter E, Thoresen M, Whitelaw A, Brocklehurst P, TOBY Study Group. Moderate hypothermia to treat perinatal asphyxial encephalopathy. <i>N Engl J Med.</i> 2009; 361(14): 1349-58.	2002-2006	*	†
Ireland	Kelly A, Carvalho M, Tejeur C. A 3-Source Capture Recapture Study of the Prevalence of Opiate Use in Ireland 2000 to 2001. Dublin, Ireland: Department of Community Health and General Practice, Trinity College Dublin, 2003.	2000-2001	*	
Ireland	Bargagli AM, Hickman M, Davoli M, Perucci CA, Schifano P, Buster M, Brugal T, Vicente J, COSMO European Group. Drug-related mortality and its impact on adult mortality in eight European countries. <i>Eur J Public Health.</i> 2006; 16(2): 198-202.	1994-1997	*	
Ireland	Kraus L, Augustin R, Frischer M, Kümmler P, Uhl A, Wiessing L. Estimating prevalence of problem drug use at national level in countries of the European Union and Norway. <i>Addiction.</i> 2003; 98(4): 471-85.	1996	*	
Ireland	Smyth BP, Barry J, Lane A, Cotter M, O'Neill M, Quinn C, Keenan E. In-patient treatment of opiate dependence: medium-term follow-up outcomes. <i>Br J Psychiatry.</i> 2005; 360-5.	1995-1999	*	
Ireland	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant.</i> 1988; 3(6): 714-27.	1985-1986		
Ireland	Berthouf F, Jones E, Gellert R, Mendel S, Saker L, Briggs D. Epidemiological data of treated end-stage renal failure in the European Union (EU) during the year 1995: report of the European Renal Association Registry and the National Registries. <i>Nephrol Dial Transplant.</i> 1999; 14(10): 2332-42.	1995		
Ireland	Mueller A, Gooren LJ, Naton-Schütz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. <i>J Clin Endocrinol Metab.</i> 2008; 93(4): 1408-11.	2005		
Ireland	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguiar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Peda I, Gilst WH van, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J.</i> 2003; 24(5): 442-63.	2000-2001		
Ireland	Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. Cancer Incidence in Five Continents. Vol. I to VIII. Lyon, France, IARC Press, 2005.	1980-1986, 1988-1992	*	
Ireland	Department of Health and Children (Ireland), Department of Health, Social Services and Public Safety (Northern Ireland), Economic and Social Research Institute (ESRI) (Ireland), Oral Health Services Research Centre, University College Cork. Ireland National Survey of Adult Oral Health 2000-2002.	2000-2002		
Ireland	al-Khateeb TL, O'Mullane D, Whelton H. Comparison of the need for periodontal care amongst 15-year-old children in Ireland and Saudi Arabia as assessed by CPITN. <i>Community Dent Oral Epidemiol.</i> 1990; 18(1): 55.	1983		
Ireland	O'Farrell A, Allwright S, Toomey D, Bedford D, Conlon K. Hospital admission for acute pancreatitis in the Irish population, 1997-2004: could the increase be due to an increase in alcohol-related pancreatitis? <i>J Public Health (Oxf).</i> 2007; 29(4): 398-404.	1997-2004	*	
Ireland	Halliday HL, Reid MM, McClure G. Results of heavy drinking in pregnancy. <i>Br J Obstet Gynaecol.</i> 1982; 89(11): 892-5.	1978-1982	*	
Ireland	Department of Health and Children (Ireland), Health Promotion Research Centre, National University of Ireland, Galway, WHO Regional Office for Europe (EURO-WHO). Ireland Health Behavior in School-Aged Children Survey 2006. Ireland: Department of Health and Children (Ireland), 2007.	2006		
Ireland	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland: World Health Organization (WHO).	2001	*	
Ireland	Björnsson S, Johannsson JH, Oddsson E. Inflammatory bowel disease in Iceland, 1980-89. A retrospective nationwide epidemiologic study. <i>Scand J Gastroenterol.</i> 1998; 33(1): 71-7.	1980-1989		
Ireland	Trichopoulos D, Bania C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overvad K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PHM, Lund E, Quirós JR, González CA, Sanchez Perez M-J, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regné S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu I, Chuang S-C, Murphy N, Boffetta P, Trichopoulos A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. <i>J Natl Cancer Inst.</i> 2011; 103(22): 1686-95.	1992-2006	*	
Ireland	Fry G, Kenny JV, Quinn M, Campion J, Gallagher E. Prevalence of hepatitis A IgG in Irish international travellers. <i>Ir Med J.</i> 1993; 86(4): 137-8.	1986-1991		
Ireland	Rajan E, O'Farrell B, Shattock AG, Fielding JF. Hepatitis A in urban Ireland. <i>Ir J Med Sci.</i> 1998; 167(4): 231-3.	1993-1996		
Ireland	Zeitlan J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT. 2008. Available from: http://www.perinataleaudit.nl/downloads/bestand/649/peristat-ii-2008-	2004		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Ireland	Ireland Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD), United Nations Demographic Yearbook - Historical Supplement 1997, New York City, United States: United Nations Statistics Division (UNSD).	1990		
Ireland	Ireland EUROCAT Data 2001 - ICBDSR as it appears in International Clearinghouse for Birth Defects Monitoring Systems, International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
Ireland	Ireland EUROCAT Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research, International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
Ireland	Ireland EUROCAT Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research, International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Ireland	Israel Birth Defects Surveillance Program Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research, International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
Ireland	European Surveillance of Congenital Anomalies (EUROCAT), Ireland EUROCAT Prevalence Tables. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	1980-2011		
Ireland	Ireland EUROCAT Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO), World Atlas of Birth Defects, 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Ireland	Ireland EUROCAT Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research, International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
Ireland	Ireland EUROCAT Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research, International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Ireland	Ireland EUROCAT Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research, International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
Israel	WHO Regional Office for Europe (EURO-WHO), European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	1999-2009		
Israel	Israel Vital Registration - Deaths 1981 ICD9 as it appears in World Health Organization (WHO), WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1981	*	
Israel	Israel Vital Registration - Deaths 1985 ICD9 as it appears in World Health Organization (WHO), WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1985	*	
Israel	Israel Vital Registration - Deaths 1999 ICD10 as it appears in World Health Organization (WHO), WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1999	*	
Israel	World Health Organization (WHO), Israel World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		
Israel	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Israel	Shibli F, Flatau E, Nitzan O, Chazan B, Edelstein H, Raz R, Colodner R, Blondheim O. Etiology of community-acquired pneumonia in hospitalized patients in Northern Israel. <i>Isr Med Assoc J.</i> 2010; 12(8): 477-82.	2006-2007		
Israel	Cohen D, Tamir D. The prevalence of middle ear pathologies in Jerusalem school children. <i>Am J Otol.</i> 1989; 10(6): 456-9.	1984-1985		
Israel	Podoshin L, Fradis M, Ben-David Y, Margalit A, Tamir A, Epstein L. Cholesteatoma: an epidemiologic study among members of kibbutzim in northern Israel. <i>Ann Otol Rhinol Laryngol.</i> 1986; 95(4 Pt 1): 365-8.	1984-1986		
Israel	Muhsen K, Shulman L, Rubinstein U, Kasem E, Kremer A, Goren S, Zilberstein I, Chodick G, Ephros M, Cohen D. Incidence, characteristics, and economic burden of rotavirus gastroenteritis associated with hospitalization of Israeli children <5 years of age, 2007-2008. <i>J Infect Dis.</i> 2009; 200(Suppl 1): S254-263.	2007-2008		
Israel	Demyttenaere K, Bruffaerts R, Lee S, Posada-Villa J, Kovess V, Angermeyer MC, Levinson D, de Girolamo G, Nakane H, Mneimneh Z, Lara C, de Graaf R, Scott KM, Gureje O, Stein DJ, Haro JM, Bromet EJ, Kessler RC, Alonso J, Von Korff M. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. <i>Pain.</i> 2007; 129(3): 332-42.	2003-2004		
Israel	Koren A, Zalman L, Palmor H, Zamir RB, Levin C, Openheim A, Daniel-Spiegel E, Shalev S, Filon D. Sickle cell anemia in northern Israel: screening and prevention. <i>Isr Med Assoc J.</i> 2009; 4(11): 229-34.	1989-2006		
Israel	World Health Organization (WHO), Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000-2009		
Israel	Yigla M, Badarna-Abu-Ria N, Tov N, Ravell-Weiller D, Rubin AH. Sarcoidosis in northern Israel: clinical characteristics of 120 patients. <i>Respirology.</i> 2002; 19(3): 220-6.	1980-1996		
Israel	Karni A, Kahana E, Zilber N, Abramsky O, Alter M, Karussis D. The frequency of multiple sclerosis in Jewish and Arab populations in greater Jerusalem. <i>Neuroepidemiology.</i> 2003; 22(1): 82-6.	1995		
Israel	Bar-On H, Friedlander Y, Kidron M, Kark JD. Serum glucose and insulin characteristics and prevalence of diabetes mellitus and impaired glucose tolerance in the adult Jewish population of Jerusalem. <i>Nutr Metab Cardiovasc Dis.</i> 1992; 2: 75-8.	1990		
Israel	Pogrud H, Rutenberg M, Makin M, Robin G, Menczel J, Steinberg R. Osteoarthritis of the hip joint and osteoporosis: a radiological study in a random population sample in Jerusalem. <i>Clin Orthop Relat Res.</i> 1982; 130-5.	1979		
Israel	Mashal A, Katz A, Shvartzman P. Atrial fibrillation: a primary care cross-sectional study. <i>Isr Med Assoc J.</i> 2011; 13(11): 666-71.	2004-2006	*	
Israel	Graif Y, Romano-Zelekha O, Livne I, Green MS, Shohat T. Increased rate and greater severity of allergic reactions to insect sting among schoolchildren with atopic diseases. <i>Pediatr Allergy Immunol.</i> 2009; 20(8): 757-62.	2003	*	
Israel	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. <i>Community Dent Oral Epidemiol.</i> 1991; 19(2): 72-3.	1987		
Israel	Dagan R, Bar-David Y, Sarov B, Katz M, Kassis I, Greenberg D, Glass RI, Margolis CZ, Sarov I. Rotavirus diarrhea in Jewish and Bedouin children in the Negev region of Israel: epidemiology, clinical aspects and possible role of malnutrition in severity of illness. <i>Pediatr Infect Dis J.</i> 1990; 9(5): 314-21.	1986-1987	*	
Israel	Perl S, Goldman M, Berkovitch M, Kozar E. Characteristics of rotavirus gastroenteritis in hospitalized children in Israel. <i>Isr Med Assoc J.</i> 2011; 13(5): 274-7.	2004-2006	*	
Israel	Ran F, Sgan-Cohen HD. Caries prevalence among 2nd and 7th grade Jerusalem schoolchildren. <i>Isr J Dent Sci.</i> 1988; 2(2): 114-6.	1986		
Israel	Mann J, Revach A, Call R, Arvas J, Sgan-Cohen H. Prevalence and distribution of caries in a Jerusalem adolescent population by age, sex, and family income. <i>J Public Health Dent.</i> 1989; 49(3): 158-62.	1986		
Israel	Zusman SP, Natapov H. Caries prevalence in Ashkelon children in 1994. <i>ASDC J Dent Child.</i> 1997; 64(5): 359-61.	1994		
Israel	Zusman SP, Crawford AN. Changes in caries prevalence in Ashkelon, Israel, children 1980-1994. <i>Community Dent Health.</i> 1995; 12(1): 35-8.	1980, 1982, 1994		
Israel	Zadik D, Deitsch A, Tamir D, Kelman MA. Trends in the prevalence of dental caries in Israel. <i>ASDC J Dent Child.</i> 1991; 58(6): 464-6.	1988		
Israel	Sgan-Cohen HD, Salinger E. Dental caries and sugar intake, during and between meals, in children of an Israeli Kibbutz. <i>Community Dent Oral Epidemiol.</i> 1982; 10(1): 52-3.	1980		
Israel	Zadik D, Zusman SP, Kelman AM. Caries prevalence in 5- and 12-year-old children in Israel. <i>Community Dent Oral Epidemiol.</i> 1992; 20(1): 54-5.	1990		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Israel	Leviv I, Kohn R, Dohrenwend BP, Shrout PE, Skodol AE, Schwartz S, Link BG, Naveh G. An epidemiological study of mental disorders in a 10-year cohort of young adults in Israel. <i>Psychol Med.</i> 1993; 23(5): 691-707.	1982-1988, 1991		
Israel	Mitrany E, Lubin F, Chetrit A, Modan B. Eating disorders among Jewish female adolescents in Israel: a 5-year study. <i>J Adolesc Health.</i> 1995; 16(6): 454-7.	1989-1993		
Israel	Kristal-Boneh E, Goffer D, Green MS. Epidemiologic features of urolithiasis among industrial employees. The Israeli CORDIS Study. <i>J Occup Med.</i> 1994; 36(10): 1115-9.	1985-1987		
Israel	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2004-2005		
Israel	Bamberger ES, Siegler E, Makler-Shiran E, Patel MV, Steinberg JM, Gershtein R, Srugo I. Chlamydia trachomatis infections in female soldiers, Israel. <i>Emerg Infect Dis.</i> 2003; 9(10): 1344-6.	2003		
Israel	De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology.</i> 2000; 54(11 Suppl 5): S21-23.	1997		
Israel	Anca M, Paleacu D, Shabtai H, Giladi N. Cross-Sectional Study of the Prevalence of Parkinson's Disease in the Kibbutz Movement in Israel. <i>Neuroepidemiology.</i> 2002; 21(1): 50-5.	1998		
Israel	Goldsmith JR, Herishanu YO, Podgaitki M, Kordysh E. Dynamics of Parkinsonism-Parkinson's Disease in Residents of Adjacent Kibbutzim in Israel's Negev. <i>Environ Res.</i> 1997; 73(1-2): 156-61.	1989-1994		
Israel	Berger K BM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology.</i> 2000; 54(11): 24-7.	1997		
Israel	Jacob T, Baras M, Zeev A, Epstein L. A longitudinal, community-based study of low back pain outcomes. <i>Spine.</i> 2004; 29(16): 1810-7.	1999-2000		
Israel	Thomson IM, Chumbley LC. Eye disease in the West Bank and Gaza Strip. <i>Br J Ophthalmol.</i> 1984; 68(8): 598-602. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	1982-1983		
Israel	Cohen DI, Davidovici BB, Smetana Z, Balicer RD, Klement E, Mendelson E, Green MS. Seroprevalence of Varicella zoster in Israel prior to large-scale use of varicella vaccines. <i>Infection.</i> 2006; 34(4): 208-13.	2000-2001		
Israel	Adler A, Herring E, Babitsky H, Gazala E, Cohen A, Levy I. Parent-dependent barriers to varicella immunization in Israel: the importance of adequate information. <i>Acta Paediatr.</i> 2007; 96(3): 428-31.	2003		
Israel	Avrahami-Heller Y, Cohen D, Orr N, Slepov R, Ashkenazi I, Danon YL. Immunity to varicella zoster virus in young Israeli adults. <i>Isr Med Assoc J.</i> 2000; 2(3): 196-9.	1985-1992		
Israel	Israel Anti-Drug Authority. Israel Psychoactive Substance Use Research Summary Report 2003. Jerusalem, Israel: Israel Anti-Drug Authority.	1992, 1998, 2001, 2003		
Israel	Gruss I, Berlin M, Greenstein T, Yagil Y, Beiser M. Etiologies of hearing impairment among infants and toddlers: 1986-1987 versus 2001. <i>Int J Pediatr Otorhinolaryngol.</i> 2007; 71(10): 1585-9.	1986-1987, 2001		
Israel	WHO Regional Office for Europe (EURO-WHO). Young People's Health in Context. Health Behaviour in School-aged Children (HBSC) Study: International Report from the 2001-2002 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2004.	2002		
Israel	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Israel	Aviram A, Rahan O, Melamed N, Hadar E, Wiznitzer A, Yogev Y. The association between young maternal age and pregnancy outcome. <i>J Matern Fetal Neonatal Med.</i> 2013; 26(15): 1554-8.	2007-2011	*	
Israel	Olby R, Shoham-Vardi I, Ruslan S, Sheiner E. Is induction of labor risky for twins compare to singleton pregnancies? <i>J Matern Fetal Neonatal Med.</i> 2013; 26(18): 1804-6.	1988-2010	*	
Israel	Salim R, Mira A, Garmi G, Shalev E. Comparison of intrapartum outcome among immigrant women from Ethiopia and the general obstetric population in Israel. <i>Int J Gynaecol Obstet.</i> 2012; 118(2): 161-5.	2004-2011	*	
Israel	Ronel D, Wiznitzer A, Sergienko R, Zlotnik A, Sheiner E. Trends, risk factors and pregnancy outcome in women with uterine rupture. <i>Arch Gynecol Obstet.</i> 2012; 285(2): 317-21.	1988-2009	*	
Israel	Achiron A, Garty B-Z, Menascu S, Magalashvili D, Dolev M, Ben-Zeev B, Pinhas-Hamiel O. Multiple sclerosis in Israeli children: incidence, an clinical, cerebrospinal fluid and magnetic resonance imaging findings. <i>Isr Med Assoc J.</i> 2012; 14(4): 234-9.	1995-2009	*	
Israel	Ponizovsky AM, Grinshpoon A. Mood and anxiety disorders and the use of services and psychotropic medication in an immigrant population: findings from the Israel National Health Survey. <i>Can J Psychiatry.</i> 2009; 54(6): 409-19.	2003-2004		
Israel	Farbstein I, Mansbach-Kleinfeld I, Levinson D, Goodman R, Levav I, Vograft I, Kanaaneh R, Ponizovsky AM, Brent DA, Apter A. Prevalence and correlates of mental disorders in Israeli adolescents: results from a national mental health survey. <i>J Child Psychol Psychiatry.</i> 2010; 51(5): 630-9.	2004-2005	*	
Israel	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Israel	Zohar AH, Ratzoni G, Pauls DL, Apter A, Bleich A, Kron S, Rappaport M, Weizman A, Cohen DJ. An epidemiological study of obsessive-compulsive disorder and related disorders in Israeli adolescents. <i>J Am Acad Child Adolesc Psychiatry.</i> 1992; 31(6): 1057-61.	1990	*	
Israel	Dan M, Sadan O, Glezerman M, Raveh D, Samra Z. Prevalence and risk factors for herpes simplex virus type 2 infection among pregnant women in Israel. <i>Sex Transm Dis.</i> 2003; 30(11): 835-8.	2000-2001	*	
Israel	Feldman PA, Steinberg J, Madeh R, Bar G, Nativ O, Tal J, Srugo I. Herpes simplex virus type 2 seropositivity in a sexually transmitted disease clinic in Israel. <i>Isr Med Assoc J.</i> 2003; 5(9): 626-8.	1998-1999	*	
Israel	Azzopardi DV, Strohm B, Edwards AD, Dyet L, Halliday HL, Juszczak E, Kapellou O, Levene M, Marlow N, Porter E, Thoresen M, Whitelaw A, Brocklehurst P, TOBY Study Group. Moderate hypothermia to treat perinatal asphyxial encephalopathy. <i>N Engl J Med.</i> 2009; 361(14): 1349-58.	2002-2006	*	†
Israel	Kalter-Leibovici O, Chetrit A, Lubin F, Atamna A, Alpert G, Ziv A, Abu-Saad K, Murad H, Eilat-Adar S, Goldbourt U. Adult-onset diabetes among Arabs and Jews in Israel: a population-based study. <i>Diabet Med.</i> 2012; 29(6): 748-54.	2002-2007		
Israel	Laron Z, Mansour T, Slepov R, Karp M, Shohat T. Incidence of diabetes mellitus in various population groups in Israel (1989 and 1990). <i>Isr J Med Sci.</i> 1994; 30(10): 770-4.	1989-1990		
Israel	Laron ZV, Karp M, Modan M. The incidence of insulin-dependent diabetes mellitus in Israeli children and adolescents 0-20 years of age: a retrospective study, 1975-1980. <i>Diabetes Care.</i> 1985; 24:8.	1975-1980		
Israel	Lerner AG, Gekopf M, Sigal M, Olyffe I. Indicators of good prognosis in naltrexone treatment: a five-year prospective study. <i>Addiction Research.</i> 1997; 4(4): 385-91.	1994	*	
Israel	Zaidman JL, Leiba H, Scharf S, Steinman I. Red cell glucose-6-phosphate dehydrogenase deficiency in ethnic groups in Israel. <i>Clin Genet.</i> 1976; 9(2): 131-3.	1970-1974		
Israel	Kaplan M, Beutler E, Vreman HJ, Hammerman C, Levy-Lahad E, Renbaum P, Stevenson DK. Neonatal hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient heterozygotes. <i>Pediatrics.</i> 1999; 104(1 Pt 1): 68-74.	1996		
Israel	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant.</i> 1988; 3(6): 714-27.	1985-1986		
Israel	Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. <i>J Clin Endocrinol Metab.</i> 2008; 93(4): 1408-11.	2005		
Israel	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguiar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Peda I, Gilst WH van, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J.</i> 2003; 24(5): 442-63.	2000-2001		
Israel	Meltzer E, Yossepowitch O, Sadik C, Dan M, Schwartz E. Epidemiology and Clinical Aspects of Enteric Fever in Israel. <i>Am J Trop Med Hyg.</i> 2006; 74(4): 540-5.	1995-2003	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Israel	Israel Neurological Association, Israel Society for the Prevention of Heart Attacks (ISPHA), Israel Society of Internal Medicine, Ministry of Health (Israel), Israel National Acute Stroke Israeli Registry Tables 2004-2010. [Unpublished].	2004, 2007, 2010	*	
Israel	Feinmesser M, Tell L, Levi H. Etiology of childhood deafness with reference to the group of unknown cause. <i>Audiology</i> . 1986; 25(2): 65-9.	1967-1983	*	
Israel	World Health Organization (WHO). Israel WHO Leishmaniasis Country Profile.	1994-2008	*	
Israel	Lieberman D, Shimoni A, Shemer-Avni Y, Keren-Naos A, Shtainberg R, Lieberman D. Respiratory viruses in adults with community-acquired pneumonia. <i>Chest</i> . 2010; 138(4): 811-6.	2004-2006	*	
Israel	Wolf DG, Greenberg D, Shemer-Avni Y, Givon-Lavi N, Bar-Ziv J, Dagan R. Association of human metapneumovirus with radiologically diagnosed community-acquired alveolar pneumonia in young children. <i>J Pediatr</i> . 2010; 156(1): 115-20.	2001-2005	*	
Israel	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1994; 69(20): 145-51.	1993	*	
Israel	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1995; 70(25): 177-82.	1994	*	
Israel	Dagan R, Isaachson M, Lang R, Karpuch J, Block C, Amir J. Epidemiology of pediatric meningitis caused by Haemophilus influenzae type b, Streptococcus pneumoniae, and Neisseria meningitidis in Israel: a 3-year nationwide prospective study. <i>J Infect Dis</i> . 1994; 169(4): 912-6.	1988-1991		
Israel	Trichopoulos D, Bamia C, Laggiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overved K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PHM, Lund E, Quirós JR, González CA, Sanchez Perez M-J, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu I, Chuang S-C, Murphy N, Boffetta P, Trichopoulou A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. <i>J Natl Cancer Inst</i> . 2011; 103(22): 1686-95.	1992-2006	*	
Israel	Kark JD, Camby NA, Shany SB. Reduction in hepatitis A antibody prevalence among young adults in Israel. <i>Public Health Rev</i> . 1992; 20(1-2): 31-40.	1977, 1984		
Israel	Kark JD, Bar-Shany S, Shor S, Merlinski L, Nili E. Serological hepatitis A virus infections and ratio of clinical to serological infections in a controlled trial of pre-exposure prophylaxis with immune serum globulin. <i>J Epidemiol Community Health</i> . 1985; 39(2): 117-22.	1977		
Israel	Elkana Y, Barkay A. Antibodies to hepatitis A in young Israeli children. <i>J Infect</i> . 1982; 4(1): 57-62.	1980		
Israel	Green MS, Melnick JL, Cohen D, Slepon R, Danon YL. Response to trivalent oral poliovirus vaccine with and without immune serum globulin in young adults in Israel in 1988. <i>J Infect Dis</i> . 1990; 162(4): 971-4.	1987		
Israel	Green MS, Zaide Y. Sibship size as a risk factor for hepatitis A infection. <i>Am J Epidemiol</i> . 1989; 129(4): 800-5.	1987		
Israel	Karetniy YV, Mendelson E, Shlyakhov E, Rubinstein E, Golubev N, Levin R, Sandler M, Schreiber M, Rubinstein U, Shif I. Prevalence of antibodies against hepatitis A virus among new immigrants in Israel. <i>J Med Virol</i> . 1995; 46(1): 61-5.	1992-1993		
Israel	Almog R, Low M, Cohen D, Robin G, Ashkenazi S, Bercovier H, Gdalevich M, Samuels Y, Ashkenazi I, Shemer J, Eldad A, Green MS. Prevalence of anti-hepatitis A antibodies, hepatitis B viral markers, and anti-hepatitis C antibodies among immigrants from the former USSR who arrived in Israel during 1990-1991. <i>Infection</i> . 1999; 27(3): 212-7.	1992-1993		
Israel	Schwartz E, Raveh D. The prevalence of hepatitis A antibodies among Israeli travellers and the economic feasibility of screening before vaccination. <i>Int J Epidemiol</i> . 1998; 27(1): 118-20.	1993-1995		
Israel	Hasin T, Dagan R, Boutboul G, Derazne E, Atias O, Cohen D. Socioeconomic correlates of antibody levels to enteric pathogens among Israeli adolescents. <i>Epidemiol Infect</i> . 2007; 135(1): 118-25.	1996		
Israel	Katz J, Gdalevich M, Ashkenazi I, Chausu G, Shemer J. Association in the seroprevalence of hepatitis A and herpes simplex-1 viruses in young adults in Israel. <i>Infection</i> . 2000; 28(4): 231-3.	1996		
Israel	Livni G, Plotkin S, Yuhay Y, Chodik G, Aloni H, Lerman Y, Ashkenazi S. Seroprevalence of hepatitis A antibodies among children's hospital staff. <i>Pediatr Infect Dis J</i> . 2002; 21(7): 618-22.	1997-1999		
Israel	Gillis D, Grotto I, Mimouni D, Huerta M, Gdalevich M, Shpilberg O. Adult infection with hepatitis A despite declining endemicity: in favor of adult vaccination. <i>Vaccine</i> . 2002; 20(17-18): 2243-8.	1998-1999		
Israel	Samuels N. Routine testing for IgG antibodies against hepatitis A virus in Israel. <i>BMC Public Health</i> . 2005; 60.	1998-2003		
Israel	Ashkenazi M, Chodik G, Littner M, Aloni H, Lerman Y. The presence of hepatitis A antibodies in dental workers. A seroepidemiologic study. <i>J Am Dent Assoc</i> . 2001; 132(4): 492-8.	2000		
Israel	Chodick G, Ashkenazi S, Aloni H, Peled T, Lerman Y. Hepatitis A virus seropositivity among hospital and community healthcare workers in Israel-the role of occupation, demography and socioeconomic background. <i>J Hosp Infect</i> . 2003; 54(2): 135-40.	2004		
Israel	Karetniy YV, Favorov MO, Khudyakova NS, Weiss P, Bar-Shani S, Handscher R, Aboudy Y, Varsano N, Schwartz E, Levin E. Serological evidence for hepatitis E virus infection in Israel. <i>J Med Virol</i> . 1995; 45(3): 316-20.	1994		
Israel	Farhi J, Ben-Haroush A. Distribution of causes of infertility in patients attending primary fertility clinics in Israel. <i>Isr Med Assoc J</i> . 2011; 13(1): 51-4.	1999-2007	*	
Israel	Bowirrat A, Treves TA, Friedland RP, Korczyn AD. Prevalence of Alzheimer's type dementia in an elderly Arab population. <i>Eur J Neurol</i> . 2001; 8(2): 119-23.	1992-1995		
Israel	Kahana E, Galper Y, Zilber N, Korczyn AD. Epidemiology of dementia in Ashkelon: the influence of education. <i>J Neurol</i> . 2003; 250(4): 424-8.	1986-1989		
Israel	Israel Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Israel	Israel Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Israel	Israel Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD), United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Israel	Israel Birth Defects Monitoring System Data 2001 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
Israel	Israel Birth Defects monitoring System Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO), World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Israel	Israel Birth Defects Monitoring System Data 1980 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1980	*	
Israel	Israel Birth Defects Monitoring System Data 1983 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1983	*	
Israel	Israel Birth Defects Monitoring System Data 1986 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1986	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Italy	Italy Vital Registration - Deaths 1997 ICD9 as it appears in World Health Organization (WHO). World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1997		
Italy	Italy Vital Registration - Deaths 1999 ICD9 as it appears in World Health Organization (WHO). World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1999		
Italy	Italy Vital Registration - Deaths 2002 ICD9 as it appears in World Health Organization (WHO). World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	2002		
Italy	Italy Vital Registration - Deaths 2003 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2003	*	
Italy	Italy Vital Registration - Deaths 2006 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2006	*	
Italy	Italy Vital Registration - Deaths 2007 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2007	*	
Italy	World Health Organization (WHO). Italy World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		
Italy	Italian National Institute of Statistics, Metron (Italy), United Nations Economic Commission for Europe (UNECE), University of Bologna (Italy). Italy Fertility and Family Survey 1995-1996. Geneva, Switzerland: United Nations Economic Commission for Europe (UNECE).	1995-1996		
Italy	Italy Vital Registration - Deaths 2008 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2008	*	
Italy	Italy Vital Registration - Deaths 2009 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2009	*	
Italy	Italy Vital Registration - Deaths 2010 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2010		
Italy	Filippi A, Bettoncelli G, Zaninelli A. Detected atrial fibrillation in North Italy: rates, calculated stroke risk and proportion of patients receiving thrombo-prophylaxis. <i>Fam Pract</i> . 2000; 17(4): 337-339.	1999		
Italy	Cacciatore F, Gallo C, Ferrara N, Abete P, Paolisso G, Canonico S, Signoriello G, Terracciano C, Napoli C, Varricchio M, Rengo F. Morbidity patterns in aged population in southern Italy. A survey sampling. <i>Arch Gen Psychiatry</i> . 1998; 26(3): 201-13.	1991-1992		
Italy	Bordin P, Mazzone C, Pandullo C, Goldstein D, Scardi S. Morbidity and mortality in 229 elderly patients with nonrheumatic atrial fibrillation. A five-year follow-up. <i>Ital Heart J</i> . 2003; 4(8): 537-43.	2001		
Italy	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. <i>Scand J Clin Lab Invest</i> . 2007; 67(1): 39-69.	1988, 2006		
Italy	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1988, 2003, 2006		
Italy	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	2009		†
Italy	Baldasseroni S, Opasich C, Gorini M, Lucci D, Marchionni N, Marini M, Campana C, Perini G, Deorsola A, Masotti G, Tavazzi L, Maggioni AP. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. <i>Am Heart J</i> . 2002; 143(3): 398-405.	1995-2000		
Italy	Naldi L, Colombo P, Placchesi EB, Piccitto R, Chatenoud L, La Vecchia C. Study design and preliminary results from the pilot phase of the PraKtis study: self-reported diagnoses of selected skin diseases in a representative sample of the Italian population. <i>Dermatology (Basel)</i> . 2004; 208(1): 38-42.	2003		
Italy	National Public Health Institute (Finland), World Health Organization (WHO). WHO MONICA Cerebrovascular Event Data 1982-1997, as provided by the Global Burden of Disease 2010 Cerebrovascular Disease Expert Group. [Unpublished].	1984-1991		
Italy	Pedalino B, Cotter B, Ciofi degli Atti M, Mandolini D, Parrocchini S, Salmaso S. Epidemiology of tetanus in Italy in years 1971-2000. <i>Euro Surveill</i> . 2002; 7(7): 103-10.	1971-1997		
Italy	Carolei A, Marini C, Di Napoli M, Di Gianfilippo G, Santalucia P, Baldassarre M, Giorgio De Matteis M, di Orio F. High Stroke Incidence in the Prospective Community-Based L'Aquila Registry (1994-1998): First Year's Results. <i>Stroke</i> . 1997; 28(12): 2500-6.	1990-1995		
Italy	Di Carlo A, Inzitari D, Galati F, Baldereschi M, Giunta V, Grillo G, Furchìgrave: A, Manno V, Naso F, Vecchio A, Consoli D. A Prospective Community-Based Study of Stroke in Southern Italy: The Vibo Valentia Incidence of Stroke Study (VISS). <i>Cerebrovasc Dis</i> . 2003; 16(4): 410-7.	1996		
Italy	Manobianca G, Zoccolella S, Petruzzelli A, Miccoli A, Logroscino G. The incidence of major stroke subtypes in Southern Italy: a population based study. <i>Eur J Neurol</i> . 2010; 17(9): 1148-55.	2001-2002		
Italy	Corso G, Bottacchi E, Giardini G, De la Pierre F, Meloni T, Pesenti Campagnoni M, Ponzetti C, Veronese Morosini M. Community-based study of stroke incidence in the Valley of Aosta, Italy. CARE-cerebrovascular Aosta Registry: years 2004-2005. <i>Neuroepidemiology</i> . 2009; 32(3): 186-95.	2004-2005		
Italy	Lauria G, Gentile M, Fassetta G, Casetta I, Agnoli F, Andreotta G, Barp C, Caneve G, Cavallaro A, Cielo R, Mongillo D, Mosca M, Olivieri P. Incidence and Prognosis of Stroke in the Belluno Province, Italy: First-Year Results of a Community-Based Study. <i>Stroke</i> . 1995; 26(10): 1787-93.	1992-1993		
Italy	Sacco S, Marini C, Toni D, Olivieri L, Carolei A. Incidence and 10-Year Survival of Intracerebral Hemorrhage in a Population-Based Registry. <i>Stroke</i> . 2009; 40(2): 394-9.	1994-1998		
Italy	D'Alessandro G, Bottacchi E, Di Giovanni M, Martinazzo C, Sironi L, Lia C, Carenini L, Corso G, Gerbaz V, Polillo C, Pesenti Campagnoni M. Temporal trends of stroke in Valle d'Aosta, Italy. Incidence and 30-day fatality rates. <i>Neurol Sci</i> . 2000; 21(1): 13-8.	1996-1997		
Italy	Manobianca G, Zoccolella S, Petruzzelli A, Miccoli A, Logroscino G. Low Incidence of Stroke in Southern Italy: A Population-Based Study. <i>Stroke</i> . 2008; 39(11): 2923-8.	2001-2002		
Italy	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol</i> . 2008; 121(4): 947-954.	1994-1995, 2002		
Italy	Cedrone C, Ricci F, Nucci C, Cesario M, Macri G, Culasso F. Age-specific changes in the prevalence of best-corrected visual impairment in an Italian population. <i>Ophthalmic Epidemiol</i> . 2007; 14(5): 320-6, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1988, 2000		
Italy	Brandonisio O, Marangi A, Panaro MA, Marzio R, Natalicchio ML, Zizzadoro P, De Santis U. Prevalence of Cryptosporidium in children with enteritis in southern Italy. <i>Eur J Epidemiol</i> . 1996; 12(2): 187-90.	1987-1994		
Italy	Chironna M, Quarto M, Biasio LR, Barbuti S. Haemophilus influenzae type b meningitis in Apulia Retrospective study from the years 1994-1995. <i>Ann Ig</i> . 1998; 10(3): 131-6.	1994-1995		
Italy	Salmaso S, Mastrantonio P, Scuderi G, Congiu ME, Stroppolini T, Pompa MG, Squarcione S. Pattern of Bacterial Meningitis in Italy, 1994. <i>Eur J Epidemiol</i> . 1997; 13(3): 317-21.	1994		
Italy	Forster J, Guarino A, Parez N, Moraga F, Román E, Mory O, Tozzi AE, de Aguilera AL, Wahn U, Graham C, Berner R, Ninan T, Barberousse C, Meyer N, Soriano-Gabarró M. Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of age. <i>Pediatrics</i> . 2009; 123(3): e393-400.	2005-2006		
Italy	Gabutti G, Marsella M, Lazzara C, Fiumana E, Cavallaro A, Borgna-Pignatti C. Epidemiology and burden of rotavirus-associated hospitalizations in Ferrara, Italy. <i>J Prev Med Hyg</i> . 2007; 48(1): 5-9.	2001-2005		
Italy	Grassi T, De Donno A, Guido M, Gabutti G. The epidemiology and disease burden of rotavirus infection in the Salento peninsula, Italy. <i>Turk J Pediatr</i> . 2008; 50(2): 132-6.	2004		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Italy	Ticca F, Catania S, Ranno O, Timpano C, Rivosecchi MR, Graziani MC, Lancella L, Comparcola D, Nicolosi L. [Haemophilus influenzae type b in meningitis: antibiotic resistance in pediatric patients]. <i>Infez Med.</i> 1997; 5(2): 96-9.	1985-1994		
Italy	Demyttenaere K, Bruhaerts R, Lee S, Posada-Villa J, Kovess V, Angermeyer MC, Levinson D, de Girolamo G, Nakane H, Mneimneh Z, Lara C, de Graaf R, Scott KM, Gureje O, Stein DJ, Haro JM, Bromet EJ, Kessler RC, Alonso J, Von Korff M. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. <i>Pain.</i> 2007; 129(3): 332-42.	2001-2002		
Italy	Russo-Mancuso G, La Spina M, Schilirò G. The changing profile of sickle cell disease in Italy. <i>Eur J Epidemiol.</i> 2003; 9(18): 923-4.	1994, 2001		
Italy	World Health Orgn. Community control of hereditary anaemias: memorandum from a WHO meeting. <i>Bull World Health Organ.</i> 1983; 61(1): 63-80.	1970-1980		
Italy	Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Origa R, Piga A, Romeo MA, Zhao H, Cnaan A. Survival and Complications in Thalassemia. <i>Ann N Y Acad Sci.</i> 2005; 1054(1): 40-7.	1985-1996		
Italy	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2002-2007, 2009		
Italy	Salaffi F, De Angelis R, Grassi W, MArche Pain Prevalence, INvestigation Group (MAPPING) study. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. <i>Clin Exp Rheumatol.</i> 2005; 23(6): 819-28.	2004		
Italy	Agostini C, Albera C, Bariffi F, De Palma M, Harari S, Lusuardi M, Pesci A, Poletti V, Richeldi L, Rizzato G, Rossi A, Schiavina M, Semenzato G, Tinelli C. First report of the Italian register for diffuse infiltrative lung disorders (RIPID). <i>Monaldi Arch Chest Dis.</i> 2001; 56(4): 364-8.	1998-2000		
Italy	Ghizzoni P, Bortone E, Bettoni L. Prevalence and incidence of multiple sclerosis in the province of Parma, 1965-1980. Preliminary data. <i>Acta Biomed Ateneo Parmense.</i> 1987; 58(1-2): 33-40.	1980		
Italy	Montomoli C, Allemanni C, Solinas G, Motta G, Bernardinelli L, Clemente S, Murgia BS, Ticca AF, Musu L, Piras ML, Ferrai R, Caria A, Sanna S, Porcu O. An ecologic study of geographical variation in multiple sclerosis risk in central Sardinia, Italy. <i>Neuroepidemiology.</i> 2002; 21(4): 187-93.	1998		
Italy	Casetta I, Granieri E, Marchi D, Murgia SB, Tola MR, Ticca A, Lauria G, Govoni V, Murgia B, Pugliatti M. An epidemiological study of multiple sclerosis in central Sardinia, Italy. <i>Acta Neurol Scand.</i> 1998; 98(6): 391-4.	1993		†
Italy	Guidetti D, Cavalletti S, Merelli E, Zanoni P, Simonazzi P, Sola P, Solimè F. Epidemiological survey of multiple sclerosis in the provinces of Reggio Emilia and Modena, Italy. <i>Neuroepidemiology.</i> 1995; 14(1): 7-13.	1970-1990		
Italy	Rosati G, Aiello I, Pirastru MI, Mannu L, Sanna G, Sau GF, Sotgiu S. Epidemiology of multiple sclerosis in Northwestern Sardinia: further evidence for higher frequency in Sardinians compared to other Italians. <i>Neuroepidemiology.</i> 1996; 15(1): 10-9.	1962-1991		
Italy	Cavalletti S, Merelli E, Cavazzuti M, Guidetti D. Frequency of MS in the province of Modena, 1970-1990. <i>Acta Neurol Scand.</i> 1994; 90(6): 377-81.	1990		
Italy	Salemi G, Ragonese P, Aridon P, Scola G, Saporito V, Conte S, Savettieri G. Incidence of multiple sclerosis in Bagheria City, Sicily, Italy. <i>Neurol Sci.</i> 2000; 21(6): 361-5.	1985-1994		
Italy	Rosati G, Aiello I, Mannu L, Pirastru MI, Agnetti V, Sau G, Garau M, Gioia R, Sanna G. Incidence of multiple sclerosis in the town of Sassari, Sardinia, 1965 to 1985 Evidence for increasing occurrence of the disease. <i>Neurology.</i> 1988; 38(3): 384-384.	1965-1975, 1985		
Italy	Ranzato F, Perini P, Tzintzeva E, Tiberio M, Calabrese M, Ermani M, Davettag F, De Zanche L, Garbin E, Verdelli F, Villacara A, Volpe G, Moretto G, Gallo P. Increasing frequency of multiple sclerosis in Padova, Italy: a 30 year epidemiological survey. <i>Multi Scler.</i> 2003; 9(4): 387-92.	1999		
Italy	Pugliatti M, Riise T, Sotgiu MA, Sotgiu S, Satta WM, Mannu L, Sanna G, Rosati G. Increasing incidence of multiple sclerosis in the province of Sassari, northern Sardinia. <i>Neuroepidemiology.</i> 2005; 25(3): 129-34.	1965-1999		
Italy	Pugliatti M, Sotgiu S, Solinas G, Castiglia P, Pirastru MI, Murgia B, Mannu L, Sanna G, Rosati G. Multiple sclerosis epidemiology in Sardinia: evidence for a true increasing risk. <i>Acta Neurol Scand.</i> 2001; 103(1): 20-6.	1968-1997		
Italy	Ragonese P, Salemi G, D'Amelio M, Gammino M, Aridon P, Savettieri G. Multiple sclerosis in southern Europe: Monreale City, Italy. A twenty-year follow-up incidence and prevalence study. <i>Neuroepidemiology.</i> 2004; 23(6): 306-9.	2000		
Italy	Nicoletti A, Bartolo MLL, Fermo SL, Cocuzza V, Panetta MR, Marletta C, Ciancio MR, Cataldi ML, Patti F, Reggio A. Prevalence and incidence of multiple sclerosis in Catania, Sicily. <i>Neurology.</i> 2001; 56(1): 62-6.	1995		
Italy	Savettieri G, Salemi G, Ragonese P, Aridon P, Scola G, Randisi G. Prevalence and incidence of multiple sclerosis in the city of Monreale, Italy. <i>J Neurol.</i> 1998; 245(1): 40-3.	1991		
Italy	Totaro R, Marini C, Cialfi A, Giunta M, Carolei A. Prevalence of multiple sclerosis in the L'Aquila district, central Italy. <i>J Neurol Neurosurg Psychiatry.</i> 2000; 68(3): 349-52.	1996		
Italy	Granieri E, Casetta I, Govoni V, Tola MR, Marchi D, Murgia SB, Ticca A, Pugliatti M, Murgia B, Rosati G. The increasing incidence and prevalence of MS in a Sardinian province. <i>Neurology.</i> 2000; 55(6): 842-8.	1955-1995		
Italy	Savettieri G, D'Ariceo B, Giordano D, Karhausen L, Dean G. The prevalence of multiple sclerosis in Sicily. I. Monreale city. <i>J Epidemiol Community Health.</i> 1981; 35(2): 114-7.	1980		
Italy	Dean G, Savettieri G, Giordano D, Butera C, Taibi G, Morreale S, Karhausen L. The prevalence of multiple sclerosis in Sicily. II. Agrigento city. <i>J Epidemiol Community Health.</i> 1981; 35(2): 118-22.	1975		
Italy	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Italy	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2002		
Italy	Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. <i>Diabetologia.</i> 1996; 39(11): 1377-84.	1993-1995		
Italy	Beghi E, Monticelli ML. Diabetic polyneuropathy in the elderly. Prevalence and risk factors in two geographic areas of Italy. Italian General Practitioner Study Group (IGPSG). <i>Acta Neurol Scand.</i> 1997; 96(4): 223-8.	1990-1996		
Italy	Fedele D, Comi G, Coscelli C, Cucinotta D, Feldman EL, Ghirlanda G, Greene DA, Negrin P, Santeusano F. A multicenter study on the prevalence of diabetic neuropathy in Italy. Italian Diabetic Neuropathy Committee. <i>Diabetes Care.</i> 1997; 20(5): 836-43.	1994		
Italy	Sangiorgio L, Iemmolo R, Le Moli R, Grasso G, Lunetta M. Diabetic neuropathy: prevalence, concordance between clinical and electrophysiological testing and impact of risk factors. <i>Panminerva Med.</i> 1997; 39(1): 1-5.	1994		
Italy	Veglio M, Sivieri R. Prevalence of neuropathy in IDDM patients in Piemonte, Italy. The Neuropathy Study Group of the Italian Society for the Study of Diabetes, Piemonte Affiliate. <i>Diabetes Care.</i> 1993; 16(2): 456-61.	1990-1992		
Italy	Rubino A, Rousculp MD, Davis K, Wang J, Girach A. Diagnosed diabetic retinopathy in France, Italy, Spain, and the United Kingdom. <i>Prim Care Diabetes.</i> 2007; 1(2): 75-80.	2006		
Italy	Garancini MP, Calori G, Manara E, Izzo A, Ebbli E, Galli L, Boari L, Gallus G. An Italian population-based study of the prevalence of diabetes: some methodological aspects. <i>Diabete Metab.</i> 1993; 19(1 Part 2): 116-20.	1990		
Italy	Prencipe M, Casini AR, Ferretti C, Santini M, Pezzella F, Scaldaferrri N, Culasso F. Prevalence of headache in an elderly population: attack frequency, disability, and use of medication. <i>J Neurol Neurosurg Psychiatry.</i> 2001; 70(3): 377-81.	1992-1993		
Italy	Camarda R, Monastero R. Prevalence of primary headaches in Italian elderly: preliminary data from the ZabaAging Project. <i>Neurol Sci.</i> 2003; 1122-124.	2001		
Italy	Mannoni A, Briganti MP, Di Bari M, Ferrucci L, Costanzo S, Semi U, Masotti G, Marchionni N. Epidemiological profile of symptomatic osteoarthritis in older adults: a population based study in Dicomano, Italy. <i>Ann Rheum Dis.</i> 2003; 62(6): 576-8.	2000		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Italy	Cazzola M, Puxeddu E, Bettoncelli G, Novelli L, Segreti A, Cricelli C, Calzetta L. The prevalence of asthma and COPD in Italy: a practice-based study. <i>Respir Med.</i> 2011; 105(3): 386-91.	2009	*	
Italy	Cibella F, Cuttita G, La Grutta S, Melis MR, Lospalluti ML, Usuf CG, Bucchieri S, Viegi G. Proportional Venn diagram and determinants of allergic respiratory diseases in Italian adolescents. <i>Pediatr Allergy Immunol.</i> 2011; 22(1 Pt 1): 60-8.	2005-2006	*	
Italy	Accortini S, Cappa V, Braggio M, Corsico AG, Bugiani M, Pirina P, Verlatto G, Villani S, de Marco R. The impact of diagnosed and undiagnosed current asthma in the general adult population. <i>Int Arch Allergy Immunol.</i> 2011; 155(4): 403-11.	1998-2000	*	
Italy	Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, Gjomarkaj M, Forsberg B, Gunnbjornsdottir M, Minov J, Brozek G, Dahlen SE, Toskala E, Kowalski ML, Olze H, Howarth P, Krämer U, Baelum J, Loureiro C, Kasper L, Bousquet PJ, Bousquet J, Bachert C, Fokkens W, Burney P. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. <i>Allergy.</i> 2012; 67(1): 91-8.	2008-2009	*	
Italy	Quercia O, Incorvaia C, Puccinelli P, Scurati S, Emiliani F, Frati F, Stefanini GF. Prevalence of allergic disorders in Italy: the Cotignola population study. <i>Eur Ann Allergy Clin Immunol.</i> 2012; 44(1): 5-11.	2009-2011	*	
Italy	Sardu C, Cocco E, Mereu A, Massa R, Cuccu A, Marrosu MG, Contu P. Population based study of 12 autoimmune diseases in Sardinia, Italy: prevalence and comorbidity. <i>PLoS One.</i> 2012; 7(3): e32487.	2009	*	
Italy	Cazzola M, Calzetta L, Bettoncelli G, Cricelli C, Romeo F, Matera MG, Rogliani P. Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. <i>Respir Med.</i> 2012; 106(2): 249-56.	1998-2009	*	
Italy	Gini R, Francesconi P, Mazzaglia G, Cricelli I, Pasqua A, Gallina P, Brugaletta S, Donato D, Donatini A, Marini A, Zocchetti C, Cricelli C, Damiani G, Bellentani M, Sturkenboom MCJM, Schuemi MJ. Chronic disease prevalence from Italian administrative databases in the VALORE project: a validation through comparison of population estimates with general practice databases and national survey. <i>BMC Public Health.</i> 2013; 15.	2008-2009		
Italy	Piccinocchi G, Laringe M, Guillaro B, Arpino G, Piccinocchi R, Nigro G, Calabrò P. Diagnosis and management of atrial fibrillation by primary care physicians in Italy: a retrospective, observational analysis. <i>Clin Drug Investig.</i> 2012; 32(11): 771-7.	2009-2011	*	
Italy	Ferro R, Besostri A, Olivieri A, Stellini E, Denotti G, Campus G. Caries experience in 14-year-olds from Northeast Italy. Is socioeconomic status (SES) still a risk factor? <i>Eur J Paediatr Dent.</i> 2012; 13(1): 46-52.	2007-2008	*	
Italy	Ferro R, Cecchin C, Besostri A, Olivieri A, Stellini E, Mazzoleni S. Social differences in tooth decay occurrence in a sample of children aged 3 to 5 in north-east Italy. <i>Community Dent Health.</i> 2010; 27(3): 163-6.	2005-2006		
Italy	Pizzo G, Piscopo MR, Matranga D, Luparello M, Pizzo I, Giuliani G. Prevalence and socio-behavioral determinants of dental caries in Sicilian schoolchildren. <i>Med Sci Monit.</i> 2010; 16(10): PH83-89.	2007	*	
Italy	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. <i>Community Dent Oral Epidemiol.</i> 1991; 19(2): 72-3.	1987		
Italy	Zani C, Pasquale L, Bressanelli M, Puoti M, Paris B, Coccaglio R, Lascioli I, Pieriaci G, Donato F. The epidemiological pattern of chronic liver diseases in a community undergoing voluntary screening for hepatitis B and C. <i>Dig Liver Dis.</i> 2011; 43(8): 653-8.	2000-2009		
Italy	Gentile C, Alberini I, Manini I, Rossi S, Montomoli E, Pozzi T, Rizzo C, Alfonsi V. Hepatitis A seroprevalence in Tuscany, Italy. <i>Euro Surveill.</i> 2009; 14(10): 1-4.	1992-2004		
Italy	Cozzolongo R, Osella AR, Elba S, Petrucci J, Buongiorno G, Giannuzzi V, Leone G, Bonfiglio C, Lanzilotta E, Manghisi OG, Leandro G, NUTRIHEP Collaborating Group, Donnalio R, Fanelli V, Mirizzi F, Parziale L, Crupi G, Detomaso P, Labbate A, Zizzari S, Depalma M, Polignano A, Lopinto D, Dapirle G. Epidemiology of HCV infection in the general population: a survey in a southern Italian town. <i>Am J Gastroenterol.</i> 2009; 104(11): 2740-6.	2005-2007		
Italy	Ferrero S, Arena E, Morando A, Remorgida V. Prevalence of newly diagnosed endometriosis in women attending the general practitioner. <i>Int J Gynaecol Obstet.</i> 2010; 110(3): 203-7.	2007-2009	*	
Italy	Migliaretti G, Delieto F, Delpiano EM, Bonino L, Berchiulla P, Dalmasso P, Cavallo F, Camanni M. Spatial analysis of the distribution of endometriosis in northwestern Italy. <i>Gynecol Obstet Invest.</i> 2012; 73(2): 135-40.	2000-2005	*	
Italy	Naldi L, Parazzini F, Gallus S, GISED Study Centres. Prevalence of atopic dermatitis in Italian schoolchildren: factors affecting its variation. <i>Acta Derm Venereol.</i> 2009; 89(2): 122-5.	1997	*	
Italy	Saraceno R, Mannheimer R, Chimenti S. Regional distribution of psoriasis in Italy. <i>J Eur Acad Dermatol Venereol.</i> 2008; 22(3): 324-9.	2006	*	
Italy	Marchisio P, Cantarutti L, Sturkenboom M, Giroto S, Picelli G, Dona D, Scamarcia A, Villa M, Giaquinto C, Pedianet. Burden of acute otitis media in primary care pediatrics in Italy: a secondary data analysis from the Pedianet database. <i>BMC Pediatr.</i> 2012; 185.	2003-2007	*	
Italy	Zimmermann A, Bernuit D, Gerlinger C, Schaeffers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. <i>BMC Womens Health.</i> 2012; 6.	2009	*	
Italy	Donelli G, Ruggeri FM, Tinari A, Marziano ML, Menichella D, Caione D, Concato C, Rocchi G, Vella S. A three-year diagnostic and epidemiological study on viral infantile diarrhoea in Rome. <i>Epidemiol Infect.</i> 1988; 100(2): 311-20.	1982-1984	*	
Italy	Caprioli A, Pezzella C, Morelli R, Giammanco A, Arista S, Crotti D, Facchini M, Guglielmetti P, Piersimoni C, Luzzi I. Enteropathogens associated with childhood diarrhea in Italy. The Italian Study Group on Gastrointestinal Infections. <i>Pediatr Infect Dis J.</i> 1996; 15(10): 876-83.	1992	*	
Italy	Giaquinto C, van Damme P, REVEAL Study Group. Age distribution of paediatric rotavirus gastroenteritis cases in Europe: the REVEAL study. <i>Scand J Infect Dis.</i> 2010; 42(2): 142-7.	2004-2005	*	
Italy	Amisano G, Fornasero S, Migliaretti G, Caramello S, Tarasco V, Savino F. Diarrheagenic Escherichia coli in acute gastroenteritis in infants in North-West Italy. <i>New Microbiol.</i> 2011; 34(1): 45-51.	2008-2009	*	
Italy	Finamore E, Vitiello M, Campanaraki A, Rao M, Galdiero M, Galdiero E, Bevilacqua P, Gallo MA, Galdiero M. G2 as an emerging rotavirus strain in pediatric gastroenteritis in southern Italy. <i>Infection.</i> 2011; 39(2): 113-9.	2007-2008	*	
Italy	Medici MC, Tummolo F, Albonetti V, Abelli LA, Chezzi C, Calderaro A. Molecular detection and epidemiology of astrovirus, bocavirus, and sapovirus in Italian children admitted to hospital with acute gastroenteritis, 2008-2009. <i>J Med Virol.</i> 2012; 84(4): 643-50.	2008-2009	*	
Italy	Palumbo E, Branchi M, Malorgio C, Siani A, Bonora G. Diarrhea in children: etiology and clinical aspects. <i>Minerva Pediatr.</i> 2010; 62(4): 347-51.	2003-2006	*	
Italy	Azzimondi G, DAlessandro R, Pandolfo G, Feruglio FS. Comparative study of the prevalence of dementia in two Sicilian communities with different psychosocial backgrounds. <i>Neuroepidemiology.</i> 1998; 17(4): 199-209.	1992-1994		†
Italy	Di Carlo A, Baldereschi M, Amaducci L, Lepore V, Bracco L, Maggi S, Bonaiuto S, Perissinotto E, Scarlato G, Farchi G, Inzitari D, ILSA Working Group. Incidence of dementia, Alzheimer's disease, and vascular dementia in Italy. The ILSA Study. <i>J Am Geriatr Soc.</i> 2002; 50(1): 41-8.	1992-1996		
Italy	De Ronchi D, Fratiglioni L, Rucci P, Paternicò A, Graziani S, Dalmonte E. The effect of education on dementia occurrence in an Italian population with middle to high socioeconomic status. <i>Neurology.</i> 1998; 50(5): 1231-8.	1991		
Italy	Ferini-Strambi L, Marcone A, Garancini P, Danelon F, Zamboni M, Massucci P, Tedesi B, Smirne S. Dementing disorders in north Italy: prevalence study in Vescovato, Cremona Province. <i>Eur J Epidemiol.</i> 1997; 13(2): 201-4.	1991		
Italy	Prencipe M, Casini AR, Ferretti C, Lattanzio MT, Fiorelli M, Culasso F. Prevalence of dementia in an elderly rural population: effects of age, sex, and education. <i>J Neurol Neurosurg Psychiatry.</i> 1996; 60(6): 628-33.	1992-1993		
Italy	Ravaglia G, Forti P, De Ronchi D, Maioli F, Nesi B, Cucinotta D, Bernardi M, Cavalli G. Prevalence and severity of dementia among northern Italian centenarians. <i>Neurology.</i> 1999; 53(2): 416-8.	1994-1995		
Italy	Ravaglia G, Forti P, Maioli F, Sacchetti L, Mariani E, Nativio V, Talerico T, Vettori C, Macini PL. Education, occupation, and prevalence of dementia: findings from the Conselice study. <i>Dement Geriatr Cogn Disord.</i> 2002; 14(2): 90-100.	1999-2000		
Italy	Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, Dalmonte E, Bianchin M, Mariani E. Incidence and etiology of dementia in a large elderly Italian population. <i>Neurology.</i> 2005; 64(9): 1525-30.	1999-2004		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Italy	Rocca WA, Bonaiuto S, Lippi A, Luciani P, Turfò F, Cavarzeran F, Amaducci L. Prevalence of clinically diagnosed Alzheimer's disease and other dementing disorders: a door-to-door survey in Appignano, Macerata Province, Italy. <i>Neurology</i> . 1990; 40(4): 626-31.	1984-1987		
Italy	Tognoni G, Ceravolo R, Nucciarone B, Bianchi F, Dell'Agnello G, Ghicopoulos I, Siciliano G, Murri L. From mild cognitive impairment to dementia: a prevalence study in a district of Tuscany, Italy. <i>Acta Neurol Scand</i> . 2005; 112(2): 65-71.	2000		
Italy	Cristina S, Nicolosi A, Hauser WA, Leite ML, Gerosa E, Nappi G. The prevalence of dementia and cognitive deficit in a rural population of 2442 residents in northern Italy. A door-to-door survey. <i>Eur J Neurol</i> . 2001; 8(6): 595-600.	1992-1993		
Italy	Mannocci A, La Torre G, Chiaradia G, De Waure C, Mainelli MT, Cernigliaro A, Bruno S, Ricciardi W. Epidemiology and direct medical costs of human leishmaniasis in Italy. <i>J Prev Med Hyg</i> . 2007; 48(1): 27-36.	1999-2003		
Italy	Zagari RM, Law GR, Fuccio L, Pozzato P, Forman D, Bazzoli F. Dyspeptic symptoms and endoscopic findings in the community: the Loiano-Monghidoro study. <i>Am J Gastroenterol</i> . 2010; 105(3): 565-71.	2000-2004	*	
Italy	Cimmino MA, Parisi M, Moggiana G, Mela GS, Accardo S. Prevalence of rheumatoid arthritis in Italy: the Chiavari Study. <i>Ann Rheum Dis</i> . 1998; 57(5): 315-8.	1991-1992		
Italy	Bolin AK, Bolin A, Koch G. Children's dental health in Europe: caries experience of 5- and 12-year-old children from eight EU countries. <i>Int J Paediatr Dent</i> . 1996; 6(3): 155-62.	1993		
Italy	Campus G, Sacco G, Cagetti M, Abati S. Changing trend of caries from 1989 to 2004 among 12-year old Sardinian children. <i>BMC Public Health</i> . 2007; 7: 28.	1989, 1992, 1995, 1999, 2004		
Italy	Angellilo IF, Anfosso R, Nobile CG, Pavia M. Prevalence of dental caries in schoolchildren in Italy. <i>Eur J Epidemiol</i> . 1998; 14(4): 351-7.	1996		
Italy	Campus G, Lumbau A, Sanna AM, Solinas G, Lugliè P, Castiglia P. Oral health condition in an Italian preschool population. <i>Eur J Paediatr Dent</i> . 2004; 5(2): 86-91.	2002		
Italy	Petti S, Cairella G, Tarisiani G. Rampant early childhood dental decay: an example from Italy. <i>J Public Health Dent</i> . 2000; 60(3): 159-66.	1997-1998		
Italy	Ferro R, Besostri A, Olivieri A. Caries prevalence and tooth surface distribution in a group of 5-year-old Italian children. <i>Eur Arch Paediatr Dent</i> . 2009; 10(1): 33-7.	2005-2006		
Italy	Campus G, Solinas G, Cagetti MG, Senna A, Minelli L, Majori S, Montagna MT, Reali D, Castiglia P, Strohmenger L. National Pathfinder survey of 12-year-old Children's Oral Health in Italy. <i>Caries Res</i> . 2007; 41(6): 512-7.	2004-2005		
Italy	Perinetti G, Varvara G, Esposito P. Prevalence of dental caries in schoolchildren living in rural and urban areas: results from the first region-wide Italian survey. <i>Oral Health Prev Dent</i> . 2006; 4(3): 199-207.	2004		
Italy	Ferro R, Besostri A, Meneghetti B. Dental caries experience in preschool children in Veneto region (Italy). <i>Community Dent Health</i> . 2006; 23(2): 91-4.	2002-2003		
Italy	Ferro R, Besostri A, Olivieri A, Stellini E, Mazzoleni S. Preschoolers' dental caries experience and its trend over 20 years in a North-East Italian Health District. <i>Eur J Paediatr Dent</i> . 2007; 8(4): 199-204.	2002-2005		
Italy	Ferro R, Besostri A, Meneghetti B, Stellini E. Prevalence and severity of dental caries in 5- and 12-year old children in the Veneto Region (Italy). <i>Community Dent Health</i> . 2007; 24(2): 88-92.	2003-2004		
Italy	Italian Society of Nephrology. Italian Society of Nephrology Register of Dialysis and Transplant (SIN-RIDT) Annual Report 2006. Italy: Italian Society of Nephrology, 2008.	1996, 2006		
Italy	Faravelli C, Abrardi L, Bartolozzi D, Cecchi C, Cosci F, D'Adamo D, Lo Iacono B, Ravaldi C, Scarpato MA, Truglia E, Rossi Prodi PM, Rosi S. The Sesto Fiorentino Study: Point and One-Year Prevalences of Psychiatric Disorders in an Italian Community Sample Using Clinical Interviewers. <i>Psychother Psychosom</i> . 2004; 73(4): 226-34.	2001-2003		
Italy	Faravelli C, Degl'Innocenti BG, Aiazzi L, Incerpi G, Pallanti S. Epidemiology of mood disorders: a community survey in Florence. <i>J Affect Disord</i> . 1990; 20(2): 135-41.	1987		†
Italy	Favaro A, Ferrara S, Santonastaso P. The Spectrum of Eating Disorders in Young Women: A Prevalence Study in a General Population Sample. <i>Psychosom Med</i> . 2003; 65(4): 701-8.	2001		
Italy	Cotrufo P, Barretta V, Monteleone P, Maj M. Full-syndrome, partial-syndrome and subclinical eating disorders: an epidemiological study of female students in Southern Italy. <i>Acta Psychiatr Scand</i> . 1998; 98(2): 112-5.	1996		
Italy	Signorini A, De Filippo E, Panico S, De Caprio C, Pisanisi F, Contaldo F. Long-term mortality in anorexia nervosa: a report after an 8-year follow-up and a review of the most recent literature. <i>Eur J Clin Nutr</i> . 2007; 61(1): 119-22.	1994-2003		
Italy	Cecchi F, Olivetto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. <i>J Am Coll Cardiol</i> . 1995; 26(6): 1529-36.	1963-1992		
Italy	Nistri S, Thiene G, Basso C, Corrado D, Vitolo A, Maron BJ. Screening for hypertrophic cardiomyopathy in a young male military population. <i>Am J Cardiol</i> . 2003; 91(8): 1021-1023.	1992-1996		
Italy	Gigantesco A, Palumbo G, Mirabella F, Pettinelli M, Morosini P. Prevalence of Psychiatric Disorders in an Italian Town: Low Prevalence Confirmed with Two Different Interviews. <i>Psychother Psychosom</i> . 2006; 75(3): 170-6.	1993, 2000		
Italy	Faravelli C, GDB, Giardinelli L. Epidemiology of anxiety disorders in Florence. <i>Acta Psychiatr Scand</i> . 1989; 79(4): 308-12.	1987		
Italy	Carta MG, Carpiello B, Morosini PL, Rudas N. Prevalence of mental disorders in Sardinia: a community study in an inland mining district. <i>Psychol Med</i> . 1991; 21(04): 1061-71.	1989		
Italy	Serio A, Fraioli A. Epidemiology of nephrolithiasis. <i>Nephron</i> . 1999; 26:30.	1983, 1993-1994		
Italy	Trinchieri A, Coppi F, Montanari E, Del Nero A, Zanetti G, Pisani E. Increase in the prevalence of symptomatic upper urinary tract stones during the last ten years. <i>Eur Urol</i> . 2000; 37(1): 23-5.	1986-1998		
Italy	Negri E, Pagano R, Decarli A, La Vecchia C. Body weight and the prevalence of chronic diseases. <i>J Epidemiol Community Health</i> . 1988; 42(1): 24-9.	1983		
Italy	Musolino R LSP. First-ever stroke incidence and 30-day case fatality in the Sicilian Aeolian archipelago, Italy. <i>Stroke</i> . 2005; 36(12): 2738-41.	1999-2002		
Italy	Carta MG, Kovess V, Hardoy MC, Morosini P, Murgia S, Carpiello B. Psychiatric disorders in Sardinian immigrants to Paris: a comparison with Parisians and Sardinians resident in Sardinia. <i>Soc Psychiatry Psychiatr Epidemiol</i> . 2002; 37(3): 112-7.	1994-1996		
Italy	Rakar S, Sinagra G, Di Lenarda A, Poletti A, Bussani R, Silvestri F, Camerini F. Epidemiology of dilated cardiomyopathy. A prospective post-mortem study of 5252 necropsies. <i>The Heart Muscle Disease Study Group</i> . <i>Eur Heart J</i> . 1997; 18(1): 117-23.	1987-1989		
Italy	Cecchi E, Forno D, Inazio M, Migliardi A, Gnani R, Dal Conte I, Trinchero R; Piemonte Infective Endocarditis Study Group. New trends in the epidemiological and clinical features of infective endocarditis: results of a multicenterprospective study. <i>Ital Heart J</i> . 2004; 5(4): 249-56.	2000-2001		
Italy	de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Künzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P. European Community Respiratory Health Survey Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. <i>Thorax</i> . 2004; 59(2): 120-125.	1991-1993		
Italy	Camarda R, Monastero R. Prevalence of primary headaches in Italian elderly: preliminary data from the Zabot Aging Project. <i>Neurol Sci</i> . 2003; S122-124.	2001		
Italy	Downes E, Sikirica V, Gilbert-Estelles J, Bolge SC, Dodd SL, Maroulis C, Subramanian D. The burden of uterine fibroids in five European countries. <i>Eur J Obstet Gynecol Reprod Biol</i> . 2010; 152(1): 96-102.	2007		
Italy	Lippman SA, Warner M, Samuels S, Olive D, Vercellini P, Eskenazi B. Uterine fibroids and gynecologic pain symptoms in a population-based study. <i>Fertil Steril</i> . 2003; 80(6): 1488-94.	1996-1998		
Italy	Orlandi G, Gelli A, Fanucchi S, Tognoni G, Acerbi G, Murri L. Prevalence of stroke and transient ischaemic attack in the elderly population of an Italian rural community. <i>Eur J Epidemiol</i> . 2003; 18(9): 879-82.	2001		
Italy	Prencipe M, Ferretti C, Casini AR, Santini M, Giubilei F, Culasso F. Stroke, disability, and dementia: results of a population survey. <i>Stroke</i> . 1997; 28(3): 531-6.	1992-1993		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Italy	United States Renal Data System Coordinating Center. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2000-2006		
Italy	United States Renal Data System Coordinating Center. USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2003.	1999		
Italy	De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000; 54(11 Suppl 5): S21-23.	1997		
Italy	Rijk MC de, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alpeirovitch A, Rocca WA. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997; 62(1): 10-5.	1988-1989		
Italy	Chiò A, Magnani C, Schiffer D. Prevalence of Parkinson's disease in northwestern Italy: Comparison of tracer methodology and clinical ascertainment of cases. Mov Disord. 1998; 13(3): 400-5.	1991		
Italy	Baldereschi M, Carlo AD, Rocca WA, Vanni P, Maggi S, Perissinotto E, Grigoletto F, Amaducci L, Inzitari D. Parkinson's disease and parkinsonism in a longitudinal study: Two-fold higher incidence in men. Neurology. 2000; 55(9): 1358-63.	1992-1996		
Italy	Casetta I, Granieri E, Govoni V, Tola MR, Paolino E, Monetti VC, Caniatti L. Epidemiology of Parkinson's disease in Italy. A descriptive survey in the U.S.L. of Cento, province of Ferrara, Emilia-Romagna. Acta Neurol (Napoli). 1990; 12(4): 284-91.	1987		
Italy	Morgante L, Rocca WA, Di Rosa AE, De Domenico P, Grigoletto F, Meneghini F, Reggio A, Savettieri G, Castiglione MG, Patti F. Prevalence of Parkinson's disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. The Sicilian Neuro-Epidemiologic Study (SNES) Group. Neurology. 1992; 42(10): 1901-7.	1987		
Italy	Nuti A, Ceravolo R, Dell'Agnello G, Gambaccini G, Bellini G, Kiferle L, Rossi C, Logi C, Bonuccelli U. Environmental factors and Parkinson's disease: a case-control study in the Tuscany region of Italy. Parkinsonism Relat Disord. 2004; 10(8): 481-5.	1990-1995		
Italy	D'Alessandro R, Gamberini G, Granieri E, Benassi G, Naccarato S, Manzaroli D. Prevalence of Parkinson's disease in the Republic of San Marino. Neurology. 1987; 37(10): 1679-82.	1985-1986		†
Italy	Raschetti R S-AS, Vanacore N, Ancona C, Mecco G. Mortality in a population-based cohort of patients treated with antiparkinsonian drugs. Acta Neurol Scand. 1998; 97(1): 20-6.	1987-1994		
Italy	Rosati G, Granieri E, Pinna L, Aiello L, Tola R, De Bastiani P, Pirisi A, Devoto MC. The risk of Parkinson disease in Mediterranean people. Neurology. 1980; 30(3): 250-5.	1961-1972		
Italy	Rozzini R, Frisoni GB, Ferrucci L, Barbisoni P, Bertozzi B, Trabucchi M. The effect of chronic diseases on physical function. Comparison between activities of daily living scales and the Physical Performance Test. Age Ageing. 1997; 26(4): 281-7.	1994		
Italy	Totaro R, Marini C, Pistoia F, Sacco S, Russo T, Carolei A. Prevalence of Parkinson's disease in the L'Aquila district, central Italy. Acta Neurol Scand. 2005; 112(1): 24-8.	2001		
Italy	Berger K BM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000; 54(11): 24-7.	1997		
Italy	De Salvia D, Barbato A, Salvo P, Zadro F. Prevalence and incidence of schizophrenic disorders in Portogruaro. An Italian case register study. J Nerv Ment Dis. 1993; 181(5): 275-82.	1982-1989		
Italy	Tansella M, Balestrieri M, Meneghelli G, Micciolo R. Trends in the provision of psychiatric care 1979-1988. Psychol Med. 1991; 5:54.	1979-1988		
Italy	Lesage AD, Trapani V, Tansella M. Excess mortality by natural causes of Italian schizophrenic patients. Eur Arch Psychiatry Neurol Sci. 1990; 239(6): 361-5.	1979-1986		
Italy	Politi P, Piccinelli M, Klersy C, Madini S, Segagni LG, Fratti C, Barale F. Mortality in psychiatric patients 5 to 21 years after hospital admission in Italy. Psychol Med. 2002; 32(2): 227-37.	1978-1994		
Italy	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN), ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Italy	Cecchi F, Debolini P, Lova RM, Macchi C, Bandinelli S, Bartali B, Lauretani F, Benvenuti E, Hicks G, Ferrucci L. Epidemiology of back pain in a representative cohort of Italian persons 65 years of age and older: the InCHIANTI study. Spine. 2006; 31(10): 1149-55.	1998-2000		
Italy	Seland JH, Vingerling JR, Aougoud CA, Bentham G, Chakravarthy U, deJong PTVM, Rahu M, Soubrane G, Tomazzoli L, Topouzis F, Flecher AE. Visual impairment and quality of life in the older European population, the EUREYE study. Acta Ophthalmol. 2011; 89(7): 608-13. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2006-2007		
Italy	Cedrone C, Nucci C, Scuderi G, Ricci F, Cerulli A, Culasso F. Prevalence of blindness and low vision in an Italian population: a comparison with other European studies. Eye (Lond). 2006; 20(6): 661-7.	2000		
Italy	Alfonsi V, Montomoli E, Manini I, Alberini I, Gentile C, Rota MC, Ciofi degli Atti ML. Susceptibility to varicella in childbearing age women, Central Italy: is there a need for vaccinating this population group? Vaccine. 2007; 25(32): 6086-8.	2001-2002		
Italy	Ciofi degli Atti ML, Rota MC, Mandolini D, Bella A, Gabutti G, Crovari P, Salmaso S. Assessment of varicella underreporting in Italy. Epidemiol Infect. 2002; 128(3): 479-84.	1999		
Italy	Romanò L, Grilli G, Zanetti AR. Seroepidemiology of varicella in a cohort of Italian adolescents. Ann Ig. 2002; 14(4 Suppl 6): 7-10.	1992-2000		
Italy	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1995, 1999, 2001, 2003, 2005		
Italy	Pavarin RM. Cocaine consumption and death risk: a follow-up study on 347 cocaine addicts in the metropolitan area of Bologna. Ann Ist Super Sanita. 2008; 44(1): 91-8.	1989-2004		
Italy	Don M, Valerio G, Korppi M, Canciani M. Hyper- and hypoglycemia in children with community-acquired pneumonia. J Pediatr Endocrinol Metab. 2008; 21(7): 657-64.	2001-2002		
Italy	Baldereschi M, Di Carlo A, Maggi S, Grigoletto F, Sciarlo G, Amaducci L, Inzitari D. Dementia is a major predictor of death among the Italian elderly. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology. 1999; 52(4): 709-13.	1992-1995		
Italy	Noale M, Maggi S, Minicuci N, Marzari C, Destro C, Farchi G, Scafato E, Baldereschi M, Di Carlo A, Crepaldi G, ILSA Working Group. Dementia and disability: impact on mortality. The Italian Longitudinal Study on Aging. Dement Geriatr Cogn Disord. 2003; 16(1): 7-14.	1997		
Italy	Bonaaiuto S, Mele M, Galluzzo L, Giannandrea E. Survival and dementia: a 7-year follow-up of an Italian elderly population. Arch Gerontol Geriatr. 1995; 20(1): 105-13.	1987-1995		
Italy	McDowell RD, Ryan A, Bunting BP, O'Neill SM, Alonso J, Bruffaerts R, de Graaf R, Florescu S, Vilagut G, de Almeida JMC, de Girolamo G, Haro JM, Hinkov H, Kovess-Masfety V, Matschinger H, Tomov T. Mood and anxiety disorders across the adult lifespan: a European perspective. Psychol Med. 2013; 1-16.	2001-2002	*	
Italy	WHO Regional Office for Europe (EURO-WHO). Young People's Health in Context. Health Behaviour in School-aged Children (HBSC) Study: International Report from the 2001-2002 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2004.	2002		
Italy	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Italy	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). Alcohol and Drug Use Among European 17-18 Year Old Students: Data from the ESPAD Project. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2007.	2003		
Italy	Cossu P, Deriu MG, Casetta I, Leoni S, Daltveit A-K, Riise T, Rosati G, Pugliatti M. Epilepsy in Sardinia, insular Italy: a population-based prevalence study. Neuroepidemiology. 2012; 39(1): 19-26.	2007	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Italy	Bouvier-Colle M-H, Mohangoo AD, Gissler M, Novak-Antolic Z, Vutuc C, Szamatulska K, Zeitlin J, Euro-Peristat Scientific Committee. What about the mothers? An analysis of maternal mortality and morbidity in perinatal health surveillance systems in Europe. <i>BJOG</i> . 2012; 119(7): 880-90.	2003-2004	*	
Italy	Donati S, Senatore S, Ronconi A, Regional Maternal Mortality Working Group. Obstetric near-miss cases among women admitted to intensive care units in Italy. <i>Acta Obstet Gynecol Scand</i> . 2012; 91(4): 452-7.	2004-2005	*	
Italy	Zanconato G, Cavaliere E, Iacovella C, Vassanelli A, Schweiger V, Cipriani S, Franchi M. Severe maternal morbidity in a tertiary care centre of northern Italy: a 5-year review. <i>J Matern Fetal Neonatal Med</i> . 2012; 25(7): 1025-8.	2005-2009	*	
Italy	Bonzini M, Ferrario MM, Bertù L, Bono G, Vidale S, Veronesi G, Chambless L, Cesana GC. Temporal trends in ischemic and hemorrhagic strokes in Northern Italy: results from the cardiovascular monitoring unit in Northern Italy population-based register, 1998-2004. <i>Neuroepidemiology</i> . 2012; 39(1): 35-42.	1998, 2004	*	
Italy	D'Alessandro G, Gallo F, Vitaliano A, Col PD, Gorraz F, Cristofaro RD, Boaretto G. Prevalence of stroke and stroke-related disability in Valle d'Aosta, Italy. <i>Neurol Sci</i> . 2010; 31(2): 137-41.	2004	*	
Italy	Gajofatto A, Stefani A, Turatti M, Bianchi MR, Lira MG, Moretto G, Salvati A, Benedetti MD. Prevalence of multiple sclerosis in Verona, Italy: an epidemiological and genetic study. <i>Eur J Neurol</i> . 2013; 20(4): 697-703.	2001	*	
Italy	Cocco E, Sardu C, Massa R, Mamusa E, Musu L, Ferrigno P, Melis M, Montomoli C, Ferretti V, Coghe G, Fenu G, Frau J, Lorence L, Carboni N, Contu P, Marrosu MG. Epidemiology of multiple sclerosis in south-western Sardinia. <i>Mult Scler</i> . 2011; 17(11): 1282-9.	2003-2007	*	
Italy	Nicoletti A, Patti F, Lo Fermo S, Messina S, Bruno E, Quattrocchi G, Lausa P, Cilia S, Mostile G, Marziolo R, Scillieri R, Maimone D, Zappia M. Increasing frequency of multiple sclerosis in Catania, Sicily: a 30-year survey. <i>Mult Scler</i> . 2011; 17(3): 273-80.	2000-2004	*	
Italy	Millefiorini E, Cortese A, Di Rezze S, Barletta G, Bellantonio P, Batocchi AP, Di Battista G, Fiore S, Gasperini C, Grasso MG, Kouidratseva T, Totaro R, Durastanti V. The prevalence of multiple sclerosis in central Italy. <i>Mult Scler</i> . 2010; 16(12): 1432-6.	2007	*	
Italy	Granieri E, Paolino E, Tola MR, Carreras M, Monetti VC, De Bastiani P, Pinna L, Merlin I, Altobelli A, Finotti L. [Epidemiology of epilepsy in the U.S.L. 34, Copparo, Emilia-Romagna]. <i>Riv Neurol</i> . 1984; 54(4): 245-64.	1981	*	
Italy	Banfi R, Borselli G, Marini C, Borgheresi A, Cavalieri A. Epidemiological study of epilepsy by monitoring prescriptions of antiepileptic drugs. <i>Pharm World Sci</i> . 1995; 17(4): 138-40.	1992-1993	*	
Italy	Granieri E, Rosati G, Tola R, Pavoni M, Paolino E, Pinna L, Monetti VC. A descriptive study of epilepsy in the district of Copparo, Italy, 1964-1978. <i>Epilepsia</i> . 1983; 24(4): 502-14.	1978	*	
Italy	Cavazzuti GB. Epidemiology of different types of epilepsy in school age children of Modena, Italy. <i>Epilepsia</i> . 1980; 21(1): 57-62.	1968-1973	*	
Italy	Benna P, Ferrero P, Bianco C, Asteggiano G, Pinessi L. Epidemiological aspects of epilepsy in the children of a Piedmontese district (Alba-Bra). <i>Panminerva Med</i> . 1994; 26(2): 113-8.	1974-1978	*	
Italy	Menegati E, Tiberti A, Perini A, Valseriati D, Giordano L, Cacciago E, Accorsi P, Battaglia S, Martelli P, Micheli R, Zucchi A. [Preliminary epidemiological data of epilepsy in the first year of life]. <i>Bollettino</i> . 1999; 219-21.	1992-1998	*	†
Italy	Marenmani C, Rossi G, Bonuccelli U, Murri L. Descriptive epidemiologic study of epilepsy syndromes in a district of northwest Tuscany, Italy. <i>Epilepsia</i> . 1991; 32(3): 294-8.	1985	*	
Italy	Pisani F, Trunfio C, Oteri G, Primerano G, Amendola D'Agostino A, Strati F, Di Perri R. Prevalence of epilepsy in children of Reggio Calabria, southern Italy. <i>Acta Neurol (Napoli)</i> . 1987; 9(1): 40-3.	1981	*	
Italy	Cornaggia CM, Canevini MP, Christe W, Guccioli D, Facheris MA, Sabbadini M, Canger R. Epidemiologic survey of epilepsy among Army draftees in Lombardy, Italy. <i>Epilepsia</i> . 1990; 31(1): 27-32.	1985-1986	*	†
Italy	Giuliani G, Terziani S, Senigaglia AR, Luccioni G, Foschi N, Maffei C. Epilepsy in an Italian community as assessed by a survey for prescriptions of antiepileptic drugs: epidemiology and patterns of care. <i>Acta Neurol Scand</i> . 1992; 85(1): 23-31.	1985-1986	*	
Italy	Rocca WA, Savettieri G, Anderson DW, Meneghini F, Grigoletto F, Morgante L, Reggio A, Salemi G, Patti F, Di Perri R, Sicilian Neuro-Epidemiologic Study (SNES) Group. Door-to-door prevalence survey of epilepsy in three Sicilian municipalities. <i>Neuroepidemiology</i> . 2001; 20(4): 237-41.	1987	*	
Italy	Gallitto G, Serra S, La Spina P, Postorino P, Laganà A, Tripodi F, Gangemi S, Calabrò S, Savica R, Di Perri R, Beghi E, Musolino R. Prevalence and characteristics of epilepsy in the Aeolian islands. <i>Epilepsia</i> . 2005; 46(11): 1828-35.	1999	*	
Italy	Copeland JR, Beekman AT, Dewey ME, Hooijer C, Jordan A, Lawlor BA, Lobo A, Magnusson H, Mann AH, Meller I, Prince MJ, Reischies F, Turina C, deVries MW, Wilson KC. Depression in Europe. Geographical distribution among older people. <i>Br J Psychiatry</i> . 1999; 174: 312-21.	1990-1991		
Italy	Gambaro G, Yabarek T, Graziani MS, Gemelli A, Abaterusso C, Frigo AC, Marchionna N, Citron L, Bonfante L, Grigoletto F, Tata S, Ferraro PM, Legnaro A, Meneghel G, Conz P, Rizzotti P, D'Angelo A, Lupo A; INCIPE Study Group. Prevalence of CKD in northeastern Italy: results of the INCIPE study and comparison with NHANES. <i>Clin J Am Soc Nephrol</i> . 2010; 5(11): 1946-53.	2006		
Italy	Corrao G, Zambon A, Torchio P, Aricò S, La Vecchia C, di Orio F. Attributable risk for symptomatic liver cirrhosis in Italy. Collaborative Groups for the Study of Liver Diseases in Italy. <i>J Hepatol</i> . 1998; 28(4): 608-14.	1989-1996		
Italy	Stroffolini T, Sagnelli E, Almasio P, Ferrigno L, Craxi A, Mele A, Italian Hospitals Collaborating Groups. Characteristics of liver cirrhosis in Italy: results from a multicenter national study. <i>Dig Liver Dis</i> . 2004; 36(1): 56-60.	2001		
Italy	Montalto G, Soresi M, Tripi S, Carroccio A, Bascone F, Di Martino D, Bonfissuto G, Notarbartolo A. [Incidence of anti-HCV positivity in a Sicilian population with liver diseases]. <i>Ann Ital Med Int</i> . 1995; 10(2): 89-92.	1995		
Italy	Sagnelli E, Stroffolini T, Mele A, Almasio P, Coppola N, Ferrigno L, Scolastico C, Onofrio M, Imparato M, Filippini P. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. <i>J Med Virol</i> . 2005; 75(4): 522-7.	2001		
Italy	Chiesa R, Donato F, Tagger A, Favret M, Ribero ML, Nardi G, Gelatti U, Bucella E, Tomasi E, Portolani N, Bonetti M, Bettini L, Pelizzari G, Salmi A, Savio A, Garatti M, Callea F. Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis. <i>Cancer Epidemiol Biomarkers Prev</i> . 2000; 9(2): 213-6.	1995-1997		
Italy	Donato F, Tagger A, Chiesa R, Ribero ML, Tomasoni V, Fasola M, Gelatti U, Portera G, Boffetta P, Nardi G. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. <i>Brescia HCC Study</i> . <i>Hepatology</i> . 1997; 26(3): 579-84.	1995-1996		
Italy	Franceschi S, Montella M, Polesel J, La Vecchia C, Crispo A, Dal Maso L, Casarin P, Izzo F, Tommasi LG, Chemin I, Trépo C, Crovatto M, Talamini R. Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. <i>Cancer Epidemiol Biomarkers Prev</i> . 2006; 15(4): 683-9.	1999-2002		
Italy	Gelatti U, Donato F, Tagger A, Fantoni C, Portolani N, Ribero ML, Martelli C, Trevisi P, Covolo L, Simonati C, Nardi G, Brescia HCC Study. Etiology of hepatocellular carcinoma influences clinical and pathologic features but not patient survival. <i>Am J Gastroenterol</i> . 2003; 98(4): 907-14.	1995-2001		
Italy	Tagger A, Donato F, Ribero ML, Chiesa R, Portera G, Gelatti U, Albertini A, Fasola M, Boffetta P, Nardi G. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. <i>Brescia HCC Study</i> . <i>Int J Cancer</i> . 1999; 81(5): 695-9.	1995-1998		
Italy	Lauder A, Schieppati A, Conte F, Remuzzi G, Battle D. Low mortality and key aspects of delivery of care for end-stage renal disease in Italy. <i>ScientificWorldJournal</i> . 2009; 9: 349-59.	2006		
Italy	Tarchini R, Segoloni GP, Gentile MG, Lupo A, Cancarini G, Salomone M, D'Amico G, Mioli V, Vercellone A, Zucchelli P. Long-term results of CAPD in Italy: a report from the Italian CAPD Study Group. <i>Clin Nephrol</i> . 1988; 30(Suppl 1): S68-70.	1980-1985		
Italy	Faravelli C, Lo Sauro C, Castellini G, Ricca V, Pallanti S. Prevalence and correlates of mental disorders in a school-survey sample. <i>Clin Pract Epidemiol Ment Health</i> . 2009; 1-8.	1997	*	
Italy	Mata I, Bepert M, Madoz V, Psicost Y. Incidence of Schizophrenia in Navarra. <i>Anales Sis San Navarra</i> . 2000; 243(Suppl 1): 29-36.	1993-1997		
Italy	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Italy	Festi D, Dormi A, Capodicasa S, Stanicica T, Attili A-F, Loria P, Pazzi P, Mazzella G, Sama C, Roda E, Colecchia A. Incidence of gallstone disease in Italy: results from a multicenter, population-based Italian study (the MICOL project). <i>World J Gastroenterol.</i> 2008; 14(34): 5282-9.	1995-1998	*	
Italy	Corazzari E, Attili AF, Angeletti C, De Santis A, Gallstones, cholecystectomy and irritable bowel syndrome (IBS) MICOL population-based study. <i>Dig Liver Dis.</i> 2008; 40(12): 944-50.	2005-2007	*	
Italy	Bianchini R, Postorino V, Grasso R, Santoro B, Migliore S, Burlò C, Tata C, Mazzone L. Prevalence of ADHD in a sample of Italian students: a population-based study. <i>Res Dev Disabil.</i> 2013; 34(9): 2543-50.	2011-2012	*	
Italy	Mascellino MT, Ciardi MR, Oliva A, Cecinato F, Hassemer MP, Borgese L. Chlamydia trachomatis detection in a population of asymptomatic and symptomatic women: correlation with the presence of serological markers for this infection. <i>New Microbiol.</i> 2008; 31(2): 249-56.	2005-2006	*	
Italy	De Punzio C, Neri E, Guazzelli G, Gremigni R. Incidence of Chlamydia trachomatis in women with PID: effectiveness of therapy. <i>Acta Eur Fert.</i> 1995; 26(4): 149-51.	1992-1994	*	†
Italy	Suligoi B, Dorrucchi M, Volpi A, Andreoni M, Zerboni R, Rezza G, Italian Seroconversion Study Group. Prevalence and determinants of herpes simplex virus type 2 infection in a cohort of HIV-positive individuals in Italy. <i>Sex Transm Dis.</i> 2002; 29(11): 665-7.	1983-1995, 1998-1999	*	
Italy	Le Donne M, Mancuso A, Leonardi MS. Sero-prevalence of cytomegalovirus, rubella, herpes simplex virus, varicella zoster virus, measles, parvovirus B19 and adenovirus in women with spontaneous abortion. <i>Ital J Gynaecol Obstet.</i> 2005; 17(1): 29-35.	2003-2004	*	
Italy	Suligoi B, Calistri A, Cusini M, Palù G, Italian Herpes Management Forum. Seroprevalence and determinants of herpes simplex type 2 infection in an STD clinic in Milan, Italy. <i>J Med Virol.</i> 2002; 67(3): 345-8.	1997-1998	*	
Italy	Locatelli A, Incerti M, Paterlini G, Doria V, Consonni S, Provero C, Ghidini A. Antepartum and intrapartum risk factors for neonatal encephalopathy at term. <i>Am J Perinatol.</i> 2010; 27(8): 649-54.	1993-2003	*	†
Italy	Ancora G, Soffritti S, Lodi R, Tonon C, Grandi S, Locatelli C, Nardi L, Bisacchi N, Testa C, Tani G, Ambrosetto P, Faldella G. A combined a-EEG and MR spectroscopy study in term newborns with hypoxic-ischemic encephalopathy. <i>Brain Dev.</i> 2010; 32(10): 835-42.	2004-2005	*	†
Italy	Ferrari F, Todeschini A, Guidotti I, Martinez-Biarge M, Roversi MF, Berardi A, Ranzi A, Cowan FM, Rutherford MA. General movements in full-term infants with perinatal asphyxia are related to Basal Ganglia and thalamic lesions. <i>J Pediatr.</i> 2011; 158(6): 904-11.	2003-2006	*	†
Italy	Minuto N, Emmanuele V, Vannati M, Russo C, Rebora C, Panarello S, Pistorio A, Lorini R, d' Annunzio G. Retinopathy screening in patients with type 1 diabetes diagnosed in young age using a non-mydratric digital stereoscopic retinal imaging. <i>J Endocrinol Invest.</i> 2012; 35(4): 389-94.	2006-2007		
Italy	Monesi L, Baviera M, Marzona I, Avanzini F, Monesi G, Nobili A, Tettamanzi M, Cortesi L, Riva E, Fortino I, Bortolotti A, Fontana G, Merlino L, Roncaglioni MC. Prevalence, incidence and mortality of diagnosed diabetes: evidence from an Italian population-based study. <i>Diabet Med.</i> 2012; 29(3): 385-92.	2002-2007		
Italy	Altobelli E, Chiarelli F, Valenti M, Verrotti A, Tumini S, Di Orto F. Incidence of insulin-dependent diabetes mellitus (0-14 years) in the Abruzzo Region, Italy, 1990-1995: results from a population-based register. <i>J Pediatr Endocrinol Metab.</i> 1998; 11(4): 555-62.	1990-1995		
Italy	Arpi ML, Fichera G, Mancuso M, Lucenti C, Italia S, Tomaselli L, Motta RM, Mazza A, Vigneri R, Purrello F, Squatrito S. A ten-year (1989-1998) perspective study of the incidence of Type 1 diabetes in the district of Catania (Sicily) in a 0-14 year age group. <i>J Endocrinol Invest.</i> 2002; 25(5): 414-9.	1989-1998		
Italy	Bizzarri C, Patera PI, Arnaldi C, Petrucci S, Bitti MLM, Scrocca R, Manfrini S, Portuesi R, Buzzetti R, Cappa M, Pozzilli P, Immunotherapy Diabetes (IMDIAB) Group. Incidence of type 1 diabetes has doubled in Rome and the Lazio region in the 0- to 14-year age-group: a 6-year prospective study (2004-2009). <i>Diabetes Care.</i> 2010; 33(11): e140.	2004-2009		
Italy	Bruno G, Novelli G, Panero F, Perotto M, Monasterolo F, Bona G, Perino A, Rabbone I, Cavallo-Perin P, Cerutti F, Piedmont Study Group for Diabetes Epidemiology. The incidence of type 1 diabetes is increasing in both children and young adults in Northern Italy: 1984-2004 temporal trends. <i>Diabetologia.</i> 2009; 52(12): 2531-5.	1984-2004		
Italy	Bruno G, Runzo C, Cavallo-Perin P, Merletti F, Rivetti M, Pinach S, Novelli G, Trovati M, Cerutti F, Pagano G, Piedmont Study Group for Diabetes Epidemiology. Incidence of type 1 and type 2 diabetes in adults aged 30-49 years: the population-based registry in the province of Turin, Italy. <i>Diabetes Care.</i> 2005; 28(11): 2613-9.	1999-2001		
Italy	Cotellessa M, Barbieri P, Mazzella M, Bonassi S, Minicucci L, Lorini R. High incidence of childhood type 1 diabetes in Liguria, Italy, from 1989 to 1998. <i>Diabetes Care.</i> 2003; 26(6): 1786-9.	1989-1998		
Italy	Iafusco D, Massa O, Pasquino B, Colombo C, Iughetti L, Bizzarri C, Mammi C, Lo Presti D, Suprani T, Schiaffini R, Nichols CG, Russo L, Grasso V, Meschi F, Bonfanti R, Bresciani S, Barbeti F, Early Diabetes Study Group of ISPED. Minimal incidence of neonatal/infancy onset diabetes in Italy is 1:90,000 live births. <i>Acta Diabetol.</i> 2012; 49(5): 405-8.	2005-2010		
Italy	Bruno G, Maule M, Biggieri A, Ledda A, Mannu C, Merletti F, Songini M, Sardinian Group for Diabetes Epidemiology. More than 20 years of registration of type 1 diabetes in Sardinian children: temporal variations of incidence with age, period of diagnosis, and year of birth. <i>Diabetes.</i> 2013; 62(10): 3542-6.	1989-2009		
Italy	Bruno G, Merletti F, De Salvia A, Lezo A, Arcari R, Pagano G. Comparison of incidence of insulin-dependent diabetes mellitus in children and young adults in the Province of Turin, Italy, 1984-91. <i>Piedmont Study Group for Diabetes Epidemiology. Diabet Med.</i> 1997; 14(11): 964-9.	1984-1991		
Italy	Cherubini V, Carle F, Gesuita R, Iannilli A, Tuomilehto J, Prisco F, Iafusco D, Altobelli E, Chiarelli F, De Giorgi G, Falorni A. Large incidence variation of Type 1 diabetes in central-southern Italy 1990-1995: lower risk in rural areas. <i>Diabetologia.</i> 1999; 42(7): 789-92.	1990-1995		
Italy	Aimoni C, Bianchini C, Borin M, Ciorba A, Fellin R, Martini A, Scanelli G, Volpato S. Diabetes, cardiovascular risk factors and idiopathic sudden sensorineural hearing loss: a case-control study. <i>Audiol Neurootol.</i> 2010; 15(2): 111-5.	2001-2005		
Italy	Mazzella M, Cotellessa M, Bonassi S, Mulas R, Caratozzolo A, Gaber S, Romano C. Incidence of type I diabetes in the Liguria Region, Italy. Results of a prospective study in a 0- to 14-year age-group. <i>Diabetes Care.</i> 1994; 17(10): 1193-6.	1987-1991		
Italy	Pinelli L, Beretta F, Dalla Bernardina P, Gonfiantini E, Groff P. Incidence of insulin dependent diabetes mellitus in children 0-14 years old in the Veneto Region, Italy. <i>J Pediatr Endocrinol Metab.</i> 1998; 11(3): 447-50.	1993-1994		
Italy	Lo Sauro C, Castellini G, Lelli L, Faravelli C, Ricca V. Psychopathological and clinical features of remitted anorexia nervosa patients: a six-year follow-up study. <i>Eur Eat Disord Rev.</i> 2013; 21(1): 78-83.	2001-2007	*	
Italy	Cotrufo P, Monteleone P, Castaldo E, Maj M. A 4-year epidemiological study of typical and atypical eating disorders: preliminary evidence for subgroups of atypical eating disorders with different natural outcomes. <i>Eur Eat Disord Rev.</i> 2004; 12(4): 234-9.	1996-2000	*	
Italy	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Italy National Report to the EMCDDA 2006.	2005-2006	*	
Italy	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Italy National Report to the EMCDDA 2000.	1996	*	
Italy	Bargagli AM, Hickman M, Davoli M, Perucci CA, Schifano P, Buster M, Brugal T, Vicente J, COSMO European Group. Drug-related mortality and its impact on adult mortality in eight European countries. <i>Eur J Public Health.</i> 2006; 16(2): 198-202.	1992-1997	*	
Italy	Bargagli AM, Sperati A, Davoli M, Forastiere F, Perucci CA. Mortality among problem drug users in Rome: an 18-year follow-up study, 1980-97. <i>Addiction.</i> 2001; 96(10): 1455-63.	1980-1997	*	
Italy	Brancato V, Delvecchio G, Simone P. [Survival and mortality in a cohort of heroin addicts in 1985-1994]. <i>Minerva Med.</i> 1995; 86(3): 97-9.	1985-1994	*	
Italy	Ferri M, Bargagli AM, Faggiano F, Belleudi V, Salamina G, Vigna-Taglianti F, Davoli M, Perucci CA. Gruppo di studio VEDETTE. [Mortality of drug users attending public treatment centers in Italy 1998-2001: a cohort study]. <i>Epidemiol Prev.</i> 2007; 31(5): 276-82.	1998-2001	*	
Italy	Galli M, Musiccio M. Mortality of intravenous drug users living in Milan, Italy: role of HIV-1 infection. <i>COMCAT Study Group. AIDS.</i> 1994; 8(10): 1457-63.	1980-1991	*	
Italy	Goedert JJ, Piza G, Gritti FM, Costigliola P, Boschini A, Bini A, Lazzari C, Palareti A. Mortality among drug users in the AIDS era. <i>Int J Epidemiol.</i> 1995; 24(6): 1204-10.	1980-1990	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Italy	Kraus L, Augustin R, Frischer M, Kimmmer P, Uhl A, Wiessing L. Estimating prevalence of problem drug use at national level in countries of the European Union and Norway. <i>Addiction</i> . 2003; 98(4): 471-85.	1999	*	
Italy	Manfredi R, Sabbatani S, Agostini D. Trend of mortality observed in a cohort of drug addicts of the metropolitan area of Bologna, North-Eastern Italy, during a 25-year-period. <i>Coll Antropol</i> . 2006; 30(3): 479-88.	1977-2002	*	
Italy	Antolini G, Pirani M, Morandi G, Sorio C. [Gender difference and mortality in a cohort of heroin users in the Provinces of Modena and Ferrara, 1975-1999]. <i>Epidemiol Prev</i> . 2006; 30(2): 91-9.	1975-1999	*	
Italy	Modiano BG, Benerecetti-Santachiara AS, Gonano F, Zei G, Capaldo A, Cavalli-Sforza L I. An analysis of ABO, MN, Rh, Hp, Tf and G-6-PD types in a sample from the human population of the Lecce province. <i>Ann Hum Genet</i> . 1965; 29(1): 19-32.	1963-1965		
Italy	Siniscalco M, Bernini L, Filippi G, Latte B, Meera Khan P, Pionelli S, Rattazzi M. Population genetics of haemoglobin variants, thalassaemia and glucose-6-phosphate dehydrogenase deficiency, with particular reference to the malaria hypothesis. <i>Bull World Health Organ</i> . 1966; 34(3): 379-93.	1964-1966		
Italy	Corrias L, Melis L. Erythrocyte G-6-PD deficiency in blood donors of Oristano. <i>Quad Sclavo Diagn</i> . 1971; 7(2): 595-9.	1969-1971		
Italy	Bottini E, Palmirino R, Lucarelli P, Lista F, Bottini N. ACP1 and human adaptability: association with past malarial morbidity in the Sardinian population. <i>Am J Hum Biol</i> . 2001; 13(6): 753-60.	1975		
Italy	Schilirò G, Russo A, Curreli R, Marino S, Sciotta A, Russo G. Glucose-6-phosphate dehydrogenase deficiency in Sicily. Incidence, biochemical characteristics and clinical implications. <i>Clin Genet</i> . 1979; 15(2): 183-8.	1977-1979		
Italy	Gualandri V, Orsini GB, Porta E, Gerli GC. Glucose-6-phosphate dehydrogenase deficiency among the student population of Milan. <i>J Genet Hum</i> . 1983; 31(3): 201-9.	1978-1981		
Italy	Cocco P. Occupational lead exposure and screening of glucose-6-phosphate dehydrogenase polymorphism: useful prevention or nonvoluntary discrimination. <i>Int Arch Occup Environ Health</i> . 1998; 71(2): 148-50.	1981-1992		
Italy	Martuzzi Veronesi F, Stangoni A, Cuccuru GB, Mulas G, Marogna G, Cossu G, Pettener D. Glucose-6-phosphate dehydrogenase deficiency and blood groups in northern Sardinia. <i>Hum Hered</i> . 1985; 35(6): 399-402.	1983-1985		
Italy	Tagarelli A, Bastone L, Cittadella R, Calabrò V, Bria M, Brancati C. Glucose-6-phosphate dehydrogenase (G6PD) deficiency in southern Italy: a study on the population of the Cosenza province. <i>Gene Geogr</i> . 1991; 5(3): 141-50.	1989-1992		
Italy	Zaffanello M, Rugolotto S, Zamboni G, Gaudino R, Tatò L. Neonatal screening for glucose-6-phosphate dehydrogenase deficiency fails to detect heterozygote females. <i>Eur J Epidemiol</i> . 2004; 19(3): 255-7.	2000-2001		
Italy	Peroni DG, Piacentini GL, Bodini A, Rigotti E, Pigozzi R, Boner AL. Prevalence and risk factors for atopic dermatitis in preschool children. <i>Br J Dermatol</i> . 2008; 158(3): 539-43.	2005-2007	*	
Italy	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant</i> . 1988; 3(6): 714-27.	1985-1986		
Italy	Berthoux F, Jones E, Gellert R, Mendel S, Saker L, Briggs D. Epidemiological data of treated end-stage renal failure in the European Union (EU) during the year 1995: report of the European Renal Association Registry and the National Registries. <i>Nephrol Dial Transplant</i> . 1999; 14(10): 2332-42.	1995		
Italy	Alloati S, Strippoli GF, Buccianti G, Daidone G, Schena FP. Italian Society of Nephrology. Current structure and organization for renal patient assistance in Italy. <i>Nephrol Dial Transplant</i> . 2008; 23(4): 1323-9.	2004		
Italy	Catalano C, Postorino M, Kelly PJ, Fabrizi F, Enia G, Goodship TH, Fulcher GR, Maggiore Q. Diabetes mellitus and renal replacement therapy in Italy: prevalence, main characteristics and complications. <i>Nephrol Dial Transplant</i> . 1990; 5(9): 788-96.	1987		
Italy	Global Lower Extremity Amputation Study Group. Epidemiology of lower extremity amputation in centres in Europe, North America and East Asia. The Global Lower Extremity Amputation Study Group. <i>Br J Surg</i> . 2000; 87(3): 328-37.	1995-1997		
Italy	Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. <i>J Clin Endocrinol Metab</i> . 2008; 93(4): 1408-11.	2005		
Italy	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda L, Gilst WH van, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J</i> . 2003; 24(5): 442-63.	2000-2001		
Italy	Strohmeier L, Cerati M, Brambilla E, Malerba A, Vogel G. Periodontal epidemiology in Italy by CPITN. <i>Int Dent J</i> . 1991; 41(5): 313-5.	1984-1985		
Italy	Quaranta A, Assennato G, Sallustio V. Epidemiology of hearing problems among adults in Italy. <i>Scand Audiol Suppl</i> . 1996; 9-13.	1989		
Italy	Faravelli C, Abrardi L, Bartolozzi D, Cecchi C, Cosci F, D'Adamo D, Lo Iacono B, Ravaldi C, Scarpato MA, Truglia E, Rosi S. The Sesto Fiorentino study: background, methods and preliminary results. Lifetime prevalence of psychiatric disorders in an Italian community sample using clinical interviewers. <i>Psychother Psychosom</i> . 2004; 73(4): 216-25.	2001		
Italy	Saia M, Pietrobon F. [Acute pancreatitis hospitalization in Veneto Region, Italy]. <i>Ann Ig</i> . 2009; 21(1): 29-34.	2000-2007	*	
Italy	Morgante L, Nicoletti A, Epifanio A, Contrafatto D, Savica R, Lanzafame S, Musolino R, La Spina P, Bonuccelli U, Marconi R, D'Amelio M, Savietieri G, Zappia M. Prevalence of Parkinson's disease and other types of parkinsonism in the Aeolian Archipelago, Sicily. <i>Parkinsonism Relat Disord</i> . 2008; 14(7): 572-5.	2000-2001		
Italy	Primates P, Del Corno G, Bonazzi MC, Waters WE. Alcohol and pregnancy: an international comparison. <i>J Public Health Med</i> . 1993; 15(1): 69-76.	1986-1987	*	
Italy	Ferrante T, Castellini P, Abrignani G, Latte L, Russo M, Camarda C, Veronesi L, Pasquarella C, Manzoni GC, Torelli P. The PACE study: past-year prevalence of migraine in Parma's adult general population. <i>Cephalalgia</i> . 2012; 32(5): 358-65.	2007-2009	*	
Italy	Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology. Guillain-Barré syndrome variants in Emilia-Romagna, Italy, 1992-3: incidence, clinical features, and prognosis. <i>J Neurol Neurosurg Psychiatry</i> . 1998; 65(2): 218-24.	1992-1993		
Italy	Aladro-Benito Y, Conde-Sendin MA, Muñoz-Fernández C, Pérez-Correa S, Alemany-Rodríguez MJ, Fiuza-Pérez MD, Alamo-Santana F. [Guillain-Barré syndrome in the northern area of Gran Canaria and the island of Lanzarote]. <i>Rev Neurol</i> . 2002; 35(8): 705-10.	1983-1998		
Italy	Beghi E, Bogliun G. The Guillain-Barré syndrome (GBS). Implementation of a register of the disease on a nationwide basis. Italian GBS Study Group. <i>Ital J Neurol Sci</i> . 1996; 17(5): 355-61.	1994-1995		
Italy	Bogliun G, Beghi E. Italian GBS Registry Study Group. Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996. <i>Acta Neurol Scand</i> . 2004; 110(2): 100-6.	1996		†
Italy	Chiò A, Cocito D, Leone M, Giordana MT, Mora G, Mutani R, Piemonte and Valle d'Aosta Register for Guillain-Barré Syndrome. Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey. <i>Neurology</i> . 2003; 60(7): 1146-50.	1995-1996		†
Italy	Congia S, Melis M, Carboni MA. Epidemiologic and clinical features of the Guillain-Barré syndrome in Sardinia in the 1961-1980 period. <i>Acta Neurol (Napoli)</i> . 1989; 11(1): 15-20.	1961-1980		†
Italy	D'Ambrosio G, De Angelis G, Vizioli R. Epidemiology of Guillain-Barré syndrome in Campania (south Italy). Preliminary results. <i>Acta Neurol (Napoli)</i> . 1983; 5(4): 245-52.	1971-1980		
Italy	Paolino E, Govoni V, Tola MR, Cassetta L, Granieri E. Incidence of the Guillain-Barré syndrome in Ferrara, northern Italy, 1981-1987. <i>Neuroepidemiology</i> . 1991; 10(3): 105-11.	1981-1987		†
Italy	Gialloreti LE, Merito M, Pezzotti P, Naldi L, Gatti A, Beillat M, Serradell L, di Marzo R, Volpi A. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. <i>BMC Infect Dis</i> . 2010; 10(1): 230.	2003-2005		
Italy	Coppo R, Gianoglio B, Porcellini MG, Maringhini S. Frequency of renal diseases and clinical indications for renal biopsy in children (report of the Italian National Registry of Renal Biopsies in Children). <i>Nephrol Dial Transplant</i> . 1998; 13(2): 293-7.	1992-1994	*	
Italy	World Health Organization (WHO). Italy WHO Leishmaniasis Country Profile.	1994-2009	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Italy	Mura M PM, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, Taglieri A, Mezzasalma F, Rottoli P, Saltini C, Rogliani P. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. <i>Eur Respir J</i> . 2012; 40(1): 101-9.	2005-2007	*	
Italy	The Italian Longitudinal Study on Aging Working Group. Prevalence of chronic diseases in older Italians: comparing self-reported and clinical diagnoses. <i>Int J Epidemiol</i> . 1997; 26(5): 995-1002.	1992-1993		
Italy	Apolone G, Cattaneo A, Colombo P, La Vecchia C, Cavazzuti L, Bamfi F. Knowledge and opinion on prostate and prevalence of self-reported BPH and prostate-related events. A cross-sectional survey in Italy. <i>Eur J Cancer Prev</i> . 2002; 11(5): 473-9.	2000	*	
Italy	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1994; 69(20): 145-51.	1993	*	
Italy	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1995; 70(25): 177-82.	1994	*	
Italy	Low Iodine Intake and Endemic Goiter in Schoolchildren from Mountainous Area of Parma, Italy as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1989		
Italy	Sutigoi B, Torri A, Grilli G, Tanzi E, Palù G. Italian Herpes Management Forum. Seroprevalence and seroincidence of herpes simplex virus type 1 and herpes simplex virus type 2 infections in a cohort of adolescents in Italy. <i>Sex Transm Dis</i> . 2004; 31(10): 608-10.	1992-1999	*	
Italy	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland: World Health Organization (WHO).	2006-2007	*	
Italy	Esposito S, Lizzioli A, Lastrico A, Begliatti E, Rognoni A, Tagliabue C, Cesati L, Carreri V, Principi N. Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age. <i>Respir Res</i> . 2007; 8(1): 12.	2002-2004	*	
Italy	Ansaldi F, Sticchi L, Durando P, Carloni R, Oreste P, Vercelli M, Crovari P, Icardi G. Decline in pneumonia and acute otitis media after the introduction of childhood pneumococcal vaccination in Liguria, Italy. <i>J Int Med Res</i> . 2008; 36(6): 1255-60.	2003-2005	*	
Italy	Faustini A, Fano V, Sangalli M, Ferro S, Celesti L, Contegiacomo P, Renzini V, Perucci CA. Estimating incidence of bacterial meningitis with capture-recapture method, Lazio Region, Italy. <i>Eur J Epidemiol</i> . 2000; 16(9): 843-8.	1995-1998		
Italy	Iodice M, Arnese A, Colapietro M, De Riu S, Prospero E, Saggiocco G, Ullucci R, Grasso GM. Study of an endemic goiter area in northern Campania. <i>J Endocrinol Invest</i> . 1992; 15(2): 103-8 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1985-1989		
Italy	Pagliara S, Spagnuolo E, D'Avanzo A, Vitale M, Macchia PE, Salvatore D, Ramundo V, Ciasullo M, Macchia V, Fenzi G. [Widespread endemic goiter and iodine deficiency in the province of Avellino]. <i>Ann Ist Super Sanita</i> . 1998; 34(3): 417-21 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1993-1995		
Italy	Panunzi C, Manca Bitti ML, Di Paolo A, Fabbrini R, Valle D, Spadoni GL, Del Duca E, Guglielmi R, Valente M, Finocchi A, Vitale S, Dituri F, Valenti M, Bauzulli N, Olivieri A, Gilardi E, D'Archivio M, Sorcini M, Boscherini B. [Goiter prevalence and urinary excretion of iodine in a sample of school age children in the city of Rome]. <i>Ann Ist Super Sanita</i> . 1998; 34(3): 409-12 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1998		
Italy	Fonzo D, Germano L, Gallone G, Migliardi M. Spot urinary iodine concentration as a measure of dietary iodine, evaluated in over 3800 young male subjects undergoing medical check-up preliminary to military enrolment in Piemonte and Aosta Valley (Italy). <i>J Endocrinol Invest</i> . 2003; 26(12): 1186-91 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2003		
Italy	Di Legami V, Gianino MM, Ciofi degli Atti M, Massari M, Migliardi A, Tomba GS, Zotti C, Zoster Study Group. Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination. <i>Vaccine</i> . 2007; 25(43): 7598-604.	2004-2005		
Italy	Di Luzio Papparati U, Arpinelli F, Visonà G. Herpes zoster and its complications in Italy: an observational survey. <i>J Infect</i> . 1999; 38(2): 116-20.	1995-1996		
Italy	Barbadoro P, Marigliano A, Ricciardi A, D'Errico MM, Prospero E. Trend of hospital utilization for encephalitis. <i>Epidemiol Infect</i> . 2012; 140(4): 753-64.	1999-2005		
Italy	World Health Organization (WHO). Mental Illness in General Health Care: An International Study. Geneva, Switzerland: World Health Organization (WHO), 1995.	1991-1992		
Italy	May PA, Fiorentino D, Coriale G, Kalberg WO, Hoyme HE, Aragón AS, Buckley D, Stellavato C, Gossage JP, Robinson LK, Jones KL, Manning M, Ceccanti M. Prevalence of children with severe fetal alcohol spectrum disorders in communities near Rome, Italy: new estimated rates are higher than previous estimates. <i>Int J Environ Res Public Health</i> . 2011; 8(6): 2331-51.	1986-1987	*	
Italy	Piccinelli M, Pini S, Bonizzato P, Paltrinieri E, Saltini A, Scantamburlo L, Bellantuono C, Tansella M. Results from the Verona Centre. In: Sartorius N and Ustun TB, editors. <i>Mental Illness in General Health Care: An International Study</i> . New York: John Wiley and Sons; 1995. p. 301-321.	1991		
Italy	Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJA, Wasserman SM, Baker N, Rosser D, Cleland JGF, Ponikowski P. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. <i>Eur Heart J</i> . 2007; 28(18): 2208-16.	1992-1995		
Italy	Alla F, Zannad F, Filippatos G. Epidemiology of acute heart failure syndromes. <i>Heart Fail Rev</i> . 2007; 12(2): 91-5.	2004		
Italy	Ansaldi F, Bruzzone B, Salmaso S, Rota MC, Durando P, Gasparini R, Icardi G. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. <i>J Med Virol</i> . 2005; 76(3): 327-32.	1996-1997		
Italy	Raffaele A, Valenti M, Iovenitti M, Matani A, Bruno ML, Altobelli E, D'Alessandro A, Barnabei R, Leonardi B, Taglieri G. High prevalence of HCV infection among the general population in a rural area of central Italy. <i>Eur J Epidemiol</i> . 2001; 17(1): 41-6.	1997		
Italy	Maio G, d'Argenio P, Stroffolini T, Bozza A, Sacco L, Tosi ME, Intorcchia M, Fossi E, d'Alessio G, Kondili LA, Rapietta M, Mele A. Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town. <i>J Hepatol</i> . 2000; 33(1): 116-20.	1997, 1999-2000		
Italy	Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, Büchele G, Clausen M, Cookson WOC, von Mutius E, Strachan DP, Williams HC, ISAAC Phase Two Study Group. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. <i>J Allergy Clin Immunol</i> . 2008; 121(1): 141-147.	2005-2007	*	
Italy	Bottini N, Meloni G, Porcu S, MathD FG-B. Cyclic Seasonal Variation of G-6-PD Deficiency in Newborn Infants from Sardinia. <i>Biol Rhythm Res</i> . 2001; 32(4): 413-21.	1993-1996	*	
Italy	Cocco P, Manca P, Dessì S. Preliminary results of a geographic correlation study on G6PD deficiency and cancer. <i>Toxicol Pathol</i> . 1987; 15(1): 106-8.	1981	*	
Italy	Campagna M, Siddu A, Meloni A, Basciu C, Ferrai L, Pettinau A, Cardia C, Masia G, Coppola RC. Changing pattern of hepatitis A virus epidemiology in an area of high endemicity. <i>Hepat Mon</i> . 2012; 12(6): 382-5.	2005-2008	*	
Italy	Attili AF, Carulli N, Roda E, Barbara B, Capocaccia L, Menotti A, Okolitsany L, Ricci G, Capocaccia R, Festi D, Lalloni L, Mariotti S, Sama C, Scafato E. Epidemiology of Gallstone Disease in Italy: Prevalence Data of the Multicenter Italian Study on Cholelithiasis (M.I.C.O.L.). <i>Am J Epidemiol</i> . 1995; 141(2): 158-65.	1984-1987		
Italy	Loria P, Diligente MA, Bozzoli M, Carubbi F, Messori R, Sassatelli R, Bertolotti M, Tampieri A, Tartoni PL, Cassinadri M. Prevalence rates of gallstone disease in Italy. The Chianciano population study. <i>Eur J Epidemiol</i> . 1994; 10(2): 143-50.	1985-1986		
Italy	Trallori G, Palli D, Saieva C, Bardazzi G, Bonanomi AG, d'Albasio G, Galli M, Vannozzi G, Milla M, Tarantino O, Renai F, Messori A, Amorosi A, Pacini F, Moretini A. A population-based study of inflammatory bowel disease in Florence over 15 years (1978-92). <i>Scand J Gastroenterol</i> . 1996; 31(9): 892-9.	1981-1992		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Italy	Tragnone A, Corrao G, Miglio F, Caprilli R, Lanfranchi GA. Incidence of inflammatory bowel disease in Italy: a nationwide population-based study. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). <i>Int J Epidemiol.</i> 1996; 25(5): 1044-52.	1989-1992		
Italy	Santi V, Buccione D, Di Micoli A, Fatti G, Frigerio M, Farinati F, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegù L, Zoli M, Borzio F, Giannini EG, Catturelli E, Chiaromonte M, Bernardi M, Trevisani F. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. <i>J Hepatol.</i> 2012; 56(2): 397-405.	1987-2008	*	
Italy	Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overved K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PHM, Lund E, Quirós JR, González CA, Sanchez Perez M-J, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu I, Chuang S-C, Murphy N, Boffetta P, Trichopoulou A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. <i>J Natl Cancer Inst.</i> 2011; 103(22): 1686-95.	1992-2006	*	
Italy	Pavia M, Iritano E, Veratti MA, Angelillo IF. Prevalence of hepatitis E antibodies in healthy persons in southern Italy. <i>Infection.</i> 1998; 26(1): 32-5.	1993-1995	*	
Italy	Stroffolini T, Menchinelli M, Dambrosio V, Menniti Ippolito F, Costantino A, Rapicetta M, Lecce R, Taliani G. Prevalence of hepatitis E in a central Italian town at high endemicity for hepatitis C virus. <i>Ital J Gastroenterol.</i> 1996; 28(9): 523-5.	1994	*	
Italy	Gessoni G, Rusca A, Valverde S. Circulating anti-HEV antibodies: An Italian retrospective seroepidemiological study. <i>Eur J Lab Med.</i> 1998; 42-6.	1995-1997	*	
Italy	Vulcano A, Angelucci M, Candelori E, Martini V, Patti AM, Mancini C, Santi AL, Calvani A, Casagni L, Lamberti A. HEV prevalence in the general population and among workers at zoonotic risk in Latium Region. <i>Ann Ig.</i> 2007; 19(3): 181-6.	2005-2006	*	
Italy	De Donno A, Chironna M, Craca R, Paiano A, Zizza A, Guido M, Carozzini F, Germinario C, Gabutti G. [Anti-HEV seroprevalence in the area of Lecce]. <i>Ann Ig.</i> 2003; 15(3): 199-205.	2000-2002	*	
Italy	Zanetti AR, Romano L, Tanzi E, Andreassi A, Pozzi A, Panuccio A, Stroffolini T. Decline in anti-HAV prevalence in the Milan area between 1958 and 1992. <i>Eur J Epidemiol.</i> 1994; 10(5): 633-5.	1958, 1977, 1992		
Italy	Meloni C, Belloni E, Giorgi A, Marchetti R, Pelissero G, Zecca E, Rondanelli EG, Carosi G, Corridori S, De Franchis R. [Epidemiological research on human viral hepatitis in the province of Pavia]. <i>Nuovi Ann Ig Microbiol.</i> 1982; 33(4-6): 697-724.	1978-1980		
Italy	Federico G, Pizzigallo E, Nervo P, Ranno O, Ortona L. [Detection of virus A antibody through epidemiology and diagnosis of hepatitis A]. <i>Boll Ist Sieroter Milan.</i> 1980; 58(6): 445-52.	1979		
Italy	Vendramini R, Fiaschi E, Naccarato R, Chiara-Monte M, Renzulli G, Canazza S, Trivello R. [Viral hepatitis type A. Seroepidemiological study in Padova and its district]. <i>Boll Ist Sieroter Milan.</i> 1980; 59(4): 338-47.	1979		
Italy	Merletti L, Frongillo R. [Prevalence of antibody to hepatitis A virus in healthy Umbrian population (author's trans)]. <i>Ann Sclavo.</i> 1980; 22(2): 165-8.	1979		
Italy	Chiaromonte M, Floreani A, Silvan C, Zampieri L, Trivello R, Renzulli G, Moschen M, Naccarato R. Hepatitis A and hepatitis B virus infection in children and adolescents in north-east Italy. <i>J Med Virol.</i> 1983; 12(3): 179-86.	1979-1980		
Italy	Uttili R, Galanti B, Da Villa G, Andreana A, Felaco FM, Filippini P, Galante D, Nardiello S, Pasquale G, Piccinino F. Hyperendemicity of viral hepatitis in the Neapolitan area: an epidemiological study. <i>Boll Ist Sieroter Milan.</i> 1983; 62(2): 145-52.	1979-1980		
Italy	Tarstani G, Mancinelli S, Pasquini P, Laurenzi M, Pileggi D. [Spread of type A viral hepatitis in Rome: study of anti-HAV antibodies in a group of students]. <i>Nuovi Ann Ig Microbiol.</i> 1981; 32(6): 363-7.	1980		
Italy	Romano G, Ginanneschi R, Mura I, Spano E. [Anti-HA antibodies in a sample of an apparently healthy population of the province of Sassari]. <i>Nuovi Ann Ig Microbiol.</i> 1981; 32(4): 239-46.	1980		
Italy	D'Argenio P, Esposito D, Mele A, Ortolani G, Adamo B, Rapicetta M, Forte P, Pisani A, Soldo L, Sarcocchia B. Decline in the exposure to hepatitis A and B infections in children in Naples, Italy. <i>Public Health.</i> 1989; 103(5): 385-9.	1980, 1988		
Italy	Pasquini P, Laurenzi M, Panà A, Maddaluno R, Perroni L, Pileggi D, MenicHELLA D. [Distribution of anti-HAV antibodies in hospital personnel in the Lazio region]. <i>Ann Sclavo.</i> 1982; 24(2): 123-8.	1980		
Italy	Biglino A, Vercellotti E, Caramello P, Pischedda P, Gioannini P. [Markers of infection with hepatitis A and B viruses among office workers in a heavy industry]. <i>Minerva Med.</i> 1980; 71(39): 2833-6.	1980		
Italy	Pasquini P, Kahn HA, Pileggi D, Panà A, Terzi J, D'Arca T. Prevalence of hepatitis A antibodies in Italy. <i>Int J Epidemiol.</i> 1984; 13(1): 83-6.	1981		
Italy	Leonardi MS, Gazzara D, Zumbo S, Mastroeni P. [Evaluation of anti-HAV IgG on 2 samples of closed populations]. <i>G Batteriol Virol Immunol.</i> 1985; 78(7-12): 217-23.	1986		
Italy	Patti AM, Zaratti L, Santi AL, De Filippis P, Paroli E, Panà A. Indirect immunofluorescence application in the epidemiological study of hepatitis A. <i>Boll Ist Sieroter Milan.</i> 1987; 66(4): 278-81.	1986		
Italy	Franco E, Patti AM, Zaratti L, Cautelli M, Vellucci L, Panà A. [Sero-epidemiologic study of hepatitis A virus infection in childhood]. <i>Nuovi Ann Ig Microbiol.</i> 1988; 39(2): 103-7.	1987		
Italy	Stroffolini T, Franco E, Romano G, Ucheddu P, Zaratti L, Pasquini P, Panà A, Maida A, Scarpa B. Hepatitis A virus infection in children in Sardinia, Italy. <i>Community Med.</i> 1989; 11(4): 336-41.	1987		
Italy	Masia G, Martignetti G, Contu P. [Epidemiology of hepatitis A in Sardinia: prevalence of anti-HAV in a sample of workers required to obtain health certificates]. <i>Ann Ig.</i> 1989; 1(5): 1125-31.	1987-1988		
Italy	Stroffolini T, Chiaromonte M, Franco E, Rapicetta M, De Mattia D, Mura I, Trivello R, Giammanco A, Rigo G, Scarpa B. Baseline seroepidemiology of hepatitis A virus infection among children and teenagers in Italy. <i>Infection.</i> 1991; 19(2): 97-100.	1987-1989		
Italy	Stroffolini T, De Crescenzo L, Giammanco A, Intonazzo V, La Rosa G, Cascio A, Sarzana A, Chiarini A, Dardanoni L. Changing patterns of hepatitis A virus infection in children in Palermo, Italy. <i>Eur J Epidemiol.</i> 1990; 6(1): 84-7.	1988		
Italy	Contu P, Ucheddu P, Doderio G, Masia G. [Epidemiology of hepatitis A in Sardinia: prevalence of anti-HAV in a sample of junior and senior high school students]. <i>Ann Ig.</i> 1989; 1(5): 1119-24.	1988		
Italy	Stroffolini T, Franco E, Mura I, Ucheddu P, Cautelli M, Azara A, Scarpa B. Age-specific prevalence of hepatitis A virus infection among teenagers in Sardinia. <i>Microbiologica.</i> 1991; 14(1): 21-4.	1989		
Italy	Stroffolini T, D'Amelio R, Matricardi PM, Chionne P, Napoli A, Rapicetta M, Crateri S, Pasquini P. The changing epidemiology of hepatitis A in Italy. <i>Ital J Gastroenterol.</i> 1993; 25(7): 372-4.	1989-1990		
Italy	Matricardi PM, Rosmini F, Ferrigno L, Nisini R, Rapicetta M, Chionne P, Stroffolini T, Pasquini P, D'Amelio R. Cross sectional retrospective study of prevalence of atopy among Italian military students with antibodies against hepatitis A virus. <i>BMJ.</i> 1997; 314(7086): 999-1003.	1990-1991		
Italy	Nuti M, Amaddeo D, Caprilli F, Crescimbeni E, Antoniazzi G, Lalli C, Prignano G, Franco E, Cristaldi M. [Tiber environment and infections: antibodies to hantaviruses, Leptospira, Borrelia and hepatitis A virus in subjects active on the river banks]. <i>Ann Ig.</i> 1993; 5(4): 259-65.	1992		
Italy	Moschen ME, Floreani A, Zamparo E, Baldo V, Majori S, Gasparini V, Trivello R. Hepatitis A infection: a seroepidemiological study in young adults in North-East Italy. <i>Eur J Epidemiol.</i> 1997; 13(8): 875-8.	1994		
Italy	Ripabelli G, Sammarco ML, Campo T, Montanaro C, D'Ascenzo E, Grasso GM. Prevalence of antibodies against enterically transmitted viral hepatitis (HAV and HEV) among adolescents in an inland territory of central Italy. <i>Eur J Epidemiol.</i> 1997; 13(1): 45-7.	1994		
Italy	Catania S, Ajassa C, Tzantzoglou S, Bellagamba R, Berandelli G, Catania N. [Seroepidemiologic study of the prevalence of anti-HAV antibodies in children in Rome]. <i>Riv Eur Sci Med Farmacol.</i> 1996; 18(1): 7-9.	1995		
Italy	Luzza F, Ineeno M, Maletta M, Paluccio G, Giancotti A, Perticone F, Focà A, Pallone F. Seroepidemiology of Helicobacter pylori infection and hepatitis A in a rural area: evidence against a common mode of transmission. <i>Gut.</i> 1997; 41(2): 164-8.	1995		
Italy	Romano F, Bassani T, Capuani MA, Scopinaro E, Staniscia T, Schioppa F. [Prevalence of hepatitis A virus antibodies in food handlers]. <i>Ann Ig.</i> 1996; 8(4): 419-23.	1995		
Italy	Russo R, Zotti C, Tappi E, Siliquini R, Bauducci M, Ditommaso S, Moiraghi Ruggenini A. Epidemiology of HAV infection in Piedmont, Italy. <i>Ann Ig.</i> 1997; 9(1): 3-8.	1996		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Italy	Ansaldi F, Bruzzone B, Rota MC, Bella A, Ciofi degli Atti M, Durando P, Gasparini R, Icardi G. Hepatitis A incidence and hospital-based seroprevalence in Italy: a nation-wide study. <i>Eur J Epidemiol.</i> 2008; 23(1): 45-53.	1996-1997		
Italy	Patti AM, Santi AL, Bellucci C, Ciapetti C, Vulcano A, Giustini C, Mastroeni I, Adorisio E, Fara GM. Seroprevalence of hepatitis A virus infection in general population of Latium. <i>Ann Ig.</i> 1999; 11(5): 391-5.	1998		
Italy	Calabri GB, Santini MG, Genovese F, Bambi F, Salvi G, Calabri G. [Prevalence of anti-HAV antibodies (hepatitis A virus) in 18-year-old males from the Florence area]. <i>Pediatr Med Chir.</i> 1999; 21(5 Suppl): 219-20.	1998		
Italy	De Silvestri A, Avanzini MA, Terulla V, Zucca S, Polatti F, Belloni C. Decline of maternal hepatitis A virus antibody levels in infants. <i>Acta Paediatr.</i> 2002; 91(8): 882-4.	1999-2000		
Italy	D'Amelio R, Mele A, Mariano A, Romano L, Biselli R, Lista F, Zanetti A, Stroffolini T. Hepatitis A, Italy. <i>Emerg Infect Dis.</i> 2005; 11(7): 1155-6.	2003		
Italy	Beggio M, Giraldo M, Borella-Venturini M, Mongillo M, Zanetti E, Bruno A, Davanzo E, Trevisan A. [Prevalence of hepatitis virus A, B, and C markers according to the geographic origin of medical students]. <i>G Ital Med Lav Ergon.</i> 2007; 29(3 Suppl): 745-7.	2006		
Italy	Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, Tolonen H, Ruokokoski E. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. <i>Lancet.</i> 1999; 353(9164): 1547-57.	1980-1995, 1997-1998		
Italy	Adamo B, Stroffolini T, Saggiocca L, Simonetti A, Iadanza F, Fossi E, Tancredi F, Mele A. Ad hoc survey of hepatitis B vaccination campaign in newborns of HBsAg positive mothers and in 12-year-old subjects in southern Italy. <i>Vaccine.</i> 1998; 16(8): 775-7.	1994		
Italy	Baldo V, Floreani A, Menegon T, Angiolelli G, Trivello R. Prevalence of antibodies against hepatitis C virus in the elderly: a seroepidemiological study in a nursing home and in an open population. <i>The Collaborative Group. Gerontology.</i> 2000; 46(4): 194-8.	2000		
Italy	Baldo V, Floreani A, Menegon T, Grella P, Paternoster DM, Trivello R. Hepatitis C virus, hepatitis B virus and human immunodeficiency virus infection in pregnant women in North-East Italy: a seroepidemiological study. <i>Eur J Epidemiol.</i> 2000; 16(1): 87-91.	1996		
Italy	Bongiorno MR, Pistone G, Aricò G. Hepatitis B and hepatitis C virus infections in dermatological patients in west Sicily: a seroepidemiological study. <i>J Eur Acad Dermatol Venerol.</i> 2002; 16(1): 43-6.	2000		
Italy	Bonura F, Sorgi M, Perna AM, Puccio G, Tramuto F, Cajozzo C, Romano N, Vitale F. Pregnant women as a sentinel population to target and implement hepatitis B virus (HBV) vaccine coverage: a three-year survey in Palermo, Sicily. <i>Vaccine.</i> 2005; 23(25): 3243-6.	2001-2003		
Italy	Brevi A, Naldi L, Cainelli T, Parazzini F. Prevalence and awareness of hepatitis B virus carrier status in Italy. <i>Genitourin Med.</i> 1993; 69(3): 241.	1989-1990		
Italy	Campello C, Poli A, Dal MG, Besozzi-Valentini F. Seroprevalence, viremia and genotype distribution of hepatitis C virus: a community-based population study in northern Italy. <i>Infection.</i> 2002; 30(1): 7-12.	1994-1995		
Italy	Cattaneo C, Nuttali PA, Molendini LO, Pellegrinelli M, Grandi M, Sokol RJ. Prevalence of HIV and hepatitis C markers among a cadaver population in Milan. <i>J Clin Pathol.</i> 1999; 52(4): 267-70.	1996-1997		
Italy	Chiaromonte M, Floreani A, Naccarato R. Hepatitis B virus infection in homes for the aged. <i>J Med Virol.</i> 1982; 9(4): 247-55.	1980		
Italy	Chiaromonte M, Moschen ME, Stroffolini T, Rapicetta M, Bertin T, Renzulli G, Ngatchu T, Chionne P, Trivello R, Naccarato R. Changing epidemiology of hepatitis A virus (HAV) infection: a comparative seroepidemiological study (1979 vs 1989) in north-east Italy. <i>Ital J Gastroenterol.</i> 1991; 23(6): 344-6.	1979, 1989		
Italy	Coppola RC, Masia G, Pradat P, Trepò C, Carboni G, Argiolas F, Rizzetto M. Impact of hepatitis C virus infection on healthy subjects on an Italian island. <i>J Viral Hepat.</i> 2000; 7(2): 130-7.	1994-1995		
Italy	Corrao G, Zambon A, Bagnardi V, Aricò S, Loguercio C, D'Amicis A. Collaborative SIDECIR Group. Nutrient intakes, nutritional patterns and the risk of liver cirrhosis: an explorative case-control study. <i>Eur J Epidemiol.</i> 2004; 19(9): 861-9.	1994-1998		
Italy	De Mercato R, Canticello JP, Celetano U, Giani U, Romano A, Guarnaccia D, D'Antonio A. Hepatitis C virus in prisoners. <i>Minerva Med.</i> 1995; 86(3): 89-91.	1992-1994		
Italy	Di Nardo V, Petrosillo N, Ippolito G, Bonaventura ME, Puro V, Chiaretti B, Tosoni M. Prevalence and incidence of hepatitis B virus, hepatitis C virus and human immunodeficiency virus among personnel and patients of a psychiatric hospital. <i>Eur J Epidemiol.</i> 1995; 11(2): 239-42.	1989		
Italy	Gessoni G, Manoni F. Hepatitis E virus infection in north-east Italy: serological study in the open population and groups at risk. <i>J Viral Hepat.</i> 1996; 3(4): 197-202.	1993-1995		
Italy	Gessoni G, Manoni F. Prevalence of anti-hepatitis C virus antibodies among teenagers in the Venetian area: a seroepidemiological study. <i>Eur J Med.</i> 1993; 2(2): 79-82.	1991		
Italy	Kondili LA, Chionne P, Costantino A, Villano U, Lo Noce C, Pannoza F, Mele A, Giampaoli S, Rapicetta M. Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population. <i>Gut.</i> 2002; 50(5): 693-6.	1983-1987		
Italy	Lodi G, Giuliani M, Majorana A, Sardella A, Bez C, Demarosi F, Carrasi A. Lichen planus and hepatitis C virus: a multicentre study of patients with oral lesions and a systematic review. <i>Br J Dermatol.</i> 2004; 151(6): 1172-81.	2004		
Italy	Malaguti M, Capece R, Marciano M, Arena G, Luciani MP, Striano M, Biagini M. Antibodies to hepatitis C virus (anti-HCV): prevalence in the same geographical area in dialysis patients, staff members, and blood donors. <i>Nephron.</i> 1992; 61(3): 346.	1992		
Italy	Marranconi F, Fabris P, Stecca C, Zampieri L, Bettini MC, Di Fabrizio N, de Lalla F. Prevalence of anti-HCV and risk factors for hepatitis C virus infection in healthy pregnant women. <i>Infection.</i> 1994; 22(5): 333-7.	1992		
Italy	Mazzei C, Imberciadori G, Saccone F, Durante C, Mattiada M, Lavagna G, Barberis G, Cavagnaro G. Infectious disease markers in autologous blood. <i>Transfusion.</i> 1989; 29(9): 829-30.	1987		
Italy	Montella M, Crispo A, Serraino D, Rezza G, Franceschi S. Is the spread of HCV in Southern Italy attributable to iatrogenic transmission through unsterile injections? <i>Eur J Cancer Prev.</i> 2003; 12(1): 85-6.	2000-2001		
Italy	Montella M, Serraino D, Crispo A, Romano N, Fusco M, Goedert JJ. Infection with human herpes virus type 8 in an area at high prevalence for hepatitis C virus infection in southern Italy. <i>J Viral Hepat.</i> 2004; 11(3): 268-70.	2000-2001		
Italy	Picerno I, Di Pietro A, Spataro P, Di Benedetto A, Romano G, Scoglio ME. Is diabetes mellitus a risk factor for HCV infection? <i>Ann Ig.</i> 2002; 14(6): 473-7.	2001		
Italy	Puro V, Girardi E, Ippolito G, Lo Presti E, Benedetto A, Zaniratti S, Giannini V, Gioia C, Nattii S, Tossini G. Prevalence of hepatitis B and C viruses and human immunodeficiency virus infections in women of reproductive age. <i>Br J Obstet Gynaecol.</i> 1992; 99(7): 598-600.	1989-1990		
Italy	Rapicetta M, Kondili LA, Pretolani S, Stroffolini T, Chionne P, Villano U, Madonna E, Casali F, Gasbarrini G. Seroprevalence and anti-HEV persistence in the general population of the Republic of San Marino. <i>J Med Virol.</i> 1999; 58(1): 49-53.	1990-1991		
Italy	Romanò L, Azara A, Chiaromonte M, De Mattia D, Giammanco A, Moschen ME, Scarpa B, Stroffolini T, Zanetti AR. Low prevalence of anti-HCV antibody among Italian children. <i>Infection.</i> 1994; 22(5): 350-2.	1987-1989		
Italy	Stroffolini T, Guadagnino V, Chionne P, Procopio B, Mazzuca EG, Quintieri F, Scerbo P, Giancotti A, Nisticò S, Foc'A, Tosti ME, Rapicetta M. A population based survey of hepatitis B virus infection in a southern Italian town. <i>Ital J Gastroenterol Hepatol.</i> 1997; 29(5): 415-8.	1996		
Italy	Stroffolini T, Menchinelli M, Taliani G, Dambrosio V, Poliandri G, Bozza A, Lecce R, Clementi C, Ippolito FM, Compagnoni A. High prevalence of hepatitis C virus infection in a small central Italian town: lack of evidence of parenteral exposure. <i>Ital J Gastroenterol.</i> 1995; 27(5): 235-8.	1994		
Italy	Stroffolini T, Rigo G, Collinassi P, Biffoni F. Prevalence of hepatitis B markers among teen-agers in Friuli. <i>Boll Ist Sieroter Milan.</i> 1990; 69(2): 455-7.	1989		
Italy	Boi S, Cristofolini M, Micciolo R, Polfa E, Dalla Palma P. Epidemiology of skin tumors: data from the cutaneous cancer registry in Trentino, Italy. <i>J Cutan Med Surg.</i> 2003; 7(4): 300-5.	1992-1997	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Italy	Flohr C, Weinnmayr G, Weiland SK, Addo-Yobo E, Annesi-Maesano I, Björkstén B, Bråbäck L, Büchele G, Chico M, Cooper P, Clausen M, El Sharif N, Martinez Gimeno A, Mathur RS, von Mutius E, Morales Suarez-Varela M, Pearce N, Svabe V, Wong GWK, Yu M, Zhong NS, Williams HC, ISAAC Phase Two Study Group. How well do questionnaires perform compared with physical examination in detecting flexural eczema? Findings from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. <i>Br J Dermatol</i> . 2009; 161(4): 846-53.	2005-2007	*	
Italy	De Ronchi D, Berardi D, Menchetti M, Ferrari G, Serretti A, Dalmonte E, Fratiglioni L. Occurrence of Cognitive Impairment and Dementia after the Age of 60: A Population-Based Study from Northern Italy. <i>Dement Geriatr Cogn Disord</i> . 2005; 19(2-3): 97-105.	1988-1991		
Italy	D'Alessandro R, Gallassi R, Benassi G, Morreale A, Lugaresi E. Dementia in subjects over 65 years of age in the Republic of San Marino. <i>Br J Psychiatry</i> . 1988; 182-6.	1985		i
Italy	Ferrario MM, Fornari C, Bolognesi L, Gussoni MT, Benedetti M, Sega R, Borchini R, Cesana G, Gruppo di Ricerca MONICA-CAMUNI in Brianza. [Recent time trends of myocardial infarction rates in northern Italy. Results from the MONICA and CAMUNI registries in Brianza: 1993-1994 versus 1997-1998]. <i>Ital Heart J Suppl</i> . 2003; 4(8): 651-7.	1997-1998		
Italy	Cusimano F, Cocita VC, D'Amico A. Sensorineural hearing loss in chronic otitis media 1989. <i>J Laryngol Otol</i> . 1989; 103(2): 158-163.	1989	*	
Italy	Cirillo M, Stellato D, Panarelli P, Laurenzi M, De Santo NG, Gubbio Study Research Group. Cross-sectional and prospective data on urinary calcium and urinary stone disease. <i>Kidney Int</i> . 2003; 63(6): 2200-6.	1989-1992	*	
Italy	Croppi E, Ferraro PM, Taddei L, Gambaro G, GEA Firenze Study Group. Prevalence of renal stones in an Italian urban population: a general practice-based study. <i>Urol Res</i> . 2012; 40(5): 517-22.	2011	*	
Italy	Cupisti A, Pasquali E, Lusso S, Carli F, Orsotto E, Melandri R. Renal colic in Pisa emergency department: epidemiology, diagnostics and treatment patterns. <i>Intern Emerg Med</i> . 2008; 3(3): 241-4.	2005	*	
Italy	Sacco S, Stracci F, Cerone D, Ricci S, Carolei A. Epidemiology of stroke in Italy. <i>Int J Stroke</i> . 2011; 6(3): 219-27.	1994-2002		
Italy	Borghesi L, Ferretti PP, Elia GF, Amato F, Melloni E, Trapassi MR, Novarini A. Epidemiological study of urinary tract stones in a northern Italian city. <i>Br J Urol</i> . 1990; 65(3): 231-5.	1990	*	
Italy	Benedetti MD, Salvati A, Filippini S, Manfredi M, De Togni L, Gomez Lira M, Stenta G, Fincati E, Pampin M, Rizzuto N, Danti G. Prevalence of dementia and apolipoprotein e genotype distribution in the elderly of Buttapietra, Verona province, Italy. <i>Neuroepidemiology</i> . 2002; 21(2): 74-80.	1993-1996		
Italy	Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Barré J, André C. The impact of headache in Europe: principal results of the Eurolight project. <i>J Headache Pain</i> . 2014; 15(31). [Unpublished data].	2008	*	
Italy	Italy Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). 2012.	2010	*	
Italy	Italy Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Italy	Italy - Tuscany Registry of Congenital Defects Data 2007 - ICBDSCR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Italy	Italy - Campania Birth Defects Registry Data 2007 - ICBDSCR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Italy	Italy - Emilia-Romagna Registry of Congenital Malformations Data 2007 - ICBDSCR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Italy	Italy - North East Italy Registry of Congenital Malformations Data 2007 - ICBDSCR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Italy	Italy - Lombardy Registry of Congenital Malformations Data 2008 - ICBDSCR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
Italy	Italy - Northern Lombardy Congenital Malformation Registry Data 2009 - ICBDSCR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Italy	Italy - Campania Birth Defects Registry Data 2009 - ICBDSCR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Italy	Italy - Emilia-Romagna Registry of Congenital Malformations Data 2009 - ICBDSCR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Italy	Italy - North East Italy Registry of Congenital Malformations Data 2009 - ICBDSCR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Italy	Italy - Tuscany Registry of Congenital Defects Data 2009 - ICBDSCR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Italy	European Surveillance of Congenital Anomalies (EUROCAT). Italy EUROCAT Prevalence Tables. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	1980-2011		
Italy	Italy - Sicilian Registry of Congenital Malformations Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Italy	Italy - North East Italy Registry of Congenital Malformations Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Italy	Italy - Campania Birth Defects Registry Data 1993-1998 - EUROCAT as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Italy	Italy - Emilia-Romagna Registry of Congenital Malformations Data 1993-1998 - EUROCAT as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Italy	Italy - Emilia-Romagna Registry of Congenital Malformations Data 1987 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1987	*	
Italy	Italian Multicentric Register of Congenital Malformations Data 1980 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1980	*	
Italy	Italian Multicentric Register of Congenital Malformations (IPIMC) Data 1981 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1981	*	
Italy	Italian Multicentric Register of Congenital Malformations (IPIMC) Data 1982 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1982	*	
Italy	Italian Multicentric Register of Congenital Malformations (IPIMC) Data 1983 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1983	*	
Italy	Italian Multicentric Register of Congenital Malformations (IPIMC) Data 1984 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1984	*	
Italy	Italian Multicentric Register of Congenital Malformations (IPIMC) Data 1985 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1985	*	
Italy	Italian Multicentric Register of Congenital Malformations (IPIMC) Data 1986 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1986	*	
Italy	Italian Multicentric Register of Congenital Malformations (IPIMC) Data 1987 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1987	*	
Italy	Italian Multicentric Register of Congenital Malformations (IPIMC) Data 1988 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1988	*	
Italy	Italy - Campania Birth Defects Registry Data 2001 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
Italy	Italy - North East Italy Registry of Congenital Malformations Data 2001 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
Italy	Italy - Tuscany Registry of Congenital Defects Data 2001 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
Jamaica	United Nations Children's Fund (UNICEF). Jamaica Multiple Indicator Cluster Survey 2000.	2000	*	
Jamaica	Statistical Institute of Jamaica (STATIN) and United Nations Children's Fund (UNICEF). Jamaica Multiple Indicator Cluster Survey 2005. New York, United States: United Nations Children's Fund (UNICEF).	2005	*	
Jamaica	Jamaica Statistical Institute (STATIN), International Statistical Institute. Jamaica World Fertility Survey 1976. Voorburg, Netherlands: International Statistical Institute.	1975		
Jamaica	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-2005		
Jamaica	King L, Fraser R, Forbes M, Grindley M, Ali S, Reid M. Newborn sickle cell disease screening: the Jamaican experience (1995-2006). J Med Screen. 2007; 14(3): 117-22.	1995-2006		
Jamaica	Thalassaemia International Federation, World Health Organization (WHO). Management of Haemoglobin Disorders: Report of a Joint WHO-TIF Meeting, Nicosia, Cyprus, 16-18 November 2007. Geneva, Switzerland: World Health Organization (WHO), 2008.	1973-1981		
Jamaica	Miall WE, Milner PF, Lovell HG, Standard KL. Haematological investigations of population samples in Jamaica. Br J Prev Soc Med. 1967; 21(2): 45-55.	1964-1966		
Jamaica	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Jamaica	Serjeant GR. Observations on the epidemiology of sickle cell disease. Trans R Soc Trop Med Hyg. 1981; 75(2): 228-33.	1973-1979		
Jamaica	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Jamaica	Lalljie GR, Lalljie SE. Characteristics, treatment and short-term survival of patients with heart failure in a cardiology private practice in Jamaica. West Indian Med J. 2007; 56(2): 139-43.	2002-2003		
Jamaica	SMadja D, Cabre P, May F, Fanon J-L, René-Corail P, Riocreux C, Charpentier J-C, Fourmerie P, Saint-Vil M, Ketterlé J. ERMANCIA: Epidemiology of Stroke in Martinique, French West Indies. Stroke. 2001; 32(12): 2741-7.	1998-1999		
Jamaica	Lee A, Thomas P, Cupidore L, Serjeant B, Serjeant G. Improved survival in homozygous sickle cell disease: lessons from a cohort study. BMJ. 1995; 7020(311): 1600-2.	1973-1992		
Jamaica	Wierenga KJ, Hambleton IR, Lewis NA, Unit SC. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet. 2001; 9257(357): 680-3.	1973-1996		
Jamaica	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997-1998, 2000-2009		
Jamaica	Wilks R, Rotimi C, Bennett F, McFarlane-Anderson N, Kaufman JS, Anderson SG, Cooper RS, Cruickshank JK, Forrester T. Diabetes in the Caribbean: results of a population survey from Spanish Town, Jamaica. Diabet Med. 1999; 16(10): 875-83.	1996		
Jamaica	University of the West Indies. Jamaica Health and Lifestyle Survey 2007-2008.	2007-2008		
Jamaica	Eldemire D, Hagle K. Diabetes mellitus in the Jamaican elderly. West Indian Med J. 1996; 45(3): 82-4.	1991		
Jamaica	Knight-Madden JM, Barton-Gooden A, Weaver SR, Reid M, Greenough A. Mortality, asthma, smoking and acute chest syndrome in young adults with sickle cell disease. Lung. 2013; 191(1): 95-100.	2001-2011	*	
Jamaica	Forman D, Bray F, Brewster DH, Gombé Mbalawa C, Kahler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version). Lyon, IARC. http://cis.iarc.fr	2003-2007	*	
Jamaica	Paul TJ, Desai P, Thorburn MJ. The prevalence of childhood disability and related medical diagnoses in Clarendon, Jamaica. West Indian Med J. 1992; 41(1): 8-11.	1989-1991	*	
Jamaica	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Jamaica	Dowe G, King SD, Maitland PB, Swaby-Ellis DE. Laboratory investigations on rotavirus in infantile gastroenteritis in Jamaica. Trans R Soc Trop Med Hyg. 1988; 82(1): 155-9.	1982-1983	*	
Jamaica	Canino G, Shrout PE, Rubio-Stipec M, et al. The DSM-IV rates of child and adolescent disorders in Puerto Rico: Prevalence, correlates, service use, and the effects of impairment. Arch Gen Psychiatry. 2004; 61(1): 85-93.	1999-2000		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Jamaica	Rubio-Stipec M, Canino GJ, Shrout P, Dulcan M, Freeman D, Bravo M. Psychometric properties of parents and children as informants in child psychiatry epidemiology with the Spanish Diagnostic Interview Schedule for Children (DISC.2). <i>J Abnorm Child Psychol.</i> 1994; 22(6): 703-20.	1992	*	
Jamaica	Canino GJ, Bird HR, Shrout PE, Rubio-Stipec M, Bravo M, Martinez R, Sesman M, Guevara LM. The prevalence of specific psychiatric disorders in Puerto Rico. <i>Arch Gen Psychiatry.</i> 1987; 44(8): 727-35.	1984		
Jamaica	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), National Council on Drug Abuse (Jamaica). <i>Jamaica National School Survey 2006.</i>	2006		
Jamaica	Soyibo K, Lee MG. Use of illicit drugs among high-school students in Jamaica. <i>Bull World Health Organ.</i> 1999; 77(3): 258-62.	1995		
Jamaica	Durkin MS, Davidson LL, Hasan ZM, Hasan Z, Hauser WA, Khan N, Paul TJ, Shrout PE, Thorburn MJ, Zaman S. Estimates of the prevalence of childhood seizure disorders in communities where professional resources are scarce: results from Bangladesh, Jamaica and Pakistan. <i>Paediatr Perinat Epidemiol.</i> 1992; 6(2): 166-80.	1991	*	†
Jamaica	Soyibo AK, Barton EN. Report from the Caribbean renal registry, 2006. <i>West Indian Med J.</i> 2007; 56(4): 355-63.	2006		
Jamaica	Hickling FW, Rodgers-Johnson P. The prevalence of schizophrenia and affective disorders in Jamaica. <i>West Indian Med J.</i> 1994; 43(Suppl 1): 12.	1992	*	
Jamaica	Hickling FW, Rodgers-Johnson P. The incidence of first contact schizophrenia in Jamaica. <i>Br J Psychiatry.</i> 1995; 167(2): 193-6.	1992	*	
Jamaica	World Health Organization (WHO). <i>WHO Tuberculosis Case Notifications.</i> Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Jamaica	Bird HR, Canino G, Rubio-Stipec M, Gould MS, Ribera J, Sesman M, Woodbury M, Huertas-Goldman S, Pagan A, Sanchez-Lacay A. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico. The use of combined measures. <i>Arch Gen Psychiatry.</i> 1988; 45(12): 1120-6.	1985-1986	*	
Jamaica	Castle PE, Escoffery C, Schachter J, Rattray C, Schiffman M, Moncada J, Sugai K, Brown C, Cranston B, Hanchard B, Palefsky JM, Burk RD, Hutchinson ML, Strickler HD. Chlamydia trachomatis, herpes simplex virus 2, and human T-cell lymphotropic virus type 1 are not associated with grade of cervical neoplasia in Jamaican colposcopy patients. <i>Sex Transm Dis.</i> 2003; 30(7): 575-80.	1993-1997	*	
Jamaica	Garbutt A, Trotman H. Outcome of neonates with hypoxic ischaemic encephalopathy admitted to the neonatal unit of the University Hospital of the West Indies. <i>Ann Trop Paediatr.</i> 2009; 29(4): 263-9.	1998-2003	*	†
Jamaica	Brooks SE, Wolff C. Age-specific incidence of cancer in Kingston and St. Andrew, Jamaica. Part I: 1978-1982. <i>West Indian Med J.</i> 1991; 40(3): 127-8.	1978-1982	*	
Jamaica	Brooks SE, Hanchard B, Wolff C, Samuels E, Allen J. Age-specific incidence of cancer in Kingston and St. Andrew, Jamaica, 1988-1992. <i>West Indian Med J.</i> 1995; 44(3): 102-5.	1988-1992	*	
Jamaica	Hanchard B, Blake G, Wolff C, Samuels E, Waugh N, Simpson D, Ramjit C, Mitchell K. Age-specific incidence of cancer in Kingston and St. Andrew, Jamaica, 1993-1997. <i>West Indian Med J.</i> 2001; 50(2): 123-9.	1993-1997	*	
Jamaica	Lyn C, Jadusingh WA, Ashman H, Chen D, Abramson A, Soutar I. Hearing screening in Jamaica: prevalence of otitis media with effusion. <i>Laryngoscope.</i> 1998; 108(2): 288-90.	1995-1997	*	
Jamaica	Miller M, Gooden M, Shah D, Soyibo AK, Williams J, Barton EN. Renal biopsy findings in Jamaican children. <i>West Indian Med J.</i> 2010; 59(3): 325-9.	1985-2008	*	
Jamaica	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Jamaica	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Jamaica	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Jamaica	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec.</i> 2008; 83(33): 293-300.	2007	*	
Jamaica	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Jamaica	Neita SM, Abel WD, Eldemire-Shearer D, James K, Gibson RC. The prevalence and associated demographic factors of dementia from a cross-sectional community survey in Kingston, Jamaica. <i>Int J Geriatr Psychiatry.</i> 2014; 29(1): 103-5.	2010	*	
Jamaica	Merikangas KR, Conway KP, Swendsen J, Febo V, Dierker L, Brunetto W, Stolar M, Canino G. Substance use and behaviour disorders in Puerto Rican youth: a migrant family study. <i>J Epidemiol Community Health.</i> 2009; 63(4): 310-6.	1990		
Jamaica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Jamaica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Jamaica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Jamaica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Jamaica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Jamaica	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Jamaica	Olando S, Cabre P, Deschamps R, Chatot-Henry C, René-Coraill P, Fournier P, Saint-Vil M, May F, Smadja D. Acute stroke in the very elderly: epidemiological features, stroke subtypes, management, and outcome in Martinique, French West Indies. <i>Stroke.</i> 2003; 34(7): 1593-7.	1998-1999		
Jamaica	Vigilance JE, Reid HL, Richards-George P. Peripheral occlusive arterial disease in diabetic clinic attendees. <i>West Indian Med J.</i> 1999; 48(3): 143-6.	1996-1998		
Jamaica	Simon S, Stephenson S, Whyte K, Stubbs M, Vickers IE, Smikle MF, Gilbert DT, Barton EN. Prevalence of chronic renal failure in the diabetic population at the University Hospital of the West Indies. <i>West Indian Med J.</i> 2004; 53(2): 85-8.	2000		
Jamaica	Foster K, Forbes M, Hayes R, Serjeant GR. Cord blood screening for sickle hemoglobin: evidence against a female preponderance of hemoglobin S. <i>J Pediatr.</i> 1981; 98(1): 79-81.	1973-1979	*	
Jamaica	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L, Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Ann Hepatol.</i> 2010; 9(1): 63-9.	2006-2008		
Jamaica	Brown MG, Lindo JF, King SD. Investigations of the epidemiology of infections with hepatitis A virus in Jamaica. <i>Ann Trop Med Parasitol.</i> 2000; 94(5): 497-502.	1995-1998		
Jamaica	Stafford JL, Hill KR, Arneaud JD. Rhesus factor distribution in the Caribbean; preliminary communication. <i>West Indian Med J.</i> 1955; 4(2): 119-25.	1952-1954	*	†
Jamaica	Barton EN, King SD, Douglas LL. The seroprevalence of hepatitis and retroviral infection in Jamaican haemodialysis patients. <i>West Indian Med J.</i> 1998; 47(3): 105-7.	1996, 1998		
Jamaica	Brady-West DC, Buchner LM. Retrospective audit of blood donation at a hospital-based blood centre. Implications for blood product supply and safety. <i>West Indian Med J.</i> 2000; 49(3): 226-8.	1995-1998		
Jamaica	King SD, Dodd RY, Haynes G, Wynter HH, Sullivan MT, Serjeant GR, Choo-Kang E, Michael E. Prevalence of antibodies to hepatitis C virus and other markers in Jamaica. <i>West Indian Med J.</i> 1995; 44(2): 55-7.	1991		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Jamaica	Vickers EE, Brathwaite AR, Levy M, Figueroa JP. Seroprevalence of sexually transmitted infections among accepted and deferred blood donors in Jamaica. <i>West Indian Med J.</i> 2006; 55(2): 89-94.	1998-1999		
Jamaica	Olughbuyi O, Sams-Vaughan M, Trotman H. Mortality of very-low-birth-weight infants in Jamaica. <i>Trop Doct.</i> 2006 Jul;36(3):169-71.	1992, 2002		†
Jamaica	Jamaica Vital Registration Birth Data 1989 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1989		
Japan	World Health Organization (WHO). Control of Foodborne Trematode Infections 1995. Geneva, Switzerland: World Health Organization (WHO), 1995.	1995	*	
Japan	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	2000		
Japan	Ministry of Health, Labour and Welfare (Japan). Japan Comprehensive Survey of Living Conditions 2010.	2010	*	
Japan	Obsawa M, Okayama A, Okamura T, Itai K, Nakamura M, Tanno K, Kato K, Yaegashi Y, Onoda T, Sakata K, Ueshima H. Mortality risk attributable to atrial fibrillation in middle-aged and elderly people in the Japanese general population: nineteen-year follow-up in NIPPON DATA80. <i>Circ J.</i> 2007; 71(6): 814-9.	1980-1999		
Japan	Nakayama T, Yokoyama T, Yoshiike N, Zaman MM, Date C, Tanaka H, Detels R. Population Attributable Fraction of Stroke Incidence in Middle-Aged and Elderly People: Contributions of Hypertension, Smoking and Atrial Fibrillation. <i>Neuroepidemiology.</i> 2000; 19(4): 217-26.	1980-1997		
Japan	Iguchi Y, Kimura K, Aoki J, Kobayashi K, Terasawa Y, Sakai K, Shibasaki K. Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan: analysis of 41,436 non-employee residents in Kurashiki-city. <i>Circ J.</i> 2008; 72(6): 909-13.	2006		
Japan	Inoue H, Fujiki A, Origasa H, Ogawa S, Okumura K, Kubota I, Aizawa Y, Yamashita T, Atarashi H, Horie M, Ohe T, Doi Y, Shimizu A, Chishaki A, Saikawa T, Yano K, Kitabatake A, Mitamura H, Kodama I, Kamakura S. Prevalence of atrial fibrillation in the general population of Japan: An analysis based on periodic health examination. <i>Int J Cardiol.</i> 2009; 137(2): 102-7.	2003		
Japan	Obsawa M, Okayama A, Sakata K, Kato K, Itai K, Onoda T, Ueshima H. Rapid increase in estimated number of persons with atrial fibrillation in Japan: an analysis from national surveys on cardiovascular diseases in 1980, 1990 and 2000. <i>J Epidemiol.</i> 2005; 15(5): 194-6.	1980-2000		
Japan	Inamura T, Sugihara J, Matsuo T, Maruyama T, Ohta Y, Sumida I, Yamaoka K, Yanase T. Frequency and distribution of structural variants of hemoglobin and thalassemic states in Western Japan. <i>Hemoglobin.</i> 1980; 4(3-4): 409-15.	1970-1978		
Japan	Centre for Health Informatics and Multiprofessional Education, University College London. <i>Modell's Haemoglobinopathologist's Almanac.</i> London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Japan	Shibata S. Hemoglobinopathies in Japan. <i>Hemoglobin.</i> 1981; 5(5): 509-15.	1953-1976		
Japan	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Japan	Furuya S, Yokoyama E, Kumamoto Y, Aoki S, Tanaka N. Studies on incidence of benign prostatic hypertrophy and prostatic cancer in cold districts. I. Mass examination of prostate in Tanno town. <i>Jpn J Urol.</i> 1985; 76(7): 957-64.	1982		
Japan	Tsakamoto T, Kumamoto Y, Masumori N, Miyake H, Rhodes T, Girman CJ, Guess HA, Jacobsen SJ, Lieber MM. Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. <i>J Urol.</i> 1995; 154(2 pt 1): 391-95.	1994		
Japan	Ukimura O, Kojima M, Inui E, Ochiai A, Hata Y, Watanabe M, Saitoh M, Watanabe H. A statistical study of the American Urological Association symptom index for benign prostatic hyperplasia in participants of mass screening program for prostatic diseases using transrectal sonography. <i>J Urol.</i> 1996; 156(5): 1673-8.	1991-1994		
Japan	Hamano-Hasegawa K, Morozumi M, Nakayama E, Chiba N, Murayama S, Takayanagi R, Iwata S, Sunakawa K, Ubukata K. Comprehensive detection of causative pathogens using real-time PCR to diagnose pediatric community-acquired pneumonia. <i>J Infect Chemother.</i> 2008; 14(6): 424-32.	2005-2006		
Japan	Maruyama T, Gabazza EC, Morser J, Takagi T, D'Alessandro-Gabazza C, Hirohata S, Nakayama S, Ramirez AY, Fujiwara A, Naito M, Nishikubo K, Yuda H, Yoshida M, Takei Y, Taguchi O. Community-acquired pneumonia and nursing home-acquired pneumonia in the very elderly patients. <i>Respir Med.</i> 2010; 104(4): 584-92.	2004-2005		
Japan	Maruyama T, Niederman MS, Kobayashi T, Kobayashi H, Takagi T, D'Alessandro-Gabazza CN, Fujimoto H, Gil Bernabe P, Hirohata S, Nakayama S, Nishikubo K, Yuda H, Yamaguchi A, Gabazza EC, Noguchi T, Takei Y, Taguchi O. A prospective comparison of nursing home-acquired pneumonia with hospital-acquired pneumonia in non-intubated elderly. <i>Respir Med.</i> 2008; 102(9): 1287-95.	2004-2005		
Japan	Tajima T, Nakayama E, Kondo Y, Hirai F, Ito H, Iitsuka T, Momomura M, Kutsuna H, Kodaka Y, Funaki N, Yanagawa Y, Ubukata K. Etiology and clinical study of community-acquired pneumonia in 157 hospitalized children. <i>J Infect Chemother.</i> 2006; 12(6): 372-9.	2001-2002		
Japan	Tsuchihashi M, Tsutsui H, Kodama K, Kasagi F, Takeshita A. Clinical characteristics and prognosis of hospitalized patients with congestive heart failure—a study in Fukuoka, Japan. <i>Jpn Circ J.</i> 2000; 64(12): 953-9.	1997		
Japan	Itoh H, Koike A, Taniguchi K, Marumo F. Severity and pathophysiology of heart failure on the basis of anaerobic threshold (AT) and related parameters. <i>Jpn Circ J.</i> 1989; 53(2): 146-54.	1978-1985		
Japan	Shiba N, Shimokawa H. Chronic heart failure in Japan: Implications of the CHART studies. <i>Vasc Health Risk Manag.</i> 2008; 4(1): 103-13.	2000-2005		
Japan	Morikawa Y, Nakagawa H, Naruse Y, Nishijo M, Miura K, Tabata M, Hirokawa W, Kagamimori S, Honda M, Yoshita K, Hayashi K. Trends in Stroke Incidence and Acute Case Fatality in a Japanese Rural Area: The Oyabe Study. <i>Stroke.</i> 2000; 31(7): 1583-7.	1980-1991		
Japan	Ogawa M, Tanaka F, Onoda T, Ohsawa M, Itai K, Sakai T, Okayama A, Nakamura M. A community based epidemiological and clinical study of hospitalization of patients with congestive heart failure in Northern Iwate, Japan. <i>Circ J.</i> 2007; 71(4): 455-9.	2002-2005		
Japan	Ishikawa T, Asano Y, Morishima T, Nagashima M, Sobue G, Watanabe K, Yamaguchi H. Epidemiology of bacterial meningitis in children: Aichi Prefecture, Japan, 1984-1993. <i>Pediatr Neurol.</i> 1996; 14(3): 244-50.	1984-1993		†
Japan	Kamiya H, Uehara S, Kato T, Shiraki K, Togashi T, Morishima T, Goto Y, Satoh O, Standaert SM. Childhood bacterial meningitis in Japan. <i>Pediatr Infect Dis J.</i> 1998; 17(9): 183-5.	1994		
Japan	Kuriki M, Fujihira N, Hasegawa S, Fujioka M. [Acute encephalitis and bacterial meningitis in children in Aichi Prefecture (1984-1993)]. <i>Jpn J Public Health.</i> 1995; 42(5): 338-45.	1984-1993		
Japan	Sakata H. [A study of bacterial meningitis in Hokkaido between 1999 and 2003]. <i>J Jpn Assoc Infect Dis.</i> 2005; 79(9): 680-7.	1994-1998		
Japan	Demyttenaere K, Bruffaerts R, Lee S, Posada-Villa J, Kovess V, Angermeyer MC, Levinson D, de Girolamo G, Nakane H, Mneimneh Z, Lara C, de Graaf R, Scott KM, Gureje O, Stein DJ, Haro JM, Bromet EJ, Kessler RC, Alonso J, Von Korff M. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. <i>Pain.</i> 2007; 129(3): 332-42.	2002-2003		
Japan	Lumbiganon P, Laopaboon M, Gülmezoglu AM, Souza JP, Taneepanichkul S, Ruyan P, Attygalle DE, Shrestha N, Mori R, Hinh ND, Bang HT, Rathavy T, Chuyun K, Cheang K, Festin M, Udomprasertgul V, Germar MJV, Yanqiu G, Roy M, Carroli G, Ba-Thike K. Method of delivery and pregnancy outcomes in Asia: the WHO global survey on maternal and perinatal health 2007-08. <i>Lancet.</i> 2010; 375(9713): 490-9.	2007-2008		
Japan	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1996, 1998, 2000-2003, 2007-2009		
Japan	Nishioka K, Mikanagi K. Hereditary and environmental factors influencing on the serum uric acid throughout ten years population study in Japan. <i>Adv Exp Med Biol.</i> 1980; 155-9.	1977		
Japan	Akizuki S. A population study of hyperuricaemia and gout in Japan—analysis of sex, age and occupational differences in thirty-four thousand people living in Nagano Prefecture. <i>Rheumatism.</i> 1982; 22(3): 201-8.	1978		
Japan	Morimoto T, Azuma A, Abe S, Usuki J, Kudoh S, Sugisaki K, Oritsu M, Nukiwa T. Epidemiology of sarcoidosis in Japan. <i>Eur Respir J.</i> 2008; 31(2): 372-9.	2004		
Japan	Katsutoshi T, Yasutaka I, Masaharu N, Toshihide S, Masahiko Y, Munehiko M. The clinical course and prognosis of patients with severe, moderate or mild sarcoidosis. <i>J Clin Epidemiol.</i> 1993; 46(4): 359-66.	1978-1990		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Japan	Araki S, Uchino M, Yoshida O. Epidemiologic study of multiple sclerosis, myasthenia gravis and polymyositis in the city of Kumamoto, Japan. <i>Clin Neurol</i> . 1983; 23(10): 838-41.	1982		
Japan	Itoh T, Aizawa H, Hashimoto K, Yoshida K, Kimura T, Katayama T, Koyama S, Yahara O, Kikuchi K. Prevalence of multiple sclerosis in Asahikawa, a city in northern Japan. <i>J Neurol Sci</i> . 2003; 214(1-2): 7-9.	2002		
Japan	Araki S, Uchino M, Kumamoto T. Prevalence studies of multiple sclerosis, myasthenia gravis, and myopathies in Kumamoto district, Japan. <i>Neuroepidemiology</i> . 1987; 6(3): 120-9.	1982		
Japan	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J</i> . 1998; 12(2): 315-35.	1993-1995		
Japan	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	1999		
Japan	Kuzuya T, Akanuma Y, Akazawa Y, Uehata T. Prevalence of chronic complications in Japanese diabetic patients. <i>Diabetes Res Clin Pract</i> . 1994; 24 Suppl(Suppl): S159-64.	1990		
Japan	Asia Pacific Cohort Studies Collaboration. Japan - Konan Health and Nutrition Study 1987-1995.	1987-1995		
Japan	Kato S, Takemori M, Kitano S, Hori S, Fukushima H, Numaga J, Yamashita H. Retinopathy in older patients with diabetes mellitus. <i>Diabetes Res Clin Pract</i> . 2002; 58(3): 187-92.	2001		
Japan	Sekikawa A, Eguchi H, Tomimaga M, Igarashi K, Abe T, Manaka H, Sasaki H, Fukuyama H, Kato T, Kiyohara Y, Fujishima M. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in a rural area of Japan. The Funagata diabetes study. <i>J Diabet Complications</i> . 2000; 14(2): 78-83.	1990		
Japan	Takeshima T, Ishizaki K, Fukuhara Y, Ijiri T, Kusumi M, Wakutani Y, Mori M, Kawashima M, Kowa H, Adachi Y, Urakami K, Nakashima K. Population-based door-to-door survey of migraine in Japan: the Daisen study. <i>Headache</i> . 2004; 44(1): 8-19.	1999		
Japan	Ando N, Fujimoto S, Ishikawa T, Teramoto J, Kobayashi S, Hattori A, Togari H. Prevalence and features of migraine in Japanese junior high school students aged 12-15 yr. <i>Brain Dev</i> . 2007; 29(8): 482-5.	2004		
Japan	Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. <i>Cephalalgia</i> . 1997; 17(1): 15-22.	1990		
Japan	Niizeki K, Kano O, Kondo Y. An epidemic study of molluscum contagiosum. Relationship to swimming. <i>Dermatologica</i> . 1984; 169(4): 197-8.	1982-1984		
Japan	Fukutomi Y, Taniguchi M, Nakamura H, Konno S, Nishimura M, Kawagishi Y, Okada C, Tanimoto Y, Takahashi K, Akasawa A, Akiyama K. Association between body mass index and asthma among Japanese adults: risk within the normal weight range. <i>Int Arch Allergy Immunol</i> . 2012; 157(3): 281-7.	2006	*	
Japan	Kurosaka F, Terada T, Tanaka A, Nakatani Y, Yamada K, Nishikawa J, Oka K, Takahashi H, Mogami A, Yamada T, Nakano T, Shima M, Nishio H. Risk factors for wheezing, eczema and rhinoconjunctivitis in the previous 12 months among six-year-old children in Himeji City, Japan: food allergy, older siblings, day-care attendance and parental allergy history. <i>Allergol Int</i> . 2011; 60(3): 317-30.	2005-2006		
Japan	Tanaka K, Miyake Y, Arakawa M, Sasaki S, Ohya Y. U-shaped association between body mass index and the prevalence of wheeze and asthma, but not eczema or rhinoconjunctivitis: the ryukyus child health study. <i>J Asthma</i> . 2011; 48(8): 804-10.	2004-2005	*	
Japan	Fukutomi Y, Nakamura H, Kobayashi F, Taniguchi M, Konno S, Nishimura M, Kawagishi Y, Watanabe J, Komase Y, Akamatsu Y, Okada C, Tanimoto Y, Takahashi K, Kimura T, Eboshida A, Hirota R, Ikei J, Odajima H, Nakagawa T, Akasawa A, Akiyama K. Nationwide cross-sectional population-based study on the prevalences of asthma and asthma symptoms among Japanese adults. <i>Int Arch Allergy Immunol</i> . 2010; 153(3): 280-7.	2006-2007	*	
Japan	Yoshimura N, Muraki S, Oka H, Tanaka S, Kawaguchi H, Nakamura K, Akune T. Accumulation of metabolic risk factors such as overweight, hypertension, dyslipidaemia, and impaired glucose tolerance raises the risk of occurrence and progression of knee osteoarthritis: a 3-year follow-up of the ROAD study. <i>Osteoarthritis Cartilage</i> . 2012; 20(11): 1217-26.	2008-2010	*	
Japan	Muraki S, Akune T, Oka H, Ishimoto Y, Nagata K, Yoshida M, Tokimura F, Nakamura K, Kawaguchi H, Yoshimura N. Incidence and risk factors for radiographic knee osteoarthritis and knee pain in Japanese men and women: a longitudinal population-based cohort study. <i>Arthritis Rheum</i> . 2012; 64(5): 1447-56.	2005-2010		
Japan	Nishimura A, Hasegawa M, Kato K, Yamada T, Uchida A, Sudo A. Risk factors for the incidence and progression of radiographic osteoarthritis of the knee among Japanese. <i>Int Orthop</i> . 2011; 35(6): 839-43.	1997-2009	*	
Japan	Nishimura A, Hasegawa M, Wakabayashi H, Yoshida K, Kato K, Yamada T, Uchida A, Sudo A. Prevalence and characteristics of unilateral knee osteoarthritis in a community sample of elderly Japanese: do fractures around the knee affect the pathogenesis of unilateral knee osteoarthritis? <i>J Orthop Sci</i> . 2012; 17(5): 556-61.	1997-2009	*	
Japan	Mitchita K, Nishiguchi S, Aoyagi Y, Hase Y, Tokumoto Y, Onji M. Japan Etiology of Liver Cirrhosis Study Group. Etiology of liver cirrhosis in Japan: a nationwide survey. <i>J Gastroenterol</i> . 2010; 45(1): 86-94.	1991, 1998, 2008		
Japan	Fukahori S, Matsuse H, Takamura N, Hirose H, Tsuchida T, Kawano T, Fukushima C, Mizuta Y, Kohno S. Prevalence of chronic obstructive pulmonary diseases in general clinics in terms of FEV1/FVC. <i>Int J Clin Pract</i> . 2009; 63(2): 269-74.	2005	*	
Japan	Suzuki S, Sagara K, Otsuka T, Kano H, Matsuno S, Takai H, Uejima T, Oikawa Y, Koike A, Nagashima K, Kirigaya H, Yajima J, Tanabe H, Sawada H, Aizawa T, Yamashita T. Usefulness of frequent supraventricular extrasystoles and a high CHADS2 score to predict first-time appearance of atrial fibrillation. <i>Am J Cardiol</i> . 2013; 111(11): 1602-7.	2004-2011	*	
Japan	Suzuki S, Yamashita T, Ohtsuka T, Sagara K, Uejima T, Oikawa Y, Yajima J, Koike A, Nagashima K, Kirigaya H, Ogasawara K, Sawada H, Yamazaki T, Aizawa T. Body size and atrial fibrillation in Japanese outpatients. <i>Circ J</i> . 2010; 74(1): 66-70.	2004-2008	*	
Japan	Ohfuiji S, Miyake Y, Arakawa M, Tanaka K, Sasaki S. Sibship size and prevalence of allergic disorders in Japan: the Ryukyus Child Health Study. <i>Pediatr Allergy Immunol</i> . 2009; 20(4): 377-84.	2004-2005	*	
Japan	Tanaka K, Miyake Y, Arakawa M, Sasaki S, Ohya Y. Dental caries and allergic disorders in Japanese children: the Ryukyus Child Health Study. <i>J Asthma</i> . 2008; 45(9): 795-9.	2004-2005		
Japan	Saeki H, Osso N, Honma M, Odajima H, Iizuka H, Kawada A, Tamaki K. Comparison of prevalence of atopic dermatitis in Japanese elementary schoolchildren between 2001/2002 and 2007/2008. <i>J Dermatol</i> . 2009; 36(9): 512-4.	2001-2002, 2007-2008	*	
Japan	Ohnishi H, Sawayama Y, Furusyo N, Maeda S, Tokunaga S, Hayashi J. Risk factors for and the prevalence of peripheral arterial disease and its relationship to carotid atherosclerosis: the Kyushu and Okinawa Population Study (KOPS). <i>J Atheroscler Thromb</i> . 2010; 17(7): 751-8.	2005-2006		
Japan	Kawashita Y, Kitamura M, Saito T. Monitoring time-related trends in dental caries in permanent teeth in Japanese national surveys. <i>Int Dent J</i> . 2012; 62(2): 100-5.	2005-2006	*	
Japan	Tanaka K, Miyake Y. Association between breastfeeding and dental caries in Japanese children. <i>J Epidemiol</i> . 2012; 22(1): 72-7.	2006-2007	*	
Japan	Tanaka H, Imai Y, Hiramatsu N, Ito Y, Imanaka K, Oshita M, Hijoka T, Katayama K, Yabuuchi I, Yoshihara H, Inoue A, Kato M, Takehara T, Tamura S, Kasahara A, Hayashi N, Tsukuma H. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. <i>Ann Intern Med</i> . 2008; 148(11): 820-6.	1990-2003	*	
Japan	Kitamura M, Takeda T, Koga S, Nagase S, Yaegashi N. Relationship between premenstrual symptoms and dysmenorrhea in Japanese high school students. <i>Arch Womens Ment Health</i> . 2012; 15(2): 131-3.	2010		
Japan	Fujii T, Matsudaira K. Prevalence of low back pain and factors associated with chronic disabling back pain in Japan. <i>Eur Spine J</i> . 2013; 22(2): 432-8.	2011	*	
Japan	Kitahara H, Ye Z, Aoyagi K, Ross PD, Abe Y, Honda S, Kanagae M, Mizukami S, Kusano Y, Tomita M, Shindo H, Osaki M. Associations of vertebral deformities and osteoarthritis with back pain among Japanese women: the Hizen-Oshima study. <i>Osteoporos Int</i> . 2013; 24(3): 907-15.	1998-1999	*	
Japan	Ono R, Yamazaki S, Takegami M, Otani K, Sekiguchi M, Onishi Y, Hayashino Y, Kikuchi S, Konno S, Fukuhara S. Gender difference in association between low back pain and metabolic syndrome: locomotive syndrome and health outcome in Aizu cohort study (LOHAS). <i>Spine</i> . 2012; 37(13): 1130-7.	2005	*	
Japan	Shinjo H, Iwata S, Sato Y, Akita H, Sunakawa K. Childhood bacterial meningitis trends in Japan from 2009 to 2010. <i>J Jpn Assoc Infect Dis</i> . 2012; 86(5): 582-91.	2009-2010		
Japan	Chan-it W, Thongprachum A, Dey SK, Phan TG, Khamrin P, Okitsu S, Nishimura S, Kobayashi M, Kikuta H, Baba T, Yamamoto A, Sugita K, Hashira S, Tajima T, Ishida S, Mizuguchi M, Ushijima H. Detection and genetic characterization of rotavirus infections in non-hospitalized children with acute gastroenteritis in Japan, 2007-2009. <i>Infect Genet Evol</i> . 2011; 11(2): 415-22.	2007-2009	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Japan	Thongprachum A, Chan-It W, Khamrin P, Okitsu S, Nishimura S, Kikuta H, Yamamoto A, Sugita K, Baba T, Mizuguchi M, Maneekarn N, Hayakawa S, Ushijima H. Reemergence of new variant G3 rotavirus in Japanese pediatric patients, 2009-2011. <i>Infect Genet Evol.</i> 2013; 13: 168-74.	2009-2011	*	
Japan	Dey SK, Thongprachum A, Ota Y, Phan TG, Nishimura S, Mizuguchi M, Okitsu S, Ushijima H. Molecular and epidemiological trend of rotavirus infection among infants and children in Japan. <i>Infect Genet Evol.</i> 2009; 9(5): 955-61.	2006-2007	*	
Japan	Ikejima C, Hisanaga A, Meguro K, Yamada T, Ouma S, Kawamura Y, Hyouki K, Nakashima K, Wada K, Yamada S, Watanabe I, Kakuma T, Aoyama Y, Mizukami K, Asada T. Multicentre population-based dementia prevalence survey in Japan: a preliminary report. <i>Psychogeriatrics.</i> 2012; 12(2): 120-3.	2009-2010		
Japan	Sekita A, Ninomiya T, Tanizaki Y, Doi Y, Hata J, Yonemoto K, Arima H, Sasaki K, Iida M, Iwaki T, Kanba S, Kiyohara Y. Trends in prevalence of Alzheimer's disease and vascular dementia in a Japanese community: the Hisayama Study. <i>Acta Psychiatr Scand.</i> 2010; 122(4): 319-25.	1998, 2005		
Japan	Wada-Isoe K, Uemura Y, Suto Y, Doi K, Imamura K, Hayashi A, Kitayama M, Watanabe Y, Adachi Y, Nakashima K. Prevalence of dementia in the rural island town of Ama-cho, Japan. <i>Neuroepidemiology.</i> 2009; 32(2): 101-6.	2008		
Japan	Hatada K, Okazaki Y, Yoshitake K, Takada K, Nakane Y. Further evidence of westernization of dementia prevalence in Nagasaki, Japan, and family recognition. <i>Int Psychogeriatr.</i> 1999; 11(2): 123-38.	1995		
Japan	Komahashi T, Ohmori K, Nakano T, Fujinuma H, Higashimoto T, Nakaya M, Kuroda J, Asahi H, Yoshikawa J, Matsumura S. Epidemiological survey of dementia and depression among the aged living in the community in Japan. <i>Jpn J Psychiatry Neurol.</i> 1994; 48(3): 517-26.	1989-1990		
Japan	Yamada T, Hattori H, Miura A, Tanabe M, Yamori Y. Prevalence of Alzheimer's disease, vascular dementia and dementia with Lewy bodies in a Japanese population. <i>Psychiatry Clin Neurosci.</i> 2001; 55(1): 21-5.	1998		
Japan	Ogura C, Nakamoto H, Uema T, Yamamoto K, Yonemori T, Yoshimura T. Prevalence of senile dementia in Okinawa, Japan. COSEPO Group. Study Group of Epidemiology for Psychiatry in Okinawa. <i>Int J Epidemiol.</i> 1995; 24(2): 373-80.	1991-1992		†
Japan	Meguro K, Tanaka N, Kasai M, Nakamura K, Ishikawa H, Nakatsuka M, Satoh M, Ouchi Y. Prevalence of dementia and dementing diseases in the old-old population in Japan: the Kurihara Project. Implications for Long-Term Care Insurance data. <i>Psychogeriatrics.</i> 2012; 12(4): 226-34.	2008-2010		
Japan	Shiozaki H, Koga Y, Omori G, Yamamoto G, Takahashi HE. Epidemiology of osteoarthritis of the knee in a rural Japanese population. <i>Knee.</i> 1999; 6(3): 183-8.	1993		
Japan	Muraki S, Oka H, Akune T, Mabuchi A, En-yo Y, Yoshida M, Saika A, Suzuki T, Yoshida H, Ishibashi H, Yamamoto S, Nakamura K, Kawaguchi H, Yoshimura N. Prevalence of radiographic knee osteoarthritis and its association with knee pain in the elderly of Japanese population-based cohorts: the ROAD study. <i>Osteoarthritis Cartilage.</i> 2009; 17(9): 1137-43.	2005-2007		
Japan	Yoshimura N, Muraki S, Oka H, Mabuchi A, En-Yo Y, Yoshida M, Saika A, Yoshida H, Suzuki T, Yamamoto S, Ishibashi H, Kawaguchi H, Nakamura K, Akune T. Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability study. <i>J Bone Miner Metab.</i> 2009; 27(5): 620-8.	2005-2007		
Japan	Sudo A, Miyamoto N, Horikawa K, Urawa M, Yamakawa T, Yamada T, Uchida A. Prevalence and risk factors for knee osteoarthritis in elderly Japanese men and women. <i>J Orthop Sci.</i> 2008; 13(5): 413-8.	2005		
Japan	Shichikawa K, Inoue K, Hirota S, Maeda A, Ota H, Kimura M, Ushiyama T, Tsujimoto M. Changes in the incidence and prevalence of rheumatoid arthritis in Kamitonda, Wakayama, Japan, 1965-1996. <i>Ann Rheum Dis.</i> 1999; 58(12): 751-6.	1965-1996		
Japan	Yonemitsu M, Sutcliffe P. Comparative study of oral health status between Scottish and Japanese schoolchildren aged 6-11 years. <i>Community Dent Oral Epidemiol.</i> 1992; 20(6): 354-8.	1989		
Japan	Miyazaki H, Morimoto M. Changes in caries prevalence in Japan. <i>Eur J Oral Sci.</i> 1996; 104(4): 452-8.	1957-1993		
Japan	Mayanagi H, Saito T, Kamiyama K. Cross-sectional comparisons of caries time trends in nursery school children in Sendai, Japan. <i>Community Dent Oral Epidemiol.</i> 1995; 23(6): 344-9.	1972-1992		
Japan	Ihara K, Muraoka Y, Oji A, Nadaoka T. Prevalence of mood disorders according to dsm-iii-r criteria in the community elderly residents in Japan. <i>Environ Health Prev Med.</i> 1998; 3(1): 44-9.	1993		
Japan	Kawakami N, Takeshima T, Ono Y, Uda H, Hata Y, Nakane Y, Nakane H, Iwata N, Furukawa TA, Kikkawa T. Twelve-month prevalence, severity, and treatment of common mental disorders in communities in Japan: preliminary finding from the World Mental Health Japan Survey 2002-2003. <i>Psychiatry Clin Neurosci.</i> 2005; 59(4): 441-52.	2002-2003		
Japan	Kawakami N, Shimizu H, Haratani T, Iwata N, Kitamura T. Lifetime and 6-month prevalence of DSM-III-R psychiatric disorders in an urban community in Japan. <i>Psychiatry Res.</i> 2004; 121(3): 293-301.	1997-1999		
Japan	Saku M, Tokudome S, Ikeda M, Kono S, Makimoto K, Uchimura H, Mukai A, Yoshimura T. Mortality in psychiatric patients, with a specific focus on cancer mortality associated with schizophrenia. <i>Int J Epidemiol.</i> 1995; 24(2): 366-72.	1950-1982		
Japan	Miura K, Nakagawa H, Morikawa Y, Sasayama S, Matsumori A, Hasegawa K, Ohno Y, Tamakoshi A, Kawamura T, Inaba Y. Epidemiology of idiopathic cardiomyopathy in Japan: results from a nationwide survey. <i>Heart.</i> 2002; 87(2): 126-30.	1998		
Japan	Matsumori A, Furukawa Y, Hasegawa K, Sato Y, Nakagawa H, Morikawa Y, Miura K, Ohno Y, Tamakoshi A, Inaba Y, Sasayama S. Co-research workers. Epidemiologic and clinical characteristics of cardiomyopathies in Japan: results from nationwide surveys. <i>Circ J.</i> 2002; 66(4): 323-36.	1998		
Japan	Ikeda H, Maki S, Yoshida N, Murohara T, Adachi H, Koga Y, Imaizumi T. Predictors of death from congestive heart failure in hypertrophic cardiomyopathy. <i>Am J Cardiol.</i> 1999; 83(8): 1280-1283.	1971-1996		
Japan	Kibira S, Miura M. Epidemiology of dilated cardiomyopathy and hypertrophic cardiomyopathy. <i>Jpn J Clin Med.</i> 2000; 58(1): 141-6.	1994		
Japan	Iguchi M, Umekawa T, Katoh Y, Kohri K, Kurita T. Prevalence of urolithiasis in Kaizuka City, Japan—an epidemiologic study of urinary stones. <i>Int J Urol.</i> 1996; 3(3): 175-9.	1991		
Japan	Terai A, Okada Y, Ohkawa T, Ogawa O, Yoshida O. Changes in the incidence of lower urinary tract stones in Japan from 1965 to 1995. <i>Int J Urol.</i> 2000; 7(12): 452-6.	1985		
Japan	Yoshida O, Terai A, Ohkawa T, Okada Y. National trend of the incidence of urolithiasis in Japan from 1965 to 1995. <i>Kidney Int.</i> 1999; 56(5): 1899-904.	1990, 1995		
Japan	Sakata H, Maruyama S. A study of bacterial meningitis in Hokkaido between 1994 and 1998. <i>J Jpn Assoc Infect Dis.</i> 2000; 74(4): 339-44.	1994-1998		
Japan	Kita Y, Turin TC, Ichikawa M, Sugihara H, Morita Y, Tomioka N, Rumana N, Okayama A, Nakamura Y, Abbott RD, Ueshima H. Trend of stroke incidence in a Japanese population: Takashima stroke registry, 1990-2001. <i>Int J Stroke.</i> 2009; 4(4): 241-9.	1990-2001		
Japan	Matsumura Y, Takata J, Kitaoka H, Kubo T, Baba Y, Hoshikawa E, Hamada T, Okawa M, Hitomi N, Sato K, Yamasaki N, Yabe T, Furuno T, Nishinaga M, Doi Y. Long-term prognosis of dilated cardiomyopathy revisited: an improvement in survival over the past 20 years. <i>Circ J.</i> 2006; 70(4): 376-83.	1982-2004		
Japan	Fukuchi Y, Nishimura M, Ichinose M, Adachi M, Nagai A, Kuriyama T, Takahashi K, Nishimura K, Ishioka S, Aizawa H, Zaher C. COPD in Japan: the Nippon COPD Epidemiology study. <i>Respirology.</i> 2004; 9(4): 458-65.	2000		
Japan	Fujita T, Hayashi K, Katano K, Matsumura Y, Lee JS, Takagi H, Suzuki S, Mizunuma H, Aso T. Prevalence of diseases and statistical power of the Japan Nurses' Health Study. <i>Ind Health.</i> 2007; 45(5): 687-94.	2001-2004		
Japan	Nishizawa S, Inubushi M, Kido A, Miyagawa M, Inoue T, Shinohara K, Kajihara M. Incidence and characteristics of uterine leiomyomas with FDG uptake. <i>Ann Nucl Med.</i> 2008; 22(9): 803-10.	2003-2006		
Japan	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2001-2004		
Japan	Takeda T, Koga S, Yaegashi N. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in Japanese high school students. <i>Arch Womens Ment Health.</i> 2010; 13(6): 535-7.	2003-2004		
Japan	United States Renal Data System Coordinating Center. USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2008.	1990-1996		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod (†)
Japan	Takahashi S, Takeyama K, Miyamoto S, Ichihara K, Maeda T, Kunishima Y, Matsukawa M, Tsukamoto T. Incidence of sexually transmitted infections in asymptomatic healthy young Japanese men. <i>J Infect Chemother.</i> 2005; 11(6): 270-3.	2005		
Japan	Imai H, Nakao H, Shinohara H, Fujii Y, Tsukino H, Hamasuna R, Osada Y, Fukushima K, Inamori M, Ikenoue T, Katoh T. Population-based study of asymptomatic infection with Chlamydia trachomatis among female and male students. <i>Int J STD AIDS.</i> 2010; 21(5): 362-6.	2005		
Japan	Kuroda K, Tataru K, Shinsho H, Okamoto E, Cho R, Nishigaki C, Takatorige T, Nakanishi N, Aoki T. [A study of attitudes toward illness and its effect on mortality in patients with Parkinson's disease]. <i>Jpn J Public Health.</i> 1990; 37(5): 333-9.	1978-1987		
Japan	Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S. Mortality and cancer incidence in patients with Parkinson's disease. <i>J Neurol.</i> 2000; 247(6): 429-34.	1984-1992		
Japan	Itoh K. [Study on the prevalence of Parkinson's disease: based on epidemiological surveys]. <i>Hokkaido J Med Sci.</i> 2003; 78(6): 491-501.	2000		
Japan	Moriwaka F, Tashiro K, Itoh K, Honma S, Okumura H, Kikuchi S, Hamada T, Kaneko S, Kurokawa Y. Prevalence of Parkinson's Disease in Hokkaido, the Northernmost Island of Japan. <i>Intern Med.</i> 1996; 35(4): 276-9.	1992-1994		
Japan	Okada K, Kobayashi S, Tsunematsu T. Prevalence of Parkinson's disease in Izumo City, Japan. <i>Gerontology.</i> 1990; 36(5-6): 340-4.	1985		
Japan	Harada H, Nishikawa S, Takahashi K. Epidemiology of Parkinson's disease in a Japanese city. <i>Arch Neurol.</i> 1983; 40(3): 151-4.	1975-1981		
Japan	Nakashima K, Yokoyama, Yoshitaka, Shimoyama, Ryoji, Saito, Hiroshi, Kuno, Nobutoshi, Sano, Kazuhiko, Rin, Yongshang, Adachi, Yoshiki, Urakami, Katsuya, Oshima, Takashi, Takeshita, Kenzo, Takahashi, Kazuro. Prevalence of Neurological Disorders in a Japanese Town. <i>Neuroepidemiology.</i> 1996; 15(4): 208-13.	1991		
Japan	Morioka S, Sakata K, Yoshida S, Nakai E, Shiba M, Yoshimura N, Hashimoto T. Incidence of Parkinson Disease in Wakayama, Japan. <i>J Epidemiol.</i> 2002; 12(6): 403-7.	1997		
Japan	Nakamura Y, Ojima T, Oki I, Tanihara S, Yanagawa H. Estimation of the future numbers of patients with mental disorders in Japan based on the results of National Patient Surveys. <i>J Epidemiol.</i> 1997; 7(4): 214-20.	1984, 1987, 1990, 1993		
Japan	Ichinowatari N, Tatsunuma T, Makiya H. Epidemiological study of old age mental disorders in the two rural areas of Japan. <i>Jpn J Psychiatry Neurol.</i> 1987; 41(4): 629-36.	1984		
Japan	Suzuki M, Morita H, Kamoshita S. Epidemiological survey of psychiatric disorders in Japanese school children. Part III: Prevalence of psychiatric disorders in junior high school children. <i>Jpn J Public Health.</i> 1990; 37(12): 991-1000.	1988-1989		
Japan	Ohta Y, Nakane Y, Nishihara J, Takemoto T. Ecological structure and incidence rates of schizophrenia in Nagasaki City. <i>Acta Psychiatr Scand.</i> 1992; 86(2): 113-20.	1979-1980		
Japan	Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganey K, Giel R, an der Heiden W, Holmberg SK, Janca A, Lee PW, León CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin SJ, Varma VK, Walsh D, Wiersma D. Recovery from psychotic illness: a 15- and 25-year international follow-up study. <i>Br J Psychiatry.</i> 2001; 178: 506-17.	1978-1993		
Japan	Tsuzuki H, Yuasa S. [An epidemiological study of deaths in mental hospitals]. <i>Psychiatr Neurol Japonica.</i> 1981; 83(5): 275-304.	1969-1973		
Japan	Iwase A, Araie M, Tomidokoro A, Yamamoto T, Shimizu H, Kitazawa Y. Prevalence and causes of low vision and blindness in a Japanese adult population: the Tajimi Study. <i>Ophthalmology.</i> 2006; 113(8): 1354-62. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2000-2001		
Japan	Iwano M, Nomura H, Ando F, Niino N, Miyake Y, Shimokata H. Visual acuity in a community-dwelling Japanese population and factors associated with visual impairment. <i>Jpn J Ophthalmol.</i> 2004; 48(1): 37-43. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1997-2000		
Japan	Yasui T, Iguchi M, Suzuki S, Okada A, Itoh Y, Tozawa K, Kohri K. Prevalence and epidemiologic characteristics of lower urinary tract stones in Japan. <i>Urology.</i> 2008; 72(5): 1001-5.	2005		
Japan	Shiotsuki Y, Matsuishi T, Yoshimura K, Yamashita F, Yano K, Tokimasa H, Shoji H. The prevalence of mental retardation (MR) in Kurume City. <i>Brain Dev.</i> 1984; 6(5): 487-90.	1969-1974		
Japan	Matsui Y, Tanizaki Y, Arima H, Yonemoto K, Doi Y, Ninomiya T, Sasaki K, Iida M, Iwaki T, Kanba S, Kiyohara Y. Incidence and survival of dementia in a general population of Japanese elderly: the Hisayama study. <i>J Neurol Neurosurg Psychiatry.</i> 2009; 80(4): 366-70.	1985-2002		
Japan	Merikangas KR, Jin R, He J-P, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Ladea M, Medina-Mora ME, Ono Y, Posada-Villa J, Sagar R, Wells JE, Zarkov Z. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. <i>Arch Gen Psychiatry.</i> 2011; 68(3): 241-51.	2002-2006	*	
Japan	Ishikuro M, Obara T, Metoki H, Ohkubo T, Yamamoto M, Akutsu K, Sakurai K, Iwama N, Katagiri M, Yagihashi K, Yaegashi N, Mori S, Suzuki M, Kuriyama S, Imai Y. Blood pressure measured in the clinic and at home during pregnancy among nulliparous and multiparous women: the BOSH study. <i>Am J Hypertens.</i> 2013; 26(1): 141-8.	2006-2010	*	
Japan	Morikawa M, Cho K, Yamada T, Yamada T, Sato S, Minakami H. Risk factors for eclampsia in Japan between 2005 and 2009. <i>Int J Gynaecol Obstet.</i> 2012; 117(1): 66-8.	2005-2009	*	
Japan	Shiozaki A, Matsuda Y, Hayashi K, Satoh S, Saito S. Comparison of risk factors for major obstetric complications between Western countries and Japan: a case-cohort study. <i>J Obstet Gynaecol Res.</i> 2011; 37(10): 1447-54.	2001-2005	*	
Japan	Shiozaki A, Matsuda Y, Satoh S, Saito S. Impact of fetal sex in pregnancy-induced hypertension and preeclampsia in Japan. <i>J Reprod Immunol.</i> 2011; 89(2): 133-9.	2001-2005	*	
Japan	Yamada T, Kuvata T, Matsuda H, Deguchi K, Morikawa M, Yamada T, Furuya K, Matsubara S, Minakami H. Risk factors of eclampsia other than hypertension: pregnancy-induced antithrombin deficiency and extraordinary weight gain. <i>Hypertens Pregnancy.</i> 2012; 31(2): 268-77.	2005-2010	*	
Japan	Turin TC, Kita Y, Rumana N, Nakamura Y, Takashima N, Ichikawa M, Sugihara H, Morita Y, Hirose K, Okayama A, Miura K, Ueshima H. Ischemic Stroke Subtypes in a Japanese Population Takashima Stroke Registry, 1988-2004. <i>Stroke.</i> 2010; 41(9): 1871-6.	1988-2004	*	
Japan	Houzen H, Niino M, Hirokami M, Fukazawa T, Kikuchi S, Tanaka K, Sasaki H. Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan. <i>J Neurol Sci.</i> 2012; 323(1-2): 117-22.	2011	*	
Japan	Tsuboi T. Prevalence and incidence of epilepsy in Tokyo. <i>Epilepsia.</i> 1988; 29(2): 103-10.	1973-1984	*	
Japan	Oka E, Ohtsuka Y, Yoshinaga H, Murakami N, Kobayashi K, Ogino T. Prevalence of childhood epilepsy and distribution of epileptic syndromes: a population-based survey in Okayama, Japan. <i>Epilepsia.</i> 2006; 47(3): 626-30.	1999	*	
Japan	Kimura M, Yoshino K, Nanba E, Ieshima A, Narai S, Takeshita K. Unprovoked Seizures and Epilepsies in Kurayoshi, Japan. <i>J Epilepsy.</i> 1998; 11(3): 162-7.	1993	*	
Japan	Nakao M, Yano E. Somatic symptoms for predicting depression: one-year follow-up study in annual health examinations. <i>Psychiatry Clin Neurosci.</i> 2006; 60(2): 219-25.	2004		
Japan	Suzuki H. Viral Hepatitis in Japan. In: Nishioka K, Suzuki H, Mishiro S, Oda T, eds. <i>Viral Hepatitis and Liver Disease. Proceedings of the International Symposium on Viral Hepatitis and Liver Disease: Molecules Today, More Cures Tomorrow; 1993 May 10-14; Tokyo, Japan.</i> Springer Japan; 1994. 426-8.	1991		
Japan	Yoshida T, Katsurashima T, Abe K, Kato A, Suzuki K, Sasaki S, Ikuta T, Narita T, Isogai K, Moriai O, Murakami A, Ono M, Watanabe T, Abe H, Ueda S, Saito Y, Takahashi T, Kooka F, Chiba T, Katsura Y, Ono Y, Kosaka Y, Yasumi S, Kawata T, Sato S. [Regional difference in the etiology of liver cirrhosis in Iwate]. <i>Jpn J Gastroenterol.</i> 1997; 94(12): 826-33.	1993-1995		
Japan	Sakugawa H, Nakasone H, Nakayoshi T, Kawakami Y, Yamashiro T, Maeshiro T, Kobayashi G, Kinjo F, Saito A. Clinical characteristics of patients with cryptogenic liver cirrhosis in Okinawa, Japan. <i>Hepatogastroenterology.</i> 2003; 50(54): 2005-8.	1992-2000		
Japan	Tanaka R, Itoshima T, Nagashima H. Follow-up study of 582 liver cirrhosis patients for 26 years in Japan. <i>Liver.</i> 1987; 7(6): 316-24.	1970-1984		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Japan	Yoshikawa M, Tsujii T, Fukui H, Yamao J, Tsukamoto N, Nishimura N, Kyo M, Takaya A, Tsujii H, Nakano H. Hepatitis C virus infection in patients with chronic liver diseases. <i>Gastroenterol Jpn</i> . 1991; 202-5.	1991		
Japan	Yoneyama K, Miyagishi K, Kinuchi Y, Shibata M, Mitamura K. Risk factors for infections in cirrhotic patients with and without hepatocellular carcinoma. <i>J Gastroenterol</i> . 2002; 37(12): 1028-34.	1997-1999		
Japan	Koide T, Ohno T, Huang XE, Iijima Y, Sugihara K, Mizokami M, Xiang J, Tokudome S. HBV/HCV Infection, Alcohol, Tobacco and Genetic Polymorphisms for Hepatocellular Carcinoma in Nagoya, Japan. <i>Asian Pac J Cancer Prev</i> . 2000; 1(3): 237-43.	1994		
Japan	Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Tsukamoto T, Hamba H, Shuto T, Okuda T, Tamori A, Kuroki T, Kinoshita H. High prevalence of infection with hepatitis B and C viruses in patients with hepatocellular carcinoma in Japan. <i>Hepatogastroenterology</i> . 1999; 46(25): 357-9.	1990-1997		
Japan	Nagaoki Y, Hyogo H, Aikata H, Tanaka M, Naeshiro N, Nakahara T, Honda Y, Miyaki D, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Inamura M, Kawakami Y, Takahashi S, Chayama K. Recent trend of clinical features in patients with hepatocellular carcinoma. <i>Hepatol Res</i> . 2012; 42(4): 368-75.	1995-2009		
Japan	Tokushige K, Hashimoto E, Horie Y, Taniai M, Higuchi S. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. <i>J Gastroenterol</i> . 2011; 46(10): 1230-7.	2006-2009		
Japan	Wang B-E, Ma W-M, Sulaiman A, Noer S, Sumoharjo S, Sumarsidi D, Tandon BN, Nakao K, Mishiro S, Miyakawa Y, Akahane Y, Suzuki H. Demographic, clinical, and virological characteristics of hepatocellular carcinoma in Asia: survey of 414 patients from four countries. <i>J Med Virol</i> . 2002; 67(3): 394-400.	2002		
Japan	Watabe H, Shiratori Y, Tateishi R, Fujishima T, Akamatsu M, Koike Y, Ohi S, Hamamura K, Sato S, Teratani T, Shiina S, Omata M. Clinical features of patients with HCC who are negative for both HBV and HCV markers. <i>Hepatogastroenterology</i> . 2003; 50(54): 2157-60.	1993-1999		
Japan	Hidaka S, Ikejima C, Kodama C, Nose M, Yamashita F, Sasaki M, Kinoshita T, Tanimukai S, Mizukami K, Takahashi H, Kakuma T, Tanaka S, Asada T. Prevalence of depression and depressive symptoms among older Japanese people: comorbidity of mild cognitive impairment and depression. <i>Int J Geriatr Psychiatry</i> . 2012; 27(3): 271-9.	2001-2002	*	
Japan	Iseki K, Horio M, Imai E, Matsuo S, Yamagata K. Geographic difference in the prevalence of chronic kidney disease among Japanese screened subjects: Ibaraki versus Okinawa. <i>Clin Exp Nephrol</i> . 2009; 13(1): 44-9.	2005-2006		
Japan	Konta T, Hao Z, Abiko H, Ishikawa M, Takahashi T, Ikeda A, Ichikawa K, Takasaki S, Kubota I. Prevalence and risk factor analysis of microalbuminuria in Japanese general population: the Takahata study. <i>Kidney Int</i> . 2006; 70(4): 751-6.	2000-2004		
Japan	Iseki K, Iseki C, Ikemiya Y, Kinjo K, Takishita S. Risk of developing low glomerular filtration rate or elevated serum creatinine in a screened cohort in Okinawa, Japan. <i>Hypertens Res</i> . 2007; 30(2): 167-74.	1983, 1993		
Japan	Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Makino H, Hishida A, Matsuo S. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. <i>Hypertens Res</i> . 2008; 31(3): 433-41.	1988-2003		
Japan	Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, Ura N, Kiyohara Y, Moriyama T, Ando Y, Fujimoto S, Konta T, Yokoyama H, Makino H, Hishida A, Matsuo S. Prevalence of chronic kidney disease in the Japanese general population. <i>Clin Exp Nephrol</i> . 2009; 13(6): 621-30.	2005		
Japan	Yamagata K, Takahashi H, Suzuki S, Mase K, Hagiwara M, Shimizu Y, Hirayama K, Kobayashi M, Narita M, Koyama A. Age distribution and yearly changes in the incidence of ESRD in Japan. <i>Am J Kidney Dis</i> . 2004; 43(3): 433-43.	1983, 1999, 2003		
Japan	Research Group on Progressive Chronic Renal Disease. Nationwide and long-term survey of primary glomerulonephritis in Japan as observed in 1,850 biopsied cases. <i>Research Group on Progressive Chronic Renal Disease. Nephron</i> . 1999; 82(3): 205-13.	1996-1998		
Japan	Honda H, Shimizu Y, Imai M, Nitto Y. Cumulative incidence of childhood autism: a total population study of better accuracy and precision. <i>Dev Med Child Neurol</i> . 2005; 47(1): 10-8.	1993-1996		
Japan	Honda H, Shimizu Y, Misumi K, Niimi M, Ohashi Y. Cumulative incidence and prevalence of childhood autism in children in Japan. <i>Br J Psychiatry</i> . 1996; 169(2): 228-35.	1994		
Japan	Sugiyama T, Abe T. The prevalence of autism in Nagoya, Japan: a total population study. <i>J Autism Dev Disord</i> . 1989; 19(1): 87D96.	1979-1984		
Japan	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Japan	Sugawara M, Mukai T, Kitamura T, Toda MA, Shima S, Tomoda A, Koizumi T, Watanabe K, Ando A. Psychiatric Disorders Among Japanese Children. <i>J Am Acad Child Adolesc Psychiatry</i> . 1999; 38(4): 444-52.	1997	*	
Japan	Inamura Y, Uto H, Hiramine Y, Hosoyamada K, Ijuin S, Yoshifuku S, Miyahara H, Maenohara S, Oketani M, Ito A, Tsubouchi H. Increasing prevalence of diabetes mellitus in association with fatty liver in a Japanese population. <i>J Gastroenterol</i> . 2013.	2011		
Japan	Okada K, Furusyo N, Sawayama Y, Kanamoto Y, Murata M, Hayashi J. Prevalence and risk factors for diabetes: a ten year follow-up study of the Yaeyama district of Okinawa. <i>Hukuoka Acta Med</i> . 2010; 101(10): 215-24.	1989, 1999		
Japan	Kitagawa T, Owada M, Urakami T, Yamauchi K. Increased incidence of non-insulin dependent diabetes mellitus among Japanese schoolchildren correlates with an increased intake of animal protein and fat. <i>Clin Pediatr (Phila)</i> . 1998; 37(2): 111-5.	1974-1995		
Japan	Urakami T, Kubota S, Nitadori Y, Harada K, Owada M, Kitagawa T. Annual incidence and clinical characteristics of type 2 diabetes in children as detected by urine glucose screening in the Tokyo metropolitan area. <i>Diabetes Care</i> . 2005; 28(8): 1876-81.	1985-2002		
Japan	Miwa S, Teramura K, Irisawa K, Ohyama H. Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. II. Incidence of G-6-PD deficiency in Japanese. <i>J Jpn Haematol Soc</i> . 1965; 28(5): 590-2.	1963-1965		
Japan	Nakatsuji T, Miwa S. Incidence and characteristics of glucose-6-phosphate dehydrogenase variants in Japan. <i>Hum Genet</i> . 1979; 51(3): 297-305.	1977-1979		
Japan	Kageoka T, Satoh C, Goriki K, Fujita M, Neriishi S, Yamamura K, Kaneko J, Masunari N. Electrophoretic variants of blood proteins in Japanese. IV. Prevalence and enzymologic characteristics of glucose-6-phosphate dehydrogenase variants in Hiroshima and Nagasaki. <i>Hum Genet</i> . 1985; 70(2): 101-8.	1983-1985		
Japan	Patient Registration Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan. An overview of regular dialysis treatment in Japan as of 31 December 2003. <i>Ther Apher Dial</i> . 2005; 9(6): 431-58.	1983-1996, 2000-2001, 2003		
Japan	Lee G. End-stage renal disease in the Asian-Pacific region. <i>Semin Nephrol</i> . 2003; 23(1): 107-14.	2000		
Japan	Global Lower Extremity Amputation Study Group. Epidemiology of lower extremity amputation in centres in Europe, North America and East Asia. The Global Lower Extremity Amputation Study Group. <i>Br J Surg</i> . 2000; 87(3): 328-37.	1995-1997		
Japan	Miyazaki H, Hanada N, Andoh MI, Yamashita Y, Saito T, Sogame A, Goto K, Shirahama R, Takehara T. Periodontal disease prevalence in different age groups in Japan as assessed according to the CPITN. <i>Community Dent Oral Epidemiol</i> . 1989; 17(2): 71-4.	1985-1987		
Japan	Miyazaki H, Ohtani I, Abe N, Ansai T, Katoh Y, Sakao S, Takehara T, Shimada N, Pilot T. Periodontal conditions in older age cohorts aged 65 years and older in Japan, measured by CPITN and loss of attachment. <i>Community Dent Health</i> . 1995; 12(4): 216-20.	1991, 1993		
Japan	Miyazaki H, Shirahama R, Itoh-Andoh M, Yamashita Y, Saito T, Sogame A, Takehara T. Prevalence and treatment needs of periodontal disease in employees of supermarkets in Japan. <i>Singapore Dent J</i> . 1988; 13(1): 10-3.	1987		
Japan	Nagata M, Ninomiya T, Doi Y, Yonemoto K, Kubo M, Hata J, Tsuruya K, Iida M, Kiyohara Y. Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population: the Hisayama Study. <i>Nephrol Dial Transplant</i> . 2010; 25(8): 2557-64.	2002		
Japan	Higuchi S, Matsushita S, Maesato H, Osaki Y. Japan: alcohol today. <i>Addiction</i> . 2007; 102(12): 1849-62.	2003		
Japan	Osaki Y, Morita Y, Kuwahara T, Miyano I, Doi Y. Prevalence of Parkinson's disease and atypical parkinsonian syndromes in a rural Japanese district. <i>Acta Neurol Scand</i> . 2011; 124(3): 182-7.	2005-2007	*	
Japan	Yamawaki M, Kusumi M, Kowa H, Nakashima K. Changes in prevalence and incidence of Parkinson's disease in Japan during a quarter of a century. <i>Neuroepidemiology</i> . 2009; 32(4): 263-9.	2005-2007	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Japan	Kusumi M, Nakashima K, Nakayama H, Takahashi K. Epidemiology of inflammatory neurological and inflammatory neuromuscular diseases in Tottori Prefecture, Japan. <i>Psychiatry Clin Neurosci.</i> 1995; 49(3): 169-74.	1988-1992		
Japan	Fukunishi I, Hayabara T, Hosokawa K. Epidemiological surveys of senile dementia in Japan. <i>Int J Soc Psychiatry.</i> 1991; 37(1): 51-6.	1987-1988		
Japan	Watanabe H, Watanabe T, Sasaki S, Nagai K, Roden DM, Aizawa Y. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. <i>Am Heart J.</i> 2009; 158(4): 629-36.	1996-2005	*	
Japan	Saji T, Matsuura H, Hasegawa K, Nishikawa T, Yamamoto E, Ohki H, Yasukochi S, Arakaki Y, Joo K, Nakazawa M. Comparison of the clinical presentation, treatment, and outcome of fulminant and acute myocarditis in children. <i>Circ J.</i> 2012; 76(5): 1222-8.	1997-2005	*	
Japan	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec.</i> 2005; 80(13): 118-24.	2001	*	
Japan	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Japan	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec.</i> 2006; 81(32): 309-16.	2005	*	
Japan	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec.</i> 2007; 82(25): 225-32.	2006	*	
Japan	World Health Organization (WHO). Global leprosy situation, 2008 (additional information). <i>Wkly Epidemiol Rec.</i> 2008; 83(50): 459.	2007	*	
Japan	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Japan	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Japan	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Japan	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Japan	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Japan	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Japan	Hashido M, Kawana T, Matsunaga Y, Inouye S. Changes in prevalence of herpes simplex virus type 1 and 2 antibodies from 1973 to 1993 in the rural districts of Japan. <i>Microbiol Immunol.</i> 1999; 43(2): 177-80.	1983, 1993	*	
Japan	Hashido M, Lee FK, Nahmias AJ, Tsugami H, Isomura S, Nagata Y, Sonoda S, Kawana T. An epidemiologic study of herpes simplex virus type 1 and 2 infection in Japan based on type-specific serological assays. <i>Epidemiol Infect.</i> 1998; 120(2): 179-86.	1985-1989	*	
Japan	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland: World Health Organization (WHO).	2000-2012	*	
Japan	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2000.	2000		
Japan	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2001.	2001		
Japan	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2002.	2002		
Japan	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2003.	2003		
Japan	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2004.	2004		
Japan	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2005.	2005		
Japan	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2006.	2006		
Japan	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2007.	2007		
Japan	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2008.	2008		
Japan	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2009.	2009		
Japan	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2010.	2010		
Japan	Toyama N, Shiraki K. Epidemiology of herpes zoster and its relationship to varicella in Japan: A 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. <i>J Med Virol.</i> 2009; 81(12): 2053-8.	1997-2006		
Japan	Yamada K, Takasaki T, Nawa M, Nakayama M, Arai YT, Morimoto K, Yabe S, Kurane I. Demographic Features of Imported Dengue Fever Cases Serodiagnosed in Japan during 2000. <i>Dengue Bull.</i> 2000; 24: 42-5.	1999-2000		
Japan	Okuno Y, Harada T, Ogawa M, Okamoto Y, Maeda K. A case of dengue hemorrhagic fever in a Japanese child. <i>Microbiol Immunol.</i> 1989; 33(8): 649-55.	1989		
Japan	Hirotsu T, Yoshihara A, Yano M, Ando Y, Miyazaki H. Longitudinal study on periodontal conditions in healthy elderly people in Japan. <i>Community Dent Oral Epidemiol.</i> 2002; 30(6): 409-17.	1998		
Japan	Hanioka T, Ojima M, Tanaka K, Aoyama H. Association of total tooth loss with smoking, drinking alcohol and nutrition in elderly Japanese: analysis of national database. <i>Gerodontology.</i> 2007; 24(2): 87-92.	1999		
Japan	Awano S, Ansai T, Takata Y, Soh I, Akifusa S, Hamasaki T, Yoshida A, Sonoki K, Fujisawa K, Takehara T. Oral health and mortality risk from pneumonia in the elderly. <i>J Dent Res.</i> 2008; 87(4): 334-9.	1998-2002		
Japan	Ishikawa T, Asano Y, Morishima T, Nagashima M, Sobue G, Watanabe K, Yamaguchi H. Epidemiology of acute childhood encephalitis. Aichi Prefecture, Japan, 1984-90. <i>Brain Dev.</i> 1993; 15(3): 192-7.	1984-1990		
Japan	Kamei S, Takasu T. Nationwide survey of the annual prevalence of viral and other neurological infections in Japanese inpatients. <i>Intern Med.</i> 2000; 39(11): 894-900.	1989-1991		
Japan	Ando A, Ohsawa M, Yaegashi Y, Sakata K, Tanno K, Onoda T, Itai K, Tanaka F, Makita S, Omama S, Ogasawara K, Ogawa A, Ishibashi Y, Kuribayashi T, Koyama T, Okayama A. Factors related to tooth loss among community-dwelling middle-aged and elderly Japanese men. <i>J Epidemiol.</i> 2013; 23(4): 301-6.	2002-2005	*	
Japan	Hayasaka K, Tomata Y, Aida J, Watanabe T, Kakizaki M, Tsuji I. Tooth loss and mortality in elderly Japanese adults: effect of oral care. <i>J Am Geriatr Soc.</i> 2013; 61(5): 815-20.	2006-2010	*	
Japan	Ohara K, Suzuki Y, Sugita T, Kobayashi K, Tamefusa K, Hattori S, Ohara K. Mortality among alcoholics discharged from a Japanese hospital. <i>Br J Addict.</i> 1989; 84(3): 287-91.	1972-1984		
Japan	Higuchi S. Mortality of Japanese female alcoholics: a comparative study with male cases. <i>Jpn J Alcohol Stud Drug Depend.</i> 1987; 22(3): 211-23.	1973-1985		
Japan	World Health Organization (WHO). Mental Illness in General Health Care: An International Study. Geneva, Switzerland: World Health Organization (WHO), 1995.	1991-1992		
Japan	Hozawa A, Ohmori K, Kuriyama S, Shimazu T, Niu K, Watando A, Ebihara S, Matsui T, Ichiki M, Nagatomi R, Sasaki H, Tsuji I. C-reactive protein and peripheral artery disease among Japanese elderly: the Tsurugaya Project. <i>Hypertens Res.</i> 2004; 27(12): 955-61.	2004		
Japan	Kumakawa T, Suzuki S, Fujii H, Miwa S. Frequency of glucose 6-phosphate dehydrogenase (G6PD) deficiency in Tokyo and a new variant: G6PD Musashino. <i>J Jpn Haematol Soc.</i> 1987; 50(1): 25-8.	1984-1985	*	
Japan	Kitahora T, Utsunomiya T, Yokota A. Epidemiological study of ulcerative colitis in Japan: incidence and familial occurrence. The Epidemiology Group of the Research Committee of Inflammatory Bowel Disease in Japan. <i>J Gastroenterol.</i> 1995; 5-8.	1980, 1985		
Japan	Morita N, Toki S, Hirohashi T, Minoda T, Ogawa K, Kono S, Tamakoshi A, Ohno Y, Sawada T, Muto T. Incidence and prevalence of inflammatory bowel disease in Japan: nationwide epidemiological survey during the year 1991. <i>J Gastroenterol.</i> 1995; 1-4.	1991		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Japan	Akahoshi H, Taura N, Ichikawa T, Miyaaki H, Akiyama M, Miura S, Ozawa E, Takeshita S, Muraoka T, Matsuzaki T, Ohtani M, Isomoto H, Matsumoto T, Takeshima F, Nakao K. Differences in prognostic factors according to viral status in patients with hepatocellular carcinoma. <i>Oncol Rep.</i> 2010; 23(5): 1317-23.	1982-2007	*	
Japan	Taura N, Fukushima N, Yasutahashi H, Takami Y, Seike M, Watanabe H, Mizuta T, Sasaki Y, Nagata K, Tabara A, Komorizono Y, Taketomi A, Matsumoto S, Tamai T, Muro T, Nakao K, Fukuzumi K, Maeshiro T, Inoue O, Sata M. The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area. <i>Med Sci Monit.</i> 2011; 17(2): PH7-11.	1996-2007	*	
Japan	Noguchi A, Hayashi J, Nakashima K, Ikematsu H, Hirata M, Kashiwagi S. Decrease of hepatitis A and B virus infections in the population of Okinawa, Japan. <i>J Infect.</i> 1991; 23(3): 255-62.	1980, 1988		
Japan	Furusyo N, Hayashi J, Sawayama Y, Kawakami Y, Kishihara Y, Kashiwagi S. The elimination of hepatitis B virus infection: changing seroepidemiology of hepatitis A and B virus infection in Okinawa, Japan over a 26-year period. <i>Am J Trop Med Hyg.</i> 1998; 59(5): 693-8.	1970, 1988, 1996		
Japan	Taylor-Wiedeman J, Moritsugu Y, Miyamura K, Yamazaki S. Seroepidemiology of hepatitis A virus in Japan. <i>Jpn J Med Sci Biol.</i> 1987; 40(3): 119-30.	1973, 1984		
Japan	Fujisawa T, Kumagai T, Akamatsu T, Kiyosawa K, Matsunaga Y. Changes in seroepidemiological pattern of <i>Helicobacter pylori</i> and hepatitis A virus over the last 20 years in Japan. <i>Am J Gastroenterol.</i> 1999; 94(8): 2094-9.	1974, 1984, 1994		
Japan	Ikematsu H, Kashiwagi S, Hayashi J, Nomura H, Kajiyama W, Tani S, Urugari Y, Goto M. A seroepidemiologic study of hepatitis A virus infections: statistical analysis of two independent cross-sectional surveys in Okinawa, Japan. <i>Am J Epidemiol.</i> 1987; 126(1): 50-4.	1968-1973, 1980-1981		
Japan	Kashiwagi S, Hayashi J, Ikematsu H, Nomura H, Kajiyama W, Ikematsu W, Shingu T, Hayashida K, Kaji M. Prevalence of immunologic markers of hepatitis A and B infection in hospital personnel in Miyazaki Prefecture, Japan. <i>Am J Epidemiol.</i> 1985; 122(6): 960-9.	1980-1983		
Japan	Ichida F, Suzuki S, Furuta S, Takahashi Y, Yamamoto M, Tanaka M, Yano M. Age specific prevalence of anti HA in Japan—from multi-institutional analysis. <i>Gastroenterol Jpn.</i> 1981; 16(4): 384-8.	1981		
Japan	Fujiyama S, Odoh K, Kuramoto I, Mizuno K, Tsurusaki R, Sato T. Current seroepidemiological status of hepatitis A with a comparison of antibody titers after infection and vaccination. <i>J Hepatol.</i> 1994; 21(4): 641-5.	1982, 1991		
Japan	Malaty HM, Tanaka E, Kumagai T, Ota H, Kiyosawa K, Graham DY, Katsuyama T. Seroepidemiology of <i>Helicobacter pylori</i> and hepatitis A virus and the mode of transmission of infection: a 9-year cohort study in rural Japan. <i>Clin Infect Dis.</i> 2003; 37(8): 1067-72.	1986		
Japan	Kiyosawa K, Oofusa H, Saitoh H, Sodeyama T, Tanaka E, Furuta S, Itoh S, Ogata H, Kobuchi H, Kameko M. Seroepidemiology of hepatitis A, B, and D viruses and human T-lymphocyte tropic viruses in Japanese drug abusers. <i>J Med Virol.</i> 1989; 29(3): 160-3.	1988		
Japan	Akbar SM, Onji M, Kanaoka M, Horiike N, Michtaka K, Masumoto T, Nonaka T, Kanda K, Kajino K, Kumamoto I. The seroepidemiology of hepatitis A and B in a Japanese town. <i>Asia Pac J Public Health.</i> 1992; 6(2): 26-9.	1989-1990		
Japan	Kiyohara T, Satoh T, Yamamoto H, Totsuka A, Moritsugu Y. The latest seroepidemiological pattern of hepatitis A in Japan. <i>Jpn J Med Sci Biol.</i> 1997; 50(3): 123-31.	1994		
Japan	Furuta T, Kamata T, Takashima M, Futami H, Arai H, Hanai H, Kaneko E. Study of transmission routes of <i>Helicobacter pylori</i> in relation to seroprevalence of hepatitis A virus. <i>J Clin Microbiol.</i> 1997; 35(7): 1891-3.	1996		
Japan	Nishise Y, Fukao A, Takahashi T. Risk factors for <i>Helicobacter pylori</i> infection among a rural population in Japan: relation to living environment and medical history. <i>J Epidemiol.</i> 2003; 13(5): 266-73.	2000-2001		
Japan	Kiyohara T, Sato T, Totsuka A, Miyamura T, Ito T, Yoneyama T. Shifting seroepidemiology of hepatitis A in Japan, 1973-2003. <i>Microbiol Immunol.</i> 2007; 51(2): 185-91.	2003		
Japan	Mitsui T, Tsukamoto Y, Hirose A, Suzuki S, Yamazaki C, Masuko K, Tsuda F, Endo K, Takahashi M, Okamoto H. Distinct changing profiles of hepatitis A and E virus infection among patients with acute hepatitis, patients on maintenance hemodialysis and healthy individuals in Japan. <i>J Med Virol.</i> 2006; 78(8): 1015-24.	2004		
Japan	Baba S, Iso H, Mannami T, Sasaki S, Okada K, Konishi M. Cigarette smoking and risk of coronary heart disease incidence among middle-aged Japanese men and women: the JPHC Study Cohort I. <i>Eur J Cardiovasc Prev Rehabil.</i> 2006; 13(2): 207-13.	1990-2001		
Japan	Fukuyama K, Kimura Y, Wakugami K, Muratani H. Incidence and long-term prognosis of initial stroke and acute myocardial infarction in Okinawa, Japan. <i>Hypertens Res.</i> 2000; 23(2): 127-35.	1988-1990		
Japan	Ishikawa S, Kayaba K, Gotoh T, Nago N, Nakamura Y, Tsutsumi A, Kajii E. Incidence of Total Stroke, Stroke Subtypes, and Myocardial Infarction in the Japanese Population: The JMS Cohort Study. <i>J Epidemiol.</i> 2008; 18(4): 144-50.	1992-2005		
Japan	Kitamura A, Sato S, Kiyama M, Imano H, Iso H, Okada T, Ohira T, Tanigawa T, Yamagishi K, Nakamura M, Konishi M, Shimamoto T, Iida M, Komachi Y. Trends in the Incidence of Coronary Heart Disease and Stroke and Their Risk Factors in Japan, 1964 to 2003: The Akita-Osaka Study. <i>J Am Coll Cardiol.</i> 2008; 52(1): 71-9.	1988-2003		
Japan	Yoshida M, Kita Y, Nakamura Y, Nozaki A, Okayama A, Sugihara H, Kasamatsu T, Hirose K, Kinoshita M, Ueshima H. Incidence of acute myocardial infarction in Takashima, Shiga, Japan. <i>Circ J.</i> 2005; 69(4): 404-8.	1988-1998		
Japan	Asakura T, Tachibana K, Watanabe S, Teshima D, Ikeda M, Tokudome S. Concomitant carriage of hepatitis B virus and human T-lymphotropic virus type I among blood donors in Kitakyushu, Japan. <i>J Infect.</i> 1991; 23(1): 33-7.	1988		
Japan	Fukuizumi K, Sata M, Suzuki H, Nakano H, Tanikawa K. Hepatitis C virus seroconversion rate in a hyperendemic area of HCV in Japan: a prospective study. <i>Scand J Infect Dis.</i> 1997; 29(4): 345-7.	1990, 1995		
Japan	Furusyo N, Hayashi J, Ariyama I, Sawayama Y, Etoh Y, Kashiwagi S. Lower hepatitis G virus infection prevalence compared to hepatitis B and C virus infection prevalences. <i>Dig Dis Sci.</i> 2000; 45(1): 188-95.	1996		
Japan	Goto K, Ito K, Sugiura T, Ando T, Mizutani F, Miyake Y, Kawabe Y, Sugiyama K, Togari H. Prevalence of hepatitis E virus infection in Japanese children. <i>J Pediatr Gastroenterol Nutr.</i> 2006; 42(1): 89-92.	1992-2003		
Japan	Hayashi J, Yoshimura E, Nabeshima A, Kishihara Y, Ikematsu H, Hirata M, Maeda Y, Kashiwagi S. Seroepidemiology of hepatitis C virus infection in hemodialysis patients and the general population in Fukuoka and Okinawa, Japan. <i>J Gastroenterol.</i> 1994; 29(3): 276-81.	1992		
Japan	Ishi K, Suzuki F, Saito A, Yoshimoto S, Kubota T. Prevalence of human immunodeficiency virus, hepatitis B and hepatitis C virus antibodies and hepatitis B antigen among commercial sex workers in Japan. <i>Infect Dis Obstet Gynecol.</i> 2001; 9(4): 215-9.	1999, 2001		
Japan	Ishizaka N, Ishizaka Y, Takahashi E, Tooda E, Hashimoto H, Nagai R, Yamakado M. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. <i>Lancet.</i> 2002; 359(9301): 133-5.	1994-2000		
Japan	Ito S, Ito M, Cho MJ, Shimotohno K, Tajima K. Massive sero-epidemiological survey of hepatitis C virus: clustering of carriers on the southwest coast of Tsushima, Japan. <i>Jpn J Cancer Res.</i> 1991; 82(1): 1-3.	1989		
Japan	Kashiwagi S, Hayashi J, Nomura H, Kajiyama W, Ikematsu H, Noguchi A. Changing pattern of intrafamilial transmission of hepatitis B virus in Okinawa, Japan. <i>Am J Epidemiol.</i> 1988; 127(4): 783-7.	1980, 1985		
Japan	Kitano M, Sakaguchi K, Miyashita M, Mouri H, Senoh T, Nishimura M, Ohta T, Fujio K, Shimomura H, Tsuji T. Prevalence of hepatitis G virus (HGV) infection in an endemic area of hepatitis C virus (HCV) infection. <i>Hepatogastroenterology.</i> 2000; 47(35): 1340-2.	1996		
Japan	Koyama T, Tsuda F, Ishikawa K, Oishi H, Tazawa M, Yoshizawa H, Sato S, Okamoto H. Antibodies to hepatitis C virus and elevated transaminase levels in a town of hyperendemicity in Iwate, Japan. <i>J Gastroenterol Hepatol.</i> 1997; 12(1): 67-72.	1992		
Japan	Maeda Y, Matsushita K, Tokudome S, Tsuji N, Ikeda M, Fujii M. Time trends of HBsAg prevalence among blood donors in Fukuoka, Japan. <i>Eur J Epidemiol.</i> 1992; 8(1): 88-92.	1977, 1980, 1983, 1986, 1988		
Japan	Matsuo A, Kusumoto Y, Ohtsuka E, Ohtsuru A, Nakamura Y, Tajima H, Shima M, Nakata K, Muro T, Satoh A. Changes in HBsAg carrier rate in Goto Islands, Nagasaki Prefecture, Japan. <i>Lancet.</i> 1990; 335(8695): 955-7.	1968-1985		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Japan	Nakashima K, Kashiwagi S, Hayashi J, Noguchi A, Hirata M, Kajiyama W, Urabe K, Minami K, Maeda Y. Sexual transmission of hepatitis C virus among female prostitutes and patients with sexually transmitted diseases in Fukuoka, Kyushu, Japan. <i>Am J Epidemiol.</i> 1992; 136(9): 1132-7.	1989		
Japan	Nishioka K. Hepatitis C virus infection in Japan. <i>Gastroenterol Jpn.</i> 1991; 152-5.	1989-1990		
Japan	Ochi S, Onji M, Shiraiishi K, Ohtu K, Akao T, Yano Y, Takei N, Matsui H, Ohta Y, Umeda M. Prevalence of hepatitis C virus antibody in an area endemic for hepatitis B virus and human T cell leukaemia virus. <i>J Gastroenterol Hepatol.</i> 1991; 6(6): 599-602.	1990		
Japan	Ohshima S, Komatsu M, Nakane K, Meng XW, Goto T, Fujii T, Yoneyama K, Wada Y, Tabori F, Mukaide M, Masamune O, Watanabe S. Iatrogenic GB virus C/hepatitis G virus infection in an area endemic for hepatitis C virus. <i>J Hosp Infect.</i> 2000; 44(3): 179-85.	1996		
Japan	Okamoto M, Nagata I, Murakami J, Kaji S, Iitsuka T, Hoshika T, Matsuda R, Tazawa Y, Shiraki K, Hino S. Prospective reevaluation of risk factors in mother-to-child transmission of hepatitis C virus: high virus load, vaginal delivery, and negative anti-NS4 antibody. <i>J Infect Dis.</i> 2000; 182(5): 1511-4.	1992-1998		
Japan	Sakugawa H, Nakasone H, Shokita H, Kawakami Y, Nakachi N, Adaniya H, Mizushima T, Nakayoshi T, Kinjo F, Saito A, Taira M, Takaesu H, Onga N. Seroepidemiological study on hepatitis delta virus infection in the Iriabu Islands, Okinawa, Japan. <i>J Gastroenterol Hepatol.</i> 1997; 12(4): 299-304.	1994-1995		
Japan	Sata M, Nakano H, Suzuki H, Noguchi S, Yamakawa Y, Tanaka E, Fukuzumi K, Tanaka K, Yoshida H, Tanikawa K. Sero-epidemiologic study of hepatitis C virus infection in Fukuoka, Japan. <i>J Gastroenterol.</i> 1998; 33(2): 218-22.	1990		
Japan	Sugauchi F, Mizokami M, Orito E, Ohno T, Kato H, Maki M, Suzuki H, Ojika K, Ueda R. Hepatitis B virus infection among residents of a nursing home for the elderly: seroepidemiological study and molecular evolutionary analysis. <i>J Med Virol.</i> 2000; 62(4): 456-62.	1999		
Japan	Tanaka E, Kiyosawa K, Sodeyama T, Hayata T, Ohike Y, Nakano Y, Yoshizawa K, Furuta S, Watanabe Y, Watanabe J, Nishioka K. Prevalence of antibody to hepatitis C virus in Japanese schoolchildren: comparison with adult blood donors. <i>Am J Trop Med Hyg.</i> 1992; 46(4): 460-4.	1986-1990		
Japan	Tanaka E, Matsumoto A, Takeda N, Li T-C, Umemura T, Yoshizawa K, Miyakawa Y, Miyamura T, Kiyosawa K. Age-specific antibody to hepatitis E virus has remained constant during the past 20 years in Japan. <i>J Viral Hepat.</i> 2005; 12(4): 439-42.	1974, 1984, 1994		
Japan	Tanaka J, Kumagai J, Katayama K, Komiya Y, Mizui M, Yamanaoka R, Suzuki K, Miyakawa Y, Yoshizawa H. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. <i>Intervirology.</i> 2004; 47(1): 32-40.	1995-2000		
Japan	Taniguchi M, Kim SR, Mishiro S, Takahashi K, Shin MH, Yun H, Park MS, Li ZM, Kim MK, Fang J, Hayashi Y. Epidemiology of hepatitis E in Northeastern China, South Korea and Japan. <i>J Infect.</i> 2009; 58(3): 232-7.	2005-2008		
Japan	Teragaki M, Nishiguchi S, Takeuchi K, Yoshiyama M, Akioka K, Yoshikawa J. Prevalence of hepatitis C virus infection among patients with hypertrophic cardiomyopathy. <i>Heart Vessels.</i> 2003; 18(4): 167-70.	1995-2000		
Japan	Yoshida K, Nakano H, Yoshitomi F, Oshika T. Prevalence of seropositivity for hepatitis C virus in cataract patients and the general population. <i>J Cataract Refract Surg.</i> 2002; 28(10): 1789-92.	1996-1999		
Japan	Itabashi K, Horuchi T, Kusuda S, Kabe K, Itani Y, Nakamura T, Fujimura M, Matsuo M. Mortality rates for extremely low birth weight infants born in Japan in 2005. <i>Pediatrics.</i> 2009; 123(2): 445-50.	2005		†
Japan	Food and Agriculture Organization of the United Nations (FAO), World Health Organization (WHO). Joint WHO/FAO Workshop on Foodborne Trematode Infections in Asia. WHO Regional Office for the Western Pacific, 2004.	2004	*	
Japan	U.S. Renal Data System. USRDS 1998 Annual Data Report. Bethesda (MD), United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 1998.	1995-1996		
Japan	United States Renal Data System Coordinating Center. USRDS 1997 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 1997.	1994		
Japan	U.S. Renal Data System. USRDS 1996 Annual Data Report. Bethesda (MD), United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 1996.	1992-1993		
Japan	U.S. Renal Data System. USRDS 1994 Annual Data Report. Bethesda (MD), United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 1994.	1989-1991		
Japan	Shiba M, Shimogaito J, Kose A, Fujuchi S, Nishiyama H, Yoshimasu F, Asai T, Rocca WA. Prevalence of dementia in the rural village of Hanazono-mura, Japan. <i>Neuroepidemiology.</i> 1999; 18(1): 32-6.	1992-1995		
Japan	Ueda K, Kawano H, Hasuo Y, Fujishima M. Prevalence and etiology of dementia in a Japanese community. <i>Stroke.</i> 1992; 23(6): 798-803.	1985		
Japan	Nakamura Y, Tomidokoro A, Sawaguchi S, Sakai H, Iwase A, Araie M. Prevalence and causes of low vision and blindness in a rural Southwest Island of Japan: the Kumejima study. <i>Ophthalmology.</i> 2010; 117(12): 2315-21.	2005-2006	*	
Japan	Fukushima K, Mimaki N, Fukuda S, Nishizaki K. Pilot study of universal newborn hearing screening in Japan: district-based screening program in Okayama. <i>Ann Otol Rhinol Laryngol.</i> 2008; 117(3): 166-71.	2001-2004	*	
Japan	Yasui T, Iguchi M, Suzuki S, Kohri K. Prevalence and epidemiological characteristics of urolithiasis in Japan: national trends between 1965 and 2005. <i>Urology.</i> 2008; 71(2): 209-13.	2005	*	
Japan	Japan Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Japan	Japan Association of Obstetricians and Gynaecologists Congenital Anomaly Data 2001 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
Japan	Japan Association of Obstetricians and Gynaecologists Congenital Anomaly Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
Japan	Japan Association of Obstetricians and Gynaecologists Congenital Anomaly Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Japan	Japan Association of Obstetricians and Gynaecologists Congenital Anomaly Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
Japan	Japan Association of Obstetricians and Gynaecologists Congenital Anomaly Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Japan	Japan - Tokyo Area Birth Defects Monitoring Programs Data 1980 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1980	*	
Japan	Japan - Tokyo Area Birth Defects Monitoring Programs Data 1983 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1983	*	
Japan	Japan - Tokyo Area Birth Defects Monitoring Programs Data 1986 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1986	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Japan	Japan - Tokyo Area Birth Defects Monitoring Programs Data 1981 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1981	*	
Japan	Japan - Tokyo Area Birth Defects Monitoring Programs Data 1987 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1987	*	
Japan	Japan Association of Obstetricians and Gynaecologists Congenital Anomaly Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
Japan	Japan Association of Obstetricians and Gynaecologists Congenital Anomaly Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Japan	Japan - Tokyo Area Birth Defects Monitoring Programs Data 1988 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1988	*	
Japan	Japan - Tokyo Area Birth Defects Monitoring Programs Data 1984 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1984	*	
Japan	Japan - Tokyo Area Birth Defects Monitoring Programs Data 1985 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1985	*	
Japan	Japan Association of Obstetricians and Gynaecologists Congenital Anomaly Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
Japan	Japan - Tokyo Area Birth Defects Monitoring Programs Data 1982 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1982	*	
Japan	Japan Association for Maternal Welfare Congenital Anomaly Data 1980 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1980	*	
Japan	Japan Association for Maternal Welfare Congenital Anomaly Data 1981 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1981	*	
Japan	Japan Association for Maternal Welfare Congenital Anomaly Data 1982 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1982	*	
Japan	Japan Association for Maternal Welfare Congenital Anomaly Data 1983 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1983	*	
Japan	Japan Association for Maternal Welfare Congenital Anomaly Data 1984 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1984	*	
Japan	Japan Association for Maternal Welfare Congenital Anomaly Data 1985 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1985	*	
Japan	Japan Association for Maternal Welfare Congenital Anomaly Data 1986 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1986	*	
Japan	Japan Association for Maternal Welfare Congenital Anomaly Data 1987 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1987	*	
Japan	Japan Association for Maternal Welfare Congenital Anomaly Data 1988 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1988	*	
Jordan	Department of Statistics (Jordan), Macro International, Inc.; Insitute for Resource Development, Ministry of Planning (Jordan). Jordan Demographic and Health Survey 1990. Calverton, United States: Macro International, Inc.	1990		†
Jordan	Department of Statistics (Jordan), Macro International, Inc. Jordan Demographic and Health Survey 1997. Calverton, United States: Macro International, Inc.	1997		†
Jordan	Department of Statistics (Jordan), Macro International, Inc. Jordan Demographic and Health Survey 2002. Calverton, United States: Macro International, Inc.	2002		†
Jordan	Department of Statistics (Jordan), Macro International, Inc. Jordan Demographic and Health Survey 2007. Calverton, United States: Macro International, Inc.	2007		†
Jordan	Department of Statistics (Jordan), ICF Macro. Jordan Interim Demographic and Health Survey 2009. Calverton, United States: ICF Macro, 2010.	2009		†
Jordan	Centers for Disease Control and Prevention (CDC), Ministry of Health (Jordan), World Health Organization (WHO). Jordan STEPS Noncommunicable Disease Risk Factors Survey 2007.	2007		
Jordan	Department of Statistics (Jordan), ICF International. Jordan Demographic and Health Survey 2012. Fairfax, United States: ICF International, 2013.	2012	*	†
Jordan	Battikhi MNG. Epidemiological study on Jordanian patients suffering from diarrhoea. New Microbiol. 2002; 25(4): 405-12.	1997-2000		
Jordan	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Jordan	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Jordan	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998, 2000-2003, 2005-2009		
Jordan	Najim Al-Din AS, Kundi A, Mubaidin A, El-Khateeb M, Khalil RW, Wriekat AL. Epidemiology of multiple sclerosis in Arabs in Jordan: a comparative study between Jordanians and Palestinians. J Neurol Sci. 1996; 135(2): 162-7.	1993		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Jordan	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	2001		
Jordan	Jbour AS, Jarrah NS, Radaideh AM, Shegem NS, Bader IM, Batiha AM, Ajlouni KM. Prevalence and predictors of diabetic foot syndrome in type 2 diabetes mellitus in Jordan. <i>Saudi Med J</i> . 2003; 24(7): 761-4.	2001		
Jordan	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Jordan	Sayegh A, Dini EL, Holt RD, Bedi R. Caries in preschool children in Amman, Jordan and the relationship to socio-demographic factors. <i>Int Dent J</i> . 2002; 52(2): 87-93.	2000		
Jordan	Rajab LD, Hamdan MAM. Early childhood caries and risk factors in Jordan. <i>Community Dent Health</i> . 2002; 19(4): 224-9.	2001		
Jordan	Al-Qutob R. Menopause-associated problems: types and magnitude. A study in the Ain Al-Basha area, Jordan. <i>J Adv Nurs</i> . 2001; 33(5): 613-20.	1997		
Jordan	Mahafzah AM, Al-Ramahi MQ, Asa'd AM, El-Khateeb MS. Prevalence of sexually transmitted infections among sexually active Jordanian females. <i>Sex Transm Dis</i> . 2008; 35(6): 607-10.	2003-2005		
Jordan	Batiha A, Abdallah S, Maghaireh M, Awad Z, Al-Akash N, Batieneh A, Ajlouni KA. Epidemiology and cost of haemodialysis in Jordan. <i>East Mediterr Health J</i> . 2007; 13(3): 654-63.	2003		
Jordan	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Jordan	Jambart S, Ammache Z, Haddad F, Younes A, Hassoun A, Abdalla K, Selwan CA, Sunna N, Wajsbrot D, Youseif E. Prevalence of painful diabetic peripheral neuropathy among patients with diabetes mellitus in the Middle East region. <i>J Int Med Res</i> . 2011; 39(2): 366-77.	2009		
Jordan	Jammal H, Khader Y, Alkhatib S, Abujbara M, Alomari M, Ajlouni K. Diabetic retinopathy in patients with newly diagnosed type 2 diabetes mellitus in Jordan: prevalence and associated factors. <i>J Diabetes</i> . 2013; 5(2): 172-9.	2009-2011		
Jordan	Ajlouni K, Qusous Y, Khawaldeh AK, Jaddou H, Batiyah A, Ammari F, Zaheri M, Mashal A. Incidence of insulin-dependent diabetes mellitus in Jordanian children aged 0-14 y during 1992-1996. <i>Acta Paediatr Suppl</i> . 1999; 88(427): 11-3.	1992-1996		
Jordan	Mousa TY, Al-Domi HA, Mashal RH, Jibril MA-K. Eating disturbances among adolescent schoolgirls in Jordan. <i>Appetite</i> . 2010; 54(1): 196-201.	2008	*	
Jordan	Karadsheh NS. Pyruvate kinase (PK) deficiency in Jordan. <i>Haematologica</i> . 1993; 78(2): 80-3.	1983-1985		
Jordan	Usanga EA, Ameen R. Glucose-6-phosphate dehydrogenase deficiency in Kuwait, Syria, Egypt, Iran, Jordan and Lebanon. <i>Hum Hered</i> . 2000; 50(3): 158-61.	1996-1997		
Jordan	Karadsheh NS, Moses L, Ismail SI, Devaney JM, Hoffman E. Molecular heterogeneity of glucose-6-phosphate dehydrogenase deficiency in Jordan. <i>Haematologica</i> . 2005; 90(12): 1693-4.	2003-2005		
Jordan	Jordan Cancer Registry, Middle East Cancer Consortium, National Cancer Institute (United States). Jordan Cancer Incidence Report 2006. Amman, Jordan: Ministry of Health (Jordan).	2006	*	
Jordan	Jordan Cancer Registry, Middle East Cancer Consortium, National Cancer Institute (United States). Jordan Cancer Incidence Report 2003. Amman, Jordan: Ministry of Health (Jordan).	2003	*	
Jordan	Jordan Cancer Registry, Middle East Cancer Consortium, National Cancer Institute (United States). Jordan Cancer Incidence Report 2008. Amman, Jordan: Ministry of Health (Jordan).	2008	*	
Jordan	Jordan Cancer Registry, Middle East Cancer Consortium, National Cancer Institute (United States). Jordan Cancer Incidence Report 2007. Amman, Jordan: Ministry of Health (Jordan).	2007	*	
Jordan	Jordan Cancer Registry, Middle East Cancer Consortium, National Cancer Institute (United States). Jordan Cancer Incidence Report 2005. Amman, Jordan: Ministry of Health (Jordan).	2005	*	
Jordan	Jordan Cancer Registry, Middle East Cancer Consortium, National Cancer Institute (United States). Jordan Cancer Incidence Report 2004. Amman, Jordan: Ministry of Health (Jordan).	2004	*	
Jordan	Jordan Cancer Registry, Middle East Cancer Consortium, National Cancer Institute (United States). Jordan Cancer Incidence Report 2002. Amman, Jordan: Ministry of Health (Jordan).	2002	*	
Jordan	Jordan Cancer Registry, Middle East Cancer Consortium, National Cancer Institute (United States). Jordan Cancer Incidence Report 2001. Amman, Jordan: Ministry of Health (Jordan).	2001	*	
Jordan	Taani DSMQ. Oral health in Jordan. <i>Int Dent J</i> . 2004; 54(6 Suppl 1): 395-400.	2002		
Jordan	Alrefai A, Hababih M, Alkhwajjah M, Darwish M, Batayha W, Khader Y, El-Salem K. Prevalence of Parkinson's disease in Northern Jordan. <i>Clin Neurol Neurosurg</i> . 2009; 111(10): 812-5.	2007-2008	*	
Jordan	World Health Organization (WHO). Jordan WHO Leishmaniasis Country Profile.	1994-2010	*	
Jordan	Jordan Study of Iodine Deficiency 1993 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1993		
Jordan	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec</i> . 2007; 82(25): 225-32.	2006	*	
Jordan	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec</i> . 2009; 84(33): 333-40.	2008	*	
Jordan	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec</i> . 2010; 85(35): 337-48.	2009	*	
Jordan	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec</i> . 2012; 87(34): 317-28.	2011	*	
Jordan	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec</i> . 2008; 83(33): 293-300.	2007	*	
Jordan	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec</i> . 2013; 88(35): 365-79.	2012	*	
Jordan	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec</i> . 2011; 86(36): 389-99.	2010	*	
Jordan	Jordan Child Iodine Deficiency Survey 2000 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2000		
Jordan	Abuharfeil N, Meqdam MM. Seroepidemiologic study of herpes simplex virus type 2 and cytomegalovirus among young adults in northern Jordan. <i>New Microbiol</i> . 2000; 23(3): 235-9.	1997-1999	*	
Jordan	Al-Ramahi M, Mahafzah A, Saleh S, Fram K. Prevalence of Chlamydia trachomatis infection in infertile women at a university hospital in Jordan. <i>East Mediterr Health J</i> . 2008; 14(5): 1148-54.	2004-2005	*	
Jordan	Awwad ZM, Al-Amarat AA, Shehabi AA. Prevalence of genital chlamydial infection in symptomatic and asymptomatic Jordanian patients. <i>Int J Infect Dis</i> . 2003; 7(3): 206-9.	2000	*	
Jordan	Ministry of Health (Jordan). Prevalence of Reproductive Tract Infections in Women Attending Selected Urban OB/GYN Clinics. Amman, Jordan: Ministry of Health (Jordan), 2004.	2003		
Jordan	Khuri-Bulos N. Diphtheria in Jordan: a diminishing yet important paediatric disease. <i>J Trop Med Hyg</i> . 1980; 83(2): 79-83.	1977-1978		
Jordan	Khuri-Bulos N, Hamzah Y, Sammerrai SM, Shehabi A, Hamed R, Arnaout MA, Turk J, Qubain H. The changing epidemiology of diphtheria in Jordan. <i>Bull World Health Organ</i> . 1988; 66(1): 65-8.	1982-1983		
Jordan	Daoud AS, al-Sheyyab M, Batchoan RG, Rawashdeh MO, Nussair MM, Pugh RN. Bacterial meningitis: still a cause of high mortality and severe neurological morbidity in childhood. <i>J Trop Pediatr</i> . 1995; 41(5): 308-10.	1990-1992		†
Jordan	Daoud AS, al-Sheyyab M, Abu-Ekteish F, Obeidat A, Ali AA, el-Shanti H. Neonatal meningitis in northern Jordan. <i>J Trop Pediatr</i> . 1996; 42(5): 267-70.	1992-1994		
Jordan	Gijwani D, Kunhar MR, Singh VB, Chadda VS, Soni PK, Nayak KC, Gupta BK. Dexamethasone therapy for bacterial meningitis in adults: a double blind placebo control study. <i>Neuro India</i> . 2002; 50(1): 63-7.	1998-1999		
Jordan	Daoud AS, Batiha A, Al-Sheyyab M, Abuekteish F, Obeidat A, Mahafza T. Lack of effectiveness of dexamethasone in neonatal bacterial meningitis. <i>Eur J Pediatr</i> . 1999; 158(3): 230-3.	1993-1995		†
Jordan	El-Migdadi F, Al-Tellawi A, Al-Hussain S, Rawashdeh M. Pyruvate kinase and glucose-6-phosphate dehydrogenase activities in children living above (Jordan Valley) and below (Amman and Irbid) sea level. <i>J Chin Clin Med</i> . 2008; 3(11): 627-32.	2000-2005	*	
Jordan	Talafih K, Hunaiti AA, Gharaibeh N, Gharaibeh M, Jaradat S. The prevalence of hemoglobin S and glucose-6-phosphate dehydrogenase deficiency in Jordanian newborn. <i>J Obstet Gynaecol Res</i> . 1996; 22(5): 417-20.	1993-1995	*	
Jordan	Madanat F, Karadsheh N, Shamayleh A, Tarawneh M, Khraisha S, Bata M, Tawil K. Glucose-6-phosphate dehydrogenase deficiency in male newborns. <i>Jordan Med J</i> . 1986; 21(2): 205-12.	1984	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Jordan	Toukan AU, Sharaiha ZK, Abu-el -Rob OA, Hmoud MK, Dahbour SS, Abu-Hassan H, Yacoub SM, Margolis HS. The seroepidemiology of hepatitis A virus infection in Jordan. <i>Trop Gastroenterol.</i> 1988; 9(2): 76-9.	1987		
Jordan	Jbara I, Abu Atshiekh NK, Almomani AM, Khasawneh RH, Omari AK. Prevalence of Hepatitis C Virus Antibodies among Blood Donors at Prince Hashem Hospital, Zarka - Jordan. <i>Jordan Med J.</i> 2006; 40(3): 190-3.	2003-2005		
Jordan	Toukan AU, Sharaiha ZK, Abu-el -Rub OA, Hmoud MK, Dahbour SS, Abu-Hassan H, Yacoub SM, Hadler SC, Margolis HS, Coleman PJ. The epidemiology of hepatitis B virus among family members in the Middle East. <i>Am J Epidemiol.</i> 1990; 132(2): 220-32.	1985		
Jordan	Khoury S, Saliba EK, Oumeish OY, Tawfig MR. Epidemiology of cutaneous leishmaniasis in Jordan: 1983-1992. <i>Int J Dermatol.</i> 1996; 35(8): 566-9.	1983-1992		
Jordan	Al-Qutob R, Mawajdeh S, Massad D. Can a home-based pelvic examination be used in assessing reproductive morbidity in population-based studies? A Jordanian experience. <i>J Adv Nurs.</i> 2001; 33(5): 603-612.	1997	*	
Jordan	Jordan Vital Registration Birth Data 1979 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1979		
Kazakhstan	Agency of the Republic of Kazakhstan on Statistics and United Nations Children's Fund (UNICEF). Kazakhstan Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006	*	†
Kazakhstan	Macro International, Inc, National Institute of Nutrition (Kazakhstan). Kazakhstan Demographic and Health Survey 1995. Calverton, United States: Macro International, Inc.	1995		†
Kazakhstan	Academy of Preventive Medicine (Kazakhstan), Macro International, Inc. Kazakhstan Demographic and Health Survey 1999. Calverton, United States: Macro International, Inc.	1999		†
Kazakhstan	World Health Organization (WHO). Kazakhstan World Health Survey 2002-2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2002-2003		†
Kazakhstan	World Health Organization (WHO). Control of Foodborne Trematode Infections 1995. Geneva, Switzerland: World Health Organization (WHO), 1995.	1995	*	
Kazakhstan	Agency of the Republic of Kazakhstan on Statistics, United Nations Children's Fund (UNICEF). Kazakhstan Multiple Indicator Cluster Survey 2010-2011. New York, United States: United Nations Children's Fund (UNICEF), 2013.	2010-2011	*	†
Kazakhstan	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Kazakhstan	Tamendarova NC, Kumisbaeva ZN, Abenova UA. Use of the passive hemagglutination reaction for diagnosing rotavirus infections. <i>Vopr Virusol.</i> 1989; 34(4): 501-3.	1985-1986		
Kazakhstan	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1999, 2002-2009		
Kazakhstan	Shaikenov BS, Vaganov TF, Torgerson PR. Cystic echinococcosis in Kazakhstan: an emerging disease since independence from the Soviet Union. <i>Parasitol Today.</i> 1999; 15(5): 172-4.	1984-1997		
Kazakhstan	Torgerson PR, Oguljahan B, Muminov AE, Karaeva RR, Kuttubaev OT, Aminjanov M, Shaikenov B. Present situation of cystic echinococcosis in Central Asia. <i>Parasitol Int.</i> 2006; 55(1): S207-S212.	1994-2003		
Kazakhstan	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Kazakhstan	Latipov R, Utegenova E, Kuatbayeva A, Kasymbekova K, Abdylkarimov S, Juraev R, Ismailov U, FLEM E. Epidemiology and burden of rotavirus disease in Central Asia. <i>Int J Infect Dis.</i> 2011; 15(7): e464-469.	2005-2009	*	
Kazakhstan	Aimukhametova G, Ukybasova T, Hamidullina Z, Zhubanysheva K, Harun-Or-Rashid M, Yoshida Y, Kasuya H, Sakamoto J. The impact of maternal obesity on mother and neonatal health: study in a tertiary hospital of Astana, Kazakhstan. <i>Nagoya J Med Sci.</i> 2012; 74(1-2): 83-92.	2008	*	
Kazakhstan	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Kazakhstan	World Health Organization (WHO). Kazakhstan WHO Leishmaniasis Country Profile.	1994-2010	*	
Kazakhstan	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Kazakhstan	Nurgaliev ZZ, Malaty HM, Graham DY, Almuchambetova R, Machmudova A, Kapsultanova D, Osato MS, Hollinger FB, Zhabgalyov A. Helicobacter pylori infection in Kazakhstan: effect of water source and household hygiene. <i>Am J Trop Med Hyg.</i> 2002; 67(2): 201-6.	1999		
Kazakhstan	Victor JC, Surdina TY, Suleimeova SZ, Favorov MO, Bell BP, Monto AS. The increasing prominence of household transmission of hepatitis A in an area undergoing a shift in endemicity. <i>Epidemiol Infect.</i> 2006; 134(3): 492-7.	2001		
Kazakhstan	USSR - Kazakh SSR Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Kenya	Central Bureau of Statistics (Kenya), UK Department for International Development (DFID), United States Agency for International Development (USAID), European Union (EU), Danish International Development Agency (DANIDA), World Bank (WB), United Nations Development Programme (UNDP). Kenya Integrated Household Budget Survey 2005-2006. Nairobi, Kenya: Central Bureau of Statistics (Kenya).	2005-2006	*	†
Kenya	Central Bureau of Statistics (Kenya), United Nations Children's Fund (UNICEF). Kenya Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Kenya	United Nations Children's Fund (UNICEF), Kenya National Bureau of Statistics. Kenya - Eastern Province Multiple Indicator Cluster Survey 2008. New York, United States: United Nations Children's Fund (UNICEF).	2008	*	†
Kenya	Central Bureau of Statistics (Kenya), International Statistical Institute. Kenya World Fertility Survey 1977-1978. Voorburg, Netherlands: International Statistical Institute.	1977-1978		
Kenya	Macro Systems, Inc., Institute for Resource Development, National Council for Population Development (NCPD). Kenya Demographic and Health Survey 1988-1989. Columbia, United States: Macro Systems, Inc.	1988-1989		
Kenya	Central Bureau of Statistics (Kenya), Macro International, Inc, National Council for Population Development (NCPD). Kenya Demographic and Health Survey 1993. Calverton, United States: Macro International, Inc.	1993		†
Kenya	Central Bureau of Statistics (Kenya), Macro International, Inc, National Council for Population Development (NCPD). Kenya Demographic and Health Survey 1998. Calverton, United States: Macro International, Inc.	1998		†
Kenya	Centers for Disease Control and Prevention (CDC), Central Bureau of Statistics (Kenya), Macro International, Inc, Ministry of Health (Kenya), National Council for Population and Development (Kenya). Kenya Demographic and Health Survey 2003. Calverton, United States: Macro International, Inc.	2003		†
Kenya	ICF Macro, Kenya Medical Research Institute (KEMRI), Kenya National Bureau of Statistics, Ministry of Public Health and Sanitation (Kenya), National AIDS and STI Control Program (Kenya), National Aids Control Council (NACC), National Coordinating Agency for Population and Development (Kenya). Kenya Demographic and Health Survey 2008-2009. Calverton, United States: ICF Macro.	2008-2009		†
Kenya	World Health Organization (WHO). Kenya World Health Survey 2004. Geneva, Switzerland: World Health Organization (WHO), 2005.	2004		†
Kenya	Kenya National Bureau of Statistics, United Nations Children's Fund (UNICEF). Kenya - Mombasa Multiple Indicator Cluster Survey 2009.	2009	*	†
Kenya	Mirza NM, Caulfield LE, Black RE, Macharia WM. Risk factors for diarrheal duration. <i>Am J Epidemiol.</i> 1997; 146(9): 776-85.	1989-1990		
Kenya	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Kenya	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Kenya	Bustinduy AL, Parraga IM, Thomas C, Mungai PL, Mutuku F, Muchiri EM, Kitron U, King CH. Anemia, impaired growth and exercise intolerance in Kenyan children: the role of schistosomiasis and polyparasitism [Abstract]. In Abstract Book. American Society of Tropical Medicine and Hygiene 59th Annual Meeting; 2010 Nov 3-7; Atlanta, United States. Am J Trop Med Hyg. 2010; 83(Suppl 5): 318.	2008-2010		
Kenya	Corbett EL, Butterworth AE, Fulford AJ, Ouma JH, Sturrock RF. Nutritional status of children with schistosomiasis mansoni in two different areas of Machakos District, Kenya. Trans R Soc Trop Med Hyg. 1992; 86(3): 266-73.	1988		†
Kenya	Greenham R. Anaemia and Schistosoma haematobium infection in the North-Eastern Province of Kenya. Trans R Soc Trop Med Hyg. 1978; 72(1): 72-5.	1976		
Kenya	Latham MC, Stephenson LS, Hall A, Wolgemuth JC, Elliott TC, Crompton DW. A comparative study of the nutritional status, parasitic infections and health of male roadworkers in four areas of Kenya. Trans R Soc Trop Med Hyg. 1982; 76(6): 734-40.	1978-1980		
Kenya	Sturrock RF, Kariuki HC, Thiongo FW, Gachare JW, Omondi BG, Ouma JH, Mbugua G, Butterworth AE. Schistosomiasis mansoni in Kenya: relationship between infection and anaemia in schoolchildren at the community level. Trans R Soc Trop Med Hyg. 1996; 90(1): 48-54.	1989-1990		†
Kenya	Sturrock RF, Kariuki HC, Thiongo FW, Gachare JW, Omondi BG, Ouma JH, Mbugua G, Butterworth AE. Schistosomiasis mansoni in Kenya: relationship between infection and anaemia in schoolchildren at the community level. Trans R Soc Trop Med Hyg. 1996; 90(1): 48-54 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989-1990	*	†
Kenya	Ashford RW, Craig PS, Oppenheimer SJ. Polyparasitism on the Kenya coast. 1. Prevalence, and association between parasitic infections. Ann Trop Med Parasitol. 1992; 86(6): 671-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985-1986	*	
Kenya	Oyoo GO, Ogola EN. Clinical and socio demographic aspects of congestive heart failure patients at Kenyatta National Hospital, Nairobi. East Afr Med J. 1999; 76(1): 23-7.	1993		
Kenya	Gibbs S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int J Dermatol. 1996; 35(9): 633-9.	1994		
Kenya	Schmeller W, Dzikus A. Skin diseases in children in rural Kenya: long-term results of a dermatology project within the primary health care system. Br J Dermatol. 2001; 144(1): 118-24.	1993, 1999		
Kenya	Schmeller W, Baumgartner S, Dzikus A. Dermatophytomycoses in children in rural Kenya: the impact of primary health care. Mycoses. 1997; 40(1-2): 55-63.	1993, 1995		
Kenya	Menge I, Esamai F, van Reken D, Anabwani G. Paediatric morbidity and mortality at the Eldoret District Hospital, Kenya. East Afr Med J. 1995; 72(3): 165-9.	1991-1992		
Kenya	Mwaniki MK, Gataaka HW, Mturi FN, Chesaro CR, Chuma JM, Peshu NM, Mason L, Kager P, Marsh K, English M, Berkley JA, Newton CR. An increase in the burden of neonatal admissions to a rural district hospital in Kenya over 19 years. BMC Public Health. 2010; 10: 591.	1990-2008		†
Kenya	Hatcher J, Smith A, Mackenzie I, Thompson S, Bal I, Macharia I, Mugue P, Okoth-Olende C, Oburra H, Wanjohi Z. A prevalence study of ear problems in school children in Kiambu district, Kenya, May 1992. Int J Pediatr Otorhinolaryngol. 1995; 33(3): 197-205.	1992		
Kenya	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. J Allergy Clin Immunol. 2008; 121(4): 947-954.	1995, 2001		
Kenya	Schmeller MD W. Community health workers reduce skin diseases in East African children. Int J Dermatol. 1998; 37(5): 370-7.	1993, 1995		
Kenya	Tornheim J, Many A, Oyando N, Kabaka S, Breiman R, Feikin D. The epidemiology of hospitalized pneumonia in rural Kenya: the potential of surveillance data in setting public health priorities. Int J Infect Dis. 2007; 6(11): 536-43.	2001-2003		
Kenya	Wafula EM, Onyango FE, Mirza WM, Macharia WM, Wamola I, Ndiinya-Achola JO, Agwanda R, Waigwa RN, Musia J. Epidemiology of acute respiratory tract infections among young children in Kenya. Rev Infect Dis. 1990; 12(Suppl 8): S1035-8.	1987-1988, 2001-2003		†
Kenya	Moisi JC, Saha SK, Falade AG, Njanpop-Lafourcade B-M, Oundo J, Zaidi AKM, Afroj S, Bakare RA, Buss JK, Lasi R, Mueller J, Odekanmi AA, Sangare L, Scott JAG, Knoll MD, Levine OS, Gessner BD. Enhanced diagnosis of pneumococcal meningitis with use of the binax NOW immunochromatographic test of Streptococcus pneumoniae antigen: A multisite study. Clin Infect Dis. 2009; 48(Suppl 2): S49-S56.	2006-2007		
Kenya	Talbert AWA, Mwaniki M, Mwarumba S, Newton CRJC, Berkley JA. Invasive bacterial infections in neonates and young infants born outside hospital admitted to a rural hospital in Kenya. Pediatr Infect Dis J. 2010; 29(10): 945-9.	2001-2009		
Kenya	Mwenda JM, Noto KM, Abebe A, Enweronu-Laryea C, Amina I, Mchomvu J, Kisakye A, Mpabawani EM, Pazvakambwa I, Amah GE, Seheri LM, Kiulia NM, Page N, Widdowson M-A, Steele AD. Burden and epidemiology of rotavirus diarrhea in selected African countries: preliminary results from the African Rotavirus Surveillance Network. J Infect Dis. 2010; 202(Suppl): S5-11.	2006-2008		
Kenya	Aidoo M, Terlouw DJ, Kolczak MS, McElroy PD, ter Kuile FO, Kariuki S, Nahlen BL, Lal AA, Udhayakumar V. Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet. 2002; 359(9359): 1311-2.	1992-1994		
Kenya	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1992-1995		
Kenya	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1995-1998, 2000-2008		
Kenya	Sanders EJ, Tukey PM. Yellow fever: an emerging threat for Kenya and other east African countries. East Afr Med J. 1996; 73(1): 10-2.	1992-1993		
Kenya	Arap Siyogok TK, Mahmoud AA, Ouma JH, Warren KS, Muller AS, Handa AK, Houser HB. Morbidity in Schistosomiasis mansoni in relation to intensity of infection: study of a community in Machakos, Kenya. Am J Trop Med Hyg. 1976; 25(2): 273-84.	1974		†
Kenya	Latham MC, Stephenson LS, Hall A, Wolgemuth JC, Elliot TC, Crompton DW. Parasitic infections, anaemia and nutritional status: a study of their interrelationships and the effect of prophylaxis and treatment on workers in Kwale District, Kenya. Trans R Soc Trop Med Hyg. 1983; 77(1): 41-8.	1979		†
Kenya	Latham MC, Stephenson LS, Kurz KM, Kinoti SN. Metrifonate or praziquantel treatment improves physical fitness and appetite of Kenyan schoolboys with Schistosoma haematobium and hookworm infections. Am J Trop Med Hyg. 1990; 43(2): 170-9.	1986		
Kenya	Masaba SC, Awiti IE, Muruka JF. Morbidity in urinary schistosomiasis in relation to the intensity of infection in Kisumu, Kenya. J Trop Med Hyg. 1983; 86(2): 65-6.	1982-1983		†
Kenya	Smith DH, Warren KS, Mahmoud AA. Morbidity in schistosomiasis mansoni in relation to intensity of infection: study of a community in Kisumu, Kenya. Am J Trop Med Hyg. 1979; 28(2): 220-9.	1974		†
Kenya	Stephenson LS, Latham MC, Kurz KM, Kinoti SN, Oduori ML, Crompton DW. Relationships of Schistosoma haematobium, hookworm and malarial infections and metrifonate treatment to hemoglobin level in Kenyan school children. Am J Trop Med Hyg. 1985; 34(3): 519-28.	1981-1982		†
Kenya	Stephenson LS, Kinoti SN, Latham MC, Kurz KM, Kyobe J. Single dose metrifonate or praziquantel treatment in Kenyan children I Effects on Schistosoma haematobium, hookworm, hemoglobin levels, splenomegaly, and hepatomegaly. Am J Trop Med Hyg. 1989; 41(4): 436-44.	1986		
Kenya	Stephenson LS, Latham MC, Kurz KM, Miller D, Kinoti SN, Oduori ML. Urinary iron loss and physical fitness of Kenyan children with urinary schistosomiasis. Am J Trop Med Hyg. 1985; 34(2): 322-30.	1982		
Kenya	Warren KS, Mahmoud AA, Muruka JF, Whittaker LR, Ouma JH, Arap Siyogok TK. Schistosomiasis haematobia in coast province Kenya. Am J Trop Med Hyg. 1979; 28(5): 864-70.	1978-1979		†
Kenya	Adam AM. Multiple sclerosis: epidemic in Kenya. East Afr Med J. 1989; 66(8): 503-6.	1988		
Kenya	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J. 1998; 12(2): 315-35.	1993-1995		
Kenya	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2001		
Kenya	Nyamu PN, Orieno CF, Amayo EO, McLigeo SO. Risk factors and prevalence of diabetic foot ulcers at Kenyatta National Hospital, Nairobi. East Afr Med J. 2003; 80(1): 36-43.	1998-1999		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Kenya	Breiman RF, Cosmas L, Njuguna H, Audi A, Olack B, Ochieng JB, Wamola N, Bigogo GM, Awiti G, Tabu CW, Burke H, Williamson J, Oundo JO, Mintz ED, Feikin DR. Population-based incidence of typhoid fever in an urban informal settlement and a rural area in Kenya: implications for typhoid vaccine use in Africa. <i>PLoS One</i> . 2012; 7(1): e29119.	2006-2009	*	
Kenya	Gathecha G, Makokha A, Wanzala P, Omolo J, Smith P. Dental caries and oral health practices among 12 year old children in Nairobi West and Mathira West Districts, Kenya. <i>Pan Afr Med J</i> . 2012; 42.	2009-2010	*	
Kenya	Njoroge NW, Kemoli AM, Gatheche LW. Prevalence and pattern of early childhood caries among 3-5 year olds in Kiambaa, Kenya. <i>East Afr Med J</i> . 2010; 87(3): 134-7.	2008	*	
Kenya	Owino RO, Masiga MA, Ng'ang'a PM, Macigo FG. Dental caries, gingivitis and the treatment needs among 12-year-olds. <i>East Afr Med J</i> . 2010; 87(1): 25-31.	2008	*	
Kenya	Blaylock JM, Maranich A, Bauer K, Nyakoe N, Waitumbi J, Martinez LJ, Lynch J. The seroprevalence and seroincidence of dengue virus infection in western Kenya. <i>Travel Med Infect Dis</i> . 2011; 9(5): 246-8.	2008-2010	*	
Kenya	Footo EM, Sullivan KM, Ruth LJ, Oremo J, Sadumah I, Williams TN, Suchdev PS. Determinants of anemia among preschool children in rural, western Kenya. <i>Am J Trop Med Hyg</i> . 2013; 88(4): 757-64.	2010	*	
Kenya	Sadarangani M, Makani J, Komba AN, Ajala-Agbo T, Newton CR, Marsh K, Williams TN. An observational study of children with sickle cell disease in Kilifi, Kenya. <i>Br J Haematol</i> . 2009; 146(6): 675-82.	2003-2004	*	
Kenya	Scott JAG, Berkley JA, Mwangi I, Ochocha L, Uyoga S, Macharia A, Ndila C, Lowe BS, Mwarumba S, Bauni E, Marsh K, Williams TN. Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. <i>Lancet</i> . 2011; 378(9799): 1316-23.	1999-2002	*	
Kenya	Williams TN, Mwangi TW, Wambua S, Alexander ND, Kortok M, Snow RW, Marsh K. Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases. <i>J Infect Dis</i> . 2005; 192(1): 178-86.	1992-2000	*	
Kenya	Mung'ala-Odera V, Meehan R, Njuguna P, Muri N, Alcock KJ, Newton CRJC. Prevalence and risk factors of neurological disability and impairment in children living in rural Kenya. <i>Int J Epidemiol</i> . 2006; 35(3): 683-8.	2001-2002	*	
Kenya	Beatty ME, Ochieng JB, Chege W, Kumar L, Okoth G, Shapiro RL, Wells JG, Parsons MB, Bopp C, Chiller T, Vulule J, Mintz E, Slutsker L, Brooks JT. Sporadic paediatric diarrhoeal illness in urban and rural sites in Nyanza Province, Kenya. <i>East Afr Med J</i> . 2009; 86(8): 387-98.	1997-2003	*	
Kenya	Saidi SM, Iijima Y, Sang WK, Mwangudza AK, Oundo JO, Taga K, Aihara M, Nagayama K, Yamamoto H, Waiyaki PG, Honda T. Epidemiological study on infectious diarrheal diseases in children in a coastal rural area of Kenya. <i>Microbiol Immunol</i> . 1997; 41(10): 773-8.	1991-1993	*	
Kenya	Nakata S, Gatheru Z, Ukae S, Adachi N, Kobayashi N, Honma S, Muli J, Ogaja P, Nyangao J, Kiplagat E, Tukei PM, Chiba S. Epidemiological study of the G serotype distribution of group A rotaviruses in Kenya from 1991 to 1994. <i>J Med Virol</i> . 1999; 58(3): 296-303.	1991-1994	*	
Kenya	Mutanda LN, Kinoti SN, Gemert W, Lichenga EO. Age distribution and seasonal pattern of rotavirus infection in children in Kenya. <i>J Diarrhoeal Dis Res</i> . 1984; 2(3): 147-50.	1981-1983	*	
Kenya	Mutanda LN. Epidemiology of acute gastroenteritis in early childhood in Kenya. III. Distribution of the aetiological agents. <i>East Afr Med J</i> . 1980; 57(5): 317-26.	1975-1977	*	
Kenya	Mutanda LN. Epidemiology of acute gastroenteritis in early childhood in Kenya: aetiological agents. <i>Trop Geogr Med</i> . 1980; 32(2): 138-44.	1975	*	
Kenya	Kiulia NM, Peenze I, Dewar J, Nyachio A, Galo M, Omolo E, Steele AD, Mwenda JM. Molecular characterisation of the rotavirus strains prevalent in Maua, Meru North, Kenya. <i>East Afr Med J</i> . 2006; 83(7): 360-5.	2004-2005	*	
Kenya	Kakai R, Wamola IA, Bwayo JJ. Association of human rotavirus infection and intestinal rotavirus-specific immunoglobulin A in children with diarrhoea. <i>East Afr Med J</i> . 1995; 72(4): 217-9.	1992-1994	*	
Kenya	Kakai R, Wamola IA, Bwayo JJ, Ndinya-Achola JO. Enteric pathogens in malnourished children with diarrhoea. <i>East Afr Med J</i> . 1995; 72(5): 288-9.	1992-1994	*	
Kenya	Makino Y, Matsumoto I, Chiba Y, Mohammed OA, Ogaja PO, Kibue AM, Muli JM, Nakitare GW. Virological survey of children in Nyeri and Mombasa. Monthly survey of rotavirus in faeces. <i>East Afr Med J</i> . 1983; 60(8): 536-41.	1981-1982	*	
Kenya	Mutanda LN, Kangethe SK, Juma R, Lichenga EO, Gathecha C. Aetiology of diarrhoea in malnourished children at Kenyatta National Hospital. <i>East Afr Med J</i> . 1985; 62(12): 835-41.	1982-1984	*	
Kenya	O'Reilly CE, Jaron P, Ochieng B, Nyaguara A, Tate JE, Parsons MB, Bopp CA, Williams KA, Vinjé J, Blanton E, Wannemuehler KA, Vulule J, Laserson KF, Breiman RF, Feikin DR, Widdowson M-A, Mintz E. Risk factors for death among children less than 5 years old hospitalized with diarrhea in rural western Kenya, 2005-2007: a cohort study. <i>PLoS Med</i> . 2012; 9(7): e1001256.	2005-2007	*	
Kenya	Nasrin D, Wu Y, Blackwelder WC, Farag TH, Saha D, Sow SO, Alonso PL, Breiman RF, Sur D, Faruque ASG, Zaidi AKM, Biswas K, Van Eijk AM, Walker DG, Levine MM, Kotloff KL. Health care seeking for childhood diarrhea in developing countries: evidence from seven sites in Africa and Asia. <i>Am J Trop Med Hyg</i> . 2013; 89(1 Suppl): 3-12.	2009-2011	*	
Kenya	Frencken J, Manji F, Moshia H. Dental caries prevalence amongst 12-year-old urban children in East Africa. <i>Community Dent Oral Epidemiol</i> . 1986; 14(2): 94-8.	1984		
Kenya	Manji F. Gingivitis, dental fluorosis, and dental caries in primary school children of Nairobi, Kenya. <i>East Afr Med J</i> . 1984; 61(7): 524-32.	1983		
Kenya	Ng'ang'a PM, Valderhaug J. Dental caries in primary school children in Nairobi, Kenya. <i>Acta Odontol Scand</i> . 1992; 50(5): 269-72.	1987		
Kenya	Seedat S, Nyamai C, Njenga F, Vythingilum B, Stein DJ. Trauma exposure and post-traumatic stress symptoms in urban African schools Survey in CapeTown and Nairobi. <i>Br J Psychiatry</i> . 2004; 184(2): 169-75.	2000		
Kenya	Whitfield R, Schwab L, Ross-Degnan D, Steinkuller P, Swartwood J. Blindness and eye disease in Kenya: ocular status survey results from the Kenya Rural Blindness Prevention Project. <i>Br J Ophthalmol</i> . 1990; 74(6): 333-40, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1987-1988		
Kenya	Mathenge W, Kuper H, Limburg H, Polack S, Onyango G, Nyaga G, Foster A. Rapid assessment of avoidable blindness in Nakuru district, Kenya. <i>Ophthalmology</i> . 2007; 114(3): 599-605, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2005		
Kenya	Karimurio J, Sheila M, Gichangi M, Adala H, Huguet P. Rapid Assessment of Cataract Surgical Services in Embu District Kenya. <i>East Afr J Ophthalmol</i> . 2007; 13: 19-25, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2007		
Kenya	Ndegwa LK, Karimurio J, Okelo RO, Adala HS. Prevalence of visual impairment and blindness in a Nairobi urban population. <i>East Afr Med J</i> . 2006; 83(4): 69-72, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2002-2003		
Kenya	Amah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN, Steele AD, Laserson KF, Anshah NA, Levine MM, Lewis K, Coia ML, Attah-Poku M, Ojwando J, Rivers SB, Victor JC, Nyambane G, Hodgson A, Schödel F, Ciarlet M, Neuzil KM. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> . 2010; 376(9741): 606-14.	2007-2009		
Kenya	Berkley JA, Munywoki P, Ngama M, Kazungu S, Abwao J, Bett A, Lassauinière R, Kresfelder T, Cane PA, Venter M, Scott JAG, Nokes DJ. Viral etiology of severe pneumonia among Kenyan infants and children. <i>JAMA</i> . 2010; 303(20): 2051-7.	2007	*	
Kenya	Anabwani GM, Bonhoeffer P. Prevalence of heart disease in school children in rural Kenya using colour-flow echocardiography. <i>East Afr Med J</i> . 1996; 73(4): 215-7.	1994		
Kenya	Ngugi AK, Bottomley C, Kleinschmidt I, Wagner RG, Kakooza-Mwesige A, Ae-Ngibise K, Owusu-Agyei S, Mwanjia H, Kamuyu G, Odhiambo R, Chengo E, Sander JW, Newton CR, SEEDS group. Prevalence of active convulsive epilepsy in sub-Saharan Africa and associated risk factors: cross-sectional and case-control studies. <i>Lancet Neurol</i> . 2013; 12(3): 253-63.	2007-2008		
Kenya	Some ES. Misuse of drugs: perceptions of household heads in Kisumu district, Kenya. <i>East Afr Med J</i> . 1994; 71(2): 93-7.	1990		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Kenya	Vogel JP, Betrán AP, Widmer M, Souza JP, Gülmezoglu AM, Seuc A, Torloni MR, Mengestu TK, Meriardi M. Role of faith-based and nongovernment organizations in the provision of obstetric services in 3 African countries. <i>Am J Obstet Gynecol.</i> 2012; 207(6): 495e1-7.	2004-2005	*	
Kenya	Edwards T, Scott A, Munyoki G, Odera V, Chengo E, Bauni E, Kwasa T, Sander L, Neville B, Newton C. Active convulsive epilepsy in a rural district of Kenya: a study of prevalence and possible risk factors. <i>Lancet Neurol.</i> 2008; 7(1): 50-6.	2003	*	†
Kenya	Mung'ala-Odera V, White S, Meehan R, Otieno GO, Njuguna P, Mturi N, Edwards T, Neville BG, Newton CRJC. Prevalence, incidence and risk factors of epilepsy in older children in rural Kenya. <i>Seizure.</i> 2008; 17(5): 396-404.	2001-2002	*	
Kenya	Kaamugisha J, Feksi AT. Determining the prevalence of epilepsy in the semi-urban population of Nakuru, Kenya, comparing two independent methods not apparently used before in epilepsy studies. <i>Neuroepidemiology.</i> 1988; 7(3): 115-21.	1985-1986	*	
Kenya	Ilako FM, McLigeo SO, Riyat MS, Lule GN, Okoth FA, Kapitch D. The prevalence of hepatitis C virus antibodies in renal patients, blood donors and patients with chronic liver disease in Kenya. <i>East Afr Med J.</i> 1995; 72(6): 362-4.	1995		
Kenya	Van't Hoog AH, Laserson KF, Githui WA, Meme HK, Agaya JA, Odeny LO, Muchiri BG, Marston BJ, DeCock KM, Borgdorff MW. High prevalence of pulmonary tuberculosis and inadequate case finding in rural western Kenya. <i>Am J Respir Crit Care Med.</i> 2011; 183(9): 1245-53.	2006-2007		
Kenya	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2010, 2012		
Kenya	Baeten JM, McClelland RS, Corey L, Overbaugh J, Lavreys L, Richardson BA, Wald A, Mandaliya K, Bwayo JJ, Kreiss JK. Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. <i>J Infect Dis.</i> 2004; 189(8): 1466-71.	1998-2000	*	
Kenya	Kaul R, Kimani J, Nagelkerke NJ, Fonck K, Ngugi EN, Keli F, MacDonald KS, Maclean IW, Bwayo JJ, Temmerman M, Ronald AR, Moses S, Kibera HIV Study Group. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. <i>JAMA.</i> 2004; 291(21): 2555-62.	1998-2002	*	
Kenya	Ayah R, Joshi MD, Wanjiru R, Njau EK, Otieno CF, Njeru EK, Mutai KK. A population-based survey of prevalence of diabetes and correlates in an urban slum community in Nairobi, Kenya. <i>BMC Public Health.</i> 2013; 13: 371.	2010		
Kenya	Oti SO, van de Vijver SIM, Agyemang C, Kyobutungi C. The magnitude of diabetes and its association with obesity in the slums of Nairobi, Kenya: results from a cross-sectional survey. <i>Trop Med Int Health.</i> 2013; 18(12): 1520-30.	2008-2009		
Kenya	Allison AC. Glucose-6-phosphate dehydrogenase deficiency in red blood cells of East Africans. <i>Nature.</i> 1960; 531-2.	1958-1960		
Kenya	Willcox MC, Beckman L. Haemoglobin variants, beta-thalassaemia and G-6-PD types in Liberia. <i>Hum Hered.</i> 1981; 31(6): 339-47.	1979-1981		
Kenya	Naicker S. Burden of end-stage renal disease in sub-Saharan Africa. <i>Clin Nephrol.</i> 2010; 74(Suppl 1): S13-6.	2008-2010		
Kenya	Kenya Medical Research Institute (KEMRI), Kenya - Nairobi Cancer Incidence Report 2000-2002. Kenya Medical Research Institute (KEMRI), 2006.	2000-2002	*	
Kenya	Baelum V, Manji F, Fejerskov O, Wanzala P. Validity of CPTIN's assumptions of hierarchical occurrence of periodontal conditions in a Kenyan population aged 15-65 years. <i>Community Dent Oral Epidemiol.</i> 1993; 21(6): 347-53.	1991		
Kenya	Kenya Society for Deaf Children. Kenya Survey on Prevention of Deafness in Children 1996.	1996		
Kenya	Daly CC, Maggwa N, Mati JK, Solomon M, Mbugua S, Tukei PM, Hunter DJ. Risk factors for gonorrhoea, syphilis, and trichomonas infections among women attending family planning clinics in Nairobi, Kenya. <i>Genitourin Med.</i> 1994; 70(3): 155-61.	1989-1991		
Kenya	Bloland PB, Boriga DA, Ruebush TK, McCormick JB, Roberts JM, Oloo AJ, Hawley W, Lal A, Nahlen B, Campbell CC. Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission II. Descriptive epidemiology of malaria infection and disease among children. <i>Am J Trop Med Hyg.</i> 1999; 60(4): 641-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Kenya	Fillinger U, Ndenga B, Githeko A, Lindsay SW. Integrated malaria vector control with microbial larvicides and insecticide-treated nets in western Kenya: a controlled trial. <i>Bull World Health Organ.</i> 2009; 87(9): 655-65 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004-2006	*	†
Kenya	World Health Organization (WHO). Kenya WHO Leishmaniasis Country Profile.	2000-2009	*	
Kenya	Estambale BB, Simonsen PE, Knight R, Bwayo JJ. Bancroftian filariasis in Kwale District of Kenya. I. Clinical and parasitological survey in an endemic community. <i>Ann Trop Med Parasitol.</i> 1994; 88(2): 145-51. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1980-2000		
Kenya	Wamae CN, Gatika SM, Roberts JM, Lammie PJ, Wuchereria bancrofti in Kwale District, Coastal Kenya: patterns of focal distribution of infection, clinical manifestations and anti-filarial IgG responsiveness. <i>Parasitology.</i> 1998; 116 (Pt 2): 173-82. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1980-2000	*	
Kenya	Njenga SM, Mwandawiro CS, Wamae CN, Mukoko DA, Omar AA, Shimada M, Bockarie MJ, Molyneux DH. Sustained reduction in prevalence of lymphatic filariasis infection in spite of missed rounds of mass drug administration in an area under mosquito nets for malaria control. <i>Parasit Vectors.</i> 2011; 90. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2002, 2009	*	
Kenya	Njenga SM, Wamae CN, Njomo DW, Mwandawiro CS, Molyneux DH. Chronic clinical manifestations related to Wuchereria bancrofti infection in a highly endemic area in Kenya. <i>Trans R Soc Trop Med Hyg.</i> 2007; 101(5): 439-44.	2002	*	
Kenya	Simonsen PE, Meyrowitsch DW, Jaoko WG, Malecela MN, Mukoko D, Pedersen EM, Ouma JH, Rwegoshora RT, Masese N, Magnussen P, Estambale BBA, Michael E. Bancroftian filariasis infection, disease, and specific antibody response patterns in a high and a low endemicity community in East Africa. <i>Am J Trop Med Hyg.</i> 2002; 66(5): 550-9. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1998	*	
Kenya	Simonsen PE, Bernhard P, Jaoko WG, Meyrowitsch DW, Malecela-Lazaro MN, Magnussen P, Michael E. Filaria dance sign and subclinical hydrocoele in two east African communities with bancroftian filariasis. <i>Trans R Soc Trop Med Hyg.</i> 2002; 96(6): 649-53.	1998	*	
Kenya	Njenga SM, Muita M, Kirigi G, Mbugua J, Mitsui Y, Fujimaki Y, Aoki Y. Bancroftian filariasis in Kwale district, Kenya. <i>East Afr Med J.</i> 2000; 77(5): 245-9. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1990	*	
Kenya	Kenya Iodine Nutrition Situation and Trends in the Control of Iodine Deficiency 2003 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2003-2004		
Kenya	Kenya National Micronutrient Survey 1994 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Kenya	Kenya National Micronutrient Survey 1994 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1994		
Kenya	Onyango CO, Njeru R, Kazungu S, Achilla R, Bulimo W, Welch SR, Cane PA, Gunson RN, Hammit LL, Scott JAG, Berkley JA, Nokes DJ. Influenza surveillance among children with pneumonia admitted to a district hospital in coastal Kenya, 2007-2010. <i>J Infect Dis.</i> 2012; S61-67.	2007-2010	*	
Kenya	Hammit LL, Kazungu S, Morpeth SC, Gibson DG, Mvera B, Brent AJ, Mwarumba S, Onyango CO, Bett A, Akech DO, Murdoch DR, Nokes DJ, Scott JAG. A preliminary study of pneumonia etiology among hospitalized children in Kenya. <i>Clin Infect Dis.</i> 2012; S190-199.	2010-2011		
Kenya	Damascono A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D, Dzudie A, Kouam CK, Suliman A, Schrueder N, Yonga G, Ba SA, Maru F, Alemayehu B, Edwards C, Davison BA, Cotter G, Sliwa K. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. <i>Arch Intern Med.</i> 2012; 172(18): 1386-94.	2007-2010		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Kenya	Sinarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. <i>Int J Health Geogr.</i> 2010; 9: 57.	1980-2010		
Kenya	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec.</i> 2005; 80(13): 118-24.	2003	*	
Kenya	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec.</i> 2006; 81(32): 309-16.	2005	*	
Kenya	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Kenya	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Kenya	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Kenya	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Kenya	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Kenya	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Kenya	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Kenya	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Kenya	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Kenya	Kohli R, Konya WP, Obura T, Stones W, Revathi G. Prevalence of genital Chlamydia infection in urban women of reproductive age, Nairobi, Kenya. <i>BMC Res Notes.</i> 2013; 44.	2010	*	
Kenya	Drake AL, Kinuthia J, Matemo D, McClelland RS, Unger J, John-Stewart G. P3.079 Prevalence and Cofactors For STIs Among Pregnant Adolescents in Western Kenya. <i>Sex Transm Infect.</i> 2013; 89(Suppl 1): A172-A172.	2010-2011	*	
Kenya	Moses S, Ngugi EN, Costigan A, Kariuki C, Plummer FA. Declining STDs and HIV prevalences among ANC attendees in Nairobi, Kenya from 1992-2001. The XIV International AIDS Conference; 2002; Barcelona, Spain. (Oral Abstract: The XIV International AIDS Conference: Abstract no. WeOrC1272).	2001	*	
Kenya	Weiss HA, Buvé A, Robinson NJ, Van Dyck E, Kahindo M, Anagonou S, Musonda R, Zekeng L, Morison L, Carael M, Laga M, Hayes RJ. Study Group on Heterogeneity of HIV Epidemics in African Cities. The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. <i>AIDS.</i> 2001; S97-108.	1997-1998	*	
Kenya	Schwab L, Steinkuller PG. Visual disability and blindness secondary to refractive errors in Africa. <i>Soc Sci Med.</i> 1983; 17(22): 1751-4.	1976-1981	*	
Kenya	Mwangi I, Berkley J, Lowe B, Peshu N, Marsh K, Newton CRJC. Acute bacterial meningitis in children admitted to a rural Kenyan hospital: increasing antibiotic resistance and outcome. <i>Pediatr Infect Dis J.</i> 2002; 21(11): 1042-8.	1996-2000		
Kenya	Kenya National Micronutrient Survey 1999 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
Kenya	Akwale WS, Lum JK, Kaneko A, Eto H, Obonyo C, Björkman A, Kobayakawa T. Anemia and malaria at different altitudes in the western highlands of Kenya. <i>Acta Trop.</i> 2004; 91(2): 167-75 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Kenya	Lyko J, Gaertner H, Kaviti JN, Kariithi MW, Akoto B. [Blood-group systems ABO and RH in the Kenyan population]. <i>Folia Med Cracov.</i> 1992; 33(1-4): 85-92.	1985-1987	*	†
Kenya	Bowry TR, Pade J, Omari M, Chentai A. A pilot study of hepatitis B virus seroepidemiology suggests widespread immunosuppression in the nomadic inhabitants of Turkana District of Kenya. <i>East Afr Med J.</i> 1985; 62(7): 501-6.	1983		
Kenya	Mwangi JW. Viral markers in a blood donor population. <i>East Afr Med J.</i> 1999; 76(1): 35-7.	1995-1998		
Kenya	Okoth F, Mbutia J, Gatheru Z, Murila F, Kanyingi F, Mugo F, Esamai F, Alawi Z, Otieno J, Kiambati H, Wanjuki N. Seroprevalence of hepatitis B markers in pregnant women in Kenya. <i>East Afr Med J.</i> 2006; 83(9): 485-93.	2001-2002		
Kenya	Okoth FA, Kobayashi M, Kapitch DC, Kaiguri PM, Tukei PM, Takayanagi T, Yamanaka T. Seroepidemiological study for HBV markers and anti-delta in Kenya. <i>East Afr Med J.</i> 1991; 68(7): 515-25.	1986-1987		
Kenya	Were FN, Bwibo NO. Two year neurological outcomes of Very Low Birth Weight infants. <i>East Afr Med J.</i> 2006; 83(5): 243-9.	2002		†
Kenya	Kagai JM, Mpoke S, Muli F, Hamburger J, Kenya EU. Molecular technique utilising sputum for detecting <i>Wuchereria bancrofti</i> infections in Malindi, Kenya. <i>East Afr Med J.</i> 2008; 85(3): 118-22, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2004	*	
Kenya	Mukoko DAN, Pedersen EM, Masese NN, Estambale BBA, Ouma JH. Bancroftian filariasis in 12 villages in Kwale district, Coast province, Kenya - variation in clinical and parasitological patterns. <i>Ann Trop Med Parasitol.</i> 2004; 98(8): 801-15, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1994	*	
Kenya	Muturi EJ, Mbogo CM, Mwangangi JM, Ng'ang'a ZW, Kabiru EW, Mwandawiro C, Beier JC. Concomitant infections of Plasmodium falciparum and <i>Wuchereria bancrofti</i> on the Kenyan coast. <i>Filaria J.</i> 2006; 8, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2002	*	
Kenya	Njenga SM, Wamae CN. Evaluation of ICT filariasis card test using whole capillary blood: comparison with Knott's concentration and counting chamber methods. <i>J Parasitol.</i> 2001; 87(5): 1140-3, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1980-2000	*	
Kenya	Simonsen PE, Meyrowitsch DW, Mukoko DA, Pedersen EM, Malecela-Lazaro MN, Rwegoshora RT, Ouma JH, Masese N, Jaoko WG, Michael E. The effect of repeated half-yearly diethylcarbamazine mass treatment on <i>Wuchereria bancrofti</i> infection and transmission in two East African communities with different levels of endemicity. <i>Am J Trop Med Hyg.</i> 2004; 70(1): 63-71, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1999-2000	*	
Kenya	Wamae CN, Njenga SM, Ngugi BM, Mbui J, Njaanake HK. Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of <i>Wuchereria bancrofti</i> infection using multiple infection parameters. <i>Acta Trop.</i> 2011; S33-38, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1998	*	
Kenya	Wijers DJ, Kaleli N. Bancroftian filariasis in Kenya. V. Mass treatment given by members of the local community. <i>Ann Trop Med Parasitol.</i> 1984; 78(4): 383-94, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1982	*	
Kenya	Beckerleg S, Telfer M, Sadiq A. A rapid assessment of heroin use in Mombasa, Kenya. <i>Subst Use Misuse.</i> 2006; 41(6-7): 1029-44.	2000-2002	*	
Kenya	Mabeya H. Characteristics of women with obstetric fistula in the rural hospitals in West Pokot, Kenya. Paper presented at: Postgraduate Training in Research Methodology and Reproductive Health; 2004 March; Geneva.	1999-2003	*	
Kenya	Evaluation of Malaria Control in Kisumu Municipality, Kenya: A Case Study [Master's thesis] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Kenya	Omumbo, J. A. 2004. Developing a risk map of malaria transmission in the East and Horn of Africa. Ph.D. thesis. Oxford University, Oxford, United Kingdom	1996		†
Kenya	Rowland M, Bouma M, Ducornez D, Durran N, Rozendaal J, Schapira A, Sondorp E. Pyrethroid-impregnated bed nets for personal protection against malaria for Afghan refugees. <i>Trans R Soc Trop Med Hyg.</i> 1996; 90(4): 357-61 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Kenya	Evidence of Plasmodium Species Interactions in an Endemic Population in Coastal Kenya as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Kenya	Malaria Epidemiology and Drug Resistance in Kisii, Kenya as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Kenya	Adaptive Integrated Malaria Vector Management at Malindi, Kenya—Final Report (May 2005–April 2006) as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Kenya	Report on the Malaria Prevalence Survey in Malindi as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008	*	†
Kenya	Dynamics of Malaria Transmission and its Epidemiology among Children Population of Kilifi District, Coast Province, Kenya [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†
Kenya	Baseline Report: Millennium Research Village Sauri, Kenya as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Kenya	Prevalence of Concomitant Infections of Plasmodium falciparum and Wuchereria bancrofti in Mosquito and Human Populations in Malindi, Kenya [Master's thesis] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002-2003	*	†
Kenya	Clinical Epidemiology of Malaria Under Differing Levels of Transmission [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998-2005	*	†
Kenya	Outbreak of Epidemic Malaria in Uasin Gishu District-1988 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Kenya	Environmental Factors Affecting the Development of Plasmodium Falciparum in Anopheles Gambiae Mosquitoes [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001-2002	*	†
Kenya	The Malaria Parasite Prevalence Rates in Settled Villages of the Mwaa Tebere Irrigation Scheme [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989-1991	*	†
Kenya	Annual Report for Dertu, Kenya, Millennium Village. Year 1: February 2006-February 2007 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Kenya	Microscopy Versus Home-based Presumptive Diagnosis of Malaria in a Rural Community in Western Kenya as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2007	*	†
Kenya	Kenya Plasmodium Falciparum Parasite Rate Data, Personal Communication with U. Fillinger 2006 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Kenya	Kenya Plasmodium Falciparum Parasite Rate Data, Personal Communication with KEMRI-Welcome Trust Research Programme, Kilifi, 2008 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Kenya	Kenya Plasmodium Falciparum Parasite Rate Data, Personal Communication with KEMRI-Welcome Trust Research Programme, Kilifi, 2009 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2009	*	†
Kenya	Kimani EW, Vulule JM, Kuria JW, Mugisha F. Use of insecticide-treated clothes for personal protection against malaria: a community trial. Malar J. 2006; 5: 63 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Kenya	Kenya Plasmodium Falciparum Parasite Rate Data, Personal Communication with C.L. King 2009 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001-2003	*	†
Kenya	Kenya Plasmodium Falciparum Parasite Rate Data, Personal Communication with H. Manda and L.C. Gouagna, International Centre of Insect Physiology and Ecology, 2005 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001-2004	*	†
Kenya	Kenya Plasmodium Falciparum Parasite Rate Data, Personal Communication with K. Marsh 2005 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Kenya	Kenya Plasmodium Falciparum Parasite Rate Data, Personal Communication with V.M. Marsh and T. Abuya 2004 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000-2004	*	†
Kenya	Kenya Plasmodium Falciparum Parasite Rate Data, Personal Communication with C.G. Nevill and R.W. Snow 1993 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†
Kenya	Kenya Plasmodium Falciparum Parasite Rate Data, Personal Communication with C.G. Nevill and R.W. Snow 1988 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Kenya	Estimation of Attributable Risk of Anemia Due to Schistosomiasis in Western Kenya as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006-2007	*	†
Kenya	Ashford R, Craig P, Oppenheimer S. Polyparasitism on the Kenya coast. 2. Spatial heterogeneity in parasite distributions. Ann Trop Med Parasitol. 1993; 87(3): 283-93 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985-1986	*	†
Kenya	Baliraine FN, Afrane YA, Amehya DA, Bonizzoni M, Menge DM, Zhou G, Zhong D, Vardo-Zalik AM, Githeko AK, Yan G. High Prevalence of Asymptomatic Plasmodium falciparum Infections in a Highland Area of Western Kenya: A Cohort Study. J Infect Dis. 2009; 200(1): 66-74 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Kenya	Beier J, Oster C, Onyango F, Bales J, Sherwood J, Perkins P, Chumo D, Koech dv, Whitmore R, Roberts C. Plasmodium falciparum incidence relative to entomologic inoculation rates at a site proposed for testing malaria vaccines in western Kenya. Am J Trop Med Hyg. 1994; 50(5): 529-36 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Kenya	Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Mshamu S, Lang T, Gould J, Dubois MC, Demoitie MA, Stallart JF, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Ballou WR, Cohen J, Riley EM, Lemnge MM, Marsh K, von Seidlein L. Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age. N Engl J Med. 2008; 359(24): 2521-32 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2007	*	†
Kenya	Bejon P, Mwacharo J, Kai O, Mwangi T, Milligan P, Todryk S, Keating S, Lang T, Lowe B, Gikonyo C, Molyneux C, Fegan G, Gilbert SC, Peshu N, Marsh K, Hill AVS. A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. PLoS Clinical Trials. 2006; 1(6): e29 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Kenya	Bonizzoni M, Afrane Y, Balirane FN, Amenia DA, Githeko AK, Yan G. Genetic structure of <i>Plasmodium falciparum</i> populations between lowland and highland sites and antimalarial drug resistance in Western Kenya. <i>Infect Genet Evol.</i> 2009; 9(5): 806-12 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006-2007	*	†
Kenya	Clarke SE, Jukes MCH, Njagi JK, Khasakhala L, Cundill B, Otido J, Crudder C, Estambale BBA, Brooker S. Effect of intermittent preventive treatment of malaria on health and education in schoolchildren: a cluster-randomised, double-blind, placebo-controlled trial. <i>Lancet.</i> 2008; 372(9633): 127-38 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005-2006	*	†
Kenya	Bustinduy AL, Parraga IM, Thomas CL, Mungai PL, Mutuku F, Muchiri EM, Kitron U, King CH. Impact of polyparasitic infections on anaemia and undernutrition among Kenyan children living in a <i>Schistosoma haematobium</i> -endemic area. <i>Am J Trop Med Hyg.</i> 2013; 88(3): 433-40 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2009-2010	*	†
Kenya	Campbell GH, Collins FH, Brandling-Bennett AD, Schwartz IK, Roberts JM. Age-specific prevalence of antibody to a synthetic peptide of the circumsporozoite protein of <i>Plasmodium falciparum</i> in children from three villages in Kenya. <i>Am J Trop Med Hyg.</i> 1987; 37(2): 220-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Kenya	Clarke SE, Brooker S, Njagi JK, Njau E, Estambale B, Muchiri E, Magnussen P. Malaria morbidity among school children living in two areas of contrasting transmission in western Kenya. <i>Am J Trop Med Hyg.</i> 2004; 71(6): 732-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Kenya	Deloron P, Campbell GH, Brandling-Bennett D, Roberts JM, Schwartz IK, Odera JS, Lal AA, Osanga CO, de la Cruz V, McCutchan TM. Antibodies to <i>Plasmodium falciparum</i> ring-infected erythrocyte surface antigen and P. falciparum and P. malariae circumsporozoite proteins: seasonal prevalence in Kenyan villages. <i>Am J Trop Med Hyg.</i> 1989; 41(4): 395-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986-1987	*	†
Kenya	Dent AE, Chelimo K, Sumba PO, Spring MD, Crabb BS, Moormann AM, Tisch DJ, Kazura JW. Temporal stability of naturally acquired immunity to Merozoite Surface Protein-1 in Kenyan Adults. <i>Malar J.</i> 2009; 8(1): 162 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004-2005	*	†
Kenya	Friis H, Mwaniki D, Omondi B, Muniu E, Magnussen P, Geissler W, Thiong'o F, Michaelsen KF. Serum retinol concentrations and <i>Schistosoma mansoni</i> , intestinal helminths, and malarial parasitemia: a cross-sectional study in Kenyan preschool and primary school children. <i>Am J Clin Nutr.</i> 1997; 66(3): 665-71 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
Kenya	Fulford AJ, Mbugua GG, Ouma JH, Kariuki HC, Sturrock RF, Butterworth AE. Differences in the rate of hepatosplenomegaly due to <i>Schistosoma mansoni</i> infection between two areas in Machakos District, Kenya. <i>Trans R Soc Trop Med Hyg.</i> 1991; 85(4): 481-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987-1988	*	†
Kenya	Gitonga CW, Karanja PN, Kihara J, Mwanje M, Juma E, Snow RW, Noor AM, Brooker S. Implementing school malaria surveys in Kenya: towards a national surveillance system. <i>Malar J.</i> 2010; 9: 306 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008-2009	*	†
Kenya	Guyatt HL, Corlett SK, Robinson TP, Ochola SA, Snow RW. Malaria prevention in highland Kenya: indoor residual house-spraying vs. insecticide-treated bednets. <i>Trop Med Int Health.</i> 2002; 7(4): 298-303 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000	*	†
Kenya	Hagos B, Khan B, Ofulla AV, Kariuki D, Martin SK. Response of falciparum malaria to chloroquine and three second line antimalarial drugs in a Kenyan coastal school age population. <i>East Afr Med J.</i> 1993; 70(10): 620-3 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Kenya	Halliday KE, Karanja P, Turner EL, Okello G, Njagi K, Dubeck MM, Allen E, Jukes MCH, Brooker SJ. Plasmodium falciparum, anaemia and cognitive and educational performance among school children in an area of moderate malaria transmission: baseline results of a cluster randomized trial on the coast of Kenya. <i>Trop Med Int Health.</i> 2012; 17(5): 532-49 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2010	*	†
Kenya	Le Sueur D, Binka F, Lengeler C, De Savigny D, Snow B, Teuscher T, Toure Y. An atlas of malaria in Africa. <i>Afr Health.</i> 1997; 19(2): 23-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Kenya	Imbahale SS, Fillingim U, Githeko A, Mukabana WR, Takken W. An exploratory survey of malaria prevalence and people's knowledge, attitudes and practices of mosquito larval source management for malaria control in western Kenya. <i>Acta Trop.</i> 2010; 115(3): 248-56 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006-2007	*	†
Kenya	John CC, McHugh MM, Moormann AM, Sumba PO, Ofulla AV. Low prevalence of <i>Plasmodium falciparum</i> infection among asymptomatic individuals in a highland area of Kenya. <i>Trans R Soc Trop Med Hyg.</i> 2005; 99(10): 780-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999-2002	*	†
Kenya	Kabiru EW, Gachare JW, Mbaabu DA, Ngindu AM, Siongok TK. In-vivo falciparum malaria response to chloroquine in Kisumu-Kenya. <i>East Afr Med J.</i> 1987; 64(9): 606-10 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Kenya	Koenraadt CJ, Paaijmans KP, Schneider P, Githeko AK, Takken W. Low larval vector survival explains unstable malaria in the western Kenya highlands. <i>Trop Med Int Health.</i> 2006; 11(8): 1195-205 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999-2001	*	†
Kenya	Kolaczinski JH, Reithinger R, Worku DT, Ocheng A, Kasimiro J, Kabatereine N, Brooker S. Risk factors of visceral leishmaniasis in East Africa: a case-control study in Pokot territory of Kenya and Uganda. <i>Int J Epidemiol.</i> 2008; 37(2): 344-52 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Kenya	Lawless JW, Latham MC, Stephenson LS, Kinoti SN, Pertet AM. Iron supplementation improves appetite and growth in anemic Kenyan primary school children. <i>J Nutr.</i> 1994; 124(5): 645-54 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Kenya	Leenstra T, Petersen LT, Kariuki SK, Oloo AJ, Kager PA, ter Kuile FO. Prevalence and severity of malnutrition and age at menarche: cross-sectional studies in adolescent schoolgirls in western Kenya. <i>Eur J Clin Nutr.</i> 2005; 59(1): 41-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997-1999	*	†
Kenya	Mbogo CM, Mwangangi JM, Nzovu J, Gu W, Yan G, Gunter JT, Swalm C, Keating J, Regens JL, Shililu JI, Githure JI, Beier JC. Spatial and temporal heterogeneity of Anopheles mosquitoes and Plasmodium falciparum transmission along the Kenyan coast. <i>Am J Trop Med Hyg.</i> 2003; 68(6): 734-42 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Kenya	Munyekenye OG, Githeko AK, Zhou G, Mushinzimana E, Minakawa N, Yan G. Plasmodium falciparum: Spatial Analysis, Western Kenya Highlands. <i>Emerg Infect Dis.</i> 2005; 11(10): 1571-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002-2003	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Kenya	Mutero CM, Kabutha C, Kimani V, Kabuage L, Gitau G, Ssenyonga J, Githure J, Muthami L, Kaida A, Musyoka L, Kiarie E, Oganda M. A transdisciplinary perspective on the links between malaria and agroecosystems in Kenya. <i>Acta Trop</i> . 2004; 89(2): 171-86 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001-2002	*	†
Kenya	Mutero CM, Mutinga MJ, Ngindu AM, Kenya PR, Amimo FA. Visceral leishmaniasis and malaria prevalence in West Pokot District, Kenya. <i>East Afr Med J</i> . 1992; 69(1): 3-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Kenya	Mutero CM, Ouma JH, Agak BK, Wanderi JA, Copeland RS. Malaria prevalence and use of self-protection measures against mosquitoes in Suba District, Kenya. <i>East Afr Med J</i> . 1998; 75(1): 11-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†
Kenya	Mutinga MJ, Mnzava A, Kimokoti R, Nyamori M, Ngindu AM. Malaria prevalence and morbidity in relation to the use of permethrin-treated wall cloths in Kenya. <i>East Afr Med J</i> . 1993; 70(12): 756-62 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Kenya	Nabakwe EC, Lichtenbelt WVM, Ngare DK, Wierik M, Westertep KR, Owino OC. Vitamin A deficiency and anaemia in young children living in a malaria endemic district of western Kenya. <i>East Afr Med J</i> . 2005; 82(6): 300-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Kenya	Nevill CG, Lury JD, Mosobo MK, Watkins HM, Watkins WM. Daily chloroquine is an effective alternative to daily proguanil in the prevention of Plasmodium falciparum malaria in Kenya. <i>Trans R Soc Trop Med Hyg</i> . 1994; 88(3): 319-20 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Kenya	Nevill CG, Watkins WM, Carter JY, Munafu CG. Comparison of mosquito nets, proguanil hydrochloride, and placebo to prevent malaria. <i>Br Med J (Clin Res Ed)</i> . 1988; 297(6645): 401-3 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Kenya	Noland GS, Hendel-Paterson B, Min XM, Moormann AM, Vulule JM, Narum DL, Lanar DE, Kazura JW, John CC. Low prevalence of antibodies to preerythrocytic but not blood-stage Plasmodium falciparum antigens in an area of unstable malaria transmission compared to prevalence in an area of stable malaria transmission. <i>Infect Immun</i> . 2008; 76(12): 5721-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Kenya	Ofula AV, Moormann AM, Embury PE, Kazura JW, Sumba PO, John CC. Age-related differences in the detection of Plasmodium falciparum infection by PCR and microscopy, in an area of Kenya with holo-endemic malaria. <i>Ann Trop Med Parasitol</i> . 2005; 99(4): 431-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Kenya	Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, Tucker K, Waitumbi JN, Diggs C, Wittes J, Malkin E, Leach A, Soisson LA, Milman JB, Otieno L, Holland CA, Polhemus M, Remich SA, Ockenhouse CF, Cohen J, Ballou WR, Martin SK, Angov E, Stewart VA, Lyon JA, Heppner DG Jr, Withers MR, for the MSP-1 Malaria Vaccine Working Group. Blood Stage Malaria Vaccine Eliciting High Antigen-Specific Antibody Concentrations Confers No Protection to Young Children in Western Kenya. <i>PLoS One</i> . 2009; 4(3): e4708 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Kenya	Oloo A, Githeko A, Adungo N, Karanja D, Vulule J, Kisia-Abok I, Seroney I, Ayisi J, Ondijo S, Koech DK, Abdullah MS. Field trial of permethrin impregnated sisal curtains in malaria control in western Kenya. <i>East Afr Med J</i> . 1996; 73(11): 735-40 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991-1992	*	†
Kenya	Seal A, Creeke P, Mirghani Z, Abdalla F, McBurney R, Pratt L, Brookes D, Ruth L, Marchand E. Iron and vitamin A deficiency in long-term African refugees. <i>J Nutr</i> . 2005; 135(4): 808-13 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Kenya	Sexton JD, Ruebush TK, Brandling-Bennett AD, Breman JG, Roberts JM, Odera JS, Were JB. Permethrin-impregnated curtains and bed-nets prevent malaria in western Kenya. <i>Am J Trop Med Hyg</i> . 1990; 43(1): 11-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Kenya	Shanks GD, Biomondo K, Guyatt HL, Snow RW. Travel as a risk factor for uncomplicated Plasmodium falciparum malaria in the highlands of western Kenya. <i>Trans R Soc Trop Med Hyg</i> . 2005; 99(1): 71-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999-2002	*	†
Kenya	Slutsker L, Tipple M, Keane V, McCance C, Campbell CC. Malaria in east African refugees resettling to the United States: development of strategies to reduce the risk of imported malaria. <i>J Infect Dis</i> . 1995; 171(2): 489-93 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†
Kenya	Snow RW, Omumbo JA, Lowe B, Molyneux CS, Obiero JO, Palmer A, Weber MW, Pinder M, Nahlen B, Obonyo C, Newbold C, Gupta S, Marsh K. Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. <i>Lancet</i> . 1997; 349(9066): 1650-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995-1996	*	†
Kenya	Wanjala CL, Waitumbi J, Zhou G, Githeko AK. Identification of malaria transmission and epidemic hotspots in the western Kenya highlands: its application to malaria epidemic prediction. <i>Parasit Vectors</i> . 2011; 4: 81 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2009	*	†
Kenya	Watkins WM, Oloo JA, Lury JD, Mosobo M, Kariuki D, Mjomba M, Koech DK, Gilles HM. Efficacy of multiple-dose halofantrine in treatment of chloroquine-resistant falciparum malaria in children in Kenya. <i>Lancet</i> . 1988; 2(8605): 247-50 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Kenya	Wilson S, Booth M, Jones FM, Mwatha JK, Kimani G, Kariuki HC, Vennervald BJ, Ouma JH, Muchiri E, Dunne DW. Age-adjusted Plasmodium falciparum antibody levels in school-aged children are a stable marker of microgeographical variations in exposure to Plasmodium infection. <i>BMC Infect Dis</i> . 2007; 7(1): 67 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003-2004	*	†
Kenya	Wilson S, Vennervald BJ, Kadzo H, Ileri E, Amaganga C, Booth M, Kariuki HC, Mwatha JK, Kimani G, Ouma JH, Muchiri E, Dunne DW. Hepatosplenomegaly in Kenyan schoolchildren: exacerbation by concurrent chronic exposure to malaria and Schistosoma mansoni infection. <i>Trop Med Int Health</i> . 2007; 12(12): 1442-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Kenya	Ye Y, Madise N, Ndugwu R, Ochola S, Snow RW. Fever treatment in the absence of malaria transmission in an urban informal settlement in Nairobi, Kenya. <i>Malar J</i> . 2009; 8(1): 160 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008	*	†
Kenya	Kenya Plasmodium Falciparum Parasite Rate Data, Personal Communication with R.W. Snow 1991 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989-1991	*	†
Kenya	Kenya Plasmodium Falciparum Parasite Rate Data, Personal Communication with D. Zurovac 2000 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Kenya	Kenya Plasmodium Falciparum Parasite Rate Data, Adungo 1992 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Kenya	Kenya Plasmodium Falciparum Parasite Rate Data, K.M. K'Omollo, Division of Vector-Borne Diseases, Ministry of Health 1994 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Kenya	Kenya Plasmodium Falciparum Parasite Rate Data, C.M. Mbogo 1990 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Kenya	Kenya Plasmodium Falciparum Parasite Rate Data, T. Mugo, Division of Vector-Borne Diseases, Ministry of Health 1994 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Kenya	Kenya Plasmodium Falciparum Parasite Rate Data, A.A. Obala, Paper 46/91, 1991 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Kenya	Ongore D. Kenya Plasmodium Falciparum Parasite Rate Data, D. Ongore 1985 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Kenya	Kenya Plasmodium Falciparum Parasite Rate Data, E.O. Oongo, Division of Vector-Borne Diseases, Ministry of Health 1996 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Kenya	Kenya Plasmodium Falciparum Parasite Rate Data, B.A. Rapuoda 1995 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Kenya	Kenya Plasmodium Falciparum Parasite Rate Data, S.B. Tosha, Division of Vector-Borne Diseases, Ministry of Health 1996 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Kiribati	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988, 1990-1994		
Kiribati	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Kiribati	Hill AV, Bowden DK, O'Shaughnessy DF, Weatherall DJ, Clegg JB. Beta thalassaemia in Melanesia: association with malaria and characterization of a common variant (IVS-1 nt 5 G→C). Blood. 1988; 72(1): 9-14.	1985-1987		
Kiribati	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998-2002, 2007-2009		
Kiribati	Secretariat of the Pacific Community (SPC), World Health Organization Regional Office for the Western Pacific (WPRO-WHO). Second Generation Surveillance Surveys of HIV, Other STIs and Risk Behaviours in 6 Pacific Island Countries 2004-2005. Geneva, Switzerland: World Health Organization (WHO), 2006.	2004		
Kiribati	Yanagihara RT, Garruto RM, Gajusek DC. Epidemiological surveillance of amyotrophic lateral sclerosis and parkinsonism-dementia in the commonwealth of the Northern Mariana Islands. Ann Neurol. 1983; 13(1): 79-86.	1980-1981		
Kiribati	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2007, 2010, 2012		
Kiribati	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Kiribati	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
Kiribati	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Kiribati	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	
Kiribati	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Kiribati	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Kiribati	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Kiribati	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
Kiribati	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Kiribati	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Kiribati	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Kiribati	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Kiribati	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2000.	2000		
Kiribati	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2001.	2001		
Kiribati	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2002.	2002		
Kiribati	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2003.	2003		
Kiribati	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2004.	2004		
Kiribati	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2005.	2005		
Kiribati	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2006.	2006		
Kiribati	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2007.	2007		
Kiribati	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2008.	2008		
Kiribati	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2009.	2009		
Kiribati	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2010.	2010		
Kiribati	Colquhoun S, Nikuata A, Kado JH, Bakatu K, Tiira T, Timeon P, Kennedy L, Wheaton G, Carapetis J. RHD Prevention and Control Programme in the Republic of Kiribati. Global Heart. 2014; 9(1): e157.	2012-2013		
Kuwait	Ministry of Health (Kuwait), World Health Organization (WHO). Kuwait STEPS Noncommunicable Disease Risk Factors Survey 2006.	2006		
Kuwait	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Kuwait	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Kuwait	Hijazi Z, Paasa A, El-Gharbawy F, Chugh TD, Essa S, El Shazli A, Abd El-Salam R. Acute lower respiratory tract infections in children in Kuwait. Ann Trop Paediatr. 1997; 17(2): 127-34.	1993-1994		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Kuwait	Abdul-Ghaffar NU, el-Sonbati MR, el-Din Abdul-Baky MS, Marafie AA, al-Said AM. Stroke in Kuwait: a three-year prospective study. <i>Neuroepidemiology</i> . 1997; 16(1): 40-7.	1989-1993		
Kuwait	Al-Shammri S, Shahid Z, Ghali A, Mehdiratta MM, Swaminathan TR, Chadha G, Sharma PN, Akanji AO. Risk Factors, Subtypes and Outcome of Ischaemic Stroke in Kuwait - A Hospital-Based Study. <i>Med Princ Pract</i> . 2003; 12(4): 218-23.	1995-1997		
Kuwait	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol</i> . 2008; 121(4): 947-954.	1995, 2001		
Kuwait	Makhseed M, Musini VM. Eclampsia in Kuwait 1981-1993. <i>Aust N Z J Obstet Gynaecol</i> . 1996; 36(3): 258-63.	1981-1994		
Kuwait	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998-2000, 2005		
Kuwait	Al-Awadhi AM, Olusi SO, Moussa M, Shehab D, Al-Zaid N, Al-Herz A, Al-Jarallah K. Musculoskeletal pain, disability and health-seeking behavior in adult Kuwaitis using a validated Arabic version of the WHO-ILAR COPCORD Core Questionnaire. <i>Clin Exp Rheumatol</i> . 2004; 22(2): 177-83.	1999, 2001		
Kuwait	Alshubaili AF, Alramzy K, Ayyad YM, Gerish Y. Epidemiology of multiple sclerosis in Kuwait: new trends in incidence and prevalence. <i>Eur Neurol</i> . 2005; 53(3): 125-31.	1993-2000		
Kuwait	Al-Din AS. Multiple sclerosis in Kuwait: clinical and epidemiological study. <i>J Neurol Neurosurg Psychiatry</i> . 1986; 49(8): 928-31.	1983		
Kuwait	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J</i> . 1998; 12(2): 315-55.	1993-1995		
Kuwait	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	2001		
Kuwait	Al-Zuabi H, Al-Tammar Y, Al-Moatiz R, Al-Sabti K, Wani VB, Hamana F, Mohammad H, Al-Suwayan MH. Retinopathy in newly diagnosed type 2 diabetes mellitus. <i>Med Princ Pract</i> . 2005; 14(5): 293-6.	2002-2004		
Kuwait	Abdella N, Al Arouj M, Al Nakhi A, Al Assoussi A, Moussa M. Non-insulin-dependent diabetes in Kuwait: prevalence rates and associated risk factors. <i>Diabetes Res Clin Pract</i> . 1998; 42(3): 187-96.	1996		
Kuwait	Abal AT, Ayed A, Nair PCMG, Mosawi M, Behbehani N. Factors responsible for asthma and rhinitis among Kuwaiti schoolchildren. <i>Med Princ Pract</i> . 2010; 19(4): 295-8.	1999	*	
Kuwait	Owayed A, Behbehani N, Al-Momen J. Changing prevalence of asthma and allergic diseases among Kuwaiti children. An ISAAC Study (Phase III). <i>Med Princ Pract</i> . 2008; 17(4): 284-9.	2001-2002	*	
Kuwait	Forman D, Bray F, Brewster DH, Gombé Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). <i>Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version)</i> . Lyon, IARC. http://ci5.iarc.fr	2003-2007	*	
Kuwait	Albert MJ, Rotimi VO, Dhar R, Silpikurian S, Pacsa AS, Molla AM, Szucs G. Diarrhoeagenic <i>Escherichia coli</i> are not a significant cause of diarrhoea in hospitalised children in Kuwait. <i>BMC Microbiol</i> . 2009; 9: 62.	2005-2007	*	
Kuwait	Al-Mutawa SA, Shiyama M, Al-Duwairi Y, Soparkar P. Dental caries experience of Kuwaiti schoolchildren. <i>Community Dent Health</i> . 2006; 23(1): 31-6.	2001		
Kuwait	Murtomaa H, Al Zaabi F, Morris RE, Metsaniitty M. Caries experience in a selected group of children in Kuwait. <i>Acta Odontol Scand</i> . 1995; 53(6): 389-91.	1993		
Kuwait	Elkilany GE, Al-Qbani MA, Sayed KA, Kabbash I. Dilated cardiomyopathy in children and adults: what is new? <i>ScientificWorldJournal</i> . 2008; 762-75.	1996-2008		
Kuwait	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Kuwait	Al-Awadhi R, Al-Ramadan BA, George SS, Sharma PN, Kapila K. Gynecologic infections seen in cervical smears in Kuwait. <i>Acta Cytol</i> . 2010; 54(1): 50-4.	2002-2007	*	
Kuwait	Al-Sweih NA, Khan S, Rotimi VO. Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae among asymptomatic women attending the Capital Health region clinics in Kuwait. <i>Sex Transm Dis</i> . 2011; 38(9): 793-7.	2004-2008	*	
Kuwait	al-Alfy A, Carroll JE, Devarajan LV, Moussa MA. Term infant asphyxia in Kuwait. <i>Ann Trop Paediatr</i> . 1990; 10(4): 355-61.	1989	*	†
Kuwait	Alarouj M, Bennakhi A, Alnesef Y, Sharifi M, Elkum N. Diabetes and associated cardiovascular risk factors in the State of Kuwait: the first national survey. <i>Int J Clin Pract</i> . 2013; 67(1): 89-96.	2010-2012		
Kuwait	Jambart S, Almmache Z, Haddad F, Younes A, Hassoun A, Abdalla K, Selwan CA, Sunna N, Wajsbort D, Youseif E. Prevalence of painful diabetic peripheral neuropathy among patients with diabetes mellitus in the Middle East region. <i>J Int Med Res</i> . 2011; 39(2): 366-77.	2009		
Kuwait	Abdul-Rasoul M, Al-Qattan H, Al-Haj A, Habib H, Ismael A. Incidence and seasonal variation of Type 1 diabetes in children in Farwania area, Kuwait (1995-1999). <i>Diabetes Res Clin Pract</i> . 2002; 56(2): 153-7.	1995-1999		
Kuwait	Shaltout AA, Moussa MAA, Qabazard M, Abdella N, Karvonen M, Al-Khawari M, Al-Arouj M, Al-Nakhi A, Tuomilehto J, El-Gammal A. Kuwait Diabetes Study Group. Further evidence for the rising incidence of childhood Type 1 diabetes in Kuwait. <i>Diabet Med</i> . 2002; 19(6): 522-5.	1992-1997		
Kuwait	Usanga EA, Ameen R. Glucose-6-phosphate dehydrogenase deficiency in Kuwait, Syria, Egypt, Iran, Jordan and Lebanon. <i>Hum Hered</i> . 2000; 50(3): 158-61.	1996-1997		
Kuwait	Samichuk E, D'Souza B, Al-Awadi S. Population study of common glucose-6-phosphate dehydrogenase mutations in Kuwait. <i>Hum Hered</i> . 1999; 49(1): 41-4.	1997-1999		
Kuwait	Alfadhli S, Kaaba S, Elshafay A, Salim M, AlAwadi A, Bastaki L. Molecular characterization of glucose-6-phosphate dehydrogenase gene defect in the Kuwaiti population. <i>Arch Pathol Lab Med</i> . 2005; 129(9): 1144-7.	2003-2005		
Kuwait	el-Reshaid K, Johny KV, Georgous M, Nampoory MR, al-Hilal N. The impact of Iraqi occupation on end-stage renal disease patients in Kuwait, 1990-1991. <i>Nephrol Dial Transplant</i> . 1993; 8(1): 7-10.	1990-1991		
Kuwait	Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M and Boyle P, eds (2007). <i>Cancer Incidence in Five Continents, Vol. IX Periodic Data (electronic version)</i> . Lyon, IARC. http://ci5.iarc.fr	1998-2002	*	
Kuwait	Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. <i>Cancer Incidence in Five Continents, Vol. 1 to VIII</i> . Lyon, France, IARC Press, 2005.	1979-1987	*	
Kuwait	Ismail EA, Shabani IS, Badawi M, Sanaa H, Madi S, Al-Tawari A, Nadi H, Zaki M, Al-saleh Q. An epidemiologic, clinical, and therapeutic study of childhood Guillain-Barré syndrome in Kuwait: is it related to the oral polio vaccine? <i>J Child Neurol</i> . 1998; 13(10): 488-92.	1992-1997		†
Kuwait	Al-Kandari JM, Alshuaib WB. Hearing evaluation of school children in Kuwait. <i>Electromyogr Clin Neurophysiol</i> . 2010; 50(6): 309-18.	2008	*	
Kuwait	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec</i> . 2010; 85(35): 337-48.	2009	*	
Kuwait	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec</i> . 2012; 87(34): 317-28.	2011	*	
Kuwait	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec</i> . 2008; 83(33): 293-300.	2007	*	
Kuwait	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec</i> . 2013; 88(35): 365-79.	2012	*	
Kuwait	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec</i> . 2011; 86(36): 389-99.	2010	*	
Kuwait	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1994; 69(20): 145-51.	1993	*	
Kuwait	Al-Sweih NA, Al-Fadhli AH, Omu AE, Rotimi VO. Prevalence of Chlamydia trachomatis, Mycoplasma hominis, Mycoplasma genitalium, and Ureaplasma urealyticum infections and seminal quality in infertile and fertile men in Kuwait. <i>J Androl</i> . 2012; 33(6): 1323-9.	2008-2009	*	
Kuwait	Al-Mutairi N, Joshi A, Nour-Eldin O, Sharma AK, El-Adawy I, Rihwani M. Clinical patterns of sexually transmitted diseases, associated sociodemographic characteristics, and sexual practices in the Farwaniya region of Kuwait. <i>Int J Dermatol</i> . 2007; 46(6): 594-9.	2007		
Kuwait	Zubaid M, Rashed WA, Saad H, Attiya A, Al-Banat BA, Ridha M, Al-Kandari MH, Baidas G, Al-Hamdan R, Zubair S, Thalib L. Kuwait Acute Coronary Syndromes Registry: Baseline Characteristics, Management Practices and In-Hospital Outcomes of Patients Hospitalized with Acute Coronary Syndromes in Kuwait. <i>Med Princ Pract</i> . 2007; 16(6): 407-12.	1981		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Kuwait	Kuwait Vital Registration Birth Data 1991 as it appears in United Nations Statistics Division (UNSD), United Nations Demographic Yearbook - Historical Supplement 1997, New York City, United States: United Nations Statistics Division (UNSD).	1991		
Kyrgyzstan	United Nations Children's Fund (UNICEF), National Statistical Committee of the Kyrgyz Republic, Kyrgyzstan Multiple Indicator Cluster Survey 2005-2006. New York, United States: United Nations Children's Fund (UNICEF).	2005-2006	*	†
Kyrgyzstan	Macro International, Inc, Ministry of Health (Kyrgyzstan), Research Institute of Obstetrics and Pediatrics (Kyrgyzstan). Kyrgyzstan Demographic and Health Survey 1997. Calverton, United States: Macro International, Inc.	1997		†
Kyrgyzstan	ICF International, Ministry of Health (Kyrgyzstan), National Statistical Committee of the Kyrgyz Republic, Kyrgyzstan Demographic and Health Survey 2012. Fairfax, United States: ICF International, 2014.	2012	*	†
Kyrgyzstan	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Kyrgyzstan	Flem ET, Kasymbekova KT, Vainio K, Gentsch J, Abdikarimov ST, Glass RI, Bresee JS. Rotavirus infection in hospitalized children and estimates of disease burden in Kyrgyzstan, 2005-2007. Vaccine. 2009; 27 Suppl 5: 35-39.	2005-2007		
Kyrgyzstan	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2002-2003, 2008		
Kyrgyzstan	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2002		
Kyrgyzstan	Torgerson PR, Oguljahan B, Muminov AE, Karaeva RR, Kuttubaev OT, Aminjanov M, Shaikenov B. Present situation of cystic echinococcosis in Central Asia. Parasitol Int. 2006; 55(1): S207-S212.	1991-2002		
Kyrgyzstan	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Kyrgyzstan	Latipov R, Utegenova E, Kuatbayeva A, Kasymbekova K, Abdikarimov S, Juraev R, Ismailov U, Flem E. Epidemiology and burden of rotavirus disease in Central Asia. Int J Infect Dis. 2011; 15(7): e464-469.	2005-2009	*	
Kyrgyzstan	Ferganews. Kyrgyzstan Interim Government Found Money For Requiring Hemodialysis. Ferganews [Internet]. 2010 Nov 5; News Central Asia [about 1 screen].	2009		
Kyrgyzstan	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 2001, 2004, 2007, 2010, 2012		
Kyrgyzstan	Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. Cancer Incidence in Five Continents. Vol. I to VIII. Lyon, France, IARC Press, 2005.	1986-1987	*	
Kyrgyzstan	Kyrgyzstan Rapid Assessment of Iodine Deficiency 1994 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1994		
Kyrgyzstan	Kadirova R, Kartoglu HU, Strebel PM. Clinical characteristics and management of 676 hospitalized diphtheria cases, Kyrgyz Republic, 1995. J Infect Dis. 2000; S110-115.	1995		
Kyrgyzstan	USSR - Kirghiz SSR Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD), United Nations Demographic Yearbook - Historical Supplement 1997, New York City, United States: United Nations Statistics Division (UNSD).	1990		
Laos	Ministry of Health (Laos), National Institute of Public Health (NIOPH), National Statistical Center (Laos), United Nations Children's Fund (UNICEF). Laos Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Laos	United Nations Children's Fund (UNICEF), Department of Statistics (Laos), Ministry of Health (Laos). Laos Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006	*	†
Laos	World Health Organization (WHO). Laos World Health Survey 2003.	2003		†
Laos	World Health Organization (WHO). Control of Foodborne Trematode Infections 1995. Geneva, Switzerland: World Health Organization (WHO), 1995.	1995	*	
Laos	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988, 1990-2006		
Laos	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Laos	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Laos	Ministry of Education and Sports (Laos), Ministry of Health (Laos), Ministry of Planning and Investment (Laos). Laos Multiple Indicator Cluster Survey 2011-2012. New York, United States: United Nations Children's Fund (UNICEF), 2013.	2011-2012	*	†
Laos	Aloun DS, Nyambat B, Phetsouvanh R, Douangboupha V, Keonakhone P, Xoumphonphakdy B, Vongsouvanh M, Kirkwood C, Bogdanovic-Sakran N, Kilgore PE. Rotavirus diarrhoea among children aged less than 5 years at Mahosot Hospital, Vientiane, Lao PDR. Vaccine. 2009; 27 Suppl 5: 85-88.	2005-2007		
Laos	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998-1999, 2006		
Laos	Senesombath S, Nakornchai S, Banditsing P, Loxomboon D. Early childhood caries and related factors in Vientiane, Lao PDR. Southeast Asian J Trop Med Public Health. 2010; 41(3): 717-25.	2008	*	
Laos	Chuckpaiwong S, Ngonephady S, Dharmbhithit J, Kasetsuwan J, Sirirat M. The prevalence of periodontal disease and oral hygiene care in Savannakhet Province, Lao People's Democratic Republic. Southeast Asian J Trop Med Public Health. 2000; 31(4): 775-9.	1998	*	
Laos	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Laos	Phetsouvanh R, Midorikawa Y, Nakamura S. The seasonal variation in the microbial agents implicated in the etiology of diarrheal diseases among children in Lao People's Democratic Republic. Southeast Asian J Trop Med Public Health. 1999; 30(2): 319-23.	1994-1995	*	
Laos	Tran D-S, Odermatt P, Le T-O, Huc P, Druet-Cabanac M, Barennes H, Strobel M, Preux P-M. Prevalence of epilepsy in a rural district of central Lao PDR. Neuroepidemiology. 2006; 26(4): 199-206.	2003-2004	*	†
Laos	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Laos	National Drug and Alcohol Research Centre, University of New South Wales, United Nations Office on Drugs and Crime (UNODC). Laos Analysis of, and Proposed Methodology for, Measuring the Socioeconomic Impact of Drugs, Crime, and Corruption 2008.	2003, 2005	*	
Laos	Iwai K, Hirono A, Matsutoka H, Kawamoto F, Horie T, Lin K, Tantular IS, Dachlan YP, Notopturo H, Hidayah NI, Salim AM, Fujii H, Miwa S, Ishii A. Distribution of glucose-6-phosphate dehydrogenase mutations in Southeast Asia. Hum Genet. 2001; 108(6): 445-9.	1997-1998		
Laos	Ministry of Health (Laos). Laos Tuberculosis Prevalence Survey 2010-2011.	2010-2011	*	
Laos	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Laos	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
Laos	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Laos	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	
Laos	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Laos	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Laos	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Laos	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
Laos	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Laos	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Laos	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Laos	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Laos	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Laos	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Laos	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Laos	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Laos	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Laos	Casson RJ, Kahawita S, Kong A, Muecke J, Sisaleumsak S, Visnavong V. Exceptionally low prevalence of refractive error and visual impairment in schoolchildren from Lao People's Democratic Republic. Ophthalmology. 2012; 119(10): 2021-7.	2009	*	
Laos	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2000.	2000		
Laos	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2001.	2001		
Laos	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2002.	2002		
Laos	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2004.	2004		
Laos	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2005.	2005		
Laos	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2007.	2007		
Laos	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2008.	2008		
Laos	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2009.	2009		
Laos	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2010.	2010		
Laos	Lao-Luxembourg Heart Institute. Laos Rheumatic Heart Disease Prevalence Survey Data 2007-2009. [Unpublished].	2007-2009		
Laos	Ng KP, Ngeow YF, K R, M R. Hepatitis B seroprevalence among University of Malaya Students in the Post-universal Infant Vaccination Era. Med J Malaysia. 2013; 68(2): 144-7.	2005-2011	*	
Laos	Jutavittum P, Yousukh A, Samountry B, Samountry K, Ounavong A, Thammavong T, Keokhamphue J, Toriyama K. Seroprevalence of hepatitis B and C virus infections among Lao blood donors. Southeast Asian J Trop Med Public Health. 2007; 38(4): 674-9.	2003-2005		
Laos	Report on Public Health Survey of Nam Theun Project as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Laos	The Health Status of Resident Populations in the Nam Theun 2 Project area, Khammouane Province, Lao PDR as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Laos	Anothay O, Pongvongsa T. Childhood malaria in the Lao People's Democratic Republic. Bull World Health Organ. 1998; 76(1): 29-34 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Laos	Giboda M, Pholsena K, Hongvanthong B, Gutvirth J, Rubik I. Malariometric survey in Keoum District, Laos: sensitivity of Plasmodium falciparum to anti-malarials and automedication with chloroquine. Southeast Asian J Trop Med Public Health. 1992; 23(3): 383-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Laos	Khaminsou N, Kritpetcharat O, Daduang J, Kritpetcharat P. A survey of malarial infection in endemic areas of Savannakhet province, Lao PDR and comparative diagnostic efficiencies of Giemsa staining, acridine orange staining, and semi-nested multiplex PCR. Parasitol Int. 2008; 57(2): 143-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Laos	Kobayashi J, Sombon P, Keomanila H, Inthavongsa S, Nambanya S, Inthakone S, Sato Y, Miyagi I. Malaria prevalence and a brief entomological survey in a village surrounded by rice fields in Khammouane province, Lao PDR. Trop Med Int Health. 2000; 5(1): 17-21 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Laos	Kobayashi J, Vannachone B, Sato Y, Sinjo M, Nambanya S, Manivong K, Inthakone S. Current status of malaria infection in a southeastern province of Lao PDR. Southeast Asian J Trop Med Public Health. 1998; 29(2): 236-41 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Laos	Toma H, Kobayashi J, Imada Y, Arakawa T, Nakajima Y, Laymanivong S, Vannachone B, Manivong K, Phompida S, Sato Y. Field application and evaluation of a rapid immunochromatographic test for detection of Plasmodium falciparum infection among the inhabitants of Lao PDR. Southeast Asian J Trop Med Public Health. 2003; 34(1): 43-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
Laos	Toma H, Kobayashi J, Vannachone B, Arakawa T, Sato Y, Nambanya S, Manivong K, Inthakone S. A field study on malaria prevalence in southeastern Laos by polymerase chain reaction assay. Am J Trop Med Hyg. 2001; 64(5-6): 257-61 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
Laos	Toma T, Miyagi I, Okazawa T, Kobayashi J, Saita S, Tuzuki A, Keomanila H, Nambanya S, Phompida S, Uza M, Takakura M. Entomological surveys of malaria in Khammouane Province, Lao PDR, in 1999 and 2000. Southeast Asian J Trop Med Public Health. 2002; 33(3): 532-46 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
Laos	Vythilingam I, Phetsouvanh R, Keokenchanh K, Yengmala V, Vanisaveth V, Phompida S, Hakim SL. The prevalence of Anopheles (Diptera: Culicidae) mosquitoes in Sekong Province, Lao PDR in relation to malaria transmission. Trop Med Int Health. 2003; 8(6): 525-35 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000-2001	*	†
Laos	Vythilingam I, Sidavong B, Chan ST, Phonemixay T, Vanisaveth V, Sisoulad P, Phetsouvanh R, Hakim SL, Phompida S. Epidemiology of malaria in Attapeu Province, Lao PDR in relation to entomological parameters. Trans R Soc Trop Med Hyg. 2005; 99(11): 833-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002-2004	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Latvia	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2004-2011		
Latvia	World Health Organization (WHO). Latvia World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		
Latvia	Central Statistical Bureau (Latvia), Centre of Demography, University of Latvia, United Nations Economic Commission for Europe (UNECE). Latvia Fertility and Family Survey 1995. Geneva, Switzerland: United Nations Economic Commission for Europe (UNECE).	1995		
Latvia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Latvia	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. J Allergy Clin Immunol. 2008; 121(4): 947-954.	1994, 2004		
Latvia	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001-2002, 2004-2009		
Latvia	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J. 1998; 12(2): 315-35.	1993-1995		
Latvia	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2004		
Latvia	Forman D, Bray F, Brewster DH, Gombé Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version). Lyon, IARC. http://cis.iarc.fr	2004-2007	*	
Latvia	Bjarnason S, Care R, Berzina S, Brinkmane A, Rence I, Mackevica I, Paeglite I, Senakola E. Caries experience in Latvian nursery school children. Community Dent Oral Epidemiol. 1995; 23(3): 138-41.	1993		
Latvia	United States Renal Data System Coordinating Center. United States Renal Data System Annual Data Report 2004. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2004.	2002		
Latvia	United States Renal Data System Coordinating Center. USRDS 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2001.	1999		
Latvia	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Latvia	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1995, 1999, 2003		
Latvia	WHO Regional Office for Europe (EURO-WHO). Young People's Health in Context. Health Behaviour in School-aged Children (HBSC) Study: International Report from the 2001-2002 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2004.	2001		
Latvia	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Latvia	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). Alcohol and Drug Use Among European 17-18 Year Old Students: Data from the ESPAD Project. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2007.	2003		
Latvia	Bouvier-Colle M-H, Mohangoo AD, Gissler M, Novak-Antolic Z, Vutuc C, Szamotulska K, Zeitlin J, Euro-Peristat Scientific Committee. What about the mothers? An analysis of maternal mortality and morbidity in perinatal health surveillance systems in Europe. BJOG. 2012; 119(7): 880-90.	2003-2004	*	
Latvia	Rancans E, Vrublevska J, Snikere S, Koroleva I, Trapencieris M. The point prevalence of depression and associated sociodemographic correlates in the general population of Latvia. J Affect Disord. 2013.	2011	*	
Latvia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Latvia	Rutkowski B. Changing pattern of end-stage renal disease in central and eastern Europe. Nephrol Dial Transplant. 2000; 15(2): 156-60.	1998		
Latvia	Locatelli F, D'Amico M, Cerpevskis H, Dainys B, Miglinas M, Luman M, Ots M, Ritz E. The epidemiology of end-stage renal disease in the Baltic countries: an evolving picture. Nephrol Dial Transplant. 2001; 16(7): 1338-42.	1999		
Latvia	Wagner KS, White JM, Lucenko I, Mercer D, Crowcroft NS, Neal S, Efstratiou A. Diphtheria Surveillance Network. Diphtheria in the postepidemic period, Europe, 2000-2009. Emerg Infect Dis. 2012; 18(2): 217-25.	2000-2009	*	
Latvia	Central Statistical Bureau (Latvia), Eurostat. Latvia European Health Interview Survey 2008.	2008	*	
Latvia	Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, Büchele G, Clausen M, Cookson WOC, von Mutius E, Strachan DP, Williams HC, ISAAC Phase Two Study Group. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. J Allergy Clin Immunol. 2008; 121(1): 141-147.	2005-2007	*	
Latvia	Flohr C, Weinmayr G, Weiland SK, Addo-Yobo E, Annesi-Maesano I, Björkstén B, Bråbäck L, Büchele G, Chico M, Cooper P, Clausen M, El Sharif N, Martínez Gimeno A, Mathur RS, von Mutius E, Morales Suarez-Varela M, Pearce N, Svabe V, Wong GWK, Yu M, Zhong NS, Williams HC, ISAAC Phase Two Study Group. How well do questionnaires perform compared with physical examination in detecting flexural eczema? Findings from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. Br J Dermatol. 2009; 161(4): 846-53.	2005-2007	*	
Latvia	Zeitlin J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT; 2008. Available from: http://www.perinataleaudit.nl/downloads/bestand/649/peristat-ii-2008-	2004		†
Latvia	Latvia Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Latvia	Latvia Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Latvia	USSR - Latvian SSR Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Lebanon	Ministry of Public Health (Lebanon), League of Arab States. Lebanon Maternal and Child Health Survey 1996.	1996		†
Lebanon	Central Administration of Statistics (Lebanon), League of Arab States, Ministry of Social Affairs (Lebanon), Pan Arab Project for Family Health (PAPFAM). Lebanon Family Health Survey 2004.	2004		†
Lebanon	Ministry of Public Health (Lebanon), World Health Organization (WHO). Lebanon WHO Multi-country Survey Study on Health and Health System Responsiveness 2000-2001.	2000-2001		
Lebanon	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Lebanon	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Lebanon	Demyttenaere K, Bruffaerts R, Lee S, Posada-Villa J, Kovess V, Angermeyer MC, Levinson D, de Girolamo G, Nakane H, Mueinneh Z, Lara C, de Graaf R, Scott KM, Gureje O, Stein DJ, Haro JM, Bromet EJ, Kessler RC, Alonso J, Von Korff M. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. <i>Pain</i> . 2007; 129(3): 332-42.	2002-2003		
Lebanon	Inati A, Jradi O, Tarabay H, Moallem H, Rachkidi Y, El Accaoui R, Ismae'el H, Wehbe R, Mfarrej BG, Dabbous I, Taher A. Sickle cell disease: the Lebanese experience. <i>Int J Lab Hematol</i> . 2007; 6(29): 399-408.	1985-2005		
Lebanon	Charafeddine K, Ismae'el H, Charafeddine M, Inati A, Koussa S, Naja M, Taher A. Survival and Complications of Beta-Thalassemia in Lebanon. <i>Acta Haematol</i> . 2008; 120(2): 112-6.	1970-2002		
Lebanon	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998-2009		
Lebanon	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J</i> . 1998; 12(2): 315-35.	1993-1995		
Lebanon	Waked N, Nacouzi R, Haddad N, Zaini R. [Epidemiology of diabetic retinopathy in Lebanon]. <i>J Fr Ophtalmol</i> . 2006; 29(3): 289-95.	2000		
Lebanon	Salti HI, Nasrallah MP, Taleb NM, Merheb M, Haddad S, El-Annan J, Khouri A, Salti IS. Prevalence and determinants of retinopathy in a cohort of Lebanese type II diabetic patients. <i>Can J Ophthalmol</i> . 2009; 44(3): 308-13.	2004-2007		
Lebanon	Salti IS, Khogali M, Alam S, Haidar NA, Masri A. Epidemiology of diabetes mellitus in relation to other cardiovascular risk factors in Lebanon. <i>East Mediterr Health J</i> . 1997; 3(3): 462-71.	1995		
Lebanon	Waked M, Salameh P. Asthma, allergic rhinitis and eczema in 5-12-year-old school children across Lebanon. <i>Public Health</i> . 2008; 122(9): 965-73.	2005	*	
Lebanon	Karout N, Hawai SM, Altuwajri S. Prevalence and pattern of menstrual disorders among Lebanese nursing students. <i>East Mediterr Health J</i> . 2012; 18(4): 346-52.	2006	*	
Lebanon	Karam EG, Mneimneh ZN, Karam AN, Fayyad JA, Nasser SC, Chatterji S, Kessler RC. Prevalence and treatment of mental disorders in Lebanon: a national epidemiological survey. <i>Lancet</i> . 2006; 367(9515): 1000-6.	2002-2003		
Lebanon	Institute for Development, Research, Advocacy, and Applied Care (Lebanon), United Nations Office on Drugs and Crime (UNODC). Lebanon Rapid Situation Assessment and Responses Study on Substance Abuse 2001.	1999		
Lebanon	Mansour AM, Kassak K, Chaya M, Hourani T, Sibai A, Alameddine MN. National survey of blindness and low vision in Lebanon. <i>Br J Ophthalmol</i> . 1997; 81(10): 905-6. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1995		
Lebanon	Deeb ME, Awwad J, Yretzian JS, Kaspar HG. Prevalence of reproductive tract infections, genital prolapse, and obesity in a rural community in Lebanon. <i>Bull World Health Organ</i> . 2003; 81(9): 639-45.	1998	*	
Lebanon	Chaya M, Slim ZN, Habib RR, Arayssi T, Dana R, Hamdan O, Assi M, Issa Z, Uthman I. High burden of rheumatic diseases in Lebanon: a COPCORD study. <i>Int J Rheum Dis</i> . 2012; 15(2): 136-43.	2007-2009	*	
Lebanon	Yaghi C, Sharara A-I, Rassam P, Moucari R, Honein K, BouJaoude J, Slim R, Noun R, Abdul-Baki H, Khalifeh M, Ramia S, Sayegh R. Hepatoacellar carcinoma in Lebanon: Etiology and prognostic factors associated with short-term survival. <i>World J Gastroenterol</i> . 2006; 12(22): 3575-80.	1998-2003		
Lebanon	Farhood L, Zurayk H, Chaya M, Saadeh F, Meshfedjian G, Sidani T. The impact of war on the physical and mental health of the family: the Lebanese experience. <i>Soc Sci Med</i> . 1993; 36(12): 1555-67.	1987	*	
Lebanon	Farhood LF, Dimassi H. Prevalence and predictors for post-traumatic stress disorder, depression and general health in a population from six villages in South Lebanon. <i>Soc Psychiatry Psychiatr Epidemiol</i> . 2012; 47(4): 639-49.	2010	*	
Lebanon	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2001, 2004, 2007, 2010, 2012		
Lebanon	Karam WG, Rady A, Abdallah Hajj Hussein I, Assaad C, Saliba J, Afimos G, Mortada M, Hazzouri M, Bedrossian N, Naji S, Leone A, Jurjus AR. Cytology and clinical spectrum of sexually transmitted infections in Lebanese women as revealed by Pap smear: a cross-sectional study from 2002-2006. <i>J Biol Regul Homeost Agents</i> . 2011; 25(3): 453-9.	2002-2006	*	
Lebanon	Jambart S, Ammache Z, Haddad F, Younes A, Hassoun A, Abdalla K, Selwan CA, Sunna N, Wajsbrot D, Youseif E. Prevalence of painful diabetic peripheral neuropathy among patients with diabetes mellitus in the Middle East region. <i>J Int Med Res</i> . 2011; 39(2): 366-77.	2009		
Lebanon	Hirbil KL, Aboujaoude JH, Ghorra FS, Barakat-el-Khoury WM. [Prevalence and incidence of diabetes mellitus in Lebanon]. <i>Diabete Metab</i> . 1990; 16(6): 479-83.	1970-1985, 1987		
Lebanon	Taleb N, Loiselet J, Guorra F, Sfeir H. On glucose-6-phosphate dehydrogenase deficiency in autochthonous populations of Lebanon. <i>C R Hebd Seances Acad Sci</i> . 1964; 5749-51.	1962-1964		
Lebanon	Usanga EA, Ameen R. Glucose-6-phosphate dehydrogenase deficiency in Kuwait, Syria, Egypt, Iran, Jordan and Lebanon. <i>Hum Hered</i> . 2000; 50(3): 158-61.	1996-1997		
Lebanon	Khneisser I, Adib SM, Loiselet J, Mégarbané A. Prevalence of G6PD deficiency and knowledge of diagnosis in a sample of previously unscreened Lebanese males: clinical implications. <i>J Med Screen</i> . 2006; 13(1): 26-8.	2004-2006		
Lebanon	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant</i> . 1988; 3(6): 714-27.	1985-1986		
Lebanon	Shamseddine A, Sibai A-M, Gehchan N, Rahal B, El-Saghir N, Ghosn M, Afimos G, Chamseddine N, Seoud M, Lebanese Cancer Epidemiology Group. Cancer Incidence in Postwar Lebanon: Findings from the First National Population-based Registry, 1998. <i>Ann Epidemiol</i> . 2004; 14(9): 663-8.	1998	*	
Lebanon	Ministry of Public Health (Lebanon). Lebanon National Cancer Registry Tables 2005. Beirut, Lebanon: Ministry of Public Health (Lebanon).	2005	*	
Lebanon	Ministry of Public Health (Lebanon). Lebanon National Cancer Registry Tables 2006. Beirut, Lebanon: Ministry of Public Health (Lebanon).	2006	*	
Lebanon	Ministry of Public Health (Lebanon). Lebanon National Cancer Registry Tables 2007. Beirut, Lebanon: Ministry of Public Health (Lebanon).	2007	*	
Lebanon	Lebanon Iodine Deficiency Disorders Survey 1993 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1993		
Lebanon	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec</i> . 2005; 80(34): 289-95.	2004	*	
Lebanon	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec</i> . 2009; 84(33): 333-40.	2008	*	
Lebanon	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec</i> . 2010; 85(35): 337-48.	2009	*	
Lebanon	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec</i> . 2012; 87(34): 317-28.	2011	*	
Lebanon	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec</i> . 2013; 88(35): 365-79.	2012	*	
Lebanon	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec</i> . 2011; 86(36): 389-99.	2010	*	
Lebanon	American University of Beirut. Lebanon Community Oriented Programme for Control of Rheumatic Diseases Survey 2008. [Unpublished].	2008	*	
Lebanon	Chedid NR, Bourgeois D, Kaloustian H, Baba NZ, Pilipli C. Caries prevalence and caries risk in a sample of Lebanese preschool children. <i>Odontostomatol Trop</i> . 2011; 34(134): 31-45.	2009	*	
Lebanon	Abdul-Baki H, ElHajj I, El-Zahabi LMN, Azar C, Aoun E, Zantout H, Nasreddine W, Ayyach B, Mourad FH, Soweid A, Barada KA, Sharara AI. Clinical epidemiology of inflammatory bowel disease in Lebanon. <i>Inflamm Bowel Dis</i> . 2007; 13(4): 475-80.	2006		
Lebanon	Irani Hakime N, Feghali Haibeh R. [Hepatitis E virus: detection of antibodies in blood donors in Lebanon]. <i>J Med Liban</i> . 1998; 46(2): 60-2.	1995	*	
Lebanon	Shamma'a MH, Abu-Samra S, Salameh V, Nassar NT. The significance of anti-HAV in different population sectors in Lebanon: a comparative seroepidemiologic study. <i>Int J Epidemiol</i> . 1982; 11(4): 406-9.	1997		
Lebanon	Sacy RG, Haddad M, Basiri G, Khoriat A, Gerbaka BJ, Abu-Elyazeed R. Hepatitis in Lebanon: a changing epidemiological pattern. <i>Am J Trop Med Hyg</i> . 2005; 73(2): 453-6.	1999-2000		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Lebanon	Bizri ARN, Nuwayhid IA, Hamadeh GN, Steitieh SW, Choukair AM, Musharrafieh UM. Association between hepatitis A virus and Helicobacter pylori in a developing country: the saga continues. J Gastroenterol Hepatol. 2006; 21(10): 1615-21.	1999-2000		
Lebanon	Castillo Taucher S. [Services for the care and prevention of birth defects. Reduced report of a World Health Organization and March of Dimes Foundation meeting]. Rev Med Chil. 2007; 135(6): 806-13.	1990-2006		
Lesotho	Bureau of Statistics (Lesotho), United Nations Children's Fund (UNICEF). Lesotho Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Lesotho	Bureau of Statistics (Lesotho), International Statistical Institute. Lesotho World Fertility Survey 1977. Voorburg, Netherlands: International Statistical Institute.	1977		
Lesotho	Bureau of Statistics (Lesotho), Macro International, Inc, Ministry of Health and Social Welfare (Lesotho), Lesotho Demographic and Health Survey 2004-2005. Calverton, United States: Macro International, Inc.	2004-2005		†
Lesotho	ICF Macro, Ministry of Health and Social Welfare (Lesotho), Lesotho Demographic and Health Survey 2009-2010. Calverton, United States: ICF Macro.	2009-2010		†
Lesotho	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Lesotho	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000, 2006-2009		
Lesotho	Seung KJ, Rigodon J, Finch M, Gove S, Vasan A, Satti H. Distribution of adult respiratory illnesses at a primary health centre in Lesotho. Int J Tuberc Lung Dis. 2012; 16(3): 418-22.	2008-2009	*	
Lesotho	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Lesotho	Moolenburgh JD, Valkenburg HA, Fourie PB. A population study on rheumatoid arthritis in Lesotho, southern Africa. Ann Rheum Dis. 1986; 45(8): 691-5.	1983		
Lesotho	Lesotho National Micronutrient Survey 1993 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1993		†
Lesotho	Hollifield M, Katon W, Spain D, Pule L. Anxiety and depression in a village in Lesotho, Africa: a comparison with the United States. Br J Psychiatry. 1990; 156: 343-50.	1986-1987		
Lesotho	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2004, 2010, 2012		
Lesotho	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Lesotho	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Lesotho	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Lesotho	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Lesotho	Van Geldermalsen AA, Wenning U. A diphtheria epidemic in Lesotho, 1989. Did vaccination increase the population's susceptibility? Ann Trop Paediatr. 1993; 13(1): 13-9.	1989		
Lesotho	Jooste PL, Langenhoven ML, Kriek JA, Kunneke E, Nyaphisi M, Sharp B. Nutritional status of rural children in the Lesotho Highlands. East Afr Med J. 1997; 74(11): 680-9 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1997		
Lesotho	Sebotsa MLD, Dannhauser A, Jooste PL, Joubert G. Iodine status as determined by urinary iodine excretion in Lesotho two years after introducing legislation on universal salt iodization. Nutrition. 2005; 21(1): 20-4 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1999		
Liberia	Ministry of Planning and Economic Affairs (Liberia), Westinghouse; Institute for Resource Development. Liberia Demographic and Health Survey 1986. Columbia, United States: Westinghouse; Institute for Resource Development.	1986		
Liberia	Liberia Institute for Statistics and Geo-information Services (LISGIS), Macro International, Inc. Liberia Demographic and Health Survey 2006-2007. Calverton, United States: Macro International, Inc.	2006-2007		†
Liberia	Liberia Malaria Indicator Survey 2008-2009 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008-2009	*	†
Liberia	Liberia Malaria Indicator Survey 2011 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2011-2012	*	†
Liberia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Liberia	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Liberia	Holzer B, Saladin K, Saladin B, Dennis E, Degrémont A. The impact of schistosomiasis among rural populations in Liberia. Acta Trop. 1983; 40(3): 239-59.	1980-1981		
Liberia	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1995, 1997-1998		
Liberia	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000-2009		
Liberia	Mutebi J-P, Barrett ADT. The epidemiology of yellow fever in Africa. Microbes Infect. 2002; 4(14): 1459-68.	1995-1997, 2000-2001		
Liberia	WHO Global Alert and Response (GAR). Yellow Fever in Liberia - Update 06 May 2009. Geneva, Switzerland: World Health Organization (WHO), 2009.	2009		
Liberia	WHO Global Alert and Response (GAR). Yellow Fever in Liberia - Update 25 April 2008. Geneva, Switzerland: World Health Organization (WHO), 2008.	2008		
Liberia	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Liberia	Vinck P, Pham PN. Association of exposure to intimate-partner physical violence and potentially traumatic war-related events with mental health in Liberia. Soc Sci Med. 2013; 77: 41-9.	2010	*	
Liberia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2010, 2012		
Liberia	Moormann AM, Embury PE, Opondo J, Sumba OP, Ouma JH, Kazura JW, John CC. Frequencies of sickle cell trait and glucose-6-phosphate dehydrogenase deficiency differ in highland and nearby lowland malaria-endemic areas of Kenya. Trans R Soc Trop Med Hyg. 2003; 97(5): 513-4.	2000-2001		
Liberia	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Liberia	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Liberia	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Liberia	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Liberia	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Liberia	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Liberia	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Liberia	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Liberia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Liberia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Liberia	Prince AM, Brotman B, Richardson L, White T, Pollock N, Riddle J. Incidence of hepatitis A virus (HAV) infection in rural Liberia. <i>J Med Virol</i> . 1985; 15(4): 421-8.	1978-1979		
Liberia	Simbebe AG. A study of some haemoglobin variants, haptoglobin types, ABO and Rh blood groups in a sample of Liberians. <i>Hum Hered</i> . 1972; 22(3): 286-9.	1969-1971	*	†
Liberia	Ministry of Planning and Economic Affairs (Liberia). Liberia Population Growth Survey 1970-1971 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1971		
Liberia	Björkman A, Wilcox M, Marbiah N, Payne D. Susceptibility of Plasmodium falciparum to different doses of quinine in vivo and to quinine and quinidine in vitro in relation to chloroquine in Liberia. <i>Bull World Health Organ</i> . 1991; 69(4): 459-65 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Liberia	Hogh B, Marbiah NT, Petersen E, Perlmann H, Dolopaye E, Hanson AP, Bjorkman A, Perlmann P. A longitudinal study of seroreactivities to Plasmodium falciparum antigens in infants and children living in a holoendemic area of Liberia. <i>Am J Trop Med Hyg</i> . 1991; 44(2): 191-200 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Libya	Committee for Health and Social Insurance (Libya), League of Arab States. Libya Maternal and Child Health Survey 1995.	1995		†
Libya	Secretariat of Health and Environment (Libya), World Health Organization (WHO). Libya STEPS Noncommunicable Disease Risk Factors Survey 2009.	2009		
Libya	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Libya	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	2009		†
Libya	Ashok PP, Radhakrishnan K, Sridharan R, el-Mangoush MA. Incidence and pattern of cerebrovascular diseases in Benghazi, Libya. <i>J Neurol Neurosurg Psychiatry</i> . 1986; 49(5): 519-23.	1983-1984		
Libya	Jain RC. Abnormal haemoglobin, thalassaemia and G-6-PD deficiency in Libya. <i>Br J Haematol</i> . 1983; 1(54): 154-5.	1978-1979		
Libya	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2005-2009		
Libya	Radhakrishnan K, Ashok PP, Sridharan R, Mousa ME. Prevalence and pattern of multiple sclerosis in Benghazi, north-eastern Libya. <i>J Neurol Sci</i> . 1985; 70(1): 39-46.	1982-1984		
Libya	Kadiki OA, Roaed RB. Epidemiological and clinical patterns of diabetes mellitus in Benghazi, Libyan Arab Jamahiriya. <i>East Mediterr Health J</i> . 1999; 5(1): 6-13.	1981-1990		
Libya	Huew R, Waterhouse PJ, Moynihan PJ, Maguire A. Prevalence and severity of dental caries in Libyan schoolchildren. <i>Int Dent J</i> . 2011; 61(4): 217-23.	2009	*	
Libya	Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version). Lyon, IARC. http://cis.iarc.fr	2003-2005	*	
Libya	Barsoum RS. Burden of chronic kidney disease: North Africa. <i>Kidney Int Suppl</i> . 2013; 3: 164-6.	2000-2010		
Libya	Ali MMM, Mohamed ZK, Klena JD, Ahmed SF, Moussa TAA, Ghengesh KS. Molecular characterization of diarrheagenic Escherichia coli from Libya. <i>Am J Trop Med Hyg</i> . 2012; 86(5): 866-71.	2000-2001	*	
Libya	El Zanni S, Ahmed M, Prakash PS, Hassan KM. Stroke: Incidence and pattern in Benghazi, Libya. <i>Ann Saudi Med</i> . 1995; 15(4): 367-9.	1991-1993		
Libya	Ashok PP, Radhakrishnan K, Sridharan R, Mousa ME. Epidemiology of Parkinson's disease in Benghazi, North-East Libya. <i>Clin Neurol Neurosurg</i> . 1986; 88(2): 109-13.	1985		
Libya	Ahmaidia A, Al-Shaikhi S. Childhood Inflammatory Bowel Disease in Libya: Epidemiological and Clinical features. <i>Libyan J Med</i> . 2009; 4(2): 70-4.	2006	*	†
Libya	Khalil MM, Alzakra E. Fetal gender and pregnancy outcomes in Libya: a retrospective study. <i>Libyan J Med</i> . 2013.	2009-2010	*	
Libya	Sridharan R, Radhakrishnan K, Ashok PP, Mousa ME. Epidemiological and clinical study of epilepsy in Benghazi, Libya. <i>Epilepsia</i> . 1986; 27(1): 60-5.	1984	*	†
Libya	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 2004, 2007, 2012		
Libya	Kadiki OA, Moawad SE. Incidence and prevalence of type 1 diabetes in children and adolescents in Benghazi, Libya. <i>Diabet Med</i> . 1993; 10(9): 866-9.	1981-1990		
Libya	Kadiki OA, Moawad SE. Ten-year incidence (1981-90) of insulin-dependent diabetes in the 0-29-year-old age group in Benghazi, Libya. <i>Diabetes Res Clin Pract</i> . 1994; 26(3): 223-8.	1981-1990		
Libya	Kadiki OA, Reddy MR, Marzouk AA. Incidence of insulin-dependent diabetes (IDDM) and non-insulin-dependent diabetes (NIDDM) (0-34 years at onset) in Benghazi, Libya. <i>Diabetes Res Clin Pract</i> . 1996; 32(3): 165-73.	1981-1990		
Libya	Kadiki OA, Roaeid RBM. Incidence of type 1 diabetes in children (0-14 years) in Benghazi Libya (1991-2000). <i>Diabetes Metab</i> . 2002; 28(6 Pt 1): 463-7.	1991-2000		
Libya	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant</i> . 1988; 3(6): 714-27.	1985-1986		
Libya	Barsoum RS. End-stage renal disease in North Africa. <i>Kidney Int Suppl</i> . 2003; 83: S111-4.	1993-2002		
Libya	Radhakrishnan K, el-Mangoush MA, Gerryo SE. Descriptive epidemiology of selected neuromuscular disorders in Benghazi, Libya. <i>Acta Neurol Scand</i> . 1987; 75(2): 95-100.	1983-1985		†
Libya	World Health Organization (WHO). Libya WHO Leishmaniasis Country Profile.	2004-2010	*	
Libya	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec</i> . 2005; 80(34): 289-95.	2004	*	
Libya	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec</i> . 2007; 82(25): 225-32.	2006	*	
Libya	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec</i> . 2009; 84(33): 333-40.	2008	*	
Libya	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec</i> . 2010; 85(35): 337-48.	2009	*	
Libya	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec</i> . 2012; 87(34): 317-28.	2011	*	
Libya	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec</i> . 2008; 83(33): 293-300.	2007	*	
Libya	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec</i> . 2013; 88(35): 365-79.	2012	*	
Libya	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec</i> . 2011; 86(36): 389-99.	2010	*	
Libya	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec</i> . 1997; 72(23): 165-72.	1996	*	
Libya	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec</i> . 1996; 71(20): 149-56.	1995	*	
Libya	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1995; 70(25): 177-82.	1994	*	
Libya	Rabiu MM, Jenf M, Fituri S, Choudhury A, Agbabiaka I, Mousa A. Prevalence and causes of visual impairment and blindness, cataract surgical coverage and outcomes of cataract surgery in Libya. <i>Ophthalmic Epidemiol</i> . 2013; 20(1): 26-32.	2010	*	
Libya	Shembesh DNM, Elbargathy SM, Kashbur IM, Rao BN, Mahmoud KS. Dexamethasone as an adjunctive treatment of bacterial meningitis. <i>Indian J Pediatr</i> . 1997; 64(4): 517-22.	1994		
Libya	Radhakrishnan K, Maloo JC, Poddar SK, Mousa ME. Central nervous system infections in Benghazi, Libya: experience from a community-based adult medical neurology set-up. <i>J Trop Med Hyg</i> . 1987; 90(3): 123-6.	1983-1984		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Libya	Mir NA, Fakhri M, Abdelaziz M, Kishan J, Elzouki A, Baxi AJ, Sheriff DS, Prasanan KG. Erythrocyte glucose-6-phosphate dehydrogenase status of newborns and adults in eastern Libya. <i>Ann Trop Paediatr</i> . 1985; 5(4): 211-3.	1984	*	
Libya	Fayrouz INE, Farida N, Ishad AH. Relation between fingerprints and different blood groups. <i>J Forensic Leg Med</i> . 2012; 19(1): 18-21.	2010	*	†
Libya	Libya Vital Registration Birth Data 1981 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1981		
Lithuania	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2001-2010		
Lithuania	Lithuania Vital Registration - Deaths 2001 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2001	*	
Lithuania	Baltic Surveys Ltd. (Lithuania), United Nations Economic Commission for Europe (UNECE). Lithuania Fertility and Family Survey 1994-1995. Geneva, Switzerland: United Nations Economic Commission for Europe (UNECE).	1994-1995		
Lithuania	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Lithuania	National Public Health Institute (Finland), World Health Organization (WHO). WHO MONICA Cerebrovascular Event Data 1982-1997, as provided by the Global Burden of Disease 2010 Cerebrovascular Disease Expert Group. [Unpublished].	1986-1992		
Lithuania	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol</i> . 2008; 121(4): 947-954.	1995, 2001-2002		
Lithuania	Reklaitiene RA, Baubienene AV, Domarkene SB, Matsiavichiute NA, Tamoshunias AA, Iurenene KS. [Prevalence of risk factors and indicators of mortality among males 40-59 years of age with various forms of ischemic heart disease (data of a 5-year prospective study)]. <i>Polish Heart Journal</i> . 1989; 29(8): 39-42.	1980-1989		
Lithuania	Minkauskiene M, Nadisauskiene RJ, Padaiga Z. Severe and acute maternal morbidity: Lithuanian experience and review. <i>Int J Fertil Womens Med</i> . 2006; 51(1): 39-46.	2005		
Lithuania	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000-2009		
Lithuania	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J</i> . 1998; 12(2): 315-35.	1993-1995		
Lithuania	Lai CK, Beasley R, Crane J, Folliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	1998		
Lithuania	Matulaitiene ZK, Zemaitiene M, Zengulyte S, Milciuviene S. Changes in dental caries and oral hygiene among 7-8 year-old schoolchildren in different regions of Lithuania 1983-2009. <i>Stomatologija</i> . 2012; 14(2): 53-9.	1983, 2009	*	
Lithuania	Razmienė J, Vanagas G, Bendoraitienė E, Vyšniauskaitė A. The relation between oral hygiene skills and the prevalence of dental caries among 4-6-year-old children. <i>Stomatologija</i> . 2011; 13(2): 62-7.	2009-2010	*	
Lithuania	Slabinskiene E, Milciuviene S, Narbutaite J, Vasiliauskiene I, Andruskeviciene V, Bendoraitiene EA, Saldūnaitė K. Severe early childhood caries and behavioral risk factors among 3-year-old children in Lithuania. <i>Medicina (Kaunas)</i> . 2010; 46(2): 135-41.	2003		
Lithuania	Adomaviciute D, Pilekyte M, Baranauskaitė A, Morvan J, Dadoniene J, Guillemin F. Prevalence survey of rheumatoid arthritis and spondyloarthritis in Lithuania. <i>Scand J Rheumatol</i> . 2008; 37(2): 113-9.	2004		
Lithuania	Milciuviene S, Bendoraitiene E, Andruskeviciene V, Narbutaite J, Sakalauskiene J, Vasiliauskiene I, Slabinskiene E. Dental caries prevalence among 12-15-year-olds in Lithuania between 1983 and 2005. <i>Medicina (Kaunas)</i> . 2009; 45(1): 68-76.	1983-1986, 1995, 2000, 2005		
Lithuania	Skudutyte R, Aleksejuniene J, Eriksen HM. Dental caries in adult Lithuanians. <i>Acta Odontol Scand</i> . 2000; 58(4): 143-7.	1997-1998		
Lithuania	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Lithuania	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1995, 1999, 2004		
Lithuania	Kiudelis G, Jonaitis L, Adamonis K, Žvirblienė A, Tamelis A, Kregždytė R, Kučinskienė R, Šventoraitytė J, Kupčinskas L. Incidence of inflammatory bowel disease in Kaunas region, Lithuania. <i>Medicina (Kaunas)</i> . 2012; 48(8): 431-5.	2007-2009	*	†
Lithuania	WHO Regional Office for Europe (EURO-WHO). Young People's Health in Context. Health Behaviour in School-aged Children (HBSC) Study: International Report from the 2001-2002 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2004.	2002		
Lithuania	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Lithuania	Endziuniene M, Pauza V, Miseviciene I. Prevalence of childhood epilepsy in Kaunas, Lithuania. <i>Brain Dev</i> . 1997; 19(6): 379-87.	1995	*	
Lithuania	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Lithuania	Urbonaitė B, Zalinkevičius R, Green A. Incidence, prevalence, and mortality of insulin-dependent (type 1) diabetes mellitus in Lithuanian children during 1983-98. <i>Pediatr Diabetes</i> . 2002; 3(1): 23-30.	1983-1998		
Lithuania	Astrauskienė A, Dobrovolskij V, Stukas R. The prevalence of problem drug use in Lithuania. <i>Medicina (Kaunas)</i> . 2011; 47(6): 340-6.	2005-2007	*	
Lithuania	Rutkowski B. Changing pattern of end-stage renal disease in central and eastern Europe. <i>Nephrol Dial Transplant</i> . 2000; 15(2): 156-60.	1998		
Lithuania	Locatelli F, D'Amico M, Cerjevskis H, Dainys B, Miglinas M, Luman M, Ots M, Ritz E. The epidemiology of end-stage renal disease in the Baltic countries: an evolving picture. <i>Nephrol Dial Transplant</i> . 2001; 16(7): 1338-42.	1999		
Lithuania	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Gilst WH van, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J</i> . 2003; 24(5): 442-63.	2000-2001		
Lithuania	Jakuskiene R, Vollmer B, Saferis V, Daugele D. Neonatal outcomes of very preterm infants admitted to a tertiary center in Lithuania between the years 2003 and 2005. <i>Eur J Pediatr</i> . 2011; 170(10): 1293-303.	2004	*	†
Lithuania	Razmienė J, Vanagas G, Bendoraitienė EA, Andruskeviciene V, Slabinskiene E. Changes in caries prevalence and oral hygiene skills among preschool-aged children in Lithuania between 2000 and 2010. <i>Medicina (Kaunas)</i> . 2012; 48(7): 364-70.	2000, 2010	*	
Lithuania	Institute of Hygiene, Ministry of Health of the Lithuanian Republic. Lithuania Health Indicators System - Prevalence of Ulcer per 100,000 Individuals. Vilnius, Lithuania: Institute of Hygiene, Ministry of Health of the Lithuanian Republic.	2001-2012	*	
Lithuania	Institute of Hygiene, Ministry of Health of the Lithuanian Republic. Lithuania Health Indicators System - Prevalence of Cholelithiasis per 100,000 Individuals. Vilnius, Lithuania: Institute of Hygiene, Ministry of Health of the Lithuanian Republic.	2001-2012	*	
Lithuania	Institute of Hygiene, Ministry of Health of the Lithuanian Republic. Lithuania Health Indicators System - Incidence of Cholelithiasis per 100,000 Individuals. Vilnius, Lithuania: Institute of Hygiene, Ministry of Health of the Lithuanian Republic.	2001-2012	*	
Lithuania	Liakina V, Valantinas J. Anti-HCV prevalence in the general population of Lithuania. <i>Med Sci Monit</i> . 2012; 18(3): PH28-35.	2010		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod (†)
Lithuania	Kuch B, Heier M, von Scheidt W, Kling B, Hoermann A, Meisinger C. 20-year trends in clinical characteristics, therapy and short-term prognosis in acute myocardial infarction according to presenting electrocardiogram: the MONICA/KORA AMI Registry (1985-2004). <i>J Intern Med</i> . 2008; 264(3): 254-64.	1984-1989		
Lithuania	Radisauskas R, Rastenyte D, Bernotiene G, Sopocius D, Jancaityte L. Morbidity and mortality from the major cardiovascular diseases in Kaunas population from 1983 to 2002. <i>Medicina (Kaunas)</i> . 2003; 39(12): 1208-14.	1983-2002		
Lithuania	National Public Health Institute (Finland), World Health Organization (WHO). MONICA Coronary Event Registration Data Book 1980-1995. Geneva, Switzerland: World Health Organization (WHO), 2000.	1980-1995		
Lithuania	Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Barré J, André C. The impact of headache in Europe: principal results of the Eurolight project. <i>J Headache Pain</i> . 2014; 15(31). [Unpublished data].	2008	*	
Lithuania	Zeitlan J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT; 2008. Available from: http://www.perinataleaudit.nl/downloads/bestand/649/peristat-ii-2008-	2004		†
Lithuania	USSR - Lithuanian SSR Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Luxembourg	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2002-2010		
Luxembourg	World Health Organization (WHO). Luxembourg World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		
Luxembourg	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. <i>Scand J Clin Lab Invest</i> . 2007; 67(1): 39-69.	1988, 2006		
Luxembourg	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1988, 1990-2006		
Luxembourg	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2003-2004, 2006-2009		
Luxembourg	Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. <i>Diabetologia</i> . 1996; 39(11): 1377-84.	1993-1995		
Luxembourg	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. <i>Community Dent Oral Epidemiol</i> . 1991; 19(2): 72-3.	1987		
Luxembourg	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2001-2008		
Luxembourg	United States Renal Data System Coordinating Center. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2000		
Luxembourg	United States Renal Data System Coordinating Center. USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2003.	1999		
Luxembourg	De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology</i> . 2000; 54(11 Suppl 5): S21-23.	1997		
Luxembourg	Berger K, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology</i> . 2000; 54(11): 24-7.	1997		
Luxembourg	Mossong J, Putz L, Schneider F. Seroprevalence and force of infection of varicella-zoster virus in Luxembourg. <i>Epidemiol Infect</i> . 2004; 132(6): 1121-7.	2000-2002		
Luxembourg	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1998		
Luxembourg	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Luxembourg	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010		
Luxembourg	De Beaufort CE, Michel G, Glaesener G. The incidence of type 1 (insulin-dependent) diabetes mellitus in subjects aged 0-19 years in Luxembourg: a retrospective study from 1977 to 1986. <i>Diabetologia</i> . 1988; 31(10): 758-61.	1977-1986		
Luxembourg	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Luxembourg National Report to the EMCDDA 2007.	1996	*	
Luxembourg	Kraus L, Augustin R, Frischer M, Kümmler P, Uhl A, Wiessing L. Estimating prevalence of problem drug use at national level in countries of the European Union and Norway. <i>Addiction</i> . 2003; 98(4): 471-85.	1999	*	
Luxembourg	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant</i> . 1988; 3(6): 714-27.	1985-1986		
Luxembourg	Berthoux F, Jones E, Gellert R, Mendel S, Saker L, Briggs D. Epidemiological data of treated end-stage renal failure in the European Union (EU) during the year 1995: report of the European Renal Association Registry and the National Registries. <i>Nephrol Dial Transplant</i> . 1999; 14(10): 2332-42.	1995		
Luxembourg	Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. <i>J Clin Endocrinol Metab</i> . 2008; 93(4): 1408-11.	2005		
Luxembourg	European Centre for Disease Prevention and Control. Review of Chlamydia Control Activities in EU Countries. Stockholm, Sweden: European Centre for Disease Prevention and Control, 2008.	2008		
Luxembourg	Trichopoulos D, Bamia C, Ligiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overvad K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PHM, Lund E, Quirós JR, González CA, Sanchez Perez M-J, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu L, Chuang S-C, Murphy N, Boffetta P, Trichopoulou A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. <i>J Natl Cancer Inst</i> . 2011; 103(22): 1686-95.	1992-2006	*	
Luxembourg	Mossong J, Putz L, Patiny S, Schneider F. Seroprevalence of hepatitis A and hepatitis B virus in Luxembourg. <i>Epidemiol Infect</i> . 2006; 134(4): 808-13.	2000-2001		
Luxembourg	Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Barré J, André C. The impact of headache in Europe: principal results of the Eurolight project. <i>J Headache Pain</i> . 2014; 15(31). [Unpublished data].	2008	*	
Luxembourg	Zeitlan J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT; 2008. Available from: http://www.perinataleaudit.nl/downloads/bestand/649/peristat-ii-2008-	2004		†
Luxembourg	Luxembourg Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Macedonia	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2005		
Macedonia	State Statistical Office (Macedonia) and United Nations Children's Fund (UNICEF). Macedonia Multiple Indicator Cluster Survey 2005. New York, United States: United Nations Children's Fund (UNICEF).	2005	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Macedonia	Institute of Public Health (Macedonia), Ipsos Strategic Puls, Ministry of Education and Science (Macedonia), Ministry of Labor and Social Policy (Macedonia), United Nations Children's Fund (UNICEF). Macedonia Multiple Indicator Cluster Survey 2011. New York, United States: United Nations Children's Fund (UNICEF), 2013.	2011	*	†
Macedonia	Macedonia Vital Registration - Deaths 2004 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2004	*	
Macedonia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Macedonia	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1999, 2001-2009		
Macedonia	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2002		
Macedonia	Institute of Public Health (Macedonia), Ipsos Strategic Puls, United Nations Children's Fund (UNICEF). Macedonia - Roma Settlements Multiple Indicator Cluster Survey 2011. New York, United States: United Nations Children's Fund (UNICEF), 2013.	2011	*	
Macedonia	Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, Gjomarkaj M, Forsberg B, Gunnbjornsdottir M, Minov J, Brozek G, Dahlen SE, Toskala E, Kowalski ML, Olze H, Howarth P, Kramer U, Baelum J, Loureiro C, Kasper L, Bousquet PJ, Bousquet J, Bachert C, Fokkens W, Burney P. Asthma in adults and its association with chronic rhinosinuitis: the GA2LEN survey in Europe. Allergy. 2012; 67(1): 91-8.	2008-2009	*	
Macedonia	Vlaski E, Stavric K, Seckova L, Kimovska M, Isjanovska R. Do household tobacco smoking habits influence asthma, rhinitis and eczema among 13-14 year-old adolescents Allergol Immunopathol (Madr). 2011; 39(1): 39-44.	2001-2002	*	
Macedonia	Vrbic V, Vulovic M, Raji Z, Topi B, Tati E, Mali M, Mili D, Aurer-Kozelj J, Neceva L, Redzepagi S. Oral health in SFR Yugoslavia in 1986. Community Dent Oral Epidemiol. 1988; 16(5): 286-8.	1986		
Macedonia	WHO Regional Office for Europe (EURO-WHO). Young People's Health in Context. Health Behaviour in School-aged Children (HBSC) Study: International Report from the 2001-2002 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2004.	2002		
Macedonia	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Macedonia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Macedonia	Fraser GR, Defaranas B, Kattamis CA, Race RR, Sanger R, Stamatoyannopoulos G. Glucose-6-phosphate dehydrogenase, colour vision and XG blood groups in Greece: linkage and population data. Ann Hum Genet. 1964; 395-403.	1962		
Macedonia	Rutkowski B. Changing pattern of end-stage renal disease in central and eastern Europe. Nephrol Dial Transplant. 2000; 15(2): 156-60.	1997-1998		
Macedonia	Stojceva-Taneva O, Selim GJ, Zafirovska K, Polenakovic M. Differences in renal registries between the Balkans and Western Europe. Prilozi. 2006; 27(2): 37-47.	2003		
Macedonia	Macedonia Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Macedonia	Macedonia Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Madagascar	Department of Applied Research for Development (Madagascar), Macro International, Inc. Madagascar Demographic and Health Survey 1992. Calverton, United States: Macro International, Inc.	1992		†
Madagascar	Macro International, Inc, National Institute of Statistics (Madagascar). Madagascar Demographic and Health Survey 1997. Calverton, United States: Macro International, Inc.	1997		†
Madagascar	Macro International, Inc, National Institute of Statistics (Madagascar). Madagascar Demographic and Health Survey 2003-2004. Calverton, United States: Macro International, Inc.	2003-2004		†
Madagascar	ICF Macro, National Institute of Statistics (Madagascar). Madagascar Demographic and Health Survey 2008-2009. Calverton, United States: ICF Macro, 2010.	2008-2009		†
Madagascar	National Institute of Statistics (Madagascar), United Nations Children's Fund (UNICEF). Madagascar Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Madagascar	Madagascar Malaria Indicator Survey 2011 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2011	*	†
Madagascar	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Madagascar	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Madagascar	Leutscher P, Ravaoalimalala VE, Raharisolo C, Ramarokoto CE, Rasendramino M, Raobelison A, Vennervald B, Esterer P, Feldmeier H. Clinical findings in female genital schistosomiasis in Madagascar. Trop Med Int Health. 1998; 3(4): 327-32.	1997-1998		
Madagascar	Leutscher P, Raharisolo C, Pecarrere JL, Ravaoalimalala VE, Serieye J, Rasendramino M, Vennervald B, Feldmeier H, Esterer P. Schistosoma haematobium induced lesions in the female genital tract in a village in Madagascar. Acta Trop. 1997; 66(1): 27-33.	1996-1997		
Madagascar	Gibbs, S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int J Dermatol. 1996; 35(9): 633-9.	1994		
Madagascar	Contet-Audonneu N, Grosjean P, Razanakolona L-R, Andriantsinjovina T, Rapelanoro R. [Tinea capitis in Madagascar: a survey in a primary school in Antsirabe]. Ann Dermatol Venerol. 2006; 133(1): 22-5.	2002		
Madagascar	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997, 1999, 2001-2002, 2009		
Madagascar	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Madagascar	Cassel-Beraud AM, Michel P, Garbarg-Chenon A. Epidemiological study of infantile rotavirus diarrhoea in Tananarive (Madagascar). J Diarrhoeal Dis Res. 1993; 11(2): 82-7.	1988-1990	*	
Madagascar	Adiku TK, Dove W, Grosjean P, Combe P, Nakagomi T, Nakagomi O, Hart CA, Cunliffe NA. Molecular characterization of rotavirus strains circulating among children with acute gastroenteritis in Madagascar during 2004-2005. J Infect Dis. 2010; S175-179.	2004-2005	*	
Madagascar	Randrianarisoa T et al. Results of the survey on hearing loss in the province of Antananarivo, Madagascar, as provided by the Global Burden of Disease 2010 Hearing Loss Expert Group. [Unpublished].	2003		
Madagascar	Petersen PE, Steengard M. Dental caries among urban schoolchildren in Madagascar. Community Dent Oral Epidemiol. 1988; 16(3): 163-6.	1986		
Madagascar	Petersen PE, Poulsen VJ, Ramahaleo J, Ratzifaritana C. Dental health among 6- and 12-year-old urban schoolchildren in Madagascar. Tandlaegebladet. 1991; 95(4): 155-60.	1986		
Madagascar	Petersen PE, Razanamihaja N. Oral health status of children and adults in Madagascar. Int Dent J. 1996; 46(1): 41-7.	1993		
Madagascar	Migliani R, Clouzeau J, Decousser J, Ravelomanana N, Rasamoelisoa J, Rabijaona H, Dromigny J, Pfister P, Roux J. Les meningites bactériennes non tuberculeuses de l'enfant à Antananarivo, Madagascar. Arch Pediatr. 2002; 9(9): 892-7.	1998-2000		
Madagascar	Razafindralambo M, Ravelomanana N, Randriamiharisoa FA, Migliani R, Clouzeau J, Raobijaona H, Rasamoelisoa J, Pfister P. Haemophilus influenzae, the second cause of bacterial meningitis in children in Madagascar. Bull Soc Pathol Exot. 2004; 97(2): 100-3.	1998-2000		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Madagascar	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Madagascar	Dodin A. Deficit en glucose 6 phosphate deshydrogenase. Arch Inst Pasteur Madagascar. 1965; 33: 233-7.	1963-1965		
Madagascar	Jaureguierry S, Hentgen V, Raholiniana N, Rasolomahefa D, Belec M. Cholera at Tamatave (Madagascar) from February to July 2000: Epidemic characteristics. Sante. 2001; 11(2): 73-8.	2000	*	
Madagascar	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Madagascar	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Madagascar	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Madagascar	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Madagascar	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Madagascar	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Madagascar	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Madagascar	World Health Organization (WHO). Leprosy. Global situation. Wkly Epidemiol Rec. 2002; 77(1): 1-8.	2001	*	
Madagascar	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Madagascar	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Madagascar	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1993; 68(25): 181-6.	1992	*	
Madagascar	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Madagascar	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Madagascar	MADAGASCAR Report of Iodine Deficiency Disorders Evaluation in 7 Sentimental Sites as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1992		
Madagascar	Ramarokoto CE, Rakotomanana F, Ratsitorahina M, Raharimanga V, Razafindratsimandresy R, Randremanana R, Rakoto-Andrianarivo M, Rousset D, Andrianaja V, Richard V, Soares J-L, Rabarijaona LP. Seroprevalence of hepatitis C and associated risk factors in urban areas of Antananarivo, Madagascar. BMC Infect Dis. 2008; 8(1): 25.	2004		
Madagascar	Carod J-F, Ratsitorahina M, Raherimandimby H, Hincky Vitrat V, Ravaomalala Andrianaja V, Contet-Audonneau N. Outbreak of Tinea capitis and corporis in a primary school in Antananarivo, Madagascar. J Infect Dev Ctries. 2011; 5(10): 732-6.	2005	*	
Madagascar	Andriantseho LM, Ralaizandry D. Prévalence communautaire de l'épilepsie chez les Malgaches. Epilepsies. 2004; 16(2): 83-6.	2001	*	†
Madagascar	Morvan JM, Boiesier P, Andrianimannana D, Razainirina J, Rakoto-Andrianarivo M, Roux JF. [Serological markers for hepatitis A, B and C in Madagascar. First investigation in a rural area]. Bull Soc Pathol Exot. 1994; 87(3): 138-42.	1993		
Madagascar	Raharimanga V, Carod J-F, Ramarokoto C-E, Chrétien J-B, Rakotomanana F, Talarmin A, Richard V. Age-specific seroprevalence of hepatitis A in Antananarivo (Madagascar). BMC Infect Dis. 2008; 78.	2004		
Madagascar	Randriamanantany ZA, Rajonatahina DH, Razafimanantsoa FE, Rasamindrakotroka MT, Andriamahenina R, Rasoarilamanarivo FB, Hanitriniaina SP, Herisoa FR, Rasamindrakotroka A, Rakoto Alison OA. Phenotypic and allelic profile of ABO and Rhésus D blood group system among blood donor in Antananarivo. Int J Immunogenet. 2012; 39(6): 477-9.	2003-2009	*	†
Madagascar	Boiesier P, Rabarijaona L, Piollet M, Roux JF, Zeller HG. Hepatitis B virus infection in general population in Madagascar: evidence for different epidemiological patterns in urban and in rural areas. Epidemiol Infect. 1996; 117(1): 133-7.	1993		
Madagascar	Varia-Human Pathology Compared as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985-1986	*	†
Madagascar	Evaluation of Lambda-Cyhalothrin in the Middle West of Madagascar: Final Report -February 1999 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Madagascar	Pasteur Institute: Malaria Research Unit Report 1987 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Madagascar	Pasteur Institute: Malaria Research Unit Report 1988 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Madagascar	Report on the Pasteur Institute Mission on the Antananarivo-Mahajanga Axis as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Madagascar	Evaluation of Insecticide Alternatives to DDT in CAID (Intra-residential Development Incecticide Spraying Campaigns) in the Central Highlands of Madagascar: First Report Comparing a DDT Treatment to a Negative Control in the Middle-East (Mahasolo Area) Between October 2002 and September 2003, as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Madagascar	Evaluation of Insecticide Alternatives to DDT in CAID (Intra-residential Development Incecticide Spraying Campaigns) in the Central Highlands of Madagascar: First Report Comparing a DDT Treatment to a Negative Control in the Middle-East (Mahasolo Area) Between October 2002 and September 2003. Antananarivo, Madagascar: Pasteur Institute of Madagascar (IPM), 2003 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002-2003	*	†
Madagascar	Evaluation of Replacement Insecticides for DDT in CAID (Intra-residential Development Incecticide Spraying Campaigns) in the Central Highlands of Madagascar: Second Report Comparing Treatment with Alpha-cypermethrin or Deltamethrin to a Negative Control in the Middle-East (Mahasolo Area) between October 2003 and September 2004 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003-2004	*	†
Madagascar	Madagascar longitudinal entomological and parasitological monitoring of malaria in the intermediate zones transmission instable: the example of Madagascar Middle West: final report as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995-1996	*	†
Madagascar	Madagascar Plasmodium Falciparum Parasite Rate Data, Personal Communication with Randrianarivojosia M, Malaria Research Unit, Pasteur Institute of Madagascar, 2007 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995-1997	*	†
Madagascar	Andriamangata-Rason MD, Lepers JP, Raharimalala L, Fontenille D, Coulanges P. [Parasitologic and serologic study of a population of schoolchildren in a village of the Highland Plateaux of Madagascar. Arch Inst Pasteur Madagascar. 1990; 57(1): 75-91 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987-1989		†
Madagascar	Brutus L, Watier L, Briand V, Hanitrasoamampionana V, Razanatosorilala H, Cot M. Parasitic co-infections: does Ascaris lumbricoides protect against Plasmodium falciparum infection? Am J Trop Med Hyg. 2006; 75(2): 194-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Madagascar	Brutus L, Watier L, Hanitrasonampionana V, Razanatsorilala H, Cot M. Confirmation of the protective effect of Ascaris lumbricoides on Plasmodium falciparum infection: results of a randomized trial in Madagascar. <i>Am J Trop Med Hyg.</i> 2007; 77(6): 1091-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Madagascar	Champetier de Ribes G, Ranaivoson G, Rakotoherisoa E, Rakotoson JD, Andriamahafazafy B. [A malaria epidemic in the south of Madagascar?]. <i>Arch Inst Pasteur Madagascar.</i> 1994; 61(2): 66-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Madagascar	Cot M, Brutus L, Le Goff G, Rajaonarivelo V, Raveloson A. [The campaign against malaria in central western Madagascar: comparison of lambda-cyhalothrin and DDT house spraying. <i>Parasite.</i> 2001; 8(4): 309-16 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
Madagascar	Kightlinger LK, Kightlinger MB, Seed JR. La situation du paludisme chez les enfants dans la forêt de Ranomafana du Sud-Est de Madagascar. <i>Arch Inst Pasteur Madagascar.</i> 1998; 64(1/2): 48-50 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Madagascar	Kightlinger MB, Kightlinger LK. In vitro response of Plasmodium falciparum to chloroquine and mefloquine in southeast Madagascar. <i>Arch Inst Pasteur Madagascar.</i> 1988; 54(1): 169-74 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Madagascar	Lepers JP, Fontenille D, Rason MD, Raharimalala L, Coulanges P. [Malaria in 1989 in a village in the Highland Plateaux of Madagascar. Parasitologic and clinical data obtained in a longitudinal study of a population representative of this region]. <i>Arch Inst Pasteur Madagascar.</i> 1990; 57(1): 11-52 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Madagascar	Lepers JP, Ramanamirija JA, Andriamangitana-Rason MD, Coulanges P. [Recent findings on the epidemiology of malaria and on the distribution of plasmodial species Madagascar in 1987]. <i>Arch Inst Pasteur Madagascar.</i> 1988; 54(1): 151-67 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Madagascar	Lepers JP, Rason MD, Raharimalala L, Rabarison P, René JP, Coulanges P. Le paludisme dans l'île de Sainte Marie en 1989. Données épidémiologiques, parasitologiques, sérologiques et cliniques. <i>Arch Inst Pasteur Madagascar.</i> 1990; 57(1): 53-74 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988-1989	*	†
Madagascar	Migot F, Chougnet C, Raharimalala L, Astagneau P, Lepers JP, Deloron P. Human immune responses to the Plasmodium falciparum ring-infected erythrocyte surface antigen (Pf155/RESA) after a decrease in malaria transmission in Madagascar. <i>Am J Trop Med Hyg.</i> 1993; 48(3): 432-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†
Madagascar	Rabarijaona LP, Randrianarivojosia M, Raharimalala LA, Ratsimbao A, Randriamanantena A, Randrianasolo L, Ranarivelo LA, Rakotomanana F, Randremanana R, Ratovonjato J, Rason MA, Duchemin JB, Tall A, Robert V, Jambou R, Arief F, Domarle O. Longitudinal survey of malaria morbidity over 10 years in Saharevo (Madagascar): further lessons for strengthening malaria control. <i>Malar J.</i> 2009; 8: 190 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Madagascar	Raharimalala L, Rabarison P, Lepers-Rason MD, Ramambanirina L, Laventure S, Lepers JP, Roux J. Surveillance épidémiologique du paludisme dans trois villages des Hautes Terres Malagaches. <i>Arch Inst Pasteur Madagascar.</i> 1993; 60(1/2): 43-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991-1992	*	†
Madagascar	Romi R, Razaizarimanga MC, Raharimanga R, Rakotondraibe EM, Ranaivo LH, Pietra V, Raveloson A, Majori G. Impact of the malaria control campaign (1993-1998) in the highlands of Madagascar: parasitological and entomological data. <i>Am J Trop Med Hyg.</i> 2002; 66(1): 2-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993-1998	*	†
Madagascar	Romi R, Sabatinelli G, Majori G, Ralamboranto L, Raveloarifera F, Ranaivoaharimina H. Plasmodium falciparum circumsporozoite antibody prevalence in Madagascar: a longitudinal study in three different epidemiologic areas. <i>Am J Trop Med Hyg.</i> 1994; 51(6): 856-63 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989-1991	*	†
Madagascar	Madagascar Vital Registration Birth Data 1972 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1972		
Malawi	United Nations Children's Fund (UNICEF), National Statistics Office (Malawi). Malawi Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006	*	†
Malawi	Macro International, Inc, National Statistical Office of Malawi. Malawi Demographic and Health Survey 1992. Calverton, United States: Macro International, Inc.	1992		†
Malawi	Macro International, Inc, National Statistical Office of Malawi. Malawi Demographic and Health Survey 2000. Calverton, United States: Macro International, Inc.	2000		†
Malawi	Macro International, Inc, National Statistical Office of Malawi. Malawi Demographic and Health Survey 2004-2005. Calverton, United States: Macro International, Inc.	2004-2005		†
Malawi	ICF Macro, National Statistical Office of Malawi. Malawi Demographic and Health Survey 2010. Calverton, United States: ICF Macro.	2010		†
Malawi	World Health Organization (WHO). Malawi World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Malawi	Ministry of Health (Malawi), World Health Organization (WHO). Malawi STEPS Noncommunicable Disease Risk Factors Survey 2009.	2009		
Malawi	Malawi Malaria Indicator Survey 2012 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2012	*	†
Malawi	Malawi Demographic Survey 1982 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1982		
Malawi	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Malawi	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Malawi	Brabin L, Verhooff FH, Kazembe P, Brabin BJ, Chimsuku L, Broadhead R. Improving antenatal care for pregnant adolescents in southern Malawi. <i>Acta Obstet Gynecol Scand.</i> 1998; 77(4): 402-9.	1993-1994		
Malawi	Gibbs, S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. <i>Int J Dermatol.</i> 1996; 35(9): 633-9.	1994		
Malawi	Molyneux E, Walsh A, Phiri A, Molyneux M. Acute bacterial meningitis in children admitted to the Queen Elizabeth Central Hospital, Blantyre, Malawi in 1996-97. <i>Trop Med Int Health.</i> 1998; 3(8): 610-8.	1996-1997		
Malawi	Cunliffe NA, Ngwira BM, Dove W, Thindwa BDM, Turner AM, Broadhead RL, Molyneux ME, Hart CA. Epidemiology of rotavirus infection in children in Blantyre, Malawi, 1997-2007. <i>J Infect Dis.</i> 2010; 202(Suppl): 168-174.	1997-2007		
Malawi	Van den Akker T, van Rhenen J, Mwangomba B, Lommerse K, Vinkhumbi S, van Roosmalen J. Reduction of Severe Acute Maternal Morbidity and Maternal Mortality in Thyolo District, Malawi: The Impact of Obstetric Audit. <i>PLoS One.</i> 2011; 6(6): e20776.	2007-2009		
Malawi	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1996-1999, 2004		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Malawi	Kjetland EF, Pogensee G, Helling-Giese G, Richter J, Sjaastad A, Chitsulo L, Kumwenda N, Gundersen SG, Krantz I, Feldmeier H. Female genital schistosomiasis due to Schistosoma haematobium. <i>Acta Trop</i> . 1996; 62(4): 239-55.	1994		
Malawi	Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Stelariova-Foucher E, Swaminathan R and Ferlay J, eds (2013). Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version). Lyon, IARC. http://cis.iarc.fr	2003-2007	*	
Malawi	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Malawi	Turner A, Ngwira B, Witte D, Mwapasa M, Dove W, Cunliffe N. Surveillance of rotavirus gastro-enteritis in children in Blantyre, Malawi. <i>Paediatr Int Child Health</i> . 2013; 33(1): 42-5.	2008-2009	*	
Malawi	Kalua K, Lindfield R, Mtupanyama M, Mtumodzi D, Msiska V. Findings from a rapid assessment of avoidable blindness (RAAB) in Southern Malawi. <i>PLoS One</i> . 2011; 6(4): e19226. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2009-2010		
Malawi	Chirambo MC, Tiesch JM, West KP Jr, Katz J, Tizazu T, Schwab L, Johnson G, Swartwood J, Taylor HR, Sommer A. Blindness and visual impairment in southern Malawi. <i>Bull World Health Organ</i> . 1986; 64(4): 567-72. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1983		
Malawi	Belman J, VAN DEN AKKER T, VAN LONKHUIJZEN L, SCHMIDT A, CHIDAKWANI R, VAN ROOSMALEN J. Beyond maternal mortality: obstetric hemorrhage in a Malawian district. <i>Acta Obstet Gynecol Scand</i> . 2011; 90(12): 1423-7.	2005	*	
Malawi	Watts AE. The natural history of untreated epilepsy in a rural community in Africa. <i>Epilepsia</i> . 1992; 33(3): 464-8.	1991	*	
Malawi	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Malawi	Hoyo C, Hoffman I, Moser BK, Hobbs MM, Kazembe P, Krysiak RG, Cohen MS. Improving the accuracy of syndromic diagnosis of genital ulcer disease in Malawi. <i>Sex Transm Dis</i> . 2005; 32(4): 231-7.	1998-1999		
Malawi	Glover SJ, Burgess PL, Cohen DB, Harding SP, Hoffland HWC, Zijlstra EE, Allain TJ. Prevalence of diabetic retinopathy, cataract and visual impairment in patients with diabetes in sub-Saharan Africa. <i>Br J Ophthalmol</i> . 2012; 96(2): 156-61.	2007		
Malawi	Brabin BJ, Prins-Geerligns PD, Verhoeff FH, Fletcher KA, Chimsuku LHE, Ngwira BM, Leich OJ, Broadhead RL. Haematological profiles of the people of rural southern Malawi: an overview. <i>Ann Trop Med Parasitol</i> . 2004; 98(1): 71-83.	1994		
Malawi	Banda LT, Parkin DM, Dzamalala CP, Liomba NG. Cancer incidence in Blantyre, Malawi 1994-1998. <i>Trop Med Int Health</i> . 2001; 6(4): 296-304.	1994-1998	*	
Malawi	Kalilani-Phiri LV, Umar E, Lazaro D, Lunguzi J, Chilungo A. Prevalence of obstetric fistula in Malawi. <i>Int J Gynaecol Obstet</i> . 2010; 109(3): 204-8.	2008	*	
Malawi	Obare F, Fleming P, Anglewicz P, Thornton R, Martinson F, Kapatuka A, Poulin M, Watkins S, Kohler H-P. Acceptance of repeat population-based voluntary counselling and testing for HIV in rural Malawi. <i>Sex Transm Infect</i> . 2009; 85(2): 139-44.	1990, 2004		
Malawi	Nielsen NO, Makaula P, Nyakupa D, Bloch P, Nyasulu Y, Simonsen PE. Lymphatic filariasis in Lower Shire, southern Malawi. <i>Trans R Soc Trop Med Hyg</i> . 2002; 96(2): 133-8. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2000	*	
Malawi	Ngwira BMM, Jabu CH, Kanyongoloka H, Mponda M, Crampin AC, Branson K, Alexander NDE. Fine PEM. Lymphatic filariasis in the Karonga district of northern Malawi: a prevalence survey. <i>Ann Trop Med Parasitol</i> . 2002; 96(2): 137-44.	2000-2001	*	
Malawi	Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. <i>Int J Health Geogr</i> . 2010; 9: 57.	1980-2010		
Malawi	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec</i> . 2005; 80(13): 118-24.	2003	*	
Malawi	World Health Organization (WHO). Global leprosy situation, 2007 (additional information). <i>Wkly Epidemiol Rec</i> . 2007; 82(44): 388.	2006	*	
Malawi	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec</i> . 2010; 85(35): 337-48.	2009	*	
Malawi	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec</i> . 1999; 74(38): 313-6.	1998	*	
Malawi	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec</i> . 2011; 86(36): 389-99.	2010	*	
Malawi	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec</i> . 2001; 76(23): 173-9.	2000	*	
Malawi	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec</i> . 2000; 75(28): 226-31.	1999	*	
Malawi	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec</i> . 1997; 72(23): 165-72.	1996	*	
Malawi	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec</i> . 1996; 71(20): 149-56.	1995	*	
Malawi	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1995; 70(25): 177-82.	1994	*	
Malawi	Sutcliffe S, Taha TE, Kumwenda NI, Taylor E, Liomba GN. HIV-1 prevalence and herpes simplex virus 2, hepatitis C virus, and hepatitis B virus infections among male workers at a sugar estate in Malawi. <i>J Acquir Immune Defic Syndr</i> . 2002; 31(1): 90-7.	1998	*	
Malawi	Malawi Survey Report on the Trend of Prevalence of Goitre in Junior Primary School Pupils and Coverage of Iodized Salt at Household Level in Seven Districts in Northern and Central Regions 1996 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1996		
Malawi	Scarborough M, Gordon SB, Whitty CJM, French N, Njalale Y, Chitani A, Peto TEA, Lalloo DG, Zijlstra EE. Corticosteroids for Bacterial Meningitis in Adults in Sub-Saharan Africa. <i>N Engl J Med</i> . 2007; 357(24): 2441-50.	2002-2005		
Malawi	Yeudall F, Gibson RS, Kayira C, Umar E. Efficacy of a multi-micronutrient dietary intervention based on haemoglobin, hair zinc concentrations, and selected functional outcomes in rural Malawian children. <i>Eur J Clin Nutr</i> . 2002; 56(12): 1176-85 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Malawi	Candotti D, Mundy C, Kadeswele G, Nkhoma W, Bates I, Allain JP. Serological and molecular screening for viruses in blood donors from Ntcheu, Malawi: high prevalence of HIV-1 subtype C and of markers of hepatitis B and C viruses. <i>J Med Virol</i> . 2001; 65(1): 1-5.	1999		
Malawi	Seasonal Patterns of Malaria and Its Health-related Consequences Among Adolescent Females in Rural Malawi [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005-2006	*	†
Malawi	Malawi Anemia and Parasitemia Survey 2006 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Malawi	Annual Report for Mwandama, Malawi, Millennium Village. Year 1: February 2006-February 2007 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Malawi	Anti-TRAP (Thrombospondin Related Adhesive Protein) Immune Response and Malaria Morbidity in an Area of Hyperendemic Malaria in Mali (West Africa) [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993-1994	*	†
Malawi	Calis JCI, Phiri KS, Faragher EB, Brabin BJ, Bates I, Cuevas LE, de Haan RJ, Phiri AI, Malange P, Khoka M, Hulshof PJM, van Lieshout L, Beld MGHM, Teo YY, Rockett KA, Richardson A, Kwiatkowski DP, Molyneux ME, van Hensbroek MB. Severe Anemia in Malawian Children. <i>N Engl J Med</i> . 2008; 358(9): 888-99 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Malawi	Mathanga DP, Campbell CH, Taylor TE, Barlow R, Wilson ML. Socially marketed insecticide-treated nets effectively reduce Plasmodium infection and anaemia among children in urban Malawi. <i>Trop Med Int Health</i> . 2006; 11(9): 1367-74 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Malawi	Prinsen Geerligs PP, Brabin B, Mkumbwa A, Broadhead R, Cuevas LE. The effect on haemoglobin of the use of iron cooking pots in rural Malawian households in an area with high malaria prevalence: a randomized trial. <i>Trop Med Int Health</i> . 2003; 8(4): 310-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000	*	†
Malawi	Wolff CG, Schroeder DG, Young MW. Effect of improved housing on illness in children under 5 years old in northern Malawi: cross sectional study. <i>Br Med J (Clin Res Ed)</i> . 2001; 322(7296): 1209-12 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
Malawi	Wondji CS, Coleman M, Kleinschmidt I, Mzilahowa T, Irving H, Ndula M, Rehman A, Morgan J, Barnes KG, Hemingway J. Impact of pyrethroid resistance on operational malaria control in Malawi. <i>Proc Natl Acad Sci U S A</i> . 2012; 109(47): 19063-70 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2009-2010	*	†
Malaysia	National Population and Family Development Board (Malaysia), International Statistical Institute. Malaysia World Fertility Survey 1974. Voorburg, Netherlands: International Statistical Institute.	1974		
Malaysia	Malaysia Vital Registration - Deaths 1997 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1997	*	
Malaysia	World Health Organization (WHO). Malaysia World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Malaysia	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1993-1999		
Malaysia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Malaysia	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Malaysia	Ngewo YF, Weil AF, Khairullah NS, Yusof MY, Luam L, Gaydos C, Quinn TC. Young Malaysian children with lower respiratory tract infections show low incidence of chlamydial infection. <i>J Paediatr Child Health</i> . 1997; 33(5): 422-5.	1992-1993		
Malaysia	Chong A-Y, Rajaratnam R, Hussein NR, Lip GYH. Heart failure in a multiethnic population in Kuala Lumpur, Malaysia. <i>Eur J Heart Fail</i> . 2003; 5(4): 569-74.	2000-2002		
Malaysia	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol</i> . 2008; 121(4): 947-954.	1995, 2001-2002		
Malaysia	Izzuddin Poo M, Lee WS. Admission to hospital with childhood acute gastroenteritis in Kuala Lumpur, Malaysia. <i>Med J Malaysia</i> . 2007; 62(3): 189-93.	2002		
Malaysia	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998-2009		
Malaysia	Veerapan K, Wigley RD, Valkenburg H. Musculoskeletal pain in Malaysia: a COPCORD survey. <i>J Rheumatol</i> . 2007; 34(1): 207-13.	1988		
Malaysia	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J</i> . 1998; 12(2): 315-35.	1993-1995		
Malaysia	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	2001		
Malaysia	Rabia K, Khoo EM. Prevalence of peripheral arterial disease in patients with diabetes mellitus in a primary care setting. <i>Med J Malaysia</i> . 2007; 62(2): 130-3.	2004		
Malaysia	Mafauzy M, Mokhtar N, Mohamad WB, Musalmah M. Diabetes mellitus and associated cardiovascular risk factors in north-east Malaysia. <i>Asia Pac J Public Health</i> . 1999; 11(1): 16-9.	1995		
Malaysia	Alders EE, Hentzen A, Tan CT. A community-based prevalence study on headache in Malaysia. <i>Headache</i> . 1996; 36(6): 379-84.	1993		
Malaysia	Hanisah A, Omar K, Shah SA. Prevalence of acne and its impact on the quality of life in school-aged adolescents in Malaysia. <i>J Prim Health Care</i> . 2009; 1(1): 20-5.	2006-2008	*	
Malaysia	Qua C-S, Goh K-L. Liver cirrhosis in Malaysia: peculiar epidemiology in a multiracial Asian country. <i>J Gastroenterol Hepatol</i> . 2011; 26(8): 1333-7.	2006-2009		
Malaysia	Masood M, Yusof N, Hassan MIA, Jaafar N. Assessment of dental caries predictors in 6-year-old school children - results from 5-year retrospective cohort study. <i>BMC Public Health</i> . 2012; 12: 989.	2004-2009	*	
Malaysia	Forman D, Bray F, Brewster DH, Gomb Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). <i>Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version)</i> . Lyon, IARC. http://ci5.iarc.fr	2004-2007	*	
Malaysia	Yap KL, Yasmin AM, Wong YH, Ooi YE, Tan SC, Jegathesan M, Khor CM, Low MC. A one year community-based study on the incidence of diarrhoea and rotavirus infection in urban and suburban Malaysian children. <i>Med J Malaysia</i> . 1992; 47(4): 303-8.	1988-1989	*	
Malaysia	Hamid TA, Krishnaswamy S, Abdullah SS, Momtaz YA. Sociodemographic risk factors and correlates of dementia in older Malaysians. <i>Dement Geriatr Cogn Disord</i> . 2010; 30(6): 533-9.	2004-2005		
Malaysia	Hussein NN, Meon R. The prevalence of dental caries in preschool children in Kuala Lumpur, Malaysia. <i>Singapore Dent J</i> . 1985; 10(1): 5-7.	1983		
Malaysia	Malaysia Dialysis and Transplant Registry data as it appears in the GBD 2010 Chronic Kidney Disease Expert Group dataset. Provided by Dr. Yudisthra M. Ganeshadeva, Dr. Loh Cheh Loong and SRN Lee Day Guat.	1990		
Malaysia	Malaysia Dialysis and Transplant Registry data as it appears in the GBD 2010 Chronic Kidney Disease Expert Group dataset. Provided by Dr. Yudisthra M. Ganeshadeva, Dr. Loh Cheh Loong and SRN Lee Day Guat. [Unpublished].	2005		
Malaysia	Kasmini K KO, Krishnaswamy S, Ramli H, Hassan S. A prevalence survey of mental disorders among children in a rural Malaysian village. <i>Acta Psychiatr Scand</i> . 1993; 87(4): 253-7.	1985		
Malaysia	Krishnaswamy S, Kavitha S, Aziz JA, Indran H, Low WY, Ramchandran P, Indran T, Indran R, Patel V. Burden, Determinant and Impact of Common Mental Disorders in Malaysia. [Unpublished].	2005-2006		
Malaysia	Venkatesubramanian N, Tan LCS, Sahadevan S, Chin JJ, Krishnamoorthy ES, Hong CY, Saw SM. Prevalence of Stroke Among Chinese, Malay, and Indian Singaporeans. <i>Stroke</i> . 2005; 36(3): 551-6.	2001-2003		
Malaysia	United States Renal Data System Coordinating Center. <i>USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States</i> . Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2004-2005		
Malaysia	United States Renal Data System Coordinating Center. <i>USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States</i> . Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2001-2003		
Malaysia	Gilbert CE, Ellwein LB. Prevalence and causes of functional low vision in school-age children: results from standardized population surveys in Asia, Africa, and Latin America. <i>Invest Ophthalmol Vis Sci</i> . 2008; 49(3): 877-81. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2003		
Malaysia	Zainal M, Ismail SM, Ropilah AR, Elias H, Arumugam G, Alias D, Fathilah J, Lim TO, Ding LM, Goh PP. Prevalence of blindness and low vision in Malaysian population: results from the National Eye Survey 1996. <i>Br J Ophthalmol</i> . 2002; 86(9): 951-6. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	1996-1997		
Malaysia	Wong TY, Chong EW, Wong W-L, Rosman M, Aung T, Loo J-L, Shen S, Loon S-C, Tan DTH, Tai ES, Saw S-M. Prevalence and causes of low vision and blindness in an urban Malay population: the Singapore Malay Eye Study. <i>Arch Ophthalmol</i> . 2008; 126(8): 1091-9. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2004-2006		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Malaysia	Reddy SC, Rampal L, Nurulaini O. Prevalence and causes of visual impairment and blindness in a rural population in Sepang district, Selangor. Med J Malaysia. 2004; 59(2): 212-7. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2000		
Malaysia	Zainal M, Masran L, Ropilah AR. Blindness and visual impairment amongst rural Malays in Kuala Selangor, Selangor. Med J Malaysia. 1998; 53(1): 46-50. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1993-1994		
Malaysia	Goh P-P, Abqariyah Y, Pokharel GP, Ellwein LB. Refractive error and visual impairment in school-age children in Gombak District, Malaysia. Ophthalmology. 2005; 112(4): 678-85. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2003		
Malaysia	Elango S, Purohit GN, Hashim M, Hilmi R. Hearing loss and ear disorders in Malaysian school children. Int J Pediatr Otorhinolaryngol. 1991; 22(1): 75-80.	1988-1990		
Malaysia	Stein Z, Belmont L, Durkin M. Mild mental retardation and severe mental retardation compared: experiences in eight less developed countries. Ups J Med Sci Suppl. 1987; 89-96.	1987		
Malaysia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2010, 2012		
Malaysia	Ravindran J, Tan YI, Ngeow YF. The prevalence of Chlamydia trachomatis in patients with pelvic inflammatory disease. Med J Malaysia. 1998; 53(1): 16-21.	1993-1994	*	†
Malaysia	Boo NY, Lye MS. Factors associated with clinically significant perinatal asphyxia in the Malaysian neonates: a case-control study. J Trop Pediatr. 1992; 38(6): 284-9.	1989	*	†
Malaysia	Wan Nazaimoon WM, Md Isa SH, Wan Mohamad WB, Khir AS, Kamaruddin NA, Kamarul IM, Mustafa N, Ismail IS, Ali O, Khalid BAK. Prevalence of diabetes in Malaysia and usefulness of HbA1c as a diagnostic criterion. Diabet Med. 2013; 30(7): 825-8.	2010-2012		
Malaysia	Lie-Injulan EN, Chin J. Abnormal haemoglobin and glucose-6-phosphate dehydrogenase in Malayan Aborigines. Nature. 1964; 204: 291-2.	1962-1964		
Malaysia	Ganesan J, Lie-Injo LE, Ong Beng P. Abnormal hemoglobins, glucose-6-phosphate dehydrogenase deficiency and hereditary ovalocytosis in the Dayaks of Sarawak. Hum Hered. 1975; 25(4): 258-62.	1973-1975		
Malaysia	Singh H. Glucose-6-phosphate dehydrogenase deficiency: a preventable cause of mental retardation. Br Med J (Clin Res Ed). 1986; 292(6517): 397-8.	1983-1984		
Malaysia	Ainoon O, Yu YH, Amir Muhriz AL, Boo NY, Cheong SK, Hamidah NH. Glucose-6-phosphate dehydrogenase (G6PD) variants in Malaysian Malays. Hum Mutat. 2003; 21(1): 101.	1999-2000		
Malaysia	Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M and Boyle P, eds (2007). Cancer Incidence in Five Continents, Vol. IX Periodic Data (electronic version). Lyon, IARC. http://c15.iarc.fr	1998-2002	*	
Malaysia	National Cancer Registry, Ministry of Health (Malaysia). Malaysia - Second Report of the National Cancer Registry: Cancer Incidence in Malaysia 2003. Kuala Lumpur, Malaysia: National Cancer Registry, Ministry of Health (Malaysia). 2004.	2003	*	
Malaysia	Saroja KI, Kyaw O. Pattern of alcoholism in the General Hospital, Kuala Lumpur. Med J Malaysia. 1993; 48(2): 129-34.	1993		
Malaysia	Elango S. Aetiology of deafness in children from a school for the deaf in Malaysia. Int J Pediatr Otorhinolaryngol. 1993; 27(1): 21-7.	1989-1991	*	
Malaysia	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Malaysia	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
Malaysia	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Malaysia	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	
Malaysia	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Malaysia	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Malaysia	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Malaysia	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
Malaysia	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Malaysia	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Malaysia	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Malaysia	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Malaysia	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Malaysia	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Malaysia	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Malaysia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Malaysia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Malaysia	Ministry of Health (Malaysia). Incidence of Dengue Cases (Clinical) In Malaysia 1973-2005. Ministry of Health [Internet]. Putrajaya, Malaysia: Ministry of Health (Malaysia).	1988-1992, 2003-2005		
Malaysia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2000.	2000		
Malaysia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2001.	2001		
Malaysia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2002.	2002		
Malaysia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2003.	2003		
Malaysia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2004.	2004		
Malaysia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2005.	2005		
Malaysia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2006.	2006		
Malaysia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2007.	2007		
Malaysia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2008.	2008		
Malaysia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2009.	2009		
Malaysia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2010.	2010		
Malaysia	Choo MM, Martin FJ, Theam LC, U-Teng C. Retinopathy of prematurity in extremely low birth weight infants in Malaysia. J AAPOS. 2009; 13(5): 446-9.	2004	*	†
Malaysia	Hussain IH, Sofiah A, Ong LC, Choo KE, Musa MN, Teh KH, Ng HP. Haemophilus influenzae meningitis in Malaysia. Pediatr Infect Dis J. 1998; 17(9 Suppl): S189-190.	1995		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Malaysia	Chen PC, Wong ML, Ong FP. The prevalence of endemic goitre in the Keningau Division of Sabah Asia Pac J Public Health. 1989; 3(1): 78-81 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1986-1987		
Malaysia	Foo LC, Zainab T, Leichuman GR, Nafikudin M, Azrman R, Dorasingam P, Khalid AK. Endemic goiter in the Lemanak and Ai river villages of Sarawak. Southeast Asian J Trop Med Public Health. 1994; 25(3): 575-8 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1993		
Malaysia	Ministry of Health (Malaysia). Malaysia Ministry of Health Annual Report 2011.	2007-2011	*	
Malaysia	Mia MS, Begum RA, Er AC, Abidin RDZRZ, Pereira JJ. Trends of dengue infections in Malaysia, 2000-2010. Asian Pac J Trop Med. 2013; 6(6): 462-6.	2000-2010	*	
Malaysia	Amudha K, Chee KH, Tan KS, Tan CT, Lang CC. Prevalence of peripheral artery disease in urban high-risk Malaysian patients. Int J Clin Pract. 2003; 57(5): 369-72.	1999-2001		
Malaysia	Ng KP, Ngeow YF, K R, M R. Hepatitis B seroprevalence among University of Malaya Students in the Post-universal Infant Vaccination Era. Med J Malaysia. 2013; 68(2): 144-7.	2005-2011	*	
Malaysia	Ton SH, Thiruselvam A, Lopez CG, Noriah R. Prevalence of hepatitis A virus infection in normal individuals and hospital patients in Kuala Lumpur. Med J Malaysia. 1983; 38(4): 279-81.	1985		
Malaysia	Musa RH, Ahmed SA, Hashim H, Ayob Y, Asidin NH, Choo PY, Al-Joudi FS. Red cell phenotyping of blood from donors at the National blood center of Malaysia. Asian J Transfus Sci. 2012; 6(1): 3-9.	2009-2011	*	†
Malaysia	Hishamuddin HM, Azmi NN, Jackson N. Acute myocardial infarction survival rate and complications after streptokinase therapy in Hospital Universiti Sains Malaysia, Kelantan—a comparative study. Singapore Med J. 1993; 34(4): 316-8.	1990-1992		
Malaysia	Lee WS, Ng KP. Seroprevalence of anti-HCV in an urban child population: a preliminary study from Kuala Lumpur. Singapore Med J. 2001; 42(3): 100-1.	1999-2000		
Malaysia	Ng KP, Saw TL, Baki A, Rozainah K, Pang KW, Ramanathan M. Impact of the Expanded Program of Immunization against hepatitis B infection in school children in Malaysia. Med Microbiol Immunol. 2005; 194(3): 163-8.	1997-2003		
Malaysia	Arunmugam K, Urquhart R. Causes for infertility: a comparative study. Ann Acad Med Singapore. 1991; 20(3): 351-2.	1986-1988	*	
Malaysia	Ali RA, Mathews S. Prevalence of dementia among elderly Malays in an urban settlement in Malaysia. Neurol J Southeast Asia. 1997; 159-62.	1995		
Malaysia	Ahmad A, Mohamad I, Mansor S, Daud MK, Sidek D. Outcome of a newborn hearing screening program in a tertiary hospital in Malaysia: the first five years. Ann Saudi Med. 2011; 31(1): 24-8.	2003-2007	*	
Malaysia	Malaria and Malaria Control in Jeli, Peninsular Malaysia [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994-1995	*	†
Malaysia	Malaysian National Neonatal Registry. Malaysia Neonatal Registry Report 2006. Kuala Lumpur, Malaysia: Malaysian National Neonatal Registry, 2008.	2006		†
Malaysia	A national study of risk factors associated with mortality in very low birthweight infants in the Malaysian neonatal intensive care units. Malaysian Very Low Birth Weight Study Group. J Paediatr Child Health. 1997 Feb;33(1):18-25.	1993		†
Malaysia	Archibald CP, Mak JW, Mathias RG, Selvajothi S. Antibodies to Plasmodium falciparum in an indigenous population from a malaria endemic area of Malaysia. Acta Trop. 1990; 48(2): 149-57 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985-1987	*	†
Malaysia	Hii JLK, Yun YS, Chin KF, Chua R, Tambakau S, Binisol ES, Fernandez E, Singh N, Chan MKC. The influence of permethrin-impregnated bednets and mass drug administration on the incidence of Plasmodium falciparum malaria in children in Sabah, Malaysia. Med Vet Entomol. 1987; 1(4): 397-407 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Malaysia	Mak JW, Normaznah Y, Chiang GL. Comparison of the quantitative buffy coat technique with the conventional thick blood film technique for malaria case detection in the field. Singapore Med J. 1992; 33(5): 452-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†
Malaysia	Rahman WA, Abu Hassan A, Adanan CR, Rashid MR. The prevalence of Plasmodium falciparum. Acta Trop. 1993; 55(4): 231-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Malaysia	Seng CM, Matusop A, Sen FK. Differences in Anopheles composition and malaria transmission in the village settlements and cultivated farming zone in Sarawak, Malaysia. Southeast Asian J Trop Med Public Health. 1999; 30(3): 454-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Malaysia	Malaysia Vital Registration Birth Data 1988 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1988		
Maldives	Ministry of Health (Maldives), Republic of Maldives, United Nations Children's Fund (UNICEF). Maldives Multiple Indicator Cluster Survey 2001.	2001		†
Maldives	ICF Macro, Ministry of Health (Maldives). Maldives Demographic and Health Survey 2009. Calverton, United States: ICF Macro, 2010.	2009		†
Maldives	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1997-1998, 2000-2008		
Maldives	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Maldives	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Maldives	Modell B, Razzak A, Hindley N. Thalassemia in the Maldives. Lancet. 1990; 335(8698): 1169-70.	1988-1997		
Maldives	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2005-2009		
Maldives	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Maldives	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Maldives	Maldives Iodine Deficiency Disorders 2002 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2002		
Maldives	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
Maldives	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	
Maldives	World Health Organization (WHO). Global leprosy situation, 2008 (additional information). Wkly Epidemiol Rec. 2008; 83(50): 459.	2007	*	
Maldives	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Maldives	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Maldives	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Maldives	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Maldives	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Maldives	Maldives Iodine Deficiency Disorders 1995 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1995		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Maldives	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Maldives	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Maldives	Shaheem I, Afeef A. Dengue and Dengue Haemorrhagic Fever and its Control in Maldives. Dengue Bull. 1999; 23; 30-3.	1988, 1999		†
Maldives	World Health Organization Regional Office for South-East Asia (SEARO). Situation Update of Dengue in the SEA Region, 2010. New Delhi, India: World Health Organization Regional Office for South-East Asia (SEARO).	2009		
Maldives	WHO Regional Office for South-East Asia (SEARO). WHO South-East Asia Region: Reported Cases and Deaths of Dengue from 2003 to 2012. New Delhi, India: WHO Regional Office for South-East Asia (SEARO), 2013.	2003-2012	*	
Maldives	Ng KP, Ngeow YF, K R, M R. Hepatitis B seroprevalence among University of Malaya Students in the Post-universal Infant Vaccination Era. Med J Malaysia. 2013; 68(2): 144-7.	2005-2011	*	
Maldives	Maldives - Expert Mission to Maldives for Verification of Elimination of Lymphatic Filariasis as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1998	*	
Maldives	Maldives Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Mali	Mali Population and Housing Census 1987 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1987		
Mali	Macro International, Inc, Ministry of Health (Mali), National Directorate of Statistics and Informatics (Mali). Mali Demographic and Health Survey 2006. Calverton, United States: Macro International, Inc.	2006		†
Mali	Sahel Institute, Westinghouse; Institute for Resource Development. Mali Demographic and Health Survey 1987. Columbia, United States: Westinghouse; Institute for Resource Development.	1987		†
Mali	Macro International, Inc, National Directorate of Statistics and Informatics (Mali), Planning and Statistics Unit, Ministry of Health (Mali). Mali Demographic and Health Survey 1995-1996. Calverton, United States: Macro International, Inc.	1995-1996		†
Mali	Macro International, Inc, National Directorate of Statistics and Informatics (Mali), Planning and Statistics Unit, Ministry of Health (Mali). Mali Demographic and Health Survey 2001. Calverton, United States: Macro International, Inc.	2001		†
Mali	World Health Organization (WHO). Mali World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Mali	Mali Special Demographic and Health Survey 2010 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2010	*	†
Mali	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Mali	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Mali	Mahé A, Prual A, Konaté M, Bobin P. Skin diseases of children in Mali: a public health problem. Trans R Soc Trop Med Hyg. 1995; 89(5): 467-70.	1993-1994		
Mali	Sow SO, Diallo S, Campbell JD, Tapia MD, Keita T, Keita MM, Murray P, Kotloff KL, Levine MM. Burden of invasive disease caused by Haemophilus influenzae type b in Bamako, Mali: impetus for routine infant immunization with conjugate vaccine. Pediatr Infect Dis J. 2005; 24(6): 533-7.	2002-2004		
Mali	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1987		
Mali	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1996-2006, 2008-2009		
Mali	Meunier DM, Aron N, Mazzariol MJ. The 1987 yellow fever epidemic in Mali: viral and immunological diagnosis. Trans R Soc Trop Med Hyg. 1988; 82(5): 767.	1987		
Mali	Tomori O. Yellow fever in Africa: public health impact and prospects for control in the 21st century. Biomedica. 2002; 22(2): 178-210.	1987		
Mali	World Health Organization (WHO). Update on progress controlling yellow fever in Africa. Wkly Epidemiol Rec. 2008; 83(50): 450-8.	1987-2005		
Mali	World Health Organization (WHO). Yellow fever in Africa and South America, 2006. Wkly Epidemiol Rec. 2008; 83(8): 60-76.	2006		
Mali	World Health Organization (WHO). Yellow fever in Africa and South America, 2007. Wkly Epidemiol Rec. 2009; 84(13): 97-104.	2007		
Mali	Traore M, Traore HA, Kardoff R, Diarra A, Landoure A, Vester U, Doehring E, Bradley DJ. The public health significance of urinary schistosomiasis as a cause of morbidity in two districts in Mali. Am J Trop Med Hyg. 1998; 59(3): 407-13.	1991-1992		†
Mali	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Mali	Nasrin D, Wu Y, Blackwelder WC, Farag TH, Saha D, Sow SO, Alonso PL, Breiman RF, Sur D, Faruque ASG, Zaidi AKM, Biswas K, Van Eijk AM, Walker DG, Levine MM, Kotloff KL. Child care seeking for childhood diarrhoea in developing countries: evidence from seven sites in Africa and Asia. Am J Trop Med Hyg. 2013; 89(1 Suppl): 3-12.	2009-2011	*	
Mali	Mali - Koulukoro Rapid Assessment of Cataract Surgical Services 2002 as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2002		
Mali	Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feika FN, Steele AD, Laserson KF, Ansah NA, Levine MM, Lewis K, Coia ML, Attah-Poku M, Ojwando J, Rivers SB, Victor JC, Nyambane G, Hodgson A, Schödel F, Ciarlet M, Neuzil KM. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 376(9741): 606-14.	2007-2009		
Mali	Teguede I, Maiga AW, Leppert PC. Maternal and neonatal outcomes of grand multiparas over two decades in Mali. Acta Obstet Gynecol Scand. 2012; 91(5): 580-6.	1985-2003	*	
Mali	Samaké BM, Traoré M, Goita L, Niani M, Traoré Y, Teketé I, Diallo A, Dolo A. [Epidemiologic and clinical profile of severe pre-eclampsia at the teaching hospital of Gabriel Touré]. Mali Med. 2011; 26(4): 5-7.	2005-2006	*	
Mali	Traore M, Tahny R, Sacko M. Prévalence de l'épilepsie chez les enfants de 3 à 15 ans dans 2 communes du district de Bamako. Rev Neurol (Paris). 2000; 156(Suppl 1): S18.	1998	*	†
Mali	Dembele M, Maiga I, Minta D, Konate A, Diarra M, Sangare D, Traore HA, Maiga MY, Tounkara A, Payan C, Lunel E, Carbonnelle B, Cales P. [Study of antigen HBs and antiviral antibodies of hepatitis C during hepatopathies in Mali]. Bull Soc Pathol Exot. 2004; 97(3): 161-4.	1998-1999		
Mali	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2004, 2007, 2010, 2012		
Mali	Kortlang C, Koster JC, Coulibaly S, Dubbeldam RP. Prevalence of blindness and visual impairment in the region of Ségou, Mali. A baseline survey for a primary eye care programme. Trop Med Int Health. 1996; 1(3): 314-9. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1990		
Mali	World Health Organization (WHO). Mali WHO Leishmaniasis Country Profile.	1997-2008	*	
Mali	Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J Health Geogr. 2010; 9: 57.	1980-2010		
Mali	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Mali	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Mali	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Mali	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Mali	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Mali	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Mali	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Mali	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Mali	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1993; 68(25): 181-6.	1992	*	
Mali	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Mali	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Mali	Patnaik P, Herrero R, Morrow RA, Munoz N, Bosch FX, Bayo S, El Gueddari B, Caceres E, Chichareon SB, Castellsague X, Meijer CJLM, Snijders PJF, Smith JS. Type-specific seroprevalence of herpes simplex virus type 2 and associated risk factors in middle-aged women from 6 countries: the IARC multicentric study. <i>Sex Transm Dis.</i> 2007; 34(12): 1019-24.	1985-1997	*	
Mali	Long-acting chloramphenicol for bacterial meningitis. <i>Bull World Health Organ.</i> 1993; 71(1): 117-25.	1989-1990		
Mali	Tapia MD, Sow SO, Sanogo K, Keita MM, Mason R, Rubin F, Dale JB, Kotloff KL. The prevalence of rheumatic heart disease among children in Bamako, Mali: preliminary results. Presented at: XVII Lancefield International Symposium on Streptococci and Streptococcal Diseases; 2008 Jun 22-26; Porto Heli, Greece.	2007		
Mali	Dufo B, Ranque P, Quilici M, Balique H, Dembele O, Diallo D, Diallo A-N, Haidara S, Maiga I. Glucose-6-Phosphate-Dehydrogenase Deficiency and Malaria in Mali. <i>Nouv Presse Med.</i> 1982; 11(36): 2713.	1979-1981	*	
Mali	Maiga I, Le Faou A, Muller CP, Venard V. Unexpected high prevalence of hepatitis B and HIV infections in Malian medical students. <i>Eur J Clin Microbiol Infect Dis.</i> 2005; 24(7): 501-2.	2003		
Mali	Coulibaly YI, Dao S, Traore AK, Diallo A, Sacko M, Traore SF. [Presence and risk of transmission of Wuchereria bancrofti is a reality in rural Mali: the case of the town of Bariambani in the Cirle of Kati]. <i>Mali Med.</i> 2006; 21(1): 12-7. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2000	*	
Mali	Study of the Behavior of the An Gambiae Complex and the Transmission of Malaria in Two Ecological Aspects of Mali and Cameroon [dissertation] as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1994-1995	*	†
Mali	Mali: International Courses in French Speaking Country as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Mali	Malaria and Pregnancy, Seasonality and Relationship with Anemia and Low Birth Weight in Bougoula-Hameau (Sikasso Mali) [dissertation] as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Mali	Survey on the Chemosensitivity of Malaria and Formation of a National Chemosensitivity Testing Team in Mali (Bamako) as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Mali	Study of Malaria Transmission in Doneguebougou (Borough of Kati) as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Mali	Epidemiology of Malaria Transmission in the Dry Season in the Ménaka Circle in the Northeast of Mali as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Mali	Epidemiology of Malaria and the Phenomenon of Chloroquinoreistance in Doneguebougou (Kati, Mali) as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Mali	Entomological and Parasitological Characteristics of the Epidemiology of Malaria in Banambani as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Mali	Annual Report for Tily, Mali, Millennium Village 2007 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Mali	Barger B, Maiga H, Traore OB, Tekete M, Tembine I, Dara A, Traore ZI, Gant S, Doumbo OK, Djimde AA. Intermittent preventive treatment using artemisinin-based combination therapy reduces malaria morbidity among school-aged children in Mali. <i>Trop Med Int Health.</i> 2009; 14(7): 784-91 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	2007-2008	*	†
Mali	Boström S, Giusti P, Arama C, Persson J-O, Dara V, Traore B, Dolo A, Doumbo O, Troye-Blomberg M. Changes in the levels of cytokines, chemokines and malaria-specific antibodies in response to Plasmodium falciparum infection in children living in sympatry in Mali. <i>Malar J.</i> 2012; 11(1): 109 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	2008	*	†
Mali	Bouvier P, Rougemont A, Breslow N, Doumbo O, Delley V, Dicko A, Diakite M, Mauris A, Robert CF. Seasonality and malaria in a West African Village: Does High Parasite Density Predict Fever Incidence? <i>Am J Epidemiol.</i> 1997; 145(9): 850-7 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†
Mali	Crompton PD, Traore B, Kayentao K, Doumbo S,ONGOIBA A, Diakite SAS, Krause MA, Dountabe D, Kone Y, Weiss G, Huang C-Y, Doumbia S, Guindo A, Fairhurst RM, Miller LH, Pierce SK, Doumbo OK. Sickle Cell Trait is Associated with a Delayed Onset of Malaria: Implications for Time-to-Event Analysis in Clinical Studies of Malaria. <i>J Infect Dis.</i> 2008; 198(9): 1265-75 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Mali	Delley V, Bouvier P, Breslow N, Doumbo O, Sagara I, Diakite M, Mauris A, Dolo A, Rougemont A. What does a single determination of malaria parasite density mean? A longitudinal survey in Mali. <i>Trop Med Int Health.</i> 2000; 5(6): 404-12 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Mali	Dicko A, Sagara I, Sissoko MS, Guindo O, Diallo AI, Kone M, Toure OB, Sacko M, Doumbo OK. Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. <i>Malar J.</i> 2008; 7(1): 123 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Mali	Dolo A, Camara F, Poudiougou B, Toure A, Kouriba B, Bagayogo M, Sangare D, Diallo M, Bosman A, Modiano D, Toure Y, Doumbo O. [Epidemiology of malaria in a village of Sudanese savannah area in Mali (Bancoumana). 2 Entomo-parasitological and clinical study]. <i>Bull Soc Pathol Exot.</i> 2003; 96(4): 308-12 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†
Mali	Doumbo O, Koita O, Traore SF, Sangare O, Coulibaly A, Robert V, Soula G, Quilici M, Toure YT. Les aspects parasitologiques de l'épidémiologie du paludisme dans le Sahara malien. <i>Med Afr Noire.</i> 1991; 38(2): 103-9 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Mali	Doumbo O, Traore S, Sow Y, Dembele M, Soula G, Coulibaly A, Dolo A, Sangare O, Koita O, Pichard E. [Impact of curtains and blankets impregnated with permethrin on the malarial indicators and the number of malarial attacks per child in a village in an area hyperendemic for malaria on the Malian savannah (preliminary results of the first year study)]. Bull Soc Pathol Exot. 1991; 84(5): 761-74 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Mali	Maiga AS, Brinkmann A. Risk in a national malaria control programme in Mali: underdosage of antimalarials. Trop Med Parasitol. 1987; 38(4): 333-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Mali	Sagara I, Dicko A, Ellis RD, Fay MP, Diawara SI, Assadou MH, Sissoko MS, Kone M, Diallo AI, Saye R, Guindo MA, Kante O, Niambele MB, Miura K, Mullen GE, Pierce M, Martin LB, Dolo A, Diallo DA, Doumbo OK, Miller LH, Saul A. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine. 2009; 27(23): 3090-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Mali	Toure Y, Traore S, Sankare O, Sow M, Coulibaly A, Esposito F, Petraarca V. Perennial transmission of malaria by the Anopheles gambiae complex in a north Sudan Savanna area of Mali. Med Vet Entomol. 1996; 10(2): 197-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Mali	Mali - Niono Parasitological and Clinical Survey 1995 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Malta	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2009-2011		
Malta	Malta Vital Registration - Deaths 1980 ICD9 as it appears in World Health Organization (WHO). World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1980		
Malta	Malta Vital Registration - Deaths 1999 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1999	*	
Malta	Malta Vital Registration - Deaths 2000 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2000	*	
Malta	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. Scand J Clin Lab Invest. 2007; 67(1): 39-69.	1990-2006		
Malta	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2006		
Malta	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. J Allergy Clin Immunol. 2008; 121(4): 947-954.	1994-1995, 2001-2002		
Malta	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000-2005, 2007-2009		
Malta	Dean G, Elian M, de Bono AG, Asciak R, Vella N, Mifsud V, Aquilina J. Multiple sclerosis in Malta in 1999: an update. J Neurol Neurosurg Psychiatry. 2002; 73(3): 256-60.	1999		
Malta	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J. 1998; 12(2): 315-35.	1993-1995		
Malta	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2002		
Malta	Schranz AG. Abnormal glucose tolerance in the Maltese. A population-based longitudinal study of the natural history of NIDDM and IGT in Malta. Diabetes Res Clin Pract. 1989; 7(1): 7-16.	1987		
Malta	Montefort S, Ellul P, Montefort M, Caruana S, Agius Muscat H. A decrease in the prevalence and improved control of allergic conditions in 13- to 15-yr-old Maltese children (ISAAC). Pediatr Allergy Immunol. 2011; 22(1 Pt 2): e107-111.	1995, 2002	*	
Malta	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. Community Dent Oral Epidemiol. 1991; 19(2): 72-3.	1987		
Malta	Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version). Lyon, IARC. http://cis.iarc.fr	2003-2007	*	
Malta	De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000; 54(11 Suppl 5): S21-23.	1997		
Malta	Berger K BM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000; 54(11): 24-7.	1997		
Malta	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Malta	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1995, 1999, 2001		
Malta	WHO Regional Office for Europe (EURO-WHO). Young People's Health in Context. Health Behaviour in School-aged Children (HBSC) Study: International Report from the 2001-2002 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2004.	2002		
Malta	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Malta	Bouvier-Colle M-H, Mohangoo AD, Gissler M, Novak-Antolic Z, Vutuc C, Szamotulska K, Zeitlin J, Euro-Peristat Scientific Committee. What about the mothers? An analysis of maternal mortality and morbidity in perinatal health surveillance systems in Europe. BJOG. 2012; 119(7): 880-90.	2003-2004	*	
Malta	Calleja-Agus J, Schembri-Wismayer P, Calleja N, Brincat M, Spiteri D. Obstetric outcome and cytokine levels in threatened miscarriage. Gynecol Endocrinol. 2011; 27(2): 121-7.	2010	*	
Malta	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Malta	Formosa N, Calleja N, Torpiano J. Incidence and modes of presentation of childhood type 1 diabetes mellitus in Malta between 2006 and 2010. Pediatr Diabetes. 2012; 13(6): 484-8.	2006-2010		
Malta	Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. J Clin Endocrinol Metab. 2008; 93(4): 1408-11.	2005		
Malta	Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. Cancer Incidence in Five Continents. Vol. 1 to VIII. Lyon, France, IARC Press, 2005.	1992-1997	*	
Malta	Cachia E, Calleja N, Aakeroy R, Degaetano J, Vassallo M. Incidence of inflammatory bowel disease in Malta between 1993 and 2005: a retrospective study. Inflamm Bowel Dis. 2008; 14(4): 550-3.	1993-2005		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Malta	Trichopoulos D, Bania C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overved K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PHM, Lund E, Quirós JR, González CA, Sanchez Perez M-J, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu I, Chuang S-C, Murphy N, Boffetta P, Trichopoulou A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. <i>J Natl Cancer Inst.</i> 2011; 103(22): 1686-95.	1992-2006	*	
Malta	Borg MA, Portelli A. Hospital laundry workers—an at-risk group for hepatitis A <i>Occup Med (Lond).</i> 1999; 49(7): 448-50.	1998		
Malta	Zeitlan J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT; 2008. Available from: http://www.perinataleaudit.nl/downloads/bestand/649/peristat-ii-2008-	2004		†
Malta	Malta Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Malta	Malta Congenital Anomalies Register Data 2001 - ICBDSMS as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
Malta	Malta Congenital Anomalies Register Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
Malta	Malta Congenital Anomalies Register Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Malta	Malta Congenital Anomalies Register Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
Malta	European Surveillance of Congenital Anomalies (EUROCAT). Malta EUROCAT Prevalence Tables. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	1986-2011		
Malta	Malta Congenital Anomalies Register Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
Malta	Malta Congenital Anomalies Register Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Malta	Malta Congenital Anomalies Register Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
Malta	Malta Congenital Anomalies Register Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). <i>World Atlas of Birth Defects</i> . 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Marshall Islands	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1989, 1991, 1994-1996, 1999-2010		
Marshall Islands	Centre for Health Informatics and Multiprofessional Education, University College London. <i>Modell's Haemoglobinopathologist's Almanac</i> . London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Marshall Islands	Hill AV, Bowden DK, O'Shaughnessy DF, Weatherall DJ, Clegg JB. Beta thalassaemia in Melanesia: association with malaria and characterization of a common variant (IVS-1 nt 5 G→C). <i>Blood</i> . 1988; 72(1): 9-14.	1985-1987		
Marshall Islands	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1999-2001, 2003-2004, 2006-2007, 2009		
Marshall Islands	Fischer GE, Thompson N, Chaves SS, Bower W, Goldstein S, Armstrong G, Williams I, Bialek S. The epidemiology of hepatitis A virus infections in four Pacific Island nations, 1995-2008. <i>Trans R Soc Trop Med Hyg.</i> 2009; 103(9): 906-10.	2007		
Marshall Islands	Yanagihara RT, Garruto RM, Gajdusek DC. Epidemiological surveillance of amyotrophic lateral sclerosis and parkinsonism-dementia in the commonwealth of the Northern Mariana Islands. <i>Ann Neurol.</i> 1983; 13(1): 79-86.	1980-1981		
Marshall Islands	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Marshall Islands	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec.</i> 2005; 80(13): 118-24.	2003	*	
Marshall Islands	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Marshall Islands	World Health Organization (WHO). Global leprosy situation, 2007 (additional information). <i>Wkly Epidemiol Rec.</i> 2007; 82(44): 388.	2006	*	
Marshall Islands	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Marshall Islands	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Marshall Islands	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Marshall Islands	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec.</i> 2008; 83(33): 293-300.	2007	*	
Marshall Islands	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Marshall Islands	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Marshall Islands	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Marshall Islands	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Marshall Islands	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2000.	2000		
Marshall Islands	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2001.	2001		
Marshall Islands	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2002.	2002		
Marshall Islands	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2003.	2003		
Marshall Islands	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2004.	2004		
Marshall Islands	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2005.	2005		
Marshall Islands	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2006.	2006		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Marshall Islands	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2009.	2009		
Mauritania	National Office of Statistics (Mauritania), League of Arab States. Mauritania Maternal and Child Health Survey 1990-1991.	1990-1991		†
Mauritania	United Nations Children's Fund (UNICEF), National Office of Statistics (Mauritania). Mauritania Multiple Indicator Cluster Survey 2007. New York, United States: United Nations Children's Fund (UNICEF).	2007	*	†
Mauritania	Department of Statistics and National Accounts (Mauritania), International Statistical Institute. Mauritania World Fertility Survey 1981. Voorburg, Netherlands: International Statistical Institute.	1981		
Mauritania	Macro International, Inc, National Office of Statistics (Mauritania). Mauritania Demographic and Health Survey 2000-2001. Calverton, United States: Macro International, Inc.	2000-2001		†
Mauritania	World Health Organization (WHO). Mauritania World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Mauritania	Ministry of Health (Mauritania), World Health Organization (WHO). Mauritania - Nouakchott STEPS Noncommunicable Disease Risk Factors Survey 2006.	2006		
Mauritania	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists' Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Mauritania	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Mauritania	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1987		
Mauritania	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997-1998, 2001-2004, 2006-2008		
Mauritania	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Mauritania	Mauritania - Nouakchott Rapid Assessment of Cataract Surgical Services 2002 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2002		
Mauritania	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2004, 2007, 2010, 2012		
Mauritania	Meiloud G, Arfa I, Kefi R, Abdelhamid I, Veten F, Lasram K, Ben Halim N, Sidi Mhamed A, Samb A, Abdelhak S, Houmeida AO. Type 2 diabetes in Mauritania: prevalence of the undiagnosed diabetes, influence of family history and maternal effect. Prim Care Diabetes. 2013; 7(1): 19-24.	2010-2012		
Mauritania	Mauritania Iodine Deficiency Disorder Survey 1995 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1995		
Mauritania	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Mauritania	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Mauritania	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Mauritania	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Mauritania	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Mauritania	Baudon D, Robert V, Darriet F, Huere M. [Impact of building a dam on the transmission of malaria. Malaria survey conducted in southeast Mauritania]. Bull Soc Pathol Exot. 1986; 79(1): 123-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Mauritania	Touray S, Winkler MS, Utzinger J, Cisse G, Ba H, Ba O, Kota M, Salem CBOA, Keita M, Traore D, Sy I. Absence of dry season Plasmodium parasitaemia, but high rates of reported acute respiratory infection and diarrhoea in preschool-aged children in Kaedi, southern Mauritania. Parasit Vectors. 2012; 5: 193 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2011	*	†
Mauritania	World Health Organization (WHO). Mauritania World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Mauritania	Ministry of Health and Quality of Life (Mauritania), World Health Organization (WHO). Mauritania STEPS Noncommunicable Disease Risk Factors Survey 2004.	2004		
Mauritania	Gibbs, S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int J Dermatol. 1996; 35(9): 633-9.	1994		
Mauritania	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1996-1997, 1999-2001, 2003-2009		
Mauritania	Shaw JE, Hodge AM, de Courten M, Dowse GK, Gareebou H, Tuomilehto J, Alberti KG, Zimmet PZ. Diabetic neuropathy in Mauritania: prevalence and risk factors. Diabetes Res Clin Pract. 1998; 42(2): 131-9.	1987-1992		
Mauritania	Dowse GK, Humphrey AR, Collins VR, Plehwe W, Gareebou H, Fareed D, Hemraj F, Taylor HR, Tuomilehto J, Alberti KG, Zimmet PZ. Prevalence and risk factors for diabetic retinopathy in the multiethnic population of Mauritania. Am J Epidemiol. 1998; 147(5): 448-57.	1992		
Mauritania	Dowse GK, Gareebou H, Zimmet PZ, Alberti KG, Tuomilehto J, Fareed D, Brissonette LG, Finch CF. High prevalence of NIDDM and impaired glucose tolerance in Indian, Creole, and Chinese Mauritians. Mauritius Noncommunicable Disease Study Group. Diabetes. 1990; 39(3): 390-6.	1987		
Mauritania	Hodge AM, Dowse GK, Zimmet PZ, Gareebou H, Westerman RA, Tuomilehto J, Alberti KG. Factors associated with impaired vibration perception in Mauritians with normal and abnormal glucose tolerance. Mauritius NCD Study Group. J Diabet Complications. 1995; 9(3): 149-57.	1992		
Mauritania	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2004, 2007, 2010, 2012		
Mauritania	Ministry of Social Security, National Solidarity and Senior Citizen Welfare and Reform Institutions, National Agency for the Treatment and Rehabilitation of Substance Abusers (NARTESA), United Nations Office on Drugs and Crime (UNODC). Mauritius Rapid Situation Assessment 2004.	2004	*	
Mauritania	Söderberg S, Zimmet P, Tuomilehto J, de Courten M, Dowse GK, Chitson P, Stenlund H, Gareebou H, Alberti KGMM, Shaw J. High incidence of type 2 diabetes and increasing conversion rates from impaired fasting glucose and impaired glucose tolerance to diabetes in Mauritius. J Intern Med. 2004; 256(1): 37-47.	1987-1998		
Mauritania	Kotea R, Kaeda JS, Yan SL, Sem Fa N, Beeson S, Jankee S, Ramasawmy R, Vulliamy T, Bradnock RW, Bautista J, Luzzatto L, Krishnamoorthy R, Mason PJ. Three major G6PD-deficient polymorphic variants identified among the Mauritian population. Br J Haematol. 1999; 104(4): 849-54.	1997-1999		
Mauritania	World Health Organization (WHO). Global leprosy situation, 2007 (additional information). Wkly Epidemiol Rec. 2007; 82(44): 388.	2006	*	
Mauritania	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Mauritania	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Mauritania	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Mauritania	Schwarz TF, Kam CC, Min GL, Jilg W, Wilske B, Gürtler L, Deinhardt F. Prevalence of antibodies against hepatitis A virus, hepatitis B virus, and Treponema pallidum in Mauritius. Scand J Infect Dis. 1991; 23(5): 535-41.	1987		
Mauritania	Mauritius Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Mexico	National Institute of Public Health (Mexico). Mexico National Survey of Health and Nutrition 2005-2006. Cuernavaca, Mexico: National Institute of Public Health (Mexico).	2005-2006		†
Mexico	Department of Statistics (Mexico), International Statistical Institute. Mexico World Fertility Survey 1976-1977. Voorburg, Netherlands: International Statistical Institute.	1976-1977		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Mexico	Ministry of Health (Mexico), National Institute of Statistics, Geography, and Informatics (Mexico). Mexico National Addiction Survey 2002. Aguascalientes, Mexico: National Institute of Statistics, Geography, and Informatics (Mexico).	2002	*	
Mexico	Macro Systems, Inc.; Institute for Resource Development, Ministry of Health (Mexico). Mexico Demographic and Health Survey 1987. Columbia, United States: Macro Systems, Inc.	1987		†
Mexico	World Health Organization (WHO). Mexico World Health Survey 2002-2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2002-2003		†
Mexico	National Institute of Statistics and Geography (Mexico). Mexico Vital Statistics - Deaths 2009.	2009	*	†
Mexico	Ministry of Health (Mexico). Mexico Ministry of Health Hospital Discharges 2000. Mexico City, Mexico: Ministry of Health (Mexico).	2000		
Mexico	Ministry of Health (Mexico). Mexico Ministry of Health Hospital Discharges 2001. Mexico City, México: Ministry of Health (Mexico).	2001		
Mexico	Ministry of Health (Mexico). Mexico Ministry of Health Hospital Discharges 2002. Mexico City, México: Ministry of Health (Mexico).	2002		
Mexico	Ministry of Health (Mexico). Mexico Ministry of Health Hospital Discharges 2003. Mexico City, México: Ministry of Health (Mexico).	2003		
Mexico	Ministry of Health (Mexico). Mexico Ministry of Health Hospital Discharges 2004. Mexico City, México: Ministry of Health (Mexico).	2004		
Mexico	Ministry of Health (Mexico). Mexico Ministry of Health Hospital Discharges 2005. Mexico City, México: Ministry of Health (Mexico).	2005		
Mexico	Ministry of Health (Mexico). Mexico Ministry of Health Hospital Discharges 2006. Mexico City, México: Ministry of Health (Mexico).	2006		
Mexico	Ministry of Health (Mexico). Mexico Ministry of Health Hospital Discharges 2007. Mexico City, México: Ministry of Health (Mexico).	2007		
Mexico	Ministry of Health (Mexico). Mexico Ministry of Health Hospital Discharges 2008. Mexico City, México: Ministry of Health (Mexico).	2008		
Mexico	Ministry of Health (Mexico). Mexico Ministry of Health Hospital Discharges 2009. Mexico City, México: Ministry of Health (Mexico).	2009		
Mexico	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-1990, 1992-2002		
Mexico	Ministry of Health (Mexico). Mexico Ministry of Health Hospital Discharges 2010. Mexico City, México: Ministry of Health (Mexico).	2010		
Mexico	Ministry of Health (Mexico). Mexico Ministry of Health Hospital Discharges 2011. Mexico City, México: Ministry of Health (Mexico).	2011		
Mexico	Rosado JL, López P, Muñoz E, Martínez H, Allen LH. Zinc supplementation reduced morbidity, but neither zinc nor iron supplementation affected growth or body composition of Mexican preschoolers. Am J Clin Nutr. 1997; 65(1): 13-9.	1995		
Mexico	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Mexico	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Mexico	Becerril Angeles M, Vázquez Merino CL, Angeles Garay U, Alvarado Motezuma LE, Vilchis Guizar E. Prevalence of allergic diseases in the elderly. Rev Alerg Mex. 2008; 55(3): 85-91.	2006-2008		
Mexico	Fidler A, Hartog R, Lezana MA, Salvatierra B, Silveira C, Tapia R. Field test of a rapid assessment technique against a probabilistic community survey: operational implications for neonatal tetanus elimination. Int J Epidemiol. 1994; 23(2): 386-92.	1987-1990		
Mexico	Guerra-Godínez JC, Larrosa-Haro A, Coello-Ramírez P, Tostado HRA, Rivera-Chávez E, Castillo de León YA, Bojórquez-Ramos M del C, Aguilar-Benavides S. Changing trends in prevalence, morbidity, and lethality in persistent diarrhea of infancy during the last decade in Mexico. Arch Med Res. 2003; 34(3): 209-13.	1988-1991, 1993-1994, 1997-1999		
Mexico	Hay RJ, Castanon RE, Hernandez HA, Lopez GC, Fuentes LF, Solis SP, Andersson N. Wastage of family income on skin disease in Mexico. BMJ. 1994; 309(6958): 848.	1993		
Mexico	Velasco-Castrejon O, Valdespino JL, Tapia-Conyer R, Salvatierra B, Guzmán-Bracho C, Magos C, Llausás A, Gutiérrez G, Sepúlveda J. Seroprevalence of Chagas disease in Mexico. Salud Publica Mex. 1992; 34(2): 186-96.	1987-1989		
Mexico	Salazar PM, Rojas G, Bucio M, Cabrera M, García G, Ruiz A, Guevara Y, Tapia R. Seroprevalence of Trypanosoma cruzi antibodies and associated risk factors among the population under 18 years of age in Veracruz, Mexico. Rev Panam Salud Publica. 2007; 22(2): 75-82.	2001		
Mexico	Licona FSM, Zavala CC. Mexico Chagas Disease: Situation of Rhodnius Prolixus.	1988		
Mexico	Estrada Castañón R, Torres Bibiano B, Alarcón Hernández H, Villegas Arrizón A, Martínez Sandoval E, Chávez López G, Andersson N. Epidemiología cutánea en dos sectores de atención médica en Guerrero, México; Cutaneous epidemiology in two sectors of Guerrero, Mexico. Dermatol rev mex. 1992; 36(1): 29-34.	1989-1991		
Mexico	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. J Allergy Clin Immunol. 2008; 121(4): 947-954.	1994, 2002		
Mexico	National Council Against Addictions (Mexico), National Institute of Psychiatry Ramón de la Fuente Muñiz (Mexico), National Institute of Public Health (Mexico). Mexico National Addiction Survey 2008. Cuernavaca, Mexico: National Institute of Public Health (Mexico).	2008	*	
Mexico	National Center for the Prevention and Control of Addictions (Mexico), National Council Against Addictions (Mexico), National Institute of Psychiatry Ramón de la Fuente Muñiz (Mexico), National Institute of Public Health (Mexico). Mexico National Addiction Survey 2011.	2011	*	
Mexico	Solis Olivares CA, Jerjes-Sánchez Díaz C, Archondo Arce T. Risk profile and survival in patients with heart failure caused by systolic function Prospective study with 4-year follow-up. Arch Cardiol Mex. 2003; 73(3): 197-204.	1997-2001		
Mexico	Demyttenaere K, Bruffaerts R, Lee S, Posada-Villa J, Kovess V, Angermeyer MC, Levinson D, de Girolamo G, Nakane H, Mneimneh Z, Lara C, de Graaf R, Scott KM, Gureje O, Stein DJ, Haro JM, Bromet EJ, Kessler RC, Alonso J, Von Korff M. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. Pain. 2007; 129(3): 332-42.	2001-2002		
Mexico	Souza JP, Cecatti JG, Faundes A, Morais SS, Villar J, Carroli G, Gulmezoglu M, Wojdyla D, Zavaleta N, Donner A, Velasco A, Bataglia V, Valladares E, Kubickas M, Acosta A. Maternal near miss and maternal death in the World Health Organization's 2005 global survey on maternal and perinatal health. Bull World Health Organ. 2010; 88(2): 113-9.	2005		
Mexico	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997-1998, 2000-2001, 2003-2005, 2008-2009		
Mexico	Cardiel MH, Rojas-Serrano J. Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol. 2002; 20(5): 617-24.	1992, 1999		
Mexico	Alvarez Nemegeyi J, Nuño Gutiérrez BL, Alcocer Sánchez JA. Rheumatic diseases and labor disability in adult rural population. Rev Med Inst Mex Seguro Soc. 2005; 43(4): 287-92.	2001		
Mexico	Bennett K, Cardiel MH, Ferraz MB, Riedemann P, Goldsmith CH, Tugwell P. Community screening for rheumatic disorder: cross cultural adaptation and screening characteristics of the COPCORD Core Questionnaire in Brazil, Chile, and Mexico. J Rheumatol. 1997; 24(1): 160-8.	1994		
Mexico	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J. 1998; 12(2): 315-35.	1993-1995		
Mexico	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2002		
Mexico	National Institute of Public Health (Mexico), World Health Organization (WHO). Mexico WHO Study on Global AGEing and Adult Health 2009-2010. Geneva, Switzerland: World Health Organization (WHO), 2011.	2009-2010		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Mexico	González Villalpando ME, González Villalpando C, Arredondo Pérez B, Stern MP. Diabetic retinopathy in Mexico. Prevalence and clinical characteristics. Arch Med Res. 1994; 25(3): 355-60.	1979-1988		
Mexico	Jiménez-Corona A, Rojas R, Gómez-Pérez FJ, Aguilar-Salinas CA. Early-onset type 2 diabetes in a Mexican survey. Results from the National Health and Nutrition Survey 2006. Salud Publica Mex. 2010; 52(Suppl 1): S27-35.	2006		
Mexico	Morillo LE, Alarcon F, Arana N, Aulet S, Chapman E, Conterno L, Estevez E, Garcia-Pedroza F, Garrido J, Macias-Islas M, Monzillo P, Nunez L, Plascencia N, Rodriguez C, Takeuchi Y, Latin American Migraine Study Group. Prevalence of migraine in Latin America. Headache. 2005; 45(2): 106-17.	1999		
Mexico	Paek SY, Koriakos A, Saxton-Daniels S, Pandya AG. Skin diseases in rural Yucatan, Mexico. Int J Dermatol. 2012; 51(7): 823-8.	2009-2010	*	
Mexico	Cardoso EJ, Valdéz GC, Campos AC, de la Luz Sanchez R, Mendoza CR, Hernández AP, Ramírez MH, Habana JR, González EB, Matzumura PD, Carlier Y. Maternal fetal transmission of Trypanosoma cruzi: a problem of public health little studied in Mexico. Exp Parasitol. 2012; 131(4): 425-32.	2006-2008	*	
Mexico	Sosa-Estani S, Gamba-León MR, Del Cid-Lemus J, Althabe F, Alger J, Almendares O, Cafferata ML, Chippaux J-P, Dumontel E, Gibbons L, Padilla-Raygoza N, Schneider D, Belizán JM, Buekens P, Working Group. Use of a rapid test on umbilical cord blood to screen for Trypanosoma cruzi infection in pregnant women in Argentina, Bolivia, Honduras, and Mexico. Am J Trop Med Hyg. 2008; 79(5): 755-9.	2006-2007		
Mexico	Mallol J, Solé D, Baeza-Bacab M, Aguirre-Camposano V, Soto-Quiros M, Baena-Cagnani C, Latin American ISAAC Group. Regional variation in asthma symptom prevalence in Latin American children. J Asthma. 2010; 47(6): 644-50.	2001-2003	*	
Mexico	Vázquez-Nava F, Morales Romero J, Crodova Fernandez JA, Saldívar-González AH, Vázquez-Rodríguez CF, Barrientos Gomez M del C, Lin-Ochoa D, Vázquez Rodríguez EM. Association between obesity and asthma in preschool Mexican children. ScientificWorldJournal. 2010; 10: 1339-46.	2005	*	
Mexico	Islas-Granillo H, Borges-Yañez SA, Lucas-Rincón SE, Medina-Solis CE, Casanova-Rosado AJ, Márquez-Corona ML, Maupomé G. Edentulism risk indicators among Mexican elders 60-year-old and older. Arch Gerontol Geriatr. 2011; 53(3): 258-62.	2009	*	
Mexico	Jiménez-Farfán MD, Hernández-Guerrero JC, Juárez-López LA, Jacinto-Alemán LF, de la Fuente-Hernández J. Fluoride consumption and its impact on oral health. Int J Environ Res Public Health. 2011; 8(1): 148-60.	2009	*	
Mexico	Vázquez EM, Vázquez F, Barrientos MC, Córdova JA, Lin D, Beltrán FJ, Vázquez CF. Association between asthma and dental caries in the primary dentition of Mexican children. World J Pediatr. 2011; 7(4): 344-9.	2005	*	
Mexico	Pineda-Lucatero A, Avila-Jiménez L, Ramos-Hernández RI, Magos C, Martínez H. Iodine deficiency and its association with intelligence quotient in schoolchildren from Colima, Mexico. Public Health Nutr. 2008; 11(7): 690-8.	2002-2003	*	
Mexico	Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 1992. [Unpublished].	1992	*	†
Mexico	Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 1994. [Unpublished].	1994	*	†
Mexico	Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 2000. [Unpublished].	2000	*	†
Mexico	Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 2010. [Unpublished].	2010	*	†
Mexico	Peláez-Ballestas I, Navarro-Zarza JE, Julian B, Lopez A, Flores-Camacho R, Casasola-Vargas JC, Sanin LH, Rivas L, Vázquez-Mellado J, Burgos-Vargas R. A community-based study on the prevalence of spondylarthritides and inflammatory back pain in Mexicans. J Clin Rheumatol. 2013; 19(2): 57-61.	2009	*	
Mexico	Peláez-Ballestas I, Flores-Camacho R, Rodríguez-Amado J, Sanin LH, Valerio JE, Navarro-Zarza E, Flores D, Rivas LL, Casasola-Vargas J, Burgos-Vargas R. Prevalence of back pain in the community. A COPCORD-based study in the Mexican population. J Rheumatol Suppl. 2011; 26-30.	2008-2009	*	
Mexico	Cravioto A, Reyes RE, Ortega R, Fernández G, Hernández R, López D. Prospective study of diarrhoeal disease in a cohort of rural Mexican children: incidence and isolated pathogens during the first two years of life. Epidemiol Infect. 1988; 101(1): 123-34.	1982-1983	*	
Mexico	Huilan S, Zhen LG, Mathan MM, Mathew MM, Olarte J, Espejo R, Khin Maung U, Ghafoor MA, Khan MA, Sami Z. Etiology of acute diarrhoea among children in developing countries: a multicentre study in five countries. Bull World Health Organ. 1991; 69(5): 549-55.	1982-1984	*	
Mexico	Puerto FI, Polanco GG, González MR, Zavala JE Jr, Ortega G. Role of rotavirus and enteric adenovirus in acute paediatric diarrhoea at an urban hospital in Mexico. Trans R Soc Trop Med Hyg. 1989; 83(3): 396-8.	1986	*	
Mexico	Mejia-Arango S, Gutierrez LM. Prevalence and incidence rates of dementia and cognitive impairment no dementia in the Mexican population: data from the Mexican Health and Aging Study. J Aging Health. 2011; 23(7): 1050-74.	2001-2004		
Mexico	Prince M, Acosta D, Ferri CP, Guerra M, Huang Y, Llibre Rodríguez JJ, Salas A, Sosa AL, Williams JD, Dewey ME, Acosta I, Jotheeswaran AT, Liu Z. Dementia incidence and mortality in middle-income countries, and associations with indicators of cognitive reserve: a 10/66 Dementia Research Group population-based cohort study. Lancet. 2012; 380(9836): 50-8.	2003-2010		
Mexico	Sousa RM, Ferri CP, Acosta D, Albanese E, Guerra M, Huang Y, Jacob KS, Jotheeswaran AT, Rodriguez JLL, Pichardo GR, Rodriguez MC, Salas A, Sosa AL, Williams J, Zuniga T, Prince M. Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population-based survey. Lancet. 2009; 374(9704): 1821-30.	2003-2005		
Mexico	Rodríguez-Amado J, Peláez-Ballestas I, Sanin LH, Esquivel-Valerio JA, Burgos-Vargas R, Pérez-Barbosa L, Riega-Torres J, Garza-Elizondo MA. Epidemiology of rheumatic diseases. A community-based study in urban and rural populations in the state of Nuevo Leon, Mexico. J Rheumatol Suppl. 2011; 9-14.	2008-2009		
Mexico	Peláez-Ballestas I, Sanin LH, Moreno-Montoya J, Alvarez-Nemegyei J, Burgos-Vargas R, Garza-Elizondo M, Rodríguez-Amado J, Goycochea-Robles M-V, Madariaga M, Zamudio J, Santana N, Cardiel MH, Grupo de Estudio Epidemiológico de Enfermedades Músculo Articulares (GEEMA). Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J Rheumatol Suppl. 2011; 3-8.	2008		
Mexico	Vallejos-Sánchez AA, Medina-Solis CE, Casanova-Rosado JF, Maupomé G, Minaya-Sánchez M, Pérez-Olivares S. Caries increment in the permanent dentition of Mexican children in relation to prior caries experience on permanent and primary dentitions. J Dent. 2006; 34(9): 709-15.	1999-2001		
Mexico	Irigoyen M, Villanueva R, de la Teja E. Dental caries status of young children in a suburban community of Mexico City. Community Dent Oral Epidemiol. 1986; 14(6): 306-9.	1987		
Mexico	Segovia-Villanueva A, Estrella-Rodríguez R, Medina-Solis CE, Maupomé G. Dental caries experience and factors among preschoolers in southeastern México: a brief communication. J Public Health Dent. 2006; 66(2): 88-91.	2004		
Mexico	Medina-Mora ME, Borges G, Lara C, Benjet C, Blanco J, Fleiz C, Villatoro J, Rojas E, Zambrano J. Prevalence, service use, and demographic correlates of 12-month DSM-IV psychiatric disorders in Mexico: results from the Mexican National Comorbidity Survey. Psychol Med. 2005; 35(12): 1773-83.	2001-2002		
Mexico	Benjet C, Borges G, Medina-Mora ME, Zambrano J, Aguilar-Gaxiola S. Youth mental health in a populous city of the developing world: results from the Mexican Adolescent Mental Health Survey. J Child Psychol Psychiatry. 2009; 50(4): 386-95.	2005		
Mexico	Juarez F, Singh S, Garcia SG, Olavarrieta CD. Estimates of induced abortion in Mexico: what's changed between 1990 and 2006? Int Fam Plan Perspect. 2008; 34(4): 158-68.	1990, 2006		
Mexico	Sousa A, Lozano R, Gakidou E. Exploring the determinants of unsafe abortion: improving the evidence base in Mexico. Health Policy Plan. 2010; 25(4): 300-10.	2002-2006		
Mexico	Cross-national comparisons of the prevalences and correlates of mental disorders. WHO International Consortium in Psychiatric Epidemiology.	1995		
Mexico	Hernández B, Ortiz-Panozo E, Pérez-Cuevas R. Facility-based care for delivery and management of complications related to pregnancy and childbirth in Mexico. Salud Publica Mex. 2012; 54(5): 496-505.	2010		
Mexico	Menezes AM, Perez-Padilla R, Jardim JR, Muiño A, Lopez MV, Valdivia G, Montes de Oca M, Talamo C, Hallal PC, Victora CG, PLATINO Team. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet. 2005; 366(9500): 1875-81.	2002-2004		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Mexico	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2004-2008		
Mexico	United States Renal Data System Coordinating Center. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	1999-2003		
Mexico	United States Renal Data System Coordinating Center. USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2003.	1999		
Mexico	Ministry of Health (Mexico). Mexico Ministry of Health Hospital Discharges 2012. Mexico City, México: Ministry of Health (Mexico).	2012	*	
Mexico	Polack S, Yorston D, López-Ramos A, Lepe-Orta S, Baia RM, Alves L, Grau-Alvidrez C, Gomez-Bastar P, Kuper H. Rapid assessment of avoidable blindness and diabetic retinopathy in Chiapas, Mexico. <i>Ophthalmology</i> . 2012; 119(5): 1033-40.	2010	*	
Mexico	Amato D, Alvarez-Aguilar C, Castañeda-Limones R, Rodriguez E, Avila-Diaz M, Arreola F, Gomez A, Ballesteros H, Becerril R, Paniagua R. Prevalence of chronic kidney disease in an urban Mexican population. <i>Kidney Int Suppl</i> . 2005; 68(97): S11-17.	1999-2000		
Mexico	Limbung H, Silva JC, Foster A. Cataract in Latin America: findings from nine recent surveys. <i>Rev Panam Salud Publica</i> . 2009; 25(5): 449-55. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2005-2006		
Mexico	Danovaro-Holliday MC, Gordon ER, Jumaan AO, Woernle C, Judy RH, Schmid DS, Seward JF. High rate of varicella complications among Mexican-born adults in Alabama. <i>Clin Infect Dis</i> . 2004; 39(11): 1633-9.	2000		
Mexico	Alvarez y Muñoz MT, Torres J, Damasio-Santana L, Gómez A, Fernández-Quintanilla G, Tapia-Conyer R, Muñoz O. Susceptibility to varicella-zoster infection in individuals 1 to 29 years of age in Mexico. <i>Arch Med Res</i> . 1999; 30(1): 60-3.	1987-1988		
Mexico	Medina-Mora ME, Cravioto P, Villatoro J, Fleiz C, Galván-Castillo F, Tapia-Conyer R. [Drugs use among adolescents: results from the National Survey on Addictions, 1998]. <i>Salud Publica Mex</i> . 2003; 45(Suppl 1): S16-25. [Unpublished].	1998		
Mexico	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Mexico Evaluation of Progress in Drug Control 2007-2009. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2011.	2011	*	
Mexico	Quet F, Preux P-M, Huerta M, Ramirez R, Abad T, Fragoso G, Morales J, Sciuotto E, Fleury A. Determining the burden of neurological disorders in populations living in tropical areas: who would be questioned? Lessons from a Mexican rural community. <i>Neuroepidemiology</i> . 2011; 36(3): 194-203.	2007	*	
Mexico	Floyd LJ, Latimer WW, Vasquez M, O'Brien M. Substance use among school-based youths in northern Mexico. <i>Am J Addict</i> . 2005; 14(5): 464-70.	2005		
Mexico	Medina-Mora ME, Borges G, Fleiz C, Benjet C, Rojas E, Zambrano J, Villatoro J, Aguilar-Gaxiola S. Prevalence and correlates of drug use disorders in Mexico. <i>Rev Panam Salud Publica</i> . 2006; 19(4): 265-76.	2001-2002		
Mexico	Reyes E, Martínez N, Parra A, Castillo-Mora A, Ortega-González C. Early intensive obstetric and medical nutrition care is associated with decreased prepregnancy obesity impact on perinatal outcomes. <i>Gynecol Obstet Invest</i> . 2012; 73(1): 75-81.	2007-2008	*	
Mexico	Cantu-Brito C, Majersik JJ, Sánchez BN, Ruano A, Becerra-Mendoza D, Wing JJ, Morgenstern LB. Door-to-Door Capture of Incident and Prevalent Stroke Cases in Durango, Mexico The Brain Attack Surveillance in Durango Study. <i>Stroke</i> . 2011; 42(3): 601-6.	2008-2009	*	
Mexico	Ferri CP, Schoenborn C, Kalra L, Acosta D, Guerra M, Huang Y, Jacob KS, Rodriguez JLL, Salas A, Sosa AL, Williams JD, Liu Z, Moriyama T, Valluerdi A, Prince MJ. Prevalence of stroke and related burden among older people living in Latin America, India and China. <i>J Neurol Neurosurg Psychiatry</i> . 2011; 82(10): 1074-82.	2007-2009	*	
Mexico	Alvarez-Nemegyei J, Pelaez-Ballesteros I, Sanin LH, Cardiel MH, Ramirez-Angulo A, Goycochea-Robles M-V. Prevalence of musculoskeletal pain and rheumatic diseases in the southeastern region of Mexico. A COPCORD-based community survey. <i>J Rheumatol</i> . 2011; 86(Suppl): 21-5.	2008	*	
Mexico	Ortega Avila R, Zarelli M, Hauser W. Prevalence of epilepsy in a rural Mexican village. <i>Epilepsia</i> . 1990; 31(5): 604.	1982	*	
Mexico	Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl RV, De Graaf R, Vollebergh W, Dragomirecka E, Kohn R, Keller M, Kessler RC, Kawakami N, Kiliç C, Olford D, Ustun TB, Wittchen H-U. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. <i>Int J Methods Psychiatr Res</i> . 2003; 12(1): 3-21.	1995		
Mexico	Slone LB, Norris FH, Murphy AD, Baker CK, Perilla JL, Diaz D, Rodriguez FG, Gutiérrez-Rodríguez J de J. Epidemiology of major depression in four cities in Mexico. <i>Depress Anxiety</i> . 2006; 23(3): 158-67.	1999-2001		
Mexico	Abdo-Francis M, Torre A, Tenorio C, Ornelas E, Villasis A. [Prevalence of hepatitis B in patients with liver cirrhosis in Mexico]. <i>Rev Med Hosp Gen</i> . 2011; 74(01).	2008		
Mexico	Gomez AR, Ruiz MAC, Lopez GAP, Padierna J. Cirrosis. <i>Dolor</i> . 2009; 4-9.	2003		
Mexico	Góngora-Biachi RA, Castro-Sansores CJ, González-Martínez P, Lara-Perera DM, Garrido-Palma J, Lara-Perera V. Frequency of antibodies against the hepatitis C virus in patients with hepatic cirrhosis in Yucatan, Mexico. <i>Salud Publica Mex</i> . 2003; 45(5): 346-50.	1998-1999		
Mexico	Méndez-Sánchez N, Aguilar-Ramírez JR, Reyes A, Dehesa M, Juárez A, Castañeda B, Sánchez-Avila F, Poo JL, Guevara González L, Lizardi J, Valdovinos MA, Uribe M, Contreras AM, Tirado P, Aguirre J, Rivera-Benítez C, Santiago-Santiago R, Bosques-Padilla F, Muñoz L, Guerrero A, Ramos M, Rodríguez-Hernández H, Jacobo-Karam J. Grupo de Estudio, Asociación Mexicana de Hepatología. Etiology of liver cirrhosis in Mexico. <i>Ann Hepatol</i> . 2004; 3(1): 30-3.	2000-2002		
Mexico	Mondragón-Sánchez R, Garduño-López AL, Hernández-Castillo E, Gómez-Gómez E, Ruiz-Molina JM. Hepatocellular carcinoma and hepatitis C in Mexico. <i>Hepatogastroenterology</i> . 2005; 52(64): 1159-62.	1992-2002		
Mexico	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Mexico	Abraham CD, Conde-Glez CJ, Cruz-Valdez A, Sánchez-Zamorano L, Hernández-Márquez C, Lazcano-Ponce E. Sexual and demographic risk factors for herpes simplex virus type 2 according to schooling level among Mexican youths. <i>Sex Transm Dis</i> . 2003; 30(7): 549-55.	2000	*	
Mexico	Sánchez-Alemán MA, Conde-Glez CJ, Gayet C, García-Cisneros S, Uribe-Salas F. Sexual behavior and herpes simplex virus 2 infection in college students. <i>Arch Med Res</i> . 2005; 36(5): 574-80.	2000-2001	*	
Mexico	Uribe-Salas F, Conde-Glez CJ, Juárez-Figueroa L, Hernández-Castellanos A. Sociodemographic dynamics and sexually transmitted infections in female sex workers at the Mexican-Guatemalan border. <i>Sex Transm Dis</i> . 2003; 30(3): 266-71.	1998	*	
Mexico	Zamitpa-Mejía LG, Uribe-Salas F, Juárez-Figueroa L, Calderón-Jaimes E, Conde-González CJ. [Prevalence and factors associated with syphilis and genital herpes in 2 groups of the female population]. <i>Salud Publica Mex</i> . 2003; S617-623.	1994-1995	*	
Mexico	Conde-González CJ, Lazcano-Ponce E, Hernández-Girón C, Juárez-Figueroa L, Smith JS, Hernández-Avila M. [Seroprevalence of type 2 herpes simplex virus infection in 3 population groups of Mexico City]. <i>Salud Publica Mex</i> . 2003; S608-616.	1994-1996	*	
Mexico	Alvar Loria P. Studies on some hereditary hematologic characteristics in the Mexican population. III. Erythrocytic glucose-6-phosphate dehydrogenase deficiency in 7 indigenous and mestizo groups. <i>Gac Med Mex</i> . 1963; 299-303.	1961-1963		
Mexico	Lisker R, Zarate G, Loria A. Studies on several genetic hematologic traits of Mexicans IX. Abnormal hemoglobins and erythrocytic glucose-6-phosphate dehydrogenase deficiency in several Indian tribes. <i>Blood</i> . 1966; 27(6): 824-30.	1964-1966		
Mexico	Lisker R, Pérez Briceno R, Sosa R, Shein M. Hereditary and epidemiological aspects of erythrocyte glucose-6-phosphate dehydrogenase deficiency in Mexico. <i>Gac Med Mex</i> . 1976; 111(6): 454-8.	1974-1976		
Mexico	Arámula E, Aguilar L JC, Vaca G. Glucose-6-phosphate dehydrogenase mutations and haplotypes in Mexican Mestizos. <i>Blood Cells Mol Dis</i> . 2000; 26(4): 387-94.	1985		
Mexico	Vaca G, Arámula E, Esparza A. Molecular heterogeneity of glucose-6-phosphate dehydrogenase deficiency in Mexico: overall results of a 7-year project. <i>Blood Cells Mol Dis</i> . 2002; 28(3): 436-44.	1995-2002		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Mexico	Fernández-Cean J, González-Martínez F, Schwedt E, Mazzuchi N. Renal replacement therapy in Latin America. <i>Kidney Int.</i> 2000; 57(s74): 55-59.	1997		
Mexico	Cusumano A, García-García G, Di Gioia C, Hermida O, Lavorato C, Carreño CA, Torrico MP, Batista PB, Romão JE, Badal HP, Miranda SE, Gomez R, Calderon MC, Sanchez SH, Lopez MA, Moscoso J, Merino RL, Polo JV, Lopez A, Romero NJ, García R, Acosta BV, Lopez AS, Delpin ES, Mena E, González C, Milanés CL, Acchiardo S. End-stage renal disease and its treatment in Latin America in the twenty-first century. <i>Ren Fail.</i> 2006; 28(8): 631-7.	2004		
Mexico	Santiago-Delpin EA, García VD. Latin American Transplant Registry VIIIth Report: 1998. <i>Transplant Proc.</i> 1999; 31(1-2): 214-6.	1995, 1997		
Mexico	Correa-Rotter R, Cusumano AM. Present, prevention, and management of chronic kidney disease in Latin America. <i>Blood Purif.</i> 2008; 26(1): 90-4.	2005		
Mexico	García-García G, Monteón-Ramos JF, García-Bejarano H, Gomez-Navarro B, Reyes IH, Lomeli AM, Palomeque M, Cortes-Sanabria L, Breien-Alcaraz H, Ruiz-Morales NM. Renal replacement therapy among disadvantaged populations in Mexico: a report from the Jalisco Dialysis and Transplant Registry (REDTJAL). <i>Kidney Int Suppl.</i> 2005; 97: S58-61.	2000		
Mexico	Moran C, Tena G, Moran S, Ruiz P, Reyna R, Duque X. Prevalence of polycystic ovary syndrome and related disorders in Mexican women. <i>Gynecol Obstet Invest.</i> 2010; 69(4): 274-80.	2007		
Mexico	Institute for the Care and Prevention of Addiction in Mexico City (IAPA), Institute for the Care of Older Adults in the Federal District (Mexico), National Institute of Psychiatry Ramón de la Fuente Muñiz (Mexico). Mexico - Mexico City Psychoactive Drug Consumption by Older Adults Study 2012.	2012	*	
Mexico	Bondy S, Medina-Mora M, Rehm J, Ialomiteanu A, Frick U. Alcohol Consumption and Harm in Mexico. Presented at: Alcohol Policy in Developing Societies Project; 1997 Apr 26-30; Mexico City, Mexico.	1988		
Mexico	Rojas Guiot E, Fleiz Bautista C, Villatoro Velázquez J, Gutiérrez López M de L, Medina-Mora Icaza ME. Tendencias del consumo de drogas de 1998 a 2005 en tres ciudades de la zona norte de México: Ciudad Juárez, Monterrey y Tijuana. <i>Salud Ment (Mex).</i> 2009; 32(1): 13-9.	1998, 2005		
Mexico	World Health Organization (WHO). Mexico WHO Leishmaniasis Country Profile.	1994-2010	*	
Mexico	Libre Rodríguez JJ, Ferri CP, Acosta D, Guerra M, Huang Y, Jacob KS, Krishnamoorthy ES, Salas A, Sosa AL, Acosta I, Dewey ME, Gason C, Jotheeswaran AT, Li S, Rodríguez D, Rodríguez G, Kumar PS, Valhuerdi A, Prince M. 10/66 Dementia Research Group. Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey. <i>Lancet.</i> 2008; 372(9637): 464-74.	2005-2006		†
Mexico	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Mexico	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Mexico	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Mexico	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Mexico	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec.</i> 2008; 83(33): 293-300.	2007	*	
Mexico	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Mexico	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Mexico	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Mexico	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Mexico	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Mexico	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Mexico	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1993; 68(25): 181-6.	1992	*	
Mexico	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Mexico	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Mexico	Directorate General of Epidemiology, Ministry of Health (Mexico). Mexico Cases of Respiratory Tuberculosis by Age Groups 2012.	2012	*	
Mexico	Lazcano-Ponce E, Smith JS, Muñoz N, Conde-Glez CJ, Juárez-Figueroa L, Cruz A, Hernández M. High prevalence of antibodies to herpes simplex virus type 2 among middle-aged women in Mexico City, Mexico: a population-based study. <i>Sex Transm Dis.</i> 2001; 28(5): 270-6.	1994-1996	*	
Mexico	Directorate General of Epidemiology, Ministry of Health (Mexico). Mexico Morbidity Yearbooks 1984-2008.	1990-1992, 2003-2006		
Mexico	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2007. Pan American Health Organization (PAHO).	2007		†
Mexico	Villalpando S, García-Guerra A, Ramírez-Silva CI, Mejía-Rodríguez F, Matute G, Shamah-Levy T, Rivera JA. Iron, zinc and iodide status in Mexican children under 12 years and women 12-49 years of age. A probabilistic national survey. <i>Salud Publica Mex.</i> 2003; S520-S529 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1998-1999		
Mexico	Martínez-Salgado H, Castañeda-Limones R, Lechuga-Martín del Campo D, Ramos-Hernández RI, Orozco-López M, Rivera-Dommarco J, Mendoza I, Magos C. [Iodine deficiency and other potential goitrogens in the persistence of endemic goiter in Mexico]. <i>Gac Med Mex.</i> 2002; 138(2): 149-56 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2002		
Mexico	Monárrez-Espino J, Greiner T. Iodine nutrition among indigenous Tarahumara schoolchildren in Mexico. <i>Eur J Clin Nutr.</i> 2005; 59(10): 1213-6 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2003		
Mexico	Medina-Solis CE, Pérez-Núñez R, Maupomé G, Avila-Burgos L, Pontigo-Loyola AP, Patiño-Marín N, Villalobos-Rodelo JJ. National survey on entulism and its geographic distribution, among Mexicans 18 years of age and older (with emphasis in WHO age groups). <i>J Oral Rehabil.</i> 2008; 35(4): 237-44.	2002-2003		
Mexico	United States Renal Data System Coordinating Center. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2013.	2010-2011		
Mexico	Chowell G, Diaz-Duenas P, Chowell D, Hews S, Ceja-Espiritu G, M. Hyman J, Castillo-Chavez C. Clinical Diagnosis Delays and Epidemiology of Dengue Fever during the 2002 Outbreak in Colima, Mexico. <i>Dengue Bull.</i> 2007; 31: 26-35.	2002	*	
Mexico	Directorate General of Epidemiology, Ministry of Health (Mexico). Mexico Dengue Surveillance Statistics 2013. Mexico City, Mexico: Directorate General of Epidemiology, Ministry of Health (Mexico).	2013	*	
Mexico	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Mexico	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Mexico	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Mexico	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Mexico	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Mexico	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Mexico	Juárez-Figueroa LA, Uribe-Salas FJ, Conde-González CJ, Sánchez-Alemán MÁ. Marcadores serológicos de hepatitis B y C, y VIH en La Calera y Cuambio, Guerrero, México. Salud Publica Mex. 2011; 53:2-S36.	2004		
Mexico	Ladrón de Guevara L, Rojas-Macuil P, Sánchez-Chávez X, Rossano-García A, Gorraez-de-la-Mora MT, Cervantes-Sánchez G, Orozco-Vázquez J, Lemus-Velázquez M, Rosas-Zúñiga L, Erazo-Valle A, Di-Silvio M. Hepatocellular carcinoma: epidemiological profile from a cohort of federal employees in Mexico. Ann Hepatol. 2009; 8(3): 212-9.	2004-2007	*	
Mexico	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L, Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. Ann Hepatol. 2010; 9(1): 63-9.	2006-2008	*	
Mexico	Bernal Reyes R, Licona Solís JE. [Seroepidemiology of hepatitis E in the State of Hidalgo]. Rev Gastroenterol Mex. 1996; 61(3): 233-8.	1993-1995		
Mexico	Tapia-Conyer R, Santos JI, Cavalcanti AM, Urdaneta E, Rivera L, Manterola A, Potin M, Ruttiman R, Tanaka Kido J. Hepatitis A in Latin America: A Changing Epidemiologic Pattern. Am J Trop Med Hyg. 1999; 61(5): 825-9.	1996-1997		
Mexico	Kumate J, Alvizouri AM, Isibasi A. Serologic survey of hepatitis A antibodies in Mexican children. Bull Pan Am Health Organ. 1982; 16(2): 156-60.	1973		
Mexico	Bustamante-Calvillo ME, Velázquez-Castillo FR, Padilla-Noriega L, Alvarez y Muñoz MT, Moreno-Altamirano L, Martínez-García MC, Guisacafre-Gallardo H, Muñoz-Hernández O. Hepatitis A antibodies: prevalence and persistence in a group of Mexican children. Bol Med Hosp Infant Mex. 1986; 43(12): 735-41.	1984-1985		
Mexico	Ramírez Mayans JA, Cervantes Bustamante R, Jiron Castro R, Oyervides García CI, Mata Rivera N, Navarrete Delgadillo Natividad MA, Sosa Martínez MC. [Prevalence of antibodies against hepatitis A virus (HAV) in a population of Mexican children]. Acta Gastroenterol Latinoam. 1997; 27(2): 99-102.	1992-1993		
Mexico	Ortiz-Ibarra FJ, Figueroa-Damián R, Lara-Sánchez J, Arredondo-García JL, Ahued-Ahued JR. [Prevalence of serologic markers of hepatitis A, B, C, and D viruses in pregnant women]. Salud Publica Mex. 1996; 38(5): 317-22.	1995		
Mexico	Redlinger T, O'Rourke K, Nickey L, Martinez G. Elevated hepatitis A and E seroprevalence rates in a Texas/Mexico border community. Tex Med. 1998; 94(5): 68-71.	1996		
Mexico	Garza-Chapa R, del Refugio González-Rendón MA, Joffre G. ABO and Rh(D) blood groups in IMSS population in the State of Nuevo León (estimation of simple and double incompatibility frequency in married couples and their offspring). Arch Invest Med (Mex). 1978; 9(4): 541-58.	1972-1975	*	†
Mexico	Alvarez-Muñoz MT, Torres J, Damasio L, Gómez A, Tapia-Conyer R, Muñoz O. Seroepidemiology of hepatitis E virus infection in Mexican subjects 1 to 29 years of age. Arch Med Res. 1999; 30(3): 251-4.	1987-1988		
Mexico	Chiquete E, Sánchez LV, Becerra G, Quintero A, Maldonado M, Panduro A. Performance of the serologic and molecular screening of blood donations for the hepatitis B and C viruses in a Mexican Transfusion Center. Ann Hepatol. 2005; 4(4): 275-8.	1999-2005		
Mexico	Cisneros-Castolo M, Hernández-Ruiz L, Ibarra-Robles IE, Fernández-Gárate RH, Escobedo-De La Peña J. Prevalence of hepatitis B virus infection and related risk factors in a rural community of Mexico. Am J Trop Med Hyg. 2001; 65(6): 759-63.	1997		
Mexico	Ramírez-Mayans J, Cervantes-Bustamante R, Zárate-Mondragón F, Mata-Rivera N, Tello M, Navarrete N, de Martínez CS. Hepatitis C virus antibodies in a Mexican population. Pediatr Infect Dis J. 1998; 17(2): 169-70.	1992-1993		
Mexico	Iglesias-Leboreiro J, Bernardes-Zapata I, Ramírez-Haua J, González-Morán R, Rendón-Macias ME. Mortality in extremely low-birth-weight neonates in México City (1985-2009). Int J Pediatr. 2010; 265146.	1990, 2007		†
Mexico	Medina MT, Rosas E, Rubio-Donnadieu F, Sotelo J. Neurocysticercosis as the main cause of late-onset epilepsy in Mexico. Arch Intern Med. 1990; 150(2): 325-7.	1988		
Mexico	National Institute of Public Health (Mexico), World Health Organization (WHO). Mexico WHO Multi-country Survey Study on Health and Health System Responsiveness 2000-2001. Geneva, Switzerland: World Health Organization (WHO).	2000-2001		
Mexico	Pan American Health Organization (PAHO), World Health Organization (WHO). Quantitative Estimation of Chagas in the Americas.	2005	*	
Mexico	Escamilla-Guerrero G, Martínez-Gordillo MN, Riverón-Negrete L, Aguilar-Escobar DV, Bravo-Lindoro A, Cob-Sosa C, Ponce-Macotela M. Trypanosoma cruzi: seroprevalence detected in the blood bank of the Instituto Nacional de Pediatría, Mexico City, in the period 2004 through 2009. Transfusion. 2012; 52(3): 595-600.	2004-2009	*	
Mexico	López-Céspedes Á, Villagrán E, Briceño Álvarez K, de Diego JA, Hernández-Montiel HL, Saldaña C, Sanchez-Moreno M, Marín C. Trypanosoma cruzi: seroprevalence detection in suburban population of Santiago de Querétaro (Mexico). ScientificWorldJournal. 2012; 914129.	2010	*	
Mexico	Contreras FT, Yerenas M de L, Gutiérrez MS, Anaya MR, Corder AJ. [Serological follow-up of Trypanosoma cruzi infection from 1987 to 1994 in individuals studies in 50 counties of the State of Jalisco, Mexico]. Rev Soc Bras Med Trop. 2000; 33(6): 591-6.	1987, 1994	*	
Mexico	Mazariego-Arana MA, Monteón VM, Ballinas-Verdugo MA, Hernández-Becerril N, Alejandre-Aguilar R, Reyes PA. Seroprevalence of human Trypanosoma cruzi infection in different geographic zones of Chiapas, Mexico. Rev Soc Bras Med Trop. 2001; 34(5): 453-8.	1998-2000	*	
Mexico	Sánchez-Guillén MC, Barnabé C, Guégan JF, Tibayrenc M, Velázquez-Rojas M, Martínez-Munguía J, Salgado-Rosas H, Torres-Rasgado E, Rosas-Ramírez MI, Pérez-Fuentes R. High prevalence anti-Trypanosoma cruzi antibodies, among blood donors in the State of Puebla, a non-endemic area of Mexico. Mem Inst Oswaldo Cruz. 2002; 97(7): 947-52.	1999-2001	*	
Mexico	Coll-Cárdenas R, Espinoza-Gómez F, Maldonado-Rodríguez A, Reyes-López PA, Huerta-Viera M, Rojas-Larios F. Active transmission of human chagas disease in Colima Mexico. Mem Inst Oswaldo Cruz. 2004; 99(4): 363-8.	1998-1999	*	
Mexico	Hernández-Becerril N, Mejía AM, Ballinas-Verdugo MA, Garza-Murillo V, Manilla-Toquero E, López R, Trevethan S, Cardenas M, Reyes PA, Hirayama K, Monteón VM. Blood transfusion and iatrogenic risks in Mexico City. Anti-Trypanosoma cruzi seroprevalence in 43,048 blood donors, evaluation of parasitemia, and electrocardiogram findings in seropositive. Mem Inst Oswaldo Cruz. 2005; 100(2): 111-6.	1999-2003	*	
Mexico	Monteon V, Alducin C, Hernández J, Ramos-Ligonio A, Lopez R. High frequency of human blood in Triatoma dimidiata captured inside dwellings in a rural community in the Yucatan Peninsula, Mexico, but low antibody seroprevalence and electrocardiographic findings compatible with Chagas disease in humans. Am J Trop Med Hyg. 2013; 88(3): 566-71.	2010	*	
Mexico	Molina-Garza ZI, Rosales-Encina JL, Mercado-Hernández R, Molina-Garza DP, Gomez-Flores R, Galaviz-Silva L. Association of Trypanosoma cruzi infection with risk factors and electrocardiographic abnormalities in northeast Mexico. BMC Infect Dis. 2014; 14: 117.	2007-2011	*	
Mexico	Martínez-Tovar JG, Rebollar-Téllez EA, Fernández Salas I. Seroprevalence of T. cruzi infection in blood donors and Chagas cardiomyopathy in patients from the coal mining region of Coahuila, Mexico. Rev Inst Med Trop Sao Paulo. 2014; 56(2): 169-74.	2011	*	
Mexico	Gamboa-León R, Ramirez-Gonzalez C, Pacheco-Tucuch FS, O'Shea M, Rosecrans K, Pippitt J, Dumonteil E, Buekens P. Seroprevalence of Trypanosoma cruzi Among Mothers and Children in Rural Mayan Communities and Associated Reproductive Outcomes. Am J Trop Med Hyg. 2014; 91(2): 348-53.	2008-2009	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Mexico	Becerril-Flores MA, Valle-De La Cruz A. [Description of chagas disease in the Valle de Iguala, Guerrero state, Mexico- Marco]. Gac Med Mex. 2003; 139(6): 539-44.	2000-2002	*	
Mexico	Sosa-Jurado F, Zumaquero-Ríos JL, Reyes PA, Cruz-García A, Guzmán-Bracho C, Monteón VM. [Biotic and abiotic determinants of seroprevalence of antibodies against Trypanosoma cruzi in Palmar de Bravo, Puebla, Mexico]. Salud Publica Mex. 2004; 46(1): 39-48.	2000-2001	*	
Mexico	Trujillo Contreras F, Lozano Kasten F, Soto Gutiérrez MM, Hernández Gutiérrez R. [The prevalence of Trypanosoma cruzi infection in blood donors in the state of Jalisco, Mexico]. Rev Soc Bras Med Trop. 1993; 26(2): 89-92.	1991-1992	*	
Mexico	Segura EL, Escobar-Mesa A. Grupo de Estudio sobre la Enfermedad de Chagas. [Epidemiology of Chagas disease in the state of Veracruz]. Salud Publica Mex. 2005; 47(3): 201-208.	1997-2001	*	
Mexico	Monteón VM, Reyes-López PA, Sosa-Palacio A, León-Tello G, Martínez-Murguía J, Sosa-Jurado F. [Heterogeneous distribution of the prevalence of anti-Trypanosoma cruzi antibodies among blood donors in the State of Puebla, Mexico]. Salud Publica Mex. 2005; 47(2): 116-125.	2003	*	
Mexico	Antibodies Against Plasmodium Vivax in a Southeast Mountain Area in Chiapas. A Seroprevalence Study [thesis] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989-1990	*	†
Mexico	González-Cerón L, Rodríguez MH. An enzyme-linked immunosorbent assay using detergent-soluble Plasmodium vivax antigen for seroprevalence surveys. Trans R Soc Trop Med Hyg. 1991; 85(3): 358-61 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Fulciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Mexico	Vandale T, del Toro Lago L, Saldívar Romero H, Mendez Galvan J, Toledo Espinoza C. [Sero-epidemiologic study of malaria in Puerto Madero, Chiapas, 1985]. Salud Publica Mex. 1987; 29(3): 211-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Fulciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Mexico	Mexico Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Mexico	Mexican Registry and Epidemiological Surveillance of External Congenital Malformations Data 2001 - ICBDSR as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
Mexico	Mexican Registry and Epidemiological Surveillance of External Congenital Malformations Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
Mexico	Mexican Registry and Epidemiological Surveillance of External Congenital Malformations Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Mexico	Mexican Registry and Epidemiological Surveillance of External Congenital Malformations Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
Mexico	Mexican Registry and Epidemiological Surveillance of External Congenital Malformations Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Mexico	Mexican Registry and Epidemiological Surveillance of External Congenital Malformations Data 1980 - ICBDSR as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1980	*	
Mexico	Mexican Registry and Epidemiological Surveillance of External Congenital Malformations Data 1983 - ICBDSR as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1983	*	
Mexico	Mexican Registry and Epidemiological Surveillance of External Congenital Malformations Data 1986 - ICBDSR as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1986	*	
Mexico	Mexican Registry and Epidemiological Surveillance of External Congenital Malformations Data 1982 - ICBDSR as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1982	*	
Mexico	Mexican Registry and Epidemiological Surveillance of External Congenital Malformations Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Mexico	Mexican Registry and Epidemiological Surveillance of External Congenital Malformations Data 1984 - ICBDSR as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1984	*	
Mexico	Mexican Registry and Epidemiological Surveillance of External Congenital Malformations Data 1987 - ICBDSR as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1987	*	
Mexico	Mexican Registry and Epidemiological Surveillance of External Congenital Malformations Data 1981 - ICBDSR as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1981	*	
Mexico	Mexican Registry and Epidemiological Surveillance of External Congenital Malformations Data 1985 - ICBDSR as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1985	*	
Mexico	Mexican Registry and Epidemiological Surveillance of External Congenital Malformations Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
Mexico	Mexican Registry and Epidemiological Surveillance of External Congenital Malformations Data 1988 - ICBDSR as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1988	*	
Mexico	Mexican Registry and Epidemiological Surveillance of External Congenital Malformations Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
Moldova	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2005		
Moldova	National Scientific and Applied Center for Preventive Medicine (NCPM) (Moldova), United Nations Children's Fund (UNICEF). Moldova Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Moldova	Division of Reproductive Health-Centers for Disease Control and Prevention (CDC) and Moldova Ministry of Health. (1998) Moldova Reproductive Health Survey 1997. Atlanta, United States: Centers for Disease Control and Prevention (CDC).	1997		
Moldova	Macro International, Inc, National Scientific and Applied Center for Preventive Medicine (Moldova). Moldova Demographic and Health Survey 2005. Calverton, United States: Macro International, Inc.	2005		†
Moldova	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists' Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Moldova	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1999, 2001, 2003-2008		
Moldova	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Moldova	Moldova Dialysis and Transplant Registry data as it appears in the GBD 2010 Chronic Kidney Disease Expert Group dataset. Provided by Igor Codreanu and Sergiu Gaibu.	1998		
Moldova	International Society of Nephrology (ISN). International Society of Nephrology Kidney Disease Data Center 2006-2009.	2006-2008		
Moldova	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Moldova	Moldova UNICEF Mission Report 17-27 September 1996 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1996		
Moldova	Drobeniuc J, Favorov MO, Shapiro CN, Bell BP, Mast EE, Dadu A, Culver D, Iarovoi P, Robertson BH, Margolis HS. Hepatitis E Virus Antibody Prevalence among Persons Who Work with Swine. J Infect Dis. 2001; 184(12): 1594-7.	1997-1998	*	
Moldova	USSR - Moldavian SSR Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Mongolia	National Statistical Office of Mongolia, United Nations Children's Fund (UNICEF). Mongolia Multiple Indicator Cluster Survey 2005. New York, United States: United Nations Children's Fund (UNICEF).	2005	*	†
Mongolia	National Statistical Office of Mongolia. Mongolia Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Mongolia	World Health Organization (WHO), Ministry of Health (Mongolia), National Medical Research Institute (Mongolia), Health Sciences University (Mongolia), National Oncology Center of Mongolia (Mongolia). Mongolia STEPS Noncommunicable Disease Risk Factors Survey 2005.	2005		
Mongolia	World Health Organization (WHO), Ministry of Health (Mongolia), National Medical Research Institute (Mongolia), Health Sciences University (Mongolia), National Oncology Center of Mongolia (Mongolia). Mongolia STEPS Noncommunicable Disease Risk Factors Survey 2009.	2009		
Mongolia	National Statistical Office of Mongolia, United Nations Children's Fund (UNICEF). Mongolia Multiple Indicator Cluster Survey 2010. New York, United States: United Nations Children's Fund (UNICEF), 2013.	2010	*	†
Mongolia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists' Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Mongolia	Gombojav N, Manaseki-Holland S, Pollock J, Henderson AJ. The effects of social variables on symptom recognition and medical care seeking behaviour for acute respiratory infections in infants in urban Mongolia. Arch Dis Child. 2009; 11(94): 849-54.	2002		
Mongolia	Mendsaikhan J, Watt JP, Mansoor O, Suvdmaa N, Edmond K, Litt DJ, Nymadawa P, Yang Baoping, Altantsetseg D, Slack M. Childhood Bacterial Meningitis in Ulaanbaatar, Mongolia, 2002-2004. Clin Infect Dis. 2009; 48 Suppl 2(Suppl 2): S141-6.	2002-2005		
Mongolia	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000-2005, 2007-2009		
Mongolia	Mongolia Chronic Kidney Disease Statistics 1961-2011, as provided by the Global Burden of Disease 2010 Chronic Kidney Disease Expert Group. [Unpublished].	1980-2006, 2010		
Mongolia	International Society of Nephrology (ISN). International Society of Nephrology Kidney Disease Data Center 2006-2009.	2007		
Mongolia	Tsatsralt-Od B, Takahashi M, Nishizawa T, Endo K, Inoue J, Okamoto H. High prevalence of dual or triple infection of hepatitis B, C, and delta viruses among patients with chronic liver disease in Mongolia. J Med Virol. 2005; 77(4): 491-9.	2004		
Mongolia	Dondog B, Lise M, Dondog O, Baldandorj B, Franceschi S. Hepatitis B and C virus infections in hepatocellular carcinoma and cirrhosis in Mongolia. Eur J Cancer Prev. 2011; 20(1): 33-9.	2000-2009		
Mongolia	Oyunsuren T, Kurbanov F, Tanaka Y, Elkady A, Sandutjav R, Khajidsuren O, Dagvadorj B, Mizokami M. High frequency of hepatocellular carcinoma in Mongolia; association with mono-, or co-infection with hepatitis C, B, and delta viruses. J Med Virol. 2006; 78(12): 1688-95.	2005		
Mongolia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Mongolia	Foster PJ, Baasanhu J, Alsirk PH, Munkhbayar D, Uranchimeg D, Johnson GJ. Glaucoma in Mongolia. A population-based survey in Hövsögöl province, northern Mongolia. Arch Ophthalmol. 1996; 114(10): 1235-41. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1995		
Mongolia	Baasanhu J, Johnson GJ, Burendei G, Minassian DC. Prevalence and causes of blindness and visual impairment in Mongolia: a survey of populations aged 40 years and older. Bull World Health Organ. 1994; 72(5): 771-6. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1991-1992		
Mongolia	Ministry of Health (Mongolia), World Health Organization (WHO). Mongolia Epidemiological Study on Prevalence of Alcohol Consumption, Alcohol Drinking Patterns, and Alcohol Related Harms 2005.	2005		
Mongolia	Mongolia National Nutrition Survey 2004 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2004		
Mongolia	Mongolia Iodine Deficiency Disorder Survey 1992-1994 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1992-1994		
Mongolia	Mongolia Iodine Deficiency Disorder Survey 2001 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2001		
Mongolia	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
Mongolia	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Mongolia	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	
Mongolia	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Mongolia	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Mongolia	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
Mongolia	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Mongolia	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Mongolia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2000.	2000		
Mongolia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2001.	2001		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Mongolia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2002.	2002		
Mongolia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2003.	2003		
Mongolia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2004.	2004		
Mongolia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2005.	2005		
Mongolia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2006.	2006		
Mongolia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2009.	2009		
Mongolia	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2010.	2010		
Mongolia	Fuse Y, Igarai T, Yamada C, Sakano S, Ito H, Umenai T, Irie M. Epidemiological survey of thyroid volume and iodine intake in schoolchildren, postpartum women and neonates living in Ulaan Baatar. Clin Endocrinol (Oxf). 2003; 59(3): 298-306 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1996		†
Mongolia	Ministry of Health (Mongolia). Sexually Transmitted Infections among Pregnant Women Attending Antenatal Clinics in Mongolia.	2005		
Mongolia	Shizuma T. [Prevalence of hepatitis B and C virus markers in patients with hepatocellular carcinoma and outpatients with liver dysfunction in Mongolia]. J Jpn Assoc Infect Dis. 2005; 79(10): 824-5.	2002-2004	*	
Mongolia	Takahashi M, Nishizawa T, Gotanda Y, Tsuda F, Komatsu F, Kawabata T, Hasegawa K, Altankhuu M, Chimedregzen U, Naran TUYA L, Hoshino H, Hino K, Kagawa Y, Okamoto H. High prevalence of antibodies to hepatitis A and E viruses and viremia of hepatitis B, C, and D viruses among apparently healthy populations in Mongolia. Clin Diagn Lab Immunol. 2004; 11(2): 392-8.	2002		
Mongolia	Tsatsralt-Od B, Takahashi M, Endo K, Agiimaa D, Buyankhuu O, Okamoto H. Comparison of hepatitis A and E virus infections among healthy children in Mongolia: evidence for a subgenotype IA HAV in children. J Med Virol. 2007; 79(1): 18-25.	2005-2006		
Mongolia	Davaalkham D, Ojima T, Nymadawa P, Tsend N, Lkhagvasuren T, Wiersma S, Uehara R, Watanabe M, Oki I, Nakamura Y. Seroepidemiology of hepatitis B virus infection among children in Mongolia: results of a nationwide survey. Pediatr Int. 2007; 49(3): 368-74.	2004		
Mongolia	Bayasgalan G, Naranbat D, Tseidmaa B, Sukhee D, Amarjargal O, Lhagvasuren T, Radnaabazar J, Rowe PJ. Clinical patterns and major causes of infertility in Mongolia. J Obstet Gynaecol Res. 2004; 30(5): 386-93.	1998-2002	*	
Mongolia	Mongolia Vital Registration Birth Data 1989 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1989		
Montenegro	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2005		
Montenegro	United Nations Children's Fund (UNICEF), Statistical Office of Montenegro. Montenegro Multiple Indicator Cluster Survey 2005. New York, United States: United Nations Children's Fund (UNICEF).	2005-2006	*	†
Montenegro	Serbia and Montenegro - Montenegro Vital Registration - Deaths 2005 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2005	*	†
Montenegro	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2006-2009		
Montenegro	Vrbic V, Vulovi M, Raji Z, Topi B, Tati E, Mali M, Mili D, Aurer-Kozelj J, Neceva L, Redzepagi S. Oral health in SFR Yugoslavia in 1986. Community Dent Oral Epidemiol. 1988; 16(5): 286-8.	1986		
Montenegro	European Agency for Reconstruction. Serbia School Survey on Psychoactive Substance Abuse Among Adolescents 2005.	2005		
Montenegro	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2007, 2010, 2012		
Montenegro	Samaradzic M, Marinkovic J, Kocav N, Curovic N, Terzic N. Increasing incidence of childhood type 1 diabetes in Montenegro from 1997 to 2006. Pediatr Diabetes. 2010; 11(6): 412-6.	1997-2006		
Montenegro	Fraser GR, Defarinas B, Kattamis CA, Race RR, Sanger R, Stamatiyannopoulos G. Glucose-6-phosphate dehydrogenase, colour vision and XG blood groups in Greece: linkage and population data. Ann Hum Genet. 1964; 395-403.	1962		
Montenegro	World Health Organization (WHO). Montenegro WHO Leishmaniasis Country Profile.	1992-2009	*	
Montenegro	Montenegro Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Montenegro	Montenegro Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Morocco	Ministry of Health (Morocco), League of Arab States. Morocco Maternal and Child Health Survey 1996-1997.	1996-1997		†
Morocco	Ministry of Public Health (Morocco), International Statistical Institute. Morocco World Fertility Survey 1980. Voorburg, Netherlands: International Statistical Institute.	1980		
Morocco	Ministry of Public Health (Morocco), Westinghouse; Institute for Resource Development. Morocco Demographic and Health Survey 1987. Columbia, United States: Westinghouse; Institute for Resource Development.	1987		†
Morocco	League of Arab States, Macro International, Inc, Ministry of Health (Morocco). Morocco Demographic and Health Survey 2003-2004. Calverton, United States: Macro International, Inc.	2003-2004		†
Morocco	Macro International, Inc, Ministry of Public Health (Morocco). Morocco Demographic and Health Survey 1992. Calverton, United States: Macro International, Inc.	1992		†
Morocco	World Health Organization (WHO). Morocco World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Morocco	Casablanca Ministry of Health (Morocco), Faculty of Medicine and Pharmacy of Casablanca (Morocco), Ibn Rochd University Hospital (Morocco), Lalla Salma Association to Fight Against Cancer (Morocco), National Institute of Oncology Sidi Mohamed Ben Abdellah Rabat (Morocco). Morocco - Cancer Registry of Greater Casablanca 2004. Rabat, Morocco: Lalla Salma Association to Fight Against Cancer (Morocco), 2007.	2004	*	
Morocco	Ministry of Health (Morocco). Morocco Cause of Death Data 2005. [Unpublished].	2005		†
Morocco	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Morocco	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Morocco	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. J Allergy Clin Immunol. 2008; 121(4): 947-954.	1995, 2001-2002		
Morocco	Morocco Vital Registration - Deaths 2008 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2008	*	
Morocco	Benhafid M, Youbi M, Klana JD, Gentsch JR, Tete N, Widdowson M-A, Elaouad R. Epidemiology of rotavirus gastroenteritis among children <5 years of age in Morocco during 1 year of sentinel hospital surveillance, June 2006-May 2007. J Infect Dis. 2009; 200 (Suppl 1): 70-75.	2006-2007		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Morocco	Filippi V, Ronsmans C, Gohou V, Goufodji S, Lardi M, Sahel A, Saizonou J, De Brouwere V. Maternity wards or emergency obstetric rooms? Incidence of near-miss events in African hospitals. <i>Acta Obstet Gynecol Scand.</i> 2005; 84(1): 11-6.	1999-2001		
Morocco	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998, 2000, 2006-2007		
Morocco	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Morocco	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2001		
Morocco	Barsoum RS. Burden of chronic kidney disease: North Africa. <i>Kidney Int Suppl.</i> 2013; 3: 164-6.	2000-2010		
Morocco	Braikat M, Barkia A, El Mdaghri N, Rainey JJ, Cohen AL, Teleb N. Vaccination with Haemophilus influenzae type b conjugate vaccine reduces bacterial meningitis in Morocco. <i>Vaccine.</i> 2012; 30(15): 2594-9.	2004-2009		
Morocco	Tazi-Lakhsassi L, Garbarg-Chenon A, Nicolas JC, Soubhi H, Benbachir M, el Mdaghri N, Tazi M, Bricout F, Huraux JM. Epidemiological and clinical study and electrophoretotyping survey of rotavirus acute diarrhoea in a children's infectious disease unit in Casablanca, Morocco. <i>Ann Inst Pasteur Virol.</i> 1988; 139(2): 205-15.	1982-1983	*	
Morocco	Benhafid M, Rguig A, Trivedi T, Elqazoui M, Teleb N, Mouane N, Maltouf AF, Parashar U, Patel M, Aouad RE. Monitoring of rotavirus vaccination in Morocco: establishing the baseline burden of rotavirus disease. <i>Vaccine.</i> 2012; 30(46): 6515-20.	2006-2010	*	
Morocco	Kadri N, Agoub M, El Gnaoui S, Berrada S, Moussaoui D. Prevalence of anxiety disorders: a population-based epidemiological study in metropolitan area of Casablanca, Morocco. <i>Ann Gen Psychiatry.</i> 2007; 6.	2004		
Morocco	Filippi V, Ronsmans C, Gohou V, Goufodji S, Lardi M, Sahel A, Saizonou J, De Brouwere V. Maternity wards or emergency obstetric rooms? Incidence of near-miss events in African hospitals. <i>Acta Obstet Gynecol Scand.</i> 2005; 84(1): 11-16.	1999		
Morocco	Bahri O, Ezzikouri S, Alaya-Bouafif NB, Iguer F, Feydi AEE, Mestiri H, Benazzouz M, Khalfallah T, Afifi R, Elkihal L, Berkane S, Marchio A, Debbi N, Dejean A, Pineau P, Triki H, Benjelloun S. First multicenter study for risk factors for hepatocellular carcinoma development in North Africa. <i>World J Hepatol.</i> 2011; 3(1): 24-30.	2002-2005		
Morocco	Bourquica A. Current status of treatment for chronic renal insufficiency in Morocco. <i>Nephrologie.</i> 1999; 20(2): 75-80.	1993-1996		
Morocco	Kadri N, Agoub M, Assouab F, Tazi MA, Didouh A, Stewart R, Paes M, Toufiq J, Moussaoui D. Moroccan national study on prevalence of mental disorders: a community-based epidemiological study. <i>Acta Psychiatr Scand.</i> 2010; 121(1): 71-4.	2004-2005		
Morocco	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Morocco	Prevention of blindness (PBL). Prevalence and causes of blindness and low vision - Weekly Epidemiological Record 1994 as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1992		
Morocco	Cowan FM, French RS, Mayaud P, Gopal R, Robinson NJ, de Oliveira SA, Faillace T, Uusküla A, Nygård-Kibur M, Ramalingam S, Sridharan G, El Aouad R, Alami K, Rbai M, Sunil-Chandra NP, Brown DW. Seroprevalence study of herpes simplex virus types 1 and 2 in Brazil, Estonia, India, Morocco, and Sri Lanka. <i>Sex Transm Infect.</i> 2003; 79(4): 286-90.	2000	*	
Morocco	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant.</i> 1988; 3(6): 714-27.	1985-1986		
Morocco	Naicker S. Burden of end-stage renal disease in sub-Saharan Africa. <i>Clin Nephrol.</i> 2010; 74(Suppl 1): S13-6.	2008-2010		
Morocco	World Health Organization (WHO). Morocco WHO Leishmaniasis Country Profile.	1994-2010	*	
Morocco	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Morocco	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec.</i> 2007; 82(25): 225-32.	2006	*	
Morocco	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Morocco	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Morocco	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Morocco	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec.</i> 2008; 83(33): 293-300.	2007	*	
Morocco	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Morocco	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Morocco	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Morocco	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Morocco	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Morocco	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Morocco	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Morocco	Patnaik P, Herrero R, Morrow RA, Munoz N, Bosch FX, Bayo S, El Gueddari B, Caceres E, Chichareon SB, Castellsague X, Meijer CJLM, Snijders PJF, Smith JS. Type-specific seroprevalence of herpes simplex virus type 2 and associated risk factors in middle-aged women from 6 countries: the IARC multicenter study. <i>Sex Transm Dis.</i> 2007; 34(12): 1019-24.	1985-1997	*	
Morocco	Abid A, Bouskraoui M, Zineddine A, Aïlal F, Najib J, Benbachir M. Méningites purulentes à pneumocoque chez l'enfant?: À propos de 167 cas. <i>Sem Hop Paris.</i> 1999; 75(35-36): 1308-15.	1980-1997		
Morocco	Faraj C, Adlaoui E, Rhajaoui M, Lyagoubi M. Estimation of malaria transmission in high-risk provinces of Morocco. <i>East Mediterr Health J.</i> 2003; 9(4): 542-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Morocco	Morocco Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Morocco	Ministry of Health (Morocco). Morocco - Rabat-Salé STI Prevalence Study Among Women Consultants of Mother and Child Health and Family Planning Services 2003.	2003		
Mozambique	Macro International, Inc, National Statistics Institute (Mozambique). Mozambique Demographic and Health Survey 1997. Calverton, United States: Macro International, Inc.	1997		†
Mozambique	Macro International, Inc, National Statistics Institute (Mozambique). Mozambique Demographic and Health Survey 2003. Calverton, United States: Macro International, Inc.	2003		†
Mozambique	United Nations Children's Fund (UNICEF), National Statistics Institute (Mozambique). Mozambique Multiple Indicator Cluster Survey 2008-2009. New York, United States: United Nations Children's Fund (UNICEF).	2008-2009	*	†
Mozambique	ICF Macro, Manhica Health Research Center (CISM), Ministry of Health (Mozambique), National Statistics Institute (Mozambique). Mozambique Demographic and Health Survey 2011. Calverton, United States: ICF Macro, 2013.	2011	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Mozambique	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Mozambique	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Mozambique	Gibbs, S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. <i>Int J Dermatol.</i> 1996; 35(9): 633-9.	1994		
Mozambique	Robertson SE, Roca A, Alonso P, Simoes EAF, Kartasasmita CB, Olaleye DO, Odaibo GN, Collinson M, Venter M, Yuwei Zhu, Wright PF. Respiratory syncytial virus infection: denominator-based studies in Indonesia, Mozambique, Nigeria and South Africa. <i>Bull World Health Organ.</i> 2004; 12(82): 914-22.	1987-2001		
Mozambique	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997, 2000-2001, 2007-2008		
Mozambique	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Mozambique	Nasrin D, Wu Y, Blackwelder WC, Farag TH, Saha D, Sow SO, Alonso PL, Breiman RF, Sur D, Faruque ASG, Zaidi AKM, Biswas K, Van Eijk AM, Walker DG, Levine MM, Kotloff KL. Health care seeking for childhood diarrhea in developing countries: evidence from seven sites in Africa and Asia. <i>Am J Trop Med Hyg.</i> 2013; 89(1 Suppl): 3-12.	2009-2011	*	
Mozambique	Olsson B, Segura-Bernal F, Tanda A. Dental caries in urban and rural areas in Mozambique. <i>Community Dent Health.</i> 1989; 6(2): 139-45.	1986		
Mozambique	Luján J, de Oñate W, Delva W, Claeys P, Sambola F, Temmerman M, Fernando J, Folgosa E. Prevalence of sexually transmitted infections in women attending antenatal care in Tete province, Mozambique. <i>S Afr Med J.</i> 2008; 98(1): 49-51.	2004		
Mozambique	Robertson SE, Roca A, Alonso P, Simoes EAF, Kartasasmita CB, Olaleye DO, Odaibo GN, Collinson M, Venter M, Zhu Y, Wright PF. Respiratory syncytial virus infection: denominator-based studies in Indonesia, Mozambique, Nigeria and South Africa. <i>Bull World Health Organ.</i> 2004; 82(12): 914-22.	1999-2000	*	
Mozambique	Damasceno A, Gomes J, Azevedo A, Carrilho C, Lobo V, Lopes H, Madede T, Pravinrai P, Silva-Matos C, Jalla S, Stewart S, Lunet N. An Epidemiological Study of Stroke Hospitalizations in Maputo, Mozambique A High Burden of Disease in a Resource-Poor Country. <i>Stroke.</i> 2010; 41(11): 2463-9.	2005-2006	*	
Mozambique	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995		
Mozambique	Silva-Matos C, Gomes A, Azevedo A, Damasceno A, Prista A, Lunet N. Diabetes in Mozambique: prevalence, management and healthcare challenges. <i>Diabetes Metab.</i> 2011; 37(3): 237-44.	2005		
Mozambique	Nieuwenhuis F, Wolf B, Bomba A, De Graaf P. Haematological study in Cabo Delgado province, Mozambique: sickle cell trait and G6PD deficiency. <i>Trop Geogr Med.</i> 1986; 38(2): 183-7.	1984-1986		
Mozambique	Vuylssteke B, Bastos R, Barreto J, Crucitti T, Folgosa E, Mondlane J, Dusauchot T, Piot P, Laga M. High prevalence of sexually transmitted diseases in a rural area in Mozambique. <i>Genitourin Med.</i> 1993; 69(6): 427-30.	1992		
Mozambique	Clark JL. Hearing loss in Mozambique: current data from Inhambane Province. <i>Int J Audiol.</i> 2008; 47:54-56.	2005-2007	*	
Mozambique	Cliff JL, Zinkin P, Martelli A. A hospital outbreak of cholera in Maputo, Mozambique. <i>Trans R Soc Trop Med Hyg.</i> 1986; 80(3): 473-6.	1981	*	
Mozambique	Siganque B, Vubil D, Sozinho A, Quintó L, Morais L, Sacoor C, Carvalho MG, Verani JR, Alonso PL, Roca A. Haemophilus influenzae type b disease among children in rural Mozambique: impact of vaccine introduction. <i>J Pediatr.</i> 2013; 163(1 Suppl): S19-24.	2006-2008, 2010-2011		
Mozambique	Mozambique Micronutrient Deficiency Survey 1998 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1998		
Mozambique	Mozambique - Niassa Iodine Deficiency Disorders Survey Draft Report 1992 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1992		
Mozambique	O'Callaghan-Gordo C, Bassat Q, Morais L, Díez-Padrís N, Machevo S, Nhampossa T, Nhalungo D, Sanz S, Quintó L, Alonso PL, Roca A. Etiology and epidemiology of viral pneumonia among hospitalized children in rural Mozambique: a malaria endemic area with high prevalence of human immunodeficiency virus. <i>Pediatr Infect Dis J.</i> 2011; 30(1): 39-44.	2006-2007	*	
Mozambique	Damasceno A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D, Dzudie A, Kouam CK, Suliman A, Schrueder N, Yonga G, Ba SA, Maru F, Alemayehu B, Edwards C, Davison BA, Cotter G, Sliwa K. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. <i>Arch Intern Med.</i> 2012; 172(18): 1386-94.	2007-2010		
Mozambique	Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courin F, Mattioli RC, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. <i>Int J Health Geogr.</i> 2010; 9: 57.	1980-2010		
Mozambique	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec.</i> 2006; 81(32): 309-16.	2005	*	
Mozambique	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Mozambique	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Mozambique	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Mozambique	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Mozambique	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Mozambique	World Health Organization (WHO). Leprosy. Global situation. <i>Wkly Epidemiol Rec.</i> 2002; 77(1): 1-8.	2001	*	
Mozambique	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Mozambique	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Mozambique	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1993; 68(25): 181-6.	1992	*	
Mozambique	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Mozambique	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Mozambique	Mozambique National Study of Iodine Deficiency in Children 2004 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2004		
Mozambique	Siganque B, Roca A, Sanz S, Oliveiras I, Martínez M, Mandomando I, Valles X, Espasa M, Abacassamo F, Sacralal J, Macete E, Nhaculo A, Aponte J, Levine MM, Alonso PL. Acute bacterial meningitis among children, in Manhiça, a rural area in Southern Mozambique. <i>Acta Trop.</i> 2008; 105(1): 21-7.	1998-2003		
Mozambique	Roca A, Bassat Q, Morais L, Machevo S, Sigande B, O'Callaghan C, Nhampossa T, Letang E, Mandomando I, Nhalungo D, Quintó L, Alonso P. Surveillance of acute bacterial meningitis among children admitted to a district hospital in rural Mozambique. <i>Clin Infect Dis.</i> 2009; S172-180.	2006-2007		
Mozambique	Ciana G, Parmar N, Antonio C, Pivetta S, Tamburini G, Cuttini M. Effectiveness of adjunctive treatment with steroids in reducing short-term mortality in a high-risk population of children with bacterial meningitis. <i>J Trop Pediatr.</i> 1995; 41(3): 164-8.	1989		
Mozambique	Mavale-Manuel S, Joaquim O, Macome C, Almeida L, Nunes E, Daniel A, Malichocho J, Pedro A, Bandeira S, Eduardo E, Maciel L, Constance E, Marques S, Tembe A, de Blic J, Annesi-Maesano I. Asthma and allergies in schoolchildren of Maputo. <i>Allergy.</i> 2007; 62(3): 265-71.	2004	*	
Mozambique	Sidat MM, Correia D, Buene TP. Tinea capitis among children at one suburban primary school in the City of Maputo, Mozambique. <i>Rev Soc Bras Med Trop.</i> 2007; 40(4): 473-5.	2001	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Mozambique	Cunha L, Plouzeau C, Ingrand P, Gudo JPS, Ingrand I, Mondlane J, Beauchant M, Agius G. Use of replacement blood donors to study the epidemiology of major blood-borne viruses in the general population of Maputo, Mozambique. <i>J Med Virol.</i> 2007; 79(12): 1832-40.	2004		
Mozambique	Dazza MC, Trebucq A, Gaudebout C, Jarretou A, Le Hésran JY, Josse R, Delaporte E, Bréchet C, Larouze B. Population-based study of serum hepatitis B virus DNA in Gabon. <i>Trans R Soc Trop Med Hyg.</i> 1993; 87(5): 539-40.	1991		
Mozambique	Crook SE, Baptista A. The effect of permethrin-impregnated wall-curtains on malaria transmission and morbidity in the suburbs of Maputo, Mozambique. <i>Trop Geogr Med.</i> 1995; 47(2): 64-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990-1991	*	†
Mozambique	Enosse S, Magnussen P, Abacassamo F, Gómez-Olivé X, Ronn AM, Thompson R, Alifrangis M. Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique. <i>Malar J.</i> 2008; 7(1): 115 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001-2003	*	†
Mozambique	Mabunda S, Casimiro S, Quinto L, Alonso P. A country-wide malaria survey in Mozambique. I. Plasmodium falciparum infection in children in different epidemiological settings. <i>Malar J.</i> 2008; 7: 216 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002-2003	*	†
Mozambique	Pividal J, Viktinski V, Streat E, Schapira A. Efficacy of dapson with pyrimethamine (Maloprim) for malaria prophylaxis in Maputo, Mozambique. <i>East Afr Med J.</i> 1992; 69(6): 303-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Mozambique	Schapira A, Da Costa F. Studies on malaria prophylaxis with chloroquine or chloroquine in Mozambique. <i>Cent Afr J Med.</i> 1988; 34(3): 44-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985-1986	*	†
Mozambique	Mozambique Plasmodium Falciparum Parasite Rate Data, Personal Communication with A. Kilian 2008 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2007	*	†
Mozambique	The assessment of Vitamin A Deficiency in Three Cities in Mozambique as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1990		
Myanmar	Central Statistical Office (Myanmar), United Nations Children's Fund (UNICEF). Myanmar Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Myanmar	World Health Organization (WHO). Myanmar World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Myanmar	Ministry of Health (Myanmar), Ministry of National Planning and Economic Development (Myanmar), United Nations Children's Fund (UNICEF). Myanmar Multiple Indicator Cluster Survey 2009-2010.	2009-2010	*	†
Myanmar	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Myanmar	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Myanmar	Htoon MT, Ngwe T, Tun N, Kyaw MM. Prevalence of Cardiovascular Diseases in Rural Area of Hmawbi and Urban Yangon City. <i>Asia Pac J Public Health.</i> 1992; 6(4): 188-94.	1980-1992		
Myanmar	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001, 2005-2006		
Myanmar	Huilan S, Zhen LG, Mathan MM, Mathew MM, Olarte J, Espejo R, Khin Maung U, Ghafoor MA, Khan MA, Sami Z. Etiology of acute diarrhoea among children in developing countries: a multicentre study in five countries. <i>Bull World Health Organ.</i> 1991; 69(5): 549-55.	1982-1984	*	
Myanmar	Mackenzie I. Hearing Impairment in Asia - final report of four country survey, as provided by the Global Burden of Disease 2010 hearing impairment expert group. [Unpublished].	2001		
Myanmar	Myanmar - Hinthada Township Rapid Assessment of Cataract Surgical Services Report 2001 as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2001		
Myanmar	Casson RJ, Newland HS, Muecke J, McGovern S, Durkin S, Sullivan T, Oo TZ, Aung TH, Shein WK, Selva D, Aung T. Prevalence and causes of visual impairment in rural Myanmar: the Meiktila Eye Study. <i>Ophthalmology.</i> 2007; 114(12): 2302-8. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2005		
Myanmar	Phyu T, Win S, Oo T, Oo S. Myanmar study on prevalence of amphetamine type substance use among high school students in Yangon.	2004		
Myanmar	Okada S, Taketa K, Ishikawa T, Koji T, Swe T, Win N, Win KM, Mra R, Myint TT. High prevalence of hepatitis C in patients with thalassemia and patients with liver diseases in Myanmar (Burma). <i>Acta Med Okayama.</i> 2000; 54(3): 137-8.	1996-1998		
Myanmar	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Myanmar	Ministry of Health (Myanmar), Research Institute of Tuberculosis/Japan Anti-Tuberculosis Association (RI/TJATA), World Health Organization (WHO). Myanmar National Tuberculosis Prevalence Survey 2009-2010.	2009-2010		
Myanmar	Myanmar - Hpann Rapid Assessment of Cataract Surgical Services Report 2001 as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2001		
Myanmar	Myanmar - Shwebo District Rapid Assessment of Cataract Surgical Services Report 2001 as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2001		
Myanmar	Myanmar - Monywa District Rapid Assessment of Cataract Surgical Services Report 2001 as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2001		
Myanmar	Myanmar - Sagaing District Rapid Assessment of Cataract Surgical Services Report 2001 as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2001		
Myanmar	Iwai K, Hirano A, Matsuoka H, Kawamoto F, Horie T, Lin K, Tantular IS, Dachlan YP, Notopuro H, Hidayah NI, Salim AM, Fujii H, Miwa S, Ishii A. Distribution of glucose-6-phosphate dehydrogenase mutations in Southeast Asia. <i>Hum Genet.</i> 2001; 108(6): 445-9.	1997-1998		
Myanmar	Jalloh A, Tantular IS, Pusarawati S, Kawilarang AP, Kerong H, Lin K, Ferreira MU, Matsuoka H, Arai M, Kita K, Kawamoto F. Rapid epidemiologic assessment of glucose-6-phosphate dehydrogenase deficiency in malaria-endemic areas in Southeast Asia using a novel diagnostic kit. <i>Trop Med Int Health.</i> 2004; 9(5): 615-23.	2002-2003		†
Myanmar	Jalloh A, Tantular IS, Pusarawati S, Kawilarang AP, Kerong H, Lin K, Ferreira MU, Matsuoka H, Arai M, Kita K, Kawamoto F. Rapid epidemiologic assessment of glucose-6-phosphate dehydrogenase deficiency in malaria-endemic areas in Southeast Asia using a novel diagnostic kit. <i>Trop Med Int Health.</i> 2004; 9(5): 615-23 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002-2003	*	†
Myanmar	Than AM, Harano T, Harano K, Myint AA, Ogino T, Okada S. High incidence of 3-thalassemia, hemoglobin E, and glucose-6-phosphate dehydrogenase deficiency in populations of malaria-endemic southern Shan State, Myanmar. <i>Int J Hematol.</i> 2005; 82(2): 119-23.	2003-2005		
Myanmar	Nuchprayoon L, Louicharoen C, Charoenvej W. Glucose-6-phosphate dehydrogenase mutations in Mon and Burmese of southern Myanmar. <i>J Hum Genet.</i> 2008; 53(1): 48-54.	2006-2008		
Myanmar	Soe-Soe, Khin-Saw-Aye, Htay-Aung, Nay-Win, Tin-Aung, Than-Swe, Roussillon C, Pérignon JL, Druilhe P. Premunition against Plasmodium falciparum in a malaria hyperendemic village in Myanmar. <i>Trans R Soc Trop Med Hyg.</i> 2001; 95(1): 81-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Myanmar	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Myanmar	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec.</i> 2007; 82(25): 225-32.	2006	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Myanmar	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Myanmar	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Myanmar	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Myanmar	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
Myanmar	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Myanmar	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Myanmar	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Myanmar	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Myanmar	World Health Organization (WHO). Leprosy. Global situation. Wkly Epidemiol Rec. 2002; 77(1): 1-8.	2001	*	
Myanmar	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Myanmar	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Myanmar	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Myanmar	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1993; 68(25): 181-6.	1992	*	
Myanmar	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Myanmar	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Myanmar	World Health Organization Regional Office for South-East Asia (SEARO). Reported Cases of DF/DHF in Selected Countries in SEA Region. New Delhi, India: World Health Organization Regional Office for South-East Asia (SEARO).	1988-2009		
Myanmar	Chu CH, Chau AM, Wong ZS, Hui BS, Lo EC. Oral health status and behaviours of children in Myanmar - a pilot study in four villages in rural areas. Oral Health Prev Dent. 2012; 10(4): 365-71.	2009	*	†
Myanmar	WHO Regional Office for South-East Asia (SEARO). WHO South-East Asia Region: Reported Cases and Deaths of Dengue from 2003 to 2012. New Delhi, India: WHO Regional Office for South-East Asia (SEARO), 2013.	2003-2012	*	
Myanmar	Ng KP, Ngeow YF, K R, M R. Hepatitis B seroprevalence among University of Malaya Students in the Post-universal Infant Vaccination Era. Med J Malaysia. 2013; 68(2): 144-7.	2005-2011	*	
Myanmar	Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M. Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011; 378(9785): 31-40.	2001		
Myanmar	Mya-Tu M, May-May-Yi, Thin-Thin-Hlaing. Blood groups of the Burmese population. Hum Hered. 1971; 21(5): 420-30.	1968-1970	*	†
Myanmar	Triteerapapab S, Songtrun J. High prevalence of bancroftian filariasis in Myanmar-migrant workers: a study in Mae Sot district, Tak province, Thailand. J Med Assoc Thai. 1999; 82(7): 735-9. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1980-2000	*	
Myanmar	Myanmar Programme to Eliminate Lymphatic Filariasis Country Report 2004 as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2004	*	
Myanmar	Oo TT, Storch V, Becker N. Anopheles dirus and its role in malaria transmission in Myanmar. J Vector Ecol. 2003; 28(2): 175-83 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
Myanmar	Paing M, Tun-Lin W, Min S, Myint Z. Malaria situation in a forested foothill area of Myanmar. Myanmar Medical Journal. 1990; 35(3/4): 1-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Myanmar	Richards AK, Banek K, Mullany LC, Lee CL, Smith L, Oo EK, Lee TJ. Cross-border malaria control for internally displaced persons: observational results from a pilot programme in eastern Burma/Myanmar. Trop Med Int Health. 2009; 14(5): 512-21 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003-2005	*	†
Myanmar	Tun-Lin W, Thu MM, Than SM, Mya MM. Hyperendemic malaria in a forested, hilly Myanmar village. J Am Mosq Control Assoc. 1995; 11(4): 401-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Myanmar	Kyaw TA. Prevention of blindness: eye health survey and services. Burma Med J. 1980; 26(2): 101-6. as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1978-1979		
Namibia	Central Statistics Office (Namibia), Macro International, Inc, Ministry of Health and Social Services (Namibia). Namibia Demographic and Health Survey 1992. Calverton, United States: Macro International, Inc.	1992		†
Namibia	Macro International, Inc, Ministry of Health and Social Services (Namibia), National Planning Commission (Namibia). Namibia Demographic and Health Survey 2000. Calverton, United States: Macro International, Inc.	2000		†
Namibia	Macro International, Inc, Ministry of Health and Social Services (Namibia). Namibia Demographic and Health Survey 2006-2007. Calverton, United States: Macro International, Inc.	2006-2007		†
Namibia	World Health Organization (WHO). Namibia World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Namibia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Namibia	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997-1999, 2001, 2004, 2007-2009		
Namibia	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Namibia	Schier M, Cleaton-Jones P. Dental caries in Namibia - the first national survey. Community Dent Oral Epidemiol. 1995; 23(5): 262-5.	1991		
Namibia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Namibia	Cancer Association of Namibia, Namibian Cancer Registry. Namibia Cancer Registry Report 2000-2005. Windhoek, Namibia: Cancer Association of Namibia, 2009.	2002	*	
Namibia	Namibia Nationwide Follow Up Survey on Iodine Deficiency Disorders 1998-1999 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1998-1999		
Namibia	World Health Organization (WHO). Global leprosy situation, 2007 (additional information). Wkly Epidemiol Rec. 2007; 82(44): 388.	2006	*	
Namibia	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Namibia	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Namibia	Jooste PL, Badenhorst CJ, Schutte CH, Faber M, Van Staden E, Oelofse A, Aalbers C. Endemic goitre among undernourished schoolchildren in eastern Caprivi, Namibia. <i>S Afr Med J</i> . 1992; 81(11): 571-4 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1990-1991		
Namibia	Joubert JJ, Prozesky OW, Lourens JG, van Straten AM, Theron JW, Swanevelder C, Meenehan GM, van der Merwe CA. Prevalence of hepatitis virus and some arbovirus infections in Kavango, northern SWA/Namibia. <i>S Afr Med J</i> . 1985; 67(13): 500-2.	1983		
Namibia	Steele AD, Bos P, Joubert JJ, Bafort JM, Lecatsas G, Aspinall S. Serologic markers for hepatitis B virus and hepatitis A virus in Bushmen in West Caprivi, Namibia. <i>East Afr Med J</i> . 1995; 72(1): 30-2.	1993		
Namibia	Aspinall S, Joubert JJ, Evans AC, Joseph S, Steele AD, Lecatsas G. Prevalence of hepatitis B in 'Kung (San) children from Bushmanland, Namibia. <i>Ann Trop Paediatr</i> . 1994; 14(2): 163-7.	1992		
Nepal	Family Planning and MCH Project, Ministry of Health and Population (Nepal), International Statistical Institute. Nepal World Fertility Survey 1976. Voorburg, Netherlands: International Statistical Institute.	1976		
Nepal	Macro International, Inc, Ministry of Health and Population (Nepal), New ERA. Nepal Demographic and Health Survey 1996. Calverton, United States: Macro International, Inc.	1996		†
Nepal	Macro International, Inc, Ministry of Health and Population (Nepal), New ERA. Nepal Demographic and Health Survey 2001. Calverton, United States: Macro International, Inc.	2001		†
Nepal	Macro International, Inc, Ministry of Health and Population (Nepal), New ERA. Nepal Demographic and Health Survey 2006. Calverton, United States: Macro International, Inc.	2006		†
Nepal	ICF Macro, Ministry of Health and Population (Nepal), New ERA. Nepal Demographic and Health Survey 2011. Calverton, United States: ICF Macro.	2011		†
Nepal	World Health Organization (WHO). Nepal World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Nepal	United Nations Children's Fund (UNICEF), Central Bureau of Statistics (Nepal). Nepal Multiple Indicator Cluster Survey 2010. New York, United States: United Nations Children's Fund (UNICEF).	2010	*	
Nepal	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1997-2005		
Nepal	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Nepal	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Nepal	Walker SL, Shah M, Hubbard VG, Pradhan HM, Ghimire M. Skin disease is common in rural Nepal: results of a point prevalence study. <i>Br J Dermatol</i> . 2008; 158(2): 334-8.	2004-2007		
Nepal	Ghimire M, Pradhan YV, Maskey MK. Community-based interventions for diarrhoeal diseases and acute respiratory infections in Nepal. <i>Bull World Health Organ</i> . 2010; 3(88): 216-21.	2006-2007		
Nepal	Sherchand JB, Nakagomi O, Dove W, Nakagomi T, Yokoo M, Pandey BD, Cuevas LE, Hart CA, Cunliffe NA. Molecular epidemiology of rotavirus diarrhoea among children aged <5 years in Nepal: predominance of emergent G12 strains during 2 years. <i>J Infect Dis</i> . 2009; 200 Suppl 1: 182-187.	2005-2007		
Nepal	Uchida R, Pandey BD, Sherchand JB, Ahmed K, Yokoo M, Nakagomi T, Cuevas LE, Cunliffe NA, Hart CA, Nakagomi O. Molecular epidemiology of rotavirus diarrhoea among children and adults in Nepal: detection of G12 strains with P6 or P8 and a G11P25 strain. <i>J Clin Microbiol</i> . 2006; 44(10): 3499-505.	2003-2004		
Nepal	Lumbiganon P, Laopaboon M, Gülmezoglu AM, Souza JP, Taneepanichskul S, Ruyan P, Attygalle DE, Shrestha N, Mori R, Hinh ND, Bang HT, Rathavy T, Chuyun K, Cheang K, Festin M, Udomprasertgul V, Germar MJV, Yanqiu G, Roy M, Carroli G, Ba-Thike K. Method of delivery and pregnancy outcomes in Asia: the WHO global survey on maternal and perinatal health 2007-08. <i>Lancet</i> . 2010; 375(9713): 490-9.	2007-2008		
Nepal	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2004		
Nepal	Sasaki H, Kawasaki T, Ogaki T, Kobayashi S, Itoh K, Yoshimizu Y, Sharma S, Acharya GP. The prevalence of diabetes mellitus and impaired fasting glucose/glycaemia (IFG) in suburban and rural Nepal-the communities-based cross-sectional study during the democratic movements in 1990. <i>Diabetes Res Clin Pract</i> . 2005; 67(2): 167-74.	1990		
Nepal	Singh DL, Bhattarai MD. High prevalence of diabetes and impaired fasting glycaemia in urban Nepal. <i>Diabet Med</i> . 2003; 20(2): 170-1.	2000		
Nepal	Shrestha UK, Singh DL, Bhattarai MD. The prevalence of hypertension and diabetes defined by fasting and 2-h plasma glucose criteria in urban Nepal. <i>Diabet Med</i> . 2006; 23(10): 1130-5.	2002		
Nepal	David J, Yee R, Lama D. The periodontal health of adult Nepalese. <i>Oral Health Prev Dent</i> . 2011; 9(1): 67-81.	2004	*	
Nepal	Subedi B, Shakya P, Kc U, Inawali M, Paudyal BD, Acharya A, Koirala S, Singh A. Prevalence of dental caries in 5-6 years and 12-13 years age group of school children of Kathmandu valley. <i>J Nepal Med Assoc</i> . 2011; 51(184): 176-81.	2007-2008	*	
Nepal	Yee R, David J, Lama D. The periodontal health of Nepalese schoolchildren. <i>Community Dent Health</i> . 2009; 26(4): 250-6.	2004	*	
Nepal	Chandra AK, Bhattacharjee A, Malik T, Ghosh S. Goiter prevalence and iodine nutritional status of school children in a sub-Himalayan Tarai region of eastern Uttar Pradesh. <i>Indian Pediatr</i> . 2008; 45(6): 469-74.	2006	*	
Nepal	Heydon EE, Thomson CD, Mann J, Williams SM, Skeaff SA, Sherpa KT, Heydon JL. Iodine status in a Sherpa community in a village of the Khumbu region of Nepal. <i>Public Health Nutr</i> . 2009; 12(9): 1431-6.	2006-2008		
Nepal	Adhikari P. Pattern of ear diseases in rural school children: experiences of free health camps in Nepal. <i>Int J Pediatr Otorhinolaryngol</i> . 2009; 73(9): 1278-80.	2006-2008	*	
Nepal	Haruki K, Sherchand JB. Rotavirus Diarrhoea in Children and Animals of Urban and Rural Nepal. <i>J Nepal Health Res Council</i> . 2008.	2001-2002	*	
Nepal	M Shariff, M Deb, R Singh. A study of diarrhoea among children in eastern Nepal with special reference to rotavirus. <i>Indian J Med Microbiol</i> . 2003; 21(2): 87.	1999-2000	*	
Nepal	Pun SB, Nakagomi T, Sherchand JB, Pandey BD, Cuevas LE, Cunliffe NA, Hart CA, Nakagomi O. Detection of G12 human rotaviruses in Nepal. <i>Emerg Infect Dis</i> . 2007; 13(3): 482-4.	2004-2005	*	
Nepal	Amatya R, Poudyal N, Gurung R, Khanal B. Prevalence of cryptosporidium species in paediatric patients in Eastern Nepal. <i>Trop Doct</i> . 2011; 41(1): 36-7.	2007-2008	*	
Nepal	Sherchand JB, Tandukar S, Sherchan JB, Rayamajhi A, Gurung B, Shrestha L, Rijal B, Pokhrel BM. Hospital-based study in children with rotavirus gastroenteritis and other enteropathogens. <i>J Nepal Health Res Council</i> . 2012; 10(21): 130-5.	2009-2010	*	
Nepal	Bern C, Joshi AB, Jha SN, Das ML, Hightower A, Thakur GD, Bista MB. Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. <i>Am J Trop Med Hyg</i> . 2000; 63(3-4): 184-8.	1999		
Nepal	Yee R, McDonald N. Caries experience of 5-6-year-old and 12-13-year-old schoolchildren in central and western Nepal. <i>Int Dent J</i> . 2002; 52(6): 453-60.	1999-2000		
Nepal	Bonetti TR, Erpelting A, Pathak LR. Listening to "Felt Needs": Investigating Genital Prolapse in Western Nepal. <i>Reprod Health Matters</i> . 2004; 12(23): 166-75.	2000		
Nepal	International Society of Nephrology (ISN). International Society of Nephrology Kidney Disease Data Center 2006-2009.	2006-2009		
Nepal	Nepal - Bagmati and Janakpur Zone Rapid Assessment for Avoidable Blindness 2008 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2008		
Nepal	Gilbert CE, Ellwein LB. Prevalence and causes of functional low vision in school-age children: results from standardized population surveys in Asia, Africa, and Latin America. <i>Invest Ophthalmol Vis Sci</i> . 2008; 49(3): 877-81. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1998		
Nepal	Pokharel GP, Negrel AD, Munoz SR, Ellwein LB. Refractive Error Study in Children: results from Mechi Zone, Nepal. <i>Am J Ophthalmol</i> . 2000; 129(4): 436-44. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1997		
Nepal	Mathisen M, Strand TA, Sharma BN, Chandoy RK, Valentiner-Branth P, Basnet S, Adhikari RK, Hvidsten D, Shrestha PS, Sommerfelt H. RNA viruses in community-acquired childhood pneumonia in semi-urban Nepal; a cross-sectional study. <i>BMC Med</i> . 2009; 35.	2004-2007	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Nepal	Williams JV, Edwards KM, Weinberg GA, Griffin MR, Hall CB, Zhu Y, Szilagyi PG, Wang CK, Yang C-F, Silva D, Ye D, Špeteć RR, Crowe JE Jr. Population-based incidence of human metapneumovirus infection among hospitalized children. <i>J Infect Dis.</i> 2010; 201(12): 1890-8.	2001-2003	*	
Nepal	Little P, Bridges A, Guragain R, Friedman D, Prasad R, Weir N. Hearing impairment and ear pathology in Nepal. <i>J Laryngol Otol.</i> 1993; 107(5): 395-400.	1990-1992		
Nepal	Bahadur KCM, Sharma D, Shrestha MP, Gurung S, Rajbhandari S, Malla R, Rajbhandari R, Limbu YR, Regmi SR, Koirala B. Prevalence of rheumatic and congenital heart disease in schoolchildren of Kathmandu valley in Nepal. <i>Indian Heart J.</i> 2003; 55(6): 615-8.	2002		
Nepal	Regmi PR, Pandey MR. Prevalence of rheumatic fever and rheumatic heart disease in school children of Kathmandu city. <i>Indian Heart J.</i> 1997; 49(5): 518-20.	1993-1995		
Nepal	Pun KD, Chauhan M. Outcome of adolescent pregnancy at Kathmandu University Hospital, Dhulikhel, Kavre. <i>Kathmandu Univ Med J.</i> 2011; 9(33): 50-3.	2007-2008	*	
Nepal	Subedi S, Tausig M, Subedi J, Broughton CL, Williams-Blangero S. Mental illness and disability among elders in developing countries: the case of Nepal. <i>J Aging Health.</i> 2004; 16(1): 71-87.	1996-1998		
Nepal	Mishra A, Shrestha P, Bista N, Bhurtel P, Bhattarai S, Thakali K, Banthia P, Pathak S. Pattern of Liver Diseases. <i>J Nepal Health Res Counc.</i> 2009; 7(14): 14-8.	2008		
Nepal	Shrestha SM, Tsuda F, Okamoto H, Tokita H, Horikita M, Tanaka T, Miyakawa Y, Mayumi M. Hepatitis B virus subtypes and hepatitis C virus genotypes in patients with chronic liver disease in Nepal. <i>Hepatology.</i> 1994; 19(4): 805-9.	1989-1992		
Nepal	Kohrt BA, Hruschka DJ, Worthman CM, Kunz RD, Baldwin JL, Upadhaya N, Acharya NR, Koirala S, Thapa SB, Tol WA, Jordans MJD, Robkin N, Sharma YD, Nepal MK. Political violence and mental health in Nepal: prospective study. <i>Br J Psychiatry.</i> 2012; 201(4): 268-75.	2007	*	
Nepal	Luitel NP, Jordans MJD, Sapkota RP, Tol WA, Kohrt BA, Thapa SB, Komproe IH, Sharma B. Conflict and mental health: a cross-sectional epidemiological study in Nepal. <i>Soc Psychiatry Psychiatr Epidemiol.</i> 2013; 48(2): 183-93.	2008	*	
Nepal	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2010, 2012		
Nepal	Sapkota YD, Pokharel GP, Nirmalan PK, Dulal S, Maharjan IM, Prakash K. Prevalence of blindness and cataract surgery in Gandaki Zone, Nepal. <i>Br J Ophthalmol.</i> 2006; 90(4): 411-6. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2002		
Nepal	Brilliant LB, Pokhrel RP, Grasset NC, Lepkowski JM, Kolstad A, Hawks W, Pararajasegaram R, Brilliant GE, Gilbert S, Shrestha SR. Epidemiology of blindness in Nepal. <i>Bull World Health Organ.</i> 1985; 63(2): 375-86. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1980-1981		
Nepal	Dongol AS, Shrestha A, Chawla CD. Post partum haemorrhage: prevalence, morbidity and management pattern in Dhulikhel Hospital. <i>Kathmandu Univ Med J.</i> 2010; 8(30): 212-5.	2007-2009	*	
Nepal	Sherchan A, Kandel RP, Sharma MK, Sapkota YD, Aghajanian J, Bassett KL. Blindness prevalence and cataract surgical coverage in Lumbini Zone and Chetwan District of Nepal. <i>Br J Ophthalmol.</i> 2010; 94(2): 161-6. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2006		
Nepal	Sapkota YD, Sunuwar M, Naito T, Akura J, Adhikari HK. The prevalence of blindness and cataract surgery in Rautahat District, Nepal. <i>Ophthalmic Epidemiol.</i> 2010; 17(2): 82-9. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2006		
Nepal	Thapa SS, Berg RVD, Khanal S, Paudyal I, Pandey P, Maharjan N, Twyana SN, Paudyal G, Gurung R, Ruit S, Rens GHMBV. Prevalence of visual impairment, cataract surgery and awareness of cataract and glaucoma in Bhaktapur district of Nepal: the Bhaktapur Glaucoma Study. <i>BMC Ophthalmol.</i> 2011; 11: 2. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2008-2009		
Nepal	Nepal - Bheri Zone Rapid Assessment of Avoidable Blindness 2009 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2009		
Nepal	Nepal - Dhawalagiri Zone Rapid Assessment of Avoidable Blindness 2010 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2010		
Nepal	Nepal - Karnali Zone Rapid Assessment of Avoidable Blindness 2008 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2008		
Nepal	Nepal - Koshi Zone Rapid Assessment of Avoidable Blindness 2008 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2008		
Nepal	Nepal - Mechi Zone Rapid Assessment of Avoidable Blindness 2009 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2009		
Nepal	Nepal - Rapti Zone Rapid Assessment of Avoidable Blindness 2010 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2010		
Nepal	Nepal - Sagarmata Zone Rapid Assessment of Avoidable Blindness 2008 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2008		
Nepal	Nepal - Seti and Mahakali Zones Rapid Assessment of Avoidable Blindness 2008 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2008		
Nepal	Lee ACC, Mullany LC, Tielsch JM, Katz J, Khatri SK, LeClerq SC, Adhikari RK, Shrestha SR, Darmstadt GL. Risk factors for neonatal mortality due to birth asphyxia in southern Nepal: a prospective, community-based cohort study. <i>Pediatrics.</i> 2008; 121(5): 1381-90.	2002-2006	*	†
Nepal	Ellis M, Shrestha L, Shrestha PS, Manandhar DS, Bolam AJ, L Costello AM. Clinical predictors of outcome following mild and moderate neonatal encephalopathy in term newborns in Kathmandu, Nepal. <i>Acta Paediatr.</i> 2001; 90(3): 316-22.	1995-1996	*	†
Nepal	Sharma SK, Ghimire A, Radhakrishnan J, Thapa L, Shrestha NR, Paudel N, Gurung K, R M, Budathoki A, Baral N, Brodie D. Prevalence of hypertension, obesity, diabetes, and metabolic syndrome in Nepal. <i>Int J Hypertens.</i> 2011; 821971.	2008-2010		
Nepal	Suzuki A, Hamano S, Shirakawa T, Watanabe K, Endo T, Sharma S, Jha B, Acharya GP, Nishiyama K, Fukumaki Y, Kobayashi S. The distribution of hereditary erythrocytic disorders associated with malaria, in a lowland area of Nepal: a micro-epidemiological study. <i>Ann Trop Med Parasitol.</i> 2007; 101(2): 113-22.	1998-2002		
Nepal	Hirachan P, Kharel T, Shah DS, Ball J. Renal replacement therapy in Nepal. <i>Hemodial Int.</i> 2010; 14(4): 383-6.	2009		
Nepal	Baker S, Holt KE, Clements ACA, Karkey A, Arjyal A, Boni MF, Dongol S, Hammond N, Koirala S, Duy PT, Nga TVT, Campbell JI, Dolecek C, Basnyat B, Dougan G, Farrar JJ. Combined high-resolution genotyping and geospatial analysis reveals modes of endemic urban typhoid fever transmission. <i>Open Biol.</i> 2011; 1(2): 110008.	2005-2009	*	
Nepal	Blacksell SD, Sharma NP, Phumratanaparin W, Jenjaroen K, Peacock SJ, White NJ, Pukrittayakamee S, Day NPJ. Serological and blood culture investigations of Nepalese fever patients. <i>Trans R Soc Trop Med Hyg.</i> 2007; 101(7): 686-90.	2002-2004	*	
Nepal	Karkey A, Arjyal A, Anders KL, Boni MF, Dongol S, Koirala S, My PVT, Nga TVT, Clements ACA, Holt KE, Duy PT, Day JN, Campbell JI, Dougan G, Dolecek C, Farrar J, Basnyat B, Baker S. The Burden and Characteristics of Enteric Fever at a Healthcare Facility in a Densely Populated Area of Kathmandu. <i>PLoS One.</i> 2010; 5(11).	2005-2009	*	
Nepal	Malla T, Malla KK, Thapalial A, Shaw C. Enteric fever: a retrospective 6-year analysis of 82 paediatric cases in a teaching hospital. <i>Kathmandu Univ Med J.</i> 2007; 5(2): 181-7.	2000-2005	*	
Nepal	Maskey AP, Basnyat B, Thwaites GE, Campbell JI, Farrar JJ, Zimmerman MD. Emerging trends in enteric fever in Nepal: 9124 cases confirmed by blood culture 1993-2003. <i>Trans R Soc Trop Med Hyg.</i> 2008; 102(1): 91-5.	1993-2003	*	
Nepal	Pokharel P, Rai SK, Karki G, Katuwal A, Vitrakoti R, Shrestha SK. Study of enteric fever and antibiogram of Salmonella isolates at a teaching hospital in Kathmandu Valley. <i>Nepal Med Coll J.</i> 2009; 11(3): 176-8.	2008-2009	*	
Nepal	Prajapati B, Rai GK, Rai SK, Upreti HC, Thapa M, Singh G, Shrestha RM. Prevalence of Salmonella typhi and paratyphi infection in children: a hospital based study. <i>Nepal Med Coll J.</i> 2008; 10(4): 238-41.	2007-2008	*	
Nepal	Joshi AB, Luman ET, Nandy R, Subedi BK, Liyanage JBL, Wierzbza TF. Measles deaths in Nepal: estimating the national case-fatality ratio. <i>Bull World Health Organ.</i> 2009; 87(6): 456-65.	2004-2005	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Nepal	Schmitz J, Pillon JP, LeClerq SC, Khattry SK, Wu LS-F, Prasad R, Karna SL, Shrestha SR, West KP Jr. Prevalence of hearing loss and ear morbidity among adolescents and young adults in rural southern Nepal. <i>Int J Audiol.</i> 2010; 49(5): 388-94.	2006-2008	*	
Nepal	World Health Organization (WHO). Nepal WHO Leishmaniasis Country Profile.	1994-2010	*	
Nepal	Nepal Assessment of Current Status of Iodine Deficiency Disorder for the Development of Future Control Program 2004 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2004		
Nepal	Nepal Micronutrient Status Survey 1997-1998 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1997-1998		
Nepal	Mathisen M, Strand TA, Valentiner-Branth P, Chandyo RK, Basnet S, Sharma BN, Adhikari RK, Hvidsten D, Shrestha PS, Sommerfelt H. Respiratory viruses in nepalese children with and without pneumonia: a case-control study. <i>Pediatr Infect Dis J.</i> 2010; 29(8): 731-5.	2006-2007	*	
Nepal	Mathisen M, Basnet S, Sharma A, Shrestha PS, Sharma BN, Valentiner-Branth P, Sommerfelt H, Strand TA. RNA viruses in young Nepalese children hospitalized with severe pneumonia. <i>Pediatr Infect Dis J.</i> 2011; 30(12): 1032-6.	2006-2008	*	
Nepal	Nepal Iodine Deficiency Disorders Status Survey 2005 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2005		
Nepal	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Nepal	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec.</i> 2007; 82(25): 225-32.	2006	*	
Nepal	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Nepal	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Nepal	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Nepal	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec.</i> 2008; 83(33): 293-300.	2007	*	
Nepal	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Nepal	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Nepal	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Nepal	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Nepal	World Health Organization (WHO). Leprosy. Global situation. <i>Wkly Epidemiol Rec.</i> 2002; 77(1): 1-8.	2001	*	
Nepal	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Nepal	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Nepal	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Nepal	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1993; 68(25): 181-6.	1992	*	
Nepal	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Nepal	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Nepal	Nepal - Rapti Adolescent Girls Nutrition Status Survey 1992-1993 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1992-1993		
Nepal	Dulal S, Sapkota YD. Prevalence of blindness and visual impairment and its causes among people aged 50 years and above in Karnali Zone, Nepal. <i>Nepal J Ophthalmol.</i> 2012; 4(2).	2009-2011	*	
Nepal	Thapa SS, Thapa R, Paudyal I, Khanal S, Aujla J, Paudyal G, Rens G van. Prevalence and pattern of vitreo-retinal diseases in Nepal: the Bhaktapur glaucoma study. <i>BMC Ophthalmol.</i> 2013; 9.	2010-2012	*	
Nepal	Sapkota YD, Dulal S, Pokharel GP, Pant P, Ellwein LB. Prevalence and correction of near vision impairment at Kaski, Nepal. <i>Nepal J Ophthalmol.</i> 2012; 4(1): 17-22.	2009-2011	*	
Nepal	Thapa SS, Paudyal I, Khanal S, Twyana SN, Paudyal G, Gurung R, Ruit S, van Rens GHMB. A population-based survey of the prevalence and types of glaucoma in Nepal: the Bhaktapur Glaucoma Study. <i>Ophthalmology.</i> 2012; 119(4): 759-64.	2009-2011	*	
Nepal	Dev MK, Shrestha GS, Paudel N, Joshi ND, Thapa M, Shah DN. Visual status and ocular morbidity in older adults living in residential care. <i>Graefes Arch Clin Exp Ophthalmol.</i> 2012; 250(9): 1387-93.	2009-2011	*	
Nepal	Khattry SK, West KP Jr, Katz J, LeClerq SC, Pradhan EK, Wu LS, Thapa MD, Pokhrel RP. Epidemiology of xerophthalmia in Nepal. A pattern of household poverty, childhood illness, and mortality. The Sarlahi Study Group. <i>Arch Ophthalmol.</i> 1995; 113(4): 425-9 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1989		
Nepal	World Health Organization Regional Office for South-East Asia (SEARO). Situation Update of Dengue in the SEA Region, 2010. New Delhi, India: World Health Organization Regional Office for South-East Asia (SEARO).	2006-2009		
Nepal	WHO Regional Office for South-East Asia (SEARO). WHO South-East Asia Region: Reported Cases and Deaths of Dengue from 2003 to 2012. New Delhi, India: WHO Regional Office for South-East Asia (SEARO), 2013.	2003-2012	*	
Nepal	Sodhi HS, Shrestha SK, Rauniyar R, Rawat B. Prevalence of peripheral arterial disease by ankle-brachial index and its correlation with carotid intimal thickness and coronary risk factors in Nepalese population over the age of forty years. <i>Kathmandu Univ Med J.</i> 2007; 5(1): 12-5.	2004-2006		
Nepal	Nakashima K, Kashiwagi S, Noguchi A, Hirata M, Hayashi J, Kawasaki T, Uezono K, Itoh K, Acharya GP, Ogata M. Human T-lymphotropic virus type-I, and hepatitis A, B and C viruses in Nepal: a serological survey. <i>J Trop Med Hyg.</i> 1995; 98(5): 347-50.	1987		
Nepal	Sawayama Y, Hayashi J, Ariyama I, Furusyo N, Kawasaki T, Kawasaki M, Itoh K, Acharya GP, Kashiwagi S. A ten year serological survey of hepatitis A, B and C viruses infections in Nepal. <i>J Epidemiol.</i> 1999; 9(5): 350-4.	1996		
Nepal	Pramanik T, Pramanik S. Distribution of ABO and Rh blood groups in Nepalese medical students: a report. <i>East Mediterr Health J.</i> 2000; 6(1): 156-8.	1997-1999	*	†
Nepal	Bhatta CP, Thapa B, Rana BB. Seroprevalence of hepatitis "B" in Kathmandu Medical College Teaching Hospital (KMCTH). <i>Kathmandu Univ Med J.</i> 2003; 1(2): 113-6.	2001		
Nepal	Chiba H, Takezaki T, Neupani D, Kim J, Yoshida S, Mizoguchi E, Takeuchi J, Suzuki J, Tanaka Y, Ito K, Kitamura T, Kuriki K, Wakai K, Samejima K, Sonoda S, Tajima K. An epidemiological study of HBV, HCV and HTLV-I in Sherpas of Nepal. <i>Asian Pac J Cancer Prev.</i> 2004; 5(4): 370-3.	2004		
Nepal	Manandhar K, Shrestha B. Prevalence of HBV infection among the healthy Nepalese males: a serological survey. <i>J Epidemiol.</i> 2000; 10(6): 410-3.	1996-1997		
Nepal	Rai SK, Shihata H, Satoh M, Murakoso K, Sumi K, Kubo T, Matsuoka A. Seroprevalence of hepatitis B and C viruses in eastern Nepal. <i>J Jpn Assoc Infect Dis.</i> 1994; 68(12): 1492-7.	1991-1993		
Nepal	Shrestha SM, Subedi NB, Shrestha S, Maharjan KG, Tsuda F, Okamoto H. Epidemiology of hepatitis C virus infection in Nepal. <i>Trop Gastroenterol.</i> 1998; 19(3): 102-4.	1994-1996		
Nepal	Shrestha SM. Seroepidemiology of hepatitis B in Nepal. <i>J Commun Dis.</i> 1990; 22(1): 27-32.	1988		
Nepal	Adhikari R, Bhusal K. Surveillance of lymphatic filariasis in selected districts of Nepal. <i>J Inst Med.</i> 2008; 35-40. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2007	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Nepal	Byanju R, Gupta R. Lymphatic Filariasis: Epidemiological Analysis of the Situation in Salyantar VDC of Dhading District, Nepal. <i>J Nat Hist Mus</i> . 2012; 136-45. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2000-2012	*	
Nepal	Gupta R, Lanichhane J. A Prospective Study of Lymphatic Filariasis in an Endemic Village of Kapilbastu District, Nepal. <i>EcoPrint</i> . 2006; 13(1): 29-34. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2000-2012	*	
Nepal	Prakash G, Das TG, Prasad YN, Raj BD, Keshab P, Kumar PR. Prevalence of Lymphatic Filariasis in an Endemic District of Nepal. <i>J Trop Med Parasitol</i> . 2013; 26(2): 57-61. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2002	*	
Nepal	Nepal - A Final Report on Epidemiological Surveillance of Lymphatic Filariasis in Makwanpur, Chitwan, Rupendehi and Nawalparasi Districts of Nepal as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2005	*	
Nepal	Institute of Medicine, Tribhuvan University, United Nations Population Fund (UNFPA). Nepal Status of Reproductive Morbidities 2006.	2006	*	
Netherlands	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2004-2005		
Netherlands	Netherlands Vital Registration - Deaths 1985 ICD9 as it appears in World Health Organization (WHO). World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1985		
Netherlands	World Health Organization (WHO). Netherlands World Health Survey 2004. Geneva, Switzerland: World Health Organization (WHO), 2005.	2004		
Netherlands	Ott A, Breteler MMB, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial Fibrillation and Dementia in a Population-Based Study: The Rotterdam Study. <i>Stroke</i> . 1997; 28(2): 316-321.	1990-1993		
Netherlands	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. <i>Scand J Clin Lab Invest</i> . 2007; 67(1): 39-69.	1988, 2006		
Netherlands	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1988, 2003, 2006		
Netherlands	Verhamme KMC, Dieleman JP, Bleumink GS, Van der Lei J, Sturkenboom MCJM, Artibani W, Begaud B, Berges R, Borkowski A, Chappel CR, Costello A, Dobronski P, Farmer RDT, Jiménez Cruz F, Jonas U, MacRae K, Pienika L, Rutten FFH, Van Schayck CP, Speakman MJ, Sturkenboom MC, Tiellac P, Tubaro A, Vallencien G, Vela Navarrete R. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care – the Triumph project. <i>Eur Urol</i> . 2002; 42(4): 323-8.	1995-2000		
Netherlands	Mohammedamin RS, van der Wouden JC, Koning S, van der Linden MW, Schellevis FG, van Suijlekom-Smit LW, Koes BW. Increasing incidence of skin disorders in children? A comparison between 1987 and 2001. <i>BMC Dermatol</i> . 2006; 6(4).	1987, 2001		
Netherlands	Vaartjes I, Reitsma JB, de Bruin A, Berger-van Sijl M, Bos MJ, Breteler MM, Grobbee DE, Bots ML. Nationwide incidence of first stroke and TIA in the Netherlands. <i>Eur J Neurol</i> . 2008; 15(12): 1315-23.	2000		
Netherlands	Smit HA, Burdorf A, Coenraads PJ. Prevalence of hand dermatitis in different occupations. <i>Int J Epidemiol</i> . 1993; 22(2): 288-93.	1992		
Netherlands	Sliedrecht A, Verheij TJM, Den Elzen WPI, Gussekloo J, Westendorp RGJ. Incidence and predictive factors of lower respiratory tract infections among the very elderly in the general population. <i>Thorax</i> . 2008; 9(63): 817-22.	1997-2004		
Netherlands	van Jaarsveld CHM, Ranchor AV, Kempen GJM, Coyne JC, van Veldhuisen DJ, Sanderman R. Epidemiology of heart failure in a community-based study of subjects aged > or = 57 years: incidence and long-term survival. <i>Eur J Heart Fail</i> . 2006; 8(1): 23-30.	1993-2001		
Netherlands	Demyttenaere K, Bruhaerts R, Lee S, Posada-Villa J, Kovess V, Angermeyer MC, Levinson D, de Girolamo G, Nakane H, Mneimneh Z, Lara C, de Graaf R, Scott KM, Gureje O, Stein DJ, Haro JM, Bromet EJ, Kessler RC, Alonso J, Von Korff M. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. <i>Pain</i> . 2007; 129(3): 332-42.	2002-2003		
Netherlands	Diepenmaat ACM, van der Wal MF, de Vet HCW, Hirasings RA. Neck/shoulder, low back, and arm pain in relation to computer use, physical activity, stress, and depression among Dutch adolescents. <i>Pediatrics</i> . 2006; 117(2): 412-6.	2002-2003		
Netherlands	Picavet HSI, Schouten JSAG. Musculoskeletal pain in the Netherlands: prevalences, consequences and risk groups, the DMC(3)-study. <i>Pain</i> . 2003; 102(1-2): 167-78.	1998, 2000		
Netherlands	Van Hangeem N, Miltenburg AS, Zwart JJ, Bloemenkamp KW n, Van Roosmalen J. Severe acute maternal morbidity in asylum seekers: a two-year nationwide cohort study in the Netherlands. <i>Acta Obstet Gynecol Scand</i> . 2011; 90(9): 1010-6.	2004-2006		
Netherlands	Kramer HMC, Schutte JM, Zwart JJ, Schuitemaker NWE, Steegers EAP, van Roosmalen J. Maternal mortality and severe morbidity from sepsis in the Netherlands. <i>Acta Obstet Gynecol Scand</i> . 2009; 88(6): 647-53.	2004-2006		
Netherlands	Giordano PC. Starting neonatal screening for haemoglobinopathies in The Netherlands. <i>J Clin Pathol</i> . 2009; 1(62): 18-21.	2007		
Netherlands	Coebergh JW, Neumann HA, Vrints LW, van der Heijden L, Meijer WJ, Verhagen-Teulings MT. Trends in the incidence of non-melanoma skin cancer in the SE Netherlands 1975-1988: a registry-based study. <i>Br J Dermatol</i> . 1991; 125(4): 353-9.	1978-1988		
Netherlands	De Vries E, van de Poll-Franse LV, Louwman WJ, de Groot FR, Coebergh JWW. Predictions of skin cancer incidence in the Netherlands up to 2015. <i>Br J Dermatol</i> . 2005; 152(3): 481-8.	2000		
Netherlands	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2002-2008		
Netherlands	Picavet HSI, Hazes JMW. Prevalence of self reported musculoskeletal diseases is high. <i>Ann Rheum Dis</i> . 2003; 62(7): 644-50.	1998		
Netherlands	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	2003		
Netherlands	Vink NM, Postma DS, Schouten JP, Rosmalen JG, Boezen HM. Gender differences in asthma development and remission during transition through puberty: the TRacking Adolescents' Individual Lives Survey (TRAILS) study. <i>J Allergy Clin Immunol</i> . 2010; 126(3): 498-504.	2001-2002		
Netherlands	Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. <i>Diabetologia</i> . 1996; 39(11): 1377-84.	1993-1995		
Netherlands	Abraham MD, Kaal HL, Cohen PDA, Centre for Drug Research, University of Amsterdam. Licit and Illicit Drug Use in Amsterdam, 1987-2001. Amsterdam, Netherlands: Centre for Drug Research, University of Amsterdam, 2002.	1987, 1990, 1994, 1997, 2001		
Netherlands	de Sonnaville JJ, Colly LP, Wijkkel D, Heine RJ. The prevalence and determinants of foot ulceration in type II diabetic patients in a primary health care setting. <i>Diabetes Res Clin Pract</i> . 1997; 35(2-3): 149-56.	1992-1995		
Netherlands	Spijkerman AM, Dekker JM, Nijpels G, Adriaanse MC, Kostense PJ, Ruwaard D, Stehouwer CD, Bouter LM, Heine RJ. Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the Hoorn Screening Study. <i>Diabetes Care</i> . 2003; 26(9): 2604-8.	1998-2001		
Netherlands	Mooy JM, Grootenhuys PA, de Vries H, Valkenburg HA, Bouter LM, Kostense PJ, Heine RJ. Prevalence and determinants of glucose intolerance in a Dutch caucasian population. <i>The Hoorn Study</i> . <i>Diabetes Care</i> . 1995; 18(9): 1270-3.	1991		
Netherlands	Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. <i>Neurology</i> . 1999; 53(3): 537-42.	1995-1996		
Netherlands	Koning S, Bruijnzeels MA, van Suijlekom-Smit LW, van der Wouden JC. Molluscum contagiosum in Dutch general practice. <i>Br J Gen Pract</i> . 1994; 44(386): 417-9.	1987-1988		
Netherlands	Mohammedamin RS, van der Wouden JC, Koning S, van der Linden MW, Schellevis FG, van Suijlekom-Smit LW, Koes BW. Self-reported prevalence of warts in children and GP consultation. <i>Eur J Gen Pract</i> . 2008; 14(1): 34-6.	2001		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Netherlands	Van Sasse JL, van Romunde LK, Cats A, Vandenbroucke JP, Valkenburg HA. Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. <i>Ann Rheum Dis.</i> 1989; 48(4): 271-80.	1975-1978		
Netherlands	Odding E, Valkenburg HA, Algra D, Vandenouwendland FA, Grobbee DE, Hofman A. Associations of radiological osteoarthritis of the hip and knee with locomotor disability in the Rotterdam Study. <i>Ann Rheum Dis.</i> 1998; 57(4): 203-8.	1990-1993		
Netherlands	Reijman M, Hazes JMW, Bierma-Zeinstra SMA, Koes BW, Christgau S, Christiansen C, Uitterlinden AG, Pols HAP. A new marker for osteoarthritis: cross-sectional and longitudinal approach. <i>Arthritis Rheum.</i> 2004; 50(8): 2471-8.	2001		
Netherlands	Garcia-Marcos L, Mallol J, Solé D, Brand PLP. EISL Study Group. International study of wheezing in infants: risk factors in affluent and non-affluent countries during the first year of life. <i>Pediatr Allergy Immunol.</i> 2010; 21(5): 878-88.	2005-2007	*	
Netherlands	Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, Gjomarkaj M, Forsberg B, Gunnbjornsdottir M, Minov J, Brozek G, Dahlen SE, Toskala E, Kowalski ML, Olze H, Howarth P, Krämer U, Baelum J, Loureiro C, Kasper L, Bousquet PJ, Bousquet J, Bachert C, Fokkens W, Burney P. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. <i>Allergy.</i> 2012; 67(1): 91-8.	2008-2009	*	
Netherlands	Visser CAN, Garcia-Marcos L, Eggink J, Brand PLP. Prevalence and risk factors of wheeze in Dutch infants in their first year of life. <i>Pediatr Pulmonol.</i> 2010; 45(2): 149-56.	2005-2007	*	
Netherlands	Mohangoo AD, de Koning HJ, Hafkamp-de Groen E, van der Wouden JC, Jaddoe VVW, Moll HA, Hofman A, Mackenbach JP, de Jongste JC, Raat H. A comparison of parent-reported wheezing or shortness of breath among infants as assessed by questionnaire and physician-interview: The Generation R study. <i>Pediatr Pulmonol.</i> 2010; 45(5): 500-7.	2005-2007	*	
Netherlands	Vanfleteren LEGW, Franssen FME, Wesseling G, Wouters EFM. The prevalence of chronic obstructive pulmonary disease in Maastricht, the Netherlands. <i>Respir Med.</i> 2012; 106(6): 871-4.	2007-2009	*	
Netherlands	Van Durme YMTA, Verhamme KMC, Stijnen T, van Rooij FJA, Van Pottelberge GR, Hofman A, Joos GF, Stricker BHC, Brusselle GG. Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam study. <i>Chest.</i> 2009; 135(2): 368-77.	1989-1993		
Netherlands	Lebon A, Labout JAM, Verbrugh HA, Jaddoe VVW, Hofman A, van Wamel WJB, van Belkum A, Moll HA. Role of <i>Staphylococcus aureus</i> nasal colonization in atopic dermatitis in infants: the Generation R Study. <i>Arch Pediatr Adolesc Med.</i> 2009; 163(8): 745-9.	2004-2007	*	
Netherlands	Gabriele C, Silva LM, Arends LR, Raat H, Moll HA, Hofman A, Jaddoe VW, de Jongste JC. Early respiratory morbidity in a multicultural birth cohort: the Generation R Study. <i>Eur J Epidemiol.</i> 2012; 27(6): 453-62.	2002-2006	*	
Netherlands	Elfrink MEC, Schuller AA, Veerkamp JSJ, Poorterman JHG, Moll HA, ten Cate BJM. Factors increasing the caries risk of second primary molars in 5-year-old Dutch children. <i>Int J Paediatr Dent.</i> 2010; 20(2): 151-7.	2005	*	
Netherlands	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. <i>Community Dent Oral Epidemiol.</i> 1991; 19(2): 72-3.	1987		
Netherlands	Verhoef L, Boot HJ, Koopmans M, Mollema L, Van Der Klis F, Reimerink J, Van Pelt W. Changing risk profile of hepatitis A in The Netherlands: a comparison of seroprevalence in 1995-1996 and 2006-2007. <i>Epidemiol Infect.</i> 2011; 139(8): 1172-80.	2006-2009		
Netherlands	Verhoef L, Koopmans M, Duizer E, Bakker J, Reimerink J, Van Pelt W. Seroprevalence of hepatitis E antibodies and risk profile of HEV seropositivity in The Netherlands, 2006-2007. <i>Epidemiol Infect.</i> 2012; 140(10): 1838-47.	2006-2007		
Netherlands	Van Schroyenstijn Lantman-de Valk HMJ, Wullink M, van den Akker M, van Heurn-Nijsten EWA, Metsemakers JFM, Dinant GJ. The prevalence of intellectual disability in Limburg, the Netherlands. <i>J Intellect Disabil Res.</i> 2006; 50(Pt 1): 61-8.	2000-2001	*	
Netherlands	Schrijvers EMC, Verhaaren BFI, Koudstaal PJ, Hofman A, Ikram MA, Breteler MMB. Is dementia incidence declining?: Trends in dementia incidence since 1990 in the Rotterdam Study. <i>Neurology.</i> 2012; 78(19): 1456-63.	1990-2010		
Netherlands	Gussekloo J, Heeren TJ, Izaks GJ, Ligthart GJ, Rooijmans HG. A community based study of the incidence of dementia in subjects aged 85 years and over. <i>J Neurol Neurosurg Psychiatry.</i> 1995; 59(5): 507-10.	1986-1992		
Netherlands	Heeren TJ, Lagaay AM, Hijmans W, Rooijmans HG. Prevalence of dementia in the "oldest old" of a Dutch community. <i>J Am Geriatr Soc.</i> 1991; 39(8): 755-9.	1986-1989		
Netherlands	Boersma F, Eefsting JA, van den Brink W, Koeter M, van Tilburg W. Prevalence of dementia in a rural Netherlands population and the influence of DSM-III-R and CAMDEX criteria for the prevalence of mild and more severe forms. <i>J Clin Epidemiol.</i> 1998; 51(3): 189-97.	1991-1992		
Netherlands	Koopman C, van Oeffelen AAM, Bots ML, Engelfriet PM, Verschuren WMM, van Rossem L, van Dis I, Capewell S, Vaartjes L. Neighbourhood socioeconomic inequalities in incidence of acute myocardial infarction: a cohort study quantifying age- and gender-specific differences in relative and absolute terms. <i>BMC Public Health.</i> 2012; 617.	1997-2007	*	
Netherlands	Dahaghin S, Bierma-Zeinstra SMA, Reijman M, Pols HA, Hazes JMW, Koes BW. Does hand osteoarthritis predict future hip or knee osteoarthritis? <i>Arthritis Rheum.</i> 2005; 52(11): 3520-7.	1990-2000		
Netherlands	Bagge E, Bjelle A, Valkenburg HA, Svanborg A. Prevalence of radiographic osteoarthritis in two elderly European populations. <i>Rheumatol Int.</i> 1992; 12(1): 33-8.	1975-1978		
Netherlands	Vandenbroucke JP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective follow-up. <i>J Rheumatol.</i> 1984; 11(2): 158-61.	1954-1981		
Netherlands	Kroot EJ, van Leeuwen MA, van Rijswijk MH, Prevoo ML, van 't Hof MA, van De Putte LB, van Riel PL. No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. <i>Ann Rheum Dis.</i> 2000; 59(12): 954-8.	1985-1997		
Netherlands	Truin GJ, Plasschaert AJ, König KG, Vogels AL. Dental caries in 5-, 7-, 9- and 11-year-old schoolchildren during a 9-year dental health campaign in The Hague. <i>Community Dent Oral Epidemiol.</i> 1981; 9(2): 55-60.	1969-1978		
Netherlands	Kalsbeek H, Truin GJ, Burgersdijk R, van 't Hof M. Tooth loss and dental caries in Dutch adults. <i>Community Dent Oral Epidemiol.</i> 1991; 19(4): 201-4.	1986		
Netherlands	Truin GJ, König KG, Ruiken HM, Vogels AL, Elvers JW. Caries prevalence and gingivitis in 5-, 7- and 10-year-old schoolchildren in The Hague between 1969 and 1984. <i>Caries Res.</i> 1986; 20(2): 131-40.	1984		
Netherlands	Ruiken R, König K, Truin GJ, Plasschaert F. Longitudinal study of dental caries development in Dutch children aged 8-12 years. <i>Community Dent Oral Epidemiol.</i> 1986; 14(1): 53-6.	1979-1983		
Netherlands	Van Son GE, van Hoeken D, Bartelds AIM, van Furth EF, Hoek HW. Time trends in the incidence of eating disorders: A primary care study in The Netherlands. <i>Int J Eat Disord.</i> 2006; 39(7): 565-9.	1985-1989, 1995-1999		
Netherlands	Verhulst FC, van der Ende J, Ferdinand RF, Kasius MC. The prevalence of DSM-III-R diagnoses in a national sample of Dutch adolescents. <i>Arch Gen Psychiatry.</i> 1997; 54(4): 329-36.	1993, 1995		
Netherlands	Kofflard MJ, Ten Cate FJ, van der Lee C, van Domburg RT. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. <i>J Am Coll Cardiol.</i> 2003; 41(6): 987-93.	1970-1999		
Netherlands	Schuermans J, Comijs HC, Beekman ATF, de Beurs E, Deeg DJH, Emmelkamp PMG, van Dyck R. The outcome of anxiety disorders in older people at 6-year follow-up: results from the Longitudinal Aging Study Amsterdam. <i>Acta Psychiatr Scand.</i> 2005; 111(6): 420-8.	1992-1999		
Netherlands	Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). <i>Soc Psychiatry Psychiatr Epidemiol.</i> 1998; 33(12): 587-95.	1996		
Netherlands	Beekman ATF, Bremmer MA, Deeg DJH, Van Balkom AJLM, Smit JH, De Beurs E, Van Dyck R, Van Tilburg W. Anxiety disorders in later life: a report from the longitudinal aging study Amsterdam. <i>Int J Geriatr Psychiatry.</i> 1998; 13(10): 717-26.	1992-1993		
Netherlands	Herman B, Leyten A, Van Luijk J, Frenken C, Op de Coul A, Schulte B. Epidemiology of stroke in Tilburg, the Netherlands. The population-based stroke incidence register: 2. Incidence, initial clinical picture and medical care, and three-week case fatality. <i>Stroke.</i> 1982; 13(5).	1980		
Netherlands	Walpot J, Blok W, van Zwielen J, Klazen C, Amsel B. Incidence and complication rate of infective endocarditis in the Dutch region of Walcheren: a 3-year retrospective study. <i>Acta Cardiol.</i> 2006; 61(2): 175-81.	2002-2004		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Netherlands	van der Meer JT, Thompson J, Valkenburg HA, Michel MF. Epidemiology of bacterial endocarditis in The Netherlands. I. Patient characteristics. Arch Intern Med. 1992; 152(9): 1863-8.	1986-1988		
Netherlands	de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Künzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P, European Community Respiratory Health Survey Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax. 2004; 59(2): 120-125.	1991-1993		
Netherlands	Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E, BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007; 9589(9589): 741-50.	2005-2006		
Netherlands	Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, Jensen RL, Falaschetti E, Schouten JP, Hankinson JL, Stocks J, Quanjer PH. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. 2008; 63(12): 1046-51.	1972-1985		
Netherlands	Bais MJM, Eskes M, Pel M, Bonsel GJ, Bleker OP. Postpartum haemorrhage in nulliparous women: incidence and risk factors in low and high risk women. A Dutch population-based cohort study on standard (> or = 500 ml) and severe (> or = 1000 ml) postpartum haemorrhage. Eur J Obstet Gynecol Reprod Biol. 2004; 115(2): 166-72.	1990-1994		
Netherlands	Kroes M, Kalf AC, Kessels AG, Steyaert J, Feron FJ, van Someren AJ, Hurks PP, Hendriksen JG, van Zeben TM, Rozendaal N, Crolla IF, Troost J, Jolles J, Vles JS. Child psychiatric diagnoses in a population of Dutch schoolchildren aged 6 to 8 years. J Am Acad Child Adolesc Psychiatry. 2001; 40(12): 1401-9.	1999		
Netherlands	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2002-2005		
Netherlands	Kothoff F, Labots-Vogeleesang M, Lagro-Janssen T. The premenstrual syndrome. Prevalence and characteristics in patients in a general practice. Huisarts Wet. 2005; 48(3): 109-12.	1996-1997		
Netherlands	United States Renal Data System Coordinating Center. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2000		
Netherlands	Rours GJG, Duijts L, Moll HA, Arends LR, de Groot R, Jaddoe VW, Hofman A, Steegers EAP, Mackenbach JP, Ort A, Willemse HF, van der Zwaan EAE, Verkooyen RP, Verbrugh HA. Chlamydia trachomatis infection during pregnancy associated with preterm delivery: a population-based prospective cohort study. Eur J Epidemiol. 2011; 26(6): 493-502.	2003-2005		
Netherlands	Van Bergen J, Gitz HM, Richardus JH, Hoebe CJPA, Broer J, Coenen AJT, PILOT CT study group. Prevalence of urogenital Chlamydia trachomatis increases significantly with level of urbanisation and suggests targeted screening approaches: results from the first national population based study in the Netherlands. Sex Transm Infect. 2005; 81(1): 17-23.	2005		
Netherlands	Thewissen EA, van der Meijden WI, Doppenberg HJ, Mulder PG, Wagenvoort JH, Stolz E, Michel MF. Screening for cervical Chlamydia trachomatis infections in two Dutch populations. Genitourin Med. 1990; 66(5): 361-6.	1988		
Netherlands	De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000; 54(11 Suppl 5): S21-23.	1997		
Netherlands	Rijk MC de, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alpiérovitch A, Rocca WA. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997; 62(1): 10-5.	1988-1989		
Netherlands	Hofman A, Collette HJA, Bartelds ADM. Incidence and Risk Factors of Parkinson's Disease in The Netherlands. Neuroepidemiology. 1989; 8(6): 296-9.	1983-1985		
Netherlands	Lau LML de, Giesbergen PCLM, Rijk MC de, Hofman A, Koudstaal PJ, Breteler MMB. Incidence of parkinsonism and Parkinson disease in a general population The Rotterdam Study. Neurology. 2004; 63(7): 1240-4.	1990-1999		
Netherlands	Rijk MC de, Breteler MMB, Graveland GA, Ott A, Grobbee DE, Meche FGA van der, Hofman A. Prevalence of Parkinson's disease in the elderly The Rotterdam Study. Neurology. 1995; 45(12): 2143-6.	1990-1993		
Netherlands	Schuurman AG, Akker M van den, Ensink KTJL, Metsemakers JFM, Knottnerus JA, Leentjens AFG, Buntinx F. Increased risk of Parkinson's disease after depression A retrospective cohort study. Neurology. 2002; 58(10): 1501-4.	1975-2000		
Netherlands	van de Vijver DA, Roos RA, Jansen PA, Porsius AJ, de Boer A. Estimation of incidence and prevalence of Parkinson's disease in the elderly using pharmacy records. Pharmacoepidemiol Drug Saf. 2001; 10(6): 549-54.	1998		
Netherlands	Berger K BM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000; 54(11): 24-7.	1997		
Netherlands	Schrier AC, van de Wetering BJ, Mulder PG, Selten JP. Point prevalence of schizophrenia in immigrant groups in Rotterdam: data from outpatient facilities. Eur Psychiatry. 2001; 16(3): 162-6.	1994		
Netherlands	Hodiamont P, Peer N, Syben N. Epidemiological aspects of psychiatric disorder in a Dutch health area. Psychol Med. 1987; 17(2): 495-505.	1985		
Netherlands	Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganey K, Giel R, an der Heiden W, Holmberg SK, Janca A, Lee PW, León CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin SJ, Varma VK, Walsh D, Wiersma D. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry. 2001; 178: 506-17.	1978-1993		
Netherlands	Centre for Drug Research, University of Amsterdam. Netherlands Licit and Illicit Drug Use 1997.	1997		
Netherlands	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN), ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Netherlands	Centre for Drug Research, University of Amsterdam. Netherlands Licit and Illicit Drug Use in Amsterdam II.	1990, 1994		
Netherlands	Smit F, Monshouwer K, Verdurmen J. Polydrug Use Among Secondary School Students: combinations, prevalences and risk profiles. Drug Educ Prev Polic. 2002; 9(4): 355-65.	1999		
Netherlands	Van Haastrecht HJ, van Ameijden EJ, van den Hoek JA, Mientjes GH, Bax JS, Coutinho RA. Predictors of mortality in the Amsterdam cohort of human immunodeficiency virus (HIV)-positive and HIV-negative drug users. Am J Epidemiol. 1996; 143(4): 380-91.	1985-1993		
Netherlands	Picavet HS, Schouten JS. Physical load in daily life and low back problems in the general population-The MORGEN study. Prev Med. 2000; 31(5): 506-12.	1993-1997		
Netherlands	Gussekloo J, de Craen AJM, Oduber C, van Bostel MPJ, Westendorp RGI. Sensory impairment and cognitive functioning in oldest-old subjects: the Leiden 85+ Study. Am J Geriatr Psychiatry. 2005; 13(9): 781-6. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1997-1999		
Netherlands	Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol. 1998; 116(5): 653-8. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1990-1993		
Netherlands	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1997-1999, 2001, 2005		
Netherlands	Trimbos Institute (Netherlands). Netherlands National Drug Monitor Annual Report 2006.	1997, 2001, 2005		
Netherlands	Romberg-Camps MJL, Hesselink-van de Kruis MAM, Schouten LJ, Dagnelie PC, Limonard CB, Kester ADM, Bos LP, Goedhard J, Hameteman WHA, Wolters FL, Russel MGVM, Stockbrugger RW. Inflammatory Bowel Disease in South Limburg (the Netherlands) 1991-2002: Incidence, diagnostic delay, and seasonal variations in onset of symptoms. J Crohns Colitis. 2009; 3(2): 115-24.	1991-2002	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Netherlands	Romberg-Camps M, Kuiper E, Schouten L, Kester A, Hesselink-van de Krujjs M, Limonard C, Bos R, Goedhard J, Hameeteman W, Wolters F, Russel M, Stockbrigger R, Dagnelie P. Mortality in inflammatory bowel disease in the Netherlands 1991-2002: results of a population-based study: the IBD South-Limburg cohort. <i>Inflamm Bowel Dis</i> . 2010; 16(8): 1397-410.	1991-2006	*	
Netherlands	McDowell RD, Ryan A, Bunting BP, O'Neill SM, Alonso J, Bruffaerts R, de Graaf R, Florescu S, Vilagut G, de Almeida JMC, de Girolamo G, Haro JM, Hinkov H, Kovess-Masfety V, Matschinger H, Tomov T. Mood and anxiety disorders across the adult lifespan: a European perspective. <i>Psychol Med</i> . 2013; 1-16.	2002-2003	*	
Netherlands	WHO Regional Office for Europe (EURO-WHO). Young People's Health in Context. Health Behaviour in School-aged Children (HBSC) Study: International Report from the 2001-2002 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2004.	2001		
Netherlands	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2005		
Netherlands	Dijkstra SC, Brouwer IA, Rooij FJA van, Hofman A, Witteman JCM, Geleijnse JM. Intake of very long chain n-3 fatty acids from fish and the incidence of heart failure: the Rotterdam Study. <i>Eur J Heart Fail</i> . 2009; 11(10): 922-8.	1990-2006		
Netherlands	Monshouwer K, VAN Dorsselaer S, Verdurmen J, Bogt TT, DE Graaf R, Vollebergh W. Cannabis use and mental health in secondary school children. Findings from a Dutch survey. <i>Br J Psychiatry</i> . 2006; 148-53.	2001		
Netherlands	Bouvier-Colle M-H, Mohangoo AD, Gissler M, Novak-Antolic Z, Vutuc C, Szamatulka K, Zeitlin J, Euro-Peristat Scientific Committee. What about the mothers? An analysis of maternal mortality and morbidity in perinatal health surveillance systems in Europe. <i>BJOG</i> . 2012; 119(7): 880-90.	2003-2004	*	
Netherlands	De Jonge A, Mesman JAJM, Manniën J, Zwart JJ, van Dillen J, van Roosmalen J. Severe adverse maternal outcomes among low risk women with planned home versus hospital births in the Netherlands: nationwide cohort study. <i>BMJ</i> . 2013; f3263.	2004-2006	*	
Netherlands	Gaillard R, Bakker R, Steegers EAP, Hofman A, Jaddoe VWV. Maternal age during pregnancy is associated with third trimester blood pressure level: the generation R study. <i>Am J Hypertens</i> . 2011; 24(9): 1046-53.	2002-2006		
Netherlands	Nugteren JJ, Snijder CA, Hofman A, Jaddoe VWV, Steegers EAP, Burdorf A. Work-related maternal risk factors and the risk of pregnancy induced hypertension and preeclampsia during pregnancy. <i>The Generation R Study</i> . <i>PLoS One</i> . 2012; 7(6): e39263.	2002-2006	*	
Netherlands	Timmermans S, Bonsel GJ, Steegers-Theunissen RPM, Mackenbach JP, Steyberg EW, Raat H, Verbrugh HA, Tiemeier HW, Hofman A, Birnie E, Looman CWN, Jaddoe VWV, Steegers EAP. Individual accumulation of heterogeneous risks explains perinatal inequalities within deprived neighbourhoods. <i>Eur J Epidemiol</i> . 2011; 26(2): 165-80.	2002-2006	*	
Netherlands	Wieberink RG, Ikram MA, Hofman A, Koudstaal PJ, Breteler MMB. Trends in stroke incidence rates and stroke risk factors in Rotterdam, the Netherlands from 1990 to 2008. <i>Eur J Epidemiol</i> . 2012; 27(4): 287-95.	1990-1997, 2000-2007	*	
Netherlands	Verweij LM, Van Schoor NM, Deeg DJ, Dekker J, Visser M. Physical activity and incident clinical knee osteoarthritis in older adults. <i>Arthritis Care Res</i> . 2009; 61(2): 152-7.	1992-2006	*	
Netherlands	Kotsopoulos I, de Krom M, Kessels F, Lodder J, Troost J, Twellaar M, van Merode T, Knotterus A. Incidence of epilepsy and predictive factors of epileptic and non-epileptic seizures. <i>Seizure</i> . 2005; 14(3): 175-82.	1998-2000	*	
Netherlands	Breteler M, de la Court A, Meinardi H, Hauser WA, Grobbee D, Hofman A. Prevalence of epilepsy in the elderly: the Rotterdam Study. <i>Epilepsia</i> . 1996; 37(2): 141-7.	1990-1993	*	
Netherlands	Beekman AT, Deeg DJ, van Tilburg T, Smit JH, Hooijer C, van Tilburg W. Major and minor depression in later life: a study of prevalence and risk factors. <i>J Affect Disord</i> . 1995; 36(1-2): 65-75.	1992-1993		
Netherlands	Lépine JP, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). <i>Int Clin Psychopharmacol</i> . 1997; 12(1): 19-29.	1995		
Netherlands	Penninx BW, Geerlings SW, Deeg DJ, van Eijk JT, van Tilburg W, Beekman AT. Minor and major depression and the risk of death in older persons. <i>Arch Gen Psychiatry</i> . 1999; 56(10): 889-95.	1992-1997		
Netherlands	Vinkers DJ, Stek ML, Gussekloo J, Van Der Mast RC, Westendorp RGJ. Does depression in old age increase only cardiovascular mortality? The Leiden 85-plus Study. <i>Int J Geriatr Psychiatry</i> . 2004; 19(9): 852-7.	1997-2002		
Netherlands	De Graaf R, ten Have M, van Gool C, van Dorsselaer S. Prevalence of mental disorders and trends from 1996 to 2009. Results from the Netherlands Mental Health Survey and Incidence Study-2. <i>Soc Psychiatry Psychiatr Epidemiol</i> . 2012; 47(2): 203-13.	2007-2009		
Netherlands	Trimbos Institute (Netherlands). Netherlands Mental Health Survey and Incidence Study 1996.	1996	*	
Netherlands	Verhave JC, Gansevoort RT, Hillege HL, Bakker SJ, De Zeeuw D, de Jong PE; PREVENT Study Group. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. <i>Kidney Int Suppl</i> . 2004; 92(Suppl): S18-21.	1997-2002		
Netherlands	Bijl RV, De Graaf R, Ravelli A, Smit F, Vollebergh WAM, Netherlands Mental Health Survey and Incidence Study. Gender and age-specific first incidence of DSM-III-R psychiatric disorders in the general population. Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). <i>Soc Psychiatry Psychiatr Epidemiol</i> . 2002; 37(8): 372-9.	1997-1998		
Netherlands	Meesters PD, de Haan L, Comijs HC, Stek ML, Smeets-Janssen MMJ, Weeda MR, Eikelenboom P, Smit JH, Beekman ATF. Schizophrenia spectrum disorders in later life: prevalence and distribution of age at onset and sex in a Dutch catchment area. <i>Am J Geriatr Psychiatry</i> . 2012; 20(1): 18-28.	2007-2008	*	
Netherlands	Sutterland AL, Dieleman J, Storosum JG, Voordouw BAC, Kroon J, Veldhuis J, Denys DAJP, de Haan L, Sturkenboom MCJM. Annual incidence rate of schizophrenia and schizophrenia spectrum disorders in a longitudinal population-based cohort study. <i>Soc Psychiatry Psychiatr Epidemiol</i> . 2013; 48(9): 1357-65.	1996-2006	*	
Netherlands	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Netherlands	Michielsens M, Semeijn E, Comijs HC, van de Ven P, Beekman ATF, Deeg DJH, Kooij JJS. Prevalence of attention-deficit hyperactivity disorder in older adults in The Netherlands. <i>Br J Psychiatry</i> . 2012; 201(4): 298-305.	2008-2010	*	
Netherlands	Wieniels NJ, Knuistingh Neven A, Rosendaal FR, Spinoven P, Zitman FG, Assendelft WJJ, Ferrari MD. Chronic frequent headache in the general population: prevalence and associated factors. <i>Cephalalgia</i> . 2006; 26(12): 1434-42.	2002-2003	*	
Netherlands	Boon ME, Holloway PA, Breijer H, Bontekoe TR, Gardnerella, Trichomonas and Candida in cervical smears of 58,904 immigrants participating in the Dutch national cervical screening program. <i>Acta Cytol</i> . 2012; 56(3): 242-6.	1996-2005	*	
Netherlands	Goossens VJ, Schreij G, van der Geest S, Van Leeuwen DM, Baas DC, Bruggeman CA, van der Ven AJ. A delay in CD4 cell response after initiation of highly active antiretroviral therapy is associated with the presence of anti-cytomegalovirus but not with anti-herpes simplex virus antibodies. <i>AIDS</i> . 2002; 16(12): 1682-4.	1999-2001	*	
Netherlands	Keet IP, Lee FK, van Griensven GJ, Lange JM, Nahmias A, Coutinho RA. Herpes simplex virus type 2 and other genital ulcerative infections as a risk factor for HIV-1 acquisition. <i>Gentourin Med</i> . 1990; 66(5): 330-3.	1984-1988	*	
Netherlands	Van Schie PEM, Becher JG, Dalmmeijer AJ, Barkhof F, Van Weissenbruch MM, Vermeulen RJ. Motor testing at 1 year improves the prediction of motor and mental outcome at 2 years after perinatal hypoxic-ischaemic encephalopathy. <i>Dev Med Child Neurol</i> . 2010; 52(1): 54-9.	2000-2002	*	†
Netherlands	Kontio T, Toet MC, Hellström-Westas L, van Handel M, Groenendaal F, Stjerna S, Vanhatalo S, de Vries LS. Early neurophysiology and MRI in predicting neurological outcome at 9-10 years after birth asphyxia. <i>Clin Neurophysiol</i> . 2013; 124(6): 1089-94.	1993-1997	*	†
Netherlands	Ruwaard D, Hirasings RA, Reeser HM, van Buuren S, Bakker K, Heine RJ, Geerdink RA, Bruining GJ, Vaandrager GJ, Verloove-Vanhorick SP. Increasing incidence of type 1 diabetes in The Netherlands. The second nationwide study among children under 20 years of age. <i>Diabetes Care</i> . 1994; 17(6): 599-601.	1988-1990		
Netherlands	Stolk RP, van Splunder IP, Schouten JS, Witteman JC, Hofman A, Grobbee DE. High blood pressure and the incidence of non-insulin dependent diabetes mellitus: findings in a 11.5 year follow-up study in The Netherlands. <i>Eur J Epidemiol</i> . 1993; 9(2): 134-9.	1975-1988		
Netherlands	Vaandrager GJ, Bruining GJ, Veenhof FJ, Drayer NM. Incidence of childhood diabetes in The Netherlands: a decrease from north to south over north-western Europe. <i>Diabetologia</i> . 1984; 27(2): 203-6.	1978-1981		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Netherlands	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Netherlands National Report to the EMCDDA 2006.	1996	*	
Netherlands	Bargagli AM, Hickman M, Davoli M, Perucci CA, Schifano P, Buster M, Brugal T, Vicente J, COSMO European Group. Drug-related mortality and its impact on adult mortality in eight European countries. <i>Eur J Public Health</i> . 2006; 16(2): 198-202.	1996-2002	*	
Netherlands	Buster MC, van Brussel GH, van den Brink W. Estimating the number of opiate users in amsterdam by capture-recapture: the importance of case definition. <i>Eur J Epidemiol</i> . 2001; 17(10): 935-42.	1997	*	
Netherlands	Korf DJ, Reijneveld SA, Toet J. Estimating the number of heroin users: a review of methods and empirical findings from The Netherlands. <i>Int J Addict</i> . 1994; 29(11): 1393-417.	1990	*	
Netherlands	Kraus L, Augustin R, Frischer M, Kümmler P, Uhl A, Wiessing L. Estimating prevalence of problem drug use at national level in countries of the European Union and Norway. <i>Addiction</i> . 2003; 98(4): 471-85.	1999	*	
Netherlands	Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ. The impact of harm-reduction-based methadone treatment on mortality among heroin users. <i>Am J Public Health</i> . 2001; 91(5): 774-80.	1985-1996	*	
Netherlands	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant</i> . 1988; 3(6): 714-27.	1985		
Netherlands	Van Dijk PC, Jager KJ, Stengel B, Grönhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). <i>Kidney Int</i> . 2005; 67(4): 1489-99.	1991-1992, 1999-2000		
Netherlands	Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. <i>Nephrol Dial Transplant</i> . 2003; 18(9): 1824-33.	1990-1991, 1998-1999		
Netherlands	Gansevoort RT, van der Heij B, Stegeman CA, de Charro FT, Nieuwenhuizen MG, de Zeeuw D, de Jong PE. Trends in the incidence of treated end-stage renal failure in The Netherlands: hope for the future? <i>Kidney Int Suppl</i> . 2004; 92: S7-10.	2004		
Netherlands	Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. <i>J Clin Endocrinol Metab</i> . 2008; 93(4): 1408-11.	2005		
Netherlands	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Gilst WH van, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J</i> . 2003; 24(5): 442-63.	2000-2001		
Netherlands	Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M and Boyle P, eds (2007). <i>Cancer Incidence in Five Continents, Vol. IX Periodic Data</i> (electronic version). Lyon, IARC. http://ci5.iarc.fr	1998-2002	*	
Netherlands	Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. <i>Cancer Incidence in Five Continents. Vol. 1 to VIII</i> . Lyon, France, IARC Press, 2005.	1978-1982, 1986-1997	*	
Netherlands	De Bruijn C, van den Brink W, de Graaf R, Vollebregt WAM. The three year course of alcohol use disorders in the general population: DSM-IV, ICD-10 and the Craving Withdrawal Model. <i>Addiction</i> . 2006; 101(3): 385-92.	1996-1999		
Netherlands	Van Koningsveld R, Van Doorn PA, Schmitz PI, Ang CW, Van der Meché FG. Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands. <i>Neurology</i> . 2000; 54(3): 620-5.	1987-1996		†
Netherlands	Consumer Safety Institute (Netherlands). Netherlands Injury Surveillance System 1998. [Unpublished].	1998	*	
Netherlands	Consumer Safety Institute (Netherlands). Netherlands Injury Surveillance System 2006.	2006	*	
Netherlands	Consumer Safety Institute (Netherlands). Netherlands Injury Surveillance System 2007.	2007	*	
Netherlands	Consumer Safety Institute (Netherlands). Netherlands Injury Surveillance System 2008.	2008	*	
Netherlands	Consumer Safety Institute (Netherlands). Netherlands Injury Surveillance System 2009.	2009	*	
Netherlands	Consumer Safety Institute (Netherlands). Netherlands Injury Surveillance System 2010.	2010	*	
Netherlands	Consumer Safety Institute (Netherlands). Netherlands Injury Surveillance System 2011.	2011	*	
Netherlands	Consumer Safety Institute (Netherlands). Netherlands Injury Surveillance System 2012.	2012	*	
Netherlands	Meijer CJ, Calame JJ, de Windt EJ, Risse EK, Bleker OP, Kenemans P, Quint WG, Meddens MJ. Prevalence of Chlamydia trachomatis infection in a population of asymptomatic women in a screening program for cervical cancer. <i>Eur J Clin Microbiol Infect Dis</i> . 1989; 8(2): 127-30.	1989		
Netherlands	Admiraal RJ, Huygen PL. Changes in the aetiology of hearing impairment in deaf-blind pupils and deaf infant pupils at an institute for the deaf. <i>Int J Pediatr Otorhinolaryngol</i> . 2000; 55(2): 133-42.	1986-1987, 1998-1999	*	
Netherlands	Dutch Hospital Data. Netherlands National Medical Registry 1998. [Unpublished].	1998	*	
Netherlands	Dutch Hospital Data. Netherlands National Medical Registry 1999. [Unpublished].	1999	*	
Netherlands	Dutch Hospital Data. Netherlands National Medical Registry 2000. [Unpublished].	2000	*	
Netherlands	Dutch Hospital Data. Netherlands National Medical Registry 2001. [Unpublished].	2001	*	
Netherlands	Dutch Hospital Data. Netherlands National Medical Registry 2002. [Unpublished].	2002	*	
Netherlands	Dutch Hospital Data. Netherlands National Medical Registry 2003. [Unpublished].	2003	*	
Netherlands	Dutch Hospital Data. Netherlands National Medical Registry 2004. [Unpublished].	2004		
Netherlands	Dutch Hospital Data. Netherlands National Medical Registry 2005. [Unpublished].	2005		
Netherlands	Dutch Hospital Data. Netherlands National Medical Registry 2006. [Unpublished].	2006	*	
Netherlands	Dutch Hospital Data. Netherlands National Medical Registry 2007. [Unpublished].	2007	*	
Netherlands	Dutch Hospital Data. Netherlands National Medical Registry 2008. [Unpublished].	2008	*	
Netherlands	Dutch Hospital Data. Netherlands National Medical Registry 2009. [Unpublished].	2009	*	
Netherlands	Dutch Hospital Data. Netherlands National Medical Registry 2010. [Unpublished].	2010	*	
Netherlands	Dutch Hospital Data. Netherlands National Medical Registry 2011. [Unpublished].	2011	*	
Netherlands	Dutch Hospital Data. Netherlands National Medical Registry 2012. [Unpublished].	2012	*	
Netherlands	Ott A, Breteler MM, van Harskamp F, Stijnen T, Hofman A. Incidence and risk of dementia. The Rotterdam Study. <i>Am J Epidemiol</i> . 1998; 147(6): 574-80.	1990-1994		
Netherlands	Heeringa J, van der Kuip DAM, Hofman A, Kors JA, van Herpen G, Stricker BHC, Stijnen T, Lip GYH, Witteman JCM. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. <i>Eur Heart J</i> . 2006; 27(8): 949-53.	1990-1999	*	
Netherlands	Koopman C, Bots ML, van Oeffelen AAM, van Dis I, Verschuren WMM, Engelfriet PM, Capewell S, Vaartjes L. Population trends and inequalities in incidence and short-term outcome of acute myocardial infarction between 1998 and 2007. <i>Int J Cardiol</i> . 2013; 168(2): 993-8.	1998-2007	*	
Netherlands	Gaytant MA, Steegers EAP, van Laere M, Semmekrot BA, Groen J, Weel JF, van der Meijden WI, Boer K, Galama JMD. Seroprevalences of herpes simplex virus type 1 and type 2 among pregnant women in the Netherlands. <i>Sex Transm Dis</i> . 2002; 29(11): 710-4.	1998	*	
Netherlands	Pebody RG, Andrews N, Brown D, Gopal R, De Melker H, François G, Gatcheva N, Hellenbrand W, Jokinen S, Klavs I, Kojouharova M, Kortbeek T, Kriz B, Prosenec K, Roubalova K, Teocharov P, Thierfelder W, Valle M, Van Damme P, Vranckx R. The seroepidemiology of herpes simplex virus type 1 and 2 in Europe. <i>Sex Transm Infect</i> . 2004; 80(3): 185-91.	1996	*	
Netherlands	National Institute for Public Health and the Environment (Netherlands). The National Immunisation Programme in the Netherlands: Developments in 2013. Bilthoven, Netherlands: National Institute for Public Health and the Environment (Netherlands), 2013.	2002-2011	*	
Netherlands	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland: World Health Organization (WHO).	2000-2008	*	
Netherlands	Mulder CJ, Zanen HC. A study of 280 cases of neonatal meningitis in The Netherlands. <i>J Infect</i> . 1984; 9(2): 177-84.	1976-1982		
Netherlands	Oostenbrink R, Maas M, Moons GKM, Moll HA. Sequelae after bacterial meningitis in childhood. <i>Scand J Infect Dis</i> . 2002; 34(5): 379-82.	1988-1998		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Netherlands	De Gans J, van de Beek D. Dexamethasone in Adults with Bacterial Meningitis. <i>N Engl J Med.</i> 2002; 347(20): 1549-56.	1993-2001		†
Netherlands	Jansen AGSC, Rodenburg GD, van der Ende A, van Alphen L, Veenhoven RH, Španjaard L, Sanders EAM, Hak E. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. <i>Clin Infect Dis.</i> 2009; 49(2): e23-29.	2004-2006		
Netherlands	Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJM, Stalman WAB, van Essen GA. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. <i>Fam Pract.</i> 2002; 19(5): 471-5.	1994-1999		†
Netherlands	De Melker H, Berbers G, Hahné S, Rümke H, van den Hof S, de Wit A, Boot H. The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. <i>Vaccine.</i> 2006; 24(18): 3946-52.	1998-2001		
Netherlands	Opstelten W, Van Essen GA, Schellevis F, Verheij TJM, Moons KGM. Gender as an independent risk factor for herpes zoster: a population-based prospective study. <i>Ann Epidemiol.</i> 2006; 16(9): 692-5.	2001		
Netherlands	World Health Organization (WHO). <i>Mental Illness in General Health Care: An International Study.</i> Geneva, Switzerland: World Health Organization (WHO), 1995.	1991-1992		
Netherlands	Bijl RV, van Zessen G, Ravelli A, de Rijk C, Langendoen Y. The Netherlands Mental Health Survey and Incidence Study (NEMESIS): objectives and design. <i>Soc Psychiatry Psychiatr Epidemiol.</i> 1998; 33(12): 581-6.	1996		
Netherlands	Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJA, Wasserman SM, Baker N, Rosser D, Cleland JGF, Ponikowski P. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. <i>Eur Heart J.</i> 2007; 28(18): 2208-16.	1992-1995		
Netherlands	Hooi JD, Kester AD, Stoffers HE, Overdijk MM, van Ree JW, Knotterus JA. Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. <i>Am J Epidemiol.</i> 2001; 153(7): 666-72.	1988-1996		
Netherlands	Feringa HHH, Bax JJ, Hoeks S, van Waning VH, Elhendy A, Karagiannis S, Vidakovic R, Schouten O, Boersma E, Poldermans D. A prognostic risk index for long-term mortality in patients with peripheral arterial disease. <i>Arch Intern Med.</i> 2007; 167(22): 2482-9.	1983-2005		
Netherlands	Vriendt HJ, Van Veen MG, Prins M, Urbanus AT, Boot HJ, Op De Coul ELM. Hepatitis C virus prevalence in The Netherlands: migrants account for most infections. <i>Epidemiol Infect.</i> 2013; 141(6): 1310-7.	2006-2007		
Netherlands	Slavenburg S, Verduyn-Lunel FM, Hermens JT, Melchers WJG, te Morsche RHM, Drenth JPH. Prevalence of hepatitis C in the general population in the Netherlands. <i>Neth J Med.</i> 2008; 66(1): 13-7.	2006		
Netherlands	Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, Büchele G, Clausen M, Cookson WOC, von Mutius E, Strachan DP, Williams HC, ISAAC Phase Two Study Group. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. <i>J Allergy Clin Immunol.</i> 2008; 121(1): 141-147.	2005-2007	*	
Netherlands	Lammers MW, Hekster YA, Keyser A, Meinardi H, Renier WO, Herings RMC. Use of antiepileptic drugs in a community-dwelling Dutch population. <i>Neurology.</i> 1996; 46(1): 62-7.	1991-1992	*	
Netherlands	Russel MG, Dorant E, Volovics A, Brummer RJ, Pop P, Muris JW, Bos LP, Limonaard CB, Stockbrügger RW. High incidence of inflammatory bowel disease in The Netherlands: results of a prospective study. The South Limburg IBD Study Group. <i>Dis Colon Rectum.</i> 1998; 41(1): 33-40.	1991-1994		
Netherlands	Trichopoulos D, Bania C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overvad K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PHM, Lund E, Quirós JR, González CA, Sánchez Pérez M-J, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu L, Chuang S-C, Murphy N, Boffetta P, Trichopoulou A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. <i>J Natl Cancer Inst.</i> 2011; 103(22): 1686-95.	1992-2006	*	
Netherlands	Zaaijer HL, Yin MF, Lelie PN. Seroprevalence of hepatitis E in The Netherlands. <i>Lancet.</i> 1992; 340(8820): 681.	1989-1991	*	
Netherlands	Herremans M, Vennema H, Bakker J, van der Veer B, Duizer E, Benne CA, Waar K, Hendriks B, Schneberger P, Blaauw G, Kooiman M, Koopmans MPG. Swine-like hepatitis E viruses are a cause of unexplained hepatitis in The Netherlands. <i>J Viral Hepat.</i> 2007; 14(2): 140-6.	2002-2004	*	
Netherlands	Zaaijer HL, Mauser-Bunschoten EP, ten Veen JH, Kapprell HP, Kok M, van den Berg HM, Lelie PN. Hepatitis E virus antibodies among patients with hemophilia, blood donors, and hepatitis patients. <i>J Med Virol.</i> 1995; 46(3): 244-6.	1992-1994	*	
Netherlands	Termorshuizen F, Dorigo-Zetsma JW, de Melker HE, van den Hof S, Conyn-Van Spaendonck MA. The prevalence of antibodies to hepatitis A virus and its determinants in The Netherlands: a population-based survey. <i>Epidemiol Infect.</i> 2000; 124(3): 459-66.	1995-1996		
Netherlands	Richardus JH, Vos D, Veldhuijzen IK, Groen J. Seroprevalence of hepatitis A virus antibodies in Turkish and Moroccan children in Rotterdam. <i>J Med Virol.</i> 2004; 72(2): 197-202.	2001		
Netherlands	Veldhuijzen IK, van Driel HF, Vos D, de Zwart O, van Doornum GJJ, de Man RA, Richardus JH. Viral hepatitis in a multi-ethnic neighborhood in the Netherlands: results of a community-based study in a low prevalence country. <i>Int J Infect Dis.</i> 2009; 13(1): e9-e13.	2004		
Netherlands	Baaten GGG, Sonder GJB, Dukers NHTM, Coutinho RA, van den Hoek JAR. Population-based study on the seroprevalence of hepatitis A, B, and C virus infection in Amsterdam, 2004. <i>J Med Virol.</i> 2007; 79(12): 1802-10.	2004		
Netherlands	Koek HL, de Bruin A, Gast A, Gevers E, Kardaun JWPF, Reitsma JB, Grobbee DE, Bots ML. Incidence of first acute myocardial infarction in the Netherlands. <i>Neth J Med.</i> 2007; 65(11): 434-41.	2000		
Netherlands	Koek HL, Kardaun JWPF, Gevers E, Bruin A, Reitsma JB, Grobbee DE, Bots ML. Acute myocardial infarction incidence and hospital mortality: routinely collected national data versus linkage of national registers. <i>Eur J Epidemiol.</i> 2007; 22(11): 755-62.	1995		
Netherlands	Grosheide PM, Wladimiroff JW, Heijink RA, Mazel JA, Christiaens GC, Nuijten AS, Schalm SW. Proposal for routine antenatal screening at 14 weeks for hepatitis B surface antigen. Dutch Study Group on Prevention of Neonatal Hepatitis. <i>BMJ.</i> 1995; 311(7014): 1197-9.	1982-1989		
Netherlands	Molijn MH, van der Linden JM, Ko LK, Gorgels J, Hop W, van Rhenen DJ. Risk factors and anti-HBe reactivity among first time blood donors. <i>Vox Sang.</i> 1997; 72(4): 207-10.	1992-1995		
Netherlands	Van Doornum GJJ, Hooykaas C, Cuypers MT, Van Der Linden MMD, Coutinho RA. Prevalence of hepatitis C virus infections among heterosexuals with multiple partners. <i>J Med Virol.</i> 1991; 35(1): 22-7.	1987-1989		
Netherlands	Van Steenberghe JE, Leentvaar-Kuijpers A, Baayen D, Dukers HT, van Doornum GJ, van den Hoek JA, Coutinho RA. Evaluation of the hepatitis B antenatal screening and neonatal immunization program in Amsterdam, 1993-1998. <i>Vaccine.</i> 2001; 20(1-2): 7-11.	1993-1998		
Netherlands	Waar K, Herremans MMPT, Vennema H, Koopmans MPG, Benne CA. Hepatitis E is a cause of unexplained hepatitis in The Netherlands. <i>J Clin Virol.</i> 2005; 33(2): 145-9.	2000-2002		
Netherlands	Flohil SC, de Vries E, Neumann HA, Coebergh JW, Nijsten T. Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. <i>Acta Derm Venereol.</i> 2011; 91(1): 24-30.	2005	*	
Netherlands	Flohr C, Weinmayr G, Weiland SK, Addo-Yobo E, Annesi-Maesano I, Björkstén B, Bråbäck L, Büchele G, Chico M, Cooper P, Clausen M, El Sharif N, Martinez Gimeno A, Mathur RS, von Mutius E, Morales Suarez-Varela M, Pearce N, Svabe V, Wong GWK, Yu M, Zhong NS, Williams HC, ISAAC Phase Two Study Group. How well do questionnaires perform compared with physical examination in detecting flexural eczema? Findings from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. <i>Br J Dermatol.</i> 2009; 161(4): 846-53.	2005-2007	*	
Netherlands	Ott A, Breteler MM, van Harskamp F, Claus JJ, van der Cammen TJ, Grobbee DE, Hofman A. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. <i>BMJ.</i> 1995; 310(6985): 970-3.	1990-1991		
Netherlands	Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Barré J, André C. The impact of headache in Europe: principal results of the Eurolight project. <i>J Headache Pain.</i> 2014; 15(31). [Unpublished data].	2008	*	
Netherlands	Anthony, S. The Dutch perinatal and neonatal registers : applications in perinatal epidemiology. [Doctoral thesis]. Leiden, Netherlands: Leiden University; 2005. 201.	1995-1996		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Netherlands	Zeitlan J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT; 2008. Available from: http://www.perinataleaudit.nl/downloads/bestand/649/peristat-ii-2008-	2004		†
Netherlands	Stoelhorst GMSJ, Rijken M, Martens SE, Brand R, Ouden AL den, Wit J-M, Veen S. Changes in Neonatology: Comparison of Two Cohorts of Very Preterm Infants (Gestational Age <32 Weeks): The Project on Preterm and Small for Gestational Age Infants 1983 and The Leiden Follow-Up Project on Prematurity 1996-1997. <i>Pediatrics</i> . 2005 Feb 1;115(2):396-405.	1983		†
Netherlands	Netherlands - Dutch Renal Registry (RENINE) Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Netherlands	Netherlands - Dutch Renal Registry (RENINE) Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Netherlands	Netherlands - Dutch Renal Registry (RENINE) Renal Replacement Therapy Data 1997 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 1998. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2003.	1997	*	
Netherlands	Netherlands Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Netherlands	Netherlands - Northern Netherlands EUROCAT Data 2001 - ICBDSR as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
Netherlands	Netherlands - Northern Netherlands EUROCAT Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
Netherlands	Netherlands - Northern Netherlands EUROCAT Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Netherlands	Netherlands - Northern Netherlands EUROCAT Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
Netherlands	European Surveillance of Congenital Anomalies (EUROCAT). Netherlands EUROCAT Prevalence Tables. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	1981-2011		
Netherlands	Netherlands - Northern Netherlands EUROCAT Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT). International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Netherlands	Netherlands - Northern Netherlands EUROCAT Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
Netherlands	Netherlands - Northern Netherlands EUROCAT Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Netherlands	Netherlands - Northern Netherlands EUROCAT Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
New Zealand	Market Research Limited (MRL), Population Studies Centre, University of Waikato (New Zealand), United Nations Economic Commission for Europe (UNECE). New Zealand Fertility and Family Survey 1995. Geneva, Switzerland: United Nations Economic Commission for Europe (UNECE).	1995		
New Zealand	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-1989, 1992, 1996-2000		
New Zealand	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
New Zealand	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
New Zealand	Gray MA, Crampton P, Weinstein P, Nacey JN. Differences in prostate disease symptoms and visits to the general practitioner among three ethnic groups in New Zealand. <i>BJU Int</i> . 2004; 94(1): 96-100.	2001-2002		
New Zealand	Paterson JE, Carter S, Wallace J, Ahmad Z, Garrett N, Silva PA. Pacific Islands families study: the prevalence of chronic middle ear disease in 2-year-old Pacific children living in New Zealand. <i>Int J Pediatr Otorhinolaryngol</i> . 2006; 70(10): 1771-8.	2000-2002		
New Zealand	Feigin V, Carter K, Hackett M, Barber PA, McNaughton H, Dyall L, Chen M, Anderson C. Ethnic disparities in incidence of stroke subtypes: Auckland Regional Community Stroke Study, 2002-2003. <i>Lancet Neurol</i> . 2006; 5(2): 130-9.	2002-2003		
New Zealand	Anderson CS, Carter KN, Hackett ML, Feigin V, Barber PA, Broad JB, Bonita R. Trends in Stroke Incidence in Auckland, New Zealand, During 1981 to 2003. <i>Stroke</i> . 2005; 36(10): 2087-93.	1991-1992, 2002-2003		
New Zealand	Bonita R, Broad JB, Beaglehole R. Changes in stroke incidence and case-fatality in Auckland, New Zealand, 1981-91. <i>Lancet</i> . 1993; 342(8885): 1470-3.	1981-1991		
New Zealand	Lello J, Pearl A, Arroll B, Yallop J, Birchall NM. Prevalence of acne vulgaris in Auckland senior high school students. <i>N Z Med J</i> . 1995; 108(1004): 287-9.	1993		
New Zealand	Purvis D, Robinson E, Watson P. Acne prevalence in secondary school students and their perceived difficulty in accessing acne treatment. <i>N Z Med J</i> . 2004; 117(1200): 1018.	2001		
New Zealand	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol</i> . 2008; 121(4): 947-954.	1993, 2001-2003		
New Zealand	Demyttenaere K, Bruffaerts R, Lee S, Posada-Villa J, Kovess V, Angermeyer MC, Levinson D, de Girolamo G, Nakane H, Mneimneh Z, Lara C, de Graaf R, Scott KM, Gureje O, Stein DJ, Haro JM, Bromet EJ, Kessler RC, Alonso J, Von Korff M. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. <i>Pain</i> . 2007; 129(3): 332-42.	2003-2004		
New Zealand	Wilkinson T. Haemoglobinopathies in Australia and New Zealand. <i>Hemoglobin</i> . 1981; 5(5): 525-30.	1977-1980		
New Zealand	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998-2007, 2009		
New Zealand	Klemp P, Stansfield SA, Castle B, Robertson MC. Gout is on the increase in New Zealand. <i>Ann Rheum Dis</i> . 1997; 56(1): 22-6.	1994		
New Zealand	Wigley RD, Prior IA, Salmond C, Stanley D, Pinfold B. Rheumatic complaints in Tokelau. I. Migrants resident in New Zealand. <i>The Tokelau Island migrant study</i> . <i>Rheumatol Int</i> . 1987; 7(2): 53-9.	1980-1982		
New Zealand	Ministry of Health (New Zealand), National Research Bureau Ltd (New Zealand). New Zealand Health Survey 2006-2007.	2006-2007		
New Zealand	Chancellor AM, Addidde M, Dawson K. Multiple sclerosis is more prevalent in northern New Zealand than previously reported. <i>Intern Med J</i> . 2003; 33(3): 79-83.	2001		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
New Zealand	Miller DH, Hornabrook RW, Purdie G. The natural history of multiple sclerosis: a regional study with some longitudinal data. <i>J Neurol Neurosurg Psychiatry</i> . 1992;55(5): 341-6.	1968-1983		
New Zealand	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J</i> . 1998; 12(2): 315-35.	1993-1995		
New Zealand	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	1998		
New Zealand	Sears MR, Greene JM, Willan AR, Wiecek EM, Taylor DR, Flannery EM, Cowan JO, Herbison GP, Silva PA, Poulton R. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. <i>N Engl J Med</i> . 2003; 349(15): 1414-1422.	1987, 1999		
New Zealand	Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart J-A. The global burden of headache: a documentation of headache prevalence and disability worldwide. <i>Cephalalgia</i> . 2007; 27(3): 193-210.	1990		
New Zealand	Shirtcliffe P, Marsh S, Travers J, Weatherall M, Beasley R. Childhood asthma and GOLD-defined chronic obstructive pulmonary disease. <i>Intern Med J</i> . 2012; 42(1): 83-8.	2003-2004	*	
New Zealand	Haisman-Welsh RJ, Thomson WM. Changes in periodontitis prevalence over two decades in New Zealand: evidence from the 1988 and 2009 national surveys. <i>N Z Dent J</i> . 2012; 108(4): 134-8.	1988, 2009	*	
New Zealand	Foster Page LA, Thomson WM. Caries prevalence, severity, and 3-year increment, and their impact upon New Zealand adolescents' oral-health-related quality of life. <i>J Public Health Dent</i> . 2012; 72(4): 287-94.	2003, 2006	*	
New Zealand	Page LAF, Thomson WM. Dental caries in Taranaki adolescents: a cohort study. <i>N Z Dent J</i> . 2011; 107(3): 91-6.	2003-2006	*	
New Zealand	Shearer DM, Thomson WM, Caspi A, Moffitt TE, Broadbent JM, Poulton R. Family history and oral health: findings from the Dunedin Study. <i>Community Dent Oral Epidemiol</i> . 2012; 40(2): 105-15.	2004-2005	*	
New Zealand	Jackson G, Wright C, Thornley S, Taylor WJ, Te Karu L, Gow PJ, Arroll B, Gribben B, Dalbeth N, Winnard D. Potential unmet need for gout diagnosis and treatment: capture-recapture analysis of a national administrative dataset. <i>Rheumatology</i> . 2012; 51(10): 1820-4.	2009	*	
New Zealand	Gribben B, Salkeld LJ, Hoare S, Jones HF. The incidence of acute otitis media in New Zealand children under five years of age in the primary care setting. <i>J Prim Health Care</i> . 2012; 4(3): 205-12.	2008-2009	*	
New Zealand	Child N, Crosson MC, Rahnama F, Anderson NE. A retrospective review of acute encephalitis in adults in Auckland over a five-year period (2005-2009). <i>J Clin Neurosci</i> . 2012; 19(11): 1483-5.	2005-2009	*	
New Zealand	Widanarko B, Legg S, Stevenson M, Devereux J, Eng A, y Mannetje A, Cheng S, Pearce N. Prevalence and work-related risk factors for reduced activities and absenteeism due to low back symptoms. <i>Arch Dis Child</i> . 2012; 43(4): 727-37.	2010	*	
New Zealand	Accident Compensation Corporation (New Zealand), CBG Health Research Ltd., Defence Dental Services of the New Zealand Defence Force, Ministry of Health (New Zealand), New Zealand Dental Association. <i>New Zealand Oral Health Survey 2009</i> .	2009		
New Zealand	Chen MS, Hunter P. Oral health and quality of life in New Zealand: a social perspective. <i>Soc Sci Med</i> . 1996; 43(8): 1213-22.	1988		
New Zealand	Broadbent JM, Thomson WM, Poulton R. Progression of dental caries and tooth loss between the third and fourth decades of life: a birth cohort study. <i>Caries Res</i> . 2006; 40(6): 459-65.	1998-2004		
New Zealand	Kanagaratnam S, Schluter P, Durward C, Mahood R, Mackay T. Enamel defects and dental caries in 9-year-old children living in fluoridated and nonfluoridated areas of Auckland, New Zealand. <i>Community Dent Oral Epidemiol</i> . 2009; 37(3): 250-9.	2007		
New Zealand	Schluter PJ, Kanagaratnam S, Durward CS, Mahood R. Prevalence of enamel defects and dental caries among 9-year-old Auckland children. <i>N Z Dent J</i> . 2008; 104(4): 145-52.	2006		
New Zealand	Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). <i>Australia and New Zealand Dialysis and Transplant Registry Annual Report 2009</i> . Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), 2009.	2009		
New Zealand	Wells JE, Browne MAO, Scott KM, McGee MA, Baxter J, Kokaua J, New Zealand Mental Health Survey Research Team. Prevalence, interference with life and severity of 12 month DSM-IV disorders in Te Rau Hinengaro: the New Zealand Mental Health Survey. <i>Aust N Z J Psychiatry</i> . 2006; 40(10): 845-54.	2003-2004		
New Zealand	Anderson JC, Williams S, McGee R, Silva PA. DSM-III disorders in preadolescent children. Prevalence in a large sample from the general population. <i>Arch Gen Psychiatry</i> . 1987; 44(1): 69-76.	1983-1984		
New Zealand	Fergusson DM HL, Lynskey MT. Prevalence and comorbidity of DSM-III-R diagnoses in a birth cohort of 15 year olds. <i>J Am Acad Child Adolesc Psychiatry</i> . 1993; 32(6): 1127-34.	1992		
New Zealand	Oakley-Browne MA JP, Wells JE, Bushnell JA, Homblow AR. Christchurch Psychiatric Epidemiology Study, Part II: Six month and other period prevalences of specific psychiatric disorders. <i>Aust N Z J Psychiatry</i> . 1989; 23(3): 327-40.	1986		
New Zealand	Poulton R, Moffitt TE, Harrington H, Milne BJ, Caspi A. Persistence and perceived consequences of cannabis use and dependence among young adults: implications for policy. <i>N Z Med J</i> . 2001; 114(1145): 544-7.	1993, 1996, 2000		
New Zealand	Feehan M MR, Raja SN, Williams SM. DSM-III-R disorders in New Zealand 18-year-olds. <i>Aust N Z J Psychiatry</i> . 1994; 28(1): 87-99.	1990-1991		
New Zealand	McGee R, Feehan M, Williams S, Partridge F, Silva PA, Kelly J. DSM-III Disorders in a Large Sample of Adolescents. <i>J Am Acad Child Adolesc Psychiatry</i> . 1990; 29(4): 611-9.	1987-1988		
New Zealand	de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Kunzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P, European Community Respiratory Health Survey Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. <i>Thorax</i> . 2004; 59(2): 120-125.	1991-1993		
New Zealand	Shirtcliffe P, Weatherall M, Marsh S, Travers J, Hansell A, McNaughton A, Aldington S, Muellerova H, Beasley R. COPD prevalence in a random population survey: a matter of definition. <i>Eur Respir J</i> . 2007; 30(2): 232-9.	2003-2004		
New Zealand	Paulin JM, Waal-Manning HJ, Simpson FO, Knight RG. The prevalence of headache in a small New Zealand town. <i>Headache</i> . 1985; 25(3): 147-51.	1981		
New Zealand	Thomson AN, White GE, West R. The prevalence of bad headaches including migraine in a multiethnic community. <i>N Z Med J</i> . 1993; 106(967): 477-80.	1990		
New Zealand	Bonita R, Solomon N, Broad JB. Prevalence of Stroke and Stroke-Related Disability: Estimates From the Auckland Stroke Studies. <i>Stroke</i> . 1997; 28(10): 1898-902.	1991-1992		
New Zealand	Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). <i>Australia and New Zealand Dialysis and Transplant Registry Annual Report 2005</i> . Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), 2005.	2005		
New Zealand	Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). <i>Australia and New Zealand Dialysis and Transplant Registry Annual Report 2000</i> . Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), 2001.	2000		
New Zealand	United States Renal Data System Coordinating Center. <i>USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States</i> . Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2001-2005		
New Zealand	Raja SN, Feehan M, Stanton WR, McGee R. Prevalence and correlates of the premenstrual syndrome in adolescence. <i>J Am Acad Child Adolesc Psychiatry</i> . 1992; 31(5): 783-9.	1988		
New Zealand	United States Renal Data System Coordinating Center. <i>USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States</i> . Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2000		
New Zealand	Baker M, Ortega-Benito J, Garret N, Bronthead C, Leslie K, MacDonald J, McNicholas A. Prevalence and risk factors for Chlamydia trachomatis infection in female New Zealand university students. <i>N Z Med J</i> . 2005; 118(1220): U1607.	2003		
New Zealand	Caradoc-Davies TH, Weatherall M, Dixon GS, Caradoc-Davies G, Hantz P. Is the prevalence of Parkinson's disease in New Zealand really changing? <i>Acta Neurol Scand</i> . 1992; 86(1): 40-4.	2005		
New Zealand	Laslett M, Crothers C, Beattie P, Cregren L, Moses A. The frequency and incidence of low back pain/sciatica in an urban population. <i>N Z Med J</i> . 1991; 104(921): 424-6.	1987-1988		
New Zealand	Du J, Johnston R, Rice M. Temporal trends of acute nephrolithiasis in Auckland, New Zealand. <i>N Z Med J</i> . 2009; 122(1299): 13-20.	1997-2007		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
New Zealand	Alcohol and Public Health Research Unit, University of Auckland (New Zealand). Drug Use in New Zealand: National Surveys Comparison 1998 and 2001. Auckland, New Zealand: Alcohol and Public Health Research Unit, University of Auckland (New Zealand), 2002.	1998, 2001		
New Zealand	Wilkins C, Sweetsur P. Trends in population drug use in New Zealand: findings from national household surveying of drug use in 1998, 2001, 2003, and 2006. <i>N Z Med J</i> . 2008; 121(1274): 61-71.	2003, 2006	*	
New Zealand	Wasywich CA, Gamble GD, Whalley GA, Doughty RN. Understanding changing patterns of survival and hospitalization for heart failure over two decades in New Zealand: utility of "days alive and out of hospital" from epidemiological data. <i>Eur J Heart Fail</i> . 2010; 12(5): 462-8.	1988-2008		
New Zealand	Coggan CA, Disley B, Patterson P, Norton R. Risk-taking behaviours in a sample of New Zealand adolescents. <i>Aust N Z J Public Health</i> . 1997; 21(5): 455-61.	1995		
New Zealand	Anderson NH, Sadler LC, Stewart AW, Fyfe EM, McCowan LME. Ethnicity, body mass index and risk of pre-eclampsia in a multiethnic New Zealand population. <i>Aust N Z J Obstet Gynaecol</i> . 2012; 52(6): 552-8.	2006-2009	*	
New Zealand	North RA, McCowan LME, Dekker GA, Poston L, Chan EHY, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. <i>BMJ</i> . 2011; d1875.	2004-2008	*	
New Zealand	Smits LJM, North RA, Kenny LC, Myers J, Dekker GA, McCowan LME. Patterns of vaginal bleeding during the first 20 weeks of pregnancy and risk of pre-eclampsia in nulliparous women: results from the SCOPE study. <i>Acta Obstet Gynecol Scand</i> . 2012; 91(11): 1331-8.	2004-2008	*	
New Zealand	Irwin J, Wright P, Reeve P. Temporal trends and clinical characteristics of spontaneous intracerebral haemorrhage in the Waikato region of New Zealand: a hospital-based analysis. <i>N Z Med J</i> . 2011; 124(1345): 16-25.	1999-2008	*	
New Zealand	Kashani JH, McGeer RO, Clarkson SE, Anderson JC, Walton LA, Williams S, Silva PA, Robins AJ, Cytryn L, McKnew DH. Depression in a sample of 9-year-old children, Prevalence and associated characteristics. <i>Arch Gen Psychiatry</i> . 1983; 40(11): 1217-23.	1981-1982		
New Zealand	Fergusson DM, Horwood LJ. The Christchurch Health and Development Study: review of findings on child and adolescent mental health. <i>Aust N Z J Psychiatry</i> . 2001; 35(3): 287-96.	1995		
New Zealand	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
New Zealand	Ekeroma AJ, Pandit L, Bartley C, Ikenasio-Thorpe B, Thompson JMD. Screening for sexually transmitted infections in pregnancy at Middlemore Hospital, 2009. <i>N Z Med J</i> . 2012; 125(1359): 23-9.	2009	*	
New Zealand	Eberhart-Phillips JE, Dickson NP, Paul C, Herbison GP, Taylor J, Cunningham AL. Rising incidence and prevalence of herpes simplex type 2 infection in a cohort of 26 year old New Zealanders. <i>Sex Transm Infect</i> . 2001; 77(5): 353-7.	1993-1999	*	
New Zealand	West CR, Harding JE, Knight DB, Battin MR. Demographic characteristics and clinical course in infants with moderate or severe neonatal encephalopathy. <i>Aust N Z J Obstet Gynaecol</i> . 2005; 45(2): 151-4.	1997-2000	*	†
New Zealand	Battin MR, Dezoete JA, Gunn TR, Gluckman PD, Gunn AJ. Neurodevelopmental outcome of infants treated with head cooling and mild hypothermia after perinatal asphyxia. <i>Pediatrics</i> . 2001; 107(3): 480-4.	1997-1998		†
New Zealand	Wilkins C, Pledger M, Bhatta K, Casswell S. Patterns of amphetamine use in New Zealand: findings from the 2001 National Drug Survey. <i>N Z Med J</i> . 2004; 117(1190): U796.	2001	*	
New Zealand	Derraik JGB, Reed PW, Jefferies C, Cutfield SW, Hofman PL, Cutfield WS. Increasing incidence and age at diagnosis among children with type 1 diabetes mellitus over a 20-year period in Auckland (New Zealand). <i>PLoS One</i> . 2012; 7(2): e32640.	1990-2009		
New Zealand	Jefferies C, Carter P, Reed PW, Cutfield W, Mout F, Hofman PL, Gunn AJ. The incidence, clinical features, and treatment of type 2 diabetes in children <15 yr in a population-based cohort from Auckland, New Zealand, 1995-2007. <i>Pediatr Diabetes</i> . 2012; 13(4): 294-300.	1995, 2007		
New Zealand	Scott RS, Brown LJ. Prevalence and incidence of insulin-treated diabetes mellitus in adults in Canterbury, New Zealand. <i>Diabet Med</i> . 1991; 8(5): 443-7.	1981-1986		
New Zealand	Willis JA, Scott RS, Darlow BA. Prospective incidence study of diabetes mellitus in New Zealand children aged 0 to 14 years. <i>Diabetologia</i> . 2005; 48(11): 2442-3.			
New Zealand	Sullivan PF, Bulik CM, Fear JL, Pickering A. Outcome of anorexia nervosa: a case-control study. <i>Am J Psychiatry</i> . 1998; 155(7): 939-46.	1981-1996	*	
New Zealand	Coggan C, Hooper R, Adams B. Self-reported injury rates in New Zealand. <i>N Z Med J</i> . 2002; 115(61): U167.	2001	*	
New Zealand	Nixon AD, Buchanan JG. Survey for erythrocyte glucose-6-phosphate dehydrogenase deficiency in Polynesians. <i>Am J Hum Genet</i> . 1969; 21(3): 305-9.	1967-1969		
New Zealand	McDonald SP, Russ GR, Kerr PG, Collins JF. Australia and New Zealand Dialysis and Transplant Registry. ESRD in Australia and New Zealand at the end of the millennium: a report from the ANZDATA registry. <i>Am J Kidney Dis</i> . 2002; 40(6): 1122-31.	2000		
New Zealand	Wells JE, Walker ND. Mortality in a follow up study of 616 alcoholics admitted to an inpatient alcoholism clinic 1972-76. <i>N Z Med J</i> . 1990; 103(882): 1-3.	1972-1983		
New Zealand	Leversha AM, Marks RE. The prevalence of fetal alcohol syndrome in New Zealand. <i>N Z Med J</i> . 1995; 108(1013): 502-5.	1993	*	
New Zealand	Institute of Environmental Science & Research Limited (New Zealand). New Zealand Notifiable and Other Diseases Annual Surveillance Report 2009. Wellington, New Zealand: Institute of Environmental Science & Research Limited (New Zealand), 2010.	2009		
New Zealand	Webb RH, Wilson NJ, Lennon DR, Wilson EM, Nicholson RW, Gentles TL, O'Donnell CP, Stirling JW, Zeng I, Trenholme AA. Optimising echocardiographic screening for rheumatic heart disease in New Zealand: not all valve disease is rheumatic. <i>Cardiol Young</i> . 2011; 21(4): 436-43.	2008-2010		
New Zealand	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec</i> . 2005; 80(13): 118-24.	2003	*	
New Zealand	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec</i> . 2005; 80(34): 289-95.	2004	*	
New Zealand	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec</i> . 2012; 87(34): 317-28.	2011	*	
New Zealand	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec</i> . 2013; 88(35): 365-79.	2012	*	
New Zealand	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec</i> . 2011; 86(36): 389-99.	2010	*	
New Zealand	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1994; 69(20): 145-51.	1993	*	
New Zealand	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland: World Health Organization (WHO).	2001-2005	*	
New Zealand	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2000.	2000		
New Zealand	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2001.	2001		
New Zealand	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2002.	2002		
New Zealand	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2003.	2003		
New Zealand	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2004.	2004		
New Zealand	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2008.	2008		
New Zealand	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2009.	2009		
New Zealand	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2010.	2010		
New Zealand	Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). Australia and New Zealand Dialysis and Transplant Registry 1990. [Unpublished].	1990		
New Zealand	Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). Australia and New Zealand Dialysis and Transplant Registry Data 1995. [Unpublished].	1995		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
New Zealand	Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). Australia and New Zealand Dialysis and Transplant Registry Annual Report 2011. Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), 2011.	2010	*	
New Zealand	Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). Australia and New Zealand Dialysis and Transplant Registry Annual Report 2012. Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), 2012.	2010-2011	*	
New Zealand	Thomson WM, Shearer DM, Broadbent JM, Foster Page LA, Poulton R. The natural history of periodontal attachment loss during the third and fourth decades of life. <i>J Clin Periodontol</i> . 2013; 40(7): 672-80.	1998-1999, 2004-2005, 2010-2011	*	
New Zealand	Broadbent JM, Page LAF, Thomson WM, Poulton R. Permanent dentition caries through the first half of life. <i>Br Dent J</i> . 2013; 215(7): E12.	1981-1982, 1987-1988, 1990-1991, 1998-1999, 2004-2005, 2010-2012	*	
New Zealand	Gowda S S, Thomson W, Foster Page LA, Croucher NA. Dental caries experience of children in Northland/Te Tai Tokerau. <i>N Z Dent J</i> . 2009; 105(4): 116-20.	2006-2007	*	
New Zealand	Mackay TD, Thomson WM. Enamel defects and dental caries among Southland children. <i>N Z Dent J</i> . 2005; 101(2): 35-43.	2002	*	
New Zealand	Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, Büchele G, Clausen M, Cookson WOC, von Mutius E, Strachan DP, Williams HC, ISAAC Phase Two Study Group. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. <i>J Allergy Clin Immunol</i> . 2008; 121(1): 141-147.	2005-2007	*	
New Zealand	Yap J, Wesley A, Mouat S, Chin S. Paediatric inflammatory bowel disease in New Zealand. <i>N Z Med J</i> . 2008; 121(1283): 19-34.	2002-2003		
New Zealand	Gearry RB, Richardson A, Frampton CMA, Collett JA, Burt MJ, Chapman BA, Barclay ML. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. <i>Inflamm Bowel Dis</i> . 2006; 12(10): 936-43.	2004-2005		†
New Zealand	Brokenshire E, Plank LD, Gillanders LK, McIlroy K, Parry BR. Adult total parenteral nutrition at Auckland City Hospital: a 6-year review. <i>N Z Med J</i> . 2009; 122(1297): 17-24.	1998-2003		
New Zealand	Austin FJ, Maguire T, Jennings LC, MacDiarmid RD. The prevalence of antibodies to hepatitis A and B viruses in Port Chalmers residents. <i>N Z Med J</i> . 1982; 95(701): 72-3.	1973-1975		
New Zealand	Tobias MI, Miller J, Mushahwar IK. Hepatitis A infection in New Zealand children. <i>N Z Med J</i> . 1986; 99(805): 488-90.	1978-1979		
New Zealand	Lucas CR, Milne A, Hopkirk N. Kawerau revisited: hepatitis A and B seroprevalence in 1984 and 1993. <i>N Z Med J</i> . 1994; 107(981): 266-8.	1984, 1993		
New Zealand	Tobias MI, Miller JA, Clements CJ, Patel AC. Hepatitis B in New Zealand children: the 1985 national immunisation survey. <i>N Z Med J</i> . 1987; 100(821): 203-6.	1985		
New Zealand	Chapman BA, Burt MJ, Frampton CM, Collett JA, Yeo KH, Wilkinson ID, Cook HB, Barclay MJ, Ross AG, George PM. The prevalence of viral hepatitis (HAV, HBV and HCV) in the Christchurch community. <i>N Z Med J</i> . 2000; 113(1118): 394-6.	1996, 1998		
New Zealand	Beaglehole R, Bonita R, Jackson R, Stewart A, Sharpe N, Fraser GE. Trends in Coronary Heart Disease Event Rates in New Zealand. <i>Am J Epidemiol</i> . 1984; 120(2): 225-35.	1981		
New Zealand	National Public Health Institute (Finland), World Health Organization (WHO). MONICA Coronary Event Registration Data Book 1980-1995. Geneva, Switzerland: World Health Organization (WHO), 2000.	1980-1995		
New Zealand	Gibbons S, Faed JM, Fong R, Pullon HW, Corbett GM, Woodfield G. Seroprevalence of hepatitis C antibody in New Zealand blood donors. <i>N Z Med J</i> . 1990; 103(899): 490.	1990		
New Zealand	Milne A, Allwood GK, Moyes CD, Pearce NE, Newell K. A seroepidemiological study of the prevalence of hepatitis B infections in a hyperendemic New Zealand community. <i>Int J Epidemiol</i> . 1987; 16(1): 84-90.	1985		
New Zealand	Robinson T, Bullen C, Humphries W, Hornell J, Moyes C. The New Zealand Hepatitis B Screening Programme: screening coverage and prevalence of chronic hepatitis B infection. <i>N Z Med J</i> . 2005; 118(1211): U1345.	1999-2002		
New Zealand	Flohr C, Weinmayr G, Weiland SK, Addo-Yobo E, Annesi-Maesano I, Björkstén B, Bråbäck L, Büchele G, Chico M, Cooper P, Clausen M, El Sharif N, Martínez Gimeno A, Mathur RS, von Mutius E, Morales Suarez-Varela M, Pearce N, Svabe V, Wong GWK, Yu M, Zhong NS, Williams HC, ISAAC Phase Two Study Group. How well do questionnaires perform compared with physical examination in detecting flexural eczema? Findings from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. <i>Br J Dermatol</i> . 2009; 161(4): 846-53.	2005-2007	*	
New Zealand	Campbell AJ, McCosh LM, Reinken J, Allan BC. Dementia in Old Age and the Need for Services. <i>Age Ageing</i> . 1983; 12(1): 11-6.	1977-1980		
New Zealand	The ACROSS Group. Epidemiology of Aneurysmal Subarachnoid Hemorrhage in Australia and New Zealand: Incidence and Case Fatality From the Australasian Cooperative Research on Subarachnoid Hemorrhage Study (ACROSS). <i>Stroke</i> . 2000; 31(8): 1843-1850.	1995-1998	*	
New Zealand	Grey C, Jackson R, Wells S, Marshall R, Riddell T, Kerr AJ. Twenty-eight day and one-year case fatality after hospitalisation with an acute coronary syndrome: a nationwide data linkage study. <i>Aust N Z J Public Health</i> . 2014; 38: 216-220.	2007-2009	*	
New Zealand	Darlow BA, Horwood LJ, Mogridge N, Clemett RS. Prospective study of New Zealand very low birthweight infants: outcome at 7-8 years. <i>J Paediatr Child Health</i> . 1997 Feb; 33(1): 47-51.	1986		†
New Zealand	New Zealand Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
New Zealand	New Zealand Birth Defects Monitoring Programme Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
New Zealand	New Zealand Congenital Anomalies Monitoring Program Data 1980 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1980	*	
New Zealand	New Zealand Congenital Anomalies Monitoring Program Data 1983 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1983	*	
New Zealand	New Zealand Congenital Anomalies Monitoring Program Data 1986 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1986	*	
New Zealand	New Zealand Birth Defects Monitoring Programme Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
New Zealand	New Zealand Birth Defects Registry Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
New Zealand	New Zealand Birth Defects Registry Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
New Zealand	New Zealand Birth Defects Monitoring Program Data 2001 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
New Zealand	New Zealand Congenital Anomalies Monitoring Program Data 1987 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1987	*	
New Zealand	New Zealand Congenital Anomalies Monitoring Programme Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
New Zealand	New Zealand Birth Defects Registry Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
New Zealand	New Zealand Congenital Anomalies Monitoring Program Data 1988 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1988	*	
New Zealand	New Zealand Congenital Anomalies Monitoring Program Data 1982 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1982	*	
New Zealand	New Zealand Congenital Anomalies Monitoring Program Data 1984 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1984	*	
New Zealand	New Zealand Congenital Anomalies Monitoring Program Data 1985 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1985	*	
New Zealand	New Zealand Congenital Anomalies Monitoring Program Data 1981 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1981	*	
New Zealand	New Zealand Birth Defects Monitoring Program Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
Nicaragua	Nicaragua Vital Registration - Deaths 1997 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1997	*	
Nicaragua	Nicaragua Vital Registration - Deaths 1999 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1999	*	
Nicaragua	Nicaragua Vital Registration - Deaths 2001 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2001	*	
Nicaragua	Nicaragua Vital Registration - Deaths 2004 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2004	*	
Nicaragua	Macro International, Inc, Ministry of Health (Nicaragua), National Institute of Statistics and Censuses (Nicaragua). Nicaragua Demographic and Health Survey 1997-1998. Calverton, United States: Macro International, Inc.	1997-1998		†
Nicaragua	Macro International, Inc, Ministry of Health (Nicaragua), National Institute of Statistics and Censuses (Nicaragua). Nicaragua Demographic and Health Survey 2001. Calverton, United States: Macro International, Inc.	2001		†
Nicaragua	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-2002		
Nicaragua	Espinoza F, Paniagua M, Hallander H, Svensson L, Strannegård O. Rotavirus infections in young Nicaraguan children. <i>Pediatr Infect Dis J</i> . 1997; 16(6): 564-71.	1991-1994		
Nicaragua	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Nicaragua	Estrada Castañón R, Torres Bibiano B, Alarcón Hernández H, Villegas Arrizón A, Martínez Sandoval E, Chávez López G, Andersson N. Epidemiología cutánea en dos sectores de atención médica en Guerrero, México; Cutaneous epidemiology in two sectors of Guerrero, Mexico. <i>Dermatol rev mex</i> . 1992; 36(1): 29-34.	1989-1991		
Nicaragua	Souza JP, Cecatti JG, Faundes A, Moraes SS, Villar J, Carroli G, Gulmezoglu M, Wojdyla D, Zavaleta N, Donner A, Velazco A, Bataglia V, Valladares E, Kublickas M, Acosta A. Maternal near miss and maternal death in the World Health Organization's 2005 global survey on maternal and perinatal health. <i>Bull World Health Organ</i> . 2010; 88(2): 113-9.	2005		
Nicaragua	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997-2009		
Nicaragua	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	2002		
Nicaragua	Mallol J, Solé D, Baeza-Bacab M, Aguirre-Camposano V, Soto-Quiros M, Baena-Cagnani C. Latin American ISAAC Group. Regional variation in asthma symptom prevalence in Latin American children. <i>J Asthma</i> . 2010; 47(6): 644-50.	2001-2003	*	
Nicaragua	Becker-Dreps S, Paniagua M, Zambrana LE, Bucardo F, Hudgens MG, Weber DJ, Morgan DR, Espinoza F. Rotavirus prevalence in the primary care setting in Nicaragua after universal infant rotavirus immunization. <i>Am J Trop Med Hyg</i> . 2011; 85(5): 957-60.	2008-2009	*	
Nicaragua	Vilchez S, Reyes D, Paniagua M, Bucardo F, Möllby R, Weintraub A. Prevalence of diarrhoeagenic <i>Escherichia coli</i> in children from León, Nicaragua. <i>J Med Microbiol</i> . 2009; 58(Pt 5): 630-7.	2005-2006	*	
Nicaragua	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Nicaragua Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2006		
Nicaragua	Saunders JE, Vaz S, Greinwald JH, Lai J, Morin L, Mojica K. Prevalence and etiology of hearing loss in rural Nicaraguan children. <i>Laryngoscope</i> . 2007; 117(3): 387-98.	2004-2005		
Nicaragua	Paar JA, Berrios NM, Rose JD, Cáceres M, Peña R, Pérez W, Chen-Mok M, Jolles E, Dale JB. Prevalence of rheumatic heart disease in children and young adults in Nicaragua. <i>Am J Cardiol</i> . 2010; 105(12): 1809-14.	2006-2009		
Nicaragua	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). CICAD Comparative Report on Nationwide School Surveys in Seven Countries: El Salvador, Guatemala, Nicaragua, Panama, Paraguay, Dominican Republic, and Uruguay 2003. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2004.	2003	3	
Nicaragua	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010		
Nicaragua	Terceiro F, Andersson R, Peña R, Rocha J, Castro N. The epidemiology of moderate and severe injuries in a Nicaraguan community: a household-based survey. <i>Public Health</i> . 2006; 120(2): 106-14.	1995	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Nicaragua	Cusumano A, Garcia-Garcia G, Di Gioia C, Hermida O, Lavorato C, Carreño CA, Torrico MP, Batista PB, Romão JE, Badal HP, Miranda SE, Gomez R, Calderon MC, Sanchez SH, Lopez MA, Moscoso J, Merino RL, Polo JV, Lopez A, Romero NJ, Garcia R, Acosta BV, Lopez AS, Delpin ES, Mena E, González C, Milanés CL, Achiardo S. End-stage renal disease and its treatment in Latin America in the twenty-first century. <i>Ren Fail.</i> 2006; 28(8): 631-7.	2004		
Nicaragua	O'Donnell JK, Tobey M, Weiner DE, Stevens LA, Johnson S, Stringham P, Cohen B, Brooks DR. Prevalence of and risk factors for chronic kidney disease in rural Nicaragua. <i>Nephrol Dial Transplant.</i> 2011; 26(9): 2798-805.	2008	*	
Nicaragua	World Health Organization (WHO). Nicaragua WHO Leishmaniasis Country Profile.	2003-2010	*	
Nicaragua	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Nicaragua	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Nicaragua	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Nicaragua	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2003. Pan American Health Organization (PAHO).	2003		†
Nicaragua	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2004. Pan American Health Organization (PAHO).	2004		†
Nicaragua	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2005. Pan American Health Organization (PAHO).	2005		†
Nicaragua	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2006. Pan American Health Organization (PAHO).	2006		†
Nicaragua	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2007. Pan American Health Organization (PAHO).	2007		†
Nicaragua	Standish K, Kuan G, Avilés W, Balmaseda A, Harris E. High dengue case capture rate in four years of a cohort study in Nicaragua compared to national surveillance data. <i>PLoS Negl Trop Dis.</i> 2010; 4(3): e633.	2005-2007		
Nicaragua	Espinoza F, Egger M, Herrmann B, Isler M, Volken K, Smith GD. STD in Nicaragua: population rate estimates and health seeking behaviour [abstract]. In: Habermehl K-O, Zeichhardt H, Sawitzky D, eds. IX International Conference on AIDS Abstracts; 1993 Jun 6-11; Berlin, Germany. Geneva (Switzerland): International AIDS Society; 1993. p. 667.	1993		
Nicaragua	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Nicaragua	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Nicaragua	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Nicaragua	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Nicaragua	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Nicaragua	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Nicaragua	Balmaseda A, Hammond SN, Tellez Y, Imhoff L, Rodriguez Y, Saborío SI, Mercado JC, Perez L, Videá E, Almanza E, Kuan G, Reyes M, Saenz L, Amador JJ, Harris E. High seroprevalence of antibodies against dengue virus in a prospective study of schoolchildren in Managua, Nicaragua. <i>Trop Med Int Health.</i> 2006; 11(6): 935-42.	2001-2003	*	
Nicaragua	Gordon A, Kuan G, Mercado JC, Gresh L, Avilés W, Balmaseda A, Harris E. The Nicaraguan pediatric dengue cohort study: incidence of inapparent and symptomatic dengue virus infections, 2004-2010. <i>PLoS Negl Trop Dis.</i> 2013; 7(9): e2462.	2004-2010	*	
Nicaragua	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L, Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Ann Hepatol.</i> 2010; 9(1): 63-9.	2006-2008	*	
Nicaragua	Perez OM, Morales W, Paniagua M, Strannegard O. Prevalence of antibodies to hepatitis A, B, C, and E viruses in a healthy population in Leon, Nicaragua. <i>Am J Trop Med Hyg.</i> 1996; 55(1): 17-21.	1990-1992		
Nicaragua	De Stefano GF. The Ladinos of Nicaragua: anthropometry, ABO and Rh(D) blood antigens and P.T.C. taste threshold. <i>Z Morphol Anthropol.</i> 1982; 73(2): 209-19.	1976	*	†
Nicaragua	Pan American Health Organization (PAHO). World Health Organization (WHO). Quantitative Estimation of Chagas in the Americas.	2005	*	
Nicaragua	Malaria en Nicaragua - Una Lucha para Ganar? [Malaria in Nicaragua - A Fight to Win?] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994-1995	*	†
Nicaragua	Nicaragua Vital Registration Birth Data 1987 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1987		
Niger	Department of Statistics and National Accounts (Niger), Macro International, Inc. Niger Demographic and Health Survey 2006. Calverton, United States: Macro International, Inc.	2006		†
Niger	Department of Statistics and National Accounts (Niger), Macro International, Inc. Niger Demographic and Health Survey 1992. Calverton, United States: Macro International, Inc.	1992		†
Niger	CARE International, Macro International, Inc. Niger Demographic and Health Survey 1998. Calverton, United States: Macro International, Inc.	1998		†
Niger	ICF International, Ministry of Public Health (Niger), National Institute of Statistics (Niger). Niger Demographic and Health Survey 2012. Fairfax, United States: ICF International. 2014.	2012	*	†
Niger	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Niger	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Niger	Campagne G, Schuchat A, Djibo S, Ousséini A, Cissé L, Chippaux JP. Epidemiology of bacterial meningitis in Niamey, Niger, 1981-96. <i>Bull World Health Organ.</i> 1999; 77(6): 499-508.	1981-1996		†
Niger	Prual A, Huguet D, Garbin O, Rabé G. Severe obstetric morbidity of the third trimester, delivery and early puerperium in Niamey (Niger). <i>Afr J Reprod Health.</i> 1998; 2(1): 10-9.	1997		
Niger	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1987, 1989, 1991, 1995, 1997-2004, 2006, 2008-2009		
Niger	Tohon ZB, Mainasara HB, Garba A, Mahamane AE, Bosqué-Oliva E, Ibrahim M-L, Duchemin J-B, Chanteau S, Boisier P. Controlling schistosomiasis: significant decrease of anaemia prevalence one year after a single dose of praziquantel in Nigerian schoolchildren. <i>PLoS Negl Trop Dis.</i> 2008; 2(5): e241.	2004		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Niger	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Niger	Petersen PE, Kaka M. Oral health status of children and adults in the Republic of Niger, Africa. <i>Int Dent J.</i> 1999; 49(3): 159-64.	1996-1998		
Niger	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2007, 2010, 2012		
Niger	Niger National Survey on Goiter Prevalence 1994 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1994		
Niger	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Niger	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Niger	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Niger	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Niger	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Niger	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Niger	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Niger	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1993; 68(25): 181-6.	1992	*	
Niger	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Niger	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Niger	Niger Iodine Deficiency Disorders in Some Sub Saharan Countries as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1998		
Niger	Hassane A, Paradis R, Mounkaila A, et al. Estimation rapide de prevalence des MST/VIH a Niamey, Niger [Quick Estimate of Prevalence of STD/HIV in Niamey, Niger]. Presented at: VIII International Conference on AIDS in Africa; 1993 Dec; Marrakech, Morocco. Abstract Th.P.C 087.	1993		
Niger	Ogunbiyi AO, Owoaje E, Ndahi A. Prevalence of skin disorders in school children in Ibadan, Nigeria. <i>Pediatr Dermatol.</i> 2005; 22(1): 6-10.	2002-2004	*	
Niger	Malaria and Urinary Schistosomiasis in Niger – Links with Anemia as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Niger	Develoux M, Chegou A, Prual A, Olivier M. Malaria in the oasis of Bilma, Republic of Niger. <i>Trans R Soc Trop Med Hyg.</i> 1994; 88(6): 644 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Niger	Julvez J, Mouchet J, Michault A, Fouta A, Hamidine M. [Eco-epidemiology of malaria in Niamey and in the river valley, the Republic of Niger, 1992-1995]. <i>Bull Soc Pathol Exot.</i> 1997; 90(2): 94-100 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992-1994	*	†
Niger	Julvez J, Mouchet J, Michault A, Fouta A, Hamidine M. [The progress of malaria in sahelian eastern Niger. An ecological disaster zone]. <i>Bull Soc Pathol Exot.</i> 1997; 90(2): 101-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Niger	Le Bras M, Soubiran G, Baraze A, Meslet B, Combe A, Giap G, Fabre A. [Urban and rural malaria in Niger. The case of the Department of Maradi]. <i>Bull Soc Pathol Exot.</i> 1986; 79(5): 695-706 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Niger	Xerophthalmia and Trachoma in Burkina Faso, Chad, Mali and Niger 1986 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1986		
Nigeria	Nigeria Food Consumption and Nutrition Survey 2001-2003 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2001-2003		†
Nigeria	Federal Office of Statistics (Nigeria), United Nations Children's Fund (UNICEF). Nigeria Multiple Indicator Cluster Survey 1995.	1995	*	
Nigeria	National Bureau of Statistics (Nigeria), United Nations Children's Fund (UNICEF). Nigeria Multiple Indicator Cluster Survey 1999. Abuja, Nigeria: National Bureau of Statistics (Nigeria).	1999	*	†
Nigeria	United Nations Children's Fund (UNICEF), National Bureau of Statistics (Nigeria). Nigeria Multiple Indicator Cluster Survey 2007. New York, United States: United Nations Children's Fund (UNICEF).	2007	*	†
Nigeria	Federal Office of Statistics (Nigeria), Macro International, Inc.; Institute for Resource Development. Nigeria Demographic and Health Survey 1990. Calverton, United States: Macro International, Inc.	1990		†
Nigeria	Macro International, Inc, National Population Commission of Nigeria. Nigeria Demographic and Health Survey 1999. Calverton, United States: Macro International, Inc.	1999		†
Nigeria	National Population Commission of Nigeria, ORC Macro, UK Department for International Development (DFID), United Nations Children's Fund (UNICEF), United Nations Population Fund (UNFPA). Nigeria Demographic and Health Survey 2003. Calverton, United States: ORC Macro.	2003		†
Nigeria	Macro Systems, Inc.; Institute for Resource Development, Ministry of Health (Nigeria), National Population Bureau (Nigeria). Nigeria Ondo State Special Demographic and Health Survey 1986-1987. Columbia, United States: Macro Systems, Inc.	1986-1987	*	†
Nigeria	Macro International, Inc, National Population Commission of Nigeria. Nigeria Demographic and Health Survey 2008. Calverton, United States: Macro International, Inc, 2009.	2008		†
Nigeria	Ejezie GC, Akpan IF. Human ecology and parasitic infections. 1. The effect of occupation on the prevalence of parasitic infections in Calabar, Nigeria. <i>J Hyg Epidemiol Microbiol Immunol.</i> 1992; 36(2): 161-7. as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	
Nigeria	Nigeria Malaria Indicator Survey 2010 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2010	*	†
Nigeria	National Bureau of Statistics (Nigeria), United Nations Children's Fund (UNICEF). Nigeria Multiple Indicator Cluster Survey 2011. New York, United States: United Nations Children's Fund (UNICEF), 2013.	2011	*	
Nigeria	University of Ibadan (Nigeria), World Health Organization (WHO). Nigeria WHO Multi-country Survey Study on Health and Health System Responsiveness 2000-2001.	2000-2001		
Nigeria	Akinyemi KO, Oyeolu AO, Opere B, Otunba-Payne VA, Oworu AO. Escherichia coli in patients with acute gastroenteritis in Lagos, Nigeria. <i>East Afr Med J.</i> 1998; 75(9): 512-5.	1995-1996		
Nigeria	Akinyanju OO. A profile of sickle cell disease in Nigeria. <i>Ann N Y Acad Sci.</i> 1989; 565(565): 126-36.	1978-1980, 1983-1985		
Nigeria	Angastiniotis M, Modell B, Englezos P, Boulyjenkov V. Prevention and control of haemoglobinopathies. <i>Bull World Health Organ.</i> 1995; 73(3): 375-86.	1991-1993		
Nigeria	Thalassaemia International Federation, World Health Organization (WHO). Management of Haemoglobin Disorders: Report of a Joint WHO-TIF Meeting, Nicosia, Cyprus, 16-18 November 2007. Geneva, Switzerland: World Health Organization (WHO), 2008.	2003		
Nigeria	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Nigeria	Odunvbun ME, Okolo AA, Rahimy CM. Newborn screening for sickle cell disease in a Nigerian hospital. <i>Public Health.</i> 2008; 122(10): 1111-6.	2000		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Nigeria	Umoh AV, Abah GM, Ekanem TI, Essien EM. Haemoglobin genotypes: a prevalence study and implications for reproductive health in Uyo, Nigeria. <i>Niger J Med.</i> 2010; 19(1): 36-41.	2003-2007		
Nigeria	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Nigeria	Antony KK. Pattern of cardiac failure in Northern Savanna Nigeria. <i>Trop Geogr Med.</i> 1980; 32(2): 118-25.	1980		
Nigeria	Karaye KM, Sani MU. Factors associated with poor prognosis among patients admitted with heart failure in a Nigerian tertiary medical centre: a cross-sectional study. <i>BMC Cardiovasc Disord.</i> 2008; 8(1): 16.	2007		
Nigeria	Ola BA, Adewuya AO, Ajayi OE, Akintomide AO, Oginni OO, Ologun YA. Relationship between depression and quality of life in Nigerian outpatients with heart failure. <i>J Psychosom Res.</i> 2006; 61(6): 797-800.	2000		
Nigeria	Ogunbiyi AO, Omigbodun Y, Owoaje E. Prevalence of skin disorders in school children in southwest Nigeria. <i>Int J Adolesc Med Health.</i> 2009; 21(2): 235-41.	2002-2004, 2006-2008		
Nigeria	Oyedele O, Okeniyi J, Ogunlesi T, Onayemi O, Oyedele G, Oyelami O. Parental factors influencing the prevalence of skin infections and infestations among Nigerian primary school pupils. <i>Internet J Dermatol.</i> 2006; 3(2): 6.	2003		
Nigeria	Ngwogu AC, Otokunefor TV. Epidemiology of dermatophytoses in a rural community in Eastern Nigeria and review of literature from Africa. <i>Mycopathologia.</i> 2007; 164(4): 149-58.	2003-2004		
Nigeria	Adekanle O, Ayodeji O, Olatunde L. Tetanus in a rural setting of South-Western Nigeria: a ten-year retrospective study. <i>Libyan J Med.</i> 2009; 4(2): 78-80.	1997-2006		
Nigeria	Adudu OP, Ogunrin OA, Adudu OG. Morbidity and mortality patterns among neurological patients in the intensive care unit of a tertiary health facility. <i>Ann Afr Med.</i> 2007; 6(4): 174-9.	1985-2003		
Nigeria	Antia-Obong OE, Ekanem EE, Udo JJ, Utsalo SJ. Septicaemia among neonates with tetanus. <i>J Trop Pediatr.</i> 1992; 38(4): 173-5.	1989		
Nigeria	Arogundade FA, Bello IS, Kuteyi EA, Akinsola A. Patterns of presentation and mortality in tetanus: a 10-year retrospective review. <i>Niger Postgrad Med J.</i> 2004; 11(3): 198-202.	1992-2001		
Nigeria	Asekun-Olarinmoye EO, Lawoyin TO, Onadeko MO. Risk factors for neonatal tetanus in Ibadan, Nigeria. <i>Eur J Pediatr.</i> 2003; 162(7-8): 526-7.	2000		
Nigeria	Bangboye EA, Famulisi JB. Mortality pattern at a children's emergency ward, University College Hospital, Ibadan, Nigeria. <i>Afr J Med Med Sci.</i> 1990; 19(2): 127-32.	1978-1986		
Nigeria	Chapp-Jumbo EN. Neurologic infections in a Nigerian university teaching hospital. <i>Afr Health Sci.</i> 2006; 6(1): 55-8.	1993-2003		
Nigeria	Chukwubike OA, Godspower AE. A 10-year review of outcome of management of tetanus in adults at a Nigerian tertiary hospital. <i>Ann Afr Med.</i> 2009; 8(3): 168-72.	1996-2005		
Nigeria	Fawibe AE. The pattern and outcome of adult tetanus at a sub-urban tertiary hospital in Nigeria. <i>J Coll Physicians Surg Pak.</i> 2010; 20(1): 68-70.	2002-2006		
Nigeria	Fetuga BM, Ogunlesi TA, Adekanmbi FA. Risk factors for mortality in neonatal tetanus: a 15-year experience in Sagamu, Nigeria. <i>World J Pediatr.</i> 2010; 6(1): 71-5.	1991-2005		
Nigeria	Ogunlesi TA, Okeniyi JA, Owa JA, Oyedele GA. Neonatal tetanus at the close of the 20th century in Nigeria. <i>Trop Doct.</i> 2007; 37(3): 165-7.	1996-2000		
Nigeria	Ogunrin OA, Unuigbo EI. Tetanus: an analysis of the prognosticating factors of cases seen in a tertiary hospital in a developing African country between 1990 and 2000. <i>Trop Doct.</i> 2004; 34(4): 240-1.	1990-2000		
Nigeria	Ojini FI, Danesi MA. Mortality of tetanus at the Lagos University Teaching Hospital, Nigeria. <i>Trop Doct.</i> 2005; 35(3): 178-81.	1990-1999		
Nigeria	Okoromah CN, Lesi FE, Egri-Okwaji MT, Iroha E. Clinical and management factors related to outcome in neonatal tetanus. <i>Niger Postgrad Med J.</i> 2003; 10(2): 92-5.	2000		
Nigeria	Ornamabo RS, Igbagiri FP. Neonatal tetanus in Port Harcourt. <i>Afr J Med Med Sci.</i> 1996; 25(3): 265-8.	1984-1990		
Nigeria	Osunsi K, Njinyam MN. A new prognostic scoring system in neonatal tetanus. <i>Afr J Med Med Sci.</i> 1997; 26(3-4): 123-5.	1994		
Nigeria	Ologe FE, Nwawolo CC. Chronic suppurative otitis media in school pupils in Nigeria. <i>East Afr Med J.</i> 2003; 80(3): 130-4.	2001-2003		
Nigeria	Ologe FE, Nwawolo CC. Prevalence of chronic suppurative otitis media (CSOM) among school children in a rural community in Nigeria. <i>Niger Postgrad Med J.</i> 2002; 9(2): 63-6.	2000-2002		
Nigeria	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol.</i> 2008; 121(4): 947-954.	1995, 2001-2002		
Nigeria	Fagbule D, Parakoyi DB, Spiegel R. Acute respiratory infections in Nigerian children: prospective cohort study of incidence and case management. <i>J Trop Pediatr.</i> 1994; 5(40): 279-84.	1988-1989		
Nigeria	Robertson SE, Roca A, Alonso P, Simoes EAF, Kartasasmita CB, Olaleye DO, Odaibo GN, Collinson M, Venter M, Yuwei Zhu, Wright PF. Respiratory syncytial virus infection: denominator-based studies in Indonesia, Mozambique, Nigeria and South Africa. <i>Bull World Health Organ.</i> 2004; 12(82): 914-22.	1987-2001		
Nigeria	Akpede O, Abiodun PO, Sykes M, Salami CE. Childhood bacterial meningitis beyond the neonatal period in southern Nigeria: changes in organisms/antibiotic susceptibility. <i>East Afr Med J.</i> 1994; 71(1): 14-20.	1985-1990		
Nigeria	Enele F. Etiologic spectrum and pattern of antimicrobial drug susceptibility in bacterial meningitis in Sokoto, Nigeria. <i>Acta Paediatr.</i> 2000; 89(8): 942-6.	1987-1992		
Nigeria	Johnson AW, Adedoyin OT, Abdul-Karim AA, Olanrewaju AW. Childhood pyogenic meningitis: clinical and investigative indicators of etiology and outcome. <i>J Natl Med Assoc.</i> 2007; 99(8): 937-47.	2001-2005		
Nigeria	Moisi JC, Saha SK, Falade AG, Njanpop-Lafourcade B-M, Oundo J, Zaidi AKM, Afroj S, Bakare RA, Buss JK, Lasi R, Mueller J, Odekanmi AA, Sangare L, Scott JAG, Knoll MD, Levine OS, Gessner BD. Enhanced diagnosis of pneumococcal meningitis with use of the binax NOW immunochromatographic test of Streptococcus pneumoniae antigen: A multistate study. <i>Clin Infect Dis.</i> 2009; 48(Suppl 2): S49-S56.	2006-2007		
Nigeria	Ozumba UC. Acute bacterial meningitis in Enugu, Nigeria. <i>Cent Afr J Med.</i> 1995; 41(2): 54-9.	1989-1993		
Nigeria	Demyttenaere K, Bruffaerts R, Lee S, Posada-Villa J, Kovess V, Angermeyer MC, Levinson D, de Girolamo G, Nakane H, Mneimneh Z, Lara C, de Graaf R, Scott KM, Gureje O, Stein DJ, Haro JM, Bromet EJ, Kessler RC, Alonso J, Von Korff M. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. <i>Pain.</i> 2007; 129(3): 332-42.	2002		
Nigeria	Ogunniyi SO, Sanusi YO, Faleyimu BL. Forceps delivery at Wesley Guild Hospital, Ilesa, Nigeria: a ten year review. <i>West Afr J Med.</i> 1997; 16(1): 30-5.	1981-1990		
Nigeria	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1980, 1983-1994, 1997		
Nigeria	Kurz X. The yellow fever epidemic in Western Mali, September-November 1987: Why did epidemiological surveillance fail? <i>Disasters.</i> 1990; 14(1): 46-54.	1986		
Nigeria	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1996, 1998, 2000-2002, 2007-2009		
Nigeria	Mutebi J-P, Barrett ADT. The epidemiology of yellow fever in Africa. <i>Microbes Infect.</i> 2002; 4(14): 1459-68.	2000		
Nigeria	Ekenna O, Chikwem JO, Mohammed I, Durojaiye SO. Epidemic yellow fever in Borno State of Nigeria: characterisation of hospitalised patients. <i>West Afr J Med.</i> 2010; 29(2): 91-7.	1990		
Nigeria	Olaleye OD, Omilabu SA, Faseru O, Fagbami AH. Nigeria: a survey for yellow fever virus haemagglutination inhibiting antibody in residents of two communities before and after the epidemics. <i>Virologie.</i> 1988; 39(4): 261-6.	1987		
Nigeria	Tomori O. Yellow fever in Africa: public health impact and prospects for control in the 21st century. <i>Biomedica.</i> 2002; 22(2): 178-210.	1991		
Nigeria	Adebajo AO, Birrell F, Hazleman BL. The pattern of rheumatic disorders seen amongst patients attending urban and rural clinics in west Africa. <i>Clin Rheumatol.</i> 1992; 11(4): 512-5.	1989		
Nigeria	Oomen JM, Meuwissen JH, Gemert W. Differences in blood status of three ethnic groups inhabiting the same locality in Northern Nigeria Anaemia, splenomegaly and associated causes. <i>Trop Geogr Med.</i> 1979; 31(4): 587-606.	1977-1978		
Nigeria	Pugh RN, Bell DR, Gilles HM. Malumfashi Endemic Diseases Research Project, XV The potential medical importance of bilharzia in northern Nigeria: a suggested rapid, cheap and effective solution for control of Schistosoma haematobium infection. <i>Ann Trop Med Parasitol.</i> 1980; 74(6): 597-613.	1975-1976		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Nigeria	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Nigeria	Lai CK, Bessley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2001		
Nigeria	Ogbera AO, Fasanmade O, Ohwovoriole AE, Adediran O. An assessment of the disease burden of foot ulcers in patients with diabetes mellitus attending a teaching hospital in Lagos, Nigeria. <i>Int J Low Extrem Wounds.</i> 2006; 5(4): 244-9.	1998-2000		
Nigeria	Emodi IJ, Ikefuna AN, Uchendu U, Duru A. Skin diseases among children attending the out patient clinic of the University of Nigeria teaching hospital, Enug. <i>Afr Health Sci.</i> 2010; 10(4).	1996-2005		
Nigeria	Osuntokun BO, Adejaja AO, Nottidge VA, Bademosi O, Alunide AO, Ige O, Yaria F, Schoenberg BS, Bolis CL. Prevalence of headache and migrainous headache in Nigerian Africans: a community-based study. <i>East Afr Med J.</i> 1992; 69(4): 196-9.	1989		
Nigeria	Longe AC, Osuntokun BO. Prevalence of neurological disorders in Udo, a rural community in southern Nigeria. <i>Trop Geogr Med.</i> 1989; 41(1): 36-40.	1985-1986		
Nigeria	Oni AO, Erhabor GE, Egbagbe EE. The prevalence, management and burden of asthma - a Nigerian study. <i>Iran J Allergy Asthma Immunol.</i> 2010; 9(1): 35-41.	2004-2005	*	
Nigeria	Adefemi SA, Odeigah LO, Alabi KM. Prevalence of dermatophytosis among primary school children in Oke-Oyi community of Kwara state. <i>Niger J Clin Pract.</i> 2011; 14(1): 23-8.	2005	*	
Nigeria	Ayanbimpe GM, Taghir H, Diya A, Wapwera S. Tinea capitis among primary school children in some parts of central Nigeria. <i>Mycoses.</i> 2008; 51(4): 336-40.	2004	*	
Nigeria	Emele FE, Oyeka CA. Tinea capitis among primary school children in Anambra state of Nigeria. <i>Mycoses.</i> 2008; 51(6): 536-41.	2002-2005	*	
Nigeria	Ikechebelu JI, Mbamara SU. Should laparoscopy and dye test be a first line evaluation for infertile women in southeast Nigeria <i>Niger J Med.</i> 2011; 20(4): 462-5.	2002-2006	*	
Nigeria	Ogebe O, Abdulmalik J, Bello-Mojeed MA, Holder N, Jones HA, Ogun OO, Omigbodun O. A comparison of the prevalence of premenstrual dysphoric disorder and comorbidities among adolescents in the United States of America and Nigeria. <i>J Pediatr Adolesc Gynecol.</i> 2011; 24(6): 397-403.	2009-2010	*	
Nigeria	Fabunmi AA, Abo SO, Odunaiya NA. Prevalence of low back pain among peasant farmers in a rural community in South West Nigeria. <i>Afr J Med Med Sci.</i> 2005; 34(3): 259-62.	2002		
Nigeria	Ayanniyi O, Mbada CE, Muolokwu CA. Prevalence and Profile of Back Pain in Nigerian Adolescents. <i>Med Princ Pract.</i> 2011; 20(4): 368-73.	2008	*	
Nigeria	Coker AO, Dosunmu-Ogunbi O, Odugbemi T, Alabi SA, Macaulay SA. A study on the prevalence of rotavirus diarrhoeas in Ohaazara local government area, Imo State, Nigeria and the Lagos University Teaching Hospital, Lagos, Nigeria. <i>East Afr Med J.</i> 1987; 64(9): 586-9.	1983-1986	*	
Nigeria	Adah MI, Rohwedder A, Olaleye OD, Durojaiye OA, Werchau H. Serotype of Nigerian rotavirus strains. <i>Trop Med Int Health.</i> 1997; 2(4): 363-70.	1993-1995	*	
Nigeria	Audu R, Omilabu SA, de Beer M, Peenze I, Steele AD. Diversity of human rotavirus VP6, VP7, and VP4 in Lagos State, Nigeria. <i>J Health Popul Nutr.</i> 2002; 20(1): 59-64.	1996-1997	*	
Nigeria	Pennap G, Peenze, De Beer M, Pager CT, Kwaga JKP, Ogalla WN, Umoh JU, Steele AD. VP6 subgroup and VP7 serotype of human rotavirus in Zaria, northern Nigeria. <i>J Trop Pediatr.</i> 2000; 46(6): 344-7.	1997-1998	*	
Nigeria	Paul MO, Paul BD. Rotavirus infection among children in hospital in Nigeria. <i>J Infect.</i> 1986; 12(1): 39-47.	1980-1982	*	
Nigeria	Gomwalk NE, Gosham LT, Umoh UJ. Rotavirus gastroenteritis in pediatric diarrhoea in Jos, Nigeria. <i>J Trop Pediatr.</i> 1990; 36(2): 52-5.	1986-1987	*	
Nigeria	Gomwalk NE, Umoh UJ, Gosham LT, Ahmad AA. Influence of climatic factors on rotavirus infection among children with acute gastroenteritis in Zaria, northern Nigeria. <i>J Trop Pediatr.</i> 1993; 39(5): 293-7.	1986-1987	*	
Nigeria	Odimayo MS, Olanrewaju WI, Omilabu SA, Adegboro B. Prevalence of rotavirus-induced diarrhoea among children under 5 years in Ilorin, Nigeria. <i>J Trop Pediatr.</i> 2008; 54(5): 343-6.	2003-2004	*	
Nigeria	Junaid SA, Umeh C, Olabode AO, Banda JM. Incidence of rotavirus infection in children with gastroenteritis attending Jos university teaching hospital, Nigeria. <i>Virolog J.</i> 2011; 233.	2008-2010	*	
Nigeria	Gureje O, Ogunniyi A, Kola L, Abiona T. Incidence of and risk factors for dementia in the Ibadan study of aging. <i>J Am Geriatr Soc.</i> 2011; 59(5): 869-74.	2004-2007		
Nigeria	Silman AJ, Ollier W, Holligan S, Birrell F, Adebajo A, Asuzu MC, Thomson W, Pepper L. Absence of rheumatoid arthritis in a rural Nigerian population. <i>J Rheumatol.</i> 1993; 20(4): 618-22.	1990		
Nigeria	Adegbenbo AO, el-Nadeef MA. National survey of periodontal status and treatment need among Nigerians. <i>Int Dent J.</i> 1995; 45(3): 197-203.	1990-1991		
Nigeria	Kubota K, Yonemitsu M, Hollist NO, Ono Y, Nakata M, Ajayi-Obe SO, Ohnishi M, Watanabe H, Grillo AI. Five-year follow-up caries study among Nigerian children. <i>Community Dent Oral Epidemiol.</i> 1990; 18(4): 197-9.	1981-1986		
Nigeria	Agbelusi GA, Jeboda SO. Oral health status of 12-year-old Nigerian children. <i>West Afr J Med.</i> 2006; 25(3): 195-8.	2003		
Nigeria	Adetoro OO. A 15-year study of illegally induced abortion mortality at Ilorin, Nigeria. <i>Int J Gynaecol Obstet.</i> 1989; 29(1): 65-72.	1980-1986		
Nigeria	Abiodun OA. Emotional illness in a paediatric population in Nigeria. <i>East Afr Med J.</i> 1992; 69(10): 557-9.	1990		
Nigeria	Adeyuya AO, Ola BA, Adewumi TA. The 12-month prevalence of DSM-IV anxiety disorders among Nigerian secondary school adolescents aged 13-18 years. <i>J Adolesc.</i> 2007; 30(6): 1071-6.	2005		
Nigeria	Gureje O, Lasebikan VO, Kola L, Makanjuola VA. Lifetime and 12-month prevalence of mental disorders in the Nigerian Survey of Mental Health and Well-Being. <i>Br J Psychiatry.</i> 2006; 188(5): 465-71.	2001		
Nigeria	Oladapo OT, Ariba AJ, Odusoga OL. Changing patterns of emergency obstetric care at a Nigerian University hospital. <i>West Afr J Med.</i> 2007; 98(3): 278-84.	1991-2001		
Nigeria	Onwudiegwu U. The effect of a depressed economy of the utilisation of maternal health services: the Nigerian Experience II. <i>J Obstet Gynaecol.</i> 1997; 17(2): 143-8.	1990-1994		
Nigeria	Gathuru IM, Bunker CH, Ukoli FA, Egbagbe EE. Differences in rates of obstructive lung disease between Africans and African Americans. <i>Ethn Dis.</i> 2002; 12(4): 3-107.	1999		
Nigeria	Oladapo OT, Sule-Odu AO, Olatunji AO, Daniel OJ. "Near Miss" obstetric events and maternal deaths in Sagamu, Nigeria: a retrospective study. <i>Reprod Health.</i> 2005; 2(9): 1-9.	2002-2004		
Nigeria	Muthhir JT, Utoo BT. Postpartum maternal morbidity in Jos, north-central Nigeria. <i>Niger J Clin Pract.</i> 2011; 14(1): 38-42.	2005-2008		
Nigeria	Danesi M, Okubadejo N, Ojini F. Prevalence of stroke in an urban, mixed-income community in Lagos, Nigeria. <i>Neuroepidemiology.</i> 2007; 28(4): 216-23.	2005-2006		
Nigeria	Osuntokun BO, Adejaja AO, Schoenberg BS, Bademosi O, Nottidge VA, Olunide AO, Ige O, Yaria F, Bolis CL. Neurological disorders in Nigerian Africans: a community-based study. <i>Acta Neurol Scand.</i> 1987; 75(1): 13-21.	1982, 1986		†
Nigeria	Okeahialam BN, Obindo JT, Ogbonna C. Prevalence of premenstrual syndrome and its relationship with blood pressure in young adult females. <i>Afr J Med Med Sci.</i> 2008; 37(4): 361-7.	2006		
Nigeria	Adenaike OC, Abioduro RO. A study of the incidence of the premenstrual syndrome in a group of Nigerian women. <i>Public Health.</i> 1987; 101(1): 49-58.	1984		
Nigeria	Adeyuya AO, Loto OM, Adewumi TA. Pattern and correlates of premenstrual symptomatology amongst Nigerian University students. <i>J Psychosom Obstet Gynaecol.</i> 2009; 30(2): 127-32.	2006		
Nigeria	Antai AB, Udezi AW, Ekanem EE, Okon UJ, Umoyiyo AU. Premenstrual syndrome: Prevalence in students of the University of Calabar, Nigeria. <i>Afr J Biomed Res.</i> 2004; 7(2): 45-50.	2001		
Nigeria	International Society of Nephrology (ISN). International Society of Nephrology Kidney Disease Data Center 2006-2009.	2007		
Nigeria	Franceschi S, Smith JS, van den Brule A, Herrero R, Arslan A, Anh P-T-H, Bosch FX, Hieu N-T, Matos E, Posso H, Qiao Y-L, Shin H-R, Sukvirach S, Thomas JO, Snijders PJF, Muñoz N, Meijer CJLM. Cervical infection with Chlamydia trachomatis and Neisseria gonorrhoeae in women from ten areas in four continents. A cross-sectional study. <i>Sex Transm Dis.</i> 2007; 34(8): 563-9.	1999-2000		
Nigeria	Omokhodion FO. Low back pain in an urban population in Southwest Nigeria. <i>Trop Doct.</i> 2004; 34(1): 17-20.	1999, 2001		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Nigeria	Onakpoya OH, Adeoye AO, Akinsola FB, Adegbehingbe BO. Prevalence of blindness and visual impairment in Atakunmosa West Local Government area of southwestern Nigeria. <i>Tanzan Health Res Bull.</i> 2007; 9(2): 126-31. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2004-2005		
Nigeria	Kyari F, Gudlavalleti MVS, Sivsubramaniam S, Gilbert CE, Abdull MM, Entekume G, Foster A. Prevalence of blindness and visual impairment in Nigeria: the National Blindness and Visual Impairment Study. <i>Invest Ophthalmol Vis Sci.</i> 2009; 50(5): 2033-9. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2007		
Nigeria	Ajaiyeoba AI, Isawumi MA, Adeoye AO, Oluleye TS. Pattern of eye diseases and visual impairment among students in southwestern Nigeria. <i>Int Ophthalmol.</i> 2007; 27(5): 287-92. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2002		
Nigeria	Ezeque UF. Magnitude and causes of blindness and low vision in Anambra State of Nigeria (results of 1992 point prevalence survey). <i>Public Health.</i> 1997; 111(5): 305-9. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1992		
Nigeria	Abdu L. Prevalence and causes of blindness and low vision in Dambatta local government area, Kano State, Nigeria. <i>Niger J Med.</i> 2002; 11(3): 108-12. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1995		
Nigeria	Robertson SE, Roca A, Alonso P, Simoes EAF, Kartasasmita CB, Olaleye DO, Odaibo GN, Collinson M, Venter M, Zhu Y, Wright PF. Respiratory syncytial virus infection: denominator-based studies in Indonesia, Mozambique, Nigeria and South Africa. <i>Bull World Health Organ.</i> 2004; 82(12): 914-22.	1999-2001	*	
Nigeria	Dunmade AD, Segun-Busari S, Olajide TG, Ologe FE. Profound bilateral sensorineural hearing loss in Nigerian children: any shift in etiology? <i>J Deaf Stud Deaf Educ.</i> 2007; 12(1): 112-8.	1999-2002		
Nigeria	Obiako MN. Profound childhood deafness in Nigeria: a three year survey. <i>Ear Hear.</i> 1987; 8(2): 74-7.	1982-1985		
Nigeria	Olusanya BO et al. The hearing profile of Nigerian school children. <i>Int J Pediatr Otorhinolaryngol</i> 2000; 55:73-79.	1997-1999		
Nigeria	Perkins AI, Hui SL, Ogunniyi A, Gureje O, Baiyewu O, Unverzagt FW, Gao S, Hall KS, Musick BS, Hendrie HC. Risk of mortality for dementia in a developing country: the Yoruba in Nigeria. <i>Int J Geriatr Psychiatry.</i> 2002; 17(6): 566-73.	1992-1997		
Nigeria	Oshodi OY, Aina OF, Onajole AT. Substance use among secondary school students in an urban setting in Nigeria: prevalence and associated factors. <i>Afr J Psychiatry (Johannesbg).</i> 2010; 52-7.	2005	*	
Nigeria	Anderson N, Omer K, Caldwell D, Dambam MM, Maikudi AY, Effiong B, Ikpi E, Udofia E, Khan A, Ansari U, Ansari N, Hamel C. Male responsibility and maternal morbidity: a cross-sectional study in two Nigerian states. <i>BMC Health Serv Res.</i> 2011; 57.	2009	*	
Nigeria	Bako B, Audu BM, Lawan ZM, Umar JB. Risk factors and microbial isolates of puerperal sepsis at the University of Maiduguri Teaching Hospital, Maiduguri, North-eastern Nigeria. <i>Arch Gynecol Obstet.</i> 2012; 285(4): 913-7.	1999-2010	*	
Nigeria	Olusanya BO. Perinatal outcomes of multiple births in southwest Nigeria. <i>J Health Popul Nutr.</i> 2011; 29(6): 639-47.	2005-2007	*	
Nigeria	Adeoye IA, Onayade AA, Fatusi AO. Incidence, determinants and perinatal outcomes of near miss maternal morbidity in Ile-Ife Nigeria: a prospective case control study. <i>BMC Pregnancy Childbirth.</i> 2013; 93.	2006-2007	*	
Nigeria	Akwurroha E, Kamanu C, Onwere S, Chigbu B, Aluka C, Umezuruike C. Grandmultiparity and pregnancy outcome in Aba, Nigeria: a case-control study. <i>Arch Gynecol Obstet.</i> 2011; 283(2): 167-72.	2003-2007	*	
Nigeria	Mustafa Adelaja L, Olufemi Taiwo O. Maternal and fetal outcome of obstetric emergencies in a tertiary health institution in South-Western Nigeria. <i>ISRN Obstet Gynecol.</i> 2011; 2011(160932).	2005-2007	*	
Nigeria	Adinma ED, Echendu DA. Pattern of clinical presentation of eclampsia at Nnamdi Azikiwe University Teaching Hospital, Nnewi, Southeastern Nigeria. <i>Niger J Med.</i> 2012; 21(3): 313-6.	2000-2009	*	
Nigeria	Eke AC, Ezebialu IU, Okafor C. Presentation and outcome of eclampsia at a tertiary center in South East Nigeria—a 6-year review. <i>Hypertens Pregnancy.</i> 2011; 30(2): 125-32.	2004-2009	*	
Nigeria	Jido TA. Eclampsia: maternal and fetal outcome. <i>Afr Health Sci.</i> 2012; 12(2): 148-52.	2010-2011	*	
Nigeria	Olusanya BO, Solanke OA. Perinatal outcomes associated with maternal hypertensive disorders of pregnancy in a developing country. <i>Hypertens Pregnancy.</i> 2012; 31(1): 120-30.	2005-2007	*	
Nigeria	Ugwu EO, Dim CC, Okonkwo CD, Nwankwo TO. Maternal and perinatal outcome of severe pre-eclampsia in Enugu, Nigeria after introduction of Magnesium sulfate. <i>Niger J Clin Pract.</i> 2011; 14(4): 418-21.	2005-2008	*	
Nigeria	Yakasai IA, Gaya SA. Maternal and fetal outcome in patients with eclampsia at Murtala Muhammad specialist Hospital Kano, Nigeria. <i>Ann Afr Med.</i> 2011; 10(4): 305-9.	2008-2009	*	
Nigeria	Mbachu I, Udigwe GO, Okafor CI, Umeonunihu OS, Ezeama C, Eleje GU. The pattern and obstetric outcome of hypertensive disorders of pregnancy in Nnewi, Nigeria. <i>Niger J Med.</i> 2013; 22(2): 117-22.	2004-2008	*	
Nigeria	Adamu AN, Ekele BA, Ahmed Y, Mohammed BA, Isezu SA, Abdullahi AA. Pregnancy outcome in women with eclampsia at a tertiary centre in northern Nigeria. <i>Afr J Med Sci.</i> 2012; 41(2): 211-9.	2000-2009	*	
Nigeria	Akinpelu A, Alonge T, Adekanla B, Odole A. Prevalence and pattern of symptomatic knee osteoarthritis in Nigeria: a community based study. <i>Internet J Allied Health Sci Pract.</i> 2009; 7(3): 1-7.	2006	*	
Nigeria	Dozie INS, Onwuliri COE, Nwoke BEB, Chukwuocha UM, Chikwendu CI, Okoro I, Njemanze PC. Onchoerciasis and epilepsy in parts of the Ino river basin, Nigeria: a preliminary report. <i>Public Health.</i> 2006; 120(5): 448-50.	2005	*	
Nigeria	Sykes RM. Epilepsy in children in Benin City, Nigeria. <i>Ann Trop Paediatr.</i> 2002; 22(3): 287-96.	1978-1991	*	
Nigeria	Adeyuya AO, Ola BA, Aloba OO, Mapayi BM, Oginni OO. Depression amongst Nigerian university students. Prevalence and sociodemographic correlates. <i>Soc Psychiatry Psychiatr Epidemiol.</i> 2006; 41(8): 674-8.	2004		
Nigeria	Amoran O, Lawoyin T, Lasebikan V. Prevalence of depression among adults in Oyo State, Nigeria: a comparative study of rural and urban communities. <i>Aust J Rural Health.</i> 2007; 15(3): 211-5.	2004		
Nigeria	Ojo OS, Thurst M, Thomas HC, Ndububa DA, Adeodu OO, Rotimi O, Lawal AA, Durosinni MA, Akonai AK, Fatusi AO. Hepatitis B virus markers, hepatitis D virus antigen and hepatitis C virus antibodies in Nigerian patients with chronic liver disease. <i>East Afr Med J.</i> 1995; 72(11): 719-21.	1993-1994		
Nigeria	Nwokediuko SC, Ijoma UN, Obienu O. Liver Cancer in Enugu, South East Nigeria. <i>Insight Bioinforma.</i> 2011; 1(1): 1-5.	1999-2005		
Nigeria	Olubuyide JO, Aliyu B, Olaleye OA, Ola SO, Olawuyi F, Malabu UH, Odemuyiwa SO, Odaibo GN, Cook GC. Hepatitis B and C virus and hepatocellular carcinoma. <i>Trans R Soc Trop Med Hyg.</i> 1997; 91(1): 38-41.	1995		
Nigeria	Gureje O, Kola L, Afolabi E. Epidemiology of major depressive disorder in elderly Nigerians in the Ibadan Study of Ageing: a community-based survey. <i>Lancet.</i> 2007; 370(9591): 957-64.	2003-2004	*	
Nigeria	Uwakwe R. The pattern of psychiatric disorders among the aged in a selected community in Nigeria. <i>Int J Geriatr Psychiatry.</i> 2000; 15(4): 355-62.	1995	*	
Nigeria	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Nigeria	Ministry of Health (Nigeria). Nigeria National Tuberculosis Prevalence Survey 2012.	2012		
Nigeria	Adegbehingbe BO, Majengbasan TO. Ocular health status of rural dwellers in south-western Nigeria. <i>Aust J Rural Health.</i> 2007; 15(4): 269-72. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2002		
Nigeria	Adeoti CO. Prevalence and causes of blindness in a tropical African population. <i>West Afr J Med.</i> 2004; 23(3): 249-52. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2001-2002		
Nigeria	Adeoye A. Survey of blindness in rural communities of south-western Nigeria. <i>Trop Med Int Health.</i> 1996; 1(5): 672-6. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1991		
Nigeria	Mpyet C, Ogoshi C, Goyol M. Prevalence of trachoma in Yobe State, north-eastern Nigeria. <i>Ophthalmic Epidemiol.</i> 2008; 15(5): 303-7. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2006		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Nigeria	Oluleye TS. Cataract blindness and barriers to cataract surgical intervention in three rural communities of Oyo State, Nigeria. <i>Niger J Med.</i> 2004; 13(2): 156-60. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2001-2002		
Nigeria	Patrick-Ferife G, Ashaye AO, Ousntonkun OO. Rapid assessment of cataract blindness among Ughelli clan in an urban/rural district of Delta State, Nigeria. <i>Ann Afr Med.</i> 2006; 4(2). as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2001		
Nigeria	Rabiu MM. Cataract blindness and barriers to uptake of cataract surgery in a rural community of northern Nigeria. <i>Br J Ophthalmol.</i> 2001; 85(7): 776-80. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	1999		
Nigeria	Ajenifuja KO, Adepiti CA, Ogunniyi SO. Post partum haemorrhage in a teaching hospital in Nigeria: a 5-year experience. <i>Afr Health Sci.</i> 2010; 10(1): 71-4.	2002-2006	*	
Nigeria	Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A, Oladepo O, Smith JS, Arslan A, Muñoz N, Snijders PJF, Meijer CJLM, Franceschi S. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. <i>Br J Cancer.</i> 2004; 90(3): 638-45.	1999-2000	*	
Nigeria	Eltom MA, Mbulateye SM, Dada AJ, Whitby D, Biggar RJ. Transmission of human herpesvirus 8 by sexual activity among adults in Lagos, Nigeria. <i>AIDS.</i> 2002; 16(18): 2473-8.	1991-1994	*	
Nigeria	Komolafe OO, Ashaye AO, Ajayi BGK, Bekibebe CO. Visual impairment from age-related cataract among an indigenous African population. <i>Eye (Lond).</i> 2010; 24(1): 53-8. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2006-2007		
Nigeria	Muhammad N, Mansur RM, Dantani AM, Elhassan E, Isiyaku S. Prevalence and causes of blindness and visual impairment in Sokoto State, Nigeria: baseline data for vision 2020: the Right to Sight Eye Care Programme. <i>Middle East Afr J Ophthalmol.</i> 2011; 18(2): 123-8. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2005		
Nigeria	Airede AI. Birth asphyxia and hypoxic-ischaemic encephalopathy: incidence and severity. <i>Ann Trop Paediatr.</i> 1991; 11(4): 331-5.	1987-1989	*	†
Nigeria	Adeleke SI, Asani MO, Belonwu RO, Gwarzo GD, Farouk ZL. Childhood diabetes mellitus in Kano, North West, Nigeria. <i>Niger J Med.</i> 2010; 19(2): 145-7.	1998-2006		
Nigeria	Ogunleye OO, Ogundele SO, Akinoyemi JO, Ogbera AO. Clustering of hypertension, diabetes mellitus and dyslipidemia in a Nigerian population: a cross sectional study. <i>Afr J Med Med Sci.</i> 2012; 41(2): 191-5.	2008		
Nigeria	Labinjo M, Juillard C, Kobusingye OC, Hyder AA. The burden of road traffic injuries in Nigeria: results of a population-based survey. <i>Inj Prev.</i> 2009; 15(3): 157-62.	2006	*	
Nigeria	Harris R, Gilles HM. Glucose-6-phosphate dehydrogenase deficiency in the peoples of the Niger Delta. <i>Ann Hum Genet.</i> 1961; 199-206.	1959-1961		
Nigeria	Allison AC, Charles LJ, McGregor IA. Erythrocyte Glucose-6-Phosphate Dehydrogenase Deficiency in West Africa. <i>Nature.</i> 1961; 190(4782): 1198-9.	1959-1961		
Nigeria	Capps FP, Gilles HM, Jolly H, Worledge SM. Glucose-6-phosphate dehydrogenase deficiency and neonatal jaundice in Nigeria: their relation to the use of prophylactic vitamin K. <i>Lancet.</i> 1963; 2(7304): 379-83.	1961-1963		
Nigeria	Nance WE. Quantitative studies of glucose-6-phosphate dehydrogenase. <i>Am J Hum Genet.</i> 1977; 29(5): 537-44.	1963		
Nigeria	Luzzatto L, Allan NC. Relationship between the genes for glucose-6-phosphate dehydrogenase and for haemoglobin in a Nigerian population. <i>Nature.</i> 1968; 219(5158): 1041-2.	1966-1968		
Nigeria	May J, Meyer CG, Grosserlinden L, Ademowo OG, Mockenhaupt FP, Olumese PE, Falusi AG, Luzzatto L, Bienzle U. Red cell glucose-6-phosphate dehydrogenase status and pyruvate kinase activity in a Nigerian population. <i>Trop Med Int Health.</i> 2000; 5(2): 119-23.	1998-2000		
Nigeria	Mockenhaupt FP, May J, Stark K, Falusi AG, Meyer CG, Bienzle U. Serum transferrin receptor levels are increased in asymptomatic and mild Plasmodium falciparum-infection. <i>Haematologica.</i> 1999; 84(10): 869-73.	1997-1999		
Nigeria	Ademowo OG, Falusi AG. Molecular epidemiology and activity of erythrocyte G6PD variants in a homogeneous Nigerian population. <i>East Afr Med J.</i> 2002; 79(1): 42-4.	2000-2002		
Nigeria	Naicker S. Burden of end-stage renal disease in sub-Saharan Africa. <i>Clin Nephrol.</i> 2010; 74(Suppl 1): S13-6.	2008-2010		
Nigeria	Bangboye EL. End-stage renal disease in sub-Saharan Africa. <i>Ethn Dis.</i> 2006; 16(2 Suppl 2): 5-9.	2000-2004		
Nigeria	Ijaiya MA, Aboyeji PA. Obstetric urogenital fistula: the Ilorin experience, Nigeria. <i>West Afr J Med.</i> 2004; 23(1): 7-9.	1989-1998	*	
Nigeria	Akinoyemi KO, Bamiro BS, Coker AO. Salmonellosis in Lagos, Nigeria: Incidence of Plasmodium falciparum-associated Co-infection, Patterns of Antimicrobial Resistance, and Emergence of Reduced Susceptibility to Fluoroquinolones. <i>J Health Popul Nutr.</i> 2007; 25(3): 351-8.	2004-2005	*	
Nigeria	Nwawolo CC. The WHO Ear and Hearing Disorders Survey Protocol: Practical Challenges in its Use in a Developing Country (Nigeria). Presented at: Informal Consultation on Epidemiology of Deafness and Hearing Impairment in Developing Countries and Update of the WHO Protocol; 2003; Geneva, Switzerland.	2000		
Nigeria	Weldegabriel GG, Gasasira A, Harvey P, Masresha B, Goodson JL, Pate MA, Abanida E, Chevez A. Measles resurgence following a nationwide measles vaccination campaign in Nigeria, 2005-2008. <i>J Infect Dis.</i> 2011; S226-231.	2008	*	
Nigeria	Ofofwe GE, Ofili AN. Prevalence and impact of headache and migraine among secondary school students in Nigeria. <i>Headache.</i> 2010; 50(10): 1570-5.	2008	*	
Nigeria	Adeniyi OF, Mabogunje CA, Okoromah CN, Renner JK. Neonatal tetanus: the Massey Street Children's Hospital experience. <i>Nig Q J Hosp Med.</i> 2010; 20(4): 147-52.	2006-2008	*	
Nigeria	Bankole IA, Danesi MA, Ojo OO, Okubadejo NU, Ojini FI. Characteristics and outcome of tetanus in adolescent and adult patients admitted to the Lagos University Teaching Hospital between 2000 and 2009. <i>J Neurol Sci.</i> 2012; 323(1-2): 201-4.	2000-2009	*	
Nigeria	Onalo R, Ishiaku HM, Ogala WN. Prevalence and outcome of neonatal tetanus in Zaria, Northwestern Nigeria. <i>J Infect Dev Ctries.</i> 2011; 5(4): 255-9.	2005-2009	*	
Nigeria	Nwosu CO, Djieyep NA. Candidiasis and trichomoniasis among pregnant women in a rural community in the semi-arid zone, north-eastern Nigeria. <i>West Afr J Med.</i> 2007; 26(1): 17-9.	2003-2004		
Nigeria	Nsofor BI, Bello CS, Ekwempu CC. Sexually transmitted disease among women attending a family planning clinic in Zaria, Nigeria. <i>Int J Gynaecol Obstet.</i> 1989; 28(4): 365-7.	1989		
Nigeria	Anosike JC, Onwuliri CO, Inyang RE, Akoh JI, Nwoke BE, Adeiyongo CM, Okoye SN, Akogun OB. Trichomoniasis amongst students of a higher institution in Nigeria. <i>Appl Parasitol.</i> 1993; 34(1): 19-25.	1993		
Nigeria	Konje JC, Otolurin EO, Ogunniyi JO, Obisesan KA, Ladipo OA. The prevalence of Gardnerella vaginalis, Trichomonas vaginalis and Candida albicans in the cytology clinic at Ibadan, Nigeria. <i>Afr J Med Med Sci.</i> 1991; 20(1): 29-34.	1986-1989		
Nigeria	Chukuezi AB. Profound and total deafness in Owerri, Nigeria. <i>East Afr Med J.</i> 1991; 68(11): 905-12.	1987-1989	*	
Nigeria	Kolo PM, Jibrin YB, Sanya EO, Alkali M, Salami AK, Omotoso AB, Tahir A. Outcome of cholera admissions in Bauchi, Nigeria. <i>South Afr J Epidemiol Infect.</i> 2013; 28(3): 143-6.	2010-2011	*	
Nigeria	Lawoyin TO, Ogunbodede NA, Olumide EA, Onadeko MO. Outbreak of cholera in Ibadan, Nigeria. <i>Eur J Epidemiol.</i> 1999; 15(4): 367-70.	1996	*	
Nigeria	Umoh JU, Adesiyun AA, Adekeye JO, Nadarajah M. Epidemiological features of an outbreak of gastroenteritis/cholera in Katsina, Northern Nigeria. <i>J Hyg (Lond).</i> 1983; 91(1): 101-11.	1982		
Nigeria	Getso KI, Kaita IM, Nguku PM, Sabitu K, Idris SH. Nigeria Field Epidemiology and Laboratory Training Program, Abuja, Nigeria, Ahmadu Bello University, Zaria, Nigeria. Cholera Outbreak in Tofa and Samawa Wards - Zamfara State, Nigeria 2011. <i>Am J Trop Med Hyg.</i> 2012; 87(5 Suppl 1): 320.	2011	*	
Nigeria	World Health Organization (WHO). Nigeria WHO Leishmaniasis Country Profile.	1994-2008	*	
Nigeria	Akogun OB. Filariasis in Gongola State Nigeria. I. Clinical and parasitological studies in Mutum-Biyu District. <i>Angew Parasitol.</i> 1992; 33(3): 125-31. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1988-1990	*	
Nigeria	Iboh CI, Okon OE, Opara KN, Asor JE, Erim SE. Lymphatic filariasis among the Yakurr people of Cross River State, Nigeria. <i>Parasit Vectors.</i> 2012; 203. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2009	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Nigeria	Richards FO, Eigege A, Miri ES, Kal A, Umaru J, Pam D, Rakers LJ, Sambo Y, Danboyi J, Ibrahim B, Adelamo SE, Ogah G, Goshit D, Oyeneke OK, Mathieu E, Withers PC, Saka YA, Jiya J, Hopkins DR. Epidemiological and entomological evaluations after six years or more of mass drug administration for lymphatic filariasis elimination in Nigeria. <i>PLoS Negl Trop Dis</i> . 2011; 5(10): e1346. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections</i> .	2000-2009	*	
Nigeria	Okon OE, Iboh CI, Opara KN. Bancroftian filariasis among the Mbembe people of Cross River state, Nigeria. <i>J Vector Borne Dis</i> . 2010; 47(2): 91-6. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections</i> .	2008-2009	*	
Nigeria	Ojorungbe O, Akinbo JA, Ogiogwa JI, Bolaji OS, Adeyeba OA. Lymphatic filariasis in a rural community in Nigeria: a challenge ahead. <i>Afr J Med Med Sci</i> . 2010; 179-83.	2000-2012	*	
Nigeria	Anosike JC, Onwuliri CO. Studies on filariasis in Bauchi State, Nigeria. II. The prevalence of human filariasis in Darazo Local Government area. <i>Appl Parasitol</i> . 1994; 35(4): 242-50. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections</i> .	1990-1991	*	
Nigeria	Ufomadu GO, Nwoke BE, Akoh JI, Sato Y, Ekejindu GO, Uchida A, Shiwaku K, Tumbau M, Ugomo KK. The occurrence of loiasis, mansoniellosis and wuchereriae in the Jarawa River Valley, central Nigeria. <i>Acta Trop</i> . 1990; 48(2): 137-47.	1984-1987	*	
Nigeria	Anosike JC. The status of human filariasis in north-western zone of Bauchi State, Nigeria. <i>Appl Parasitol</i> . 1994; 35(2): 133-40. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections</i> .	1990-1992	*	
Nigeria	Hendrie HC, Ogunniyi A, Hall KS, Baiyewo O, Unverzagt FW, Gureje O, Gao S, Evans RM, Ogunseyinde AO, Adeyinka AO, Musick B, Hui SL. Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. <i>JAMA</i> . 2001; 285(6): 739-47.	1992-1995		
Nigeria	Nigeria National Micronutrient Survey 1993 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1993		
Nigeria	Damascono A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D, Dzudie A, Kouam CK, Suliman A, Schrueder N, Yonga G, Ba SA, Maru F, Alemayehu B, Edwards C, Davison BA, Cotter G, Sliwa K. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. <i>Arch Intern Med</i> . 2012; 172(18): 1386-94.	2007-2010		
Nigeria	Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. <i>Int J Health Geogr</i> . 2010; 9: 57.	1980-2010		
Nigeria	Udo S, Chukwu J, Obasanya J. Leprosy situation in Nigeria. <i>Lepr Rev</i> . 2013; 84(3): 229-37.	2001-2012	*	
Nigeria	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec</i> . 2006; 81(32): 309-16.	2005	*	
Nigeria	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec</i> . 1999; 74(38): 313-6.	1998	*	
Nigeria	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec</i> . 2013; 88(35): 365-79.	2012	*	
Nigeria	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec</i> . 2011; 86(36): 389-99.	2010	*	
Nigeria	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec</i> . 2001; 76(23): 173-9.	2000	*	
Nigeria	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec</i> . 2000; 75(28): 226-31.	1999	*	
Nigeria	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec</i> . 1997; 72(23): 165-72.	1996	*	
Nigeria	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec</i> . 1993; 68(25): 181-6.	1992	*	
Nigeria	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec</i> . 1996; 71(20): 149-56.	1995	*	
Nigeria	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1995; 70(25): 177-82.	1994	*	
Nigeria	Obunge OK, Brabin L, Dollimore N, Kemp J, Ikoku-Wonodi C, Babatunde S, White S, Briggs ND, Hart CA. A flowchart for managing sexually transmitted infections among Nigerian adolescent females. <i>Bull World Health Organ</i> . 2001; 79(4): 301-5.	1998-1999	*	
Nigeria	Nimorsi OP, Egunyenga AO, Bajomo DO. Survey of urinary schistosomiasis and trichomoniasis in a rural community in Edo State, Nigeria. <i>J Commun Dis</i> . 2001; 33(2): 96-101.	1999-2000	*	
Nigeria	Ejimadu CS, Adio AO. The burden of low vision in farming communities in South-South Nigeria. <i>Niger J Med</i> . 2012; 21(2): 218-22.	2007	*	
Nigeria	Fafowora OF. Prevalence of blindness in a rural ophthalmically underserved Nigerian community. <i>West Afr J Med</i> . 1996; 15(4): 228-31.	1993-1995	*	
Nigeria	Oduabo OP, Mpyet CD, Chiroma MR, Aboje AO. Cataract blindness, surgical coverage, outcome, and barriers to uptake of cataract services in Plateau State, Nigeria. <i>Middle East Afr J Ophthalmol</i> . 2012; 19(3): 282-8.	2007	*	
Nigeria	Megbelayin EO. Prevalence of amblyopia among secondary school students in Calabar, south-south Nigeria. <i>Niger J Med</i> . 2012; 21(4): 407-11.	2009-2010	*	
Nigeria	Kolawole OU, Ashaye AO, Mahmoud AO, Adeoti CO. Cataract blindness in Osun state, Nigeria: results of a survey. <i>Middle East Afr J Ophthalmol</i> . 2012; 19(4): 364-71.	2005	*	
Nigeria	Fleming AF, Storey J, Molineaux L, Iroko EA, Attai ED. Abnormal haemoglobins in the Sudan savanna of Nigeria. I. Prevalence of haemoglobins and relationships between sickle cell trait, malaria and survival. <i>Ann Trop Med Parasitol</i> . 1979; 73(2): 161-72.	1970-1974		
Nigeria	Ogunlesi TA, Okeniyi JAO, Oyelami OA. Pyogenic meningitis in Ilesa, Nigeria. <i>Indian Pediatr</i> . 2005; 42(10): 1019-23.	1998-2003		
Nigeria	Akpede GO, Akuhwa RT, Ogiji EO, Ambe JP. Risk factors for an adverse outcome in bacterial meningitis in the tropics: a reappraisal with focus on the significance and risk of seizures. <i>Ann Trop Paediatr</i> . 1999; 19(2): 151-9.	1993-1996		
Nigeria	Airede KI, Adeyemi O, Ibrahim T. Neonatal bacterial meningitis and dexamethasone adjunctive usage in Nigeria. <i>Niger J Clin Pract</i> . 2008; 11(3): 235-45.	1992-1995		
Nigeria	Bademosi O, Osuntokun BO. Prednisolone in the treatment of pneumococcal meningitis. <i>Trop Geogr Med</i> . 1979; 31(1): 53-6.	1975		
Nigeria	Das SC, Isichei UP, Egbuta JO, Banwo AI. Cations and anions in drinking water as putative contributory factors to endemic goitre in Plateau State, Nigeria. <i>Trop Geogr Med</i> . 1989; 41(4): 346-52 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1983-1987		
Nigeria	Taiwo JO, Omokhodion F. Pattern of tooth loss in an elderly population from Ibadan, Nigeria. <i>Gerodontology</i> . 2006; 23(2): 117-22.	2001-2004		
Nigeria	Nwosu CM, Njeze GE, Opara C, Nwajuaku C, Chukwurah CK. Central nervous system infections in the rainforest zone of Nigeria. <i>East Afr Med J</i> . 2001; 78(2): 97-101.	1991-1993		
Nigeria	Folayan MO, Sofola OO, Oginni AB. Caries incidence in a cohort of primary school students in Lagos State, Nigeria followed up over a 3 years period. <i>Eur Arch Paediatr Dent</i> . 2012; 13(6): 312-8.	2000, 2003	*	
Nigeria	World Health Organization (WHO). Mental Illness in General Health Care: An International Study. Geneva, Switzerland: World Health Organization (WHO), 1995.	1991-1992		
Ghana	Eastwood JB, Kerry SM, Plange-Rhule J, Micah FB, Antwi S, Boa FG, Banerjee D, Emmett L, Miller MA, Cappuccio FP. Assessment of GFR by four methods in adults in Ashanti, Ghana: the need for an eGFR equation for lean African populations. <i>Nephrol Dial Transplant</i> . 2010; 25(7): 2178-87.	2009	*	
Nigeria	Arogundade FA, Sanusi AA, Hassan MO, Akinsola A. The pattern, clinical characteristics and outcome of ESRD in Ile-Ife, Nigeria: is there a change in trend? <i>Afr Health Sci</i> . 2011; 11(4): 594-601.	1989-2007	*	
Nigeria	Alikor EA, Erhabor ON. Seroprevalence of hepatitis B surface antigenaemia in children in a tertiary health institution in the Niger Delta of Nigeria. <i>Niger J Med</i> . 2007; 16(3): 250-1.	1999-2004		
Nigeria	Akingugbe FM. Anaemia in a rural population in Nigeria (Ilori). <i>Ann Trop Med Parasitol</i> . 1980; 74(6): 625-33.	1977-1979	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Nigeria	Egesie OJ, Joseph DE, Isiguzoro I, Egesie UG. Glucose-6-phosphate dehydrogenase (G6PD) activity and deficiency in a population of Nigerian males resident in Jos. <i>Niger J Physiol Sci.</i> 2008; 23(1-2): 9-11.	2005-2007	*	
Nigeria	Afegbua SL, Bugaje MA, Ahmad AA. Seroprevalence of hepatitis A virus infection among schoolchildren and adolescents in Kaduna, Nigeria. <i>Trans R Soc Trop Med Hyg.</i> 2013; 107(10): 627-30.	2009	*	
Nigeria	Kulkarni AG, Jekeme SD. Cord blood screening for haemoglobinopathies in northern Nigeria. <i>Ann Trop Med Parasitol.</i> 1986; 80(5): 549-51.	1983-1984	*	
Nigeria	Danesi MA. Epilepsy and the secondary schools in Nigeria. <i>Trop Geogr Med.</i> 1994; 46(3 Suppl): S25-27.	1994	*	†
Nigeria	Ahmed H, Yukubu AM, Hendrickse RG. Neonatal jaundice in Zaria, Nigeria—a second prospective study. <i>West Afr J Med.</i> 1995; 14(1): 15-23.	1988	*	
Nigeria	Azubuikwe JC. Neonatal jaundice in eastern Nigeria. <i>East Afr Med J.</i> 1979; 56(7): 320-4.	1974-1975	*	
Nigeria	Effiong CE, Aimaku VE, Bienzle U, Oyedeji GA, Ikpe DE. Neonatal jaundice in Ibadan. Incidence and etiologic factors in babies born in hospital. <i>J Natl Med Assoc.</i> 1975; 67(3): 208-13.	1971-1972	*	
Nigeria	Ibekwe RC, Ihekwe MU, Muoneke VU. Outcome of exchange blood transfusions done for neonatal jaundice in abakaliki, South eastern Nigeria. <i>J Clin Neonatol.</i> 2012; 1(1): 34-7.	2007-2009	*	
Nigeria	Okonkwo UC, Nwosu MN, Ukah C, Okpala OC, Ahaneku JI. The clinical and pathological features of hepatocellular carcinoma in Nnewi, Nigeria. <i>Niger J Med.</i> 2011; 20(3): 366-71.	2007-2008	*	
Nigeria	Ayoola EA. Antibody to hepatitis A virus in healthy Nigerians. <i>J Natl Med Assoc.</i> 1982; 74(5): 465-8.	1981	*	
Nigeria	Jeremiah ZA, Oduomodoye C. Rh antigens and phenotype frequencies of the Ibibio, Efik, and Ibo ethnic nationalities in Calabar, Nigeria. <i>Immunohematology.</i> 2005; 21(1): 21-4.	2002-2004	*	†
Nigeria	Omotade OO, Adeyemo AA, Kayode CM, Falade SL, Ikpe S. Gene frequencies of ABO and Rh (D) blood group alleles in a healthy infant population in Ibadan, Nigeria. <i>West Afr J Med.</i> 1999; 18(4): 294-7.	1988-1992	*	†
Nigeria	Enosolease ME, Bazuaie GN. Distribution of ABO and Rh-D blood groups in the Benin area of Niger-Delta: Implication for regional blood transfusion. <i>Asian J Transfus Sci.</i> 2008; 2(1): 3-5.	1986-2005	*	†
Nigeria	Adebami OJ. Factors associated with the incidence of acute bilirubin encephalopathy in Nigerian population. <i>J Pediatr Neurol.</i> 2011; 9(3): 347-53.	2007-2009	*	†
Nigeria	Ogunlesi TA, Dedeke IOF, Adekanmbi AF, Fetuga MB, Ogunfowora OB. The incidence and outcome of bilirubin encephalopathy in Nigeria: a bi-centre study. <i>Niger J Med.</i> 2007; 16(4): 354-9.	2001-2005	*	†
Nigeria	Eneh AU, Oruamabo RS. Neonatal jaundice in a Special Care Baby Unit (SCBU) in Port Harcourt, Nigeria: a prospective study. <i>Port Harcourt Med J.</i> 2008; 2(2): 110-7.	2002	*	†
Nigeria	Owa JA, Ogunlesi TA. Why we are still doing so many exchange blood transfusion for neonatal jaundice in Nigeria. <i>World J Pediatr.</i> 2009; 5(1): 51-5.	2005-2008	*	†
Nigeria	Slusher TM, Vreman HJ, McLaren DW, Lewison LJ, Brown AK, Stevenson DK. Glucose-6-phosphate dehydrogenase deficiency and carboxyhemoglobin concentrations associated with bilirubin-related morbidity and death in Nigerian infants. <i>J Pediatr.</i> 1995; 126(1): 102-8.	1991-1992	*	†
Nigeria	Adebajo AO, Smith DJ, Hazleman BL, Wreghitt TG. Seroprevalence of tuberculosis, malaria, hepatitis B, and AIDS in West Africa. <i>J Med Virol.</i> 1994; 42(4): 366-8.	1990	*	
Nigeria	Amazigo UO, Chime AB. Hepatitis-B virus infection in rural and urban populations of eastern Nigeria: prevalence of serological markers. <i>East Afr Med J.</i> 1990; 67(8): 539-44.	1988	*	
Nigeria	Bada AS, Olatunji PO, Adeguyi JO, Iseniyi JO, Onile BA. Hepatitis B surface antigenaemia in Ilorin, Kwara State, Nigeria. <i>Cent Afr J Med.</i> 1996; 42(5): 139-41.	1994	*	
Nigeria	Balogun WO, Adeleye JO, Akinlade KS, Kuti M, Otegbayo JA. Low prevalence of hepatitis-C viral seropositivity among patients with type-2 diabetes mellitus in a tertiary hospital. <i>J Natl Med Assoc.</i> 2006; 98(11): 1805-8.	2004	*	
Nigeria	Belo AC. Prevalence of hepatitis B virus markers in surgeons in Lagos, Nigeria. <i>East Afr Med J.</i> 2000; 77(5): 283-5.	1998	*	
Nigeria	Chikwem JO, Mohammed I, Okara GC, Ukwandu NC, Ola TO. Prevalence of transmissible blood infections among blood donors at the University of Maiduguri Teaching Hospital, Maiduguri, Nigeria. <i>East Afr Med J.</i> 1997; 74(4): 213-6.	1992	*	
Nigeria	Daramola OOM, George AO, Ogunbiyi AO, Otegbayo JA. Hepatitis B virus in Nigerians with lichen planus. <i>West Afr J Med.</i> 2004; 23(2): 104-6.	2002	*	
Nigeria	Halim NK, Ajayi OI. Risk factors and seroprevalence of hepatitis C antibody in blood donors in Nigeria. <i>East Afr Med J.</i> 2000; 77(8): 410-2.	1998	*	
Nigeria	Halim NK, Madukwe U, Saheeb BD, Airaui LU. Hepatitis B surface antigen and antibody to hepatitis C virus among accident and emergency patients. <i>East Afr Med J.</i> 2001; 78(9): 480-3.	1995	*	
Nigeria	Harry TO, Bajani MD, Moses AE. Hepatitis B virus infection among blood donors and pregnant women in Maiduguri, Nigeria. <i>East Afr Med J.</i> 1994; 71(9): 596-7.	1992	*	
Nigeria	Ikeme AC, Ezegwui HU, Ogbonna C. Sero prevalence of hepatitis B surface antigen (HBsAg) in pregnant women in Southeast Nigeria. <i>Trop Doct.</i> 2006; 36(2): 128.	2000-2004	*	
Nigeria	Kosate BBD, Buseri FI, Jeremiah ZA. Seroprevalence of hepatitis C virus among blood donors in Rivers State, Nigeria. <i>Transfus Med.</i> 2005; 15(5): 449-51.	2005	*	
Nigeria	Mabuyoje VO, Oparinde DP, Akanni EO, Taiwo SS, Muhibi MA, Adebayo TO. Seroprevalence of hepatitis B and C and of human immunodeficiency virus among blood donors in south-west Nigeria. <i>Br J Biomed Sci.</i> 2007; 64(4): 177-9.	2004-2005	*	
Nigeria	Nasidi A, Harry TO, Vyazov SO, Munube GM, Azzan BB, Ananiev VA. Prevalence of hepatitis B infection markers in representative areas of Nigeria. <i>Int J Epidemiol.</i> 1986; 15(2): 274-6.	1984	*	
Nigeria	Obi CL, Anyiwo CE, Nnatu SN, Agbolanbor DE, Esumeh FI, Karpas A. A comparison of human immunodeficiency virus (HIV) seropositivity and hepatitis B surface antigenemia (HBsAg) among the same group of apparently healthy pregnant women in Lagos, Nigeria: a preliminary report. <i>Viral Immunol.</i> 1993; 6(1): 43-7.	1991	*	
Nigeria	Ojo OS, Akonai AK, Thurst M, Ndububa DA, Durosini MA, Adeodu OO, Fatusi OA, Goldin RD. Hepatitis D virus antigen in HBsAg positive chronic liver disease in Nigeria. <i>East Afr Med J.</i> 1998; 75(6): 329-31.	1995-1997	*	
Nigeria	Olubuyide JO, Maxwell SM, Akinyinka OO, Hart CA, Neal GE, Hendrickse RG. HBsAg and aflatoxins in sera of rural (Igbora) and urban (Ibadan) populations in Nigeria. <i>Afr J Med Med Sci.</i> 1993; 22(4): 77-80.	1991	*	
Nigeria	Onakewhor JU, Ofor E, Okonofua FE. Maternal and neonatal seroprevalence of hepatitis B surface antigen (HBsAg) in Benin City, Nigeria. <i>J Obstet Gynaecol.</i> 2001; 21(6): 583-6.	1997-1998	*	
Nigeria	Otegbayo JA, Fasola FA, Abja A. Prevalence of hepatitis B surface and e antigens, risk factors for viral acquisition and serum transaminase among blood donors in Ibadan, Nigeria. <i>Trop Gastroenterol.</i> 2003; 24(4): 196-7.	2001	*	
Nigeria	Salawu L, Murainah HA. Pre-donation screening of intending blood donors for antibodies to infectious agents in a Nigerian tertiary health institution: a pilot study. <i>Afr J Med Med Sci.</i> 2006; 35(4): 453-6.	2003-2004	*	
Nigeria	Sirisen ND, Njoku MO, Idoko JA, Isamade E, Barau C, Jelpe D, Zamani A, Otowo S. Carriage rate of hepatitis-B surface antigen (HBsAg) in an urban community in Jos, Plateau State, Nigeria. <i>Niger Postgrad Med J.</i> 2002; 9(1): 7-10.	1999	*	
Nigeria	Umolu PI, Okoror LE, Orhue P. Human immunodeficiency virus (HIV) seropositivity and hepatitis B surface antigenemia (HBsAg) among blood donors in Benin city, Edo state, Nigeria. <i>Afr Health Sci.</i> 2005; 5(1): 55-8.	2003	*	
Nigeria	Uneke CI, Ogbu O, Inyama PU, Anyanwu GI, Njoku MO, Idoko JH. Prevalence of hepatitis-B surface antigen among blood donors and human immunodeficiency virus-infected patients in Jos, Nigeria. <i>Mem Inst Oswaldo Cruz.</i> 2005; 100(1): 13-6.	1999-2002	*	
Nigeria	Gestational age-specific neonatal mortality among preterm singleton births in a Nigerian tertiary institution. <i>International Journal of Gynecology & Obstetrics.</i> 2003 Mar; 80(3): 319-20.	1998, 2003		†
Nigeria	Agi PI, Ebenezer A. Observations on Filariasis Infection in Amassoma Community in the Niger Delta, Nigeria. <i>Niger J Appl Sci Environ Manag.</i> 2009; 13(1), as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2006-2007	*	
Nigeria	Ajero CMU, Nwoke BEB, Nwanjo HU, Oze G, Okafor MC, Nwosu D, Anyaehie B, Uloneme GC. Bancroftian Filariasis in the Niger Delta Area of Eastern Nigeria. <i>Res J Med Sci.</i> 2007; 1(2): 113-7, as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2000-2012	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Nigeria	Anosike JC, Nwoke BE, Ajayi EG, Onwuliri CO, Okoro OU, Oku EE, Asor JE, Amajuoyi OU, Ikpeana CA, Ogbusu FI, Meribe CO. Lymphatic filariasis among the Ezza people of Ebonyi State, eastern Nigeria. <i>Ann Agric Environ Med</i> . 2005; 12(2): 181-6. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2002-2003	*	
Nigeria	Anosike JC, Onwuliri COE, Onwuliri VA. Human filariasis in Dass local government area of Bauchi state, Nigeria. <i>Trop Ecol</i> . 2003; 44(2): 217-27. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1995	*	
Nigeria	Dogara MM, Nock HI, Agbede RIS, Ndams SI, Joseph KK. Prevalence Of Lymphatic Filariasis In Three Villages In Kano State, Nigeria. <i>Internet J Trop Med</i> . 2012; 8(1), as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2000-2012	*	
Nigeria	Ebenezer A, Amadi EC, Agi PI. Studies on the microfilaria, antigenemia and clinical signs of bancroftian filariasis in Epie creek communities, Niger Delta, Nigeria. <i>Int Res J Microbiol</i> . 2011; 2(9): 370-4. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2009-2010	*	
Nigeria	Obi RK, Nwawnebu FC, Ndubuisi-NNaji UU, Okangba CC, Braide W, Orji NM, Ukegbu AD, Ukegbu PO. Endemicity of lymphatic filariasis in Three Local Government Areas of Imo State, Nigeria. <i>Aust J Basic Appl Sci</i> . 2011; 5(5): 875-79. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2000-2012	*	
Nigeria	Ojiako OA, Onyeze GOC. Epidemiological And Biochemical Studies Of Human Lymphatic Filariasis And Associated Parasitoses In Oguta, Southeastern Nigeria. <i>Internet J Parasit Dis</i> . 2008; 4(1), as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2000-2012	*	
Nigeria	Okorie PN, Ademowo GO, Saka Y, Davies E, Okoronkwo C, Bockarie MJ, Molyneux DH, Kelly-Hope LA. Lymphatic filariasis in Nigeria; micro-stratification overlap mapping (MOM) as a prerequisite for cost-effective resource utilization in control and surveillance. <i>PLoS Negl Trop Dis</i> . 2013; 7(9): e2416. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2004	*	
Nigeria	Targema CN, Onwuliri COE, Mwanat GS. Bancroftian filariasis in Ushongo Local Government Area of Benue State, Nigeria: Clinical, parasitological and serological studies in an endemic community. <i>Int J Environ Health Hum Develop</i> . 2003; 1-4. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2001	*	
Nigeria	Udonsi JK. Bancroftian filariasis in the Igunwun basin, Nigeria: an epidemiological, parasitological, and clinical study in relation to the transmission dynamics. <i>Folia Parasitol (Praha)</i> . 1988; 35(2): 147-55. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1984-1985	*	
Nigeria	Udonsi JK. The status of human filariasis in relation to clinical signs in endemic areas of the Niger Delta. <i>Ann Trop Med Parasitol</i> . 1986; 80(4): 425-32. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1983-1985	*	
Nigeria	Utah E, Ibeh DC. Multiple filarial species microfilaraemia: a comparative study of areas with endemic and sporadic onchocerciasis. <i>J Vector Borne Dis</i> . 2011; 48(4): 197-204. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2000-2012	*	
Nigeria	Utah EC, Simonsen PE, Pedersen EM, Udonsi JK. Bancroftian filariasis in the lower Imo River Basin, Nigeria. <i>Afr J Appl Zool Environ Biol</i> . 2004; 65-75. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2000-2012	*	
Nigeria	Chukudebelu WO, Esege N, Megafu U. Etiological factors in infertility in Enugu, Nigeria. <i>Infertility</i> . 1979; 2(2): 193-200.	1977-1979	*	
Nigeria	Orhue A, Aziken M. Experience with a comprehensive university hospital-based infertility program in Nigeria. <i>Int J Gynaecol Obstet</i> . 2008; 101(1): 11-5.	1993-2004	*	
Nigeria	Ugwu EO, Onwuka CI, Okezie OA. Pattern and outcome of infertility in Enugu: the need to improve diagnostic facilities and approaches to management. <i>Niger J Med</i> . 2012; 21(2): 180-4.	2004-2008	*	
Nigeria	Studies on the status of Bancroftian filariasis in parts of Benue state, Nigeria as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2001	*	
Nigeria	Ogunniyi A, Baiyewu O, Gureje O, Hall KS, Unverzagt F, Siu SH, Gao S, Farlow M, Oluwole OSA, Komolafe O, Hendrie HC. Epidemiology of dementia in Nigeria: results from the Indianapolis-Ibadan study. <i>Eur J Neurol</i> . 2000; 7(5): 485-90.	1992-1994		
Nigeria	Adelekan ML, Ndom RJE, Makanjuola AB, Parakoyi DB, Osagbemi GK, Fagbemi O, Petu AO. Trend analysis of substance use among undergraduates of University of Ilorin, Nigeria, 1988-1998. <i>Afr J Drug Alcohol Stud</i> . 2000; 1(1): 39-52.	1998	*	
Nigeria	Olusanya BO, Somefun AO. Place of birth and characteristics of infants with congenital and early-onset hearing loss in a developing country. <i>Int J Pediatr Otorhinolaryngol</i> . 2009; 73(9): 1263-9.	2005-2008		
Nigeria	Annual Report for Pampaida, Nigeria, Millennium Village. Year 1: February 2006 - February 2007 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006-2007	*	†
Nigeria	Malaria Among Asymptomatic School Children in Ezinihitte Local Government Area of Imo State, Nigeria as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008	*	†
Nigeria	Mosquito Control Strategies and Prevalence of Malaria in Children (0-15 years) in Amucha Community, Abia State, Nigeria as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2007	*	†
Nigeria	Characteristics of P. Falciparum Infections in Children in a Suburb of Ibadan, Nigeria as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Nigeria	Malaria Situation in Nigeria as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Nigeria	Boureima SH. Sondage Paludométrique dans les différentes zones épidémiologiques du Niger en période de saison des pluies [Malaria survey in different epidemiological zones in Niger during the rainy season]. <i>Malar Infect Dis Afr</i> . 1995; 2: 12-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Nigeria	Ademowo OG, Falusi AG, Mewoyeka OO. Prevalence of asymptomatic parasitaemia in an urban and rural community in south western Nigeria. <i>Cent Afr J Med</i> . 1995; 41(1): 18-21 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Nigeria	Anumudu C, Afolami M, Igwe C, Nwagwu M, Keshinro O. Nutritional anaemia and malaria in pre-school and school age children. <i>Ann Afr Med</i> . 2008; 7(1): 11 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Nigeria	Anumudu CI, Adepoju A, Adediran M, Adeoye O, Kassim A, Oyewole I, Nwuba RI. Malaria prevalence and treatment seeking behaviour of young Nigerian adults. <i>Ann Afr Med</i> . 2007; 5(2): 82-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Nigeria	Arinola O. Complement factors and circulating immune complexes in children with urinary schistosomiasis and asymptomatic malaria. <i>Afr J Med Med Sci</i> . 2005; 34(1): 9-13 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Nigeria	Brieger W, Sesay H, Adesina H, Mosanya M, Ogunlade P, Ayodele I, Orisasona S. Urban malaria treatment behaviour in the context of low levels of malaria transmission in Lagos, Nigeria. <i>Afr J Med Med Sci</i> . 2000; 30(Suppl): 7-15 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Nigeria	Ejezie GC, Onyezili NI, Okeke GC, Enwonwu CO, Ijanikin: a study of environmental health in a rural Nigerian community. <i>J Hyg Epidemiol Microbiol Immunol</i> . 1987; 31(2): 163-72 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Nigeria	Ekpenyong EA, Eyo JE. Malaria control and treatment strategies among school children in semi-urban tropical communities. <i>West Indian Med J</i> . 2008; 57(5): 456-61 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Nigeria	Eneanya CI. Seasonal variation in malaria episodes among residents in a semi-urban community in South-East Nigeria. <i>Niger J Parasitol.</i> 1998; 19: 39-43 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Nigeria	Engelbrecht F, Tiget E, Beck H-P, Enwezor F, Oestli A, Felger I. Analysis of Plasmodium falciparum infections in a village community in Northern Nigeria: determination of msp2 genotypes and parasite-specific IgG responses. <i>Acta Trop.</i> 2000; 74(1): 63-71 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Nigeria	Etieng MU. Effect of Plasmodium falciparum parasitaemia on some haematological parameters in adolescent and adult Nigerian HbAA and HbAS blood genotypes. <i>Cent Afr J Med.</i> 2002; 48(11-12): 129-32 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000	*	†
Nigeria	Ezedinachi EN, Ejezie GC, Usanga EA, Gemade EI, Ikpat NW, Alaribe AA. New trends in chloroquine efficacy in the treatment of malaria: chloroquine-resistant Plasmodium falciparum in Anambra and Benue States of Nigeria. <i>Cent Afr J Med.</i> 1991; 37(6): 180-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Nigeria	Falade CO, Nash O, Akingbola TS, Michael OS, Olojede F, Ademowo OG. Blood banking in a malaria-endemic area: evaluating the problem posed by malarial parasitaemias. <i>Ann Trop Med Parasitol.</i> 2009; 103(5): 383-92 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005-2006	*	†
Nigeria	Ibadin MO, Ogbimi A. Antiphospholipid antibodies in African school aged children with malaria. <i>West Afr J Med.</i> 2004; 23(4): 276-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
Nigeria	Igbeneghu C, Odaibo AB, Olaleye DO. Impact of asymptomatic malaria on some hematological parameters in the Iwo community in Southwestern Nigeria. <i>Med Princ Pract.</i> 2011; 20(5): 459-63 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008-2009	*	†
Nigeria	Iriemem NC, Okafor CMF, Balogun HA, Ayede I, Omosun Y, Persson J-O, Hagstedt M, Anumudu CI, Nwuba RI, Trye-Blomberg M, Berzins K. Cytokine profiles and antibody responses to Plasmodium falciparum malaria infection in individuals living in Ibadan, southwest Nigeria. <i>Afr Health Sci.</i> 2009; 9(2): 66-74 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Nigeria	Jeremiah ZA, Uko E. Childhood asymptomatic malaria and nutritional status among Port Harcourt children. <i>East Afr J Public Health.</i> 2007; 4(2): 55-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005-2006	*	†
Nigeria	May J, Falusi AG, Mockenhaupt FP, Ademowo OG, Olumese PE, Bienze U, Meyer CG. Impact of subpatent multi-species and multi-clonal plasmodial infections on anaemia in children from Nigeria. <i>Trans R Soc Trop Med Hyg.</i> 2000; 94(4): 399-403 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996-1997	*	†
Nigeria	May J, Mockenhaupt FP, Ademowo OG, Falusi AG, Olumese PE, Bienze U, Meyer CG. High rate of mixed and subpatent malarial infections in southwest Nigeria. <i>Am J Trop Med Hyg.</i> 1999; 61(2): 339-43 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996-1997	*	†
Nigeria	Molta NB, Daniel HI, Watila IM, Oguce SO, Otu TI, Ameh JO, Gadzama NM. Efficacies of chloroquine, pyrimethamine/sulphadoxine and pyrimethamine/sulphalene against P. falciparum in northeastern Nigeria. <i>J Trop Med Hyg.</i> 1992; 95(4): 253-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988-1990	*	†
Nigeria	Ojirongbe O, Adegbayi AM, Bolaji OS, Akindele AA, Adefioye OA, Adeyeba OA asymptomatic falciparum malaria and intestinal helminths co-infection among school children in Osogbo, Nigeria. <i>J Res Med Sci.</i> 2011; 16: 680-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2009	*	†
Nigeria	Okonofua FE, Feyisetan BJ, Davies-Adetugbo A, Sanusi YO. Influence of socioeconomic factors on the treatment and prevention of malaria in pregnant and non-pregnant adolescent girls in Nigeria. <i>J Trop Med Hyg.</i> 1992; 95(5): 309-15 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Nigeria	Omosun YO, Anumudu CI, Adoro S, Odaibo AB, Sodeinde O, Holder AA, Nwagwu M, Nwuba RI. Variation in the relationship between anti-MSP-1(19) antibody response and age in children infected with Plasmodium falciparum during the dry and rainy seasons. <i>Acta Trop.</i> 2005; 95(3): 233-47 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Nigeria	Oparaacha E. The impact of haemoglobin level and concomitant infections on malaria parasitaemia and on-set of fever during malaria attack in Ikwuano local government area of Abia state, Nigeria. <i>Niger J Parasitol.</i> 2003; 24: 25-32 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Nigeria	Salako LA, Ajayi FO, Sowunmi A, Walker O. Malaria in Nigeria: a revisit. <i>Ann Trop Med Parasitol.</i> 1990; 84(5): 435-45 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987-1988	*	†
Nigeria	Sowunmi A. Body temperature and malaria parasitaemia in rural African children. <i>East Afr Med J.</i> 1995; 72(7): 427-30 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Nigeria	Udoh EE, Oyo-Ita AE, Odey FA, Eyang KI, Oranganje CM, Oduwole OA, Okebe JU, Esu EB, Meremikwu MM, Asindi AA. Malarial indices among Nigerian children in a rural setting. Malaria research and treatment. 2013; 2013: 716805 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008	*	†
North Korea	Korea, North Multiple Indicator Cluster Survey 1998 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1998		†
North Korea	Central Bureau of Statistics (North Korea), United Nations Children's Fund (UNICEF). Korea, North Multiple Indicator Cluster Survey 2000.	2000	*	†
North Korea	Central Bureau of Statistics (North Korea), Institute of Children's Nutrition (North Korea), United Nations Children's Fund (UNICEF). Korea, North Multiple Indicator Cluster Survey 2009.	2009	*	†
North Korea	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
North Korea	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1999, 2003-2009		
North Korea	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
North Korea	Chen C-C, Chen T-F, Hwang Y-C, Wen Y-R, Chiu Y-H, Wu C-Y, Chen R-C, Chen T-H, Liou H-H. Population-based survey on prevalence of adult patients with epilepsy in Taiwan (Keelung community-based integrated screening no. 12). <i>Epilepsy Res.</i> 2006; 72(1): 67-74.	2001	*	†
North Korea	Su C, Chang S, Chen Z, Lee C, Chen R. Neuroepidemiological survey in Ilan, Taiwan (NEST): (4) Prevalence of epilepsy. <i>Acta Neurol Taiwan.</i> 1998; 7(2): 75-84.	1993-1995	*	†
North Korea	Hsieh L-P, Huang C-Y. Prevalence of treated epilepsy in western medicine among the adult population in Taiwan: a study conducted using antiepileptic drug prescription data. <i>Epilepsy Res.</i> 2008; 80(2-3): 114-8.	2004	*	†
North Korea	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
North Korea	North Korea Vital Registration Birth Data 1993 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1993		
Norway	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2002-2011		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Norway	World Health Organization (WHO). Norway World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		
Norway	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. <i>Scand J Clin Lab Invest.</i> 2007; 67(1): 39-69.	1988, 2006		
Norway	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1988, 2003, 2006		
Norway	Overland GB, Vatten L, Rhodes T, DeMuro C, Jacobsen G, Vada K, Angelsen A, Girman CJ. Lower urinary tract symptoms, prostate volume and uroflow in Norwegian community men. <i>Eur Urol.</i> 2001; 39(1): 36-41.	2000		
Norway	Dalgard F, Svensson A, Holm JØ, Sundby J. Self-reported skin morbidity in Oslo. Associations with sociodemographic factors among adults in a cross-sectional study. <i>BMC Dermatol.</i> 2004; 6(4): 452-7.	2000-2001		
Norway	Ellekjær H, Holmen J, Indredavik B, Terent A. Epidemiology of Stroke in Inherred, Norway, 1994 to 1996: Incidence and 30-Day Case-Fatality Rate. <i>Stroke.</i> 1997; 28(11): 2180-4.	1994-1996		
Norway	Halvorsen JA, Braae Olesen A, Thoresen M, Holm JØ, Bjertness E, Dalgard F. Comparison of self-reported skin complaints with objective skin signs among adolescents. <i>Acta Derm Venereol.</i> 2008; 88(6): 573-7.	2006		
Norway	Bovim G, Schrader H, Sand T. Neck pain in the general population. <i>Spine.</i> 1994; 19(12): 1307-9.	1991		
Norway	Hertzberg A. Prediction of cervical and low-back pain based on routine school health examinations. A nine- to twelve-year follow-up study. <i>Scand J Prim Health Care.</i> 1985; 3(4): 247-53.	1982		
Norway	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001-2006, 2008-2009		
Norway	von Plessen C, Grinde O, Gulsvik A. Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. <i>Respir Med.</i> 2003; 97(4): 428-35.	1984-1998		
Norway	Larsen JP, Riise T, Nylund H, Kvåle G, Aarli JA. Clustering of multiple sclerosis in the county of Hordaland, Western Norway. <i>Acta Neurol Scand.</i> 1985; 71(5): 390-5.	1963-1983		
Norway	Riise T, Grønning M, Klauber MR, Barrett-Connor E, Nylund H, Albrektsson G. Clustering of residence of multiple sclerosis patients at age 13 to 20 years in Hordaland, Norway. <i>Am J Epidemiol.</i> 1991; 133(9): 932-9.	1987		
Norway	Midgard R, Riise T, Kvåle G, Nylund H. Disability and mortality in multiple sclerosis in western Norway. <i>Acta Neurol Scand.</i> 1996; 93(5): 307-14.	1981-1991		
Norway	Edland A, Nylund H, Riise T, Larsen JP. Epidemiology of multiple sclerosis in the county of Vestfold, eastern Norway: incidence and prevalence calculations. <i>Acta Neurol Scand.</i> 1996; 93(2-3): 104-9.	1983		
Norway	Grønning M, Riise T, Kvåle G, Nylund H, Larsen JP, Aarli JA. Incidence of multiple sclerosis in Hordaland, western Norway: a fluctuating pattern. <i>Neuroepidemiology.</i> 1991; 10(2): 53-61.	1953-1987		
Norway	Midgard R, Riise T, Svanes C, Kvåle G, Nylund H. Incidence of multiple sclerosis in More and Romsdal, Norway from 1950 to 1991: An age-period-cohort analysis. <i>Brain.</i> 1996; 119(1): 203-11.	1950-1954, 1985-1991		
Norway	Dahl OP, Aarseth JH, Myhr KM, Nylund H, Midgard R. Multiple sclerosis in Nord-Trøndelag County, Norway: a prevalence and incidence study. <i>Acta Neurol Scand.</i> 2004; 109(6): 378-84.	1974-2000		
Norway	Gronlie SA, Myrvoll E, Hansen G, Grønning M, Mellgren SI. Multiple sclerosis in North Norway, and first appearance in an indigenous population. <i>J Neurol.</i> 2000; 247(2): 129-33.	1973-1993		
Norway	Koch-Henriksen N. Multiple sclerosis in Scandinavia and Finland. <i>Acta Neurol Scand.</i> 1995; 91(S161): 55-9.	1950-1980		
Norway	Alstadhaug KB, Olavsen J, Salvesen R. Occurrence of multiple sclerosis in Nordland, 1970-1999. <i>J Nor Med Assoc.</i> 2005; 125(4): 431-3.	1985-1999		
Norway	Holm M, Omenaas E, Gislason T, Svanes C, Jøgi R, Norman E, Janson C, Torén K. Remission of asthma: a prospective longitudinal study from northern Europe (RHINE study). <i>Eur Respir J.</i> 2007; 30(1): 62-65.	1989-2001		
Norway	Jenssen TG, Tonstad S, Claudi T, Midtjell K, Cooper J. The gap between guidelines and practice in the treatment of type 2 diabetes: A nationwide survey in Norway. <i>Diabetes Res Clin Pract.</i> 2008; 80(2): 314-20.	2003-2004		
Norway	Hildrum B, Mykletun A, Hole T, Midtjell K, Dahl AA. Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study. <i>BMC Public Health.</i> 2007; 7: 220.	1996		
Norway	Association of Nordic Cancer Registries (ANCR). Norway NORDCAN Cancer Incidence Data Tables. Age-Specific by Countries. Copenhagen, Denmark: Association of Nordic Cancer Registries (ANCR).	2003-2004, 2006-2008	*	
Norway	Hagen K, Zwart JA, Vatten L, Stovner LJ, Bovim G. Prevalence of migraine and non-migrainous headache-head-HUNT, a large population-based study. <i>Cephalalgia.</i> 2000; 20(10): 900-6.	1995-1997		
Norway	Zwart J-A, Dyb G, Holmen TL, Stovner LJ, Sand T. The prevalence of migraine and tension-type headaches among adolescents in Norway. The Nord-Trøndelag Health Study (Head-HUNT-Youth), a large population-based epidemiological study. <i>Cephalalgia.</i> 2004; 24(5): 373-9.	1995-1997		
Norway	Olsen AO, Gijbowski A, Magnus P, Tams K, Harris JR. Psoriasis in Norway as observed in a population-based Norwegian twin panel. <i>Br J Dermatol.</i> 2005; 153(2): 346-51.	1998		
Norway	Grotle M, Hagen KB, Natvig B, Dahl FA, Kvien TK. Obesity and osteoarthritis in knee, hip and/or hand: An epidemiological study in the general population with 10 years follow-up. <i>BMC Musculoskelet Disord.</i> 2008; 9(1): 132.	1994-2004		
Norway	Grotle M, Hagen KB, Natvig B, Dahl FA, Kvien TK. Prevalence and burden of osteoarthritis: results from a population survey in Norway. <i>J Rheumatol.</i> 2008; 35(4): 677-84.	2004		
Norway	Kvaerner KJ, Naftad P, Jaakkola JJ. Upper respiratory morbidity in preschool children: a cross-sectional study. <i>Arch Otolaryngol Head Neck Surg.</i> 2000; 126(10): 1201-6.	1996	*	†
Norway	Bertelsen RJ, Carlsen KCL, Carlsen K-H, Granum B, Doekes G, Håland G, Mowinckel P, Lovik M. Childhood asthma and early life exposure to indoor allergens, endotoxin and beta(1,3)-glucans. <i>Clin Exp Allergy.</i> 2010; 40(2): 307-16.	2002-2003	*	
Norway	Hansen TE, Evjenth B, Holt J. Increasing prevalence of asthma, allergic rhinoconjunctivitis and eczema among schoolchildren: three surveys during the period 1985-2008. <i>Acta Paediatr.</i> 2013; 102(1): 47-52.	1995, 2008	*	
Norway	Smidesang I, Saunes M, Storø O, Øien T, Holmen TL, Johnsen R, Henriksen AH. Atopic dermatitis among 2-year olds; high prevalence, but predominantly mild disease—the PACT study, Norway. <i>Pediatr Dermatol.</i> 2008; 25(1): 13-8.	2003-2005	*	
Norway	Norderyd O, Henriksen BM, Jansson H. Periodontal disease in Norwegian old-age pensioners. <i>Gerodontology.</i> 2012; 29(1): 4-8.	2010	*	
Norway	Skudutyte-Rysstad R, Eriksen HM, Hansen BF. Trends in periodontal health among 35-year-olds in Oslo, 1973-2003. <i>J Clin Periodontol.</i> 2007; 34(10): 867-72.	1984, 1993, 2003	*	
Norway	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. <i>Community Dent Oral Epidemiol.</i> 1991; 19(2): 72-3.	1987		
Norway	Rårveit S, Skutlberg DH, Langeland N, Rørtveit G. Impetigo in a population over 8.5 years: incidence, fusidic acid resistance and molecular characteristics. <i>J Antimicrob Chemother.</i> 2011; 66(6): 1360-4.	2001-2009	*	
Norway	Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version). Lyon, IARC. http://cis.iarc.fr	2003-2007	*	
Norway	Søndenaa E, Rasmussen K, Nøttestad JA, Lauvrud C. Prevalence of intellectual disabilities in Norway: Domestic variance. <i>J Intellect Disabil Res.</i> 2010; 54(2): 161-7.	2008	*	
Norway	Høftun GB, Romundstad PR, Zwart J-A, Rygg M. Chronic idiopathic pain in adolescence - high prevalence and disability: The young HUNT study 2008. <i>Pain.</i> 2011; 152(10): 2259-66.	2006-2008	*	
Norway	Tveitnes D, Natås OB, Skadberg Ø, Øymar K. Lyme meningitis, the major cause of childhood meningitis in an endemic area: a population based study. <i>Arch Dis Child.</i> 2012; 97(3): 215-20.	2001-2009	*	
Norway	Hopstock LA, Wisgaard T, Njølstad I, Mannsverk J, Mathiesen EB, Løchen M-L, Bønaa KH. Seasonal variation in incidence of acute myocardial infarction in a sub-Arctic population: The Tromsø Study 1974-2004. <i>Eur J Cardiovasc Prev Rehabil.</i> 2011; 18(2): 320-5.	1974-2004	*	
Norway	Odegård S, Kvien TK, Uhlig T. Incidence of clinically important 10-year health status and disease activity levels in population-based cohorts with rheumatoid arthritis. <i>J Rheumatol.</i> 2008; 35(1): 54-60.	1988-1993		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Norway	Tambs K, Hoffman HJ, Borchgrevink HM, Holmen J, Samuelsen SO. Hearing loss induced by noise, ear infections, and head injuries: results from the Nord-Trøndelag Hearing Loss Study. <i>Int J Audiol.</i> 2003; 42(2): 89-105.	1996		
Norway	Schuller AA, Holst D. Changes in the oral health of adults from Trøndelag, Norway, 1973-1983-1994. <i>Community Dent Oral Epidemiol.</i> 1998; 26(3): 201-8.	1973-1994		
Norway	Birkeland JM, Haugejorden O, von der Fehr FR. Analyses of the caries decline and incidence among Norwegian adolescents 1985-2000. <i>Acta Odontol Scand.</i> 2002; 60(5): 281-9.	1985-2000		
Norway	Sönju Clasen AB, von der Fehr FR, Kant van Daal JM. Caries prevalence of kindergarten children in Salzgitter and Oslo. <i>Caries Res.</i> 1992; 26(3): 201-4.	1989		
Norway	Kringlen E, Torgersen S, Cramer V. A Norwegian psychiatric epidemiological study. <i>Am J Psychiatry.</i> 2001; 158(7): 1091-8.	1994-1999		
Norway	Gøtestam KG, Agras WS. General Population-Based Epidemiological Study of Eating Disorders in Norway. <i>Int J Eat Disord.</i> 1995; 18(2): 119-26.	1991		
Norway	Halvorsen I, Andersen A, Heyerdahl S. Good outcome of adolescent onset anorexia nervosa after systematic treatment: intermediate to long-term follow-up of a representative county-sample. <i>Eur Child Adolesc Psychiatry.</i> 2004; 13(5): 295-306.	1986-2001		
Norway	Heiervang E, Stormark KM, Lundervold AJ, Heimann M, Goodman R, Posserud M-B, Ullebø AK, Plessen KJ, Bjelland I, Lie SA, Gillberg C. Psychiatric disorders in Norwegian 8- to 10-year-olds: an epidemiological survey of prevalence, risk factors, and service use. <i>J Am Acad Child Adolesc Psychiatry.</i> 2007; 46(4): 438-47.	2002-2003		
Norway	Sandanger I, Nygård JF, Ingebrigtsen G, Sørensen T, Dalgard OS. Prevalence, incidence and age at onset of psychiatric disorders in Norway. <i>Soc Psychiatry Psychiatr Epidemiol.</i> 1999; 34(11): 570-9.	1989-1991		
Norway	Ayuso-Mateos JL, Vázquez-Barquero JL, Dowrick C, Lehtinen V, Dalgard OS, Casey P, Wilkinson C, Lasa L, Page H, Dunn G, Wilkinson G. Depressive disorders in Europe: prevalence figures from the ODIN study. <i>Br J Psychiatry.</i> 2001; 179(4): 308-16.	1999-2001		
Norway	de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Künzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P. European Community Respiratory Health Survey Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. <i>Thorax.</i> 2004; 59(2): 120-125.	1991-1993		
Norway	Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E, BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. <i>Lancet.</i> 2007; 9589(9589): 741-50.	2005-2006		
Norway	Medbo A, Melbye H. Lung function testing in the elderly – can we still use FEV1/FVC < 70% as a criterion of COPD. <i>Respir Med.</i> 2007; 101(6): 1097-1105.	2001-2002		
Norway	Eriksen BO, Garpestad OK, Søndén H, Burhol PG. Peptic ulcer patterns in Arctic Norway. <i>J Clin Gastroenterol.</i> 1995; 20(2): 100-3.	1983-1984		
Norway	United States Renal Data System Coordinating Center. <i>USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States.</i> Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2004-2005		
Norway	United States Renal Data System Coordinating Center. <i>USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States.</i> Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2000-2003		
Norway	Skjeldstad FE, Jerve F. Chlamydia trachomatis and Neisseria gonorrhoeae among women seeking abortion in Norway. Results from a nationwide study. <i>J Nor Med Assoc.</i> 1992; 112(16): 2082-4.	1991		
Norway	De Rijk MC, Launer LJ, Berger K, Breteler MM, Darigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology.</i> 2000; 54(11 Suppl 5): S21-23.	1997		
Norway	Bekkelund SI SB, Mellgren SL. Parkinsons sykdom i en nordnorsk befolkningsgruppe. <i>J Nor Med Assoc.</i> 1989; 109(5): 561-3.	1986		
Norway	Herlofson K, Lie SA, Årslund D, Larsen JP. Mortality and Parkinson disease: A community based study. <i>Neurology.</i> 2004; 62(6): 937-42.	1993-2001		
Norway	Tandberg E, Larsen JP, Nessler EG, Riise T, Aarli JA. The epidemiology of Parkinson's disease in the county of Rogaland, Norway. <i>Mov Disord.</i> 1995; 10(5): 541-9.	1992-1993		
Norway	Berger K BM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology.</i> 2000; 54(11): 24-7.	1997		
Norway	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). <i>ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries.</i> Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Norway	Natvig B, Bruusgaard D, Eriksen W. Localized low back pain and low back pain as part of widespread musculoskeletal pain: two different disorders? A cross-sectional population study. <i>J Rehabil Med.</i> 2001; 33(1): 21-5.	1994		
Norway	Brage S, Laerum E. Spinal disorders in Norway – an epidemiological report. <i>J Nor Med Assoc.</i> 1999; 119(11): 1619-23.	1995		
Norway	Seland JH, Vingerling JR, Aougoud CA, Bentham G, Chakravarthy U, deJong PTVM, Rahu M, Soubbrane G, Tomazzoli L, Topouzis F, Fletcher AE. Visual impairment and quality of life in the older European population, the EUREYE study. <i>Acta Ophthalmol.</i> 2011; 89(7): 608-13. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2006-2007		
Norway	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). <i>European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008.</i> Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1995, 1999, 2004		
Norway	Strømme P, Valvatne K. Mental retardation in Norway: prevalence and sub-classification in a cohort of 30037 children born between 1980 and 1985. <i>Acta Paediatr.</i> 1998; 87(3): 291-6.	1998		
Norway	Kringlen E, Torgersen S, Cramer V. Mental illness in a rural area: a Norwegian psychiatric epidemiological study. <i>Soc Psychiatry Psychiatr Epidemiol.</i> 2006; 41(9): 713-9.	1997-1999	*	
Norway	Sund AM, Larsson B, Wichstrøm L. Prevalence and characteristics of depressive disorders in early adolescents in central Norway. <i>Child Adolesc Psychiatry Ment Health.</i> 2011; 28.	1998-1999	*	
Norway	Wichstrøm L, Berg-Nielsen TS, Angold A, Egger HL, Solheim E, Sveen TH. Prevalence of psychiatric disorders in preschoolers. <i>J Child Psychol Psychiatry.</i> 2012; 53(6): 695-705.	2007-2008	*	
Norway	Statistics Norway. <i>Norway Survey of Living Conditions 2008-2009.</i> Oslo, Norway: Statistics Norway.	2008-2009	*	
Norway	Statistics Norway. <i>Norway Survey of Living Conditions 2005-2006.</i> Oslo, Norway: Statistics Norway.	2005-2006	*	
Norway	Statistics Norway. <i>Norway Survey of Living Conditions 2002.</i> Oslo, Norway: Statistics Norway.	2002	*	
Norway	Strøm-Roum EM, Haavaldsen C, Tanbo TG, Eskild A. Paternal age, placental weight and placental to birthweight ratio: a population-based study of 590,835 pregnancies. <i>Hum Reprod.</i> 2013; 28(11): 3126-33.	1999-2009	*	
Norway	Ahmad AS, Samuelsen SO. Hypertensive disorders in pregnancy and fetal death at different gestational lengths: a population study of 2 121 371 pregnancies. <i>BJOG.</i> 2012; 119(12): 1521-8.	1967-2006	*	
Norway	Børthen I, Eide MG, Dalveit AK, Gilhus NE. Obstetric outcome in women with epilepsy: a hospital-based, retrospective study. <i>BJOG.</i> 2011; 118(8): 956-65.	1999-2006	*	
Norway	Brantsæter AL, Myhre R, Haugen M, Myking S, Sengpiel V, Magnus P, Jacobsson B, Meltzer HM. Intake of probiotic food and risk of preeclampsia in primiparous women: the Norwegian Mother and Child Cohort Study. <i>Am J Epidemiol.</i> 2011; 174(7): 807-15.	2002-2008	*	
Norway	Klungøy K, Morken NH, Irgens L, Vollset SE, Skjaerven R. Secular trends in the epidemiology of pre-eclampsia throughout 40 years in Norway: prevalence, risk factors and perinatal survival. <i>Paediatr Perinat Epidemiol.</i> 2012; 26(3): 190-8.	1967-2008	*	
Norway	Mykkestad K, Vatten LJ, Salvesen KÅ, Davey Smith G, Romundstad PR. Hypertensive disorders in pregnancy and paternal cardiovascular risk: a population-based study. <i>Ann Epidemiol.</i> 2011; 21(6): 407-12.	1967-1997	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Norway	Roberts CL, Ford JB, Algert CS, Antonsen S, Chalmers J, Chatterji S, Gokhale M, Kotelchuck M, Melve KK, Langridge A, Morris C, Morris JM, Nassar N, Norman JE, Norrie J, Sørensen HT, Walker R, Weir CJ. Population-based trends in pregnancy hypertension and pre-eclampsia: an international comparative study. <i>BMJ Open</i> . 2011; 1(1): e000101.	1999-2006	*	
Norway	Vatne A, Mygland A, Ljøstad U. Multiple sclerosis in Vest-Agder County, Norway. <i>Acta Neurol Scand</i> . 2011; 123(6): 396-9.	1996-2007	*	
Norway	Risberg G, Aarseth JH, Nyland H, Lauer K, Myhr K-M, Midgard R. Prevalence and incidence of multiple sclerosis in Oppland County: a cross-sectional population-based study in a landlocked county of Eastern Norway. <i>Acta Neurol Scand</i> . 2011; 124(4): 250-7.	1989-2002	*	
Norway	Brodtkorb E, Sjaastad O. Epilepsy prevalence by individual interview in a Norwegian community. <i>Seizure</i> . 2008; 17(7): 646-50.	1995-1996	*	†
Norway	Svensden T, Lossius M, Nakken KO. Age-specific prevalence of epilepsy in Oppland County, Norway. <i>Acta Neurol Scand</i> . 2007; 116(5): 307-11.	2001-2002	*	†
Norway	Waalder PE, Blom BH, Skeidsvoll H, Mykletun A. Prevalence, classification, and severity of epilepsy in children in western Norway. <i>Epilepsia</i> . 2000; 41(7): 802-10.	1995	*	†
Norway	Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, Hallan HA, Lydersen S, Holmen J. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. <i>J Am Soc Nephrol</i> . 2006; 17(8): 2275-84.	1995-1997		
Norway	Brunes A. The Association Between Physical Activity, Mental Health, and Personality: The HUNT Study [master's thesis]. (Trondheim, Norway): Norwegian University of Science and Technology; 2011.	2006-2008	*	
Norway	Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, Dekker FW. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. <i>BMJ</i> . 2006; 333(7577): 1047.	1995-2004		
Norway	Isaksen J, Diseth TH, Schjølberg S, Skjeldal OH. Observed prevalence of autism spectrum disorders in two Norwegian counties. <i>Eur J Paediatr Neurol</i> . 2012; 16(6): 592-8.	2008	*	
Norway	Sponheim E, Skjeldal O. Autism and related disorders: epidemiological findings in a Norwegian study using ICD-10 diagnostic criteria. <i>J Autism Dev Disord</i> . 1998; 28(3): 217-27.	1992		
Norway	Statistics Norway. Norway Survey of Living Conditions 2012. Oslo, Norway: Statistics Norway.	2012	*	
Norway	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010		
Norway	Bakken IJ, Ghaderi S. Incidence of pelvic inflammatory disease in a large cohort of women tested for Chlamydia trachomatis: a historical follow-up study. <i>BMC Infect Dis</i> . 2009; 9: 130.	1990-2005	*	
Norway	Zwart J-A, Dyb G, Hagen K, Svebak S, Stovner LJ, Holmen J. Analgesic overuse among subjects with headache, neck, and low-back pain. <i>Neurology</i> . 2004; 62(9): 1540-4.	1995-1997	*	
Norway	Dyb G, Holmen TL, Zwart J-A. Analgesic overuse among adolescents with headache: the Head-HUNT-Youth Study. <i>Neurology</i> . 2006; 66(2): 198-201.	1995-1997	*	
Norway	Aaseth K, Grande RB, Kvaerner KJ, Gulbrandsen P, Lundqvist C, Russell MB. Prevalence of secondary chronic headaches in a population-based sample of 30-44-year-old persons. The Akershus study of chronic headache. <i>Cephalalgia</i> . 2008; 28(7): 705-13.	2005	*	
Norway	Linde M, Stovner LJ, Zwart J-A, Hagen K. Time trends in the prevalence of headache disorders. The Nord-Trøndelag Health Studies (HUNT 2 and HUNT 3). <i>Cephalalgia</i> . 2011; 31(5): 585-96.	2006-2008	*	
Norway	Faber MT, Nielsen A, Nygård M, Sparén P, Tryggvadottir L, Hansen BT, Liaw K-L, Kjaer SK. Genital chlamydia, genital herpes, Trichomonas vaginalis and gonorrhoea prevalence, and risk factors among nearly 70,000 randomly selected women in 4 Nordic countries. <i>Sex Transm Dis</i> . 2011; 38(8): 727-34.	2004-2005	*	
Norway	Jensen AJ, Kleveland CR, Moghaddam A, Haasheim H, Hjelmevoll SO, Skogen V. Chlamydia trachomatis, Mycoplasma genitalium and Ureaplasma urealyticum among students in northern Norway. <i>J Eur Acad Dermatol Venereol</i> . 2013; 27(1): e91-96.	2007	*	
Norway	Kløvstad H, Grjibovski A, Aavitsland P. Population based study of genital Chlamydia trachomatis prevalence and associated factors in Norway: a cross sectional study. <i>BMC Infect Dis</i> . 2012; 150.	2006		
Norway	Gravningen K, Furberg A-S, Simonsen GS, Wilsgaard T. Early sexual behaviour and Chlamydia trachomatis infection - a population based cross-sectional study on gender differences among adolescents in Norway. <i>BMC Infect Dis</i> . 2012; 319.	2009	*	
Norway	Eskild A, Jeansson S, Jenum PA. [Antibodies against Herpes simplex virus type 2 among pregnant women in Norway]. <i>J Nor Med Assoc</i> . 1999; 119(16): 2323-6.	1984-1988	*	
Norway	Bernersen B, Johnsen R, Straume B, Burhol PG, Jensen TG, Stakkevold PA. Towards a true prevalence of peptic ulcer: the Sarsreisa gastrointestinal disorder study. <i>Gut</i> . 1990; 31(9): 989-92.	1987	*	
Norway	Sundling V, Platou CGP, Jansson RW, Bertelsen G, Wøllo E, Gulbrandsen P. Retinopathy and visual impairment in diabetes, impaired glucose tolerance and normal glucose tolerance: the Nord-Trøndelag Health Study (the HUNT study). <i>Acta Ophthalmol</i> . 2012; 90(3): 237-43.	2004-2005		
Norway	Joner G, Søvik O. Incidence, age at onset and seasonal variation of diabetes mellitus in Norwegian children, 1973-1977. <i>Acta Paediatr Scand</i> . 1981; 70(3): 329-35.	1973-1977		
Norway	Joner G, Søvik O. Increasing incidence of diabetes mellitus in Norwegian children 0-14 years of age 1973-1982. <i>Diabetologia</i> . 1989; 32(2): 79-83.	1978-1982		
Norway	Joner G, Søvik O. The incidence of type 1 (insulin-dependent) diabetes mellitus 15-29 years in Norway 1978-1982. <i>Diabetologia</i> . 1991; 34(4): 271-4.	1978-1982		
Norway	Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. <i>Drug Alcohol Depend</i> . 2008; 94(1-3): 151-7.	1997-2003	*	
Norway	Eskild A, Magnus P, Samuelsen SO, Sohlberg C, Kittelsen P. Differences in mortality rates and causes of death between HIV positive and HIV negative intravenous drug users. <i>Int J Epidemiol</i> . 1993; 22(2): 315-20.	1985-1991	*	
Norway	Haarr D, Nessa J. [Treatment of opiate-dependent patients in a general practice]. <i>J Nor Med Assoc</i> . 2007; 127(13): 1770-2.	1997-2006	*	
Norway	Odegård E, Amundsen EJ, Kielland KB. Fatal overdoses and deaths by other causes in a cohort of Norwegian drug abusers - a competing risk approach. <i>Drug Alcohol Depend</i> . 2007; 89(2-3): 176-82.	1981-2003	*	
Norway	Rossov I. Suicide among drug addicts in Norway. <i>Addiction</i> . 1994; 89(12): 1667-73.	1961-1992	*	
Norway	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant</i> . 1988; 3(6): 714-27.	1985		
Norway	Van Dijk PC, Jager KJ, Stengel B, Grünhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). <i>Kidney Int</i> . 2005; 67(4): 1489-99.	1991-1992, 1999-2000		
Norway	Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. <i>Nephrol Dial Transplant</i> . 2003; 18(9): 1824-33.	1990-1991, 1998-1999		
Norway	Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. <i>J Clin Endocrinol Metab</i> . 2008; 93(4): 1408-11.	2005		
Norway	Grytten Torkildsen N, Lie SA, Aarseth JH, Nyland H and Myhr KM. Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. <i>Mult Scler</i> . 2008; 1191-8.	1953-2003	*	
Norway	Smestad C, Sandvik L and Celius EG. Excess mortality and cause of death in a cohort of Norwegian multiple sclerosis patients. <i>Mult Scler</i> . 2009; 15(11): 1263-70.	1972-2005	*	
Norway	Omdal T, Dale J, Lie SA, Iversen KB, Flaatten H, Ovrebo K. Time trends in incidence, etiology, and case fatality rate of the first attack of acute pancreatitis. <i>Scand J Gastroenterol</i> . 2011; 46(11): 1389-98.	1996-2006		
Norway	Alves G, Müller B, Herlofson K, HogenEsch I, Telstad W, Aarland D, Tysnes O-B, Larsen JP. Norwegian ParkWest study group. Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study. <i>J Neurol Neurosurg Psychiatry</i> . 2009; 80(8): 851-7.	2004-2006	*	
Norway	Elgen I, Bruaroy S, Laegreid LM. Lack of recognition and complexity of foetal alcohol neuroimpairments. <i>Acta Paediatr</i> . 2007; 96(2): 237-41.	1999-2004	*	
Norway	Tronvik E, Zwart J-A, Hagen K, Dyb G, Holmen TL, Stovner LJ. Association between blood pressure measures and recurrent headache in adolescents: cross-sectional data from the HUNT-Youth study. <i>J Headache Pain</i> . 2011; 12(3): 347-53.	1995-1997	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Norway	Larsen JP, Kvåle G, Nylund H. Epidemiology of the Guillain-Barré syndrome in the county of Hordaland, Western Norway. <i>Acta Neurol Scand.</i> 1985; 71(1): 43-7.	1957-1982		†
Norway	Moen MH, Schei B. Epidemiology of endometriosis in a Norwegian county. <i>Acta Obstet Gynecol Scand.</i> 1997; 76(6): 559-62.	1992-1993		
Norway	Kvaerner KJ, Arnesen AR. Hearing impairment in Oslo born children 1989-91. Incidence, etiology and diagnostic delay. <i>Scand Audiol.</i> 1994; 23(4): 233-9.	1989-1991	*	
Norway	Olsen AO, Orstavik I, Dillner J, Vestergaard BF, Magnus P. Herpes simplex virus and human papillomavirus in a population-based case-control study of cervical intraepithelial neoplasia grade II-III. <i>APMIS.</i> 1998; 106(3): 417-24.	1991-1992	*	
Norway	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland: World Health Organization (WHO).	2005-2007	*	
Norway	Riise T, Jacobsen BK, Gran J. Incidence and prevalence of rheumatoid arthritis in the county of Troms, northern Norway. <i>J Rheumatol.</i> 2000; 27(6): 1386-9.	1989, 1994	*	
Norway	Bekkelund SI, Selseth B, Mellgren SI [Parkinson's disease in a population group in northern Norway]. <i>Tidsskr Nor Lægeforen.</i> 1989; 109(5): 561-3.	1986		
Norway	Henriksen BM, Ambjørnsen E, Laake K, Axéll T. Prevalence of teeth and dentures among elderly in Norway receiving social care. <i>Acta Odontol Scand.</i> 2003; 61(3): 184-91.	1996-1997		
Norway	European Centre for Disease Prevention and Control. Review of Chlamydia Control Activities in EU Countries. Stockholm, Sweden: European Centre for Disease Prevention and Control, 2008.	2008		
Norway	Koposova N, Eriksen HM, Widström E, Handegård BH, Pastbin M, Kuposov R. Caries prevalence and determinants among 12-year-olds in North-West Russia and Northern Norway. <i>Stomatologija.</i> 2013; 15(1): 3-11.	2009	*	
Norway	Sundby P. Alcoholism and Mortality. Oslo, Norway: Universitetsforlaget, 1967.	1925-1962		
Norway	Statistics Norway. Norway Road traffic accidents involving personal injury January 2014. Oslo, Norway: Statistics Norway, 2014.	2014	*	
Norway	Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, Büchele G, Clausen M, Cookson WOC, von Mutius E, Strachan DP, Williams HC, ISAAC Phase Two Study Group. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. <i>J Allergy Clin Immunol.</i> 2008; 121(1): 141-147.	2005-2007	*	
Norway	Kvalvik AG, Jones MA, Symmons DP. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. <i>Scand J Rheumatol.</i> 2000; 29(1): 29-37.	1977-1992	*	
Norway	Glanbek I, Kvale G, Arnesjö B, Søreide O. Prevalence of gallstones in a Norwegian population. <i>Scand J Gastroenterol.</i> 1987; 22(9): 1089-94.	1983		
Norway	Kildebo S, Nordgaard K, Aronsen O, Breckan R, Burhol PG, Jorde R. The incidence of ulcerative colitis in Northern Norway from 1983 to 1986. The Northern Norwegian Gastroenterology Society. <i>Scand J Gastroenterol.</i> 1990; 25(9): 890-6.	1983-1986		
Norway	Moum B, Vatn MH, Ekbo A, Aadland E, Fausa O, Lygren I, Saur J, Schulz T, Stray N. Incidence of ulcerative colitis and indeterminate colitis in four counties of southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists. <i>Scand J Gastroenterol.</i> 1996; 31(4): 362-6.	1990-1993		
Norway	Moum B, Vatn MH, Ekbo A, Aadland E, Fausa O, Lygren I, Saur J, Schulz T. Incidence of Crohn's disease in four counties in southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists. <i>Scand J Gastroenterol.</i> 1996; 31(4): 355-61.	1990-1993		
Norway	Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overvad K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PHM, Lund E, Quirós JR, González CA, Sanchez Perez M-J, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu J, Chuang S-C, Murphy N, Boffetta P, Trichopoulou A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. <i>J Natl Cancer Inst.</i> 2011; 103(22): 1686-95.	1992-2006	*	
Norway	Siebek JC, Degré M, Rfidan S, Enger SC. Prevalence of hepatitis A antibodies in a normal population and some selected groups of patients in Norway. <i>Am J Epidemiol.</i> 1982; 115(2): 185-91.	1978-1979		
Norway	Hurlen B, Jonsen J, Aas E. Viral hepatitis in dentists in Norway. <i>Acta Odontol Scand.</i> 1980; 38(5): 321-4.	1979		
Norway	Flohr C, Weinmayr G, Weiland SK, Addo-Yobo E, Annesi-Maesano I, Björkstén B, Bråbäck L, Büchele G, Chico M, Cooper P, Clausen M, El Sharif N, Martinez Gimeno A, Mathur RS, von Mutius E, Morales Suarez-Varela M, Pearce N, Svabe V, Wong GWK, Yu M, Zhong NS, Williams HC, ISAAC Phase Two Study Group. How well do questionnaires perform compared with physical examination in detecting flexural eczema? Findings from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. <i>Br J Dermatol.</i> 2009; 161(4): 846-53.	2005-2007	*	
Norway	Norwegian Directorate of Health. Norway Patient Register 2008.	2008		
Norway	Norwegian Directorate of Health. Norway Patient Register 2009.	2009		
Norway	Norwegian Directorate of Health. Norway Patient Register 2010.	2010		
Norway	Norwegian Directorate of Health. Norway Patient Register 2011.	2011		
Norway	Norwegian Directorate of Health. Norway Patient Register 2012.	2012		
Norway	Engedal K, Haugen PK. The Prevalence of Dementia in a Sample of Elderly Norwegians. <i>Int J Geriatr Psychiatry.</i> 1993; 8(7): 565-70.	1984-1985		
Norway	Langengen J, Iglund J, Vollset SE, Averina M, Nordrehaug JE, Tell GS, Irgens LM, Nygård O. Short-term and long-term case fatality in 11 878 patients hospitalized with a first acute myocardial infarction, 1979-2001: the Western Norway cardiovascular registry. <i>Eur J Cardiovasc Prev Rehabil.</i> 2009; 16(5): 621-627.	1979-2001	*	
Norway	Zeitlan J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT; 2008. Available from: http://www.perinataleaudit.nl/downloads/bestand/649/peristat-ii-2008-	2004		†
Norway	Markestad T, Kaarensen PI, Rønnestad A, Reigstad H, Lossius K, Medbø S, Zanussi G, Englund IE, Skjaerven R, Irgens LM. Norwegian Extreme Prematurity Study Group. Early death, morbidity, and need of treatment among extremely premature infants. <i>Pediatrics.</i> 2005 May;115(5):1289-98.	1999		†
Norway	Norwegian Renal Registry Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Norway	Norwegian Renal Registry Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Norway	Norwegian Renal Registry Renal Replacement Therapy Data 1997 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 1998. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2003.	1997	*	
Norway	Norway Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Norway	European Surveillance of Congenital Anomalies (EUROCAT). Norway EUROCAT Prevalence Tables. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	1999-2011		
Norway	Norway Medical Birth Registry Congenital Anomaly Data 1980 - ICBDMS as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1980	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Norway	Norway Medical Birth Registry Congenital Anomaly Data 1983 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1983	*	
Norway	Norway Medical Birth Registry Congenital Anomaly Data 1986 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1986	*	
Norway	Norway Medical Birth Registry Congenital Anomaly Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Norway	Norway Medical Birth Registry Congenital Anomaly Data 1985 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1985	*	
Norway	Norway Medical Birth Registry Congenital Anomaly Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
Norway	Norway Medical Birth Registry Congenital Anomaly Data 1981 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1981	*	
Norway	Norway Medical Birth Registry Congenital Anomaly Data 2001 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
Norway	Norway Medical Birth Registry Congenital Anomaly Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
Norway	Norway Medical Birth Registry Congenital Anomaly Data 1987 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1987	*	
Norway	Norway Medical Birth Registry Congenital Anomaly Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
Norway	Norway Medical Birth Registry Congenital Anomaly Data 1982 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1982	*	
Norway	Norway Medical Birth Registry Congenital Anomaly Data 1984 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1984	*	
Norway	Norway Medical Birth Registry Congenital Anomaly Data 1988 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1988	*	
Norway	Norway Medical Birth Registry Congenital Anomaly Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Norway	Norway Medical Birth Registry Congenital Anomaly Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
Norway	Norway Medical Birth Registry Congenital Anomaly Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Oman	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Oman	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		i
Oman	Agarwal AK, Venugopalan P, de Bono D. Prevalence and aetiology of heart failure in an Arab population. Eur J Heart Fail. 2001; 3(3): 301-5.	1992-1994		
Oman	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. J Allergy Clin Immunol. 2008; 121(4): 947-954.	1995, 2001		
Oman	Al Awaidy SA, Bawikar S, Al Busaidy S, Bajiani S, Al Abedani I, Varghese R, Abdoan HS, Al Abdoon H, Bhatnagar S, Al Hasini KS, Mohan P, Shah S, Elamir E, Klena J, Ahmed SF, Teleh N, Parashar U, Patel MM. Considerations for introduction of a rotavirus vaccine in Oman: rotavirus disease and economic burden. J Infect Dis. 2009; 200(Suppl 1): 248-253.	2006-2008		
Oman	Al-Riyami A, Ebrahim GJ. Genetic Blood Disorders Survey in the Sultanate of Oman. J Trop Pediatr. 2003; Suppl 1(49): 1-20.	1995, 2000-2001		
Oman	White JM, Byrne M, Richards R, Buchanan T, Katsoulis E, Weerasingh K. Red cell genetic abnormalities in Peninsular Arabs: sickle haemoglobin, G6PD deficiency, and alpha and beta thalassaemia. J Med Genet. 1986; 3(23): 245-51.	1984-1986		
Oman	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998-2003, 2005-2009		
Oman	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J. 1998; 12(2): 315-35.	1993-1995		
Oman	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2002		
Oman	Khandekar R, Al Lawatiji J, Mohammed AJ, Al Raisi A. Diabetic retinopathy in Oman: a hospital based study. Br J Ophthalmol. 2003; 87(9): 1061-4.	2000-2001		
Oman	Asfour MG, Lamboume A, Soliman A, Al-Behlani S, Al-Asfour D, Bold A, Mahtab H, King H. High prevalence of diabetes mellitus and impaired glucose tolerance in the Sultanate of Oman: results of the 1991 national survey. Diabet Med. 1995; 12(12): 1122-5.	1991		
Oman	Aithala G, Al Dhahry SH, Saha A, Elbualy MS. Epidemiological and clinical features of rotavirus gastroenteritis in Oman. J Trop Pediatr. 1996; 42(1): 54-7.	1990-1992	*	
Oman	Pountain G. The prevalence of rheumatoid arthritis in the Sultanate of Oman. Br J Rheumatol. 1991; 30(1): 24-8.	1987		
Oman	al-Ismaily M, Chestnutt JG, al-Khussaiby A, Stephen KW, al-Riyami A, Abbas M, Knight M. Prevalence of dental caries in Omani 6-year-old children. Community Dent Health. 1997; 14(3): 171-4.	1994		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Oman	Agarwal AK, Venugopalan P, Meharali AK, de Debono D. Idiopathic dilated cardiomyopathy in an Omani population of the Arabian Peninsula: prevalence, clinical profile and natural history. <i>Int J Cardiol.</i> 2000; 75(2-3): 147-159.	1992-1994		
Oman	Al Khabori M, Khandekar R. The prevalence and causes of hearing impairment in Oman: a community-based cross-sectional study. <i>Int J Audiol.</i> 2004; 43(8): 486-92.	1996-1997		
Oman	Hasab AA, Jaffer A, Riyami AM. Rheumatic heart disease among Omani schoolchildren. <i>East Mediterr Health J.</i> 1997; 17-23.	1994-1996		
Oman	Affifi M, Al Riyami A, Morsi M, Al Kharusil H. Depressive symptoms among high school adolescents in Oman. <i>East Mediterr Health J.</i> 2006; 12(Suppl 2): S126-137.	2004		
Oman	Al-Farsi YM, Al-Sharbaty MM, Al-Farsi OA, Al-Shafae MS, Brooks DR, Waly ML. Brief report: Prevalence of autistic spectrum disorders in the Sultanate of Oman. <i>J Autism Dev Disord.</i> 2011; 41(6): 821-5.	2009	*	
Oman	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Oman	Khandekar R, Mohammed AJ, Negrel AD, Riyami AA. The prevalence and causes of blindness in the Sultanate of Oman: the Oman Eye Study (OES). <i>Br J Ophthalmol.</i> 2002; 86(9): 957-62. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	1996-1997		
Oman	Khandekar R, Mohammed AJ, Raisi AA. Prevalence and causes of blindness and low vision: before and five years after "VISION 2020" initiatives in Oman: a review. <i>Ophthalmic Epidemiol.</i> 2007; 14(1): 9-15. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2005		
Oman	Al Khabori M. Causes of severe to profound deafness in Omani paediatric population. <i>Int J Pediatr Otorhinolaryngol.</i> 2004; 68(10): 1307-13.	1986-2000	*	
Oman	World Health Organization (WHO). Oman WHO Leishmaniasis Country Profile.	1994-2010	*	
Oman	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Oman	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec.</i> 2007; 82(25): 225-32.	2006	*	
Oman	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Oman	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Oman	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Oman	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec.</i> 2008; 83(33): 293-300.	2007	*	
Oman	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Oman	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Oman	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Oman	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Oman	Nair PMC, Ganesh A, Mitra S, Ganguly SS. Retinopathy of prematurity in VLBW and extreme LBW babies. <i>Indian J Pediatr.</i> 2003; 70(4): 303-6.	2000	*	†
Oman	Bassiouny MR. Risk Factors Associated with Retinopathy of Prematurity: A Study from Oman. <i>J Trop Pediatr.</i> 1996; 42(6): 355-8.	1993	*	†
Oman	Daar S, Vulliamy TJ, Kaeda J, Mason PJ, Luzzatto L. Molecular characterization of G6PD deficiency in Oman. <i>Hum Hered.</i> 1996; 46(3): 172-6.	1994-1995	*	
Oman	Radhakrishnan S, Zubaidi G, Daniel M, Sachdev GK, Mohan AN. Ulcerative colitis in Oman. A prospective study of the incidence and disease pattern from 1987 to 1994. <i>Digestion.</i> 1997; 58(3): 266-70.	1987		
Oman	Al-Riyami A, Affifi M, Morsi M, Mabry R. A national study of gynecological morbidities in Oman. Effect of women's autonomy. <i>Saudi Med J.</i> 2007; 28(6): 881-890.	2000	*	
Pakistan	Population Welfare Division, Ministry of Planning and Development (Pakistan), International Statistical Institute. <i>Pakistan World Fertility Survey 1975.</i> Voorburg, Netherlands: International Statistical Institute.	1975		
Pakistan	Macro International, Inc., Institute for Resource Development, National Institute of Population Studies (Pakistan). <i>Pakistan Demographic and Health Survey 1990-1991.</i> Calverton, United States: Macro International, Inc.	1990-1991		†
Pakistan	Macro International, Inc. National Institute of Population Studies (Pakistan). <i>Pakistan Demographic and Health Survey 2006-2007.</i> Calverton, United States: Macro International, Inc.	2006-2007		†
Pakistan	World Health Organization (WHO). <i>Pakistan World Health Survey 2003-2004.</i> Geneva, Switzerland: World Health Organization (WHO), 2005.	2003-2004		†
Pakistan	<i>Pakistan Demographic Survey 1990</i> as it appears in United Nations Statistics Division (UNSD), <i>United Nations Demographic Yearbook - Historical Supplement 1997.</i> New York City, United States: United Nations Statistics Division (UNSD).	1990		
Pakistan	Government of Balochistan (Pakistan), United Nations Children's Fund (UNICEF). <i>Pakistan - Balochistan Multiple Indicator Cluster Survey 2010.</i> New York, United States: United Nations Children's Fund (UNICEF).	2010	*	
Pakistan	ICF International, National Institute of Population Studies (Pakistan), Pakistan Bureau of Statistics. <i>Pakistan Demographic and Health Survey 2012-2013.</i> Fairfax, United States: ICF International, 2014.	2012-2013	*	†
Pakistan	Owais A, Tikmani SS, Sultana S, Zaman U, Ahmed I, Allana S, Zaidi AK. Incidence of pneumonia, bacteraemia, and invasive pneumococcal disease in Pakistani children. <i>Trop Med Int Health.</i> 2010; 15(9): 1029-36.	2007-2008		
Pakistan	Centre for Health Informatics and Multiprofessional Education, University College London. <i>Modell's Haemoglobinopathologist's Almanac.</i> London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Pakistan	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Pakistan	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol.</i> 2008; 121(4): 947-954.	1995, 2001		
Pakistan	Bureau of Statistics (Punjab), United Nations Children's Fund (UNICEF), United Nations Development Programme (UNDP). <i>Pakistan - Punjab Multiple Indicator Cluster Survey 2011.</i> New York, United States: United Nations Children's Fund (UNICEF), 2013.	2011	*	†
Pakistan	Federal Bureau of Statistics (Pakistan). <i>Pakistan Demographic Survey 1991.</i>	1991		
Pakistan	Federal Bureau of Statistics (Pakistan). <i>Pakistan Demographic Survey 1992.</i>	1992		
Pakistan	Moisi JC, Saha SK, Falade AG, Njanpop-Lafourcade B-M, Oundo J, Zaidi AKM, Afroj S, Bakare RA, Buss JK, Lasi R, Mueller J, Odekanmi AA, Sangare L, Scott JAG, Knoll MD, Levine OS, Gessner BD. Enhanced diagnosis of pneumococcal meningitis with use of the binax NOW immunochromatographic test of Streptococcus pneumoniae antigen: A multisite study. <i>Clin Infect Dis.</i> 2009; 48(Suppl 2): S49-S56.	2006-2007		
Pakistan	Zaidi AKM, Khan H, Lasi R, Mahesar W. Surveillance of pneumococcal meningitis among children in Sindh, Southern Pakistan. <i>Clin Infect Dis.</i> 2009; 48 Suppl 2(Suppl 2): S129-S135.	2005-2006		
Pakistan	Von Seidlein L, Kim DR, Ali M, Lee H, Wang X, Thiem VD, Canh DG, Chaicumpa W, Agtini MD, Hossain A, Bhutta ZA, Mason C, Sethabutr O, Talukder K, Nair GB, Deen JL, Kotloff K, Clemens J. A Multicentre Study of Shigella Diarrhoea in Six Asian Countries: Disease Burden, Clinical Manifestations, and Microbiology. <i>PLoS Med.</i> 2006; 3(9): e353.	2002-2003		
Pakistan	Jafar TH, Qadri Z, Chaturvedi N. Coronary artery disease epidemic in Pakistan: more electrocardiographic evidence of ischaemia in women than in men. <i>Heart.</i> 2008; 94(4): 408-13.	1980-2007		
Pakistan	Jafary MH, Samad A, Ishaq SA, Ahmad M, Vohra EA. Profile of Acute Myocardial Infarction (AMI) In Pakistan. <i>Pak J Med Sci.</i> 2007; 23(4): 485-9.	1980-2006		
Pakistan	Farooqi A, Gibson T. Prevalence of the major rheumatic disorders in the adult population of north Pakistan. <i>Br J Rheumatol.</i> 1998; 37(5): 491-5.	1995		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Pakistan	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J</i> . 1998; 12(2): 315-35.	1993-1995		
Pakistan	Lai CK, Bessley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	2002		
Pakistan	Ahmed K, Muhammad Z, Qayum I. Prevalence of cutaneous manifestations of diabetes mellitus. <i>J Ayub Med Coll Abbottabad</i> . 2009; 21(2): 76-9.	2008		
Pakistan	Basit A, Hydrie MZ, Hakeem R, Ahmedani MY, Masood Q. Frequency of chronic complications of type II diabetes. <i>J Coll Physicians Surg Pak</i> . 2004; 14(2): 79-83.	1996-2001		
Pakistan	Basit A, Hydrie MZ, Ahmed K, Hakeem R. Prevalence of diabetes, impaired fasting glucose and associated risk factors in a rural area of Baluchistan province according to new ADA criteria. <i>J Pak Med Assoc</i> . 2002; 52(8): 357-60.	1994		
Pakistan	Khan MI, Soofi SB, Ochiai RL, Khan MJ, Sahito SM, Habib MA, Puri MK, Von Seidlein L, Park JK, You YA, Ali M, Nizami SQ, Acosta CJ, Sack RB, Clemens JD, Bhutta ZA. Epidemiology, clinical presentation, and patterns of drug resistance of <i>Salmonella Typhi</i> in Karachi, Pakistan. <i>J Infect Dev Ctries</i> . 2012; 6(10): 704-14.	2002-2004	*	
Pakistan	Owais A, Sultana S, Zaman U, Rizvi A, Zaidi AKM. Incidence of typhoid bacteremia in infants and young children in southern coastal Pakistan. <i>Pediatr Infect Dis J</i> . 2010; 29(11): 1035-9.	2007-2008	*	
Pakistan	Dawani N, Nisar N, Khan N, Syed S, Tanweer N. Prevalence and factors related to dental caries among pre-school children of Saldar town, Karachi, Pakistan: a cross-sectional study. <i>BMC Oral Health</i> . 2012; 59.	2010	*	
Pakistan	Sufia S, Chaudhry S, Izhaf F, Syed A, Mirza BA, Khan AA. Dental caries experience in preschool children: is it related to a child's place of residence and family income Oral Health Prev Dent. 2011; 9(4): 375-9.	2009	*	
Pakistan	Siddiqui FJ, Haider SR, Bhutta ZA. Endemic dengue fever: a seldom recognized hazard for Pakistani children. <i>J Infect Dev Ctries</i> . 2009; 3(4): 306-12.	1999-2001	*	
Pakistan	Pal SA, Dennerstein L, Lebert P. Premenstrual symptoms in Pakistani women and their effect on activities of daily life. <i>J Pak Med Assoc</i> . 2011; 61(8): 763-8.	2008	*	
Pakistan	Zaidi AKM, Khan H, Sherail AR, Lasi R, Sindh Meningitis Study Group. Burden of Haemophilus influenzae type b disease in Pakistani children. <i>East Mediterr Health J</i> . 2010; 16(6): 590-4.	2004-2005		
Pakistan	Huilan S, Zhen LG, Mathan MM, Mathew MM, Olarte J, Espejo R, Khin Maung U, Ghafoor MA, Khan MA, Sami Z. Etiology of acute diarrhoea among children in developing countries: a multicentre study in five countries. <i>Bull World Health Organ</i> . 1991; 69(5): 549-55.	1983-1985	*	
Pakistan	Nishio O, Matsui K, Oka T, Ushijima H, Mubina A, Dure-Samin A, Isomura S. Rotavirus infection among infants with diarrhea in Pakistan. <i>Pediatr Int</i> . 2000; 42(4): 425-7.	1990-1997	*	
Pakistan	Mahmud A, Jalil F, Karlberg J, Lindblad BS. Early child health in Lahore, Pakistan: VII. Diarrhoea. <i>Acta Paediatr Suppl</i> . 1993; 79-85.	1984-1989	*	
Pakistan	Nasrin D, Wu Y, Blackwelder WC, Farag TH, Saha D, Sow SO, Alonso PL, Breiman RF, Sur D, Faruque ASG, Zaidi AKM, Biswas K, Van Eijk AM, Walker DG, Levine MM, Kotloff KL. Health care seeking for childhood diarrhea in developing countries: evidence from seven sites in Africa and Asia. <i>Am J Trop Med Hyg</i> . 2013; 89(1 Suppl): 3-12.	2009-2011	*	
Pakistan	Gibson T, Hameed K, Kadir M, Sultana S, Fatima Z, Syed A. Knee pain amongst the poor and affluent in Pakistan. <i>Br J Rheumatol</i> . 1996; 35(2): 146-9.	1993		
Pakistan	Khan AA. Prevalence of dental caries in school children of Lahore, Pakistan. <i>Community Dent Oral Epidemiol</i> . 1992; 20(3): 155.	1990		
Pakistan	Sajan F, Fikree FF. Perceived gynecological morbidity among young ever-married women living in squatter settlements of Karachi, Pakistan. <i>J Pak Med Assoc</i> . 1999; 49(4): 92-7.	1996		
Pakistan	Kamal AK, Itrat A, Murtaza M, Khan M, Rasheed A, Ali A, Akber A, Akber Z, Iqbal N, Shoukat S, Majeed F, Saleheen D. The burden of stroke and transient ischemic attack in Pakistan: a community-based prevalence study. <i>BMC Neurol</i> . 2009; 9(1): 58.	2008-2009		
Pakistan	Shershah S, Morrison JJ, Jafarey S. Prevalence of premenstrual syndrome in Pakistani women. <i>J Pak Med Assoc</i> . 1991; 41(5): 101-3.	1989		
Pakistan	Tabassum S, Afridi B, Aman Z, Tabassum W, Durrani R. Premenstrual syndrome: frequency and severity in young college girls. <i>J Pak Med Assoc</i> . 2005; 55(12): 546-9.	2004		†
Pakistan	Nisar N, Zehra N, Haider G, Munir AA, Sohoo NA. Frequency, intensity and impact of premenstrual syndrome in medical students. <i>J Coll Physicians Surg Pak</i> . 2008; 18(8): 481-4.	2006		†
Pakistan	United States Renal Data System Coordinating Center. <i>USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States</i> . Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2003, 2005-2007		
Pakistan	United States Renal Data System Coordinating Center. <i>USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States</i> . Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2007.	2002-2003		
Pakistan	United States Renal Data System Coordinating Center. <i>United States Renal Data System Annual Data Report 2004</i> . Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2004.	2001		
Pakistan	Pakistan National Survey on Blindness and Low Vision 2002-2004 [Unpublished] as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2002-2004		
Pakistan	Haider S, Hussain A, Limburg H. Cataract blindness in Chakwal District, Pakistan: results of a survey. <i>Ophthalmic Epidemiol</i> . 2003; 10(4): 249-58. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2000-2001		
Pakistan	Ahmad K, Khan MD, Qureshi MB, Munami S, Shah RA, Rasheed H, Jamali B, Baluch A, Khan MA. Prevalence and causes of blindness and low vision in a rural setting in Pakistan. <i>Ophthalmic Epidemiol</i> . 2005; 12(1): 19-23. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	1998		
Pakistan	Shaikh SP, Aziz TM. Pattern of eye diseases in children of 5-15 years at Bazzertaline Area (South Karachi) Pakistan. <i>J Coll Physicians Surg Pak</i> . 2005; 15(5): 291-4. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2003		
Pakistan	Akram DS, Qureshi H, Mahmud A, Khan AA, Kundi Z, Shafi S, N-ur-Rehman, Olowokure B, Weil J, Bock H, Yazdani I. Seroepidemiology of varicella-zoster in Pakistan. <i>Southeast Asian J Trop Med Public Health</i> . 2000; 31(4): 646-9.	1997-1998		
Pakistan	Durkin MS, Hasan ZM, Hasan KZ. Prevalence and correlates of mental retardation among children in Karachi, Pakistan. <i>Am J Epidemiol</i> . 1998; 147(3): 281-8.	1983		
Pakistan	Stein Z, Belmont L, Durkin M. Mild mental retardation and severe mental retardation compared: experiences in eight less developed countries. <i>Ups J Med Sci Suppl</i> . 1987; 89-96.	1987		
Pakistan	Rizvi SF, Khan MA, Kundi A, Marsh DR, Samad A, Pasha O. Status of rheumatic heart disease in rural Pakistan. <i>Heart</i> . 2004; 90(4): 394-9.	1993-1994		
Pakistan	Sadiq M, Islam K, Abid R, Latif F, Rehman AU, Waheed A, Azhar M, Khan JS. Prevalence of rheumatic heart disease in school children of urban Lahore. <i>Heart</i> . 2009; 95(5): 353-7.	2001-2002		
Pakistan	Malik MA, Akram RM, Tarar MA, Sultan A. Childhood epilepsy. <i>J Coll Physicians Surg Pak</i> . 2011; 21(2): 74-8.	2007	*	
Pakistan	Siddiqui SA, Somozi N, Shahib-ul-Hasnain F. Severe obstetric morbidity and its outcome in patients presenting in a tertiary care hospital of Karachi. <i>J Pak Med Assoc</i> . 2012; 62(3): 226-31.	2010	*	
Pakistan	Rohra DK, Zeb A, Qureshi RN, Azam SI, Khan NB, Zuberi HS, Sikandar R. Prediction of pre-eclampsia during early pregnancy in primiparas with soluble fms-like tyrosine kinase-1 and placental growth factor. <i>Natl Med J India</i> . 2012; 25(2): 68-73.	2010-2011	*	
Pakistan	Saeed F, Jawad A, Azmat A, Azam I, Kagazwala S. Anthropometric measurements as a risk for hypertensive disorders in pregnancy: a hospital based study in South Asian population. <i>J Pak Med Assoc</i> . 2011; 61(1): 58-63.	2000-2005	*	
Pakistan	Aziz H, Güvener A, Akhtar SW, Hasan KZ. Comparative epidemiology of epilepsy in Pakistan and Turkey: population-based studies using identical protocols. <i>Epilepsia</i> . 1997; 38(6): 716-22.	1987	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Pakistan	Durkin MS, Davidson LL, Hasan ZM, Hauser Z, Hauser WA, Khan N, Paul TJ, Shrout PE, Thorburn MJ, Zaman S. Estimates of the prevalence of childhood seizure disorders in communities where professional resources are scarce: results from Bangladesh, Jamaica and Pakistan. <i>Paediatr Perinat Epidemiol.</i> 1992; 6(2): 166-80.	1991	*	†
Pakistan	Nisar N, Billoo N, Gadit AA. Prevalence of depression and the associated risks factors among adult women in a fishing community. <i>J Pak Med Assoc.</i> 2004; 54(10): 519-25.	2000		
Pakistan	Almani SA, Memon AS, Memon AI, Shah MI, Rahpoto MQ, Solangi R. Cirrhosis of liver: Etiological factors, complications and prognosis. <i>JLUMHS.</i> 2008; 61-6.	2005-2007		
Pakistan	Bukhtari N, Hussain T, Iqbal M, Malik AM, Qureshi AH, Hussain A. Hepatitis B and C single and co-infection in chronic liver disease and their effect on the disease pattern. <i>J Pak Med Assoc.</i> 2003; 53(4): 136-40.	1999-2000		
Pakistan	Durrani AB, Rana AB, Siddiqi HS, Marwat BU. The Spectrum of Chronic Liver Disease in Balochistan. <i>J Coll Physicians Surg Pak.</i> 2001; 95-7.	1997-2000		
Pakistan	Iqbal RS. Liver cirrhosis in Northwest frontier province of Pakistan. <i>J Coll Physicians Surg Pak.</i> 2002; 12(5): 289-91.	2002		
Pakistan	Liaqat A, Humara M, Mashoor A. Hepatitis C in chronic liver disease. <i>Pak J Med Sci.</i> 2000; 16(3): 146-51.	2000		
Pakistan	Makki K, Haikh I, Memon A, Qureshi A. Hepatitis C and chronic liver disease. <i>Biomedica.</i> 1995; 11(1): 33-5.	1995		
Pakistan	Malik I, Ahmad N, Butt S, Tariq W, Muzaffar M, Bakhtari N. Role of HBV and HCV in etiology of HCC in northern Pakistan. <i>J Coll Physicians Surg Pak.</i> 1995; 5(1): 26-8.	1995		
Pakistan	Malik IA, Ahmad N, Luqman M, Legters LJ, Khalil-Ullah, Zaheeruddin, Ahmed A, Bukhtari N, Nabi S, Mubarak A. Hepatitis C as a cause of chronic liver disease in northern Pakistan. <i>J Pak Med Assoc.</i> 1992; 42(3): 67-8.	1992		
Pakistan	Mashud I, Khan H, Khattak AM. Relative frequency of hepatitis B and C viruses in patients with hepatic cirrhosis at DHQ Teaching Hospital D. I. Khan. <i>J Ayub Med Coll Abbottabad.</i> 2004; 16(1): 32-4.	2004		
Pakistan	Shah F, Salih M, Malik I, Hussain I. Increasing prevalence of chronic hepatitis and associated risk factors. <i>Pak J Med Res.</i> 2002; 41(2): 46-50.	2002		
Pakistan	Umar M, Bushra H, Younis N, Bashir N. Clinical Spectrum of chronic liver disease due to HBV, HCV and dual infection – a comparative study. <i>Pak J Gastroenterol.</i> 1999; 13(1-2): 1-3.	1999		
Pakistan	Alam JM, Mahmood SR, Shaheen R, Asghar SS. Hepatitis "B" and "C" viral infections in patients with hepatocellular carcinoma. <i>Pak J Pharmacol.</i> 2009; 26(2): 25-32.	2005-2007		
Pakistan	Khokhar N. Spectrum of chronic liver disease in a tertiary care hospital. <i>J Pak Med Assoc.</i> 2002; 52(2): 56-8.	1994-2000		
Pakistan	Mumford DB, Minhas FA, Akhtar I, Akhter S, Mubbashar MH. Stress and psychiatric disorder in urban Rawalpindi. <i>Community survey.</i> <i>Br J Psychiatry.</i> 2000; 557-62.	1998	*	
Pakistan	Mumford DB, Nazir M, Jilani FU, Baig IY. Stress and psychiatric disorder in the Hindu Kush: a community survey of mountain villages in Chitral, Pakistan. <i>Br J Psychiatry.</i> 1996; 168(3): 299-307.	1994	*	
Pakistan	Mumford DB, Saeed K, Ahmad I, Latif S, Mubbashar MH. Stress and psychiatric disorder in rural Punjab. A community survey. <i>Br J Psychiatry.</i> 1997; 473-8.	1994	*	
Pakistan	Jafar TH, Schmid CH, Levey AS. Serum creatinine as marker of kidney function in South Asians: a study of reduced GFR in adults in Pakistan. <i>J Am Soc Nephrol.</i> 2005; 16(5): 1413-9.	2000-2001		
Pakistan	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2001, 2004, 2007, 2010, 2012		
Pakistan	Shaiikh SP, Aziz TM. Rapid assessment of cataract surgical services in age group 50 years and above in Lower Dir District Malakand, Pakistan. <i>J Coll Physicians Surg Pak.</i> 2005; 15(3): 145-8. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2003		
Pakistan	Anjum KM, Qureshi MB, Khan MA, Jan N, Ali A, Ahmad K, Khan MD. Cataract blindness and visual outcome of cataract surgery in a tribal area in Pakistan. <i>Br J Ophthalmol.</i> 2006; 90(2): 135-8. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2003-2004		
Pakistan	JM A. Factors affecting the outcome in babies with hypoxic ischemic encephalopathy. <i>Ann Pak Inst Med Sci.</i> 2006; 2(3): 158-62.	1997	*	†
Pakistan	Basit A, Danish Alvi SF, Fawwad A, Ahmed K, Yakoob Ahmedani M, Hakeem R. Temporal changes in the prevalence of diabetes, impaired fasting glucose and its associated risk factors in the rural area of Baluchistan. <i>Diabetes Res Clin Pract.</i> 2011; 94(3): 456-62.	2002-2010		
Pakistan	Mahar PS, Awan MZ, Manzar N, Memon MS. Prevalence of type-II diabetes mellitus and diabetic retinopathy: the Gaddap study. <i>J Coll Physicians Surg Pak.</i> 2010; 20(8): 528-32.	2006-2008		
Pakistan	Zafar J, Bhatti F, Akhtar N, Rashed U, Bashir R, Humayun S, Waheed A, Younus F, Nazir M, Unaimato. Prevalence and risk factors for diabetes mellitus in a selected urban population of a city in Punjab. <i>J Pak Med Assoc.</i> 2011; 61(1): 40-7.	2008		
Pakistan	Zuhaid M, Zahir KK, Dju IU. Knowledge and perceptions of diabetes in urban and semi urban population of Peshawar, Pakistan. <i>J Ayub Med Coll Abbottabad.</i> 2012; 24(1): 105-8.	2010		
Pakistan	Staines A, Hanif S, Ahmed S, McKinney PA, Shera S, Bodansky HJ. Incidence of insulin dependent diabetes mellitus in Karachi, Pakistan. <i>Arch Dis Child.</i> 1997; 76(2): 121-3.	1989-1993		
Pakistan	Ministry of Narcotics Control (Pakistan), United Nations Office on Drugs and Crime (UNODC). <i>Pakistan National Drug Abuse Assessment Study 2006-2007.</i>	2006-2007	*	
Pakistan	Mufti KA, Said S, Farooq S, Haroon A, Nazeer A, Naeem S, Hussain I. Five year follow up of 100 heroin addicts in Peshawar. <i>J Ayub Med Coll Abbottabad.</i> 2004; 16(3): 5-9.	1992-1998	*	
Pakistan	Fatmi Z, Hadden WC, Razzak JA, Qureshi HI, Hyder AA, Pappas G. Incidence, patterns and severity of reported unintentional injuries in Pakistan for persons five years and older: results of the National Health Survey of Pakistan 1990-94. <i>BMC Public Health.</i> 2007; 152.	1990-1994	*	
Pakistan	Luhy SP, Aghotwala M, Feikin DR, Painter J, Billhimer W, Altaf A, Hoekstra, RM. Effect of handwashing on child health: a randomised controlled trial. <i>Lancet.</i> 2005; 366(9481): 225-233.	2002-2003		
Pakistan	Ronald AR, Underwood BA, Woodward TE. Glucose-6-phosphate dehydrogenase deficiency in Pakistani males. <i>Trans R Soc Trop Med Hyg.</i> 1968; 62(4): 531-3.	1966-1968		
Pakistan	Ali N, Anwar M, Ayyub M, Bhatti FA, Nadeem M, Nadeem A. Frequency of glucose-6-phosphate dehydrogenase deficiency in some ethnic groups of Pakistan. <i>J Coll Physicians Surg Pak.</i> 2005; 15(3): 137-41.	2003-2004		
Pakistan	Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M and Boyle P, eds (2007). <i>Cancer Incidence in Five Continents, Vol. IX Periodic Data (electronic version).</i> Lyon, IARC. http://ci5.iarc.fr	1998-2002	*	
Pakistan	Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. <i>Cancer Incidence in Five Continents. Vol. 1 to VIII.</i> Lyon, France, IARC Press, 2005.	1995-1997	*	
Pakistan	Butt T, Ahmad RN, Salman M, Kazmi SY. Changing trends in drug resistance among typhoid salmonellae in Rawalpindi, Pakistan. <i>East Med J Health J.</i> 2005; 11(5-6): 1038-44.	1996-2003	*	
Pakistan	Hasan R, Zafar A, Abbas Z, Mahraj V, Malik F, Zaidi A. Antibiotic resistance among <i>Salmonella enterica</i> serovars Typhi and Paratyphi A in Pakistan (2001-2006). <i>J Infect Dev Ctries.</i> 2008; 2(04): 289-94.	2001-2006	*	
Pakistan	Khan MI, Sahito SM, Khan MJ, Wassan SM, Shaikh AW, Maheshwari AK, Acosta CJ, Galindo CM, Ochiai RL, Rasool S, Peerwani S, Puri MK, Ali M, Zafar A, Hassan R, von Seidlein L, Clemens JD, Nizami SQ, Bhutta ZA. Enhanced disease surveillance through private health care sector cooperation in Karachi, Pakistan: experience from a vaccine trial. <i>Bull World Health Organ.</i> 2006; 84(1): 72-7.	2003-2004		
Pakistan	Ochiai RL, Wang X, von Seidlein L, Yang J, Bhutta ZA, Bhattacharya SK, Agtini M, Deen JL, Wain J, Kim DR, Ali M, Acosta CJ, Jodar L, Clemens JD. <i>Salmonella Paratyphi A Rates, Asia.</i> <i>Emerg Infect Dis.</i> 2005; 11(11): 1764-6.	2002-2003	*	
Pakistan	Siddiqui FJ, Rabbani F, Hasan R, Nizami SQ, Bhutta ZA. Typhoid fever in children: some epidemiological considerations from Karachi, Pakistan. <i>Int J Infect Dis.</i> 2006; 10(3): 215-22.	1999-2001		
Pakistan	Elahi MM, Elahi F, Elahi A, Elahi SB. Paediatric hearing loss in rural Pakistan. <i>J Otolaryngol.</i> 1998; 27(6): 348-53.	1997		
Pakistan	Herekar A, Ahmed B, Effendi J, Latif U, Alvi Z, Steiner TJ on behalf of the Headache Research Foundation of Pakistan and Lifting The Burden: the Global Campaign against Headache. <i>Pakistan Measuring the Burden of Headache in the General Population 2009</i> [Unpublished].	2009	*	
Pakistan	Lambo JA, Memon MI, Khahro ZH, Lashari MI. Epidemiology of neonatal tetanus in rural Pakistan. <i>J Pak Med Assoc.</i> 2011; 61(11): 1099-103.	1993-2003	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Pakistan	Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agtini MD, Bhutta ZA, Canh DG, Ali M, Shin S, Wain J, Page A-L, Albert MJ, Farrar J, Abu-Elyazed R, Pang T, Galindo CM, von Seidlein L, Clemens JD, Domi Typhoid Study Group. A study of typhoid fever in five Asian countries: disease burden and implications for controls. <i>Bull World Health Organ.</i> 2008; 86(4): 260-8.	2002-2003		
Pakistan	Khan MI, Ochiai RL, Soofi SB, Von-Seidlein L, Khan MJ, Sahito SM, Habib MA, Puri MK, Park JK, You YA, Ali M, Nizami SQ, Acosta CJ, Bradley-Sack R, Clemens JD, Bhutta ZA. Risk factors associated with typhoid fever in children aged 2-16 years in Karachi, Pakistan. <i>Epidemiol Infect.</i> 2012; 140(4): 665-72.	2003-2006		
Pakistan	Musani MA, Rauf A, Ahsan M, Khan FA. Frequency and causes of hearing impairment in tertiary care center. <i>J Pak Med Assoc.</i> 2011; 61(2): 141-4.	1998-2000	*	
Pakistan	KNCV Tuberculosis Foundation, Ministry of Inter Provincial Coordination (Pakistan), National Tuberculosis Control Program (Pakistan). Pakistan Prevalence of Pulmonary Tuberculosis Among the Adult Population 2010-2011.	2010-2011	*	
Pakistan	Rabbani MA, Memon GM, Ahmad B, Memon S, Tahir SA, Tahir S. Percutaneous renal biopsy results: a retrospective analysis of 511 consecutive cases. <i>Saudi J Kidney Dis Transpl.</i> 2012; 23(3): 614-8.	1990-2008	*	
Pakistan	World Health Organization (WHO). Pakistan WHO Leishmaniasis Country Profile.	2001-2010	*	
Pakistan	Luby SP, Agboatwalla M, Bowen A, Kenah E, Sharker Y, Hoekstra RM. Difficulties in maintaining improved handwashing behavior, Karachi, Pakistan. <i>Am J Trop Med Hyg.</i> 2009; 81(1): 140-5.	2005-2006	*	
Pakistan	Pakistan National Nutrition Survey 2001-2002 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2001-2002		
Pakistan	Pakistan National Nutrition Survey 2001-2002 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2001-2002		
Pakistan	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Pakistan	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec.</i> 2007; 82(25): 225-32.	2006	*	
Pakistan	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Pakistan	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Pakistan	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Pakistan	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec.</i> 2008; 83(33): 293-300.	2007	*	
Pakistan	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Pakistan	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Pakistan	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Pakistan	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Pakistan	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Pakistan	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Pakistan	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Pakistan	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1993; 68(25): 181-6.	1992	*	
Pakistan	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Pakistan	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Pakistan	Mir AM, Wajid A, Reichenbach L, Khan M. STI prevalence and associated factors among urban men in Pakistan. <i>Sex Transm Infect.</i> 2009; 85(3): 199-200.	2007	*	
Pakistan	Faisal A, Cleland J. Migrant men: a priority for HIV control in Pakistan <i>Sex Transm Infect.</i> 2006; 82(4): 307-10.	2003-2004	*	
Pakistan	Hameed K, Gibson T, Kadir M, Sultana S, Fatima Z, Syed A. The prevalence of rheumatoid arthritis in affluent and poor urban communities of Pakistan. <i>Rheumatology.</i> 1995; 34(3): 252-6.	1992	*	
Pakistan	Qazi SA, Khan MA, Mughal N, Ahmad M, Joomro B, Sakata Y, Kuriya N, Matsushita T, Abbas KA, Yamashita F. Dexamethasone and bacterial meningitis in Pakistan. <i>Arch Dis Child.</i> 1996; 75(6): 482-8.	1990-1992		
Pakistan	Akhtar R, Ullah Z, Paracha P, G Lutfullah. Impact assessment of salt iodization on the prevalence of goiter in district Swat. <i>Pak J Med Sci.</i> 2004; 30(3): 303-7 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2000		
Pakistan	Khan E, Siddiqui J, Shakoor S, Mehraj V, Jamil B, Hasan R. Dengue outbreak in Karachi, Pakistan, 2006: experience at a tertiary care center. <i>Trans R Soc Trop Med Hyg.</i> 2007; 101(11): 1114-9.	2005-2006		
Pakistan	Bachani AM, Ghaffar A, Hyder AA. Burden of fall injuries in Pakistan--analysis of the National Injury Survey of Pakistan. <i>East Mediterr Health J.</i> 2011; 17(5): 375-81.	1997	*	
Pakistan	Ghaffar A, Hyder AA, Masud TL. The burden of road traffic injuries in developing countries: the 1st national injury survey of Pakistan. <i>Public Health.</i> 2004; 118(3): 211-7.	1997	*	
Pakistan	Qureshi H, Bile KM, Joona R, Alam SE, Afridi HUR. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. <i>East Mediterr Health J.</i> 2010; 15(23): 284-5.	2007-2008		
Pakistan	Ali A, Ahmad H, Ali I, Khan S, Zaidi G, Idrees M. Prevalence of active hepatitis c virus infection in district manshera pakistan. <i>Virology.</i> 2010; 7(1): 334.	2009-2010		
Pakistan	Hakim S, Kazmi S, Bagasra O. Seroprevalence of Hepatitis B and C Genotypes Among Young Apparently Healthy Females of Karachi-Pakistan. <i>Libyan J Med.</i> 2008; 3(2): 66-70.	2002-2006		
Pakistan	Saha N, Ramzan M, Tay JS, Low PS, Basair JB, Khan FM. Molecular characterisation of red cell glucose-6-phosphate dehydrogenase deficiency in north-west Pakistan. <i>Hum Hered.</i> 1994; 44(2): 85-9.	1991-1993	*	
Pakistan	Khan A, Tanaka Y, Azam Z, Abbas Z, Kurbanov F, Saleem U, Hamid S, Jafri W, Mizokami M. Epidemic spread of hepatitis C virus genotype 3a and relation to high incidence of hepatocellular carcinoma in Pakistan. <i>J Med Virol.</i> 2009; 81(7): 1189-97.	2006-2007	*	
Pakistan	Agboatwalla M, Isomura S, Miyake K, Yamashita T, Morishita T, Akram D. Hepatitis A, B and C seroprevalence in Pakistan. <i>Indian J Pediatr.</i> 1994; 61(5): 545-9.	1990-1991		
Pakistan	Qureshi H, Hafiz S. Exposure rate of hepatitis A and E (IgG) in children. <i>J Pak Med Assoc.</i> 2000; 50(8): 284-5.	1997-1999		
Pakistan	Khan MS, Subhan F, Tahir F, Kazi BM, Dil AS, Sultan S, Deepa F, Khan F, Sheikh MA. Prevalence of blood groups and Rh factor in Bannu region (NWFP) Pakistan. <i>Pak J Med Res.</i> 2004; 43(1).	2002-2003	*	†
Pakistan	Abdul Mujeeb S, Aamir K, Mehmood K. Seroprevalence of HBV, HCV and HIV infections among college going first time voluntary blood donors. <i>J Pak Med Assoc.</i> 2000; 50(8): 269-70.	1998-1999		
Pakistan	Abdul Mujeeb S, Nanan D, Sabir S, Altaf A, Kadir M. Hepatitis B and C infection in first-time blood donors in Karachi--a possible subgroup for sentinel surveillance. <i>East Mediterr Health J.</i> 2006; 12(6): 735-41.	2000		
Pakistan	Akhtar S, Younus M, Adil S, Jafri SH, Hassan F. Hepatitis C virus infection in asymptomatic male volunteer blood donors in Karachi, Pakistan. <i>J Viral Hepat.</i> 2004; 11(6): 527-35.	1998-2002		
Pakistan	Aslam M, Aslam J, Mitchell BD, Munir KM. Association between smallpox vaccination and hepatitis C antibody positive serology in Pakistani volunteers. <i>J Clin Gastroenterol.</i> 2005; 39(3): 243-6.	2005		
Pakistan	Bilwani F, Zaidi Y, Kakepoto GN, Adil SN, Khurshid M. Prevalence of hepatitis C virus in lymphoproliferative disorders. <i>J Pak Med Assoc.</i> 2004; 54(4): 202-6.	1998-2001		
Pakistan	Khan NR, Sadiq F. Prenatal screening for hepatitis B virus. <i>Int J Gynaecol Obstet.</i> 1996; 55(1): 79-80.	1994		
Pakistan	Luby SP, Qamruddin K, Shah AA, Omair A, Palhsa O, Khan AJ, McCormick JB, Hoodbhoy F, Fisher-Hoch S. The relationship between therapeutic injections and high prevalence of hepatitis C infection in Hafizabad, Pakistan. <i>Epidemiol Infect.</i> 1997; 119(3): 349-56.	1993		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Pakistan	Masood Z. Screening for Hepatitis B & C: A routine pre-operative investigation. Pak J Med Sci. 2005; 21(4): 455-9.	2004		
Pakistan	Parker SP, Khan HI, Cubitt WD. Detection of antibodies to hepatitis C virus in dried blood spot samples from mothers and their offspring in Lahore, Pakistan. J Clin Microbiol. 1999; 37(6): 2061-3.	1999		
Pakistan	Sultan F, Mehmood T, Mahmood MT. Infectious pathogens in volunteer and replacement blood donors in Pakistan: a ten-year experience. Int J Infect Dis. 2007; 11(5): 407-12.	1996-2005		
Pakistan	Tareen S, Eslick GD, Kam EPY, Byles JE, Durrani AB, Maree SM. High prevalence of hepatitis B virus (HBV) among male blood donors in a developing country: urgent need for systematic screening. Scand J Infect Dis. 2002; 34(9): 712-3.	1996		
Pakistan	Aziz S, Muzaffar R, Hafiz S, Abbas Z, Zafar MN, Naqvi SA, Rizvi SA. Helicobacter Pylori, Hepatitis Viruses A, C, E, Antibodies And HBsAg - Prevalence And Associated Risk Factors In Pediatric Communities Of Karachi. J Coll Physicians Surg Pak. 2007; 17(4): 195-8.	2002-2004		
Pakistan	Jokhio AH, Rizvi RM, Rizvi J, MacArthur C. Prevalence of obstetric fistula: a population-based study in rural Pakistan. BJOG. 2014; 121(8): 1039-46.	2010-2012	*	
Pakistan	Rowland M, Bouma M, Ducomet D, Durrani N, Rozendaal J, Schapira A, Sondorp E. Pyrethroid-impregnated bed nets for personal protection against malaria for Afghan refugees. Trans R Soc Trop Med Hyg. 1996; 90(4): 357-61 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†
Pakistan	Bouma M, Rowland M. Failure of passive zoophylaxis: cattle ownership in Pakistan is associated with a higher prevalence of malaria. Trans R Soc Trop Med Hyg. 1995; 89(4): 351-3 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989-1990	*	†
Pakistan	Bouma MJ, Parvez SD, Nesbit R, Winkler AM. Malaria control using permethrin applied to tents of nomadic Afghan refugees in northern Pakistan. Bull World Health Organ. 1996; 74(4): 413-21 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989-1990	*	†
Pakistan	Rowland M, Durrani N, Kenward M, Mohammed N, Urahman H, Hewitt S. Control of malaria in Pakistan by applying deltamethrin insecticide to cattle: a community-randomised trial. Lancet. 2001; 357(9271): 1837-41 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995-1996	*	†
Pakistan	Rowland M, Hewitt S, Durrani N, Bano N, Wirtz R. Transmission and control of vivax malaria in Afghan refugee settlements in Pakistan. Trans R Soc Trop Med Hyg. 1997; 91(3): 252-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†
Pakistan	Rowland M, Hewitt S, Durrani N, Bano N, Wirtz R. Transmission and control of vivax malaria in Afghan refugee settlements in Pakistan. Trans R Soc Trop Med Hyg. 1997; 91(3): 252-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Pakistan	Rowland M, Mahmood P, Iqbal J, Carneiro I, Chavasse D. Indoor residual spraying with alphacypermethrin controls malaria in Pakistan: a community-randomized trial. Trop Med Int Health. 2000; 5(7): 472-81 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
Pakistan	Strickland G, Zafar-Latif A, Fox E, Kaliq A, Chowdhry M. Endemic malaria in four villages of the Pakistani province of Punjab. Trans R Soc Trop Med Hyg. 1987; 81(1): 36-41 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Palestine	Al Rifai, AM. Palestine Knowledge of Palestinian Girls & Women about HIV/AIDS: Behavioural Policy-Oriented Approach for Health Promotion. Presented at XXVII International Union for the Scientific Study of Population (IUSSP) International Population Conference; 2009; Marrakech.	2010		
Palestine	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Palestine	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2000		
Palestine	Abdul-Rahim HF, Hussein A, Giacaman R, Jervell J, Bjertness E. Diabetes mellitus in an urban Palestinian population: prevalence and associated factors. East Mediterr Health J. 2001; 7(1-2): 67-78.	1998		
Palestine	Sweileh WM, Sawalha AF, Al-Aqad SM, Zyoud SH, Al-Jabi SW. The Epidemiology of Stroke in Northern Palestine: A 1-Year, Hospital-Based Study. J Stroke Cerebrovasc Dis. 2008; 17(6): 406-11.	2006-2007		
Palestine	Madianos MG, Sarhan AL, Koukia E. Major depression across West Bank: a cross-sectional general population study. Int J Soc Psychiatry. 2012; 58(3): 315-22.	2007	*	
Palestine	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 2007, 2010, 2012		
Palestine	Chiang F, Kuper H, Lindfield R, Keenan T, Seyam N, Magauran D, Khalilia N, Batta H, Abdeen Z, Sargent N. Rapid assessment of avoidable blindness in the Occupied Palestinian Territories. PLoS One. 2010; 5(7): e11854, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2008		
Palestine	Palestinian Central Bureau of Statistics. Palestine - West Bank Vital Registration - Deaths 2003. [Unpublished].	2003	*	†
Palestine	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Palestine	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Palestine	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Palestine	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Palestine	Ministry of Health (Palestine). Palestine Trichomoniasis and Candidiasis Prevalence Survey 2004-2005.	2004-2005	*	
Palestine	Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, Büchele G, Clausen M, Cookson WOC, von Mutius E, Strachan DP, Williams HC. ISAAC Phase Two Study Group. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. J Allergy Clin Immunol. 2008; 121(1): 141-147.	2005-2007	*	
Palestine	Amro A, Hamarsheh O. Epidemiology of scabies in the West Bank, Palestinian Territories (Occupied). Int J Infect Dis. 2012; 16(2): e117-120.	2005-2010	*	
Palestine	Yassin K, Awad R, Tebi A, Queder A, Laaser U. The epidemiology of hepatitis A infection in Palestine: a universal vaccination programme is not yet needed. Epidemiol Infect. 2001; 127(2): 335-9.	1998-2000		
Palestine	Gottlieb S, Harpaz D, Shotan A, Boyko V, Leor J, Cohen M, Mandelzweig L, Mazouz B, Stern S, Behar S. Sex Differences in Management and Outcome After Acute Myocardial Infarction in the 1990s?: A Prospective Observational Community-Based Study. Circulation. 2000; 102(20): 2484-2490.	1992-1996		
Panama	International Statistical Institute, Ministry of Health (Panama), Office of Population Studies. Panama World Fertility Survey 1975-1976. International Statistical Institute.	1975-1976		
Panama	Panama Vital Registration - Deaths 2007 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2007	*	
Panama	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-2002		
Panama	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Panama	Estrada Castañón R, Torres Bibiano B, Alarcón Hernández H, Villegas Arrizón A, Martínez Sandoval E, Chávez López G, Andersson N. Epidemiología cutánea en dos sectores de atención médica en Guerrero, México; Cutaneous epidemiology in two sectors of Guerrero, Mexico. <i>Dermatol rev mex.</i> 1992; 36(1): 29-34.	1989-1991		
Panama	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol.</i> 2008; 121(4): 947-954.	1995, 2001		
Panama	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997-1998, 2000-2001, 2003-2009		
Panama	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Panama	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2001		
Panama	Calzada JE, Pineda V, Garisto JD, Samudio F, Santamaria AM, Saldaña A. Human trypanosomiasis in the eastern region of the Panama Province: new endemic areas for Chagas disease. <i>Am J Trop Med Hyg.</i> 2010; 82(4): 580-2.	2006-2007		
Panama	Mallol J, Solé D, Baeza-Bacab M, Aguirre-Camposano V, Soto-Quiros M, Baena-Cagnani C, Latin American ISAAC Group. Regional variation in asthma symptom prevalence in Latin American children. <i>J Asthma.</i> 2010; 47(6): 644-50.	2001-2003	*	
Panama	Astroth J, Berg R, Berkey D, McDowell J, Hamman R, Mann J. Dental caries prevalence and treatment need in Chiriqui Province, Panama. <i>Int Dent J.</i> 1998; 48(3): 203-9.	1993		
Panama	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). CICAD Comparative Report on Nationwide School Surveys in Seven Countries: El Salvador, Guatemala, Nicaragua, Panama, Paraguay, Dominican Republic, and Uruguay 2003. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2004.	2003	4	
Panama	Gracia F, Castillo LC, Benzaón A, Larreategui M, Villareal F, Triana E, Arango AC, Lee D, Pascale JM, Gomez E, Armién B. Prevalence and incidence of multiple sclerosis in Panama (2000-2005). <i>Neuroepidemiology.</i> 2009; 32(4): 287-93.	2005	*	
Panama	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 2001, 2004, 2007, 2010, 2012		
Panama	Fernández-Cean J, González-Martínez F, Schwedt E, Mazzuchi N. Renal replacement therapy in Latin America. <i>Kidney Int.</i> 2000; 57(574): 55-59.	1997		
Panama	Cusumano A, García-García G, Di Gioia C, Hermida O, Lavorato C, Carreño CA, Torrico MP, Batista PB, Romão JE, Badal HP, Miranda SE, Gomez R, Calderon MC, Sanchez SH, Lopez MA, Moscoso J, Merino RL, Polo JV, Lopez A, Romero NJ, Garcia R, Acosta BV, Lopez AS, Delpin ES, Mena E, González C, Millánés CL, Acchiardo S. End-stage renal disease and its treatment in Latin America in the twenty-first century. <i>Ren Fail.</i> 2006; 28(8): 631-7.	2004		
Panama	World Health Organization (WHO). Panama WHO Leishmaniasis Country Profile.	1980-2010	*	
Panama	Panama National Survey of Goiter and Anemia in School Children 6 to 12 Years Old 1990 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1990		
Panama	Panama National Survey of Goiter and Anemia in School Children 6 to 12 Years Old 1999 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1999		
Panama	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Panama	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Panama	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Panama	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Panama	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Panama	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Panama	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2003. Pan American Health Organization (PAHO).	2003		†
Panama	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2004. Pan American Health Organization (PAHO).	2004		†
Panama	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2005. Pan American Health Organization (PAHO).	2005		†
Panama	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2006. Pan American Health Organization (PAHO).	2006		†
Panama	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2007. Pan American Health Organization (PAHO).	2007		†
Panama	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Panama	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Panama	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Panama	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Panama	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Panama	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Panama	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L. Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Ann Hepatol.</i> 2010; 9(1): 63-9.	2006-2008	*	
Panama	Pan American Health Organization (PAHO), World Health Organization (WHO). Quantitative Estimation of Chagas in the Americas.	2005	*	
Panama	Saldaña A, Pineda V, Martínez I, Santamaria G, Santamaria AM, Miranda A, Calzada JE. A new endemic focus of Chagas disease in the northern region of Veraguas Province, Western Half Panama, Central America. <i>PLoS One.</i> 2012; 7(4): e34657.	2005-2008	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Panama	Saldaña A, Samudio F, Miranda A, Herrera LM, Saavedra SP, Cáceres L, Bayard V, Calzada JE. Predominance of Trypanosoma rangeli infection in children from a Chagas disease endemic area in the west-shore of the Panama canal. Mem Inst Oswaldo Cruz. 2005; 100(7): 729-31.	2004	*	
Panama	Panama Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD), United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Papua New Guinea	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1991, 1995, 2001-2002		
Papua New Guinea	Lavu EK, Oswyn G, Vince JD. Sickle-cell/beta+ -thalassaemia in a Papua New Guinean: the first reported case of the sickle gene in Papua New Guinea. Med J Aust. 2002; 176(2): 70-1.	1990-2002		
Papua New Guinea	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Papua New Guinea	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Papua New Guinea	World Health Organization (WHO). Papua New Guinea STEPS Noncommunicable Disease Risk Factors Survey 2007-2008.	2007-2008		
Papua New Guinea	Hill AV, Bowden DK, O'Shaughnessy DF, Weatherall DJ, Clegg JB. Beta thalassaemia in Melanesia: association with malaria and characterization of a common variant (IVS-1 nt 5 G→C). Blood. 1988; 72(1): 9-14.	1985-1987		
Papua New Guinea	Dowse GK, Spark RA, Mavo B, Hodge AM, Erasmus RT, Gwalimu M, Knight LT, Koki G, Zimmet PZ. Extraordinary prevalence of non-insulin-dependent diabetes mellitus and binodal plasma glucose distribution in the Wanigela people of Papua New Guinea. Med J Aust. 1994; 160(12): 767-74.	1991		
Papua New Guinea	Fowkes FJL, Michon P, Pilling L, Ripley RM, Tavul L, Imrie HJ, Woods CM, Mgone CS, Luty AJF, Day KP. Host erythrocyte polymorphisms and exposure to Plasmodium falciparum in Papua New Guinea. Malar J. 2008; 1.	1999-2000		
Papua New Guinea	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Papua New Guinea	Howard P, Alexander ND, Atkinson A, Clegg AO, Gerega G, Javati A, Kajoi M, Lupiwa S, Lupiwa T, Mens M, Saleu G, Sanders RC, West B, Alpers MP. Bacterial, viral and parasitic aetiology of paediatric diarrhoea in the highlands of Papua New Guinea. J Trop Pediatr. 2000; 46(1): 10-4.	1985-1990	*	
Papua New Guinea	Wysch M, Coakley K, Alexander N, Saleu G, Taimé J, Kakazo M, Howard P, Lehmann D. Diarrhoea morbidity in children in the Asaro Valley, Eastern Highlands Province, Papua New Guinea. P N G Med J. 1998; 41(1): 7-14.	1986-1989	*	
Papua New Guinea	Klufio CA, Amoa AB, Delamare O, Kariwiga G. Endocervical Chlamydia trachomatis infection in pregnancy: direct test and clinico-sociodemographic survey of pregnant patients at the Port Moresby General Hospital antenatal clinic to determine prevalence and risk markers. Aust N Z J Obstet Gynaecol. 1992; 32(1): 43-6.	1990-1991		
Papua New Guinea	Yanagihara RT, Garruto RM, Gajusek DC. Epidemiological surveillance of amyotrophic lateral sclerosis and parkinsonism-dementia in the commonwealth of the Northern Mariana Islands. Ann Neurol. 1983; 13(1): 79-86.	1980-1981		
Papua New Guinea	Garap JN, Sheeladevi S, Shamanna BR, Nirmalan PK, Brian G, Williams C. Blindness and vision impairment in the elderly of Papua New Guinea. Clin Experiment Ophthalmol. 2006; 34(4): 335-41, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2004-2005		
Papua New Guinea	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Papua New Guinea	Passes M, Mgone CS, Lupiwa S, Suve N, Tiwara S, Lupiwa T, Clegg A, Alpers MP. Community based study of sexually transmitted diseases in rural women in the highlands of Papua New Guinea: prevalence and risk factors. Sex Transm Infect. 1998; 74(2): 120-7.	1995	*	
Papua New Guinea	Suligoi B, Danaya RT, Sarmati L, Owen IL, Boros S, Pozio E, Andreoni M, Rezza G. Infection with human immunodeficiency virus, herpes simplex virus type 2, and human herpes virus 8 in remote villages of southwestern Papua New Guinea. Am J Trop Med Hyg. 2005; 72(1): 33-6.	2001	*	
Papua New Guinea	Oswyn G, Vince JD, Friesen H. Perinatal asphyxia at Port Moresby General Hospital: a study of incidence, risk factors and outcome. P N G Med J. 2000; 43(1-2): 110-20.	1995-1997	*	†
Papua New Guinea	Kidson C. Deficiency of glucose-6-phosphate dehydrogenase: some aspects of the trait in people of Papua-New Guinea. Med J Aust. 1961; 48(2): 506-9.	1959-1961		
Papua New Guinea	Prins HK, Loos JA, Meuwissen JH. Glucose-6-phosphate dehydrogenase (G6PD) deficiency in West New Guinea. Trop Geogr Med. 1963; 361-70.	1962		
Papua New Guinea	Brabin L, Brabin BJ. Malaria and glucose 6-phosphate dehydrogenase deficiency in populations with high and low spleen rates in Madang, Papua New Guinea. Hum Hered. 1990; 40(1): 15-21.	1987-1988		
Papua New Guinea	Kazura JW, Bockarie M, Alexander N, Perry R, Bockarie F, Dagoro H, Dimber Z, Hyun P, Alpers MP. Transmission intensity and its relationship to infection and disease due to Wuchereria bancrofti in Papua New Guinea. J Infect Dis. 1997; 176(1): 242-6.	1993-1994	*	
Papua New Guinea	Bockarie MJ, Tavul L, Kastens W, Michael E, Kazura JW. Impact of untreated bednets on prevalence of Wuchereria bancrofti transmitted by Anopheles farauti in Papua New Guinea. Med Vet Entomol. 2002; 16(1): 116-9.	2002	*	
Papua New Guinea	Alexander ND. Wuchereria bancrofti infection and disease in a rural area of Papua New Guinea. P N G Med J. 2000; 43(3-4): 166-71.	1993-1994	*	
Papua New Guinea	Sapak P, Williams G, Bryan J, Riley I. Efficacy of mass single-dose diethylcarbamazine and DEC-fortified salt against bancroftian filariasis in Papua New Guinea six months after treatment. P N G Med J. 2000; 43(3-4): 213-20.	1997-1999	*	
Papua New Guinea	Soli KW, Maure T, Kas MP, Bande G, Bebes S, Luang-Suarkia D, Siba PM, Morita A, Umezaki M, Greenhill AR, Horwood PF. Detection of enteric viral and bacterial pathogens associated with paediatric diarrhoea in Goroka, Papua New Guinea. Int J Infect Dis. 2014; 27: 54-58.	2009-2010	*	
Papua New Guinea	Papua New Guinea - Morobe Iodine Deficiency Disorders 1996 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1996		
Papua New Guinea	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Papua New Guinea	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
Papua New Guinea	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Papua New Guinea	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	
Papua New Guinea	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Papua New Guinea	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Papua New Guinea	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Papua New Guinea	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
Papua New Guinea	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Papua New Guinea	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Papua New Guinea	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Papua New Guinea	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Papua New Guinea	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Papua New Guinea	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Papua New Guinea	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Papua New Guinea	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Papua New Guinea	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Papua New Guinea	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2009.	2009		
Papua New Guinea	Richmond P, Phuanukoonnon S, Jacoby P, et al. Effect of neonatal and early immunisation with heptavalent pneumococcal conjugate vaccine on morbidity and pneumonia in Papua New Guinea [abstract]. 6th International Symposium on Pneumococci and Pneumococcal Disease; 2008 Jun 8–12; Reykjavik, Iceland.	2003-2005	*	
Papua New Guinea	Temple V, Mapira P, Adeniyi K, Sims P. Iodine deficiency in Papua New Guinea (sub-clinical iodine deficiency and salt iodization in the highlands of Papua New Guinea). J Public Health (Oxf). 2005; 27(1): 45-8 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2004		
Papua New Guinea	Chockkalingam K, Board PG. Further evidence for heterogeneity of glucose-6-phosphate dehydrogenase deficiency in Papua New Guinea. Hum Genet. 1980; 55(2): 209-12.	1977-1979	*	
Papua New Guinea	Chockkalingam K, Board PG, Nurse GT. Glucose-6-Phosphate Dehydrogenase Deficiency in Papua New Guinea. Hum Genet. 1982; 189-92.	1979-1981	*	
Papua New Guinea	Hawkes RA, Boughton CR, Ferguson V. The seroepidemiology of hepatitis in Papua New Guinea. I. A long-term study of hepatitis A. Am J Epidemiol. 1981; 114(4): 554-62.	1963-1964, 1972		
Papua New Guinea	Brabin L, Brabin BJ, Dimitrakakis M, Gust I. Factors affecting the prevalence of infection with hepatitis B virus among non-pregnant women in the Alexishafen area of Papua New Guinea. Am Trop Med Parasitol. 1989; 83(4): 365-74.	1985-1987		
Papua New Guinea	Hawkes RA, Boughton CR, Ferguson V, Vale TG. The Seroepidemiology of Hepatitis in Papua New Guinea II. a Long-Term Study of Hepatitis B. Am J Epidemiol. 1981; 114(4): 563-73.	1963-1964, 1972		
Papua New Guinea	Rezza G, Danaya RT, Wagner TM, Sarmati L, Owen IL, Monini P, Andreoni M, Suligoi B, Ensolio E. Human herpesvirus-8 and other viral infections, Papua New Guinea. Emerg Infect Dis. 2001; 7(5): 893-5.	1999		
Papua New Guinea	Sanders RC, Lewis D, Dyke T, Alpers MP. Markers of hepatitis B infection in Tari District, Southern Highlands Province, Papua New Guinea. P N G Med J. 1992; 35(3): 197-201.	1990		
Papua New Guinea	Yamaguchi K, Inaoka T, Ohtsuka R, Akimichi T, Hongo T, Kawabe T, Nakazawa M, Futatsuka M, Takatsuki K. HTLV-I, HIV-I, and hepatitis B and C viruses in Western Province, Papua New Guinea: a serological survey. Jpn J Cancer Res. 1993; 84(7): 715-9.	1989		
Papua New Guinea	Epidemiology of Malaria the Southern Highlands and the Gulf Province Papua New Guinea [Master's thesis] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Papua New Guinea	The Genetic Diversity of Plasmodium Falciparum [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Papua New Guinea	Papua New Guinea Plasmodium Falciparum Parasite Rate Data. Personal Communication with PNG Institute of Medical Research 2006 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985-1986	*	†
Papua New Guinea	Barry AE, Schultz L, Senn N, Nale J, Kiniboro B, Siba PM, Mueller I, Reeder JC. High Levels of Genetic Diversity of Plasmodium falciparum Populations in Papua New Guinea despite Variable Infection Prevalence. Am J Trop Med Hyg. 2013; 88(4): 718-25 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Papua New Guinea	Burkot TR, Garner P, Paru R, Daghero H, Barnes A, McDougall S, Wirtz RA, Campbell G, Spark R. Effects of untreated bed nets on the transmission of Plasmodium falciparum, P. vivax and Wuchereria bancrofti in Papua New Guinea. Trans R Soc Trop Med Hyg. 1990; 84(6): 773-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986-1987	*	†
Papua New Guinea	Cox MJ, Kum DE, Tavul L, Narara A, Raiko A, Baisor M, Alpers MP, Medley GF, Day KP. Dynamics of malaria parasitaemia associated with febrile illness in children from a rural area of Madang, Papua New Guinea. Trans R Soc Trop Med Hyg. 1994; 88(2): 191-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Papua New Guinea	Hii J, Dyke T, Daghero H, Sanders RC. Health Impact assessments of malaria and Ross River virus. P N G Med J. 1997; 40(1): 14-25 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Papua New Guinea	Inrie H, Fowkes FJ, Michon P, Tavul L, Hume JC, Piper KP, Reeder JC, Day KP. Haptoglobin levels are associated with haptoglobin genotype and alpha+ -Thalassemia in a malaria-endemic area. Am J Trop Med Hyg. 2006; 74(6): 965-71 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999-2000	*	†
Papua New Guinea	Mehlotra RK, Kasehagen LJ, Baisor M, Lorry K, Kazura JW, Bockarie MJ, Zimmerman PA. Malaria infections are randomly distributed in diverse holoendemic areas of Papua New Guinea. Am J Trop Med Hyg. 2002; 67(6): 555-62 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998-2000	*	†
Papua New Guinea	Michon P, Cole-Tobian JL, Dabod E, Schoepflin S, Igu J, Susapu M, Tarongka N, Zimmerman PA, Reeder JC, Beeson JG, Schofield L, King CL, Mueller I. The risk of malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg. 2007; 76(6): 997-1008 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Papua New Guinea	Pluess B, Mueller I, Levi D, King G, Smith TA, Lengeler C. Malaria – a major health problem within an oil palm plantation around Malar J. 2009; 8: 56 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Papua New Guinea	Smith T, Hii JL, Genton B, Mher I, Booth M, Gibson N, Narara A, Alpers MP. Associations of peak shifts in age-prevalence for human malaria with bednet coverage. Trans R Soc Trop Med Hyg. 2001; 95(1): 1-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990-1992	*	†
Paraguay	Department of Statistics and Censuses (Paraguay), International Statistical Institute. Paraguay World Fertility Survey 1979. Voorburg, Netherlands: International Statistical Institute.	1979		
Paraguay	Paraguay Vital Registration - Deaths 1981 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1981	*	
Paraguay	Paraguay Vital Registration - Deaths 2003 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2003	*	
Paraguay	Paraguay Vital Registration - Deaths 2004 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2004	*	
Paraguay	Paraguay Vital Registration - Deaths 2005 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2005	*	
Paraguay	Paraguay Vital Registration - Deaths 2006 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2006	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Paraguay	Macro Systems, Inc.; Institute for Resource Development, Paraguayan Center for Population Studies (CEPEP). Paraguay Demographic and Health Survey 1990. Columbia, United States: Macro Systems, Inc.	1990		†
Paraguay	World Health Organization (WHO). Paraguay World Health Survey 2002-2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2002-2003		†
Paraguay	Paraguay Vital Registration - Deaths 2008 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2008	*	
Paraguay	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-1994, 1996, 1999-2002		
Paraguay	Paraguay Vital Registration - Deaths 2009 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2009	*	
Paraguay	Paraguay Vital Registration - Deaths 2007 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2007	*	
Paraguay	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Paraguay	Pan American Health Organization (PAHO), Southern Cone Initiative (INCOSUR). Xth Meeting of the Intergovernmental Committee for the Elimination of Triatoma Infestans and the Interruption of American Trypanosomiasis by Transfusion. Washington, D.C., United States: Pan American Health Organization (PAHO), 2002.	2001		
Paraguay	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol.</i> 2008; 121(4): 947-954.	1997, 2002		
Paraguay	De Oliveira LH, Danovaro-Holliday MC, Andrus JK, de Filipis AMB, Gentsch J, Matus CR, Widdowson M-A. Sentinel hospital surveillance for rotavirus in Latin American and Caribbean countries. <i>J Infect Dis.</i> 2009; 200 Suppl 1: 131-139.	2006-2007		
Paraguay	Souza JP, Cecatti JG, Faundes A, Morais SS, Villar J, Carroli G, Gulmezoglu M, Wojdyla D, Zavaleta N, Donner A, Velazco A, Bataglia V, Valladares E, Kublickas M, Acosta A. Maternal near miss and maternal death in the World Health Organization's 2005 global survey on maternal and perinatal health. <i>Bull World Health Organ.</i> 2010; 88(2): 113-9.	2005		
Paraguay	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997-1998, 2000-2009		
Paraguay	World Health Organization (WHO). Yellow fever, Paraguay. <i>Wkly Epidemiol Rec.</i> 2008; 83(12): 105.	2008		
Paraguay	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Paraguay	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2002		
Paraguay	Jimenez JT, Palacios M, Cañete F, Barriocanal LA, Medina U, Figueredo R, Martinez S, de Melgarejo MV, Weik S, Kiefer R, Alberti KG, Moreno-Azoreo R. Prevalence of diabetes mellitus and associated cardiovascular risk factors in an adult urban population in Paraguay. <i>Diabet Med.</i> 1998; 15(4): 334-8.	1992		
Paraguay	Mallol J, Solé D, Baeza-Bacab M, Aguirre-Camposano V, Soto-Quiros M, Baena-Cagnani C. Latin American ISAAC Group. Regional variation in asthma symptom prevalence in Latin American children. <i>J Asthma.</i> 2010; 47(6): 644-50.	2001-2003	*	
Paraguay	Amarilla A, Espinola EE, Galeano ME, Fariña N, Russomando G, Parra GI. Rotavirus infection in the Paraguayan population from 2004 to 2005: high incidence of rotavirus strains with short electropherotype in children and adults. <i>Med Sci Monit.</i> 2007; 13(7): CR333-337.	2004-2005	*	
Paraguay	Grimaldi G Jr, Tesh RB, McMahon-Pratt D. A review of the geographic distribution and epidemiology of leishmaniasis in the New World. <i>Am J Trop Med Hyg.</i> 1989; 41(6): 687-725.	1981-1982		
Paraguay	Duerksen R, Limburg H, Carron JE, Foster A. Cataract blindness in Paraguay - results of a national survey. <i>Ophthalmic Epidemiol.</i> 2003; 10(5): 349-57. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1999		
Paraguay	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Paraguay Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2005		
Paraguay	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), United Nations Office on Drugs and Crime (UNODC). Youth and Drugs in South American Countries: A Public Policy Challenge 2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2006.	2005		
Paraguay	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). CICAD Comparative Report on Nationwide School Surveys in Seven Countries: El Salvador, Guatemala, Nicaragua, Panama, Paraguay, Dominican Republic, and Uruguay 2003. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2004.	2003	5	
Paraguay	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Paraguay	Paraguay Rapid Assessment of Avoidable Blindness 2011 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2011		
Paraguay	Fernández-Cean J, González-Martínez F, Schwedi E, Mazzuchi N. Renal replacement therapy in Latin America. <i>Kidney Int.</i> 2000; 57(s74): 55-59.	1997		
Paraguay	Lagon JR, Strogoff de Matos JP. Disparities in end-stage renal disease care in South America. <i>Clin Nephrol.</i> 2010; 74(Suppl 1): S66-71.	2008-2010		
Paraguay	Cusumano A, Garcia-Garcia G, Di Gioia C, Hermida O, Lavorato C, Carreño CA, Torrico MP, Batista PB, Romão JE, Badal HP, Miranda SE, Gomez R, Calderon MC, Sanchez SH, Lopez MA, Moscoso J, Merino RL, Polo JV, Lopez A, Romero NJ, Garcia R, Acosta BV, Lopez AS, Delpin ES, Mena E, González C, Milanés CL, Acchiardo S. End-stage renal disease and its treatment in Latin America in the twenty-first century. <i>Ren Fail.</i> 2006; 28(8): 631-7.	2004		
Paraguay	Santa Cruz F, Cabrera W, Barreto S, Mayor MM, Báez D. Kidney disease in Paraguay. <i>Kidney Int Suppl.</i> 2005; 97: S120-5.	1992-1997, 1999		
Paraguay	Cusumano A, Garcia GG, Di Gioia C, Hermida O, Lavorato C. Latin American Registry of Dialysis and Transplantation. The Latin American Dialysis and Transplantation Registry (RLDT) annual report 2004. <i>Ethn Dis.</i> 2006; 16(2 Suppl 2): 10-3.	2003		
Paraguay	Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. Cancer Incidence in Five Continents. Vol. 1 to VIII. Lyon, France, IARC Press, 2005.	1988-1989	*	
Paraguay	Hart DE, Rojas LA, Rosario JA, Recalde H, Román GC. Childhood Guillain-Barré syndrome in Paraguay, 1990 to 1991. <i>Ann Neurol.</i> 1994; 36(6): 859-63.	1990-1992		†
Paraguay	World Health Organization (WHO). Paraguay WHO Leishmaniasis Country Profile.	1994-2010	*	
Paraguay	Paraguay Vital Registration - Deaths 2010 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2010	*	
Paraguay	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Paraguay	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Paraguay	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Paraguay	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Paraguay	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec.</i> 2008; 83(33): 293-300.	2007	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Paraguay	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Paraguay	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Paraguay	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Paraguay	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Paraguay	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Paraguay	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Paraguay	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Paraguay	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Paraguay	Ministry of Public Health and Welfare (Paraguay). Paraguay - Dengue Control, Prevention, and Mitigation 2010. Asunción, Paraguay: Ministry of Public Health and Welfare (Paraguay).	2009-2010		
Paraguay	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2003. Pan American Health Organization (PAHO).	2003		†
Paraguay	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2004. Pan American Health Organization (PAHO).	2004		†
Paraguay	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2005. Pan American Health Organization (PAHO).	2005		†
Paraguay	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2006. Pan American Health Organization (PAHO).	2006		†
Paraguay	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2007. Pan American Health Organization (PAHO).	2007		†
Paraguay	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Paraguay	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Paraguay	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Paraguay	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Paraguay	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Paraguay	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Paraguay	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L. Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. Ann Hepatol. 2010; 9(1): 63-9.	2006-2008	*	
Paraguay	Pan American Health Organization (PAHO), World Health Organization (WHO). Quantitative Estimation of Chagas in the Americas.	2005	*	
Paraguay	Paraguay Vital Registration Birth Data 1991 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1991		
Paraguay	Paraguay Latin American Collaborative Study of Congenital Malformations Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Peru	International Statistical Institute, National Institute of Statistics (Peru). Peru World Fertility Survey 1977-1978. International Statistical Institute.	1977-1978		
Peru	Peru Vital Registration - Deaths 1981 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1981	*	
Peru	Peru Vital Registration - Deaths 1999 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1999	*	
Peru	National Institute of Statistics (Peru), Westinghouse; Institute for Resource Development. Peru Demographic and Health Survey 1986. Columbia, United States: Westinghouse; Institute for Resource Development.	1986		
Peru	Macro International, Inc, National Institute of Statistics (Peru), PRISMA (Peru). Peru Demographic and Health Survey 1991-1992. Calverton, United States: Macro International, Inc.	1991-1992		†
Peru	Macro International, Inc, National Institute of Statistics (Peru). Peru Demographic and Health Survey 1996. Calverton, United States: Macro International, Inc.	1996		†
Peru	Macro International, Inc, National Institute of Statistics (Peru). Peru Demographic and Health Survey 2000. Calverton, United States: Macro International, Inc.	2000		†
Peru	Macro International, Inc, National Institute of Statistics and Informatics (INEI) (Peru). Peru Continuous Demographic and Health Survey. Calverton, United States: Macro International, Inc.	2003-2012		†
Peru	Macro Systems, Inc.; Institute for Resource Development, Princeton University; Office of Population Research. Peru Experimental Demographic and Health Survey 1986. Columbia, United States: Macro Systems, Inc.	1986		
Peru	World Health Organization (WHO). Control of Foodborne Trematode Infections 1995. Geneva, Switzerland: World Health Organization (WHO), 1995.	1995	*	
Peru	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-2002		
Peru	Lanata CF, Black RE, Gilman RH, Lazo F, Del Aguila R. Epidemiologic, clinical, and laboratory characteristics of acute vs. persistent diarrhea in periurban Lima, Peru. J Pediatr Gastroenterol Nutr. 1991; 12(1): 82-8.	1985-1987		
Peru	Oberhelman RA, Gilman RH, Sheen P, Taylor DN, Black RE, Cabrera L, Lescano AG, Meza R, Madico G. A placebo-controlled trial of Lactobacillus GG to prevent diarrhea in undernourished Peruvian children. J Pediatr. 1999; 134(1): 15-20.	1995-1996		
Peru	Pazzaglia G, Sack RB, Salazar E, Yi A, Chea E, Leon-Barua R, Guerrero CE, Palomino J. High frequency of coinfecting enteropathogens in Aeromonas-associated diarrhea of hospitalized Peruvian infants. J Clin Microbiol. 1991; 29(6): 1151-6.	1988-1989		
Peru	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists' Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Peru	Gutierrez E, Galarza C, Ramos W, Tello M, Rojas I, Chia H, Ronceros G, Ortega-Loayza A. Prevalence of skin diseases in a rural area of Peruvian Amazonia. <i>Dermatol Peru</i> . 2009; 19(2): 104-12.	2005		
Peru	Flores JM, Castillo VB, Franco FC, Huata AB. Superficial fungal infections: clinical and epidemiological study in adolescents from marginal districts of Lima and Callao, Peru. <i>J Infect Dev Ctries</i> . 2009; 3(4): 313-7.	2006		
Peru	Cama RI, Parashar UD, Taylor DN, Hickey T, Figueroa D, Ortega YR, Romero S, Perez J, Sterling CR, Gentsch JR, Gilman RH, Glass RI. Enteropathogens and other factors associated with severe disease in children with acute watery diarrhea in Lima, Peru. <i>J Infect Dis</i> . 1999; 179(5): 1139-44.	1995-1997		
Peru	Gutierrez EL, Galarza C, Ramos W. Prevalencia de Enfermedades Dermatológicas en una comunidad rural de Ucayali, Perú. <i>Dermatol Peru</i> . 2009; 19(2): 104-13.	2005		
Peru	Freyre EA, Rebaza RM, Sami DA, Lozada CP. The prevalence of facial acne in Peruvian adolescents and its relation to their ethnicity. <i>J Adolesc Health</i> . 1998; 22(6): 480-4.	1995		
Peru	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol</i> . 2008; 121(4): 947-954.	1995, 2001		
Peru	Instituto Nacional de Salud (Peru) Grupo Multifuncional de Neumonías. Vigilancia epidemiológica centinela de Haemophilus influenzae y Streptococcus pneumoniae en menores de 5 años en el Perú. <i>Rev Peru Med Exp Salud Publica</i> . 2003; 20(3): 150-5.	2000-2001		
Peru	Figueroa-Quintanilla D, Salazar-Lindo E, Sack RB, León-Barúa R, Sarabia-Arce S, Campos-Sánchez M, Eyzaguirre-Maccan E. A controlled trial of bismuth subsalicylate in infants with acute watery diarrheal disease. <i>N Engl J Med</i> . 1993; 328(23): 1653-8.	1990-1991		
Peru	Greenberg BL, Sack RB, Salazar-Lindo E, Budge E, Gutierrez M, Campos M, Visberg A, Leon-Barua R, Yi A, Maurutia D. Measles-associated diarrhea in hospitalized children in Lima, Peru: pathogenic agents and impact on growth. <i>J Infect Dis</i> . 1991; 163(3): 495-502.	1985-1987		
Peru	Souza JP, Cecatti JG, Faundes A, Morais SS, Villar J, Carroli G, Gulmezoglu M, Wojdyla D, Zavaleta N, Donner A, Velazco A, Bataglia V, Valladares E, Kubickas M, Acosta A. Maternal near miss and maternal death in the World Health Organization's 2005 global survey on maternal and perinatal health. <i>Bull World Health Organ</i> . 2010; 88(2): 113-9.	2005		
Peru	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1980-1998		
Peru	Pan American Health Organization (PAHO). Update on yellow fever in the Americas. <i>Epidemiol Bull</i> . 2000; 21(2):13.	1985-1995		
Peru	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2002, 2004-2005, 2007-2009		
Peru	Vasconcelos PF da C. Febre amarela. <i>Rev Soc Bras Med Trop</i> . 2003; 36(2): 275-93.	1980-2001		
Peru	World Health Organization (WHO). Yellow fever in Africa and South America, 2006. <i>Wkly Epidemiol Rec</i> . 2008; 83(8): 60-76.	2006		
Peru	World Health Organization (WHO). Yellow fever in Africa and South America, 2007. <i>Wkly Epidemiol Rec</i> . 2009; 84(13): 97-104.	2007		
Peru	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J</i> . 1998; 12(2): 315-35.	1993-1995		
Peru	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	2001		
Peru	Medina-Lezama J, Zea-Diaz H, Morey-Vargas OL, Bolaños-Salazar JF, Postigo-Macdonald M, Paredes-Díaz S, Corrales-Medina F, Valdivia-Ascuña Z, Cuba-Bustinza C, Villalobos-Tapia P, Muñoz-Atahualpa E, Chirinos-Pacheco J, Raj L, Chirinos JA. Prevalence and patterns of hypertension in Peruvian Andean Hispanics: the PREVENCIÓN study. <i>J Am Soc Hypertens</i> . 2007; 1(3): 216-25.	2005		
Peru	Arregui A, Cabrera J, Leon-Velarde F, Paredes S, Viscarra D, Arbaiza D. High prevalence of migraine in a high-altitude population. <i>Neurology</i> . 1991; 41(10): 1668-9.	1988		
Peru	Jaillard AS, Mazetti P, Kala E. Prevalence of migraine and headache in a high-altitude town of Peru: a population-based study. <i>Headache</i> . 1997; 37(2): 95-101.	1988		
Peru	Bowman NM, Kawai V, Levy MZ, Cornejo del Carpio JG, Cabrera L, Delgado F, Malaga F, Cordova Benzaquen E, Pinedo VV, Steurer F, Seitz AE, Gilman RH, Bern C. Chagas disease transmission in periurban communities of Arequipa, Peru. <i>Clin Infect Dis</i> . 2008; 46(12): 1822-8.	2005-2007		
Peru	Mallot J, Solé D, Baeza-Bacab M, Aguirre-Camposano V, Soto-Quiros M, Baena-Cagnani C. Latin American ISAAC Group. Regional variation in asthma symptom prevalence in Latin American children. <i>J Asthma</i> . 2010; 47(6): 644-50.	2001-2003	*	
Peru	Gutierrez EL, Galarza C, Ramos W, Tello M, Jiménez G, Ronceros G, Chia H, Hurtado J, Ortega-Loayza AG. Skin diseases in the Peruvian Amazonia. <i>Int J Dermatol</i> . 2010; 49(7): 794-800.	2006-2008	*	
Peru	Lescano AG, Garcia HH, Gilman RH, Gavidia CM, Tsang VCW, Rodriguez S, Moulton LH, Villarain MV, Montano SM, Gonzalez AE, Cysticercosis Working Group in Peru. Taenia solium cysticercosis hotspots surrounding tapeworm carriers: clustering on human seroprevalence but not on seizures. <i>PLoS Negl Trop Dis</i> . 2009; 3(1): e371.	1999	*	
Peru	Ochoa TJ, Ecker L, Barletta F, Mispireta ML, Gil AI, Contreras C, Molina M, Amemiya I, Verastegui H, Hall ER, Cleary TG, Lanata CF. Age-related susceptibility to infection with diarrheagenic Escherichia coli among infants from Periurban areas in Lima, Peru. <i>Clin Infect Dis</i> . 2009; 49(11): 1694-702.	2006-2007	*	
Peru	Black RE, Lopez de Romaña G, Brown KH, Bravo N, Bazalar OG, Kanashiro HC. Incidence and etiology of infantile diarrhea and major routes of transmission in Huascar, Peru. <i>Am J Epidemiol</i> . 1989; 129(4): 785-99.	1982-1984	*	
Peru	CHOICE Study Group. Multicenter, randomized, double-blind clinical trial to evaluate the efficacy and safety of a reduced osmolarity oral rehydration salts solution in children with acute watery diarrhea. <i>Pediatrics</i> . 2001; 107(4): 613-8.	1995-1997	*	
Peru	Lanata CF, Black RE, Mañrta D, Gil A, Gabilondo A, Yi A, Miranda E, Gilman RH, León-Barúa R, Sack RB. Etiologic agents in acute vs persistent diarrhea in children under three years of age in peri-urban Lima, Per. <i>Acta Paediatr Suppl</i> . 1992; 32-8.	1985-1987	*	
Peru	Penny ME, Paredes P, Brown KH, Laughan B, Smith H. Lack of a role of the duodenal microflora in pathogenesis of persistent diarrhea and diarrhea-related malabsorption in Peruvian children. <i>Pediatr Infect Dis J</i> . 1990; 9(7): 479-87.	1987-1989	*	
Peru	Yori PP, Schwab K, Gilman RH, Nappier S, Portocarrero DV, Black RE, Olortegui MP, Hall ER, Moe C, Leon J, Cama VA, Kosek M. Norovirus highly prevalent cause of endemic acute diarrhea in children in the peruvian Amazon. <i>Pediatr Infect Dis J</i> . 2009; 28(9): 844-7.	2003-2006	*	
Peru	Rivera FP, Ochoa TJ, Maves RC, Bernal M, Medina AM, Meza R, Barletta F, Mercado E, Ecker L, Gil AI, Hall ER, Huicho L, Lanata CF. Genotypic and phenotypic characterization of enterotoxigenic Escherichia coli strains isolated from Peruvian children. <i>J Clin Microbiol</i> . 2010; 48(9): 3198-203.	2006-2008	*	
Peru	Yeager BA, Lanata CF, Lazo F, Verastegui H, Black RE. Transmission factors and socioeconomic status as determinants of diarrhoeal incidence in Lima, Peru. <i>J Diarrhoeal Dis Res</i> . 1991; 9(3): 186-93.	1986-1987	*	
Peru	Lanata CF, Black RE, del Aguila R, Gil A, Verastegui H, Gerna G, Flores J, Kapikian AZ, Andre FE. Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. <i>J Infect Dis</i> . 1989; 159(3): 452-9.	1985-1986	*	
Peru	Lanata CF, Black RE, Flores J, Lazo F, Butron B, Linares A, Huapaya A, Ventura G, Gil A, Kapikian AZ. Immunogenicity, safety and protective efficacy of one dose of the rhesus rotavirus vaccine and serotype 1 and 2 human-rhesus rotavirus reassortants in children from Lima, Peru. <i>Vaccine</i> . 1996; 14(3): 237-43.	1987-1990	*	
Peru	Prince M, Acosta D, Ferri CP, Guerra M, Huang Y, Llibre Rodriguez JJ, Salas A, Sosa AL, Williams JD, Dewey ME, Acosta I, Jotheeswaran AT, Liu Z. Dementia incidence and mortality in middle-income countries, and associations with indicators of cognitive reserve: a 10/66 Dementia Research Group population-based cohort study. <i>Lancet</i> . 2012; 380(9836): 50-8.	2003-2010		
Peru	Sousa RM, Ferri CP, Acosta D, Albanese E, Guerra M, Huang Y, Jacob KS, Jotheeswaran AT, Rodriguez JLL, Pichardo GR, Rodriguez MC, Salas A, Sosa AL, Williams J, Zuniga T, Prince M. Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population-based survey. <i>Lancet</i> . 2009; 374(9704): 1821-30.	2003-2005		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod (†)
Peru	Grimaldi G Jr, Tesh RB, McMahon-Pratt D. A review of the geographic distribution and epidemiology of leishmaniasis in the New World. <i>Am J Trop Med Hyg.</i> 1989; 41(6): 687-725.	1984		
Peru	Paul KJ, Garcia PJ, Giesel AE, Holmes KK, Hitti JE. Generation C: prevalence of and risk factors for chlamydia trachomatis among adolescents and young women in Lima, Peru. <i>J Womens Health (Larchmt).</i> 2009; 18(9): 1419-24.	2003		
Peru	Pongo Aguila L, Carrión R, Luna W, Silva JC, Limburg H. [Cataract blindness in people 50 years old or older in a semirural area of northern Peru]. <i>Rev Panam Salud Publica.</i> 2005; 17(5-6): 387-93. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2002		
Peru	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). <i>Peru Evaluation of Progress in Drug Control 2005-2006.</i> Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2005		
Peru	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), United Nations Office on Drugs and Crime (UNODC). <i>Youth and Drugs in South American Countries: A Public Policy Challenge 2006.</i> Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2006.	2005		
Peru	Villarán MV, Montano SM, Gonzalvez G, Moyano LM, Chero JC, Rodriguez S, Gonzalez AE, Pan W, Tsang VCV, Gilman RH, Garcia HH, Cysticercosis Working Group in Peru. Epilepsy and neurocysticercosis: an incidence study in a Peruvian rural population. <i>Neuroepidemiology.</i> 2009; 33(1): 25-31.	1999-2005	*	
Peru	Gonzales GF, Tapia V, Gasco M, Carrillo CE, Fort AL. Association of hemoglobin values at booking with adverse maternal outcomes among Peruvian populations living at different altitudes. <i>Int J Gynaecol Obstet.</i> 2012; 117(2): 134-9.	2000-2010	*	
Peru	Ferri CP, Schoenborn C, Kalra L, Acosta D, Guerra M, Huang Y, Jacob KS, Rodriguez JIL, Salas A, Sosa AL, Williams JD, Liu Z, Moriama T, Valhuerdi A, Prince MJ. Prevalence of stroke and related burden among older people living in Latin America, India and China. <i>J Neurol Neurosurg Psychiatry.</i> 2011; 82(10): 1074-82.	2007-2009	*	
Peru	Montano SM, Villaran MV, Yliquimiche L, Figueroa JJ, Rodriguez S, Bautista CT, Gonzalez AE, Tsang VCV, Gilman RH, Garcia HH, others. Neurocysticercosis: Association between seizures, serology, and brain CT in rural Peru. <i>Neurology.</i> 2005; 65(2): 229-33.	1999-2000		
Peru	Barham WB, Figueroa R, Phillips IA, Hyams KC. Chronic liver disease in Peru: role of viral hepatitis. <i>J Med Virol.</i> 1994; 42(2): 129-32.	1991-1992		
Peru	Ruiz E, Almonte M M, Pizarro R, Celis J, Montalbeli JA, Urbano R. [Hepatitis B and C virus infection as risk factors for hepatocarcinoma in Peru: case and control study]. <i>Rev Gastroenterol Peru.</i> 1998; 18(3): 199-212.	1995-1998		
Peru	World Health Organization (WHO). <i>WHO Tuberculosis Case Notifications.</i> Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007		
Peru	Cárcamo CP, Campos PE, García PJ, Hughes JP, Garnett GP, Holmes KK, Peru PREVEN study team. Prevalences of sexually transmitted infections in young adults and female sex workers in Peru: a national population-based survey. <i>Lancet Infect Dis.</i> 2012; 12(10): 765-73.	2002-2003	*	
Peru	Peru Rapid Assessment of Avoidable Blindness 2011 [Unpublished] as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2011		
Peru	Villena JE, Yoshiyama CA, Sánchez JE, Hilario NL, Merin LM. Prevalence of diabetic retinopathy in Peruvian patients with type 2 diabetes: results of a hospital-based retinal telemedicine program. <i>Rev Panam Salud Publica.</i> 2011; 30(5): 408-14.	2007-2010		
Peru	National Institute of Mental Health "Honorio Delgado - Hideyo Noguchi". <i>Peru Metropolitan Epidemiological Study on Mental Health 2002.</i>	2002		
Peru	Fernández-Cean J, González-Martínez F, Schwedt E, Mazzuchi N. Renal replacement therapy in Latin America. <i>Kidney Int.</i> 2000; 57(s74): 55-59.	1997		
Peru	Lugon JR, Strogoff de Matos JP. Disparities in end-stage renal disease care in South America. <i>Clin Nephrol.</i> 2010; 74(Suppl 1): S66-71.	2008-2010		
Peru	Cusumano A, García-García G, Di Gioia C, Hermida O, Lavorato C, Carreño CA, Torrico MP, Batista PB, Romão JE, Badal HP, Miranda SE, Gomez R, Calderon MC, Sanchez SH, Lopez MA, Moscoso J, Merino RL, Polo JV, Lopez A, Romero NJ, García R, Acosta BV, Lopez AS, Delpin ES, Mena E, González C, Milanés CL, Acchiardo S. End-stage renal disease and its treatment in Latin America in the twenty-first century. <i>Ren Fail.</i> 2006; 28(8): 631-7.	2004		
Peru	Cusumano A, García GG, Di Gioia C, Hermida O, Lavorato C. Latin American Registry of Dialysis and Transplantation. The Latin American Dialysis and Transplantation Registry (RLDT) annual report 2004. <i>Ethn Dis.</i> 2006; 16(2 Suppl 2): 10-3.	2003		
Peru	Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M and Boyle P, eds (2007). <i>Cancer Incidence in Five Continents, Vol. IX Periodic Data (electronic version).</i> Lyon, IARC. http://c5.iarc.fr	1998-2002	*	
Peru	Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. <i>Cancer Incidence in Five Continents, Vol. I to VIII.</i> Lyon, France, IARC Press, 2005.	1984-1991	*	
Peru	Omaeche M, Whittembury A, Pun M, Suarez-Ogñio L. HIV and syphilis seroprevalence and associated factors in pregnant women and their couples in 6 Amazonian indigenous populations in Peru 2007-2008. <i>Int J Infect Dis.</i> 2010; 14(Suppl 1): e412.	2007		
Peru	Quick RE, Vargas R, Moreno D, Mujica O, Beingolea L, Palacios AM, Seminario L, Tauxe RV. Epidemic cholera in the Amazon: the challenge of preventing death. <i>Am J Trop Med Hyg.</i> 1993; 48(5): 597-602.	1991	*	
Peru	Roper MH, Torres RS, Goicochea CG, Andersen EM, Guarda JS, Calampa C, Hightower AW, Magill AJ. The epidemiology of malaria in an epidemic area of the Peruvian Amazon. <i>Am J Trop Med Hyg.</i> 2000; 62(2): 247-56 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database.</i> Oxford, United Kingdom: Malaria Atlas Project.	1998	*	‡
Peru	World Health Organization (WHO). <i>Peru WHO Leishmaniasis Country Profile.</i>	1970, 1975, 1980, 1985, 1990, 1994-1996, 2004-2010	*	
Peru	Llibre Rodriguez JJ, Ferri CP, Acosta D, Guerra M, Huang Y, Jacob KS, Krishnamoorthy ES, Salas A, Sosa AL, Acosta I, Dewey ME, Gaona C, Jotheeswaran AT, Li S, Rodriguez D, Rodriguez G, Kumar PS, Valhuerdi A, Prince M, 10/66 Dementia Research Group. Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey. <i>Lancet.</i> 2008; 372(9637): 464-74.	2005-2006		‡
Peru	Peru Vital Registration - Deaths 2008 ICD10 as it appears in World Health Organization (WHO). <i>WHO Mortality Database Version February 2014.</i> Geneva, Switzerland: World Health Organization (WHO), 2014.	2008	*	
Peru	World Health Organization (WHO). <i>Global leprosy situation, 2005.</i> <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Peru	World Health Organization (WHO). <i>Global leprosy situation, 2009.</i> <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Peru	World Health Organization (WHO). <i>Global leprosy situation, 2010.</i> <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Peru	World Health Organization (WHO). <i>Global leprosy situation, 2012.</i> <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Peru	World Health Organization (WHO). <i>Global leprosy situation, beginning of 2008.</i> <i>Wkly Epidemiol Rec.</i> 2008; 83(33): 293-300.	2007	*	
Peru	World Health Organization (WHO). <i>Global leprosy situation, September 1999.</i> <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Peru	World Health Organization (WHO). <i>Global leprosy: update on the 2012 situation.</i> <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Peru	World Health Organization (WHO). <i>Leprosy update, 2011.</i> <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Peru	World Health Organization (WHO). <i>Leprosy.</i> <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Peru	World Health Organization (WHO). <i>Leprosy - Global situation.</i> <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Peru	World Health Organization (WHO). <i>Progress towards eliminating leprosy as a public health problem. Part I.</i> <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Peru	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Peru	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Peru	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Peru	Patnaik P, Herrero R, Morrow RA, Munoz N, Bosch FX, Bayo S, El Gueddari B, Caceres E, Chichareon SB, Castellsague X, Meijer CJLM, Snijders PJF, Smith JS. Type-specific seroprevalence of herpes simplex virus type 2 and associated risk factors in middle-aged women from 6 countries: the IARC multicentric study. <i>Sex Transm Dis.</i> 2007; 34(12): 1019-24.	1985-1997	*	
Peru	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2003. Pan American Health Organization (PAHO).	2003		†
Peru	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2005. Pan American Health Organization (PAHO).	2005		†
Peru	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2006. Pan American Health Organization (PAHO).	2006		†
Peru	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2007. Pan American Health Organization (PAHO).	2007		†
Peru	Ministry of Health (Peru). Prevalencia nacional de caries dental, fluorosis del esmalte y urgencia de tratamiento en escolares de 6 a 8, 10 y 15 años, Peru. 2001-2002 [National Prevalence of Dental Caries, Enamel Fluorosis, and the Urgency of Treatment in Schoolchildren Aged 6 to 8, 10, 12, and 15. 2001-2002]. Lima, Peru: Ministry of Health (Peru), 2005.	2001-2002	*	
Peru	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Peru	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Peru	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Peru	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Peru	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Peru	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Peru	Rocha C, Morrison AC, Forshey BM, Blair PJ, Olson JG, Stancil JD, Sihuinchu M, Scott TW, Kochel TJ. Comparison of two active surveillance programs for the detection of clinical dengue cases in Iquitos, Peru. <i>Am J Trop Med Hyg.</i> 2009; 80(4): 656-60.	2004	*	
Peru	Moro PL, Checkley W, Gilman RH, Lescano G, Bonilla JJ, Silva B, Garcia HH. Gallstone disease in high-altitude Peruvian rural populations. <i>Am J Gastroenterol.</i> 1999; 94(1): 153-8.	1994-1996		
Peru	Fassio E, Diaz S, Santa C, Reig ME, Martinez Artola Y, Alves de Mattos A, Miguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernandez N, Panchuk L, Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Ann Hepatol.</i> 2010; 9(1): 63-9.	2006-2008	*	
Peru	Méndez M, Arce M, Kruger H, Sánchez S. [Prevalence of serologic markers of viral hepatitis in various population groups in Peru]. <i>Bol Oficina Sanit Panam.</i> 1989; 106(2): 127-38.	1979-1984		
Peru	Kilpatrick ME, Escamilla J. Hepatitis A in Peru. The role of children. <i>Am J Epidemiol.</i> 1986; 124(1): 111-3.	1983-1984		
Peru	Cabezas C, Gotuzzo E, Escamilla J, Phillips I. [Prevalence of serological markers of viral hepatitis A, B and delta in apparently healthy schoolchildren of Huanta, Peru]. <i>Rev Gastroenterol Peru.</i> 1994; 14(2): 123-34.	1991-1993		
Peru	Vildósola H, Colichón A, Rubio Md M del P, Weil J. [Anti-Hav IgG prevalence in a population between 1 and 39 years old in Lima, Peru]. <i>Rev Gastroenterol Peru.</i> 2000; 20(2): 141-5.	1999		
Peru	Gaffo AL, Guillén-Pinto D, Campos-Olazábal P, Burneo JG. [Cysticercosis as the main cause of partial seizures in children in Peru]. <i>Rev Neurol.</i> 2004; 39(10): 924-6.	1998-1999		
Peru	Pan American Health Organization (PAHO), World Health Organization (WHO). Quantitative Estimation of Chagas in the Americas.	2005	*	
Peru	Delgado S, Castillo Neyra R, Quispe Machaca VR, Ancca Juárez J, Chou Chu L, Verastegui MR, Moscoso Apaza GM, Bocángel CD, Tustin AW, Sterling CR, Comrie AC, Náquira C, Cornejo del Carpio JG, Gilman RH, Bern C, Levy MZ. A history of chagas disease transmission, control, and re-emergence in peri-rural La Joya, Peru. <i>PLoS Negl Trop Dis.</i> 2011; 5(2): e970.	2008	*	
Peru	Environmental Risk Factors for Malaria: A Case-control Study in Piura, Peru [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996-1997	*	†
Peru	Malaria in Ecuador and Peru: Alternative Control Strategies as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991-1992	*	†
Peru	Branch O, Casapia WM, Gamboa DV, Hernandez JN, Alava FF, Roncal N, Alvarez E, Perez EJ, Gotuzzo E. Clustered local transmission and asymptomatic Plasmodium falciparum and Plasmodium vivax malaria infections in a recently emerged, hypoendemic Peruvian Amazon community. <i>Malar J.</i> 2005; 4(1): 27 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Peru	Richard SA, Zavaleta N, Caulfield LE, Black RE, Witzig RS, Shankar AH. Zinc and iron supplementation and malaria, diarrhea, and respiratory infections in children in the Peruvian Amazon. <i>Am J Trop Med Hyg.</i> 2006; 75(1): 126-32 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Peru	Roshanravan B, Kari E, Gilman RH, Cabrera L, Lee E, Metcalfe J, Calderon M, Lescano AG, Montenegro SH, Calampa C, Vinetz JM. Endemic malaria in the Peruvian Amazon region of Iquitos. <i>Am J Trop Med Hyg.</i> 2003; 69(1): 45-52 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
Peru	Torres KJ, Clark EH, Hernandez JN, Soto-Cornejo KE, Gamboa D, Branch OH. Antibody response dynamics to the Plasmodium falciparum conserved vaccine candidate antigen, merozoite surface protein-1 C-terminal 19kD (MSP1-19kD), in Peruvians exposed to hypoendemic malaria transmission. <i>Malar J.</i> 2008; 7: 173 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Peru	Peru Vital Registration Birth Data 1985 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1985		
Philippines	Philippines National Nutrition Survey 1993 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1993		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Philippines	Philippines National Nutrition Survey 1993 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1993		†
Philippines	National Statistics Office (Philippines). International Statistical Institute. Philippines World Fertility Survey 1978. Voorburg, Netherlands: International Statistical Institute.	1978		
Philippines	Philippines Vital Registration - Deaths 1992 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1992	*	
Philippines	Philippines Vital Registration - Deaths 1993 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1993	*	
Philippines	Philippines Vital Registration - Deaths 1995 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1995	*	
Philippines	Philippines Vital Registration - Deaths 1996 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1996	*	
Philippines	Macro International, Inc. National Statistics Office (Philippines). Philippines Demographic and Health Survey 1993. Calverton, United States: Macro International, Inc.	1993		†
Philippines	Department of Health (Philippines). Macro International, Inc. National Statistics Office (Philippines). Philippines Demographic and Health Survey 1998. Calverton, United States: Macro International, Inc.	1998		†
Philippines	Macro International, Inc. National Statistics Office (Philippines). Philippines Demographic and Health Survey 2003. Calverton, United States: Macro International, Inc.	2003		†
Philippines	Macro International, Inc. National Statistics Office (Philippines). Philippines Demographic and Health Survey 2008. Calverton, United States: Macro International, Inc. 2010.	2008		†
Philippines	World Health Organization (WHO). Philippines World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Philippines	Department of Health (Philippines). Philippines Health Statistics 2004. Manila, Philippines: Department of Health (Philippines).	1984-2004	*	
Philippines	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-1999, 2001-2007		
Philippines	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Philippines	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Philippines	Ezeamama AE, Friedman JF, Acosta LP, Bellinger DC, Langdon GC, Manalo DL, Olveda RM, Kurtis JD, McGarvey ST. Helminth infection and cognitive impairment among Filipino children. Am J Trop Med Hyg. 2005; 72(5): 540-8.	2005		
Philippines	Friedman JF, Kanzaria HK, Acosta LP, Langdon GC, Manalo DL, Wu H, Olveda RM, McGarvey ST, Kurtis JD. Relationship between Schistosoma japonicum and nutritional status among children and young adults in Leyte, the Philippines. Am J Trop Med Hyg. 2005; 72(5): 527-33.	2002-2003		
Philippines	Olveda RM, Tiu E, Fevidal P Jr, de Veyra F Jr, Icatlo FC Jr, Domingo EO. Relationship of prevalence and intensity of infection to morbidity in schistosomiasis japonica: a study of three communities in Leyte, Philippines. Am J Trop Med Hyg. 1983; 32(6): 1312-2.	1980		
Philippines	Lucero MG, Tallo V, Lupisan S, Sanvictores D, Ugpo J, Lechago M, Abucejo-Ladesma E, Sombrero L, Nohynek H, Puumalainen T, Nissinen A, Soininen A, Ruutu P, Makela HP, Williams G, Forsyth S, De Campo M, Riley I, Simoes EAF. Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: A randomized, double-blind, placebo-controlled trial. Pediatr Infect Dis J. 2009; 28(6): 455-62.	2000-2004		
Philippines	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. J Allergy Clin Immunol. 2008; 121(4): 947-954.	1994, 2001		
Philippines	Selwyn BJ. The Epidemiology of Acute Respiratory Tract Infection in Young Children: Comparison of Findings from Several Developing Countries. Rev Infect Dis. 1990; 12(12): S870-S888.	1985-1987		†
Philippines	Tupasi TE, de Leon LE, Lupisan S, Torres CU, Leonor ZA, Sunico ES, Mangubat NV, Miguel CA, Medalla F, Tan ST, et al. Patterns of acute respiratory tract infection in children: a longitudinal study in a depressed community in Metro Manila. Rev Infect Dis. 1990; 12 suppl 8(12 Suppl 8): 940-9.	1985-1987		†
Philippines	Manahan L, Caragay R, Muirden KD, Allander E, Valkenburg HA, Wigley RD. Rheumatic pain in a Philippine village. A WHO-ILAR COPCORD Study. Rheumatol Int. 1985; 5(4): 149-53.	1982		
Philippines	Lumbiganon P, Laopaboon M, Gülmezoglu AM, Souza JP, Taneepanichskul S, Ruyan P, Attygalle DE, Shrestha N, Mori R, Hinh ND, Bang HT, Rathavy T, Chuyun K, Cheang K, Festin M, Udomprasertgul V, Germar MJV, Yanju G, Roy M, Carroli G, Ba-Thike K. Method of delivery and pregnancy outcomes in Asia: the WHO global survey on maternal and perinatal health 2007-08. Lancet. 2010; 375(9713): 490-9.	2007-2008		
Philippines	Stewart MK, Festin M. Validation study of women's reporting and recall of major obstetric complications treated at the Philippine General Hospital. Int J Gynaecol Obstet. 1995; 48(Suppl 1): S53-S66.	1994		
Philippines	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1999, 2005, 2008-2009		
Philippines	Wigley R, Manahan L, Muirden KD, Caragay R, Pinfold B, Couchman KG, Valkenburg HA. Rheumatic disease in a Philippine village. II: a WHO-ILAR-APLAR COPCORD study, phases II and III. Rheumatol Int. 1991; 11(4-5): 157-61.	1981, 1988		
Philippines	Dans LF, Tankeh-Torres S, Amante CM, Penserger EG. The prevalence of rheumatic diseases in a Filipino urban population: a WHO-ILAR COPCORD Study. World Health Organization. International League of Associations for Rheumatology. Community Oriented Programme for the Control of the Rheumatic Diseases. J Rheumatol. 1997; 24(9): 1814-9.	1990, 1994		
Philippines	Domingo EO, Tiu E, Peters PA, Warren KS, Mahmoud AA, Houser HB. Morbidity in schistosomiasis japonica in relation to intensity of infection: study of a community in Leyte, Philippines. Am J Trop Med Hyg. 1980; 29(5): 858-67.	1978-1979		
Philippines	Leenstra T, Acosta LP, Langdon GC, Manalo DL, Su L, Olveda RM, McGarvey ST, Kurtis JD, Friedman JF. Schistosomiasis japonica, anemia, and iron status in children, adolescents, and young adults in Leyte, Philippines. Am J Clin Nutr. 2006; 83(2): 371-9.	2002-2003		
Philippines	McGarvey ST, Aligui G, Graham KK, Peters P, Olds GR, Olveda R. Schistosomiasis japonica and childhood nutritional status in northeastern Leyte, the Philippines: a randomized trial of praziquantel versus placebo. Am J Trop Med Hyg. 1996; 54(5): 498-502.	1991-1992		
Philippines	Quantitative aspects of the epidemiology of Schistosoma japonicum infection in a rural community of Luzon, Philippines. WHO workshop.	1978		
Philippines	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J. 1998; 12(2): 315-35.	1993-1995		
Philippines	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2001		
Philippines	Lantion-Ang LC. Epidemiology of diabetes mellitus in Western Pacific region focus on Philippines. Diabetes Res Clin Pract. 2000; 50(Suppl 2): S29-34.	1998		
Philippines	Tanchoco CC, Cruz AJ, Duante CA, Litojua AD. Prevalence of metabolic syndrome among Filipino adults aged 20 years and over. Asia Pac J Clin Nutr. 2003; 12(3): 271-6.	1998		
Philippines	Baltazar JC, Ancheta CA, Aban IB, Fernando RE, Baquilod MM. Prevalence and correlates of diabetes mellitus and impaired glucose tolerance among adults in Luzon, Philippines. Diabetes Res Clin Pract. 2004; 64(2): 107-15.	2002		
Philippines	Garcia ML, Cutress TW. A national survey of periodontal treatment needs of adults in the Philippines. Community Dent Oral Epidemiol. 1986; 14(6): 313-6.	1983	*	
Philippines	Adkins HJ, Escamilla J, Santiago LT, Rañoa C, Echeverria P, Cross JH. Two-year survey of etiologic agents of diarrheal disease at San Lazaro Hospital, Manila, Republic of the Philippines. J Clin Microbiol. 1987; 25(7): 1143-7.	1983-1984	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Philippines	Singh PB, Sreenivasan MA, Pavri KM. Viruses in acute gastroenteritis in children in Pune, India. <i>Epidemiol Infect.</i> 1989; 102(2): 345-53.	1981-1982	*	
Philippines	Heinrich-Weltzien R, Monse B, van Palenstein Helderma W. Black stain and dental caries in Filipino schoolchildren. <i>Community Dent Oral Epidemiol.</i> 2009; 37(2): 182-7.	2003		
Philippines	Cariño KMG, Shinada K, Kawaguchi Y. Early childhood caries in northern Philippines. <i>Community Dent Oral Epidemiol.</i> 2003; 31(2): 81-9.	1999		
Philippines	Yabao RN, Duante CA, Velandria FV, Lucas M, Kassu A, Nakamori M, Yamamoto S. Prevalence of dental caries and sugar consumption among 6-12-y-old schoolchildren in La Trinidad, Benguet, Philippines. <i>Eur J Clin Nutr.</i> 2005; 59(12): 1429-38.	2003		
Philippines	Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E, BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. <i>Lancet.</i> 2007; 9589(9589): 741-50.	2008-2009		
Philippines	United States Renal Data System Coordinating Center. <i>USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States.</i> Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2001-2008		
Philippines	United States Renal Data System Coordinating Center. <i>USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States.</i> Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2000		
Philippines	United States Renal Data System Coordinating Center. <i>USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States.</i> Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2003.	1998-1999		
Philippines	Saion F, Mahilum-Tapay L, Michel C-EE, Buttress ND, Nadala ECB Jr, Magbanua JPV, Harding-Esch EM, Villaruel MO, Caonog L, Celis RL, Lee HH. Prevalence of Chlamydia trachomatis infection among low- and high-risk Filipino women and performance of Chlamydia rapid tests in resource-limited settings. <i>J Clin Microbiol.</i> 2007; 45(12): 4011-7.	2005		
Philippines	Tupasi TE, Radhakrishna S, Rivera AB, Pascual ML, Quelapio MI, Co VM, Villa ML, Beltran G, Legaspi JD, Mangubat NV, Sarol JN Jr, Reyes AC, Sarmiento A, Solon M, Solon FS, Mantala MJ. The 1997 Nationwide Tuberculosis Prevalence Survey in the Philippines. <i>Int J Tuberc Lung Dis.</i> 1999; 3(6): 471-7.	1997		
Philippines	Eusebio C, Kuper H, Polack S, Enconado J, Tongson N, Dionio D, Dumdam A, Limburg H, Foster A. Rapid assessment of avoidable blindness in Negros Island and Antique District, Philippines. <i>Br J Ophthalmol.</i> 2007; 91(12): 1588-92. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2005-2006		
Philippines	Stein Z, Belmont L, Durkin M. Mild mental retardation and severe mental retardation compared: experiences in eight less developed countries. <i>Ups J Med Sci Suppl.</i> 1987; 89-96.	1987		
Philippines	Philippines National Nutrition Survey 2003 as it appears in World Health Organization (WHO). <i>WHO Global Database on Iodine Deficiency.</i> Geneva, Switzerland: World Health Organization (WHO).	2003		†
Philippines	Tupasi TE, Radhakrishna S, Chua JA, Mangubat NV, Guilatco R, Galipot M, Ramos G, Quelapio MID, Beltran G, Legaspi J, Vianzon RG, Lagahid J. Significant decline in the tuberculosis burden in the Philippines ten years after initiating DOTS. <i>Int J Tuberc Lung Dis.</i> 2009; 13(10): 1224-30.	2007		
Philippines	World Health Organization (WHO). <i>WHO Tuberculosis Case Notifications.</i> Geneva, Switzerland: World Health Organization (WHO).	2004, 2007, 2010, 2012		
Philippines	United Nations Children's Fund (UNICEF). <i>Child Mortality and Injury in Asia.</i> New York, United States: United Nations Children's Fund (UNICEF), 2008. (Innocenti Working Papers: Special Series on Child Injuries Nos. 1-4).	2003	*	
Philippines	Soria MLB, Sy RG, Vega BS, Ty-Willing T, Abenir-Gallardo A, Velandria F, Punzalan FE. The incidence of type 2 diabetes mellitus in the Philippines: a 9-year cohort study. <i>Diabetes Res Clin Pract.</i> 2009; 86(2): 130-3.	1998-2007		
Philippines	Motulsky AG, Stransky E, Fraser GR. Glucose-6-phosphate dehydrogenase (G6PD) deficiency, thalassaemia, and abnormal haemoglobins in the Philippines. <i>J Med Genet.</i> 1964; 1(2): 102-6.	1962-1964		
Philippines	Padilla CD. Newborn screening in the Philippines. <i>Southeast Asian J Trop Med Public Health.</i> 2003; 87-8.	2001		
Philippines	Lee G. End-stage renal disease in the Asian-Pacific region. <i>Semin Nephrol.</i> 2003; 23(1): 107-14.	2000		
Philippines	Suzuki A, Lupisan S, Furuse Y, Fuji N, Saito M, Tamaki R, Galang H, Sombrero L, Mondoy M, Aniceto R, Olveda R, Oshitani H. Respiratory viruses from hospitalized children with severe pneumonia in the Philippines. <i>BMC Infect Dis.</i> 2012; 267.	2008-2009	*	
Philippines	Philippines National Nutrition Survey 1998 as it appears in World Health Organization (WHO). <i>WHO Global Database on Iodine Deficiency.</i> Geneva, Switzerland: World Health Organization (WHO).	1998		
Philippines	World Health Organization (WHO). <i>Global leprosy situation, 2004.</i> <i>Wkly Epidemiol Rec.</i> 2005; 80(13): 118-24.	2003	*	
Philippines	World Health Organization (WHO). <i>Global leprosy situation, 2005.</i> <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Philippines	World Health Organization (WHO). <i>Global leprosy situation, 2006.</i> <i>Wkly Epidemiol Rec.</i> 2006; 81(32): 309-16.	2005	*	
Philippines	World Health Organization (WHO). <i>Global leprosy situation, 2007.</i> <i>Wkly Epidemiol Rec.</i> 2007; 82(25): 225-32.	2006	*	
Philippines	World Health Organization (WHO). <i>Global leprosy situation, 2009.</i> <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Philippines	World Health Organization (WHO). <i>Global leprosy situation, 2010.</i> <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Philippines	World Health Organization (WHO). <i>Global leprosy situation, 2012.</i> <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Philippines	World Health Organization (WHO). <i>Global leprosy situation, beginning of 2008.</i> <i>Wkly Epidemiol Rec.</i> 2008; 83(33): 293-300.	2007	*	
Philippines	World Health Organization (WHO). <i>Global leprosy situation, September 1999.</i> <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Philippines	World Health Organization (WHO). <i>Global leprosy: update on the 2012 situation.</i> <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Philippines	World Health Organization (WHO). <i>Leprosy update, 2011.</i> <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Philippines	World Health Organization (WHO). <i>Leprosy.</i> <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Philippines	World Health Organization (WHO). <i>Leprosy - Global situation.</i> <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Philippines	World Health Organization (WHO). <i>Progress towards eliminating leprosy as a public health problem. Part I.</i> <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Philippines	World Health Organization (WHO). <i>Progress towards leprosy elimination.</i> <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Philippines	World Health Organization (WHO). <i>Progress towards the elimination of leprosy as a public health problem.</i> <i>Wkly Epidemiol Rec.</i> 1993; 68(25): 181-6.	1992	*	
Philippines	World Health Organization (WHO). <i>Progress towards the elimination of leprosy as a public health problem.</i> <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Philippines	World Health Organization (WHO). <i>Progress towards the elimination of leprosy as a public health problem. Part I.</i> <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Philippines	Smith JS, Herrero R, Muñoz N, Eluf-Neto J, Ngelangel C, Bosch FX, Ashley RL. Prevalence and risk factors for herpes simplex virus type 2 infection among middle-age women in Brazil and the Philippines. <i>Sex Transm Dis.</i> 2001; 28(4): 187-94.	1991-1993	*	
Philippines	World Health Organization Regional Office for the Western Pacific. <i>Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2000.</i>	2000		
Philippines	World Health Organization Regional Office for the Western Pacific. <i>Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2001.</i>	2001		
Philippines	World Health Organization Regional Office for the Western Pacific. <i>Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2002.</i>	2002		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Philippines	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2003.	2003		
Philippines	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2004.	2004		
Philippines	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2005.	2005		
Philippines	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2006.	2006		
Philippines	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2007.	2007		
Philippines	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2008.	2008		
Philippines	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2009.	2009		
Philippines	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2010.	2010		
Philippines	Manzon LVLA, King SVB, Garcia RDJ. Haemophilus Influenzae Type B Conjugate Vaccine (HibCV) And Heptavalent Pneumococcal Conjugate Vaccine (PCV7) Immunization Status Of Patients 5 Years And Below Hospitalized For Pneumonia. PIDS P J. 2012; 13(2): 30-36.	2009-2010	*	
Philippines	Tanchoco C, Cilindro P, Pingol M, Magbintang J, Flores E, Mendoza S, Velandria F. Third national nutrition survey - clinical and anthropometric phase. J Philipp Med Assoc. 1990; 33-50 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1987		
Philippines	World Health Organization (WHO). WHO Global Programme for the Prevention of Rheumatic Fever and Rheumatic Heart Disease: Report of a Consultation to Review Progress and Develop Future Activities. Geneva, Switzerland: World Health Organization (WHO), 2000.	1987-1990, 1995-1997		
Philippines	Ng KP, Ngeow YF, K R, M R. Hepatitis B seroprevalence among University of Malaya Students in the Post-universal Infant Vaccination Era. Med J Malaysia. 2013; 68(2): 144-7.	2005-2011	*	
Philippines	Wong SN, Ong JP, Labio MED, Cabahug OT, Daez MLO, Valdellon EV, Sollano JD Jr, Arguillas MO. Hepatitis B infection among adults in the philippines: A national seroprevalence study. World J Hepatol. 2013; 5(4): 214-9.	2003	*	
Philippines	Agdamag DM, Kageyama S, Alesna ET, Solante RM, Leaño PS, Heredia AML, Abellanos-Tac-An IP, Vibal ET, Jereza LD, Ichimura H. Rapid spread of hepatitis C virus among injecting-drug users in the Philippines: Implications for HIV epidemics. J Med Virol. 2005; 77(2): 221-6.	2002		
Philippines	Arguillas MO, Domingo EO, Tsuda F, Mayumi M, Suzuki H. Seroepidemiology of hepatitis C virus infection in the Philippines: a preliminary study and comparison with hepatitis B virus infection among blood donors, medical personnel, and patient groups in Davao, Philippines. Gastroenterol Jpn. 1991; 170-5.	1990		
Philippines	Kardorff R, Olveda RM, Acosta LP, Duebbelde UJ, Aligui GD, Alcorn NJ, Doehring E. Hepatosplenic morbidity in schistosomiasis japonica: evaluation with Doppler sonography. Am J Trop Med Hyg. 1999; 60(6): 954-9.	1997		
Philippines	Lingao AL, Domingo EO, West S, Reyes CM, Gasmen S, Viterbo G, Tiu E, Lansang MA. Seroepidemiology of hepatitis B virus in the Philippines. Am J Epidemiol. 1986; 123(3): 473-80.	1979-1982		
Philippines	Richards AL, Perrault JG, Caringal LT, Manaloto CR, Sie A, Graham R, Ramos RM, Leonardo JB, Hyams KC. A non-invasive assessment of hepatitis B virus carrier status using saliva samples. Southeast Asian J Trop Med Public Health. 1996; 27(1): 80-4.	1994		
Philippines	Subida RD, Zhang ZW, Agetano MC, Nakatsuka H, Watanabe T, Shimbo S, Higashikawa K, Ikeda M. Hepatitis B and C virus infection prevalence among women in Manila, the Philippines. Southeast Asian J Trop Med Public Health. 1997; 28(4): 683-8.	1997		
Philippines	Yanase Y, Ohida T, Kaneita Y, Agdamag DMD, Leaño PSA, Gill CJ. The prevalence of HIV, HBV and HCV among Filipino blood donors and overseas work visa applicants. Bull World Health Organ. 2007; 85(2): 131-7.	2002-2004		
Philippines	Cross J, Basaca-Sevilla V. Intestinal Parasitic Infections in Southeast Asia. Southeast Asian J Trop Med Public Health. 1981; 12(2): 262-74.	1981	*	
Philippines	Cross JH, Basaca-Sevilla V. United States Naval Medical Research Unit No. 2. Biomedical Surveys in the Philippines. Manila, Philippines: United States Naval Medical Research Unit No. 2, 1984.	1967-1983	*	
Philippines	Straughn HK, Goldenberg RL, Tolosa JE, Daly S, de Codes J, Festin MR, Limpongsanurak S, Lumbiganon P, Paul VK, Peedicyail A, Purwar M, Sabogal JC, Shenoy S. Birthweight-specific neonatal mortality in developing countries and obstetric practices. Int J Gynaecol Obstet. 2003 Jan;80(1):71-8.	2003		†
Philippines	Somalia Plasmodium Falciparum Parasite Rate Data, Personal Communication with FAO Somalia and UNICEF Somalia 2009 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991-1992	*	†
Philippines	Progress Report on Malarionetric Survey of School Children, Agusan del Sur, 1996 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Philippines	Bustos MD, Saul A, Salazar NP, Gomes M. Profile of Morong, Bataan, an area of low malaria endemicity in the Philippines. Acta Trop. 1997; 63(4): 195-207 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Philippines	Tongol-Rivera P, Kano S, Miguel E, Tongol P, Suzuki M. Application of seroepidemiology in identification of local foci in a malarious community in Palawan, The Philippines. Am J Trop Med Hyg. 1993; 49(5): 608-12 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991-1992	*	†
Philippines	Philippines Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Poland	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2003-2010		
Poland	Central Statistical Office (Poland), United Nations Economic Commission for Europe (UNECE), Warsaw School of Economics, Institute of Statistics and Demography (Poland). Poland Fertility and Family Survey 1991. Geneva, Switzerland: United Nations Economic Commission for Europe (UNECE).	1991		
Poland	Centre for Health Informatics and Multiprofessional Education, University College London, Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Poland	Bogdan M, Nartowicz E, Grabczewska Z. Retrospective analysis of prognostic factors for annual mortality in 97 patients with chronic congestive heart failure. Wiad Lek. 2000; 53(7-8): 372-80.	1992-1995		
Poland	National Public Health Institute (Finland), World Health Organization (WHO). WHO MONICA Cerebrovascular Event Data 1982-1997, as provided by the Global Burden of Disease 2010 Cerebrovascular Disease Expert Group. [Unpublished].	1984-1991		
Poland	Sitarska-Golebiowska J, Zieliński A. [Tetanus in 2001]. Przegl Epidemiol. 2003; 57(1): 135-7.	2001		
Poland	Tomaszunas-Błaszczyk J. [Tetanus in 1997]. Przegl Epidemiol. 1999; 53(1-2): 129-35.	1997		
Poland	Zieliski A. Tetanus in 1998. Przegl Epidemiol. 2000; 54(1-2): 151-6.	1998		
Poland	Zieliski A. Tetanus in Poland in 1999. Przegl Epidemiol. 2001; 55(1-2): 137-40.	1999		
Poland	Zieliski A. Tetanus in Poland in 2000. Przegl Epidemiol. 2002; 56(2): 335-8.	2000		
Poland	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. J Allergy Clin Immunol. 2008; 121(4): 947-954.	1994-1995, 2001-2002		
Poland	Korewicki J, Rywik S, Rywik T. Management of heart failure patients in Poland European Journal of Heart Failure. Eur J Heart Fail. 2002; 4(2): 215-9.	1995, 2000-2001		
Poland	Rywik S, Broda G, Jasinski B. Heart Failure - Mortality and Hospital Morbidity in Polish Population. Polish Heart Journal. 1999; 50(1): 20-34.	1980-1995		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Poland	Rosinska M, Zielinski A. Zapalenia opon mózgowo-rdzeniowych i zapalenia mózgu w 2002 roku. <i>Przegl Epidemiol.</i> 2004; 58(1): 57-65.	2002		
Poland	Skoczynska A, Kriz P, Bossen Konradsen H, Hryniewicz W. Characteristics of the Major Etiologic Agents of Bacterial Meningitis Isolated in Poland in 1997-1998. <i>Microb Drug Resist.</i> 2000; 6(2): 147-53.	1997-1998		
Poland	Zabicka J. Zapalenia opon mózgowo-rdzeniowych i zapalenia mózgu w 1997 roku. <i>Przegl Epidemiol.</i> 1999; 53(1-2): 57-66.	1997		
Poland	Zielinski A, Tomasznas-Blaszczyk J, Kuklinska D. Epidemiology of Childhood Bacterial Meningitis in Poland: Incidence of Bacterial Meningitis with Special Reference to Haemophilus influenzae Type b among Children 0-59 Months Old in the Former Kielce and Bydgoszcz Districts in Poland in 1998-1999. <i>Eur J Epidemiol.</i> 2001; 17(8): 779-82.	1998-2000		
Poland	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000-2007, 2009		
Poland	Lobinska A, Stelmasiak Z. Epidemiological aspects of multiple sclerosis in Lublin (Poland). <i>Neurol Neurochir Pol.</i> 2004; 38(5): 361-6.	1997		†
Poland	Wender M, Kowal P, Pruchnik-Grabowska D, Hertmanowska H, Zielinska M, Namysl I. Epidemiology of multiple sclerosis in the Wielkopolska region. <i>Przegl Epidemiol.</i> 1986; 40(4): 387-97.	1981		
Poland	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Poland	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2002		
Poland	Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. <i>Diabetologia.</i> 1996; 39(11): 1377-84.	1993-1995		
Poland	Jarvis D, Newson R, Lovvall J, Hastan D, Tomassen P, Keil T, Gjomarkaj M, Forsberg B, Gunnbjornsdottir M, Minov J, Brozek G, Dahlen SE, Toskala E, Kowalski ML, Olze H, Howarth P, Krämer U, Baelum J, Loureiro C, Kasper L, Bousquet PJ, Bousquet J, Bachert C, Fokkens W, Burney P. Asthma in adults and its association with chronic rhinosinitis: the GA2LEN survey in Europe. <i>Allergy.</i> 2012; 67(1): 91-8.	2008-2009	*	
Poland	Kuprys-Lipinska I, Elgatal A, Kuna P. The underdiagnosis and undertreatment of asthma in general population of the Lodz Province (Poland). <i>Pneumonol Alergol Pol.</i> 2010; 78(1): 21-7.	1998	*	
Poland	Mrukowicz JZ, Krobicka B, Duplaga M, Kowalska-Duplaga K, Domański J, Szajewska H, Kantecki M, Iwańczak F, Pytrus T. Epidemiology and impact of rotavirus diarrhoea in Poland. <i>Acta Paediatr Suppl.</i> 1999; 88(426): 53-60.	1994-1996	*	
Poland	Oldak E, Sulik A, Rozkiewicz D, Liwoch-Nienartowicz N. Norovirus infections in children under 5 years of age hospitalized due to the acute viral gastroenteritis in northeastern Poland. <i>Eur J Clin Microbiol Infect Dis.</i> 2012; 31(4): 417-22.	2009-2010	*	
Poland	Vrbic V, Vulovi M, Raji Z, Topi B, Tati E, Mali M, Mili D, Aurer-Kozelj J, Neceva L, Redzepagi S. Oral health in SFR Yugoslavia in 1986. <i>Community Dent Oral Epidemiol.</i> 1988; 16(5): 286-8.	1986		
Poland	Szatko F, Wierzbicka M, Dybizbanska E, Struzycza I, Iwanicka-Frankowska E. Oral health of Polish three-year-olds and mothers' oral health-related knowledge. <i>Community Dent Health.</i> 2004; 21(2): 175-80.	2002		
Poland	Wierzbicka M, Petersen PE, Szatko F, Dybizbanska E, Kalo I. Changing oral health status and oral health behaviour of schoolchildren in Poland. <i>Community Dent Health.</i> 2002; 19(4): 243-50.	1995, 1997, 1999-2000		
Poland	Stefanoff P, Rosińska M. Meningitis and encephalitis in Poland in 2004. <i>Przegl Epidemiol.</i> 2006; 60(3): 419-28.	2004		
Poland	Stefanoff P, Zielinski A. [Meningitis and encephalitis in Poland in 2000]. <i>Przegl Epidemiol.</i> 2002; 56(2): 265-73.	2002		
Poland	Zabicka J. Cerebrospinal meningitis and encephalitis in 1995. <i>Przegl Epidemiol.</i> 1997; 51(1-2): 67-77.	1997		
Poland	Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E. BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. <i>Lancet.</i> 2007; 9589(9589): 741-50.	2005-2006		
Poland	Bednarek M, Plywaczewski R, Jonczak L, Zielinski J. There is no relationship between chronic obstructive pulmonary disease and obstructive sleep apnea syndrome: a population study. <i>Respiration.</i> 2005; 72(2): 142-9.	2000-2002		
Poland	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2002-2008		
Poland	United States Renal Data System Coordinating Center. USRDS 2006 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2006.	2001-2003		
Poland	United States Renal Data System Coordinating Center. USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2002.	1998		
Poland	United States Renal Data System Coordinating Center. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2005.	1999-2000		
Poland	Wender M, Pruchnik D, Kowal P, Florczak J, Zalejski M. [Epidemiology of Parkinson disease in the Poznań province]. <i>Przegl Epidemiol.</i> 1989; 43(2): 150-5.	1986		
Poland	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Poland	National Bureau for Drug Prevention (Poland). Poland National Report to the EMCDDA 2006.	2005		
Poland	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1995, 1999, 2002, 2006		
Poland	Karolewska-Bochenek K, Lazowska-Przeorek I, Albrecht P, Grzybowska K, Ryzko J, Szamotulska K, Radzikowski A, Landowski P, Krzesiek E, Jęnski L, Fyderek K, Czerwonka-Szaflarska M, Jarocka-Cyrta E. Epidemiology of inflammatory bowel disease among children in Poland. A prospective, population-based, 2-year study, 2002-2004. <i>Digestion.</i> 2009; 79(2): 121-9.	2002-2004	*	†
Poland	WHO Regional Office for Europe (EURO-WHO). Young People's Health in Context. Health Behaviour in School-aged Children (HBSC) Study: International Report from the 2001-2002 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2004.	2002		
Poland	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Poland	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). Alcohol and Drug Use Among European 17-18 Year Old Students: Data from the ESPAD Project. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2007.	2003		
Poland	Bouvier-Colle M-H, Mohangoo AD, Gissler M, Novak-Antolic Z, Vutuc C, Szamotulska K, Zeitlin J. Euro-Peristat Scientific Committee. What about the mothers? An analysis of maternal mortality and morbidity in perinatal health surveillance systems in Europe. <i>BJOG.</i> 2012; 119(7): 880-90.	2003-2004	*	
Poland	Sienkiewicz-Jarosz H, Gluszkiewicz M, Pniewski J, Niewada M, Członkowska A, Wolfe C, Rygiewicz D. Incidence and case fatality rates of first-ever stroke - comparison of data from two prospective population-based studies conducted in Warsaw. <i>Neurol Neurochir Pol.</i> 2011; 45(3): 207-12.	1991-1992, 2005	*	
Poland	Wawrzynczyk M, Pierzchała K, Braczkowska B, Manka-Gaca I, Kumor K, Borowski D, Grodzicka-Zawisza L, Zejda J. Estimates of stroke incidence and case fatality in Zabrze, 2005-2006. <i>Neurol Neurochir Pol.</i> 2011; 45(1): 3-10.	2005-2006	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Poland	Kuran W, Boksowicz C, Golezyk-Wojnar A, Horyd W, Kozlak M, Lipczyńska-Lojkowska W, Niedzielska K, Popielarska A, Witkowska-Olearska K, Zieliński JJ. [Epileptic seizures among the population of Mokotów: incidence and prognosis]. <i>Neurol Neurochir Pol.</i> 1983; 17(1): 33-40.	1976-1979	*	
Poland	Rutkowski B, Król E. Epidemiology of chronic kidney disease in central and eastern Europe. <i>Blood Purif.</i> 2008; 26(4): 381-5.	2004-2005		
Poland	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Poland	Dziatkowiak H, Ciechanowska M, Wasikowa R, Symonides-lawecka A, Bieniasz J, Trippenbach-Dulska H, Korniszewski L, Szybiński Z. Increase in the incidence of type 1 diabetes mellitus in children in three cities in Poland, 1987-1999. <i>J Pediatr Endocrinol Metab.</i> 2002; 15(8): 1153-60.	1987-1999		
Poland	Jarosz-Chobot P, Polanska J, Szadkowska A, Kretowski A, Bandurska-Stankiewicz E, Ciechanowska M, Deja G, Mysliwiec M, Peczyńska J, Rutkowska J, Sobel-Maruniak A, Fichna P, Chobot A, Rewers M. Rapid increase in the incidence of type 1 diabetes in Polish children from 1989 to 2004, and predictions for 2010 to 2025. <i>Diabetologia.</i> 2011; 54(3): 508-15.	1989-2004		
Poland	Kretowski A, Kowalska I, Peczyńska J, Urban M, Green A, Kinalska I. The large increase in incidence of Type 1 diabetes mellitus in Poland. <i>Diabetologia.</i> 2001; B48-50.	1994-1998		
Poland	Sobel-Maruniak A, Grzywa M, Orłowska-Florek R, Stanisławski A. The rising incidence of type 1 diabetes in south-eastern Poland. A study of the 0-29 year-old age group, 1980-1999. <i>Endokrynol Pol.</i> 2006; 57(2): 127-30.	1980-1999		
Poland	Wysocki MJ, Chanska M, Bak M, Czyżyk AS. Incidence of insulin-dependent diabetes mellitus in Warsaw, Poland, in children and young adults, 1983-1988. <i>World Health Stat Q.</i> 1992; 45(4): 315-20.	1983-1988		
Poland	Moskalewicz J, Sterosławski J. [Mortality of narcotic addicts using injections]. <i>Przeegl Epidemiol.</i> 1996; 50(3): 323-32.	1983-1992	*	
Poland	Fraser GR, Defarinas B, Kattamis CA, Race RR, Sanger R, Stamatoyannopoulos G. Glucose-6-phosphate dehydrogenase, colour vision and XG blood groups in Greece: linkage and population data. <i>Ann Hum Genet.</i> 1964; 395-403.	1962		
Poland	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant.</i> 1988; 3(6): 714-27.	1985-1986		
Poland	Mircescu G, Capsa D, Covic M, Caprioara MG, Gluhovschi G, Golea O, Ursea N, Gârnea L, Cepoi V, Constantinovici N, Covic A. Nephrology and renal replacement therapy in Romania – transition still continues (Cinderella story revisited). <i>Nephrol Dial Transplant.</i> 2004; 19(12): 2971-80.	1995, 2003		
Poland	European Surveillance of Congenital Anomalies (EUROCAT). Poland EUROCAT Prevalence Tables. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	1992, 1999-2011		
Poland	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguiar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Gilst WH van, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J.</i> 2003; 24(5): 442-63.	2000-2001		
Poland	Gierek T, Gwóźdź-Jezińska M, Slaska-Kaspera A, Senderski A. [The results of hearing screening in selected population of primary schoolchildren in Silesia]. <i>Otolaryngol Pol.</i> 2007; 61(2): 171-7.	2002	*	
Poland	Gabryelewicz T. [The prevalence of dementia in the population of the Warsaw district of Mokotów from 65 to 84 years of age]. <i>Psychiatr Pol.</i> 1999; 33(3): 353-66.	1991-1994		
Poland	Patrzalek M, Albrecht P, Sobczynski M. Significant decline in pneumonia admission rate after the introduction of routine 2+1 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7) in children under 5 years of age in Kielce, Poland. <i>Eur J Clin Microbiol Infect Dis.</i> 2010; 29(7): 787-92.	2007-2008	*	
Poland	Rodakowska E, Wilczyńska-Borawska M, Bagińska J, Stokowska E. Epidemiological analysis of dental caries in 12-year-old children residing in urban and rural settings in the Podlaskie region of north-eastern Poland. <i>Ann Agric Environ Med.</i> 2013; 20(2): 325-8.	2003, 2010	*	
Poland	Rywik TM, Kołodziej P, Targoński R, Fedyk-Lukasik M, Nowicka A, Zinka E, Zbyszynski B, Achremczyk P, Górski J, Muder A, Sadowski J, Leszek P, Kurjata P, Broda G, Korewicki J. Characteristics of the heart failure population in Poland: ZOPAN, a multicentre national programme. <i>Kardiol Pol.</i> 2011; 69(1): 24-31.	2009		
Poland	Zalewska M, Gładysz A, Simon K. [Incidence of markers of HBV and HAV infections in workers of the departments and clinics of anesthesiology and intensive care at the medical academy in Wrocław]. <i>Przeegl Epidemiol.</i> 1989; 43(4): 379-87.	1988		
Poland	Polz-Dacewicz MA, Policzekiewicz P, Badach Z. Changing epidemiology of hepatitis A virus infection—a comparative study in central eastern Poland (1990-1999). <i>Med Sci Monit.</i> 2000; 6(5): 989-93.	1990, 1998-1999		
Poland	Cianciara J. Hepatitis A shifting epidemiology in Poland and Eastern Europe. <i>Vaccine.</i> 2000; S68-70.	1997		
Poland	Ryszowska A, Gładysz A, Inglot M, Molin I. [Prevalence of anti-HAV antibodies in selected groups of children]. <i>Przeegl Epidemiol.</i> 2000; 54(3-4): 375-83.	1997-1999		
Poland	Grzeszczuk A, Sokolewicz-Bobrowska E, Chlabicz S. Occupational risk of hepatitis A infection among health care providers in northeastern Poland. <i>Med Sci Monit.</i> 2003; 9(7): PH11-14.	1999-2000		
Poland	Janaszek-Seydlitz W, Bucholec B, Wiatrzyk A. [Prevalence of anti-HAV antibodies in Warsaw population]. <i>Przeegl Epidemiol.</i> 2007; 61(4): 675-82.	2004-2005		
Poland	Broda G, Rywik S, Kurjata P. Trends in myocardial infarction incidence and fatality in Warsaw Pol-MONICA population from 1984 to 1988. <i>Int J Angiol.</i> 1995; 4(2): 113-6.	1983-1988		
Poland	Pajak A. Myocardial infarction and complications. Longitudinal observation of a population of 280,000 women and men—Project POL-MONICA Krakow. I. Genesis and objectives of the WHO MONICA Project. <i>Przeegl Lek.</i> 1996; 53(10): 703-6.	1984-1993		
Poland	Rekosz J, Wasutyrska E, Dyduszyński A. The Causes of Death in Patients with Acute Myocardial Infarction - Results from a Single Cardiac Centre. <i>Kardiol Pol.</i> 1998; 48(2): 113-8.	1986		
Poland	Sznajd J, Pajak A, Magdoń M, Misiowiec P, Malczewska-Malec M, Idziur-Waluś B, Celiński A, Baczynska E. Pol-MONICA Cracow on-going study: initial findings. <i>Acta Med Scand Suppl.</i> 1988; 224(S728): 106-12.	1983-1984		
Poland	National Public Health Institute (Finland), World Health Organization (WHO). MONICA Coronary Event Registration Data Book 1980-1995. Geneva, Switzerland: World Health Organization (WHO), 2000.	1980-1995		
Poland	Chlabicz S, Bonifatiuk I, Radziwon P. Prevalence of hepatitis C virus antibodies among blood donors in north-eastern Poland. <i>Hepatol Res.</i> 2005; 33(3): 206-10.	1998-2003		
Poland	U.S. Renal Data System. USRDS 1998 Annual Data Report. Bethesda (MD), United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 1998.	1995-1996		
Poland	United States Renal Data System Coordinating Center. USRDS 1997 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 1997.	1994		
Poland	U.S. Renal Data System. USRDS 1996 Annual Data Report. Bethesda (MD), United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 1996.	1992-1993		
Poland	U.S. Renal Data System. USRDS 1994 Annual Data Report. Bethesda (MD), United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 1994.	1989-1991		
Poland	Jucha R. Stroke incidence and case-fatality rates in population of Krosno County. <i>Przeegl Lek.</i> 2013; 70(4): 191-4.	2003-2004		
Poland	Zeitlan J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT; 2008. Available from: http://www.perinataleaudit.nl/downloads/bestand/649/peristat-ii-2008-	2004		†
Poland	Poland Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Poland	Poland Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Poland	Poland Renal Replacement Therapy Data 1997 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 1998. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2003.	1997	*	
Poland	Poland Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Portugal	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2004-2008		
Portugal	National Institute of Statistics (Portugal), International Statistical Institute. Portugal World Fertility Survey 1979-1980. Voorburg, Netherlands: International Statistical Institute.	1979-1980		
Portugal	Portugal Vital Registration - Deaths 1980 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1980	*	
Portugal	Portugal Vital Registration - Deaths 1981 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1981	*	
Portugal	Portugal Vital Registration - Deaths 1982 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1982	*	
Portugal	Portugal Vital Registration - Deaths 1983 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1983	*	
Portugal	Portugal Vital Registration - Deaths 1984 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1984		
Portugal	Portugal Vital Registration - Deaths 1985 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1985		
Portugal	Portugal Vital Registration - Deaths 1986 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1986		
Portugal	Portugal Vital Registration - Deaths 1987 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1987		
Portugal	Portugal Vital Registration - Deaths 1988 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1988		
Portugal	Portugal Vital Registration - Deaths 1990 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1990		
Portugal	Portugal Vital Registration - Deaths 1991 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1991		
Portugal	Portugal Vital Registration - Deaths 1992 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1992		
Portugal	Portugal Vital Registration - Deaths 1993 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1993		
Portugal	Portugal Vital Registration - Deaths 1994 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1994		
Portugal	Portugal Vital Registration - Deaths 1995 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1995		
Portugal	Portugal Vital Registration - Deaths 1997 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1997		
Portugal	Portugal Vital Registration - Deaths 2000 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	2000		
Portugal	Portugal Vital Registration - Deaths 2002 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2002	*	
Portugal	World Health Organization (WHO). Portugal World Health Survey 2002. Geneva, Switzerland: World Health Organization (WHO), 2006.	2002		
Portugal	Portugal Vital Registration - Deaths 2009 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2009	*	
Portugal	Portugal Vital Registration - Deaths 2008 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2008	*	
Portugal	World Health Organization (WHO). Control of Foodborne Trematode Infections 1995. Geneva, Switzerland: World Health Organization (WHO), 1995.	1995	*	
Portugal	Portugal Vital Registration - Deaths 2011 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2011		
Portugal	Thalassemia International Federation, World Health Organization (WHO). Management of Haemoglobin Disorders: Report of a Joint WHO-TIF Meeting, Nicosia, Cyprus, 16-18 November 2007. Geneva, Switzerland: World Health Organization (WHO), 2008.	2004		
Portugal	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. Scand J Clin Lab Invest. 2007; 67(1): 39-69.	1988, 2006		
Portugal	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1988, 2003, 2006		
Portugal	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	2009		†
Portugal	Massa A, Alves R, Amado J, Matos E, Sanches M, Selores M, Santos C, Costa V, Velho G, Oliveira M, Ferreira E, Taveira M, Silva NS, Granado E, Lemos A, Calheiros JM. Prevalence of cutaneous lesions in Freixo de Espada à Cinta. Acta Med Port. 2000; 13(5-6): 247-54.	1994, 1998		
Portugal	Correia M, Silva MR, Matos I, Magalhães R, Lopes JC, Ferro JM, Silva MC. Prospective Community-Based Study of Stroke in Northern Portugal: Incidence and Case Fatality in Rural and Urban Populations. Stroke. 2004; 35(9): 2048-53.	1998-2000		
Portugal	Amado JM, Matos ME, Abreu AM, Loureiro L, Oliveira J, Verde A, Massa A. The prevalence of acne in the north of Portugal. J Eur Acad Dermatol Venereol. 2006; 20(10): 1287-95.	2005-2006		
Portugal	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. J Allergy Clin Immunol. 2008; 121(4): 947-954.	1993-1995, 2001-2002		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Portugal	Cabrira J, Pires I, Vlaes L, Coignau H, Levy J, Goossens H, Goncalves AP, De Mol P, Butzler JP. Campylobacter enteritis in Portugal: epidemiological features and biological markers. <i>Eur J Epidemiol.</i> 1992; 8(1): 22-6.	1984-1989		
Portugal	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2002-2007		
Portugal	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Portugal	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2002		
Portugal	Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. <i>Diabetologia.</i> 1996; 39(11): 1377-84.	1993-1995		
Portugal	Massa A, Alves R, Amado J, Matos E, Sanches M, Selores M, Santos C, Costa V, Velho G, Oliveira M, Ferreira E, Taveira M, Silva NS, Granado E, Lemos A, Calheiros JM. Prevalência das lesões cutâneas em Freixo de Espada à Cinta. <i>Acta Med Port.</i> 2000; 13(5-6): 247-54.	1998		
Portugal	De Sousa JC, Santo ME, Colaço T, Almada-Lobo F, Yaphe J. Asthma in an urban population in Portugal: a prevalence study. <i>BMC Public Health.</i> 2011; 11: 347.	2009	*	
Portugal	Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, Gjomarkaj M, Forsberg B, Gunnbjornsdottir M, Minov J, Brozek G, Dahlen SE, Toskala E, Kowalski ML, Olze H, Howarth P, Krämer U, Baelum J, Loureiro C, Kasper L, Bousquet PJ, Bousquet J, Bachert C, Fokkens W, Burney P. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. <i>Allergy.</i> 2012; 67(1): 91-8.	2008-2009	*	
Portugal	Pegas PN, Alves CA, Scotto MG, Evtvygina MG, Pio CA, Freitas MC. Risk factors and prevalence of asthma and rhinitis among primary school children in Lisbon. <i>Rev Port Pneumol.</i> 2011; 17(3): 109-16.	2008	*	
Portugal	Bonhorst D, Mendes M, Adragão P, De Sousa J, Primo J, Leiria E, Rocha P. Prevalence of atrial fibrillation in the Portuguese population aged 40 and over: the FAMA study. <i>Rev Port Cardiol.</i> 2010; 29(3): 331-50.	2007-2009	*	
Portugal	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. <i>Community Dent Oral Epidemiol.</i> 1991; 19(2): 72-3.	1987		
Portugal	De Almeida CM, Petersen PE, André SJ, Toscano A. Changing oral health status of 6- and 12-year-old schoolchildren in Portugal. <i>Community Dent Health.</i> 2003; 20(4): 211-6.	1999		
Portugal	Machado PPP, Machado BC, Gonçalves S, Hoek HW. The prevalence of eating disorders not otherwise specified. <i>Int J Eat Disord.</i> 2007; 40(3): 212-7.	2005		
Portugal	Do Carmo I, Reis D, Varandas P, Bouça D, Santo DP, Neves A, André I, Sampaio D, Galvão-Teles A. Prevalence of Anorexia Nervosa: a Portuguese Population Study. <i>Eur Eat Disord Rev.</i> 1996; 4(3): 157-70.	1991-1993		
Portugal	Domingos F, Serra A. Nephrolithiasis is associated with an increased prevalence of cardiovascular disease. <i>Nephrol Dial Transplant.</i> 2011; 26(3): 864-8.	2005-2006		
Portugal	Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E, BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. <i>Lancet.</i> 2007; 9589(9589): 741-50.	2008-2009		
Portugal	Mascarenhas J, Falcão H, Lourenço P, Paulo C, Patacho M, Bettencourt P, Azevedo A. Population-Based Study on the Prevalence of Spirometric Obstructive Pattern in Porto, Portugal. <i>Respir Care.</i> 2011; 56(5): 619-25.	2001-2003		
Portugal	De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology.</i> 2000; 54(11 Suppl 5): S21-23.	1997		
Portugal	Dias JA, Felgueiras MM, Sanchez JP, Gonçalves JM, Falcão JM, Pimenta ZP. The Prevalence of Parkinson's Disease in Portugal: A Population Approach. <i>Eur J Epidemiol.</i> 1994; 10(6): 763-7.	1992		
Portugal	Berger K BM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology.</i> 2000; 54(11): 24-7.	1997		
Portugal	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Portugal	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1995, 1999, 2001, 2007		
Portugal	McDowell RD, Ryan A, Bunting BP, O'Neill SM, Alonso J, Bruffaerts R, de Graaf R, Florescu S, Vilagut G, de Almeida JMC, de Girolamo G, Haro JM, Hinkov H, Kovess-Masfety V, Matschinger H, Tomov T. Mood and anxiety disorders across the adult lifespan: a European perspective. <i>Psychol Med.</i> 2013; 1-16.	2008-2009	*	
Portugal	WHO Regional Office for Europe (EURO-WHO). Young People's Health in Context. Health Behaviour in School-aged Children (HBSC) Study: International Report from the 2001-2002 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2004.	2002		
Portugal	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Portugal	Alves E, Azevedo A, Rodrigues T, Santos AC, Barros H. Impact of risk factors on hypertensive disorders in pregnancy, in primiparae and multiparae. <i>Ann Hum Biol.</i> 2013; 40(5): 377-84.	2005-2006	*	
Portugal	Fernandes C, Alves D, Amado J, Oliveira L, Lima L, Almeida R. Epidemiological study of epilepsy at two community health centers. <i>Bollettino.</i> 1990; 313-5.	1987	*	
Portugal	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Portugal	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Portugal National Report to the EMCDDA 2002.	2001	*	
Portugal	Gardete-Correia L, Boavida JM, Raposo JF, Mesquita AC, Fona C, Carvalho R, Massano-Cardoso S. First diabetes prevalence study in Portugal: PREVADIAB study. <i>Diabet Med.</i> 2010; 27(8): 879-81.	2009		
Portugal	Bargagli AM, Hickman M, Davoli M, Perucci CA, Schifano P, Buster M, Brugal T, Vicente J, COSMO European Group. Drug-related mortality and its impact on adult mortality in eight European countries. <i>Eur J Public Health.</i> 2006; 16(2): 198-202.	1992-2003	*	
Portugal	Hailes AM, Roberts DF. Glucose-6-phosphate dehydrogenase deficiency screening in Madeira. <i>Hum Biol.</i> 1962; 206-13.	1961		
Portugal	Rodrigues M-O, Freire AP, Martins G, Pereira J, Martins M-C, Monteiro C. Glucose-6-phosphate dehydrogenase deficiency in Portugal: biochemical and mutational profiles, heterogeneity, and haplotype association. <i>Blood Cells Mol Dis.</i> 2002; 28(2): 249-59.	2000-2002		
Portugal	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant.</i> 1988; 3(6): 714-27.	1985-1986		
Portugal	Berthouix F, Jones E, Gellert R, Mendel S, Saker L, Briggs D. Epidemiological data of treated end-stage renal failure in the European Union (EU) during the year 1995: report of the European Renal Association Registry and the National Registries. <i>Nephrol Dial Transplant.</i> 1999; 14(10): 2332-42.	1995		
Portugal	Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. <i>J Clin Endocrinol Metab.</i> 2008; 93(4): 1408-11.	2005		
Portugal	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Gilst WH van, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J.</i> 2003; 24(5): 442-63.	2000-2001		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Portugal	Dias O, Andrea M. Childhood deafness in Portugal – aetiological factors and diagnosis of hearing loss. <i>Int J Pediatr Otorhinolaryngol.</i> 1990; 18(3): 247-55.	1985-1989	*	
Portugal	World Health Organization (WHO). Portugal WHO Leishmaniasis Country Profile.	1996-2010	*	
Portugal	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Portugal	Mendes H, Zagalo-Cardoso JA. [Endemic goiter epidemiological study of prevalence in Oleiros]. <i>Acta Med Port.</i> 2002; 15(2): 101-11 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1995-1996		
Portugal	De Oliveria AL, Gonçalves MJ, Sobrinho LG. Endemic goitre in the island of S. Miguel (the Azores). <i>Acta Endocrinol.</i> 1986; 111(2): 200-3 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1985		
Portugal	Parry GI, Ogston SA. EUROMAC. A European concerted action: maternal alcohol consumption and its relation to the outcome of pregnancy and child development at 18 months. Results—child development at age 18 months. <i>Int J Epidemiol.</i> 1992; S72-78.	1992	*	
Portugal	Martins MC, Olim G, Melo J, Magalhães HA, Rodrigues MO. Hereditary anaemias in Portugal: epidemiology, public health significance, and control. <i>J Med Genet.</i> 1993; 30(3): 235-9.	1988	*	
Portugal	Monteiro C, Rueff J, Falcao AB, Portugal S, Weatherall DJ, Kulozik AE. The frequency and origin of the sickle cell mutation in the district of Coruche/Portugal. <i>Hum Genet.</i> 1989; 82(3): 255-8.	1986-1988	*	
Portugal	Peres MJ, Carreiro MH, Machado MC, Seixas T, Picanço I, Batalha L, Lavinha J, Martins MC. [Neonatal screening of hemoglobinopathies in a population residing in Portugal]. <i>Acta Med Port.</i> 1996; 9(4-6): 135-9.	1993-1995	*	
Portugal	Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overved K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PHM, Lund E, Quirós JR, González CA, Sanchez Perez M-J, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu L, Chuang S-C, Murphy N, Boffetta P, Trichopoulou A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. <i>J Natl Cancer Inst.</i> 2011; 103(22): 1686-95.	1992-2006	*	
Portugal	Macedo G, Pinto T, Sarmento JA, Vale AM, Ribeiro T. [The first assessment of hepatitis E virus seroprevalence in northern Portugal]. <i>Acta Med Port.</i> 1998; 11(12): 1065-8.	1995-1997	*	
Portugal	Lecour H, Ribeiro AT, Amaral I, Rodrigues MA. Prevalence of viral hepatitis markers in the population of Portugal. <i>Bull World Health Organ.</i> 1984; 62(5): 743-7.	1983		
Portugal	Marinho RT, Valente AR, Ramalho FJ, de Moura MC. The changing epidemiological pattern of hepatitis A in Lisbon, Portugal. <i>Eur J Gastroenterol Hepatol.</i> 1997; 9(8): 795-7.	1990-1992		
Portugal	Macedo G, Ribeiro T. Hepatitis A: insights into new trends in epidemiology. <i>Eur J Gastroenterol Hepatol.</i> 1998; 10(2): 175.	1993		
Portugal	Cunha I, Antunes H. [Prevalence of antibodies against hepatitis A virus in a population from northern Portugal]. <i>Acta Med Port.</i> 2001; 14(5-6): 479-82.	1996		
Portugal	Barros H, Oliveira F, Miranda H. A survey on hepatitis A in Portuguese children and adolescents. <i>J Viral Hepat.</i> 1999; 6(3): 249-53.	1998		
Portugal	Antunes H, Macedo M, Estrada A. [Hepatitis A virus prevalence: Portuguese first results of low endemicity]. <i>Acta Med Port.</i> 2004; 17(3): 219-24.	1999-2003		
Portugal	Santos A, Carvalho A, Bento D, Sá R, Tomáz J, Rodrigues V, Pais L, Porto A. Epidemiology of hepatitis C in central Portugal. Prevalence of anti-HCV in the population of the Coimbra District. <i>Acta Med Port.</i> 1994; 83-8.	1991-1993		
Portugal	Zeitlan J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT: 2008. Available from: http://www.perinataleaudit.nl/downloads/bestand/649/peristat-ii-2008-	2004		†
Portugal	Portuguese Society of Nephrology Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Portugal	Portuguese Society of Nephrology Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Portugal	Portugal Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Portugal	European Surveillance of Congenital Anomalies (EUROCAT). Portugal EUROCAT Prevalence Tables. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	1990-2011		
Portugal	Portugal - Southern Portugal Congenital Anomaly Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Qatar	Hamad Medical Corporation (Qatar), Supreme Council of Health (Qatar). Qatar Annual Health Report 2011. Doha, Qatar: Hamad Medical Corporation (Qatar), 2012.	2011	*	
Qatar	Hamad Medical Corporation (Qatar), National Health Authority (Qatar). Qatar Annual Health Report 2006. Doha, Qatar: Hamad Medical Corporation (Qatar), 2007.	2006	*	
Qatar	Hamad Medical Corporation (Qatar), National Health Authority (Qatar). Qatar Annual Health Report 2005. Doha, Qatar: Hamad Medical Corporation (Qatar), 2006.	2005	*	
Qatar	Hamad Medical Corporation (Qatar), Ministry of Public Health (Qatar). Qatar Annual Health Report 2004. Doha, Qatar: Hamad Medical Corporation (Qatar), 2005.	2004	*	
Qatar	Qatar Statistics Authority, Supreme Council of Health (Qatar), World Health Organization (WHO). Qatar STEPS Noncommunicable Disease Risk Factors Survey 2012.	2012		
Qatar	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Qatar	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Qatar	Hamad A, Hamad A, Sokrab TEO, Momeni S, Mesraoua B, Lingren A. Stroke in Qatar: A one-year, hospital-based study. <i>J Stroke Cerebrovasc Dis.</i> 2001; 10(5): 236-41.	1997		
Qatar	Al Suwaidi J, Bener A, Hajar H, Numan M. Does hospitalization for congestive heart failure occur more frequently in Ramadan: a population-based study (1991-2001). <i>Int J Cardiol.</i> 2004; 96(2): 217-21.	1991-2001		
Qatar	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998, 2000-2003, 2005-2007, 2009		
Qatar	Bener A, Zirie M, Janahi IM, Al-Hamaq AO, Musallam M, Wareham NJ. Prevalence of diagnosed and undiagnosed diabetes mellitus and its risk factors in a population-based study of Qatar. <i>Diabetes Res Clin Pract.</i> 2009; 84(1): 99-106.	2008		
Qatar	Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version). Lyon, IARC. http://cis.iarc.fr	2003-2007	*	
Qatar	El-Menayar AA, Bener A, Numan MT, Morcos S, Taha RY, Al-Suwaidi J. Epidemiology of idiopathic cardiomyopathy in Qatar during 1996-2003. <i>Med Princ Pract.</i> 2006; 15(1): 56-61.	1996-2003		
Qatar	Bessiso MS, Bener A, Elsaid MF, Al-Khalaf FA, Huzaima KA. Pattern of headache in school children in the State of Qatar. <i>Saudi Med J.</i> 2005; 26(4): 566-70.	2001-2003		
Qatar	United States Renal Data System Coordinating Center. USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2003.	1999		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
	United States Renal Data System Coordinating Center. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2005.	2000-2002		
Qatar	Bener A, Al-Nufal M, Vachhani PJ, Ali AI, Samson N, Saleh NM. Maternal complications and neonatal outcome in Arab women of a fast developing country. <i>J Family Community Med.</i> 2013; 20(1): 27-34.	2010-2011	*	
Qatar	Bener A, Saleh NM, Al-Hamaq A. Prevalence of gestational diabetes and associated maternal and neonatal complications in a fast-developing community: global comparisons. <i>Int J Womens Health.</i> 2011; 367-73.	2010-2011	*	
Qatar	Deleu D, Mir D, Al Tabouki A, Mesraoua R, Mesraoua B, Akhtar N, Al Hail H, D'souza A, Melikyan G, Imam YZB, Osman Y, Elalamy O, Sokrab T, Kamran S, Ruiz Miyares F, Ibrahim F. Prevalence, demographics and clinical characteristics of multiple sclerosis in Qatar. <i>Mult Scler.</i> 2013; 19(6): 816-9.	2010	*	
Qatar	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Qatar	Al Gamra H, Al Mansouri F, Khandekar R, Elshafei M, Al Qahtani O, Singh R, Hashim SP, Mujahed A, Makled A, Pai A. Prevalence and causes of blindness, low vision and status of cataract in 50 years and older citizen of Qatar – a community based survey. <i>Ophthalmic Epidemiol.</i> 2010; 17(5): 292-300, as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2009		
Qatar	Elshafei M, Gamra H, Khandekar R, Al Hashimi M, Pai A, Ahmed MF. Prevalence and determinants of diabetic retinopathy among persons ≥40 years of age with diabetes in Qatar: a community-based survey. <i>Eur J Ophthalmol.</i> 2011; 21(1): 39-47.	2009		
Qatar	Bener A, Eihakeem AAM, Abdulhadi K. Is there any association between consanguinity and hearing loss? <i>Int J Pediatr Otorhinolaryngol.</i> 2005; 69(3): 327-33.	2003	*	
Qatar	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec.</i> 2007; 82(25): 225-32.	2006	*	
Qatar	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Qatar	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Qatar	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Qatar	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Qatar	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Qatar	Al-Mansouri FA, Kanaan A, Gamra H, Khandekar R, Hashim SP, Al Qahtani O, Ahmed MF. Prevalence and Determinants of Glaucoma in Citizens of Qatar Aged 40 Years or Older: A Community-Based Survey. <i>Middle East Afr J Ophthalmol.</i> 2011; 18(2): 141-9.	2006-2009	*	
Qatar	Al-Thani A, Abdul-Rahim H, Alabsi E, Bsaisu HN, Haddad P, Mumtaz GR, Abu-Raddad LJ. Prevalence of Chlamydia trachomatis infection in the general population of women in Qatar. <i>Sex Transm Infect.</i> 2013; iii57-60.	2008	*	
Qatar	Chaikhouni A, Chouhan L, Pomposello C, Banna A, Mahrous F, Thomas G, Abu Al-Hassan N, Khalifa S, Jaddan A, Bsata MW, Hajar HA. Myocardial infarction in qatar: The first 2515 patients. <i>Clin Cardiol.</i> 1993; 16(3): 227-30.	1984, 1993		
Qatar	Qatar Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Romania	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2005		
Romania	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. <i>Scand J Clin Lab Invest.</i> 2007; 67(1): 39-69.	1990-2006		
Romania	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2006		
Romania	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Romania	Popescu R, Popescu CM, Williams HC, Forsea D. The prevalence of skin conditions in Romanian school children. <i>Br J Dermatol.</i> 1999; 140(5): 891-6.	1995		
Romania	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol.</i> 2008; 121(4): 947-954.	1994, 2001		
Romania	Luca V, Gessner BD, Luca C, Turcu T, Rugina S, Rugina C, Ilie M, Novakova E, Vlasich C. Incidence and etiological agents of bacterial meningitis among children <5 years of age in two districts of Romania. <i>Eur J Clin Microbiol Infect Dis.</i> 2004; 23(7): 523-8.	2000-2002		
Romania	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1999-2009		
Romania	Becus T, Popoviciu L. Epidemiologic survey of multiple sclerosis in Mureş County, Romania. <i>Rom J Neurol Psychiatry.</i> 1994; 32(2): 115-22.	1986		
Romania	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Romania	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2001		
Romania	Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. <i>Diabetologia.</i> 1996; 39(11): 1377-84.	1993-1995		
Romania	Calma CL, Neghina AM, Vlaicu B, Neghina R. Cystic echinococcosis in the human population of a western Romanian county, 2004-2010. <i>Clin Microbiol Infect.</i> 2011; 17(11): 1731-4.	2004-2010	*	
Romania	Moldovan R, Neghina AM, Calma CL, Marinicu I, Neghina R. Human cystic echinococcosis in two south-western and central-western Romanian counties: a 7-year epidemiological and clinical overview. <i>Acta Trop.</i> 2012; 121(1): 26-9.	2004-2010	*	
Romania	Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Smira G, Regep L. The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey 2006 - 2008. <i>J Gastrointest Liver Dis.</i> 2010; 19(4): 373-9.	2006-2008		
Romania	Petersen PE, Danila I, Delean A, Grivu O, Ionita G, Pop M, Samolia A. Oral health status among schoolchildren in Romania, 1992. <i>Community Dent Oral Epidemiol.</i> 1994; 22(2): 90-3.	1992		
Romania	Vrbic V, Vulovi M, Raji Z, Topi B, Tati E, Mali M, Mili D, Aurer-Kozelj J, Neceva L, Redzepagi S. Oral health in SFR Yugoslavia in 1986. <i>Community Dent Oral Epidemiol.</i> 1988; 16(5): 286-8.	1986		
Romania	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	1991, 1996, 2003, 2005-2008		
Romania	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Romania	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1999		
Romania	Merikangas KR, Jin R, He J-P, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Ladea M, Medina-Mora ME, Ono Y, Posada-Villa J, Sagar R, Wells JE, Zarkov Z. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. <i>Arch Gen Psychiatry.</i> 2011; 68(3): 241-51.	2005-2006	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Romania	McDowell RD, Ryan A, Bunting BP, O'Neill SM, Alonso J, Bruñaerts R, de Graaf R, Florescu S, Vilagut G, de Almeida JMC, de Girolamo G, Haro JM, Hinkov H, Kovess-Masfety V, Matschinger H, Tomov T. Mood and anxiety disorders across the adult lifespan: a European perspective. <i>Psychol Med.</i> 2013; 1-16.	2005-2006	*	
Romania	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Romania	Constantin CV, Streba CT, Rogoveanu I, Nita-Stefanescu L, Ionescu AG. Cirrhosis and Chronic Viral Hepatitis as Risk Factors for Hepatocellular Carcinoma: Romanian Single-clinic Experience. <i>Maedica (Buchar).</i> 2010; 5(4): 265-70.	2006-2009		
Romania	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Romania	Ionescu-Tirgoviste C, Guja C, Călin A, Moța M. An increasing trend in the incidence of type 1 diabetes mellitus in children aged 0-14 years in Romania—ten years (1988-1997) EURODIAB study experience. <i>J Pediatr Endocrinol Metab.</i> 2004; 17(7): 983-91.	1988-1997		
Romania	Fraser GR, Defarinas B, Kattamis CA, Race RR, Sanger R, Stamatoyannopoulos G. Glucose-6-phosphate dehydrogenase, colour vision and XG blood groups in Greece: linkage and population data. <i>Ann Hum Genet.</i> 1964; 395-403.	1962		
Romania	Schneer JH. A survey for erythrocyte glucose-6-phosphate dehydrogenase deficiency in Rumania. <i>Acta Haematol.</i> 1968; 40(1): 44-7.	1966-1968		
Romania	Mircescu G, Capsa D, Covic M, Caprioara MG, Gluhovschi G, Golea O, Ursea N, Gârmeata L, Cepoi V, Constantinovici N, Covic A. Nephrology and renal replacement therapy in Romania – transition still continues (Cinderella story revisited). <i>Nephrol Dial Transplant.</i> 2004; 19(12): 2971-80.	1991, 1995-1996, 2003		
Romania	Rutkowski B. Changing pattern of end-stage renal disease in central and eastern Europe. <i>Nephrol Dial Transplant.</i> 2000; 15(2): 156-60.	1998		
Romania	Olinic N, Blaga S, Vida-Simiti L, Olinic D, Pop S, Nistor L, Pop D, Sa(ba)ciag A. Clinical and etiopathogenic profile of heart failure in the First Medical Clinic of Cluj-Napoca. A study of 5 years. <i>Rom J Intern Med.</i> 1996; 34(1-2): 19-25.	1990-1994		
Romania	Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. <i>Cancer Incidence in Five Continents. Vol. I to VIII.</i> Lyon, France, IARC Press, 2005.	1979-1987	*	
Romania	Romania - Nutritional Status of Pregnant Women, Children Under 5 Years and School Children Aged 6-7 Years - 2005 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2004-2005		
Romania	Poland Iodine Deficiency in First Grade Children 2001-2003 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2001-2003		
Romania	Poland Iodine Deficiency in First Grade Children 2003-2004 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2003-2004		
Romania	Circo E, Buzoianu O, Dascalu G, Muscalu A, Ionita I. Study of the nontoxic goiter prevalence in a paraendemic territory. <i>Rom J Endocrinol.</i> 1996; 25-39 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1995		
Romania	Vasilescu G, Totoianu IG, Ismănescu I, Hirschfeld I, Horga M, Kun I, Maior MR, Ciobanu-Sonea V, Vancza R, Dungaciu G. Prevalence of endemic goiter in Mureș County. <i>Endocrinologie.</i> 1986; 24(1): 27-32 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1985		
Romania	Simescu M, Popa M, Nicolaescu E, Gutekunst R. Epidemiological surveillance of iodine deficiency in Romania by urinary iodine determinations in children aged 6-16 years from 30 counties. <i>Endocrinologie.</i> 1991; 29(3-4): 167-74 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1991		
Romania	United States Renal Data System Coordinating Center. <i>USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States.</i> Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2013.	2006-2008		
Romania	Eurostat, National Institute of Statistics (Romania). <i>Romania European Health Interview Survey 2008.</i>	2008	*	
Romania	Liana Gheorghe SI. Prevalence of hepatitis C in Romania: different from European rates <i>J Hepatol.</i> 2008; 49(4): 661-3.	2006-2007		
Romania	Vlad DC, Neghina AM, Dumitrascu V, Marinu I, Neghina R, Calma CL. Cystic echinococcosis in children and adults: a seven-year comparative study in western Romania. <i>Foodborne Pathog Dis.</i> 2013; 10(2): 189-95.	2004-2010	*	
Romania	Onesciuc C, Szantay I, Gorgan V, Serban I, Onesciuc I, Gidaly M, Crîstina D. [Incidence of antibodies against hepatitis virus A (anti-HA) in a non-selected urban population]. <i>Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumofiziol.</i> 1981; 26(3): 167-73.	1978-1980		
Romania	Săbău M, Kiss E, Muntean I, Căpîlnă E. Serologic markers of hepatitis B and A infections in the healthy population. <i>Virologie.</i> 1983; 34(3): 197-201.	1980-1982		
Romania	Paquet C, Babes VT, Drucker J, Sénémaud B, Dobrescu A. Viral hepatitis in Bucharest. <i>Bull World Health Organ.</i> 1993; 71(6): 781-6.	1990		
Romania	Iacob E, Durnea C, Năstase A, Scripcaru L, Pisciă-Donose G. [Viral hepatitis A as an occupational disease in the city of Iași]. <i>Rev Med Chir Soc Med Nat Iasi.</i> 1999; 103(3-4): 161-6.	1993-1997		
Romania	Beldescu N, Bălan A, Popa R. [The prevalence of viral hepatitis markers in the general population]. <i>Bacteriol Virusol Parazitol Epidemiol.</i> 1995; 40(2): 101-8.	1994		
Romania	Cernescu C, Ruță S, Diaconu C, Bleotu C, Grancea C, Truică C, Crăciun D, Nedelcu IN. Low rates of seroconversion after hepatitis B vaccination in orphanages with high prevalence of virus carriers. <i>Rom J Virol.</i> 1998; 49(1-4): 73-81.	1997		
Romania	Romanian Renal Registry (RRR) Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). <i>European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011.</i> Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Romania	Romanian Renal Registry (RRR) Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). <i>European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010.</i> Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Romania	Romania Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). <i>United Nations Demographic Yearbook - Historical Supplement 1997.</i> New York City, United States: United Nations Statistics Division (UNSD).	1990		
Russia	WHO Regional Office for Europe (EURO-WHO). <i>European Hospital Morbidity Database.</i> Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2005		
Russia	Russia Longitudinal Monitoring Survey (RLMS-HSE), Round IX 2000. National Research University Higher School of Economics, ZAO Demoscope, Carolina Population Center, University of North Carolina at Chapel Hill, Institute of Sociology, Russian Academy of Sciences.	2000	*	‡
Russia	World Health Organization (WHO). <i>Russia World Health Survey 2003.</i> Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		‡
Russia	World Health Organization (WHO). <i>Control of Foodborne Trematode Infections 1995.</i> Geneva, Switzerland: World Health Organization (WHO), 1995.	1995	*	
Russia	Centre for Health Informatics and Multiprofessional Education, University College London. <i>Modell's Haemoglobinopathologist's Almanac.</i> London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Russia	National Public Health Institute (Finland), World Health Organization (WHO). <i>WHO MONICA Cerebrovascular Event Data 1982-1997,</i> as provided by the Global Burden of Disease 2010 Cerebrovascular Disease Expert Group. [Unpublished].	1985-1993		
Russia	Feigin VL, Wiebers DO, Nikitin YP, O'Fallon WM, Whisnant JP. <i>Stroke Epidemiology in Novosibirsk, Russia: A Population-Based Study.</i> <i>Mayo Clin Proc.</i> 1995; 70(9): 847-52.	1992		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Russia	Hugg T, Ruotsalainen R, Jaakkola MS, Pushkarev V, Jaakkola JJK. Comparison of allergic diseases, symptoms and respiratory infections between Finnish and Russian school children. <i>Eur J Epidemiol.</i> 2008; 23(2): 123-33.	2003		
Russia	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol.</i> 2008; 121(4): 947-954.	1996, 2002		
Russia	Podkolzin AT, Fenske EB, Abramychyeva NY, Shipulin GA, Sagalova OL, Mazepa VN, Ivanova GN, Semena AV, Tagirova ZG, Alekseeva MN, Molochny VP, Parashar UD, Vinje J, Maleev VV, Glass RI, Pokrovsky VI. Hospital-based surveillance of rotavirus and other viral agents of diarrhea in children and adults in Russia, 2005-2007. <i>J Infect Dis.</i> 2009; 200(Suppl 1): 228-233.	2005-2007		
Russia	Abernathy J, Thorn M, Trobaugh G, Ekelund L, Maciolowski M, Lupovetsky B, Shelnova S, Zhukovsky G, Shestov D, Deev A. Prevalence of ischemic resting and stress electrocardiographic abnormalities and angina among 40- to 59-year-old men in selected US and USSR populations. <i>Circulation.</i> 1988; 77(2): 270-8.	1980-1998		
Russia	Akimova EV, Dracheva LV, Gakova EI, Purgina GI, Gafarov VV, Kuznetsov VA. Results of the one-stage screening for ischemic heart disease in the Tumen population sample. <i>Ter Arkh.</i> 2001; 73(1): 18-21.	1980-2001		
Russia	Chazova LV, Prokhoras R, Zborovsky EI, Glasunov IS, Apanasevich VV, Baubinine AV, Balavazde MB, Fomina RF, Misjavicene I, Kozlov ID, Reklaitene R, Deev AD. Prevalence of ischaemic heart disease and of various electrocardiographic changes according to findings of the cooperative Moscow-Kaunas-Minsk study. <i>Cor Vasa.</i> 1983; 25(1): 9-Jan.	1980-1983		
Russia	Kalinina AM, Baubinine AV, Vodianskaia NA, Gorbas' IM, Davydova LI, Deev AD, Domarkene SB, Malkova OA, Reklaitene RA, Terzov AN. [Detection of ischemic heart disease in a survey of a male population 40-59 years of age (data of cooperative studies performed in Moscow, Kaunas, Kiev and Kharkov)]. <i>Polish Heart Journal.</i> 1989; 29(12): 93-7.	1980-1988		
Russia	Konstantinov VV, Zhukovskii GS, Konstantinova OS, Timofeeva TN, Kapustina AV, Olferev AM, Deev AD. [The dynamics of ischemic heart disease and the risk factors among the male population of Moscow in the 1985 to 1995 period]. <i>Ter Arkh.</i> 1997; 69(1): 12-4.	1985		
Russia	Iurenev AP, Lediasheva GA, Lupanov VP, Rubanovich AI, Zhukova IM. Results of a 10-year prospective study of patients with ischemic heart disease. <i>Polish Heart Journal.</i> 1990; 30(6): 47-51.	1980		
Russia	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001-2002, 2008		
Russia	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Russia	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2002		
Russia	Russian Academy of Medical Science, World Health Organization (WHO). Russia WHO Study on Global AGEing and Adult Health 2007-2010.	2007-2010		
Russia	Ibragimov SI. The structure of skin pathology in middle-aged and elderly subjects. <i>Vestn Dermatol Venerol.</i> 1990; 2: 37-40.	1989-1990		
Russia	Ayzenberg I, Katsarava Z, Sborowski A, Chernysh M, Osipova V, Tabeeva G, Yakhno N, Steiner TJ, Lifting the Burden. The prevalence of primary headache disorders in Russia: a countrywide survey. <i>Cephalalgia.</i> 2012; 32(5): 373-81.	2008		†
Russia	Gorbatova MA, Gorbatova LN, Grjibovski AM. Dental caries experience among 15-year-old adolescents in north-west Russia. <i>Int J Circumpolar Health.</i> 2011; 70(3): 232-5.	2007-2008	*	
Russia	Gorbatova MA, Gorbatova LN, Pastbin MU, Grjibovski AM. Urban-rural differences in dental caries experience among 6-year-old children in the Russian north. <i>Rural Remote Health.</i> 2012; 1999.	2007-2008	*	
Russia	Gorbatova MA, Grjibovski AM, Gorbatova LN, Honkala E. Dental caries experience among 12-year-old children in Northwest Russia. <i>Community Dent Health.</i> 2012; 29(1): 20-4.	2007-2008	*	
Russia	Hardwick KS, Jones DB, Phipps KR. The oral health status among residents of the Magadan Oblast, Russian Far East. <i>J Public Health Dent.</i> 1993; 53(2): 101-8.	1991		
Russia	Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version). Lyon, IARC. http://cis.iarc.fr	2003-2007	*	
Russia	Russia Dialysis and Transplant Registry data as it appears in the GBD 2010 Chronic Kidney Disease Expert Group dataset. Provided by Natalia Tomilina and Boris Bikbov.	2005		
Russia	Pakriev S, Vasar V, Aluoja A, Saarma M, Shlik J. Prevalence of mood disorders in the rural population of Udmurtia. <i>Acta Psychiatr Scand.</i> 1998; 97(3): 169-74.	1995		
Russia	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2004-2005		
Russia	United States Renal Data System Coordinating Center. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2002-2003		
Russia	Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganey K, Giel R, an der Heiden W, Holmberg SK, Janca A, Lee PW, León CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirikin SJ, Varma VK, Walsh D, Wiersma D. Recovery from psychotic illness: a 15- and 25-year international follow-up study. <i>Br J Psychiatry.</i> 2001; 178: 506-17.	1978-1993		
Russia	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Russia	Russia - Samara District Rapid Assessment for Avoidable Blindness Survey 2008 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2008		
Russia	Folomeeva OM, Benevolenskaia LI. Rheumatism in the Russian Federation: statistic and reality. <i>Vestn Ross Akad Med Nauk.</i> 1996; 21-4.	1994		
Russia	WHO Regional Office for Europe (EURO-WHO). Young People's Health in Context. Health Behaviour in School-aged Children (HBSC) Study: International Report from the 2001-2002 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2004.	2002		
Russia	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Russia	Abdourakmanov DT, Hasaev AS, Castro FJ, Guardia J. Epidemiological and clinical aspects of hepatitis C virus infection in the Russian Republic of Dagestan. <i>Eur J Epidemiol.</i> 1998; 14(6): 549-53.	1994-1996		
Russia	Khazanov AI. [Current problems of viral and alcohol diseases of the liver]. <i>Klin Med (Mosk).</i> 2002; 80(3): 14-9.	1996-2000		
Russia	Zakirov IG. [Liver cirrhosis and liver cancer associated with viral hepatitis B and C in republic of Tatarstan]. <i>Zh Mikrobiol Epidemiol Immunobiol.</i> 2003; 26-8.	1996-2000		
Russia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2007, 2010, 2012		
Russia	Goodman R, Slobodskaya H, Knyazev G. Russian child mental health – a cross-sectional study of prevalence and risk factors. <i>Eur Child Adolesc Psychiatry.</i> 2005; 14(1): 28-33.	2003		
Russia	Kondrashova A, Reunanen A, Romanov A, Karvonen A, Viskari H, Vesikari T, Ilonen J, Knap M, Hyöty H. A six-fold gradient in the incidence of type 1 diabetes at the eastern border of Finland. <i>Ann Med.</i> 2005; 37(1): 67-72.	1990-1999		
Russia	Pronina EA, Petraikina EE, Antsiferov MB, Duchareva OV, Petrone A, Buzzetti R, Pizzilli P. A 10-year (1996-2005) prospective study of the incidence of Type 1 diabetes in Moscow in the age group 0-14 years. <i>Diabet Med.</i> 2008; 25(8): 956-9.	1996-2005		
Russia	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Gilst WH van, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J.</i> 2003; 24(5): 442-63.	2000-2001		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Russia	Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M and Boyle P, eds (2007). Cancer Incidence in Five Continents, Vol. IX Periodic Data (electronic version). Lyon, IARC. http://ci5.iarc.fr	1998-2002	*	
Russia	Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. Cancer Incidence in Five Continents, Vol. I to VIII. Lyon, France, IARC Press, 2005.	1983-1987, 1994-1997	*	
Russia	Van Pottelbergh C, Gurina N, Degryse J, Frolova E. Prevalence of impaired renal function in the elderly in the St. Petersburg District: results of the Crystal study. <i>Adv Gerontol.</i> 2011; 24(1): 108-13.	2009	*	
Russia	Averina M, Nilssen O, Brenn T, Brox J, Arkhipovsky VL, Kalinin AG. Social and lifestyle determinants of depression, anxiety, sleeping disorders and self-evaluated quality of life in Russia – a population-based study in Arkhangelsk. <i>Soc Psychiatry Psychiatr Epidemiol.</i> 2005; 40(7): 511-8.	1999-2000		
Russia	Pakriev S, Vasar V, Aluoja A, Shlik J. Prevalence of ICD-10 harmful use of alcohol and alcohol dependence among the rural population in Udmurtia. <i>Alcohol Alcohol.</i> 1998; 33(3): 255-64.	1995		
Russia	Winter Y, Bezdolnyy Y, Katunina E, Avakjan G, Reese JP, Klotsche J, Oertel WH, Dodel R, Gusev E. Incidence of Parkinson's disease and atypical parkinsonism: Russian population-based study. <i>Mov Disord.</i> 2010; 25(3): 349-56.	2006-2008	*	
Russia	Russia - Komi Iodine Deficiency Disorder Survey 2000 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2000		
Russia	Russia - Tyva Iodine Deficiency Disorder Survey 2000 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2000		
Russia	Russia - Sakhalin Evaluation of Iodine Status and Goitre Prevalence in Child Population 2001 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2001		
Russia	Russia - Belgorod Iodine Deficiency Disorder Survey 2001 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2001		
Russia	World Health Organization (WHO). <i>Leprosy. Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Russia	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Russia	Russia Urinary Iodine and Thyroid Volume 2002 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2002		
Russia	Russian Registry of Renal Replacement Therapy data as it appears in the GBD 2010 Chronic Kidney Disease Expert Group dataset. Provided by Natalia Tomilina and Boris Bikbov	2007-2012	*	
Russia	Koposova N, Eriksen HM, Widström E, Handegård BH, Pastbin M, Kopusov R. Caries prevalence and determinants among 12-year-olds in North-West Russia and Northern Norway. <i>Stomatologija.</i> 2013; 15(1): 3-11.	2009	*	
Russia	Reshetnikov OV, Ryabikov AN, Shakhmatov SG, Maljutina SK. Gallstone disease prevalence in Western Siberia: cross-sectional ultrasound study versus autopsy. <i>J Gastroenterol Hepatol.</i> 2002; 17(6): 702-7.	1990, 1995		
Russia	Balayan MS, Fedorova OE, Mikhailov MI, Rytick PG, Eremin VF, Danilova TL, Shevelev BI, Gorbacheva EC, Pankova GY. Antibody to hepatitis E virus in HIV-infected individuals and AIDS patients. <i>J Viral Hepat.</i> 1997; 4(4): 279-83.	1994-1996	*	
Russia	Von Hertzen LC, Laatikainen T, Mäkelä MJ, Jousilahti P, Kosunen TU, Petays T, Pussinen PJ, Hahtela T, Variainen E. Infectious burden as a determinant of atopy – a comparison between adults in Finnish and Russian Karelia. <i>Int Arch Allergy Immunol.</i> 2006; 140(2): 89-95.	1997		
Russia	Savinskaia SS, Tol'skaia EA, Balaian MS. [Antibodies to the hepatitis A virus in the healthy population of Moscow]. <i>Zh Mikrobiol Epidemiol Immunobiol.</i> 1982; 34-7.	1977-1981		
Russia	Kornachev AS, Mikhailova NB, Dubrovskaya LR, Sitkov VI. [The determination of hepatitis A antibodies in epidemiological practice]. <i>Zh Mikrobiol Epidemiol Immunobiol.</i> 1990; 59-60.	1981-1984		
Russia	Prikazhnikov SA, Karetnyi Iu V, Vakar EI, Balaian MS, Zenkov VA. [Characteristics of the development of humoral immunity to hepatitis A in children's day care centers]. <i>Vopr Virusol.</i> 1988; 33(2): 169-73.	1985-1986		
Russia	Shliakhtenko LI, Kryga LN, Alelnik MD, Vasil'eva VI, Mukomolov SL, Rumovskii VI, Shargorodskaya EP, Asratian AA, Bystrova TN. [The morbidity and immunological structure of the population in viral hepatitis A at different phases in the development of multiyear epidemic cycles]. <i>Zh Mikrobiol Epidemiol Immunobiol.</i> 1994; 42-5.	1986-1989		
Russia	Shliakhtenko L, Plotnikova V, Levakova I, Rubis L, Solovieva E, Mukomolov S. Modern epidemiology of hepatitis A in the north-western region of the Russian Federation. <i>J Viral Hepat.</i> 2008; 38-42.	1986-1997		
Russia	Karetnyi Iu V, Vasil'eva ZN, Balaian MS, Zenkov VA, Sysoliatin VA, Sobina GV, Lysenko GV, Tsvetova GV, Tesheva Sch, Klimenko LA, et al. [The development of the epidemic process and the formation of humoral immunity to the hepatitis A virus in adolescent collectives]. <i>Zh Mikrobiol Epidemiol Immunobiol.</i> 1990; 71-6.	1987		
Russia	Balayan MS, Zamyatina NA, Mikhailov MI, Sychev AV, Usmanov RK, Dvoynikova OV, Nelga IV, Grishina GK, Ankhundinova LA. Serological survey on hepatitis E virus infection in an endemic area: diagnosis potential of enzyme immunoassay for detection of IgG antibody. <i>Clin Diagn Virol.</i> 1994; 2(4-5): 297-304.	1994		
Russia	Mukomolov SL, Shliakhtenko LI, Valle M, Plotnikova VA, Davidkin I, Levakova IA, Samokhina EV, Andreeva IA, Dmitrieva TG. [Characteristics of the manifest and latent components of the hepatitis A epidemic process in cities of Russia]. <i>Zh Mikrobiol Epidemiol Immunobiol.</i> 2001; 35-9.	1999		
Russia	Tsoi RM, Pak IV, Bobrova IA. [Distribution of blood types of four systems and ABO incompatibility in migration population of a northern town]. <i>Fiziol Cheloveka.</i> 2003; 29(3): 125-8.	1997-1998	*	†
Russia	Gafarov VV. [20-year monitoring of acute cardiovascular diseases in population of large industrial city in West Siberia (epidemiological study)]. <i>Ter Arkh.</i> 2000; 72(1): 15-21.	1987, 1990, 1993, 1996		
Russia	Varlamova T, Zhukovski G, Chazova L, Britov A. Monitoring of Major Cardiovascular Diseases in Moscow, USSR. <i>Acta Med Scand Suppl.</i> 1988; 224(S728): 73-8.	1985		
Russia	National Public Health Institute (Finland), World Health Organization (WHO). MONICA Coronary Event Registration Data Book 1980-1995. Geneva, Switzerland: World Health Organization (WHO), 2000.	1980-1995		
Russia	Dobrodeeva LK, Kornienko EB, Petrenya NN, Lutfaliev GT, Schegoleva LS, Demeneva LV, Duberman BL, Tkachev AV, Chiba H, Senoo H, Ito K, Mizoguchi E, Yoshida S, Tajima K. A unique seroepidemiological pattern of HBV, HCV and HTLV-I in Nenets and Komi in northwestern Russia. <i>Asian Pac J Cancer Prev.</i> 2005; 6(3): 342-5.	2004		
Russia	Oiba K, Mizokami M, Kato T, Ueda R, Gursentsev V, Senyuta N, Sirtsev A, Zoya K, Yamashita M, Hayami M. Seroprevalence of hepatitis B virus, hepatitis C virus and GB virus-C infections in Siberia. <i>Epidemiol Infect.</i> 1999; 122(1): 139-43.	1994-1995		
Russia	Reshetnikov OV, Khryanin AA, Teinina TR, Krivenchuk NA, Zimina IY. Hepatitis B and C seroprevalence in Novosibirsk, western Siberia. <i>Sex Transm Infect.</i> 2001; 77(6): 463.	1995-1999		
Russia	Shustov AV, Kochneva GV, Sivolobova GF, Grazhdantseva AA, Gavrilova IV, Akinfeeva LA, Rakova IG, Aleshina MV, Bukin VN, Orlovsky VG, Beshpalov VS, Robertson BH, Netesov SV. Molecular epidemiology of the hepatitis C virus in Western Siberia. <i>J Med Virol.</i> 2005; 77(3): 382-9.	2001-2002		
Russia	Syskova TG, Tsybina TN, Sidorenko AG, Iasin'skii AA. [Parasitic diseases morbidity in the Russian Federation in 1999]. <i>Med Parazitol (Mosk).</i> 2001; 31-5.	1999	*	
Russia	Kharakoz OS, Kanorski SG, Shehelchikova IS, Kizhvatova NV, Varakin Iula, Vereshchagin NV. [Hypertension – main risk factor of stroke. Results of a three years register in Krasnodar]. <i>Kardiologija.</i> 2002; 42(10): 31-5.	1997-2000	*	
Russia	Kotova E. Clinical-epidemiological Characteristics, Leading Risk Factors, and the Nature of Stroke in Ulyanovsk (Based on Stroke Registry Data) [dissertation]. Ulyanovsk, Russia: Ulyanovsk State University; 2009.	2004-2006	*	
Russia	Ulimbasheva ES, Varakin YY, Chudopal SM. [Recurrent stroke in patients with hypertension (according to the Nalchik stroke registry)]. <i>Cardiovasc Ther Prev.</i> 2007; 6(4): 20-4.	2003-2004	*	
Russia	Tret'yakova NN, Varakin YY, Kuzmina ZM, Chuprova NG, Gogolev MP. [Clinical and epidemiological study of stroke in Yakutsk city]. <i>Ann Clin Exp Neurol.</i> 2008; 2(2): 18-22.	2002-2004	*	
Russia	[Comparative characteristics of the prevalence of coronary heart disease in men 40-54 years of age in various cities of the Soviet Union (an epidemiologic survey)]. <i>Ter Arkh.</i> 1989; 61(3): 101-5.	1980-1988		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Russia	Russia Nationwide Register of CKD Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Russia	Russia Nationwide Register of CKD Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Russia	USSR - Russian SFSR Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Russia	Russia - Moscow Regional Registry of Congenital Malformation Data 2001 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
Russia	Russia - Moscow Regional Registry of Congenital Malformation Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
Russia	Russia - Moscow Regional Registry of Congenital Malformation Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Russia	Russia - Tomsk Birth Defects Monitoring Programme Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Russia	Russia - Moscow Regional Registry of Congenital Malformation Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Russia	Russia - Moscow Regional Registry of Congenital Malformation Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
Russia	Russia - Moscow Regional Registry of Congenital Malformation Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
Rwanda	Macro International, Inc. National Office of Population (Rwanda). Rwanda Demographic and Health Survey 1992. Calverton, United States: Macro International, Inc.	1992		†
Rwanda	Macro International, Inc. National Office of Population (Rwanda). Rwanda Demographic and Health Survey 2000. Calverton, United States: Macro International, Inc.	2000		†
Rwanda	Macro International, Inc. National Institute of Statistics of Rwanda. Rwanda Demographic and Health Survey 2005. Calverton, United States: Macro International, Inc.	2005		†
Rwanda	Macro International, Inc. Ministry of Health (Rwanda), National Institute of Statistics of Rwanda. Rwanda Interim Demographic and Health Survey 2007-2008. Calverton, United States: Macro International, Inc.	2007-2008		†
Rwanda	Rwanda Interim Demographic and Health Survey 2007-2008 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2007-2008	*	†
Rwanda	Department of Statistics (Rwanda), United Nations Children's Fund (UNICEF). Rwanda Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Rwanda	ICF Macro, Ministry of Health (Rwanda), National Institute of Statistics of Rwanda. Rwanda Demographic and Health Survey 2010-2011. Calverton, United States: ICF Macro.	2010-2011		†
Rwanda	Rwanda Demographic and Health Survey 2010-2011 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2010-2011	*	†
Rwanda	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Rwanda	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Rwanda	Gibbs, S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int J Dermatol. 1996; 35(9): 633-9.	1994		
Rwanda	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1996-1997, 1999-2000, 2002-2003, 2005		
Rwanda	Musafiri S, van Meerbeek J, Musungu L, Brusselle G, Joos G, Seminega B, Rutayisire C. Prevalence of atopy, asthma and COPD in an urban and a rural area of an African country. Respir Med. 2011; 105(11): 1596-605.	2008-2009	*	
Rwanda	Gahutu J-B, Musemakwiri A, Harms G, Mockenhaupt FP. Prevalence of classic erythrocyte polymorphisms among 749 children in southern highland Rwanda. Trans R Soc Trop Med Hyg. 2012; 106(1): 63-5.	2010	*	
Rwanda	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Rwanda	Pham PN, Weinstein HM, Longman T. Trauma and PTSD symptoms in Rwanda: implications for attitudes toward justice and reconciliation. JAMA. 2004; 292(5): 602-12.	1994		
Rwanda	Simms V, Atijosan O, Kuper H, Nuhu A, Rischewski D, Lavy C. Prevalence of epilepsy in Rwanda: a national cross-sectional survey. Trop Med Int Health. 2008; 13(8): 1047-53.	2005	*	†
Rwanda	Bolton P, Neugebauer R, Ndogoni L. Prevalence of depression in rural Rwanda based on symptom and functional criteria. J Nerv Ment Dis. 2002; 190(9): 631-7.	1999		
Rwanda	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2004, 2007, 2010, 2012		
Rwanda	Rwanda Biomedical Center. Rwanda National Tuberculosis Prevalence Survey 2012.	2012		
Rwanda	Mathenge W NJ, Limburg H, Kuper H. Rapid assessment of avoidable blindness in Western Rwanda: blindness in a postconflict setting. PLoS Med. 2007; 4(7): as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2006		
Rwanda	Munyanganziri R, Cotton F, Vertongen F, Gulbis B. Red blood cell disorders in Rwandese neonates: screening for sickle cell disease and glucose-6-phosphate dehydrogenase deficiency. J Med Screen. 2006; 13(3): 129-31.	2005		
Rwanda	Naicker S. Burden of end-stage renal disease in sub-Saharan Africa. Clin Nephrol. 2010; 74(Suppl 1): S13-6.	2008-2010		
Rwanda	Rwanda National Nutrition Survey of Women and Children 1996 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1996		
Rwanda	Rwanda Survey of Prevalence of Disorders in Iodine Deficiency in Six Prefectures 1990 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1990		
Rwanda	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Rwanda	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Rwanda	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Rwanda	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Rwanda	Muvunyi CM, Dhont N, Verhelst R, Temmerman M, Claeys G, Padalko E. Chlamydia trachomatis infection in fertile and subfertile women in Rwanda: prevalence and diagnostic significance of IgG and IgA antibodies testing. Hum Reprod. 2011; 26(12): 3319-26.	2007-2010	*	
Rwanda	Gascon J. [Endemic goiter in Nyarutovu, Rwanda]. Ann Soc Belg Med Trop. 1986; 66(3): 251-255 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1984-1985		
Rwanda	Hogewoning A, Amoah A, Bavnick JNB, Boakye D, Yazdanbakhsh M, Adegnik A, De Smedt S, Fonteyne Y, Willemze R, Lavrijsen A. Skin diseases among schoolchildren in Ghana, Gabon, and Rwanda. Int J Dermatol. 2013; 52(5): 589-600.	2007	*	
Rwanda	Hogewoning AA, Bouwes Bavnick JN, Amoah AS, Boakye DA, Yazdanbakhsh M, Krensner PG, Adegnik AA, De Smedt SKAD, Willemze R, Lavrijsen APM. Point and period prevalences of eczema in rural and urban schoolchildren in Ghana, Gabon and Rwanda. J Eur Acad Dermatol Venereol. 2012; 26(4): 488-94.	2007	*	
Rwanda	Mutesa L, Boemer F, Ngendahayo L, Rulisa S, Rusingiza EK, Cwinya-Ay N, Mazina D, Kariyo PC, Bours V, Schoos R. Neonatal screening for sickle cell disease in Central Africa: a study of 1825 newborns with a new enzyme-linked immunosorbent assay test. J Med Screen. 2007; 14(3): 113-6.	2004-2006	*	
Rwanda	Dhont N, van de Wijgert J, Vyanankandondera J, Busasa R, Gasarabwa A, Temmerman M. Results of infertility investigations and follow-up among 312 infertile women and their partners in Kigali, Rwanda. Trop Doct. 2011; 41(2): 96-101.	2007-2009	*	
Rwanda	Gascon J, Merlos A, Madrenys N, Torres JM, Bada JL. Epidemiology of malaria in Nyarutovu (Rwanda): a clinical, parasitological and serological study. Trans R Soc Trop Med Hyg. 1988; 82(2): 222 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1984-1985	*	†
Rwanda	Rwanda Vital Registration Birth Data 1978 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1978		
Rwanda	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-2005		
Saint Lucia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Saint Lucia	Cook JA, Jordan P, Woodstock L, Pilgrim V. A controlled trial of hycanthone and placebo in schistosomiasis mansoni in St. Lucia. Ann Trop Med Parasitol. 1977; 71(2): 197-202.	1972-1973		
Saint Lucia	Cook JA, Baker ST, Warren KS, Jordan P. A controlled study of morbidity of schistosomiasis mansoni in St. Lucian children, based on quantitative egg excretion. Am J Trop Med Hyg. 1974; 23(4): 625-33.	1972		
Saint Lucia	Smadja D, Cabre P, May F, Fanon J-L, René-Corail P, Riocreux C, Charpentier J-C, Fournier P, Saint-Vil M, Ketterlé J. ERMANCIA: Epidemiology of Stroke in Martinique, French West Indies. Stroke. 2001; 32(12): 2741-7.	1998-1999		
Saint Lucia	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000-2004, 2006-2009		
Saint Lucia	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Saint Lucia	Canino G, Shrout PE, Rubio-Stipec M, et al. The DSM-IV rates of child and adolescent disorders in Puerto Rico: Prevalence, correlates, service use, and the effects of impairment. Arch Gen Psychiatry. 2004; 61(1): 85-93.	1999-2000		
Saint Lucia	Rubio-Stipec M, Canino GJ, Shrout P, Dulcan M, Freeman D, Bravo M. Psychometric properties of parents and children as informants in child psychiatry epidemiology with the Spanish Diagnostic Interview Schedule for Children (DISC.2). J Abnorm Child Psychol. 1994; 22(6): 703-20.	1992	*	
Saint Lucia	Canino GJ, Bird HR, Shrout PE, Rubio-Stipec M, Bravo M, Martinez R, Sesman M, Guevara LM. The prevalence of specific psychiatric disorders in Puerto Rico. Arch Gen Psychiatry. 1987; 44(8): 727-35.	1984		
Saint Lucia	Garnett GP, Cox MJ, Bundy DA, Didier JM, St Catharine J. The age of infection with varicella-zoster virus in St Lucia, West Indies. Epidemiol Infect. 1993; 110(2): 361-72.	1985-1986		
Saint Lucia	Inter-American Drug Abuse Control Commission (CICAD). Organization of American States (OAS). Saint Lucia Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2005		
Saint Lucia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Saint Lucia	Bird HR, Canino G, Rubio-Stipec M, Gould MS, Ribera J, Sesman M, Woodbury M, Huertas-Goldman S, Pagan A, Sanchez-Lacay A. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico. The use of combined measures. Arch Gen Psychiatry. 1988; 45(12): 1120-6.	1985-1986	*	
Saint Lucia	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
Saint Lucia	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Saint Lucia	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Saint Lucia	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Saint Lucia	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
Saint Lucia	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Saint Lucia	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Saint Lucia	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Saint Lucia	Merikangas KR, Conway KP, Swendsen J, Febo V, Dierker L, Brunetto W, Stolar M, Canino G. Substance use and behaviour disorders in Puerto Rican youth: a migrant family study. J Epidemiol Community Health. 2009; 63(4): 310-6.	1990		
Saint Lucia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Saint Lucia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Saint Lucia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Saint Lucia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Saint Lucia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Saint Lucia	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Saint Lucia	Olindo S, Cabre P, Deschamps R, Chatot-Henry C, René-Corail P, Fournier P, Saint-Vil M, May F, Smadja D. Acute stroke in the very elderly: epidemiological features, stroke subtypes, management, and outcome in Martinique, French West Indies. Stroke. 2003; 34(7): 1593-7.	1998-1999		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Saint Lucia	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L, Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Ann Hepatol</i> . 2010; 9(1): 63-9.	2006-2008	*	
Saint Lucia	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), Ministry of Health (Saint Lucia). Saint Lucia Survey of Drug Use among Secondary School Students 2005.	2005		
Saint Lucia	Saint Lucia Vital Registration Birth Data 1986 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1986		
Saint Vincent and the Grenadines	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-2005		
Saint Vincent and the Grenadines	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Saint Vincent and the Grenadines	Smadja D, Cabre P, May F, Fanon J-L, René-Coraïl P, Riocreux C, Charpentier J-C, Fournier P, Saint-Vil M, Ketterlé J. ERMANCIA: Epidemiology of Stroke in Martinique, French West Indies. <i>Stroke</i> . 2001; 32(12): 2741-7.	1998-1999		
Saint Vincent and the Grenadines	De Oliveira LH, Danovaro-Holliday MC, Andrus JK, de Fillips AMB, Gentsch J, Matus CR, Widdowson M-A. Sentinel hospital surveillance for rotavirus in Latin American and Caribbean countries. <i>J Infect Dis</i> . 2009; 200 Suppl 1: 131-139.	2006-2007		
Saint Vincent and the Grenadines	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000-2002, 2004-2009		
Saint Vincent and the Grenadines	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Nephrology Expert Group. [Unpublished].	1990, 2005, 2010		
Saint Vincent and the Grenadines	Alonge OK, Narendran S. Dental caries experience among school children in St Vincent and The Grenadines: report of the first national oral health survey. <i>Community Dent Health</i> . 1999; 16(1): 45-9.	1991		
Saint Vincent and the Grenadines	Canino G, ShROUT PE, Rubio-Stipec M, et al. The DSM-IV rates of child and adolescent disorders in Puerto Rico: Prevalence, correlates, service use, and the effects of impairment. <i>Arch Gen Psychiatry</i> . 2004; 61(1): 85-93.	1999-2000		
Saint Vincent and the Grenadines	Rubio-Stipec M, Canino GJ, ShROUT P, Dulcan M, Freeman D, Bravo M. Psychometric properties of parents and children as informants in child psychiatry epidemiology with the Spanish Diagnostic Interview Schedule for Children (DISC.2). <i>J Abnorm Child Psychol</i> . 1994; 22(6): 703-20.	1992	*	
Saint Vincent and the Grenadines	Canino GJ, Bird HR, ShROUT PE, Rubio-Stipec M, Bravo M, Martinez R, Sesman M, Guevara LM. The prevalence of specific psychiatric disorders in Puerto Rico. <i>Arch Gen Psychiatry</i> . 1987; 44(8): 727-35.	1984		
Saint Vincent and the Grenadines	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Saint Vincent and the Grenadines Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2006		
Saint Vincent and the Grenadines	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2007, 2010, 2012		
Saint Vincent and the Grenadines	Bird HR, Canino G, Rubio-Stipec M, Gould MS, Ribera J, Sesman M, Woodbury M, Huertas-Goldman S, Pagan A, Sanchez-Lacay A. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico. The use of combined measures. <i>Arch Gen Psychiatry</i> . 1988; 45(12): 1120-6.	1985-1986	*	
Saint Vincent and the Grenadines	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec</i> . 2010; 85(35): 337-48.	2009	*	
Saint Vincent and the Grenadines	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec</i> . 2008; 83(33): 293-300.	2007	*	
Saint Vincent and the Grenadines	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec</i> . 2013; 88(35): 365-79.	2012	*	
Saint Vincent and the Grenadines	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1994; 69(20): 145-51.	1993	*	
Saint Vincent and the Grenadines	Merikangas KR, Conway KP, Swendsen J, Febo V, Dierker L, Brunetto W, Stolar M, Canino G. Substance use and behaviour disorders in Puerto Rican youth: a migrant family study. <i>J Epidemiol Community Health</i> . 2009; 63(4): 310-6.	1990		
Saint Vincent and the Grenadines	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Saint Vincent and the Grenadines	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Saint Vincent and the Grenadines	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Saint Vincent and the Grenadines	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Saint Vincent and the Grenadines	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Saint Vincent and the Grenadines	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Saint Vincent and the Grenadines	Olindo S, Cabre P, Deschamps R, Chatot-Henry C, René-Coraïl P, Fournier P, Saint-Vil M, May F, Smadja D. Acute stroke in the very elderly: epidemiological features, stroke subtypes, management, and outcome in Martinique, French West Indies. <i>Stroke</i> . 2003; 34(7): 1593-7.	1998-1999		
Saint Vincent and the Grenadines	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L, Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Ann Hepatol</i> . 2010; 9(1): 63-9.	2006-2008	*	
Saint Vincent and the Grenadines	Saint Vincent and the Grenadines Vital Registration Birth Data 1992 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1992		
Samoa	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1989, 1991-1993, 1995-1998, 2000-2009		
Samoa	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Samoa	Foliaki S, Annesi-Measano I, Daniel R, Fakakovikaetau T, Magatongia M, Tuuu-Potoi N, Waqatakiwira L, Cheng S, Pearce N. Prevalence of symptoms of childhood asthma, allergic rhinoconjunctivitis and eczema in the Pacific: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Allergy</i> . 2007; 62(3): 259-64.	1998-2003		
Samoa	Ministry of Health (Samoa). Samoa STEPS Noncommunicable Disease Risk Factors Survey 2002.	2002		
Samoa	Hill AV, Bowden DK, O'Shaughnessy DF, Weatherall DJ, Clegg JB. Beta thalassaemia in Melanesia: association with malaria and characterization of a common variant (IVS-1 nt 5 G→C). <i>Blood</i> . 1988; 72(1): 9-14.	1985-1987		
Samoa	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2006, 2009		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Samoa	Jackson L, Taylor R, Faaiuso S, Ainuu SP, Whitehouse S, Zimmet P. Hyperuricaemia and gout in Western Samoans. J Chronic Dis. 1981; 34(2-3): 65-75.	1978		
Samoa	Lai CK, Bessley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2003		
Samoa	McGarvey ST. Cardiovascular disease (CVD) risk factors in Samoa and American Samoa. Pac Health Dialog. 2001; 8(1): 157-62.	1995		
Samoa	Collins VR, Dowse GK, Toelupe PM, Imo TT, Aloaina FL, Spark RA, Zimmet PZ. Increasing prevalence of NIDDM in the Pacific island population of Western Samoa over a 13-year period. Diabetes Care. 1994; 17(4): 288-96.	1991		
Samoa	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Samoa	Secretariat of the Pacific Community (SPC), World Health Organization Regional Office for the Western Pacific (WPRO-WHO). Second Generation Surveillance Surveys of HIV, Other STIs and Risk Behaviours in 6 Pacific Island Countries 2004-2005. Geneva, Switzerland: World Health Organization (WHO), 2006.	2004		
Samoa	Yangihara RT, Garruto RM, Gajusek DC. Epidemiological surveillance of amyotrophic lateral sclerosis and parkinsonism-dementia in the commonwealth of the Northern Mariana Islands. Ann Neurol. 1983; 13(1): 79-86.	1980-1981		
Samoa	Viali S. Rheumatic fever and rheumatic heart disease in Samoa. Pac Health Dialog. 2006; 13(2): 31-8.	2004-2005		
Samoa	Odden HL. Alcohol, tobacco, marijuana and hallucinogen use in Samoan adolescents. Drug Alcohol Rev. 2012; 31(1): 47-55.	2008	*	
Samoa	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2010, 2012		
Samoa	Kimura E, Spears GF, Singh KI, Samarawickrema WA, Penaia L, Sone PF, Pelenatu S, Faaiuso ST, Self LS, Dazo BC. Long-term efficacy of single-dose mass treatment with diethylcarbamazine citrate against diurnally subperiodic Wuchereria bancrofti: eight years' experience in Samoa. Bull World Health Organ. 1992; 70(6): 769-76. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1982-1983, 1986	*	
Samoa	Joseph H, Maiava F, Naseri T, Silva U, Lammie P, Melrose W. Epidemiological assessment of continuing transmission of lymphatic filariasis in Samoa. Ann Trop Med Parasitol. 2011; 105(8): 567-78. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2007-2008	*	
Samoa	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Samoa	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
Samoa	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Samoa	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	
Samoa	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Samoa	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Samoa	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Samoa	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Samoa	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Samoa	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2000.	2000		
Samoa	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2001.	2001		
Samoa	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2002.	2002		
Samoa	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2003.	2003		
Samoa	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2004.	2004		
Samoa	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2005.	2005		
Samoa	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2006.	2006		
Samoa	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2007.	2007		
Samoa	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2008.	2008		
Samoa	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2010.	2010		
Samoa	Ichimori K, Tupuimalagi-Toelupe P, Iosia VT, Graves PM. Wuchereria bancrofti Filariasis Control in Samoa before PacELF (Pacific Programme to Eliminate Lymphatic Filariasis). Trop Med Health. 2007; 35(3): 261-9. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1993-1998	*	
Samoa	Samoa - Pacific Programme to Eliminate Lymphatic Filariasis: National activities carried out to date as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2008	*	
Samoa	Samoa Vital Registration Birth Data 1980 as it appears in United Nations Statistics Division (UNSD), United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1980		
Sao Tome and Principe	ICF Macro, Ministry of Health (Sao Tome and Principe), National Institute of Statistics (Sao Tome and Principe). Sao Tome and Principe Demographic and Health Survey 2008-2009. Calverton, United States: ICF Macro.	2008-2009		†
Sao Tome and Principe	National Institute of Statistics (Sao Tome and Principe), United Nations Children's Fund (UNICEF). Sao Tome and Principe Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Sao Tome and Principe	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Sao Tome and Principe	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Sao Tome and Principe	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1996-1997, 2000-2009		
Sao Tome and Principe	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Sao Tome and Principe	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2004, 2007, 2010, 2012		
Sao Tome and Principe	Ruiz L, Campo E, Corachán M. Elephantiasis in São Tomé and Príncipe. Acta Trop. 1994; 57(1): 29-34.	1988	*	
Sao Tome and Principe	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Sao Tome and Principe	World Health Organization (WHO). Global leprosy situation, 2007 (additional information). Wkly Epidemiol Rec. 2007; 82(44): 388.	2006	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Sao Tome and Principe	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Sao Tome and Principe	Hagmann R, Charlwood JD, Gil V, Ferreira C, do Rosário V, Smith TA. Malaria and its possible control on the island of Principe. <i>Malar J.</i> 2003; 2(1): 15 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
Sao Tome and Principe	Müller DA, Charlwood JD, Felger I, Ferreira C, do Rosário V, Smith T. Prospective risk of morbidity in relation to multiplicity of infection with <i>Plasmodium falciparum</i> in São Tomé. <i>Acta Trop.</i> 2001; 78(2): 155-62 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Sao Tome and Principe	Pinto J, Sousa CA, Gil V, Ferreira C, Gonçalves L, Lopes D, Petarca V, Charlwood JD, do Rosário VE. Malaria in São Tomé and Príncipe: parasite prevalences and vector densities. <i>Acta Trop.</i> 2000; 76(2): 185-93 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
Sao Tome and Principe	Tseng LF, Chang WC, Ferreira MC, Wu CH, Rampaio HS, Lien JC. Rapid control of malaria by means of indoor residual spraying of alphacypermethrin in the Democratic Republic of São Tomé and Príncipe. <i>Am J Trop Med Hyg.</i> 2008; 78(2): 248-50 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Sao Tome and Principe	Sao Tome and Principe Vital Registration Birth Data 1979 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1979		
Saudi Arabia	Ministry of Health (Saudi Arabia). Saudi Arabia Health Statistical Yearbook 2009. Riyadh, Saudi Arabia: Ministry of Health (Saudi Arabia).	1979-2009		
Saudi Arabia	Ministry of Health (Saudi Arabia). Saudi Arabia Health Statistical Yearbook 2008. Riyadh, Saudi Arabia: Ministry of Health (Saudi Arabia).	1979-2008		
Saudi Arabia	Ministry of Health (Saudi Arabia). Saudi Arabia Health Statistical Yearbook 2007. Riyadh, Saudi Arabia: Ministry of Health (Saudi Arabia).	1979-2007		
Saudi Arabia	Ministry of Health (Saudi Arabia). Saudi Arabia Health Statistical Yearbook 2006. Riyadh, Saudi Arabia: Ministry of Health (Saudi Arabia).	1979-2006		
Saudi Arabia	National Cancer Registry (Saudi Arabia). Saudi Arabia Cancer Incidence Report 1994-1996. Riyadh, Saudi Arabia: National Cancer Registry (Saudi Arabia), 1999.	1994-1996	*	
Saudi Arabia	National Cancer Registry (Saudi Arabia). Saudi Arabia Cancer Incidence Report 1997-1998. Riyadh, Saudi Arabia: National Cancer Registry (Saudi Arabia), 2001.	1997-1998	*	
Saudi Arabia	Ministry of Health (Saudi Arabia). Saudi Arabia Vital Registration - Deaths 2008-2011.	2008-2011	*	†
Saudi Arabia	Ministry of Health (Saudi Arabia). Saudi Arabia Vital Registration - Deaths 1996-2011.	1996-2011	*	†
Saudi Arabia	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1994		
Saudi Arabia	El-Hazmi MAF, Warys AS. Appraisal of sickle-cell and thalassaemia genes in Saudi Arabia. <i>East Mediterr Health J.</i> 1999; 5(6): 1147-53.	1982-1992		
Saudi Arabia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Saudi Arabia	Perrine RP, Pembrey ME, John P, Perrine S, Shoup F. Natural history of sickle cell anemia in Saudi Arabs A study of 270 subjects. <i>Ann Intern Med.</i> 1978; 88(1): 1-6.	1969-1979		
Saudi Arabia	Weatherall D. Sickle Cell and Thalassaemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Saudi Arabia	Al-Saeed WY, Al-Dawood KM, Bukhari IA, Bahnassy AA. Prevalence and pattern of skin disorders among female schoolchildren in Eastern Saudi Arabia. <i>Saudi Med J.</i> 2006; 27(2): 227-34.	2003		
Saudi Arabia	Amin TT, Ali A, Kalyadan F. Skin disorders among male primary school children in Al Hassa, Saudi Arabia: prevalence and socio-demographic correlates-a comparison of urban and rural populations. <i>Rural Remote Health.</i> 2011; 11(1517).	2009		
Saudi Arabia	Abolfotoh MA, Ghieth MM, Badawi IA. Hearing loss and other ear problems among schoolboys in Abha, Saudi Arabia. <i>Ann Saudi Med.</i> 1995; 15(4): 323-6.	1993-1995		
Saudi Arabia	Zakouk SM, Jamal TS, Daghistani KJ. Epidemiology of acute otitis media among Saudi children. <i>Int J Pediatr Otorhinolaryngol.</i> 2002; 62(3): 219-22.	1997-2000		
Saudi Arabia	al-Rajeh S, Larbi EB, Bademosi O, Awada A, Yousef A, al-Freih H, Miniawi H. Stroke register: experience from the eastern province of Saudi Arabia. <i>Cerebrovasc Dis.</i> 1998; 8(2): 86-9.	1989-1993		
Saudi Arabia	Al Rajeh S. Stroke in the Elderly Aged 75 Years and Above. <i>Cerebrovasc Dis.</i> 1994; 4(6): 402-6.	1981-1991		
Saudi Arabia	al-Rajeh SM, Larbi EB, al-Freih H, Ahmed K, Muhana F, Bademosi O. A clinical study of stroke. <i>East Afr Med J.</i> 1989; 66(3): 183-91.	1983-1994		
Saudi Arabia	Awada A, Daif A, Obeid T, Al Rajeh S. Nontraumatic cerebral hemorrhage in the young: A study of 107 cases. <i>J Stroke Cerebrovasc Dis.</i> 1998; 7(3): 200-4.	1981-1995		
Saudi Arabia	Awada A, Russell N, Al Rajeh S, Omojola M. Non-traumatic cerebral hemorrhage in Saudi Arabs: a hospital-based study of 243 cases. <i>J Neurol Sci.</i> 1996; 144(1-2): 198-203.	1981-1994		
Saudi Arabia	Awada A. Stroke in Saudi Arabian young adults: a study of 120 cases. <i>Acta Neurol Scand.</i> 1994; 89(5): 323-8.	1983-1993		
Saudi Arabia	Mallick AA, O'Callaghan FJK. The epidemiology of childhood stroke. <i>Eur J Paediatr Neurol.</i> 2010; 14(3): 197-205.	1989-1993		
Saudi Arabia	Muhaimeid H, Zakouk S, Bafaqeh S. Epidemiology of chronic suppurative otitis media in Saudi children. <i>Int J Pediatr Otorhinolaryngol.</i> 1993; 26(2): 101-8.	1988-1990		
Saudi Arabia	Amin TT, Ali A, Kalyadan F. Skin disorders among male primary school children in Al Hassa, Saudi Arabia: prevalence and socio-demographic correlates-a comparison of urban and rural populations. <i>Rural Remote Health.</i> 2011; 11(1): 1517.	2009-2010		
Saudi Arabia	Bahandan K, Mahfouz AA, Tallab T, Badawi IA, al-Amari OM. Skin diseases among adolescent boys in Abha, Saudi Arabia. <i>Int J Dermatol.</i> 1996; 35(6): 405-7.	1995-1996		
Saudi Arabia	Ahanamy A, Shuja M, Khaleel M, Ghazal S, Cherian M, Salman H, Abdul Alim S. Childhood bacterial meningitis in Riyadh. <i>Ann Saudi Med.</i> 1991; 11(6): 628-32.	1985-1990		
Saudi Arabia	Al-Mazrou Y, Al-Jeffri M, Al-Haggag S, Musa E, Mohamed O, Abdalla M. Haemophilus Type B Meningitis in Saudi Children under 5 Years Old. <i>J Trop Pediatr.</i> 2004; 50(3): 131-6.	1999-2001		
Saudi Arabia	Almuneef M, Alshaaan M, Memish Z, Alola SA. Bacterial Meningitis in Saudi Arabia: The Impact of Haemophilus influenzae Type B Vaccination. <i>J Chemother.</i> 2001; 13: 34-9.	1995-2000		
Saudi Arabia	Almuneef M, Memish Z, Khan Y, Kagallwala A, Alshaaan M. Childhood bacterial meningitis in Saudi Arabia. <i>J Infect.</i> 1998; 36(2): 157-60.	1984-1995		
Saudi Arabia	Al-Tawfiq J, AbuKhamis A. Burden and etiology of community-acquired bacterial meningitis in a hospital in Eastern Saudi Arabia: 1993-2005. <i>Med Sci Monit.</i> 2009; 15(2): P110-P114.	1993-2005		
Saudi Arabia	Kheyami AM, Nakagomi T, Nakagomi O, Dove W, Hart CA, Cumliffe NA. Molecular epidemiology of rotavirus diarrhea among children in Saudi Arabia: first detection of G9 and G12 strains. <i>J Clin Microbiol.</i> 2008; 46(4): 1185-9.	2004-2005		
Saudi Arabia	Zaman R. Campylobacter enteritis in Saudi Arabia. <i>Epidemiol Infect.</i> 1992; 108(1): 51-8.	1989-1990		
Saudi Arabia	Al-Nozha MM, Arafath MR, Al-Mazrou YY, Al-Maatouq MA, Khan NB, Khalil MZ, Al-Khadra AH, Al-Marzouki K, Abdullah MA, Al-Harhi SS, Al-Shahid MS, Nouth MS, Al-Mobeireek A. Coronary artery disease in Saudi Arabia. <i>Saudi Med J.</i> 2004; 25(9): 1165-71.	1980-2000		
Saudi Arabia	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998-1999, 2001-2003, 2005-2009		
Saudi Arabia	Al Rajeh S, Bademosi O, Ismail H, Awada A, Dawodu A, al-Freih H, Assuhaimi S, Borollosi M, al-Shanmisi S. A community survey of neurological disorders in Saudi Arabia: the Thughah study. <i>Neuroepidemiology.</i> 1993; 12(3): 164-78.	1989-1990		
Saudi Arabia	Halawa MR, Karawagh A, Zeidan A, Mahmoud AE, Sakr M, Hegazy A. Prevalence of painful diabetic peripheral neuropathy among patients suffering from diabetes mellitus in Saudi Arabia. <i>Curr Med Res Opin.</i> 2010; 26(2): 337-43.	2006-2007		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Saudi Arabia	Alwakeel JS, Al-Suwaidi A, Isnani AC, Al-Harbi A, Alam A. Concomitant macro and microvascular complications in diabetic nephropathy. <i>Saudi J Kidney Dis Transpl</i> . 2009; 20(3): 402-9.	1989-2004		
Saudi Arabia	Khan AR, Wiseberg JA, Lateef ZA, Khan SA. Prevalence and determinants of diabetic retinopathy in Al hasa region of Saudi Arabia: primary health care centre based cross-sectional survey, 2007-2009. <i>Middle East Afr J Ophthalmol</i> . 2010; 17(3): 257-63.	2007-2009		
Saudi Arabia	Warsy AS, el-Hazmi MA. Diabetes mellitus, hypertension and obesity—common multifactorial disorders in Saudis. <i>East Mediterr Health J</i> . 1999; 5(6): 1236-42.	1994		
Saudi Arabia	Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, Al-Harhi SS, Arafah MR, Khalil MZ, Khan NB, Al-Khadra A, Al-Marzouki K, Nough MS, Abdullah M, Attas O, Al-Shahid MS, Al-Mobeireek A. Diabetes mellitus in Saudi Arabia. <i>Saudi Med J</i> . 2004; 25(11): 1603-10.	1998		
Saudi Arabia	Abduljabbar M, Ogunniji A, al Balla S, Albaila S, al-Dalaan A. Prevalence of primary headache syndrome in adults in the Qassim region of Saudi Arabia. <i>Headache</i> . 1996; 36(6): 385-8.	1994-1995		
Saudi Arabia	Al Ghobain MO, Al-Hajjaj MS, Al Moamry MS. Asthma prevalence among 16- to 18-year-old adolescents in Saudi Arabia using the ISAAC questionnaire. <i>BMC Public Health</i> . 2012; 12: 239.	2009-2010	*	
Saudi Arabia	Nahas M, Bhopal R, Anandan C, Elton R, Sheikh A. Prevalence of allergic disorders among primary school-aged children in Madinah, Saudi Arabia: two-stage cross-sectional survey. <i>PLoS One</i> . 2012; 7(5): e36848.	2009	*	
Saudi Arabia	Farsi N. Developmental enamel defects and their association with dental caries in preschoolers in Jeddah, Saudi Arabia. <i>Oral Health Prev Dent</i> . 2010; 8(1): 85-92.	2008	*	
Saudi Arabia	al-Khateeb TL, O'Mullane DM, Whelton H, Sulaiman MI. Periodontal treatment needs among Saudi Arabian adults and their relationship to the use of the Miswak. <i>Community Dent Health</i> . 1991; 8(4): 323-8.	1989	*	
Saudi Arabia	Guile EE. Periodontal status of adults in central Saudi Arabia. <i>Community Dent Oral Epidemiol</i> . 1992; 20(3): 159-60.	1990	*	
Saudi Arabia	Al Faleh FZ, Ali S, Aljebreen AM, Alhammad E, Abdo AA. Seroprevalence rates of <i>Helicobacter pylori</i> and viral hepatitis A among adolescents in three regions of the Kingdom of Saudi Arabia: is there any correlation? <i>Helicobacter</i> . 2010; 15(6): 532-7.	2007-2008		
Saudi Arabia	Abdel-Moneim AS, Bamaga MS, Shehab GM, Abu-Elsaad A-ASA, Farahat FM. HCV infection among Saudi population: high prevalence of genotype 4 and increased viral clearance rate. <i>PLoS One</i> . 2012; 7(1): e29781.	2008-2011		
Saudi Arabia	Al Kahtani MA, AlQahtani M, Alshebaili MM, Abd Elzahr M, Moawad A, Aljohani N. Morbidity and pregnancy outcomes associated with sickle cell anemia among Saudi women. <i>Int J Gynaecol Obstet</i> . 2012; 119(3): 224-6.	2001-2010	*	
Saudi Arabia	Al Jama FE, Gasem T, Burshaid S, Rahman J, Al Suleiman SA, Rahman MS. Pregnancy outcome in patients with homozygous sickle cell disease in a university hospital, Eastern Saudi Arabia. <i>Arch Gynecol Obstet</i> . 2009; 280(5): 793-7.	2000-2008	*	
Saudi Arabia	Al-Arfaj AS, Alballa SR, Al-Saleh SS, Al-Dalaan AM, Bahabry SA, Mousa MA, Al-Sekait MA. Knee osteoarthritis in Al-Qaseem, Saudi Arabia. <i>Saudi Med J</i> . 2003; 24(3): 291-3.	1993-1995		
Saudi Arabia	Al-Dalaan A, Al Ballaa S, Bahabry S, Biyari T, Al Sukait M, Mousa M. The prevalence of rheumatoid arthritis in the Qassim region of Saudi Arabia. <i>Ann Saudi Med</i> . 1998; 18(5): 396-7.	1995		
Saudi Arabia	Abolfotouh MA, Hassan KH, Khattab MS, Youssef RM, Sadek A, El-Sebaiei M. Dental caries: experience in relation to wasting and stunted growth among schoolboys in Abha, Saudi Arabia. <i>Ann Saudi Med</i> . 2000; 20(5-6): 360-3.	1998		
Saudi Arabia	Younes SA, El-Angbawi MF. Dental caries prevalence in intermediate Saudi schoolchildren in Riyadh. <i>Community Dent Oral Epidemiol</i> . 1982; 10(2): 74-6.	1980		
Saudi Arabia	Alamoudi N, Salako NO, Massoud I. Caries experience of children aged 6-9 years in Jeddah, Saudi Arabia. <i>Int J Paediatr Dent</i> . 1996; 6(2): 101-5.	1994		
Saudi Arabia	Khan MU, Abu-Zeid HA, Faraj A. Teething pattern and prevalence of dental caries. <i>Indian J Pediatr</i> . 1990; 57(1): 105-8.	1987		
Saudi Arabia	Paul TR. Dental health status and caries pattern of preschool children in Al-Kharj, Saudi Arabia. <i>Saudi Med J</i> . 2003; 24(12): 1347-51.	1994		
Saudi Arabia	Al-Malik MI, Holt RD, Bedi R. Prevalence and patterns of caries, rampant caries, and oral health in two- to five-year-old children in Saudi Arabia. <i>J Dent Child (Chic)</i> . 2003; 70(3): 235-42.	1998		
Saudi Arabia	al-Mohammadi SM, Rugg-Gunn AJ, Butler TJ. Caries prevalence in boys aged 2, 4 and 6 years according to socio-economic status in Riyadh, Saudi Arabia. <i>Community Dent Oral Epidemiol</i> . 1997; 25(2): 184-6.	1994		
Saudi Arabia	Wyne A, Darwish S, Adenubi J, Battata S, Khan N. The prevalence and pattern of nursing caries in Saudi preschool children. <i>Int J Paediatr Dent</i> . 2001; 11(5): 361-4.	1999		
Saudi Arabia	Wyne AH, Al-Ghannam NA, Al-Shammery AR, Khan NB. Caries prevalence, severity and pattern in pre-school children. <i>Saudi Med J</i> . 2002; 23(5): 580-4.	2000		
Saudi Arabia	Al Mughery AS, Attwood D, Blinkhorn A. Dental health of 5-year-old children in Abu Dhabi, United Arab Emirates. <i>Community Dent Oral Epidemiol</i> . 1991; 19(5): 308-9.	1989		
Saudi Arabia	Al-Malik MI, Holt RD, Bedi R. Erosion, caries and rampant caries in preschool children in Jeddah, Saudi Arabia. <i>Community Dent Oral Epidemiol</i> . 2002; 30(1): 16-23.	2000		
Saudi Arabia	al-Tamimi S, Petersen PE. Oral health situation of schoolchildren, mothers and schoolteachers in Saudi Arabia. <i>Int Dent J</i> . 1998; 48(3): 180-6.	1996		
Saudi Arabia	Al-Malik MI, Rehbi YA. Prevalence of dental caries, severity, and pattern in age 6 to 7-year-old children in a selected community in Saudi Arabia. <i>J Contemp Dent Pract</i> . 2006; 7(2): 46-54.	2004		
Saudi Arabia	Wyne AH. Caries prevalence, severity, and pattern in preschool children. <i>J Contemp Dent Pract</i> . 2008; 9(3): 24-31.	2006		
Saudi Arabia	Paul T, Maktabi A. Caries experience of 5-year-old children in Alkharj, Saudi Arabia. <i>Int J Paediatr Dent</i> . 1997; 7(1): 43-4.	1995		
Saudi Arabia	Ayoola A, Banzal S, Elamin A, Gadour M, Elsammani E, Al-Hazmi M. Profile of stroke in Gizan, Kingdom of Saudi Arabia. <i>Neurosciences (Riyadh, Saudi Arabia)</i> . 2003; 8(4): 229-32.	1997-1998		
Saudi Arabia	Ministry of Health (Saudi Arabia), Saudi Center for Organ Transplantation, Saudi Arabia Center for Organ Transplantation Annual Report 2008. Riyadh, Saudi Arabia: Saudi Center for Organ Transplantation.	2008		
Saudi Arabia	Ministry of Health (Saudi Arabia), Saudi Center for Organ Transplantation, Saudi Arabia Center for Organ Transplantation Annual Report 2009. Riyadh, Saudi Arabia: Saudi Center for Organ Transplantation.	1992-1995		
Saudi Arabia	Rasheed P, Al-Sowielem LS. Prevalence and predictors of premenstrual syndrome among college-aged women in Saudi Arabia. <i>Ann Saudi Med</i> . 2003; 23(6): 381-7.	1999		
Saudi Arabia	Al-Arfaj AS, Al-Saleh SS, Alballa SR, Al-Dalaan AN, Bahabry SA, Al-Sekait MA, Mousa MA. How common is back pain in Al-Qaseem region. <i>Saudi Med J</i> . 2003; 24(2): 170-3.	1993-1995		
Saudi Arabia	Hossain A. Herpes simplex virus type 1 (HSV-1) and varicella-zoster virus (VZV) infections in Saudi Arabia. <i>J Trop Pediatr</i> . 1989; 35(4): 171-4.	1986		
Saudi Arabia	Zakzouk SM, Al-Anazy F. Sensorineural hearing impaired children with unknown causes: a comprehensive etiological study. <i>Int J Pediatr Otorhinolaryngol</i> . 2002; 64(1): 17-21.	1999-2001		
Saudi Arabia	al-Sekait MA, al-Swielem AA, Tahir M. Rheumatic heart disease in schoolchildren in western district, Saudi Arabia. <i>J R Soc Health</i> . 1990; 110(1): 15-6, 19.	1987		
Saudi Arabia	Abdelaziz A, Maher MA, Sayyed TM, Bazeed MF, Mohamed NS. Early pregnancy screening for hypertensive disorders in women without a-priori high risk. <i>Ultrasound Obstet Gynecol</i> . 2012; 40(4): 398-405.	2009-2010	*	
Saudi Arabia	Gasim T. Gestational diabetes mellitus: maternal and perinatal outcomes in 220 Saudi women. <i>Oman Med J</i> . 2012; 27(2): 140-4.	2001-2008	*	
Saudi Arabia	Al Rajeh S, Awada A, Bademosi O, Ogunniji A. The prevalence of epilepsy and other seizure disorders in an Arab population: a community-based study. <i>Seizure</i> . 2001; 10(6): 410-4.	1989	*	
Saudi Arabia	Fashir B, Sivasubramanian V, Al Momen S, Assaf H. Pattern of liver disease in a Saudi patient population: a decade of experience at security forces hospital, Riyadh, KSA. <i>Saudi J Gastroenterol</i> . 1996; 2(1): 50-2.	1983-1993		
Saudi Arabia	Jamjoom GA, Quli SK. Serodiagnosis of hepatitis C in acute and chronic liver disease in southwestern Saudi Arabia. <i>J Trop Med Hyg</i> . 1992; 95(6): 428-31.	1990-1991		
Saudi Arabia	Ayoola EA, Gadour MOEH. Hepatocellular carcinoma in Saudi Arabia: role of hepatitis B and C infection. <i>J Gastroenterol Hepatol</i> . 2004; 19(6): 665-9.	1995-1996		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Saudi Arabia	Al-Kassimi FA, Abdullah AK, Al-Hajjaj MS, Al-Orainey JO, Bangboye EA, Chowdhury MNH. Nationwide community survey of tuberculosis epidemiology in Saudi Arabia. <i>Tuber Lung Dis.</i> 1993; 74(4): 254-60.	1993		
Saudi Arabia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2001, 2004, 2007, 2010, 2012		
Saudi Arabia	Badr IA, Saif AM, Al-Rajhi AA. Changing patterns of visual loss in the Eastern Province, Kingdom of Saudi Arabia. <i>Saudi J Ophthalmol.</i> 2004; 18: S16-S164. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1984, 1989-1990		
Saudi Arabia	Al-Faran MF, al-Rajhi AA, al-Omar OM, al-Ghamdi SA, Jabak M. Prevalence and causes of visual impairment and blindness in the south western region of Saudi Arabia. <i>Int Ophthalmol.</i> 1993; 17(3): 161-5. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1991		
Saudi Arabia	Ito BA, Al-Hawsawi ZM, Khan AH. Hypoxic ischemic encephalopathy. Incidence and risk factors in North Western Saudi Arabia. <i>Saudi Med J.</i> 2003; 24(2): 147-53.	1995-1996	*	†
Saudi Arabia	Al-Baghli NA, Al-Ghamdi AJ, Al-Turki KA, Al-Elq AH, El-Zubairi AG, Bahnassy A. Prevalence of diabetes mellitus and impaired fasting glucose levels in the Eastern Province of Saudi Arabia: results of a screening campaign. <i>Singapore Med J.</i> 2010; 51(12): 923-30.	2004-2005		
Saudi Arabia	Alqurashi KA, Aljabri KS, Bokhari SA. Prevalence of diabetes mellitus in a Saudi community. <i>Ann Saudi Med.</i> 2011; 31(1): 19-23.	2009		
Saudi Arabia	Habeb AM, Al-Magamsi MSF, Eid IM, Ali MI, Hattersley AT, Hussain K, Ellard S. Incidence, genetics, and clinical phenotype of permanent neonatal diabetes mellitus in northwest Saudi Arabia. <i>Pediatr Diabetes.</i> 2012; 13(6): 499-505.	2001-2010		
Saudi Arabia	Habeb AM, Al-Magamsi MS, Halabi S, Eid IM, Shalaby S, Bakoush O. High incidence of childhood type 1 diabetes in Al-Madinah, North West Saudi Arabia (2004-2009). <i>Pediatr Diabetes.</i> 2011; 12(8): 676-81.	2004-2009		
Saudi Arabia	Beutler E, Johnson C, Powars D, West C. Prevalence of Glucose-6-Phosphate Dehydrogenase Deficiency in Sickle-Cell Disease. <i>N Engl J Med.</i> 1974; 290(15): 826-8.	1983-1985		
Saudi Arabia	el-Hazmi MA, Al-Swailem AR, Al-Faleh FZ, Warsy AS. Frequency of glucose-6-phosphate dehydrogenase, pyruvate kinase and hexokinase deficiency in the Saudi population. <i>Hum Hered.</i> 1986; 36(1): 45-9.	1984-1986		
Saudi Arabia	Samuel AP, Saha N. Distribution of red cell G6PD and 6PGD phenotypes in Saudi Arabia. <i>Trop Geogr Med.</i> 1986; 38(3): 287-91.	1984-1986		
Saudi Arabia	Saleem TH, Mendis BS, Osanyintuyo SO. Glucose-6-phosphate dehydrogenase deficiency in a rural Saudi population. <i>J Trop Med Hyg.</i> 1991; 94(5): 327-8.	1986-1990		
Saudi Arabia	el-Hazmi MA, Warsy AS. Frequency of glucose-6-phosphate dehydrogenase phenotypes and deficiency in Al-Baha. <i>Hum Hered.</i> 1989; 39(6): 313-7.	1987-1989		
Saudi Arabia	el-Hazmi MA, Jabbar FA, Al-Faleh FZ, Al-Swailem AR, Warsy AS. Patterns of sickle cell, thalassaemia and glucose-6-phosphate dehydrogenase deficiency genes in north-western Saudi Arabia. <i>Hum Hered.</i> 1991; 41(1): 26-34.	1989-1991		
Saudi Arabia	el-Hazmi MA, Warsy AS, Bahakim HH, al-Swailem A. Glucose-6-phosphate dehydrogenase deficiency and the sickle cell gene in Makkah, Saudi Arabia. <i>J Trop Pediatr.</i> 1994; 40(1): 12-6.	1992-1994		
Saudi Arabia	el-Hazmi MA, al-Swailem A, Warsy AS. Glucose-6-phosphate dehydrogenase deficiency and sickle cell genes in Bisha. <i>J Trop Pediatr.</i> 1995; 41(4): 225-9.	1993-1995		
Saudi Arabia	al-Nuaim L, Talib ZA, el-Hazmi MA, Warsy AS. Sickle cell and G-6-PD deficiency gene in cord blood samples: experience at King Khalid University Hospital, Riyadh. <i>J Trop Pediatr.</i> 1997; 43(2): 71-4.	1994-1995		
Saudi Arabia	Muzaffer MA. Neonatal screening of glucose-6-phosphate dehydrogenase deficiency in Yanbu, Saudi Arabia. <i>J Med Screen.</i> 2005; 12(4): 170-1.	1996-1998		
Saudi Arabia	el-Hazmi MA. Genetic diseases in Arab populations. <i>East Mediterr Health J.</i> 1999; 5(6): 1102-3.	1997-1999		
Saudi Arabia	Ibrahim MA, Kordy MN. End-stage renal disease (ESRD) in Saudi Arabia. <i>Asia Pac J Public Health.</i> 1992; 6(3): 140-5.	1985-1986		
Saudi Arabia	Mitwalli AH, Al-Swailem AR, Aziz KM, Aswad S, Paul T, Mohammed AR, Diwan M, Wafa AM. The incidence of end-stage renal disease in two regions of Kingdom of Saudi Arabia. <i>Saudi J Kidney Dis Transpl.</i> 1995; 6(3): 280-5.	1988		
Saudi Arabia	Nielsen JV. Peripheral neuropathy, hypertension, foot ulcers and amputations among Saudi Arabian patients with type 2 diabetes. <i>Diabetes Res Clin Pract.</i> 1998; 41(1): 63-9.	1995-1996		
Saudi Arabia	al-Khateeb TL, O'Mullane D, Whelton H. Comparison of the need for periodontal care amongst 15-year-old children in Ireland and Saudi Arabia as assessed by CPITN. <i>Community Dent Oral Epidemiol.</i> 1990; 18(1): 55.	1984		
Saudi Arabia	Alsuwaidi AO, Farag YMK, Al Sayyari AA, Mousa D, Alhejaili F, Al-Harbi A, Housawi A, Mittal BV, Singh AK. Epidemiology of chronic kidney disease in the Kingdom of Saudi Arabia (SEEK-Saudi investigators) - a pilot study. <i>Saudi J Kidney Dis Transpl.</i> 2010; 21(6): 1066-72.	2008	*	
Saudi Arabia	Zakzouk SM, al-Muhaimeed HS. Hearing impairment among 'at risk' children. <i>Int J Pediatr Otorhinolaryngol.</i> 1996; 34(1-2): 75-85.	1988-1990	*	
Saudi Arabia	Nawaz Z, Mushtaq F, Mousa D, Rehman E, Sulaiman M, Aslam N, Khawaja N. Pattern of glomerular disease in the Saudi population: a single-center, five-year retrospective study. <i>Saudi J Kidney Dis Transpl.</i> 2013; 24(6): 1265-70.	2005-2009	*	
Saudi Arabia	World Health Organization (WHO). Saudi Arabia WHO Leishmaniasis Country Profile.	1999-2009	*	
Saudi Arabia	Saudia Arabia National Iodine Deficiency Disorders Survey 1994-1995 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1994-1995		
Saudi Arabia	Al-Aboud F, Al-Aboud K. Leprosy in Saudi Arabia. <i>Lepr Rev.</i> 2007; 78(4): 405-8.	1995-2005	*	
Saudi Arabia	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Saudi Arabia	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec.</i> 2007; 82(25): 225-32.	2006	*	
Saudi Arabia	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Saudi Arabia	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Saudi Arabia	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Saudi Arabia	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec.</i> 2008; 83(33): 293-300.	2007	*	
Saudi Arabia	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Saudi Arabia	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Saudi Arabia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Saudi Arabia	Ghazal HO, Telmesani AM, Mahomed MF. TORCH agents in pregnant Saudi women. <i>Med Princ Pract.</i> 2002; 11(4): 180-2.	1999-2001	*	
Saudi Arabia	Al-Ghamdi AH, Rabiu M, Hajar S, Yorston D, Kuper H, Polack S. Rapid assessment of avoidable blindness and diabetic retinopathy in Taif, Saudi Arabia. <i>Br J Ophthalmol.</i> 2012; 96(9): 1168-72.	2009-2011	*	
Saudi Arabia	Fakeeh M, Zaki A. Dengue in Jeddah, Saudi Arabia, 1994-2002. <i>Dengue Bull.</i> 2003; 27: 13-8.	1995-2002		
Saudi Arabia	Binkhathlan AA, Almahmoud LA, Saleh MJ, Sringeri S. Retinopathy of prematurity in Saudi Arabia: incidence, risk factors, and the applicability of current screening criteria. <i>Br J Ophthalmol.</i> 2008; 92(2): 167-9.	2004	*	†
Saudi Arabia	Abu-Eshy SA, Abolfotouh MA, Al-Naggar YM. Endemic goitre in schoolchildren in high and low altitude areas of Asir region, Saudi Arabia. <i>Saudi Med J.</i> 2001; 22(2): 146-9 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2001		
Saudi Arabia	Bakir TM, Hossain A, De-Silva S, Siddiqui A, Sengupta BS, el-Sheikh MM, Bakir AF. Enzyme immunoassay in the diagnosis of Chlamydia trachomatis infections in diverse patient groups. <i>J Hyg Epidemiol Microbiol Immunol.</i> 1989; 33(2): 189-97.	1989		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Saudi Arabia	Guile EE, al-Shammery A, el-Backly M. Prevalence and severity of periodontal diseases in Saudi Arabian schoolchildren aged 6, 9 and 12 years. <i>Community Dent Health</i> . 1990; 7(4): 429-32.	1987-1988	*	
Saudi Arabia	Akpa ES, al-Shammery AR, Saeed HI. Dental caries, sugar consumption and restorative dental care in 12-13-year-old children in Riyadh, Saudi Arabia. <i>Community Dent Oral Epidemiol</i> . 1992; 20(6): 343-6.	1989-1990	*	
Saudi Arabia	Al Dosari AM, Wyne AH, Akpa ES, Khan NB. Caries prevalence and its relation to water fluoride levels among schoolchildren in Central Province of Saudi Arabia. <i>Int Dent J</i> . 2004; 54(6): 424-8.	2001-2002	*	
Saudi Arabia	al-Khateeb TL, Darwish SK, Bastawi AE, O'Mullane DM. Dental caries in children residing in communities in Saudi Arabia with differing levels of natural fluoride in the drinking water. <i>Community Dent Health</i> . 1990; 7(2): 165-71.	1987-1988	*	
Saudi Arabia	Al-Sekait MA, Al-Nasser A. Dental Caries Prevalence in Primary Saudi Schoolchildren in Riyadh District. <i>Saudi Med J</i> . 1988; 9(6): 606-9.	1986	*	
Saudi Arabia	al-Shammery AR. Caries experience of urban and rural children in Saudi Arabia. <i>J Public Health Dent</i> . 1999; 59(1): 60-4.	1994	*	
Saudi Arabia	Al-Wazzan KA. Dental caries prevalence in 6-7 year-old schoolchildren in Riyadh region: A comparative study with the 1987 - Oral Health Survey of Saudi Arabia Phase I. <i>Saudi Dent J</i> . 2004; 16(2): 54-61.	2002	*	
Saudi Arabia	Khan NB, Al-Ghannam NA, Al Shammery AR, Wyne AH. Caries in primary school children: prevalence, severity and pattern in Al-Ahsa, Saudi Arabia. <i>Saudi Dent J</i> . 2001; 13(2): 71-4.	1997	*	
Saudi Arabia	Mansour M, Anwar S, Pine C. Comparison of caries in 6-7 year old Saudi girls attending public and Armed Forces schools in Riyadh, Saudi Arabia. <i>Saudi Dent J</i> . 2000; 12(1): 33-6.	1996-1997	*	
Saudi Arabia	Wyne AH, Al-Ghorabi BM, Al-Asiri YA, Khan NB. Caries prevalence in Saudi primary schoolchildren of Riyadh and their teachers' oral health knowledge, attitude and practices. <i>Saudi Med J</i> . 2002; 23(1): 77-81.	1999-2000	*	
Saudi Arabia	el-Hazmi MA, Warsy AS. Interaction between glucose-6-phosphate dehydrogenase deficiency and sickle cell gene in Saudi Arabia. <i>Trop Geogr Med</i> . 1987; 39(1): 32-5.	1984-1986	*	
Saudi Arabia	Nasserullah Z, Al Jame A, Abu Srair H, Al Qatari G, Al Naim S, Al Aqib A, Mokhtar M. Neonatal screening for sickle cell disease, glucose-6-phosphate dehydrogenase deficiency and a-thalassemia in Qatif and Al Hasa. <i>Ann Saudi Med</i> . 1998; 18(4): 289-92.	1992-1993	*	
Saudi Arabia	El-Gilany A-H, Hammad S, Refaat K, Al-Enazi R. Seroprevalence of hepatitis A antibodies among children in a Saudi community. <i>Asian Pac J Trop Med</i> . 2010; 3(4): 278-82.	2006-2007	*	
Saudi Arabia	Al-Awamy BH, Al-Muzan M, Al-Turki M, Serjeant GR. Neonatal screening for sickle cell disease in the Eastern Province of Saudi Arabia. <i>Trans R Soc Trop Med Hyg</i> . 1984; 78(6): 792-94.	1982-1983	*	
Saudi Arabia	Abu-Eshy SA, Mahfouz AA, Badr A, El Gamal MN, Al-Shehri MY, Salati MI, Rabie ME. Prevalence and risk factors of gallstone disease in a high altitude Saudi population. <i>East Mediterr Health J</i> . 2007; 13(4): 794-802.	2005		
Saudi Arabia	Arif M, Qattan I, al-Faleh F, Ramia S. Epidemiology of hepatitis E virus (HEV) infection in Saudi Arabia. <i>Ann Trop Med Parasitol</i> . 1994; 88(2): 163-8.	1990-1993	*	
Saudi Arabia	Abdelaal M, Zawawi TH, Sobhi E al, Jeje O, Gilpin C, Kinsara A, Osoba A, Oni GA. Epidemiology of hepatitis E virus in male blood donors in Jeddah, Saudi Arabia. <i>Ir J Med Sci</i> . 1998; 167(2): 94-6.	1995	*	
Saudi Arabia	Ramia S. Antibody against hepatitis A in Saudi Arabians and in expatriates from various parts of the world working in Saudi Arabia. <i>J Infect</i> . 1986; 12(2): 153-5.	1985		
Saudi Arabia	Fathalla SE, Al-Jama AA, Al-Sheikh IH, Islam SI. Seroprevalence of hepatitis A virus markers in Eastern Saudi Arabia. <i>Saudi Med J</i> . 2000; 21(10): 945-9.	1987-1999		
Saudi Arabia	el-Hazmi MA. Hepatitis A antibodies: prevalence in Saudi Arabia. <i>J Trop Med Hyg</i> . 1989; 92(6): 427-30.	1988		
Saudi Arabia	Al Rashed RS. Prevalence of hepatitis A virus among Saudi Arabian children: A community-based study. <i>Ann Saudi Med</i> . 1997; 17(2): 200-3.	1989-1990		
Saudi Arabia	Arif M. Enterically transmitted hepatitis in Saudi Arabia: an epidemiological study. <i>Ann Trop Med Parasitol</i> . 1996; 90(2): 197-201.	1995		
Saudi Arabia	Khalil M, Al-Mazrou Y, Al-Jeffri M, Al-Howasi M. Childhood epidemiology of hepatitis A virus in Riyadh, Saudi Arabia. <i>Ann Saudi Med</i> . 1998; 18(1): 18-21.	1995-1996		
Saudi Arabia	Jaber SM. Prevalence of anti-hepatitis B and anti-hepatitis A antibodies among school aged children in Western Saudi Arabia. <i>Saudi Med J</i> . 2006; 27(10): 1515-22.	2004		
Saudi Arabia	Almuneef MA, Memish ZA, Balkhy HH, Qahtani M, Alotaibi B, Hajeer A, Qasim L, Al Knawy B. Epidemiologic shift in the prevalence of Hepatitis A virus in Saudi Arabia: a case for routine Hepatitis A vaccination. <i>Vaccine</i> . 2006; 24(27-28): 5599-603.	2005		
Saudi Arabia	Al Faleh F, Al Shehri S, Al Ansari S, Al Jeffri M, Al Mazrou Y, Shaffi A, Abdo A-A. Changing patterns of hepatitis A prevalence within the Saudi population over the last 18 years. <i>World J Gastroenterol</i> . 2008; 14(48): 7371-5.	2007-2008		
Saudi Arabia	Eweidah MH, Rahiman S, Ali MDH, Al-Shamary AMD. Distribution of ABO and Rhesus (RHD) Blood Groups in Al-Jouf Province of the Saudi Arabia. <i>Anthropologist</i> . 2011; 13(2): 99-102.	2008-2010	*	†
Saudi Arabia	al-Faleh FZ, Ramia S, Arif M, Ayoola EA, al-Rashed RS, al-Jeffri M, Hossain A, el-Hazmi M. Profile of hepatitis C virus and the possible modes of transmission of the virus in the Gizan area of Saudi Arabia: a community-based study. <i>Ann Trop Med Parasitol</i> . 1995; 89(4): 431-7.	1993, 1995		
Saudi Arabia	Al-Traif I, Ali A, Dafalla M, Al-Tamimi W, Qassem L. Prevalence of hepatitis delta antibody among HBsAg carriers in Saudi Arabia. <i>Ann Saudi Med</i> . 2004; 24(5): 343-4.	1996-1997		
Saudi Arabia	Bakir TM, Kurbaan KM, al Fawaz I, Ramia S. Infection with hepatitis viruses (B and C) and human retroviruses (HTLV-1 and HIV) in Saudi children receiving cycled cancer chemotherapy. <i>J Trop Pediatr</i> . 1995; 41(4): 206-9.	1993, 1995		
Saudi Arabia	El-Hazmi MM. Prevalence of HBV, HCV, HIV-1, 2 and HTLV-III infections among blood donors in a teaching hospital in the Central region of Saudi Arabia. <i>Saudi Med J</i> . 2004; 25(1): 26-33.	2000-2002		
Saudi Arabia	Panhotra BR, Al-Bahrani A, Ul-Hassan Z. Epidemiology of antibody to hepatitis B core antigen screening among blood donors in Eastern Saudi Arabia. Need to replace the test by HBV DNA testing. <i>Saudi Med J</i> . 2005; 26(2): 270-3.	2000-2003		
Saudi Arabia	Shobokhi OA, Serebour FE, Al-Drees AZ, Mitwalli AH, Qahtani A, Skakni LI. Hepatitis C virus seroprevalence rate among Saudis. <i>Saudi Med J</i> . 2003; 23(8): 881-6.	1998-2002		
Saudi Arabia	Tamimi WG, Altraif IM, Auumah A, Albuhanian BS, Alenzi FQB, Bernvil S, Sonbol RH, Cruse RJ. Impact of new AABB guidelines on hepatitis B and C testing among Saudi blood donors. <i>Br J Biomed Sci</i> . 2004; 61(4): 215-7.	1992-2002		
Saudi Arabia	Zekri A-RN, Awlia AA, El Mahalawi H, Ismail EF, Mabrouk GM. Evaluation of blood units with isolated anti HBC for the presence of HBV DNA. <i>Dis Markers</i> . 2002; 18(3): 107-10.	1999-2000		
Saudi Arabia	World Health Organization (WHO). Report of the Consultative Meeting on Cutaneous Leishmaniasis. Geneva, Switzerland: World Health Organization (WHO), 2008.	1980		
Saudi Arabia	World Health Organization (WHO). Dengue: guidelines for diagnosis, treatment, prevention and control. Geneva, Switzerland: World Health Organization (WHO), 2009.	2005		
Saudi Arabia	Annual Report on Malaria Control Programme in the Kingdom of Saudi Arabia 1986 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Saudi Arabia	Hammouda NA, Lebshtein AK, Abdel Fattah MM, Wasfi AS, Omar EA, Higazi NA. Parasitic infections and nutritional status of school children in the western region of Saudi Arabia. <i>J Egypt Soc Parasitol</i> . 1986; 16(2): 675-88 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Saudi Arabia	Saudi Arabia Medical Service Department Birth Defect Registry Data 2010 - ICBD/SR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
Senegal	Diallo S, Ndir O, Faye O, Diop BM, Dieng Y, Bah IB, Dieng T, Gaye O, Konate L, Faye O. [Malaria in the southern sanitary district of Dakar (Senegal)]. 1. Parasitemia and malarial attacks. <i>Bull Soc Pathol Exot</i> . 1998; 91(3): 208-13. as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994-1995	*	
Senegal	Senegal Malaria Indicator Survey 2008-2009 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008-2009	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Senegal	Department of Statistics (Senegal), Westinghouse; Institute for Resource Development. Senegal Demographic and Health Survey 1986. Columbia, United States: Westinghouse; Institute for Resource Development.	1986		†
Senegal	Directorate of Forecasting and Statistics (Senegal), Macro International, Inc. Senegal Demographic and Health Survey 1992-1993. Calverton, United States: Macro International, Inc.	1992-1993		†
Senegal	Directorate of Forecasting and Statistics (Senegal), Macro International, Inc. Senegal Demographic and Health Survey 1997. Calverton, United States: Macro International, Inc.	1997		
Senegal	World Health Organization (WHO). Senegal World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Senegal	Ministry of Health and Prevention (Senegal), Research Center for Human Development (Senegal). Senegal Demographic and Health Survey 2005. Calverton, United States: Macro International, Inc.	2005		†
Senegal	Department of Statistics (Senegal), International Statistical Institute. Senegal World Fertility Survey 1978. Voorburg, Netherlands: International Statistical Institute.	1978		
Senegal	Directorate of Forecasting and Statistics (Senegal), Ministry of Economics and Finance (Senegal), United Nations Children's Fund (UNICEF). Senegal Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Senegal	Center for Research in Human Development (CRDH), Cheikh Anta Diop University, Hospital Aristide Le Dantec, ICF Macro, National Agency of Statistics and Demography (Senegal). Senegal Demographic and Health Survey 2010-2011. Calverton, United States: ICF Macro.	2010-2011	*	†
Senegal	ICF International, Ministry of Health and Social Action (Senegal), National Agency of Statistics and Demography (Senegal). Senegal Continuous Service Provision Assessment 2012-2013. Fairfax, United States: ICF International.	2012-2013	*	
Senegal	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Senegal	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Senegal	Thiam M. Cardiac insufficiency in the African cardiology milieu. Bull Soc Pathol Exot. 2003; 96(3): 217-8.	2006		
Senegal	Soumaré M, Seydi M, Ndour CT, Diack KC, Diop BM, Kane A. Cardiovascular events in the course of tetanus: a prospective study on 30 cases in the infectious diseases clinic, in the Fann teaching hospital, Dakar. Med Mal Infect. 2005; 35(9): 450-4.	2002		
Senegal	Soumaré M, Seydi M, Ndour CT, Ndour JD, Diop BM. Epidemiology, clinical features and prognosis of juvenile tetanus in Dakar. Senegal. Bull Soc Pathol Exot. 2005; 98(5): 371-3.	2002		
Senegal	Soumaré M, Seydi M, Dia NM, Diop SA, Ndour CT, Diouf L, Diop BM, Sow PS. Post-circumcision tetanus in Dakar, Senegal. Bull Soc Pathol Exot. 2008; 101(1): 54-7.	1999-2006		
Senegal	Gassama A, Sow PS, Fall F, Camara P, Guèye-N'diaye A, Seng R, Samb B, M'Boup S, Aidara-Kane A. Ordinary and opportunistic enteropathogens associated with diarrhea in Senegalese adults in relation to human immunodeficiency virus serostatus. Int J Infect Dis. 2001; 5(4): 192-8.	1997-2000		
Senegal	Cisse MF, Bg M, Breugelmanns JG, Mueller JE, Gessner BD, Diop MB, Koffi D, Faye PC, Mhlanga B. The elimination of haemophilus influenzae type b meningitis following conjugate vaccine introduction in Senegal. Pediatr Infect Dis J. 2010; 29(6): 499-503.	2003-2007		
Senegal	De Bernis L, Dumont A, Bouillin D, Gueye A, Dompnier J-P, Bouvier-Colle M-H. Maternal morbidity and mortality in two different populations of Senegal: a prospective study (MOMA survey). BJOG. 2000; 107(1): 68-74.	1994-1996		
Senegal	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1981, 1995-1996		
Senegal	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1991-1993, 1997, 1999-2001, 2003-2006, 2008-2009		
Senegal	Thomson J, Spiegel A, Diallo M, Sylla R, Fall A, Mondo M, Fontenille D. Yellow fever outbreak in Kaffrine, Senegal 1996: epidemiological and entomological findings. Trop Med Int Health. 1998; 3(11): 872-7.	1996		†
Senegal	World Health Organization (WHO). Yellow fever in Africa and South America, 2007. Wkly Epidemiol Rec. 2009; 84(13): 97-104.	2007		
Senegal	WHO Global Alert and Response (GAR). Yellow Fever in Senegal—1 December 2011. Geneva, Switzerland: World Health Organization (WHO), 2011.	2010		
Senegal	World Health Organization (WHO). Yellow fever virus surveillance in Western Africa. Wkly Epidemiol Rec. 1994; 69(13): 93-5.	1983, 1987, 1989-1990, 1992-1993		
Senegal	Niang SO, Dieng MT, Kane A, Diop SN, Ndiaye B. Sarcoidosis in Dakar: 30 case reports. Dakar Med. 2007; 52(3): 216-22.	1968-1998		
Senegal	ICF International, Ministry of Health and Social Action (Senegal), National Agency of Statistics and Demography (Senegal). Senegal Continuous Demographic and Health Survey 2012-2013. Fairfax, United States: ICF International, 2014.	2012	*	†
Senegal	Pessinaba S, Mbaye A, Kane A, Guene BD, Mbaye Ndour M, Niang K, Jobe M, Cazaubon M, Mathieu J-BS, Kane M, Sow DD, Diack B, Kane A. [Screening for asymptomatic peripheral arterial occlusive disease of the lower limbs by measuring the ankle-brachial index in the general population (Senegal)]. J Mal Vasc. 2012; 37(4): 195-200.	2010		
Senegal	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Senegal	Gueye Ndiaye A, Faye CM, Ndiaye I, Fall K, Gueye Gaye A, Diop IL, M'bout S. Screening for HIV, syphilis, Chlamydia trachomatis and Neisseria gonorrhoeae during a combined survey conducted in Malicouana, a Senegalese rural area. Bull Soc Pathol Exot. 2009; 102(3): 150-4.	1989-1993, 2003		
Senegal	Ndoye NF, Sow AD, Diop AG, Sessouma B, Séné-Diouf F, Boissy L, Wone I, Touré K, Ndiaye M, Ndiaye P, de Boer H, Engel J, Mandhate C, Meinardi H, Prilipko L, Sander JWAS. Prevalence of epilepsy its treatment gap and knowledge, attitude and practice of its population in sub-urban Senegal an ILAE/IBE/WHO study. Seizure. 2005; 14(2): 106-11.	2004	*	†
Senegal	Mbaye PS, Renaudineau Y, Diallo A, Haudrechy D, Sane M, Michel G, Raphenon G, Klotz F. [Hepatitis C virus and chronic hepatopathies in Dakar: case-control study]. Med Trop (Mars). 2000; 60(1): 47-52.	1995		
Senegal	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2010, 2012		
Senegal	Duboz P, Chapuis-Lucciani N, Boëtsch G, Gueye L. Prevalence of diabetes and associated risk factors in a Senegalese urban (Dakar) population. Diabetes Metab. 2012; 38(4): 332-6.	2009		
Senegal	Linhard J, Baylet R, Malvoisin J. First results on glucose-6-phosphate dehydrogenase deficiencies in the Dakar region. Preliminary notes. Bull Soc Med Afr Noire Lang Fr. 1964; 269-70.	1962-1964		
Senegal	Sokhna CS, Rogier C, Dieye A, Trape JF. Host factors affecting the delay of reappearance of Plasmodium falciparum after radical treatment among a semi-immune population exposed to intense perennial transmission. Am J Trop Med Hyg. 2000; 62(2): 266-70.	1992		
Senegal	De Araujo C, Migot-Nabias F, Guitard J, Pelleau S, Vulliamy T, Ducrocq R. The role of the G6PD Aeth376G/968C allele in glucose-6-phosphate dehydrogenase deficiency in the seerer population of Senegal. Haematologica. 2006; 91(2): 262-3.	2004-2006		
Senegal	Naicker S. Burden of end-stage renal disease in sub-Saharan Africa. Clin Nephrol. 2010; 74(Suppl 1): S13-6.	2008-2010		
Senegal	Seydi M, Soumaré M, Sow AI, Diop BM, Sow PS. Aspects actuels des bactériémies à Salmonella à la clinique des maladies infectieuses Ibrahim Diop Mar du centre hospitalier national de Fann (Sénégal). Med Mal Infect. 2005; 35(1): 23-7.	1996-2003	*	
Senegal	Diallo S, Konate L, Ndir O, Dieng T, Dieng Y, Bah IB, Faye O, Gaye O. [Malaria in the central health district of Dakar (Senegal). Entomological, parasitological and clinical data]. Sante. 2000; 10(3): 221-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996-1997	*	†
Senegal	World Health Organization (WHO). Senegal WHO Leishmaniasis Country Profile.	1994-2008	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Senegal	Damasceno A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D, Dzudie A, Kouam CK, Suliman A, Schrueder N, Yonga G, Ba SA, Maru F, Alemayehu B, Edwards C, Davison BA, Cotter G, Sliwa K. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. <i>Arch Intern Med.</i> 2012; 172(18): 1386-94.	2007-2010		
Senegal	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec.</i> 2006; 81(32): 309-16.	2005	*	
Senegal	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Senegal	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Senegal	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Senegal	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Senegal	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Senegal	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Senegal	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Senegal	Camara B, Faye P-M, Diouf S, Gueye-Diagne N-R, Diagne I, Cissé M-F, Ba M, Sow H-D, Kuakui N. Méningite pédiatrique à haemophilus influenzae b à Dakar. <i>Med Mal Infect.</i> 2007; 37(11): 753-7.	1985-2000		
Senegal	Lazarus JH, Parkes AB, John R, NDiaye M, Pryor-Jones SG. Endemic goitre in Senegal—thyroid function etiological factors and treatment with oral iodized oil. <i>Acta Endocrinol.</i> 1992; 126(2): 149-54 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1987		
Senegal	Dillon J, Sall G, Ciomei G, Fèvre D, Monnerie F, Fouere T, Chevalier P. Prevalence de la carence en iode et du goitre endémique au Sénégal oriental et en Casamance. <i>Med Afr Noire.</i> 2000 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1995-1997		
Senegal	Monlun E, Zeller H, Traore-Lamizana M, Hervy JP, Adam F, Mondo M, Digoutte JP. Caractères cliniques et épidémiologiques de la dengue 2 au Sénégal. <i>Med Mal Infect.</i> 1992; 22(8-9): 718-21.	1990		
Senegal	N'Diaye IP, Mauferon JB, Diagne M. Épidémiologie de l'épilepsie au Sénégal [Epidemiology of Epilepsy in Senegal]. Presented at: 7th Congress of the Pan-African Association of Neurological Sciences; 1986 Apr 23-30; Abidjan, Cote d'Ivoire.	1982-1985	*	
Senegal	Barin F, Denis F, Chotard J, Paulin R, Diop Mar I, Chiron JP, Maupas P, Goudeau A, Coursaget P. [Sero-epidemiological study of hepatitis A infection in Senegalese children (author's transl)]. <i>Ann Pediatr (Paris).</i> 1980; 27(8): 539-42.	1980		
Senegal	Baylet R, Lemaire JM, Ridet J. [Sero-epidemiology of hepatitis A. Results obtained in Senegal (Fleuve and Casamance regions) (author's transl)]. <i>Pathol Biol.</i> 1981; 29(4): 217-21.	1980		
Senegal	Vangenderhuysen C, Prual A, Ould el Joud D. Obstetric fistulae: incidence estimates for sub-Saharan Africa. <i>Int J Gynaecol Obstet.</i> 2001; 73(1): 65-66.	1994-1996	*	
Senegal	Epidemiological Situation of Malaria in Children in Sahelian Area During a Transmission Season. Study of Family Similarities [Master's thesis] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Senegal	Epidemiology of Malaria in the Saloum Delta (Fatick, Senegal): Role of Anopheles Melas in Transmission [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995-1997	*	†
Senegal	Impact of Irrigation Development on Malaria: Studies Conducted in Villages Along the Senegal River and Guieres Lake [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Senegal	Endemic Malaria: Demographic and Epidemiological Situation in the Region of Niakhar, Senegal 1984-1996 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Senegal	Malaria in the Mesoendemic Area: Relationships between Transmission, Infection and Malaria Morbidity in Ndiop (Senegal) [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†
Senegal	Epidemiological, Parasitological and Clinical Aspects of Malaria in Louga (Senegal) as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2007	*	†
Senegal	Impact of Chloroquine Resistance on Malaria Endemicity in Mlomp (Casamance) as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Senegal	Annual Report for Potou, Senegal, Millenium Village. Year 1: February 2006 - February 2007 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2007	*	†
Senegal	Senegal Plasmodium Falciparum Parasite Rate Data, Personal Communication with R.E.L. Paul 2006 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004-2005	*	†
Senegal	Carrara GC, Petrarca V, Niang M, Coluzzi M. Anopheles pharoensis and transmission of Plasmodium falciparum in the Senegal River delta, West Africa. <i>Med Vet Entomol.</i> 1990; 4(4): 421-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Senegal	Cissé B, Sokhna C, Boulanger D, Milet J, Bâ EH, Richardson K, Hallett R, Sutherland C, Simonon F, Simonon F, Alexander N, Gaye O, Targett G, Lines J, Greenwood B, Trape J-F. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. <i>Lancet.</i> 2006; 367(9511): 659-67 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Senegal	Dia I, Konate L, Samb B, Sarr J-B, Diop A, Rogerie F, Faye M, Riveau G, Remoue F, Diallo M, Fontenille D. Bionomics of malaria vectors and relationship with malaria transmission and epidemiology in three physiographic zones in the Senegal River Basin. <i>Acta Trop.</i> 2008; 105(2): 145-53 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Senegal	Diallo A, Ndam NT, Moussilou A, Dos Santos S, Ndonky A, Borderon M, Oliveau S, Lalou R, Le Hesran J-Y asymptomatic Carriage of Plasmodium in Urban Dakar: The Risk of Malaria Should Not Be Underestimated. <i>PLoS One.</i> 2012; 7(2): e31100 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008	*	†
Senegal	Faye O, Bâ M, Ndir O, Gaye O, Ousmane F, Dieng T, Bah IB, Dieng Y, Diallo S. [Endemic parasitoses in the villages surrounding the Saloum fossil valley, Senegal]. <i>Dakar Med.</i> 1998; 43(1): 104-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Senegal	Faye O, Diallo S, Gaye O, Faye O, Mouchet J. [Evaluation de l'efficacité du fénitrothion (Sumithion PM40) sur la densité du vecteur et la prévalence du paludisme à Pout (Thiès, Sénégal)]. <i>Ann Soc Belg Med Trop.</i> 1992; 72(2): 103-12 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Senegal	Faye O, Diop A, Gaye O, Diop BM, Bah IB, Dieng T, Dieng Y, Ndir O, Diallo S. [Evaluation of parasitic risks for the population bordering on the Mbeubeuss public waste disposal, Dakar]. <i>Dakar Med.</i> 1998; 43(1): 90-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Senegal	Faye O, Fontenille D, Gaye O, Sy N, Molez JF, Konate L, Hebrard G, Herve JP, Trouillet J, Diallo S. [Malaria and rice growing in the Senegal River delta (Senegal)]. Ann Soc Belg Med Trop. 1995; 75(3): 179-89 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993-1994	*	†
Senegal	Faye O, Gaye O, Fontenille D, Hébrard G, Konate L, Sy N, Hervé JP, Touré Y, Diallo S, Molez JF. [Drought and malaria decrease in the Niayes area of Senegal]. Sante. 1995; 5(5): 299-305 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991-1993	*	†
Senegal	Faye O, Gaye O, Hervé JP, Diack PA, Diallo S. [Malaria in the Saharan region of Senegal. 2. Parasitological indices]. Ann Soc Belg Med Trop. 1993; 73(1): 31-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990-1991	*	†
Senegal	Faye O, NDIR B, Corréa J, Faye O, NDIR O, Gaye O, Bah IB, Dieng T, Dieng Y, Diallo S. [Evaluation of parasitic risks related to the revitalization of the Ferlo fossil valley (Senegal)]. Dakar Med. 1998; 43(2): 183-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Senegal	Gardella F, Assi S, Simon F, Bogueau H, Egele T, Ba F, Founane V, Henry M-C, Kientega PT, Basco L, Trape J-F, Lafou R, Martelloni M, Desbordes M, Baragatti M, Briolant S, Almeras L, Pradines B, Fusai T, Rogier C. Antimalarial drug use in general populations of tropical Africa. Malar J. 2008; 7(1): 124 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Senegal	Gaye O, Bah IB, Diallo S, Faye O, Baudon D. [Malaria morbidity in rural and urban areas in Senegal]. Med Trop (Mars). 1989; 49(1): 59-62 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Senegal	Lawaly R, Konate L, Marrama L, Dia I, Diallo D, Diène Sarr F, Schneider BS, Casademont I, Diallo M, Brey PT, Sakuntabhai A, Mecheri S, Paul R. Impact of mosquito bites on asexual parasite density and gametocyte prevalence in asymptomatic chronic Plasmodium falciparum infections and correlation with IgE and IgG titers. Infect Immun. 2012; 80(6): 2240-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Senegal	Ntoumi F, Rogier C, Dieye A, Trape JF, Millet P, Mercereau-Pujalon O. Imbalanced distribution of Plasmodium falciparum MSP-1 genotypes related to sickle-cell trait. Molecular Medicine. 1997; 3(9): 581-92 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Senegal	Sagna AB, Sarr JB, Gaayeb L, Drame PM, Ndiath MO, Senghor S, Sow CS, Poincignon A, Seck M, Hermann E, Schacht A-M, Faye N, Sokhna C, Remoue F, Riveau G. gSG6-P1 salivary biomarker discriminates micro-geographical heterogeneity of human exposure to Anopheles bites in low and seasonal malaria areas. Parasit Vectors. 2013; 6(1): 68 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008-2010	*	†
Senegal	Sarr JB, Remoue F, Samb B, Dia I, Guindo S, Sow C, Maiga S, Tine S, Thiam C, Schacht AM, Simondon F, Konate L, Riveau G. Evaluation of antibody response to Plasmodium falciparum in children according to exposure of Anopheles gambiae s.l. or Anopheles funestus vectors. Malar J. 2007; 117 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Senegal	Sokhna C, Le Hesran JY, Mbaye PA, Akianga J, Camara P, Diop M, Ly A, Druilhe P. Increase of malaria attacks among children presenting concomitant infection by Schistosoma mansoni in Senegal. Malar J. 2004; 3: 43 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Senegal	Tall A, Sokhna C, Perraut R, Fontenille D, Marrama L, Ly AB, Sarr FD, Toure A, Trape JF, Spiegel A, Rogier C, Druilhe P. Assessment of the relative success of sporozoite inoculations in individuals exposed to moderate seasonal transmission. Malar J. 2009; 8: 161 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
Senegal	Trape J, Lefebvre-Zante E, Legros F, Druilhe P, Rogier C, Bouganali H, Salem G. Malaria morbidity among children exposed to low seasonal transmission in Dakar, Senegal and its implications for malaria control in tropical Africa. Am J Trop Med Hyg. 1993; 48(6): 748-56 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Senegal	Trape J, Lefebvre-Zante E, Legros F, Ndiaye G, Bouganali H, Druilhe P, Salem G. Vector density gradients and the epidemiology of urban malaria in Dakar, Senegal. Am J Trop Med Hyg. 1992; 47(2): 181-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987-1988	*	†
Senegal	Trape JF, Rogier C, Konate L, Diagne N, Bouganali H, Canque B, Legros F, Badji A, Ndiaye G, Ndiaye P. The Dielmo project: a longitudinal study of natural malaria infection and the mechanisms of protective immunity in a community living in a holoendemic area of Senegal. Am J Trop Med Hyg. 1994; 51(2): 123-37 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Serbia	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2005		
Serbia	United Nations Children's Fund (UNICEF), Statistical Office of the Republic of Serbia (SORS), Strategic Marketing Research Agency (SMMRI). Serbia Multiple Indicator Cluster Survey 2005-2006. New York, United States: United Nations Children's Fund (UNICEF).	2005-2006	*	†
Serbia	Serbia and Montenegro - Montenegro Vital Registration - Deaths 2005 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2005	*	†
Serbia	Statistical Office of the Republic of Serbia, United Nations Children's Fund (UNICEF). Serbia Multiple Indicator Cluster Survey 2010. New York, United States: United Nations Children's Fund (UNICEF).	2010	*	†
Serbia	Centre for Health Informatics and Multiprofessional Education, University College London. Model's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Serbia	National Public Health Institute (Finland), World Health Organization (WHO). WHO MONICA Cerebrovascular Event Data 1982-1997, as provided by the Global Burden of Disease 2010 Cerebrovascular Disease Expert Group. [Unpublished].	1984-1993		
Serbia	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1999-2000, 2002, 2004, 2006-2008		
Serbia	Buddenhagen F, Pantović MM. Comparative epidemiologic analysis of multiple sclerosis in areas of Central and Southern Europe. Psychiatr Neurol Med Psychol (Leipz). 1985; 37(10): 565-72.	1984		
Serbia	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2002		
Serbia	Milenković B, Mitić-Milkić M, Rebić P, Vučković M, Dudarski-Jlić A, Nagorni-Ohradović L, Lazić Z, Bosnjak-Petrović V. Asthma and chronic bronchitis symptoms among adult population of Belgrade. Srp Arh Celok Lek. 2011; 139(3-4): 149-54.	2003	*	
Serbia	Begzati A, Berisha M, Meqa K. Early childhood caries in preschool children of Kosovo - a serious public health problem. BMC Public Health. 2010; 10: 788.	2007		
Serbia	Forman D, Bray F, Brewster DH, Gombé Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version). Lyon, IARC. http://ci5.iarc.fr	2003-2007	*	
Serbia	Vrbic V, Vulović M, Raji Z, Topić B, Tati E, Mali M, Mili D, Aurer-Kozelj J, Neceva L, Redzepagi S. Oral health in SFR Yugoslavia in 1986. Community Dent Oral Epidemiol. 1988; 16(5): 286-8.	1986		
Serbia	Eytan A, Gex-Fabry M, Toscani L, Deroo L, Loutan L, Bovier PA. Determinants of postconflict symptoms in Albanian Kosovars. J Nerv Ment Dis. 2004; 192(10): 664-71.	2001		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Serbia	European Agency for Reconstruction. Serbia School Survey on Psychoactive Substance Abuse Among Adolescents 2005.	2005		
Serbia	Tonecv G, Miletić Drakulić S, Knezević Z, Bosković Matic T, Gavrilović A, Tonecv S, Druļović J, Pekmezović T. Prevalence of multiple sclerosis in the Serbian district Sumadija. <i>Neuroepidemiology</i> . 2011; 37(2): 102-6.	2006	*	
Serbia	Pavlović M, Jarebinski M, Pekmezović T, Levic Z. Seizure disorders in preschool children in a Serbian district. <i>Neuroepidemiology</i> . 1998; 17(2): 105-10.	1989-1995	*	
Serbia	Başoğlu M, Livanou M, Crnobarčić C, Francisković T, Suljić E, Durić D, Vranesić M. Psychiatric and cognitive effects of war in former Yugoslavia: association of lack of redress for trauma and posttraumatic stress reactions. <i>JAMA</i> . 2005; 294(5): 580-90.	2000-2002	*	
Serbia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2007, 2010, 2012		
Serbia	Natasa Cerovac, Petrović I, Klein C, Kostić VS. Delayed-onset dystonia due to perinatal asphyxia: a prospective study. <i>Mov Disord</i> . 2007; 22(16): 2426-9.	1991-1997	*	†
Serbia	Šipetić S, Maksimović J, Vljajina H, Ratkov I, Sajić S, Zdravković D, Šipetić T. Rising incidence of Type 1 diabetes in Belgrade children aged 0-14 years in the period from 1982 to 2005. <i>J Endocrinol Invest</i> . 2013; 36(5): 307-12.	1982-2005		
Serbia	Tešić DS, Pantelić P, Avramov S, Vukobratov V, Pasternak J, Jeffcoat W. Changing incidence of major amputation for diabetes in Novi Sad, Serbia and Montenegro, between 1994 and 2004. <i>Diabetes Care</i> . 2006; 29(3): 741-2.	1994, 2004		
Serbia	Vljajina HD, Bojović BM, Šipetić SB, Adanja BJ, Jarebinski MS, Radmanović SZ, Zdravković DS. Insulin dependent diabetes mellitus: incidence in childhood in Belgrade 1982-92. <i>J Epidemiol Community Health</i> . 1995; 49(1): 107-8.	1982-1992		
Serbia	Fraser GR, Defarinas B, Kattamis CA, Race RR, Sanger R, Stamatoyannopoulos G. Glucose-6-phosphate dehydrogenase, colour vision and XG blood groups in Greece: linkage and population data. <i>Ann Hum Genet</i> . 1964; 395-403.	1962		
Serbia	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant</i> . 1988; 3(6): 714-27.	1985-1986		
Serbia	Djukanović L, Radović M, Baković J, Budosan I, Bukvić D, Cveticanin A, Davinić S, Dragoljčić B, Djordjević V, Djurić S, Haviza-Lilić B, Ilić M, Janos B, Jelčić R, Jelić S, Kostić N, Mandić M, Ostrić V, Pljesa S, Radisic M, Radojević M, Rakić N, Rangelov V, Ratković M, Stojanović M, Stojanović R, Tintor D, Vasić V. Epidemiology of end-stage renal disease and current status of hemodialysis in Yugoslavia. <i>Int J Artif Organs</i> . 2002; 25(9): 852-9.	1997-1999		
Serbia	Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M and Boyle P, eds (2007). <i>Cancer Incidence in Five Continents, Vol. IX Periodic Data (electronic version)</i> . Lyon, IARC. http://ci5.iarc.fr	1999-2002	*	
Serbia	Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. <i>Cancer Incidence in Five Continents, Vol. I to VIII</i> . Lyon, France, IARC Press, 2005.	1988-1997	*	
Serbia	Yugoslavia, Federal Republic - Serbia Iodine Deficiency of School Children Survey 1998-1999 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1998-1999		
Serbia	Yugoslavia, Federal Republic - Serbia Micronutrient Status Survey 2001 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2001		
Serbia	Zlatković-Švenda MI, Stojanović RM, B Šipetić-Grujičić S, Guillemin F. Prevalence of rheumatoid arthritis in Serbia. <i>Rheumatol Int</i> . 2014; 34(5): 649-58.	2008	*	
Serbia	Kanazir M, Boricic I, Delic D, Tepavcevic DK, Knezevic A, Jovanovic T, Pekmezovic T. Risk factors for hepatocellular carcinoma: a case-control study in Belgrade (Serbia). <i>Tumori</i> . 2010; 96(6): 911-7.	2004-2007	*	
Serbia	Quaglio G, Ramadani N, Pattaro C, Cami A, Dentico P, Volpe A, Pellizzer G, Berisha A, Smacchia C, Figliomeni M, Schinaia N, Rezza G, Putoto G. Prevalence and risk factors for viral hepatitis in the Kosovar population: implications for health policy. <i>J Med Virol</i> . 2008; 80(5): 833-40.	2005		
Serbia	Serbian Society of Nephrology Dialysis and Kidney Transplantation Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Serbia	Serbian Society of Nephrology Dialysis and Kidney Transplantation Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Serbia	Serbia and Montenegro Renal Replacement Therapy Data 1997 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 1998. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2003.	1997	*	
Seychelles	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Seychelles	Gibbs S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. <i>Int J Dermatol</i> . 1996; 35(9): 633-9.	1994		
Seychelles	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1995-1999, 2001-2009		
Seychelles	Alwan H, Viswanathan B, Rousson V, Paccaud F, Bovet P. Association between substance use and psychosocial characteristics among adolescents of the Seychelles. <i>BMC Pediatr</i> . 2011; 11: 85.	2007	*	
Seychelles	Faeh D, Viswanathan B, Chiolerio A, Warren W, Bovet P. Clustering of smoking, alcohol drinking and cannabis use in adolescents in a rapidly developing country. <i>BMC Public Health</i> . 2006; 169.	2004		
Seychelles	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2010, 2012		
Seychelles	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec</i> . 2006; 81(32): 309-16.	2005	*	
Sierra Leone	Central Statistics Office (Sierra Leone), United Nations Children's Fund (UNICEF). Sierra Leone Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
Sierra Leone	United Nations Children's Fund (UNICEF), Statistics Sierra Leone. Sierra Leone Multiple Indicator Cluster Survey 2005. New York, United States: United Nations Children's Fund (UNICEF).	2005	*	†
Sierra Leone	Macro International, Inc. Statistics Sierra Leone. Sierra Leone Demographic and Health Survey 2008. Calverton, United States: Macro International, Inc.	2008		†
Sierra Leone	Statistics Sierra Leone, United Nations Children's Fund (UNICEF). Sierra Leone Multiple Indicator Cluster Survey 2010. New York, United States: United Nations Children's Fund (UNICEF).	2010	*	†
Sierra Leone	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Sierra Leone	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Sierra Leone	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1995		
Sierra Leone	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000, 2003, 2005-2009		
Sierra Leone	World Health Organization (WHO). Sierra Leone Yellow Fever Fact Sheet 2005. Geneva, Switzerland: World Health Organization (WHO), 2005.	1980-2004		
Sierra Leone	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Sierra Leone	Nörmark S. Social indicators of dental caries among Sierra Leonean schoolchildren. <i>Scand J Dent Res</i> . 1993; 101(3): 121-9.	1991		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Sierra Leone	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Sierra Leone	Sierra Leone Rapid Assessment of Avoidable Blindness 2010-2011 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2010-2011		
Sierra Leone	Nørmark S. Oral health among 15- and 35-44-year-olds in Sierra Leone. Tandlaegebladet. 1991; 95(4): 132-8.	1989		
Sierra Leone	Seely DR, Gloyd SS, Wright AD, Norton SJ. Hearing loss prevalence and risk factors among Sierra Leonean children. Arch Otolaryngol Head Neck Surg. 1995; 121(8): 853-8.	1992		
Sierra Leone	Gbakima AA, Sahr F. Filariasis in the Kaiyamba Chiefdom, Moyamba District Sierra Leone: an epidemiological and clinical study. Public Health. 1996; 110(3): 169-74. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1993	*	
Sierra Leone	Koroma JB, Bangura MM, Hodges MH, Bah MS, Zhang Y, Bockarie MJ. Lymphatic filariasis mapping by immunochromatographic test cards and baseline microfilaria survey prior to mass drug administration in Sierra Leone. Parasit Vectors. 2012; 10. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2007-2008	*	
Sierra Leone	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Sierra Leone	World Health Organization (WHO). Global leprosy situation, 2007 (additional information). Wkly Epidemiol Rec. 2007; 82(44): 388.	2006	*	
Sierra Leone	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Sierra Leone	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Sierra Leone	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Sierra Leone	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Sierra Leone	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Sierra Leone	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Sierra Leone	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Sierra Leone	Hodges M, Sanders E, Aitken C. Seroprevalence of hepatitis markers; HAV, HBV, HCV and HEV amongst primary school children in Freetown, Sierra Leone. West Afr J Med. 1998; 17(1): 36-7.	1980-1997		
Sierra Leone	Gbakima AA. Inland valley swamp rice development: malaria, schistosomiasis, onchocerciasis in south central Sierra Leone. Public Health. 1994; 108(2): 149-57 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†
Sierra Leone	Base-line Malaria Prevalence Monitoring Results in Largo and Tobanda Refugee Camps, Sierra Leone as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Sierra Leone	Barnish G, Maude G, Bockarie M, Erunkulu O, Dumbaya M, Greenwood B. Malaria in a rural area of Sierra Leone. II. Parasitological and related results from pre- and post-rains clinical surveys. Ann Trop Med Parasitol. 1993; 87(2): 137-48 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Singapore	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-1999, 2003-2006		
Singapore	Ministry of Health (Singapore), World Health Organization (WHO). Singapore WHO Multi-country Survey Study on Health and Health System Responsiveness 2001.	2001		
Singapore	Yap KB, Ng TP, Ong HY. Low prevalence of atrial fibrillation in community-dwelling Chinese aged 55 years or older in Singapore: a population-based study. J Electrocardiol. 2008; 41(2): 94-8.	2005		
Singapore	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Singapore	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Singapore	Tan HY, Choo WC, Archibald C, Esuvaranathan K. A community based study of prostatic symptoms in Singapore. J Urol. 1997; 157(3): 890-3.	1990, 1994		
Singapore	Tay KP, Chin CM, Lim PH, Chng HC. Prostate screening – the Singapore experience. Int J Urol. 1996; 3(2): 102-07.	1994		
Singapore	Tay Y-K, Kong K-H, Khoo L, Goh C-L, Giam Y-C. The prevalence and descriptive epidemiology of atopic dermatitis in Singapore school children. Br J Dermatol. 2002; 146(1): 101-6.	1999		
Singapore	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. J Allergy Clin Immunol. 2008; 121(4): 947-954.	1994, 2001		
Singapore	Lim YS, Tay L. A one-year study of enteric Campylobacter infections in Singapore. J Trop Med Hyg. 1992; 95(2): 119-23.	1989-1990		
Singapore	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998-2000, 2002-2009		
Singapore	Anantham D, Ong SJ, Chuah KL, Fook-Chong S, Hsu A, Eng P. Sarcoidosis in Singapore: epidemiology, clinical presentation and ethnic differences. Respirology. 2007; 12(3): 355-60.	1998-2004		
Singapore	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J. 1998; 12(2): 315-35.	1993-1995		
Singapore	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2001		
Singapore	Nang EE, Khoo CM, Tai ES, Lim SC, Tavintharan S, Wong TY, Heng D, Lee J. Is there a clear threshold for fasting plasma glucose that differentiates between those with and without neuropathy and chronic kidney disease?: the Singapore Prospective Study Program. Am J Epidemiol. 2009; 169(12): 1454-62.	2004-2007		
Singapore	Lau HC, Voo YO, Yeo KT, Ling SL, Jap A. Mass screening for diabetic retinopathy – a report on diabetic retinal screening in primary care clinics in Singapore. Singapore Med J. 1995; 36(5): 510-3.	1991-1993		
Singapore	Wong TY, Cheung N, Tay WT, Wang JJ, Aung T, Saw SM, Lim SC, Tai ES, Mitchell P. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology. 2008; 115(11): 1869-75.	2007		
Singapore	Ho K-H, Ong BK-C. A community-based study of headache diagnosis and prevalence in Singapore. Cephalalgia. 2003; 23(1): 6-13.	1990		
Singapore	Zuraini MS, Tham K-W, Chew F-T, Ooi P-L, Koh D. Home air-conditioning, traffic exposure, and asthma and allergic symptoms among preschool children. Pediatr Allergy Immunol. 2011; 22(1 Pt 2): e112-118.	2006-2008	*	
Singapore	Subramaniam T, Nang EEK, Lim SC, Wu Y, Khoo CM, Lee J, Heng D, Chew SK, Wong TY, Tai ES. Distribution of ankle-brachial index and the risk factors of peripheral artery disease in a multi-ethnic Asian population. Vasc Med. 2011; 16(2): 87-95.	2004-2007		
Singapore	Ang LW, Tey SH, Cutter J, James L, Goh KT. Seroprevalence of hepatitis B virus infection among children and adolescents in Singapore, 2008-2010. J Med Virol. 2013; 85(4): 583-8.	2008-2010		
Singapore	Sahadevan S, Saw SM, Gao W, Tan LCS, Chin JJ, Hong CY, Venketasubramanian N. Ethnic differences in Singapore's dementia prevalence: the stroke, Parkinson's disease, epilepsy, and dementia in Singapore study. J Am Geriatr Soc. 2008; 56(11): 2061-8.	2001-2003		
Singapore	Lim KA. Dental caries status of children and youth in Singapore. Ann Acad Med Singapore. 1986; 15(3): 275-9.	1957-1967, 1970-1984		
Singapore	Lo GL, Bagramian RA. Declining prevalence of dental caries in school children in Singapore. Oral Dis. 1997; 3(2): 121-5.	1970, 1979, 1984, 1989, 1994		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Singapore	Reichart PA, Gehring F, Becker J, Geerlings H. Prevalence of dental caries and Streptococcus mutans in Meo of Northern Thailand. Community Dent Oral Epidemiol. 1986; 14(1): 57-9.	1984		
Singapore	Gao XL, Hsu CYS, Loh T, Koh D, Hwang HB, Xu Y. Dental caries prevalence and distribution among preschoolers in Singapore. Community Dent Health. 2009; 26(1): 12-7.	2005		
Singapore	Health Promotion Board (Singapore), Singapore Renal Registry. Singapore Renal Registry Report 1998. Singapore, Singapore: Health Promotion Board (Singapore), 2005.	1998		
Singapore	Singapore Renal Registry. Singapore Renal Registry Report 2005-2006. Singapore, Singapore: Health Promotion Board (Singapore), 2009.	2005		
Singapore	Fones CS KE, Ng TP, Ko SM. Studying the mental health of a nation: a preliminary report on a population survey in Singapore. Singapore Med J. 1998; 39(6): 251-5.	1996		
Singapore	Ng TP, Niti M, Fones C, Yap KB, Tan WC. Co-morbid association of depression and COPD: a population-based study. Respir Med. 2009; 103(6): 895.	2004-2005		
Singapore	Venketasubramanian N, Tan LCS, Sahadevan S, Chin JJ, Krishnamoorthy ES, Hong CY, Saw SM. Prevalence of Stroke Among Chinese, Malay, and Indian Singaporeans. Stroke. 2005; 36(3): 551-6.	2001-2003		
Singapore	Gopalakrishnakone D, Appan DP, Singh K. Prevalence of Chlamydia trachomatis in Singaporean women undergoing termination of pregnancy. Ann Acad Med Singapore. 2009; 38(5): 457-454.	2006		
Singapore	Tan LCS, Venketasubramanian N, Hong CY, Sahadevan S, Chin JJ, Krishnamoorthy ES, Tan AKY, Saw SM. Prevalence of Parkinson disease in Singapore Chinese vs Malays vs Indians. Neurology. 2004; 62(11): 1999-2004.	2001		
Singapore	Saw S-M, Foster PJ, Gazzard G, Seah S. Causes of blindness, low vision, and questionnaire-assessed poor visual function in Singaporean Chinese adults: The Tanjong Pagar Survey. Ophthalmology. 2004; 111(6): 1161-8, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1997-1998		
Singapore	Ooi PL, Goh KT, Doraisingham S, Ling AE. Prevalence of varicella-zoster virus infection in Singapore. Southeast Asian J Trop Med Public Health. 1992; 23(1): 22-5.	1989-1990		
Singapore	Lee WL. Long-term outcome of children with febrile seizures. Ann Acad Med Singapore. 1989; 18(1): 32-4.	1980-1982	*	
Singapore	Sabanayagam C, Lim SC, Wong TY, Lee J, Shankar A, Tai ES. Ethnic disparities in prevalence and impact of risk factors of chronic kidney disease. Nephrol Dial Transplant. 2010; 25(8): 2564-70.	2008-2010		
Singapore	Khin LW, Teo CJ, Guan R. Seroprevalence of hepatitis B and C viral markers in patients with primary hepatocellular carcinoma in Singapore. Singapore Med J. 1996; 37(5): 492-6.	1990-1993		
Singapore	Woo KT. The Singapore Renal Registry: an overview. Singapore Med J. 1993; 34(2): 157-63.	1981, 1983, 1987-1993		
Singapore	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010		
Singapore	Dirani M, Zhou B, Hornbeak D, Chang BC, Gazzard G, Chia A, Ling Y, Selvaraj P, Young TL, Varma R, Wong TY, Saw SM. Prevalence and causes of decreased visual acuity in Singaporean Chinese preschoolers. Br J Ophthalmol. 2010; 94(12): 1561-5.	2007-2008		
Singapore	Toh V, Rajadurai VS. Term infants with hypoxic ischaemic encephalopathy: poor neurodevelopmental outcome despite standard neonatal intensive care. J Trop Pediatr. 1999; 45(4): 229-32.	1992-1995	*	†
Singapore	Vella F. The incidence of erythrocyte glucose-6-phosphate dehydrogenase deficiency in Singapore. Experientia. 1961; 181-2.	1959		
Singapore	Saha N, Banerjee B. Erythrocyte G-6-PD deficiency among Chinese and Malays of Singapore. Trop Geogr Med. 1971; 23(2): 141-4.	1969-1971		
Singapore	Lim MK, Tan EH, Wan A, Chao AK. Prevalence of G6PD deficiency among recruits in the Singapore Armed Forces. Ann Acad Med Singapore. 1995; 24(2): 322-4.	1986-1990		
Singapore	Joseph R, Ho LY, Gomez JM, Rajadurai VS, Sivasankaran S, Yip YY. Mass newborn screening for glucose-6-phosphate dehydrogenase deficiency in Singapore. Southeast Asian J Trop Med Public Health. 1999; 70-1.	1990-1997		
Singapore	Seow S-C, Chai P, Lee Y-P, Chan Y-H, Kwok BWK, Yeo T-C, Chia B-L. Heart Failure Mortality in Southeast Asian Patients With Left Ventricular Systolic Dysfunction. J Card Fail. 2007; 13(6): 476-81.	1998		
Singapore	Ty AU, Ang GY, Ang LW, James L, Goh KT. Changing epidemiology of enteric fevers in Singapore. Ann Acad Med Singapore. 2010; 39(12): 889.	1990-2009	*	
Singapore	Chong SA, Abidin E, Vaingankar JA, Heng D, Sherbourne C, Yap M, Lim YW, Wong HB, Ghosh-Dastidar B, Kwok KW, Subramaniam M. A population-based survey of mental disorders in Singapore. Ann Acad Med Singapore. 2012; 41(2): 49-66.	2009-2010		
Singapore	Tan LCS, Venketasubramanian N, Jamora RDG, Heng D. Incidence of Parkinson's disease in Singapore. Parkinsonism Relat Disord. 2007; 13(1): 40-3.	2001-2002	*	
Singapore	Chong S-C, Chan Y-H, Ong H-T, Low P-S, Tay SK-H. Headache diagnosis, disability and co-morbidities in a multi-ethnic, heterogeneous paediatric Asian population. Cephalalgia. 2010; 30(8): 953-61.	2005-2006	*	
Singapore	Teng GG, Ang L-W, Saag KG, Yu MC, Yuan J-M, Koh W-P. Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Ann Rheum Dis. 2012; 71(6): 924-8.	1999-2004	*	
Singapore	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Singapore	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
Singapore	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Singapore	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	
Singapore	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Singapore	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Singapore	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Singapore	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
Singapore	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Singapore	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Singapore	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Singapore	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Singapore	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Singapore	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland: World Health Organization (WHO).	2000-2012	*	
Singapore	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2000.	2000		
Singapore	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2001.	2001		
Singapore	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2002.	2002		
Singapore	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2003.	2003		
Singapore	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2004.	2004		
Singapore	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2005.	2005		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Singapore	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2006.	2006		
Singapore	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2007.	2007		
Singapore	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2008.	2008		
Singapore	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2009.	2009		
Singapore	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2010.	2010		
Singapore	Shah VA, Yeo CL, Ling YLF, Ho LY. Incidence, risk factors of retinopathy of prematurity among very low birth weight infants in Singapore. <i>Ann Acad Med Singapore</i> . 2005; 34(2): 169-78.	1995	*	†
Singapore	World Health Organization (WHO). Global Prevalence and Incidence of Selected Curable Sexually Transmitted Diseases: Overviews and Estimates 1995. Geneva, Switzerland: World Health Organization (WHO), 1995.	1987		
Singapore	Jeganathan VSE, Wong TY, Foster PJ, Crowston JG, Tay WT, Lim SC, Saw S-M, Tai ES, Aung T. Peripheral artery disease and glaucoma: the singapore malay eye study. <i>Arch Ophthalmol</i> . 2009; 127(7): 888-93.	2004-2006		
Singapore	Chan YK, Tay MT, Lim MK. Xq28: epidemiology and sex-linkage between red-green colour blindness and G6PD deficiency. <i>Ann Acad Med Singapore</i> . 1992; 21(3): 318-22.	1990-1991	*	
Singapore	Goh KT, Wong LY, Oon CJ, Kumarapathy S. The prevalence of antibody to hepatitis A virus in Singapore. <i>Asia Pac J Public Health</i> . 1987; 1(2): 9-11.	1984-1985		
Singapore	Fock KM, Tay HH, Phua KB, Guan R, Chia SC, Chong R, Chee AE, Chew CN. Seroprevalence of antibodies against hepatitis A (anti-HAV) in Singapore: the NFDD experience. <i>Singapore Med J</i> . 1995; 36(1): 26-7.	1991		
Singapore	Mak K-H, Chia K-S, Kark JD, Chua T, Tan C, Foong B-H, Lim Y-L, Chew S-K. Ethnic differences in acute myocardial infarction in Singapore. <i>Eur Heart J</i> . 2003; 24(2): 151-60.	1991, 1995, 1999		
Singapore	Tan ATH, Emmanuel SC, Tan BY, Teo WS, Chua TSJ, Tan BH. Myocardial infarction in Singapore: a nationwide 10-year study of multiethnic differences in incidence and mortality. <i>Ann Acad Med Singapore</i> . 2002; 31(4): 479-86.	1990, 1997		
Singapore	Chow WC, Ng HS, Lim GK, Oon CJ. Hepatitis E in Singapore—a seroprevalence study. <i>Singapore Med J</i> . 1996; 37(6): 579-81.	1993		
Singapore	Goh KT, Chan YW, Wong LY, Kong KH, Oon CJ, Guan R. The prevalence of hepatitis B virus markers in dental personnel in Singapore. <i>Trans R Soc Trop Med Hyg</i> . 1988; 82(6): 908-10.	1986		
Singapore	Goh KT, Kong KH, Heng BH, Oon CJ. Seroprevalence of hepatitis A and hepatitis B virus infection in a Gurkha community in Singapore. <i>J Med Virol</i> . 1993; 41(2): 146-9.	1991		
Singapore	Goh KT. Prevention and control of hepatitis B virus infection in Singapore. <i>Ann Acad Med Singapore</i> . 1997; 26(5): 671-81.	1978-1992		
Singapore	James L, Fong CW, Foong BH, Wee MK, Chow A, Shum E, Chew SK. Hepatitis B Seroprevalence Study 1999. <i>Singapore Med J</i> . 2001; 42(9): 420-4.	1999		
Singapore	Kuperan P, Choon AT, Ding SH, Lee G. Prevalence of antibodies to hepatitis C virus in relation to surrogate markers in a blood donor population of Singapore. <i>Southeast Asian J Trop Med Public Health</i> . 1993; 127-9.	1991		
Singapore	Tan N, Teoh Y-L, Phua K-B, Quak S-H, Lee B-W, Teo HJEL, Jacobsen A, Boudville IC, Ng T, Verstraeten T, Bock HL. An update of paediatric intussusception incidence in Singapore: 1997-2007, 11 years of intussusception surveillance. <i>Ann Acad Med Singapore</i> . 2009; 38(8): 690-2.	1997-2004		
Singapore	Kua EH. Prevalence of mental disorders in the elderly in Singapore—a preliminary report. <i>Ann Acad Med Singapore</i> . 1987; 16(2): 264-6.	1982-1985		
Singapore	Kua EH, Ko SM. Prevalence of dementia among elderly Chinese and Malay residents of Singapore. <i>Int Psychogeriatr</i> . 1995; 7(3): 439-46.	1990		
Singapore	Mak KH, Kark JD, Chia KS, Sim LL, Foong BH, Ding ZP, Kam R, Chew SK. Ethnic variations in female vulnerability after an acute coronary event. <i>Heart</i> . 2004; 90(6): 621-626.	1991-1999	*	
Singapore	Zeitlan J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT; 2008. Available from: http://www.perinataleaudit.nl/downloads/bestand/649/peristat-ii-2008-	2004		†
Singapore	Lian WB, Yeo CL, Ho LY. Two-year outcome of normal-birth-weight infants admitted to a Singapore neonatal intensive care unit. <i>Ann Acad Med Singapore</i> . 2002 Mar; 31(2): 199-205.	1992		†
Singapore	Singapore Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Slovakia	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2002-2010		
Slovakia	World Health Organization (WHO). Slovakia World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Slovakia	Public Health Authority of the Slovak Republic, World Health Organization (WHO). Slovakia WHO Multi-country Survey Study on Health and Health System Responsiveness 2000.	2000		
Slovakia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Slovakia	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001-2009		
Slovakia	Vrbic V, Vulovi M, Raji Z, Topi B, Tati E, Mali M, Mili D, Aurer-Kozelj J, Neeveva L, Redzepagi S. Oral health in SFR Yugoslavia in 1986. <i>Community Dent Oral Epidemiol</i> . 1988; 16(5): 286-8.	1986		
Slovakia	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Slovakia	Nardone A, de Ory F, Carton M, Cohen D, van Damme P, Davidkin I, Rota MC, de Melker H, Mossong J, Slacikova M, Tischer A, Andrews N, Berbers G, Gabutti G, Gay N, Jones L, Jokinen S, Kafatos G, de Aragón MVM, Schneider F, Smetana Z, Vargova B, Vranckx R, Miller E. The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. <i>Vaccine</i> . 2007; 25(45): 7866-72.	2002		
Slovakia	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1995-1996, 1998-2000, 2002, 2004-2006		
Slovakia	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Slovakia	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). Alcohol and Drug Use Among European 17-18 Year Old Students: Data from the ESPAD Project. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2007.	2003		
Slovakia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Slovakia	Statistical Office of the Slovak Republic. Slovakia Drug Prevalence 2006 According to Gender and Age.	2006	*	
Slovakia	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Slovakia National Report to the EMCDDA 2006.	2005-2006	*	
Slovakia	Okruhlica L, Mihalkova A, Klempova D, Skovayova L. Three-year follow-up study of heroin users in Bratislava. <i>Eur Addict Res</i> . 2002; 8(2): 103-6.	1996-2000	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Slovakia	Fraser GR, Defarinas B, Kattamis CA, Race RR, Sanger R, Stamatoyannopoulos G. Glucose-6-phosphate dehydrogenase, colour vision and XG blood groups in Greece: linkage and population data. <i>Ann Hum Genet.</i> 1964; 395-403.	1962		
Slovakia	Rutkowski B. Changing pattern of end-stage renal disease in central and eastern Europe. <i>Nephrol Dial Transplant.</i> 2000; 15(2): 156-60.	1998		
Slovakia	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguiar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Gilst WH van, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J.</i> 2003; 24(5): 442-63.	2000-2001		
Slovakia	Zoubek V. [Incidence of cholelithiasis in a population 20-59 years of age]. <i>Cas Lek Cesk.</i> 1992; 131(9): 268-70.	1989-1990		
Slovakia	Zeitlan J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT; 2008. Available from: http://www.perinataleaudit.nl/downloads/bestand/649/peristat-ii-2008-	2004		†
Slovakia	Slovakia Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Slovakia	Slovakia Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Slovakia	Slovakia Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Slovakia	Slovakia - Slovak Republic Congenital Malformations Monitoring Program Data 2004 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
Slovakia	Slovakia - Slovak Republic Congenital Malformations Monitoring Program Data 2003 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
Slovakia	Slovakia - Slovak Teratologic Information Centre, Slovak Medical University Data 2007 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Slovakia	Slovakia - Slovak Teratologic Information Centre, Slovak Medical University Data 2008 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
Slovakia	Slovakia - Slovak Teratologic Information Centre, Slovak Medical University Data 2009 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Slovakia	Slovakia - Slovak Teratologic Information Centre, Slovak Medical University Data 2010 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
Slovenia	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2004-2009		
Slovenia	World Health Organization (WHO). Slovenia World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Slovenia	Department of Obstetrics and Gynaecology, University Hospital of Ljubljana (Slovenia), Institute of Public Health (Slovenia), Sociomedical Institute, Research Centre of the Slovenian Academy of Sciences and Art (ZRC SAZU) (Slovenia), Statistical Office of the Republic of Slovenia, United Nations Economic Commission for Europe (UNECE), Slovenia Fertility and Family Survey 1994-1995. Geneva, Switzerland: United Nations Economic Commission for Europe (UNECE).	1995		
Slovenia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Slovenia	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001-2009		
Slovenia	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. <i>Community Dent Oral Epidemiol.</i> 1991; 19(2): 72-3.	1987		
Slovenia	Turk Z, Vauhnik R, Micetic-Turk D. Prevalence of Nonspecific Low Back Pain in Schoolchildren in North-Eastern Slovenia. <i>Coll Antropol.</i> 2011; 35(4): 1031-5.	2008	*	
Slovenia	Skaleric U, Kovac-Kavcic M. DMFT counts in the adult population of Ljubljana, Yugoslavia. <i>Community Dent Oral Epidemiol.</i> 1991; 19(3): 182-3.	1983-1987		
Slovenia	Vrbic V. Reasons for the caries decline in Slovenia. <i>Community Dent Oral Epidemiol.</i> 2000; 28(2): 126-32.	1987-1998		
Slovenia	Vrbic V, Vulovi M, Raji Z, Topi B, Tati E, Mali M, Mili D, Aurer-Kozelj J, Neeveva L, Redzepagi S. Oral health in SFR Yugoslavia in 1986. <i>Community Dent Oral Epidemiol.</i> 1988; 16(5): 286-8.	1986		
Slovenia	Vrbic VL. The prevalence of dental caries in Slovenia in 1987 and 1993. <i>Community Dent Health.</i> 1995; 12(1): 39-41.	1983-1987, 1993-1997		
Slovenia	Mlacak B, Blinc A, Pohar M, Stare J. Peripheral Arterial Disease and Ankle-Brachial Pressure Index as Predictors of Mortality in Residents of Metlika County, Slovenia. <i>Croat Med J.</i> 2006; 47(2): 327-34.	1987		
Slovenia	Slovenian Society of Nephrology. Slovenia Renal Replacement Therapy Registry Report 2006.	1970-2006		
Slovenia	Slovenian Society of Nephrology. Slovenia Renal Replacement Therapy Registry Report 2007-2008.	2007-2008		
Slovenia	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Slovenia	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1995, 1999		
Slovenia	Orel R, Kamhi T, Vidmar G, Mamula P. Epidemiology of pediatric chronic inflammatory bowel disease in central and western Slovenia, 1994-2005. <i>J Pediatr Gastroenterol Nutr.</i> 2009; 48(5): 579-86.	1994-2005	*	†
Slovenia	WHO Regional Office for Europe (EURO-WHO). Young People's Health in Context. Health Behaviour in School-aged Children (HBSC) Study: International Report from the 2001-2002 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2004.	2002		
Slovenia	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Slovenia	Bouvier-Colle M-H, Mohangoo AD, Gissler M, Novak-Antolic Z, Vutuc C, Szamotulska K, Zeitlin J, Euro-Peristat Scientific Committee. What about the mothers? An analysis of maternal mortality and morbidity in perinatal health surveillance systems in Europe. <i>BJOG.</i> 2012; 119(7): 880-90.	2003-2004	*	
Slovenia	Buturović-Ponikvar J, Republic of Slovenia Expert Group for Dialysis in Slovenia at the Ministry of Health. Renal replacement therapy in Slovenia: annual report 2001. <i>Nephrol Dial Transplant.</i> 2003; 18(Suppl 5): v53-5.	1998-2001		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Slovenia	Malovrh M, Kandus A, Ponikvar R, Premru V, Kosej M, Kveder R. The incidence and etiology of chronic renal failure in the Republic of Slovenia. <i>Transplant Proc.</i> 1992; 24(5): 1857-8.	1986-1990		
Slovenia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Slovenia	Battelino T, Krzisnik C. Incidence of type 1 diabetes mellitus in children in Slovenia during the years 1988-1995. <i>Acta Diabetol.</i> 1998; 35(2): 112-4.	1988-1995		
Slovenia	Nolimal D. Estimating the extent of the heroin problem in Slovenia: application of the key informant approach and the nomination technique where there are no other reliable sources of information. <i>Bull Narc.</i> 1996; 48(1-2): 121-34.	1991-1993	*	
Slovenia	Fraser GR, Defaranas B, Kattamis CA, Race RR, Sanger R, Stamatoyannopoulos G. Glucose-6-phosphate dehydrogenase, colour vision and XG blood groups in Greece: linkage and population data. <i>Ann Hum Genet.</i> 1964; 395-403.	1962		
Slovenia	Van Dijk PC, Jager KJ, Stengel B, Grönhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). <i>Kidney Int.</i> 2005; 67(4): 1489-99.	1998-2001		
Slovenia	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Gilst WH van, Widimsky J, Freemanle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J.</i> 2003; 24(5): 442-63.	2000-2001		
Slovenia	Skaleric U, Kovac-Kavcic M. Periodontal treatment needs in a population of Ljubljana, Yugoslavia. <i>Community Dent Oral Epidemiol.</i> 1989; 17(6): 304-6.	1983-1987		
Slovenia	Socan M, Berginc N, Lajovic J. Varicella susceptibility and transmission dynamics in Slovenia. <i>BMC Public Health.</i> 2010; 360.	2006	*	
Slovenia	M S, M B. Surveillance of varicella and herpes zoster in Slovenia, 1996 - 2005. <i>Euro Surveill.</i> 2007; 12(2).	1996-2005		
Slovenia	Cizman M, Zajbec J. Etiology of acute encephalitis in childhood in Slovenia. <i>Pediatr Infect Dis J.</i> 1993; 12(11): 903-8.	1979-1991		
Slovenia	Zeitlan J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT; 2008. Available from: http://www.perinataleaudit.nl/downloads/bestand/649/peristat-ii-2008-	2004		†
Slovenia	Slovenia Renal Replacement Therapy Registry Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Solomon Islands	Fiji School of Medicine, Ministry of Health and Medical Services (Solomon Islands), World Health Organization (WHO). Solomon Islands STEPS Noncommunicable Disease Risk Factors Survey 2005-2006.	2005-2006		
Solomon Islands	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1994-1996, 2002-2010		
Solomon Islands	Centre for Health Informatics and Multiprofessional Education, University College London, Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Solomon Islands	Eason RJ, Harding E, Nicholson R, Nicholson D, Pada J, Gathercole J. Chronic suppurative otitis media in the Solomon Islands: a prospective, microbiological, audiometric and therapeutic survey. <i>N Z Med J.</i> 1986; 99(812): 812-5.	1985-1986		
Solomon Islands	Hill AV, Bowden DK, O'Shaughnessy DF, Weatherall DJ, Clegg JB. Beta thalassaemia in Melanesia: association with malaria and characterization of a common variant (IVS-1 nt 5 G→C). <i>Blood.</i> 1988; 72(1): 9-14.	1985-1987		
Solomon Islands	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001-2002, 2004, 2006-2009		
Solomon Islands	Eason RJ, Tasman-Jones T. Resurgent yaws and other skin diseases in the Western Province of the Solomon Islands. <i>P N G Med J.</i> 1985; 28(4): 247-50.	1984		
Solomon Islands	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Solomon Islands	Secretariat of the Pacific Community (SPC), World Health Organization Regional Office for the Western Pacific (WPRO-WHO). Second Generation Surveillance Surveys of HIV, Other STIs and Risk Behaviours in 6 Pacific Island Countries 2004-2005. Geneva, Switzerland: World Health Organization (WHO), 2006.	2005		
Solomon Islands	Yanagihara RT, Garruto RM, Gajdusek DC. Epidemiological surveillance of amyotrophic lateral sclerosis and parkinsonism-dementia in the commonwealth of the Northern Mariana Islands. <i>Ann Neurol.</i> 1983; 13(1): 79-86.	1980-1981		
Solomon Islands	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2004, 2007, 2010, 2012	*	
Solomon Islands	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec.</i> 2005; 80(13): 118-24.	2003	*	
Solomon Islands	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Solomon Islands	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec.</i> 2006; 81(32): 309-16.	2005	*	
Solomon Islands	World Health Organization (WHO). Global leprosy situation, 2007 (additional information). <i>Wkly Epidemiol Rec.</i> 2007; 82(44): 388.	2006	*	
Solomon Islands	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Solomon Islands	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Solomon Islands	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec.</i> 2008; 83(33): 293-300.	2007	*	
Solomon Islands	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Solomon Islands	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Solomon Islands	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993		
Solomon Islands	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2000.	2000		
Solomon Islands	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2001.	2001		
Solomon Islands	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2002.	2002		
Solomon Islands	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2003.	2003		
Solomon Islands	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2004.	2004		
Solomon Islands	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2008.	2008		
Solomon Islands	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2009.	2009		
Solomon Islands	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2010.	2010	*	
Solomon Islands	Kuwahata M, Wijesinghe R, Ho M-F, Pelecanos A, Bobogare A, Landry L, Bugora H, Vallely A, McCarthy J. Population screening for glucose-6-phosphate dehydrogenase deficiencies in Isabel Province, Solomon Islands, using a modified enzyme assay on filter paper dried bloodspots. <i>Malar J.</i> 2010; 223.	2009		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Solomon Islands	Furusyo N, Hayashi J, Kakuda K, Sawayama Y, Ariyama I, Eddie R, Kashiwagi S. Markedly high seroprevalence of hepatitis B virus infection in comparison to hepatitis C virus and human T lymphotropic virus type-1 infections in selected Solomon Islands populations. <i>Am J Trop Med Hyg.</i> 1999; 61(1): 85-91.	1994		
Solomon Islands	Lucas RE, Faogalii JL. The serological status of Solomon Island blood donors. <i>Southeast Asian J Trop Med Public Health.</i> 1999; 30(3): 542-5.	1994-1995		
Solomon Islands	Kennedy L, Nasi T, Ludawane B, Ogaoga D, Colquhoun S, Carapetis J, Keniforea G, Wheaton G. Burden of Rheumatic Heart Disease in the Solomon Islands. <i>Global.</i> 9(1, Supplement): e260.	2013	*	†
Solomon Islands	Permethrin Impregnated Bednets and DDT Residual Spraying, Multicentre Comparative Trial in Solomon Islands [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987-1989	*	
Solomon Islands	Hii JL, Kanai L, Foligela A, Kan SK, Burkot TR, Wirtz RA. Impact of permethrin-impregnated mosquito nets compared with DDT house-spraying against malaria transmission by <i>Anopheles farauti</i> and <i>An. punctulatus</i> in the Solomon Islands. <i>Med Vet Entomol.</i> 1993; 7(4): 333-9. as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Solomon Islands	Mizushima Y, Kato H, Ohmae H, Tanaka T, Bobogare A, Ishii A. Prevalence of malaria and its relationship to anemia, blood glucose levels, and serum somatomedin c (IGF-1) levels in the Solomon Islands. <i>Acta Trop.</i> 1994; 58(3-4): 207-20 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†
Solomon Islands	The usefulness and limitations of clinical diagnosis in primary health care for malaria control as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993		
Solomon Islands	Solomon Islands Vital Registration Birth Data 1969 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1969	*	†
Somalia	Pan Arab Project for Family Health (PAPFAM), United Nations Children's Fund (UNICEF). Somalia Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006	*	
Somalia	Ministry of National Planning and Development (Somaliland), United Nations Children's Fund (UNICEF). Somalia - Somaliland Multiple Indicator Cluster Survey 2011.	2011	*	
Somalia	Puntland Ministry of Planning and International Cooperation (Somalia), United Nations Children's Fund (UNICEF). Somalia - Northeast Zone Multiple Indicator Cluster Survey 2011.	2011		
Somalia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		†
Somalia	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		
Somalia	Gibbs. S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. <i>Int J Dermatol.</i> 1996; 35(9): 633-9.	1994		
Somalia	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010	*	
Somalia	Casalino M, Yusuf MW, Nicoletti M, Bazzicalupo P, Coppo A, Colonna B, Cappelli C, Bianchini C, Falbo V, Ahmed HJ. A two-year study of enteric infections associated with diarrhoeal diseases in children in urban Somalia. <i>Trans R Soc Trop Med Hyg.</i> 1988; 82(4): 637-41.	1983-1984		
Somalia	Nyssa LJ, Pinsky NA, Bratberg JP, Babar-Weber AY, Samuel TT, Krych EH, Ziegler AW, Jimala MA, Vierkant RA, Jacobson RM, Poland GA. Seroprevalence of antibody to varicella among Somali refugees. <i>Mayo Clin Proc.</i> 2007; 82(2): 175-80.	1998		
Somalia	Acefi A, Taliiani G, Bruni R, Sharif OS, Moallin KA, Celestino D, Quaranta G, Sebastiani A. Hepatitis C virus infection in chronic liver disease in Somalia. <i>Am J Trop Med Hyg.</i> 1993; 48(4): 581-4.	1988-1990		
Somalia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012	*	
Somalia	Coppo A, Colombo M, Pazzani C, Bruni R, Mohamad KA, Omar KH, Mastrandrea S, Salvia AM, Rotigliano G, Maimone F. Vibrio cholerae in the horn of Africa: epidemiology, plasmids, tetracycline resistance gene amplification, and comparison between O1 and non-O1 strains. <i>Am J Trop Med Hyg.</i> 1995; 53(4): 351-9.	1983-1985	*	
Somalia	World Health Organization (WHO). Somalia WHO Leishmaniasis Country Profile.	2008	*	
Somalia	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec.</i> 2005; 80(13): 118-24.	2003	*	
Somalia	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Somalia	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec.</i> 2007; 82(25): 225-32.	2006	*	
Somalia	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Somalia	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Somalia	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Somalia	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec.</i> 2008; 83(33): 293-300.	2007	*	
Somalia	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Somalia	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Somalia	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Somalia	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Somalia	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Somalia	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Somalia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Somalia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994		
Somalia	Bile K, Mohamad O, Aden C, Isse A, Norder H, Nilsson L, Magnus L. The risk for hepatitis A, B, and C at two institutions for children in Somalia with different socioeconomic conditions. <i>Am J Trop Med Hyg.</i> 1992; 47(3): 357-64.	1987	*	†
Somalia	Sistonen P, Koistinen J, Aden Abdulle O. Distribution of blood groups in the East African Somali population. <i>Hum Hered.</i> 1987; 37(5): 300-13.	1984-1986		
Somalia	Ismail SO, Ahmed HJ, Grillner L, Hederstedt B, Issa A, Bygdeman SM. Sexually transmitted diseases in men in Mogadishu, Somalia. <i>Int J STD AIDS.</i> 1990; 1(2): 102-6.	1986		
Somalia	Nur YA, Groen J, Elmi AM, Ott A, Osterhaus AD. Prevalence of serum antibodies against bloodborne and sexually transmitted agents in selected groups in Somalia. <i>Epidemiol Infect.</i> 2000; 124(1): 137-41.	1995	*	†
Somalia	Somalia National Malaria Prevalence Survey 2005 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Somalia	Malaria: A Baseline Assessment for Somalia May-July 2002 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Somalia	Impact of population movements on malaria transmission in Somalia as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Somalia	Somalia Plasmodium Falciparum Parasite Rate Data. Personal Communication with FAO Somalia and UNICEF Somalia 2009 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2007-2009	*	†
Somalia	Ildardi I, Sebastiani A, Leone F, Madera A, Bile MK, Shiddo SC, Mohamed HH, Amiconi G. Epidemiological study of parasitic infections in Somali nomads. <i>Trans R Soc Trop Med Hyg.</i> 1987; 81(5): 771-2 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Somalia	Noor AM, Clements AC, Gething PW, Moloney G, Borle M, Shewchuk T, Hay SI, Snow RW. Spatial prediction of Plasmodium falciparum prevalence in Somalia. <i>Malar J.</i> 2008; 7: 159 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Somalia	Warsame M, Lebbad M, Ali S, Wernsdorfer WH, Björkman A. Susceptibility of Plasmodium falciparum to chloroquine and mefloquine in Somalia. <i>Trans R Soc Trop Med Hyg.</i> 1988; 82(2): 202-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Somalia	Warsame M, Perlmann H, Ali S, Hagi H, Farah S, Lebbad M, Björkman A. The seroreactivity against Pfl55 (RESA) antigen in villagers from a mesoendemic area in Somalia. <i>Trop Med Parasitol.</i> 1989; 40(4): 412-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Somalia	Youssef RM, Alegana VA, Amran J, Noor AM, Snow RW. Fever prevalence and management among three rural communities in the North West Zone, Somalia. <i>East Mediterr Health J.</i> 2010; 16(6): 460-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008		†
South Africa	Department of Health (South Africa), Macro International, Inc, South African Medical Research Council. South Africa Demographic and Health Survey 1998. Calverton, United States: Macro International, Inc.	1998		†
South Africa	World Health Organization (WHO). South Africa World Health Survey 2002-2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2002-2003		
South Africa	Hergtun IEA, Gundersen KMS. Genital Symptoms - A Pre-Pubertal Experience: Are There Symptoms of Genital Schistosomiasis in Children? Presented at: Clinical Manifestations of Female Genital Schistosomiasis in Adults and Children Symposium. American Society of Tropical Medicine and Hygiene 59th Meeting; 2010 Nov 4; Atlanta, Georgia.	2010		
South Africa	Loening WE, Coovadia YM, Van den Ende J. Aetiological factors of infantile diarrhoea: a community-based study. <i>Ann Trop Paediatr.</i> 1989; 9(4): 248-55.	1985-1986		
South Africa	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		†
South Africa	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		
South Africa	Cooppan RM, Schutte CH, Mayet FG, Dingle CE, Van Deventer JM, Mosese PG. Morbidity from urinary schistosomiasis in relation to intensity of infection in the Natal Province of South Africa. <i>Am J Trop Med Hyg.</i> 1986; 35(4): 765-76.	1985		
South Africa	Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N, Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. <i>N Engl J Med.</i> 2003; 349(14): 1341-8.	1998-2001		
South Africa	Sliwa K, Wilkinson D, Hansen C, Ntyintyane L, Tibazarwa K, Becker A, Stewart S. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. <i>Lancet.</i> 2008; 371(9616): 915-22.	2006		
South Africa	Prescott CA, Kibel MA. Ear and hearing disorders in rural grade 2 (Sub B) schoolchildren in the western Cape. <i>S Afr Med J.</i> 1991; 79(2): 90-3.	1989-1991		
South Africa	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol.</i> 2008; 121(4): 947-954.	1995, 2002		
South Africa	Hussey G, Schaaf H, Hanslo D, Hitchcock J, Coetzee G, Pitout J, Malan H, Donald P. Epidemiology of post-neonatal bacterial meningitis in Cape Town children. <i>S Afr Med J.</i> 1997; 87(1): 51-6.	1991-1992		
South Africa	Mapaseka SL, Dewar JB, van der Merwe L, Geyer A, Tumbo J, Zweygarth M, Bos P, Esona MD, Steele AD, Sommerfelt H. Prospective hospital-based surveillance to estimate rotavirus disease burden in the Gauteng and North West Province of South Africa during 2003-2005. <i>J Infect Dis.</i> 2010; 202 Suppl: 131-138.	2003-2005		
South Africa	Demyttenaere K, Bruffaerts R, Lee S, Posada-Villa J, Kovess V, Angermeyer MC, Levinson D, de Girolamo G, Nakane H, Mneimneh Z, Lara C, de Graaf R, Scott KM, Gureje O, Stein DJ, Hayer JM, Bromet EJ, Kessler RC, Alonso J, Von Korff M. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. <i>Pain.</i> 2007; 129(3): 332-42.	2004		
South Africa	Bird AR, Ellis P, Wood K, Mathew C, Karabus C. Inherited haemoglobin variants in a South African population. <i>J Med Genet.</i> 1987; 4(24): 215-9.	1981-1983		
South Africa	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1989-1993, 1996-1998, 2000-2001, 2003-2006, 2009		
South Africa	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
South Africa	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2003		
South Africa	Department of Health (South Africa), Human Sciences Research Council, World Health Organization (WHO). South Africa WHO Study on Global AGEing and Adult Health 2007-2008. Geneva, Switzerland: World Health Organization (WHO).	2007-2008		
South Africa	Levitt NS, Bradshaw D, Zwarenstein MF, Bawa AA, Maphumolo S. Audit of public sector primary diabetes care in Cape Town, South Africa: high prevalence of complications, uncontrolled hyperglycaemia, and hypertension. <i>Diabet Med.</i> 1997; 14(12): 1073-7.	1992		
South Africa	Rotchford AP, Rotchford KM. Diabetes in rural South Africa – an assessment of care and complications. <i>S Afr Med J.</i> 2002; 92(7): 536-41.	1999		
South Africa	Mash B, Powell D, du Plessis F, van Vuuren U, Michalowska M, Levitt N. Screening for diabetic retinopathy in primary care with a mobile fundal camera – evaluation of a South African pilot project. <i>S Afr Med J.</i> 2007; 97(12): 1284-8.	2006		
South Africa	Mollentze WF, Moore AJ, Steyn AF, Joubert G, Steyn K, Oosthuizen GM, Weich DJ. Coronary heart disease risk factors in a rural and urban Orange Free State black population. <i>S Afr Med J.</i> 1995; 85(2): 90-6.	1990		
South Africa	Levitt NS, Katzenellenbogen JM, Bradshaw D, Hoffman MN, Bonnici F. The prevalence and identification of risk factors for NIDDM in urban Africans in Cape Town, South Africa. <i>Diabetes Care.</i> 1993; 16(4): 601-7.	1990		
South Africa	Motala AA, Esterhuizen T, Gouws E, Pirie FJ, Omar MA. Diabetes and other disorders of glycaemia in a rural South African community: prevalence and associated risk factors. <i>Diabetes Care.</i> 2008; 31(9): 1783-8.	2005		
South Africa	Solomon L, Beighton P, Lawrence JS. Osteoarthritis in a rural South African Negro population. <i>Ann Rheum Dis.</i> 1976; 35(3): 274-8.	1973	*	
South Africa	Sliwa K, Carrington MJ, Klug E, Opie L, Lee G, Ball J, Stewart S. Predisposing factors and incidence of newly diagnosed atrial fibrillation in an urban African community: insights from the Heart of Soweto Study. <i>Heart.</i> 2010; 96(23): 1878-82.	2006-2008		
South Africa	Sliwa K, Carrington M, Mayosi BM, Zigiariadis E, Mvungi R, Stewart S. Incidence and characteristics of newly diagnosed rheumatic heart disease in Urban African adults: insights from the Heart of Soweto Study. <i>Eur Heart J.</i> 2010; 31(6): 719-27.	2006-2007	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
South Africa	Wichmann J, Wolvaardt JE, Maritz C, Voji KVV. Household conditions, eczema symptoms and rhinitis symptoms: relationship with wheeze and severe wheeze in children living in the Polokwane area, South Africa. <i>Matern Child Health J</i> . 2009; 13(1): 107-18.	2004-2005	*	
South Africa	Couper J. Prevalence of childhood disability in rural KwaZulu-Natal. <i>S Afr Med J</i> . 2002; 92(7): 549-52.	1999-2001		
South Africa	Foyaca-Sibat H, Cowan LD, Carabin H, Targonska I, Anwary MA, Serrano-Oca-a G, Kreecek RC, Willingham AL 3rd. Accuracy of serological testing for the diagnosis of prevalent neurocysticercosis in outpatients with epilepsy, Eastern Cape Province, South Africa. <i>PLoS Negl Trop Dis</i> . 2009; 3(12): e562.	2004-2005	*	
South Africa	Haffejee IE, Windsor I, Moosa A. Asymptomatic rotavirus infections among normal Indian children in Chatsworth, Durban. <i>S Afr Med J</i> . 1989; 76(11): 599-601.	1985-1987	*	
South Africa	Steele AD, Alexander JJ, Hay IT. Rotavirus-associated gastro-enteritis at Ga-Rankuwa Hospital. A pilot study. <i>S Afr Med J</i> . 1986; 69(1): 21-2.	1982	*	
South Africa	Househam KC, Mann MD, Bowie MD. Enteropathogens associated with acute infantile diarrhoea in Cape Town. <i>S Afr Med J</i> . 1988; 73(2): 83-7.	1981-1982	*	
South Africa	Sebata T, Steele AD. Atypical rotavirus identified from young children with diarrhoea in South Africa. <i>J Health Popul Nutr</i> . 2001; 19(3): 199-203.	1996-1997	*	
South Africa	Steele AD, Mnsi YN, Williams MM, Bos P, Aspinall S. Electrophoretic typing of nosocomial rotavirus infection in a general paediatric unit showing the continual introduction of community strains. <i>J Med Virol</i> . 1993; 40(2): 126-32.	1989	*	
South Africa	Tiemessen CT, Wegerhoff FO, Erasmus MJ, Kidd AH. Infection by enteric adenoviruses, rotaviruses, and other agents in a rural African environment. <i>J Med Virol</i> . 1989; 28(3): 176-82.	1985-1986	*	
South Africa	Griffiths FH, Steele AD, Alexander JJ. The molecular epidemiology of rotavirus-associated gastro-enteritis in the Transkei, southern Africa. <i>Ann Trop Paediatr</i> . 1992; 12(3): 259-64.	1988-1989	*	
South Africa	Sannie A, Guerrant RL, Barrett L, Bessong PO, Igumbor EO, Obi CL. Prevalence of intestinal parasitic and bacterial pathogens in diarrhoeal and non-diarrhoeal human stools from Vhembe district, South Africa. <i>J Health Popul Nutr</i> . 2009; 27(6): 739-45.	2003-2005		
South Africa	Solomon L, Robin G, Valkenburg HA. Rheumatoid arthritis in an urban South African Negro population. <i>Ann Rheum Dis</i> . 1975; 34(2): 128-35.	1972		
South Africa	Beighton P, Solomon L, Valkenburg HA. Rheumatoid arthritis in a rural South African Negro population. <i>Ann Rheum Dis</i> . 1975; 34(2): 136-41.	1972		
South Africa	Van Wyk PJ, van Wyk C. Oral health in South Africa. <i>Int Dent J</i> . 2004; 54(6): 373-7.	1988-1989, 1999-2001		
South Africa	Chikte UM, Rudolph MJ, Smythe AE. Dental caries of 12- and 15-year-old schoolchildren in Gazankulu, South Africa. <i>Community Dent Oral Epidemiol</i> . 1991; 19(4): 237-8.	1986, 1989		
South Africa	Cleaton-Jones P, Williams S, Fatti P. Surveillance of primary dentition caries in Germiston, South Africa, 1981-97. <i>Community Dent Oral Epidemiol</i> . 2000; 28(4): 267-73.	1981-1997		
South Africa	Brindle R, Wilkinson D, Harrison A, Connolly C, Cleaton-Jones P. Oral health in Hlabisa, KwaZulu-Natal—a rural school and community based survey. <i>Int Dent J</i> . 2000; 50(1): 13-20.	1996-1998		
South Africa	Bajomo AS, Rudolph MJ, Ogunbodede EO. Dental caries in six, 12 and 15 year old Venda children in South Africa. <i>East Afr Med J</i> . 2004; 81(5): 236-43.	2002		
South Africa	Rees H, Katzenellenbogen J, Shabodien R, Jewkes R, Fawcus S, McIntyre J, Lombard C, Truter H. The epidemiology of incompetent abortion in South Africa. <i>S Afr Med J</i> . 1997; 87(4): 432-7.	1994		
South Africa	Seedat S, Nyamai C, Njenga F, Vythingilum B, Stein DJ. Trauma exposure and post-traumatic stress symptoms in urban African schools Survey in CapeTown and Nairobi. <i>Br J Psychiatry</i> . 2004; 184(2): 169-75.	2000		
South Africa	Bhagwanjee A PA, Paruk Z, Petersen I, Subedar H. Prevalence of minor psychiatric disorders in an adult African rural community in South Africa. <i>Psychol Med</i> . 1998; 28(5): 1137-47.	1996		
South Africa	Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E, BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. <i>Lancet</i> . 2007; 9589(9589): 741-50.	2005		
South Africa	Connor MD, Thorogood M, Casserly B, Dobson C, Warlow CP. Prevalence of stroke survivors in rural South Africa: results from the Southern Africa Stroke Prevention Initiative (SASPI) Agincourt field site. <i>Stroke</i> . 2004; 35(3): 627-32.	2001-2002		
South Africa	Govender S, Theron GB, Odendaal HJ, Chalkley LJ. Prevalence of genital mycoplasmas, ureaplasmas and chlamydia in pregnancy. <i>J Obstet Gynaecol</i> . 2009; 29(8): 698-701.	2003		
South Africa	Sturm PJD, Connolly C, Khan N, Ebrahim S, Sturm AW. Vaginal tampons as specimen collection device for the molecular diagnosis of non-ulcerative sexually transmitted infections in antenatal clinic attendees. <i>Int J STD AIDS</i> . 2004; 15(2): 94-8.	1988, 2004		
South Africa	Gilbert CE, Ellwein LB. Prevalence and causes of functional low vision in school-age children: results from standardized population surveys in Asia, Africa, and Latin America. <i>Invest Ophthalmol Vis Sci</i> . 2008; 49(3): 877-81. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2002	*	
South Africa	Ngugi AK, Bottomley C, Kleinschmidt I, Wagner RG, Kakooza-Mwesige A, Ae-Ngibise K, Owusu-Agyei S, Masanja H, Kamuyu G, Odhiambo R, Chengo E, Sander JW, Newton CR, SEEDS group. Prevalence of active convulsive epilepsy in sub-Saharan Africa and associated risk factors: cross-sectional and case-control studies. <i>Lancet Neurol</i> . 2013; 12(3): 253-63.	2008-2009	*	
South Africa	Kalumba VMS, Moodley J, Naidoo TD. Is the prevalence of pre-eclampsia affected by HIV/AIDS? A retrospective case-control study. <i>Cardiovasc J Afr</i> . 2013; 24(2): 24-7.	2008-2010	*	
South Africa	Christianson AL, Zwane ME, Manga P, Rosen E, Venter A, Kromberg JG. Epilepsy in rural South African children – prevalence, associated disability and management. <i>S Afr Med J</i> . 2000; 90(3): 262-6.	2000		†
South Africa	Soni PN, Tait DR, Gopaal W, Sathar MA, Simjee AE. Hepatitis C virus infection in chronic liver disease in Natal. <i>S Afr Med J</i> . 1996; 86(1): 80-3.	1991-1992	*	
South Africa	Tomlinson M, Grimsrud AT, Stein DJ, Williams DR, Myer L. The epidemiology of major depression in South Africa: results from the South African stress and health study. <i>S Afr Med J</i> . 2009; 99(5 Pt 2): 367-73.	2002-2004		
South Africa	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2007, 2010, 2012		
South Africa	Cook CD, Knight SE, Crofton-Briggs I. Prevalence and causes of low vision and blindness in northern KwaZulu. <i>S Afr Med J</i> . 1993; 83(8): 590-3. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	1990-1991		
South Africa	Salmon JF, Mermoud A, Ivey A, Swanevelder SA, Hoffman M. The prevalence of primary angle closure glaucoma and open angle glaucoma in Mamre, western Cape, South Africa. <i>Arch Ophthalmol</i> . 1993; 111(9): 1263-9. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	1992		
South Africa	Rotchford AP, Johnson GJ. Glaucoma in Zulul: a population-based cross-sectional survey in a rural district in South Africa. <i>Arch Ophthalmol</i> . 2002; 120(4): 471-8. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	1998-1999	*	
South Africa	Ramjee G, Williams B, Gouws E, Van Dyck E, De Deken B, Karim SA. The impact of incident and prevalent herpes simplex virus-2 infection on the incidence of HIV-1 infection among commercial sex workers in South Africa. <i>J Acquir Immune Defic Syndr</i> . 2005; 39(3): 333-9.	2002-2004	*	†
South Africa	Harrison V, Fawcus S, Jordaan E. Magnesium supplementation and perinatal hypoxia: outcome of a parallel group randomised trial in pregnancy. <i>BJOG</i> . 2007; 114(8): 994-1002.	2001	*	†
South Africa	Thompson CM, Puterman AS, Linley LL, Hann FM, van der Elst CW, Molteno CD, Malan AF. The value of a scoring system for hypoxic ischaemic encephalopathy in predicting neurodevelopmental outcome. <i>Acta Paediatr</i> . 1997; 757-61.	1994-1996		
South Africa	Thomas RL, Distiller L, Luzio SD, Chowdhury SR, Melville VJ, Kramer B, Owens DR. Ethnic differences in the prevalence of diabetic retinopathy in persons with diabetes when first presenting at a diabetes clinic in South Africa. <i>Diabetes Care</i> . 2013; 36(2): 336-41.	2001-2010		
South Africa	Charlton RW, Bothwell TH. Primaquine-sensitivity of red cells in various races in Southern Africa. <i>Br Med J</i> . 1961; 1(5230): 941-4.	1959-1961		
South Africa	Bernstein RE. Occurrence and clinical implications of red-cell glucose-6-phosphate dehydrogenase deficiency in South African racial groups. <i>S Afr Med J</i> . 1963; 447-51.	1961-1963		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
South Africa	Naicker S. End-stage renal disease in sub-Saharan and South Africa. <i>Kidney Int Suppl.</i> 2003; 83: S19-22.	1994-1998		
South Africa	Naicker S. Burden of end-stage renal disease in sub-Saharan Africa. <i>Clin Nephrol.</i> 2010; 74(Suppl 1): S13-6.	2008-2010		
South Africa	Arogundade FA, Barsoum RS. CKD prevention in Sub-Saharan Africa: a call for governmental, nongovernmental, and community support. <i>Am J Kidney Dis.</i> 2008; 51(3): 515-23.	2004		
South Africa	Bangboye EL. End-stage renal disease in sub-Saharan Africa. <i>Ethn Dis.</i> 2006; 16(2 Suppl 2): 5-9.	2004		
South Africa	Gillis LS. The mortality rate and causes of death of treated chronic alcoholics. <i>S Afr Med J.</i> 1969; 43(9): 230-2.	1959-1964		
South Africa	Williams DR, Herman A, Stein DJ, Heeringa SG, Jackson PB, Moomal H, Kessler RC. Twelve-month mental disorders in South Africa: prevalence, service use and demographic correlates in the population-based South African Stress and Health Study. <i>Psychol Med.</i> 2008; 38(2): 211-20.	2002-2004	*	
South Africa	Centers for Disease Control and Prevention (CDC). Fetal Alcohol Syndrome - South Africa, 2001. <i>Morb Mortal Wkly Rep.</i> 2003; 52(28): 660-2.	2001	*	†
South Africa	Viljoen DL, Gossage JP, Brooke L, Adnams CM, Jones KL, Robinson LK, Hoyme HE, Snell C, Khaole NCO, Koditwakku P, Asante KO, Findlay R, Quinton B, Marais A-S, Kalberg WO, May PA. Fetal alcohol syndrome epidemiology in a South African community: a second study of a very high prevalence area. <i>J Stud Alcohol.</i> 2005; 66(5): 593-604.	2000		
South Africa	Klugman KP, Gilbertson IT, Koornhof HJ, Robbins JB, Schneerson R, Schulz D, Cadoz M, Armand J. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. <i>Lancet.</i> 1987; 2(8569): 1165-9.	1985-1987		
South Africa	Cronje HS, Joubert G, Muir A, Chapman RD, Divall P, Bam RH. Prevalence of vaginitis, syphilis and HIV infection in women in the Orange Free State. <i>S Afr Med J.</i> 1994; 84(9): 602-5.	1994	*	
South Africa	Okpechi I, Swanepoel C, Duffield M, Mahala B, Wearne N, Alagbe S, Barday Z, Arendse C, Rayner B. Patterns of renal disease in Cape Town South Africa: a 10-year review of a single-centre renal biopsy database. <i>Nephrol Dial Transplant.</i> 2011; 26(6): 1853-61.	2000-2009	*	
South Africa	Jeena PM, Wesley AG, Coovadia HM. Infectious diseases at the paediatric isolation units of Clairwood and King Edward VIII Hospitals, Durban. Trends in admission and mortality rates (1985-1996) and the early impact of HIV (1994-1996). <i>S Afr Med J.</i> 1998; 88(7): 867-72.	1985-1988	*	
South Africa	Küstner HG, Du Plessis G. The cholera epidemic in South Africa, 1980-1987. Epidemiological features. <i>S Afr Med J.</i> 1991; 79(9): 539-44.	1980-1987	*	
South Africa	Bamgboye AA, Hofmeyr GJ, Merrell DA. Rectal misoprostol in the prevention of postpartum hemorrhage: a placebo-controlled trial. <i>Am J Obstet Gynecol.</i> 1998; 179(4): 1043-6.	1995-1997		
South Africa	Damascono A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojiji D, Dzudie A, Kouam CK, Suliman A, Schrueder N, Yonga G, Ba SA, Maru F, Alemayehu B, Edwards C, Davison BA, Cotter G, Sliwa K. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. <i>Arch Intern Med.</i> 2012; 172(18): 1386-94.	2007-2010	*	
South Africa	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
South Africa	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
South Africa	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
South Africa	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
South Africa	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
South Africa	Waaaj DJ de, Dubbink J, Eem L van der, Bos MLA, Ouburg S, Lewis DA, Struthers H, McIntyre JA, Morrè SA, Peters RPH. P3.011 Dry Swab Evaluation by Roche 4800 CT/NG and the Presto-Plus: Cross-Sectional Study of Genital, Rectal and Pharyngeal Chlamydia and Gonorrhoea Infection in Women in Rural South Africa. <i>Sex Transm Infect.</i> 2013; 89(Suppl 1): A151-A151.	2011-2012	*	
South Africa	De Jongh M, Lekalaka MR, Le Roux M, Hoosen AA. Risk of having a sexually transmitted infection in women presenting at a termination of pregnancy clinic in Pretoria, South Africa. <i>J Obstet Gynaecol.</i> 2010; 30(5): 480-3.	2007-2008	*	
South Africa	Williams BG, Taljaard D, Campbell CM, Gouws E, Ndlovu L, Van Dam J, Carael M, Auvert B. Changing patterns of knowledge, reported behaviour and sexually transmitted infections in a South African gold mining community. <i>AIDS.</i> 2003; 17(14): 2099-107.	2000	*	
South Africa	Myer L, Denny L, De Souza M, Barone MA, Wright TC Jr, Kuhn L. Intra-vaginal practices, HIV and other sexually transmitted diseases among South African women. <i>Sex Transm Dis.</i> 2004; 31(3): 174-9.	2001-2002	*	
South Africa	Sturm A, Moodley P, Sturm P, Karim F, Khan N. Trends in the prevalence of sexually transmitted infections and HIV in pregnant women in KwaZulu/Natal from 1995-2002. In: <i>South African AIDS Conference: 3-6 August 2003; Durban, South Africa.</i>	2002		
South Africa	Frohlich J, Abdoal Karim Q, Abdoal Karim S. Missed opportunities for treating sexually transmitted infections at a rural primary health care setting in South Africa. In: <i>South African AIDS Conference: 3-6 August 2003; Durban, South Africa.</i>	2002	*	
South Africa	Auvert B, Ballard R, Campbell C, Carael M, Carton M, Fehler G, Gouws E, MacPhail C, Taljaard D, Van Dam J, Williams B. HIV infection among youth in a South African mining town is associated with herpes simplex virus-2 seropositivity and sexual behaviour. <i>AIDS.</i> 2001; 15(7): 885-98.	1999	*	
South Africa	Cockburn N, Steven D, Lecuona K, Joubert F, Rogers G, Cook C, Polack S. Prevalence, Causes and Socio-Economic Determinants of Vision Loss in Cape Town, South Africa. <i>Atashili J, editor. PLoS One.</i> 2012; 7(2): e30718.	2010	*	
South Africa	Cook D. Prevalence and incidence of blindness due to age-related cataract in the rural areas of South Africa. <i>S Afr Med J.</i> 1995; 85(1): 26-7.	1990, 1993	*	
South Africa	Madhi SA, Kuvanda L, Cutland C, Klugman KP. The Impact of a 9-Valent Pneumococcal Conjugate Vaccine on the Public Health Burden of Pneumonia in HIV-Infected and -Uninfected Children. <i>Clin Infect Dis.</i> 2005; 40(10): 1511-8.	1998-2001	*	†
South Africa	Delport SD, Swanepoel JC, Odendaal PJ, Roux P, Chu SY, Tsai WY, Chen LH, Wei ML, Chien YH, Clifton CE. Incidence of retinopathy of prematurity in very-low-birth-weight infants born at Kalafong Hospital Pretoria. <i>S Afr Med J.</i> 2002; 92(12): 986-90.	1999		
South Africa	Nel E. Neonatal meningitis: mortality, cerebrospinal fluid, and microbiological findings. <i>J Trop Pediatr.</i> 2000; 46(4): 237-9.	1981-1992		†
South Africa	Grobler AC, Hay IT. Bacterial meningitis in children at Kalafong Hospital, 1990-1995. <i>S Afr Med J.</i> 1997; 87(8 Suppl): 1052-4.	1990-1995		
South Africa	Friedland IR, Klugman KP. Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis. <i>Lancet.</i> 1992; 339(8790): 405-8.	1989-1991		
South Africa	Benedé JG, Oelofse A, van Stuijvenberg ME, Jooste PL, Weight MJ, Benadé AJ. Endemic goitre in a rural community of KwaZulu-Natal. <i>S Afr Med J.</i> 1997; 87(3): 310-3 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1995		
South Africa	Jooste PL, Weight MJ, Lombard CJ. Short-term effectiveness of mandatory iodization of table salt, at an elevated iodine concentration, on the iodine and goiter status of schoolchildren with endemic goiter. <i>Am J Clin Nutr.</i> 2000; 71(1): 75-80 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1995		
South Africa	Kalk WJ, Paiker J, van Arb MG, Pick W. Dietary iodine deficiency in South Africa. Surveys before the introduction of universal salt iodisation. <i>S Afr Med J.</i> 1998; 88(3 Endocrinology): 357-8 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1994		
South Africa	O'Farrell N, Hoosen AA, Kharsany AB, van den Ende J. Sexually transmitted pathogens in pregnant women in a rural South African community. <i>Genitourin Med.</i> 1989; 65(4): 276-80.	1988		
South Africa	Dietrich M, Hoosen AA, Moodley J, Moodley S. Urogenital tract infections in pregnancy at King Edward VIII Hospital, Durban, South Africa. <i>Genitourin Med.</i> 1992; 68(1): 39-41.	1991		
South Africa	O'Farrell N. Increasing prevalence of genital herpes in developing countries: implications for heterosexual HIV transmission and STI control programmes. <i>Sex Transm Infect.</i> 1999; 75(6): 377-84.	2004	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
South Africa	Thekiso M, Yengopal V, Rudolph MJ, Bhayat A. Caries status among children in the West Rand District of Gauteng Province, South Africa. <i>SADJ</i> . 2012; 67(7): 318-20.	2010	*	
South Africa	May PA, Gossage JP, Marais A-S, Adnams CM, Hoyme HE, Jones KL, Robinson LK, Khaole NCO, Snell C, Kalberg WO, Hendricks L, Brooke L, Stellavato C, Viljoen DL. The epidemiology of fetal alcohol syndrome and partial FAS in a South African community. <i>Drug Alcohol Depend</i> . 2007; 88(2-3): 259-71.	2004		
South Africa	Stewart S, Wilkinson D, Hansen C, Vaghela V, Mvungi R, McMurray J, Sliwa K. Predominance of heart failure in the Heart of Soweto Study cohort: emerging challenges for urban African communities. <i>Circulation</i> . 2008; 118(23): 2360-7.	2006		
South Africa	Fowkes FGR, Thorogood M, Connor MD, Lewando-Hundt G, Tzoulaki I, Tollman SM. Distribution of a subclinical marker of cardiovascular risk, the ankle brachial index, in a rural African population: SASPI study. <i>Eur J Cardiovasc Prev Rehabil</i> . 2006; 13(6): 964-9.	2002-2003	*	
South Africa	Chalmers DA, Todd G, Saxe N, Milne JT, Tolosana S, Ngcelwane PN, Hlaba BN, Mngomeni LN, Nonxuba TG, Williams HC. Validation of the U.K. Working Party diagnostic criteria for atopic eczema in a Xhosa-speaking African population. <i>Br J Dermatol</i> . 2007; 156(1): 111-6.	2004-2006	*	
South Africa	Zar HJ, Ehrlich RI, Workman L, Weinberg EG. The changing prevalence of asthma, allergic rhinitis and atopic eczema in African adolescents from 1995 to 2002. <i>Pediatr Allergy Immunol</i> . 2007; 18(7): 560-5.	1995, 2002	*	
South Africa	Wahlers K, Menezes CN, Wong M, Mogyoe B, Frean J, Romig T, Kern P, Grobusch MP. Human cystic echinococcosis in South Africa. <i>Acta Trop</i> . 2011; 120(3): 179-84.	2005-2010	*	
South Africa	Tucker TJ, Kirsch RE, Louw SJ, Isaacs S, Kannemeyer J, Robson SC. Hepatitis E in South Africa: evidence for sporadic spread and increased seroprevalence in rural areas. <i>J Med Virol</i> . 1996; 50(2): 117-9.	1993-1995		
South Africa	Botha JF, Blackburn NK, Schoub BD, Kew MC. The prevalence of antibodies to the hepatitis A virus in Owambo children. <i>Trop Gastroenterol</i> . 1994; 15(1): 15-7.	1981-1983		
South Africa	Abdool Karim SS, Coutoudis A. Sero-epidemiology of hepatitis A in black South African children. <i>S Afr Med J</i> . 1993; 83(10): 748-50.	1985		
South Africa	Dibisceglie AM, Kew MC, Dusheiko GM, Berger EL, Song E, Paterson AC, Hodgkinson HJ. Prevalence of hepatitis B virus infection among black children in Soweto. <i>Br Med J (Clin Res Ed)</i> . 1986; 292(6533): 1440-2.	1984-1985		
South Africa	Martin DJ, Blackburn NK, Johnson S, McAnerney JM. The current epidemiology of hepatitis A infection in South Africa: implications for vaccination. <i>Trans R Soc Trop Med Hyg</i> . 1994; 88(3): 288-91.	1988-1991		
South Africa	Sathar MA, Soni PN, Fernandes-Costa FJ, Wittenberg DF, Simjee AE. Racial differences in the seroprevalence of hepatitis A virus infection in Natal/KwaZulu, South Africa. <i>J Med Virol</i> . 1994; 44(1): 9-12.	1991-1993		
South Africa	Taylor MB, Becker PJ, Van Rensburg EJ, Harris BN, Bailey IW, Grabow WO. A serosurvey of water-borne pathogens amongst canoeists in South Africa. <i>Epidemiol Infect</i> . 1995; 115(2): 299-307.	1992		
South Africa	Du Plessis R, Webber L, Saayman G. Bloodborne viruses in forensic medical practice in South Africa. <i>Am J Forensic Med Pathol</i> . 1999; 20(4): 364-8.	1996-1998		
South Africa	Hino K, Katoh Y, Vardas E, Sim J, Okita K, Carman WF. The effect of introduction of universal childhood hepatitis B immunization in South Africa on the prevalence of serologically negative hepatitis B virus infection and the selection of immune escape variants. <i>Vaccine</i> . 2001; 19(28-29): 3912-8.	1995-1997		
South Africa	Schoub BD, Johnson S, McAnerney JM, Blackburn NK. The role of sexual transmission in the epidemiology of hepatitis C virus in black South Africans. <i>Trans R Soc Trop Med Hyg</i> . 1992; 86(4): 431-3.	1989-1991		†
South Africa	Velaphi SC, Mokachane M, Mphahlele RM, Beckh-Arnold E, Kuwanda ML, Cooper PA. Survival of very-low-birth-weight infants according to birth weight and gestational age in a public hospital. <i>S Afr Med J</i> . 2005; 95(7): 504-9.	2001	*	
South Africa	Chigumadzi PT, Moodley J, Bagratee J. Infertility profile at King Edward VIII Hospital, Durban, South Africa. <i>Trop Doct</i> . 1998; 28(3): 168-72.	1995	*	
South Africa	South African Medical Research Council, University of Cape Town. South Africa - Western Cape Heroin Use in Cape Town Community Survey 2003-2004.	2003-2004		†
South Africa	Cooper PA, Sandler DL. Outcome of very low birth weight infants at 12 to 18 months of age in Soweto, South Africa. <i>Pediatrics</i> . 1997 Apr; 99(4): 537-44.	1990		†
South Africa	Ballot DE, Chirwa TF, Cooper PA. Determinants of survival in very low birth weight neonates in a public sector hospital in Johannesburg. <i>BMC Pediatr</i> . 2010; 10:30.	2006	*	†
South Africa	South Africa Malaria Control Programme Monthly Report: Period 01-05-95 to 31-05-95 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
South Africa	Plasmodium Falciparum Infection in Children Aged 2-15 Years as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000	*	
South Africa	South African Birth Defects Surveillance Systems Data 2001 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
South Africa	South African Birth Defects Surveillance Systems Data 1993-1997 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1997	*	
South Africa	South African Birth Defects Surveillance Systems Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003		
South Korea	National Bureau of Statistics (South Korea), Economic Planning Board, International Statistical Institute. Korea, Rep. World Fertility Survey 1974. Voorburg, Netherlands: International Statistical Institute.	1974	*	
South Korea	Korea, South Vital Registration - Deaths 1985 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1985	*	
South Korea	World Health Organization (WHO). Control of Foodborne Trematode Infections 1995. Geneva, Switzerland: World Health Organization (WHO), 1995.	1995		†
South Korea	Korea Centers for Disease Control and Prevention. Korea, South National Health and Nutrition Examination Survey 2005.	2005		
South Korea	Jeong JH. Prevalence of and Risk Factors for Atrial Fibrillation in Korean Adults Older than 40 Years. <i>J Korean Med Sci</i> . 2005; 20(1): 26-30.	2000		
South Korea	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
South Korea	Lee E, Park MS, Shin C, Lee H, Yoo K, Kim Y, Shin Y, Paik HY, Lee C. A high-risk group for prostatism: a population-based epidemiological study in Korea. <i>J Urol</i> . 1997; 79(5): 736-41.	1995		
South Korea	Lee EH, Chun KH, Lee Y. Benign prostatic hyperplasia in community-dwelling elderly in Korea. <i>J Korean Acad Nurs</i> . 2005; 35(8): 1508-13.	2003-2005		
South Korea	Lee E, Yoo KY, Kim Y, Shin Y, Lee C. Prevalence of lower urinary tract symptoms in Korean men in a community-based study. <i>Eur Urol</i> . 1998; 33(1): 17-21.	1995		
South Korea	Shin DH, Yu HS, Park JH, Shin JH, Kim SJ. Recently occurring adult tetanus in Korea: emphasis on immunization and awareness of tetanus. <i>J Korean Med Sci</i> . 2003; 18(1): 11-6.	2000-2001		
South Korea	Kim CS, Jung HW, Yoo KY. Prevalence of otitis media and allied diseases in Korea—results of a nation-wide survey, 1991. <i>J Korean Med Sci</i> . 1993; 8(1): 34-40.	1973, 1976-1977, 1991		
South Korea	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol</i> . 2008; 121(4): 947-954.	1995, 2000		
South Korea	Cho HK, Lee H, Kim K-H, Kang JH, Kim J-H, Hur JK, Kim KN, Kim DS, Kim YK, Kim JS, Kim CH, Kim HM, Park S-E, Oh SH, Chung EH, Cha SH, Choi YY, Hong YJ, Lee HJ. The causative organisms of bacterial meningitis in Korean children in 1996-2005. <i>J Korean Med Sci</i> . 2010; 25(6): 895-9.	1996-2005		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
South Korea	Kim JS, Jang YT, Kim JD, Park TH, Park JM, Kilgore PE, Kennedy WA, Park E, Nyambat B, Kim DR, Hwang PH, Kim SJ, Eun SH, Lee HS, Cho JH, Kim YS, Chang SJ, Huang HF, Clemens JD, Ward JI. Incidence of Haemophilus influenzae type b and other invasive diseases in South Korean children. <i>Vaccine</i> . 2004; 22(29-30): 3952-62.	1999-2001		
South Korea	Lee SY, Hong SK, Lee SG, Suh CI, Park SW, Lee JH, Kim JH, Kim DS, Kim HM, Jang YT, Ma SH, Kim SY, Sohn YS, Kang JH, Paik SY. Human rotavirus genotypes in hospitalized children, South Korea, April 2005 to March 2007. <i>Vaccine</i> . 2009; 27(Suppl 5): 97-101.	2005-2007		
South Korea	Cheun H-I, Cho S-H, Lee J-H, Lim Y-Y, Jeon J-H, Yu J-R, Kim T-S, Lee W-J, Cho S-H, Lee D-Y, Park M-S, Jeong H-S, Chen D-S, Ji Y-M, Kwon M-H. Infection status of hospitalized diarrheal patients with gastrointestinal protozoa, bacteria, and viruses in the Republic of Korea. <i>Korean J Parasitol</i> . 2010; 48(2): 113-20.	2004-2006		
South Korea	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2003-2009		
South Korea	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J</i> . 1998; 12(2): 315-35.	1993-1995		
South Korea	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	2000		†
South Korea	Korea Centers for Disease Control and Prevention. Korea, South National Health and Nutrition Examination Survey 2001.	2001		†
South Korea	Korea Centers for Disease Control and Prevention. Korea, South National Health and Nutrition Examination Survey 1998.	1998		
South Korea	Korea Centers for Disease Control and Prevention. Korea, South National Health and Nutrition Examination Survey 2007.	2007		
South Korea	Park Y, Lee H, Koh CS, Min H, Yoo K, Kim Y, Shin Y. Prevalence of diabetes and IGT in Yoncheon County, South Korea. <i>Diabetes Care</i> . 1995; 18(4): 545-8.	1988		
South Korea	Roh JK, Kim JS, Ahn YO. Epidemiologic and clinical characteristics of migraine and tension-type headache in Korea. <i>Headache</i> . 1998; 38(5): 356-65.	1996	*	
South Korea	Hwang G-S, Choi J-W, Yoo Y, Chung J-T, Yoon C-S. Residential environmental risk factors for childhood asthma prevalence in metropolitan and semirural cities in Korea. <i>Asia Pac J Public Health</i> . 2012; 24(1): 58-67.	2009	*	
South Korea	Kim B-J, Kwon J-W, Seo J-H, Kim H-B, Lee S-Y, Park K-S, Yu J, Kim H-C, Leem J-H, Sakong J, Kim S-Y, Lee C-G, Kang D-M, Ha M, Hong Y-C, Kwon H-J, Hong S-J. Association of ozone exposure with asthma, allergic rhinitis, and allergic sensitization. <i>Ann Allergy Asthma Immunol</i> . 2011; 107(3): 214-219.e1.	2005-2006	*	
South Korea	Song W-J, Kim S-H, Lim S, Park Y-J, Kim M-H, Lee S-M, Lee S-B, Kim K-W, Jang H-C, Cho S-H, Min K-U, Chang Y-S. Association between obesity and asthma in the elderly population: potential roles of abdominal subcutaneous adiposity and sarcopenia. <i>Ann Allergy Asthma Immunol</i> . 2012; 109(4): 243-8.	2005-2006	*	
South Korea	Suh M, Kim H-H, Choi DP, Kim KW, Sohn MH, Ha KH, Hwang WJ, Kim C, Kim K-E, Shin DC. Association between body mass index and asthma symptoms among Korean children: a nation-wide study. <i>J Korean Med Sci</i> . 2011; 26(12): 1541-7.	2006	*	
South Korea	Suh M, Kim H-H, Sohn MH, Kim K-E, Kim C, Shin DC. Prevalence of allergic diseases among Korean school-age children: a nationwide cross-sectional questionnaire study. <i>J Korean Med Sci</i> . 2011; 26(3): 332-8.	2006	*	
South Korea	Cho HJ, Chang CB, Kim KW, Park JH, Yoo JH, Koh B, Kim TK. Gender and prevalence of knee osteoarthritis types in elderly Koreans. <i>J Arthroplasty</i> . 2011; 26(7): 994-9.	2005-2006		
South Korea	Kim I, Kim HA, Seo Y-I, Song YW, Jeong J-Y, Kim DH. The prevalence of knee osteoarthritis in elderly community residents in Korea. <i>J Korean Med Sci</i> . 2010; 25(2): 293-8.	2007	*	
South Korea	Lee S, Kim T-N, Kim S-H. Sarcopenic obesity is more closely associated with knee osteoarthritis than is nonsarcopenic obesity: a cross-sectional study. <i>Arthritis Rheum</i> . 2012; 64(12): 3947-54.	2010	*	
South Korea	Chung CY, Park MS, Lee KM, Lee SH, Kim TK, Kim KW, Park JH, Lee JJ. Hip osteoarthritis and risk factors in elderly Korean population. <i>Osteoarthritis Cartilage</i> . 2010; 18(3): 312-6.	2005-2006		
South Korea	Lee SS, Byoun Y-S, Jeong S-H, Kim YM, Gil H, Min B-Y, Seong MH, Jang ES, Kim J-W. Type and cause of liver disease in Korea: single-center experience, 2005-2010. <i>Clin Mol Hepatol</i> . 2012; 18(3): 309-15.	2005-2010	*	
South Korea	Joo H, Park J, Lee SD, Oh Y-M. Comorbidities of chronic obstructive pulmonary disease in Koreans: a population-based study. <i>J Korean Med Sci</i> . 2012; 27(8): 901-6.	2008	*	
South Korea	Yoo KH, Kim YS, Sheen SS, Park JH, Hwang YI, Kim S-H, Yoon HI, Lim SC, Park JY, Park SJ, Seo KH, Kim KU, Oh Y-M, Lee NY, Kim JS, Oh KW, Kim YT, Park I-W, Lee S-D, Kim SK, Kim YK, Han SK. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008. <i>Respirology</i> . 2011; 16(4): 659-65.	2008	*	
South Korea	Choi WJ, Ko JY, Kim JW, Lee KH, Park CW, Kim KH, Kim MN, Lee AY, Cho SH, Park YL, Choi JH, Seo SI, Lee YW, Roh JY, Park YM, Kim DJ, Ro YS. Prevalence and risk factors for atopic dermatitis: a cross-sectional study of 6,453 Korean preschool children. <i>Acta Derm Venereol</i> . 2012; 92(5): 467-71.	2008		
South Korea	Lee J-Y, Seo J-H, Kwon J-W, Yu J, Kim B-J, Lee S-Y, Kim H-B, Kim W-K, Kim K-W, Shin Y-J, Hong S-J. Exposure to gene-environment interactions before 1 year of age may favor the development of atopic dermatitis. <i>Int Arch Allergy Immunol</i> . 2012; 157(4): 363-71.	2008	*	
South Korea	Han D-H, Kim J-B, Park D-Y. The decline in dental caries among children of different ages in Korea, 2000-2006. <i>Int Dent J</i> . 2010; 60(5): 329-35.	2000, 2006	*	
South Korea	Zimmermann A, Bernuit D, Gerlinger C, Schaeffers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. <i>BMC Womens Health</i> . 2012; 6.	2009	*	
South Korea	Cho NH, Jung YO, Lim SH, Chung C-K, Kim HA. The prevalence and risk factors of low back pain in rural community residents of Korea. <i>Spine</i> . 2012; 37(24): 2001-10.	2009	*	
South Korea	Huh J-W, Kim W-H, Moon S-G, Lee J-B, Lim Y-H. Viral etiology and incidence associated with acute gastroenteritis in a 5-year survey in Gyeonggi province, South Korea. <i>J Clin Virol</i> . 2009; 44(2): 152-6.	2001-2005	*	
South Korea	Lee JI, Lee G-C, Chung JY, Han TH, Lee YK, Kim MS, Lee CH. Detection and molecular characterization of adenoviruses in Korean children hospitalized with acute gastroenteritis. <i>Microbiol Immunol</i> . 2012; 56(8): 523-8.	2004-2006	*	
South Korea	Park SH, Kim EJ, Oh SA, Kim CK, Choi SS, Cho SJ, Han KY, Lee JI, Kim MY, Jung HS, Chun DS, Kim HS. Viral agents associated with acute gastroenteritis in Seoul, Korea. <i>Clin Lab</i> . 2011; 57(1-2): 59-65.	2004-2008		
South Korea	Kim KW, Park JH, Kim M-H, Kim MD, Kim B-J, Kim S-K, Kim JL, Moon SW, Bae JN, Woo JI, Ryu S-H, Yoon JC, Lee N-J, Lee DY, Lee DW, Lee SB, Lee JJ, Lee J-Y, Lee C-U, Chang SM, Jhoo JH, Cho MJ. A nationwide survey on the prevalence of dementia and mild cognitive impairment in South Korea. <i>J Alzheimers Dis</i> . 2011; 23(2): 281-91.	2008		
South Korea	Kim J, Jeong I, Chun J-H, Lee S. The prevalence of dementia in a metropolitan city of South Korea. <i>Int J Geriatr Psychiatry</i> . 2003; 18(7): 617-22.	2001-2002		
South Korea	Lee DY, Lee JH, Ju Y-S, Lee KU, Kim KW, Jhoo JH, Yoon JC, Ha J, Woo JI. The prevalence of dementia in older people in an urban population of Korea: the Seoul study. <i>J Am Geriatr Soc</i> . 2002; 50(7): 1233-9.	1990-2000		
South Korea	Suh G-H, Kim JK, Cho MJ. Community study of dementia in the older Korean rural population. <i>Aust N Z J Psychiatry</i> . 2003; 37(5): 606-12.	1996-1997	*	
South Korea	Kim RB, Kim B-G, Kim Y-M, Seo JW, Lim YS, Kim HS, Lee HJ, Moon JY, Kim KY, Shin J-Y, Park H-K, Song J-K, Park K-S, Jeong BG, Park CG, Shin H-Y, Kang J-W, Oh G-J, Lee Y-H, Seong I-W, Yoo W-S, Hong Y-S. Trends in the Incidence of Hospitalized Acute Myocardial Infarction and Stroke in Korea, 2006-2010. <i>J Korean Med Sci</i> . 2013; 28(1): 16.	2006-2010		
South Korea	Lee J-H, Cho HK, Kim K-H, Kim CH, Kim DS, Kim KN, Cha S-H, Oh SH, Hur JK, Kang JH, Kim JH, Kim Y-K, Hong YJ, Chung EH, Park S-E, Choi YY, Kim JS, Kim HM, Choi EH, Lee HJ. Etiology of invasive bacterial infections in immunocompetent children in Korea (1996-2005): a retrospective multicenter study. <i>J Korean Med Sci</i> . 2011; 26(2): 174-83.	1996-2005		
South Korea	Cho MJ, Kim J-K, Jeon HJ, Suh T, Chung I-W, Hong JP, Bae J-N, Lee D-W, Park J-I, Cho S-J, Lee C-K, Hahn B-J. Lifetime and 12-month prevalence of DSM-IV psychiatric disorders among Korean adults. <i>J Nerv Ment Dis</i> . 2007; 195(3): 203-10.	2001		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
South Korea	Kim SC, Moon YT, Hong YP, Hwang TK, Choi SH, Kim KJ, Sul CK, Park TC, Kim YG, Park KS. Prevalence and risk factors of urinary stones in Koreans. <i>J Korean Med Sci.</i> 1998; 13(2): 138-46.	1995-1996		
South Korea	Kim DS, Kim YS, Jung KS, Chang JH, Lim CM, Lee JH, Uh ST, Shim JJ, Lew WJ. Korean Academy of Tuberculosis and Respiratory Diseases. Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey. <i>Am J Respir Crit Care Med.</i> 2005; 172(7): 842-7.	2001-2002		
South Korea	Kim SJ, Suk MH, Choi HM, Kimm KC, Jung KH, Lee SY, Lee SY, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Yoo SH. The local prevalence of COPD by post-bronchodilator GOLD criteria in Korea. <i>Int J Tuberc Lung Dis.</i> 2006; 10(12): 1393-8.	2003-2004		
South Korea	Kim YS, Leventhal BL, Koh Y-J, Fombonne E, Laska E, Lim E-C, Cheon K-A, Kim S-J, Kim Y-K, Lee H, Song D-H, Grinker RR. Prevalence of Autism Spectrum Disorders in a Total Population Sample. <i>Am J Psychiatry.</i> 2011; 168(9): 904-12.	2005-2006		
South Korea	Yoo HI, Cho SC, Kim BN, Kim SY, Shin MS, Hong KE. Psychiatric Morbidity of Second and Third Grade Primary School Children in Korea. <i>Child Psychiatry Hum Dev.</i> 2005; 36(2): 215-25.	2003		
South Korea	United States Renal Data System Coordinating Center. <i>USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States.</i> Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2004-2008		†
South Korea	Choi D, Lee D-Y, Lebert P, Lee IS, Kim SH, Dennerstein L. The impact of premenstrual symptoms on activities of daily life in Korean women. <i>J Psychosom Obstet Gynaecol.</i> 2010; 31(1): 10-5.	2008		
South Korea	United States Renal Data System Coordinating Center. <i>USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States.</i> Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	1999-2003		
South Korea	United States Renal Data System Coordinating Center. <i>USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States.</i> Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2003.	1999		
South Korea	Lee S-J, Cho Y-H, Ha U-S, Kim SW, Yoon MS, Bae K. Sexual behavior survey and screening for chlamydia and gonorrhea in university students in South Korea. <i>Int J Urol.</i> 2005; 12(2): 187-93.	2005		
South Korea	Yang S-K, Yun S, Kim J-H, Park JY, Kim HY, Kim Y-H, Chang DK, Kim JS, Song IS, Park JB, Park E-R, Kim KJ, Moon G, Yang SH. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. <i>Inflamm Bowel Dis.</i> 2008; 14(4): 542-9.	1986-2005	*	
South Korea	Kim S, Lim CS, Han DC, Kim GS, Chin HJ, Kim SJ, Cho WY, Kim YH, Kim YS. The prevalence of chronic kidney disease (CKD) and the associated factors to CKD in urban Korea: a population-based cross-sectional epidemiologic study. <i>J Korean Med Sci.</i> 2009; 24(Suppl): S11-21.	2005-2006		
South Korea	Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, Joyce PR, Karam EG, Lee CK, Lellouch J, Lépine JP, Newman SC, Rubio-Stipec M, Wells JE, Wickramaratne PJ, Wittchen H, Yeh EK. Cross-national epidemiology of major depression and bipolar disorder. <i>JAMA.</i> 1996; 276(4): 293-9.	1984		
South Korea	Han Y, Kim B, Baek I, Lee D, Kim K, Dong S, Kim H, Chang Y, Lee J, Chang R. [The change of the etiology, complications and cause of death of the liver cirrhosis in 1990s]. <i>Korean J Hepatol.</i> 2000; 6(3): 328-39.	1991-1998		
South Korea	Kim YS, Um SH, Ryu HS, Lee JB, Lee JW, Park DK, Kim YS, Jin YT, Chun HJ, Lee HS, Lee SW, Choi JH, Kim CD, Hyun JH. The prognosis of liver cirrhosis in recent years in Korea. <i>J Korean Med Sci.</i> 2003; 18(6): 833-41.	1991-1999		
South Korea	Shim J, Kim B-H, Kim NH, Dong SH, Kim HJ, Chang YW, Lee JI, Chang R. Clinical features of HBsAg-negative but anti-HBc-positive hepatocellular carcinoma in a hepatitis B virus endemic area. <i>J Gastroenterol Hepatol.</i> 2005; 20(5): 746-51.	1995-2000		
South Korea	Hong YP, Kim SJ, Lew WJ, Lee EK, Han YC. The seventh nationwide tuberculosis prevalence survey in Korea, 1995. <i>Int J Tuberc Lung Dis.</i> 1998; 2(1): 27-36.	1985, 1990, 1995		
South Korea	World Health Organization (WHO). <i>WHO Tuberculosis Case Notifications.</i> Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012	*	
South Korea	Chang Y, Sung E, Ryu S, Park Y-W, Jang YM, Park M. Insulin resistance is associated with gallstones even in non-obese, non-diabetic Korean men. <i>J Korean Med Sci.</i> 2008; 23(4): 644-50.	2005	*	
South Korea	Cho S-C, Kim B-N, Kim J-W, Rohde LA, Hwang J-W, Chung D-S, Shin M-S, Lyoo IK, Go B-J, Lee S-E, Kim H-W. Full syndrome and subthreshold attention-deficit/hyperactivity disorder in a Korean community sample: comorbidity and temperament findings. <i>Eur Child Adolesc Psychiatry.</i> 2009; 18(7): 447-57.	2005	*	
South Korea	Chu MK, Oh K, Kim B-K. Prevalence and impact of chronic daily headache in Korea: Results from Korean headache survey. <i>Cephalalgia.</i> 2011; 31(Suppl 1): 138-9.	2009		
South Korea	Choe H-S, Lee S-J, Kim CS, Cho Y-H. Prevalence of sexually transmitted infections and the sexual behavior of elderly people presenting to health examination centers in Korea. <i>J Infect Chemother.</i> 2011; 17(4): 456-61.	2009	*	
South Korea	Choe H-S, Lee DS, Lee S-J, Lee CB, Lee WC, Cho Y-H. Prevalence of sexually transmitted infections and sexual behavior of young adults and middle-aged people presenting to health examination centers in Korea. <i>J Infect Chemother.</i> 2012; 18(2): 207-12.	2010		
South Korea	Kim O, Kim S-S, Park M-S, Suh S-D, Lee M-W, Kim K-S, Yoon J-D, Lee J-S. Seroprevalence of sexually transmitted viruses in Korean populations including HIV-seropositive individuals. <i>Int J STD AIDS.</i> 2003; 14(1): 46-9.	2000		
South Korea	Lee HY, Won JC, Kang YJ, Yoon SH, Choi EO, Bae JY, Sung MH, Kim H-R, Yang JH, Oh J, Lee YM, Park NH, Ko KS, Rhee BD. Type 2 diabetes in urban and rural districts in Korea: factors associated with prevalence difference. <i>J Korean Med Sci.</i> 2010; 25(12): 1777-83.	2006		
South Korea	Lee J-E, Jung S-C, Jung G-H, Ha S-W, Kim B-W, Chae S-C, Park W-H, Lim J-S, Yang J-H, Kam S, Chun B-Y, Kim J-Y, Lee J-J, Lee K-S, Ahn M-Y, Kim Y-A, Kim J-G. Prevalence of Diabetes Mellitus and Prediabetes in Dalseong-gun, Daegu City, Korea. <i>Diabetes Metab J.</i> 2011; 35(3): 255-63.	2003		
South Korea	Park C-Y, Park SE, Bae JC, Kim WJ, Park SW, Ha MM, Song SJ. Prevalence of and risk factors for diabetic retinopathy in Koreans with type II diabetes: baseline characteristics of Seoul Metropolitan City-Diabetes Prevention Program (SMC-DPP) participants. <i>Br J Ophthalmol.</i> 2012; 96(2): 151-5.	2008-2009		
South Korea	Yun J-S, Ko S-H, Kim J-H, Moon K-W, Park Y-M, Yoo K-D, Ahn Y-B. Diabetic retinopathy and endothelial dysfunction in patients with type 2 diabetes mellitus. <i>Diabetes Metab J.</i> 2013; 37(4): 262-9.	2010-2011		
South Korea	Song K-H, Nam-Goong IS, Han S-M, Kim M-S, Lee E-J, Lee YS, Lee MS, Yoon S, Lee K-U, Park J-Y. Change in prevalence and 6-year incidence of diabetes and impaired fasting glucose in Korean subjects living in a rural area. <i>Diabetes Res Clin Pract.</i> 2007; 78(3): 378-84.	1997, 2003		
South Korea	Lee G. End-stage renal disease in the Asian-Pacific region. <i>Semin Nephrol.</i> 2003; 23(1): 107-14.	1998, 2000		
South Korea	Park K, Kim YS, Kim SL, Kim MS, Kim HJ, Jeon KO. Kidney transplantation in Korea: past and present. <i>Clin Transpl.</i> 2000; 376-8.	1997, 1999		
South Korea	Lee HK, Chou SP, Cho MJ, Park J-I, Dawson DA, Grant BF. The prevalence and correlates of alcohol use disorders in the United States and Korea - a cross-national comparative study. <i>Alcohol.</i> 2010; 44(4): 297-306.	2001		
South Korea	Min S, Noh S, Shin J, Ahn J-S, Kim T-H. Alcohol dependence, mortality, and chronic health conditions in a rural population in Korea. <i>J Korean Med Sci.</i> 2008; 23(1): 1-9.	1998-2004	*	
South Korea	Seo W-K, Koh S-B, Kim B-J, Yu S-W, Park M-H, Park K-W, Lee D-H. Prevalence of Parkinson's disease in Korea. <i>J Clin Neurosci.</i> 2007; 14(12): 1155-7.	1999-2001	*	
South Korea	Rho Y-I, Chung H-J, Lee K-H, Eun B-L, Eun S-H, Nam S-O, Kim W-S, Kim Y-O, Park H-J, Kim H-S. Prevalence and clinical characteristics of primary headaches among school children in South Korea: a nationwide survey. <i>Headache.</i> 2012; 52(4): 592-9.	2009	*	
South Korea	Korea Centers for Disease Control and Prevention. <i>Korea, South National Health and Nutrition Examination Survey 2012.</i>	2012	*	
South Korea	Cheun H-I, Lee J-S, Cho S-H, Kong Y, Kim T-S. Elimination of lymphatic filariasis in the Republic of Korea: an epidemiological survey of formerly endemic areas, 2002-2006. <i>Trop Med Int Health.</i> 2009; 14(4): 445-9. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2002	*	
South Korea	Choi S-H, Hong S-B, Ko G-B, Lee Y, Park HJ, Park S-Y, Moon SM, Cho O-H, Park K-H, Chong YP, Kim S-H, Huh JW, Sung H, Do K-H, Lee S-O, Kim M-N, Jeong J-Y, Lim C-M, Kim YS, Woo JH, Koh Y. Viral infection in patients with severe pneumonia requiring intensive care unit admission. <i>Am J Respir Crit Care Med.</i> 2012; 186(4): 325-32.	2010-2011	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
South Korea	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
South Korea	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
South Korea	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
South Korea	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	
South Korea	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
South Korea	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
South Korea	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
South Korea	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
South Korea	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
South Korea	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
South Korea	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
South Korea	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
South Korea	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
South Korea	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
South Korea	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
South Korea	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
South Korea	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
South Korea	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland; World Health Organization (WHO).	2001-2011		
South Korea	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2000.	2000		
South Korea	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2001.	2001		
South Korea	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2002.	2002		
South Korea	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2003.	2003		
South Korea	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2004.	2004		
South Korea	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2005.	2005		
South Korea	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2006.	2006		
South Korea	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2007.	2007		
South Korea	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2009.	2009		
South Korea	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2010.	2010	*	
South Korea	Jhoon JH, Kim KW, Huh Y, Lee SB, Park JH, Lee JJ, Choi EA, Han C, Choo IH, Youn JC, Lee DY, Woo JI. Prevalence of dementia and its subtypes in an elderly urban Korean population: results from the Korean Longitudinal Study on Health And Aging (KLoSHA). Dement Geriatr Cogn Disord. 2008; 26(3): 270-6.	2005-2006		
South Korea	Lee HR, Lee MJ, Hahm JH. Clinical Study and Acyclovir Therapy of Herpes Zoster. Korean J Dermatol. 1995; 33(4): 661-88.	1990-1993		
South Korea	Kang C-I, Choi C-M, Park T-S, Lee D-J, Oh M, Choe K-W. Incidence of herpes zoster and seroprevalence of varicella-zoster virus in young adults of South Korea. Int J Infect Dis. 2008; 12(3): 245-7.	2004-2005	*	
South Korea	Kim B-K, Chu MK, Lee TG, Kim J-M, Chung C-S, Lee K-S. Prevalence and impact of migraine and tension-type headache in Korea. J Clin Neurol. 2012; 8(3): 204-11.	2009		
South Korea	Sung Y, Kim D, Yoo S, Baik S, Oh J, Lee H. The prevalence and phenotypes of polycystic ovary syndrome in Korean women. Endocr Abstr. 2010; 22: 486.	2008-2009		
South Korea	Kweon S-S, Shin M-H, Park K-S, Nam H-S, Jeong S-K, Ryu S-Y, Chung E-K, Choi J-S. Distribution of the ankle-brachial index and associated cardiovascular risk factors in a population of middle-aged and elderly Koreans. J Korean Med Sci. 2005; 20(3): 373-8.	2004	*	
South Korea	Park S, Oh S, Lee J, Park G, Choi S, Chae Y, Kim H. Genotypes of rotavirus associated with acute gastroenteritis in Seoul, Korea. Microbiol Immunol. 2011; 55(9): 641-4.	2009	*	
South Korea	Huh J-W, Kim W-H, Yoon M-H, Lim Y-H. Genotypic distribution of rotavirus strains causing severe gastroenteritis in Gyeonggi province, South Korea, from 2003 to 2005. Arch Virol. 2009; 154(1): 167-70.	2003-2005	*	
South Korea	Kang JO, Kim CR, Kilgore PE, Choi TY. G and P genotyping of human rotavirus isolated in a university hospital in Korea: implications for nosocomial infections. J Korean Med Sci. 2006; 21(6): 983-8.	2001-2003	*	
South Korea	Kim JS, Kang JO, Cho SC, Jang YT, Min SA, Park TH, Nyambat B, Jo DS, Gentsch J, Bressee JS, Mast TC, Kilgore PE. Epidemiological profile of rotavirus infection in the Republic of Korea: results from prospective surveillance in the Jeongneub District, 1 July 2002 through 30 June 2004. J Infect Dis. 2005; 191(5): 549-56.	2002-2004	*	
South Korea	Le VP, Kim J-Y, Cho S-L, Nam S-W, Lim I, Lee H-J, Kim K, Chung S-I, Song W, Lee KM, Rhee M-S, Lee J-S, Kim W. Detection of unusual rotavirus genotypes G8P[8] and G12P[6] in South Korea. J Med Virol. 2008; 80(1): 175-82.	2004-2006	*	
South Korea	Moon S-S, Green YS, Song J-W, Ahn CN, Kim H, Park KS, Song K-J, Lee JH, Baek LJ. Genetic distribution of group A human rotavirus types isolated in Gyeonggi province of Korea, 1999-2002. J Clin Virol. 2007; 38(1): 57-63.	1999-2002	*	
South Korea	Song M-O, Kim K-J, Chung S-I, Lim I, Kang S-Y, An C-N, Kim W. Distribution of human group A rotavirus VP7 and VP4 types circulating in Seoul, Korea between 1998 and 2000. J Med Virol. 2003; 70(2): 324-8.	1998-2000	*	
South Korea	Chang K, Kim C, Oh S, Lee H, Lee K. A clinical and epidemiological study on rotavirus gastroenteritis in children. J Korean Pediatr Soc. 1988; 961-76.	1983-1987	*	
South Korea	Bae GY, Oh ET, Jung WS, Kim SS. A Study of Serum Transaminase Level and Its Correlation with Several Symptoms in Children with HRV Gastroenteritis. J Korean Pediatr Soc. 1993; 36(8): 1146-55.	1991	*	
South Korea	Han S, Seo S, Min K, Kim J, Kim K, Ryoo K. Clinical observations on human rotavirus (HRV) gastroenteritis. J Korean Pediatr Soc. 1992; 226-33.	1987-1989	*	
South Korea	Hong G, Jeon H, Choi W, Namgoong M, Kim J. A study of relation between serum aminotransferase elevation and clinical symptoms from human rotavirus gastroenteritis. J Korean Pediatr Soc. 1995; 54-60.	1991-1993	*	
South Korea	Kim D, Park B, Jung D, Ahn J, Kim C, Kang S. Prevalence and identification of rotaviruses in stool specimens of patients with acute diarrhea from several regions of Korea. J Korean Pediatr Soc. 1999; 501-9.	1991-1992	*	
South Korea	Rhee E, Hwang N, Choi Y, Seo S. Clinical studies of human rotavirus gastroenteritis. J Korean Pediatr Soc. 1989; 369-79.	1986-1987	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
South Korea	Chung GE, Yim JY, Kim D, Lim SH, Park MJ, Kim YS, Yang SY, Yang JI, Cho S-H. Seroprevalence of hepatitis a and associated socioeconomic factors in young healthy Korean adults. <i>Gut Liver</i> . 2011; 5(1): 88-92.	2009-2010	*	
South Korea	Yun H, Lee H-J, Cheon D, Chu C, Oh KW, Kim YT, Jee Y. Seroprevalence of Hepatitis A and E Viruses Based on the Third Korea National Health and Nutrition Survey in Korea. <i>Osong Public Health Res Perspect</i> . 2011; 2(1): 46-50.	2005		
South Korea	Yang S-K, Hong W-S, Min YI, Kim HY, Yoo JY, Rhee P-L, Rhee JC, Chang DK, Song IS, Jung SA, Park E-B, Yoo HM, Lee DK, Kim YK. Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986-1997. <i>J Gastroenterol Hepatol</i> . 2000; 15(9): 1037-42.	1986-1997	*	
South Korea	Lee SS, Jeong S-H, Byoun Y-S, Chung SM, Seong MH, Sohn HR, Min B-Y, Jang ES, Kim J-W, Park GJ, Lee YJ, Lee KH, Ahn S. Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma. <i>BMC Cancer</i> . 2013; 335.	2003-2012	*	
South Korea	Choi I-S, Kwon H-J, Shin N-R, Yoo HS. Identification of swine hepatitis E virus (HEV) and prevalence of anti-HEV antibodies in swine and human populations in Korea. <i>J Clin Microbiol</i> . 2003; 41(8): 3602-8.	1995		
South Korea	Park C-H, Cho Y-K, Park J-H, Jun J-S, Park E-S, Seo J-H, Lim J-Y, Woo H-O, Youn H-S, Ko G-H, Kang H-L, Baik S-C, Lee W-K, Cho M-J, Rhee K-H. Changes in the age-specific prevalence of hepatitis A virus antibodies: a 10-year cohort study in Jinju, South Korea. <i>Clin Infect Dis</i> . 2006; 42(8): 1148-50.	1988-1997		
South Korea	Sohn YM, Rho HO, Park MS, Park JH, Choi BY, Ki M, Jang WI. The changing epidemiology of hepatitis A in children and the consideration of active immunization in Korea. <i>Yonsei Med J</i> . 2000; 41(1): 34-9.	1996-1997		
South Korea	Kim TY, Sohn JH, Ahn SB, Son BK, Lee HL, Eun CS, Jeon CS, Han DS. Comparison of Recent IgG Anti-HAV Prevalence between Two Hospitals in Seoul and Gyeonggi area. <i>Korean J Hepatol</i> . 2007; 13(3): 363.	2002-2006		
South Korea	Song YB, Lee JH, Choi MS, Koh KC, Paik SW, Yoo BC, Choi Y-H, Sohn HJ, Lee KH, Rhee JC. [The age-specific seroprevalence of hepatitis A virus antibody in Korea]. <i>Korean J Hepatol</i> . 2007; 13(1): 27-33.	2006		
South Korea	Ahn J-M, Kang S-G, Lee D-Y, Shin SJ, Yoo HS. Identification of novel human hepatitis E virus (HEV) isolates and determination of the seroprevalence of HEV in Korea. <i>J Clin Microbiol</i> . 2005; 43(7): 3042-8.	2003-2004		
South Korea	Jang MK, Lee JY, Lee JH, Kim YB, Kim HY, Lee MS, Park CK, Yoo JY. Seroprevalence of HBV infection in South Korea, 1995 through 1999. <i>Korean J Intern Med</i> . 2001; 16(3): 153-9.	1995-1999		
South Korea	Shin H-R, Hwang SY, Nam C-M. The Prevalence of Hepatitis C Virus Infection in Korea: Pooled Analysis. <i>J Korean Med Sci</i> . 2005; 20(6): 985-8.	1990-2001		
South Korea	Shin HR, Kim JY, Jung KY, Kim WS, Hong YS, Kim BG, Kim SR, Lee BO, Park TS, Lee YH, Ok ID, Kim SR, Yang MK, Taniguchi M, Kim MM, Kim KL. Prevalence of hepatitis B and C virus infection among adults in Korea. <i>Hepatol Res</i> . 1997; 7(3): 213-25.	1994		
South Korea	Shin HR, Kim JY, Kim JI, Lee DH, Yoo KY, Lee DS, Franceschi S. Hepatitis B and C virus prevalence in a rural area of South Korea: the role of acupuncture. <i>Br J Cancer</i> . 2002; 87(3): 314-8.	1988-1994		
South Korea	Shin, Kim, Ohno, Cao, Mizokami, Risch, Kim. Prevalence and risk factors of hepatitis C virus infection among Koreans in rural area of Korea. <i>Hepatol Res</i> . 2000; 17(3): 185-96.	1993		
South Korea	Taniguchi M, Kim SR, Mishiho S, Takahashi K, Shin MH, Yun H, Park MS, Li ZM, Kim MK, Fang J, Hayashi Y. Epidemiology of hepatitis E in Northeastern China, South Korea and Japan. <i>J Infect</i> . 2009; 58(3): 232-7.	2005-2008		†
South Korea	Hahn W-H, Chang J-Y, Chang YS, Shim KS, Bae C-W. Recent trends in neonatal mortality in very low birth weight Korean infants: in comparison with Japan and the USA. <i>J Korean Med Sci</i> . 2011; 26(4): 467-73.	2002, 2009	*	
South Korea	Chai J-Y, Lee S-H, Choi S-Y, Lee J-S, Yong T-S, Park K-J, Yang K-A, Lee K-H, Park M-J, Park H-R, Kim M-J, Rim H-J. A survey of <i>Brugia malayi</i> infection on the Heugans Islands, Korea. <i>Korean J Parasitol</i> . 2003; 41(1): 69-73. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections</i> .	2000	*	
South Korea	Cheun H-I, Kong Y, Cho S-H, Lee J-S, Chai J-Y, Lee J-S, Lee J-K, Kim T-S. Successful control of lymphatic filariasis in the Republic of Korea. <i>Korean J Parasitol</i> . 2009; 47(4): 323-35. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections</i> .	1980, 1982-1992, 2000	*	
South Korea	Kim DC, Lee OY, Jeong EB, Jeong MG. [Natural Transition Of Endemicity Of Malayan Filariasis In Inland Korea: Pattern Of Change In Microfilaria Rate Among Inhabitants Of Yongpung (Former Yongju) Area During The Period Of The Last Seven Years]. <i>Kisaengchunghak Chapchi</i> . 1980; 18(2): 171-8. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections</i> .	1980-2001	*	
South Korea	Korea Association of Health. Collected Papers on Parasite Control in Korea. Seoul, South Korea: Korea Association of Health, 1994.	1971, 1976, 1981, 1986, 1992	*	
South Korea	Food and Agriculture Organization of the United Nations (FAO), World Health Organization (WHO). Joint WHO/FAO Workshop on Foodborne Trematode Infections in Asia. WHO Regional Office for the Western Pacific, 2004.	2004	*	
South Korea	Korea Centers for Disease Control and Prevention, Korea National Institute of Health, Ministry of Health and Welfare (South Korea). Korea, South National Survey of the Prevalence of Intestinal Parasitic Infections 2004.	2004	*	
South Korea	Jeong IG, Kang T, Bang JK, Park J, Kim W, Hwang SS, Kim HK, Park HK. Association between metabolic syndrome and the presence of kidney stones in a screened population. <i>Am J Kidney Dis</i> . 2011; 58(3): 383-8.	2006	*	
South Korea	Kim Hh, Jo MK, Kwak C, Park SK, Yoo KY, Kang D, Lee C. Prevalence and epidemiologic characteristics of urolithiasis in Seoul, Korea. <i>Urology</i> . 2002; 59(4): 517-21.	1998		
South Korea	Woo JI, Lee JH, Yoo KY, Kim CY, Kim YI, Shin YS. Prevalence estimation of dementia in a rural area of Korea. <i>J Am Geriatr Soc</i> . 1998; 46(8): 983-7.	1992-1993		
South Sudan	Gibbs, S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. <i>Int J Dermatol</i> . 1996; 35(9): 633-9.	1994		
South Sudan	Seaman J, Mercer AJ, Sondorp HE, Herwaldt BL. Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. <i>Ann Intern Med</i> . 1996; 124(7): 664-72.	1990-1991		
South Sudan	Ngondi J, Ole-Sempole F, Onsarigo A, Matende I, Baba S, Reacher M, Matthews F, Brayne C, Emerson PM. Prevalence and causes of blindness and low vision in southern Sudan. <i>PLoS Med</i> . 2006; 3(12): e477. as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	2005	*	
South Sudan	Ayazi T, Lien L, Eide AH, Ruom MM, Hauff E. What are the risk factors for the comorbidity of posttraumatic stress disorder and depression in a war-affected population? A cross-sectional community study in South Sudan. <i>BMC Psychiatry</i> . 2012; 12: 175.	2010	*	
South Sudan	Roberts B, Damundu EY, Lomoro O, Sondorp E. Post-conflict mental health needs: a cross-sectional survey of trauma, depression and associated factors in Juba, Southern Sudan. <i>BMC Psychiatry</i> . 2009; 7.	2007		
South Sudan	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2012	*	
South Sudan	World Health Organization (WHO). South Sudan WHO Leishmaniasis Country Profile.	1989-2011	*	
South Sudan	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec</i> . 2005; 80(13): 118-24.	2003	*	
South Sudan	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec</i> . 2005; 80(34): 289-95.	2004	*	
South Sudan	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec</i> . 2007; 82(25): 225-32.	2006	*	
South Sudan	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec</i> . 2009; 84(33): 333-40.	2008	*	
South Sudan	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec</i> . 2010; 85(35): 337-48.	2009	*	
South Sudan	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec</i> . 2012; 87(34): 317-28.	2011	*	
South Sudan	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec</i> . 2008; 83(33): 293-300.	2007	*	
South Sudan	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec</i> . 1999; 74(38): 313-6.	1998	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
South Sudan	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
South Sudan	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
South Sudan	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
South Sudan	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
South Sudan	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
South Sudan	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
South Sudan	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1993; 68(25): 181-6.	1992	*	
South Sudan	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
South Sudan	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	†
South Sudan	A Continuous Assessment of the Impact of Impregnated Bed Nets in the Transmission of Malaria in Selected Areas in the Upper Nile State During the Period 7-17 December 1998 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
South Sudan	Taha TE, Broadhead RL. Malaria in primary school children in Juba, southern Sudan. East Afr Med J. 1986; 63(8): 546-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985		
Spain	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2000-2005		
Spain	Spain Vital Registration - Deaths 1980 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1980		
Spain	Spain Vital Registration - Deaths 1981 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1981		
Spain	Spain Vital Registration - Deaths 1982 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1982		
Spain	Spain Vital Registration - Deaths 1983 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1983		
Spain	Spain Vital Registration - Deaths 1984 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1984		
Spain	Spain Vital Registration - Deaths 1985 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1985		
Spain	Spain Vital Registration - Deaths 1986 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1986		
Spain	Spain Vital Registration - Deaths 1987 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1987		
Spain	Spain Vital Registration - Deaths 1988 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1988		
Spain	Spain Vital Registration - Deaths 1989 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1989		
Spain	Spain Vital Registration - Deaths 1991 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1991		
Spain	Spain Vital Registration - Deaths 1992 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1992		
Spain	Spain Vital Registration - Deaths 1993 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1993		
Spain	Spain Vital Registration - Deaths 1994 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1994		
Spain	Spain Vital Registration - Deaths 1995 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1995		
Spain	Spain Vital Registration - Deaths 1996 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1996		
Spain	Spain Vital Registration - Deaths 1997 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1997		
Spain	Spain Vital Registration - Deaths 1998 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1998	*	
Spain	Spain Vital Registration - Deaths 1999 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1999	*	
Spain	Spain Vital Registration - Deaths 2000 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2000	*	
Spain	Spain Vital Registration - Deaths 2001 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2001	*	
Spain	Spain Vital Registration - Deaths 2002 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2002	*	
Spain	Spain Vital Registration - Deaths 2003 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2003	*	
Spain	Spain Vital Registration - Deaths 2004 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2004	*	
Spain	Spain Vital Registration - Deaths 2005 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2005		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Spain	World Health Organization (WHO). Spain World Health Survey 2002-2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2002-2003	*	
Spain	Spain Vital Registration - Deaths 2008 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2008	*	
Spain	Spain Vital Registration - Deaths 2007 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2007	*	
Spain	Spain Vital Registration - Deaths 2006 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2006		
Spain	National Statistics Institute (Spain), United Nations Economic Commission for Europe (UNECE). Spain Fertility and Family Survey 1994-1995. Geneva, Switzerland: United Nations Economic Commission for Europe (UNECE).	1994-1995	*	
Spain	World Health Organization (WHO). Control of Foodborne Trematode Infections 1995. Geneva, Switzerland: World Health Organization (WHO), 1995.	1995	*	
Spain	Spain Vital Registration - Deaths 2009 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2009	*	
Spain	Spain Vital Registration - Deaths 2010 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2010		
Spain	Spain Vital Registration - Deaths 2011 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2011		
Spain	Clua Espuny JL, Dalmáu Llorca MR, Aguilar Martín C. [Characteristics of oral anti-coagulation treatment in high-risk chronic atricular fibrillation]. <i>Aten Primaria</i> . 2004; 34(8): 414-9.	2002		
Spain	González-Paredo R, Muñoz-Esteban C, Amado-Fernández C, Riancho JA. [Known and concealed atricular fibrillation in the population consulting in a health area]. <i>Aten Primaria</i> . 2007; 39(2): 106-7.	2004-2005		
Spain	Candel FJ, Matesanz M, Cogolludo F, Candel I, Mora C, Bescos T, Martín M, Vila i Costa I. Prevalencia de fibrilación auricular y factores relacionados en una población del centro de Madrid. <i>An Med Interna</i> . 2004; 21(10): 17-22.	2000-2001		
Spain	Masia R, Sala J, Marrugat J, Pena A. Prevalencia de fibrilación auricular en la provincia de Girona: el Estudio REGICOR. <i>Rev Esp Cardiol</i> . 2001; 54(10): 1240.	1994-1996		
Spain	Cea-Calvo L, Redón J, Lozano JV, Fernández-Pérez C, Martí-Canales JC, Llisteri JL, González-Esteban J, Aznar J. Prevalencia de fibrilación auricular en la población española de 60 o más años de edad. <i>Estudio PREV-ICTUS</i> . <i>Rev Esp Cardiol</i> . 2007; 60(6): 616-24.	2005		
Spain	Labrador García MS, Merino Segovia R, Jiménez Domínguez C, García Salvador Y, Segura Frago A, Hernández Lanchas C. [Prevalence of atricular fibrillation in people over 65 years of age in a health area]. <i>Aten Primaria</i> . 2001; 28(10): 648-51.	1999		
Spain	Martín Acicoya D, Pedrero Pérez P, Martínez García JA, González Alvaro A, Hernando López T, Herreros Hernanz I. [Prevention of thromboembolism in patients with chronic atrial fibrillation in primary health care]. <i>Med Clin (Barc)</i> . 2004; 122(2): 53-6.	2002		
Spain	Thalassaemia International Federation, World Health Organization (WHO). Management of Haemoglobin Disorders: Report of a Joint WHO-TIF Meeting, Nicosia, Cyprus, 16-18 November 2007. Geneva, Switzerland: World Health Organization (WHO), 2008.	2004, 2006		
Spain	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. <i>Scand J Clin Lab Invest</i> . 2007; 67(1): 39-69.	1988, 2006		
Spain	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1988, 2003, 2006		†
Spain	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	2009		
Spain	Chicharro Molero JA, Burgos Rodríguez R. Epidemiology of benign prostatic hyperplasia. Definition of the condition. <i>Rev Clin Esp</i> . 1999; 199(Suppl 2): 12-8.	1997-1999		
Spain	Fernández Pérez C, Moreno Sierra J, Cano Escudero S, Fuentes Ferrer ME, Bocado Fajardo G, Salmi Moyano A. Prevalence of lower urinary tract symptoms related with benign prostatic hyperplasia. Study of 1804 men aged 40 or older in Madrid. <i>Actas Urol Esp</i> . 2009; 33(1): 43-51.	1999-2000		
Spain	Chicharro-Molero JA, Burgos-Rodríguez R, Sanchez-Cruz JJ, Del Rosal-Samaniego JM, Rodero-Carcia P, Rodriguez-Vallejo JM. Prevalence of benign prostatic hyperplasia in Spanish men 40 years old or older. <i>J Urol</i> . 1998; 159(3): 878-82.	1996		
Spain	Hunter DJ, Berra-Unamuno A, Martín-Gordo A. Prevalence of urinary symptoms and other urological conditions in Spanish men 50 years old or older. <i>J Urol</i> . 1996; 155(6): 1965-70.	1995		
Spain	Briones ML, Blanquer J, Ferrando D, Blasco ML, Gimeno C, Marín J. Assessment of analysis of urinary pneumococcal antigen by immunochromatography for etiologic diagnosis of community-acquired pneumonia in adults. <i>Clin Vaccine Immunol</i> . 2006; 13(10): 1092-7.	2000-2004		
Spain	Gaig P, Olona M, Muñoz Lejarazu D, Caballero MT, Domínguez FJ, Echechipia S, García Abujeta JL, Gonzalo MA, Lleonor R, Martínez Cocera C, Rodríguez A, Ferrer M. Epidemiology of urticaria in Spain. <i>J Investig Allergol Clin Immunol</i> . 2004; 14(3): 214-20.	2002-2004		
Spain	Garcés-Sánchez M, Díez-Domingo J, Alvarez de Labiada T, Planelles V, Graullera M, Baldo JM, García Llop LA, García López M, Peris Vidal A, Gallego García MD, Ballester Sanz A, Peidro C, Villarroya J, Jubert A, Colomer Revuelta J, Casani C. Epidemiology and burden of acute otitis media in Valencia (Spain). <i>An Pediatr (Barc)</i> . 2004; 60(2): 125-32.	1995-2001		
Spain	Cáceres Udina MJ, Alvarez Martínez JA, Argente del Castillo J, Chumilla Valderas MA, Fernández Alvarez E, Garrido Romera A, Sánchez Gascón F, García-Marcos L. Incidence, air pollution and risk factors of acute otitis media in the first year of life: a prospective study. <i>An Pediatr (Barc)</i> . 2004; 60(2): 133-8.	2002-2004		
Spain	Alzamora MT, Sorribes M, Heras A, Vila N, Vicheto M, Forés R, Sánchez-Ojanguen J, Sancho A, the, Pera G. Ischemic stroke incidence in Santa Coloma de Gramenet (ISISCOG), Spain. A community-based study. <i>BMC Neurol</i> . 2008; 8(1): 5.	2003		
Spain	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol</i> . 2008; 121(4): 947-954.	1993-1994, 1997, 2001-2002		
Spain	Cilla G, Onate E, Perez-Yarza EG, Nogueas A, Perez-Trallero E. Incidence of Hospitalization Due to Pneumonia in Children Aged Less than 3 Years. <i>Open Infect Dis J</i> . 2009; 1(3): 27-30.	2004-2006		
Spain	Martínez León M, García Martín FJ, Martínez Marín ML, Martínez Valverde A. Meningitis bacterianas Estudio clínico-epidemiológico Revisión de 8 años (1988-1995). <i>An Esp Pediatr</i> . 1998; 48(3): 277-82.	1988-1995		
Spain	Cilla G, Gomariz M, Montes M, Mendiburu ML, Pérez-Yarza EG, Pérez-Trallero E. Incidence of hospitalization due to community-acquired rotavirus infection: a 12-year study (1996-2008). <i>Epidemiol Infect</i> . 2010; 138(9): 1235-4.	1996-2008		
Spain	Forster J, Guarino A, Parez N, Moraga F, Román E, Mory O, Tozzi AE, de Aguilera AL, Wahn U, Graham C, Berner R, Ninan T, Barberousse C, Meyer N, Soriano-Gabarró M. Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of age. <i>Pediatrics</i> . 2009; 123(3): e393-400.	2005-2006		
Spain	Bassols A, Bosch F, Campillo M, Cañellas M, Baños JE. An epidemiological comparison of pain complaints in the general population of Catalonia (Spain). <i>Pain</i> . 1999; 83(1): 9-16.	1994		
Spain	Demyttenaere K, Bruffaerts R, Lee S, Posada-Villa J, Kovess V, Angermeyer MC, Levinson D, de Girolamo G, Nakane H, Mneimneh Z, Lara C, de Graaf R, Scott KM, Gureje O, Stein DJ, Haro JM, Bromet EJ, Kessler RC, Alonso J, Von Korff M. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. <i>Pain</i> . 2007; 129(3): 332-42.	2001-2002		
Spain	Cosín J, Asín E, Marrugat J, Elosua R, Arós F, De los Reyes M, Castro-Beiras A, Cabadés A, Diago JL, López-Bescos L, Vila J. Prevalence of angina pectoris in Spain. <i>Eur J Epidemiol</i> . 1999; 15(4): 323-30.	1980-1996		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Spain	Marrugat J, Elosua R, Martí H. Epidemiology of ischaemic heart disease in Spain: estimation of the number of cases and trends from 1997 to 2005. <i>Rev Esp Cardiol</i> . 2002; 55(4): 337-46.	1980-1997		
Spain	Revenaig A, Paricio Rubio JF, Mar Vázquez Salvado M, del Villar Sordo V. Descriptive epidemiology of basal cell carcinoma and cutaneous squamous cell carcinoma in Soria (north-eastern Spain) 1998-2000: a hospital-based survey. <i>J Eur Acad Dermatol Venerol</i> . 2004; 18(2): 137-41.	1998-2000		
Spain	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000, 2002, 2004-2009		
Spain	González Buitrago JM, Arroyo A, Vega L, García Fernández N, De la Rúa A, Navajo JA. Prevalence of excess blood uric acid and gout in a sample of a rural Castilian population 40-50 years of age. <i>Rev Clin Esp</i> . 1988; 182(9): 454-8.	1985		
Spain	Alcoba Leza M, Pérez-Simón MR, Guerra Laso JM, Carro Fernández JA, Alonso Fernández MA, Blanco Iglesias B, Bueno Suárez P, Muñelo Voces I. Sarcoidosis en el área sanitaria de León. <i>Epidemiología y clínica. An Med Interna</i> . 2003; 20(12): 617-20.	1993-2001		
Spain	López-Campos JL, Rodríguez-Becerra E. Incidence of interstitial lung diseases in the south of Spain 1998-2000: the RENIA study. <i>Eur J Epidemiol</i> . 2004; 19(2): 155-61.	1998-2000		
Spain	Antón Aranda E, Martínez-Lage JM, Maraví Petri E, Gállego Cullerí J, de Castro P, Villanueva Eusa JA. Epidemiology and clinical evolutionary aspects of multiple sclerosis in Navarra. <i>Neurología</i> . 1991; 6(5): 160-9.	1986		
Spain	Hernández MA. Epidemiology of multiple sclerosis in the Canary Islands (Spain). <i>J Neurol</i> . 2002; 249(10): 1378-81.	1998		
Spain	Uria DF, Calatayud MT, Virgala P, Diaz A, Chamizo C, Dean G. Multiple sclerosis in Gijón health district, Asturias, northern Spain. <i>Acta Neurol Scand</i> . 1997; 96(6): 375-9.	1994		
Spain	Benito-León J, Martín E, Vela L, Villar ME, Felgueroso B, Marrero C, Guerrero A, Ruiz-Galiana J. Multiple sclerosis in Móstoles, central Spain. <i>Acta Neurol Scand</i> . 1998; 98(4): 238-42.	1993-1998		
Spain	Nicoletti A, Patti F, Lo Fermo S, Sorbello V, Reggio E, Maimone D, Zappia M, Reggio A. Possible increasing risk of multiple sclerosis in Catania, Sicily. <i>Neurology</i> . 2005; 65(8): 1259-63.	1990-1999		
Spain	García JR, Rodríguez S, Sosa Henríquez M, Batista E, Corujo E, Font de Mora Turon A, Hernandez Hernandez D, Betancor Leon P. Prevalence of multiple sclerosis in Lanzarote (Canary Islands). <i>Neurology</i> . 1989; 39(2 Pt 1): 265-7.	1987		
Spain	Pardo PJM, Latorre MAP, López A, Errea JM, Modrego PJ. Prevalence of multiple sclerosis in the province of Teruel, Spain. <i>J Neurol</i> . 1997; 244(3): 182-5.	1996		
Spain	Buñil E, Blesa R, Galan I, Dean G. Prevalence of multiple sclerosis in the region of Osona, Catalonia, northern Spain. <i>J Neurol Neurosurg Psychiatry</i> . 1995; 58(5): 577-81.	1991		
Spain	Pina MA, Ara JR, Modrego PJ, Morales F, Capablo JL. Prevalence of multiple sclerosis in the sanitary district of Calatayud, Northern Spain: is Spain a zone of high risk for this disease? <i>Neuroepidemiology</i> . 1998; 17(5): 258-64.	1980-1989, 1995		†
Spain	Arribas MAT, Yugueros MI, Fernández-Buey N, Fernández-Herranz R. Prevalence of multiple sclerosis in Valladolid, northern Spain. <i>J Neurol</i> . 1999; 246(3): 170-4.	1997		
Spain	Modrego PJ, Pina MA. Trends in prevalence and incidence of multiple sclerosis in Bajo Aragón, Spain. <i>J Neurol Sci</i> . 2003; 216(1): 89-93.	1984-2003		
Spain	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J</i> . 1998; 12(2): 315-35.	1993-1995		
Spain	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	2001		
Spain	Cabezas-Cerrato J. The prevalence of clinical diabetic polyneuropathy in Spain: a study in primary care and hospital clinic groups. <i>Neuropathy Spanish Study Group of the Spanish Diabetes Society (SDS). Diabetologia</i> . 1998; 41(11): 1263-9.	1996-1997		
Spain	Romero-Aroca P, Fernández-Balart J, Baget-Bernaldiz M, Martínez-Salcedo I, Méndez-Marín I, Salvat-Serra M, Buil-Calvo JA. Changes in the diabetic retinopathy epidemiology after 14 years in a population of Type 1 and 2 diabetic patients after the new diabetes mellitus diagnosis criteria and a more strict control of the patients. <i>J Diabet Complications</i> . 2009; 23(4): 229-38.	2006		
Spain	Rubino A, Rousculp MD, Davis K, Wang J, Girach A. Diagnosed diabetic retinopathy in France, Italy, Spain, and the United Kingdom. <i>Prim Care Diabetes</i> . 2007; 1(2): 75-80.	2006		
Spain	López IM, Díez A, Velilla S, Rueda A, Alvarez A, Pastor CJ. Prevalence of diabetic retinopathy and eye care in a rural area of Spain. <i>Ophthalmic Epidemiol</i> . 2002; 9(3): 205-14.	1993-1997		
Spain	Santos-Bueso E, Fernández-Pérez C, Macarro A, Fernández-Vigo J. Prevalence of diabetic retinopathy in the city of Badajoz 2002 (Extremadura project to prevent blindness). <i>Arch Soc Esp Ophthalmol</i> . 2007; 82(3): 153-8.	2002		
Spain	Teruel Maicas C, Fernández-Real JM, Ricart W, Valent Ferrer R, Vallés Prats M. Prevalence of diabetic retinopathy in the region of Girona. Study of related factors. <i>Arch Soc Esp Ophthalmol</i> . 2005; 80(2): 85-91.	2004		
Spain	Pedro RA, Ramon SA, Marc BB, Juan FB, Isabel MM. Prevalence and relationship between diabetic retinopathy and nephropathy, and its risk factors in the North-East of Spain, a population-based study. <i>Ophthalmic Epidemiol</i> . 2010; 17(4): 251-65.	2008		
Spain	DECODE Study Group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. <i>Diabetes Care</i> . 2003; 26(1): 61-9.	1994		
Spain	Masiá R, Sala J, Rohlfs I, Piulats R, Manresa JM, Marrugat J; Investigadores del estudio REGICOR. Prevalence of diabetes mellitus in the province of Girona, Spain: the REGICOR study. <i>Rev Esp Cardiol</i> . 2004; 57(3): 261-4.	1996		
Spain	López Suárez A, Elvira González J, Beltrán Robles M, Alwakil M, Saucedo JM, Bascuñana Quiñel A, Barón Ramos MA, Fernández Palacín F. Prevalence of obesity, diabetes, hypertension, hypercholesterolemia and metabolic syndrome in over 50-year-olds in Sanlúcar de Barrameda, Spain. <i>Rev Esp Cardiol</i> . 2008; 61(11): 1150-8.	2006		
Spain	Palencia R, Sinovas MI. Prevalence of migraine in a sample population of school children. <i>Rev Neurol</i> . 1997; 25(148): 1879-82.	1991-1992		
Spain	Quintana JM, Arostegui I, Escobar A, Azkarate J, Goenaga JJ, Lafuente I. Prevalence of knee and hip osteoarthritis and the appropriateness of joint replacement in an older population. <i>Arch Intern Med</i> . 2008; 168(14): 1576-84.	2002-2003	*	
Spain	García-Marcos L, Mallol J, Solé D, Brand PLP, EISL Study Group. International study of wheezing in infants: risk factors in affluent and non-affluent countries during the first year of life. <i>Pediatr Allergy Immunol</i> . 2010; 21(5): 878-88.	2005-2007	*	
Spain	Gonzalez Barcala FJ, Pertega S, Bamonde L, Garnelo L, Perez Castro T, Sampedro M, Sanchez Lastres J, San Jose Gonzalez MA, Lopez Silvarrey A. Mediterranean diet and asthma in Spanish schoolchildren. <i>Pediatr Allergy Immunol</i> . 2010; 21(7): 1021-7.	2006-2007	*	
Spain	López-Silvarrey-Varela A, Pértega-Díaz S, Rueda-Esteban S, Sánchez-Lastres JM, San José-González MA, Sampedro-Campos M, Pérez-Castro T, Garnelo-Suárez L, Bamonde-Rodríguez L, López-Silvarrey-Varela J, González-Barcala J. Prevalence and geographic variations in asthma symptoms in children and adolescents in Galicia (Spain). <i>Arch Bronconeumol</i> . 2011; 47(6): 274-82.	2006-2007	*	
Spain	Pellegrini-Belinchón J, Miguel-Miguel G, De Dios-Martín B, Vicente-Galindo E, Lorente-Toledo F, García-Marcos L. Study of wheezing and its risk factors in the first year of life in the Province of Salamanca, Spain. <i>The EISL Study. Allergol Immunopathol (Madr)</i> . 2012; 40(3): 164-71.	2008-2009	*	
Spain	Soriano JB, Ancochea J, Miravittles M, García-Río F, Durán-Tauteria E, Muñoz L, Jiménez-Ruiz CA, Masa JF, Viejo JL, Villassante C, Fernández-Fan L, Sánchez G, Sobradillo-Peña V. Recent trends in COPD prevalence in Spain: a repeated cross-sectional survey 1997-2007. <i>Eur Respir J</i> . 2010; 36(4): 758-65.	1996-1997		
Spain	Miravittles M, Soriano JB, García-Río F, Muñoz L, Durán-Tauteria E, Sanchez G, Sobradillo V, Ancochea J. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. <i>Thorax</i> . 2009; 64(10): 863-8.	2006-2007	*	
Spain	Batlles-Garrido J, Torres-Borrego J, Rubi-Ruiz T, Bonillo-Perales A, González-Jiménez Y, Mombián De Cabo J, Aguirre-Rodríguez J, Losillas-Maldonado A, Torres-Daza M. Prevalence and factors linked to atopy in 10- and 11-year-old children in Almería, Spain. <i>Allergol Immunopathol (Madr)</i> . 2010; 38(1): 13-9.	2007-2009		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Spain	Alzamora MT, Forés R, Baena-Díez JM, Pera G, Toran P, Sorribes M, Vicheto M, Reina MD, Sancho A, Albaladejo C, Llussà J, PERART/ARTPER study group. The peripheral arterial disease study (PERART/ARTPER): prevalence and risk factors in the general population. <i>BMC Public Health</i> . 2010; 38.	2006-2008		
Spain	Merino J, Planas A, Eloua R, de Moner A, Gasol A, Contreras C, Vidal-Barraquer F, Clarà A. Incidence and risk factors of peripheral arterial occlusive disease in a prospective cohort of 700 adult elderly men followed for 5 years. <i>World J Surg</i> . 2010; 34(8): 1975-9.	1996-2002	*	
Spain	Lopez-Jornet P, Saura-Perez M, Llevat-Espinosa N. Effect of oral health dental state and risk of malnutrition in elderly people. <i>Geriatr Gerontol Int</i> . 2013; 13(1): 43-9.	2011		
Spain	Eustaquio M-V, Montiel J-M, Almerich J-M. Oral health survey of the adult population of the Valencia region (Spain). <i>Med Oral Patol Oral Cir Bucal</i> . 2010; 15(3): e538-544.	2006		
Spain	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. <i>Community Dent Oral Epidemiol</i> . 1991; 19(2): 72-3.	1987	*	
Spain	Dueñas JL, Lete I, Bermejo R, Arbat A, Pérez-Campos E, Martínez-Salmeán J, Serrano I, Doval JL, Coll C. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in a representative cohort of Spanish women of fertile age. <i>Eur J Obstet Gynecol Reprod Biol</i> . 2011; 156(1): 72-7.	2008	*	
Spain	Rodríguez-Oviedo P, Ruano-Ravina A, Pérez-Ríos M, García FB, Gómez-Fernández D, Fernández-Alonso A, Carreira-Núñez I, García-Pacios P, Turiso J. School children's backpacks, back pain and back pathologies. <i>Arch Dis Child</i> . 2012; 97(8): 730-2.	2005-2006		
Spain	Fernández-de-las-Peñas C, Hernández-Barrera V, Alonso-Blanco C, Palacios-Ceña D, Carrasco-Garrido P, Jiménez-Sánchez S, Jiménez-García R. Prevalence of neck and low back pain in community-dwelling adults in Spain: a population-based national study. <i>Spine</i> . 2011; 36(3): E213-219.	2006-2007	*	
Spain	Martinón-Torres F, Martínón-Torres N, Bouzón Alejandro M, Redondo Collazo L, Pértega-Díaz S, Seoane-Pillado MT, Aboal Viñas J, San-Martín M. Acute gastroenteritis hospitalizations among children aged < 5 years before and after introduction of rotavirus vaccines: a hospital-based surveillance study in Galicia, Spain. <i>Hum Vaccin Immunother</i> . 2012; 8(7): 946-52.	2003-2007	*	
Spain	Giaquinto C, van Damme P, REVEAL Study Group. Age distribution of paediatric rotavirus gastroenteritis cases in Europe: the REVEAL study. <i>Scand J Infect Dis</i> . 2010; 42(2): 142-7.	2004-2005	*	
Spain	Junquera CG, de Baranda CS, Mialdea OG, Serrano EB, Sánchez-Fauquier A. Prevalence and clinical characteristics of norovirus gastroenteritis among hospitalized children in Spain. <i>Pediatr Infect Dis J</i> . 2009; 28(7): 604-7.	2005-2008	*	
Spain	Gonzalez-Galan V, Sánchez-Fauquier A, Obando I, Montero V, Fernandez M, Torres MJ, Neth O, Aznar-Martín J. High prevalence of community-acquired norovirus gastroenteritis among hospitalized children: a prospective study. <i>Clin Microbiol Infect</i> . 2011; 17(12): 1895-9.	2006-2007	*	
Spain	Sánchez-Fauquier A, Montero V, Colomina J, González-Galán V, Aznar J, Aisa ML, Gutierrez C, Sainz de Baranda C, Wilhelm I. Global study of viral diarrhea in hospitalized children in Spain: results of structural surveillance of viral gastroenteritis net work (VIGESS-net) 2006-2008. <i>J Clin Virol</i> . 2011; 52(4): 353-8.	2006-2008		
Spain	Gavrilá D, Antúnez C, Tormo MJ, Carles R, García Santos JM, Parrilla G, Fortuna L, Jiménez J, Salmerón D, Navarro C. Prevalence of dementia and cognitive impairment in Southeastern Spain: the Ariadna study. <i>Acta Neurol Scand</i> . 2009; 120(5): 300-7.	2003-2005		
Spain	Fernández Martínez M, Castro Flores J, Pérez de Las Heras S, Mandaluniz Lekumberri A, Gordejuela Menocal M, Zarranz Inirizaldu JJ. Risk factors for dementia in the epidemiological study of Mungualde County (Basque Country-Spain). <i>BMC Neurol</i> . 2008; 39.	2005-2007		
Spain	Rodríguez-Sánchez E, Mora-Simón S, Patino-Alonso MC, García-García R, Escibano-Hernández A, García-Ortiz L, Perea-Bartolomé MV, Gómez-Marcos MA. Prevalence of cognitive impairment in individuals aged over 65 in an urban area: DERIVA study. <i>BMC Neurol</i> . 2011; 147.	2009		
Spain	Coria F, Gomez de Caso JA, Minguez L, Rodríguez-Artalejo F, Clavería LE. Prevalence of age-associated memory impairment and dementia in a rural community. <i>J Neurol Neurosurg Psychiatry</i> . 1993; 56(9): 973-6.	1990		
Spain	Pi J, Olivé JM, Roca J, Masana L. Prevalence of dementia in a semi-rural population of Catalunya, Spain. <i>Neuroepidemiology</i> . 1996; 15(1): 33-41.	1992-1993		
Spain	Manubens JM, Martínez-Lage JM, Lacruz F, Muruzabal J, Larumbe R, Guarch C, Urrutia T, Sarrasqueta P, Martínez-Lage P, Rocca WA. Prevalence of Alzheimer's disease and other dementing disorders in Pamplona, Spain. <i>Neuroepidemiology</i> . 1995; 14(4): 155-64.	1991		
Spain	López-Pousa S, Vilalta-Franch J, Llinàs-Regla J, Garre-Olmo J, Román GC. Incidence of dementia in a rural community in Spain: the Girona cohort study. <i>Neuroepidemiology</i> . 2004; 23(4): 170-7.	1990-1995		
Spain	Gascón-Bayarri J, Reñé R, Del Barrio JL, De Pedro-Cuesta J, Ramón JM, Manubens JM, Sánchez C, Hernández M, Estela J, Juncadella M, Rubio FR. Prevalence of dementia subtypes in El Prat de Llobregat, Catalonia, Spain: the PRATICON study. <i>Neuroepidemiology</i> . 2007; 28(4): 224-34.	2002-2003		
Spain	Fernández M C-FJ. Prevalencia de la demencia en mayores de 65 años en una comarca del País Vasco. <i>Rev Neurol</i> . 2008; 46(2): 16-31.	2004		
Spain	García García FJ, Sánchez Ayala MI, Pérez Martín A, Martín Correa E, Marsal Alonso C, Rodríguez Ferrer G, García Colmenero C, Romero Rizos L, Rodríguez Barquera MJ, Gutiérrez Avila G. [The prevalence of dementia and its main subtypes in subjects older than 65 years: impact of occupation and education. The Toledo Study]. <i>Med Clin (Barc)</i> . 2001; 116(11): 401-7.	1991-1995		
Spain	Vilalta-Franch J, López-Pousa S, Llinàs-Regl J. The prevalence of dementias in a rural area. A study in Girona. <i>Rev Neurol</i> . 2000; 30(11): 1026-32.	1997-1999		
Spain	Lobo A, Lopez-Anton R, Santabàrbara J, de-la-Cámara C, Ventura T, Quintanilla MA, Roy JF, Campayo AJ, Lobo E, Palomo T, Rodríguez-Jimenez R, Saz P, Marcos G. Incidence and lifetime risk of dementia and Alzheimer's disease in a Southern European population. <i>Acta Psychiatr Scand</i> . 2011; 124(5): 372-83.	1997-1999	*	
Spain	Ferra A, Bihonil MDM, Zapata ME, Pich J, Pons A, Tur JA. Body mass index, life-style, and healthy status in free living elderly people in Menorca Island. <i>J Nutr Health Aging</i> . 2012; 16(4): 298-305.	2009	*	
Spain	Pérez-Aisa MA, Del Pino D, Siles M, Lanás A. Clinical trends in ulcer diagnosis in a population with high prevalence of <i>Helicobacter pylori</i> infection. <i>Aliment Pharmacol Ther</i> . 2005; 21(1): 65-72.	1985, 1990, 1995, 1999-2000		
Spain	Carmona L, Ballina J, Gabriel R, Laffon A, EPISER Study Group. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. <i>Ann Rheum Dis</i> . 2001; 60(11): 1040-5.	1998-1999		
Spain	Fernandez-Lopez JC, Laffon A, Blanco FJ, Carmona L, EPISER Study Group. Prevalence, risk factors, and impact of knee pain suggesting osteoarthritis in Spain. <i>Clin Exp Rheumatol</i> . 2008; 26(2): 324-32.	2000		
Spain	Carmona L, Descalzo MÁ, Perez-Pampin E, Ruiz-Montesinos D, Erra A, Cobo T, Gómez-Reino JJ. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. <i>Ann Rheum Dis</i> . 2007; 66(7): 880-5.	1999-2005		
Spain	Martínez MS, García-Monforte A, Rivera J. Survival study of rheumatoid arthritis patients in Madrid (Spain). A 9-year prospective follow-up. <i>Scand J Rheumatol</i> . 2001; 30(4): 195-8.	1989-1998		
Spain	Bolin AK, Bolin A, Koch G. Children's dental health in Europe: caries experience of 5- and 12-year-old children from eight EU countries. <i>Int J Paediatr Dent</i> . 1996; 6(3): 155-62.	1994		
Spain	Rodríguez-Contreras Pelayo R, Delgado Rodríguez M, Gálvez Vargas R. Prevalence of dental caries in school children of the province of Granada (Spain). <i>Eur J Epidemiol</i> . 1989; 5(2): 193-8.	1984-1985		
Spain	Alvarez-Arenal A, Alvarez-Riesgo JA, Peña-Lopez JM, Fernandez-Vazquez JP. DMFT, dmft and treatment requirements of schoolchildren in Asturias, Spain. <i>Community Dent Oral Epidemiol</i> . 1998; 26(3): 166-9.	1992		
Spain	García-Closas R, García-Closas M, Serra-Majem L. A cross-sectional study of dental caries, intake of confectionery and foods rich in starch and sugars, and salivary counts of <i>Streptococcus mutans</i> in children in Spain. <i>Am J Clin Nutr</i> . 1997; 66(5): 1257-63.	1992		
Spain	Lorenzo García V, Smyth Chamosa E, Hervada Vidal X, Fernández Casal R, Alonso Meijide JM, Amigo Quintana M, González-Zaera Barreal J, Montes Martínez A, Taracido Trunk M, Cerdá Mota T. La salud bucodental en los escolares gallegos. <i>Rev Esp Salud Pública</i> . 1998; 72(6): 539-46.	1995		
Spain	Gómez-Santos G, González-Sierra MA, Vázquez-García-Machiñena J. Evolution of caries and fluorosis in schoolchildren of the Canary Islands (Spain): 1991, 1998, 2006. <i>Med Oral Patol Oral Cir Bucal</i> . 2008; 13(9): E599-608.	1991, 1998, 2006		
Spain	Salas-Wadge MH. Dental caries experience in 7-, 12- and 14-year-old children in Andalucía, Spain. <i>Community Dent Health</i> . 1994; 11(3): 135-41.	1992		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Spain	Almerich Silla JM, Montiel Company JM. Oral health survey of the child population in the Valencia Region of Spain (2004). <i>Med Oral Patol Oral Cir Bucal</i> . 2006; 11(4): E369-381.	2004		
Spain	Casado Flores J, García Teresa MA, Cambra F, Pilar Orive J, Teja JL, Rodríguez Núñez A, Quiroga E, Calvo C, Ruiz Extremera MA, Pérez Navero J, Melendo J, Soult JA. Multicenter prospective study on severe bacterial meningitis in children. <i>An Esp Pediatr</i> . 1997; 47(5): 466-72.	1994-1995		
Spain	Gual P, Pérez-Gaspar M, Martínez-González MA, Lahortiga F, Irala-Estévez J de, Cervera-Enguix S. Self-esteem, personality, and eating disorders: Baseline assessment of a prospective population-based cohort. <i>Int J Eat Disord</i> . 2002; 31(3): 261-73.	1997		
Spain	Fernández MAP, Labrador FJ, Raich RM. Prevalence of eating disorders among adolescent and young adult scholastic population in the region of Madrid (Spain). <i>J Psychosom Res</i> . 2007; 62(6): 681-90.	2001-2002		
Spain	Canals J, Doménech E, Carbajo G, Bladé J. Prevalence of DSM-III-R and ICD-10 psychiatric disorders in a Spanish population of 18-year-olds. <i>Acta Psychiatr Scand</i> . 1997; 96(4): 287-94.	1994-1995		
Spain	University of Zaragoza. Spain Adolescent Eating Disorders Prevalence Survey 1999.	1999		
Spain	Lahortiga-Ramos F, De Irala-Estévez J, Cano-Prous A, Gual-García P, Martínez-González MA, Cervera-Enguix S. Incidence of eating disorders in Navarra (Spain). <i>Eur Psychiatry</i> . 2005; 20(2): 179-85.	1997-1999		
Spain	Ayuso-Mateos JL, Vázquez-Barquero JL, Dowrick C, Lehtinen V, Dalgard OS, Casey P, Wilkinson C, Lasa L, Page H, Dunn G, Wilkinson G. Depressive disorders in Europe: prevalence figures from the ODIN study. <i>Br J Psychiatry</i> . 2001; 179(4): 308-16.	1999-2001		
Spain	de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Künzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P, European Community Respiratory Health Survey Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. <i>Thorax</i> . 2004; 59(2): 120-125.	1991-1993		
Spain	Downes E, Sikirica V, Gilabert-Estelles J, Bolge SC, Dodd SL, Maroulis C, Subramanian D. The burden of uterine fibroids in five European countries. <i>Eur J Obstet Gynecol Reprod Biol</i> . 2010; 152(1): 96-102.	2007		
Spain	Bermejo F, Vega S, Morales JM, Díaz J, López L, Parra D, Colmenero J, Gabriel R. Prevalence of stroke in two samples (rural and urban) of old people in Spain. A pilot door-to-door study carried out by health professionals. <i>Neurologia</i> . 1997; 12(4): 157-61.	1988-1992		
Spain	Díaz-Guzmán J, Bermejo-Pareja F, Benito-León J, Vega S, Gabriel R, Medrano MJ. Prevalence of stroke and transient ischemic attack in three elderly populations of central Spain. <i>Neuroepidemiology</i> . 2008; 30(4): 247-53.	1994		
Spain	Andrés MA, Catalá MA, Gómez-Beneyto M. Prevalence, comorbidity, risk factors and service utilisation of disruptive behaviour disorders in a community sample of children in Valencia (Spain). <i>Soc Psychiatry Psychiatr Epidemiol</i> . 1999; 34(4): 175.	1993		
Spain	Gómez-Beneyto M, Bonet A, Catalá MA, Puche E, Vila V. Prevalence of mental disorders among children in Valencia, Spain. <i>Acta Psychiatr Scand</i> . 1994; 89(5): 352-7.	1992		
Spain	Heinemann LAJ, Minh TD, Filonenko A, Uhl-Hochgräber K. Explorative evaluation of the impact of severe premenstrual disorders on work absenteeism and productivity. <i>Womens Health Issues</i> . 2010; 20(1): 58-65.	2007		
Spain	De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martínez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. <i>Neurology</i> . 2000; 54(11 Suppl 5): S21-23.	1997		
Spain	Benito-León J, Bermejo-Pareja F, Morales-González JM, Porta-Etessam J, Trincado R, Vega S, Louis ED. Neurological Disorders in Central Spain (NEDICES) Study Group. Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. <i>Neurology</i> . 2004; 62(5): 734-41.	1994-1998		
Spain	Benito-León J, Bermejo-Pareja F, Rodríguez J, Molina J-A, Gabriel R, Morales J-M. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. <i>Mov Disord</i> . 2003; 18(3): 267-74.	1994		
Spain	Bergareche A, De La Puente E, López de Munain A, Sarasqueta C, de Arce A, Poza JJ, Martí-Massó JF. Prevalence of Parkinson's disease and other types of Parkinsonism. A door-to-door survey in Bidasoa, Spain. <i>J Neurol</i> . 2004; 251(3): 340-5.	1996, 1999		
Spain	Errea JM, Ara JR, Aibar C, de Pedro-Cuesta J. Prevalence of Parkinson's disease in lower Aragon, Spain. <i>Mov Disord</i> . 1999; 14(4): 596-604.	1987-1995		
Spain	Clavería LE, Duarte J, Sevillano MD, Pérez-Sempere A, Cabezas C, Rodríguez F, de Pedro-Cuesta J. Prevalence of Parkinson's disease in Cantalejo, Spain: A door-to-door survey. <i>Mov Disord</i> . 2002; 17(2): 242-9.	1994-1997		
Spain	Rijk MC de, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alpvrovitch A, Rocca WA. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. <i>J Neurol Neurosurg Psychiatry</i> . 1997; 62(1): 10-5.	1988-1989		
Spain	Artáczoz Sanz MT, Viñes Rueda JJ. Estimación de la prevalencia de la enfermedad de Parkinson en Navarra. Estudio farmacoepidemiológico del consumo de antiparkinsonianos. <i>Rev Esp Salud Publica</i> . 1995; 69(6).	1993-1994		
Spain	Viñes JJ, Larumbe R, Gaminde I, Artáczoz MT. [Incidence of idiopathic and secondary Parkinson disease in Navarre. Population-based case registry]. <i>Neurologia</i> . 1999; 14(1): 16-22.	1994-1995		
Spain	Berger K BM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. <i>Neurology</i> . 2000; 54(11): 24-7.	1997		
Spain	Vázquez-Barquero JL, Cuesta Nuñez MJ, de la Varga M, Herrera Castanedo S, Gaité L, Arenal A. The Cantabria first episode schizophrenia study: a summary of general findings. <i>Acta Psychiatr Scand</i> . 1995; 91(3): 156-62.	1989-1990		
Spain	Ministry of Health and Consumer Affairs (Spain). Spain Household Survey on Alcohol and Drugs 2007-2008.	2007-2008		
Spain	Miró J, Paredes S, Rull M, Querol R, Miralles R, Nieto R, Huguet A, Baos J. Pain in older adults: a prevalence study in the Mediterranean region of Catalonia. <i>Eur J Pain</i> . 2007; 11(1): 83-92.	2004		
Spain	Catalá E, Reig E, Ariés M, Aliaga L, López JS, Segú JL. Prevalence of pain in the Spanish population: telephone survey in 5000 homes. <i>Eur J Pain</i> . 2002; 6(2): 133-40.	1998		
Spain	Pinto-Meza A, Serrano-Blanco A, Codony M, Reneses B, von Korff M, Haro JM, Alonso J. Prevalence and physical-mental comorbidity of chronic back and neck pain in Spain: results from the ESEMeD Study. <i>Med Clin (Barc)</i> . 2006; 127(9): 325-30.	2003		
Spain	Ballina García FJ, Hernandez Mejía R, Martín Lascuevas P, Fernandez Santana J, Cueto Espinar A. Epidemiology of musculoskeletal complaints and use of health services in Asturias, Spain. <i>Scand J Rheumatol</i> . 1994; 23(3): 137-41.	1990		
Spain	Esteban JIN, Martínez MS, Navalón PG, Serrano OP, Patiño JRC, Purón MEC, Martínez-Vizcaíno V. Visual impairment and quality of life: gender differences in the elderly in Cuenca, Spain. <i>Qual Life Res</i> . 2008; 17(1): 37-45. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2005-2006		
Spain	Nardone A, de Ory F, Carton M, Cohen D, van Damme P, Davidkin I, Rota MC, de Melker H, Mossong J, Slacikova M, Tischer A, Andrews N, Berbers G, Gabutti G, Gay N, Jones L, Jokinen S, Kafatos G, de Aragón MVM, Schneider F, Smetana Z, Vargova B, Vranckx R, Miller E. The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. <i>Vaccine</i> . 2007; 25(45): 7866-72.	1996		
Spain	De Ory F, Ramírez R, García Comas L, León P, Sagüés MJ, Sanz JC. Is there a change in cytomegalovirus seroepidemiology in Spain Eur J Epidemiol. 2004; 19(1): 85-9.	1993-1994, 1999-2000		
Spain	Salleras L, Domínguez A, Plans P, Costa J, Cardeñosa N, Torner N, Plasència A. Seroprevalence of varicella zoster virus infection in child and adult population of Catalonia (Spain). <i>Med Microbiol Immunol</i> . 2008; 197(3): 329-33.	2002		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Spain	Díez-Domingo J, Gil A, San-Martín M, González A, Esteban J, Baldo JM, Planelles MV, Ubeda MI, Graullera M, Peris A, Martínez M, Antón V, Gallego D, Álvarez T, Villarroya JV, Jubert A, Casaní C, Peidro C, García M, Ballester A. Seroprevalence of varicella among children and adolescents in Valencia, Spain. Reliability of the parent's reported history and the medical file for identification of potential candidates for vaccination. <i>Hum Vaccin</i> . 2005; 1(5): 204-6.	2003		
Spain	Gil Miguel A, Lasheras Lozano ML, Jiménez García R, Calle Purón ME, Santos Santos M, Rey Calero J, Martín Hernández D. The seroepidemiology of the varicella-zoster virus in children and adolescents. <i>Aten Primaria</i> . 1993; 11(8): 416-8.	1990		
Spain	Salleras L, Domínguez A, Vidal J, Plans P, Salleras M, Taberner JL. Seroepidemiology of varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes. <i>Vaccine</i> . 2000; 19(2-3): 183-8.	1996		
Spain	Cilla Eguiluz G, Perez Trallero E, García Arenzana JM. Seroepidemiology of varicella in children from Spain. <i>J Infect Dis</i> . 1987; 156(5): 851.	1986		
Spain	Suárez González A, Otero Guerra L, De La Guerra GV, La Iglesia Martínez Pd P de, Solís Sánchez G, Rodríguez Fernández A. Varicella and parvovirus B19 immunity among pregnant women in Gijón, Spain. <i>Med Clin (Barc)</i> . 2002; 119(5): 171-3.	1997-1998		
Spain	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1997, 1999, 2001, 2003, 2005-2006	*	
Spain	Cilla G, Oñate E, Perez-Yarza EG, Montes M, Vicente D, Perez-Trallero E. Viruses in community-acquired pneumonia in children aged less than 3 years old: High rate of viral coinfection. <i>J Med Virol</i> . 2008; 80(10): 1843-9.	2004-2006		
Spain	Tomás Vila M, Paricio Talayero JM, Colomer Revuelta C, Andrés Celma M, Moratal A. Epidemiology of mental deficiency. The study of Safor (J): prevalence and etiology. <i>An Esp Pediatr</i> . 1991; 34(5): 365-71.	1991		
Spain	Saz P, Launer LJ, Díaz JL, De-La-Cámara C, Marcos G, Lobo A. Mortality and mental disorders in a Spanish elderly population. <i>Int J Geriatr Psychiatry</i> . 1999; 14(12): 1031-8.	1987-1993		
Spain	Llinàs-Regla J, López-Pousa S, Vilalta-Franch J, Garre-Olmo J, Román GC. Mortality after a diagnosis of dementia in a population aged 75 and over in Spain. <i>Neuroepidemiology</i> . 2008; 31(2): 80-8.	2000-2006	*	†
Spain	López-Serrano P, Pérez-Calle JL, Carrera-Alonso E, Pérez-Fernández T, Rodríguez-Caravaca G, Boixeda-de-Miguel D, Fernández-Rodríguez CM. Epidemiologic study on the current incidence of inflammatory bowel disease in Madrid. <i>Rev Esp Enferm Dig</i> . 2009; 101(11): 768-72.	2003-2005	*	†
Spain	Ariñ Letamendia A, Borda Celaya F, Burusco Paternain MJ, Prieto Martínez C, Martínez Echeverría A, Elizalde Apestegui I, Laiglesia Izquierdo M, Macías Mendizábal E, Tamburri Moso P, Sánchez Valverde F. [High incidence rates of inflammatory bowel disease in Navarra (Spain). Results of a prospective, population-based study]. <i>Gastroenterol Hepatol</i> . 2008; 31(3): 111-6.	2001-2003	*	
Spain	Costas Armada P, García-Mayor RV, Larrañaga A, Seguin P. [Prevalence and incidence of Crohn's disease in Galicia, Spain]. <i>Med Clin (Barc)</i> . 2008; 130(18): 715.	1998, 2000-2005	*	
Spain	Antón Martínez J, Ortega Gómez A, Arranz Carrero A, Molina Sánchez A, Alvarez García JF, Moreiras Jiménez JL, González Blanco P, Gutiérrez Sampedro N, Torres García E. [Incidence of inflammatory bowel disease in the health area of Navalmaral de la Mata (Caceres, Spain) between 2000 and 2009]. <i>Gastroenterol Hepatol</i> . 2010; 33(10): 694-9.	2000-2009	*	
Spain	McDowell RD, Ryan A, Bunting BP, O'Neill SM, Alonso J, Bruffaerts R, de Graaf R, Florescu S, Vilagut G, de Almeida JMC, de Girolamo G, Haro JM, Hinkov H, Kovess-Masfety V, Matschinger H, Tomov T. Mood and anxiety disorders across the adult lifespan: a European perspective. <i>Psychol Med</i> . 2013; 1-16.	2001-2002		
Spain	WHO Regional Office for Europe (EURO-WHO). Young People's Health in Context. Health Behaviour in School-aged Children (HBSC) Study: International Report from the 2001-2002 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2004.	2002		
Spain	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006	*	
Spain	Benavente I, Rubio E, Morales C, Tajada N, Tamargo P. Prevalence of epilepsy amongst adolescents in Huesca, Spain: a community-based study. <i>Eur J Neurol</i> . 2009; 16(10): 1138-43.	2003	*	†
Spain	Bouvier-Colle M-H, Mohango AD, Gissler M, Novak-Antolic Z, Vutuc C, Szamotulska K, Zeitlin J, Euro-Peristat Scientific Committee. What about the mothers? An analysis of maternal mortality and morbidity in perinatal health surveillance systems in Europe. <i>BJOG</i> . 2012; 119(7): 880-90.	2003-2004		
Spain	Canto MJ, Reus A, Cortés S, Ojeda F. Pregnancy outcome in a Spanish population of women beyond age 40 delivered above 32 weeks' gestation. <i>J Matern Fetal Neonatal Med</i> . 2012; 25(5): 461-6.	2000-2007	*	
Spain	Dadvand P, Basagaña X, Figueras F, Amoly E, Tobias A, de Nazelle A, Querol X, Sunyer J, Nieuwenhuisen MJ. Saharan dust episodes and pregnancy. <i>J Environ Monit</i> . 2011; 13(11): 3222-8.	2003-2005	*	
Spain	Otero-Romero S, Roura P, Solà J, Altamiras J, Sastre-Garriga J, Nos C, Vagué J, Montalban X, Buñil E. Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain. <i>Mult Scler</i> . 2013; 19(2): 245-8.	2008	*	
Spain	Fernández O, Fernández V, Guerrero M, León A, López-Madróna JC, Alonso A, Bustamante R, Tamayo JA, Romero F, Bravo M, Luque G, García L, Sanchís G, San Roman C, Romero M, Papais-Alvarenga M, de Ramon E. Multiple sclerosis prevalence in Malaga, Southern Spain estimated by the capture-recapture method. <i>Mult Scler</i> . 2012; 18(3): 372-6.	2008	*	
Spain	Durá-Travé T, Yoldi-Petri ME, Gallinas-Victoriano F. Incidence of epilepsies and epileptic syndromes among children in Navarre, Spain: 2002 through 2005. <i>J Child Neurol</i> . 2008; 23(8): 878-82.	2002-2005	*	†
Spain	Onsurbe Ramírez I, Hernández Rodríguez M, Aparicio Meix JM, Carrascos Romero C. [Incidence of epilepsy and epileptic syndromes in children in the province of Albacete]. <i>An Esp Pediatr</i> . 1999; 51(2): 154-8.	1987-1991	*	
Spain	Ferrero Arias J, Pilo Martín I. [Prevalence of several neurological diseases in the central provinces of the Iberian Peninsula in eighteen-year-old males]. <i>Neurologia</i> . 1991; 6(3): 89-94.	1985-1989		
Spain	Cruz Gutierrez-del-Olmo M, Schoenberg BS, Portera-Sanchez A. Prevalence of neurological diseases in Madrid, Spain. <i>Neuroepidemiology</i> . 1989; 8(1): 43-7.	1984	*	
Spain	Ochoa Sangrador C, Palencia Luaces R. Study of the prevalence of epilepsy among schoolchildren in Valladolid, Spain. <i>Epilepsia</i> . 1991; 32(6): 791-7.	1987	*	
Spain	Acosta-Varo J, De Pedro-Cuesta J. Prevalence survey of movement disorders, epilepsy, hypertension and smoking habit in Vejer de la Frontera, Southern Spain-I. Methodology. <i>Parkinsonism Relat Disord</i> . 1996; 2(4): 195-203.	1987		†
Spain	Otero A, Gayoso P, García F, de Francisco AL; EPIRCE study group. Epidemiology of chronic renal disease in the Galician population: results of the pilot Spanish EPIRCE study. <i>Kidney Int Suppl</i> . 2005; 99(Suppl): S16-9.	2004		
Spain	Copeland JR, Beekman AT, Dewey ME, Hooijer C, Jordan A, Lawlor BA, Lobo A, Magnusson H, Mann AH, Meller I, Prince MJ, Reischies F, Turrina C, deVries MW, Wilson KC. Depression in Europe. Geographical distribution among older people. <i>Br J Psychiatry</i> . 1999; 174: 312-21.	1988-1989		
Spain	Lépine JP, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). <i>Int Clin Psychopharmacol</i> . 1997; 12(1): 19-29.	1995		
Spain	García-Torres ML, Zaragoza A, Giner R, Primo J, del Olmo JA. Incidence and epidemiological factors of hepatocellular carcinoma in Valencia during the year 2000. <i>Rev Esp Enferm Dig</i> . 2003; 95(6): 381-8.	2000		
Spain	Macías Rodríguez MA, Rendón Unceta P, Tejada Cabrera M, Infante Hernández JM, Correro Aguilar F, Díaz García F, Benítez Rodríguez E, Mangas Rojas A, Martín Herrera L. Risk factors for hepatocellular carcinoma in patients with liver cirrhosis. <i>Rev Esp Enferm Dig</i> . 2000; 92(7): 458-69.	1990-1994		
Spain	Rodríguez-Vidal FF, Baz MJ, Romero J, del Puerto M. [Epidemiology of hepatocellular carcinoma in a rural area. Role of hepatotropic viruses on survival]. <i>An Med Interna</i> . 2005; 22(4): 162-6.	1994-2002	*	
Spain	Doménech-Llaberia E, Viñas F, Pla E, Jané MC, Mitjavila M, Corbella T, Canals J. Prevalence of major depression in preschool children. <i>Eur Child Adolesc Psychiatry</i> . 2009; 18(10): 597-604.	2007		
Spain	de Francisco AL, De la Cruz JJ, Cases A, de la Figuera M, Egocheaga MI, Górriz JJ, Llisterri JL, Marín R, Martínez Castela A. Prevalence of kidney insufficiency in primary care population in Spain: EROCAP study. <i>Nefrologia</i> . 2007; 27(3): 300-12.	2005-2006		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Spain	Simal F, Martín Escudero JC, Bellido J, Arzuza D, Mena FJ, González Melgosa I, Alvarez Hurtado AA, Tabuyo MB, Molina A. Prevalence of mild to moderate chronic kidney disease in the general population of Spain. <i>Nefrologia</i> . 2004; 24(4): 329-33.	1997-2000		
Spain	de Francisco AL, Sanjuán F, Foraster A, Fabado S, Carretero D, Santamaría C, Aguilera J, Alcalá MI, Aljama P. Epidemiological study on chronic renal failure elderly patients on hemodialysis. <i>Nefrologia</i> . 2008; 28(1): 48-55.	2005		
Spain	Lorenzo V, Boronat M, Saavedra P, Rufino M, Maceira B, Novoa FJ, Torres A. Disproportionately high incidence of diabetes-related end-stage renal disease in the Canary Islands. An analysis based on estimated population at risk. <i>Nephrol Dial Transplant</i> . 2010; 25(7): 2283-8.	2004	*	
Spain	Moreno B, García-Alonso CR, Negrín Hernández MA, Torres-González F, Salvador-Carulla L. Spatial analysis to identify hotspots of prevalence of schizophrenia. <i>Soc Psychiatry Psychiatr Epidemiol</i> . 2008; 43(10): 782-91.	1999		
Spain	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 2001, 2004, 2007, 2010, 2012	*	
Spain	Castillo J, Muñoz P, Guitera V, Pascual J, Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. <i>Headache</i> . 1999; 39(3): 190-6.	1995-1997	*	
Spain	Colas R, Muñoz P, Temprano R, Gomez C, Pascual J. Chronic daily headache with analgesic overuse: Epidemiology and impact on quality of life. <i>Neurology</i> . 2004; 62(8): 1338-42.	1998-1999	*	
Spain	Varela JA, García-Corbrea P, Aguilera MV, Boceta R, Ballesteros J, Aguilera L, Vázquez-Valdés F, Dal-r é R. Herpes simplex virus type 2 seroprevalence in Spain: prevalence and seroconversion rate among sexually transmitted disease clinic attendees. <i>Sex Transm Dis</i> . 2001; 28(1): 47-50.	1992-1994	*	†
Spain	García-Alix A, Martínez-Biarge M, Díez J, Gayá F, Quero J. [Neonatal hypoxic-ischemic encephalopathy: Incidence and prevalence in the first decade of the 21st century]. <i>An Pediatr (Barc)</i> . 2009; 71(4): 319-26.	2000-2008		
Spain	Almaraz MC, González-Romero S, Bravo M, Caballero FF, Palomo MJ, Vallejo R, Esteve I, Calleja F, Soriguer F. Incidence of lower limb amputations in individuals with and without diabetes mellitus in Andalusia (Spain) from 1998 to 2006. <i>Diabetes Res Clin Pract</i> . 2012; 95(3): 399-405.	1998-2006		
Spain	Bañillo MP, Hermoso F, Ochoa C, García-Fernández JA, Rodrigo J, Marugán JM, de la Torre S, Manzano F, Lema T, García-Velázquez J, Castilla-León Childhood Type 1 Diabetes Epidemiology Study Group. Incidence and prevalence of type 1 diabetes in children aged <15 yr in Castilla-León (Spain). <i>Pediatr Diabetes</i> . 2007; 8(6): 369-73.	2003-2004		
Spain	Chueca M, Oyarzabal M, Reparaz F, Garagorri JM, Sola A. Incidence of type 1 diabetes mellitus in Navarre, Spain (1975-91). <i>Acta Paediatr</i> . 1997; 86(6): 632-7.	1975-1991		
Spain	Goday A, Castell C, Tresserras R, Canela J, Taberner JL, Lloveras G. Incidence of type 1 (insulin-dependent) diabetes mellitus in Catalonia, Spain. The Catalan Epidemiology Diabetes Study Group. <i>Diabetologia</i> . 1992; 35(3): 267-71.	1987-1990		
Spain	López-Siguero JP, Del Pino-De la Fuente A, Martínez-Aedo MJ, Moreno-Molina JA. Increased incidence of type 1 diabetes in the south of Spain. <i>Diabetes Care</i> . 2002; 25(6): 1099.	1982-2000		
Spain	Lora-Gómez RE, Morales-Pérez FM, Arroyo-Díez FJ, Barquero-Romero J. Incidence of Type 1 diabetes in children in Cáceres, Spain, during 1988-1999. <i>Diabetes Res Clin Pract</i> . 2005; 69(2): 169-74.	1988-1999		
Spain	Morales-Pérez FM, Barquero-Romero J, Pérez-Miranda M. Incidence of type 1 diabetes among children and young adults (0-29 years) in the province of Badajoz, Spain during 1992 to 1996. <i>Acta Paediatr</i> . 2000; 89(1): 101-4.	1992-1996		
Spain	Romero-Aroca P, Fernández-Alart J, Baget-Bernaldiz M, Méndez-Marín I, Salvat-Serra M. [Diabetic retinopathy epidemiology in type II diabetic patients. Effect of the changes in the diagnostic criteria and stricter control of the diabetes between 1993 and 2005 on the incidence of diabetic retinopathy]. <i>Arch Soc Esp Otolmol</i> . 2007; 82(4): 209-18.	2005		
Spain	Serrano Ríos M, Moy CS, Martín Serrano R, Minuesa Asensio A, de Tomás Labat ME, Zarandieta Romero G, Herrera J. Incidence of type 1 (insulin-dependent) diabetes mellitus in subjects 0-14 years of age in the Comunidad de Madrid, Spain. <i>Diabetologia</i> . 1990; 33(7): 422-4.	1985-1988		
Spain	Soriguer F, Rojo-Martínez G, Almaraz MC, Esteve I, Ruiz de Adana MS, Morcillo S, Valdés S, García-Fuentes E, García-Escobar E, Cardona I, Gomez-Zumaquero JM, Oliveira-Fuster G. Incidence of type 2 diabetes in southern Spain (Pizarra Study). <i>Eur J Clin Invest</i> . 2008; 38(2): 126-33.	1997-2004	*	
Spain	Beato-Fernández L, Rodríguez-Cano T, Belmonte-Llario A, Martínez-Delgado C. Risk factors for eating disorders in adolescents. A Spanish community-based longitudinal study. <i>Eur Child Adolesc Psychiatry</i> . 2004; 13(5): 287-94.	2000-2001	*	
Spain	Sancho C, Arja MV, Canals J. Personality in non-clinical adolescents with eating disorders. <i>Eur Eat Disord Rev</i> . 2008; 16(2): 133-8.	2006	*	
Spain	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Government Delegation for the National Plan on Drugs (Spain). Spain National Report to the EMCDDA 2006.	1998-2000, 2002	*	
Spain	Bargagli AM, Hickman M, Davoli M, Perucci CA, Schifano P, Buser M, Brugal T, Vicente J, COSMO European Group. Drug-related mortality and its impact on adult mortality in eight European countries. <i>Eur J Public Health</i> . 2006; 16(2): 198-202.	1992-2001	*	
Spain	Brugal MT, Domingo-Salvany A, Maguire A, Cayla JA, Villalbi JR, Hartnoll R. A small area analysis estimating the prevalence of addiction to opioids in Barcelona, 1993. <i>J Epidemiol Community Health</i> . 1999; 53(8): 488-94.	1993	*	
Spain	Esteban J, Gimeno C, Barril J, Aragónés A, Climent JM, de la Cruz Pellín M. Survival study of opioid addicts in relation to its adherence to methadone maintenance treatment. <i>Drug Alcohol Depend</i> . 2003; 70(2): 193-200.	1990-1997	*	
Spain	Pérez Madruga A, Avila Escribano JJ, Rodríguez Treceño M, Paniagua Paniagua C, Recio Pérez J. Análisis retrospectivo y de seguimiento de pacientes dependientes a opiáceos, atendidos durante los años 1985-1990. <i>Psiquis (Madr)</i> . 1998; 19(1): 17-22.	1985-1997	*	
Spain	Muga R, Langohr K, Tor J, Sanvicens A, Serra I, Rey-Joly C, Muñoz A. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs. <i>Clin Infect Dis</i> . 2007; 45(3): 370-6.	1987-2004	*	
Spain	Ortí RM, Domingo-Salvany A, Muñoz A, Macfarlane D, Suelves JM, Antó JM. Mortality trends in a cohort of opiate addicts, Catalonia, Spain. <i>Int J Epidemiol</i> . 1996; 25(3): 545-53.	1985-1991	*	
Spain	Sánchez-Carbonell X, Seus L. Ten-year survival analysis of a cohort of heroin addicts in Catalonia: the EMETYST project. <i>Addiction</i> . 2000; 95(6): 941-8.	1985-1995		
Spain	Flatz G, Düren R. Glucose-6-phosphate dehydrogenase deficiency in Spain. <i>Hum Genet</i> . 1967; 4(1): 81-3.	1965-1967		
Spain	Pellicer A, Casado A. Frequency of thalassemia and G6PD deficiency in five provinces of Spain. <i>Am J Hum Genet</i> . 1970; 22(3): 298-303.	1968-1970		
Spain	García SC, Moragón AC, López-Fernández ME. Frequency of glutathione reductase, pyruvate kinase and glucose-6-phosphate dehydrogenase deficiency in a Spanish population. <i>Hum Hered</i> . 1979; 29(5): 310-3.	1977-1979		
Spain	Miguel A, Ramon M, Petitpierre E, Goos CM, Vermeesch-Markslag AM, Vermorken AJ. Population screening for glucose-6-phosphate dehydrogenase deficiency on the Balears. <i>Hum Genet</i> . 1983; 64(2): 176-9.	1981-1983		
Spain	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant</i> . 1988; 3(6): 714-27.	1985-1986		
Spain	Van Dijk PC, Jager KJ, Stengel B, Grönhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). <i>Kidney Int</i> . 2005; 67(4): 1489-99.	1991-1992, 1999-2000		
Spain	López Revuelta K, Saracho R, García López F, Gentil MA, Castro P, Castilla J, Gutiérrez JA, Martín-Martínez E, Alonso R, Bernabéu R, Munat MA, Lorenzo V, Vega N, Escallada R, Sierra T, Lara M, Estébanez C, Cléries M, Vela E, Tallón S, García-Blasco MJ, Zurriaga O, Vázquez C, Sánchez-Casajús A, Torralbo A, Rodado R, Genovés A, Ripoll J, Asín JL, Magaz A, Aranzabal J. Dialysis and Transplant Registry of the Spanish Society of Nephrology and regional registries. <i>Rapport</i> 2001. <i>Nefrologia</i> . 2004; 24(1): 21-33.	2001		
Spain	Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. <i>Nephrol Dial Transplant</i> . 2003; 18(9): 1824-33.	1998-1999		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Spain	Global Lower Extremity Amputation Study Group. Epidemiology of lower extremity amputation in centres in Europe, North America and East Asia. The Global Lower Extremity Amputation Study Group. Br J Surg. 2000; 87(3): 328-37.	1995-1997		
Spain	Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000; 85(7): 2434-8.	1999		
Spain	Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. J Clin Endocrinol Metab. 2008; 93(4): 1408-11.	2005		
Spain	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Gilst WH van, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. Eur Heart J. 2003; 24(5): 442-63.	2000-2001		
Spain	Morales-Suárez-Varela M, Ibáñez-Cabanell P, Gimeno-Clemente N, Roig-García JM, Nieto-García MA, Llopis-González A. Oral and dental health of non-institutionalized elderly people in Spain. Arch Gen Psychiatry. 2011; 52(2): 159-63.	2005-2006	*	
Spain	Gil R, Álvarez JL, Gómez C, Álvaro A, Gil Á. Epidemiology of typhoid and paratyphoid fever hospitalizations in Spain (1997-2005). Hum Vaccin. 2013; 5(6): 420-4.	1997-2005	*	
Spain	Otero A, de Francisco A, Gayoso P, García F, EPIRCE Study Group. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrología. 2010; 30(1): 78-86.	2004-2008		
Spain	National Statistics Institute (Spain). Spain Hospital Morbidity Survey 2005. Madrid, Spain: National Statistics Institute (Spain).	2005	*	
Spain	Seijo-Martínez M, Castro del Río M, Rodríguez Álvarez J, Suárez Prado R, Torres Salgado E, Paz Esquete J, Sobrido MJ. Prevalence of parkinsonism and Parkinson's disease in the Arosa Island (Spain): a community-based door-to-door survey. J Neurol Sci. 2011; 304(1-2): 49-54.	2004	*	
Spain	Catalá-López F, Fernández de Larrea-Baz N, Morant-Ginestar C, Álvarez-Martín E, Díaz-Guzmán J, Gènova-Maleras. The national burden of cerebrovascular diseases in Spain: a population-based study using disability-adjusted life years. Med Clin (Barc). 2014.	2008	*	
Spain	Fernández-de-Las-Peñas C, Hernández-Barrera V, Carrasco-Garrido P, Alonso-Blanco C, Palacios-Ceña D, Jiménez-Sánchez S, Jiménez-García R. Population-based study of migraine in Spanish adults: relation to socio-demographic factors, lifestyle and comorbidity with other conditions. J Headache Pain. 2010; 11(2): 97-104.	2006-2007		†
Spain	Cuadrado JL de Pedro-Cuesta J, Ara JR, Cemillán CA, Díaz M, Duarte J, Fernández MD, Fernández O, García-López F, García-Merino A, García-Montero R, Martínez-Matos JA, Palomo F, Pardo J, Tobias A. Spanish GBS Epidemiological Study Group. Guillain-Barré syndrome in Spain, 1985-1997: epidemiological and public health views. Eur Neurol. 2001; 46(2): 83-91.	1985-1997		†
Spain	Cuadrado J, Pedro-Cuesta J, Ara J, Cemillan C, Diaz M, Duarte J. Public health surveillance and incidence of adulthood Guillain-Barré syndrome in Spain, 1998-1999: the view from a sentinel network of neurologists. Neurol Sci. 2004; 57-65.	1998-1999		†
Spain	Sedano MJ, Calleja J, Canga E, Berciano J. Guillain-Barré syndrome in Cantabria, Spain. An epidemiological and clinical study. Acta Neurol Scand. 1994; 89(4): 287-92.	1975-1988		
Spain	Cebrián-Cuenca AM, Díez-Domingo J, Rodríguez MS-M, Puig-Barberá J, Navarro-Pérez J. Herpes Zoster Research Group of the Valencian Community. Epidemiology of herpes zoster infection among patients treated in primary care centres in the Valencian community (Spain). BMC Fam Pract. 2010; 11(1): 33.	2006-2007	*	
Spain	Morales-Angulo C, Gallo-Terán J, Azuara N, Quintela JR. [Etiology of severe/profound, pre/perilingual bilateral hearing loss in Cantabria (Spain)]. Acta Otorrinolaringol Esp. 2004; 55(8): 351-5.	1983-2003	*	
Spain	World Health Organization (WHO). Spain WHO Leishmaniasis Country Profile.	1994-2008		
Spain	Bermejo-Pareja F, Benito-León J, Vega S, Medrano MJ, Román GC, Neurological Disorders in Central Spain (NEDICES) Study Group. Incidence and subtypes of dementia in three elderly populations of central Spain. J Neurol Sci. 2008; 264(1-2): 63-72.	1994-1998		
Spain	Lobo A, Saz P, Marcos G, Día JL, De-la-Cámara C. The prevalence of dementia and depression in the elderly community in a southern European population. The Zaragoza study. Arch Gen Psychiatry. 1995; 52(6): 497-506.	1987-1992		
Spain	Carbayo JA, División JA, Escrivano J, López-Abril J, López de Coca E, Artigao LM, Martínez E, Sanchis C, Massó J, Carrión L, Grupo de Enfermedades Vasculares de Albacete (GEVA). Using ankle-brachial index to detect peripheral arterial disease: prevalence and associated risk factors in a random population sample. Nutr Metab Cardiovasc Dis. 2007; 17(1): 41-9.	2004		
Spain	Gomez-Soto FM, Andrey JL, Garcia-Egido AA, Escobar MA, Romero SP, Garcia-Arjona R, Gutierrez J, Gomez F. Incidence and mortality of heart failure: a community-based study. Int J Cardiol. 2011; 151(1): 40-5.	2000-2007	*	
Spain	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Spain	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Spain	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Spain	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Spain	López-Bescós L, Cosín J, Elosua R, Cabadés A, de los Reyes M, Arós F, Diago JL, Asín E, Castro-Beiras A, Marrugat J. [The prevalence of angina and cardiovascular risk factors in the different autonomous communities of Spain: the PANES Study. Prevalencia de Angina en España]. Rev Esp Cardiol. 1999; 52(12): 1045-56.	1995-1996		
Spain	Gil M, Martí H, Elosúa R, Grau M, Sala J, Masiá R, Pérez G, Roset P, Bielsa O, Vila J, Marrugat J. [Analysis of trends in myocardial infarction case-fatality, incidence and mortality rates in Girona, Spain, 1990-1999]. Rev Esp Cardiol. 2007; 60(4): 349-56.	1990-1999	*	
Spain	Sans S, Puigdefàbregas A, Paluzie G, Monerde D, Balaguer-Vintró I. Increasing trends of acute myocardial infarction in Spain: the MONICA-Catalonia Study. Eur Heart J. 2005; 26(5): 505-15.	1985-1997	*	
Spain	Patnaik P, Herrero R, Morrow RA, Munoz N, Bosch FX, Bayo S, El Gueddari B, Caceres E, Chichareon SB, Castellsague X, Meijer CJLM, Sniijders PJF, Smith JS. Type-specific seroprevalence of herpes simplex virus type 2 and associated risk factors in middle-aged women from 6 countries: the IARC multicentric study. Sex Transm Dis. 2007; 34(12): 1019-24.	1985-1997	*	
Spain	De Ory F, Pachón I, Echevarría JM, Ramírez R. Seroepidemiological study of herpes simplex virus in the female population in the autonomous region of Madrid, Spain. Eur J Clin Microbiol Infect Dis. 1999; 18(9): 678-80.	1993-1994	*	
Spain	García-Corbeira P, Dal-Ré R, Aguilar L, Granizo JJ, García-de-Lomas J. Is sexual transmission an important pattern for herpes simplex type 2 virus seroconversion in the Spanish general population? J Med Virol. 1999; 59(2): 194-7.	1992-1993		
Spain	Gil A, González A, Dal-Ré R, Ortega P, Domínguez V. Prevalence of antibodies against varicella zoster, herpes simplex (types 1 and 2), hepatitis B and hepatitis A viruses among Spanish adolescents. J Infect. 1998; 36(1): 53-6.	1993, 1995-1997	*	
Spain	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland: World Health Organization (WHO).	2001-2008	*	
Spain	Quiñtana JM, Escobar A, Arostegui I, Bilbao A, Armendariz P, Lafuente I, Aguirre U. Prevalence of symptoms of knee or hip joints in older adults from the general population. Aging Clin Exp Res. 2008; 20(4): 329-36.	2002-2003		†
Spain	Hernández M, Orduña C, Bosch V, Salinas R, Alcaraz JL, Marín JM. [Retinopathy of prematurity in the Murcia region of Spain. Incidence and severity]. Arch Soc Esp Oftalmol. 2008; 83(7): 423-8.	2004		
Spain	Peris Roig B, Atienzar Herráez N, Merchante Alfaro AA, Calvo Rigual F, Tenías Burillo JM, Sefía Moreno S, López García MJ. [Endemic goiter and iodine deficiency: are they still a reality in Spain]. An Pediatr (Barc). 2006; 65(3): 234-40 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2001-2002		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Spain	García Cenoz M, Castilla J, Montes Y, Morán J, Salaberri A, Elfa F, Floristán Y, Rodrigo I, Irsarri F, Arriazu M, Zabala A, Barriarte A. [Varicella and herpes zoster incidence prior to the introduction of systematic child vaccination in Navarre, 2005-2006]. <i>An Sist Sanit Navar</i> . 2008; 31(1): 71-80.	2005-2006		
Spain	Cortes Martincorena FJ, Moreno Iribas C, Ardanaz Aicua E. Tooth loss and dental caries in an adult population in Navarra, Spain. <i>Community Dent Oral Epidemiol</i> . 1993; 21(3): 172-3.	1989		
Spain	Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJA, Wasserman SM, Baker N, Rosser D, Cleland JGF, Ponikowski P. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. <i>Eur Heart J</i> . 2007; 28(18): 2208-16.	1992-1995		
Spain	Ramos R, Quesada M, Solanas P, Subirana I, Sala J, Vila J, Masía R, Cerezo C, Elosua R, Grau M, Cerdón F, Juvinyà D, Fitó M, Isabel Covas M, Clarà A, Angel Muñoz M, Marrugat J, REGICOR Investigators. Prevalence of symptomatic and asymptomatic peripheral arterial disease and the value of the ankle-brachial index to stratify cardiovascular risk. <i>Eur J Vasc Endovasc Surg</i> . 2009; 38(3): 305-11.	2005-2006		
Spain	López-Izquierdo R, Antonia Udaondo Ma, Zarzosa P, García-Ramón E, Garcinuño S, Ángel Bratos M, Orduña A, Rodríguez-Torres A, Almaraz A. Seroprevalencia de las hepatitis virales en población general representativa de una zona básica de salud urbana en Castilla y León. <i>Enferm Infecc Microbiol Clin</i> . 2007; 25(5): 317-23.	2003		†
Spain	Riestra S, Fernández E, Leiva P, García S, Ocio G, Rodrigo L. Prevalence of hepatitis C virus infection in the general population of northern Spain. <i>Eur J Gastroenterol Hepatol</i> . 2001; 13(5): 477-81.	1997-1998	*	
Spain	Domínguez A, Bruguera M, Vidal J, Plans P, Salleras L. Changes in the seroepidemiology of hepatitis B infection in Catalonia 1989-1996. <i>Vaccine</i> . 2000; 18(22): 2345-50.	1996	*	
Spain	Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, Büchele G, Clausen M, Cookson WOC, von Mutius E, Strachan DP, Williams HC, ISAAC Phase Two Study Group. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. <i>J Allergy Clin Immunol</i> . 2008; 121(1): 141-147.	2005-2007	*	
Spain	Pérez-González M, Torres-Rodríguez JM, Martínez-Roig A, Segura S, Griera G, Triviño L, Pasarín M. Prevalence of tinea pedis, tinea unguium of toenails and tinea capitis in school children from Barcelona. <i>Rev Iberoam Micol</i> . 2009; 26(4): 228-32.	2003-2004	*	
Spain	Cladera Serra A, Oliva Berini E, Torrent Quetglas M, Bartolozzi Castilla E. [Prevalence of glucose-6-phosphate dehydrogenase deficiency in a student population on the island of Menorca]. <i>Sangre (Barc)</i> . 1997; 42(5): 363-7.	1993-1996	*	
Spain	Prieto-Alhambra D, Judge A, Javaid MK, Cooper C, Díez-Pérez A, Arden NK. Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints. <i>Ann Rheum Dis</i> . 2013.	2006-2010		
Spain	Martínez de Pancorbo C, Carballo F, Horcajo P, Aldegue M, de la Villa I, Nieto E, Gaspar MJ, de la Morena J. Prevalence and associated factors for gallstone disease: results of a population survey in Spain. <i>J Clin Epidemiol</i> . 1997; 50(12): 1347-55.	1991-1992		
Spain	Rodrigo L, Riestra S, Niño P, Cadahía V, Tojo R, Fuentes D, Moreno M, González Ballina E, Fernández E. A population-based study on the incidence of inflammatory bowel disease in Oviedo (Northern Spain). <i>Rev Esp Enferm Dig</i> . 2004; 96(5): 296-305.	2000-2003	*	
Spain	Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overved K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PHM, Lund E, Quirós JR, González CA, Sanchez Perez M-J, Navarro C, Dorronsoro M, Barriarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu L, Chuang S-C, Murphy N, Boffetta P, Trichopoulos A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. <i>J Natl Cancer Inst</i> . 2011; 103(22): 1686-95.	1992-2006		
Spain	Montes Martínez I, Agulla Budiño A. [Prevalence of antibodies against hepatitis A, B, C and E viruses in the rural child population in Northern Extremadura]. <i>An Esp Pediatr</i> . 1996; 45(2): 133-6.	1993-1995	*	
Spain	Bernal MC, Leyva A, García F, Galán I, Piedrola G, Heyermann H, Maroto MC. Seroepidemiological study of hepatitis E virus in different population groups. <i>Eur J Clin Microbiol Infect Dis</i> . 1995; 14(11): 954-8.	1992-1994		
Spain	Rivera F, Ruiz J, García de Pesquera F. [Evolution of the prevalence of hepatitis A antibody in Seville]. <i>Aten Primaria</i> . 1998; 21(2): 97-100.	1981, 1985		
Spain	Carreño García V, González Alonso R, Porres Cubero JC, Ortiz Maslorens F, Martín Calderín F, Hernández Guío C. [Prevalence of anti-HAV in the Spanish population]. <i>Rev Esp Enferm Apar Dig</i> . 1983; 64(3): 187-90.	1982		
Spain	Grau A, Bertomeu F, Luna J, Llorente A, Vich JM, Anzueto A, Alberio J, Bofill D, Simo E. [Epidemiological study of hepatitis A using the measurement of anti-VHA antibody]. <i>Rev Clin Esp</i> . 1982; 165(1): 11-3.	1982		
Spain	Salleras L, Bruguera M, Vidal J, Taberner JL, Plans P, Jiménez de Anta MT, Rodés J. [A change in the epidemiologic pattern of hepatitis A in Spain]. <i>Med Clin (Barc)</i> . 1992; 99(3): 87-9.	1985-1989		
Spain	Pérez Trallero E, Cilla G, Equiluz G, Urbieto Egaña M, García Bengochea M. Prevalence of hepatitis A virus infection in Spain. <i>Scand J Infect Dis</i> . 1988; 20(1): 113-4.	1986-1987		
Spain	Pérez-Trallero E, Cilla G, Urbieto M, Dorronsoro M, Otero F, Marimon JM. Falling incidence and prevalence of hepatitis A in northern Spain. <i>Scand J Infect Dis</i> . 1994; 26(2): 133-6.	1986-1987, 1992		
Spain	Ruiz Moreno M, García Aguado J, Carreño García V, Alvarez Sala L, Rincón Víctor P, López-Linares del Prado M, Bas Pérez C. [Prevalence of hepatitis caused by A, B and D virus in children]. <i>An Esp Pediatr</i> . 1988; 29(5): 357-62.	1987		
Spain	Jiménez Rodríguez-Vila M, Hernández Gajate M, Pascual Martín ML, Martín Rojo M, Fernández Alonso MC, Gómez Arranz A, Hernández Pérez P, Martín Rodríguez JF, Orduña Domingo A, Caro-Patón Gómez A. [Antibody titers against the hepatitis A virus in a healthy population from an urban health area]. <i>Aten Primaria</i> . 1992; 9(1): 10-2.	1988		
Spain	Amela C, Pachon I, Bueno R, de Miguel C, Martínez-Navarro F. Trends in hepatitis A virus infection with reference to the process of urbanization in the greater Madrid area (Spain). <i>Eur J Epidemiol</i> . 1995; 11(5): 569-73.	1988		
Spain	Bolmar F, Giner-Duran R, Hernandez-Aguado I, Serra-Desfilis MA, Rebagliato M, Rodrigo JM. Epidemiology of hepatitis A in Valencia, Spain: public health implications. <i>J Viral Hepat</i> . 1995; 2(3): 145-9.	1988-1989		
Spain	Dal-Ré R, Aguilar L, Coronel P. Current prevalence of hepatitis B, A and C in a healthy Spanish population. A seroepidemiological study. <i>Infection</i> . 1991; 19(6): 409-13.	1989		
Spain	Morales JL, Huber L, Gallego S, Alvarez G, Díez-Delgado J, González A, Aguilar L, Dal-Ré R. A seroepidemiologic study of hepatitis A in Spanish children. Relationship of prevalence to age and socio-environmental factors. <i>Infection</i> . 1992; 20(4): 194-6.	1990		
Spain	Gil A, González A, Dal-Ré R, Aguilar L, Rey Calero J. [Seroprotection against hepatitis A, measles, rubella, and parotiditis in an urban school population]. <i>Med Clin (Barc)</i> . 1991; 96(18): 681-4.	1990		
Spain	Lasheras Lozano ML, Gil Miguel A, Santos Santos M, Rey Calero J. [The seroepidemiology of the hepatitis A virus in children and adolescents]. <i>Aten Primaria</i> . 1994; 13(1): 36-8.	1990-1991		
Spain	Cilla G, Pérez-Trallero E, Marimon JM, Erdozain S, Gutiérrez C. Prevalence of hepatitis A antibody among disadvantaged gypsy children in northern Spain. <i>Epidemiol Infect</i> . 1995; 115(1): 157-61.	1991-1993		
Spain	González A, Bruguera M, Calbo Torrecillas F, Monge V, Dal-Ré R, Costa J. [Seroepidemiologic survey of hepatitis A antibodies in the young adult Spanish population. Spanish Study Group on hepatitis A (1)]. <i>Med Clin (Barc)</i> . 1994; 103(12): 445-8.	1992		
Spain	Dal-Ré R, García-Corbeira P, García-de-Lomas J. A large percentage of the Spanish population under 30 years of age is not protected against hepatitis A. <i>J Med Virol</i> . 2000; 60(4): 363-6.	1992-1993		
Spain	García-Fulgueiras A, Rodríguez T, Tormo MJ, Pérez-Flores D, Chirlaque D, Navarro C. Prevalence of hepatitis A antibodies in southeastern Spain: a population-based study. <i>Eur J Epidemiol</i> . 1997; 13(4): 481-3.	1992-1993		
Spain	Bayas JM, Bruguera M, Vilella A, Carbó JM, Vidal J, Navarro G, Nebot X, Prat A, Salleras L. [Prevalence of hepatitis B and hepatitis A virus infection among health sciences students in Catalonia, Spain]. <i>Med Clin (Barc)</i> . 1996; 107(8): 281-4.	1992-1994		
Spain	Rodríguez-Iglesias MA, Pérez-Gracia MT, García-Valdivia MS, Pérez-Ramos S. Seroprevalence of hepatitis A virus antibodies in a pediatric population of southern Spain. <i>Infection</i> . 1995; 23(5): 309.	1994		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Spain	Benito Ruesca R, Gil-Tomás J, Doiz Unzué O, López Cerero L. [The immune status against hepatitis A virus in medical residents]. <i>Med Clin (Barc)</i> . 1997; 109(6): 236-7.	1994-1996		
Spain	Suárez A, Navascués CA, García R, Peredo B, Miguel D, Menéndez MT, Saro C, Román F. [The prevalence of markers for the hepatitis A and B viruses in the population of Gijón between 6 and 25 years old]. <i>Med Clin (Barc)</i> . 1996; 106(13): 491-4.	1995		
Spain	Gil Miguel A, González López A, Dal-r é R, Domínguez Rojas V. [A serial questionnaire on the prevalence of hepatitis A antibodies in adolescents in urban area: comparative study (1990-1995)]. <i>Aten Primaria</i> . 1996; 18(10): 584-586.	1995		
Spain	Buti M, Campins M, Jardí R, Navas E, Cotrina M, Llobet E, Vaqué J, Esteban R. [Seroepidemiology of hepatitis A virus infection in medical and nursing students. The role of vaccination]. <i>Gastroenterol Hepatol</i> . 1996; 19(4): 199-202.	1995		
Spain	Suárez A, Viejo G, Navascués CA, García R, Díaz G, Saro C, Román FJ. [The prevalence of hepatitis A, B and C viral markers in the population of Gijón between 26 and 65 years old]. <i>Gastroenterol Hepatol</i> . 1997; 20(7): 347-52.	1995		
Spain	Santana OE, Rivero LE, Limiñana JM, Hernández LA, Santana M, Martín AM. [Seroepidemiological study of hepatitis A in Gran Canaria (Spain)]. <i>Enferm Infecc Microbiol Clin</i> . 2000; 18(4): 170-3.	1995-1996		
Spain	Bruguera M, Salleras L, Plans P, Vidal J, Navas E, Domínguez A, Batalla J, Taberner JL, Espuñes J. [Changes in seroepidemiology of hepatitis A virus infection in Catalonia in the period 1989-1996. Implications for new vaccination strategy]. <i>Med Clin (Barc)</i> . 1999; 112(11): 406-8.	1995-1996		
Spain	Gil A, González A, Dal-Ré R, Domínguez V, Astasio P, Aguilar L. Detection of antibodies against hepatitis A in blood spots dried on filter paper. Is this a reliable method for epidemiological studies? <i>Epidemiol Infect</i> . 1997; 118(2): 189-91.	1996		
Spain	García Erce J, Solano Bernad VM, Ferrer Torres J, Gimeno Lozano JJ. [Seroprevalence of hepatitis A in Aragonese donors]. <i>Sangre (Barc)</i> . 1996; 41(6): 484-5.	1996		
Spain	De Juanes JR, Arrazola MP, González A. Risk of hepatitis A among hospital personnel in an intermediate-endemicity area. <i>Infect Control Hosp Epidemiol</i> . 1999; 20(9): 590-1.	1996		
Spain	Gil Miguel A, González López A, San Martín Rodríguez M. [Prevalence of hepatitis A antibodies in 6-7 year-old children: follow-up study 1990-1998]. <i>An Esp Pediatr</i> . 1999; 51(5): 569-70.	1998		
Spain	De Juanes JR, González A, Arrazola MP, San-Martín M. Cost analysis of two strategies for hepatitis A vaccination of hospital health-care personnel in an intermediate endemicity area. <i>Vaccine</i> . 2001; 19(30): 4130-4.	1999-2000		
Spain	González-Praetorius A, Rodríguez-Avial C, Fernández C, Teresa Pérez-Pomata Mf M, Gimeno C, Bisquert J. [The prevalence of hepatitis A in the Guadalupe province. Is Spain a country with low endemicity?]. <i>Enferm Infecc Microbiol Clin</i> . 2001; 19(9): 428-31.	2000		
Spain	Domínguez A, Bruguera M, Plans P, Costa J, Salleras L. Prevalence of hepatitis A antibodies in schoolchildren in Catalonia (Spain) after the introduction of universal hepatitis A immunization. <i>J Med Virol</i> . 2004; 73(2): 172-6.	2001		
Spain	Junquera S, Mateos M, Lasa E, Chacón J, Baquero F. [Seroepidemiologic study of hepatitis A in the community of Madrid during the year 2002]. <i>Enferm Infecc Microbiol Clin</i> . 2004; 22(8): 448-51.	2002		
Spain	Domínguez A, Bruguera M, Plans P, Espuñes J, Costa J, Plasencia A, Salleras L. Declining hepatitis A seroprevalence in adults in Catalonia (Spain): a population-based study. <i>BMC Infect Dis</i> . 2007; 7: 3.	2002		
Spain	Cilla G, Pérez-Trallero E, Artieda J, Serrano-Bengochea E, Montes M, Vicente D. Marked decrease in the incidence and prevalence of hepatitis A in the Basque Country, Spain, 1986-2004. <i>Epidemiol Infect</i> . 2007; 135(3): 402-8.	2004		
Spain	Gonzalez-Quintela A, Gude F, Boquete O, Aguilera A, Rey J, Meijide LM, Fernandez-Merino MC, Vidal C. Association of hepatitis A virus infection with allergic sensitization in a population with high prevalence of hepatitis A virus exposure. <i>Allergy</i> . 2005; 60(1): 98-103.	2004		
Spain	Moreno C, Turumbay J, García V, Erzeleta I, De Los Arcos E, Manrique A, Alegría E. [Myocardial Infarction in the population aged 25-74 in Navarra. Incidence, lethality and treatment in the period 1997-98. IBERICA study]. <i>An Sist Sanit Navar</i> . 2002; 25(2): 155-66.	1997-1998		
Spain	Tunstall-Pedoe H, Kuulasmaa K, Mahönen M, Tolonen H, Ruokkoski E. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. <i>Lancet</i> . 1999; 353(9164): 1547-57.	1980-1995		
Spain	Buti M, Domínguez A, Plans P, Jardí R, Schaper M, Espuñes J, Cardoña N, Rodríguez-Frías F, Esteban R, Plasencia A, Salleras L. Community-based seroepidemiological survey of hepatitis E virus infection in Catalonia, Spain. <i>Clin Vaccine Immunol</i> . 2006; 13(12): 1328-32.	2002		
Spain	Domínguez A, Bruguera M, Vidal J, Plans P, Salleras L. Community-based seroepidemiological survey of HCV infection in Catalonia, Spain. <i>J Med Virol</i> . 2001; 65(4): 688-93.	1996		
Spain	Esteban JI, López-Talavera JC, Genesà J, Madoz P, Viladomiu L, Muñoz E, Martín-Vega C, Rosell M, Allende H, Vidal X. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. <i>Ann Intern Med</i> . 1991; 115(6): 443-9.	1989-1990		
Spain	García-Fulgueiras A, Tormo MJ, Rodríguez T, Perez-Flores D, Chirlaque D, Navarro C. Prevalence of hepatitis B and C markers in the south-east of Spain: an unlinked community-based serosurvey of 2,203 adults. <i>Scand J Infect Dis</i> . 1996; 28(1): 17-20.	1992-1993		
Spain	González L, Roses A, Alomar P, del Valle JM, Garau A, Ferrer P, Maim-M, Llinares R, Blanco L, Lardinois R. The maternal-infant center in the control of hepatitis B. <i>Acta Obstet Gynecol Scand</i> . 1988; 67(5): 421-7.	1984-1986		
Spain	Pereira A, Sanz C, Tassies D, Ramírez B. Do patient-related blood donors represent a threat to the safety of the blood supply? <i>Haematologica</i> . 2002; 87(4): 427-33.	1996-2001		
Spain	Salleras L, Domínguez A, Bruguera M, Plans P, Costa J, Cardoña N, Batalla J, Plasencia A. Declining prevalence of hepatitis B virus infection in Catalonia (Spain) 12 years after the introduction of universal vaccination. <i>Vaccine</i> . 2007; 25(52): 8726-31.	2002		
Spain	Santana Rodríguez OE, Malé Gil ML, Hernández-Santana JF, Limiñana Cañal JM, Martín Sánchez AM. Prevalence of serologic markers of HBV, HDV, HCV and HIV in non-injection drug users compared to injection drug users in Gran Canaria, Spain. <i>Eur J Epidemiol</i> . 1998; 14(6): 555-61.	1993-1994		
Spain	Soto B, Rodrigo L, García-Bengochea M, Sanchez-Quijano A, Riestra S, Arenas JI, Andreu J, Rodríguez M, Emparanza JI, Torres Y. Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency virus infection in the index case. A multicentre study of 423 pairings. <i>J Intern Med</i> . 1994; 236(5): 515-9.	1986-1991		
Spain	Suárez González A, Solís Sánchez G, Otero Guerra L, Viejo De La Guerra G, Alvarez Navascués C, García López R. [Prevalence of immunity to hepatitis viruses in pregnant women from the health area of Gijón (Spain)]. <i>Gastroenterol Hepatol</i> . 2004; 27(6): 347-52.	2000-2002	*	
Spain	Bielsa I, Soria X, Esteve M, Ferrándiz C, Skin Cancer Study Group of Barcelonès Nord. Population-based incidence of basal cell carcinoma in a Spanish Mediterranean area. <i>Br J Dermatol</i> . 2009; 161(6): 1341-6.	2006-2007	*	
Spain	Flohr C, Weinmayr G, Weiland SK, Addo-Yobo E, Annesi-Maesano I, Björkstén B, Bräbäck L, Büchele G, Chico M, Cooper P, Clausen M, El Sharif N, Martínez Gimeno A, Mathur RS, von Mutius E, Morales Suarez-Varela M, Pearce N, Svabe V, Wong GWK, Yu M, Zhong NS, Williams HC, ISAAC Phase Two Study Group. How well do questionnaires perform compared with physical examination in detecting flexural eczema? Findings from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. <i>Br J Dermatol</i> . 2009; 161(4): 846-53.	2005-2007		
Spain	Fernández M, Castro-Flores J, Perez-de las Heras S, Mandaluniz-Lekumberri A, Gordejuela M, Zarranz J. [Prevalence of dementia in the elderly aged above 65 in a district in the Basque Country]. <i>Rev Neurol</i> . 2008; 46(2): 89-96.	2001-2004	*	
Spain	Mateos ML, Camarero C, Lasa E, Teruel JL, Mir N, Baquero F. Hepatitis E virus: relevance in blood donors and risk groups. <i>Vox Sang</i> . 1999; 76(2): 78-80.	1996-1997	*	
Spain	Steiner TJ, Stovner LJ, Katsarava Z, Láinez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Barré J, André C. The impact of headache in Europe: principal results of the Eurolight project. <i>J Headache Pain</i> . 2014; 15(31). [Unpublished data].	2008	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Spain	García-García C, Subirana I, Sala J, Bruguera J, Sanz G, Valle V, Arós F, Fiol M, Molina L, Serra J, Marrugat J, Elosua R. Long-Term Prognosis of First Myocardial Infarction According to the Electrocardiographic Pattern (ST Elevation Myocardial Infarction, Non-ST Elevation Myocardial Infarction and Non-Classified Myocardial Infarction) and Revascularization Procedures. <i>Am J Cardiol.</i> 2011; 108: 1061–1067.	2001-2003		†
Spain	Carrascosa A, Yeste D, Copil A, Audi L, Gusiñe M, Vicens-Calvet E, Clemente M. Fetal growth regulation and intrauterine growth retardation. <i>J Pediatr Endocrinol Metab.</i> 2004; 17(Suppl 3): 435–43.	2000		†
Spain	Zeitlan J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT; 2008. Available from: http://www.perinataleaudit.nl/downloads/bestand/649/peristat-ii-2008-	2004	*	
Spain	Spain Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
Spain	Spain Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Spain	Spain - Catalonia Renal Replacement Therapy Data 1997 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 1998. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2003.	1997		
Spain	Spain Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
Spain	European Surveillance of Congenital Anomalies (EUROCAT). Spain EUROCAT Prevalence Tables. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	1980-2011	*	
Spain	Spain - El Valles Congenital Anomaly Data 1993-1997 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1997	*	
Spain	Spain - Asturias Congenital Anomaly Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Spain	Spain - Barcelona Birth Defects Registry Data 1993-1998 - EUROCAT as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Spain	Spain - Basque Country Registry of Congenital Anomalies Data 1993-1997 - EUROCAT as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1997	*	
Spain	Spanish Collaborative Study of Congenital Malformations Data 1993-1998 - EUROCAT as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Spain	Spanish Collaborative Study of Congenital Malformations Data 1988 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1988	*	
Spain	Spanish Collaborative Study of Congenital Malformations Data 1987 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1987	*	
Spain	Spanish Collaborative Study of Congenital Malformations Data 1985 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1985	*	
Spain	Spanish Collaborative Study of Congenital Malformations Data 1986 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1986	*	
Spain	Spanish Collaborative Study of Congenital Malformations Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
Spain	Spanish Collaborative Study of Congenital Malformations Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
Spain	Spanish Collaborative Study of Congenital Malformations Data 1983 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1983	*	
Spain	Spanish Collaborative Study of Congenital Malformations Data 1980 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1980	*	
Spain	Spanish Collaborative Study of Congenital Malformations Data 1981 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1981	*	
Spain	Spanish Collaborative Study of Congenital Malformations Data 1984 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1984	*	
Spain	Spanish Collaborative Study of Congenital Malformations Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Spain	Spanish Collaborative Study of Congenital Malformations Data 1982 - ICBDSM as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1982	*	
Spain	Spanish Collaborative Study of Congenital Malformations Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Spain	Spanish Collaborative Study of Congenital Malformations Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Spain	Spanish Collaborative Study of Congenital Malformations Data 2001 - ICBDSR as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
Spain	Spanish Collaborative Study of Congenital Malformations Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003		†
Sri Lanka	Department of Census and Statistics (Sri Lanka), Westinghouse; Institute for Resource Development, Sri Lanka Demographic and Health Survey 1987. Columbia, United States: Westinghouse; Institute for Resource Development.	1987		†
Sri Lanka	World Health Organization (WHO). Sri Lanka World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003	*	
Sri Lanka	National Cancer Control Programme, Ministry of Health (Sri Lanka), Sri Lanka - Cancer Incidence Data: Sri Lanka Year 2001-2005. Colombo, Sri Lanka: National Cancer Control Programme, Ministry of Health (Sri Lanka), 2009.	2001-2005		
Sri Lanka	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		†
Sri Lanka	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		
Sri Lanka	Perera A, Atukorale DN, Sivayogan S, Ariyaratne VS, Karunaratne LDA. Prevalence of skin diseases in suburban Sri Lanka. Ceylon Med J. 2000; 45(3): 123-8.	1997		
Sri Lanka	Batuwanthudawe R, Rajapakse L, Somaratne P, Dassanayake M, Abeyasinghe N. Incidence of childhood Haemophilus influenzae type b meningitis in Sri Lanka. Int J Infect Dis. 2010; 14(5): e372-e376.	2004		
Sri Lanka	Lumbiganon P, Laopaboon M, Gülmezoglu AM, Souza JP, Taneepanichskul S, Ruyan P, Attygalle DE, Shrestha N, Mori R, Hinh ND, Bang HT, Rathay T, Chuyun K, Cheang K, Festin M, Udomsartergul V, Germar MJV, Yanqiu G, Roy M, Carroll G, Ba-Thike K. Method of delivery and pregnancy outcomes in Asia: the WHO global survey on maternal and perinatal health 2007-08. Lancet. 2010; 375(9713): 490-9.	2007-2008		
Sri Lanka	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998, 2000-2002, 2004-2005, 2009		
Sri Lanka	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2002		
Sri Lanka	Fernando DJ. The prevalence of neuropathic foot ulceration in Sri Lankan diabetic patients. Ceylon Med J. 1996; 41(3): 96-8.	1993		
Sri Lanka	Weerasuriya N, Siribaddana S, Dissanayake A, Subasinghe Z, Wariyapola D, Fernando DJ. Long-term complications in newly diagnosed Sri Lankan patients with type 2 diabetes mellitus. QJM. 1998; 91(6): 439-43.	1995		
Sri Lanka	Malavige GN, de Alwis NM, Weerasooriya N, Fernando DJ, Siribaddana SH. Increasing diabetes and vascular risk factors in a sub-urban Sri Lankan population. Diabetes Res Clin Pract. 2002; 57(2): 143-5.	2000		
Sri Lanka	Katulanda P, Constantine GR, Mahesh JG, Sheriff R, Seneviratne RD, Wijeratne S, Wijesuriya M, McCarthy ML, Adler AI, Matthews DR. Prevalence and projections of diabetes and pre-diabetes in adults in Sri Lanka-Sri Lanka Diabetes, Cardiovascular Study (SLDCS). Diabet Med. 2008; 25(9): 1062-9.	2006	*	
Sri Lanka	Amarasekera NDDM, Gunawardena NK, de Silva NR, Weerasinghe A. Prevalence of childhood atopic diseases in the Western Province of Sri Lanka. Ceylon Med J. 2010; 55(1): 5-8.	2006	*	
Sri Lanka	Perera R, Ekanayake L. Tooth loss in Sri Lankan adults. Int Dent J. 2011; 61(1): 7-11.	2009	*	
Sri Lanka	Perera PJ, Abeyweera NT, Fernando MP, Warnakulasuriya TD, Ranathunga N. Prevalence of dental caries among a cohort of preschool children living in Gampaha district, Sri Lanka: a descriptive cross sectional study. BMC Oral Health. 2012; 49.	2010	*	
Sri Lanka	Wellappuli N, Amaraseena N. Influence of family structure on dental caries experience of preschool children in Sri Lanka. Caries Res. 2012; 46(3): 208-12.	2010	*	
Sri Lanka	Olivieri NF, Muraca GM, O'Donnell A, Premawardhana A, Fisher C, Weatherall DJ. Studies in haemoglobin E beta-thalassaemia. Br J Haematol. 2008; 141(3): 388-97.	1997-2002	*	
Sri Lanka	Chandraratne NK, Gunawardena NS. Premenstrual syndrome: the experience from a sample of Sri Lankan adolescents. J Pediatr Adolesc Gynecol. 2011; 24(5): 304-10.	2010		
Sri Lanka	Mackenzie I. Hearing Impairment in Asia - final report of four country survey, as provided by the Global Burden of Disease 2010 hearing impairment expert group. [Unpublished].	2001		
Sri Lanka	Liyanage NPM, Fernando S, Malavige GN, Mallikahewa R, Sivayogan S, Jiffy MTM, Vitarana T. Seroprevalence of varicella zoster virus infections in Colombo district, Sri Lanka. Indian J Med Sci. 2007; 61(3): 128-34.	1999-2000		
Sri Lanka	Stein Z, Belmont L, Durkin M. Mild mental retardation and severe mental retardation compared: experiences in eight less developed countries. Ups J Med Sci Suppl. 1987; 89-96.	1987	*	
Sri Lanka	Niriella MA, De Silva AP, Dayaratne AHG, Ariyasinghe MHADP, Navarathne MMN, Peiris RSK, Samarasekara DN, Satharasinghe RL, Rajindrajith S, Dassanayake AS, Wickramasinghe AR, de Silva HJ. Prevalence of inflammatory bowel disease in two districts of Sri Lanka: a hospital based survey. BMC Gastroenterol. 2010; 32.	2007-2008	*	
Sri Lanka	Catani C, Jacob N, Schauer E, Kohila M, Neuner F. Family violence, war, and natural disasters: a study of the effect of extreme stress on children's mental health in Sri Lanka. BMC Psychiatry. 2008; 8(1): 33.	2006		
Sri Lanka	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Sri Lanka	Edussuriya K, Sennanayake S, Senaratne T, Marshall D, Sullivan T, Selva D, Casson RJ. The prevalence and causes of visual impairment in central Sri Lanka: the Kandy Eye study. Ophthalmology. 2009; 116(1): 52-6. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2006-2007		
Sri Lanka	Piniidiyapathirage MJ, Kasturiratne A, Ranawaka UK, Gunasekara D, Wijekoon N, Medagoda K, Perera S, Takeuchi F, Kato N, Warnakulasuriya T, Wickremasinghe AR. The burden of diabetes mellitus and impaired fasting glucose in an urban population of Sri Lanka. Diabet Med. 2013; 30(3): 326-32.	2007		
Sri Lanka	Abeyaratne KP, Premawansa S, Rajapakse L, Roberts DF, Pipha SS. A survey of glucose-6-phosphate-dehydrogenase deficiency in the North Central Province of Sri Lanka (formerly Ceylon). Am J Phys Anthropol. 1976; 44(1): 135-8.	1974-1976		
Sri Lanka	Kumarapeli V, Seneviratne R de A, Wijeyaratne CN, Yapa RMSC, Dodampahala SH. A simple screening approach for assessing community prevalence and phenotype of polycystic ovary syndrome in a semi-urban population in Sri Lanka. Am J Epidemiol. 2008; 168(3): 321-8.	2005-2006	*	
Sri Lanka	World Health Organization (WHO). Sri Lanka WHO Leishmaniasis Country Profile.	2001-2010	*	
Sri Lanka	Wijegunawardana NDAD, Gunawardene YNS, Manamperi A, Senarathne H, Abeyewickreme W. Geographic information system (GIS) mapping of lymphatic filariasis endemic areas of Gampaha District, Sri Lanka based on epidemiological and entomological screening. Southeast Asian J Trop Med Public Health. 2012; 43(3): 557-66. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2009	*	
Sri Lanka	Weerasooriya MV, Weerasooriya TR, Gunawardena NK, Samarawickrema WA, Kimura E. Epidemiology of bancroftian filariasis in three suburban areas of Matara, Sri Lanka. Ann Trop Med Parasitol. 2001; 95(3): 263-73. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1992		
Sri Lanka	De Silva HA, Gunatillake SB, Smith AD. Prevalence of dementia in a semi-urban population in Sri Lanka: report from a regional survey. Int J Geriatr Psychiatry. 2003; 18(8): 711-5.	2000-2001		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Sri Lanka	Sri Lanka Iodine Deficiency Status of Children Survey 2000-2001 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2000		
Sri Lanka	Sri Lanka Iodine Nutrition Status Survey 2005 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2005	*	
Sri Lanka	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
Sri Lanka	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	
Sri Lanka	World Health Organization (WHO). Global leprosy situation, 2008 (additional information). Wkly Epidemiol Rec. 2008; 83(50): 459.	2007	*	
Sri Lanka	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Sri Lanka	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Sri Lanka	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Sri Lanka	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Sri Lanka	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Sri Lanka	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Sri Lanka	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Sri Lanka	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Sri Lanka	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Sri Lanka	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Sri Lanka	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Sri Lanka	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994		
Sri Lanka	Katugampola SL, Balasuriya S, Fernando MA. Prevalence of goiter in a rural community in Sri Lanka Asia Pac J Public Health. 1992; 6(4): 182-7 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1988-1989		
Sri Lanka	World Health Organization Regional Office for South-East Asia (SEARO). Reported Cases of DF/DHF in Selected Countries in SEA Region. New Delhi, India: World Health Organization Regional Office for South-East Asia (SEARO).	1988-2006		
Sri Lanka	World Health Organization Regional Office for South-East Asia (SEARO). Situation Update of Dengue in the SEA Region, 2010. New Delhi, India: World Health Organization Regional Office for South-East Asia (SEARO).	2007-2009		
Sri Lanka	Pallegedara C, Ekanayake L. Tooth loss, the wearing of dentures and associated factors in Sri Lankan older individuals. Gerodontology. 2005; 22(4): 193-9.	2003		
Sri Lanka	World Health Organization (WHO). Global Prevalence and Incidence of Selected Curable Sexually Transmitted Diseases: Overviews and Estimates 1995. Geneva, Switzerland: World Health Organization (WHO), 1995.	1992		
Sri Lanka	Fernando SD, Herath S, Rodrigo C, Rajapakse L. Clinical features and sociodemographic factors affecting Trichomonas vaginalis infection in women attending a central sexually transmitted diseases clinic in Sri Lanka. Indian J Sex Transm Dis. 2012; 33(1): 25-31.	2007	*	
Sri Lanka	WHO Regional Office for South-East Asia (SEARO). WHO South-East Asia Region: Reported Cases and Deaths of Dengue from 2003 to 2012. New Delhi, India: WHO Regional Office for South-East Asia (SEARO), 2013.	2003-2012	*	
Sri Lanka	Ng KP, Ngeow YF, K R, M R. Hepatitis B seroprevalence among University of Malaya Students in the Post-universal Infant Vaccination Era. Med J Malaysia. 2013; 68(2): 144-7.	2005-2011	*	†
Sri Lanka	Fernando SD, Paranavitane SR, Rajakaruna J, Weerasinghe S, Silva D, Wickremasinghe AR. The health and nutritional status of school children in two rural communities in Sri Lanka. Trop Med Int Health. 2000; 5(6): 450-2 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997		
Sri Lanka	Gunasekera HAKM, Sunil-Chandra NP, de Silva HJ. Low community seroprevalence of hepatitis C virus infection in the Gampaha district. Ceylon Med J. 2002; 47(4): 122.	2002		
Sri Lanka	Padmasiri E, Rajapaksa L, Jayakuru WS, Withana N. The prevalence of hepatitis B surface antigen in the Gampaha district. Ceylon Med J. 1995; 40(1): 10-3.	1993	*	
Sri Lanka	Chandrasena TGAN, Premaratna R, Abeyewickrema W, de Silva NR. Evaluation of the ICT whole-blood antigen card test to detect infection due to Wuchereria bancrofti in Sri Lanka. Trans R Soc Trop Med Hyg. 2002; 96(1): 60-3. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1999	*	
Sri Lanka	Dissanayake S. Microfilaraemia, serum antibody and development of clinical disease in microfilaraemic subjects infected with Wuchereria bancrofti and treated with diethylcarbamazine citrate. Trans R Soc Trop Med Hyg. 1989; 83(3): 384-8. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1987	*	
Sri Lanka	Gunawardena GSA, Ismail MM, Bradley MH, Karunaweera ND. Impact of the 2004 mass drug administration for the control of lymphatic filariasis, in urban and rural areas of the Western province of Sri Lanka. Ann Trop Med Parasitol. 2007; 101(4): 335-41. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2004-2005	*	
Sri Lanka	Itoh M, Gunawardena NK, Qiu XG, Weerasooriya MV, Kimura E. The use of whole blood absorbed on filter paper to detect Wuchereria bancrofti circulating antigen. Trans R Soc Trop Med Hyg. 1998; 92(5): 513-5. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1980-2000	*	
Sri Lanka	Weerasooriya MV, Gunawardena NK, Itoh M, Qiu XG, Kimura E. Prevalence and intensity of Wuchereria bancrofti antigenaemia in Sri Lanka by Og4C3 ELISA using filter paper-absorbed whole blood. Trans R Soc Trop Med Hyg. 2002; 96(1): 41-5. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1996-1997	*	
Sri Lanka	Sri Lanka Programme to Eliminate Lymphatic Filariasis Country Report 2004 as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2004	*	
Sri Lanka	Sri Lanka - Expert Mission to Sri Lanka for Verification of Elimination of Lymphatic Filariasis as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2006-2008	*	†
Sri Lanka	Malaria and proximity to irrigation projects: A parasitaemia prevalence study from Sri Lanka as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Sri Lanka	Mendis C, Gamage-Mendis AC, De Zoysa AP, Abhayawardena TA, Carter R, Herath PR, Mendis KN. Characteristics of malaria transmission in Kataragama, Sri Lanka: a focus for immuno-epidemiological studies. Am J Trop Med Hyg. 1990; 42(4): 298-308 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986-1988	*	†
Sri Lanka	Ramasamy R, De Alwis R, Wijesundera A, Ramasamy MS. Malaria transmission at a new irrigation project in Sri Lanka: the emergence of Anopheles annularis as a major vector. Am J Trop Med Hyg. 1992; 47(5): 547-53 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Sri Lanka	Ramasamy R, Ramasamy MS, Wijesundera DA, Wijesundera AP, Dewit I, Ranasinghe C, Srikrishnaraj KA, Wickremaratne C. High seasonal malaria transmission rates in the intermediate rainfall zone of Sri Lanka. <i>Ann Trop Med Parasitol</i> . 1992; 86(6): 591-600 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990-1991	*	†
Sri Lanka	Wijesundera MD, Peiris JS, Ariyaratne YG, Verdini AS, Pessi A, Del Giudice G. Antibodies to Plasmodium falciparum sporozoites following a malarial outbreak in a non-endemic area of Sri Lanka. <i>Trans R Soc Trop Med Hyg</i> . 1990; 84(1): 35-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Sri Lanka	Yapabandara AM, Curtis CF, Wickramasinghe MB, Fernando WP. Control of malaria vectors with the insect growth regulator pyriproxyfen in a gem-mining area in Sri Lanka. <i>Acta Trop</i> . 2001; 80(3): 265-76 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993-1994		
Sri Lanka	Sri Lanka Vital Registration Birth Data 1991 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1991	*	†
Sudan	United Nations Children's Fund (UNICEF). South Sudan Multiple Indicator Cluster Survey 1999. New York, United States: United Nations Children's Fund (UNICEF).	1999		
Sudan	Department of Statistics (Sudan), International Statistical Institute, Ministry of National Planning (North Sudan). Sudan World Fertility Survey 1978-1979. International Statistical Institute.	1978		†
Sudan	Federal Ministry of Health (Sudan), League of Arab States. Sudan Maternal and Child Health Survey 1992-1993.	1992-1993		†
Sudan	Ministry of Finance and Economic Planning, Department of Statistics, Macro Systems, Inc.; Institute for Resource Development. Sudan Demographic and Health Survey 1989-1990. Columbia, United States: Macro Systems, Inc.	1989-1990	*	
Sudan	Central Bureau of Statistics (Sudan), Federal Ministry of Health (Sudan), Government of Sudan, Ministry of Health (South Sudan), Southern Sudan Centre for Census, Statistics and Evaluation. Sudan - South Multiple Indicator Cluster Survey 2010.	2010		
Sudan	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		†
Sudan	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		†
Sudan	Abdel-Rahman TA, Collins KJ, Doré C. Oxylog studies of energy expenditure and schistosomiasis in the Sudan. <i>J Trop Med Hyg</i> . 1990; 93(6): 365-7.	1990		
Sudan	Salih SY, Marshall TF, Radalowicz A. Morbidity in relation to the clinical forms and to intensity of infection in Schistosoma mansoni infections in the Sudan. <i>Ann Trop Med Parasitol</i> . 1979; 73(5): 439-49.	1973-1977	*	
Sudan	Central Bureau of Statistics (Sudan). Sudan Statistical Yearbook 2009. Khartoum, Sudan: Central Bureau of Statistics (Sudan).	2007, 2009		
Sudan	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001-2002		
Sudan	Farnon EC, Gould LH, Griffith KS, Osman MS, Kholy AE, Brair M-E, Panella AJ, Kosoy O, Laven JJ, Godsey MS, Perea W, Hayes EB. Household-based sero-epidemiologic survey after a yellow fever epidemic, Sudan, 2005. <i>Am J Trop Med Hyg</i> . 2010; 82(6): 1146-52.	2005		
Sudan	Gould LH, Osman MS, Farnon EC, Griffith KS, Godsey MS, Karch S, Mulenda B, El Kholy A, Grandesso F, De Radiguès X, Brair M-E, Briand S, El Tayeb ESM, Hayes EB, Zeller H, Perea W. An outbreak of yellow fever with concurrent chikungunya virus transmission in South Kordofan, Sudan, 2005. <i>Trans R Soc Trop Med Hyg</i> . 2005; 102(12): 1247-54.	2005		
Sudan	Onyango CO, Ofiala VO, Sang RC, Konongoi SL, Sow A, De Cock KM, Tukei PM, Okoth FA, Swanepoel R, Burt FJ, Waters NC, Coldren RL. Yellow fever outbreak, Imatong, southern Sudan. <i>Emerg Infect Dis</i> . 2004; 10(6): 1063-8.	2003		
Sudan	El Karim MA, Collins KJ, Dore C. Energy expenditure of agricultural workers in an area of endemic schistosomiasis in the Sudan. <i>Br J Ind Med</i> . 1987; 44(1): 64-7.	1985		†
Sudan	Omer AH, Hamilton PJ, Marshall TF, Draper CC. Infection with Schistosoma mansoni in the Gezire area of the Sudan. <i>J Trop Med Hyg</i> . 1976; 79(7): 151-7.	1973		
Sudan	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	2003		
Sudan	el Mahdi EM, Abdel Rahman I, Mukhtar Sel D. Pattern of diabetes mellitus in the Sudan. <i>Trop Geogr Med</i> . 1989; 41(4): 353-7.	1986		
Sudan	Elbagir MN, Eltom MA, Mahadi EO, Berne C. Pattern of long-term complications in Sudanese insulin-treated diabetic patients. <i>Diabetes Res Clin Pract</i> . 1995; 30(1): 59-67.	1992		
Sudan	Elmahdi EM, Kaballo AM, Mukhtar EA. Features of non-insulin-dependent diabetes mellitus (NIDDM) in the Sudan. <i>Diabetes Res Clin Pract</i> . 1991; 11(1): 59-63.	1986	*	
Sudan	Berrang-Ford L, Lundine J, Breau S. Conflict and human African trypanosomiasis. <i>Soc Sci Med</i> . 2011; 72(3): 398-407.	2002-2003	*	
Sudan	Khalifa N, Allen PF, Abu-bakr Neamat H, Abdel-Rahman ME, Abdelghafar KO. A survey of oral health in a Sudanese population. <i>BMC Oral Health</i> . 2012; 12: 5.	2009-2010		
Sudan	Raadal M, Elhassan FE, Rasmussen P. The prevalence of caries in groups of children aged 4-5 and 7-8 years in Khartoum, Sudan. <i>Int J Paediatr Dent</i> . 1993; 1(3): 9-15.	1990	*	
Sudan	Mueller YK, Nackers F, Ahmed KA, Boelaert M, Djoumessi J-C, Eltigani R, Gorashi HA, Hammam O, Rimeijer K, Salih N, Worku D, Etard J-F, Chappuis F. Burden of visceral leishmaniasis in villages of eastern Gedaref State, Sudan: an exhaustive cross-sectional survey. <i>PLoS Negl Trop Dis</i> . 2012; 6(11): e1872.	2011		
Sudan	Moukhyer ME, de Vries NK, Bosma H, van Eijk JTM. The prevalence of self-reported health problems and haemoglobin status of Sudanese adolescents. <i>J Adolesc</i> . 2006; 29(4): 613-26.	2001		
Sudan	Ngondi J, Ole-Sempole F, Onsargo A, Matende I, Baba S, Reacher M, Matthews F, Brayne C, Emerson PM. Prevalence and causes of blindness and low vision in southern Sudan. <i>PLoS Med</i> . 2006; 3(12): e177. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2005		
Sudan	Ibrahim-Khalil S, Elhag M, Ali E, Mahgoub F, Hakiem S, Omer N, Shafie S, Mahgoub E. An epidemiological survey of rheumatic fever and rheumatic heart disease in Sahafa Town, Sudan. <i>J Epidemiol Community Health</i> . 1992; 46(5): 477-9.	1984	*	
Sudan	Ali AAA, Khojali A, Okud A, Adam GK, Adam I. Maternal near-miss in a rural hospital in Sudan. <i>BMC Pregnancy Childbirth</i> . 2011; 11: 48.	2008-2010	*	
Sudan	Ali AA, Okud A, Khojali A, Adam I. High incidence of obstetric complications in Kassala Hospital, Eastern Sudan. <i>J Obstet Gynaecol</i> . 2012; 32(2): 148-9.	2009	*	
Sudan	Ali AA, Rayis DA, Abdallah TM, Elbashir MI, Adam I. Severe anaemia is associated with a higher risk for preeclampsia and poor perinatal outcomes in Kassala hospital, eastern Sudan. <i>BMC Res Notes</i> . 2011; 3: 11.	2008-2010		
Sudan	Omer RE, Vant Veer P, Kadaru AM, Kampman E, el Khidir IM, Fedail SS, Kok FJ. The role of hepatitis B and hepatitis C viral infections in the incidence of hepatocellular carcinoma in Sudan. <i>Trans R Soc Trop Med Hyg</i> . 2001; 95(5): 487-91.	1996-1998		
Sudan	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Sudan	Elamin A, Ghalib M, Eltayeb B, Tuvemo T. High incidence of type 1 diabetes mellitus in Sudanese children, 1991-1995. <i>Ann Saudi Med</i> . 1997; 17(4): 478-80.	1991-1995		
Sudan	Saha N, Samuel AP, Omer A, Hoffbrand AV. The inter- and intra-tribal distribution of red cell G6PD phenotypes in Sudan. <i>Hum Hered</i> . 1983; 33(1): 39-43.	1981-1983		
Sudan	Naicker S. Burden of end-stage renal disease in sub-Saharan Africa. <i>Clin Nephrol</i> . 2010; 74(Suppl 1): S13-6.	2008-2010	*	
Sudan	Abdelraheem MB, Ali E-TMA, Mohamed RM, Hassan EG, Abdalla OA, Mekki SO, Yousif BM, Watson AR. Pattern of glomerular diseases in Sudanese children: a clinico-pathological study. <i>Saudi J Kidney Dis Transpl</i> . 2010; 21(4): 778-83.	2002-2007	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Sudan	Federal Ministry of Health and Central Bureau of Statistics, Sudan Household and Health Survey - 2, 2012, National report. Khartoum, Republic of Sudan: Federal Ministry of Health and Central Bureau of Statistics.	2010		†
Sudan	World Health Organization (WHO). Sudan WHO Leishmaniasis Country Profile.	1997-2011		
Sudan	Sudan Comprehensive Nutrition Survey 1995 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1995		
Sudan	Sudan Iodine Deficiency Disorder Baseline Survey 1997 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1997		
Sudan	Damasceno A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D, Dzudie A, Kouam CK, Suliman A, Schrueder N, Yonga G, Ba SA, Maru F, Alemayehu B, Edwards C, Davison BA, Cotter G, Sliwa K. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med. 2012; 172(18): 1386-94.	2007-2010	*	
Sudan	Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Janin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J Health Geogr. 2010; 9: 57.	1980-2010	*	
Sudan	World Health Organization (WHO). Global leprosy situation, 2004. Wkly Epidemiol Rec. 2005; 80(13): 118-24.	2003	*	
Sudan	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
Sudan	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	
Sudan	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Sudan	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Sudan	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Sudan	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
Sudan	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Sudan	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Sudan	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Sudan	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Sudan	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Sudan	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Sudan	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Sudan	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1993; 68(25): 181-6.	1992	*	
Sudan	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Sudan	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Sudan	Kafi SK, Mohamed AO, Musa HA. Prevalence of sexually transmitted diseases (STD) among women in a suburban Sudanese community. Ups J Med Sci. 2000; 105(3): 249-53.	1997-1998		
Sudan	World Health Organization (WHO). Report of the WHO Strategic and Technical Advisory Group for Neglected Tropical Diseases (STAG-NTD) 2010. Geneva, Switzerland: World Health Organization (WHO), 2010.	2010		
Sudan	Salih MA, Suliman GI, Hassan HS. Complications of diphtheria seen during the 1978 outbreak in Khartoum. Ann Trop Paediatr. 1981; 1(2): 97-101.	1978		†
Sudan	Loevisohn BP. The changing age structure of diphtheria patients: evidence for the effectiveness of EPI in the Sudan. Bull World Health Organ. 1990; 68(3): 353-7.	1988		
Sudan	Salih MA, Khaleefa OH, Bushara M, Taha ZB, Musa ZA, Kamil I, Hofvander Y, Olcén P. Long term sequelae of childhood acute bacterial meningitis in a developing country. A study from the Sudan. Scand J Infect Dis. 1991; 23(2): 175-82.	1985-1986	*	†
Sudan	El Bushra HE, el Tom AR. Vitamin A deficiency: a public health problem in eastern Sudan. East Afr Med J. 1987; 64(11): 782-9 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1983		
Sudan	Abu-Sin AY, Ayoub M, Abdelrazig H. Antenatal blood group serology in Sudanese women. Vox Sang. 1978; 34(6): 347-50.	1975-1976	*	
Sudan	Hyams KC, al-Arabi MA, al-Tagani AA, Messiter JF, al-Gaali AA, George JF. Epidemiology of hepatitis B in the Gezira region of Sudan. Am J Trop Med Hyg. 1989; 40(2): 200-6.	1986	*	†
Sudan	Elussein EA, Magid YM, Omer MM, Adam I. Clinical patterns and major causes of infertility among Sudanese couples. Trop Doct. 2008; 38(4): 243-4.	2004	*	†
Sudan	Epidemiology of Malaria in Displaced Population South Khartoum [Master's thesis] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Sudan	Studies on Anopheles Arabiensis and the Impact of Microclimatic Conditions on Malaria Transmission in the Gezira Area [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Sudan	Transmission and Risk Factors of Urban and Peri-urban Malaria in Khartoum State, Sudan [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995-1996	*	†
Sudan	Epidemiology of Malaria in Displaced Population South Khartoum. Prevalence, Environmental and Entomological Aspects [Master's thesis] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Sudan	Inmuno-epidemiological Study of Malaria in Rahad River Area, Eastern Sudan [Master's thesis] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000-2001	*	†
Sudan	On the Epidemiology of Malaria in the Kordofan [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988-1989	*	†
Sudan	Malaria Vector and Efforts of Control in Khartoum State [Master's thesis] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Sudan	Sero-prevalence of Anti-merozoite Surface Protein 1-19 (MSP19) Antibodies in an Area of Unstable Malaria Transmission: Examining a Candidate Vaccine for Malaria [Master's thesis] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Sudan	Deltamethrin-treated Sudanese Thobs, a Control Method for Malaria in an Endemic Region as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998-1999	*	†
Sudan	Assessment of Malaria in Sennar Sugar Project: 7-18 February 1987 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Sudan	United Nations High Commission for Refugees Programme and Technical Support Section, East Sudan Medical Entomology Mission, 18th August-19th September 1997 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
Sudan	Malaria Epidemiology in Sudan as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Sudan	Five Years Plan of Action in Malaria Control in Red Sea State 1998-2002 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Sudan	Sudan Malaria Control Programme Annual Report 1990 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Sudan	Malaria Transmission After 10 Years of the End of a Comprehensive Control Programme (BNHP) in a Village in Gezira Irrigated Area, Central Sudan as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Sudan	Hamad AA, Nugud AEHD, Arnot DE, Giha HA, Abdel-Muhsin A-MA, Satti GMH, Theander TG, Creasey AM, Babiker HA, Elnaieim D-EA. A marked seasonality of malaria transmission in two rural sites in eastern Sudan. Acta Trop. 2002; 83(1): 71-82 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Sudan	El-Sayed B, El-Zaki S-E, Babiker H, Gadalla N, Ageep T, Mansour F, Baraka O, Milligan P, Babiker A. A Randomized Open-Label Trial of Artesunate- Sulfadoxine-Pyrimethamine with or without Primaquine for Elimination of Sub-Microscopic P. falciparum Parasitaemia and Gametocyte Carriage in Eastern Sudan. PLoS One. 2007; 2(12): e1311 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Sudan	Giha HA, Nasr A, Iriememam NC, Balogun HA, Arnot D, Theander TG, Troye-Blomberg M, Berzins K, ElGhazali G. Age-dependent association between IgG2 and IgG3 subclasses to Pf332-C231 antigen and protection from malaria, and induction of protective antibodies by sub-patent malaria infections, in Daraweesh. Vaccine. 2010; 28(7): 1732-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Sudan	Himeidan YE-S, Elbahir MI, El-Rayah E-A, Adam I. Epidemiology of malaria in New Halfa, an irrigated area in eastern Sudan. East Mediterr Health J. 2005; 11(3): 499-504 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
Sudan	Le Sueur D, Binka F, Lengeler C, De Savigny D, Snow B, Teuscher T, Toure Y. An atlas of malaria in Africa. Afr Health. 1997; 19(2): 23-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Sudan	Lienhardt C, Ghebray R, Candolfi E, Kien T, Hedlin G. Malaria in refugee camps in eastern Sudan: a sero-epidemiological approach. Ann Trop Med Parasitol. 1990; 84(3): 215-22 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Sudan	Mahgoub HM, Mohamed AA, Magzoub M, Gasim GI, Eldein WN, Ahmed AA, Adam I. Schistosoma mansoni infection as a predictor of severe anaemia in schoolchildren in eastern Sudan. J Helminthol. 2010; 84(2): 132-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008	*	†
Sudan	Mustafa HS, Malik EM, Tuok HT, Mohamed AA, Julla AI, Bassili A. Malaria preventive measures, health care seeking behaviour and malaria burden in different epidemiological settings in Sudan. Trop Med Int Health. 2009; 14(12): 1488-95 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005-2006	*	†
Sudan	Sato K, Kano S, Yamaguchi H, Omer FM, el Safi SH, el Gaddal AA, Suzuki M. An ABC-ELISA for malaria serology in the field. Am J Trop Med Hyg. 1990; 42(1): 24-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Sudan	Tagelsir N, Salim E, Younis S, Elimiari G, Eglaffar A, Ahmed M, Elhasan I. A clinico-epidemiological study of falciparum malaria in a cluster of villages in the eastern bank of the River Nile in Northern Sudan. Sudanese Journal of Public Health. 2008; 3(1): 11-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
Sudan	Sudan Plasmodium Falciparum Parasite Rate Data, Blue Nile Health Project 1999 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
Sudan	Sudan Plasmodium Falciparum Parasite Rate Data, M.M. Salih, Thesis 2005 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004-2005	*	†
Sudan	Vitamin A Deficiency and Xerophthalmia Prevalence Assessment Survey in Northern Darfur 1988 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1988	*	†
Suriname	General Bureau of Statistics (Suriname), Pan American Health Organization (PAHO), United Nations Children's Fund (UNICEF), United Nations Development Programme (UNDP). Suriname Multiple Indicator Cluster Survey 1999-2000. New York, United States: United Nations Children's Fund (UNICEF).	1999-2000	*	†
Suriname	General Statistical Office (Suriname), United Nations Children's Fund (UNICEF). Suriname Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006	*	†
Suriname	General Bureau of Statistics (Suriname), Ministry of Social Affairs and Housing (Suriname), Ministry of Planning and Development Cooperation (Suriname), United Nations Children's Fund (UNICEF), Suriname Multiple Indicator Cluster Survey 2010. New York, United States: United Nations Children's Fund (UNICEF), 2013.	2010	*	†
Suriname	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-2005	*	†
Suriname	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003	*	†
Suriname	Smadja D, Cabre P, May F, Fanon J-L, René-Coral P, Riocreux C, Charpentier J-C, Fournier P, Saint-Vil M, Ketterlé J. ERMANCIA: Epidemiology of Stroke in Martinique, French West Indies. Stroke. 2001; 32(12): 2741-7.	1998-1999	*	†
Suriname	De Oliveira LH, Danovaro-Holliday MC, Andrus JK, de Filipis AMB, Gentsch J, Matus CR, Widdowson M-A. Sentinel hospital surveillance for rotavirus in Latin American and Caribbean countries. J Infect Dis. 2009; 200 Suppl 1: 131-139.	2006-2007	*	†
Suriname	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000-2002, 2004-2009	*	†
Suriname	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010	*	†
Suriname	Van Gemert-Schriks M, van Amerongen W, ten Cate J. Caries prevalence in Suriname schoolchildren. Community Dent Health. 2009; 26(2): 116-20.	2006	*	†
Suriname	Canino G, ShROUT PE, Rubio-Stipec M, et al. The DSM-IV rates of child and adolescent disorders in Puerto Rico: Prevalence, correlates, service use, and the effects of impairment. Arch Gen Psychiatry. 2004; 61(1): 85-93.	1999-2000	*	†
Suriname	Rubio-Stipec M, Canino GJ, ShROUT P, Dulcan M, Freeman D, Bravo M. Psychometric properties of parents and children as informants in child psychiatry epidemiology with the Spanish Diagnostic Interview Schedule for Children (DISC.2). J Abnorm Child Psychol. 1994; 22(6): 703-20.	1992	*	†
Suriname	Canino GJ, Bird HR, ShROUT PE, Rubio-Stipec M, Bravo M, Martinez R, Sesman M, Guevara LM. The prevalence of specific psychiatric disorders in Puerto Rico. Arch Gen Psychiatry. 1987; 44(8): 727-35.	1984	*	†
Suriname	Poveda JD, Babin M, Bonnici JF, du Pasquier P, Fleury HJ. Serological study of the occurrence of Herpesviridae in French Guyana. Bull Soc Pathol Exot Filiales. 1986; 79(2): 207-12.	1983	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Suriname	Selten J-P, Zeyl C, Dworkasing R, Lumsden V, Kahn RS, Van Harten PN. First-contact incidence of schizophrenia in Surinam. <i>Br J Psychiatry</i> . 2005; 74-5.	2002-2003	*	
Suriname	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2001, 2004, 2010, 2012		
Suriname	Bird HR, Canino G, Rubio-Stipec M, Gould MS, Ribera J, Sesman M, Woodbury M, Huertas-Goldman S, Pagan A, Sanchez-Lacay A. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico. The use of combined measures. <i>Arch Gen Psychiatry</i> . 1988; 45(12): 1120-6.	1985-1986		
Suriname	Smink DA, Prins HK. Hereditary and acquired blood factors in the negroid population of Surinam. V. Electrophoretic heterogeneity of glucose-6-phosphate dehydrogenase. <i>Trop Geogr Med</i> . 1965; 17(3): 236-42.	1963-1965	*	
Suriname	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Suriname Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2006	*	
Suriname	World Health Organization (WHO). Suriname WHO Leishmaniasis Country Profile.	2004-2010	*	
Suriname	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec</i> . 2005; 80(34): 289-95.	2004	*	
Suriname	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec</i> . 2009; 84(33): 333-40.	2008	*	
Suriname	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec</i> . 2010; 85(35): 337-48.	2009	*	
Suriname	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec</i> . 2012; 87(34): 317-28.	2011	*	
Suriname	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec</i> . 2008; 83(33): 293-300.	2007	*	
Suriname	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec</i> . 2013; 88(35): 365-79.	2012	*	
Suriname	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec</i> . 2011; 86(36): 389-99.	2010	*	
Suriname	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec</i> . 2001; 76(23): 173-9.	2000	*	
Suriname	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec</i> . 2000; 75(28): 226-31.	1999	*	
Suriname	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1994; 69(20): 145-51.	1993	*	
Suriname	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec</i> . 1997; 72(23): 165-72.	1996	*	
Suriname	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec</i> . 1996; 71(20): 149-56.	1995	*	
Suriname	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1995; 70(25): 177-82.	1994	*	
Suriname	Merikangas KR, Conway KP, Swendsen J, Febo V, Dierker L, Brunetto W, Stolar M, Canino G. Substance use and behaviour disorders in Puerto Rican youth: a migrant family study. <i>J Epidemiol Community Health</i> . 2009; 63(4): 310-6.	1990	*	
Suriname	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Suriname	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Suriname	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Suriname	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Suriname	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Suriname	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Suriname	Olando S, Cabre P, Deschamps R, Chatot-Henry C, René-Corail P, Fournier P, Saint-Vil M, May F, Smadja D. Acute stroke in the very elderly: epidemiological features, stroke subtypes, management, and outcome in Martinique, French West Indies. <i>Stroke</i> . 2003; 34(7): 1593-7.	1998-1999	*	†
Suriname	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L, Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Ann Hepatol</i> . 2010; 9(1): 63-9.	2006-2008		
Suriname	Geerdink RA, Nijhuis LE, van Loghem E, Sjöe EL. Blood groups and immunoglobulin groups in Trio and Wajana Indians from Surinam. <i>Am J Hum Genet</i> . 1974; 26(1): 45-53.	1967-1968	*	
Suriname	Meide WF van der, Jensen AJ, Akrum RAE, Sabajo LOA, Fat RFMLA, Lambregts L, Schallig HDFH, Paardt M van der, Faber WR. Epidemiology of cutaneous leishmaniasis in Suriname: a study performed in 2006. <i>Am J Trop Med Hyg</i> . 2008; 79(2): 192-7.	1979-1985, 2006		
Suriname	Pan American Health Organization (PAHO), World Health Organization (WHO). Quantitative Estimation of Chagas in the Americas.	2005	*	†
Suriname	Suriname Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		†
Swaziland	Central Statistical Office (Swaziland), United Nations Children's Fund (UNICEF). Swaziland Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000		†
Swaziland	Central Statistical Office (Swaziland), Macro International, Inc. Swaziland Demographic and Health Survey 2006-2007. Calverton, United States: Macro International, Inc.	2006-2007	*	†
Swaziland	World Health Organization (WHO). Swaziland World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		
Swaziland	Central Statistical Office (Swaziland), United Nations Children's Fund (UNICEF). Swaziland Multiple Indicator Cluster Survey 2010. New York, United States: United Nations Children's Fund (UNICEF).	2010		
Swaziland	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Swaziland	Swart SM, Lemmer R, Parhoo JN, Prescott CA. A survey of ear and hearing disorders amongst a representative sample of grade 1 schoolchildren in Swaziland. <i>Int J Pediatr Otorhinolaryngol</i> . 1995; 32(1): 23-34.	1992		
Swaziland	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1995-1997, 1999, 2004-2009		
Swaziland	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Swaziland	Klausen B, Fanõe JG. An epidemiologic survey of oral health in Swaziland. <i>Community Dent Oral Epidemiol</i> . 1983; 11(1): 63-8.	1981		†
Swaziland	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 2001, 2004, 2007, 2010, 2012	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Swaziland	Ford H, Wright J. Bacterial meningitis in Swaziland: an 18 month prospective study of its impact. <i>J Epidemiol Community Health</i> . 1994; 48(3): 276-80.	1991-1992	*	†
Swaziland	Trangle KL, Goluska MJ, O'Leary MJ, Douglas SD. Distribution of blood groups and secretor status in schistosomiasis. <i>Parasite Immunol</i> . 1979; 1(2): 133-40.	1976-1978	*	†
Swaziland	Swaziland Malaria Indicator Survey 2010 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2010		
Swaziland	The Potential Impact of the Maguga Dam, Hhohho District, Swaziland on Malaria Transmission in the Catchment Area and Implications for the Agricultural Irrigation Area as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997		
Sweden	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2005, 2010		
Sweden	Sweden Vital Registration - Deaths 1995 ICD9 as it appears in World Health Organization (WHO). World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1995		
Sweden	World Health Organization (WHO). Sweden World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		
Sweden	Wändell P. A survey of subjects with present or previous atrial fibrillation in a Swedish community. <i>Scand J Prim Health Care</i> . 2001; 19(1): 20-4.	1998		
Sweden	Molander U, Dey DK, Sundh V, Steen B. ECG abnormalities in the elderly: prevalence, time and generation trends and association with mortality. <i>Aging Clin Exp Res</i> . 2003; 15(6): 488-93.	1980-2001		
Sweden	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. <i>Scand J Clin Lab Invest</i> . 2007; 67(1): 39-69.	1988, 2006		
Sweden	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1988, 2003, 2006		
Sweden	Andersson S-O, Rashidkhani B, Karlberg L, Wolk A, Johansson J-E. Prevalence of lower urinary tract symptoms in men aged 45-79 years: a population-based study of 40 000 Swedish men. <i>BJU Int</i> . 2004; 94(3): 327-31.	1997		
Sweden	Johansson N, Kalin M, Tiveljung-Lindell A, Giske CG, Hedlund J. Etiology of Community-Acquired pneumonia: Increased microbiological yield with new diagnostic methods. <i>Clin Infect Dis</i> . 2010; 50(2): 202-9.	2004-2005		
Sweden	National Public Health Institute (Finland), World Health Organization (WHO). WHO MONICA Cerebrovascular Event Data 1982-1997, as provided by the Global Burden of Disease 2010 Cerebrovascular Disease Expert Group. [Unpublished].	1984-1994		
Sweden	Lundgren K, Ingvarsson L. Epidemiology of acute otitis media in children. <i>Scand J Infect Dis Suppl</i> . 1983; 39: 19-25.	1980		
Sweden	Appelros P, Nydevik I, Seiger & Aring, ke, Teréacute;nt A. High Incidence Rates of Stroke in Orebro, Sweden: Further Support for Regional Incidence Differences within Scandinavia. <i>Cerebrovasc Dis</i> . 2002; 14(3-4): 161-8.	1999-2000		
Sweden	Hallström B, Jönsson A-C, Nerbrand C, Norrving B, Lindgren A. Stroke Incidence and Survival in the Beginning of the 21st Century in Southern Sweden: Comparisons With the Late 20th Century and Projections Into the Future. <i>Stroke</i> . 2008; 39(1): 10-5.	2001-2002		
Sweden	Terént A. Trends in Stroke Incidence and 10-Year Survival in Söderhamn, Sweden, 1975-2001. <i>Stroke</i> . 2003; 34(6): 1353-8.	1987-1990		
Sweden	Meding B, Järholm B. Hand eczema in Swedish adults - changes in prevalence between 1983 and 1996. <i>J Invest Dermatol</i> . 2002; 118(4): 719-23.	1996		
Sweden	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol</i> . 2008; 121(4): 947-954.	1994, 2002		
Sweden	Bergman S, Herrström P, Högstrom K, Petersson IF, Svensson B, Jacobsson LT. Chronic musculoskeletal pain, prevalence rates, and sociodemographic associations in a Swedish population study. <i>J Rheumatol</i> . 2001; 28(6): 1369-77.	1995		
Sweden	Ektor-Andersen J, Isacson SO, Lindgren A, Orbaek P. The experience of pain from the shoulder-neck area related to the total body pain, self-experienced health and mental distress. The Malmö Shoulder-Neck Study group. <i>Pain</i> . 1999; 82(3): 289-95.	1996		
Sweden	Fredriksson K, Alfredsson L, Köster M, Thorbjörnsson CB, Toomingas A, Torgén M, Kilbom A. Risk factors for neck and upper limb disorders: results from 24 years of follow up. <i>Occup Environ Med</i> . 1999; 56(1): 59-66.	1993		
Sweden	Linton SJ, Hellsing AL, Halldén K. A population-based study of spinal pain among 35-45-year-old individuals. Prevalence, sick leave, and health care use. <i>Spine</i> . 1998; 23(13): 1457-63.	1995		
Sweden	Palm P, Hansson Risberg E, Mortimer M, Palmerud G, Toomingas A, Wigaecus Tornqvist E. Computer use, neck and upper-extremity symptoms, eyestrain and headache among female and male upper secondary school students. <i>SJWEH Suppl</i> . 2007; 3(3): 33-41.	2005		
Sweden	Westering D, Jonsson BG. Pain from the neck-shoulder region and sick leave. <i>Scand J Soc Med</i> . 1980; 8(3): 131-6.	1969-1971		
Sweden	Glader EL, Stegmayr B. Declining prevalence of angina pectoris in middle-aged men and women A population-based study within the Northern Sweden MONICA Project Multinational Monitoring of Trends and Cardiovascular Disease. <i>J Intern Med</i> . 1999; 246(3): 285-91.	1980-1994		
Sweden	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000-2009		
Sweden	Bergström G, Bjelle A, Sorensen LB, Sundh V, Svanborg A. Prevalence of rheumatoid arthritis, osteoarthritis, chondrocalcinosis and gouty arthritis at age 79. <i>J Rheumatol</i> . 1986; 13(3): 527-34.	1981		
Sweden	Svenningsson A, Runmarker B, Lycke J, Andersen O. Incidence of MS during two fifteen-year periods in the Gothenburg region of Sweden. <i>Acta Neurol Scand</i> . 1990; 82(3): 161-8.	1982-1988		
Sweden	Koch-Henriksen N. Multiple sclerosis in Scandinavia and Finland. <i>Acta Neurol Scand</i> . 1995; 91(S161): 55-9.	1950-1985		
Sweden	Sundström P, Nyström L, Forsgren L. Prevalence of multiple sclerosis in Västerbotten County in northern Sweden. <i>Acta Neurol Scand</i> . 2001; 103(4): 214-8.	1997		
Sweden	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J</i> . 1998; 12(2): 315-35.	1993-1995		
Sweden	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	2002		
Sweden	Rönmark E, Jönsson E, Lundbäck B. Remission of asthma in the middle aged and elderly: report from the Obstructive Lung Disease in Northern Sweden study. <i>Thorax</i> . 1999; 54(7): 611-3.	1986-1996		
Sweden	Norman E, Nyström L, Jönssö E, Stjernberg N. Prevalence and incidence of asthma and rhinoconjunctivitis in Swedish teenagers. <i>Allergy</i> . 1998; 53: 28-35.	1991		
Sweden	Rönmark E, Lindberg A, Watson L, Lundbäck B. Outcome and severity of adult onset asthma-Report from the obstructive lung disease in northern Sweden studies (OLIN). <i>Respir Med</i> . 2007; 101(11): 2370-2377.	1995-2003		
Sweden	Bjerg-Bäcklund A, Bäcklund AB, Perzanowski MS, Platts-Mills T, Sandström T, Lundbäck B, Rönmark E. Asthma during the primary school ages - prevalence, remission and the impact of allergic sensitization. <i>Allergy</i> . 2006; 61(5): 549.	1996, 2000		
Sweden	Rönmark E, Jönsson E, Platts-Mills T, Lundbäck B. Incidence and remission of asthma in schoolchildren: report from the obstructive lung disease in northern Sweden studies. <i>Pediatrics</i> . 2001; 107(5): e37-e37.	1996-1997		
Sweden	Holm M, Omenaas E, Gislason T, Svanes C, Jögi R, Norman E, Janson C, Torén K. Remission of asthma: a prospective longitudinal study from northern Europe (RHINE study). <i>Eur Respir J</i> . 2007; 30(1): 62-65.	1989-2001		
Sweden	Lundman B, Engström L. Diabetes and its complications in a Swedish county. <i>Diabetes Res Clin Pract</i> . 1998; 39(2): 157-64.	1991-1992		
Sweden	Sandberg GE, Wikblad KF. Oral dryness and peripheral neuropathy in subjects with type 2 diabetes. <i>J Diabet Complications</i> . 2003; 17(4): 192-8.	2000-2002		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Sweden	Kärvestedt L, Mårtensson E, Grill V, Elofsson S, von Wendt G, Hamsten A, Brismar K. Peripheral sensory neuropathy associates with micro- or macroangiopathy: results from a population-based study of type 2 diabetic patients in Sweden. <i>Diabetes Care</i> . 2009; 32(2): 317-22.	2005		
Sweden	Statistics Sweden, Swedish National Institute of Public Health. Sweden National Survey of Public Health 2009.	2009		
Sweden	Statistics Sweden, Swedish National Institute of Public Health. Sweden National Survey of Public Health 2007.	2007		
Sweden	Borssén B, Bergenheim T, Lithner F. The epidemiology of foot lesions in diabetic patients aged 15-50 years. <i>Diabet Med</i> . 1990; 7(5): 438-44.	1989		
Sweden	Kernell A, Dedorsson I, Johansson B, Wickström CP, Ludvigsson J, Tuvemo T, Neiderud J, Sjöström K, Malmgren K, Kanulf P, Mellvig L, Götterberg M, Sule J, Persson LA, Larsson LI, Aman J, Dahlquist G. Prevalence of diabetic retinopathy in children and adolescents with IDDM. A population-based multicentre study. <i>Diabetologia</i> . 1997; 40(3): 307-10.	1996		
Sweden	Henricsson M, Nilsson A, Groop L, Heijl A, Janzon L. Prevalence of diabetic retinopathy in relation to age at onset of the diabetes, treatment, duration and glycaemic control. <i>Acta Ophthalmol Scand</i> . 1996; 74(6): 523-7.	1991-1993		
Sweden	Cederholm J, Lidell C, Nordgren L, Wibell L. Prevalences of risk factors and angiopathy in diabetic patients in Uppsala. <i>Ups J Med Sci</i> . 1992; 97(1): 69-77.	1991		
Sweden	Eliasson M, Lindahl B, Lundberg V, Stegmayr B. No increase in the prevalence of known diabetes between 1986 and 1999 in subjects 25-64 years of age in northern Sweden. <i>Diabet Med</i> . 2002; 19(10): 874-80.	1986, 1990	*	
Sweden	Wein L, Adlerberth A, Caidahl K, Eriksson H, Hansson PO, Johansson S, Rosengren A, Svärdsudd K, Wein C, Wilhelmson L. Prevalence of cardiovascular risk factors and the metabolic syndrome in middle-aged men and women in Gothenburg, Sweden. <i>BMC Public Health</i> . 2008; 8: 403.	2004		
Sweden	Association of Nordic Cancer Registries (ANCR). Sweden NORDCAN Cancer Incidence Data Tables, Age-Specific by Countries. Copenhagen, Denmark: Association of Nordic Cancer Registries (ANCR).	2003-2004, 2006-2007		
Sweden	Dahlöf C, Linde M. One-year prevalence of migraine in Sweden: a population-based study in adults. <i>Cephalalgia</i> . 2001; 21(6): 664-71.	1997		
Sweden	Laurell K, Larsson B, Eeg-Olofsson O. Prevalence of headache in Swedish schoolchildren, with a focus on tension-type headache. <i>Cephalalgia</i> . 2004; 24(5): 380-8.	1997		
Sweden	Danielsson L, Lindberg H, Nilsson BO. Prevalence of coxarthrosis. <i>Clin Orthop Relat Res</i> . 1984; 110-5.	1975-1982	*	
Sweden	Forsberg K, Nilsson BE. Coxarthrosis on the island of Gotland. Increased prevalence in a rural population. <i>Acta Orthop Scand</i> . 1992; 63(1): 1-3.	1979-1987	*	
Sweden	Bjerg A, Ekerljung L, Middelved R, Dahlén S-E, Forsberg B, Franklin K, Larsson K, Lötval J, Olafsdóttir IS, Torén K, Lundbäck B, Janson C. Increased prevalence of symptoms of rhinitis but not of asthma between 1990 and 2008 in Swedish adults: comparisons of the ECRHS and GA2LEN surveys. <i>PLoS One</i> . 2011; 6(2): e16082.	1990, 2008	*	
Sweden	Bjerg A, Sandström T, Lundbäck B, Rönmark E. Time trends in asthma and wheeze in Swedish children 1996-2006: prevalence and risk factors by sex. <i>Allergy</i> . 2010; 65(1): 48-55.	1996, 2006	*	
Sweden	Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, Gjomarkaj M, Forsberg B, Gunnbjörnsdóttir M, Minov J, Brozek G, Dahlen SE, Toskala E, Kowalski ML, Olze H, Howarth P, Krämer U, Baelum J, Loureiro C, Kasper L, Bousquet PJ, Bousquet J, Bachert C, Fokkens W, Burney P. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. <i>Allergy</i> . 2012; 67(1): 91-8.	2008-2009	*	
Sweden	Wennergren G, Ekerljung L, Alm B, Eriksson J, Lötval J, Lundbäck B. Asthma in late adolescence – farm childhood is protective and the prevalence increase has levelled off. <i>Pediatr Allergy Immunol</i> . 2010; 21(5): 806-13.	2008	*	
Sweden	Ekerljung L, Bossios A, Lötval J, Olin A-C, Rönmark E, Wennergren G, Torén K, Lundbäck B. Multi-symptom asthma as an indication of disease severity in epidemiology. <i>Eur Respir J</i> . 2011; 38(4): 825-32.	2008	*	
Sweden	Eriksson JK, Neovius M, Ernestam S, Lindblad S, Simard JF, Askling J. Incidence of rheumatoid arthritis in Sweden: a nationwide population-based assessment of incidence, its determinants, and treatment penetration. <i>Arthritis Care Res (Hoboken)</i> . 2013; 65(6): 870-8.	2006-2008	*	
Sweden	Neovius M, Simard JF, Askling J, ARTIS study group. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. <i>Ann Rheum Dis</i> . 2011; 70(4): 624-9.	2008	*	
Sweden	Andersson P, Löndahl M, Abdou N-J, Terent A. The prevalence of atrial fibrillation in a geographically well-defined population in northern Sweden: implications for anticoagulation prophylaxis. <i>J Intern Med</i> . 2012; 272(2): 170-6.	2008-2010	*	
Sweden	Smith JG, Newton-Cheh C, Almgren P, Struck J, Morgenthaler NG, Bergmann A, Platonov PG, Hedblad B, Engström G, Wang TJ, Melander O. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. <i>J Am Coll Cardiol</i> . 2010; 56(21): 1712-9.	1991-2007	*	
Sweden	Ballardini N, Kull I, Söderhäll C, Lilja G, Wickman M, Wahlgren CF. Eczema severity in preadolescent children and its relation to sex, filaggrin mutations, asthma, rhinitis, aggravating factors and topical treatment: a report from the BAMSE birth cohort. <i>Br J Dermatol</i> . 2013; 168(3): 588-94.	2008		
Sweden	Edman K, Öhrn K, Holmlund A, Nordström B, Hedin M, Hellberg D. Comparison of oral status in an adult population 35-75 year of age in the county of Dalarna, Sweden in 1983 and 2008. <i>Swed Dent J</i> . 2012; 36(2): 61-70.	1982-1983, 2007-2008	*	
Sweden	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. <i>Community Dent Oral Epidemiol</i> . 1991; 19(2): 72-3.	1987	*	
Sweden	Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). <i>Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version)</i> . Lyon, IARC. http://cis.iarc.fr	2003-2007		
Sweden	Grimby-Ekman A, Hagberg M. Simple neck pain questions used in surveys, evaluated in relation to health outcomes: a cohort study. <i>BMC Res Notes</i> . 2012; 5: 587.	2002	*	
Sweden	Andersson HI, Eijertsson G, Leden I, Rosenberg C. Chronic pain in a geographically defined general population: studies of differences in age, gender, social class, and pain localization. <i>Clin J Pain</i> . 1993; 9(3): 174-82.	1988	*	
Sweden	Uhnöo I, Wadell G, Svensson L, Olding-Stenkvist E, Ekwall E, Mölby R. Aetiology and epidemiology of acute gastro-enteritis in Swedish children. <i>J Infect</i> . 1986; 13(1): 73-89.	1981	*	
Sweden	Giaquinto C, van Damme P, REVEAL Study Group. Age distribution of paediatric rotavirus gastroenteritis cases in Europe: the REVEAL study. <i>Scand J Infect Dis</i> . 2010; 42(2): 142-7.	2004-2005		
Sweden	Svantesson B, Thorén A, Castor B, Barkenius G, Bergdahl U, Tufvesson B, Hansson HB, Mölby R, Jublin I. Acute diarrhoea in adults: aetiology, clinical appearance and therapeutic aspects. <i>Scand J Infect Dis</i> . 1988; 20(3): 303-14.	1981-1982		
Sweden	Andersson M, Guo X, Börjesson-Hanson A, Liebetrau M, Östling S, Skoog I. A population-based study on dementia and stroke in 97 year olds. <i>Age Ageing</i> . 2012; 41(4): 529-33.	1998-2007		
Sweden	Börjesson-Hanson A, Waern M, Ostling S, Gustafson D, Skoog I. One-month prevalence of mental disorders in a population sample of 95-year olds. <i>Am J Geriatr Psychiatry</i> . 2011; 19(3): 284-91.	1996-1998		
Sweden	Mathillas J, Lövhelm H, Gustafson Y. Increasing prevalence of dementia among very old people. <i>Age Ageing</i> . 2011; 40(2): 243-9.	2000-2002, 2005-2007		
Sweden	Sacuiu S, Gustafson D, Sjögren M, Guo X, Ostling S, Johansson B, Skoog I. Secular changes in cognitive predictors of dementia and mortality in 70-year-olds. <i>Neurology</i> . 2010; 75(9): 779-85.	2000-2001		
Sweden	Skoog I, Nilsson L, Palmertz B, Andreasson LA, Svanborg A. A population-based study of dementia in 85-year-olds. <i>N Engl J Med</i> . 1993; 328(3): 153-8.	1986-1988		
Sweden	Von Strauss E, Viitanen M, De Ronchi D, Winblad B, Fratiglioni L. Aging and the occurrence of dementia: findings from a population-based cohort with a large sample of nonagenarians. <i>Arch Neurol</i> . 1999; 56(5): 587-92.	1992		
Sweden	Fratiglioni L, Grut M, Forsell Y, Viitanen M, Grafström M, Holmén K, Ericsson K, Bäckman L, Ahlborn A, Winblad B. Prevalence of Alzheimer's disease and other dementias in an elderly urban population: relationship with age, sex, and education. <i>Neurology</i> . 1991; 41(12): 1886-92.	1987		
Sweden	Pettersson IF, Boegård T, Saxne T, Silman AJ, Svensson B. Radiographic osteoarthritis of the knee classified by the Ahlbäck and Kellgren and Lawrence systems for the tibiofemoral joint in people aged 35-54 years with chronic knee pain. <i>Ann Rheum Dis</i> . 1997; 56(8): 493-6.	1994		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Sweden	Bagge E, Bjelle A, Valkenburg HA, Svanborg A. Prevalence of radiographic osteoarthritis in two elderly European populations. <i>Rheumatol Int.</i> 1992; 12(1): 33-8.	1980-1982		
Sweden	Allebeck P, Ahlbom A, Allander E. Increased mortality among persons with rheumatoid arthritis, but where RA does not appear on death certificate: eleven-year follow-up of an epidemiological study. <i>Scand J Rheumatol.</i> 1981; 10(4): 301-6.	1965-1978		
Sweden	Allebeck P. Increased mortality in rheumatoid arthritis: The use of a medical information system for assessment of death risks. <i>Scand J Rheumatol.</i> 1982; 11(2): 81-6.	1971-1978		
Sweden	Björnådal L, Baecklund E, Yin L, Granath F, Klareskog L, Ekblom A. Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95. <i>J Rheumatol.</i> 2002; 29(5): 906-12.	1964-1994		
Sweden	Lindqvist E, Eberhardt K. Mortality in rheumatoid arthritis patients with disease onset in the 1980s. <i>Ann Rheum Dis.</i> 1999; 58(1): 11-4.	1985-1997		
Sweden	Englund M, Jöud A, Geborek P, Felson DT, Jacobsson LT, Petersson IF. Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics. <i>Rheumatology.</i> 2010; 49(8): 1563-9.	2008		
Sweden	Bjelle A, Allander E. Regional distribution of rheumatic complaints in Sweden. <i>Scand J Rheumatol.</i> 1981; 10(1): 9-15.	1975		
Sweden	Margareta Simonsson, Stefan Bergman. The prevalence of rheumatoid arthritis in Sweden. <i>Scand J Rheumatol.</i> 1999; 28(6): 340-3.	1995		
Sweden	Jacobsson L, Lindgärde F, Manthorpe R. The commonest rheumatic complaints of over six weeks' duration in a twelve-month period in a defined Swedish population. Prevalences and relationships. <i>Scand J Rheumatol.</i> 1989; 18(6): 353-60.	1985		
Sweden	Söderlin MK, Björsson O, Kautiainen H, Skogh T, Leirisalo-Repo M. Annual incidence of inflammatory joint diseases in a population based study in southern Sweden. <i>Ann Rheum Dis.</i> 2002; 61(10): 911-5.	1999-2000		
Sweden	Johansson MSK, Arlinger SD. Prevalence of hearing impairment in a population in Sweden. <i>Int J Audiol.</i> 2003; 42(1): 18-28.	1986, 1990-1992, 1998		
Sweden	Bolin AK, Bolin A, Koch G. Children's dental health in Europe: caries experience of 5- and 12-year-old children from eight EU countries. <i>Int J Paediatr Dent.</i> 1996; 6(3): 155-62.	1994		
Sweden	Crossner CG, Unell L. A longitudinal study of dental health and treatment need in Swedish teenagers. <i>Community Dent Oral Epidemiol.</i> 1986; 14(1): 10-4.	1979-1984		
Sweden	Hugoson A, Koch G, Bergendal T, Laurell L, Lundgren D. Caries prevalence and distribution in individuals aged 20-80 years in Jönköping, Sweden, 1973 and 1983. <i>Swed Dent J.</i> 1988; 12(4): 133-40.	1973-1983		
Sweden	Fure S, Zickert I. Incidence of tooth loss and dental caries in 60-, 70- and 80-year-old Swedish individuals. <i>Community Dent Oral Epidemiol.</i> 1997; 25(2): 137-42.	1987-1992		
Sweden	Sundberg H. Changes in the prevalence of caries in children and adolescents in Sweden 1985-1994. <i>Eur J Oral Sci.</i> 1996; 104(4): 470-6.	1978-1994		
Sweden	Johanson CN, Osterberg T, Steen B, Birkhed D. Prevalence and incidence of dental caries and related risk factors in 70- to 76-year-olds. <i>Acta Odontol Scand.</i> 2009; 67(5): 304-12.	1978-1994, 2001-2007		
Sweden	Mejäre I, Stenlund H, Zelezny-Holmlund C. Caries incidence and lesion progression from adolescence to young adulthood: a prospective 15-year cohort study in Sweden. <i>Caries Res.</i> 2004; 38(2): 130-41.	1983-1998		
Sweden	Hugoson A, Koch G, Hallonsten AL, Norderyd J, Aberg A. Caries prevalence and distribution in 3-20-year-olds in Jönköping, Sweden, in 1973, 1978, 1983, and 1993. <i>Community Dent Oral Epidemiol.</i> 2000; 28(2): 83-9.	1973, 1978, 1983, 1993		
Sweden	Stecksén-Blicks C, Kieri C, Nyman J-E, Pilebro C, Borssén E. Caries prevalence and background factors in Swedish 4-year-old children - a 40-year perspective. <i>Int J Paediatr Dent.</i> 2008; 18(5): 317-24.	1967, 1971, 1976, 1980, 1987, 1992, 1997, 2002, 2007		
Sweden	Pettersson LG, Twetman S, Pakhomov GN. The efficiency of semiannual silane fluoride varnish applications: a two-year clinical study in preschool children. <i>J Public Health Dent.</i> 1998; 58(1): 57-60.	1991-1993		
Sweden	Holst A, Braune K, Kjellberg M. Changes in caries experience among 6-year-olds in Blekinge, Sweden between 1994 and 2000. <i>Swed Dent J.</i> 2004; 28(3): 129-35.	1994, 2000		
Sweden	Holst A, Braune K, Kjellberg-Larsson M. Occurrence and distribution of caries in 6-year-old children in Blekinge, Sweden. <i>Swed Dent J.</i> 1999; 23(2-3): 71-6.	1994		
Sweden	Osby U, Brandt L, Correia N, Ekblom A, Sparén P. Excess mortality in bipolar and unipolar disorder in Sweden. <i>Arch Gen Psychiatry.</i> 2001; 58(9): 844-50.	1973-1995		
Sweden	Cullberg J, Engström-Lindberg M. Prevalence and incidence of eating disorders in a suburban area. <i>Acta Psychiatr Scand.</i> 1988; 78(3): 314-9.	1984-1985		
Sweden	Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, Wahlberg E. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. <i>J Vasc Surg.</i> 2007; 45(6): 1185-91.	2004		
Sweden	Andersson B, Caidahl K, Waagstein F. Idiopathic dilated cardiomyopathy among Swedish patients with congestive heart failure. <i>Eur Heart J.</i> 1995; 16(1): 53-60.	1980-1987		
Sweden	Hogevik H, Olaison L, Andersson R, Lindberg J, Alestig K. Epidemiologic aspects of infective endocarditis in an urban population. A 5-year prospective study. <i>Medicine (Baltimore).</i> 1995; 74(6): 324-39.	1984-1988		
Sweden	de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Künzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P, European Community Respiratory Health Survey Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. <i>Thorax.</i> 2004; 59(2): 120-125.	1991-1993		
Sweden	Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E, BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. <i>Lancet.</i> 2007; 9589(9589): 741-50.	2005-2006		
Sweden	Ekberg-Aronsson M, Löfdahl K, Nilsson JA, Löfdahl CG, Nilsson PM. Hospital admission rates among men and women with symptoms of chronic bronchitis and airflow limitation corresponding to the GOLD stages of chronic obstructive pulmonary disease: A population-based study. <i>Respir Med.</i> 2008; 102(1): 109-20.	1974-1992		
Sweden	Lindberg A, Bjerg A, Rönmark E, Larsson LG, Lundbäck B. Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking Report from the Obstructive Lung Disease in Northern Sweden Studies. <i>Respir Med.</i> 2006; 100(2): 264-72.	1996		
Sweden	Lindberg A, Jonsson AC, Rönmark E, Lundgren R, Larsson LG, Lundbäck B. Prevalence of chronic obstructive pulmonary disease according to BTS, ERS, GOLD and ATS criteria in relation to doctor's diagnosis, symptoms, age, gender, and smoking habits. <i>Respir Med.</i> 2006; 129(4): 264-72.	1994		
Sweden	Kadesjö B, Gillberg C, Hagberg B. Brief report: autism and Asperger syndrome in seven-year-old children: a total population study. <i>J Autism Dev Disord.</i> 1999; 29(4): 327-31.	1992		
Sweden	Gillberg C, Cederlund M, Lamberg K, Zeijlon L. Brief Report: "The Autism Epidemic". The Registered Prevalence of Autism in a Swedish Urban Area. <i>J Autism Dev Disord.</i> 2006; 36(3): 429-35.	1977-2001		
Sweden	Ehlers S GC. The epidemiology of Asperger syndrome. A total population study. <i>J Child Psychol Psychiatry.</i> 1993; 34(8): 1327-50.	1991		
Sweden	Cederlund M, Hagberg B, Billstedt E, Gillberg IC, Gillberg C. Asperger Syndrome and Autism: A Comparative Longitudinal Follow-Up Study More than 5 Years after Original Diagnosis. <i>J Autism Dev Disord.</i> 2008; 38(1): 72-85.	1985-1999		
Sweden	Borgfeldt C, Andolf E. Transvaginal ultrasonographic findings in the uterus and the endometrium: Low prevalence of leiomyoma in a random sample of women age 25-40 years. <i>Acta Obstet Gynecol Scand.</i> 2000; 79(3): 202-7.	1996-1997		
Sweden	Samuelsson EC, Arne Victor FT, Tibblin G, Svärdsudd KF. Signs of genital prolapse in a Swedish population of women 20 to 59 years of age and possible related factors. <i>Am J Obstet Gynecol.</i> 1999; 180(2): 299-305.	1993		
Sweden	Kadesjö B, Gillberg C. The Comorbidity of ADHD in the General Population of Swedish School-age Children. <i>J Child Psychol Psychiatry.</i> 2001; 42(4): 487.	1992		
Sweden	Rasmussen P, Gillberg C. Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study. <i>J Am Acad Child Adolesc Psychiatry.</i> 2000; 39(11): 1424-31.	1977-1992		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Sweden	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2004-2005		
Sweden	Hallman J. The premenstrual syndrome – an equivalent of depression Acta Psychiatr Scand. 1986; 73(4): 403-11.	1985		
Sweden	Andersch B, Wendestam C, Hahn L, Öhman R. Premenstrual complaints. I. Prevalence of premenstrual symptoms in a Swedish urban population. J Psychosom Obstet Gynaecol. 1986; 5(1): 39-49.	1983		
Sweden	United States Renal Data System Coordinating Center. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2000-2003		
Sweden	Novak DP, Carlsson RB. Simplifying chlamydia testing: an innovative Chlamydia trachomatis testing approach using the internet and a home sampling strategy: population based study. Sex Transm Infect. 2006; 82(2): 142-53.	2008		
Sweden	De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000; 54(11 Suppl 5): S21-23.	1997		
Sweden	Fall P-A, Axelson O, Fredriksson M, Hansson G, Lindvall B, Olsson J-E, Granerus A-K. Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community. J Clin Epidemiol. 1996; 49(6): 637-41.	1986-1989		
Sweden	Wirdefeldt K, Gatz M, Schalling M, Pedersen NL. No evidence for heritability of Parkinson disease in Swedish twins. Neurology. 2004; 63(2): 305-11.	2001		
Sweden	Berger K BM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000; 54(11): 24-7.	1997		
Sweden	Lindström E, Widerlöv B, von Knorring L. The ICD-10 and DSM-IV diagnostic criteria and the prevalence of schizophrenia. Eur Psychiatry. 1997; 12(5): 217-23.	1991	*	
Sweden	Widerlöv B, Lindström E, von Knorring L. One-year prevalence of long-term functional psychosis in three different areas of Uppsala. Acta Psychiatr Scand. 1997; 96(6): 452-8.	1991		
Sweden	Jørgensen L, Ahlhom A, Allebeck P, Dalman C. The Stockholm non-affective psychoses study (snaps): the importance of including out-patient data in incidence studies. Acta Psychiatr Scand. 2010; 121(5): 389-92.	1997-2006		
Sweden	Svedberg B, Mesterton A, Cullberg J. First-episode non-affective psychosis in a total urban population: a 5-year follow-up. Soc Psychiatry Psychiatr Epidemiol. 2001; 36(7): 332-7.	1991-1992		
Sweden	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Sweden	Fügelstad A, Anell A, Rajs J, Agren G. Mortality and causes and manner of death among drug addicts in Stockholm during the period 1981-1992. Acta Psychiatr Scand. 1997; 96(3): 169-75.	1985-1992		
Sweden	Fridell M, Hesse M. Psychiatric severity and mortality in substance abusers: a 15-year follow-up of drug users. Addict Behav. 2006; 31(4): 559-65.	1985-2003		
Sweden	Guez M, Hildingsson C, Nasic S, Toolanen G. Chronic low back pain in individuals with chronic neck pain of traumatic and non-traumatic origin: a population-based study. Acta Orthop. 2006; 77(1): 132-7.	1999		
Sweden	Bingefors K, Isacson D. Epidemiology, co-morbidity, and impact on health-related quality of life of self-reported headache and musculoskeletal pain – a gender perspective. Eur J Pain. 2004; 8(5): 435-50.	1995		
Sweden	Reigo T, Timppa T, Tropp H. The epidemiology of back pain in vocational age groups. Scand J Prim Health Care. 1999; 17(1): 17-21.	1987-1989		
Sweden	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 1995, 1998-2000, 2004	1995, 1998-2000, 2004		
Sweden	Hagberg G, Lewerth A, Olsson E, Westerberg B. Mild mental retardation in Gothenburg children born between 1966-70. Changes between two points of time. Ups J Med Sci Suppl. 1987; 52-7.	1968		
Sweden	Gustavson K-H, Umb-Carlsson O, Sonnander K. A follow-up study of mortality, health conditions and associated disabilities of people with intellectual disabilities in a Swedish county. J Intellect Disabil Res. 2005; 49(Pt 12): 905-14.	1959-2005		
Sweden	Agüero-Torres H, Fratiglioni L, Guo Z, Viitanen M, Winblad B. Mortality from dementia in advanced age: a 5-year follow-up study of incident dementia cases. J Clin Epidemiol. 1999; 52(8): 737-43.	1987-1992		
Sweden	Börjesson-Hanson A, Gustafson D, Skoog I. Five-year mortality in relation to dementia and cognitive function in 95-year-olds. Neurology. 2007; 69(22): 2069-75.	1995-2000		
Sweden	Schiano V, Laurenzano E, Brevetti G, De Maio JJ, Lanero S, Scopacasa F, Chiariello M. Omega-3 polyunsaturated fatty acid in peripheral arterial disease: effect on lipid pattern, disease severity, inflammation profile, and endothelial function. Clin Nutr. 2008; 27(2): 241-7.	1988-2005	*	
Sweden	Skoog I, Andreasson LA, Landahl S, Lernfelt B. A population-based study on blood pressure and brain atrophy in 85-year-olds. Hypertension. 1998; 32(3): 404-9.	1986-1989		
Sweden	Crump C, Sundquist K, Winkleby MA, Sundquist J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry. 2013; 70(9): 931-9.	2003-2009		
Sweden	WHO Regional Office for Europe (EURO-WHO). Young People's Health in Context. Health Behaviour in School-aged Children (HBSC) Study: International Report from the 2001-2002 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2004.	2001		
Sweden	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2005		
Sweden	Statistics Sweden, Swedish National Institute of Public Health. Sweden National Survey of Public Health 2006.	2006		
Sweden	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). Alcohol and Drug Use Among European 17-18 Year Old Students: Data from the ESPAD Project. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2007.	2003		
Sweden	Rautainen S, Levitan EB, Mittleman MA, Wolk A. Total Antioxidant Capacity of Diet and Risk of Heart Failure: A Population-based Prospective Cohort of Women. Am J Med. 2013; 126(6): 494-500.	1997-2009	*	
Sweden	Shafazand M, Schaufelberger M, Lappas G, Swedberg K, Rosengren A. Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry. Eur Heart J. 2009; 30(6): 671-8.	1987-2004	*	
Sweden	Wahlberg A, Rööst M, Haglund B, Högberg U, Essén B. Increased risk of severe maternal morbidity (near-miss) among immigrant women in Sweden: a population register-based study. BJOG. 2013.	1998-2007	*	
Sweden	Karlström A, Lindgren H, Hildingsson I. Maternal and infant outcome after caesarean section without recorded medical indication: findings from a Swedish case-control study. BJOG. 2013; 120(4): 479-86.	1997-2006	*	
Sweden	Hagman A, Källén K, Barrenäs M-L, Landin-Wilhelmsen K, Hanson C, Bryman I, Wennerholm U-B. Obstetric outcomes in women with Turner karyotype. J Clin Endocrinol Metab. 2011; 96(11): 3475-82.	1973-2007	*	
Sweden	Heshmati A, Mishra G, Koupil I. Childhood and adulthood socio-economic position and hypertensive disorders in pregnancy: the Uppsala Birth Cohort Multigenerational Study. J Epidemiol Community Health. 2013; 67(11): 939-46.	1982-2008	*	
Sweden	Källén B, Nilsson E, Otterblad Olausson P. Delivery outcome after maternal use of drugs for migraine: a register study in Sweden. Drug Saf. 2011; 34(8): 691-703.	1995-2008	*	
Sweden	Sandström A, Chantingius S, Wikström AK, Stephansson O. Labour dystocia—risk of recurrence and instrumental delivery in following labour—a population-based cohort study. BJOG. 2012; 119(13): 1648-56.	1992-2006	*	
Sweden	Lee BK, Zhang Z, Wikman A, Lindqvist PG, Reilly M. ABO and RhD blood groups and gestational hypertensive disorders: a population-based cohort study. BJOG. 2012; 119(10): 1232-7.	1987-2002	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Sweden	Persson M, Pasupathy D, Hanson U, Westgren M, Norman M. Pre-pregnancy body mass index and the risk of adverse outcome in type 1 diabetic pregnancies: a population-based cohort study. <i>BMJ Open</i> . 2012; 2(1): e000601.	1998-2007	*	
Sweden	Roberts CL, Ford JB, Algert CS, Antonsen S, Chalmers J, Cnattingius S, Grahale M, Kotelchuck M, Melve KK, Langridge A, Morris C, Morris JM, Nassar N, Norman JE, Norrie J, Sørensen HT, Walker R, Weir CJ. Population-based trends in pregnancy hypertension and pre-eclampsia: an international comparative study. <i>BMJ Open</i> . 2011; 1(1): e000101.	1997-2006	*	
Sweden	Rylander A, Lindqvist PG. Eclampsia is more prevalent during the winter season in Sweden. <i>Acta Obstet Gynecol Scand</i> . 2011; 90(1): 114-7.	1990-1994	*	
Sweden	Sohlberg S, Stephansson O, Cnattingius S, Wikström A-K. Maternal body mass index, height, and risks of preeclampsia. <i>Am J Hypertens</i> . 2012; 25(1): 120-5.	1992-2006	*	
Sweden	Wikström A-K, Stephansson O, Cnattingius S. Previous preeclampsia and risks of adverse outcomes in subsequent nonpreeclamptic pregnancies. <i>Am J Obstet Gynecol</i> . 2011; 204(2): 148e1-6.	1992-2006	*	
Sweden	Rönblom A, Samuelsson S-M, Ekblom A. Ulcerative colitis in the county of Uppsala 1945-2007: incidence and clinical characteristics. <i>J Crohns Colitis</i> . 2010; 4(5): 532-6.	1950-1984, 2005-2007	*	
Sweden	Silfvenius H, Olivecrona M. Epilepsy in Sweden as revealed by mortality, disability pensions, and drug consumption, 1971-1984. <i>Acta Neurol Scand Suppl</i> . 1988; 15-23.	1971-1984	*	
Sweden	Brorson LO, Wranne L. Long-term prognosis in childhood epilepsy: survival and seizure prognosis. <i>Epilepsia</i> . 1987; 28(4): 324-30.	1964-1977	*	†
Sweden	Forsgren L, Bucht G, Eriksson S, Bergmark L. Incidence and clinical characterization of unprovoked seizures in adults: a prospective population-based study. <i>Epilepsia</i> . 1996; 37(3): 224-9.	1985	*	
Sweden	Sidenvall R, Forsgren L, Blomquist HK, Heijbel J. A community-based prospective incidence study of epileptic seizures in children. <i>Acta Paediatr</i> . 1993; 82(1): 60-5.	1985	*	
Sweden	Adelöw C, Andell E, Amark P, Andersson T, Hellebro E, Ahlborn A, Tomson T. Newly diagnosed single unprovoked seizures and epilepsy in Stockholm, Sweden: First report from the Stockholm Incidence Registry of Epilepsy (SIRE). <i>Epilepsia</i> . 2009; 50(5): 1094-101.	2001-2004	*	†
Sweden	Larsson K, Eeg-Olofsson O. A population based study of epilepsy in children from a Swedish county. <i>Eur J Paediatr Neurol</i> . 2006; 10(3): 107-13.	2000	*	
Sweden	Forsgren L. Prevalence of epilepsy in adults in northern Sweden. <i>Epilepsia</i> . 1992; 33(3): 450-8.	1985	*	
Sweden	Sidenvall R, Forsgren L, Heijbel J. Prevalence and characteristics of epilepsy in children in northern Sweden. <i>Seizure</i> . 1996; 5(2): 139-46.	1985	*	
Sweden	Bergdahl E, Gustavsson JMC, Kallin K, von Heideken Wägert P, Lundman B, Bucht G, Gustafson Y. Depression among the oldest old: the Umeå 85+ study. <i>Int Psychogeriatr</i> . 2005; 17(4): 557-75.	2002-2005	*	
Sweden	Marengoni A, Rizzuto D, Wang H-X, Winblad B, Fratiglioni L. Patterns of chronic multimorbidity in the elderly population. <i>J Am Geriatr Soc</i> . 2009; 57(2): 225-30.	1987-1989	*	
Sweden	Gillberg C, Billstedt E, Sundh V, Gillberg IC. Mortality in autism: a prospective longitudinal community-based study. <i>J Autism Dev Disord</i> . 2010; 40(3): 352-7.	2008	*	
Sweden	Nygren G, Cederlund M, Sandberg E, Gillstedt F, Arvidsson T, Carina Gillberg I, Westman Andersson G, Gillberg C. The prevalence of autism spectrum disorders in toddlers: a population study of 2-year-old Swedish children. <i>J Autism Dev Disord</i> . 2012; 42(7): 1491-7.	2010	*	
Sweden	Arvidsson T, Danielsson B, Forsberg P, Gillberg C, Johansson M, Kjellgren G. Autism in 3-6-Year-Old Children in a Suburb of Göteborg, Sweden. <i>Autism</i> . 1997; 1(2): 163-73.	1994	*	
Sweden	Billstedt E, Gillberg IC, Gillberg C, Gillberg C. Autism after adolescence: population-based 13- to 22-year follow-up study of 120 individuals with autism diagnosed in childhood. <i>J Autism Dev Disord</i> . 2005; 35(3): 351-60.	1980-2001	*	
Sweden	Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. <i>Am J Psychiatry</i> . 2013; 170(3): 324-33.	2003-2009	*	
Sweden	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012	*	†
Sweden	Halldestam I, Kullman E, Borch K. Incidence of and potential risk factors for gallstone disease in a general population sample. <i>Br J Surg</i> . 2009; 96(11): 1315-22.	2006-2008	*	
Sweden	Kamwendo F, Forslin L, Bodin L, Danielsson D. Decreasing incidences of gonorrhoea- and chlamydia-associated acute pelvic inflammatory disease. A 25-year study from an urban area of central Sweden. <i>Sex Transm Dis</i> . 1996; 23(5): 384-91.	1970-1994	*	
Sweden	Jonsson P, Linde M, Hensing G, Hedenrud T. Sociodemographic differences in medication use, health-care contacts and sickness absence among individuals with medication-overuse headache. <i>J Headache Pain</i> . 2012; 13(4): 281-90.	2009-2010	*	
Sweden	Faber MT, Nielsen A, Nygård M, Sparén P, Tryggvadottir L, Hansen BT, Liaw K-L, Kjaer SK. Genital chlamydia, genital herpes, Trichomonas vaginalis and gonorrhoea prevalence, and risk factors among nearly 70,000 randomly selected women in 4 Nordic countries. <i>Sex Transm Dis</i> . 2011; 38(8): 727-34.	2004-2005	*	
Sweden	Kvarnström G, Jakobsson P, Lennérstrand G. Visual screening of Swedish children: an ophthalmological evaluation. <i>Acta Ophthalmol Scand</i> . 2001; 79(3): 240-4.	1982-1993	*	
Sweden	Tunbäck P, Bergström T, Andersson A-S, Nordin P, Krantz I, Löwhagen G-B. Prevalence of herpes simplex virus antibodies in childhood and adolescence: a cross-sectional study. <i>Scand J Infect Dis</i> . 2003; 35(8): 498-502.	1996-1997	*	
Sweden	Christenson B, Böttiger M, Svensson A, Jeansson S. A 15-year surveillance study of antibodies to herpes simplex virus types 1 and 2 in a cohort of young girls. <i>J Infect</i> . 1992; 25(2): 147-54.	1972-1980	*	†
Sweden	Andersson-Ellström A, Svennerholm B, Forsman L. Prevalence of antibodies to herpes simplex virus types 1 and 2, Epstein-Barr virus and cytomegalovirus in teenage girls. <i>Scand J Infect Dis</i> . 1995; 27(4): 315-8.	1980-1987	*	†
Sweden	Hellström-Westas L, Forsblad K, Sjörs G, Saugstad OD, Björklund LJ, Marsál K, Källén K. Earlier Apgar score increase in severely depressed term infants cared for in Swedish level III units with 40% oxygen versus 100% oxygen resuscitation strategies: a population-based register study. <i>Pediatrics</i> . 2006; 118(6): 1798-1804.	1998-2003	*	†
Sweden	Azzopardi DV, Strohm B, Edwards AD, Dyet L, Halliday HL, Juszczak E, Kapellou O, Levene M, Marlow N, Porter E, Thoresen M, Whitelaw A, Brocklehurst P, TOBY Study Group. Moderate hypothermia to treat perinatal asphyxial encephalopathy. <i>N Engl J Med</i> . 2009; 361(14): 1349-58.	2002-2006	*	†
Sweden	Lindström K, Hallberg B, Blennow M, Wolff K, Fernell E, Westgren M. Moderate neonatal encephalopathy: pre- and perinatal risk factors and long-term outcome. <i>Acta Obstet Gynecol Scand</i> . 2008; 87(5): 503-9.	1985	*	
Sweden	Thornberg E, Thiringer K, Odeback A, Milsom I. Birth asphyxia: incidence, clinical course and outcome in a Swedish population. <i>Acta Paediatr</i> . 1995; 84(8): 927-32.	1985-1991	*	
Sweden	Kärvestedt L, Mårtensson E, Grill V, Elofsson S, von Wendt G, Hamsten A, Brismar K. The prevalence of peripheral neuropathy in a population-based study of patients with type 2 diabetes in Sweden. <i>J Diabetes Complicat</i> . 2011; 25(2): 97-106.	1997	*	
Sweden	Olafsdottir E, Andersson DRG, Dedorsson I, Stefánsson E. The prevalence of retinopathy in subjects with and without type 2 diabetes mellitus. <i>Acta Ophthalmol</i> . 2013.	1996-1998	*	
Sweden	Andersson DK, Svärdsudd K, Tibblin G. Prevalence and incidence of diabetes in a Swedish community 1972-1987. <i>Diabet Med</i> . 1991; 8(5): 428-34.	1972-1987	*	
Sweden	Holmqvist B-M, Lofman O, Samuelsson U. A low incidence of Type 1 diabetes between 1977 and 2001 in south-eastern Sweden in areas with high population density and which are more deprived. <i>Diabet Med</i> . 2008; 25(3): 255-60.	1977-2001	*	
Sweden	Jansson SPO, Andersson DRG, Svärdsudd K. Prevalence and incidence rate of diabetes mellitus in a Swedish community during 30 years of follow-up. <i>Diabetologia</i> . 2007; 50(4): 703-10.	1972-2001	*	
Sweden	Berger B, Stenström G, Sundkvist G. Incidence, prevalence, and mortality of diabetes in a large population. A report from the Skaraborg Diabetes Registry. <i>Diabetes Care</i> . 1999; 22(5): 773-8.	1991-1995	*	
Sweden	Landgren H, Bengtsson C, Blöhm G, Lapidus L, Sjöström L. Adiposity and adipose tissue distribution in relation to incidence of diabetes in women: results from a prospective population study in Gothenburg, Sweden. <i>Int J Obes (Lond)</i> . 1989; 13(4): 413-23.	1980-1981	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Sweden	Nordwall M, Bojestig M, Arqvist HJ, Ludvigsson J. Linköping Diabetes Complications Study. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of Type 1 diabetes-the Linköping Diabetes Complications Study. <i>Diabetologia</i> . 2004; 47(7): 1266-72.	1961-1997		
Sweden	Rosengren A, Dotevall A, Wilhelmsen L, Thelle D, Johansson S. Coffee and incidence of diabetes in Swedish women: a prospective 18-year follow-up study. <i>J Intern Med</i> . 2004; 255(1): 89-95.	1979-1999	*	
Sweden	Thunander M, Pettersson C, Jonzon K, Forander J, Ossiansson B, Torn C, Edvardsson S, Landin-Olsson M. Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. <i>Diabetes Res Clin Pract</i> . 2008; 82(2): 247-55.	1998-2001	*	
Sweden	Nilsson K, Hägglöf B. Long-term follow-up of adolescent onset anorexia nervosa in northern Sweden. <i>Eur Eat Disord Rev</i> . 2005; 13(2): 89-100.	1980-1999	*	
Sweden	Norring CE, Söhlberg SS. Outcome, recovery, relapse and mortality across six years in patients with clinical eating disorders. <i>Acta Psychiatr Scand</i> . 1993; 87(6): 437-44.	1984-1990	*	
Sweden	Papadopoulos FC, Ekblom A, Brandt L, Ekselius L. Excess mortality, causes of death and prognostic factors in anorexia nervosa. <i>Br J Psychiatry</i> . 2009; 194(1): 10-7.	1973-2003	*	
Sweden	Rosling AM, Sparén P, Norring C, von Knorring A-L. Mortality of eating disorders: a follow-up study of treatment in a specialist unit 1974-2000. <i>Int J Eat Disord</i> . 2011; 44(4): 304-10.	1984-2001	*	
Sweden	Wentz E, Gillberg JC, Anckarsäter H, Gillberg C, Råstam M. Adolescent-onset anorexia nervosa: 18-year outcome. <i>Br J Psychiatry</i> . 2009; 194(2): 168-74.	1985-2003	*	
Sweden	Rönmark EP, Ekerjung L, Lötvall J, Wennberg G, Rönmark E, Torén K, Lundbäck B. Eczema among adults: prevalence, risk factors and relation to airway diseases. Results from a large-scale population survey in Sweden. <i>Br J Dermatol</i> . 2012; 166(6): 1301-08.	2008	*	
Sweden	Stenbacka M, Leifman A, Romelsjö A. Mortality Among Opiate Abusers in Stockholm: A Longitudinal Study. <i>Heroin Addict Relate Clin Probl</i> . 2007; 9(3): 41-50.	1967-2003		
Sweden	Wahren CA, Brandt L, Allebeck P. Has mortality in drug addicts increased? A comparison between two hospitalized cohorts in Stockholm. <i>Int J Epidemiol</i> . 1997; 26(6): 1219-26.	1971-1991		
Sweden	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant</i> . 1988; 3(6): 714-27.	1985		
Sweden	Van Dijk PC, Jager KJ, Stengel B, Grünhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). <i>Kidney Int</i> . 2005; 67(4): 1489-99.	1991-1992, 1999-2000		
Sweden	Bell M; SWING, Granath F, Schön S, Ekblom A, Martling CR. Continuous renal replacement therapy is associated with less chronic renal failure than intermittent haemodialysis after acute renal failure. <i>Intensive Care Med</i> . 2007; 33(5): 773-80.	1995-2004		
Sweden	Esbjörner E, Aronson S, Berg U, Jodal U, Linne T. Children with chronic renal failure in Sweden 1978-1985. <i>Pediatr Nephrol</i> . 1990; 4(3): 249-52.	1985		
Sweden	European Surveillance of Congenital Anomalies (EUROCAT). Sweden EUROCAT Prevalence Tables. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	2007-2011		
Sweden	Johannesson A, Larsson G-U, Ramstrand N, Turkiewicz A, Wirehn A-B, Atroshi I. Incidence of lower-limb amputation in the diabetic and nondiabetic general population: a 10-year population-based cohort study of initial unilateral and contralateral amputations and reamputations. <i>Diabetes Care</i> . 2009; 32(2): 275-80.	1997-2006		
Sweden	Jonasson JM, Ye W, Sparén P, Apelqvist J, Nyrén O, Brismar K. Risks of nontraumatic lower-extremity amputations in patients with type 1 diabetes: a population-based cohort study in Sweden. <i>Diabetes Care</i> . 2008; 31(8): 1536-40.	1975-2004		
Sweden	Lindholm A, Andersson L, Eliasson M, Bixo M, Sundström-Poromaa I. Prevalence of symptoms associated with polycystic ovary syndrome. <i>Int J Gynaecol Obstet</i> . 2008; 102(1): 39-43.	2004		
Sweden	Mueller A, Gooren LJ, Naton-Schütz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. <i>J Clin Endocrinol Metab</i> . 2008; 93(4): 1408-11.	2005		
Sweden	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguiar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Gilst WH van, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J</i> . 2003; 24(5): 442-63.	2000-2001		
Sweden	Hvitfeldt T, Romelsjö A, Danström TK, Karolinska Institute. Alkohol och droger: vanor och problem i Stockholms län 1996 [Alcohol and Drug Use: Patterns and Problems in Stockholm County in 1996]. Stockholm, Sweden: Karolinska Institute, 1999.	1996		
Sweden	Andersson S, Allebeck P, Romelsjö A. Alcohol and mortality among young men: longitudinal study of Swedish conscripts. <i>Br Med J (Clin Res Ed)</i> . 1988; 296(6628): 1021-5.	1969-1985		
Sweden	Rehm J, Room R, van den Brink W, Jacobi F. Alcohol use disorders in EU countries and Norway: an overview of the epidemiology. <i>Eur Neuropsychopharmacol</i> . 2005; 15(4): 377-88.	2002	*	
Sweden	Spak F, Hallström T. Prevalence of female alcohol dependence and abuse in Sweden. <i>Addiction</i> . 1995; 90(8): 1077-88.	1985	*	
Sweden	Oskarsson V, Sadr-Azodi O, Orsini N, Andrén-Sandberg Å, Wolk A. Vegetables, fruit and risk of non-gallstone-related acute pancreatitis: a population-based prospective cohort study. <i>Gut</i> . 2013; 62(8): 1187-92.	1998-2009	*	
Sweden	Sandzén B, Rosenmüller M, Haapamäki MM, Nilsson E, Stenlund HC, Oman M. First attack of acute pancreatitis in Sweden 1988-2003: incidence, aetiological classification, procedures and mortality – a register study. <i>BMC Gastroenterol</i> . 2009; 9: 18.	1988-2003	*	
Sweden	Linder J, Stenlund H, Forsgren L. Incidence of Parkinson's disease and parkinsonism in northern Sweden: a population-based study. <i>Mov Disord</i> . 2010; 25(3): 341-8.	2004-2007	*	
Sweden	Larsson G. Prevention of fetal alcohol effects. An antenatal program for early detection of pregnancies at risk. <i>Acta Obstet Gynecol Scand</i> . 1983; 62(2): 171-8.	1979	*	
Sweden	Olegård R, Sabel KG, Aronsson M, Sandin B, Johansson PR, Carlsson C, Kyllerman M, Iversen K, Hrbek A. Effects on the child of alcohol abuse during pregnancy. Retrospective and prospective studies. <i>Acta Paediatr Scand Suppl</i> . 1979; 112-21.	1977-1978		
Sweden	Svensson HO, Andersson GB, Johansson S, Wilhelmsson C, Vedin A. A retrospective study of low-back pain in 38- to 64-year-old women. Frequency of occurrence and impact on medical services. <i>Spine</i> . 1988; 13(5): 548-52.	1979-1981		
Sweden	Lindberg A, Eriksson B, Larsson L-G, Rönmark E, Sandström T, Lundbäck B. Seven-year cumulative incidence of COPD in an age-stratified general population sample. <i>Chest</i> . 2006; 129(4): 879-85.	1996-2003		
Sweden	Cheng Q, Jiang GX, Fredrikson S, Link H, De Pedro-Cuesta J. Incidence of Guillain-Barré syndrome in Sweden 1996. <i>Eur J Neurol</i> . 2000; 7(1): 11-6.	1996		
Sweden	Jiang GX, Cheng Q, Ehrnst A, Link H, de Pedro-Cuesta J. Guillain-Barré syndrome in Stockholm County, 1973-1991. <i>Eur J Epidemiol</i> . 1997; 13(1): 25-32.	1973-1991		
Sweden	Jiang GX, Cheng Q, Link H, de Pedro-Cuesta J. Epidemiological features of Guillain-Barré syndrome in Sweden, 1978-93. <i>J Neurol Neurosurg Psychiatry</i> . 1997; 62(5): 447-53.	1978-1993		
Sweden	Jiang GX, de Pedro-Cuesta J, Fredrikson S. Guillain-Barré syndrome in south-west Stockholm, 1973-1991. 1. Quality of registered hospital diagnoses and incidence. <i>Acta Neurol Scand</i> . 1995; 91(2): 109-17.	1973-1991	*	
Sweden	Eggert J, Li X, Sundquist K. Country of birth and hospitalization for pelvic inflammatory disease, ectopic pregnancy, endometriosis, and infertility: a nationwide study of 2 million women in Sweden. <i>Fertil Steril</i> . 2008; 90(4): 1019-25.	1990-2004		
Sweden	Augustsson I, Nilson C, Engstrand I. The preventive value of audiometric screening of preschool and young school-children. <i>Int J Pediatr Otorhinolaryngol</i> . 1990; 20(1): 51-62.	1984-1987		
Sweden	Fratiglioni L, Viitanen M, von Strauss E, Tontodonati V, Herlitz A, Winblad B. Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen Project, Stockholm. <i>Neurology</i> . 1997; 48(1): 132-8.	1987-1992	*	
Sweden	Mostofsky E, Levitan EB, Wolk A, Mittleman MA. Chocolate intake and incidence of heart failure: a population-based prospective study of middle-aged and elderly women. <i>Circ Heart Fail</i> . 2010; 3(5): 612-6.	1998-2006	*	
Sweden	Forsgren M, Skoog E, Jeansson S, Olofsson S, Giesecke J. Prevalence of antibodies to herpes simplex virus in pregnant women in Stockholm in 1969, 1983 and 1989: implications for STD epidemiology. <i>Int J STD AIDS</i> . 1994; 5(2): 113-6.	1983, 1989		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Sweden	Persson K, Månsson A, Jönsson E, Nordenfelt E. Decline of herpes simplex virus type 2 and Chlamydia trachomatis infections from 1970 to 1993 indicated by a similar change in antibody pattern. <i>Scand J Infect Dis.</i> 1995; 27(3): 195-9.	1987-1993	*	
Sweden	Statistics Sweden, Swedish National Institute of Public Health. Sweden National Survey of Public Health 2010.	2010		
Sweden	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland: World Health Organization (WHO).	2003-2011	*	
Sweden	Esbjörner E, Berg U, Hansson S. Epidemiology of chronic renal failure in children: a report from Sweden 1986-1994. <i>Pediatr Nephrol.</i> 1997; 11(4): 438-42.	1986-1994	*	†
Sweden	Danielsson L, Lindberg H. Prevalence of coxarthrosis in an urban population during four decades. <i>Clin Orthop Relat Res.</i> 1997; 106-10.	1987-1995	*	†
Sweden	Barnekow BB, Stigmar G. Retinopathy of prematurity in the southern part of Sweden. <i>Acta Ophthalmol (Copenh).</i> 1993; 71(S210): 48-51.	1990	*	†
Sweden	Böhm B, Katz-Salamon M, Smeder A-C, Lagercrantz H, Forsberg H. Developmental risks and protective factors for influencing cognitive outcome at 5½ years of age in very-low-birthweight children. <i>Dev Med Child Neurol.</i> 2002; 44(8): 508-16.	1991	*	†
Sweden	Hård A-L, Hellström A. Ophthalmological follow-up at 2 years of age of all children previously screened for retinopathy of prematurity: is it worthwhile? <i>Acta Ophthalmol Scand.</i> 2006; 84(5): 631-5.	2001		
Sweden	Holmström G, Azazi M et al, Jacobson L, Lennerstrand G. A population based, prospective study of the development of ROP in prematurely born children in the Stockholm area of Sweden. <i>Br J Ophthalmol.</i> 1993; 77(7): 417-23.	1989		
Sweden	Bennhagen R, Svenningsen NW, Bekássy AN. Changing pattern of neonatal meningitis in Sweden. A comparative study 1976 vs. 1983. <i>Scand J Infect Dis.</i> 1987; 19(6): 587-93.	1983		
Sweden	E Persson BT. Septicaemia and meningitis in neonates and during early infancy in the Göteborg area of Sweden. <i>Acta Paediatr.</i> 2002; 91(10): 1087-92.	1987-1996		†
Sweden	Tessin I, Trollfors B, Thiringer K. Incidence and etiology of neonatal septicaemia and meningitis in western Sweden 1975-1986. <i>Acta Paediatr Scand.</i> 1990; 79(11): 1023-30.	1975-1986		
Sweden	Berg S, Trollfors B, Hugosson S, Fernell E, Svensson E. Long-term follow-up of children with bacterial meningitis with emphasis on behavioural characteristics. <i>Eur J Pediatr.</i> 2002; 161(6): 330-6.	1987-1989		
Sweden	Statistics Sweden, Swedish National Institute of Public Health. Sweden National Survey of Public Health 2004.	2004		
Sweden	Statistics Sweden, Swedish National Institute of Public Health. Sweden National Survey of Public Health 2005.	2005		
Sweden	Nordström G, Bergman B, Borg K, Nilsson H, Tillberg A, Wenslöv JH. A 9-year longitudinal study of reported oral problems and dental and periodontal status in 70- and 79-year-old city cohorts in northern Sweden. <i>Acta Odontol Scand.</i> 1998; 56(2): 76-84.	1981-1990		
Sweden	Ahlgvist M, Bengtsson C, Hakeberg M, Hägglin C. Dental status of women in a 24-year longitudinal and cross-sectional study. Results from a population study of women in Göteborg. <i>Acta Odontol Scand.</i> 1999; 57(3): 162-7.	1969-1993		
Sweden	Axelsson P, Paulander J, Lindhe J. Relationship between smoking and dental status in 35-, 50-, 65-, and 75-year-old individuals. <i>J Clin Periodontol.</i> 1998; 25(4): 297-305.	1996-1998		†
Sweden	Nordström G, Bergman B, Tillberg A, Osterlind PO. A comparison of oral health in 70-year-old city cohorts in Umeå northern Sweden in 1981 and 1990: oral problems, dental and periodontal status. <i>Swed Dent J.</i> 1995; 19(5): 195-204.	1981, 1990		
Sweden	Osterberg T, Era P, Gause-Nilsson I, Steen B. Dental state and functional capacity in 75-year-olds in three Nordic localities. <i>J Oral Rehabil.</i> 1995; 22(8): 653-60.	1993		
Sweden	Heldén L, Salonen L, Gustafsson I. Oral health status in an adult Swedish population. Prevalence of teeth, removable dentures and occlusal supporting zones. <i>Swed Dent J.</i> 1989; 13(1-2): 45-60.	1983-1984	*	
Sweden	Osterberg T, Carlsson GE, Sundh V, Mellström D. Number of teeth—a predictor of mortality in 70-year-old subjects. <i>Community Dent Oral Epidemiol.</i> 2008; 36(3): 258-68.	1971-1999	*	
Sweden	Isaksson H, Alm A, Koch G, Birkhed D, Wendt LK. Caries prevalence in Swedish 20-year-olds in relation to their previous caries experience. <i>Caries Res.</i> 2013; 47(3): 234-42.	2007		
Sweden	Isacson A, Hanson BS, Ranstam J, Råstam L, Isacson SO. Social network, social support and the prevalence of neck and low back pain after retirement. A population study of men born in 1914 in Malmö, Sweden. <i>Scand J Soc Med.</i> 1995; 23(1): 17-22.	1982-1983		
Sweden	Medhus A. Mortality among female alcoholics. <i>Scand J Soc Med.</i> 1975; 3(3): 111-5.	1961-1968		
Sweden	Dahlgren L, Myrhed M. Alcoholic females. II. Causes of death with reference to sex difference. <i>Acta Psychiatr Scand.</i> 1977; 56(2): 81-91.	1963-1975		
Sweden	Berglund M, Tunving K. Assaultive alcoholics 20 years later. <i>Acta Psychiatr Scand.</i> 1985; 71(2): 141-7.	1960-1983		
Sweden	Lindberg S, Agren G. Mortality among male and female hospitalized alcoholics in Stockholm 1962-1983. <i>Br J Addict.</i> 1988; 83(10): 1193-200.	1962-1983	*	
Sweden	Örholm M, Sørensen TI, Bentsen K, Højbye G, Eghøj K, Christoffersen P. Mortality of alcohol abusing men prospectively assessed in relation to history of abuse and degree of liver injury. <i>Liver.</i> 1985; 5(5): 253-60.	1968-1981	*	
Sweden	Karlström O, Fryklund B, Tullus K, Burman LG. A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. The Swedish C. difficile Study Group. <i>Clin Infect Dis.</i> 1998; 26(1): 141-5.	1995	*	
Sweden	Norén T, Akerlund T, Bäck E, Sjöberg L, Persson I, Alriksson I, Burman LG. Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county. <i>J Clin Microbiol.</i> 2004; 42(8): 3635-43.	1999-2000	*	
Sweden	Lindberg M, Isacson D, Binge K. Self-reported skin diseases, quality of life and medication use: a nationwide pharmaco-epidemiological survey in Sweden. <i>Acta Derm Venereol.</i> 2014; 94(2): 188-91.	2004-2005	*	
Sweden	Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, Büchele G, Clausen M, Cookson WOC, von Mutius E, Strachan DP, Williams HC, ISAAC Phase Two Study Group. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. <i>J Allergy Clin Immunol.</i> 2008; 121(1): 141-147.	2005-2007		
Sweden	Book C, Saxne T, Jacobson LTH. Prediction of mortality in rheumatoid arthritis based on disease activity markers. <i>J Rheumatol.</i> 2005; 32(3): 430-4.	1978-1998		
Sweden	Muhrbeck O, Ahlberg J. Prevalence of gallstone disease in a Swedish population. <i>Scand J Gastroenterol.</i> 1995; 30(11): 1125-8.	1992		
Sweden	Weiber H, Borch K, Lindström C, Toth E, Fernlund P. Hyperplasia of gastric antral beta-microseminoprotein endocrine-like cells and increased serum levels of beta-microseminoprotein in atrophic corpus gastritis. <i>Scand J Gastroenterol.</i> 1998; 33(9): 911-5.	1996		
Sweden	Lapidus A, Bemell O, Hellers G, Persson PG, Löfberg R. Incidence of Crohn's disease in Stockholm County 1955-1989. <i>Gut.</i> 1997; 41(4): 480-6.	1980-1991		†
Sweden	Lindberg E, Jömerot G. The incidence of Crohn's disease is not decreasing in Sweden. <i>Scand J Gastroenterol.</i> 1991; 26(5): 495-500.	1983-1987		
Sweden	Askling J, Grahngquist L, Ekbohm A, Finkel Y. Incidence of paediatric Crohn's disease in Stockholm, Sweden. <i>Lancet.</i> 1999; 354(9185): 1179.	1990-1998	*	
Sweden	Lapidus A. Crohn's disease in Stockholm County during 1990-2001: an epidemiological update. <i>World J Gastroenterol.</i> 2006; 12(1): 75-81.	1992-2002	*	
Sweden	Trichopoulos D, Bania C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overved K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PHM, Lund E, Quirós JR, González CA, Sanchez Perez M-J, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regné S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu I, Chuang S-C, Murphy N, Boffetta P, Trichopoulou A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. <i>J Natl Cancer Inst.</i> 2011; 103(22): 1686-95.	1992-2006		
Sweden	Olsen B, Axelsson-Olsson D, Thelin A, Weiland O. Unexpected high prevalence of IgG-antibodies to hepatitis E virus in Swedish pig farmers and controls. <i>Scand J Infect Dis.</i> 2006; 38(1): 55-8.	1995-1997		
Sweden	Weiland, Jv B, P L. Prevalence of antibody against hepatitis A in Sweden in relation to age and type of community. <i>Scand J Infect Dis.</i> 1980; 12(3): 171.	1968	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Sweden	Böttiger M, Christenson B. [First study of hepatitis occurrence in Sweden: low immunity is associated with susceptibility to infection]. <i>Lakartidningen</i> . 1998; 95(16): 1801-4.	1990-1991		
Sweden	Dan Lundblad LH. Gender differences in trends of acute myocardial infarction events: the Northern Sweden MONICA study 1985 - 2004. <i>BMC Cardiovasc Disord</i> . 2008; 8:17.	1985-2006		
Sweden	Tunstall-Pedoe H, Kuulasmaa K, Mahönen M, Tolonen H, Ruokokoski E. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality. 10-year results from 37 WHO MONICA Project populations. <i>Lancet</i> . 1999; 353(9164): 1547-57.	1980-1995		
Sweden	Hansson BG, Hansson HB, Ohlin AK, Nordenfelt E. Screening for anti-HIV and HBsAg in pooled sera from a clinical chemistry section as a tool for epidemiological survey. <i>Scand J Infect Dis</i> . 1993; 25(3): 297-303.	1988-1991		
Sweden	Struve J, Giesecke J, Olcen P, von Sydow M, Weiland O. Prevalence of hepatitis B virus markers in Sweden: a community-based serosurvey of 4,000 young Swedish adults. <i>Am J Epidemiol</i> . 1992; 135(4): 409-17.	1988-1989		†
Sweden	Sylvan SP. The high rate of antibodies to hepatitis E virus in young, intravenous drug-abusers with acute hepatitis B-virus infection in a Swedish community: a study of hepatitis markers in individuals with intravenously or sexually acquired hepatitis B-virus infection. <i>Scand J Infect Dis</i> . 1998; 30(4): 429-30.	1983-1986	*	
Sweden	Lundqvist P, Killén K, Hallström I, Westas LH. Trends in outcomes for very preterm infants in the southern region of Sweden over a 10-year period. <i>Acta Paediatr</i> . 2009; 98(4): 648-53.	1997, 2002	*	
Sweden	Dahl E, Aberg M, Rausing A, Rausing EL. Basal cell carcinoma. An epidemiologic study in a defined population. <i>Cancer</i> . 1992; 70(1): 104-8.	1985-1986		
Sweden	Swedish Stroke Register. Sweden Stroke Register Ischemic Stroke Data 2012. [Unpublished].	2012		
Sweden	Börjesson-Hanson A, Edin E, Gislason T, Skoog I. The prevalence of dementia in 95 year olds. <i>Neurology</i> . 2004; 63(12): 2436-8.	1998-2001	*	
Sweden	Lindmark A, Glader E-L, Asplund K, Norrving B, Eriksson M, Riks-Stroke Collaboration. Socioeconomic disparities in stroke case fatality—Observations from Riks-Stroke, the Swedish stroke register. <i>Int J Stroke</i> . 2014; 9(4): 429–36.	2001-2009	*	
Sweden	Ekberg-Aronsson M, Pehrsson K, Nilsson JA, Nilsson PM, Löfdahl CG. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. <i>Respir Res</i> . 2005; 6: 98.	1974-1992	*	
Sweden	Sjöberg D, Holmström T, Larsson M, Nielsen AL, Holmquist L, Ekbohm A, Rönblom A. Incidence and natural history of ulcerative colitis in the Uppsala Region of Sweden 2005-2009 - results from the IBD cohort of the Uppsala Region (ICURE). <i>J Crohns Colitis</i> . 2013; 7(9): e351-7.	2005-2009		†
Sweden	Peltonen M, Lundberg V, Huhtasaari F, Asplund K. Marked improvement in survival after acute myocardial infarction in middle-aged men but not in women. The Northern Sweden MONICA study 1985-94. <i>J Intern Med</i> . 2000; 247(5): 579–587.	1985-1994		†
Sweden	Zeitlan J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT: 2008. Available from: http://www.perinataleaudit.nl/downloads/bestand/649/peristat-ii-2008-	2004		†
Sweden	Bylund B, Cervin T, Finnström O, Gäddlin PO, Kernell A, Leijon I, Sandstedt P, Wängård O. Morbidity and neurological function of very low birthweight infants from the newborn period to 4 y of age. A prospective study from the south-east region of Sweden. <i>Acta Paediatr</i> . 1998 Jul;87(7):758–63.	1987, 1991	*	
Sweden	Finnström O, Olausson PO, Sedin G, Serenius F, Svenningsen N, Thiringer K, Tunell R, Wennegren M, Weström G. The Swedish national prospective study on extremely low birthweight (ELBW) infants. Incidence, mortality, morbidity and survival in relation to level of care. <i>Acta Paediatr</i> . 1997; 86(5): 503–11.	1993	*	
Sweden	Swedish Renal Registry (SNR) Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010		
Sweden	Swedish Renal Registry (SNR) Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Sweden	Sweden Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990	*	
Sweden	Swedish Registry of Congenital Malformations and Medical Birth Registry Data 1980 - ICBDS as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1980	*	
Sweden	Swedish Registry of Congenital Malformations and Medical Birth Registry Data 1983 - ICBDS as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1983	*	
Sweden	Swedish Registry of Congenital Malformations and Medical Birth Registry Data 1986 - ICBDS as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1986	*	
Sweden	Swedish Registry of Congenital Malformations and Medical Birth Registry Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Sweden	Swedish Registry of Congenital Malformations and Medical Birth Registry Data 1987 - ICBDS as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1987	*	
Sweden	Swedish Registry of Congenital Malformations and Medical Birth Registry Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
Sweden	Swedish Registry of Congenital Malformations and Medical Birth Registry Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
Sweden	Swedish Registry of Congenital Malformations and Medical Birth Registry Data 1981 - ICBDS as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1981	*	
Sweden	Swedish Registry of Congenital Malformations and Medical Birth Registry Data 2001 - ICBDS as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
Sweden	Swedish Registry of Congenital Malformations and Medical Birth Registry Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
Sweden	Swedish Registry of Congenital Malformations and Medical Birth Registry Data 1985 - ICBDS as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1985	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Sweden	Swedish Registry of Congenital Malformations and Medical Birth Registry Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
Sweden	Swedish Registry of Congenital Malformations and Medical Birth Registry Data 1988 - ICBDSR as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1988	*	
Sweden	Swedish Registry of Congenital Malformations and Medical Birth Registry. Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Sweden	Swedish Registry of Congenital Malformations and Medical Birth Registry Data 1984 - ICBDSR as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1984		
Sweden	Swedish Registry of Congenital Malformations and Medical Birth Registry Data 1982 - ICBDSR as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1982	*	
Switzerland	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2002-2010	*	
Switzerland	Federal Statistical Office (Switzerland), Swiss National Science Foundation, University of Neuchatel. Switzerland Household Panel Survey 1999-2000. Lausanne, Switzerland: Swiss Foundation for Research in Social Sciences.	1999-2000	*	
Switzerland	Federal Statistical Office (Switzerland), Swiss National Science Foundation, University of Neuchatel. Switzerland Household Panel Survey 2000-2001. Lausanne, Switzerland: Swiss Foundation for Research in Social Sciences.	2000-2001	*	
Switzerland	Federal Statistical Office (Switzerland), Swiss National Science Foundation, University of Neuchatel. Switzerland Household Panel Survey 2001-2002. Lausanne, Switzerland: Swiss Foundation for Research in Social Sciences.	2001-2002	*	
Switzerland	Federal Statistical Office (Switzerland), Swiss National Science Foundation, University of Neuchatel. Switzerland Household Panel Survey 2002-2003. Lausanne, Switzerland: Swiss Foundation for Research in Social Sciences.	2002-2003	*	
Switzerland	Federal Statistical Office (Switzerland), Swiss National Science Foundation, University of Neuchatel. Switzerland Household Panel Survey 2003-2004. Lausanne, Switzerland: Swiss Foundation for Research in Social Sciences.	2003-2004	*	
Switzerland	Federal Statistical Office (Switzerland), Swiss National Science Foundation, University of Neuchatel. Switzerland Household Panel Survey 2004-2005. Lausanne, Switzerland: Swiss Foundation for Research in Social Sciences.	2004-2005	*	
Switzerland	Federal Statistical Office (Switzerland), Swiss National Science Foundation, University of Neuchatel. Switzerland Household Panel Survey 2006-2007. Lausanne, Switzerland: Swiss Foundation for Research in Social Sciences.	2006-2007	*	
Switzerland	Federal Statistical Office (Switzerland), Swiss National Science Foundation, University of Neuchatel. Switzerland Household Panel Survey 2007-2008. Lausanne, Switzerland: Swiss Foundation for Research in Social Sciences.	2007-2008		
Switzerland	Swiss Foundation for Research in Social Sciences. Switzerland Household Panel Survey 2008-2009. Lausanne, Switzerland: Swiss Foundation for Research in Social Sciences.	2008-2009		
Switzerland	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. Scand J Clin Lab Invest. 2007; 67(1): 39-69.	1988, 2006		
Switzerland	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1988, 2003, 2006		
Switzerland	Cevey-Macherel M, Galetto-Lacour A, Gervais A, Siegrist C-A, Bille J, Bescher-Ninet B, Kaiser L, Krahenbuhl J-D, Gehri M. Etiology of community-acquired pneumonia in hospitalized children based on WHO clinical guidelines. Eur J Pediatr. 2009; 168(12): 1429-36.	2003-2005		
Switzerland	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2001-2009		
Switzerland	Kesselring J, Beer S. Clinical data bank at the University Department of Neurology, Bern, Switzerland: basis for an epidemiological study of multiple sclerosis in a high prevalence area. Ital J Neurol Sci. 1987; 29:34.	1986		
Switzerland	Beer S, Kesselring J. High Prevalence of Multiple Sclerosis in Switzerland. Neuroepidemiology. 1994; 13(1-2): 14-8.	1986		
Switzerland	Ajdacic-Gross V, Schmid M, Tschopp A, Gutzwiller F. Recording of multiple sclerosis in Swiss cause of death statistics. A 10-year mortality follow-up of the Bern prevalence study. Soz Praventivmed. 1999; 44(1): 30-5.	1986-1996	*	
Switzerland	Ziegler D, Gries FA, Spüler M, Lessmann F. The epidemiology of diabetic neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. J Diabet Complications. 1992; 6(1): 49-57.	1989-1991	*	
Switzerland	Probst-Hensch NM, Curjuri I, Pierre-Olivier B, Ackermann-Liebrich U, Bettschart RW, Brändli O, Brutsche M, Burdet L, Gerbase MW, Knöpfli B, Künzli N, Pons MG, Schindler C, Tschopp J-M, Rochat T, Russi EW. Longitudinal change of prebronchodilator spirometric obstruction and health outcomes: results from the SAPALDIA cohort. Thorax. 2010; 65(2): 150-6.	2002	*	
Switzerland	Schmutz M, Beer-Borst S, Meiltz A, Urban P, Gaspoz J-M, Costanza MC, Morabia A, Zimmermann M. Low prevalence of atrial fibrillation in asymptomatic adults in Geneva, Switzerland. Europace. 2010; 12(4): 475-81.	2005-2007		
Switzerland	Katsoulis J, Schimmel M, Avrampou M, Stuck AE, Mericske-Stern R. Oral and general health status in patients treated in a dental consultation clinic of a geriatric ward in Bern, Switzerland. Gerodontology. 2012; 29(2): e602-610.	2008-2011	*	
Switzerland	Vrbic V, Homan D, Zavrsnik B. Oral health in Slovenia, Yugoslavia. Community Dent Oral Epidemiol. 1991; 19(2): 72-3.	1987	*	
Switzerland	Erne C, Elfering A. Low back pain at school: unique risk deriving from unsatisfactory grade in maths and school-type recommendation. Eur Spine J. 2011; 20(12): 2126-33.	2008		
Switzerland	Kolb E, Canjuga M, Bauer GF, Läubli T. Course of back pain across 5 years: a retrospective cohort study in the general population of Switzerland. Spine. 2011; 36(4): E268-273.	1999-2003		
Switzerland	Gostynski M, Ajdacic-Gross V, Gutzwiller F, Michel J-P, Herrmann F. Prevalence of dementia in the City of Zurich. Soz Praventivmed. 2002; 47(5): 330-5.	1995-1996		
Switzerland	Marthaler TM, Steiner M, Menghini G, Bandi A. Caries prevalence in Switzerland. Int Dent J. 1994; 44(4): 393-401.	1964-1988		
Switzerland	Steinhausen HC, Winkler C, Meier M. Eating disorders in adolescence in a Swiss epidemiological study. Int J Eat Disord. 1997; 22(2): 147-51.	1994-1995		
Switzerland	Angst J, Wicki W. The Zurich Study. XI. Is dysthymia a separate form of depression? Results of the Zurich Cohort Study. Eur Arch Psychiatry Clin Neurosci. 1991; 240(6): 349-54.	1986		
Switzerland	de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Künzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P. European Community Respiratory Health Survey Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax. 2004; 59(2): 120-125.	1991-1993		
Switzerland	Tschudin S, Berte PC, Zemp E. Prevalence and predictors of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample. Arch Womens Ment Health. 2010; 13(6): 485-94.	2007		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Switzerland	De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology</i> . 2000; 54(11 Suppl 5): S21-23.	1997		
Switzerland	Berger K BM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. <i>Neurologic Diseases in the Elderly Research Group. Neurology</i> . 2000; 54(11): 24-7.	1997		
Switzerland	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Switzerland	Balagué F, Nordin M, Skovron ML, Dutoit G, Yee A, Waldburger M. Non-specific low-back pain among schoolchildren: a field survey with analysis of some associated factors. <i>J Spinal Disord</i> . 1994; 7(5): 374-9.	1989		
Switzerland	Santos-Eggimann B, Wietlisbach V, Rickenbach M, Paccaud F, Gutzwiller F. One-year prevalence of low back pain in two Swiss regions: estimates from the population participating in the 1992-1993 MONICA project. <i>Spine</i> . 2000; 25(19): 2473-9.	1992-1993		
Switzerland	WHO Regional Office for Europe (EURO-WHO). Young People's Health in Context. Health Behaviour in School-aged Children (HBSC) Study: International Report from the 2001-2002 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2004.	2002		
Switzerland	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Switzerland	Angst J, Merikangas K, Scheidegger P, Wicki W. Recurrent brief depression: a new subtype of affective disorder. <i>J Affect Disord</i> . 1990; 19(2): 87-98.	1988		
Switzerland	Nitsch D, Felber Dietrich D, von Eckardstein A, Gaspoz JM, Downs SH, Leuenberger P, Tschopp JM, Brändli O, Keller R, Gerbase MW, Probst-Hensch NM, Stutz EZ, Ackermann-Lieblich U; SAPALDIA team. Prevalence of renal impairment and its association with cardiovascular risk factors in a general population: results of the Swiss SAPALDIA study. <i>Nephrol Dial Transplant</i> . 2006; 21(4): 935-44.	2002-2003	*	
Switzerland	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012	*	
Switzerland	Steinhausen HC, Metzke CW, Meier M, Kannenberg R. Prevalence of child and adolescent psychiatric disorders: the Zürich Epidemiological Study. <i>Acta Psychiatr Scand</i> . 1998; 98(4): 262-71.	1996	*	†
Switzerland	Bünzli D, Wietlisbach V, Barazzoni F, Sahli R, Meylan PRA. Seroepidemiology of Herpes Simplex virus type 1 and 2 in Western and Southern Switzerland in adults aged 25-74 in 1992-93: a population-based study. <i>BMC Infect Dis</i> . 2004; 10.	1992-1993	*	†
Switzerland	Perez A, Ritter S, Brotschi B, Werner H, Cafilisch J, Martin E, Latal B. Long-term neurodevelopmental outcome with hypoxic-ischemic encephalopathy. <i>J Pediatr</i> . 2013; 163(2): 454-9.	1989-2003	*	†
Switzerland	Lipp-Zwahlen AE, Deonna T, Micheli JL, Calame A, Chrzanoski R, Cêtre E. Prognostic value of neonatal CT scans in asphyxiated term babies: low density score compared with neonatal neurological signs. <i>Neuropediatrics</i> . 1985; 16(4): 209-17.	1979-1980		
Switzerland	Pfenninger J, Bachmann D, Wagner BP. Survivors with bad outcome after hypoxic-ischaemic encephalopathy: full-term neonates compare unfavourably with children. <i>Swiss Med Wkly</i> . 2001; 131(19-20): 267-72.	1992-1996		
Switzerland	Schoenle EJ, Lang-Muritano M, Gschwend S, Laimbacher J, Mullis PE, Torresani T, Biason-Laubner A, Molinari L. Epidemiology of type 1 diabetes mellitus in Switzerland: steep rise in incidence in under 5 year old children in the past decade. <i>Diabetologia</i> . 2001; 44(3): 286-9.	1991-1999		
Switzerland	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant</i> . 1988; 3(6): 714-27.	1985-1986		
Switzerland	Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. <i>J Clin Endocrinol Metab</i> . 2008; 93(4): 1408-11.	2005	*	
Switzerland	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguiar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Peda I, Gilst WH van, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J</i> . 2003; 24(5): 442-63.	2000-2001	*	
Switzerland	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1994; 69(20): 145-51.	1993	*	
Switzerland	Laubereau B, Zwahlen M, Neuschwander B, Heininger U, Schaad UB, Desgrandchamps D. [Herpes simplex virus type 1 and 2 in Switzerland]. <i>Schweiz Med Wochenschr</i> . 2000; 130(5): 143-50.	1997		
Switzerland	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland: World Health Organization (WHO).	2006		
Switzerland	Schaad UB, Lips U, Gnehm HE, Blumberg A, Heinzer J, Wedgwood J. Dexamethasone therapy for bacterial meningitis in children. <i>Swiss Meningitis Study Group. Lancet</i> . 1993; 342(8869): 457-61.	1990-1992		
Switzerland	Fleury Y, van Melle G, Woringer V, Temler E, Gaillard RC, Portmann L. [Iodine nutrition and prevalence of goiter in adolescents in the Canton of Vaud]. <i>Schweiz Med Wochenschr</i> . 1999; 129(47): 1831-8 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1995		
Switzerland	Supersaxo Z, Selz B, Hasler P, Wespi HJ, Abelin T, Bürgi H. [Is iodination of cooking salt still necessary? Current studies on iodine supply in Switzerland]. <i>Schweiz Med Wochenschr</i> . 1991; 121(10): 317-23 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1988		
Switzerland	Hoang Truong T, Gerber H, Haenel AF, Bürgi H. [Iodine supply at various periods in life and ultrasonographic thyroid volume in school children in a region of Switzerland]. <i>Schweiz Med Wochenschr</i> . 1997; 127(17): 715-21 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1994	*	
Switzerland	Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJA, Wasserman SM, Baker N, Rosser D, Cleland JGF, Ponikowski P. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. <i>Eur Heart J</i> . 2007; 28(18): 2208-16.	1992-1995		
Switzerland	Trichopoulos D, Bania C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overvad K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PHM, Lund E, Quirós JR, González CA, Sanchez Perez M-J, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu I, Chuang S-C, Murphy N, Boffetta P, Trichopoulos A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. <i>J Natl Cancer Inst</i> . 2011; 103(22): 1686-95.	1992-2006		
Switzerland	Stadelmann W, Gasser M, Löffler H. [The incidence of antibodies against hepatitis A virus in various age groups in the Basle population 1978-79]. <i>Schweiz Med Wochenschr</i> . 1980; 110(25): 975-8.	1978-1979		
Switzerland	Holdener F, Grob PJ, Joller-Jemelka HI. Hepatitis virus infection in flying airline personnel. <i>Aviat Space Environ Med</i> . 1982; 53(6): 587-90.	1979-1980		
Switzerland	Studer S, Joller-Jemelka HI, Steffen R, Grob PJ. Prevalence of hepatitis A antibodies in Swiss travellers. <i>Eur J Epidemiol</i> . 1993; 9(1): 50-4.	1990		
Switzerland	Bart PA, Jacquier P, Zuber PL, Lavanchy D, Frei PC. Seroprevalence of HBV (anti-HBc, HBsAg and anti-HBs) and HDV infections among 9006 women at delivery. <i>Liver</i> . 1996; 16(2): 110-6.	1990-1991	*	
Switzerland	Beckers K, Schaad UB, Heininger U. Compliance with antenatal screening for hepatitis B surface antigen carrier status in pregnant women and consecutive procedures in exposed newborns. <i>Eur J Pediatr</i> . 2004; 163(11): 654-7.	2001		
Switzerland	Lavanchy D, Morel B, Frei PC. Seroprevalence of hepatitis E virus in Switzerland. <i>Lancet</i> . 1994; 344(8924): 747-8.	1991-1992		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Switzerland	Switzerland Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990	*	
Switzerland	European Surveillance of Congenital Anomalies (EUROCAT). Switzerland EUROCAT Prevalence Tables. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	1989-2011	*	
Switzerland	Switzerland - Zurich Registry of Switzerland Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998		†
Syria	General Administration for Palestine Arab Refugees (GAPAR), Palestinian Central Bureau of Statistics, Pan Arab Project for Family Health (PAPFAM), United Nations Children's Fund (UNICEF). Palestinians in Syria Multiple Indicator Cluster Survey 2006.	2006		†
Syria	Central Bureau of Statistics (Syria), League of Arab States. Syria Family Health Survey 2001.	2001	*	†
Syria	Central Bureau of Statistics (Syria), League of Arab States. Syria Maternal and Child Health Survey 1993.	1993		
Syria	United Nations Children's Fund (UNICEF), Central Bureau of Statistics (Syria), Ministry of Health (Syria), Pan Arab Project for Family Health (PAPFAM). Syria Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006		
Syria	Central Bureau of Statistics (Syria), International Statistical Institute. Syria World Fertility Survey 1978. International Statistical Institute.	1978		
Syria	Ministry of Health (Syria), World Health Organization (WHO). Syria WHO Multi-country Survey Study on Health and Health System Responsiveness 2000-2001.	2000-2001		†
Syria	Centre for Health Informatics and Multiprofessional Education, University College London. Model's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Syria	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		
Syria	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1999-2001, 2003, 2005, 2007-2009	*	
Syria	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2001	*	
Syria	Mohammad Y, Tabbah K, Mohammad S, Yassine F, Clayton T, Hassan M. International study of asthma and allergies in childhood: phase 3 in the Syrian Arab Republic. East Mediterr Health J. 2010; 16(7): 710-6.	2001-2003		
Syria	Qadri G, Nourallah A, Splieth CH. Early childhood caries and feeding practices in kindergarten children. Quintessence Int. 2012; 43(6): 503-10.	2010		
Syria	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012	*	
Syria	Albahe N, Al Ali R, Rastam S, Fouad FM, Mzayek F, Maziak W. Epidemiology of Type 2 diabetes mellitus in Aleppo, Syria. J Diabetes. 2010; 2(2): 85-91.	2006		
Syria	Maziak W, Ward KD, Rastam S. Injuries in Aleppo, Syria: first population-based estimates and characterization of predominant types. BMC Public Health. 2006; 6:3.	2004	*	
Syria	Usanga EA, Ameen R. Glucose-6-phosphate dehydrogenase deficiency in Kuwait, Syria, Egypt, Iran, Jordan and Lebanon. Hum Hered. 2000; 50(3): 158-61.	1996-1997	*	
Syria	World Health Organization (WHO). Syria WHO Leishmaniasis Country Profile.	1994-2010	*	
Syria	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
Syria	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	
Syria	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Syria	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Syria	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Syria	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
Syria	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Syria	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Syria	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Syria	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Syria	Ibrahim AI, Kouwathi KM, Obeid MT. Frequency of herpes simplex virus in Syria based on type-specific serological assay. Saudi Med J. 2000; 21(4): 355-60.	1995-1998	*	
Syria	Joint United Nations Program on HIV/AIDS (UNAIDS), United Nations Children's Fund (UNICEF), World Health Organization (WHO). Syria Epidemiological Fact Sheet on HIV/AIDS and STIs 2004.	2003		
Syria	Mohammad Y, Shaaban R, Yassine F, Allouch J, Daaboul N, Bassam AA-Z, Mohammad A-B, Taha D, Sabha S, Dyhan G, Al-Sheih K, Balleh H, Ibrahim M, Al Khaer H, Dayoub M, Halloum R, Fadil I, Abbas AF, Khouri A, Khaltaev N, Bousquet J, Khaddouj M, Suleiman I, Meri M, Bakir M, Naem A, Said H, Al-Dmeirawi F, Mayhoub H, Dib G. Executive summary of the multicenter survey on the prevalence and risk factors of chronic respiratory diseases in patients presenting to primary care centers and emergency rooms in Syria. J Thorac Dis. 2012; 4(2): 203-5.	2009-2010		
Syria	Antaki N, Kebbewar MK. Hepatitis A seroprevalence rate in Syria. Trop Doct. 2000; 30(2): 99-101.	1999		
Syria	Othman BM, Monem FS. Prevalence of hepatitis C virus antibodies among health care workers in Damascus, Syria. Saudi Med J. 2001; 22(7): 603-5.	1999		
Syria	Othman BM, Monem FS. Prevalence of hepatitis C virus antibodies among intravenous drug abusers and prostitutes in Damascus, Syria. Saudi Med J. 2002; 23(4): 393-5.	2000		
Syria	Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol. 1996; 14(5): 417-23.	1987, 1993		
Taiwan (Province of China)	Chien K-L, Su T-C, Hsu H-C, Chang W-T, Chen P-C, Chen M-F, Lee Y-T. Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese. Int J Cardiol. 2010; 139(2): 173-80.	1990-1991		
Taiwan (Province of China)	Centre for Health Informatics and Multiprofessional Education, University College London. Model's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Taiwan (Province of China)	Chen G-Y, Cheng Y-W, Wang C-Y, Hsu T-J, Hsu MM-L, Yang P-T, Chen W-C. Prevalence of skin diseases among schoolchildren in Magong, Penghu, Taiwan: a community-based clinical survey. J Formos Med Assoc. 2008; 107(1): 21-9.	2005		
Taiwan (Province of China)	Yang Y-C, Cheng Y-W, Lai C-S, Chen W. Prevalence of childhood acne, epheleides, warts, atopic dermatitis, psoriasis, alopecia areata and keloid in Kaohsiung County, Taiwan: a community-based clinical survey. J Eur Acad Dermatol Venereol. 2007; 21(5): 643-9.	2004		
Taiwan (Province of China)	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. J Allergy Clin Immunol. 2008; 121(4): 947-954.	1994-1995, 2001		
Taiwan (Province of China)	Wu P-S, Chang I-S, Tsai F-Y, Hsieh Y-C, Shao P-L, Chang L-Y, Huang L-M. Epidemiology and impacts of children hospitalized with pneumonia from 1997 to 2004 in Taiwan. Pediatr Pulmonol. 2009; 24(4): 162-6.	1997-2004		
Taiwan (Province of China)	Huang C-H, Chien K-L, Chen W-J, Sung F-C, Hsu H-C, Su T-C, Lee Y-T. Impact of heart failure and left ventricular function on long-term survival - report of a community-based cohort study in Taiwan. Eur J Heart Fail. 2007; 9(6-7): 587-93.	1991-1992		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Taiwan (Province of China)	Shao PL, Chie WC, Wang CY, Yang CY, Lu CY, Chang LY, Huang LM, Lee CY. Epidemiology of Haemophilus influenzae type b meningitis in Taiwan, 1997 and 2000. J Microbiol Immunol Infect. 2004; 37(3): 164-8.	1997, 2000		
Taiwan (Province of China)	Wu FT, Liang SY, Tsao KC, Huang CG, Lin CY, Lin JS, Su CY, Eng HL, Yang JY, Chen PJ, Yang CF. Hospital-based surveillance and molecular epidemiology of rotavirus infection in Taiwan, 2005-2007. Vaccine. 2009; 27(Suppl 5): 50-54.	2005-2007		
Taiwan (Province of China)	Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol. 2000; 27(4): 1045-50.	1991-1992		
Taiwan (Province of China)	Chou CT, Pei L, Chang DM, Lee CF, Schumacher HR, Liang MH. Prevalence of rheumatic diseases in Taiwan: a population study of urban, suburban, rural differences. J Rheumatol. 1994; 21(2): 302-6.	1989-1991		
Taiwan (Province of China)	Chang HY, Pan WH, Yeh WT, Tsai KS. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-96). J Rheumatol. 2001; 28(7): 1640-6.	1993-1996		
Taiwan (Province of China)	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J. 1998; 12(2): 315-35.	1993-1995		
Taiwan (Province of China)	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2002		
Taiwan (Province of China)	Hsu WC, Chiu YH, Chiu HC, Liou HH, Jeng YC, Chen TH. Two-stage community-based screening model for estimating prevalence of diabetic polyneuropathy (KCIS no. 6). Neuroepidemiology. 2005; 25(1): 1-7.	1999-2001		
Taiwan (Province of China)	Hsu WC, Yen AM, Liou HH, Wang HC, Chen TH. Prevalence and risk factors of somatic and autonomic neuropathy in prediabetic and diabetic patients. Neuroepidemiology. 2009; 33(4): 344-9.	2002-2003		
Taiwan (Province of China)	Tseng CH. Prevalence and risk factors of diabetic foot problems in Taiwan: a cross-sectional survey of non-type 1 diabetic patients from a nationally representative sample. Diabetes Care. 2003; 26(12): 3351.	2000		
Taiwan (Province of China)	Wu YH, Su HY, Hsieh YJ. Survey of infectious skin diseases and skin infestations among primary school students of Taitung County, eastern Taiwan. J Formos Med Assoc. 2000; 99(2): 128-34.	1998		
Taiwan (Province of China)	Chou P, Chen HH, Hsiao KJ. Community-based epidemiological study on diabetes in Pu-Li, Taiwan. Diabetes Care. 1992; 15(1): 81-9.	1988		
Taiwan (Province of China)	Chou P, Liao MJ, Kuo HS, Hsiao KJ, Tsai ST. A population survey on the prevalence of diabetes in Kin-Hu, Kinmen. Diabetes Care. 1994; 17(9): 1055-8.	1991		
Taiwan (Province of China)	Lu FH, Yang YC, Wu JS, Wu CH, Chang CJ. A population-based study of the prevalence and associated factors of diabetes mellitus in southern Taiwan. Diabet Med. 1998; 15(7): 564-72.	1995		
Taiwan (Province of China)	Chen KT, Chen CJ, Gregg EW, Williamson DF, Narayan KM. High prevalence of impaired fasting glucose and type 2 diabetes mellitus in Penghu Islets, Taiwan: evidence of a rapidly emerging epidemic? Diabetes Res Clin Pract. 1999; 44(1): 59-69.	1996		
Taiwan (Province of China)	Chen KT, Chen CJ, Gregg EW, Engelgau MM, Narayan KM. Prevalence of type 2 diabetes mellitus in Taiwan: ethnic variation and risk factors. Diabetes Res Clin Pract. 2001; 51(1): 59-66.	1997		
Taiwan (Province of China)	Fuh JL, Wang SJ, Hwu CM, Lu SR. Glucose tolerance status and cognitive impairment in early middle-aged women. Diabet Med. 2007; 24(7): 788-91.	2003		
Taiwan (Province of China)	Lu SR, Fuh JL, Juang KD, Wang SJ. Migraine prevalence in adolescents aged 13-15: a student population-based study in Taiwan. Cephalalgia. 2000; 20(5): 479-85.	1998-1999		
Taiwan (Province of China)	Wang SJ, Fuh JL, Young YH, Lu SR, Shia BC. Prevalence of migraine in Taipei, Taiwan: a population-based survey. Cephalalgia. 2000; 20(6): 566-72.	1997-1998	*	
Taiwan (Province of China)	Wang S-J, Fuh J-L, Juang K-D, Lu S-R. Rising prevalence of migraine in Taiwanese adolescents aged 13-15 years. Cephalalgia. 2005; 25(6): 433-8.	1999-2001	*	
Taiwan (Province of China)	Hwang C-Y, Chen Y-J, Lin M-W, Chen T-J, Chu S-Y, Chen C-C, Lee D-D, Chang Y-T, Wang W-J, Liu H-N. Prevalence of atopic dermatitis, allergic rhinitis and asthma in Taiwan: a national study 2000 to 2007. Acta Derm Venereol. 2010; 90(6): 589-94.	2000-2007	*	
Taiwan (Province of China)	Wu WF, Wan KS, Wang SJ, Yang W, Liu WL. Prevalence, severity, and time trends of allergic conditions in 6-to-7-year-old schoolchildren in Taipei. J Investig Allergol Clin Immunol. 2011; 21(7): 556-62.	2007	*	
Taiwan (Province of China)	Yao T-C, Ou L-S, Yeh K-W, Lee W-I, Chen L-C, Huang J-L. PATCH Study Group. Associations of age, gender, and BMI with prevalence of allergic diseases in children: PATCH study. J Asthma. 2011; 48(5): 503-10.	2007	*	
Taiwan (Province of China)	Lai CH, Lai MS, Lai KL, Chen HH, Chiu YM. Nationwide population-based epidemiologic study of rheumatoid arthritis in Taiwan. Clin Exp Rheumatol. 2012; 30(3): 358-63.	2000-2007	*	
Taiwan (Province of China)	Huang C-C, Chan W-L, Luo J-C, Chen Y-C, Chen T-J, Chung C-M, Huang P-H, Lin S-J, Chen J-W, Leu H-B. Gastroesophageal reflux disease and atrial fibrillation: a nationwide population-based study. PLoS One. 2012; 7(10): e47575.	2000-2002	*	
Taiwan (Province of China)	Hsu N-Y, Wu P-C, Bornehag C-G, Sundell J, Su H-J. Feeding bottles usage and the prevalence of childhood allergy and asthma. Clin Dev Immunol. 2012; 1-8.	2005-2006	*	
Taiwan (Province of China)	Liao M-F, Liao M-N, Lin S-N, Chen J-Y, Huang J-L. Prevalence of allergic diseases of schoolchildren in central Taiwan. From ISAAC surveys 5 years apart. J Asthma. 2009; 46(6): 541-5.	2002, 2007	*	
Taiwan (Province of China)	Chen J-H, Yeh W-T, Chuang S-Y, Wu Y-Y, Pan W-H. Gender-specific risk factors for incident gout: a prospective cohort study. Clin Rheumatol. 2012; 31(2): 239-45.	1994-2002		
Taiwan (Province of China)	Chuang S-Y, Lee S-C, Hsieh Y-T, Pan W-H. Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008. Asia Pac J Clin Nutr. 2011; 20(2): 301-8.	1993-1996, 2005-2008		
Taiwan (Province of China)	Tsai C-F, Lin D-B, Chen S-C, Chang Y-H, Chen C-Y, Lin J-B. Seroprevalence of hepatitis A virus infection among schoolchildren in Taiwan. J Med Virol. 2011; 83(2): 196-200.	2008-2010		
Taiwan (Province of China)	Yang J-F, Lin C-I, Huang J-F, Dai C-Y, Lin W-Y, Ho C-K, Hsieh M-Y, Lee L-P, Ho N-J, Lin Z-Y, Chen S-C, Hsieh M-Y, Wang L-Y, Yu M-L, Chuang W-L, Chang W-Y. Viral hepatitis infections in southern Taiwan: a multicenter community-based study. Kaohsiung J Med Sci. 2010; 26(9): 461-9.	1999-2005		
Taiwan (Province of China)	Lee M-H, Yang H-J, Jen C-L, Lu S-N, Yeh S-H, Liu C-J, You S-L, Sun C-A, Wang L-Y, Chen W-I, Chen C-J, R.E.V.E.A.L.-HCV Study Group. Community and personal risk factors for hepatitis C virus infection: a survey of 23,820 residents in Taiwan in 1991-2. Gut. 2011; 60(5): 688-94.	1991-1992	*	
Taiwan (Province of China)	Chang Y-T, Chen T-J, Liu P-C, Chen Y-C, Chen Y-J, Huang Y-L, Jih J-S, Chen C-C, Lee D-D, Wang W-J, Lin M-W, Liu H-N. Epidemiological study of psoriasis in the national health insurance database in Taiwan. Acta Derm Venereol. 2009; 89(3): 262-6.	2000-2006	*	
Taiwan (Province of China)	Wang P-C, Chang Y-H, Chuang L-J, Su H-F, Li C-Y. Incidence and recurrence of acute otitis media in Taiwan's pediatric population. Clinics (Sao Paulo). 2011; 66(3): 395-9.	2006	*	
Taiwan (Province of China)	Ting P-J, Lin C-H, Huang F-L, Lin M-C, Hwang K-P, Huang Y-C, Chiu C-H, Lin T-Y, Chen P-Y. Epidemiology of acute otitis media among young children: a multiple database study in Taiwan. J Microbiol Immunol Infect. 2012; 45(6): 453-8.	2005-2010		
Taiwan (Province of China)	Lai D-C, Tseng Y-C, Hou Y-M, Guo H-R. Gender and geographic differences in the prevalence of intellectual disability in children: analysis of data from the national disability registry of Taiwan. Res Dev Disabil. 2012; 33(6): 2301-7.	2004-2010		
Taiwan (Province of China)	Lin RT, Lai CL, Tai CT, Liu CK, Yen YY, Howng SL. Prevalence and subtypes of dementia in southern Taiwan: impact of age, sex, education, and urbanization. J Neurol Sci. 1998; 160(1): 67-75.	1993		
Taiwan (Province of China)	Liu CK, Lai CL, Tai CT, Lin RT, Yen YY, Howng SL. Incidence and subtypes of dementia in southern Taiwan: impact of socio-demographic factors. Neurology. 1998; 50(6): 1572-9.	1997		
Taiwan (Province of China)	Liu HC, Fuh JL, Wang SJ, Liu CY, Larson EB, Lin KN, Wang HC, Chou P, Wu ZA, Lin CH, Wang PN, Teng EL. Prevalence and subtypes of dementia in a rural Chinese population. Alzheimer Dis Assoc Disord. 1998; 12(3): 127-34.	1993-1994		
Taiwan (Province of China)	Liu HC, Lin KN, Teng EL, Wang SJ, Fuh JL, Guo NW, Chou P, Hu HH, Chiang BN. Prevalence and subtypes of dementia in Taiwan: a community survey of 5297 individuals. J Am Geriatr Soc. 1995; 43(2): 144-9.	1993-1994		
Taiwan (Province of China)	Gau SSF, Chong MY, Chen THH, Cheng ATA. A 3-year panel study of mental disorders among adolescents in Taiwan. Am J Psychiatry. 2005; 162(7): 1344-50.	1994-1997		
Taiwan (Province of China)	Lee C-H, Liu P-Y, Lin L-J, Chen J-H, Tsai L-M. Clinical characteristics and outcomes of hypertrophic cardiomyopathy in Taiwan—a tertiary center experience. Clin Cardiol. 2007; 30(4): 177-82.	1990-2005		
Taiwan (Province of China)	Lee Y-H, Huang W-C, Tsai J-Y, Lu C-M, Chen W-C, Lee M-H, Hsu S-H, Huang J-K, Chang LS. Epidemiological studies on the prevalence of upper urinary calculi in Taiwan. Urol Int. 2002; 68(3): 172-7.	1994-1996		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Taiwan (Province of China)	Yang H-J, Soong W-T, Kuo P-H, Chang H-L, Chen WJ. Using the CES-D in a two-phase survey for depressive disorders among nonreferred adolescents in Taipei: a stratum-specific likelihood ratio analysis. <i>J Affect Disord.</i> 2004; 82(3): 419-30.	1998-1999		
Taiwan (Province of China)	Fuh JL, Wang SJ, Larson EB, Liu HC. Prevalence of stroke in Kinmen. <i>Stroke.</i> 1996; 27(8): 1338-41.	1993-1994		
Taiwan (Province of China)	Huang Z-S, Chiang T-L, Lee T-K. Stroke Prevalence in Taiwan: Findings From the 1994 National Health Interview Survey. <i>Stroke.</i> 1997; 28(8): 1579-84.	1994		
Taiwan (Province of China)	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2001-2005		
Taiwan (Province of China)	United States Renal Data System Coordinating Center. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2000		
Taiwan (Province of China)	United States Renal Data System Coordinating Center. USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2003.	1998-1999		
Taiwan (Province of China)	Hwu HG, Yeh EK, Chang LY. Prevalence of psychiatric disorders in Taiwan defined by the Chinese Diagnostic Interview Schedule. <i>Acta Psychiatr Scand.</i> 1989; 79(2): 136-47.	1982-1986		
Taiwan (Province of China)	Tsai C-Y, Wong L-C, Chou P, Yang C-S, Sheu M-M, Wu J-R, Chuang T-L, Tung T-H. The current status of visual disability in the elderly population of Taiwan. <i>Jpn J Ophthalmol.</i> 2005; 49(2): 166-72, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2002		
Taiwan (Province of China)	Liu JH, Cheng CY, Chen SJ, Lee FL. Visual impairment in a Taiwanese population: prevalence, causes, and socioeconomic factors. <i>Ophthalmic Epidemiol.</i> 2001; 8(5): 339-50, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1993-1995		
Taiwan (Province of China)	Lin YJ, Huang LM, Lee CY, Chih TW, Lee PL, Chang LY, Hsu CM. A seroepidemiological study of Varicella-Zoster virus in Taipei City. <i>Acta Paediatr Sin.</i> 1996; 37(1): 11-5.	1992-1994		
Taiwan (Province of China)	Chang CK, Tan HF, Tseng HF, Lin CC. Analysis of factors associated with varicella-zoster virus susceptibility among children 0-12 years old in Taiwan. <i>Med Mal Infect.</i> 2007; 37(4): 222-8.	2003	*	
Taiwan (Province of China)	Tseng HF, Tan HF, Chang CK, Wang LY, Yang SE, Liu MY, Pan MJ, Chen CY, Huang SP. A seroepidemiology study of varicella among children aged 0-12 years in Taiwan. <i>Southeast Asian J Trop Med Public Health.</i> 2005; 36(5): 1201-7.	2003	*	
Taiwan (Province of China)	Chen Y-H, Keller J, Wang LT, Lin C-C, Lin H-C. Pneumonia and pregnancy outcomes: a nationwide population-based study. <i>Am J Obstet Gynecol.</i> 2012; 207(4): 288e1-7.	2005	*	
Taiwan (Province of China)	Wei P-L, Keller JJ, Liang H-H, Lin H-C. Acute appendicitis and adverse pregnancy outcomes: a nationwide population-based study. <i>J Gastrointest Surg.</i> 2012; 16(6): 1204-11.	2005	*	
Taiwan (Province of China)	Yang Y-W, Chen C-S, Chen Y-H, Lin H-C. Psoriasis and pregnancy outcomes: a nationwide population-based study. <i>J Am Acad Dermatol.</i> 2011; 64(1): 71-7.	2001-2003	*	
Taiwan (Province of China)	Chen C-C, Chen T-F, Hwang Y-C, Wen Y-R, Chiu Y-H, Wu C-Y, Chen R-C, Chen TH-H, Liou H-H. Population-based survey on prevalence of adult patients with epilepsy in Taiwan (Keelung community-based integrated screening no. 12). <i>Epilepsy Res.</i> 2006; 72(1): 67-74.	2001	*	
Taiwan (Province of China)	Su C, Chang S, Chen Z, Lee C, Chen R. Neuroepidemiological survey in Ilan, Taiwan (NEST): (4) Prevalence of epilepsy. <i>Acta Neurol Taiwan.</i> 1998; 7(2): 75-84.	1993-1995		†
Taiwan (Province of China)	Hsieh L-P, Huang C-Y. Prevalence of treated epilepsy in western medicine among the adult population in Taiwan: a study conducted using antiepileptic drug prescription data. <i>Epilepsy Res.</i> 2008; 80(2-3): 114-8.	2004		
Taiwan (Province of China)	Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, Chiang PH, Hsu CC, Sung PK, Hsu YH, Wen SF. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. <i>Lancet.</i> 2008; 371(9631): 2173-82.	1994-2006		
Taiwan (Province of China)	Hwang SJ, Lin MY, Chen HC, Hwang SC, Yang WC, Hsu CC, Chiu HC, Mau LW. Increased risk of mortality in the elderly population with late-stage chronic kidney disease: a cohort study in Taiwan. <i>Nephrol Dial Transplant.</i> 2008; 23(10): 3192-8.	2002-2004		
Taiwan (Province of China)	Chong MY, Tsang HY, Chen CS, Tang TC, Chen CC, Yeh TL, Lee YH, Lo HY. Community study of depression in old age in Taiwan: prevalence, life events and socio-demographic correlates. <i>Br J Psychiatry.</i> 2001; 178(1): 29-35.	1996-1998		
Taiwan (Province of China)	Hwu HG, Chang IH, Yeh EK, Chang CJ, Yeh LL. Major depressive disorder in Taiwan defined by the Chinese diagnostic Interview Schedule. <i>J Nerv Ment Dis.</i> 1996; 184(8): 497-502.	1982-1985		
Taiwan (Province of China)	Tsai J-F, Jeng J-E, Chuang L-Y, Ho M-S, Ko Y-C, Lin Z-Y, Hsieh M-Y, Chen S-C, Chuang W-L, Wang L-Y, Yu M-L, Dai C-Y, Ho C. Habitual betel quid chewing as a risk factor for cirrhosis: a case-control study. <i>Medicine (Baltimore).</i> 2003; 82(5): 365-72.	1996-1997		
Taiwan (Province of China)	Lee CM, Lu SN, Changchien CS, Yeh CT, Hsu TT, Tang JH, Wang JH, Lin DY, Chen CL, Chen WJ. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. <i>Cancer.</i> 1999; 86(7): 1143-50.	1996-1997	*	
Taiwan (Province of China)	Hsu CC, Hwang SJ, Wen CP, Chang HY, Chen T, Shiu RS, Hong SS, Chang YK, Yang WC. High prevalence and low awareness of CKD in Taiwan: a study on the relationship between serum creatinine and awareness from a nationally representative survey. <i>Am J Kidney Dis.</i> 2006; 48(5): 727-38.	2001-2002	*	
Taiwan (Province of China)	Wang SJ, Fuh JL, Lu SR, Liu CY, Hsu LC, Wang PN, Liu HC. Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up. <i>Neurology.</i> 2000; 54(2): 314-9.	1993-1994	*	
Taiwan (Province of China)	Lu SR, Fuh JL, Chen WT, Juang KD, Wang SJ. Chronic daily headache in Taipei, Taiwan: prevalence, follow-up and outcome predictors. <i>Cephalalgia.</i> 2001; 21(10): 980-6.	1997-1998	*	
Taiwan (Province of China)	Wang S-J, Fuh J-L, Lu S-R, Juang K-D. Chronic daily headache in adolescents: prevalence, impact, and medication overuse. <i>Neurology.</i> 2006; 66(2): 193-7.	2000		
Taiwan (Province of China)	Chiang S-C, Chen C-Y, Chang Y-Y, Sun H-J, Chen WJ. Prevalence of heroin and methamphetamine male users in the northern Taiwan, 1999-2002: capture-recapture estimates. <i>BMC Public Health.</i> 2007; 292.	1999-2002		
Taiwan (Province of China)	Lee T-C, Shih L-Y, Huang P-C, Lin C-C, Blackwell B-N, Blackwell RQ, Hsia DY-Y. Glucose-6-Phosphate Dehydrogenase Deficiency in Taiwan. <i>Am J Hum Genet.</i> 1963; 15(2): 126-32.	1961-1963		
Taiwan (Province of China)	Motulsky AG, Lee TC, Fraser GR. Glucose-6-phosphate dehydrogenase (G6PD) deficiency, thalassaemia, and abnormal haemoglobins in Taiwan. <i>J Med Genet.</i> 1965; 2(1): 18-20.	1963-1965		
Taiwan (Province of China)	Chiang SH, Wu SJ, Wu KF, Hsiao KJ. Neonatal screening for glucose-6-phosphate dehydrogenase deficiency in Taiwan. <i>Southeast Asian J Trop Med Public Health.</i> 1999; 72-4.	1987-1997		
Taiwan (Province of China)	Tang TK, Huang WY, Tang CJ, Hsu M, Cheng TA, Chen KH. Molecular basis of glucose-6-phosphate dehydrogenase (G6PD) deficiency in three Taiwan aboriginal tribes. <i>Hum Genet.</i> 1995; 95(6): 630-2.	1993-1995		
Taiwan (Province of China)	Yang WC, Hwang SJ. Taiwan Society of Nephrology. Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance. <i>Nephrol Dial Transplant.</i> 2008; 23(12): 3977-82.	1990-2001		
Taiwan (Province of China)	Global Lower Extremity Amputation Study Group. Epidemiology of lower extremity amputation in centres in Europe, North America and East Asia. <i>The Global Lower Extremity Amputation Study Group. Br J Surg.</i> 2000; 87(3): 328-37.	1995-1997	*	
Taiwan (Province of China)	Tseng C-H, Chong C-K, Tseng C-P, Cheng J-C, Wong M-K, Tai T-Y. Mortality, causes of death and associated risk factors in a cohort of diabetic patients after lower-extremity amputation: a 6.5-year follow-up study in Taiwan. <i>Atherosclerosis.</i> 2008; 197(1): 111-7.	1995-2001		
Taiwan (Province of China)	Taiwan Cancer Registry. Taiwan Cancer Incidence and Mortality 1980-2007. [Unpublished].	1980-2007	*	
Taiwan (Province of China)	Lai H, Lo M-T, Wang P-E, Wang T-T, Chen TH-H, Wu GH-M. A community-based epidemiological study of periodontal disease in Keelung, Taiwan: a model from Keelung community-based integrated screening programme (KCIS No. 18). <i>J Clin Periodontol.</i> 2007; 34(10): 851-9.	2003-2005	*	
Taiwan (Province of China)	Shen H-N, Lu C-L. Incidence, resource use, and outcome of acute pancreatitis with/without intensive care: a nationwide population-based study in Taiwan. <i>Pancreas.</i> 2011; 40(1): 10-15.	2005-2007		†
Taiwan (Province of China)	Fu C-Y, Yeh C-N, Hsu J-T, Jan Y-Y, Hwang T-L. Timing of mortality in severe acute pancreatitis: experience from 643 patients. <i>World J Gastroenterol.</i> 2007; 13(13): 1966-9.	1996-2005	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Taiwan (Province of China)	Chen CC, Chen TF, Hwang YC, Wen YR, Chiu YH, Wu CY, Chen RC, Tai JJ, Chen THH, Liou HH. Different prevalence rates of Parkinson's disease in urban and rural areas: a population-based study in Taiwan. <i>Neuroepidemiology</i> . 2009; 33(4): 350-7.	1999-2005		†
Taiwan (Province of China)	Lu S-R, Fuh J-L, Wang S-J, Juang K-D, Chen S-P, Liao Y-C, Wang Y-F. Incidence and risk factors of chronic daily headache in young adolescents: a school cohort study. <i>Pediatrics</i> . 2013; 132(1): e9-e16.	2005-2009	*	
Taiwan (Province of China)	Hung KL, Wang HS, Liou WY, Mak SC, Chi CS, Shen EY, Lin MI, Wang PJ, Shen YZ, Chang KP. Guillain-Barré syndrome in children: a cooperative study in Taiwan. <i>Brain Dev</i> . 1994; 16(3): 204-8.	1986-1990	*	
Taiwan (Province of China)	Jih J-S, Chen Y-J, Lin M-W, Chen Y-C, Chen T-J, Huang Y-L, Chen C-C, Lee D-D, Chang Y-T, Wang W-J, Liu H-N. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. <i>Acta Derm Venereol</i> . 2009; 89(6): 612-6.	2000-2006	*	
Taiwan (Province of China)	Hung TP, Landsborough D, Hsi MS. Multiple sclerosis amongst Chinese in Taiwan. <i>J Neurol Sci</i> . 1976; 27(4): 459-84.	1954-1975		
Taiwan (Province of China)	Tsai CP, Yuan CL, Yu HY, Chen C, Guo YC, Shan DE. Multiple sclerosis in Taiwan. <i>J Chin Med Assoc</i> . 2004; 67(10): 500-05.	1995-2002	*	
Taiwan (Province of China)	Wang PD, Lin RS. Epidemiologic differences between candidal and trichomonal infections as detected in cytologic smears in Taiwan. <i>Public Health</i> . 1995; 109(6): 443-50.	1991-1992	*	
Taiwan (Province of China)	Kuo C-F, Grainge MJ, See L-C, Yu K-H, Luo S-F, Valdes AM, Zhang W, Doherty M. Familial aggregation of gout and relative genetic and environmental contributions: a nationwide population study in Taiwan. <i>Ann Rheum Dis</i> . 2013.	2004	*	
Taiwan (Province of China)	Yu K-H, Kuo C-F, Luo S-F, See L-C, Chou I-J, Chang H-C, Chiou M-J. Risk of end-stage renal disease associated with gout: a nationwide population study. <i>Arthritis Res Ther</i> . 2012; 14(2): R83.	1996-1999	*	
Taiwan (Province of China)	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1995; 70(25): 177-82.	1994	*	
Taiwan (Province of China)	Cheng H-M, Sun H-Y, Lin DP-C, Chang H-H, Chen S-T, Yeh S-M, Peng M-L, Tseng J-K, Su K-C, Tseng K-W, Chen B-Y, Hsiao C-J, Huang S-Y, Cheng C-Y. Characterising visual deficits in children of an urban elementary school in Taiwan. <i>Clin Exp Optom</i> . 2012; 95(5): 531-7.	2009-2010		†
Taiwan (Province of China)	Chen S-J, Cheng C-Y, Li A-F, Peng K-L, Chou P, Chiou S-H, Hsu W-M. Prevalence and associated risk factors of myopic maculopathy in elderly Chinese: the Shihpai eye study. <i>Invest Ophthalmol Vis Sci</i> . 2012; 53(8): 4868-73.	2009-2011		
Taiwan (Province of China)	Lin C-C, Huang Y-H, Shu P-Y, Wu H-S, Lin Y-S, Yeh T-M, Liu H-S, Liu C-C, Lei H-Y. Characteristic of dengue disease in Taiwan: 2002-2007. <i>Am J Trop Med Hyg</i> . 2010; 82(4): 731-9.	2002-2007	*	
Taiwan (Province of China)	Yang YS, Lee TY, Chang FM, Ko TM. Chlamydia trachomatis infection in pregnant women. <i>J Formos Med Assoc</i> . 1988; 87(12): 1177-81.	1986		
Taiwan (Province of China)	Chien W-C, Lai C-H, Chung C-H, Lin C-H. A retrospective population-based data analyses of unintentional fall mortality and hospitalisation in Taiwan during 2005-2007. <i>Int J Inj Contr Saf Promot</i> . 2013; 20(1): 50-8.	2005-2007	*	
Taiwan (Province of China)	Chen C-H, Yang P-M, Huang G-T, Lee H-S, Sung J-L, Sheu J-C. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. <i>J Formos Med Assoc</i> . 2007; 106(2): 148-55.	1996-2005	*	
Taiwan (Province of China)	Department of Health (Taiwan). Taiwan Tuberculosis Control Report 2007. Taipei City, Taiwan: Department of Health (Taiwan), 2007.	2006-2007	*	
Taiwan (Province of China)	Department of Health (Taiwan). Taiwan Tuberculosis Control Report 2008. Taipei City, Taiwan: Department of Health (Taiwan), 2008.	2007-2008	*	
Taiwan (Province of China)	Department of Health (Taiwan). Taiwan Tuberculosis Control Report 2009. Taipei City, Taiwan: Department of Health (Taiwan), 2009.	2008-2009	*	
Taiwan (Province of China)	Department of Health (Taiwan). Taiwan Tuberculosis Control Report 2010. Taipei City, Taiwan: Department of Health (Taiwan), 2010.	2009-2010	*	
Taiwan (Province of China)	Department of Health (Taiwan). Taiwan Tuberculosis Control Report 2012. Taipei City, Taiwan: Department of Health (Taiwan), 2012.	2011-2012	*	
Taiwan (Province of China)	Chang H-C, Yen C-J, Lee Y-C, Chiu T-Y, Jan C-F. Seroprevalence of hepatitis B viral markers among freshmen—20 years after mass hepatitis B vaccination program in Taiwan. <i>J Formos Med Assoc</i> . 2007; 106(7): 513-9.	2003-2004	*	
Taiwan (Province of China)	Su F-H, Cheng S-H, Li C-Y, Chen J-D, Hsiao C-Y, Chien C-C, Yang Y-C, Hung H-H, Chu F-Y. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. <i>Vaccine</i> . 2007; 25(47): 8085-90.	2006	*	
Taiwan (Province of China)	Chien Y-H, Lee N-C, Wu S-T, Liou J-J, Chen H-C, Hwu W-L. Changes in incidence and sex ratio of glucose-6-phosphate dehydrogenase deficiency by population drift in Taiwan. <i>Southeast Asian J Trop Med Public Health</i> . 2008; 39(1): 154-61.	1996-2005	*	
Taiwan (Province of China)	Chen J-Y, Chiang J-C, Lu S-N, Hung S-F, Kao J-T, Yen Y-H, Wang J-H. Changing prevalence of anti-hepatitis A virus in adolescents in a rural township in Taiwan. <i>Chang Gung Med J</i> . 2010; 33(3): 321-6.	1999, 2006	*	
Taiwan (Province of China)	Su S-B, Lin C-Y, Sheu M-J, Kan W-C, Wang H-Y, Guo H-R. Decrease in seroprevalence of hepatitis A after the implementation of nationwide disposable tableware use in Taiwan. <i>BMC Public Health</i> . 2010; 719.	2005	*	
Taiwan (Province of China)	Yu K-H, See L-C, Kuo C-F, Chou I-J, Chou M-J. Prevalence and incidence in patients with autoimmune rheumatic diseases: a nationwide population-based study in Taiwan. <i>Arthritis Care Res (Hoboken)</i> . 2013; 65(2): 244-50.	2000-2008		
Taiwan (Province of China)	Su CH, Lui WY, Peng FK. Relative prevalence of gallstone diseases in Taiwan. A nationwide cooperative study. <i>Dig Dis Sci</i> . 1992; 37(5): 764-8.	1981-1982, 1988-1989	*	
Taiwan (Province of China)	Chen C-H, Huang M-H, Yang J-C, Nien C-K, Etheredge GD, Yang C-C, Yeh Y-H, Wu H-S, Chou D-A, Yueh S-K. Prevalence and risk factors of gallstone disease in an adult population of Taiwan: an epidemiological survey. <i>J Gastroenterol Hepatol</i> . 2006; 21(11): 1737-43.	2003-2004	*	
Taiwan (Province of China)	Lee C-C, Shih Y-L, Laio C-S, Lin S-M, Huang M-M, Chen C-J, Chen C-P, Chang C-L, Chen L-R, Tschen S-Y, Wang C-H. Prevalence of antibody to hepatitis E virus among haemodialysis patients in Taiwan: possible infection by blood transfusion. <i>Nephron Clin Pract</i> . 2005; 99(4): e122-127.	2002-2004	*	
Taiwan (Province of China)	Lin D-B, Lin J-B, Chen S-C, Yang C-C, Chen W-K, Chen C-J. Seroprevalence of hepatitis E virus infection among preschool children in Taiwan. <i>J Med Virol</i> . 2004; 74(3): 414-8.	2001-2003	*	†
Taiwan (Province of China)	Peng CF, Lin MR, Chue PY, Tsai JF, Shih CH, Chen IL, He J, Carl M. Prevalence of antibody to hepatitis E virus among healthy individuals in southern Taiwan. <i>Microbiol Immunol</i> . 1995; 39(9): 733-6.	1993-1994		
Taiwan (Province of China)	Weng Y-H, Chiu Y-W. Spectrum and outcome analysis of marked neonatal hyperbilirubinemia with blood group incompatibility. <i>Chang Gung Med J</i> . 2009; 32(4): 400-8.	1995-2007		
Taiwan (Province of China)	Lin YH, Huang LM, Chang IS, Tsai FY, Lu CY, Shao PL, Chang LY. Varicella-Zoster Working Group. Advisory Committee on Immunization Practices, Taiwan. Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan. <i>Vaccine</i> . 2010; 28(5): 1217-20.	2000-2005		
Taiwan (Province of China)	Tsen YJ, Chang MH, Hsu HY, Lee CY, Sung JL, Chen DS. Seroprevalence of hepatitis B virus infection in children in Taipei, 1989: five years after a mass hepatitis B vaccination program. <i>J Med Virol</i> . 1991; 34(2): 96-9.	1984, 1989		
Taiwan (Province of China)	Wang CS, Wang ST, Chou P. Using the prevalence of an elevated serum alanine aminotransferase level for identifying communities with a high prevalence of hepatitis C virus infection. <i>Arch Intern Med</i> . 2001; 161(3): 392-4.	1999	*	
Taiwan (Province of China)	Wang L-Y, Hu C-T, Ho T-Y, Lin HH. Geographic and ethnic variations of long-term efficacy and immunogenicity of hepatitis B vaccination in Hualien, a HBV hyperendemic area. <i>Vaccine</i> . 2006; 24(20): 4427-32.	2002-2004	*	
Taiwan (Province of China)	Huang WY, Chen YF, Chen SC, Lee YJ, Lan CF, Huang KH. Pediatric urolithiasis in Taiwan: a nationwide study, 1997-2006. <i>Urology</i> . 2012; 79(6): 1355-9.	1997-2006		
Taiwan (Province of China)	Hu HH, Sheng WY, Chu FL, Lan CF, Chiang BN. Incidence of stroke in Taiwan. <i>Stroke</i> . 1992; 23: 1237-1241.	1986-1990	*	
Taiwan (Province of China)	Liu CK, Lin RT, Chen YF, Tai CT, Yen YY, Howng SL. Prevalence of dementia in an urban area in Taiwan. <i>J Formos Med Assoc</i> . 1996; 95(10): 762-8.	1989-1995	*	†
Tajikistan	National State Statistical Agency (Tajikistan), United Nations Children's Fund (UNICEF). Tajikistan Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Tajikistan	United Nations Children's Fund (UNICEF), State Committee on Statistics of the Republic of Tajikistan. Tajikistan Multiple Indicator Cluster Survey 2005. New York, United States: United Nations Children's Fund (UNICEF).	2005		
Tajikistan	ICF International, Ministry of Health (Tajikistan), Statistical Agency under the President of the Republic of Tajikistan. Tajikistan Demographic and Health Survey 2012. Fairfax, United States: ICF International, 2013.	2012		†
Tajikistan	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists' Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Tajikistan	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		
Tajikistan	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1999, 2001-2004, 2006		
Tajikistan	Torgerson PR, Oguljahan B, Muminov AE, Karaeva RR, Kuttubaev OT, Aminjanov M, Shaikenov B. Present situation of cystic echinococcosis in Central Asia. Parasitol Int. 2006; 55(1): S207-S212.	1992, 2002	*	
Tajikistan	National Center of Urology (Tajikistan). Tajikistan Dialysis Report 1977-2011. [Unpublished].	1977-1992, 2005-2010	*	
Tajikistan	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010	*	
Tajikistan	Rebholz CE, Michel AJ, Maselli DA, Saipphudin K, Wyss K. Frequency of malaria and glucose-6-phosphate dehydrogenase deficiency in Tajikistan. Malar J. 2006; 5:1.	2004-2006		
Tajikistan	World Health Organization (WHO). Tajikistan WHO Leishmaniasis Country Profile.	1994-2008	*	†
Tajikistan	Rafiev KK. [Viral hepatitis E: its epidemiological characteristics in the Republic of Tajikistan]. Zh Mikrobiol Epidemiol Immunobiol. 1999; 26:9.	1998	*	†
Tajikistan	Mazières S, Temory SA, Vasseur H, Gallian P, Di Cristofaro J, Chiaroni J. Blood group typing in five Afghan populations in the North Hindu-Kush region: implications for blood transfusion practice. Transfus Med. 2013; 23(3): 167-74.	2009-2011	*	†
Tajikistan	Roll Back Malaria Field Project in Tajikistan as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001		
Tajikistan	Matthys B, Sherkanov T, Karimov SS, Khabirov Z, Mostowlansky T, Utzinger J, Wyss K. History of malaria control in Tajikistan and rapid malaria appraisal in an agro-ecological setting. Malar J. 2008; 7: 217 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2007	*	†
Tajikistan	USSR - Tajik SSR Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD), United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		†
Tanzania	Tanzania HIV/AIDS and Malaria Indicator Survey 2007-2008, as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2007-2008		†
Tanzania	Bureau of Statistics (Tanzania), Macro International, Inc, Ministry of Health (Tanzania). Tanzania Demographic and Health Survey 1991-1992. Calverton, United States: Macro International, Inc.	1991-1992		†
Tanzania	Bureau of Statistics (Tanzania), Macro International, Inc, Planning Commission (Tanzania). Tanzania Demographic and Health Survey 1996. Calverton, United States: Macro International, Inc.	1996		†
Tanzania	Bureau of Statistics (Tanzania), Macro International, Inc. Tanzania Demographic and Health Survey 1999. Calverton, United States: Macro International, Inc.	1999		†
Tanzania	Macro International, Inc, National Bureau of Statistics (Tanzania). Tanzania Demographic and Health Survey 2004-2005. Calverton, United States: Macro International, Inc.	2004-2005	*	†
Tanzania	ICF Macro, National Bureau of Statistics (Tanzania). Tanzania Demographic and Health Survey 2009-2010. Calverton, United States: ICF Macro.	2009-2010	*	†
Tanzania	Tanzania AIDS Indicator Survey 2011-2012 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2011-2012		
Tanzania	Economic Development Initiatives (EDI), Muhimbili University of Health and Allied Sciences (Tanzania), Rockwool Foundation Research Unit. Tanzania - Kagera Living Standards Measurement Study 2010. Washington DC, United States: World Bank.	2010		†
Tanzania	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists' Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		†
Tanzania	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		
Tanzania	Forsyth DM, Bradley DJ. The consequences of Bilharziasis. Medical and public health importance in North-west Tanzania. Bull World Health Organ. 1966; 34(5): 715-35.	1965		†
Tanzania	Forsyth D, Bradley D. Irreversible damage by schistosoma haematobium in schoolchildren. Lancet. 1964; 2(7352): 169-7.	1962		
Tanzania	Forsyth DM. Anaemia in Zanzibar. Trans R Soc Trop Med Hyg. 1970; 64(4): 601-6.	1964-1965		†
Tanzania	Jordan P, Randall K. Bilharziasis in Tanganyika: observations on its effects and the effects of treatment in schoolchildren. J Trop Med Hyg. 1962; 65: 1-6.	1962	*	†
Tanzania	Jukes MCH, Nokes CA, Alcock KJ, Lambo JK, Kihamia C, Ngorosho N, Mbise A, Lorri W, Yona E, Mwanri L, Baddeley AD, Hall A, Bundy DAP. Heavy schistosomiasis associated with poor short-term memory and slower reaction times in Tanzanian schoolchildren. Trop Med Int Health. 2002; 7(2): 104-17.	1997		
Tanzania	Jukes MCH, Nokes CA, Alcock KJ, Lambo JK, Kihamia C, Ngorosho N, Mbise A, Lorri W, Yona E, Mwanri L, Baddeley AD, Hall A, Bundy DAP. Heavy schistosomiasis associated with poor short-term memory and slower reaction times in Tanzanian schoolchildren. Trop Med Int Health. 2002; 7(2): 104-17 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997-1998		
Tanzania	Meakins RH, Harland PS, Carswell F. A preliminary survey of malnutrition and helminthiasis among schoolchildren in one mountain and one lowland ujamaa village in Northern Tanzania. Trans R Soc Trop Med Hyg. 1981; 75(5): 731-5.	1976		
Tanzania	Swai B, Poggensee G, Mtweve S, Krantz I. Female genital schistosomiasis as an evidence of a neglected cause for reproductive ill-health: a retrospective histopathological study from Tanzania. BMC Infect Dis. 2006; 6: 134.	1999-2005		
Tanzania	Gibbs, S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int J Dermatol. 1996; 35(9): 633-9.	1994-1995		
Tanzania	Feríé J, Dinkela A, Mbata M, Idindili B, Schmid-Grendelmeier P, Hatz C. Skin disorders among school children in rural Tanzania and an assessment of therapeutic needs. Trop Doct. 2006; 36(4): 219-21.	2003		
Tanzania	Komba EV, Mgonda YM. The spectrum of dermatological disorders among primary school children in Dar es Salaam. BMC Public Health. 2010; 10(1): 765.	2007-2010		
Tanzania	Bastos I, Malyla J, Ingarsson L, Reimer A, Andréasson L. Middle ear disease and hearing impairment in northern Tanzania A prevalence study of schoolchildren in the Moshi and Monduli districts. Int J Pediatr Otorhinolaryngol. 1995; 32(1): 1-12.	1992-1993		
Tanzania	Minja BM, Machecha A. Prevalence of otitis media, hearing impairment and cerumen impaction among school children in rural and urban Dar es Salaam, Tanzania. Int J Pediatr Otorhinolaryngol. 1996; 37(1): 29-34.	1993-1996		
Tanzania	Satimia FT, McBride SR, Leppard B. Prevalence of skin disease in rural Tanzania and factors influencing the choice of health care, modern or traditional. Arch Dermatol. 1998; 134(11): 1363-6.	1995-1996		
Tanzania	Henderson CA. Skin disease in rural Tanzania. Int J Dermatol. 1996; 35(9): 640-2.	1991		
Tanzania	Mwenda JM, Noto KM, Abebe A, Enweronu-Laryea C, Amina I, Mchomvu J, Kisakye A, Mpabalwani EM, Pazvakambwa I, Armah GE, Seheri LM, Kiulia NM, Page N, Widdowson M-A, Steele AD. Burden and epidemiology of rotavirus diarrhea in selected African countries: preliminary results from the African Rotavirus Surveillance Network. J Infect Dis. 2010; 202(Suppl): S5-11.	2007-2008		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Tanzania	Makani J, Cox SE, Soka D, Komba AN, Oruo J, Mwamtemi H, Magesa P, Rwezuala S, Meda E, Mgaya J, Lowe B, Muturi D, Roberts DJ, Williams TN, Pallangyo K, Kitundu J, Fegan G, Kirkham FJ, Marsh K, Newton CR. Mortality in sickle cell anemia in Africa: a prospective cohort study in Tanzania. <i>PLoS One</i> . 2011; 2(6): e14699.	2004-2009		
Tanzania	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997, 2002, 2004-2007		†
Tanzania	Downs JA, Mguta C, Kaatano GM, Mitchell KB, Kinung'hi S, Simplice H, Kalluvya SE, Changalucha JM, Johnson WD Jr, Fitzgerald DW. Female urogenital schistosomiasis in Tanzania's Lake Zone region: a highly-sporadic distribution [Abstract]. <i>Am J Trop Med Hyg</i> . 2010; 83(Suppl 5): 211-82.	2009-2010		
Tanzania	Guyatt HL, Brooker S, Kihamia CM, Hall A, Bundy DA. Evaluation of efficacy of school-based anthelmintic treatments against anaemia in children in the United Republic of Tanzania. <i>Bull World Health Organ</i> . 2001; 79(8): 695-703.	1995-1997		†
Tanzania	Klinger, E.V. Measuring micro-albuminuria: An innovative approach to estimating Intensity of Schistosoma haematobium infection in zanzibari school children. Cambridge, MA: Harvard Center for Population and Development Studies; 2004. 41 p. (Working paper series; vol 14 no. 5).	2004		
Tanzania	Lwambo NJ, Brooker S, Siza JE, Bundy DA, Guyatt H. Age patterns in stunting and anaemia in African schoolchildren: a cross-sectional study in Tanzania. <i>Eur J Clin Nutr</i> . 2000; 54(1): 36-40.	1995-1999		
Tanzania	Poggensee G, Krantz J, Kiwelu I, Feldmeier H. Screening of Tanzanian women of childbearing age for urinary schistosomiasis: validity of urine reagent strip readings and self-reported symptoms. <i>Bull World Health Organ</i> . 2000; 78(4): 542-8.	1995		
Tanzania	Rollinson D, Klinger EV, Mgeni AF, Khamis IS, Stothard JR. Urinary schistosomiasis on Zanzibar: application of two novel assays for the detection of excreted albumin and haemoglobin in urine. <i>J Helminthol</i> . 2005; 79(3): 199-206.	2004		
Tanzania	Rugemalila JB. The impact of urinary schistosomiasis on the health of two community populations living in endemic areas in Tanzania. <i>Trop Geogr Med</i> . 1979; 31(3): 375-80.	1978-1979		
Tanzania	Tatala S, Svanberg U, Mduma B. Low dietary iron availability is a major cause of anemia: a nutrition survey in the Lindi District of Tanzania. <i>Am J Clin Nutr</i> . 1998; 68(1): 171-8.	1992		
Tanzania	Abbas ZG, Lutale JK, Bakker K, Baker N, Archibald LK. The 'Step by Step' Diabetic Foot Project in Tanzania: a model for improving patient outcomes in less-developed countries. <i>Int Wound J</i> . 2011; 8(2): 169-75.	2005-2006		
Tanzania	Majaliwa ES, Munubhi E, Ramaiya K, Mpenbeni R, Sanyasiwa A, Mohn A, Chiarelli F. Survey on acute and chronic complications in children and adolescents with type 1 diabetes at Muhimbili National Hospital in Dar es Salaam, Tanzania. <i>Diabetes Care</i> . 2007; 30(9): 2187-92.	2005-2006		
Tanzania	McLarty DG, Swai AB, Kitange HM, Masuki G, Mfinangi BL, Kilima PM, Makene WJ, Chuwa LM, Alberti KG. Prevalence of diabetes and impaired glucose tolerance in rural Tanzania. <i>Lancet</i> . 1989; 1(8643): 871-5.	1987		
Tanzania	Swai AB, McLarty DG, Mfinangi BL, Tatala S, Kitange HM, Mlingi N, Rosling H, Howlett WP, Brubaker GR, Alberti KG. Diabetes is not caused by cassava toxicity. A study in a Tanzanian community. <i>Diabetes Care</i> . 1992; 15(10): 1378-85.	1989	*	
Tanzania	Dent W, Spiss H, Helbok R, Matuja W, Scheunemann S, Schmutzhard E. Prevalence of migraine in a rural area in South Tanzania: a door-to-door survey. <i>Cephalalgia</i> . 2004; 24(11): 960-6.	1999	*	
Tanzania	Masumo R, Bardsen A, Mashoto K, Åström AN. Prevalence and socio-behavioral influence of early childhood caries, ECC, and feeding habits among 6-36 months old children in Uganda and Tanzania. <i>BMC Oral Health</i> . 2012; 24.	2007, 2010-2011	*	
Tanzania	Mbawalla HS, Mtaya M, Masalu JR, Brudvik P, Astrom AN. Discriminative ability of the generic and condition-specific Child-Oral Impacts on Daily Performances (Child-OIDP) by the Limpopo-Arusha School Health (LASH) project: a cross-sectional study. <i>BMC Pediatr</i> . 2011; 45.	2006, 2009	*	
Tanzania	Rwakatema DS, Ng'anga PM. Early childhood caries in Moshi, Tanzania. <i>East Afr Med J</i> . 2010; 87(7): 304-10.	2008	*	
Tanzania	Mumghamba EG, Markkanen HA, Honkala E. Periodontal status and treatment needs in a rural area of Ukonga, Tanzania. <i>Int Dent J</i> . 1996; 46(3): 156-60.	1994	*	
Tanzania	Assey VD, Mgoba C, Mlingi N, Sanga A, Ndossi GD, Greiner T, Peterson S. Remaining challenges in Tanzania's efforts to eliminate iodine deficiency. <i>Public Health Nutr</i> . 2007; 10(10): 1032-8.	1999		
Tanzania	Cox SE, Makani J, Fulford AJ, Komba AN, Soka D, Williams TN, Newton CR, Marsh K, Prentice AM. Nutritional status, hospitalization and mortality among patients with sickle cell anemia in Tanzania. <i>Haematologica</i> . 2011; 96(7): 948-53.	2004-2009		
Tanzania	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Tanzania	Paddick S-M, Longdon AR, Kisoli A, Dotchin C, Gray WK, Dewhurst F, Chaote P, Kalaria R, Jusabani AM, Walker R. Dementia prevalence estimates in sub-Saharan Africa: comparison of two diagnostic criteria. <i>Glob Health Action</i> . 2013; 6: 19646.	2009-2010		
Tanzania	Frencken J, Manji F, Moshia H. Dental caries prevalence amongst 12-year-old urban children in East Africa. <i>Community Dent Oral Epidemiol</i> . 1986; 14(2): 94-8.	1984		
Tanzania	Mosha HJ, Fejerskov O, Langebaek J, Thylstrup A, Baelum V, Manji F. Caries experience in urban Tanzanian children 1973-84. <i>Scand J Dent Res</i> . 1988; 96(5): 385-9.	1973-1985		
Tanzania	Frencken JE, Truin GJ, König KG, Ruiken RM, Elvers HJ. Prevalence of caries, plaque and gingivitis in an urban and rural Tanzanian child population. <i>Community Dent Oral Epidemiol</i> . 1986; 14(3): 161-4.	1984		
Tanzania	Mosha HJ, Scheutz F. Dental caries in the permanent dentition of schoolchildren in Dar es Salaam in 1979, 1983 and 1989. <i>Community Dent Oral Epidemiol</i> . 1992; 20(6): 381-2.	1979		
Tanzania	Kikwilu EN, Mandari GJ. Dental caries and periodontal conditions among primary school children in Morogoro municipality, Tanzania. <i>East Afr Med J</i> . 2001; 78(3): 152-6.	2000		
Tanzania	Kerosuo H, Honkala E. Caries experience in the primary dentition of Tanzanian and Finnish 3-7-year-old children. <i>Community Dent Oral Epidemiol</i> . 1991; 19(5): 272-6.	1984		
Tanzania	Petersen PE, Mzee MO. Oral health profile of schoolchildren, mothers and schoolteachers in Zanzibar. <i>Community Dent Health</i> . 1998; 15(4): 256-62.	1996		
Tanzania	Walker R, Unwin N, Mugusi F, Swai M, Aris E, Jusabani A, Kabadi G, Gray W, Lewanga M, Alberti G, Whiting D. Stroke incidence in rural and urban Tanzania: a prospective, community-based study. <i>Lancet Neurol</i> . 2010; 9(8): 786-92.	2003-2006		
Tanzania	Walker RW, McLarty DG, Kitange HM, Whiting D, Masuki G, Mtasiwa DM, Machibya H, Unwin N, Alberti KGMM. Stroke mortality in urban and rural Tanzania. <i>Lancet</i> . 2000; 355(9216): 1684.	1992-1995		
Tanzania	Prytherch H, Massawe S, Kuelker R, Hunger C, Mtiatifikolo F, Jahn A. The unmet need for Emergency Obstetric Care in Tanga Region, Tanzania. <i>BMC Pregnancy Childbirth</i> . 2007; 7(16).	2000-2002		
Tanzania	Walker R, McLarty D, Masuki G, Kitange H, Whiting D, Moshi A, Massawe J, Amaro R, Mhina A, Alberti K. Age specific prevalence of impairment and disability relating to hemiplegic stroke in the Hai District of northern Tanzania. <i>J Neurol Neurosurg Psychiatry</i> . 2000; 68(6): 744-9.	1994		†
Tanzania	Klinger EV, Kapiga SH, Sam NE, Aboud S, Chen C-Y, Ballard RC, Larsen U. A community-based study of risk factors for Trichomonas vaginalis infection among women and their male partners in Moshi urban district, northern Tanzania. <i>Sex Transm Dis</i> . 2006; 33(12): 712-8.	2002-2003		
Tanzania	Bondestam S, Garsen J, Abdulwakil AI. Prevalence and treatment of mental disorders and epilepsy in Zanzibar. <i>Acta Psychiatr Scand</i> . 1990; 81(4): 327-31.	1988		
Tanzania	Tanzania - Zanzibar Rapid Assessment of Avoidable Blindness 2007 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2007		
Tanzania	Rapoza PA, West SK, Katala SJ, Taylor HR. Prevalence and causes of vision loss in central Tanzania. <i>Int Ophthalmol</i> . 1991; 15(2): 123-9, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1986	*	
Tanzania	Habiyakire C, Kabona G, Courtright P, Lewallen S. Rapid assessment of avoidable blindness and cataract surgical services in Kilimanjaro region, Tanzania. <i>Ophthalmic Epidemiol</i> . 2010; 17(2): 90-4, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2007	*	
Tanzania	Burton KJ, Rogathe J, Whittaker R, Mankad K, Hunter E, Burton MJ, Todd J, Neville BGR, Walker R, Newton CRJC. Epilepsy in Tanzanian children: association with perinatal events and other risk factors. <i>Epilepsia</i> . 2012; 53(4): 752-60.	2009	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Tanzania	Hunter E, Rogathi J, Chigudu S, Jusabani A, Jackson M, McNally R, Gray W, Whittaker RG, Iqbal A, Birchall D, Aris E, Walker R. Prevalence of active epilepsy in rural Tanzania: a large community-based survey in an adult population. <i>Seizure</i> . 2012; 21(9): 691-8.	2009	*	
Tanzania	Ngugi AK, Bottomley C, Kleinschmidt I, Wagner RG, Kakuza-Mwesige A, Ae-Ngibise K, Owusu-Agyei S, Masanja H, Kamuyu G, Odhiambo R, Chengo E, Sander JW, Newton CR, SEEDS group. Prevalence of active convulsive epilepsy in sub-Saharan Africa and associated risk factors: cross-sectional and case-control studies. <i>Lancet Neurol</i> . 2013; 12(3): 253-63.	2009	*	
Tanzania	Winkler AS, Kerschbaumsteiner K, Stelzhammer B, Meindl M, Kaaya J, Schmutzhard E. Prevalence, incidence, and clinical characteristics of epilepsy—a community-based door-to-door study in northern Tanzania. <i>Epilepsia</i> . 2009; 50(10): 2310-3.	1999-2004	*	†
Tanzania	Neissen EJ, Mduma E, Ersdal HL, Evjen-Olsen B, van Roosmalen JJ, Stekelburg J. Maternal near miss and mortality in a rural referral hospital in northern Tanzania: a cross-sectional study. <i>BMC Pregnancy Childbirth</i> . 2013; 13(1): 141.	2009-2011	*	
Tanzania	Ndaboine EM, Kihunrwa A, Rumanyika R, Im HB, Massinde AN. Maternal and perinatal outcomes among eclamptic patients admitted to Bugando Medical Centre, Mwanza, Tanzania. <i>Afr J Reprod Health</i> . 2012; 16(1): 35-41.	2009-2010	*	
Tanzania	Tuffon N, Patel RR. Prevalence of hypertensive disorders in a prenatal clinic in Zanzibar. <i>Int J Gynaecol Obstet</i> . 2011; 112(1): 69-70.	2007	*	
Tanzania	Walker RW, Jusabani A, Aris E, Gray WK, Mugusi F, Swai M, Alberti KG, Unwin N. Correlates of short- and long-term case fatality within an incident stroke population in Tanzania. <i>S Afr Med J</i> . 2013; 103(2): 107-12.	2003-2006	*	
Tanzania	Rwiza H, Kilongo G, Haule J, Matuja W, Mteza I, Mbena P, Kilima P, Mwaluko G, Mwangombola R, Mwaijande F. Prevalence and incidence of epilepsy in Ulugua, a rural Tanzanian district: a community-based study. <i>Epilepsia</i> . 1992; 33(6).	1979-1989	*	†
Tanzania	Dent W, Helbok R, Matuja WBP, Scheunemann S, Schmutzhard E. Prevalence of active epilepsy in a rural area in South Tanzania: a door-to-door survey. <i>Epilepsia</i> . 2005; 46(12): 1963-9.	1999	*	†
Tanzania	Matuja WB, Kilongo G, Mbena P, Mwangombola RL, Wong P, Goodfellow P, Jilek-Aall L. Risk factors for epilepsy in a rural area in Tanzania. A community-based case-control study. <i>Neuroepidemiology</i> . 2001; 20(4): 242-7.	2000	*	
Tanzania	Mosser P, Schmutzhard E, Winkler AS. The pattern of epileptic seizures in rural Tanzania. <i>J Neurol Sci</i> . 2007; 258(1-2): 33-8.	2002-2003	*	
Tanzania	World Health Organization (2005). Study on Global Ageing and Adult Health (SAGE), Pilot Study. 2005 (Data Set 27-28, Cunningham, Shanya.) [machine-readable data file and documentation]. Geneva, Switzerland: World Health Organization (Producer). Los Altos, CA: Sociometrics Corporation, Data Archive of Social Research on Aging (Producer & Distributor).	2005	*	
Tanzania	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2012	*	
Tanzania	Mwansasu A, Mwakagile D, Haarr L, Langeland N. Detection of HSV-2 in genital ulcers from STD patients in Dar es Salaam, Tanzania. <i>J Clin Virol</i> . 2002; 24(3): 183-92.	1999-2001	*	†
Tanzania	Msuya SE, Mbizvo E, Hussain A, Sam NE, Jeansson S, Stray-Pedersen B. Seroprevalence and correlates of herpes simplex virus type 2 among urban Tanzanian women. <i>Sex Transm Dis</i> . 2003; 30(7): 588-92.	1999	*	
Tanzania	Mwakysa SD, Manji KP, Massawe AW. The hypoxic ischaemic encephalopathy score in predicting neurodevelopmental outcomes among infants with birth asphyxia at the Muhimbili National Hospital, Dar-es-Salaam, Tanzania. <i>J Trop Pediatr</i> . 2009; 55(1): 8-14.	2002-2003	*	
Tanzania	Swai AB, Lutale JL, McLarty DG. Prospective study of incidence of juvenile diabetes mellitus over 10 years in Dar es Salaam, Tanzania. <i>BMJ</i> . 1993; 306(6892): 1570-2.	1982-1991	*	
Tanzania	Eddy KT, Hennessey M, Thompson-Brenner H. Eating pathology in East African women: the role of media exposure and globalization. <i>J Nerv Ment Dis</i> . 2007; 195(3): 196-202.	2005	*	
Tanzania	Marti HR, Schoepf K, Gsell OR. Frequency of Haemoglobin S and Glucose-6-Phosphate Dehydrogenase Deficiency in Southern Tanzania. <i>Br Med J</i> . 1965; 1(5448): 1476-7.	1964	*	
Tanzania	Dewhurst F, Dewhurst MJ, Gray WK, Aris E, Orega G, Howlett W, Warren N, Walker RW. The prevalence of neurological disorders in older people in Tanzania. <i>Acta Neurol Scand</i> . 2013; 127(3): 198-207.	2009-2010	*	
Tanzania	Dotchin C, Msuya O, Kissima J, Massawe J, Mhina A, Moshy A, Aris E, Jusabani A, Whiting D, Masuki G, Walker R. The prevalence of Parkinson's disease in rural Tanzania. <i>Mov Disord</i> . 2008; 23(11): 1567-672.	2003-2006	*	†
Tanzania	Winkler AS, Dent W, Stelzhammer B, Kerschbaumsteiner K, Meindl M, Kaaya J, Matuja WBP, Schmutzhard E. Prevalence of migraine headache in a rural area of northern Tanzania: a community-based door-to-door survey. <i>Cephalalgia</i> . 2010; 30(5): 582-92.	2003-2004	*	
Tanzania	Howlett WP, Vedeler CA, Nyland H, Aarli JA. Guillain-Barré syndrome in northern Tanzania: a comparison of epidemiological and clinical findings with western Norway. <i>Acta Neurol Scand</i> . 1996; 93(1): 44-9.	1984-1992	*	
Tanzania	Mwakagile D, Swai AB, Sandström E, Urassa E, Biberfeld G, Mhalu FS. High frequency of sexually transmitted diseases among pregnant women in Dar es Salaam, Tanzania: need for intervention. <i>East Afr Med J</i> . 1996; 73(10): 675-8.	1993	*	
Tanzania	Minja BM. Aetiology of deafness among children at the Buguruni School for the Deaf in Dar es Salaam, Tanzania. <i>Int J Pediatr Otorhinolaryngol</i> . 1998; 42(3): 225-31.	1974-1994	*	†
Tanzania	Ministry of Health and Social Welfare (Tanzania). Tanzania Tuberculosis Prevalence Survey 2012.	2012	*	†
Tanzania	Alonso PL, Smith T, Schellenberg JR, Masanja H, Mwankusye S, Urassa H, Bastos de Azevedo I, Chongela J, Kobero S, Menendez C. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. <i>Lancet</i> . 1994; 344(8931): 1175-81 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993	*	
Tanzania	Lemnge MM, Msangeni HA, Rønn AM, Salum FM, Jakobsen PH, Mhina JL, Akida JA, Bygbjerg KC. Maloprim malaria prophylaxis in children living in a holoendemic village in north-eastern Tanzania. <i>Trans R Soc Trop Med Hyg</i> . 1997; 91(1): 68-73 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993	*	
Tanzania	Meyrowitsch DW, Simonsen PE, Makunde WH. Bancroftian filariasis: analysis of infection and disease in five endemic communities of north-eastern Tanzania. <i>Ann Trop Med Parasitol</i> . 1995; 89(6): 653-63. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1991-1992	*	
Tanzania	Pedersen EM, Kilama WL, Swai AB, Kihamia CM, Rwiza H, Kisumku UM. Bancroftian filariasis on Pemba Island, Zanzibar, Tanzania: an update on the status in urban and semi-urban communities. <i>Trop Med Int Health</i> . 1999; 4(4): 295-301. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1990	*	
Tanzania	Simonsen PE, Meyrowitsch DW, Makunde WH, Magnussen P. Bancroftian filariasis: the pattern of microfilaraemia and clinical manifestations in three endemic communities of Northeastern Tanzania. <i>Acta Trop</i> . 1995; 60(3): 179-87. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1991-1994	*	
Tanzania	Simonsen PE, Derua YA, Kisinza WN, Magesa SM, Malecela MN, Pedersen EM. Lymphatic filariasis control in Tanzania: effect of six rounds of mass drug administration with ivermectin and albendazole on infection and transmission. <i>BMC Infect Dis</i> . 2013; 13: 335. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2004, 2006-2011	*	
Tanzania	Simonsen PE, Pedersen EM, Rwegoshora RT, Malecela MN, Derua YA, Magesa SM. Lymphatic filariasis control in Tanzania: effect of repeated mass drug administration with ivermectin and albendazole on infection and transmission. <i>PLoS Negl Trop Dis</i> . 2010; 4(6): e966. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2004, 2006-2008	*	
Tanzania	Gasarasi DB, Premji ZG, Mujinja PG, Mpenbeni R. Acute adenolymphangitis due to bancroftian filariasis in Rufiji district, south east Tanzania. <i>Acta Trop</i> . 2000; 75(1): 19-28. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1992-1997	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Tanzania	Simonsen PE, Meyrowitsch DW, Jaoko WG, Malecela MN, Mukoko D, Pedersen EM, Ouma JH, Rwegoshora RT, Masese N, Magnussen P, Estambale BBA, Michael E. Bancroftian filariasis infection, disease, and specific antibody response patterns in a high and a low endemicity community in East Africa. <i>Am J Trop Med Hyg.</i> 2002; 66(5): 550-9. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1998	*	
Tanzania	Simonsen PE, Bernhard P, Jaoko WG, Meyrowitsch DW, Malecela-Lazaro MN, Magnussen P, Michael E. Filaria dance sign and subclinical hydrocoele in two east African communities with bancroftian filariasis. <i>Trans R Soc Trop Med Hyg.</i> 2002; 96(6): 649-53.	1998		
Tanzania	Bernhard P, Makunde RW, Magnussen P, Lemnge MM. Genital manifestations and reproductive health in female residents of a Wuchereria bancrofti-endemic area in Tanzania. <i>Trans R Soc Trop Med Hyg.</i> 2000; 94(4): 409-12. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1998	*	
Tanzania	Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. <i>Int J Health Geogr.</i> 2010; 9: 57.	1980-2010	*	
Tanzania	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec.</i> 2006; 81(32): 309-16.	2005		
Tanzania	World Health Organization (WHO). Global leprosy situation, 2008 (additional information). <i>Wkly Epidemiol Rec.</i> 2008; 83(50): 459.	2007	*	
Tanzania	Tanzania MICAH Program Survey Report as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1996-2000	*	
Tanzania	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Tanzania	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Tanzania	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Tanzania	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Tanzania	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Tanzania	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Tanzania	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994		
Tanzania	Clift S, Anemona A, Watson-Jones D, Kanga Z, Ndeki L, Chungalucha J, Gavyole A, Ross DA. Variations of HIV and STI prevalences within communities neighbouring new goldmines in Tanzania: importance for intervention design. <i>Sex Transm Infect.</i> 2003; 79(4): 307-12.	2000-2001	*	
Tanzania	Msuya SE, Mbitzo EM, Stray-Pedersen B, Uriyo J, Sam NE, Rusakaniko S, Hussain A. Decline in HIV prevalence among women of childbearing age in Moshi urban, Tanzania. <i>Int J STD AIDS.</i> 2007; 18(10): 680-7.	2002-2004	*	
Tanzania	Msuya SE, Uriyo J, Hussain A, Mbitzo EM, Jeansson S, Sam NE, Stray-Pedersen B. Prevalence of sexually transmitted infections among pregnant women with known HIV status in northern Tanzania. <i>Reprod Health.</i> 2009; 4.	2002-2004		
Tanzania	Obasi A, Moshia F, Quigley M, Sekirassa Z, Gibbs T, Munguti K, Todd J, Grosskurth H, Mayaud P, Chungalucha J, Brown D, Mabej D, Hayes R. Antibody to herpes simplex virus type 2 as a marker of sexual risk behavior in rural Tanzania. <i>J Infect Dis.</i> 1999; 179(1): 16-24.	1993		
Tanzania	Tantengco VO, Marzan AM, Rapanot N, Villanueva L, De Castro CR. Nutritional anaemia in Filipino school children. <i>Southeast Asian J Trop Med Public Health.</i> 1973; 4(4): 524-33 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1993		
Tanzania	Todd J, Mayaud P, et al. An examination of risk factors associated with STD/RTI infections among women attending rural antenatal clinics. Presented at: VIII International Conference on AIDS in Africa; 1993; Marrakech, Morocco. Poster. W. P. C. 078.	1992		
Tanzania	Mayaud P, Chungalucha J, et al. Risk score approach in the diagnosis of sexually transmitted diseases in an antenatal population in Mwanza, NW-Tanzania. Presented at: VII International Conference on AIDS in Africa; 1992 July; Amsterdam, The Netherlands. Poster W.P. 187.	1992		
Tanzania	Msuya SE, Mbitzo EM, Hussain A, Sam NE, Stray-Pedersen B. Seroprevalence of hepatitis B and C viruses among women of childbearing age in Moshi Urban, Tanzania. <i>East Afr Med J.</i> 2006; 83(2): 91-4.	1999	*	
Tanzania	Miller WC, Shao JF, Weaver DJ, Shimokura GH, Paul DA, Lallinger GJ. Seroprevalence of viral hepatitis in Tanzanian adults. <i>Trop Med Int Health.</i> 1998; 3(9): 757-63.	1992, 1998	*	
Tanzania	Muro FJ, Fiorillo SP, Sakasaka P, Odhiambo C, Reddy EA, Cunningham CK, Buchanan AM. Seroprevalence of Hepatitis B and C Viruses Among Children in Kilimanjaro Region, Tanzania. <i>J Pediatr Infect Dis.</i> 2013.	2006-2008		
Tanzania	Stirnadel HA, Stöckle M, Felger I, Smith T, Tanner M, Beck HP. Malaria infection and morbidity in infants in relation to genetic polymorphisms in Tanzania. <i>Trop Med Int Health.</i> 1999; 4(3): 187-93.	1993-1995	*	
Tanzania	Stark K, Poggensee G, Höhne M, Bienzle U, Kiwelu I, Schreiber E. Seroepidemiology of TT virus, GBC-C/HGV, and hepatitis viruses B, C, and E among women in a rural area of Tanzania. <i>J Med Virol.</i> 2000; 62(4): 524-30.	1996	*	
Tanzania	Makunde WH, Kamugisha ML, Makunde RA, Malecela-Lazaro MN, Kitua AY. Implication of diethylcarbamazine induced morbidity and the role of cellular responses associated with bancroftian filariasis pathologies. <i>Tanzan Health Res Bull.</i> 2006; 8(1): 11-6. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1999-2001	*	
Tanzania	Matola YG. Prospects of human malaria and Bancroftian filariasis infections in the Lower Rufiji Basin, Tanzania II. Bancroftian filariasis. <i>Trop Geogr Med.</i> 1985; 37(2): 108-13. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1981	*	
Tanzania	Maxwell CA, Curtis CF, Haji H, Kisumku S, Thalib AI, Yahya SA. Control of Bancroftian filariasis by integrating therapy with vector control using polystyrene beads in wet pit latrines. <i>Trans R Soc Trop Med Hyg.</i> 1990; 84(5): 709-14. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1988-1989	*	
Tanzania	Meyrowitsch DW, Simonsen PE, Magesa SM. A 26-year follow-up of bancroftian filariasis in two communities in north-eastern Tanzania. <i>Ann Trop Med Parasitol.</i> 2004; 98(2): 155-69. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2001	*	
Tanzania	Simonsen PE, Lemnge MM, Msangeni HA, Jakobsen PH, Bygbjerg IC. Bancroftian filariasis?: the patterns of filarial-specific immunoglobulin G1 (IgG1), IgG4, and circulating antigens in an endemic community of Northeastern Tanzania. <i>Am J Trop Med Hyg.</i> 1996; 55(1): 69-75. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1992	*	
Tanzania	Simonsen PE, Meyrowitsch DW, Mukoko DA, Pedersen EM, Malecela-Lazaro MN, Rwegoshora RT, Ouma JH, Masese N, Jaoko WG, Michael E. The effect of repeated half-yearly diethylcarbamazine mass treatment on Wuchereria bancrofti infection and transmission in two East African communities with different levels of endemicity. <i>Am J Trop Med Hyg.</i> 2004; 70(1): 63-71. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1999-2001	*	
Tanzania	Larsen U, Masenga G, Mlay J. Infertility in a community and clinic-based sample of couples in Moshi, Northern Tanzania. <i>East Afr Med J.</i> 2006; 83(1): 10-7.	2002-2003		
Tanzania	Filariasis elimination, Zanzibar - Weekly Epidemiological Record 2001 as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	2001	*	†
Tanzania	Winkler AS, Blocher J, Auer H, Gotwald T, Matuja W, Schmutzhard E. Epilepsy and neurocysticercosis in rural Tanzania-An imaging study. <i>Epilepsia.</i> 2009; 50(5): 987-93.	2006	*	†
Tanzania	Variation in Malaria Risk in the Usambara Mountains, Tanzania [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Tanzania	Malaria Studies in Dodoma - Urban and Rural as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Tanzania	Epidemiology and Control of Malaria Transmission by Residual House Spraying with DDT and Lambda-cyhalothrin in Two Populations of the Anopheles Gambiae Complex in Tanga Region, Tanzania [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987-1988	*	†
Tanzania	Malaria Epidemiological Studies in Iringa Rural District, Tanzania as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Tanzania	Repeat Malaria Studies in Babati and Hanang Districts, Arusha Region as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Tanzania	The Ifakara Project: A District Based Research-cum-action Programme in Southeastern Tanzania (Kilombero District, Morogoro Region). Child Survival Fact Sheet as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Tanzania	The Health and Nutrition Status of the Under Fives in Mtwara CSD Program Area 1987 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Tanzania	Regular Micronutrient Supplementation Including Iron to Young Children in Tanzania: Effect on Anaemia and Malaria [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Tanzania	Malaria Control in the United Republic of Tanzania (1993-1996) as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988-1995	*	†
Tanzania	Anaemia and related factors in Unga and Pemba: a survey carried out as part of ZINSP Campaign as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Tanzania	Does malaria treatment with chloroquine increase infectiousness? as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Tanzania	Tanzania Plasmodium Falciparum Parasite Rate Data, Personal Communication with M. Bangs 2009 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000	*	†
Tanzania	Tanzania Plasmodium Falciparum Parasite Rate Data, Personal Communication with D. Chandramohan, I. Carneiro, and J. Cox 2005 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Tanzania	Malaria Situation Analysis in Korogwe District as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Tanzania	Follow-up Malaria and Social-economic Studies of the Malaria Control Project in Pawaga Division, Iringa Region as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Tanzania	Malaria Survey in Ruvuma and Mtwara Regions of Southern Tanzania as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Tanzania	A Continuous Assessment of the Impact of Impregnated Bed Nets in the Transmission of Malaria in Selected Areas in the Upper Nile State During the Period 7-17 December 1998 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Tanzania	Zanzibar Malaria Control Programme/USAID as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Tanzania	Regional CSD Co-ordinators Meeting at UNICEF Office, DSM, June 1988 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Tanzania	Tanzania Plasmodium Falciparum Parasite Rate Data, Personal Communication with G.F. Killeen 2009 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004-2007	*	†
Tanzania	Malaria in Bulambya, Iljeje district south-west Tanzania as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Tanzania	Malaria and nutritional status in children living in the East Usambara Mountains, north-eastern Tanzania as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Tanzania	Malaria prevalence and health-seeking behaviour among communities of the lowlands and highlands of Gonja as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000	*	†
Tanzania	Urban malaria in Dodoma and Iringa, Tanzania as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Tanzania	Tanzania Plasmodium Falciparum Parasite Rate Data, Personal Communication with F. Molteni 2006 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Tanzania	Tanzania Plasmodium Falciparum Parasite Rate Data, Personal Communication with F. Molteni 2008 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008	*	†
Tanzania	Abdulla S, Gemperli A, Mukasa O, Armstrong Schellenberg JRM, Lengeler C, Vounatsou P, Smith T. Spatial effects of the social marketing of insecticide-treated nets on malaria morbidity. Trop Med Int Health. 2005; 10(1): 11-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Tanzania	Babiker H, Lines J, Hill W, Walliker D. Population structure of Plasmodium falciparum in villages with different malaria endemicity in east Africa. Am J Trop Med Hyg. 1997; 56(2): 141-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†
Tanzania	Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Mshamu S, Lang T, Gould J, Dubois MC, Demotie MA, Stallert JF, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Ballou WR, Cohen J, Riley EM, Lemnge MM, Marsh K, von Seidlein L. Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age. N Engl J Med. 2008; 359(24): 2521-32 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2007	*	†
Tanzania	Berezcky S, Liljander A, Rooth I, Faraja L, Granath F, Montgomery SM, Färnert A. Multiclonal asymptomatic Plasmodium falciparum infections predict a reduced risk of malaria disease in a Tanzanian population. Microbes Infect. 2007; 9(1): 103-10 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
Tanzania	Bhattarai A, Ali AS, Kachur SP, Mårtensson A, Abbas AK, Khatib R, Al-Mafazy AW, Ramsan M, Rottlant G, Gerstenmaier JF, Molteni F, Abdulla S, Montgomery SM, Kaneko A, Björkman A. Impact of Artemisinin-Based Combination Therapy and Insecticide-Treated Nets on Malaria Burden in Zanzibar. PLoS Med. 2007; 4(11): e309 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005-2006	*	†
Tanzania	Bodker R, Kisinza W, Malima R, Msangeni H, Lindsay S. Resurgence of Malaria in the Usambara Mountains, Tanzania, An Epidemic of Drug-Resistant Parasites. Global Change & Human Health. 2000; 1(2): 134-53 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996-1998	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Tanzania	Drakeley CJ, Carneiro I, Reyburn H, Malima R, Lusingu JPA, Cox J, Theander TG, Nkya WMMM, Lemnge MM, Riley EM. Altitude-Dependent and -Independent Variations in Plasmodium falciparum Prevalence in Northeastern Tanzania. <i>J Infect Dis.</i> 2005; 191(10): 1589-98 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001-2002	*	†
Tanzania	Ellman R, Maxwell C, Finch R, Shayo D. Malaria and anaemia at different altitudes in the Muheza district of Tanzania: childhood morbidity in relation to level of exposure to infection. <i>Am J Trop Med Parasitol.</i> 1998; 92(7): 741-53 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Tanzania	Enevold A, Lusingu JP, Mmbando B, Alifrangis M, Lemnge MM, Bygbjerg IC, Theander TG, Vestergaard LS. Reduced Risk of Uncomplicated Malaria Episodes in Children with Alpha+-Thalassemia in Northeastern Tanzania. <i>Am J Trop Med Hyg.</i> 2008; 78(5): 714-20 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Tanzania	Farnert A, Snounou G, Rooth I, Bjorkman A. Daily dynamics of Plasmodium falciparum subpopulations in asymptomatic children in a holoendemic area. <i>Am J Trop Med Hyg.</i> 1997; 56(5): 538-47 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Tanzania	Fraser-Hurt N, Felger I, Edoh D, Steiger S, Mashaka M, Masanja H, Smith T, Mbena F, Beck H-P. Effect of insecticide-treated bed nets on haemoglobin values, prevalence and multiplicity of infection with Plasmodium falciparum in a randomized controlled trial in Tanzania. <i>Trans R Soc Trop Med Hyg.</i> 1999; 93(Suppl 1): 47-51 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Tanzania	Hellgren U, Ericsson O, Kihamia CM, Rombo L. Malaria parasites and chloroquine concentrations in Tanzanian schoolchildren. <i>Trop Med Parasitol.</i> 1994; 45(4): 293-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Tanzania	Hellgren U, Kihamia CM, Bergqvist Y, Lebbad M, Premji Z, Rombo L. Standard and reduced doses of sulfadoxine-pyrimethamine for treatment of Plasmodium falciparum in Tanzania, with determination of drug concentrations and susceptibility in vitro. <i>Trans R Soc Trop Med Hyg.</i> 1990; 84(4): 469-72 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Tanzania	Patrick Kachur S, Schulden J, Goodman CA, Kassala H, Elling BF, Khatib RA, Causer LM, Mwikima S, Abdulla S, Bioland PB. Prevalence of malaria parasitemia among clients seeking treatment for fever or malaria at drug stores in rural Tanzania 2004. <i>Trop Med Int Health.</i> 2006; 11(4): 441-51 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000-2006	*	†
Tanzania	Laurent A, Schellenberg J, Shirima K, Ketende SC, Alonso PL, Mshinda H, Tanner M, Schellenberg D. Performance of HRP-2 based rapid diagnostic test for malaria and its variation with age in an area of intense malaria transmission in southern Tanzania. <i>Malar J.</i> 2010; 9: 294 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Tanzania	Lemnge M, Alifrangis M, Kafuye MY, Segeja MD, Gesase S, Minja D, Massaga JJ, Ronn AM, Bygbjerg IC. High reinfection rate and treatment failures in children treated with amodiaquine for falciparum malaria in Muheza villages, Northeastern Tanzania. <i>Am J Trop Med Hyg.</i> 2006; 75(2): 188-93 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Tanzania	Mehrahtu T, Stoltzfus RJ, Chwaya HM, Jape JK, Savioli L, Montresor A, Albonico M, Tielsch JM. Low-dose daily iron supplementation for 12 months does not increase the prevalence of malarial infection or density of parasites in young Zanzibari children. <i>J Nutr.</i> 2004; 134(11): 3037-41 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
Tanzania	Mmbando BP, Segeja MD, Msangeni HA, Sembuche SH, Ishengoma DS, Seth MD, Francis F, Rutta AS, Kamugisha ML, Lemnge MM. Epidemiology of malaria in an area prepared for clinical trials in Korogwe, north-eastern Tanzania. <i>Malar J.</i> 2009; 8: 165 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005-2007	*	†
Tanzania	Mnzava AE, Rwegoshora RT, Tanner M, Msuya FH, Curtis CF, Irare SG. The effects of house spraying with DDT or lambda-cyhalothrin against Anopheles arabiensis on measures of malarial morbidity in children in Tanzania. <i>Acta Trop.</i> 1993; 54(2): 141-51 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988-1989	*	†
Tanzania	Rooth IB, Bjorkman A. Suppression of Plasmodium falciparum infections during concomitant measles or influenza but not during pertussis. <i>Am J Trop Med Hyg.</i> 1992; 47(5): 675-81 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Tanzania	Shekalaghe SA, Bousema JT, Kunei KK, Lushino P, Masokoto A, Wolters LR, Mwakalinga S, Moshia FW, Sauerwein RW, Drakeley CJ. Submicroscopic Plasmodium falciparum gametocyte carriage is common in an area of low and seasonal transmission in Tanzania. <i>Trop Med Int Health.</i> 2007; 12(4): 547-53 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Tanzania	Shiff CJ, Minjas JN, Hall T, Hunt RH, Lyimo S, Davis JR. Malaria infection potential of anopheline mosquitoes sampled by light trapping indoors in coastal Tanzanian villages. <i>Med Vet Entomol.</i> 1995; 9(3): 256-62 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Tanzania	Stich AH, Maxwell CA, Haji AA, Haji DM, Machano AY, Mussa JK, Matteelli A, Haji H, Curtis CF. Insecticide-impregnated bed nets reduce malaria transmission in rural Zanzibar. <i>Trans R Soc Trop Med Hyg.</i> 1994; 88(2): 150-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Tanzania	The Kilombero Malaria Project. The level of anti-sporozoite antibodies in a highly endemic malaria area and its relationship with exposure to mosquitoes. <i>Trans R Soc Trop Med Hyg.</i> 1992; 86(5): 499-504 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Tanzania	Tomashek KM, Woodruff BA, Gotway CA, Bioland P, Mbaruku G. Randomized intervention study comparing several regimens for the treatment of moderate anemia among refugee children in the Kigoma Region, Tanzania. <i>Am J Trop Med Hyg.</i> 2001; 64(3-4): 164-71 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Tanzania	Trigg J, Mbwana H, Chambo O, Hills E, Watkins W, Curtis C. Resistance to pyrimethamine/sulfadoxine in Plasmodium falciparum in 12 villages in north east Tanzania and a test of chloroquine/dapsone. <i>Acta Trop.</i> 1997; 63(2-3): 185-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Tanzania	Wakibara JV, Mboera LE, Ndawi BT. Malaria in Mvuni, central Tanzania and the in vivo response of Plasmodium falciparum to chloroquine and sulphadoxine pyrimethamine. <i>East Afr Med J.</i> 1997; 74(2): 69-71 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Tanzania	Wang SJ, Lengeler C, Mtasiwa D, Mshana T, Manane L, Maro G, Tanner M. Rapid Urban Malaria Appraisal (RUMA) II: epidemiology of urban malaria in Dar es Salaam (Tanzania). <i>Malar J.</i> 2006; 5: 28 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Tanzania	Tanzania Plasmodium Falciparum Parasite Rate Data, Personal Communication with D.M. Schellenberg 2006 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Tanzania	Tanzania Plasmodium Falciparum Parasite Rate Data, M. Alilio, National Institute for Medical Research 1990 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Tanzania	Tanzania Plasmodium Falciparum Parasite Rate Data, Y.G. Matola, National Institute of Medical Research 1990 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
Tanzania	Tanzania Plasmodium Falciparum Parasite Rate Data, Y.G. Matola 1991 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†
Tanzania	Tanzania Plasmodium Falciparum Parasite Rate Data, J.K.M. Chuwa, M. Med. Muhimbili University, 1991 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988		
Thailand	National Statistical Office (Thailand), United Nations Children's Fund (UNICEF). Thailand Multiple Indicator Cluster Survey 2005-2006. New York, United States: United Nations Children's Fund (UNICEF).	2005-2006		†
Thailand	Ministry of Public Health (Thailand). Thailand National Health and Examination Survey 2003-2004.	2003-2004	*	
Thailand	Chulalongkorn University, Institute of Population Studies (Thailand), Westinghouse; Institute for Resource Development. Thailand Demographic and Health Survey 1987. Columbia, United States: Westinghouse; Institute for Resource Development.	1987		
Thailand	World Health Organization (WHO). Control of Foodborne Trematode Infections 1995. Geneva, Switzerland: World Health Organization (WHO), 1995.	1995		
Thailand	Jiraphongsa C, Bresee JS, Pongsuwanna Y, Kluabwang P, Poonawagut U, Arpontip P, Kanoksil M, Premsri N, Intusoma U. Epidemiology and burden of rotavirus diarrhea in Thailand: results of sentinel surveillance. <i>J Infect Dis.</i> 2005; 192(Suppl 1): S87-93.	2001-2003		
Thailand	Ministry of Public Health (Thailand). Thailand National Health Examination Survey 1991-1992.	1991-1992		†
Thailand	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Thailand	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		
Thailand	Tantiwong A, Nuanyong C, Vanprapar N, Swasdipala P, Chittaphaphi S. Benign prostatic hyperplasia in elderly Thai men in an urban community: the prevalence, natural history and health related behavior. <i>J Med Assoc Thai.</i> 2002; 85(3): 356-60.	1998-1999		
Thailand	Olsen SI, Thambitwat S, Baggett HC, Maloney S, Peruski LF, Chantra S, Chittaganpitch M, Sawanpanyalert P, Fry AM, Simmerman JM, Peret TCT, Erdman D, Benson R, Thacker L, Tondella ML, Winchell J, Fields B, Talkington D, Nicholson WL, Ungchusak K, Dowell SF. Incidence of respiratory pathogens in persons hospitalized with pneumonia in two provinces in Thailand. <i>Epidemiol Infect.</i> 2010; 138(12): 1811-22.	2003-2005		
Thailand	Sunakorn P, Chunchit L, Niltawat S, Wangweerawong M, Jacobs RF. Epidemiology of acute respiratory infections in young children from Thailand. <i>Pediatr Infect Dis J.</i> 1990; 9(12): 873-7.	1988-1989		
Thailand	Echeverria P, Seriwatana J, Taylor DN, Yangtrakee S, Tirapat C. A comparative study of enterotoxigenic Escherichia coli, Shigella, Aeromonas, and Vibrio as etiologies of diarrhea in northeastern Thailand. <i>Am J Trop Med Hyg.</i> 1985; 34(3): 547-54.	1982-1983		
Thailand	Chayapham S, Stuart J, Chongsuvitwong V, Chinpaioj S, Lim A. A study of the prevalence of and risk factors for ear diseases and hearing loss in primary school children in Hat Yai, Thailand. <i>J Med Assoc Thai.</i> 1996; 79(7): 468-72.	1993-1995		
Thailand	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol.</i> 2008; 121(4): 947-954.	1995, 2001		†
Thailand	Suwanjutha S, Sunakorn P, Chantarojanasiri T, Siritantikom S, Nawapanarukul S, Rattanadilok Na Bhuket T, Teeyapaiboonsilpa P, Preuthiphan A, Sareebutr W, Puthavathana P. Respiratory syncytial virus-associated lower respiratory tract infection in under-5-year-old children in a rural community of central Thailand, a population-based study. <i>J Med Assoc Thai.</i> 2002; (85): 1111-9.	1998-2001		
Thailand	Vathanophas K, Sangchai R, Raktham S, Pariyanonda A, Thangsuvan J, Bunyaratbandhu P, Athipanyakorn S, Suwanjutha S, Jayanetra P, Wasi C, et al. A community-based study of acute respiratory tract infection in Thai children. <i>Rev Infect Dis.</i> 1990; 12 Suppl 8: 957-65.	1986-1987		
Thailand	Chotpitayasonondh T. Bacterial meningitis in children: etiology and clinical features, an 11-year review of 618 cases. <i>Southeast Asian J Trop Med Public Health.</i> 1994; 25(1): 107-15.	1980-1990		
Thailand	Khamrin P, Peerakome S, Tonusin S, Malasao R, Okitsu S, Mizuguchi M, Ushijima H, Maneekarn N. Changing pattern of rotavirus G genotype distribution in Chiang Mai, Thailand from 2002 to 2004: decline of G9 and reemergence of G1 and G2. <i>J Med Virol.</i> 2007; 79(11): 1775-82.	2002-2004		
Thailand	Khamrin P, Maneekarn N, Malasao R, Nguyen TA, Ishida S, Okitsu S, Ushijima H. Genotypic linkages of VP4, VP6, VP7, NSP4, NSP5 genes of rotaviruses circulating among children with acute gastroenteritis in Thailand. <i>Infect Genet Evol.</i> 2010; 10(4): 467-72.	2005		
Thailand	Punyaratabandhu P, Vathanophas K, Varavithya W, Sangchai R, Athipanyakorn S, Echeverria P, Wasi C. Childhood diarrhoea in a low-income urban community in Bangkok: incidence, clinical features, and child caretaker's behaviours. <i>J Diarrhoeal Dis Res.</i> 1991; 9(3): 244-9.	1988-1989		
Thailand	Reks-Ngarn S, Treleaven SC, Chunsuttiwat S, Muangchana C, Jolley D, Brooks A, Dejsirilert S, Warintraat S, Guiver M, Kunasol P, Maynard JE, Biggs BA, Steinhoff M. Prospective population-based incidence of Haemophilus influenzae type b meningitis in Thailand. <i>Vaccine.</i> 2004; 22(8): 975-83.	1994-1998, 2000-2001		
Thailand	Poocharoen L, Bruin CW. Campylobacter jejuni in hospitalized children with diarrhoea in Chiang Mai, Thailand. <i>Southeast Asian J Trop Med Public Health.</i> 1986; 17(1): 53-8.	1983-1984		
Thailand	Von Seidlein L, Kim DR, Ali M, Lee H, Wang X, Thiem VD, Canh DG, Chaicumpa W, Agtini MD, Hossain A, Bhutta ZA, Mason C, Sethabutr O, Talukder K, Nair GB, Deen JL, Kotloff K, Clemens J. A Multicentre Study of Shigella Diarrhoea in Six Asian Countries: Disease Burden, Clinical Manifestations, and Microbiology. <i>PLoS Med.</i> 2006; 3(9): e353.	2000-2003		
Thailand	Chaiamnuay P, Darmawan J, Muirden KD, Assawatanaabodee P. Epidemiology of rheumatic disease in rural Thailand: a WHO-ILAR COPCORD study. Community Oriented Programme for the Control of Rheumatic Disease. <i>J Rheumatol.</i> 1998; 25(7): 1382-7.	1995		
Thailand	Tatsanavivat P, Klungboonkrong V, Chirawatkul A, Bhuripanyo K, Mammontri A, Chitanondh H, Yipintsoi T. Prevalence of coronary heart disease and major cardiovascular risk factors in Thailand. <i>Int J Epidemiol.</i> 1998; 27(3): 405-9.	1980-1991		
Thailand	Lumbiganon P, Laopaiboon M, Gülmezoglu AM, Souza JP, Taneepanichskul S, Ruyan P, Attygalle DE, Shrestha N, Mori R, Hinh ND, Bang HT, Rathay T, Chuyun K, Cheang K, Festin M, Udombasertgul V, Germar MJV, Yanquig G, Roy M, Carroli G, Ba-Thike K. Method of delivery and pregnancy outcomes in Asia: the WHO global survey on maternal and perinatal health 2007-08. <i>Lancet.</i> 2010; 375(9713): 490-9.	2007-2008		
Thailand	World Health Organ. Community control of hereditary anaemias: memorandum from a WHO meeting. <i>Bull World Health Organ.</i> 1983; 61(1): 63-80.	1977-1999		
Thailand	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998-2001, 2003-2007, 2009		
Thailand	Deesomchok U, Tumrasvin T. Common arthritis in practice. <i>J Med Assoc Thai.</i> 1988; 71(12): 671-6.	1986		
Thailand	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Thailand	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	1999		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Thailand	Leelawattana R, Pratiapanawatr T, Bunnag P, Kosachunhanun N, Suwanwalaikom S, Krittiyawong S, Chethakul T, Plengvidhya N, Benjasuratwong Y, Deerochanawong C, Mongkolsomlit S, Ngarmukos C, Rawdaree P. Thailand diabetes registry project: prevalence of vascular complications in long-standing type 2 diabetes. <i>J Med Assoc Thai.</i> 2006; 89(Suppl 1): S54-9.	2003		
Thailand	Nitiyanan W, Chethakul T, Sang-A-kad P, Therakiatunjom C, Kunsuikmengrai K, Yeo JP. A survey study on diabetes management and complication status in primary care setting in Thailand. <i>J Med Assoc Thai.</i> 2007; 90(1): 65-71.	2004		
Thailand	Chethakul T, Likitmaskul S, Plengvidhya N, Suwanwalaikom S, Kosachunhanun N, Deerochanawong C, Krittiyawong S, Leelawattana R, Benjasuratwong Y, Bunnag P, Prathipanawatr T, Ngarmukos C, Mongkolsomlit S, Rawdaree P. Thailand diabetes registry project: prevalence of diabetic retinopathy and associated factors in type 1 diabetes mellitus. <i>J Med Assoc Thai.</i> 2006; 89(Suppl 1): S17-26.	2003		
Thailand	Thai Multicenter Research Group on Diabetes Mellitus. Vascular complications in non-insulin dependent diabetics in Thailand. <i>Diabetes Res Clin Pract.</i> 1994; 25(1): 61-9.	1993	*	
Thailand	Phanthumchinda K, Sithi-Amorn C. Prevalence and clinical features of migraine: a community survey in Bangkok, Thailand. <i>Headache.</i> 1989; 29(9): 594-7.	1988-1989	*	
Thailand	Bunjean K, Sukasem K, Noppacron N, Yamkaew N, Janthayanont D, Theerapancharern W, Chokkanchitchai S, Mounthong G. Prevalence of allergic rhinitis and types of sensitized allergen in adult at Wat Intaram community, Hua Raeu, Phra Nakhon Si Ayutthaya District, Phra Nakhon Si Ayutthaya Province, Thailand. <i>J Med Assoc Thai.</i> 2012; S63-68.	2008	*	
Thailand	Uthaisangsook S. Risk factors for development of asthma in Thai adults in Phitsanulok: a university-based study. <i>Asian Pac J Allergy Immunol.</i> 2010; 28(1): 23-8.	2004	*	
Thailand	Tangtrakulvanich B, Suwanno P. Epidemiology and risk factors of patellofemoral osteoarthritis in adults: a population-based study in southern Thailand. <i>J Med Assoc Thai.</i> 2012; 95(8): 1048-52.	2008-2010	*	
Thailand	Srimachota S, Boonyaratavej S, Kanjanavanit R, Sritara P, Krittiyaphong R, Kunjara-Na-ayudhya R, Tatsananavit P, TR ACS Group. Thai Registry in Acute Coronary Syndrome (TRACS) – an extension of Thai Acute Coronary Syndrome registry (TACS) group: lower in-hospital but still high mortality at one-year. <i>J Med Assoc Thai.</i> 2012; 95(4): 508-18.	2007-2008	*	
Thailand	Sabchareon A, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Margolis HS, Lelson GW. Dengue infection in children in Ratchaburi, Thailand: a cohort study. <i>I Epidemiology of symptomatic acute dengue infection in children.</i> 2006-2009. <i>PLoS Negl Trop Dis.</i> 2012; 6(7): e1732.	2006-2009	*	
Thailand	Echeverria P, Hoge CW, Bodhidatta L, Tungtaem C, Herrmann J, Inlarp S, Tamara K. Etiology of diarrhea in a rural community in western Thailand: importance of enteric viruses and enterovirulent <i>Escherichia coli</i> . <i>J Infect Dis.</i> 1994; 169(4): 916-9.	1991	*	
Thailand	Varavithya W, Vathanophas K, Bodhidatta L, Punyaratabandhu P, Sangchai R, Athipanyakom S, Wasi C, Echeverria P. Importance of salmonellae and <i>Campylobacter jejuni</i> in the etiology of diarrheal disease among children less than 5 years of age in a community in Bangkok, Thailand. <i>J Clin Microbiol.</i> 1990; 28(11): 2507-10.	1988-1989	*	
Thailand	Pipittajan P, Kasempimolporn S, Ikegami N, Akatani K, Wasi C, Sinarachatanant P. Molecular epidemiology of rotaviruses associated with pediatric diarrhea in Bangkok, Thailand. <i>J Clin Microbiol.</i> 1991; 29(3): 617-24.	1985-1987	*	
Thailand	Echeverria P, Taylor DN, Lexsomboun U, Bhaibulaya M, Blacklow NR, Tamara K, Sakazaki R. Case-control study of endemic diarrheal disease in Thai children. <i>J Infect Dis.</i> 1989; 159(3): 543-8.	1985-1986	*	
Thailand	Herrmann JE, Blacklow NR, Perron-Henry DM, Clements E, Taylor DN, Echeverria P. Incidence of enteric adenoviruses among children in Thailand and the significance of these viruses in gastroenteritis. <i>J Clin Microbiol.</i> 1988; 26(9): 1783-6.	1985-1987	*	
Thailand	Poocharoen L, Bruin CW, Srisanthana V, Vannareumol P, Leechanachai P, Sukhavat K. The relative importance of various enteropathogens as a cause of diarrhoea in hospitalized children in Chiang Mai, Thailand. <i>J Diarrhoeal Dis Res.</i> 1986; 4(1): 10-5.	1983-1984	*	
Thailand	Wasi C, Louisirothanakul S, Thakerngol K, Satrasook S, Surakhala M, Varavithya W, Thongcharoen P. The epidemiological study on viral diarrhoea in Thailand. <i>J Med Assoc Thai.</i> 1984; 67(7): 369-75.	1982-1983	*	
Thailand	Echeverria P, Blacklow NR, Cukor GG, Vibulbandhikit S, Changchawalit S, Boonthai P. Rotavirus as a cause of severe gastroenteritis in adults. <i>J Clin Microbiol.</i> 1983; 18(3): 663-7.	1980-1981	*	
Thailand	Bodhidatta L, McDaniel P, Sornsakrin S, Srijan A, Serichantalergs O, Mason CJ. Case-control study of diarrheal disease etiology in a remote rural area in Western Thailand. <i>Am J Trop Med Hyg.</i> 2010; 83(5): 1106-9.	2001-2002	*	
Thailand	Kittigul L, Pombubpa K, Taweekate Y, Yeepoo T, Khamrin P, Ushijima H. Molecular characterization of rotaviruses, noroviruses, sapovirus, and adenoviruses in patients with acute gastroenteritis in Thailand. <i>J Med Virol.</i> 2009; 81(2): 345-53.	2006-2007	*	
Thailand	Maiklang O, Vutithanachot V, Vutithanachot C, Hacharoen P, Chiochansin T, Poovorawan Y. Prevalence of group A genotype human rotavirus among children with diarrhea in Thailand, 2009-2011. <i>Southeast Asian J Trop Med Public Health.</i> 2012; 43(4): 904-16.	2009-2011		
Thailand	Thongprachum A, Khamrin P, Chan-R W, Malasao R, Chaimongkol N, Okitsu S, Mizuguchi M, Maneekarn N, Hayakawa S, Ushijima H. Emergence of norovirus GII.4 2006a and 2006b variants in hospitalized children with acute gastroenteritis in Thailand. <i>Clin Lab.</i> 2013; 59(3-4): 271-6.	2006		
Thailand	Wangtongkum S, Sucharitkul P, Silprasert N, Inthrachak R. Prevalence of dementia among population age over 45 years in Chiang Mai, Thailand. <i>J Med Assoc Thai.</i> 2008; 91(11): 1685-90.	2004-2005		
Thailand	Phanthumchinda K, Jitapunkul S, Sithi-amron C, Bunnag SC, Ebrahim S. Prevalence of dementia in an urban slum population in Thailand: Validity of screening methods. <i>Int J Geriatr Psychiatry.</i> 1991; 6(9): 639-46.	1989		
Thailand	Sutthavong S, Taebanpakul S, Kuruchitkosol C, Ajudhya TIN, Chantveerawong T, Fuangroong S, Cae-Ngow S, Rangsin R. Oral health status, dental caries risk factors of the children of public kindergarten and schools in Phranakornsiyadudhya, Thailand. <i>J Med Assoc Thai.</i> 2010; 93 Suppl 6: S71-78.	2005		
Thailand	Nephrology Society of Thailand. Thailand Renal Replacement Therapy Report 2008.	2008		
Thailand	Maranetra KN, Chuaychoo B, Dejsomritrutai W, Chierakul N, Nana A, Lertkayamee J, Naruman C, Suthamsmai T, Sangkaew S, Sreelum W, Aksornin M, Dechapol J, Sathet W. The prevalence and incidence of COPD among urban older persons of Bangkok Metropolitan. <i>J Med Assoc Thai.</i> 2002; 85(11): 1147-55.	1998		
Thailand	Rueangchaimonhom W, Srisuwan S, Prommas S, Sarapak S. Risk factors for primary postpartum hemorrhage in Bhumibol Adulyadej Hospital. <i>J Med Assoc Thai.</i> 2009; 92(12): 1586-90.	2004-2007		
Thailand	Benjasuwantep B RN, Visudhiphan P. Prevalence and clinical characteristics of attention deficit hyperactivity disorder among primary school students in Bangkok. <i>J Med Assoc Thai.</i> 2002; 1232-40.	2000		
Thailand	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2004, 2007-2008		
Thailand	Chayachinda C, Rattanachaiyanont M, Phatharayuttawat S, Kooptiwoot S. Premenstrual syndrome in Thai nurses. <i>J Psychosom Obstet Gynaecol.</i> 2008; 29(3): 199-205.	2005-2006		
Thailand	Thu M, Diaz E O and Sawhsarkapaw. Premenstrual Syndrome among Female University Students in Thailand. <i>AU J Technol.</i> 2006; 158-62.	2003		
Thailand	United States Renal Data System Coordinating Center. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2000-2001, 2003		
Thailand	United States Renal Data System Coordinating Center. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2007.	2002		
Thailand	Ruangkanchanasetr S, Pitponkarn P, Hetrakul P, Kongsakon R. Youth risk behavior survey: Bangkok, Thailand. <i>J Adolesc Health.</i> 2005; 36(3): 227-35.	2001		
Thailand	Quan VM, Vongchak T, Jitwitukarn J, Kawichai S, Sriak N, Wiboonnatakul K, Razak MH, Suriyanon V, Celentano DD. Predictors of mortality among injecting and non-injecting HIV-negative drug users in northern Thailand. <i>Addiction.</i> 2007; 102(3): 441-6.	1999-2002		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Thailand	Thailand National Survey of Blindness and Low Vision 1994 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1994		
Thailand	Singalavanija A, Methetrirat A, Ruangvaravate N, Tuchinda R, Wanunakarn N. Ocular diseases and blindness in elderly Thais. J Med Assoc Thai. 2001; 84(10): 1383-8, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1997-1998		
Thailand	Lolekha S, Tantiaphabha W, Sornchai P, Kosuwan P, Sutra S, Warachit B, Chup-Upprakarn S, Hutagalung Y, Weil J, Bock HL. Effect of climatic factors and population density on varicella zoster virus epidemiology within a tropical country. Am J Trop Med Hyg. 2001; 64(3-4): 131-6.	1997-1998		
Thailand	Kowitadrong E, Panchareon C, Thamabororn R, Bhattarakosol P. The prevalence of varicella-zoster virus infection in normal healthy individuals aged above 6 months. J Med Assoc Thai. 2005; 87: 11.	1998-2000	*	
Thailand	Office of the Narcotics Control Board (Thailand). Preliminary Report of Project Estimation of Population related with Substance Abuse: Status of Drug and Substance Abuse: 2001. Bangkok, Thailand: Office of the Narcotics Control Board (Thailand), 2002.	2001	*	
Thailand	Samransamruajit R, Hiranat T, Chieochansin T, Sritippayawan S, Deerojanawong J, Prapphal N, Poovorawan Y. Prevalence, clinical presentations and complications among hospitalized children with influenza pneumonia. Jpn J Infect Dis. 2008; 61(6): 446-9.	2006-2007	*	
Thailand	Saereponcharekul K. Correlation of BMI to pregnancy outcomes in Thai women delivered in Rajavithi Hospital. J Med Assoc Thai. 2011; 94(Suppl 2): S52-58.	2009	*	
Thailand	Piakkarnkul S, Phaloprakorn C, Wiriyasirivaj B, Manusirivithaya S, Tangitgamol S. Seasonal variation in the prevalence of preeclampsia. J Med Assoc Thai. 2011; 94(11): 1293-8.	2008-2009		
Thailand	Hanchaiphiboolkul S, Pongvarin N, Nidhinandana S, Suwanwela NC, Puthkhaio P, Towanabut S, Tantiritisak T, Suwantamee J, Samson M. Prevalence of stroke and stroke risk factors in Thailand: Thai Epidemiologic Stroke (TES) Study. J Med Assoc Thai. 2011; 94(4): 427-36.	2004-2006		
Thailand	Chittinandana A, Chalimpamontree W, Chaloeiphap P. Prevalence of chronic kidney disease in Thai adult population. J Med Assoc Thai. 2006; 89(Suppl 2): S112-20.	2002-2003		
Thailand	Domrongkitchaiporn S, Sritara P, Kitiyakara C, Stitachantrakul W, Krittaphol V, Lolekha P, Cheepudomwit S, Yipintsoi T. Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J Am Soc Nephrol. 2005; 16(3): 791-9.	1985-1997		
Thailand	Luengrojankul P, Vareesangthip K, Chainuvati T, Murata K, Tsuda F, Tokita H, Okamoto H, Miyakawa Y, Mayumi M. Hepatitis C virus infection in patients with chronic liver disease or chronic renal failure and blood donors in Thailand. J Med Virol. 1994; 44(3): 287-92.	1994		
Thailand	Tangkijvanich P, Theamboonlers A, Hirsch P, Thongngam D, Kullavanijaya P, Poovorawan Y. Hepatitis viruses and chronic liver disease. Southeast Asian J Trop Med Public Health. 1999; 30(3): 489-95.	1997-1998		
Thailand	Tangkijvanich P, Hirsch P, Theamboonlers A, Nuchprayoon I, Poovorawan Y. Association of hepatitis viruses with hepatocellular carcinoma in Thailand. J Gastroenterol. 1999; 34(2): 227-33.	1996-1998	*	
Thailand	Perkovic V, Cass A, Patel AA, Suriyawongpaisal P, Barzi F, Chadban S, Macmahon S, Neal B; InterASIA Collaborative Group. High prevalence of chronic kidney disease in Thailand. Kidney Int. 2008; 73(4): 473-9.	2000		
Thailand	Phanthunane P, Vos T, Whiteford H, Bertram M, Udomratn P. Schizophrenia in Thailand: prevalence and burden of disease. Popul Health Metr. 2010; 24.	2003		
Thailand	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012	*	
Thailand	Ministry of Public Health (Thailand). Thailand National Tuberculosis Prevalence Survey 2012.	2012	*	
Thailand	Wacharasindhu A, Panyayong B. Psychiatric disorders in Thai school-aged children: I Prevalence. J Med Assoc Thai. 2002; 85: 125-136.	1996-1997	*	
Thailand	United Nations Children's Fund (UNICEF). Child Mortality and Injury in Asia. New York, United States: United Nations Children's Fund (UNICEF), 2008. (Innocenti Working Papers: Special Series on Child Injuries Nos. 1-4).	2003		
Thailand	Institute of Health Research, Chulalongkorn University (Thailand), Ministry of Public Health (Thailand), The Alliance for Safe Children (TASC), United Nations Children's Fund (UNICEF). Thailand National Injury Survey 2003-2004.	2003	*	
Thailand	Bourne RRA, Sukudom P, Foster PJ, Tantisevi V, Jitapunkul S, Lee PS, Johnson GJ, Rojanapongpun P. Prevalence of glaucoma in Thailand: a population based survey in Rom Klao District, Bangkok. Br J Ophthalmol. 2003; 87(9): 1069-74, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1997-1999	*	
Thailand	Sukvirach S, Smith JS, Tunsakul S, Muñoz N, Kesarat V, Opasanth O, Chichareon S, Kaenploy V, Ashley R, Meijer CJLM, Snijders P, Coursaget P, Franceschi S, Herrero R. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis. 2003; 187(8): 1246-56.	1991-2002		
Thailand	Nelson KE, Eiumtrakul S, Celentano D, Maclean I, Ronald A, Suprasert S, Hoover DR, Kuntolbutra S, Zenilman JM. The association of herpes simplex virus type 2 (HSV-2), Haemophilus ducreyi, and syphilis with HIV infection in young men in northern Thailand. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 16(4): 293-300.	1991-1993		
Thailand	Krairitichai U, Potisat S, Jongsareejit A, Sattaputh C. Prevalence and risk factors of diabetic nephropathy among Thai patients with type 2 diabetes mellitus. J Med Assoc Thai. 2011; 87: 5.	2007-2008		
Thailand	Sriwijitkamol A, Moungern Y, Vannaseang S. Assessment and prevalences of diabetic complications in 722 Thai type 2 diabetes patients. J Med Assoc Thai. 2011; 94(Suppl 1): S168-174.	2006		
Thailand	Potisat S, Krairitichai U, Jongsareejit A, Sattaputh C, Arunratnachote W. A 4-year prospective study on long-term complications of type 2 diabetic patients: the Thai DMS diabetes complications (DD.Comp) project. J Med Assoc Thai. 2013; 96(6): 637-43.	2006-2010		
Thailand	Panamonta O, Laopaboom M, Tuchinda C. Incidence of childhood type 1 (insulin dependent) diabetes mellitus in northeastern Thailand. J Med Assoc Thai. 2000; 83(8): 821-4.	1991-1995		
Thailand	Panamonta O, Thanjaroen J, Panamonta M, Panamonta N, Suesrisawat C. The rising incidence of type 1 diabetes in the northeastern part of Thailand. J Med Assoc Thai. 2011; 94(12): 1447-50.	1996-2005		
Thailand	Patarakuyavich N, Tuchinda C. Incidence of diabetes mellitus type 1 in children of southern Thailand. J Med Assoc Thai. 2001; 84(8): 1071-4.	1992-1996	*	
Thailand	Unachak K, Tuchinda C. Incidence of type 1 diabetes in children under 15 years in northern Thailand, from 1991 to 1997. J Med Assoc Thai. 2001; 84(7): 923-8.	1991-1997	*	
Thailand	Böhning D, Suppawattanabodee B, Kusolvisitkul W, Viatwongkasem C. Estimating the number of drug users in Bangkok 2001: a capture-recapture approach using repeated entries in one list. Eur J Epidemiol. 2004; 19(12): 1075-83.	2001	*	
Thailand	Mastro TD, Kitayaporn D, Weniger BG, Vanichseni S, Laosonthorn V, Uneklabh T, Uneklabh C, Choopanya K, Limpakarnjanarat K. Estimating the number of HIV-infected injection drug users in Bangkok: a capture-recapture method. Am J Public Health. 1994; 84(7): 1094-9.	1991		
Thailand	Verachai V, Punjawanun J, Perfas F. The results of drug dependence treatment by therapeutic community in Thanayarak Institute on Drug Abuse. J Med Assoc Thai. 2003; 86(5): 407-14.	1991-2000		
Thailand	Kruatrachue M, Charoenlarp P, Chongsuphajasiddhi T, Harinasuta C. Erythrocyte glucose-6-phosphate dehydrogenase and malaria in Thailand. Lancet. 1962; 2(7267): 1183-6.	1960-1962		
Thailand	Flatz G, Sringam S. Glucose-6-phosphate dehydrogenase deficiency in different ethnic groups in Thailand. Ann Hum Genet. 1964; 315-8.	1962-1964		
Thailand	Flatz G, Thanangkul O, Simarak S, Manmontri M. Glucose-6-phosphate dehydrogenase deficiency and jaundice in newborn infants in northern Thailand. Ann Paediatr. 1964; 39-45.	1962-1964		
Thailand	Wasi P, Na-Nakorn S, Suingdumrong A. Studies of the distribution of haemoglobin E, thalassaemias and glucose-6-phosphate dehydrogenase deficiency in north-eastern Thailand. Nature. 1967; 214(5087): 501-2.	1963		
Thailand	Tuchinda S, Rucknagel DL, Na-Nakorn S, Wasi P. The Thai variant and the distribution of alleles of 6-phosphogluconate dehydrogenase and the distribution of glucose 6-phosphate dehydrogenase deficiency in Thailand. Biochem Genet. 1968; 2(3): 253-64.	1966-1968		
Thailand	Buchachart K, Krudsood S, Singhasivanon P, Treeprasertsuk S, Phophak N, Srivilairit S, Chalermrut K, Rattanapong Y, Supeeranuntha L, Wilairatana P, Brittenham G, Looareesuwan S. Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand. Southeast Asian J Trop Med Public Health. 2001; 32(4): 720-6.	1992-1997		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Thailand	Ratrisawadi V, Horpaopan S, Chotigeat U, Sangtawesin V, Kanjanapattanakul W, Ningsaonod V, Sunthorntheparakul T, Khooramopatana S, Charonsirawatana W, Neonatal screening program in Rajavithi Hospital, Thailand. Southeast Asian J Trop Med Public Health. 1999; 28-32.	1996-1998		
Thailand	Silachamroon U, Krudsood S, Treeraprasertuk S, Wilairatana P, Chalearmrult K, Mint HY, Maneekan P, White NJ, Gourdeuk VR, Brittenham GM, Loaresuwat S. Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand. Am J Trop Med Hyg. 2003; 69(1): 14-8.	1999-2001		
Thailand	Nuchprayoon I, Sanpavat S, Nuchprayoon S. Glucose-6-phosphate dehydrogenase (G6PD) mutations in Thailand: G6PD Viangchan (871G>A) is the most common deficiency variant in the Thai population. Hum Mutat. 2002; 19(2): 185.	2000-2002		
Thailand	Ninokata A, Kimura R, Samakkarn U, Settheetham-Ishida W, Ishida T. Coexistence of five G6PD variants indicates ethnic complexity of Phuket islanders, Southern Thailand. J Hum Genet. 2006; 51(5): 424-8.	2004-2006		
Thailand	Ong-Ajyooth L, Vareesangthip K, Khonputsa P, Aekplakorn W. Prevalence of chronic kidney disease in Thai adults: a national health survey. BMC Nephrol. 2009; 10: 35.	2004		
Thailand	Vutyanich T, Khanjao V, Wongra-Ngan S, Sreshtaputra O, Sreshtaputra R, Piromlertamorn W. Clinical, endocrine and ultrasonographic features of polycystic ovary syndrome in Thai women. J Obstet Gynaecol Res. 2007; 33(5): 677-80.	2004		
Thailand	Baelum V, Pisuithanakan S, Teanpaisan R, Pithpornchaiyakul W, Pongpaisal S, Pappanou PN, Dahlen G, Fejerskov O. Periodontal conditions among adults in Southern Thailand. J Periodont Res. 2003; 38(2): 156-63.	2001	*	
Thailand	Songpaisan Y, Davies GN. Periodontal status and treatment needs in the Chiangmai/Lamphun provinces of Thailand. Community Dent Oral Epidemiol. 1989; 17(4): 196-9.	1987		
Thailand	Ingathit A, Thakkinsian A, Chairprasert A, Sangthawan P, Gojani P, Kiattisunthorn K, Ongajyooth L, Vanavan S, Sirivongs D, Thirakupt P, Mittal B, Singh AK, Thai-SEEK Group. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dial Transplant. 2010; 25(5): 1567-75.	2007-2008		
Thailand	Prasansuk S. Incidence/prevalence of sensorineural hearing impairment in Thailand and Southeast Asia. Audiology. 2000; 39(4): 207-11.	1989-1990		
Thailand	Assanangkornchai S, Sam-Angsri N, Rerngpongpan S, Lertnakorn A. Patterns of alcohol consumption in the Thai population: results of the National Household Survey of 2007. Alcohol Alcohol. 2010; 45(3): 278-85.	2003, 2007	*	
Thailand	Ministry of Public Health (Thailand). Thailand Burden of Disease and Injuries 1998-1999. [Unpublished].	1998-1999	*	
Thailand	Bhidayasiri R, Wannachai N, Limpabandhu S, Choeyim S, Suchonwanich Y, Tananyakul S, Tharathep C, Panjajaykul P, Srismith R, Chimabutra K, Phanthunchinda K, Asawachienjinda T. A national registry to determine the distribution and prevalence of Parkinson's disease in Thailand: implications of urbanization and pesticides as risk factors for Parkinson's disease. Neuroepidemiology. 2011; 37(3-4): 222-30.	2005-2011	*	†
Thailand	Visudtibhan A, Boonsopa C, Thampratankul L, Nuntnarumit P, Okaschareon C, Khongkhatithum C, Chiemchanya S, Visudhiphan P. Headache in junior high school students: types and characteristics in Thai children. J Med Assoc Thai. 2010; 93(5): 550-7.	2006	*	
Thailand	Luxemburger C, Thwai KL, White NJ, Webster HK, Kyle DE, Maclankirri L, Chongsuphajasiddhi T, Nosten F. The epidemiology of malaria in a Karen population on the western border of Thailand. Trans R Soc Trop Med Hyg. 1996; 90(2): 105-11 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	
Thailand	World Health Organization (WHO). Thailand WHO Leishmaniasis Country Profile.	1977, 1981-1982, 1984-1987, 1997, 2006-2010	*	
Thailand	Nuchprayoon S, Sanprasert V, Porksakorn C, Nuchprayoon L. Prevalence of bancroftian filariasis on the Thai-Myanmar border. Asian Pac J Allergy Immunol. 2003; 21(3): 179-88, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1998	*	
Thailand	Triteeraprapab S, Kamjanopas K, Porksakorn C, Sai-Ngam A, Yentakam S, Loymak S. Lymphatic filariasis caused by Brugia malayi in an endemic area of Narathiwat Province, southern of Thailand. J Med Assoc Thai. 2001; 82: 182-188, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2001	*	
Thailand	Massaga JJ, Salum FM, Savael ZX. Clinical and parasitological aspects of Bancroftian filariasis in Hale, northeast Tanzania. Cent Afr J Med. 2000; 46(9): 237-41.	1997-1999	*	
Thailand	Hara K, Yahara K, Gotoh K, Nakazono Y, Kashiwagi T, Imamura Y, Hamada N, Khositsakulchai W, Sanchai T, Khantawa B, Tharavichitkul P, Maneekarn N, Sirisanthana T, Watanabe H. Clinical study concerning the relationship between community-acquired pneumonia and viral infection in northern Thailand. Intern Med. 2011; 50(9): 991-8.	2006-2008	*	
Thailand	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
Thailand	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	
Thailand	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Thailand	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Thailand	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Thailand	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
Thailand	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Thailand	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Thailand	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Thailand	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Thailand	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Thailand	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Thailand	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Thailand	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Thailand	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Thailand	Patnaik P, Herrero R, Morrow RA, Munoz N, Bosch FX, Bayo S, El Gueddari B, Caceres E, Chichareon SB, Castellsague X, Meijer CJLM, Snijders PJF, Smith JS. Type-specific seroprevalence of herpes simplex virus type 2 and associated risk factors in middle-aged women from 6 countries: the IARC multicentric study. Sex Transm Dis. 2007; 34(12): 1019-24.	1985-1997		
Thailand	Dobbins JG, Mastro TD, Nokesom T, Sangkharomya S, Limpakamjanarat K, Weniger BG, Schmid DS. Herpes in the time of AIDS: a comparison of the epidemiology of HIV-1 and HSV-2 in young men in northern Thailand. Sex Transm Dis. 1999; 26(2): 67-74.	1991		
Thailand	Thailand Iodine Deficiency Disorder Prevalence Rate of School Children Annual Surveys 1992-2000 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1992-2000		
Thailand	Thailand Tracking Progress Towards the Sustainable Elimination of Iodine Deficiency Disorder 2000-2004 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2000-2004		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Thailand	Bureau of Epidemiology (Thailand). Thailand Annual Epidemiological Surveillance Report 2009. Nonthaburi, Thailand: Bureau of Epidemiology (Thailand), 2010.	2009		
Thailand	Panchareon C, Mekmullika J, Thisyakorn U, Nimmannitya S. Clinical features of diphtheria in Thai children: a historic perspective. Southeast Asian J Trop Med Public Health. 2002; 33(2): 352-4.	1976-1985		
Thailand	Muangchana C, Chunsuttiwat S, Rerks-Ngarm S, Kunasol P. Bacterial meningitis incidence in Thai children estimated by a rapid assessment tool (RAT). Southeast Asian J Trop Med Public Health. 2009; 40(3): 553-62.	2000-2001		
Thailand	Jacobs BB. Endemic goitre in highland villages in Northern Thailand Asia Pac J Public Health. 1988; 2(2): 127-34 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1986		
Thailand	Supawan V, Tungtrongchitr R, Prayurachong B, Pongpaew P, Sanchaisuriya P, Kassomboon P, Saowakontha S, Schelp FP, Migasena P. Urine iodine concentration and prevalence of goiter among rural women of child bearing ages in Northeast Thailand. J Med Assoc Thai. 1993; 76(4): 210-6 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1993		
Thailand	Aramrattana A, Limpjankit L, Leelapat P, Sriphrapradang A, Mangklabruks A, Pruenglampoo S, Vachiranakorn J, Rajatanavin R. Difference in goiter rates between two areas in Mae Hong Son Province despite an equally sufficient iodine supply. J Med Assoc Thai. 2002; 85(7): 831-8 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1998		
Thailand	World Health Organization Regional Office for South-East Asia (SEARO). Reported Cases of DF/DHF in Selected Countries in SEA Region. New Delhi, India: World Health Organization Regional Office for South-East Asia (SEARO).	1988-2008		
Thailand	Henrich TJ, Hutchaleela S, Jiwariyavej V, Barbazan P, Nitapattana N, Yoksan S, Gonzalez J-P. Geographic dynamics of viral encephalitis in Thailand. Microbes Infect. 2003; 5(7): 603-11.	1993-1998		
Thailand	Niamsanit S, Nunthapad P, Limpongpanurak S. Prevalence of Chlamydia trachomatis among women attending an antenatal clinic in Bangkok. Southeast Asian J Trop Med Public Health. 1988; 19(4): 609-13.	1988	*	
Thailand	Sirivanarungsun P, Kongsuk T, Arunpongpaian S, Kittirattanapaiboon P, Charatsingha A. Prevalence of Mental disorders in Thailand: A national survey 2003. J Ment Health Thai. 2004; 12(3): 178.	2003	*	
Thailand	WHO Regional Office for South-East Asia (SEARO). WHO South-East Asia Region: Reported Cases and Deaths of Dengue from 2003 to 2012. New Delhi, India: WHO Regional Office for South-East Asia (SEARO), 2013.	2003-2012	*	
Thailand	Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg. 1988; 38(1): 172-80.	1980-1981	*	
Thailand	Ng KP, Ngeow YF, K R, M R. Hepatitis B seroprevalence among University of Malaya Students in the Post-universal Infant Vaccination Era. Med J Malaysia. 2013; 68(2): 144-7.	2005-2011		
Thailand	Rianthavorn P, Fakhongyoo A, Yamsut S, Theamboonlers A, Poovorawan Y. Seroprevalence of hepatitis A among Thai population residing near Myanmar border. J Health Popul Nutr. 2011; 29(2): 174-7.	2009-2010		
Thailand	Prathanadi P, Miki M, Suprasert S. Incidence of cholelithiasis in the northern part of Thailand. J Med Assoc Thai. 1992; 75(8): 462-70.	1987-1990		
Thailand	Burke DS, Snitbhan R, Johnson DE, Scott RM. Age-specific prevalence of hepatitis A virus antibody in Thailand. Am J Epidemiol. 1981; 113(3): 245-9.	1971-1977		
Thailand	Viranuvatti V, Hemindra P, Chainuvati T. Anti-HAV in Thai population. J Med Assoc Thai. 1982; 65(7): 379-82.	1981		
Thailand	Innis BL, Snitbhan R, Hoke CH, Munindhorn W, Laorakpongse T. The declining transmission of hepatitis A in Thailand. J Infect Dis. 1991; 163(5): 989-95.	1985-1987		
Thailand	Poovorawan Y, Vimolkeij T, Chongsrisawat V, Theamboonlers A, Chumdermpadetsuk S. The declining pattern of seroepidemiology of hepatitis A virus infection among adolescents in Bangkok, Thailand. Southeast Asian J Trop Med Public Health. 1997; 28(1): 154-7.	1987, 1993, 1996		
Thailand	Issaragrisil S, Kaufman D, Thongput A, Chansung K, Thamprasit T, Piankijagum A, Anderson T, Shapiro S, Leaverton P, Young NS. Association of seropositivity for hepatitis viruses and aplastic anemia in Thailand. Hepatology. 1997; 25(5): 1255-7.	1989-1994		
Thailand	Kosuwon P, Sutra S, Kosalaraksa P, Poovorawan Y. Seroepidemiology of hepatitis A virus antibody in primary school children in Khon Kaen Province, northeastern Thailand. Southeast Asian J Trop Med Public Health. 1996; 27(4): 650-3.	1996		
Thailand	Panchareon C, Mekmullika J, Kasempimolporn S, Thisyakorn U, Wilde H. Seroprevalence of hepatitis A virus antibody among children and young adults in Bangkok. J Med Assoc Thai. 2001; 84(10): 1477-80.	1998-1999		
Thailand	Jutavittum P, Jiviriyawat Y, Jiviriyawat W, Youssukh A, Hayashi S, Toriyama K. Present epidemiological pattern of antibody to hepatitis A virus among Chiang Mai children, Northern Thailand. Southeast Asian J Trop Med Public Health. 2002; 33(2): 268-71.	1998-2000		
Thailand	Pramoosinsap C, Attamasirul K, Busagorn N, Maneerat Y, Nuchprayoon C, Tanprasert S, Srivatanakul P, Theamboonlers A, Hirsch P, Poovorawan Y. Susceptibility to hepatitis A virus infection among chronic liver disease patients and healthy blood donors in Thailand. Southeast Asian J Trop Med Public Health. 1999; 30(1): 91-5.	1999		
Thailand	Luksamjarulkul P, Tongpradit S, Vatanasomboon P, Utrarachki F. Sero-epidemiological study of hepatitis A virus infection among hill-tribe youth and household environmental sanitation, a hill-tribe community in northern Thailand. Southeast Asian J Trop Med Public Health. 2003; 34(3): 569-76.	1999-2000		
Thailand	Louisirothanakul S, Myint KSA, Srimee B, Kanoksinombat C, Khamboonruang C, Kunstadter P, Wasi C. The prevalence of viral hepatitis among the Hmong people of northern Thailand. Southeast Asian J Trop Med Public Health. 2002; 33(4): 837-44.	2000		
Thailand	Ratanasuwon W, Sonji A, Tiengrim S, Techasathit W, Suwanagoon S. Serological survey of viral hepatitis A, B, and C at Thai Central Region and Bangkok: a population base study. Southeast Asian J Trop Med Public Health. 2004; 35(2): 416-20.	2000-2002	*	†
Thailand	Chatproedprai S, Chongsrisawat V, Chatchatee P, Theamboonlers A, Yoocharoen P, Warinsathien P, Tharmaphompilas P, Waritratwat S, Sinlaparatsamee S, Chaiear K, Khwanjapanich S, Paupunwatanana S, Poovorawan Y. Declining trend in the seroprevalence of infection with hepatitis A virus in Thailand. Ann Trop Med Parasitol. 2007; 101(1): 61-8.	2004	*	†
Thailand	Nathalang O, Kuvanont S, Punyaprasidhi P, Tasaniyanonda C, Sriphaisal T. A preliminary study of the distribution of blood group systems in Thai blood donors determined by the gel test. Southeast Asian J Trop Med Public Health. 2001; 32(1): 204-7.	1998-2000		
Thailand	Sanpavat S. Exchange transfusion and its morbidity in ten-year period at King Chulalongkorn Hospital. J Med Assoc Thai. 2005; 88(5): 588-92.	1994-2003		
Thailand	Barusux S, Urvijitartoon Y, Puapairoj C, Romphruk A, Sriwanichtrak P. Association of HCV and Treponema pallidum infection in HIV infected northeastern Thai male blood donors. J Med Assoc Thai. 1997; S106-111.	1995-1997		
Thailand	Chongsrisawat V, Thawonsuk N, Theamboonlers A, Louisirothanakul S, Poovorawan Y. Hepatitis B virus DNA in unusual serological profiles of hepatitis B surface antigen-positive sera. Viral Immunol. 2006; 19(4): 623-9.	2004		
Thailand	Chunsuttiwat S, Biggs BA, Maynard J, Thamapalo S, Laoboripat S, Bovornsin S, Charanasri U, Pinyowiwat W, Kunasol P. Integration of hepatitis B vaccination into the expanded programme on immunization in Chonburi and Chiangmai provinces, Thailand. Vaccine. 1997; 15(6-7): 769-74.	1988, 1993		
Thailand	Ishida T, Takao S, Settheatham-Ishida W, Tiwawech D. Prevalence of hepatitis B and C virus infection in rural ethnic populations of Northern Thailand. J Clin Virol. 2002; 24(1-2): 31-5.	1996-1998		
Thailand	Johnson DE, Snitbhan R, Scott RM, Pearlman EJ, Kennedy RS. Hepatitis B in the rural tropics. Int J Epidemiol. 1980; 9(2): 123-9.	1975-1976		
Thailand	Luksamjarulkul P, Thammata N, Sujirarat D, Tiloklurs M. Hepatitis C virus infection among Thai blood donors: antibody prevalence, risk factors and development of risk screening form. Southeast Asian J Trop Med Public Health. 2004; 35(1): 147-54.	1999-2000		
Thailand	Nelson KE, Suriyanon V, Taylor E, Wongchak T, Kingkeow C, Srirak N, Lertsrimongkol C, Cheewawat W, Celentano D. The incidence of HIV-1 infections in village populations of northern Thailand. AIDS. 1994; 8(7): 951-5.	1990		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Thailand	Pichainarong N, Chaveepojnkajorn W, Luksamjarukul P, Sujjarat D, Keerecansuk T. Hepatitis B carrier among married hilltribe women in northern Thailand. <i>Southeast Asian J Trop Med Public Health</i> . 2003; 34(1): 114-9.	1999		
Thailand	Sawanpanyalert P, Boonmar S, Maeda T, Matsuura Y, Miyamura T. Risk factors for hepatitis C virus infection among blood donors in an HIV-epidemic area in Thailand. <i>J Epidemiol Community Health</i> . 1996; 50(2): 174-7.	1994		†
Thailand	Songsivilai S, Jinathongthai S, Wongsena W, Tiangpitayakorn C, Dharakul T. High prevalence of hepatitis C infection among blood donors in northeastern Thailand. <i>Am J Trop Med Hyg</i> . 1997; 57(1): 66-9.	1995		†
Thailand	Chanvitan P, Ruangnapa K, Janjindamai W, Disaneevate S. Outcomes of very low birth weight infants in Songklanagarind Hospital. <i>J Med Assoc Thai</i> . 2010; 93(2): 191-8.	2004	*	
Thailand	Sritipsukho S, Suarod T, Sritipsukho P. Survival and outcome of very low birth weight infants born in a university hospital with level II NICU. <i>J Med Assoc Thai</i> . 2007; 90(7): 1323-9.	2004	*	
Thailand	Bhumiratana A, Koyadun S, Suvannadabha S, Karnjanapas K, Rojanapremkus J, Buddhirakul P, Tantiwattanasup W. Field trial of the ICT filarisis for diagnosis of Wuchereria bancrofti infections in an endemic population of Thailand. <i>Southeast Asian J Trop Med Public Health</i> . 1999; 30(3): 562-8. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections</i> .	1998	*	
Thailand	Bhumiratana A, Wattanakul B, Koyadun S, Suvannadabha S, Rojanapremkus J, Tantiwattanasup W. Relationship between male hydrocele and infection prevalences in clustered communities with uncertain transmission of Wuchereria bancrofti on the Thailand-Myanmar border. <i>Southeast Asian J Trop Med Public Health</i> . 2002; 33(1): 7-17. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections</i> .	1999	*	
Thailand	Nuchprayoon S, Yentakam S, Sangprakarn S, Junpee A. Endemic bancroftian filariasis in Thailand: detection by Og4C3 antigen capture ELISA and the polymerase chain reaction. <i>J Med Assoc Thai</i> . 2001; 84(9): 1300-7. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections</i> .	1980-2000	*	
Thailand	Zielke E, Hinz E, Sucharit S. Lymphatic Filariasis in Thailand A Review on Distribution and Transmission. <i>Tropenmed Parasitol</i> . 1993; 141-8. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections</i> .	1985, 1987	*	
Thailand	Food and Agriculture Organization of the United Nations (FAO), World Health Organization (WHO), Joint WHO/FAO Workshop on Foodborne Trematode Infections in Asia. WHO Regional Office for the Western Pacific, 2004.	2004	*	
Thailand	Jongsuksuntigul P, Insombon T. Opisthorchiasis control in Thailand. <i>Acta Trop</i> . 2003; 88(3): 229-32.	2001		
Thailand	Thailand Programme to Eliminate Lymphatic Filariasis Country Report 2004 as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections</i> .	2004	*	
Thailand	Senanarong V, Harnhadungkit K, Pongvarin N, Thongtang O, Sukhatunga K, Vannasaeng S, International Stroke Society. Prevalence of Dementia, Including Vascular Dementia, in 1,070 Thai Elderly in Bangkok. <i>J Stroke Cerebrovasc Dis</i> . 2000; 9(2): 121-2.	1994-1997		†
Thailand	Jutavijittum P, Jiviriyawat Y, Jiviriyamat W, Yousukh A, Hayashi S, Itakura H, Toriyama K. Seroprevalence of Antibody to Hepatitis E Virus in Voluntary Blood Donors in Northern Thailand. <i>Tropical Medicine</i> . 2000; 42(2): 135-9.	1998-1999	*	†
Thailand	Straughn HK, Goldenberg RL, Tolosa JE, Daly S, de Codes J, Festin MR, Limpongsanurak S, Lumbiganon P, Paul VK, Peedicyal A, Purwar M, Sabogal JC, Shenoy S. Birthweight-specific neonatal mortality in developing countries and obstetric practices. <i>Int J Gynaecol Obstet</i> . 2003 Jan; 80(1): 71-8.	1998	*	†
Thailand	Thailand Plasmodium Falciparum Parasite Rate Data, Personal Communication with F. Nosten and V. Carrara, Shokto Malaria Research Unit, 2009 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database</i> . Oxford, United Kingdom: Malaria Atlas Project.	1998-2002	*	†
Thailand	Coleman RE, Maneechai N, Ponlawat A, Kumpitak C, Rachapaew N, Miller RS, Sattabongkot J. Short report: Failure of the OptiMAL rapid malaria test as a tool for the detection of asymptomatic malaria in an area of Thailand endemic for Plasmodium falciparum. <i>Am J Trop Med Hyg</i> . 2002; 67(6): 563-5 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database</i> . Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Thailand	Kitvatanachai S, Janyapoon K, Rhongbutsri P, Thap LC. A survey on malaria in mobile Cambodians in Aranyaprathet, Sa Kaeo Province, Thailand. <i>Southeast Asian J Trop Med Public Health</i> . 2003; 34(1): 48-53 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database</i> . Oxford, United Kingdom: Malaria Atlas Project.	2000	*	†
Thailand	Luxemburger C, Perea WA, Delmas G, Pruja C, Pecoul B, Moren A. Permethrin-impregnated bed nets for the prevention of malaria in schoolchildren on the Thai-Burmese border. <i>Trans R Soc Trop Med Hyg</i> . 1994; 88(2): 155-9 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database</i> . Oxford, United Kingdom: Malaria Atlas Project.	1990-1991	*	†
Thailand	Maneeboonyang W, Yimsamran S, Thanayavanich N, Puangsa-Art S, Wuthisen P, Prommongkol S, Charusabha C, Limsomboon J. Baseline epidemiological study of malaria and soil-transmitted helminthiasis in Thai rural communities near the Myanmar border. <i>J Trop Med Parasitol</i> . 2006; 29(1): 11-22 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database</i> . Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Thailand	Phimpraphi W, Paul RE, Yimsamran S, Puangsa-art S, Thanayavanich N, Maneeboonyang W, Prommongkol S, Sornklom S, Chaimungkun W, Chavez IF, Blanc H, Loareesuwan S, Sakuntabhai A, Singhasivanon P. Longitudinal study of Plasmodium falciparum and Plasmodium vivax in a Karen population in Thailand. <i>Malar J</i> . 2008; 7: 99 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database</i> . Oxford, United Kingdom: Malaria Atlas Project.	1994		
Thailand	Pothipak N, Srivilairit S, Pengruksa C, Faithong S, Haohan O, Chalermrut K, Tangpukdee N, Maneekan P, Radomyos P, Wilairatana P, Loareesuwan S. Health status: malaria, anemia and intestinal parasitic infections on the Thai-Myanmar border. <i>J Trop Med Parasitol</i> . 2005; 28(1): 26-30 as it appears in Malaria Atlas Project. <i>Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database</i> . Oxford, United Kingdom: Malaria Atlas Project.	2003		
Thailand	Thailand Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
The Bahamas	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-1992, 1995-2005		†
The Bahamas	Centre for Health Informatics and Multiprofessional Education, University College London. <i>Modell's Haemoglobinopathologist's Almanac</i> . London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
The Bahamas	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		
The Bahamas	Smadja D, Cabre P, May F, Fanon J-L, René-Corail P, Riocreux C, Charpentier J-C, Fournier P, Saint-Vil M, Ketterlé J. ERMANCIA: Epidemiology of Stroke in Martinique, French West Indies. <i>Stroke</i> . 2001; 32(12): 2741-7.	1998-1999		
The Bahamas	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997-1998, 2001, 2004, 2006-2009		
The Bahamas	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
The Bahamas	Ministry of Health (The Bahamas), Pan American Health Organization (PAHO). Bahamas Oral Health Survey of School Children 1999-2000.	1999-2000	*	
The Bahamas	Canino G, Shrout PE, Rubio-Stipec M, et al. The DSM-IV rates of child and adolescent disorders in Puerto Rico: Prevalence, correlates, service use, and the effects of impairment. <i>Arch Gen Psychiatry</i> . 2004; 61(1): 85-93.	1999-2000		
The Bahamas	Rubio-Stipec M, Canino GJ, Shrout P, Dulcan M, Freeman D, Bravo M. Psychometric properties of parents and children as informants in child psychiatry epidemiology with the Spanish Diagnostic Interview Schedule for Children (DISC.2). <i>J Abnorm Child Psychol</i> . 1994; 22(6): 703-20.	1992		
The Bahamas	Canino GJ, Bird HR, Shrout PE, Rubio-Stipec M, Bravo M, Martinez R, Sesman M, Guevara LM. The prevalence of specific psychiatric disorders in Puerto Rico. <i>Arch Gen Psychiatry</i> . 1987; 44(8): 727-35.	1984		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
The Bahamas	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), Ministry of Health (The Bahamas), United Nations Office on Drugs and Crime (UNODC). Bahamas Secondary School Drug Prevalence Survey 2003.	2003		
The Bahamas	Soyibo AK, Barton EN. Report from the Caribbean renal registry, 2006. West Indian Med J. 2007; 56(4): 355-63.	2006	*	
The Bahamas	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2004, 2007, 2010, 2012		
The Bahamas	Bird HR, Canino G, Rubio-Stipec M, Gould MS, Ribera J, Sesman M, Woodbury M, Huertas-Goldman S, Pagan A, Sanchez-Lacay A. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico. The use of combined measures. Arch Gen Psychiatry. 1988; 45(12): 1120-6.	1985-1986	*	
The Bahamas	Merikangas KR, Conway KP, Swendsen J, Febo V, Dierker L, Brunetto W, Stolar M, Canino G. Substance use and behaviour disorders in Puerto Rican youth: a migrant family study. J Epidemiol Community Health. 2009; 63(4): 310-6.	1990	*	
The Bahamas	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
The Bahamas	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
The Bahamas	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
The Bahamas	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
The Bahamas	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012		
The Bahamas	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
The Bahamas	Olindo S, Cabre P, Deschamps R, Chatot-Henry C, René-Corail P, Fournier P, Saint-Vil M, May F, Smadja D. Acute stroke in the very elderly: epidemiological features, stroke subtypes, management, and outcome in Martinique, French West Indies. Stroke. 2003; 34(7): 1593-7.	1998-1999		
The Bahamas	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Panchuk L, Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. Ann Hepatol. 2010; 9(1): 63-9.	2006-2008	*	†
The Bahamas	The Bahamas Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990	*	†
The Gambia	Central Statistics Department (Gambia), United Nations Children's Fund (UNICEF). Gambia Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	†
The Gambia	Gambia Bureau of Statistics (GBOS), United Nations Children's Fund (UNICEF). Gambia Multiple Indicator Cluster Survey 2005-2006. New York, United States: United Nations Children's Fund (UNICEF).	2005-2006	*	†
The Gambia	Gambia Bureau of Statistics (GBOS), United Nations Children's Fund (UNICEF). Gambia Multiple Indicator Cluster Survey 2010.	2010		
The Gambia	D'Alessandro U, Olaleye BO, McGuire W, Langerock P, Bennett S, Aikins MK, Thomson MC, Cham MK, Cham BA, Greenwood BM. Mortality and morbidity from malaria in Gambian children after introduction of an impregnated bednet programme. 1995; 345(8948): 479-83 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991-1992		†
The Gambia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		†
The Gambia	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		
The Gambia	Wilkins HA, Goll PH, Moore PJ. Schistosoma haematobium infection and haemoglobin concentrations in a Gambian community. Ann Trop Med Parasitol. 1985; 79(2): 159-6.	1980		
The Gambia	Adegbola RA, Falade AG, Sam BE, Aidoo M, Baldeh I, Hazlett D, Whittle H, Greenwood BM, Mulholland EK. The etiology of pneumonia in malnourished and well-nourished Gambian children. Pediatr Infect Dis J. 1994; 13(11): 975-82.	1990-1992		
The Gambia	Forgie IM, O'Neill KP, Lloyd-Evans N, Leinonen M, Campbell H, Whittle HC, Greenwood BM. Etiology of acute lower respiratory tract infections in Gambian children: I Acute lower respiratory tract infections in infants presenting at the hospital. Pediatr Infect Dis J. 1991; 10(1): 33-41.	1987-1988		
The Gambia	Forgie IM, O'Neill KP, Lloyd-Evans N, Leinonen M, Campbell H, Whittle HC, Greenwood BM. Etiology of acute lower respiratory tract infections in Gambian children: II Acute lower respiratory tract infection in children ages one to nine years presenting at the hospital. Pediatr Infect Dis J. 1991; 10(1): 42-7.	1986-1988		
The Gambia	Cutts F, Zaman SM, Enwere G, Jaffar S, Levine O, Okoko J, Oluwalana C, Vaughan A, Obaro S, Leach A, McAdam K, Biney E, Saaka M, Onwuchekwa U, Yallop F, Pierce N, Greenwood B, Adegbola R. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005; 365(9465): 1139-46.	2000-2004		
The Gambia	Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, Omosigho C, Weber M, Palmer A, Schneider G, Jobe K, Lahai G, Jaffar S, Secka O, Lin K, Ethevenaux C, Greenwood B. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine corrected for prevention of pneumonia and meningitis in Gambian infants. Lancet. 1997; 349(9060): 1191-7.	1993-1995		
The Gambia	Enwere G, Cheung YB, Zaman SMA, Akano A, Oluwalana C, Brown O, Vaughan A, Adegbola R, Greenwood B, Cutts F. Epidemiology and clinical features of pneumonia according to radiographic findings in Gambian children. Trop Med Int Health. 2007; 11(12): 1377-85.	2000-2004		
The Gambia	Robertson SE, Roca A, Alonso P, Simoes EAF, Kartasasmita CB, Olaleye DO, Odaibo GN, Collinson M, Venter M, Yuwei Zhu, Wright PF. Respiratory syncytial virus infection: denominator-based studies in Indonesia, Mozambique, Nigeria and South Africa. Bull World Health Organ. 2004; 12(82): 914-22.	1987-2001		
The Gambia	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997, 1999, 2001-2009		
The Gambia	World Health Organization (WHO). Assessment of yellow fever epidemic risk - a decision-making tool for preventive immunization campaigns. Wkly Epidemiol Rec. 2007; 82(18): 153-60.	1979-2007	*	
The Gambia	van der Sande MA, Milligan PJ, Nyan OA, Rowley JT, Banya WA, Ceessay SM, Dolmans WM, Thien T, McAdam KP, Walraven GE. Blood pressure patterns and cardiovascular risk factors in rural and urban Gambian communities. J Hum Hypertens. 2000; 14(8): 489-96.	1997		
The Gambia	Adegbembo AO, Adeyinka A, Danfillo IS, Mafeni JO, George MO, Aihveba N, Thorpe SJ, Enwonwo CO. National pathfinder survey of periodontal status and treatment needs in The Gambia. SADJ. 2000; 55(3): 151-7.	1995	*	
The Gambia	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
The Gambia	Nasrin D, Wu Y, Blackwelder WC, Farag TH, Saha D, Sow SO, Alonso PL, Breiman RF, Sur D, Faruque ASG, Zaidi AKM, Biswas K, Van Eijk AM, Walker DG, Levine MM, Kotloff KL. Health care seeking for childhood diarrhea in developing countries: evidence from seven sites in Africa and Asia. Am J Trop Med Hyg. 2013; 89(1 Suppl): 3-12.	2009-2011		
The Gambia	Gambia Rapid Assessment of Avoidable Blindness 2008 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2008		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
The Gambia	Faal H, Minassian DC, Dolin PJ, Mohamed AA, Ajewole J, Johnson GJ. Evaluation of a national eye care programme: re-survey after 10 years. <i>Br J Ophthalmol</i> . 2000; 84(9): 948-51. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1996	*	
The Gambia	Faal H, Minassian D, Sowa S, Foster A. National survey of blindness and low vision in The Gambia: results. <i>Br J Ophthalmol</i> . 1989; 73(2): 82-7. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1986		
The Gambia	Coleman R, Lopy L, Walraven G. The treatment gap and primary health care for people with epilepsy in rural Gambia. <i>Bull World Health Organ</i> . 2002; 80(5): 378-83.	1997-1999		†
The Gambia	Coleman R, Morison L, Paine K, Powell RA, Walraven G. Women's reproductive health and depression: a community survey in the Gambia, West Africa. <i>Soc Psychiatry Psychiatr Epidemiol</i> . 2006; 41(9): 720-7.	1999		
The Gambia	Kirk GD, Lesi OA, Mendy M, Akano AO, Sam O, Goedert JJ, Hainaut P, Hall AJ, Whittle H, Montesano R. The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. <i>Hepatology</i> . 2004; 39(1): 211-9.	1997-2001		
The Gambia	Mboto CI, Davies-Russell A, Fielder M, Jewell AP. Hepatocellular Carcinoma in The Gambia and the role of Hepatitis B and Hepatitis C. <i>Int Semin Surg Oncol</i> . 2005; 20.	2002		
The Gambia	Umoh NJ, Lesi OA, Mendy M, Bah E, Akano A, Whittle H, Hainaut P, Kirk GD. Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia. <i>Liver Int</i> . 2011; 31(2): 215-21.	1997-2001		
The Gambia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2004, 2010, 2012		
The Gambia	Ministry of Health and Social Welfare (Gambia). Gambia National Tuberculosis Prevalence Survey 2011-2012.	2011-2012		
The Gambia	Knox EG, McGregor IA. Glucose-6-phosphate dehydrogenase deficiency in a Gambian village. <i>Trans R Soc Trop Med Hyg</i> . 1965; 46-58.	1958-1961		
The Gambia	Allison AC, Charles LJ, McGregor IA. Erythrocyte Glucose-6-Phosphate Dehydrogenase Deficiency in West Africa. <i>Nature</i> . 1961; 190(4782): 1198-9.	1959-1961	*	
The Gambia	Welch SG, Lee J, McGregor IA, Williams K. Red cell glucose 6 phosphate dehydrogenase genotypes of the population of two West African villages. <i>Hum Genet</i> . 1978; 43(3): 315-20.	1963-1965	*	
The Gambia	Bah E, Parkin DM, Hall AJ, Jack AD, Whittle H. Cancer in the Gambia: 1988-97. <i>Br J Cancer</i> . 2001; 84(9): 1207-14.	1988-1997		
The Gambia	Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. Cancer Incidence in Five Continents. Vol. I to VIII. Lyon, France, IARC Press, 2005.	1987-1989, 1997-1998	*	
The Gambia	Mabey DC, Lloyd-Evans NE, Conteh S, Forsey T. Sexually transmitted diseases among randomly selected attendees at an antenatal clinic in The Gambia. <i>Br J Vener Dis</i> . 1984; 60(5): 331-6.	1981-1982	*	
The Gambia	Walraven G, Blum J, Dampha Y, Sowe M, Morison L, Winikoff B, Sloan N. Misoprostol in the management of the third stage of labour in the home delivery setting in rural Gambia: a randomised controlled trial. <i>BJOG</i> . 2005; 112(9): 1277-83.	2001-2004	*	
The Gambia	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec</i> . 2005; 80(13): 118-24.	2003	*	
The Gambia	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec</i> . 2010; 85(35): 337-48.	2009	*	
The Gambia	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec</i> . 2012; 87(34): 317-28.	2011	*	
The Gambia	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec</i> . 1999; 74(38): 313-6.	1998	*	
The Gambia	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec</i> . 2013; 88(35): 365-79.	2012	*	
The Gambia	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec</i> . 2011; 86(36): 389-99.	2010	*	
The Gambia	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec</i> . 2000; 75(28): 226-31.	1999	*	
The Gambia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1995; 70(25): 177-82.	1994	*	
The Gambia	Shaw M, van der Sande M, West B, Paine K, Ceessay S, Bailey R, Walraven G, Morison L, McAdam K. Prevalence of herpes simplex type 2 and syphilis serology among young adults in a rural Gambian community. <i>Sex Transm Infect</i> . 2001; 77(5): 358-65.	1998		†
The Gambia	Walraven G, Scherf C, West B, Ekpo G, Paine K, Coleman R, Bailey R, Morison L. The burden of reproductive-organ disease in rural women in The Gambia, West Africa. <i>Lancet</i> . 2001; 357(9263): 1161-7.	1999		
The Gambia	Goetghebuer T, West TE, Wermenbol V, Cadbury AL, Milligan P, Lloyd-Evans N, Adegbola RA, Mulholland EK, Greenwood BM, Weber MW. Outcome of meningitis caused by Streptococcus pneumoniae and Haemophilus influenzae type b in children in The Gambia. <i>Trop Med Int Health</i> . 2000; 5(3): 207-13.	1990-1995	*	†
The Gambia	Bijlmer HA, van Alphen L, Greenwood BM, Brown J, Schneider G, Hughes A, Menon A, Zanen HC, Valkenburg HA. The epidemiology of Haemophilus influenzae meningitis in children under five years of age in The Gambia, West Africa. <i>J Infect Dis</i> . 1990; 161(6): 1210-5.	1985-1987	*	
The Gambia	Atkinson SH, Rockett K, Sirugo G, Bejon PA, Fulford A, O'Connell MA, Bailey R, Kwiatkowski DP, Prentice AM. Seasonal childhood anaemia in West Africa is associated with the haptoglobin 2-2 genotype. <i>PLoS Med</i> . 2006; 3(5): e172 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001		
The Gambia	Allen SJ, Bennett S, Riley EM, Rowe PA, Jakobsen PH, O'Donnell A, Greenwood BM. Morbidity from malaria and immune responses to defined Plasmodium falciparum antigens in children with sickle cell trait in The Gambia. <i>Trans R Soc Trop Med Hyg</i> . 1992; 86(5): 494-8.	1989-1991	*	†
The Gambia	Mboto CI, Davies-Russell A, Fielder M, Jewell AP. Hepatitis C antibodies in asymptomatic first-time blood donors in The Gambia: prevalence and risk factors. <i>Br J Biomed Sci</i> . 2005; 62(2): 89-91.	2002	*	†
The Gambia	Gambia Plasmodium Falciparum Parasite Rate Data, Personal Communication with C.J. Drakeley 2008 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1990	*	†
The Gambia	Gambia Plasmodium Falciparum Parasite Rate Data, Personal Communication with S.W. Lindsay, MRC Laboratories, 2009 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006-2007	*	†
The Gambia	Gambia Plasmodium Falciparum Parasite Rate Data, Personal Communication with M. Pinder, MRC Laboratories, 2008 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988-1989		†
The Gambia	Akoghena OJ, Duah NO, Tetteh KKA, Dunyo S, Lanar DE, Pinder M, Conway DJ. Duration of naturally acquired antibody responses to blood-stage Plasmodium falciparum is age dependent and antigen specific. <i>Infect Immun</i> . 2008; 76(4): 1748-55 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
The Gambia	Allen SJ, Otoo LN, Cooke GA, O'Donnell A, Greenwood BM. Sensitivity of Plasmodium falciparum to chloroquine in Gambian children after five years of continuous chemoprophylaxis. <i>Trans R Soc Trop Med Hyg</i> . 1990; 84(2): 218 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
The Gambia	Clarke SE, Bøgh C, Brown RC, Pinder M, Walraven GE, Lindsay SW. Do untreated bednets protect against malaria? <i>Trans R Soc Trop Med Hyg</i> . 2001; 95(5): 457-62 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996-1997	*	†
The Gambia	Greenwood BM, David PH, Otoo-Forbes LN, Allen SJ, Alonso PL, Schellenberg JRA, Byass P, Hurwitz M, Menon A, Snow RW. Mortality and morbidity from malaria after stopping malaria chemoprophylaxis. <i>Trans R Soc Trop Med Hyg</i> . 1995; 89(6): 629-33 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991-1992	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
The Gambia	Greenwood BM, Greenwood AM, Smith AW, Menon A, Bradley AK, Snow RW, Sisay F, Bennett S, Watkins WM, N'jie ABH. A comparative study of Lapudrine- (chlorproguanil) and Maloprim- (pyrimethamine and dapsone) as chemoprophylactics against malaria in Gambian children. <i>Trans R Soc Trop Med Hyg.</i> 1989; 83(2): 182-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
The Gambia	Koram KA, Bennett S, Adiamah JH, Greenwood BM. Socio-economic risk factors for malaria in a peri-urban area of The Gambia. <i>Trans R Soc Trop Med Hyg.</i> 1995; 89(2): 146-50 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†
The Gambia	Lindsay SW, Campbell H, Adiamah JH, Greenwood AM, Bangali JE, Greenwood BM. Malaria in a peri-urban area of The Gambia. <i>Ann Trop Med Parasitol.</i> 1990; 84(6): 553-62 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
The Gambia	Lindsay SW, Wilkins HA, Zieler HA, Daly RJ, Petrarca V, Byass P. Ability of Anopheles gambiae mosquitoes to transmit malaria during the dry and wet seasons in an area of irrigated rice cultivation in The Gambia. <i>J Trop Med Hyg.</i> 1991; 94(5): 313-24 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
The Gambia	Majumbers S, Lindsay SW, Green C, Kandeh B, Fillinger U. Microbial larvicides for malaria control in The Gambia. <i>Malar J.</i> 2007; 6: 76 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006-2007	*	†
The Gambia	Marsh K, Hayes RH, Carson DC, Otoo L, Shenton F, Byass P, Zavala F, Greenwood BM. Anti-sporozoite antibodies and immunity to malaria in a rural Gambian population. <i>Trans R Soc Trop Med Hyg.</i> 1988; 82(4): 532-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
The Gambia	Nogaro SI, Hafalla JC, Walther B, Remarque EJ, Tetteh KK, Conway DJ, Riley EM, Walther M. The breadth, but not the magnitude, of circulating memory B cell responses to P. falciparum increases with age/exposure in an area of low transmission. <i>PLoS One.</i> 2011; 6(10): 25582 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2009	*	†
The Gambia	Riley EM, Allen SJ, Bennett S, Thomas PJ, O'Donnell A, Lindsay SW, Good MF, Greenwood BM. Recognition of dominant T cell-stimulating epitopes from the circumsporozoite protein of Plasmodium falciparum and relationship to malaria morbidity in Gambian children. <i>Trans R Soc Trop Med Hyg.</i> 1990; 84(5): 648-57 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
The Gambia	Sadiq ST, Glasgow KW, Drakeley CJ, Muller O, Greenwood BM, Mabey DC, Bailey RL. Effects of azithromycin on malariorimetric indices in The Gambia. <i>Lancet.</i> 1995; 346(8979): 881-2 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
The Gambia	Snow RW, Omumbo JA, Lowe B, Molyneux CS, Obiero JO, Palmer A, Weber MW, Pinder M, Nahlen B, Obonyo C, Newbold C, Gupta S, Marsh K. Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. <i>Lancet.</i> 1997; 349(9066): 1650-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996	*	†
The Gambia	Snow RW, Rowan KM, Greenwood BM. A trial of permethrin-treated bed nets in the prevention of malaria in Gambian children. <i>Trans R Soc Trop Med Hyg.</i> 1987; 81(4): 563-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
The Gambia	Snow RW, Rowan KM, Lindsay SW, Greenwood BM. A trial of bed nets (mosquito nets) as a malaria control strategy in a rural area of The Gambia, West Africa. <i>Trans R Soc Trop Med Hyg.</i> 1988; 82(2): 212-5 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986-1987	*	†
The Gambia	Von Seidlein L, Walraven G, Milligan PJ, Alexander N, Manneh F, Deen JL, Coleman R, Jawara M, Lindsay SW, Drakeley C, De Martin S, Oliaro P, Bennett S, Schim van der Loeff M, Okunoye K, Targett GA, McAdam KP, Doherty JF, Greenwood BM, Pinder M. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. <i>Trans R Soc Trop Med Hyg.</i> 2003; 97(2): 217-25 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999		†
The Gambia	Gambia Plasmodium Falciparum Parasite Rate Data, Personal Communication with M. Walther, MRC Laboratories, 2008 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008		
Timor-Leste	ICF Macro, Ministry of Finance (Timor-Leste), National Statistics Directorate (Timor-Leste). Timor-Leste Demographic and Health Survey 2009-2010. Calverton, United States: ICF Macro.	2009-2010		
Timor-Leste	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Timor-Leste	Brian G, Palagyi A, Ramke J, du Toit R, Naduvilath T. Cataract and its surgery in Timor-Leste. <i>Clin Experiment Ophthalmol.</i> 2006; 34(9): 870-9.	2005	*	
Timor-Leste	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2002-2005, 2007-2009		
Timor-Leste	Dos Santos MM, Amaral S, Harmen SP, Joseph HM, Fernandes JL, Counahan ML. The prevalence of common skin infections in four districts in Timor-Leste: a cross sectional survey. <i>BMC Infect Dis.</i> 2010; 61.	2007		
Timor-Leste	Ramke J, du Toit R, Palagyi A, Brian G, Naduvilath T. Correction of refractive error and presbyopia in Timor-Leste. <i>Br J Ophthalmol.</i> 2007; 91(7): 860-6. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2005		
Timor-Leste	Silove D, Bateman CR, Brooks RT, Fonseca CAZ, Steel Z, Rodger J, Soosay I, Fox G, Patel V, Bauman A. Estimating clinically relevant mental disorders in a rural and an urban setting in postconflict Timor Leste. <i>Arch Gen Psychiatry.</i> 2008; 65(10): 1205-12.	2006		
Timor-Leste	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2004, 2007, 2012		
Timor-Leste	Ramke J, Palagyi A, Naduvilath T, du Toit R, Brian G. Prevalence and causes of blindness and low vision in Timor-Leste. <i>Br J Ophthalmol.</i> 2007; 91(9): 1117-21. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2005	*	
Timor-Leste	Ramke J, Lee L, Brian G. Prevalence of diabetes among adults aged ≥40 years in Timor-Leste. <i>J Diabetes.</i> 2012; 4(4): 392-4.	2010	*	
Timor-Leste	Chhotray GP, Ranjit MR, Khuntia HK, Acharya AS. Precontrol observations on lymphatic filariasis and geo-helminthiasis in two coastal districts of rural Orissa. <i>Indian J Med Res.</i> 2005; 122(5): 388-94. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2001	*	
Timor-Leste	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Timor-Leste	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec.</i> 2007; 82(25): 225-32.	2006	*	
Timor-Leste	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Timor-Leste	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Timor-Leste	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Timor-Leste	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec.</i> 2008; 83(33): 293-300.	2007	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Timor-Leste	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012		
Timor-Leste	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010		
Timor-Leste	World Health Organization Regional Office for South-East Asia (SEARO). Reported Cases of DF/DHF in Selected Countries in SEA Region. New Delhi, India: World Health Organization Regional Office for South-East Asia (SEARO).	2004-2006	*	
Timor-Leste	World Health Organization Regional Office for South-East Asia (SEARO). Situation Update of Dengue in the SEA Region, 2010. New Delhi, India: World Health Organization Regional Office for South-East Asia (SEARO).	2007-2009	*	
Timor-Leste	WHO Regional Office for South-East Asia (SEARO). WHO South-East Asia Region: Reported Cases and Deaths of Dengue from 2003 to 2012. New Delhi, India: WHO Regional Office for South-East Asia (SEARO), 2013.	2004-2012	*	†
Timor-Leste	Ng KP, Ngeow YF, K R, M R. Hepatitis B seroprevalence among University of Malaya Students in the Post-universal Infant Vaccination Era. Med J Malaysia. 2013; 68(2): 144-7.	2005-2011	*	†
Timor-Leste	Merlin WHO Emergency Control of Malaria and other Vector Borne Diseases in East Timor as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000		
Timor-Leste	Bragoner R, Reyburn H, Nasveld P, Edstein M, Auliffe A. Rainy-season prevalence of malaria in Bobonaro district, East Timor. Ann Trop Med Parasitol. 2002; 96(7): 739-43 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001		
Timor-Leste	Timor-Leste Vital Registration Birth Data 1954 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1954	*	
Togo	Togo Demographic Survey 1961 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1961	*	†
Togo	United Nations Children's Fund (UNICEF). Togo Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000		†
Togo	Directorate General of Statistics and National Accounting (Togo), United Nations Children's Fund (UNICEF). Togo Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006		†
Togo	Demographic Research Unit (Togo), Department of Statistics (Togo), Macro Systems, Inc.; Institute for Resource Development, Ministry of Public Health, Social Affairs and the Status of Women (Togo). Togo Demographic and Health Survey 1988. Columbia, United States: Macro Systems, Inc.	1988	*	†
Togo	Department of Statistics (Togo), Macro International, Inc. Togo Demographic and Health Survey 1998. Calverton, United States: Macro International, Inc.	1998		
Togo	Directorate General of Statistics and National Accounting (Togo), United Nations Children's Fund (UNICEF). Togo Multiple Indicator Cluster Survey 2010. New York, United States: United Nations Children's Fund (UNICEF).	2010		†
Togo	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Togo	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		
Togo	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1984, 1987		
Togo	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1995, 1997-2009		
Togo	World Health Organization (WHO). Yellow fever in Africa and South America, 2007. Wkly Epidemiol Rec. 2009; 84(13): 97-104.	2007		
Togo	World Health Organization (WHO). Yellow fever, Togo. Wkly Epidemiol Rec. 2009; 82(5): 33-4.	2007		
Togo	Lai CK, Beasley R, Crane J, Folaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2001		
Togo	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010	*	
Togo	Delrieu I, Yaro S, Tamekloé TAS, Njanpop-Lafourcade B-M, Tall H, Jaillard P, Ouedraogo MS, Badziklou K, Sanou O, Drabo A, Gessner BD, Kambou JL, Mueller JE. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One. 2011; 6(5): e19513.	2007		
Togo	Balogou AA, Doh A, Grunitzky KE, others. [Neurological disorders and endemic goiter: comparative analysis of 2 provinces in Togo]. Bull Soc Pathol Exot. 2001; 94(5): 406.	1989, 1995		†
Togo	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2004, 2007, 2010, 2012	*	
Togo	Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J Health Geogr. 2010; 9: 57.	1980-2010	*	
Togo	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Togo	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Togo	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Togo	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Togo	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Togo	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Togo	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994		
Togo	Tchelougou D, Karou DS, Kpotsra A, Balaka A, Assih M, Bamoke M, Katawa G, Anani K, Simpore J, de Souza C. [Vaginal infections in pregnant women at the Regional Hospital of Sokode (Togo) in 2010 and 2011]. Med Sante Trop. 2013; 23(1): 49-54.	2010-2011		†
Togo	Togo Neurological Disorders in a Goitre Endemic Region: An Exhaustive Survey of a Rural Population of 4182 Inhabitants 1995 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1995		
Togo	Traore Y, Tamekloé TA, Njanpop-Lafourcade B-M, Loud M, Yaro S, Niamba D, Drabo A, Mueller JE, Koeck J-L, Gessner BD. Incidence, seasonality, age distribution, and mortality of pneumococcal meningitis in Burkina Faso and Togo. Clin Infect Dis. 2009; 49(3): 181-189.	2003-2006		
Togo	United Nations Office on Drugs and Crime (UNODC). Togo - Lomé Consumption of Drugs in Secondary Schools Study 2007.	2007	*	
Togo	Delange FM, Kibambe TN, Ouedraogo A, Acakpo A, Salami M, Jooste PL. Standardized evaluation of iodine nutrition in West Africa: the African phase of the thyromobil program. Food Nutr Bull. 2002; 23(4): 395-401 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1999	*	
Togo	Segbena AY, Prehu C, Wajcman H, Bardakjian-Michau J, Messie K, Feteke L, Vovor A, David M, Feingold J, Galacteros F. Hemoglobins in Togolese newborns: Hb S, Hb C, Hb Bart's, and alpha-globin gene status. Am J Hematol. 1998; 59(3): 208-13.	1995-1997	*	†
Togo	North ML, Piffaut MC, Duwig I, Locoh-Donou AG, Locoh-Donou AM. Detection of haemoglobinopathies at birth in Togo. Nouv Rev Fr Hematol. 1988; 30(4): 237-41.	1985-1987	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Togo	Togo Malaria and Anemia Among Children 0-12 Years in Afagnan 1991-1992 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991-1992	*	†
Togo	Agbo K, Gnyibor HA, Kessie K, Gnamey K. Anticorps et densité parasitaire chez les enfants de 0-3 ans sous chimioprophylaxie antipalustre a Korbonou (Nord-Togo). Afrique. Medecale. 1990; 29(284): 196-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989		
Togo	Gbary AR, Guiguemdé TR, Ouedraogo JB. [Emergence of chloroquine-resistant malaria in West Africa: the case of Sokode (Togo)]. Trop Med Parasitol. 1988; 39(2): 142-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987		
Tonga	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-1994, 1996, 1998		
Tonga	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Tonga	Foliaki S, Annesi-Measano I, Daniel R, Fakakovikaetau T, Magatongia M, Tuau-Potoi N, Waqatakirewa L, Cheng S, Pearce N. Prevalence of symptoms of childhood asthma, allergic rhinoconjunctivitis and eczema in the Pacific: the International Study of Asthma and Allergies in Childhood (ISAAC). Allergy. 2007; 62(3): 259-64.	1998-2003		
Tonga	Hill AV, Bowden DK, O'Shaughnessy DF, Weatherall DJ, Clegg JB. Beta thalassaemia in Melanesia: association with malaria and characterization of a common variant (IVS-1 nt 5 G→C). Blood. 1988; 72(1): 9-14.	1985-1987		
Tonga	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1999, 2001-2002, 2006, 2008-2009		
Tonga	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2002		
Tonga	Colagiuri S, Colagiuri R, Na'ati S, Muimuiheata S, Hussain Z, Palu T. The prevalence of diabetes in the Kingdom of Tonga. Diabetes Care. 2002; 25(2): 1378-83.	1999		
Tonga	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Tonga	Secretariat of the Pacific Community (SPC), World Health Organization Regional Office for the Western Pacific (WPRO-WHO). Second Generation Surveillance Surveys of HIV, Other STIs and Risk Behaviours in 6 Pacific Island Countries 2004-2005. Geneva, Switzerland: World Health Organization (WHO), 2006.	2005		
Tonga	Yanagihara RT, Garruto RM, Gajusek DC. Epidemiological surveillance of amyotrophic lateral sclerosis and parkinsonism-dementia in the commonwealth of the Northern Mariana Islands. Ann Neurol. 1983; 13(1): 79-86.	1980-1981		
Tonga	Newland HS, Woodward AJ, Taumoepeau LA, Karunaratne NS, Duguid IG. Epidemiology of blindness and visual impairment in the kingdom of Tonga. Br J Ophthalmol. 1994; 78(5): 344-8. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1991		
Tonga	Carapetis JR, Hardy M, Fakakovikaetau T, Taib R, Wilkinson L, Penny DJ, Steer AC. Evaluation of a screening protocol using auscultation and portable echocardiography to detect asymptomatic rheumatic heart disease in Tongan schoolchildren. Nat Clin Pract Cardiovasc Med. 2008; 5(7): 411-7.	2003-2004		
Tonga	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2007, 2010, 2012	*	
Tonga	Lutui T, Ofanoa M, Finau SA, Veikune MK. Typhoid fever in Tonga. Pac Health Dialog. 1999; 6(2): 240-4.	1980-1997	*	
Tonga	World Health Organization (WHO). Global leprosy situation, 2005. Wkly Epidemiol Rec. 2005; 80(34): 289-95.	2004	*	
Tonga	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Tonga	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	
Tonga	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Tonga	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Tonga	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
Tonga	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010		
Tonga	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993		
Tonga	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2000.	2000		
Tonga	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2001.	2001		
Tonga	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2002.	2002		
Tonga	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2003.	2003		
Tonga	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2004.	2004		
Tonga	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2007.	2007		
Tonga	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2008.	2008		
Tonga	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2009.	2009		
Tonga	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2010.	2010	*	†
Tonga	Tonga Vital Registration Birth Data 1994 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1994	*	
Trinidad and Tobago	Central Statistical Office (Trinidad and Tobago), United Nations Children's Fund (UNICEF). Trinidad and Tobago Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000		
Trinidad and Tobago	Central Statistical Office (Trinidad and Tobago) and United Nations Children's Fund (UNICEF). Trinidad and Tobago Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006		†
Trinidad and Tobago	Central Statistical Office (Trinidad and Tobago), International Statistical Institute. Trinidad and Tobago World Fertility Survey 1977. Voorburg, Netherlands: International Statistical Institute.	1977		
Trinidad and Tobago	Family Planning Association (Trinidad and Tobago), Westinghouse; Institute for Resource Development. Trinidad and Tobago Demographic and Health Survey 1987. Columbia, United States: Westinghouse; Institute for Resource Development.	1987		
Trinidad and Tobago	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-2003		
Trinidad and Tobago	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Trinidad and Tobago	Smadja D, Cabre P, May F, Fanon J-L, René-Corail P, Riocreux C, Charpentier J-C, Fournier P, Saint-Vil M, Ketterlé J. ERMANCIA: Epidemiology of Stroke in Martinique, French West Indies. <i>Stroke</i> . 2001; 32(12): 2741-7.	1998-1999		
Trinidad and Tobago	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997-1998, 2000-2002, 2004-2009		
Trinidad and Tobago	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	2002		
Trinidad and Tobago	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Trinidad and Tobago	Nathan MB, Beckles G, Tikasingh ES, Hamilton PJ, Monteil S. Parasitological and clinical studies of <i>Wuchereria bancrofti</i> and <i>Mansonella ozzardi</i> in coastal north Trinidad, West Indies. <i>West Indian Med J</i> . 1982; 31(4): 168-76.	2002-2009	*	
Trinidad and Tobago	Canino G, Shrout PE, Rubio-Stipec M, et al. The DSM-IV rates of child and adolescent disorders in Puerto Rico: Prevalence, correlates, service use, and the effects of impairment. <i>Arch Gen Psychiatry</i> . 2004; 61(1): 85-93.	1999-2000		
Trinidad and Tobago	Rubio-Stipec M, Canino GJ, Shrout P, Dulcan M, Freeman D, Bravo M. Psychometric properties of parents and children as informants in child psychiatry epidemiology with the Spanish Diagnostic Interview Schedule for Children (DISC-2.2). <i>J Abnorm Child Psychol</i> . 1994; 22(6): 703-20.	1992	*	
Trinidad and Tobago	Canino GJ, Bird HR, Shrout PE, Rubio-Stipec M, Bravo M, Martinez R, Sesman M, Guevara LM. The prevalence of specific psychiatric disorders in Puerto Rico. <i>Arch Gen Psychiatry</i> . 1987; 44(8): 727-35.	1984	*	
Trinidad and Tobago	Bassaw B, Khan A, Ramjohn M, Ramoutar V, Bassaw L. Pregnancy outcome in early-onset severe pre-eclampsia in Trinidad. <i>Int J Gynaecol Obstet</i> . 2012; 116(1): 78-80.	1998-2007	*	
Trinidad and Tobago	Kandimala BH, Sijusingh A, Nayak BS, Maiya SS. Early antenatal serum lipid levels and the risk of pre-eclampsia in Trinidad and Tobago. <i>Arch Physiol Biochem</i> . 2011; 117(4): 215-21.	2006-2008		
Trinidad and Tobago	Maharaj RG, Alli F, Cumberbatch K, Laloo P, Mohammed S, Ramesar A, Rampersad N, Roopnarinesingh N, Ramtahal I. Depression among adolescents, aged 13-19 years, attending secondary schools in Trinidad: prevalence and associated factors. <i>West Indian Med J</i> . 2008; 57(4): 352-9.	2003	*	
Trinidad and Tobago	Soyibo AK, Barton EN. Report from the Caribbean renal registry, 2006. <i>West Indian Med J</i> . 2007; 56(4): 355-63.	2006		
Trinidad and Tobago	Bhugra D, Hilwig M, Hossein B, Marceau H, Neehall J, Leff J, Mallett R, Der G. First-contact incidence rates of schizophrenia in Trinidad and one-year follow-up. <i>Br J Psychiatry</i> . 1996; 169(5): 587-92.	1992	*	
Trinidad and Tobago	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Trinidad and Tobago	Bird HR, Canino G, Rubio-Stipec M, Gould MS, Ribera J, Sesman M, Woodbury M, Huertas-Goldman S, Pagan A, Sanchez-Lacay A. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico. The use of combined measures. <i>Arch Gen Psychiatry</i> . 1988; 45(12): 1120-6.	1985-1986		
Trinidad and Tobago	Batson YA, Teelucksingh S, Maharaj R, Singh V, Balkaran S, Cockburn B. Screening for diabetes in schoolchildren in Trinidad, West Indies. <i>Paediatr Int Child Health</i> . 2013; 33(1): 37-41.	2009	*	
Trinidad and Tobago	Sutton RN. Erythrocyte glucose-6-phosphate-dehydrogenase deficiency in Trinidad. <i>Lancet</i> . 1963; 1(7286): 855.	1961-1963	*	
Trinidad and Tobago	Dr. Elizabeth Quamina Cancer Registry, Ministry of Health (Trinidad and Tobago). Trinidad and Tobago Cancer Incidence 1995-2006. [Unpublished].	1995-2006	*	
Trinidad and Tobago	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec</i> . 2005; 80(34): 289-95.	2004	*	
Trinidad and Tobago	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec</i> . 2009; 84(33): 333-40.	2008	*	
Trinidad and Tobago	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec</i> . 2010; 85(35): 337-48.	2009	*	
Trinidad and Tobago	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec</i> . 2008; 83(33): 293-300.	2007	*	
Trinidad and Tobago	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec</i> . 2011; 86(36): 389-99.	2010	*	
Trinidad and Tobago	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1994; 69(20): 145-51.	1993		
Trinidad and Tobago	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1995; 70(25): 177-82.	1994	*	
Trinidad and Tobago	Merikangas KR, Conway KP, Swendsen J, Febo V, Dierker L, Brunetto W, Stolar M, Canino G. Substance use and behaviour disorders in Puerto Rican youth: a migrant family study. <i>J Epidemiol Community Health</i> . 2009; 63(4): 310-6.	1990	*	
Trinidad and Tobago	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Trinidad and Tobago	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Trinidad and Tobago	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Trinidad and Tobago	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Trinidad and Tobago	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012		
Trinidad and Tobago	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Trinidad and Tobago	Olindo S, Cabre P, Deschamps R, Chatot-Henry C, René-Corail P, Fournier P, Saint-Vil M, May F, Smadja D. Acute stroke in the very elderly: epidemiological features, stroke subtypes, management, and outcome in Martinique, French West Indies. <i>Stroke</i> . 2003; 34(7): 1593-7.	1998-1999		
Trinidad and Tobago	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L, Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Ann Hepatol</i> . 2010; 9(1): 63-9.	2006-2008		†
Trinidad and Tobago	Blattner WA, Saxinger C, Riedel D, Hull B, Taylor G, Cleghorn F, Gallo R, Blumberg B, Bartholomew C. A study of HTLV-I and its associated risk factors in Trinidad and Tobago. <i>J Acquir Immune Defic Syndr</i> . 1990; 3(11): 1102-8.	1982-1984	*	
Trinidad and Tobago	Stafford JL, Hill KR, Arneaud JD. Rhesus factor distribution in the Caribbean; preliminary communication. <i>West Indian Med J</i> . 1955; 4(2): 119-25.	1949-1951		
Trinidad and Tobago	Nathan MB, Hamilton PJ, Monteil S, Tikasingh ES. Bancroftian filariasis in coastal north Trinidad: the effects of mass chemotherapy using spaced doses of diethylcarbamazine citrate on human microfilaraemias and vector infection rates. <i>Trans R Soc Trop Med Hyg</i> . 1987; 81(4): 663-8. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections</i> .	1980-1981		†
Trinidad and Tobago	Trinidad and Tobago Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		†
Tunisia	Ministry of Public Health (Tunisia), National Office for Family and Population (Tunisia), League of Arab States. Tunisia Maternal and Child Health Survey 1994-1995.	1994-1995		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Tunisia	Macro Systems, Inc.; Institute for Resource Development, National Office for Family and Population, Ministry of Public Health (Tunisia), Tunisia Demographic and Health Survey 1988. Columbia, United States: Macro Systems, Inc.	1988	*	†
Tunisia	World Health Organization (WHO). Tunisia World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		
Tunisia	Ministry of Regional Development and Planning (Tunisia), National Institute of Statistics (Tunisia), United Nations Children's Fund (UNICEF). Tunisia Multiple Indicator Cluster Survey 2011-2012. New York, United States: United Nations Children's Fund (UNICEF), 2014.	2011-2012		
Tunisia	Al-Gallas N, Bahri O, Bouratben A, Ben Haasen A, Ben Aissa R. Etiology of acute diarrhea in children and adults in Tunis, Tunisia, with emphasis on diarrheagenic Escherichia coli: prevalence, phenotyping, and molecular epidemiology. <i>Am J Trop Med Hyg.</i> 2007; 77(3): 571-82.	2001-2004		†
Tunisia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Tunisia	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		
Tunisia	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol.</i> 2008; 121(4): 947-954.	1996, 2001		
Tunisia	Soltani MS, Behir A, Amri F, Gueddiche N, Sfar T, Sahloul S, Garbouj M. Epidemiologie des meningites a Haemophilus influenzae en Tunisie. <i>East Mediterr Health J.</i> 2005; 11(1-2): 14-27.	2000-2001		
Tunisia	Fatoum S, Abbas S. Some data on the epidemiology of hemoglobinopathies in Tunisia. <i>Hemoglobin.</i> 1985; 4(9): 423-9.	1982-1985		
Tunisia	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2003, 2006-2007		
Tunisia	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Tunisia	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2001		
Tunisia	Papoz L, Ben Khalifa F, Eschwege E, Ben Ayed H. Diabetes mellitus in Tunisia: description in urban and rural populations. <i>Int J Epidemiol.</i> 1988; 17(2): 419-22.	1981		
Tunisia	Gharbi M, Akrouf M, Zouari B. Prevalence and risk factors of non-insulin-dependent diabetes mellitus in the rural and urban population of Tunisia. <i>Rev Epidemiol Sante Publique.</i> 2002; 50(4): 349-55.	1990		
Tunisia	Bouguerra R, Alberti H, Salem LB, Rayana CB, Atti JE, Gaigi S, Slama CB, Zouari B, Alberti K. The global diabetes pandemic: the Tunisian experience. <i>Eur J Clin Nutr.</i> 2007; 61(2): 160-5.	1997		
Tunisia	Ben Romdhane H, Skhiri H, Bougafes S, Ennigrou S, Gharbi D, Chahed MK, Achour N. Hypertension prevalence, awareness, treatment and control: results from a community based survey. <i>Tunis Med.</i> 2005; 83(Suppl 5): 41-6.	2001	*	
Tunisia	Attia Romdhane N, Ben Hamida M, Mrabet A, Lamaout A, Samoud S, Ben Hamda M, Ben Hamda M, Oueslati S. Prevalence study of neurologic disorders in Kelibia (Tunisia). <i>Neuroepidemiology.</i> 1993; 12(5): 285-99.	1985-1990		
Tunisia	Hajer S, Neila T, Sondess HF, Fekria O, Nabila A, Mahboubia K, Melika D, Faïda O, Amina B, Raja B, Hedi R, Sadok M, Naima K, Slaheddine F, Taieb M. A lower-cost protocol for sickle cell disease neonatal screening in Tunisia. <i>Ann Saudi Med.</i> 2012; 32(1): 49-52.	2010-2011	*	
Tunisia	Barsoum RS. Burden of chronic kidney disease: North Africa. <i>Kidney Int Suppl.</i> 2013; 3: 164-6.	2000-2010	*	
Tunisia	Soltani M, Bouanene I, Trabelsi A, Harbi A, Hachicha M, Amri F, Boussina S, Gueddiche MN, Sfar MT, Teheb N, Ben Ghorbel M, Ben Hamida E. [Epidemiology of rotavirus gastroenteritis among children under 5 years of age in Tunisia - results of sentinel hospital surveillance 2009 to 2011]. <i>Rev Epidemiol Sante Publique.</i> 2012; 60(6): 473-80.	2009-2011	*	
Tunisia	Fodha I, Choukha A, Peenze I, De Beer M, Dewar J, Geyer A, Messaadi F, Trabelsi A, Boujaafar N, Taylor MB, Steele D. Identification of viral agents causing diarrhea among children in the Eastern Center of Tunisia. <i>J Med Virol.</i> 2006; 78(9): 1198-203.	2003-2005		
Tunisia	Trabelsi A, Peenze I, Pager C, Jeddi M, Steele D. Distribution of rotavirus VP7 serotypes and VP4 genotypes circulating in Sousse, Tunisia, from 1995 to 1999: emergence of natural human reassortants. <i>J Clin Microbiol.</i> 2000; 38(9): 3415-9.	1995-1999		
Tunisia	Letaief A, Boughzala E, Kaabia N, Ernez S, Abid F, Ben Chaabane T, Ben Jemaa M, Boujnah R, Chakroun M, Daoud M, Gaha R, Kafsi N, Khalfallah A, Slimane L, Zaouali M. Epidemiology of infective endocarditis in Tunisia: a 10-year multicenter retrospective study. <i>Int J Infect Dis.</i> 2007; 11(5): 430-3.	1991-2000		
Tunisia	Mrabet A, Attia-Romdhane N, Ben Hamida M, Gharbi N, Le Noan H, Hentati R, Ben Mansour J, Srairi I. Epidemiologic aspects of cerebrovascular accidents in Tunisia. <i>Rev Neurol (Paris).</i> 1990; 146(4): 297-301.	1988	*	
Tunisia	Ayed S, Négre AD, Nabi M, Kamel N, Jebri AM, Siddhom M. [Prevalence and causes of blindness in the Tunisian Republic. Results of a national survey conducted in 1993. Tunisian Team on the Evaluation of Blindness]. <i>Sante.</i> 1998; 8(4): 275-82, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1993		
Tunisia	Attia-Romdhane N, Mrabet A, Ben Hamida M. Prevalence of epilepsy in Kelibia, Tunisia. <i>Epilepsia.</i> 1993; 34(6): 1028-32.	1985		
Tunisia	Coursaget P, Simpson B, el Goulli N, Ben Khelifa H, Kastally R. Hepatitis C core antibody detection in acute hepatitis and cirrhosis patients from Tunisia. <i>Pathol Biol.</i> 1992; 40(6): 646-8.	1992		
Tunisia	Triki H. [Epidemiology of hepatitis B virus, hepatitis C virus and Delta virus in the general population and in liver cirrhosis in Tunisia]. <i>Arch Inst Pasteur Tunis.</i> 1994; 71(3-4): 403-6.	1994		
Tunisia	Bahri O, Ezrikouri S, Alaya-Bouafif NB, Iguer F, Feydi AEE, Mestiri H, Benazzouz M, Khalfallah T, Afifi R, Elkhilal L, Berkane S, Marchio A, Debi N, Dejean A, Pineau P, Triki H, Benjelloun S. First multicenter study for risk factors for hepatocellular carcinoma development in North Africa. <i>World J Hepatol.</i> 2011; 3(1): 24-30.	2002-2005		
Tunisia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
Tunisia	Hammami S, Mehri S, Hajem S, Koubaa N, Souid H, Hammami M. Prevalence of diabetes mellitus among non institutionalized elderly in Monastir City. <i>BMC Endocr Disord.</i> 2012; 15.	2008-2009		
Tunisia	Ben Khalifa F, Mekaouar A, Taktak S, Hamhoum M, Jebara H, Kodja A, Zouari B, Chakroun M. A five-year study of the incidence of insulin-dependent diabetes mellitus in young Tunisians (preliminary results). <i>Diabetes Metab.</i> 1997; 23(5): 395-401.	1990-1994		
Tunisia	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant.</i> 1988; 3(6): 714-27.	1985-1986		
Tunisia	Couñil E, Chermi N, Kharrat M, Achour A, Trimech H. Trends of incident dialysis patients in Tunisia between 1992 and 2001. <i>Am J Kidney Dis.</i> 2008; 51(3): 463-70.	1992-2001		
Tunisia	Barsoum RS. End-stage renal disease in North Africa. <i>Kidney Int Suppl.</i> 2003; 83: S111-4.	1993-2002	*	
Tunisia	Naicker S. Burden of end-stage renal disease in sub-Saharan Africa. <i>Clin Nephrol.</i> 2010; 74(Suppl 1): S13-6.	2008-2010	*	
Tunisia	Helal I, Kaaroud H, Gouche R, Ben Moussa F, Ben Maiz H, Kheder A. The pattern of histologically-proven acute post-infectious glomerulonephritis in Tunisian adults seen in 1976-2004. <i>Arab J Nephrol Transplant.</i> 2012; 5(2): 93-6.	1976-2004	*	
Tunisia	World Health Organization (WHO). Tunisia WHO Leishmaniasis Country Profile.	1996-2008	*	
Tunisia	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec.</i> 2007; 82(25): 225-32.	2006	*	
Tunisia	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Tunisia	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Tunisia	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Tunisia	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec.</i> 2008; 83(33): 293-300.	2007	*	
Tunisia	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Tunisia	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
Tunisia	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
Tunisia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Tunisia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994		†
Tunisia	Znazen A, Zribi N, Maazoun L, Khrouf S, Hammami A. Epidemiological features of sexually transmitted infections among women in Tunisia: high prevalence of Chlamydia trachomatis among women requesting abortion. <i>Sex Transm Infect.</i> 2013; 89(1): 56.	2010-2011		
Tunisia	Tunisia National Nutrition Survey 1996-1997 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1996-1997		
Tunisia	Thabet F, Tilouche S, Tabarki B, Amri F, Guediche M-N, Sfar M-T, Harbi A, Yacoub M, Essoussi A-S. [Pneumococcal meningitis mortality in children. Prognostic factors in a series of 73 cases]. <i>Arch Pediatr.</i> 2007; 14(4): 334-7.	1995-2002		
Tunisia	Hsairi M, Ben Slama F, Ben Rayana C, Fakhfakh R, Ben Romdhane H, Vester A, Kallal Z, Achour N. [Prevalence of endemic goiter in the north western region of Tunisia-1993]. <i>Tunis Med.</i> 1994; 72(12): 663-9 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1993	*	
Tunisia	Ben Salem N, Ben Rachid M, Hanks C, Zribi A, Gherbi M, Lapointe N. STD/HIV seroprevalence among women attending an antenatal clinic in Tunis. Paper presented at: International Conference on AIDS; 1993 June 6-11; Berlin, Germany. Abstract number PO-C09-2792.	1991	*	
Tunisia	Houcine N, Jacques R, Salma F, Anne-Gaëlle D, Amin S, Mohsen H, Hamadi B, Christophe R, Patrice A, Mahjoub A, Caroline S. Seroprevalence of hepatitis E virus infection in rural and urban populations, Tunisia. <i>Clin Microbiol Infect.</i> 2012; 18(5): E119-121.	2007-2008		
Tunisia	Blibech R, Gharbi Y, Mrad A, Zahra H, Mahjoub T, Belhaj A, Laatri Z, Kastally R, Rosa R. Incidence of glucose-6-phosphate dehydrogenase (G6PD) deficiency in Tunisian populations. <i>Nouv Rev Fr Hematol.</i> 1989; 31(3): 189-91.	1986-1988		
Tunisia	Letaief A, Kaabia N, Gaha R, Bousaadia A, Lazrag F, Trabelsi H, Ghannem H, Jenni L. Age-specific seroprevalence of hepatitis a among school children in central Tunisia. <i>Am J Trop Med Hyg.</i> 2005; 73(1): 40-3.	2001-2002	*	
Tunisia	Safer L, Bdioui F, Braham A, Ben Salem K, Soltani MS, Bchir A, Saffar H. [Epidemiology of cholelithiasis in central Tunisia. Prevalence and associated factors in a nonselected population]. <i>Gastroenterol Clin Biol.</i> 2000; 24(10): 883-7.	1998		
Tunisia	Said Y, Debbeche R, Ben Ali Z, Bouzid K, Trabelsi S, Bouzaïdi S, Salem M, Rajhi H, Kouni Chahed M, Najjar T. [Epidemiological, clinical and therapeutic features of hepatocellular carcinoma in cirrhotic patients]. <i>Tunis Med.</i> 2012; 90(6): 468-72.	1997-2009	*	†
Tunisia	Reziz D, Ouneissa R, Mhiri L, Mejri S, Haddad-Boubaker S, Ben Alaya N, Triki H. [Seroprevalences of hepatitis A and E infections in Tunisia]. <i>Pathol Biol.</i> 2008; 56(3): 148-53.	2004-2006		
Tunisia	Kacem N, Chakroun T, Moussa H, Abdelkefi S, Houissa B, Chiaroni J, Jenni Yacoub S. RHD zygosity assignments based on most probable genotype and hybrid Rhesus box detection in Tunisia. <i>Transfus Med.</i> 2012; 22(5): 362-6.	2010-2012		
Tunisia	Triki H, Said N, Ben Salah A, Arrouji A, Ben Ahmed F, Bouguerra A, Hmida S, Dhahri R, Dellagi K. Seroprevalence of hepatitis B, C and delta viruses in Tunisia. <i>Trans R Soc Trop Med Hyg.</i> 1997; 91(1): 11-4.	1993-1994	*	
Tunisia	Desjeux P. Leishmaniasis. Public health aspects and control. <i>Clin Dermatol.</i> 1996; 14(5): 417-23.	1983	*	
Tunisia	Alaya A, Najjar MF, Nouri A. Pediatric urolithiasis in the central coast of Tunisia: Epidemiologic changes over the past twenty-five years. <i>Saudi J Kidney Dis Transpl.</i> 2010; 21(4): 762-71.	1991-1994, 2007		
Tunisia	Alaya A, Nouri A, Najjar MF. Paediatric renal stone disease in Tunisia: a 12 years experience. <i>Arch Ital Urol Androl.</i> 2008; 80(2): 50-5.	1994-2006		
Tunisia	Tunisia Vital Registration Birth Data 1989 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1989		
Tunisia	League of Arab States, National Office for Family and Population, Ministry of Public Health (Tunisia), Pan Arab Project for Family Health (PAPFAM). Tunisia Family Health Survey 2001.	2001		†
Turkey	Institute of Population Studies, Hacettepe University (Turkey), International Statistical Institute. Turkey World Fertility Survey 1978. Voorburg, Netherlands: International Statistical Institute.	1978		†
Turkey	Institute of Population Studies, Hacettepe University, Macro International, Inc, Ministry of Health (Turkey). Turkey Demographic and Health Survey 1993. Calverton, United States: Macro International, Inc.	1993		†
Turkey	Institute of Population Studies, Hacettepe University, Macro International, Inc. Turkey Demographic and Health Survey 1998. Calverton, United States: Macro International, Inc.	1998		
Turkey	Institute of Population Studies, Hacettepe University, Ministry of Health (Turkey). Turkey Demographic and Health Survey 2003-2004. Ankara, Turkey: Institute of Population Studies, Hacettepe University.	2003-2004		
Turkey	World Health Organization (WHO). Turkey World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		
Turkey	Turkey Demographic Survey 1989 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1989		
Turkey	AMATEM (Turkey), Plaza Ltd. Research, World Health Organization (WHO). Turkey WHO Multi-country Survey Study on Health and Health System Responsiveness 2000-2001. Geneva, Switzerland: World Health Organization (WHO).	2000-2001		
Turkey	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romano L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. <i>Scand J Clin Lab Invest.</i> 2007; 67(1): 39-69.	1990-2006		†
Turkey	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2006		
Turkey	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		
Turkey	Koksal I, Bayraktar O, Yilmaz G, Cayan R, Aydin K, Sucu N, Ozlu T, Bulbul Y, Oztuna F, Ozcan DI, OguS C, Tekeli E, Kaya A, Ayaz C, Dagli CE, Yildiz O, Oymak FS, Kalkan A, Muz MH, Turgut H, Fiseki F, Heper Y, Uzaslan E. Etiological agents of community-acquired pneumonia in adult patients in Turkey: a multicentric, cross-sectional study. <i>Tuberk Toraks.</i> 2010; 58(2): 119-27.	2003-2008		
Turkey	Kiliç A, Gül U, Aslan E, Soylu S. Dermatological findings in the senior population of nursing homes in Turkey. <i>Arch Gerontol Geriatr.</i> 2008; 47(1): 93-8.	2006		
Turkey	Ergonul O, Erbay A, Eren S, Dokuzoguz B. Analysis of the case fatality rate of tetanus among adults in a tertiary hospital in Turkey. <i>Eur J Clin Microbiol Infect Dis.</i> 2003; 22(3): 188-90.	1990-2000		
Turkey	Erem M, Cakmak A, Saka G, Ceylan A. Neonatal tetanus in the South-Eastern region of Turkey: changes in prognostic aspects by better health care. <i>J Trop Pediatr.</i> 2004; 50(5): 297-300.	1994-2001		
Turkey	Boru UT, Oztürk E, Taşdemir M, Sur H. Living alone following first-ever stroke: a prospective study in Turkey identifying the risk factors and evaluating their effects. <i>N Z Med J.</i> 2007; 120(1255): U2559.	2002-2003		
Turkey	Kumral E, Ozkaya B, Sagduyu A, Sirin H, Vardarli E, Pehlivan M. The Edge Stroke Registry: A Hospital-Based Study in the Aegean Region, Izmir, Turkey. <i>Cerebrovasc Dis.</i> 1998; 8(5): 278-88.	1991-1995		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Turkey	Aksu AEK, Metintas S, Saracoglu ZN, Gurel G, Sabuncu I, Arikan I, Kalyoncu C. Acne: prevalence and relationship with dietary habits in Eskisehir, Turkey. <i>J Eur Acad Dermatol Venereol</i> . 2012; 26(12): 1503-9.	2011		
Turkey	Aktan S, Ozmen E, Sanli B. Anxiety, depression, and nature of acne vulgaris in adolescents. <i>Int J Dermatol</i> . 2000; 39(5): 354-7.	1998-2000		
Turkey	Tuncel AA, Erbagci Z. Prevalence of skin diseases among male adolescent and post-adolescent boarding school students in Turkey. <i>J Dermatol</i> . 2005; 32(7): 557-64.	2004		
Turkey	Uslu G, Sendur N, Uslu M, Savk E, Karaman G, Eskin M. Acne: prevalence, perceptions and effects on psychological health among adolescents in Aydin, Turkey. <i>J Eur Acad Dermatol Venereol</i> . 2008; 22(4): 462-9.	2006		
Turkey	Ministry of Health (Turkey). Turkey Chronic Diseases and Risk Factors Study 2011.	2011		
Turkey	Eitler N, Velipasoglu S, Aktekin M. Incidence of acute respiratory infections and the relationship with some factors in infancy in Antalya, Turkey. <i>Pediatr Int</i> . 2002; 1(44): 64-9.	1997-1999		
Turkey	Ceyhan M, Yildirim I, Secmeer G, Balmer P, Borrow R, Gray S, Dikici B, Turgut M, Kurt N, Aydogan A, Ecevit C, Anlar Y, Gulmuser O, Tahir G, Salman N, Gurler N, Hatipoglu N, Camcioglu Y, Hacimustafaoglu M, Celebi S, Coskun Y, Alhan E, Celik U, G. A prospective study of etiology of childhood acute bacterial meningitis, Turkey. <i>Emerg Infect Dis</i> . 2008; 14(7): 1089-96.	2005-2006		
Turkey	Ceyhan M, Alhan E, Salman N, Kurugol Z, Yildirim I, Celik U, Keser M, Koturoglu G, Tezer H, Bulbul EK, Karabucoglu M, Halicioglu O, Anis S, Pawinski R. Multicenter prospective study on the burden of rotavirus gastroenteritis in Turkey, 2005-2006: a hospital-based study. <i>J Infect Dis</i> . 2009; 200 Suppl 1: 234-238.	2005-2006		
Turkey	Ozdemir S, Delialiolu N, Emekda G. Investigation of rotavirus, adenovirus and astrovirus frequencies in children with acute gastroenteritis and evaluation of epidemiological features. <i>Mikrobiyol Bul</i> . 2010; 44(4): 571-8.	2008		
Turkey	Onat A, Senocak MS, Surdum-Avci G, Ornek E. Prevalence of coronary heart disease in Turkish adults. <i>Int J Cardiol</i> . 1993; 39(1): 23-31.	1980-1990		
Turkey	Koc A, Kosecik M, Vural H, Erel O, Atas A, Tatli MM. The frequency and etiology of anemia among children 6-16 years of age in the southeast region of Turkey. <i>Turk J Pediatr</i> . 2000; 42(2): 91-5.	1996		
Turkey	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2005-2006, 2009		
Turkey	Musellim B, Kumbasar OO, Ongen G, Cetinkaya E, Turker H, Uzaslan E, Yenturk E, Uzun O, Saglam L, Celik G, Okumus G, Annakaya AN, Altıay G, Tabak L, Sakar A, Kiter G, Erturan S, Turkas H, Yalıniz E, Akkoçlu A, Oğus C, Dogan OT, Ozkan M, Aktogu S, Uzel I. Epidemiological features of Turkish patients with sarcoidosis. <i>Respir Med</i> . 2009; 103(6): 907-12.	2004-2006		
Turkey	Kelestimur F, Cetin M, Paşaoğlu H, Coksevim B, Cetinkaya F, Unluhizarci K, Unal S, Koker AH. The prevalence and identification of risk factors for type 2 diabetes mellitus and impaired glucose tolerance in Kayseri, central Anatolia, Turkey. <i>Acta Diabetol</i> . 1999; 36(1-2): 85-91.	1994		
Turkey	Erem C, Yildiz R, Kavgaci H, Karahan C, Deger O, Can G, Telatar M. Prevalence of diabetes, obesity and hypertension in a Turkish population (Trabzon city). <i>Diabetes Res Clin Pract</i> . 2001; 54(3): 203-8.	1999		
Turkey	Yumuk VD, Hatemi H, Tarakci T, Uyar N, Turan N, Bagriacik N, Ipbuker A. High prevalence of obesity and diabetes mellitus in Konya, a central Anatolian city in Turkey. <i>Diabetes Res Clin Pract</i> . 2005; 70(2): 151-8.	2001	*	
Turkey	Sekuri C, Eser E, Alpınar G, Cakir H, Sitti I, Gulomur O, Ozcan C. Cardiovascular disease risk factors in post-menopausal women in West Anatolia. <i>Jpn Heart J</i> . 2004; 45(1): 119-31.	2001	*	
Turkey	Cancer Control Department, Ministry of Health (Turkey). Turkey Active Cancer Registration System 9 Provinces Incidence 2008. [Unpublished].	2008		
Turkey	Cancer Control Department, Ministry of Health (Turkey). Turkey Active Cancer Registration System 8 Provinces Incidence 2007. [Unpublished].	2007		
Turkey	Akyol A, Kiyiligioglu N, Aydin I, Erturk A, Kaya E, Telli E, Akyildiz U. Epidemiology and clinical characteristics of migraine among school children in the Menderes region. <i>Cephalalgia</i> . 2007; 27(7): 781-7.	2004		
Turkey	Zencir M, Ergin H, Sahiner T, Kiliç I, Alkiş E, Ozdel L, Gürses D, Ergin A. Epidemiology and symptomatology of migraine among school children: Denizli urban area in Turkey. <i>Headache</i> . 2004; 44(8): 780-5.	2000		
Turkey	Karli N, Akiş N, Zarifoğlu M, Akgöz S, Irgil E, Ayvacioglu U, Calişir N, Haran N, Akdoğan O. Headache prevalence in adolescents aged 12 to 17: a student-based epidemiological study in Bursa. <i>Headache</i> . 2006; 46(4): 649-55.	2003-2004	*	
Turkey	Bugdayci R, Ozge A, Sasmaz T, Kurt AO, Kalegasi H, Karakelle A, Tezcan H, Siva A. Prevalence and factors affecting headache in Turkish schoolchildren. <i>Pediatr Int</i> . 2005; 47(3): 316-22.	2002	*	
Turkey	Altiparmak S, Altıparmak O, Sari HY. Asthma and quality of life in adolescents in Manisa, Turkey. <i>Int J Adolesc Med Health</i> . 2011; 23(3): 217-21.	2008	*	
Turkey	Civelek E, Cakir B, Boz AB, Yuksel H, Orhan F, Uner A, Sekerel BE. Extent and burden of allergic diseases in elementary schoolchildren: a national multicenter study. <i>J Investig Allergol Clin Immunol</i> . 2010; 20(4): 280-8.	2005-2006	*	
Turkey	Demir AU, Celikel S, Karakaya G, Kalyoncu AF. Asthma and allergic diseases in school children from 1992 to 2007 with incidence data. <i>J Asthma</i> . 2010; 47(10): 1128-35.	1992, 1997, 2002, 2007	*	
Turkey	Ekici A, Ekici M, Kocoyigit P, Karlidag A. Prevalence of self-reported asthma in urban and rural areas of Turkey. <i>J Asthma</i> . 2012; 49(5): 522-6.	2004	*	
Turkey	Selcuk ZT, Demir AU, Tabakoglu E, Caglar T. Prevalence of asthma and allergic diseases in primary school children in Edirne, Turkey, two surveys 10 years apart. <i>Pediatr Allergy Immunol</i> . 2010; 21(4 Pt 2): e711-717.	1994, 2004		
Turkey	Unsal A, Ayranci U. Prevalence of students with symptoms of depression among high school students in a district of western Turkey: an epidemiological study. <i>J Sch Health</i> . 2008; 78(5): 287-93.	2006	*	
Turkey	Deveci F, Deveci SE, Turkoglu S, Turgut T, Kirişli G, Rahman S, Açıık Y, Muz MH. The prevalence of chronic obstructive pulmonary disease in Elazığ, Eastern Turkey. <i>Eur J Intern Med</i> . 2011; 22(2): 172-6.	2007	*	
Turkey	Civelek E, Sahiner UM, Yuksel H, Boz AB, Orhan F, Uner A, Cakir B, Sekerel BE. Prevalence, burden, and risk factors of atopic eczema in schoolchildren aged 10-11 years: a national multicenter study. <i>J Investig Allergol Clin Immunol</i> . 2011; 21(4): 270-7.	2005-2006	*	
Turkey	Guner SN, Gokturk B, Kilic M, Ozkiraz S. The prevalences of allergic diseases in rural and urban areas are similar. <i>Allergol Immunopathol (Madr)</i> . 2011; 39(3): 140-4.	2007		
Turkey	Kurt E, Metintas S, Basyigit I, Bulut I, Coskun E, Dabak S, Deveci F, Fidan F, Kaynar H, Uzaslan EK, Onbasi K, Ozkurt S, Karakis GP, Sahan S, Sahin U, Oguzulgen K, Yildiz F, Mungan D, Yorgancioglu A, Gemicioglu B, Fuat Kalyoncu A. Prevalence and Risk Factors of Allergies in Turkey (PARFAIT): results of a multicentre cross-sectional study in adults. <i>Eur Respir J</i> . 2009; 33(4): 724-33.	2006-2008	*	
Turkey	Gökalp SG, Doğan BG, Tekçiçek MT, Berberoğlu A, Unlüer S. National survey of oral health status of children and adults in Turkey. <i>Community Dent Health</i> . 2010; 27(1): 12-7.	2004-2005	*	
Turkey	Ozer S, Sen Tunc E, Bayrak S, Egişmez T. Evaluation of certain risk factors for early childhood caries in Samsun, Turkey. <i>Eur J Paediatr Dent</i> . 2011; 12(2): 103-6.	2009		
Turkey	Ereş G, Sarıbay A, Akkaya M. Periodontal treatment needs and prevalence of localized aggressive periodontitis in a young Turkish population. <i>J Periodontol</i> . 2009; 80(6): 940-4.	2007		
Turkey	Kurugol Z, Aslan A, Turkoglu E, Koturoglu G. Changing epidemiology of hepatitis A infection in Izmir, Turkey. <i>Vaccine</i> . 2011; 29(37): 6259-61.	2008		
Turkey	Akcam FZ, Uskun E, Avsar K, Songur Y. Hepatitis B virus and hepatitis C virus seroprevalence in rural areas of the southwestern region of Turkey. <i>Int J Infect Dis</i> . 2009; 13(2): 274-84.	2006-2007	*	
Turkey	Yildirim B, Barut S, Bulut Y, Yenişihirli G, Ozdemir M, Cetin I, Etikan I, Akbaş A, Atiş O, Ozyurt H, Sahin S. Seroprevalence of hepatitis B and C viruses in the province of Tokat in the Black Sea region of Turkey: A population-based study. <i>Turk J Gastroenterol</i> . 2009; 20(1): 27-30.	2006-2007	*	
Turkey	Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version). Lyon, IARC. http://ci5.iarc.fr	2005-2007		
Turkey	Hacimustafaoglu M, Celebi S, Agin M, Ozkaya G. Rotavirus epidemiology of children in Bursa, Turkey: a multi-centered hospital-based descriptive study. <i>Turk J Pediatr</i> . 2011; 53(6): 604-13.	2010		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Turkey	Arslantaş D, Ozbabalik D, Metintaş S, Ozkan S, Kalyoncu C, Ozdemir G, Arslantas A. Prevalence of dementia and associated risk factors in Middle Anatolia, Turkey. <i>J Clin Neurosci</i> . 2009; 16(11): 1455-9.	2002-2004		
Turkey	Gurvit H, Enre M, Tinaz S, Bilgic B, Hanagasi H, Sahin H, Guroi E, Kvaloy JT, Harmanci H. The prevalence of dementia in an urban Turkish population. <i>Am J Alzheimers Dis Other Demen</i> . 2008; 23(1): 67-76.	2005-2007		
Turkey	Kaçar C, Gilgili E, Urhan S, Arıkan V, Dündar U, Oksüz MC, Sümbüloğlu G, Yıldırım C, Tekeoğlu I, Büttin B, Apaydin A, Tuncer T. The prevalence of symptomatic knee and distal interphalangeal joint osteoarthritis in the urban population of Antalya, Turkey. <i>Rheumatol Int</i> . 2005; 25(3): 201-4.	2002		
Turkey	Kaçar C, Gilgili E, Tuncer T, Büttin B, Urhan S, Arıkan V, Dündar U, Oksüz MC, Sümbüloğlu G, Yıldırım C, Tekeoğlu I, Yücel G. Prevalence of rheumatoid arthritis in Antalya, Turkey. <i>Clin Rheumatol</i> . 2005; 24(3): 212-4.	2000-2001		
Turkey	Akar S, Birlık M, Gurler O, Sari I, Onen F, Manisali M, Tirpan K, Demir T, Meral M, Akkoc N. The prevalence of rheumatoid arthritis in an urban population of Izmir-Turkey. <i>Clin Exp Rheumatol</i> . 2004; 22(4): 416-20.	2001-2002		
Turkey	Cross-national comparisons of the prevalences and correlates of mental disorders. WHO International Consortium in Psychiatric Epidemiology.	1991-1994, 1996		
Turkey	Yasan A, Saka G, Ozkan M, Ertem M. Trauma type, gender, and risk of PTSD in a region within an area of conflict. <i>J Trauma Stress</i> . 2009; 22(6): 663-6.	2005		
Turkey	Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E, BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. <i>Lancet</i> . 2007; 9589(9589): 741-50.	2003-2004		
Turkey	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2004-2005		
Turkey	Derman O, Kanbur NO, Tokur TE, Kutluk T. Premenstrual syndrome and associated symptoms in adolescent girls. <i>Eur J Obstet Gynecol Reprod Biol</i> . 2004; 116(2): 201-6.	2001-2002		
Turkey	Adıgüzel H, Taşkin EO, Danacı AE. The symptomatology and prevalence of symptoms of premenstrual syndrome in Manisa, Turkey. <i>Turk J Psychiatry</i> . 2007; 18(3): 215-22.	2004		
Turkey	Yücel U, Bilge A, Oran N, Ersoy MA, Gencdoğan B, Özveren O. The prevalence of premenstrual syndrome and its relationship with depression risk in adolescents. <i>Anatol J Psychiatry</i> . 2009; 10(1): 55-61.	1996-1997		
Turkey	Ünsal A, Metintas S, Sarıboycu MA, Arslantaş D, İskili B, Kalyoncu C. The frequency of premenstrual syndrome in the rural region of Eskisehir, Turk Bull Gynecol Obstet. 1997; 6(4): 157-62.	1996-1997		
Turkey	Duzcan F, Zencir M, Ozdemir F, Cetin GO, Bagci H, Heutink P, Bonifati V, Sahiner T. Familial influence on parkinsonism in a rural area of Turkey (Kizilcabuluk-Denizli): a community-based case-control study. <i>Mov Disord</i> . 2003; 18(7): 799-804.	1999-2000		
Turkey	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN), ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Turkey	Erdine S. Pain Prevalence Among Adults in Turkey. <i>Agri</i> . 2004; 13(2-3): 22-30.	1999		
Turkey	Oksuz E. Prevalence, risk factors, and preference-based health states of low back pain in a Turkish population. <i>Spine</i> . 2006; 31(25): E968-972.	2003		
Turkey	Negrel AD, Massian DC, Sayek F. Blindness and low vision in southeast Turkey. <i>Ophthalmic Epidemiol</i> . 1996; 3(3): 127-34, as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	1989		
Turkey	Alp H, Altinkaynak S, Ertekin V, Kiliçaslan B, Gıiraksin A. Seroepidemiology of varicella-zoster virus infection in a cosmopolitan city (Erzurum) in the eastern Turkey. <i>Health Policy</i> . 2005; 72(1): 119-24.	2002		
Turkey	Kanra G, Tezcan S, Badur S, Turkish National Study Team. Varicella seroprevalence in a random sample of the Turkish population. <i>Vaccine</i> . 2002; 20(9-10): 1425-8.	1999		
Turkey	Ozkan S, Maral I, İlhan F, Aycan S, Cırak MY, Beyazova U, Aygun R. Varicella zoster seroprevalence in children less than 5 years old. <i>J Trop Pediatr</i> . 2005; 51(3): 141-4.	2002		
Turkey	Dereköy FS. Etiology of deafness in Afyon school for the deaf in Turkey. <i>Int J Pediatr Otorhinolaryngol</i> . 2000; 55(2): 125-31.	1999-2000		
Turkey	Ozürk O, Silan F, Oghan F, Egeli E, Belli S, Tokmak A, Egeli A, Harputluoğlu U, Onder HI, Zafer C. Evaluation of deaf children in a large series in Turkey. <i>Int J Pediatr Otorhinolaryngol</i> . 2005; 69(3): 367-73.	2001-2003	*	
Turkey	Egeli E, Çiçekçi G, Öztürk O. Ear examination findings at the Yeditepe School for the Deaf. <i>Int J Pediatr Otorhinolaryngol</i> . 2003; 67(8): 905-10.	2001-2002		
Turkey	Tozun N, Atug O, İmeryüz N, Hamzaoğlu HO, Tiftikci A, Parlak E, Dağlı U, Ulker A, Hulaga S, Akpınar H, Tuncer C, Süleymanlar I, Övunc O, Hilmioglu F, Aslan S, Turkdogan K, Bahcecioglu HI, Yurdaydin C, Members of the Turkish IBD Study Group. Clinical characteristics of inflammatory bowel disease in Turkey: a multicenter epidemiologic survey. <i>J Clin Gastroenterol</i> . 2009; 43(1): 51-7.	2001-2003	*	
Turkey	Silan F, Demireli L, Egeli A, Egeli E, Onder HI, Ozürk O, Unal ZS. Syndromic etiology in children at schools for the deaf in Turkey. <i>Int J Pediatr Otorhinolaryngol</i> . 2004; 68(11): 1399-406.	2001-2003		
Turkey	Demir T, Karacetin G, Demir DE, Uysal O. Epidemiology of depression in an urban population of Turkish children and adolescents. <i>J Affect Disord</i> . 2011; 134(1-3): 168-76.	2010	*	
Turkey	Olguntürk R, Aydın GB, Tunaoğlu FS, Akalin N. Rheumatic heart disease prevalence among schoolchildren in Ankara, Turkey. <i>Turk J Pediatr</i> . 1999; 41(2): 201-6.	1995	*	
Turkey	Velioğlu SK, Bakirdemir M, Can G, Topbas M. Prevalence of epilepsy in northeast Turkey. <i>Epileptic Disord</i> . 2010; 12(1): 22-37.	2004-2005	*	†
Turkey	Hasseyinoğlu N, Özben S, Arhan E, Palancı Y, Gunes N. Prevalence and risk factors of epilepsy among school children in eastern Turkey. <i>Pediatr Neurol</i> . 2012; 47(1): 13-8.	2009-2010	*	
Turkey	Özkan ZS, Atlıgan R, Goktolga G, Simsek M, Sapmaz E. Impact of grandmultiparity on perinatal outcomes in eastern region of Turkey. <i>J Matern Fetal Neonatal Med</i> . 2013; 26(13): 1325-7.	2008-2011	*	
Turkey	Ayrim A, Keskin EA, Ozol D, Onaran Y, Yüldürüm Z, Kafalı H. Influence of self-reported snoring and witnessed sleep apnea on gestational hypertension and fetal outcome in pregnancy. <i>Arch Gynecol Obstet</i> . 2011; 283(2): 195-9.	2009-2010	*	
Turkey	Çakır N, Pamuk ÖN, Derviş E, İmeryüz N, Uslu H, Benian Ö, Elelçi E, Erdem G, Sarvan FO, Senocak M. The prevalences of some rheumatic diseases in western Turkey: Havsa study. <i>Rheumatol Int</i> . 2012; 32(4): 895-908.	2008	*	
Turkey	Börü UT, Taşdemir M, Güler N, Ayık ED, Kuş A, Yıldırım S, Duman A, Sur H, Kurtzke JF. Prevalence of multiple sclerosis: door-to-door survey in three rural areas of coastal Black Sea regions of Turkey. <i>Neuroepidemiology</i> . 2011; 37(3-4): 231-5.	2006	*	
Turkey	Çalışır N, Bora I, Irgil E, Boz M. Prevalence of epilepsy in Bursa city center, an urban area of Turkey. <i>Epilepsia</i> . 2006; 47(10): 1691-9.	2004-2005	*	†
Turkey	Aziz H, Güvener A, Akhtar SW, Hasan KZ. Comparative epidemiology of epilepsy in Pakistan and Turkey: population-based studies using identical protocols. <i>Epilepsia</i> . 1997; 38(6): 716-22.	1987	*	†
Turkey	Topalkara K, Akyuz A, Sumer H, Bekar D, Topaktas S, Dener S. An epilepsy prevalence study performed using a stratified sampling method among urban residents of Sivas. <i>Epilepsi</i> . 1999; 5(1): 24-9.	1997	*	†
Turkey	Onal AE, Tumerdem Y, Öztürk MK, Gürses C, Baykan B, Gökçigit A, Ozel S. Epilepsy prevalence in a rural area in Istanbul. <i>Seizure</i> . 2002; 11(6): 397-401.	1999-2000	*	
Turkey	Aydın A, Ergor A, Ergor G, Dirik E. The prevalence of epilepsy amongst school children in Izmir, Turkey. <i>Seizure</i> . 2002; 11(6): 392-6.	1999	*	
Turkey	Sahin A, Bolayir E, Sumer H, Tas A, Mollaoglu M, Dener S. Epidemiologic evaluation of epileptic and nonepileptic seizures in Sivas region of middle Anatolia. <i>Neurol Psych Brain Res</i> . 2004; 97-102.	2003		†
Turkey	Karaağaç N, Yeni SN, Senocak M, Bozluoğlu Y, Savrun FK, Özdemir H, Cagatay P. Prevalence of epilepsy in Silivri, a rural area of Turkey. <i>Epilepsia</i> . 1999; 40(5): 637-42.	1994		†
Turkey	Süleymanlar G, Utaş C, Arınsoy T, Ateş K, Altun B, Altıparmak MR, Eder T, Yılmaz ME, Çamsarı T, Başçı A, Odabas AR, Serdengeçti K. A population-based survey of Chronic Renal Disease in Turkey – the CREDIT study. <i>Nephrol Dial Transplant</i> . 2011; 26(6): 1862-71.	2000, 2008-2010		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Turkey	Ölmez S. Yoğun Bakım Yatırılan Sirozlu Olgularda Prognostik Belirleyen Risk Faktörleri [Prognostic Risk Factors in Cirrhotic Patients Admitted to Intensive Care] [dissertation]. Balçalı, Turkey: Çukurova University, 2008.	2004-2006		
Turkey	Ozer B, Serin E, Yılmaz U, Güntüridilli Y, Saygılı OB, Kayaselçuk F, Boyacıoğlu S. Clinicopathologic features and risk factors for hepatocellular carcinoma: results from a single center in southern Turkey. <i>Turk J Gastroenterol.</i> 2003; 14(2): 85-90.	1999-2002		
Turkey	Bayan K, Yılmaz S, Tuzun Y, Yıldırım Y. Epidemiological and clinical aspects of liver cirrhosis in adult patients living in Southeastern Anatolia: leading role of HBV in 505 cases. <i>Hepatogastroenterology.</i> 2007; 54(80): 2198-202.	2001-2006		
Turkey	Alacacioglu A, Somali I, Simsek I, Astarcioglu I, Ozkan M, Camci C, Alkis N, Karaoglu A, Tarhan O, Unek T, Yilmaz U. Epidemiology and survival of hepatocellular carcinoma in Turkey: outcome of multicenter study. <i>Jpn J Clin Oncol.</i> 2008; 38(10): 683-8.	1994-2007		
Turkey	Ozyilkán O, Arslan M, Ozyilkán E. Hepatitis B virus and hepatitis C virus infections in Turkish patients with hepatocellular carcinoma. <i>Am J Gastroenterol.</i> 1996; 91(7): 1479-80.	1996	*	
Turkey	Uzunalmışoğlu O, Yurdaydın C, Cetinkaya H, Bozkaya H, Sahin T, Colakoğlu S, Tankurt E, Sarioglu M, Ozenirler S, Akkiz H, Tözün N, Değertekin H, Okten A. Risk factors for hepatocellular carcinoma in Turkey. <i>Dig Dis Sci.</i> 2001; 46(5): 1022-8.	1994-1997		
Turkey	Abant İzzet Baysal University, Ankara University, Faculty of Medicine, Hacettepe University, Ministry of Health (Turkey), World Health Organization (WHO). Turkey Mental Health Survey 1995-1996.	1996	*	†
Turkey	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2007, 2010, 2012	*	
Turkey	Velioglu SK, Bakirdemir M, Can G, Topbas M. Prevalence of epilepsy in northeast Turkey. <i>Epileptic Disord.</i> 2010; 12(1): 22-37.	2004-2005	*	†
Turkey	Ertas M, Baykan B, Orhan EK, Zarifoğlu M, Karli N, Saip S, Onal AE, Siva A. One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults. <i>J Headache Pain.</i> 2012; 13(2): 147-57.	2008	*	
Turkey	Karabulut A, Alan T, Ali Ekiz M, İritaş A, Kesen Z, Yahşi S. Evaluation of cervical screening results in a population at normal risk. <i>Int J Gynaecol Obstet.</i> 2010; 110(1): 40-2.	2004-2005	*	
Turkey	Haltas H, Bayrak R, Yenidunya S. To determine of the prevalence of Bacterial Vaginosis, Candida sp, mixed infections (Bacterial Vaginosis + Candida sp), Trichomonas Vaginalis, Actinomyces sp in Turkish women from Ankara, Turkey. <i>Ginekol Pol.</i> 2012; 83(10): 744-8.	2007-2011	*	†
Turkey	Yıldız A, Güner H, Rota S, Gürsoy R, Erdem A. A prevalence study of Chlamydia infections in Turkish population. <i>Braz J Infect Dis.</i> 2013; 17(1): 114-5.	2003-2004		
Turkey	Hallıoğlu O, Topaloğlu AK, Zenciroğlu A, Duzovalı O, Yılgor E, Saribas S. Denver developmental screening test II for early identification of the infants who will develop major neurological deficit as a sequelae of hypoxic-ischemic encephalopathy. <i>Pediatr Int.</i> 2001; 43(4): 400-4.	1995		
Turkey	Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dincag N, Karsidag K, Genc S, Telci A, Canbaz B, Turker F, Yilmaz T, Cakir B, Tuomilehto J, TURDEP-II Study Group. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. <i>Eur J Epidemiol.</i> 2013; 28(2): 169-80.	2010		
Turkey	Demirbilek H, Özbek MN, Baran RT. Incidence of type 1 diabetes mellitus in Turkish children from the southeastern region of the country: a regional report. <i>J Clin Res Pediatr Endocrinol.</i> 2013; 5(2): 98-103.	2010-2011	*	
Turkey	Maral I, Tütüncü NB, Bakar C, Durukan E, Budakoğlu İI, Ozkan S, Aycan S, Aygün R, Bumin MA. The 5-year incidence of type 2 diabetes mellitus in women older than 15 years in Ankara, Turkey: a population-based study. <i>J Investig Med.</i> 2010; 58(6): 796-800.	1998-2003		
Turkey	Vardar E, Erzen M. The prevalence of eating disorders (EDs) and comorbid psychiatric disorders in adolescents: a two-stage community-based study. <i>Turk J Psychiatry.</i> 2011; 22(4): 205-12.	2009		
Turkey	Say B, Ozand P, Berkel I, Cevik N. Erythrocyte glucose-6-phosphate dehydrogenase deficiency in Turkey. <i>Acta Paediatr Scand.</i> 1965; 319-24.	1963		
Turkey	Aksu TA, Esen F, Dolunay MS, Alicigüzel Y, Yücel G, Cali S, Baykal Y. Erythrocyte glucose-6-phosphate dehydrogenase (1.1.1.49) deficiency in Antalya province, Turkey: an epidemiologic and biochemical study. <i>Am J Epidemiol.</i> 1990; 131(6): 1094-7.	1986-1988		
Turkey	Keskin N, Özdes I, Keskin A, Acikbas I, Bağcı H. Incidence and molecular analysis of glucose-6-phosphate dehydrogenase deficiency in the province of Denizli, Turkey. <i>Med Sci Monit.</i> 2002; 8(6): CR453-456.	2000-2002		
Turkey	Atay E, Bozaykut A, İpek İO. Glucose-6-phosphate Dehydrogenase Deficiency in Neonatal Indirect Hyperbilirubinemia. <i>J Trop Pediatr.</i> 2006; 52(1): 56-8.	2001-2004		
Turkey	Turan Y. Prevalence of erythrocyte glucose-6-phosphate dehydrogenase (G6PD) deficiency in the population of western Turkey. <i>Arch Med Res.</i> 2006; 37(7): 880-2.	2004-2006	*	
Turkey	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant.</i> 1988; 3(6): 714-27.	1985-1986		
Turkey	Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M and Boyle P, eds (2007). <i>Cancer Incidence in Five Continents, Vol. IX Periodic Data</i> (electronic version). Lyon, IARC. http://ci5.iarc.fr	1998-2002		
Turkey	Kikwilu EN, Frencken JE, Masalu JR, Mulder J. Barriers to restorative care as perceived by dental practitioners in Tanzania. <i>Community Dent Health.</i> 2010; 27(1): 23-8.	2004-2005		
Turkey	Kulak-Ozkan Y, Ozkan Y, Kazazoglu E, Arıkan A. Dental caries prevalence, tooth brushing and periodontal status in 150 young people in Istanbul: a pilot study. <i>Int Dent J.</i> 2001; 51(6): 451-6.	1999	*	
Turkey	Woods N, Considine J, Lucey S, Whelton H, Nyhan T. The influence of economic incentives on treatment patterns in a third-party funded dental service. <i>Community Dent Health.</i> 2010; 27(1): 18-22.	2004-2005		
Turkey	Soylemezoglu O, Duzova A, Yalçinkaya F, Arınsöy T, Süleymanlar G. Chronic renal disease in children aged 5-18 years: a population-based survey in Turkey, the CREDIT-C study. <i>Nephrol Dial Transplant.</i> 2012; iii146-151.	2007-2008	*	
Turkey	Ministry of Health (Turkey). Turkey Infectious Disease Registration System 2005-2012. [Unpublished].	2005-2011		
Turkey	Alp R, Alp SI, Palancı Y, Sur H, Boru UT, Özge A, Yapıcı Z. Use of the International Classification of Headache Disorders, Second Edition, criteria in the diagnosis of primary headache in schoolchildren: epidemiology study from eastern Turkey. <i>Cephalalgia.</i> 2010; 30(7): 868-77.	2006	*	
Turkey	Artan R. Childhood Guillain Barre Syndrome in Antalya, Turkey. <i>Int Med J.</i> 1997; 215-7.	1990-1996	*	
Turkey	Oghan F, Harputluoglu U, Ozturk O, Guclu E, Mayda A. Does the prevalence of otolaryngological diseases in deaf children differ from children without hearing impairment? <i>Eur Arch Otorhinolaryngol.</i> 2008; 265(2): 223-6.	2004-2006	*	
Turkey	Izmir Cancer Registry (KIDEM). Turkey - Izmir Cancer Registry Incidence 2006.	2006	*	
Turkey	World Health Organization (WHO). Turkey WHO Leishmaniasis Country Profile.	1994-2010		
Turkey	Akarsu E, Akçay G, Capoğlu I, Unlivan N. Iodine deficiency and goiter prevalence of the adult population in Erzurum. <i>Acta Med (Hradec Kralove).</i> 2005; 48(1): 39-42.	2002-2004	*	
Turkey	Turkey Training and Research Project on Nutrition in 15 Provinces 1995 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1995	*	
Turkey	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993		
Turkey	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Turkey	Turkey Final Report of the Iodine Status Monitoring Project in 20 Regions 2002 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2002	*	
Turkey	Dolar N, Serdaroglu S, Yilmaz G, Ergin S. Seroprevalence of herpes simplex virus type 1 and type 2 in Turkey. <i>J Eur Acad Dermatol Venereol.</i> 2006; 20(10): 1232-6.	2003-2005		
Turkey	Gul U, Kiliç A, Sakizigil B, Aksaray S, Bilgili S, Demirel O, Erincan C. Magnitude of sexually transmitted infections among female sex workers in Turkey. <i>J Eur Acad Dermatol Venereol.</i> 2008; 22(9): 1123-4.	2005	*	
Turkey	Maral I, Biri A, Korucuoğlu U, Bakar C, Cırak M, Ali Bumin M. Seroprevalences of herpes simplex virus type 2 and Chlamydia trachomatis in Turkey. <i>Arch Gynecol Obstet.</i> 2009; 280(5): 739-43.	2006-2008	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Turkey	Arseven G, Tuncel E, Tuncel S, Sönmez E, Gülen AK. [Distribution of HSV-1 and HSV-2 antibodies in pregnant women]. Mikrobiyol Bul. 1992; 26(4): 359-66.	1991-1992	*	
Turkey	Duran N, Yarkin F, Evrucke C, Koksak F. Asymptomatic herpes simplex virus type 2 (HSV-2) infection among pregnant women in Turkey. Indian J Med Res. 2004; 120(2): 106-10.	1999-2001		
Turkey	Caca I, Cingu AK, Sahin A, Ari S, Dursun ME, Dag U, Balsak S, Alakus F, Yavuz A, Palanci Y. Amblyopia and refractive errors among school-aged children with low socioeconomic status in southeastern Turkey. J Pediatr Ophthalmol Strabismus. 2013; 50(1): 37-43.	2008-2009	*	†
Turkey	Hasanoğlu HC, Gokirmak M, Baysal T, Yildirim Z, Koksak N, Onal Y. Environmental Exposure to Asbestos in Eastern Turkey. Arch Environ Health. 2003; 58(3): 144-50.	2002		
Turkey	Fin M, Hi A, T M, H K, S K, M K, Su S, F A. Screening for retinopathy of prematurity in a tertiary care newborn unit in Turkey: frequency, outcomes, and risk factor analysis. J Pediatr Ophthalmol Strabismus. 2007; 45(5): 291-8.	2002		
Turkey	Kanra GY, Ozen H, Seçmeer G, Ceyhan M, Ecevit Z, Belgin E. Beneficial effects of dexamethasone in children with pneumococcal meningitis. Pediatr Infect Dis J. 1995; 14(6): 490-4.	1990-1994		
Turkey	Semiz S, Senol U, Bircan O, Gümlüslü S, Akurcu S, Bircan I. Thyroid gland volume and urinary iodine excretion in children 6-11 years old in an endemic area. J Pediatr Endocrinol Metab. 2000; 13(3): 245-51 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2000		
Turkey	Yordam N, Özön A, Alikasıfoğlu A, Özgen A, Ceren N, Zafer Y, Simsek E. Iodine deficiency in Turkey. Eur J Pediatr. 1999; 158(6): 501-5 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1998		
Turkey	Gür E, Ercan O, Can G, Akkus S, Guzeloz S, Ciftçili S, Arvas A, İter O. Prevalence and risk factors of iodine deficiency among schoolchildren. J Trop Pediatr. 2003; 49(3): 168-71 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1999		
Turkey	Simsek E, Safak A, Yavuz O, Aras S, Dogan S, Kocabay K. Sensitivity of iodine deficiency indicators and iodine status in Turkey. J Pediatr Endocrinol Metab. 2003; 16(2): 197-202 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	2003		
Turkey	Genç M, Ağaçağdian A, Yegenoglu Y, Turan O, Kuru U, Mårdh PA. Screening for Chlamydia trachomatis and Neisseria gonorrhoeae in pregnant Turkish women. Eur J Clin Microbiol Infect Dis. 1993; 12(5): 395-6.	1987		
Turkey	Yıldız A, Güner H, Rota S, Gırsöy R, Erdem A. Prevalence of Chlamydia trachomatis infection in the Turkish female population. Gynecol Obstet Invest. 1990; 29(4): 282-4.	1987	*	
Turkey	Akan E. Determination of anti-chlamydial serum IgG and IgM levels in women and their mature infants born in term. Turk Mikrobiyol Cemiy Derg. 1987; 17: 205-12.	1992		
Turkey	Nazlıel HE, Hersek N, Ozbek M, Karaagaoglu E. Oral health status in a group of the elderly population residing at home. Gerodontology. 2012; 29(2): e761-767.	2009	*	
Turkey	World Health Organization (WHO). Mental Illness in General Health Care: An International Study. Geneva, Switzerland: World Health Organization (WHO), 1995.	1991-1992		
Turkey	Cevahir N, Demir M, Bozkurt AI, Ergin A, Kaleli I. Seroprevalence of Hepatitis E virus among primary school children. Pak J Med Sci. 2013; 29(2): 629-32.	2010-2011		
Turkey	Kangin M, Turhanoglu M, Gulsun S, Cakabay B. Seroprevalence of Hepatitis B and C among Children in Endemic Areas of Turkey. Hepat Mon. 2010; 10(1): 36-41.	2005-2008		
Turkey	Kanra G, Tezcan S, Badur S, Turkish National Study Team. Hepatitis B and measles seroprevalence among Turkish children. Turk J Pediatr. 2005; 47(2): 105-10.	1998	*	
Turkey	Karabay O, Serin E, Tamer A, Gökdoğan F, Alpteker H, Özcan A, Gündüz H. Hepatitis B carriage and Brucella seroprevalence in urban and rural areas of Bolu province of Turkey: a prospective epidemiologic study. Turk J Gastroenterol. 2004; 15(1): 11-3.	2003	*	
Turkey	Karatekin G, Kiliç M, Gulcan Öksüz B, İgde M. Hepatitis B seroprevalence in children and women and the impact of the hepatitis B vaccination program in the Black Sea Region of Turkey. J Infect Dev Ctries. 2013; 7(12): 960-5.	2007-2009	*	
Turkey	Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, Büchele G, Clausen M, Cookson WOC, von Mutius E, Strachan DP, Williams HC, ISAAC Phase Two Study Group. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. J Allergy Clin Immunol. 2008; 121(1): 141-147.	2005-2007	*	
Turkey	Kurugöl Z, Koturoğlu G, Akışt S, Özacar T. Seroprevalence of Hepatitis A Infection in the Turkish Republic of Northern Cyprus. Turk J Med Sci. 2009; 39(1): 109-13.	2006		
Turkey	Sac RU, Bostanci I, Dallal Y, Cihan G, Atlı O. Hepatitis A seroprevalence and demographics in Turkish children in Ankara. Pediatr Int. 2009; 51(1): 5-8.	2002		
Turkey	Tazel A, Dökmeçi G, Eskiocak M, Ümit H, Soylu AR. Epidemiological Features of Ulcerative Colitis in Trakya, Turkey. J Int Med Res. 2003; 31(2): 141-8.	1998-2002		
Turkey	Thomas DL, Mahley RW, Badur S, Palaoglu KE, Quinn TC. Epidemiology of hepatitis E virus infection in Turkey. Lancet. 1993; 341(8860): 1561-2.	1990-1992		
Turkey	Baki A, Aynaci M, Köksal I. Prevalence of antibody to hepatitis A virus among children in Trabzon, Turkey. Infection. 1993; 21(2): 132-3.	1991		
Turkey	Ersoy B, Aydoğan A, Dinçoğuz A, Sinan Meral M, Turul T. The seroprevalence of anti-HAV among 0-16-year-olds referred to pediatric outpatients clinics of a hospital. J Trop Pediatr. 1998; 44(1): 55-6.	1995-1997		
Turkey	Çolak D, Oğunc D, Gunseren F, Velipasoglu S, Aktekin MR, Gültekin M. Seroprevalence of antibodies to hepatitis A and E viruses in pediatric age groups in Turkey. Acta Microbiol Immunol Hung. 2002; 49(1): 93-7.	1996-1997		
Turkey	Sidal M, Ünüvar E, Oğuz F, Cihan C, Onel D, Badur S. Age-specific seroepidemiology of hepatitis A, B, and E infections among children in Istanbul, Turkey. Eur J Epidemiol. 2001; 17(2): 141-4.	1997-1998		
Turkey	Kanra G, Tezcan S, Badur S. Hepatitis A seroprevalence in a random sample of the Turkish population by simultaneous EPI cluster and comparison with surveys in Turkey. Turk J Pediatr. 2002; 44(3): 204-10.	1998		
Turkey	Yapıcıoğlu H, Alhan E, Yıldızdas D, Yaman A, Bozdemir N. Prevalence of hepatitis A in children and adolescents in Adana, Turkey. Indian Pediatr. 2002; 39(10): 936-41.	1998		
Turkey	Üngan M, Yaman H, Taheri N. The seroprevalence of specific antibodies to hepatitis A virus in a Turkish population. Eur J Gastroenterol Hepatol. 2002; 14(9): 1033-4.	1998		
Turkey	Coskun O, Erdem H, Gul HC, Eyigun CP. Changes in hepatitis A prevalence rates between 1998 and 2007 in Eskisehir, Turkey. Int J Infect Dis. 2008; 12(6): e141.	1998-2007		
Turkey	Derya A, Necmi A, Emre A, Akgün Y. Decline of maternal hepatitis A antibodies during the first 2 years of life in infants born in Turkey. Am J Trop Med Hyg. 2005; 73(2): 457-9.	1999-2002		
Turkey	Tosun S, Ertan P, Kasirga E, Atman U. Changes in seroprevalence of hepatitis A in children and adolescents in Manisa, Turkey. Pediatr Int. 2004; 46(6): 669-72.	2000-2001		
Turkey	Cesur S, Akin K, Doğanoglu I, Birengel S, Balık I. [Hepatitis A and hepatitis E seroprevalence in adults in the Ankara area]. Mikrobiyol Bul. 2002; 36(1): 79-83.	2000-2001		
Turkey	Erdogan MS, Otkun M, Tatman-Otkun M, Akata F, Tire M. The epidemiology of hepatitis A virus infection in children, in Edirne, Turkey. Eur J Epidemiol. 2004; 19(3): 267-73.	2000-2002		
Turkey	Atabek ME, Fyındık D, Guluz A, Erkul I. Prevalence of anti-HAV and anti-HEV antibodies in Konya, Turkey. Health Policy. 2004; 67(3): 265-9.	2001-2002		
Turkey	Tosun SY, Kasirga E, Ertan P, Aksu S. Evidence against the fecal-oral route of transmission for Helicobacter pylori infection in childhood. Med Sci Monit. 2003; 9(11): CR489-492.	2001-2002		
Turkey	Vancelik S, Guraksin A, Alp H. Hepatitis A seroepidemiology in Eastern Turkey. East Afr Med J. 2006; 83(2): 86-90.	2002		
Turkey	Soysal A, Gökçe I, Pehlivan T, Bakır M. Interchangeability of a hepatitis A vaccine second dose: Avaxim 80 following a first dose of Vaqta 25 or Havrix 720 in children in Turkey. Eur J Pediatr. 2007; 166(6): 533-9.	2003		
Turkey	Egemen A, Yilmaz O, Akil I, Altuğlu I. Evaluation of association between hepatitis A and Helicobacter pylori infections and routes of transmission. Turk J Pediatr. 2006; 48(2): 135-9.	2003-2005		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Turkey	Kaya D, Güler E, Ekerbicer HC, Dilber C, Karabiber H, Güler S, Davutoğlu M, Ciralp P. Hepatitis A seroprevalence and its relationship with environmental factors in children of different age groups in Kahramanmaraş, Eastern Mediterranean region of Turkey. <i>J Viral Hepat</i> . 2007; 14(12): 830-4.	2005	*	†
Turkey	Çeyhan M, Yıldırım I, Kurt N, Uysal G, Dikici B, Ecevit C, Aydoğan A, Koc A, Yasa O, Köseoğlu M, Onal K, Hacimustafaoglu M, Celebi S. Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendations. <i>J Viral Hepat</i> . 2008; 69-72.	2005-2006		
Turkey	Ürün Y, Utkan G, Yalcin Ş, Coşkun HŞ, Koçer M, Özdemir NY, Kaplan MA, Arslan ÜY, Özdemir F, Öztuna D, Akbulut H, İçli F. Lack of any relationship between ABO and Rh blood groups and clinicopathological features in patients with gastrointestinal stromal tumors: Turkish Oncology Group. <i>Asian Pac J Cancer Prev</i> . 2012; 13(8): 4129-31.	2004-2011		
Turkey	Akbayır N, Gökdemir G, Mansur T, Sökmen M, Gündüz S, Alkim C, Barutcuoğlu B, Erdem L. Is there any relationship between hepatitis C virus and vitiligo? <i>J Clin Gastroenterol</i> . 2004; 38(9): 815-7.	2001-2003		
Turkey	Atabek ME, Kart H, Erkul I. Prevalence of hepatitis A, B, C and E virus in adolescents with type-1 diabetes mellitus. <i>Int J Adolesc Med Health</i> . 2003; 15(2): 133-7.	2001, 2003		
Turkey	Cetinkaya F, Gürses N, Öztürk F. Hepatitis B seroprevalence among children in a Turkish hospital. <i>J Hosp Infect</i> . 1995; 29(3): 217-9.	1993-1994		
Turkey	Değertekin H, Tuzcu A, Yalçın K. Horizontal transmission of HBV infection among students in Turkey. <i>Public Health</i> . 2000; 114(5): 411-2.	1997-1999		
Turkey	Demirel Y, Duran B, Toktamış A, Erden O, Cetin M. Seroprevalence of syphilis, hepatitis B and C, and human immunodeficiency virus infections among women. <i>Saudi Med J</i> . 2004; 25(12): 2037-8.	2002		
Turkey	Demirtürk N, Demirdal T, Toprak D, Altındiş M, Aktepe OC. Hepatitis B and C virus in West-Central Turkey: seroprevalence in healthy individuals admitted to a university hospital for routine health checks. <i>Turk J Gastroenterol</i> . 2006; 17(4): 267-72.	2002-2004		
Turkey	Dikici B, Bosnak M, Haspolat K. The prevalence of anti-HCV seropositivity among children in Turkey. <i>J Clin Virol</i> . 2002; 24(1-2): 135-6.	1999		
Turkey	Dilek, Demir C, Bay A, Akdeniz H, Öner AF. Seropositivity rates of HBSAg, anti-HCV, anti-HIV and VDRL in blood donors in Eastern Turkey. <i>Turk J Haematol</i> . 2007; 24(1): 4-7.	1995-2003		
Turkey	Eker A, Tansel O, Kunduracılar H, Tokuş B, Yuluğkural Z, Yüksel P. [Hepatitis E virus epidemiology in adult population in Edirne province, Turkey]. <i>Mikrobiyol Bul</i> . 2009; 43(2): 251-8.	2006-2008		
Turkey	Erden S, Büyükoztürk S, Calangu S, Yılmaz G, Palanduz S, Badur S. A study of serological markers of hepatitis B and C viruses in Istanbul, Turkey. <i>Med Princ Pract</i> . 2003; 12(3): 184-8.	1998-2001		
Turkey	Ertekin V, Selimoğlu MA, Altınkaynak S. Sero-epidemiology of hepatitis B infection in an urban paediatric population in Turkey. <i>Public Health</i> . 2003; 117(1): 49-53.	2001		
Turkey	Gürol E, Saban C, Oral O, Cigdem A, Armağan A. Trends in Hepatitis B and Hepatitis C Virus among Blood Donors over 16 Years in Turkey. <i>Eur J Epidemiol</i> . 2006; 21(4): 299-305.	1989-2004		
Turkey	Kurçer M, Pehlivan E. Hepatitis B seroprevalence and risk factors in urban areas of Malatya. <i>Turk J Gastroenterol</i> . 2002; 13(1): 1-5.	1997		
Turkey	Kuyucu N, Dökmen A, Yöney A, Teziç T. Seroprevalence of hepatitis B infection in Turkish children. <i>Infection</i> . 1998; 26(5): 317-8.	1996		
Turkey	Mehmet D, Meliksah E, Serif Y, Gunay S, Tuncer O, Zeynep S. Prevalence of hepatitis B infection in the southeastern region of Turkey: comparison of risk factors for HBV infection in rural and urban areas. <i>Jpn J Infect Dis</i> . 2005; 58(1): 15-9.	2003		
Turkey	Nas T, Taner MZ, Yıldız A. Seroprevalence of syphilis, human immunodeficiency virus type-1, and hepatitis B virus infections among pregnant women in Turkey. <i>Int J Gynaecol Obstet</i> . 1999; 66(2): 171-2.	1997		
Turkey	Özdemir O, Arda K, Soylu M, Alyan O, Demir AD, Kilitik E. Seroprevalence of hepatitis B and C in subjects admitted to a cardiology clinics in Turkey. <i>Eur J Epidemiol</i> . 2003; 18(3): 255-8.	1999-2001		
Turkey	Ossoy MF, Oncul O, Cavuslu S, Erdemoglu A, Emekdas G, Palsa A. Seroprevalences of hepatitis B and C among health care workers in Turkey. <i>J Viral Hepat</i> . 2003; 10(2): 150-6.	1998-2000	*	
Turkey	Thomas DL, Mahley RW, Badur S, Palaoglu E, Quinn TC. The epidemiology of hepatitis C in Turkey. <i>Infection</i> . 1994; 22(6): 411-4.	1990-1992	*	
Turkey	Flohr C, Weinmayr G, Weiland SK, Addo-Yobo E, Annesi-Maesano I, Björkstén B, Bråbäck L, Büchele G, Chico M, Cooper P, Clausen M, El Sharif N, Martínez Gimeno A, Mathur RS, von Mutius E, Morales Suarez-Varela M, Pearce N, Svabe V, Wong GWK, Yu M, Zhong NS, Williams HC, ISAAC Phase Two Study Group. How well do questionnaires perform compared with physical examination in detecting flexural eczema? Findings from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. <i>Br J Dermatol</i> . 2009; 161(4): 846-53.	2005-2007	*	
Turkey	Tüz M, Dogru H, Uygun K, Aynalı G. Sensorineural hearing loss associated with chronic otitis media. <i>SDU Ypp Fak Derg</i> . 2006; 13: 1-2.	1994-1999	*	
Turkey	Muslimanoglu AY, Binbay M, Yuruk E, Akman T, Tepeker A, Esen T, Tefekli AH. Updated epidemiologic study of urolithiasis in Turkey. I. Changing characteristics of urolithiasis. <i>Urol Res</i> . 2011; 39(4): 309-14.	2008	*	
Turkey	Akgin C, Kayan M, Tuncer O, Arslan S, Caksen H, Atas B, Akbayram S. The prevalence of urinary lithiasis in children in Van Region, Turkey. <i>Hiroshima J Med Sci</i> . 2009; 58(2-3): 61-6.	2003	*	
Turkey	Akinci M, Esen T, Tellaloglu S. Urinary stone disease in Turkey: an updated epidemiological study. <i>Eur Urol</i> . 1991; 20(3): 200-3.	1989		†
Turkey	Bulut A, Filippi V, Marshall T, Nalbant H, Yolsal N, Graham W. Contraceptive Choice and Reproductive Morbidity in Istanbul. <i>Stud Fam Plann</i> . 1997; 28(1): 35-43.	1993	*	
Turkey	Duman N, Kumral A, Gülcen H, Özkan H. Outcome of very-low-birth-weight infants in a developing country: a prospective study from the western region of Turkey. <i>J Matern Fetal Neonatal Med</i> . 2003 Jan 1; 13(1): 54-8.	1998	*	
Turkey	Turkish Society of Nephrology (TSN) Registry Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	†
Turkey	Turkish Society of Nephrology (TSN) Registry Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	†
Turkey	Alten B, Caglar S, Simsek F, Kaynas S. Effect of insecticide-treated bednets for malaria control in Southeast Anatolia-Turkey. <i>J Vector Ecol</i> . 2003; 28(1): 97-107 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000		
Turkey	Zeyrek FY, Kurcer MA, Zeyrek D, Simsek Z. Parasite density and serum cytokine levels in Plasmodium vivax malaria in Turkey. <i>Parasite Immunol</i> . 2006; 28(5): 201-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002		
Turkmenistan	Centre for Health Informatics and Multiprofessional Education, University College London. Model's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Turkmenistan	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1999, 2001-2004, 2006		
Turkmenistan	Torgerson PR, Oguljahan B, Muminov AE, Karavaeva RR, Kuttubaeva OT, Aminjanov M, Shaikenov B. Present situation of cystic echinococcosis in Central Asia. <i>Parasitol Int</i> . 2006; 55(1): S207-S212.	2000		
Turkmenistan	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010	*	
Turkmenistan	Amansakhatov S, Volokhovskaya ZP, Afanasyeva AN, Limburg H. Cataract blindness in Turkmenistan: results of a national survey. <i>Br J Ophthalmol</i> . 2002; 86(11): 1207-10, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2000-2001	*	
Turkmenistan	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Turkmenistan	World Health Organization (WHO). Turkmenistan WHO Leishmaniasis Country Profile.	1986-1990, 2000-2008		
Turkmenistan	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000		
Turkmenistan	USSR - Turkmen SSR Vital Registration Birth Data 1989 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1989	*	†
Uganda	Division of Reproductive Health, Centers for Disease Control and Prevention (CDC), Ministry of Health (Uganda). Uganda AIDS Indicator Survey 2004-2005. Calverton, United States: Macro International, Inc.	2004-2005		†
Uganda	Uganda Malaria Indicator Survey 2009-2010 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2009-2010		†
Uganda	Macro Systems, Inc.; Institute for Resource Development, Makerere University, Ministry of Health (Uganda). Uganda Demographic and Health Survey 1988-1989. Columbia, United States: Macro Systems, Inc.	1988-1989		†
Uganda	Macro International, Inc, Statistics Department (Uganda). Uganda Demographic and Health Survey 1995. Calverton, United States: Macro International, Inc.	1995		†
Uganda	Macro International, Inc, Uganda Bureau of Statistics. Uganda Demographic and Health Survey 2000-2001. Calverton, United States: Macro International, Inc.	2000-2001	*	†
Uganda	Macro International, Inc, Uganda Bureau of Statistics. Uganda Demographic and Health Survey 2006. Calverton, United States: Macro International, Inc.	2006		
Uganda	ICF Macro, Uganda Bureau of Statistics. Uganda Demographic and Health Survey 2011. Calverton, United States: ICF Macro.	2011		†
Uganda	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Uganda	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		
Uganda	Eriksson J, Reimert CM, Kabatereine NB, Kazibwe F, Ileri E, Kadzo H, Eltahir HB, Mohamed AO, Vennervald BJ, Venge P. The 434(G-C) polymorphism within the coding sequence of Eosinophil Cationic Protein (ECP) correlates with the natural course of Schistosoma mansoni infection. Int J Parasitol. 2007; 37(12): 1359-66.	2005		
Uganda	Gibbs, S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int J Dermatol. 1996; 35(9): 633-9.	1994		
Uganda	Williams EH, Hayes RJ, Smith PG. Admissions to a rural hospital in the West Nile District of Uganda over a 27 year period. J Trop Med Hyg. 1986; 89(4): 193-211.	1951-1978		
Uganda	Tumwine JK, Kekitiniwa A, Bakoera-Kitaka S, Ndeezi G, Downing R, Feng X, Akiyoshi DE, Tzipori S. Cryptosporidiosis and microsporidiosis in ugandan children with persistent diarrhea with and without concurrent infection with the human immunodeficiency virus. Am J Trop Med Hyg. 2005; 73(5): 921-5.	2002-2003		
Uganda	Mwenda JM, Ntoto KM, Abebe A, Enweronu-Laryea C, Amina I, Mchomvu J, Kisakyi A, Mpabalwani EM, Pazvakavambwa I, Amah GE, Seheri LM, Kiulia NM, Page N, Widdowson M-A, Steele AD. Burden and epidemiology of rotavirus diarrhea in selected African countries: preliminary results from the African Rotavirus Surveillance Network. J Infect Dis. 2010; 202(Suppl): S5-11.	2006-2008		
Uganda	Mutyaba S, Mmiro F. Maternal morbidity during labor in Mulago hospital. Int J Gynaecol Obstet. 2001; 75(1): 79-80.	1997		
Uganda	Okong P, Byamugisha J, Mirembe F, Byaruhanga R, Bergstrom S. Audit of severe maternal morbidity in Uganda - implications for quality of obstetric care. Acta Obstet Gynecol Scand. 2006; 85(7): 797-804.	1999-2000		
Uganda	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997-1998, 2000, 2003, 2005-2009		†
Uganda	Koukounari A, Fenwick A, Whawell S, Kabatereine NB, Kazibwe F, Tukahebwa EM, Stothard JR, Donnelly CA, Webster JP. Morbidity indicators of Schistosoma mansoni: relationship between infection and anemia in Ugandan schoolchildren before and after praziquantel and albendazole chemotherapy. Am J Trop Med Hyg. 2006; 75(2): 278-86.	2003-2004		
Uganda	Ongom VL, Bradley DJ. The epidemiology and consequences of Schistosoma mansoni infection in West Nile, Uganda. Trans R Soc Trop Med Hyg. 1972; 66(6): 835-51.	1970		
Uganda	Fèvre EM, Odiit M, Coleman PG, Woolhouse MEJ, Welburn SC. Estimating the burden of rhodesiense sleeping sickness during an outbreak in Serere, eastern Uganda. BMC Public Health. 2008; 8: 96.	1995-2005	*	
Uganda	Nambuya AP, Otim MA, Whitehead H, Mulvany D, Kennedy R, Hadden DR. The presentation of newly-diagnosed diabetic patients in Uganda. QJM. 1996; 89(9): 705-11.	1993-1994	*	
Uganda	Berrang-Ford L, Lundine J, Breau S. Conflict and human African trypanosomiasis. Soc Sci Med. 2011; 72(3): 398-407.	1978-1981		
Uganda	Rwenyonyi CM, Muwazi LM, Buwembo W. Assessment of factors associated with dental caries in rural communities in Rakai District, Uganda. Clin Oral Investig. 2011; 15(1): 75-80.	2009	*	
Uganda	Stabinski L, Reynolds SJ, Ocama P, Laeyendecker O, Serwadda D, Gray RH, Wawer M, Thomas DL, Quinn TC, Kirk GD. Hepatitis B virus and sexual behavior in Rakai, Uganda. J Med Virol. 2011; 83(5): 796-800.	1998	*	
Uganda	Somigliana E, Viganò P, Benaglia L, Crovetto F, Vercellini P, Fedele L. Endometriosis in a rural remote setting: a cross-sectional study. Gynecol Endocrinol. 2012; 28(12): 979-82.	2009-2010		
Uganda	Forman D, Bray F, Brewster DH, Gombé Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version). Lyon, IARC. http://ci5.iarc.fr	2003-2007		
Uganda	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Uganda	Rwenyonyi CM, Birkeland JM, Haugejorden O, Bjorvatn K. Dental caries among 10- to 14-year-old children in Ugandan rural areas with 05 and 25 mg fluoride per liter in drinking water. Clin Oral Investig. 2001; 5(1): 45-50.	1996-1997		
Uganda	Nalweyiso N, Busingye J, Whitworth J, Robinson PG. Dental treatment needs of children in a rural subcounty of Uganda. Int J Paediatr Dent. 2004; 14(1): 27-33.	2002		
Uganda	Kiwanuka SN, Aström AN, Trovik TA. Dental caries experience and its relationship to social and behavioural factors among 3-5-year-old children in Uganda. Int J Paediatr Dent. 2004; 14(5): 336-46.	2002		
Uganda	Orley J, Wing JK. Psychiatric disorders in two african villages. Arch Gen Psychiatry. 1979; 36(5): 513-20.	1972		
Uganda	Tann CJ, Mpairwe H, Morison L, Nassimu K, Hughes P, Omara M, Mabey D, Muwanga M, Grosskurth H, Elliott AM. Lack of effectiveness of syndromic management in targeting vaginal infections in pregnancy in Entebbe, Uganda. Sex Transm Infect. 2006; 82(4): 285-9.	1991, 2004		
Uganda	Råsjö E-B, Kambugu F, Tunwesigye MN, Tenywa T, Darj E. Prevalence of sexually transmitted infections among adolescents in Kampala, Uganda, and theoretical models for improving syndromic management. J Adolesc Health. 2006; 38(3): 213-21.	2002		
Uganda	Uganda - Masaka Rapid Assessment of Cataract Surgical Services 2007 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2007	*	
Uganda	Mbulaitwe SM, Reeves BC, Karabalinde A, Ruberantwari A, Mulwanyani F, Whitworth JAG, Johnson GJ. Evaluation of E-optotypes as a screening test and the prevalence and causes of visual loss in a rural population in SW Uganda. Ophthalmic Epidemiol. 2002; 9(4): 251-62, as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1999-2000	*	
Uganda	Kinyanda E, Kizza R, Abbo C, Ndyabangi S, Levin J. Prevalence and risk factors of depression in childhood and adolescence as seen in four districts of North-Eastern Uganda. BMC Int Health Hum Rights. 2013; 19.	2002	*	
Uganda	Ngugi AK, Bottomley C, Kleinschmidt I, Wagner RG, Kakooza-Mwesige A, Ae-Ngibise K, Owusu-Agyei S, Masanja H, Kamuyu G, Odhiambo R, Chengo E, Sander JW, Newton CR, SEEDS group. Prevalence of active convulsive epilepsy in sub-Saharan Africa and associated risk factors: cross-sectional and case-control studies. Lancet Neurol. 2013; 12(3): 253-63.	2009	*	
Uganda	Kabakyenga JK, Östergren P-O, Turyakira E, Mukasa PK, Pettersson KO. Individual and health facility factors and the risk for obstructed labour and its adverse outcomes in south-western Uganda. BMC Pregnancy Childbirth. 2011; 73.	2006	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Uganda	Vogel JP, Betrán AP, Widmer M, Souza JP, Gülmezoglu AM, Seuc A, Torloni MR, Mengestu TK, Meriardi M. Role of faith-based and nongovernment organizations in the provision of obstetric services in 3 African countries. <i>Am J Obstet Gynecol.</i> 2012; 207(6): 495e1-7.	2004-2005	*	
Uganda	Kaiser C, Asaba G, Leichenring M, Kabagambe G. High incidence of epilepsy related to onchocerciasis in West Uganda. <i>Epilepsy Res.</i> 1998; 30(3): 247-51.	1994	*	
Uganda	Kaiser C, Kipp W, Asaba G, Mugisa C, Kabagambe G, Rating D, Leichenring M. The prevalence of epilepsy follows the distribution of onchocerciasis in a west Ugandan focus. <i>Bull World Health Organ.</i> 1996; 74(4): 361-7.	1994		†
Uganda	Kaiser C, Asaba G, Kasoro S, Rubaale T, Kabagambe G, Mbabazi M. Mortality from epilepsy in an onchocerciasis-endemic area in West Uganda. <i>Trans R Soc Trop Med Hyg.</i> 2007; 101(1): 48-55.	1994		
Uganda	Bolton P, Wilk CM, Ndogoni L. Assessment of depression prevalence in rural Uganda using symptom and function criteria. <i>Soc Psychiatry Psychiatr Epidemiol.</i> 2004; 39(6): 442-7.	2000	*	
Uganda	Ovuga E, Boardman J, Wasserman D. The prevalence of depression in two districts of Uganda. <i>Soc Psychiatry Psychiatr Epidemiol.</i> 2005; 40(6): 439-45.	2003		
Uganda	Vinck P, Pham PN, Stover E, Weinstein HM. Exposure to war crimes and implications for peace building in northern Uganda. <i>JAMA.</i> 2007; 298(5): 543-54.	2005	*	
Uganda	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012	*	
Uganda	Kamali A, Quigley M, Nakiyingi J, Kinsman J, Kengeya-Kayondo J, Gopal R, Ojwiya A, Hughes P, Carpenter LM, Whitworth J. Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. <i>Lancet.</i> 2003; 361(9358): 645-52.	1994-2000	*	
Uganda	Kamali A, Nunn AJ, Mulder DW, Van Dyck E, Dobbins JG, Whitworth JA. Seroprevalence and incidence of genital ulcer infections in a rural Ugandan population. <i>Sex Transm Infect.</i> 1999; 75(2): 98-102.	1990-1993	*	†
Uganda	Wagner HU, Van Dyck E, Roggen E, Nunn AJ, Kamali A, Schmid DS, Dobbins JG, Mulder DW. Seroprevalence and incidence of sexually transmitted diseases in a rural Ugandan population. <i>Int J STD AIDS.</i> 1994; 5(5): 332-7.	1989-1990		
Uganda	Robertson NJ, Nakakeeto M, Hagmann C, Cowan FM, Acolet D, Iwata O, Allen E, Elbourne D, Costello A, Jacobs I. Therapeutic hypothermia for birth asphyxia in low-resource settings: a pilot randomised controlled trial. <i>Lancet.</i> 2008; 372(9641): 801-3.	2007		
Uganda	Mayega RW, Guwatudde D, Makumbi F, Nakwagala FN, Peterson S, Tomson G, Ostenson C-G. Diabetes and pre-diabetes among persons aged 35 to 60 years in eastern Uganda: prevalence and associated factors. <i>PLoS One.</i> 2013; 8(8): e72554.	2012		
Uganda	Luttrell V, Lea C. Glucose-6-phosphate dehydrogenase deficiency in East Africans. <i>East Afr Med J.</i> 1965; 313-5.	1963-1965		
Uganda	Lothe F. Erythrocyte glucose-6-phosphate dehydrogenase deficiency in Uganda. <i>Nature.</i> 1967; 215(5098): 299-300.	1965-1967		†
Uganda	Parikh S, Dorsey G, Rosenthal PJ. Host polymorphisms and the incidence of malaria in Ugandan children. <i>Am J Trop Med Hyg.</i> 2004; 71(6): 750-3.	2000-2001	*	†
Uganda	Davis JC, Clark TD, Kemble SK, Talemwa N, Njama-Meya D, Staedke SG, Dorsey G. Longitudinal study of urban malaria in a cohort of Ugandan children: description of study site, census and recruitment. <i>Malar J.</i> 2006; 18.	2004-2005	*	
Uganda	Davis JC, Clark TD, Kemble SK, Talemwa N, Njama-Meya D, Staedke SG, Dorsey G. Longitudinal study of urban malaria in a cohort of Ugandan children: description of study site, census and recruitment. <i>Malar J.</i> 2006; 5(1): 18 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004-2005	*	
Uganda	Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M and Boyle P, eds (2007). Cancer Incidence in Five Continents, Vol. IX Periodic Data (electronic version). Lyon, IARC. http://ci5.iarc.fr	1998-2002	*	
Uganda	Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. Cancer Incidence in Five Continents. Vol. I to VIII. Lyon, France, IARC Press, 2005.	1991-1997	*	
Uganda	World Health Organization (WHO). Uganda WHO Leishmaniasis Country Profile.	2000-2008		
Uganda	Ashton RA, Kyabayinze DJ, Opio T, Auma A, Edwards T, Matwale G, Onapa A, Brooker S, Kolaczinski JH. The impact of mass drug administration and long-lasting insecticidal net distribution on <i>Wuchereria bancrofti</i> infection in humans and mosquitoes: an observational study in northern Uganda. <i>Parasit Vectors.</i> 2011; 134. as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	2007		
Uganda	Onapa AW, Simonsen PE, Pedersen EM, Okello DO. Lymphatic filariasis in Uganda: baseline investigations in Lira, Soroti and Katakwi districts. <i>Trans R Soc Trop Med Hyg.</i> 2001; 95(2): 161-7, as it appears in London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections.	1998		
Uganda	Beaton A, Okello E, Lwabi P, Mondo C, McCarter R, Sable C. Echocardiography screening for rheumatic heart disease in Ugandan schoolchildren. <i>Circulation.</i> 2012; 125(25): 3127-32.	2010		
Uganda	Damasceano A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D, Dzudie A, Kouam CK, Suliman A, Schrueder N, Yonga G, Ba SA, Maru F, Alemayehu B, Edwards C, Davison BA, Cotter G, Sliwa K. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. <i>Arch Intern Med.</i> 2012; 172(18): 1386-94.	2007-2010	*	
Uganda	Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. <i>Int J Health Geogr.</i> 2010; 9: 57.	1980-2010		
Uganda	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec.</i> 2006; 81(32): 309-16.	2005	*	
Uganda	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec.</i> 1999; 74(38): 313-6.	1998	*	
Uganda	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec.</i> 2013; 88(35): 365-79.	2012	*	
Uganda	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec.</i> 2001; 76(23): 173-9.	2000	*	
Uganda	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec.</i> 2000; 75(28): 226-31.	1999	*	
Uganda	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Uganda	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995	*	
Uganda	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994		
Uganda	Wawer MJ, Eng SM, Serwadda D, Sewankambo NK, Kiwanuka N, Li C, Gray RH. Prevalence of Kaposi sarcoma-associated herpesvirus compared with selected sexually transmitted diseases in adolescents and young adults in rural Rakai District, Uganda. <i>Sex Transm Dis.</i> 2001; 28(2): 77-81.	1994-1995		
Uganda	Nsubuga P, Mirembe F, et al. Reported sexual behaviour and sexually transmitted infection prevalence among women attending a prenatal clinic in Kampala, Uganda. VIII International Conference on AIDS; 1992 Jul 19-24; Amsterdam, The Netherlands. Amsterdam. The Netherlands: CONGREX Holland BV. 1992. Abstract no. PoC4619.&	1991		†
Uganda	Mayama S, Cuevas LE, Sheldon J, Omar OH, Smith DH, Okong P, Silvel B, Hart CA, Schulz TF. Prevalence and transmission of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in Ugandan children and adolescents. <i>Int J Cancer.</i> 1998; 77(6): 817-20.	1997	*	†
Uganda	Ssebabi EC, Nzaro E. Distribution of ABO and Rh(D) phenotypes in Uganda. <i>Vox Sang.</i> 1974; 26(1): 74-82.	1971-1973	*	†
Uganda	Malaria Situation Analysis in Apac, Kabarole, Kampala, and Rukungiri Districts: January to May 1992 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Uganda	Malaria Control in Kabarole and Bundibugyo Districts, Western Uganda as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Uganda	First Year Summary Report: Development of a Community-based Environmental Management Program for Malaria Control in Kampala and Jinja, Uganda as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002-2003	*	†
Uganda	Malaria Study in Children 0-14 Years at Atatur, Kumi District, Uganda as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Uganda	Annual Report for Ruhira, Uganda Millennium Village Year 1: February 2006-February 2007 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Uganda	Brooker SJ, Pullan RL, Gitonga CW, Ashton RA, Kolaczinski JH, Kabatereine NB, Snow RW. Plasmodium-Helminth Coinfection and Its Sources of Heterogeneity Across East Africa. J Infect Dis. 2012; 205(5): 841-52 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2010	*	†
Uganda	Egwang TG, Apio B, Riley E, Okello D. Plasmodium falciparum malariometric indices in Apac district, northern Uganda. East Afr Med J. 2000; 77(8): 413-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Uganda	Brooker S, Akhwale W, Pullan R, Estambale B, Clarke SE, Snow RW, Hotez PJ. Epidemiology of Plasmodium-Helminth Coinfection in Africa: Populations at Risk, Potential Impact on Anemia, and Prospects for Combining Control. Am J Trop Med Hyg. 2007; 77(Suppl 6): 88-98 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Uganda	Kolaczinski JH, Reithinger R, Worku DT, Ocheng A, Kasimiro J, Kabatereine N, Brooker S. Risk factors of visceral leishmaniasis in East Africa: a case-control study in Pokot territory of Kenya and Uganda. Int J Epidemiol. 2008; 37(2): 344-52 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Uganda	Ndyomugenyi R, Magnussen P. In vivo sensitivity of Plasmodium falciparum to chloroquine and sulfadoxine-pyrimethamine in school children in Hoima district, western Uganda. Acta Trop. 1997; 66(3): 137-43 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1995	*	†
Uganda	Prugger C, Engl M, Ogwang M, Ploner F, Ploner M, Gluderer D, Wernsdorfer G, Wernsdorfer WH. Malariological baseline survey and in vitro antimalarial drug resistance in Gulu district, Northern Uganda. Wien Klin Wochenschr. 2008; 120(19-20): 63-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2007	*	†
Uganda	Pullan RL, Bukirwa H, Staedke SG, Snow RW, Brooker S. Plasmodium infection and its risk factors in eastern Uganda. Malar J. 2010; 9: 2 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008	*	†
Uganda	Seal A, Creeke P, Mirghani Z, Abdalla F, McBurney R, Pratt L, Brookes D, Ruth L, Marchand E. Iron and vitamin A deficiency in long-term African refugees. J Nutr. 2005; 135(4): 808-13 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Uganda	Staedke SG, Mwebaza N, Kanya MR, Clark TD, Dorsey G, Rosenthal PJ, Whitty CJ. Home management of malaria with artemether-lumefantrine compared with standard care in urban Ugandan children: a randomised controlled trial. Lancet. 2009; 373(9675): 1623-31 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Uganda	Stothard JR, Sousa-Figueiredo, Betson M, Seto EYW, Kabatereine NB. Investigating the spatial micro-epidemiology of diseases within a point-prevalence sample: a field applicable method for rapid mapping of households using low-cost GPS-dataloggers. Trans R Soc Trop Med Hyg. 2011; 105(9): 500-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2009	*	†
Uganda	Talisuna A, Langi P, Bakayita N, Egwang T, Mutabingwa T, Watkins W, Van Marck E, D'Alessandro U. Intensity of malaria transmission, antimalarial-drug use and resistance in Uganda: what is the relationship between these three factors? Trans R Soc Trop Med Hyg. 2002; 96(3): 310-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999	*	†
Uganda	Uganda Plasmodium Falciparum Parasite Rate Data, Personal Communication with A. Talisuna, Uganda Ministry of Health / Medicines for Malaria Venture, 2009 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2009	*	†
Uganda	Uganda Plasmodium Falciparum Parasite Rate Data, African Pest and Environment Management Foundation 1994 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†
Uganda	Uganda Plasmodium Falciparum Parasite Rate Data, Kamugisha 1992 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Uganda	Okia M. Uganda Plasmodium Falciparum Parasite Rate Data, M. Okia, Ministry of Health, 1996 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992-1996		
Uganda	Uganda Plasmodium Falciparum Parasite Rate Data 1994 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994		
Ukraine	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2005		†
Ukraine	Division of Reproductive Health-Centers for Disease Control and Prevention (CDC) and Kiev International Institute of Sociology. (2001) Ukraine Reproductive Health Survey 1999. Atlanta, United States: Centers for Disease Control and Prevention (CDC).	1999		†
Ukraine	Macro International, Inc. State Statistical Committee (Ukraine), Ukrainian Center for Social Reforms (UCSR). Ukraine Demographic and Health Survey 2007. Calverton, United States: Macro International, Inc.	2007	*	
Ukraine	World Health Organization (WHO). Ukraine World Health Survey 2002-2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2002-2003		
Ukraine	World Health Organization (WHO). Control of Foodborne Trematode Infections 1995. Geneva, Switzerland: World Health Organization (WHO), 1995.	1995		
Ukraine	Mihalka L, Smolanka V, Bulecza B, Mulesa S, Bereczki D. A Population Study of Stroke in West Ukraine: Incidence, Stroke Services, and 30-Day Case Fatality. Stroke. 2001; 32(10): 2227-31.	1999-2000		
Ukraine	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. J Allergy Clin Immunol. 2008; 121(4): 947-954.	1998, 2002		
Ukraine	Demyttenaere K, Bruffaerts R, Lee S, Posada-Villa J, Kovess V, Angermeyer MC, Levinson D, de Girolamo G, Nakane H, Mneinneh Z, Lara C, de Graaf R, Scott KM, Gureje O, Stein DJ, Haro JM, Bromet EJ, Kessler RC, Alonso J, Von Korff M. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. Pain. 2007; 129(3): 332-42.	2002		
Ukraine	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000-2003, 2006-2008		
Ukraine	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J. 1998; 12(2): 315-35.	1993-1995	*	
Ukraine	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2002	*	
Ukraine	Ukrainian National Cancer Registry. Cancer in Ukraine 2009-2010. Kiev, Ukraine: Ukrainian National Cancer Registry, 2011.	2009	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Ukraine	Ukrainian National Cancer Registry. Ukraine - Cancer in Ukraine 2010-2011. Ukraine: Ukrainian National Cancer Registry, 2012.	2010		
Ukraine	Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version). Lyon, IARC. http://ci5.iarc.fr	2003-2007		
Ukraine	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Ukraine	Bromet EJ, Gluzman SF, Paniotto VI, Webb CPM, Tintle NL, Zakhozha V, Havenaar JM, Gutkovich Z, Kostyuchenko S, Schwartz JE. Epidemiology of psychiatric and alcohol disorders in Ukraine. Soc Psychiatry Psychiatr Epidemiol. 2005; 40(9): 681-90.	2001-2002		
Ukraine	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
Ukraine	WHO Regional Office for Europe (EURO-WHO). Young People's Health in Context. Health Behaviour in School-aged Children (HBSC) Study: International Report from the 2001-2002 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2004.	2002		
Ukraine	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006		
Ukraine	Bromet EJ, Gluzman SF, Paniotto VI, Webb CP, Tintle NL, Zakhozha V, Havenaar JM, Gutkovich Z, Kostyuchenko S, Schwartz JE. Epidemiology of psychiatric and alcohol disorders in Ukraine: findings from the Ukraine World Mental Health survey. Soc Psychiatry Psychiatr Epidemiol. 2005; 40(9): 681-90.	2002	*	
Ukraine	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2012	*	
Ukraine	Ukrainian National Cancer Registry. Ukraine - Cancer in Ukraine 2000-2001. Ukraine: Ukrainian National Cancer Registry, 2002.	2000-2001	*	
Ukraine	Ukrainian National Cancer Registry. Ukraine - Cancer in Ukraine 2003-2004. Ukraine: Ukrainian National Cancer Registry, 2005.	2003	*	
Ukraine	Ukrainian National Cancer Registry. Ukraine - Cancer in Ukraine 2006-2007. Ukraine: Ukrainian National Cancer Registry, 2008.	2006	*	
Ukraine	Ukrainian National Cancer Registry. Ukraine - Cancer in Ukraine 2002-2003. Ukraine: Ukrainian National Cancer Registry, 2004.	2002	*	
Ukraine	Ukrainian National Cancer Registry. Ukraine - Cancer in Ukraine 2004-2005. Ukraine: Ukrainian National Cancer Registry, 2006.	2004	*	
Ukraine	StatInform Consulting, State Statistics Service (Ukraine), Ukrainian Center for Social Reforms (UCSR), United Nations Children's Fund (UNICEF). Ukraine Multiple Indicator Cluster Survey 2012. New York, United States: United Nations Children's Fund (UNICEF), 2014.	2012	*	
Ukraine	Clark CG, Kravetz AN, Alekseenko VV, Krendelew YuD, Johnson WM. Microbiological and epidemiological investigation of cholera epidemic in Ukraine during 1994 and 1995. Epidemiol Infect. 1998; 121(1): 1-13.	1994-1995	*	
Ukraine	Ukrainian National Cancer Registry. Ukraine - Cancer in Ukraine 2007-2008. Ukraine: Ukrainian National Cancer Registry, 2009.	2007		
Ukraine	World Health Organization (WHO). Ukraine WHO Leishmaniasis Country Profile.	1995-1997, 2001, 2003, 2005-2008	*	†
Ukraine	Moisseeva AV, Marichev IL, Biloschitchkay NA, Pavlenko KI, Novik LV, Kovinko LV, Lyabis OI, Houillon G, Rasuli AM. Hepatitis A seroprevalence in children and adults in Kiev City, Ukraine. J Viral Hepat. 2008; 43-6.	1997, 2007	*	
Ukraine	Tsoi RM, Pak IV, Bobrova IA. [Distribution of blood types of four systems and ABO incompatibility in migration population of a northern town]. <i>Fiziol Cheloveka</i> . 2003; 29(3): 125-8.	1997-1998	*	
Ukraine	Ukraine Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010		
Ukraine	Ukraine Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
Ukraine	European Surveillance of Congenital Anomalies (EUROCAT). Ukraine EUROCAT Prevalence Tables. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	2005-2011	*	
Ukraine	Ukraine - Rivne and Volyn OMNI-Net Birth Defects Program Data 2009 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
Ukraine	Ukraine - Rivne and Volyn OMNI-Net Birth Defects Program Data 2010 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
Ukraine	Ukraine - Ukrainian-American Birth Defects Program Data 2003 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
Ukraine	Ukraine - Northwest Ukraine OMNI-Net Birth Defects Program Data 2007 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
Ukraine	Ukraine - Rivne and Volyn OMNI-Net Birth Defects Program Data 2008 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
Ukraine	Ukraine - Ukrainian-American Birth Defects Program Data 2001 - ICBDMS as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001		
Ukraine	Ukraine - Ukrainian-American Birth Defects Program Data 2004 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004		†
Ukraine	USSR - Ukrainian SSR Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990		
United Arab Emirates	World Health Organization (WHO). United Arab Emirates World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		
United Arab Emirates	Al Hosani H, Salah M, Osman HM, Farag HM, Anversy SM. Incidence of haemoglobinopathies detected through neonatal screening in the United Arab Emirates. East Mediterr Health J. 2005; 11(3): 300-7.	1990-2002		†
United Arab Emirates	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
United Arab Emirates	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		
United Arab Emirates	Dash N, Ameen A, Sheek-Hussein M, Smego R. Epidemiology of meningitis in Al-Ain, United Arab Emirates, 2000-2005. Int J Infect Dis. 2007; 11(4): 309-12.	2000-2005		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United Arab Emirates	White JM, Byrne M, Richards R, Buchanan T, Katsoulis E, Weerasingh K. Red cell genetic abnormalities in Peninsular Arabs: sickle haemoglobin, G6PD deficiency, and alpha and beta thalassaemia. <i>J Med Genet.</i> 1986; 3(23): 245-51.	1984-1986		
United Arab Emirates	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1999-2005, 2008		
United Arab Emirates	Al-Maskari F, El-Sadig M. Prevalence of risk factors for diabetic foot complications. <i>BMC Fam Pract.</i> 2007; 8(1): 59.	2003-2004		
United Arab Emirates	Al-Maskari F, El-Sadig M. Prevalence of diabetic retinopathy in the United Arab Emirates: a cross-sectional survey. <i>BMC Ophthalmol.</i> 2007; 7(1).	2003-2004		
United Arab Emirates	Saadi H, Carruthers SG, Nagelkerke N, Al-Maskari F, Afandi B, Reed R, Lukic M, Nicholls MG, Kazam E, Algawi K, Al-Kaabi J, Leduc C, Sabri S, El-Sadig M, Elkhumaidi S, Agarwal M, Benedict S. Prevalence of diabetes mellitus and its complications in a population-based sample in Al Ain, United Arab Emirates. <i>Diabetes Res Clin Pract.</i> 2007; 78(3): 369-77.	2006	*	
United Arab Emirates	Bener A, Swadi H, Qassimi EM, Uduman S. Prevalence of headache and migraine in schoolchildren in the United Arab Emirates. <i>Ann Saudi Med.</i> 1998; 18(6): 522-4.	1995-1996	*	
United Arab Emirates	Alsowaidi S, Abdulle A, Bernsen R. Prevalence and risk factors of asthma among adolescents and their parents in Al-Ain (United Arab Emirates). <i>Respiration.</i> 2010; 79(2): 105-11.	2007-2008	*	
United Arab Emirates	Mahboub BH, Al-Hammadi S, Rafique M, Sulaiman N, Pawankar R, Al Redha AL, Mehta AC. Population prevalence of asthma and its determinants based on European Community Respiratory Health Survey in the United Arab Emirates. <i>BMC Pulm Med.</i> 2012; 4.	2010		
United Arab Emirates	Hashim R, Williams S, Thomson WM. Severe early childhood caries and behavioural risk indicators among young children in Ajman, United Arab Emirates. <i>Eur Arch Paediatr Dent.</i> 2011; 12(4): 205-10.	2009		
United Arab Emirates	Hashim R, Williams SM, Thomson WM, Awad MA. Caries prevalence and intra-oral pattern among young children in Ajman. <i>Community Dent Health.</i> 2010; 27(2): 109-13.	2007-2008		
United Arab Emirates	Eapen V, Mabrouk AA, Bin-Othman S. Disordered eating attitudes and symptomatology among adolescent girls in the United Arab Emirates. <i>Eat Behav.</i> 2006; 7(1): 53-60.	2003-2004		
United Arab Emirates	Eapen V, Al-Gazali L, Bin-Othman S, Abou-Saleh M. Mental Health Problems Among Schoolchildren in United Arab Emirates: Prevalence and Risk Factors. <i>J Am Acad Child Adolesc Psychiatry.</i> 1998; 37(8): 880-6.	1995-1996		
United Arab Emirates	Ghubash R, Hamdi E, Bebbington P. The Dubai Community Psychiatric Survey: I. Prevalence and socio-demographic correlates. <i>Soc Psychiatry Psychiatr Epidemiol.</i> 1992; 27(2): 53-61.	1989-1990		
United Arab Emirates	Eapen V, Jakka ME, Abou-Saleh MT. Children With Psychiatric Disorders: The Al Ain Community Psychiatric Survey. <i>Can J Psychiatry.</i> 2003; 48(6): 402-7.	2001		
United Arab Emirates	Rizk DEE, Mosallam M, Alyan S, Nagelkerke N. Prevalence and impact of premenstrual syndrome in adolescent schoolgirls in the United Arab Emirates. <i>Acta Obstet Gynecol Scand.</i> 2006; 85(5): 589-98.	2003	*	
United Arab Emirates	Uduman SA, Tahira AM, Al-Wash R, Usmani MA, Bener A. Varicella susceptibility among children and healthy adults in the United Arab Emirates. <i>East Mediterr Health J.</i> 2001; 7(4-5): 604-8.	1998	*	
United Arab Emirates	Ghazal-Aswad S, Badrinath P, Sidky I, Safi TH, Gargash H, Abdul-Razak Y, Mirghani H. Severe acute maternal morbidity in a high-income developing multiethnic country. <i>Matern Child Health J.</i> 2013; 17(3): 399-404.	1998-2003		
United Arab Emirates	Inshasi J, Thakre M. Prevalence of multiple sclerosis in Dubai, United Arab Emirates. <i>Int J Neurosci.</i> 2011; 121(7): 393-8.	2000-2007		
United Arab Emirates	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2004, 2007, 2010, 2012		
United Arab Emirates	Bayoumi RA, Nur-E-Kamal MS, Tadayyon M, Mohamed KK, Mahboob BH, Qureshi MM, Lakhani MS, Awaad MO, Kaeda J, Vulliamy TJ, Luzzatto L. Molecular characterization of erythrocyte glucose-6-phosphate dehydrogenase deficiency in Al-Ain District, United Arab Emirates. <i>Hum Hered.</i> 1996; 46(3): 136-41.	1994-1996	*	
United Arab Emirates	Abdulrazzaq YM, Micallef R, Qureshi M, Dawodu A, Ahmed I, Khidr A, Bastaki SM, Al-Khayat A, Bayoumi RA. Diversity in expression of glucose-6-phosphate dehydrogenase deficiency in females. <i>Clin Genet.</i> 1999; 55(1): 13-9.	1994-1996	*	
United Arab Emirates	World Health Organization (WHO). Global leprosy situation, 2007 (additional information). <i>Wkly Epidemiol Rec.</i> 2007; 82(44): 388.	2006	*	
United Arab Emirates	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
United Arab Emirates	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
United Arab Emirates	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec.</i> 2008; 83(33): 293-300.	2007	*	
United Arab Emirates	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010	*	
United Arab Emirates	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	
United Arab Emirates	Ghazal-Aswad S, Badrinath P, Osman N, Abdul-Khaliq S, Mc Ilvenny S, Sidky I. Prevalence of Chlamydia trachomatis infection among women in a Middle Eastern community. <i>BMC Womens Health.</i> 2004; 4(1): 3.	2001-2002		
United Arab Emirates	Sarma DK, Shukla R, Lodha A, Abdulla A, Pataridze L. Neonatal screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency: Experience in a private hospital. <i>Emirates Med J.</i> 2006; 24(3): 211-4.	2002-2005		†
United Arab Emirates	Sharar ZA, Rajah J, Parsons H. Childhood seroprevalence of hepatitis A in the United Arab Emirates. <i>Trop Doct.</i> 2008; 38(1): 65-6.	2004-2005		
United Arab Emirates	Chedid F, Shanteer S, Haddad H, Musharraf I, Shihab Z, Imran A, Adma HA, Salman N, Rahmani A. Short-term outcome of very low birth weight infants in a developing country: comparison with the Vermont Oxford Network. <i>J Trop. Pediatr.</i> 2009 Feb; 55(1): 15-9.	2005	*	
United Arab Emirates	United Arab Emirates Vital Registration Birth Data 1982 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1982	*	
United Arab Emirates	United Arab Emirates - Al Ain Medical District Congenital Abnormality Study Group Data 2001 - ICBDMS as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
United Arab Emirates	United Arab Emirates - Al Ain Medical District Congenital Abnormality Study Group Data 1996-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). <i>World Atlas of Birth Defects.</i> 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1996-1998		
United Arab Emirates	United Arab Emirates - Al Ain Medical District Congenital Abnormality Study Group Data 2003 - ICBDMS as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003		
United Arab Emirates	WHO Regional Office for Europe (EURO-WHO). European Hospital Morbidity Database. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO).	2000-2010		
United Kingdom	Joint Health Surveys Unit, University College London and Medical Research Council. Social and Public Health Sciences Unit, Scottish Health Survey, 2003 [computer file]. Colchester, Essex: UK Data Archive [distributor], February 2006. SN: 5318.	2003		
United Kingdom	World Health Organization (WHO). United Kingdom World Health Survey 2004. Geneva, Switzerland: World Health Organization (WHO), 2005.	2004	*	
United Kingdom	National Centre for Social Research and University College London. Department of Epidemiology and Public Health. Health Survey for England, 2003 [computer file]. Colchester, Essex: UK Data Archive [distributor], March 2005. SN: 5098.	2003	*	
United Kingdom	National Centre for Social Research and University College London. Department of Epidemiology and Public Health. Health Survey for England, 2005 [computer file]. Colchester, Essex: UK Data Archive [distributor], July 2007. SN: 5675.	2005		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United Kingdom	National Centre for Social Research and University College London. Department of Epidemiology and Public Health, Health Survey for England, 2006 [computer file]. 4th Edition. Colchester, Essex: UK Data Archive [distributor], July 2011. SN: 5809, http://dx.doi.org/10.5255/UKDA-SN-5809-1	2006		
United Kingdom	Royal College of General Practitioners. United Kingdom - England and Wales Weekly Returns Service Annual Report 2009. London, United Kingdom: Royal College of General Practitioners.	2000	*	
United Kingdom	Royal College of General Practitioners. United Kingdom - England and Wales Weekly Returns Service Annual Report 2005. London, United Kingdom: Royal College of General Practitioners.	2005		
United Kingdom	NatCen Social Research and University College London. Department of Epidemiology and Public Health, Health Survey for England, 2011 [computer file]. Colchester, Essex: UK Data Archive [distributor], April 2013. SN: 7260, http://dx.doi.org/10.5255/UKDA-SN-7260-1	2011		
United Kingdom	Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. <i>Am J Med.</i> 2002; 113(5): 359-64.	1980-1996		
United Kingdom	Lip GY, Golding DJ, Nazir M, Beevers DG, Child DL, Fletcher RL. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. <i>Br J Gen Pract.</i> 1997; 47(418): 285-9.	1995		
United Kingdom	Lip GY, Bawden L, Hodson R, Rutland E, Snatchfold J, Beevers DG. Atrial fibrillation amongst the Indo-Asian general practice population: The West Birmingham Atrial Fibrillation Project. <i>Int J Cardiol.</i> 1998; 65(2): 187-92.	1996		
United Kingdom	O'Connell JE, Gray CS. Atrial Fibrillation and Stroke Prevention in the Community. <i>Age Ageing.</i> 1996; 25(4): 307-309.	1995		
United Kingdom	Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. <i>Am Heart J.</i> 2008; 156(1): 57-64.	1987-2005		
United Kingdom	Carroll K, Majeed A. Comorbidity associated with atrial fibrillation: a general practice-based study. <i>Br J Gen Pract.</i> 2001; 51(472): 884-91.	1999		
United Kingdom	Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. <i>Lancet.</i> 1998; 352(9135): 1167-71.	1996-1997		
United Kingdom	De Lusignan S, Van Vlymen J, Hague N, Thana L, Dzegah B, Chan T. Preventing stroke in people with atrial fibrillation: a cross-sectional study. <i>J Public Health (Oxf).</i> 2005; 27(1): 85-92.	2004		
United Kingdom	Hill JD, Mottram EM, Killen PD. Study of the prevalence of atrial fibrillation in general practice patients over 65 years of age. <i>J R Coll Gen Pract.</i> 1987; 37(297): 172-3.	1983-1984		
United Kingdom	Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database. <i>Heart.</i> 2001; 86(3): 284-288.	1994-1998		
United Kingdom	DeWilde S, Carey IM, Emmas C, Richards N, Cook DG. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. <i>Heart.</i> 2006; 92(8): 1064-70.	1994-2003		
United Kingdom	Almeida AM, Henthorn JS, Davies SC. Neonatal screening for haemoglobinopathies: the results of a 10-year programme in an English Health Region. <i>Br J Haematol.</i> 2001; 112(1): 32-5.	1990-2000		
United Kingdom	Davies SC, Cronin E, Gill M, Greengross P, Hickman M, Normand C. Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research. <i>Health Technol Assess.</i> 2000; 4(3): 1-99.	1998		
United Kingdom	Mann JR. Sickle cell haemoglobinopathies in England. <i>Arch Dis Child.</i> 1981; 56(9): 676-83.	1969-1979		
United Kingdom	Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. <i>Scand J Clin Lab Invest.</i> 2007; 67(1): 39-69.	1988, 2006		
United Kingdom	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1988, 1990-2003, 2006		
United Kingdom	Streetyl A, Clarke M, Downing M, Farrar L, Foo Y, Hall K, Kemp H, Newbold J, Walsh P, Yates J, Henthorn J. Implementation of the newborn screening programme for sickle cell disease in England: results for 2003-2005. <i>J Med Screen.</i> 2008; 15(1): 9-13.	2004-2007		†
United Kingdom	Streetyl A, Latinovic R, Hall K, Henthorn J. Implementation of universal newborn bloodspot screening for sickle cell disease and other clinically significant haemoglobinopathies in England: screening results for 2005-7. <i>J Clin Pathol.</i> 2009; 62(1): 26-30.	2005-2007		
United Kingdom	Weatherall D. Sickle Cell and Thalassaemias Prevalence Data. Personal Correspondence with David Weatherall.	2009		
United Kingdom	Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. <i>Lancet.</i> 1991; 338(8765): 469-71.	1990		
United Kingdom	Simpson RJ, Fisher W, Lee AJ, Russell EB, Garraway M. Benign prostatic hyperplasia in an unselected community-based population: a survey of urinary symptoms, bothersomeness and prostatic enlargement. <i>Br J Urol.</i> 1996; 77(2): 186-91.	1990-1991		
United Kingdom	Mair FS, Crowley TS, Bundred PE. Prevalence, aetiology and management of heart failure in general practice. <i>Br J Gen Pract.</i> 1996; 46(403): 77-9.	1994		
United Kingdom	Berzon DB. Ear disease in a group general practice A review of world communities. <i>J Laryngol Otol.</i> 1983; 97(9): 817-24.	1970-1976		
United Kingdom	Browning GG, Gatehouse S. The prevalence of middle ear disease in the adult British population. <i>Clin Otolaryngol Allied Sci.</i> 1992; 17(4): 317-21.	1980-1986		
United Kingdom	Stathakis V, Kilkenny M, Marks R. Descriptive epidemiology of acne vulgaris in the community. <i>Australas J Dermatol.</i> 1997; 38(3): 115-23.	1987-1988		
United Kingdom	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol.</i> 2008; 121(4): 947-954.	1992, 1995-1996, 2001-2002		
United Kingdom	Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. <i>Arch Dis Child.</i> 2003; 12(88): 1065-9.	1996-1999		
United Kingdom	Fox KF, Cowie MR, Wood DA, Coats AJS, Gibbs JSR, Underwood SR, Turner RM, Poole-Wilson PA, Davies SW, Sutton GC. Coronary artery disease as the cause of incident heart failure in the population. <i>Eur Heart J.</i> 2001; 22(3): 228-36.	1998, 2000-2001		
United Kingdom	Murphy NF, Simpson CR, McAlister FA, Stewart S, MacIntyre K, Kirkpatrick M, Chalmers J, Redpath A, Capewell S, McMurray JJV. National survey of the prevalence, incidence, primary care burden, and treatment of heart failure in Scotland. <i>Heart.</i> 2004; 90(10): 1129-36.	1999-2000		
United Kingdom	de Guali F, Khaw KT, Cowie MR, Sutton GC, Ferrari R, Poole-Wilson PA. Incidence and outcome of persons with a clinical diagnosis of heart failure in a general practice population of 696,884 in the United Kingdom. <i>Eur J Heart Fail.</i> 2005; 7(3): 295-302.	1991-1994		
United Kingdom	Jones IR, Urwin G, Feldman RA, Banatvala N. Social deprivation and bacterial meningitis in north east Thames region: three year study using small area statistics. <i>BMJ.</i> 1997; 314(7083): 794-5.	1991-1993		
United Kingdom	Kyaw M, Christie P, Jones I, Campbell H. The Changing Epidemiology of Bacterial Meningitis and Invasive Non-meningitic Bacterial Disease in Scotland During the Period 1983-99. <i>Scand J Infect Dis.</i> 2002; 34(4): 289-98.	1983-1999		
United Kingdom	Forster J, Guarino A, Parez N, Moraga F, Rondán E, Mory O, Tozzi AE, de Aguieta AL, Wahn U, Graham C, Berner R, Ninan T, Barberousse C, Meyer N, Soriano-Gabarró M. Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of age. <i>Pediatrics.</i> 2009; 123(3): e393-400.	2005-2006		
United Kingdom	Watson B, Ellis M, Mandal B, Dunbar E, Whale K, Brennan J. A comparison of the clinico-pathological features with stool pathogens in patients hospitalised with the symptom of diarrhoea. <i>J Infect Dis.</i> 1986; 18(6): 553-9.	1981-1982		
United Kingdom	Lacey RJ, Lewis M, Sim J. Presentation of pain drawings in questionnaire surveys: influence on prevalence of neck and upper limb pain in the community. <i>Pain.</i> 2003; 105(1-2): 293-301.	2000		
United Kingdom	Palmer KT, Walker-Bone K, Griffin MJ, Syddall H, Pannett B, Coggon D, Cooper C. Prevalence and occupational associations of neck pain in the British population. <i>Scand J Work Environ Health.</i> 2001; 27(1): 49-56.	1997-1998		
United Kingdom	Sim J, Lacey RJ, Lewis M. The impact of workplace risk factors on the occurrence of neck and upper limb pain: a general population study. <i>BMC Public Health.</i> 2006; 6(1): 234.	2001-2002		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United Kingdom	Thomas E, Peat G, Harris L, Wilkie R, Croft PR. The prevalence of pain and pain interference in a general population of older adults: cross-sectional findings from the North Staffordshire Osteoarthritis Project (NorStOP). <i>Pain</i> . 2004; 110(1-2): 361-8.	2001		
United Kingdom	Urwin M, Symmons D, Allison T, Brammah T, Busby H, Roxby M, Simmons A, Williams G. Estimating the burden of musculoskeletal disorders in the community: the comparative prevalence of symptoms at different anatomical sites, and the relation to social deprivation. <i>Ann Rheum Dis</i> . 1998; 57(11): 649-55.	1995		
United Kingdom	Webb R, Brammah T, Lunt M, Urwin M, Allison T, Symmons D. Prevalence and predictors of intense, chronic, and disabling neck and back pain in the UK general population. <i>Spine</i> . 2003; 28(11): 1195-202.	2000		
United Kingdom	Lampe FC, Whincup PH, Wannamethee SG, Shaper AG, Walker M, Ebrahim S. The natural history of prevalent ischaemic heart disease in middle-aged men. <i>Eur Heart J</i> . 2000; 21(13): 1052-62.	1980-1995		
United Kingdom	Lampe F, Morris R, Whincup P, Walker M, Ebrahim S, Shaper A. Is the prevalence of coronary heart disease falling in British men? <i>Heart</i> . 2001; 86(5): 499-505.	1992, 1996		
United Kingdom	Murphy NF, Stewart S, Hart CL, MacIntyre K, Hole D, McMurray JJV. A population study of the long-term consequences of Rose angina: 20-year follow-up of the Renfrew-Paisley study. <i>Heart</i> . 2006; 92(12): 1739-46.	1980-1996		
United Kingdom	Douglas KA, Redman CWG. Eclampsia in the United Kingdom. <i>BMJ</i> . 1994; 309(6966): 1395-400.	1992		
United Kingdom	Telfer P, Coen P, Chakravorty S, Wilkey O, Evans J, Newell H, Smalling B, Amos R, Stephens A, Rogers D, Kirkham F. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. <i>Haematologica</i> . 2007; 79(2): 905-12.	1983-2005		
United Kingdom	Bath-Hextall F, Leonardi-Bee J, Smith C, Meal A, Hubbard R. Trends in incidence of skin basal cell carcinoma. Additional evidence from a UK primary care database study. <i>Int J Cancer</i> . 2007; 121(9): 2105-8.	1996-2003		
United Kingdom	Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK. <i>Lancet</i> . 2000; 355(9220): 2051-2.	1950-1998		
United Kingdom	Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. <i>J Cardiovasc Magn Reson</i> . 2008; 10(1): 42.	1960-2003		
United Kingdom	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2000-2003, 2005-2009		
United Kingdom	Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. <i>Ann Rheum Dis</i> . 2005; 64(2): 267-72.	1990-1999		
United Kingdom	Currie WJ. Prevalence and incidence of the diagnosis of gout in Great Britain. <i>Ann Rheum Dis</i> . 1979; 38(2): 101-6.	1971-1975		
United Kingdom	Cea Soriano L, Rothenbacher D, Choi HK, García Rodríguez LA. Contemporary epidemiology of gout in the UK general population. <i>Arthritis Res Ther</i> . 2011; 13(2): R39.	2000-2007		
United Kingdom	Steven MM. Prevalence of chronic arthritis in four geographical areas of the Scottish Highlands. <i>Ann Rheum Dis</i> . 1992; 51(2): 186-94.	1986-1987		
United Kingdom	Annenmans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. <i>Ann Rheum Dis</i> . 2008; 67(7): 960-6.	2000-2005		†
United Kingdom	Harris CM, Lloyd DC, Lewis J. The prevalence and prophylaxis of gout in England. <i>J Clin Epidemiol</i> . 1995; 48(9): 1153-8.	1993		
United Kingdom	Gardner MJ, Power C, Barker DJ, Paddy R. The prevalence of gout in three English towns. <i>Int J Epidemiol</i> . 1982; 11(1): 71-5.	1979		
United Kingdom	Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. <i>Thorax</i> . 2006; 61(11): 980-5.	1991-2003		
United Kingdom	Rice-Oxley M, Williams ES, Rees JE. A prevalence survey of multiple sclerosis in Sussex. <i>J Neurol Neurosurg Psychiatry</i> . 1995; 58(1): 27-30.	1991		
United Kingdom	Swingler RJ, Compston DA. Demographic characteristics of multiple sclerosis in south east Wales. <i>Neuroepidemiology</i> . 1990; 9(2): 68-77.	1985		
United Kingdom	Murray S, Bashir K, Penrice G, Womersley SJ. Epidemiology of multiple sclerosis in Glasgow. <i>Scott Med J</i> . 2004; 49(3): 100-4.	2000		
United Kingdom	Phadke JG, Downie AW. Epidemiology of multiple sclerosis in the north-east (Grampian region) of Scotland—an update. <i>J Epidemiol Community Health</i> . 1987; 41(1): 5-13.	1974-1976, 1980		
United Kingdom	Rothwell PM, Charlton D. High incidence and prevalence of multiple sclerosis in south east Scotland: evidence of a genetic predisposition. <i>J Neurol Neurosurg Psychiatry</i> . 1998; 64(6): 730-5.	1989-1992, 1995		
United Kingdom	Hirst C, Ingram G, Pickersgill T, Swingler R, Compston DA, Robertson NP. Increasing prevalence and incidence of multiple sclerosis in South East Wales. <i>J Neurol Neurosurg Psychiatry</i> . 2009; 80(4): 386-91.	1985-2007		
United Kingdom	Sharpe G, Price SE, Last A, Thompson RJ. Multiple sclerosis in island populations: prevalence in the Bailiwicks of Guernsey and Jersey. <i>J Neurol Neurosurg Psychiatry</i> . 1995; 58(1): 22-6.	1991		
United Kingdom	Mumford CJ, Fraser MB, Wood NW, Compston DA. Multiple sclerosis in the Cambridge health district of east Anglia. <i>J Neurol Neurosurg Psychiatry</i> . 1992; 55(10): 877-82.	1989-1991		
United Kingdom	Poskanzer DC, Prenney LB, Sheridan JL, Kondy JY. Multiple sclerosis in the Orkney and Shetland Islands. I. Epidemiology, clinical factors, and methodology. <i>J Epidemiol Community Health</i> . 1980; 34(4): 229-39.	1950-1974		
United Kingdom	Cook SD, MacDonald J, Tapp W, Poskanzer D, Dowling PC. Multiple sclerosis in the Shetland Islands: an update. <i>Acta Neurol Scand</i> . 1988; 77(2): 148-51.	1984		
United Kingdom	Williams ES, McKeran RO. Prevalence of multiple sclerosis in a south London borough. <i>Br Med J (Clin Res Ed)</i> . 1986; 293(6541): 237-9.	1976-1985		
United Kingdom	Lockyer MJ. Prevalence of multiple sclerosis in five rural Suffolk practices. <i>BMJ</i> . 1991; 303(6798): 347-8.	1988		
United Kingdom	Shepherd DI, Summers A. Prevalence of multiple sclerosis in Rochdale. <i>J Neurol Neurosurg Psychiatry</i> . 1996; 61(4): 415-7.	1989		
United Kingdom	Hennessy A, Swingler RJ, Compston DA. The incidence and mortality of multiple sclerosis in south east Wales. <i>J Neurol Neurosurg Psychiatry</i> . 1989; 52(9): 1085-9.	1985-1988		
United Kingdom	Ford HL, Gerry E, Airey CM, Vail A, Johnson MH, Williams DRR. The prevalence of multiple sclerosis in the Leeds Health Authority. <i>J Neurol Neurosurg Psychiatry</i> . 1998; 64(5): 605-10.	1996		
United Kingdom	Roberts MH, Martin JP, McLellan DL, McIntosh-Michaelis SA, Spackman AJ. The prevalence of multiple sclerosis in the Southampton and South West Hampshire Health Authority. <i>J Neurol Neurosurg Psychiatry</i> . 1991; 54(1): 55-9.	1987		
United Kingdom	Forbes RB, Wilson SV, Swingler RJ. The prevalence of multiple sclerosis in Tayside, Scotland: do latitudinal gradients really exist? <i>J Neurol</i> . 1999; 246(11): 1033-40.	1996		
United Kingdom	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J</i> . 1998; 12(2): 315-35.	1993-1995		
United Kingdom	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax</i> . 2009; 64(6): 476-483.	2002		
United Kingdom	Stamatakis E, Primates P. Department of Epidemiology and Public Health, University College London, National Centre for Social Research (NatCen). Health Survey for England 2001: Respiratory Symptoms, Atopic Conditions and Lung Function. London, United Kingdom: The Stationery Office, 2003.	2001		
United Kingdom	Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. <i>Diabetologia</i> . 1996; 39(11): 1377-84.	1993-1995		
United Kingdom	Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. <i>Diabetologia</i> . 1993; 36(2): 150-4.	1990		
United Kingdom	Sampson MJ, Shepstone L, Greenwood RH, Harvey I, Humphries J, Heyburn PJ, Temple RC, Dole G. An integrated mobile foot and retinal screening programme for people with Type 2 diabetes managed in primary care. <i>Diabet Med</i> . 2002; 19(1): 74-6.	1997-2001		
United Kingdom	Walters DP, Gatling W, Mullee MA, Hill RD. The prevalence of diabetic distal sensory neuropathy in an English community. <i>Diabet Med</i> . 1992; 9(4): 349-53.	1989-1991		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United Kingdom	Edmonds M, Boulton A, Buckenham T, Every N, Foster A, Freeman D, Gadsby R, Gibby O, Knowles A, Pooke M, Tovey F, Unwin N, Wolfe J. Report of the Diabetic Foot and Amputation Group. <i>Diabet Med.</i> 1996; 13(9 Suppl 4): S27-42.	1993		
United Kingdom	Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K.. <i>Diabetes Care.</i> 2011; 34(10): 2220-4.	2006-2010		
United Kingdom	Rubino A, Rousculp MD, Davis K, Wang J, Girach A. Diagnosed diabetic retinopathy in France, Italy, Spain, and the United Kingdom. <i>Prim Care Diabetes.</i> 2007; 1(2): 75-80.	2006		
United Kingdom	Pannell RS, Fleming DM, Cross KW. The incidence of molluscum contagiosum, scabies and lichen planus. <i>Epidemiol Infect.</i> 2005; 133(6): 985-91.	1994-2003		
United Kingdom	Swerdlow AJ, Jones ME. Mortality during 25 years of follow-up of a cohort with diabetes. <i>Int J Epidemiol.</i> 1996; 25(6): 1250-61.	1966-1992		
United Kingdom	Laing SP, Swerdlow AJ, Slater SD, Botha JL, Burden AC, Waugh NR, Smith AW, Hill RD, Bingley PJ, Patterson CC, Qiao Z, Keen H. The British Diabetic Association Cohort Study. I: all-cause mortality in patients with insulin-treated diabetes mellitus. <i>Diabet Med.</i> 1999; 16(6): 459-65.	1972-1997		
United Kingdom	Croxon SC, Burden AC, Bodington M, Botha JL. The prevalence of diabetes in elderly people. <i>Diabet Med.</i> 1991; 8(1): 28-31.	1987		
United Kingdom	Pierce MB, Zaninotto P, Steel N, Mindell J. Undiagnosed diabetes-data from the English longitudinal study of ageing. <i>Diabet Med.</i> 2009; 26(7): 679-85.	2005		
United Kingdom	Abu-Arefeh I, Russell G. Prevalence of headache and migraine in schoolchildren. <i>BMJ.</i> 1994; 309(6957): 765-9.	1991		
United Kingdom	Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. <i>Cephalalgia.</i> 2003; 23(7): 519-27.	2000		
United Kingdom	Royal College of General Practitioners. United Kingdom - England and Wales Weekly Returns Service Annual Prevalence Report 2004. London, United Kingdom: Royal College of General Practitioners.	2001		
United Kingdom	Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. <i>Br J Dermatol.</i> 1996; 135(4): 533-7.	1995		
United Kingdom	Badley EM, Tennant A. Changing profile of joint disorders with age: findings from a postal survey of the population of Calderdale, West Yorkshire, United Kingdom. <i>Ann Rheum Dis.</i> 1992; 51(3): 366-71.	1986		
United Kingdom	Birrell F, Lunt M, Macfarlane G, Silman A. Association between pain in the hip region and radiographic changes of osteoarthritis: results from a population-based study. <i>Rheumatology.</i> 2005; 44(3): 337-41.	2002		
United Kingdom	Croft P, Coggon D, Cruddas M, Cooper C. Osteoarthritis of the hip: an occupational disease in farmers. <i>BMJ.</i> 1992; 304(6837): 1269-72.	1989		
United Kingdom	Dawson J, Linsell L, Zondervan K, Rose P, Randall T, Carr A, Fitzpatrick R. Epidemiology of hip and knee pain and its impact on overall health status in older adults. <i>Rheumatology.</i> 2004; 43(4): 497-504.	2002		
United Kingdom	Nüesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Juni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. <i>BMJ.</i> 2011; 342: d1165.	1994-2008	*	
United Kingdom	Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. <i>J Rheumatol.</i> 2003; 30(6): 1196-202.	1987-2000	*	
United Kingdom	Konstantinou GN, Papadopoulos NG, Tavladaki T, Tsekoura T, Tsilimigaki A, Grattan CEH. Childhood acute urticaria in northern and southern Europe shows a similar epidemiological pattern and significant meteorological influences. <i>Pediatr Allergy Immunol.</i> 2011; 22(1 Pt 1): 36-42.	2005-2007	*	
United Kingdom	Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, Gjomarkaj M, Forsberg B, Gunnbjornsdottir M, Minov J, Brozek G, Dahlen SE, Toskala E, Kowalski ML, Olze H, Howarth P, Krämer U, Bachlum J, Loureiro C, Kasper L, Bousquet PJ, Bousquet J, Bachert C, Fokkens W, Burney P. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. <i>Allergy.</i> 2012; 67(1): 91-8.	2008-2009	*	
United Kingdom	Malik G, Tagiyeva N, Aucott L, McNeill G, Turner SW. Changing trends in asthma in 9-12 year olds between 1964 and 2009. <i>Arch Dis Child.</i> 2011; 96(3): 227-31.	1999, 2004, 2009	*	
United Kingdom	Shiue I. Associated social factors of prevalent asthma in adults and the very old in the UK. <i>Allergy.</i> 2013; 68(3): 392-6.	2009-2010	*	
United Kingdom	Duncan R, Francis RM, Collerton J, Davies K, Jagger C, Kingston A, Kirkwood T, Robinson L, Birrell F. Prevalence of arthritis and joint pain in the oldest old: findings from the Newcastle 85+ study. <i>Age Ageing.</i> 2011; 40(6): 752-5.	2008-2010		
United Kingdom	Leyland KM, Hart DJ, Javadi MK, Judge A, Kiran A, Soni A, Goulston LM, Cooper C, Spector TD, Arden NK. The natural history of radiographic knee osteoarthritis: a fourteen-year population-based cohort study. <i>Arthritis Rheum.</i> 2012; 64(7): 2243-51.	1990-2004	*	
United Kingdom	Fleming KM, Aithal GP, Solaymani-Dodaran M, Card TR, West J. Incidence and prevalence of cirrhosis in the United Kingdom, 1992-2001: a general population-based study. <i>J Hepatol.</i> 2008; 49(5): 732-8.	1992-2001	*	
United Kingdom	Muthur R, Pollara E, Hull S, Schofield P, Ashworth M, Robson J. Ethnicity and stroke risk in patients with atrial fibrillation. <i>Heart.</i> 2013; 99(15): 1087-92.	2008-2011	*	
United Kingdom	Mallen CD, Mottram S, Wynne-Jones G, Thomas E. Birth-related exposures and asthma and allergy in adulthood: a population-based cross-sectional study of young adults in North Staffordshire. <i>J Asthma.</i> 2008; 45(4): 309-12.	2002	*	
United Kingdom	Simpson CR, Newton J, Hippisley-Cox J, Sheikh A. Trends in the epidemiology and prescribing of medication for eczema in England. <i>J R Soc Med.</i> 2009; 102(3): 108-17.	2001-2005	*	
United Kingdom	Ziyab AH, Raza A, Karmas W, Tongue N, Zhang H, Matthews S, Arshad SH, Roberts G. Trends in eczema in the first 18 years of life: results from the Isle of Wight 1989 birth cohort study. <i>Clin Exp Allergy.</i> 2010; 40(12): 1776-84.	1989-1990, 1993, 2007	*	
United Kingdom	Davies GM, Jones CM, Monaghan N, Morgan MZ, Neville JS, Pitts NB. The caries experience of 11 to 12 year-old children in Scotland and Wales and 12 year-olds in England in 2008-2009: reports of co-ordinated surveys using BASCD methodology. <i>Community Dent Health.</i> 2012; 29(1): 8-13.	2008-2009	*	
United Kingdom	Davies GM, Jones CM, Monaghan N, Morgan MZ, Pine CM, Pitts NB, Neville JS, Rooney E. The caries experience of 5 year-old children in Scotland, Wales and England in 2007-2008 and the impact of consent arrangements. Reports of co-ordinated surveys using BASCD criteria. <i>Community Dent Health.</i> 2011; 28(1): 5-11.	2007-2008		
United Kingdom	McMahon AD, Blair Y, McCall DR, Macpherson LM. Reductions in dental decay in 3-year old children in Greater Glasgow and Clyde: repeated population inspection studies over four years. <i>BMC Oral Health.</i> 2011; 29.	2006-2010	*	
United Kingdom	Vrbic V, Homan D, Završnik B. Oral health in Slovenia, Yugoslavia. <i>Community Dent Oral Epidemiol.</i> 1991; 19(2): 72-3.	1987	*	
United Kingdom	Naftalin J, Hoo W, Pateman K, Mavrelis D, Holland T, Jurkovic D. How common is adenomyosis? A prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic. <i>Hum Reprod.</i> 2012; 27(12): 3432-9.	2009-2010	*	
United Kingdom	Bhattacharya S, Porter M, Amalraj E, Templeton A, Hamilton M, Lee AJ, Kurinczuk JJ. The epidemiology of infertility in the North East of Scotland. <i>Hum Reprod.</i> 2009; 24(12): 3096-107.	2007	*	
United Kingdom	Oakley L, Doyle P, Maconochie N. Lifetime prevalence of infertility and infertility treatment in the UK: results from a population-based survey of reproduction. <i>Hum Reprod.</i> 2008; 23(2): 447-50.	2001	*	
United Kingdom	Wilkes S, Chinn DJ, Murdoch A, Rubin G. Epidemiology and management of infertility: a population-based study in UK primary care. <i>Fam Pract.</i> 2009; 26(4): 269-74.	2005-2006	*	
United Kingdom	Day TG, Thein SL, Drasar E, Dick MC, Height SE, O'Driscoll S, Rees DC. Changing pattern of hospital admissions of children with sickle cell disease over the last 50 years. <i>J Pediatr Hematol Oncol.</i> 2011; 33(7): 491-5.	2008-2009	*	
United Kingdom	Huerta C, Rivero E, Rodríguez LAG. Incidence and risk factors for psoriasis in the general population. <i>Arch Dermatol.</i> 2007; 143(12): 1559-65.	1996-1997	*	
United Kingdom	Emerson E. Deprivation, ethnicity and the prevalence of intellectual and developmental disabilities. <i>J Epidemiol Community Health.</i> 2012; 66(3): 218-24.	2008		
United Kingdom	Zimmermann A, Bernut D, Gerlinger C, Schaefers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. <i>BMC Womens Health.</i> 2012; 6.	2009	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod (†)
United Kingdom	Macfarlane GJ, Beasley M, Jones EA, Prescott GJ, Docking R, Keeley P, McBeth J, Jones GT. The prevalence and management of low back pain across adulthood: Results from a population-based cross-sectional study (the MUSICIAN study). <i>Pain</i> . 2012; 153(1): 27-32.	2008	*	
United Kingdom	Docking RE, Fleming J, Brayne C, Zhao J, Macfarlane GJ, Jones GT, Cambridge City over-75s Cohort Study collaboration. Epidemiology of back pain in older adults: prevalence and risk factors for back pain onset. <i>Rheumatology</i> . 2011; 50(9): 1645-53.	1988-1989, 1992-1993		
United Kingdom	Giaquinto C, van Damme P, REVEAL Study Group. Age distribution of paediatric rotavirus gastroenteritis cases in Europe: the REVEAL study. <i>Scand J Infect Dis</i> . 2010; 42(2): 142-7.	2004-2005		
United Kingdom	Fish M, Bayer AJ, Gallacher JEJ, Bell T, Pickering J, Pedro S, Dunstan FD, Ben-Shlomo Y, Ebrahim S. Prevalence and pattern of cognitive impairment in a community cohort of men in South Wales: methodology and findings from the Caerphilly Prospective Study. <i>Neuroepidemiology</i> . 2008; 30(1): 25-33.	2002-2004		
United Kingdom	Copeland JR, McCracken CF, Dewey ME, Wilson KC, Doran M, Gilmore C, Scott A, Larkin BA. Undifferentiated dementia, Alzheimer's disease and vascular dementia: age- and gender-related incidence in Liverpool. The MRC-ALPHA Study. <i>Br J Psychiatry</i> . 1999; 433-8.	1989-1998	*	
United Kingdom	Livingston G, Sax K, Willison J, Blizard B, Mann A. The Gospel Oak Study stage II: the diagnosis of dementia in the community. <i>Psychol Med</i> . 1990; 20(4): 881-91.	1987-1989	*	
United Kingdom	Davies AR, Grundy E, Nitsch D, Smeeth L. Constituent country inequalities in myocardial infarction incidence and case fatality in men and women in the United Kingdom, 1996-2005. <i>J Public Health (Oxf)</i> . 2011; 33(1): 131-8.	1996, 2000, 2005		
United Kingdom	Smolina K, Wright FL, Rayner M, Goldacre MJ. Incidence and 30-day case fatality for acute myocardial infarction in England in 2010: national-linked database study. <i>Eur J Public Health</i> . 2012; 22(6): 848-53.	2010		
United Kingdom	Matthews FE, Arthar, Antony, Barnes, Linda E, Bond, John, Jagger, Carol, Robinson, Louise, Brayne, Carol. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. <i>Lancet</i> . 2013; 382(9902): 1405-1412.	1990-1993, 2008-2011		
United Kingdom	Hart DJ, Spector TD. The relationship of obesity, fat distribution and osteoarthritis in women in the general population: the Chingford Study. <i>J Rheumatol</i> . 1993; 20(2): 331-5.	1989-1993		
United Kingdom	Cooper C, Snow S, McAindon TE, Kellingray S, Stuart B, Coggon D, Dieppe PA. Risk factors for the incidence and progression of radiographic knee osteoarthritis. <i>Arthritis Rheum</i> . 2000; 43(5): 995-1000.	1991-1996		
United Kingdom	Neame RL, Carr AJ, Muir K, Doherty M. UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte. <i>Ann Rheum Dis</i> . 2003; 62(6): 513-8.	2000		
United Kingdom	Symmons DP, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. <i>J Rheumatol</i> . 1998; 25(6): 1072-7.	1982-1990		
United Kingdom	Symmons DP, Prior P, Scott DL, Brown R, Hawkins CF. Factors influencing mortality in rheumatoid arthritis. <i>J Chronic Dis</i> . 1986; 39(2): 137-45.	1964-1981		
United Kingdom	Chehata JC, Hassell AB, Clarke SA, Mathey DL, Jones MA, Jones PW, Dawes PT. Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. <i>Rheumatology</i> . 2001; 40(4): 447-52.	1981-1998		
United Kingdom	Goodson N, Marks J, Lunt M, Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. <i>Ann Rheum Dis</i> . 2005; 64(11): 1595-601.	1981-2002		
United Kingdom	Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DPM. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. <i>Arthritis Rheum</i> . 2002; 46(8): 2010-9.	1990-1999		
United Kingdom	Thomas E, Symmons DPM, Brewster DH, Black RJ, Macfarlane GJ. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. <i>J Rheumatol</i> . 2003; 30(5): 958-65.	1981-2000		
United Kingdom	Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S, Dixey J. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. <i>Rheumatology</i> . 2007; 46(2): 350-7.	1986-2004		
United Kingdom	Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, Scott D, Silman A. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. <i>Rheumatology</i> . 2002; 41(7): 793-800.	1999		
United Kingdom	Rodríguez LAG, Tolosa LB, Ruigómez A, Johansson S, Wallander M-A. Rheumatoid arthritis in UK primary care: incidence and prior morbidity. <i>Scand J Rheumatol</i> . 2009; 38(3): 173-7.	1996-1997		
United Kingdom	Symmons DP, Barrett EM, Bankhead CR, Scott DG, Silman AJ. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. <i>Br J Rheumatol</i> . 1994; 33(8): 735-9.	1990-1991		
United Kingdom	Wiles N, Symmons DP, Harrison B, Barrett E, Barrett JH, Scott DG, Silman AJ. Estimating the incidence of rheumatoid arthritis: trying to hit a moving target. <i>Arthritis Rheum</i> . 1999; 42(7): 1339-46.	1996		
United Kingdom	Davis A, Smith P, Ferguson M, Stephens D, Gianopoulos I. Acceptability, benefit and costs of early screening for hearing disability: a study of potential screening tests and models. <i>Health Technol Assess</i> . 2007; 11(42): 1-294.	1996		
United Kingdom	Smith P, Davis A, Ferguson M, Lutman M. Hearing in Young Adults: Report to ISO/TC43/WG1. <i>Noise Health</i> . 1999; 1(4): 1-10.	1994		
United Kingdom	Davis AC. The prevalence of hearing impairment and reported hearing disability among adults in Great Britain. <i>Int J Epidemiol</i> . 1989; 18(4): 911-7.	1983		
United Kingdom	Office for National Statistics (United Kingdom). United Kingdom Adult Dental Health Survey 2009-2010.	2009-2010		
United Kingdom	Office for National Statistics (United Kingdom). United Kingdom Children's Dental Health Survey 2003 - ONS.	2003		
United Kingdom	Crocombe LA, Mejia GC, Koster CR, Slade GD. Comparison of adult oral health in Australia, the USA, Germany and the UK. <i>Aust Dent J</i> . 2009; 54(2): 147-53.	1998		
United Kingdom	Bolin AK, Bolin A, Koch G. Children's dental health in Europe: caries experience of 5- and 12-year-old children from eight EU countries. <i>Int J Paediatr Dent</i> . 1996; 6(3): 155-62.	1993		
United Kingdom	Downer MC, Nordling H, Blinkhorn AS, Koistinen A. The Edinburgh-Helsinki study: a comparison of dental care for children. <i>Int Dent J</i> . 1985; 35(3): 226-31.	1983		
United Kingdom	Yonemitsu M, Sutcliffe P. Comparative study of oral health status between Scottish and Japanese schoolchildren aged 6-11 years. <i>Community Dent Oral Epidemiol</i> . 1992; 20(6): 354-8.	1990		
United Kingdom	Anderson RJ, Bradnock G, James PM. The dental health of Guernsey school children 1984. <i>Br Dent J</i> . 1986; 160(9): 323-5.	1984		
United Kingdom	Silver DH. Improvements in the dental health of 3-year-old Hertfordshire children after 8 years. <i>Br Dent J</i> . 1982; 153(5): 179-83.	1973, 1981		
United Kingdom	Hargreaves JA, Cleaton-Jones PE. Dental caries changes in the Scottish Isle of Lewis. <i>Caries Res</i> . 1990; 24(2): 137-41.	1968-1971, 1981-1987		
United Kingdom	Mansbridge JN, Brown MD. Changes in dental caries prevalence in Ayr children over 25 years and a comparison with Edinburgh children over the same period. <i>Community Dent Health</i> . 1986; 3(1): 41-52.	1959, 1967, 1983		
United Kingdom	Attwood D, Blinkhorn AS, MacMillan AS. A three year follow up study of the dental health of 12- and 15-year-old schoolchildren in Glasgow. <i>Community Dent Health</i> . 1990; 7(2): 143-8.	1984-1987		
United Kingdom	Jenkins P. West Midlands caries prevalence studies, 15 year old schoolchildren 1986. <i>Community Dent Health</i> . 1989; 6(1): 67-8.	1986		
United Kingdom	Andlaw RJ, Burchell CK, Tucker GJ. Comparison of dental health of 11-year-old children in 1970 and 1979, and of 14-year-old children in 1973 and 1979: studies in Bristol, England. <i>Caries Res</i> . 1982; 16(3): 257-64.	1970-1973		
United Kingdom	Zoitopoulos L, Athanassoulis T, Gelbier S, Apostolopoulos A. Caries prevalence of 5-year-old children in Athens and in South London. <i>Int J Paediatr Dent</i> . 1996; 6(1): 3-6.	1993		
United Kingdom	Holt RD, Winter GB, Downer MC, Bellis WJ, Hay IS. Caries in pre-school children in Camden 1993/94. <i>Br Dent J</i> . 1996; 181(11-12): 405-10.	1986, 1993-1994		
United Kingdom	Sweeney PC, Gelbier S. The dental health of pre-school children in a deprived urban community in Glasgow. <i>Community Dent Health</i> . 1999; 16(1): 22-5.	1996-1998		
United Kingdom	Silver DH. A comparison of 3-year-olds' caries experience in 1973, 1981 and 1989 in a Hertfordshire town, related to family behaviour and social class. <i>Br Dent J</i> . 1992; 172(5): 191-7.	1973, 1981, 1989		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United Kingdom	Freeman R, Breistein B, McQueen A, Stewart M. The dental health status of five-year-old children in north and west Belfast. <i>Community Dent Health</i> . 1997; 14(4): 253-7.	1995		
United Kingdom	Jones SG, Nunn JH. The dental health of 3-year-old children in east Cumbria 1993. <i>Community Dent Health</i> . 1995; 12(3): 161-6.	1993		
United Kingdom	Davies GM, Worthington HV, Ellwood RP, Bentley EM, Blinkhorn AS, Taylor GO, Davies RM. A randomised controlled trial of the effectiveness of providing free fluoride toothpaste from the age of 12 months on reducing caries in 5-6 year old children. <i>Community Dent Health</i> . 2002; 19(3): 131-6.	1993		
United Kingdom	Marchment MD, Gray MM. A caries prevalence study of 5-year-old children in South-East Staffordshire in 1985 which resulted in the unexpected finding of a naturally fluoridated water supply to the town of Uttoxeter. <i>Community Dent Health</i> . 1987; 4(2): 117-9.	1984-1986		
United Kingdom	Davies GM, Blinkhorn FA, Duxbury JT. Caries among 3-year-olds in greater Manchester. <i>Br Dent J</i> . 2001; 190(7): 381-4.	1999		
United Kingdom	Pitts NB, Davies JA. The Scottish Health Boards' Dental Epidemiological Programme: initial surveys of 5- and 12-year-olds. <i>Br Dent J</i> . 1992; 172(11): 408-13.	1989		
United Kingdom	West P, Sweeting H, Der G, Barton J, Lucas C. Voice-DISC identified DSM-IV disorders among 15-year-olds in the west of Scotland. <i>J Am Acad Child Adolesc Psychiatry</i> . 2003; 42(8): 941-9.	1994-1999, 2001		
United Kingdom	Crisp AH, Callender JS, Halek C, Hsu LK. Long-term mortality in anorexia nervosa. A 20-year follow-up of the St George's and Aberdeen cohorts. <i>Br J Psychiatry</i> . 1992; 161(1): 104-7.	1965-1990		
United Kingdom	Millar HR, Wardell F, Vyvyan JP, Naji SA, Prescott GJ, Eagles JM. Anorexia nervosa mortality in Northeast Scotland, 1965-1999. <i>Am J Psychiatry</i> . 2005; 162(4): 753-7.	1965-2002		
United Kingdom	Ford T, Goodman R, Meltzer H. The British Child and Adolescent Mental Health Survey 1999: the prevalence of DSM-IV disorders. <i>J Am Acad Child Adolesc Psychiatry</i> . 2003; 42(10): 1203-11.	1999		
United Kingdom	Messer J, Goodman, Robert, Rowe, Richard, Meltzer, Howard, Maughan, Barbara. Preadolescent Conduct Problems in Girls and Boys. <i>J Am Acad Child Adolesc Psychiatry</i> . 2006; 45(2): 184-91.	1997		
United Kingdom	Kim-Cohen J, Arseneault L, Caspi A, Tomás MP, Taylor A, Moffitt TE. Validity of DSM-IV conduct disorder in 41/2-5-year-old children: a longitudinal epidemiological study. <i>Am J Psychiatry</i> . 2005; 162(6): 1108-17.	1997	*	†
United Kingdom	Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, Tome Esteban MT, McKenna WJ. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. <i>Heart</i> . 2006; 92(6): 785-91.	1988-2002	*	†
United Kingdom	Office for National Statistics (United Kingdom). United Kingdom - England and Wales Mortality Data 1981-1994. [Unpublished].	1981-1994	*	†
United Kingdom	Office for National Statistics (United Kingdom). United Kingdom - England and Wales Mortality Data 1995-2000. [Unpublished].	1995-2000		
United Kingdom	Office for National Statistics (United Kingdom). United Kingdom - England and Wales Mortality Data 2001-2012.	2001-2002		
United Kingdom	McCONNELL P, Bebbington P, McCLELLAND ROY, Gillespie K, Houghton S. Prevalence of psychiatric disorder and the need for psychiatric care in Northern Ireland Population study in the District of Derry. <i>Br J Psychiatry</i> . 2002; 181(3): 214-9.	1993-1994		
United Kingdom	Robertson WG, Peacock M, Baker M, Marshall DH, Pearlman B, Speed R, Sergeant V, Smith A. Studies on the prevalence and epidemiology of urinary stone disease in men in Leeds. <i>Br J Urol</i> . 1983; 55(6): 595-8.	1981-1983		
United Kingdom	Ayuso-Mateos JL, Vázquez-Barquero JL, Dowrick C, Lehtinen V, Dalgard OS, Casey P, Wilkinson C, Lasa L, Page H, Dunn G, Wilkinson G. Depressive disorders in Europe: prevalence figures from the ODIN study. <i>Br J Psychiatry</i> . 2001; 179(4): 308-16.	1999-2001		
United Kingdom	Venugopalan P, Houston A, Agarwal AK. The outcome of idiopathic dilated cardiomyopathy and myocarditis in children from the west of Scotland. <i>Int J Cardiol</i> . 2001; 78(2): 135-41.	1980-1997		
United Kingdom	Skehan JD, Murray M, Mills PG. Infective endocarditis: incidence and mortality in the North East Thames Region. <i>Br Heart J</i> . 1988; 59(1): 62-8.	1982-1984		
United Kingdom	Waterstone M, Bewley S, Wolfe C. Incidence and predictors of severe obstetrics morbidity: case-control study. <i>BMJ</i> . 2001; 322(7294): 1089-94.	1997-1998		
United Kingdom	Brace V, Penney G, Hall M. Quantifying severe maternal morbidity: a Scottish population study. <i>BJOG</i> . 2004; 111(5): 481-4.	2001		
United Kingdom	de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Künzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P, European Community Respiratory Health Survey Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. <i>Thorax</i> . 2004; 59(2): 120-125.	1991-1993		
United Kingdom	Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E, BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. <i>Lancet</i> . 2007; 9589(9589): 741-50.	1991-2000, 2005-2006		
United Kingdom	Higham J, Kang J-Y, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. <i>Gut</i> . 2002; 50(4): 460-4.	1989-1998		
United Kingdom	Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children. <i>JAMA</i> . 2001; 285(24): 3093-9.	1998-2003		
United Kingdom	Chakrabarti S, Fombonne E. Pervasive Developmental Disorders in Preschool Children: Confirmation of High Prevalence. <i>Am J Psychiatry</i> . 2005; 162(6): 1133-41.	2000-2003		
United Kingdom	Powell J, Edwards A, Edwards M, Pandit B, Sungum-Paliwal S, Whitehouse W. Changes in the incidence of childhood autism and other autistic spectrum disorders in preschool children from two areas of the West Midlands, UK. <i>Dev Med Child Neurol</i> . 2000; 42(9): 624-8.	1991-1996		
United Kingdom	Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, Charman T. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). <i>Lancet</i> . 2006; 368(9531): 210-5.	2003		
United Kingdom	Selo-Ojeme D, Lawal O, Shah J, Mandal R, Pathak S, Selo-Ojeme U, Samuel D. The incidence of uterine leiomyoma and other pelvic ultrasonographic findings in 2,034 consecutive women in a north London hospital. <i>J Obstet Gynaecol</i> . 2008; 28(4): 421-3.	2005		
United Kingdom	Downes E, Sikirica V, Glabert-Estelles J, Bolge SC, Dodd SL, Maroulis C, Subramanian D. The burden of uterine fibroids in five European countries. <i>Eur J Obstet Gynecol Reprod Biol</i> . 2010; 152(1): 96-102.	2007		
United Kingdom	Stones W, Lim W, Al-Azzawi F, Kelly M. An investigation of maternal morbidity with identification of life-threatening 'near miss' episodes. <i>Health Trends</i> . 1991; 23(1): 13-5.	1986		
United Kingdom	Sébire NJ, Jolly M, Harris JP, Wadsworth J, Joffe M, Beard RW, Regan L, Robinson S. Maternal obesity and pregnancy outcome: a study of 287213 pregnancies in London. <i>Int J Obes Relat Metab Disord</i> . 2001; 25(8): 1175-1182.	1989-1997		
United Kingdom	Goodman R FT, Richards H, Gatward R, Meltzer H. The Development and Well-Being Assessment: description and initial validation of an integrated assessment of child and adolescent psychopathology. <i>J Child Psychol Psychiatry</i> . 2000; 41(5): 645-55.	1998		
United Kingdom	McArdle P, Prosser J, Kolvin I. Prevalence of psychiatric disorder: with and without psychosocial impairment. <i>Eur Child Adolesc Psychiatry</i> . 2004; 13(6): 347-53.	2002		
United Kingdom	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2004-2008		
United Kingdom	United States Renal Data System Coordinating Center. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2000-2003		
United Kingdom	United States Renal Data System Coordinating Center. USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2003.	1998-1999		
United Kingdom	LaMontagne DS, Fenton KA, Randall S, Anderson S, Carter P. Establishing the National Chlamydia Screening Programme in England: results from the first full year of screening. <i>Sex Transm Infect</i> . 2004; 80(5): 335-41.	2004		
United Kingdom	NHS England. United Kingdom - England Hospital Episode Statistics 2002-2003.	2002		
United Kingdom	NHS England. United Kingdom - England Hospital Episode Statistics 2003-2004.	2003		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United Kingdom	NHS England. United Kingdom - England Hospital Episode Statistics 2004-2005.	2004-2005		
United Kingdom	NHS England. United Kingdom - England Hospital Episode Statistics 2005-2006.	2005		
United Kingdom	NHS England. United Kingdom - England Hospital Episode Statistics 2006-2007.	2006		
United Kingdom	NHS England. United Kingdom - England Hospital Episode Statistics 2007-2008.	2007		
United Kingdom	NHS England. United Kingdom - England Hospital Episode Statistics 2008-2009.	2008		
United Kingdom	NHS England. United Kingdom - England Hospital Episode Statistics 2009-2010.	2009		
United Kingdom	NHS England. United Kingdom - England Hospital Episode Statistics 2010-2011.	2010	*	
United Kingdom	NHS England. United Kingdom - England Hospital Episode Statistics 2011-2012.	2011-2012		
United Kingdom	Office of Population Censuses and Surveys. Social Survey Division. OPCS Surveys of Psychiatric Morbidity : Private Household Survey, 1993 [computer file]. Colchester, Essex: UK Data Archive [distributor], September 1996. SN: 3560. http://dx.doi.org/10.5255/UKDA-SN-3560-1	1993		
United Kingdom	Office for National Statistics. Psychiatric Morbidity among Adults Living in Private Households, 2000 [computer file]. Colchester, Essex: UK Data Archive [distributor], May 2003. SN: 4653. http://dx.doi.org/10.5255/UKDA-SN-4653-1	2000		
United Kingdom	De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology</i> . 2000; 54(11 Suppl 5): S21-23.	1997		
United Kingdom	Foltnie T, Brayne CEG, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaGN study. <i>Brain</i> . 2004; 127(3): 550-60.	2000-2003		†
United Kingdom	Hobson P, Gallacher J, Meara J. Cross-sectional survey of Parkinson's disease and parkinsonism in a rural area of the United Kingdom. <i>Mov Disord</i> . 2005; 20(8): 995-8.	1998		
United Kingdom	Mutch WJ, Dingwall-Fordyce I, Downie AW, Paterson JG, Roy SK. Parkinson's disease in a Scottish city. <i>Br Med J (Clin Res Ed)</i> . 1986; 292(6519): 534-6.	1983-1984		
United Kingdom	Cockereel O, Goodridge DM, Brodie D, Sander JWA, Shorvon S. Neurological Disease in a Defined Population: The Results of a Pilot Study in Two General Practices. <i>Neuroepidemiology</i> . 1996; 15(2): 73-82.	1993		
United Kingdom	Prettyman R. Extrapyramidal signs in cognitively intact elderly people. <i>Age Ageing</i> . 1998; 27(5): 557-60.	1995		
United Kingdom	Schrag A, Ben-Shlomo Y, Quinn NP. Cross sectional prevalence survey of idiopathic Parkinson's disease and parkinsonism in London. <i>BMJ</i> . 2000; 321(7252): 21-2.	1997		
United Kingdom	Smith WC MW. Time trends and geographical variation in Parkinson's disease in Scotland. <i>Scott Med J</i> . 1992; 37(4): 112-5.	1980-1990		
United Kingdom	Sutcliffe RL, Prior R, Mawby B, McQuillan WJ. Parkinson's disease in the district of the Northampton Health Authority, United Kingdom. A study of prevalence and disability. <i>Acta Neurol Scand</i> . 1985; 72(4): 363-79.	1982		
United Kingdom	Sutcliffe RLG, Meara JR. Parkinson's disease epidemiology in the Northampton District, England, 1992. <i>Acta Neurol Scand</i> . 1995; 92(6): 443-50.	1989		
United Kingdom	Wade DT, Hewer RL. Epidemiology of some neurological diseases with special reference to work load on the NHS. <i>Disabil Rehabil</i> . 1986; 8(3): 129-37.	1984		
United Kingdom	Berger K BM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, Hofman A, Launer LJ. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. <i>Neurology</i> . 2000; 54(11): 24-7.	1997		
United Kingdom	Goldacre M, Shiwach R, Yeates D. Estimating incidence and prevalence of treated psychiatric disorders from routine statistics: the example of schizophrenia in Oxfordshire. <i>J Epidemiol Community Health</i> . 1994; 48(3): 318-22.	1986		
United Kingdom	McCreadie RG, Leese M, Tilak-Singh D, Loftus L, MacEwan T, Thornicroft G, Nithsdale, Nunhead and Norwood: similarities and differences in prevalence of schizophrenia and utilisation of services in rural and urban areas. <i>Br J Psychiatry</i> . 1997; 31-6.	1992-1993		
United Kingdom	Bamrah JS, Freeman HL, Goldberg DP. Epidemiology of schizophrenia in Salford, 1974-84. Changes in an urban community over ten years. <i>Br J Psychiatry</i> . 1991; 802-10.	1983-1984		
United Kingdom	Jeffreys SE, Harvey CA, McNaught AS, Quayle AS, King MB, Bird AS. The Hampstead Schizophrenia Survey 1991. I: Prevalence and service use comparisons in an inner London health authority, 1986-1991. <i>Br J Psychiatry</i> . 1997; 301-6.	1991		
United Kingdom	Harvey CA, Pantelis C, Taylor J, McCabe PJ, Lefevre K, Campbell PG, Hirsch SR. The Camden schizophrenia surveys. II. High prevalence of schizophrenia in an inner London borough and its relationship to socio-demographic factors. <i>Br J Psychiatry</i> . 1996; 168(4): 418-26.	1981, 1985-1986		
United Kingdom	King M, Coker E, Leavey G, Hoare A, Johnson-Sabine E. Incidence of psychotic illness in London: comparison of ethnic groups. <i>BMJ</i> . 1994; 309(6962): 1115-9.	1991-1992		
United Kingdom	McNaught AS, Jeffreys SE, Harvey CA, Quayle AS, King MB, Bird AS. The Hampstead Schizophrenia Survey 1991. II: Incidence and migration in inner London. <i>Br J Psychiatry</i> . 1997; 307-11.	1986-1991		
United Kingdom	Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganey K, Giel R, an der Heiden W, Holmberg SK, Janca A, Lee PW, Leon CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin SJ, Varma VK, Walsh D, Wiersma D. Recovery from psychotic illness: a 15- and 25-year international follow-up study. <i>Br J Psychiatry</i> . 2001; 178: 506-17.	1978-1993		
United Kingdom	British Market Research Bureau (BMRB), Scottish Government. Drug Misuse in Scotland: Findings from the 2006 Scottish Crime and Victimization Survey. Edinburgh, Scotland: Scottish Government, 2007.	2006		
United Kingdom	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pampidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 2003: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 2004.	2003		
United Kingdom	Singleton N, Bumpstead R, O'Brien M, Lee A, Meltzer H. Psychiatric morbidity among adults living in private households, 2000. <i>Int Rev Psychiatry</i> . 2003; 15(1-2): 65-73.	2000		
United Kingdom	Wadsworth EJK, Simpson SA, Moss SC, Smith AP. Recreational Drug Use: Patterns from a South Wales Self-Report Survey. <i>J Psychopharmacol</i> . 2004; 18(2): 228-37.	2001		
United Kingdom	Department of Health (United Kingdom), Office for National Statistics (United Kingdom). The Prevalence of Back Pain in Great Britain in 1998. United Kingdom: Department of Health (United Kingdom), 1999.	1998		
United Kingdom	Murphy S, Buckle P, Stubbs D. A cross-sectional study of self-reported back and neck pain among English schoolchildren and associated physical and psychological risk factors. <i>Arch Dis Child</i> . 2007; 38(6): 797-804.	2001		
United Kingdom	Palmer KT, Walsh K, Bendall H, Cooper C, Coggon D. Back pain in Britain: comparison of two prevalence surveys at an interval of 10 years. <i>BMJ</i> . 2000; 320(7249): 1577-8.	1997-1998		
United Kingdom	Zhang L, Zhang W-H, Zhang L, Wang P-Y. Prevalence of overweight/obesity and its associations with hypertension, diabetes, dyslipidemia, and metabolic syndrome: a survey in the suburban area of Beijing, 2007. <i>Obes Facts</i> . 2011; 4(4): 284-9.	1998		
United Kingdom	Croft PR, Rigby AS. Socioeconomic influences on back problems in the community in Britain. <i>J Epidemiol Community Health</i> . 1994; 48(2): 166-70.	1984-1985, 1989, 1993		
United Kingdom	Elliott AM, Smith BH, Penny KI, Smith WC, Chambers WA. The epidemiology of chronic pain in the community. <i>Lancet</i> . 1999; 354(9186): 1248-52.	1996, 1999		
United Kingdom	Watson KD, Papageorgiou AC, Jones GT, Taylor S, Symons DPM, Silman AJ, Macfarlane GJ. Low back pain in schoolchildren: occurrence and characteristics. <i>Pain</i> . 2002; 97(1-2): 87-92.	1994-1997, 1999-2000		
United Kingdom	Harkness EF, Macfarlane GJ, Silman AJ, McBeth J. Is musculoskeletal pain more common now than 40 years ago?: Two population-based cross-sectional studies. <i>Rheumatology</i> . 2005; 44(7): 890-5.	1994-1995		
United Kingdom	Papageorgiou AC, Croft PR, Ferry S, Jayson MI, Silman AJ. Estimating the prevalence of low back pain in the general population. Evidence from the South Manchester Back Pain Survey. <i>Spine</i> . 1995; 20(17): 1889-94.	1992		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United Kingdom	Seland JH, Vingerling JR, Aungood CA, Bentham G, Chakravarthy U, deJong PTVM, Rahu M, Soubrane G, Tomazzoli L, Topouzis F, Fletcher AE. Visual impairment and quality of life in the older European population, the EUREYE study. <i>Acta Ophthalmol.</i> 2011; 89(7): 608-13. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2006-2007		
United Kingdom	Wormald RP, Wright LA, Courtney P, Beaumont B, Haines AP. Visual problems in the elderly population and implications for services. <i>BMJ.</i> 1992; 304(6836): 1226-9. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1989-1990		
United Kingdom	Van der Pols JC, Bates CJ, McGraw PV, Thompson JR, Reacher M, Prentice A, Finch S. Visual acuity measurements in a national sample of British elderly people. <i>Br J Ophthalmol.</i> 2000; 84(2): 165-70. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1994-1995		
United Kingdom	Stewart-Brown S, Butler N. Visual acuity in a national sample of 10 year old children. <i>J Epidemiol Community Health.</i> 1985; 39(2): 107-12. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1980		
United Kingdom	Gibson JM, Lavery JR, Rosenthal AR. Blindness and partial sight in an elderly population. <i>Br J Ophthalmol.</i> 1986; 70(9): 700-5. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1982-1984		
United Kingdom	Kangro HO, Osman HK, Lau YL, Heath RB, Yeung CY, Ng MH. Seroprevalence of antibodies to human herpesviruses in England and Hong Kong. <i>J Med Virol.</i> 1994; 43(1): 91-6.	1991		
United Kingdom	Vyse AJ, Gay NJ, Hecketh LM, Morgan-Capner P, Miller E. Seroprevalence of antibody to varicella zoster virus in England and Wales in children and young adults. <i>Epidemiol Infect.</i> 2004; 132(6): 1129-34.	1996		
United Kingdom	Kudesia G, Partridge S, Farrington CP, Soltanpoor N. Changes in age related seroprevalence of antibody to varicella zoster virus: impact on vaccine strategy. <i>J Clin Pathol.</i> 2002; 55(2): 154-5.	1966-1992		
United Kingdom	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2008. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).	1994-1996, 1998-2007		
United Kingdom	Department of Health, Social Services and Public Safety (Northern Ireland), National Advisory Committee on Drugs (Ireland). Ireland and Northern Ireland Drug Prevalence Survey 2002-2003.	2002-2003		
United Kingdom	Home Office (United Kingdom). Drug Misuse Declared: Findings from the 2006/07 British Crime Survey England and Wales. London, United Kingdom: Home Office (United Kingdom), 2007.	1996, 1998, 2000-2003, 2006-2007		
United Kingdom	National Centre for Social Research (NatCen), National Foundation for Educational Research (NFER) (UK). Smoking, Drinking and Drug Use Among Young People in Scotland in 2000. London, United Kingdom: The Stationery Office, 2001.	1998, 2000		
United Kingdom	Department of Justice (Northern Ireland). Northern Ireland Experience of Drug Misuse: Findings from the Northern Ireland Crime Survey 2006-2007.	2006-2007		
United Kingdom	Das VK. Aetiology of bilateral sensorineural hearing impairment in children: a 10 year study. <i>Arch Dis Child.</i> 1996; 74(1): 8-12.	1981-1994	*	
United Kingdom	MacAndie C, Kubba H, McFarlane M. Epidemiology of permanent childhood hearing loss in Glasgow, 1985-1994. <i>Scott Med J.</i> 2003; 48(4): 117-9.	1985-1994	*	
United Kingdom	Gunesh S, Thomas GAO, Williams GT, Roberts A, Hawthorne AB. The incidence of Crohn's disease in Cardiff over the last 75 years: an update for 1996-2005. <i>Aliment Pharmacol Ther.</i> 2008; 27(3): 211-9.	1981-2005		
United Kingdom	Steed H, Walsh S, Reynolds N. Crohn's disease incidence in NHS Tayside. <i>Scott Med J.</i> 2010; 55(3): 22-5.	1998-2007		
United Kingdom	Northern Ireland Office, Northern Ireland Statistics and Research Agency (NISRA). Northern Ireland Experience of Drug Misuse: Findings from the Northern Ireland Crime Survey 2001. Belfast, United Kingdom: Northern Ireland Office, 2003.	2001		
United Kingdom	Northern Ireland Office, Northern Ireland Statistics and Research Agency (NISRA). Northern Ireland Experience of Drug Misuse: Findings from the Northern Ireland Crime Survey 2003-2004. Belfast, United Kingdom: Northern Ireland Office, 2005.	2003-2004		
United Kingdom	Northern Ireland Office, Northern Ireland Statistics and Research Agency (NISRA). Northern Ireland Experience of Drug Misuse: Findings from the Northern Ireland Crime Survey 2005. Belfast, United Kingdom: Northern Ireland Office, 2006.	2005		
United Kingdom	Department of Health, Social Services and Public Safety (Northern Ireland), National Advisory Committee on Drugs (Ireland). Ireland and Northern Ireland Drug Prevalence Survey 2006-2007.	2006-2007		
United Kingdom	Home Office (United Kingdom). Drug Misuse Declared: Results of the 1994 British Crime Survey. London, United Kingdom: Home Office (United Kingdom), 1996.	1994		
United Kingdom	WHO Regional Office for Europe (EURO-WHO). Young People's Health in Context. Health Behaviour in School-aged Children (HBSC) Study: International Report from the 2001-2002 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2004.	2002		
United Kingdom	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006	*	
United Kingdom	European School Survey Project on Alcohol and Other Drugs (ESPAD), Pompidou Group, Council of Europe, Swedish Council for Information on Alcohol and Other Drugs (CAN). ESPAD Report 1995: Alcohol and Other Drug Use Among Students in 26 European Countries. Stockholm, Sweden: Swedish Council for Information on Alcohol and Other Drugs (CAN), 1997.	1995		
United Kingdom	Eltze CM, Chong WK, Cox T, Whitney A, Cortina-Borja M, Chin RFM, Scott RC, Cross JH. A population-based study of newly diagnosed epilepsy in infants. <i>Epilepsia.</i> 2013; 54(3): 437-45.	2005-2006		
United Kingdom	British Market Research Bureau (BMRB), Scottish Government. United Kingdom - Scottish Crime and Victimisation Survey 2006 - Scottish Government.	2006		
United Kingdom	National Centre for Social Research (NatCen), National Foundation for Educational Research (NFER) (UK). United Kingdom - Smoking, Drinking and Drug Use Among Young People in England in 2006: Headline Figures. Leeds, England: Information Centre for Health and Social Care, NHS, 2007.	2001-2006		
United Kingdom	Hawkins NM, Scholes S, Bajekal M, Love H, O'Flaherty M, Raine R, Capewell S. Community care in England: reducing socioeconomic inequalities in heart failure. <i>Circulation.</i> 2012; 126(9): 1050-7.	1999, 2007	*	
United Kingdom	Jhund PS, MacIntyre K, Simpson CR, Lewsey JD, Stewart S, Redpath A, Chalmers JWT, Capewell S, McMurray JJV. Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003 A Population Study of 5.1 Million People. <i>Circulation.</i> 2009; 119(4): 515-23.	1986-2003	*	
United Kingdom	Acosta CD, Bhattacharya S, Tuffnell D, Kurinczuk JJ, Knight M. Maternal sepsis: a Scottish population-based case-control study. <i>BJOG.</i> 2012; 119(4): 474-83.	1987-2008	*	
United Kingdom	Bouvier-Colle M-H, Mohangoo AD, Gissler M, Novak-Antolic Z, Vutuc C, Szamotulska K, Zeitlin J, Euro-Peristat Scientific Committee. What about the mothers? An analysis of maternal mortality and morbidity in perinatal health surveillance systems in Europe. <i>BJOG.</i> 2012; 119(7): 880-90.	2003-2004	*	
United Kingdom	Eagles JM, Lee AJ, Raja EA, Millar HR, Bhattacharya S. Pregnancy outcomes of women with and without a history of anorexia nervosa. <i>Psychol Med.</i> 2012; 42(12): 2651-60.	1965-2007	*	
United Kingdom	Oteng-Ntim E, Kopeika J, Seed P, Wandiembe S, Doyle P. Impact of obesity on pregnancy outcome in different ethnic groups: calculating population attributable fractions. <i>PLoS One.</i> 2013; 8(1): e53749.	2004-2008	*	
United Kingdom	Akolekar R, Syngelaki A, Sarguis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. <i>Prenat Diagn.</i> 2011; 31(1): 66-74.	2006-2009	*	
United Kingdom	Dennedy MC, Avalos G, O'Reilly MW, O'Sullivan EP, Gaffney G, Dunne F. ATLANTIC-DIP: raised maternal body mass index (BMI) adversely affects maternal and fetal outcomes in glucose-tolerant women according to International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria. <i>J Clin Endocrinol Metab.</i> 2012; 97(4): E608-12.	2006-2009	*	
United Kingdom	Kayem G, Kurinczuk JJ, Spark P, Brocklehurst P, Knight M, UK Obstetric Surveillance System. Maternal and obstetric factors associated with delayed postpartum eclampsia: a national study population. <i>Acta Obstet Gynecol Scand.</i> 2011; 90(9): 1017-23.	2005-2006	*	
United Kingdom	Khalil A, Akolekar R, Syngelaki A, Elkhouli M, Nicolaides KH. Maternal hemodynamics at 11-13 weeks' gestation and risk of pre-eclampsia. <i>Ultrasound Obstet Gynecol.</i> 2012; 40(1): 28-34.	2009-2011	*	
United Kingdom	Khalil A, Rezende J, Akolekar R, Syngelaki A, Nicolaides KH. Maternal racial origin and adverse pregnancy outcome: a cohort study. <i>Ultrasound Obstet Gynecol.</i> 2013; 41(3): 278-85.	2009-2011	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United Kingdom	North RA, McCowan LME, Dekker GA, Poston L, Chan EHY, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. <i>BMJ</i> . 2011; d1875.	2004-2008	*	
United Kingdom	Roberts CL, Ford JB, Algert CS, Antonsen S, Chalmers J, Chantingius S, Gokhale M, Kotelchuck M, Melve KK, Langridge A, Morris C, Morris JM, Nassar N, Norman JE, Norrie J, Sorensen HT, Walker R, Weir CJ. Population-based trends in pregnancy hypertension and pre-eclampsia: an international comparative study. <i>BMJ Open</i> . 2011; 1(1): e000101.	1997-2006	*	
United Kingdom	Smits LJM, North RA, Kenny LC, Myers J, Dekker GA, McCowan LME. Patterns of vaginal bleeding during the first 20 weeks of pregnancy and risk of pre-eclampsia in nulliparous women: results from the SCOPE study. <i>Acta Obstet Gynecol Scand</i> . 2012; 91(11): 1331-8.	2004-2008	*	
United Kingdom	Wallace JM, Horgan GW, Bhattacharya S. Placental weight and efficiency in relation to maternal body mass index and the risk of pregnancy complications in women delivering singleton babies. <i>Placenta</i> . 2012; 33(8): 611-8.	1976-2007	*	
United Kingdom	Wright D, Akolekar R, Syngelaki A, Poon LCY, Nicolaides KH. A competing risks model in early screening for preeclampsia. <i>Fetal Diagn Ther</i> . 2012; 32(3): 171-8.	2006-2010	*	
United Kingdom	Flynn RWV, MacDonald TM, Murray GD, Ferguson C, Shah K, Doney ASF. The Tayside Stroke Cohort: exploiting advanced regional medical informatics to create a region-wide database for studying the pharmacoepidemiology of stroke. <i>Pharmacoepidemiol Drug Saf</i> . 2010; 19(7): 737-44.	1994-2005	*	
United Kingdom	Livshits G, Zhai G, Hart DJ, Kato BS, Wang H, Williams FM, Spector TD. Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: The Chingford study. <i>Arthritis Rheum</i> . 2009; 60(7): 2037-45.	1989	*	
United Kingdom	Visser EM, Wilde K, Wilson JF, Yong KK, Counsell CE. A new prevalence study of multiple sclerosis in Orkney, Shetland and Aberdeen city. <i>J Neurol Neurosurg Psychiatry</i> . 2012; 83(7): 719-24.	2009	*	
United Kingdom	Kurtz Z, Tookey P, Ross E. Epilepsy in young people: 23 year follow up of the British national child development study. <i>BMJ</i> . 1998; 316(7128): 339-42.	1958-1981	*	
United Kingdom	MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. <i>Brain</i> . 2000; 123 (Pt 4): 665-76.	1996	*	
United Kingdom	Cockerell OC, Eckle I, Goodridge DM, Sander JW, Shorvon SD. Epilepsy in a population of 6000 re-examined: secular trends in first attendance rates, prevalence, and prognosis. <i>J Neurol Neurosurg Psychiatry</i> . 1995; 58(5): 570-6.	1983	*	
United Kingdom	Heaney DC, MacDonald BK, Everitt A, Stevenson S, Leonard GS, Wilkinson P, Sander JW. Socioeconomic variation in incidence of epilepsy: prospective community based study in south east England. <i>BMJ</i> . 2002; 325(7371): 1013-6.	1995-1997	*	
United Kingdom	Hamsy NA, Ginby D, Feltbower R, Ferrie CD. Ethnic differences in the incidence of seizure disorders in children from Bradford, United Kingdom. <i>Epilepsia</i> . 2007; 48(5): 913-6.	1999-2000	*	
United Kingdom	Tallis R, Hall G, Craig I, Dean A. How common are epileptic seizures in old age. <i>Age Ageing</i> . 1991; 20(6): 442-8.	1989	*	
United Kingdom	Hart YM, Shorvon SD. The nature of epilepsy in the general population. I. Characteristics of patients receiving medication for epilepsy. <i>Epilepsy Res</i> . 1995; 21(1): 43-9.	1994	*	†
United Kingdom	Tidman L, Saravanan K, Gibbs J. Epilepsy in mainstream and special educational primary school settings. <i>Seizure</i> . 2003; 12(1): 47-51.	1996-1997	*	†
United Kingdom	Verity CM, Ross EM, Golding J. Epilepsy in the first 10 years of life: findings of the child health and education study. <i>BMJ</i> . 1992; 305(6858): 857-61.	1980	*	
United Kingdom	Wallace H, Shorvon S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. <i>Lancet</i> . 1998; 352(9145): 1970-3.	1995	*	
United Kingdom	Wright J, Pickard N, Whitfield A, Hakin N. A population-based study of the prevalence, clinical characteristics and effect of ethnicity in epilepsy. <i>Seizure</i> . 2000; 9(5): 309-13.	1998		†
United Kingdom	Mohanraj R, Norrie J, Stephen LJ, Kelly K, Hitiris N, Brodie MJ. Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative study. <i>Lancet Neurol</i> . 2006; 5(6): 481-7.	1981-2001		
United Kingdom	Raymond NT, Zehnder D, Smith SC, Stinson JA, Lehner H, Higgins RM. Elevated relative mortality risk with mild-to-moderate chronic kidney disease decreases with age. <i>Nephrol Dial Transplant</i> . 2007; 22(11): 3214-20.	2000-2003		
United Kingdom	Adamson JA, Price GM, Breeze E, Bulpitt CJ, Fletcher AE. Are older people dying of depression? Findings from the Medical Research Council trial of the assessment and management of older people in the community. <i>J Am Geriatr Soc</i> . 2005; 53(7): 1128-32.	1996-2001		
United Kingdom	Copeland JR, Beekman AT, Dewey ME, Hooijer C, Jordan A, Lawlor BA, Lobo A, Magnusson H, Mann AH, Meller I, Prince MJ, Reischies F, Turrina C, deVries MW, Wilson KC. Depression in Europe. Geographical distribution among older people. <i>Br J Psychiatry</i> . 1999; 174: 312-21.	1993-1994		
United Kingdom	Donnelly M. Depression among adolescents in Northern Ireland. <i>Adolescence</i> . 1995; 30(118): 339-50.	1993		
United Kingdom	Lépine JP, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). <i>Int Clin Psychopharmacol</i> . 1997; 12(1): 19-29.	1995		
United Kingdom	Meltzer H, Gatward R, Goodman R, Ford T. Mental health of children and adolescents in Great Britain. <i>Int Rev Psychiatry</i> . 2003; 15(1-2): 185-7.	1999	*	
United Kingdom	Saunders PA, Copeland JR, Dewey ME, Gilmore C, Larkin BA, Phaterpekar H, Scott A. The prevalence of dementia, depression and neurosis in later life: the Liverpool MRC-ALPHA Study. <i>Int J Epidemiol</i> . 1993; 22(5): 838-47.	1986-1989	*	
United Kingdom	McDougall FA, Kvaal K, Matthews FE, Paykel E, Jones PB, Dewey ME, Brayne C, Medical Research Council Cognitive Function and Ageing Study. Prevalence of depression in older people in England and Wales: the MRC CFA Study. <i>Psychol Med</i> . 2007; 37(12): 1787-95.	1990-1994		
United Kingdom	Baron-Cohen S, Scott FJ, Allison C, Williams J, Bolton P, Matthews FE, Brayne C. Prevalence of autism-spectrum conditions: UK school-based population study. <i>Br J Psychiatry</i> . 2009; 194(6): 500-9.	2005-2006	*	
United Kingdom	Howlin P, Goode S, Hutton J, Rutter M. Adult outcome for children with autism. <i>J Child Psychol Psychiatry</i> . 2004; 45(2): 212-29.	1970-1988	*	
United Kingdom	Durham RC, Higgins C, Chambers JA, Swan JS, Dow MGT. Long-term outcome of eight clinical trials of CBT for anxiety disorders: symptom profile of sustained recovery and treatment-resistant groups. <i>J Affect Disord</i> . 2012; 136(3): 875-81.	1993-2011	*	
United Kingdom	Brewin J, Cantwell R, Dalkin T, Fox R, Medley I, Glazebrook C, Kwiecinski R, Harrison G. Incidence of schizophrenia in Nottingham. A comparison of two cohorts, 1978-80 and 1992-94. <i>Br J Psychiatry</i> . 1997; 140-4.	1992-1994	*	
United Kingdom	Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. <i>Br J Psychiatry</i> . 2010; 196(2): 116-21.	1981-1982		
United Kingdom	Kirkbride JB, Croudace T, Brewin J, Donoghue K, Mason P, Glazebrook C, Medley I, Harrison G, Cooper JE, Doody GA, Jones PB. Is the incidence of psychotic disorder in decline? Epidemiological evidence from two decades of research. <i>Int J Epidemiol</i> . 2009; 38(5): 1255-64.	1992-1994	*	
United Kingdom	Pantelis C, Taylor J, Campbell P. The South Camden schizophrenia survey - an experience of community-based research. <i>Psychiatric Bulletin</i> . 1988; 98-101.	1985		
United Kingdom	Shivashankar S, Telfer S, Arunagiriraj J, McKinnon M, Jauhar S, Krishnadas R, McCreadie R. Has the prevalence, clinical presentation and social functioning of schizophrenia changed over the last 25 years? Nithsdale schizophrenia survey revisited. <i>Schizophr Res</i> . 2013; 146(1-3): 349-56.	1981, 2006		
United Kingdom	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012		
United Kingdom	Office for National Statistics. Social and Vital Statistics Division et al. . Mental Health of Children and Young People in Great Britain, 2004 [computer file]. Colchester, Essex: UK Data Archive [distributor], October 2005. SN: 5269. http://dx.doi.org/10.5255/UKDA-SN-5269-1	2004	*	†
United Kingdom	National Centre for Social Research and University of Leicester. Adult Psychiatric Morbidity Survey, 2007 [computer file]. 3rd Edition. Colchester, Essex: UK Data Archive [distributor], January 2011. SN: 6379. http://dx.doi.org/10.5255/UKDA-SN-6379-1	2007	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United Kingdom	Bevan CD, Ridgway GL, Roethermel CD. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. <i>J Int Med Res.</i> 2003; 31(1): 45-54.	2001-2002	*	†
United Kingdom	Phyadigamage A, Wilson JD. An audit of outpatient management of pelvic inflammatory disease. <i>Int J STD AIDS.</i> 2002; 13(8): 577-9.	2000	*	†
United Kingdom	Bevan CD, Johal BJ, Mumtaz G, Ridgway GL, Siddie NC. Clinical, laparoscopic and microbiological findings in acute salpingitis: report on a United Kingdom cohort. <i>Br J Obstet Gynaecol.</i> 1995; 102(5): 407-14.	1989-1993		
United Kingdom	Simms I, Stephenson JM, Mallinson H, Peeling RW, Thomas K, Gokhale R, Rogers PA, Hay P, Oakeshott P, Hopwood J, Birley H, Hernon M. Risk factors associated with pelvic inflammatory disease. <i>Sex Transm Infect.</i> 2006; 82(6): 452-7.	2000-2002	*	
United Kingdom	Evans JR, Fletcher AE, Wormald RPL. Age-related macular degeneration causing visual impairment in people 75 years or older in Britain: an add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community. <i>Ophthalmology.</i> 2004; 111(3): 513-7. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1995-2000	*	
United Kingdom	Morris-Cunnington M, Brown D, Pimenta J, Robinson NJ, Miller E. New estimates of herpes simplex virus type 2 seroprevalence in England: "high" but stable seroprevalence over the last decade. <i>Sex Transm Dis.</i> 2004; 31(4): 243-6.	1991, 2000	*	
United Kingdom	Narouz N, Allan PS, Wade AH, Wagstaffe S. Genital herpes serotyping: a study of the epidemiology and patients' knowledge and attitude among STD clinic attenders in Coventry, UK. <i>Sex Transm Infect.</i> 2003; 79(1): 35-41.	2000-2002	*	
United Kingdom	Evans BA, Kell PD, Bond RA, MacRae KD, Slomka MJ, Brown DWG. Predictors of seropositivity to herpes simplex virus type 2 in women. <i>Int J STD AIDS.</i> 2003; 14(1): 30-6.	1992	*	†
United Kingdom	Opaneye AA, Bashford J. Seroprevalence of antibodies to herpes simplex virus types 1 and 2 among two sexually active female populations in Middlesbrough, England. <i>J R Soc Promot Health.</i> 2002; 122(2): 108-11.	1992, 1996-1997	*	†
United Kingdom	Yates HL, McCullough S, Harrison C, Gill AB. Hypoxic ischaemic encephalopathy: accuracy of the reported incidence. <i>Arch Dis Child Fetal Neonatal Ed.</i> 2012; 97(1): F77-78.	2006-2009	*	†
United Kingdom	Yeh P, Emary K, Impey L. The relationship between umbilical cord arterial pH and serious adverse neonatal outcome: analysis of 51,519 consecutive validated samples. <i>BJOG.</i> 2012; 119(7): 824-31.	1991-2009	*	†
United Kingdom	Becher J-C, Stenson BJ, Lyon AJ. Is intrapartum asphyxia preventable <i>BJOG.</i> 2007; 114(11): 1442-4.	1994-2005	*	†
United Kingdom	Hull J, Dodd KL. Falling incidence of hypoxic-ischaemic encephalopathy in term infants. <i>Br J Obstet Gynaecol.</i> 1992; 99(5): 386-91.	1984-1988	*	†
United Kingdom	Levene ML, Kornberg J, Williams TH. The incidence and severity of post-asphyxial encephalopathy in full-term infants. <i>Early Hum Dev.</i> 1985; 11(1): 21-6.	1980-1983	*	†
United Kingdom	Smith J, Wells L, Dodd K. The continuing fall in incidence of hypoxic-ischaemic encephalopathy in term infants. <i>BJOG.</i> 2000; 107(4): 461-6.	1992-1996	*	†
United Kingdom	Azzopardi DV, Strohm B, Edwards AD, Dyet L, Halliday HL, Juszczak E, Kapellou O, Levene M, Marlow N, Porter E, Thoresen M, Whitelaw A, Brocklehurst P, TOBY Study Group. Moderate hypothermia to treat perinatal asphyxial encephalopathy. <i>N Engl J Med.</i> 2009; 361(14): 1349-58.	2002-2006	*	
United Kingdom	Barnett A, Mercuri E, Rutherford M, Haataja L, Frisone MF, Henderson S, Cowan F, Dubowitz L. Neurological and perceptual-motor outcome at 5 - 6 years of age in children with neonatal encephalopathy: relationship with neonatal brain MRI. <i>Neuropediatrics.</i> 2002; 33(5): 242-8.	1991-1996		
United Kingdom	Williams L, Parker H. Alcohol, cannabis, ecstasy and cocaine: Drugs of reasoned choice amongst young adult recreational drug users in England. <i>Int J Drug Policy.</i> 1999; 12(5-6): 397-413.	1995, 1999		
United Kingdom	Song SH, Gray TA. Early-onset type 2 diabetes: high risk for premature diabetic retinopathy. <i>Diabetes Res Clin Pract.</i> 2011; 94(2): 207-11.	2008-2010		
United Kingdom	Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J, Hann AW, Hussein A, Jackson N, Johnson KE, Ryder CH, Torkington R, Van Ross ERE, Whalley AM, Widdows P, Williamson S, Boulton AJM, North-West Diabetes Foot Care Study. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. <i>Diabet Med.</i> 2002; 19(5): 377-84.	1994-1996		
United Kingdom	Barclay RP, Craig JO, Galloway CA, Richardson JE, Shepherd RC, Small PJ. The incidence of childhood diabetes in certain parts of Scotland. <i>Scott Med J.</i> 1988; 33(2): 237-9.	1976-1986		
United Kingdom	Barker DJ, Gardner MJ, Power C. Incidence of diabetes amongst people aged 18-50 years in nine British towns: a collaborative study. <i>Diabetologia.</i> 1982; 22(6): 421-5.	1977-1979		
United Kingdom	Canavan RJ, Unwin NC, Kelly WF, Connolly VM. Diabetes- and nondiabetes-related lower extremity amputation incidence before and after the introduction of better organized diabetes foot care: continuous longitudinal monitoring using a standard method. <i>Diabetes Care.</i> 2008; 31(3): 459-63.	1995-2000		
United Kingdom	Cohen DL, Neil HA, Thorogood M, Mann JI. A population-based study of the incidence of complications associated with type 2 diabetes in the elderly. <i>Diabet Med.</i> 1991; 8(10): 928-33.	1982-1988		
United Kingdom	Feltbower RG, McKinney PA, Bodansky HJ. Rising incidence of childhood diabetes is seen at all ages and in urban and rural settings in Yorkshire, United Kingdom. <i>Diabetologia.</i> 2000; 43(5): 682-4.	1978-1998		
United Kingdom	Gardner SG, Bingley PJ, Sawtell PA, Weeks S, Gale EA. Rising incidence of insulin dependent diabetes in children aged under 5 years in the Oxford region: time trend analysis. The Bart's-Oxford Study Group. <i>BMJ.</i> 1997; 315(7110): 713-7.	1985-1995		
United Kingdom	Patterson CC, Smith PG, Webb J, Heasman MA, Mann JI. Geographical variation in the incidence of diabetes mellitus in Scottish children during the period 1977-1983. <i>Diabet Med.</i> 1988; 5(2): 160-5.	1977-1983		
United Kingdom	Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Rodgers H, Evans JG, Clark F, Tunbridge F, Young ET. The incidence of diabetes mellitus in an English community: a 20-year follow-up of the Whickham Survey. <i>Diabet Med.</i> 1996; 13(8): 741-7.	1992-1993		
United Kingdom	Waugh NR. Insulin-dependent diabetes in a Scottish region: incidence and urban/rural differences. <i>J Epidemiol Community Health.</i> 1986; 40(3): 240-3.	1980-1983	*	
United Kingdom	Zhao HX, Stenhouse E, Soper C, Hughes P, Sanderson E, Baumer JH, Demaine AG, Millward BA. Incidence of childhood-onset Type 1 diabetes mellitus in Devon and Cornwall, England, 1975-1996. <i>Diabet Med.</i> 1999; 16(12): 1030-5.	1975-1996	*	
United Kingdom	Button EJ, Chadalavada B, Palmer RL. Mortality and predictors of death in a cohort of patients presenting to an eating disorders service. <i>Int J Eat Disord.</i> 2010; 43(5): 387-92.	1992-2007	*	
United Kingdom	Crisp A. 1.6. Death, survival and recovery in anorexia nervosa: a thirty five year study. <i>Eur Eat Disord Rev.</i> 2006; 14(3): 168-75.	1960-1990	*	
United Kingdom	Collings S, King M. Ten-year follow-up of 50 patients with bulimia nervosa. <i>Br J Psychiatry.</i> 1994; 164(1): 80-7.	1981-1991	*	
United Kingdom	Fairburn CG, Cooper Z, Doll HA, Norman P, O'Connor M. The natural course of bulimia nervosa and binge eating disorder in young women. <i>Arch Gen Psychiatry.</i> 2000; 57(7): 659-65.	1993-1998	*	
United Kingdom	Bargagli AM, Hickman M, Davoli M, Perucci CA, Schifano P, Buster M, Brugal T, Vicente J, COSMO European Group. Drug-related mortality and its impact on adult mortality in eight European countries. <i>Eur J Public Health.</i> 2006; 16(2): 198-202.	1997-2001	*	
United Kingdom	De Angelis D, Hickman M, Yang S. Estimating long-term trends in the incidence and prevalence of opiate use/injecting drug use and the number of former users: back-calculation methods and opiate overdose deaths. <i>Am J Epidemiol.</i> 2004; 160(10): 994-1004.	2000	*	
United Kingdom	Frischer M, Hickman M, Kraus L, Mariani F, Wiessing L. A comparison of different methods for estimating the prevalence of problematic drug misuse in Great Britain. <i>Addiction.</i> 2001; 96(10): 1465-76.	1996	*	
United Kingdom	Ghods H, Oyefeso A, Kilpatrick B. Mortality of drug addicts in the United Kingdom 1967-1993. <i>Int J Epidemiol.</i> 1998; 27(3): 473-8.	1967-1993	*	
United Kingdom	Oppenheimer E, Tobutt C, Taylor C, Andrew T. Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow-up study. <i>Addiction.</i> 1994; 89(10): 1299-308.	1969-1991	*	
United Kingdom	Rathod NHR, Addenbrooke WM, Rosenbach AF. Heroin dependence in an English town: 33-year follow-up. <i>Br J Psychiatry.</i> 2005; 421-5.	1966-1999		
United Kingdom	Seaman SR, Brettell RP, Gore SM. Mortality from overdose among injecting drug users recently released from prison: database linkage study. <i>BMJ.</i> 1998; 316(7129): 426-8.	1983-1994		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United Kingdom	Jenkins R, Lewis G, Bebbington P, Brugha T, Farrell M, Gill B, Meltzer H. The National Psychiatric Morbidity surveys of Great Britain-initial findings from the household survey. <i>Psychol Med.</i> 1997; 27(4): 775-89.	1993		
United Kingdom	Lai HC, Lai MP, Leung KS. Glucose-6-phosphate dehydrogenase deficiency in Chinese. <i>J Clin Pathol.</i> 1968; 21(1): 44-7.	1964-1968		
United Kingdom	Erdohazi M, Highman W. Glucose-6-phosphate-dehydrogenase deficiency in Britain. <i>Lancet.</i> 1962; 280(7268): 1274.	1960-1962		
United Kingdom	Demography of dialysis and transplantation in Europe in 1985 and 1986: trends over the previous decade. Report from the European Dialysis and Transplant Association Registry. <i>Nephrol Dial Transplant.</i> 1988; 3(6): 714-27.	1985		
United Kingdom	Van Dijk PC, Jager KJ, Stengel B, Grönhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). <i>Kidney Int.</i> 2005; 67(4): 1489-99.	1991-1992, 1999-2000		
United Kingdom	Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. <i>Nephrol Dial Transplant.</i> 2003; 18(9): 1824-33.	1990-1991, 1998-1999		
United Kingdom	Global Lower Extremity Amputation Study Group. Epidemiology of lower extremity amputation in centres in Europe, North America and East Asia. The Global Lower Extremity Amputation Study Group. <i>Br J Surg.</i> 2000; 87(3): 328-37.	1995-1997		
United Kingdom	Schofield CJ, Yu N, Jain AS, Leese GP. Decreasing amputation rates in patients with diabetes-a population-based study. <i>Diabet Med.</i> 2009; 26(8): 773-7.	2000-2006		
United Kingdom	Leggetter S, Chaturvedi N, Fuller JH, Edmonds ME. Ethnicity and risk of diabetes-related lower extremity amputation: a population-based, case-control study of African Caribbeans and Europeans in the United Kingdom. <i>Arch Intern Med.</i> 2002; 162(1): 73-8.	1992-1997		
United Kingdom	Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. <i>Clin Endocrinol (Oxf).</i> 1999; 51(6): 779-86.	1996-1997		
United Kingdom	Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. <i>J Clin Endocrinol Metab.</i> 2008; 93(4): 1408-11.	2005		
United Kingdom	Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Gilst WH van, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>Eur Heart J.</i> 2003; 24(5): 442-63.	2000-2001		
United Kingdom	Morris AJ, Steele J, White DA. The oral cleanliness and periodontal health of UK adults in 1998. <i>Br Dent J.</i> 2001; 191(4): 186-92.	1998		
United Kingdom	National Centre for Social Research (NatCen), University of Leicester. Adult Psychiatric Morbidity in England, 2007: Results of a Household Survey. Leeds, England: Information Centre for Health and Social Care, NHS, 2009.	2007	*	
United Kingdom	Nicholls P, Edwards G, Kyle E. Alcoholics admitted to four hospitals in England. II. General and cause-specific mortality. <i>Q J Stud Alcohol.</i> 1974; 35(3): 841-55.	1953-1967	*	
United Kingdom	Hirst C, Swingle R, Compston DA, Ben-Shlomo Y and Robertson NP. Survival and cause of death in multiple sclerosis: a prospective population-based study. <i>J Neurol Neurosurg Psychiatry.</i> 2008; 79(9): 1016-21.	1985-2005	*	
United Kingdom	Roberts SE, Williams JG, Meddings D, Goldacre MJ. Incidence and case fatality for acute pancreatitis in England: geographical variation, social deprivation, alcohol consumption and aetiology - a record linkage study. <i>Aliment Pharmacol Ther.</i> 2008; 28(7): 931-41.	1998-2003	*	
United Kingdom	Newman EJ, Grosset KA, Grosset DG. Geographical difference in Parkinson's disease prevalence within West Scotland. <i>Mov Disord.</i> 2009; 24(3): 401-6.	2006-2007	*	
United Kingdom	Walker RW, Hand A, Jones C, Wood BH, Gray WK. The prevalence of Parkinson's disease in a rural area of North-East England. <i>Parkinsonism Relat Disord.</i> 2010; 16(9): 572-5.	2007-2008	*	
United Kingdom	Wickremaratchi MM, Perera D, O'Loghlen C, Sastry D, Morgan E, Jones A, Edwards P, Robertson NP, Butler C, Morris HR, Ben-Shlomo Y. Prevalence and age of onset of Parkinson's disease in Cardiff: a community based cross sectional study and meta-analysis. <i>J Neurol Neurosurg Psychiatry.</i> 2009; 80(7): 805-7.	2006		
United Kingdom	Walsh K, Cruddas M, Coggon D. Low back pain in eight areas of Britain. <i>J Epidemiol Community Health.</i> 1992; 46(3): 227-30.	1989		
United Kingdom	Haberman S, Benjamin B, Capildeo R, Rose FC. North West Thames registry of neurological disease. <i>J R Soc Med.</i> 1982; 75(6): 443-9.	1978		
United Kingdom	Hughes RA, Charlton J, Latinovic R, Gulliford MC. No association between immunization and Guillain-Barré syndrome in the United Kingdom, 1992 to 2000. <i>Arch Intern Med.</i> 2006; 166(12): 1301-4.	1992-2000		
United Kingdom	Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barré syndrome in south east England. <i>J Neurol Neurosurg Psychiatry.</i> 1998; 64(1): 74-7.	1993-1994		
United Kingdom	Sridharan GV, Tallis RC, Gautam PC. Guillain-Barré syndrome in the elderly. A retrospective comparative study. <i>Gerontology.</i> 1993; 39(3): 170-5.	1980-1988		
United Kingdom	Winner SJ, Evans JG. Guillain-Barré syndrome in Oxfordshire: clinical features in relation to age. <i>Age Ageing.</i> 1993; 22(3): 164-70.	1990-1992		
United Kingdom	Winner SJ, Evans JG. Age specific incidence of Guillain-Barré syndrome in Oxfordshire. <i>Q J Med.</i> 1990; 77(3): 1297-1304.	1974-1986	*	
United Kingdom	Reddy S, Rangaiah J, Addiman S, Wareham D, Wilson P, Sefton A. Epidemiology, antibiotic resistance trends and the cost of enteric fever in East London, 2005-2010. <i>Travel Med Infect Dis.</i> 2011; 9(4): 206-12.	2006-2009		
United Kingdom	Wagner KS, White JM, Lucenko I, Mercer D, Crowcroft NS, Neal S, Efstratiou A. Diphtheria Surveillance Network. Diphtheria in the postepidemic period, Europe, 2000-2009. <i>Emerg Infect Dis.</i> 2012; 18(2): 217-25.	2000-2009		
United Kingdom	Pugsley Z, Ballard K. Management of endometriosis in general practice: the pathway to diagnosis. <i>Br J Gen Pract.</i> 2007; 57(539): 470-6.	2004		
United Kingdom	Ballard KD, Seaman HE, de Vries CS, Wright JT. Can symptomatology help in the diagnosis of endometriosis? Findings from a national case-control study - Part I. <i>BJOG.</i> 2008; 115(11): 1382-91.	1992-2001	*	
United Kingdom	Office for National Statistics. Social Survey Division, Adult Dental Health Survey, 1998 [computer file]. 2nd Edition. Colchester, Essex: UK Data Archive [distributor], October 2013. SN: 4226. http://dx.doi.org/10.5255/UKDA-SN-4226-2	1998	*	
United Kingdom	Davis A, Wood S, Healy R, Webb H, Rowe S. Risk factors for hearing disorders: epidemiologic evidence of change over time in the UK. <i>J Am Acad Audiol.</i> 1995; 6(5): 365-70.	1983-1988	*	
United Kingdom	Fortnum HM, Marshall DH, Summerfield AQ. Epidemiology of the UK population of hearing-impaired children, including characteristics of those with and without cochlear implants - audiology, aetiology, comorbidity and affluence. <i>Int J Audiol.</i> 2002; 41(3): 170-9.	1980-1998	*	
United Kingdom	Parving A, Stephens D. Profound permanent hearing impairment in childhood: causative factors in two European countries. <i>Acta Otolaryngol.</i> 1997; 117(2): 158-60.	1975-1980		
United Kingdom	Watkin P, Hasan J, Baldwin M, Ahmed M. Neonatal hearing screening: Have we taken the right road? Results from a 10-year targeted screen longitudinally followed up in a single district. <i>Audiol Med.</i> 2005; 3(3).	1990-2000		
United Kingdom	Mathews F, Brayne C, Medical Research Council Cognitive Function and Ageing Study Investigators. The incidence of dementia in England and Wales: findings from the five identical sites of the MRC CFA Study. <i>PLoS Med.</i> 2005; 2(8): e193.	1990-1996		
United Kingdom	Paykel ES, Brayne C, Huppert FA, Gill C, Barkley C, Gehlhaar E, Beardsall L, Girling DM, Pollitt P, O'Connor D. Incidence of dementia in a population older than 75 years in the United Kingdom. <i>Arch Gen Psychiatry.</i> 1994; 51(4): 325-32.	1985-1990		
United Kingdom	Copeland JR, Dewey ME, Davidson IA, Saunders PA, Scott A. Geriatric Mental State-AGECAT: prevalence, incidence and long-term outcome of dementia and organic disorders in the Liverpool study of continuing health in the community. <i>Neuroepidemiology.</i> 1992; 84-7.	1982-1985		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United Kingdom	Brayne C, Best N, Muir M, Richards SJ, Gill C. Five-year incidence and prediction of dementia and cognitive decline in a population sample of women aged 70-79 at baseline. <i>Int J Geriatr Psychiatry</i> . 1997; 12(11): 1107-18.	1994-1996	*	
United Kingdom	O'Connor DW, Pollitt PA, Hyde JB, Fellows JL, Miller ND, Brook CP, Reiss BB, Roth M. The prevalence of dementia as measured by the Cambridge Mental Disorders of the Elderly Examination. <i>Acta Psychiatr Scand</i> . 1989; 79(2): 190-8.	1983-1986	*	
United Kingdom	Kuo C-F, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. <i>Ann Rheum Dis</i> . 2014.	1997-2012	*	
United Kingdom	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1995; 70(25): 177-82.	1994	*	
United Kingdom	Health Protection Agency (United Kingdom). Tuberculosis in the UK: Report on Tuberculosis Surveillance in the UK 2010. London, England: Health Protection Agency (United Kingdom), 2010.	2001, 2004, 2007	*	
United Kingdom	Ades AE, Peckham CS, Dale GE, Best JM, Jeansson S. Prevalence of antibodies to herpes simplex virus types 1 and 2 in pregnant women, and estimated rates of infection. <i>J Epidemiol Community Health</i> . 1989; 43(1): 53-60.	1980-1981	*	
United Kingdom	Cowan FM, Johnson AM, Ashley R, Corey L, Mindel A. Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. <i>BMJ</i> . 1994; 309(6965): 1325-9.	1990-1992	*	
United Kingdom	Jha PK, Beral V, Peto J, Hack S, Hemon C, Deacon J, Mant D, Chilvers C, Vessey MP, Pike MC. Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk. <i>Lancet</i> . 1993; 341(8853): 1116-8.	1990	*	
United Kingdom	Pebody RG, Andrews N, Brown D, Gopal R, De Melker H, François G, Gatcheva N, Hellenbrand W, Jokinen S, Klavs I, Kojouharova M, Kortbeek T, Kriz B, Prosenec K, Roubalova K, Teocharov P, Thierfelder W, Valle M, Van Damme P, Vranckx R. The seroepidemiology of herpes simplex virus type 1 and 2 in Europe. <i>Sex Transm Infect</i> . 2004; 80(3): 185-91.	1994	*	
United Kingdom	Khawaja AP, Chan MPY, Hayat S, Broadway DC, Luben R, Garway-Heath DF, Sherwin JC, Yip JLY, Dalzell N, Wareham NJ, Khaw K-T, Foster PJ. The EPIC-Norfolk Eye Study: rationale, methods and a cross-sectional analysis of visual impairment in a population-based cohort. <i>BMJ Open</i> . 2013; 3(3).	2004-2011		
United Kingdom	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland: World Health Organization (WHO).	2000-2012	*	
United Kingdom	Wagner KS, White JM, Crowcroft NS, De Martin S, Mann G, Efstratiou A. Diphtheria in the United Kingdom, 1986-2008: the increasing role of <i>Corynebacterium ulcerans</i> . <i>Epidemiol Infect</i> . 2010; 138(11): 1519-30.	1986-2008		
United Kingdom	National Centre for Social Research and National Foundation for Educational Research, Smoking, Drinking and Drug Use among Young People, 2012 [computer file]. Colchester, Essex: UK Data Archive [distributor], October 2013. SN: 7393, http://dx.doi.org/10.5255/UKDA-SN-7393-1	2012	*	
United Kingdom	Garraway WM, Russell EB, Lee RJ, Collins GN, McKelvie GB, Hehir M, Rogers AC, Simpson RJ. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. <i>Br J Gen Pract</i> . 1993; 43(373): 318-21.	1990		
United Kingdom	Ng Y, Shaw D, Fielder A, Levene M. Epidemiology of retinopathy of prematurity. <i>Lancet</i> . 1988; 332(8622): 1235-8.	1986		†
United Kingdom	Fortnum HM, Davis AC. Epidemiology of bacterial meningitis. <i>Arch Dis Child</i> . 1993; 68(6): 763-7.	1980-1989		†
United Kingdom	Holt D, Halket S, de Louvois J, Harvey D. Neonatal meningitis in England and Wales: 10 years on. <i>Arch Dis Child Fetal Neonatal Ed</i> . 2001; 84(2): F85-F89.	1996-1997		
United Kingdom	De Louvois J, Blackburn J, Hurley R, Harvey D. Infantile meningitis in England and Wales: a two year study. <i>Arch Dis Child</i> . 1991; 66(5): 603-7.	1985-1987		
United Kingdom	Department of Health (United Kingdom), Office of Population Censuses and Surveys (United Kingdom), Royal College of General Practitioners. Morbidity Statistics from General Practice: Fourth National Study 1991-1992. London, United Kingdom: Her Majesty's Stationery Office (HMSO), 1995.	1991-1992		
United Kingdom	Gauthier A, Breuer J, Carrington D, Martin M, Rémy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. <i>Epidemiol Infect</i> . 2009; 137(1): 38-47.	2000-2006		
United Kingdom	Fleming DM, Cross KW, Cobb WA, Chapman RS. Gender difference in the incidence of shingles. <i>Epidemiol Infect</i> . 2004; 132(1): 1-5.	1994-2001		
United Kingdom	Hope-Simpson RE. The Nature of Herpes Zoster: A Long-term Study and a New Hypothesis. <i>Proc R Soc Med</i> . 1965; 58(1): 9-20.	1950-1962		
United Kingdom	Glynn C, Crockford G, Gavaghan D, Cardno P, Price D, Miller J. Epidemiology of Shingles. <i>J R Soc Med</i> . 1990; 83(10): 617-9.	1978-1986		
United Kingdom	Ross CAC, Brown WK, Clarke A, Caldwell WF, Gordon ER, Harvey J, McAlister AMT, McGlone J, Prentice RTW, Thorburn W, Tobias C. Herpes zoster in general practice. <i>J R Coll Gen Pract</i> . 1975; 25(150): 29-32.	1972-1973		
United Kingdom	Fairley CK, Miller E. Varicella-Zoster Virus Epidemiology-A Changing Scene? <i>J Infect Dis</i> . 1996; 174(Supplement 3): S314-S319.	1980-1989		
United Kingdom	Wilson JB. Thirty years of herpes zoster in a rural practice. <i>Br Med J (Clin Res Ed)</i> . 1986; 293(6558): 1349-51.	1955-1985		
United Kingdom	Cunningham R, Mutton K. Dengue haemorrhagic fever. <i>BMJ</i> . 1991; 302(6784): 1083-4.	1990		
United Kingdom	Davison KL, Crowcroft NS, Ramsay ME, Brown DWG, Andrews NJ. Viral encephalitis in England, 1989-1998: what did we miss <i>Emerg Infect Dis</i> . 2003; 9(2): 234-40.	1989-1998	*	
United Kingdom	Cohn M, Stewart P. Prevalence of potential pathogens in cervical canal before termination of pregnancy. <i>BMJ</i> . 1992; 304(6840): 1479.	1992		
United Kingdom	Wright D, Barrow S, Fisher AD, Horsley SD, Jayson MI. Influence of physical, psychological and behavioural factors on consultations for back pain. <i>Br J Rheumatol</i> . 1995; 34(2): 156-61.	1992		
United Kingdom	World Health Organization (WHO). Mental Illness in General Health Care: An International Study. Geneva, Switzerland: World Health Organization (WHO), 1995.	1991-1992		
United Kingdom	Kendell RE, Staton MC. The fate of untreated alcoholics. <i>Q J Stud Alcohol</i> . 1966; 27(1): 30-41.	1950-1970		
United Kingdom	Adelstein A, White G. Alcoholism and mortality. <i>Popul Trends</i> . 1976; 6: 13-Jul.	1953-1974	*	
United Kingdom	Marshall EJ, Edwards G, Taylor C. Mortality in men with drinking problems: a 20-year follow-up. <i>Addiction</i> . 1994; 89(10): 1293-8.	1968-1990		
United Kingdom	Plant M. Women, Drinking, and Pregnancy. London, United Kingdom: Tavistock Publications, 1985.	1980-1996, 1998-2008	*	
United Kingdom	Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJA, Wasserman SM, Baker N, Rosser D, Cleland JGF, Ponikowski P. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. <i>Eur Heart J</i> . 2007; 28(18): 2208-16.	1992-1995	*	
United Kingdom	Margolis DJ, Bilker W, Knauss J, Baumgarten M, Strom BL. The incidence and prevalence of pressure ulcers among elderly patients in general medical practice. <i>Ann Epidemiol</i> . 2002; 12(5): 321-5.	1988-1996	*	
United Kingdom	Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, Büchele G, Clausen M, Cookson WOC, von Mutius E, Strachan DP, Williams HC, ISAAC Phase Two Study Group. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. <i>J Allergy Clin Immunol</i> . 2008; 121(1): 141-147.	2005-2007	*	
United Kingdom	Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. <i>Arch Dermatol</i> . 2005; 141(12): 1537-41.	1987-2002	*	
United Kingdom	Henthorn J, Anionwu E, Brozovic M. Screening cord blood for sickle haemoglobinopathies in Brent. <i>Br Med J (Clin Res Ed)</i> . 1984; 289(6443): 479-80.	1981-1983		
United Kingdom	Trichopoulos D, Bania C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overvad K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PHM, Lund E, Quirós JR, González CA, Sanchez Perez M-J, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw K-T, Wareham N, Key T, Romieu I, Chuang S-C, Murphy N, Boffetta P, Trichopoulos A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. <i>J Natl Cancer Inst</i> . 2011; 103(22): 1686-95.	1992-2006		
United Kingdom	Gay NJ, Morgan-Capner P, Wright J, Farrington CP, Miller E. Age-specific antibody prevalence to hepatitis A in England: implications for disease control. <i>Epidemiol Infect</i> . 1994; 113(1): 113-20.	1986-1987		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United Kingdom	Masterton RG, Strike PW, Tetmar RE. Hepatitis A immunity and travel history. <i>J Infect.</i> 1991; 23(3): 321-6.	1987-1988		
United Kingdom	Scott NJ, Harrison JF, Zuckerman AJ. Hepatitis A antibody in blood donors in North East Thames region: implications to prevention policies. <i>Epidemiol Infect.</i> 1989; 103(2): 377-82.	1988		
United Kingdom	Bernal W, Smith H, Williams R. A Community Prevalence of Antibodies to Hepatitis A and E in Inner-City London. <i>J Med Virol.</i> 1996; 230-4.	1988-1989		
United Kingdom	Cumberland NS, Masterton RG, Green AD, Sims MM. Prevalence of immunity to hepatitis A in recruits to the British Army and Royal Air Force. <i>J R Army Med Corps.</i> 1994; 140(2): 71-5.	1989-1992		
United Kingdom	Zuckerman JN, Powell L. Hepatitis A antibodies in attenders of London travel clinics: Cost-benefit of screening prior to hepatitis A immunisation. <i>J Med Virol.</i> 1994; 44(4): 393-4.	1991-1993		
United Kingdom	Morris MC, Gay NJ, Hesketh LM, Morgan-Capner P, Miller E. The changing epidemiological pattern of hepatitis A in England and Wales. <i>Epidemiol Infect.</i> 2002; 128(3): 457-63.	1996		
United Kingdom	Ross JDC, Ghanem M, Tariq A, Gilleran G, Winter AJ. Seroprevalence of hepatitis A immunity in male genitourinary medicine clinic attenders: a case control study of heterosexual and homosexual men. <i>Sex Transm Infect.</i> 2002; 78(3): 174-9.	2000		
United Kingdom	Morris-Cunnington MC, Edmunds WJ, Miller E, Brown DWG. A population-based seroprevalence study of hepatitis A virus using oral fluid in England and Wales. <i>Am J Epidemiol.</i> 2004; 159(8): 786-94.	2001-2003		
United Kingdom	Jarvis D, Luczynska C, Chinn S, Burney P. The association of hepatitis A and <i>Helicobacter pylori</i> with sensitization to common allergens, asthma and hay fever in a population of young British adults. <i>Allergy.</i> 2004; 59(10): 1063-7.	2003		
United Kingdom	Dalton HR, Stableforth W, Hazeldine S, Thuraiajah P, Ramnarace R, Warshow U, Ijaz S, Ellis V, Bendall R. Autochthonous hepatitis E in Southwest England: a comparison with hepatitis A. <i>Eur J Clin Microbiol Infect Dis.</i> 2008; 27(7): 579-85.	2005-2006		
United Kingdom	Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, Tolonen H, Ruokokoski E. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. <i>Lancet.</i> 1999; 353(9164): 1547-57.	1980-1995		
United Kingdom	Abusheikha N, Akagbosi F, Marcus S, Lass A, Cousins C, Brinsden P. Viral screening and assisted conception treatment—the Bourn Hall experience. <i>J Assist Reprod Genet.</i> 1999; 16(6): 337-9.	1987-1998		
United Kingdom	Anderson SR, Righarts A, Maguire H. Surveillance of antenatal infections—HIV, hepatitis B, syphilis and rubella susceptibility in London. <i>Commun Dis Public Health.</i> 2004; 7(4): 251-7.	2002		
United Kingdom	Balogun MA, Ramsay ME, Hesketh LM, Andrews N, Osborne KP, Gay NJ, Morgan-Capner P. The prevalence of hepatitis C in England and Wales. <i>J Infect.</i> 2002; 45(4): 219-26.	1986, 1991, 1996		
United Kingdom	Bracebridge S, Irwin D, Millership S. Prevention of perinatal hepatitis B transmission in a health authority area: an audit. <i>Commun Dis Public Health.</i> 2004; 7(2): 138-41.	1996-2002		
United Kingdom	Brant LJ, Hurrelle M, Balogun MA, Klapper P, Ahmad F, Boxall E, Hale A, Hollyoak V, Ibrahim IB, Irving W, Meigh R, Mutton KJ, Patel BC, Paver WK, Pugh S, Taylor C, Turner AJ, Ramsay ME. Sentinel laboratory surveillance of hepatitis C antibody testing in England: understanding the epidemiology of HCV infection. <i>Epidemiol Infect.</i> 2007; 135(3): 417-26.	2002-2003		
United Kingdom	Christie I, Sumner D, Palmer S, Kenney A, Banatvala J. Screening of pregnant women for evidence of current hepatitis B infection: selective or universal Health Trends. 1992; 24(1): 13-5.	1988-1990		
United Kingdom	Cunningham R, Northwood JL, Kelly CD, Boxall EH, Andrews NJ. Routine antenatal screening for hepatitis B using pooled sera: validation and review of 10 years experience. <i>J Clin Pathol.</i> 1998; 51(5): 392-5.	1986-1996		
United Kingdom	Gay NJ, Hesketh LM, Osborne KP, Farrington CP, Morgan-Capner P, Miller E. The prevalence of hepatitis B infection in adults in England and Wales. <i>Epidemiol Infect.</i> 1999; 122(1): 133-8.	1996		
United Kingdom	Gore SM, Brettell RP, Burns SM, Lewis SC. Pilot study to estimate survivors to 1995 of 1983-1984 prevalent hepatitis C infections in Lothian patients who tested positive or negative for hepatitis B surface antigen in 1983-1984. <i>J Infect.</i> 1998; 37(2): 159-65.	1983-1984		
United Kingdom	Hutchinson SJ, Goldberg DJ, King M, Cameron SO, Shaw LE, Brown A, MacKenzie J, Wilson K, MacDonald L. Hepatitis C virus among childbearing women in Scotland: prevalence, deprivation, and diagnosis. <i>Gut.</i> 2004; 53(4): 593-8.	2000		
United Kingdom	Ijaz S, Vyse AJ, Morgan D, Pebody RG, Tedder RS, Brown D. Indigenous hepatitis E virus infection in England: more common than it seems. <i>J Clin Virol.</i> 2009; 44(4): 272-6.	1991, 2004		
United Kingdom	MacLean AB, Cameron S, Follett EAC. Prevalence of hepatitis B and C viruses and human immunodeficiency virus infections in women of reproductive age. <i>Br J Obstet Gynaecol.</i> 1993; 100(7): 702-3.	1991, 1993	*	
United Kingdom	Castillo Taucher S. [Services for the care and prevention of birth defects. Reduced report of a World Health Organization and March of Dimes Foundation meeting]. <i>Rev Med Chil.</i> 2007; 135(6): 806-13.	1955-2000	*	
United Kingdom	Arumugam K, Urquhart R. Causes for infertility: a comparative study. <i>Ann Acad Med Singapore.</i> 1991; 20(3): 351-2.	1986-1988	*	
United Kingdom	Hull MG, Glazener CM, Kelly NJ, Conway DI, Foster PA, Hinton RA, Coulson C, Lambert PA, Watt EM, Desai KM. Population study of causes, treatment, and outcome of infertility. <i>Br Med J (Clin Res Ed).</i> 1985; 291(6510): 1693-7.	1982-1983	*	
United Kingdom	Maheshwari A, Hamilton M, Bhattacharya S. Effect of female age on the diagnostic categories of infertility. <i>Hum Reprod.</i> 2008; 23(3): 538-42.	1993-2006	*	
United Kingdom	Holme SA, Malinovsky K, Roberts DL. Changing trends in non-melanoma skin cancer in South Wales, 1988-98. <i>Br J Dermatol.</i> 2000; 143(6): 1224-9.	1988, 1998	*	
United Kingdom	Roberts DL. Incidence of non-melanoma skin cancer in West Glamorgan, South Wales. <i>Br J Dermatol.</i> 1990; 122(3): 399-403.	1988		
United Kingdom	Flohr C, Weinmayr G, Weiland SK, Addo-Yobo E, Annesi-Maesano I, Björkstén B, Bråbäck L, Büchele G, Chico M, Cooper P, Clausen M, El Sharif N, Martinez Gimeno A, Mathur RS, von Mutius E, Morales Suarez-Varela M, Pearce N, Svabe V, Wong GWK, Yu M, Zhong NS, Williams HC, ISAAC Phase Two Study Group. How well do questionnaires perform compared with physical examination in detecting flexural eczema? Findings from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. <i>Br J Dermatol.</i> 2009; 161(4): 846-53.	2005-2007	*	
United Kingdom	Muir MS, Brayne C. A longitudinal study in progress: a five-year follow-up of women aged 70-79 years living in a rural community. <i>Neuroepidemiology.</i> 1992; 11(Suppl 1): 67-70.	1982-1985	*	†
United Kingdom	Kennedy CR, Kimm L, Cafarelli Dees D. Controlled trial of universal neonatal screening for early identification of permanent childhood hearing impairment. <i>Lancet.</i> 1998; 352(9145): 1957-64.	1993-1996	*	
United Kingdom	Surman G, Newdick H, King A, Gallagher M, Kurinczuk JJ. 4Child: Four Counties Database of Cerebral Palsy, Vision Loss and Hearing Loss in Children. Annual Report 2009, including data for births 1984 to 2003. Oxford, United Kingdom: National Perinatal Epidemiology Unit, 2009.	1984-2003	*	
United Kingdom	Watkin P, Baldwin M. The longitudinal follow up of a universal neonatal hearing screen: the implications for confirming deafness in childhood. <i>Int J Audiol.</i> 2012; 51(7): 519-28.	1992-2002	*	
United Kingdom	Wang Y, Rudd AG, Wolfe CD. Age and ethnic disparities in incidence of stroke over time: the South London Stroke Register. <i>Stroke.</i> 2013; 44(12): 3298-304. [Unpublished data].	1995-2010	*	
United Kingdom	Markowe HL, Bulpitt CJ, Shipley MJ, Rose G, Crombie DL, Fleming DM. Prognosis in adult asthma: a national study. <i>Br Med J (Clin Res Ed).</i> 1987; 295(6604): 949-52.	1970-1976	*	
United Kingdom	Jones DA, Rathod KS, Sekhri N, Junghans C, Gallagher S, Rothman MT, Mohiddin S, Kapur A, Knight C, Archbold A, Jain AK, Mills PG, Uppal R, Mathur A, Timmis AD, Wragg A. Case fatality rates for South Asian and Caucasian patients show no difference 2.5 years after percutaneous coronary intervention. <i>Heart.</i> 2012; 98: 414-419.	2003-2008		†
United Kingdom	Capewell S, Murphy NF, MacIntyre K, Frame S, Stewart S, Chalmers JWT, Boyd J, Finlayson A, Redpath A, McMurray JJV. Short-term and long-term outcomes in 133,429 emergency patients admitted with angina or myocardial infarction in Scotland, 1990-2000: population-based cohort study. <i>Heart.</i> 2006; 92(11): 1563-1570.	1990-2001		†
United Kingdom	Zeitlan J, Mohangoo A. European Perinatal Health Report [Internet]. EURO-PERISTAT, SCPE, EUROCAT, EURONEOSTAT; 2008. Available from: http://www.perinataleaudit.nl/downloads/bestand/649/peristat-ii-2008-	2004		†
United Kingdom	Confidential Enquiry into Maternal and Child Health. Perinatal Mortality 2005: England, Wales and Northern Ireland. London: CEMACH; 2001 Apr p. 1-64.	2005		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United Kingdom	Jones RA, Cummins M, Davies PA. Infants of very low birthweight. A 15-year analysis. <i>Lancet</i> . 1979 Jun 23;1(8130):1332-5.	1963, 1968		†
United Kingdom	Pharoah PO, Alberman ED. Mortality of low birthweight infants in England and Wales 1953 to 1979. <i>Arch. Dis. Child</i> . 1981 Feb;56(2):86-9.	1965, 1971, 1974, 1977-1978		†
United Kingdom	Brown ER, Taeusch HW. Intensive care and the very low birthweight infant. <i>Lancet</i> . 1979 Aug 18;2(8138):362-3.	1973		†
United Kingdom	Mutch LM, Brown NJ, Speidel BD, Dunn PM. Perinatal mortality and neonatal survival in Avon: 1976-9. <i>Br Med J (Clin Res Ed)</i> . 1981 Jan 10;282(6258):119-22.	1977		†
United Kingdom	Tin W, Wariyar U, Hey E. Changing prognosis for babies of less than 28 weeks' gestation in the north of England between 1983 and 1994. Northern Neonatal Network. <i>BMJ</i> . 1997 Jan 11;314(7074):107-11.	1988, 1992, 1996, 2001		†
United Kingdom	Carlidge PH, Stewart JH. Survival of very low birthweight and very preterm infants in a geographically defined population. <i>Acta Paediatr</i> . 1997 Jan;86(1):105-10.	1993		†
United Kingdom	Wariyar U, Richmond S, Hey E. Pregnancy outcome at 24-31 weeks' gestation: neonatal survivors. <i>Arch. Dis. Child</i> . 1989 May;64(5):678-86.	1983	*	
United Kingdom	Lumley J, Kitchen WH, Roy RN, Yu VY, Drew JH. The survival of extremely-low-birthweight infants in Victoria: 1982-1985. <i>Med. J. Aust</i> . 1988 Sep 5;149(5):242, 244-6.	1984	*	
United Kingdom	United Kingdom - England UK Renal Registry (UKRR) Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
United Kingdom	United Kingdom - Wales UK Renal Registry (UKRR) Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
United Kingdom	United Kingdom - Northern Ireland UK Renal Registry (UKRR) Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
United Kingdom	United Kingdom - Northern Ireland UK Renal Registry (UKRR) Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
United Kingdom	United Kingdom - Wales UK Renal Registry (UKRR) Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011	*	
United Kingdom	United Kingdom - England UK Renal Registry (UKRR) Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010	*	
United Kingdom	United Kingdom - Scottish Renal Registry (SRR) Renal Replacement Therapy Data 2010 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2010. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2012.	2010		
United Kingdom	United Kingdom - Scottish Renal Registry (SRR) Renal Replacement Therapy Data 2011 - ERA-EDTA as it appears in European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). European Renal Association-European Dialysis and Transplant Association Registry Annual Report 2011. Parma, Italy: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), 2013.	2011		
United Kingdom	United Kingdom Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990	*	
United Kingdom	European Surveillance of Congenital Anomalies (EUROCAT). United Kingdom EUROCAT Prevalence Tables. Newtownabbey, Northern Ireland: European Surveillance of Congenital Anomalies (EUROCAT).	1980-2011	*	
United Kingdom	Scotland - Greater Glasgow NHS Board Congenital Anomalies Register Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT). International Centre on Birth Defects. World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
United Kingdom	United Kingdom - England and Wales National Congenital Anomaly System Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT). International Centre on Birth Defects. World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
United Kingdom	United Kingdom - Northern Ireland Malformation Registry Data 1980 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1980	*	
United Kingdom	United Kingdom - Northern Ireland Malformation Registry Data 1983 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1983	*	
United Kingdom	United Kingdom - England and Wales Congenital Malformation Monitoring Program Data 1980 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1980	*	
United Kingdom	United Kingdom - England and Wales Congenital Malformation Monitoring Program Data 1983 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1983	*	
United Kingdom	United Kingdom - England and Wales Congenital Malformation Monitoring Program Data 1986 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1986	*	
United Kingdom	United Kingdom - Wales Congenital Anomaly Register and Information Service Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
United Kingdom	United Kingdom - Northern Ireland Malformation Registry Data 1982 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1982	*	
United Kingdom	United Kingdom - Wales Congenital Anomaly Register and Information Service Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United Kingdom	United Kingdom - Wales Congenital Anomaly Register and Information System Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
United Kingdom	United Kingdom - Wales Congenital Anomaly Register and Information Service Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
United Kingdom	United Kingdom - England and Wales Congenital Malformation Monitoring Program Data 1987 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1987	*	
United Kingdom	United Kingdom - Northern Ireland Malformation Registry Data 1981 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1981	*	
United Kingdom	United Kingdom - Northern Ireland Malformation Registry Data 1985 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1985	*	
United Kingdom	United Kingdom - Wales Congenital Anomaly Register and Information System Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
United Kingdom	United Kingdom - Northern Ireland Malformation Registry Data 1984 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1984	*	
United Kingdom	United Kingdom - England Mersey Congenital Anomaly Survey Data 1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1998	*	
United Kingdom	United Kingdom - England and Wales Congenital Malformation Monitoring Program Data 1981 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1981	*	
United Kingdom	United Kingdom - England and Wales National Congenital Anomaly System Data 2001 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
United Kingdom	United Kingdom - England and Wales Congenital Malformation Monitoring Program Data 1988 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1988	*	
United Kingdom	United Kingdom - England and Wales National Congenital Anomaly System Data 2004 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
United Kingdom	United Kingdom - Wessex Antenatally Detected Anomalies Register Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008	*	
United Kingdom	United Kingdom - England and Wales Congenital Malformation Monitoring Program Data 1985 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1985	*	
United Kingdom	United Kingdom - England and Wales Congenital Malformation Monitoring Program Data 1984 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1984	*	
United Kingdom	United Kingdom - England North Thames (West) Congenital Malformation Register Data 1997-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1997-1998	*	
United Kingdom	United Kingdom - England and Wales Congenital Malformation Monitoring Program Data 1982 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1982	*	
United Kingdom	United Kingdom - Wessex Antenatally Detected Anomalies Register Data 2007 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
United Kingdom	United Kingdom - England and Wales National Congenital Anomaly System Data 2003 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
United States	Constella Group, National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), US Census Bureau. United States National Ambulatory Medical Care Survey 2002. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).	2002	*	
United States	National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), US Census Bureau. United States National Hospital Ambulatory Medical Care Survey 1992. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).	1992	*	
United States	United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality. National Survey on Drug Use and Health, 2010. ICPSR32722-v3. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2012-10-19. doi:10.3886/ICPSR32722.v3	2010	*	
United States	Centers for Disease Control and Prevention (CDC), United States Behavioral Risk Factor Surveillance System 1997. Atlanta, Georgia: CDC, US Department of Health and Human Services.	1997		
United States	Centers for Disease Control and Prevention (CDC), United States Behavioral Risk Factor Surveillance System 1996. Atlanta, Georgia: CDC, US Department of Health and Human Services.	1996		
United States	United States Vital Registration - Deaths 1988 ICD9 as it appears in World Health Organization (WHO). World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1988		
United States	United States Vital Registration - Deaths 1989 ICD9 as it appears in World Health Organization (WHO). World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1989		†
United States	United States Vital Registration - Deaths 1990 ICD9 as it appears in World Health Organization (WHO). World Health Organization (WHO). WHO Mortality Database Version July 2012. Geneva, Switzerland: World Health Organization (WHO), 2012.	1990	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	Constella Group, National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), US Census Bureau. United States National Ambulatory Medical Care Survey 2004. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).	2004		
United States	Constella Group, National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), US Census Bureau. United States National Ambulatory Medical Care Survey 2005. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).	2005		
United States	Constella Group, National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), US Census Bureau. United States National Ambulatory Medical Care Survey 2006. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).	2006		
United States	National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), SRA International, Inc., US Census Bureau. United States National Ambulatory Medical Care Survey 2007. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).	2007		
United States	National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), SRA International, Inc., US Census Bureau. United States National Ambulatory Medical Care Survey 2008. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).	2008		
United States	National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), SRA International, Inc., US Census Bureau. United States National Ambulatory Medical Care Survey 2009. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).	2009		
United States	Analytical Sciences, Inc., National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), US Census Bureau. United States National Ambulatory Medical Care Survey 2001. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).	2001		
United States	Analytical Sciences, Inc., National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), US Census Bureau. United States National Ambulatory Medical Care Survey 2000. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).	2000		
United States	Analytical Sciences, Inc., National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), US Census Bureau. United States National Ambulatory Medical Care Survey 1999. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).	1999		
United States	Analytical Sciences, Inc., National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), US Census Bureau. United States National Ambulatory Medical Care Survey 1998. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).	1998		
United States	Analytical Sciences, Inc., National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), US Census Bureau. United States National Ambulatory Medical Care Survey 1997. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).	1997		
United States	Analytical Sciences, Inc., National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), US Census Bureau. United States National Ambulatory Medical Care Survey 1996. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).	1996	*	
United States	Analytical Sciences, Inc., National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), US Census Bureau. United States National Ambulatory Medical Care Survey 1995. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).	1995	*	
United States	National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), US Census Bureau. United States National Ambulatory Medical Care Survey 1994. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).	1994		
United States	National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), US Census Bureau. United States National Ambulatory Medical Care Survey 1993. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).	1993	*	
United States	United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Survey on Drug Use and Health, 2005. ICPSR04596-v3. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2013-01-22. doi:10.3886/ICPSR04596.v3	2005		
United States	United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Household Survey on Drug Abuse, 2000. ICPSR03262-v4. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2006-12-07. doi:10.3886/ICPSR03262.v4	2000		
United States	United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Household Survey on Drug Abuse, 1994. ICPSR06949-v1. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2008-10-28. doi:10.3886/ICPSR06949.v1	1994		
United States	United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Survey on Drug Use and Health, 2002. ICPSR03903-v3. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2006-10-26. doi:10.3886/ICPSR03903.v3	2002		
United States	United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Survey on Drug Use and Health, 2003. ICPSR04138-v2. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2006-10-17. doi:10.3886/ICPSR04138.v2	2003		
United States	United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Survey on Drug Use and Health, 2004. ICPSR04373-v1. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2006-05-12. doi:10.3886/ICPSR04373.v1	2004	*	
United States	United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Survey on Drug Use and Health, 2006. ICPSR21240-v5. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2013-01-07. doi:10.3886/ICPSR21240.v5	2006	*	
United States	United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Survey on Drug Use and Health, 2009. ICPSR29621-v3. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2012-11-16. doi:10.3886/ICPSR29621.v3	2009		
United States	United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality. National Survey on Drug Use and Health, 2011. ICPSR34481-v1. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2012-11-28. doi:10.3886/ICPSR34481.v1	2011		
United States	United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Survey on Drug Use and Health, 2007. ICPSR23782-v3. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2013-01-04. doi:10.3886/ICPSR23782.v3	2007		
United States	Centers for Disease Control and Prevention (CDC). United States Behavioral Risk Factor Surveillance System 2010. Atlanta, Georgia: CDC, US Department of Health and Human Services.	2010		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	Vaziri S, Larson M, Benjamin E, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. <i>Circulation</i> . 1994; 89(2): 724-730.	1980-1981		
United States	Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent Risk Factors for Atrial Fibrillation in a Population-Based Cohort. <i>JAMA</i> . 1994; 271(11): 840-844.	1980-1986		
United States	Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson P, Benjamin EJ, D'Agostino RB. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. <i>N Engl J Med</i> . 1994; 331(19): 1249-52.	1980		
United States	Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). <i>Am J Cardiol</i> . 1994; 74(3): 236-41.	1989-1992		
United States	Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention. <i>JAMA</i> . 2001; 285(18): 2370-2375.	1996-1997		
United States	Mitchell GF, Vasan RS, Keyes MJ, Parise H, Wang TJ, Larson MG, D'Agostino RB, Kannel WB, Levy D, Benjamin EJ. Pulse Pressure and Risk of New-Onset Atrial Fibrillation. <i>JAMA</i> . 2007; 297(7): 709-715.	1980-2004		
United States	Borzecki AM, Bridgers DK, Liebschutz JM, Kader B, Kazis LE, Berlowitz DR. Racial differences in the prevalence of atrial fibrillation among males. <i>J Natl Med Assoc</i> . 2008; 100(2): 237-45.	1999-2000		
United States	Upshaw CB. Reduced prevalence of atrial fibrillation in black patients compared with white patients attending an urban hospital: an electrocardiographic study. <i>J Natl Med Assoc</i> . 2002; 94(4): 204-8.	1996-1998		
United States	Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TSM. Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence. <i>Circulation</i> . 2006; 114(2): 119-125.	1980-2000		
United States	Wolf PA, Benjamin EJ, Belanger AJ, Kannel WB, Levy D, D'Agostino RB. Secular trends in the prevalence of atrial fibrillation: The Framingham study. <i>Am Heart J</i> . 1996; 131(4): 790-5.	1980-1989		
United States	Centre for Health Informatics and Multiprofessional Education, University College London. <i>Modell's Haemoglobinopathologist's Almanac</i> . London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	2003		
United States	Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease Life expectancy and risk factors for early death. <i>N Engl J Med</i> . 1994; 330(23): 1639-44.	1978-1992		†
United States	Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. <i>Blood</i> . 2004; 103(11): 4023-7.	1983-2002		
United States	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	2009		
United States	Sarma AV, Jacobson DJ, McGree ME, Roberts RO, Lieber MM, Jacobsen SJ. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota. <i>J Urol</i> . 2005; 173(6): 2048-53.	1987-1997		
United States	Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, Lieber MM. The prevalence of prostatism: a population-based survey of urinary symptoms. <i>J Urol</i> . 1993; 150(1): 85-9.	1990		
United States	Kristal AR, Arnold KB, Schenk JM, Neuhaus ML, Goodman P, Penson DF, Thompson IM. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. <i>J Epidemiol</i> . 2008; 167(8): 925-34.	1994-2003		
United States	Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O'Leary MP, Pappas P, Robertson C, Giuliano F. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male. <i>Eur Urol</i> . 2003; 44(6): 637-49.	2001		
United States	Moon TD, Brannan W, Stone NN, Ercole C, Crawford ED, Chodak G, Brawer M, Heisey D, Bruskewitz RC. Effect of age, educational status, ethnicity and geographic location on prostate symptom scores. <i>J Urol</i> . 1994; 152(5 pt 1): 1498-500.	1991		
United States	Sidney S. Vasectomy and the risk of prostatic cancer and benign prostatic hypertrophy. <i>J Urol</i> . 1987; 138(4): 795-7.	1977-1982		
United States	Arrighi HM, Guess HA, Metter EJ, Fozard JL. Symptoms and signs of prostatism as risk factors for prostatectomy. <i>Prostate</i> . 1990; 16(3): 253-61.	1958-1988		
United States	Anger JT, Saigal CS, Wang M, Yano EM. Urologic disease burden in the United States: Veteran users of Department of Veterans Affairs healthcare. <i>Urology</i> . 2008; 72(1): 37-41.	2001		
United States	Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, Noyes J, Lewis E, Ray P, Lee J, Hackell J. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. <i>Pediatr Infect Dis J</i> . 2002; 21(9): 810-5.	1995-1999		
United States	Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM. Congestive heart failure in the community: trends in incidence and survival in a 10-year period. <i>Arch Intern Med</i> . 1999; 159(1): 29-34.	1981, 1991		
United States	Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. <i>Circulation</i> . 1998; 98(21): 2282-9.	1981, 1991		
United States	The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. <i>N Engl J Med</i> . 1997; 336(8): 525-33.	1991-1993		
United States	Santosham M, Sack RB, Reid R, Black R, Croll J, Yolken R, Aurelian L, Wolff M, Chan E, Garrett S. Diarrhoeal diseases in the White Mountain Apaches: epidemiologic studies. <i>J Diarrhoeal Dis Res</i> . 1995; 13(1): 18-28.	1981-1985		
United States	Bardenheier B, Prevots DR, Khetsuriani N, Wharton M, Centers for Disease Control and Prevention (CDC). Tetanus Surveillance - United States 1995-1997. <i>MMWR CDC Surveill Summ</i> . 1998; 47(2): 1-13.	1995-1997		
United States	Centers for Disease Control and Prevention (CDC). Tetanus surveillance—United States, 2001-2008. <i>Morb Mortal Wkly Rep</i> . 2011; 60(12): 365-9.	1998-2008		
United States	Izurieta HS, Sutter RW, Strebel PM, Bardenheier B, Prevots DR, Wharton M, Hadler SC, Centers for Disease Control and Prevention (CDC). Tetanus Surveillance - United States 1991-1994. <i>MMWR CDC Surveill Summ</i> . 1997; 46(2): 15-25.	1991-1994		
United States	Nelson SM, Berry RI. Ear disease and hearing loss among Navajo children—a mass survey. <i>Laryngoscope</i> . 1984; 94(3): 316-23.	1978-1980		
United States	Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. <i>J Infect Dis</i> . 1989; 160(1): 83-94.	1975-1984		
United States	Teele DW, Klein JO, Rosner BA. Epidemiology of otitis media in children. <i>Ann Otol Rhinol Laryngol Suppl</i> . 1980; 89(1): 5-6.	1975-1979		
United States	Todd NW Jr, Bowman CA. Otitis media at Canyon Day, Ariz A 16-year follow-up in Apache Indians. <i>Arch Otolaryngol</i> . 1985; 111(9): 606-8.	1967, 1983		
United States	Broderick J, Brott T, Kothari R, Miller R, Khoury J, Pancioli A, Gebel J, Mills D, Minneci L, Shukla R. The Greater Cincinnati/Northern Kentucky Stroke Study: Preliminary First-Ever and Total Incidence Rates of Stroke Among Blacks. <i>Stroke</i> . 1998; 29(2): 415-21.	1999		
United States	Earley CJ, Kitterer SJ, Feeser BR, Gardner J, Epstein A, Wozniak MA, Wityk R, Stern BJ, Price TR, Macko RF, Johnson C, Sloan MA, Buchholz D. Stroke in children and sickle-cell disease: Baltimore-Washington Cooperative Young Stroke Study. <i>Neurology</i> . 1998; 51(1): 169-76.	1988-1991		
United States	Mallick AA, O'Callaghan FJK. The epidemiology of childhood stroke. <i>Eur J Paediatr Neurol</i> . 2010; 14(3): 197-205.	1980-2003		
United States	Laughter D, Istrvan JA, Tofte SJ, Hanifin JM. The prevalence of atopic dermatitis in Oregon schoolchildren. <i>J Am Acad Dermatol</i> . 2000; 43(4): 649-55.	1999	*	
United States	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. <i>J Allergy Clin Immunol</i> . 2008; 121(4): 947-954.	1995, 2003		
United States	Centers for Disease Control and Prevention (CDC). United States Behavioral Risk Factor Surveillance System 2012. Atlanta, Georgia: CDC, US Department of Health and Human Services, 2013.	2012		
United States	Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality (AHRQ). United States Nationwide Inpatient Sample 1988. Rockville, United States: Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality (AHRQ).	1988		
United States	Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality (AHRQ). United States Nationwide Inpatient Sample 1989. Rockville, United States: Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality (AHRQ).	1989		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality (AHRQ). United States Nationwide Inpatient Sample 1999. Rockville, United States: Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality (AHRQ).	1990		
United States	Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality (AHRQ). United States Nationwide Inpatient Sample 2005. Rockville, United States: Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality (AHRQ).	2005		
United States	Yorita KL, Holman RC, Steiner CA, Effler PV, Miyamura J, Forbes S, Anderson LJ, Balaraman V. Severe bronchiolitis and respiratory syncytial virus among young children in Hawaii. <i>Pediatr Infect Dis J</i> . 2007; 12(26): 1081-8.	1997-2004		
United States	Goldberg RJ, Ciampa J, Lessard D, Meyer TE, Spencer FA. Long-term Survival After Heart Failure: A Contemporary Population-Based Perspective. <i>Arch Intern Med</i> . 2007; 167(5): 490-6.	2000		
United States	Kannel WB, Belanger AJ. Epidemiology of heart failure. <i>Am Heart J</i> . 1991; 121(3 Part 1): 951-7.	1956-1990		
United States	Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KKL, Murabito JM, Vasan RS. Long-term trends in the incidence of and survival with heart failure. <i>N Engl J Med</i> . 2002; 347(18): 1397-402.	1980-1999		
United States	Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Roger VL, Stafford R, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. <i>Circulation</i> . 2010; 121(7): e46-e215.	2003-2006		
United States	Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart Failure Incidence and Survival (from the Atherosclerosis Risk in Communities Study). <i>Am J Cardiol</i> . 2008; 101(7): 1016-22.	1987-2002		
United States	Mozaffarian D, Anker SD, Anand I, Linker DT, Sullivan MD, Cleland JGF, Carson PE, Maggioni AP, Mann DL, Pitt B, Poole-Wilson PA, Levy WC. Prediction of Mode of Death in Heart Failure. <i>Circulation</i> . 2007; 116(4): 392-8.	1985-2003		
United States	Ni H. Prevalence of self-reported heart failure among US adults: results from the 1999 National Health Interview Survey. <i>Am Heart J</i> . 2003; 146(1): 121-8.	1999		
United States	Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ. Trends in Heart Failure Incidence and Survival in a Community-Based Population JAMA: The Journal of the American Medical Association. <i>JAMA</i> . 2004; 292(3): 344-50.	1985-2000		
United States	National Heart, Lung, and Blood Institute, National Institutes of Health. Incidence and Prevalence: 2006 Chart Book on Cardiovascular and Lung Diseases. Bethesda, United States: National Institutes of Health (NIH), 2006.	1980-2003		
United States	Wiberg K, Birnbaum A, Gradon J. Causes and presentation of meningitis in a Baltimore community hospital 1997-2006. <i>South Med J</i> . 2008; 101(10): 1012-6.	1997-2006		
United States	Demyttenaere K, Bruffaerts R, Lee S, Posada-Villa J, Kovess V, Angermeyer MC, Levinson D, de Girolamo G, Nakane H, Mneimneh Z, Lara C, de Graaf R, Scott KM, Gureje O, Stein DJ, Haro JM, Bromet EJ, Kessler RC, Alonso J, Von Korff M. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. <i>Pain</i> . 2007; 129(3): 332-42.	2002-2003		
United States	Strine TW, Hootman JM. US national prevalence and correlates of low back and neck pain among adults. <i>Arthritis Rheum</i> . 2007; 57(4): 656-65.	2002		
United States	Von Korff M, Crane P, Lane M, Miglioretti DL, Simon G, Saunders K, Stang P, Brandenburg N, Kessler R. Chronic spinal pain and physical-mental comorbidity in the United States: results from the national comorbidity survey replication. <i>Pain</i> . 2005; 113(3): 331-9.	2001-2002		
United States	Ford ES, Giles WH, Croft JB. Prevalence of nonfatal coronary heart disease among American adults. <i>Am Heart J</i> . 2000; 139(3): 371-7.	1980-1994		
United States	Mozaffarian D, Bryson CL, Spertus JA, McDonell MB, Fihn SD. Anginal symptoms consistently predict total mortality among outpatients with coronary artery disease. <i>Am Heart J</i> . 2003; 146(6): 1015-22.	1980-2000		
United States	Saftlas AF, Olson DR, Franks AL, Atrash HK, Pokras R. Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986. <i>Am J Obstet Gynecol</i> . 1990; 163(2): 460-5.	1979-1986		
United States	Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease. <i>Pediatrics</i> . 1989; 3(84): 500-8.	1979-1987		
United States	Shankar SM, Arbogast PG, Mitchel E, Cooper WO, Wang WC, Griffin MR. Medical care utilization and mortality in sickle cell disease: A population-based study. <i>Am J Hematol</i> . 2005; 4(80): 262-70.	1995-2002		
United States	Harris RB, Griffith K, Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996. <i>J Am Acad Dermatol</i> . 2001; 45(4): 528-36.	1985, 1989, 1993, 1996		
United States	Christenson LJ, Borrowman TA, Vachon CM, Tollefson MM, Otley CC, Weaver AL, Roenigk RK. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. <i>JAMA</i> . 2005; 294(6): 681-90.	1990-2003		
United States	Safavi K. Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. <i>Arch Dermatol</i> . 1992; 128(5): 702.	1971-1974	*	
United States	Vichinsky EP, MacKlin EA, Waye JS, Lorey F, Olivieri NF. Changes in the Epidemiology of Thalassemia in North America: A New Minority Disease. <i>Pediatrics</i> . 2005; 116(6): 1536.	1977-1985, 1990-2002		
United States	National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC). United States National Health and Nutrition Examination Survey 2011-2012. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), 2013.	2011-2012		
United States	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1996		
United States	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998, 2000-2003, 2008		
United States	Arroondee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? <i>J Rheumatol</i> . 2002; 29(11): 2403-6.	1977-1978, 1995-1996		
United States	Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. <i>N Engl J Med</i> . 2004; 350(11): 1093-103.	1986-1998		
United States	Hochberg MC, Thomas J, Thomas DJ, Mead L, Levine DM, Klag MJ. Racial differences in the incidence of gout. The role of hypertension. <i>Arthritis Rheum</i> . 1995; 38(5): 628-32.	1957-1992		
United States	Roubenoff R, Klag MJ, Mead LA, Liang KY, Seidler AJ, Hochberg MC. Incidence and risk factors for gout in white men. <i>JAMA</i> . 1991; 266(21): 3004-7.	1950-1989		
United States	Novak S, Melkonian AK, Patel PA, Kleinman NL, Joseph-Ridge N, Brook RA. Metabolic syndrome-related conditions among people with and without gout: prevalence and resource use. <i>Curr Med Res Opin</i> . 2007; 23(3): 623-30.	2001-2004		
United States	Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. <i>J Rheumatol</i> . 2004; 31(8): 1582-7.	1990-1999		
United States	Adams PF, Hardy AM. National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC). Current Estimates from the National Health Interview Survey, 1988. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), 1989. (Vital and Health Statistics, Series 10; no. 173).	1988		
United States	Collins JG. National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC). Prevalence of selected chronic conditions, United States, 1983-85. Hyattsville, MD: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC); 1988. 16 p. (Advance data From vital and health statistics; No. 155. DHHS Pub. No. (PHS) 88-1250. Public Health Service).	1983-1985		
United States	Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. <i>Arthritis Rheum</i> . 2011; 63(10): 3136-41.	2007-2008		
United States	Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. <i>Am J Kidney Dis</i> . 2002; 40(1): 37-42.	1988-1994		
United States	Curb JD, Reed DM, Miller FD, Yano K. Health status and life style in elderly Japanese men with a long life expectancy. <i>J Gerontol</i> . 1990; 45(5): S206-211.	1980-1982		
United States	Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH, MRFIT Research Group. Long-term cardiovascular mortality among middle-aged men with gout. <i>Arch Intern Med</i> . 2008; 168(10): 1104-10.	1982-1999		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. <i>Am J Respir Crit Care Med.</i> 1994; 150(4): 967-72.	1988-1990		
United States	Cragin LA, Laney AS, Lohft CJ, Martin B, Pandiani JA, Blevins LZ. Use of insurance claims data to determine prevalence and confirm a cluster of sarcoidosis cases in Vermont. <i>Public Health Rep.</i> 2009; 124(3): 442-6.	2004-2005		
United States	Fernández Pérez ER, Daniels CE, Schroeder DR, St Sauver J, Hartman TE, Bartholmai BJ, Yi ES, Ryu JH. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. <i>Chest.</i> 2010; 137(1): 129-37.	1997-2005		
United States	Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. <i>Am J Respir Crit Care Med.</i> 2006; 174(7): 810-6.	1998-2000		
United States	Wynn DR, Rodriguez M, OFallon WM, Kurland LT. A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota. <i>Neurology.</i> 1990; 40(5): 780-6.	1975-1985		
United States	Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. <i>Neurology.</i> 2003; 61(10): 1373-7.	1985-2000		
United States	Malmgren RM, Dudley JP, Visscher BR, Valdiviezo NL, Clark VA, Detels R. Mortality in persons with multiple sclerosis in the Seattle and Los Angeles areas. <i>JAMA.</i> 1981; 246(18): 2042-5.	1970-1979		
United States	Hopkins RS, Indian RW, Pinnow E, Conomy J. Multiple sclerosis in Galion, Ohio: prevalence and results of a case-control study. <i>Neuroepidemiology.</i> 1991; 10(4): 192-9.	1987		
United States	Helmsick CG, Wrigley JM, Zack MM, Bigler WJ, Lehman JL, Janssen RS, Hartwig EC, Witte JJ. Multiple sclerosis in Key West, Florida. <i>Am J Epidemiol.</i> 1989; 130(5): 935-49.	1985		
United States	Goodin DS, Reeder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, DeSimone TM, Knappertz V. Survival in MS A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. <i>Neurology.</i> 2012; 78(17): 1315-22.	1988-2010		†
United States	Hader WJ, Seland TP, Hader MB, Harris CJ, Dietrich DW. The occurrence of multiple sclerosis in the Hutterites of North America. <i>Can J Neurol Sci.</i> 1996; 23(4): 291-5.	1990		
United States	Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Weigand SD, Noseworthy JH, Rodriguez M. Disability profile of MS did not change over 10 years in a population-based prevalence cohort. <i>Neurology.</i> 2004; 62(4): 601-6.	1991, 2000		
United States	Detels R, Visscher BR, Malmgren RM, Coulson AH, Lucia MV, Dudley JP. Evidence for Lower Susceptibility to Multiple Sclerosis in Japanese-Americans. <i>Am J Epidemiol.</i> 1977; 105(4): 303-10.	1970		
United States	Nelson LM, Hamman RF, Thompson DS, Baum HM, Boteler DL, Burks JS, Franklin GM. Higher than Expected Prevalence of Multiple Sclerosis in Northern Colorado: Dependence on Methodologic Issues. <i>Neuroepidemiology.</i> 1986; 5(1): 17-28.	1982		
United States	Hoffman RE, Zack MM, Davis LE, Burchfiel CM. Increased incidence and prevalence of multiple sclerosis in Los Alamos County, New Mexico. <i>Neurology.</i> 1981; 31(11): 1489-1489.	1970-1979		
United States	Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. <i>Neurology.</i> 2002; 58(1): 136-8.	1989-1994		
United States	Baum HM, Rothschild BB. The incidence and prevalence of reported multiple sclerosis. <i>Ann Neurol.</i> 1981; 10(5): 420-8.	1976		
United States	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
United States	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Thorax.</i> 2009; 64(6): 476-483.	2002		
United States	Guerra S, Wright AL, Morgan WJ, Sherrill DL, Holberg CJ, Martinez FD. Persistence of Asthma Symptoms during Adolescence Role of Obesity and Age at the Onset of Puberty. <i>Am J Respir Crit Care Med.</i> 2004; 170(1): 78-85.	1980-1984	*	†
United States	National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC). United States National Health and Nutrition Examination Survey 2005-2008. National Center for Health Statistics (NCHS).	2005-2008		
United States	Agency for Healthcare Research and Quality. United States Medical Expenditure Panel Survey 2011. Agency for Healthcare Research and Quality.	2011		
United States	Hartsfield CL, Komer EJ, Ellis JL, Raebel MA, Merenich J, Brandenburg N. Painful diabetic peripheral neuropathy in a managed care setting: patient identification, prevalence estimates, and pharmacy utilization patterns. <i>Popul Health Manag.</i> 2008; 11(6): 317-28.	1998-2003		
United States	Candrilli SD, Davis KL, Kan HJ, Lucero MA, Roussculp MD. Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy. <i>J Diabet Complications.</i> 2007; 21(5): 306-14.	1999-2002		
United States	Gregg EW, Sorlie P, Paulose-Ram R, Gu Q, Eberhardt MS, Wolz M, Burr V, Curtin L, Engelgau M, Geiss L. Prevalence of lower-extremity disease in the US adult population ≥40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. <i>Diabetes Care.</i> 2004; 27(7): 1591-7.	1999-2000		
United States	Franklin GM, Kahn LB, Baxter J, Marshall JA, Hamman RF. Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley Diabetes Study. <i>Am J Epidemiol.</i> 1990; 131(4): 633-43.	1984-1986		
United States	Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, Wilson DM, O'Brien PC, Melton LJ 3rd, Service FJ. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. <i>Neurology.</i> 1993; 43(4): 817-24.	1986-1992		
United States	Wong TY, Klein R, Islam FM, Cotch MF, Folsom AR, Klein BE, Sharrett AR, Shea S. Diabetic retinopathy in a multi-ethnic cohort in the United States. <i>Am J Ophthalmol.</i> 2006; 141(3): 446-455.	2002-2004		
United States	Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, Geiss LS, Gregg EW, Albright AL, Klein BE, Klein R. Prevalence of diabetic retinopathy in the United States, 2005-2008. <i>JAMA.</i> 2010; 304(6): 649-56.	2005-2006		
United States	Klein R, Sharrett AR, Klein BE, Moss SE, Folsom AR, Wong TY, Brancati FL, Hubbard LD, Couper D; ARIC Group. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study. <i>Ophthalmology.</i> 2002; 109(7): 1225-34.	1993-1995		
United States	Leibson CL, Burke JP, Ransom JE, Forsgren J, Melton J, Bailey KR, Palumbo PJ. Relative risk of mortality associated with diabetes. <i>Diabetes Care.</i> 2005; 28(12): 2839-43.	1960-1995		
United States	Bertoni AG, Krop JS, Anderson GF, Brancati FL. Diabetes-related morbidity and mortality in a national sample of U.S. elders. <i>Diabetes Care.</i> 2002; 25(3): 471-5.	1994		
United States	National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), SRA International, Inc., US Census Bureau. United States National Hospital Ambulatory Medical Care Survey 2010. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).	2010		
United States	Ellis Simonsen SM, van Orman ER, Hatch BE, Jones SS, Gren LH, Hegmann KT, Lyon JL. Cellulitis incidence in a defined population. <i>Epidemiol Infect.</i> 2006; 134(2): 293-299.	1997-2002		
United States	National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), SRA International, Inc., US Census Bureau. United States National Ambulatory Medical Care Survey 2010. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).	2010		
United States	Kryst S, Scherl E. A population-based survey of the social and personal impact of headache. <i>Headache.</i> 1994; 34(6): 344-50.	1990-1991		
United States	Linet MS, Stewart WF, Celentano DD, Ziegler D, Sprecher M. An epidemiologic study of headache among adolescents and young adults. <i>JAMA.</i> 1989; 261(15): 2211-6.	1986-1987		
United States	Cook NR, Evans DA, Funkenstein HH, Scherr PA, Ostfeld AM, Taylor JO, Hennekens CH. Correlates of headache in a population-based cohort of elderly. <i>Arch Neurol.</i> 1989; 46(12): 1338-44.	1982-1983		
United States	Carson AP, Carson ALP, Rose KM, Sanford CP, Ephross SA, Stang PE, Hunt KJ, Brown CA, Szklo M. Lifetime prevalence of migraine and other headaches lasting 4 or more hours: the Atherosclerosis Risk in Communities (ARIC) study. <i>Headache.</i> 2004; 44(1): 20-8.	1993-1995		
United States	Bigal ME, Lipton RB, Winner P, Reed ML, Diamond S, Stewart WF. AMPP advisory group. Migraine in adolescents: association with socioeconomic status and family history. <i>Neurology.</i> 2007; 69(1): 16-25.	2004		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. <i>Neurology</i> . 2002; 58(6): 885-94.	1998		
United States	Breslau N, Davis GC, Andreski P. Migraine, psychiatric disorders, and suicide attempts: an epidemiologic study of young adults. <i>Psychiatry Res</i> . 1991; 37(1): 11-23.	1989		
United States	Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. <i>Headache</i> . 2001; 41(7): 646-57.	1999		
United States	Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. <i>JAMA</i> . 1992; 267(1): 64-9.	1989		
United States	Stewart WF, Lipton RB, Liberman J. Variation in migraine prevalence by race. <i>Neurology</i> . 1996; 47(1): 52-9.	1993-1994		
United States	Beauregard S, Gilchrist BA. A survey of skin problems and skin care regimens in the elderly. <i>Arch Dermatol</i> . 1987; 123(12): 1638-43.	1985-1987		
United States	Cunningham LS, Kelsey JL. Epidemiology of musculoskeletal impairments and associated disability. <i>Am J Public Health</i> . 1984; 74(6): 574-9.	1971-1975		
United States	Oliveria SA, Felson DT, Reed JL, Cirillo PA, Walker AM. Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. <i>Arthritis Rheum</i> . 1995; 38(8): 1134-41.	1988-1992		
United States	Wilson MG, Michet CJ Jr, Istrup DM, Melton LJ 3rd. Idiopathic symptomatic osteoarthritis of the hip and knee: a population-based incidence study. <i>Mayo Clin Proc</i> . 1990; 65(9): 1214-21.	1985		
United States	Jordan JM, Helmiak CG, Renner JB, Luta G, Dragomir AD, Woodard J, Fang F, Schwartz TA, Nelson AE, Abbate LM, Callahan LF, Kalsbeek WD, Hochberg MC. Prevalence of hip symptoms and radiographic and symptomatic hip osteoarthritis in African Americans and Caucasians: the Johnston County Osteoarthritis Project. <i>J Rheumatol</i> . 2009; 36(4): 809-15.	1991-1997		
United States	Grubber JM, Callahan LF, Helmiak CG, Zack MM, Pollard RA. Prevalence of radiographic hip and knee osteoarthritis by place of residence. <i>J Rheumatol</i> . 1998; 25(5): 959-63.	1971-1975		
United States	Tepper S, Hochberg MC. Factors associated with hip osteoarthritis: data from the First National Health and Nutrition Examination Survey (NHANES-I). <i>Am J Epidemiol</i> . 1993; 137(10): 1081-8.	1971-1975		
United States	Christmas C, Crespo CJ, Franckowiak SC, Bathon JM, Bartlett SJ, Andersen RE. How common is hip pain among older adults? Results from the Third National Health and Nutrition Examination Survey. <i>J Fam Pract</i> . 2002; 51(4): 345-8.	1988-1994	*	
United States	Corononi-Huntley J, Huntley RR, Feldman JJ, editors. <i>Health Status and Well-being of the Elderly: National Health and Nutrition Examination Survey—Epidemiologic Follow-up Study</i> . New York: Oxford University Press; 1990. 320 p.	1971-1975	*	
United States	Akinbami LJ, Lynch CD, Parker JD, Woodruff TJ. The association between childhood asthma prevalence and monitored air pollutants in metropolitan areas. <i>United States, 2001-2004</i> . <i>Environ Res</i> . 2010; 110(3): 294-301.	2001-2004	*	
United States	Barry AC, Mannino DM, Hopenhayn C, Bush H. Exposure to indoor biomass fuel pollutants and asthma prevalence in Southeastern Kentucky: results from the Burden of Lung Disease (BOLD) study. <i>J Asthma</i> . 2010; 47(7): 735-41.	2007-2009	*	
United States	Eaton DK, Kann L, Kinchen S, Shanklin S, Flint KH, Hawkins J, Harris WA, Lowry R, McManus T, Chyen D, Whittle L, Lim C, Wechsler H. Centers for Disease Control and Prevention (CDC). Youth Risk Behavior Surveillance - United States 2011. <i>MMWR Surveill Summ</i> . 2012; 61(4): 1-162.	2011	*	
United States	Frazier JC, Loveland KM, Zimmerman HJ, Helgeson SD, Harwell TS. Prevalence of asthma among adults in metropolitan versus nonmetropolitan areas in Montana, 2008. <i>Prev Chronic Dis</i> . 2012; E09.	2008	*	
United States	Hughes E, Gilmer G, Li Y, Valluru B, Brown J, Colclough G, Geathers S, Roberts H, Elam-Evans L, Balluz L, Centers for Disease Control and Prevention (CDC). Surveillance for Certain Health Behaviors Among States and Selected Local Areas - United States, 2008. <i>MMWR Surveill Summ</i> . 2010; 59(10): 1-221.	2008	*	
United States	Li C, Balluz LS, Okoro CA, Strine TW, Lin JMS, Town M, Garvin W, Murphy W, Bartoli W, Valluru B, Centers for Disease Control and Prevention (CDC). Surveillance of Certain Health Behaviors and Conditions Among States and Selected Local Areas - Behavioral Risk Factor Surveillance System, United States 2009. <i>MMWR Surveill Summ</i> . 2011; 60(9): 1-250.	2009	*	
United States	Ma J, Xiao L, Knowles SB. Obesity, insulin resistance and the prevalence of atopy and asthma in US adults. <i>Allergy</i> . 2010; 65(11): 1455-63.	2005-2006	*	
United States	Moorman JE, Zahran H, Truman BI, Molla MT, Centers for Disease Control and Prevention (CDC). Current Asthma Prevalence - United States, 2006-2008. <i>MMWR Surveill Summ</i> . 2011; 60(01): 84-6.	2006-2008	*	
United States	Nachman KE, Parker JD. Exposures to fine particulate air pollution and respiratory outcomes in adults using two national datasets: a cross-sectional study. <i>Environ Health</i> . 2012; 25.	2002-2005	*	
United States	Oraka E, Iqbal S, Flanders WD, Brinker K, Garbe P. Racial and ethnic disparities in current asthma and emergency department visits: findings from the National Health Interview Survey, 2001-2010. <i>J Asthma</i> . 2013; 50(5): 488-96.	2001-2010	*	
United States	Oraka E, King ME, Callahan DB. Asthma and serious psychological distress: prevalence and risk factors among US adults, 2001-2007. <i>Chest</i> . 2010; 137(3): 609-16.	2001-2007	*	
United States	Sun Y, Sundell J. Life style and home environment are associated with racial disparities of asthma and allergy in Northeast Texas children. <i>Sci Total Environ</i> . 2011; 409(20): 4229-34.	2008-2009	*	
United States	Teramoto M, Moonie S. Physical activity participation among adult Nevadans with self-reported asthma. <i>J Asthma</i> . 2011; 48(5): 517-22.	2009	*	
United States	Xu F, Town M, Balluz LS, Bartoli WP, Murphy W, Chowdhury PP, Garvin WS, Pierannunzi C, Zhong Y, Salandy SW, Jones CK, Crawford CA. Centers for Disease Control and Prevention (CDC). Surveillance for Certain Health Behaviors Among States and Selected Local Areas - United States, 2010. <i>MMWR Surveill Summ</i> . 2013; 62(1): 1-247.	2010	*	
United States	National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC). Asthma Prevalence, Health Care Use, and Mortality: United States, 2005-2009. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), 2011. (National Statistics Health Reports; no. 32).	2009	*	
United States	Simons WR, Rosenblatt LC, Trivedi DN. The economic consequences of rheumatoid arthritis: analysis of Medical Expenditure Panel Survey 2004, 2005, and 2006 data. <i>J Occup Environ Med</i> . 2012; 54(1): 48-55.	2004-2006	*	
United States	Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, Davis JM 3rd, Hunder GG, Therau TM, Gabriel SE. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. <i>Arthritis Rheum</i> . 2011; 63(3): 633-9.	1995-2007	*	
United States	Goode AP, Marshall SW, Renner JB, Carey TS, Kraus VB, Irwin DE, Stürmer T, Jordan JM. Lumbar spine radiographic features and demographic, clinical, and radiographic knee, hip, and hand osteoarthritis. <i>Arthritis Care Res (Hoboken)</i> . 2012; 64(10): 1536-44.	2003-2004	*	
United States	Ford ES, Croft JB, Posner SF, Goodman RA, Giles WH. Co-occurrence of leading lifestyle-related chronic conditions among adults in the United States, 2002-2009. <i>Prev Chronic Dis</i> . 2013; E60.	2002-2009	*	
United States	Centers for Disease Control and Prevention (CDC). Chronic Obstructive Pulmonary Disease Among Adults - United States, 2011. <i>MMWR Morb Mortal Wkly Rep</i> . 2012; 61(46): 938-43.	2011	*	
United States	Oraka E, Kim HJE, King ME, Callahan DB. Asthma prevalence among US elderly by age groups: age still matters. <i>J Asthma</i> . 2012; 49(6): 593-9.	2001-2010	*	
United States	Diaz-Guzman E, Khosravi M, Mannino DM. Asthma, chronic obstructive pulmonary disease, and mortality in the U.S. population. <i>COPD</i> . 2011; 8(6): 400-7.	1988-2006	*	
United States	Methvin JN, Mannino DM, Casey BR. COPD prevalence in southeastern Kentucky: the burden of lung disease study. <i>Chest</i> . 2009; 135(1): 102-7.	2006-2008	*	
United States	Savji N, Rockman CB, Skolnick AH, Guo Y, Adelman MA, Riles T, Berger JS. Association between advanced age and vascular disease in different arterial territories: a population database of over 3.6 million subjects. <i>J Am Coll Cardiol</i> . 2013; 61(16): 1736-43.	2003-2008	*	
United States	Wassel CL, Lombara R, Ik JH, Allison MA, Denenberg JO, Criqui MH. Family history of peripheral artery disease is associated with prevalence and severity of peripheral artery disease: the San Diego population study. <i>J Am Coll Cardiol</i> . 2011; 58(13): 1386-92.	1994-1998	*	
United States	Bell RA, Arcury TA, Anderson AM, Chen H, Savoca MR, Gilbert GH, Quandt SA. Dental anxiety and oral health outcomes among rural older adults. <i>J Public Health Dent</i> . 2012; 72(1): 53-9.	2010	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	Acharya A, VanWormer JJ, Waring SC, Miller AW, Fuehrer JT, Nycz GR. Regional epidemiologic assessment of prevalent periodontitis using an electronic health record system. <i>Am J Epidemiol</i> . 2013; 177(7): 700-7.	2006-2010		
United States	Ahluwalia KP, Cheng B, Josephs PK, Lalla E, Lamster IB. Oral disease experience of older adults seeking oral health services. <i>Gerodontology</i> . 2010; 27(2): 96-103.	2006	*	
United States	Anderson L, Martin NR, Burdick A, Flynn RT, Blaney DD. Oral health status of New Hampshire Head Start children, 2007-2008. <i>J Public Health Dent</i> . 2010; 70(3): 245-8.	2007-2008	*	
United States	Davis MM, Hilton TJ, Benson S, Schott J, Howard A, McGinnis P, Fagnan L. Unmet dental needs in rural primary care: a clinic-, community-, and practice-based research network collaborative. <i>J Am Board Fam Med</i> . 2010; 23(4): 514-22.	2008	*	
United States	Ditmyer M, Dounis G, Mobley C, Schwarz E. Inequalities of caries experience in Nevada youth expressed by DMFT index vs. Significant Caries Index (SiC) over time. <i>BMC Oral Health</i> . 2011; 12.	2001-2009	*	
United States	Holtfreter B, Demmer RT, Bernhardt O, Papanou PN, Schwahn C, Kocher T, Desvarieux M. A comparison of periodontal status in the two regional, population-based studies of SHIP and INVEST. <i>J Clin Periodontol</i> . 2012; 39(12): 1115-24.	1999-2003	*	
United States	Polk DE, Weyant RJ, Manz MC. Socioeconomic factors in adolescents' oral health: are they mediated by oral hygiene behaviors or preventive interventions? <i>Community Dent Oral Epidemiol</i> . 2010; 38(1): 1-9.	2000	*	
United States	Bader JD, Rozier RG, McFall WT, Ramsey DL. Periodontal status and treatment needs among regular dental patients. <i>Int Dent J</i> . 1988; 38(4): 255-60.	1986	*	
United States	Carpic KT, Wingard DL, Kritz-Silverstein D, Barrett-Connor E. The association of angina pectoris with heart disease mortality among men and women by diabetes status: the Rancho Bernardo Study. <i>J Womens Health (Larchmt)</i> . 2010; 19(8): 1433-9.	1984-1987	*	
United States	Bhole V, de Vera M, Rahman MM, Krishnan E, Choi H. Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort. <i>Arthritis Rheum</i> . 2010; 62(4): 1069-76.	1950-2002	*	
United States	Stroup SP, Palazzi-Churas K, Kopp RP, Parsons JK. Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008. <i>BJU Int</i> . 2012; 109(1): 84-7.	1998-2008	*	
United States	Hagar RW, Michlitsch JG, Gardner J, Vichinsky EP, Morris CR. Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. <i>Br J Haematol</i> . 2008; 140(1): 104-12.	2003-2007	*	
United States	Lerner NB, Platania BL, LaBella S. Newborn sickle cell screening in a region of Western New York State. <i>J Pediatr</i> . 2009; 154(1): 121-5.	1980-2006	*	
United States	Michlitsch J, Azimi M, Hoppe C, Walters MC, Lubin B, Lorey F, Vichinsky E. Newborn screening for hemoglobinopathies in California. <i>Pediatr Blood Cancer</i> . 2009; 52(4): 486-90.	1998-2006	*	
United States	Ileen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Maradit Kremers H. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. <i>J Am Acad Dermatol</i> . 2009; 60(3): 394-401.	1970-1999	*	
United States	Tollefson MM, Crowson CS, McEvoy MT, Maradit Kremers H. Incidence of psoriasis in children: a population-based study. <i>J Am Acad Dermatol</i> . 2010; 62(6): 979-87.	1970-1999	*	
United States	Buttner MM, Mott SL, Pearlstein T, Stuart S, Zlotnick C, O'Hara MW. Examination of premenstrual symptoms as a risk factor for depression in postpartum women. <i>Arch Womens Ment Health</i> . 2013; 16(3): 219-25.	2009-2011	*	
United States	Ogebe O, Abdulmalik J, Bello-Mojeed MA, Holder N, Jones HA, Ogun OO, Omigbodun O. A comparison of the prevalence of premenstrual dysphoric disorder and comorbidities among adolescents in the United States of America and Nigeria. <i>J Pediatr Adolesc Gynecol</i> . 2011; 24(6): 397-403.	2009-2010	*	
United States	Schieve LA, Gonzalez V, Boulet SL, Visser SN, Rice CE, Van Naarden Braun K, Boyle CA. Concurrent medical conditions and health care use and needs among children with learning and behavioral developmental disabilities, National Health Interview Survey, 2006-2010. <i>Res Dev Disabil</i> . 2012; 33(2): 467-76.	2006-2010	*	
United States	Obi O, Van Naarden Braun K, Baio J, Drews-Botsch C, Devine O, Yeargin-Allsopp M. Effect of incorporating adaptive functioning scores on the prevalence of intellectual disability. <i>Am J Intellect Dev Disabil</i> . 2011; 116(5): 360-70.	2002-2006	*	
United States	Zimmermann A, Bernuit D, Gerlinger C, Schaefer M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. <i>BMC Womens Health</i> . 2012; 6.	2009		
United States	Bachmann GA, Bahouth LA, Amalraj P, Mhamunkar V, Hoes K, Ananth CV. Uterine fibroids: Correlations of anemia and pain to fibroid location and uterine weight. <i>J Reprod Med</i> . 2011; 56(11-12): 463-6.	2001-2009	*	
United States	Thigpen MC, Whitney CG, Messonnier NE, Zell ER, Lynfield R, Hadler JL, Harrison LH, Farley MM, Reingold A, Bennett NM, Craig AS, Schaffner W, Thomas A, Lewis MM, Scallan E, Schuchat A. Emerging Infections Programs Network. Bacterial meningitis in the United States, 1998-2007. <i>N Engl J Med</i> . 2011; 364(21): 2016-25.	1998-2007		
United States	Bresee JS, Marcus R, Venezia RA, Keene WE, Morse D, Thanassi M, Brunett P, Bulens S, Beard RS, Dauphin LA, Slutsker L, Bopp C, Eberhard M, Hall A, Vinje J, Monroe SS, Glass RI. US Acute Gastroenteritis Etiology Study Team. The etiology of severe acute gastroenteritis among adults visiting emergency departments in the United States. <i>J Infect Dis</i> . 2012; 205(9): 1374-81.	1999-2001	*	
United States	Rodriguez WJ, Kim HW, Brandt CD, Schwartz RH, Gardner MK, Jeffries B, Parrott RH, Kaslow RA, Smith JI, Kapikian AZ. Longitudinal study of rotavirus infection and gastroenteritis in families served by a pediatric medical practice: clinical and epidemiologic observations. <i>Pediatr Infect Dis J</i> . 1987; 6(2): 170-6.	1977-1980	*	
United States	Parashar UD, Holman RC, Clarke MJ, Bresee JS, Glass RI. Hospitalizations associated with rotavirus diarrhea in the United States, 1993 through 1995: surveillance based on the new ICD-9-CM rotavirus-specific diagnostic code. <i>J Infect Dis</i> . 1998; 177(1): 13-7.	1990-1995	*	
United States	Anderson EJ, Katz BZ, Polin JA, Reddy S, Weinrobe MH, Noskin GA. Rotavirus in adults requiring hospitalization. <i>J Infect</i> . 2012; 64(1): 89-95.	2005-2006	*	
United States	Denno DM, Shaikh N, Stapp JR, Qin X, Hutter CM, Hoffman V, Mooney JC, Wood KM, Stevens HJ, Jones R, Tarr PI, Klein EJ. Diarrhea etiology in a pediatric emergency department: a case control study. <i>Clin Infect Dis</i> . 2012; 55(7): 897-904.	2003-2005	*	
United States	Hall AJ, Rosenthal M, Gregoricus N, Greene SA, Ferguson J, Henao OL, Vinje J, Lopman BA, Parashar UD, Widdowson M-A. Incidence of acute gastroenteritis and role of norovirus, Georgia, USA, 2004-2005. <i>Emerg Infect Dis</i> . 2011; 17(8): 1381-8.	2004-2005	*	
United States	Payne DC, Vinje J, Szilagyi PG, Edwards KM, Staat MA, Weinberg GA, Hall CB, Chappell J, Bernstein DI, Burns AT, Wikswo M, Shirley SH, Hall AJ, Lopman B, Parashar UD. Norovirus and medically attended gastroenteritis in U.S. children. <i>N Engl J Med</i> . 2013; 368(12): 1121-30.	2008-2010		
United States	Wilhelm CM, Hanna SL, Welch CA, Shahid H, Minnich LL, Daly SB, Udall JN Jr. Viral gastroenteritis in Charleston, West Virginia, in 2007: from birth to 99 years of age. <i>Infect Control Hosp Epidemiol</i> . 2010; 31(8): 816-21.	2007		
United States	Katz MJ, Lipton RB, Hall CB, Zimmerman ME, Sanders AE, Verghese J, Dickson DW, Derby CA. Age-specific and sex-specific prevalence and incidence of mild cognitive impairment, dementia, and Alzheimer dementia in blacks and whites: a report from the Einstein Aging Study. <i>Alzheimer Dis Assoc Disord</i> . 2012; 26(4): 335-43.	1993-2006		
United States	Poon LW, Woodard JL, Stephen Miller L, Green R, Gearing M, Davey A, Arnold J, Martin P, Siegler IC, Nahapetyan L, Kim YS, Markesbery W. Understanding dementia prevalence among centenarians. <i>J Gerontol A Biol Sci Med Sci</i> . 2012; 67(4): 358-65.	2008-2010		
United States	Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, Burke JR, Hurd MD, Potter GG, Rodgers WL, Steffens DC, Willis RJ, Wallace RB. Prevalence of dementia in the United States: the aging, demographics, and memory study. <i>Neuroepidemiology</i> . 2007; 29(1-2): 125-32.	2001-2003	*	
United States	Folstein MF, Bassett SS, Anthony JC, Romanoski AJ, Nestadt GR. Dementia: case ascertainment in a community survey. <i>J Gerontol</i> . 1991; 46(4): M132-138.	1981-1982		
United States	McManus DD, Piacentini SM, Lessard D, Gore JM, Yarzebski J, Spencer FA, Goldberg RJ. Thirty-Year (1975 to 2005) Trends in the Incidence Rates, Clinical Features, Treatment Practices, and Short-Term Outcomes of Patients <55 Years of Age Hospitalized With an Initial Acute Myocardial Infarction. <i>Am J Cardiol</i> . 2011; 108(4): 477-82.	1975-2005		
United States	Lachance L, Sowers MF, Jamadar D, Hochberg M. The natural history of emergent osteoarthritis of the knee in women. <i>Osteoarthritis Cartilage</i> . 2002; 10(11): 849-54.	1995-1998		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	Murphy L, Schwartz TA, Helmeck CG, Renner JB, Tudor G, Koch G, Dragomir A, Kalsbeek WD, Luta G, Jordan JM. Lifetime risk of symptomatic knee osteoarthritis. <i>Arthritis Rheum.</i> 2008; 59(9): 1207-13.	1991-2003		
United States	Felson DT, Naimark A, Anderson J, Kazis L, Castelli W, Meenan RF. The prevalence of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. <i>Arthritis Rheum.</i> 1987; 30(8): 914-8.	1983-1985		
United States	Anderson JJ, Felson DT. Factors associated with osteoarthritis of the knee in the first national Health and Nutrition Examination Survey (HANES I). Evidence for an association with overweight, race, and physical demands of work. <i>Am J Epidemiol.</i> 1988; 128(1): 179-89.	1971-1975		
United States	Davis MA, Eitinger WH, Neuhaus JM, Hauck WW. Sex differences in osteoarthritis of the knee. The role of obesity. <i>Am J Epidemiol.</i> 1988; 127(5): 1019-30.	1971-1975		
United States	Eitinger WH, Davis MA, Neuhaus JM, Mallon KP. Long-term physical functioning in persons with knee osteoarthritis from NHANES. I. Effects of comorbid medical conditions. <i>J Clin Epidemiol.</i> 1994; 47(7): 809-15.	1971-1975		
United States	Jordan JM, Helmeck CG, Renner JB, Luta G, Dragomir AD, Woodard J, Fang F, Schwartz TA, Abbate LM, Callahan LF, Kalsbeek WD, Hochberg MC. Prevalence of knee symptoms and radiographic and symptomatic knee osteoarthritis in African Americans and Caucasians: the Johnston County Osteoarthritis Project. <i>J Rheumatol.</i> 2007; 34(1): 172-80.	1991-1997		
United States	Andersen RE, Crespo CJ, Ling SM, Bathon JM, Bartlett SJ. Prevalence of significant knee pain among older Americans: results from the Third National Health and Nutrition Examination Survey. <i>J Am Geriatr Soc.</i> 1999; 47(12): 1435-8.	1988-1994		
United States	Dillon CF, Rasch EK, Gu Q, Hirsch R. Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991-94. <i>J Rheumatol.</i> 2006; 33(11): 2271-9.	1991-1994		
United States	Gonzalez A, Maradit Kremers H, Crowson CS, Nicola PJ, Davis JM 3rd, Thorneau TM, Roger VL, Gabriel SE. The widening mortality gap between rheumatoid arthritis patients and the general population. <i>Arthritis Rheum.</i> 2007; 56(11): 3583-7.	1955-2000		
United States	Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, Spitz PW, Hagen M, Kleinheksel SM, Cathey MA. The mortality of rheumatoid arthritis. <i>Arthritis Rheum.</i> 1994; 37(4): 481-94.	1965-1990		
United States	Gabriel SE, Crowson CS, O'Fallon WM. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? <i>J Rheumatol.</i> 1999; 26(12): 2529-33.	1955-1985		
United States	Yelin E, Trupin L, Wong B, Rush S. The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. <i>J Rheumatol.</i> 2002; 29(9): 1851-7.	1982-2000		
United States	Pincus T, Keyser J, Sokka T, Krishnan E, Callahan LF. Patient questionnaires and formal education level as prospective predictors of mortality over 10 years in 97% of 1416 patients with rheumatoid arthritis from 15 United States private practices. <i>J Rheumatol.</i> 2004; 31(2): 229-34.	1985-1995		
United States	Rasch EK, Hirsch R, Paulose-Ram R, Hochberg MC. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. <i>Arthritis Rheum.</i> 2003; 48(4): 917-26.	1988-1994		
United States	Gabriel SE, Crowson CS, O'Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. <i>Arthritis Rheum.</i> 1999; 42(3): 415-20.	1955-1985		
United States	Han C, Zhao N, Gaslightwala A, Bala M. An epidemiological and healthcare utilisation study of rheumatoid arthritis in an adult population in the US. <i>J Med Econ.</i> 2007; 10(4): 489-99.	2003		
United States	Dugowson CE, Koepsell TD, Voigt LF, Bley L, Nelson JL, Daling JR. Rheumatoid arthritis in women. Incidence rates in Group Health Cooperative, Seattle, Washington, 1987-1989. <i>Arthritis Rheum.</i> 1991; 34(12): 1502-7.	1987-1989		
United States	Chan KW, Felson DT, Yood RA, Walker AM. Incidence of rheumatoid arthritis in central Massachusetts. <i>Arthritis Rheum.</i> 1993; 36(12): 1691-6.	1987-1990		
United States	Doran MF, Pond GR, Crowson CS, O'Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. <i>Arthritis Rheum.</i> 2002; 46(3): 625-31.	1955-1995		
United States	Myasoedova E, Crowson CS, Kremers HM, Thorneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising? results from Olmsted County, Minnesota, 1955-2007. <i>Arthritis Rheum.</i> 2010; 62(6): 1576-82.	1995-2007		
United States	Linos A, Worthington JW, O'Fallon M, Kurland LT. The Epidemiology of Rheumatoid Arthritis in Rochester Minnesota: A Study of Incidence, Prevalence, and Mortality. <i>Am J Epidemiol.</i> 1980; 111(1): 87-98.	1950-1974		
United States	Crocobbe LA, Mejia GC, Koster CR, Slade GD. Comparison of adult oral health in Australia, the USA, Germany and the UK. <i>Aust Dent J.</i> 2009; 54(2): 147-53.	1999-2004		
United States	Kingman A, Little W, Gomez I, Heifetz SB, Driscoll WS, Sheats R, Supan P. Salivary levels of Streptococcus mutans and lactobacilli and dental caries experiences in a US adolescent population. <i>Community Dent Oral Epidemiol.</i> 1988; 16(2): 98-103.	1983-1986		
United States	Warren JJ, Watkins CA, Cowen HJ, Hand JS, Levy SM, Kuthy RA. Tooth loss in the very old: 13-15-year incidence among elderly Iowans. <i>Community Dent Oral Epidemiol.</i> 2002; 30(1): 29-37.	1983-1998		
United States	Bryan ET, Collier DR, Howard WR, VanCleave ML. Dental health status of school children in Tennessee - a 25 year comparison. <i>J Tenn Dent Assoc.</i> 1982; 62(1): 31-3.	1954, 1979		
United States	Stokey GK, Park KK, Drook CA, Sergeant JW, Jackson RD. Prevalence of dental caries in Indiana school children: results of 1982 survey. <i>Pediatr Dent.</i> 1985; 7(1): 8-13.	1981-1982		
United States	Horowitz HS, Heifetz SB, Meyers RJ, Driscoll WS, Li SH. A program self-administered fluorides in a rural school system. <i>Community Dent Oral Epidemiol.</i> 1980; 8(4): 177-83.	1972		
United States	Warren JJ, Levy SM, Hand JS, Maurer WC, Beltran ED. Results of the 1994 Iowa Oral Health Survey. <i>Iowa Dent J.</i> 1996; 82(1): 55-61.	1994		
United States	Lawrence HP, Beck JD, Hunt RJ, Koch GG. Adjustment of the M-component of the DMFS index for prevalence studies of older adults. <i>Community Dent Oral Epidemiol.</i> 1996; 24(5): 322-31.	1988-1993		
United States	Brumley DE, Gillcrist JA. Oral health status of children in Tennessee: a survey of caries prevalence and oral health needs. <i>J Tenn Dent Assoc.</i> 1999; 79(2): 18-22.	1997		
United States	Glass RL, Alman JE, Chauncey HH. A 10-year longitudinal study of caries incidence rates in a sample of male adults in the USA. <i>Caries Res.</i> 1987; 21(4): 360-7.	1969-1979		
United States	Burt BA, Eklund SA, Morgan KJ, Larkin FE, Guire KE, Brown LO, Weintraub JA. The effects of sugars intake and frequency of ingestion on dental caries increment in a three-year longitudinal study. <i>J Dent Res.</i> 1988; 67(11): 1422-9.	1982-1985		
United States	Hamasha AA-H, Warren JJ, Hand JS, Levy SM. Coronal and root caries in the older Iowans: 9- to 11-year incidence. <i>Spec Care Dentist.</i> 2005; 25(2): 106-10.	1987-1998		
United States	Williamson DD, Narendran S, Martin RD. Dental caries among third grade children in Harris County, Texas: a baseline study. <i>Tex Dent J.</i> 2003; 120(5): 408-20.	1991		
United States	Wilson JH. 1988 West Virginia Dental Caries Prevalence Survey, Part II. <i>W V Dent J.</i> 1990; 64(4): 4, 6-7.	1988		
United States	Szpunar SM, Burt BA. Dental caries, fluorosis, and fluoride exposure in Michigan schoolchildren. <i>J Dent Res.</i> 1988; 67(5): 802-6.	1986		
United States	Tang JM, Altman DS, Robertson DC, O'Sullivan DM, Douglass JM, Tinanoff N. Dental caries prevalence and treatment levels in Arizona preschool children. <i>Public Health Rep.</i> 1997; 112(4): 319-331.	1994-1995		
United States	Kaste LM, Marianos D, Chang R, Phipps KR. The assessment of nursing caries and its relationship to high caries in the permanent dentition. <i>J Public Health Dent.</i> 1992; 52(2): 64-8.	1977-1978		
United States	Chung LH, Shain SG, Stephen SM, Weintraub JA. Oral health status of San Francisco public school kindergartners 2000-2005. <i>J Public Health Dent.</i> 2006; 66(4): 235-41.	2000-2005		
United States	Warren JJ, Weber-Gasparoni K, Marshall TA, Drake DR, Dehkordi-Vakil F, Dawson DV, Tharp KM. A longitudinal study of dental caries risk among very young low SES children. <i>Community Dent Oral Epidemiol.</i> 2009; 37(2): 116-22.	2002-2003, 2005-2006		
United States	Kopycka-Kedzierska DT, Billings RJ. Prevalence of dental caries and dental care utilisation in preschool urban children enrolled in a comparative-effectiveness study. <i>Eur Arch Paediatr Dent.</i> 2011; 12(3): 133-8.	2008-2009		
United States	Gum AM, King-Kallimianis B, Kohn R. Prevalence of mood, anxiety, and substance-abuse disorders for older Americans in the national comorbidity survey-replication. <i>Am J Geriatr Psychiatry.</i> 2009; 17(9): 769-81.	2001-2003		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	Costello EJ. Child psychiatric disorders and their correlates: a primary care pediatric sample. <i>J Am Acad Child Adolesc Psychiatry.</i> 1989; 28(6): 851-5.	1984-1985		
United States	Lewinsohn PM, Klein DN, Seeley JR. Bipolar disorders in a community sample of older adolescents: prevalence, phenomenology, comorbidity, and course. <i>J Am Acad Child Adolesc Psychiatry.</i> 1995; 34(4): 454-63.	1987-1990		
United States	Lewinsohn PM, Hops H, Roberts RE, Seeley JR, Andrews JA. Adolescent psychopathology: I. Prevalence and incidence of depression and other DSM-III-R disorders in high school students. <i>J Abnorm Psychol.</i> 1993; 102(1): 133-44.	1987-1990		
United States	Weissman MM, Leaf PJ, Tischler GL, Blazer DG, Karno M, Bruce ML, Florio LP. Affective disorders in five United States communities. <i>Psychol Med.</i> 1988; 18(1): 141-53.	1980-1983		
United States	Black DW, Winokur G, Nasrallah A. Mortality in patients with primary unipolar depression, secondary unipolar depression, and bipolar affective disorder: a comparison with general population mortality. <i>Int J Psychiatry Med.</i> 1987; 17(4): 351-60.	1970-1981		
United States	Lewinsohn PM, Striegel-Moore RH, Seeley JR. Epidemiology and Natural Course of Eating Disorders in Young Women From Adolescence to Young Adulthood. <i>J Am Acad Child Adolesc Psychiatry.</i> 2000; 39(10): 1284-92.	1987-1989		
United States	Hudson JL, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. <i>Biol Psychiatry.</i> 2007; 61(3): 348-58.	2001-2003		
United States	Lucas AR, Beard CM, O'Fallon WM, Kurland LT. 50-year trends in the incidence of anorexia nervosa in Rochester, Minn.: a population-based study. <i>Am J Psychiatry.</i> 1991; 148(7): 917-22.	1935-1984		
United States	Herzog DB, Dorer DJ, Keel PK, Selwyn SE, Ekeblad ER, Flores AT, Greenwood DN, Burwell RA, Keller MB. Recovery and relapse in anorexia and bulimia nervosa: a 7.5-year follow-up study. <i>J Am Acad Child Adolesc Psychiatry.</i> 1999; 38(7): 829-37.	1987-1996		
United States	Agras WS, Crow S, Mitchell JE, Halmi KA, Bryson S. A 4-year prospective study of eating disorder NOS compared with full eating disorder syndromes. <i>Int J Eat Disord.</i> 2009; 42(6): 565-70.	2003-2007		
United States	Eckert ED, Halmi KA, Marchi P, Grove W, Crosby R. Ten-year follow-up of anorexia nervosa: clinical course and outcome. <i>Psychol Med.</i> 1995; 25(1): 143-56.	1975-1985		
United States	Keel PK, Dorer DJ, Eddy KT, Franko D, Charatan DL, Herzog DB. Predictors of mortality in eating disorders. <i>Arch Gen Psychiatry.</i> 2003; 60(2): 179-83.	1987-1998		
United States	Cantwell DP, Baker L. Stability and Natural History of DSM-III Childhood Diagnoses. <i>J Am Acad Child Adolesc Psychiatry.</i> 1989; 28(5): 691-700.	1978-1985		
United States	Lahey BB, Loeber R, Burke JD, Applegate B. Predicting Future Antisocial Personality Disorder in Males From a Clinical Assessment in Childhood. <i>J Consult Clin Psychol.</i> 2005; 73(3): 389-99.	1997		
United States	Colan SD, Lipshultz SE, Lowe AM, Sleeper LA, Messere J, Cox GF, Lurie PR, Orav EJ, Towbin JA. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. <i>Circulation.</i> 2007; 115(6): 773-81.	1996-2003		
United States	Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, Lurie PR, McCoy KL, McDonald MA, Messere JE, Colan SD. The incidence of pediatric cardiomyopathy in two regions of the United States. <i>N Engl J Med.</i> 2003; 348(17): 1647-55.	1996-1999		
United States	Codd MB, Sugrue DD, Gersh BJ, Melton LJ 3rd. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. <i>Circulation.</i> 1989; 80(3): 564-72.	1975-1985		
United States	Cross-national comparisons of the prevalences and correlates of mental disorders. WHO International Consortium in Psychiatric Epidemiology.	1990-1992		
United States	Angold A, Erkanli A, Farmer EZ, et al. Psychiatric disorder, impairment, and service use in rural African American and white youth. <i>Arch Gen Psychiatry.</i> 2002; 59(10): 893-901.	1980-1984, 1997-1998, 2000		
United States	Costello E, Mustillo S, Erkanli A, Keeler G, Angold A. Prevalence and development of psychiatric disorders in childhood and adolescence. <i>Arch Gen Psychiatry.</i> 2003; 60(8): 837-44.	1992-2000		
United States	Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of dsm-iii-r psychiatric disorders in the united states: Results from the national comorbidity survey. <i>Arch Gen Psychiatry.</i> 1994; 51(1): 8-9.	1990-1992		
United States	Regier DA, Narrow WE, Rae DS. The epidemiology of anxiety disorders: The epidemiologic catchment area (ECA) experience. <i>J Psychiatr Res.</i> 1990; 3: 1-4.	1980-1983		
United States	Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disorders in the united states: Using a clinical significance criterion to reconcile 2 surveys' estimates. <i>Arch Gen Psychiatry.</i> 2002; 59(2): 115-23.	1989-1992		
United States	Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. <i>Kidney Int.</i> 2003; 63(5): 1817-23.	1976-1980, 1988-1994		
United States	Sowers MR, Jannausch M, Wood C, Pope SK, Lachance LL, Peterson B. Prevalence of renal stones in a population-based study with dietary calcium, oxalate, and medication exposures. <i>Am J Epidemiol.</i> 1998; 147(10): 914-20.	1993-1994		
United States	Hall WD, Pettinger M, Oberman A, Watts NB, Johnson KC, Paskett ED, Limacher MC, Hays J. Risk factors for kidney stones in older women in the southern United States. <i>Am J Med Sci.</i> 2001; 322(1): 12-8.	1992-1998		
United States	Lieske JC, Peña de la Vega LS, Slezak JM, Bergstralh EJ, Leibson CL, Ho K-L, Gettman MT. Renal stone epidemiology in Rochester, Minnesota: an update. <i>Kidney Int.</i> 2006; 69(4): 760-4.	1980, 1990, 2000		
United States	Keel PK, Graveron JA, Joiner TE, Haedt AA. Twenty-year follow-up of bulimia nervosa and related eating disorders not otherwise specified. <i>Int J Eat Disord.</i> 2010; 43(6): 492-7.	1982-2002		
United States	Compton WM, Grant BF, Coliver JD, Glantz MD, Stinson FS. Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. <i>JAMA.</i> 2004; 291(17): 2114-21.	1991-1992, 2001-2002		
United States	Newcomb MD, Galaif ER, Locke TF. Substance use diagnoses within a community sample of adults: Distinction, comorbidity, and progression over time. <i>Prof Psychol Res Pr.</i> 2001; 32(3): 239-47.	1992, 1997		
United States	Reardon SF, Buka SL. Differences in onset and persistence of substance abuse and dependence among whites, blacks, and Hispanics. <i>Public Health Rep.</i> 2002; S51-59.	1997, 1999		
United States	Stinson FS, Ruan WJ, Pickering R, Grant BF. Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. <i>Psychol Med.</i> 2006; 36(10): 1447-60.	2004		
United States	Zahuranec DB, Brown DL, Lisabeth LD, Morgenstern LB. Is it time for a large, collaborative study of pediatric stroke? <i>Stroke.</i> 2005; 36(9): 1825-9.	2002-2003		
United States	Regier DA, Boyd JH, Burke JD Jr, Rae DS, Myers JK, Kramer M, Robins LN, George LK, Karno M, Locke BZ. One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. <i>Arch Gen Psychiatry.</i> 1988; 45(11): 977-86.	1980-1984		
United States	Bland RC, Newman SC, Orn H. Period Prevalence of Psychiatric Disorders in Edmonton. <i>Acta Psychiatr Scand.</i> 1988; 77(S338): 33-42.	1983-1986		
United States	Garrison CZ, Addy CL, Jackson KL, McKeown RE, Waller JL. Major depressive disorder and dysthymia in young adolescents. <i>Am J Epidemiol.</i> 1992; 135(7): 792-802.	1986-1988		
United States	Klein DN, Shankman SA, Rose S. Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression. <i>Am J Psychiatry.</i> 2006; 163(5): 872-80.	1994-2004		
United States	Murabito JM, Evans JC, Larson MG, Nieto K, Levy D, Wilson PWF. The Ankle-Brachial Index in the Elderly and Risk of Stroke, Coronary Disease, and Death: The Framingham Study. <i>Arch Intern Med.</i> 2003; 163(16): 1939-42.	1993-1995		
United States	Ostchega Y, Paulose-Ram R, Dillon CF, Gu Q, Hughes JP. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. <i>J Am Geriatr Soc.</i> 2007; 55(4): 583-9.	1999-2004		
United States	Curb JD, Masaki K, Rodriguez BL, Abbott RD, Burchfiel CM, Chen R, Petrovitch H, Sharp D, Yano K. Peripheral Artery Disease and Cardiovascular Risk Factors in the Elderly: The Honolulu Heart Program. <i>Arterioscler Thromb Vasc Biol.</i> 1996; 16(12): 1495-1500.	1999-2004		
United States	Fabsitz RR, Sidawy AN, Go O, Lee ET, Welty TK, Devereux RB, Howard BV. Prevalence of peripheral arterial disease and associated risk factors in American Indians: the Strong Heart Study. <i>Am J Epidemiol.</i> 1999; 149(4): 330-8.	1989-1992		
United States	Criqui MH, Vargas V, Denenberg JO, Ho E, Allison M, Langer RD, Gamst A, Bundens WP, Fronck A. Ethnicity and Peripheral Arterial Disease: The San Diego Population Study. <i>Circulation.</i> 2005; 112(17): 2703-2707.	1996-1999		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	Criqui MH, Fronck A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. <i>Circulation</i> . 1985; 71(3): 510-515.	1980-1981		
United States	Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, Messere J, Cox GF, Lurie PR, Hsu D, Canter C, Wilkinson JD, Lipshultz SE. Incidence, Causes, and Outcomes of Dilated Cardiomyopathy in Children. <i>JAMA</i> . 2006; 296(15): 1867-1876.	1996-2002		†
United States	Berlin JA, Abrutyn E, Strom BL, Kinman JL, Levison ME, Korzeniowski OM, Feldman RS, Kaye D. Incidence of infective endocarditis in the Delaware Valley, 1988-1990. <i>Am J Cardiol</i> . 1995; 76(12): 933-6.	1988-1990		†
United States	King JW, Nguyen VQ, Conrad SA. Results of a prospective statewide reporting system for infective endocarditis. <i>Am J Med Sci</i> . 1988; 295(6): 517-27.	1985-1986		
United States	Tleyjeh IM, Steckelberg JM, Murad HS, Anavekar NS, Ghonrawi HM, Mirzoyev Z, Moustafa SE, Hoskin TL, Mandrekar JN, Wilson WR, Baddour LM. Temporal trends in infective endocarditis: a population-based study in Olmsted County, Minnesota. <i>JAMA</i> . 2005; 293(24): 3022-8.	1980-2000		
United States	Lydon-Rochelle M, Holt VL, Easterling TR, Martin DP. Risk of uterine rupture during labor among women with a prior cesarean delivery. <i>N Engl J Med</i> . 2001; 345(1): 4-8.	1987-1996		
United States	de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Künzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P. European Community Respiratory Health Survey Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. <i>Thorax</i> . 2004; 59(2): 120-125.	1991-1993		
United States	Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E, BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. <i>Lancet</i> . 2007; 9589(9589): 741-50.	2005-2006		
United States	Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, Jensen RL, Falaschetti E, Schouten JP, Hankinson JL, Stocks J, Quanjer PH. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. <i>Thorax</i> . 2008; 63(12): 1046-51.	1988-1994		
United States	O'Connor GT, Sparrow D, Weiss ST. Normal range of methacholine responsiveness in relation to prechallenge pulmonary function The Normative Aging Study. <i>Chest</i> . 1994; 105(3): 661-6.	1984-1990		
United States	Bertrand J, Mars A, Boyle C, Bove F, Yeargin-Allsopp M, Decoufle P. Prevalence of Autism in a United States Population: The Brick Township, New Jersey, Investigation. <i>Pediatrics</i> . 2001; 108(5): 1155-61.	1998		
United States	Schwartz BS, Stewart WF, Simon D, Lipton RB. Epidemiology of tension-type headache. <i>JAMA</i> . 1998; 279(5): 381-3.	1993-1994		
United States	Templeman C, Marshall SF, Clarke CA, Henderson KD, Largent J, Neuhausen S, Reynolds P, Ursin G, Bernstein L. Risk factors for surgically-removed fibroids in a large cohort of teachers. <i>Fertil Steril</i> . 2009; 92(4): 1436-46.	1995-2006		
United States	Boynton-Jarrett R, Rich-Edwards J, Malspeis S, Missmer SA, Wright R. A Prospective Study of Hypertension and Risk of Uterine Leiomyomata. <i>Am J Epidemiol</i> . 2005; 161(7): 628-38.	1989-1999		
United States	Marshall LM SD, Barbieri RL, Goldman MB, Manson JE, Colditz GA, Willett WC, Hunter DJ. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. <i>Obstet Gynecol</i> . 1997; 90(6): 967-73.	1989-1993		†
United States	Nygaard I, Barber MD, Burgio KL, Kenton K, Meikle S, Schaffer J, Spino C, Whitehead WE, Wu J, Brody DJ. Pelvic Floor Disorders Network. Prevalence of symptomatic pelvic floor disorders in US women. <i>JAMA</i> . 2008; 300(11): 1311-6.	2005-2006		
United States	Lawrence JM LE, Nager CW, Hsu JW, Luber KM. Prevalence and co-occurrence of pelvic floor disorders in community-dwelling women. <i>Obstet Gynecol</i> . 2008; 111(3): 678-85.	2004-2005		
United States	Kashani JH, Beck NC, Hooper EW, Fallahi C, Corcoran CM, McAllister JA, Rosenberg TK, Reid JC. Psychiatric disorders in a community sample of adolescents. <i>Am J Psychiatry</i> . 1987; 144(5): 584-9.	1985		
United States	Shaffer D FP, Dulcan MK, Davies M, Piacentini J, Schwab-Stone ME, Lahey BB, Bourdon K, Jensen PS, Bird HR, Canino G, Regier DA. The NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC-2.3): description, acceptability, prevalence rates, and performance in the MECA Study. Methods for the Epidemiology of Child and Adolescent Mental Disorders Study. <i>J Am Acad Child Adolesc Psychiatry</i> . 1996; 35(7): 865-77.	1994		
United States	Biederman J, Monuteaux MC, Mick E, Spencer T, Wilens TE, Klein KL, Price JE, Faraone SV. Psychopathology in Females with Attention-Deficit/Hyperactivity Disorder: A Controlled, Five-Year Prospective Study. <i>Biol Psychiatry</i> . 2006; 60(10): 1098-105.	1994-1999		
United States	Hart EL, Lahey BB, Loeber R, Applegate B, Frick PJ. Developmental change in attention-deficit hyperactivity disorder in boys: a four-year longitudinal study. <i>J Abnorm Child Psychol</i> . 1995; 23(6): 729-49.	1987-1991		
United States	Mannuzza S, Gittelman R. The adolescent outcome of hyperactive girls. <i>Psychiatry Res</i> . 1984; 13(1): 19-29.	1973-1983		
United States	Barkley RA, Fischer M, Smallish L, Fletcher K. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. <i>J Abnorm Psychol</i> . 2002; 111(2): 279-89.	1979-1996		
United States	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	1990, 2005, 2009		
United States	Borenstein JE, Dean BB, Youkors KA, Endicott J. Using the daily record of severity of problems as a screening instrument for premenstrual syndrome. <i>Obstet Gynecol</i> . 2007; 109(5): 1068-75.	1998-1999		†
United States	Freeman EW, Sammel MD, Rinaudo PJ, Sheng L. Premenstrual syndrome as a predictor of menopausal symptoms. <i>Obstet Gynecol</i> . 2004; 103(5 Pt 1): 960-6.	1997, 2001		
United States	Deuster PA, Adera T, South-Paul J. Biological, social, and behavioral factors associated with premenstrual syndrome. <i>Arch Fam Med</i> . 1999; 8(2): 122-8.	1994		
United States	Vichnin M, Freeman EW, Lin H, Hillman J, Bui S. Premenstrual syndrome (PMS) in adolescents: severity and impairment. <i>J Pediatr Adolesc Gynecol</i> . 2006; 19(6): 397-402.	2004		
United States	Rosignol AM, Bonnlander H. Prevalence and severity of the premenstrual syndrome. Effects of foods and beverages that are sweet or high in sugar content. <i>J Reprod Med</i> . 1991; 36(2): 131-6.	1988		
United States	Bertone-Johnson ER, Hankinson SE, Johnson SR, Manson JE. A simple method of assessing premenstrual syndrome in large prospective studies. <i>J Reprod Med</i> . 2007; 52(9): 779-86.	2001		
United States	Bertone-Johnson ER, Hankinson SE, Johnson SR, Manson JE. Timing of alcohol use and the incidence of premenstrual syndrome and probable premenstrual dysphoric disorder. <i>J Womens Health (Larchmt)</i> . 2009; 18(12): 1945-53.	1991-2001		
United States	Bertone-Johnson ER, Chocano-Bedoya PO, Zagarins SE, Micka AE, Ronnenberg AG. Dietary vitamin D intake, 25-hydroxyvitamin D3 levels and premenstrual syndrome in a college-aged population. <i>J Steroid Biochem Mol Biol</i> . 2010; 121(1-2): 434-7.	2006-2008		
United States	Hargrove JT, Abraham GE. The incidence of premenstrual tension in a gynecologic clinic. <i>J Reprod Med</i> . 1982; 27(12): 721-4.	1980-1982	*	
United States	United States Renal Data System Coordinating Center. USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2008.	2008		
United States	National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), US Census Bureau. United States National Ambulatory Medical Care Survey 1993 and United States National Hospital Ambulatory Medical Care Survey 1993.	1993		
United States	United States Renal Data System Coordinating Center. USRDS 2006 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2006.	2006		
United States	United States Renal Data System Coordinating Center. USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2003.	2003		
United States	United States Renal Data System Coordinating Center. USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2002.	2002		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	United States Renal Data System Coordinating Center. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2007.	2007		
United States	United States Renal Data System Coordinating Center. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2005.	2005		
United States	United States Renal Data System Coordinating Center. United States Renal Data System Annual Data Report 2004. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2004.	2004		
United States	United States Renal Data System Coordinating Center. USRDS 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2001.	2001		
United States	Amortegul AJ, Meyer MP, Gnatuk CL. Prevalence of Chlamydia trachomatis and other micro-organisms in women seeking abortions in Pittsburgh, Pennsylvania, United States of America. <i>Genitourin Med.</i> 1986; 62(2): 88-92.	1986		
United States	Schoenberg BS, Anderson DW, Haerer AF. Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi. <i>Neurology.</i> 1985; 35(6): 841-5.	1982		
United States	Morens DM, Davis JW, Grandinetti A, Ross GW, Popper JS, White LR. Epidemiologic observations on Parkinson's disease: Incidence and mortality in a prospective study of middle-aged men. <i>Neurology.</i> 1996; 46(4): 1044-50.	1965-1994		
United States	Mayeux R, Marder K, Cote LJ, Denaro J, Hemeneigido N, Mejia H, Tang M-X, Lantigua R, Wilder D, Gurland B, Hauser A. The Frequency of Idiopathic Parkinson's Disease by Age, Ethnic Group, and Sex in Northern Manhattan, 1988-1993. <i>Am J Epidemiol.</i> 1995; 142(8): 820-7.	1988-1991		
United States	Eeden SKVD, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM. Incidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity. <i>Am J Epidemiol.</i> 2003; 157(11): 1015-22.	1994-1995		
United States	Mayeux R, Denaro J, Hemeneigido N, Marder K, Tang MX, Cote LJ, Stern Y. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. <i>Arch Neurol.</i> 1992; 49(5): 492-7.	1988-1990		
United States	Haerer AF AD, Schoenberg BS. Survey of major neurologic disorders in a biracial United States population: the Copiah County Study. <i>South Med J.</i> 1987; 80(3): 339-43.	1978		
United States	Saylor ME, Street JS, Bosomworth JC, Potvin JH, Kotsanos JG. Analysis of Mortality in Pergolide-Treated Patients with Parkinson's Disease. <i>Neuroepidemiology.</i> 1996; 15(1): 26-32.	1985-1995		
United States	Kramer M, German PS, Anthony JC, Von Korff M, Skinner EA. Patterns of mental disorders among the elderly residents of eastern Baltimore. <i>J Am Geriatr Soc.</i> 1985; 33(4): 236-45.	1981		
United States	Leaf PJ, Myers JK, McEvoy LT. Procedures Used in the Epidemiologic Catchment Area Study. In: Robins LN and Regier DA, editors. <i>Psychiatric Disorders in America.</i> New York, United States: Free Press; 1991. 11-32.	1989		
United States	Auslander LA, Jeste DV. Sustained remission of schizophrenia among community-dwelling older outpatients. <i>Am J Psychiatry.</i> 2004; 161(8): 1490-3.	1990-2002		
United States	Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganey K, Giel R, an der Heiden W, Holmberg SK, Janca A, Lee PW, León CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin SJ, Varma VK, Walsh D, Wiersma D. Recovery from psychotic illness: a 15- and 25-year international follow-up study. <i>Br J Psychiatry.</i> 2001; 178: 506-17.	1978-1993		
United States	Martin RL, Cloninger CR, Guze SB, Clayton PJ. Mortality in a follow-up of 500 psychiatric outpatients. I. Total mortality. <i>Arch Gen Psychiatry.</i> 1985; 42(1): 47-54.	1967-1973		
United States	Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. <i>Arch Gen Psychiatry.</i> 2007; 64(5): 566-76.	2001-2002		
United States	Grant BF. Comorbidity between DSM-IV drug use disorders and major depression: results of a national survey of adults. <i>J Subst Abuse.</i> 1995; 7(4): 481-97.	1992		
United States	Oetting ER, Deffenbacher JL, Taylor MJ, Luther N, Beauvais F, Edwards RW. Methamphetamine Use by High School Students: Recent Trends, Gender and Ethnicity Differences, and Use of Other Drugs. <i>J Child Adolesc Subst Abuse.</i> 2000; 10(1): 33-50.	1990-1992		
United States	United States - Arizona Proyecto VER Survey 2000 [Unpublished] as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology.</i>	2000		
United States	Galil K, Lee B, Strine T, Carraher C, Baughman AL, Eaton M, Montero J, Seward J. Outbreak of varicella at a day-care center despite vaccination. <i>N Engl J Med.</i> 2002; 347(24): 1909-15.	2000-2001		
United States	Lieu TA, Black SB, Takahashi H, Ray P, Capra AM, Shinefield HR, Adler NE. Varicella serology among school age children with a negative or uncertain history of chickenpox. <i>Pediatr Infect Dis J.</i> 1998; 17(2): 120-5.	1995-1996		
United States	Gershon AA, Steinberg SP. Antibody responses to varicella-zoster virus and the role of antibody in host defense. <i>Am J Med Sci.</i> 1981; 282(1): 12-7.	1978		
United States	Kilgore PE, Kruszon-Moran D, Seward JF, Jumaan A, Van Loon FPL, Forghani B, McQuillan GM, Wharton M, Fehrs LJ, Cossen CK, Hadler SC. Varicella in Americans from NHANES III: implications for control through routine immunization. <i>J Med Virol.</i> 2003; S111-118.	1988-1994		
United States	Centers for Disease Control and Prevention (CDC). Outbreak of Varicella Among Vaccinated Children - Michigan 2003. <i>Morb Mortal Wkly Rep.</i> 2004; 53(18): 389-92.	2001		
United States	Wang C, Vlahov D, Galai N, Cole SR, Bareta J, Pollini R, Mehta SH, Nelson KE, Galea S. The effect of HIV infection on overdose mortality. <i>AIDS.</i> 2005; 19(9): 935-42.	1988-2001		
United States	Hser Y-I, Stark ME, Paredes A, Huang D, Anglin MD, Rawson R. A 12-year follow-up of a treated cocaine-dependent sample. <i>J Subst Abuse Treat.</i> 2006; 30(3): 219-26.	1990-2003		
United States	Simpson DD, Joe GW, Broome KM. A national 5-year follow-up of treatment outcomes for cocaine dependence. <i>Arch Gen Psychiatry.</i> 2002; 59(6): 538-44.	1991-1998		
United States	O'Driscoll PT, McGough J, Hagan H, Thiede H, Critchlow C, Alexander ER. Predictors of accidental fatal drug overdose among a cohort of injection drug users. <i>Am J Public Health.</i> 2001; 91(6): 984-7.	1994-1997		
United States	Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. United States Monitoring the Future: National Survey Results on Drug Use, 1975-2004: Volume I. Secondary School Students (NIH Publication No. 05-5727). Bethesda, MD: National Institute on Drug Abuse; 2005. 680 p.	1990-1992, 2004		
United States	Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. United States Monitoring the Future: National Survey Results on Drug Use, 1975-2006: Volume II: College Students and Adults Ages 19-45 (NIH Publication 07-6206). Bethesda, MD: National Institute on Drug Abuse; 2007. 307 p.	1990-1994, 2004-2006		
United States	Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. United States Monitoring the Future: National Survey Results on Drug Use, 1975-2006: Volume I. Secondary School Students (NIH Publication No. 07-6205). Bethesda, MD: National Institute on Drug Abuse; 2007. 699 p.	1990-1992, 2004-2006		
United States	Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. United States Monitoring the Future: National Survey Results on Drug Use, 1975-2005: Volume I. Secondary School Students (NIH Publication No. 06-5883). Bethesda, MD: National Institute on Drug Abuse; 2006. 684 p.	2004-2005	*	
United States	Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. United States Monitoring the Future: National Survey Results on Drug Use, 1975-2005: Volume II: College Students and Adults Ages 19-45 (NIH Publication No. 06-5884). Bethesda, MD: National Institute on Drug Abuse; 2006. 302 p.	2005	*	
United States	Sandora TJ, Desai R, Miko BA, Harper MB. Assessing quality indicators for pediatric community-acquired pneumonia. <i>Am J Med Qual.</i> 2009; 24(5): 419-27.	2003-2004		
United States	Singleton RJ, Bulkow LR, Miernyk K, DeByle C, Pruitt L, Hummel KB, Bruden D, Englund JA, Anderson LJ, Lucher L, Holman RC, Hennessy TW. Viral respiratory infections in hospitalized and community control children in Alaska. <i>J Med Virol.</i> 2010; 82(7): 1282-90.	2005-2007		
United States	Drews CD, Yeargin-Allsopp M, Murphy CC, Decouffé P. Hearing impairment among 10-year-old children: metropolitan Atlanta, 1985 through 1987. <i>Am J Public Health.</i> 1994; 84(7): 1164-6.	1985-1987		
United States	Billings KR, Kenna MA. Causes of pediatric sensorineural hearing loss: yesterday and today. <i>Arch Otolaryngol Head Neck Surg.</i> 1999; 125(5): 517-21.	1993-1996		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	Murphy CC, Yeargin-Allsopp M, Decoufflé P, Drews CD. The administrative prevalence of mental retardation in 10-year-old children in metropolitan Atlanta, 1985 through 1987. <i>Am J Public Health</i> . 1995; 85(3): 319-23.	1976		
United States	Decoufflé P, Autry A. Increased mortality in children and adolescents with developmental disabilities. <i>Paediatr Perinat Epidemiol</i> . 2002; 16(4): 375-82.	1987-1997	*	
United States	Tschanz JT, Corcoran C, Skoog I, Khachaturian AS, Herrick J, Hayden KM, Welsh-Bohmer KA, Calvert T, Norton MC, Zandi P, Breitner JCS, Cache County Study Group. Dementia: the leading predictor of death in a defined elderly population: the Cache County Study. <i>Neurology</i> . 2004; 62(7): 1156-62.	1996-2001	*	
United States	Steffens DC, Skoog I, Norton MC, Hart AD, Tschanz JT, Plassman BL, Wyse BW, Welsh-Bohmer KA, Breitner JC. Prevalence of depression and its treatment in an elderly population: the Cache County study. <i>Arch Gen Psychiatry</i> . 2000; 57(6): 601-7.	1995-1996	*	
United States	Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. <i>Arch Gen Psychiatry</i> . 2004; 61(8): 807-16.	2001-2002		
United States	Roberts RE, Roberts CR, Xing Y. Rates of DSM-IV psychiatric disorders among adolescents in a large metropolitan area. <i>J Psychiatr Res</i> . 2007; 41(11): 959-67.	2000-2001		
United States	WHO Regional Office for Europe (EURO-WHO). Young People's Health in Context. Health Behaviour in School-aged Children (HBSC) Study: International Report from the 2001-2002 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2004.	2001		
United States	WHO Regional Office for Europe (EURO-WHO). Inequalities in Young People's Health: HBSC International Report from the 2005/2006 Survey. Copenhagen, Denmark: WHO Regional Office for Europe (EURO-WHO), 2008.	2006	*	
United States	National Institute on Alcohol Abuse and Alcoholism (NIAAA). United States National Epidemiologic Survey on Alcohol and Related Conditions 2001-2002.	2001-2002	*	
United States	National Institute on Alcohol Abuse and Alcoholism (NIAAA). United States National Epidemiologic Survey on Alcohol and Related Conditions 2004-2005.	2004-2005	*	
United States	United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality. National Survey on Drug Use and Health, 2012. ICPSR34933-v1. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2013-11-26. doi:10.3886/ICPSR34933.v1	2012		
United States	Coomber K, Tombourou JW, Miller P, Staiger PK, Hemphill SA, Catalano RF. Rural adolescent alcohol, tobacco, and illicit drug use: a comparison of students in Victoria, Australia, and Washington State, United States. <i>J Rural Health</i> . 2011; 27(4): 409-15.	2002		
United States	Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. United States Monitoring the Future: National Survey Results on Drug Use, 1975-2004: Volume II: College Students and Adults Ages 19-45. Bethesda, MD: National Institute on Drug Abuse; 2005. 278 p.	2004		
United States	Aitken SS, DeSantis J, Harford TC, Cases MF. Marijuana use among adults. A longitudinal study of current and former users. <i>J Subst Abuse</i> . 2000; 12(3): 213-26.	1994	*	
United States	Miech R, Chilcoat H. The formation of a socioeconomic disparity: a case study of cocaine and marijuana use in the 1990s. <i>Am J Prev Med</i> . 2007; 32(6 Suppl): S171-176.	1992, 1994, 1998	*	
United States	Acosta CD, Knight M, Lee HC, Kurinczuk JJ, Gould JB, Lyndon A. The continuum of maternal sepsis severity: incidence and risk factors in a population-based cohort study. <i>PLoS One</i> . 2013; 8(7): e67175.	2005-2007	*	
United States	Bryant A, Mhyre JM, Leftert LR, Hoban RA, Yakoob MY, Bateman BT. The association of maternal race and ethnicity and the risk of postpartum hemorrhage. <i>Anesth Analg</i> . 2012; 115(5): 1127-36.	2005-2008	*	
United States	Cabangan ET, Ngu EM, McGinley EL. Racial/ethnic disparities in maternal morbidities: a statewide study of labor and delivery hospitalizations in Wisconsin. <i>Matern Child Health J</i> . 2012; 16(7): 1455-67.	2005-2007		
United States	Knight KM, Pressman EK, Hackney DN, Thornburg LL. Perinatal outcomes in type 2 diabetic patients compared with non-diabetic patients matched by body mass index. <i>J Matern Fetal Neonatal Med</i> . 2012; 25(6): 611-5.	2000-2008	*	
United States	Kramer MS, Berg C, Abenhaim H, Dahhou M, Rouleau J, Mehrabadi A, Joseph KS. Incidence, risk factors, and temporal trends in severe postpartum hemorrhage. <i>Am J Obstet Gynecol</i> . 2013; 209(5): 449e1-7.	1999-2008	*	
United States	Magann EF, Doherty DA, Sandlin AT, Chauhan SP, Morrison JC. The effects of an increasing gradient of maternal obesity on pregnancy outcomes. <i>Aust N Z J Obstet Gynaecol</i> . 2013; 53(3): 250-7.	2007-2008		
United States	Mendola P, Laughon SK, Männistö TI, Leishar K, Reddy UM, Chen Z, Zhang J. Obstetric complications among US women with asthma. <i>Am J Obstet Gynecol</i> . 2013; 208(2): 127e1-8.	2002-2008	*	
United States	Small MJ, James AH, Kershaw T, Thames B, Gunatilake R, Brown H. Near-miss maternal mortality: cardiac dysfunction as the principal cause of obstetric intensive care unit admissions. <i>Obstet Gynecol</i> . 2012; 119(2 Pt 1): 250-5.	2005-2011	*	
United States	Savitz DA, Danilack VA, Engel SM, Elston B, Lipkind HS. Descriptive Epidemiology of Chronic Hypertension, Gestational Hypertension, and Preeclampsia in New York State, 1995-2004. <i>Matern Child Health J</i> . 2013.	1995-2004	*	
United States	Al-Safi Z, Inudia AN, Filetti LC, Hobson DT, Bahado-Singh RO, Awonuga AO. Delayed postpartum preeclampsia and eclampsia: demographics, clinical course, and complications. <i>Obstet Gynecol</i> . 2011; 118(5): 1102-7.	2003-2009	*	
United States	Bullock N, Breese McCoy SJ, Payton ME. Role of race in the seasonality of deliveries with preeclampsia. <i>Med Hypotheses</i> . 2011; 77(4): 674-6.	2005-2007	*	
United States	Cripe SM, O'Brien W, Gelaye B, Williams MA. Perinatal outcomes of Southeast Asians with pregnancies complicated by gestational diabetes mellitus or preeclampsia. <i>J Immigr Minor Health</i> . 2012; 14(5): 747-53.	1993-2006	*	
United States	Cruz MO, Gao W, Hibbard JU. Obstetrical and perinatal outcomes among women with gestational hypertension, mild preeclampsia, and mild chronic hypertension. <i>Am J Obstet Gynecol</i> . 2011; 205(3): 260e1-9.	2002-2008	*	
United States	Czerwinski S, Gollero J, Qiu C, Sorensen TK, Williams MA. Migraine-asthma comorbidity and risk of hypertensive disorders of pregnancy. <i>J Pregnancy</i> . 2012; 2012(858097).	1996-2008	*	
United States	Fong A, Chau CT, Pan D, Ogunyemi DA. Clinical morbidities, trends, and demographics of eclampsia: a population-based study. <i>Am J Obstet Gynecol</i> . 2013; 209(3): 229e1-7.	2001-2007	*	
United States	Fortner RT, Pekow PS, Whitcomb BW, Sievert LL, Markenson G, Chasan-Taber L. Physical activity and hypertensive disorders of pregnancy among Hispanic women. <i>Med Sci Sports Exerc</i> . 2011; 43(4): 639-46.	2000-2004	*	
United States	Gong J, Savitz DA, Stein CR, Engel SM. Maternal ethnicity and pre-eclampsia in New York City, 1995-2003. <i>Paediatr Perinat Epidemiol</i> . 2012; 26(1): 45-52.	1995-2003	*	
United States	Cheng YW, Kaimal AJ, Snowden JM, Nicholson JM, Caughey AB. Induction of labor compared to expectant management in low-risk women and associated perinatal outcomes. <i>Am J Obstet Gynecol</i> . 2012; 207(6): 502e1-8.	2005	*	
United States	Mann JR, McDermott S. Maternal pre-eclampsia is associated with childhood epilepsy in South Carolina children insured by Medicaid. <i>Epilepsy Behav</i> . 2011; 20(3): 506-11.	1996-2002	*	
United States	Mbah AK, Alio AP, Fombo DW, Bruder K, Dagne G, Saliu HM. Association between cocaine abuse in pregnancy and placenta-associated syndromes using propensity score matching approach. <i>Early Hum Dev</i> . 2012; 88(6): 333-7.	1998-2007	*	
United States	McPherson JA, Harper LM, Odibo AO, Roehl KA, Cahill AG. Maternal seizure disorder and risk of adverse pregnancy outcomes. <i>Am J Obstet Gynecol</i> . 2013; 208(5): 378e1-5.	1990-2009	*	
United States	Myatt L, Clifton RG, Roberts JM, Spong CY, Hautz JC, Varner MW, Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Iams JD, Sciscione A, Harper M, Tolosa JE, Saade G, Sorokin Y, Anderson GD, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. First-trimester prediction of preeclampsia in nulliparous women at low risk. <i>Obstet Gynecol</i> . 2012; 119(6): 1234-42.	2004-2008	*	
United States	Myatt L, Clifton RG, Roberts JM, Spong CY, Hautz JC, Varner MW, Wapner RJ, Thorp JM Jr, Mercer BM, Grobman WA, Ramin SM, Carpenter MW, Samuels P, Sciscione A, Harper M, Tolosa JE, Saade G, Sorokin Y, Anderson GD, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units Network (MFMU). The utility of uterine artery Doppler velocimetry in prediction of preeclampsia in a low-risk population. <i>Obstet Gynecol</i> . 2012; 120(4): 815-22.	2004-2008	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	O'Brien LM, Bullough AS, Owusu JT, Tremblay KA, Brincat CA, Chames MC, Kalbfleisch JD, Chervin RD. Pregnancy-onset habitual snoring, gestational hypertension, and preeclampsia: prospective cohort study. <i>Am J Obstet Gynecol.</i> 2012; 207(6): 487e1-9.	2007-2010	*	
United States	Roberts CL, Ford JB, Aljert CS, Antonsen S, Chalmers J, Cnattingius S, Grakhal M, Kotelchuck M, Melve KK, Langridge A, Morris C, Morris JM, Nassar N, Norman JE, Norrie J, Sorensen HT, Walker R, Weir CJ. Population-based trends in pregnancy hypertension and pre-eclampsia: an international comparative study. <i>BMJ Open.</i> 2011; 1(1): e000101.	1998-2007	*	
United States	Rudra CB, Williams MA, Sheppard L, Koenig JQ, Schiff MA. Ambient carbon monoxide and fine particulate matter in relation to preeclampsia and preterm delivery in western Washington State. <i>Environ Health Perspect.</i> 2011; 119(6): 886-92.	1996-2006	*	
United States	Salihi HM, Kornosky JL, Lynch O, Alio AP, August EM, Marty PJ. Impact of prenatal alcohol consumption on placenta-associated syndromes. <i>Alcohol.</i> 2011; 45(1): 73-9.	1989-2005	*	
United States	Schenone MH, Miller D, Samson JE, Mari G. Eclampsia characteristics and outcomes: a comparison of two eras. <i>J Pregnancy.</i> 2013; 2013: 826045.	1998-2011	*	
United States	Tong VT, Zotti ME, Hsia J. Impact of the Red River catastrophic flood on women giving birth in North Dakota, 1994-2000. <i>Matern Child Health J.</i> 2011; 15(3): 281-8.	1994-2000	*	
United States	Wellington K, Mulla ZD. Seasonal trend in the occurrence of preeclampsia and eclampsia in Texas. <i>Am J Hypertens.</i> 2012; 25(1): 115-9.	2007	*	
United States	Baker AM, Haeri S. Estimating risk factors for development of preeclampsia in teen mothers. <i>Arch Gynecol Obstet.</i> 2012; 286(5): 1093-6.	2000-2004	*	
United States	Aliyu MH, Lynch O, Wilson RE, Alio AP, Kristensen S, Marty PJ, Whiteman VE, Salihi HM. Association between tobacco use in pregnancy and placenta-associated syndromes: a population-based study. <i>Arch Gynecol Obstet.</i> 2011; 283(4): 729-34.	1989-2005	*	
United States	Noonan CW, Williamson DM, Henry JP, Indian R, Lynch SG, Neuberger JS, Schiffer R, Trotter J, Wagner L, Marrie RA. The prevalence of multiple sclerosis in 3 US communities. <i>Prev Chronic Dis.</i> 2010; 7(1): A12.	1998-2000	*	
United States	Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. <i>Epilepsia.</i> 1993; 34(3): 453-68.	1980	*	
United States	Annegers JF, Dubinsky S, Coan SP, Newmark ME, Rohl L. The incidence of epilepsy and unprovoked seizures in multiethnic, urban health maintenance organizations. <i>Epilepsia.</i> 1999; 40(4): 502-6.	1988-1994	*	
United States	Benn EKT, Hauser WA, Shih T, Leary L, Bagiella E, Dayan P, Green R, Andrews H, Thurman DJ, Hesdorffer DC. Estimating the incidence of first unprovoked seizure and newly diagnosed epilepsy in the low-income urban community of Northern Manhattan, New York City. <i>Epilepsia.</i> 2008; 49(8): 1431-9.	2003-2005	*	
United States	Hussain SA, Haut SR, Lipton RB, Derby C, Markowitz SY, Shinnar S. Incidence of epilepsy in a racially diverse, community-dwelling, elderly cohort: results from the Einstein aging study. <i>Epilepsy Res.</i> 2006; 71(2-3): 195-205.	2003-2006	*	
United States	Holden EW, Thanh Nguyen H, Grossman E, Robinson S, Nelson LS, Gunter MJ, Von Worley A, Thurman DJ. Estimating prevalence, incidence, and disease-related mortality for patients with epilepsy in managed care organizations. <i>Epilepsia.</i> 2005; 46(2): 311-9.	1996-2001	*	
United States	Logrosino G, Hesdorffer DC. Methodologic issues in studies of mortality following epilepsy: measures, types of studies, sources of cases, cohort effects, and competing risks. <i>Epilepsia.</i> 2005; 3-7.	1980	*	
United States	Ruggles KH, Haessly SM, Berg RL. Prospective study of seizures in the elderly in the Marshfield Epidemiologic Study Area (MESA). <i>Epilepsia.</i> 2001; 42(12): 1594-9.	1996-1998	*	
United States	Kelvin EA, Hesdorffer DC, Bagiella E, Andrews H, Pedley TA, Shih TT, Leary L, Thurman DJ, Hauser WA. Prevalence of self-reported epilepsy in a multiracial and multiethnic community in New York City. <i>Epilepsy Res.</i> 2007; 77(2-3): 141-50.	2004-2005	*	†
United States	Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940-1980. <i>Epilepsia.</i> 1991; 32(4): 429-45.	1980	*	
United States	Cowan LD, Bodensteiner JB, Leviton A, Doherty L. Prevalence of the epilepsies in children and adolescents. <i>Epilepsia.</i> 1989; 30(1): 94-106.	1983	*	
United States	Ferguson PL, Chirpich J, Smith G, Dong B, Wannamaker BB, Kobau R, Thurman DJ, Selassie AW. Prevalence of self-reported epilepsy, health care access, and health behaviors among adults in South Carolina. <i>Epilepsy Behav.</i> 2008; 13(3): 529-34.	2003-2005	*	
United States	Kobau R, Zahran H, Thurman DJ, Zack MM, Henry TR, Schachter SC, Price PH. Centers for Disease Control and Prevention (CDC). <i>Epilepsy Surveillance Among Adults - 19 States, Behavioral Risk Factor Surveillance System, 2005. MMWR Surveill Summ.</i> 2008; 57(6): 1-20.	2005	*	
United States	Kobau R, Zahran H, Grant D, Thurman DJ, Price PH, Zack MM. Prevalence of active epilepsy and health-related quality of life among adults with self-reported epilepsy in California: California Health Interview Survey, 2003. <i>Epilepsia.</i> 2007; 48(10): 1904-13.	2003	*	
United States	Kobau R, Gilliam F, Thurman DJ. Prevalence of self-reported epilepsy or seizure disorder and its associations with self-reported depression and anxiety: results from the 2004 HealthStyles Survey. <i>Epilepsia.</i> 2006; 47(11): 1915-21.	2004	*	
United States	Centers for Disease Control and Prevention (CDC). Recommendations of the International Task Force for Disease Eradication. <i>MMWR Recomm Rep.</i> 1993; 42(RR-16): 1-38.	1986-1990		
United States	Haerer AF, Anderson DW, Schoenberg BS. Prevalence and clinical features of epilepsy in a biracial United States population. <i>Epilepsia.</i> 1986; 27(1): 66-75.	1978		†
United States	McClellan W, Warnock DG, McClure L, Campbell RC, Newsome BB, Howard V, Cushman M, Howard G. Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study. <i>J Am Soc Nephrol.</i> 2006; 17(6): 1710-5.	2005		
United States	Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. <i>Am J Psychiatry.</i> 1994; 151(7): 979-86.	1990-1992		
United States	Bruce ML, Leaf PJ, Rozal GP, Florio L, Hoff RA. Psychiatric status and 9-year mortality data in the New Haven Epidemiologic Catchment Area Study. <i>Am J Psychiatry.</i> 1994; 151(5): 716-21.	1980-1989		
United States	Cohen P, Cohen J, Kasen S, Velez CN, Hartmark C, Johnson J, Rojas M, Brook J, Streuning EL. An epidemiological study of disorders in late childhood and adolescence-I. Age- and gender-specific prevalence. <i>J Child Psychol Psychiatry.</i> 1993; 34(6): 851-67.	1983-1986		
United States	Gallo JJ, Bogner HR, Morales KH, Post EP, Ten Have T, Bruce ML. Depression, cardiovascular disease, diabetes, and two-year mortality among older, primary-care patients. <i>Am J Geriatr Psychiatry.</i> 2005; 13(9): 748-55.	2001-2003		
United States	Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. <i>J Affect Disord.</i> 1993; 29(2-3): 85-96.	1990-1992		
United States	Kessler RC, Walters EE. Epidemiology of DSM-III-R major depression and minor depression among adolescents and young adults in the National Comorbidity Survey. <i>Depress Anxiety.</i> 1998; 7(1): 3-14.	1990-1992		
United States	Mojtabai R, Olfson M. Major depression in community-dwelling middle-aged and older adults: prevalence and 2- and 4-year follow-up symptoms. <i>Psychol Med.</i> 2004; 34(4): 623-34.	1996		
United States	Zheng D, Macera CA, Croft JB, Giles WH, Davis D, Scott WK. Major depression and all-cause mortality among white adults in the United States. <i>Ann Epidemiol.</i> 1997; 7(3): 213-8.	1989-1991		
United States	Fox CS, Larson MG, Vasan RS, Guo CY, Parise H, Levy D, Leip EP, O'donnell CJ, D'Agostino RB Sr, Benjamin EJ. Cross-sectional association of kidney function with valvular and annular calcification: the Framingham heart study. <i>J Am Soc Nephrol.</i> 2006; 17(2): 521-7.	1995-1998		
United States	Brown WW, Peters RM, Ohmit SE, Keane WF, Collins A, Chen SC, King K, Klag MJ, Molony DA, Flack JM. Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP). <i>Am J Kidney Dis.</i> 2003; 42(1): 22-35.	2000-2001		
United States	Bell BP, Manos MM, Zaman A, Terrault N, Thomas A, Navarro VJ, Dhore KB, Murphy RC, Van Ness GR, Stabach N, Robert ME, Bower WA, Bialek SR, Sofair AN. The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance. <i>Am J Gastroenterol.</i> 2008; 103(11): 2727-37.	1999-2001		
United States	Hyams KC. Chronic liver disease among U.S. military patients: the role of hepatitis C and G virus infection. <i>Mil Med.</i> 2000; 165(3): 178-9.	1994-1996		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	Sarbah SA, Gramlich T, Younoszai A, Osmack P, Goormastic M, Grosso L, Cooper JN, Di Bisceglie A, Seneca R, Younoszai ZM. Risk factors for hepatocellular carcinoma in patients with cirrhosis. <i>Dig Dis Sci.</i> 2004; 49(5): 850-3.	1989-2000		
United States	Chalasani N, Horlander JC Sr, Said A, Hoen H, Kopecky KK, Stockberger SM Jr, Manam R, Kwo PY, Lumeng L. Screening for hepatocellular carcinoma in patients with advanced cirrhosis. <i>Am J Gastroenterol.</i> 1999; 94(10): 2988-93.	1994-1997		
United States	Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. <i>Gastroenterology.</i> 2004; 127(5): 1372-80.	1993-1999		
United States	Davila JA, Weston A, Smalley W, El-Serag HB. Utilization of screening for hepatocellular carcinoma in the United States. <i>J Clin Gastroenterol.</i> 2007; 41(8): 777-82.	1998-2003		
United States	Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, Lok ASF, Hussain KB, Gish R, Van Thiel DH, Younoszai Z, Tong M, Hassanein T, Balart L, Fleckenstein J, Flamm S, Blei A, Befeler AS, Liver Cancer Network. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. <i>Am J Gastroenterol.</i> 2003; 98(9): 2060-3.	1997-1999		
United States	Hassan MM, Frome A, Patt YZ, El-Serag HB. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. <i>J Clin Gastroenterol.</i> 2002; 35(3): 266-9.	1993-1998		
United States	Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. <i>J Hepatol.</i> 2005; 42(2): 218-24.	2002-2003		
United States	Yang JD, Harnsen WS, Slettedahl SW, Chaiterakij R, Enders FT, Therneau TM, Orsini L, Kim WR, Roberts LR. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. <i>Clin Gastroenterol Hepatol.</i> 2011; 9(7): 617-623.	2007-2009		
United States	Yang JD, Kim B, Sanderson SO, St Sauver JL, Yawn BP, Pedersen RA, Larson JJ, Therneau TM, Roberts LR, Kim WR. Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008. <i>Mayo Clin Proc.</i> 2012; 87(1): 9-16.	1991-2008	*	
United States	Yu L, Sloane DA, Guo C, Howell CD. Risk factors for primary hepatocellular carcinoma in black and white Americans in 2000. <i>Clin Gastroenterol Hepatol.</i> 2006; 4(3): 355-60.	2000	*	
United States	Gwynn RC, McQuiston HL, McVeigh KH, Garg RK, Frieden TR, Thorpe LE. Prevalence, diagnosis, and treatment of depression and generalized anxiety disorder in a diverse urban community. <i>Psychiatr Serv.</i> 2008; 59(6): 641-7.	2004	*	
United States	Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. <i>Arch Gen Psychiatry.</i> 2005; 62(10): 1097-106.	2001-2002	*	
United States	Lavigne JV, Lebaillly SA, Hopkins J, Gouze KR, Binns HJ. The prevalence of ADHD, ODD, depression, and anxiety in a community sample of 4-year-olds. <i>J Clin Child Adolesc Psychol.</i> 2009; 38(3): 315-28.	2005-2006		
United States	Steffens DC, Fisher GG, Langa KM, Potter GG, Plassman BL. Prevalence of depression among older Americans: the Aging, Demographics and Memory Study. <i>Int Psychogeriatr.</i> 2009; 21(5): 879-88.	2001-2003		
United States	Kramer H, Toto R, Peshock R, Cooper R, Victor R. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. <i>J Am Soc Nephrol.</i> 2005; 16(2): 507-13.	2000-2002		
United States	Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, Bleyer A, Newman A, Siscovick D, Psaty B. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. <i>JAMA.</i> 2005; 293(14): 1737-45.	1989-1993		
United States	McCullough PA, Li S, Jurkovic CT, Stevens L, Collins AJ, Chen SC, Norris KC, McFarlane S, Johnson B, Shlipak MG, Obialo CI, Brown WW, Vassalotti J, Whaley-Connell AT, Brenner RM, Bakris GL, KEEP Investigators. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. <i>Am Heart J.</i> 2008; 156(2): 277-83.	2000-2005		
United States	Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. <i>Kidney Int.</i> 2003; 63(3): 1121-9.	1989-1994		
United States	Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. <i>JAMA.</i> 2007; 298(17): 2038-47.	1988-1994, 1999-2004		
United States	Ibrahim HN, Wang C, Ishani A, Collins AJ, Foley RN. Screening for chronic kidney disease complications in US adults: racial implications of a single GFR threshold. <i>Clin J Am Soc Nephrol.</i> 2008; 3(6): 1792-9.	2003-2006	*	
United States	Shankar A, Klein R, Klein BE. The association among smoking, heavy drinking, and chronic kidney disease. <i>Am J Epidemiol.</i> 2006; 164(3): 263-71.	1993-1995	*	
United States	Barbareis WJ, Colligan RC, Weaver AL, Katusic SK. The incidence of clinically diagnosed versus research-identified autism in Olmsted County, Minnesota, 1976-1997: results from a retrospective, population-based study. <i>J Autism Dev Disord.</i> 2009; 39(3): 464-70.	1980-1997	*	
United States	Centers for Disease Control and Prevention (CDC). Prevalence of Autism Spectrum Disorders - Autism and Developmental Disabilities Monitoring Network, 14 Sites, United States, 2008. <i>MMWR Surveill Summ.</i> 2012; 61(3): 1-19.	2008		
United States	Windham GC, Anderson MC, Croen LA, Smith KS, Collins J, Grether JK. Birth prevalence of autism spectrum disorders in the San Francisco Bay area by demographic and ascertainment source characteristics. <i>J Autism Dev Disord.</i> 2011; 41(10): 1362-72.	1994, 1996		
United States	Croen LA, Grether JK, Hoogstrate J, Selvin S. The Changing Prevalence of Autism in California. <i>J Autism Dev Disord.</i> 2002; 32(3): 207D15.	1987-1999		
United States	Ritvo ER, Freeman BJ, Pingree C, Mason-Brothers A, Jorde L, Jensen WR, McMahon WM, Petersen PB, Mo A, Ritvo A. The UCLA-University of Utah epidemiologic survey of autism: prevalence. <i>Am J Psychiatry.</i> 1989; 146(2): 194D9.	1985		
United States	Shavelle RM, Strauss DJ, Pickett J. Causes of Death in Autism. <i>J Autism Dev Disord.</i> 2001; 31(6): 569D76.	1997	*	
United States	Yeargin-Allsopp M, Rice C, Karapurkar T, Doernberg N, Boyle C, Murphy C. Prevalence of autism in a US metropolitan area. <i>JAMA.</i> 2003; 289(1): 49D55.	1996	*	
United States	Kessler RC, Avenevoli S, Costello EJ, Georgiades K, Green JG, Gruber MJ, He J, Koretz D, McLaughlin KA, Petukhova M, Sampson NA, Zaslavsky AM, Merikangas KR. Prevalence, persistence, and sociodemographic correlates of DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement. <i>Arch Gen Psychiatry.</i> 2012; 69(4): 372-80.	2001-2004	*	
United States	Merikangas KR, He J-P, Brody D, Fisher PW, Bourdon K, Koretz DS. Prevalence and treatment of mental disorders among US children in the 2001-2004 NHANES. <i>Pediatrics.</i> 2010; 125(1): 75-81.	2001-2004	*	
United States	Roberts RE, Roberts CR, Chan W. One-year incidence of psychiatric disorders and associated risk factors among adolescents in the community. <i>J Child Psychol Psychiatry.</i> 2009; 50(4): 405-15.	2000-2001	*	
United States	Grant BF, Goldstein RB, Chou SP, Huang B, Stinson FS, Dawson DA, Saha TD, Smith SM, Pulay AJ, Pickering RP, Ruan WJ, Compton WM. Sociodemographic and psychopathologic predictors of first incidence of DSM-IV substance use, mood and anxiety disorders: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. <i>Mol Psychiatry.</i> 2009; 14(11): 1051-66.	2001-2005		
United States	Tien AY, Eaton WW. Psychopathologic precursors and sociodemographic risk factors for the schizophrenia syndrome. <i>Arch Gen Psychiatry.</i> 1992; 49(1): 37-46.	1980-1984	*	
United States	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012	*	
United States	August GI, Realnuto GM, MacDonald AW 3rd, Nugent SM, Crosby R. Prevalence of ADHD and comorbid disorders among elementary school children screened for disruptive behavior. <i>J Abnorm Child Psychol.</i> 1996; 24(5): 571-95.	1994	*	
United States	Barbareis WJ, Colligan RC, Weaver AL, Voigt RG, Killian JM, Katusic SK. Mortality, ADHD, and psychosocial adversity in adults with childhood ADHD: a prospective study. <i>Pediatrics.</i> 2013; 131(4): 637-44.	1972-2009	*	
United States	Biederman J, Petty CR, Evans M, Small J, Faraone SV. How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD. <i>Psychiatry Res.</i> 2010; 177(3): 299-304.	1990-2004	*	
United States	Loeber R, Farrington DP, Stouthamer-Loeber M, Moffitt TE, Caspi A, Lynam D. Male mental health problems, psychopathy, and personality traits: key findings from the first 14 years of the Pittsburgh Youth Study. <i>Clin Child Fam Psychol Rev.</i> 2001; 4(4): 273-97.	1987	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult psychiatric status of hyperactive boys grown up. <i>Am J Psychiatry</i> . 1998; 155(4): 493-8.	1974-1991	*	
United States	Rowland AS, Umbach DM, Catoe KE, Stallone L, Long S, Rabiner D, Nafel AJ, Panke D, Faulk R, Sandler DP. Studying the epidemiology of attention-deficit hyperactivity disorder: screening method and pilot results. <i>Can J Psychiatry</i> . 2001; 46(10): 931-40.	1997	*	
United States	Shekim WO, Kashani J, Beck N, Cantwell DP, Martin J, Rosenberg J, Costello A. The prevalence of attention deficit disorders in a rural midwestern community sample of nine-year-old children. <i>J Am Acad Child Psychiatry</i> . 1985; 24(6): 765-70.	1983	*	†
United States	Velez CN, Johnson J, Cohen P. A longitudinal analysis of selected risk factors for childhood psychopathology. <i>J Am Acad Child Adolesc Psychiatry</i> . 1989; 28(6): 861-4.	1987	*	†
United States	Burnett AM, Anderson CP, Zwank MD. Laboratory-confirmed gonorrhea and/or chlamydia rates in clinically diagnosed pelvic inflammatory disease and cervicitis. <i>Am J Emerg Med</i> . 2012; 30(7): 1114-7.	2009-2010		
United States	Jossens MO, Schachter J, Sweet RL. Risk factors associated with pelvic inflammatory disease of differing microbial etiologies. <i>Obstet Gynecol</i> . 1994; 83(6): 989-97.	1981-1988		
United States	Scholes D, Satterwhite CL, Yu O, Fine D, Weinstock H, Berman S. Long-term trends in Chlamydia trachomatis infections and related outcomes in a U.S. managed care population. <i>Sex Transm Dis</i> . 2012; 39(2): 81-8.	1997-2007	*	
United States	United States - Wisconsin Beaver Dam Eye Study 1988-1990 [Unpublished] as it appears in Bourne, Rupert. <i>Vision Loss Database - Survey data on vision loss by severity and etiology</i> .	1988-1990	*	
United States	Eggleston E, Rogers SM, Turner CF, Miller WC, Roman AM, Hobbs MM, Erbeling E, Tan S, Villarreal MA, Ganapathi L. Chlamydia trachomatis infection among 15- to 35-year-olds in Baltimore, MD. <i>Sex Transm Dis</i> . 2011; 38(8): 743-9.	2006-2009	*	
United States	Blatt AJ, Lieberman JM, Hoover DR, Kaufman HW. Chlamydial and gonococcal testing during pregnancy in the United States. <i>Am J Obstet Gynecol</i> . 2012; 207(1): 55e1-8.	2005-2008	*	
United States	Berggren EK, Patchen L. Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae and repeat infection among pregnant urban adolescents. <i>Sex Transm Dis</i> . 2011; 38(3): 172-4.	2003-2006		
United States	Roberts SW, Sheffield JS, McIntire DD, Alexander JM. Urine screening for Chlamydia trachomatis during pregnancy. <i>Obstet Gynecol</i> . 2011; 117(4): 883-5.	2009	*	
United States	Choi TB, Lee DA, Oelrich FO, Amnonash D, Bateman JB, Christensen RE. A retrospective study of eye disease among first grade children in Los Angeles. <i>J Am Optom Assoc</i> . 1995; 66(8): 484-8.	1979-1988	*	
United States	Bateman BT, Berman MF, Riley LE, Leffert LR. The epidemiology of postpartum hemorrhage in a large, nationwide sample of deliveries. <i>Anesth Analg</i> . 2010; 110(5): 1368-73.	2004	*	
United States	Cherpes TL, Meyn LA, Krohn MA, Hillier SL. Risk factors for infection with herpes simplex virus type 2: role of smoking, douching, uncircumcised males, and vaginal flora. <i>Sex Transm Dis</i> . 2003; 30(5): 405-10.	1998-2000	*	
United States	Dickerson FB, Boronow JJ, Stallings C, Orioni AE, Cole S, Krivogorsky B, Yolken RH. Infection with herpes simplex virus type 1 is associated with cognitive deficits in bipolar disorder. <i>Biol Psychiatry</i> . 2004; 55(6): 588-93.	2001-2002	*	
United States	Fife KH, Bernstein DI, Tu W, Zimet GD, Brady R, Wu J, Fortenberry JD, Stone KM, Rosenthal SL, Stanberry LR. Predictors of herpes simplex virus type 2 antibody positivity among persons with no history of genital herpes. <i>Sex Transm Dis</i> . 2004; 31(11): 676-81.	1998-1999		
United States	Friedman SR, Flom PL, Kottiri BJ, Zenilman J, Curtis R, Neaigus A, Sandoval M, Quinn T, Des Jarlais DC. Drug use patterns and infection with sexually transmissible agents among young adults in a high-risk neighbourhood in New York City. <i>Addiction</i> . 2003; 98(2): 159-69.	2000-2002	*	
United States	Gottlieb SL, Douglas JM Jr, Schmid DS, Bolan G, Iatesta M, Malotte CK, Zenilman J, Foster M, Barón AE, Steiner JF, Peterman TA, Kamb ML, Project RESPECT Study Group. Seroprevalence and correlates of herpes simplex virus type 2 infection in five sexually transmitted-disease clinics. <i>J Infect Dis</i> . 2002; 186(10): 1381-9.	1993-1996	*	
United States	Kreimer AR, Alberg AJ, Daniel R, Gravitt PE, Viscidi R, Garrett ES, Shah KV, Gillison ML. Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. <i>J Infect Dis</i> . 2004; 189(4): 686-98.	2001-2002	*	
United States	Leone P, Fleming DT, Gilseman AW, Li L, Justus S. Seroprevalence of herpes simplex virus-2 in suburban primary care offices in the United States. <i>Sex Transm Dis</i> . 2004; 31(5): 311-6.	2002	*	
United States	Marrazzo JM, Stine K, Wald A. Prevalence and risk factors for infection with herpes simplex virus type-1 and -2 among lesbians. <i>Sex Transm Dis</i> . 2003; 30(12): 890-5.	1998	*	
United States	Miyai T, Turner KR, Kent CK, Klausner J. The psychosocial impact of testing individuals with no history of genital herpes for herpes simplex virus type 2. <i>Sex Transm Dis</i> . 2004; 31(9): 517-21.	2001	*	
United States	Plitt SS, Sherman SG, Strathdee SA, Taha TE. Herpes simplex virus 2 and syphilis among young drug users in Baltimore, Maryland. <i>Sex Transm Infect</i> . 2005; 81(3): 248-53.	1999-2002	*	
United States	Renzi C, Douglas JM Jr, Foster M, Critchlow CW, Ashley-Morrow R, Buchbinder SP, Koblin BA, McKirnan DJ, Mayer KH, Celum CL. Herpes simplex virus type 2 infection as a risk factor for human immunodeficiency virus acquisition in men who have sex with men. <i>J Infect Dis</i> . 2003; 187(1): 19-25.	1993-1997		
United States	Ross MW, Hwang L-Y, Zack C, Bull L, Williams ML. Sexual risk behaviours and STIs in drug abuse treatment populations whose drug of choice is crack cocaine. <i>Int J STD AIDS</i> . 2002; 13(11): 769-74.	1998-1999	*	
United States	Stanberry LR, Rosenthal SL, Mills L, Succop PA, Biro FM, Morrow RA, Bernstein DI. Longitudinal risk of herpes simplex virus (HSV) type 1, HSV type 2, and cytomegalovirus infections among young adolescent girls. <i>Clin Infect Dis</i> . 2004; 39(10): 1433-8.	2001-2003	*	
United States	Stover CT, Smith DK, Schmid DS, Pellett PE, Stewart JA, Klein RS, Mayer K, Vlahov D, Schuman P, Cannon MJ, HIV Epidemiology Research Study Group. Prevalence of and risk factors for viral infections among human immunodeficiency virus (HIV)-infected and high-risk HIV-uninfected women. <i>J Infect Dis</i> . 2003; 187(9): 1388-96.	1993-1999	*	
United States	Turner KR, McFarland W, Kellogg TA, Wong E, Page-Shafer K, Louie B, Dilley J, Kent CK, Klausner J. Incidence and prevalence of herpes simplex virus type 2 infection in persons seeking repeat HIV counseling and testing. <i>Sex Transm Dis</i> . 2003; 30(4): 331-4.	1997-2000	*	
United States	Wald A, Zeh J, Selke S, Warren T, Ashley R, Corey L. Genital shedding of herpes simplex virus among men. <i>J Infect Dis</i> . 2002; 184: 334-39.	1999-2001	*	
United States	Boucher FD, Yasukawa LL, Bronzan RN, Hensleigh PA, Arvin AM, Prober CG. A prospective evaluation of primary genital herpes simplex virus type 2 infections acquired during pregnancy. <i>Pediatr Infect Dis J</i> . 1990; 9(7): 499-504.	1993-2001	*	
United States	Bunnell RE, Dahlberg L, Rofis R, Ransom R, Gershman K, Farshy C, Newhall WJ, Schmid S, Stone K, St Louis M. High prevalence and incidence of sexually transmitted diseases in urban adolescent females despite moderate risk behaviors. <i>J Infect Dis</i> . 1999; 180(5): 1624-31.	1987-1989	*	
United States	Noell J, Rohde P, Ochs L, Yovanoff P, Alter MJ, Schmid S, Bullard J, Black C. Incidence and prevalence of chlamydia, herpes, and viral hepatitis in a homeless adolescent population. <i>Sex Transm Dis</i> . 2001; 28(1): 4-10.	1991-1997		
United States	Tabet SR, Krone MR, Paradise MA, Corey L, Stamm WE, Celum CL. Incidence of HIV and sexually transmitted diseases (STD) in a cohort of HIV-negative men who have sex with men (MSM). <i>AIDS</i> . 1998; 12(15): 2041-8.	1984-1985	*	†
United States	Gonzales, R. Assessing participants in the Methamphetamine Treatment Project 3 years After Treatment. Presented at: Annual Scientific College on Problems of Drug Dependence Conference on Women, Gender, and Drug Abuse Research; 2007; Quebec City, Canada.	1997	*	†
United States	Wu YW, Pham TN, Danielsen B, Townner D, Smith L, Johnston SC. Nighttime delivery and risk of neonatal encephalopathy. <i>Am J Obstet Gynecol</i> . 2011; 204(1): 37.	1999-2002	*	†
United States	Blume HK, Loch CM, Li CL. Neonatal encephalopathy and socioeconomic status: population-based case-control study. <i>Arch Pediatr Adolesc Med</i> . 2007; 161(7): 663-8.	1994-2002	*	†
United States	Shankaran S, Pappas A, McDonald SA, Vohr BR, Hintz SR, Yoltan K, Gustafson KE, Leach TM, Green C, Bara R, Petrie Huitema CM, Ehrenkrantz RA, Tyson JE, Das A, Hammond J, Peralta-Carcelen M, Evans PW, Heyne RJ, Wilson-Costello DE, Vaucher YE, Bauer CR, Dusick AM, Adams-Chapman I, Goldstein RF, Guillet R, Papile L-A, Higgins RD, Eunice Kennedy Shriver NICHD Neonatal Research Network. Childhood outcomes after hypothermia for neonatal encephalopathy. <i>N Engl J Med</i> . 2012; 366(22): 2085-92.	2000-2003	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	Eicher DJ, Wagner CL, Katikaneni LP, Hulsey TC, Bass WT, Kaufman DA, Horgan MJ, Langui S, Bhatia JJ, Givelihood LM, Sankaran K, Yager JY. Moderate hypothermia in neonatal encephalopathy: efficacy outcomes. <i>Pediatr Neurol.</i> 2005; 32(1): 11-7.	1999	*	
United States	Miller SP, Latal B, Clark H, Barnwell A, Glidden D, Barkovich AJ, Ferriero DM, Partridge JC. Clinical signs predict 30-month neurodevelopmental outcome after neonatal encephalopathy. <i>Am J Obstet Gynecol.</i> 2004; 93-9.	1994-2000		
United States	Research Triangle Institute, Inc. (RTI), Substance Abuse and Mental Health Services Administration (SAMHSA). United States National Survey on Drug Use and Health Report: Methamphetamine Use, Abuse and Dependence 2002, 2003, 2004. Rockville, United States: Substance Abuse and Mental Health Services Administration (SAMHSA), 2005.	2004	*	
United States	Pinhas-Hamiel O, Dolan LM, Daniels SR, Standiford D, Khoury PR, Zeitler P. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. <i>J Pediatr.</i> 1996; 128(5 Pt 1): 608-15.	1982, 1994	*	
United States	Courturier J, Lock J. What is recovery in adolescent anorexia nervosa? <i>Int J Eat Disord.</i> 2006; 39(7): 550-5.	1998-2004	*	
United States	Crow SJ, Peterson CB, Swanson SA, Raymond NC, Specker S, Eckert ED, Mitchell JE. Increased mortality in bulimia nervosa and other eating disorders. <i>Am J Psychiatry.</i> 2009; 166(12): 1342-6.	1997-2004	*	
United States	Korndörfer SR, Lucas AR, Suman VJ, Crowson CS, Krahn LE, Melton LJ 3rd. Long-term survival of patients with anorexia nervosa: a population-based study in Rochester, Minn. <i>Mayo Clin Proc.</i> 2003; 78(3): 278-84.	1935-1989	*	
United States	Strober M, Freeman R, Morrell W. The long-term course of severe anorexia nervosa in adolescents: survival analysis of recovery, relapse, and outcome predictors over 10-15 years in a prospective study. <i>Int J Eat Disord.</i> 1997; 22(4): 339-60.	1980-1995	*	
United States	Swanson SA, Crow SJ, Le Grange D, Swendsen J, Merikangas KR. Prevalence and correlates of eating disorders in adolescents. Results from the national comorbidity survey replication adolescent supplement. <i>Arch Gen Psychiatry.</i> 2011; 68(7): 714-23.	2001-2004	*	
United States	Keel PK, Mitchell JE, Miller KB, Davis TL, Crow SJ. Long-term outcome of bulimia nervosa. <i>Arch Gen Psychiatry.</i> 1999; 56(1): 63-9.	1981-1996	*	
United States	Goldstein A, Herrera J. Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up. <i>Drug Alcohol Depend.</i> 1995; 40(2): 139-50.	1969-1993	*	
United States	Hser Y-I. Predicting long-term stable recovery from heroin addiction: findings from a 33-year follow-up study. <i>J Addict Dis.</i> 2007; 26(1): 51-60.	1962-1997	*	
United States	Lynskey MT, Agrawal A. Psychometric properties of DSM assessments of illicit drug abuse and dependence: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). <i>Psychol Med.</i> 2007; 37(9): 1345-55.	2001-2002		
United States	Teesson M, Baillie A, Lynskey M, Manor B, Degenhardt L. Substance use, dependence and treatment seeking in the United States and Australia: a cross-national comparison. <i>Drug Alcohol Depend.</i> 2006; 81(2): 149-55.	1992		
United States	Frischer H, Bowman JE, Carson PE, Rieckmann KH, Willerson D Jr, Colwell EJ. Erythrocytic glutathione reductase, glucose-6-phosphate dehydrogenase, and 6-phosphogluconic dehydrogenase deficiencies in populations of the United States, South Vietnam, Iran, and Ethiopia. <i>J Lab Clin Med.</i> 1973; 81(4): 603-12.	1971-1973		
United States	Jim RT. Survey for erythrocyte glucose-6-phosphate dehydrogenase deficiency in Hawaii. <i>Acta Haematol.</i> 1967; 37(2): 94-9.	1965-1967		
United States	Doebelin TD, Ingall GB, Pinkerton PH, Dronamraju KR, Bannerman RM. Genetic studies of the Seneca Indians: haptoglobins, transferrins, G-6-PD deficiency, hemoglobinopathy, color blindness, morphological traits and dermatoglyphics. <i>Acta Genet Stat Med.</i> 1968; 18(3): 251-60.	1966-1968		
United States	Petrakis NL, Wiesenfeld SL, Sams BJ, Collen MF, Cutler JL, Siegelau AB. Prevalence of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency. <i>N Engl J Med.</i> 1970; 282(14): 767-70.	1968-1970		
United States	Uddin DE, Dickson LG, Brodine CE. Glucose-6-phosphate dehydrogenase deficiency in military recruits. <i>JAMA.</i> 1974; 227(12): 1408-9.	1972		
United States	Heller P, Best WR, Nelson RB, Bechtel J. Clinical implications of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency in hospitalized black male patients. <i>N Engl J Med.</i> 1979; 300(18): 1001-5.	1972-1975		
United States	Calvert AF, Trimble GE. Glucose-6-phosphate dehydrogenase in an Afro-American population. <i>Hum Hered.</i> 1980; 30(5): 271-7.	1978-1980		
United States	Hsia YE, Miyakawa F, Baltazar J, Ching NS, Yuen J, Westwood B, Beutler E. Frequency of glucose-6-phosphate dehydrogenase (G6PD) mutations in Chinese, Filipinos, and Laotians from Hawaii. <i>Hum Genet.</i> 1993; 92(5): 470-6.	1986-1992		
United States	Mansouri A, Nandy I. NADH-methemoglobin reductase (cytochrome b5 reductase) levels in two groups of American blacks and whites. <i>J Invest Med.</i> 1998; 46(2): 82-6.	1996-1998		
United States	Tungsrirat M, Drechsler H, Sarlone C, Amyot K, Laffey E, Aberg J. Prevalence and significance of G6PD deficiency in patients of an urban HIV clinic. <i>J Int Assoc Physicians AIDS Care (Chic).</i> 2008; 7(2): 88-90.	1997-2003		
United States	Chinevere TD, Murray CK, Grant E Jr, Johnson GA, Duell F, Hosenpahl DR. Prevalence of glucose-6-phosphate dehydrogenase deficiency in U.S. Army personnel. <i>Mil Med.</i> 2006; 171(9): 905-7.	2004-2005		
United States	Reiber GE, Boyko EJ, Smith DG. Lower Extremity Foot Ulcers and Amputations in Diabetes. In: <i>Diabetes in America</i> . 2nd Edition. Bethesda, MD: National Institutes of Health (NIH); 1995. 409-428.	1989		
United States	Global Lower Extremity Amputation Study Group. Epidemiology of lower extremity amputation in centres in Europe, North America and East Asia. The Global Lower Extremity Amputation Study Group. <i>Br J Surg.</i> 2000; 87(3): 328-37.	1995-1997		
United States	Otiniano ME, Du X, Ottenbacher K, Black SA, Markides KS. Lower extremity amputations in diabetic Mexican American elders: incidence, prevalence and correlates. <i>J Diabetes Complicat.</i> 2003; 17(2): 59-65.	1993-1999		
United States	Wrobel JS, Mayfield JA, Reiber GE. Geographic variation of lower-extremity major amputation in individuals with and without diabetes in the Medicare population. <i>Diabetes Care.</i> 2001; 24(5): 860-4.	1996-1997		
United States	Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. <i>J Clin Endocrinol Metab.</i> 1998; 83(9): 3078-82.	1996-1997		
United States	Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. <i>J Clin Endocrinol Metab.</i> 2004; 89(6): 2745-9.	1998-1999		
United States	Taerlink JR, Goldhaber SZ, Pfeffer MA. An overview of contemporary etiologies of congestive heart failure. <i>Am Heart J.</i> 1991; 121(6 Pt 1): 1852-3.	1989-1990		
United States	Albandar JM, Brunelle JA, Kingman A. Destructive periodontal disease in adults 30 years of age and older in the United States, 1988-1994. <i>J Periodontol.</i> 1999; 70(1): 13-29.	1988-1994		
United States	Beck JD, Lainson PA, Field HM, Hawkins BF. Risk factors for various levels of periodontal disease and treatment needs in Iowa. <i>Community Dent Oral Epidemiol.</i> 1984; 12(1): 17-22.	1980		
United States	Bhat M. Periodontal health of 14-17-year-old US schoolchildren. <i>J Public Health Dent.</i> 1991; 51(1): 5-11.	1986-1987		
United States	Brown LJ, Brunelle JA, Kingman A. Periodontal status in the United States, 1988-1991: prevalence, extent, and demographic variation. <i>J Dent Res.</i> 1996; 672-83.	1988-1991		
United States	DeStefano F, Anda RF, Kahn HS, Williamson DF, Russell CM. Dental disease and risk of coronary heart disease and mortality. <i>BMJ.</i> 1993; 306(6879): 688-91.	1971-1992		
United States	Hujoel PP, Drangsholt M, Spiekerman C, DeRouen TA. Periodontal disease and coronary heart disease risk. <i>JAMA.</i> 2000; 284(11): 1406-10.	1982-1992		
United States	Qian F, Levy SM, Warren JJ, Hand JS. Incidence of Periodontal Attachment Loss over 8 to 10 Years among Iowa Elders Aged 71+ at Baseline. <i>J Public Health Dent.</i> 2007; 67(3): 162-70.	1988-1996		
United States	Wu T, Trevisan M, Genco RJ, Dorn JP, Falkner KL, Sempos CT. Periodontal disease and risk of cerebrovascular disease: The first national health and nutrition examination survey and its follow-up study. <i>Arch Intern Med.</i> 2000; 160(18): 2749-55.	1971-1992		
United States	Barr HL, Antes D, Ottenberg DJ, Rosen A. Mortality of treated alcoholics and drug addicts: the benefits of abstinence. <i>J Stud Alcohol.</i> 1984; 45(5): 440-52.	1970-1978		
United States	Boffetta P, Garfinkel L. Alcohol drinking and mortality among men enrolled in an American Cancer Society prospective study. <i>Epidemiology.</i> 1990; 1(5): 342-8.	1959-1971		
United States	Brenner B. Alcoholism and fatal accidents. <i>Q J Stud Alcohol.</i> 1967; 28(3): 517-28.	1954-1961		
United States	Caetano R, Cunradi C. Alcohol dependence: a public health perspective. <i>Addiction.</i> 2002; 97(6): 633-45.	1990, 1995		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	Cherpitel CJ. Screening for alcohol problems in the U.S. general population: comparison of the CAGE, RAPS4, and RAPS4-QF by gender, ethnicity, and service utilization. <i>Rapid Alcohol Problems Screen. Alcohol Clin Exp Res.</i> 2002; 26(11): 1686-91.	2000		
United States	Dawson DA. Alcohol consumption, alcohol dependence, and all-cause mortality. <i>Alcohol Clin Exp Res.</i> 2000; 24(1): 72-81.	1988-1995		
United States	Grant BF. Prevalence and correlates of alcohol use and DSM-IV alcohol dependence in the United States: results of the National Longitudinal Alcohol Epidemiologic Survey. <i>J Stud Alcohol.</i> 1997; 58(5): 464-73.	1991		
United States	Hurt RD, Offord KP, Croghan IT, Gomez-Dahl L, Kotike TE, Morse RM, Melton LJ 3rd. Mortality following inpatient addictions treatment. Role of tobacco use in a community-based cohort. <i>JAMA.</i> 1996; 275(14): 1097-103.	1972-1994		
United States	Johnson RH, Robinson BJ. Mortality in alcoholics with autonomic neuropathy. <i>J Neurol Neurosurg Psychiatry.</i> 1988; 51(4): 476-80.	1979-1986		
United States	Liskow BI, Powell BJ, Penick EC, Nickel EJ, Wallace D, Landon JF, Campbell J, Cantrell PJ. Mortality in male alcoholics after ten to fourteen years. <i>J Stud Alcohol.</i> 2000; 61(6): 853-61.	1980-1994		
United States	Neumark YD, Van Etten ML, Anthony JC. "Alcohol dependence" and death: survival analysis of the Baltimore ECA sample from 1981 to 1995. <i>Subst Use Misuse.</i> 2000; 35(4): 533-49.	1981-1995		
United States	Pell S, D'Alonzo CA. A five-year mortality study of alcoholics. <i>J Occup Med.</i> 1973; 15(2): 120-5.	1965-1969		
United States	Rehm J, Greenfield TK, Rogers JD. Average volume of alcohol consumption, patterns of drinking, and all-cause mortality: results from the US National Alcohol Survey. <i>Am J Epidemiol.</i> 2001; 153(1): 64-71.	1984-1995		
United States	Vaillant GE. A 60-year follow-up of alcoholic men. <i>Addiction.</i> 2003; 98(8): 1043-51.	1940-2000	*	
United States	Woerle S, Roerber J, Landen MG. Prevalence of alcohol dependence among excessive drinkers in New Mexico. <i>Alcohol Clin Exp Res.</i> 2007; 31(2): 293-8.	2002	*	
United States	Frey CF, Zhou H, Harvey DJ, White RH. The incidence and case-fatality rates of acute biliary, alcoholic, and idiopathic pancreatitis in California, 1994-2001. <i>Pancreas.</i> 2006; 33(4): 336-44.	1994-2001	*	
United States	Yadav D, Timmons L, Benson JT, Dierkhising RA, Chari ST. Incidence, prevalence, and survival of chronic pancreatitis: a population-based study. <i>Am J Gastroenterol.</i> 2011; 106(12): 2192-9.	1977-2006		
United States	Agency for Healthcare Research and Quality. United States Medical Expenditure Panel Survey 1996-2011. Agency for Healthcare Research and Quality.	1996-2011	*	
United States	Kaye J, Michael Y, Calvert J, Leahy M, Crawford D, Kramer P. Exceptional brain aging in a rural population-based cohort. <i>J Rural Health.</i> 2009; 25(3): 320-5.	2001	*	
United States	Gordon PH, Mehal JM, Holman RC, Rowland AS, Cheek JE. Parkinson's disease among American Indians and Alaska natives: a nationwide prevalence study. <i>Mov Disord.</i> 2012; 27(11): 1456-9.	2002-2009	*	
United States	Centers for Disease Control and Prevention (CDC). Surveillance for Fetal Alcohol Syndrome Using Multiple Sources - Atlanta, Georgia, 1981-1989. <i>MMWR Morb Mortal Wkly Rep.</i> 1997; 46(47): 1118-20.	1981-1989	*	
United States	Centers for Disease Control and Prevention (CDC). Update: Trends in Fetal Alcohol Syndrome - United States, 1979-1993. <i>Morb Mortal Wkly Rep.</i> 1995; 44(13): 249-51.	1993	*	
United States	Centers for Disease Control and Prevention (CDC). Fetal Alcohol Syndrome - Alaska, Arizona, Colorado, and New York, 1995-1997. <i>Morb Mortal Wkly Rep.</i> 2002; 51(20): 433-5.	1995-1997	*	
United States	Clarren SK, Randels SP, Sanderson M, Fineman RM. Screening for fetal alcohol syndrome in primary schools: a feasibility study. <i>Teratology.</i> 2001; 63(1): 3-10.	1995-1997	*	
United States	Druschel CM, Fox DJ. Issues in estimating the prevalence of fetal alcohol syndrome: examination of 2 counties in New York State. <i>Pediatrics.</i> 2007; 119(2): e384-390.	1995-1999	*	
United States	Duimstra C, Johnson D, Kutsch C, Wang B, Zentner M, Kellerman S, Welty T. A fetal alcohol syndrome surveillance pilot project in American Indian communities in the Northern Plains. <i>Public Health Rep.</i> 1993; 108(2): 225-9.	1987-1990	*	
United States	Egeland GM, Perham-Hester KA, Gessner BD, Ingle D, Berner JE, Middaugh JP. Fetal alcohol syndrome in Alaska, 1977 through 1992: an administrative prevalence derived from multiple data sources. <i>Am J Public Health.</i> 1998; 88(5): 781-6.	1977-1992	*	
United States	May PA, Hymnbaugh KJ, Aase JM, Samet JM. Epidemiology of fetal alcohol syndrome among American Indians of the Southwest. <i>Soc Biol.</i> 1983; 30(4): 374-87.	1969-1982	*	
United States	Burd L, Klug MG, Martsoff JT, Kerbeshian J. Fetal alcohol syndrome: neuropsychiatric phenomics. <i>Neurotoxicol Teratol.</i> 2003; 25(6): 697-705.	1995-2002	*	
United States	Ouellette EM, Rossett HL, Rosman NP, Weiner L. Adverse effects on offspring of maternal alcohol abuse during pregnancy. <i>N Engl J Med.</i> 1977; 297(10): 528-30.	1974-1975	*	
United States	Sokol RJ, Miller SI, Reed G. Alcohol abuse during pregnancy: an epidemiologic study. <i>Alcohol Clin Exp Res.</i> 1980; 4(2): 135-45.	1973-1979	*	
United States	Tennes K, Blackard C. Maternal alcohol consumption, birth weight, and minor physical anomalies. <i>Am J Obstet Gynecol.</i> 1980; 138(7 Pt 1): 774-80.	1973-1979	*	
United States	Weiss M, Cronk CE, Mahkorn S, Glyschr R, Zirbel S. The Wisconsin Fetal Alcohol Syndrome Screening Project. <i>Wis Med J.</i> 2004; 103(5): 53-60.	1998-2002	*	†
United States	Chang AY, Ayers C, Minhajuddin A, Jain T, Nurenberg P, de Lemos JA, Wild RA, Auchus RJ. Polycystic ovarian syndrome and subclinical atherosclerosis among women of reproductive age in the Dallas heart study. <i>Clin Endocrinol (Oxf).</i> 2011; 74(1): 89-96.	2000-2002	*	
United States	Lipton RB, Manack A, Ricci JA, Chee E, Turkel CC, Winner P. Prevalence and burden of chronic migraine in adolescents: results of the chronic daily headache in adolescents study (C-dAS). <i>Headache.</i> 2011; 51(5): 693-706.	2010		
United States	Stewart WF, Roy J, Lipton RB. Migraine prevalence, socioeconomic status, and social causation. <i>Neurology.</i> 2013; 81(11): 948-55.	2004		
United States	Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS. Prevalence of Marijuana Use Disorders in the United States 1991-1992 and 2001-2002. <i>JAMA.</i> 2004; 291(17): 2114-21. [Unpublished].	1991-1992, 2001-2002		†
United States	Alshekhlee A, Hussain Z, Sultan B, Katriji B. Guillain-Barré syndrome: incidence and mortality rates in US hospitals. <i>Neurology.</i> 2008; 70(18): 1608-13.	2000-2004		
United States	Beghi E, Kurland LT, Mulder DW, Wiederholt WC. Guillain-Barré syndrome. Clinicoepidemiologic features and effect of influenza vaccine. <i>Arch Neurol.</i> 1985; 42(11): 1053-7.	1935-1980		†
United States	Church Potter R, Kaneene JB. A descriptive study of Guillain-Barré syndrome in high and low <i>Campylobacter jejuni</i> incidence regions of Michigan: 1992-1999. <i>Neuroepidemiology.</i> 2003; 22(4): 245-8.	1992-1999		†
United States	Hoppock KC, Greer GG, Walling AD. The incidence of Guillain-Barré syndrome in a metropolitan county, 1984-1988. <i>Kans Med.</i> 1994; 95(2): 45-7.	1984-1988		†
United States	Kaplan JE, Poduska PJ, McIntosh GC, Hopkins RS, Ferguson SW, Schonberger LB. Guillain-Barré syndrome in Larimer County, Colorado: a high-incidence area. <i>Neurology.</i> 1985; 35(4): 581-4.	1975-1983		†
United States	Koobatian TJ, Birkhead GS, Schramm MM, Vogt RL. The use of hospital discharge data for public health surveillance of Guillain-Barré syndrome. <i>Ann Neurol.</i> 1991; 30(4): 618-21.	1980-1985		
United States	Rantala H, Cherry JD, Shields WD, Uhari M. Epidemiology of Guillain-Barré syndrome in children: relationship of oral polio vaccine administration to occurrence. <i>J Pediatr.</i> 1994; 124(2): 220-3.	1980-1986		
United States	Riggs JE, Gutmann L, Whited JD. Guillain-Barre syndrome. Another immune-mediated disease with a predilection for young women? <i>W V Med J.</i> 1989; 85(9): 382-3.	1967-1987		
United States	Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailiau HF, Eddins DL, Bryan JA. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. <i>Am J Epidemiol.</i> 1979; 110(2): 105-23.	1976-1977		
United States	Adamson R, Reddy V, Jones L, Antwi M, Bregman B, Weiss D, Phillips M, Horowitz HW. Epidemiology and burden of hepatitis A, malaria, and typhoid in New York City associated with travel: implications for public health policy. <i>Am J Public Health.</i> 2010; 100(7): 1249-52.	2000-2005		
United States	Houston DE, Noller KL, Melton LJ 3rd, Selwyn BJ, Hardy RJ. Incidence of pelvic endometriosis in Rochester, Minnesota, 1970-1979. <i>Am J Epidemiol.</i> 1987; 125(6): 959-69.	1970-1979		
United States	Kjerulf KH, Erickson BA, Langenberg PW. Chronic gynecological conditions reported by US women: findings from the National Health Interview Survey, 1984 to 1992. <i>Am J Public Health.</i> 1996; 86(2): 195-9.	1984-1992		
United States	Leibson CL, Good AE, Hass SL, Ransom J, Yawn BP, OFallon WM, Melton LJ 3rd. Incidence and characterization of diagnosed endometriosis in a geographically defined population. <i>Fertil Steril.</i> 2004; 82(2): 314-21.	1987-1999		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	Missmer SA, Hankinson SE, Spiegelman D, Barbieri RL, Marshall LM, Hunter DJ. Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. <i>Am J Epidemiol</i> . 2004; 160(8): 784-96.	1989-1999		
United States	Templeman C, Marshall S, Ursin G, Hornross P, Clarke C, Allen M, Deapen D, Zogas A, Reynolds P, Cress R. Adenomyosis and Endometriosis in the California Teachers Study: Reproductive and Lifestyle Correlates. <i>Fertil Steril</i> . 2008; 90(2): 415-24.	1991-2003		
United States	Jeremias J, Draper D, Ziegert M, Jones W, Inglis S, McGregor JA, Witkin SS. Detection of <i>Trichomonas vaginalis</i> using the polymerase chain reaction in pregnant and non-pregnant women. <i>Infect Dis Obstet Gynecol</i> . 1994; 2(1): 16-9.	1994	*	
United States	Weinberger MW, Harger JH. Accuracy of the Papanicolaou smear in the diagnosis of asymptomatic infection with <i>Trichomonas vaginalis</i> . <i>Obstet Gynecol</i> . 1993; 82(3): 425-9.	1993	*	
United States	Van Naarden K, Decoufflé P, Caldwell K. Prevalence and characteristics of children with serious hearing impairment in metropolitan Atlanta, 1991-1993. <i>Pediatrics</i> . 1999; 103(3): 570-5.	1991-1993	*	
United States	Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson's disease. <i>Mov Disord</i> . 2000; 15(5): 819-25.	1976-1990	*	
United States	Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA. Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. <i>JAMA Neurol</i> . 2013; 70(7): 859-66.	1991-2005		
United States	Lamas DJ KS, Bagjella E, Philip N, Arcosoy SM, Lederer DJ. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. <i>Am J Respir Crit Care Med</i> . 2011; 184(7): 842-7.	2007-2010		
United States	Fillenbaum GG, Heyman A, Huber MS, Woodbury MA, Leiss J, Schmadre KE, Bohannon A, Trapp-Moen B. The prevalence and 3-year incidence of dementia in older Black and White community residents. <i>J Clin Epidemiol</i> . 1998; 51(7): 587-95.	1987-1989		
United States	Hendrie HC, Ogunniyi A, Hall KS, Baiyewu O, Unverzagt FW, Gureje O, Gao S, Evans RM, Ogunseyinde AO, Adeyinka AO, Musick B, Hui SL. Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. <i>JAMA</i> . 2001; 285(6): 739-47.	1992-1995	*	
United States	Miech RA, Bretnier JCS, Zandi PP, Khachaturian AS, Anthony JC, Mayer L. Incidence of AD may decline in the early 90s for men, later for women: The Cache County study. <i>Neurology</i> . 2002; 58(2): 209-18.	1995-1999	*	
United States	Fretts AM, Mozaffarian D, Siscovick DS, Heckbert SR, McKnight B, King IB, Rimm EB, Psaty BM, Sacks FM, Song X, Spiegelman D, Lemaitre RN. Associations of plasma phospholipid and dietary alpha linolenic acid with incident atrial fibrillation in older adults: the Cardiovascular Health Study. <i>J Am Heart Assoc</i> . 2013; 2(1): e003814.	1990-2008		
United States	Maynard JW, McAdams DeMarco MA, Baer AN, Kötgen A, Folsom AR, Coresh J, Gelber AC. Incident gout in women and association with obesity in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Am J Med</i> . 2012; 125(7): 717.	1987-1998	*	
United States	Shah SA, Kambur T, Chan C, Herrington DM, Liu K, Shah SJ. Relation of short-term heart rate variability to incident heart failure (from the Multi-Ethnic Study of Atherosclerosis). <i>Am J Cardiol</i> . 2013; 112(4): 533-40.	2000-2010	*	
United States	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec</i> . 2005; 80(34): 289-95.	2004	*	
United States	World Health Organization (WHO). Global leprosy situation, 2008 (additional information). <i>Wkly Epidemiol Rec</i> . 2008; 83(50): 459.	2007	*	
United States	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec</i> . 2009; 84(33): 333-40.	2008	*	
United States	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec</i> . 2010; 85(35): 337-48.	2009	*	
United States	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec</i> . 2012; 87(34): 317-28.	2011	*	
United States	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec</i> . 2013; 88(35): 365-79.	2012	*	
United States	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec</i> . 2011; 86(36): 389-99.	2010	*	
United States	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec</i> . 2001; 76(23): 173-9.	2000	*	
United States	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec</i> . 2000; 75(28): 226-31.	1999	*	
United States	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1994; 69(20): 145-51.	1993	*	
United States	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec</i> . 1997; 72(23): 165-72.	1996	*	
United States	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec</i> . 1996; 71(20): 149-56.	1995	*	
United States	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1995; 70(25): 177-82.	1994	*	
United States	Armed Forces Health Surveillance Center. Sexually transmitted infections, active component, U.S. Armed Forces, 2000-2012. <i>MSMR</i> . 2013; 20(2): 5-10.	2000-2012	*	
United States	Frenkel LM, Garratty EM, Shen JP, Wheeler N, Clark O, Bryson YJ. Clinical reactivation of herpes simplex virus type 2 infection in seropositive pregnant women with no history of genital herpes. <i>Ann Intern Med</i> . 1993; 118(6): 414-8.	1985-1988	*	
United States	Buchacz K, McFarland W, Hernandez M, Klausner JD, Page-Shafer K, Padian N, Molitor F, Ruiz JD, Bolan G, Morrow S, Katz MH. Prevalence and correlates of herpes simplex virus type 2 infection in a population-based survey of young women in low-income neighborhoods of Northern California. The Young Women's Survey Team. <i>Sex Transm Dis</i> . 2000; 27(7): 393-400.	1996-1998	*	
United States	Breinig MK, Kingsley LA, Armstrong JA, Freeman DJ, Ho M. Epidemiology of genital herpes in Pittsburgh: serologic, sexual, and racial correlates of apparent and inapparent herpes simplex infections. <i>J Infect Dis</i> . 1990; 162(2): 299-305.	1984-1987	*	
United States	Brown ZA, Selke S, Zeh J, Kopelman J, Maslow A, Ashley RL, Watts DH, Berry S, Herd M, Corey L. The acquisition of herpes simplex virus during pregnancy. <i>N Engl J Med</i> . 1997; 337(8): 509-15.	1989-1993	*	†
United States	Cook RL, Pollock NK, Rao AK, Clark DB. Increased prevalence of herpes simplex virus type 2 among adolescent women with alcohol use disorders. <i>J Adolesc Health</i> . 2002; 30(3): 169-74.	1991-1995	*	
United States	Fleming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK, St Louis ME. Herpes simplex virus type 2 in the United States, 1976 to 1994. <i>N Engl J Med</i> . 1997; 337(16): 1105-11.	1988-1994	*	
United States	Gibson JJ, Hornung CA, Alexander GR, Lee FK, Potts WA, Nahmias AJ. A cross-sectional study of herpes simplex virus types 1 and 2 in college students: occurrence and determinants of infection. <i>J Infect Dis</i> . 1990; 162(2): 306-12.	1983-1984	*	
United States	Hitti J, Watts DH, Burchett SK, Schacker T, Selke S, Brown ZA, Corey L. Herpes simplex virus seropositivity and reactivation at delivery among pregnant women infected with human immunodeficiency virus-1. <i>Am J Obstet Gynecol</i> . 1997; 177(2): 450-4.	1989-1995	*	
United States	Koutsky LA, Ashley RL, Holmes KK, Stevens CE, Critchlow CW, Kiviat N, Lipinski CM, Wolner-Hanssen P, Corey L. The frequency of unrecognized type 2 herpes simplex virus infection among women. Implications for the control of genital herpes. <i>Sex Transm Dis</i> . 1990; 17(2): 90-4.	1986	*	
United States	Lewis LM, Bernstein DI, Rosenthal SL, Stanberry LR. Seroprevalence of herpes simplex virus-type 2 in African-American college women. <i>J Natl Med Assoc</i> . 1999; 91(4): 210-2.	1996-1998	*	
United States	Sucato G, Celum C, Dithmer D, Ashley R, Wald A. Demographic rather than behavioral risk factors predict herpes simplex virus type 2 infection in sexually active adolescents. <i>Pediatr Infect Dis J</i> . 2001; 20(4): 422-6.	1994-1996	*	
United States	Wald A, Koutsky L, Ashley RL, Corey L. Genital herpes in a primary care clinic. Demographic and sexual correlates of herpes simplex type 2 infections. <i>Sex Transm Dis</i> . 1997; 24(3): 149-55.	1991-1993	*	
United States	Adler-Storzh K, Dreesman GR, Kaufman RH, Melnick JL, Adam E. A prospective study of herpes simplex virus infection in a defined population in Houston, Texas. <i>Am J Obstet Gynecol</i> . 1985; 151(5): 582-6.	1982-1984	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	Maden C, Beckmann AM, Thomas DB, McKnight B, Sherman KJ, Ashley RL, Corey L, Daling JR. Human papillomaviruses, herpes simplex viruses, and the risk of oral cancer in men. <i>Am J Epidemiol</i> . 1992; 135(10): 1093-102.	1985-1989	*	
United States	Becker TM, Wheeler CM, McGough NS, Parmenter CA, Jordan SW, Stidley CA, McPherson RS, Dorin MH. Sexually transmitted diseases and other risk factors for cervical dysplasia among southwestern Hispanic and non-Hispanic white women. <i>JAMA</i> . 1994; 271(15): 1181-8.	1989-1992		
United States	Siegel D, Golden E, Washington AE, Morse SA, Fullilove MT, Catania JA, Marin B, Hulley SB. Prevalence and correlates of herpes simplex infections. The population-based AIDS in Multiethnic Neighborhoods Study. <i>JAMA</i> . 1992; 268(13): 1702-8.	1988-1989		
United States	National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention (CDC). United States - Silicosis: Number of cases by ascertainment source—Michigan, New Jersey, Ohio, 1993-2002. Washington DC, United States: National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention (CDC), 2008.	1993-2002	*	
United States	Rosenman KD, Reilly MJ, Henneberger PK. Estimating the total number of newly-recognized silicosis cases in the United States. <i>Am J Ind Med</i> . 2003; 44(2): 141-7.	1987-1996	*	
United States	World Health Organization (WHO). WHO Global Health Observatory - Cholera: Number of Reported Cases by Country. Geneva, Switzerland: World Health Organization (WHO).	2000-2012	*	
United States	Felson DT, Zhang Y, Hannan MT, Naimark A, Weissman BN, Aliabadi P, Levy D. The incidence and natural history of knee osteoarthritis in the elderly, the Framingham Osteoarthritis Study. <i>Arthritis Rheum</i> . 1995; 38(10): 1500-5.	1984-1993	*	
United States	O'Brien KL, David A, Benson J. The effect of conjugate pneumococcal vaccine on pneumonia and otitis media among Navajo and White Mountain Apache Children. Presented at the Third International Symposium on Pneumococci and Pneumococcal Diseases; 2002 May 5-8; Anchorage (AK) United States.	1997-2000	*	
United States	Nelson JC, Jackson M, Yu O, Whitney CG, Bounds L, Bittner R, Zavitkovsky A, Jackson LA. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. <i>Vaccine</i> . 2008; 26(38): 4947-54.	1998-2004	*	
United States	Hansen J, Black S, Shinefield H, Cherian T, Benson J, Fireman B, Lewis E, Ray P, Lee J. Effectiveness of Heptavalent Pneumococcal Conjugate Vaccine in Children Younger Than 5 Years of Age for Prevention of Pneumonia: Updated Analysis Using World Health Organization Standardized Interpretation of Chest Radiographs. <i>Pediatr Infect Dis J</i> . 2006; 25(9): 779-81.	1995-1998	*	
United States	Grijalva CG, Nuorti JP, Zhu Y, Griffin MR. Increasing Incidence of Empyema Complicating Childhood Community-Acquired Pneumonia in the United States. <i>Clin Infect Dis</i> . 2010; 50(6): 805-13.	2001-2007	*	
United States	Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. <i>Lancet</i> . 2007; 369(9568): 1179-86.	2001-2004	*	
United States	Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP. Impact of Pneumococcal Conjugate Vaccination of Infants on Pneumonia and Influenza Hospitalization and Mortality in All Age Groups in the United States. <i>MBio</i> . 2011; 2(1): e00309-10.	2005-2006	*	
United States	Zhou F, Kyaw MH, Shefer A, Winston CA, Nuorti J. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. <i>Arch Pediatr Adolesc Med</i> . 2007; 161(12): 1162-8.	2004	*	†
United States	Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. <i>N Engl J Med</i> . 2013; 369(2): 155-63.	2007-2009		
United States	Lee BH, Stoll BJ, McDonald SA, Higgins RD. Neurodevelopmental Outcomes of Extremely Low Birth Weight Infants Exposed Prenatally to Dexamethasone Versus Betamethasone. <i>Pediatrics</i> . 2008; 121(2): 289-96.	2002		
United States	Lebel MH, Freij BJ, Syrogianopoulos GA, Chrane DF, Hoyt MJ, Stewart SM, Kennard BD, Olsen KD, McCracken GH Jr. Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials. <i>N Engl J Med</i> . 1988; 319(15): 964-71.	1984-1988		
United States	Wald ER, Kaplan SL, Mason EO Jr, Sabo D, Ross L, Ardit M, Wiedermann BL, Barson W, Kim KS, Yogov R. Dexamethasone therapy for children with bacterial meningitis. <i>Pediatrics</i> . 1995; 95(1): 21-8.	1989-1992		
United States	Walling AD, Kallail KJ, Phillips D, Rice RB. The epidemiology of bacterial meningitis. <i>J Am Board Fam Pract</i> . 1991; 4(5): 307-11.	1983-1987		
United States	Aronson SM, DeBuono BA, Buechner JS. Acute bacterial meningitis in Rhode Island: a survey of the years 1976 to 1985. <i>R I Med J</i> . 1991; 74(1): 33-6.	1976-1985		
United States	Belsey MA, Hoffpauir CW, Smith MHD. Dexamethasone in the Treatment of Acute Bacterial Meningitis: The Effect of Study Design on the Interpretation of Results. <i>Pediatrics</i> . 1969; 44(4): 503-13.	1960-1964		†
United States	deLemos RA, Haggerty RJ. Corticosteroids as an adjunct to treatment in bacterial meningitis: a controlled clinical trial. <i>Pediatrics</i> . 1969; 44(1): 30-4.	1959-1966		
United States	Letson GW, Gellin BG, Bulkow LR, Parks DJ, Ward JL. Severity and frequency of sequelae of bacterial meningitis in Alaska Native infants. Correlation with a scoring system for severity of sequelae. <i>Am J Dis Child</i> . 1992; 146(5): 560-6.	1980-1988		
United States	Lepper MH, Spies HW. Treatment of pneumococcal meningitis: Results when penicillin was used alone compared with those when penicillin and streptomycin were used together, with and without hydrocortisone: alternate patient studies. <i>AMA Arch Intern Med</i> . 1959; 104(2): 253-9.	1956		
United States	Cooperative Study Group. The effectiveness of hydrocortisone in the management of severe infections: A double-blind study. <i>JAMA</i> . 1963; 183(6): 462-5.	1959-1962		
United States	Arbor Research Collaborative for Health, University of Michigan Kidney Epidemiology and Cost Center (UM-KECC). United States Renal Data Extraction and Referencing System.	1994-2000		
United States	Civen R, Chaves SS, Jumaan A, Wu H, Mascota L, Gargiullo P, Seward JF. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. <i>Pediatr Infect Dis J</i> . 2009; 28(11): 954-9.	2000-2007		
United States	Choo PW, Donahue JG, Manson JE, Platt R. The Epidemiology of Varicella and Its Complications. <i>J Infect Dis</i> . 1995; 172(3): 706-12.	1990-1992		
United States	Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The Incidence of Herpes Zoster in a United States Administrative Database. <i>J Gen Intern Med</i> . 2005; 20(8): 748-53.	2000-2001		
United States	Mullooly JP, Riedinger K, Chun C, Weinmann S, Houston H. Incidence of herpes zoster, 1997-2002. <i>Epidemiol Infect</i> . 2005; 133(2): 245-53.	1997-2002		
United States	Yawn BP, Saddier P, Wollan PC, Sauer JLS, Kurland MJ, Sy LS. A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction. <i>Mayo Clin Proc</i> . 2007; 82(11): 1341-9.	1996-2001		
United States	Ragozzino MW ML 3rd, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. <i>Medicine (Baltimore)</i> . 1982; 61(5): 310-6.	1950-1959		
United States	Guess HA, Broughton DD, Melton LJ, Kurland LT. Epidemiology of Herpes Zoster in Children and Adolescents: A Population-Based Study. <i>Pediatrics</i> . 1985; 76(4): 512-7.	1960-1981		
United States	Richards P. Shingles in one family practice. <i>Arch Fam Med</i> . 1996; 5(1): 42-6.	1960-1981, 1983-1992		
United States	Effler PV, Pang L, Kisuatani P, Vorndam V, Nakata M, Ayers T, Elm J, Tom T, Reiter P, Rigau-Perez JG, Hayes JM, Mills K, Napier M, Clark GG, Gubler DJ. Dengue fever, Hawaii, 2001-2002. <i>Emerg Infect Dis</i> . 2005; 11(5): 742-9.	2001-2002		
United States	Rawlings JA, Hendricks KA, Burgess CR, Campman RM, Clark GG, Tabony LJ, Patterson MA. Dengue surveillance in Texas, 1995. <i>Am J Trop Med Hyg</i> . 1998; 59(1): 95-9.	1995		
United States	Hand JS, Hunt RJ, Kohout FJ. Five-year incidence of tooth loss in Iowans aged 65 and older. <i>Community Dent Oral Epidemiol</i> . 1991; 19(1): 48-51.	1981-1986		
United States	Hunt RJ, Hand JS, Kohout FJ, Beck JD. Incidence of tooth loss among elderly Iowans. <i>Am J Public Health</i> . 1988; 78(10): 1330-2.	1981-1983		
United States	Hunt RJ, Drake CW, Beck JD. Eighteen-month incidence of tooth loss among older adults in North Carolina. <i>Am J Public Health</i> . 1995; 85(4): 561-3.	1988-1990		
United States	Eklund SA, Burt BA. Risk factors for total tooth loss in the United States; longitudinal analysis of national data. <i>J Public Health Dent</i> . 1994; 54(1): 5-14.	1971-1984		
United States	Burt BA, Ismail AI, Morrison EC, Beltran ED. Risk factors for tooth loss over a 28-year period. <i>J Dent Res</i> . 1990; 69(5): 1126-30.	1959-1987		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	Marcus SE, Drury TF, Brown LJ, Zion GR. Tooth retention and tooth loss in the permanent dentition of adults: United States, 1988-1991. <i>J Dent Res.</i> 1996; 684-95.	1988-1991		
United States	Marcus SE, Kaste LM, Brown LJ. Prevalence and demographic correlates of tooth loss among the elderly in the United States. <i>Spec Care Dentist.</i> 1994; 14(3): 123-7.	1985-1986		
United States	Ismaïl AI, Burt BA, Brunelle JA. Prevalence of total tooth loss, dental caries, and periodontal disease in Mexican-American adults: results from the southwestern HHANES. <i>J Dent Res.</i> 1987; 66(6): 1183-8.	1982-1984		
United States	Padilha DMP, Hilgert JB, Hugo FN, Bós AJG, Ferrucci L. Number of teeth and mortality risk in the Baltimore Longitudinal Study of Aging. <i>J Gerontol A Biol Sci Med Sci.</i> 2008; 63(7): 739-44.	1978-2004		
United States	United States Renal Data System Coordinating Center. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2013.	1995, 2000, 2010-2011		
United States	Khetsuriani N, Holman RC, Lamonte-Fowlkes AC, Selik RM, Anderson LJ. Trends in encephalitis-associated deaths in the United States. <i>Epidemiol Infect.</i> 2007; 135(4): 583-91.	1988-1997, 2004		
United States	Beghi E, Nicolosi A, Kurland LT, Mulder DW, Hauser WA, Shuster L. Encephalitis and aseptic meningitis, Olmsted County, Minnesota, 1950-1981: I. Epidemiology. <i>Ann Neurol.</i> 1984; 16(3): 283-94.	1950-1981	*	
United States	Nicolosi A, Hauser WA, Beghi E, Kurland LT. Epidemiology of central nervous system infections in Olmsted County, Minnesota, 1950-1981. <i>J Infect Dis.</i> 1986; 154(3): 399-408.	1950-1981		
United States	Jiang Y, Okoro CA, Oh J, Fuller DL. Sociodemographic and health-related risk factors associated with tooth loss among adults in Rhode Island. <i>Prev Chronic Dis.</i> 2013; E45.	2008-2010		
United States	World Health Organization (WHO). Mental Illness in General Health Care: An International Study. Geneva, Switzerland: World Health Organization (WHO), 1995.	1991-1992		
United States	Robinette CD, Hrubec Z, Fraumeni JF Jr. Chronic alcoholism and subsequent mortality in World War II veterans. <i>Am J Epidemiol.</i> 1979; 109(6): 687-700.	1946-1974		
United States	Smith EM, Cloninger CR, Bradford S. Predictors of mortality in alcoholic women: prospective follow-up study. <i>Alcohol Clin Exp Res.</i> 1983; 7(2): 237-43.	1967-1980		
United States	Mackenzie A, Allen RP, Funderburk FR. Mortality and illness in male alcoholics: an 8-year follow-up. <i>Int J Addict.</i> 1986; 21(8): 865-82.	1969-1979		
United States	Hoffman JH1, Welte JW, Barnes GM. Alcohol consumption and alcohol dependence in adults in New. <i>Drug Alcohol Depend.</i> 1999; 56(1): 17-23.	1993-1994		
United States	Caetano R, Babor TF. Diagnosis of alcohol dependence in epidemiological surveys: an epidemic of youthful alcohol dependence or a case of measurement error? <i>Addiction.</i> 2006; 111-4.	2001	*	
United States	Institute for Health Metrics and Evaluation (IHME). United States National Epidemiologic Surveys on Alcohol and Related Conditions Analysis 2001-2005. [Unpublished].	2001-2005	*	
United States	Chávez GF, Cordero JF, Becerra JE. Leading major congenital malformations among minority groups in the United States, 1981-1986. <i>MMWR Surveill Summ.</i> 1988; 37(3).	1981-1986	*	
United States	Fox DJ, Druschel CM. Estimating prevalence of fetal alcohol syndrome (FAS): effectiveness of a passive birth defects registry system. <i>Birth Defects Res A Clin Mol Teratol.</i> 2003; 67(9): 604-8.	1995-1998		
United States	Streissguth AP, Barr HM, Bookstein FL, Sampson PD. The Enduring Effects of Prenatal Alcohol Exposure on Child Development: Birth Through Seven Years, a Partial Least Squares Solution. <i>Ann Arbor (MI), United States: University of Michigan Press.</i> 1993.	1974-1975	*	
United States	Gheorghade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. <i>Circulation.</i> 1998; 97(3): 282-9.	1986-1997	*	
United States	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
United States	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
United States	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
United States	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012		
United States	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013		
United States	Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, Wolfson SK. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. <i>Cardiovascular Health Study (CHS) Collaborative Research Group. Circulation.</i> 1993; 88(3): 837-45.	1989-1990		
United States	Lamar Welch VL, Casper M, Greenlund K, Zheng Z-J, Giles W, Rith-Najarian S. Prevalence of lower extremity arterial disease defined by the ankle-brachial index among American Indians: the Inter-Tribal Heart Project. <i>Ethn Dis.</i> 2002; 12(1): S1-63-7.	1992-1994		
United States	Rooks RN, Simonsick EM, Miles T, Newman A, Kritchevsky SB, Schulz R, Harris T. The Association of Race and Socioeconomic Status With Cardiovascular Disease Indicators Among Older Adults in the Health, Aging, and Body Composition Study. <i>J Gerontol B Psychol Sci Soc Sci.</i> 2002; 57(4): S247-S256.	1997-1998	*	
United States	Wattanakit K, Williams JE, Schreiner PJ, Hirsch AT, Folsom AR. Association of anger proneness, depression and low social support with peripheral arterial disease: the Atherosclerosis Risk in Communities Study. <i>Vasc Med.</i> 2005; 10(3): 199-206.	1987-1996	*	
United States	Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, Harnsen WS, Zinsmeister AR. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. <i>Am J Gastroenterol.</i> 2012; 107(1): 89-95.	1991-2005		
United States	Kuntz JL, Chrischilles EA, Pengergast JF, Herwaldt LA, Polgreen PM. Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study. <i>BMC Infect Dis.</i> 2011; 194.	2004-2007	*	
United States	National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC). United States National Ambulatory Medical Care Survey Data 1994-2009.	1994-2009	*	
United States	Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. <i>J Invest Dermatol.</i> 2011; 131(1): 67-73.	2003	*	
United States	Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. <i>J Allergy Clin Immunol.</i> 2013; 132(5): 1132-8.	2010	*	
United States	Silverberg JI, Silverberg NB. Childhood atopic dermatitis and warts are associated with increased risk of infection: A US population-based study. <i>J Allergy Clin Immunol.</i> 2014; 133(4): 1041-7.	2007	*	
United States	Bell LM, Sedlack R, Beard CM, Perry HO, Michet CJ, Kurland LT. Incidence of psoriasis in Rochester, Minn, 1980-1983. <i>Arch Dermatol.</i> 1991; 127(8): 1184-7.	1980-1983		
United States	Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. <i>J Am Acad Dermatol.</i> 2004; 51(5): 704-8.	2001	*	
United States	Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, Stern RS, Feldman SR, Rolstad T. Epidemiology of psoriatic arthritis in the population of the United States. <i>J Am Acad Dermatol.</i> 2005; 53(4): 573.	2001	*	
United States	Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. <i>J Am Acad Dermatol.</i> 2009; 60(2): 218-24.	2003-2004	*	
United States	Shibeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. <i>J Rheumatol.</i> 2000; 27(5): 1247-50.	1982-1992	*	
United States	Ballas SK, Park D, Wapner RJ. Neonatal screening for sickle cell disease in a metropolitan university hospital: efficacy and problems. <i>J Med Screen.</i> 1994; 1(4): 229-32.	1989-1990		
United States	Ewing N, Powars D, Hilburn J, Schroeder WA. Newborn diagnosis of abnormal hemoglobins from a large municipal hospital in Los Angeles. <i>Am J Public Health.</i> 1981; 71(6): 629-31.	1973-1980	*	
United States	Lorey FW, Arnopp J, Cunningham GC. Distribution of hemoglobinopathy variants by ethnicity in a multiethnic state. <i>Genet Epidemiol.</i> 1996; 13(5): 501-12.	1990-1995		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	Adamiak T, Walkiewicz-Jedrzejczak D, Fish D, Brown C, Tung J, Khan K, Faubion W Jr, Park R, Heikenen J, Yaffee M, Rivera-Bennett MT, Wiedkamp M, Stephens M, Noel R, Nugent M, Nebel J, Simpson P, Kappelman MD, Kugathasan S. Incidence, clinical characteristics, and natural history of pediatric IBD in Wisconsin: a population-based epidemiological study. <i>Inflamm Bowel Dis</i> . 2013; 19(6): 1218-23.	2000-2007		
United States	Everhart JE, Khare M, Hill M, Maurer KR. Prevalence and ethnic differences in gallbladder disease in the United States. <i>Gastroenterology</i> . 1999; 117(3): 632-9.	1988-1994		
United States	Stowe SP, Redmond SR, Stormont JM, Shah AN, Chessin LN, Segal HL, Chey WY. An epidemiologic study of inflammatory bowel disease in Rochester, New York. <i>Hospital incidence. Gastroenterology</i> . 1990; 98(1): 104-10.	1980-1989		
United States	Loftus EV Jr, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. <i>Gut</i> . 2000; 46(3): 336-43.	1984-1993		
United States	Thompson LV, Johnson SA, Shoeman JA. Single soleus muscle fiber function after hindlimb unweighting in adult and aged rats. <i>J Appl Physiol</i> . 1998; 84(6): 1937-42.	1984-1993		
United States	Ogunbi SO, Ransom JA, Sullivan K, Schoen BT, Gold BD. Inflammatory bowel disease in African-American children living in Georgia. <i>J Pediatr</i> . 1998; 133(1): 103-7.	1986-1995		
United States	Loftus CG, Loftus EVJ, Harmsen SWM, Zinsmeister AR, Tremaine WJ, Melton JLI, Sandborn WJ. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. <i>Inflamm Bowel Dis</i> . 2007; 13(3): 254-61.	1990-2001		
United States	Loftus EV Jr, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. <i>Gastroenterology</i> . 1998; 114(6): 1161-8.	1991	*	
United States	Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J. Incidence and Prevalence of Inflammatory Bowel Disease in a Northern California Managed Care Organization, 1996-2002. <i>Am J Gastroenterol</i> . 2008; 103(8): 1998-2006.	1996-2002	*	
United States	Welzel TM, Graubard BI, Quraishi S, Zeuzem S, Davila JA, El-Serag HB, McGlynn KA. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. <i>Am J Gastroenterol</i> . 2013; 108(8): 1314-21.	1994-2010	*	
United States	Meng XJ, Wiseman B, Elvinger F, Guenet DK, Toth TE, Engle RE, Emerson SU, Purcell RH. Prevalence of antibodies to hepatitis E virus in veterinarians working with swine and in normal blood donors in the United States and other countries. <i>J Clin Microbiol</i> . 2002; 40(1): 117-22.	1999-2001		
United States	Karetyny YV, Gilchrist MJ, Naides SJ. Hepatitis E virus infection prevalence among selected populations in Iowa. <i>J Clin Virol</i> . 1999; 14(1): 51-5.	1989, 1998		
United States	Redlinger T, O'Rourke K, Nickey L, Martinez G. Elevated hepatitis A and E seroprevalence rates in a Texas/Mexico border community. <i>Tex Med</i> . 1998; 94(5): 68-71.	1995		
United States	James JJ, Heath DG, Cowan DN, Polk AJ, Johnson WL, Stienmier RH. Serological markers for hepatitis types A and B among United States Army blood donors. <i>Mil Med</i> . 1981; 146(8): 562-7.	1979		
United States	Hooper RR, Cunnion SO, Conwill DE, Merrell BR, Wallace JG, Batchelor RA. Hepatitis A and B in a naval population. <i>Mil Med</i> . 1988; 153(7): 350-5.	1987		
United States	Ansdel, Abou-Sayf. Prevalence of Hepatitis A Antibody in Travelers from Hawaii. <i>J Travel Med</i> . 1996; 3(1): 27-31.	1987-1990		
United States	Hyams KC, Struewing JP, Gray GC. Seroprevalence of hepatitis A, B, and C in a United States military recruit population. <i>Mil Med</i> . 1992; 157(11): 579-82.	1989		
United States	Hawkins RE, Malone JD, Cloninger LA, Rozmajzl PJ, Lewis D, Butler J, Cross E, Gray S, Hyams KC. Risk of viral hepatitis among military personnel assigned to US Navy ships. <i>J Infect Dis</i> . 1992; 165(4): 716-9.	1989-1990		
United States	Redlinger T, O'Rourke K, VanDerslice J. Hepatitis A among schoolchildren in a US-Mexico border community. <i>Am J Public Health</i> . 1997; 87(10): 1715-7.	1996		
United States	Villano SA, Nelson KE, Vlahov D, Purcell RH, Saah AJ, Thomas DL. Hepatitis A among homosexual men and injection drug users: more evidence for vaccination. <i>Clin Infect Dis</i> . 1997; 25(3): 726-8.	1996		
United States	Leach CT, Koo FC, Hilsenbeck SG, Jensen HB. The epidemiology of viral hepatitis in children in South Texas: increased prevalence of hepatitis A along the Texas-Mexico border. <i>J Infect Dis</i> . 1999; 180(2): 509-13.	1996-1997		
United States	Chien NT, Dundoo G, Horani MH, Osmack P, Morley JH, Di Bisceglie AM. Seroprevalence of viral hepatitis in an older nursing home population. <i>J Am Geriatr Soc</i> . 1999; 47(9): 1110-3.	1996-1997		
United States	Fishbain JT, Eckart RE, Harner KC, Hospenthal DR. Empiric immunization versus serologic screening: developing a cost-effective strategy for the use of hepatitis A immunization in travelers. <i>J Travel Med</i> . 2002; 9(2): 71-5.	1997-1998		
United States	Dentinger CM, Heinrich NL, Bell BP, Fox LM, Katz DJ, Culver DH, Shapiro CN. A prevalence study of hepatitis A virus infection in a migrant community: Is hepatitis A vaccine indicated? <i>J Pediatr</i> . 2001; 138(5): 705-9.	1998		
United States	Alagappan K, Barnett B, Napolitano A, Gressin J, Auerbach C. Seroprevalence of hepatitis A among hospital dietary workers: implications for screening and immunization. <i>Am J Med Qual</i> . 2001; 16(4): 145-8.	1998-1999		
United States	Hirota WK, Duncan MB, Hirota WK, Tsuchida A. The utility of prescreening for hepatitis A in military recruits prior to vaccination. <i>Mil Med</i> . 2002; 167(11): 907-10.	1999	*	†
United States	Nevin RL, Niebuhr DW. Rising hepatitis A immunity in U.S. military recruits. <i>Mil Med</i> . 2007; 172(7): 787-93.	2004	*	†
United States	Johnson L, Bhutani VK, Karp K, Sivieri EM, Shapiro SM. Clinical report from the pilot USA Kernicterus Registry (1992 to 2004). <i>J Perinatol</i> . 2009; S25-45.	1992-2004		
United States	Steiner LA, Bizarro MJ, Ehrenkranz RA, Gallagher PG. A decline in the frequency of neonatal exchange transfusions and its effect on exchange-related morbidity and mortality. <i>Pediatrics</i> . 2007; 120(1): 27-32.	1986-2006		
United States	Arciero TJ, Jacobsen SJ, Reeder GS, Frye RL, Weston SA, Killian JM, Roger Vr Vé. Temporal trends in the incidence of coronary disease. <i>Am J Med</i> . 2004; 117(4): 228-33.	1979-2001		
United States	Ergin A, Muntner P, Sherwin R, He J. Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States. <i>Am J Med</i> . 2004; 117(4): 219-27.	1982-1992		
United States	McGovern PG, Jacobs DR, Shahar E, Arnett DK, Folsom AR, Blackburn H, Luepker RV. Trends in Acute Coronary Heart Disease Mortality, Morbidity, and Medical Care From 1985 Through 1997?: The Minnesota Heart Survey. <i>Circulation</i> . 2001; 104(1): 19-24.	1990, 1995		
United States	Parikh NI, Gona P, Larson MG, Fox CS, Benjamin EJ, Murabito JM, O'Donnell CJ, Vasan RS, Levy D. Long-Term Trends in Myocardial Infarction Incidence and Case Fatality in the National Heart, Lung, and Blood Institute's Framingham Heart Study. <i>Circulation</i> . 2009; 119(9): 1203-10.	1980-1999		
United States	Rosamond WD, Folsom AR, Chambless LE, Wang CH. Coronary heart disease trends in four United States communities. The Atherosclerosis Risk in Communities (ARIC) study 1987-1996. <i>Int J Epidemiol</i> . 2001; S17-22.	1990, 1995		†
United States	Tahir SM, Price LL, Shah PB, Welt FGP. Eighteen year (1985-2002) analysis of incidence, mortality, and cardiac procedure outcomes of acute myocardial infarction in patients > or = 65 years of age. <i>Am J Cardiol</i> . 2008; 101(7): 930-6.	1985, 2002		
United States	Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. <i>N Engl J Med</i> . 1999; 341(8): 556-62.	1988-1994		†
United States	Armstrong GL, Wasey A, Simard EP, McQuillan GM, Kuhnet WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. <i>Ann Intern Med</i> . 2006; 144(10): 705-14.	1999-2002		†
United States	Bode MM, DEugenio DB, Forsyth N, Coleman J, Gross CR, Gross SJ. Outcome of extreme prematurity: a prospective comparison of 2 regional cohorts born 20 years apart. <i>Pediatrics</i> . 2009; 124(3): 866-74.	1985, 2005	*	
United States	Famaroff AA, Stoll BJ, Wright LL, Carlo WA, Ehrenkranz RA, Stark AR, Bauer CR, Donovan EF, Korones SB, Laptook AR, Lemons JA, Oh W, Papile L-A, Shankaran S, Stevenson DK, Tyson JE, Poole WK, NICHD Neonatal Research Network. Trends in neonatal morbidity and mortality for very low birthweight infants. <i>Am J Obstet Gynecol</i> . 2007; 196(2): 147.	2000	*	
United States	Karagas MR, Greenberg ER, Spencer, Steven K, Stukel TA, Mott LA. Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA. <i>Int J Cancer</i> . 1999; 81(4): 555-9.	1979-1980, 1993-1994	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	Chuang TY PN, Su WP, Chute CG. Squamous cell carcinoma. A population-based incidence study in Rochester, Minn. Arch Dermatol. 1990; 126(2): 185-8.	1976-1984	*	
United States	Reizner GT CT, Elpern DJ, Stone JL, Farmer ER. Basal cell carcinoma in Kauai, Hawaii: the highest documented incidence in the United States. J Am Acad Dermatol. 1993; 29(2): 184-9.	1983-1987		
United States	Logroschino G, Hestdorffer DC, Cascino G, Annegers JF, Hauser WA. Time trends in incidence, mortality, and case-fatality after first episode of status epilepticus. Epilepsia. 2001; 42(8): 1031-5.	1975-1984		
United States	Centers for Disease Control and Prevention (CDC). Prevalence of Heart Disease—United States, 2005. MMWR Morb Mortal Wkly Rep. 2007; 56(6): 113-8.	1980-2005		†
United States	Trevejo RT. Acute encephalitis hospitalizations, California, 1990-1999: unrecognized arboviral encephalitis? Emerg Infect Dis. 2004; 10(8): 1442-9.	1990-1999		
United States	Pfeffer RI, Afifi AA, Chance JM. Prevalence of Alzheimer's disease in a retirement community. Am J Epidemiol. 1987; 125(3): 420-36.	1980-1981		
United States	McHugh CP, Melby PC, LaFon SG. Leishmaniasis in Texas: epidemiology and clinical aspects of human cases. Am J Trop Med Hyg. 1996; 55(5): 547-55.	1980-1993	*	
United States	Wright NA, Davis LE, Atergut KS, Parrish CA, Cockerell CJ. Cutaneous leishmaniasis in Texas: A northern spread of endemic areas. J Am Acad Dermatol. 2008; 58(4): 650-2.	2005-2007	*	
United States	Eke PI, Dye BA, Wei L, Thornton-Evans GO, Genco RJ. CDC Periodontal Disease Surveillance workgroup: James Beck (University of North Carolina, Chapel Hill, USA), Gordon Douglas (Past President, American Academy of Periodontology), Roy Page (University of Washington). Prevalence of periodontitis in adults in the United States: 2009 and 2010. J Dent Res. 2012; 91(10): 914-20.	2009-2010	*	
United States	Centers for Disease Control and Prevention (CDC). United States Hearing Screening and Follow-up Survey 2009.	2009		
United States	Scales CD Jr, Smith AC, Hanley JM, Saigal CS. Urologic Diseases in America Project. Prevalence of kidney stones in the United States. Eur Urol. 2012; 62(1): 160-5.	2007-2010	*	
United States	Breitner JC, Wyse BW, Anthony JC, Welsh-Bohmer KA, Steffens DC, Norton MC, Tschanz JT, Plassman BL, Meyer MR, Skoog I, Khachaturian A. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology. 1999; 53(2): 321-31.	1992-1995		
United States	Howard VJ, Kleindorfer DO, Judd SE, McClure LA, Safford MM, Rhodes JD, Cushman M, Moy CS, Soliman EZ, Kissela BM, Howard G. Disparities in stroke incidence contributing to disparities in stroke mortality. Ann Neurol. 2011; 69(4): 619-627.	2003-2010		
United States	Wellenius GA, Mittleman MA. Disparities in myocardial infarction case fatality rates among the elderly: the 20-year Medicare experience. Am Heart J. 2008; 156(3): 483-490.	1984, 1988, 1991, 1994, 1997, 2000, 2003		†
United States	Gamsu HR, Light F, Potter A, Price JF, Jones RK, Cummins M, Davies P, Nelson JR R, Resnick M, Eitzman D. INTENSIVE CARE AND THE VERY-LOW-BIRTHWEIGHT INFANT. The Lancet. 1979 Oct 6;314(8145):736-7.	1977		†
United States	Vohr BR, Wright LL, Poole WK, McDonald SA. Neurodevelopmental Outcomes of Extremely Low Birth Weight Infants <32 Weeks' Gestation Between 1993 and 1998. Pediatrics. 2005 Sep 1;116(3):635-43.	1993, 1995, 1997		
United States	Gargus RA, Vohr BR, Tyson JE, High P, Higgins RD, Wraga LA, Poole K. Unimpaired Outcome in Extremely Low Birth Weight Infants at 18-22 Months. Pediatrics. 2009 Jul;124(1):112-21.	1999	*	
United States	United States Vital Registration Birth Data 1991 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1991	*	
United States	United States - Texas Birth Defects Epidemiology & Surveillance Branch Data 2003 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2005. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2003	*	
United States	United States - Utah Birth Defects Network Data 2004 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
United States	United States - Metropolitan Atlanta Congenital Defects Program Data 2004 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
United States	United States - Texas Center for Birth Defects Research Data 2003 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2006. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2007.	2004	*	
United States	United States - Texas Birth Defects Epidemiology and Surveillance Branch Data 2006 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2006	*	
United States	United States - Utah Birth Defects Network Data 2007 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
United States	United States - Metropolitan Atlanta Congenital Defects Program Data 2007 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2009. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research.	2007	*	
United States	United States - Georgia Metropolitan Atlanta Congenital Defects Program Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
United States	United States - Georgia Metropolitan Atlanta Congenital Defects Program Data 1980 - ICBDMS as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1980	*	
United States	United States - Georgia Metropolitan Atlanta Congenital Defects Program Data 1983 - ICBDMS as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1983	*	
United States	United States - Georgia Metropolitan Atlanta Congenital Defects Program Data 1986 - ICBDMS as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1986	*	
United States	United States - Georgia Metropolitan Atlanta Congenital Defects Program Data 2009 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	2009	*	
United States	United States - Texas Birth Defects Epidemiology & Surveillance Branch Data 2009 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	
United States	United States - Utah Birth Defects Network Data 2009 - ICBDSDR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2011. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2012.	2009	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
United States	United States - Georgia Metropolitan Atlanta Congenital Defects Program Data 1988 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1988	*	
United States	United States - Georgia Metropolitan Atlanta Congenital Defects Program Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2012. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2013.	2010	*	
United States	United States - Texas Birth Defects Epidemiology & Surveillance Branch Data 2009 - ICBDSR as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2010	*	
United States	United States - Utah Birth Defects Network Data 2010 - ICBDSR as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2010	*	
United States	United States - Georgia Metropolitan Atlanta Congenital Defects Program Data 2001 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. International Clearinghouse for Birth Defects Monitoring Systems Annual Report 2003. Rome, Italy: International Centre on Birth Defects.	2001	*	
United States	United States - Georgia Metropolitan Atlanta Congenital Defects Program Data 1987 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1987	*	
United States	United States - Georgia Metropolitan Atlanta Congenital Defects Program Data 1981 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1981	*	
United States	United States - Georgia Metropolitan Atlanta Congenital Defects Program Data 1984 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1984	*	
United States	United States - Georgia Metropolitan Atlanta Congenital Defects Program Data 1985 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1985	*	
United States	United States - Georgia Metropolitan Atlanta Congenital Defects Program Data 1982 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1982	*	
United States	United States Birth Defects Monitoring Program Data 1980 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1980	*	
United States	United States Birth Defects Monitoring Program Data 1981 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1981	*	
United States	United States Birth Defects Monitoring Program Data 1982 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1982	*	
United States	United States Birth Defects Monitoring Program Data 1983 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1983	*	
United States	United States Birth Defects Monitoring Program Data 1984 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1984	*	
United States	United States Birth Defects Monitoring Program Data 1985 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1985	*	
United States	United States Birth Defects Monitoring Program Data 1986 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1986	*	
United States	United States Birth Defects Monitoring Program Data 1987 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1987	*	
United States	United States Birth Defects Monitoring Program Data 1988 - ICBDMs as it appears in International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide: A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Netherlands: Elsevier, 1991.	1988		†
United States	United States - Georgia Metropolitan Atlanta Congenital Defects Program Data 2008 - ICBDSR as it appears in International Clearinghouse for Birth Defects Surveillance and Research. International Clearinghouse for Birth Defects Surveillance and Research Annual Report 2010. Rome, Italy: International Clearinghouse for Birth Defects Surveillance and Research, 2011.	2008		†
United States	National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC). Infant Mortality Statistics from the 2004 Period Linked Birth/Infant Death Data Set. Hyattsville, United States: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), 2007. (National Vital Statistics Reports 55; no.14).	2004		
Uruguay	World Health Organization (WHO). Uruguay World Health Survey 2002-2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2002-2003		
Uruguay	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	2003-2005		
Uruguay	Centre for Health Informatics and Multiprofessional Education, University College London. Model's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Uruguay	Salvatella R, Rosa R, Gonzalez M, Basmadján Y, Combol A, Benavidez U, Mancebo R, Fernandez N, Calegari L. Seroprevalence of T cruzi infection in 6- and 12- year-old school children from three Uruguayan endemic departments. Bol Chil Parasitol. 1999; 54(3-4): 51-6.	1986, 1994		†
Uruguay	Williams H, Stewart A, Von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide. J Allergy Clin Immunol. 2008; 121(4): 947-954.	1994, 2002		
Uruguay	Selwyn BJ. The Epidemiology of Acute Respiratory Tract Infection in Young Children: Comparison of Findings from Several Developing Countries. Rev Infect Dis. 1990; 12(12): S870-S888.	1985-1988		
Uruguay	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1995-2009		
Uruguay	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J. 1998; 12(2): 315-35.	1993-1995		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Uruguay	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2002		
Uruguay	Moro P, Schantz PM. Cystic echinococcosis in the Americas. Parasitol Int. 2006; 55(1): S181-6.	1991-1992, 1997	*	
Uruguay	Honorary Commission for Cardiovascular Health (Uruguay). Uruguay Cardiovascular Disease, Epidemiology, and Statistics 1990-1992. Montevideo, Uruguay: Honorary Commission for Cardiovascular Health (Uruguay), 1996.	1992	*	
Uruguay	Honorary Commission for the Fight Against Cancer (Uruguay), National Cancer Registry (Uruguay). Uruguay Cancer Incidence Atlas 2002-2006. Montevideo, Uruguay: Honorary Commission for the Fight Against Cancer (Uruguay), 2010.	2002-2006	*	
Uruguay	Mallol J, Solé D, Baeza-Bacab M, Aguirre-Camposano V, Soto-Quiros M, Baena-Cagnani C. Latin American ISAAC Group. Regional variation in asthma symptom prevalence in Latin American children. J Asthma. 2010; 47(6): 644-50.	2001-2003		
Uruguay	Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J, eds (2013). Cancer Incidence in Five Continents, Vol. X Summary Database (electronic version). Lyon, IARC. http://ci5.iarc.fr	2005-2007		
Uruguay	Menezes AM, Perez-Padilla R, Jardim JR, Muñio A, Lopez MV, Valdivia G, Montes de Oca M, Talamo C, Hallal PC, Victora CG, PLATINO Team. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet. 2005; 366(9500): 1875-81.	2002-2004		
Uruguay	United States Renal Data System Coordinating Center. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2010.	2004-2005		
Uruguay	Uruguay Society of Nephrology. Uruguay Dialysis Registry Report 2005. Montevideo, Uruguay: Uruguay Society of Nephrology.	2005		
Uruguay	Uruguay Dialysis and Transplant Registry data as it appears in the GBD 2010 Chronic Kidney Disease Expert Group dataset. Provided by Carlota Gonzalez-Bedat, Emma Schwedt, and Francisco Gonzalez-Martinez	1995		
Uruguay	United States Renal Data System Coordinating Center. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, United States: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2009.	2000, 2002-2003		
Uruguay	Ketzoian C. Estudio piloto de la prevalencia de las principales enfermedades neurológicas en el Uruguay. Rev Neurol Argentina. 1994; 19(1): 21-31.	1994		
Uruguay	Chouza C, Ketzoian C, Caamaño JL, Cáceres R, Coirolo G, Dieguez E, Rega I. Prevalence of Parkinson's disease in a population of Uruguay. Preliminary results. Adv Neurol. 1996; 13-7.	1993-1994		
Uruguay	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Uruguay Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2005-2006	6	
Uruguay	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), United Nations Office on Drugs and Crime (UNODC). Youth and Drugs in South American Countries: A Public Policy Challenge 2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2006.	2005		
Uruguay	Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). CICAD Comparative Report on Nationwide School Surveys in Seven Countries: El Salvador, Guatemala, Nicaragua, Panama, Paraguay, Dominican Republic, and Uruguay 2003. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2004.	2003		
Uruguay	González C, Fernández-Cean J, González-Martínez F, Schwedt E, Mazzuchi N. Chronic dialysis in Uruguay: mortality trends from 1981 to 1998. Nefrología. 2001; 21(4): 342-8.	1981-1998		
Uruguay	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012	*	
Uruguay	Uruguay Rapid Assessment of Avoidable Blindness 2011 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2011		
Uruguay	Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. Cancer Incidence in Five Continents. Vol. 1 to VIII. Lyon, France, IARC Press, 2005.	1990-1995	*	
Uruguay	Balsa AL, French MT. Alcohol use and the labor market in Uruguay. Health Econ. 2010; 19(7): 833-54.	2001	*	
Uruguay	Magri R, Hutson J, Míguez H, Suarez H, Menendez A, Parodi V, Koren G, Bustos R. Advances in the determination of alcohol and other drug consumption during pregnancy: A study of 900 births in Montevideo, Uruguay. Contemp Drug Probs. 2007; 34(3): 445-76.	2005	*	
Uruguay	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	
Uruguay	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Uruguay	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Uruguay	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Uruguay	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
Uruguay	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Uruguay	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Uruguay	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993		
Uruguay	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Uruguay	Camou T, Palacio R, Di Fabio JL, Hortal M. Invasive pneumococcal diseases in Uruguayan children: comparison between serotype distribution and conjugate vaccine formulations. Vaccine. 2003; 21(17-18): 2093-6.	1994-2001	*	
Uruguay	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Uruguay	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Uruguay	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Uruguay	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Uruguay	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012		
Uruguay	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	†
Uruguay	Cruells MR, Mescia G, Gabisso R, Ramirez M, Gutiérrez M, Kohen S, González M, Russi J, Chiparelli H, Ucar L, Pérez MT. [Epidemiological study of hepatitis A and E viruses in different populations in Uruguay]. Gastroenterol Hepatol. 1997; 20(6): 295-8.	1996-1997	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Uruguay	Ronco AL, Stoll M, De Stefani E, Maisonneuve JE, Mendoza BA, Deneo-Pellegrini H. Rh factor, family history and risk of breast cancer: a case-control study in Uruguay. <i>Cancer Detect Prev.</i> 2009; 32(4): 277-85.	2005-2007		
Uruguay	Pan American Health Organization (PAHO), World Health Organization (WHO). Quantitative Estimation of Chagas in the Americas.	2005	*	
Uruguay	Uruguay Vital Registration Birth Data 1988 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1988	*	
Uruguay	Uruguay Latin American Collaborative Study of Congenital Malformations Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	†
Uzbekistan	United Nations Children's Fund (UNICEF), Ministry of Macroeconomics and Statistics (Uzbekistan). Uzbekistan Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000		†
Uzbekistan	United Nations Children's Fund (UNICEF), State Committee of the Republic of Uzbekistan on Statistics. Uzbekistan Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006		
Uzbekistan	Institute of Obstetrics and Gynecology, Ministry of Health (Uzbekistan), Macro International, Inc., Ministry of Health (Uzbekistan). Uzbekistan Demographic and Health Survey 1996. Calverton, United States: Macro International, Inc.	1996		†
Uzbekistan	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Uzbekistan	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		
Uzbekistan	Flem ET, Musabaev E, Juraev R, Kerim T, Gentsch J, Glass RI, Bresee JS. Rotavirus gastroenteritis in Uzbekistan: implications for vaccine policy in central Asia. <i>J Infect Dis.</i> 2009; 200 Suppl 1: 154-159.	2005-2006		
Uzbekistan	Isakbaeva ET, Musabaev E, Antil L, Rheingans R, Juraev R, Glass RI, Bresee JS. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. <i>Vaccine.</i> 2007; 25(2): 373-80.	2004		
Uzbekistan	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1999, 2001-2006, 2008-2009		
Uzbekistan	Boiko A, Deomina T, Favorova O, Gusev E, Sudomoina M, Turetskaya R. Epidemiology of multiple sclerosis in Russia and other countries of the former Soviet Union: investigations of environmental and genetic factors. <i>Acta Neurol Scand Suppl.</i> 1995; 71-6.	1975-1985		
Uzbekistan	Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). <i>Eur Respir J.</i> 1998; 12(2): 315-35.	1993-1995		
Uzbekistan	Torgerson PR, Oglujahan B, Muminov AE, Karaeva RR, Kuttubaev OT, Aminjanov M, Shaikenov B. Present situation of cystic echinococcosis in Central Asia. <i>Parasitol Int.</i> 2006; 55(1): S207-S212.	1988, 1998, 2000-2001	*	
Uzbekistan	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010	*	
Uzbekistan	Latipov R, Utegenova E, Kuartbayeva A, Kasymbekova K, Abdylkarimov S, Juraev R, Ismailov U, Flem E. Epidemiology and burden of rotavirus disease in Central Asia. <i>Int J Infect Dis.</i> 2011; 15(7): e464-469.	2005-2009	*	
Uzbekistan	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2001, 2004, 2007, 2010, 2012	*	
Uzbekistan	World Health Organization (WHO). Uzbekistan WHO Leishmaniasis Country Profile.	1994-2010		
Uzbekistan	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993	*	†
Uzbekistan	Doroshenko NV, Schastnyy EI, Iagodoskii VV, Abdullaeva FA, Stakhanova VM. [Specific immunity in preschool children at high risk of infection with hepatitis A virus]. <i>Vopr Virozol.</i> 1990; 35(1): 26-9.	1997		
Uzbekistan	Mazieres S, Temory SA, Vasseur H, Gallian P, Di Cristofaro J, Chiaroni J. Blood group typing in five Afghan populations in the North Hindu-Kush region: implications for blood transfusion practice. <i>Transfus Med.</i> 2013; 23(3): 167-74.	2009-2011		
Uzbekistan	Ruzibakiev R, Kato H, Ueda R, Yuldasheva N, Hegay T, Avazova D, Kurbanov F, Zalaliev M, Tuichiev L, Achundjanov B, Mizokami M. Risk factors and seroprevalence of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection in Uzbekistan. <i>Intervirology.</i> 2001; 44(6): 327-32.	1990-2000	*	†
Uzbekistan	USSR - Uzbek SSR Vital Registration Birth Data 1989 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1989		
Vanuatu	Ministry of Health (Vanuatu), United Nations Children's Fund (UNICEF). Vanuatu Multiple Indicator Cluster Survey 2007-2008. New York, United States: United Nations Children's Fund (UNICEF).	2007-2008		
Vanuatu	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988, 1990-1996, 1999		
Vanuatu	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Vanuatu	Hill AV, Bowden DK, O'Shaughnessy DF, Weatherall DJ, Clegg JB. Beta thalassaemia in Melanesia: association with malaria and characterization of a common variant (IVS-1 nt 5 G→C). <i>Blood.</i> 1988; 72(1): 9-14.	1985-1987		
Vanuatu	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1998-1999, 2001		
Vanuatu	Smith TS, Szeu J, Bourne RR. The prevalence and severity of diabetic retinopathy, associated risk factors and vision loss in patients registered with type 2 diabetes in Luganville, Vanuatu. <i>Br J Ophthalmol.</i> 2007; 91(4): 415-9.	2004		
Vanuatu	Harris M, Nako D, Hopkins T, Powell DM, Kenny C, Carroll C, Carroll K. Skin infections in Tanna, Vanuatu in 1989. <i>P N G Med J.</i> 1992; 35(2): 137-43.	1989		
Vanuatu	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Vanuatu	Secretariat of the Pacific Community (SPC), World Health Organization Regional Office for the Western Pacific (WPRO-WHO). Second Generation Surveillance Surveys of HIV, Other STIs and Risk Behaviours in 6 Pacific Island Countries 2004-2005. Geneva, Switzerland: World Health Organization (WHO), 2006.	1990, 2005		
Vanuatu	Yanagihara RT, Garruto RM, Gajusek DC. Epidemiological surveillance of amyotrophic lateral sclerosis and parkinsonism-dementia in the commonwealth of the Northern Mariana Islands. <i>Ann Neurol.</i> 1983; 13(1): 79-86.	1980-1981		
Vanuatu	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Vanuatu	Newland HS, Harris MF, Walland M, McKnight D, Galbraith JE, Iwasaki W, Momomura K. Epidemiology of blindness and visual impairment in Vanuatu. <i>Bull World Health Organ.</i> 1992; 70(3): 369-72. as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	1989		†
Vanuatu	Ganczakowski M, Town M, Bowden DK, Vulliamy TJ, Kaneko A, Clegg JB, Weatherall DJ, Luzzatto L. Multiple glucose 6-phosphate dehydrogenase-deficient variants correlate with malaria endemicity in the Vanuatu archipelago (southwestern Pacific). <i>Am J Hum Genet.</i> 1995; 56(1): 294-301.	1993-1995	*	†
Vanuatu	Kaneko A, Taleo G, Kalkoa M, Yaviong J, Reeve PA, Ganczakowski M, Shirakawa C, Palmer K, Kobayakawa T, Björkman A. Malaria epidemiology, glucose 6-phosphate dehydrogenase deficiency and human settlement in the Vanuatu Archipelago. <i>Acta Trop.</i> 1998; 70(3): 285-302.	1985-1992	*	
Vanuatu	Kaneko A, Taleo G, Kalkoa M, Yaviong J, Reeve PA, Ganczakowski M, Shirakawa C, Palmer K, Kobayakawa T, Björkman A. Malaria epidemiology, glucose 6-phosphate dehydrogenase deficiency and human settlement in the Vanuatu Archipelago. <i>Acta Trop.</i> 1998; 70(3): 285-302 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Vanuatu	Fraser M, Taleo G, Taleo F, Yaviong J, Amos M, Babu M, Kalkoa M. Evaluation of the program to eliminate lymphatic filariasis in Vanuatu following two years of mass drug administration implementation: results and methodologic approach. <i>Am J Trop Med Hyg.</i> 2005; 73(4): 753-8. as it appears in London School of Hygiene and Tropical Medicine. <i>Global Atlas of Helminth Infections.</i>	1998, 2002	*	
Vanuatu	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec.</i> 2005; 80(13): 118-24.	2003	*	
Vanuatu	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec.</i> 2005; 80(34): 289-95.	2004	*	
Vanuatu	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec.</i> 2006; 81(32): 309-16.	2005	*	
Vanuatu	World Health Organization (WHO). Global leprosy situation, 2007 (additional information). <i>Wkly Epidemiol Rec.</i> 2007; 82(44): 388.	2006	*	
Vanuatu	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec.</i> 2009; 84(33): 333-40.	2008	*	
Vanuatu	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec.</i> 2010; 85(35): 337-48.	2009	*	
Vanuatu	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec.</i> 2012; 87(34): 317-28.	2011	*	
Vanuatu	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec.</i> 2008; 83(33): 293-300.	2007	*	
Vanuatu	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec.</i> 2011; 86(36): 389-99.	2010		
Vanuatu	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1994; 69(20): 145-51.	1993		
Vanuatu	Taleo G, Capuano C, Burkot T. Dengue Control in Vanuatu: Towards an Integrated Vertical and Horizontal Control Programme. <i>Dengue Bull.</i> 2000; 24; 11-7.	1989, 1998		
Vanuatu	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2000.	2000		
Vanuatu	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2001.	2001		
Vanuatu	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2002.	2002		
Vanuatu	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2003.	2003		
Vanuatu	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2004.	2004		
Vanuatu	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2005.	2005		
Vanuatu	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2006.	2006		
Vanuatu	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2007.	2007		
Vanuatu	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2008.	2008		
Vanuatu	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2009.	2009		
Vanuatu	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2010.	2010		
Vanuatu	Carroll K, Carroll C. The epidemiology of bacterial meningitis occurring in a Pacific Island population. <i>P N G Med J.</i> 1993; 36(3): 234-42.	1988-1991		
Vanuatu	Maher CP, Harris MS, Milne A, Johnston A, Stewart A, Waldon JA. Seroepidemiology of hepatitis B infection in children in Vanuatu. Implications for vaccination strategy. <i>Med J Aust.</i> 1991; 154(4): 249-53.	1989	*	†
Vanuatu	Bowden DK, Higgs DR, Hill AVS, Weatherall DJ, Clegg JB. Relative roles of genetic factors, dietary deficiency, and infection in anaemia in Vanuatu, South-West Pacific. <i>Lancet.</i> 1985; 2(8463): 1025-8.	1977-1985	*	†
Vanuatu	Human and Parasite Diversities and Implications for Malaria Control in Vanuatu [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996-1998	*	†
Vanuatu	The Epidemiology of Malaria on Espiritu Santo, Vanuatu, South West Pacific [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	
Vanuatu	Maguire JD, Bangs MJ, Brennan L, Rieckmann K, Taleo G. Cross-sectional characterization of malaria in Sanma and Shefa Provinces, Republic of Vanuatu: malaria control implications. <i>P N G Med J.</i> 2006; 49(1-2): 22-31 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002		
Venezuela	National Institute of Statistics (Venezuela), United Nations Children's Fund (UNICEF). Venezuela Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000	*	
Venezuela	Central Office of Statistics and Information (Venezuela), International Statistical Institute. Venezuela World Fertility Survey 1977. Voorburg, Netherlands: International Statistical Institute.	1977		
Venezuela	Venezuela Vital Registration - Deaths 2006 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2006	*	
Venezuela	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-2002	*	
Venezuela	Venezuela Vital Registration - Deaths 1980 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1980	*	
Venezuela	Venezuela Vital Registration - Deaths 1996 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1996	*	
Venezuela	Venezuela Vital Registration - Deaths 1997 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1997	*	
Venezuela	Venezuela Vital Registration - Deaths 1998 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1998	*	
Venezuela	Venezuela Vital Registration - Deaths 1999 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1999	*	
Venezuela	Venezuela Vital Registration - Deaths 2000 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2000	*	
Venezuela	Venezuela Vital Registration - Deaths 2001 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2001	*	
Venezuela	Venezuela Vital Registration - Deaths 2002 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2002	*	
Venezuela	Venezuela Vital Registration - Deaths 2003 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2003	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Venezuela	Venezuela Vital Registration - Deaths 2004 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2004		
Venezuela	Venezuela Vital Registration - Deaths 2005 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2005		‡
Venezuela	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Venezuela	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		
Venezuela	World Health Organization (WHO). Expanded programme on immunization: neonatal tetanus, 1970-1992. Wkly Epidemiol Rec. 1993; 68(16): 109-12.	1970-1986, 1988-1990		
Venezuela	Aché A, Matos AJ. Interrupting Chagas disease transmission in Venezuela. Rev Inst Med Trop Sao Paulo. 2001; 43(1): 37-43.	1980-1998		
Venezuela	Estrada Castañón R, Torres Bibiano B, Alarcón Hernández H, Villegas Arrizón A, Martínez Sandoval E, Chávez López G, Andersson N. Epidemiología cutánea en dos sectores de atención médica en Guerrero, México; Cutaneous epidemiology in two sectors of Guerrero, Mexico. Dermatol rev mex. 1992; 36(1): 29-34.	1989-1991		
Venezuela	ORyan M, Pérez-Schael I, Mamani N, Peña A, Salinas B, González G, González F, Matson DO, Gómez J. Rotavirus-associated medical visits and hospitalizations in South America: a prospective study at three large sentinel hospitals. Pediatr Infect Dis J. 2001; 20(7): 685-93.	1997-1999		
Venezuela	Salinas B, González G, González R, Escalona M, Materán M, Schael IP. Epidemiologic and clinical characteristics of rotavirus disease during five years of surveillance in Venezuela. Pediatr Infect Dis J. 2004; 23(10 Suppl): 161-167.	1998-2002		
Venezuela	WHO Department of Communicable Disease Surveillance and Response. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases 2000.	1980, 1998		
Venezuela	Pan American Health Organization (PAHO). Update on yellow fever in the Americas. Epidemiol Bull. 2000; 21(2):13.	1985-1995		
Venezuela	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1995, 1997, 2000-2009		
Venezuela	Vasconcelos PF da C. Febre amarela. Rev Soc Bras Med Trop. 2003; 36(2): 275-93.	1980-2001		
Venezuela	Sylvatic yellow fever outbreak in Bolivia. EPI NewsL. 1999; 1(21): 1-3.	1998		
Venezuela	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2002		
Venezuela	Morillo LE, Alarcon F, Aranaga N, Aulet S, Chapman E, Conterno L, Estevez E, Garcia-Pedroza F, Garrido J, Macías-Islas M, Monzillo P, Nunez L, Plascencia N, Rodriguez C, Takeuchi Y, Latin American Migraine Study Group. Prevalence of migraine in Latin America. Headache. 2005; 45(2): 106-17.	1999	*	
Venezuela	Bravo Tobar I, Parra F, Nello Pérez C, Rodríguez-Bonfante C, Useche F, Bonfante-Cabarcas R. Prevalence of Trypanosoma cruzi antibodies and inflammatory markers in uncompensated heart failure. Rev Soc Bras Med Trop. 2011; 44(6): 691-6.	2008-2010	*	
Venezuela	García-Marcos L, Mallol J, Solé D, Brand PLP. EISL Study Group. International study of wheezing in infants: risk factors in affluent and non-affluent countries during the first year of life. Pediatr Allergy Immunol. 2010; 21(5): 878-88.	2005-2007	*	
Venezuela	Mallol J, Solé D, Baeza-Bacab M, Aguirre-Camposano V, Soto-Quiros M, Baena-Cagnani C, Latin American ISAAC Group. Regional variation in asthma symptom prevalence in Latin American children. J Asthma. 2010; 47(6): 644-50.	2001-2003	*	
Venezuela	Giménez OG, Torrealba MC, Urquiola MB, Ortiz GG, Fonseca SM, Merzón R, de Donato M, Castillo O, Arends de Pérez A. Diagnosis of hemoglobinopathies in newborns in Venezuela hospitals. An Pediatr (Barc). 2009; 71(4): 314-8.	2007-2008	*	
Venezuela	Pérez-Schael I, González R, Fernández R, Alfonso E, Inaty D, Boher Y, Sarmiento L. Epidemiological features of rotavirus infection in Caracas, Venezuela: implications for rotavirus immunization programs. J Med Virol. 1999; 59(4): 520-6.	1992-1993	*	
Venezuela	Araque M. Nontyphoid Salmonella gastroenteritis in pediatric patients from urban areas in the city of Mérida, Venezuela. J Infect Dev Ctries. 2009; 3(1): 28-34.	2004-2005		
Venezuela	González GG, Liprandi F, Ludert JE. Molecular epidemiology of enteric viruses in children with sporadic gastroenteritis in Valencia, Venezuela. J Med Virol. 2011; 83(11): 1972-82.	2003		
Venezuela	Prince M, Acosta D, Ferri CP, Guerra M, Huang Y, Llibre Rodriguez JJ, Salas A, Sosa AL, Williams JD, Dewey ME, Acosta I, Jotheeswaran AT, Liu Z. Dementia incidence and mortality in middle-income countries, and associations with indicators of cognitive reserve: a 10/66 Dementia Research Group population-based cohort study. Lancet. 2012; 380(9836): 50-8.	2003-2010		
Venezuela	Sousa RM, Ferri CP, Acosta D, Albanese E, Guerra M, Huang Y, Jacob KS, Jotheeswaran AT, Rodriguez JLL, Pichardo GR, Rodriguez MC, Salas A, Sosa AL, Williams J, Zuniga T, Prince M. Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population-based survey. Lancet. 2009; 374(9704): 1821-30.	2003-2005		
Venezuela	Molero AE, Pino-Ramírez G, Maestre GE. High prevalence of dementia in a Caribbean population. Neuroepidemiology. 2007; 29(1-2): 107-12.	1998-2001		
Venezuela	Menezes AM, Perez-Padilla R, Jardim JR, Muiño A, Lopez MV, Valdivia G, Montes de Oca M, Talamo C, Hallal PC, Victora CG, PLATINO Team. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet. 2005; 366(9500): 1875-81.	2002-2004		
Venezuela	Montiel-Nava C, Peña JA. Epidemiological findings of pervasive developmental disorders in a Venezuelan study. Autism. 2008; 12(2): 191-202.	2006	*	
Venezuela	Inter-American Drug Abuse Control Commission (CICAD). Organization of American States (OAS). Venezuela Evaluation of Progress in Drug Control 2005-2006. Washington, D.C., United States: Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), 2008.	2005		
Venezuela	Ferri CP, Schoenborn C, Kalra L, Acosta D, Guerra M, Huang Y, Jacob KS, Rodriguez JLL, Salas A, Sosa AL, Williams JD, Liu Z, Moriyama T, Valhuerdi A, Prince MJ. Prevalence of stroke and related burden among older people living in Latin America, India and China. J Neurol Neurosurg Psychiatry. 2011; 82(10): 1074-82.	2007-2009	*	
Venezuela	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2004, 2007, 2010, 2012		
Venezuela	Montiel C, Peña JA, Montiel-Barbero I, Polanczyk G. Prevalence rates of attention deficit/hyperactivity disorder in a school sample of Venezuelan children. Child Psychiatry Hum Dev. 2008; 39(3): 311-22.	2001-2002		
Venezuela	Venezuela Rapid Assessment of Cataract Surgical Services 2004 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2004		
Venezuela	Fernández-Cean J, González-Martínez F, Schwedt E, Mazzuchi N. Renal replacement therapy in Latin America. Kidney Int. 2000; 57(s74): 55-59.	1997		
Venezuela	Lugon JR, Strogoff de Matos JP. Disparities in end-stage renal disease care in South America. Clin Nephrol. 2010; 74(Suppl 1): S66-71.	2008-2010		
Venezuela	Cusumano A, García-García G, Di Gioia C, Hermida O, Lavorato C, Carreño CA, Torrico MP, Batista PB, Romão JE, Badal HP, Miranda SE, Gomez R, Calderon MC, Sanchez SH, Lopez MA, Moscoso J, Merino RL, Polo JV, Lopez A, Romero NJ, Garcia R, Acosta BV, Lopez AS, Delpin ES, Mena E, González C, Milanés CL, Acchiardo S. End-stage renal disease and its treatment in Latin America in the twenty-first century. Ren Fail. 2006; 28(8): 631-7.	2004	*	
Venezuela	Bellorin-Font E, Milanés CL, Rodríguez-Irube B. End-stage renal disease and its treatment in Venezuela. Artif Organs. 2002; 26(9): 747-9.	2000	*	
Venezuela	Herrera J, Rodríguez-Irube B. End-stage renal disease and acute glomerulonephritis in Goajiro Indians. Kidney Int. 2003; 63(S83): S22-S26.	1991-1998		‡
Venezuela	World Health Organization (WHO). Venezuela WHO Leishmaniasis Country Profile.	1990-2010	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Venezuela	Libre Rodriguez JJ, Ferri CP, Acosta D, Guerra M, Huang Y, Jacob KS, Krishnamoorthy ES, Salas A, Sosa AL, Acosta I, Dewey ME, Gaona C, Jotheeswaran AT, Li S, Rodriguez D, Rodriguez G, Kumar PS, Valluerdi A, Prince M. 10/66 Dementia Research Group. Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey. <i>Lancet</i> . 2008; 372(9637): 464-74.	2004-2005	*	
Venezuela	Venezuela Vital Registration - Deaths 2008 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2008	*	
Venezuela	Venezuela Vital Registration - Deaths 2009 ICD10 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	2009	*	
Venezuela	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec</i> . 2005; 80(34): 289-95.	2004	*	
Venezuela	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec</i> . 2007; 82(25): 225-32.	2006	*	
Venezuela	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec</i> . 2009; 84(33): 333-40.	2008	*	
Venezuela	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec</i> . 2010; 85(35): 337-48.	2009	*	
Venezuela	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec</i> . 2012; 87(34): 317-28.	2011	*	
Venezuela	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec</i> . 2008; 83(33): 293-300.	2007	*	
Venezuela	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec</i> . 1999; 74(38): 313-6.	1998	*	
Venezuela	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec</i> . 2013; 88(35): 365-79.	2012	*	
Venezuela	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec</i> . 2011; 86(36): 389-99.	2010	*	
Venezuela	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec</i> . 2001; 76(23): 173-9.	2000	*	
Venezuela	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec</i> . 2000; 75(28): 226-31.	1999	*	
Venezuela	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1994; 69(20): 145-51.	1993	*	
Venezuela	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec</i> . 1997; 72(23): 165-72.	1996	*	
Venezuela	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec</i> . 1996; 71(20): 149-56.	1995		†
Venezuela	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1995; 70(25): 177-82.	1994		†
Venezuela	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2003. Pan American Health Organization (PAHO).	2003		†
Venezuela	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2004. Pan American Health Organization (PAHO).	2004		†
Venezuela	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2005. Pan American Health Organization (PAHO).	2005		†
Venezuela	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2006. Pan American Health Organization (PAHO).	2006	*	
Venezuela	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country 2007. Pan American Health Organization (PAHO).	2007	*	
Venezuela	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2008. Washington, D.C., United States: Pan American Health Organization (PAHO).	2008	*	
Venezuela	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2009. Washington, D.C., United States: Pan American Health Organization (PAHO).	2009	*	
Venezuela	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2010. Washington, D.C., United States: Pan American Health Organization (PAHO).	2010	*	
Venezuela	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2011. Washington, D.C., United States: Pan American Health Organization (PAHO).	2011	*	
Venezuela	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2012. Washington, D.C., United States: Pan American Health Organization (PAHO).	2012	*	
Venezuela	Pan American Health Organization (PAHO). Number of Reported Cases of Dengue and Severe Dengue (DS) in the Americas, by Country 2013. Washington, D.C., United States: Pan American Health Organization (PAHO).	2013	*	
Venezuela	Torres-Guerra E, Torres-Guerra T, Valbuena G, Arteaga Vizcaino M, Soto L. [Frequency of sickle-cell anemia in the population of "Cuatro Bocas," Parroquia Ricaurte, Mara municipality, Zulia state, Venezuela]. <i>Invest Clin</i> . 1993; 34(2): 99-105.	1990-1992		
Venezuela	Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L. Multicenter Group for Study of Hepatocarcinoma in Latin America, Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Ann Hepatol</i> . 2010; 9(1): 63-9.	2006-2008		
Venezuela	Tapia-Conyer R, Santos JI, Cavalcanti AM, Urdaneta E, Rivera L, Manterola A, Potin M, Ruttiman R, Tanaka Kido J. Hepatitis A in Latin America: A Changing Epidemiologic Pattern. <i>Am J Trop Med Hyg</i> . 1999; 61(5): 825-9.	1996-1997		
Venezuela	Amesty-Valbuena A, González-Pirela Y, Rivero M. [Seroepidemiologic study of hepatitis A virus among children of Maracaibo, Venezuela]. <i>Invest Clin</i> . 1989; 30(4): 215-28.	1984-1986		
Venezuela	Pujol FH, Favorov MO, Marciano T, Esté JA, Magris M, Liprandi F, Khudyakov YE, Khudyakova NS, Fields HA. Prevalence of antibodies against hepatitis E virus among urban and rural populations in Venezuela. <i>J Med Virol</i> . 1994; 42(3): 234-6.	1991-1992		
Venezuela	Blitz-Dorfman L, Monsalve F, Atencio R, Porto L, Monzon M, Favorov MO, Fields HA, Pujol FH, Echevarria JM. Serological survey of markers of infection with viral hepatitis among the Yukpa Amerindians from Western Venezuela. <i>Ann Trop Med Parasitol</i> . 1996; 90(6): 655-7.	1994	*	
Venezuela	Desjeux P. The increase in risk factors for leishmaniasis worldwide. <i>Trans R Soc Trop Med Hyg</i> . 2001; 95(3): 239-43.	1998	*	†
Venezuela	Pan American Health Organization (PAHO), World Health Organization (WHO). Quantitative Estimation of Chagas in the Americas.	2005	*	†
Venezuela	Malaria Control Trial Using Lambda-cyhalothrin Treated Nets in Yanomami Communities in Amazonas State, Venezuela [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998		†
Venezuela	Molecular diagnosis of mixed Plasmodium species and sub-clinical malaria in mining regions in the Bolivar state, Venezuela as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Venezuela	Asymptomatic malaria infection in the indigenous Jivi population, Amazonas state as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Venezuela	Venezuela Plasmodium Falciparum Parasite Rate Data. Personal Communication with M. Magris-Crestini 2006 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999-2000	*	†
Venezuela	Pérez Mato S. Anemia and malaria in a Yanomami Amerindian population from the southern Venezuelan Amazon. Am J Trop Med Hyg. 1998; 59(6): 998-1001 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992	*	†
Venezuela	Rodulfo H, De Donato M, Mora R, González L, Contreras CE. Comparison of the diagnosis of malaria by microscopy, immunochromatography and PCR in endemic areas of Venezuela. Braz J Med Biol Res. 2007; 40(4): 535-43 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Venezuela	Vivas L, ODea KP, Noya O, Pabon R, Magris M, Botto C, Holder AA, Brown KN. Hyperreactive malarial splenomegaly is associated with low levels of antibodies against red blood cell and Plasmodium falciparum derived glycolipids in Yanomami Amerindians from Venezuela. Acta Trop. 2008; 105(3): 207-14 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991		
Venezuela	Zerpa N, Pabón R, Wide A, Gavidia M, Medina M, Cáceres JL, Capaldo J, Baker M, Noya O. Evaluation of the OptiMAL test for diagnosis of malaria in Venezuela. Invest Clin. 2008; 49(1): 93-101 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000	*	
Venezuela	Venezuela Vital Registration Birth Data 1990 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1990	*	†
Venezuela	Venezuela Latin American Collaborative Study of Congenital Malformations Data 1993-1998 - WHO as it appears in European Surveillance of Congenital Anomalies (EUROCAT), International Centre on Birth Defects, World Health Organization (WHO). World Atlas of Birth Defects. 2nd ed. Geneva, Switzerland: World Health Organization (WHO), 2003.	1993-1998	*	
Vietnam	General Statistics Office (Viet Nam), United Nations Children's Fund (UNICEF). Vietnam Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).	2000		†
Vietnam	General Statistics Office (Viet Nam), United Nations Children's Fund (UNICEF). Vietnam Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006		†
Vietnam	Macro International, Inc, National Committee for Population and Family Planning. Vietnam Demographic and Health Survey 1997. Calverton, United States: Macro International, Inc.	1997		†
Vietnam	General Statistics Office (Viet Nam), Macro International, Inc. Vietnam Demographic and Health Survey 2002. Calverton, United States: Macro International, Inc.	2002	*	†
Vietnam	World Health Organization (WHO). Viet Nam World Health Survey 2002-2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2002-2003	*	
Vietnam	General Statistics Office (Viet Nam), United Nations Children's Fund (UNICEF). Vietnam Multiple Indicator Cluster Survey 2010-2011. New York, United States: United Nations Children's Fund (UNICEF).	2010-2011		
Vietnam	World Health Organization (WHO). Control of Foodborne Trematode Infections 1995. Geneva, Switzerland: World Health Organization (WHO), 1995.	1995		
Vietnam	World Health Organization (WHO). WHO DengueNet. Geneva, Switzerland: World Health Organization (WHO).	1988-1999		
Vietnam	Ngan PK, Khanh NG, Tuong CV, Quy PP, Anh DN, Thuy HT. Persistent diarrhea in Vietnamese children: a preliminary report. Acta Paediatr. 1992; 81 Suppl 381: 124-6.	1988-1989		†
Vietnam	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologists Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Vietnam	Weatherall D. Sickle Cell and Thalassemias Prevalence Data. Personal Correspondence with David Weatherall.	1990-2009		
Vietnam	Do TT, Bui TTH, Mølbak K, Phung DC, Dalsgaard A. Epidemiology and aetiology of diarrhoeal diseases in adults engaged in wastewater-fed agriculture and aquaculture in Hanoi, Vietnam. Trop Med Int Health. 2007; 12(Suppl 2): 23-33.	2002-2004		
Vietnam	Balle VH, Tos M, Dang HS, Nhan TS, Le T, Tran KP, Tran TT, Vu MT. Prevalence of chronic otitis media in a randomly selected population from two communes in southern Vietnam. Acta Otolaryngol Suppl. 2000; 543: 51-3.	1995		
Vietnam	Tram TT, Thinh LQ, Nga TT, VY NNT, Pedersen FK, Schlumberger M. The etiology of bacterial pneumonia and meningitis in Vietnam. Pediatr Infect Dis J. 1998; 17 Suppl(9 Suppl): S192-S194.	1995-1996		
Vietnam	Van Man N, Luan LT, Trach DD, Thanh NTH, Van Tu P, Long NT, Anh DD, Fischer TK, Ivanoff B, Gentsch JR, Glass RL. Epidemiological profile and burden of rotavirus diarrhea in Vietnam: 5 years of sentinel hospital surveillance, 1998-2003. J Infect Dis. 2005; 192(Suppl 1): 127-132.	1998-2003		
Vietnam	Von Seidlein L, Kim DR, Ali M, Lee H, Wang X, Thiem VD, Canh DG, Chaicumpa W, Agtini MD, Hossain A, Bhutta ZA, Mason C, Sethabur O, Talukder K, Nair GB, Deen JL, Kotloff K, Clemens J. A Multicentre Study of Shigella Diarrhoea in Six Asian Countries: Disease Burden, Clinical Manifestations, and Microbiology. PLoS Med. 2006; 3(9): e353.	2001-2003		
Vietnam	Lumbiganon P, Laopaboon M, Gülmezoglu AM, Souza JP, Taneepanichkul S, Ruyan P, Attygalle DE, Shrestha N, Mori R, Hinh ND, Bang HT, Rathavy T, Chuyun K, Cheang K, Festin M, Udomprasertgul V, Germar MJV, Yanqiu G, Roy M, Carroli G, Ba-Thike K. Method of delivery and pregnancy outcomes in Asia: the WHO global survey on maternal and perinatal health 2007-08. Lancet. 2010; 375(9713): 490-9.	2007-2008		
Vietnam	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1999, 2001, 2003		
Vietnam	Minh Hoa TT, Darmawan J, Chen SL, Van Hung N, Thi Nhi C, Ngoc An T, Damarwan J, Shun Le C. Prevalence of the rheumatic diseases in urban Vietnam: a WHO-ILAR COPCORD study. J Rheumatol. 2003; 30(10): 2252-6.	2000		
Vietnam	Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6): 476-483.	2000	*	
Vietnam	Duc Son LN, Kusama K, Hung NT, Loan TT, Chuyen NV, Kunii D, Sakai T, Yamamoto S. Prevalence and risk factors for diabetes in Ho Chi Minh City, Vietnam. Diabet Med. 2004; 21(4): 371-6.	2001		
Vietnam	Lâm HT, Rönmark E, Tuõng NV, Ekerljung L, Chùc NTK, Lundbäck B. Increase in asthma and a high prevalence of bronchitis: results from a population study among adults in urban and rural Vietnam. Respir Med. 2011; 105(2): 177-85.	2007-2008		
Vietnam	Loc Giang Do, Spencer AJ, Roberts-Thomson KF, Hai Dinh Trinh, Thuy Thanh Nguyen. Oral health status of Vietnamese children: findings from the National Oral Health Survey of Vietnam 1999. Asia Pac J Public Health. 2011; 23(2): 217-27.	1999	*	
Vietnam	Nguyen TC, Witter DJ, Bronkhorst EM, Truong NB, Creugers NHJ. Oral health status of adults in Southern Vietnam - a cross-sectional epidemiological study. BMC Oral Health. 2010; 10(10): 2.	2006-2009		
Vietnam	Roberts-Thomson KF, Spencer AJ. The Second National Oral Health Survey of Vietnam - 1999: variation in the prevalence of dental diseases. N Z Dent J. 2010; 106(3): 103-8.	1999	*	
Vietnam	Duong TH, Nguyen PH, Henley K, Peters M. Risk factors for hepatitis B infection in rural Vietnam. Asian Pac J Cancer Prev. 2009; 10(1): 97-102.	2006	*	
Vietnam	Nguyen VM, Nguyen VT, Huynh PL, Dang DT, Nguyen TH, Phan VT, Nguyen TL, Le TL, Ivanoff B, Gentsch JR, Glass RL. Vietnam Rotavirus Surveillance Network. The epidemiology and disease burden of rotavirus in Vietnam: sentinel surveillance at 6 hospitals. J Infect Dis. 2001; 183(12): 1707-12.	1998-2000	*	
Vietnam	Trang NV, Luan LT, Kim-Anh LT, Hau VTB, Nhung LTH, Phasuk P, Setrabur O, Shirley H, Vinjé J, Anh DD, Mason CJ. Detection and molecular characterization of noroviruses and sapoviruses in children admitted to hospital with acute gastroenteritis in Vietnam. J Med Virol. 2012; 84(2): 290-7.	2007-2008	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Vietnam	CHOICE Study Group. Multicenter, randomized, double-blind clinical trial to evaluate the efficacy and safety of a reduced osmolarity oral rehydration salts solution in children with acute watery diarrhea. <i>Pediatrics</i> . 2001; 107(4): 613-8.	1995-1997		
Vietnam	Thompson CN, Phan VTM, Le TPT, Pham TNT, Hoang LP, Ha V, Nguyen VMH, Pham VM, Nguyen TV, Cao TT, Tran TTN, Nguyen TTH, Dao MT, Campbell JI, Nguyen TC, Tang CT, Ha MT, Farrar J, Baker S. Epidemiological features and risk factors of Salmonella gastroenteritis in children resident in Ho Chi Minh City, Vietnam. <i>Epidemiol Infect</i> . 2013; 141(8): 1604-13.	2009-2010		
Vietnam	Tsu VD, Mai TTP, Nguyen YH, Luu HTT. Reducing postpartum hemorrhage in Vietnam: assessing the effectiveness of active management of third-stage labor. <i>J Obstet Gynaecol Res</i> . 2006; 32(5): 489-96.	2004-2005		
Vietnam	Lê VT, Lê TL, Nguyễn TH, Nguyễn HH, Đào TX, Nguyễn VT, Phạm MB. Strokes in South Vietnam: an epidemiologic study. <i>Rev Neurol (Paris)</i> . 1999; 155(2): 137-40.	1994-1995		
Vietnam	Lan PT, Lundborg CS, Phuc HD, Sihavong A, Unemo M, Chuc NTK, Khang TH, Mogen I. Reproductive tract infections including sexually transmitted infections: a population-based study of women of reproductive age in a rural district of Vietnam. <i>Sex Transm Infect</i> . 2008; 84(2): 126-32.	2003, 2006		
Vietnam	Hoa NB, Sy DN, Nhung NV, Tiemersma EW, Borgdorff MW, Cobelens FGJ. National survey of tuberculosis prevalence in Viet Nam. <i>Bull World Health Organ</i> . 2010; 88(4): 273-80.	2006-2007	*	
Vietnam	Dung TT, Cio PT, Thuy NB. Preliminary result of survey Ear and Hearing Disorder in Vietnam. Informal Consultation on Epidemiology of Deafness and Hearing Impairment in Developing Countries and Update of the WHO Protocol. 2003. World Health Organization, Geneva.	2001	*	
Vietnam	Tuan NA, Cuong LQ, Allebeck P, Chuc NTK, Persson HE, Tomson T. The incidence of epilepsy in a rural district of Vietnam: a community-based epidemiologic study. <i>Epilepsia</i> . 2010; 51(12): 2377-83.	2005-2008	*	†
Vietnam	Cuong L, Doanh N, Jallon P. Prevalence of epilepsy in Thai Bao-BAC NINH, a region in Vietnam affected by neurocysticercosis. <i>Epilepsia</i> . 2005; 132.	2004		
Vietnam	Tuan NA, Cuong LQ, Allebeck P, Chuc NTK, Persson HE, Tomson T. The prevalence of epilepsy in a rural district of Vietnam: a population-based study from the EPIBAVI project. <i>Epilepsia</i> . 2008; 49(9): 1634-7.	2005		
Vietnam	Ito J, Dung DT, Vuong MT, Tuyen do G, Vinh le D, Huong NT, Ngoc TB, Ngoc NT, Hien MT, Hao DD, Oanh LT, Lieu do T, Fujisawa M, Kawabata M, Shirakawa T. Impact and perspective on chronic kidney disease in an Asian developing country: a large-scale survey in North Vietnam. <i>Nephron Clin Pract</i> . 2008; 109(1): e25-32.	2006		
Vietnam	Hanoi School of Public Health, Ministry of Health (Viet Nam), School of Population Health, University of Queensland (Australia). Vietnam Burden of Disease and Injury Study 2008.	2006	*	
Vietnam	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1998, 2001, 2004, 2007, 2010, 2012	*	
Vietnam	Hanoi School of Public Health, The Alliance for Safe Children (TASC), United Nations Children's Fund (UNICEF). Vietnam Multi-Center Injury Survey 2001.	2001	*	
Vietnam	United Nations Children's Fund (UNICEF). Child Mortality and Injury in Asia. New York, United States: United Nations Children's Fund (UNICEF). 2008. (Innocent Working Papers: Special Series on Child Injuries Nos. 1-4).	2000-2001		
Vietnam	Nguyen TLH, Nguyen THT, Morita S, Sakamoto J. Injury and pre-hospital trauma care in Hanoi, Vietnam. <i>Injury</i> . 2008; 39(9): 1026-33.	2005-2006	*	
Vietnam	Vietnam - Results of Rapid Assessment for Avoidable Blindness (RAAB) in 16 provinces of Viet Nam as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2000-2002	*	
Vietnam	Hang HM, Ekman R, Bach TT, Byass P, Svanström L. Community-based assessment of unintentional injuries: a pilot study in rural Vietnam. <i>Scand J Public Health Suppl</i> . 2003; 38-44.	1999		
Vietnam	Hang HM, Bach TT, Byass P. Unintentional injuries over a 1-year period in a rural Vietnamese community: describing an iceberg. <i>Public Health</i> . 2005; 119(6): 466-73.	2000		
Vietnam	Frischer H, Bowman JE, Carson PE, Rieckmann KH, Willerson D Jr, Colwell EJ. Erythrocytic glutathione reductase, glucose-6-phosphate dehydrogenase, and 6-phosphogluconic dehydrogenase deficiencies in populations of the United States, South Vietnam, Iran, and Ethiopia. <i>J Lab Clin Med</i> . 1973; 81(4): 603-12.	1971-1973		
Vietnam	Le-Xuan-Chat, Le-Si-Quang, Humbert C, Chu-Quang-Giao. Glucose-6-phosphate dehydrogenase deficiency in Viet-nam. <i>Nouv Rev Fr Hematol</i> . 1968; 8(6): 878-84.	1966-1968		
Vietnam	Youel DB, Strickland GT, Binh BA, Clarkson R, Blackwell RQ. Low incidence of erythrocyte G-6-P D deficiency in Vietnamese and Montagnards of South Vietnam. <i>Vox Sang</i> . 1971; 20(6): 555-8.	1969-1971		
Vietnam	Panich V, Bumrungrakul P, Jitjai C, Kamolmatyakul S, Khoprasert B, Klaisuvan C, Kongmuang U, Maneechai P, Pompatkul M, Ruengrataranarop P, Surapruk P, Viriyayudhakorn S. Glucose-6-phosphate dehydrogenase deficiency in South Vietnamese. <i>Hum Hered</i> . 1980; 30(6): 361-4.	1978-1980		
Vietnam	Verlé P, Nhan DH, Tinh TT, Uyen TT, Thuong ND, Kongs A, Stuyft P, Coosemans M. Glucose-6-phosphate dehydrogenase deficiency in northern Vietnam. <i>Trop Med Int Health</i> . 2000; 5(3): 203-6.	1996-1997	*	
Vietnam	Matsuoka H, Thuan DTV, van Thien H, Kanbe T, Jalloh A, Hirai M, Arai M, Dung NT, Kawamoto F. Seven different glucose-6-phosphate dehydrogenase variants including a new variant distributed in Lam Dong Province in southern Vietnam. <i>Acta Med Okayama</i> . 2007; 61(4): 213-9.	1997-2004		
Vietnam	Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. Cancer Incidence in Five Continents. Vol. 1 to VIII. Lyon, France, IARC Press. 2005.	1991-1998		
Vietnam	Loc Giang Do, Spencer AJ, Roberts-Thomson KF, Hai Dinh Trinh, Thuy Thanh Nguyen. Oral health status of Vietnamese adults: findings from the National Oral Health Survey of Vietnam. <i>Asia Pac J Public Health</i> . 2011; 23(2): 228-36.	1999		
Vietnam	Giang KB, Spak F, Dzong TV, Allebeck P. The use of audit to assess level of alcohol problems in rural Vietnam. <i>Alcohol Alcohol</i> . 2005; 40(6): 578-83.	2002-2003		
Vietnam	Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agtini MD, Bhutta ZA, Canh DG, Ali M, Shin S, Wain J, Page A-L, Albert MJ, Farrar J, Abu-Elyazed R, Pang T, Galindo CM, von Seidlein L, Clemens JD, Domi Typhoid Study Group. A study of typhoid fever in five Asian countries: disease burden and implications for controls. <i>Bull World Health Organ</i> . 2008; 86(4): 260-8.	2002-2003		
Vietnam	Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, Kossaczka Z, Bryla DA, Shiloach J, Robbins JB, Schneerson R, Szu SC. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. <i>N Engl J Med</i> . 2001; 344(17): 1263-9.	1998		
Vietnam	Nguyen MH, Kurtzhals J, Do TTT, Rasch V. Reproductive tract infections in women seeking abortion in Vietnam. <i>BMC Womens Health</i> . 2009; 1.	2003	*	
Vietnam	Goto A, Nguyen QV, Pham NM, Kato K, Cao TPN, Le THC, Hoang QK, Le TQN, Nguyen BT, Katsube M, Ishii S, Yasumura S. Prevalence of and factors associated with reproductive tract infections among pregnant women in ten communes in Nghe An Province, Vietnam. <i>J Epidemiol</i> . 2005; 15(5): 163-72.	2003	*	†
Vietnam	Trach DD, Clemens JD, Ke NT, Thuy HT, Son ND, Canh DG, Hang PV, Rao MR. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. <i>Lancet</i> . 1997; 349(9047): 231-5.	1993		†
Vietnam	Erhart A, Thang ND, Bien TH, Tung NM, Hung NQ, Hung LX, Tuy TQ, Speybroeck N, Cong LD, Coosemans M, D'Alessandro U. Malaria epidemiology in a rural area of the Mekong Delta: a prospective community-based study. <i>Trop Med Int Health</i> . 2004; 9(10): 1081-90 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999-2001	*	
Vietnam	Erhart A, Thang ND, Hung NQ, Toi LV, Hung LX, Tuy TQ, Cong LD, Speybroeck N, Coosemans M, D'Alessandro U. Forest malaria in Vietnam: a challenge for control. <i>Am J Trop Med Hyg</i> . 2004; 70(2): 110-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1999-2001		
Vietnam	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec</i> . 2005; 80(13): 118-24.	2003	*	
Vietnam	Vietnam National Vitamin A Deficiency and Protein Energy Malnutrition Prevalence Survey 1994 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1994	*	
Vietnam	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec</i> . 2005; 80(34): 289-95.	2004	*	
Vietnam	World Health Organization (WHO). Global leprosy situation, 2006. <i>Wkly Epidemiol Rec</i> . 2006; 81(32): 309-16.	2005	*	

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Vietnam	World Health Organization (WHO). Global leprosy situation, 2007. Wkly Epidemiol Rec. 2007; 82(25): 225-32.	2006	*	
Vietnam	World Health Organization (WHO). Global leprosy situation, 2009. Wkly Epidemiol Rec. 2009; 84(33): 333-40.	2008	*	
Vietnam	World Health Organization (WHO). Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35): 337-48.	2009	*	
Vietnam	World Health Organization (WHO). Global leprosy situation, 2012. Wkly Epidemiol Rec. 2012; 87(34): 317-28.	2011	*	
Vietnam	World Health Organization (WHO). Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008; 83(33): 293-300.	2007	*	
Vietnam	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Vietnam	World Health Organization (WHO). Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec. 2013; 88(35): 365-79.	2012	*	
Vietnam	World Health Organization (WHO). Leprosy update, 2011. Wkly Epidemiol Rec. 2011; 86(36): 389-99.	2010	*	
Vietnam	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Vietnam	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Vietnam	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1994; 69(20): 145-51.	1993	*	
Vietnam	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Vietnam	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1993; 68(25): 181-6.	1992	*	
Vietnam	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Vietnam	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Vietnam	Vietnam Report to the FAO/WHO International Conference on Nutrition 1992 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1985-1989	*	
Vietnam	The Impact of High-dose Vitamin A Supplementation on Morbidity and Nutritional Status of Young Children: A Community-based Trial as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1991		
Vietnam	Paudel P, Ramson P, Naduvilath T, Wilson D, Phuong HT, Ho SM, Giap NV. Prevalence of vision impairment and refractive error in school children in Ba Ria - Vung Tau province, Vietnam. Clin Experiment Ophthalmol. 2014.	2011		
Vietnam	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2000.	2000		
Vietnam	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2001.	2001		
Vietnam	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2002.	2002		
Vietnam	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2003.	2003		
Vietnam	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2004.	2004		
Vietnam	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2005.	2005		
Vietnam	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2006.	2006		
Vietnam	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2007.	2007		
Vietnam	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2008.	2008		
Vietnam	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2009.	2009		
Vietnam	World Health Organization Regional Office for the Western Pacific. Number of Reported Cases of Dengue Fever and Dengue Hemorrhagic Fever in the Western Pacific Region, by Country 2010.	2010		
Vietnam	Mai NTH, Chau TTH, Thwaites G, Chuong LV, Sinh DX, Nghia HDT, Tuan PQ, Phong ND, Phu NH, Diep TS, Chau N van V, Duong NM, Campbell J, Schultsz C, Parry C, Torok ME, White N, Chinh NT, Hien TT, Stepniowska K, Farrar JJ. Dexamethasone in Vietnamese Adolescents and Adults with Bacterial Meningitis. N Engl J Med. 2007; 357(24): 2431-40.	1996-2005		†
Vietnam	Tuong P, Khoi H, Dan P, Roanh L. Vitamin A deficiency and xerophthalmia in children in the northern mountainous areas of Vietnam. J Hyg Epidemiol. 1994; 27-31 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1994		
Vietnam	Gay T, Khoi H, Nhan N, Khan N, Dung N, Dung P, Anh H. Vitamin A deficiency and xerophthalmia in preschool children in some provinces of North Vietnam today. Acta Med Vietnam. 1986; 21-7 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1985-1986	*	
Vietnam	Ministry of Health (Viet Nam), University of Queensland (Australia). Vietnam Evidence Base for Health Policy (VINE) Project 2006-2010. [Unpublished].	2006	*	
Vietnam	Nguyen TV, Dalman C, Le TC, Nguyen TV, Tran NV, Allebeck P. Suicide attempt in a rural area of Vietnam: Incidence, methods used and access to mental health care. Int J Ment Health Syst. 2010; 4(1): 3.	2003-2007	*	
Vietnam	Zhao Y-F, Guo X-J, Zhang Z-S, Ma X-Q, Wang R, Yan X-Y, He J. Epidemiology of functional diarrhea and comparison with diarrhea-predominant irritable bowel syndrome: a population-based survey in China. PLoS One. 2012; 7(8): e43749.	2002		
Vietnam	Ng KP, Ngsow YF, K R, M R. Hepatitis B seroprevalence among University of Malaya Students in the Post-universal Infant Vaccination Era. Med J Malaysia. 2013; 68(2): 144-7.	2005-2011		
Vietnam	Hau CH, Hien TT, Tien NT, Khiem HB, Sac PK, Nhung VT, Larasati RP, Laras K, Putri MP, Doss R, Hyams KC, Corwin AL. Prevalence of Enteric Hepatitis A and E Viruses in the Mekong River Delta Region of Vietnam. Am J Trop Med Hyg. 1999; 60(2): 277-80.	1994		
Vietnam	Katellaris PH, Robertson G, Bradbury R, Tippett G, Hoa DQ, Ngu MC. Seroprevalence of hepatitis viruses in children in rural Viet Nam. Trans R Soc Trop Med Hyg. 1995; 89(5): 487.	1994		
Vietnam	Song P, Duc DD, Hien B, Nakata S, Chosa T, Watanabe J, Tsuda F, Murata K, Okamoto H. Markers of hepatitis C and B virus infections among blood donors in Ho Chi Minh City and Hanoi, Vietnam. Clin Diagn Lab Immunol. 1994; 1(4): 413-8.	1992		
Vietnam	Nakata S, Song P, Duc DD, Nguyen XQ, Murata K, Tsuda F, Okamoto H. Hepatitis C and B virus infections in populations at low or high risk in Ho Chi Minh and Hanoi, Vietnam. J Gastroenterol Hepatol. 1994; 9(4): 416-9.	1993	*	†
Vietnam	United Nations Office on Drugs and Crime (UNODC). World Drug Report 2008. Vienna, Austria: United Nations Office on Drugs and Crime (UNODC), 2008.	2002	*	†
Vietnam	Evaluation of Environment Changes of Replanted Forest to Distribution of Malaria Vectors and Vector Control Measures in Lao Cai and Son La Provinces as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Vietnam	Malaria Epidemiological Characters and Evaluation on Malaria Control Measures in Son La Hydro-electricity Plant Zone as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Vietnam	Study on the Epidemiological Characteristics of Malaria for the Rubber Workers in Central Highland and Southeast Vietnam as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Vietnam	Evaluation of the Performance of ICON in Malaria Prevention at Some Sites that have An. Minimus, An. Dirus as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988-1989	*	†
Vietnam	Effectiveness of Peripel 55EC and K-othrine 2.5 EC Impregnated Bednets for Malaria Control in Kim Boi District, Hoa Binh Province as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993-1994	*	†
Vietnam	Studies on Vector Prevention Measures in Mulberry-silkmoth Area in Lam Dong Province as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Vietnam	Study on Epidemiological and Entomological Characteristics of Malaria Transmission and the Relative factors of Sedang Ethnic Minority People in Quang Nam Province as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2000	*	†
Vietnam	Evaluation of Malaria Epidemiological Situation by IFA Test as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†
Vietnam	Anonymous. [Results on integrated malaria prevention measures in Early Health Care in 4 locations at Phu Quoc district]. J Vector Borne Dis. 1995; 1: 7-12 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993-1994	*	†
Vietnam	Dang T, Christophel E. [Survey on malaria in Na Hang, Tuyen Quang province in Oct 1994]. J Vector Borne Dis. 1996; 2: 3-10 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Vietnam	Dang T, Van Thai P. [Evaluation on outbreak of malaria in Hmong and Dao ethnic minority people in Yen Huong commune, Ham Yen district, Tuyen Quang province in 1997]. J Vector Borne Dis. 1998; 1: 6-10 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
Vietnam	Doan HN, Nguyen DT, Tran TU, Le DC. [Some remarks on immuno-response and resistant P. falciparum in Khanh Nam – a highly endemic malaria area]. J Vector Borne Dis. 1995; 1: 13-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†
Vietnam	Erhart A, Ngo DT, Phan VK, Ta TT, Van Overmeir C, Speybroeck N, Obsomer V, Le XH, Le KT, Coosemans M, D'Alessandro U. Epidemiology of forest malaria in central Vietnam: a large scale cross-sectional survey. Malar J. 2005; 4: 58 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Vietnam	Flohr C. The links between gut worms, malaria, and atopic dermatitis: a study in rural Vietnam. J Invest Dermatol. 2005; 125: 594 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2005	*	†
Vietnam	Hoang H. [Malaria situation and associated infection factors in Thanh commune and malaria control measures]. J Vector Borne Dis. 2005; 6: 3-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Vietnam	Hung le Q, Vries PJ, Giao PT, Nam NV, Binh TQ, Chong MT, Quoc NT, Thanh TN, Hung LN, Kager PA. Control of malaria: a successful experience from Viet Nam. Bull World Health Organ. 2002; 80(8): 660-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994-1999	*	†
Vietnam	Le DC. [Malaria status and suggestions on malaria prevention in Krong Bong district]. J Vector Borne Dis. 1994; 3: 3-14 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†
Vietnam	Le KT, Ly VN, Ly BL. [Evaluation on malaria and suggestion of measures to protect people and the soldiers in the highly endemic malaria area]. J Vector Borne Dis. 2007; 1: 10-20 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Vietnam	Nguyen DM, Le DD, Vo VX. [Some remarks on the malaria and anopheline mosquitoes in Quang Binh province based on the data of the surveys in the third quarter, 2004]. J Vector Borne Dis. 2004; 6: 18-26 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Vietnam	Nguyen DM, Tran DH, Nguyen VQ. [Evaluation on Icon 2.5 CS impregnated on bednets on a study site in North Viet Nam]. J Vector Borne Dis. 1999; 1: 45-52 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1997	*	†
Vietnam	Nguyen QH. [Brief evaluation on malaria prevention project in Lam Ha District (Lam Dong Province) 1993]. J Vector Borne Dis. 1994; 2: 18-24 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1993	*	†
Vietnam	Nguyen QT, Trieu NT, Nguyen NS. [Evaluation on the effectiveness of the rapid Paracheck-F test for diagnosis of malaria in the community]. J Vector Borne Dis. 2002; 6: 41-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Vietnam	Nguyen VH, Luong VD. [The risk of malaria outbreak and measures applied to prevent in A Luoi district, Thua Thien - Hue province 1997-1998]. J Vector Borne Dis. 1999; 2: 26-33 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Vietnam	Sanh NH, Van Dung N, Thanh NX, Trung TN, Van Co T, Cooper RD. Forest malaria in central Vietnam. Am J Trop Med Hyg. 2008; 79(5): 652-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2006	*	†
Vietnam	Vu TT, Nguyen TH, Nguyen PT. [Quick diagnosis malaria parasite by acridine orange staining technique]. J Vector Borne Dis. 1997; 2: 47-52 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994		†
Vietnam	Wang L, Crouch L, Richie TL, Nhan DH, Coppel RL. Naturally acquired antibody responses to the components of the Plasmodium falciparum merozoite surface protein 1 complex. Parasite Immunol. 2003; 25(8-9): 403-12 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	
Yemen	Central Statistical Organization (Yemen), League of Arab States, Ministry of Public Health and Population (Yemen), Pan Arab Project for Family Health (PAPFAM). Yemen Family Health Survey 2003.	2003		†
Yemen	Ministry of Health (Yemen) and United Nations Children's Fund (UNICEF). Yemen Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).	2006		
Yemen	Central Statistical Organization (Yemen), League of Arab States, Macro International, Inc. Yemen Demographic and Health Survey 1991-1992. Calverton, United States: Macro International, Inc.	1991-1992		†
Yemen	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		
Yemen	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		
Yemen	White JM, Byrne M, Richards R, Buchanan T, Katsoulis E, Weerasingh K. Red cell genetic abnormalities in Peninsular Arabs: sickle haemoglobin, G6PD deficiency, and alpha and beta thalassaemia. J Med Genet. 1986; 3(23): 245-51.	1984-1986		
Yemen	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	2008-2009	*	
Yemen	Warren KS, Mahmoud AA, Cummings P, Murphy DJ, Houser HB. Schistosomiasis mansoni in Yemeni in California: duration of infection, presence of disease, therapeutic management. Am J Trop Med Hyg. 1974; 23(5): 902-9.	1971		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Yemen	Al-Haddad KA, Al-Hebshi NN, Al-Akhali MS. Oral health status and treatment needs among school children in Sana'a City, Yemen. <i>Int J Dent Hyg</i> . 2010; 8(2): 80-5.	2002-2003		
Yemen	Mengel R, Eigenbrodt M, Schittenmann T, Florès-de-Jacoby L. Periodontal status of a subject sample of Yemen. <i>J Clin Periodontol</i> . 1996; 23(5): 437-43.	1991		
Yemen	Bawazir AA, Hart CA, Sallam TA, Parry CM, Beeching NJ, Cuevas LE. Seroepidemiology of hepatitis A and hepatitis E viruses in Aden, Yemen. <i>Trans R Soc Trop Med Hyg</i> . 2010; 104(12): 801-5.	2005	*	
Yemen	Alyahri A, Goodman R. The prevalence of DSM-IV psychiatric disorders among 7-10 year old Yemeni schoolchildren. <i>Soc Psychiatry Psychiatr Epidemiol</i> . 2008; 43(3): 224-30.	2002-2003		
Yemen	Shuaib AA, Frass KA, Al-Harazi AH, Ghanem NS. Pregnancy outcomes of mothers aged 17 years or less. <i>Saudi Med J</i> . 2011; 32(2): 166-70.	2009		
Yemen	Selm SAB. Prevalence of hepatitis B and C viral markers in chronic liver disease patients: A single center experience from Yemen. <i>Arab J Gastroenterol</i> . 2010; 11(2): 105-7.	2007		
Yemen	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	1995, 1998, 2001, 2004, 2007, 2010, 2012		
Yemen	Yemen - Amran Rapid Assessment of Avoidable Blindness 2009 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2009		
Yemen	Yemen - Lahj Rapid Assessment of Avoidable Blindness 2009 [Unpublished] as it appears in Bourne, Rupert. Vision Loss Database - Survey data on vision loss by severity and etiology.	2009		
Yemen	Modesti PA, Bamoshmooch M, Rapi S, Massetti L, Bianchi S, Al-Hidabi D, Al-Goshae H. Relationship between hypertension, diabetes and proteinuria in rural and urban households in Yemen. <i>J Hum Hypertens</i> . 2013; 27(9): 572-9.	2007-2008	*	
Yemen	Al-Rohani M. Renal failure in Yemen. <i>Transplant Proc</i> . 2004; 36(6): 1777-9.	1998-2002	*	
Yemen	World Health Organization (WHO). Yemen WHO Leishmaniasis Country Profile.	2005-2009	*	
Yemen	World Health Organization (WHO). Global leprosy situation, 2004. <i>Wkly Epidemiol Rec</i> . 2005; 80(13): 118-24.	2003	*	
Yemen	World Health Organization (WHO). Global leprosy situation, 2005. <i>Wkly Epidemiol Rec</i> . 2005; 80(34): 289-95.	2004	*	
Yemen	World Health Organization (WHO). Global leprosy situation, 2007. <i>Wkly Epidemiol Rec</i> . 2007; 82(25): 225-32.	2006	*	
Yemen	World Health Organization (WHO). Global leprosy situation, 2009. <i>Wkly Epidemiol Rec</i> . 2009; 84(33): 333-40.	2008	*	
Yemen	World Health Organization (WHO). Global leprosy situation, 2010. <i>Wkly Epidemiol Rec</i> . 2010; 85(35): 337-48.	2009	*	
Yemen	World Health Organization (WHO). Global leprosy situation, 2012. <i>Wkly Epidemiol Rec</i> . 2012; 87(34): 317-28.	2011	*	
Yemen	World Health Organization (WHO). Global leprosy situation, beginning of 2008. <i>Wkly Epidemiol Rec</i> . 2008; 83(33): 293-300.	2007	*	
Yemen	World Health Organization (WHO). Global leprosy situation, September 1999. <i>Wkly Epidemiol Rec</i> . 1999; 74(38): 313-6.	1998	*	
Yemen	World Health Organization (WHO). Global leprosy: update on the 2012 situation. <i>Wkly Epidemiol Rec</i> . 2013; 88(35): 365-79.	2012	*	
Yemen	World Health Organization (WHO). Leprosy update, 2011. <i>Wkly Epidemiol Rec</i> . 2011; 86(36): 389-99.	2010	*	
Yemen	World Health Organization (WHO). Leprosy. <i>Wkly Epidemiol Rec</i> . 2001; 76(23): 173-9.	2000	*	
Yemen	World Health Organization (WHO). Leprosy - Global situation. <i>Wkly Epidemiol Rec</i> . 2000; 75(28): 226-31.	1999	*	
Yemen	World Health Organization (WHO). Progress towards eliminating leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1994; 69(20): 145-51.	1993	*	
Yemen	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec</i> . 1997; 72(23): 165-72.	1996	*	
Yemen	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec</i> . 1996; 71(20): 149-56.	1995		
Yemen	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec</i> . 1995; 70(25): 177-82.	1994		
Yemen	WHO Regional Office for the Eastern Mediterranean. Outbreak of Dengue Fever in Yemen 2005. <i>Div Commun Disease Control NewsL</i> . 2005; 5: 6.	2005		
Yemen	Jones EE, Kim-Farley RJ, Algunaid M, Parvez MA, Ballad YA, Hightower AW, Orenstein WA, Broome CV. Diphtheria: a possible foodborne outbreak in Hodeida, Yemen Arab Republic. <i>Bull World Health Organ</i> . 1985; 63(2): 287-93.	1981-1982		†
Yemen	Al Khorasani A, Banajeh S. Bacterial profile and clinical outcome of childhood meningitis in rural Yemen: a 2-year hospital-based study. <i>J Infect</i> . 2006; 53(4): 228-34.	1999-2001		
Yemen	Rosen DS, al-Sharif Z, Bashir M, al-Shabooti A, Pizzarello LD. Vitamin A deficiency and xerophthalmia in western Yemen. <i>Eur J Clin Nutr</i> . 1996; 50(1): 54-7 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1992		
Yemen	Munibari AA. A Study on Rheumatic Fever and Rheumatic Heart Disease in Yemen [dissertation]. Khartoum, Sudan: University of Khartoum; 1997. 195.	1994	*	
Yemen	Gacche RN, Al-Mohani SK. Seroprevalence and Risk Factors for Hepatitis C Virus Infection among General Population in Central Region of Yemen. <i>Hepat Res Treat</i> . 2012.	2010-2011		
Yemen	Salem AK, Abdulrab A, Alfakih Y, Aown A. Hepatocellular carcinoma in Yemeni patients: a single centre experience over an 8-year period. <i>East Mediterr Health J</i> . 2012; 18(7): 693-9.	2001-2008	*	†
Yemen	Scott DA, Burans JP, al-Ouzeib HD, Arunkumar BK, al-Fadeel M, Nigad YR, al-Hadad A, Elyazeed RR, Hyams KC, Woody JN. A seroepidemiological survey of viral hepatitis in the Yemen Arab Republic. <i>Trans R Soc Trop Med Hyg</i> . 1990; 84(2): 288-91.	1988		
Yemen	Chaabani H, Sanchez-Mazas A, Sallami SF. Genetic differentiation of Yemeni people according to rhesus and Gm polymorphisms. <i>Ann Genet</i> . 2000; 43(3-4): 155-62.	1997-1999		
Yemen	Janousek S, Al-Kubati M, Al-Shwafi KA. Risk factors, clinical features and outcome of acute myocardial infarction in Sana'a, Yemen. <i>Ann Saudi Med</i> . 2008; 28(3): 223-4.	1984-1986		
Yemen	Al-Moslih MI, Al-Huraibi MA. Prevalence of hepatitis C virus among patients with liver disease in the Republic of Yemen. <i>East Mediterr Health J</i> . 2001; 7(4-5): 771-8.	2001		†
Yemen	Al-Nassiri K, Raja'a Y. Hepatitis B infection in Yemenis in Sana'a: pattern and risk factors. <i>East Mediterr Health J</i> . 2000; 7(1-2): 147-52.	1999	*	†
Yemen	Gray GC, Kassira EN, Rodier GR, Myers MC, Calamaio CA, Gregory M, Nagi MA, Kamal K, Botros BA, Soliman AK, Hassan NF, Gregory R, Arunkumar BK, Cope A, Hyams KC. Remote village survey for agents causing hepatosplenic disease in the Republic of Yemen. <i>Trop Doct</i> . 1999; 29(4): 212-9.	1992		
Yemen	Gray GC, Kassira EN, Rodier GR, Myers MC, Calamaio CA, Gregory M, Nagi MA, Kamal K, Botros BA, Soliman AK, Hassan NF, Gregory R, Arunkumar BK, Cope A, Hyams KC. Remote village survey for agents causing hepatosplenic disease in the Republic of Yemen. <i>Trop Doct</i> . 1999; 29(4): 212-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992		
Yemen	Sallam TA, Cuevas LE, Tong CYW. Increase in susceptibility of young adults to hepatitis B infection in the Republic of Yemen. <i>Trans R Soc Trop Med Hyg</i> . 2003; 97(3): 302-4.	1999-2000		
Yemen	Sallam TA, Tong CYW, Cuevas LE, Raja'a YA, Othman AM, Al-Kharsa KR. Prevalence of blood-borne viral hepatitis in different communities in Yemen. <i>Epidemiol Infect</i> . 2003; 131(1): 771-5.	2000-2002	*	†
Yemen	Scott DA, Constantine NT, Callahan J, Burans JP, Olson JG, al-Fadeel M, al-Ozib H, Arunkumar H, Hyams KC. The epidemiology of hepatitis C virus antibody in Yemen. <i>Am J Trop Med Hyg</i> . 1992; 46(1): 63-8.	1988	*	†
Yemen	Malaria Situation in Zabid District, Al-Hodeidah Governorate, Republic of Yemen [Master's thesis] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1994	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Yemen	Report on a Visit to the Yemen Arab Republic from 14-2 to 13-3-1989 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Yemen	Malaria Situation in Hodeidah Governorate, Republic of Yemen as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	†
Yemen	Assignment Report on Malaria Control in Yemen. 14 September-25 November 1985 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Yemen	Malaria in Socotra Island, Democratic Yemen as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1987	*	†
Yemen	Malaria in Hajjar Valley: School Malariometry, March 2001 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2001	*	†
Yemen	Malaria and Anaemia Survey, Basateen and Kharaz Camps, Yemen 2009 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2009	*	†
Yemen	Al-Maktari M, Bassiouny H, Al-Hamd Z, Assabri AM, El-Masry EG, Shatat HZ. Malaria status in Al-Hodeidah Governorate, Yemen: malariometric parasitic survey and chloroquine resistance P. falciparum local strain. J Egypt Soc Parasitol. 2003; 33(2): 361-72 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998-1999	*	†
Yemen	Al-Ta'iar A, Assabri A, Al-Habori M, Azazy A, Algabri A, Alganadi M, Whitty CJM, Jaffar S. Socioeconomic and environmental factors important for acquiring non-severe malaria in children in Yemen: a case-control study. Trans R Soc Trop Med Hyg. 2009; 103(1): 72-8 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002-2004	*	†
Yemen	Alkadi HO, Al-Maktari MT, Noonan MA. Chloroquine-Resistant Plasmodium falciparum Local Strain in Taiz Governorate, Republic of Yemen. Chemotherapy. 2006; 52(4): 166-70 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003-2004	*	†
Yemen	Daoud W. [Epidemiologic study of malaria in the foothill area of the Taz region of the Arabic Republic of Yemen]. Bull Soc Pathol Exot. 1988; 81(3): 351-9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986-1987	*	†
Yemen	Yemen Plasmodium Falciparum Parasite Rate Data, Assabari 1997 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1996-1997	*	†
Yemen	Yemen Plasmodium Falciparum Parasite Rate Data, Yemen Ministry of Health 1989 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985-1989	*	†
Zambia	Central Statistical Office (Zambia). Zambia Living Conditions Monitoring Survey 2006.	2006		†
Zambia	Central Statistical Office (Zambia). Food Security, Health and Nutrition Information System (Zambia), United Nations Children's Fund (UNICEF). Zambia Multiple Indicator Cluster Survey 1999. New York, United States: United Nations Children's Fund (UNICEF).	1999		†
Zambia	Central Statistical Office (Zambia), Macro International, Inc, University of Zambia. Zambia Demographic and Health Survey 1992. Calverton, United States: Macro International, Inc.	1992		†
Zambia	Central Statistical Office (Zambia), Macro International, Inc, Ministry of Health (Zambia). Zambia Demographic and Health Survey 1996-1997. Calverton, United States: Macro International, Inc.	1996-1997		†
Zambia	Central Board of Health (Zambia), Central Statistical Office (Zambia), Macro International, Inc. Zambia Demographic and Health Survey 2001-2002. Calverton, United States: Macro International, Inc.	2001-2002		†
Zambia	Central Statistical Office (Zambia), Macro International, Inc. Zambia Demographic and Health Survey 2007. Calverton, United States: Macro International, Inc.	2007	*	†
Zambia	World Health Organization (WHO). Zambia World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Zambia	Central Statistical Office (Zambia). Zambia Living Conditions Monitoring Survey 2010.	2010		†
Zambia	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		†
Zambia	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		†
Zambia	Wenlock RW. Hydroxyproline index as a tool for nutrition status surveys in malarial regions. Br J Nutr. 1977; 38(2): 239-43.	1973-1974		†
Zambia	Gibbs, S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int J Dermatol. 1996; 35(9): 633-9.	1994		†
Zambia	Chintu C, Luo C, Baboo S, Khumalo-Ngwenya B, Mathewson J, DuPont HL, Zumla A. Intestinal parasites in HIV-seropositive Zambian children with diarrhoea. J Trop Pediatr. 1995; 41(3): 149-52.	1993-1994		†
Zambia	Mwenda JM, Noto KM, Abebe A, Enweronu-Laryea C, Amina I, Mchomvu J, Kisakyi A, Mpahawani EM, Pazvakambwa I, Armah GE, Seheri LM, Kiulia NM, Page N, Widdowson M-A, Steele AD. Burden and epidemiology of rotavirus diarrhea in selected African countries: preliminary results from the African Rotavirus Surveillance Network. J Infect Dis. 2010; 202(Suppl): S5-11.	2006-2008		†
Zambia	Amadi B, Kelly P, Mwiya M, Mulwazi E, Sianongo S, Changwe F, Thomson M, Hachungula J, Watuka A, Walker-Smith J, Chintu C. Intestinal and systemic infection, HIV, and mortality in Zambian children with persistent diarrhea and malnutrition. J Pediatr Gastroenterol Nutr. 2001; 32(5): 550-4.	1998-2000		†
Zambia	World Health Organization (WHO). Yellow Fever Reported Cases. WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997, 1999-2001, 2003-2009		†
Zambia	Mungomba LM, Kalumba K. Validation of schistosomiasis morbidity symptoms in schoolchildren of Siavonga, Lake Kariba, Zambia. Ann Trop Med Parasitol. 1995; 89(4): 439-42.	1992-1993		†
Zambia	Sukwa TY, Bulsara MK, Wurapa FK. The relationship between morbidity and intensity of Schistosoma mansoni infection in a rural Zambian community. Int J Epidemiol. 1986; 15(2): 248-51.	1978-1986		†
Zambia	Sukwa TY, Bulsara MK, Wurapa FK. Evaluation of selected symptoms in the diagnosis of Schistosoma mansoni infection. Trop Geogr Med. 1985; 37(4): 295-7.	1984-1985		†
Zambia	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		†
Zambia	Noar J, Portnoy S. Dental status of children in a primary and secondary school in rural Zambia. Int Dent J. 1991; 41(3): 142-8.	1989		†
Zambia	Stein Z, Belmont L, Durkin M. Mild mental retardation and severe mental retardation compared: experiences in eight less developed countries. Ups J Med Sci Suppl. 1987; 89-96.	1987	*	†
Zambia	Mukelabai K, Pobee JOM, Shilaluke-Ngoma M, Malek ANA, Pankajam MI, Mupela M. Rheumatic heart disease in a sub-Saharan African city: epidemiology, prophylaxis and health education. Cardiol Trop. 2000; 26(102): 25-8.	1987-1991		†
Zambia	Birbeck GL, Kalichi EMN. Epilepsy prevalence in rural Zambia: a door-to-door survey. Trop Med Int Health. 2004; 9(1): 92-5.	2000-2001	*	†
Zambia	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2012	*	†
Zambia	Crucitti T, Jespers V, Mulenga C, Khondowe S, Vandepitte J, Buvé A. Non-sexual transmission of Trichomonas vaginalis in adolescent girls attending school in Ndola, Zambia. PLoS One. 2011; 6(1): e16310.	2008-2010		†
Zambia	Mbewe E, Zairethiama P, Yeh HH, Paul R, Birbeck GL, Steiner TJ. The epidemiology of primary headache disorders in Zambia: a population-based door-to-door survey. J Headache Pain. [Forthcoming].	2010		†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Zambia	Crucitti T, Jespers V, Mulenga C, Khondowe S, Vandepitte J, Buve A. Trichomonas vaginalis is highly prevalent in adolescent girls, pregnant women, and commercial sex workers in Ndola, Zambia. Sex Transm Dis. 2010; 37(4): 223-7.	2003-2004	*	
Zambia	Sinarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jamin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J Health Geogr. 2010; 9: 57.	1980-2010	*	
Zambia	World Health Organization (WHO). Global leprosy situation, 2006. Wkly Epidemiol Rec. 2006; 81(32): 309-16.	2005	*	
Zambia	World Health Organization (WHO). Global leprosy situation, 2008 (additional information). Wkly Epidemiol Rec. 2008; 83(50): 459.	2007	*	
Zambia	World Health Organization (WHO). Global leprosy situation, September 1999. Wkly Epidemiol Rec. 1999; 74(38): 313-6.	1998	*	
Zambia	World Health Organization (WHO). Leprosy. Wkly Epidemiol Rec. 2001; 76(23): 173-9.	2000	*	
Zambia	World Health Organization (WHO). Leprosy - Global situation. Wkly Epidemiol Rec. 2000; 75(28): 226-31.	1999	*	
Zambia	World Health Organization (WHO). Progress towards leprosy elimination. Wkly Epidemiol Rec. 1997; 72(23): 165-72.	1996	*	
Zambia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Wkly Epidemiol Rec. 1996; 71(20): 149-56.	1995	*	
Zambia	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. Wkly Epidemiol Rec. 1995; 70(25): 177-82.	1994	*	
Zambia	Weiss HA, Buve A, Robinson NJ, Van Dyck E, Kahinda M, Anagonou S, Musonda R, Zekeng L, Morison L, Caraël M, Laga M, Hayes RJ, Study Group on Heterogeneity of HIV Epidemics in African Cities. The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. AIDS. 2001; S97-108.	1997-1998		†
Zambia	Lindfield R, Griffiths U, Bozzani F, Mumba M, Munsanje J. A Rapid Assessment of Avoidable Blindness in Southern Zambia. PLoS One. 2012; 7(6): e38483.	2010	*	†
Zambia	Sukwa T, Mwandu D, Kapui A, Siziya S, Vamoer A, Mukunyandela M, Chelembu V. The prevalence and distribution of xerophthalmia in pre-school age children of the Luapula Valley, Zambia. J Trop Pediatr. 1988; 34(1): 12-5 as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1985		
Zambia	Barclay GP. Haemolytic disease of the newborn in a Zambian community. Vox Sang. 1972; 23(4): 357-62.	1969-1971	*	†
Zambia	Oshitani H, Kasolo F, Tembo C, Mpabwani M, Mizuta K, Luo N, Suzuki H, Numazaki Y. Hepatitis B virus infection among pregnant women in Zambia. East Afr Med J. 1995; 72(12): 813-5.	1992-1993	*	†
Zambia	Malaria and Chloroquine Use in Northern Zambia [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1989	*	†
Zambia	Humoral Immune Response to the Plasmodium Falciparum Malaria Antigens PF155/RESA and CS Protein in Rural Zambian Populations [dissertation] as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1988	*	†
Zambia	Baseline Malaria Parasite Rates in Five Communities on the Copperbelt Province of Zambia as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003	*	†
Zambia	Zambia Plasmodium Falciparum Parasite Rate Data, Personal Communication with S. Mharakurwa 2007 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003-2005	*	†
Zambia	Zambia Plasmodium Falciparum Parasite Rate Data, Personal Communication with S. Mharakurwa 2009 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008-2009	*	†
Zambia	Chanda E, Hemingway J, Kleinschmidt I, Rehman AM, Ramdeen V, Phiri FN, Coetzer S, Mthembu D, Shinondo CJ, Chizema-Kawesha E, Kamuliwo M, Mukonka V, Baboo KS, Coleman M. Insecticide Resistance and the Future of Malaria Control in Zambia. PLoS One. 2011; 6(9): e24336 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008-2010	*	†
Zambia	Eisele TP, Miller JM, Moonga HB, Hamaiza B, Hutchinson P, Keating J. Malaria Infection and Anemia Prevalence in Zambia's Luangwa District: An Area of Near-Universal Insecticide-Treated Mosquito Net Coverage. Am J Trop Med Hyg. 2011; 84(1): 152-7 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2008	*	†
Zambia	Lemnge MM, Inambao AW. In vivo and in vitro sensitivity of Plasmodium falciparum to chloroquine at Lubwe and Kalene in Zambia: use of amodiaquine as an alternative antimalarial drug. Trans R Soc Trop Med Hyg. 1988; 82(2): 194-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1986	*	†
Zambia	Maboshe MN, Wurapa FK. A comparison of the sensitivity of Plasmodium falciparum malaria to chloroquine in two areas of Isoka District-Zambia. Cent Afr J Med. 1988; 34(10): 244-6 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Zambia	Watts TE, Wray JR, Ng'andu NH, Draper CC. Malaria in an urban and a rural area of Zambia. Trans R Soc Trop Med Hyg. 1990; 84(2): 196-200 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Zambia	Zambia Plasmodium Falciparum Parasite Rate Data, Personal Communication with P. Thuma 2003 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2003		
Zambia	McClean KL, Senthilselvan A. Mosquito bed nets: implementation in rural villages in Zambia and the effect on subclinical parasitaemia and haemoglobin. Trop Doct. 2002; 32(3): 139-42 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1998	*	
Zimbabwe	Zimbabwe Population and Housing Census 1992 as it appears in United Nations Statistics Division (UNSD). United Nations Demographic Yearbook - Historical Supplement 1997. New York City, United States: United Nations Statistics Division (UNSD).	1992		†
Zimbabwe	Zimbabwe Vital Registration - Deaths 1990 ICD9 as it appears in World Health Organization (WHO). WHO Mortality Database Version February 2014. Geneva, Switzerland: World Health Organization (WHO), 2014.	1990		†
Zimbabwe	Central Statistical Office (Zimbabwe), Macro Systems, Inc.; Institute for Resource Development. Zimbabwe Demographic and Health Survey 1988-1989. Columbia, United States: Macro Systems, Inc.	1988-1989		†
Zimbabwe	Central Statistical Office (Zimbabwe), Macro International, Inc. Zimbabwe Demographic and Health Survey 1994. Calverton, United States: Macro International, Inc.	1994		†
Zimbabwe	Central Statistical Office (Zimbabwe), Macro International, Inc. Zimbabwe Demographic and Health Survey 1999. Calverton, United States: Macro International, Inc.	1999		†
Zimbabwe	Central Statistical Office (Zimbabwe), Macro International, Inc. Zimbabwe Demographic and Health Survey 2005-2006. Calverton, United States: Macro International, Inc.	2005-2006	*	†
Zimbabwe	World Health Organization (WHO). Zimbabwe World Health Survey 2003. Geneva, Switzerland: World Health Organization (WHO), 2005.	2003		†
Zimbabwe	Central Statistical Office (Zimbabwe). Zimbabwe Multiple Indicator Monitoring Survey 2009. New York, United States: United Nations Children's Fund (UNICEF).	2009		
Zimbabwe	ICF Macro, Zimbabwe National Statistics Agency. Zimbabwe Demographic and Health Survey 2010-2011. Calverton, United States: ICF Macro, 2012.	2010-2011		†
Zimbabwe	Centre for Health Informatics and Multiprofessional Education, University College London. Modell's Haemoglobinopathologist's Almanac. London, United Kingdom: Centre for Health Informatics and Multiprofessional Education, University College London, 2008.	1990-2003		†
Zimbabwe	Weatherall D. Sickle Cell and Thalassemias Prevalence Data, Personal Correspondence with David Weatherall.	1990-2009		

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Zimbabwe	Ndamba J, Makaza N, Kaondera KC, Munjoma M. Morbidity due to Schistosoma mansoni among sugar-cane cutters in Zimbabwe. <i>Int J Epidemiol.</i> 1991; 20(3): 787-95.	1991		
Zimbabwe	Chandiwana SK. Human bilharziasis in a peri-urban area in Zimbabwe with special reference to its relationship to malnutrition in school children. <i>Cent Afr J Med.</i> 1983; 29(2): 23-6.	1980		
Zimbabwe	Kjetland EF, Kurewa EN, Mduluzi T, Midzi N, Gomo E, Friis H, Gundersen SG, Ndhlovu PD. The first community-based report on the effect of genital Schistosoma haematobium infection on female fertility. <i>Fertil Steril.</i> 2010; 94(4): 1551-3.	1998-1999		
Zimbabwe	Hakim JG, Manyemba J. Cardiac disease distribution among patients referred for echocardiography in Harare, Zimbabwe. <i>Cent Afr J Med.</i> 1998; 44(6): 140-4.	1995		
Zimbabwe	Mwenda JM, Ntoto KM, Abebe A, Enweronu-Laryea C, Amina I, Mchomvu J, Kisakyi A, Mpabalwani EM, Pazvakavambwa I, Amah GE, Seheri LM, Kiulia NM, Page N, Widdowson M-A, Steele AD. Burden and epidemiology of rotavirus diarrhea in selected African countries: preliminary results from the African Rotavirus Surveillance Network. <i>J Infect Dis.</i> 2010; 202(Suppl): S5-11.	2007-2008		
Zimbabwe	World Health Organization (WHO). Yellow Fever Reported Cases, WHO Vaccine-Preventable Diseases: Monitoring System. Geneva, Switzerland: World Health Organization (WHO).	1997, 2009		
Zimbabwe	Lutalo SK. Chronic inflammatory rheumatic diseases in black Zimbabweans. <i>Ann Rheum Dis.</i> 1985; 44(2): 121-5.	1973-1983		
Zimbabwe	Kjetland EF, Kurewa EN, Ndhlovu PD, Midzi N, Gwanzura L, Mason PR, Gomo E, Sandvik L, Mduluzi T, Friis H, Gundersen SG. Female genital schistosomiasis—a differential diagnosis to sexually transmitted disease: genital itch and vaginal discharge as indicators of genital Schistosoma haematobium morbidity in a cross-sectional study in endemic rural Zimbabwe. <i>Trop Med Int Health.</i> 2008; 13(12): 1509-17.	1998-1999	*	
Zimbabwe	Kidney transplant and dialysis availability by country identified through systematic review, as provided by the Global Burden of Disease 2010 Genitourinary Expert Group. [Unpublished].	1990, 2005, 2010		
Zimbabwe	Tswana SA, Jorgensen PH, Halliwell RW, Kapaata R, Moyo SR. The incidence of rotavirus infection in children from two selected study areas in Zimbabwe. <i>Cent Afr J Med.</i> 1990; 36(10): 241-6.	1987-1988		
Zimbabwe	Chironga L, Manji F. Dental caries in 12-year-old urban and rural children in Zimbabwe. <i>Community Dent Oral Epidemiol.</i> 1989; 17(1): 31-3.	1985		
Zimbabwe	Frencken JE, Sithole WD, Mwaenga R, Htoon HM, Simon E. National oral health survey Zimbabwe 1995: dental caries situation. <i>Int Dent J.</i> 1999; 49(1): 3-9.	1995		
Zimbabwe	Sathananthan K, Vos T, Bango G. Dental caries, fluoride levels and oral hygiene practices of school children in Matebeleland South, Zimbabwe. <i>Community Dent Oral Epidemiol.</i> 1996; 24(1): 21-4.	1991-1992		
Zimbabwe	Abas MA BJ. Depression and anxiety among women in an urban setting in Zimbabwe. <i>Psychol Med.</i> 1997; 27(1): 59-71.	1991-1992		
Zimbabwe	Matenga J. Stroke incidence rates among black residents of Harare - a prospective community-based study. <i>S Afr Med J.</i> 1997; 87(5): 606-8.	1991		
Zimbabwe	Westerberg BD, Skowronski DM, Stewart IF, Stewart L, Bernauer M, Mudarikwa L. Prevalence of hearing loss in primary school children in Zimbabwe. <i>Int J Pediatr Otorhinolaryngol.</i> 2005; 69(4): 517-25.	1992, 1998		
Zimbabwe	Weinig M, Hakim JG, Gudza I, Tobaiwa O. Hepatitis C virus and HIV antibodies in patients with hepatocellular carcinoma in Zimbabwe: a pilot study. <i>Trans R Soc Trop Med Hyg.</i> 1997; 91(5): 570-2.	1997	*	
Zimbabwe	World Health Organization (WHO). WHO Tuberculosis Case Notifications. Geneva, Switzerland: World Health Organization (WHO).	2007, 2010, 2012	*	
Zimbabwe	Kurewa NE, Mapingure MP, Munjoma MW, Chirenje MZ, Rusakaniko S, Stray-Pedersen B. The burden and risk factors of Sexually Transmitted Infections and Reproductive Tract Infections among pregnant women in Zimbabwe. <i>BMC Infect Dis.</i> 2010; 10: 127.	2002-2003		
Zimbabwe	Munjoma MW, Kurewa EN, Mapingure MP, Mashavave GV, Chirenje MZ, Rusakaniko S, Hussain A, Stray-Pedersen B. The prevalence, incidence and risk factors of herpes simplex virus type 2 infection among pregnant Zimbabwean women followed up nine months after childbirth. <i>BMC Womens Health.</i> 2010; 2.	2002	*	
Zimbabwe	Allain TJ, Wilson AO, Gomo ZA, Mushangi E, Senzanje B, Adamchak DJ, Matenga JA. Morbidity and disability in elderly Zimbabweans. <i>Age Ageing.</i> 1997; 26(2): 115-21.	1994-1995	*	
Zimbabwe	Cowan FM, Hargrove JW, Langhaug LF, Jaffar S, Mhuriyengwe L, Swarouth TD, Peeling R, Latif A, Bassett MT, Brown DWG, Mabey D, Hayes RJ, Wilson D. The appropriateness of core group interventions using presumptive periodic treatment among rural Zimbabwean women who exchange sex for gifts or money. <i>J Acquir Immune Defic Syndr.</i> 2005; 38(2): 202-7.	2002-2004	*	
Zimbabwe	Kjetland EF, Gwanzura L, Ndhlovu PD, Mduluzi T, Gomo E, Mason PR, Midzi N, Friis H, Gundersen SG. Herpes simplex virus type 2 prevalence of epidemic proportions in rural Zimbabwean women: association with other sexually transmitted infections. <i>Arch Gynecol Obstet.</i> 2005; 272(1): 67-73.	1998-1999	*	
Zimbabwe	Gwanzura L, Chigonda TG, Mvere D, De Villiers DM, Sizuya S, Mason PR. The prevalence of Herpes simplex virus type-2 infection in blood donors in Harare, Zimbabwe. <i>Cent Afr J Med.</i> 2002; 48(3-4): 38-42.	1999-2001	*	
Zimbabwe	Mbizvo EM, Msuya S, Stray-Pedersen B, Chirenje MZ, Munjoma M, Hussain A. Association of herpes simplex virus type 2 with the human immunodeficiency virus among urban women in Zimbabwe. <i>Int J STD AIDS.</i> 2002; 13(5): 343-8.	1999-2000	*	
Zimbabwe	McFarland W, Gwanzura L, Bassett MT, Machezano R, Latif AS, Ley C, Parsonnet J, Burke RL, Katzenstein D. Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers. <i>J Infect Dis.</i> 1999; 180(5): 1459-65.	1993-1997		
Zimbabwe	Acuda SW, Eide AH. Epidemiological study of drug use in urban and rural secondary schools in Zimbabwe. <i>Cent Afr J Med.</i> 1994; 40(8): 207-12.	1990		
Zimbabwe	Frencken JE, Sithole WD, Mwaenga R, Htoon HM, Simon E. National oral health survey Zimbabwe 1995: periodontal conditions. <i>Int Dent J.</i> 1999; 49(1): 10-4.	1995	*	
Zimbabwe	Acuda SW. Alcohol and health: a perspective from Africa. 1995. Located at: Department of Psychiatry, University of Zimbabwe, Harare, Zimbabwe.	1993		
Zimbabwe	Kundodyiya TW, Majoko F, Rusakaniko S. Misoprostol versus oxytocin in the third stage of labor. <i>Int J Gynaecol Obstet.</i> 2001; 75(3): 235-41.	1999-2000		
Zimbabwe	Zimbabwe National Micronutrient Survey 1999 as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1999	*	
Zimbabwe	Simarro PP, Cecchi G, Paoe M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. <i>Int J Health Geogr.</i> 2010; 9: 57.	1980-2010	*	
Zimbabwe	World Health Organization (WHO). Global leprosy situation, 2007 (additional information). <i>Wkly Epidemiol Rec.</i> 2007; 82(44): 388.	2006	*	
Zimbabwe	World Health Organization (WHO). Progress towards leprosy elimination. <i>Wkly Epidemiol Rec.</i> 1997; 72(23): 165-72.	1996	*	
Zimbabwe	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. <i>Wkly Epidemiol Rec.</i> 1996; 71(20): 149-56.	1995		
Zimbabwe	World Health Organization (WHO). Progress towards the elimination of leprosy as a public health problem. Part I. <i>Wkly Epidemiol Rec.</i> 1995; 70(25): 177-82.	1994	*	
Zimbabwe	Report of the National Intersectoral Consultative Meeting for the Control of Iodine Deficiency Disorders in Zimbabwe as it appears in World Health Organization (WHO). WHO Global Database on Iodine Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1989	*	
Zimbabwe	Mbizvo EM, Msuya SE, Stray-Pedersen B, Sundby J, Chirenje MZ, Hussain A. Determinants of reproductive tract infections among asymptomatic women in Harare, Zimbabwe. <i>Cent Afr J Med.</i> 2001; 47(3): 57-64.	2000	*	
Zimbabwe	Cowan FM, Langhaug LF, Mashungu GP, Nyamurera T, Hargrove J, Jaffar S, Peeling RW, Brown DWG, Power R, Johnson AM, Stephenson JM, Bassett MT, Hayes RJ, Regai Dzive Shiri Project. School based HIV prevention in Zimbabwe: feasibility and acceptability of evaluation trials using biological outcomes. <i>AIDS.</i> 2002; 16(12): 1673-8.	1999-2001	*	
Zimbabwe	Mbizvo EM, Msuya SE, Hussain A, Chirenje MZ, Stray-Pedersen B. HIV prevalence in Zimbabwean women: 54-67% knowledge and perceived risk. <i>Int J STD AIDS.</i> 2003; 14(3): 202-7.	2003	*	†
Zimbabwe	Gregson S, Mason PR, Garnett GP, Zhuwau T, Nyamukapa CA, Anderson RM, Chandiwana SK. A rural HIV epidemic in Zimbabwe? Findings from a population-based survey. <i>Int J STD AIDS.</i> 2001; 12(3): 189-96.	1998	*	†

Appendix Table A.3a - Citations for Dismod model input data by country

Country	Citation	Year*	New for GBD 2013 (*)	Input for dismod and non-dismod models (†)
Zimbabwe	Cakana AZ, Ngenya L. Is antenatal antibody screening worthwhile in the Zimbabwean population? Cent Afr J Med. 2000; 46(2): 38-41.	1996		
Zimbabwe	Wolf MJ, Beunen G, Casar P, Wolf B. Neurological status in severely jaundiced Zimbabwean neonates. J Trop Pediatr. 1998; 44(3): 161-4.	1991-1992		
Zimbabwe	Zimbabwe Sexually Transmitted Disease Data 2003 from the WHO Database on STDs, as provided by the Global Burden of Disease 2010 Sexually Transmitted Disease Expert Group. [Unpublished].	2003		
Zimbabwe	Gangaidzo IT, Moyo VM, Khumalo H, Saungweme T, Gomo Z, Rouault T, Gordeuk VR. Hepatitis C virus in Zimbabwe. Cent Afr J Med. 1997; 43(5): 122-5.	1994		
Zimbabwe	Madzime S, Adem M, Mahomed K, Woelk GB, Mudzamiri S, Williams MA. Hepatitis B virus infection among pregnant women delivering at Harare Maternity Hospital, Harare Zimbabwe, 1996 to 1997. Cent Afr J Med. 1999; 45(8).	1996-1997	*	†
Zimbabwe	Madzime S, William MA, Mohamed K, October T, Adem M, Mudzamiri S, Woelk GB. Seroprevalence of hepatitis C virus infection among indigent urban pregnant women in Zimbabwe. Cent Afr J Med. 2000; 46(1): 1-4.	1996-1997	*	†
Zimbabwe	Freeman TW, Chandiwana SK. A retrospective analysis of data from the 1991 national malaria prevalence survey in Zimbabwe. Malar Infect Dis Afr. 1996; 4: 19-24 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1991	*	†
Zimbabwe	Makanda CD. Chloroquine-resistant Plasmodium falciparum at two farms near Mhangura. Cent Afr J Med. 1987; 33(3): 66-70 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1985	*	†
Zimbabwe	Midzi N, Mtapuri-Zinyowera S, Mapingure MP, Paul NH, Sangweme D, Hlerema G, Mutsaka MJ, Tongogara F, Makware G, Chadukura V, Brouwer KC, Mutapi F, Kumar N, Mduluzi T. Knowledge attitudes and practices of grade three primary schoolchildren in relation to schistosomiasis, soil transmitted helminthiasis and malaria in Zimbabwe. BMC Infect Dis. 2011; 11: 169 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Zimbabwe	Midzi N, Mtapuri-Zinyowera S, Sangweme D, Paul NH, Makware G, Mapingure MP, Brouwer KC, Mudzori J, Hlerema G, Chadukura V, Mutapi F, Kumar N, Mduluzi T. Efficacy of integrated school based de-worming and prompt malaria treatment on helminths -Plasmodium falciparum co-infections: A 33 months follow up study. BMC Int Health Hum Rights. 2011; 11: 9 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004	*	†
Zimbabwe	Reilly L, Magkrioti C, Mduluzi T, Cavanagh DR, Mutapi F. Effect of treating Schistosoma haematobium infection on Plasmodium falciparum-specific antibody responses. BMC Infect Dis. 2008; 8: 158 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2002	*	†
Zimbabwe	Sangweme DT, Midzi N, Zinyowera-Mutapuri S, Mduluzi T, Diener-West M, Kumar N. Impact of schistosome infection on Plasmodium falciparum Malariometric indices and immune correlates in school age children in Burma Valley, Zimbabwe. PLoS Negl Trop Dis. 2010; 4(11): 882 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	2004-2005		
Zimbabwe	Siziya S, Watts TE, Mason PR. Malaria in Zimbabwe: comparisons of IFAT levels, parasite and spleen rates among high, medium and lower altitude areas and between dry and rainy seasons. Cent Afr J Med. 1997; 43(9): 251-4 as it appears in Malaria Atlas Project. Malaria Atlas Project Plasmodium Falciparum Parasite Rate Database. Oxford, United Kingdom: Malaria Atlas Project.	1992-1993		
Zimbabwe	Neube TN, Vos ET, Madonko SM, Moyo I. The prevalence of vitamin A deficiency; Matabeleland north province Zimbabwe (draft). Bulawayo, Provincial Medical Director Matabeleland. 1992. as it appears in World Health Organization (WHO). WHO Global Database on Vitamin A Deficiency. Geneva, Switzerland: World Health Organization (WHO).	1985		
Zimbabwe	collection.			

Appendix Table A.3b - Citations for non-dismod model input data

National Institute of Statistics (Albania), United Nations Children's Fund (UNICEF). Albania Multiple Indicator Cluster Survey 2005. New York, United States: United Nations Children's Fund (UNICEF).

Joint United Nations Program on HIV/AIDS (UNAIDS), Ministry of Health, Population and Hospital Reform (Algeria), National Office of Statistics (Algeria), United Nations Children's Fund (UNICEF), United Nations Population Fund (UNFPA). Algeria Multiple Indicator Cluster Survey 2006.

Central Statistics Organization (Bahrain), Ministry of Health (Bahrain). Bahrain Child Health Survey 1989.

Ministry of Health (Bahrain), Council of Health Ministers of GCC States. Bahrain Family Health Survey 1995. Manama, Bahrain: Ministry of Health (Bahrain).

Bangladesh Bureau of Statistics, Government of Bangladesh. Bangladesh Household Expenditure Survey 1985.

Centers for Disease Control and Prevention (CDC), INDEPTH, International Vaccine Institute. Bangladesh - Abhoynagar, Mirsarai, and Kamalapur Health and Demographic Surveillance System.

INDEPTH, International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B). Bangladesh - Matlab Health and Demographic Surveillance System. Dhaka, Bangladesh: International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B).

Central Statistics Office (Botswana). Botswana Family Health Survey 1996. Gaborone, Botswana: Central Statistics Office (Botswana).

Central Statistics Office (Botswana), United Nations Children's Fund (UNICEF). Botswana Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).

Brazilian Institute of Geography and Statistics (IBGE), World Bank (WB). Brazil Living Standards Measurement Survey 1996-1997. Washington DC, United States: World Bank (WB).

INDEPTH, Nouna Health Research Center (Burkina Faso). Burkina Faso - Nouna Health and Demographic Surveillance System.

Carolina Population Center, University of North Carolina at Chapel Hill, Chinese Center for Disease Control and Prevention (CCDC). China Health and Nutrition Survey 2004.

World Bank (WB). China Health and Nutrition Survey 1991.

World Bank (WB). China Health and Nutrition Survey 1993.

World Bank (WB). China Health and Nutrition Survey 1997.

World Bank (WB). China Health and Nutrition Survey 2000.

Carolina Population Center, University of North Carolina at Chapel Hill, Chinese Center for Disease Control and Prevention (CCDC). China Health and Nutrition Survey 2006.

Carolina Population Center, University of North Carolina at Chapel Hill, Chinese Center for Disease Control and Prevention (CCDC). China Health and Nutrition Survey 1989. Chapel Hill, United States: Carolina Population Center, University of North Carolina at Chapel Hill.

United Nations Development Programme (UNDP). Comoros Household Survey 2004.

United Nations Children's Fund (UNICEF). Zaire Multiple Indicator Cluster Survey 1995. New York, United States: United Nations Children's Fund (UNICEF).

Ministry of Public Health (Cuba), United Nations Children's Fund (UNICEF). Cuba Multiple Indicator Cluster Survey 2000.

National Directorate of Statistics, Ministry of Commerce and Tourism, World Bank (WB). Djibouti Household Survey - Social Indicators 1996. Djibouti, Djibouti: National Directorate of Statistics, Ministry of Commerce and Tourism.

National Statistics Office (Dominican Republic), United Nations Children's Fund (UNICEF). Dominican Republic National Multipurpose Household Survey 2006. Santo Domingo, Dominican Republic: National Statistics Office (Dominican Republic).

Social Research Centre, American University in Cairo and United Nations Children's Fund (UNICEF). Egypt Multiple Indicator Cluster Survey 1996. New York, United States: United Nations Children's Fund (UNICEF).

INDEPTH. Ethiopia - Butajira Health and Demographic Surveillance System.

National Center for Disease Control (Georgia), State Department of Statistics of Georgia, United Nations Children's Fund (UNICEF). Georgia Multiple Indicator Cluster Survey 1999.

Navrongo Health Research Centre. Ghana - Navrongo Health and Demographic Surveillance System.

Guatemala Ministry of Health and Social Assistance, University of Valle and Division of Reproductive Health-Centers for Disease Control and Prevention (CDC). Guatemala Reproductive Health Survey 2008-2009. Atlanta, United States: Centers for Disease Control and Prevention (CDC).

National Institute of Statistics (Guinea). Guinea Household Living Conditions Survey 1994-1995.

Honduras Family Planning Association (ASHONPLAFA), Ministry of Health (Honduras), Family Health International (FHI). (1992): Honduras Family Planning/Maternal and Child Survey 1991-1992. Tegucigalpa, Honduras: ASHONPLAFA.

Office of the Registrar General and Census Commissioner (India). India Vital Statistics 1980. New Delhi, India: Office of the Registrar General and Census Commissioner (India).

Office of the Registrar General and Census Commissioner (India). India Vital Statistics 1988. New Delhi, India: Office of the Registrar General and Census Commissioner (India).

RAND Corporation, University of Indonesia. Indonesia Family Life Survey 1993-1994. Santa Monica, United States: RAND Corporation.

Appendix Table A.3b - Citations for non-dismod model input data

Macro International, Inc, RAND Corporation, University of California, Los Angeles (UCLA), University of Indonesia. Indonesia Family Life Survey 1997.
Center for Population and Policy Studies, Gadjah Mada University (Indonesia), RAND Corporation. Indonesia Family Life Survey 2000. Santa Monica, United States: RAND Corporation.
Center for Population and Policy Studies, Gadjah Mada University (Indonesia), RAND Corporation, SurveyMETER. Indonesia Family Life Survey 2007-2008. Santa Monica, United States: RAND Corporation.
National Institute of Health Research and Development (NIHRD), Ministry of Health (Indonesia). Indonesia National Health Survey - Round 2 2004.
Planning Institute of Jamaica, Statistical Institute of Jamaica. Jamaica Survey of Living Conditions 2001.
Planning Institute of Jamaica, Statistical Institute of Jamaica. Jamaica Survey of Living Conditions 1989.
Planning Institute of Jamaica, Statistical Institute of Jamaica. Jamaica Survey of Living Conditions 1992.
Planning Institute of Jamaica, Statistical Institute of Jamaica. Jamaica Survey of Living Conditions 1991.
African Population and Health Research Center, INDEPTH. Kenya - Nairobi Urban Health and Demographic Surveillance System.
Centers for Disease Control and Prevention (CDC), Kenya Medical Research Institute (KEMRI). Kenya KEMRI/CDC Health and Demographic Surveillance System.
Council of Health Ministers of GCC States, Ministry of Health (Kuwait), United Nations Statistics Division (UNSD). Kuwait Family Health Survey 1996.
Ministry of Health (Laos), National Statistical Center (Laos). Laos Social Indicator Survey 1993.
Palestinian Central Bureau of Statistics, Pan Arab Project for Family Health (PAPFAM), United Nations Children's Fund (UNICEF). Palestinians in Lebanon Multiple Indicator Cluster Survey 2005-2006. New York, United States: United Nations Children's Fund (UNICEF).
Bureau of Statistics (Liberia), United Nations Children's Fund (UNICEF). Liberia Multiple Indicator Cluster Survey 1995.
National Institute of Statistics (Madagascar). Madagascar Multiple Indicator Cluster Survey 1995.
National Institute of Statistics (Madagascar). Madagascar Permanent Household Survey 1993-1994.
National Statistical Office of Malawi, United Nations Children's Fund (UNICEF). Malawi Multiple Indicator Cluster Survey 1995.
National Directorate of Statistics and Informatics (DNSI) (Mali), United Nations Children's Fund (UNICEF). Mali Multiple Indicator Cluster Survey 1996.
United Nations Children's Fund (UNICEF). Mauritania Multiple Indicator Cluster Survey 1996.
Center for Research and Teaching in Economics (CIDE) (Mexico), National Institute of Perinatology (Mexico), National Institute of Statistics and Geography (Mexico), Universidad Iberoamericana. Mexico Family Life Survey 2002.
INDEPTH, Manhica Health Research Center (CISM). Mozambique - Manhica Health and Demographic Surveillance System.
Ministry of Health (Mozambique), National Department of Statistics (Mozambique), United Nations Children's Fund (UNICEF). Mozambique Multiple Indicator Cluster Survey 1995.
National Statistics Institute (Mozambique). Mozambique Core Welfare Indicators Questionnaire Survey 2000-2001.
Division of Reproductive Health-Centers for Disease Control and Prevention (CDC), National Institute for Development Information (Nicaragua). Nicaragua Reproductive Health Survey 2006-2007. Managua, Nicaragua: National Institute for Development Information (Nicaragua).
National Institute of Statistics and Censuses (Nicaragua), World Bank. Nicaragua Living Standards Measurement Survey 1993.
National Institute of Statistics and Censuses (Nicaragua), World Bank. Nicaragua Living Standards Measurement Survey 1998-1999.
Government of Niger, Macro International, Inc, United Nations Children's Fund (UNICEF). Niger Multiple Indicator Cluster Survey 2000. New York, United States: United Nations Children's Fund (UNICEF).
Council of Health Ministers of GCC States, Ministry of Health (Oman). Oman Family Health Survey 1995.
Federal Bureau of Statistics (Pakistan) and World Bank. Pakistan Living Standards Measurement Survey 1991. Islamabad, Pakistan: Federal Bureau of Statistics (Pakistan).
League of Arab States, Palestinian Central Bureau of Statistics, United Nations Children's Fund (UNICEF). Palestine Family Health Survey 2006-2007.
Directorate of Statistics and Census (Panama), Ministry of Economy and Finance (Panama), World Bank. Panama Living Standard Measurement Survey 2003. Washington DC, United States: World Bank.
Ministry of Planning and Economic Policy (Panama), World Bank. Panama Living Standards Measurement Survey 1997. Washington DC, United States: World Bank.
Food and Nutrition Research Institute, Department of Science and Technology (Philippines). Philippines National Nutrition Survey 1998.
Food and Nutrition Research Institute, Department of Science and Technology (Philippines). Philippines Third National Nutrition Survey 1987.
Philippines Third National Nutrition Survey 1987 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

Philippines National Nutrition Survey 1993 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Carolina Population Center, University of North Carolina at Chapel Hill, Institute of Sociology, Russian Academy of Sciences, National Research University Higher School of Economics (Russia), ZAO Demoscope. Russia Longitudinal Monitoring Survey of HSE, Round III 1993.

National Institute of Statistics (São Tomé and Príncipe), United Nations Children's Fund (UNICEF). Sao Tome and Principe Multiple Indicator Cluster Survey 2006. New York, United States: United Nations Children's Fund (UNICEF).

Arab Fund for Economic and Social Development (AFESD), Arab Gulf Program for Development (AGFUND), Gulf-Co-operation Council (GCC), Ministry of Health (Saudi Arabia), United Nations Children's Fund (UNICEF), United Nations Population Fund (UNFPA), United Nations Statistics Division (UNSD), World Health Organization (WHO). Saudi Arabia Family Health Survey 1996-1997.

United Nations Children's Fund (UNICEF). Somalia Multiple Indicator Cluster Survey 1999.

MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), INDEPTH. South Africa - Agincourt Health and Socio-Demographic Surveillance System.

International Food Policy Research Institute (IFPRI), University of Natal, University of Wisconsin, Data Research Africa (DRA), Policy and Praxis, Southern Africa Labour Development Research Unit (SALDRU), School of Economics, University of Cape Town. South Africa KwaZulu-Natal Income Dynamics Study 1998. Durban, South Africa: University of Natal.

Federal Ministry of Health (Sudan), Central Bureau of Statistics (Sudan), United Nations Children's Fund (UNICEF). Sudan Multiple Indicator Cluster Survey, North Sudan 2000. New York, United States: United Nations Children's Fund (UNICEF).

United Nations Children's Fund (UNICEF). Syria Multiple Indicator Cluster Survey 1996.

National State Statistical Agency (Tajikistan), World Bank. Tajikistan Living Standards Measurement Survey 2007.

INDEPTH. Tanzania - Ifakara Health and Demographic Surveillance System.

INDEPTH, Ministry of Health and Social Welfare (Tanzania), School of Public Health, Columbia University. Tanzania - Rufiji Health and Demographic Surveillance System.

Insan Hitawasana Sejahtera, National Statistics Directorate (Timor-Leste), United Nations Children's Fund (UNICEF). Timor-Leste Multiple Indicator Cluster Survey 2002.

Ministry of Public Health (Tunisia), United Nations Children's Fund (UNICEF). Tunisia Multiple Indicator Cluster Survey 2000.

Ministry of Public Health (Tunisia), National Office for Family and Population, Ministry of Public Health (Tunisia), United Nations Children's Fund (UNICEF). Tunisia Multiple Indicator Cluster Survey 2006.

Baskent University, Ministry of Health (Turkey), State Institute of Statistics (Turkey). Turkey Verbal Autopsy Survey 2003.

United Nations Children's Fund (UNICEF). Turkmenistan Multiple Indicator Cluster Survey 2006.

State Statistical Committee (Ukraine), United Nations Children's Fund (UNICEF). Ukraine Multiple Indicator Cluster Survey 2000.

Council of Health Ministers of GCC States, Ministry of Health (United Arab Emirates). United Arab Emirates Family Health Survey 1995.

World Bank (WB), General Statistics Office (Viet Nam). Viet Nam Living Standards Measurement Survey 1992-1993. Washington D.C., United States: World Bank (WB)

Central Statistical Office (Zambia). Zambia Living Conditions Monitoring Survey 1996. Lusaka, Zambia: Central Statistical Office (Zambia).

Central Statistical Office (Zambia), London School of Hygiene and Tropical Medicine. Zambia Living Conditions Monitoring Survey 1998. Lusaka, Zambia: Central Statistical Office (Zambia).

Central Statistical Office (Zambia). Zambia Living Conditions Monitoring Survey 2002-2003. Lusaka, Zambia: Central Statistical Office (Zambia).

Central Statistical Office (Zambia). Zambia Living Conditions Monitoring Survey 2004-2005. Lusaka, Zambia: Central Statistical Office (Zambia).

National Institute of Statistics and Demography (INSD). Burkina Faso Core Welfare Indicators Questionnaire Survey 2007. Ouagadougou, Burkina Faso: National Institute of Statistics and Demography (INSD), 2008.

Department of Census and Statistics (Sri Lanka). Sri Lanka Demographic and Health Survey 2006-2007.

Macro International, Inc, Secretariat of the Pacific Community (SPC), Tuvalu Central Statistics Division. Tuvalu Demographic and Health Survey 2007.

Armenia Demographic and Health Survey 2000 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Armenia Demographic and Health Survey 2005 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Benin Demographic and Health Survey 2001 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Benin Demographic and Health Survey 2006 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Bolivia Demographic and Health Survey 1998 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

Bolivia Demographic and Health Survey 2003-2004 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Burkina Faso Demographic and Health Survey 2003 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Cambodia Demographic and Health Survey 2000 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Cambodia Demographic and Health Survey 2005-2006 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Cameroon Demographic and Health Survey 2004 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
El-Zanaty and Associates, Macro International, Inc. Egypt Interim Demographic and Health Survey 1997-1998.
Egypt Demographic and Health Survey 2000 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Egypt Demographic and Health Survey 2005 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Ethiopia Demographic and Health Survey 2005 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Ghana Demographic and Health Survey 2003 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Guinea Demographic and Health Survey 2005 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Haiti Demographic and Health Survey 2000 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Haiti Demographic and Health Survey 2005-2006 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Honduras Demographic and Health Survey 2005-2006 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
India Demographic and Health Survey 1998-1999 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Palestinian Central Bureau of Statistics. Palestine Demographic and Health Survey 2004.
Rwanda Demographic and Health Survey 2005 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Department of Health (South Africa), Macro International, Inc, South African Medical Research Council. South Africa Demographic and Health Survey 2003-2004.
Timor-Leste Demographic and Health Survey 2003 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Turkmenistan Demographic and Health Survey 2000 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Uzbekistan Demographic and Health Survey 1996 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Analytical and Information Center of the Ministry of Health of Uzbekistan, Macro International, Inc, Ministry of Macroeconomics and Statistics (Uzbekistan). Uzbekistan Special Demographic and Health Survey 2002. Calverton, United States: Macro International, Inc.
Uzbekistan Special Demographic and Health Survey 2002 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Central Statistical Organization (Yemen), Macro International, Inc. Yemen Demographic and Health Survey 1997. Calverton, United States: Macro International, Inc.
Zimbabwe Demographic and Health Survey 2005-2006 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Ghana Health Service, Ghana Statistical Service, Macro International, Inc. Ghana Special Demographic and Health Survey 2007-2008. Calverton, United States: Macro International, Inc, 2010.
Nauru Bureau of Statistics, Secretariat of the Pacific Community (SPC), Macro International, Inc., Nauru Demographic and Health Survey 2007. Noumea, New Caledonia, France: Secretariat of the Pacific Community (SPC).
Macro International, Inc, Ministry of Health (Solomon Islands), Secretariat of the Pacific Community (SPC), Solomon Islands National Statistics Office (SINSO). Solomon Islands Demographic and Health Survey 2006-2007.
Central Statistics Office (Botswana). Botswana Family Health Survey 2007-2008. Gaborone, Botswana: Central Statistics Office (Botswana), 2009.
National Institute of Health Research and Development (NIHRD), Ministry of Health (Indonesia). Indonesia Basic Health Research 2007-2008.
Central Statistical Organization (Yemen). Yemen Household Budget Survey 2005-2006. Sana'a, Yemen: Central Statistical Organization (Yemen).

Appendix Table A.3b - Citations for non-dismod model input data

MEASURE Evaluation Project, Carolina Population Center, University of North Carolina, Macro International, Inc, Ministry of Health (Uganda), Uganda Bureau of Statistics. Uganda Child Verbal Autopsy Study 2007. Calverton, United States: Macro International, Inc.

Ministry of Health (Southern Sudan), Federal Ministry of Health (Sudan), Southern Sudan Centre for Census, Statistics and Evaluation (SSCCSE), Central Bureau of Statistics (Sudan). Sudan Family Health Survey 2006.

Centers for Disease Control and Prevention (CDC), MEASURE Evaluation Project, Carolina Population Center, University of North Carolina, Ministry of Health (Mozambique), National Statistics Institute (Mozambique), US Census Bureau. Mozambique National Survey on the Causes of Death 2007-2008.

Ministry of Health and Population (Algeria), United Nations Children's Fund (UNICEF). Algeria Multiple Indicator Cluster Survey 1995.

Ministry of Health and Population (Algeria), National Institute of Public Health (Algeria), National Office of Statistics (Algeria), United Nations Children's Fund (UNICEF). Algeria Multiple Indicator Cluster Survey 2000.

Senegal Demographic and Health Survey 2005 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

National Statistical Institute (Congo, DR), Ministry of Planning (Congo, DR), United Nations Children's Fund (UNICEF). Congo, DR Multiple Indicator Cluster Survey 2010. New York, United States: United Nations Children's Fund (UNICEF).

Government of Senegal, United Nations Children's Fund (UNICEF). Senegal Multiple Indicator Cluster Survey 1996.

Central Bureau of Statistics (Syria), United Nations Children's Fund (UNICEF). Syria Multiple Indicator Cluster Survey 2000.

Centers for Disease Control and Prevention (CDC), National Statistics Institute (Guinea-Bissau), United Nations Children's Fund (UNICEF). Guinea-Bissau Multiple Indicator Cluster Survey 2010.

Adventist Development and Relief Agency (ADRA), Azerbaijan Ministry of Health, State Statistical Committee of Azerbaijan, and Centers for Disease Control and Prevention (CDC). (2003) Azerbaijan Reproductive Health Survey 2001. Atlanta, United States: Centers for Disease Control and Prevention (CDC).

Guatemala Ministry of Health and Social Assistance, University of Valle, Division of Reproductive Health-Centers for Disease Control and Prevention (CDC). (2003) Guatemala Reproductive Health Survey 2002. Atlanta, United States: Centers for Disease Control and Prevention (CDC).

El Salvador Demographic Association (ADS), Division of Reproductive Health-Centers for Disease Control and Prevention (CDC). El Salvador Family Planning/Maternal and Child Survey 1993. Atlanta, United States: Centers for Disease Control and Prevention (CDC).

Asociación Demográfica Salvadoreña (ADS), Division of Reproductive Health-Centers for Disease Control and Prevention (CDC). (2004) El Salvador Reproductive Health Survey 2002-2003. San Salvador, El Salvador: ADS.

National Epidemiology Center, Department of Health (Philippines). Philippines Field Health Service Information System (FHSIS) Annual Report 2007. Manila, Philippines: National Epidemiology Center, Department of Health (Philippines), .

National Epidemiology Center, Department of Health (Philippines). Philippines Field Health Service Information System (FHSIS) Annual Report 2006. Manila, Philippines: National Epidemiology Center, Department of Health (Philippines), .

University of Cape Town, Southern Africa Labour and Development Research Unit. National Income Dynamics Study (NIDS) Wave 1 [computer files]. Cape Town: Southern Africa Labour and Development Research Unit [producer], 2009. Cape Town: DataFirst [distributor], 2009

National Epidemiology Center, Department of Health (Philippines). Philippines Field Health Service Information System Annual Report 2003. Manila, Philippines: National Epidemiology Center, Department of Health (Philippines).

National Epidemiology Center, Department of Health (Philippines). Philippines Field Health Service Information System Annual Report 2002. Manila, Philippines: National Epidemiology Center, Department of Health (Philippines).

National Epidemiology Center, Department of Health (Philippines). Philippines Field Health Service Information System Annual Report 2001. Manila, Philippines: National Epidemiology Center, Department of Health (Philippines).

National Epidemiology Center, Department of Health (Philippines). Philippines Field Health Service Information System Annual Report 2000. Manila, Philippines: National Epidemiology Center, Department of Health (Philippines).

National Epidemiology Center, Department of Health (Philippines). Philippines Field Health Service Information System Annual Report 1998. Manila, Philippines: National Epidemiology Center, Department of Health (Philippines).

National Epidemiology Center, Department of Health (Philippines). Philippines Field Health Service Information System Annual Report 1997. Manila, Philippines: National Epidemiology Center, Department of Health (Philippines).

National Epidemiology Center, Department of Health (Philippines). Philippines Field Health Service Information System Annual Report 1993. Manila, Philippines: National Epidemiology Center, Department of Health (Philippines).

National Institute of Statistics (Cambodia). Cambodia Socioeconomic Survey 1996. Phnom Penh, Cambodia: National Institute of Statistics (Cambodia).

University of Kwazulu-Natal, University of Wisconsin, London School of Hygiene and Tropical Medicine, International Food Policy Research Institute (IFPRI), Department of Social Development (South Africa), Norwegian Institute for Urban and Regional Research (NIBR). South Africa KwaZulu-Natal Income Dynamics Study 2004. Durban, South Africa: University of Kwazulu-Natal.

Institute of Population Studies, Hacettepe University, Ministry of Health (Turkey), State Planning Organization (Turkey), Turkish Statistical Institute. Turkey Demographic and Health Survey 2008. Ankara, Turkey: Institute of Population Studies, Hacettepe University.

Department of Statistics (Malaysia). Malaysia - Peninsular Vital Statistics 1969. Putrajaya, Malaysia: Department of Statistics (Malaysia), 1971.

Appendix Table A.3b - Citations for non-dismod model input data

Office of the Registrar General and Census Commissioner (India). India Vital Statistics 1989. New Delhi, India: Office of the Registrar General and Census Commissioner (India).
National Institute of Food and Nutrition (INAN) (Brazil), Institute of Applied Economic Research (IPEA) (Brazil), Inter-University Consortium for Political and Social Research (ICPSR). Brazil National Survey on Health and Nutrition 1989. Ann Arbor, United States: Inter-University Consortium for Political and Social Research (ICPSR).
Office of the Registrar General and Census Commissioner (India). India Vital Statistics 1987. New Delhi, India: Office of the Registrar General and Census Commissioner (India).
Office of the Registrar General and Census Commissioner (India). India Vital Statistics 1986. New Delhi, India: Office of the Registrar General and Census Commissioner (India).
Office of the Registrar General and Census Commissioner (India). India Vital Statistics 1983. New Delhi, India: Office of the Registrar General and Census Commissioner (India).
Office of the Registrar General and Census Commissioner (India). India Vital Statistics 1982. New Delhi, India: Office of the Registrar General and Census Commissioner (India).
Office of the Registrar General and Census Commissioner (India). India Vital Statistics 1981. New Delhi, India: Office of the Registrar General and Census Commissioner (India).
Central Organization for Statistics and Information Technology (Iraq). Iraq Living Conditions Survey 2004.
National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC). United States NVSS Mortality Data 2008. Atlanta, United States: Centers for Disease Control and Prevention (CDC).
National Institute of Statistics (INE) (Cape Verde) and World Bank (WB), Cape Verde Core Welfare Indicator Questionnaire Survey 2006. Praia, Cape Verde: National Institute of Statistics (INE) (Cape Verde).
National Statistics Bureau (Bhutan), United Nations Children's Fund (UNICEF), United Nations Population Fund (UNFPA). Bhutan Multiple Indicator Cluster Survey 2010. New York, United States: United Nations Children's Fund (UNICEF).
National Institute of Statistics (Albania), World Bank (WB). Albania Living Standards Measurement Survey 2002. Washington DC, United States: World Bank (WB).
National Institute of Statistics and Censuses (Nicaragua), World Bank. Nicaragua Living Standards Measurement Survey 2005.
Planning Institute of Jamaica, Statistical Institute of Jamaica. Jamaica Survey of Living Conditions 1993.
Planning Institute of Jamaica, Statistical Institute of Jamaica. Jamaica Survey of Living Conditions 1994.
Planning Institute of Jamaica, Statistical Institute of Jamaica. Jamaica Survey of Living Conditions 1995.
Planning Institute of Jamaica, Statistical Institute of Jamaica. Jamaica Survey of Living Conditions 1996.
Planning Institute of Jamaica, Statistical Institute of Jamaica. Jamaica Survey of Living Conditions 1997.
Planning Institute of Jamaica, Statistical Institute of Jamaica. Jamaica Survey of Living Conditions 1998.
Planning Institute of Jamaica, Statistical Institute of Jamaica. Jamaica Survey of Living Conditions 1999.
Planning Institute of Jamaica, Statistical Institute of Jamaica. Jamaica Survey of Living Conditions 2000.
National Statistics Directorate (Timor-Leste), World Bank. Timor-Leste Living Standards and Measurement Survey 2007-2008. Washington DC, United States: World Bank.
National Institute of Statistics and Censuses (Ecuador), World Bank. Ecuador Living Standards Measurement Survey 1998. Washington DC, United States: World Bank.
Central Statistics Organization (Afghanistan), ICF Macro, Indian Institute of Health Management Research (IIHMR), Ministry of Public Health (Afghanistan), World Health Organization Regional Office for the Eastern Mediterranean (EMRO-WHO). Afghanistan Special Demographic and Health Survey 2010. Calverton, United States: ICF Macro.
National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC). United States NVSS Mortality Data 2009. Atlanta, United States: Centers for Disease Control and Prevention (CDC).
Ministry of Health (Burkina Faso). Burkina Faso National Nutrition Survey 2009.
Ministry of Social Protection (Colombia), National Administrative Department of Statistics (Colombia). Colombia Vital Registration 1980-2005.
Central Bureau of Statistics (North Korea), United Nations Children's Fund (UNICEF), World Food Programme (WFP). Korea, North Nutrition Assessment 2002.
Central Bureau of Statistics (North Korea), United Nations Children's Fund (UNICEF), World Food Programme (WFP). Korea, North Nutrition Assessment 2004.
Indian Council of Medical Research (ICMR). India Study on Causes of Death by Verbal Autopsy 2003.
General Directorate of Statistics and Forecasting (Comoros), ICF International. Comoros Demographic and Health Survey 2012-2013. Fairfax, United States: ICF International, 2014.
ICF International, Ministry of Health and Social Welfare (Equatorial Guinea), Ministry of Planning, Economic Development and Public Investment (Equatorial Guinea). Equatorial Guinea Demographic and Health Survey 2011.
Gambia Bureau of Statistics (GBOS), ICF International, Ministry of Health and Social Welfare (Gambia). Gambia Demographic and Health Survey 2013.

Appendix Table A.3b - Citations for non-dismod model input data

- ICF International, Liberia Institute for Statistics and Geo-information Services (LISGIS), National AIDS and STI Control Program (NACP), Ministry of Health and Social Welfare (Liberia). Liberia Demographic and Health Survey 2013.
- ICF International, INFO-STAT (Mali), Ministry of Health (Mali), National Institute of Statistics (INSTAT) (Mali), Planning and Statistics Unit, Ministry of Health (Mali). Mali Demographic and Health Survey 2012-2013. Fairfax, United States: ICF International, 2014.
- ICF International, National Population Commission of Nigeria. Nigeria Demographic and Health Survey 2013. Fairfax, United States: ICF International, 2014.
- Planning Institute of Jamaica, Statistical Institute of Jamaica. Jamaica Survey of Living Conditions 2002.
- Uganda Bureau of Statistics. Uganda Living Standards Measurement Survey - Integrated Survey on Agriculture 2009-2010. Washington DC, United States: World Bank.
- United Nations Children's Fund (UNICEF), World Health Organization (WHO). WHO and UNICEF Reported Disease Incidence Time Series. Geneva, Switzerland: World Health Organization (WHO).
- Department of Census and Statistics (Sri Lanka). Sri Lanka Demographic and Health Survey 1993.
- Department of Census and Statistics (Sri Lanka), Ministry of Health, Nutrition and Welfare (Sri Lanka). Sri Lanka Demographic and Health Survey 2000. Colombo, Sri Lanka: Department of Census and Statistics (Sri Lanka), 2008.
- United Nations Children's Fund (UNICEF). Maldives Multiple Indicator Cluster Survey 1995.
- Centers for Disease Control and Prevention (CDC), Ministry of Health (Kuwait), WHO Regional Office for the Eastern Mediterranean. Kuwait Nutrition Surveillance System.
- Ministry of Health (Jordan). Jordan Vital Registration - Deaths 2004-2006.
- Ministry of Health (Syria). Syria Vital Statistics - Deaths 2005-2007.
- Registrar General's Department (Sri Lanka). Sri Lanka Vital Statistics - Deaths 2004-2005.
- Registrar General's Department (Sri Lanka). Sri Lanka Vital Statistics - Deaths 1993-1996.
- Abu-Rashid N, Al-Jirf S, Bashour H. Causes of death among Syrian children using verbal autopsy. *East Mediterr Health J.* 1996; 2(3): 440-8.
- Centers for Disease Control and Prevention (CDC), Ministry of Public Health (Afghanistan). Afghanistan Centers for Disease Control and Prevention Country Report 2003.
- Anand K, Patro BK, Paul E, Kapoor SK. Management of Sick Children by Health Workers in Ballabgarh: Lessons for Implementation of IMCI in India. *J Trop Pediatr.* 2004; 50(1): 41-7.
- Arifeen S, Black RE, Antelman G, Baqui A, Caulfield L, Becker S. Exclusive breastfeeding reduces acute respiratory infection and diarrhea deaths among infants in Dhaka slums. *Pediatrics.* 2001; 108(4): E67.
- Awasthi S, Pande VK. Cause-specific mortality in under fives in the urban slums of Lucknow, north India. *J Trop Pediatr.* 1998; 44(6): 358-61.
- Baqui AH, Sabir AA, Begum N, Arifeen SE, Mitra SN, Black RE. Causes of childhood deaths in Bangladesh: an update. *Acta Paediatr.* 2001; 90(6): 682-90.
- Barnish G, Maude GH, Bockarie MJ, Eggelte TA, Greenwood BM, Ceesay S. Malaria in a rural area of Sierra Leone. I. Initial results. *Ann Trop Med Parasitol.* 1993; 87(2): 125-36.
- Bawah AA, Binka FN. How many years of life could be saved if malaria were eliminated from a hyperendemic area of northern Ghana? *Am J Trop Med Hyg.* 2007; 77(6 Suppl): 145-52.
- Benara SK, Singh P. Validity of causes of infant death by verbal autopsy. *Indian Pediatr.* 1999; 66(5): 647-50.
- Births and Deaths Registry (Ghana). Ghana - Accra Births and Deaths Registry - Deaths 2000-2007.
- Coghlan B, Brennan RJ, Ngoy P, Dofara D, Otto B, Clements M, Stewart T. Mortality in the Democratic Republic of Congo: a nationwide survey. *Lancet.* 2006; 367(9504): 44-51.
- Department of Health (Taiwan). Taiwan Vital Statistics - Deaths 2007.
- Deribew A, Tessema F, Girma B. Determinants of under-five mortality in Gilgel Gibe Field Research Center, Southwest Ethiopia. *Ethiop J Health Dev.* 2007; 21(2): 117-24.
- Ekanem EE, Asindi AA, Okoi OU. Community-based surveillance of paediatric deaths in Cross River State, Nigeria. *Trop Geogr Med.* 1994; 46(5): 305-8.
- Fantahun M, Fottrell E, Berhane Y, Wall S, Högberg U, Byass P. Assessing a new approach to verbal autopsy interpretation in a rural Ethiopian community: the InterVA model. *Bull World Health Organ.* 2006; 84(3): 204-10.
- Garrib A, Jaffar S, Knight S, Bradshaw D, Bennish ML. Rates and causes of child mortality in an area of high HIV prevalence in rural South Africa. *Trop Med Int Health.* 2006; 11(12): 1841-8.
- Halder AK, Gurley ES, Naheed A, Saha SK, Brooks WA, Arifeen SE, Sazzad HMS, Kenah E, Luby SP. Causes of early childhood deaths in urban Dhaka, Bangladesh. *PLoS One.* 2009; 4(12): e8145.
- Hussain A, Ali SM, Kvåle G. Determinants of mortality among children in the urban slums of Dhaka city, Bangladesh. *Trop Med Int Health.* 1999; 4(11): 758-64.
- Jaffar S, Leach A, Greenwood AM, Jepson A, Muller O, Ota MO, Bojang K, Obaro S, Greenwood BM. Changes in the pattern of infant and childhood mortality in upper river division, The Gambia, from 1989 to 1993. *Trop Med Int Health.* 1997; 2(1): 28-37.

Appendix Table A.3b - Citations for non-dismod model input data

- Kaatano GM, Mashauri FM, Kinung'hi SM, Mwangi JR, Malima RC, Kishamawe C, Nnko SE, Magesa SM, Mboera LE. Patterns of malaria related mortality based on verbal autopsy in Muleba District, north-western Tanzania. *Tanzan J Health Res.* 2009; 11(4): 210-8.
- Khanna R, Kumar A, Vaghela JF, Sreenivas V, Puliyel JM. Community based retrospective study of sex in infant mortality in India. *BMJ.* 2003; 327(7407): 126.
- Lawoyin TO. Infant and maternal deaths in rural south west Nigeria: a prospective study. *Afr J Med Med Sci.* 2007; 36(3): 235-41.
- Hoa NP, Rao C, Hoy DG, Hinh ND, Chuc NT, Ngo DA. Mortality measures from sample-based surveillance: evidence of the epidemiological transition in Viet Nam. *Bull World Health Organ.* 2012; 90(10): 764-72. [Unpublished data].
- Ministry of Health (Tanzania), Newcastle University, UK Department for International Development (DFID). *The Policy Implications of Tanzania's Mortality Burden.* Tanzania: Ministry of Health (Tanzania), 2004.
- Ministry of Health (Tonga). *Tonga Vital Statistics - Deaths 2003.*
- Bangladesh Rural Advancement Committee (BRAC), International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B). *Bangladesh - Dhaka Causes of Maternal, Neonatal and Child Deaths: An Exploratory Study of Dhaka's Slum Dwellers.* Dhaka, Bangladesh: International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B), 2009.
- Mudenda SS, Kamocha S, Mswia R, Conkling M, Sikanyiti P, Potter D, Mayaka WC, Marx MA. Feasibility of using a WHO-standard methodology for Sample Vital Registration with Verbal Autopsy (SAVVY) to report leading causes of death in Zambia: results of a pilot in four provinces, 2010. *Popul Health Metr.* 2011; 9: 40.
- Muhwava W. Contributions of the Africa Centre Demographic Surveillance to the Community. *Umbiko.* 2011; 12: 3-4.
- Myint, S, Ministry of Health (Myanmar). *Cause of Death Verification Study in Myanmar.* Presentation at: World Health Organization Regional Office for South East Asia. Regional Consultation on Mortality Statistics; 2007; New Delhi, India.
- Pacqué-Margolis S, Pacqué M, Dukuly Z, Boateng J, Taylor HR. Application of the verbal autopsy during a clinical trial. *Soc Sci Med.* 1990; 31(5): 585-91.
- Perry HB, Ross AG, Fernand F. Assessing the causes of under-five mortality in the Albert Schweitzer Hospital service area of rural Haiti. *Rev Panam Salud Publica.* 2005; 18(3): 178-86.
- Waltisperger D, Cantrelle P, Ralijaona J, Population and Development Research Center (CEPED) (France). *Madagascar - Antananorivo Mortality Report 1984-1995.* Paris, France: Population and Development Research Center (CEPED) (France), 1998.
- Salway S, Nasim SM. Levels, Trends and Causes of Mortality in Children Below 5 Years of Age in Bangladesh: Findings from a national survey. *J Diarrhoeal Dis Res.* 1994; 12(3): 187-193.
- Basic Support for Institutionalizing Child Survival (BASICS), Save the Children USA. *Guinea - Mandiana Mortality Study 1998-1999.*
- Sutrisna B, Reingold A, Kresno S, Harrison G, Utomo B. Care-seeking for fatal illnesses in young children in Indramayu, West Java, Indonesia. *Lancet.* 1993; 342(8874): 787-89.
- Centers for Disease Control and Prevention (CDC), United Nations Children's Fund (UNICEF). *Afghanistan - Badghis Nutrition and Health Survey 2002.*
- Würthwein R, Gbangou A, Sauerborn R, Schmidt CM. Measuring the local burden of disease. A study of years of life lost in sub-Saharan Africa. *Int J Epidemiol.* 2001; 30(3): 501-8.
- Yassin KM. Indices and sociodemographic determinants of childhood mortality in rural Upper Egypt. *Soc Sci Med.* 2000; 51(2): 185-97.
- Institute of Health Systems (India). *India Cause of Death Dataset Version 1.3 1980-1998.* Hyderabad, India: Institute of Health Systems (India), 2002.
- Office of the Registrar General and Census Commissioner (India). *India Medical Certification of Cause of Death Vital Statistics 1999-2001.*
- Office of the Registrar General and Census Commissioner (India). *India Medical Certification of Cause of Death Vital Statistics 1990-1998.*
- Department of Health (Philippines). *Philippines Vital Statistics - Deaths 1979-2000.*
- Ministry of Health (Brazil). *Brazil Deaths Data 1990-2009.*
- Department of Statistics (Malaysia). *Malaysia - Peninsular Vital Statistics - Deaths 1998.*
- United Nations Children's Fund (UNICEF). *Infant Mortality in Tajikistan: Two Studies Look at Risk Factors.* New York, United States: United Nations Children's Fund (UNICEF). (Child Research Digest, No. 4).
- National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC). *United States NVSS Mortality Data 2010.* Atlanta, United States: Centers for Disease Control and Prevention (CDC).
- National Statistical Office of Malawi, World Bank. *Malawi Living Standards Measurement Survey 2010-2011.* Washington DC, United States: World Bank.
- Central Statistical Agency (Ethiopia), World Bank. *Ethiopia Living Standards Measurement Study - Integrated Survey on Agriculture 2011-2012.* Washington DC, United States: World Bank.
- Korea, South National Health and Nutrition Examination Survey 2005 as it appears in World Health Organization (WHO). *WHO Global Database on Anemia, Nutrition Landscape Information System.*
- Ministry of Health (Jordan). *Jordan Vital Registration - Deaths 2010.*
- Turkish Statistical Institute. *Turkey Causes of Death Statistics 2010-2012.* Ankara, Turkey: Turkish Statistical Institute.

Appendix Table A.3b - Citations for non-dismod model input data

- Forsyth DM, Bradley DJ. The consequences of Bilharziasis. Medical and public health importance in North-west Tanzania. *Bull World Health Organ.* 1966; 34(5): 715-35. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Ndamba J, Makaza N, Kaondera KC, Munjoma M. Morbidity due to *Schistosoma mansoni* among sugar-cane cutters in Zimbabwe. *Int J Epidemiol.* 1991; 20(3): 787-95. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Abdel-Wahab MF, Esmat G, Ramzy I, Naroos S, Medhat E, Ibrahim M, El-Boraey Y, Strickland GT. The epidemiology of schistosomiasis in Egypt: Fayoum Governorate. *Am J Trop Med Hyg.* 2000; 62 Suppl 2: 55-64. as it appears in van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. *Acta Trop.* 2003; 86(2-3): 125-39.
- Abdel-Wahab MF, Esmat G, Ramzy I, Naroos S, Medhat E, Ibrahim M, El-Boraey Y, Strickland GT. The epidemiology of schistosomiasis in Egypt: Fayoum Governorate. *Am J Trop Med Hyg.* 2000; 62 Suppl 2: 55-64. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Abdel-Wahab MF, Esmat G, Ramzy I, Naroos S, Medhat E, Ibrahim M, El-Boraey Y, Strickland GT. The epidemiology of schistosomiasis in Egypt: Fayoum Governorate. *Am J Trop Med Hyg.* 2000; 62 Suppl 2: 55-64. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Habib M, Abdel Aziz F, Gamil F, Cline BL. The epidemiology of schistosomiasis in Egypt: Qalyubia Governorate. *Am J Trop Med Hyg.* 2000; 62 Suppl 2(2): 49-54. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Habib M, Abdel Aziz F, Gamil F, Cline BL. The epidemiology of schistosomiasis in Egypt: Qalyubia Governorate. *Am J Trop Med Hyg.* 2000; 62 Suppl 2(2): 49-54. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Abdel-Rahman TA, Collins KJ, Doré C. Oxylog studies of energy expenditure and schistosomiasis in the Sudan. *J Trop Med Hyg.* 1990; 93(6): 365-71. as it appears in King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet.* 2005; 365(9470): 1561-9.
- Corbett EL, Butterworth AE, Fulford AJ, Ouma JH, Sturrock RF. Nutritional status of children with schistosomiasis mansoni in two different areas of Machakos District, Kenya. *Trans R Soc Trop Med Hyg.* 1992; 86(3): 266-73. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Forsyth DM. Anaemia in Zanzibar. *Trans R Soc Trop Med Hyg.* 1970; 64(4): 601-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Lehman JS Jr, Mott KE, Morrow RH Jr, Muniz TM, Boyer MH. The intensity and effects of infection with *Schistosoma mansoni* in a rural community in northeast Brazil. *Am J Trop Med Hyg.* 1976; 25(2): 285-94. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Wilkins HA, Goll PH, Moore PJ. *Schistosoma haematobium* infection and haemoglobin concentrations in a Gambian community. *Ann Trop Med Parasitol.* 1985; 79(2): 159-6. as it appears in King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet.* 2005; 365(9470): 1561-9.
- Ministry of Health (Saudi Arabia). Saudi Arabia Vital Registration - Deaths 2012.
- Checchi F, Nyasulu P, Chandramohan D, Roberts B. Rates and causes of death in Chiradzulu District, Malawi, 2008: a key informant study. *Trop Med Int Health.* 2011; 16(3): 375-8.
- Chihana M, Floyd S, Molesworth A, Crampin AC, Kayuni N, Price A, Zaba B, Jahn A, Mvula H, Dube A, Ngwira B, Glynn JR, French N. Adult mortality and probable cause of death in rural northern Malawi in the era of HIV treatment. *Trop Med Int Health.* 2012; 17(8): E74-83.
- Registrar General's Department (Zimbabwe), Zimbabwe National Statistics Agency. Zimbabwe Mortality Report 2007.
- Delacollette C, Van der Stuyft P, Molima K, Delacollette-Lebrun C, Wery M. Etude de la mortalité globale et de la mortalité liée au paludisme dans le Kivu montagneux, Zaïre. *Rev Epidemiol Sante Publique.* 1989; 37(2): 161-6.
- Khalique N, Sinha SN, Yunus M, Malik A. Early childhood mortality - a rural study. *J R Soc Health.* 1993; 113(5): 247-9.
- Shamebo D, Muhe L, Sandström A, Wall S. The Butajira rural health project in Ethiopia: mortality pattern of the under fives. *J Trop Pediatr.* 1991; 37(5): 254-61.
- Reddaiah VP, Kapoor SK. Socio-biological factors in underfive deaths in a rural area. *Indian J Pediatr.* 1992; 59(5): 567-71.
- Mtango FD, Neuvians D, Broome CV, Hightower AW, Pio A. Risk factors for deaths in children under 5 years old in Bagamoyo district, Tanzania. *Trop Med Parasitol.* 1992; 43(4): 229-33.

Appendix Table A.3b - Citations for non-dismod model input data

- Slutsker L, Bloland P, Steketee RW, Wirima JJ, Heymann DL, Breman JG. Infant and second-year mortality in rural Malawi: causes and descriptive epidemiology. *Am J Trop Med Hyg.* 1996; 55(1 Suppl): 77-81.
- Anwar Z, Djamil H, Pardede N, Ismail R. The pattern of the causes of death in children in rural swampy area of South Sumatra, Indonesia. *Paediatr Indones.* 1987; 27(6-May): 93-8.
- Bailey P, Tsui AO, Janowitz B, Dominik R, Araujo L. A study of infant mortality and causes of death in a rural north-east Brazilian community. *J Biosoc Sci.* 1990; 22(3): 349-63.
- Becker SR, Diop F, Thornton JN. Infant and child mortality in two counties of Liberia: results of a survey in 1988 and trends since 1984. *Int J Epidemiol.* 1993; 22(Suppl 1): S56-63.
- Kumar V, Datta N, Wadhwa SS, Singhi S. Morbidity and mortality in diarrhea in rural Haryana Indian. *Indian J Pediatr.* 1985; 52(418): 455-61.
- Kwast BE, Rochat RW, Kidane-Mariam W. Maternal mortality in Addis Ababa, Ethiopia. *Stud Fam Plann.* 1986; 17(6 (Pt 1)): 288-301.
- Department of Home Affairs (South Africa), Statistics South Africa. South Africa Vital Registration - Causes of Death 1997-2005. Pretoria, South Africa: Statistics South Africa.
- Department of Health (Taiwan). Taiwan Statistics of Causes of Death 2009.
- Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 2011.
- Bassani DG, Kumar R, Awasthi S, Morris SK, Paul VK, Shet A, Ram U, Gaffey MF, Black RE, Jha P. Causes of neonatal and child mortality in India: a nationally representative mortality survey. *Lancet.* 2010; 376(9755): 1853-60.
- Garenne M, Willie D, Maire B, Fontaine O, Eeckels R, Briend A, Van den Broeck J. Incidence and duration of severe wasting in two African populations. *Public Health Nutr.* 2009; 12(11): 1974-82.
- Pandey MR, Sharma PR, Gubhaju BB, Shakya GM, Neupane RP, Gautam A, Shrestha IB. Impact of a pilot acute respiratory infection (ARI) control programme in a rural community of the hill region of Nepal. *Ann Trop Paediatr.* 1989; 9(4): 212-20.
- Singhal PK, Mathur GP, Mathur S, Singh YD. Mortality patterns in under six children in I.C.D.S. urban slum. *Indian Pediatr.* 1986; 23(8): 617-22.
- Turnbull E, Lembalemba MK, Brad Guffey M, Bolton-Moore C, Mubiana-Mbewe M, Chintu N, Giganti MJ, Nalubamba-Phiri M, Stringer EM, Stringer JS. Causes of stillbirth, neonatal death and early childhood death in rural Zambia by verbal autopsy assessments. *Trop Med Int Health.* 2011; 16(7): 894-901.
- Ramroth H, Lorenz E, Rankin JC, Fottrell E, Yé M, Neuhann F, Ssenono M, Sié A, Byass P, Becher H. Causas de la distribución de muerte con el modelo InterVA y la codificación de médicos en un área rural de Burkina Faso. *Trop Med Int Health.* 2012; 17(7): 904-13.
- Suraweera W, Morris SK, Kumar R, Warrell DA, Warrell MJ, Jha P. Deaths from Symptomatically Identifiable Furious Rabies in India: A Nationally Representative Mortality Survey. *PLoS Negl Trop Dis.* 2012; 6(10): e1847.
- League of Arab States, National Center for Disease Control (Libya), Pan Arab Project for Family Health (PAPFAM). Libya Family Health Survey 2007.
- Office of the Registrar General and Census Commissioner (India). India Medical Certification of Cause of Death Report 2002. New Delhi, India: Office of the Registrar General and Census Commissioner (India), 2009.
- Office of the Registrar General and Census Commissioner (India). India Medical Certification of Cause of Death Report 2003. New Delhi, India: Office of the Registrar General and Census Commissioner (India).
- Office of the Registrar General and Census Commissioner (India). India Medical Certification of Cause of Death Report 2004. New Delhi, India: Office of the Registrar General and Census Commissioner (India).
- Office of the Registrar General and Census Commissioner (India). India Medical Certification of Cause of Death Report 2005. New Delhi, India: Office of the Registrar General and Census Commissioner (India).
- Office of the Registrar General and Census Commissioner (India). India Medical Certification of Cause of Death Report 2006. New Delhi, India: Office of the Registrar General and Census Commissioner (India).
- Kanungo S, Tsuzuki A, Deen JL, Lopez AL, Rajendran K, Manna B, Sur D, Kim DR, Gupta VK, Ochiai RL, Ali M, von Seidlein L, Bhattacharya SK, Clemens JD. Use of verbal autopsy to determine mortality patterns in an urban slum in Kolkata, India. *Bull World Health Organ.* 2010; 88(9): 667-74.
- Kumar R, Kapoor SK, Krishnan A. Performance of cause-specific childhood mortality surveillance by health workers using a short verbal autopsy tool. *Southeast Asia J Public Health.* 2012; 1(2): 151-158.
- Shah MS, Khaliq N, Khan Z. Determinants of childhood mortality. *Indian J Prev Soc Med.* 2011; 42(2): 118-22.
- Upadhyaya S, Shetty S, Kumarc SS, Dongred A, Deshmukhe P. Institutionalizing district level infant death review: an experience from southern India. *Southeast Asia J Public Health.* 2012; 1(4): 446-56.
- Office of the Registrar General and Census Commissioner (India). India Medical Certification of Cause of Death Report 2008. New Delhi, India: Office of the Registrar General and Census Commissioner (India).
- Australian Bureau of Statistics. Australia Vital Registration - Deaths 2005.
- Al-Riyami A, Ebrahim GJ. Genetic Blood Disorders Survey in the Sultanate of Oman. *J Trop Pediatr.* 2003; 49(Suppl 1): 1-20. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Bayoumi RA, Abu Zeid YA, Abdul Sadig A, Awad Elkarim O. Sickle cell disease in Sudan. *Trans R Soc Trop Med Hyg.* 1988; 82(1): 164-8.

Appendix Table A.3b - Citations for non-dismod model input data

- Vasconcelos PF, Rodrigues SG, Degallier N, Moraes MA, Da Rosa JF, Da Rosa ES, Mondet B, Barros VL, Da Rosa AP. An epidemic of sylvatic yellow fever in the southeast region of Maranhao State, Brazil, 1993-1994: epidemiologic and entomologic findings. *Am J Trop Med Hyg.* 1997; 57(2): 132-7. as it appears in Johansson MA, Vasconcelos PFC, Staples JE. The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases. *Trans R Soc Trop Med Hyg.* 2014; 108(8): 482-7.
- Thonnon J, Spiegel A, Diallo M, Sylla R, Fall A, Mondo M, Fontenille D. Yellow fever outbreak in Kaffrine, Senegal 1996: epidemiological and entomological findings. *Trop Med Int Health.* 1998; 3(11): 872-7. as it appears in Johansson MA, Vasconcelos PFC, Staples JE. The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases. *Trans R Soc Trop Med Hyg.* 2014; 108(8): 482-7.
- Abdel-Wahab MF, Esmat G, Narooz SI, Yosery A, Struewing JP, Strickland GT. Sonographic studies of schoolchildren in a village endemic for *Schistosoma mansoni*. *Trans R Soc Trop Med Hyg.* 1990; 84(1): 69-73. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Arap Siogok TK, Mahmoud AA, Ouma JH, Warren KS, Muller AS, Handa AK, Houser HB. Morbidity in Schistosomiasis mansoni in relation to intensity of infection: study of a community in Machakos, Kenya. *Am J Trop Med Hyg.* 1976; 25(2): 273-84. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Befidi-Mengue RN, Ratard RC, Beltran G, D'Alessandro A, Rice J, Befidi-Mengue R, Kouemien LE, Cline BL. Impact of *Schistosoma haematobium* infection and of praziquantel treatment on anaemia of primary school children in Bertoua, Cameroon. *J Trop Med Hyg.* 1993; 9(8): 225-30. as it appears in King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet.* 2005; 365(9470): 1561-9.
- Curtale F, Nabil M, el Wakeel A, Shamy MY. Anaemia and intestinal parasitic infections among school age children in Behera Governorate, Egypt Behera Survey Team. *J Trop Pediatr.* 1998; 44(6): 323-8. as it appears in King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet.* 2005; 365(9470): 1561-9.
- Curtale F, Nabil M, el Wakeel A, Shamy MY. Anaemia and intestinal parasitic infections among school age children in Behera Governorate, Egypt Behera Survey Team. *J Trop Pediatr.* 1998; 44(6): 323-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- De Lima e Costa MF, Rocha RS, Katz N. Schistosomiasis morbidity and its relation to the *Schistosoma mansoni* egg count in an hyperendemic area in the State of Minas Gerais. *Rev Inst Med Trop Sao Paulo.* 1985; 27(2): 66-75. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Gryseels B, Nkulikyinka L. The morbidity of schistosomiasis mansoni in the highland focus of Lake Cohoha, Burundi. *Trans R Soc Trop Med Hyg.* 1990; 84(4): 542-7. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Gryseels B. The morbidity of schistosomiasis mansoni in the Rusizi Plain (Burundi). *Trans R Soc Trop Med Hyg.* 1988; 82(4): 582-7. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Guimarães MD, de Barros HL, Katz N. A clinical epidemiologic study in a schistosomiasis mansoni endemic area (Tuparecê, Minas Gerais). *Rev Inst Med Trop Sao Paulo.* 1985; 27(3): 123-31. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Guyatt HL, Brooker S, Kihamia CM, Hall A, Bundy DA. Evaluation of efficacy of school-based anthelmintic treatments against anaemia in children in the United Republic of Tanzania. *Bull World Health Organ.* 2001; 79(8): 695-703. as it appears in King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet.* 2005; 365(9470): 1561-9.
- Hiatt RA. Morbidity from *Schistosoma mansoni* infections: an epidemiologic study based on quantitative analysis of egg excretion in two highland Ethiopian villages. *Am J Trop Med Hyg.* 1976; 25(6): 808-17. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Latham MC, Stephenson LS, Hall A, Wolgemuth JC, Elliot TC, Crompton DW. Parasitic infections, anaemia and nutritional status: a study of their interrelationships and the effect of prophylaxis and treatment on workers in Kwale District, Kenya. *Trans R Soc Trop Med Hyg.* 1983; 77(1): 41-8. as it appears in King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet.* 2005; 365(9470): 1561-9.
- Lwambo NJ, Brooker S, Siza JE, Bundy DA, Guyatt H. Age patterns in stunting and anaemia in African schoolchildren: a cross-sectional study in Tanzania. *Eur J Clin Nutr.* 2000; 54(1): 36-40. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Mansour MM, Francis WM, Farid Z. Prevalence of latent iron deficiency in patients with chronic *S mansoni* infection. *Trop Geogr Med.* 1985; 37(2): 124-8. as it appears in King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet.* 2005; 365(9470): 1561-9.

Appendix Table A.3b - Citations for non-dismod model input data

- Masaba SC, Awiti IE, Muruka JF. Morbidity in urinary schistosomiasis in relation to the intensity of infection in Kisumu, Kenya. *J Trop Med Hyg.* 1983; 86(2): 65-6. as it appears in van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. *Acta Trop.* 2003; 86(2-3): 125-39.
- Masaba SC, Awiti IE, Muruka JF. Morbidity in urinary schistosomiasis in relation to the intensity of infection in Kisumu, Kenya. *J Trop Med Hyg.* 1983; 86(2): 65-6. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Mungomba LM, Kalumba K. Validation of schistosomiasis morbidity symptoms in schoolchildren of Siavonga, Lake Kariba, Zambia. *Ann Trop Med Parasitol.* 1995; 89(4): 439-42. as it appears in van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. *Acta Trop.* 2003; 86(2-3): 125-39.
- Mungomba LM, Kalumba K. Validation of schistosomiasis morbidity symptoms in schoolchildren of Siavonga, Lake Kariba, Zambia. *Ann Trop Med Parasitol.* 1995; 89(4): 439-42. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Mungomba LM, Kalumba K. Validation of schistosomiasis morbidity symptoms in schoolchildren of Siavonga, Lake Kariba, Zambia. *Ann Trop Med Parasitol.* 1995; 89(4): 439-42. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Omer AH, Hamilton PJ, Marshall TF, Draper CC. Infection with *Schistosoma mansoni* in the Gezire area of the Sudan. *J Trop Med Hyg.* 1976; 79(7): 151-7. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Omer AH, Hamilton PJ, Marshall TF, Draper CC. Infection with *Schistosoma mansoni* in the Gezire area of the Sudan. *J Trop Med Hyg.* 1976; 79(7): 151-7. as it appears in King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet.* 2005; 365(9470): 1561-9.
- Ongom VL, Bradley DJ. The epidemiology and consequences of *Schistosoma mansoni* infection in West Nile, Uganda. *Trans R Soc Trop Med Hyg.* 1972; 66(6): 835-51. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Smith DH, Warren KS, Mahmoud AA. Morbidity in schistosomiasis mansoni in relation to intensity of infection: study of a community in Kisumu, Kenya. *Am J Trop Med Hyg.* 1979; 28(2): 220-9. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Stephenson LS, Latham MC, Kurz KM, Kinoti SN, Oduori ML, Crompton DW. Relationships of *Schistosoma hematobium*, hookworm and malarial infections and metrifonate treatment to hemoglobin level in Kenyan school children. *Am J Trop Med Hyg.* 1985; 34(3): 519-28. as it appears in King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet.* 2005; 365(9470): 1561-9.
- Sukwa TY, Bulsara MK, Wurapa FK. The relationship between morbidity and intensity of *Schistosoma mansoni* infection in a rural Zambian community. *Int J Epidemiol.* 1986; 15(2): 248-51. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Traore M, Traore HA, Kardorff R, Diarra A, Landoure A, Vester U, Doehring E, Bradley DJ. The public health significance of urinary schistosomiasis as a cause of morbidity in two districts in Mali. *Am J Trop Med Hyg.* 1998; 59(3): 407-13. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Walker AR, Fletcher DC, Traill V. An investigation of haemoglobin concentration and of blood loss in stools in adult South African Bantu infested with intestinal *Schistosoma mansoni*. *Trans R Soc Trop Med Hyg.* 1954; 48(6): 501-5. as it appears in King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet.* 2005; 365(9470): 1561-9.
- Warren KS, Mahmoud AA, Muruka JF, Whittaker LR, Ouma JH, Arap Siongok TK. Schistosomiasis haematobia in coast province Kenya. *Am J Trop Med Hyg.* 1979; 28(5): 864-70. as it appears in van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. *Acta Trop.* 2003; 86(2-3): 125-39.
- Warren KS, Mahmoud AA, Muruka JF, Whittaker LR, Ouma JH, Arap Siongok TK. Schistosomiasis haematobia in coast province Kenya. *Am J Trop Med Hyg.* 1979; 28(5): 864-70. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Wu X-H, Wang T-P, Lu D-B, Hu H-T, Gao Z-B, Zhu C-G, Fang G-R, He Y-C, Mei Q-J, Wu W-D, Ge J-H, Zheng J. Studies of impact on physical fitness and working capacity of patients with advanced *Schistosomiasis japonica* in Susong County, Anhui Province. *Acta Trop.* 2002; 82(2): 247-52. as it appears in King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet.* 2005; 365(9470): 1561-9.

Appendix Table A.3b - Citations for non-dismod model input data

Houzen H, Niino M, Kikuchi S, Fukazawa T, Nogoshi S, Matsumoto H, Tashiro K. The prevalence and clinical characteristics of MS in northern Japan. *J Neurol Sci.* 2003; 211(1-2): 49-53.

Bahrain National Nutrition Survey 1998-1999 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Chile National Health Survey 2003 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Korea, South National Health and Nutrition Examination Survey 2001 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Federal Bureau of Statistics (Pakistan), Pakistan Medical Research Council. Pakistan National Health Survey 1990-1994.

Mexico National Nutrition Survey 1998-1999 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Zhu C, Kang W, Xu F, Cheng X, Zhang Z, Jia L, Ji L, Guo X, Xiong H, Simbruner G, Blomgren K, Wang X. Erythropoietin Improved Neurologic Outcomes in Newborns With Hypoxic-Ischemic Encephalopathy. *Pediatrics.* 2009; 124(2): e218-e226.

Korea, South National Health and Nutrition Examination Survey 1998 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Isik U, Ersu RH, Ay P, Save D, Arman AR, Karakoc F, Dagli E. Prevalence of headache and its association with sleep disorders in children. *Pediatr Neurol.* 2007; 36(3): 146-51.

Russia Longitudinal Monitoring Survey (RLMS-HSE), Round VI 1995. National Research University Higher School of Economics, ZAO Demoscope, Carolina Population Center, University of North Carolina at Chapel Hill, Institute of Sociology, Russian Academy of Sciences.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 1980.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 1981.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 1982.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 1983.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 1984.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 1985.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 1986.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 1987.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 1988.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 1989.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 1990.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 1991.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 1993.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 1995.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 1996.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 1997.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 1998.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 1999.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 2001.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 2002.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 2003.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 2004.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 2005.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 2006.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 2007.

Ministry of Health (Mexico), National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 2008.

Abeyasinghe RR, Galappaththy GNL, Smith Gueye C, Kahn JG, Feachem RGA. Malaria control and elimination in Sri Lanka: documenting progress and success factors in a conflict setting. *PLoS One.* 2012; 7(8): e43162.

Van den Berg H, Velayudhan R, Ebo A, Catbagan BHG Jr, Turingan R, Tuso M, Hii J. Operational efficiency and sustainability of vector control of malaria and dengue: descriptive case studies from the Philippines. *Malar J.* 2012; 269.

Appendix Table A.3b - Citations for non-dismod model input data

- Doodoo D, Atuguba F, Bosomprah S, Ansah NA, Ansah P, Lamptey H, Egyir B, Oduro AR, Gyan B, Hodgson A, Koram KA. Antibody levels to multiple malaria vaccine candidate antigens in relation to clinical malaria episodes in children in the Kasena-Nankana district of Northern Ghana. *Malar J.* 2011; 10: 108.
- Guinovart C, Dobaño C, Bassat Q, Nhabomba A, Quintó L, Manaca MN, Aguilar R, Rodríguez MH, Barbosa A, Aponte JJ, Mayor AG, Renom M, Moraleda C, Roberts DJ, Schwarzer E, Le Souëf PN, Schofield L, Chitnis CE, Doolan DL, Alonso PL. The role of age and exposure to *Plasmodium falciparum* in the rate of acquisition of naturally acquired immunity: a randomized controlled trial. *PLoS One.* 2012; 7(3): e32362.
- Gupta V, Perez-Perez GI, Dorsey G, Rosenthal PJ, Blaser MJ. The seroprevalence of *Helicobacter pylori* and its relationship to malaria in Ugandan children. *Trans R Soc Trop Med Hyg.* 2012; 106(1): 35-42.
- Hamusse SD, Balcha TT, Belachew T. The impact of indoor residual spraying on malaria incidence in East Shoa Zone, Ethiopia. *Glob Health Action.* 2012; 11619.
- Haque U, Glass GE, Bomblies A, Hashizume M, Mitra D, Noman N, Haque W, Kabir MM, Yamamoto T, Overgaard HJ. Risk factors associated with clinical malaria episodes in Bangladesh: a longitudinal study. *Am J Trop Med Hyg.* 2013; 88(4): 727-32.
- Jonker FAM, Calis JCJ, van Hensbroek MB, Phiri K, Geskus RB, Brabin BJ, Leenstra T. Iron status predicts malaria risk in Malawian preschool children. *PLoS One.* 2012; 7(8): e42670.
- Kajeguka D, Mwanziva C, Daou M, Ndaro A, Matondo S, Mbugi E, Dolmans W, Chilongola J. CD36 c.1264 T>G null mutation impairs acquisition of IgG antibodies to *Plasmodium falciparum* MSP119 antigen and is associated with higher malaria incidences in Tanzanian children. *Scand J Immunol.* 2012; 75(3): 355-60.
- Khosa E, Kuonza LR, Kruger P, Maimela E. Towards the elimination of malaria in South Africa: a review of surveillance data in Mutale Municipality, Limpopo Province, 2005 to 2010. *Malar J.* 2013; 7.
- Kinde-Gazard D, Baglo T. Assessment of microbial larvicide spraying with *Bacillus thuringiensis israelensis*, for the prevention of malaria. *Med Mal Infect.* 2012; 42(3): 114-8.
- Konaté AT, Yaro JB, Ouédraogo AZ, Diarra A, Gansané A, Soulama I, Kangoyé DT, Kaboré Y, Ouédraogo E, Ouédraogo A, Tiono AB, Ouédraogo IN, Chandramohan D, Cousens S, Milligan PJ, Sirima SB, Greenwood BM, Diallo DA. Morbidity from malaria in children in the year after they had received intermittent preventive treatment of malaria: a randomised trial. *PLoS One.* 2011; 6(8): e23391.
- Krefis AC, Schwarz NG, Krüger A, Fobil J, Nkrumah B, Acquah S, Loag W, Sarpong N, Adu-Sarkodie Y, Ranft U, May J. Modeling the relationship between precipitation and malaria incidence in children from a holoendemic area in Ghana. *Am J Trop Med Hyg.* 2011; 84(2): 285-91.
- Loha E, Lindtjörn B. Predictors of *Plasmodium falciparum* malaria incidence in Chano Mille, South Ethiopia: a longitudinal study. *Am J Trop Med Hyg.* 2012; 87(3): 450-9.
- Manimunda SP, Sugunan AP, Sha WA, Singh SS, Shriram AN, Vijayachari P. Tsunami, post-tsunami malaria situation in Nancowry group of islands, Nicobar district, Andaman and Nicobar Islands. *Indian J Med Res.* 2011; 76-82.
- Mitjà O, Paru R, Selve B, Betuela I, Siba P, De Lazzari E, Bassat Q. Malaria epidemiology in Lihir Island, Papua New Guinea. *Malar J.* 2013; 98.
- Mtove G, Amos B, Nadjm B, Hendriksen ICE, Dondorp AM, Mwambuli A, Kim DR, Ochiai RL, Clemens JD, von Seidlein L, Reyburn H, Deen J. Decreasing incidence of severe malaria and community-acquired bacteraemia among hospitalized children in Muheza, north-eastern Tanzania, 2006-2010. *Malar J.* 2011; 10: 320.
- Özbilgin A, Topluoglu S, Es S, Islek E, Mollahaliloglu S, Erkoc Y. Malaria in Turkey: successful control and strategies for achieving elimination. *Acta Trop.* 2011; 120(1-2): 15-23.
- Ouédraogo A, Tiono AB, Diarra A, Sanon S, Yaro JB, Ouedraogo E, Bougouma EC, Soulama I, Gansané A, Ouedraogo A, Konate AT, Nebie I, Watson NL, Sanza M, Dube TJT, Sirima SB. Malaria morbidity in high and seasonal malaria transmission area of Burkina Faso. *PLoS One.* 2013; 8(1): e50036.
- Reid HL, Haque U, Roy S, Islam N, Clements ACA. Characterizing the spatial and temporal variation of malaria incidence in Bangladesh, 2007. *Malar J.* 2012; 170.
- Rolfes MA, McCarra M, Magak NG, Ernst KC, Dent AE, Lindblade KA, John CC. Development of clinical immunity to malaria in highland areas of low and unstable transmission. *Am J Trop Med Hyg.* 2012; 87(5): 806-12.
- Rutta ASM, Francis F, Mmbando BP, Ishengoma DS, Sembuche SH, Malecela EK, Sadi JY, Kamugisha ML, Lemnge MM. Using community-owned resource persons to provide early diagnosis and treatment and estimate malaria burden at community level in north-eastern Tanzania. *Malar J.* 2012; 152.
- Senn N, Rarau P, Stanisis DI, Robinson L, Barnadas C, Manong D, Salib M, Iga J, Tarongka N, Ley S, Rosanas-Urgell A, Aponte JJ, Zimmerman PA, Beeson JG, Schofield L, Siba P, Rogerson SJ, Reeder JC, Mueller I. Intermittent preventive treatment for malaria in Papua New Guinean infants exposed to *Plasmodium falciparum* and *P. vivax*: a randomized controlled trial. *PLoS Med.* 2012; 9(3): e1001195.
- Singh N, Shukla MM, Chand G, Bharti PK, Singh MP, Shukla MK, Mehra RK, Sharma RK, Dash AP. Epidemic of *Plasmodium falciparum* malaria in Central India, an area where chloroquine has been replaced by artemisinin-based combination therapy. *Trans R Soc Trop Med Hyg.* 2011; 105(3): 133-9.
- Stefani A, Hanf M, Nacher M, Girod R, Carme B. Environmental, entomological, socioeconomic and behavioural risk factors for malaria attacks in Amerindian children of Camopi, French Guiana. *Malar J.* 2011; 246.
- Thiam S, Thwing J, Diallo I, Fall FB, Diouf MB, Pery R, Ndiop M, Diouf ML, Cisse MM, Diaw MM, Thior M. Scale-up of home-based management of malaria based on rapid diagnostic tests and artemisinin-based combination therapy in a resource-poor country: results in Senegal. *Malar J.* 2012; 334.

Appendix Table A.3b - Citations for non-dismod model input data

- Thriemer K, Ley B, Ame S, von Seidlein L, Pak GD, Chang NY, Hashim R, Schmieid WH, Busch CJ-L, Nixon S, Morrissey A, Puri MK, Ali M, Ochiai RL, Wierzbta T, Jiddawi MS, Clemens JD, Ali SM, Deen JL. The burden of invasive bacterial infections in Pemba, Zanzibar. *PLoS One*. 2012; 7(2): e30350.
- Veenemans J, Milligan P, Prentice AM, Schouten LRA, Inja N, van der Heijden AC, de Boer LCC, Jansen EJS, Koopmans AE, Enthoven WTM, Kraaijenhagen RJ, Demir AY, Uges DRA, Mbugi EV, Savelkoul HFJ, Verhoef H. Effect of supplementation with zinc and other micronutrients on malaria in Tanzanian children: a randomised trial. *PLoS Med*. 2011; 8(11): e1001125.
- Webb EL, Mawa PA, Ndibazza J, Kizito D, Namatovu A, Kyosiimire-Lugemwa J, Nanteza B, Nampijja M, Muhangi L, Woodburn PW, Akurut H, Mpairwe H, Akello M, Lyadda N, Bukusuba J, Kihembo M, Kizza M, Kizindo R, Nabulime J, Ameke C, Namujju PB, Tweyongere R, Muwanga M, Whitworth JAG, Elliott AM. Effect of single-dose anthelmintic treatment during pregnancy on an infant's response to immunisation and on susceptibility to infectious diseases in infancy: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2011; 377(9759): 52-62.
- Yamazaki A, Yasunami M, Ofori M, Horie H, Kikuchi M, Helegbe G, Takaki A, Ishii K, Omar AH, Akanmori BD, Hirayama K. Human leukocyte antigen class I polymorphisms influence the mild clinical manifestation of *Plasmodium falciparum* infection in Ghanaian children. *Hum Immunol*. 2011; 72(10): 881-8.
- Ndibazza J, Mpairwe H, Webb EL, Mawa PA, Nampijja M, Muhangi L, Kihembo M, Lule SA, Rutebarika D, Apule B, Akello F, Akurut H, Oduru G, Naniima P, Kizito D, Kizza M, Kizindo R, Tweyongere R, Alcock KJ, Muwanga M, Elliott AM. Impact of anthelmintic treatment in pregnancy and childhood on immunisations, infections and eczema in childhood: a randomised controlled trial. *PLoS One*. 2012; 7(12): e50325.
- Bhatt RM, Sharma SN, Urugayala S, Dash AP, Kamaraju R. Effectiveness and durability of Interceptor® long-lasting insecticidal nets in a malaria endemic area of central India. *Malar J*. 2012; 189.
- Ngomane L, de Jager C. Changes in malaria morbidity and mortality in Mpumalanga Province, South Africa (2001-2009): a retrospective study. *Malar J*. 2012; 19.
- Trape J-F, Tall A, Diagne N, Ndiath O, Ly AB, Faye J, Dieye-Ba F, Roucher C, Bouganali C, Badiane A, Sarr FD, Mazenot C, Touré-Baldé A, Raoult D, Druilhe P, Mercereau-Puijalon O, Rogier C, Sokhna C. Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: a longitudinal study. *Lancet Infect Dis*. 2011; 11(12): 925-32.
- Parise EV, de Araújo GC, Pinheiro RT. [Spatial analysis and determination of priority areas for malaria control in the State of Tocantins, from 2003 to 2008]. *Rev Soc Bras Med Trop*. 2011; 44(1): 63-9.
- Sesay S, Milligan P, Touray E, Sowe M, Webb EL, Greenwood BM, Bojang KA. A trial of intermittent preventive treatment and home-based management of malaria in a rural area of The Gambia. *Malar J*. 2011; 10.
- Bâgenholm GC, Nasher AA. Mortality among children in rural areas of the People's Democratic Republic of Yemen. *Ann Trop Paediatr*. 1989; 9(2): 75-81.
- Ministry of Health (Chile), National Institute of Statistics (Chile). Chile Vital Registration - Deaths 1985.
- De Sa DDC, Tleyjeh IM, Anavekar NS, Schultz JC, Thomas JM, Lahr BD, Bachuwar A, Pazdernik M, Steckelberg JM, Wilson WR, Baddour LM. Epidemiological Trends of Infective Endocarditis: A Population-Based Study in Olmsted County, Minnesota. *Mayo Clin Proc*. 2010; 85(5): 422-6.
- China National Nutrition Survey 1992 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Northern Ireland Statistics and Research Agency (NISRA). United Kingdom - Northern Ireland Registrar General Annual Report 2011. Belfast, Northern Ireland: Northern Ireland Statistics and Research Agency (NISRA), 2012.
- National Records of Scotland. United Kingdom - Scotland Vital Events Reference Tables 2011. Edinburgh, Scotland: National Records of Scotland.
- National Records of Scotland. United Kingdom - Scotland Vital Events Reference Tables 2012. Edinburgh, Scotland: National Records of Scotland.
- Danso KA, Martey JO, Wall LL, Elkins TE. The epidemiology of genitourinary fistulae in Kumasi, Ghana, 1977-1992. *Int Urogynecol J Pelvic Floor Dysfunct*. 1996; 7(3): 117-20.
- Rubin CH, Esteban E, Reissman DB, Daley WR, Noonan GP, Karpati A, Gurvitch E, Kuzmin SV, Privalova LI, Zukov A, Zlepko A. Lead poisoning among young children in Russia: concurrent evaluation of childhood lead exposure in Ekaterinburg, Krasnouralsk, and Volgograd. *Environ Health Perspect*. 2002; 110(6): 559-62. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Public Commission for Health Care Planning (Libya), United Nations Children's Fund (UNICEF). Libya Multiple Indicator Cluster Survey 2003.
- French Institute of Scientific Research for Development in Cooperation, Ministry of Health (Congo, Rep.). Congo National Survey on the Nutritional Status of Preschool Age Children 1987.
- Sibai AM, Hwalla N, Adra N, Rahal B. Prevalence and covariates of obesity in Lebanon: findings from the first epidemiological study. *Obes Res*. 2003; 11(11): 1353-61.
- Branca F, Pastore G, Rossi L, Sette S, Stojanovska Ancevska B, Janeva N, Kolevska L, Peova S, Muratovska O, Venovska K. Multiple Indicators Cluster Survey in FYR Macedonia With Micronutrient Component. Rome, Italy: National Institute of Nutrition, 2000.
- Macedonia - Multiple Indicators Cluster Survey in FYR Macedonia With Micronutrient Component as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

Department of Women and Child Development, Ministry of Human Resource Development (India). India Nutrition Profile Survey 1995-1996.
Australian Bureau of Statistics, Department of Health and Family Services (Australia). Australia National Nutrition Survey 1995-1996. Canberra, Australia: Australian Bureau of Statistics.
Kazakh Academy of Nutrition, Ministry of Health (Tajikistan), National Institute for Research on Food and Nutrition (INRAN) (Italy), United Nations Children's Fund (UNICEF). Tajikistan Micronutrient Status Survey 2003.
Tajikistan Micronutrient Status Survey 2003 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Ministry of Public Health (Thailand). Thailand National Nutrition Survey 1995.
Thailand National Nutrition Survey 1995 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Macedonia Health and Nutritional Status of the Elderly Survey 1999 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
National Institute of Nutrition and Food Technology, Ministry of Public Health (Tunisia). Tunisia National Nutrition Survey 1996-1997.
Centers for Disease Control and Prevention (CDC), Ministry of Health (Ukraine), National Academy of Medical Science of Ukraine, State Statistical Committee (Ukraine), United Nations Children's Fund (UNICEF). Ukraine National Micronutrient Survey 2002.
Ukraine National Micronutrient Survey 2002 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
National Institute of Statistics and Geography (Mexico). Mexico Vital Registration - Deaths 2012.
United Kingdom National Diet and Nutrition Survey: Adults Aged 19 to 64 Years 2000-2001 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
National Food and Nutrition Committee (Fiji). Fiji National Nutrition Survey 1993.
Fiji National Nutrition Survey 1993 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
United Kingdom Dietary and Nutritional Survey of British Adults 1986-1987 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Ministry of Health and Social Welfare (Lesotho), United Nations Children's Fund (UNICEF). Lesotho National Micronutrient Survey 1993.
Australian Agency for International Development (AusAID), Ministry of Health (Vanuatu). Vanuatu National Nutrition Survey 1996.
Vanuatu National Nutrition Survey 1996 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
New Zealand National Nutrition Survey 1996-1997 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Nicaragua Integrated Surveillance System of Nutrition Interventions 2005 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Joensen P. Multiple sclerosis incidence in the Faroe Islands 1986-2007. <i>Acta Neurol Scand.</i> 2010; 121(5): 348-53.
Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. <i>Epilepsia.</i> 1979; 20(6): 729-37.
Diallo AH, Meda N, Sommerfelt H, Traore GS, Cousens S, Tylleskar T. The high burden of infant deaths in rural Burkina Faso: a prospective community-based cohort study. <i>BMC Public Health.</i> 2012; 12(739).
Manortney S, Carey A, Ansong D, Harvey R, Good B, Boaheng J, Crookston B, Dickerson T. Verbal autopsy: an analysis of the common causes of childhood death in the Barekese sub-district of Ghana. <i>J Public Health Africa.</i> 2011; 2(e18): 73-7.
Food and Nutrition Research Institute, Department of Science and Technology (Philippines). Philippines National Nutrition Survey 2008-2009.
Byrraju Foundation, Centre for Chronic Disease Control (India), Cooperative for Assistance and Relief Everywhere (CARE), School of Population Health, University of Queensland (Australia). India - Andhra Pradesh Rural Health Initiative Mortality Surveillance 2003-2007.
Central Bureau of Statistics (Syria), League of Arab States. Syria Family Health Survey 2009.
Chinese Center for Disease Control and Prevention (CCDC). China Disease Surveillance Points 2004 - China CDC.
Chinese Center for Disease Control and Prevention (CCDC). China Disease Surveillance Points 2005 - China CDC.
Chinese Center for Disease Control and Prevention (CCDC). China Disease Surveillance Points 2006 - China CDC.
Chinese Center for Disease Control and Prevention (CCDC). China Mortality Registration and Reporting System 2008.
Chinese Center for Disease Control and Prevention (CCDC). China Mortality Registration and Reporting System 2009.
Chinese Center for Disease Control and Prevention (CCDC). China Mortality Registration and Reporting System 2010.
Chinese Center for Disease Control and Prevention (CCDC). China Mortality Registration and Reporting System 2012.
Memon S, Shaikh S, Bibi S. To compare the outcome (early) of neonates with birth asphyxia in-relation to place of delivery and age at time of admission. <i>J Pak Med Assoc.</i> 2012; 62(12): 1277-81.

Appendix Table A.3b - Citations for non-dismod model input data

- Adamson SJ, Alessandri LM, Badawi N, Burton PR, Pemberton PJ, Stanley F. Predictors of neonatal encephalopathy in full-term infants. *BMJ*. 1995; 311(7005): 598-602.
- Ellis M, Manandhar DS, Manandhar N, Wyatt J, Bolam AJ, Costello AM. Stillbirths and neonatal encephalopathy in Kathmandu, Nepal: an estimate of the contribution of birth asphyxia to perinatal mortality in a low-income urban population. *Paediatr Perinat Epidemiol*. 2000; 14(1): 39-52.
- Moster D, Lie RT, Markestad T. Joint association of Apgar scores and early neonatal symptoms with minor disabilities at school age. *Arch Dis Child Fetal Neonatal Ed*. 2002; 86(1): F16-21.
- Nair MKC, George B, Jeyaseelan L. Pyritinol for post asphyxial encephalopathy in term babies – a randomized double-blind controlled trial. *Indian Pediatr*. 2009; 46(Suppl): S37-42.
- Jacobs SE, Morley CJ, Inder TE, Stewart MJ, Smith KR, McNamara PJ, Wright IMR, Kirpalani HM, Darlow BA, Doyle LW, Infant Cooling Evaluation Collaboration. Whole-body hypothermia for term and near-term newborns with hypoxic-ischemic encephalopathy: a randomized controlled trial. *Arch Pediatr Adolesc Med*. 2011; 165(8): 692-700.
- Nadeem M, Murray D, Boylan G, Dempsey EM, Ryan CA. Blood carbon dioxide levels and adverse outcome in neonatal hypoxic-ischemic encephalopathy. *Am J Perinatol*. 2010; 27(5): 361-5.
- Simbruner G, Mittal RA, Rohlmann F, Mueche R, neo.nEURO.network Trial Participants. Systemic hypothermia after neonatal encephalopathy: outcomes of neo.nEURO.network RCT. *Pediatrics*. 2010; 126(4): e771-8.
- Twomey E, Twomey A, Ryan S, Murphy J, Donoghue VB. MR imaging of term infants with hypoxic-ischaemic encephalopathy as a predictor of neurodevelopmental outcome and late MRI appearances. *Pediatr Radiol*. 2010; 40(9): 1526-35.
- Wang Y-J, Pan K-L, Zhao X-L, Qiang H, Cheng S-Q. [Therapeutic effects of erythropoietin on hypoxic-ischemic encephalopathy in neonates]. *Chin J Contemp Pediatr*. 2011; 13(11): 855-8.
- Hayes BC, Cooley S, Donnelly J, Doherty E, Grehan A, Madigan C, McGarvey C, Mulvany S, Ryan S, Gillian J, Geary MP, Matthews TG, King MD. The placenta in infants >36 weeks gestation with neonatal encephalopathy: a case control study. *Arch Dis Child Fetal Neonatal Ed*. 2013; 98(3): F233-9.
- Archer LN, Levene MI, Evans DH. Cerebral artery Doppler ultrasonography for prediction of outcome after perinatal asphyxia. *Lancet*. 1986; 2(8516): 1116-8.
- Da Silva LFG, Höefel Filho JR, Anés M, Nunes ML. Prognostic value of 1H-MRS in neonatal encephalopathy. *Pediatr Neurol*. 2006; 34(5): 360-6.
- Dixon G, Badawi N, Kurinczuk JJ, Keogh JM, Silburn SR, Zubrick SR, Stanley FJ. Early developmental outcomes after newborn encephalopathy. *Pediatrics*. 2002; 109(1): 26-33.
- Gluckman PD, Wyatt JS, Azzopardi D, Ballard R, Edwards AD, Ferriero DM, Polin RA, Robertson CM, Thoresen M, Whitelaw A, Gunn AJ. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. *Lancet*. 2005; 365(9460): 663-70.
- Gray PH, Tudehope DI, Masel JP, Burns YR, Mohay HA, O'Callaghan MJ, Williams GM. Perinatal hypoxic-ischaemic brain injury: prediction of outcome. *Dev Med Child Neurol*. 1993; 35(11): 965-73.
- L'Abée C, de Vries LS, van der Grond J, Groenendaal F. Early diffusion-weighted MRI and 1H-Magnetic Resonance Spectroscopy in asphyxiated full-term neonates. *Biol Neonate*. 2005; 88(4): 306-12.
- Pisani F, Orsini M, Braibanti S, Copioli C, Sisti L, Turco EC. Development of epilepsy in newborns with moderate hypoxic-ischemic encephalopathy and neonatal seizures. *Brain Dev*. 2009; 31(1): 64-8.
- Prechtl HF, Ferrari F, Cioni G. Predictive value of general movements in asphyxiated fullterm infants. *Early Hum Dev*. 1993; 35(2): 91-120.
- Shah P, Riphagen S, Beyene J, Perlman M. Multiorgan dysfunction in infants with post-asphyxial hypoxic-ischaemic encephalopathy. *Arch Dis Child Fetal Neonatal Ed*. 2004; 89(2): F152-5.
- Chinese Center for Disease Control and Prevention (CCDC). China Mortality Registration and Reporting System 2011.
- Chinese Center for Disease Control and Prevention (CCDC). China Disease Surveillance Points 1991 - China CDC.
- Chinese Center for Disease Control and Prevention (CCDC). China Disease Surveillance Points 1992 - China CDC.
- Chinese Center for Disease Control and Prevention (CCDC). China Disease Surveillance Points 1993 - China CDC.
- Chinese Center for Disease Control and Prevention (CCDC). China Disease Surveillance Points 1996 - China CDC.
- Chinese Center for Disease Control and Prevention (CCDC). China Disease Surveillance Points 1998 - China CDC.
- Chinese Center for Disease Control and Prevention (CCDC). China Disease Surveillance Points 1999 - China CDC.
- Chinese Center for Disease Control and Prevention (CCDC). China Disease Surveillance Points 2001 - China CDC.
- Chinese Center for Disease Control and Prevention (CCDC). China Disease Surveillance Points 2002 - China CDC.
- Chinese Center for Disease Control and Prevention (CCDC). China Disease Surveillance Points 2000 - China CDC.
- United Kingdom National Diet and Nutrition Survey: Young People Aged 4 to 18 Years 1997 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- United Kingdom National Diet and Nutrition Survey: People Aged 65 Years and Over 1994-1995 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- United Kingdom National Diet, Nutrition, and Dental Survey of Children Aged 1 1/2 to 4 1/2 Years 1992-1993 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Department of Health (Taiwan). Taiwan Statistics of Causes of Death 2008.
- Department of Health (Taiwan). Taiwan Statistics of Causes of Death 2010.
- Department of Health (Taiwan). Taiwan Statistics of Causes of Death 2011.
- Department of Health (Taiwan). Taiwan Statistics of Causes of Death 2012.
- National Nutrition Monitoring Bureau (India). India Rural Third Repeat Survey of Diet and Nutritional Status 2011-2012.
- National Nutrition Monitoring Bureau (India). India Tribal Second Repeat Survey of Diet and Nutritional Status 2007-2008.
- National Nutrition Monitoring Bureau (India). India Rural Survey of Diet and Nutritional Status 2004-2005.
- Porapakham Y, Rao C, Pattaraarchachai J, Polprasert W, Vos T, Adair T, Lopez AD. Estimated causes of death in Thailand, 2005: implications for health policy. *Popul Health Metr.* 2010; 8:14.
- Van Den Broeck J, Eeckels R, Vuylsteke J. Influence of nutritional status on child mortality in rural Zaire. *Lancet.* 1993; 341(8859): 1491-5.
- Wermuth L, Bech S, Petersen MS, Joensen P, Weihe P, Grandjean P. Prevalence and incidence of Parkinson's disease in The Faroe Islands. *Acta Neurol Scand.* 2008; 118(2): 126-31.
- Hanson JW, Streissguth AP, Smith DW. The effects of moderate alcohol consumption during pregnancy on fetal growth and morphogenesis. *J Pediatr.* 1978; 92(3): 457-60.
- Baqui AH, Black RE, Arifeen SE, Hill K, Mitra SN, al Sabir A. Causes of childhood deaths in Bangladesh: results of a nationwide verbal autopsy study. *Bull World Health Organ.* 1998; 76(2): 161-71.
- Ministry of Public Health (Morocco). Morocco National Survey on Causes and Circumstances of Infant and Child Deaths 1988-1989.
- Garenne M, Maire B, Fontaine O, Dieng K, Briend A. Risques de deces associes a differents etats nutritionnels chez l'enfant d'age prescolaire: Etude realisee a Niakhar (Senegal), 1983-1986 [Risk of Death Associated with Different Nutritional States in Children of Preschool age: Study Conducted in Niakhar (Senegal) 1983-1986]. Paris, France: Population and Development Research Center (CEPED) (France); 2000.
- New Zealand National Children's Nutrition Survey 2002 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ministry of Health (China). China National Maternal and Child Health Surveillance System Child Mortality Data By Cause 1996-2012 - MCHS.
- ICF International, Ministry of Health and Sanitation (Sierra Leone), Statistics Sierra Leone. Sierra Leone Demographic and Health Survey 2013. Fairfax, United States: ICF International, 2014.
- Federal Environment Agency (Germany), Robert Koch Institute. Germany Environmental Survey for Children 2003-2006. Berlin, Germany: Federal Environment Agency (Germany).
- Greenwood BM, Greenwood AM, Bradley AK, Tulloch S, Hayes R, Oldfield FS. Deaths in infancy and early childhood in a well-vaccinated, rural, West African population. *Ann Trop Paediatr.* 1987; 7 (2): 91-9.
- Fantahun M. Patterns of childhood mortality in three districts of north Gondar Administrative Zone. A community based study using the verbal autopsy method. *Ethiop Med J.* 1998; 36(2): 71-81.
- Kristiansen HA, Kværner KJ, Akre H, Overland B, Russell MB. Migraine and sleep apnea in the general population. *J Headache Pain.* 2011; 12(1): 55-61.
- Semiz M, Şentürk IA, Balaban H, Yağız AK, Kavakçı Ö. Prevalence of migraine and co-morbid psychiatric disorders among students of Cumhuriyet University. *J Headache Pain.* 2013; 14(1): 34.
- Dent W, Stelzhammer B, Meindl M, Matuja WBP, Schmutzhard E, Winkler AS. Migraine attack frequency, duration, and pain intensity: disease burden derived from a community-based survey in northern Tanzania. *Headache.* 2011; 51(10): 1483-92.
- Palestinian Central Bureau of Statistics. Palestine - West Bank Vital Registration - Deaths 2004.
- Palestinian Central Bureau of Statistics. Palestine - West Bank Vital Registration - Deaths 2005.
- Palestinian Central Bureau of Statistics. Palestine - West Bank Vital Registration - Deaths 2007.
- Palestinian Central Bureau of Statistics. Palestine - West Bank Vital Registration - Deaths 2008.
- Palestinian Central Bureau of Statistics. Palestine - West Bank Vital Registration - Deaths 2009.
- Palestinian Central Bureau of Statistics. Palestine - West Bank Vital Registration - Deaths 1998.
- Palestinian Central Bureau of Statistics. Palestine - West Bank Vital Registration - Deaths 1999.
- Palestinian Central Bureau of Statistics. Palestine - West Bank Vital Registration - Deaths 2000.
- Palestinian Central Bureau of Statistics. Palestine - West Bank Vital Registration - Deaths 2001.
- Palestinian Central Bureau of Statistics. Palestine - West Bank Vital Registration - Deaths 2002.
- Govoni V, Granieri E, Tola MR, Casetta I, Ruppi P, Vaghi L. The frequency of clinical variants of Guillain-Barré syndrome in Ferrara, Italy. *J Neurol.* 1999; 246(11): 1010-4.
- Van Koningsveld R, Rico R, Gerstenbluth I, Schmitz PI, Ang CW, Merckies IS, Jacobs BC, Halabi Y, Endtz HP, van der Meché FG, van Doorn PA. Gastroenteritis-associated Guillain-Barré syndrome on the Caribbean island Curaçao. *Neurology.* 2001; 56(11): 1467-72.

Appendix Table A.3b - Citations for non-dismod model input data

- Center for Demographic Research, New Economic School (Russia). Russia Mortality Rates by Region, Age, Sex, and Cause of Death 1989-1998. Moscow, Russia: Center for Demographic Research, New Economic School (Russia), 2014-02-12. http://demogr.nes.ru/index.php/ru/demogr_indicat/data
- Center for Demographic Research, New Economic School (Russia). Russia Mortality Rates by Region, Age, Sex, and Cause of Death 1999-2005. Moscow, Russia: Center for Demographic Research, New Economic School (Russia).
- Center for Demographic Research, New Economic School (Russia). Russia Mortality Rates by Region, Age, Sex, and Cause of Death 2006-2012. Moscow, Russia: Center for Demographic Research, New Economic School (Russia).
- Institute for Health Metrics and Evaluation (IHME). Greece - Rhodes SF-12 Survey 2013.
- Institute for Health Metrics and Evaluation (IHME). United States - Seattle SF-12 Survey 2013.
- Institute for Health Metrics and Evaluation (IHME). United States - Seattle SF-12 Survey 2011-2012.
- India Micronutrient Deficiency Survey 2002-2003 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Centers for Disease Control and Prevention (CDC), Ministry of Public Health (Afghanistan), National Institute for Research on Food and Nutrition (INRAN) (Italy), Tufts University, United Nations Children's Fund (UNICEF). Afghanistan National Nutrition Survey 2004.
- Afghanistan National Nutrition Survey 2004 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Grobusch MP, Lell B, Schwarz NG, Gabor J, Dornemann J, Potschke M, Oyakhrome S, Kiessling GC, Necek M, Langin MU, Klein Klouwenberg P, Klopfer A, Naumann B, Altun H, Agnandji ST, Goesch J, Decker M, Salazar CLO, Supan C, Kombila DU, Borchert L, Koster KB, Pongratz P, Adegnikaa AA, Glasenapp I von, Issifou S, Kremsner PG. Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial. *J Infect Dis.* 2007; 196(11): 1595-602.
- Ijumba JN, Shenton FC, Clarke SE, Mosha FW, Lindsay SW. Irrigated crop production is associated with less malaria than traditional agricultural practices in Tanzania. *Trans R Soc Trop Med Hyg.* 2002; 96(5): 476-80.
- Kobbe R, Kreuzberg C, Adjei S, Thompson B, Langefeld I, Thompson PA, Abruquah HH, Kreuels B, Ayim M, Busch W, Marks F, Amoah K, Opoku E, Meyer CG, Adjei O, May J. A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants. *Clin Infect Dis.* 2007; 45(1): 16-25.
- McGuinness D, Koram K, Bennett S, Wagner G, Nkrumah F, Riley E. Clinical case definitions for malaria: clinical malaria associated with very low parasite densities in African infants. *Trans R Soc Trop Med Hyg.* 1998; 92(5): 527-31.
- Menendez C, Kahigwa E, Hirt R, Vounatsou P, Aponte JJ, Font F, Acosta CJ, Schellenberg DM, Galindo CM, Kimario J, Urassa H, Brabin B, Smith TA, Kitua AY, Tanner M, Alonso PL. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. *Lancet.* 1997; 350(9081): 844-50.
- Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M, Mshinda H, Alonso P. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. *Lancet.* 2001; 357(9267): 1471-7.
- Schellenberg DM, Aponte JJ, Kahigwa EA, Mshinda H, Tanner M, Menendez C, Alonso PL. The incidence of clinical malaria detected by active case detection in children in Ifakara, southern Tanzania. *Trans R Soc Trop Med Hyg.* 2003; 97(6): 647-54.
- Thompson R, Begtrup K, Cuamba N, Dgedge M, Mendis C, Gamage-Mendis A, Enosse SM, Barreto J, Sinden RE, Hogh B. The Matola malaria project: a temporal and spatial study of malaria transmission and disease in a suburban area of Maputo, Mozambique. *Am J Trop Med Hyg.* 1997; 57(5): 550-9.
- Yé Y, Kyobutungi C, Louis VR, Sauerborn R. Micro-epidemiology of Plasmodium falciparum malaria: Is there any difference in transmission risk between neighbouring villages? *Malar J.* 2007; 46.
- Kenya National Bureau of Statistics, United Nations Children's Fund (UNICEF). Kenya - Nyanza Province Multiple Indicator Cluster Survey 2011. Nairobi, Kenya: Kenya National Bureau of Statistics.
- Dicko A, Sagara I, Diemert D, Sogoba M, Niamele MB, Dao A, Dolo G, Yalcouye D, Diallo DA, Saul A, Miller LH, Toure YT, Klion AD, Doumbo OK. Year-to-year variation in the age-specific incidence of clinical malaria in two potential vaccine testing sites in Mali with different levels of malaria transmission intensity. *Am J Trop Med Hyg.* 2007; 77(6): 1028-33.
- Sharma SK, Tyagi PK, Padhan K, Upadhyay AK, Haque MA, Nanda N, Joshi H, Biswas S, Adak T, Das BS, Chauhan VS, Chitnis CE, Subbarao SK. Epidemiology of malaria transmission in forest and plain ecotype villages in Sundargarh District, Orissa, India. *Trans R Soc Trop Med Hyg.* 2006; 100(10): 917-25.
- Sharma SK, Tyagi PK, Padhan K, Adak T, Subbarao SK. Malarial morbidity in tribal communities living in the forest and plain ecotypes of Orissa, India. *Ann Trop Med Parasitol.* 2004; 98(5): 459-68.
- Ghosh SK, Tiwari SN, Sathyanarayan TS, Sampath TRR, Sharma VP, Nanda N, Joshi H, Adak T, Subbarao SK. Larvivorous fish in wells target the malaria vector sibling species of the Anopheles culicifacies complex in villages in Karnataka, India. *Trans R Soc Trop Med Hyg.* 2005; 99(2): 101-5.
- Jambulingam P, Mohapatra SS, Govardhini P, Das LK, Manoharan A, Pani SP, Das PK. Microlevel epidemiological variations in malaria & its implications on control strategy. *Indian J Med Res.* 1991; 371-8.
- Pani SP. Epidemiology of Malaria Persistence in Koraput District Orissa State [thesis]. Pondicherry, India: Vector Control Research Centre; 1990.
- Yadav RS, Sampath TR, Sharma VP, Adak T, Ghosh SK. Evaluation of lambda-delta-cyhalothrin-impregnated bednets in a malaria endemic area of India. Part 3. Effects on malaria incidence and clinical measures. *J Am Mosq Control Assoc.* 1998; 14(4): 444-50.

Appendix Table A.3b - Citations for non-dismod model input data

- Subramanian S, Manoharan A, Sahu S, Jambulingam P, Govardhini P, Mohapatra SS, Das PK. Living conditions and occurrence of malaria in a rural community. *Indian J Malariol.* 1991; 28(1): 29-37.
- Dev V, Phookan S, Sharma VP, Anand SP. Physiographic and entomologic risk factors of malaria in Assam, India. *Am J Trop Med Hyg.* 2004; 71(4): 451-6.
- Prakash A, Bhattacharyya DR, Mohapatra PK, Mahanta J. Role of the prevalent *Anopheles* species in the transmission of *Plasmodium falciparum* and *P. vivax* in Assam state, north-eastern India. *Ann Trop Med Parasitol.* 2004; 98(6): 559-68.
- Sharma SK, Tyagi PK, Upadhyay AK, Haque MA, Adak T, Dash AP. Building small dams can decrease malaria: a comparative study from Sundargarh District, Orissa, India. *Acta Trop.* 2008; 107(2): 174-8.
- Singh N, Mishra SS, Singh MP, Sharma VP. Seasonality of *Plasmodium vivax* and *P. falciparum* in tribal villages in central India (1987-1995). *Ann Trop Med Parasitol.* 2000; 94(2): 101-12.
- Yadav RS, Sharma VP, Ghosh SK, Kumar A. Quartan malaria--an investigation on the incidence of *Plasmodium malariae* in Bisra PHC, District Sundargarh, Orissa. *Indian J Malariol.* 1990; 27(2): 85-94.
- Van der Hoek W, Konradsen F, Dijkstra DS, Amerasinghe PH, Amerasinghe FP. Risk factors for malaria: a microepidemiological study in a village in Sri Lanka. *Trans R Soc Trop Med Hyg.* 1998; 92(3): 265-9.
- Kamolratanakul P, Butraporn P, Prasittisuk M, Prasittisuk C, Indaratna K. Cost-effectiveness and sustainability of lambda-delta-cyhalothrin-treated mosquito nets in comparison to DDT spraying for malaria control in western Thailand. *Am J Trop Med Hyg.* 2001; 65(4): 279-84.
- Kamolratanakul P, Dhanamun B, Lertmaharit S, Seublinwong T, Udomsangpetch R, Chirakalwasorn N, Thaithong S. Malaria in a rural area of eastern Thailand: baseline epidemiological studies at Bo Thong. *Southeast Asian J Trop Med Public Health.* 1992; 23(4): 783-7.
- Erhart A, Thang ND, Xa NX, Thieu NQ, Hung LX, Hung NQ, Nam NV, Toi LV, Tung NM, Bien TH, Tuy TQ, Cong LD, Thuan LK, Coosemans M, D'Alessandro U. Accuracy of the health information system on malaria surveillance in Vietnam. *Trans R Soc Trop Med Hyg.* 2007; 101(3): 216-25.
- Ministry of Health (Oman). Oman Protein-Energy Malnutrition Survey 2008-2009.
- Centers for Disease Control and Prevention (CDC), Department of Health (Papua New Guinea), United Nations Children's Fund (UNICEF), University of Papua New Guinea. Papua New Guinea National Nutrition Survey 2005.
- National Institute of Statistics (Cambodia). Cambodia Anthropometrics Survey 2008. Phnom Penh, Cambodia: National Institute of Statistics (Cambodia), 2011.
- Albania Institute of Public Health (IPH). Albania National Nutrition Survey 1996-1998.
- Institute of Child Health, University College London, United Nations High Commissioner for Refugees (UNHCR), World Food Programme (WFP). Algeria - Tindouf Nutrition Survey 2002.
- Ministry of Health (Angola). Relatorio do Inquerito sobre a Nutricao em Angola 2007 [Angola Investigation Report on Nutrition 2007]. Luanda, Angola: Ministry of Health (Angola), 2008.
- Borrel A, Collins S, Kennedy B, Mc Cullough G, Long J. Nutritional surveillance and progress in N'Dalatando, Angola. Dublin: Concern Worldwide, 1995.
- Action Against Hunger. Angola - Lunda Norte Anthropometric Nutritional Survey in Cafunfo 1995.
- Angola - Assessing Vitamin A and Iron Deficiency Anaemia, Nutritional Anaemia among Children Aged 0-60 Months in the Republic of Angola - 2000 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Calvo EB, Longo EN et al. Encuesta antropométrica en menores de 6 años bajo programa materno infantil [Anthropometric Survey of Children under 6 Years Under the Maternal and Child Program]. In: Estudios antropométricos en la población infante-junvenil [Anthropometric studies in Child and Adolescent Population]. Republic of Argentina 1993-1996. Ministry of Health and Social Action: Buenos Aires, 1999.
- National Institute of Health Research and Development (NIHRD), Ministry of Health (Indonesia). Indonesia Sample Registration System 2012, Indonesia Cause of Death Survey 2010-2011, Indonesia Mortality Registration System Strengthening Project (IMRSSP), and Indonesia Basic Health Research 2007-2008.
- Elnour A, Hambraeus L, Eltom M, Dramaix M, Bourdoux P. Endemic goiter with iodine sufficiency: a possible role for the consumption of pearl millet in the etiology of endemic goiter. *Am J Clin Nutr.* 2000; 71(1): 59-66. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Argentina - Tierra del Fuego Project Baseline Health and Nutrition Survey 1995 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Bangladesh Rural Nutrition Survey 1975-1976 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Sudan Comprehensive Nutrition Survey 1995 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Nigeria National Micronutrient Survey 1993 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Zimbabwe National Micronutrient Survey 1999 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Botswana Micronutrient Malnutrition Survey 1994 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

Rwanda National Nutrition Survey of Women and Children 1996 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Mozambique Micronutrient Deficiency Survey 1998 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Pakistan National Nutrition Survey 2001-2002 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Nepal Micronutrient Status Survey 1997-1998 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Mauritius and Rodrigues Survey of Nutrition 1995 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Ministry of Health (Viet Nam), United Nations Children's Fund (UNICEF). Vietnam National Survey Assessment of the Status of Iodine Deficiency and Disorders 2000.
Research Institute of Endocrinology (Uzbekistan), United Nations Children's Fund (UNICEF). Uzbekistan Stratified Cluster Survey of Iodine Deficiency Disorders 2005.
Philippines National Nutrition Survey 1998 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Romania - Nutritional Status of Pregnant Women, Children Under 5 Years and School Children Aged 6-7 Years - 2005 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Yugoslavia, Federal Republic - Serbia Micronutrient Status Survey 2001 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Panama National Survey of Goiter and Anemia in School Children 6 to 12 Years Old 1999 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Pandav CS. United Arab Emirates Survey of Prevalence of Iodine Deficiency Disorders 1994. Geneva, Switzerland: World Health Organization (WHO).
Bangladesh National Vitamin A Survey 1997-1998 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Burkina Faso - Situational Analysis of the Health Status of Students in Formal Schools in Boulkiemde, Oudalan, Sanguie, Sanmatenga, and Zoundweogo as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Selga G, Sauka M, Gerasimov G. Status of Iodine Deficiency in Latvia Reconsidered: Results of Nation-wide Survey of 587 school children in the Year 2000. <i>IDD Newsletter</i> . 2000; 16(4).
Ministry of Health (Viet Nam). Vietnam Knowledge, Attitude and Practices Survey on Iodine Deficiency Disorders Control and Goiter Survey in School Children 2003. Hanoi, Vietnam: Ministry of Health (Viet Nam), 2003.
Szybinksi Z. Data tables provided in relation to the 1992-3 National Survey [unpublished data]. Krakow, Jagiellonian University, Department of Endocrinology, 2002.
Caribbean Food and Nutrition Institute, Pan American Health Organization, Ministry of Health (Guyana), Pan American Health Organization (PAHO). Guyana Micronutrient Survey 1996-1997.
Guyana Micronutrient Survey 1996-1997 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Yemen Arab Republic National Nutrition Survey 1979 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Vietnam National Anemia Survey 2000 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Vietnam National Nutrition Anemia and Intestinal Helminth Survey 1995 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Baird PA, Sadovnick AD. Life expectancy in Down syndrome. <i>J Pediatr</i> . 1987; 110(6): 849-54.
Frid C, Drott P, Otterblad Olausson P, Sundelin C, Annerén G. Maternal and neonatal factors and mortality in children with Down syndrome born in 1973-1980 and 1995-1998. <i>Acta Paediatr</i> . 2004; 93(1): 106-12.
Hijji T, Fukushige J, Igarashi H, Takahashi N, Ueda K. Life expectancy and social adaptation in individuals with Down syndrome with and without surgery for congenital heart disease. <i>Clin Pediatr (Phila)</i> . 1997; 36(6): 327-32.
United States - Diet and Iron Status, a Study of Relationships: United States, 1971-1974 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
United States - Hematological and Nutritional Biochemistry Reference Data for Persons 6 Months-74 Years of Age: United States, 1976-1980 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Tunisia National Nutrition Survey 1973-1975 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Maclean E, Badcock J, Bach F. The 1986 National Nutrition Survey of the Kingdom of Tonga: Technical Report Prepared for the National Food and Nutrition Committee. Nourmea, New Caledonia: South Pacific Commission, 1987.
Tonga - The 1986 National Nutrition Survey of the Kingdom of Tonga: Technical Report Prepared for the National Food and Nutrition Committee as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

Togo Nutrition Status Survey 1976-1977 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Togo Survey on Anemia and Associated Factors in Households 1999-2000 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Gambia Nationwide Survey on the Prevalence of Vitamin A and Iron Deficiency in Women and Children 2001 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Thailand Evaluation of Efficacy of Fortification of Common Salt with Iron in Preventing Iron Deficiency Anaemia 1981 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Ministry of Health, Nutrition and Welfare (Sri Lanka). Sri Lanka Assessment of Anemia Status 2001.
Sri Lanka Assessment of Anemia Status 2001 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Korea, South National Nutrition Survey 1993 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Korea, South National Nutrition Survey 1994 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Korea, South National Nutrition Survey 1995 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Somalia - Somaliland Anemia Survey 2001 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Singapore National Nutrition Survey 1998 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Sierra Leone National Nutrition Survey 1977-1978 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Ministry of Health and Sanitation (Sierra Leone), United Nations Children's Fund (UNICEF). Sierra Leone National Nutrition Survey 1989-1990.
Sierra Leone National Nutrition Survey 1989-1990 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Saudi Arabia - Ar Ryiad Prevalence of Anaemia Among Primary school Girls in Riyadh City 1997 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Ministry of Health (Samoa). Samoa National Nutrition Survey 1999.
Samoa National Nutrition Survey 1999 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Branca F, Rossi L. The Health and Nutrition Status of Children Under Five and their Mothers in the Republic of Ingushetia (Russian Federation). Rome, Italy: National Institute for Research on Food and Nutrition (INRAN) (Italy), 2001.
The Health and Nutrition Status of Children Under Five and their Mothers in the Republic of Ingushetia (Russian Federation) as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Centers for Disease Control and Prevention (CDC), Ministry of Health (Romania), United Nations Children's Fund (UNICEF). Romania National Nutrition Survey 1991.
Romania National Nutrition Survey 1991 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Romania - National Nutritional Surveillance Program 1993-2000: Evolution of the Nutritional Status and of Feeding Practices from Birth to the Age of 5 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Romania School Health and Nutrition Baseline Survey 1997 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Amine EK. Qatar Nutritional Assessment 1995; Oct 20-Nov 3 [assignment report]. WHO Regional Office for the Eastern Mediterranean, 1995.
Qatar Nutritional Assessment 1995 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Qatar Nutritional Assessment 1994 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Food and Nutrition Research Institute, Department of Science and Technology (Philippines). Philippines Second Nationwide Nutrition Survey 1982.
Philippines Second Nationwide Nutrition Survey 1982 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Department of Health (Philippines). Philippines Vital Statistics - Deaths 2001-2005.
National Institute of Nutrition and Food Technology, Ministry of Public Health (Tunisia). Tunisia National Nutrition Survey 1996-1997.
Afghanistan National Malaria Prevalence Survey 2002 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

Jadavji T, Biggar WD, Gold R, Prober CG. Sequelae of acute bacterial meningitis in children treated for seven days. *Pediatrics*. 1986; 78(1): 21-5. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.

Girgis NI, Farid Z, Mikhail IA, Farrag I, Sultan Y, Kilpatrick ME. Dexamethasone treatment for bacterial meningitis in children and adults. *Pediatr Infect Dis J*. 1989; 8(12): 848-51. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.

Farag HFM, Abdel-Fattah MM, Youssri AM. Epidemiological, clinical and prognostic profile of acute bacterial meningitis among children in Alexandria, Egypt. *Indian J Med Microbiol*. 2005; 23(2): 95-101. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.

Kilpi T, Peltola H, Jauhainen T, Kallio MJ. Oral glycerol and intravenous dexamethasone in preventing neurologic and audiologic sequelae of childhood bacterial meningitis. *Pediatr Infect Dis J*. 1995; 14(4): 270-8. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.

Goetghebuer T, West TE, Wermenbol V, Cadbury AL, Milligan P, Lloyd-Evans N, Adegbola RA, Mulholland EK, Greenwood BM, Weber MW. Outcome of meningitis caused by *Streptococcus pneumoniae* and *Haemophilus influenzae* type b in children in The Gambia. *Trop Med Int Health*. 2000; 5(3): 207-13. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.

Daoud AS, al-Sheyyab M, Batchoun RG, Rawashdeh MO, Nussair MM, Pugh RN. Bacterial meningitis: still a cause of high mortality and severe neurological morbidity in childhood. *J Trop Pediatr*. 1995; 41(5): 308-10. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.

Akpede GO, Akuhwa RT, Ogiji EO, Ambe JP. Risk factors for an adverse outcome in bacterial meningitis in the tropics: a reappraisal with focus on the significance and risk of seizures. *Ann Trop Paediatr*. 1999; 19(2): 151-9. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.

Oostenbrink R, Maas M, Moons KGM, Moll HA. Sequelae after bacterial meningitis in childhood. *Scand J Infect Dis*. 2002; 34(5): 379-82. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.

De Gans J, van de Beek D. Dexamethasone in Adults with Bacterial Meningitis. *N Engl J Med*. 2002; 347(20): 1549-56. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.

Salih MA, Khaleefa OH, Bushara M, Taha ZB, Musa ZA, Kamil I, Hofvander Y, Olcén P. Long term sequelae of childhood acute bacterial meningitis in a developing country. A study from the Sudan. *Scand J Infect Dis*. 1991; 23(2): 175-82. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.

Berg S, Trollfors B, Hugosson S, Fernell E, Svensson E. Long-term follow-up of children with bacterial meningitis with emphasis on behavioural characteristics. *Eur J Pediatr*. 2002; 161(6): 330-6. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.

Ford H, Wright J. Bacterial meningitis in Swaziland: an 18 month prospective study of its impact. *J Epidemiol Community Health*. 1994; 48(3): 276-80. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.

Letson GW, Gellin BG, Bulkow LR, Parks DJ, Ward JI. Severity and frequency of sequelae of bacterial meningitis in Alaska Native infants. Correlation with a scoring system for severity of sequelae. *Am J Dis Child*. 1992; 146(5): 560-6. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.

Branca F, Napoletano A, Coclite D, Rossi L. Armenia Health and Nutritional Status of Children and Women 1998. Rome, Italy: National Institute for Research on Food and Nutrition (INRAN) (Italy), 1998.

Armenia Health and Nutritional Status of Children and Women 1998 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Centers for Disease Control and Prevention (CDC). Azerbaijan Health and Nutrition Survey of Internally Displaced and Resident Population 1996.

Azerbaijan Health and Nutrition Survey of Internally Displaced and Resident Population 1996 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Bahrain Nutrition Status Survey - 1980 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Bahrain National Flour Fortification Program First Monitoring Study 2002 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Anemia, A Severe Public Health Problem in Pre-school Children and Pregnant Women in Rural Bangladesh 2002 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- High Anemia Prevalence Among Bangladeshi Children in Urban Slums: An Ethical and Economic Rationale for Multi-micronutrient Supplementation as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Determinants of Haemoglobin Level During Pregnancy and Relationship with Pregnancy Outcome in Bangladeshi Urban Poor as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Bangladesh National Nutrition Programme Baseline Survey 2004-2005 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Bangladesh - The Burden of Anemia in Rural Bangladesh - 2006 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Caribbean Food and Nutrition Institute, Pan American Health Organization, Ministry of Health (Barbados). Barbados National Health and Nutrition Survey 1981.
- Barbados National Health and Nutrition Survey 1981 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Barbados National Food and Nutrition Survey 1969 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Belize Iron Deficiency Anemia Survey 1994-1995 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Bhutan Anemia Among Men, Women, and Children as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Bhutan - Occurrence and Causes of Nutritional Anaemia in Bhutan as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Botswana - Nutrition Survey in Botswana. June-July 1971 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Brazil - Sergipe Third Study on Maternal and Child Health and Nutrition 1998 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Brazil - Bahia Living Conditions, Health, and Nutrition of Children in Salvador 1996 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Brazil Iron Deficiency, Folate and Anemia in Pregnant Women in Maternal and Child Institute of Pernambuco: Magnitude, Risk Factors and Some Implications for their Concepts 1992 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Brazil - Piauí Children and Adolescents: Health, Education, and Work 1991 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Brazil Analysis of the Relationship Between the Levels of Iron in Mothers and Newborns at Term 1999 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Brazil - Prevalence of Anemia in Low-income Pregnant Women: Some Associated Variables and Their Repercussion on the Newborn as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Iron Deficiency and Iron Deficiency Anemia in the Population of 6 Months to 6 Years in Vitória, Espírito Santo, Southeastern Brazil as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Brazil - School Lunch: History, Evolution and Contribution in Addressing the Nutritional Needs of the Child as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Rodríguez-Ojea A, Menéndez R, Terry B, Vega L, Abreu Y, Díaz Z. Low levels of urinary iodine excretion in schoolchildren of rural areas in Cuba. *Eur J Clin Nutr.* 1998; 52(5): 372-5.
- Ospanova F. [Iodine urine excretion as estimation of +A29 status of reproductive age women]. *Astana Med J.* 2000; 109-11.
- Mityukova TA, Astakhova LN, Asenchyk LD, Orlov MM, VanMiddlesworth L. Urinary iodine excretion in Belarus children. *Eur J Endocrinol.* 1995; 133(2): 216-7.
- Hollowell JG, Staehling NW, Hannon WH, Flanders DW, Gunter EW, Maberly GF, Braverman LE, Pino S, Miller DT, Garbe PL, DeLozier DM, Jackson RJ. Iodine nutrition in the United States. Trends and public health implications: iodine excretion data from National Health and Nutrition Examination Surveys I and III (1971-1974 and 1988-1994). *J Clin Endocrinol Metab.* 1998; 83(10): 3401-8.
- Caldwell KL, Jones R, Hollowell JG. Urinary iodine concentration: United States National Health And Nutrition Examination Survey 2001-2002. *Thyroid.* 2005; 15(7): 692-9.
- Kapil U, Pathak P, Tandon M, Singh C, Pradhan R, Dwivedi SN. Micronutrient deficiency disorders amongst pregnant women in three urban slum communities of Delhi. *Indian Pediatr.* 1999; 36(10): 983-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Pathak P, Singh P, Kapil U, Raghuvanshi RS. Prevalence of iron, vitamin A, and iodine deficiencies amongst adolescent pregnant mothers. *Indian J Pediatr.* 2003; 70(4): 299-301. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

Hess SY, Zimmermann MB, Adou P, Torresani T, Hurrell RF. Treatment of iron deficiency in goitrous children improves the efficacy of iodized salt in Côte d'Ivoire. *Am J Clin Nutr.* 2002; 75(4): 743-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

The health and nutritional status of schoolchildren in Africa: evidence from school-based health programmes in Ghana and Tanzania. The Partnership for Child Development. *Trans. R. Soc. Trop. Med. Hyg.* 1998; 92(3): 254-61. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Nigeria National Nutritional Status Survey 1997 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Nutritional Status of Children Under Five Years Old and Pregnant Women in Brunei Darussalam 1995-1996 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Bulgaria National Survey of Institutionalised Socially-Deprived Children Aged 0-3 Years 1999 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Burundi National Anemia Survey 2003 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Iron Deficiency in Cambodia: The Need for Iron Supplementation Among Preschool-aged Children as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Cambodia Seth Koma Follow-up Survey 2003 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Cameroon - Study on the Factors Influencing Nutrition Status of Adolescent Girls in Cameroon as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Cameroon National Nutrition Survey 1977-1978 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Cameroon - East Nutrition Survey in the Moloundou Health District 2000 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Cameroon - Centre Nutrition Survey in the Eseka Health District 2000 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Cameroon - Far North Nutrition Survey in the Kousseri Health District 2000 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Cameroon - West Nutrition Survey in the Fouban and Malentouen Health Districts 2000 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Cameroon National Survey on Vitamin A Deficiency and Anemia 2000 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Hubert B, Halstead SB. Dengue 1 virus and dengue hemorrhagic fever, French Polynesia, 2001. *Emerg Infect Dis.* 2009; 15(8): 1265-70.

Tennant PWG, Pearce MS, Bythell M, Rankin J. 20-year survival of children born with congenital anomalies: a population-based study. *Lancet.* 2010; 375(9715): 649-56.

Bojesen A, Juul S, Birkebaek N, Gravholt CH. Increased mortality in Klinefelter syndrome. *J Clin Endocrinol Metab.* 2004; 89(8): 3830-4.

Egypt National Nutrition Survey 1978 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

National Institute of Health (Pakistan). Pakistan National Nutrition Survey 1985-1987.

Pakistan National Nutrition Survey 1985-1987 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Brazil - Anemia, Stunting, and Intestinal Parasites in the Maceió Public School Network as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Brazil - Pernambuco Second State Survey of Health and Nutrition 1997 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Cambodia Follow-up Survey of Households in Community Action for Social Development Villages 2000 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Cambodia Joint UNICEF-WFP Baseline Survey of CASD Project and WFP Target Areas 1998 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Central African Republic National Survey on Vitamin A Deficiency, Iron Deficiency and the Consumption of Iodized Salt 1998-1999 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Congo, DR Survey on the Prevalence of Anemia 2005 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Jeje B, Bategeki W, Mwikongi S, Njebete C, Nyang'ali E, Kimboka S, Ruhiye D, Mbunda J, Kaijage P, Mduma B, Ndossi G, Kisanga P. Tanzania Health and Nutrition Project-Component II. Baseline Survey Report. Dar es Salaam, The United Republic of Tanzania, Prime Minister's Office, Regional Administration, 1994.

Tanzania Health and Nutrition Project-Component II: Baseline Survey Report as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

South African Vitamin A Consultative Group (SAVACG). South Africa Anthropometric, Vitamin A, Iron and Immunisation Coverage Status in Children Aged 6 to 71 Months 1994.

Appendix Table A.3b - Citations for non-dismod model input data

South Africa Anthropometric, Vitamin A, Iron and Immunisation Coverage Status in Children Aged 6 to 71 Months 1994 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Peru - Biochemical Study of the Iron and Vitamin A Status: Regions Lima and Libertadores-Wari 1992-93 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Behavior of Nutrition Indicators in Peru: Monitoring National Nutritional Indicators 2002-2004 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Peru - National Report of Hemoglobin Levels and Prevalence of Anemia in Children 12 to 36 Months and Women of Childbearing Age 2003 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Peru National Nutrition Survey and Cultural Indicators, Biochemical, Socioeconomic Related Chronic Degenerative Diseases 2004-2005 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Ministry of Health (Panama). Panama National Survey on Vitamin A 1992.

Panama National Survey on Vitamin A 1992 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Panama National Survey on Vitamin A and Iron Deficiency Anemia 1999 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Nutritional Anemia and Vitamin A Deficiency in Oman: A Multivariate Analysis as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Oman - Health and Nutritional Status of Omani Families as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Oman Nutrition Status Survey 1979 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Oman - Evaluation of Nutritional Anemia Control Programme in the Sultanate of Oman as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

National Planning Commission (Nigeria), United Nations Children's Fund (UNICEF). Nigeria - Nutritional Status of Women and Children in Nigeria. New York, United States: United Nations Children's Fund (UNICEF), 1994.

Nigeria - Nutritional Status of Women and Children in Nigeria as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Nicaragua National Micronutrient Survey 2000 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Nicaragua National Survey of Micronutrient Deficiencies 1993 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

A Study on Hemoglobin Status and Food Practices of Myanmar Women as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Morocco National Survey of Iron Deficiency, Use of Iodized Salt, and Vitamin A Supplementation 2000 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Kachondham Y. Report on the 2nd National Child and Nutrition Survey, Mongolia 1999. Thailand, Institute of Nutrition, Faculty of Medicine, Ramathibodi Hospital Mahidol University, 2000.

Report on the 2nd National Child and Nutrition Survey, Mongolia 1999 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Mongolia Survey Assessing the Nutritional Consequences of the Dzud 2001 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Cameroon - Centre Water and Health in the Context of Component Development. Prevalence of Anemia in Mbandjock as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Cape Verde - Evaluation of the Nutritional Situation in the Republic of Cape Verde, 10-4 September 1977 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Ecuador Vitamin A Deficiency in Critical Poverty Provinces as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

High Institute of Public Health, Alexandria University, United Nations Children's Fund (UNICEF). Egypt - Menia, Assiut, and Sohag Assessment of Protein Energy Malnutrition, Iron Deficiency Anemia and Vitamin A Deficiency. Alexandria, Egypt: High Institute of Public Health, Alexandria University, 1997.

Egypt - Menia, Assiut, and Sohag Assessment of Protein Energy Malnutrition, Iron Deficiency Anemia and Vitamin A Deficiency as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

El Salvador Demographic Association (ADS), Institute of Nutrition of Central America and Panama, Ministry of Public Health and Social Assistance (El Salvador). El Salvador Assessment of Nutritional Food Situation 1988. Institute of Nutrition of Central America and Panama, 1990.

El Salvador Assessment of Nutritional Food Situation 1988 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

El Salvador - Evaluation of Nutritional Status, Serum Retinol (Vitamin A) and Hemoglobin in Schools as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

Results of Vitamin A, Anemia and Blood Lead Survey Among 2-4 Year Old Children and Reproductive-aged Women in Yap Proper and Kosrae State, Federated States of Micronesia as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Micronesia - Maternal-Child Health Survey: Pohnpei, Federated States of Micronesia, 1993 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Gabon - Estuaire Study of factors of anemia in a population of pregnant women in Libreville as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Ghana - Proceedings of the Workshop on Dissemination of Findings of Vitamin A and Anaemia Prevalence Surveys - 1998 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Grenada - Assessment of Iron Status of the Grenadian Population as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Guatemala National Micronutrient Survey 1995 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
National Survey of Iron Deficiency Anemia 2000 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Guyana National Food and Nutrition Survey 1971 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Jordan National Baseline Survey on Iron Deficiency Anemia and Vitamin A Deficiency 2002 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
An Investigation of Undernutrition in Iran Year 1380 [2001] as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
International Eye Foundation, John Snow, Inc., Ministry of Health (Honduras), USAID. Honduras National Micronutrients Survey 1996.
Honduras National Micronutrients Survey 1996 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Kenya Medical Research Institute (KEMRI), Ministry of Health (Kenya), Social Sciences and Medicine Africa Network (SOMA-NET), United Nations Children's Fund (UNICEF), University of Nairobi. Kenya National Micronutrient Survey 1999.
Kenya National Micronutrient Survey 1999 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Assessment of the Nutritional Status of Vulnerable Groups in Kuwait as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Iran Multi-center Study on Iron Deficiency Anemia Among 15 to 49 Year Old Women as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Micronutrient Study Report: An Assessment of the Vitamin A, E, Betacarotene, and Iron Status in Jamaica as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Jamaica - Nutritional and Health Determinants of School Failure and Dropout in Adolescent Girls in Kingston, Jamaica as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Preventing and Controlling Iron Deficiency in Kuwait: Short Term Consultancy 1-19 March 1997 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Mauritius Survey on the Nutritional Status of Preschool Children 1985 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Mauritania - Gorgol Survey of Anemia in Women of Childbearing Age 2000 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Marshall Islands National Nutrition Survey 1990-1991 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Maldives National Nutrition Survey 1994 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Kuwait - Nutritional Status of Kuwaiti Pregnant Women as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Prevalence and Selected Determinant of Iron Deficiency Anemia in Women and Under Five Children in Lebanon as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Liberia National Micronutrients Survey 1999 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Malaysia Family Health Sub System Health Management Information System 2004 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Malaysia Family Health Sub System Health Management Information System 2003 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
The Epidemiology of Anaemia in Kuwait as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
Mozambique - Manica School-based Iron/Folate Supplementation for Girls Pilot Project Baseline Survey 2001 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

Mozambique Survey on Vitamin A Deficiency and Prevalence of Anemia and Malaria 2001-2002 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Indonesia - Iron Status of Indonesian Adolescent School Girls After 16 Weeks Cessation of Weekly Iron Supplementation: A Randomized Controlled Trial as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Concentration of Hemoglobin and Plasma Ferritin are not Related to Riboflavin Status but to Vitamin A Status in Indonesian Adolescent Schoolgirls as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

India - Orissa Impact of Vitamin A Supplementation Delivered with Oral Polio Vaccine as Part of Immunization Campaign as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Bhargava SK, Singh KK, Saxena BN, India Council of Medical Research (ICMR). ICMR Task Force National Collaborative Study on Identification of High Risk Families, Mothers and Outcome of their Off-springs with particular reference to the problem of maternal nutrition, low birth weight, perinatal and infant morbidity and mortality in rural and urban slum communities. Summary, conclusions and recommendations. 1991; 28(12): 1473-80. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Ministry of Health (Malaysia). A Study of Malnutrition in Under Five Children in Malaysia. Kuala Lumpur, Malaysia: Ministry of Health (Malaysia), 1999.

Madagascar Survey on Vitamin A Deficiency in Women and Children and Survey of Anemia in Schoolchildren from 6-14 Years 2000 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Morasso M del C, Molero J, Vinocur P, Acosta L, Paccussi N, Raselli S, Falivene G, Viteri FE. [Iron and vitamin A deficiencies and prevalence of anemia in boys and girls between 6 to 24 months of age in Chaco, Argentina]. Arch Latinoam Nutr. 2003; 53(1): 21-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Ministry of Health (Nigeria). Nigeria Health and Nutrition Status Survey 1983-1984.

Ministry of Public Health (Niger). Niger National Survey on Morbidity and Mortality 1985.

Sahn DE. Malnutrition in Côte d'Ivoire: Prevalence and Determinants. Washington DC, United States: World Bank, 1990.

Central Bureau of Statistics (Kenya). Kenya Rural Child Nutrition Survey 1982.

Adrianasolo R. Madagascar Study of the Epidemiology of Breastfeeding. Ministry of Public Health (Madagascar), 1986.

Ministry of Health and Quality of Life (Mauritius), United Nations Children's Fund (UNICEF). Mauritius National Nutrition Survey 1985.

London School of Hygiene and Tropical Medicine. Afghanistan The Threat of Famine 1984. London, United Kingdom: Afghanistanid, 1984.

WHO Regional Office for the Eastern Mediterranean. Afghanistan - Jalalabad City and Internally Displaced People Camps Comparative Malnutrition Survey 1996.

World Health Organization (WHO). Afghanistan Nutrition Survey 1996.

Nutritional survey. Surrounding of Mehterlam (Laghman Province). Comprehensive Care for Malnourished Afghan Children.

Focus Humanitarian Assistance, Aga Khan Development Network (FOCUS). Afghanistan - Badakshan Children Under-5 Nutrition Survey 2000.

Action Against Hunger, World Food Programme (WFP). Afghanistan - Kabul City Nutritional and Mortality Survey 2000.

Action Against Hunger, World Food Programme (WFP). Afghanistan - Herat City Nutritional and Mortality Survey 2000.

Action Against Hunger. Afghanistan - Mazar-e Sharif City Nutritional and Mortality Survey 2000.

Action Against Hunger. Afghanistan - Faizabad City Nutritional and Mortality Survey 2000.

Action Against Hunger, World Food Programme (WFP). Afghanistan - Jalalabad City Nutritional and Mortality Survey 2000.

Action Against Hunger. Afghanistan - Kabul City Nutritional and Mortality Survey 2001.

Action Against Hunger. Afghanistan - Panjshir Valley and Shamali Plains Nutritional and Mortality Survey 2002.

Central Bureau of Statistics (Kenya). Kenya Child Nutrition Survey 1994.

Afghanistan Nutritional Anthropometry, Health, Food Security, and Agriculture Assessment 2001.

GOAL. Afghanistan - Jowzjan Nutrition Survey 2002.

Action Against Hunger. Afghanistan - Sang Charak District Nutritional Anthropometric Survey in Children Under-5 2002.

Save the Children Federation. Afghanistan - Kohistan District Nutritional and Food Security Survey 2002.

GOAL. Afghanistan - Samangan Nutrition Survey 2002.

International Federation of Red Cross and Red Crescent Societies. Azerbaijan Internally Displaced Persons Living in the Southern Camps and Surrounding Areas 1999.

Ministry of Public Health (Burundi). Burundi - Bubanza Food Survey in North and Central Imbo 1985.

Ministry of Public Health (Burundi). Burundi - Bururi Nutritional Survey in Bututsi 1985.

Appendix Table A.3b - Citations for non-dismod model input data

Nutritional Surveillance for Disaster Preparedness and Prevention of Nutritional Blindness: Seasonality of Nutritional Status. New York City, United States: Helen Keller International, 1993.

Chinese Academy of Preventive Medicine. China Pilot Study for the Food and Nutrition Surveillance System.

Baseline survey on the nutritional status of children under five years of age in Kabul. Data presented in the country report of Afghanistan for the International Conference on Nutrition 4-11 Dec 1992 in Rome.

Action Against Hunger. Afghanistan - Kabul Nutrition Survey 2000.

Institute of Tropical Medicine. Burundi Child Population Groups from 0-5 Years of Age: Percentage of Children Below -2 SDs of the National Center for Health Statistics Reference. Antwerp, Belgium: Institute of Tropical Medicine, 1986.

Nutrition intervention: an anthropometric evaluation of changes in nutritional status, with reference to the National Nutrition Program in Bahia, Brazil [thesis]. London: London School Hygiene and Tropical Medicine, 1981.

Review of the 100-county growth survey procedures and results. A consultation report. China: UNICEF, 1991.

Nutritional status of children - 1992 Child Survey. State Statistic Bureau. Presented at 7th Asian Congress of Nutrition. Beijing, China, 1995.

Growth standards for Hong Kong: a territory wide survey in 1993. Hong Kong: The Chinese University of Hong Kong, 1995.

National document of Cape Verde for the International Conference of Nutrition. Provisional data presented in table III, annex 2. Rome: FAO/WHO, 1992.

Costa Rican Institute for Research and Education on Nutrition and Health, Costa Rican Social Security Fund (CCCS), Institute of Nutrition of Central America and Panama, Ministry of Health (Costa Rica), National Institute of Statistics and Censuses (Costa Rica). Costa Rica National Nutrition Survey 2008-2009.

Nutrition and Food Hygiene Institute (Cuba). Cuba National Survey of the Nutrition and Food Hygiene Institute 2005.

Nutritional baseline survey for the integrated food security programme in Gash and Setit. Eschborn: Deutsche Gesellschaft für Internationale Zusammenarbeit, 1994.

The impact of supplementary feeding programmes on the nutritional status of beneficiaries in Addis Ababa. Ethiopian Nutrition Institute. Addis Ababa, Ethiopia; 1982.

Central Statistical Agency (Ethiopia). Ethiopia National Rural Nutrition Survey 1982-1983.

WHO/UNICEF Joint Nutrition Support Programme. Annual Report. Addis Ababa, Ethiopia, October 1985.

National Center for Disease Control and Public Health (Georgia), United Nations Children's Fund (UNICEF). Georgia National Nutrition Survey 2009.

Prevalence of undernutrition in the western Highlands of Guatemala during the 1980s: preschoolers. Guatemala: INCAP, 1988.

Malnutrition and poverty in Guatemala. Policy Research Working Paper 2967. The World Bank, Latin America and the Caribbean Region, Human Development Sector Unit, 2003.

Ministry of Public Health and Population (Haiti), Pan American Health Organization (PAHO), United Nations Children's Fund (UNICEF), World Health Organization (WHO). Nutritional Surveillance for Program Planning: Haiti 1995 Nutrition Surveys by Department. Port-au-Prince, Haiti: Ministry of Public Health and Population (Haiti), 1997.

Helen Keller International. Indonesia - South Kalimantan and South Sulawesi Localvita Project Baseline Survey 1996-1997.

Nutritional survey, Ambon Island, Moluccas Province, Indonesia. Action Contre la Faim, 1999.

Steinhoff MC, Hilder AS, Srilatha VL, Mukarji D. Prevalence of malnutrition in Indian preschool-age children: a survey of wasting and stunting in rural Tamil Nadu, 1983. Bull World Health Organ. 1986; 64(3): 457-463.

Nutritional status survey at primary health centres during polio national immunization days in Iraq. Baghdad: UNICEF, 1997.

FAO/WFP food supply and nutrition assessment mission to Iraq. Rome: FAO and WFP, 1997

Nutritional status of children under five in the Autonomous Northern Region, Iraq. Baghdad, Iraq, 1998

Nutritional status survey of infants in Iraq (15 governorates in the South/Centre). Baghdad, Iraq, 1998.

Nutrition survey of children under two attending routine immunization sessions at primary health care centres in Iraq. Baghdad, Iraq, 1999.

Integrated nutritional status survey of under five years and breastfeeding/ complementary feeding practices of under two years in South/Center Iraq. Baghdad, Iraq: UNICEF, 2002.

Baseline survey on nutrition and health for the Marsabit development programme. Eschborn: German Agency for Technical Cooperation, 1994.

Kakuma refugee camp: results of the nutrition and immunization coverage surveys, April 1997. Nairobi: Tuasha & Associates consulting agency, 1997.

Anthropometric and micronutrient nutrition survey: Kakuma refugee camp, NW Kenya, 22 March - 12 April 2001. International Rescue Committee, UNHCR and Centre for International Child Health -Institute of Child Health, 2002.

Physical growth patterns of Lebanese infants and children. American University of Beirut. Beirut, Lebanon; 1986.

Medical Research Institute (Sri Lanka), Ministry of Policy Planning and Implementation (Sri Lanka). Sri Lanka Nutritional Status Survey 1988-1989.

Medical Research Institute (Sri Lanka). Sri Lanka Vitamin A Deficiency Status of Children Survey 1995-1996.

Appendix Table A.3b - Citations for non-dismod model input data

Food and Nutrition Coordination Office (FNCO) (Lesotho). Lesotho National Nutrition Survey 2007.
National control of intestinal parasitic infection with a view to improve nutritional status of mothers and children in Maldives (travel report). New Dehli: WHO Regional Office South-east Asia, 1996.
An epidemiological study of the current nutritional demographic status of two populations of the Gao Region (Mali). Geneva: League of Red Cross and Red Crescent Societies, 1985.
Feeding practices in infants and young children in Rangoon Division. 1980-1981. Rangoon, Myanmar, 1981.
Ministry of Health (Myanmar). Myanmar National Nutrition Survey 1991.
Ministry of Health (Myanmar). Myanmar National Nutrition Survey 1994.
Ministry of Health (Swaziland). Swaziland National Nutrition Survey 2008.
Report of a consultancy on the Mongolian Child Nutrition Survey. Institute of Nutrition. Nakornpathom, Thailand, 1992.
Mozambique Vulnerability Assessment Committee. Mozambique Emergency Vulnerability Report November-December 2002. Maputo, Mozambique: Mozambique Vulnerability Assessment Committee, 2003.
National Statistical Office of Malawi. Malawi National Sample Survey of Agriculture 1980-1981.
Government of Malawi. A Relative Profile of Poverty in 1998: A Quintile-based Poverty Analysis of the Malawi Integrated Household Survey 1997-98.
Department of Nutrition, HIV and AIDS in the Office of President and Cabinet (DHNA-OPC), Ministry of Health (MOH), National Statistics Office (NSO), UNICEF and CDC. The national micronutrient survey 2009. Lilongwe, Malawi: Ministry of Health, UNICEF, Irish Aid and CDC, 2011.
Status of community nutrition in poverty kampungs. Bulletin of the Institute for Medical Research No. 22. Malaysia, 1984.
Ministry of Health and Social Services (Namibia), United Nations Children's Fund (UNICEF). Namibia Household Health and Nutrition Survey 1990. New York, United States: United Nations Children's Fund (UNICEF).
International Food Policy Research Institute (IFPRI). Poverty, Household Food Security, and Nutrition in Rural Pakistan. Washington, D.C., United States: International Food Policy Research Institute (IFPRI), 1993.
Centers for Disease Control and Prevention (CDC), Doctors Without Borders (MSF), United Nations High Commissioner for Refugees (UNHCR). Pakistan - Balochistan and North West Frontier Afghan Refugee Infant Mortality and Childhood Nutritional Status Survey 1990.
Survey of nutritional status of children under five among Afghan refugees in Balochistan, Pakistan, 1991. Peshawar: MSF Holland, 1992.
United Nations High Commissioner for Refugees (UNHCR). Pakistan Survey of Nutritional Status and Infant Mortality of Afghan Refugee Children 1992.
Evaluation of the nutritional status of Afghan refugee children in NWFP/Punjab and Balochistan, Pakistan, 1994. Peshawar: UNHCR, 1994.
United Nations High Commissioner for Refugees (UNHCR). Pakistan - Nutritional Survey of Afghan Refugees in Balochistan, NWFP and Punjab 1995.
United Nations High Commissioner for Refugees (UNHCR). Pakistan Nutrition Survey of Afghan Refugees 1997.
Government of Sindh (Pakistan), CIET International, United Nations Children's Fund (UNICEF). Sindh Maternal Care Survey 1998.
Doctors Without Borders (MSF). Pakistan Nutritional Survey of Shamshatoo Refugee Camp, Peshawar, N.W.F.P. 2000.
Doctors Without Borders (MSF). Pakistan - Balochistan Baseline Nutritional Assessment Survey Report in Landi Karez Afghan Refugee Camp in Chaman District 2002.
Jenkins C, Zemel B. Ancient diversity and contemporary change in the growth patterns of Papua New Guinea children. Presented at: 59th Annual Meeting of the American Association of Physical Anthropologists; 1990; Miami, Florida.
European Commission (EC), Government of North Korea, United Nations Children's Fund (UNICEF), World Food Programme (WFP). Korea, North Nutrition Survey 1998.
United Nations Relief and Works Agency (UNRWA). UNRWA Nutrition Survey of Palestinian Refugees 1990.
Kumar B. Assessment of the Nutritional Status of Children Under 5 in the Gaza Strip. Jerusalem: Terres Des Hommes (Ard El Insan), 1995.
Centers for Disease Control and Prevention (CDC), United Nations Relief and Works Agency (UNRWA). Palestine - Gaza Strip Nutrition Survey 1998.
Federal Ministry of Health (Sudan). Sudan Nutrition Monitoring Report 1 1988.
Federal Ministry of Health (Sudan). Sudan Nutrition Monitoring Report 2 1988.
Ministry of Health. Reports on the nutrition monitoring programme in the displaced settlements of Greater Khartoum. Khartoum, Sudan; 1991.
Federal Ministry of Health (Sudan). Sudan - Red Sea Nutrition Survey 1990.
Federal Ministry of Health (Sudan). Sudan - Northern Kordofan Nutrition Survey 1990.
Federal Ministry of Health (Sudan). Sudan - Red Sea Nutrition Survey 1991.
Federal Ministry of Health (Sudan). Sudan - Hamadi and Debeit Rural Councils Nutrition Survey 1991.

Appendix Table A.3b - Citations for non-dismod model input data

Federal Ministry of Health (Sudan). Sudan - Hamrat El Wiz and Gebrat El Sheik Rural Councils Nutrition Survey 1992.
Ministry of Health. Report on the nutrition monitoring programme in the displaced settlements of Greater Khartoum. Khartoum, Sudan; 1992.
Federal Ministry of Health (Sudan). Sudan - El Fasher Rapid Assessment Nutrition Survey 1992.
Federal Ministry of Health (Sudan). Sudan - White Nile Nutrition Survey 1992.
Federal Ministry of Health (Sudan). Sudan - Blue Nile Nutrition Survey 1993.
Federal Ministry of Health (Sudan). Sudan - Kassala Nutrition Survey 1994.
Federal Ministry of Health (Sudan). Sudan - Kordofan Nutrition Survey 1994.
Sudan - Upper Nile Health and Nutrition Survey 1995
Federal Ministry of Health (Sudan). Sudan - Gedaref Nutrition Survey 1995.
Federal Ministry of Health (Sudan). Sudan - White Nile Nutrition Survey 1995.
Federal Ministry of Health (Sudan). Sudan - Gedaref Nutrition Survey 1996.
Directorate of Forecasting and Statistics (Senegal). Senegal Social Dimensions of Adjustment Household Priority Survey 1991-1992.
Solomon Islands A Nutrition Survey of Infants and Children in the Community Accessible to Atoifi, Adventist Hospital
The prevalence of acute malnutrition and edema in Sierra Leonean refugee children living in Koulumba, Guinea. Survey report by the Gueckedou Ministry of Health and Medecins sans Frontières Belgium. Gueckedou, Guinea; 1992.
Action Against Hunger. Sierra Leone - Southern Nutritional Survey of Bo Township 1995.
Action Against Hunger. Sierra Leone - Western Area Nutritional Survey of Freetown 1995.
Action Against Hunger. Somalia - Banaadir Nutritional Survey in Mogadishu 1994.
Action Against Hunger. Somalia - Gedo Nutritional Anthropometric Survey in Bardera 1995.
Action Against Hunger. Somalia - Banaadir Nutritional Anthropometric Survey of Displaced and Residents in Mogadishu 1995.
Food Security Assessment Unit (Somalia), United Nations Children's Fund (UNICEF). Somalia - Gedo Nutrition Survey May 2000.
National Institute of Statistics and Censuses (Argentina). Argentina Childhood Living Conditions. Buenos Aires, Argentina: National Institute of Statistics and Censuses (Argentina), 1996.
Armenia Refugee Nutrition Survey 1993
Report on the nutritional status of vulnerable groups in Antigua & Barbuda. Jamaica: Caribbean Food and Nutrition Institute, 1982 (and additional analysis).
Helen Keller International, Institute of Public Health Nutrition (Bangladesh). Bangladesh Nutritional Blindness Study 1982-1983.
Bangladesh Bureau of Statistics. Bangladesh Child Nutrition Status Survey 1989-1990.
Bangladesh Bureau of Statistics. Bangladesh Child Nutrition Survey 1992.
Bangladesh Bureau of Statistics, United Nations Children's Fund (UNICEF). Bangladesh Child Nutrition Survey 1995-1996.
Helen Keller International. Bangladesh Annual Report of the Nutritional Surveillance Project 2001. New York City, United States: Helen Keller International, 2002.
Bloem MW, Moench-Pfanner R, Panagides D, eds. Health and Nutritional Surveillance for Development. Singapore: Helen Keller Worldwide; 2003.
Helen Keller International, Institute of Public Health Nutrition (Bangladesh). Bangladesh in Facts and Figures: Annual Report of the Nutritional Surveillance Project 2003. New York City, United States: Helen Keller International, 2004.
Helen Keller International, Institute of Public Health Nutrition (Bangladesh). Bangladesh in Facts and Figures: 2004 Annual Report of the Nutritional Surveillance Project. New York City, United States: Helen Keller International, 2005.
National Center of Public Health and Analyses (Bulgaria). Bulgaria National Nutrition Survey 2004.
Centers for Disease Control and Prevention (CDC), United States Agency for International Development (USAID). Bolivia National Nutrition Survey 1981.
Ministry of Planning and Coordination (Bolivia), Office of Scientific and Technical Research Overseas (ORSTOM) (France). Bolivia Farmers and the Crisis: A Study of Rural Communities. La Paz, Bolivia: Ministry of Planning and Coordination (Bolivia), 1987.
Ministry of Health and Education (Bhutan). Bhutan National Anthropometric Survey of Under Five Children 1999.
Ministry of Health, National Statistics Bureau and Centre for Research Initiative. National Nutrition, Infant & Young Child Feeding Survey 2008. Thimphu, Bhutan: Ministry of Health and UN.
China National Growth Development Survey of Children 1987
Chen Chunming, He Wu, Wang Yuying. Nutritional status of children aged 0-5 years old in China (1990) - National surveillance system in 7 provinces. Beijing, China: Chinese Center for Disease Control and Prevention, 2010.
Chen Chunming, He Wu, Wang Yuying. Nutritional status of children aged 0-5 years old in China (1995) - National surveillance system in 7 provinces. Beijing, China: Chinese Center for Disease Control and Prevention, 2010.

Appendix Table A.3b - Citations for non-dismod model input data

- Chen Chunming, He Wu, Wang Yuying. Nutritional status of children aged 0-5 years old in China (1998) - National (40 nutrition surveillance sites from 26 provinces). Beijing, China: Chinese Center for Disease Control and Prevention, 2010.
- Chen Chunming, He Wu, Wang Yuying. Nutritional status of children aged 0-5 years old in China (2000) - National (40 nutrition surveillance sites from 26 provinces). Beijing, China: Chinese Center for Disease Control and Prevention, 2010.
- Chen Chunming, He Wu, Wang Yuying. Nutritional status of children aged 0-5 years old in China (2005) - National (40 nutrition surveillance sites from 26 provinces). Beijing, China: Chinese Center for Disease Control and Prevention, 2010.
- Chen Chunming, He Wu, Wang Yuying. Nutritional Status of Children Aged 0-5 Years Old in China (2008) - National (26 Nutrition Surveillance Sites from Rural Areas). Beijing, China: Chinese Center for Disease Control and Prevention, 2010.
- Chen Chunming, He Wu, Wang Yuying. Nutritional Status of Children Aged 0-5 Years Old in China (2010) - National (38 Nutrition Surveillance Sites from 25 Provinces). Beijing, China: Chinese Center for Disease Control and Prevention, 2012 (and additional analysis).
- Chen Chunming, He Wu, Wang Yuying. Nutrition and Rapid Economic Development - 2010 Research Report on Nutrition Policy in China. Beijing, China: Chinese Center for Disease Control and Prevention, 2010 (and additional analysis).
- Centers for Disease Control and Prevention (CDC), Ministry of Health and Population (Egypt), National Nutrition Institute (Egypt), United States Agency for International Development (USAID). Egypt Nutrition Status Survey 1980.
- Lhotska L, Blaha P, Vignerova J, Roth Z, Prokopec M. Vth. Nation-wide anthropological survey of children and adolescents 1991 (Czech Republic). Prague: National Institute of Public Health, 1993 (and additional analysis).
- National Institute of Public Health (Czech Republic). Czech Republic Sixth Nationwide Anthropological Survey of Children and Adolescents 2001.
- European Community Humanitarian Office (ECHO), International Committee for the Development of Peoples (CISP), National Institute for Research on Food and Nutrition (INRAN) (Italy). Algeria Strategies to Fight Anemia and Growth Retardation in Saharawi Refugee Children.
- Ministry of Finance and Development. Children and women in Eritrea: 1994. Government of the State of Eritrea/UNICEF Situation Analysis. Asmara, Eritrea, 1994 (and additional analysis).
- Centers for Disease Control and Prevention (CDC), National Center for Disease Control and Public Health (Georgia), Save the Children USA. Georgia Nutritional Status of Children Less than Five Years of Age in Six Drought Affected Regions 2000-2001.
- Buzina R, Buzina-Suboticanec K, Kapetanovic T. Growth and nutritional status of children in kindergartens in Croatia 1988-1990. Institute of Public Health and Institute of Mother and Child Health. Zagreb, Croatia
- Growth monitoring of preschool children: an overall report 1993-1996. Zagreb: United Nations Children's Fund, 1997 (and additional analysis).
- Government of Indonesia, Helen Keller International. Indonesia Nutrition and Health Surveillance System Annual Report 2000-2001.
- Caribbean Food and Nutrition Institute, Pan American Health Organization. Guyana Nutritional Status Survey 1981.
- Institute of Nutrition of Central America and Panama, Management Sciences for Health (MSH), Ministry of Health (Honduras). Honduras National Nutrition Survey 1987.
- Scott W, Mathew NT. A Development Monitoring Service at the Local Level: Monitoring Change in Kerala: The First Five Years. Geneva, Switzerland: United Nations Research Institute for Social Development (UNRISD), 1985.
- Ford Foundation, Nutrition Foundation of India. India Profiles of Undernutrition and Underdevelopment: Studies of Poor Communities in Seven Regions of the Country. New Delhi, India: Nutrition Foundation of India. (Scientific Report Series No. 8).
- National Nutrition Monitoring Bureau (India). India National Nutrition Monitoring Bureau Eight States Pooled Data 1988-1990.
- National Institute of Nutrition (India), National Nutrition Monitoring Bureau (India). India National Nutrition Monitoring Bureau Eight States Pooled Data 1991-1992.
- Djazavery A. Nutritional status of rural Iranian children. Abstract No 497, XII International Nutrition Congress. San Diego, California, 1981 (and additional analysis).
- Nutrition and health surveillance system (NNS) - Monitoring the economic crisis: Impact and Transition, 1998-2000. Jakarta: Helen Keller International/Indonesia, 2000 (and additional analysis: urban slums in Jakarta).
- Center for Economic and Social Rights (CESR). Iraq Infant and Child Mortality and Nutrition Survey 1991.
- Institute of Nutrition and Food Technology, Shaheed Beheshti Medical University (Iran). Iran Rapid Nutritional Assessment of 0 to 5 Year Old Kurdish Refugee Children.
- Central Statistical Organization (Iraq), Ministry of Health (Iraq), World Food Programme (WFP). Iraq Baseline Food Security Analysis 2003.
- Planning Institute of Jamaica, Statistical Institute of Jamaica. Jamaica Survey of Living Conditions 2004.
- Planning Institute of Jamaica, Statistical Institute of Jamaica. Jamaica Survey of Living Conditions 2006.
- Planning Institute of Jamaica, Statistical Institute of Jamaica. Jamaica Survey of Living Conditions 2007.
- Central Bureau of Statistics (Kenya). Kenya Rural Child Nutrition Survey 1987.
- Popkin B, Martinchik AN. Nutritional conditions of the Kyrgyz population, 1993. Chapel Hill: University of North Carolina, 1994 (and additional analysis).
- Ministry of Health (Cambodia), United Nations Children's Fund (UNICEF). Cambodia Nutritional Status Survey in 12 Villages 1993-1994.
- Helen Keller International, Ministry of Health (Cambodia). Cambodia National Micronutrient Survey 2000.

Appendix Table A.3b - Citations for non-dismod model input data

- Ministry of Health and Family Planning (Kiribati). Kiribati National Nutrition Survey 1985.
- German Technical Cooperation Agency (GTZ). Laos - IFSP Nutrition Survey Muang Sing and Nalae Luang, Namtha Province 1997.
- Kaufmann S. Nutrition and poverty situation in Nalae and Sing districts: Achievements after four years of intensive interventions. Lao-German Integrated Food-Security Programme (IFSP) Muang Sing and Nalae, Luan Namtha Province, Laos P.D.R. Eschborn: GTZ, 2001.
- Ministry of Health and Social Welfare (Liberia), United Nations Children's Fund (UNICEF). Liberia National Nutrition Survey 1999-2000.
- Ministry of Policy Planning and Implementation (Sri Lanka). Sri Lanka Food and Nutrition Statistics 1982.
- Medical Research Institute (Sri Lanka), United Nations Children's Fund (UNICEF), World Food Programme (WFP). Sri Lanka Nutrition and Food Security Assessment 2009.
- Ministry of Health and Social Services. Nutrition surveillance. Maseru, the Kingdom of Lesotho, 1981 (and additional analysis).
- Department of Public Health. Nutrition Research Project on the Seenu Atoll. Maldives; 1982.
- Ministry of Health (Maldives). Maldives Health Survey 1983.
- Ministry of Planning and National Development (Maldives), United Nations Development Programme (UNDP). Maldives Vulnerability and Poverty Assessment 1997-1998.
- Daw Cho Nwe Oo. Feeding practices in young children and infants. Department of Medical Research, Rangoon, Myanmar, 1986 (and additional analysis).
- Ministry of Health (Myanmar). Myanmar National Nutrition Survey 1997.
- Public Health Institute, Ministry of Health (Mongolia). Mongolia Nutrition Research Center Survey 1997.
- Ministry of Health (Oman). Oman National Nutrition Survey 1991.
- Ministry of Health (Oman). Oman National Study on the Prevalence of Vitamin A Deficiency Among Children 6 Months to 7 Years.
- Franklin DL, Harrell M, Tamaro J, Frazao B, Vial I, Parillon C. Nutrition evaluation project: second annual report. North Carolina: Research Triangle Institute, 1982 (and additional analysis.)
- National Economics and Statistics Section. Regional Updating of Nutritional Status of Filipino Children, 1989-90. Food and Nutrition Research Institute. Manila, Philippines; 1991 (and additional analysis).
- Department of Science and Technology. The 1992 regional nutrition survey. Food and Nutrition Research Institute. Manila, Philippines; 1994 (and additional analysis).
- Ministry of Health (Seychelles). Seychelles Nutritional Status of Children.
- Ministry of Health (Togo), United Nations Children's Fund (UNICEF). Togo National Survey of Nutrition and Survival of Children Aged 0 to 59 Months 2008.
- Faculty of Tropical Medicine, Mahidol University. Report on the improvement of health and nutrition in the Nam Pong irrigation area, northeast Thailand. Bangkok; 1981.
- Thailand Child Population Groups from 0-5 Years of Age - Percentage of Children Below -2 SDs of the National Center for Health Statistics Reference
- Thailand Nutritional Change and Ten Years of Development in the Northeast
- Kachondham Y, Winichagoon, Tontisirin K. Nutrition and health in Thailand: trends and actions. United Nations ACC/SCN, Institute of Nutrition, Mahidol University. Bangkok, Thailand; 1992.
- CARE International, Centers for Disease Control and Prevention (CDC). Tajikistan Rapid Food Security and Nutrition Assessment 1994.
- Wstefeld M. Food security, health and nutritional status analysis of the population of selected districts in Leninabad region and the Regions of Republican Subordination in Tajikistan. Bonn: Deutsche Welthungerhilfe and German Agro Action, 1996.
- Action Against Hunger. Tajikistan National Nutrition Survey 1999.
- Action Against Hunger. Tajikistan National Nutrition Survey 2000.
- Action Against Hunger. Tajikistan National Nutrition Survey 2001.
- Action Against Hunger, European Community Humanitarian Office (ECHO). Tajikistan National Nutrition Survey 2002.
- German Technical Cooperation Agency (GTZ). Timor-Leste Nutrition Baseline Survey: Baucau and Viqueque 2003.
- Mpanju WFK, Msamanga GI, Gerverdinck IHA, Kabalimu TK, Kawau FMN, Rongo LMB, et al. Assessment of nutritional status and associated factors of under-fives in Dar es Salaam region from 9-23 September 1991. Institute of Public Health, Muhimbili University College of Health Sciences. Dar es Salaam, Tanzania; 1992.
- Gerverdinck IHA, Kawau FMN, Kabalimu TK, Rongo LMB, Munubi, Urassa D, et al. Nutritional status and associated factors of under-fives in Handeni rural from 6-20 September 1992. Institute of Public Health, Muhimbili University College of Health Sciences. Dar-es-Salaam, Tanzania; 1993.
- Uganda Northeast Uganda Rural Health, Water and Community Development Project Baseline Survey 1985
- Vella V. An epidemiological analysis of predictors of childhood malnutrition and mortality in southwest Uganda [dissertation]. London: University of London, 1990.
- National Institute of Nutrition (Venezuela). Venezuela National Nutrition Survey 1981-1982.

Appendix Table A.3b - Citations for non-dismod model input data

- Fundacresta- Division de Investigaciones Biologicas. Proyecto Venezuela- Classification Nutricional Antrometria [Project Venezuela: Nutritional Anthropometry Classification]. 1987.
- Foundation Center for Studies on Growth and Development of the Venezuelan Population (FUNDACREDESA). Project Venezuela 1981-1987.
- Tu Giay, Ha Huy Khoi, Luong Tan Thanh. Some characteristics about protein energy nutritional status in Vietnamese children. In: Applied nutrition, proceedings of the international conference on applied nutrition, Hanoi 25/26 April 1986, pp. 201-208 (and additional analysis).
- National Institute of Nutrition (Vietnam). Vietnam National Protein Energy Malnutrition Survey 1998.
- Khoi HH, Khan NC, Tuyen LD, Ngu T, Xuan TT. 1999 Viet Nam - child nutrition situation. The national goal for child malnutrition control. Hanoi: Medical Publishing House, 2000 (and additional analysis.)
- National Institute of Nutrition and General Statistical Office. 2000 - Vietnam child and mother nutrition situation. Hanoi: Medical Publishing House, 2001 (and additional analysis).
- Department of Health (South Africa). South Africa Anthropometric Survey in Primary Schools 1994.
- Valdez EC. [Epidemiological Investigation Report in the District of Agbangnizoun] Rapport d'enquête épidémiologique dans le district d'Agbangnizoun. Institut Universitaire d'Etudes du Développement. Genève, Suisse; 1989
- Valdez EC. Epidemiological Investigation Report for the Sub-Prefecture of Tchaourou. Graduate Institute of Development Studies: Geneva, Switzerland; 1991.
- Nakoulma GA. Land Issues, Agricultural Production and Nutritional Status of Rural Populations in Central Burkina Faso [dissertation]. Lausanne, Switzerland: Société Nouvelle, Jacques & Demontrond, 1998.
- Helen Keller International. Bangladesh Nutritional Surveillance Project Data on Urban Poor Using the WHO Child Growth Standards 1991.
- Helen Keller International. Bangladesh Nutritional Surveillance Project Data on Urban Poor Using the WHO Child Growth Standards 1992.
- Helen Keller International. Bangladesh Nutritional Surveillance Project Data on Urban Poor Using the WHO Child Growth Standards 1993.
- Helen Keller International. Bangladesh Nutritional Surveillance Project Data on Urban Poor Using the WHO Child Growth Standards 1994.
- Helen Keller International. Bangladesh Nutritional Surveillance Project Data on Urban Poor Using the WHO Child Growth Standards 1995.
- Helen Keller International. Bangladesh Nutritional Surveillance Project Data on Urban Poor Using the WHO Child Growth Standards 1996.
- Helen Keller International. Bangladesh Nutritional Surveillance Project Data on Urban Poor Using the WHO Child Growth Standards 1997.
- Helen Keller International. Bangladesh Nutritional Surveillance Project Data on Rural National Using the WHO Child Growth Standards 1998.
- Helen Keller International. Bangladesh Nutritional Surveillance Project Data on Urban Poor Using the WHO Child Growth Standards 1998.
- Helen Keller International. Bangladesh Nutritional Surveillance Project Data on Urban Poor Using the WHO Child Growth Standards 1999.
- Helen Keller International. Bangladesh Nutritional Surveillance Project Data on Urban Poor Using the WHO Child Growth Standards 2000.
- Helen Keller International. Bangladesh Nutritional Surveillance Project Data on Urban Poor Using the WHO Child Growth Standards 2001.
- Helen Keller International. Bangladesh Nutritional Surveillance Project Data on Urban Poor Using the WHO Child Growth Standards 2002.
- Helen Keller International. Bangladesh Nutritional Surveillance Project Data on Urban Poor Using the WHO Child Growth Standards 2003.
- Helen Keller International. Bangladesh Nutritional Surveillance Project Data on Urban Poor Using the WHO Child Growth Standards 2004.
- Helen Keller International. Bangladesh Nutritional Surveillance Project Data on Urban Poor Using the WHO Child Growth Standards 2005.
- Helen Keller International. Bangladesh Nutritional Surveillance Project Data on Urban Poor Using the WHO Child Growth Standards 2006.
- Helen Keller International. Bangladesh Nutritional Surveillance Project National Rural Data Using the WHO Child Growth Standards 1991.
- Helen Keller International. Bangladesh Nutritional Surveillance Project National Rural Data Using the WHO Child Growth Standards 1992.
- Helen Keller International. Bangladesh Nutritional Surveillance Project National Rural Data Using the WHO Child Growth Standards 1993.

Appendix Table A.3b - Citations for non-dismod model input data

Helen Keller International. Bangladesh Nutritional Surveillance Project National Rural Data Using the WHO Child Growth Standards 1994.
Helen Keller International. Bangladesh Nutritional Surveillance Project National Rural Data Using the WHO Child Growth Standards 1995.
Helen Keller International. Bangladesh Nutritional Surveillance Project National Rural Data Using the WHO Child Growth Standards 1996.
Helen Keller International. Bangladesh Nutritional Surveillance Project National Rural Data Using the WHO Child Growth Standards 1999.
Helen Keller International. Bangladesh Nutritional Surveillance Project National Rural Data Using the WHO Child Growth Standards 2000.
Helen Keller International. Bangladesh Nutritional Surveillance Project National Rural Data Using the WHO Child Growth Standards 2001.
Helen Keller International. Bangladesh Nutritional Surveillance Project National Rural Data Using the WHO Child Growth Standards 2002.
Helen Keller International. Bangladesh Nutritional Surveillance Project National Rural Data Using the WHO Child Growth Standards 2003.
Helen Keller International. Bangladesh Nutritional Surveillance Project National Rural Data Using the WHO Child Growth Standards 2004.
Helen Keller International. Bangladesh Nutritional Surveillance Project Rural Data Using the WHO Child Growth Standards 2005.
Helen Keller International. Bangladesh Nutritional Surveillance Project National Rural Data Using the WHO Child Growth Standards 2006.
Helen Keller International, Institute of Public Health Nutrition (Bangladesh). Bangladesh Nutrition and Health Surveillance in the Chittagong Hill Tracts.
Victora CG, Barros FC, Horta BL, Cesar JA. Saude e nutricao das criancas nordestinas; pesquisas estaduais 1987-92. UNICEF/Universidade Federal de Pelotas. Brasilia: UNICEF, 1995.
Ministry of Public Health and Population (Central African Republic). Central African Republic Nutrition Survey 1995.
Avila B, Garcia F, Vera G. [Food nutrition situation of Chile, period 1984-87] [Situacion alimentaria nutricional de Chile, periodo 1984-87.] Santiago de Chile: Universidad de Chile, 1988 (and additional analysis).
Ministerio de Salud, SISVAN. [Chile Nutritional Status of the Child Population 1987] Estado nutricional de la poblacion infantil, 1986. Santiago, Republica de Chile, 1987 (and additional analysis).
Ministerio de Salud. [Annual Nutrition Monitoring Newsletter 1998] Boletin anual de vigilancia nutricional, año 1998. Departamento Coordinacion e Informatica. Santiago, Republica de Chile, 1999 (and additional analysis).
Ministerio de Salud. [Annual Nutrition Monitoring Newsletter 1999] Boletin anual de vigilancia nutricional, año 1998. Departamento Coordinacion e Informatica. Santiago, Republica de Chile, 1999 (and additional analysis).
Cote d'Ivoire - Bas-Sassandra Nutritional Survey of a Population of Liberian Refugees in the Prefecture of Tabou 1994
Tschannen AB, Rohner F, Gohou V, Bosso E, Malan A. [Evaluation of Vitamin A and Iron Deficiencies in Côte d'Ivoire] Evaluation des carences en vitamine A et fer en Côte d'Ivoire (Rapport final). Ministère de la Santé et de l'Hygiène Publique et Helen Keller Int., Abidjan, Côte d'Ivoire, 2009 (and additional analysis).
United Nations Children's Fund (UNICEF). Afghanistan Multiple Indicator Baseline Survey 1997.
Ministry of Human Development (Bolivia), National Directorate of Epidemiology (Bolivia), United Nations Children's Fund (UNICEF). Bolivia National Survey of Multiple Indicators 1996 .
Ministry of Health (Myanmar), United Nations Children's Fund (UNICEF). Myanmar Multiple Indicator Cluster Survey 2003.
Central Bureau of Statistics (Indonesia), United Nations Children's Fund (UNICEF). Indonesia Multiple Indicator Cluster Survey 1995.
Central Bureau of Statistics (Sudan), Federal Ministry of Health (Sudan), United Nations Children's Fund (UNICEF), University of Khartoum. Sudan Multiple Indicator Cluster Survey 1995.
National Planning Commission. Nepal multiple indicator surveillance: cycle I, Jan to March 1995 health and nutrition - final report (MICS). Kathmandu, Nepal, 1996.
[Anthropometric Characteristics of a Socio-Economically Privileged Group of Children in Brazzaville] Caractéristiques anthropométriques d'un groupe enfants socio-économique privilégié à Brazzaville. In: Lemonnier D, Ingenbleek Y (eds). Les carences nutritionnelles dans les pays en voie de developpement. Paris: ACCT, 1989;57-62.
Ferreira Medina JB, Skard T, Sobhy S, America Ungaretti M. [The Health of Children Under Five Years of Age in Cape Verde] A saude das criancas menores de cinco anos em Cabo Verde. Ministério de Saude e Promoção Social e UNICEF. Cabo Verde, 1996 (and additional analysis.)
Ministry of Health (Costa Rica). Costa Rica National Nutrition Survey 1982.
Ministère de la Santé Publique et de la Population. [Comoros Report on the Nutritional Status and the Factors Involved in Children Less Than Two Years 1991] Rapport sur l'état nutritionnel et les facteurs impliqués chez les enfants de moins de deux ans en République Fédérale Islamique des Comores 1991. Direction de la Santé Familiale. Comores, 1995.
Costa Rican Institute for Research and Education on Nutrition and Health, Ministry of Health (Costa Rica). Costa Rica National Nutrition Survey 1996.

Appendix Table A.3b - Citations for non-dismod model input data

- Bruxelle J. Prospective epidemiologic study of painful and neurologic sequelae induced by herpes zoster in patients treated early with oral acyclovir. *Neurology*. 1995; 45(12 Suppl 8): S78-9.
- Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, Patrick D, Blanchette C, Mansi JA. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. *CMAJ*. 2010; 182(16): 1731-6.
- Ministerio de Salud Publica. [Nutrition Situation of the Country 1988] Situacion nutricional del pais, Cuba 1988. Report to the ACC/SCN. Habana, Cuba, 1988 (and additional analysis).
- Grupo de Crecimiento y Desarrollo. [Analysis of Changes in the Physical Development Occuring in the Child Population of the City of Havana Between 1972-1993] Analisis de los cambios del desarrollo fisico ocurridos en la poblacion infantil de ciudad de La Habana entre 1972 y 1993. La Habana: Facultad de Ciencias Medicas Julio Trigo Lopez, Instituto Superior de Ciencias Medicas de La Habana, 1994.
- Ministry of Public Health and Social Affairs (Djibouti). Djibouti Survey of Nutrition and Risk Factors for Cardiovascular Diseases 1995.
- Ministry of Health (Djibouti). Survey Report on the Nutritional Status of Children Aged 6 to 59 Months in the Republic of Djibouti. Djibouti, Djibouti: Ministry of Health (Djibouti), 2007.
- Ministry of Public Health (Ecuador), National Development Council (Ecuador), National Institute of Statistics and Censuses (Ecuador), Pan American Health Organization (PAHO). Ecuador Diagnosis of the Food, Nutrition, and Health Situation of the Under-5 Population 1986.
- Brazilian Center for Analysis and Planning (CEBRAP), Ministry of Health (Brazil). Brazil National Demographic and Health Survey of Children and Women 2006-2007. Rio de Janeiro, Brazil: Ministry of Health (Brazil).
- Alderman H. Nutritional status in Ghana and its determinants. Working paper No. 3. Washington, D.C.: The World Bank, 1989 (and additional analysis on the Living Standards Survey, Ghana 1987-88).
- Ministry of Health and Public Hygiene (Guinea). Guinea National Survey of Iron Deficiency Anemia 2000.
- Government of Guinea-Bissau, United Nations Children's Fund (UNICEF). Enquête Nutritionnel SMART. Evaluation de la Situation Nutritionnelle en Guinée Bissau: Rapport Final, Décembre 2008 (and additional analysis). [Guinea-Bissau SMART Nutrition Survey 2008].
- Ministère de la Santé de la Guinée équatoriale. [Assessment of Nutritional Status and Infant Mortality in the Continental Region] L'évaluation de l'état nutritionnel et la mortalité infantile dans la région continentale de la Guinée équatoriale. Technique 840/SG/DSP papier. Yaoundé: Organisation de coopération dans la lutte contre les Endemes en Afrique centrale, 1993.
- Saez C. [Evaluation of Nutritional Status of Children Aged 0-6 Years in the Valley of Maroni (thesis)] Evaluation de l'état nutritionnel des enfants âgés de 0 ... 6 ans dans la vallée de Maroni [thèse]. Bordeaux: Université de Bordeaux II, 1988.
- Fernandez-Arche J. [Nutritional Assessment of Children Under Five Years in a Pech Indiana Community in Honduras (thesis)] Evaluacion nutricional de niños menores de cinco años en una comunidad indígena "Pech" de Honduras [thesis]. Montreal: Universit, de Montreal, 1992.
- Ministerio de Salud, Centro de Investigacion y Estudios de la Salud. [Nicaragua Risk Approach and Nutritional Status of Children Under 5 Years in Region III 1988] Enfoque de riesgo y estado nutricional de los niños menores de 5 años en la region III, 1988. Managua, Nicaragua; 1988.
- National Institute of Statistics (Guinea). Guinea National Survey on Nutritional Status and Tracking Key Indicators of Child Survival 2007-2008.
- Ministère de la Population, de la jeunesse et des sports. [Identification of Vulnerable Households in Vohipeno, Taolagnaro, Ravolondramiarama and Razafimanjato] Identification des ménages vulnérables Vohipeno et Taolagnaro, Ravolondramiarama et Razafimanjato. Antananarivo, Madagascar, 1988.
- German Technical Cooperation Agency (GTZ). Madagascar - Toliara Baseline Survey on the Situation of Food Security in the Bekily Area 1997.
- National Institute of Nutrition Salvador Zubirán (Mexico). Mexico National Nutrition Survey in Rural Areas 1989.
- Ministry of Planning and Development (Yemen), United Nations Children's Fund (UNICEF). Yemen Multiple Indicator Cluster Survey 1996.
- Tuyen le D. Annual national nutrition monitoring. Nutrition Surveillance Department. Hanoi, Vietnam: National Institute of Nutrition, 2009 (and additional analysis).
- Instituto Nacional de Nutrición. [Food and Nutrition Surveillance 2007] Sistema de vigilancia alimentaria y nutricional Venezuela 2007. Caracas, Venezuela: Instituto Nacional de Nutrición, 2009 (y análisis adicional).
- Oficina SISVAN. [Nutritional Anthropometric Assessment of Children Under 5 Years for International Comparison 2000] Evaluacion antropometrica nutricional de los menores de cinco años, para comparacion internacional. Venezuela 2000. Caracas: Instituto Nacional de Nutrition, 2001 (and additional analysis)
- Oficina SISVAN. [Nutritional Anthropometric Classification, Venezuela 1994. INN-SISVAN Under 5 Years Component] Clasificacion antropometrica nutricional, Venezuela 1994. INN-SISVAN componente menores de 5 años. Caracas: Instituto Nacional de Nutricion, 1996 (and additional analysis).
- Oficina SISVAN. [Nutritional Anthropometric Assessment of Children Under Five Years for International Comparison. Venezuela 1990-1998] Evaluacion antropometrica nutricional de los menores de cinco años, para comparacion internacional. Venezuela 1990-1998. Caracas: Instituto Nacional de Nutricion, 1999 (and additional analysis)
- Oficina SISVAN. [Nutritional Anthropometric Assessment of Children Under Five Years for International Comparison. Venezuela 1990-1999] Evaluacion antropometrica nutricional de los menores de cinco años, para comparacion internacional. Venezuela 1990-1999. Caracas: Instituto Nacional de Nutricion, 2000 (and additional analysis)

Appendix Table A.3b - Citations for non-dismod model input data

- Oficina SISVAN. [Nutritional Anthropometric Assessment of Children Under Five Years for International Comparison. Venezuela 1990-1999] Evaluación antropométrica nutricional de los menores de cinco años, para comparación internacional. Venezuela 1995-1997. Caracas: Instituto Nacional de Nutrición, 1998 (and additional analysis)
- Oficina SISVAN. [Results of the Anthropometric Evaluation from the Food and Nutrition Surveillance System Children Under Five Years Component. Venezuela 1990-1993] Resultados de la evaluación antropométrica del componente menores de 5 años del Sistema de Vigilancia Alimentaria y Nutricional (SISVAN): Venezuela 1990-1993. Caracas: Instituto Nacional de Nutrición, 1996 (and additional analysis).
- Federal Ministry of Health (Sudan). Sudan Emergency and Recovery Information and Surveillance System Reports of 1986 and 1987.
- Federal Ministry of Health (Sudan). Sudan - Blue Nile Nutrition Monitoring Survey in 1994.
- Federal Ministry of Health (Sudan). Sudan Nutrition Monitoring Survey in Eastern State 1992.
- Federal Ministry of Health (Sudan). Sudan Nutrition Survey in the South Provinces of Eastern State 1991.
- Federal Ministry of Health (Sudan). Sudan Nutrition Survey in the Butana Province 1992.
- Ministry of Health (El Salvador). El Salvador Final Report on the Baseline Evaluation of the National Nutrition Education Program.
- Delebecque KH, Delebecque P. [Growth of Children Between Birth and Two Years in Tahiti] Croissance des enfants de Tahiti entre la naissance et deux ans. Papeete, Tahiti, 1982.
- Food and Agriculture Organization of the United Nations (FAO). Laos Assessment of Nutritional Status and Food Consumption 1994. Rome, Italy: Food and Agriculture Organization of the United Nations (FAO), 1995.
- Tylleskär K. Cassava and child health among Sakata: a nutritional study of an ethnic group in northern Bandundu region in Zaire. Field study report No 16. Uppsala: International Child Health Unit, 1988.
- Gouvernement du Mali et Médecins sans frontières. Situation nutritionnelle en Vlemé Région. Enquête transversale - juillet 1986. Bamako, Mali, 1986.
- Mockenhaupt FP, Rong B, Günther M, Beck S, Till H, Kohne E, Thompson WN, Bienzle U. Anaemia in pregnant Ghanaian women: importance of malaria, iron deficiency, and haemoglobinopathies. *Trans R Soc Trop Med Hyg.* 2000; 94(5): 477-83. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Elder JA. The socio-economic determinants of nutritional status among children under five in Mauritania. *Social Dimensions of Adjustment Surveys.* Washington D.C.: The World Bank, 1990 (and additional analysis.)
- Ministry of Health and Social Affairs (Mauritania). Mauritania Nutrition Survey in Amourj (Hodh el Chargui), Koboni (Hodh el Gharbi), Bababe (Brakna).
- ANED, Office National de la Statistique (ONS) et UNICEF. Enquête rapide nationale sur la nutrition et survie de l'enfant en Mauritanie: Rapport final. Nouakchott, Mauritanie: ANED, ONS et UNICEF, 2008 (and additional analysis).
- University of Connecticut, National Institute of Nutrition Salvador Zubirán (Mexico). Mexico Nutrition Collaborative Research Support Program 1982-1986.
- National Institute of Nutrition Salvador Zubirán (Mexico). Mexico - Mexico City Urban Food and Nutrition Survey 1995.
- Doctors Without Borders (MSF). Mozambique - Gaza Nutrition Survey in the Guija District 1995.
- Ministry of Planning and Development (Venezuela). Sistema Integrado de Indicadores Sociales para Venezuela [Integrated System of Social Indicators for Venezuela], 2008.
- Panama Ministry of Health. Panama Survey of Prevalence of Malnutrition of Pregnant Women and Children Under Five Years Attending Health Centers in Panama 1992.
- Ministry of Public Health (Uruguay). Uruguay National Nutrition Monitoring System 2004.
- Ministry of Public Health (Uruguay). Uruguay National Nutrition Monitoring System 2002.
- Ministry of Public Health (Uruguay). Uruguay National Nutrition Monitoring System Bulletin No 2 1987-1989.
- Ministry of Public Health (Uruguay). Uruguay National Nutrition Monitoring System 1992-1993.
- Ministère de la Santé Publique, Ministère du Plan et des Mines, Ministère du Développement Rural. [National Policy on Food and Nutrition. Synthesis Document] Politique nationale d'alimentation et de nutrition. Document de synthèse. Lomé, République Togolaise, 1989 (and additional analysis).
- Action Against Hunger, Mercy Corps (MC). Tajikistan National Nutrition, Water, and Sanitation Survey 2003.
- Alfred Rusescu Institute for Mother and Child Care. Romania National Nutritional Surveillance Program 1993-2000. 2002.
- Maximova T. The children of Russia 2000-2001. Moscow, Russia: Russian Academy of Medical Sciences, the National Research Institute of Public Health, 2004 (and additional analysis).
- Solomon Islands Government. Solomon Islands National Nutrition Survey 1989.
- National healthcare group polyclinics' anthropometric growth charts for Singapore preschool children 2000. Singapore Health Booklet, revised edition April 2003 (and additional analysis).
- Report for the Societ, de la Croix-Rouge. Evaluation de la prevalence de la malnutrition dans les départements de Maradi, Tahoua et Zinder fin novembre debut decembre 1985. Croix-Rouge Nigerienne, 1986.
- NIGER/OMS/UNICEF. [Nutritional Assessment Report in the Boroughs of Ouallam, Goure and Tchintabaraden Oct-Nov, 1987] Rapport de l'évaluation nutritionnelle dans les arrondissements de Ouallam, Goure et Tchintabaraden Oct-Nov, 1987. Niamey, Niger, 1988.

Appendix Table A.3b - Citations for non-dismod model input data

- Smith T, Keig G, Marks J, Grau R. Summary results by environmental zone from the 1982/83 National Nutrition Survey of Papua New Guinea. Papua New Guinea Institute of Medical Research. Goroka, Papua New Guinea, 1992 (and additional analysis).
- Sanabria MC. [Consultancy Final Report: Analysis of the Situation of Child Health and Anthropometry in Children Under 5 Years 2005] Informe final de consultoria: Analisis de la situacion de salud infantil y antropometria en menores de 5 años. Paraguay EPH 2005. Asuncion, Paraguay: PNUD Paraguay, 2006.
- Ministry of Health (Peru). Nutritional Situation in Peru. Lima, Peru: Ministry of Health (Peru), 1988.
- Ministry of Agriculture and Animal Resources (MINAGRI) (Rwanda). Rwanda National Nutrition and Food Security Policy Survey for Children 0-5 Years of Age and their Mothers 1991-1992.
- Ministerio de Saude. [Sao Tome and Principe Nutritional and Immunization Coverage of Children Under 5] Estado nutricional e cobertura vacinal des criancas menores de 5 anos na. Seccao de Nutricao. Sao Tome, Republica Democratica de Sao Tome e Principe, 1986 (and additional analysis.)
- Bakol Region Somalia - nutrition surveys & analyses. Nairobi: Food Security Assessment Unit, April 2000.
- International Medical Corps (IMC). Somalia - Bakool Health and Nutrition Survey in El Berde and Rabdure Districts August 2000.
- Food Security Assessment Unit (Somalia), United Nations Development Programme (UNDP). Somalia Bakol Region Nutrition Surveys & Analysis April 2000. Nairobi, Kenya: Food Security Assessment Unit (Somalia), 2000.
- International Medical Corps (IMC). Somalia - Bakool Health and Nutrition Survey in Huddor District July 2000.
- International Medical Corps (IMC), United Nations Children's Fund (UNICEF), World Food Programme (WFP). Somalia - Bakool Nutrition Survey in Rabdure District October 2001.
- Food and Nutrition Security Analysis Unit (Somalia), United Nations Children's Fund (UNICEF). Somalia - Bay Nutrition Survey in Burhakaba District June 2000.
- Somali Red Crescent Society (SRCS), United Nations Children's Fund (UNICEF). Somalia - Hiiraan Nutrition Survey Beledweyne District April 2000.
- Catholic Organisation for Relief and Development Aid (CORDAID), Food and Nutrition Security Analysis Unit (Somalia), United Nations Children's Fund (UNICEF). Somalia - Gedo Nutrition Survey in Burdubo District September 2000.
- Food and Nutrition Security Analysis Unit (Somalia), International Medical Corps (IMC), United Nations Children's Fund (UNICEF). Somalia - Bay Nutrition Survey in Kansadere District October 2001.
- Ministry of Health and Labor (Somalia), United Nations Children's Fund (UNICEF). Somalia - Woqooyi Galbeed Nutrition Survey in Hargeisa District September 2001.
- Food and Nutrition Security Analysis Unit (Somalia), Ministry of Health and Labor (Somalia), United Nations Children's Fund (UNICEF). Somalia - Togdheer Nutrition Survey in Burao District 2002.
- Food and Nutrition Security Analysis Unit (Somalia), United Nations Children's Fund (UNICEF). Somalia - Jubbada Hoose Nutrition Survey in Jamame District 2001.
- Food and Nutrition Security Analysis Unit (Somalia), Ministry of Health and Labor (Somalia), United Nations Children's Fund (UNICEF). Somalia - Awdal Nutrition Survey in Lughaya and Zeila Districts 2002.
- Food Security Assessment Unit (Somalia), United Nations Children's Fund (UNICEF). Somalia - Mudug Nutrition Survey in Goldogob Town 2002.
- Food and Nutrition Security Analysis Unit (Somalia), International Medical Corps (IMC), Somali Red Crescent Society (SRCS), United Nations Children's Fund (UNICEF). Somalia - Hiiraan Nutrition Survey Beledweyne District June 2002.
- Ministry of Social Affairs (Somalia), United Nations Children's Fund (UNICEF). Somalia - Mudug Nutrition Survey in Galkaio District May 2002.
- International Medical Corps (IMC), United Nations Children's Fund (UNICEF). Somalia - Bakool Nutrition Survey in Rabdure District 2002.
- Food Security Assessment Unit (Somalia), United Nations Children's Fund (UNICEF). Somalia - Mudug Nutrition Survey in Jerriban District 2002.
- Food Security Assessment Unit (Somalia), United Nations Children's Fund (UNICEF). Somalia - Mudug Nutrition Survey in Galkaio District 2003.
- International Federation of Red Cross and Red Crescent Societies, Muslim Aid, United Nations Children's Fund (UNICEF). Somalia - Jubbada Hoose Nutrition Survey in Kismayo District 2003.
- Food Security Assessment Unit (Somalia), United Nations Children's Fund (UNICEF). Somalia - Hiiraan Nutrition Survey Beledweyne District 2003.
- Ministry of Health and Labor (Somaliland), United Nations Children's Fund (UNICEF). Somalia - Woqooyi Galbeed Nutrition Survey of Hargesia Returnees and Internally Displaced People Areas 2003.
- United Nations Children's Fund (UNICEF). Somalia - Bay Nutrition Survey in Burhakab and Baido Town August 1999.
- International Medical Corps (IMC). Somalia - Bay IMC Coverage Survey of MCH, Nutrition and EPI in Dinsor and Berdale Districts 2000.
- Food and Nutrition Security Analysis Unit (Somalia), International Committee for the Development of Peoples (CISP), United Nations Children's Fund (UNICEF). Somalia - Galguduud Nutrition Survey of Children Aged 6-59 Months in Elder District August 2001.
- Food Security Assessment Unit (Somalia), United Nations Children's Fund (UNICEF). Somalia - Gedo Nutrition Survey in Belet Hawa District December 2001.

Appendix Table A.3b - Citations for non-dismod model input data

- Food and Nutrition Security Analysis Unit (Somalia), World Vision, Inc.. Somalia - Jubbada Dhexe Knowledge, Practice and Coverage Survey 2001.
- Action Against Hunger. Somalia - Banaadir Anthropometrical Survey of Internally Displaced People Camps in Mogadishu, 17-27 June 2000.
- United Nations Children's Fund (UNICEF). Somalia - Bari Internally Displaced People Nutrition Survey in Bossaso 2003.
- Food and Nutrition Security Analysis Unit (Somalia), International Medical Corps (IMC). Somalia - Bay Nutrition Survey in Berdaale District May 2002.
- Food and Nutrition Security Analysis Unit (Somalia), Ministry of Health and Labor (Somalia), Somali Red Crescent Society (SRCS), United Nations Children's Fund (UNICEF). Somalia - Somaliland Nutrition Survey in Sahil Region April-May 2002.
- Food Security Assessment Unit (Somalia), International Federation of Red Cross and Red Crescent Societies, United Nations Children's Fund (UNICEF). Somalia - Togdheer Nutrition Survey August 2003.
- Pilot survey of the national food and surveillance system. Chinese Academy of Preventive Medicine and State Statistics Bureau. Beijing, China, 1997 (and additional analysis).
- Undersecretary for Public Affairs, Ministry of Health and Medical Education. Cluster survey for evaluation of mid decade goal indicators (MICS). Theran, Islamic Republic of Iran, April 1996 (and additional analysis).
- Ministry of Health (Iraq), United Nations Children's Fund (UNICEF). Iraq Nutritional Status Survey at Primary Health Centres During Polio National Immunization Days in Centre/South Iraq 1999.
- Cartier PA. [Nutritional Monitoring of the Affected Population: Results of the Bi-monthly Survey of December 1994; Provisional summary.] Suivi nutritionnel des populations sinistrées: résultats de l'enquête bimestrielle de décembre 1994; résumé provisoire. Projet de Lutte contre les Maladies Transmissibles et Carencielles, Section Nutrition. Bujumbura, Burundi, 1995.
- Rocaboy S. Enquête nutritionnelle dans la villa de N'Djamena. N'Djamena: Action International Contre la Faim, 1995.
- Ministerio de Salud. [Nutritional Status of the Population in Health Check: System of Food and Nutrition Surveillance] Estado nutricional de la población en control de salud. Sistema de vigilancia alimentaria y nutricional. Departamento de Control y Evaluación. Santiago, República de Chile, 1986.
- Tebi A, Diarra Nama AJ, Malan Kla A, Coulibaly A, Otro M, Koffi NM. [Evaluation of Vitamin A Status of Children Aged 6-59 Months] Evaluation du statut en vitamine A de l'enfant de 6 ... 59 mois du nord ouest de la Côte d'Ivoire. Abidjan: Institut National de Santé, Publique, 1994.
- Republic of Guinea. Enquête sur l'alimentation et la nutrition en moyenne-Guinée (ENAMOG) [Guinea Average Food and Nutrition Survey]. National document for the International Conference on Nutrition: 1992 December 5-11; Rome, Italy.
- Sastroamidjodjo S, Gross R, Schultink W. SEAMEO-GTZ combined nutrition surveys. Jakarta: SEAMO-TROPMED-GTZ, 1994.
- Kripps R. Nutrition services in the Lao People's Democratic Republic. Assignment Report (WP)NUT/LAO/NUT/001. Geneva: World Health Organization, 1984.
- Central Statistics Department [The Gambia], et al. Report of the progress of the mid-decade goals in the Gambia (MICS), 1996. Banjul: The Republic of The Gambia and UNICEF, 1998 (and additional analysis.)
- Spring CA. Mid-decade goals: progress towards the world summit, May 1996 (MICS). Maseru: Bureau of Statistics and UNICEF, 1996.
- Ministry of Health (Chile). Chile National Health Service System 1994.
- Ministry of Health (Chile). Chile National Health Service System 1995.
- Ministry of Health (Chile). Chile National Health Service System 1996.
- Ministry of Health (Chile). Chile National Health Service System 2007.
- Ministry of Health (Chile). Chile National Health Service System 2008.
- China Prevalence of Anemia in China by Age and Gender 2002 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Brazil Anemia in Pregnant Women of the Maternity Professor Monteiro de Moraes and Birth Weight: Correlation with Macro and Micro Structural as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Malawi Nutrition Surveillance Project Annual Report 2001 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Kiribati Pacific Helminth Initiative 2002 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- United States Pregnancy Nutrition Surveillance System 2002 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Aguilar CY, Maramba-Lazarte CC. A cross-sectional analysis of neonatal bacteremia in the neonatal intensive care unit of the Philippine general hospital from July to December 2006. PIDSP J. 2011; 12(1): 17-27.
- Liang J, Zhen X, Zhu J, Mu D, Li X, Li Y, He C, Miao L, Lu Z, Wang Y. Neonatal infection-associated mortality in China, a population-based study, 2003-2008. J Matern Fetal Neonatal Med. 2012; 25(12): 2750-5.
- Child population groups from 0 to 5 years of age: percentage of children below -2 SDS of the NCHS reference in Zaire. Studygroup on maternal and child health in the tropics. Institute of Tropical Medicine. Antwerpen, Belgium, 1986.

Appendix Table A.3b - Citations for non-dismod model input data

- Ministère de la Santé, Public. Enquête nationale de surveillance nutritionnelle des populations soumises à l'aide alimentaire, Décembre 1995. Bujumbura, Burundi, 1996.
- Ministry of Health (Chile). Chile National Health Service System 2001.
- Ministry of Health (Chile). Chile National Health Service System 2002.
- Ministry of Health (Chile). Chile National Health Service System 2003-2004.
- Ministry of Health (Chile). Chile National Health Service System 2006.
- Ge Keyou. The dietary and nutritional status of Chinese population (1992 national nutrition survey). Beijing: Institute of Nutrition and Food Hygiene, 1995 (and additional analysis).
- Stanger M. Brazil - Training Report of the Germano Sival Faria Training Unit. Rio de Janeiro, Brazil: German Sival Faria Health Center, Sergio Arouca National School of Public Health, 1983.
- Philippines Sixth National Nutrition Survey 2003 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- United States National Health and Nutrition Examination Survey 1999-2000, 2001-2002 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Amatayakul K. The Maharaj Nakhorn Chiang Mai Hospital. Chang Mai University. Chang Mai, Thailand; 1983.
- South Africa First RHOSA Nutrition Survey: Anthropometric Assessment of Nutritional Status in Black Under -5s in Rural South Africa 1986
- Oshaug A, Diarra MM, Demb, J, SN, Bendech MA, Pedersen J, Hatloey A, Beseth M, Diakit, M. [Food and Nutrition Situation in the Household Level and the Role of Women in the Management and Exploitation of Natural Resources for Food Security for Gourman et a Koutiala: Progress Report , Food / Women, June 1992] La situation alimentaire et nutritionnelle au niveau des menages et le role des femmes dans la gestion et l'exploitation des ressources naturelles en vue de la securite alimentaire au Gourman et a Koutiala. Rapport d'Etape, Securite, Alimentaire/Femmes, Centre National de la Recherche Scientifique et Technologique, Bamako, Mali, 1992.
- Simondon F, Cornu A, Delpuech F, Lallemand M, Tchibindat F, Goma I et al. Etat nutritionnel des enfants d'âge préscolaire à Brazzaville. In: Urbanisation et santé dans le Tiers Monde, transition épidémiologique, changement social et soins de santé primaires, Paris, ORSTOM, Collection Colloques et séminaires, 1989.
- Batista MF, Oliveira Bazante M, Costa Salzano A. Estado nutricional de pré-escolares de comunidades rurais do nordeste brasileiro. Rev Bras Med. 1985; 42(7): 236-41.
- De Lira PI, Cartagena HA, Romani S de A, Torres MA, Batista Filho M. [Nutritional status of children under 6, according to land tenure, in rural areas of the State of Pernambuco, Northeast of Brazil]. Arch Latinoam Nutr. 1985; 35(2): 247-57.
- Benigna MJ, Dricot J, d' Ans CD. [Growth and nutritional status of children from 0 to 11, State of Paraíba (Brazilian Northeast)]. Rev Saude Publica. 1987; 21(6): 480-9.
- Victora CG, Vaughan JP, Kirkwood BR, Martines JC, Barcelos LB. Risk factors for malnutrition in Brazilian children: the role of social and environmental variables. Bull World Health Organ. 1986; 64(2): 299-309.
- Victora CG, Barros FC, Martines JC, Béria JU, Vaughan JP. [Longitudinal study of children born in Pelotas, RS, Brazil in 1982. Methodology and preliminary results]. Rev Saude Publica. 1985; 19(1): 58-68.
- Santos RV, Coimbra Júnior CE. Socioeconomic transition and physical growth of Tupí-Mondê Amerindian children of the Aripuanã Park, Brazilian Amazon. Hum Biol. 1991; 63(6): 795-819.
- Santos LM, Marlúcia O Assis A, Baqueiro CM, Quaglia GM, Morris SS, Barreto ML. [Nutritional and feeding status of preschool children in the semi-arid region of Bahia (Brazil): I. Anthropometric assessment]. Rev Saude Publica. 1995; 29(6): 463-71.
- Marins VMR, Almeida RMVR. Undernutrition prevalence and social determinants in children aged 0-59 months, Niterói, Brazil. Ann Hum Biol. 2002; 29(6): 609-18.
- Michaelsen KF. Hookworm infection in Kweneng District, Botswana, A prevalence survey and a controlled treatment trial. Trans R Soc Trop Med Hyg. 1985; 79(6): 848-51.
- McCall RD Jr, Baumslag NS, Tessier SF. Malnutrition of children in rural Botswana. Cent Afr J Med. 1986; 32(9): 203-8.
- Castillo LC, Atalah Samur E, Castro Santoro R. Alimentación del menor de 18 meses: relación con el estado nutricional. Rev Chil Pediatr. 1996; 67(1): 22-8.
- Hsiao RL, Miao TS, Lu CC, Tsai CH, Lin MT, Wu CC, Lin MH, Lin SP, Lin WH, Liu CT. [A survey on weight and height of children (1 month-7 years) and plotting of growth curves (1 month-18 years) in Taiwan, 1987-1988]. Acta Paediatr Sin. 1990; 31(3): 166-75.
- Chang Y, Zhai F, Li W, Ge K, Jin D, de Onis M. Nutritional status of preschool children in poor rural areas of China. Bull World Health Organ. 1994; 72(1): 105-12.
- Chang Y, Zhai F, Li W, Ge K, Jin D, de Onis M. Nutritional status of preschool children in poor rural areas of China. Bull World Health Organ. 1994; 72(1): 105-12. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Dang S, Yan H, Yamamoto S, Wang X, Zeng L. Poor nutritional status of younger Tibetan children living at high altitudes. Eur J Clin Nutr. 2004; 58(6): 938-46. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Xiaoguang Y, Zhihong W, Yuna H, Wentao Y, Yisong H, Fengying Z. Trends and prevalence of malnutrition among Chinese children under five years old. Acta Nutri Sin. 2004; 27(3): 185-8.
- Zhu L, Chen F, Yan S, Mi J. Growth evaluation of children under 5-year-old in Beijing and Shenzhen. Chin J Child Health Care. 2007.

Appendix Table A.3b - Citations for non-dismod model input data

- Varaine F, Michelet MJ. Mortality and malnutrition among displaced Liberians in Ivory Coast. *Lancet*. 1995; 345(8957): 1114-5.
- Mendoza Aldana J, Piechulek H. [Nutritional status of 0-to-59-month-old children in urban and rural areas of Cameroon]. *Bull World Health Organ*. 1992; 70(6): 725-32.
- The Kasongo Project Team. Anthropometric assessment of young children's nutritional status as an indicator of subsequent risk of dying. *J Trop Pediatr*. 1983; 29(2): 69-75.
- Bertrand WE, Mock NB, Franklin RR. Differential correlates of nutritional status in Kinshasa, Zaire. *Int J Epidemiol*. 1988; 17(3): 556-67.
- Arbyn M, Dedeurwaerder M, Miakala M, Bikangi N, Boelaert M. [Surveillance of the nutritional status of the population in Kinshasa, Zaire (1991-1994)]. *Ann Soc Belg Med Trop*. 1995; 75(2): 115-24.
- Lambert ML, Brown V, Villagi F, Voiret I. Malnutrition in displaced persons in Zaire. *Lancet*. 1994; 343(8908): 1296.
- Cornu A, Massamba JP, Traissac P, Simondon F, Villeneuve P, Delpuech F. Nutritional change and economic crisis in an urban Congolese community. *Int J Epidemiol*. 1995; 24(1): 155-64.
- Martin-Prével Y, Delpuech F, Traissac P, Massamba JP, Adoua-Oyila G, Coudert K, Trèche S. Deterioration in the nutritional status of young children and their mothers in Brazzaville, Congo, following the 1994 devaluation of the CFA franc. *Bull World Health Organ*. 2000; 78(1): 108-18.
- Mora JO, de Paredes B, de Navarro L, Rodríguez E. Consistent improvement in the nutritional status of Colombian children between 1965 and 1989. *Bull Pan Am Health Organ*. 1992; 26(1): 1-13.
- Wennberg A. Anthropometric assessment of the nutritional status of preschool-age children in Cape Verde. *Bull World Health Organ*. 1988; 66(3): 375-86.
- Reitmaier P, Dupret A, Cutting WA. Better health data with a portable microcomputer at the periphery: an anthropometric survey in Cape Verde. *Bull World Health Organ*. 1987; 65(5): 651-7.
- Esquivel M, Romero JM, Berdasco A, Gutiérrez JA, Jiménez JM, Posada E, Ruben M. [Nutritional status of preschool children in Ciudad de La Habana from 1972 to 1993]. *Rev Panam Salud Publica*. 1997; 1(5): 349-54.
- Esquivel M, González C. [Desarrollo físico y nutrición de preescolares habaneros según nuevos patrones de crecimiento de la OMS]. *Rev Cubana Salud Publica*. 2009; 31(1).
- Close GC, van den Hazel P. Nutritional status of young children in Dominica. *West Indian Med J*. 1986; 35(2): 103-5.
- Hollak CE, Hoogendijk WJ, Griffioen FM, Oosting IJ. Anthropometric study of Dominican pre-school children. *J Trop Pediatr*. 1988; 34(1): 42-8.
- Abolfotouh MA, Nofal LM, Safwat H. Growth and nutritional status of preschool children attending the well-baby clinics. *J Egypt Public Health Assoc*. 1990; 65(5-6): 485-507.
- Briones E, Perea E, Ruiz MP, Torro C, Gili M. The Andalusian Nutritional Survey: comparison of the nutritional status of Andalusian children aged 6-60 months with that of the NCHS/CDC reference population. *Bull World Health Organ*. 1989; 67(4): 409-16.
- Carrascosa Lezcano A, Fernández García JM, Fernández Ramos C, Ferrández Longás A, López-Siguero JP, Sánchez González E, Sobradillo Ruiz B, Yeste Fernández D, Grupo Colaborador Español. [Spanish cross-sectional growth study 2008. Part II. Height, weight and body mass index values from birth to adulthood]. *An Pediatr (Barc)*. 2008; 68(6): 552-69.
- Lindtjørn B, Alemu T, Bjorvatn B. Dietary pattern and state of nutrition among children in drought-prone areas of southern Ethiopia. *Ann Trop Paediatr*. 1993; 13(1): 21-32.
- Hailu A, Tessema T. Anthropometric study of Ethiopian pre-school children. *Ethiop Med J*. 1997; 35(4): 235-44.
- Abate G, Kogi-Makau W, Muroki NM. Health seeking and hygiene behaviours predict nutritional status of pre-school children in a slum area of Addis Ababa, Ethiopia. *Ethiop Med J*. 2000; 38(4): 253-65.
- Salama P, Assefa F, Talley L, Spiegel P, van Der Veen A, Gotway CA. Malnutrition, measles, mortality, and the humanitarian response during a famine in Ehiopia. *JAMA*. 2001; 286(5): 563-71.
- Centers for Disease Control and Prevention (CDC). Vitamin A deficiency among children--Federated States of Micronesia, 2000. *MMWR Morb Mortal Wkly Rep*. 2001; 50(24): 509-12.
- Takyi EE. Nutritional status and nutrient intake of preschool children in northern Ghana. *East Afr Med J*. 1999; 76(9): 510-5.
- Centers for Disease Control (CDC). Health and nutritional status of Liberian refugee children--Guinea, 1990. *MMWR Morb Mortal Wkly Rep*. 1991; 40(1): 13-5.
- Mock NB, Magnani RJ, Abdoh AA, Kondé MK. Intra-household correlations in maternal-child nutritional status in rural Guinea: implications for programme-screening strategies. *Bull World Health Organ*. 1994; 72(1): 119-27.
- Tomkins AM, Dunn DT, Hayes RJ, Bradley AK. Seasonal variations in the nutritional status of urban Gambian children. *Br J Nutr*. 1986; 56(3): 533-43.
- Custodio E, Descalzo MA, Roche J, Molina L, Sánchez I, Lwanga M, Torres AM, Fernández-Zincke E, Bernis C, Villamor E, Baylin A. The economic and nutrition transition in Equatorial Guinea coincided with a double burden of over- and under nutrition. *Econ Hum Biol*. 2010; 8(1): 80-7.
- Custodio E, Descalzo MA, Roche J, Sánchez I, Molina L, Lwanga M, Bernis C, Villamor E, Baylin A. Nutritional status and its correlates in Equatorial Guinean preschool children: results from a nationally representative survey. *Food Nutr Bull*. 2008; 29(1): 49-58.
- Hassapidou M, Papadopoulou S, Tzotzas T. Prevalence of obesity in preschool children in northern Greece. *Int J Pediatr Obes*. 2010; 57.
- Stein AD, Wang M, Digirolamo A, Hoddinott J, Martorell R, Ramirez-Zea M, Yount K. Height for age increased while body mass index for age remained stable between 1968 and 2007 among Guatemalan children. *J Nutr*. 2009; 139(2): 365-9.

Appendix Table A.3b - Citations for non-dismod model input data

- Centers for Disease Control (CDC). Nutritional assessment of children in drought-affected areas--Haiti, 1990. *MMWR Morb Mortal Wkly Rep.* 1991; 40(13): 222-5.
- Abel R, Sampathkumar V. Tamil Nadu nutritional survey comparing children aged 0-3 years with the NCHS/CDC reference population. *Indian J Pediatr.* 1998; 65(4): 565-72.
- Saxena N, Nayar D, Kapil U. Prevalence of underweight, stunting and wasting. *Indian Pediatr.* 1997; 34(7): 627-31.
- Awasthi S, Das R, Verma T, Vir S. Anemia and undernutrition among preschool children in Uttar Pradesh, India. *Indian Pediatr.* 2003; 40(10): 985-90.
- Navab SW, Hamed P, Sadre M. Heights and weights of Iranian preschool children in a rural health care network. *J Trop Pediatr.* 1982; 28(4): 180-6.
- Nojomi M, Tehrani A, Najm-Abadi S. Risk analysis of growth failure in under-5-year children. *Arch Iran Med.* 2004; 7(3): 195-200.
- Yip R, Sharp TW. Acute malnutrition and high childhood mortality related to diarrhea. Lessons from the 1991 Kurdish refugee crisis. *JAMA.* 1993; 270(5): 587-90.
- Field JO, Russell RM. Nutrition mission to Iraq for UNICEF. *Nutr Rev.* 1992; 50(2): 41-6.
- Sato N, Obeid O, Brun T. Malnutrition in southern Iraq. *Lancet.* 1991; 338(8776): 1202.
- Zaidi S, Fawzi MC. Health of Baghdad's children. *Lancet.* 1995; 346(8988): 1485.
- Dangour AD, Hill HL, Ismail SJ. Height, weight and haemoglobin status of 6 to 59-month-old Kazakh children living in Kzyl-Orda region, Kazakhstan. *Eur J Clin Nutr.* 2002; 56(10): 1030-8.
- Dangour AD, Hill HL, Ismail SJ. Height, weight and haemoglobin status of 6 to 59-month-old Kazakh children living in Kzyl-Orda region, Kazakhstan. *Eur J Clin Nutr.* 2002; 56(10): 1030-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Sook B, Young-Ok K, Hae-Kyung C. Field appraisal of the nutritional status of preschool children and their mothers and the investigation of its determinants in rural Korea. *Korean J Epidemiol.* 1986; 269-313.
- Schwekendiek D, Pak S. Recent growth of children in the two Koreas: a meta-analysis. *Econ Hum Biol.* 2009; 7(1): 109-12.
- Bayoumi A, Moussa MA. Kuwait nutritional survey: comparison of the nutritional status of Kuwaiti children aged 0-5 years with the NCHS/CDC reference population. *Bull World Health Organ.* 1985; 63(3): 521-6.
- Bayoumi A, Moussa MA. Kuwait nutritional survey: comparison of the nutritional status of Kuwaiti children aged 6-9 years with the NCHS/CDC reference population. *Int J Epidemiol.* 1985; 14(3): 415-9.
- Amine EK, Al-Awadi F. Nutritional status survey of preschool children in Kuwait. *East Mediterr Health J.* 1996; 2(3): 386-95.
- Amine EK, Al-Awadi F. Nutritional status survey of preschool children in Kuwait. *East Mediterr Health J.* 1996; 2(3): 386-95. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Khamhoung K, Bodhisane N, Pathammavong C, Ouenvilay S, Senthavisouk B, Pongpaew P, Tungtrongchitr R, Phonrat B, Saowakontha S, Merkle A, Schelp FP. Nutritional status of pre-school children and women in selected villages in the Suvannakhet Province, Lao PDR--an intervention trial. *Southeast Asian J Trop Med Public Health.* 2000; 63-74.
- Adel ET, Marie-Françoise R-C, Mahmud Salaheddin M, Najeeb E, Ahmed AM, Ibrahim B, Gerard L. Nutritional status of under-five children in Libya; a national population-based survey. *Libyan J Med.* 2008; 3(1): 13-9.
- Cousens SN, Mertens TE, Fernando MA. The anthropometric status of children in Kurunegala district in Sri Lanka: its relation to water supply, sanitation and hygiene practice. *Trop Med Parasitol.* 1990; 41(1): 105-14.
- Ramanujam P, Nestel P. Preliminary report on the fourth national nutrition and health survey July - August, 1995. *Ceylon J Med Sci.* 1997.
- Sepulveda A, Lezana M, Tapia CR, Valdespino I, Madrigal H, Kumate J. Estado nutricional de preescolares y las mujeres en Mexico: resultados de una encuesta probabilística nacional. *Gac Med Mex.* 1990.
- Ochoa-Díaz López H, Sánchez-Pérez HJ, Ruíz-Flores M, Fuller M. Social inequalities and health in rural Chiapas, Mexico: agricultural economy, nutrition, and child health in La Fraylesca region. *Cad Saude Publica.* 1999; 15(2): 261-70.
- Avila-Curiel A, Shamah-Levy T, Galindo-Gómez C, Rodríguez-Hernández G, Barragán-Heredia LM. [Child malnutrition in the Mexican rural setting]. *Salud Publica Mex.* 1998; 40(2): 150-60.
- Monárrez J, Martínez H. [Prevalence of malnutrition in Tarahumara children under 5 years of age in the municipality of Guachochi, Chihuahua]. *Salud Publica Mex.* 2000; 42(1): 8-16.
- Rivera JA, Monterrubio EA, González-Cossío T, García-Feregrino R, García-Guerra A, Sepúlveda-Amor J. Nutritional status of indigenous children younger than five years of age in Mexico: results of a national probabilistic survey. *Salud Publica Mex.* 2003; S466-476.
- Dimitrovska Z, Kendrovski V, Spiroski I, Gudeva-Nikovska D, Aleksoski B. Nutritional status and early detection of health risk determinants in childhood. *Makedon Med Pregl Suppl.* 2006; 60(68): 119.
- Carnell MA, Guyon AB. Nutritional status, migration, mortality, and measles vaccine coverage during the 1983-1985 drought period: Timbuktu, Mali. *J Trop Pediatr.* 1990; 36(3): 109-13.
- Hatløy A, Hallund J, Diarra MM, Oshaug A. Food variety, socioeconomic status and nutritional status in urban and rural areas in Koutiala (Mali). *Public Health Nutr.* 2000; 3(1): 57-65.
- Schémann J-F, Banou AA, Guindo A, Joret V, Traore L, Malvy D. Prevalence of undernutrition and vitamin A deficiency in the Dogon Region, Mali. *J Am Coll Nutr.* 2002; 21(5): 381-7.
- Kachondham Y, Dhanamitta S, Oyunbileg M, Brown L. Child health and nutritional status in Ulaanbaatar, Mongolia: a preliminary assessment. *Asia Pac J Public Health.* 1992; 6(4): 226-32.

Appendix Table A.3b - Citations for non-dismod model input data

- Centers for Disease Control and Prevention (CDC). Nutritional assessment of children after severe winter weather--Mongolia, June 2001. *MMWR Morb Mortal Wkly Rep.* 2002; 51(1): 5-7.
- Centers for Disease Control (CDC). Evaluation of drought-related acute undernutrition--Mauritania, 1983. *MMWR Morb Mortal Wkly Rep.* 1984; 33(40): 566-7.
- Lindskog U, Lindskog P, Gebre-Medhin M. Child health and household water supply: a longitudinal study of growth and its environmental determinants in rural Malawi. *Hum Nutr Clin Nutr.* 1987; 41(6): 409-23.
- Kandiah M, Lee M, Ng TK, Chong YH. Malnutrition in malaria endemic villages of Bengkoka Peninsula, Sabah. *J Trop Pediatr.* 1984; 30(1): 23-9.
- Kandiah M, Lee M, Ng TK, Chong YH. Malnutrition in malaria endemic villages of Bengkoka Peninsula, Sabah. *J Trop Pediatr.* 1984; 30(1): 23-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Gan CY, Chin B, Teoh ST, Chan MK. Nutritional status of Kadazan children in a rural district in Sabah, Malaysia. *Southeast Asian J Trop Med Public Health.* 1993; 24(2): 293-301.
- Kiyu A, Teo B, Hardin S, Ong F. Nutritional status of children in rural Sarawak, Malaysia. *Southeast Asian J Trop Med Public Health.* 1991; 22(2): 211-5.
- Khor G, Tee ES. Nutritional assessment of rural villages and estates in Peninsular Malaysia II. Nutritional status of children aged 18 years and below. *Malays J Nutr.* 1997; 3(1): 21-47.
- Marjan ZM, Kandiah M, Lin KG, Siong TE. Socioeconomic profile and nutritional status of children in rubber smallholdings. *Asia Pac J Clin Nutr.* 2002; 11(2): 133-41.
- Quelin G, Pecoul B, Amadou B, Baker S. [Risk factors for malnutrition in 0-59-month-old infants in 2 districts of Niger]. *Med Trop (Mars).* 1991; 51(3): 335-42.
- Zeitlin M. The tallstick: A tool for community-based assessment of nutritional stunting. *Food Nutr Bull.* 1990; 12(2).
- Seireg M, Zeitlin MF, LaMontagne J, Morales CM. Field validation of the Tallstick in marginal communities in Nicaragua. *J Trop Pediatr.* 1992; 38(5): 214-23.
- Roede MJ. The secular trend in The Netherlands. The third nation-wide growth study. *Arztl Jugendkd.* 1990; 81(5): 330-6.
- Hotchkiss DR, Mock NB, Seiber EE. The effect of the health care supply environment on children's nutritional status in rural Nepal. *J Biosoc Sci.* 2002; 34(2): 173-92.
- Sims MR. Growth of Auckland preschool children. *N Z Med J.* 1982; 95(707): 305-7.
- Alasfoor D, Mohammed AJ. Implications of the use of the new WHO growth charts on the interpretation of malnutrition and obesity in infants and young children in Oman. *East Mediterr Health J.* 2009; 15(4): 890-8.
- Nuruddin R, Lim MK, Hadden WC, Azam I. Comparison of estimates of under-nutrition for pre-school rural Pakistani children based on the WHO standard and the National Center for Health Statistics (NCHS) reference. *Public Health Nutr.* 2009; 12(5): 716-22.
- Wolff MC, Perez L, Gibson JG, Lopez LS, Peniston B, Wolff MM. Nutritional status of children in the health district of Cusco, Peru. *Am J Clin Nutr.* 1985; 42(3): 531-41.
- Crittenden R. Assessments of the nutritional status of children on the Nembi Plateau in 1978 and 1980. *Ecol Food Nutr.* 1985; 131-47.
- Katona-Apte J, Mokdad A. Malnutrition of children in the Democratic People's Republic of North Korea. *J Nutr.* 1998; 128(8): 1315-9.
- Rito A. Comparison of Portuguese prevalence of childhood overweight and obesity using WHO child growth standards, CDC 2000 growth charts, IOTF criteria and NCHS growth charts. *Int J Pediatr Obes.* 2010.
- Padez C, Fernandes T, Mourão I, Moreira P, Rosado V. Prevalence of overweight and obesity in 7-9-year-old Portuguese children: trends in body mass index from 1970-2002. *Am J Hum Biol.* 2004; 16(6): 670-8.
- Magoni M, Jaber M, Piera R. Fighting anaemia and malnutrition in Hebron (Palestine): impact evaluation of a humanitarian project. *Acta Trop.* 2008; 105(3): 242-8.
- Engelhard F. Child health in Rwanda. *Lancet.* 1995; 346(8977): 777.
- Serenius F, Swailem AR. Growth and nutritional status of less privileged urban children in Saudi Arabia. *Acta Paediatr Scand Suppl.* 1988; 93-103.
- Al-Mazrou YY, Al-Amoud MM, El-Gizouli SE, Khoja T, Al-Turki K, Tantawi NE, Khalil MK, Aziz KM. Comparison of the growth standards between Saudi and American children aged 0-5 years. *Saudi Med J.* 2003; 24(6): 598-602.
- El-Mouzan MI, Al-Herbish AS, Al-Salloum AA, Qurachi MM, Al-Omar AA. Growth charts for Saudi children and adolescents. *Saudi Med J.* 2007; 28(10): 1555-68.
- Tayeh A, Cairncross S. The impact of dracunculiasis on the nutritional status of children in South Kordofan, Sudan. *Ann Trop Paediatr.* 1996; 16(3): 221-6.
- Herrera MG, Nestel P, el Amin A, Fawzi WW, Mohamed KA, Weld L. Vitamin A supplementation and child survival. *Lancet.* 1992; 340(8814): 267-71.
- Centers for Disease Control and Prevention (CDC). Nutrition and mortality assessment--southern Sudan, March 1993. *MMWR Morb Mortal Wkly Rep.* 1993; 42(16): 304-8.
- Creusvaux H, Brown V, Lewis R, Coudert K, Baquet S. Famine in southern Sudan. *Lancet.* 1999; 354(9181): 832.
- Eason RJ. Childhood malnutrition in the Western Province of the Solomon Islands. *Trop Doct.* 1986; 16(3): 135-8.

Appendix Table A.3b - Citations for non-dismod model input data

- Brentlinger PE, Hernán MA, Hernández-Díaz S, Azaroff LS, McCall M. Childhood malnutrition and postwar reconstruction in rural El Salvador: a community-based survey. *JAMA*. 1999; 281(2): 184-90.
- Serdula MK, Aphae JM, Kunene PF, Gama DM, Staehling N, Peck R, Seward J, Sullivan B, Trowbridge FL. Acute and chronic undernutrition in Swaziland. *J Trop Pediatr*. 1987; 33(1): 35-42.
- Delisle H, Alladoum M, Begin F, Nandjingar K, Lasorsa C. Household food consumption and nutritional adequacy in Wadi zones of Chad, Central Africa. *Ecol Food Nutr*. 1991.
- Kitvorapat W, Chaotilittakul N, Sinawat S, Wanaratana L. Random survey on nutritional status of children of ages under five. *Thai J Health Promot Environ Health*. 1996.
- Vella V, Tomkins A, Borghesi A, Migliori GB, Adriko BC, Crevatin E. Determinants of child nutrition and mortality in north-west Uganda. *Bull World Health Organ*. 1992; 70(5): 637-43.
- Tumwine JK, Barugahare W. Nutrition status of children in Kasese district at the Uganda-Congo border. *East Afr Med J*. 2002; 79(8): 427-34.
- Mei Z, Ogden CL, Flegal KM, Grummer-Strawn LM. Comparison of the prevalence of shortness, underweight, and overweight among US children aged 0 to 59 months by using the CDC 2000 and the WHO 2006 growth charts. *J Pediatr*. 2008; 153(5): 622-8.
- Bindon J. Growth patterns of height and weight among three groups of Samoan preadolescents. *Ann Hum Biol*. 1986; 171-178.
- Meshram II, Arlappa N, Balakrishna N, Laxmaiah A, Mallikarjun Rao K, Gal Reddy C, Ravindranath M, Sharad Kumar S, Brahman GNV. Prevalence and determinants of undernutrition and its trends among pre-school tribal children of Maharashtra State, India. *J Trop Pediatr*. 2012; 58(2): 125-32.
- Meshram II, Balakrishna N, Arlappa N, Rao KM, Laxmaiah A, Brahman GNV. Prevalence of Undernutrition, Its Determinants, and Seasonal Variation Among Tribal Preschool Children of Odisha State, India. *Asia Pac J Public Health*. 2012.
- Meshram II, Arlappa N, Balakrishna N, Mallikharjuna Rao K, Laxmaiah A, Brahman GN. Trends in the prevalence of undernutrition, nutrient & food intake and predictors of undernutrition among under five year tribal children in India. *Asia Pac J Clin Nutr*. 2012; 21(4).
- Mathad V, Metgud C, Mallapur MD. Nutritional status of under-fives in rural area of South India. *Indian J Med Sci*. 2011; 65(4): 151-6.
- Meshram II, A L, K V, N V BG. Impact of feeding and breastfeeding practices on the nutritional status of infants in a district of Andhra Pradesh, India. *Natl Med J India*. 2012; 25(4): 201-6.
- Meshram II, Kodavanti MR, Chitty GR, Manchala R, Kumar S, Kakani SK, Kodavalla V, Avula L, Ginnela Narsimhachary Veera B. Influence of Feeding Practices and Associated Factors on the Nutritional Status of Infants in Rural Areas of Madhya Pradesh State, India. *Asia Pac J Public Health*. 2013.
- Das S, Bapat U, More NS, Alcock G, Fernandez A, Osrin D. Nutritional status of young children in Mumbai slums: a follow-up anthropometric study. *Nutr J*. 2012; 100.
- Bågenholm G, Kristiansson B, Nasher AA. Growth and malnutrition among preschool children in Democratic Yemen. *Bull World Health Organ*. 1988; 66(4): 491-8.
- Hassaan FI. Anthropometric assessment of young children attending a health center in Sana'a. *Int Child Health*. 1996; 7(4): 59-70.
- Richardson BD, Cleaton-Jones PE. Social class classification in the RSA--a comparison of four ethnic groups. *S Afr Med J*. 1985; 68(6): 369-70.
- Hugo-Hamman CT, Kibel MA, Michie CA, Yach D. Nutrition status of pre-school children in a Cape Town township. *S Afr Med J*. 1987; 72(5): 353-5.
- Labadarios D, Steyn NP, Maunder E, MacIntyre U, Gericke G, Swart R, Huskisson J, Dannhauser A, Vorster HH, Nesmvuni AE, Nel JH. The National Food Consumption Survey (NFCS): South Africa, 1999. *Public Health Nutr*. 2005; 8(5): 533-43.
- Smuts C, Faber M, Schoeman S, Laubscher J, Oelofse A, Benade A, Dhansay M. Socio-demographic factors and anthropometric status of 0-71-month-old children and their caregivers in rural districts of the Eastern Cape and KwaZulu-Natal provinces of South Africa. *S Afr J Clin Nutr*. 2008; 21(3): 117-24.
- Assefa F, Jabarkhil MZ, Salama P, Spiegel P. Malnutrition and mortality in Kohistan District, Afghanistan, April 2001. *JAMA*. 2001; 286(21): 2723-8.
- Buonomo E, Godo A, Marazzi MC, Scarcella P, Mancinelli S, Palombi L. Child malnutrition in north Albania: results from an anthropometric survey. *Ann Ig*. 2000; 12(6): 505-11.
- Calvo E, Carmuega E, Gnazzo D, Sosa E, Gonzalez S. Evaluación del estado nutricional de la población de niños de 9 a 24 meses de edad, residentes en los partidos del Gran Buenos Aires. *Arch Argent Pediatr*. 1991; 132-41.
- Lejarraga H, Markevich L, Sanchirico F, Cusminsky M. [Reference tables of arm circumference from birth to 12 years of age for Argentinian girls and boys]. *Arch Latinoam Nutr*. 1983; 33(1): 139-57.
- Durán P, Mangialavori G, Biglieri A, Kogan L, Abeyá Gilardon E. [Nutrition status in Argentinean children 6 to 72 months old: results from the National Nutrition and Health Survey (ENNyS)]. *Arch Argent Pediatr*. 2009; 107(5): 397-404.
- Briend A, Hasan KZ, Aziz KM, Hoque BA, Henry FJ. Measuring change in nutritional status: a comparison of different anthropometric indices and the sample sizes required. *Eur J Clin Nutr*. 1989; 43(11): 769-78.
- Robertson A, Fronczak N, Jaganjac N, Hailey P, Copeland P, Duprat M. Nutrition and infant feeding survey of women and children in Sarajevo during July 1993. *Eur J Clin Nutr*. 1995; S11-16.
- Goma Epidemiology Group. Public health impact of Rwandan refugee crisis: what happened in Goma, Zaire, in July, 1994? *Lancet*. 1995; 345(8946): 339-44.
- Vijayaraghavan K, Rao DH. Diet & nutrition situation in rural India. *Indian J Med Res*. 1998; 243-53.

Appendix Table A.3b - Citations for non-dismod model input data

- Mongolia National Nutrition Survey 2004 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Vietnam - Report on Anemia and Sub-clinical Vitamin A Deficiency in Some Provinces in Viet Nam, March 2006 as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Buonomo E, Cenko F, Altan AMD, Godo A, Marazzi MC, Palombi L. Iron deficiency anemia and feeding practices in Albanian children. *Ann Ig.* 2005; 17(1): 27-33. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Eggert W, Eggert S, de Ceita F, Xavier J. [The status of hemoglobin concentration and hematocrit in Angola children]. *Kinderarztl Prax.* 1992; 60(2): 49-53. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Micronutrient Working Group. Iron and vitamin A status in five Caribbean countries. *Cajanus.* 2002; 4-34. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Calvo EB, Gnazzo N. Prevalence of iron deficiency in children aged 9-24 mo from a large urban area of Argentina. *Am J Clin Nutr.* 1990; 52(3): 534-40. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Calvo E, Islam J, Gnazzo N, Ibáñez M, de Martínez C, de Vacaliuc R, Quintana E, Carmuega E. Encuesta nutricional en niños de 2 años de la provincia de misiones, II: indicadores dietéticos y hematológicos. *Arch Argent Pediatr.* 1987; 260-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Morasso M del C, Molero J, Vinocur P, Acosta L, Paccussi N, Raselli S, Falivene G, Viteri FE. [Iron deficiency and anemia in pregnant women from Chaco, Argentina]. *Arch Latinoam Nutr.* 2002; 52(4): 336-43. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Calvo EB, Sosa EM. Iron status in non-pregnant women of child-bearing age living at Greater Buenos Aires. *Eur J Clin Nutr.* 1991; 45(4): 215-20. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Marín GH, Fazio P, Rubbo S, Baistrocchi A, Sager G, Gelemur A. [Prevalence of anaemia in pregnancy and analysis of the underlying factors]. *Aten Primaria.* 2002; 29(3): 158-63. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hopkins RM, Gracey MS, Hobbs RP, Spargo RM, Yates M, Thompson RC. The prevalence of hookworm infection, iron deficiency and anaemia in an aboriginal community in north-west Australia. *Med J Aust.* 1997; 166(5): 241-4. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Watson DS, Tozer RA. Anaemia in Yirrkala. *Med J Aust.* 1986; 13-15. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Rangan AM, Aitkin I, Blight GD, Binns CW. Factors affecting iron status in 15-30 year old female students. *Asia Pac J Clin Nutr.* 1997; 6(4): 291-5. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Fleming AF, Stenhouse NS. Anaemia in pregnancy in Western Australia. *Med J Aust.* 1969; 2(14): 673-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Fleming AF, Martin JD, Stenhouse NS. Pregnancy anaemia, iron and folate deficiency in Western Australia. *Med J Aust.* 1974; 2(13): 479-84. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Müller MM, Kuzmits R, Lorant P, Frass M, Trombik E. [Laboratory findings in the "Vienna Health Study 79" (author's transl)]. *Wien Med Wochenschr.* 1982; 132(2): 35-42. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Stoltzfus R, Chakraborty J, Rice A, Briere B, Francisco A. Plausible evidence of effectiveness of an iron supplementation programme for pregnant and post-partum women in rural Bangladesh. *Food Nutr Bull.* 1998; 197-204. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ahmed F, Khan MR, Karim R, Taj S, Hyderi T, Faruque MO, Margetts BM, Jackson AA. Serum retinol and biochemical measures of iron status in adolescent schoolgirls in urban Bangladesh. *Eur J Clin Nutr.* 1996; 50(6): 346-51. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ahmed F, Mahmuda I, Sattar A, Akhtaruzzaman M. Anaemia and vitamin A deficiency in poor urban pregnant women of Bangladesh. *Asia Pac J Clin Nutr.* 2003; 12(4): 460-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Bhargava A, Bouis HE, Scrimshaw NS. Dietary intakes and socioeconomic factors are associated with the hemoglobin concentration of Bangladeshi women. *J Nutr.* 2001; 131(3): 758-64. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ekström E-C, Hyder SMZ, Chowdhury AMR, Chowdhury SA, Lönnerdal B, Habicht J-P, Persson LA. Efficacy and trial effectiveness of weekly and daily iron supplementation among pregnant women in rural Bangladesh: disentangling the issues. *Am J Clin Nutr.* 2002; 76(6): 1392-400. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Kolsteren P, Rahman SR, Hilderbrand K, Diniz A. Treatment for iron deficiency anaemia with a combined supplementation of iron, vitamin A and zinc in women of Dinajpur, Bangladesh. *Eur J Clin Nutr.* 1999; 53(2): 102-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Hasin A, Begum R, Khan MR, Ahmed F. Relationship between birth weight and biochemical measures of maternal nutritional status at delivery in Bangladeshi urban poor. *Int J Food Sci Nutr.* 1996; 47(3): 273-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Rahman S, Hilderbrand K, Kolsteren P, Diniz A. A nutritional profile of non-pregnant women from the slums of Dinajpur, Bangladesh. *Trop Doct.* 1999; 29(4): 221-4. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Persson V, Ahmed F, Gebre-Medhin M, Greiner T. Relationships between vitamin A, iron status and helminthiasis in Bangladeshi school children. *Public Health Nutr.* 2000; 3(1): 83-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ziauddin Hyder S, Persson Lk, Chowdhury A, Ekström EC. Anaemia among non-pregnant women in rural Bangladesh. *Public Health Nutr.* 2001; 4(1): 79-83. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Monawarul Islam AI, Siddiqua R, Rahman A, Rahman A, Ara I. Iron-deficiency anaemia in pregnancy: (biochemical investigations of iron-deficiency and nutritional status). *Bangladesh Med Res Counc Bull.* 1977; 3(1): 1-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hussain MA, Khan AK, Abedin Z, Ferdous Z, Ahmad K. Studies on the nutritional status of expectant mothers and newborn babies. *Bangladesh Med Res Counc Bull.* 1976; 2(2): 120-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ahmed F, Khan MR, Islam M, Kabir I, Fuchs GJ. Anaemia and iron deficiency among adolescent schoolgirls in peri-urban Bangladesh. *Eur J Clin Nutr.* 2000; 54(9): 678-83. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Petrova A, Gnedko T, Maistrova I, Zafranskaya M, Dainiak N. Morbidity in a large cohort study of children born to mothers exposed to radiation from Chernobyl. *Stem Cells.* 1997; 141-50. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Dirren H, Decarli B, Lesourd B, Schlienger JL, Deslypere JP, Kiepuski A. Nutritional status: haematology and albumin. Euronut SENECA investigators. *Eur J Clin Nutr.* 1991; 45 (Suppl 3): 43-52. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Massot C, Vanderpas J. A survey of iron deficiency anaemia during pregnancy in Belgium: analysis of routine hospital laboratory data in Mons. *Acta Clin Belg.* 2003; 58(3): 169-77. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Elwood PC, Hughes J, Abernethy M, Davies R, Gough R, Johnson AP, Dubourg AY. An international haematological survey. *Bull World Health Organ.* 1976; 54(1): 87-95. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hoyoux C, Gawrylkiewicz A, Jason F. [Prevalence and prevention of iron deficiency in infants under 1 year old]. *Rev Med Liege.* 1995; 50(2): 67-70. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hercberg S, Chauillac M, Galán P, Devanlay M, Zohoun I, Agboton Y, Soustre Y, Bories C, Christides JP, Potier de Courcy G. Relationship between anaemia, iron and folacin deficiency, haemoglobinopathies and parasitic infection. *Hum Nutr Clin Nutr.* 1986; 40(5): 371-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hercberg S, Chauillac M, Galan P, Devanlay M, Zohoun I, Agboton Y, Soustre Y, Auvert B, Masse-Raimbault AM, Dupin H. Prevalence of iron deficiency and iron-deficiency anaemia in Benin. *Public Health.* 1988; 102(1): 73-83. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hercberg S, Chauillac M, Devanlay M, Galán P, Pureur J, Soustre Y, Houdegbe A, Agboton Y, Zohoun I, Masse-Raimbault AM, Dupin H. Evaluation of the iron status of a rural population in south Benin. *Nutr Res.* 1986; 627-34. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ogbeide O, Wagbatsoma V, Orhue A. Anaemia in pregnancy. *East Afr Med J.* 1994; 672-3. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ballew C, Haas JD. Hematologic evidence of fetal hypoxia among newborn infants at high altitude in Bolivia. *Am J Obstet Gynecol.* 1986; 155(1): 166-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Berger J, Aguayo VM, Téllez W, Luján C, Traissac P, San Miguel JL. Weekly iron supplementation is as effective as 5 day per week iron supplementation in Bolivian school children living at high altitude. *Eur J Clin Nutr.* 1997; 51(6): 381-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Szarfarc SC, de Souza SB, Furumoto RAV, Brunken GS, Assis AMO, Gaudenzi EN, Silva R de CR, de Souza JMP. [Hemoglobin concentration in children from birth to one year of age]. *Cad Saude Publica.* 2004; 20(1): 266-74. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Stefanini ML, Colli C, Lerner BR, Lei DL, Chaves SP, Di Pietro MS, Oliveira AA, Szarfarc SC. [Anemia and malnutrition in children at public schools in Osasco, São Paulo, Brazil]. *Cad Saude Publica.* 1995; 11(3): 439-47. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Torres MA, Sato K, Queiroz S de S. [Anemia in children under 2 years in basic health care units in the State of São Paulo, Brazil]. *Rev Saude Publica*. 1994; 28(4): 290-4. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ferreira MLM, Ferreira LOC, da Silva AA, Batista Filho M. [Effectiveness of weekly iron sulfate in the Family Health Program in Caruaru, Pernambuco State, Brazil]. *Cad Saude Publica*. 2003; 19(2): 375-81. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Szarfarc SC. [Nutritional anemia in pregnant women attending health centers of the State of São Paulo (Brazil)]. *Rev Saude Publica*. 1985; 19(5): 450-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Muniz-Junqueira MI, Queiroz EFO. Relationship between protein-energy malnutrition, vitamin A, and parasitoses in living in Brasília. *Rev Soc Bras Med Trop*. 2002; 35(2): 133-41. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Osório MM, Lira PI, Batista-Filho M, Ashworth A. Prevalence of anemia in children 6-59 months old in the state of Pernambuco, Brazil. *Rev Panam Salud Publica*. 2001; 10(2): 101-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- De Paula RA, Fisberg M. The use of sugar fortified with iron tris-glycinate chelate in the prevention of iron deficiency anemia in preschool children. *Arch Latinoam Nutr*. 2001; 51(1 Suppl 1): 54-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Salzano AC, Torres MA, Batista Filho M, Romani S de A. [Anemia in children at 2 health centers in Recife, PE (Brazil)]. *Rev Saude Publica*. 1985; 19(6): 499-507. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Assis, Santos, Martins, Araújo, Amorim, Morris, Barreto. [Distribution of anemia among preschool children from the semi-arid region of Bahia]. *Cad Saude Publica*. 1997; 13(2): 237-44. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Oliveira RS de, Diniz Ad A da S, Benigna MJC, Miranda-Silva SM, Lola MM, Goncalves MC, Ascitti-Moura L, Rivera MA, Santos LMP. [Magnitude, geographic distribution and trends of anemia in preschoolers, Brazil]. *Rev Saude Publica*. 2002; 36(1): 26-32. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Guerra EM, Barretto OC, Pinto AV, Castellão KG. [The prevalence of iron deficiency in pregnant women at their first consultation in health centers in a metropolitan area, Brazil. Etiology of anemia]. *Rev Saude Publica*. 1992; 26(2): 88-95. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Iuliano B, Frutuoso M, Gambardella A. Anemia em adolescentes segundo maturação sexual [Anemia among adolescents according to sexual maturation]. *Rev Nutr*. 2004; 37-43. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Szarfarc SC. [Iron deficiency anemia in populations of the southern area of the State of Sao Paulo]. *Rev Saude Publica*. 1972; 6(2): 125-33. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Monteiro CA, Szarfarc SC, Mondini L. [Secular trends in childhood in the city of São Paulo, Brazil (1984-1996)]. *Rev Saude Publica*. 2000; 34(6 Suppl): 62-72. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Torres MA, Sato K, Juliano Y, Queiroz SS. [Treatment with prophylactic doses of ferrous sulphate as an intervention measure in the campaign++ against iron deficiency in children cared for in basic health units]. *Rev Saude Publica*. 1994; 28(6): 410-5. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Da Silva D, Franceschini A, Priore S, Ribeiro S, Szarfarc S, Souza S, Almeida L, de Lima N, de Castro Maffia U. Anemia ferropriva em crianças de 6 a 12 meses atendidas na rede pública de saúde do município de Viçosa, Minas Gerais [Iron deficiency anemia in 6 to 12 month old infants attended at the public health service of Viçosa, Minas Gerais, Brazil]. *Rev Nutr*. 2002; 301-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Rondo PH, Abbott R, Rodrigues LC, Tomkins AM. Vitamin A, folate, and iron concentrations in cord and maternal blood of intra-uterine growth retarded and appropriate birth weight babies. *Eur J Clin Nutr*. 1995; 49(6): 391-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- De Souza SB, Szarfarc SC, de Souza JM. [Anemia in the first year of life and its relation to breast-feeding]. *Rev Saude Publica*. 1997; 31(1): 15-20. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Lima AV, Lira P, Romani S, Eickman S, Piscocoy M, Lima M. Factores determinantes dos níveis de hemoglobina em crianças aos 12 meses de vida na Zona de Mata Meridional de Pernambuco [Determinant factors of haemoglobin levels in 12 months old infants in the South of the Zona da Mata de Pernambuco]. *Rev Bras Saude Mater Infant*. 2004; 35-43. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Silva LS, Giuglian ER, Aerts DR. [Prevalence and risk factors for anemia among children in Brazil]. *Rev Saude Publica*. 2001; 35(1): 66-73. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Giorgini E, Fisberg M, De Paula RA, Ferreira AM, Valle J, Braga JA. The use of sweet rolls fortified with iron bis-glycinate chelate in the prevention of iron deficiency anemia in preschool children. *Arch Latinoam Nutr*. 2001; 51(1 Suppl 1): 48-53. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Monteiro CA, Szarfarc SC. [Health conditions of children of the municipality of São Paulo, SP (Brazil), 1984-1985. V--Anemia]. *Rev Saude Publica*. 1987; 21(3): 255-60. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Romani S de A, de Lira PI, Batista Filho M, Sequeira LA, de Freitas CL. [Anemias in preschool children: diagnosis, treatment and evaluation, Recife-PE, Brazil]. *Arch Latinoam Nutr*. 1991; 41(2): 159-67. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Sigulem DM, Tudisco ES, Goldenberg P, Athaide MM, Vaisman E. [Iron-deficiency anemia in children of the Municipality of São Paulo]. *Rev Saude Publica*. 1978; 12(2): 168-78. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Sigulem DM, Tudisco ES, de Paiva ER, Guerra CC. [Nutritional anemia and intestinal parasitosis in children under 5]. *Rev Paul Med*. 1985; 103(6): 308-12. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Brunken GS, Guimarães LV, Fisberg M. [Anemia in children under 3 years of age in public day care centers]. *J Pediatr (Rio J)*. 2002; 78(1): 50-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Szarfarc SC. [Iron-deficiency anemia in pregnant women and newborn infants]. *Rev Saude Publica*. 1974; 8(4): 369-74. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Assis AMO, Gaudenzi EN, Gomes G, Ribeiro R de C, Szarfarc SC, Souza SB de. [Hemoglobin concentration, breastfeeding and complementary feeding in the first year of life]. *Rev Saude Publica*. 2004; 38(4): 543-51. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Norton RC, Figueiredo RC, Diamante R, Goulart EM, Mota JA, Viana MB, Penna FJ, Leão E. Prevalence of anemia among school-children from Rio Acima (State of Minas Gerais, Brazil): use of the standardized prevalence method and evaluation of iron deficiency. *Braz J Med Biol Res*. 1996; 29(12): 1617-24. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Frutuoso M, Vigantzky V, Gambardella A. Níveis séricos de hemoglobina em adolescentes segundo estágio de maturação sexual [Hemoglobin serum levels in adolescents according to sexual maturation stage]. *Rev Nutr*. 2003; 155-62. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Cardoso MA, Ferreira MU, Camargo LM, Szarfarc SC. [Anemia in a population from an endemic area of malaria, Rondônia (Brazil)]. *Rev Saude Publica*. 1992; 26(3): 161-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Rodriguez OT, Szarfarc SC, Benicio MH. [Maternal anemia and malnutrition and their relation to birth weight]. *Rev Saude Publica*. 1991; 25(3): 193-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hadler MCCM, Juliano Y, Sigulem DM. [Anemia in infancy: etiology and prevalence]. *J Pediatr (Rio J)*. 2002; 78(4): 321-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Szarfarc SC, Berg G, Santos AL, de Souza SB, Monteiro CA. [Prevention of anemia in the first year of life in health centers of Santo André, São Paulo]. *J Pediatr (Rio J)*. 1996; 72(5): 329-34. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Miglioranza LHS, Matsuo T, Caballero-Córdoba GM, Dichi JB, Cyrino ES, Oliveira IBN, Martins MS, Polezer NM, Dichi I. Effect of long-term fortification of whey drink with ferrous bisglycinate on anemia prevalence in children and adolescents from deprived areas in Londrina, Paraná, Brazil. *Nutrition*. 2003; 19(5): 419-21. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Torres MA, Sato K, Lobo NF, de Souza Queiroz S. [The effect of the use of milk fortified with iron and vitamin C on hemoglobin levels and nutritional status of children under 2]. *Rev Saude Publica*. 1995; 29(4): 301-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Neuman NA, Tanaka OY, Szarfarc SC, Guimarães PR, Victora CG. [Prevalence and risk factors for anemia in Southern Brazil]. *Rev Saude Publica*. 2000; 34(1): 56-63. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Miranda A, Francechini S, Priore S, Euclides M, Araujo R, Ribeiro S, Netto M, Fonseca M, Rocha D, Silva D, Lima N, Maffia U. Anemia ferropriva e estado nutricional de crianças com idade de 12 a 60 meses do município de Viçosa, MG [Iron deficiency anemia and nutritional status of children aged 12 to 60 months in the city of Viçosa, MG, Brazil]. *Rev Nutr*. 2003; 163-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Fujimori E, de Oliveira IM, de Cassana LM, Szarfarc SC. [Iron nutritional status in pregnant adolescents, São Paulo, Brazil]. *Arch Latinoam Nutr*. 1999; 49(1): 8-12. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Tsuyuoka R, Bailey JW, Nery Guimarães AM, Gurgel RQ, Cuevas LE. Anemia and intestinal parasitic infections in primary school students in Aracaju, Sergipe, Brazil. *Cad Saude Publica*. 1999; 15(2): 413-21. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Lacerda E, Cunha AJ. [Iron deficiency anemia and nutrition in the second year of life in Rio de Janeiro, Brazil]. *Rev Panam Salud Publica*. 2001; 9(5): 294-301. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Torres MA, Lobo NF, Sato K, Queiroz S de S. [Fortification of fluid milk for the prevention and treatment of iron deficiency anemia in children under 4 years of age]. *Rev Saude Publica*. 1996; 30(4): 350-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Petrova K. [Assessment of the risk of iron-deficiency state in one to three year-old children from the town of Varna]. *Hyg Public Health*. 1998; XLI: 25-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Donchev V. Pregravid hematological profile of women at fertile age in the town of Burgas [in Bulgarian]. *Akush Ginekol (Sofia)*. 1973; 369-80. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ivanova L, Pentieva K, Petrova S, Vatalova K, Angelova K, Lipova M, Iancheva M. [The effect of the diet on the iron status and incidence of anemia in pregnant women]. *Akush Ginekol (Sofia)*. 1995; 34(1): 6-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Meda N, Cousens S, Kanki B. Anaemia among women of reproductive age in Burkina Faso. *World Health Forum*. 1996; 17(4): 369-72. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Meda N, Mandelbrot L, Cartoux M, Dao B, Ouangré A, Dabis F. Anaemia during pregnancy in Burkina Faso, west Africa, 1995-96: prevalence and associated factors. DITRAME Study Group. *Bull World Health Organ*. 1999; 77(11): 916-22. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Meda N, Dao Y, Touré B, Yameogo B, Cousens S, Graham W. [Assessing severe maternal anemia and its consequences: the value of a simple examination of the coloration of palpebral conjunctiva]. *Sante*. 1999; 9(1): 12-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Coulibaly M, Costagliola D, Zittoun J, Mary JY. Modifications of hemato-biological parameters in pregnant women in a migrating population in northern Cameroon: prevalence of anemia, iron and folates deficiencies. *Int J Vitam Nutr Res*. 1987; 57(2): 173-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Valberg LS, Sorbie J, Ludwig J, Pelletier O. Serum ferritin and the iron status of Canadians. *Can Med Assoc J*. 1976; 114(5): 417-21. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hodgins S, Dewailly E, Chatwood S, Bruneau S, Bernier F. Iron-deficiency anemia in Nunavik: pregnancy and infancy. *Int J Circumpolar Health*. 1998; 57 (Suppl 1): 135-40. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Brault-Dubuc M, Nadeau M, Dickie J. Iron status of French-Canadian children: a three year follow-up study. *Hum Nutr Appl Nutr*. 1983; 37 A(3): 210-21. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Zlotkin SH, Ste-Marie M, Kopelman H, Jones A, Adam J. The prevalence of iron depletion and iron-deficiency anaemia in a randomly selected group of infants from four Canadian cities. *Nutr Res*. 1996; 729-33. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Willows ND, Gray-Donald K. Blood lead concentrations and iron deficiency in Canadian aboriginal infants. *Sci Total Environ*. 2002; 289(1-3): 255-60. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Yeung GS, Zlotkin SH. Efficacy of meat and iron-fortified commercial cereal to prevent iron depletion in cow milk-fed infants 6 to 12 months of age: a randomized controlled trial. *Can J Public Health*. 2000; 91(4): 263-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Lehmann F, Gray-Donald K, Mongeon M, Di Tommaso S. Iron deficiency anemia in 1-year-old children of disadvantaged families in Montreal. *CMAJ*. 1992; 146(9): 1571-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Kuhnlein H, Burgess S. Improved retinol, carotene, ferritin, and folate status in Nuxalk teenagers and adults after a health promotion programme. *Food Nutr Bull*. 1997; 202-10. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Rioux MF, Michaud J. [Maternal anemia in the southeast and northeast regions of New Brunswick and the impact on hematological parameters and the growth of the newborn]. *Can J Diet Pract Res*. 2001; 62(2): 70-5. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Willows ND, Morel J, Gray-Donald K. Prevalence of anemia among James Bay Cree infants of northern Quebec. *CMAJ*. 2000; 162(3): 323-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ndoyo J, Mbiye K. [Hematologic disorders in pregnant women in a health center in Bangui]. *Rev Fr Gynecol Obstet*. 1985; 80(8-9): 651-2. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Beasley M, Brooker S, Ndinarmtan M, Madjiouroum EM, Baboguel M, Djenguinabe E, Bundy DAP. First nationwide survey of the health of schoolchildren in Chad. *Trop Med Int Health*. 2002; 7(7): 625-30. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Renaudin P, Lombart JP. [Anemia in infants less than 1 year old in Moundou, Chad: prevalence and etiology]. *Med Trop (Mars)*. 1994; 54(4): 337-42. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Winter A, Taboada H, Galoira A, Maiz A, Arteaga A. Prevalencia de anemia ferropriva y deficiencia de hierro en una población materno infantil del área sur oriente de Santiago de Chile, 1970. *Rev Chil Pediatr*. 1974; 53-61. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Mardones F, Rioseco A, Ocqueteau M, Urrutia MT, Javet L, Rojas I, Villarroel del L. [Anemia in pregnant women from the community of Puente Alto, Chile]. *Rev Med Chil.* 2003; 131(5): 520-5. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hertrampf E, Olivares M, Letelier A, Castillo C. [Iron nutritional status in pregnant adolescents at the beginning of gestation]. *Rev Med Chil.* 1994; 122(12): 1372-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Pak N, Araya J, Vera G, Atalah E. [Evaluation of the nutritional status of the population of the northern area of Santiago. Biochemical indicators]. *Rev Chil Pediatr.* 1978; 49(1-6): 96-102. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Olivares M, Hertrampf E, Capurro MT, Wegner D. Prevalence of anemia in elderly subjects living at home: role of micronutrient deficiency and inflammation. *Eur J Clin Nutr.* 2000; 54(11): 834-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Lira P, Foradori A, Grebe G, Vela P. [Iron and folate deficiency in pregnant women at term]. *Rev Med Chil.* 1984; 112(2): 127-31. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hertrampf E, Dinamarca M, Llaguno TM, Stekel A. [Iron nutrition and breast feeding in Chilean infants]. *Rev Chil Pediatr.* 1987; 58(3): 193-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Franco E, Rodríguez E, Raquel Espinoza TM, Stekel A, Hertrampf E. [Prevalence of anemia caused by iron deficiency in Mapuche infants fed breast milk]. *Rev Chil Pediatr.* 1987; 58(5): 361-5. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Stekel A, Olivares M, Cayazzo M, Chadud P, Llaguno S, Pizarro F. Prevention of iron deficiency by milk fortification. II. A field trial with a full-fat acidified milk. *Am J Clin Nutr.* 1988; 47(2): 265-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Díaz A, Guerra H, Campos S, Letelier C, Olivares G. Prevalencia de deficiencia de hierro en preescolares de la comuna la Pintana [Prevalence of iron deficiency in preschool children from la Pintana county]. *Rev Chilena Nutr.* 2002; 10-3. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hesketh T, Ding QJ, Tomkins AM. Disparities in economic development in Eastern China: impact on nutritional status of adolescents. *Public Health Nutr.* 2002; 5(2): 313-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Li AM, Cheng MY. Anaemia and thalassaemia in healthy adolescents from southern Chinese families. *J Paediatr Child Health.* 1990; 26(6): 339-42. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Chen M-Y, James K, Liao J. Health issues of aboriginal female adolescents in Taiwan. *J Adv Nurs.* 2004; 47(4): 401-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Cai MQ, Yan WY. Study on iron nutritional status in adolescence. *Biomed Environ Sci.* 1990; 3(1): 113-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Jia F, Fu Z. [Preliminary analysis of the hemoglobin levels of children under 6 years of age]. *J Hyg Res.* 2000; 29(5): 298-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Wang W, Wu Y, Chen X, Liu D, Feng L, Yu S, Sun A, Jin Y. Studies on iron deficiency anemia of preschool children. I: a survey of iron deficiency anemia among preschool children in Beijing [in Chinese]. *Acta Nutri Sin.* 1983; 73-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- China's National Group On Students' Constitution And Health Survey, Ji C. Dynamic analysis on the detecting rate of iron-deficient anemia of Chinese students. *Chin J Prev Med.* 2002; 36(2): 81-3. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Shi Z, Lien N, Kumar BN, Dalen I, Holmboe-Ottesen G. The sociodemographic correlates of nutritional status of school adolescents in Jiangsu Province, China. *J Adolesc Health.* 2005; 37(4): 313-22. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Zeng L, Yan H, Chen Z, Dang S, Xie H. [Analysis on the prevalence of anemia among children under 3-year-old in 5 provinces in Western China]. *Chin J Epidemiol.* 2004; 25(3): 225-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Xiong X, Buekens P, Fraser WD, Guo Z. Anemia during pregnancy in a Chinese population. *Int J Gynaecol Obstet.* 2003; 83(2): 159-64. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Wang W, Chen X, Liu D. Hematologic response to iron and ascorbic acid administration in preschool children with anemia. *Nutr Res.* 1986; 241-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ma A-G, Chen X-C, Wang Y, Xu R-X, Zheng M-C, Li J-S. The multiple vitamin status of Chinese pregnant women with anemia and nonanemia in the last trimester. *J Nutr Sci Vitaminol.* 2004; 50(2): 87-92. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Shaw NS. Iron deficiency and anemia in school children and adolescents. *J Formos Med Assoc.* 1996; 95(9): 692-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Todd D, Kan PS. Anaemia in pregnancy in Hong Kong. *J Obstet Gynaecol Br Commonw.* 1965; 72(5): 738-44. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Lao TT, Pun TC. Anaemia in pregnancy--is the current definition meaningful? *Eur J Obstet Gynecol Reprod Biol.* 1996; 68(1-2): 53-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- He Y, Zhai F, Li Y, Jia F. [Effect of nutrition on the health improvement of preschool children in rural areas]. *J Hyg Res.* 1999; 28(3): 172-5. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Gao J, Zeng S, Sun BL, Fan HM, Han LH. Menstrual blood loss and hematologic indices in healthy Chinese women. *J Reprod Med.* 1987; 32(11): 822-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Dang S, Yan H, Wang X. [Study on the hemoglobin levels of children under the age of three years and the prevalence of anemia at high altitude in Tibet of China]. *Chin J Epidemiol.* 2003; 24(12): 1108-11. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Zhou LM, Yang WW, Hua JZ, Deng CQ, Tao X, Stoltzfus RJ. Relation of hemoglobin measured at different times in pregnancy to preterm birth and low birth weight in Shanghai, China. *Am J Epidemiol.* 1998; 148(10): 998-1006. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Leung SS, Davies DP, Lui S, Lo L, Yuen P, Swaminathan R. Iron deficiency is uncommon in healthy Hong Kong infants at 18 months. *J Trop Pediatr.* 1988; 34(3): 100-3. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Agudelo GM, Cardona OL, Posada M, Montoya MN, Ocampo NE, Marín CM, Correa MC, López C. [Prevalence of iron-deficiency anemia in schoolchildren and adolescents, Medellín, Colombia, 1999]. *Rev Panam Salud Publica.* 2003; 13(6): 376-86. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Rodríguez S, Blanco A, Cunningham L, Ascencio M, Chávez M, Muñoz L. [Prevalence of nutritional anemia in women of reproductive age. Costa Rica. National nutrition survey, 1996]. *Arch Latinoam Nutr.* 2001; 51(1): 19-24. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Villarejos VM, Bickers J, Alvaro Riveraaa S, Peña Chavarria A, Hunter GW 3rd, Kotcher E. Pathogenesis of anemia in Costa Rica. Epidemiologic study of hemoglobin and serum protein levels and hookworm infection in children. *Am J Trop Med Hyg.* 1970; 19(4): 603-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Jiménez E, Brittenham GM, Jiménez R, Lozoff B, Mora L, Gómez I, Carrillo JM. [Iron deficiency anemia in unweaned infants: a prospective study]. *Bol Med Hosp Infant Mex.* 1987; 44(6): 309-15. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Cunningham L, Blanco A, Rodríguez S, Ascencio M. [Prevalence of anemia, iron and folate deficiency in children 7 years smaller. Costa Rica, 1996]. *Arch Latinoam Nutr.* 2001; 51(1): 37-43. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Monge-Rojas R, Barrantes M, Holst I, Nuñez-Rivas H, Alfaro T, Rodríguez S, Cunningham L, Cambroner P, Salazar L, Herrmann FH. Biochemical indicators of nutritional status and dietary intake in Costa Rican Cabécar Indian adolescents. *Food Nutr Bull.* 2005; 26(1): 3-16. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Monge R, Faiges F, Rivero A. Iron and folate status in urban and rural Costa Rican teenagers. *Food Nutr Bull.* 2001; 45-52. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Blanco A, Rodríguez S, Cunningham L. [Nutritional anemia in nursing women in Costa Rica]. *Arch Latinoam Nutr.* 2003; 53(1): 28-34. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Asobayire FS, Adou P, Davidsson L, Cook JD, Hurrell RF. Prevalence of iron deficiency with and without concurrent anemia in population groups with high prevalences of malaria and other infections: a study in Côte d'Ivoire. *Am J Clin Nutr.* 2001; 74(6): 776-82. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Carré N, Eono P, Kouakou K, Duponchel J-L, Marquis M, Zahui KH. [Iron supplementation associated with malaria prevention among pregnant women in Abidjan]. *Rev Epidemiol Sante Publique.* 2003; 51(1 Pt 1): 31-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Reinhardt MC. Maternal anaemia in Abidjan--Its influence on placenta and newborns. *Helv Paediatr Acta Suppl.* 1978; 43-63. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Reinhardt MC, Marti HR. Haematological data of African newborns and their mothers in Abidjan. *Helv Paediatr Acta Suppl.* 1978; 85-99. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Buzina R, Jusić M, Sapunar J, Milanovic N, Zimolo A, Rajcic V. Impaired growth and nutritional status of schoolchildren in rural Croatia. *Int J Vitam Nutr Res.* 1972; 42(2): 169-83. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Degac K, Kaic-Rak A, Petrovic Z, Mesaros-Kanjnski E. Anem ija i prehrabene navike skolske djece u hrvatskoj [Anaemia and the nutritional habits of school-children in Croatia]. *Paediatrics Croatia.* 2002; 23-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Rodríguez J, Perez J, Hernández A, Triana M, Chong A, Sá chez M. Anemia nutricional en un grupo de niños aparentemente sanos de 2 a 4 años de edad. *Rev Cubana Aliment Nutr.* 2002; 31-4. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Reboso Pérez J, Jiménez Acosta S, Gay Rodríguez J, Cabrera A, Sánchez M. Anemia en un grupo de niños de 14 a 57 meses de edad, aparentemente sanos [Anemia in a group of children of 14 to 57 months of age, apparently health]. *Rev Cubana Salud Publica.* 2003; 128-31. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Prendes Labrada M, Baños Rodríguez A, Toledo Dieppa O, Lescay Megret O. Prevalencia de anemia en gestantes en un área de salud [Prevalence of anemia in pregnant women in a health area]. *Rev Cubana Med General Integral*. 2000; 25-30. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Gautier H, Forrellat M, Fernandez N, Sanchez Y, Gumis I. Factores de riesgo de la anemia por deficiencia de hierro en lactantes de un área de salud [Risk factors of iron-deficiency anemia in infants from a health area]. *Rev Cubana Hematol Inmunol Hemoter*. 1999; 175-81. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Vidal H, Puente R, Gautier du Defaix H. Deficiencia nutricional de hierro en niños de 6 meses a 2 años [Nutritional iron deficiency in children aged 6 months to 2 years]. *Rev Cubana Pediatr*. 1985; 384-91. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Osancová K, Hejda S. Nutrition and its reflection on the health status of the population. *Rev Czech Med*. 1968; 14(2): 101-17. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Kalenga M-K, Nyembo M-K, Nshimba M, Foidart J-M. [Anemia prevalence in pregnant and breast-feeding women in Lubumbashi (Democratic Republic of the Congo). Impact of malaria and intestinal helminthiasis]. *J Gynecol Obstet Biol Reprod (Paris)*. 2003; 32(7): 647-53.
- Kalenga M-K, Nyembo M-K, Nshimba M, Foidart J-M. [Anemia prevalence in pregnant and breast-feeding women in Lubumbashi (Democratic Republic of the Congo). Impact of malaria and intestinal helminthiasis]. *J Gynecol Obstet Biol Reprod (Paris)*. 2003; 32(7): 647-53. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Jackson DJ, Klee EB, Green SD, Mokili JL, Elton RA, Cutting WA. Severe anaemia in pregnancy: a problem of primigravidae in rural Zaire. *Trans R Soc Trop Med Hyg*. 1991; 85(6): 829-32. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Milman N, Cohn J, Pedersen NS. Serum ferritin and iron status of children in the Faroe Islands. *Eur J Pediatr*. 1984; 142(2): 89-92. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hagerup L, Eriksen M, Schroll M, Hollnagel H, Agner E, Larsen S. The Glostrup population studies. Collection of epidemiologic tables. Reference values for use in cardiovascular population studies. *Scand J Soc Med Suppl*. 1981; 1-112. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Milman N, Heitman B, Lyhne N, Rosdahl N, Jensen K, Graudal N. Iron status in 1113 Danish men and women aged 35-65 years: relation to dietary and supplemental iron intake. *Scand J Nutr*. 1993; 98-103. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Milman N, Agger AO, Nielsen OJ. Iron supplementation during pregnancy. Effect on iron status markers, serum erythropoietin and human placental lactogen. A placebo controlled study in 207 Danish women. *Dan Med Bull*. 1991; 38(6): 471-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Milman N, Byg KE, Mulvad G, Pedersen HS, Bjerregaard P. Haemoglobin concentrations appear to be lower in indigenous Greenlanders than in Danes: assessment of haemoglobin in 234 Greenlanders and in 2804 Danes. *Eur J Haematol*. 2001; 67(1): 23-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Milman N, Ulrik CS, Graudal N, Jordal R. Iron status in young Danes. Evaluation by serum ferritin and haemoglobin in a population survey of 634 individuals aged 14-23 yr. *Eur J Haematol*. 1997; 58(3): 160-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Milman N, Schultz-Larsen K. Iron stores in 70-year-old Danish men and women. Evaluation in 469 individuals by serum ferritin and hemoglobin. *Aging (Milano)*. 1994; 6(2): 97-103. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Moller IA. [A study of hemoglobin values in school children in rural population]. *Ugeskr Laeger*. 1967; 129(20): 658-60. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Milman N, Clausen JO, Jordal R. Iron status in young Danish men and women: a population survey comprising 548 individuals. *Ann Hematol*. 1995; 70(4): 215-21. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Milman N, Thomsen H, Mathiassen B. Serum ferritin, iron status and plasma ascorbic acid in 40- to 49-year-old males in the Faroe Islands. *Scand J Clin Lab Invest*. 1990; 50(5): 559-64. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Marnier T. Haemoglobin, erythrocytes and serum iron values in normal children 3-6 years of age. *Acta Paediatr Scand*. 1969; 58(4): 363-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Calcaño-García E, Laureano-Guzmán C, Estrella-L A, Japa-Peguero D, Puello-F B, Rosario B. Prevalencia de anemia en embarazadas que acuden a la consulta externa de hospital general docente [Prevalence of anaemia in pregnant women who went to the external consultation of the general hospital]. *Rev Med Dominicana*. 1994; 17-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Quizhpe E, San Sebastián M, Hurtig AK, Llamas A. [Prevalence of anaemia in schoolchildren in the Amazon area of Ecuador]. *Rev Panam Salud Publica*. 2003; 13(6): 355-61. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Barduagni P, Ahmed AS, Curtale F, Raafat M, Soliman L. Performance of Sahli and colour scale methods in diagnosing anaemia among school children in low prevalence areas. *Trop Med Int Health*. 2003; 8(7): 615-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

el-Sahn F, Sallam S, Mandil A, Galal O. Anaemia among Egyptian adolescents: prevalence and determinants. *East Mediterr Health J.* 2000; 6(5-6): 1017-25. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Hussein M, Hassan H, Noor E, El-Shafie M. Nutritional assessment of preschool children in Egypt. *Gaz Egypt Paediatr Assoc.* 1989; 27-35. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Mahfouz A. Anaemia among elderly in Alexandria: an epidemiologic study. *J Egypt Public Health Assoc.* 1986; 359-70. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

El Bassiouny S, Ibrahim O, Gabr A, Mekkawy A. Iron deficiency in Egyptian rural infants: nutrition correlates and relevance to screening. *Med J Cairo Univ.* 1997; 893-901. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Abdou IA, Ali HE, Said AK, Mousa WA, Demian HG, Soliman AM, el-Hawary LH. Incidence of nutritional deficiencies, goitre and dental caries among school children in Cairo. *J Egypt Public Health Assoc.* 1967; 42(4): 175-84. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Shukry AS, Labib FM, Kamel LM. Assessment of the health and nutritional standards of infants and preschool children in high density Cairo community. *Gaz Egypt Paediatr Assoc.* 1973; 21(3): 47-56. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

El-Shobaki F, El-Hawary Z, Saleh N. Combating anaemia among school children using a highly available iron preparation. *Egypt J Community Med.* 1990; 81-94. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Abdou IA, Ali HE, Said AK, Mousa WA, Demian HG, Soliman AM, el-Hawary LH. Incidence of nutritional deficiencies, goitre and dental caries among school children in Cairo. *J Egypt Public Health Assoc.* 1967; 42(4): 175-84. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Hussein M, Hassan H, Noor E, El-Shafie M. Nutritional assessment of preschool children in Egypt. *Gaz Egypt Paediatr Assoc.* 1989; 27-35. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Mahfouz A. Anaemia among elderly in Alexandria: an epidemiologic study. *J Egypt Public Health Assoc.* 1986; 359-70. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Topozada HK, Ghoneim SM. A hematologic study of pregnant women in free and insurance hospital populations. *Int J Gynaecol Obstet.* 1983; 21(6): 439-42. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

el-Sahn F, Sallam S, Mandil A, Galal O. Anaemia among Egyptian adolescents: prevalence and determinants. *East Mediterr Health J.* 2000; 6(5-6): 1017-25. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Winham D, Harrison G, Galal O, El-Tobgui M. Anemia and infection in school-aged Egyptian children. *Ecol Food Nutr.* 2004; 21-40. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Stetler HC, Huong AY. [Epidemiology of anemia in preschool children and their mothers in El Salvador]. *Arch Latinoam Nutr.* 1981; 31(4): 679-97. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Haidar J, Muroki NM, Omwega AM, Ayana G. Malnutrition and iron deficiency in lactating women in urban slum communities from Addis Ababa, Ethiopia. *East Afr Med J.* 2003; 80(4): 191-4. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Ross SM. Haemoglobin and haematocrit values in pregnant women on a high iron intake and living at a high altitude. *J Obstet Gynaecol Br Commonw.* 1972; 79(12): 1103-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Haidar J, Nekatibeb H, Urga K. Iron deficiency anemia in pregnant and lactating mothers in rural Ethiopia. *East Afr Med J.* 1999; 76(11): 618-22. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Desalegn S. Prevalence of anaemia in pregnancy in Jima town, southwestern Ethiopia. *Ethiop Med J.* 1993; 31(4): 251-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Gies S, Brabin BJ, Yassin MA, Cuevas LE. Comparison of screening methods for anaemia in pregnant women in Awassa, Ethiopia. *Trop Med Int Health.* 2003; 8(4): 301-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Lloyd-Puryear M, Mahoney J, Humphrey J, Mahoney F, Siren N, Moorman C, West KJ. Vitamin A deficiency in Micronesia: a statewide survey in Chuuk. *Nutr Res.* 1991; 1101-1110. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Buchanan JG, Nixon AD, Pettit JE, Meerkin M, Patel R, Pillai MV, Goundar RP, Alexander H. Iron deficiency and anemia among Indian women in Fiji. *Pathology.* 1982; 14(3): 269-75. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Lahti-Koski M, Valsta LM, Alfthan G, Tapanainen H, Aro A. Iron status of adults in the capital area of Finland. *Eur J Nutr.* 2003; 42(5): 287-92. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Takkunen H. Iron deficiency in the Finnish adult population: an epidemiological survey from 1967 to 1972 inclusive. *Scand J Haematol Suppl.* 1976; 1-91. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Siimes MA, Saarinen UM, Dallman PR. Relationship between hemoglobin concentration and transferrin saturation in iron-sufficient infants. *Am J Clin Nutr*. 1979; 32(11): 2295-300. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Siimes MA, Tiitinen A, Karjalainen O. [Iron prophylaxis and maternal hematological levels during pregnancy]. *Duodecim*. 1994; 110(14): 1329-32. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Knuiman JT, Westenbrink S, van der Heyden L, West CE, Burema J, de Boer J, Hautvast JG, Räsänen L, Virkkunen L, Viikari J. Determinants of total and high density lipoprotein cholesterol in boys from Finland, The Netherlands, Italy, the Philippines and Ghana with special reference to diet. *Hum Nutr Clin Nutr*. 1983; 37(4): 237-54. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Widholm O, Vartiainen E, Tenhunen T. On iron requirement in menstruating teen-age girls. Iron study among teen-agers. I. *Acta Obstet Gynecol Scand*. 1967; 46(Suppl 1): 29-46. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Gayral-Taminh M, Arnaud C, Parant O, Fournié A, Rème JM, Grandjean H. [Pregnancy and labor of women born in Maghreb and Black Africa followed to delivery at the Maternity Hospital of Toulouse]. *J Gynecol Obstet Biol Reprod (Paris)*. 1999; 28(5): 462-71. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hercberg S, Dhur A, Mekki N, Galan P. [Comparison of 2 methods for evaluating the prevalence of anemia in young children]. *Rev Epidemiol Sante Publique*. 1989; 37(4): 319-25. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Galan P, Yoon HC, Preziosi P, Viteri F, Valeix P, Fieux B, Briançon S, Malvy D, Roussel AM, Favier A, Hercberg S. Determining factors in the iron status of adult women in the SU.VI.MAX study. *Supplementation en Vitamines et Minéraux Antioxydants*. *Eur J Clin Nutr*. 1998; 52(6): 383-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Mekki N, Galan P, Rossignol C, Farnier MA, Hercberg S. [Iron status in presumably healthy children 10 months, 2 years and 4 years of age]. *Arch Fr Pediatr*. 1989; 46(7): 481-5. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hercberg S, Galán P, Soustre Y, Devanlay M, Dupin H. Prevalence of iron deficiency during pregnancy in a French area. *Nutr Report Int*. 1985; 719-26. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hercberg S, Wainer R, Bard D, Soustre Y, Galan P. [Study of the iron status of a population of pregnant women]. *Rev Fr Gynecol Obstet*. 1985; 80(6 Pt 2): 467-72. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Galán P, Hercberg S, Soustre Y, Dop MC, Dupin H. Factors affecting iron stores in French female students. *Hum Nutr Clin Nutr*. 1985; 39(4): 279-87. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Blot I, Papiernik E, Kaltwasser JP, Werner E, Tchernia G. Influence of routine administration of folic acid and iron during pregnancy. *Gynecol Obstet Invest*. 1981; 12(6): 294-304. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Archambeaud-Breton MP, Dommergues JP, Ducot B, Rossignol C, Yvart J, Tchernia G. Reevaluation of the utility of mean cell hemoglobin (MCH) screening in infants for iron deficiency. *Nouv Rev Fr Hematol*. 1989; 31(4): 307-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Dommergues JP, Breton MP, Ducot B, Yvart J, Rossignol C, Tchernia G. [Iron deficiency in infants. Study of risk factors]. *Arch Fr Pediatr*. 1984; 41(9): 623-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hercberg S, Bard D, Galan P, Soustre Y, Devanlay M, Dupin H. [Relations between iron levels in mothers and in their newborn infants]. *J Gynecol Obstet Biol Reprod (Paris)*. 1984; 13(8): 855-60. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Blot I, Rey A, Kaltwasser JP, Francoual J, Papiernik E, Tchernia G. Folate and iron deficiencies in mothers and their newborn children. *Blut*. 1982; 44(5): 297-303. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hercberg S, Galán P, Soustre Y, Dop MC, Devanlay M, Dupin H. Effects of iron supplementation on serum ferritin and other hematological indices of iron status in menstruating women. *Ann Nutr Metab*. 1985; 29(4): 232-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Zittoun J, Blot I, Hill C, Zittoun R, Papiernik E, Tchernia G. Iron supplements versus placebo during pregnancy: its effects on iron and folate status on mothers and newborns. *Ann Nutr Metab*. 1983; 27(4): 320-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Bergmann RL, Gravens-Müller L, Hertwig K, Hinkel J, Andres B, Bergmann KE, Dudenhausen JW. Iron deficiency is prevalent in a sample of pregnant women at delivery in Germany. *Eur J Obstet Gynecol Reprod Biol*. 2002; 102(2): 155-60. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Browne EN, Maude GH, Binka FN. The impact of insecticide-treated bednets on malaria and anaemia in pregnancy in Kassena-Nankana district, Ghana: a randomized controlled trial. *Trop Med Int Health*. 2001; 6(9): 667-76. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Agyepong IA, Wellington EK, Abbey MA. A comparative study of clinical and sociocultural aspects of anaemia among adolescent girls in rural Ghana. *Acta Trop*. 1997; 65(3): 123-38. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Lassey AT, Klufio CA, Annan BD, Wilson JB. Antenatal haemoglobin profile at Korle-Bu Teaching Hospital. *East Afr Med J*. 1999; 76(4): 228-32. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Kafatos A, Diacatou A, Labadarios D, Kounali D, Apostolaki J, Vlachonikolis J, Mamalakis G, Megremis S. Nutrition status of the elderly in Anogia, Crete, Greece. *J Am Coll Nutr*. 1993; 12(6): 685-92. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Kattamis C, Metaxotou-Mavromnati A, Konidaris C, Toulaiatos N, Constantas N, Matsaniotis N. Iron deficiency in Greece. Epidemiologic and hematologic studies. *J Pediatr*. 1974; 84(5): 666-71. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Diallo MS, Diallo TS, Diallo FB, Diallo Y, Camara AY, Onivogui G, Keita N, Diawo SA. [Anemia and pregnancy. Epidemiologic, clinical and prognostic study at the university clinic of the Ignace Deen Hospital, Conakry (Guinee)]. *Rev Fr Gynecol Obstet*. 1995; 90(3): 138-41. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Diallo MS, Diallo TS, Diallo FB, Diallo Y, Camara AY, Onivogui G, Keita N, Diawo SA. [Anemia and pregnancy. Epidemiologic, clinical and prognostic study at the university clinic of the Ignace Deen Hospital, Conakry (Guinee)]. *Rev Fr Gynecol Obstet*. 1995; 90(3): 138-41. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Johnson AA, Latham MC, Roe DA. The prevalence and the etiology of the nutritional anemias in Guyana. *Am J Clin Nutr*. 1982; 35(2): 309-18. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Nicklas TA, Kuvibidila S, Gatewood LC, Metzinger AB, Frempong KO. Prevalence of anaemia and iron deficiency in urban Haitian children two to five years of age. *J Trop Pediatr*. 1998; 44(3): 133-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Domellöf M, Cohen RJ, Dewey KG, Hernell O, Rivera LL, Lönnerdal B. Iron supplementation of breast-fed Honduran and Swedish infants from 4 to 9 months of age. *J Pediatr*. 2001; 138(5): 679-87. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Antal M, Regöly-Mérei A, Biró L, Greiner E, Sági K, Agfalvy R, Nagy K, Biró G. Iron status in a healthy population of Hungarian secondary school boys and girls. *Ann Nutr Metab*. 1998; 42(1): 33-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Jonsson JJ, Johannesson GM, Sigfusson N, Magnusson B, Thjodleifsson B, Magnusson S. Prevalence of iron deficiency and iron overload in the adult Icelandic population. *J Clin Epidemiol*. 1991; 44(12): 1289-97. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Thorsdottir I, Gunnarsson BS, Atladottir H, Michaelsen KF, Palsson G. Iron status at 12 months of age -- effects of body size, growth and diet in a population with high birth weight. *Eur J Clin Nutr*. 2003; 57(4): 505-13. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Chakma T, Rao PV, Tiwary RS. Prevalence of anaemia and worm infestation in tribal areas of Madhya Pradesh. *J Indian Med Assoc*. 2000; 98(9): 567-571. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Kapoor G, Aneja S. Nutritional disorders in adolescent girls. *Indian Pediatr*. 1992; 29(8): 969-73. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Working Group on Fortification of Salt with Iron. Use of common salt fortified with iron in the control and prevention of anemia--a collaborative study. Report of the Working Group on Fortification of Salt with Iron. *Am J Clin Nutr*. 1982; 35(6): 1442-51. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Pathak P, Tandon M, Kapil U, Singh C. Prevalence of iron deficiency anemia amongst pregnant women in urban slum communities of Delhi. *Indian Pediatr*. 1999; 36(3): 322-3. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Dahiya S, Kapoor AC. Anaemia in women in a selected rural area of Haryana: effect of dietary intake level. *Indian J Nutr Diet*. 1995; 224-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Gupta V, Shukla K. Epidemiology of anaemia in pre-school children from a rural and a slum community of Varanasi. *Indian J Prev Soc Med*. 1985; 85-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Rao KV, Radhaiah G, Raju SV. Association of growth status and the prevalence of anaemia in preschool children. *Indian J Med Res*. 1980; 237-46. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Brabin L, Nicholas S, Gogate A, Gogate S, Karande A. High prevalence of anaemia among women in Mumbai, India. *Food Nutr Bull*. 1998; 205-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Verma M, Chhatwal J, Kaur G. Prevalence of anemia among urban school children of Punjab. *Indian Pediatr*. 1998; 35(12): 1181-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Sidhu S, Kumari K, Uppal M. Prevalence of anemia in Schedule Caste preschool children of Punjab. *Indian J Med Sci.* 2002; 56(5): 218-21. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Jain S, Chopra H, Garg SK, Bhatnagar M, Singh JV. Anemia in children: early iron supplementation. *Indian J Pediatr.* 2000; 67(1): 19-21. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Swaminathan M, Apte S, Someswara Rao K. Nutrition of the people of Ankola Taluk N. Kanara. *Indian J Med Res.* 1960; 762-74. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Abel R, Rajaratnam J, Kalaimani A, Kirubakaran S. Can iron status be improved in each of the three trimesters? A community-based study. *Eur J Clin Nutr.* 2000; 54(6): 490-3. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Mehrotra SK, Mathur JS, Maheshwari BB. Epidemiological aspects of nutritional anaemia in children below five years. *Indian J Pediatr.* 1976; 43(340): 132-5. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Agarwal KN, Gomber S, Bisht H, Som M. Anemia prophylaxis in adolescent school girls by weekly or daily iron-folate supplementation. *Indian Pediatr.* 2003; 40(4): 296-301. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Sivakumar B, Brahmam GN, Madhavan Nair K, Ranganathan S, Vishnuvardhan Rao M, Vijayaraghavan K, Krishnaswamy K. Prospects of fortification of salt with iron and iodine. *Br J Nutr.* 2001; 167-173. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Sethi V, Goindi G, Kapil U. Prevalence of anemia amongst primary school age children (6-11 years) in National Capital Territory of Delhi. *Indian J Pediatr.* 2003; 70(6): 519-20. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Agarwal DK, Bhardwaj B, Singla PN, Tripathi AM, Agarwal KN. Etiology of maternal and early childhood deficiency anemia. *Indian J Pediatr.* 1986; 53(3): 389-95. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Agarwal DK, Agarwal KN, Tripathi AM. Nutritional status in rural pregnant women of Bihar and Uttar Pradesh. *Indian Pediatr.* 1987; 24(2): 119-25. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Raman L, Subbalaxmi P, Vasumathi N, Rawal A, Vasanthi G, Parvathi C, Adinarayana K, Pawashe A, Rao K. Iron and folic acid nutritional status of women in slum. *Nutr Report Int.* 1989; 73-81. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Singla PN, Agarwal KN. Studies on normal hemoglobin and hematocrit values in healthy children based on hematinic supplementation. *Indian Pediatr.* 1981; 18(11): 821-5. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Satyanarayana K, Pradhan DR, Ramnath T, Rao NP. Anemia and physical fitness of school children of rural Hyderabad. *Indian Pediatr.* 1990; 27(7): 715-21. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Sharma JB, Soni D, Murthy NS, Malhotra M. Effect of dietary habits on prevalence of anemia in pregnant women of Delhi. *J Obstet Gynaecol Res.* 2003; 29(2): 73-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Agarwal AK, Sen AK, Kalra NK, Gupta N. Prevalence of anaemia during pregnancy in district Burdwan, West Bengal. *Indian J Public Health.* 1999; 43(1): 26-31. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Rajaratnam J, Abel R, Asokan JS, Jonathan P. Prevalence of anemia among adolescent girls of rural Tamilnadu. *Indian Pediatr.* 2000; 37(5): 532-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Rajaratnam J, Abel R, Ganesan C, Jayaseelan SA. Maternal anaemia: a persistent problem in rural Tamil Nadu. *Natl Med J India.* 2000; 13(5): 242-5. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Kapoor D, Agarwal KN, Sharma S, Kela K, Kaur I. Iron status of children aged 9-36 months in an urban slum Integrated Child Development Services project in Delhi. *Indian Pediatr.* 2002; 39(2): 136-44. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Rusia U, Gupta S, Agarwal N, Singh K, Sikka M, Madan N. Efficacy of the new program of iron supplementation in pregnancy in India. *Indian J Hematol Blood Transfus.* 1999; 87-91. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Chiplonkar S, Agte V, Mengale S. Relative importance of micronutrient deficiencies in iron deficiency anemia. *Nutr Res.* 2003; 1355-67. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ghosh SK, Yadav RS, Das BS, Sharma VP. Influence of nutritional and haemoglobin status on malaria infection in children. *Indian J Pediatr.* 1995; 62(3): 321-6.
- Ghosh SK, Yadav RS, Das BS, Sharma VP. Influence of nutritional and haemoglobin status on malaria infection in children. *Indian J Pediatr.* 1995; 62(3): 321-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Reddaiah VP, Raj PP, Ramachandran K, Nath LM, Sood SK, Madan N, Rusia U. Supplementary iron dose in pregnancy anemia prophylaxis. *Indian J Pediatr.* 1989; 56(1): 109-14. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- India Community Trials with Iron and Iodine Fortified Salt (Double Fortified Salt) as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Abel R, Rajaratnam J, Gnanasekaran VJ, Jayaraman P. Prevalence of anaemia and iron deficiency in three trimesters in Rural Vellore district, South India. *Trop Doct.* 2001; 31(2): 86-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Thilothammal N, Sujaritha R, Banu K, Ratnam S, Ezhlarasi. The nutritional status of south Indian women in child bearing age and its influence on birth weight and maturity of offspring. *J Obstet Gynaecol India.* 1993; 871-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Parasuramalu BG, Vastrad SA, Shivaram C. Prevalence of anaemia in the aged population in selected slums of Hubli City. *Indian J Public Health.* 1990; 34(2): 117-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Agarwal DK, Upadhyay SK, Agarwal KN, Singh RD, Tripathi AM. Anaemia and mental functions in rural primary school children. *Ann Trop Paediatr.* 1989; 9(4): 194-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Shobha S, Sharada D. Efficacy of twice weekly iron supplementation in anemic adolescent girls. *Indian Pediatr.* 2003; 40(12): 1186-90. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Bhargava M, Iyer PU, Kumar R, Ramji S, Kapani V, Bhargava SK. Relationship of maternal serum ferritin with foetal serum ferritin, birth weight and gestation. *J Trop Pediatr.* 1991; 37(4): 149-52. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Sarin A. Severe anemia of pregnancy, recent experience. *Int J Gynaecol Obstet.* 1995; 50(Suppl 2): 45-49. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Kumar CSV, Anand Kumar H, Sunita V, Kapur I. Prevalence of anemia and worm infestation in school going girls at Gulbarga, Karnataka. *Indian Pediatr.* 2003; 40(1): 70-2. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Rawat CM, Garg SK, Singh JV, Bhatnagar M, Chopra H, Bajpai SK. Prevalence of anaemia among adolescent girls in rural area of District Meerut, U.P. *Indian J Public Health.* 2001; 45(1): 24-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Rusia U, Madan N, Agarwal N, Sikka M, Sood SK. Effect of maternal iron deficiency anaemia on foetal outcome. *Indian J Pathol Microbiol.* 1995; 38(3): 273-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Sidhu S. Incidence of anaemia among scheduled caste pre-school children of Punjab. *Indian J Matern Child Health.* 1996; 7(3): 76-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Nadiger HA, Krishnamachari KA, Naidu AN, Rao BS, Srikantia SG. The use of common salt (sodium chloride) fortified with iron to control anaemia: results of a preliminary study. *Br J Nutr.* 1980; 43(1): 45-51. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Gupta PC, Subramoney S, Sreevidya S. Smokeless tobacco use, birth weight, and gestational age: population based, prospective cohort study of 1217 women in Mumbai, India. *BMJ.* 2004; 328(7455): 1538. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Sharma A, Prasad K, Rao KV. Identification of an appropriate strategy to control anemia in adolescent girls of poor communities. *Indian Pediatr.* 2000; 37(3): 261-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Bains K, Mann S. Physical fitness in relation to energy and iron status of female college students. *Food Nutr Bull.* 2000; 305-10. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Gomber S, Kumar S, Rusia U, Gupta P, Agarwal KN, Sharma S. Prevalence & etiology of nutritional anaemias in early childhood in an urban slum. *Indian J Med Res.* 1998; 269-73. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Thangaleela T, Vijayalakshmi P. Prevalence of anaemia in pregnancy. *Indian J Nutr Diet.* 1994; 26-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Sarma KV, Naidu AN. Anemia in children. *Indian Pediatr.* 1984; 21(4): 295-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Uberoi IS, DeSweemer C, Taylor CE. A study of anemia among rural Punjabi children. *Indian J Med Res.* 1972; 60(5): 793-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Purohit CK, Sharma R. A study of general health status of persons aged 60 years and above in the Rural Health Training Centre Area, Naila. *Indian J Med Res.* 1976; 64(2): 202-10. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Yusufji, Mathan VI, Baker SJ. Iron, folate, and vitamin B 12 nutrition in pregnancy: a study of 1000 women from southern India. *Bull World Health Organ.* 1973; 48(1): 15-22. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Agarwal KN, Agarwal DK, Mishra KP. Impact of anaemia prophylaxis in pregnancy on maternal haemoglobin, serum ferritin & birth weight. *Indian J Med Res.* 1991; 277-80. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Koen M, Lemson M, Sampathkumar V, Abel R. Prevalence of anaemia among pregnant mothers in a rural South Indian population. *J Obstet Gynaecol India.* 1992; 283-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ghosh R, Bharati P. Haemoglobin status of adult women of two ethnic groups living in a peri-urban area of Kolkata city, India: a micro-level study. *Asia Pac J Clin Nutr.* 2003; 12(4): 451-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Chaturvedi S, Kapil U, Gnanasekaran N, Sachdev HP, Pandey RM, Bhanti T. Nutrient intake amongst adolescent girls belonging to poor socioeconomic group of rural area of Rajasthan. *Indian Pediatr.* 1996; 33(3): 197-201. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Luwang N, Gupta V. Anaemia in pregnancy in a rural community-influence of dietary intake in the multifactorial aetiology. *Indian J Nutr Diet.* 1980; 414-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Bharati P, Ghosh R, Gupta R. Socioeconomic Condition and Anaemia among the Mahishya Population of Southern West Bengal, India. *Malays J Nutr.* 2004; 10(1): 23-30. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Gopaldas T, Kale M. Prophylactic iron supplementation for underprivileged school boys. I. Two levels of dosing and efficacy of teacher-distributions. *Indian Pediatr.* 1985; 22(10): 731-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Swain S, Singh S, Bhatia BD, Pandey S, Krishna M. Maternal hemoglobin and serum albumin and fetal growth. *Indian Pediatr.* 1994; 31(7): 777-82. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ray SK, Mallick S, Kumar S, Biswas B. A rapid assessment of anaemia in pregnancy in West Bengal with special reference to care seeking behaviour of mothers. *Indian J Public Health.* 2000; 44(2): 58-64. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Shah SN, Bakash A, Rauf A, Muzzafar A, Zuthshi ML. Incidence of iron deficiency anaemia in rural population of Kashmir. *Indian J Public Health.* 1982; 26(3): 144-54. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Sari M, de Pee S, Martini E, Herman S, Sugiati, Bloem MW, Yip R. Estimating the prevalence of anaemia: a comparison of three methods. *Bull World Health Organ.* 2001; 79(6): 506-11. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Kusin JA, Kardjati S, Suryohudoyo P, De With C. Anemia and hypovitaminosis A among rural women in East Java, Indonesia. *Trop Geogr Med.* 1980; 32(1): 30-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Pegelow K, Gross R, Pietrzik K, Lukito W, Richards AL, Fryauff DJ. Parasitological and nutritional situation of school children in the Sukaraja district, West Java, Indonesia. *Southeast Asian J Trop Med Public Health.* 1997; 28(1): 173-90. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- De Pee S, Bloem MW, Sari M, Kiess L, Yip R, Kosen S. The high prevalence of low hemoglobin concentration among Indonesian infants aged 3-5 months is related to maternal anemia. *J Nutr.* 2002; 132(8): 2215-21. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Sari M, Bloem MW, de Pee S, Schultink WJ, Sastroamidjojo S. Effect of iron-fortified candies on the iron status of children aged 4-6 y in East Jakarta, Indonesia. *Am J Clin Nutr.* 2001; 73(6): 1034-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Soekarjo DD, de Pee S, Bloem MW, Tjiong R, Yip R, Schreurs WH, Muhilal. Socio-economic status and puberty are the main factors determining anaemia in adolescent girls and boys in East Java, Indonesia. *Eur J Clin Nutr.* 2001; 55(11): 932-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Muslimatun S, Schmidt MK, Schultink W, West CE, Hautvast JA, Gross R, Muhilal. Weekly supplementation with iron and vitamin A during pregnancy increases hemoglobin concentration but decreases serum ferritin concentration in Indonesian pregnant women. *J Nutr.* 2001; 131(1): 85-90. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Suega K, Dharmayuda TG, Sutarga IM, Bakta IM. Iron-deficiency anemia in pregnant women in Bali, Indonesia: a profile of risk factors and epidemiology. *Southeast Asian J Trop Med Public Health.* 2002; 33(3): 604-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Lind T, Lönnerdal B, Stenlund H, Ismail D, Seswandhana R, Ekström E-C, Persson L-A. A community-based randomized controlled trial of iron and zinc supplementation in Indonesian infants: interactions between iron and zinc. *Am J Clin Nutr.* 2003; 77(4): 883-90. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Chi IC, Agoestina T, Harbin J. Maternal mortality at twelve teaching hospitals in Indonesia-an epidemiologic analysis. *Int J Gynaecol Obstet.* 1981; 19(4): 259-66. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Thorand B, Schultink W, Gross R, Sastroamidjojo S, Wentzel S. Efficiency of the iron supplementation programme for pregnant women in Jenepono, Sulawesi, Indonesia. *Asia Pac J Clin Nutr.* 1994; 3(4): 211-5. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Andrade Juguan J, Lukito W, Schultink W. Thiamine deficiency is prevalent in a selected group of urban Indonesian elderly people. *J Nutr.* 1999; 129(2): 366-71. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Angeles-Agdeppa I, Schultink W, Sastroamidjojo S, Gross R, Karyadi D. Weekly micronutrient supplementation to build iron stores in female Indonesian adolescents. *Am J Clin Nutr.* 1997; 66(1): 177-83. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Palupi L, Schultink W, Achadi E, Gross R. Effective community intervention to improve hemoglobin status in preschoolers receiving once-weekly iron supplementation. *Am J Clin Nutr.* 1997; 65(4): 1057-61. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Nurdia DS, Sumarni S, Suyoko, Hakim M, Winkvist A. Impact of intestinal helminth infection on anemia and iron status during pregnancy: a community based study in Indonesia. *Southeast Asian J Trop Med Public Health.* 2001; 32(1): 14-22. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Dijkhuizen MA, Wieringa FT, West CE, Muherdiyantiningsih, Muhilal. Concurrent micronutrient deficiencies in lactating mothers and their infants in Indonesia. *Am J Clin Nutr.* 2001; 73(4): 786-91. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ridwan E, Schultink W, Dillon D, Gross R. Effects of weekly iron supplementation on pregnant Indonesian women are similar to those of daily supplementation. *Am J Clin Nutr.* 1996; 63(6): 884-90. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Suharno D, West CE, Muhilal, Logman MH, de Waart FG, Karyadi D, Hautvast JG. Cross-sectional study on the iron and vitamin A status of pregnant women in West Java, Indonesia. *Am J Clin Nutr.* 1992; 56(6): 988-93. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Moshirfatemi M, Faghihi M, Salimi M, Banan A, Khatibi A. Hemoglobin levels in an obstetric population in Isfahan, Iran. *Iran J Public Health.* 1976; 113-20. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Kianfar H, Kimiagar M, Ghaffarpour M. Effect of daily and intermittent iron supplementation on iron status of high school girls. *Int J Vitam Nutr Res.* 2000; 70(4): 172-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Froozani MD, Vahdani F, Montazami K, Maiekafzali H. Maternal and newborn iron status in a public and a private maternity hospital at delivery in Tehran. *J Trop Pediatr Environ Child Health.* 1978; 24(4): 182-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Karimi M, Kadivar R, Yarmohammadi H. Assessment of the prevalence of iron deficiency anemia, by serum ferritin, in pregnant women of Southern Iran. *Med Sci Monit.* 2002; 8(7): 488-492. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Mukhlis G. Level of hemoglobin concentration in Baghdad kindergarten children. *Bull Endem Dis (Baghdad).* 1982; 99-106. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Alkasab F, Alkafajei A, Kutty P, Al-Windawi S, Antony R, Zuiabie A, Al-Septi S. Hematological profile of women in the reproductive age in southern Iraq. *Iraqi Med J.* 1987; 33-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Al-Sharbatti SS, Al-Ward NJ, Al-Timimi DJ. Anemia among adolescents. *Saudi Med J.* 2003; 24(2): 189-94. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Armstrong PL. Iron deficiency in adolescents. *BMJ.* 1989; 298(6672): 499. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Shehab S, Nutenker K, Ron M, Salahov E, Tulchinsky TH. Hemoglobin levels among Arab and Druze children aged 1-2 years in Akko subdistrict. *Public Health Rev.* 2000; 28(1-4): 75-81. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Inelmen EM, D'Alessio M, Gatto MR, Baggio MB, Jimenez G, Bizzotto MG, Enzi G. Descriptive analysis of the prevalence of anemia in a randomly selected sample of elderly people living at home: some results of an Italian multicentric study. *Aging (Milano).* 1994; 6(2): 81-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Fidanza F, Losito G. Nutritional status of the elderly. Anthropometry, diet and clinical data from old pensioners in Perugia, Italy. *Bibl Nutr Dieta.* 1981; 70-80. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Frondaroli F, Di Leonardo A, Tella D, Khalig JG. [The epidemiology of sideropenic anemia and beta-thalassemia in pregnancy in the Chieti area]. *Minerva Ginecol.* 1994; 46(10): 557-60. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Grantham-McGregor SM, Desai P, Milner PF. Haematological levels in Jamaican infants. *Arch Dis Child.* 1974; 49(7): 525-30. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Simmons WK, Jutsum PJ, Fox K, Spence M, Gueri M, Paradis R, Gurney JM. A survey of the anemia status of preschool age children and pregnant and lactating women in Jamaica. *Am J Clin Nutr.* 1982; 35(2): 319-26. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Micronutrient Working Group. Assessment of the iron supplementation programme for pregnant women in Jamaica. *Cajanus.* 2002; 35-49. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ahern EJ, Swan AV, Ahern VN. The prevalence of iron deficient erythropoiesis and anaemia in a rural Jamaican community. *Br J Haematol.* 1972; 22(3): 273-80. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Mesfin E, Sinha D, Jutsum P, Simmons W, Eldemire D. Nutritional status, socio-economic environment and the lifestyle of the elderly in August Town, Kingston, Jamaica, 1984. *Cajanus.* 1987; 23-47. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Maeda M, Yamamoto M, Yamauchi K. Prevalence of anemia in Japanese adolescents: 30 years' experience in screening for anemia. *Int J Hematol.* 1999; 69(2): 75-80. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Fujii M, Miyoshi T, Tada T, Goto H, Ishimoto H. Incidence of anemia in women in fishing villages. *Tokushima J Exp Med.* 1993; 40(3-4): 183-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Watanabe T, Ishihara N, Miyasaka M, Koizumi A, Fujita H, Ikeda M. Hemoglobin levels among Japanese farmers: with special reference to climate and work intensity. *Hum Biol.* 1986; 58(2): 197-208. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hokama T. A study of the hemoglobin levels in breast-fed infants in one village of Okinawa prefecture. *Acta Paediatr Jpn.* 1993; 35(2): 138-40. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Albsoul-Younes AM, Al-Ramahi RJ, Al-Safi SA. Frequency of anemia in pregnancy in Northern Jordan. *Saudi Med J.* 2004; 25(10): 1525-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Mawajdeh SM, Al-Qutob R, Schmidt A. Measuring reproductive morbidity: a community-based approach, Jordan. *Health Care Women Int.* 2003; 24(7): 635-49. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Dangour AD, Hill HL, Ismail SJ. Haemoglobin status of adult non-pregnant Kazakh women living in Kzyl-Orda region, Kazakhstan. *Eur J Clin Nutr.* 2001; 55(12): 1068-75. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hashizume M, Kunii O, Sasaki S, Shimoda T, Wakai S, Mazhitova Z, Dauletbaev D, Caypil W, Aldiyarova M, Farmer A, Yamashiro Y, Chiba M. Anemia and iron deficiency among schoolchildren in the Aral Sea region, Kazakhstan. *J Trop Pediatr.* 2003; 49(3): 172-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Newton CR, Warn PA, Winstanley PA, Peshu N, Snow RW, Pasvol G, Marsh K. Severe anaemia in children living in a malaria endemic area of Kenya. *Trop Med Int Health.* 1997; 2(2): 165-78. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Brooker S, Peshu N, Warn PA, Mosobo M, Guyatt HL, Marsh K, Snow RW. The epidemiology of hookworm infection and its contribution to anaemia among pre-school children on the Kenyan coast. *Trans R Soc Trop Med Hyg.* 1999; 93(3): 240-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Olsen A, Magnussen P, Ouma JH, Andreassen J, Friis H. The contribution of hookworm and other parasitic infections to haemoglobin and iron status among children and adults in western Kenya. *Trans R Soc Trop Med Hyg.* 1998; 92(6): 643-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Geissler PW, Mwaniki DL, Thiong'o F, Michaelsen KF, Friis H. Geophagy, iron status and anaemia among primary school children in Western Kenya. *Trop Med Int Health.* 1998; 3(7): 529-34. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Akhwale WS, Lum JK, Kaneko A, Eto H, Obonyo C, Björkman A, Kobayakawa T. Anemia and malaria at different altitudes in the western highlands of Kenya. *Acta Trop.* 2004; 91(2): 167-75.
- Akhwale WS, Lum JK, Kaneko A, Eto H, Obonyo C, Björkman A, Kobayakawa T. Anemia and malaria at different altitudes in the western highlands of Kenya. *Acta Trop.* 2004; 91(2): 167-75. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Leenstra T, Kariuki SK, Kurtis JD, Oloo AJ, Kager PA, ter Kuile FO. Prevalence and severity of anemia and iron deficiency: cross-sectional studies in adolescent schoolgirls in western Kenya. *Eur J Clin Nutr.* 2004; 58(4): 681-91. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Friis H, Mwaniki D, Omondi B, Muniu E, Thiong'o F, Ouma J, Magnussen P, Geissler PW, Michaelsen KF. Effects on haemoglobin of multi-micronutrient supplementation and multi-helminth chemotherapy: a randomized, controlled trial in Kenyan school children. *Eur J Clin Nutr.* 2003; 57(4): 573-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Shulman CE, Levene M, Morison L, Dorman E, Peshu N, Marsh K. Screening for severe anaemia in pregnancy in Kenya, using pallor examination and self-reported morbidity. *Trans R Soc Trop Med Hyg.* 2001; 95(3): 250-5. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

Neumann CG, Bwibo NO, Murphy SP, Sigman M, Whaley S, Allen LH, Guthrie D, Weiss RE, Demment MW. Animal source foods improve dietary quality, micronutrient status, growth and cognitive function in Kenyan school children: background, study design and baseline findings. *J Nutr.* 2003; 133(11 Suppl 2): 3941-3949. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Ter Kuile FO, Terlouw DJ, Phillips-Howard PA, Hawley WA, Friedman JF, Kolczak MS, Kariuki SK, Shi YP, Kwena AM, Vulule JM, Nahlen BL. Impact of permethrin-treated bed nets on malaria and all-cause morbidity in young children in an area of intense perennial malaria transmission in western Kenya: cross-sectional survey. *Am J Trop Med Hyg.* 2003; 68(4 Suppl): 100-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Zucker JR, Lackritz EM, Ruebush TK, Hightower AW, Adungosi JE, Were JB, Campbell CC. Anaemia, blood transfusion practices, HIV and mortality among women of reproductive age in western Kenya. *Trans R Soc Trop Med Hyg.* 1994; 88(2): 173-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Shulman CE, Graham WJ, Jilo H, Lowe BS, New L, Obiero J, Snow RW, Marsh K. Malaria is an important cause of anaemia in primigravidae: evidence from a district hospital in coastal Kenya. *Trans R Soc Trop Med Hyg.* 1996; 90(5): 535-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Spencer HC, Kaseje DC, Sempebwa EK, Huong AY, Roberts JM. Malaria chemoprophylaxis to pregnant women provided by community health workers in Saradidi, Kenya. II. Effect on parasitaemia and haemoglobin levels. *Ann Trop Med Parasitol.* 1987; 83-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Roberts AB, Roberts P, Tira T, Tulimanu K. Malnutrition and anaemia in Gilbertese pre-school children: a case-finding and epidemiological survey. *J Trop Pediatr.* 1981; 27(2): 78-82. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Jackson R, Al Hamad N, Al-Somaie M, Al Guoad N, Prakash P. Gender and age differences in anemia prevalence during the lifecycle in Kuwait. *Ecol Food Nutr.* 2004; 61-75. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Al-Haifi A, Huffman F. Feeding practices influence weight and hemoglobin status in Kuwaiti infants. *Ecol Food Nutr.* 2004; 41-59. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Jackson RT, Al-Mousa Z. Iron deficiency is a more important cause of anemia than hemoglobinopathies in Kuwaiti adolescent girls. *J Nutr.* 2000; 130(5): 1212-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Eid N, Al-Hooti S, Bourisly N, Khalafawi M. Anaemia in school children: a preliminary study. *J Kuwait Med Assoc.* 1986; 39-43. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Dawood J, Prakash P, Shubber K. Iron deficiency anaemia among pregnant Arab women in Kuwait. *J Kuwait Med Assoc.* 1990; 167-72. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Al Mousa Z, Prakash P, Jackson R, Al Raqua M. A comparison of selected nutrient intakes in anemic and nonanemic adolescent girls in Kuwait. *Nutr Res.* 2003; 425-433. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Hershko C, Moreb J, Gaziel Y, Konijn AM, Rachmilewitz EA. Reduced frequency of iron deficiency anaemia in sickle cell trait. *Scand J Haematol.* 1982; 29(4): 304-10. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Al Khatib L, Obeid O, Sibai A-M, Batal M, Adra N, Hwalla N. Folate deficiency is associated with nutritional anaemia in Lebanese women of childbearing age. *Public Health Nutr.* 2006; 9(7): 921-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Jackson RT. Hemoglobin levels and anemia-associated symptoms in pregnant Liberian women. *Nutrition.* 1992; 8(6): 430-3. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Jackson RT, Latham MC. Anemia of pregnancy in Liberia, West Africa: a therapeutic trial. *Am J Clin Nutr.* 1982; 35(4): 710-4. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Bredan AS, Kumar NS, Bshiwah SM. Hematologic values and prevalence of anaemia in Libyan school children. *Trop Geogr Med.* 1983; 35(4): 357-61. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Verhoeff FH, Brabin BJ, Chimsuku L, Kazembe P, Broadhead RL. Malaria in pregnancy and its consequences for the infant in rural Malawi. *Ann Trop Med Parasitol.* 1999; 25-33. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Van den Broek NR, Rogerson SJ, Mhango CG, Kambala B, White SA, Molyneux ME. Anaemia in pregnancy in southern Malawi: prevalence and risk factors. *BJOG.* 2000; 107(4): 445-51. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Mukiibi JM, Mtimavalye LA, Broadhead R, Mzula E, Dzinyemba WE, Merrick R, Khoromana CO, Ching'ani GW. Some haematological parameters in Malawian neonates. *East Afr Med J.* 1995; 72(1): 10-4. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Semba RD, Kumwenda N, Taha TE, Mtimavalye L, Broadhead R, Garrett E, Miotti PG, Chipangwi JD. Impact of vitamin A supplementation on anaemia and plasma erythropoietin concentrations in pregnant women: a controlled clinical trial. *Eur J Haematol.* 2001; 66(6): 389-95. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Yeudall F, Gibson RS, Kayira C, Umar E. Efficacy of a multi-micronutrient dietary intervention based on haemoglobin, hair zinc concentrations, and selected functional outcomes in rural Malawian children. *Eur J Clin Nutr.* 2002; 56(12): 1176-85.
- Yeudall F, Gibson RS, Kayira C, Umar E. Efficacy of a multi-micronutrient dietary intervention based on haemoglobin, hair zinc concentrations, and selected functional outcomes in rural Malawian children. *Eur J Clin Nutr.* 2002; 56(12): 1176-85. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Fazio-Tirrozzo G, Brabin L, Brabin B, Agbaje O, Harper G, Broadhead R. A community based study of vitamin A and vitamin E status of adolescent girls living in the Shire Valley, Southern Malawi. *Eur J Clin Nutr.* 1998; 52(9): 637-42. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Van den Broek NR, Ntonya C, Mhango E, White SA. Diagnosing anaemia in pregnancy in rural clinics: assessing the potential of the Haemoglobin Colour Scale. *Bull World Health Organ.* 1999; 77(1): 15-21. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Sagin DD, Ismail G, Mohamad M, Pang EKH, Sya OT. Anemia in remote interior communities in Sarawak, Malaysia. *Southeast Asian J Trop Med Public Health.* 2002; 33(2): 373-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Tee ES Jr, Khor G, Tony N, Yassin Z, Chee H, Mdyusof S. Nutritional assessment of rural villages and estates in Peninsular Malaysia*. III. Prevalence of anaemia. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ahmad Z Jr, Jaafar R, Mohd Hassan M, Othman M, Hashim A. Anaemia during pregnancy in rural Kelantan. *Malays J Nutr.* 1997; 3(1): 83-90. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Foo LH, Khor GL, Tee E-S, Prabakaran D. Iron status and dietary iron intake of adolescents from a rural community in Sabah, Malaysia. *Asia Pac J Clin Nutr.* 2004; 13(1): 48-55. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Tee ES, Kandiah M, Awin N, Chong SM, Satgunasingam N, Kamarudin L, Milani S, Dugdale AE, Viteri FE. School-administered weekly iron-folate supplements improve hemoglobin and ferritin concentrations in Malaysian adolescent girls. *Am J Clin Nutr.* 1999; 69(6): 1249-56. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ahmad Z Jr, Jaafar R, Mohd Hassan M, Othman M, Hashim A. Anaemia during pregnancy in rural Kelantan. *Malays J Nutr.* 1997; 3(1): 83-90. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Shahar S, Earland J, Powers HJ, Rahman SA. Nutritional status of rural elderly Malays: dietary and biochemical findings. *Int J Vitam Nutr Res.* 1999; 69(4): 277-84. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Tee ES Jr, Khor G, Tony N, Yassin Z, Chee H, Mdyusof S. Nutritional assessment of rural villages and estates in Peninsular Malaysia*. III. Prevalence of anaemia. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ong HC. Anaemia in pregnancy in an aboriginal population. *J Trop Med Hyg.* 1974; 77(1): 22-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hall A, Roschnik N, Ouattara F, Touré I, Maiga F, Sacko M, Moestue H, Bendeck MA. A randomised trial in Mali of the effectiveness of weekly iron supplements given by teachers on the haemoglobin concentrations of schoolchildren. *Public Health Nutr.* 2002; 5(3): 413-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Palafox NA, Gamble MV, Dancheck B, Ricks MO, Briand K, Semba RD. Vitamin A deficiency, iron deficiency, and anemia among preschool children in the Republic of the Marshall Islands. *Nutrition.* 2003; 19(5): 405-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Urbani C, Touré A, Hamed AO, Albonico M, Kane I, Cheikna D, Hamed NO, Montresor A, Savioli L. [Intestinal parasitic infections and schistosomiasis in the valley of the Senegal river in the Islamic Republic of Mauritania]. *Med Trop (Mars).* 1997; 57(2): 157-60. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Monárrez-Espino J, Martínez H, Martínez V, Greiner T. Nutritional status of indigenous children at boarding schools in northern Mexico. *Eur J Clin Nutr.* 2004; 58(3): 532-40. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Loría A, Sánchez Medal L, García Viveros J, Piedras J. [Nutritional anemia. 3. Iron deficiency in children under 7 years of age and of low socioeconomic condition]. *Rev Invest Clin.* 1971; 23(1): 11-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Vásquez-Garibay EM, Romero-Velarde E, Nápoles-Rodríguez F, Nuño-Cosío ME, Trujillo-Contreras F, Sánchez-Mercado O. [Prevalence of iron and iodine deficiency, and parasitosis among children from Arandas, Jalisco, Mexico]. *Salud Publica Mex.* 2002; 44(3): 195-200. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Kordas K, Lopez P, Rosado JL, García Vargas G, Alatorre Rico J, Ronquillo D, Cebrián ME, Stoltzfus RJ. Blood lead, anemia, and short stature are independently associated with cognitive performance in Mexican school children. *J Nutr.* 2004; 134(2): 363-71. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Martínez H, González-Cossío T, Flores M, Rivera-Dommarco J, Lezana MA, Sepúlveda-Amor J. [Anemia in women of reproductive age. The results of a national probability survey]. *Salud Publica Mex.* 1995; 37(2): 108-19. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

Tejas AR, Wyatt CJ, Ramírez MJ. Prevalence of undernutrition and iron deficiency in pre-school children from different socioeconomic regions in the city of Oaxaca, Oaxaca, Mexico. *J Nutr Sci Vitaminol*. 2001; 47(1): 47-51. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Ramakrishnan U, González-Cossio T, Neufeld L, Rivera J, Martorell R. Multiple micronutrient supplementation during pregnancy does not lead to greater infant birth size than does iron-only supplementation: a randomized controlled trial in a semirural community in Mexico. *Am J Clin Nutr*. 2003; 720-5. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Báez Flores M, Chávez Villasana A, Trimer Hernández C, Lara JM. [Anemia in pregnancy. Study of 600 pregnant women in the city of Saltillo, Coah]. *Salud Publica Mex*. 1966; 8(4): 573-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Monárrez-Espino J, Martínez H, Greiner T. Iron deficiency anemia in Tarahumara women of reproductive-age in northern Mexico. *Salud Publica Mex*. 2001; 43(5): 392-401. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Rivera R, Ruiz R, Hegenauer J, Saltman P, Green R. Bioavailability of iron- and copper-supplemented milk for Mexican school children. *Am J Clin Nutr*. 1982; 36(6): 1162-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Maulen-Radovan I, Villagómez S, Soler E, Villicaña R, Hernández-Ronquillo L, Rosado JL. [Nutritional impact of whole milk supplemented with vitamins and minerals in children]. *Salud Publica Mex*. 1999; 41(5): 389-96. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Vásquez-Molina ME, Corral-Terrazas M, Apezteguia MA, Carmona-Sawasky J, Levario-Carrillo M. [Relationship between maternal and neonatal iron stores]. *Salud Publica Mex*. 2001; 43(5): 402-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Black AK, Allen LH, Pelto GH, de Mata MP, Chávez A. Iron, vitamin B-12 and folate status in Mexico: associated factors in men and women and during pregnancy and lactation. *J Nutr*. 1994; 124(8): 1179-88. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Ramírez-Mateos C, Loría A, Nieto-Gómez M, Malacara JM, Piedras J. [Anemia and iron deficiency in 490 Mexican pregnant women]. *Rev Invest Clin*. 1998; 50(2): 119-26. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Moriarty-Craige SE, Ramakrishnan U, Neufeld L, Rivera J, Martorell R. Multivitamin-mineral supplementation is not as efficacious as is iron supplementation in improving hemoglobin concentrations in nonpregnant anemic women living in Mexico. *Am J Clin Nutr*. 2004; 80(5): 1308-11. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Jaime-Pérez JC, Gómez-Almaguer D. Iron stores in low-income pregnant Mexican women at term. *Arch Med Res*. 2002; 33(1): 81-4. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Rivera Damm R, Ruiz Astorga MR, Carrillo de Jiménez H, Hernández Alvarado AB, Sosa Curiel S. [Prevalence of anemia in a sample of school children in Durango City]. *Bol Med Hosp Infant Mex*. 1979; 36(3): 507-17. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Allen LH, Rosado JL, Casterline JE, López P, Muñoz E, García OP, Martínez H. Lack of hemoglobin response to iron supplementation in anemic Mexican preschoolers with multiple micronutrient deficiencies. *Am J Clin Nutr*. 2000; 71(6): 1485-94. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Zimmermann MB, Wegmueller R, Zeder C, Chaouki N, Rohner F, Saïssi M, Torresani T, Hurrell RF. Dual fortification of salt with iodine and micronized ferric pyrophosphate: a randomized, double-blind, controlled trial. *Am J Clin Nutr*. 2004; 80(4): 952-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Liljestrand J, Bergström S, Birgegård G. Anaemia of pregnancy in Mozambique. *Trans R Soc Trop Med Hyg*. 1986; 80(2): 249-55. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Bergström S, Fernandes A, Schwalbach J, Perez O, Miyar R. Materno-fetal transmission of pregnancy malaria: an immunoparasitological study on 202 parturients in Maputo. *Gynecol Obstet Invest*. 1993; 35(2): 103-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Batu AT, Toe T, Pe H, Nyunt KK. A prophylactic trial of iron and folic acid supplements in pregnant Burmese women. *Isr J Med Sci*. 1976; 12(12): 1410-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Batu AT, Hla-Pe U, Than T, Nyunt KK. Iron deficiency in Burmese population groups. *Am J Clin Nutr*. 1972; 25(2): 210-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Thomson J. Anaemia in pregnant women in eastern Caprivi, Namibia. *S Afr Med J*. 1997; 87(11): 1544-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Christian P, Shrestha J, LeClerq SC, Khatri SK, Jiang T, Wagner T, Katz J, West KP Jr. Supplementation with micronutrients in addition to iron and folic acid does not further improve the hematologic status of pregnant women in rural Nepal. *J Nutr*. 2003; 133(11): 3492-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Shrestha PN. Anemia in children of rural Kathmandu. *Indian J Pediatr*. 1986; 53(5): 647-50. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Brink EW, Khan IH, Splitter JL, Staehling NW, Lane JM, Nichaman MZ. Nutritional status of children in Nepal, 1975. *Bull World Health Organ.* 1976; 54(3): 311-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Dreyfuss M, Shrestha J, Khatri S, Shrestha S, Dali S, Adhikari R, Pokhrel R. The prevalence of anaemia among pregnant and lactating women, and among their infants in Sarlahi district. *J Nepal Med Assoc.* 1997; 234-40. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Adams WH, Gurung S. Anaemia of pregnancy in Kathmandu, Nepal. A clinical appraisal of statistical predictions of anaemia in a population. *Trop Geogr Med.* 1977; 29(4): 359-64. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Curtale F, Tilden R, Muhilal, Vaidya Y, Pokhrel RP, Guerra R. Intestinal helminths and risk of anaemia among Nepalese children. *Panminerva Med.* 1993; 35(3): 159-66. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Jiang T, Christian P, Khatri SK, Wu L, West KP Jr. Micronutrient deficiencies in early pregnancy are common, concurrent, and vary by season among rural Nepali pregnant women. *J Nutr.* 2005; 135(5): 1106-12. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Dreyfuss ML, Stoltzfus RJ, Shrestha JB, Pradhan EK, LeClerq SC, Khatri SK, Shrestha SR, Katz J, Albonico M, West KP Jr. Hookworms, malaria and vitamin A deficiency contribute to anemia and iron deficiency among pregnant women in the plains of Nepal. *J Nutr.* 2000; 130(10): 2527-36. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Fawcett JP, Brooke M, Beresford CH. Iron deficiency and anaemia in a longitudinal study of New Zealanders at ages 11 and 21 years. *N Z Med J.* 1998; 111(1076): 400-2. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Campbell AJ, Murphy C, Reinken J, Allan B. Anaemia in old age: a study of prevalence and causes. *N Z Med J.* 1981; 94(692): 209-11. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Soh P, Ferguson EL, McKenzie JE, Homs MYV, Gibson RS. Iron deficiency and risk factors for lower iron stores in 6-24-month-old New Zealanders. *Eur J Clin Nutr.* 2004; 58(1): 71-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Neave M. The treatment of iron deficiency anaemia among Maori pre-school children. *N Z Med J.* 1965; 64(395): 389-91. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Schaaf D, Scragg R, Metcalf P, Grant C, Buchanan J. Prevalence of iron deficiency in Auckland high school students. *N Z Med J.* 2000; 113(1116): 347-50. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- NEAVE M, PRIOR IA, TOMS V. The prevalence of anaemia in two Maori rural communities. *N Z Med J.* 1963; 20-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Emery D, Barry D. Comparison of Maori and non-Maori maternal and fetal iron parameters. *N Z Med J.* 2004; 117(1195): 909. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Heath AL, Skeaff CM, Williams S, Gibson RS. The role of blood loss and diet in the aetiology of mild iron deficiency in premenopausal adult New Zealand women. *Public Health Nutr.* 2001; 4(2): 197-206. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Anyon CP. Normal haemoglobin values in urban Polynesian infants: the possible deleterious influence of artificial feeding. *N Z Med J.* 1976; 84(578): 474-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Gyssens IC, Meheus AZ. Anemia of pregnancy in Niger, West Africa: a prevalence study. *Ann Soc Belg Med Trop.* 1986; 66(3): 257-64. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Preziosi P, Prual A, Galan P, Daouda H, Boureima H, Hercberg S. Effect of iron supplementation on the iron status of pregnant women: consequences for newborns. *Am J Clin Nutr.* 1997; 66(5): 1178-82. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Prual A, Daouda H, Develoux M, Sellin B, Galan P, Hercberg S. Consequences of *Schistosoma haematobium* infection on the iron status of schoolchildren in Niger. *Am J Trop Med Hyg.* 1992; 47(3): 291-7. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Prual A, Daouda H, Develoux M, Sellin B, Galan P, Hercberg S. Consequences of *Schistosoma haematobium* infection on the iron status of schoolchildren in Niger. *Am J Trop Med Hyg.* 1992; 47(3): 291-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Lyko Z, Lyko J, Gaertner H. Anemia in pregnancy in Nigeria: hemoglobin level in pregnant patients of the Ife region hospital. *Hamdard Medicus.* 1993; 116-24. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Reid H. Physiological changes in packed-cell volume and haemoglobin levels in Nigerian Igbo women during pregnancy. *East Afr Med J.* 1996; 201-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Ozumba BC, Igwegbe AO. The challenge of grandmultiparity in Nigerian obstetric practice. *Int J Gynaecol Obstet.* 1992; 37(4): 259-64. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Brabin L, Ikimalo J, Dollimore N, Kemp J, Ikoku-Wonodi C, Babatunde S, Obunge O, Briggs N. How do they grow? A study of south-eastern Nigerian adolescent girls. *Acta Paediatr.* 1997; 86(10): 1114-20. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Onadeko MO, Avokey F, Lawoyin TO. Observations of stillbirths, birthweight and maternal haemoglobin in teenage pregnancy in Ibadan, Nigeria. *Afr J Med Med Sci.* 1996; 25(1): 81-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Barr F, Brabin L, Agbaje S, Buseri F, Ikimalo J, Briggs N. Reducing iron deficiency anaemia due to heavy menstrual blood loss in Nigerian rural adolescents. *Public Health Nutr.* 1998; 1(4): 249-57. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Gwarzo MY, Sen KK, Atiku MK. Diet and serum iron status in pregnant and lactating Hausa women in Kano State, Nigeria. *Ann Trop Med Parasitol.* 1994; 88(6): 673-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Fleming AF, Harrison KA, Briggs ND, Attai ED, Ghatoura GB, Akintunde EA, Shah N. Anaemia in young primigravidae in the guinea savanna of Nigeria: sickle-cell trait gives partial protection against malaria. *Ann Trop Med Parasitol.* 1984; 78(4): 395-404. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Borch-Iohnsen B, Sandstad B, Asberg A. Iron status among 3005 women aged 20-55 years in Central Norway: the Nord-Trøndelag Health Study (the HUNT study). *Scand J Clin Lab Invest.* 2005; 65(1): 45-54. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Eskeland B, Hunskaar S. Anaemia and iron deficiency screening in adolescence: a pilot study of iron stores and haemoglobin response to iron treatment in a population of 14-15-year-olds in Norway. *Acta Paediatr.* 1999; 88(8): 815-21. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Borch-Iohnsen B, Sandstad B, Asberg A. Iron status among 3005 women aged 20-55 years in Central Norway: the Nord-Trøndelag Health Study (the HUNT study). *Scand J Clin Lab Invest.* 2005; 65(1): 45-54. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hamedani P, Hashmi KZ, Manji M. Iron depletion and anaemia: prevalence, consequences, diagnostic and therapeutic implications in a developing Pakistani population. *Curr Med Res Opin.* 1987; 10(7): 480-5. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Paracha PI, Hameed A, Simon J, Jamil A, Nawab G. Prevalence of anaemia in semi-urban areas of Peshawar, Pakistan: a challenge for health professionals and policy makers. *J Pak Med Assoc.* 1997; 47(2): 49-53. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Molla A, Khurshid M, Molla AM. Prevalence of iron deficiency anaemia in children of the urban slums of Karachi. *J Pak Med Assoc.* 1992; 42(5): 118-21. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Aziz-Karim S, Khurshid M, Rizvi JH, Jafarey SN, Siddiqui RI. Anaemia in pregnancy--a study of 709 women in Karachi. *Trop Doct.* 1990; 20(4): 184-5. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Karim SA, Khurshid M, Memon AM, Jafarey SN. Anaemia in pregnancy--its cause in the underprivileged class of Karachi. *J Pak Med Assoc.* 1994; 44(4): 90-2. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Agha F, Hasan TJ, Khan RA, Jafarey S. Iron stores in maternal and cord blood. *Asia Oceania J Obstet Gynaecol.* 1988; 14(4): 405-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hassan K, Hayat A, Khan U, Ikram N, Dodhy M, Afghan R, Tahir M. Reference values of hematological parameters in full term normal neonates in Rawalpindi and Islamabad. *Pak J Obstet Gynecol.* 1994; 29-31. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Baig L, Thaver IH, Iqbal R. Risk factors associated with anaemia in children less than 5 years of age residing in a squatter settlement of Karachi. *Pak J Med Res.* 1996; 35(4): 176-178. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Sill PR, White JC, Cheetham JM. A survey of haemoglobin concentration in pregnancy in Port Moresby, Papua New Guinea. *P N G Med J.* 1986; 29(3): 221-4. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Crane G, Hornabrook R, Kelly A. Anemia on the coast and highlands of New Guinea. *Hum Biol Oceania.* 1972; 234-41. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Brabin B, Piper C. Anaemia- and malaria-attributable low birthweight in two populations in Papua New Guinea. *Ann Hum Biol.* 1997; 24(6): 547-55. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Mola G, Permezel M, Amoa AB, Klufio CA. Anaemia and perinatal outcome in Port Moresby. *Aust N Z J Obstet Gynaecol.* 1999; 39(1): 31-4. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Tracer DP. Reproductive and socio-economic correlates of maternal haemoglobin levels in a rural area of Papua New Guinea. *Trop Med Int Health*. 1997; 2(6): 513-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Nakazawa M, Ohtsuka R, Kawabe T, Hongo T, Inaoka T, Akimichi T, Suzuki T. Iron nutrition and anaemia in a malaria-endemic environment: haematological investigation of the Gidra-speaking population in lowland Papua New Guinea. *Br J Nutr*. 1996; 76(3): 333-46. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Brabin BJ, Ginny M, Sapau J, Galme K, Paino J. Consequences of maternal anaemia on outcome of pregnancy in a malaria endemic area in Papua New Guinea. *Ann Trop Med Parasitol*. 1990; 84(1): 11-24. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Amoa AB, Klufio CA, Kariwiga G, Heywood S. Antenatal haemoglobin profile at the Port Moresby General Hospital. *P N G Med J*. 1998; 41(3-4): 119-25. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Zavaleta N, Caulfield LE, Garcia T. Changes in iron status during pregnancy in peruvian women receiving prenatal iron and folic acid supplements with or without zinc. *Am J Clin Nutr*. 2000; 71(4): 956-61. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- López de Romaña G, Cusirramos S, López de Romaña D, Gross R. Efficacy of multiple micronutrient supplementation for improving anemia, micronutrient status, growth, and morbidity of Peruvian infants. *J Nutr*. 2005; 135(3): 646-652. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Bradfield RB, Jensen MV, Quiroz A, Gonzales L, Garrayar C, Hernandez V. Effect of low levels of iron and trace elements on hematological values of parasitized school children. *Am J Clin Nutr*. 1968; 21(1): 68-77. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Becerra C, Gonzales GF, Villena A, de la Cruz D, Florián A. [Prevalence of anemia in pregnancy, Pucallpa Regional Hospital, Perú]. *Rev Panam Salud Publica*. 1998; 3(5): 285-92. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Zavaleta N, Respicio G, Garcia T. Efficacy and acceptability of two iron supplementation schedules in adolescent school girls in Lima, Peru. *J Nutr*. 2000; 130(2S Suppl): 462-464. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Creed-Kanashiro HM, Uribe TG, Bartolini RM, Fukumoto MN, López TT, Zavaleta NM, Bentley ME. Improving dietary intake to prevent anemia in adolescent girls through community kitchens in a periurban population of Lima, Peru. *J Nutr*. 2000; 130(2S Suppl): 459-461. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Alarcon K, Kolsteren PW, Prada AM, Chian AM, Velarde RE, Pecho IL, Hoeree TF. Effects of separate delivery of zinc or zinc and vitamin A on hemoglobin response, growth, and diarrhea in young Peruvian children receiving iron therapy for anemia. *Am J Clin Nutr*. 2004; 80(5): 1276-82. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Gonzalez L, Gevan O, Picar B, Florentino R, Solon F. Nutritional baseline evaluation of Kapitbahayan. *Philipp J Nutr*. 1980; 29-35. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Kuizon MD, Natera MG, Ancheta LP, Platon TP, Desnacido JA, Macapinlac MP. Assessment of the iron status of Filipino adolescents. *Southeast Asian J Trop Med Public Health*. 1982; 13(1): 81-5. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Marzan AM, Tantengco VO, Caviles AP. Nutritional anaemias among Filipinos during pregnancy. *Southeast Asian J Trop Med Public Health*. 1971; 2(4): 564-74. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- De Jong N, Romano ABA, Gibson RS. Zinc and iron status during pregnancy of Filipino women. *Asia Pac J Clin Nutr*. 2002; 11(3): 186-93. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Roschnik N, Parawan A, Baylon MAB, Chua T, Hall A. Weekly iron supplements given by teachers sustain the haemoglobin concentration of schoolchildren in the Philippines. *Trop Med Int Health*. 2004; 9(8): 904-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Spodaryk K. Disparity between dietary iron intake and iron status of children aged 10-12 years. *Arch Physiol Biochem*. 1999; 107(5): 361-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Antunes H, Costa-Pereira A, Cunha I, Raposo T, Garcia M, Beirão I. [Prevalence of iron-deficiency anemia according to infant nutrition regime]. *Acta Med Port*. 2002; 15(3): 193-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Wood CS, Gans LP. Hematological status of reproductive women in Western Samoa: an analysis of biometric data. *Hum Biol*. 1981; 53(2): 269-72. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Abalkhail B, Shawky S. Prevalence of daily breakfast intake, iron deficiency anaemia and awareness of being anaemic among Saudi school students. *Int J Food Sci Nutr*. 2002; 53(6): 519-28. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Al Fawaz I. Surveillance for iron deficiency anemia at a well baby clinic in Riyadh, Saudi Arabia. *Saudi Med J*. 1993; 27-31. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Ghafouri H, Al Fares A, Islam S, Ahmed A, Jan M. Haematological reference values assessed from birth to adolescence in Saudi subjects in the area of Jeddah. *Saudi Med J.* 1987; 575-82. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hawa L, Rowland A, Ahmed G, Dery J. Haemoglobin and iron status in mothers and their babies at delivery. *Saudi Med J.* 1993; 110-5. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ahmed MM. Haematological values and parasitic infections in school children in Riyadh, Saudi Arabia. *J Egypt Soc Parasitol.* 1991; 21(3): 831-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Al Hifzi I, Pejaver RK, Qureshi I. Screening for iron deficiency anemia in a well baby clinic. *Ann Saudi Med.* 1996; 16(6): 622-4. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Niazi G. Haematological profile of Saudi new borns. *Saudi Med J.* 1994; 243-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Mahfouz AA, el-Said MM, Alakija W, Badawi IA, al-Erian RA, Moneim MA. Anemia among pregnant women in the Asir region, Saudi Arabia: an epidemiologic study. *Southeast Asian J Trop Med Public Health.* 1994; 25(1): 84-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ahmed MM, el Hady HM, Morsy TA. Parasitic infections and haemoglobin level among school children of different socioeconomic classes in Abha, Saudi Arabia. *J Egypt Soc Parasitol.* 1990; 20(1): 61-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- al-Othaimen A, Osman AK, al Orf S. Prevalence of nutritional anaemia among primary school girls in Riyadh City, Saudi Arabia. *Int J Food Sci Nutr.* 1999; 50(4): 237-43. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Khoja S. Iron status in pregnant Saudi Arabia women in the Jeddah area. *Saudi Med J.* 1994; 43-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Al-Shagrawi R, El-Masry E, El-Shayeb I, El-Badr N. Prevalence of anaemia among Saudi female university students: dietary factors. *Bull High Inst Public Health.* 1997; 237-41. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Smart I, Duncan M, Kalina J. Haemoglobin levels and anaemia in pregnant Saudi women. *Saudi Med J.* 1983; 263-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- al-Momen AK, al-Meshari A, al-Nuaim L, Saddique A, Abotalib Z, Khashogji T, Abbas M. Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. *Eur J Obstet Gynecol Reprod Biol.* 1996; 69(2): 121-4. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Blot IC, Zucker JM, Tchernia G, Vuylsteke P, Giorgi R, Hellegouarch R. [Trial evaluation of iron deficiency in children in Senegal]. *Ann Pediatr (Paris).* 1971; 18(3): 181-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Blot IC, Zucker JM, Tchernia G, Vuylsteke P, Giorgi R, Hellegouarch R. [Trial evaluation of iron deficiency in children in Senegal]. *Ann Pediatr (Paris).* 1971; 18(3): 181-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- FOY H, KONDI A. Report on incidence, aetiology, treatment and prophylaxis of the anaemias in the Seychelles: a study in iron-deficiency anaemias and ancylostomiasis in the tropics. *Ann Trop Med Parasitol.* 1961; 25-45. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Singh K, Fong YF, Arulkumaran S. Anaemia in pregnancy--a cross-sectional study in Singapore. *Eur J Clin Nutr.* 1998; 52(1): 65-70. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Kwa SB, Ko M. Haemoglobin values in pregnancy--a survey of 1,000 consecutive normal mothers. *Singapore Med J.* 1968; 9(1): 27-30. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Nadarajah S, Leong NK. Adolescent pregnancies managed at KK Hospital. *Singapore Med J.* 2000; 41(1): 29-31. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Lim W. A survey of haemoglobin levels among primary six children in Singapore. *Med J Malaysia.* 1966; 21(2): 169-76. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Mayet FG. The prevalence of anaemia and iron deficiency in the Indian community in Natal. *S Afr Med J.* 1976; 50(47): 1889-92. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Oelofse A, Faber M, Benadé JG, Benadé AJ, Kenoyer DG. The nutritional status of a rural community in KwaZulu-Natal, South Africa: the Nduvakazi project. *Cent Afr J Med.* 1999; 45(1): 14-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Margo G, Baroni Y, Green R, Metz J. Anemia in urban underprivileged children. Iron, folate, and vitamin B12 nutrition. *Am J Clin Nutr.* 1977; 30(6): 947-54. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Margo G, Baroni Y, Wells G, Green R, Metz J. Protein energy malnutrition and nutritional anaemia in preschool children in rural KwaZulu. *S Afr Med J.* 1978; 53(1): 21-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Ballot DE, MacPhail AP, Bothwell TH, Gillooly M, Mayet FG. Fortification of curry powder with NaFe(111)EDTA in an iron-deficient population: initial survey of iron status. *Am J Clin Nutr.* 1989; 49(1): 156-61. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Lamparelli RD, van der Westhuyzen J, Steyn NP, Baynes RD, MacFarlane BJ, Green A, Bothwell TH. Nutritional anaemia in 11-year-old schoolchildren in the western Cape. *S Afr Med J.* 1988; 73(8): 473-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Baynes RD, Meriwether WD, Bothwell TH, Fernandes Costa FJ, Bezwoda WR, MacPhail AP. Iron and folate status of pregnant black women in Gazankulu. *S Afr Med J.* 1986; 70(3): 148-51. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Lamparelli RD, Bothwell TH, MacPhail AP, van der Westhuyzen J, Baynes RD, MacFarlane BJ. Nutritional anaemia in pregnant coloured women in Johannesburg. *S Afr Med J.* 1988; 73(8): 477-81. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Faber M, Jogessar VB, Benadé AJ. Nutritional status and dietary intakes of children aged 2-5 years and their caregivers in a rural South African community. *Int J Food Sci Nutr.* 2001; 52(5): 401-11. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Wilkinson D, Sach ME. Cost-effective on-site screening for anaemia in pregnancy in primary care clinics. *S Afr Med J.* 1997; 87(4): 463-5. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Kruger M, Baderhorst C, Mansvelt E, Laubscher J, Spinnler Benade A. Effects of iron fortification in a school feeding scheme and anthelmintic therapy on the iron status and growth of six-to-eight-year-old schoolchildren. *Food Nutr Bull.* 1996; 11-2. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Choi CW, Lee J, Park KH, Yoon SY, Choi IK, Oh SC, Seo JH, Kim BS, Shin SW, Kim YH, Kim JS. Prevalence and characteristics of anemia in the elderly: cross-sectional study of three urban Korean population samples. *Am J Hematol.* 2004; 77(1): 26-30. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Choi JW, Kim CS, Pai SH. Erythropoietic activity and soluble transferrin receptor level in neonates and maternal blood. *Acta Paediatr.* 2000; 89(6): 675-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Henríquez Sánchez P, Díaz Romero C, Rodríguez Rodríguez E, López Blanco F, Álvarez León E, Díaz Cremádes J, Pastor Ferrer MC, Serra Majem L. [Biochemical assessment of nutritional status in the Canary Islands population (1998)]. *Arch Latinoam Nutr.* 2000; 50(1 Suppl 1): 43-54. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Mudalige R, Nestel P. Prevalence of anaemia in Sri Lanka. *Ceylon J Med Sci.* 1996; 9-16. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Pathmeswaran A, Jayatissa R, Samarasinghe S, Fernando A, de Silva RP, Thattil RO, de Silva NR. Health status of primary schoolchildren in Sri Lanka. *Ceylon Med J.* 2005; 50(2): 46-50. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Fernando SD, Paranavitane SR, Rajakaruna J, Weerasinghe S, Silva D, Wickremasinghe AR. The health and nutritional status of school children in two rural communities in Sri Lanka. *Trop Med Int Health.* 2000; 5(6): 450-2.
- Fernando SD, Paranavitane SR, Rajakaruna J, Weerasinghe S, Silva D, Wickremasinghe AR. The health and nutritional status of school children in two rural communities in Sri Lanka. *Trop Med Int Health.* 2000; 5(6): 450-2. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Goonewardene M, Seekkuge J, Liyanage C. Iron stores and its correlation to haemoglobin levels in pregnant women attending an antenatal clinic. *Ceylon Med J.* 1995; 40(2): 67-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Atukorala TM, Lanerolle P. Soil-transmitted helminth infection and its effect on nutritional status of adolescent schoolgirls of low socioeconomic status in Sri Lanka. *J Trop Pediatr.* 1999; 45(1): 18-22. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Nilsson-Ehle H, Jagenburg R, Landahl S, Svanborg A. Blood haemoglobin declines in the elderly: implications for reference intervals from age 70 to 88. *Eur J Haematol.* 2000; 65(5): 297-305. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Akesson A, Bjellerup P, Berglund M, Bremme K, Vahter M. Serum transferrin receptor: a specific marker of iron deficiency in pregnancy. *Am J Clin Nutr.* 1998; 68(6): 1241-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hallberg L, Hultén L, Lindstedt G, Lundberg PA, Mark A, Puren J, Svanberg B, Swolin B. Prevalence of iron deficiency in Swedish adolescents. *Pediatr Res.* 1993; 34(5): 680-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Samuelson G, Bratteby LE, Berggren K, Elverby JE, Kempe B. Dietary iron intake and iron status in adolescents. *Acta Paediatr.* 1996; 85(9): 1033-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hess SY, Zimmermann MB, Brogli S, Hurrell RF. A national survey of iron and folate status in pregnant women in Switzerland. *Int J Vitam Nutr Res.* 2001; 71(5): 268-73. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

Kitange H, Swai A, Kilima P, Masuki G, Alberti K, McLarty D. Anaemia is a major public health problem in Tanzania. Health Policy Plan. 1993; 413-24. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Valyasevi A, Benchakarn V, Dhanamitta S. Anemia in pregnant women, infants and pre-school children in Thailand. J Med Assoc Thai. 1974; 57(6): 301-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Massawe SN, Urassa EN, Nyström L, Lindmark G. Effectiveness of primary level antenatal care in decreasing anemia at term in Tanzania. Acta Obstet Gynecol Scand. 1999; 78(7): 573-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Beasley NM, Hall A, Tomkins AM, Donnelly C, Ntimbwa P, Kivuga J, Kihamia CM, Lorri W, Bundy DA. The health of enrolled and non enrolled children of school age in Tanga, Tanzania. Acta Trop. 2000; 76(3): 223-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Stoltzfus RJ, Chwaya HM, Tielsch JM, Schulze KJ, Albonico M, Savioli L. Epidemiology of iron deficiency anemia in Zanzibari schoolchildren: the importance of hookworms. Am J Clin Nutr. 1997; 65(1): 153-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Bergsjö P, Seha AM, Ole-King'ori N. Hemoglobin concentration in pregnant women. Experience from Moshi, Tanzania. Acta Obstet Gynecol Scand. 1996; 75(3): 241-4. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Stoltzfus RJ, Edward-Raj A, Dreyfuss ML, Albonico M, Montresor A, Dhoj Thapa M, West KP Jr, Chwaya HM, Savioli L, Tielsch J. Clinical pallor is useful to detect severe anemia in populations where anemia is prevalent and severe. J Nutr. 1999; 129(9): 1675-81. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Bhargava A, Jukes M, Lambo J, Kihamia CM, Lorri W, Nokes C, Drake L, Bundy D. Anthelmintic treatment improves the hemoglobin and serum ferritin concentrations of Tanzanian schoolchildren. Food Nutr Bull. 2003; 24(4): 332-42. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Mwanukuzi E, Nhonoli AM. Anaemia in expectant mothers. East Afr Med J. 1972; 49(2): 101-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Bloem MW, Wedel M, Egger RJ, Speek AJ, Schrijver J, Saowakontha S, Schreurs WH. Iron metabolism and vitamin A deficiency in children in northeast Thailand. Am J Clin Nutr. 1989; 50(2): 332-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Vichitbandha C, Panichasasilawat C. Hematological values in healthy Thai infants and preschool children. J Med Assoc Thai. 1980; 63(6): 321-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Sungthong R, Mo-Suwan L, Chongsuvivatwong V, Geater AF. Once weekly is superior to daily iron supplementation on height gain but not on hematological improvement among schoolchildren in Thailand. J Nutr. 2002; 132(3): 418-22. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Saowakontha S, Pongpaew P, Schelp FP, Rojsathaporn K, Sriboonlue P, Vudhivai N, Intarakhao C, Pipitgool V, Mahaweerawat U, Supawan V. Quetelet index, hemoglobin and parasitic infection of rural women in northeast Thailand. Southeast Asian J Trop Med Public Health. 1994; 25(3): 474-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Changnam P, Thumpenjit S, Koowatanasiri P. Anemia in Sakon Nakhon Province. J Med Assoc Thai. 1999; 82(6): 545-51. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Chaturachinda K. Anaemia of pregnancy. I. An epidemiologic study. J Med Assoc Thai. 1972; 55(2): 94-100. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Areekul S, Ukoskit K, Yamarat P, Panatampon P, Tanapongpipatana S. Prevalence of anaemia in pregnant Thai women. J Med Assoc Thai. 1976; 59(12): 525-31. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Sundharagiati B, Kulpradith S, Petchkla S, Chanchum Y, Harinasuta C. Iron-deficiency anaemia in Bangkok, Thailand: anaemia in pregnancy. Ann Trop Med Parasitol. 1967; 61(1): 35-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Linpisarn S, Thanangkul O, Suwanraj K, Kaewvichit R, Cricka LJ, Whitehead TP. Iron deficiency in a Northern Thai population: the effects of iron supplements studied by means of plasma ferritin estimations. Ann Clin Biochem. 1984; 21 (Pt 4): 268-74. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Laosombat V, Kiewkankah V. Hematological values in healthy Thai infants in southern Thailand. J Med Assoc Thai. 1983; 66(12): 746-54. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Sanchaisuriya P, Pongpaew P, Saowakontha S, Supawan V, Migasena P, Schelp FP. Nutritional health and parasitic infection of rural Thai women of the child bearing age. J Med Assoc Thai. 1993; 76(3): 138-45. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Suwanik R, Punyaprateep B, Pleehachinda R, Tuntawiroon M, Pattanachak S, Pattanapunyasat K. Iron status of Thai population in Bangkok and of villagers in northeastern Thailand. J Med Assoc Thai. 1981; 64(6): 283-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Areekul S, Devakul K, Smitananda N, Boonyananta C, Klongskumnuangarn K. Prevalence of anaemia in Thai school children. *J Med Assoc Thai*. 1972; 55(8): 457-63. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Suthutvoravut S, Chaturachinda K. Risk of low birthweight at Ramathibodi Hospital. *J Med Assoc Thai*. 1988; 6-11. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Linpisarn S, Tienboon P, Promtet N, Putsyainunt P, Santawanpat S, Fuchs GJ. Iron deficiency and anaemia in children with a high prevalence of haemoglobinopathies: implications for screening. *Int J Epidemiol*. 1996; 25(6): 1262-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Tungtrongchitr R, Pongpaew P, Schelp FP, Phonrat B, Mahaweerawat U, Paksanont S, Sanchaisuriya P, Jotking P, Intarakhao C, Saowakhontha S. Vitamin B12, folic acid, ferritin and haemoglobin status of rural women in child-bearing age in northeast Thailand. *J Med Assoc Thai*. 1997; 80(12): 785-90. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Dop MC, Blot I, Dyck JL, Assimadi K, Hodonou AK, Doh A. [Anemia at delivery in Lome (Togo): prevalence, risk factors and consequences in newborn infants]. *Rev Epidemiol Sante Publique*. 1992; 40(4): 259-67. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Berger J, Dyck JL, Galan P, Aplogan A, Schneider D, Traissac P, Hercberg S. Effect of daily iron supplementation on iron status, cell-mediated immunity, and incidence of infections in 6-36 month old Togolese children. *Eur J Clin Nutr*. 2000; 54(1): 29-35. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Chopra JG, Byam NT. Anemia survey in Trinidad and Tobago. *Am J Public Health Nations Health*. 1968; 58(10): 1922-36. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Chenoufi B, Essafi B, Sfar E, Chelli H, Ben Hamida A, Ben Ammar S, Ben Tanfous N, Ben Abdallah K, Kastalli R. [Screening for parental anemia in pregnant women: prospective study. Report of 200 cases]. *Tunis Med*. 2001; 79(8-9): 423-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Koubaa C, Jarraya S, Zouari S, Kaabachi N, Michiri A, Fattoum S, Mbazza R, Mhenni H, Hamza B. L'anémie carencielle parmi les enfants de 6 à 35 mois dans la région de Mellassine- cité Hellal (Tunisie) [Iron deficiency anemia in 6-35 months children in the Mellassine district (Tunisia)]. *Rev Maghreb Pédiatr*. 1993; 307-12. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Kiliç M, Yüregir GT, Ekerbiçer H. Anaemia and iron-deficiency anaemia in south-east Anatolia. *Eur J Haematol*. 2002; 69(5-6): 280-3. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Kiwanuka GN, Isharaza WK, Mahmoud S. Iron status of pregnant women at first antenatal booking in Mbarara University Teaching Hospital. *Trop Doct*. 1999; 29(4): 228-30. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Musaiger AO, Abdulghafoor A, Radwan H. Anaemia among 6 year old children in the United Arab Emirates. *Eur J Clin Nutr*. 1996; 50(9): 636-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hossain MM, Bakir M, Pugh RN, Sheekh-Hussen M, Bin Ishaq SA, Berg DB, Lindblad BS. The prevalence and correlates of anaemia among young children and women of childbearing age in Al Ain, United Arab Emirates. *Ann Trop Paediatr*. 1995; 15(3): 227-35. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Fischbacher C, Bhopal R, Patel S, White M, Unwin N, Alberti KG. Anaemia in Chinese, South Asian, and European populations in Newcastle upon Tyne: cross sectional study. *BMJ*. 2001; 322(7292): 958-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Huxley RR, Lloyd BB, Goldacre M, Neil HA. Nutritional research in World War 2: the Oxford Nutrition Survey and its research potential 50 years later. *Br J Nutr*. 2000; 84(2): 247-51. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Wright CM, Kelly J, Trail A, Parkinson KN, Summerfield G. The diagnosis of borderline iron deficiency: results of a therapeutic trial. *Arch Dis Child*. 2004; 89(11): 1028-31. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Lawson MS, Thomas M, Hardiman A. Iron status of Asian children aged 2 years living in England. *Arch Dis Child*. 1998; 78(5): 420-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- McLennan WJ, Andrews GR, Macleod C, Caird FI. Anaemia in the elderly. *Q J Med*. 1973; 42(165): 1-13. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Nelson M, White J, Rhodes C. Haemoglobin, ferritin, and iron intakes in British children aged 12-14 years: a preliminary investigation. *Br J Nutr*. 1993; 70(1): 147-55. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Clarke R, Refsum H, Birks J, Evans JG, Johnston C, Sherliker P, Ueland PM, Schneede J, McPartlin J, Nexø E, Scott JM. Screening for vitamin B-12 and folate deficiency in older persons. *Am J Clin Nutr*. 2003; 77(5): 1241-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Sherriff A, Emond A, Hawkins N, Golding J. Haemoglobin and ferritin concentrations in children aged 12 and 18 months. ALSPAC Children in Focus Study Team. *Arch Dis Child*. 1999; 80(2): 153-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Emond AM, Hawkins N, Pennock C, Golding J. Haemoglobin and ferritin concentrations in infants at 8 months of age. *Arch Dis Child*. 1996; 74(1): 36-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Osbourne GK, Howat RC, Jordan MM. The obstetric outcome of teenage pregnancy. *Br J Obstet Gynaecol*. 1981; 88(3): 215-21. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Robinson S, Godfrey K, Denne J, Cox V. The determinants of iron status in early pregnancy. *Br J Nutr*. 1998; 79(3): 249-55. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Goel KM, Logan RW, House F, Connell MD, Strevens E, Watson WH, Bulloch CB. The prevalence of haemoglobinopathies, nutritional iron and folate deficiencies in native and immigrant children in Glasgow. *Health Bull (Edinb)*. 1978; 36(4): 176-83. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- KILPATRICK GS, HARDISTY RM. The prevalence of anaemia in the community. A survey of a random sample of the population. *Br Med J*. 1961; 1(5228): 778-82. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Nelson M, Bakaliou F, Trivedi A. Iron-deficiency anaemia and physical performance in adolescent girls from different ethnic backgrounds. *Br J Nutr*. 1994; 72(3): 427-33. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Cole SK, Thomson AM, Billewicz WZ, Black AE. Haematological characteristics and menstrual blood losses. *J Obstet Gynaecol Br Commonw*. 1972; 79(11): 994-1001. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hindmarsh PC, Geary MP, Rodeck CH, Jackson MR, Kingdom JC. Effect of early maternal iron stores on placental weight and structure. *Lancet*. 2000; 356(9231): 719-23. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Burman D. Haemoglobin levels in normal infants aged 3 to 24 months, and the effect of iron. *Arch Dis Child*. 1972; 47(252): 261-71. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Duggan MB, Steel G, Elwys G, Harbottle L, Noble C. Iron status, energy intake, and nutritional status of healthy young Asian children. *Arch Dis Child*. 1991; 66(12): 1386-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Cook JD, Finch CA, Smith NJ. Evaluation of the iron status of a population. *Blood*. 1976; 48(3): 449-55. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Rettmer RL, Carlson TH, Origenes ML, Jack RM, Labb RF. Zinc protoporphyrin/heme ratio for diagnosis of preanemic iron deficiency. *Pediatrics*. 1999; 104(3): 37. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Kripke SS, Sanders E. Prevalence of iron-deficiency anemia among infants and young children seen at rural ambulatory clinics. *Am J Clin Nutr*. 1970; 23(6): 716-24. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Lipschitz DA, Mitchell CO, Thompson C. The anemia of senescence. *Am J Hematol*. 1981; 11(1): 47-54. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Gershoff SN, Brusis OA, Nino HV, Huber AM. Studies of the elderly in Boston. I. The effects of iron fortification on moderately anemic people. *Am J Clin Nutr*. 1977; 30(2): 226-34. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Gutelius MF. The problem of iron deficiency anemia in preschool Negro children. *Am J Public Health Nations Health*. 1969; 59(2): 290-5. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Brown K, Lubin B, Smith R, Oski F. Prevalence of anemia among preadolescent and young adolescent urban black Americans. *J Pediatr*. 1972; 81(4): 714-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Penrod JC, Anderson K, Acosta PB. Impact on iron status of introducing cow's milk in the second six months of life. *J Pediatr Gastroenterol Nutr*. 1990; 10(4): 462-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. *Blood*. 2004; 104(8): 2263-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Shott RJ, Andrews BF. Iron status of a medical high-risk population at delivery. *Am J Dis Child*. 1972; 124(3): 369-71. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Tershakovec AM, Weller SC. Iron status of inner-city elementary school children: lack of correlation between anemia and iron deficiency. *Am J Clin Nutr*. 1991; 54(6): 1071-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Reeves JD, Yip R, Kiley VA, Dallman PR. Iron deficiency in infants: the influence of mild antecedent infection. *J Pediatr*. 1984; 105(6): 874-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Bodnar LM, Scanlon KS, Freedman DS, Siega-Riz AM, Cogswell ME. High prevalence of postpartum anemia among low-income women in the United States. *Am J Obstet Gynecol*. 2001; 185(2): 438-43. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Fuerth JH. Incidence of anemia in full-term infants seen in private practice. *J Pediatr.* 1971; 79(4): 560-2. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Boutry M, Needlman R. Use of diet history in the screening of iron deficiency. *Pediatrics.* 1996; 98(6 Pt 1): 1138-42. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Pastides H. Iron deficiency anemia among three groups of adolescents and young adults. *Yale J Biol Med.* 1981; 54(4): 265-71. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Driggers DA, Reeves JD, Lo EY, Dallman PR. Iron deficiency in one-year-old infants: comparison of results of a therapeutic trial in infants with anemia or low-normal hemoglobin values. *J Pediatr.* 1981; 98(5): 753-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Bogen DL, Duggan AK, Dover GJ, Wilson MH. Screening for iron deficiency anemia by dietary history in a high-risk population. *Pediatrics.* 2000; 105(6): 1254-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Owen GM, Garry PJ, Kram KM, Nelsen CE, Montalvo JM. Nutritional status of Mississippi preschool children. A pilot study. *Am J Clin Nutr.* 1969; 22(11): 1444-58. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Carriaga MT, Skikne BS, Finley B, Cutler B, Cook JD. Serum transferrin receptor for the detection of iron deficiency in pregnancy. *Am J Clin Nutr.* 1991; 54(6): 1077-81. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Adams WG, Geva J, Coffman J, Palfrey S, Bauchner H. Anemia and elevated lead levels in underimmunized inner-city children. *Pediatrics.* 1998; 101(3): 6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Wright RO, Tsaih S-W, Schwartz J, Wright RJ, Hu H. Association between iron deficiency and blood lead level in a longitudinal analysis of children followed in an urban primary care clinic. *J Pediatr.* 2003; 142(1): 9-14. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Salive ME, Cornoni-Huntley J, Guralnik JM, Phillips CL, Wallace RB, Ostfeld AM, Cohen HJ. Anemia and hemoglobin levels in older persons: relationship with age, gender, and health status. *J Am Geriatr Soc.* 1992; 40(5): 489-96. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Fleming DJ, Jacques PF, Tucker KL, Massaro JM, D'Agostino RB Sr, Wilson PW, Wood RJ. Iron status of the free-living, elderly Framingham Heart Study cohort: an iron-replete population with a high prevalence of elevated iron stores. *Am J Clin Nutr.* 2001; 73(3): 638-46. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Chang S-C, O'Brien KO, Nathanson MS, Mancini J, Witter FR. Hemoglobin concentrations influence birth outcomes in pregnant African-American adolescents. *J Nutr.* 2003; 133(7): 2348-55. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Alper BS, Kimber R, Reddy AK. Using ferritin levels to determine iron-deficiency anemia in pregnancy. *J Fam Pract.* 2000; 49(9): 829-32. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Vazquez-Seoane P, Windom R, Pearson HA. Disappearance of iron-deficiency anemia in a high-risk infant population given supplemental iron. *N Engl J Med.* 1985; 313(19): 1239-40. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Garry PJ, Goodwin JS, Hunt WC. Iron status and anemia in the elderly: new findings and a review of previous studies. *J Am Geriatr Soc.* 1983; 31(7): 389-99. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Cresanta JL, Croft JB, Webber LS, Nicklas TA, Berenson GS. Racial difference in hemoglobin concentration of young adults. *Prev Med.* 1987; 16(5): 659-69. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Johnson CC, Futrell MF. Anemia in black preschool children in Mississippi. Dietary and hematologic findings. *J Am Diet Assoc.* 1974; 65(5): 536-41. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- High prevalence of iron deficiency anemia among Alaskan native children as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Adams WG, Geva J, Coffman J, Palfrey S, Bauchner H. Anemia and elevated lead levels in underimmunized inner-city children. *Pediatrics.* 1998; 101(3): 6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Chang S-C, O'Brien KO, Nathanson MS, Mancini J, Witter FR. Hemoglobin concentrations influence birth outcomes in pregnant African-American adolescents. *J Nutr.* 2003; 133(7): 2348-55. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Salive ME, Cornoni-Huntley J, Guralnik JM, Phillips CL, Wallace RB, Ostfeld AM, Cohen HJ. Anemia and hemoglobin levels in older persons: relationship with age, gender, and health status. *J Am Geriatr Soc.* 1992; 40(5): 489-96. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Petersen KM, Parkinson AJ, Nobmann ED, Bulkow L, Yip R, Mokdad A. Iron deficiency anemia among Alaska Natives may be due to fecal loss rather than inadequate intake. *J Nutr.* 1996; 126(11): 2774-83. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Gupta S, Venkateswaran R, Gorenflo DW, Eyler AE. Childhood iron deficiency anemia, maternal nutritional knowledge, and maternal feeding practices in a high-risk population. *Prev Med.* 1999; 29(3): 152-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Wright RO, Tsaih S-W, Schwartz J, Wright RJ, Hu H. Association between iron deficiency and blood lead level in a longitudinal analysis of children followed in an urban primary care clinic. *J Pediatr.* 2003; 142(1): 9-14. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Irigoyen M, Davidson LL, Carriero D, Seaman C. Randomized, placebo-controlled trial of iron supplementation in infants with low hemoglobin levels fed iron-fortified formula. *Pediatrics.* 1991; 88(2): 320-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Garry PJ, Goodwin JS, Hunt WC. Iron status and anemia in the elderly: new findings and a review of previous studies. *J Am Geriatr Soc.* 1983; 31(7): 389-99. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Bailey LB, Wagner PA, Christakis GJ, Davis CG, Appledorf H, Araujo PE, Dorsey E, Dinning JS. Folic acid and iron status and hematological findings in black and Spanish-American adolescents from urban low-income households. *Am J Clin Nutr.* 1982; 35(5): 1023-32. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Fleming DJ, Jacques PF, Tucker KL, Massaro JM, D'Agostino RB Sr, Wilson PW, Wood RJ. Iron status of the free-living, elderly Framingham Heart Study cohort: an iron-replete population with a high prevalence of elevated iron stores. *Am J Clin Nutr.* 2001; 73(3): 638-46. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Mitchell MC, Lerner E. Maternal hematologic measures and pregnancy outcome. *J Am Diet Assoc.* 1992; 92(4): 484-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Sarnak MJ, Tighiouart H, Manjunath G, MacLeod B, Griffith J, Salem D, Levey AS. Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. *J Am Coll Cardiol.* 2002; 40(1): 27-33. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Bogen DL, Krause JP, Serwint JR. Outcome of children identified as anemic by routine screening in an inner-city clinic. *Arch Pediatr Adolesc Med.* 2001; 155(3): 366-71. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Cresanta JL, Croft JB, Webber LS, Nicklas TA, Berenson GS. Racial difference in hemoglobin concentration of young adults. *Prev Med.* 1987; 16(5): 659-69. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Jalaludin B, Taylor R, Levy S, Montaville B, Gee K. Prevalence of anaemia and iron deficiency at different levels of urbanization in Vanuatu. *P N G Med J.* 1992; 35(2): 128-36. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Burrows RF. Maternal characteristics and their influences on birth weight in a Melanesian population. *Asia Oceania J Obstet Gynaecol.* 1988; 14(1): 1-5. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Layrisse M, Chaves JF, Mendez-Castellano, Bosch V, Tropper E, Bastardo B, González E. Early response to the effect of iron fortification in the Venezuelan population. *Am J Clin Nutr.* 1996; 64(6): 903-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Taylor PG, Martínez-Torres C, Méndez-Castellano H, Bosch V, Leets I, Tropper E, Layrisse M. The relationship between iron deficiency and anemia in Venezuelan children. *Am J Clin Nutr.* 1993; 58(2): 215-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Diez-Ewald M, Molina RA. Iron and folic acid deficiency during pregnancy in western Venezuela. *Am J Trop Med Hyg.* 1972; 21(5): 587-91. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Castejon HV, Ortega P, Amaya D, Gomez G, Leal J, Castejon OJ. Co-existence of anemia, vitamin A deficiency and growth retardation among children 24-84 months old in Maracaibo, Venezuela. *Nutr Neurosci.* 2004; 7(2): 113-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Del Real S, Páez MC, Solano L, Fajardo Z. [Pre-cooked corn flour intake and its contribution of iron and vitamin A in low income preschoolers]. *Arch Latinoam Nutr.* 2002; 52(3): 274-81. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Diez-Ewald M, Torr es-Guerra E, Leets I, Layrisse M, Vizca no G, Arteaga Vizca no M. [Anemia in indigenous population of the West of Venezuela]. *Invest Clin.* 1999; 40(3): 191-202. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Mart -Carvajal A, Pe a-Mart  G, Comunian G, Mu oz S. Prevalence of anemia during pregnancy: results of Valencia (Venezuela) anemia during pregnancy study. *Arch Latinoam Nutr.* 2002; 52(1): 5-11. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Pe a E, S nchez A, Solano L. [Profile of nutritional risk in pregnant adolescents]. *Arch Latinoam Nutr.* 2003; 53(2): 141-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Thu BD, Schultink W, Dillon D, Gross R, Leswara ND, Khoi HH. Effect of daily and weekly micronutrient supplementation on micronutrient deficiencies and growth in young Vietnamese children. *Am J Clin Nutr.* 1999; 69(1): 80-6. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.

Appendix Table A.3b - Citations for non-dismod model input data

- Nguyen XN, Berger J, Dao TQ, Nguyen CK, Traissac P, Ha HK. [Efficacy of daily and weekly iron supplementation for the control of iron deficiency anaemia in infants in rural Vietnam]. *Sante*. 2002; 12(1): 31-7. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Raja'a YA, Sulaiman SM, Elkarib SA, Mubarak JS. Nutritional status of Yemeni schoolchildren in Al-Mahweet Governorate. *East Mediterr Health J*. 2001; 7(1-2): 204-10. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Sikosana PL, Bhebhe S, Katuli S. A prevalence survey of iron deficiency and iron deficiency anaemia in pregnant and lactating women, adult males and pre-school children in Zimbabwe. *Cent Afr J Med*. 1998; 44(12): 297-305. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Friis H, Gomo E, Koestel P, Ndhlovu P, Nyazema N, Krarup H, Michaelsen KF. HIV and other predictors of serum folate, serum ferritin, and hemoglobin in pregnancy: a cross-sectional study in Zimbabwe. *Am J Clin Nutr*. 2001; 73(6): 1066-73. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Nemapare P. Maternal health and nutrition survey for Masvingo Province, Zimbabwe: an appraisal of pregnant women. *Nutr Report Int*. 1989; 265-79. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Neube TN, Malaba L, Greiner T, Gebre-Medhin M. Evidence of grave vitamin A deficiency among lactating women in the semi-arid rural area of Makhaza in Zimbabwe. A population-based study. *Eur J Clin Nutr*. 2001; 55(4): 229-34. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Owen GM, Lubin AH, Garry PJ. Preschool children in the United States: who has iron deficiency? *J Pediatr*. 1971; 79(4): 563-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Eden AN, Mir MA. Iron deficiency in 1- to 3-year-old children. A pediatric failure? *Arch Pediatr Adolesc Med*. 1997; 151(10): 986-8. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Sherard GB 3rd, Newton ER. Is routine hemoglobin and hematocrit testing on admission to labor and delivery needed? *Obstet Gynecol*. 2001; 98(6): 1038-40. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Hughes PF, Morrison J. Pregnancy outcome data in a United Arab Emirates population: what can they tell us? *Asia Oceania J Obstet Gynaecol*. 1994; 20(2): 183-90. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Mahfouz AA, el-Said MM, al-Erian RA, Hamid AM. Teenage pregnancy: are teenagers a high risk group? *Eur J Obstet Gynecol Reprod Biol*. 1995; 59(1): 17-20. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Molla A, Khurshid M, Molla AM, Badruddin SH, Hendricks K, Snyder JD. Is anemia an accurate predictor of vitamin A status in Pakistani children? *Am J Trop Med Hyg*. 1993; 49(2): 276-9. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Ross SM, Read MD, Dhupelia I. Iron prophylaxis in pregnancy--is it useful? *S Afr Med J*. 1981; 60(18): 698-701. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Thaver IH, Baig L, Inam-ul-Haq, Iqbal R. Anaemia in children: Part II. Should primary health care providers prescribe iron supplements by the observation and presence of assumed symptoms? *J Pak Med Assoc*. 1994; 44(12): 284-5. as it appears in World Health Organization (WHO). WHO Global Database on Anemia, Nutrition Landscape Information System.
- Checchi F, Filipe J, Haydon D, Chandramohan D, and Chappuis F. Estimates of the duration of early and late stage of gambiense sleeping sickness. *BMC Infect Dis*. 2008; 8: 16.
- Chiaroni J, Touinssi M, Frassati C, Degioanni A, Gibert M, Reviron D, Mercier P, Boëtsch G. Genetic characterization of the population of Grande Comore Island (Njazidja) according to major blood groups. *Hum Biol*. 2004; 76(4): 527-41.
- Tripathy V, Satapathy KC, Gupta R. ABO and Rh D polymorphism among Tibetans in India. *Hum Biol*. 2006; 78(2): 229-33.
- Loyo MA, de Guerra DC, Izaguirre MH, Rodriguez-Larralde A. Admixture estimates for Churuguara, a Venezuelan town in the State of Falcón. *Ann Hum Biol*. 2004; 31(6): 669-80.
- Sinaii N, Plumb K, Cotton L, Lambert A, Kennedy S, Zondervan K, Stratton P. Differences in characteristics among 1,000 women with endometriosis based on extent of disease. *Fertil Steril*. 2007; 89(3): 538-45.
- Sinaii N, Cleary SD, Ballweg ML, Nieman LK, Stratton P. High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. *Hum Reprod*. 2002; 17(10): 2715-24.
- Gomman HM, Nossier SA, Fotuhi EM, Kholeif AE. Prevalence and factors associated with genital prolapse: a hospital-based study in Alexandria (Part I). *J Egypt Public Health Assoc*. 2001; 76(5-6): 313-35.
- Chuenchompoonut V, Bunyavejchevin S, Wisawasukmongchol W, Taechakraichana N. Prevalence of genital prolapse in Thai menopausal women (using new standardization classification). *J Med Assoc Thai*. 2005; 88(1): 1-4.
- Robinson RL, Swindle RW. Premenstrual symptom severity: impact on social functioning and treatment-seeking behaviors. *J Womens Health Gend Based Med*. 2000; 9(7): 757-68.
- Hylan TR, Sundell K, Judge R. The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: experience from the United States, United Kingdom, and France. *J Womens Health Gend Based Med*. 1999; 8(8): 1043-52.
- ICF International, National Institute of Statistics (Honduras), Secretary of Health (Honduras). Honduras Demographic and Health Survey - Complete Birth History Data.

Appendix Table A.3b - Citations for non-dismod model input data

- Macro International, Inc, Ministry of Health (Nicaragua), National Institute of Statistics and Censuses (Nicaragua). Nicaragua Demographic and Health Survey - Complete Birth History Data.
- Macro International, Inc, Ministry of Health (Uzbekistan), Ministry of Macroeconomics and Statistics (Uzbekistan). Ukraine Demographic and Health Survey - Complete Birth History Data.
- Yu TF. Diversity of clinical features in gouty arthritis. *Semin Arthritis Rheum*. 1984; 13(4): 360-8.
- Yu KH, Luo SF. Younger age of onset of gout in Taiwan. *Rheumatology (Oxford)*. 2003; 42(1): 166-70.
- Wang CC, Lien SB, Huang GS, Pan RY, Shen HC, Kuo CL, Shen PH, Lee CH. Arthroscopic elimination of monosodium urate deposition of the first metatarsophalangeal joint reduces the recurrence of gout. *Arthroscopy*. 2009; 25(2): 153-8.
- Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. *Arthritis Rheum*. 2010; 62(4): 1060-8.
- Edwards NL, Sundry JS, Forsythe A, Blume S, Pan F, Becker MA. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. *J Med Econ*. 2011; 14(1): 10-5.
- Becker MA, Schumacher HR, Benjamin KL, Gorevic P, Greenwald M, Fessel J, Edwards L, Kawata AK, Frank L, Waltrip R, Maroli A, Huang B, Gout Natural History Study Group, Sundry JS. Quality of life and disability in patients with treatment-failure gout. *J Rheumatol*. 2009; 36(5): 1041-8.
- Bushmakina AG, Cappelleri JC, Taylor-Stokes G, Sayers J, Sadosky A, Carroll D, Gosden T, Emery P. Relationship between patient-reported disease severity and other clinical outcomes in osteoarthritis: a European perspective. *J Med Econ*. 2011; 14(4): 381-9.
- Kapstad H, Hanestad BR, Langeland N, Rustøen T, Stavem K. Cutpoints for mild, moderate and severe pain in patients with osteoarthritis of the hip or knee ready for joint replacement surgery. *BMC Musculoskelet Disord*. 2008; 9: 55.
- Baddoura R, Haddad S, Awada H, Al-Masri AF, Merheb G, Attoui S, Okais J, Messayke J, Ghandour F. Severity of rheumatoid arthritis: the SEVERA study. *Clin Rheumatol*. 2006; 25(5): 700-4.
- Calvo-Alén J, Corrales A, Sánchez-Andrada S, Fernández-Echevarría MA, Peña JL, Rodríguez-Valverde V. Functional outcome and subset identification in RA patients from meridional Europe: analysis of a Spanish cohort. *Clin Rheumatol*. 2003; 22(2): 77-83.
- Carmona L, González-Alvaro I, Balsa A, Angel Belmonte M, Tena X, Sanmartí R. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. *Ann Rheum Dis*. 2003; 62(9): 897-900.
- Jääntti JK, Kaarela K, Belt EA, Kautiainen HJ. Incidence of severe outcome in rheumatoid arthritis during 20 years. *J Rheumatol*. 2002; 29(4): 688-92.
- Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, Esdaile JM, Anis AH. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. *Soc Sci Med*. 2005; 60(7): 1571-82.
- Sany J, Bourgeois P, Saraux A, Durieux S, Lafuma A, Daurès JP, Guillemin F, Sibilia J. Characteristics of patients with rheumatoid arthritis in France: a study of 1109 patients managed by hospital based rheumatologists. *Ann Rheum Dis*. 2005; 63(10): 1235-40.
- Wickrematilake GWG, Wijeratne LS. Assessing the impact of rheumatoid arthritis on quality of life in a group of patients attending a rheumatology clinic in Sri Lanka. *Indian J Rheumatol*. 2013; 8(1): 14-8.
- Wolfe F, Michaud K, Strand V. Expanding the definition of clinical differences: From minimally clinically important differences to really important differences. Analysis in 8931 patients with rheumatoid arthritis. *J Rheumatol*. 2005; 32(4): 583-9.
- Kamphuis MI, Ottenkamp J, Vliegen HW, Vogels T, Zwinderman KH, Kamphuis RP, Verloove-Vanhorick SP. Health related quality of life and health status in adult survivors with previously operated complex congenital heart disease. *Heart*. 2002; 87(4): 356-62.
- Epstein CJ (1995). Down syndrome (trisomy 21). In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). *The Metabolic Basis of Inherited Disease*, 7th edn. New York: McGraw Hill Inc., 1995.
- Christensen K, Juel K, Herskind AM, Murray JC. Long term follow up study of survival associated with cleft lip and palate at birth. *BMJ*. 2004; 328: 1405.
- Lane DA, Lip GYH, Milane, TA. Quality of life in adults with congenital heart disease. *Heart*. 2002; 88(1): 71-5.
- Price WH, Clayton JF, Collyer S, De Mey R, Wilson J. Mortality ratios, life expectancy, and causes of death in patients with Turner's syndrome. *J Epidemiol Community Health*. 1986; 40(2): 97-102.
- Hunt GM, Oakeshott P. Outcome in people with open spina bifida at age 35: prospective community based cohort study. *BMJ*. 2003; 326(7403): 1365-6.
- Adjusted data from: (1. Hunt GM, Oakeshott P. Outcome in people with open spina bifida at age 35: prospective community based cohort study. *BMJ*. 2003; 326(7403): 1365-6) and (2. Bowman RM, McLone DG, Grant JA, Tomita T, Ito JA. Spina bifida outcome: a 25-year prospective. *Pediatr Neurosurg*. 2001; 34(3): 114-20.)
- Smile Train. China and India Smile Train Congenital Anomalies Data 2004-2009.
- Congenital Heart Anomalies Mortality Risk With No Diagnosis or Care Estimates as provided by the Global Burden of Disease 2010 congenital anomaly expert group. [Unpublished].
- Jayatissa R, Bekele A, Piyasena CL, Mahamithawa S. Assessment of nutritional status of children under five years of age, pregnant women, and lactating women living in relief camps after the tsunami in Sri Lanka. *Food Nutr Bull*. 2006; 27(2): 144-52.
- Abdeen Z, Greenough PG, Chandran A, Qasrawi R. Assessment of the nutritional status of preschool-age children during the second Intifada in Palestine. *Food Nutr Bull*. 2007; 28(3): 274-82.
- Chowdhury A, Santra A, Chaudhuri S, Dhali GK, Chaudhuri S, Maity SG, Naik TN, Bhattacharya SK, Mazumder DN. Hepatitis C virus infection in the general population: a community-based study in West Bengal, India. *Hepatology*. 2003; 37: 802-9.

Appendix Table A.3b - Citations for non-dismod model input data

- Dalgaard O, Jeansson S, Skaug K, Raknerud N, Bell H. Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum. *Scand J Gastroenterol.* 2003; 38: 864-70.
- Guadagnino V, Stroffolini T, Rapicetta M, Costantino A, Kondili LA, Menniti-Ippolito F, Caroleo B, Costa C, Griffo G, Loiacono L, Pisani V, Focà A, Piazza M. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. *Hepatology.* 1997; 26: 1006-11.
- Chang CJ, Chang WN, Huang LT, Huang SC, Chang YC, Hung PL, Tasi CY, Lu CH, Cheng BC, Lee PY, Chang HW. Neonatal bacterial meningitis in southern Taiwan. *Pediatr Neurol.* 2003; 29(4): 288-94.
- Thonnon J, Fontenille D, Tall A, Diallo M, Renaudineau Y, Baudez B, Raphenon G. Re-Emergence of Yellow Fever in Senegal in 1995. *Am J Trop Med Hyg.* 1998; 59(1): 108-14. as it appears in Johansson MA, Vasconcelos PFC, Staples JE. The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases. *Trans R Soc Trop Med Hyg.* 2014; 108(8): 482-7.
- Cadoz M, Denis F, Mar Diop I. Etude épidémiologique des cas de méningites purulentes hospitalisées à Dakar pendant la décennie 1970-1979. *Bull World Health Organ.* 1981; 59(4): 575-584.
- Global Burden of Disease Study 2010. Disability Weights Measurement Study 2009-2010.
- Global Burden of Disease Study 2010. Disability Weights Measurement Study 2010-2011.
- European Centre for Disease Prevention and Control, Institute for Health Metrics and Evaluation (IHME), National Institute for Public Health and the Environment (Netherlands). Europe Disability Weights Measurement Study 2013.
- Institute for Health Metrics and Evaluation (IHME). Greece - Disability Weight Measurement Study 2014.
- Hagberg B, Hagberg G, Olow I, von Wendt L. The changing panorama of cerebral palsy in Sweden. VII. Prevalence and origin in the birth year period 1987-90. *Acta Paediatr.* 1996; 85(8): 954-60.
- Badawi N, Felix JF, Kurinczuk JJ, Dixon G, Watson L, Keogh JM, Valentine J, Stanley FJ. Cerebral palsy following term newborn encephalopathy: a population-based study. *Dev Med Child Neurol.* 2005; 47(5): 293-8.
- D'Alessandro R, Pandolfo G, Azzimondi G, Feruglio FS. Prevalence of dementia among elderly people in Troina, Sicily. *Eur J Epidemiol.* 1996; 12(6): 595-9.
- Brayne C, Calloway P. An epidemiological study of dementia in a rural population of elderly women. *Br J Psychiatry.* 1989; 155: 214-9.
- Clarke M, Jagger C, Anderson J, Battcock T, Kelly F, Stern MC. The prevalence of dementia in a total population: a comparison of two screening instruments. *Age Ageing.* 1991; 20(6): 396-403.
- Levy LM. An epidemiological study of headache in an urban population in Zimbabwe. *Headache.* 1983; 23(1): 2-9.
- Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology. A prospective study on the incidence and prognosis of Guillain-Barré syndrome in Emilia-Romagna region, Italy (1992-1993). *Neurology.* 1997; 48(1): 214-21.
- Cabre P, Heinzlef O, Merle H, Buisson GG, Bera O, Bellance R, Vernant JC, Smadja D. MS and neuromyelitis optica in Martinique (French West Indies). *Neurology.* 2001; 56(4): 507-14.
- Arruda WO, Scola RH, Teive HA, Werneck LC. Multiple sclerosis: report on 200 cases from Curitiba, Southern Brazil and comparison with other Brazilian series. *Arq Neuropsiquiatr.* 2001; 59(2-A): 165-70.
- Al-Araji A, Mohammed AI. Multiple sclerosis in Iraq: Does it have the same features encountered in Western countries? *J Neurol Sci.* 2005; 234(1-2): 67-71.
- McDonnell GV, Hawkins SA. An assessment of the spectrum of disability and handicap in multiple sclerosis: a population-based study. *Mult Scler.* 2001; 7(2): 111-7.
- Shyu W-C, Lin S-Z, Chiang M-F, Pang C-Y, Chen S-Y, Hsin Y-L, Thajeb P, Lee Y-J, Li H. Early-onset Parkinson's disease in a Chinese population: 99mTc-TRODAT-1 SPECT, Parkin gene analysis and clinical study. *Parkinsonism Relat Disord.* 2005; 11(3): 173-80.
- Tsai CH, Lu CS. Early onset parkinsonism in Chinese. *J Formos Med Assoc.* 1991; 90(10): 964-9.
- Rojo A, Aguilar M, Garolera MT, Cubo E, Navas I, Quintana S. Depression in Parkinson's disease: clinical correlates and outcome. *Parkinsonism Relat Disord.* 2003; 10(1): 23-8.
- Roos RA, Jongen JC, van der Velde EA. Clinical course of patients with idiopathic Parkinson's disease. *Mov Disord.* 1996; 11(3): 236-42.
- Sabaté M, Rodríguez M, Méndez E, Enríquez E, González I. Obstructive and restrictive pulmonary dysfunction increases disability in Parkinson disease. *Arch Phys Med Rehabil.* 1996; 77(1): 29-34.
- Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? *J Neurol Neurosurg Psychiatry.* 2000; 69(3): 308-12.
- Scigliano G, Musicco M, Soliveri P, Piccolo I, Girotti F, Giovannini P, Caraceni T. Mortality associated with early and late levodopa therapy initiation in Parkinson's disease. *Neurology.* 1990; 40(2): 265-9.
- Kaplan HI, Freedman AM, Sadock BJ. *Comprehensive Textbook of Psychiatry, III: Vol. 2.* Baltimore, United States: Williams & Wilkins; 1980.
- Regier DA, Robins LN, eds. *Psychiatric disorders in America: the epidemiologic catchment area study.* New York City, United States: Free Press; 1991.
- Bearn D, Mildinhal S, Murphy T, Murray JJ, Sell D, Shaw WC, Williams AC, Sandy JR. Cleft lip and palate care in the United Kingdom--the Clinical Standards Advisory Group (CSAG) Study. Part 4: outcome comparisons, training, and conclusions. 2001; 38(1): 38-43.
- Williams AC, Bearn D, Mildinhal S, Murphy T, Sell D, Shaw WC, Murray JJ, Sandy JR. Cleft lip and palate care in the United Kingdom--the Clinical Standards Advisory Group (CSAG) Study. Part 2: dentofacial outcomes and patient satisfaction. 2001; 38(1): 24-9.
- Williams AC, Bearn D, Mildinhal S, Murphy T, Sell D, Shaw WC, Murray JJ, Sandy JR. Cleft lip and palate care in the United Kingdom--the Clinical Standards Advisory Group (CSAG) Study. Part 2: dentofacial outcomes and patient satisfaction. 2001; 38(1): 24-9.

Appendix Table A.3b - Citations for non-dismod model input data

- Shen YC, Zhang WX, Shu L, Yang XL, Cui YH, Zhou DF, Shi HY, Su ET. Investigation of mental disorders in Beijing suburban district. *Chin Med J (Engl)*. 1981; 94(3): 153-6.
- Zharikov NM. Epidemiological study of mental illness in the U.S.S.R. *Soc Psychiatry Psychiatr Epidemiol*. 1968; 3(4).
- Fichter MM, Narrow WE, Roper MT, Rehm J, Elton M, Rae DS, Locke BZ, Regier DA. Prevalence of mental illness in Germany and the United States. Comparison of the Upper Bavarian Study and the Epidemiologic Catchment Area Program. *J Nerv Ment Dis*. 1996; 184(10): 598-606.
- Robinson GC, Conry JL, Conry RF. Clinical profile and prevalence of fetal alcohol syndrome in an isolated community in British Columbia. *CMAJ*. 1987; 137(3): 203-7.
- Steinhausen HC, Spohr HL. Long-term outcome of children with fetal alcohol syndrome: psychopathology, behavior, and intelligence. *Alcohol Clin Exp Res*. 1998; 22(2): 334-8.
- Mattson SN, Riley EP, Gramling L, Delis DC, Jones KL. Heavy prenatal alcohol exposure with or without physical features of fetal alcohol syndrome leads to IQ deficits. *J Pediatr*. 1997; 131(5): 718-21.
- Morgan VA, Mitchell PB, Jablensky AV. The epidemiology of bipolar disorder: sociodemographic, disability and service utilization data from the Australian National Study of Low Prevalence (Psychotic) Disorders. *Bipolar Disord*. 2005; 7(4): 326-37.
- Negash A, Alem A, Kebede D, Deyessa N, Shibre T, Kullgren G. Prevalence and clinical characteristics of bipolar I disorder in Butajira, Ethiopia: a community-based study. *J Affect Disord*. 2005; 87(2-3): 193-201.
- Cruz N, Vieta E, Comes M, Haro JM, Reed C, Bertsch J, EMBLEM Advisory Board. Rapid-cycling bipolar I disorder: course and treatment outcome of a large sample across Europe. *J Psychiatr Res*. 2008; 42(13): 1068-75.
- Have M, Vollebergh W, Bijl R, Nolen W. Bipolar disorder in the general population in the Netherlands (prevalence, consequences and care utilisation): results from the Netherlands mental health and incidence study (NEMESIS). *J Affect Disord*. 2002; 68(2-3): 202-13.
- Blader JC, Carlson GA. Increased rates of bipolar disorder diagnoses among U.S. child, adolescent, and adult inpatients, 1996-2004. *Biol Psychiatry*. 2007; 62(2): 107-14.
- Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. *JAMA*. 2004; 291(23): 2847-50.
- Huault G. *Tétanos du nouveau-né: Traitement par la ventilation artificielle et la curarisation prolongées [dissertation]*. Paris, France: A.G.E.M.P.; 1964.
- Khoo BH, Lee EL, Lam KL. Neonatal tetanus treated with high dosage diazepam. *Arch Dis Child*. 1978; 53: 737-739.
- Okan M, acimustafaoglu M, Ildirim I, Dönmez O, Eralp O, Ozer ET. Long-Term Neurologic and Psychomotor Sequelae After Neonatal Tetanus. *J Child Neurol*. 1997; 12: 270-272.
- J. L. Barlow JL, Mung'ala-Odera V, Gona J, Newton CRJC. Brain damage after neonatal tetanus in a rural Kenyan hospital. *Trop Med Int Health*. 2001; 6(4): 305-308.
- Khanna SS, Bharucha B, Bhatia AK, Dastur FD. Neonatal tetanus: Psychomotor development in survivors. *Indian Pediatr*. 1985; 22(2): 125-130.
- Salimpour R. Amobarbital chlorpromazine in the treatment of tetanus neonatorum. *Trop Geogr Med*. 1971; 23(2): 131-134.
- Anlar B, Yalaz K, Dizmen R. Long-term prognosis after neonatal tetanus. *Dev Med Child Neurol*. 1989; 31(1): 76-80.
- Tutuncuoğlu S, Demir E, Koprubasi, F, Selcuki D. The evaluation of late sequelae of tetanus infection. *Indian J Pediatr*. 1994; 61: 243-267.
- He M, Abdou A, Ellwein LB, Naidoo KS, Sapkota YD, Thulasiraj RD, Varma R, Zhao J, Kocur I, Congdon NG. Age-related Prevalence and Met Need for Correctable and Uncorrectable Near Vision Impairment in a Multi-country Study. *Ophthalmology*. 2014; 121: 417-422.
- Fria TJ, Cantekin EI, Eichler JA. Hearing Acuity of Children With Otitis Media With Effusion. *Arch Otolaryngol*. 1985; 111(1): 10-16.
- Satoguina JS, Oriero EC, Nwakanma D, Ebonyi A, Okebe J, Vincent T, Gomez-Escobar N, Corran P, Riley E, Conway D, Walther M. Altered malaria endemicity in rural communities in the Gambia and in Guinea Bissau. *Am J Trop Med Hyg*. 2008; 79(6): 1016.
- Teknetzi P, Manios S, Katsoutanopoulos. Neonatal tetanus--long-term residual handicaps. *Arch Dis Child*. 1983; 58(1): 68-69.
- Weström L, Joesoef R, Reynolds G, Hagdu A, Thompson SE. Pelvic Inflammatory Disease and Fertility. a Cohort Study of 1,844 Women with Laparoscopically Verified Disease and 657 Control Women with Normal Laparoscopic Results. *Sex Transm Dis*. 1992; 19(4): 185-92.
- National Center for Human Nutrition Planning (CEPLANUT) (Congo, DR). Congo, DR Study of Mothers Motivators on Attendance and Non-Attendance at the Pre-School Consultation. Kinshasa, Democratic Republic of the Congo: National Center for Human Nutrition Planning (CEPLANUT) (Congo, DR), 1988.
- Ministry of Scientific and Technological Research for Development (Madagascar). Synthesis of Existing Data on Nutritional Status in Madagascar. Antananarivo, Madagascar: Ministry of Scientific and Technological Research for Development (Madagascar), 1990.
- Fulford AJ, Mbugua GG, Ouma JH, Kariuki HC, Sturrock RF, Butterworth AE. Differences in the rate of hepatosplenomegaly due to *Schistosoma mansoni* infection between two areas in Machakos District, Kenya. *Trans R Soc Trop Med Hyg*. 1991; 85(4): 481-8. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop*. 2002; 82(2): 127-37.
- Republic of Guinea. Enquête de consommation des ménages de Conakry (ENCOMEC) [Household consumption survey of Conakry]. National document for the International Conference on Nutrition: 1992 December 5-11; Rome, Italy.
- Ministry of Health (Maldives). Maldives Country Health Programming. Male, Maldives: Ministry of Health, 1981.

Appendix Table A.3b - Citations for non-dismod model input data

- WHO/UNICEF Joint Nutrition Support Programme in Mozambique Annual Report 1990
- WHO/UNICEF Joint Nutrition Support Programme in Mozambique Plan of Action 1991
- United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA). Refugee camps in Jordan, Gaza, and the West Bank Child Underweight Data 1984. Vienna, Austria: UNRWA, 1984.
- Andrien M. Nutrition education of young children's mothers: study of needs in Pikine (Senegal). Health Education Collection No. 3. Liège, Belgium: Experimental Education Laboratory of the University of Liège, 1986.
- Central Statistical Office (Zambia), United Nations Children's Fund (UNICEF). Zambia Crop Forecasting Survey Nutrition Module 1989-1990.
- Ministry of Health (Nicaragua). Nicaragua Ministry of Health Child Underweight Data 1980-1982.
- Ministry of Health (Vietnam). Vietnam Ministry of Health Report on Re-Analyzed Data Collected by the General Nutrition Survey 1987-89.
- Ministry of Health and Medical Education (Iran). Iran Anthropometric Nutritional Indicators Survey 1998.
- Ministry of Health and Medical Education (Iran). Iran Anthropometric Nutritional Indicators Survey 2004.
- Ministry of Public Health (Niger), National Institute of Statistics (Niger). Niger Nutrition and Child Survival Survey 2008.
- Eltom AR, Elbushra HE. Results of the Baseline Survey, Part 3. Khartoum, Sudan: Department of Community Medicine, Faculty of Medicine, University of Khartoum, 1984.
- Hartyánszky I, Dobos M, Szabolcs J, Mihályi S, Lozsádi K, Fekete G. [Life expectancy in Down syndrome infants and children with congenital heart defects, 1974-1997]. *Orv Hetil.* 2000; 141(39): 2119-22.
- Henderson A, Lynch SA, Wilkinson S, Hunter M. Adults with Down's syndrome: the prevalence of complications and health care in the community. *Br J Gen Pract.* 2007; 57(534): 50-5.
- Bender BG, Linden MG, Harmon R. Neuropsychological and functional cognitive skills of 35 unselected adults with sex chromosome abnormalities. *Am J Med Genet.* 2001; 102(4): 309-13.
- Bender BG, Linden MG, Robinson A. Neuropsychological impairment in 42 adolescents with sex chromosome abnormalities. *Am J Med Genet.* 1993; 48(3): 169-73.
- Boone KB, Swerdloff RS, Miller BL, Geschwind DH, Razani J, Lee A, Gonzalo IG, Haddad A, Rankin K, Lu P, Paul L. Neuropsychological profiles of adults with Klinefelter syndrome. *J Int Neuropsychol Soc.* 2001; 7(4): 446-56.
- Fales CL, Knowlton BJ, Holyoak KJ, Geschwind DH, Swerdloff RS, Gonzalo IG. Working memory and relational reasoning in Klinefelter syndrome. *J Int Neuropsychol Soc.* 2003; 9(6): 839-46.
- Ross JL, Roeltgen DP, Stefanatos G, Benecke R, Zeger MPD, Kushner H, Ramos P, Elder FF, Zinn AR. Cognitive and motor development during childhood in boys with Klinefelter syndrome. *J Int Neuropsychol Soc.* 2008; 14(6): 708-19.
- Temple CM, Sanfilippo PM. Executive skills in Klinefelter's syndrome. *Neuropsychologia.* 2003; 41(11): 1547-59.
- Mazzanti L, Cacciari E. Congenital heart disease in patients with Turner's syndrome. Italian Study Group for Turner Syndrome (ISGTS). *J Pediatr.* 1998; 133(5): 688-92.
- Dirdal M, Adeler A, Andersen EN, Nielsen-Brøchner T, Erlendsson J, Haahr J, Jelert H, Jeune B, Kehler K, Pedersen IL. [Purulent meningitis in children. Mortality and sequelae]. *Ugeskr Laeger.* 1981; 143(27): 1689-93. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis.* 2010; 10(5): 317-28.
- Vienny H, Despland PA, Lütsch J, Deonna T, Dutoit-Marco ML, Gander C. Early diagnosis and evolution of deafness in childhood bacterial meningitis: a study using brainstem auditory evoked potentials. *Pediatrics.* 1984; 73(5): 579-86. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis.* 2010; 10(5): 317-28.
- Schaad UB, Krucko J, Pfenninger J. An extended experience with cefuroxime therapy of childhood bacterial meningitis. *Pediatr Infect Dis.* 1984; 3(5): 410-6. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis.* 2010; 10(5): 317-28.
- Baselga Asensio C, Ramos Fuentes FJ, Gracia Casanova M, Abad Alegría F, González Matilla I, Castellano Bendicho MJ, Bori Aiguabella MA, Bueno Sánchez M. [Cortical evoked auditory evoked potentials in a series of patients who had bacterial meningitis during childhood]. *An Esp Pediatr.* 1987; 27(5): 339-42. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis.* 2010; 10(5): 317-28.
- Fortnum H, Davis A. Hearing impairment in children after bacterial meningitis: incidence and resource implications. *Br J Audiol.* 1993; 27(1): 43-52. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis.* 2010; 10(5): 317-28.
- Lutsar I, Siirde T, Soopõld T. Long term follow-up of Estonian children after bacterial meningitis. *Pediatr Infect Dis J.* 1995; 14(7): 624-5. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis.* 2010; 10(5): 317-28.
- Kaarsen PI, Flaegstad T. Prognostic factors in childhood bacterial meningitis. *Acta Paediatr.* 1995; 84(8): 873-8. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis.* 2010; 10(5): 317-28.

Appendix Table A.3b - Citations for non-dismod model input data

- Kilpi T, Anttila M, Kallio MJ, Peltola H. Length of prediagnostic history related to the course and sequelae of childhood bacterial meningitis. *Pediatr Infect Dis J*. 1993; 12(3): 184-8. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Duclaux R, Sevin F, Ferber C, Draï MF, Dubreuil C. Brainstem auditory evoked potentials following meningitis in children. *Brain Dev*. 1993; 15(5): 340-5. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Katona G, Farkas Z, Hirschberg J, Hajdi G, Nyerges G. [Hearing loss resulting from purulent meningitis in the light of adjuvant dexamethasone therapy]. *Orv Hetil*. 1993; 134(5): 247-9. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Wilken B, van Wees J, Tegtmeier FK, Aksu F. [Hearing disorders in children less than 16 months of age after bacterial meningitis with reference to cerebrospinal fluid elastase]. *Klin Padiatr*. 1995; 207(1): 12-6. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Lütschg J. Hearing disorders in meningitis. *Antibiot Chemother* (1971). 1992; 218-25. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Palla G, Villirillo A, Ughi C, Berrettini S, Sellari Franceschini S, Ursino F. [Sequelae of bacterial meningitis in childhood: a study of hearing impairment]. *Minerva Pediatr*. 1995; 47(10): 401-8. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- François M, Laccourreye L, Huy ET, Narcy P. Hearing impairment in infants after meningitis: detection by transient evoked otoacoustic emissions. *J Pediatr*. 1997; 130(5): 712-7. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Biesheuvel CJ, Kooen I, Vergouwe Y, Van Furth M, Oostenbrink R, Moll HA, Grobbee DE, Moons KGM. Validating and updating a prediction rule for neurological sequelae after childhood bacterial meningitis. *Scand J Infect Dis*. 2006; 38(1): 19-26. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Kooen I, Grobbee DE, Roord JJ, Jennekens-Schinkel A, van der Lei HDW, Kraak M a. C, van Furth AM. Prediction of academic and behavioural limitations in school-age survivors of bacterial meningitis. *Acta Paediatr*. 2004; 93(10): 1378-85. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Richardson M, Williamson T, Reid A, Tarlow M, Rudd P. Testing for hearing loss after meningitis. *J Pediatr*. 1998; 132(4): 749-50. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Bedford H, de Louvois J, Halket S, Peckham C, Hurley R, Harvey D. Meningitis in infancy in England and Wales: follow up at age 5 years. *BMJ*. 2001; 323(7312): 533-6. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Kooen I, van Furth AM, Kraak MAC, Grobbee DE, Roord JJ, Jennekens-Schinkel A. Neuropsychology of academic and behavioural limitations in school-age survivors of bacterial meningitis. *Dev Med Child Neurol*. 2004; 46(11): 724-32. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Ozen M, Kanra G, Kara A, Bakar EE, Ceyhan M, Secmeer G, Cengiz AB. Long-term beneficial effects of dexamethasone on intellectual and neuropsychological outcome of children with pneumococcal meningitis. *Scand J Infect Dis*. 2006; 38(2): 104-9. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Pomeroy SL, Holmes SJ, Dodge PR, Feigin RD. Seizures and other neurologic sequelae of bacterial meningitis in children. *N Engl J Med*. 1990; 323(24): 1651-7. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Dodge PR, Davis H, Feigin RD, Holmes SJ, Kaplan SL, Jubelirer DP, Stechenberg BW, Hirsh SK. Prospective evaluation of hearing impairment as a sequela of acute bacterial meningitis. *N Engl J Med*. 1984; 311(14): 869-74. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Muñoz AI. Bacterial meningitis in pediatric patients: a five-year experience. *Bol Asoc Med P R*. 1982; 74(3): 62-5. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.

Appendix Table A.3b - Citations for non-dismod model input data

- Lebel MH, McCracken GH. Delayed cerebrospinal fluid sterilization and adverse outcome of bacterial meningitis in infants and children. *Pediatrics*. 1989; 83(2): 161-7. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Couto MI, Monteiro SR, Lichtig I, Casella EB, Carvalho RM, de Navarro JM. [Audiological assessment and follow-up after bacterial meningitis]. *Arq Neuropsiquiatr*. 1999; 57(3B): 808-12. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Wellman MB, Sommer DD, McKenna J. Sensorineural hearing loss in postmeningitic children. *Otol Neurotol*. 2003; 24(6): 907-12. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Anjos LP, Queirós F, Pereira MC, Brandão M, Melo A, Lucena R. [Audiologic late prognosis due to meningitis in children]. *Arq Neuropsiquiatr*. 2004; 62(3A): 635-40. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Shaltout AA, Auger LT, Awadallah NB, Hijazi Z, Johny M, Hajj KE, Kandil H. Morbidity and mortality of bacterial meningitis in Arab children. *J Trop Med Hyg*. 1989; 92(6): 402-6. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Zaki M, Daoud AS, ElSaleh Q, West PW. Childhood bacterial meningitis in Kuwait. *J Trop Med Hyg*. 1990; 93(1): 7-11. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Salih MA, el Hag AI, Sid Ahmed H, Bushara M, Yasin I, Omer MI, Hofvander Y, Olcen P. Endemic bacterial meningitis in Sudanese children: aetiology, clinical findings, treatment and short-term outcome. *Ann Trop Paediatr*. 1990; 10(2): 203-10. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Dawson KP, Abbott GD, Mogridge N. Bacterial meningitis in childhood: a 13 year review. *N Z Med J*. 1988; 101(857): 758-60. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Jiang ZD, Liu XY, Wu YY, Zheng MS, Liu HC. Long-term impairments of brain and auditory functions of children recovered from purulent meningitis. *Dev Med Child Neurol*. 1990; 32(6): 473-80. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Grimwood K, Anderson P, Anderson V, Tan L, Nolan T. Twelve year outcomes following bacterial meningitis: further evidence for persisting effects. *Arch Dis Child*. 2000; 83(2): 111-6. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Carroll KJ, Carroll C. A prospective investigation of the long-term auditory-neurological sequelae associated with bacterial meningitis: a study from Vanuatu. *J Trop Med Hyg*. 1994; 97(3): 145-50. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Yeat SW, Mukari SZ, Said H, Motilal R. Post meningitic sensori-neural hearing loss in children--alterations in hearing level. *Med J Malaysia*. 1997; 52(3): 285-90. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Chang C-J, Chang H-W, Chang W-N, Huang L-T, Huang S-C, Chang Y-C, Hung P-L, Chang C-S, Chuang Y-C, Huang C-R, Tsai N-W, Tsui H-W, Wang K-W, Lu C-H. Seizures complicating infantile and childhood bacterial meningitis. *Pediatr Neurol*. 2004; 31(3): 165-71. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Wang K-W, Chang W-N, Chang H-W, Chuang Y-C, Tsai N-W, Wang H-C, Lu C-H. The significance of seizures and other predictive factors during the acute illness for the long-term outcome after bacterial meningitis. *Seizure*. 2005; 14(8): 586-92. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Wandi F, Kiagi G, Duke T. Long-term outcome for children with bacterial meningitis in rural Papua New Guinea. *J Trop Pediatr*. 2005; 51(1): 51-3. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Gupta V. Hearing evaluation in children with bacterial meningitis. *Indian Pediatr*. 1993; 30(10): 1175-9. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.
- Singhi P, Bansal A, Geeta P, Singhi S. Predictors of long term neurological outcome in bacterial meningitis. *Indian J Pediatr*. 2007; 74(4): 369-74. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010; 10(5): 317-28.

Appendix Table A.3b - Citations for non-dismod model input data

- George CN, Letha S, Bai SS. A clinical study of chronic morbidity in children following pyogenic meningitis. *Indian Pediatr.* 2002; 39(7): 663-7. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis.* 2010; 10(5): 317-28.
- Hodgson A, Smith T, Gagneux S, Akumah I, Adjuik M, Pluschke G, Binka F, Genton B. Survival and sequelae of meningococcal meningitis in Ghana. *Int J Epidemiol.* 2001; 30(6): 1440-6. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis.* 2010; 10(5): 317-28.
- Molyneux EM, Tembo M, Kayira K, Bwanaisa L, Mweneychanya J, Njobvu A, Forsyth H, Rogerson S, Walsh AL, Molyneux ME. The effect of HIV infection on paediatric bacterial meningitis in Blantyre, Malawi. *Arch Dis Child.* 2003; 88(12): 1112-8. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis.* 2010; 10(5): 317-28.
- Melaku A. Sensorineural hearing loss in children with epidemic meningococcal meningitis at Tikur Anbessa Hospital. *Ethiop Med J.* 2003; 41(2): 113-21. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis.* 2010; 10(5): 317-28.
- Pitkäranta A, Pelkonen T, de Sousa E Silva MO, Bernardino L, Roine I, Peltola H. Setting up hearing screening in meningitis children in Luanda, Angola. *Int J Pediatr Otorhinolaryngol.* 2007; 71(12): 1929-31. as it appears in Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis.* 2010; 10(5): 317-28.
- Scherf C, Morison L, Fiander A, Ekpo G, Walraven G. Epidemiology of pelvic organ prolapse in rural Gambia, West Africa. *BJOG.* 2002; 109(4): 431-6.
- Slieker-ten Hove MCP, Pool-Goudzwaard AL, Eijkemans MJC, Steegers-Theunissen RPM, Burger CW, Vierhout ME. Prediction model and prognostic index to estimate clinically relevant pelvic organ prolapse in a general female population. *Int Urogynecol J Pelvic Floor Dysfunct.* 2009; 20(9): 1013-21.
- Yarnell JW, Voyle GJ, Richards CJ, Stephenson TP. The prevalence and severity of urinary incontinence in women. *J Epidemiol Community Health.* 1981; 35(1): 71-4.
- Arene FO, Ibanga E, Asor JE. Epidemiology of paragonimiasis in Cross River basin, Nigeria: prevalence and intensity of infection due to *Paragonimus uterobilateralis* in Yakurr local government area. *Public Health.* 1998; 112(2): 119-22.
- Chung DI, Kim YI, Lee KR, Choi DW. Epidemiological studies of digenetic trematodes in Yongyang County, Kyungpook Province. *Kisaengchunghak Chapchi.* 1991; 29(4): 325-38.
- Esteban JG, Flores A, Aguirre C, Strauss W, Angles R, Mas-Coma S. Presence of very high prevalence and intensity of infection with *Fasciola hepatica* among Aymara children from the Northern Bolivian Altiplano. *Acta Trop.* 1997; 66(1): 1-14.
- Esteban JG, González C, Bargues MD, Angles R, Sánchez C, Nájaira C, Mas-Coma S. High fascioliasis infection in children linked to a man-made irrigation zone in Peru. *Trop Med Int Health.* 2002; 7(4): 339-48.
- Ibanga ES, Eyo VM. Pulmonary paragonimiasis in Oban community in Akamkpa Local Government Area, Cross River State, Nigeria: prevalence and intensity of infection. *Trans R Soc Trop Med Hyg.* 2001; 95(2): 159-60.
- Joo CY. Epidemiological studies of *Clonorchis sinensis* in vicinity of river Taewha, Kyungnam province, Korea. *Kisaengchunghak Chapchi.* 1980; 18(2): 199-214.
- Oh SJ. Cerebral paragonimiasis. *J Neurol Sci.* 1969; 8(1): 27-48.
- Seo BS, Lee SH, Cho SY, Chai JY, Hong ST, Han IS, Sohn JS, Cho BH, Ahn SR, Lee SK, Chung SC, Kang KS, Shim HS, Hwang IS. An epidemiological study on clonorchiasis and metagonimiasis in riverside areas in Korea. *Kisaengchunghak Chapchi.* 1981; 19(2): 137-50.
- Song I-C, Lee J-S, Rim H-J. Epidemiological studies on the distribution of *Clonorchis sinensis* infection in Korea. *Korea Univ Med J.* 1983; 20(1): 165-90.
- Sriamporn S, Parkin DM, Pisani P, Vatanasapt V, Suwanrungruang K, Kamsa-ard P, Pengsaa P, Kritpetcharat O, Pipitgool V, Vatanasapt P. A prospective study of diet, lifestyle, and genetic factors and the risk of cancer in Khon Kaen Province, northeast Thailand: description of the cohort. *Asian Pac J Cancer Prev.* 2005; 6(3): 295-303.
- Udonsi JK. Endemic *Paragonimus* infection in upper Igwun Basin, Nigeria: a preliminary report on a renewed outbreak. *Ann Trop Med Parasitol.* 1987; 81(1): 57-62.
- Carey DE, Kemp GE, Troup JM, White HA, Smith EA, Addy RF, Fom AL, Pifer J, Jones EM, Brès P, Shope RE. Epidemiological aspects of the 1969 yellow fever epidemic in Nigeria. *Bull World Health Organ.* 1972; 46(5): 645-51. as it appears in Johansson MA, Vasconcelos PFC, Staples JE. The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases. *Trans R Soc Trop Med Hyg.* 2014; 108(8): 482-7.
- De Cock KM, Monath TP, Nasidi A, Tukei PM, Enriquez J, Lichfield P, Craven RB, Fabiyi A, Okafor BC, Ravaonjanahary C, Sorungbe A. Epidemic yellow fever in eastern Nigeria, 1986. *Lancet.* 1988; 1(8586): 630-3. as it appears in Johansson MA, Vasconcelos PFC, Staples JE. The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases. *Trans R Soc Trop Med Hyg.* 2014; 108(8): 482-7.
- Monath TP, Craven RB, Adjukiewicz A, Germain M, Francy DB, Ferrara L, Samba EM, N'Jie H, Cham K, Fitzgerald SA, Crippen PH, Simpson DI, Bowen ET, Fabiyi A, Salaun JJ. Yellow fever in the Gambia, 1978-1979: epidemiologic aspects with observations on the occurrence of orungo virus infections. *Am J Trop Med Hyg.* 1980; 29(5): 912-28. as it appears in Johansson MA, Vasconcelos PFC, Staples JE. The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases. *Trans R Soc Trop Med Hyg.* 2014; 108(8): 482-7.

Appendix Table A.3b - Citations for non-dismod model input data

- Hadler SC, Webster HM, Erben JJ, Swanson JE, Maynard JE. Hepatitis A in day-care centers. A community-wide assessment. *N Engl J Med.* 1980; 302(22): 1222-7. as it appears in Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. *Pediatrics.* 2002; 109(5): 839-45.
- Benenson MW, Takafuji ET, Bancroft WH, Lemon SM, Callahan MC, Leach DA. A military community outbreak of hepatitis type A related to transmission in a child care facility. *Am J Epidemiol.* 1980; 112(4): 471-81. as it appears in Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. *Pediatrics.* 2002; 109(5): 839-45.
- Gingrich GA, Hadler SC, Elder HA, Ash KO. Serologic investigation of an outbreak of hepatitis A in a rural day-care center. *Am J Public Health.* 1983; 73(10): 1190-93. as it appears in Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. *Pediatrics.* 2002; 109(5): 839-45.
- Lednar WM, Lemon SM, Kirkpatrick JW, Redfield RR, Fields ML, Kelley PW. Frequency of illness associated with epidemic hepatitis A virus infections in adults. *Am J Epidemiol.* 1985; 122(2): 226-33. as it appears in Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. *Pediatrics.* 2002; 109(5): 839-45.
- Ghana Statistical Service, Ministry of Health (Ghana), United Nations Children's Fund (UNICEF). Ghana District Multiple Indicator Cluster Survey 2007-2008.
- Pavia AT, Nielsen L, Armington L, Thurman DJ, Tierney E, Nichols CR. A community-wide outbreak of hepatitis A in a religious community: impact of mass administration of immune globulin. *Am J Epidemiol.* 1990; 131(6): 1085-93. as it appears in Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. *Pediatrics.* 2002; 109(5): 839-45.
- Staes CJ, Schlenker TL, Risk I, Cannon KG, Harris H, Pavia AT, Shapiro CN, Bell BP. Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak. *Am J Epidemiol.* 2000; 106(4): E54. as it appears in Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. *Pediatrics.* 2002; 109(5): 839-45.
- Hanson JW, Jones KL, Smith DW. Fetal alcohol syndrome. Experience with 41 patients. *JAMA.* 1976; 235(14): 1458-60.
- Clarren SK, Smith DW. The fetal alcohol syndrome. *N Engl J Med.* 1978; 298(19): 1063-7.
- Boniphace I, Omari M, Susan Fred R, Ferdinand M, Marcel T. HIV/AIDS Clinical Manifestations and their Implication for Patient Clinical Staging in Resource Limited Settings in Tanzania. *Open AIDS J.* 2011; 5: 9-16.
- Baveewo S, Ssali F, Karamagi C, Kalyango JN, Hahn JA, Ekoru K, Mugenyi P, Katabira E. Validation of World Health Organisation HIV/AIDS clinical staging in predicting initiation of antiretroviral therapy and clinical predictors of low CD4 cell count in Uganda. *PLoS One.* 2011; 6(5): e19089.
- French N, Mujugira A, Nakiyingi J, Mulder D, Janoff EN, Gilks CF. Immunologic and clinical stages in HIV-1-infected Ugandan adults are comparable and provide no evidence of rapid progression but poor survival with advanced disease. *J Acquir Immune Defic Syndr.* 1999; 22(5): 509-16.
- Azizi F, Sheikholeslam R, Hedayati M, Mirmiran P, Malekafzali H, Kimiagar M, Pajouhi MSustainable control of iodine deficiency in Iran: beneficial results of the implementation of the mandatory law on salt iodization. *J Endocrinol Invest.* 2002; 25(5): 409-13.
- Drolshammer I, Wiesmann E, Eckert J. [Echinococcosis in humans in Switzerland 1956-1969]. *Schweiz Med Wochenschr.* 1973; 103(39): 1337-41.
- Checchi F, Cox AP, Chappuis F, Priotto G, Chandramohan D, Haydon DT. Prevalence and under-detection of gambiense human African trypanosomiasis during mass screening sessions in Uganda and Sudan. *Parasit Vectors.* 2012; 5: 157.
- Doctors Without Borders (MSF). Human African Trypanosomiasis: Update on Progress and Future Perspectives. Geneva, Switzerland: Doctors Without Borders (MSF), 2006.
- Bern C. Clinical manifestations and diagnosis of visceral leishmaniasis. Alphen aan den Rijn, Netherlands: UpToDate, Inc. 2014.
- Pearson RD, Sousa AQ. Clinical spectrum of Leishmaniasis. *Clin Infect Dis.* 1996; 22(1): 1-13.
- Benedetti JK, Zeh J, Corey L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. *Ann Intern Med.* 1999; 131(1): 14-20.
- Coleman JS, Gaydos CA, Witter F. *Trichomonas vaginalis* Vaginitis in Obstetrics and Gynecology Practice: New Concepts and Controversies. *Obstet Gynecol Surv.* 2013; 68(1): 43-50.
- Judson FN. Gonorrhoea. *Med Clin North Am.* 1990; 74(6): 1353-66.
- Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. *N Engl J Med.* 1987; 316(23): 1444-9.
- Rein DB, Kassler WJ, Irwin KL, Rabiee L. Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial. *Obstet Gynecol.* 2000; 95(3): 397-402.
- Schillinger JA, McKinney CM, Garg R, Gwynn RC, White K, Lee F, Blank S, Thorpe L, Frieden T. Seroprevalence of herpes simplex virus type 2 and characteristics associated with undiagnosed infection: New York City, 2004. *Sex Transm Dis.* 2008; 35(6): 599-606.
- Solomon L, Cannon MJ, Reyes M, Graber JM, Wetherall NT, Reeves WC, Task Force on Herpes Simplex Virus Resistance. Epidemiology of recurrent genital herpes simplex virus types 1 and 2. *Sex Transm Infect.* 2003; 79(6): 456-9.
- Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R, Krieger JN, Corey L. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. *N Engl J Med.* 2000; 342(12): 844-50.

Appendix Table A.3b - Citations for non-dismod model input data

- Adeyolu AB, Olujohungbe AB, Morris J, Yardumian A, Bareford D, Akenova A, Akinyanju O, Cinkotai K, O'Reilly PH. Priapism in sickle-cell disease; incidence, risk factors and complications – an international multicentre study. *BJU Int.* 2002; 90(9): 898–902.
- Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, Sabato V, Melevendi C, Cappellini MD, Verlato G. Survival and disease complications in thalassemia major. *Ann N Y Acad Sci.* 1998; 850(1): 227–31.
- Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, Vera JC, Levy PS. The acute chest syndrome in sickle cell disease: incidence and risk factors. *The Cooperative Study of Sickle Cell Disease. Blood.* 1994; 84(2): 643–9.
- Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR, Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. *Blood.* 2004; 104(1): 34–9.
- Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, Wethers DL, Pegelow CH, Gill FM. Cerebrovascular Accidents in Sickle Cell Disease: Rates and Risk Factors. *Blood.* 1998; 91(1): 288–94.
- Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, Kinney TR. Pain in sickle cell disease. Rates and risk factors. *N Engl J Med.* 1991; 325(1): 11–6.
- Shamshirsaz AA, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Bouzari N, Habibzadeh M, Hashemi R, Shamshirsaz AA, Aghakhani S, Homayoun H, Larijani B. Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. *BMC Endocr Disord.* 2003; 3(1): 4.
- Chiò A, Magnani C, Schiffer D. Prevalence of Parkinson's disease in Northwestern Italy: comparison of tracer methodology and clinical ascertainment of cases. *Mov Disord.* 1998; 13(3): 400–5.
- Araki I, Kitahara M, Oida T, Kuno S. Voiding dysfunction and Parkinson's disease: urodynamic abnormalities and urinary symptoms. *J Urol.* 2000; 164(5): 1640–3.
- El-Tallawy HN, Farghaly WM, Shehata GA, Rageh TA, Hakeem NMA, Hamed MAA, Badry R. Prevalence of Parkinson's disease and other types of Parkinsonism in Al Kharga district, Egypt. *Neuropsychiatr Dis Treat.* 2013; 9: 1821–6.
- Global Parkinson's Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. *Mov Disord.* 2002; 17(1): 60–7.
- Ilovi CS, Lule GN, Obel AO, Irimu HM. Correlation of WHO clinical staging with CD4 counts in adult HIV/AIDS patients at Kenyatta National Hospital, Nairobi. *East Afr Med J.* 2011; 88(2): 65–70.
- Tsakos G, Herrick K, Sheiham A, Watt RG. Edentulism and fruit and vegetable intake in low-income adults. *J Dent Res.* 2010; 89(5): 462–7.
- Nuttall NM, Steele JG, Evans D, Chadwick B, Morris AJ, Hill K. The reported impact of oral condition on children in the United Kingdom, 2003. *Br Dent J.* 2006; 200(10): 551–5.
- Al-Riyami AA, Suleiman AJ, Afifi M, Al-Lamki ZM, Daar S. A community-based study of common hereditary blood disorders in Oman. *East Mediterr Health J.* 2001; 7(6): 1004–11.
- Ankra-Badu GA, Al-Jama A, Al Kadim Y. Hemoglobin H disease in the Al-Qatif Region of Saudi Arabia. 2001; 21(5-6): 308–11.
- Brooker S, Hotez PJ, Bundy DAP. Hookworm-related anaemia among pregnant women: a systematic review. *PLoS Negl Trop Dis.* 2008; 2(9): e291.
- Deyde VM, Lo BB, Khalifa IO, Ly B, Ball A, Fattoum S. Epidemiological profile of hemoglobinopathies in the Mauritanian population. *Ann Hematol.* 2002; 81(6): 320–1.
- Gupte SC, Shaw AN, Shah KC. Hematological findings and severity of G6PD deficiency in Vataliya Prajapati subjects. *J Assoc Physicians India.* 2005; 53: 1027–30.
- King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet.* 2005; 365(9470): 1561–9.
- Liu N-J, Lee C-S, Tang J-H, Cheng H-T, Chu Y-Y, Sung K-F, Lin C-H, Tsou Y-K, Lien J-M, Chen P-C, Chiu C-T, Cheng C-L. Outcomes of bleeding peptic ulcers: a prospective study. *J Gastroenterol Hepatol.* 2008; 23(8 Pt 2): e340–7.
- Nahon S, Lahmek P, Massard J, Lesgourgues B, Mariaud de Serre N, Traissac L, Bodiguel V, Adotti F, Delas N. Helicobacter pylori-associated chronic gastritis and unexplained iron deficiency anemia: a reliable association? *Helicobacter.* 2003; 8(6): 573–7.
- Smith JL, Brooker S. Impact of hookworm infection and deworming on anaemia in non-pregnant populations: a systematic review. *Trop Med Int Health.* 2010; 15(7): 776–95.
- Tagarelli A, Piro A, Bastone L, Tagarelli G. Identification of glucose 6-phosphate dehydrogenase deficiency in a population with a high frequency of thalassemia. *FEBS Lett.* 2000; 466(1): 139–42.
- Van-Dunem JCC, Alves JGB, Bernardino L, Figueiroa JN, Braga C, do Nascimento M de LP, da Silva SJ. Factors associated with sickle cell disease mortality among hospitalized Angolan children and adolescents. *West Afr J Med.* 2007; 26(4): 269–73.
- Venugopal S, Dhuri S, Al Jabal KB, Shaju A. Hemoglobin H disease in Muscat, Oman - A 5 year study. *Oman Med J.* 2008; 23(2): 82–5.
- Wagner KS, Ronsmans C, Thomas SL, Calvert C, Adler A, Ganaba R, Goufodji S, Filippi V. Women who experience obstetric haemorrhage are at higher risk of anaemia, in both rich and poor countries. *Trop Med Int Health.* 2012; 17(1): 9–22.
- Piomelli S, Siniscalco M. The Haematological Effects of Glucosed-Phosphate Dehydrogenase Deficiency and Thalassemia Trait: Interaction between the Two Genes at the Phenotype Level. *Br J Haematol.* 1969; 16(6): 537–49.
- Zago MA, Costa FF. Hereditary haemoglobin disorders in Brazil. *Trans R Soc Trop Med Hyg.* 1985; 79(3): 385–8.
- Isanaka S, Grais RF, Briend A, Checchi F. Estimates of the duration of untreated acute malnutrition in children from Niger. *Am J Epidemiol.* 2011; 173(8): 932–40.
- Lapidus N, Minetti A, Djibo A, Guerin PJ, Hustache S, Gaboulaud V, Grais RF. Mortality risk among children admitted in a large-scale nutritional program in Niger, 2006. *PLoS One.* 2009; 4(1): e4313.

Appendix Table A.3b - Citations for non-dismod model input data

- Ministry of Health (Chile). Chile National Survey of Breastfeeding 2005.
- Chimanuka GD. Association between Clinical Stages (WHO) and CD4+T-Cell count in HIV infected adults at University Teaching Hospital in Lusaka, Zambia [Master's Thesis]. Lusaka, Zambia: University of Zambia;2010.
- Sheiham A, Steele J. Does the condition of the mouth and teeth affect the ability to eat certain foods, nutrient and dietary intake and nutritional status amongst older people? *Public Health Nutr.* 2001; 4(3): 797-803.
- Whyman RA, Treasure ET, Ayers KM. Dental disease levels and reasons for emergency clinic attendance in patients seeking relief of pain in Auckland. *N Z Dent J.* 1996; 92(410): 114-7.
- Mason C, Porter SR, Madland G, Parry J. Early management of dental pain in children and adolescents. *J Dent.* 1997; 25(1): 31-4.
- Bradbury J, Thomason JM, Jepson NJA, Walls AWG, Mulvaney CE, Allen PF, Moynihan PJ. Perceived chewing ability and intake of fruit and vegetables. *J Dent Res.* 2008; 87(8): 720-5.
- Shepherd MA, Nadanovsky P, Sheiham A. The prevalence and impact of dental pain in 8-year-old school children in Harrow, England. *Br Dent J.* 1999; 187(1): 38-41.
- Naidoo S, Chikte UM, Sheiham A. Prevalence and impact of dental pain in 8-10-year-olds in the western Cape. *SADJ.* 2001; 56(11): 521-3.
- Okullo I, Astrøm AN, Haugejorden O. Social inequalities in oral health and in use of oral health care services among adolescents in Uganda. *Int J Paediatr Dent.* 2004; 14(5): 326-35.
- Vargas CM, Macek MD, Goodman HS, Wagner ML. Dental pain in Maryland school children. *J Public Health Dent.* 2005; 65(1): 3-6.
- Ratnayake N, Ekanayake L. Prevalence and impact of oral pain in 8-year-old children in Sri Lanka. *Int J Paediatr Dent.* 2005; 15(2): 105-12.
- Bastos JL, Nomura LH, Peres MA. Dental pain, socioeconomic status, and dental caries in young male adults from southern Brazil. *Cad Saude Publica.* 2005; 21(5): 1416-23.
- Jiang H, Petersen PE, Peng B, Tai B, Bian Z. Self-assessed dental health, oral health practices, and general health behaviors in Chinese urban adolescents. *Acta Odontol Scand.* 2005; 63(6): 343-52.
- Pau A, Baxevasos KG, Croucher R. Family structure is associated with oral pain in 12-year-old Greek schoolchildren. *Int J Paediatr Dent.* 2007; 17(5): 345-51.
- Goes PS, Watt R, Hardy RG, Sheiham A. The prevalence and severity of dental pain in 14-15 year old Brazilian schoolchildren. *Community Dent Health.* 2007; 24(4): 217-24.
- Pau A, Khan SS, Babar MG, Croucher R. Dental pain and care-seeking in 11-14-yr-old adolescents in a low-income country. *Eur J Oral Sci.* 2008; 116(5): 451-7.
- Rebello MA, Lopes MC, Vieira JM, Parente RC. Dental caries and gingivitis among 15 to 19 year-old students in Manaus, AM, Brazil. *Braz Oral Res.* 2009; 23(3): 248-54.
- Dandi KK, Rao EV, Margabandhu S. Dental pain as a determinant of expressed need for dental care among 12-year-old school children in India. *Indian J Dent Res.* 2011; 22(4): 611.
- Clarke M, Locker D, Murray H, Payne B. The oral health of disadvantaged adolescents in North York, Ontario. *Can J Public Health.* 1996; 87(4): 261-3.
- Lipton JA, Ship JA, Larach-Robinson D. Estimated prevalence and distribution of reported orofacial pain in the United States. *J Am Dent Assoc.* 1993; 124(10): 115-21.
- Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. *J Infect Dis.* 2005; 191(2): 150-8.
- Allen S, Batungwanayo J, Kerlikowske K, Lifson AR, Wolf W, Granich R, Taelman H, Van de Perre P, Serufilira A, Bogaerts J. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. *Am Rev Respir Dis.* 1992; 146(6): 1439-44.
- Braun MM, Badi N, Ryder RW, Baende E, Mukadi Y, Nsuami M, Matela B, Willame JC, Kaboto M, Heyward W. A retrospective cohort study of the risk of tuberculosis among women of childbearing age with HIV infection in Zaire. *Am Rev Respir Dis.* 1991; 143(3): 501-4.
- Keizer ST, Langendam MM, van Deutekom H, Coutinho RA, van Ameijden EJ. How does tuberculosis relate to HIV positive and HIV negative drug users? *J Epidemiol Community Health.* 2000; 54(1): 64-8.
- Leroy V, Msellati P, Lepage P, Batungwanayo J, Hitimana DG, Taelman H, Bogaerts J, Boineau F, Van de Perre P, Simonon A. Four years of natural history of HIV-1 infection in african women: a prospective cohort study in Kigali (Rwanda), 1988-1993. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1995; 9(4): 415-21.
- Houben RMGJ, Glynn JR, Mboma S, Mzamba T, Mwaungulu NJ, Mwaungulu L, Mwenibabu M, Mpunga J, French N, Crampin AC. The impact of HIV and ART on recurrent tuberculosis in a sub-Saharan setting. *AIDS.* 2012; 26(17): 2233-9.
- Ferreira MM, Ferrazoli L, Palaci M, Salles PS, Medeiros LA, Novoa P, Kiefer CR, Schechtmann M, Kritski AL, Johnson WD, Riley LW, Ferreira Júnior OC. Tuberculosis and HIV infection among female inmates in São Paulo, Brazil: a prospective cohort study. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1996; 13(2): 177-83.
- Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. *Lancet.* 2002; 359(9323): 2059-64.
- Ezpeleta L, Keeler G, Erkanli A, Costello EJ, Angold A. Epidemiology of Psychiatric Disability in Childhood and Adolescence. *J Child Psychol Psychiatry.* 2001; 41(7): 901-14.
- Ahmad KA, Khan LH, Roshan B, Bhutta ZA. Factors associated with typhoid relapse in the era of multiple drug resistant strains. *J Infect Dev Ctries.* 2011; 5(10): 727-31. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.

Appendix Table A.3b - Citations for non-dismod model input data

- Ali Omer MI. Trimethoprim-sulphamethoxazole in the treatment of enteric fever. *J Trop Med Hyg.* 1975; 78(7): 162-6. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Arora RK, Gupta A, Joshi NM, Kataria VK, Lall P, Anand AC. Multidrug resistant typhoid fever: study of an outbreak in Calcutta. *Indian Pediatr.* 1992; 29(1): 61-6. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Bhutta ZA, Mansoorali N, Hussain R. Plasma cytokines in paediatric typhoidal salmonellosis: correlation with clinical course and outcome. *J Infect.* 1997; 35(3): 253-6. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Bhutta ZA, Naqvi SH, Durrani S, Suria A. Chloramphenicol therapy of typhoid fever and its relationship to hepatic dysfunction. *J Trop Pediatr.* 1991; 37(6): 320-2. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Bhutta ZA, Naqvi SH, Razzaq RA, Farooqui BJ. Multidrug-resistant typhoid in children: presentation and clinical features. *Rev Infect Dis.* 1991; 13(5): 832-6. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Bhutta ZA, Naqvi SH. Hepatic dysfunction in paediatric typhoidal salmonellosis. *Ann Trop Paediatr.* 1991; 11(3): 203-5. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Bhutta ZA, Niazi SK, Suria A. Chloramphenicol clearance in typhoid fever: implications for therapy. *Indian J Pediatr.* 1992; 59(2): 213-9. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Bhutta ZA. Fulminant hepatic failure with typhoid fever in childhood. *J Pak Med Assoc.* 1991; 41(6): 123-6. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Bhutta ZA. Impact of age and drug resistance on mortality in typhoid fever. *Arch Dis Child.* 1996; 75(3): 214-7. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Biswal N, Mathai B, Bhatia BD, Srinivasan S, Nalini P. Enteric fever: a changing perspective. *Indian Pediatr.* 1994; 31(7): 813-9. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Brian MJ. Typhoid in children in Goroka. *P N G Med J.* 1990; 33(1): 68-9. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Buch NA, Hassan MU, Kakroo DK. Enteric fever--a changing sensitivity pattern, clinical profile and outcome. *Indian Pediatr.* 1994; 31(8): 981-5. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Caglar MK, Ozsoylu S, Kanra G. Relative granulocytosis in childhood typhoid fever. *J Pediatr.* 1983; 102(4): 603-4. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Chandra R, Srinivasan S, Nalini P, Rao RS. Multidrug resistant enteric fever. *J Trop Med Hyg.* 1992; 95(4): 284-7. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Chawla V, Bhujwala RA, Chandra RK, Ghai OP. Typhoid fever in children. Clinical and bacteriological studies. *Indian J Pediatr.* 1970; 37(269): 239-44. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Chiu CH, Lin TY. Typhoid fever in children. *Lancet.* 1999; 354(9194): 2001-2. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Chiu CH, Tsai JR, Ou JT, Lin TY. Typhoid fever in children: a fourteen-year experience. *Acta Paediatr Taiwan.* 2000; 41(1): 28-32. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Choo KE, Razif A, Ariffin WA, Sepiah M, Gururaj A. Typhoid fever in hospitalized children in Kelantan, Malaysia. *Ann Trop Paediatr.* 1988; 8(4): 207-12. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Ciftçi E, Güriz H, Derya Aysev A, Ince E, Erdem B, Doğru U. Salmonella bacteraemia in Turkish children: 37 cases seen in a university hospital between 1993 and 2002. *Ann Trop Paediatr.* 2004; 24(1): 75-80. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Collins RN, Marine WM, Nahmias AJ. The 1964 epidemic of typhoid fever in Atlanta. Clinical and epidemiologic observations. *JAMA.* 1966; 197(3): 179-84. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.

Appendix Table A.3b - Citations for non-dismod model input data

- Colon AR. Gastrointestinal phenomena in childhood typhoid fever. *South Med J.* 1976; 69(7): 914. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Daoud AS, Zaki M, Pugh RN, al-Mutairi G, Beseiso R, Nasrallah AY. Clinical presentation of enteric fever: its changing pattern in Kuwait. *J Trop Med Hyg.* 1991; 94(5): 341-7. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Dheer G, Kundra S, Singh T. Clinical and laboratory profile of enteric fever in children in northern India. *Trop Doct.* 2012; 42(3): 154-6. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Duggan MB, Beyer L. Enteric fever in young Yoruba children. *Arch Dis Child.* 1975; 50(1): 67-71. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Dutta P, Lahiri M, Bhattacharya SK, Saha MR, Mitra U, Rasaily R, Pal SC. Hepatitis-like presentation in typhoid fever. *Trans R Soc Trop Med Hyg.* 1992; 86(1): 92. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Ellis ME, Moosa A, Hillier V. A review of typhoid fever in South African black children. *Postgrad Med J.* 1990; 66(782): 1032-6. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Emary K, Moore CE, Chanpheaktra N, An KP, Chheng K, Sona S, Duy PT, Nga TVT, Wuthiekanun V, Amornchai P, Kumar V, Wijedoru L, Stoesser NE, Carter MJ, Baker S, Day NPJ, Parry CM. Enteric fever in Cambodian children is dominated by multidrug-resistant H58 *Salmonella enterica* serovar Typhi with intermediate susceptibility to ciprofloxacin. *Trans R Soc Trop Med Hyg.* 2012; 106(12): 718-24. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Galloway H, Clark NS, Blackhall M. Paediatric aspects of the Aberdeen typhoid outbreak. *Arch Dis Child.* 1966; 41(215): 63-8. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Girgis NI, Tribble DR, Sultan Y, Farid Z. Short course chemotherapy with cefixime in children with multidrug-resistant *Salmonella typhi* Septicaemia. *J Trop Pediatr.* 1995; 41(6): 364-5. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Gulati S, Marwaha RK, Singhi S, Ayyagari A, Kumar L. Third generation cephalosporins in multi-drug resistant typhoid fever. *Indian Pediatr.* 1992; 29(4): 513-6. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Hardy G, Padfield CJ, Chadwick P, Partington MW. Typhoid outbreak in Kingston, Ont: experience with high-dose oral ampicillin. *Can Med Assoc J.* 1977; 116(7): 761-7. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Hassan M. Multiply-resistant *Salmonella typhi* in children. *Drugs.* 1995; 457-9. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Hoa NT, Diep TS, Wain J, Parry CM, Hien TT, Smith MD, Walsh AL, White NJ. Community-acquired septicaemia in southern Viet Nam: the importance of multidrug-resistant *Salmonella typhi*. *Trans R Soc Trop Med Hyg.* 1998; 92(5): 503-8. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Ispahani P, Slack RC. Enteric fever and other extraintestinal salmonellosis in University Hospital, Nottingham, UK, between 1980 and 1997. *Eur J Clin Microbiol Infect Dis.* 2000; 19(9): 679-87. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Jagadish K, Patwari AK, Sarin SK, Prakash C, Srivastava DK, Anand VK. Hepatic manifestations in typhoid fever. *Indian Pediatr.* 1994; 31(7): 807-11. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Jain S, Chitnis DS, Sham A, Rathi S, Inamdar S, Rindani GJ. Outbreak of chloramphenicol resistant typhoid fever. *Indian Pediatr.* 1987; 24(3): 193-7. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Johnson AO, Aderere WI. Enteric fever in childhood. *J Trop Med Hyg.* 1981; 84(1): 29-35. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Kabra SK, Madhulika, Talati A, Soni N, Patel S, Modi RR. Multidrug-resistant typhoid fever. *Trop Doct.* 2000; 30(4): 195-7. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Kagwa-Nyanzi JA. Typhoid fever in African children. *J Trop Pediatr Environ Child Health.* 1971; 17(3): 105-9. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.

Appendix Table A.3b - Citations for non-dismod model input data

- Kapoor JP, Mohan M, Talwar V, Daral TS, Bhargava SK. Typhoid fever in young children. *Indian Pediatr.* 1985; 22(11): 811-3. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Khan M, Coovadia YM, Connolly C, Sturm AW. Influence of sex on clinical features, laboratory findings, and complications of typhoid fever. *Am J Trop Med Hyg.* 1999; 61(1): 41-6. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Khuri-Bulos N. Enteric fevers in children. The importance of age in the varying clinical picture. *Clin Pediatr (Phila).* 1981; 20(7): 448-52. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Koul PB, Murali MV, Sharma PP, Ghai OP, Ramchandran VG, Talwar V. Multi drug resistant *Salmonella typhi* infection: clinical profile and therapy. *Indian Pediatr.* 1991; 28(4): 357-61. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Kulkarni ML, Rego SJ. Acute acalculous cholecystitis in typhoid fever. *Indian Pediatr.* 1995; 32(7): 829-30. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Laditan AA, Alausa KO. Problems in the clinical diagnosis of typhoid fever in children in the tropics. *Ann Trop Paediatr.* 1981; 1(3): 191-5. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Lepage P, Bogaerts J, Van Goethem C, Ntchorutaba M, Nsengumuremyi F, Hitimana DG, Vandepitte J, Butzler JP, Levy J. Community-acquired bacteraemia in African children. *Lancet.* 1987; 1(8548): 1458-61. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Leung DT, Bogetz J, Itoh M, Ganapathi L, Pietroni MAC, Ryan ET, Chisti MJ. Factors associated with encephalopathy in patients with *Salmonella enterica* serotype Typhi bacteremia presenting to a diarrheal hospital in Dhaka, Bangladesh. *Am J Trop Med Hyg.* 2012; 86(4): 698-702. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Libov A. Enteric fever in children. *Indian J Pediatr.* 1960; 125-8. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Malik AS, Malik RH. Typhoid fever in Malaysian children. *Med J Malaysia.* 2001; 56(4): 478-90. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Malik AS. Complications of bacteriologically confirmed typhoid fever in children. *J Trop Pediatr.* 2002; 48(2): 102-8. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Mallouh AA, Sa'di AR. White blood cells and bone marrow in typhoid fever. *Pediatr Infect Dis J.* 1987; 6(6): 527-9. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Memon IA, Billoo AG, Memon HI. Cefixime: an oral option for the treatment of multidrug-resistant enteric fever in children. *South Med J.* 1997; 90(12): 1204-7. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Mishra S, Patwari AK, Anand VK, Pillai PK, Aneja S, Chandra J, Sharma D. A clinical profile of multidrug resistant typhoid fever. *Indian Pediatr.* 1991; 28(10): 1171-4. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Misra S, Diaz PS, Rowley AH. Characteristics of typhoid fever in children and adolescents in a major metropolitan area in the United States. *Clin Infect Dis.* 1997; 24(5): 998-1000. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Mtove G, Amos B, von Seidlein L, Hendriksen I, Mwambuli A, Kimera J, Mallahiyo R, Kim DR, Ochiai RL, Clemens JD, Reyburn H, Magesa S, Deen JL. Invasive salmonellosis among children admitted to a rural Tanzanian hospital and a comparison with previous studies. *PLoS One.* 2010; 5(2): e9244. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Nesbitt A, Mirza NB. *Salmonella* septicaemias in Kenyan children. *J Trop Pediatr.* 1989; 35(1): 35-9. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Oh HM, Masayu Z, Chew SK. Typhoid fever in hospitalized children in Singapore. *J Infect.* 1997; 34(3): 237-42. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Papaevangelou V, Syriopoulou V, Charissiadou A, Pangalis A, Mostrou G, Theodoridou M. *Salmonella* bacteraemia in a tertiary children's hospital. *Scand J Infect Dis.* 2004; 36(8): 547-51. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.

Appendix Table A.3b - Citations for non-dismod model input data

- Rajjee S, Anandi TB, Subha S, Vatsala BR. Patterns of resistant *Salmonella typhi* infection in infants. *J Trop Pediatr*. 1995; 41(1): 52-4. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Raman TS, Krishnamurthy L, Menon PK, Singh D, Jayaprakash DG. Clinical profile and therapy in enteric fever. *Indian Pediatr*. 1994; 31(2): 196-9. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Ramanan A, Pandit N, Yeshwanth M. Unusual complications in a multidrug resistant *Salmonella typhi* outbreak. *Indian Pediatr*. 1992; 29(1): 118-20. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Rasaily R, Dutta P, Saha MR, Mitra U, Lahiri M, Pal SC. Multi-drug resistant typhoid fever in hospitalised children. Clinical, bacteriological and epidemiological profiles. *Eur J Epidemiol*. 1994; 10(1): 41-6. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Rathore MH, Bux D, Hasan M. Multidrug-resistant *Salmonella typhi* in Pakistani children: clinical features and treatment. *South Med J*. 1996; 89(2): 235-7. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Scragg JN, Rubidge CJ. Trimethoprim and sulphamethoxazole in typhoid fever in children. *Br Med J*. 1971; 3(5777): 738-41. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Seçmeer G, Kanra G, Cemeroglu AP, Ozen H, Ceyhan M, Ecevit Z. *Salmonella typhi* infections. A 10-year retrospective study. *Turk J Pediatr*. 1995; 37(4): 339-41. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Sethuraman S, Mahamood M, Kareem S. Furazolidone in multi-resistant childhood typhoid fever. *Ann Trop Paediatr*. 1994; 14(4): 321-4. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Sharma A, Gathwala G. Clinical profile and outcome in enteric fever. *Indian Pediatr*. 1993; 30(1): 47-50. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Shetty AK, Mital SR, Bahrainwala AH, Khubchandani RP, Kumta NB. Typhoid hepatitis in children. *J Trop Pediatr*. 1999; 45(5): 287-90. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Smith M. Typhoid admissions in childhood. *Trop Doct*. 1986; 16(4): 150-2. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Su C-P, Chen Y-C, Chang S-C. Changing characteristics of typhoid fever in Taiwan. *J Microbiol Immunol Infect*. 2004; 37(2): 109-14. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Takkar VP, Kumar R, Takkar R, Khurana S. Resurgence of chloramphenicol sensitive *Salmonella typhi*. *Indian Pediatr*. 1995; 32(5): 586-7. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Tatli MM, Aktas G, Kosecik M, Yilmaz A. Treatment of typhoid fever in children with a flexible-duration of ceftriaxone, compared with 14-day treatment with chloramphenicol. *Int J Antimicrob Agents*. 2003; 21(4): 350-3. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Thambidorai CR, Shyamala J, Sarala R, Vatsala RB, Tamizhisai S. Acute acalculous cholecystitis associated with enteric fever in children. *Pediatr Infect Dis J*. 1995; 14(9): 812-3. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Thisyakorn U, Mansuwan P, Taylor DN. Typhoid and paratyphoid fever in 192 hospitalized children in Thailand. *Am J Dis Child*. 1987; 141(8): 862-5. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Thisyakorn U, Mansuwan P. Comparative efficacy of mecillinam, mecillinam/amoxicillin and trimethoprim-sulfamethoxazole for treatment of typhoid fever in children. *Pediatr Infect Dis J*. 1992; 11(11): 979-80. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Topley JM. Mild typhoid fever. *Arch Dis Child*. 1986; 61(2): 164-7. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Verma PS, Mullick P, Ghosh S. Neurological manifestations of enteric fever: clinical profile and correlation with ultimate outcome. *Indian Pediatr*. 1972; 9(11): 681-5. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.

Appendix Table A.3b - Citations for non-dismod model input data

- Walia M, Gaid R, Mehta R, Paul P, Aggarwal P, Kalaivani M. Current perspectives of enteric fever: a hospital-based study from India. *Ann Trop Paediatr*. 2005; 25(3): 161-74. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Walia M, Gaid R, Paul P, Mehta R, Aggarwal P, Kalaivani M. Age-related clinical and microbiological characteristics of enteric fever in India. *Trans R Soc Trop Med Hyg*. 2006; 100(10): 942-8. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Wang J-L, Kao J-H, Tseng S-P, Teng L-J, Ho S-W, Hsueh P-R. Typhoid fever and typhoid hepatitis in Taiwan. *Epidemiol Infect*. 2005; 133(6): 1073-9. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Wongsawat J, Pancharoen C, Thisyakorn U. Typhoid fever in children: experience in King Chulalongkorn Memorial Hospital. *J Med Assoc Thai*. 2002; 85(12): 1247-50. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Yap YF, Puthuchery SD. Typhoid fever in children--a retrospective study of 54 cases from Malaysia. *Singapore Med J*. 1998; 39(6): 260-2. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Tolaymat A, Fakhreddine F, David CB, Whitworth JM. Typhoid fever in children: a forgotten disease? *South Med J*. 1979; 72(2): 136-8. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Del Rosario AJ, Haynes RE, Cramblett HG. Typhoid fever in children. *Ohio State Med J*. 1971; 67(6): 516-20. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Colon AR, Gross DR, Tamer MA. Typhoid fever in children. *Pediatrics*. 1975; 56(4): 606-9. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Soelistyowati S, Soenarto Y, Soesilo H, Widiarto, Widiatmodjo, Ismangoen. Typhoid fever in children. *Paediatr Indones*. 1982; 22(7-8): 138-46. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Mulligan TO. Typhoid fever in young children. *Br Med J*. 1971; 4(5788): 665-7. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Kumar R, Gupta N, Shalini. Multidrug-resistant typhoid fever. *Indian J Pediatr*. 2007; 74(1): 39-42. as it appears in Azmatullah A, Qamar FN, Zaidi AKM, Thaver D, Bhutta Z. A systematic review of the global epidemiology, clinical and laboratory profile of Typhoid Fever. August 18, 2014. 32 leaves.
- Monath TP, Nasidi A. Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria. *Am J Trop Med Hyg*. 1993; 48(2): 274-99. as it appears in Johansson MA, Vasconcelos PFC, Staples JE. The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases. *Trans R Soc Trop Med Hyg*. 2014; 108(8): 482-7.
- Monath TP, Wilson DC, Lee VH, Stroh G, Kuteyi K, Smith EA. The 1970 yellow fever epidemic in Okwoga District, Benue Plateau State, Nigeria. I. Epidemiological observations. *Bull World Health Organ*. 1973; 49(2): 113-21. as it appears in Johansson MA, Vasconcelos PFC, Staples JE. The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases. *Trans R Soc Trop Med Hyg*. 2014; 108(8): 482-7.
- Stam WE, Holmes KK. Chlamydia trachomatis infections in the adult. In: Holmes KK, Mardh PA, Sparling PE, et al., editors. *Sexually transmitted diseases*. New York: McGraw-Hill; 1980.181-193.
- Wall LL, Karshima JA, Kirschner C, Arrowsmith SD. The obstetric vesicovaginal fistula: Characteristics of 899 patients from Jos, Nigeria. *Am J Obstet Gynecol*. 2004; 190(4): 1011-9.
- Das RK, Sengupta SK. Vesico-vaginal fistula of obstetric origin. *J Obstet Gynaecol India*. 1969; 19: 383-9.
- Mahfouz N. Urinary and faecal fistulae. *J Obstet Gynaecol Br Emp*. 1938; 45: 405-24.
- Brussé I, Duvekot J, Jongerling J, Steegers E, De Koning I. Impaired maternal cognitive functioning after pregnancies complicated by severe pre-eclampsia: a pilot case-control study. *Acta Obstet Gynecol Scand*. 2008; 87(4): 408-12.
- Okanloma KA, Moodley J. Neurological complications associated with the preeclampsia/eclampsia syndrome. *Int J Gynaecol Obstet*. 2000; 71(3): 223-5.
- Roes EM, Raijmakers MT, Schoonenberg M, Wanner N, Peters WH, Steegers EA. Physical wellbeing in women with a history of severe preeclampsia. *J Matern Fetal Neonatal Med*. 2005; 18(1): 39-45.
- Shah AK, Rajamani K, Whitty JE. Eclampsia: a neurological perspective. *J Neurol Sci*. 2008; 271(1-2): 158-67.
- Sloan N, Durocher J, Aldrich T, Blum J, Winikoff B. What measured blood loss tells us about postpartum bleeding: a systematic review. *BJOG*. 2010; 117(7): 788-800.
- Tebeu PM, Fomulu JN, Khaddaj S, de Bernis L, Delvaux T, Rochat CH. Risk factors for obstetric fistula: a clinical review. *Int Urogynecol J*. 2012; 23(4): 387-94.
- Westrom LV. Chlamydia and its effect on reproduction. *J Br Fer Soc*. 1996; 1(1): 23-30.

Appendix Table A.3b - Citations for non-dismod model input data

- Gryseels B. The epidemiology of schistosomiasis in Burundi and its consequences for control. *Trans R Soc Trop Med Hyg.* 1991; 85(5): 626-33. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Garba A, Kinde-Gazard D, Makoutodé M, Boyer N, Ernoult JC, Chippaux JP, Massougboji A. [Preliminary evaluation of morbidity due to *S. haematobium* and *S. mansoni* in the area of the future Adjarala Dam in Benin]. *Sante.* 2000; 10(5): 323-8. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Adom H, Guerin B, Commenges D, Le Bras M. L'hématurie comme indicateur des bilharzioses urinaires en campagne de masse: A propos d'une enquête au Burkina-Faso. *Med Afr Noire.* 1992; 39(8-9): 550-6. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Garba A, Campagne G, Poda JN, Parent G, Kambire R, Chippaux JP. [Schistosomiasis in the region of Ziga (Burkina Faso) before the construction of a dam]. *Bull Soc Pathol Exot.* 1999; 92(3): 195-7. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Barreto ML, Loureiro S, Melo AS, Anjos CF. The effect of *Schistosoma mansoni* infection on child morbidity in the State of Bahia, Brazil. II--Analysis at the individual level. *Rev Inst Med Trop Sao Paulo.* 1985; 27(4): 167-71. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Gerspacher-Lara R, Pinto-Silva RA, Serufo JC, Rayes AA, Drummond SC, Lambertucci JR. Splenic palpation for the evaluation of morbidity due to schistosomiasis mansoni. *Mem Inst Oswaldo Cruz.* 1998; 245-8. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Kloetzel K, Schuster NH. Repeated mass treatment of schistosomiasis mansoni: experience in hyperendemic areas of Brazil. I. Parasitological effects and morbidity. *Trans R Soc Trop Med Hyg.* 1987; 81(3): 365-70. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Martins MJ, Pinto-Silva RA, Serufo JC, Rayes AA, Damasceno MP, Martins ML, Santos AP, Drummond SC, Bezerra MA, Lambertucci JR. Morbidity of schistosomiasis in an endemic area of the northeast of the state of Minas Gerais in Brazil: a clinical and sonographic study. *Mem Inst Oswaldo Cruz.* 1998; 243-4. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- N'Goran KE, Yapi Yapi Y, Rey JL, Soro B, Coulibaly A, Bellec C. [Screening for urinary schistosoma by strips reactive to hematuria. Evaluation in zones of intermediate and weak endemicity in the Ivory Coast]. *Bull Soc Pathol Exot Filiales.* 1989; 82(2): 236-42. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Utzinger J, N'Goran EK, Ossey YA, Booth M, Traoré M, Lohourignon KL, Allangba A, Ahiba LA, Tanner M, Lengeler C. Rapid screening for *Schistosoma mansoni* in western Côte d'Ivoire using a simple school questionnaire. *Bull World Health Organ.* 2000; 78(3): 389-98. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Lengeler C, Makwala J, Ngimbi D, Utzinger J. Simple school questionnaires can map both *Schistosoma mansoni* and *Schistosoma haematobium* in the Democratic Republic of Congo. *Acta Trop.* 2000; 74(1): 77-87. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- De Clercq D, Henry MC, Kiyombo M, Hubert P. [Assessment of a focus of schistosomiasis caused by *Schistosoma mansoni* in Mayombe, Republic of Zaire]. *Ann Soc Belg Med Trop.* 1985; 65(2): 153-62. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Gryseels B, Polderman AM. The morbidity of schistosomiasis mansoni in Maniema (Zaire). *Trans R Soc Trop Med Hyg.* 1987; 81(2): 202-9. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Tshikuka JG, Scott ME, Gray-Donald K, Kalumba ON. Multiple infection with *Plasmodium* and helminths in communities of low and relatively high socio-economic status. *Ann Trop Med Parasitol.* 1996; 90(3): 277-93. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Abdel-Wahab MF, Esmat G, Ramzy I, Fouad R, Abdel-Rahman M, Yosery A, Narooz S, Strickland GT. *Schistosoma haematobium* infection in Egyptian schoolchildren: Demonstration of both hepatic and urinary tract morbidity by ultrasonography. *Trans R Soc Trop Med Hyg.* 1992; 86(4): 406-9. as it appears in van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. *Acta Trop.* 2003; 86(2-3): 125-39.

Appendix Table A.3b - Citations for non-dismod model input data

- Abdel-Wahab MF, Esmat G, Ramzy I, Fouad R, Abdel-Rahman M, Yosery A, Narooz S, Strickland GT. Schistosoma haematobium infection in Egyptian schoolchildren: Demonstration of both hepatic and urinary tract morbidity by ultrasonography. *Trans R Soc Trop Med Hyg.* 1992; 86(4): 406-9. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Abdel-Wahab MF, Esmat G, Medhat E, Narooz S, Ramzy I, El-Boraey Y, Strickland GT. The epidemiology of schistosomiasis in Egypt: Menofia Governorate. *Am J Trop Med Hyg.* 2000; 62(2 Suppl): 28-34. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of Schistosoma mansoni infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- el-Sayed HF, Rizkalla NH, Mehanna S, Abaza SM, Winch PJ. Prevalence and epidemiology of Schistosoma mansoni and S. haematobium infection in two areas of Egypt recently reclaimed from the desert. *Am J Trop Med Hyg.* 1995; 52(2): 194-8. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- el-Sayed HF, Rizkalla NH, Mehanna S, Abaza SM, Winch PJ. Prevalence and epidemiology of Schistosoma mansoni and S. haematobium infection in two areas of Egypt recently reclaimed from the desert. *Am J Trop Med Hyg.* 1995; 52(2): 194-8. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of Schistosoma mansoni infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- El-Hawey AM, Amr MM, Abdel-Rahman AH, El-Ibiary SA, Agina AM, Abdel-Hafez MA, Waheeb AA, Hussein MH, Strickland GT. The epidemiology of schistosomiasis in Egypt: Gharbia Governorate. *Am J Trop Med Hyg.* 2000; 62(2 Suppl): 42-8. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Gabr NS, Hammad TA, Oriebay A, Shawky E, Khattab MA, Strickland GT. The epidemiology of schistosomiasis in Egypt: Minya Governorate. *Am J Trop Med Hyg.* 2000; 62(2 Suppl): 65-72. as it appears in van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. *Acta Trop.* 2003; 86(2-3): 125-39.
- Gabr NS, Hammad TA, Oriebay A, Shawky E, Khattab MA, Strickland GT. The epidemiology of schistosomiasis in Egypt: Minya Governorate. *Am J Trop Med Hyg.* 2000; 62(2 Suppl): 65-72. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Gabr NS, Hammad TA, Oriebay A, Shawky E, Khattab MA, Strickland GT. The epidemiology of schistosomiasis in Egypt: Minya Governorate. *Am J Trop Med Hyg.* 2000; 62(2 Suppl): 65-72. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of Schistosoma mansoni infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Hammam HM, Allam FA, Mofteh FM, Abdel-Aty MA, Hany AH, Abd-El-Motagaly KF, Nafeh MA, Khalifa R, Mikhail NN, Talaat M, Hussein MH, Strickland GT. The epidemiology of schistosomiasis in Egypt: Assiut governorate. *Am J Trop Med Hyg.* 2000; 62(2 Suppl): 73-9. as it appears in van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. *Acta Trop.* 2003; 86(2-3): 125-39.
- Hammam HM, Allam FA, Mofteh FM, Abdel-Aty MA, Hany AH, Abd-El-Motagaly KF, Nafeh MA, Khalifa R, Mikhail NN, Talaat M, Hussein MH, Strickland GT. The epidemiology of schistosomiasis in Egypt: Assiut governorate. *Am J Trop Med Hyg.* 2000; 62(2 Suppl): 73-9. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Hammam HM, Allam FA, Mofteh FM, Abdel-Aty MA, Hany AH, Abd-El-Motagaly KF, Nafeh MA, Khalifa R, Mikhail NN, Talaat M, Hussein MH, Strickland GT. The epidemiology of schistosomiasis in Egypt: Assiut governorate. *Am J Trop Med Hyg.* 2000; 62(2 Suppl): 73-9. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of Schistosoma mansoni infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Hammam HM, Zarzour AH, Mofteh FM, Abdel-Aty MA, Hany AH, El-Kady AY, Nasr AM, Abd-El-Samie A, Qayed MH, Mikhail NN, Talaat M, Hussein MH. The epidemiology of schistosomiasis in Egypt: Qena governorate. *Am J Trop Med Hyg.* 2000; 62(2 Suppl): 80-7. as it appears in van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. *Acta Trop.* 2003; 86(2-3): 125-39.
- Hammam HM, Zarzour AH, Mofteh FM, Abdel-Aty MA, Hany AH, El-Kady AY, Nasr AM, Abd-El-Samie A, Qayed MH, Mikhail NN, Talaat M, Hussein MH. The epidemiology of schistosomiasis in Egypt: Qena governorate. *Am J Trop Med Hyg.* 2000; 62(2 Suppl): 80-7. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Hammam HM, Zarzour AH, Mofteh FM, Abdel-Aty MA, Hany AH, El-Kady AY, Nasr AM, Abd-El-Samie A, Qayed MH, Mikhail NN, Talaat M, Hussein MH. The epidemiology of schistosomiasis in Egypt: Qena governorate. *Am J Trop Med Hyg.* 2000; 62(2 Suppl): 80-7. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of Schistosoma mansoni infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Medhat A, Zarzour A, Nafeh M, Shata T, Sweifie Y, Attia M, Helmy A, Shehata M, Zaki S, Mikhail N, Ibrahim S, King C, Strickland GT. Evaluation of an ultrasonographic score for urinary bladder morbidity in Schistosoma haematobium infection. *Am J Trop Med Hyg.* 1997; 57(1): 16-9. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.

Appendix Table A.3b - Citations for non-dismod model input data

- Nooman ZM, Hasan AH, Waheeb Y, Mishriky AM, Ragheb M, Abu-Saif AN, Abaza SM, Serwah AA, El-Gohary A, Saad A, El-Sayed M, Fouad M. The epidemiology of schistosomiasis in Egypt: Ismailia governorate. *Am J Trop Med Hyg.* 2000; 62(2 Suppl): 35-41. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Strickland GT, Merritt W, El-Sahly A, Abdel-Wahab F. Clinical characteristics and response to therapy in Egyptian children heavily infected with *Schistosoma mansoni*. *J Infect Dis.* 1982; 146(1): 20-9. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Hiatt RA, Gebre-Medhin M. Morbidity from *Schistosoma mansoni* infections: an epidemiologic study based on quantitative analysis of egg excretion in Ethiopian children. *Am J Trop Med Hyg.* 1977; 26(3): 473-81. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Jemaneh L, Tedla S, Birrie H. The use of reagent strips for detection of urinary schistosomiasis infection in the middle Awash Valley, Ethiopia. *East Afr Med J.* 1994; 71(10): 679-83. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Wilkins HA, Goll P, Marshall TF, Moore P. The significance of proteinuria and haematuria in *Schistosoma haematobium* infection. *Trans R Soc Trop Med Hyg.* 1979; 73(1): 74-80. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Hall A, Fentiman A. Blood in the urine of adolescent girls in an area of Ghana with a low prevalence of infection with *Schistosoma haematobium*. *Trans R Soc Trop Med Hyg.* 1999; 93(4): 411-2. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Mott KE, Dixon H, Osei-Tutu E, England EC. Relation between intensity of *Schistosoma haematobium* infection and clinical haematuria and proteinuria. *Lancet.* 1983; 1(8332): 1005-8. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Johansen MV, Simonsen PE, Butterworth AE, Ouma JH, Mbugua GG, Sturrock RF, Orinda DA, Christensen NO. A survey of *Schistosoma mansoni* induced kidney disease in children in an endemic area of Machakos District, Kenya. *Acta Trop.* 1994; 58(1): 21-8. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Kiliku FM, Kimura E, Muhoho N, Migwi DK, Katsumata T. The usefulness of urinalysis reagent strips in selecting *Schistosoma haematobium* egg positives before and after treatment with praziquantel. *J Trop Med Hyg.* 1991; 94(6): 401-6. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- King CH, Keating CE, Muruka JF, Ouma JH, Houser H, Siongok TK, Mahmoud AA. Urinary tract morbidity in schistosomiasis haematobia: associations with age and intensity of infection in an endemic area of Coast Province, Kenya. *Am J Trop Med Hyg.* 1988; 39(4): 361-8. as it appears in van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. *Acta Trop.* 2003; 86(2-3): 125-39.
- King CH, Keating CE, Muruka JF, Ouma JH, Houser H, Siongok TK, Mahmoud AA. Urinary tract morbidity in schistosomiasis haematobia: associations with age and intensity of infection in an endemic area of Coast Province, Kenya. *Am J Trop Med Hyg.* 1988; 39(4): 361-8. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- King CH, Lombardi G, Lombardi C, Greenblatt R, Hodder S, Kinyanjui H, Ouma J, Odiambo O, Bryan PJ, Muruka J. Chemotherapy-based control of schistosomiasis haematobia. I. Metrifonate versus praziquantel in control of intensity and prevalence of infection. *Am J Trop Med Hyg.* 1988; 39(3): 295-305. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Sato K, Shimada M, Noda S, Muhoho ND, Katsumata T, Sato A, Aoki Y. Efficacy of metrifonate in a highly endemic area of urinary schistosomiasis in Kenya. *Am J Trop Med Hyg.* 1988; 38(1): 81-5. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Stephenson LS, Latham MC, Kinoti SN, Oduori ML. Sensitivity and specificity of reagent strips in screening of Kenyan children for *Schistosoma haematobium* infection. *Am J Trop Med Hyg.* 1984; 33(5): 862-71. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Subramanian AK, Mungai P, Ouma JH, Magak P, King CH, Mahmoud AA, King CL. Long-term suppression of adult bladder morbidity and severe hydronephrosis following selective population chemotherapy for *Schistosoma haematobium*. *Am J Trop Med Hyg.* 1999; 61(3): 476-81. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.

Appendix Table A.3b - Citations for non-dismod model input data

- Wamae CN, Lammie PJ. Haematuria in coastal Kenya is associated with *Schistosoma haematobium* but not *Wuchereria bancrofti* infection. *Trans R Soc Trop Med Hyg.* 1998; 92(1): 63-4. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Boisier P, Ramarokoto CE, Ravaoalimalala VE, Rabarijaona L, Serieye J, Roux J, Esterre P. Reversibility of *Schistosoma mansoni*-associated morbidity after yearly mass praziquantel therapy: ultrasonographic assessment. *Trans R Soc Trop Med Hyg.* 1998; 92(4): 451-3. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Boisier P, Serieye J, Ravaoalimalala VE, Roux J, Esterre P. Ultrasonographical assessment of morbidity in schistosomiasis mansoni in Madagascar: a community-based study in a rural population. *Trans R Soc Trop Med Hyg.* 1995; 89(2): 208-12. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Rasendramino MH, Rajaona HR, Ramarokoto CE, Ravaoalimalala VE, Leutscher P, Cordonnier D, Esterre P. [Prevalence of uro-nephrologic complications of urinary bilharziasis in hyperendemic focus in Madagascar]. *Nephrologie.* 1998; 19(6): 341-5. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Serieye J, Boisier P, Ravaoalimalala VE, Ramarokoto CE, Leutscher P, Esterre P, Roux J. *Schistosoma haematobium* infection in western Madagascar: morbidity determined by ultrasonography. *Trans R Soc Trop Med Hyg.* 1996; 90(4): 398-401. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Dabo A, Traoré HA, Diakité M, Kouriba B, Camara F, Coulibaly CO, Sacko M, Doumbo O. [Echographic morbidity due to *Schistosoma haematobium* in a peripheral district of Bamako in Mali, Missabougou]. *Bull Soc Pathol Exot.* 1995; 88(1): 11-4. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Traquinho GA, Quintó L, Nalá RM, Gama Vaz R, Corachan M. Schistosomiasis in northern Mozambique. *Trans R Soc Trop Med Hyg.* 1998; 92(3): 279-81. as it appears in van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. *Acta Trop.* 2003; 86(2-3): 125-39.
- Traquinho GA, Quintó L, Nalá RM, Gama Vaz R, Corachan M. Schistosomiasis in northern Mozambique. *Trans R Soc Trop Med Hyg.* 1998; 92(3): 279-81. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Campagne G, Garba A, Barkiré H, Vera C, Sidiki A, Chippaux JP. [Continued ultrasonic follow-up of children infected with *Schistosoma haematobium* after treatment with praziquantel]. *Trop Med Int Health.* 2001; 6(1): 24-30. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Chippaux JP, Campagne G, Garba A, Véra C. [Significance of rapid evaluation indicators during the monitoring of graduated treatment against *Schistosoma haematobium*]. *Bull Soc Pathol Exot.* 2001; 94(1): 36-41. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Heurtier Y, Lamothe F, Develoux M, Docquier J, Mouchet F, Sellin E, Sellin B. Urinary tract lesions due to *Schistosoma haematobium* infection assessed by ultrasonography in a community based study in Niger. *Am J Trop Med Hyg.* 1986; 35(6): 1163-72. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Sellin B, Simonkovich E, Ovazza L, Sellin E, Desfontaine M, Rey JL. Valeur de l'examen macroscopique des urines et des bandelettes réactives pour la détection de l'hématurie et de la protéinurie dans le diagnostic de masse de la schistosomiase urinaire, avant et après traitement. *Med Trop (Mars).* 1982; 42(5): 521-6. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Anosike JC, Nwoke BE, Njoku AJ. The validity of haematuria in the community diagnosis of urinary schistosomiasis infections. *J Helminthol.* 2001; 75(3): 223-5. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Garba A, Tohon Z, Sidiki A, Chippaux JP, de Chabaliel F. [Efficacy of praziquantel in school-aged children in a hyperendemic zone for *Schistosoma haematobium* (Niger, 1999)]. *Bull Soc Pathol Exot.* 2001; 94(1): 42-5. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Lamothe F, Develoux M, Devidas A, Mouchet F, Sellin B. [Echographic study of the morbidity due to urinary bilharziasis in a hyperendemic village in Niger]. *Bull Soc Pathol Exot Filiales.* 1989; 82(5): 678-84. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.

Appendix Table A.3b - Citations for non-dismod model input data

- Mafe MA. The diagnostic potential of three indirect tests for urinary schistosomiasis in Nigeria. *Acta Trop.* 1997; 68(3): 277-84. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Nduka FO, Ajaero CM, Nwoke BE. Urinary schistosomiasis among school children in an endemic community in south-eastern Nigeria. *Appl Parasitol.* 1995; 36(1): 34-40. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Ofoezie IE, Asaulu SO, Christensen NO, Madsen H. Patterns of infection with *Schistosoma haematobium* in lakeside resettlement communities at the Oyan Reservoir in Ogun State, south-western Nigeria. *Ann Trop Med Parasitol.* 1997; 91(2): 187-97. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Ozumba NA, Christensen NO, Nwosu AB, Nwaorgu OC. Endemicity, focality and seasonality of transmission of human schistosomiasis in Amagunze Village, eastern Nigeria. *J Helminthol.* 1989; 63(3): 206-12. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Gremillion DH, Geckler RW, Kuntz RE, Marraro RV. Schistosomiasis in Saudi Arabian recruits. A morbidity study based on quantitative egg excretion. *Am J Trop Med Hyg.* 1978; 27(5): 924-7. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Eltoum IA, Sulaiman S, Ismail BM, Ali MM, Elfatih M, Homeida MM. Evaluation of haematuria as an indirect screening test for schistosomiasis haematobium: a population-based study in the White Nile province, Sudan. *Acta Trop.* 1992; 51(2): 151-7. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Homeida MM, Eltoum IA, Ali MM, Suliaman SM, Elobied EA, Mansour M, Saad AM, Bennett JL. The effectiveness of annual versus biennial mass chemotherapy in reducing morbidity due to schistosomiasis: a prospective study in Gezira-Managil, Sudan. *Am J Trop Med Hyg.* 1996; 54(2): 140-5. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Delegue P, Picquet M, Shaw DJ, Vercurysse J, Sambou B, Ly A. Morbidity induced by *Schistosoma haematobium* infections, as assessed by ultrasound before and after treatment with praziquantel, in a recently expanded focus (Senegal River basin). *Ann Trop Med Parasitol.* 1998; 92(7): 775-83. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Gaye O, Diallo S, Ndir O, Diaw T, Diouf M, Ndiaye AA, Faye O. Bilharziose intestinale dans la commune de Richard-Toll: aspects épidémiologiques et retentissements cliniques. *Med Afr Noire.* 1991; 38(11): 732-4. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Stelma FF, Talla I, Verle P, Niang M, Gryseels B. Morbidity due to heavy *Schistosoma mansoni* infections in a recently established focus in northern Senegal. *Am J Trop Med Hyg.* 1994; 50(5): 575-9. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Gigase PL, Mangelschots E, Bockaert R, Autier P, Kestens L. [Simple indicators of prevalence and intensity of urinary bilharziasis in Chad]. *Ann Soc Belg Med Trop.* 1988; 68(2): 123-32. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Guyatt H, Brooker S, Lwambo NJ, Siza JE, Bundy DA. The performance of school-based questionnaires of reported blood in urine in diagnosing *Schistosoma haematobium* infection: patterns by age and sex. *Trop Med Int Health.* 1999; 4(11): 751-7. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Hatz CF, Vennervald BJ, Nkulila T, Vounatsou P, Kombe Y, Mayombana C, Mshinda H, Tanner M. Evolution of *Schistosoma haematobium*-related pathology over 24 months after treatment with praziquantel among school children in southeastern Tanzania. *Am J Trop Med Hyg.* 1998; 59(5): 775-81. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Kardorff R, Gabone RM, Mugashe C, Obiga D, Ramarokoto CE, Mahler C, Spannbrucker N, Lang A, Günzler V, Gryseels B, Ehrlich JH, Doehring E. *Schistosoma mansoni*-related morbidity on Ukerewe Island, Tanzania: clinical, ultrasonographical and biochemical parameters. *Trop Med Int Health.* 1997; 2(3): 230-9. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Kitange HM, Swai AB, McLarty DG, Alberti KG. Schistosomiasis prevalence after administration of praziquantel to school children in Melela village, Morogoro region, Tanzania. *East Afr Med J.* 1993; 70(12): 782-6. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.

Appendix Table A.3b - Citations for non-dismod model input data

- Lwambo NJS, Savioli L, Kisumku UM, Alawi KS, Bundy D a. P. The relationship between prevalence of *Schistosoma haematobium* infection and different morbidity indicators during the course of a control programme on Pemba Island. *Trans R Soc Trop Med Hyg.* 1997; 91(6): 643-6. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Mtasiwa D, Mayombana C, Kilima P, Tanner M. Validation of reagent sticks in diagnosing urinary schistosomiasis in an urban setting. *East Afr Med J.* 1996; 73(3): 198-200. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Ndyomugenyeni R, Minjas JN. Urinary schistosomiasis in schoolchildren in Dar-es-Salaam, Tanzania, and the factors influencing its transmission. *Ann Trop Med Parasitol.* 2001; 95(7): 697-706. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Sarda RK, Minjas JN, Mahikwano LF. Evaluation of indirect screening techniques for the detection of *Schistosoma haematobium* infection in an urban area, Dar es Salaam, Tanzania. *Acta Trop.* 1985; 42(3): 241-7. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Sarda RK, Simonsen PE, Mahikwano LF. Urban transmission of urinary schistosomiasis in Dar es Salaam, Tanzania. *Acta Trop.* 1985; 42(1): 71-8. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Savioli L, Hatz C, Dixon H, Kisumku UM, Mott KE. Control of morbidity due to *Schistosoma haematobium* on Pemba Island: egg excretion and hematuria as indicators of infection. *Am J Trop Med Hyg.* 1990; 43(3): 289-95. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Bulsara MK, Sukwa TY, Wurapa FK. Risks of liver and spleen enlargement in schistosomiasis mansoni infection in a rural Zambian community. *Trans R Soc Trop Med Hyg.* 1985; 79(4): 535-6. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Taylor P, Chandiwana SK, Matanhire D. Evaluation of the reagent strip test for haematuria in the control of *Schistosoma haematobium* infection in schoolchildren. *Acta Trop.* 1990; 47(2): 91-100. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Birrie H, Medhin G, Jemaneh L. Comparison of urine filtration and a chemical reagent strip in the diagnosis of urinary schistosomiasis in Ethiopia. *East Afr Med J.* 1995; 72(3): 180-5. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Emejulu AC, Alabaronye FF, Ezenwaji HM, Okafor FC. Investigation into the prevalence of urinary schistosomiasis in the Agulu Lake area of Anambra State, Nigeria. *J Helminthol.* 1994; 68(2): 119-23. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Bello AB, Edungbola LD. *Schistosoma haematobium*: a neglected common parasitic disease of childhood in Nigeria. Incidence and intensity of infection. *Acta Paediatr.* 1992; 81(8): 601-4. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Lengeler C, de Savigny D, Mshinda H, Mayombana C, Tayari S, Hatz C, Degrémont A, Tanner M. Community-based questionnaires and health statistics as tools for the cost-efficient identification of communities at risk of urinary schistosomiasis. *Int J Epidemiol.* 1991; 20(3): 796-807. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Campagne G, Garba A, Barkire H, Vera C, Boulanger D, Chippaux JP. [Quality control during ultrasonographic evaluation of morbidity due to *Schistosoma haematobium* in Niger]. *Med Trop (Mars).* 2000; 60(1): 35-41. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Eltoum IA, Sulaiman SM, Elturabi H, Mahgoub E, Homeida MM. Infection with *Schistosoma mansoni* in two different endemic areas: a comparative population-based study in Elziedab and Gezira-Managil irrigation schemes, Sudan. *J Trop Med Hyg.* 1993; 96(2): 100-6. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Friis H, Byskov J. *Schistosoma mansoni*: intensity of infection and morbidity among schoolchildren in Matlapaneng, Ngamiland, Botswana. *Trop Geogr Med.* 1987; 39(3): 251-5. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.

Appendix Table A.3b - Citations for non-dismod model input data

- Ofori-Adjei D, Adjepon-Yamoah KK, Ashitey GA, Osei-Tutu E. Screening methods for urinary schistosomiasis in an endemic area (the Kraboa/Coaltar district of Ghana). *Ann Trop Med Parasitol.* 1986; 80(3): 365-6. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Sarda RK. Frequency of haematuria and proteinuria in relation to prevalence and intensity of *Schistosoma haematobium* infection in Dar es Salaam, Tanzania. *East Afr Med J.* 1986; 63(2): 105-8. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- Wiselka MJ, Robinson MB, Clipsham K, Weddon S. The epidemiology of schistosomiasis in central Malawi. *East Afr Med J.* 1988; 65(2): 102-7. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Sarda RK, Minjas JN, Mahikwano LF. Further observations on the use of gross haematuria as an indirect screening technique for the detection of *Schistosoma haematobium* infection in school children in Dar es Salaam, Tanzania. *J Trop Med Hyg.* 1986; 89(6): 309-12. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg.* 2004; 71(1): 98-106.
- El-Hawey AM, Abdel-Rahman AH, Agina AA, Amer MM, Hashem YA, Goma, AA, Abou el-Dahab MO, Tolba MA. Prevalence and morbidity of schistosomiasis among rural fishermen at two Egyptian villages (Gharbia Governorate). *J Egypt Soc Parasitol.* 1995; 25(3): 649-657. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Ripert C, Leugueun-Ngougbeou J, Same-Ekobo A. [An epidemiological study of intestinal bilharziasis and roundworm infections in Bafia (Cameroon)]. *Bull Soc Pathol Exot Filiales.* 1982; 75(1): 55-61. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Barakat R, Farghaly A, El Masry AG, El-Sayed MK, Hussein MH. The epidemiology of schistosomiasis in Egypt: patterns of *Schistosoma mansoni* infection and morbidity in Kafer El-Sheikh. *Am J Trop Med Hyg.* 2000; 62(2 Suppl): 21-7. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.
- Awad El Karim MA, Collins KJ, Sukkar MY, Omer AH, Amin MA, Doré C. An assessment of anti-schistosomal treatment on physical work capacity. *J Trop Med Hyg.* 1981; 84(2): 67-72. as it appears in King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet.* 2005; 365(9470): 1561-9.
- Barbosa FS, Costa DPPD. Incapacitating Effects of Schistosomiasis Mansoni on the Productivity of Sugar-Cane Cutters in Northeastern Brazil. *Am J Epidemiol.* 1981; 114(1): 102-11. as it appears in King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet.* 2005; 365(9470): 1561-9.
- Beet EA. Observations on haemoglobin values in African children. *Trans R Soc Trop Med Hyg.* 1949; 43(3): 317-28. as it appears in King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet.* 2005; 365(9470): 1561-9.
- Collins KJ, Brotherhood RJ, Davies CT, Doré C, Hackett AJ, Imms FJ, Musgrove J, Weiner JS, Amin MA, El Karim M, Ismail HM, Omer AH, Sukkar MY. Physiological performance and work capacity of Sudanese cane cutters with *Schistosoma mansoni* infection. *Am J Trop Med Hyg.* 1976; 25(3): 410-21. as it appears in King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet.* 2005; 365(9470): 1561-9.
- El Karim MA, Collins KJ, Brotherhood JR, Doré C, Weiner JS, Sukkar MY, Omer AH, Amin MA. Quantitative egg excretion and work capacity in a Gezira population infected with *Schistosoma mansoni*. *Am J Trop Med Hyg.* 1980; 29(1): 54-61. as it appears in King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet.* 2005; 365(9470): 1561-9.
- Ndamba J, Makaza N, Munjoma M, Gomo E, Kaondera KC. The physical fitness and work performance of agricultural workers infected with *Schistosoma mansoni* in Zimbabwe. *Ann Trop Med Parasitol.* 1993; 87(6): 553-61. as it appears in King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet.* 2005; 365(9470): 1561-9.
- Ndamba J. Schistosomiasis: its effects on the physical performance of school children in Zimbabwe. *Cent Afr J Med.* 1986; 32(12): 289-93. as it appears in King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet.* 2005; 365(9470): 1561-9.
- Olds GR, King C, Hewlett J, Olveda R, Wu G, Ouma J, Peters P, McGarvey S, Odhiambo O, Koech D, Liu CY, Aligui G, Gachihi G, Kombe Y, Parraga I, Ramirez B, Whalen C, Horton RJ, Reeve P. Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. *J Infect Dis.* 1999; 179(4): 996-1003. as it appears in King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet.* 2005; 365(9470): 1561-9.
- Kabatereine NB, Brooker S, Tukahebwa EM, Kazibwe F, Onapa AW. *Schistosoma mansoni* in a fishing community on the shores of Lake Albert at Butiaba, Uganda: epidemiology, morbidity, re-infection patterns and impact of treatment with praziquantel. *Acta Trop.* 2004; 9(3): 372-380. as it appears in van der Werf MJ, de Vlas SJ, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Associating community prevalence of *Schistosoma mansoni* infection with prevalence of signs and symptoms. *Acta Trop.* 2002; 82(2): 127-37.

Appendix Table A.3b - Citations for non-dismod model input data

- Nasidi A, Monath TP, DeCock K, Tomori O, Cordellier R, Olaleye OD, Harry TO, Adeniyi JA, Sorungbe AO, Ajose-Coker AO. Urban yellow fever epidemic in western Nigeria, 1987. *Trans R Soc Trop Med Hyg.* 1989; 83(3): 401-6. as it appears in Johansson MA, Vasconcelos PFC, Staples JE. The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases. *Trans R Soc Trop Med Hyg.* 2014; 108(8): 482–7.
- Pinheiro FP, Travassos da Rosa AP, Moraes MA, Almeida Neto JC, Camargo S, Filgueiras JP. An epidemic of yellow fever in central Brazil. 1972-1973. I. Epidemiological studies. *Am J Trop Med Hyg.* 1978; 27(1 Pt 1): 125-32. as it appears in Johansson MA, Vasconcelos PFC, Staples JE. The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases. *Trans R Soc Trop Med Hyg.* 2014; 108(8): 482–7.
- Adams EJ, Stephenson LS, Latham MC, Kinoti SN. Physical activity and growth of Kenyan school children with hookworm, *Trichuris trichiura* and *Ascaris lumbricoides* infections are improved after treatment with albendazole. *J Nutr.* 1994; 124(8): 1199-206. as it appears in Hall A, Hewitt G, Tuffrey V, de Silva N. A review and meta-analysis of the impact of intestinal worms on child growth and nutrition. *Matern Child Nutr.* 2008; 4(Suppl 1): 118–236.
- Alderman H, Konde-Lule J, Sebuliba I, Bundy D, Hall A. Effect on weight gain of routinely giving albendazole to preschool children during child health days in Uganda: cluster randomised controlled trial. *BMJ.* 2006; 333(7559): 122. as it appears in Hall A, Hewitt G, Tuffrey V, de Silva N. A review and meta-analysis of the impact of intestinal worms on child growth and nutrition. *Matern Child Nutr.* 2008; 4(Suppl 1): 118–236.
- Dossa RA, Ategbro EA, de Koning FL, van Raaij JM, Hautvast JG. Impact of iron supplementation and deworming on growth performance in preschool Beninese children. *Eur J Clin Nutr.* 2001; 55(4): 223-8. as it appears in Hall A, Hewitt G, Tuffrey V, de Silva N. A review and meta-analysis of the impact of intestinal worms on child growth and nutrition. *Matern Child Nutr.* 2008; 4(Suppl 1): 118–236.
- Gupta MC, Urrutia JJ. Effect of periodic anti-ascaris and anti-giardia treatment on nutritional status of preschool children. *Am J Clin Nutr.* 1982; 36(1): 79-86. as it appears in Hall A, Hewitt G, Tuffrey V, de Silva N. A review and meta-analysis of the impact of intestinal worms on child growth and nutrition. *Matern Child Nutr.* 2008; 4(Suppl 1): 118–236.
- Koroma MM, Williams RA, de la Haye R R, Hodges M. Effects of albendazole on growth of primary school children and the prevalence and intensity of soil-transmitted helminths in Sierra Leone. *J Trop Pediatr.* 1996; 42(6): 371-2. as it appears in Hall A, Hewitt G, Tuffrey V, de Silva N. A review and meta-analysis of the impact of intestinal worms on child growth and nutrition. *Matern Child Nutr.* 2008; 4(Suppl 1): 118–236.
- Northrop-Clewes CA, Rousham EK, Mascie-Taylor CN, Lunn PG. Anthelmintic treatment of rural Bangladeshi children: effect on host physiology, growth, and biochemical status. *Am J Clin Nutr.* 2000; 73(1): 53-60. as it appears in Hall A, Hewitt G, Tuffrey V, de Silva N. A review and meta-analysis of the impact of intestinal worms on child growth and nutrition. *Matern Child Nutr.* 2008; 4(Suppl 1): 118–236.
- Sarkar NR, Anwar KS, Biswas KB, Mannan MA. Effect of deworming on nutritional status of ascaris infested slum children of Dhaka, Bangladesh. *Indian Pediatr.* 2002; 39(11): 1021-6. as it appears in Hall A, Hewitt G, Tuffrey V, de Silva N. A review and meta-analysis of the impact of intestinal worms on child growth and nutrition. *Matern Child Nutr.* 2008; 4(Suppl 1): 118–236.
- Simeon DT, Grantham-McGregor SM, Callender JE, Wong MS. Treatment of *Trichuris trichiura* infections improves growth, spelling scores and school attendance in some children. *J Nutr.* 1995; 125(7): 1875-83. as it appears in Hall A, Hewitt G, Tuffrey V, de Silva N. A review and meta-analysis of the impact of intestinal worms on child growth and nutrition. *Matern Child Nutr.* 2008; 4(Suppl 1): 118–236.
- Stephenson LS, Latham MC, Adams EJ, Kinoti SN, Pertet A. Physical fitness, growth and appetite of Kenyan school boys with hookworm, *Trichuris trichiura* and *Ascaris lumbricoides* infections are improved four months after a single dose of albendazole. *J Nutr.* 1993; 123(6): 1036-46. as it appears in Hall A, Hewitt G, Tuffrey V, de Silva N. A review and meta-analysis of the impact of intestinal worms on child growth and nutrition. *Matern Child Nutr.* 2008; 4(Suppl 1): 118–236.
- Stephenson LS, Latham MC, Adams EJ, Kinoti SN, Pertet A. Weight gain of Kenyan school children infected with hookworm, *Trichuris trichiura* and *Ascaris lumbricoides* is improved following once- or twice-yearly treatment with albendazole. *J Nutr.* 1993; 123(4): 656-65. as it appears in Hall A, Hewitt G, Tuffrey V, de Silva N. A review and meta-analysis of the impact of intestinal worms on child growth and nutrition. *Matern Child Nutr.* 2008; 4(Suppl 1): 118–236.
- Stephenson LS, Latham MC, Kurz KM, Kinoti SN, Brigham H. Treatment with a single dose of albendazole improves growth of Kenyan schoolchildren with hookworm, *Trichuris trichiura*, and *Ascaris lumbricoides* infections. *Am J Trop Med Hyg.* 1989; 41(1): 78-87. as it appears in Hall A, Hewitt G, Tuffrey V, de Silva N. A review and meta-analysis of the impact of intestinal worms on child growth and nutrition. *Matern Child Nutr.* 2008; 4(Suppl 1): 118–236.
- Stoltzfus RJ, Albonico M, Chwaya HM, Tielsch JM, Schulze KJ, Savioli L. Effects of the Zanzibar school-based deworming program on iron status of children. *Am J Clin Nutr.* 1998; 68(1): 179-86. as it appears in Hall A, Hewitt G, Tuffrey V, de Silva N. A review and meta-analysis of the impact of intestinal worms on child growth and nutrition. *Matern Child Nutr.* 2008; 4(Suppl 1): 118–236.
- Stoltzfus RJ, Albonico M, Tielsch JM, Chwaya HM, Savioli L. School-based deworming program yields small improvement in growth of Zanzibari school children after one year. *J Nutr.* 1997; 127(11): 2187-93. as it appears in Hall A, Hewitt G, Tuffrey V, de Silva N. A review and meta-analysis of the impact of intestinal worms on child growth and nutrition. *Matern Child Nutr.* 2008; 4(Suppl 1): 118–236.
- Stoltzfus RJ, Chway HM, Montresor A, Tielsch JM, Jape JK, Albonico M, Savioli L. Low dose daily iron supplementation improves iron status and appetite but not anemia, whereas quarterly anthelmintic treatment improves growth, appetite and anemia in Zanzibari preschool children. *J Nutr.* 2004; 134(2): 348-56. as it appears in Hall A, Hewitt G, Tuffrey V, de Silva N. A review and meta-analysis of the impact of intestinal worms on child growth and nutrition. *Matern Child Nutr.* 2008; 4(Suppl 1): 118–236.

Appendix Table A.3b - Citations for non-dismod model input data

- Tanumihardjo SA, Permaesih D, Muherdiyantiningsih null, Rustan E, Rusmil K, Fatah AC, Wilbur S, Muhilal null, Karyadi D, Olson JA. Vitamin A status of Indonesian children infected with *Ascaris lumbricoides* after dosing with vitamin A supplements and albendazole. *J Nutr*. 1996; 126(2): 451-7. as it appears in Hall A, Hewitt G, Tuffrey V, de Silva N. A review and meta-analysis of the impact of intestinal worms on child growth and nutrition. *Matern Child Nutr*. 2008; 4(Suppl 1): 118–236.
- Tanumihardjo SA, Permaesih D, Muhilal. Vitamin A status and hemoglobin concentrations are improved in Indonesian children with vitamin A and deworming interventions. *Eur J Clin Nutr*. 2004; 58(9): 1223-30. as it appears in Hall A, Hewitt G, Tuffrey V, de Silva N. A review and meta-analysis of the impact of intestinal worms on child growth and nutrition. *Matern Child Nutr*. 2008; 4(Suppl 1): 118–236.
- Thein-Hlaing, Thane-Toe, Than-Saw, Myat-Lay-Kyin, Myint-Lwin. A controlled chemotherapeutic intervention trial on the relationship between *Ascaris lumbricoides* infection and malnutrition in children. *Trans R Soc Trop Med Hyg*. 1991; 85(4): 523-8. as it appears in Hall A, Hewitt G, Tuffrey V, de Silva N. A review and meta-analysis of the impact of intestinal worms on child growth and nutrition. *Matern Child Nutr*. 2008; 4(Suppl 1): 118–236.
- Watkins WE, Pollitt E. Effect of removing *Ascaris* on the growth of Guatemalan schoolchildren. *Pediatrics*. 1996; 97(6 Pt 1): 871-6. as it appears in Hall A, Hewitt G, Tuffrey V, de Silva N. A review and meta-analysis of the impact of intestinal worms on child growth and nutrition. *Matern Child Nutr*. 2008; 4(Suppl 1): 118–236.
- A randomised cluster trial of six-monthly deworming and its effects on the growth and educational achievements of Vietnamese school children. as it appears in Hall A, Hewitt G, Tuffrey V, de Silva N. A review and meta-analysis of the impact of intestinal worms on child growth and nutrition. *Matern Child Nutr*. 2008; 4(Suppl 1): 118–236.
- McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, Maynard JE. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. *J Infect Dis*. 1985; 151(4): 599-603.
- Sabino EC, Ribeiro AL, Salemi VM, Di Lorenzo Oliveira C, Antunes AP, Menezes MM, Ianni BM, Nastari L, Fernandes F, Patavino GM, Sachdev V, Capuani L, de Almeida-Neto C, Carrick DM, Wright D, Kavounis K, Gonzalez TT, Carneiro-Proietti AB, Custer B, Busch MP, Murphy EL; National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study-II (REDS-II), International Component.. Ten-Year Incidence of Chagas Cardiomyopathy Among Asymptomatic *Trypanosoma cruzi*-Seropositive Former Blood Donors. *Circulation*. 2013; 127(10): 1105-15.
- Coura JR, Pereira JB. A follow-up evaluation of Chagas' Disease in two endemic areas in Brazil. *Mem Inst Oswaldo Cruz*. 1984; 79(Suppl): 107-12.
- Marcolino MS, Palhares DM, Alkmim MB, Ribeiro AL. Prevalence of normal electrocardiograms in primary care patients. *Rev Assoc Med Bras*. 2014; 60(3): 236-41.
- Ingole N, Nataraj G, Mehta P, Paranjpe S, Sarkate P. CD4 counts in laboratory monitoring of HIV disease—experience from western India. *J Int Assoc Provid AIDS Care*. 2014; 13(4): 324–7.
- Edathodu J, Ali B, Alrajhi AA. CD4 validation for the World Health Organization classification and clinical staging of HIV/AIDS in a developing country. *Int J Infect Dis*. 2009; 13(2): 243-6.
- Kassa E, Rinke de Wit TF, Hailu E, Girma M, Messele T, Mariam HG, Yohannes S, Jurriaans S, Yeneneh H, Coutinho RA, Fontanet AL. Evaluation of the World Health Organization staging system for HIV infection and disease in Ethiopia: association between clinical stages and laboratory markers. *AIDS*. 1999; 13(3): 381-9.
- McGrath N, Kranzer K, Saul J, Crampin AC, Malema S, Kachiwanda L, Zaba B, Jahn A, Fine PE, Glynn JR. Estimating the need for antiretroviral treatment and an assessment of a simplified HIV/AIDS case definition in rural Malawi. *AIDS*. 2007; 21(Suppl 6): S105–13.
- Torpey K, Lartey M, Amenyah R, Addo NA, Obeng-Baah J, Rahman Y, Suzuki C, Mukadi YD, Colebunders R. Initiating antiretroviral treatment in a resource-constrained setting: does clinical staging effectively identify patients in need? *Int J STD AIDS*. 2009; 20(6): 395-8.
- Alvarez G. Multiple Sclerosis in Chile 1992. *Acta Neurol Scand*. 1992; 85(1): 1-4.
- Mott KE, Dixon H, Osei-Tutu E, England EC, Ekue K, Tekle A. Evaluation of reagent strips in urine tests for detection of *Schistosoma haematobium* infection: a comparative study in Ghana and Zambia. *Bull World Health Organ*. 1985; 63(1): 125–33. as it appears in van der Werf MJ, de Vlas SJ. Diagnosis of urinary schistosomiasis: a novel approach to compare bladder pathology measured by ultrasound and three methods for hematuria detection. *Am J Trop Med Hyg*. 2004; 71(1): 98-106.
- Institute for Health Metrics and Evaluation (IHME), Joint United Nations Program on HIV/AIDS (UNAIDS). Institute for Health Metrics and Evaluation HIV Mortality Estimates Based on the UNAIDS Spectrum Model Framework.
- Menzies Research Institute Tasmania. Tasmania Older Adult Cohort Study.
- University of Adelaide. Australia - North West Adelaide Health Study.
- National Health and Medical Research Council (Australia), University of Sydney. Australia Long-term Evaluation of Glucosamine Sulphate Study.
- Boston University. United States - Framingham Osteoarthritis Study 2002-2005.
- Bălașa R, Feier C, Dan M, Motaitianu A, Balaianu M, Chebut C, Constantin V, Bajko Z, Pascu I. The prevalence of multiple sclerosis in Mures County, central Romania. 2007; 1(2): 80-84.
- The Scottish low birthweight study: I. Survival, growth, neuromotor and sensory impairment. *Arch Dis Child*. 1992; 67(6): 675-81.
- World Health Organization (WHO). African Programme for Onchocerciasis Control Community-directed Treatment with Ivermectin Database.

Appendix Table A.3b - Citations for non-dismod model input data

- Noma M, Nwoke BE, Nutall I, Tambala PA, Enyong P, Namsenmo A, Remme J, Amazigo UV, Kale OO, Sékétéli A. Rapid epidemiological mapping of onchocerciasis (REMO): its application by the African Programme for Onchocerciasis Control (APOC). *Ann Trop Med Parasitol* . 2002; 96(Suppl 1): S29-39.
- Diawara L, Traoré MO, Badji A, Bissan Y, Doumbia K, Goita SF, Konaté L, Mounkoro K, Sarr MD, Seck AF, Toé L, Tourée S, Remme JH. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. *PLoS Negl Trop Dis* . 2009; 3(7): e497.
- Murdoch ME, Asuzu MC, Hagan M, Makunde WH, Ngoumou P, Ogbuagu KF, Okello D, Ozoh G, Remme J. Onchocerciasis: the clinical and epidemiological burden of skin disease in Africa. *Ann Trop Med Parasitol* . 2002; 96(3): 283-96.
- Brieger WR, Awedoba AK, Eneanya CI, Hagan M, Ogbuagu KF, Okello DO, Ososanya OO, Ovuga EB, Noma M, Kale OO, Burnham GM, Remme JH. The effects of ivermectin on onchocercal skin disease and severe itching: results of a multicentre trial. *Trop Med Int Health* . 1998; 3(12): 951-61.
- Traore MO, Sarr MD, Badji A, Bissan Y, Diawara L, Doumbia K, Goita SF, Konate L, Mounkoro K, Seck AF, Toe L, Toure S, Remme JH. Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. *PLoS Negl Trop Dis* . 2012; 6(9): e1825.
- Gbenou H. Contribution to the Study of Onchocerciasis-Epilepsy Association [Contribution à l'étude de l'association onchocercose-épilepsie: résultats préliminaires d'une enquête neuroépidémiologique à Agbogbomé—commune de Paouignan, Sous-Préfecture de Dassa, Zoumé, au Bénin] [MD thesis]. Cotonou, Benin: National University of Benin; 1995.
- Kouadjo Y. Génétique et épilepsie: À propos d'un foyer d'épilepsie observé dans un village ivoirien [medical thesis]. Abidjan, Côte d'Ivoire; 1990. nbsp;nbsp;
- Beran RG, Hall L, Michelazzi J. An accurate assessment of the prevalence ratio of epilepsy adequately adjusted by influencing factors. *Neuroepidemiology*. 1985; 4(2): 71-81.
- Nieto Barrera M. [Neuroepidemiology of epilepsies]. *An Esp Pediatr*. 1988; 29(Supp 33): 59-63.
- Gracia F, de Lao SL, Castillo L, Larreategi M, Archbold C, Brenes MM, Reeves WC. Epidemiology of epilepsy in Guaymi Indians from Bocas del Toro Province, Republic of Panama. *Epilepsia*. 1990; 31(6): 718-23.
- Gomes Md M da M, Zeitoune RG, Kropf LAL, Beeck Ed E da S van. A house-to-house survey of epileptic seizures in an urban community of Rio de Janeiro, Brazil. *Arq Neuropsiquiatr*. 2002; 60(3-B): 708-11.
- Somoza MJ, Forlenza RH, Brussino M, Licciardi L. Epidemiological survey of epilepsy in the primary school population in Buenos Aires. *Neuroepidemiology*. 2005; 25(2): 62-8.
- Farnarier G, Diop S, Coulibaly B, Arborio S, Dabo A, Diakite M, Traore S, Banou A, Nimaga K, Vaz T, Doumbo O. [Onchocerciasis and epilepsy. Epidemiological survey in Mali]. *Med Trop (Mars)*. 2000; 60(2): 151-5.
- Del Rio-Romero AH, Foyaca-Sibat H, Ibanez-Valdes L, Vega-Novoa E. Prevalence Of Epilepsy And General Knowledge About Neurocysticercosis At Nkalukeni Village, South Africa. *Internet J Neurol*. 2005; 3(2).
- Debrock C, Preux PM, Houinato D, Druet-Cabanac M, Kassa F, Adjien C, Avode G, Denis F, Boutros-Toni F, Dumas M. Estimation of the prevalence of epilepsy in the Benin region of Zinvié using the capture-recapture method. *Int J Epidemiol*. 2000; 29(2): 330-5.
- Haimanot RT, Abebe M, Mariam AG, Forsgren L, Holmgren G, Heijbel J, Ekstedt J. Community-based study of neurological disorders in Ethiopia: development of a screening instrument. *Ethiop Med J*. 1990; 28(3): 123-37.
- Sureka RK, Sureka R. Prevalence of epilepsy in rural Rajasthan--a door-to-door survey. *J Assoc Physicians India*. 2007; 55: 741-2.
- Muir TM, Bradley A, Wood SF, Murray GD, Brodie MJ. An audit of treated epilepsy in Glasgow. West of Scotland Epilepsy Research Group. *Seizure*. 1996; 5(1): 41-6.
- Kwong KL, Chak WK, Wong SN, So KT. Epidemiology of childhood epilepsy in a cohort of 309 Chinese children. *Pediatr Neurol*. 2001; 24(4): 276-82.
- Pascual López MA, Pascual Gispert J, Rodríguez Rivera L, Rojas Ochoa F, Tejeiros A. [Epilepsy: epidemiological study in a child population]. *Bol Med Hosp Infant Mex*. 1980; 37(4): 811-21.
- Singh A, Kaur A. Epilepsy in rural Haryana – prevalence and treatment seeking behaviour. *J Indian Med Assoc*. 1997; 95(2): 37-47.
- Ross EM, Peckham CS, West PB, Butler NR. Epilepsy in childhood: findings from the National Child Development Study. *Br Med J*. 1980; 280(6209): 207-10.
- Rantala H, Ingalsuo H. Occurrence and outcome of epilepsy in children younger than 2 years. *J Pediatr*. 1999; 135(6): 761-4.
- Chen R-C, Chang Y-C, Chen TH-H, Wu H-M, Liou H-H. Mortality in adult patients with epilepsy in Taiwan. *Epileptic Disord*. 2005; 7(3): 213-9.
- Arruda WO. Etiology of epilepsy. A prospective study of 210 cases. *Arq Neuropsiquiatr*. 1991; 49(3): 251-4.
- Mwinzi SMG, Ruberti FR, Stewart JD. Epilepsy in the Kenyan Africa. *Med Afr Noire*. 1976; 23: 331-334.
- Ruberti RF, Mwinzi SMG, Dekker N. Epilepsy in the Kenyan African. *Afr J Neurol Sci*. 1985; 4() : 1-3.
- Feksi AT, Kaamugisha J, Gatiti S, Sander JW, Shorvon SD. A comprehensive community epilepsy programme: the Nakuru project. *Epilepsy Res*. 1991; 8(3): 252-9.
- Andriantseheno LM, Andrianasy TF. The features of epilepsy in the Malagasy: a hospital study on 213 cases from the North Western part of Madagascar. *Afr J Neurol Sci*. 1997; 16() : 28-33.
- Dada TO. Epilepsy in Lagos, Nigeria. *Afr J Med Sci*. 1970; 1() : 161-184.

Appendix Table A.3b - Citations for non-dismod model input data

- Van Der Waals FW, Goudsmit J, Gajdusek DC. Clinical characteristics of highly prevalent seizure disorders in the Gbawein and Wroughbarh Clan Region of Grand Bassa County, Liberia. *Neuroepidemiology*. 1983; 2(): 35-44.
- Danesi MA, Oni K. Features of partial epilepsy in Nigerians: a 3 year clinical and electroencephalographic study of 282 cases seen at the Lagos University Teaching Hospital. *Afr J Neurol Sci*. 1983; 2(): 1-6.
- Danesi MA. Acquired aetiological factors in Nigerian epileptics (an investigation of 378 patients). *Trop Geogr Med*. 1983; 35(3): 293-297.
- Iloje SO. The pattern of childhood epilepsy with mental retardation in Nigeria. *J Trop Pediatr*. 1989; 35(4): 163-168.
- Ojuawo A, Joiner KT. Childhood epilepsy in Ilorin, Nigeria. *East Afr Med J*. 1997; 74(2): 72-75.
- Piroux A. Les épilepsies en Afrique Centrale [Epilepsy in Central Africa]. *World Neurol*. 1960; 1: 510-522.
- Collomb H, Girard PL, Konate S. L'épilepsie en milieu hospitalier à Dakar. *Med Afr Noire*. 1976; 23: 299-304.
- Lisk DR. Epilepsy pattern and clinic compliance in Sierra Leonean epileptics. *Afr J Neurol Sci*. 1992; 11(): 4-6.
- Matuja WB. Aetiological factors in Tanzanian epileptics. *East Afr Med J*. 1989; 66(5): 343-348.
- Newton CR, Gero BT. The epilepsies among rural blacks. *S Afr Med J*. 1984; 66(1): 21-23.
- Cardozo LJ, Patel MG. Epilepsy in Zambia. *East Afr Med J*. 1976; 53(8): 488-493.
- Chuke PO, Muras J. Experience in epilepsy in Lusaka. *Med J Zambia*. 1977; 11: 65-70.
- Levy LF. Epilepsy in Rhodesia, Zambia, and Malawi. *Afr J Med Sci*. 1970; 1(): 291-203.
- Cruz-Campos GA, Baquero-Toledo M. [Epilepsies in an outpatient setting: a study of 150 cases]. *Rev Neurol*. 2000; 30(12): 1108-12.
- Moran NF, Poole K, Bell G, Solomon J, Kendall S, McCarthy M, McCormick D, Nashef L, Sander J, Shorvon SD. Epilepsy in the United Kingdom: seizure frequency and severity, anti-epileptic drug utilization and impact on life in 1652 people with epilepsy. *Seizure*. 2004; 13(6): 425-33.
- Okuma T, Kumashiro H. Natural history and prognosis of epilepsy: report of a multi-institutional study in Japan. The group for the study of prognosis of epilepsy in Japan. *Epilepsia*. 1981; 22(1): 35-53.
- Feksi AT, Kaamugisha J, Sander JW, Gatiti S, Shorvon SD. Comprehensive primary health care antiepileptic drug treatment programme in rural and semi-urban Kenya. ICBERG (International Community-based Epilepsy Research Group). *Lancet*. 1991; 337(8738): 406-9.
- Manonmani V, Tan CT. A study of newly diagnosed epilepsy in Malaysia. *Singapore Med J*. 1999; 40(1): 32-5.
- Mrabet H, Mrabet A, Zouari B, Ghachem R. Health-related quality of life of people with epilepsy compared with a general reference population: a Tunisian study. *Epilepsia*. 2004; 45(7): 838-43.
- Chang EF, Potts MB, Keles GE, Lamborn KR, Chang SM, Barbaro NM, Berger MS. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. *J Neurosurg*. 2008; 108(2): 227-35.
- Marks WJ Jr. When epilepsy surgery fails... There is often a second chance. *Epilepsy Curr*. 2005; 5(4): 149-51.
- Massey EW, Schoenberg BS. Mortality from epilepsy. International patterns and changes over time. *Neuroepidemiology*. 1985; 4(2): 65-70.
- Lee WL, Low PS, Murugasu B, Rajan U. Epidemiology of epilepsy in Singapore children. *Neurol J Southeast Asia*. 1997; 2: 31-35.
- Yaqub BA, Panayiotopoulos CP, Al-Nozha M, Qteishat W, Al-Dalaan A. Causes of late onset epilepsy in Saudi Arabia: the role of cerebral granuloma. *J Neurol Neurosurg Psychiatry*. 1987; 50(1): 90-2.
- Uuriintuya M, Ulziibayar D, Bayarmaa D. Epilepsy in Mongolia. *Neurology Asia*. 2007; 12: 61-63.
- Battaglia D, Randó T, Deodato F, Bruccini G, Baglio G, Frisone MF, Pantó T, Tortorella G, Guzzetta F. Epileptic disorders with onset in the first year of life: neurological and cognitive outcome. *Eur J Paediatr Neurol*. 1999; 3(3): 95-103.
- Olafsson E, Ludvigsson P, Gudmundsson G, Hesdorffer D, Kjartansson O, Hauser WA. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. *Lancet Neurol*. 2005; 4(10): 627-34.
- Reyes JA, Molina SC. La Epilepsia en el Hospital Psiquiátrico de Agudos "Dr. Mario Mendoza". 1988; 56: 207-15.
- Diallo TM, Cisse A, Morel Y, Cisse AF, Souare IS. [Late occurrence of first epileptic seizures: a 42-case series]. *Med Trop (Mars)*. 2004; 64(2): 155-9.
- Tekle-Haimanot R. The pattern of epilepsy in Ethiopia: analysis of 468 cases. *Ethiop Med J*. 1984; 22(3): 113-8.
- Tekle-Haimanot R, Forsgren L, Ekstedt J. Incidence of epilepsy in rural central Ethiopia. *Epilepsia*. 1997; 38(5): 541-6.
- Cockerell OC, Johnson AL, Sander JW, Shorvon SD. Prognosis of epilepsy: a review and further analysis of the first nine years of the British National General Practice Study of Epilepsy, a prospective population-based study. *Epilepsia*. 1997; 38(1): 31-46.
- Chaves-Sell F, Dubuisson-Schonemberg V. [Profile of epilepsy in a neurology clinic in Costa Rica]. *Rev Neurol*. 2001; 33(5): 411-13.
- Hernández-Cossio O, Hernández-Oramas N, Enríquez-Cáceres M, Hernández-Fustes OJ. [Etiology of late-onset epilepsy]. *Rev Neurol*. 2001; 32(7): 628-30.
- Arteaga-Rodríguez C, Ramírez-Chávez J, Rodríguez-Rivera L, Morera-Méndez F, Hernández-Fustes OJ. Aetiological factors of the epilepsies. *Rev Neurol*. 1998; 27: 427-30.
- Ng KK, Ng PW, Tsang KL, Hong Kong Epilepsy Study Group. Clinical characteristics of adult epilepsy patients in the 1997 Hong Kong epilepsy registry. *Chin Med J (Engl)*. 2001; 114(1): 84-7.

Appendix Table A.3b - Citations for non-dismod model input data

Hui AC, Wong A, Wong HC, Man BL, Au-Yeung KM, Wong KS. Refractory epilepsy in a Chinese population. *Clin Neurol Neurosurg*. 2007; 109(8): 672-5.

Wang WZ, Wu JZ, Ma GY, Dai XY, Yang B, Wang TP, Yuan CL, Hong Z, Bell GS, Prilipko L, de Boer HM, Sander JW. Efficacy assessment of phenobarbital in epilepsy: a large community-based intervention trial in rural China. *Lancet Neurol*. 2006; 5(1): 46-52.

Ding D, Hong Z, Chen GS, Dai XY, Wu JZ, Wang WZ, De Boer HM, Sander JW, Prilipko L, Chisholm D. Primary care treatment of epilepsy with phenobarbital in rural China: Cost-outcome analysis from the WHO/ILAE/IBE global campaign against epilepsy demonstration project. *Epilepsia*. 2008; 49(3): 535-9.

Appendix Table A.4: Model type and fit metrics: R-squared

Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
All causes				
Communicable, maternal, neonatal, and nutritional diseases				
HIV/AIDS and tuberculosis				
Tuberculosis	mixed effects regression on case notifications and deaths to estimate incidence; compositional analysis model for proportion of all forms, smear-positive and bacteriologically positive cases; DisMod-MR 2.0 to fit between incidence, prevalence, excess mortality and cause specific mortality rates	0.76	0.92	
Tuberculosis	UNAIDS Spectrum model; DisMod-MR 2.0 and meta-analysis of mortality rates on and without ART; vital registration mortality data for concentrated epidemics			
HIV/AIDS resulting in mycobacterial infection	meta-regression relative risk data of TB by CD4 count			
HIV/AIDS resulting in other diseases				
Early HIV	Meta-analysis			
Symptomatic HIV	Meta-analysis			
AIDS with antiretroviral treatment	Meta-analysis			
AIDS without antiretroviral treatment	Meta-analysis			
Diarhea, lower respiratory, and other common infectious diseases				
Diarheal diseases	DisMod-MR 2.0 of prevalence, incidence and cause specific mortality data; remission set to reflect average duration of 5 days; counterfactual analysis of underlying etiologies	0.72		
Mild diarrehal diseases	DHS analysis: proportion of cases of diarrhea who did not seek medical care			
Moderate diarrehal diseases	DHS analysis: proportion of cases of diarrhea seeking medical care who did not have severe dehydration or seizures			
Severe diarrehal diseases	DHS analysis: proportion of cases of diarrhea seeking medical care who had severe dehydration or seizures			
Guillain-Barre syndrome due to diarrehal diseases	DisMod-MR 2.0 of incidence and remission data all GBS + meta-analysis of proportion of all cases following diarrehal disease			
Intestinal infectious diseases				
Typhoid and paratyphoid fever	(1) DisMod-MR 2.0 of incidence with crosswalk from passive to active case detection estimates; (2) assumed duration of 2 weeks		0.92	
Typhoid fever	DisMod-MR 2.0 proportion of typhoid and paratyphoid that is typhoid			0.27
Acute typhoid infection	Meta-analysis			
Severe typhoid fever	Meta-analysis			
Intestinal perforation due to typhoid	Meta-analysis			
Gastrointestinal bleeding due to typhoid	Meta-analysis			
Paratyphoid fever	DisMod-MR 2.0 proportion of typhoid and paratyphoid that is paratyphoid			0.72
Acute paratyphoid infection	Proportion from literature			
Moderate paratyphoid fever	Proportion from literature			
Severe paratyphoid fever	Proportion from literature			
Intestinal perforation due to paratyphoid	Proportion from literature			
Other intestinal infectious diseases	YLD to YLL ratio of typhoid and paratyphoid applied to YLL for other intestinal infectious diseases			
Lower respiratory infections	DisMod-MR 2.0 of prevalence data and remission setting to reflect 10 day average duration	0.96		
Moderate lower respiratory infections	remainder of all lower respiratory infections after subtraction of severe cases			
Severe lower respiratory infections	coefficient in DisMod-MR 2.0 on data points for severe lower respiratory infections			
Guillain-Barre syndrome due to lower respiratory infections	DisMod-MR 2.0 of incidence and remission data all GBS + meta-analysis of proportion of all cases following upper respiratory infection			
Upper respiratory infections	DisMod-MR 2.0 of prevalence data and remission setting to reflect 5 day average duration	0.70		
Mild upper respiratory infections	DisMod-MR 2.0 coefficient on covariate for data on moderate (tonsillitis, laryngitis, pharyngitis, tracheitis, sinusitis and epiglottitis) vs mild infections			
Moderate upper respiratory infections	DisMod-MR 2.0 coefficient on covariate for data on moderate (tonsillitis, laryngitis, pharyngitis, tracheitis, sinusitis and epiglottitis) vs mild infections			
Guillain-Barre syndrome due to upper respiratory infections	DisMod-MR 2.0 of incidence and remission data all GBS + meta-analysis of proportion of all cases following upper respiratory infection			
Otitis media		0.82		
Acute otitis media	DisMod-MR 2.0 of incidence and prevalence with remission set to reflect average duration of 2-3 weeks	0.64	0.97	
Chronic otitis media	DisMod-MR 2.0 of incidence, prevalence and remission data	0.69	0.50	
Vertigo with mild hearing loss due to chronic otitis media	Proportion of cases with vertigo from literature and multiplication of prevalence of chronic otitis media and proportion hearing loss by severity from literature			
Vertigo with mild hearing loss and ringing due to chronic otitis media	Proportion of cases with vertigo from literature and multiplication of prevalence of chronic otitis media and proportion hearing loss by severity from literature			
Mild hearing loss due to chronic otitis media	multiplication of prevalence of chronic otitis media and proportion hearing loss by severity from literature			
Mild hearing loss with ringing due to chronic otitis media	multiplication of prevalence of chronic otitis media and proportion hearing loss by severity from literature			
Vertigo with moderate hearing loss due to chronic otitis media	Proportion of cases with vertigo from literature and multiplication of prevalence of chronic otitis media and proportion hearing loss by severity from literature			
Vertigo with moderate hearing loss and ringing due to chronic otitis media	Proportion of cases with vertigo from literature and multiplication of prevalence of chronic otitis media and proportion hearing loss by severity from literature			
Moderate hearing loss due to chronic otitis media	multiplication of prevalence of chronic otitis media and proportion hearing loss by severity from literature			
Moderate hearing loss with ringing due to chronic otitis media	multiplication of prevalence of chronic otitis media and proportion hearing loss by severity from literature			
Meningitis	DisMod-MR 2.0 model for all meningitis incidence and excess mortality with remission set to reflect average duration between 3 and 6 weeks		0.75	
Pneumococcal meningitis				
Proportion of meningitis due to pneumococcus	DisMod-MR 2.0 pooling of data on proportion of meningitis due to pneumococcus			0.78
Acute pneumococcal meningitis	multiplication of proportion pneumococcal meningitis and overall meningitis prevalence			
Mild behavioral problems due to pneumococcal meningitis	(1) Incidence of overall meningitis model adjusted by excess mortality rate converted to a case fatality proportion to get incidence of meningitis survivors; (2) multiplication of incidence of meningitis survivors by proportion pneumococcal meningitis and proportion of cases of pneumococcal meningitis with long term mild impairment based on a meta-analysis; (3) stream out prevalence from incidence assuming no excess mortality risk and no remission; (4) meta-analysis of types of long term mild impairment			
Mild motor impairment due to long term due to pneumococcal meningitis	(1) Incidence of overall meningitis model adjusted by excess mortality rate converted to a case fatality proportion to get incidence of meningitis survivors; (2) multiplication of incidence of meningitis survivors by proportion pneumococcal meningitis and proportion of cases of pneumococcal meningitis with long term mild impairment based on a meta-analysis; (3) stream out prevalence from incidence assuming no excess mortality risk and no remission; (4) meta-analysis of types of long term mild impairment			
Mild motor plus cognitive impairments due to pneumococcal meningitis	(1) Incidence of overall meningitis model adjusted by excess mortality rate converted to a case fatality proportion to get incidence of meningitis survivors; (2) multiplication of incidence of meningitis survivors by proportion pneumococcal meningitis and proportion of cases of pneumococcal meningitis with long term mild impairment based on a meta-analysis; (3) stream out prevalence from incidence assuming no excess mortality risk and no remission; (4) meta-analysis of types of long term mild impairment			
Borderline intellectual disability due to pneumococcal meningitis	(1) Incidence of overall meningitis model adjusted by excess mortality rate converted to a case fatality proportion to get incidence of meningitis survivors; (2) multiplication of incidence of meningitis survivors by proportion pneumococcal meningitis and proportion of cases of pneumococcal meningitis with long term mild impairment based on a meta-analysis; (3) stream out prevalence from incidence assuming no excess mortality risk and no remission; (4) meta-analysis of types of long term mild impairment			

Appendix Table A.4: Model type and fit metrics: R-squared				
Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
Mild hearing loss due with ringing to other bacterial meningitis	(1) Incidence of overall meningitis model adjusted by excess mortality rate converted to a case fatality proportion to get incidence of meningitis survivors; (2) multiplication of incidence of meningitis survivors by proportion other bacterial meningitis and proportion of cases of other bacterial meningitis with long term mild impairment based on a meta-analysis; (3) stream out prevalence from incidence assuming no excess mortality risk and no remission; (4) meta-analysis of types of long term mild impairment; (5) apply severity split from hearing loss envelope			
Moderate hearing loss due to other bacterial meningitis	(1) Incidence of overall meningitis model adjusted by excess mortality rate converted to a case fatality proportion to get incidence of meningitis survivors; (2) multiplication of incidence of meningitis survivors by proportion other bacterial meningitis and proportion of cases of other bacterial meningitis with long term mild impairment based on a meta-analysis; (3) stream out prevalence from incidence assuming no excess mortality risk and no remission; (4) meta-analysis of types of long term mild impairment; (5) apply severity split from hearing loss envelope			
Moderate hearing loss with ringing due to other bacterial meningitis	(1) Incidence of overall meningitis model adjusted by excess mortality rate converted to a case fatality proportion to get incidence of meningitis survivors; (2) multiplication of incidence of meningitis survivors by proportion other bacterial meningitis and proportion of cases of other bacterial meningitis with long term mild impairment based on a meta-analysis; (3) stream out prevalence from incidence assuming no excess mortality risk and no remission; (4) meta-analysis of types of long term mild impairment; (5) apply severity split from hearing loss envelope			
Moderately severe hearing loss due to other bacterial meningitis	(1) Incidence of overall meningitis model adjusted by excess mortality rate converted to a case fatality proportion to get incidence of meningitis survivors; (2) multiplication of incidence of meningitis survivors by proportion other bacterial meningitis and proportion of cases of other bacterial meningitis with long term mild impairment based on a meta-analysis; (3) stream out prevalence from incidence assuming no excess mortality risk and no remission; (4) meta-analysis of types of long term mild impairment; (5) apply severity split from hearing loss envelope			
Moderately severe hearing loss with ringing due to other bacterial meningitis	(1) Incidence of overall meningitis model adjusted by excess mortality rate converted to a case fatality proportion to get incidence of meningitis survivors; (2) multiplication of incidence of meningitis survivors by proportion other bacterial meningitis and proportion of cases of other bacterial meningitis with long term mild impairment based on a meta-analysis; (3) stream out prevalence from incidence assuming no excess mortality risk and no remission; (4) meta-analysis of types of long term mild impairment; (5) apply severity split from hearing loss envelope			
Severe hearing loss due to other bacterial meningitis	(1) Incidence of overall meningitis model adjusted by excess mortality rate converted to a case fatality proportion to get incidence of meningitis survivors; (2) multiplication of incidence of meningitis survivors by proportion other bacterial meningitis and proportion of cases of other bacterial meningitis with long term mild impairment based on a meta-analysis; (3) stream out prevalence from incidence assuming no excess mortality risk and no remission; (4) meta-analysis of types of long term mild impairment; (5) apply severity split from hearing loss envelope			
Severe hearing loss with ringing due to other bacterial meningitis	(1) Incidence of overall meningitis model adjusted by excess mortality rate converted to a case fatality proportion to get incidence of meningitis survivors; (2) multiplication of incidence of meningitis survivors by proportion other bacterial meningitis and proportion of cases of other bacterial meningitis with long term mild impairment based on a meta-analysis; (3) stream out prevalence from incidence assuming no excess mortality risk and no remission; (4) meta-analysis of types of long term mild impairment; (5) apply severity split from hearing loss envelope			
Profound hearing loss due to other bacterial meningitis	(1) Incidence of overall meningitis model adjusted by excess mortality rate converted to a case fatality proportion to get incidence of meningitis survivors; (2) multiplication of incidence of meningitis survivors by proportion other bacterial meningitis and proportion of cases of other bacterial meningitis with long term mild impairment based on a meta-analysis; (3) stream out prevalence from incidence assuming no excess mortality risk and no remission; (4) meta-analysis of types of long term mild impairment; (5) apply severity split from hearing loss envelope			
Profound hearing loss with ringing due to other bacterial meningitis	(1) Incidence of overall meningitis model adjusted by excess mortality rate converted to a case fatality proportion to get incidence of meningitis survivors; (2) multiplication of incidence of meningitis survivors by proportion other bacterial meningitis and proportion of cases of other bacterial meningitis with long term mild impairment based on a meta-analysis; (3) stream out prevalence from incidence assuming no excess mortality risk and no remission; (4) meta-analysis of types of long term mild impairment; (5) apply severity split from hearing loss envelope			
Complete hearing loss due to other bacterial meningitis	(1) Incidence of overall meningitis model adjusted by excess mortality rate converted to a case fatality proportion to get incidence of meningitis survivors; (2) multiplication of incidence of meningitis survivors by proportion other bacterial meningitis and proportion of cases of other bacterial meningitis with long term mild impairment based on a meta-analysis; (3) stream out prevalence from incidence assuming no excess mortality risk and no remission; (4) meta-analysis of types of long term mild impairment; (5) apply severity split from hearing loss envelope			
Complete hearing loss with ringing due to other bacterial meningitis	(1) Incidence of overall meningitis model adjusted by excess mortality rate converted to a case fatality proportion to get incidence of meningitis survivors; (2) multiplication of incidence of meningitis survivors by proportion other bacterial meningitis and proportion of cases of other bacterial meningitis with long term mild impairment based on a meta-analysis; (3) stream out prevalence from incidence assuming no excess mortality risk and no remission; (4) meta-analysis of types of long term mild impairment; (5) apply severity split from hearing loss envelope			
Encephalitis				
Acute encephalitis	DisMod-MR 2.0 of incidence and remission set to reflect 3 week average duration		0.69	
Mild behavioral problems due to encephalitis	Assume same proportion of cases have long term mild impairment as in non-pneumococcal meningitis			
Mild motor impairment due to long term due to encephalitis	Assume same proportion of cases have long term mild impairment as in non-pneumococcal meningitis			
Mild motor plus cognitive impairments due to encephalitis	Assume same proportion of cases have long term mild impairment as in non-pneumococcal meningitis			
Borderline intellectual disability due to encephalitis	Assume same proportion of cases have long term mild impairment as in non-pneumococcal meningitis			
Monocular distance vision loss due to encephalitis	Assume same proportion of cases have long term mild impairment as in non-pneumococcal meningitis			
Moderate to severe impairment due to encephalitis	Intermediate model based on (1) incidence of overall encephalitis model adjusted by excess mortality rate converted to a case fatality proportion to get incidence of encephalitis survivors; (2) multiplication of incidence of encephalitis survivors by proportion of cases of non-pneumococcal meningitis with long term moderate to severe impairment based on a meta-analysis; (3) streaming out prevalence from incidence and SMR data from cerebral palsy literature assuming no remission		0.97	
Mild intellectual disability due to encephalitis	Assume same proportion of cases have long term moderate to severe impairments as in non-pneumococcal meningitis			
Moderate motor impairment due to encephalitis	Assume same proportion of cases have long term moderate to severe impairments as in non-pneumococcal meningitis			
Severe motor impairment due to encephalitis	Assume same proportion of cases have long term moderate to severe impairments as in non-pneumococcal meningitis			
Moderate motor plus cognitive impairments due to encephalitis	Assume same proportion of cases have long term moderate to severe impairments as in non-pneumococcal meningitis			
Severe motor plus cognitive impairments due to encephalitis	Assume same proportion of cases have long term moderate to severe impairments as in non-pneumococcal meningitis			
Epilepsy due to encephalitis	(1) assume same proportion of cases have long term moderate to severe impairments as in non-pneumococcal meningitis; (2) proportion of those with epilepsy as from meningitis meta-analysis for non-pneumococcal meningitis; (3) DisMod-MR 2.0 model to stream out prevalence using excess mortality and remission data from epilepsy envelope model		0.95	
Blindness due to encephalitis	Assume same proportion of cases have long term moderate to severe impairments as in non-pneumococcal meningitis			
Diphtheria	Natural history model of case fatality data applied to deaths from CODEM			0.87
Moderate diphtheria	Proportion from literature			
Severe diphtheria	Proportion from literature			
Whooping cough	Natural history model of incidence from notification data, case fatality and duration of 50 days	0.17		
Tetanus	Natural history model of case fatality data applied to deaths from CODEM			0.69
Severe tetanus	Natural history model of case fatality data applied to deaths from CODEM			
Mild impairment due to neonatal tetanus	proportion of neonatal tetanus cases with mild long term impairment from meta-analysis		0.98	
Mild motor impairment due to neonatal tetanus	(1) incidence from overall tetanus DisMod-MR 2.0 model multiplied by case fatality proportion implied by excess mortality rates to get incidence of neonatal tetanus survivors; (2) apply proportion of neonatal tetanus cases with mild long term impairment from meta-analysis; (3) assume constant prevalence as no excess mortality; (4) assume same distribution of mild impairments as in neonatal encephalopathy			
Mild motor plus cognitive impairments due to neonatal tetanus	(1) incidence from overall tetanus DisMod-MR 2.0 model multiplied by case fatality proportion implied by excess mortality rates to get incidence of neonatal tetanus survivors; (2) apply proportion of neonatal tetanus cases with mild long term impairment from meta-analysis; (3) assume constant prevalence as no excess mortality; (4) assume same distribution of mild impairments as in neonatal encephalopathy			
Moderate to severe impairment due to neonatal tetanus	DisMod-MR 2.0 + meta-analysis		0.98	
Moderate motor impairment due to neonatal tetanus	(1) incidence from overall tetanus DisMod-MR 2.0 model multiplied by case fatality proportion implied by excess mortality rates to get incidence of neonatal tetanus survivors; (2) apply proportion of neonatal tetanus cases with moderate to severe long term impairment from meta-analysis; (3) DisMod-MR 2.0 to stream out incidence of moderate to severe long term impairment with excess mortality from cerebral palsy literature; (4) assume same distribution of moderate to severe impairments as in neonatal encephalopathy			

Appendix Table A.4: Model type and fit metrics: R-squared				
Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
Severe motor plus cognitive impairment with blindness and epilepsy due to malaria	(1) proportion of long term neurological sequelae from literature; (2) assumed same long term impairment distribution as for neonatal encephalopathy			
Mild anemia due to malaria parasitemia (PPR)	(1) mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Moderate anemia due to malaria parasitemia (PPR)	(1) mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Severe anemia due to malaria parasitemia (PPR)	(1) mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Chagas disease	DisMod-MR 2.0 of Chagas sero-prevalence and cause-specific mortality, excess mortality (based on first iteration of prevalence model and cause-specific mortality rates) and no remission	0.88		
Acute Chagas disease	Proportion from literature			
Mild chronic digestive disease due to Chagas disease	Proportion from literature			
Moderate chronic digestive disease due to Chagas disease	Proportion from literature			
Asymptomatic Chagas disease	subtraction of prevalence of symptomatic health states from sero-prevalence			
Atrial fibrillation and flutter due to Chagas disease	Proportion from literature			
Mild heart failure due to Chagas disease	Proportion from literature and severity distribution for all heart failure from MEPS			
Moderate heart failure due to Chagas disease	Proportion from literature and severity distribution for all heart failure from MEPS			
Severe heart failure due to Chagas disease	Proportion from literature and severity distribution for all heart failure from MEPS			
Leishmaniasis				
Visceral leishmaniasis	(1) excess mortality derived from mortality to incidence ratios in countries with data on both and predicted out to country, year, age, sex; (2) DisMod-MR 2.0 of incidence and excess mortality assuming remission consistent with a three month duration		0.89	
Moderate visceral leishmaniasis	Proportion from literature			
Severe visceral leishmaniasis	Proportion from literature			
Cutaneous and mucocutaneous leishmaniasis	(1) DisMod-MR 2.0 model of incidence, zero remission and zero mortality; (2) correction of incidence for underreporting based on literature; (3) proportion with life long disfigurement based on proportion from literature for those with facial involvement and a scaling of this proportion between countries based on health system access covariate		0.95	
African trypanosomiasis	(1) apply case detection rate based on regression of incidence vs. screening coverage; (2) DISMod-MR 2.0 of reported incidence corrected for underreporting; (3) assume mean duration in treated cases is 3 months and in untreated cases is 3 years	0.85		
Disfigurement due to African trypanosomiasis	Proportion from literature			
Severe motor plus cognitive impairments due to African trypanosomiasis	Proportion from literature			
Schistosomiasis	(1) DisMod-MR 2.0 model of pre-control prevalence; (2) estimate species-specific prevalence based on country; (3) predict post-control prevalence adjusting for treatment impact (cumulative number of treatments per person at risk from WHO PCT databank) and species-specific efficacy from meta-analysis; (4) assume treatment effect same for reversible sequelae; (5) assume for advance hepatic disease, hematemesis and ascites that incidence among treated fraction of population is zero and 10% of prevalent cases die annually from the sequela	0.96		
Schistosomiasis stage 1	DisMod-MR 2.0			
Schistosomiasis stage 2	DisMod-MR 2.0			
Schistosomiasis stage 3	DisMod-MR 2.0			
Mild schistosomiasis	Proportion from literature			
Mild diarrhea due to schistosomiasis	Proportion from literature			
Hematemesis due to schistosomiasis	Proportion from literature			
Hepatomegaly due to schistosomiasis	Proportion from literature			
Ascites due to schistosomiasis	Proportion from literature			
Dysuria due to schistosomiasis	Proportion from literature			
Bladder pathology due to schistosomiasis	Proportion from literature			
Hydronephrosis due to schistosomiasis	Proportion from literature			
Mild anemia due to schistosomiasis	(1) mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Moderate anemia due to schistosomiasis	(1) mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Severe anemia due to schistosomiasis	(1) mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Cysticercosis		0.78		
Neurocysticercosis with epilepsy	(1) DisMod-MR 2.0 oflata on proportion of epilepsy patients with neurocysticercosis based on studies in endemic areas; (2) applied this proportion to epilepsy impairment envelope			
Cystic echinococcosis	DisMod-MR 2.0 of incidence from literature and inpatient hospital data on surgical cases		0.53	
Abdominal problems due to cystic echinococcosis	Proportion from literature			
Chronic respiratory disease due to cystic echinococcosis	Proportion from literature			
Epilepsy due to echinococcosis	Proportion from literature			
Lymphatic filariasis		0.93		
Prevalence of detectable microfilaria due to lymphatic filariasis	(1) DisMod-MR 2.0 for pre-control prevalence of microfilaria infection in populations at risk from LF atlas; (2) predict post-control prevalence adjusting for treatment impact (cumulative number of treatments per person at risk from WHO PCT databank)			
Lymphedema due to lymphatic filariasis	(1) DisMod-MR 2.0 for pre-control prevalence of lymphedema in populations at risk from LF atlas; (2) predict post-control prevalence adjusting for treatment impact (cumulative number of treatments per person at risk from WHO PCT databank) assuming zero incidence in the treated fraction of the population and no excess mortality among individuals with lymphedema			
Hydrocele due to lymphatic filariasis	(1) DisMod-MR 2.0 for pre-control prevalence of hydrocele in populations at risk from LF atlas; (2) predict post-control prevalence adjusting for treatment impact (cumulative number of treatments per person at risk from WHO PCT databank)			
Onchocerciasis	Based on estimates of numbers of cases supplied by expert group for GBD2010			
Asymptomatic onchocerciasis	Proportion from literature			
Mild skin disease due to onchocerciasis	Proportion from literature			
Mild skin disease without itch due to onchocerciasis	Proportion from literature			
Moderate skin disease due to onchocerciasis	Proportion from literature			
Severe skin disease due to onchocerciasis	Proportion from literature			
Severe skin disease without itch due to onchocerciasis	Proportion from literature			
Moderate vision impairment due to onchocerciasis	Proportion of cases with vision loss from literature			

Appendix Table A.4: Model type and fit metrics: R-squared				
Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
Severe vision impairment due to onchocerciasis	Proportion of cases with vision loss from literature			
Blindness due to onchocerciasis	Proportion of cases with vision loss by level of severity from literature			
Trachoma				
Vision impairment due to trachoma	DisMod-MR 2.0 of proportion of all vision loss (not blindness) in countries that are known to have trachoma	0.74		
Moderate vision impairment due to trachoma	(1) DisMod-MR 2.0 of proportion of all vision loss (not blindness) in countries that are known to have trachoma; (2) split between moderate and severe vision loss from vision loss envelope			
Severe vision impairment due to trachoma	(1) DisMod-MR 2.0 of proportion of all vision loss (not blindness) in countries that are known to have trachoma; (2) split between moderate and severe vision loss from vision loss envelope			
Blindness due to trachoma	(1) DisMod-MR 2.0 of proportion of blindness in countries that are known to have trachoma	0.52		
Dengue	(1) Mixed effects negative binomial regression of reported cases; (2) adjustment for underreporting from ratios of country random effects from (1) and empirical data on underreporting	0.95		
Moderate dengue	Meta-analysis			
Severe dengue	Meta-analysis			
Post-dengue chronic fatigue syndrome	Proportion from literature			
Yellow fever	Negative binomial regression of reported cases accounting for underreporting borrowing estimates of underreporting from dengue model			
Asymptomatic yellow fever	Meta-analysis			
Moderate yellow fever	Meta-analysis			
Severe yellow fever	Meta-analysis			
Rabies	Natural history model of deaths from CODEM divided by case fatality proportion data from literature	0.98		
Intestinal nematode infections				
Ascariasis	(1) Bayesian geostatistical models of pre-control prevalence using environmental predictor variables; (2) post-control prevalence based on modelled reduction in prevalence due to preventive chemotherapy			
Heavy infestation of ascariasis	Proportion from literature			
Mild abdominopelvic problems due to ascariasis	Proportion from literature			
Severe wasting due to ascariasis	Proportion from literature			
Asymptomatic ascariasis	Proportion from literature			
Trichuriasis	(1) Bayesian geostatistical models of pre-control prevalence using environmental predictor variables; (2) post-control prevalence based on modelled reduction in prevalence due to preventive chemotherapy			
Heavy infestation of trichuriasis	Proportion from literature			
Mild abdominopelvic problems due to trichuriasis	Proportion from literature			
Severe wasting due to trichuriasis	Proportion from literature			
Asymptomatic trichuriasis	Proportion from literature			
Hookworm disease	(1) Bayesian geostatistical models of pre-control prevalence using environmental predictor variables; (2) post-control prevalence based on modelled reduction in prevalence due to preventive chemotherapy			
Heavy infestation of hookworm	Proportion from literature			
Mild abdominopelvic problems due to hookworm disease	Proportion from literature			
Severe wasting due to hookworm disease	Proportion from literature			
Mild anemia due to hookworm disease	(1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Moderate anemia due to hookworm disease	(1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Severe anemia due to hookworm disease	(1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Asymptomatic hookworm disease	Empirical proportion			
Food-borne trematodiasis				
Asymptomatic clonorchiasis	(1) DisMod-MR 2.0 of prevalence only; (2) assigning prevalence in countries with a known problem and national prevalence estimates; (3) disability awarded to proportion of cases with heavy infection from meta-analysis			
Asymptomatic fascioliasis	(1) DisMod-MR 2.0 of prevalence only; (2) assigning prevalence in countries with a known problem and national prevalence estimates; (3) disability awarded to proportion of cases with heavy infection from meta-analysis			
Asymptomatic intestinal fluke infection	(1) DisMod-MR 2.0 of prevalence only; (2) assigning prevalence in countries with a known problem and national prevalence estimates; (3) disability awarded to proportion of cases with heavy infection from meta-analysis			
Asymptomatic opisthorchiasis	(1) DisMod-MR 2.0 of prevalence only; (2) assigning prevalence in countries with a known problem and national prevalence estimates; (3) disability awarded to proportion of cases with heavy infection from meta-analysis			
Asymptomatic paragonimiasis	(1) DisMod-MR 2.0 of prevalence only; (2) assigning prevalence in countries with a known problem and national prevalence estimates; (3) disability awarded to proportion of cases with heavy infection from meta-analysis			
Heavy opisthorchiasis due to food-borne trematodiasis	(1) DisMod-MR 2.0 of prevalence only; (2) assigning prevalence in countries with a known problem and national prevalence estimates; (3) disability awarded to proportion of cases with heavy infection from meta-analysis			
Heavy clonorchiasis due to food-borne trematodiasis	(1) DisMod-MR 2.0 of prevalence only; (2) assigning prevalence in countries with a known problem and national prevalence estimates; (3) disability awarded to proportion of cases with heavy infection from meta-analysis			
Heavy intestinal fluke infection due to food-borne trematodiasis	(1) DisMod-MR 2.0 of prevalence only; (2) assigning prevalence in countries with a known problem and national prevalence estimates; (3) disability awarded to proportion of cases with heavy infection from meta-analysis			
Heavy fascioliasis due to food-borne trematodiasis	(1) DisMod-MR 2.0 of prevalence only; (2) assigning prevalence in countries with a known problem and national prevalence estimates; (3) disability awarded to proportion of cases with heavy infection from meta-analysis			
Heavy paragonimiasis due to food-borne trematodiasis	(1) DisMod-MR 2.0 of prevalence only; (2) assigning prevalence in countries with a known problem and national prevalence estimates; (3) disability awarded to proportion of cases with heavy infection from meta-analysis			
Cerebral paragonimiasis	(1) DisMod-MR 2.0 of prevalence only; (2) assigning prevalence in countries with a known problem and national prevalence estimates; (3) disability awarded to proportion of cases with cerebral paragonimiasis from literature			
Clonorchiasis due to food-borne trematodiasis all countries	DisMod-MR 2.0	0.81		
Fascioliasis due to food-borne trematodiasis all countries	DisMod-MR 2.0	1.00		
Intestinal fluke infection due to food-borne trematodiasis all countries	DisMod-MR 2.0	0.64		
Opisthorchiasis due to food-borne trematodiasis all countries	DisMod-MR 2.0	1.00		
Paragonimiasis due to food-borne trematodiasis all countries	DisMod-MR 2.0	0.66		
Other neglected tropical diseases				
Acute infection due to other neglected tropical diseases	Ratio of YLD from acute NTD infections to YLL for those conditions multiplied by YLL estimated for other NTD from CODEM modelling			
Mild anemia due to other neglected tropical diseases	(1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Moderate anemia due to other neglected tropical diseases	(1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			

Appendix Table A.4: Model type and fit metrics: R-squared				
Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
Severe anemia due to other neglected tropical diseases	(1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Maternal disorders				
Maternal hemorrhage	(1) DisMod-MR 2.0 of incidence per live birth; (2) multiplication of incidence by age-specific fertility rate to get incidence per population; (3) prevalence by multiplication of ..day duration		0.91	
Maternal hemorrhage (< 1L blood lost)	Meta-analysis			
Maternal hemorrhage (> 1L blood lost)	Meta-analysis			
Mild anemia due to maternal hemorrhage	(1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Moderate anemia due to maternal hemorrhage	(1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Severe anemia due to maternal hemorrhage	(1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Maternal sepsis and other maternal infections				
Puerperal sepsis	(1) DisMod-MR 2.0 of incidence per live birth; (2) multiplication of incidence by age-specific fertility rate to get incidence per population; (3) prevalence by multiplication of ..day duration		0.77	
Other maternal infections	(1) DisMod-MR 2.0 of incidence per live birth; (2) multiplication of incidence by age-specific fertility rate to get incidence per population; (3) prevalence by multiplication of ..day duration		0.67	
Infertility due to puerperal sepsis	(1) assume same proportion of risk of infertility after pelvic inflammatory disease applies to puerperal sepsis; (2) DisMod-MR 2.0 of incidence infertility after puerperal sepsis to stream out prevalence until age 50			
Maternal hypertensive disorders	(1) DisMod-MR 2.0 of incidence per live birth; (2) multiplication of incidence by age-specific fertility rate to get incidence per population; (3) prevalence by multiplication of ..day duration		0.72	
Other hypertensive disorders of pregnancy	Proportion from literature			
Severe pre-eclampsia	Proportion from literature			
Long term sequelae of severe pre-eclampsia	Meta-analysis			
Eclampsia	(1) DisMod-MR 2.0 of incidence per live birth; (2) multiplication of incidence by age-specific fertility rate to get incidence per population; (3) prevalence by multiplication of ..day duration		0.69	
Long term sequelae of eclampsia	Meta-analysis			
Obstructed labor				
Obstructed labor, acute event	(1) DisMod-MR 2.0 of incidence per live birth; (2) multiplication of incidence by age-specific fertility rate to get incidence per population; (3) prevalence by multiplication of ..day duration		0.82	
Fistula	DisMod-MR 2.0 of prevalence, incidence, remission and excess mortality	0.69		
Rectovaginal fistula	Proportion from literature			
Vesicovaginal fistula	Proportion from literature			
Complications of abortion				
Maternal abortive outcome	(1) DisMod-MR 2.0 of incidence per live birth; (2) multiplication of incidence by age-specific fertility rate to get incidence per population; (3) prevalence by multiplication of ..day duration		0.42	
Other maternal disorders	YLD to YLL ratio for stated maternal disorders multiplied by YLL from other maternal causes from CODEM			
Neonatal disorders				
Preterm birth complications	(1) mixed effect models of birth prevalence all preterm births by three gestational age categories: <28 weeks; 28-31.9 weeks and 32-36.9 weeks; (2) mixed effects models of case fatality proportion in first 28 days, proportion with mild long term impairment and proportion with moderate to severe long term impairment, each for three gestational age categories; (3) DisMod-MR 2.0 to stream out prevalence of moderate to severe long term problems from birth prevalence x (1- case fatality proportion) x probability of long term impairment and SMR data from cerebral palsy literature; 4) for mild impairment we assume no excess mortality and hence keep birth prevalence constant at all ages; (5) severity distribution between sequelae and combinations of sequelae from literature			
Asymptomatic retinopathy of prematurity	Meta-analysis			
Mild vision impairment due to retinopathy of prematurity	Meta-analysis			
Moderate vision impairment due to retinopathy of prematurity	Meta-analysis			
Severe vision impairment due to retinopathy of prematurity	Meta-analysis			
Blindness due to retinopathy of prematurity	Meta-analysis			
Mild motor impairment due to neonatal preterm birth complications <28wks	Proportion from literature			
Mild motor plus cognitive impairments due to neonatal preterm birth complications <28wks	Proportion from literature			
Mild motor impairment due to neonatal preterm birth complications 28-32wks	Proportion from literature			
Mild motor plus cognitive impairments due to neonatal preterm birth complications 28-32wks	Proportion from literature			
Mild motor impairment due to neonatal preterm birth complications 32-36wks	Proportion from literature			
Mild motor plus cognitive impairments due to neonatal preterm birth complications 32-36wks	Proportion from literature			
Moderate to severe impairment due to neonatal preterm birth complications <28wks	(1) mixed effect models of birth prevalence all preterm births <28 weeks; (2) mixed effects models of case fatality proportion in first 28 days and proportion with moderate to severe long term impairment; (3) DisMod-MR 2.0 to stream out prevalence of moderate to severe long term problems from birth prevalence x (1- case fatality proportion) x probability of long term impairment and SMR data from cerebral palsy literature	0.83		
Moderate motor impairment due to neonatal preterm birth complications <28wks	Proportion from literature			
Moderate motor impairment with blindness due to neonatal preterm birth complications <28wks	Proportion from literature			
Moderate motor impairment with epilepsy due to neonatal preterm birth complications <28wks	Proportion from literature			
Moderate motor impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks	Proportion from literature			
Moderate motor plus cognitive impairment with blindness due to neonatal preterm birth complications <28wks	Proportion from literature			
Moderate motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications <28wks	Proportion from literature			
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks	Proportion from literature			
Severe motor impairment due to neonatal preterm birth complications <28wks	Proportion from literature			
Severe motor impairment with blindness due to neonatal preterm birth complications <28wks	Proportion from literature			

Appendix Table A.4: Model type and fit metrics: R-squared				
Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
Severe motor impairment with epilepsy due to neonatal preterm birth complications <28wks	Proportion from literature			
Severe motor impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks	Proportion from literature			
Severe motor plus cognitive impairment with blindness due to neonatal preterm birth complications <28wks	Proportion from literature			
Severe motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications <28wks	Proportion from literature			
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks	Proportion from literature			
Moderate to severe impairment due to neonatal preterm birth complications 28-32wks	(1) mixed effect models of birth prevalence all preterm births 28-31.9 weeks; (2) mixed effects models of case fatality proportion in first 28 days and proportion with moderate to severe long term impairment; (3) DisMod-MR 2.0 to stream out prevalence of moderate to severe long term problems from birth prevalence x (1- case fatality proportion) x probability of long term impairment and SMR data from cerebral palsy literature	0.88		
Moderate motor impairment due to neonatal preterm birth complications 28-32wks	Proportion from literature			
Moderate motor impairment with blindness due to neonatal preterm birth complications 28-32wks	Proportion from literature			
Moderate motor impairment with epilepsy due to neonatal preterm birth complications 28-32wks	Proportion from literature			
Moderate motor impairment with blindness and epilepsy due to neonatal preterm birth complications 28-32wks	Proportion from literature			
Moderate motor plus cognitive impairment with blindness due to neonatal preterm birth complications 28-32wks	Proportion from literature			
Moderate motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications 28-32wks	Proportion from literature			
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications 28-32wks	Proportion from literature			
Severe motor impairment due to neonatal preterm birth complications 28-32wks	Proportion from literature			
Severe motor impairment with blindness due to neonatal preterm birth complications 28-32wks	Proportion from literature			
Severe motor impairment with epilepsy due to neonatal preterm birth complications 28-32wks	Proportion from literature			
Severe motor impairment with blindness and epilepsy due to neonatal preterm birth complications 28-32wks	Proportion from literature			
Severe motor plus cognitive impairment with blindness due to neonatal preterm birth complications 28-32wks	Proportion from literature			
Severe motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications 28-32wks	Proportion from literature			
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications 28-32wks	Proportion from literature			
Moderate to severe impairment due to neonatal preterm birth complications 32-36wks	(1) mixed effect models of birth prevalence all preterm births 32-36.9 weeks; (2) mixed effects models of case fatality proportion in first 28 days and proportion with moderate to severe long term impairment; (3) DisMod-MR 2.0 to stream out prevalence of moderate to severe long term problems from birth prevalence x (1- case fatality proportion) x probability of long term impairment and SMR data from cerebral palsy literature	0.72		
Moderate motor impairment due to neonatal preterm birth complications 32-36wks	Proportion from literature			
Moderate motor impairment with blindness due to neonatal preterm birth complications 32-36wks	Proportion from literature			
Moderate motor impairment with epilepsy due to neonatal preterm birth complications 32-36wks	Proportion from literature			
Moderate motor impairment with blindness and epilepsy due to neonatal preterm birth complications 32-36wks	Proportion from literature			
Moderate motor plus cognitive impairment with blindness due to neonatal preterm birth complications 32-36wks	Proportion from literature			
Moderate motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications 32-36wks	Proportion from literature			
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications 32-36wks	Proportion from literature			
Severe motor impairment due to neonatal preterm birth complications 32-36wks	Proportion from literature			
Severe motor impairment with blindness due to neonatal preterm birth complications 32-36wks	Proportion from literature			
Severe motor impairment with epilepsy due to neonatal preterm birth complications 32-36wks	Proportion from literature			
Severe motor impairment with blindness and epilepsy due to neonatal preterm birth complications 32-36wks	Proportion from literature			
Severe motor plus cognitive impairment with blindness due to neonatal preterm birth complications 32-36wks	Proportion from literature			
Severe motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications 32-36wks	Proportion from literature			
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications 32-36wks	Proportion from literature			
Neonatal encephalopathy due to birth asphyxia and trauma	(1) mixed effect models of birth prevalence, case fatality proportion in first 28 days, proportion with mild long term impairment and proportion with moderate to severe long term impairment; (2) for mild impairment we assume no excess mortality and hence keep birth prevalence constant at all ages; 3) DisMod-MR 2.0 to stream out prevalence of moderate to severe long term problems from birth prevalence x (1- case fatality proportion) x probability of long term impairment and SMR data from cerebral palsy literature; (4) severity distribution between sequelae and combinations of sequelae from literature			
Mild motor plus cognitive impairments due to neonatal encephalopathy due to birth asphyxia and trauma	Proportion from literature			
Mild motor impairment due to neonatal encephalopathy due to birth asphyxia and trauma	Proportion from literature			

Appendix Table A.4: Model type and fit metrics: R-squared				
Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
Moderate to severe impairment due to neonatal encephalopathy due to birth asphyxia and trauma	(1) mixed effect models of birth prevalence, case fatality proportion in first 28 days and proportion with moderate to severe long term impairment; (2) DisMod-MR 2.0 to stream out prevalence of moderate to severe long term problems from birth prevalence x (1- case fatality proportion) x probability of long term impairment and SMR data from cerebral palsy literature	0.99		
Moderate motor impairment due to neonatal encephalopathy due to birth asphyxia and trauma	Proportion from literature			
Moderate motor impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma	Proportion from literature			
Moderate motor impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	Proportion from literature			
Moderate motor impairment with blindness and epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	Proportion from literature			
Moderate motor plus cognitive impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma	Proportion from literature			
Moderate motor plus cognitive impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	Proportion from literature			
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	Proportion from literature			
Severe motor impairment due to neonatal encephalopathy due to birth asphyxia and trauma	Proportion from literature			
Severe motor impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma	Proportion from literature			
Severe motor impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	Proportion from literature			
Severe motor impairment with blindness and epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	Proportion from literature			
Severe motor plus cognitive impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma	Proportion from literature			
Severe motor plus cognitive impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	Proportion from literature			
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	Proportion from literature			
Neonatal sepsis and other neonatal infections				
Severe infection due to neonatal sepsis and other neonatal infections	Natural history model of deaths from CODEM divided by 28-day case fatality proportion data from neonatal meningitis literature	0.97		
Hemolytic disease and other neonatal jaundice	1) mixed effects models of prevalence of Rh negativity; Rhogam doses distributed to countries in 2010; and proportion of children who are not firstborn; 2) proportion of Rh-incompatibility exposed who develop kernicterus from literature; 3) proportions from literature on risk of extreme hyperbilirubinemia in babies born with G6PD, pre-term babies and all other babies; 4) proportions from literature on risk of kernicterus in babies with extreme hyperbilirubinemia; 5) DisMod-MR 2.0 to stream out prevalence of moderate to severe long term outcomes from data on birth prevalence of kernicterus (steps 1-4) and SMR data from cerebral palsy literature			
Long-term, moderate, or severe consequences due to neonatal jaundice	DisMod-MR 2.0	0.78		
Moderate motor impairment due to hemolytic disease and other neonatal jaundice	Proportion from literature			
Moderate motor impairment with blindness due to hemolytic disease and other neonatal jaundice	Proportion from literature			
Moderate motor impairment with epilepsy due to hemolytic disease and other neonatal jaundice	Proportion from literature			
Moderate motor impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice	Proportion from literature			
Moderate motor plus cognitive impairment with blindness due to hemolytic disease and other neonatal jaundice	Proportion from literature			
Moderate motor plus cognitive impairment with epilepsy due to hemolytic disease and other neonatal jaundice	Proportion from literature			
Moderate motor plus cognitive impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice	Proportion from literature			
Severe motor impairment severe due to hemolytic disease and other neonatal jaundice	Proportion from literature			
Severe motor impairment with blindness due to hemolytic disease and other neonatal jaundice	Proportion from literature			
Severe motor impairment with epilepsy due to hemolytic disease and other neonatal jaundice	Proportion from literature			
Severe motor impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice	Proportion from literature			
Severe motor plus cognitive impairment with blindness due to hemolytic disease and other neonatal jaundice	Proportion from literature			
Severe motor plus cognitive impairment with epilepsy due to hemolytic disease and other neonatal jaundice	Proportion from literature			
Severe motor plus cognitive impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice	Proportion from literature			
Other neonatal disorders	YLD to YLL ratio for stated neonatal disorders applied to YLL of other neonatal conditions from CODEM analyses			
Nutritional deficiencies				
Protein-energy malnutrition				
Kwashiorkor due to protein-energy malnutrition	Natural history model of CODEM deaths, case fatality and average duration			
Marasmus due to protein-energy malnutrition	Natural history model of CODEM deaths, case fatality and average duration			
Severe wasting due to protein-energy malnutrition	Gaussian process regression of anthropometric data of prevalence 3 z scores below mean on weight for height			
Iodine deficiency				
Goiter due to iodine deficiency	DisMod-MR 2.0 of prevalence only	0.70		
Visible goiter without symptoms	Proportion from literature			
Visible goiter without heart failure due to iodine deficiency	Proportion from literature			

Appendix Table A.4: Model type and fit metrics: R-squared				
Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
Visible goiter with mild heart failure due to iodine deficiency	Proportion of visible goitre from literature and for heart failure: (1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to endocarditis (3) MEPS analysis of severity distribution of all heart failure			
Visible goiter with moderate heart failure due to iodine deficiency	Proportion of visible goitre from literature and for heart failure: (1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to endocarditis (3) MEPS analysis of severity distribution of all heart failure			
Visible goiter with severe heart failure due to iodine deficiency	Proportion of visible goitre from literature and for heart failure: (1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to endocarditis (3) MEPS analysis of severity distribution of all heart failure			
Visible goiter with signs and symptoms	Proportion from literature			
Intellectual disability due to iodine deficiency	DisMod-MR 2.0		0.97	
Severe intellectual disability due to iodine deficiency	(1) regression model of ratio of cretinism incidence to goitre prevalence; (2) DisMod-MR 2.0 of incidence from step (1) to stream out prevalence; (3) proportion of severe and profound intellectual disability from envelope of intellectual disability			
Profound intellectual disability due to iodine deficiency	(1) regression model of ratio of cretinism incidence to goitre prevalence; (2) DisMod-MR 2.0 of incidence from step (1) to stream out prevalence; (3) proportion of severe and profound intellectual disability from envelope of intellectual disability			
Vitamin A deficiency				
Vision loss due to vitamin A deficiency	DisMod-MR 2.0 of proportion of all vision loss in countries that are known to have vitamin A deficiency	0.46		
Moderate vision impairment loss due to vitamin A deficiency	(1) DisMod-MR 2.0 of proportion of all vision loss in countries that are known to have vitamin A deficiency; (2) split between moderate and severe vision loss and blindness from vision loss envelope			
Severe vision impairment loss due to vitamin A deficiency	(1) DisMod-MR 2.0 of proportion of all vision loss in countries that are known to have vitamin A deficiency; (2) split between moderate and severe vision loss and blindness from vision loss envelope			
Blindness due to vitamin A deficiency	(1) DisMod-MR 2.0 of proportion of all vision loss in countries that are known to have vitamin A deficiency; (2) split between moderate and severe vision loss and blindness from vision loss envelope			
Iron-deficiency anemia				
Mild iron-deficiency anemia	(1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) age- and sex-specific redistribution to determine aetiology-specific overall anemia prevalence; (4) Bayesian contingency table modeling of severity distribution for each cause			
Moderate iron-deficiency anemia	(1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) age- and sex-specific redistribution to determine aetiology-specific overall anemia prevalence; (4) Bayesian contingency table modeling of severity distribution for each cause			
Severe iron-deficiency anemia	(1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) age- and sex-specific redistribution to determine aetiology-specific overall anemia prevalence; (4) Bayesian contingency table modeling of severity distribution for each cause			
Mild heart failure due to iron-deficiency anemia	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to endocarditis (3) MEPS analysis of severity distribution of all heart failure			
Moderate heart failure due to iron-deficiency anemia	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to endocarditis (3) MEPS analysis of severity distribution of all heart failure			
Severe heart failure due to iron-deficiency anemia	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to endocarditis (3) MEPS analysis of severity distribution of all heart failure			
Other nutritional deficiencies	YLD to YLL ratio of protein-energy malnutrition applied to YLL for other nutritional disorders			
Other communicable, maternal, neonatal, and nutritional diseases				
Sexually transmitted diseases excluding HIV				
Syphilis				
Adult tertiary syphilis	DisMod-MR 2.0	0.71		
Chlamydial infection	DisMod-MR 2.0 of incidence	0.56		
Asymptomatic chlamydial infection	Meta-analysis			
Mild chlamydial infection	Meta-analysis			
Epididymo-orchitis due to chlamydial infection	Meta-analysis			
Pelvic inflammatory diseases due to chlamydial infection	(1) DisMod-MR 2.0 incidence all pelvic inflammatory disease with remission setting reflecting average duration of 3-4 weeks; (2) DisMod-MR 2.0 proportion PID due to chlamydia			0.72
Moderate pelvic inflammatory diseases due to chlamydial infection	Meta-analysis			
Severe pelvic inflammatory diseases due to chlamydial infection	Meta-analysis			
Primary infertility due to chlamydial infection	(1) proportion of risk of infertility from literature applied to incidence of PID DisMod-MR 2.0 model; (2) prevalence of infertility streamed out from incidence in step (1) across fertile age range; (3) after subtracting causes that only cause primary infertility (Turner syndrome) or secondary infertility (maternal sepsis) the ratio of the remaining prevalence of primary and secondary infertility is applied to the prevalence of infertility from step (2)			
Secondary infertility due to chlamydial infection	(1) proportion of risk of infertility from literature applied to incidence of PID DisMod-MR 2.0 model; (2) prevalence of infertility streamed out from incidence in step (1) across fertile age range; (3) after subtracting causes that only cause primary infertility (Turner syndrome) or secondary infertility (maternal sepsis) the ratio of the remaining prevalence of primary and secondary infertility is applied to the prevalence of infertility from step (2)			
Gonococcal infection	DisMod-MR 2.0	0.67		
Asymptomatic gonococcal infection	Meta-analysis			
Mild gonococcal infection	Meta-analysis			
Epididymo-orchitis due to gonococcal infection	Meta-analysis			
Pelvic inflammatory diseases due to gonococcal infection	(1) DisMod-MR 2.0 incidence all pelvic inflammatory disease with remission setting reflecting average duration of 3-4 weeks; (2) DisMod-MR 2.0 proportion PID due to gonorrhoea			0.44
Moderate pelvic inflammatory diseases due to gonococcal infection	Meta-analysis			
Severe pelvic inflammatory diseases due to gonococcal infection	Meta-analysis			
Primary infertility due to gonococcal infection	(1) proportion of risk of infertility from literature applied to incidence of PID DisMod-MR 2.0 model; (2) prevalence of infertility streamed out from incidence in step (1) across fertile age range; (3) after subtracting causes that only cause primary infertility (Turner syndrome) or secondary infertility (maternal sepsis) the ratio of the remaining prevalence of primary and secondary infertility is applied to the prevalence of infertility from step (2)			
Secondary infertility due to gonococcal infection	(1) proportion of risk of infertility from literature applied to incidence of PID DisMod-MR 2.0 model; (2) prevalence of infertility streamed out from incidence in step (1) across fertile age range; (3) after subtracting causes that only cause primary infertility (Turner syndrome) or secondary infertility (maternal sepsis) the ratio of the remaining prevalence of primary and secondary infertility is applied to the prevalence of infertility from step (2)			
Trichomoniasis	DisMod-MR 2.0	0.71		
Asymptomatic trichomoniasis infection	Meta-analysis			
Acute trichomoniasis infection	Meta-analysis			
Genital herpes	DisMod-MR 2.0	0.62	0.44	
Asymptomatic genital herpes	Meta-analysis			
Symptomatic genital herpes	Meta-analysis			
Moderate infection due to initial genital herpes episode	Meta-analysis			
Other sexually transmitted diseases				
Pelvic inflammatory diseases due to other sexually transmitted diseases	(1) DisMod-MR 2.0 incidence all pelvic inflammatory disease with remission setting reflecting average duration of 3-4 weeks; (2) DisMod-MR 2.0 proportion PID due to other STDs			0.41

Appendix Table A.4: Model type and fit metrics: R-squared				
Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
Moderate pelvic inflammatory diseases due to other sexually transmitted diseases	Meta-analysis			
Severe pelvic inflammatory diseases due to other sexually transmitted diseases	Meta-analysis			
Primary infertility due to other sexually transmitted diseases	(1) proportion of risk of infertility from literature applied to incidence of PID DisMod-MR 2.0 model; (2) prevalence of infertility streamed out from incidence in step (1) across fertile age range; (3) after subtracting causes that only cause primary infertility (Turner syndrome) or secondary infertility (maternal sepsis) the ratio of the remaining prevalence of primary and secondary infertility is applied to the prevalence of infertility from step (2)			
Secondary infertility due to other sexually transmitted diseases	(1) proportion of risk of infertility from literature applied to incidence of PID DisMod-MR 2.0 model; (2) prevalence of infertility streamed out from incidence in step (1) across fertile age range; (3) after subtracting causes that only cause primary infertility (Turner syndrome) or secondary infertility (maternal sepsis) the ratio of the remaining prevalence of primary and secondary infertility is applied to the prevalence of infertility from step (2)			
Hepatitis				
Hepatitis A	catalytic Binomial Model of sero-prevalence	0.34		
Asymptomatic acute hepatitis A	Meta-analysis			
Mild acute hepatitis A	Meta-analysis of proportion symptomatic and proportion from literature on level of severity			
Moderate acute hepatitis A	Meta-analysis of proportion symptomatic and proportion from literature on level of severity			
Severe acute hepatitis A	Meta-analysis of proportion symptomatic and proportion from literature on level of severity			
Hepatitis B	(1) DisMod-MR 2.0 of seroprevalence Hb surface antigen; (2) division of (1) results by age-specific proportions who become chronic carrier; (3) assumed duration of 6 weeks for symptomatic cases	0.70		
Asymptomatic acute hepatitis B	Proportion from literature			
Moderate acute hepatitis B	Proportion from literature			
Severe acute hepatitis B	Proportion from literature			
Chronic Hepatitis B	Meta-analysis			
Hepatitis C	(1) DisMod-MR 2.0 of seroprevalence of anti-HCV; (3) assumed duration of 6 weeks for symptomatic cases	0.97		
Asymptomatic acute hepatitis C	Empirical proportion			
Moderate acute hepatitis C	Empirical proportion			
Severe acute hepatitis C	Empirical proportion			
Chronic Hepatitis C	Meta-analysis			
Hepatitis E	(1) DisMod-MR 2.0 of seroprevalence of anti hepatitis E; (2) assumed duration of 4 weeks in those symptomatic	0.60		
Asymptomatic acute hepatitis E	Empirical proportion			
Moderate acute hepatitis E	Empirical proportion			
Severe acute hepatitis E	Empirical proportion			
Leprosy	DisMod-MR 2.0		0.96	
Disfigurement level 1 due to leprosy	Empirical proportion			
Disfigurement level 2 due to leprosy	Empirical proportion			
Other infectious diseases				
Acute other infectious diseases	YLD to YLL ratio for all acute infectious disease health states applied to YLL from acute other infectious diseases			
Mild anemia due to other infectious diseases	(1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) age- and sex-specific redistribution to determine aetiology-specific overall anemia prevalence; (4) Bayesian contingency table modeling of severity distribution for each cause			
Moderate anemia due to other infectious diseases	(1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) age- and sex-specific redistribution to determine aetiology-specific overall anemia prevalence; (4) Bayesian contingency table modeling of severity distribution for each cause			
Severe anemia due to other infectious diseases	(1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) age- and sex-specific redistribution to determine aetiology-specific overall anemia prevalence; (4) Bayesian contingency table modeling of severity distribution for each cause			
Guillain-Barré syndrome due to other infectious diseases	DisMod-MR 2.0 of incidence and remission data all GBS + meta-analysis of proportion of all cases following other infectious disease			
Non-communicable diseases				
Neoplasms				
Esophageal cancer	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data Duration based on literature review		0.97	
Diagnosis and primary therapy phase of esophageal cancer	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Controlled phase of esophageal cancer	Duration based on SEER data			
Metastatic phase of esophageal cancer	Last month of life in fatal cases			
Terminal phase of esophageal cancer	Last month of life in fatal cases			
Stomach cancer	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data Duration based on literature review		0.94	
Diagnosis and primary therapy phase of stomach cancer	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Controlled phase of stomach cancer	Duration based on SEER data			
Metastatic phase of stomach cancer	Last month of life in fatal cases			
Terminal phase of stomach cancer	Last month of life in fatal cases			
Liver cancer			0.96	
Liver cancer due to hepatitis B	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data; (3) DisMod-MR 2.0 of proportion of liver cancer due to hepatitis B			0.73
Diagnosis and primary therapy phase of liver cancer due to hepatitis B	Duration based on literature review			
Controlled phase of liver cancer due to hepatitis B	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of liver cancer due to hepatitis B	Duration based on SEER data			
Terminal phase of liver cancer due to hepatitis B	Last month of life in fatal cases			
Liver cancer due to hepatitis C	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data; (3) DisMod-MR 2.0 of proportion of liver cancer due to hepatitis C			0.63
Diagnosis and primary therapy phase of liver cancer due to hepatitis C	Duration based on literature review			
Controlled phase of liver cancer due to hepatitis C	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of liver cancer due to hepatitis C	Duration based on SEER data			
Terminal phase of liver cancer due to hepatitis C	Last month of life in fatal cases			
Liver cancer due to alcohol use	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data; (3) DisMod-MR 2.0 of proportion of liver cancer due to alcohol			0.55
Diagnosis and primary therapy phase of liver cancer due to alcohol use	Duration based on literature review			

Appendix Table A.4: Model type and fit metrics: R-squared

Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
Controlled phase of liver cancer due to alcohol use	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of liver cancer due to alcohol use	Duration based on SEER data			
Terminal phase of liver cancer due to alcohol use	Last month of life in fatal cases			
Liver cancer due to other causes	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data; (3) DisMod-MR 2.0 of proportion of liver cancer due to other causes			0.73
Diagnosis and primary therapy phase of liver cancer due to other causes	Duration based on literature review			
Controlled phase of liver cancer due to other causes	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of liver cancer due to other causes	Duration based on SEER data			
Terminal phase of liver cancer due to other causes	Last month of life in fatal cases			
Larynx cancer	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.97	0.80
Diagnosis and primary therapy phase of larynx cancer	Duration based on literature review			
Controlled phase of larynx cancer	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of larynx cancer	Duration based on SEER data			
Terminal phase of larynx cancer	Last month of life in fatal cases			
Laryngectomy due to larynx cancer	(1) DisMod-MR 2.0 of proportion of cases undergoing laryngectomy applied to incident cases; (2) DisMod-MR 2.0 to stream out prevalence in those who survive and average duration applied to those who do not survive		0.97	
Tracheal, bronchus and lung cancer	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.98	
Diagnosis and primary therapy phase of lung, bronchus, and trachea cancer	Duration based on literature review			
Controlled phase of lung, bronchus, and trachea cancer	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of lung, bronchus, and trachea cancer	Duration based on SEER data			
Terminal phase of lung, bronchus, and trachea cancer	Last month of life in fatal cases			
Breast cancer	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.99	0.96
Diagnosis and primary therapy phase of breast cancer	Duration based on literature review			
Controlled phase of breast cancer	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of breast cancer	Duration based on SEER data			
Terminal phase of breast cancer	Last month of life in fatal cases			
Mastectomy due to breast cancer	(1) DisMod-MR 2.0 of proportion of cases undergoing mastectomy applied to incident cases; (2) DisMod-MR 2.0 to stream out prevalence in those who survive and average duration applied to those who do not survive		0.99	
Cervical cancer	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.94	
Diagnosis and primary therapy phase of cervical cancer	Duration based on literature review			
Controlled phase of cervical cancer	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of cervical cancer	Duration based on SEER data			
Terminal phase of cervical cancer	Last month of life in fatal cases			
Uterine cancer	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.92	
Diagnosis and primary therapy phase of uterine cancer	Duration based on literature review			
Controlled phase of uterine cancer	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of uterine cancer	Duration based on SEER data			
Terminal phase of uterine cancer	Last month of life in fatal cases			
Prostate cancer	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.99	0.97
Diagnosis and primary therapy phase of prostate cancer	Duration based on literature review			
Controlled phase of prostate cancer	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of prostate cancer	Duration based on SEER data			
Terminal phase of prostate cancer	Last month of life in fatal cases			
Impotence and incontinence due to prostate cancer	(1) DisMod-MR 2.0 of proportion of cases with impotence and/or incontinence applied to incident cases; (2) DisMod-MR 2.0 to stream out prevalence in those who survive and average duration applied to those who do not survive		0.99	
Impotence due to prostate cancer	Proportion from literature			
Incontinence due to prostate cancer	Proportion from literature			
Colon and rectum cancer	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.96	0.87
Diagnosis and primary therapy phase of colon and rectum cancers	Duration based on literature review			
Controlled phase of colon and rectum cancers	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of colon and rectum cancers	Duration based on SEER data			
Terminal phase of colon and rectum cancers	Last month of life in fatal cases			
Stoma due to colon and rectum cancer	(1) DisMod-MR 2.0 of proportion of cases with stoma applied to incident cases; (2) DisMod-MR 2.0 to stream out prevalence in those who survive and average duration applied to those who do not survive			
Lip and oral cavity cancer	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.91	
Diagnosis and primary therapy phase of mouth cancer	Duration based on literature review			
Controlled phase of mouth cancer	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of mouth cancer	Duration based on SEER data			
Terminal phase of mouth cancer	Last month of life in fatal cases			
Nasopharynx cancer	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.93	
Diagnosis and primary therapy phase of nasopharynx cancer	Duration based on literature review			
Controlled phase of nasopharynx cancer	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of nasopharynx cancer	Duration based on SEER data			
Terminal phase of nasopharynx cancer	Last month of life in fatal cases			
Other pharynx cancer	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.96	

Appendix Table A.4: Model type and fit metrics: R-squared				
Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
Diagnosis and primary therapy phase of other pharynx cancer	Duration based on literature review			
Controlled phase of other pharynx cancer	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of other pharynx cancer	Duration based on SEER data			
Terminal phase of other pharynx cancer	Last month of life in fatal cases			
Gallbladder and biliary tract cancer	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.95	
Diagnosis and primary therapy phase of gallbladder and biliary tract cancer	Duration based on literature review			
Controlled phase of gallbladder and biliary tract cancer	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of gallbladder and biliary tract cancer	Duration based on SEER data			
Terminal phase of gallbladder and biliary tract cancer	Last month of life in fatal cases			
Pancreatic cancer	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.97	
Diagnosis and primary therapy phase of pancreatic cancer	Duration based on literature review			
Controlled phase of pancreatic cancer	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of pancreatic cancer	Duration based on SEER data			
Terminal phase of pancreatic cancer	Last month of life in fatal cases			
Malignant skin melanoma	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.96	
Diagnosis and primary therapy phase of malignant skin melanoma	Duration based on literature review			
Controlled phase of malignant skin melanoma	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of malignant skin melanoma	Duration based on SEER data			
Terminal phase of malignant skin melanoma	Last month of life in fatal cases			
Non-melanoma skin cancer	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.90	
Cutaneous squamous cell carcinoma	Duration based on literature review			
Diagnosis and primary therapy phase of cutaneous squamous cell carcinoma	Duration based on literature review			
Control phase of cutaneous squamous cell carcinoma	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of cutaneous squamous cell carcinoma	Duration based on SEER data			
Terminal phase of cutaneous squamous cell carcinoma	Last month of life in fatal cases			
Basal cell carcinoma	(1) duration estimated to vary between 1 and 10 years using covariate of health system access to differentiate estimates by country and year; DisMod-MR 2.0 of incidence and remission (inverse of duration estimates from (1))		0.98	
Disfigurement due to basal cell carcinoma	Proportion from literature			
Ovarian cancer	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.94	
Diagnosis and primary therapy phase of ovarian cancer	Duration based on literature review			
Controlled phase of ovarian cancer	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of ovarian cancer	Duration based on SEER data			
Terminal phase of ovarian cancer	Last month of life in fatal cases			
Testicular cancer	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.95	
Diagnosis and primary therapy phase of testicular cancer	Duration based on literature review			
Controlled phase of testicular cancer	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of testicular cancer	Duration based on SEER data			
Terminal phase of testicular cancer	Last month of life in fatal cases			
Kidney cancer	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.92	
Diagnosis and primary therapy phase of kidney cancer	Duration based on literature review			
Controlled phase of kidney cancer	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of kidney cancer	Duration based on SEER data			
Terminal phase of kidney cancer	Last month of life in fatal cases			
Bladder cancer	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.96	
Diagnosis and primary therapy phase of bladder cancer	Duration based on literature review			
Controlled phase of bladder cancer	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of bladder cancer	Duration based on SEER data			
Terminal phase of bladder cancer	Last month of life in fatal cases			
Urinary incontinence due to bladder cancer	DisMod-MR 2.0 proportion with urinary incontinence applied to incident cases; (2) DisMod-MR 2.0 to stream out prevalence in those who survive and average duration applied to those who do not survive		0.92	
Brain and nervous system cancer	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.93	
Diagnosis and primary therapy phase of brain and nervous system cancers	Duration based on literature review			
Controlled phase of brain and nervous system cancers	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of brain and nervous system cancers	Duration based on SEER data			
Terminal phase of brain and nervous system cancers	Last month of life in fatal cases			
Thyroid cancer	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.88	
Diagnosis and primary therapy phase of thyroid cancer	Duration based on literature review			
Controlled phase of thyroid cancer	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of thyroid cancer	Duration based on SEER data			
Terminal phase of thyroid cancer	Last month of life in fatal cases			
Mesothelioma	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.94	

Appendix Table A.4: Model type and fit metrics: R-squared				
Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
Diagnosis and primary therapy phase of mesothelioma	Duration based on literature review			
Controlled phase of mesothelioma	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of mesothelioma	Duration based on SEER data			
Terminal phase of mesothelioma	Last month of life in fatal cases			
Hodgkin lymphoma	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.90	
Diagnosis and primary therapy phase of Hodgkin disease	Duration based on literature review			
Controlled phase of Hodgkin disease	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of Hodgkin disease	Duration based on SEER data			
Terminal phase of Hodgkin disease	Last month of life in fatal cases			
Non-Hodgkin lymphoma	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.85	
Diagnosis and primary therapy phase of non-Hodgkin lymphoma	Duration based on literature review			
Controlled phase of non-Hodgkin lymphoma	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of non-Hodgkin lymphoma	Duration based on SEER data			
Terminal phase of non-Hodgkin lymphoma	Last month of life in fatal cases			
Multiple myeloma	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.95	
Diagnosis and primary therapy phase of multiple myeloma	Duration based on literature review			
Controlled phase of multiple myeloma	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of multiple myeloma	Duration based on SEER data			
Terminal phase of multiple myeloma	Last month of life in fatal cases			
Leukemia	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.93	
Diagnosis and primary therapy phase of leukemia	Duration based on literature review			
Controlled phase of leukemia	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of leukemia	Duration based on SEER data			
Terminal phase of leukemia	Last month of life in fatal cases			
Other neoplasms	(1) custom model to generate incidence using incidence and mortality to incidence ratios from cancer registries and deaths estimated in CODEM; (2) prevalence estimated from survival data		0.93	
Diagnosis and primary therapy phase of other neoplasms	Duration based on literature review			
Controlled phase of other neoplasms	Duration by subtraction of sum of durations of the other three health states in fatal cases and by subtraction from 10 years for those who survive			
Metastatic phase of other neoplasms	Duration based on SEER data			
Terminal phase of other neoplasms	Last month of life in fatal cases			
Cardiovascular diseases				
Rheumatic heart disease	DisMod-MR 2.0 of prevalence run separately for data from high and low income countries to better reflect differences in age pattern			
Rheumatic heart disease - Low income	DisMod-MR 2.0	0.56		
Rheumatic heart disease - High income	DisMod-MR 2.0	0.93		
Rheumatic heart disease, without heart failure	subtraction of heart failure cases from DisMod-MR 2.0 prevalence of all rheumatic heart disease			
Mild heart failure due to rheumatic heart disease	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to rheumatic heart disease; (3) MEPS analysis of severity distribution of all heart failure			
Moderate heart failure due to rheumatic heart disease	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to rheumatic heart disease; (3) MEPS analysis of severity distribution of all heart failure			
Severe heart failure due to rheumatic heart disease	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to rheumatic heart disease; (3) MEPS analysis of severity distribution of all heart failure			
Ischemic heart disease				
Myocardial infarction due to ischemic heart disease	(1) Proportional model of CODEM deaths from ischemic heart disease that are due to myocardial infarction; (2) DisMod-MR 2.0 of incidence, excess mortality and cause-specific mortality due to myocardial infarction and remission assumption to reflect 28 duration		0.95	
Asymptomatic ischemic heart disease following myocardial infarction	Empirical proportion			
Acute myocardial infarction first 2 days	application of higher disability weight for the first two days following myocardial infarction			
Acute myocardial infarction 3 to 28 days	application of lower disability weight days 3-28 following myocardial infarction			
Angina due to ischemic heart disease	DisMod-MR 2.0 of prevalence, incidence, excess mortality	0.62		
Asymptomatic angina due to ischemic heart disease	MEPS regression analysis	0.43		
Mild angina due to ischemic heart disease	MEPS regression analysis	0.43		
Moderate angina due to ischemic heart disease	MEPS regression analysis	0.43		
Severe angina due to ischemic heart disease	MEPS regression analysis	0.43		
Mild heart failure due to ischemic heart disease	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to ischemic heart disease; (3) MEPS analysis of severity distribution of all heart failure			
Moderate heart failure due to ischemic heart disease	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to ischemic heart disease; (3) MEPS analysis of severity distribution of all heart failure			
Severe heart failure due to ischemic heart disease	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to ischemic heart disease; (3) MEPS analysis of severity distribution of all heart failure			
MI to IHD ratio	intermediate model of ratio deaths coded to myocardial infarction to all deaths from ischemic heart disease			0.95
Cerebrovascular disease				
Cerebrovascular disease acute first ever	DisMod-MR 2.0		0.96	
Cerebrovascular disease acute	DisMod-MR 2.0		0.96	
Cerebrovascular disease chronic	DisMod-MR 2.0	0.79	0.99	
Ischemic stroke				
Asymptomatic chronic ischemic stroke	MEPS regression analysis	0.43		
Chronic ischemic stroke severity level 1	MEPS regression analysis	0.43		
Chronic ischemic stroke severity level 2	MEPS regression analysis	0.43		
Chronic ischemic stroke severity level 4	MEPS regression analysis	0.43		
Chronic ischemic stroke severity level 3	MEPS regression analysis	0.43		
Chronic ischemic stroke severity level 5	MEPS regression analysis	0.43		

Appendix Table A.4: Model type and fit metrics: R-squared				
Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
Acute ischemic stroke first ever	DisMod-MR 2.0		0.95	
Acute ischemic stroke	(1) split CODEM cause-specific mortality due to stroke into mortality from early and late stroke deaths based on estimated cause specific mortality from an early iteration of DisMod-MR 2.0 models of acute and chronic stroke; (2) DisMod-MR 2.0 of incidence of acute ischemic stroke, excess mortality and remission setting to reflect 28 day duration; (3) result from acute ischemic and hemorrhagic stroke DisMod models scaled to prevalence from another DisMod-MR 2.0 model of incidence of all stroke, excess mortality and cause-specific mortality due to acute stroke from (1)		0.95	
Acute ischemic stroke severity level 1	MEPS regression analysis	0.43		
Acute ischemic stroke severity level 2	MEPS regression analysis	0.43		
Acute ischemic stroke severity level 4	MEPS regression analysis	0.43		
Acute ischemic stroke severity level 3	MEPS regression analysis	0.43		
Acute ischemic stroke severity level 5	MEPS regression analysis	0.43		
Hemorrhagic stroke				
Asymptomatic chronic hemorrhagic stroke	MEPS regression analysis	0.43		
Chronic hemorrhagic stroke severity level 1	MEPS regression analysis	0.43		
Chronic hemorrhagic stroke severity level 2	MEPS regression analysis	0.43		
Chronic hemorrhagic stroke severity level 4	MEPS regression analysis	0.43		
Chronic hemorrhagic stroke severity level 3	MEPS regression analysis	0.43		
Chronic hemorrhagic stroke severity level 5	MEPS regression analysis	0.43		
Acute hemorrhagic stroke first ever	DisMod-MR 2.0		0.84	
Acute hemorrhagic stroke	(1) split CODEM cause-specific mortality due to stroke into mortality from early and late stroke deaths based on estimated cause specific mortality from an early iteration of DisMod-MR 2.0 models of acute and chronic stroke; (2) DisMod-MR 2.0 of incidence of acute hemorrhagic stroke, excess mortality and remission setting to reflect 28 day duration; (3) result from acute ischemic and hemorrhagic stroke DisMod models scaled to prevalence from another DisMod-MR 2.0 model of incidence of all stroke, excess mortality and cause-specific mortality due to acute stroke from (1)		0.85	
Acute hemorrhagic stroke severity level 1	MEPS regression analysis	0.43		
Acute hemorrhagic stroke severity level 2	MEPS regression analysis	0.43		
Acute hemorrhagic stroke severity level 4	MEPS regression analysis	0.43		
Acute hemorrhagic stroke severity level 3	MEPS regression analysis	0.43		
Acute hemorrhagic stroke severity level 5	MEPS regression analysis	0.43		
Hypertensive heart disease				0.52
Mild heart failure due to hypertensive heart disease	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to hypertensive heart disease; (3) MEPS analysis of severity distribution of all heart failure			
Moderate heart failure due to hypertensive heart disease	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to hypertensive heart disease; (3) MEPS analysis of severity distribution of all heart failure			
Severe heart failure due to hypertensive heart disease	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to hypertensive heart disease; (3) MEPS analysis of severity distribution of all heart failure			
Cardiomyopathy and myocarditis				
Acute myocarditis	DisMod-MR 2.0 of incidence only model and estimation of prevalence based on duration of 3 months		0.95	
Mild heart failure due to cardiomyopathy and myocarditis	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to cardiomyopathy; (3) MEPS analysis of severity distribution of all heart failure			
Moderate heart failure due to cardiomyopathy and myocarditis	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to cardiomyopathy; (3) MEPS analysis of severity distribution of all heart failure			
Severe heart failure due to cardiomyopathy and myocarditis	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to cardiomyopathy; (3) MEPS analysis of severity distribution of all heart failure			
Atrial fibrillation and flutter	DisMod-MR 2.0 of incidence, prevalence and excess mortality data and remission set to zero	0.67	0.78	
Asymptomatic atrial fibrillation and flutter	MEPS regression analysis	0.43		
Symptomatic atrial fibrillation and flutter	MEPS regression analysis	0.43		
Peripheral vascular disease	DisMod-MR 2.0 prevalence Ankle Brachial Index <0.9	0.79		
Proportion of peripheral vascular disease with intermittent claudication	DisMod-MR 2.0 of proportion Ankle Brachial Index <0.9 who report symptoms of claudication			0.50
Asymptomatic peripheral vascular disease	(1) DisMod-MR 2.0 all cases with Ankle Brachial Index <0.9; (2) DisMod-MR 2.0 proportion of people with ABI<.9 who report symptoms; (3) multiplication of results from step (1) by 1 minus results from step (2)			
Symptomatic claudication due to peripheral vascular disease	(1) DisMod-MR 2.0 all cases with Ankle Brachial Index <0.9; (2) DisMod-MR 2.0 proportion of people with ABI<.9 who report symptoms; (3) multiplication of results from step (1) by results from step (2)			
Endocarditis	DisMod-MR 2.0 incidence, excess mortality and remission		0.83	
Moderate endocarditis	Proportion from literature			
Severe endocarditis	Proportion from literature			
Mild heart failure due to endocarditis	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to endocarditis (3) MEPS analysis of severity distribution of all heart failure			
Moderate heart failure due to endocarditis	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to endocarditis (3) MEPS analysis of severity distribution of all heart failure			
Severe heart failure due to endocarditis	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to endocarditis (3) MEPS analysis of severity distribution of all heart failure			
Other cardiovascular and circulatory diseases				
Mild heart failure due to other cardiovascular diseases	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to other cardiovascular diseases (3) MEPS analysis of severity distribution of all heart failure			
Moderate heart failure due to other cardiovascular diseases	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to other cardiovascular diseases (3) MEPS analysis of severity distribution of all heart failure			
Severe heart failure due to other cardiovascular diseases	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to other cardiovascular diseases (3) MEPS analysis of severity distribution of all heart failure			
Asymptomatic other cardiovascular diseases	MEPS regression analysis	0.43		
Mild other cardiovascular diseases	MEPS regression analysis	0.43		
Moderate other cardiovascular diseases	MEPS regression analysis	0.43		
Severe other cardiovascular diseases	MEPS regression analysis	0.43		
Chronic respiratory diseases				
Chronic obstructive pulmonary disease	DisMod-MR 2.0 of prevalence, incidence, excess mortality and zero remission of all COPD cases	0.67		
Mild chronic obstructive pulmonary disease proportion	(1) DisMod-MR 2.0 of proportion by Gold class; map USA proportion to MEPS regression analysis severity; apply ratios to all other countries			0.67
Moderate chronic obstructive pulmonary disease proportion	DisMod-MR 2.0			0.32
Severe chronic obstructive pulmonary disease proportion	DisMod-MR 2.0			0.64

Appendix Table A.4: Model type and fit metrics: R-squared

Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
Severe interstitial lung disease and pulmonary sarcoidosis without heart failure	MEPS regression analysis	0.43		
Mild heart failure due to severe interstitial lung disease and pulmonary sarcoidosis	MEPS regression analysis severity of interstitial lung disease and for heart failure: (1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to other cardiovascular diseases (3) MEPS analysis of severity distribution of all heart failure			
Moderate heart failure due to severe interstitial lung disease and pulmonary sarcoidosis	MEPS regression analysis severity of interstitial lung disease and for heart failure: (1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to other cardiovascular diseases (3) MEPS analysis of severity distribution of all heart failure			
Severe heart failure due to severe interstitial lung disease and pulmonary sarcoidosis	MEPS regression analysis severity of interstitial lung disease and for heart failure: (1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to other cardiovascular diseases (3) MEPS analysis of severity distribution of all heart failure			
Other chronic respiratory diseases	YLD to YLL ratio for COPD, pneumoconiosis and interstitial lung disease applied to YLL from other chronic respiratory disease			
Cirrhosis	DisMod-MR 2.0 of prevalence, cause-specific mortality rates and excess mortality rates (for countries with prevalence data derived from an earlier iteration of DisMod-MR 2.0 model)	0.90		
Cirrhosis due to hepatitis B	DisMod-MR 2.0 proportion cirrhosis due to hepatitis B			0.91
Cirrhosis due to hepatitis C	DisMod-MR 2.0 proportion cirrhosis due to hepatitis C			0.75
Cirrhosis due to alcohol use	DisMod-MR 2.0 proportion cirrhosis due to alcohol			0.87
Cirrhosis due to other causes	DisMod-MR 2.0 proportion cirrhosis due to other causes			
Cirrhosis of the liver due to other cause	DisMod-MR 2.0			0.32
Digestive diseases				
Peptic ulcer disease				
Peptic ulcer disease, symptomatic episodes	DisMod-MR 2.0 of incidence and prevalence and remission setting to reflect 2 week duration		0.37	
Mild anemia due to peptic ulcer disease	calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity			
Moderate anemia due to peptic ulcer disease	calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity			
Severe anemia due to peptic ulcer disease	calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity			
Gastritis and duodenitis				
Gastritis and duodenitis, symptomatic episodes	DisMod-MR 2.0 of incidence and prevalence and remission setting to reflect 1 week duration		0.55	
Mild anemia due to gastritis and duodenitis	calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity			
Moderate anemia due to gastritis and duodenitis	calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity			
Severe anemia due to gastritis and duodenitis	calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity			
Appendicitis	DisMod-MR 2.0 of incidence and remission setting to reflect 2 week duration		0.94	
Paralytic ileus and intestinal obstruction	DisMod-MR 2.0 of incidence and remission setting to reflect 2 week duration		0.96	
Inguinal, femoral, and abdominal hernia	(1) regression model to estimate waiting time for surgery based on health system access; (2) DisMod-MR 2.0 of incidence and remission from step (1)		0.36	
Inflammatory bowel disease				
Ulcerative colitis	(1) DisMod-MR 2.0 of incidence, prevalence and excess mortality data and zero remission setting; (2) adjustment of prevalence for (small) fraction of cases of 'undetermined colitis'	0.51	0.52	
Crohn's disease	(1) DisMod-MR 2.0 of incidence, prevalence and excess mortality data and zero remission setting; (2) adjustment of prevalence for (small) fraction of cases of 'undetermined colitis'	0.91	0.57	
Vascular intestinal disorders	DisMod-MR 2.0 of incidence and remission setting to reflect 6 week duration		0.93	
Gallbladder and biliary diseases	DisMod-MR 2.0 of incidence and remission setting to reflect 2-6 week duration	0.44	0.94	
Pancreatitis	DisMod-MR 2.0 of incidence and remission setting to reflect 6 week duration	0.86	0.87	
Other digestive diseases	YLD to YLL ratio for stated digestive diseases applied to YLL from other digestive diseases			
Neurological disorders				
Alzheimer disease and other dementias	DisMod-MR 2.0 of incidence, prevalence and excess mortality data and zero remission	0.82	0.72	
Mild Alzheimer disease and other dementias	Meta-analysis			
Moderate Alzheimer disease and other dementias	Meta-analysis			
Severe Alzheimer disease and other dementias	Meta-analysis			
Parkinson disease	DisMod-MR 2.0 of incidence, prevalence and excess mortality data and zero remission	0.76		
Mild Parkinson disease	Meta-analysis			
Moderate Parkinson disease	Meta-analysis			
Severe Parkinson disease	Meta-analysis			
Epilepsy	(1) DisMod-MR 2.0 of 'envelope' of epilepsy based on incidence, prevalence, excess mortality and remission data; (2) mixed effects models of (a) the proportion idiopathic vs secondary epilepsy, (b) the proportion with severe epilepsy (i.e. one or more seizures per month), (c) the proportion treated and (d) the proportion seizure-free (i.e. no seizure in last year) while on treatment	0.40	0.34	
Seizure-free, treated epilepsy	epilepsy envelope x % idiopathic x (1 - % severe) x % treated x % seizure-free on treatment			
Less severe epilepsy	epilepsy envelope x % idiopathic x (1 - % severe) x (1 - % treated x % seizure-free on treatment)			
Severe epilepsy	epilepsy envelope x % idiopathic x % severe			
Multiple sclerosis	DisMod-MR 2.0 of incidence, prevalence and excess mortality data and zero remission	0.76	0.38	
Mild multiple sclerosis	Meta-analysis			
Moderate multiple sclerosis	Meta-analysis			
Severe multiple sclerosis	Meta-analysis			
Migraine	DisMod-MR 2.0 of prevalence only	0.68		
Asymptomatic migraine	Meta-analysis duration and frequency of episodes			
Symptomatic migraine	Meta-analysis duration and frequency of episodes			
Tension-type headache	DisMod-MR 2.0 of prevalence only	0.78		
Asymptomatic tension-type headache	Meta-analysis duration and frequency of episodes			
Symptomatic tension-type headache	Meta-analysis duration and frequency of episodes			
Medication overuse headache	DisMod-MR 2.0	0.77		
Asymptomatic medication overuse headache	Proportion from literature			
Symptomatic medication overuse headache	Proportion from literature			
Other neurological disorders				
Other neurological disorders	YLD to YLL ratio for dementia, Parkinson's and multiple sclerosis applied to YLL from other neurological disorders			
Guillain-Barré syndrome due to other neurological disorders	DisMod-MR 2.0 of incidence and remission data all GBS + meta-analysis of proportion of all cases not attributed to an underlying infectious disease			
Mental and substance use disorders				
Schizophrenia	DisMod-MR 2.0 of prevalence, incidence, remission and excess mortality	0.89	0.69	
Schizophrenia residual state	Meta-analysis			
Schizophrenia acute state	Meta-analysis			
Alcohol use disorders				
Alcohol dependence cases	DisMod-MR 2.0 of prevalence, incidence, remission and excess mortality	0.69		
Asymptomatic alcohol dependence	MEPS, NESARC, and NSMHWB regression analysis	0.43		

Appendix Table A.4: Model type and fit metrics: R-squared

Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
Very mild alcohol dependence	MEPS, NESARC, and NSMHWB regression analysis	0.43		
Mild alcohol dependence	MEPS, NESARC, and NSMHWB regression analysis	0.43		
Moderate alcohol dependence	MEPS, NESARC, and NSMHWB regression analysis	0.43		
Severe alcohol dependence	MEPS, NESARC, and NSMHWB regression analysis	0.43		
Fetal alcohol syndrome cases	DisMod-MR 2.0 of prevalence, excess mortality and zero remission	0.51		
Asymptomatic fetal alcohol syndrome	Meta-analysis of IQ loss in fetal alcohol syndrome assuming mild FAS corresponds with IQ 70-84; moderate FAS with IQ50-69 and severe FAS with IQ<50 based on the descriptions of intellectual disability in the lay descriptions for FAS that were used in the disability surveys			
Mild fetal alcohol syndrome	Meta-analysis of IQ loss in fetal alcohol syndrome assuming mild FAS corresponds with IQ 70-84; moderate FAS with IQ50-69 and severe FAS with IQ<50 based on the descriptions of intellectual disability in the lay descriptions for FAS that were used in the disability surveys			
Moderate fetal alcohol syndrome	Meta-analysis of IQ loss in fetal alcohol syndrome assuming mild FAS corresponds with IQ 70-84; moderate FAS with IQ50-69 and severe FAS with IQ<50 based on the descriptions of intellectual disability in the lay descriptions for FAS that were used in the disability surveys			
Severe fetal alcohol syndrome	Meta-analysis of IQ loss in fetal alcohol syndrome assuming mild FAS corresponds with IQ 70-84; moderate FAS with IQ50-69 and severe FAS with IQ<50 based on the descriptions of intellectual disability in the lay descriptions for FAS that were used in the disability surveys			
Drug use disorders				
Opioid use disorders	DisMod-MR 2.0 of prevalence, excess mortality and remission data	0.82		
Asymptomatic opioid dependence	NESARC % asymptomatic applied to subset of cases identifiable through surveys (from DisMod-MR 2.0 coefficient for survey data vs 'indirect' or estimates triangulated between needle exchange, treatment and judiciary data sources)			
Mild opioid dependence	(1) NESARC % asymptomatic applied to subset of cases identifiable through surveys (from DisMod-MR 2.0 coefficient for survey data vs 'indirect' or estimates triangulated between needle exchange, treatment and judiciary data sources); (2) proportion mild and severe from analysis of Australian cohort			
Severe opioid dependence	(1) NESARC % asymptomatic applied to subset of cases identifiable through surveys (from DisMod-MR 2.0 coefficient for survey data vs 'indirect' or estimates triangulated between needle exchange, treatment and judiciary data sources); (2) proportion mild and severe from analysis of Australian cohort			
Cocaine use disorders	DisMod-MR 2.0 of prevalence, excess mortality and remission data	0.66		
Asymptomatic cocaine dependence	NESARC % asymptomatic			
Mild cocaine dependence	(1) NESARC % asymptomatic; (2) proportion mild and severe from analysis of Australian cohort			
Severe cocaine dependence	(1) NESARC % asymptomatic; (2) proportion mild and severe from analysis of Australian cohort			
Amphetamine use disorders	DisMod-MR 2.0 of prevalence, excess mortality and remission data	0.58		
Asymptomatic amphetamine dependence	NESARC % asymptomatic			
Mild amphetamine dependence	(1) NESARC % asymptomatic; (2) proportion mild and severe from analysis of Australian cohort			
Severe amphetamine dependence	(1) NESARC % asymptomatic; (2) proportion mild and severe from analysis of Australian cohort			
Cannabis use disorders	DisMod-MR 2.0 of prevalence, excess mortality and remission data	0.70		
Asymptomatic cannabis dependence	NESARC			
Mild cannabis dependence	NESARC			
Severe cannabis dependence	NESARC			
Other drug use disorders	prevalence ratio other drugs to cocaine and amphetamine dependence from NESARC applied to YLD from those two drugs by country/year/age/sex			
Depressive disorders				
Major depressive disorder	DisMod-MR 2.0 of prevalence only	0.60		
Major depressive disorder, currently without symptoms	MEPS, NESARC, and NSMHWB regression analysis	0.43		
Mild major depressive disorder	MEPS, NESARC, and NSMHWB regression analysis	0.43		
Moderate major depressive disorder	MEPS, NESARC, and NSMHWB regression analysis	0.43		
Severe major depressive disorder	MEPS, NESARC, and NSMHWB regression analysis	0.43		
Dysthymia	DisMod-MR 2.0 of prevalence only	0.53		
Dysthymia, currently without symptoms	MEPS, NESARC, and NSMHWB regression analysis	0.43		
Symptomatic dysthymia	MEPS, NESARC, and NSMHWB regression analysis	0.43		
Bipolar disorder	DisMod-MR 2.0 of prevalence, excess mortality and remission data	0.39		
Bipolar disorder residual state	Meta-analysis			
Bipolar disorder depressive state	Meta-analysis			
Bipolar disorder manic state	Meta-analysis			
Anxiety disorders	DisMod-MR 2.0 of prevalence and remission data and assumption of zero excess mortality	0.71		
Anxiety disorders, currently without symptoms	MEPS, NESARC, and NSMHWB regression analysis	0.43		
Mild anxiety disorders	MEPS, NESARC, and NSMHWB regression analysis	0.43		
Moderate anxiety disorders	MEPS, NESARC, and NSMHWB regression analysis	0.43		
Severe anxiety disorders	MEPS, NESARC, and NSMHWB regression analysis	0.43		
Eating disorders				
Anorexia nervosa	DisMod-MR 2.0 of incidence, prevalence, excess mortality and remission data			
Bulimia nervosa	DisMod-MR 2.0 of incidence, prevalence and remission data and assumption of zero excess mortality	0.83		
Autistic spectrum disorders				
Autism	DisMod-MR 2.0 of incidence, prevalence, excess mortality and remission data	0.43	0.40	
Asperger syndrome	DisMod-MR 2.0 of incidence and prevalence and remission data assuming zero excess mortality	0.55	0.78	
Attention-deficit/hyperactivity disorder	DisMod-MR 2.0 of incidence, prevalence and remission data and assumption of zero excess mortality	0.09		
Attention-deficit/hyperactivity disorder, currently without symptoms	Proportion from literature			
Symptomatic attention-deficit/hyperactivity disorder	Proportion from literature			
Conduct disorder	DisMod-MR 2.0 of incidence, prevalence and remission data and assumption of zero excess mortality	0.53	0.11	
Conduct disorder, currently without symptoms	Proportion from literature			
Symptomatic conduct disorder	Proportion from literature			
Idiopathic intellectual disability				
Borderline idiopathic intellectual disability	(1) DisMod-MR 2.0 of all intellectual disability with IQ <70; (2) meta-analysis of ratio of prevalence IQ70-84 to IQ<70; (3) subtraction of all stated causes of borderline intellectual disability from envelope to get idiopathic borderline intellectual disability			
Mild idiopathic intellectual disability	(1) DisMod-MR 2.0 of all intellectual disability with IQ <70; (2) meta-analysis of ratio of prevalence IQ50-69 to IQ<70; (3) subtraction of all stated causes of mild intellectual disability from envelope to get idiopathic mild intellectual disability			
Moderate idiopathic intellectual disability	(1) DisMod-MR 2.0 of all intellectual disability with IQ <70; (2) meta-analysis of ratio of prevalence IQ50-69 to IQ<70; (3) subtraction of all stated causes of moderate intellectual disability from envelope to get idiopathic moderate intellectual disability			
Severe idiopathic intellectual disability	(1) DisMod-MR 2.0 of all intellectual disability with IQ <70; (2) meta-analysis of ratio of prevalence IQ50-69 to IQ<70; (3) subtraction of all stated causes of severe intellectual disability from envelope to get idiopathic severe intellectual disability			
Profound idiopathic intellectual disability	(1) DisMod-MR 2.0 of all intellectual disability with IQ <70; (2) meta-analysis of ratio of prevalence IQ50-69 to IQ<70; (3) subtraction of all stated causes of profound intellectual disability from envelope to get idiopathic profound intellectual disability			
Other mental and substance use disorders	Prevalence of personality disorders in NESARC and NSMHWB in individuals who do not have a diagnosis of any of the stated mental or substance use disorders			

Appendix Table A.4: Model type and fit metrics: R-squared

Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
Other mental disorders, currently without symptoms	NESARC and NSMHWB regression analysis			
Mild other mental disorders	NESARC and NSMHWB regression analysis			
Moderate other mental disorders	NESARC and NSMHWB regression analysis			
Severe other mental disorders	NESARC and NSMHWB regression analysis			
Diabetes, urogenital, blood, and endocrine diseases				
Diabetes mellitus	(1) calculated crosswalks for non-reference case definitions in NHANES; (2) DisMod-MR 2.0 of crosswalked incidence and prevalence, and excess mortality assuming no remission	0.81	0.72	
Uncomplicated diabetes mellitus	residual of DisMod-MR 2.0 proportions with complications			
Diabetic neuropathy	DisMod-MR 2.0 proportion model			0.71
Diabetic foot due to neuropathy	DisMod-MR 2.0 proportion model			0.64
Diabetic neuropathy and amputation with treatment	Proportion from literature			
Diabetic neuropathy and amputation without treatment	Proportion from literature			
Moderate vision impairment due to diabetes mellitus	(1) DisMod-MR 2.0 of prevalence of vision loss (not blindness) due to diabetes; (2) split into moderate and severe based on vision loss envelope			
Severe vision impairment due to diabetes mellitus	(1) DisMod-MR 2.0 of prevalence of vision loss (not blindness) due to diabetes; (2) split into moderate and severe based on vision loss envelope			
Blindness due to diabetes mellitus	(1) DisMod-MR 2.0 of prevalence of blindness due to diabetes			
Amputation due to diabetes mellitus proportion	DisMod-MR 2.0 proportion model	0.87	0.36	
Vision impairment due to diabetes mellitus	DisMod-MR 2.0 of prevalence of vision loss (not blindness) due to diabetes	0.86		
Acute glomerulonephritis			0.17	
Chronic kidney disease				
Stage III chronic kidney disease	DisMod-MR 2.0	0.72		
Stage IV chronic kidney disease	DisMod-MR 2.0	0.67		
End-stage renal disease after transplant	DisMod-MR 2.0	0.43		
End-stage renal disease on dialysis	DisMod-MR 2.0	0.93	0.82	
Stage V chronic kidney disease untreated	DisMod-MR 2.0	0.73		
Chronic kidney disease due to diabetes mellitus				0.89
Stage III chronic kidney disease without anemia due to diabetes mellitus	(1) DisMod-MR 2.0 of prevalence of stage III chronic kidney disease only; (2) DisMod-MR 2.0 of proportion that is due to diabetes; subtraction of health states combined with anemia			
Stage III chronic kidney disease and mild anemia due to diabetes mellitus	(1) DisMod-MR 2.0 of prevalence of stage III chronic kidney disease only; (2) DisMod-MR 2.0 of proportion that is due to diabetes; for anemia: (1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Stage III chronic kidney disease and moderate anemia due to diabetes mellitus	(1) DisMod-MR 2.0 of prevalence of stage III chronic kidney disease only; (2) DisMod-MR 2.0 of proportion that is due to diabetes; for anemia: (1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Stage III chronic kidney disease and severe anemia due to diabetes mellitus	(1) DisMod-MR 2.0 of prevalence of stage III chronic kidney disease only; (2) DisMod-MR 2.0 of proportion that is due to diabetes; for anemia: (1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Stage IV chronic kidney disease without anemia due to diabetes mellitus	(1) DisMod-MR 2.0 of prevalence of stage IV chronic kidney disease only; (2) DisMod-MR 2.0 of proportion that is due to diabetes; subtraction of health states combined with anemia			
Stage IV chronic kidney disease and mild anemia due to diabetes mellitus	(1) DisMod-MR 2.0 of prevalence of stage IV chronic kidney disease only; (2) DisMod-MR 2.0 of proportion that is due to diabetes; for anemia: (1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Stage IV chronic kidney disease and moderate anemia due to diabetes mellitus	(1) DisMod-MR 2.0 of prevalence of stage IV chronic kidney disease only; (2) DisMod-MR 2.0 of proportion that is due to diabetes; for anemia: (1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Stage IV chronic kidney disease and severe anemia due to diabetes mellitus	(1) DisMod-MR 2.0 of prevalence of stage IV chronic kidney disease only; (2) DisMod-MR 2.0 of proportion that is due to diabetes; for anemia: (1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Stage V chronic kidney disease untreated due to diabetes mellitus	(1) DisMod-MR 2.0 of prevalence only; (2) DisMod-MR 2.0 proportion due to diabetes			
End-stage renal disease after transplant due to diabetes mellitus	(1) DisMod-MR 2.0 of prevalence, incidence, excess mortality and remission; (2) DisMod-MR 2.0 proportion due to diabetes			
End-stage renal disease on dialysis due to diabetes mellitus	(1) DisMod-MR 2.0 of prevalence, incidence, excess mortality and remission; (2) DisMod-MR 2.0 proportion due to diabetes			
Chronic kidney disease due to hypertension				0.45
Stage III chronic kidney disease without anemia due to hypertension	(1) DisMod-MR 2.0 of prevalence of stage III chronic kidney disease only; (2) DisMod-MR 2.0 of proportion that is due to hypertension; subtraction of health states combined with anemia			
Stage III chronic kidney disease and mild anemia due to hypertension	(1) DisMod-MR 2.0 of prevalence of stage III chronic kidney disease only; (2) DisMod-MR 2.0 of proportion that is due to hypertension; for anemia: (1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Stage III chronic kidney disease and moderate anemia due to hypertension	(1) DisMod-MR 2.0 of prevalence of stage III chronic kidney disease only; (2) DisMod-MR 2.0 of proportion that is due to hypertension; for anemia: (1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Stage III chronic kidney disease and severe anemia due to hypertension	(1) DisMod-MR 2.0 of prevalence of stage III chronic kidney disease only; (2) DisMod-MR 2.0 of proportion that is due to hypertension; for anemia: (1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Stage IV chronic kidney disease without anemia due to hypertension	(1) DisMod-MR 2.0 of prevalence of stage IV chronic kidney disease only; (2) DisMod-MR 2.0 of proportion that is due to hypertension; subtraction of health states combined with anemia			

Appendix Table A.4: Model type and fit metrics: R-squared

Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
Stage IV chronic kidney disease and severe anemia due to other causes	(1) DisMod-MR 2.0 of prevalence of stage IV chronic kidney disease only; (2) DisMod-MR 2.0 of proportion that is due to other causes; for anemia: (1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Stage V chronic kidney disease untreated due to other causes	(1) DisMod-MR 2.0 of prevalence, incidence, excess mortality and remission; (2) DisMod-MR 2.0 proportion due to other causes			
End-stage renal disease after transplant due to other causes	(1) DisMod-MR 2.0 of prevalence only; (2) DisMod-MR 2.0 proportion due to other causes			
End-stage renal disease on dialysis due to other causes	(1) DisMod-MR 2.0 of prevalence, incidence, excess mortality and remission; (2) DisMod-MR 2.0 proportion due to other causes			
Urinary diseases and male infertility				
Interstitial nephritis and urinary tract infections	DisMod-MR 2.0 of incidence data and remission setting consistent with one week duration		0.80	
Mild interstitial nephritis and urinary tract infections	MEPS regression analysis	0.43		
Moderate interstitial nephritis and urinary tract infections	MEPS regression analysis	0.43		
Urolithiasis				
Acute urolithiasis	DisMod-MR 2.0 of incidence data and remission setting consistent with two week duration		0.93	
Chronic urolithiasis	DisMod-MR 2.0 of incidence and prevalence data assuming zero remission and cap on excess mortality of 0.01	0.88	0.82	
Benign prostatic hyperplasia	DisMod-MR 2.0 of incidence and prevalence data assuming range of remission from 0 to 0.1 and no excess mortality	0.94	0.10	
Asymptomatic benign prostatic hyperplasia	MEPS regression analysis	0.43		
Symptomatic benign prostatic hyperplasia	MEPS regression analysis	0.43		
Male infertility due to other causes				
Primary male infertility	(1) DisMod-MR 2.0 prevalence among 'exposed' couples (i.e. with child wish but no live birth and no contraceptives used in last five years); (2) DisMod-MR 2.0 of proportion 'exposed' out of total population; (3) DisMod-MR 2.0 proportion of primary infertility in men; (4) subtraction of infertility due to Klinefelter			
Secondary male infertility	(1) DisMod-MR 2.0 prevalence among 'exposed' couples (i.e. with child wish and no contraceptives used in five years since last live birth); (2) DisMod-MR 2.0 of proportion 'exposed' out of total population; (3) DisMod-MR 2.0 proportion of secondary infertility in men			
Other urinary diseases	YLD to YLL ratio of urinary tract infections and urolithiasis applied to YLL from other urinary diseases			
Gynecological diseases				
Uterine fibroids	DisMod-MR 2.0	0.17	0.71	
Asymptomatic uterine fibroids	MEPS regression analysis	0.43		
Mild abdominal pain due to uterine fibroids, without anemia	MEPS regression analysis of symptomatic cases	0.43		
Mild abdominal pain due to uterine fibroids, with mild anemia	(1) MEPS regression analysis of symptomatic cases (2) Mixed-effects regression to predict mean hemoglobin; (3) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (4) age- and sex-specific redistribution to determine aetiology-specific overall anemia prevalence; (5) Bayesian contingency table modeling of severity distribution for each cause			
Mild abdominal pain due to uterine fibroids, with moderate anemia	(1) MEPS regression analysis of symptomatic cases (2) Mixed-effects regression to predict mean hemoglobin; (3) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (4) age- and sex-specific redistribution to determine aetiology-specific overall anemia prevalence; (5) Bayesian contingency table modeling of severity distribution for each cause			
Mild abdominal pain due to uterine fibroids, with severe anemia	(1) MEPS regression analysis of symptomatic cases (2) Mixed-effects regression to predict mean hemoglobin; (3) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (4) age- and sex-specific redistribution to determine aetiology-specific overall anemia prevalence; (5) Bayesian contingency table modeling of severity distribution for each cause			
Polycystic ovarian syndrome	DisMod-MR 2.0	0.48		
Asymptomatic polycystic ovarian syndrome	Proportion from literature			
Hirsutism due to polycystic ovarian syndrome	Proportion from literature			
Hirsutism and primary infertility due to polycystic ovarian syndrome	Proportion with androgenic features and infertility from literature; proportion primary and secondary infertility from envelope of infertility after subtraction of causes that only cause primary (Turner) or secondary (maternal sepsis) infertility			
Primary infertility due to polycystic ovarian syndrome	Proportion infertility from literature; proportion primary and secondary infertility from envelope of infertility after subtraction of causes that only cause primary (Turner) or secondary (maternal sepsis) infertility			
Hirsutism and secondary infertility due to polycystic ovarian syndrome	Proportion with androgenic features and infertility from literature; proportion primary and secondary infertility from envelope of infertility after subtraction of causes that only cause primary (Turner) or secondary (maternal sepsis) infertility			
Secondary infertility due to polycystic ovarian syndrome	Proportion infertility from literature; proportion primary and secondary infertility from envelope of infertility after subtraction of causes that only cause primary (Turner) or secondary (maternal sepsis) infertility			
Female infertility due to other causes				
Idiopathic primary female infertility	(1) DisMod-MR 2.0 prevalence among 'exposed' couples (i.e. with child wish but no live birth and no contraceptives used in last five years); (2) DisMod-MR 2.0 of proportion 'exposed' out of total population; (3) DisMod-MR 2.0 proportion of primary infertility in women; (4) subtraction of primary infertility due to Turner syndrome, endometriosis, polycystic ovarian syndrome, and sexually transmitted diseases			
Idiopathic secondary female infertility	(1) DisMod-MR 2.0 prevalence among 'exposed' couples (i.e. with child wish and no contraceptives used in five years since last live birth); (2) DisMod-MR 2.0 of proportion 'exposed' out of total population; (3) DisMod-MR 2.0 proportion of secondary infertility in women; (4) subtraction of primary infertility due to Turner syndrome, endometriosis, polycystic ovarian syndrome, maternal sepsis and sexually transmitted diseases			
Endometriosis	DisMod-MR 2.0		0.18	
Asymptomatic endometriosis	Proportion from literature			
Mild abdominal pain due to endometriosis	Proportion from literature			
Moderate abdominal pain due to endometriosis	Proportion from literature			
Severe endometriosis	Proportion from literature			
Primary infertility due to endometriosis	Proportion infertility from literature; proportion primary and secondary infertility from envelope of infertility after subtraction of causes that only cause primary (Turner) or secondary (maternal sepsis) infertility			
Mild abdominal pain and primary infertility due to endometriosis	Proportion with abdominal pain and infertility from literature; proportion primary and secondary infertility from envelope of infertility after subtraction of causes that only cause primary (Turner) or secondary (maternal sepsis) infertility			
Moderate abdominal pain and primary infertility due to endometriosis	Proportion with abdominal pain and infertility from literature; proportion primary and secondary infertility from envelope of infertility after subtraction of causes that only cause primary (Turner) or secondary (maternal sepsis) infertility			
Severe abdominal pain and primary infertility due to endometriosis	Proportion with abdominal pain and infertility from literature; proportion primary and secondary infertility from envelope of infertility after subtraction of causes that only cause primary (Turner) or secondary (maternal sepsis) infertility			
Secondary infertility due to endometriosis	Proportion with abdominal pain and infertility from literature; proportion primary and secondary infertility from envelope of infertility after subtraction of causes that only cause primary (Turner) or secondary (maternal sepsis) infertility			
Mild abdominal pain and secondary infertility due to endometriosis	Proportion with abdominal pain and infertility from literature; proportion primary and secondary infertility from envelope of infertility after subtraction of causes that only cause primary (Turner) or secondary (maternal sepsis) infertility			
Moderate abdominal pain and secondary infertility due to endometriosis	Proportion with abdominal pain and infertility from literature; proportion primary and secondary infertility from envelope of infertility after subtraction of causes that only cause primary (Turner) or secondary (maternal sepsis) infertility			
Severe abdominal pain and secondary infertility due to endometriosis	Proportion with abdominal pain and infertility from literature; proportion primary and secondary infertility from envelope of infertility after subtraction of causes that only cause primary (Turner) or secondary (maternal sepsis) infertility			

Appendix Table A.4: Model type and fit metrics: R-squared				
Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
Genital prolapse	DisMod-MR 2.0	0.68		
Asymptomatic genital prolapse	Proportion from literature			
Abdominal pain due to genital prolapse	Proportion from literature			
Stress incontinence due to genital prolapse	Proportion from literature			
Abdominal pain and stress incontinence due to genital prolapse	Proportion from literature			
Premenstrual syndrome	DisMod-MR 2.0 proportion model	0.38		
Asymptomatic premenstrual syndrome	Proportion from literature			
Abdominal pain and depression due to premenstrual syndrome	Proportion from literature			
Abdominal pain due to premenstrual syndrome	Proportion from literature			
Depression due to premenstrual syndrome	Proportion from literature			
Other gynecological diseases	DisMod-MR 2.0 of prevalence from hospital admission data of other gynaecological disorders that do not lead to anemia	0.78		
Asymptomatic other gynecological disorders	MEPS regression analysis	0.43		
Mild other gynecological disorders	MEPS regression analysis	0.43		
Moderate other gynecological disorders	MEPS regression analysis	0.43		
Severe other gynecological disorders	MEPS regression analysis	0.43		
Mild anemia due to other gynecological diseases	(1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) age- and sex-specific redistribution to determine aetiology-specific overall anemia prevalence; (4) Bayesian contingency table modeling of severity distribution for each cause			
Moderate anemia due to other gynecological diseases	(1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) age- and sex-specific redistribution to determine aetiology-specific overall anemia prevalence; (4) Bayesian contingency table modeling of severity distribution for each cause			
Severe anemia due to other gynecological diseases	(1) Mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) age- and sex-specific redistribution to determine aetiology-specific overall anemia prevalence; (4) Bayesian contingency table modeling of severity distribution for each cause			
Hemoglobinopathies and hemolytic anemias				
Thalassemias				
Other combined sequelae of beta-thalassemia major	intermediate DisMod-MR 2.0 of birth prevalence and excess mortality assuming no remission	0.91		
Beta-thalassemia major, with mild anemia	(1) mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Beta-thalassemia major, with moderate anemia	(1) mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Beta-thalassemia major, with severe anemia	(1) mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Beta-thalassemia major, severe infection with severe anemia	(1) Meta-analysis of cases of severe infection (2) mixed-effects regression to predict mean hemoglobin; (3) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (4) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (5) Bayesian contingency table modeling of severity distribution for each cause			
Other combined sequelae of hemoglobin E/beta-thalassemia	intermediate DisMod-MR 2.0 of birth prevalence and excess mortality assuming no remission	0.93		
Hemoglobin E/beta-thalassemia, with mild anemia	(1) mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Hemoglobin E/beta-thalassemia, with moderate anemia	(1) mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Hemoglobin E/beta-thalassemia, with severe anemia	(1) mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Hemoglobin E/beta-thalassemia, severe infection with severe anemia	(1) Meta-analysis of cases of severe infection (2) mixed-effects regression to predict mean hemoglobin; (3) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (4) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (5) Bayesian contingency table modeling of severity distribution for each cause			
Other combined sequelae of hemoglobin H disease	intermediate DisMod-MR 2.0 of birth prevalence and excess mortality assuming no remission	0.24		
Hemoglobin H disease, with mild anemia	(1) mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Hemoglobin H disease, with moderate anemia	(1) mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Hemoglobin H disease, with severe anemia	(1) mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Hemoglobin H disease, severe infection with severe anemia	(1) Meta-analysis of cases of severe infection (2) mixed-effects regression to predict mean hemoglobin; (3) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (4) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (5) Bayesian contingency table modeling of severity distribution for each cause			
Mild heart failure due to thalassemias	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to other cardiovascular diseases (3) MEPS analysis of severity distribution of all heart failure			
Moderate heart failure due to thalassemias	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to other cardiovascular diseases (3) MEPS analysis of severity distribution of all heart failure			
Severe heart failure due to thalassemias	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to other cardiovascular diseases (3) MEPS analysis of severity distribution of all heart failure			
Hemoglobin H disease, without anemia	subtraction of hemoglobin H disease with anemia sequelae from DisMod-MR 2.0 parent model of hemoglobin H disease			
Beta-thalassemia major, without anemia	subtraction of beta-thalassaemia major with anemia sequelae from DisMod-MR 2.0 parent model of beta-thalassaemia major			
Hemoglobin E/beta-thalassemia, without anemia	subtraction of hemoglobin E/beta-thalassemia with anemia sequelae from DisMod-MR 2.0 parent model of hemoglobin E/beta-thalassemia			
Thalassemia trait				

Appendix Table A.4: Model type and fit metrics: R-squared

Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
Severe anemia due to endocrine, metabolic, blood, and immune disorders	(1) mixed-effects regression to predict mean hemoglobin; (2) weibull fit based on mean hemoglobin and subsequent calculation of mild, moderate and severe anemia prevalence based on 2011 WHO classification; (3) calculation of overall anemia prevalence for each cause using aetiology-specific prevalence from DisMod-MR 2.0 model and aetiology-specific meta-analysis of anemia severity; (4) Bayesian contingency table modeling of severity distribution for each cause			
Mild heart failure due to endocrine, metabolic, blood, and immune disorders	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to other cardiovascular diseases (3) MEPS analysis of severity distribution of all heart failure			
Moderate heart failure due to endocrine, metabolic, blood, and immune disorders	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to other cardiovascular diseases (3) MEPS analysis of severity distribution of all heart failure			
Severe heart failure due to endocrine, metabolic, blood, and immune disorders	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to other cardiovascular diseases (3) MEPS analysis of severity distribution of all heart failure			
Musculoskeletal disorders				
Rheumatoid arthritis	DisMod-MR 2.0 of incidence, prevalence, excess mortality and remission data	0.69	0.30	
Mild rheumatoid arthritis	Meta-analysis			
Moderate rheumatoid arthritis	Meta-analysis			
Severe rheumatoid arthritis	Meta-analysis			
Osteoarthritis				
Osteoarthritis of the hip	DisMod-MR 2.0 of incidence, prevalence, excess mortality and remission data	0.75	0.61	
Mild osteoarthritis of the hip	Meta-analysis			
Moderate osteoarthritis of the hip	Meta-analysis			
Severe osteoarthritis of the hip	Meta-analysis			
Osteoarthritis of the knee	DisMod-MR 2.0 of incidence, prevalence, excess mortality and remission data	0.49	0.11	
Mild osteoarthritis of the knee	Meta-analysis			
Moderate osteoarthritis of the knee	Meta-analysis			
Severe osteoarthritis of the knee	Meta-analysis			
Low back and neck pain				
Low back pain	DisMod-MR 2.0 model of prevalence only	0.60		
Mild low back pain without leg pain	MEPS regression analysis	0.43		
Mild low back pain with leg pain	MEPS regression analysis	0.43		
Moderate low back pain without leg pain	MEPS regression analysis	0.43		
Moderate low back pain with leg pain	MEPS regression analysis	0.43		
Severe low back pain without leg pain	MEPS regression analysis	0.43		
Severe low back pain with leg pain	MEPS regression analysis	0.43		
Most severe low back pain without leg pain	MEPS regression analysis	0.43		
Most severe low back pain with leg pain	MEPS regression analysis	0.43		
Neck pain	DisMod-MR 2.0 model of prevalence only	0.69		
Mild neck pain	MEPS regression analysis	0.43		
Moderate neck pain	MEPS regression analysis	0.43		
Severe neck pain	MEPS regression analysis	0.43		
Most severe neck pain	MEPS regression analysis	0.43		
Gout	DisMod-MR 2.0 of incidence, prevalence, excess mortality and remission data	0.71		
Asymptomatic gout	Meta-analysis			
Symptomatic episodes of gout	DisMod-MR 2.0			
Polyarticular gout	Meta-analysis			
Other musculoskeletal disorders	DisMod-MR 2.0 of prevalence only	0.87		
Asymptomatic other musculoskeletal disorders	MEPS regression analysis	0.43		
Other musculoskeletal disorders severity level 2	MEPS regression analysis	0.43		
Other musculoskeletal disorders severity level 3	MEPS regression analysis	0.43		
Other musculoskeletal disorders severity level 5	MEPS regression analysis	0.43		
Other musculoskeletal disorders severity level 6	MEPS regression analysis	0.43		
Other musculoskeletal disorders severity level 1	MEPS regression analysis	0.43		
Other musculoskeletal disorders severity level 4	MEPS regression analysis	0.43		
Other non-communicable diseases				
Congenital anomalies				
Neural tube defects				
Moderate motor impairment due to moderate neural tube defects	(1) SMR from literature; (2) estimation of excess mortality by age, sex, country year from SMR and all-cause mortality rates; (3) DisMod-MR 2.0 of birth prevalence and excess mortality assuming no remission	0.61		
Severe neural tube defects	(1) SMR from literature; (2) estimation of excess mortality by age, sex, country year from SMR and all-cause mortality rates; (3) DisMod-MR 2.0 of birth prevalence and excess mortality assuming no remission	0.61		
Severe motor impairment due to severe neural tube defects	Meta-analysis			
Severe motor plus cognitive impairments due to severe neural tube defects	Meta-analysis			
Severe motor impairment with incontinence due to severe neural tube defects	Meta-analysis			
Congenital heart anomalies				
Less severe congenital heart anomalies	(1) SMR from literature; (2) estimation of excess mortality by age, sex, country year from SMR and all-cause mortality rates; (3) DisMod-MR 2.0 of birth prevalence and excess mortality assuming no remission	0.42		
Asymptomatic less severe congenital heart anomalies	(1) SMR from literature; (2) estimation of excess mortality by age, sex, country year from SMR and all-cause mortality rates; (3) DisMod-MR 2.0 of birth prevalence and excess mortality assuming no remission			
Symptomatic less severe congenital heart anomalies	(1) SMR from literature; (2) estimation of excess mortality by age, sex, country year from SMR and all-cause mortality rates; (3) DisMod-MR 2.0 of birth prevalence and excess mortality assuming no remission			
Severe congenital heart anomalies	(1) SMR from literature; (2) estimation of excess mortality by age, sex, country year from SMR and all-cause mortality rates; (3) DisMod-MR 2.0 of birth prevalence and excess mortality assuming no remission	0.31		
Critical congenital heart anomalies	(1) SMR from literature; (2) estimation of excess mortality by age, sex, country year from SMR and all-cause mortality rates; (3) DisMod-MR 2.0 of birth prevalence and excess mortality assuming no remission	0.28		
Mild heart failure due to congenital heart anomalies	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to congenital heart disease; (3) MEPS analysis of severity distribution of all heart failure			
Moderate heart failure due to congenital heart anomalies	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to congenital heart disease; (3) MEPS analysis of severity distribution of all heart failure			
Severe heart failure due to congenital heart anomalies	(1) DisMod-MR 2.0 of prevalence, incidence, no remission and excess mortality of all heart failure; (2) separate DisMod-MR 2.0 model for the proportion of all heart failure due to congenital heart disease; (3) MEPS analysis of severity distribution of all heart failure			
Orofacial clefts	DisMod-MR 2.0			
Asymptomatic orofacial clefts	Proportion from literature			
Disfigurement level 1 due to orofacial clefts	Proportion from literature			

Appendix Table A.4: Model type and fit metrics: R-squared

Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
Disfigurement level 2 due to orofacial clefts	Proportion from literature			
Disfigurement level 2 and speech problems due to orofacial clefts	Proportion from literature			
Down syndrome	(1) meta-analysis of SMR data for Down syndrome; (2) estimation of excess mortality by age, sex, country year from pooled SMR value and all-cause mortality rates; (3) DisMod-MR 2.0 of birth prevalence and excess mortality assuming no remission	0.48		
Asymptomatic Down syndrome	Proportion from literature			
Intellectual disability due to Down syndrome	Proportion from literature			
Intellectual disability with congenital heart disease due to Down syndrome	Proportion from literature			
Intellectual disability with dementia due to Down syndrome	Proportion from literature			
Intellectual disability with congenital heart disease and dementia due to Down syndrome	Proportion from literature			
Isolated congenital heart disease due to Down syndrome	Proportion from literature			
Turner syndrome	(1) SMR from literature; (2) estimation of excess mortality by age, sex, country year from SMR and all-cause mortality rates; (3) DisMod-MR 2.0 of birth prevalence and excess mortality assuming no remission	0.24		
Asymptomatic Turner syndrome	Proportion from literature			
Congenital heart disease due to Turner syndrome	Proportion from literature			
Primary infertility due to Turner syndrome	Proportion from literature			
Congenital heart disease with infertility due to Turner syndrome	Proportion from literature			
Klinefelter syndrome	(1) SMR from literature; (2) estimation of excess mortality by age, sex, country year from SMR and all-cause mortality rates; (3) DisMod-MR 2.0 of birth prevalence and excess mortality assuming no remission	0.21		
Asymptomatic Klinefelter syndrome	Proportion from literature			
Borderline intellectual disability due to Klinefelter syndrome	Proportion from literature			
Borderline intellectual disability with infertility due to Klinefelter syndrome	Proportion from literature			
Mild intellectual disability due to Klinefelter syndrome	Proportion from literature			
Mild intellectual disability with infertility due to Klinefelter syndrome	Proportion from literature			
Primary infertility due to Klinefelter syndrome	Proportion from literature			
Chromosomal unbalanced rearrangements	(1) meta-analysis of SMR data for Down syndrome; (2) estimation of excess mortality by age, sex, country year from pooled SMR value and all-cause mortality rates; (3) DisMod-MR 2.0 of birth prevalence and excess mortality assuming no remission	0.63		
Asymptomatic chromosomal unbalanced rearrangements	assumed same distribution of sequelae as for Down syndrome			
Intellectual disability due to chromosomal unbalanced rearrangements	assumed same distribution of sequelae as for Down syndrome			
Intellectual disability with congenital heart disease due to chromosomal unbalanced rearrangements	assumed same distribution of sequelae as for Down syndrome			
Intellectual disability with dementia due to chromosomal unbalanced rearrangements	assumed same distribution of sequelae as for Down syndrome			
Intellectual disability with congenital heart disease and dementia due to chromosomal unbalanced rearrangements	assumed same distribution of sequelae as for Down syndrome			
Isolated congenital heart disease due to chromosomal unbalanced rearrangements	assumed same distribution of sequelae as for Down syndrome			
Other congenital anomalies				
Hearing loss due to other congenital anomalies	DisMod-MR 2.0	0.45		
Mild hearing loss due to other congenital anomalies	(1) DisMod-MR 2.0 model of hearing loss by severity from all causes; (2) assumption that birth prevalence reflects prevalence of congenital hearing loss that remains constant with age as there is no excess mortality			
Mild hearing loss with ringing due to other congenital anomalies	(1) DisMod-MR 2.0 model of hearing loss by severity from all causes; (2) assumption that birth prevalence reflects prevalence of congenital hearing loss that remains constant with age as there is no excess mortality			
Moderate hearing loss due to other congenital anomalies	(1) DisMod-MR 2.0 model of hearing loss by severity from all causes; (2) assumption that birth prevalence reflects prevalence of congenital hearing loss that remains constant with age as there is no excess mortality			
Moderate hearing loss with ringing due to other congenital anomalies	(1) DisMod-MR 2.0 model of hearing loss by severity from all causes; (2) assumption that birth prevalence reflects prevalence of congenital hearing loss that remains constant with age as there is no excess mortality			
Moderately severe hearing loss due to other congenital anomalies	(1) DisMod-MR 2.0 model of hearing loss by severity from all causes; (2) assumption that birth prevalence reflects prevalence of congenital hearing loss that remains constant with age as there is no excess mortality			
Moderately severe hearing loss with ringing due to other congenital anomalies	(1) DisMod-MR 2.0 model of hearing loss by severity from all causes; (2) assumption that birth prevalence reflects prevalence of congenital hearing loss that remains constant with age as there is no excess mortality			
Severe hearing loss due to other congenital anomalies	(1) DisMod-MR 2.0 model of hearing loss by severity from all causes; (2) assumption that birth prevalence reflects prevalence of congenital hearing loss that remains constant with age as there is no excess mortality			
Severe hearing loss with ringing due to other congenital anomalies	(1) DisMod-MR 2.0 model of hearing loss by severity from all causes; (2) assumption that birth prevalence reflects prevalence of congenital hearing loss that remains constant with age as there is no excess mortality			
Profound hearing loss due to other congenital anomalies	(1) DisMod-MR 2.0 model of hearing loss by severity from all causes; (2) assumption that birth prevalence reflects prevalence of congenital hearing loss that remains constant with age as there is no excess mortality			
Profound hearing loss with ringing due to other congenital anomalies	(1) DisMod-MR 2.0 model of hearing loss by severity from all causes; (2) assumption that birth prevalence reflects prevalence of congenital hearing loss that remains constant with age as there is no excess mortality			
Complete hearing loss due to other congenital anomalies	(1) DisMod-MR 2.0 model of hearing loss by severity from all causes; (2) assumption that birth prevalence reflects prevalence of congenital hearing loss that remains constant with age as there is no excess mortality			
Complete hearing loss with ringing due to other congenital anomalies	(1) DisMod-MR 2.0 model of hearing loss by severity from all causes; (2) assumption that birth prevalence reflects prevalence of congenital hearing loss that remains constant with age as there is no excess mortality			
Other congenital anomalies	YLD to YLL ratio for congenital heart disease and neural tube defects applied to YLL for other congenital anomalies			
Skin and subcutaneous diseases				
Dermatitis				
Mild eczema	MEPS regression analysis	0.43		
Moderate eczema	MEPS regression analysis	0.43		
Severe eczema	MEPS regression analysis	0.43		
Asymptomatic contact dermatitis	MEPS regression analysis	0.43		
Mild contact dermatitis	MEPS regression analysis	0.43		
Severe contact dermatitis	MEPS regression analysis	0.43		
Asymptomatic seborrheic dermatitis	MEPS regression analysis	0.43		
Symptomatic seborrheic dermatitis	MEPS regression analysis	0.43		
Eczema	DisMod-MR 2.0 of prevalence, no excess mortality and remission bounded between 0 and 0.2	0.52		
Contact dermatitis	DisMod-MR 2.0 of prevalence only			
Seborrheic dermatitis	DisMod-MR 2.0 of prevalence only	0.81		
Psoriasis	DisMod-MR 2.0 of incidence and prevalence; setting on remission to range between 0.05 and 0.15	0.83	0.88	
Mild psoriasis	MEPS regression analysis	0.43		
Moderate psoriasis	MEPS regression analysis	0.43		
Severe psoriasis	MEPS regression analysis	0.43		
Cellulitis	DisMod-MR 2.0 of incidence and setting on remission consistent with a range of 10 day to 4 week duration		0.73	

Appendix Table A.4: Model type and fit metrics: R-squared				
Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
Mild cellulitis	MEPS regression analysis	0.43		
Severe cellulitis	MEPS regression analysis	0.43		
Pyoderma				
Impetigo	DisMod-MR 2.0 of incidence and setting on remission consistent with a range of 2 to 4 week duration		0.69	
Abscess and other bacterial skin diseases	DisMod-MR 2.0 of incidence and setting on remission consistent with a range of 1 to 3 week duration		0.62	
Scabies		0.70	0.50	
Fungal skin diseases				
Tinea capitis	DisMod-MR 2.0 of prevalence only	0.67		
Other fungal skin diseases	DisMod-MR 2.0 of prevalence only	0.59		
Viral skin diseases				
Mild molluscum contagiosum	MEPS regression analysis	0.43		
Severe molluscum contagiosum	MEPS regression analysis	0.43		
Viral warts	DisMod-MR 2.0 of incidence and prevalence and setting on remission consistent with a range of 6 months to 4 year duration	0.63		
Mild viral warts	MEPS regression analysis	0.43		
Severe viral warts	MEPS regression analysis	0.43		
Molluscum contagiosum	DisMod-MR 2.0 of incidence and prevalence and setting on remission consistent with a range of 6 months to 1 year duration		0.58	
Acne vulgaris		0.90		
Alopecia areata	DisMod-MR 2.0 of prevalence only	0.17		
Mild alopecia areata	MEPS regression analysis	0.43		
Severe alopecia areata	MEPS regression analysis	0.43		
Pruritus				
Urticaria	DisMod-MR 2.0 of prevalence only	0.75		
Mild urticaria	MEPS regression analysis	0.43		
Severe urticaria	MEPS regression analysis	0.43		
Decubitus ulcer	DisMod-MR 2.0 of incidence and prevalence and setting on remission consistent with a range of 2 months to 2 year duration		0.95	
Mild decubitus ulcer	MEPS regression analysis	0.43		
Moderate decubitus ulcer	MEPS regression analysis	0.43		
Severe decubitus ulcer	MEPS regression analysis	0.43		
Other skin and subcutaneous diseases	DisMod-MR 2.0 model of prevalence only from MEPS			
Asymptomatic other skin and subcutaneous diseases	MEPS regression analysis	0.43		
Symptomatic other skin and subcutaneous diseases	MEPS regression analysis	0.43		
Sense organ diseases				
Glaucoma				
Vision impairment due to glaucoma	DisMod-MR 2.0 of prevalence of vision loss (not blindness) due to glaucoma	0.75		
Moderate vision impairment due to glaucoma	(1) DisMod-MR 2.0 of prevalence of vision loss (not blindness) due to glaucoma (2) split into moderate and severe based on vision loss envelope			
Severe vision impairment due to glaucoma	(1) DisMod-MR 2.0 of prevalence of vision loss (not blindness) due to glaucoma (2) split into moderate and severe based on vision loss envelope			
Blindness due to glaucoma	DisMod-MR 2.0 of prevalence of blindness due to glaucoma	0.91		
Cataract				
Vision impairment due to cataract	DisMod-MR 2.0 of prevalence of vision loss (not blindness) due to cataract	0.86		
Moderate vision impairment due to cataract	(1) DisMod-MR 2.0 of prevalence of vision loss (not blindness) due to cataract (2) split into moderate and severe based on vision loss envelope			
Severe vision impairment due to cataract	(1) DisMod-MR 2.0 of prevalence of vision loss (not blindness) due to cataract (2) split into moderate and severe based on vision loss envelope			
Blindness due to cataract	DisMod-MR 2.0 of prevalence of blindness due to cataract			
Macular degeneration				
Vision impairment due to macular degeneration	DisMod-MR 2.0 of prevalence of vision loss (not blindness) due to macular degeneration	0.61		
Moderate vision impairment due to macular degeneration	(1) DisMod-MR 2.0 of prevalence of vision loss (not blindness) due to macular degeneration (2) split into moderate and severe based on vision loss envelope			
Severe vision impairment due to macular degeneration	(1) DisMod-MR 2.0 of prevalence of vision loss (not blindness) due to macular degeneration (2) split into moderate and severe based on vision loss envelope			
Blindness due to macular degeneration	DisMod-MR 2.0 of prevalence of blindness due to macular degeneration	0.99		
Uncorrected refractive error				
Moderate vision impairment due to uncorrected refractive error	Mixed effects regression of vision loss data by age, separately for level of severity, from studies that presented both 'best corrected' and 'presenting' vision. Difference between presenting and best corrected vision loss reflect uncorrected refractive error			
Severe vision impairment due to uncorrected refractive error	Mixed effects regression of vision loss data by age, separately for level of severity, from studies that presented both 'best corrected' and 'presenting' vision. Difference between presenting and best corrected vision loss reflect uncorrected refractive error			
Blindness due to uncorrected refractive error	Mixed effects regression of vision loss data by age, separately for level of severity, from studies that presented both 'best corrected' and 'presenting' vision. Difference between presenting and best corrected vision loss reflect uncorrected refractive error			
Near vision impairment due to presbyopia due to uncorrected refractive error	DisMod-MR 2.0 of prevalence presbyopia in people who do not have long-distance vision loss			
Age-related and other hearing loss		0.32		
Mild hearing loss due to age-related and other hearing loss	(1) DisMod-MR 2.0 of prevalence of all age-related and other hearing loss ; (2) severity split based on hearing loss envelope			
Mild hearing loss with ringing due to age-related and other hearing loss	(1) DisMod-MR 2.0 of prevalence of all age-related and other hearing loss ; (2) severity split based on hearing loss envelope			
Moderate hearing loss due to age-related and other hearing loss	(1) DisMod-MR 2.0 of prevalence of all age-related and other hearing loss ; (2) severity split based on hearing loss envelope			
Moderate hearing loss with ringing due to age-related and other hearing loss	(1) DisMod-MR 2.0 of prevalence of all age-related and other hearing loss ; (2) severity split based on hearing loss envelope			
Moderately severe hearing loss due to age-related and other hearing loss	(1) DisMod-MR 2.0 of prevalence of all age-related and other hearing loss ; (2) severity split based on hearing loss envelope			
Moderately severe hearing loss with ringing due to age-related and other hearing loss	(1) DisMod-MR 2.0 of prevalence of all age-related and other hearing loss ; (2) severity split based on hearing loss envelope			
Severe hearing loss with ringing due to age-related and other hearing loss	(1) DisMod-MR 2.0 of prevalence of all age-related and other hearing loss ; (2) severity split based on hearing loss envelope			
Severe hearing loss due to age-related and other hearing loss	(1) DisMod-MR 2.0 of prevalence of all age-related and other hearing loss ; (2) severity split based on hearing loss envelope			
Profound hearing loss due to age-related and other hearing loss	(1) DisMod-MR 2.0 of prevalence of all age-related and other hearing loss ; (2) severity split based on hearing loss envelope			
Profound hearing loss with ringing due to age-related and other hearing loss	(1) DisMod-MR 2.0 of prevalence of all age-related and other hearing loss ; (2) severity split based on hearing loss envelope			
Complete hearing loss due to age-related and other hearing loss	(1) DisMod-MR 2.0 of prevalence of all age-related and other hearing loss ; (2) severity split based on hearing loss envelope			
Complete hearing loss with ringing due to age-related and other hearing loss	(1) DisMod-MR 2.0 of prevalence of all age-related and other hearing loss ; (2) severity split based on hearing loss envelope			

Appendix Table A.4: Model type and fit metrics: R-squared

Cause, sequelae, or intermediate model	Model description	R-squared (prevalence)	R-squared (incidence)	R-squared (proportion)
Other vision loss				
Vision impairment due to other vision loss	DisMod-MR 2.0 of prevalence of other vision loss from surveys that at least measured vision loss from glaucoma, cataract and macular degeneration explicitly	0.44		
Moderate vision impairment due to other vision loss	DisMod-MR 2.0 of prevalence of other vision loss from surveys that at least measured vision loss from glaucoma, cataract and macular degeneration explicitly, split into moderate and severe			
Severe vision impairment due to other vision loss	DisMod-MR 2.0 of prevalence of other vision loss from surveys that at least measured vision loss from glaucoma, cataract and macular degeneration explicitly, split into moderate and severe			
Blindness due to other vision loss	DisMod-MR 2.0 of prevalence of other vision loss from surveys that at least measured vision loss from glaucoma, cataract and macular degeneration explicitly	0.73		
Other sense organ diseases	DisMod-MR 2.0 based on USA outpatient data	0.59		
Asymptomatic other sense organ diseases	MEPS regression analysis	0.43		
Mild other sense organ diseases	MEPS regression analysis	0.43		
Moderate other sense organ diseases	MEPS regression analysis	0.43		
Severe other sense organ diseases	MEPS regression analysis	0.43		
Oral disorders				
Deciduous caries	DisMod-MR 2.0 of prevalence and incidence data assuming remission that is consistent with average duration of 7 to 18 months	0.27	0.28	
Asymptomatic deciduous caries	Meta-analysis			
Tooth pain due to deciduous caries	Meta-analysis			
Permanent caries	(1) DisMod-MR 2.0 of prevalence, incidence and no excess mortality; remission set to range consistent with a duration of 2 to 12 months; (2) correction for proportion of population who are edentulous	0.65	0.19	
Asymptomatic permanent caries	Meta-analysis			
Tooth pain due to permanent caries	Meta-analysis			
Periodontal diseases	(1) DisMod-MR 2.0 of prevalence, incidence and excess mortality; (2) correction for proportion of population who are edentulous	0.67		
Chronic periodontal diseases	(1) DisMod-MR 2.0 of prevalence, incidence and excess mortality; (2) correction for proportion of population who are edentulous			
Edentulism and severe tooth loss	DisMod-MR 2.0 of prevalence, incidence and excess mortality	0.83		
Asymptomatic edentulism and severe tooth loss	Meta-analysis			
Difficulty eating due to edentulism and severe tooth loss	Meta-analysis			
Other oral disorders	DisMod-MR 2.0 of prevalence	0.53		
Mild other oral disorders	MEPS regression analysis	0.43		
Severe other oral disorders	MEPS regression analysis	0.43		
Injuries	<i>See injuries analysis appendix section for all injuries listed</i>			
Transport injuries				
Road injuries			0.76	
Pedestrian road injuries			0.43	
Cyclist road injuries			0.79	
Motorcyclist road injuries			0.82	
Motor vehicle road injuries			0.39	
Other road injuries			0.43	
Other transport injuries			0.76	
Unintentional injuries				
Falls			0.85	
Drowning			0.45	
Fire, heat, and hot substances			0.57	
Poisonings			0.60	
Exposure to mechanical forces			0.69	
Unintentional firearm injuries			0.64	
Unintentional suffocation			0.68	
Other exposure to mechanical forces			0.69	
Adverse effects of medical treatment			0.79	
Animal contact			0.68	
Venomous animal contact			0.48	
Non-venomous animal contact			0.59	
Foreign body				
Pulmonary aspiration and foreign body in airway			0.68	
Foreign body in eyes			0.63	
Foreign body in other body part			0.62	
Other unintentional injuries			0.78	
Self-harm and interpersonal violence				
Self-harm			0.32	
Interpersonal violence			0.65	
Assault by firearm			0.60	
Assault by sharp object			0.77	
Assault by other means			0.70	
Forces of nature, war, and legal intervention				
Exposure to forces of nature				
Collective violence and legal intervention				

Appendix Table A.5: ICD-9-CM mapped to MEPS data by GBD 2013 cause list

Cause name	Sequelae name	ICD-9-CM
Acne vulgaris	Acne	706
Alcohol use disorders	Alcohol use disorders	291, 303
Alopecia areata	Alopecia	704
Alzheimer disease and other dementias	Alzheimer's disease and other dementias	209-331
Anxiety disorders	Anxiety disorders	300, 308
Asthma	Asthma	493
Atrial fibrillation and flutter	Atrial fibrillation and flutter	427
Attention-deficit/hyperactivity disorder	ADHD	314
Benign prostatic hyperplasia	Hyperplasia of prostate	600
Bipolar disorder	Bipolar affective disorder	296
Bladder cancer	Bladder cancer	188
Brain and nervous system cancer	Brain and nervous system cancers	191-192
Breast cancer	Breast cancer	174-175
Cardiomyopathy and myocarditis	Cardiomyopathy and myocarditis	422, 425
Cataract	Cataracts	366
Cerebrovascular disease	Cerebrovascular disease	342, 430-438
Cervical cancer	Cervix uteri cancer	180
Chromosomal unbalanced rearrangements	Other chromosomal abnormalities	758
Chronic kidney disease	Chronic kidney diseases	581-589
Chronic kidney disease due to hypertension	CKD due to hypertension	403
Chronic obstructive pulmonary disease	Chronic obstructive pulmonary disease (COPD)	490-492, 494, 495, 513, 515-516
Cirrhosis	Cirrhosis of the liver	570-571
Orofacial clefts	Cleft lip and cleft palate	749
Colon and rectum cancer	Colon and rectum cancers	153-154
Conduct disorder	Conduct disorder	312
Congenital heart anomalies	Congenital heart anomalies	745-747
Decubitus ulcer	Skin ulcer	707
Dermatitis	Dermatitis (eczema)	690-692
Diabetes mellitus	Diabetes mellitus	250
Endocrine, metabolic, blood, and immune disorders	Other Endocrine, nutritional, blood and immune disorders	251-259, 270-271, 273, 277, 279, 286-289, 242-246
Endometriosis	Endometriosis	617
Epilepsy	Epilepsy	345
Esophageal cancer	Oesophagus cancer	150
Female infertility due to other causes	Infertility (female)	628
Fungal skin diseases	Dermatophytosis	110-111
Gallbladder and biliary diseases	Gall bladder and bile duct disease	574-576
Gastritis and duodenitis	Gastritis and duodenitis	535
Genital prolapse	Genital prolapse	618
Glaucoma	Glaucoma	365
Gout	Gout	274
HIV/AIDS resulting in other diseases	HIV/AIDS	42
Hodgkin lymphoma	Hodgkin's disease	201
Hypertensive heart disease	Hypertensive heart disease	402, 404
Idiopathic intellectual disability	Intellectual disability	317-319
Inflammatory bowel disease	Noninfective inflammatory bowel disease	555-556, 558
Inguinal, femoral, and abdominal hernia	Inguinal/femoral hernia	550
Interstitial lung disease and pulmonary sarcoidosis	Sarcoidosis	135
Interstitial nephritis and urinary tract infections	Acute tubulointerstitial nephritis , pyelonephritis and Urinary tract infections	590, 595, 597
Iodine deficiency	Goitre and Hypothyroidism	240-241
Iron-deficiency anemia	Iron-deficiency anemia	280-281
Kidney cancer	Kidney and other urinary organ cancers	189
Larynx cancer	Larynx cancer	161
Leukemia	Leukemia	204-208
Liver cancer	Liver cancer	155
Tracheal, bronchus and lung cancer	Trachea, bronchus and lung cancers	162
Major depressive disorder	Unipolar depressive disorders	311
Malignant skin melanoma	Malignant melanoma of skin	172
Maternal hypertensive disorders	Hypertensive disorders of pregnancy	642
Meningitis	Meningitis and encephalitis	36, 48-49, 62-64, 320-323

Appendix Table A.5: ICD-9-CM mapped to MEPS data by GBD 2013 cause list

Cause name	Sequelae name	ICD-9-CM
Migraine	Migraine	346
Lip and oral cavity cancer	Mouth cancer	140-146
Multiple myeloma	Multiple myeloma	203
Multiple sclerosis	Multiple sclerosis	340
Neck pain	Neck pain	723
Neural tube defects	Neural tube defects	740-741
Non-Hodgkin lymphoma	Non-Hodgkin's lymphoma	202
Osteoarthritis	Osteoarthritis	715
Other cardiovascular and circulatory diseases	Other circulatory diseases	420, 423-424, 426, 429, 441-442, 444, 446-448, 451, 453-459
Other chronic respiratory diseases	Other respiratory diseases	470-471, 478, 495, 508, 510-512, 517-519
Other congenital anomalies	Other congenital anomalies	742-744, 748, 750-757, 759
Other gynecological diseases	Other gynecological disorders	610-611, 620-626, 629
Other maternal disorders	Other maternal conditions	643-648, 650-659, 661-665, 667-669, 671-677
Other mental and substance use disorders	Other mental and behavioral disorders	301-302, 306-307, 309-310, 313, 315-316
Other musculoskeletal disorders	Other musculoskeletal disorders	710-713, 716-720, 725-729, 731-739
Other neoplasms	Other malignant neoplasms	152, 158, 160, 163-164, 170-171, 176, 181, 184, 187, 190, 194, 196-198, 200
Other neurological disorders	Other neurological conditions	324-326, 333-337, 341, 344, 347-359
Other nutritional deficiencies	Other nutritional disorders	265-269
Other oral disorders	Other oral	520, 522, 524, 526-529
Other pneumoconiosis	Pneumoconiosis	500-506
Other sense organ diseases	Other sense organ disorders	360, 370-377, 379-380, 384, 386, 388
Other skin and subcutaneous diseases	Residual skin conditions	132, 685, 694-695, 697, 700-703, 705, 709
Other urinary diseases	Other urinary diseases	591, 593, 596, 598-599, 601-608
Otitis media	Otitis media	381-383
Pancreatic cancer	Pancreas cancer	157
Pancreatitis	Pancreatitis	577
Parkinson disease	Parkinson's disease	332
Peptic ulcer disease	Peptic ulcer disease	531-534
Peripheral vascular disease	Peripheral vascular disease	440
Prostate cancer	Prostate cancer	185
Protein-energy malnutrition	Protein-energy malnutrition	260-263
Pruritus	Pruritus	698
Psoriasis	Psoriasis	696
Rheumatic heart disease	Rheumatic heart disease	390-398
Rheumatoid arthritis	Rheumatoid arthritis	714
Scabies	Scabies	133
Schizophrenia	Schizophrenia	293-294, 297-299, 295
Stomach cancer	Stomach cancer	151
Testicular cancer	Testis cancer	186
Thyroid cancer	Thyroid cancer	193
Tuberculosis	Tuberculosis	10-18, 137
Uncorrected refractive error	Refraction and accommodation disorders	367, 368, 378
Urolithiasis	Urolithiasis	592, 594
Urticaria	Urticaria	708
Uterine cancer	Corpus uteri cancer	180
Uterine fibroids	Fibroids	218
Varicella and herpes zoster	Varicella (chickenpox)	52
Vascular intestinal disorders	Vascular insufficiency of intestine	557
Viral skin diseases	Viral wart	78
N/A	Amputation of finger(s) (with or without thumb or toe)	885-886, 895
N/A	Burns	940-949
N/A	Severe chest injury	860-862, 874, 901, 908
N/A	Long term outcome of dislocation of hip/knee/shoulder	831, 835-836, 844
N/A	Injury Requiring Emergency Care	863-869, 902
N/A	Fracture of radius or ulna	813
N/A	Fracture of wrist and other distal part of hand, fracture of foot except ankle	814-819, 827
N/A	Fracture of femur	821
N/A	Fracture of clavicle, scapula, humerus, or skull	800-801, 803, 810-812
N/A	Fracture of Hip	820

Appendix Table A.5: ICD-9-CM mapped to MEPS data by GBD 2013 cause list

Cause name	Sequelae name	ICD-9-CM
N/A	Fracture of patella, tibia, fibula, or ankle	822-824
N/A	Fracture of pelvis	808-809
N/A	Fracture of sternum, rib, or face bone	802, 807, 825-826
N/A	Fracture of vertebral column	805
N/A	Head Injury	804, 850-854, 905
N/A	Injured nerves	951, 953-957
N/A	Open wound, superficial injuries and dislocations	830, 832-834, 837-843, 845-848 870-873, 875-884, 890-894, 900, 903-904, 906, 910-920
N/A	Spinal Cord Lesion	806, 952
N/A	Injury Requiring Urgent Care	925-929, 935-939, 960-989, 990, 992-999
N/A	Allergic rhinitis	477
N/A	Hemolytic anemias	282-285
N/A	Candidiasis	112
N/A	Cerebral palsy	343
N/A	Gastroesophageal reflux disease	530
N/A	Hearing loss not due to other diseases or injuries	385, 387, 389
N/A	Hepatitis	70
N/A	Drug use disorders	292, 304-305
N/A	Other neoplasms	210-217, 219-234, 236-239
N/A	Non-melanoma skin cancer	173
N/A	Unspecified cancer site	149, 159, 165, 179, 183, 195, 199, 235
N/A	Neonatal conditions	760-779
N/A	Osteomyelitis	730
N/A	Unspecified symptoms	780-799
N/A	Pelvic inflammatory disease	614-615
N/A	Poliomyelitis	138
N/A	Pulmonary heart disease	415-417
N/A	Chronic sinusitis	473
N/A	Other vision loss	361-364, 369
N/A	Any heart failure	428
N/A	Angina pectoris	413
N/A	Back pain	721, 724
N/A	Intervertebral disk disorders	722
N/A	Bacterial skin infection (abscess and cellulitis)	35, 680, 683, 686, 135, 681-682
N/A	Bacterial skin infection (impetigo)	684

Web Table A.6-Disability weight lay descriptions

Healthstate ID	Healthstate Name	Healthstate Description	hhsseqid (Healthstate sequela ID?)	Disability Weight
351	Infectious disease, acute episode, mild	has a low fever and mild discomfort, but no difficulty with daily activities.	207	0.006 (0.002-0.012)
352	Infectious disease, acute episode, moderate	has a fever and aches, and feels weak, which causes some difficulty with daily activities.	208	0.051 (0.032-0.074)
353	Infectious disease, acute episode, severe	has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.	209	0.133 (0.088-0.19)
354	Infectious disease, post-acute consequences (fatigue, emotional lability, insomnia)	is always tired and easily upset. The person feels pain all over the body and is depressed.	210	0.219 (0.148-0.308)
355	Diarrhea, mild	has diarrhea three or more times a day with occasional discomfort in the belly.	145	0.074 (0.049-0.104)
356	Diarrhea, moderate	has diarrhea three or more times a day, with painful cramps in the belly and feeling thirsty	146	0.188 (0.125-0.264)
357	Diarrhea, severe	has diarrhea three or more times a day with severe belly cramps. The person is very thirsty and feels nauseous and tired.	147	0.247 (0.164-0.348)
358	Epididymo-orchitis	has swelling and tenderness in the testicles and pain during urination.	155	0.128 (0.086-0.18)
359	Herpes zoster	has a blistering skin rash that causes pain, with some burning and itching.	202	0.058 (0.035-0.09)
360	HIV cases, symptomatic, pre-AIDS	has weight loss, fatigue, and frequent infections.	203	0.274 (0.184-0.377)
361	HIV/AIDS cases, receiving ARV treatment	has occasional fevers and infections. The person takes daily medication that sometimes causes diarrhea.	205	0.078 (0.052-0.111)
362	AIDS cases, not receiving ARV treatment	has severe weight loss, weakness, fatigue, cough and fever, and frequent infections, skin rashes and diarrhea.	204	0.582 (0.406-0.743)
363	Intestinal nematode infections, symptomatic	has cramping pain and a bloated feeling in the belly.	212	0.027 (0.015-0.043)
364	Lymphatic filariasis, symptomatic	has swollen legs with hard and thick skin, which causes difficulty in moving around.	221	0.109 (0.073-0.154)
365	Ear pain	has an ear-ache that causes some difficulty with daily activities.	28	0.013 (0.007-0.024)
366	Tuberculosis, not HIV infected	has a persistent cough and fever, is short of breath, feels weak, and has lost a lot of weight.	102	0.333 (0.234-0.454)
367	Tuberculosis, HIV infected	has a persistent cough and fever, shortness of breath, night sweats, weakness and fatigue and severe weight loss.	249	0.408 (0.274-0.549)
368	Cancer, diagnosis and primary therapy	has pain, nausea, fatigue, weight loss and high anxiety.	127	0.288 (0.193-0.399)
369	Cancer, metastatic	has severe pain, extreme fatigue, weight loss and high anxiety.	128	0.451 (0.307-0.6)
370	Mastectomy	had one of her breasts removed and sometimes has pain or swelling in the arms.	130	0.036 (0.02-0.057)
371	Stoma	has a pouch attached to an opening in the belly to collect and empty stools.	131	0.095 (0.063-0.131)
372	Terminal phase, with medication (for cancers, end-stage kidney/liver disease)	has lost a lot of weight and regularly uses strong medication to avoid constant pain. The person has no appetite, feels nauseous, and needs to spend most of the day in bed.	21	0.54 (0.377-0.687)
373	Terminal phase, without medication (for cancers, end-stage kidney/liver disease)	has lost a lot of weight and has constant pain. The person has no appetite, feels nauseous, and needs to spend most of the day in bed.	129	0.569 (0.389-0.727)
374	Acute myocardial infarction, days 1-2	has severe chest pain that becomes worse with any physical activity. The person feels nauseous, short of breath, and very anxious.	112	0.432 (0.288-0.579)
375	Acute myocardial infarction, days 3-28	gets short of breath after heavy physical activity, and tires easily, but has no problems when at rest. The person has to take medication every day and has some anxiety.	113	0.074 (0.049-0.105)
376	Angina pectoris, mild	has chest pain that occurs with strenuous physical activity, such as running or lifting heavy objects. After a brief rest, the pain goes away.	96	0.033 (0.02-0.052)
377	Angina pectoris, moderate	has chest pain that occurs with moderate physical activity, such as walking uphill or more than half a kilometer (around a quarter-mile) on level ground. After a brief rest, the pain goes away.	115	0.08 (0.052-0.113)
378	Angina pectoris, severe	has chest pain that occurs with minimal physical activity, such as walking only a short distance. After a brief rest, the pain goes away. The person avoids most physical activities because of the pain.	116	0.167 (0.11-0.24)
379	Cardiac conduction disorders and cardiac dysrhythmias	has periods of rapid and irregular heartbeats and occasional fainting.	132	0.224 (0.151-0.312)
380	Claudication	has cramping pains in the legs after walking a medium distance. The pain goes away after a short rest.	136	0.014 (0.007-0.025)
381	Heart failure, mild	is short of breath and easily tires with moderate physical activity, such as walking uphill or more than a quarter-mile on level ground. The person feels comfortable at rest or during activities requiring less effort.	200	0.041 (0.026-0.062)
382	Heart failure, moderate	is short of breath and easily tires with minimal physical activity, such as walking only a short distance. The person feels comfortable at rest but avoids moderate activity.	201	0.072 (0.047-0.103)
383	Heart failure, severe	is short of breath and feels tired when at rest. The person avoids any physical activity, for fear of worsening the breathing problems.	101	0.179 (0.122-0.251)
384	Stroke, long-term consequences, mild	has some difficulty in moving around and some weakness in one hand, but is able to walk without help.	243	0.019 (0.01-0.032)
385	Stroke, long-term consequences, moderate	has some difficulty in moving around, and in using the hands for lifting and holding things, dressing and grooming.	244	0.07 (0.046-0.099)
386	Stroke, long-term consequences, moderate plus cognition problems	has some difficulty in moving around, in using the hands for lifting and holding things, dressing and grooming, and in speaking. The person is often forgetful and confused.	245	0.316 (0.206-0.437)
387	Stroke, long-term consequences, severe	is confined to bed or a wheelchair, has difficulty speaking and depends on others for feeding, toileting and dressing.	246	0.552 (0.377-0.707)
388	Stroke, long-term consequences, severe plus cognition problems	is confined to bed or a wheelchair, depends on others for feeding, toileting and dressing, and has difficulty speaking, thinking clearly and remembering things.	247	0.588 (0.411-0.744)
389	Diabetic foot	has a sore on the foot that is swollen and causes some difficulty in walking.	143	0.02 (0.01-0.034)
390	Diabetic neuropathy	has pain, tingling and numbness in the arms, legs, hands and feet. The person sometimes gets cramps and muscle weakness.	144	0.133 (0.089-0.187)
391	Chronic kidney disease (stage IV)	tires easily, has nausea, reduced appetite and difficulty sleeping.	215	0.104 (0.07-0.147)
392	End-stage renal disease, with kidney transplant	sometimes feels tired and down, and has some difficulty with daily activities.	216	0.024 (0.014-0.039)
393	End-stage renal disease, on dialysis	is tired and has itching, cramps, headache, joint pains and shortness of breath. The person needs intensive medical care every other day lasting about half a day.	217	0.571 (0.398-0.725)
394	Decompensated cirrhosis of the liver	has a swollen belly and swollen legs. The person feels weakness, fatigue and loss of appetite.	135	0.178 (0.123-0.25)
395	Gastric bleeding	vomits blood and feels nauseous.	181	0.325 (0.209-0.462)
396	Crohn disease or ulcerative colitis	has cramping abdominal pain, has diarrhea several times a day, and feels very tired for two months every year. When the person does not have symptoms, there is anxiety about them returning.	104	0.231 (0.156-0.32)
397	Benign prostatic hypertrophy, symptomatic cases	feels the urge to urinate frequently, but when passing urine it comes out slowly and sometimes is painful.	120	0.067 (0.043-0.097)
398	Urinary incontinence	cannot control urinating.	251	0.139 (0.094-0.198)
793	Stress incontinence	loses small amounts of urine without meaning to when coughing, sneezing, laughing or during physical exercise.	345	0.02 (0.011-0.035)
399	Impotence	has difficulty in obtaining or maintaining an erection.	206	0.017 (0.009-0.03)
400	Infertility, primary	wants to have a child and has a fertile partner, but the couple cannot conceive.	1	0.008 (0.003-0.015)
401	Infertility, secondary	has at least one child, and wants to have more children. The person has a fertile partner, but the couple cannot conceive.	2	0.005 (0.002-0.011)
402	Asthma, controlled	has wheezing and cough once a month, which does not cause difficulty with daily activities.	117	0.015 (0.007-0.026)
403	Asthma, partially controlled	has wheezing and cough once a week, which causes some difficulty with daily activities.	118	0.036 (0.022-0.055)
404	Asthma, uncontrolled	has wheezing, cough and shortness of breath more than twice a week, which causes difficulty with daily activities and sometimes wakes the person at night.	119	0.133 (0.086-0.192)
405	COPD and other chronic respiratory problems, mild	has cough and shortness of breath after heavy physical activity, but is able to walk long distances and climb stairs.	138	0.019 (0.011-0.033)
406	COPD and other chronic respiratory problems, moderate	has cough, wheezing and shortness of breath, even after light physical activity. The person feels tired and can walk only short distances or climb only a few stairs.	139	0.225 (0.153-0.31)
407	COPD and other chronic respiratory problems, severe	has cough, wheezing and shortness of breath all the time. The person has great difficulty walking even short distances or climbing any stairs, feels tired when at rest, and is anxious.	140	0.408 (0.273-0.556)
408	Dementia, mild	has some trouble remembering recent events, and finds it hard to concentrate and make decisions and plans.	25	0.069 (0.046-0.099)
409	Dementia, moderate	has memory problems and confusion, feels disoriented, at times hears voices that are not real, and needs help with some daily activities.	26	0.377 (0.252-0.508)

Web Table A.6-Disability weight lay descriptions

Healthstate ID	Healthstate Name	Healthstate Description	hhsqid (Healthstate sequela ID?)	Disability Weight
410	Dementia, severe	has complete memory loss; no longer recognizes close family members; and requires help with all daily activities.	27	0.449 (0.304-0.595)
411	Headache, migraine	has severe, throbbing head pain and nausea that cause great difficulty in daily activities and sometimes confine the person to bed. Moving around, light, and noise make it worse.	184	0.441 (0.294-0.588)
412	Headache, tension-type	has a moderate headache that also affects the neck, which causes difficulty in daily activities.	186	0.037 (0.022-0.057)
413	Headache, medication overuse	has daily headaches, felt as dull pain and often lasting all day, with poor sleep, nausea and fatigue. The person takes medicine for the headaches, which provides little relief but is needed to avoid having worse symptoms.	188	0.217 (0.138-0.311)
414	Multiple sclerosis, mild	has mild loss of feeling in one hand, is a little unsteady while walking, has slight loss of vision in one eye, and often needs to urinate urgently.	106	0.183 (0.124-0.253)
415	Multiple sclerosis, moderate	needs help walking, has difficulty with writing and arm coordination, has loss of vision in one eye and cannot control urinating.	107	0.463 (0.313-0.613)
416	Multiple sclerosis, severe	has slurred speech and difficulty swallowing. The person has weak arms and hands, very limited and stiff leg movement, has loss of vision in both eyes and cannot control urinating.	108	0.719 (0.534-0.858)
417	Epilepsy, treated, seizure free			#N/A
418	Epilepsy, treated, with recent seizures			#N/A
419	Epilepsy, untreated			#N/A
420	Epilepsy, severe			#N/A
745	Epilepsy, severe (seizures >= once per month)	has sudden seizures one or more times each month, with violent muscle contractions and stiffness, loss of consciousness, and loss of urine or bowel control. Between seizures the person has memory loss and difficulty concentrating.	318	0.552 (0.375-0.71)
746	Epilepsy, less severe (seizures < once per month)	has sudden seizures two to five times a year, with violent muscle contractions and stiffness, loss of consciousness, and loss of urine or bowel control.	319	0.263 (0.173-0.367)
421	Parkinson disease, mild	has mild tremors and moves a little slowly, but is able to walk and do daily activities without assistance.	59	0.01 (0.005-0.019)
422	Parkinson disease, moderate	has moderate tremors and moves slowly, which causes some difficulty in walking and daily activities. The person has some trouble swallowing, talking, sleeping, and remembering things.	60	0.267 (0.181-0.372)
423	Parkinson disease, severe	has severe tremors and moves very slowly, which causes great difficulty in walking and daily activities. The person falls easily and has a lot of difficulty talking, swallowing, sleeping, and remembering things.	61	0.575 (0.396-0.73)
747	Alcohol use disorder, very mild	drinks alcohol daily and has difficulty controlling the urge to drink. When sober, the person functions normally, drinks a lot of alcohol and sometimes has difficulty controlling the urge to drink. While intoxicated, the person has difficulty performing daily activities.	320	0.123 (0.082-0.177)
424	Alcohol use disorder, mild	drinks a lot, gets drunk almost every week and has great difficulty controlling the urge to drink. Drinking and recovering cause great difficulty in daily activities, sleep loss, and fatigue.	32	0.235 (0.16-0.327)
425	Alcohol use disorder, moderate	gets drunk almost every day and is unable to control the urge to drink. Drinking and recovering replace most daily activities. The person has difficulty thinking, remembering and communicating, and feels constant pain and fatigue.	33	0.373 (0.248-0.508)
426	Alcohol use disorder, severe	is a little slow in developing physically and mentally, which causes some difficulty in learning but no other difficulties in daily activities.	34	0.57 (0.396-0.732)
427	Fetal alcohol syndrome, mild	is slow in developing physically and mentally, which causes some difficulty in daily activities.	161	0.016 (0.008-0.03)
428	Fetal alcohol syndrome, moderate	is very slow in developing physically and mentally, which causes great difficulty in daily activities.	162	0.056 (0.035-0.083)
429	Fetal alcohol syndrome, severe	uses marijuana at least once a week and has some difficulty controlling the habit. When not using, the person functions normally.	163	0.179 (0.119-0.257)
586	Cannabis dependence, mild	uses marijuana daily and has difficulty controlling the habit. The person sometimes has mood swings, anxiety and hallucinations, and has some difficulty in daily activities.	321	0.039 (0.024-0.06)
430	Cannabis dependence	uses stimulants (drugs) at least once a week and has some difficulty controlling the habit. When not using, the person functions normally.	36	0.266 (0.178-0.364)
583	Amphetamine dependence, mild	uses stimulants (drugs) and has difficulty controlling the habit. The person sometimes has depression, hallucinations and mood swings, and has difficulty in daily activities.	322	0.079 (0.051-0.114)
431	Amphetamine dependence	uses cocaine at least once a week and has some difficulty controlling the habit. When not using, the person functions normally.	153	0.486 (0.329-0.637)
580	Cocaine dependence, mild	uses cocaine and has difficulty controlling the habit. The person sometimes has mood swings, anxiety, paranoia, hallucinations and sleep problems, and has some difficulty in daily activities.	323	0.116 (0.074-0.165)
432	Cocaine dependence	uses heroin (or methadone) daily and has difficulty controlling the habit. When not using, the person functions normally.	154	0.479 (0.324-0.634)
577	Heroin and other opioid dependence, mild	uses heroin daily and has difficulty controlling the habit. When the effects wear off, the person feels severe nausea, agitation, vomiting and fever. The person has a lot of difficulty in daily activities.	324	0.335 (0.221-0.473)
433	Heroin and other opioid dependence	feels mildly anxious and worried, which makes it slightly difficult to concentrate, remember things, and sleep. The person tires easily but is able to perform daily activities.	35	0.697 (0.51-0.843)
434	Anxiety disorders, mild	feels anxious and worried, which makes it difficult to concentrate, remember things, and sleep. The person tires easily and finds it difficult to perform daily activities.	22	0.03 (0.018-0.046)
435	Anxiety disorders, moderate	constantly feels very anxious and worried, which makes it difficult to concentrate, remember things and sleep. The person has lost pleasure in life and thinks about suicide.	23	0.133 (0.091-0.186)
436	Anxiety disorders, severe	feels persistent sadness and has lost interest in usual activities. The person sometimes sleeps badly, feels tired, or has trouble concentrating but still manages to function in daily life with extra effort.	24	0.823 (0.362-0.677)
437	Major depressive disorder, mild episode	has constant sadness and has lost interest in usual activities. The person has some difficulty in daily life, sleeps badly, has trouble concentrating, and sometimes thinks about harming himself (or herself).	285	0.145 (0.099-0.209)
438	Major depressive disorder, moderate episode	has overwhelming, constant sadness and cannot function in daily life. The person sometimes loses touch with reality and wants to harm or kill himself (or herself).	30	0.396 (0.267-0.531)
439	Major depressive disorder, severe episode	is hyperactive, hears and believes things that are not real, and engages in impulsive and aggressive behavior that endanger the person and others.	31	0.658 (0.477-0.807)
440	Bipolar disorder, manic episode	has mild mood swings, irritability and some difficulty with daily activities.	37	0.492 (0.341-0.646)
441	Bipolar disorder, residual state	hears and sees things that are not real and is afraid, confused, and sometimes violent. The person has great difficulty with communication and daily activities, and sometimes wants to harm or kill himself (or herself).	121	0.032 (0.018-0.051)
442	Schizophrenia, acute state	hears and sees things that are not real and has trouble communicating. The person can be forgetful, has difficulty with daily activities, and thinks about hurting himself (or herself).	38	0.588 (0.606-0.9)
443	Schizophrenia, residual state	feels an overwhelming need to starve and exercises excessively to lose weight. The person is very thin, weak and anxious.	238	0.224 (0.411-0.754)
444	Anorexia nervosa	has uncontrolled overeating followed by guilt, starving, and vomiting to lose weight.	39	0.224 (0.15-0.312)
445	Bulimia nervosa	is hyperactive and has difficulty concentrating, remembering things, and completing tasks.	40	0.223 (0.149-0.311)
446	Attention deficit hyperactivity disorder	has frequent behavior problems, which are sometimes violent. The person often has difficulty interacting with other people and feels irritable.	43	0.045 (0.028-0.066)
447	Conduct disorder	has difficulty interacting with other people, and is slow to understand or respond to questions. The person is often preoccupied with one thing and has some difficulty with basic daily activities.	134	0.241 (0.159-0.341)
448	Asperger syndrome	has severe problems interacting with others and difficulty understanding simple questions or directions. The person has great difficulty with basic daily activities and becomes distressed by any change in routine.	42	0.104 (0.071-0.147)
449	Autism	is slow in learning at school. As an adult, the person has some difficulty doing complex or unfamiliar tasks but otherwise functions independently.	41	0.262 (0.176-0.365)
450	Borderline intellectual functioning	has low intelligence and is slow in learning at school. As an adult, the person can live independently, but often needs help to raise children and can only work at simple supervised jobs.	286	0.011 (0.005-0.02)
451	Intellectual disability / mental retardation, mild	has low intelligence, and is slow in learning to speak and to do even simple tasks. As an adult, the person requires a lot of support to live independently and raise children. The person can only work at the simplest supervised jobs.	287	0.043 (0.026-0.064)
452	Intellectual disability / mental retardation, moderate	has very low intelligence and cannot speak more than a few words, needs constant supervision and help with most daily activities, and can do only the simplest tasks.	288	0.1 (0.066-0.142)
453	Intellectual disability / mental retardation, severe	has very low intelligence, has almost no language, and does not understand even the most basic requests or instructions. The person requires constant supervision and help for all activities.	289	0.16 (0.107-0.226)
454	Intellectual disability / mental retardation, profound	is unable to hear and understand another person talking in a noisy place (for example, on an urban street), and has difficulty hearing another person talking even in a quiet place or on the phone.	290	0.2 (0.133-0.285)
455	Hearing loss, mild		307	0.01 (0.004-0.019)
456	Hearing loss, moderate		309	0.027 (0.015-0.042)

Web Table A.6-Disability weight lay descriptions

Healthstate ID	Healthstate Name	Healthstate Description	hhsqid (Healthstate sequela ID?)	Disability Weight
457	Hearing loss, severe	is unable to hear and understand another person talking, even in a quiet place, and unable to take part in a phone conversation. Difficulties with communicating and relating to others cause emotional impact at times (for example worry or depression).	311	0.158 (0.105-0.227)
458	Hearing loss, profound	is unable to hear and understand another person talking, even in a quiet place, is unable to take part in a phone conversation, and has great difficulty hearing anything in any other situation. Difficulties with communicating and relating to others often cause worry, depression or loneliness.	313	0.204 (0.134-0.288)
459	Hearing loss, complete	cannot hear at all in any situation, including even the loudest sounds, and cannot communicate verbally or use a phone. Difficulties with communicating and relating to others often cause worry, depression or loneliness.	315	0.215 (0.144-0.307)
460	Hearing loss, mild, with ringing	has great difficulty hearing and understanding another person talking in a noisy place (for example, on an urban street), and sometimes has annoying ringing in the ears.	308	0.021 (0.012-0.036)
461	Hearing loss, moderate, with ringing	is unable to hear and understand another person talking in a noisy place (for example, on an urban street), has difficulty hearing another person talking even in a quiet place or on the phone, and has annoying ringing in the ears for 5 minutes at a time, almost every day.	310	0.074 (0.049-0.107)
462	Hearing loss, severe, with ringing	is unable to hear and understand another person talking, even in a quiet place, is unable to take part in a phone conversation, and has annoying ringing in the ears for more than 5 minutes at a time, almost every day. Difficulties with communicating and relating to others cause emotional impact at times (for example worry or depression).	312	0.261 (0.175-0.36)
463	Hearing loss, profound, with ringing	is unable to hear and understand another person talking, even in a quiet place, is unable to take part in a phone conversation, has great difficulty hearing anything in any other situation, and has annoying ringing in the ears for more than 5 minutes at a time, several times a day. Difficulties with communicating and relating to others often cause worry, depression, or loneliness.	314	0.277 (0.182-0.387)
464	Hearing loss, complete, with ringing	cannot hear at all in any situation, including even the loudest sounds, and cannot communicate verbally or use a phone, and has very annoying ringing in the ears for more than half of the day. Difficulties with communicating and relating to others often cause worry, depression or loneliness.	316	0.316 (0.212-0.435)
465	Distance vision, mild impairment	has some difficulty with distance vision, for example reading signs, but no other problems with eyesight.	3	0.003 (0.001-0.007)
466	Distance vision, moderate impairment	has vision problems that make it difficult to recognize faces or objects across a room.	4	0.031 (0.019-0.049)
467	Distance vision, severe impairment	has severe vision loss, which causes difficulty in daily activities, some emotional impact (for example worry), and some difficulty going outside the home without assistance.	5	0.184 (0.125-0.258)
468	Distance vision blindness	is completely blind, which causes great difficulty in some daily activities, worry and anxiety, and great difficulty going outside the home without assistance.	6	0.187 (0.124-0.26)
469	Presbyopia	has difficulty seeing things that are nearer than 3 feet, but has no difficulty with seeing things at a distance.	252	0.011 (0.005-0.02)
704	Distance vision, monocular	is blind in one eye and has difficulty judging distances	79	0.017 (0.009-0.029)
748	Low back pain, mild	has mild back pain, which causes some difficulty dressing, standing, and lifting things.	325	0.02 (0.011-0.035)
749	Low back pain, moderate	has moderate back pain, which causes difficulty dressing, sitting, standing, walking, and lifting things.	326	0.054 (0.035-0.079)
470	Back pain, severe, without leg pain	has severe back pain, which causes difficulty dressing, sitting, standing, walking, and lifting things. The person sleeps poorly and feels worried.	44	0.272 (0.182-0.373)
471	Back pain, severe, with leg pain	has severe back and leg pain, which causes difficulty dressing, sitting, standing, walking, and lifting things. The person sleeps poorly and feels worried.	45	0.325 (0.219-0.446)
472	Back pain, most severe, without leg pain	has constant back pain, which causes difficulty dressing, sitting, standing, walking, and lifting things. The person sleeps poorly, is worried, and has lost some enjoyment in life.	46	0.372 (0.25-0.506)
473	Back pain, most severe, with leg pain	has constant back and leg pain, which causes difficulty dressing, sitting, standing, walking, and lifting things. The person sleeps poorly, is worried, and has lost some enjoyment in life.	47	0.384 (0.256-0.518)
474	Neck pain, mild	has neck pain, and has difficulty turning the head and lifting things.	283	0.053 (0.034-0.078)
476	Neck pain, moderate	has constant neck pain, and has difficulty turning the head, holding arms up, and lifting things	284	0.114 (0.075-0.162)
475	Neck pain, severe	has severe neck pain, and difficulty turning the head and lifting things. The person gets headaches and arm pain, sleeps poorly, and feels tired and worried.	48	0.229 (0.153-0.317)
477	Neck pain, most severe	has constant neck pain and arm pain, and difficulty turning the head, holding arms up, and lifting things. The person gets headaches, sleeps poorly, and feels tired and worried.	49	0.304 (0.202-0.415)
478	Musculoskeletal problems, lower limbs, mild	has pain in the leg, which causes some difficulty running, walking long distances, and getting up and down.	223	0.023 (0.013-0.037)
479	Musculoskeletal problems, lower limbs, moderate	has moderate pain in the leg, which makes the person limp, and causes some difficulty walking, standing, lifting and carrying heavy things, getting up and down and sleeping.	53	0.079 (0.054-0.11)
480	Musculoskeletal problems, lower limbs, severe	has severe pain in the leg, which makes the person limp and causes a lot of difficulty walking, standing, lifting and carrying heavy things, getting up and down, and sleeping.	52	0.165 (0.112-0.232)
481	Musculoskeletal problems, upper limbs, mild	has mild pain and stiffness in the arms and hands. The person has some difficulty lifting, carrying and holding things.	226	0.028 (0.017-0.045)
482	Musculoskeletal problems, upper limbs, moderate	has moderate pain and stiffness in the arms and hands, which causes difficulty lifting, carrying, and holding things, and trouble sleeping because of the pain.	55	0.117 (0.08-0.163)
483	Musculoskeletal problems, generalized, moderate	has pain and deformity in most joints, causing difficulty moving around, getting up and down, and using the hands for lifting and carrying. The person often feels fatigue.	224	0.317 (0.216-0.44)
484	Musculoskeletal problems, generalized, severe	has severe, constant pain and deformity in most joints, causing difficulty moving around, getting up and down, eating, dressing, lifting, carrying and using the hands. The person often feels sadness, anxiety and extreme fatigue.	225	0.581 (0.403-0.739)
485	Gout, acute	has severe pain and swelling in the leg, making it very difficult to get up and down, stand, walk, lift, and carry heavy things. The person has trouble sleeping because of the pain.	54	0.295 (0.196-0.409)
486	Amputation of finger(s), excluding thumb	has lost a finger of one hand. At times there is pain and tingling in the stump.	295	0.005 (0.002-0.01)
487	Amputation of thumb (long term)	has lost one thumb, causing some difficulty in using the hand, pain, and tingling in the stump.	86	0.011 (0.005-0.021)
488	Amputation of one upper limb (long term, with treatment)	has lost one hand and part of the arm, leaving pain and tingling in the stump. The person has an artificial arm that makes it possible to lift objects and do daily activities such as cooking, with some extra effort.	294	0.039 (0.024-0.059)
756	Amputation of one upper limb (long term, without treatment)	has lost one hand and part of the arm, leaving pain and tingling in the stump. The person needs help from others to lift objects or do daily activities such as cooking.	328	0.118 (0.079-0.167)
489	Amputation of both upper limbs (long term, with treatment)	has lost part of both arms, leaving pain and tingling in the stumps. The person has two artificial arms that make it possible to do daily activities, with a great deal of extra effort.	300	0.123 (0.081-0.176)
490	Amputation of both upper limbs (long term, without treatment)	has lost part of both arms, leaving pain and tingling in the stumps. The person needs a great deal of help from others to do even basic daily activities such as eating and using the toilet, and the person is very limited in other activities.	299	0.383 (0.251-0.525)
491	Amputation of toe(s)	has lost one toe, leaving occasional pain and tingling in the stump.	114	0.006 (0.002-0.012)
492	Amputation of one lower limb (long term, with treatment)	has lost part of one leg, leaving pain and tingling in the stump. The person has an artificial leg that helps in moving around.	296	0.039 (0.023-0.059)
493	Amputation of one lower limb (long term, without treatment)	has lost part of one leg, leaving pain and tingling in the stump. The person does not have an artificial leg, has frequent sores, and uses crutches.	89	0.173 (0.118-0.24)
494	Amputation of both lower limbs (long term, with treatment)	has lost part of both legs, leaving pain and tingling in the stumps. The person has two artificial legs that make moving around possible, with extra effort.	297	0.088 (0.057-0.124)
495	Amputation of both lower limbs (long term, without treatment)	has lost part of both legs, leaving pain, tingling, and frequent sores in the stumps. The person has great difficulty moving around, has episodes of depression and anxiety, and needs help from others to do many daily activities.	298	0.443 (0.297-0.589)
496	Burns, <20% total burned surface area without lower airway burns (short term, with or without treatment)	has a burn on part of the body. Parts of the burned area are painful, and other parts have lost feeling.	125	0.141 (0.094-0.196)
497	Burns, <20% total burned surface area or <10% total burned surface area if head/neck or hands/wrist involved (long term, with or without treatment)	has scars caused by a burn. The scars are sometimes painful and itchy.	73	0.016 (0.008-0.028)
498	Burns, >20% total burned surface area (short term, with or without treatment)	has a painful burn over a large part of the body. Parts of the burned area have lost feeling, and the person feels anxious and unwell.	126	0.314 (0.211-0.441)
499	Burns, >20% total burned surface area or >10% total burned surface area if head/neck or hands/wrist involved (long term, with treatment)	has scars caused by burns over a large part of the body. The scars are frequently painful and itchy, and the person is often sad.	71	0.135 (0.092-0.19)
500	Burns, >20% total burned surface area or >10% total burned surface area if head/neck or hands/wrist involved (long term, without treatment)	has severe, disfiguring and itchy scars caused by burns over a large part of the body. The person cannot move some joints, feels sad, and has great difficulty with self-care such as dressing and toileting.	72	0.455 (0.302-0.601)
501	Lower airway burns (with or without treatment)	has a burn in the throat and lungs, which causes great difficulty breathing and a lot of anxiety.	124	0.376 (0.24-0.524)
502	Crush injury (short or long term, with or without treatment)	had part of the body crushed, leaving pain, swelling, tingling and limited feeling in the affected area.	141	0.132 (0.089-0.189)
503	Dislocation of hip (long term, with or without treatment)	walks with a limp and feels discomfort when walking.	151	0.016 (0.008-0.028)
504	Dislocation of knee (long term, with or without treatment)	has a knee out of joint, causing pain and difficulty moving the knee, which sometimes gives way. The person needs crutches for walking and help with self-care such as dressing.	93	0.113 (0.075-0.16)
505	Dislocation of shoulder (long term, with or without treatment)	has a shoulder that is out of joint, causing pain and difficulty moving. The person has difficulty with daily activities such as dressing and cooking.	92	0.062 (0.041-0.088)

Web Table A.6-Disability weight lay descriptions

Healthstate ID	Healthstate Name	Healthstate Description	hhsseqid (Healthstate sequela ID?)	Disability Weight
506	Other injuries of muscle and tendon (includes sprains, strains and dislocations other than shoulder, knee, hip)	has a strained muscle that causes pain and swelling.	227	0.038 (0.003-0.015)
507	Drowning and nonfatal submersion (short or long term, with or without treatment)	has breathlessness, anxiety, cough, and vomiting.	152	0.247 (0.164-0.341)
508	Fracture of clavicle, scapula or humerus (short or long term, with or without treatment)	has a broken shoulder bone, which is painful and swollen. The person cannot use the affected arm and has difficulty with getting dressed.	166	0.035 (0.021-0.053)
509	Fracture of face bone (short or long term, with or without treatment)	has a broken cheek bone or a broken nose or chipped teeth, with swelling and severe pain.	305	0.067 (0.044-0.097)
510	Fracture of foot bones (short term, with or without treatment)	has a broken foot bone, which causes pain, swelling, and difficulty walking.	168	0.026 (0.015-0.043)
511	Fracture of foot bones (long term, without treatment)	had a broken foot in the past that did not heal properly. The person now has pain in the foot and has some difficulty walking.	169	0.026 (0.015-0.042)
512	Fracture of hand (short term, with or without treatment)	has a broken hand, causing pain and swelling.	170	0.01 (0.005-0.019)
513	Fracture of hand (long term, without treatment)	has stiffness in the hand and a weak grip.	171	0.014 (0.007-0.025)
514	Fracture of neck of femur (short term, with or without treatment)	has broken a hip and is in pain. The person cannot stand or walk, and needs help washing, dressing, and going to the toilet.	172	0.258 (0.172-0.356)
515	Fracture of neck of femur (long term, with treatment)	had a broken hip in the past, which was fixed with treatment. The person can only walk short distances, has discomfort when moving around, and has some difficulty in daily activities.	75	0.058 (0.038-0.084)
516	Fracture of neck of femur (long term, without treatment)	had a broken hip bone in the past, which was never treated and did not heal properly. The person cannot get out of bed and needs help washing and going to the toilet.	74	0.402 (0.269-0.541)
517	Fracture, other than femoral neck (short term, with or without treatment)	has a broken thigh bone. The person has severe pain and swelling and cannot walk.	179	0.111 (0.074-0.156)
518	Fracture, other than femoral neck (long term, without treatment)	had a broken thigh bone in the past, which was never treated and did not heal properly. The person now has a limp and discomfort when walking.	76	0.042 (0.027-0.063)
519	Fracture of patella, tibia or fibula or ankle (short term, with or without treatment)	has a broken shin bone, which causes severe pain, swelling, and difficulty walking.	173	0.05 (0.032-0.075)
520	Fracture of patella, tibia or fibula or ankle (long term, with or without treatment)	had a broken shin bone in the past that did not heal properly. The person has pain in the knee and ankle, and has difficulty walking.	82	0.055 (0.036-0.081)
521	Fracture of pelvis (short term)	has a broken pelvis bone, with swelling and bruising. The person has severe pain, and cannot walk or do daily activities.	174	0.279 (0.188-0.384)
522	Fracture of pelvis (long term)	had a broken pelvis in the past and now walks with a limp. There is often pain in the back and groin, and when urinating and sitting for a long time.	78	0.182 (0.123-0.253)
523	Fracture of radius or ulna (short term, with or without treatment)	has a broken forearm, which causes severe pain, swelling, and limited movement.	175	0.028 (0.016-0.046)
524	Fracture of radius or ulna (long term, without treatment)	had a broken forearm in the past that did not heal properly, causing some pain and limited movement in the elbow and wrist. The person has difficulty with daily activities such as dressing.	81	0.043 (0.028-0.064)
525	Fracture of skull (short or long term, with or without treatment)	has a broken skull, but does not have brain damage. The broken area is painful and swollen.	176	0.071 (0.048-0.1)
526	Fracture of sternum and/or fracture of one or two ribs (short term, with or without treatment)	has a broken rib that causes severe pain in the chest, especially when breathing in. The person has difficulty with daily activities such as dressing.	177	0.103 (0.068-0.145)
527	Fracture of vertebral column (short or long term, with or without treatment)	has broken back bones and is in pain, but still has full use of arms and legs.	178	0.111 (0.075-0.156)
528	Fractures, treated (long term)	has slight pain in a bone that was broken in the past.	180	0.005 (0.002-0.01)
529	Injured nerves (short term)	has a nerve injury, which causes difficulty moving and some loss of feeling in the affected area.	211	0.1 (0.067-0.14)
530	Injured nerves (long term)	had a nerve injury in the past, which continues to cause some difficulty moving. The person often injures the affected part because it is numb.	80	0.113 (0.076-0.157)
531	Injury to eyes (short term)	has an injury to one eye, which causes pain and difficulty seeing.	160	0.054 (0.035-0.081)
532	Severe traumatic brain injury, short term (with or without treatment)	cannot concentrate and has headaches, memory problems, dizziness, and feels angry.	123	0.214 (0.141-0.297)
533	Traumatic brain injury, long-term consequences, minor (with or without treatment)	has episodes of headaches, memory problems, and difficulty concentrating.	70	0.094 (0.063-0.133)
534	Traumatic brain injury, long-term consequences, moderate (with or without treatment)	has frequent headaches, memory problems, difficulty concentrating, and dizziness. The person is often anxious and moody.	68	0.231 (0.156-0.324)
535	Traumatic brain injury, long-term consequences, severe (with or without treatment)	cannot think clearly and has frequent headaches, memory problems, difficulty concentrating and dizziness. The person is often anxious and moody, and depends on others for feeding, toileting, dressing and walking.	69	0.637 (0.462-0.789)
536	Open wound (short term, with or without treatment)	has a cut in the skin, which causes pain and numbness around the cut.	234	0.006 (0.002-0.012)
537	Poisoning (short term with or without treatment)	has drowsiness, stomach pain and vomiting.	237	0.163 (0.109-0.227)
538	Severe chest injury (long term, with or without treatment)	had a severe chest injury in the past that has now healed. The person still gets breathless when walking and feels discomfort in the chest.	77	0.047 (0.03-0.07)
539	Severe chest injury (short term, with or without treatment)	has a serious chest injury, which causes severe pain, shortness of breath and anxiety.	133	0.369 (0.248-0.501)
540	Spinal cord lesion below neck level (treated)	is paralyzed from the waist down, cannot feel or move the legs and has difficulties with urine and bowel control. The person uses a wheelchair to move around.	301	0.296 (0.198-0.414)
541	Spinal cord lesion below neck level (untreated)	is paralyzed from the waist down, cannot feel or move the legs and has difficulties with urine and bowel control. Legs are in fixed, bent positions, and the person gets frequent infections and pressure sores.	302	0.623 (0.434-0.777)
542	Spinal cord lesion at neck level (treated)	is paralyzed from the neck down, with no feeling or control over any part of the body below the neck, and no urine or bowel control.	303	0.589 (0.415-0.748)
543	Spinal cord lesion at neck level (untreated)	is paralyzed from the neck down, with no feeling or control over any part of the body below the neck, and no urine or bowel control. Arms and legs are in fixed, bent positions, and the person gets frequent infections and pressure sores.	304	0.732 (0.544-0.871)
750	Concussion	has headaches, dizziness, nausea and difficulty concentrating.	354	0.11 (0.074-0.158)
544	Abdominopelvic problem, mild	has some pain in the belly that causes nausea but does not interfere with daily activities.	109	0.011 (0.005-0.021)
545	Abdominopelvic problem, moderate	has pain in the belly and feels nauseous. The person has difficulties with daily activities.	110	0.114 (0.078-0.159)
546	Abdominopelvic problem, severe	has severe pain in the belly and feels nauseous. The person is anxious and unable to carry out daily activities.	111	0.324 (0.22-0.442)
547	Anemia, mild	feels slightly tired and weak at times, but this does not interfere with normal daily activities.	13	0.004 (0.001-0.008)
548	Anemia, moderate	feels moderate fatigue, weakness, and shortness of breath after exercise, making daily activities more difficult.	14	0.052 (0.034-0.076)
549	Anemia, severe	feels very weak, tired and short of breath, and has problems with activities that require physical effort or deep concentration.	15	0.149 (0.101-0.209)
550	Periodontitis	has minor bleeding of the gums from time to time, with mild discomfort.	280	0.007 (0.003-0.014)
551	Dental caries, symptomatic	has a toothache, which causes some difficulty in eating.	236	0.01 (0.005-0.019)
552	Severe tooth loss	has lost more than 20 teeth including front and back, and has great difficulty in eating meat, fruits, and vegetables.	94	0.067 (0.045-0.095)
553	Disfigurement, level 1	has a slight, visible physical deformity that others notice, which causes some worry and discomfort.	65	0.011 (0.005-0.021)
554	Disfigurement, level 2	has a visible physical deformity that causes others to stare and comment. As a result, the person is worried and has trouble sleeping and concentrating.	66	0.067 (0.044-0.096)
555	Disfigurement, level 3	has an obvious physical deformity that makes others uncomfortable, which causes the person to avoid social contact, feel worried, sleep poorly, and think about suicide.	67	0.405 (0.275-0.546)
556	Disfigurement, level 1 with itch/pain	has a slight, visible physical deformity that is sometimes sore or itchy. Others notice the deformity, which causes some worry and discomfort.	148	0.027 (0.015-0.042)
557	Disfigurement, level 2, with itch/pain	has a visible physical deformity that is sore and itchy. Other people stare and comment, which causes the person to worry. The person has trouble sleeping and concentrating.	149	0.188 (0.125-0.267)
558	Disfigurement, level 3, with itch/pain	has an obvious physical deformity that is very painful and itchy. The physical deformity makes others uncomfortable, which causes the person to avoid social contact, feel worried, sleep poorly, and think about suicide.	150	0.576 (0.401-0.731)
559	Generic uncomplicated disease: worry and daily medication	has a chronic disease that requires medication every day and causes some worry but minimal interference with daily activities.	182	0.049 (0.031-0.072)
560	Generic uncomplicated disease: anxiety about diagnosis	has a disease diagnosis that causes some worry but minimal interference with daily activities.	306	0.012 (0.006-0.023)
561	Iodine-deficiency goiter	has a large mass in the front of the neck. The person sometimes has weakness and fatigue, constipation and weight gain.	213	0.199 (0.133-0.276)
562	Kwashiorkor	is very tired and irritable and has diarrhea.	218	0.051 (0.031-0.079)
563	Severe wasting	is extremely skinny and has no energy.	254	0.128 (0.082-0.183)
564	Speech problems	has difficulty speaking, and others find it difficult to understand.	219	0.051 (0.032-0.078)

Web Table A.6-Disability weight lay descriptions

Healthstate ID	Healthstate Name	Healthstate Description	hhsqid (Healthstate sequela ID?)	Disability Weight
565	Motor impairment, mild	has some difficulty in moving around but is able to walk without help.	228	0.01 (0.005-0.019)
566	Motor impairment, moderate	has some difficulty in moving around, and difficulty in lifting and holding objects, dressing and sitting upright, but is able to walk without help.	229	0.061 (0.04-0.089)
567	Motor impairment, severe	is unable to move around without help, and is not able to lift or hold objects, get dressed or sit upright.	230	0.402 (0.268-0.545)
568	Motor plus cognitive impairments, mild	has some difficulty in moving around but is able to walk without help. The person is slow in learning at school. As an adult, the person has some difficulty doing complex or unfamiliar tasks but otherwise functions independently.	291	0.031 (0.018-0.05)
569	Motor plus cognitive impairments, moderate	has some difficulty in moving around, holding objects, dressing and sitting upright, but can walk without help. The person has low intelligence and is slow in learning to speak and to do simple tasks.	292	0.203 (0.134-0.29)
570	Motor plus cognitive impairments, severe	cannot move around without help, and cannot lift or hold objects, get dressed or sit upright. The person also has very low intelligence, speaks few words, and needs constant supervision and help with all daily activities.	293	0.542 (0.374-0.702)
571	Rectovaginal fistula	has an abnormal opening between her vagina and rectum causing flatulence and feces to escape through the vagina. The person gets infections in her vagina, and has pain when urinating.	164	0.501 (0.339-0.657)
572	Vesicovaginal fistula	has an abnormal opening between the bladder and the vagina, which makes her unable to control urinating. The woman is anxious and depressed.	165	0.342 (0.227-0.478)
589	Harmful alcohol use	(custom DW from MEPS)		#N/A
573	Other cardiovascular and circulatory disease	(custom DW from MEPS)		#N/A
574	Congenital heart disease	(custom DW from MEPS)		#N/A
575	Hearing loss, moderately severe	(custom DW from hearing loss impairment envelope)		#N/A
576	Hearing loss, moderately severe, with ringing	(custom DW from hearing loss impairment envelope)		#N/A
772	Epilepsy	(combined DW)		#N/A
775	Moderate motor impairment with blindness	(combined DW)		#N/A
776	Moderate motor impairment with epilepsy	(combined DW)		#N/A
777	Moderate motor impairment with blindness and epilepsy	(combined DW)		#N/A
778	Moderate motor plus cognitive impairment with blindness	(combined DW)		#N/A
779	Moderate motor plus cognitive impairment with epilepsy	(combined DW)		#N/A
780	Moderate motor plus cognitive impairment with blindness and epilepsy	(combined DW)		#N/A
781	Severe motor impairment with blindness	(combined DW)		#N/A
782	Severe motor impairment with epilepsy	(combined DW)		#N/A
783	Severe motor impairment with blindness and epilepsy	(combined DW)		#N/A
784	Severe motor plus cognitive impairment with blindness	(combined DW)		#N/A
785	Severe motor plus cognitive impairment with epilepsy	(combined DW)		#N/A
786	Severe motor plus cognitive impairment with blindness and epilepsy	(combined DW)		#N/A
766	Severe motor impairment with incontinence	(combined DW)		#N/A
787	Congenital heart disease with primary infertility	(combined DW)		#N/A
773	Speech problems with disfigurement level 2	(combined DW)		#N/A
768	Intellectual disability	(combined DW)		#N/A
769	Intellectual disability with congenital heart disease	(combined DW)		#N/A
770	Intellectual disability with dementia	(combined DW)		#N/A
771	Intellectual disability with congenital heart disease and dementia	(combined DW)		#N/A
788	Borderline intellectual disability with primary infertility	(combined DW)		#N/A
774	Mild intellectual disability with primary infertility	(combined DW)		#N/A
764	Mild low back pain with leg pain	(combined DW)	325	0.02 (0.011-0.035)
765	Moderate low back pain with leg pain	(combined DW)	326	0.054 (0.035-0.079)
590	Amputation of both lower limbs	(custom DW from injuries)		#N/A
591	Amputation of both upper limbs	(custom DW from injuries)		#N/A
592	Amputation of finger (excluding thumb)	(custom DW from injuries)		#N/A
593	Amputation of one lower limb	(custom DW from injuries)		#N/A
594	Amputation of one upper limb	(custom DW from injuries)		#N/A
595	Amputation of thumb	(custom DW from injuries)		#N/A
596	Amputation of toe	(custom DW from injuries)		#N/A
597	Burns with <20% total burned surface area	(custom DW from injuries)		#N/A
598	Burns with >=20% total burned surface area or >=10% if burns include face and/or hands	(custom DW from injuries)		#N/A
599	Lower airway burns	(custom DW from injuries)		#N/A
600	Dislocation of hip	(custom DW from injuries)		#N/A
601	Dislocation of knee	(custom DW from injuries)		#N/A
602	Dislocation of shoulder	(custom DW from injuries)		#N/A
603	Other injuries of muscle & tendon and other dislocations	(custom DW from injuries)		#N/A
604	Fracture of clavicle, scapula, or humerus	(custom DW from injuries)		#N/A
605	Fracture of face bone	(custom DW from injuries)		#N/A
606	Fracture of foot bone	(custom DW from injuries)		#N/A
607	Fracture of hand bone	(custom DW from injuries)		#N/A
608	Fracture of neck of femur	(custom DW from injuries)		#N/A
609	Fracture of patella, tibia, fibula, or ankle	(custom DW from injuries)		#N/A
610	Fracture of pelvis	(custom DW from injuries)		#N/A
611	Fracture of radius or ulna	(custom DW from injuries)		#N/A
612	Fracture of skull	(custom DW from injuries)		#N/A
613	Fracture of sternum or rib(s)	(custom DW from injuries)		#N/A
614	Fracture of vertebral column	(custom DW from injuries)		#N/A
615	Fracture of femur, other than femoral neck	(custom DW from injuries)		#N/A
616	Minor traumatic brain injury	(custom DW from injuries)		#N/A
617	Moderate traumatic brain injury	(custom DW from injuries)		#N/A
618	Severe traumatic brain injury	(custom DW from injuries)		#N/A
619	Foreign body in ear	(custom DW from injuries)		#N/A
620	Foreign body in respiratory system	(custom DW from injuries)		#N/A
621	Foreign body in gastrointestinal or urogenital system	(custom DW from injuries)		#N/A
622	Spinal cord lesion at neck level	(custom DW from injuries)		#N/A
623	Spinal cord lesion below neck level	(custom DW from injuries)		#N/A
624	Non-fatal submersion	(custom DW from injuries)		#N/A
625	Asphyxiation	(custom DW from injuries)		#N/A
626	Crush injury	(custom DW from injuries)		#N/A
627	Injured nerves	(custom DW from injuries)		#N/A
628	Injury to eyes (including foreign body eye)	(custom DW from injuries)		#N/A
629	Open wound	(custom DW from injuries)		#N/A
630	Poisoning	(custom DW from injuries)		#N/A
631	Severe chest injury	(custom DW from injuries)		#N/A
632	Internal hemorrhage in abdomen or pelvis	(custom DW from injuries)		#N/A
633	Contusion	(custom DW from injuries)		#N/A
634	Effect of environmental factors	(custom DW from injuries)		#N/A
635	Complications of medical treatment	(custom DW from injuries)		#N/A
636	Superficial injury	(custom DW from injuries)		#N/A
637	Multi-trauma	(custom DW from injuries)		#N/A
643	Hearing loss impairment at 20+ dB			#N/A
644	Hearing loss impairment at 35+ dB			#N/A

Web Table A.6-Disability weight lay descriptions

Healthstate ID	Healthstate Name	Healthstate Description	hhsseqid (Healthstate sequela ID?)	Disability Weight
645	Hearing loss impairment at 50+ dB			#N/A
646	Hearing loss impairment at 65+ dB			#N/A
647	Hearing loss impairment at 80+ dB			#N/A
648	Hearing loss impairment at 95+ dB			#N/A
790	Hearing loss impairment at 0-19 dB			#N/A
751	Hearing loss impairment at 20-34 dB			#N/A
752	Hearing loss impairment at 35-49 dB			#N/A
753	Hearing loss impairment at 50-64 dB			#N/A
754	Hearing loss impairment at 65-79 dB			#N/A
755	Hearing loss impairment at 80-94 dB			#N/A
649	Hearing aids (proportion of total hearing loss)			#N/A
791	Primary Infertility Exposure			#N/A
792	Secondary Infertility Exposure			#N/A
794	Proportion of males who are the cause of couple primary infertility			#N/A
795	Proportion of females who are the cause of primary infertility			#N/A
796	Proportion of males who are the cause of couple secondary infertility			#N/A
797	Proportion of females who are the cause of couple secondary infertility			#N/A
705	Cannabis use			#N/A
706	Vitamin A deficiency			#N/A
800	Disfigurement level 1 and primary infertility	(combined DW)		#N/A
821	Disfigurement level 1 and secondary infertility	(combined DW)		#N/A
801	Mild abdominal pain and primary infertility	(combined DW)		#N/A
802	Moderate abdominal pain and primary infertility	(combined DW)		#N/A
803	Severe abdominal pain and primary infertility	(combined DW)		#N/A
804	Mild abdominal pain and secondary infertility	(combined DW)		#N/A
805	Moderate abdominal pain and secondary infertility	(combined DW)		#N/A
806	Severe abdominal pain and secondary infertility	(combined DW)		#N/A
807	Mild abdominal pain and stress incontinence	(combined DW)		#N/A
808	Mild abdominal pain and mild depression	(combined DW)		#N/A
811	Thrombocytopenic purpura	easily bruises and sometimes bleeds from the gums and nose; feels weak and has some difficulty with daily activities.	351	0.159 (0.106-0.226)
812	Hypothyroidism	has low energy and feels cold.	336	0.019 (0.01-0.032)
813	Hyperthyroidism	feels nervous, has palpitations, sweats a lot and has difficulty sleeping.	340	0.145 (0.096-0.202)
814	Generic uncomplicated disease anxiety and severe abdominopelvic problem			#N/A
815	Generic uncomplicated disease anxiety; long-term consequences due to stroke			#N/A
816	Generic uncomplicated disease anxiety; long-term consequences due to stroke; severe abdominopelvic problem			#N/A
817	Infectious disease, acute episode, severe; Generic uncomplicated disease anxiety			#N/A
820	Moderate motor impairment with incontinence			#N/A
822	Symptomatic urolithiasis			#N/A
823	Vertigo		339	#N/A
824	Moderate abdominal pain, tension-type headaches, mild motor plus cognitive impairment	(combined DW)		#N/A
825	Tension-type headaches, mild motor plus cognitive impairment	(combined DW)		#N/A
826	Moderate abdominal pain and severe epilepsy	(combined DW)		#N/A
827	Vertigo with mild hearing loss			#N/A
828	Vertigo with mild hearing loss and ringing			#N/A
829	Disfigurement, level 1, with mild heart failure			#N/A
830	Disfigurement, level 1, with moderate heart failure			#N/A
831	Disfigurement, level 1, with severe heart failure			#N/A
832	Severe anemia with mild heart failure			#N/A
833	Severe anemia with moderate heart failure			#N/A
834	Severe anemia with severe heart failure			#N/A
835	Mild anemia with Stage IV CKD			#N/A
836	Moderate anemia with Stage IV CKD			#N/A
837	Severe anemia with Stage IV CKD			#N/A
838	Diabetic neuropathy with diabetic foot			#N/A
839	Diabetic neuropathy with treated amputation			#N/A
840	Diabetic neuropathy with untreated amputation			#N/A
850	Severe COPD and other chronic respiratory, with mild heart failure			#N/A
851	Severe COPD and other chronic respiratory, with moderate heart failure			#N/A
852	Severe COPD and other chronic respiratory, with severe heart failure			#N/A
853	Mild Anemia with moderate abdominopelvic problem			#N/A
854	Moderate Anemia with moderate abdominopelvic problem			#N/A
855	Severe Anemia with moderate abdominopelvic problem			#N/A

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Early HIV	has a disease diagnosis that causes some worry but minimal interference with daily activities
Symptomatic HIV	HIV infection, WHO clinical stage 2 or 3 not meeting criteria for AIDS
AIDS with antiretroviral treatment	AIDS with antiretroviral treatment
AIDS without antiretroviral treatment	AIDS without antiretroviral treatment
Mild diarrheal diseases	mild diarrhea causing occasional discomfort
Moderate diarrheal diseases	diarrhea with painful cramps and thirst
Severe diarrheal diseases	diarrhea with severe cramps and dehydration
Guillain-Barré syndrome due to diarrheal diseases	paralysis from the waist down
Acute typhoid infection	moderate infectious disease episode with fever, aches and fatigue
Severe typhoid fever	severe infectious disease episode with high fever, pain and severe fatigue
Intestinal perforation due to typhoid	severe abdominal pain and nausea due to intestinal perforation
Gastrointestinal bleeding due to typhoid	has gastrointestinal bleeding due to typhoid infection, resulting in vomiting blood and nausea
Acute paratyphoid infection	mild infectious disease episode with low fever and mild discomfort
Moderate paratyphoid fever	moderate infectious disease episode with fever, aches and fatigue
Severe paratyphoid fever	severe infectious disease episode with high fever, pain and severe fatigue
Intestinal perforation due to paratyphoid	severe abdominal pain and nausea due to intestinal perforation
Moderate lower respiratory infections	moderate infectious disease episode with fever, aches and fatigue
Severe lower respiratory infections	severe infectious disease episode with high fever, pain and severe fatigue
Guillain-Barré syndrome due to lower respiratory infections	paralysis from the waist down
Mild upper respiratory infections	mild infectious disease episode with low fever and mild discomfort
Moderate upper respiratory infections	moderate infectious disease episode with fever, aches and fatigue
Guillain-Barré syndrome due to upper respiratory infections	paralysis from the waist down
Acute otitis media	acute episode of otitis media with fever and ear pain
Severe infectious complications due to chronic otitis media	subperiosteal abscess, meningitis or brain abscess as a complication of chronic otitis media
Moderate hearing loss due to chronic otitis media	moderate hearing loss (35-49dB)
Moderate hearing loss with ringing due to chronic otitis media	moderate hearing loss (35-49dB) with ringing
Moderately severe hearing loss due to otitis media	moderately severe hearing loss (50-64dB)
Moderately severe hearing loss with ringing due to otitis media	moderately severe hearing loss (50-64dB) with ringing
Severe hearing loss due to otitis media	severe hearing loss (65-79dB)
Severe hearing loss with ringing due to otitis media	severe hearing loss (65-79dB) with ringing
Profound hearing loss due to otitis media	profound hearing loss (80-94dB)
Profound hearing loss with ringing due to otitis media	profound hearing loss (80-94dB) with ringing
Complete hearing loss due to otitis media	complete hearing loss (95dB+)
Complete hearing loss with ringing due to otitis media	complete hearing loss (95dB+) with ringing
Vertigo with mild hearing loss due to chronic otitis media	short spells of dizziness and loss of balance with mild hearing loss (20-34dB)
Vertigo with mild hearing loss and ringing due to chronic otitis media	short spells of dizziness and loss of balance with mild hearing loss (20-34dB) and ringing
Mild hearing loss due to chronic otitis media	mild hearing loss (20-34dB)

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Mild hearing loss with ringing due to chronic otitis media	mild hearing loss (20-34dB) with ringing
Acute pneumococcal meningitis	severe infectious disease episode with high fever, pain and severe fatigue
Mild behavioral problems due to pneumococcal meningitis	mild behavioral problems
Mild motor impairment due to long term due to pneumococcal meningitis	mild motor impairment (muscle weakness and some problems with gait or balance)
Mild motor plus cognitive impairments due to pneumococcal meningitis	mild motor impairment (muscle weakness and some problems with gait or balance) plus intellectual disability (IQ 70-84)
Borderline intellectual disability due to pneumococcal meningitis	intellectual disability (IQ 70-84)
Monocular distance vision loss due to pneumococcal meningitis	blind in one eye (vision <3/60) but not in the other due to pneumococcal meningitis infection
Mild intellectual disability due to pneumococcal meningitis	intellectual disability (IQ 50-69)
Moderate motor impairment due to pneumococcal meningitis	moderate motor impairment (spasticity and paresis but able to walk)
Severe motor impairment due to pneumococcal meningitis	severe motor impairment (unable to walk)
Moderate motor plus cognitive impairments due to pneumococcal meningitis	moderate motor (spasticity and paresis but able to walk) plus intellectual disability (IQ <70)
Severe motor plus cognitive impairments due to pneumococcal meningitis	severe motor impairment (unable to walk) plus intellectual disability (IQ <70)
Epilepsy due to pneumococcal meningitis	epilepsy
Blindness due to pneumococcal meningitis	blindness (vision <3/60 in better eye)
Mild hearing loss due to pneumococcal meningitis	mild hearing loss (20-34dB)
Mild hearing loss with ringing due to pneumococcal meningitis	mild hearing loss (20-34dB) with ringing
Moderate hearing loss due to pneumococcal meningitis	moderate hearing loss (35-49dB)
Moderate hearing loss with ringing due to pneumococcal meningitis	moderate hearing loss (35-49dB) with ringing
Moderately severe hearing loss due to pneumococcal meningitis	moderately severe hearing loss (50-64dB)
Moderately severe hearing loss with ringing due to pneumococcal meningitis	moderately severe hearing loss (50-64dB) with ringing
Severe hearing loss due to pneumococcal meningitis	severe hearing loss (65-79dB)
Severe hearing loss with ringing due to pneumococcal meningitis	severe hearing loss (65-79dB) with ringing
Profound hearing loss due to pneumococcal meningitis	profound hearing loss (80-94dB)
Profound hearing loss with ringing due to pneumococcal meningitis	profound hearing loss (80-94dB) with ringing
Complete hearing loss due to pneumococcal meningitis	complete hearing loss (95dB+)
Complete hearing loss with ringing due to pneumococcal meningitis	complete hearing loss (95dB+) with ringing
Acute H influenzae type B meningitis	severe infectious disease episode with high fever, pain and severe fatigue
Mild behavioral problems due to H influenzae type B meningitis	mild behavioral problems
Mild motor impairment due to long term due to H influenzae type B meningitis	mild motor impairment (muscle weakness and some problems with gait or balance)

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Mild motor plus cognitive impairments due to H influenzae type B meningitis	mild motor impairment (muscle weakness and some problems with gait or balance) plus intellectual disability (IQ 70-84)
Borderline intellectual disability due to H influenzae type B meningitis	intellectual disability (IQ 70-84)
Monocular distance vision loss due to H influenzae type B meningitis	blind in one eye (vision <3/60) but not in the other due to H influenzae type B meningitis infection
Mild intellectual disability due to H influenzae type B meningitis	intellectual disability (IQ 50-69)
Moderate motor impairment due to H influenzae type B meningitis	moderate motor impairment (spasticity and paresis but able to walk)
Severe motor impairment due to H influenzae type B meningitis	severe motor impairment (unable to walk)
Moderate motor plus cognitive impairments due to H influenzae type B meningitis	moderate motor (spasticity and paresis but able to walk) plus intellectual disability (IQ <70)
Severe motor plus cognitive impairments due to H influenzae type B meningitis	severe motor impairment (unable to walk) plus intellectual disability (IQ <70)
Epilepsy due to H influenzae type B meningitis	epilepsy
Blindness due to H influenzae type B meningitis	blindness (vision <3/60 in better eye)
Mild hearing loss due to H influenzae type B meningitis	mild hearing loss (20-34dB)
Mild hearing loss with ringing due to H influenzae type B meningitis	mild hearing loss (20-34dB) with ringing
Moderate hearing loss due to H influenzae type B meningitis	moderate hearing loss (35-49dB)
Moderate hearing loss with ringing due to H influenzae type B meningitis	moderate hearing loss (35-49dB) with ringing
Moderately severe hearing loss due to H influenzae type B meningitis	moderately severe hearing loss (50-64dB)
Moderately severe hearing loss with ringing due to H influenzae type B meningitis	moderately severe hearing loss (50-64dB) with ringing
Severe hearing loss due to H influenzae type B meningitis	severe hearing loss (65-79dB)
Severe hearing loss with ringing due to H influenzae type B meningitis	severe hearing loss (65-79dB) with ringing
Profound hearing loss due to H influenzae type B meningitis	profound hearing loss (80-94dB)
Profound hearing loss with ringing due to H influenzae type B meningitis	profound hearing loss (80-94dB) with ringing
Complete hearing loss due to H influenzae type B meningitis	complete hearing loss (95dB+)
Complete hearing loss with ringing due to H influenzae type B meningitis	complete hearing loss (95dB+) with ringing
Acute meningococcal meningitis	severe infectious disease episode with high fever, pain and severe fatigue
Mild behavioral problems due to meningococcal meningitis	mild behavioral problems
Mild motor impairment due to long term due to meningococcal meningitis	mild motor impairment (muscle weakness and some problems with gait or balance)
Mild motor plus cognitive impairments due to meningococcal meningitis	mild motor impairment (muscle weakness and some problems with gait or balance) plus intellectual disability (IQ 70-84)
Borderline intellectual disability due to meningococcal meningitis	intellectual disability (IQ 70-84)
Monocular distance vision loss due to meningococcal meningitis	blind in one eye (vision <3/60) but not in the other due to meningococcal meningitis infection

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Mild intellectual disability due to meningococcal meningitis	intellectual disability (IQ 50-69)
Moderate motor impairment due to meningococcal meningitis	moderate motor impairment (spasticity and paresis but able to walk)
Severe motor impairment due to meningococcal meningitis	severe motor impairment (unable to walk)
Moderate motor plus cognitive impairments due to meningococcal meningitis	moderate motor (spasticity and paresis but able to walk) plus intellectual disability (IQ <70)
Severe motor plus cognitive impairments due to meningococcal meningitis	severe motor impairment (unable to walk) plus intellectual disability (IQ <70)
Epilepsy due to meningococcal meningitis	epilepsy
Blindness due to meningococcal meningitis	blindness (vision <3/60 in better eye)
Mild hearing loss due to meningococcal meningitis	mild hearing loss (20-34dB)
Mild hearing loss with ringing due to meningococcal meningitis	mild hearing loss (20-34dB) with ringing
Moderate hearing loss due to meningococcal meningitis	moderate hearing loss (35-49dB)
Moderate hearing loss with ringing due to meningococcal meningitis	moderate hearing loss (35-49dB) with ringing
Moderately severe hearing loss due to meningococcal meningitis	moderately severe hearing loss (50-64dB)
Moderately severe hearing loss with ringing due to meningococcal meningitis	moderately severe hearing loss (50-64dB) with ringing
Severe hearing loss due to meningococcal meningitis	severe hearing loss (65-79dB)
Severe hearing loss with ringing due to meningococcal meningitis	severe hearing loss (65-79dB) with ringing
Profound hearing loss due to meningococcal meningitis	profound hearing loss (80-94dB)
Profound hearing loss with ringing due to meningococcal meningitis	profound hearing loss (80-94dB) with ringing
Complete hearing loss due to meningococcal meningitis	complete hearing loss (95dB+)
Complete hearing loss with ringing due to meningococcal meningitis	complete hearing loss (95dB+) with ringing
Acute viral meningitis	severe infectious disease episode with high fever, pain and severe fatigue
Other acute bacterial meningitis	severe infectious disease episode with high fever, pain and severe fatigue
Mild behavioral problems due to other bacterial meningitis	mild behavioral problems
Mild motor impairment due to long term due to other bacterial meningitis	mild motor impairment (muscle weakness and some problems with gait or balance)
Mild motor plus cognitive impairments due to other bacterial meningitis	mild motor impairment (muscle weakness and some problems with gait or balance) plus intellectual disability (IQ 70-84)
Borderline intellectual disability due to other bacterial meningitis	intellectual disability (IQ 70-84)
Monocular distance vision loss due to other bacterial meningitis	blind in one eye (vision <3/60) but not in the other due to other bacterial meningitis infection
Mild intellectual disability due to other bacterial meningitis	intellectual disability (IQ 50-69)
Moderate motor impairment due to other bacterial meningitis	moderate motor impairment (spasticity and paresis but able to walk)
Severe motor impairment due to other bacterial meningitis	severe motor impairment (unable to walk)

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Moderate motor plus cognitive impairments due to other bacterial meningitis	moderate motor (spasticity and paresis but able to walk) plus intellectual disability (IQ <70)
Severe motor plus cognitive impairments due to other bacterial meningitis	severe motor impairment (unable to walk) plus intellectual disability (IQ <70)
Epilepsy due to other meningitis	epilepsy
Blindness due to other bacterial meningitis	blindness (vision <3/60 in better eye)
Mild hearing loss due to other bacterial meningitis	mild hearing loss (20-34dB)
Mild hearing loss due with ringing to other bacterial meningitis	mild hearing loss (20-34dB) with ringing
Moderate hearing loss due to other bacterial meningitis	moderate hearing loss (35-49dB)
Moderate hearing loss with ringing due to other bacterial meningitis	moderate hearing loss (35-49dB) with ringing
Moderately severe hearing loss due to other bacterial meningitis	moderately severe hearing loss (50-64dB)
Moderately severe hearing loss with ringing due to other bacterial meningitis	moderately severe hearing loss (50-64dB) with ringing
Severe hearing loss due to other bacterial meningitis	severe hearing loss (65-79dB)
Severe hearing loss with ringing due to other bacterial meningitis	severe hearing loss (65-79dB) with ringing
Profound hearing loss due to other bacterial meningitis	profound hearing loss (80-94dB)
Profound hearing loss with ringing due to other bacterial meningitis	profound hearing loss (80-94dB) with ringing
Complete hearing loss due to other bacterial meningitis	complete hearing loss (95dB+)
Complete hearing loss with ringing due to other bacterial meningitis	complete hearing loss (95dB+) with ringing
Acute encephalitis	severe infectious disease episode with high fever, pain and severe fatigue
Mild behavioral problems due to encephalitis	mild behavioral problems
Mild motor impairment due to long term due to encephalitis	mild motor impairment (muscle weakness and some problems with gait or balance)
Mild motor plus cognitive impairments due to encephalitis	mild motor impairment (muscle weakness and some problems with gait or balance) plus intellectual disability (IQ 70-84)
Borderline intellectual disability due to encephalitis	intellectual disability (IQ 70-84)
Monocular distance vision loss due to encephalitis	blind in one eye (vision <3/60) but not in the other due to encephalitis infection
Mild intellectual disability due to encephalitis	intellectual disability (IQ 50-69)
Moderate motor impairment due to encephalitis	moderate motor impairment (spasticity and paresis but able to walk)
Severe motor impairment due to encephalitis	severe motor impairment (unable to walk)
Moderate motor plus cognitive impairments due to encephalitis	moderate motor (spasticity and paresis but able to walk) plus intellectual disability (IQ <70)
Severe motor plus cognitive impairments due to encephalitis	severe motor impairment (unable to walk) plus intellectual disability (IQ <70)

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Epilepsy due to encephalitis	epilepsy
Blindness due to encephalitis	blindness (vision <3/60 in better eye)
Moderate diphtheria	moderate infectious disease episode with fever, aches and fatigue
Severe diphtheria	severe infectious disease episode with high fever, pain and severe fatigue
Severe tetanus	severe infectious disease episode with high fever, pain and severe fatigue
Mild motor impairment due to neonatal tetanus	mild motor impairment (muscle weakness and some problems with gait or balance)
Mild motor plus cognitive impairments due to neonatal tetanus	mild motor impairment (muscle weakness and some problems with gait or balance) plus intellectual disability (IQ 70-84)
Moderate motor impairment due to neonatal tetanus	moderate motor impairment (spasticity and paresis but able to walk)
Moderate motor impairment with blindness due to neonatal tetanus	moderate motor impairment (spasticity and paresis but able to walk) with blindness (vision <3/60 in better eye)
Moderate motor impairment with epilepsy due to neonatal tetanus	moderate motor impairment (spasticity and paresis but able to walk) with epilepsy
Moderate motor impairment with blindness and epilepsy due to neonatal tetanus	moderate motor impairment (spasticity and paresis but able to walk) with blindness (vision <3/60 in better eye) and epilepsy
Moderate motor plus cognitive impairment with blindness due to neonatal tetanus	moderate motor impairment (spasticity and paresis but able to walk) plus intellectual disability (IQ <70) with blindness (vision <3/60 in better eye)
Moderate motor plus cognitive impairment with epilepsy due to neonatal tetanus	moderate motor impairment (spasticity and paresis but able to walk) plus intellectual disability (IQ <70) with epilepsy
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal tetanus	moderate motor impairment (spasticity and paresis but able to walk) plus intellectual disability (IQ <70) with blindness (vision <3/60 in better eye) and epilepsy
Severe motor impairment due to neonatal tetanus	severe motor impairment (unable to walk)
Severe motor impairment with blindness due to neonatal tetanus	severe motor impairment (unable to walk) with blindness (vision <3/60 in better eye)
Severe motor impairment with epilepsy due to neonatal tetanus	severe motor impairment (unable to walk) with epilepsy
Severe motor impairment with blindness and epilepsy due to neonatal tetanus	severe motor impairment (unable to walk) with blindness (vision <3/60 in better eye) and epilepsy
Severe motor plus cognitive impairment with blindness due to neonatal tetanus	severe motor impairment (unable to walk) plus intellectual disability (IQ <70) with blindness (vision <3/60 in better eye)
Severe motor plus cognitive impairment with epilepsy due to neonatal tetanus	severe motor impairment (unable to walk) plus intellectual disability (IQ <70) with epilepsy
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal tetanus	severe motor impairment (unable to walk) plus intellectual disability (IQ <70) with blindness (vision <3/60 in better eye) and epilepsy
Moderate measles	moderate infectious disease episode with fever, aches and fatigue
Severe measles	severe infectious disease episode with high fever, pain and severe fatigue
Asymptomatic malaria parasitemia (PfPR)	malaria parasitemia without symptoms
Mild malaria	mild infectious disease episode with low fever and mild discomfort
Moderate malaria	moderate infectious disease episode with fever, aches and fatigue
Severe malaria	severe infectious disease episode with high fever, pain and severe fatigue

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Moderate motor impairment due to malaria	moderate motor impairment (spasticity and paresis but able to walk)
Moderate motor impairment with blindness due to malaria	moderate motor impairment (spasticity and paresis but able to walk) with blindness (vision <3/60 in better eye)
Moderate motor impairment with epilepsy due to malaria	moderate motor impairment (spasticity and paresis but able to walk) with blindness (vision <3/60 in better eye) and epilepsy
Moderate motor impairment with blindness and epilepsy due to malaria	moderate motor impairment (spasticity and paresis but able to walk) with blindness (vision <3/60 in better eye) and epilepsy
Moderate motor plus cognitive impairment with blindness due to malaria	moderate motor (spasticity and paresis but able to walk) plus cognitive impairment with blindness (vision <3/60 in better eye)
Moderate motor plus cognitive impairment with epilepsy due to malaria	moderate motor (spasticity and paresis but able to walk) plus cognitive impairment with epilepsy
Moderate motor plus cognitive impairment with blindness and epilepsy due to malaria	moderate motor (spasticity and paresis but able to walk) plus cognitive impairment with blindness (vision <3/60 in better eye) and epilepsy
Severe motor impairment due to malaria	severe motor impairment (unable to walk)
Severe motor impairment with blindness due to malaria	severe motor impairment (unable to walk) with blindness (vision <3/60 in better eye)
Severe motor impairment with epilepsy due to malaria	severe motor impairment (unable to walk) with epilepsy
Severe motor impairment with blindness and epilepsy due to malaria	severe motor impairment (unable to walk) with blindness (vision <3/60 in better eye) (vision <3/60 in better eye) and epilepsy
Severe motor plus cognitive impairment with blindness due to malaria	severe motor impairment (unable to walk) plus cognitive impairment with blindness (vision <3/60 in better eye)
Severe motor plus cognitive impairment with epilepsy due to malaria	severe motor impairment (unable to walk) plus cognitive impairment with epilepsy
Severe motor plus cognitive impairment with blindness and epilepsy due to malaria	severe motor impairment (unable to walk) plus cognitive impairment with blindness (vision <3/60 in better eye) and epilepsy
Mild anemia due to malaria parasitemia (PfPR)	malaria parasitemia causing minor fatigue associated with mild anemia (2011 WHO classification)
Moderate anemia due to malaria parasitemia (PfPR)	malaria parasitemia causing moderate fatigue associated with moderate anemia (2011 WHO classification)
Severe anemia due to malaria parasitemia (PfPR)	malaria parasitemia causing severe fatigue associated with severe anemia (2011 WHO classification)
Acute Chagas disease	moderate infectious disease episode with fever, aches and fatigue
Mild chronic digestive disease due to Chagas disease	abdominal pain and nausea reported as mild
Moderate chronic digestive disease due to Chagas disease	abdominal pain and nausea reported as moderate
Asymptomatic Chagas disease	person infected with Chagas, currently without symptoms
Atrial fibrillation and flutter due to Chagas disease	has periods of rapid and irregular heartbeats and occasional fainting that are attributable to infection with the <i>T. cruzi</i> parasite
Mild heart failure due to Chagas disease	shortness of breath and fatigue after moderate physical activity that goes away after a rest (NYHA Class I-II heart failure)
Moderate heart failure due to Chagas disease	shortness of breath and fatigue after minimal physical activity that goes away after a rest (NYHA Class III heart failure)
Severe heart failure due to Chagas disease	shortness of breath and fatigue even when at rest causing a person to avoid any physical activity (NYHA Class IV heart failure)
Moderate visceral leishmaniasis	moderate infectious disease episode with fever, aches and fatigue
Severe visceral leishmaniasis	severe infectious disease episode with high fever, pain and severe fatigue

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Disfigurement due to African trypanosomiasis	visible physical deformity that causes others to stare and comment which causes anxiety
Severe motor plus cognitive impairments due to African trypanosomiasis	severe motor impairment (unable to walk) plus intellectual disability (IQ <70)
Mild schistosomiasis	mild infectious disease episode with low fever and mild discomfort
Mild diarrhea due to schistosomiasis	mild diarrhea causing occasional discomfort
Hematemesis due to schistosomiasis	vomits blood and feels nauseous
Hepatomegaly due to schistosomiasis	abdominal pain and nausea reported as mild
Ascites due to schistosomiasis	abdominal pain and nausea reported as moderate
Dysuria due to schistosomiasis	abdominal pain and nausea reported as mild
Bladder pathology due to schistosomiasis	abdominal pain and nausea reported as mild
Hydronephrosis due to schistosomiasis	abdominal pain and nausea reported as mild
Mild anemia due to schistosomiasis	schistosomiasis with minor fatigue associated with mild anemia (2011 WHO classification)
Moderate anemia due to schistosomiasis	schistosomiasis with moderate fatigue associated with moderate anemia (2011 WHO classification)
Severe anemia due to schistosomiasis	schistosomiasis with severe fatigue associated with severe anemia (2011 WHO classification)
Neurocysticercosis with epilepsy	epilepsy
Abdominal problems due to cystic echinococcosis	abdominal pain and nausea reported as moderate
Chronic respiratory disease due to cystic echinococcosis	cough and shortness of breath after heavy physical activity, but able to walk long distances and climb stairs
Epilepsy due to echinococcosis	epilepsy
Prevalence of detectable microfilaria due to lymphatic filariasis	lymphatic filariasis, currently without symptoms
Lymphedema due to lymphatic filariasis	swollen legs with hard and thick skin, which causes difficulty in moving around
Hydrocele due to lymphatic filariasis	hydrocele
Asymptomatic onchocerciasis	onchocerciasis, currently without symptoms
Mild skin disease due to onchocerciasis	slight visible physical deformity with sometimes pain or itch that others notice which causes some worry and discomfort
Mild skin disease without itch due to onchocerciasis	slight visible physical deformity that others notice which causes some worry and discomfort
Moderate skin disease due to onchocerciasis	visible physical deformity that is sore and itchy and causes others to stare and comment which causes anxiety
Severe skin disease due to onchocerciasis	visible physical deformity that is sore and itchy and causes others to stare and comment which causes anxiety
Severe skin disease without itch due to onchocerciasis	obvious physical deformity that makes others uncomfortable, which causes the person to avoid social contact, feel worried, sleep poorly, and think about suicide
Moderate vision impairment due to onchocerciasis	moderate vision impairment (vision <6/18 & ≥6/60 in better eye)

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Severe vision impairment due to onchocerciasis	severe vision impairment (vision <6/60 & ≥3/60 in better eye)
Blindness due to onchocerciasis	blindness (vision <3/60 in better eye)
Moderate vision impairment due to trachoma	moderate vision impairment (vision <6/18 & ≥6/60 in better eye)
Severe vision impairment due to trachoma	severe vision impairment (vision <6/60 & ≥3/60 in better eye)
Blindness due to trachoma	blindness (vision <3/60 in better eye)
Moderate dengue	moderate infectious disease episode with fever, aches and fatigue
Severe dengue	severe infectious disease episode with high fever, pain and severe fatigue
Post-dengue chronic fatigue syndrome	period of extreme fatigue following an acute dengue infection
Moderate yellow fever	moderate infectious disease episode with fever, aches and fatigue
Severe yellow fever	severe infectious disease episode with high fever, pain and severe fatigue
Heavy infestation of ascariasis	cramping pain and a bloated feeling in the belly
Mild abdominopelvic problems due to ascariasis	abdominal pain and nausea reported as mild
Severe wasting due to ascariasis	weight for height (below -3z scores of the median WHO growth standards)
Asymptomatic ascariasis	ascariasis, currently without symptoms
Heavy infestation of trichuriasis	cramping pain and a bloated feeling in the belly
Mild abdominopelvic problems due to trichuriasis	abdominal pain and nausea reported as mild
Severe wasting due to trichuriasis	weight for height (below -3z scores of the median WHO growth standards)
Asymptomatic trichuriasis	trichuriasis, currently without symptoms
Heavy infestation of hookworm	cramping pain and a bloated feeling in the belly
Mild abdominopelvic problems due to hookworm disease	abdominal pain and nausea reported as mild
Severe wasting due to hookworm disease	weight for height (below -3z scores of the median WHO growth standards)
Mild anemia due to hookworm disease	hookworm disease with minor fatigue associated with mild anemia (2011 WHO classification)
Moderate anemia due to hookworm disease	hookworm disease with moderate fatigue associated with moderate anemia (2011 WHO classification)
Severe anemia due to hookworm disease	hookworm disease with severe fatigue associated with severe anemia (2011 WHO classification)
Asymptomatic hookworm disease	hookworm disease, currently without symptoms
Asymptomatic clonorchiasis	clonorchiasis, currently without symptoms
Asymptomatic fascioliasis	fascioliasis, currently without symptoms

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Asymptomatic intestinal fluke infection	intestinal fluke infection, currently without symptoms
Asymptomatic opisthorchiasis	opisthorchiasis, currently without symptoms
Asymptomatic paragonimiasis	paragonimiasis, currently without symptoms
Heavy opisthorchiasis due to food-borne trematodiasis	abdominal pain and nausea reported as moderate
Heavy clonorchiasis due to food-borne trematodiasis	abdominal pain and nausea reported as moderate
Heavy intestinal fluke infection due to food-borne trematodiasis	abdominal pain and nausea reported as moderate
Heavy fascioliasis due to food-borne trematodiasis	abdominal pain and nausea reported as moderate
Heavy paragonimiasis due to food-borne trematodiasis	cough, fever and weight loss
Cerebral paragonimiasis	epilepsy due to cerebral paragonimiasis
Mild anemia due to other neglected tropical diseases	other neglected tropical diseases with minor fatigue associated with mild anemia (2011 WHO classification)
Moderate anemia due to other neglected tropical diseases	other neglected tropical diseases with moderate fatigue associated with moderate anemia (2011 WHO classification)
Severe anemia due to other neglected tropical diseases	other neglected tropical diseases with severe fatigue associated with severe anemia (2011 WHO classification)
Maternal hemorrhage (< 1L blood lost)	abdominal pain and nausea reported as moderate
Maternal hemorrhage (> 1L blood lost)	abdominal pain and nausea reported as severe
Mild anemia due to maternal hemorrhage	maternal hemorrhage causing moderate fatigue associated with moderate anemia (2011 WHO classification)
Moderate anemia due to maternal hemorrhage	moderate fatigue associated with moderate anemia (2011 WHO classification)
Severe anemia due to maternal hemorrhage	maternal hemorrhage causing severe fatigue associated with severe anemia (2011 WHO classification)
Puerperal sepsis	severe infectious disease episode with high fever, pain and severe fatigue
Other maternal infections	moderate infectious disease episode with fever, aches and fatigue
Infertility due to puerperal sepsis	absence of a live birth in a woman who desires a child and has been in a union for at least five years since her last live birth without using contraceptives
Other hypertensive disorders of pregnancy	has a chronic disease that requires medication every day and causes some worry but minimal interference with daily activities.
Severe pre-eclampsia	moderate abdominal pain and nausea, headache and mild motor and cognitive problems
Long term sequelae of severe pre-eclampsia	mild motor impairment (muscle weakness and some problems with gait or balance) plus intellectual disability (IQ 70-84)
Eclampsia	moderate abdominal pain and nausea and seizures
Long term sequelae of eclampsia	mild motor impairment (muscle weakness and some problems with gait or balance) plus intellectual disability (IQ 70-84)
Obstructed labor, acute event	abdominal pain and nausea, reported as severe
Rectovaginal fistula	abnormal opening between her vagina and rectum causing flatulence and feces to escape through the vagina

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Vesicovaginal fistula	abnormal opening between the bladder and the vagina, which makes a woman unable to control urinating
Maternal abortive outcome	abdominal pain and nausea reported as moderate
Asymptomatic retinopathy of prematurity	retinopathy of prematurity without vision loss
Mild vision impairment due to retinopathy of prematurity	mild vision impairment (vision equal to or better than 6/18 and worse than 12/18)
Moderate vision impairment due to retinopathy of prematurity	moderate vision impairment (vision equal to or better than 6/60 and worse than 6/18)
Severe vision impairment due to retinopathy of prematurity	severe vision impairment (equal or better than 3/60 and worse than 6/60)
Blindness due to retinopathy of prematurity	blindness (vision <3/60 in better eye)
Mild motor impairment due to neonatal preterm birth complications <28wks	mild motor impairment (muscle weakness and some problems with gait or balance)
Mild motor plus cognitive impairments due to neonatal preterm birth complications <28wks	mild motor impairment (muscle weakness and some problems with gait or balance) plus intellectual disability (IQ 70-84) impairments
Mild motor impairment due to neonatal preterm birth complications 28-32wks	mild motor impairment (muscle weakness and some problems with gait or balance)
Mild motor plus cognitive impairments due to neonatal preterm birth complications 28-32wks	mild motor impairment (muscle weakness and some problems with gait or balance) plus intellectual disability (IQ 70-84)
Mild motor impairment due to neonatal preterm birth complications 32-36wks	mild motor impairment (muscle weakness and some problems with gait or balance)
Mild motor plus cognitive impairments due to neonatal preterm birth complications 32-36wks	mild motor impairment (muscle weakness and some problems with gait or balance) plus intellectual disability (IQ 70-84)
Moderate motor impairment due to neonatal preterm birth complications <28wks	moderate motor impairment (spasticity and paresis but able to walk)
Moderate motor impairment with blindness due to neonatal preterm birth complications <28wks	moderate motor impairment (spasticity and paresis but able to walk) with blindness (vision <3/60 in better eye)
Moderate motor impairment with epilepsy due to neonatal preterm birth complications <28wks	moderate motor impairment (spasticity and paresis but able to walk) with epilepsy
Moderate motor impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks	moderate motor impairment (spasticity and paresis but able to walk) with blindness (vision <3/60 in better eye) and epilepsy
Moderate motor plus cognitive impairment with blindness due to neonatal preterm birth complications <28wks	moderate motor (spasticity and paresis but able to walk) plus cognitive impairment with blindness (vision <3/60 in better eye)
Moderate motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications <28wks	moderate motor (spasticity and paresis but able to walk) plus cognitive impairment with epilepsy
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks	moderate motor (spasticity and paresis but able to walk) plus cognitive impairment with blindness (vision <3/60 in better eye) and epilepsy
Severe motor impairment due to neonatal preterm birth complications <28wks	severe motor impairment (unable to walk)
Severe motor impairment with blindness due to neonatal preterm birth complications <28wks	severe motor impairment (unable to walk) with blindness (vision <3/60 in better eye)
Severe motor impairment with epilepsy due to neonatal preterm birth complications <28wks	severe motor impairment (unable to walk) with epilepsy
Severe motor impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks	severe motor impairment (unable to walk) with blindness (vision <3/60 in better eye) and epilepsy
Severe motor plus cognitive impairment with blindness due to neonatal preterm birth complications <28wks	severe motor impairment (unable to walk) plus intellectual disability (IQ <70) with blindness (vision <3/60 in better eye)
Severe motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications <28wks	severe motor impairment (unable to walk) plus intellectual disability (IQ <70) with epilepsy
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks	severe motor impairment (unable to walk) plus intellectual disability (IQ <70) with blindness (vision <3/60 in better eye) and epilepsy

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
and epilepsy due to neonatal preterm birth complications 32-36wks	severe motor impairment (unable to walk) plus intellectual disability (IQ <70) with blindness (vision <3/60 in better eye) and epilepsy
Mild motor plus cognitive impairments due to neonatal encephalopathy due to birth asphyxia and trauma	mild motor impairment (muscle weakness and some problems with gait or balance) plus intellectual disability (IQ 70-84)
Mild motor impairment due to neonatal encephalopathy due to birth asphyxia and trauma	mild motor impairment (muscle weakness and some problems with gait or balance)
Moderate motor impairment due to neonatal encephalopathy due to birth asphyxia and trauma	moderate motor impairment (spasticity and paresis but able to walk)
Moderate motor impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma	moderate motor impairment (spasticity and paresis but able to walk) with blindness (vision <3/60 in better eye)
Moderate motor impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	moderate motor impairment (spasticity and paresis but able to walk) with epilepsy
due to neonatal encephalopathy due to birth asphyxia and trauma	moderate motor impairment (spasticity and paresis but able to walk) with blindness (vision <3/60 in better eye) and epilepsy
due to neonatal encephalopathy due to birth asphyxia and trauma	moderate motor (spasticity and paresis but able to walk) plus cognitive impairment with blindness (vision <3/60 in better eye)
due to neonatal encephalopathy due to birth asphyxia and trauma	moderate motor (spasticity and paresis but able to walk) plus cognitive impairment with epilepsy
and epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	moderate motor (spasticity and paresis but able to walk) plus cognitive impairment with blindness (vision <3/60 in better eye) and epilepsy
Severe motor impairment due to neonatal encephalopathy due to birth asphyxia and trauma	severe motor impairment (unable to walk)
Severe motor impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma	severe motor impairment (unable to walk) with blindness (vision <3/60 in better eye)
Severe motor impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	severe motor impairment (unable to walk) with epilepsy
to neonatal encephalopathy due to birth asphyxia and trauma	severe motor impairment (unable to walk) with blindness (vision <3/60 in better eye) and epilepsy
due to neonatal encephalopathy due to birth asphyxia and trauma	severe motor impairment (unable to walk) plus intellectual disability (IQ <70) with blindness (vision <3/60 in better eye)
to neonatal encephalopathy due to birth asphyxia and trauma	severe motor impairment (unable to walk) plus intellectual disability (IQ <70) with epilepsy
and epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	severe motor impairment (unable to walk) plus intellectual disability (IQ <70) with blindness (vision <3/60 in better eye) and epilepsy
Moderate motor impairment due to hemolytic disease and other neonatal jaundice	moderate motor impairment (spasticity and paresis but able to walk)
Moderate motor impairment with blindness due to hemolytic disease and other neonatal jaundice	moderate motor impairment (spasticity and paresis but able to walk) with blindness (vision <3/60 in better eye)
Moderate motor impairment with epilepsy due to hemolytic disease and other neonatal jaundice	moderate motor impairment (spasticity and paresis but able to walk) with epilepsy
Moderate motor impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice	moderate motor impairment (spasticity and paresis but able to walk) with blindness (vision <3/60 in better eye) and epilepsy
Moderate motor plus cognitive impairment with blindness due to hemolytic disease and other neonatal jaundice	moderate motor (spasticity and paresis but able to walk) plus cognitive impairment with blindness (vision <3/60 in better eye)
Moderate motor plus cognitive impairment with epilepsy due to hemolytic disease and other neonatal jaundice	moderate motor (spasticity and paresis but able to walk) plus cognitive impairment with epilepsy
and epilepsy due to hemolytic disease and other neonatal jaundice	moderate motor (spasticity and paresis but able to walk) plus cognitive impairment with blindness (vision <3/60 in better eye) and epilepsy
Severe motor impairment severe due to hemolytic disease and other neonatal jaundice	severe motor impairment (unable to walk)
Severe motor impairment with blindness due to hemolytic disease and other neonatal jaundice	severe motor impairment (unable to walk) with blindness (vision <3/60 in better eye)
Severe motor impairment with epilepsy due to hemolytic disease and other neonatal jaundice	severe motor impairment (unable to walk) with epilepsy

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Severe motor impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice	severe motor impairment (unable to walk) with blindness (vision <3/60 in better eye) and epilepsy
Severe motor plus cognitive impairment with blindness due to hemolytic disease and other neonatal jaundice	severe motor impairment (unable to walk) plus intellectual disability (IQ <70) with blindness (vision <3/60 in better eye)
Severe motor plus cognitive impairment with epilepsy due to hemolytic disease and other neonatal jaundice	severe motor impairment (unable to walk) plus intellectual disability (IQ <70) with epilepsy
and epilepsy due to hemolytic disease and other neonatal jaundice	severe motor impairment (unable to walk) plus intellectual disability (IQ <70) with blindness (vision <3/60 in better eye) and epilepsy
Kwashiokor due to protein-energy malnutrition	severe malnutrition with swollen abdomen and oedema
Marasmus due to protein-energy malnutrition	clinical diagnosis of severe wasting
Severe wasting due to protein-energy malnutrition	weight for height (below -3z scores of the median WHO growth standards)
Visible goiter without symptoms	visible physical deformity that causes others to stare and comment which causes anxiety
Visible goiter without heart failure due to iodine deficiency	slight visible physical deformity that others notice which causes some worry and discomfort
Visible goiter with mild heart failure due to iodine deficiency	"slight visible physical deformity that others notice which causes some worry and discomfort" and mild heart failure (MEPS analysis)
Visible goiter with moderate heart failure due to iodine deficiency	"slight visible physical deformity that others notice which causes some worry and discomfort" and moderate heart failure (MEPS analysis)
Visible goiter with severe heart failure due to iodine deficiency	"slight visible physical deformity that others notice which causes some worry and discomfort" and severe heart failure (MEPS analysis)
Visible goiter with signs and symptoms	visible goiter with signs of hypothyroidism (fatigue, weight gain and/or constipation)
Severe intellectual disability due to iodine deficiency	intellectual disability (IQ 20-34)
Profound intellectual disability due to iodine deficiency	intellectual disability (IQ <20)
Moderate vision impairment loss due to vitamin A deficiency	moderate vision impairment (vision <6/18 & ≥6/60 in better eye)
Severe vision impairment loss due to vitamin A deficiency	severe vision impairment (vision <6/60 & ≥3/60 in better eye)
Blindness due to vitamin A deficiency	blindness (vision <3/60 in better eye)
Mild iron-deficiency anemia	iron deficiency with minor fatigue associated with mild anemia (2011 WHO classification)
Moderate iron-deficiency anemia	iron deficiency with moderate fatigue associated with moderate anemia (2011 WHO classification)
Severe iron-deficiency anemia	iron deficiency with severe fatigue associated with severe anemia (2011 WHO classification)
Mild heart failure due to iron-deficiency anemia	iron deficiency with shortness of breath and fatigue after moderate physical activity that goes away after a rest (NYHA Class I-II heart failure)
Moderate heart failure due to iron-deficiency anemia	iron deficiency with shortness of breath and fatigue after minimal physical activity that goes away after a rest (NYHA Class III heart failure)
Severe heart failure due to iron-deficiency anemia	iron deficiency with shortness of breath and fatigue even when at rest causing a person to avoid any physical activity (NYHA Class IV heart failure)
Asymptomatic chlamydial infection	chlamydial infection without symptoms
Mild chlamydial infection	mild infectious disease episode with low fever and mild discomfort
Epididymo-orchitis due to chlamydial infection	swollen tender testicles and painful urination

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Moderate pelvic inflammatory diseases due to chlamydial infection	abdominal pain and nausea reported as moderate
Severe pelvic inflammatory diseases due to chlamydial infection	abdominal pain and nausea reported as severe
Primary infertility due to chlamydial infection	absence of a live birth in a woman who desires a child and has been in a union for at least five years without using contraceptives
Secondary infertility due to chlamydial infection	absence of a live birth in a woman who desires a child and has been in a union for at least five years since her last live birth, without using contraceptives
Asymptomatic gonococcal infection	gonococcal infection without symptoms
Mild gonococcal infection	mild infectious disease episode with low fever and mild discomfort
Epididymo-orchitis due to gonococcal infection	swollen tender testicles and painful urination
Moderate pelvic inflammatory diseases due to gonococcal infection	abdominal pain and nausea reported as moderate
Severe pelvic inflammatory diseases due to gonococcal infection	abdominal pain and nausea reported as severe
Primary infertility due to gonococcal infection	absence of a live birth in a woman who desires a child and has been in a union for at least five years without using contraceptives
Secondary infertility due to gonococcal infection	absence of a live birth in a woman who desires a child and has been in a union for at least five years since her last live birth, without using contraceptives
Asymptomatic trichomoniasis infection	trichomoniasis infection without symptoms
Acute trichomoniasis infection	mild infectious disease episode with low fever and mild discomfort
Asymptomatic genital herpes	genital herpes, currently without symptoms
Symptomatic genital herpes	mild infectious disease episode with low fever and mild discomfort
Moderate infection due to initial genital herpes episode	moderate infectious disease episode with fever, aches and fatigue
Moderate pelvic inflammatory diseases due to other sexually transmitted diseases	abdominal pain and nausea reported as moderate
Severe pelvic inflammatory diseases due to other sexually transmitted diseases	abdominal pain and nausea reported as severe
Primary infertility due to other sexually transmitted diseases	absence of a live birth in a woman who desires a child and has been in a union for at least five years without using contraceptives
Secondary infertility due to other sexually transmitted diseases	absence of a live birth in a woman who desires a child and has been in a union for at least five years since her last live birth, without using contraceptives
Asymptomatic acute hepatitis A	acute hepatitis A infection, currently without symptoms
Mild acute hepatitis A	mild infectious disease episode with low fever and mild discomfort
Moderate acute hepatitis A	moderate infectious disease episode with fever, aches and fatigue
Severe acute hepatitis A	severe infectious disease episode with high fever, pain and severe fatigue
Asymptomatic acute hepatitis B	asymptomatic chronic hepatitis B infection
Moderate acute hepatitis B	moderate infectious disease episode with fever, aches and fatigue
Severe acute hepatitis B	severe infectious disease episode with high fever, pain and severe fatigue

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Asymptomatic acute hepatitis C	asymptomatic chronic hepatitis C infection
Moderate acute hepatitis C	moderate infectious disease episode with fever, aches and fatigue
Severe acute hepatitis C	severe infectious disease episode with high fever, pain and severe fatigue
Asymptomatic acute hepatitis E	asymptomatic chronic hepatitis E infection
Moderate acute hepatitis E	moderate infectious disease episode with fever, aches and fatigue
Severe acute hepatitis E	severe infectious disease episode with high fever, pain and severe fatigue
Disfigurement level 1 due to leprosy	slight visible physical deformity that others notice which causes some worry and discomfort
Disfigurement level 2 due to leprosy	visible physical deformity that causes others to stare and comment which causes anxiety
Mild anemia due to other infectious diseases	other infectious disease with minor fatigue associated with mild anemia (2011 WHO classification)
Moderate anemia due to other infectious diseases	other infectious disease with moderate fatigue associated with moderate anemia (2011 WHO classification)
Severe anemia due to other infectious diseases	other infectious disease with severe fatigue associated with severe anemia (2011 WHO classification)
Guillain-Barré syndrome due to other infectious diseases	paralysis from the waist down
Diagnosis and primary therapy phase of esophageal cancer	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of esophageal cancer	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of esophageal cancer	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of esophageal cancer	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of stomach cancer	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of stomach cancer	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of stomach cancer	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of stomach cancer	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of liver cancer due to hepatitis B	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of liver cancer due to hepatitis B	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of liver cancer due to hepatitis B	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of liver cancer due to hepatitis B	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of liver cancer due to hepatitis C	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of liver cancer due to hepatitis C	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of liver cancer due to hepatitis C	metastasized cancer with severe pain, weight loss and high anxiety

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Terminal phase of liver cancer due to hepatitis C	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of liver cancer due to alcohol use	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of liver cancer due to alcohol use	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of liver cancer due to alcohol use	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of liver cancer due to alcohol use	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of liver cancer due to other causes	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of liver cancer due to other causes	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of liver cancer due to other causes	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of liver cancer due to other causes	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of larynx cancer	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of larynx cancer	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of larynx cancer	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of larynx cancer	terminal disease with constant pain, severe weight loss, severe fatigue
Laryngectomy due to larynx cancer	difficulty speaking and being understood after removal larynx as cancer therapy
Diagnosis and primary therapy phase of lung, bronchus, and trachea cancer	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of lung, bronchus, and trachea cancer	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of lung, bronchus, and trachea cancer	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of lung, bronchus, and trachea cancer	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of breast cancer	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of breast cancer	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of breast cancer	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of breast cancer	terminal disease with constant pain, severe weight loss, severe fatigue
Mastectomy due to breast cancer	breast removed as cancer therapy
Diagnosis and primary therapy phase of cervical cancer	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of cervical cancer	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of cervical cancer	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of cervical cancer	terminal disease with constant pain, severe weight loss, severe fatigue

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Diagnosis and primary therapy phase of uterine cancer	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of uterine cancer	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of uterine cancer	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of uterine cancer	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of prostate cancer	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of prostate cancer	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of prostate cancer	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of prostate cancer	terminal disease with constant pain, severe weight loss, severe fatigue
Impotence due to prostate cancer	difficulty in obtaining or maintaining an erection
Incontinence due to prostate cancer	urinary incontinence
Diagnosis and primary therapy phase of colon and rectum cancers	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of colon and rectum cancers	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of colon and rectum cancers	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of colon and rectum cancers	terminal disease with constant pain, severe weight loss, severe fatigue
Stoma due to colon and rectum cancer	stoma after surgery for colon and rectum cancer
Diagnosis and primary therapy phase of mouth cancer	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of mouth cancer	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of mouth cancer	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of mouth cancer	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of nasopharynx cancer	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of nasopharynx cancer	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of nasopharynx cancer	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of nasopharynx cancer	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of other pharynx cancer	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of other pharynx cancer	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of other pharynx cancer	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of other pharynx cancer	terminal disease with constant pain, severe weight loss, severe fatigue

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Diagnosis and primary therapy phase of gallbladder and biliary tract cancer	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of gallbladder and biliary tract cancer	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of gallbladder and biliary tract cancer	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of gallbladder and biliary tract cancer	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of pancreatic cancer	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of pancreatic cancer	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of pancreatic cancer	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of pancreatic cancer	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of malignant skin melanoma	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of malignant skin melanoma	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of malignant skin melanoma	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of malignant skin melanoma	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of cutaneous squamous cell carcinoma	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Control phase of cutaneous squamous cell carcinoma	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of cutaneous squamous cell carcinoma	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of cutaneous squamous cell carcinoma	terminal disease with constant pain, severe weight loss, severe fatigue
Disfigurement due to basal cell carcinoma	slight visible physical deformity that others notice which causes some worry and discomfort
Diagnosis and primary therapy phase of ovarian cancer	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of ovarian cancer	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of ovarian cancer	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of ovarian cancer	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of testicular cancer	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of testicular cancer	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of testicular cancer	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of testicular cancer	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of kidney cancer	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of kidney cancer	takes daily medication for a chronic disease with some worry but minimal interference with daily activities

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Metastatic phase of kidney cancer	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of kidney cancer	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of bladder cancer	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of bladder cancer	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of bladder cancer	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of bladder cancer	terminal disease with constant pain, severe weight loss, severe fatigue
Urinary incontinence due to bladder cancer	urinary incontinence
Diagnosis and primary therapy phase of brain and nervous system cancers	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of brain and nervous system cancers	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of brain and nervous system cancers	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of brain and nervous system cancers	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of thyroid cancer	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of thyroid cancer	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of thyroid cancer	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of thyroid cancer	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of mesothelioma	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of mesothelioma	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of mesothelioma	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of mesothelioma	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of Hodgkin disease	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of Hodgkin disease	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of Hodgkin disease	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of Hodgkin disease	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of non-Hodgkin lymphoma	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of non-Hodgkin lymphoma	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of non-Hodgkin lymphoma	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of non-Hodgkin lymphoma	terminal disease with constant pain, severe weight loss, severe fatigue

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Diagnosis and primary therapy phase of multiple myeloma	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of multiple myeloma	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of multiple myeloma	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of multiple myeloma	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of leukemia	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of leukemia	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of leukemia	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of leukemia	terminal disease with constant pain, severe weight loss, severe fatigue
Diagnosis and primary therapy phase of other neoplasms	pain, nausea, fatigue, weight loss and high anxiety associated with cancer diagnosis and initial treatment
Controlled phase of other neoplasms	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Metastatic phase of other neoplasms	metastasized cancer with severe pain, weight loss and high anxiety
Terminal phase of other neoplasms	terminal disease with constant pain, severe weight loss, severe fatigue
Rheumatic heart disease, without heart failure	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Mild heart failure due to rheumatic heart disease	shortness of breath and fatigue after moderate physical activity that goes away after a rest (NYHA Class I-II heart failure)
Moderate heart failure due to rheumatic heart disease	shortness of breath and fatigue after minimal physical activity that goes away after a rest (NYHA Class III heart failure)
Severe heart failure due to rheumatic heart disease	shortness of breath and fatigue even when at rest causing a person to avoid any physical activity (NYHA Class IV heart failure)
Asymptomatic ischemic heart disease following myocardial infarction	Ischemic heart disease, currently without symptoms
Acute myocardial infarction first 2 days	severe chest pain, nausea, shortness of breath, and high anxiety first two days after a heart attack
Acute myocardial infarction 3 to 28 days	shortness of breath. Fatigue and some anxiety at day 3 to day 28 after a heart attack
Asymptomatic angina due to ischemic heart disease	angina, currently without symptoms
Mild angina due to ischemic heart disease	mild chest pain after strenuous physical activity that goes away after a brief rest
Moderate angina due to ischemic heart disease	chest pain after moderate physical activity that goes away after a brief rest
Severe angina due to ischemic heart disease	chest pain after minimal physical activity that goes away after a brief rest; the person avoids most physical activities because of the pain
Mild heart failure due to ischemic heart disease	shortness of breath and fatigue after moderate physical activity that goes away after a rest (NYHA Class I-II heart failure)
Moderate heart failure due to ischemic heart disease	shortness of breath and fatigue after minimal physical activity that goes away after a rest (NYHA Class III heart failure)
Severe heart failure due to ischemic heart disease	shortness of breath and fatigue even when at rest causing a person to avoid any physical activity (NYHA Class IV heart failure)
Asymptomatic chronic ischemic stroke	ischemic stroke, currently without symptoms

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Chronic ischemic stroke severity level 1	first (least severe) of five levels of motor and cognitive impairment after stroke
Chronic ischemic stroke severity level 2	second of five levels of motor and cognitive impairment after stroke
Chronic ischemic stroke severity level 3	third of five levels of motor and cognitive impairment after stroke
Chronic ischemic stroke severity level 4	fourth of five levels of motor and cognitive impairment after stroke
Chronic ischemic stroke severity level 5	fifth and most severe of five levels of motor and cognitive impairment after stroke
Acute ischemic stroke severity level 1	first (least severe) of five levels of motor and cognitive impairment after stroke
Acute ischemic stroke severity level 2	second of five levels of motor and cognitive impairment after stroke
Acute ischemic stroke severity level 3	third of five levels of motor and cognitive impairment after stroke
Acute ischemic stroke severity level 4	fourth of five levels of motor and cognitive impairment after stroke
Acute ischemic stroke severity level 5	fifth and most severe of five levels of motor and cognitive impairment after stroke
Asymptomatic chronic hemorrhagic stroke	hemorrhagic stroke, currently without symptoms
Chronic hemorrhagic stroke severity level 1	first (least severe) of five levels of motor and cognitive impairment after stroke
Chronic hemorrhagic stroke severity level 2	second of five levels of motor and cognitive impairment after stroke
Chronic hemorrhagic stroke severity level 3	third of five levels of motor and cognitive impairment after stroke
Chronic hemorrhagic stroke severity level 4	fourth of five levels of motor and cognitive impairment after stroke
Chronic hemorrhagic stroke severity level 5	fifth and most severe of five levels of motor and cognitive impairment after stroke
Acute hemorrhagic stroke severity level 1	first (least severe) of five levels of motor and cognitive impairment after stroke
Acute hemorrhagic stroke severity level 2	second of five levels of motor and cognitive impairment after stroke
Acute hemorrhagic stroke severity level 3	third of five levels of motor and cognitive impairment after stroke
Acute hemorrhagic stroke severity level 4	fourth of five levels of motor and cognitive impairment after stroke
Acute hemorrhagic stroke severity level 5	fifth and most severe of five levels of motor and cognitive impairment after stroke
Mild heart failure due to hypertensive heart disease	shortness of breath and fatigue after moderate physical activity that goes away after a rest (NYHA Class I-II heart failure)
Moderate heart failure due to hypertensive heart disease	shortness of breath and fatigue after minimal physical activity that goes away after a rest (NYHA Class III heart failure)
Severe heart failure due to hypertensive heart disease	shortness of breath and fatigue even when at rest causing a person to avoid any physical activity (NYHA Class IV heart failure)
Acute myocarditis	moderate infectious disease episode with fever, aches and fatigue
Mild heart failure due to cardiomyopathy and myocarditis	shortness of breath and fatigue after moderate physical activity that goes away after a rest (NYHA Class I-II heart failure)
Moderate heart failure due to cardiomyopathy and myocarditis	shortness of breath and fatigue after minimal physical activity that goes away after a rest (NYHA Class III heart failure)

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Severe heart failure due to cardiomyopathy and myocarditis	shortness of breath and fatigue even when at rest causing a person to avoid any physical activity (NYHA Class IV heart failure)
Asymptomatic atrial fibrillation and flutter	atrial fibrillation, currently without symptoms
Symptomatic atrial fibrillation and flutter	has periods of rapid and irregular heartbeats and occasional fainting
Asymptomatic peripheral vascular disease	Ankle brachial pressure index of less than 0,9 but no symptoms of claudication
Symptomatic claudication due to peripheral vascular disease	cramping pains in the legs after walking a medium distance that goes away after a short rest
Moderate endocarditis	moderate infectious disease episode with fever, aches and fatigue
Severe endocarditis	severe infectious disease episode with high fever, pain and severe fatigue
Mild heart failure due to endocarditis	shortness of breath and fatigue after moderate physical activity that goes away after a rest (NYHA Class I-II heart failure)
Moderate heart failure due to endocarditis	shortness of breath and fatigue after minimal physical activity that goes away after a rest (NYHA Class III heart failure)
Severe heart failure due to endocarditis	shortness of breath and fatigue even when at rest causing a person to avoid any physical activity (NYHA Class IV heart failure)
Mild heart failure due to other cardiovascular diseases	shortness of breath and fatigue after moderate physical activity that goes away after a rest (NYHA Class I-II heart failure)
Moderate heart failure due to other cardiovascular diseases	shortness of breath and fatigue after minimal physical activity that goes away after a rest (NYHA Class III heart failure)
Severe heart failure due to other cardiovascular diseases	shortness of breath and fatigue even when at rest causing a person to avoid any physical activity (NYHA Class IV heart failure)
Asymptomatic other cardiovascular diseases	other cardiovascular disease, currently without symptoms
Mild other cardiovascular diseases	shortness of breath and fatigue after moderate physical activity that goes away after a rest (NYHA Class I-II heart failure)
Moderate other cardiovascular diseases	shortness of breath and fatigue after minimal physical activity that goes away after a rest (NYHA Class III heart failure)
Severe other cardiovascular diseases	shortness of breath and fatigue even when at rest causing a person to avoid any physical activity (NYHA Class IV heart failure)
Asymptomatic chronic obstructive pulmonary disease	chronic obstructive pulmonary disease, currently without symptoms
Mild chronic obstructive pulmonary disease	cough and shortness of breath after heavy physical activity, but able to walk long distances and climb stairs
Moderate chronic obstructive pulmonary disease	cough, wheezing and shortness of breath after light physical activity; able to walk only short distances or climb only a few stairs.
Severe chronic obstructive pulmonary disease without heart failure	cough, wheezing and shortness of breath all the time; great difficulty walking even short distances or climbing any stairs, feels tired when at rest, and is anxious.
Mild heart failure due to severe chronic obstructive pulmonary disease	cough, wheezing, constant shortness of breath, great difficulty walking even short distances, fatigue and anxiety
Moderate heart failure due to severe chronic obstructive pulmonary disease	cough, wheezing, constant shortness of breath, great difficulty walking even short distances, feels tired even when at rest and has anxiety
Severe heart failure due to severe chronic obstructive pulmonary disease	cough, wheezing, constant shortness of breath, great difficulty walking even short distances, feels tired even when at rest and avoids any physical activity, and high anxiety
Asymptomatic silicosis	silicosis, currently without symptoms
Mild silicosis	cough and shortness of breath after heavy physical activity, but able to walk long distances and climb stairs
Moderate silicosis	cough, wheezing and shortness of breath after light physical activity; able to walk only short distances or climb only a few stairs.

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Severe silicosis without heart failure	cough, wheezing and shortness of breath all the time; great difficulty walking even short distances or climbing any stairs, feels tired when at rest, and is anxious.
Mild heart failure due to severe silicosis	cough, wheezing, constant shortness of breath, great difficulty walking even short distances, fatigue and anxiety
Moderate heart failure due to severe silicosis	cough, wheezing, constant shortness of breath, great difficulty walking even short distances, feels tired even when at rest and has anxiety
Severe heart failure due to severe silicosis	cough, wheezing, constant shortness of breath, great difficulty walking even short distances, feels tired even when at rest and avoids any physical activity, and high anxiety
Asymptomatic asbestosis	asbestosis, currently without symptoms
Mild asbestosis	cough and shortness of breath after heavy physical activity, but able to walk long distances and climb stairs
Moderate asbestosis	cough, wheezing and shortness of breath after light physical activity; able to walk only short distances or climb only a few stairs.
Severe asbestosis without heart failure	cough, wheezing and shortness of breath all the time; great difficulty walking even short distances or climbing any stairs, feels tired when at rest, and is anxious.
Mild heart failure due to severe asbestosis	cough, wheezing, constant shortness of breath, great difficulty walking even short distances, fatigue and anxiety
Moderate heart failure due to severe asbestosis	cough, wheezing, constant shortness of breath, great difficulty walking even short distances, feels tired even when at rest and has anxiety
Severe heart failure due to severe asbestosis	cough, wheezing, constant shortness of breath, great difficulty walking even short distances, feels tired even when at rest and avoids any physical activity, and high anxiety
Asymptomatic coal workers pneumoconiosis	coal workers pneumoconiosis, currently without symptoms
Mild coal workers pneumoconiosis	cough and shortness of breath after heavy physical activity, but able to walk long distances and climb stairs
Moderate coal workers pneumoconiosis	cough, wheezing and shortness of breath after light physical activity; able to walk only short distances or climb only a few stairs.
Severe coal workers pneumoconiosis without heart failure	cough, wheezing and shortness of breath all the time; great difficulty walking even short distances or climbing any stairs, feels tired when at rest, and is anxious.
Mild heart failure due to severe coal workers pneumoconiosis	cough, wheezing, constant shortness of breath, great difficulty walking even short distances, fatigue and anxiety
Moderate heart failure due to severe coal workers pneumoconiosis	cough, wheezing, constant shortness of breath, great difficulty walking even short distances, feels tired even when at rest and has anxiety
Severe heart failure due to severe coal workers pneumoconiosis	cough, wheezing, constant shortness of breath, great difficulty walking even short distances, feels tired even when at rest and avoids any physical activity, and high anxiety
Asymptomatic other pneumoconiosis	other pneumoconiosis, currently without symptoms
Mild other pneumoconiosis	cough and shortness of breath after heavy physical activity, but able to walk long distances and climb stairs
Moderate other pneumoconiosis	cough, wheezing and shortness of breath after light physical activity; able to walk only short distances or climb only a few stairs.
Severe other pneumoconiosis without heart failure	cough, wheezing and shortness of breath all the time; great difficulty walking even short distances or climbing any stairs, feels tired when at rest, and is anxious.
Mild heart failure due to severe other pneumoconiosis	cough, wheezing, constant shortness of breath, great difficulty walking even short distances, fatigue and anxiety
Moderate heart failure due to severe other pneumoconiosis	cough, wheezing, constant shortness of breath, great difficulty walking even short distances, feels tired even when at rest and has anxiety
Severe heart failure due to severe other pneumoconiosis	cough, wheezing, constant shortness of breath, great difficulty walking even short distances, feels tired even when at rest and avoids any physical activity, and high anxiety
Asymptomatic asthma	asthma, currently without symptoms
Controlled asthma	asthmatic wheezing and cough once a month, which does not cause difficulty with daily activities.

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Partially controlled asthma	wheezing and cough once a week due to partially controlled asthma, which causes some difficulty with daily activities
Uncontrolled asthma	wheezing, cough and shortness of breath more than twice a week which causes difficulty with daily activities and sometimes wakes the person at night.
Asymptomatic interstitial lung disease and pulmonary sarcoidosis	interstitial lung disease and pulmonary sarcoidosis, currently without symptoms
Mild interstitial lung disease and pulmonary sarcoidosis	cough and shortness of breath after heavy physical activity, but able to walk long distances and climb stairs
Moderate interstitial lung disease and pulmonary sarcoidosis	cough, wheezing and shortness of breath after light physical activity; able to walk only short distances or climb only a few stairs.
Severe interstitial lung disease and pulmonary sarcoidosis without heart failure	cough, wheezing and shortness of breath all the time; great difficulty walking even short distances or climbing any stairs, feels tired when at rest, and is anxious.
Mild heart failure due to severe interstitial lung disease and pulmonary sarcoidosis	cough, wheezing, constant shortness of breath, great difficulty walking even short distances, fatigue and anxiety
Moderate heart failure due to severe interstitial lung disease and pulmonary sarcoidosis	cough, wheezing, constant shortness of breath, great difficulty walking even short distances, feels tired even when at rest and has anxiety
Severe heart failure due to severe interstitial lung disease and pulmonary sarcoidosis	cough, wheezing, constant shortness of breath, great difficulty walking even short distances, feels tired even when at rest and avoids any physical activity, and high anxiety
Peptic ulcer disease, symptomatic episodes, with mild anemia (2011 WHO classification)	abdominal pain reported as mild and minor fatigue associated with mild anemia (2011 WHO classification)
Peptic ulcer disease, symptomatic episodes, with moderate anemia (2011 WHO classification)	abdominal pain reported as moderate and moderate fatigue associated with moderate anemia (2011 WHO classification)
Peptic ulcer disease, symptomatic episodes, with severe anemia (2011 WHO classification)	abdominal pain reported as moderate and severe fatigue associated with severe anemia (2011 WHO classification)
Peptic ulcer disease, symptomatic episodes	abdominal pain and nausea reported as moderate
Gastritis and duodenitis, symptomatic episodes, with mild anemia (2011 WHO classification)	abdominal pain reported as mild and minor fatigue associated with mild anemia (2011 WHO classification)
Gastritis and duodenitis, symptomatic episodes, with moderate anemia (2011 WHO classification)	abdominal pain reported as moderate and moderate fatigue associated with moderate anemia (2011 WHO classification)
Gastritis and duodenitis, symptomatic episodes, with severe anemia (2011 WHO classification)	abdominal pain reported as moderate and severe fatigue associated with severe anemia (2011 WHO classification)
Gastritis and duodenitis, symptomatic episodes	abdominal pain and nausea reported as moderate
Paralytic ileus and intestinal obstruction	abdominal pain and nausea reported as severe
Ulcerative colitis	chronic episodic abdominal pain with diarrhea and fatigue
Crohn's disease	chronic episodic abdominal pain with diarrhea and fatigue
Mild Alzheimer disease and other dementias	Clinical Dementia Rating (CDR) 21-25
Moderate Alzheimer disease and other dementias	Clinical Dementia Rating (CDR) 11-20
Severe Alzheimer disease and other dementias	Clinical Dementia Rating (CDR) <10
Mild Parkinson disease	Hoehn and Yahr score ≤ 2
Moderate Parkinson disease	Hoehn and Yahr score 2.5-4
Severe Parkinson disease	Hoehn and Yahr score >4
Seizure-free, treated epilepsy	takes daily medication for a chronic disease with some worry but minimal interference with daily activities

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Less severe epilepsy	1-11 epileptic seizures in past year
Severe epilepsy	epileptic seizures more than once a month
Mild multiple sclerosis	Expanded Disability Status Scale (EDSS) 0-3
Moderate multiple sclerosis	Expanded Disability Status Scale (EDSS) 3.5-6
Severe multiple sclerosis	Expanded Disability Status Scale (EDSS) 6.5-9
Asymptomatic migraine	migraine, currently without symptoms
Symptomatic migraine	severe, throbbing head pain, light sensitivity and nausea
Asymptomatic tension-type headache	tension-type headache, currently without symptoms
Symptomatic tension-type headache	moderate headache that also affects the neck
Asymptomatic medication overuse headache	medication overuse headache, currently without symptoms
Symptomatic medication overuse headache	chronic headache (>15 days per month for at least three months) worsened by medication intake (at least every other day) and improving after stopping medication
Guillain-Barré syndrome due to other neurological disorders	paralysis from the waist down
Schizophrenia residual state	a residual state of predominantly negative symptoms such as flat affect, loss of interest, and emotional withdrawal as defined in DSM-IV
Schizophrenia acute state	an acute state of predominantly positive symptoms such as delusions, hallucinations, and thought disorder as defined in DSM-IV
Asymptomatic alcohol dependence	alcohol dependence, currently without symptoms
Very mild alcohol dependence	very mild alcohol dependence (MEPS, NESARC and NSMHWB analysis)
Mild alcohol dependence	mild alcohol dependence (MEPS, NESARC and NSMHWB analysis)
Moderate alcohol dependence	moderate alcohol dependence (MEPS, NESARC and NSMHWB analysis)
Severe alcohol dependence	severe alcohol dependence (MEPS, NESARC and NSMHWB analysis)
Asymptomatic fetal alcohol syndrome	fetal alcohol syndrome with IQ greater than 85
Mild fetal alcohol syndrome	fetal alcohol syndrome with intellectual disability (IQ 70-85)
Moderate fetal alcohol syndrome	fetal alcohol syndrome with intellectual disability (IQ 50-70)
Severe fetal alcohol syndrome	fetal alcohol syndrome with intellectual disability (IQ <50)
Asymptomatic opioid dependence	opioid dependence, currently without symptoms (NESARC analysis)
Mild opioid dependence	mild opioid dependence (NESARC analysis)
Severe opioid dependence	opioid dependence with hallucinations and disturbed mood causing difficulty in daily functioning
Asymptomatic cocaine dependence	cocaine dependence, currently without symptoms (NESARC analysis)

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Mild cocaine dependence	mild cocaine dependence (NESARC analysis)
Severe cocaine dependence	cocaine dependence with hallucinations and disturbed mood causing difficulty in daily functioning
Asymptomatic amphetamine dependence	amphetamine dependence, currently without symptoms (NESARC analysis)
Mild amphetamine dependence	mild amphetamine dependence (NESARC analysis)
Severe amphetamine dependence	amphetamine dependence with hallucinations and disturbed mood causing difficulty in daily functioning
Asymptomatic cannabis dependence	cannabis dependence, currently without symptoms
Mild cannabis dependence	mild cannabis dependence (NESARC analysis)
Severe cannabis dependence	severe cannabis dependence (NESARC analysis)
Major depressive disorder, currently without symptoms	major depressive disorder, currently without symptoms
Mild major depressive disorder	mild major depressive disorder (MEPS, NESARC and NSMHWB analyses)
Moderate major depressive disorder	moderate major depressive disorder (MEPS, NESARC and NSMHWB analyses)
Severe major depressive disorder	severe major depressive disorder (MEPS, NESARC and NSMHWB analyses)
Dysthymia, currently without symptoms	dysthymia, currently without symptoms
Symptomatic dysthymia	dysthymia, currently with symptoms (MEPS, NESARC and NSMHWB analyses)
Bipolar disorder residual state	residual state of bipolar disorder as defined in DSM-IV or ICD-10 which may include sub-threshold depressive or manic symptoms
Bipolar disorder depressive state	DSM-IV or ICD-10 defined episode of mania
Bipolar disorder manic state	DSM-IV or ICD-10 defined episode of depression
Anxiety disorders, currently without symptoms	anxiety disorder, currently without symptoms
Mild anxiety disorders	mild anxiety disorders (MEPS, NESARC and NSMHWB analyses)
Moderate anxiety disorders	moderate anxiety disorders (MEPS, NESARC and NSMHWB analyses)
Severe anxiety disorders	severe anxiety disorders (MEPS, NESARC and NSMHWB analyses)
Attention-deficit/hyperactivity disorder, currently without symptoms	Attention-Deficit Hyperactivity Disorder, currently without symptoms
Symptomatic attention-deficit/hyperactivity disorder	hyperactive and difficulty concentrating, remembering things, and completing tasks
Conduct disorder, currently without symptoms	conduct disorder, currently without symptoms
Symptomatic conduct disorder	behavior problems, which are sometimes violent, irritation and difficulty interacting with other people
Borderline idiopathic intellectual disability	intellectual disability (IQ 70-84)
Mild idiopathic intellectual disability	intellectual disability (IQ 50-69)

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Moderate idiopathic intellectual disability	moderate idiopathic intellectual disability (IQ 35-49)
Severe idiopathic intellectual disability	intellectual disability (IQ 20-34)
Profound idiopathic intellectual disability	intellectual disability (IQ <20)
Other mental disorders, currently without symptoms	other mental disorders, currently without symptoms
Mild other mental disorders	mild other mental disorders (NESARC and NSMHWB analysis)
Moderate other mental disorders	moderately severe other mental disorders (NESARC and NSMHWB analysis)
Severe other mental disorders	severe other mental disorders (NESARC and NSMHWB analysis)
Uncomplicated diabetes mellitus	takes daily medication for a chronic disease with some worry but minimal interference with daily activities
Diabetic neuropathy	pain, tingling and numbness in the arms, legs, hands and feet due to diabetes
Diabetic foot due to neuropathy	sore on the foot due to diabetes that is swollen and causes some difficulty in walking
Diabetic neuropathy and amputation with treatment	amputation with an artificial leg
Diabetic neuropathy and amputation without treatment	amputation without an artificial leg
Moderate vision impairment due to diabetes mellitus	moderate vision impairment (vision <6/18 & ≥6/60 in better eye)
Severe vision impairment due to diabetes mellitus	severe vision impairment (vision <6/60 & ≥3/60 in better eye)
Blindness due to diabetes mellitus	blindness (vision <3/60 in better eye)
Stage III chronic kidney disease without anemia due to diabetes mellitus	stage III chronic kidney disease due to diabetes mellitus, currently without symptoms
Stage III chronic kidney disease and mild anemia due to diabetes mellitus	minor fatigue associated with mild anemia (2011 WHO classification) (2011 WHO classification)
Stage III chronic kidney disease and moderate anemia due to diabetes mellitus	moderate fatigue associated with moderate anemia (2011 WHO classification)
Stage III chronic kidney disease and severe anemia due to diabetes mellitus	severe fatigue associated with severe anemia (2011 WHO classification)
Stage IV chronic kidney disease without anemia due to diabetes mellitus	fatigue, nausea, reduced appetite and difficulty sleeping
Stage IV chronic kidney disease and mild anemia due to diabetes mellitus	minor fatigue associated with mild anemia (2011 WHO classification)
Stage IV chronic kidney disease and moderate anemia due to diabetes mellitus	moderate fatigue associated with moderate anemia (2011 WHO classification)
Stage IV chronic kidney disease and severe anemia due to diabetes mellitus	severe fatigue associated with severe anemia (2011 WHO classification)
Stage V chronic kidney disease untreated due to diabetes mellitus	terminal disease with constant pain, severe weight loss, severe fatigue
End-stage renal disease after transplant due to diabetes mellitus	occasional fatigue or mood problems after transplant
End-stage renal disease on dialysis due to diabetes mellitus	fatigue, pains and shortness of breath in person undergoing intensive dialysis medical care every other day
Stage III chronic kidney disease without anemia due to hypertension	stage III chronic kidney disease due to hypertension, currently without symptoms

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Stage III chronic kidney disease and mild anemia due to hypertension	minor fatigue associated with mild anemia (2011 WHO classification)
Stage III chronic kidney disease and moderate anemia due to hypertension	moderate fatigue associated with moderate anemia (2011 WHO classification)
Stage III chronic kidney disease and severe anemia due to hypertension	severe fatigue associated with severe anemia (2011 WHO classification)
Stage IV chronic kidney disease without anemia due to hypertension	fatigue, nausea, reduced appetite and difficulty sleeping
Stage IV chronic kidney disease and mild anemia due to hypertension	minor fatigue associated with mild anemia (2011 WHO classification)
Stage IV chronic kidney disease and moderate anemia due to hypertension	moderate fatigue associated with moderate anemia (2011 WHO classification)
Stage IV chronic kidney disease and severe anemia due to hypertension	severe fatigue associated with severe anemia (2011 WHO classification)
Stage V chronic kidney disease untreated due to hypertension	terminal disease with constant pain, severe weight loss, severe fatigue
End-stage renal disease after transplant due to hypertension	occasional fatigue or mood problems after transplant
End-stage renal disease on dialysis due to hypertension	fatigue, pains and shortness of breath in person undergoing intensive dialysis medical care every other day
Stage III chronic kidney disease without anemia due to glomerulonephritis	stage III chronic kidney disease due to glomerulonephritis, currently without symptoms
Stage III chronic kidney disease and mild anemia due to glomerulonephritis	minor fatigue associated with mild anemia (2011 WHO classification)
Stage III chronic kidney disease and moderate anemia due to glomerulonephritis	moderate fatigue associated with moderate anemia (2011 WHO classification)
Stage III chronic kidney disease and severe anemia due to glomerulonephritis	severe fatigue associated with severe anemia (2011 WHO classification)
Stage IV chronic kidney disease without anemia due to glomerulonephritis	fatigue, nausea, reduced appetite and difficulty sleeping
Stage IV chronic kidney disease and mild anemia due to glomerulonephritis	minor fatigue associated with mild anemia (2011 WHO classification)
Stage IV chronic kidney disease and moderate anemia due to glomerulonephritis	moderate fatigue associated with moderate anemia (2011 WHO classification)
Stage IV chronic kidney disease and severe anemia due to glomerulonephritis	severe fatigue associated with severe anemia (2011 WHO classification)
Stage V chronic kidney disease untreated due to glomerulonephritis	terminal disease with constant pain, severe weight loss, severe fatigue
End-stage renal disease after transplant due to glomerulonephritis	occasional fatigue or mood problems after transplant
End-stage renal disease on dialysis due to glomerulonephritis	fatigue, pains and shortness of breath in person undergoing intensive dialysis medical care every other day
Stage III chronic kidney disease without anemia due to other causes	stage III chronic kidney disease due to other causes, currently without symptoms
Stage III chronic kidney disease and mild anemia due to other causes	minor fatigue associated with mild anemia (2011 WHO classification)
Stage III chronic kidney disease and moderate anemia due to other causes	moderate fatigue associated with moderate anemia (2011 WHO classification)
Stage III chronic kidney disease and severe anemia due to other causes	severe fatigue associated with severe anemia (2011 WHO classification)
Stage IV chronic kidney disease without anemia due to other causes	fatigue, nausea, reduced appetite and difficulty sleeping
Stage IV chronic kidney disease and mild anemia due to other causes	minor fatigue associated with mild anemia (2011 WHO classification)

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Stage IV chronic kidney disease and moderate anemia due to other causes	moderate fatigue associated with moderate anemia (2011 WHO classification)
Stage IV chronic kidney disease and severe anemia due to other causes	severe fatigue associated with severe anemia (2011 WHO classification)
Stage V chronic kidney disease untreated due to other causes	terminal disease with constant pain, severe weight loss, severe fatigue
End-stage renal disease after transplant due to other causes	occasional fatigue or mood problems after transplant
End-stage renal disease on dialysis due to other causes	fatigue, pains and shortness of breath in person undergoing intensive dialysis medical care every other day
Mild interstitial nephritis and urinary tract infections	mild infectious disease episode with low fever and mild discomfort
Moderate interstitial nephritis and urinary tract infections	moderate infectious disease episode with fever, aches and fatigue
Acute urolithiasis	abdominal pain and nausea reported as moderate
Chronic urolithiasis	has ever had kidney stones, now either asymptomatic or with worry associated with knowledge of disease.
Asymptomatic benign prostatic hyperplasia	benign prostatic hyperplasia, currently without symptoms
Symptomatic benign prostatic hyperplasia	frequent urge and weak flow of urine
Primary male infertility	absence of a live birth in a man who desires a child and has been in a union for at least five years without using contraceptives
Secondary male infertility	absence of a live birth in a man who desires a child and has been in a union for at least five years since the last live birth, without using contraceptives
Asymptomatic uterine fibroids	uterine fibroids, currently without symptoms
Symptomatic uterine fibroids	abdominal pain and nausea reported as mild
Mild anemia due to uterine fibroids	uterine fibroids with abdominal pain and nausea reported as mild and minor fatigue associated with mild anemia (2011 WHO classification)
Moderate anemia due to uterine fibroids	uterine fibroids with abdominal pain and nausea reported as mild and moderate fatigue associated with moderate anemia (2011 WHO classification)
Severe anemia due to uterine fibroids	uterine fibroids with abdominal pain and nausea reported as mild and severe fatigue associated with severe anemia (2011 WHO classification)
Asymptomatic polycystic ovarian syndrome	polycystic ovarian syndrome without symptoms
Hirsutism due to polycystic ovarian syndrome	hirsutism
Hirsutism and primary infertility due to polycystic ovarian syndrome	hirsutism and absence of a live birth in a woman who desires a child and has been in a union for at least five years without using contraceptives
Primary infertility due to polycystic ovarian syndrome	absence of a live birth in a woman who desires a child and has been in a union for at least five years without using contraceptives
Hirsutism and secondary infertility due to polycystic ovarian syndrome	hirsutism and absence of a live birth in a woman who desires a child and has been in a union for at least five years since her last live birth without using contraceptives
Secondary infertility due to polycystic ovarian syndrome	hirsutism and absence of a live birth in a woman who desires a child and has been in a union for at least five years since her last live birth, without using contraceptives
Idiopathic primary female infertility	absence of a live birth in a woman who desires a child and has been in a union for at least five years without using contraceptives
Idiopathic secondary female infertility	absence of a live birth in a woman who desires a child and has been in a union for at least five years since her last live birth without using contraceptives
Asymptomatic endometriosis	endometriosis, currently without symptoms

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Mild abdominal pain due to endometriosis	abdominal pain and nausea reported as mild
Moderate abdominal pain due to endometriosis	abdominal pain and nausea reported as moderate
Severe endometriosis	abdominal pain and nausea reported as severe
Primary infertility due to endometriosis	absence of a live birth in a woman who desires a child and has been in a union for at least five years without using contraceptives
Mild abdominal pain and primary infertility due to endometriosis	abdominal pain and nausea reported as mild and absence of a live birth in a woman who desires a child and has been in a union for at least five years without using contraceptives
Moderate abdominal pain and primary infertility due to endometriosis	abdominal pain and nausea reported as moderate and absence of a live birth in a woman who desires a child and has been in a union for at least five years without using contraceptives
Severe abdominal pain and primary infertility due to endometriosis	abdominal pain and nausea reported as severe and absence of a live birth in a woman who desires a child and has been in a union for at least five years without using contraceptives
Secondary infertility due to endometriosis	absence of a live birth in a woman who desires a child and has been in a union for at least five years since her last live birth, without using contraceptives
Mild abdominal pain and secondary infertility due to endometriosis	abdominal pain and nausea reported as mild and absence of a live birth in a woman who desires a child and has been in a union for at least five years since her last live birth without
Moderate abdominal pain and secondary infertility due to endometriosis	abdominal pain and nausea reported as moderate and absence of a live birth in a woman who desires a child and has been in a union for at least five years since her last live birth without
Severe abdominal pain and secondary infertility due to endometriosis	abdominal pain and nausea reported as severe and absence of a live birth in a woman who desires a child and has been in a union for at least five years since her last live birth without
Asymptomatic genital prolapse	genital prolapse without symptoms
Abdominal pain due to genital prolapse	abdominal pain and nausea reported as mild
Stress incontinence due to genital prolapse	stress incontinence
Abdominal pain and stress incontinence due to genital prolapse	abdominal pain and nausea reported as mild and stress incontinence
Asymptomatic premenstrual syndrome	premenstrual syndrome without symptoms
Abdominal pain and depression due to premenstrual syndrome	abdominal pain and nausea reported as mild and DSM-IV premenstrual dysphoric disorder
Abdominal pain due to premenstrual syndrome	abdominal pain and nausea reported as mild
Depression due to premenstrual syndrome	DSM-IV premenstrual dysphoric disorder
Asymptomatic other gynecological disorders	other gynecological disorders without symptoms
Mild other gynecological disorders	mild other gynecological disorders (MEPS analysis)
Moderate other gynecological disorders	moderately severe other gynecological disorders (MEPS analysis)
Severe other gynecological disorders	severe other gynecological disorders (MEPS analysis)
Mild anemia due to other gynecological diseases	other gynecological disorders with minor fatigue associated with mild anemia (2011 WHO classification)
Moderate anemia due to other gynecological diseases	other gynecological disorders with moderate fatigue associated with moderate anemia (2011 WHO classification)
Severe anemia due to other gynecological diseases	other gynecological disorders with severe fatigue associated with severe anemia (2011 WHO classification)
Severe infection associated with beta-thalassemia major	severe infectious disease episode from beta-thalassemia major with high fever, pain and severe fatigue

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Mild anemia due to beta-thalassemia major	beta-thalassemia major with minor fatigue associated with mild anemia (2011 WHO classification)
Moderate anemia due to beta-thalassemia major	beta-thalassemia major with moderate fatigue associated with moderate anemia (2011 WHO classification)
Severe anemia due to beta-thalassemia major	beta-thalassemia major with severe fatigue associated with severe anemia (2011 WHO classification)
Severe infection associated with hemoglobin E/beta-thalassemia	severe infectious disease episode from hemoglobin E/beta-thalassemia with high fever, pain and severe fatigue
Mild anemia due to hemoglobin E/beta-thalassemia	hemoglobin E/beta-thalassemia with minor fatigue associated with mild anemia (2011 WHO classification)
Moderate anemia due to hemoglobin E/beta-thalassemia	hemoglobin E/beta-thalassemia with moderate fatigue associated with moderate anemia (2011 WHO classification)
Severe anemia due to hemoglobin E/beta-thalassemia	hemoglobin E/beta-thalassemia with severe fatigue associated with severe anemia (2011 WHO classification)
Severe infection associated with hemoglobin H disease	severe infectious disease episode from hemoglobin H disease with high fever, pain and severe fatigue
Mild anemia due to hemoglobin H disease	hemoglobin H disease with minor fatigue associated with mild anemia (2011 WHO classification)
Moderate anemia due to hemoglobin H disease	hemoglobin H disease with moderate fatigue associated with moderate anemia (2011 WHO classification)
Severe anemia due to hemoglobin H disease	hemoglobin H disease with severe fatigue associated with severe anemia (2011 WHO classification)
Mild heart failure due to thalassemias	severe thalassemia with shortness of breath and fatigue after moderate physical activity that goes away after a rest (NYHA Class I-II heart failure)
Moderate heart failure due to thalassemias	severe thalassemia with shortness of breath and fatigue after minimal physical activity that goes away after a rest (NYHA Class III heart failure)
Severe heart failure due to thalassemias	severe thalassemia with shortness of breath and fatigue even when at rest causing a person to avoid any physical activity (NYHA Class IV heart failure)
Asymptomatic B-thalassemia trait	B-thalassemia trait without symptoms
Mild anemia due to B-thalassemia trait	B-thalassemia trait with minor fatigue associated with mild anemia (2011 WHO classification)
Moderate anemia due to B-thalassemia trait	B-thalassemia trait with moderate fatigue associated with moderate anemia (2011 WHO classification)
Severe anemia due to B-thalassemia trait	B-thalassemia trait with severe fatigue associated with severe anemia (2011 WHO classification)
Asymptomatic hemoglobin E trait	hemoglobin E trait without symptoms
Mild anemia due to hemoglobin E trait	hemoglobin E trait with minor fatigue associated with mild anemia (2011 WHO classification)
Moderate anemia due to hemoglobin E trait	hemoglobin E trait with moderate fatigue associated with moderate anemia (2011 WHO classification)
Severe anemia due to hemoglobin E trait	hemoglobin E trait with severe fatigue associated with severe anemia (2011 WHO classification)
Vaso-occlusive crises due to homozygous sickle cell and severe sickle cell/beta-thalassemia	severe pain crisis due to homozygous sickle cell and severe sickle cell/beta-thalassemia with worry and anxiety
Stroke due to homozygous sickle cell and severe sickle cell/beta-thalassemia	fourth of five levels of motor and cognitive impairment after stroke due to homozygous sickle cell and severe sickle cell/beta-thalassemia and with worry and anxiety
Vaso-occlusive crises and stroke due to homozygous sickle cell and severe sickle cell/beta-thalassemia	severe pain crisis with fourth of five levels of motor and cognitive impairment after stroke due to homozygous sickle cell and severe sickle cell/beta-thalassemia and with worry and
Mild anemia due to homozygous sickle cell and severe sickle cell/B-thalassemia	homozygous sickle cell and severe sickle cell/B-thalassemia with minor fatigue associated with mild anemia (2011 WHO classification)
Moderate anemia due to homozygous sickle cell and severe sickle cell/B-thalassemia	homozygous sickle cell and severe sickle cell/B-thalassemia with moderate fatigue associated with moderate anemia (2011 WHO classification)

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Severe anemia due to homozygous sickle cell and severe sickle cell/B-thalassemia	homozygous sickle cell and severe sickle cell/B-thalassemia with severe fatigue associated with severe anemia (2011 WHO classification)
Vaso-occlusive crises due to hemoglobin SC disease	severe pain crisis due to hemoglobin SC disease with worry and anxiety
Stroke due to hemoglobin SC disease	fourth of five levels of motor and cognitive impairment after stroke due to hemoglobin SC disease and with worry and anxiety
Vaso-occlusive crises and stroke due to hemoglobin SC disease	severe pain crisis with fourth of five levels of motor and cognitive impairment after stroke due to hemoglobin SC disease and with worry and anxiety
Mild anemia due to hemoglobin SC disease	hemoglobin SC disease with minor fatigue associated with mild anemia (2011 WHO classification)
Moderate anemia due to hemoglobin SC disease	hemoglobin SC disease with moderate fatigue associated with moderate anemia (2011 WHO classification)
Severe anemia due to hemoglobin SC disease	hemoglobin SC disease with severe fatigue associated with severe anemia (2011 WHO classification)
Vaso-occlusive crises due to mild sickle cell/beta-thalassemia	severe pain crisis due to mild sickle cell/beta-thalassemia with worry and anxiety
Stroke due to mild sickle cell/beta-thalassemia	fourth of five levels of motor and cognitive impairment after stroke due to mild sickle cell/beta-thalassemia and with worry and anxiety
Vaso-occlusive crises and stroke due to mild sickle cell/beta-thalassemia	severe pain crisis with fourth of five levels of motor and cognitive impairment after stroke due to mild sickle cell/beta-thalassemia and with worry and anxiety
Mild anemia due to mild sickle cell/B-thalassemia	mild sickle cell/B-thalassemia with minor fatigue associated with mild anemia (2011 WHO classification)
Moderate anemia due to mild sickle cell/B-thalassemia	mild sickle cell/B-thalassemia with moderate fatigue associated with moderate anemia (2011 WHO classification)
Severe anemia due to mild sickle cell/B-thalassemia	mild sickle cell/B-thalassemia with severe fatigue associated with severe anemia (2011 WHO classification)
Asymptomatic sickle cell trait	sickle cell trait without symptoms
Mild anemia due to sickle cell trait	sickle cell trait with minor fatigue associated with mild anemia (2011 WHO classification)
Moderate anemia due to sickle cell trait	sickle cell trait with moderate fatigue associated with moderate anemia (2011 WHO classification)
Severe anemia due to sickle cell trait	sickle cell trait with severe fatigue associated with severe anemia (2011 WHO classification)
Asymptomatic G6PD deficiency	G6PD deficiency without symptoms
Mild anemia due to G6PD deficiency	G6PD deficiency with minor fatigue associated with mild anemia (2011 WHO classification)
Moderate anemia due to G6PD deficiency	G6PD deficiency with moderate fatigue associated with moderate anemia (2011 WHO classification)
Severe anemia due to G6PD deficiency	G6PD deficiency with severe fatigue associated with severe anemia (2011 WHO classification)
Mild heart failure due to G6PD deficiency	G6PD deficiency with shortness of breath and fatigue after moderate physical activity that goes away after a rest (NYHA Class I-II heart failure)
Moderate heart failure due to G6PD deficiency	G6PD deficiency with shortness of breath and fatigue after minimal physical activity that goes away after a rest (NYHA Class III heart failure)
Severe heart failure due to G6PD deficiency	G6PD deficiency with shortness of breath and fatigue even when at rest causing a person to avoid any physical activity (NYHA Class IV heart failure)
Asymptomatic hemizygous G6PD deficiency	hemizygous G6PD deficiency without symptoms
Mild anemia due to hemizygous G6PD deficiency	hemizygous G6PD deficiency with minor fatigue associated with mild anemia (2011 WHO classification)
Moderate anemia due to hemizygous G6PD deficiency	hemizygous G6PD deficiency with moderate fatigue associated with moderate anemia (2011 WHO classification)

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Severe anemia due to hemizygous G6PD deficiency	hemizygous G6PD deficiency with severe fatigue associated with severe anemia (2011 WHO classification)
Mild anemia due to other hemoglobinopathies and hemolytic anemias	other hemoglobinopathies and hemolytic anemias with minor fatigue associated with mild anemia (2011 WHO classification)
Moderate anemia due to other hemoglobinopathies and hemolytic anemias	other hemoglobinopathies and hemolytic anemias with moderate fatigue associated with moderate anemia (2011 WHO classification)
Severe anemia due to other hemoglobinopathies and hemolytic anemias	other hemoglobinopathies and hemolytic anemias with severe fatigue associated with severe anemia (2011 WHO classification)
Mild heart failure due to other hemoglobinopathies and hemolytic anemias	other hemoglobinopathies and hemolytic anemias with shortness of breath and fatigue after moderate physical activity that goes away after a rest (NYHA Class I-II heart failure)
Moderate heart failure due to other hemoglobinopathies and hemolytic anemias	other hemoglobinopathies and hemolytic anemias with shortness of breath and fatigue after minimal physical activity that goes away after a rest (NYHA Class III heart failure)
Severe heart failure due to other hemoglobinopathies and hemolytic anemias	other hemoglobinopathies and hemolytic anemias with shortness of breath and fatigue even when at rest causing a person to avoid physical activity (NYHA Class IV heart failure)
Asymptomatic endocrine, metabolic, blood, and immune disorders	endocrine, metabolic, blood, and immune disorders, currently without symptoms
	First of three levels of severity for endocrine, metabolic, blood and immune disorders
Mild endocrine, metabolic, blood, and immune disorders	
Moderate endocrine, metabolic, blood, and immune disorders	Second of three levels of severity for endocrine, metabolic, blood and immune disorders
Severe endocrine, metabolic, blood, and immune disorders	third of three levels of severity for endocrine, metabolic, blood and immune disorders
Mild anemia due to endocrine, metabolic, blood, and immune disorders	endocrine, metabolic, blood, and immune disorders with minor fatigue associated with mild anemia (2011 WHO classification)
Moderate anemia due to endocrine, metabolic, blood, and immune disorders	endocrine, metabolic, blood, and immune disorders with moderate fatigue associated with moderate anemia (2011 WHO classification)
Severe anemia due to endocrine, metabolic, blood, and immune disorders	endocrine, metabolic, blood, and immune disorders with severe fatigue associated with severe anemia (2011 WHO classification)
Mild heart failure due to endocrine, metabolic, blood, and immune disorders	shortness of breath and fatigue after moderate physical activity that goes away after a rest (NYHA Class I-II heart failure)
Moderate heart failure due to endocrine, metabolic, blood, and immune disorders	shortness of breath and fatigue after minimal physical activity that goes away after a rest (NYHA Class III heart failure)
Severe heart failure due to endocrine, metabolic, blood, and immune disorders	shortness of breath and fatigue even when at rest causing a person to avoid any physical activity (NYHA Class IV heart failure)
	Health Assessment Questionnaire score 0.25-0.5
Mild rheumatoid arthritis	
	Health Assessment Questionnaire score 0.6-1.3
Moderate rheumatoid arthritis	
	Health Assessment Questionnaire score >1.4
Severe rheumatoid arthritis	
Mild osteoarthritis of the hip	mild pain in the hip (Western Ontario and McMaster Osteoarthritis Arthritis Index [WOMAC] score 0-5)
Moderate osteoarthritis of the hip	moderate pain in the hip (Western Ontario and McMaster Osteoarthritis Arthritis Index [WOMAC] 6-13)
Severe osteoarthritis of the hip	severe pain in the hip (Western Ontario and McMaster Osteoarthritis Arthritis Index [WOMAC] 14-20)
Mild osteoarthritis of the knee	mild pain in the knee (Western Ontario and McMaster Osteoarthritis Arthritis Index [WOMAC] score 0-5)
Moderate osteoarthritis of the knee	moderate pain in the knee (Western Ontario and McMaster Osteoarthritis Arthritis Index [WOMAC] 6-13)
Severe osteoarthritis of the knee	severe pain in the knee (Western Ontario and McMaster Osteoarthritis Arthritis Index [WOMAC] 14-20)
Mild low back pain without leg pain	least severe of four levels of severity of low back pain (MEPS analysis)

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Mild low back pain with leg pain	least severe of four levels of severity of low back pain (MEPS analysis)
Moderate low back pain without leg pain	second of four levels of severity of low back pain (MEPS analysis)
Moderate low back pain with leg pain	second of four levels of severity of low back pain (MEPS analysis)
Severe low back pain without leg pain	third of four levels of severity of low back pain (MEPS analysis)
Severe low back pain with leg pain	third of four levels of severity of low back pain with leg involvement (MEPS analysis)
Most severe low back pain without leg pain	most severe of four levels of severity of low back pain (MEPS analysis)
Most severe low back pain with leg pain	most severe of four levels of severity of low back pain with leg involvement (MEPS analysis)
Mild neck pain	least severe of four levels of severity of neck pain (MEPS analysis)
Moderate neck pain	second of four levels of severity of neck pain (MEPS analysis)
Severe neck pain	third of four levels of severity of neck pain (MEPS analysis)
Most severe neck pain	most severe of four levels of severity of neck pain (MEPS analysis)
Asymptomatic gout	gout, currently without symptoms
Symptomatic episodes of gout	severe pain and swelling in the leg
Polyarticular gout	chronic severe pain and swelling in the leg
Asymptomatic other musculoskeletal disorders	other musculoskeletal disorders, currently without symptoms
Other musculoskeletal disorders severity level 1	least severe of six levels of severity of other musculoskeletal disorders (MEPS analysis)
Other musculoskeletal disorders severity level 2	second of six levels of severity of other musculoskeletal disorders (MEPS analysis)
Other musculoskeletal disorders severity level 3	third of six levels of severity of other musculoskeletal disorders (MEPS analysis)
Other musculoskeletal disorders severity level 4	fourth of six levels of severity of other musculoskeletal disorders (MEPS analysis)
Other musculoskeletal disorders severity level 5	fifth of six levels of severity of other musculoskeletal disorders (MEPS analysis)
Other musculoskeletal disorders severity level 6	most severe of six levels of severity of other musculoskeletal disorders (MEPS analysis)
Moderate motor impairment due to moderate neural tube defects	moderate motor impairment (spasticity and paresis but able to walk)
Severe motor impairment due to severe neural tube defects	severe motor impairment (unable to walk)
Severe motor plus cognitive impairments due to severe neural tube defects	severe motor impairment (unable to walk) plus intellectual disability (IQ <70)
Severe motor impairment with incontinence due to severe neural tube defects	severe motor impairment (unable to walk) and incontinent
Mild heart failure due to congenital heart anomalies	shortness of breath and fatigue after moderate physical activity that goes away after a rest (NYHA Class I-II heart failure)
Moderate heart failure due to congenital heart anomalies	shortness of breath and fatigue after minimal physical activity that goes away after a rest (NYHA Class III heart failure)

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Severe heart failure due to congenital heart anomalies	shortness of breath and fatigue even when at rest causing a person to avoid any physical activity (NYHA Class IV heart failure)
Symptomatic less severe congenital heart anomalies	physical and mental function limitations due to congenital heart disease
Severe congenital heart anomalies	physical and mental function limitations due to congenital heart disease
Critical congenital heart anomalies	physical and mental function limitations due to congenital heart disease
Asymptomatic orofacial clefts	cleft lip and palate after successful surgery, without symptoms
Disfigurement level 1 due to orofacial clefts	slight visible physical deformity that others notice which causes some worry and discomfort
Disfigurement level 2 due to orofacial clefts	visible physical deformity that causes others to stare and comment which causes anxiety
Disfigurement level 2 and speech problems due to orofacial clefts	difficulty speaking and being understood; and visible physical deformity that is sore and itchy and causes others to stare and comment which causes anxiety
Asymptomatic Down syndrome	down syndrome with normal intelligence and no congenital heart disease
Intellectual disability due to Down syndrome	intellectual disability (IQ <85)
Intellectual disability with congenital heart disease due to Down syndrome	intellectual disability (IQ <85) and mental function limitations due to congenital heart disease
Intellectual disability with dementia due to Down syndrome	intellectual disability (IQ <85) and dementia
Intellectual disability with congenital heart disease and dementia due to Down syndrome	intellectual disability (IQ <85), physical and mental function limitations due to congenital heart disease, and dementia
Isolated congenital heart disease due to Down syndrome	physical and mental function limitations due to congenital heart disease
Asymptomatic Turner syndrome	Turner syndrome without congenital heart disease at age range outside the fertility period
Congenital heart disease due to Turner syndrome	physical and mental function limitations due to congenital heart disease
Primary infertility due to Turner syndrome	absence of a live birth in a woman who desires a child and has been in a union for at least five years without using contraceptives
Congenital heart disease with infertility due to Turner syndrome	physical and mental function limitations due to congenital heart disease and absence of a live birth in a woman who desires a child and has been in a union for at least five years without
Asymptomatic Klinefelter syndrome	Klinefelter syndrome with normal intelligence and age range outside the fertility period
Borderline intellectual disability due to Klinefelter syndrome	borderline intellectual disability (IQ 70-84)
Borderline intellectual disability with infertility due to Klinefelter syndrome	borderline intellectual disability (IQ 70-84) and absence of a live birth in a man who desires a child and has been in a union for at least five years without using contraceptives
Mild intellectual disability due to Klinefelter syndrome	intellectual disability (IQ 50-69)
Mild intellectual disability with infertility due to Klinefelter syndrome	intellectual disability (IQ 50-69) and absence of a live birth in a man who desires a child and has been in a union for at least five years without using contraceptives
Primary infertility due to Klinefelter syndrome	absence of a live birth in a man who desires a child and has been in a union for at least five years without using contraceptives
Asymptomatic chromosomal unbalanced rearrangements	chromosomal unbalanced rearrangement with normal intelligence and no congenital heart disease
Intellectual disability due to chromosomal unbalanced rearrangements	intellectual disability (IQ <85)
Intellectual disability with congenital heart disease due to chromosomal unbalanced rearrangements	intellectual disability (IQ <85) and physical and mental function limitations due to congenital heart disease

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Intellectual disability with dementia due to chromosomal unbalanced rearrangements	intellectual disability (IQ <85) and dementia
Intellectual disability with congenital heart disease and dementia due to chromosomal unbalanced rearrangements	intellectual disability (IQ <85), physical and mental function limitations due to congenital heart disease, and dementia
Isolated congenital heart disease due to chromosomal unbalanced rearrangements	physical and mental function limitations due to congenital heart disease
Mild hearing loss due to other congenital anomalies	mild hearing loss (20-34dB)
Mild hearing loss with ringing due to other congenital anomalies	mild hearing loss (20-34dB) with ringing
Moderate hearing loss due to other congenital anomalies	moderate hearing loss (35-49dB)
Moderate hearing loss with ringing due to other congenital anomalies	moderate hearing loss (35-49dB) with ringing
Moderately severe hearing loss due to other congenital anomalies	moderately severe hearing loss (50-64dB)
Moderately severe hearing loss with ringing due to other congenital anomalies	moderately severe hearing loss (50-64dB) with ringing
Severe hearing loss with ringing due to other congenital anomalies	severe hearing loss (65-79dB) with ringing
Severe hearing loss due to other congenital anomalies	severe hearing loss (65-79dB)
Profound hearing loss due to other congenital anomalies	profound hearing loss (80-94dB)
Profound hearing loss with ringing due to other congenital anomalies	profound hearing loss (80-94dB) with ringing
Complete hearing loss due to other congenital anomalies	complete hearing loss (95dB+)
Complete hearing loss with ringing due to other congenital anomalies	complete hearing loss (95dB+) with ringing
Mild eczema	slight visible physical deformity with sometimes pain or itch that others notice which causes some worry and discomfort
Moderate eczema	visible physical deformity that is sore and itchy and causes others to stare and comment which causes anxiety
Severe eczema	obvious physical deformity that is very painful or itchy and makes others uncomfortable, which causes the person to avoid social contact, feel worried, sleep poorly, and think about contact dermatitis, currently without symptoms
Asymptomatic contact dermatitis	contact dermatitis, currently without symptoms
Mild contact dermatitis	slight visible physical deformity with sometimes pain or itch that others notice which causes some worry and discomfort
Severe contact dermatitis	visible physical deformity that is sore and itchy and causes others to stare and comment which causes anxiety
Asymptomatic seborrheic dermatitis	seborrheic dermatitis, currently without symptoms
Symptomatic seborrheic dermatitis	slight visible physical deformity with sometimes pain or itch that others notice which causes some worry and discomfort
Mild psoriasis	slight visible physical deformity with sometimes pain or itch that others notice which causes some worry and discomfort
Moderate psoriasis	visible physical deformity that is sore and itchy and causes others to stare and comment which causes anxiety
Severe psoriasis	obvious physical deformity that is very painful or itchy and makes others uncomfortable, which causes the person to avoid social contact, feel worried, sleep poorly, and think about
Mild cellulitis	slight visible physical deformity with sometimes pain or itch that others notice which causes some worry and discomfort

Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Severe cellulitis	visible physical deformity that is sore and itchy and causes others to stare and comment which causes anxiety
Impetigo	mild infectious disease episode with low fever and mild discomfort
Abscess and other bacterial skin diseases	mild infectious disease episode with low fever and mild discomfort
Tinea capitis	mild infectious disease episode with low fever and mild discomfort
Other fungal skin diseases	mild infectious disease episode with low fever and mild discomfort
Mild molluscum contagiosum	mild infectious disease episode with low fever and mild discomfort
Severe molluscum contagiosum	visible physical deformity that causes others to stare and comment which causes anxiety
Mild viral warts	mild infectious disease episode with low fever and mild discomfort
Severe viral warts	visible physical deformity that causes others to stare and comment which causes anxiety
Mild alopecia areata	slight visible physical deformity that others notice which causes some worry and discomfort
Severe alopecia areata	visible physical deformity that causes others to stare and comment which causes anxiety
Mild urticaria	slight visible physical deformity with sometimes pain or itch that others notice which causes some worry and discomfort
Severe urticaria	visible physical deformity that is sore and itchy and causes others to stare and comment which causes anxiety
Mild decubitus ulcer	slight visible physical deformity that others notice which causes some worry and discomfort
Moderate decubitus ulcer	visible physical deformity that causes others to stare and comment which causes anxiety
Severe decubitus ulcer	obvious physical deformity that makes others uncomfortable, which causes the person to avoid social contact, feel worried, sleep poorly, and think about suicide
Asymptomatic other skin and subcutaneous diseases	other skin disease, currently without symptoms
Symptomatic other skin and subcutaneous diseases	slight visible physical deformity that others notice which causes some worry and discomfort
Moderate vision impairment due to glaucoma	moderate vision impairment (vision <6/18 & ≥6/60 in better eye)
Severe vision impairment due to glaucoma	severe vision impairment (vision <6/60 & ≥3/60 in better eye)
Blindness due to glaucoma	blindness (vision <3/60 in better eye)
Moderate vision impairment due to cataract	moderate vision impairment (vision <6/18 & ≥6/60 in better eye)
Severe vision impairment due to cataract	severe vision impairment (vision <6/60 & ≥3/60 in better eye)
Blindness due to cataract	blindness (vision <3/60 in better eye)
Moderate vision impairment due to macular degeneration	moderate vision impairment (vision <6/18 & ≥6/60 in better eye)
Severe vision impairment due to macular degeneration	severe vision impairment (vision <6/60 & ≥3/60 in better eye)
Blindness due to macular degeneration	blindness (vision <3/60 in better eye)


Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Moderate vision impairment due to uncorrected refractive error	moderate vision impairment (vision <6/18 & ≥6/60 in better eye)
Severe vision impairment due to uncorrected refractive error	severe vision impairment (vision <6/60 & ≥3/60 in better eye)
Blindness due to uncorrected refractive error	blindness (vision <3/60 in better eye)
Mild hearing loss due to age-related and other hearing loss	mild hearing loss (20-34dB)
Mild hearing loss with ringing due to age-related and other hearing loss	mild hearing loss (20-34dB) with ringing
Moderate hearing loss due to age-related and other hearing loss	moderate hearing loss (35-49dB)
Moderate hearing loss with ringing due to age-related and other hearing loss	moderate hearing loss (35-49dB) with ringing
Moderately severe hearing loss due to age-related and other hearing loss	moderately severe hearing loss (50-64dB)
Moderately severe hearing loss with ringing due to age-related and other hearing loss	moderately severe hearing loss (50-64dB) with ringing
Severe hearing loss with ringing due to age-related and other hearing loss	severe hearing loss (65-79dB) with ringing
Severe hearing loss due to age-related and other hearing loss	severe hearing loss (65-79dB)
Profound hearing loss due to age-related and other hearing loss	profound hearing loss (80-94dB)
Profound hearing loss with ringing due to age-related and other hearing loss	profound hearing loss (80-94dB) with ringing
Complete hearing loss due to age-related and other hearing loss	complete hearing loss (95dB+)
Complete hearing loss with ringing due to age-related and other hearing loss	complete hearing loss (95dB+) with ringing
Near vision impairment due to presbyopia due to uncorrected refractive error	near vision impairment (near vision <6/12 & distance vision ≥6/12)
Moderate vision impairment due to other vision loss	moderate vision impairment (vision <6/18 & ≥6/60 in better eye)
Severe vision impairment due to other vision loss	severe vision impairment (vision <6/60 & ≥3/60 in better eye)
Blindness due to other vision loss	blindness (vision <3/60 in better eye)
Asymptomatic other sense organ diseases	other sense organ disease, currently without symptoms
Mild other sense organ diseases	mild infectious disease episode with low fever and mild discomfort
Moderate other sense organ diseases	slight visible physical deformity that other notice which causes some worry and discomfort
Severe other sense organ diseases	short spells of dizziness and loss of balance
Asymptomatic deciduous caries	deciduous caries, currently without symptoms
Tooth pain due to deciduous caries	tooth pain due to deciduous caries
Asymptomatic permanent caries	permanent caries, currently without symptoms
Tooth pain due to permanent caries	tooth pain due to permanent caries


Appendix Table A.7: Sequelae severity distribution descriptions

Sequela name	Severity description
Chronic periodontal diseases	minor bleeding of the gums from time to time, with mild discomfort
Asymptomatic edentulism and severe tooth loss	9 or fewer teeth without difficulty eating meat, fruits and vegetables
Difficulty eating due to edentulism and severe tooth loss	9 or fewer teeth remaining with difficulty in eating meat, fruits, and vegetables
Mild other oral disorders	mild infectious disease episode with low fever and mild discomfort
Severe other oral disorders	moderate infectious disease episode with fever, aches and fatigue

Appendix Figure B.1: GBD 2010 DisMod 1.0 Cascade



Appendix Figure B.2: GBD 2013 DisMod-MR 2.0 Cascade



Appendix Table B.1: DisMod-MR 2.0 statistical output by cause

Cause	Holdout	RMSE, adjusted data (log space)		Coverage	
		In sample	Out of Sample	In sample	Out of Sample
Low Back Pain	1	0.49	0.54	0.98	0.94
	2	0.49	0.54	0.98	0.96
	3	0.50	0.52	0.98	0.95
	4	0.49	0.53	0.98	0.96
	5	0.50	0.52	0.98	0.96
Alzheimer disease and other dementias	1	0.54	0.59	0.97	0.95
	2	0.54	0.62	0.97	0.97
	3	0.54	0.60	0.98	0.96
	4	0.55	0.55	0.97	0.96
	5	0.56	0.56	0.97	0.95
Epilepsy	1	0.65	0.75	0.95	0.93
	2	0.63	0.81	0.96	0.88
	3	0.68	0.66	0.95	0.93
	4	0.65	0.78	0.95	0.88
	5	0.67	0.74	0.95	0.91
Neck Pain	1	0.44	0.32	0.97	0.96
	2	0.34	0.41	0.97	0.97
	3	0.36	0.33	0.97	0.98
	4	0.34	0.42	0.98	0.95
	5	0.36	0.34	0.97	0.97
Anxiety disorders	1	0.61	0.69	0.98	0.95
	2	0.59	0.81	0.99	0.91
	3	0.57	0.76	0.98	0.91
	4	0.59	0.72	0.99	0.94
	5	0.59	0.75	0.98	0.92
Major Depression Disorders	1	0.57	0.76	0.98	0.88
	2	0.56	0.72	0.97	0.91
	3	0.60	0.60	0.97	0.90
	4	0.68	0.58	0.98	0.93
	5	0.57	0.70	0.98	0.89
Lower respiratory infections	1	0.86	0.86	0.97	0.90
	2	0.87	0.91	0.97	0.89
	3	0.88	0.86	0.97	0.89
	4	0.88	0.92	0.97	0.90
	5	0.86	0.89	0.97	0.91
Cirrhosis	1	0.60	0.62	0.98	0.97
	2	0.60	0.62	0.98	0.97
	3	0.60	0.63	0.98	0.97
	4	0.60	0.62	0.98	0.98
	5	0.61	0.58	0.98	0.98
Chronic obstructive pulmonary disease	1	0.50	0.60	0.98	0.91
	2	0.50	0.60	0.97	0.90
	3	0.53	0.55	0.97	0.89
	4	0.53	0.55	0.96	0.91

Appendix Table B.1: DisMod-MR 2.0 statistical output by cause

Cause	Holdout	RMSE, adjusted data (log space)		Coverage	
		In sample	Out of Sample	In sample	Out of Sample
	5	0.54	0.53	0.97	0.90
Ischemic heart disease	1	0.49	0.57	0.99	0.96
	2	0.49	0.57	0.99	0.94
	3	0.49	0.58	0.99	0.96
	4	0.53	0.53	0.99	0.96
	5	0.55	0.59	0.99	0.98

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
All causes	-	-	-	-
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-
HIV/AIDS and tuberculosis	-	-	-	-
Tuberculosis	7,981.6 (7,742.7 to 8,231.3)	12,111.8 (11,791.6 to 12,452.0)	51.6 (49.3 to 54.0)	-1.9 (-3.3 to -0.3)
HIV/AIDS	-	-	-	-
HIV/AIDS resulting in mycobacterial infection	194.4 (126.7 to 270.2)	724.7 (496.0 to 922.5)	275.7 (221.2 to 335.0)	144.0 (107.3 to 184.1)
HIV/AIDS resulting in other diseases	8,485.7 (7,844.6 to 9,086.9)	28,506.6 (27,415.1 to 30,970.4)	234.1 (217.8 to 262.8)	134.5 (122.8 to 154.8)
Early HIV	5,810.0 (5,381.4 to 6,208.4)	11,948.7 (11,294.9 to 13,254.0)	104.3 (92.6 to 125.3)	43.2 (35.2 to 58.4)
Symptomatic HIV	1,971.6 (1,824.3 to 2,112.0)	4,166.1 (3,938.3 to 4,615.3)	109.9 (98.1 to 131.6)	46.8 (38.6 to 62.0)
AIDS with antiretroviral treatment	0.0 (0.0 to 0.0)	8,640.9 (8,338.7 to 8,945.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
AIDS without antiretroviral treatment	704.0 (572.5 to 850.0)	3,751.0 (3,137.5 to 4,464.5)	432.4 (316.7 to 583.8)	236.3 (161.9 to 332.9)
Diarhea, lower respiratory, and other common infectious diseases	-	-	-	-
Diarrheal diseases	45,464.6 (44,673.7 to 46,188.5)	42,409.6 (41,769.5 to 43,170.2)	-6.9 (-8.9 to -4.7)	-18.3 (-20.1 to -16.4)
Mild diarrheal diseases	11,040.5 (10,614.4 to 11,467.8)	10,298.5 (9,884.7 to 10,711.8)	-6.9 (-8.9 to -4.7)	-18.3 (-20.1 to -16.4)
Moderate diarrheal diseases	28,045.6 (27,392.2 to 28,684.0)	26,160.0 (25,587.1 to 26,761.1)	-6.9 (-8.9 to -4.7)	-18.3 (-20.1 to -16.4)
Severe diarrheal diseases	6,375.5 (5,986.5 to 6,762.8)	5,946.9 (5,591.6 to 6,318.7)	-6.9 (-8.9 to -4.7)	-18.3 (-20.1 to -16.4)
Guillain-Barré syndrome due to diarrheal diseases	2.9 (2.3 to 3.6)	4.2 (3.3 to 5.2)	45.0 (35.2 to 55.3)	0.9 (-5.6 to 7.8)
Intestinal infectious diseases	-	-	-	-
Typhoid fever	1,496.4 (1,325.1 to 1,653.9)	1,198.3 (1,103.3 to 1,300.6)	-19.9 (-30.7 to -6.5)	-33.3 (-41.9 to -22.4)
Acute typhoid infection	525.0 (410.3 to 656.5)	420.4 (327.6 to 513.3)	-19.9 (-30.7 to -6.5)	-33.3 (-41.9 to -22.4)
Severe typhoid fever	714.8 (595.0 to 849.1)	572.4 (471.5 to 673.5)	-19.9 (-30.7 to -6.5)	-33.3 (-41.9 to -22.4)
Intestinal perforation due to typhoid	252.5 (156.8 to 346.6)	202.2 (126.4 to 282.5)	-19.9 (-30.7 to -6.5)	-33.3 (-41.9 to -22.4)
Gastrointestinal bleeding due to typhoid	4.1 (0.0 to 27.0)	3.3 (0.0 to 21.9)	-19.9 (-30.7 to -6.5)	-33.3 (-41.9 to -22.3)
Paratyphoid fever	1,020.7 (895.5 to 1,176.2)	735.9 (640.4 to 836.9)	-27.9 (-41.8 to -12.8)	-39.1 (-50.9 to -26.5)
Acute paratyphoid infection	293.5 (172.2 to 451.4)	211.7 (120.2 to 317.1)	-27.9 (-41.8 to -12.8)	-39.1 (-50.9 to -26.5)
Moderate paratyphoid fever	527.2 (342.1 to 688.7)	380.1 (250.7 to 494.5)	-27.9 (-41.8 to -12.8)	-39.1 (-50.9 to -26.5)
Severe paratyphoid fever	147.9 (78.8 to 238.9)	106.5 (57.8 to 174.7)	-27.9 (-41.8 to -12.8)	-39.1 (-50.9 to -26.5)
Intestinal perforation due to paratyphoid	52.2 (26.9 to 89.2)	37.6 (19.6 to 63.0)	-27.9 (-41.8 to -12.8)	-39.1 (-50.9 to -26.5)
Other intestinal infectious diseases	-	-	-	-
Lower respiratory infections	5,125.2 (5,052.7 to 5,205.5)	4,473.3 (4,374.7 to 4,554.2)	-12.8 (-15.7 to -10.7)	-25.5 (-27.9 to -23.8)
Moderate lower respiratory infections	1,526.7 (1,162.9 to 1,897.7)	1,332.0 (1,012.9 to 1,652.5)	-12.8 (-15.7 to -10.7)	-25.5 (-27.9 to -23.8)
Severe lower respiratory infections	3,595.5 (3,214.4 to 3,964.6)	3,136.8 (2,810.8 to 3,455.9)	-12.8 (-15.7 to -10.7)	-25.5 (-27.9 to -23.8)
Guillain-Barré syndrome due to lower respiratory infections	3.1 (1.8 to 4.5)	4.5 (2.6 to 6.5)	45.0 (35.2 to 55.3)	0.9 (-5.6 to 7.8)
Upper respiratory infections	176,323.2 (173,446.6 to 179,319.5)	244,327.5 (240,789.6 to 247,629.2)	38.4 (35.7 to 41.5)	6.3 (4.2 to 8.6)
Mild upper respiratory infections	151,626.8 (148,532.4 to 154,595.8)	210,105.1 (206,524.3 to 213,734.7)	38.4 (35.7 to 41.5)	6.3 (4.2 to 8.6)
Moderate upper respiratory infections	24,688.0 (23,074.2 to 26,237.0)	34,210.3 (32,002.0 to 36,351.3)	38.4 (35.7 to 41.5)	6.3 (4.2 to 8.6)
Guillain-Barré syndrome due to upper respiratory infections	8.4 (7.3 to 9.6)	12.2 (10.5 to 14.0)	45.0 (35.2 to 55.3)	0.9 (-5.6 to 7.8)
Otitis media	74,415.8 (71,498.9 to 77,339.8)	85,228.0 (82,190.3 to 88,667.4)	14.4 (11.9 to 16.9)	-11.1 (-12.9 to -9.1)
Acute otitis media	18,082.6 (17,692.1 to 18,501.6)	17,900.7 (17,463.0 to 18,398.8)	-1.2 (-4.3 to 2.2)	-12.7 (-15.3 to -9.8)
Severe infectious complications due to chronic otitis media	41.5 (1.5 to 150.6)	45.6 (1.7 to 165.6)	9.7 (7.0 to 12.8)	-9.7 (-11.9 to -7.1)
Vertigo with mild hearing loss due to chronic otitis media	605.8 (494.9 to 729.2)	665.5 (546.3 to 800.2)	9.7 (7.0 to 12.8)	-9.7 (-11.9 to -7.1)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Vertigo with mild hearing loss and ringing due to chronic otitis media	605.7 (494.9 to 729.1)	665.5 (546.1 to 800.0)	9.7 (7.0 to 12.8)	-9.7 (-11.8 to -7.1)
Mild hearing loss due to chronic otitis media	34,531.8 (32,357.0 to 36,654.2)	41,371.2 (39,041.0 to 43,991.5)	19.7 (16.9 to 22.6)	-11.0 (-12.9 to -8.9)
Mild hearing loss with ringing due to chronic otitis media	8,702.3 (8,053.6 to 9,333.5)	10,471.0 (9,775.8 to 11,221.3)	20.2 (17.2 to 23.4)	-11.1 (-13.0 to -8.9)
Vertigo with moderate hearing loss due to chronic otitis media	598.3 (490.6 to 717.7)	657.8 (542.1 to 786.8)	9.8 (7.1 to 13.1)	-9.8 (-12.0 to -7.1)
Vertigo with moderate hearing loss and ringing due to chronic otitis media	583.5 (480.0 to 697.7)	643.3 (533.6 to 766.9)	10.1 (7.3 to 13.5)	-9.9 (-12.1 to -7.1)
Moderate hearing loss due to chronic otitis media	7,667.7 (6,526.7 to 8,819.4)	9,186.4 (7,764.2 to 10,607.3)	19.6 (15.1 to 25.0)	-9.0 (-12.5 to -5.6)
Moderate hearing loss with ringing due to chronic otitis media	2,996.6 (2,464.1 to 3,557.1)	3,620.9 (2,975.6 to 4,304.9)	20.6 (15.5 to 26.5)	-9.0 (-12.6 to -5.3)
Meningitis	-	-	-	-
Pneumococcal meningitis	8,229.4 (5,201.4 to 11,979.2)	7,805.6 (4,929.9 to 11,605.5)	-5.5 (-11.3 to 1.8)	-30.7 (-34.7 to -25.6)
Acute pneumococcal meningitis	65.8 (62.3 to 69.6)	54.0 (51.1 to 57.2)	-18.1 (-23.9 to -12.0)	-26.6 (-31.8 to -21.5)
Mild behavioral problems due to pneumococcal meningitis	432.9 (185.5 to 783.0)	405.2 (171.3 to 740.5)	-7.2 (-15.1 to 2.5)	-32.7 (-38.4 to -25.8)
Mild motor impairment due to long term due to pneumococcal meningitis	1,229.2 (526.3 to 2,217.7)	1,221.7 (528.3 to 2,222.2)	-1.1 (-11.4 to 10.5)	-28.8 (-36.1 to -20.6)
Mild motor plus cognitive impairments due to pneumococcal meningitis	695.7 (314.3 to 1,198.8)	619.1 (271.8 to 1,061.9)	-11.7 (-19.5 to -2.1)	-35.7 (-41.5 to -28.9)
Borderline intellectual disability due to pneumococcal meningitis	845.0 (371.5 to 1,445.9)	751.8 (339.1 to 1,296.9)	-11.7 (-19.5 to -2.1)	-35.7 (-41.5 to -28.9)
Monocular distance vision loss due to pneumococcal meningitis	776.6 (330.3 to 1,381.2)	727.1 (299.1 to 1,320.5)	-7.2 (-15.1 to 2.5)	-32.7 (-38.4 to -25.8)
Mild intellectual disability due to pneumococcal meningitis	659.5 (519.0 to 818.1)	594.7 (470.2 to 728.7)	-10.1 (-17.1 to 1.4)	-30.6 (-35.9 to -21.6)
Moderate motor impairment due to pneumococcal meningitis	402.9 (319.1 to 505.0)	454.0 (368.8 to 547.5)	12.8 (-1.4 to 29.1)	-13.6 (-24.6 to -1.0)
Severe motor impairment due to pneumococcal meningitis	380.2 (292.8 to 469.8)	380.9 (300.6 to 473.2)	0.1 (-9.1 to 12.3)	-23.1 (-30.0 to -13.9)
Moderate motor plus cognitive impairments due to pneumococcal meningitis	466.7 (357.4 to 581.0)	420.8 (324.1 to 520.2)	-10.1 (-17.1 to 1.4)	-30.6 (-35.9 to -21.6)
Severe motor plus cognitive impairments due to pneumococcal meningitis	462.5 (353.1 to 587.3)	417.3 (318.4 to 527.4)	-10.1 (-17.1 to 1.4)	-30.6 (-35.9 to -21.6)
Epilepsy due to pneumococcal meningitis	136.5 (125.8 to 150.7)	187.3 (163.7 to 212.8)	37.5 (17.2 to 56.6)	8.6 (-7.7 to 23.8)
Blindness due to pneumococcal meningitis	172.8 (96.8 to 251.0)	137.0 (70.4 to 214.2)	-21.7 (-32.2 to -9.5)	-47.6 (-54.0 to -40.2)
Mild hearing loss due to pneumococcal meningitis	696.3 (49.8 to 1,205.2)	689.2 (47.7 to 1,242.5)	-1.7 (-10.8 to 8.5)	-33.3 (-39.5 to -26.6)
Mild hearing loss with ringing due to pneumococcal meningitis	184.2 (13.1 to 316.5)	182.4 (12.4 to 327.5)	-1.7 (-11.0 to 8.5)	-33.3 (-39.5 to -26.5)
Moderate hearing loss due to pneumococcal meningitis	269.5 (20.2 to 471.3)	277.7 (20.6 to 496.5)	1.9 (-10.3 to 17.1)	-27.5 (-35.4 to -17.5)
Moderate hearing loss with ringing due to pneumococcal meningitis	116.8 (8.9 to 202.8)	120.3 (8.9 to 215.9)	1.9 (-10.3 to 16.6)	-27.5 (-35.2 to -17.4)
Moderately severe hearing loss due to pneumococcal meningitis	93.4 (7.3 to 163.4)	72.9 (4.9 to 132.2)	-23.2 (-35.7 to -7.9)	-42.6 (-51.1 to -32.3)
Moderately severe hearing loss with ringing due to pneumococcal meningitis	45.0 (3.4 to 78.1)	35.1 (2.4 to 63.8)	-23.0 (-35.6 to -8.4)	-42.5 (-51.2 to -32.4)
Severe hearing loss due to pneumococcal meningitis	17.7 (1.3 to 31.3)	12.4 (0.9 to 22.9)	-30.6 (-41.0 to -18.4)	-42.5 (-51.2 to -32.8)
Severe hearing loss with ringing due to pneumococcal meningitis	31.2 (2.3 to 54.3)	21.8 (1.5 to 40.6)	-30.7 (-41.3 to -18.0)	-42.7 (-51.5 to -32.4)
Profound hearing loss due to pneumococcal meningitis	12.1 (0.8 to 23.1)	5.1 (0.3 to 10.5)	-57.9 (-70.6 to -45.4)	-61.1 (-72.9 to -49.7)
Profound hearing loss with ringing due to pneumococcal meningitis	21.7 (1.5 to 40.7)	9.2 (0.5 to 18.9)	-58.0 (-70.6 to -45.5)	-61.3 (-72.8 to -49.9)
Complete hearing loss due to pneumococcal meningitis	6.9 (0.5 to 12.9)	3.8 (0.3 to 7.2)	-45.7 (-51.3 to -38.3)	-54.7 (-58.9 to -49.6)
Complete hearing loss with ringing due to pneumococcal meningitis	8.3 (0.6 to 15.8)	4.6 (0.3 to 8.8)	-45.5 (-51.4 to -38.7)	-54.5 (-59.0 to -49.5)
H influenzae type B meningitis	4,000.6 (1,588.0 to 7,254.4)	3,246.2 (1,373.4 to 5,962.2)	-19.1 (-26.4 to -12.0)	-38.5 (-43.6 to -32.2)
Acute H influenzae type B meningitis	71.7 (68.1 to 75.5)	46.9 (44.6 to 49.3)	-34.7 (-38.8 to -29.7)	-38.4 (-42.3 to -33.7)
Mild behavioral problems due to H influenzae type B meningitis	94.5 (6.1 to 245.3)	72.1 (2.1 to 197.1)	-25.0 (-61.2 to -13.9)	-44.2 (-71.1 to -36.1)
Mild motor impairment due to long term due to H influenzae type B meningitis	375.0 (21.2 to 1,005.6)	309.8 (7.6 to 848.1)	-19.1 (-59.5 to -3.1)	-40.3 (-70.0 to -28.5)
Mild motor plus cognitive impairments due to H influenzae type B meningitis	203.9 (13.2 to 509.6)	149.5 (4.5 to 395.0)	-27.8 (-62.4 to -18.2)	-46.1 (-71.9 to -39.0)
Borderline intellectual disability due to H influenzae type B meningitis	604.9 (43.7 to 1,504.9)	443.5 (15.0 to 1,172.0)	-27.8 (-62.4 to -18.2)	-46.1 (-71.9 to -39.0)
Monocular distance vision loss due to H influenzae type B meningitis	375.7 (24.4 to 965.9)	286.3 (9.0 to 766.9)	-25.0 (-61.2 to -13.9)	-44.2 (-71.1 to -36.1)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Mild intellectual disability due to H influenzae type B meningitis	211.4 (161.1 to 267.4)	179.6 (135.4 to 231.2)	-15.9 (-23.8 to -2.7)	-32.7 (-39.0 to -22.1)
Moderate motor impairment due to H influenzae type B meningitis	217.4 (170.4 to 270.6)	219.9 (174.6 to 271.7)	1.2 (-12.1 to 16.5)	-19.2 (-29.9 to -7.0)
Severe motor impairment due to H influenzae type B meningitis	208.6 (162.8 to 263.5)	191.2 (149.5 to 240.0)	-8.8 (-18.7 to 4.0)	-27.2 (-35.2 to -17.1)
Moderate motor plus cognitive impairments due to H influenzae type B meningitis	318.5 (249.3 to 386.9)	270.5 (211.1 to 341.0)	-15.9 (-23.8 to -2.7)	-32.7 (-39.0 to -22.1)
Severe motor plus cognitive impairments due to H influenzae type B meningitis	314.0 (246.8 to 390.2)	266.7 (204.7 to 334.6)	-15.9 (-23.8 to -2.7)	-32.7 (-39.0 to -22.1)
Epilepsy due to H influenzae type B meningitis	89.5 (81.5 to 97.0)	112.0 (98.8 to 125.9)	25.2 (7.3 to 45.0)	6.6 (-8.9 to 23.3)
Blindness due to H influenzae type B meningitis	19.7 (2.4 to 35.8)	11.9 (0.5 to 24.0)	-40.5 (-74.9 to -29.4)	-59.1 (-82.2 to -52.1)
Mild hearing loss due to H influenzae type B meningitis	402.9 (9.1 to 884.9)	319.0 (4.3 to 745.3)	-22.4 (-62.2 to -11.1)	-46.5 (-74.1 to -38.7)
Mild hearing loss with ringing due to H influenzae type B meningitis	106.6 (2.4 to 234.4)	84.4 (1.1 to 198.7)	-22.3 (-62.2 to -11.0)	-46.5 (-74.1 to -38.6)
Moderate hearing loss due to H influenzae type B meningitis	162.3 (4.7 to 351.9)	135.1 (2.1 to 311.7)	-18.5 (-61.6 to -3.4)	-40.8 (-71.8 to -30.3)
Moderate hearing loss with ringing due to H influenzae type B meningitis	70.3 (2.0 to 151.9)	58.5 (0.9 to 135.2)	-18.5 (-61.6 to -3.4)	-40.8 (-71.7 to -30.2)
Moderately severe hearing loss due to H influenzae type B meningitis	57.5 (1.6 to 125.4)	36.7 (0.5 to 87.3)	-38.6 (-72.8 to -22.3)	-52.8 (-78.8 to -40.4)
Moderately severe hearing loss with ringing due to H influenzae type B meningitis	27.7 (0.8 to 61.4)	17.7 (0.2 to 42.4)	-38.5 (-72.6 to -22.0)	-52.8 (-78.9 to -40.3)
Severe hearing loss due to H influenzae type B meningitis	12.5 (0.3 to 28.0)	7.5 (0.1 to 18.0)	-41.5 (-64.7 to -27.6)	-50.4 (-70.4 to -38.9)
Severe hearing loss with ringing due to H influenzae type B meningitis	22.0 (0.6 to 48.6)	13.3 (0.3 to 32.2)	-41.4 (-64.7 to -27.9)	-50.3 (-69.9 to -39.1)
Profound hearing loss due to H influenzae type B meningitis	8.4 (0.3 to 19.8)	3.2 (0.1 to 8.7)	-63.3 (-82.4 to -50.1)	-66.2 (-83.6 to -54.0)
Profound hearing loss with ringing due to H influenzae type B meningitis	15.1 (0.4 to 35.8)	5.8 (0.1 to 15.5)	-63.4 (-82.5 to -50.5)	-66.2 (-83.9 to -54.3)
Complete hearing loss due to H influenzae type B meningitis	4.9 (0.1 to 11.7)	2.3 (0.1 to 5.8)	-53.5 (-64.8 to -45.6)	-60.5 (-70.1 to -54.3)
Complete hearing loss with ringing due to H influenzae type B meningitis	5.9 (0.2 to 13.9)	2.8 (0.1 to 7.0)	-53.5 (-64.7 to -45.9)	-60.4 (-69.8 to -54.3)
Meningococcal meningitis	1,644.2 (596.9 to 3,569.6)	1,321.2 (490.6 to 2,847.6)	-19.9 (-28.5 to -12.0)	-40.9 (-46.6 to -34.5)
Acute meningococcal meningitis	53.4 (50.1 to 56.7)	39.6 (37.4 to 42.1)	-26.1 (-32.0 to -19.2)	-32.7 (-38.0 to -26.5)
Mild behavioral problems due to meningococcal meningitis	26.0 (0.1 to 114.7)	20.0 (0.1 to 89.4)	-24.4 (-57.1 to -13.9)	-44.5 (-68.8 to -37.1)
Mild motor impairment due to long term due to meningococcal meningitis	99.5 (0.5 to 429.4)	81.0 (0.3 to 362.0)	-20.1 (-55.1 to -7.8)	-41.8 (-67.3 to -33.0)
Mild motor plus cognitive impairments due to meningococcal meningitis	58.1 (0.3 to 251.5)	43.6 (0.2 to 198.1)	-26.2 (-56.8 to -16.0)	-45.8 (-68.6 to -38.6)
Borderline intellectual disability due to meningococcal meningitis	170.9 (0.8 to 785.6)	128.2 (0.6 to 596.5)	-26.2 (-56.8 to -16.0)	-45.8 (-68.6 to -38.6)
Monocular distance vision loss due to meningococcal meningitis	102.5 (0.6 to 439.7)	78.8 (0.4 to 350.9)	-24.4 (-57.1 to -13.9)	-44.5 (-68.8 to -37.1)
Mild intellectual disability due to meningococcal meningitis	77.0 (58.7 to 98.4)	64.1 (48.8 to 81.6)	-16.5 (-27.6 to -4.2)	-34.4 (-42.8 to -24.9)
Moderate motor impairment due to meningococcal meningitis	76.0 (57.8 to 95.6)	70.4 (55.2 to 87.5)	-7.2 (-19.4 to 7.3)	-27.4 (-36.5 to -16.3)
Severe motor impairment due to meningococcal meningitis	74.5 (56.9 to 95.9)	65.6 (51.1 to 82.5)	-11.8 (-23.2 to 1.6)	-30.9 (-39.5 to -20.8)
Moderate motor plus cognitive impairments due to meningococcal meningitis	115.9 (90.4 to 144.3)	96.6 (76.3 to 119.4)	-16.5 (-27.6 to -4.2)	-34.4 (-42.8 to -24.9)
Severe motor plus cognitive impairments due to meningococcal meningitis	116.2 (90.7 to 144.2)	96.8 (76.4 to 118.9)	-16.5 (-27.6 to -4.2)	-34.4 (-42.8 to -24.9)
Epilepsy due to meningococcal meningitis	20.1 (19.2 to 21.1)	29.3 (27.2 to 31.5)	45.6 (32.4 to 57.9)	15.5 (4.9 to 25.4)
Blindness due to meningococcal meningitis	255.4 (27.5 to 459.4)	191.3 (8.8 to 377.5)	-26.9 (-65.1 to -14.3)	-50.5 (-75.5 to -42.5)
Mild hearing loss due to meningococcal meningitis	191.3 (4.2 to 430.8)	156.7 (2.1 to 375.4)	-19.9 (-54.9 to -9.7)	-45.3 (-69.3 to -38.2)
Mild hearing loss with ringing due to meningococcal meningitis	50.6 (1.1 to 112.6)	41.5 (0.6 to 98.0)	-19.9 (-55.0 to -9.7)	-45.3 (-69.5 to -38.2)
Moderate hearing loss due to meningococcal meningitis	66.2 (1.7 to 146.7)	56.3 (0.9 to 132.6)	-16.8 (-56.7 to -1.7)	-40.0 (-68.9 to -30.5)
Moderate hearing loss with ringing due to meningococcal meningitis	28.7 (0.7 to 63.9)	24.4 (0.4 to 56.5)	-16.7 (-56.7 to -1.5)	-40.0 (-68.9 to -30.5)
Moderately severe hearing loss due to meningococcal meningitis	23.3 (0.5 to 51.5)	14.8 (0.2 to 36.2)	-38.3 (-67.1 to -24.2)	-52.8 (-75.2 to -42.7)
Moderately severe hearing loss with ringing due to meningococcal meningitis	11.2 (0.2 to 25.2)	7.1 (0.1 to 17.1)	-38.1 (-67.2 to -24.2)	-52.8 (-75.3 to -42.8)
Severe hearing loss due to meningococcal meningitis	4.7 (0.1 to 10.6)	3.0 (0.1 to 7.3)	-36.9 (-58.6 to -25.7)	-48.2 (-65.7 to -39.2)
Severe hearing loss with ringing due to meningococcal meningitis	8.3 (0.2 to 18.8)	5.4 (0.1 to 12.6)	-36.8 (-58.6 to -25.9)	-48.1 (-65.8 to -39.5)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
	3.8 (0.1 to 8.8)	1.7 (0.0 to 4.5)	-56.4 (-75.3 to -40.8)	-59.3 (-77.2 to -44.9)
Profound hearing loss due to meningococcal meningitis				
	6.7 (0.1 to 15.3)	3.1 (0.0 to 7.5)	-56.2 (-75.1 to -40.3)	-59.3 (-76.9 to -44.5)
Profound hearing loss with ringing due to meningococcal meningitis				
	1.8 (0.0 to 4.3)	0.9 (0.0 to 2.2)	-52.5 (-67.1 to -43.5)	-60.4 (-71.9 to -53.5)
Complete hearing loss due to meningococcal meningitis				
	2.2 (0.1 to 5.1)	1.1 (0.0 to 2.7)	-52.6 (-67.3 to -43.2)	-60.3 (-71.8 to -53.4)
Complete hearing loss with ringing due to meningococcal meningitis				
Other meningitis	4,489.2 (2,277.5 to 7,735.1)	3,595.2 (1,901.7 to 6,305.8)	-20.2 (-27.9 to -12.9)	-39.6 (-44.9 to -33.2)
	840.3 (817.3 to 863.8)	780.9 (752.2 to 811.5)	-7.1 (-11.7 to -2.4)	-19.7 (-23.7 to -15.6)
Acute viral meningitis				
	75.6 (71.4 to 79.9)	55.9 (51.6 to 60.5)	-26.1 (-32.9 to -18.7)	-33.8 (-39.6 to -27.0)
Other acute bacterial meningitis				
	74.5 (4.2 to 223.6)	55.2 (1.1 to 178.6)	-27.3 (-71.9 to -13.6)	-47.2 (-79.6 to -37.4)
Mild behavioral problems due to other bacterial meningitis				
	289.5 (17.9 to 897.1)	232.4 (4.3 to 765.6)	-21.8 (-69.0 to -3.8)	-43.5 (-77.6 to -30.8)
Mild motor impairment due to long term due to other bacterial meningitis				
	162.1 (9.0 to 495.3)	115.5 (2.4 to 372.7)	-29.9 (-73.0 to -17.0)	-49.0 (-80.4 to -39.5)
Mild motor plus cognitive impairments due to other bacterial meningitis				
	477.8 (28.2 to 1,446.7)	340.7 (7.5 to 1,111.8)	-29.9 (-73.0 to -17.0)	-49.0 (-80.4 to -39.5)
Borderline intellectual disability due to other bacterial meningitis				
	295.0 (18.4 to 893.6)	218.6 (4.4 to 712.1)	-27.3 (-71.9 to -13.6)	-47.2 (-79.6 to -37.4)
Monocular distance vision loss due to other bacterial meningitis				
	192.5 (149.3 to 244.9)	149.6 (115.0 to 193.2)	-22.5 (-30.4 to -12.1)	-39.6 (-45.8 to -31.6)
Mild intellectual disability due to other bacterial meningitis				
	194.2 (152.9 to 244.5)	178.6 (140.8 to 219.0)	-8.5 (-19.0 to 5.6)	-28.9 (-36.9 to -18.2)
Moderate motor impairment due to other bacterial meningitis				
	186.7 (145.3 to 232.9)	157.3 (123.5 to 194.4)	-16.2 (-25.1 to -9.9)	-34.8 (-41.7 to -26.3)
Severe motor impairment due to other bacterial meningitis				
	286.3 (226.8 to 357.1)	222.4 (174.3 to 277.3)	-22.5 (-30.4 to -12.1)	-39.5 (-45.8 to -31.6)
Moderate motor plus cognitive impairments due to other bacterial meningitis				
	285.6 (222.8 to 356.6)	221.8 (172.5 to 276.3)	-22.5 (-30.4 to -12.1)	-39.6 (-45.8 to -31.6)
Severe motor plus cognitive impairments due to other bacterial meningitis				
	70.1 (65.1 to 75.2)	86.1 (76.4 to 95.2)	23.1 (7.9 to 38.1)	-3.4 (-15.4 to 8.4)
Epilepsy due to other meningitis				
	226.8 (25.9 to 415.4)	157.6 (5.9 to 329.5)	-31.9 (-75.1 to -16.3)	-54.5 (-83.1 to -44.3)
Blindness due to other bacterial meningitis				
	391.9 (10.3 to 842.6)	297.7 (3.8 to 711.4)	-26.0 (-73.6 to -10.8)	-49.4 (-82.0 to -39.3)
Mild hearing loss due to other bacterial meningitis				
	103.7 (2.7 to 224.6)	78.8 (1.0 to 189.5)	-26.0 (-73.5 to -10.9)	-49.4 (-82.0 to -39.4)
Mild hearing loss due with ringing to other bacterial meningitis				
	144.7 (4.5 to 302.6)	121.6 (1.7 to 288.2)	-18.5 (-69.8 to 0.9)	-42.3 (-78.5 to -29.5)
Moderate hearing loss due to other bacterial meningitis				
	62.7 (1.9 to 132.2)	52.7 (0.7 to 126.2)	-18.6 (-69.8 to 0.1)	-42.2 (-78.7 to -29.5)
Moderate hearing loss with ringing due to other bacterial meningitis				
	46.8 (1.4 to 101.8)	31.1 (0.4 to 74.1)	-36.4 (-78.6 to -18.3)	-52.4 (-84.5 to -39.9)
Moderately severe hearing loss due to other bacterial meningitis				
	22.6 (0.7 to 49.1)	15.0 (0.2 to 35.5)	-36.1 (-79.0 to -18.9)	-52.2 (-84.3 to -40.1)
Moderately severe hearing loss with ringing due to other bacterial meningitis				
	10.7 (0.3 to 23.8)	5.6 (0.1 to 13.8)	-48.9 (-76.6 to -36.5)	-57.4 (-81.1 to -47.3)
Severe hearing loss due to other bacterial meningitis				
	18.8 (0.6 to 41.2)	9.9 (0.2 to 24.7)	-48.7 (-76.4 to -36.8)	-57.3 (-80.5 to -47.5)
Severe hearing loss with ringing due to other bacterial meningitis				
	6.6 (0.2 to 15.2)	1.9 (0.0 to 5.1)	-71.9 (-90.6 to -61.3)	-74.2 (-91.3 to -64.6)
Profound hearing loss due to other bacterial meningitis				
	11.8 (0.4 to 27.9)	3.5 (0.0 to 9.4)	-72.0 (-90.7 to -61.6)	-74.1 (-91.5 to -64.7)
Profound hearing loss with ringing due to other bacterial meningitis				
	5.4 (0.2 to 13.2)	2.1 (0.0 to 5.5)	-62.1 (-78.3 to -51.7)	-68.0 (-81.6 to -60.0)
Complete hearing loss due to other bacterial meningitis				
	6.5 (0.2 to 15.0)	2.5 (0.0 to 6.3)	-61.9 (-78.0 to -51.7)	-67.9 (-81.0 to -60.2)
Complete hearing loss with ringing due to other bacterial meningitis				
Encephalitis	1,692.1 (753.7 to 3,631.6)	1,739.8 (795.7 to 4,003.7)	3.1 (-16.5 to 12.6)	-27.5 (-41.1 to -21.1)
	43.9 (43.3 to 44.5)	46.1 (45.4 to 46.7)	4.7 (2.9 to 6.7)	-16.4 (-17.8 to -14.8)
Acute encephalitis				
	54.5 (2.5 to 163.7)	53.3 (0.3 to 178.2)	-4.4 (-84.4 to 14.1)	-34.2 (-89.3 to -21.9)
Mild behavioral problems due to encephalitis				
	210.1 (8.9 to 643.9)	212.5 (1.1 to 735.5)	-0.9 (-82.7 to 18.2)	-32.1 (-88.2 to -19.4)
Mild motor impairment due to long term due to encephalitis				
	119.2 (5.8 to 361.2)	114.8 (0.9 to 389.5)	-5.8 (-85.1 to 12.6)	-35.1 (-89.8 to -22.7)
Mild motor plus cognitive impairments due to encephalitis				
	350.4 (16.9 to 1,051.0)	337.4 (2.3 to 1,128.4)	-5.8 (-85.1 to 12.6)	-35.1 (-89.8 to -22.7)
Borderline intellectual disability due to encephalitis				
	215.2 (9.8 to 668.6)	210.7 (1.3 to 742.0)	-4.4 (-84.4 to 14.1)	-34.2 (-89.3 to -21.9)
Monocular distance vision loss due to encephalitis				
	100.7 (78.7 to 124.9)	108.7 (84.4 to 135.2)	7.6 (1.1 to 15.5)	-23.2 (-27.3 to -17.5)
Mild intellectual disability due to encephalitis				
	99.6 (77.3 to 123.5)	112.4 (88.3 to 139.1)	12.7 (5.2 to 21.4)	-19.6 (-24.8 to -13.5)
Moderate motor impairment due to encephalitis				
	98.4 (76.2 to 122.4)	109.7 (84.8 to 135.2)	11.3 (4.5 to 19.1)	-20.6 (-25.2 to -15.1)
Severe motor impairment due to encephalitis				

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Moderate motor plus cognitive impairments due to encephalitis	150.6 (119.7 to 184.0)	162.6 (129.0 to 201.2)	7.6 (1.1 to 15.5)	-23.2 (-27.3 to -17.5)
Severe motor plus cognitive impairments due to encephalitis	150.4 (117.4 to 184.8)	162.3 (126.2 to 197.1)	7.6 (1.1 to 15.5)	-23.2 (-27.3 to -17.5)
Epilepsy due to encephalitis	67.4 (61.8 to 72.1)	83.9 (74.3 to 91.8)	24.8 (8.4 to 40.8)	-8.5 (-20.4 to 2.6)
Blindness due to encephalitis	31.7 (2.2 to 64.6)	25.5 (0.3 to 59.7)	-21.6 (-85.6 to -5.3)	-49.5 (-90.9 to -39.4)
Diphtheria	3.0 (1.8 to 5.7)	1.1 (0.7 to 2.0)	-62.1 (-83.4 to -15.4)	-65.7 (-84.6 to -25.0)
Moderate diphtheria	2.1 (1.2 to 4.0)	0.8 (0.5 to 1.4)	-62.1 (-83.4 to -15.4)	-65.7 (-84.6 to -25.0)
Severe diphtheria	0.9 (0.5 to 1.8)	0.3 (0.2 to 0.6)	-62.1 (-83.4 to -15.4)	-65.7 (-84.6 to -25.0)
Whooping cough	3,613.3 (2,799.2 to 4,637.4)	2,532.5 (1,965.7 to 3,239.2)	-30.0 (-30.6 to -29.4)	-32.5 (-33.1 to -31.8)
Tetanus	1,355.2 (986.9 to 1,992.9)	177.1 (117.5 to 265.7)	-87.1 (-92.5 to -77.9)	-90.1 (-94.2 to -82.9)
Severe tetanus	68.5 (48.2 to 113.4)	11.3 (7.4 to 16.0)	-82.5 (-92.7 to -73.4)	-84.4 (-93.3 to -76.1)
Mild motor impairment due to neonatal tetanus	651.1 (393.0 to 1,038.2)	72.7 (38.0 to 126.8)	-89.1 (-94.2 to -79.9)	-91.6 (-95.6 to -84.7)
Mild motor plus cognitive impairments due to neonatal tetanus	554.8 (294.8 to 920.2)	64.9 (31.5 to 113.8)	-88.5 (-94.1 to -78.0)	-91.3 (-95.5 to -83.4)
Moderate motor impairment due to neonatal tetanus	27.1 (17.9 to 42.9)	10.8 (5.3 to 21.5)	-62.5 (-83.1 to -8.8)	-67.0 (-85.0 to -20.7)
Moderate motor impairment with blindness due to neonatal tetanus	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.1)	-72.1 (-89.0 to -40.0)	-78.3 (-91.4 to -53.7)
Moderate motor impairment with epilepsy due to neonatal tetanus	4.8 (3.1 to 6.8)	1.3 (0.7 to 2.1)	-73.4 (-86.5 to -51.1)	-77.5 (-88.7 to -59.1)
Moderate motor impairment with blindness and epilepsy due to neonatal tetanus	0.4 (0.3 to 0.7)	0.1 (0.1 to 0.2)	-73.4 (-86.5 to -51.1)	-77.5 (-88.7 to -59.1)
Moderate motor plus cognitive impairment with blindness due to neonatal tetanus	1.6 (1.1 to 2.4)	0.5 (0.3 to 0.9)	-68.4 (-83.2 to -39.5)	-73.2 (-85.7 to -49.4)
Moderate motor plus cognitive impairment with epilepsy due to neonatal tetanus	8.7 (5.7 to 12.6)	2.3 (1.3 to 3.8)	-73.4 (-86.5 to -51.1)	-77.5 (-88.7 to -59.1)
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal tetanus	0.8 (0.5 to 1.2)	0.2 (0.1 to 0.4)	-73.4 (-86.5 to -51.1)	-77.5 (-88.7 to -59.1)
Severe motor impairment due to neonatal tetanus	22.0 (14.5 to 35.1)	8.9 (4.2 to 18.0)	-62.1 (-83.5 to -7.2)	-66.9 (-85.4 to -17.7)
Severe motor impairment with blindness due to neonatal tetanus	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-72.1 (-89.0 to -40.0)	-78.3 (-91.4 to -53.7)
Severe motor impairment with epilepsy due to neonatal tetanus	1.6 (1.0 to 2.3)	0.4 (0.2 to 0.7)	-73.4 (-86.5 to -51.1)	-77.5 (-88.7 to -59.1)
Severe motor impairment with blindness and epilepsy due to neonatal tetanus	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-73.4 (-86.5 to -51.1)	-77.5 (-88.7 to -59.1)
Severe motor plus cognitive impairment with blindness due to neonatal tetanus	1.9 (1.3 to 2.9)	0.6 (0.4 to 1.1)	-68.4 (-83.2 to -39.5)	-73.2 (-85.7 to -49.4)
Severe motor plus cognitive impairment with epilepsy due to neonatal tetanus	10.3 (6.8 to 14.9)	2.7 (1.5 to 4.5)	-73.4 (-86.5 to -51.1)	-77.5 (-88.7 to -59.1)
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal tetanus	1.0 (0.6 to 1.4)	0.3 (0.1 to 0.4)	-73.4 (-86.5 to -51.1)	-77.5 (-88.7 to -59.1)
Measles	840.7 (645.3 to 1,079.5)	192.4 (150.4 to 242.9)	-77.1 (-79.2 to -74.9)	-78.0 (-80.1 to -75.9)
Moderate measles	421.1 (310.2 to 561.4)	96.4 (72.1 to 125.0)	-77.1 (-79.2 to -74.9)	-78.0 (-80.1 to -75.9)
Severe measles	419.6 (308.5 to 551.0)	96.0 (71.6 to 123.9)	-77.1 (-79.2 to -74.9)	-78.0 (-80.1 to -75.9)
Varicella and herpes zoster	4,445.7 (4,367.9 to 4,525.1)	5,715.8 (5,587.6 to 5,835.3)	28.4 (25.5 to 31.7)	-2.4 (-4.9 to 0.3)
Chickenpox	2,231.9 (2,202.4 to 2,260.2)	2,338.8 (2,319.9 to 2,357.2)	4.6 (3.4 to 6.4)	-3.1 (-4.2 to -1.7)
Herpes zoster	2,213.8 (2,148.4 to 2,292.0)	3,377.0 (3,252.3 to 3,495.5)	52.4 (45.8 to 59.2)	-1.9 (-6.0 to 2.6)
Neglected tropical diseases and malaria	-	-	-	-
Malaria	268,118.8 (263,086.2 to 273,669.6)	351,051.1 (344,772.1 to 358,013.6)	30.8 (28.4 to 33.2)	3.0 (1.1 to 4.9)
Asymptomatic malaria parasitemia (PIPR)	200,145.8 (191,754.9 to 207,461.2)	261,819.5 (251,615.8 to 270,485.8)	30.7 (27.2 to 34.2)	1.9 (-0.9 to 4.6)
Mild malaria	6,593.4 (3,390.4 to 11,250.7)	5,603.7 (2,756.1 to 10,664.5)	-16.6 (-34.7 to 12.5)	-29.8 (-44.9 to -5.9)
Moderate malaria	3,302.0 (1,700.7 to 5,610.7)	2,806.2 (1,379.8 to 5,368.5)	-16.6 (-34.7 to 12.5)	-29.8 (-44.9 to -5.9)
Severe malaria	50.4 (4.7 to 162.2)	42.9 (3.9 to 140.0)	-16.6 (-34.7 to 12.5)	-29.8 (-44.9 to -5.9)
Moderate motor impairment due to malaria	19.3 (15.1 to 24.4)	38.5 (28.2 to 53.2)	95.0 (40.2 to 202.0)	63.3 (17.0 to 152.5)
Moderate motor impairment with blindness due to malaria	0.7 (0.5 to 0.9)	0.7 (0.5 to 1.0)	3.9 (-24.1 to 47.9)	-19.1 (-41.1 to 16.2)
Moderate motor impairment with epilepsy due to malaria	9.0 (7.1 to 10.7)	13.1 (10.7 to 15.6)	43.7 (15.9 to 88.8)	19.3 (-3.8 to 57.6)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Moderate motor impairment with blindness and epilepsy due to malaria	0.8 (0.7 to 1.0)	1.2 (1.0 to 1.5)	43.7 (15.9 to 88.8)	19.3 (-3.8 to 57.6)
Moderate motor plus cognitive impairment with blindness due to malaria	2.9 (2.3 to 3.5)	4.5 (3.7 to 5.4)	53.0 (24.4 to 98.8)	27.1 (3.0 to 65.5)
Moderate motor plus cognitive impairment with epilepsy due to malaria	16.4 (13.0 to 19.6)	23.8 (19.7 to 28.6)	43.7 (15.9 to 88.8)	19.3 (-3.8 to 57.6)
Moderate motor plus cognitive impairment with blindness and epilepsy due to malaria	1.5 (1.2 to 1.9)	2.2 (1.8 to 2.8)	43.7 (15.9 to 88.8)	19.3 (-3.8 to 57.6)
Severe motor impairment due to malaria	15.5 (12.1 to 19.6)	31.2 (22.5 to 43.3)	96.9 (37.6 to 209.4)	64.2 (14.9 to 158.5)
Severe motor impairment with blindness due to malaria	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	3.9 (-24.1 to 47.9)	-19.1 (-41.1 to 16.2)
Severe motor impairment with epilepsy due to malaria	3.0 (2.4 to 3.6)	4.3 (3.5 to 5.2)	43.7 (15.9 to 88.8)	19.3 (-3.8 to 57.6)
Severe motor impairment with blindness and epilepsy due to malaria	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	43.7 (15.9 to 88.8)	19.3 (-3.8 to 57.6)
Severe motor plus cognitive impairment with blindness due to malaria	3.4 (2.7 to 4.1)	5.3 (4.3 to 6.5)	53.0 (24.4 to 98.8)	27.1 (3.0 to 65.5)
Severe motor plus cognitive impairment with epilepsy due to malaria	19.4 (15.4 to 23.0)	28.2 (23.0 to 33.9)	43.7 (15.9 to 88.8)	19.3 (-3.8 to 57.6)
Severe motor plus cognitive impairment with blindness and epilepsy due to malaria	1.8 (1.4 to 2.2)	2.6 (2.1 to 3.2)	43.7 (15.9 to 88.8)	19.3 (-3.8 to 57.6)
Mild anemia due to malaria parasitemia (PIPR)	22,242.9 (21,547.8 to 23,078.1)	32,355.1 (31,458.6 to 33,003.3)	45.5 (39.6 to 50.9)	12.7 (8.7 to 16.8)
Moderate anemia due to malaria parasitemia (PIPR)	32,029.3 (30,828.8 to 32,859.7)	43,882.8 (43,305.7 to 44,949.8)	36.6 (33.1 to 42.3)	12.6 (9.6 to 16.9)
Severe anemia due to malaria parasitemia (PIPR)	3,660.7 (3,400.6 to 3,864.0)	4,384.5 (4,105.6 to 4,694.9)	19.7 (6.8 to 32.4)	0.3 (-10.4 to 11.1)
Chagas disease	7,693.3 (7,562.4 to 7,810.3)	9,433.9 (9,241.1 to 9,628.4)	22.4 (19.5 to 25.7)	-16.3 (-18.3 to -14.0)
Acute Chagas disease	1.4 (1.2 to 1.7)	1.3 (1.1 to 1.5)	-9.2 (-26.3 to 13.9)	-21.6 (-36.4 to -1.6)
Mild chronic digestive disease due to Chagas disease	370.3 (297.2 to 444.1)	463.6 (370.4 to 557.0)	25.0 (21.5 to 28.7)	-18.4 (-20.6 to -15.9)
Moderate chronic digestive disease due to Chagas disease	246.9 (198.2 to 296.0)	309.1 (247.0 to 371.3)	25.0 (21.5 to 28.7)	-18.4 (-20.6 to -15.9)
Asymptomatic Chagas disease	6,738.5 (6,551.6 to 6,923.6)	8,191.2 (7,919.3 to 8,452.5)	21.4 (18.5 to 24.5)	-16.1 (-18.0 to -13.8)
Atrial fibrillation and flutter due to Chagas disease	56.2 (44.1 to 71.0)	84.5 (66.2 to 108.2)	50.1 (43.6 to 58.0)	-13.6 (-17.2 to -9.7)
Mild heart failure due to Chagas disease	69.5 (39.7 to 107.6)	95.3 (54.7 to 147.1)	37.0 (32.7 to 42.5)	-18.1 (-20.7 to -14.9)
Moderate heart failure due to Chagas disease	57.1 (34.5 to 88.7)	78.4 (47.8 to 121.2)	37.0 (32.7 to 42.5)	-18.1 (-20.7 to -14.9)
Severe heart failure due to Chagas disease	153.3 (102.1 to 220.1)	210.4 (140.8 to 301.9)	37.0 (32.7 to 42.5)	-18.1 (-20.7 to -14.9)
Leishmaniasis	-	-	-	-
Visceral leishmaniasis	84.2 (66.6 to 106.6)	113.7 (94.1 to 140.9)	35.1 (17.1 to 54.9)	14.4 (-0.4 to 30.5)
Moderate visceral leishmaniasis	63.2 (50.0 to 79.9)	85.3 (70.6 to 105.7)	35.1 (17.1 to 54.9)	14.4 (-0.4 to 30.5)
Severe visceral leishmaniasis	21.1 (16.7 to 26.6)	28.4 (23.5 to 35.2)	35.1 (17.1 to 54.9)	14.4 (-0.4 to 30.5)
Cutaneous and mucocutaneous leishmaniasis	1,424.0 (1,213.6 to 1,692.5)	3,914.8 (3,300.4 to 4,669.6)	174.2 (144.5 to 209.2)	95.3 (75.2 to 119.9)
African trypanosomiasis	69.5 (31.0 to 138.3)	19.7 (10.6 to 34.3)	-71.1 (-75.3 to -65.9)	-79.5 (-82.4 to -75.8)
Disfigurement due to African trypanosomiasis	35.7 (16.4 to 70.5)	10.3 (5.8 to 17.6)	-70.5 (-75.0 to -64.9)	-79.1 (-82.3 to -75.1)
Severe motor plus cognitive impairments due to African trypanosomiasis	33.8 (14.6 to 67.8)	9.4 (4.9 to 16.6)	-71.7 (-75.5 to -66.8)	-79.9 (-82.6 to -76.4)
Schistosomiasis	219,166.9 (196,779.3 to 240,732.7)	290,627.9 (252,098.7 to 337,576.1)	30.9 (22.9 to 51.9)	-3.7 (-9.7 to 11.8)
Mild schistosomiasis	118,901.4 (110,948.9 to 126,954.0)	150,984.4 (137,298.4 to 169,292.8)	25.8 (16.9 to 40.3)	-9.4 (-16.0 to 1.3)
Mild diarrhea due to schistosomiasis	164.6 (68.2 to 352.2)	248.3 (92.4 to 557.4)	53.6 (2.6 to 79.8)	17.0 (-22.8 to 37.4)
Hematemesis due to schistosomiasis	4.1 (3.5 to 4.7)	7.2 (6.2 to 8.3)	76.9 (71.1 to 81.4)	17.4 (7.0 to 27.1)
Hepatomegaly due to schistosomiasis	9,142.4 (7,411.5 to 11,263.8)	16,638.2 (13,398.5 to 20,539.1)	81.9 (75.0 to 87.8)	34.1 (27.1 to 41.2)
Ascites due to schistosomiasis	289.9 (250.2 to 333.2)	512.0 (444.5 to 586.7)	76.6 (70.9 to 81.1)	17.2 (6.8 to 26.8)
Dysuria due to schistosomiasis	6,145.0 (3,775.4 to 9,496.9)	7,715.7 (3,956.4 to 13,876.7)	21.3 (-7.4 to 74.6)	-7.6 (-29.4 to 32.0)
Bladder pathology due to schistosomiasis	59,252.4 (47,923.4 to 70,890.8)	79,200.1 (58,321.6 to 109,537.6)	30.1 (15.7 to 76.1)	-1.2 (-12.8 to 34.3)
Hydronephrosis due to schistosomiasis	10,791.3 (9,043.9 to 12,613.1)	14,684.1 (11,301.7 to 19,636.4)	32.2 (18.9 to 77.8)	0.5 (-10.0 to 34.0)
Mild anemia due to schistosomiasis	6,490.3 (6,313.2 to 6,835.0)	9,548.4 (9,149.3 to 10,554.2)	46.3 (37.7 to 63.1)	5.8 (-0.2 to 17.7)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Moderate anemia due to schistosomiasis	7,257.0 (6,818.8 to 7,433.3)	10,151.8 (9,225.2 to 10,566.2)	40.3 (26.8 to 50.6)	7.8 (-2.5 to 16.0)
Severe anemia due to schistosomiasis	728.5 (652.1 to 780.3)	937.5 (866.8 to 1,021.1)	28.0 (16.5 to 46.2)	0.1 (-8.8 to 13.9)
Cysticercosis	1,387.6 (1,221.2 to 1,570.6)	1,030.8 (901.4 to 1,185.6)	-26.3 (-37.3 to -10.0)	-50.2 (-57.5 to -39.0)
Cystic echinococcosis	1,002.3 (949.1 to 1,060.4)	849.2 (822.5 to 893.2)	-15.4 (-17.0 to -12.9)	-42.4 (-43.5 to -40.8)
Abdominal problems due to cystic echinococcosis	810.3 (750.3 to 870.8)	686.7 (644.7 to 734.7)	-15.4 (-17.0 to -12.9)	-42.4 (-43.5 to -40.8)
Chronic respiratory disease due to cystic echinococcosis	183.8 (147.1 to 221.8)	155.7 (125.6 to 187.2)	-15.4 (-17.0 to -12.9)	-42.4 (-43.5 to -40.8)
Epilepsy due to echinococcosis	8.2 (2.4 to 18.1)	6.8 (1.9 to 14.9)	-18.1 (-23.5 to -11.9)	-44.2 (-47.8 to -40.3)
Lymphatic filariasis	64,448.9 (57,555.6 to 73,112.5)	43,850.0 (36,940.8 to 52,905.8)	-32.1 (-39.1 to -24.7)	-53.3 (-58.0 to -48.4)
Prevalence of detectable microfilaria due to lymphatic filariasis	47,269.3 (45,536.4 to 49,187.2)	25,462.8 (22,796.9 to 28,356.7)	-46.2 (-52.2 to -39.8)	-62.1 (-66.2 to -57.5)
Lymphedema due to lymphatic filariasis	6,489.3 (4,124.0 to 9,035.9)	9,153.7 (5,854.0 to 12,873.3)	41.0 (35.0 to 46.7)	-9.9 (-13.8 to -6.1)
Hydrocele due to lymphatic filariasis	10,690.3 (4,560.3 to 18,875.8)	9,233.4 (3,984.4 to 17,116.2)	-13.3 (-38.4 to 13.3)	-44.8 (-60.7 to -28.4)
Onchocerciasis	24,602.8 (16,696.9 to 37,280.3)	16,956.4 (11,477.5 to 26,789.4)	-31.2 (-39.8 to -21.9)	-51.5 (-57.6 to -45.3)
Asymptomatic onchocerciasis	7,633.6 (1,132.5 to 18,734.5)	3,163.1 (36.8 to 11,410.4)	-65.9 (-97.3 to -38.1)	-75.5 (-98.1 to -54.8)
Mild skin disease due to onchocerciasis	1,702.2 (661.5 to 2,794.6)	1,503.7 (457.1 to 2,673.4)	-13.7 (-35.1 to 9.1)	-31.0 (-46.9 to -14.2)
Mild skin disease without itch due to onchocerciasis	5,782.3 (3,049.7 to 9,425.5)	5,360.4 (2,396.4 to 9,525.6)	-9.0 (-22.4 to 3.5)	-34.6 (-45.6 to -25.0)
Moderate skin disease due to onchocerciasis	5,197.5 (2,647.3 to 8,327.2)	3,898.6 (1,609.5 to 6,871.9)	-27.3 (-44.3 to -3.9)	-50.1 (-62.7 to -33.3)
Severe skin disease due to onchocerciasis	2,328.0 (792.1 to 4,061.7)	1,800.5 (477.8 to 3,354.8)	-23.5 (-40.6 to -11.2)	-47.5 (-60.0 to -37.1)
Severe skin disease without itch due to onchocerciasis	52.8 (4.9 to 116.2)	45.5 (4.3 to 102.4)	-13.3 (-23.5 to -7.3)	-48.8 (-54.4 to -39.2)
Moderate vision impairment due to onchocerciasis	1,374.2 (1,038.6 to 1,769.6)	857.1 (477.0 to 1,350.0)	-38.8 (-54.4 to -22.4)	-62.4 (-71.8 to -52.1)
Severe vision impairment due to onchocerciasis	226.4 (168.3 to 290.6)	142.6 (81.1 to 226.2)	-38.3 (-53.8 to -20.3)	-62.6 (-72.2 to -51.7)
Blindness due to onchocerciasis	305.8 (221.4 to 415.9)	184.9 (105.2 to 295.4)	-40.8 (-54.9 to -25.8)	-64.9 (-73.3 to -55.9)
Trachoma	3,980.6 (3,147.2 to 4,929.1)	2,428.8 (1,924.2 to 2,981.2)	-39.2 (-46.3 to -30.1)	-65.4 (-69.5 to -60.3)
Moderate vision impairment due to trachoma	2,778.2 (2,167.2 to 3,484.5)	1,660.0 (1,300.3 to 2,040.4)	-40.5 (-49.1 to -28.9)	-66.1 (-71.2 to -59.6)
Severe vision impairment due to trachoma	543.9 (427.3 to 676.4)	330.0 (258.0 to 408.8)	-39.2 (-47.9 to -30.6)	-65.4 (-70.5 to -60.6)
Blindness due to trachoma	658.5 (500.2 to 832.7)	438.9 (334.1 to 553.1)	-33.5 (-41.4 to -23.0)	-62.5 (-66.9 to -57.0)
Dengue	490.3 (179.4 to 1,099.7)	3,485.5 (1,283.7 to 7,818.6)	610.9 (606.3 to 615.5)	447.3 (443.6 to 450.9)
Moderate dengue	127.6 (51.6 to 267.9)	907.3 (369.6 to 1,897.9)	610.9 (606.3 to 615.5)	447.3 (443.6 to 450.9)
Severe dengue	17.5 (6.5 to 38.5)	124.2 (46.7 to 272.9)	610.9 (606.3 to 615.5)	447.3 (443.6 to 450.9)
Post-dengue chronic fatigue syndrome	345.2 (116.5 to 838.1)	2,453.9 (831.3 to 5,953.0)	610.9 (606.3 to 615.5)	447.3 (443.6 to 450.9)
Yellow fever	5.2 (1.8 to 11.8)	2.1 (0.7 to 4.9)	-59.8 (-63.7 to -54.3)	-68.3 (-71.4 to -64.0)
Asymptomatic yellow fever	2.8 (0.9 to 6.6)	1.2 (0.4 to 2.7)	-59.8 (-63.7 to -54.3)	-68.3 (-71.4 to -64.0)
Moderate yellow fever	1.7 (0.5 to 4.1)	0.7 (0.2 to 1.7)	-59.8 (-63.7 to -54.3)	-68.3 (-71.4 to -64.0)
Severe yellow fever	0.7 (0.2 to 1.8)	0.3 (0.1 to 0.8)	-59.8 (-63.7 to -54.3)	-68.3 (-71.4 to -64.0)
Rabies	1.5 (1.1 to 1.9)	0.9 (0.7 to 1.1)	-39.8 (-54.3 to -27.3)	-55.2 (-65.1 to -46.1)
Intestinal nematode infections	-	-	-	-
Ascariasis	1,078,935.2 (952,859.1 to 1,239,751.2)	804,370.1 (713,417.5 to 922,212.1)	-25.5 (-37.8 to -10.4)	-44.8 (-54.2 to -33.1)
Heavy infestation of ascariasis	70,096.9 (62,391.2 to 77,947.0)	25,166.7 (22,329.8 to 28,227.0)	-64.2 (-69.3 to -57.9)	-73.9 (-77.8 to -69.3)
Mild abdominopelvic problems due to ascariasis	165,871.4 (159,037.8 to 173,356.7)	25,806.4 (23,496.0 to 28,824.5)	-84.5 (-85.9 to -82.7)	-87.3 (-88.5 to -85.8)
Severe wasting due to ascariasis	125.6 (93.6 to 166.3)	77.7 (55.4 to 105.0)	-38.4 (-56.1 to -12.9)	-40.3 (-57.4 to -15.4)
Asymptomatic ascariasis	842,841.2 (714,800.3 to 1,003,021.3)	753,319.3 (661,852.6 to 869,854.4)	-10.4 (-27.7 to 11.2)	-34.8 (-48.0 to -18.7)
Trichuriasis	543,402.0 (465,655.8 to 645,140.1)	477,374.4 (441,256.8 to 518,365.1)	-11.6 (-28.7 to 4.9)	-34.4 (-47.8 to -21.0)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Heavy infestation of trichuriasis	24,181.5 (21,471.0 to 28,091.6)	17,750.1 (14,955.5 to 22,404.9)	-27.4 (-41.3 to -7.1)	-45.9 (-56.7 to -30.3)
Mild abdominopelvic problems due to trichuriasis	15,032.1 (13,611.4 to 16,884.7)	10,887.7 (9,643.8 to 12,570.8)	-27.6 (-39.2 to -13.9)	-46.2 (-55.1 to -35.7)
Severe wasting due to trichuriasis	38.6 (28.4 to 51.3)	21.3 (14.9 to 30.0)	-45.4 (-61.5 to -19.1)	-47.0 (-62.6 to -21.5)
Asymptomatic trichuriasis	504,149.8 (426,593.5 to 606,572.0)	448,715.2 (412,019.3 to 489,083.3)	-10.5 (-28.9 to 7.3)	-33.4 (-47.9 to -19.1)
Hookworm disease	498,224.3 (436,949.1 to 577,352.6)	471,816.2 (437,049.6 to 511,318.8)	-5.1 (-20.2 to 9.7)	-30.1 (-41.6 to -18.4)
Heavy infestation of hookworm	46,241.6 (41,943.8 to 50,996.4)	37,303.9 (34,261.3 to 40,461.4)	-19.4 (-29.5 to -7.5)	-41.3 (-48.9 to -32.3)
Mild abdominopelvic problems due to hookworm disease	21,128.2 (19,863.4 to 22,482.9)	19,846.2 (18,779.6 to 21,023.6)	-6.2 (-13.2 to 1.3)	-31.0 (-36.4 to -25.4)
Severe wasting due to hookworm disease	81.9 (61.9 to 106.8)	58.3 (44.3 to 75.1)	-28.9 (-45.1 to -8.9)	-31.0 (-46.8 to -11.6)
Mild anemia due to hookworm disease	15,134.6 (14,747.7 to 15,848.8)	18,018.7 (17,353.9 to 19,347.6)	18.6 (12.1 to 28.1)	-12.5 (-17.1 to -5.4)
Moderate anemia due to hookworm disease	15,445.1 (14,706.7 to 15,852.5)	15,295.6 (13,778.2 to 15,919.4)	-0.7 (-11.3 to 5.7)	-22.4 (-30.7 to -17.2)
Severe anemia due to hookworm disease	1,372.5 (1,226.4 to 1,566.6)	1,233.1 (1,079.5 to 1,430.4)	-9.8 (-26.1 to 8.7)	-28.4 (-41.7 to -13.3)
Asymptomatic hookworm disease	398,820.4 (335,424.8 to 479,088.0)	380,060.4 (345,503.2 to 418,887.3)	-4.4 (-22.3 to 14.9)	-29.5 (-43.5 to -14.7)
Food-borne trematodiasis	52,957.7 (41,937.1 to 64,062.2)	80,194.5 (64,648.1 to 96,212.4)	51.1 (44.2 to 59.7)	-0.1 (-4.8 to 5.6)
Asymptomatic clonorchiasis	15,666.1 (13,133.9 to 18,782.4)	24,112.4 (19,781.2 to 28,207.5)	53.5 (41.2 to 70.7)	5.1 (-0.3 to 16.9)
Asymptomatic fascioliasis	935.5 (688.5 to 1,151.7)	1,503.1 (1,099.7 to 1,874.8)	59.9 (36.8 to 88.8)	3.6 (-11.5 to 22.5)
Asymptomatic intestinal fluke infection	1,475.7 (1,282.0 to 1,655.5)	2,319.9 (2,004.9 to 2,673.2)	56.5 (35.5 to 89.1)	-1.0 (-13.8 to 18.8)
Asymptomatic opisthorchiasis	4,023.7 (3,220.6 to 4,804.7)	6,134.9 (4,834.1 to 7,406.7)	52.6 (28.3 to 82.5)	0.9 (-14.6 to 19.3)
Asymptomatic paragonimiasis	19,676.0 (11,286.9 to 25,233.6)	28,927.2 (16,381.2 to 37,097.6)	46.7 (36.6 to 57.1)	-4.8 (-11.3 to 1.9)
Heavy opisthorchiasis due to food-borne trematodiasis	1,170.6 (610.2 to 1,831.1)	1,935.2 (1,007.7 to 3,048.4)	64.9 (32.2 to 103.1)	3.9 (-14.0 to 24.1)
Heavy clonorchiasis due to food-borne trematodiasis	3,531.5 (2,857.7 to 4,370.6)	5,728.4 (4,480.4 to 6,991.6)	61.5 (47.7 to 80.4)	7.6 (1.3 to 19.6)
Heavy intestinal fluke infection due to food-borne trematodiasis	179.9 (95.5 to 289.5)	291.4 (146.8 to 494.5)	60.8 (26.8 to 99.5)	0.6 (-17.1 to 21.5)
Heavy fascioliasis due to food-borne trematodiasis	221.2 (57.9 to 487.6)	355.4 (88.8 to 773.4)	59.9 (36.8 to 88.8)	3.6 (-11.5 to 22.5)
Heavy paragonimiasis due to food-borne trematodiasis	5,966.0 (805.6 to 14,334.9)	8,779.1 (1,202.9 to 21,493.3)	46.7 (36.6 to 57.1)	-4.8 (-11.3 to 1.9)
Cerebral paragonimiasis	111.4 (31.4 to 226.2)	107.6 (29.6 to 219.0)	-4.0 (-24.2 to 24.4)	-27.9 (-42.6 to -6.9)
Other neglected tropical diseases	62,763.7 (58,570.6 to 66,943.0)	59,705.9 (58,703.5 to 61,020.1)	-5.0 (-11.0 to 1.6)	-18.3 (-23.3 to -12.8)
Acute infection due to other neglected tropical diseases	-	-	-	-
Mild anemia due to other neglected tropical diseases	26,361.1 (25,070.9 to 30,513.1)	25,985.0 (25,186.4 to 27,078.9)	-0.5 (-15.0 to 5.2)	-18.0 (-29.2 to -13.4)
Moderate anemia due to other neglected tropical diseases	32,991.4 (29,120.5 to 34,366.4)	31,005.8 (30,114.2 to 32,119.3)	-6.9 (-10.8 to 6.7)	-17.6 (-20.9 to -5.5)
Severe anemia due to other neglected tropical diseases	3,411.2 (3,073.6 to 3,570.5)	2,715.2 (2,341.4 to 2,877.0)	-20.2 (-32.8 to -9.8)	-28.4 (-39.8 to -19.3)
Maternal disorders	-	-	-	-
Maternal hemorrhage	1,551.1 (1,479.6 to 1,629.4)	2,027.4 (1,932.4 to 2,119.8)	30.5 (22.2 to 39.2)	-2.1 (-8.1 to 4.4)
Maternal hemorrhage (< 1L blood lost)	140.6 (123.3 to 163.2)	146.6 (132.0 to 161.8)	4.3 (-9.9 to 19.4)	-21.8 (-32.0 to -11.0)
Maternal hemorrhage (> 1L blood lost)	24.7 (17.3 to 33.3)	25.7 (18.1 to 34.0)	4.3 (-9.9 to 19.4)	-21.8 (-32.0 to -11.0)
Mild anemia due to maternal hemorrhage	706.1 (672.9 to 776.4)	1,097.7 (1,037.4 to 1,180.9)	55.4 (37.7 to 69.8)	16.0 (3.3 to 26.7)
Moderate anemia due to maternal hemorrhage	647.7 (590.6 to 683.5)	723.0 (642.1 to 785.3)	11.7 (-1.7 to 26.9)	-15.8 (-25.8 to -4.2)
Severe anemia due to maternal hemorrhage	32.1 (24.6 to 42.8)	34.3 (25.8 to 43.4)	9.8 (-36.7 to 66.0)	-19.7 (-52.2 to 21.4)
Maternal sepsis and other maternal infections	2,064.5 (1,378.4 to 2,850.9)	1,781.4 (1,235.4 to 2,515.9)	-13.5 (-23.5 to -5.0)	-41.6 (-47.7 to -35.6)
Puerperal sepsis	138.2 (73.3 to 208.3)	98.2 (53.6 to 147.3)	-29.2 (-40.7 to -16.8)	-45.6 (-54.2 to -36.4)
Other maternal infections	8.1 (4.5 to 12.5)	7.8 (4.2 to 12.4)	-4.5 (-15.2 to 12.8)	-25.7 (-33.8 to -12.8)
Infertility due to puerperal sepsis	1,918.2 (1,231.9 to 2,687.6)	1,675.5 (1,133.2 to 2,398.0)	-12.3 (-23.2 to -3.6)	-41.5 (-48.0 to -35.2)
Maternal hypertensive disorders	1,232.5 (710.6 to 1,924.3)	1,277.6 (756.3 to 1,978.8)	3.5 (-0.4 to 10.2)	-21.3 (-23.8 to -17.2)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Other hypertensive disorders of pregnancy	1,088.9 (598.7 to 1,759.2)	1,146.4 (634.2 to 1,832.6)	5.3 (0.6 to 12.7)	-20.2 (-23.0 to -15.4)
Severe pre-eclampsia	3.5 (1.2 to 7.9)	3.6 (1.2 to 8.4)	5.3 (0.6 to 12.7)	-20.2 (-23.0 to -15.4)
Long term sequelae of severe pre-eclampsia	28.4 (8.6 to 63.8)	29.8 (9.2 to 65.9)	4.7 (0.1 to 12.8)	-20.6 (-23.4 to -15.1)
Eclampsia	2.8 (1.0 to 5.4)	2.4 (0.9 to 4.8)	-12.2 (-17.3 to -4.5)	-31.7 (-35.1 to -27.3)
Long term sequelae of eclampsia	109.0 (72.1 to 143.8)	95.4 (64.5 to 124.5)	-12.7 (-18.3 to -4.3)	-32.1 (-35.8 to -27.4)
Obstructed labor	2,412.1 (2,092.1 to 2,751.2)	2,902.1 (2,600.1 to 3,222.1)	20.4 (12.9 to 27.5)	-14.8 (-19.8 to -10.2)
Obstructed labor, acute event	73.2 (46.3 to 105.3)	69.9 (44.5 to 100.1)	-4.2 (-19.9 to 10.2)	-28.0 (-39.4 to -17.4)
Rectovaginal fistula	215.3 (117.9 to 337.8)	260.7 (143.7 to 404.7)	21.2 (13.6 to 28.4)	-14.5 (-19.6 to -9.7)
Vesicovaginal fistula	2,123.6 (1,817.8 to 2,443.0)	2,571.5 (2,268.0 to 2,883.9)	21.2 (13.6 to 28.4)	-14.5 (-19.6 to -9.7)
Complications of abortion	19.5 (13.3 to 26.5)	21.8 (14.6 to 29.7)	11.5 (1.8 to 20.9)	-16.9 (-24.0 to -10.1)
Other maternal disorders	-	-	-	-
Neonatal disorders	-	-	-	-
Preterm birth complications	21,144.8 (18,524.0 to 24,247.1)	56,272.0 (49,504.6 to 64,204.4)	165.4 (143.0 to 192.5)	98.9 (81.9 to 118.4)
Asymptomatic retinopathy of prematurity	819.6 (579.5 to 1,132.2)	2,146.2 (1,481.5 to 3,050.8)	161.6 (126.0 to 199.3)	88.1 (61.2 to 116.4)
Mild vision impairment due to retinopathy of prematurity	178.1 (53.0 to 370.5)	466.3 (136.0 to 969.3)	161.6 (126.1 to 199.3)	88.1 (61.1 to 116.4)
Moderate vision impairment due to retinopathy of prematurity	509.2 (273.3 to 778.2)	1,021.9 (542.7 to 1,634.6)	100.9 (70.0 to 135.8)	40.8 (17.5 to 65.9)
Severe vision impairment due to retinopathy of prematurity	266.3 (185.0 to 365.0)	563.3 (388.0 to 785.7)	111.2 (86.6 to 138.2)	43.2 (25.1 to 63.1)
Blindness due to retinopathy of prematurity	169.5 (54.6 to 296.8)	408.2 (134.5 to 719.1)	141.0 (108.1 to 179.9)	57.8 (35.2 to 82.7)
Mild motor impairment due to neonatal preterm birth complications <28wks	1,010.6 (715.3 to 1,384.9)	3,541.5 (2,571.6 to 4,682.8)	248.7 (210.2 to 311.3)	157.0 (127.0 to 206.1)
Mild motor plus cognitive impairments due to neonatal preterm birth complications <28wks	776.3 (474.9 to 1,160.2)	2,288.1 (1,420.4 to 3,357.0)	194.9 (173.4 to 219.5)	114.7 (98.4 to 132.1)
Mild motor impairment due to neonatal preterm birth complications 28-32wks	3,290.8 (1,941.2 to 4,781.3)	7,842.0 (5,044.3 to 11,154.7)	136.6 (89.5 to 214.5)	76.9 (43.1 to 132.3)
Mild motor plus cognitive impairments due to neonatal preterm birth complications 28-32wks	2,588.1 (1,507.0 to 3,943.5)	5,399.0 (3,306.8 to 8,051.7)	108.7 (76.0 to 154.2)	54.0 (30.7 to 86.0)
Mild motor impairment due to neonatal preterm birth complications 32-36wks	2,265.9 (1,584.8 to 2,981.7)	5,530.3 (4,016.2 to 7,145.5)	143.6 (112.8 to 187.7)	82.3 (59.7 to 116.7)
Mild motor plus cognitive impairments due to neonatal preterm birth complications 32-36wks	1,771.1 (1,077.2 to 2,531.4)	3,789.4 (2,350.1 to 5,358.7)	113.5 (96.1 to 133.3)	58.0 (45.0 to 72.8)
Moderate motor impairment due to neonatal preterm birth complications <28wks	620.7 (455.7 to 797.4)	2,480.9 (1,852.9 to 3,176.5)	299.3 (237.9 to 382.9)	208.0 (160.8 to 273.6)
Moderate motor impairment with blindness due to neonatal preterm birth complications <28wks	16.9 (8.9 to 27.3)	52.8 (27.7 to 83.9)	212.2 (163.0 to 273.9)	119.7 (86.8 to 159.6)
Moderate motor impairment with epilepsy due to neonatal preterm birth complications <28wks	117.3 (72.5 to 170.0)	396.7 (247.6 to 570.6)	237.3 (200.1 to 285.5)	154.9 (127.1 to 190.4)
Moderate motor impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks	21.3 (9.4 to 38.2)	72.1 (32.5 to 129.1)	237.3 (200.1 to 285.5)	154.9 (127.1 to 190.4)
Moderate motor plus cognitive impairment with blindness due to neonatal preterm birth complications <28wks	33.5 (17.0 to 53.4)	118.2 (60.7 to 187.6)	251.2 (214.6 to 300.3)	165.0 (138.3 to 202.1)
Moderate motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications <28wks	45.1 (25.4 to 69.4)	152.5 (85.7 to 237.5)	237.3 (200.1 to 285.5)	154.9 (127.1 to 190.4)
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks	8.3 (3.8 to 15.1)	28.2 (13.2 to 49.5)	237.3 (200.1 to 285.5)	154.9 (127.1 to 190.4)
Severe motor impairment due to neonatal preterm birth complications <28wks	391.1 (275.9 to 538.9)	1,563.3 (1,114.2 to 2,130.1)	299.9 (238.4 to 377.6)	208.1 (161.9 to 268.6)
Severe motor impairment with blindness due to neonatal preterm birth complications <28wks	10.7 (5.6 to 17.2)	33.5 (17.8 to 54.8)	212.2 (163.0 to 273.9)	119.7 (86.8 to 159.6)
Severe motor impairment with epilepsy due to neonatal preterm birth complications <28wks	74.2 (44.3 to 110.6)	251.1 (150.9 to 376.8)	237.3 (200.1 to 285.5)	154.9 (127.1 to 190.4)
Severe motor impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks	13.6 (6.5 to 23.0)	46.1 (22.0 to 78.2)	237.3 (200.1 to 285.5)	154.9 (127.1 to 190.4)
Severe motor plus cognitive impairment with blindness due to neonatal preterm birth complications <28wks	21.3 (10.6 to 36.0)	75.3 (37.6 to 127.9)	251.2 (214.6 to 300.3)	165.0 (138.3 to 202.1)
Severe motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications <28wks	28.7 (15.8 to 47.0)	97.0 (52.8 to 156.2)	237.3 (200.1 to 285.5)	154.9 (127.1 to 190.4)
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks	5.2 (2.3 to 9.7)	17.7 (8.2 to 32.2)	237.3 (200.1 to 285.5)	154.9 (127.1 to 190.4)
Moderate motor impairment due to neonatal preterm birth complications 28-32wks	1,677.3 (1,222.1 to 2,176.7)	5,058.8 (3,802.4 to 6,483.6)	199.6 (149.3 to 274.8)	135.9 (96.9 to 194.7)
Moderate motor impairment with blindness due to neonatal preterm birth complications 28-32wks	53.7 (29.7 to 86.2)	130.4 (73.4 to 211.3)	141.4 (98.2 to 201.4)	72.0 (41.2 to 113.7)
Moderate motor impairment with epilepsy due to neonatal preterm birth complications 28-32wks	322.1 (200.4 to 465.4)	779.2 (480.4 to 1,128.1)	141.5 (106.2 to 183.8)	85.2 (59.2 to 117.2)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Moderate motor impairment with blindness and epilepsy due to neonatal preterm birth complications 28-32wks	58.9 (27.8 to 98.8)	142.5 (67.8 to 246.4)	141.5 (106.2 to 183.8)	85.2 (59.2 to 117.2)
Moderate motor plus cognitive impairment with blindness due to neonatal preterm birth complications 28-32wks	91.8 (46.6 to 147.7)	238.0 (118.1 to 389.9)	158.5 (129.7 to 196.0)	98.4 (76.3 to 127.1)
Moderate motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications 28-32wks	125.4 (67.5 to 198.2)	303.7 (162.1 to 468.0)	141.5 (106.2 to 183.8)	85.2 (59.2 to 117.2)
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications 28-32wks	22.7 (9.5 to 40.7)	55.0 (24.4 to 98.6)	141.5 (106.2 to 183.8)	85.2 (59.2 to 117.2)
Severe motor impairment due to neonatal preterm birth complications 28-32wks	1,066.7 (742.3 to 1,467.4)	3,219.1 (2,259.9 to 4,271.1)	200.1 (150.5 to 273.1)	136.0 (96.7 to 193.0)
Severe motor impairment with blindness due to neonatal preterm birth complications 28-32wks	33.7 (18.5 to 53.9)	81.9 (44.1 to 130.8)	141.4 (98.2 to 201.4)	72.0 (41.2 to 113.7)
Severe motor impairment with epilepsy due to neonatal preterm birth complications 28-32wks	206.0 (124.4 to 300.9)	498.5 (294.5 to 737.5)	141.5 (106.2 to 183.8)	85.2 (59.2 to 117.2)
Severe motor impairment with blindness and epilepsy due to neonatal preterm birth complications 28-32wks	37.6 (17.0 to 67.0)	91.1 (41.3 to 162.2)	141.5 (106.2 to 183.8)	85.2 (59.2 to 117.2)
Severe motor plus cognitive impairment with blindness due to neonatal preterm birth complications 28-32wks	59.3 (30.0 to 96.0)	153.7 (77.3 to 255.1)	158.5 (129.7 to 196.0)	98.4 (76.3 to 127.1)
Severe motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications 28-32wks	80.7 (45.6 to 126.6)	195.5 (110.0 to 307.9)	141.5 (106.2 to 183.8)	85.2 (59.2 to 117.2)
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications 28-32wks	14.5 (6.3 to 26.5)	35.3 (15.7 to 65.2)	141.5 (106.2 to 183.8)	85.2 (59.2 to 117.2)
Moderate motor impairment due to neonatal preterm birth complications 32-36wks	977.2 (723.2 to 1,293.6)	3,182.0 (2,389.7 to 4,132.3)	223.6 (176.4 to 295.7)	152.7 (116.5 to 209.3)
Moderate motor impairment with blindness due to neonatal preterm birth complications 32-36wks	30.3 (16.8 to 51.4)	77.5 (43.0 to 128.6)	153.2 (104.2 to 210.4)	80.0 (46.6 to 117.7)
Moderate motor impairment with epilepsy due to neonatal preterm birth complications 32-36wks	189.8 (119.2 to 273.0)	500.3 (311.1 to 706.2)	163.0 (132.7 to 198.2)	100.8 (77.7 to 127.2)
Moderate motor impairment with blindness and epilepsy due to neonatal preterm birth complications 32-36wks	33.9 (14.8 to 59.0)	89.3 (39.9 to 154.4)	163.0 (132.7 to 198.2)	100.8 (77.7 to 127.2)
Moderate motor plus cognitive impairment with blindness due to neonatal preterm birth complications 32-36wks	54.1 (27.6 to 87.6)	151.6 (77.1 to 246.1)	180.1 (152.9 to 211.3)	113.6 (93.6 to 137.2)
Moderate motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications 32-36wks	73.6 (38.9 to 119.1)	194.2 (102.7 to 312.5)	163.0 (132.7 to 198.2)	100.8 (77.7 to 127.2)
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications 32-36wks	13.4 (6.1 to 23.8)	35.2 (16.1 to 61.9)	163.0 (132.7 to 198.2)	100.8 (77.7 to 127.2)
Severe motor impairment due to neonatal preterm birth complications 32-36wks	617.2 (426.7 to 835.4)	2,011.6 (1,447.1 to 2,734.3)	223.6 (176.7 to 290.0)	152.8 (116.6 to 204.7)
Severe motor impairment with blindness due to neonatal preterm birth complications 32-36wks	18.9 (10.2 to 30.8)	48.3 (25.0 to 83.3)	153.2 (104.2 to 210.4)	80.0 (46.6 to 117.7)
Severe motor impairment with epilepsy due to neonatal preterm birth complications 32-36wks	120.4 (76.2 to 178.7)	317.0 (202.0 to 475.3)	163.0 (132.7 to 198.2)	100.8 (77.7 to 127.2)
Severe motor impairment with blindness and epilepsy due to neonatal preterm birth complications 32-36wks	21.9 (10.1 to 38.3)	57.6 (26.2 to 98.2)	163.0 (132.7 to 198.2)	100.8 (77.7 to 127.2)
Severe motor plus cognitive impairment with blindness due to neonatal preterm birth complications 32-36wks	34.1 (16.4 to 56.5)	95.8 (47.2 to 159.2)	180.1 (152.9 to 211.3)	113.6 (93.6 to 137.2)
Severe motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications 32-36wks	47.1 (25.7 to 75.1)	124.1 (69.1 to 197.0)	163.0 (132.7 to 198.2)	100.8 (77.7 to 127.2)
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications 32-36wks	8.8 (3.8 to 15.4)	23.1 (9.9 to 41.6)	163.0 (132.7 to 198.2)	100.8 (77.7 to 127.2)
Neonatal encephalopathy due to birth asphyxia and trauma	22,202.9 (8,970.8 to 40,584.6)	22,858.6 (11,831.4 to 38,618.7)	3.4 (-18.7 to 53.4)	-20.5 (-37.6 to 19.2)
Mild motor plus cognitive impairments due to neonatal encephalopathy due to birth asphyxia and trauma	8,345.5 (2,343.8 to 17,179.0)	7,127.6 (2,213.5 to 15,305.8)	-15.6 (-37.7 to 26.5)	-36.0 (-52.8 to -4.6)
Mild motor impairment due to neonatal encephalopathy due to birth asphyxia and trauma	10,418.0 (2,811.2 to 21,491.4)	9,265.5 (3,069.0 to 18,251.1)	-11.6 (-36.5 to 44.9)	-32.3 (-51.8 to 9.8)
Moderate motor impairment due to neonatal encephalopathy due to birth asphyxia and trauma	1,076.0 (876.3 to 1,336.7)	2,265.4 (1,760.6 to 2,867.3)	109.4 (53.6 to 184.3)	74.5 (27.8 to 136.4)
Moderate motor impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma	8.3 (6.2 to 11.1)	13.8 (10.8 to 17.8)	68.7 (30.8 to 100.6)	25.9 (-0.3 to 51.1)
Moderate motor impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	226.7 (196.7 to 259.7)	350.9 (301.7 to 404.0)	54.4 (32.2 to 81.3)	24.2 (6.6 to 45.8)
Moderate motor impairment with blindness and epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	21.3 (18.2 to 25.2)	33.0 (28.0 to 38.4)	54.4 (32.2 to 81.3)	24.2 (6.6 to 45.8)
Moderate motor plus cognitive impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma	77.3 (65.1 to 90.9)	130.2 (112.0 to 150.1)	67.7 (48.1 to 92.2)	34.8 (19.4 to 54.5)
Moderate motor plus cognitive impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	415.1 (361.1 to 481.3)	642.3 (553.8 to 743.4)	54.4 (32.2 to 81.3)	24.2 (6.6 to 45.8)
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	38.9 (33.0 to 46.1)	60.3 (51.1 to 71.0)	54.4 (32.2 to 81.3)	24.2 (6.6 to 45.8)
Severe motor impairment due to neonatal encephalopathy due to birth asphyxia and trauma	861.9 (696.0 to 1,064.4)	1,851.7 (1,418.7 to 2,386.0)	113.0 (51.9 to 195.9)	77.7 (27.1 to 145.7)
Severe motor impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma	2.8 (2.1 to 3.7)	4.6 (3.7 to 6.0)	68.7 (30.8 to 100.6)	25.9 (-0.3 to 51.1)
Severe motor impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	75.6 (65.0 to 87.7)	117.0 (101.0 to 135.5)	54.4 (32.2 to 81.3)	24.2 (6.6 to 45.8)
Severe motor impairment with blindness and epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	7.1 (6.0 to 8.5)	11.0 (9.3 to 12.7)	54.4 (32.2 to 81.3)	24.2 (6.6 to 45.8)
Severe motor plus cognitive impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma	91.4 (77.5 to 107.7)	154.0 (133.0 to 178.6)	67.7 (48.1 to 92.2)	34.8 (19.4 to 54.5)
Severe motor plus cognitive impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	491.2 (420.3 to 566.5)	760.2 (656.4 to 879.3)	54.4 (32.2 to 81.3)	24.2 (6.6 to 45.8)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	46.1 (38.8 to 54.8)	71.3 (59.5 to 85.0)	54.4 (32.2 to 81.3)	24.2 (6.6 to 45.8)
Neonatal sepsis and other neonatal infections	23.7 (7.9 to 48.0)	50.3 (16.5 to 106.6)	110.0 (100.0 to 127.5)	107.7 (97.8 to 125.0)
Hemolytic disease and other neonatal jaundice	2,111.2 (1,686.4 to 2,715.9)	4,999.3 (3,893.0 to 6,792.3)	132.9 (66.8 to 276.7)	84.2 (33.6 to 197.8)
Moderate motor impairment due to hemolytic disease and other neonatal jaundice	621.4 (474.5 to 852.7)	1,753.8 (1,254.3 to 2,575.1)	177.1 (76.2 to 390.8)	123.3 (44.5 to 288.4)
Moderate motor impairment with blindness due to hemolytic disease and other neonatal jaundice	7.4 (5.3 to 10.1)	13.2 (9.6 to 18.1)	78.0 (20.6 to 163.5)	28.8 (-13.3 to 93.9)
Moderate motor impairment with epilepsy due to hemolytic disease and other neonatal jaundice	150.4 (120.8 to 188.7)	270.5 (219.7 to 333.8)	77.6 (41.4 to 146.1)	38.6 (10.7 to 91.5)
Moderate motor impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice	14.1 (11.3 to 17.6)	25.3 (20.3 to 30.8)	77.6 (41.4 to 146.1)	38.6 (10.7 to 91.5)
Moderate motor plus cognitive impairment with blindness due to hemolytic disease and other neonatal jaundice	51.1 (40.1 to 64.4)	101.5 (81.6 to 125.0)	95.3 (53.5 to 181.1)	52.6 (20.7 to 119.2)
Moderate motor plus cognitive impairment with epilepsy due to hemolytic disease and other neonatal jaundice	274.6 (219.0 to 338.1)	493.8 (404.7 to 604.3)	77.6 (41.4 to 146.1)	38.6 (10.7 to 91.5)
Moderate motor plus cognitive impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice	25.8 (20.3 to 32.9)	46.4 (37.0 to 58.5)	77.6 (41.4 to 146.1)	38.6 (10.7 to 91.5)
Severe motor impairment severe due to hemolytic disease and other neonatal jaundice	493.5 (374.5 to 691.6)	1,433.7 (997.3 to 2,231.8)	184.6 (77.0 to 421.8)	129.7 (43.8 to 314.1)
Severe motor impairment with blindness due to hemolytic disease and other neonatal jaundice	2.5 (1.8 to 3.4)	4.4 (3.2 to 6.0)	78.0 (20.6 to 163.5)	28.8 (-13.3 to 93.9)
Severe motor impairment with epilepsy due to hemolytic disease and other neonatal jaundice	49.9 (39.3 to 62.3)	89.7 (73.6 to 109.0)	77.6 (41.4 to 146.1)	38.6 (10.7 to 91.5)
Severe motor impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice	4.7 (3.7 to 5.9)	8.4 (6.8 to 10.3)	77.6 (41.4 to 146.1)	38.6 (10.7 to 91.5)
Severe motor plus cognitive impairment with blindness due to hemolytic disease and other neonatal jaundice	60.2 (47.6 to 75.3)	119.7 (96.6 to 150.1)	95.3 (53.5 to 181.1)	52.6 (20.7 to 119.2)
Severe motor plus cognitive impairment with epilepsy due to hemolytic disease and other neonatal jaundice	324.9 (259.3 to 397.6)	583.9 (480.2 to 708.9)	77.6 (41.4 to 146.1)	38.6 (10.7 to 91.5)
Severe motor plus cognitive impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice	30.6 (24.1 to 38.2)	54.9 (43.8 to 68.7)	77.6 (41.4 to 146.1)	38.6 (10.7 to 91.5)
Other neonatal disorders	-	-	-	-
Nutritional deficiencies	-	-	-	-
Protein-energy malnutrition	23,790.5 (19,620.3 to 29,534.9)	20,756.9 (16,985.3 to 25,759.4)	-13.2 (-34.7 to 16.1)	-16.7 (-37.0 to 11.6)
Kwashiorkor due to protein-energy malnutrition	55.8 (32.6 to 85.6)	35.9 (20.9 to 55.6)	-35.7 (-48.1 to -20.8)	-37.7 (-49.7 to -23.1)
Marasmus due to protein-energy malnutrition	1,364.2 (810.7 to 2,052.1)	1,277.8 (760.2 to 1,939.0)	-6.1 (-21.5 to 8.8)	-21.9 (-34.0 to -11.0)
Severe wasting due to protein-energy malnutrition	22,370.5 (18,244.2 to 28,065.7)	19,443.2 (15,522.7 to 24,656.1)	-13.6 (-36.3 to 18.0)	-16.1 (-38.1 to 14.7)
Iodine deficiency	130,222.5 (124,180.4 to 136,611.0)	115,602.4 (110,007.2 to 120,997.1)	-11.4 (-16.8 to -5.4)	-37.0 (-40.9 to -32.5)
Visible goiter without symptoms	11,062.3 (10,528.1 to 11,615.9)	9,821.5 (9,341.8 to 10,289.8)	-11.4 (-16.8 to -5.4)	-37.0 (-40.9 to -32.6)
Visible goiter without heart failure due to iodine deficiency	117,142.9 (111,723.6 to 122,862.2)	104,001.5 (99,014.7 to 108,855.5)	-11.4 (-16.8 to -5.4)	-37.0 (-40.9 to -32.6)
Visible goiter with mild heart failure due to iodine deficiency	1.0 (0.6 to 1.7)	1.7 (0.9 to 3.0)	56.0 (5.2 to 175.3)	1.0 (-33.8 to 81.6)
Visible goiter with moderate heart failure due to iodine deficiency	0.9 (0.5 to 1.4)	1.4 (0.8 to 2.4)	56.0 (5.2 to 175.3)	1.0 (-33.8 to 81.6)
Visible goiter with severe heart failure due to iodine deficiency	2.4 (1.5 to 3.5)	3.8 (2.3 to 6.3)	56.0 (5.2 to 175.3)	1.0 (-33.8 to 81.7)
Visible goiter with signs and symptoms	1,953.1 (1,797.4 to 2,114.3)	1,734.1 (1,590.7 to 1,879.3)	-11.4 (-16.8 to -5.4)	-37.0 (-40.9 to -32.6)
Severe intellectual disability due to iodine deficiency	44.6 (32.8 to 71.4)	28.5 (21.9 to 35.5)	-32.9 (-62.3 to -15.8)	-35.2 (-63.6 to -18.6)
Profound intellectual disability due to iodine deficiency	15.4 (5.7 to 28.5)	9.8 (3.9 to 15.5)	-32.9 (-62.3 to -15.4)	-35.2 (-63.6 to -18.2)
Vitamin A deficiency	4,178.2 (3,427.4 to 4,855.4)	3,372.4 (2,732.4 to 3,926.3)	-19.4 (-24.4 to -14.6)	-34.9 (-39.3 to -31.1)
Moderate vision impairment loss due to vitamin A deficiency	3,672.3 (3,005.7 to 4,279.1)	3,014.7 (2,445.1 to 3,504.4)	-18.0 (-23.2 to -12.9)	-33.1 (-37.7 to -29.2)
Severe vision impairment loss due to vitamin A deficiency	263.2 (206.0 to 319.3)	203.5 (152.5 to 252.4)	-22.8 (-30.2 to -15.3)	-39.5 (-45.6 to -33.6)
Blindness due to vitamin A deficiency	242.8 (172.8 to 321.9)	154.2 (112.8 to 206.9)	-36.7 (-44.4 to -28.5)	-53.5 (-58.3 to -47.2)
Iron-deficiency anemia	1,209,664.8 (1,205,539.1 to 1,213,899.4)	1,208,216.4 (1,205,927.2 to 1,210,477.8)	-0.2 (-0.6 to 0.1)	-21.9 (-22.2 to -21.7)
Mild iron-deficiency anemia	559,003.8 (555,201.8 to 561,042.9)	607,562.6 (605,577.0 to 609,457.6)	8.5 (8.0 to 9.4)	-18.4 (-18.9 to -17.8)
Moderate iron-deficiency anemia	592,398.7 (590,371.8 to 596,262.0)	554,016.6 (552,262.5 to 556,217.2)	-6.5 (-7.3 to -6.1)	-24.3 (-24.8 to -23.9)
Severe iron-deficiency anemia	57,889.9 (57,006.5 to 58,364.4)	46,190.8 (45,615.7 to 46,598.3)	-20.3 (-21.2 to -19.1)	-34.7 (-35.4 to -33.4)
Mild heart failure due to iron-deficiency anemia	91.8 (55.2 to 133.7)	110.0 (65.4 to 159.4)	20.4 (0.2 to 36.6)	-22.4 (-35.2 to -11.5)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Moderate heart failure due to iron-deficiency anemia	75.8 (51.1 to 107.3)	90.8 (58.5 to 130.4)	20.4 (0.2 to 36.6)	-22.4 (-35.2 to -11.5)
Severe heart failure due to iron-deficiency anemia	205.0 (152.4 to 277.7)	245.6 (168.2 to 328.3)	20.4 (0.2 to 36.6)	-22.4 (-35.2 to -11.5)
Other nutritional deficiencies	-	-	-	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-
Sexually transmitted diseases excluding HIV	-	-	-	-
Syphilis	309.8 (299.0 to 321.1)	315.2 (306.5 to 324.5)	1.5 (-2.5 to 6.4)	-37.1 (-39.5 to -34.3)
Chlamydial infection	114,121.8 (111,339.6 to 117,161.4)	147,846.5 (144,169.7 to 151,027.5)	29.5 (24.8 to 33.4)	-5.5 (-8.8 to -2.8)
Asymptomatic chlamydial infection	77,486.0 (75,324.2 to 79,815.2)	99,518.9 (96,623.8 to 102,067.2)	28.4 (22.9 to 33.0)	-6.2 (-10.2 to -2.9)
Mild chlamydial infection	33,293.4 (32,357.6 to 34,165.9)	44,069.5 (42,938.4 to 45,197.4)	32.4 (28.0 to 35.9)	-3.3 (-6.4 to -0.7)
Epididymo-orchitis due to chlamydial infection	2,184.6 (1,813.4 to 2,571.0)	3,113.6 (2,620.0 to 3,668.0)	42.4 (34.6 to 51.1)	4.5 (-1.2 to 10.6)
Moderate pelvic inflammatory diseases due to chlamydial infection	55.5 (51.7 to 59.5)	49.9 (46.7 to 53.5)	-10.1 (-17.9 to -2.7)	-35.7 (-41.2 to -30.7)
Severe pelvic inflammatory diseases due to chlamydial infection	6.9 (5.9 to 7.9)	6.2 (5.4 to 7.1)	-10.1 (-17.9 to -2.7)	-35.7 (-41.2 to -30.7)
Primary infertility due to chlamydial infection	446.4 (316.6 to 584.6)	447.2 (331.2 to 587.0)	-0.1 (-6.7 to 9.1)	-31.8 (-36.5 to -25.7)
Secondary infertility due to chlamydial infection	649.0 (463.5 to 880.6)	641.2 (481.7 to 859.0)	-1.5 (-8.2 to 6.9)	-35.7 (-40.1 to -30.6)
Gonococcal infection	23,591.0 (22,405.9 to 24,803.4)	32,726.1 (31,162.7 to 34,316.7)	38.8 (29.6 to 47.6)	4.8 (-2.0 to 11.4)
Asymptomatic gonococcal infection	11,956.8 (11,347.1 to 12,584.2)	16,613.0 (15,829.5 to 17,399.6)	38.9 (28.7 to 48.1)	5.9 (-1.6 to 12.6)
Mild gonococcal infection	9,527.0 (8,981.0 to 10,111.2)	13,466.8 (12,712.6 to 14,199.7)	41.3 (31.0 to 52.5)	7.6 (-0.0 to 16.0)
Epididymo-orchitis due to gonococcal infection	689.0 (547.5 to 844.9)	1,050.2 (840.0 to 1,276.7)	51.9 (32.7 to 77.7)	16.1 (1.6 to 35.3)
Moderate pelvic inflammatory diseases due to gonococcal infection	69.4 (62.9 to 76.5)	71.0 (62.0 to 79.9)	2.3 (-12.0 to 18.4)	-27.3 (-37.3 to -16.1)
Severe pelvic inflammatory diseases due to gonococcal infection	8.6 (7.3 to 10.1)	8.8 (7.4 to 10.3)	2.3 (-12.0 to 18.4)	-27.3 (-37.3 to -16.1)
Primary infertility due to gonococcal infection	560.4 (395.4 to 738.5)	654.7 (474.8 to 872.7)	16.4 (6.8 to 27.6)	-21.2 (-28.2 to -13.3)
Secondary infertility due to gonococcal infection	779.8 (562.8 to 1,041.1)	861.6 (632.1 to 1,172.8)	10.3 (4.2 to 16.5)	-28.3 (-31.9 to -23.8)
Trichomoniasis	45,821.0 (42,691.6 to 49,094.4)	67,075.9 (62,762.6 to 72,764.6)	45.6 (33.3 to 62.3)	4.0 (-4.4 to 15.6)
Asymptomatic trichomoniasis infection	30,240.1 (27,973.6 to 32,643.8)	44,268.6 (40,711.5 to 48,526.4)	45.6 (33.3 to 62.3)	4.0 (-4.4 to 15.6)
Acute trichomoniasis infection	15,580.9 (14,102.4 to 17,182.0)	22,807.2 (20,567.2 to 25,437.4)	45.6 (33.3 to 62.3)	4.0 (-4.4 to 15.6)
Genital herpes	795,830.0 (785,325.3 to 807,530.8)	1,176,494.5 (1,160,277.4 to 1,194,517.2)	47.6 (44.7 to 50.6)	-5.3 (-7.1 to -3.5)
Asymptomatic genital herpes	760,730.8 (733,076.8 to 783,160.9)	1,124,669.7 (1,087,198.8 to 1,157,160.6)	47.7 (44.7 to 50.6)	-5.3 (-7.1 to -3.5)
Symptomatic genital herpes	34,740.8 (16,168.1 to 58,478.9)	51,371.6 (23,699.4 to 86,899.5)	47.7 (44.7 to 50.6)	-5.3 (-7.1 to -3.5)
Moderate infection due to initial genital herpes episode	358.4 (79.3 to 845.0)	453.3 (100.8 to 1,062.4)	26.3 (22.8 to 30.1)	-1.9 (-4.5 to 1.1)
Other sexually transmitted diseases	1,220.8 (901.0 to 1,588.9)	1,248.2 (971.7 to 1,612.4)	1.9 (-4.1 to 10.2)	-31.9 (-35.8 to -26.5)
Moderate pelvic inflammatory diseases due to other sexually transmitted diseases	111.4 (104.5 to 119.5)	142.1 (133.6 to 151.5)	27.5 (17.7 to 37.5)	-10.2 (-17.0 to -3.4)
Severe pelvic inflammatory diseases due to other sexually transmitted diseases	13.9 (12.1 to 15.9)	17.7 (15.4 to 20.2)	27.5 (17.7 to 37.5)	-10.2 (-17.0 to -3.4)
Primary infertility due to other sexually transmitted diseases	446.4 (316.6 to 584.6)	447.2 (331.2 to 587.0)	-0.1 (-6.7 to 9.1)	-31.8 (-36.5 to -25.7)
Secondary infertility due to other sexually transmitted diseases	649.0 (463.5 to 880.6)	641.2 (481.7 to 859.0)	-1.5 (-8.2 to 6.9)	-35.7 (-40.1 to -30.6)
Hepatitis	-	-	-	-
Hepatitis A	6,984.7 (6,689.9 to 7,279.6)	7,823.9 (7,532.8 to 8,115.3)	11.9 (11.3 to 12.5)	-5.8 (-6.1 to -5.3)
Asymptomatic acute hepatitis A	3,370.3 (3,120.2 to 3,639.3)	3,258.3 (3,047.4 to 3,484.5)	-3.5 (-4.4 to -2.5)	-11.8 (-12.2 to -11.3)
Mild acute hepatitis A	516.3 (510.0 to 519.9)	652.2 (640.8 to 661.5)	26.2 (25.5 to 27.1)	-0.9 (-2.2 to 0.6)
Moderate acute hepatitis A	3,072.2 (3,034.4 to 3,093.5)	3,880.8 (3,812.8 to 3,935.9)	26.2 (25.5 to 27.1)	-0.9 (-2.2 to 0.6)
Severe acute hepatitis A	25.8 (25.5 to 26.0)	32.6 (32.0 to 33.1)	26.2 (25.5 to 27.1)	-0.9 (-2.2 to 0.6)
Hepatitis B	349,879.8 (343,974.4 to 355,897.3)	331,037.0 (325,359.6 to 336,638.4)	-5.5 (-7.9 to -3.4)	-32.1 (-33.7 to -30.6)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Asymptomatic acute hepatitis B	12,497.5 (12,143.7 to 12,985.3)	11,443.8 (11,064.3 to 11,778.7)	-8.5 (-11.8 to -4.9)	-32.9 (-35.4 to -30.2)
Moderate acute hepatitis B	3,327.5 (3,208.2 to 3,485.4)	3,405.1 (3,289.0 to 3,530.4)	2.2 (-2.2 to 6.9)	-32.0 (-35.2 to -28.8)
Severe acute hepatitis B	56.4 (54.4 to 59.1)	57.7 (55.7 to 59.8)	2.2 (-2.2 to 6.9)	-32.0 (-35.2 to -28.8)
Chronic Hepatitis B	333,998.4 (328,310.4 to 339,583.6)	316,130.3 (310,692.3 to 321,465.7)	-5.4 (-7.9 to -3.3)	-32.1 (-33.7 to -30.5)
Hepatitis C	127,284.1 (125,459.5 to 129,248.9)	147,826.3 (145,520.7 to 150,080.2)	16.0 (13.6 to 18.5)	-23.3 (-24.8 to -21.7)
Asymptomatic acute hepatitis C	800.7 (784.6 to 816.5)	926.8 (909.1 to 943.4)	15.6 (12.3 to 19.1)	-21.5 (-24.0 to -18.9)
Moderate acute hepatitis C	268.8 (261.6 to 276.4)	310.8 (302.9 to 319.0)	15.5 (11.1 to 19.9)	-21.6 (-24.9 to -18.5)
Severe acute hepatitis C	11.4 (11.1 to 11.7)	13.2 (12.8 to 13.6)	15.6 (10.9 to 21.0)	-21.5 (-25.0 to -17.8)
Chronic Hepatitis C	126,203.2 (124,380.1 to 128,154.5)	146,575.6 (144,285.1 to 148,811.8)	16.0 (13.6 to 18.5)	-23.3 (-24.8 to -21.7)
Hepatitis E	1,843.6 (1,757.0 to 1,920.7)	2,188.2 (2,083.3 to 2,311.9)	18.4 (11.3 to 26.9)	-10.9 (-16.2 to -4.6)
Asymptomatic acute hepatitis E	953.6 (912.9 to 989.6)	1,095.0 (1,049.8 to 1,148.8)	14.6 (8.3 to 22.3)	-12.7 (-17.4 to -6.9)
Moderate acute hepatitis E	860.4 (812.0 to 905.5)	1,056.7 (994.4 to 1,124.5)	22.5 (14.0 to 32.3)	-8.9 (-15.2 to -1.6)
Severe acute hepatitis E	29.7 (28.0 to 31.2)	36.4 (34.3 to 38.8)	22.5 (14.0 to 32.3)	-8.9 (-15.2 to -1.6)
Leprosy	408.3 (374.8 to 438.8)	658.8 (613.6 to 707.5)	61.3 (54.0 to 69.6)	-1.5 (-6.0 to 3.5)
Disfigurement level 1 due to leprosy	46.9 (40.7 to 52.3)	20.3 (18.1 to 22.6)	-56.8 (-62.9 to -48.3)	-73.4 (-77.2 to -67.9)
Disfigurement level 2 due to leprosy	361.4 (333.3 to 387.6)	638.5 (594.1 to 686.7)	76.3 (69.2 to 84.8)	7.1 (2.6 to 12.0)
Other infectious diseases	52,236.1 (50,132.4 to 54,496.2)	49,759.6 (48,625.5 to 51,029.0)	-4.9 (-7.8 to -2.0)	-20.6 (-22.9 to -18.2)
Acute other infectious diseases	-	-	-	-
Mild anemia due to other infectious diseases	23,868.1 (23,179.8 to 26,503.8)	24,493.0 (23,918.3 to 25,713.2)	2.5 (-2.1 to 8.0)	-18.6 (-21.7 to -14.3)
Moderate anemia due to other infectious diseases	25,900.4 (23,280.2 to 26,665.7)	23,320.8 (22,284.7 to 23,817.6)	-10.1 (-14.8 to -5.6)	-21.8 (-25.9 to -17.9)
Severe anemia due to other infectious diseases	2,465.6 (2,079.5 to 2,592.5)	1,943.0 (1,772.5 to 2,050.0)	-22.0 (-28.7 to -6.3)	-30.6 (-36.6 to -16.2)
Guillain-Barré syndrome due to other infectious diseases	1.9 (1.4 to 2.4)	2.7 (2.0 to 3.5)	45.0 (35.2 to 55.3)	0.9 (-5.6 to 7.8)
Non-communicable diseases	-	-	-	-
Neoplasms	-	-	-	-
Esophageal cancer	535.9 (452.9 to 620.8)	840.5 (706.3 to 1,015.2)	56.2 (30.8 to 90.0)	-9.5 (-24.2 to 9.9)
Diagnosis and primary therapy phase of esophageal cancer	47.6 (40.2 to 55.2)	74.1 (62.4 to 89.5)	55.0 (30.4 to 87.8)	-10.4 (-24.8 to 8.5)
Controlled phase of esophageal cancer	356.3 (290.8 to 422.2)	576.0 (472.5 to 706.7)	61.4 (30.5 to 102.5)	-6.4 (-24.5 to 17.1)
Metastatic phase of esophageal cancer	108.4 (95.6 to 121.9)	156.4 (138.3 to 183.4)	44.0 (28.6 to 62.0)	-17.0 (-25.6 to -6.9)
Terminal phase of esophageal cancer	23.6 (20.8 to 26.5)	34.0 (30.1 to 39.9)	44.0 (28.6 to 62.0)	-17.0 (-25.6 to -6.9)
Stomach cancer	1,858.0 (1,737.4 to 1,993.3)	2,532.1 (2,347.7 to 2,736.5)	36.1 (25.8 to 47.4)	-21.0 (-26.9 to -14.7)
Diagnosis and primary therapy phase of stomach cancer	176.9 (166.7 to 188.3)	230.4 (214.8 to 247.1)	30.2 (20.8 to 39.7)	-24.9 (-30.1 to -19.4)
Controlled phase of stomach cancer	1,393.9 (1,295.9 to 1,504.3)	1,956.2 (1,806.1 to 2,120.8)	40.2 (29.1 to 52.8)	-18.5 (-24.9 to -11.2)
Metastatic phase of stomach cancer	228.3 (216.8 to 240.9)	274.7 (257.9 to 292.7)	20.2 (12.7 to 28.0)	-30.8 (-35.1 to -26.4)
Terminal phase of stomach cancer	58.8 (55.9 to 62.1)	70.8 (66.5 to 75.4)	20.2 (12.7 to 28.0)	-30.8 (-35.1 to -26.4)
Liver cancer	-	-	-	-
Liver cancer due to hepatitis B	234.8 (190.3 to 286.3)	450.9 (373.3 to 538.8)	91.2 (48.7 to 150.7)	14.2 (-10.8 to 48.5)
Diagnosis and primary therapy phase of liver cancer due to hepatitis B	39.6 (35.6 to 44.0)	66.2 (58.8 to 74.4)	67.1 (43.3 to 94.3)	-0.3 (-14.2 to 15.4)
Controlled phase of liver cancer due to hepatitis B	147.7 (107.8 to 192.4)	308.7 (241.8 to 385.8)	107.9 (50.5 to 198.4)	24.2 (-9.5 to 78.0)
Metastatic phase of liver cancer due to hepatitis B	34.0 (30.9 to 37.0)	54.4 (48.7 to 60.2)	60.2 (40.2 to 82.3)	-4.5 (-15.9 to 8.0)
Terminal phase of liver cancer due to hepatitis B	13.5 (12.3 to 14.7)	21.7 (19.4 to 24.0)	60.2 (40.1 to 82.3)	-4.5 (-15.9 to 8.0)
Liver cancer due to hepatitis C	109.3 (92.5 to 127.3)	512.6 (438.6 to 599.8)	367.6 (284.7 to 478.2)	168.7 (120.7 to 230.0)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Diagnosis and primary therapy phase of liver cancer due to hepatitis C	18.0 (16.1 to 19.9)	75.2 (68.5 to 83.7)	315.9 (268.4 to 382.1)	139.1 (111.7 to 176.8)
Controlled phase of liver cancer due to hepatitis C	70.0 (55.8 to 84.8)	351.1 (288.3 to 422.6)	401.1 (289.2 to 556.2)	188.5 (125.6 to 274.9)
Metastatic phase of liver cancer due to hepatitis C	15.3 (13.8 to 16.7)	61.7 (56.8 to 67.8)	302.3 (258.3 to 359.4)	130.9 (106.5 to 163.7)
Terminal phase of liver cancer due to hepatitis C	6.1 (5.5 to 6.7)	24.6 (22.6 to 27.0)	302.3 (258.3 to 359.4)	130.9 (106.5 to 163.8)
Liver cancer due to alcohol use	178.1 (151.0 to 207.7)	197.2 (168.7 to 226.8)	10.2 (-8.8 to 34.4)	-35.8 (-46.5 to -22.2)
Diagnosis and primary therapy phase of liver cancer due to alcohol use	29.7 (27.0 to 32.6)	29.3 (26.5 to 32.5)	-1.4 (-12.2 to 11.1)	-42.8 (-48.9 to -35.4)
Controlled phase of liver cancer due to alcohol use	112.9 (89.0 to 138.5)	134.1 (109.5 to 160.5)	18.2 (-7.2 to 53.6)	-30.9 (-45.5 to -10.8)
Metastatic phase of liver cancer due to alcohol use	25.4 (23.3 to 27.5)	24.2 (22.0 to 26.5)	-5.0 (-14.6 to 5.6)	-44.8 (-50.2 to -38.9)
Terminal phase of liver cancer due to alcohol use	10.1 (9.3 to 11.0)	9.6 (8.8 to 10.6)	-5.0 (-14.6 to 5.7)	-44.8 (-50.2 to -38.9)
Liver cancer due to other causes	123.7 (103.9 to 146.8)	121.5 (102.1 to 143.0)	-1.0 (-23.1 to 22.3)	-40.7 (-54.1 to -27.0)
Diagnosis and primary therapy phase of liver cancer due to other causes	20.6 (18.7 to 22.7)	18.1 (16.1 to 20.3)	-12.0 (-25.3 to 1.3)	-47.4 (-55.2 to -39.6)
Controlled phase of liver cancer due to other causes	78.5 (61.4 to 98.6)	82.6 (65.6 to 101.5)	6.2 (-23.1 to 39.7)	-36.3 (-54.0 to -16.0)
Metastatic phase of liver cancer due to other causes	17.6 (16.1 to 19.1)	14.9 (13.5 to 16.6)	-15.0 (-26.4 to -3.4)	-49.2 (-55.8 to -42.2)
Terminal phase of liver cancer due to other causes	7.0 (6.4 to 7.6)	5.9 (5.4 to 6.6)	-15.0 (-26.4 to -3.4)	-49.2 (-55.8 to -42.2)
Larynx cancer	631.0 (532.0 to 736.4)	899.8 (749.7 to 1,069.8)	41.6 (30.2 to 58.1)	-16.6 (-23.0 to -7.1)
Diagnosis and primary therapy phase of larynx cancer	46.9 (38.6 to 54.5)	61.3 (50.7 to 74.3)	29.7 (20.0 to 46.4)	-24.0 (-29.7 to -14.4)
Controlled phase of larynx cancer	465.8 (382.8 to 552.4)	700.8 (576.7 to 844.8)	49.4 (36.1 to 68.4)	-11.9 (-19.6 to -1.0)
Metastatic phase of larynx cancer	59.0 (48.5 to 68.1)	73.9 (61.5 to 89.0)	24.1 (15.8 to 38.9)	-27.5 (-32.4 to -19.0)
Terminal phase of larynx cancer	7.8 (6.4 to 9.0)	9.7 (8.1 to 11.7)	23.5 (15.2 to 38.1)	-27.9 (-32.7 to -19.5)
Laryngectomy due to larynx cancer	51.6 (47.1 to 58.4)	54.2 (49.4 to 58.6)	6.0 (-12.8 to 21.0)	-37.2 (-48.9 to -28.0)
Tracheal, bronchus and lung cancer	1,871.1 (1,783.7 to 1,949.3)	3,227.4 (3,039.7 to 3,426.8)	72.2 (61.9 to 82.1)	0.8 (-5.4 to 6.5)
Diagnosis and primary therapy phase of lung, bronchus, and trachea cancer	124.6 (119.2 to 129.3)	210.3 (198.7 to 222.2)	68.5 (58.8 to 78.0)	-1.5 (-7.3 to 3.9)
Controlled phase of lung, bronchus, and trachea cancer	1,265.7 (1,201.0 to 1,328.5)	2,246.4 (2,098.1 to 2,407.0)	77.2 (65.2 to 88.7)	3.9 (-2.9 to 10.6)
Metastatic phase of lung, bronchus, and trachea cancer	393.5 (379.5 to 404.6)	630.8 (602.0 to 657.9)	60.3 (51.8 to 67.4)	-6.4 (-11.3 to -2.6)
Terminal phase of lung, bronchus, and trachea cancer	87.3 (84.1 to 89.7)	139.9 (133.5 to 145.9)	60.3 (51.8 to 67.4)	-6.4 (-11.3 to -2.6)
Breast cancer	8,108.0 (7,634.3 to 8,465.3)	18,419.0 (17,740.6 to 19,141.4)	126.9 (115.5 to 139.4)	29.7 (23.5 to 36.5)
Diagnosis and primary therapy phase of breast cancer	191.0 (169.5 to 212.8)	400.1 (359.9 to 440.8)	109.5 (95.1 to 123.2)	21.0 (13.0 to 28.7)
Controlled phase of breast cancer	3,395.8 (3,089.5 to 3,687.3)	6,218.8 (5,666.0 to 6,803.5)	82.8 (66.4 to 102.7)	6.2 (-3.4 to 17.8)
Metastatic phase of breast cancer	460.9 (405.6 to 512.2)	755.0 (665.6 to 821.0)	64.0 (53.3 to 73.3)	-6.0 (-12.4 to -0.6)
Terminal phase of breast cancer	30.9 (27.2 to 34.4)	49.5 (43.7 to 53.7)	60.4 (49.9 to 69.3)	-8.0 (-14.2 to -2.8)
Mastectomy due to breast cancer	4,029.4 (3,862.7 to 4,207.1)	10,995.7 (10,769.5 to 11,222.6)	173.3 (159.1 to 186.3)	51.5 (43.9 to 58.9)
Cervical cancer	2,965.6 (2,504.7 to 3,307.7)	3,180.8 (2,623.1 to 3,599.0)	7.2 (-5.4 to 21.9)	-35.2 (-42.6 to -26.8)
Diagnosis and primary therapy phase of cervical cancer	146.1 (123.1 to 162.4)	157.2 (130.0 to 177.1)	7.5 (-4.7 to 21.5)	-35.3 (-42.3 to -27.2)
Controlled phase of cervical cancer	2,666.3 (2,253.1 to 2,977.2)	2,855.9 (2,352.1 to 3,231.0)	7.0 (-5.9 to 22.0)	-35.3 (-42.7 to -26.7)
Metastatic phase of cervical cancer	135.4 (113.0 to 149.4)	148.2 (125.9 to 166.2)	9.3 (-0.7 to 20.5)	-34.9 (-40.9 to -28.4)
Terminal phase of cervical cancer	17.8 (14.9 to 19.6)	19.6 (16.7 to 22.0)	9.9 (0.2 to 21.2)	-34.4 (-40.4 to -28.0)
Uterine cancer	1,779.8 (1,447.9 to 2,158.9)	2,960.8 (2,307.9 to 3,516.4)	66.5 (39.0 to 97.8)	-3.8 (-19.0 to 13.3)
Diagnosis and primary therapy phase of uterine cancer	75.1 (61.2 to 90.9)	123.2 (96.2 to 145.9)	64.1 (37.7 to 94.1)	-5.4 (-20.1 to 10.8)
Controlled phase of uterine cancer	1,647.0 (1,339.3 to 1,999.7)	2,751.9 (2,144.7 to 3,270.5)	67.2 (39.5 to 99.0)	-3.3 (-18.7 to 14.1)
Metastatic phase of uterine cancer	52.2 (42.5 to 62.8)	77.5 (61.1 to 90.7)	48.6 (28.1 to 69.7)	-15.8 (-27.0 to -4.3)
Terminal phase of uterine cancer	5.5 (4.5 to 6.6)	8.2 (6.4 to 9.5)	49.6 (28.8 to 70.9)	-15.1 (-26.3 to -3.4)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Prostate cancer	3,957.2 (3,491.5 to 4,328.2)	11,135.9 (10,002.5 to 13,123.4)	178.8 (158.1 to 212.7)	56.0 (44.6 to 75.0)
Diagnosis and primary therapy phase of prostate cancer	114.2 (88.8 to 135.7)	410.0 (352.4 to 539.7)	247.8 (206.7 to 336.1)	97.0 (73.4 to 148.3)
Controlled phase of prostate cancer	1,471.4 (1,144.0 to 1,768.3)	5,629.7 (4,740.2 to 7,267.6)	276.2 (228.4 to 357.5)	113.5 (87.3 to 161.2)
Metastatic phase of prostate cancer	407.5 (318.5 to 489.7)	958.0 (811.8 to 1,239.8)	129.1 (108.6 to 177.9)	28.1 (16.3 to 55.7)
Terminal phase of prostate cancer	18.2 (14.3 to 22.0)	40.3 (34.1 to 52.3)	115.8 (97.5 to 160.0)	20.7 (10.0 to 45.6)
Impotence due to prostate cancer	1,472.8 (1,393.6 to 1,549.6)	3,101.9 (2,964.6 to 3,255.8)	110.5 (96.6 to 126.4)	17.8 (9.9 to 26.9)
Incontinence due to prostate cancer	472.9 (447.5 to 497.6)	996.0 (951.9 to 1,045.5)	110.5 (96.6 to 126.4)	17.8 (9.9 to 26.9)
Colon and rectum cancer	4,144.5 (4,028.4 to 4,281.5)	8,591.6 (8,252.7 to 8,917.0)	107.2 (97.8 to 115.6)	18.4 (13.1 to 23.2)
Diagnosis and primary therapy phase of colon and rectum cancers	195.9 (190.5 to 202.4)	399.8 (384.0 to 414.8)	104.1 (95.3 to 111.8)	16.0 (11.0 to 20.5)
Controlled phase of colon and rectum cancers	3,484.7 (3,383.7 to 3,604.0)	7,412.5 (7,118.7 to 7,702.3)	112.7 (102.7 to 121.3)	21.9 (16.2 to 27.0)
Metastatic phase of colon and rectum cancers	322.5 (313.7 to 331.9)	574.4 (552.9 to 595.2)	78.2 (71.4 to 84.3)	0.2 (-3.6 to 3.8)
Terminal phase of colon and rectum cancers	42.6 (41.4 to 43.8)	74.3 (71.5 to 77.1)	74.6 (68.1 to 80.5)	-1.6 (-5.2 to 1.9)
Stoma due to colon and rectum cancer	98.9 (95.8 to 102.6)	130.6 (125.9 to 135.8)	31.8 (25.3 to 38.7)	-26.2 (-30.1 to -22.1)
Lip and oral cavity cancer	1,360.3 (1,202.7 to 1,590.9)	2,416.5 (2,044.4 to 2,782.1)	76.8 (56.3 to 103.4)	2.9 (-9.0 to 18.2)
Diagnosis and primary therapy phase of mouth cancer	82.3 (72.9 to 96.1)	143.3 (121.2 to 165.4)	73.1 (53.9 to 99.0)	0.4 (-10.9 to 14.8)
Controlled phase of mouth cancer	1,169.1 (1,032.3 to 1,370.0)	2,093.0 (1,770.1 to 2,406.8)	78.3 (57.2 to 105.4)	4.0 (-8.1 to 19.3)
Metastatic phase of mouth cancer	96.5 (85.1 to 113.2)	159.8 (135.4 to 185.2)	65.0 (48.1 to 86.8)	-5.3 (-14.9 to 7.5)
Terminal phase of mouth cancer	12.4 (10.9 to 14.4)	20.4 (17.3 to 23.6)	64.4 (48.3 to 85.8)	-5.5 (-14.8 to 6.9)
Nasopharynx cancer	386.8 (326.3 to 461.5)	501.1 (422.3 to 596.2)	29.7 (5.8 to 58.5)	-21.1 (-35.7 to -4.0)
Diagnosis and primary therapy phase of nasopharynx cancer	21.7 (18.7 to 25.6)	27.7 (23.6 to 33.0)	27.8 (5.7 to 54.1)	-22.5 (-36.1 to -7.2)
Controlled phase of nasopharynx cancer	328.1 (275.2 to 395.0)	429.0 (358.7 to 513.5)	31.1 (6.5 to 61.2)	-20.1 (-35.2 to -2.1)
Metastatic phase of nasopharynx cancer	33.6 (29.6 to 39.4)	40.3 (35.6 to 46.6)	19.9 (4.1 to 37.3)	-28.0 (-37.3 to -17.6)
Terminal phase of nasopharynx cancer	3.4 (3.0 to 4.0)	4.0 (3.5 to 4.6)	18.2 (3.4 to 34.0)	-29.0 (-37.5 to -19.4)
Other pharynx cancer	415.7 (366.2 to 464.8)	752.5 (644.9 to 857.1)	81.2 (53.9 to 109.4)	4.7 (-10.9 to 20.6)
Diagnosis and primary therapy phase of other pharynx cancer	25.0 (22.2 to 27.9)	44.5 (38.2 to 50.6)	77.9 (52.2 to 104.4)	2.6 (-12.2 to 17.8)
Controlled phase of other pharynx cancer	357.1 (313.7 to 401.1)	651.7 (556.6 to 746.2)	82.7 (54.6 to 112.3)	5.7 (-10.5 to 22.1)
Metastatic phase of other pharynx cancer	29.1 (26.0 to 32.3)	48.8 (41.7 to 54.3)	67.3 (47.1 to 88.2)	-3.8 (-15.6 to 8.2)
Terminal phase of other pharynx cancer	4.4 (3.9 to 4.9)	7.4 (6.3 to 8.2)	66.4 (47.1 to 86.5)	-4.3 (-15.4 to 6.8)
Gallbladder and biliary tract cancer	108.2 (93.9 to 123.7)	158.3 (135.9 to 177.6)	46.7 (29.3 to 62.7)	-17.1 (-27.2 to -8.0)
Diagnosis and primary therapy phase of gallbladder and biliary tract cancer	21.2 (18.5 to 24.1)	29.9 (25.7 to 33.5)	41.4 (25.1 to 55.6)	-20.0 (-29.7 to -11.8)
Controlled phase of gallbladder and biliary tract cancer	39.3 (34.0 to 46.0)	64.5 (55.2 to 73.9)	64.2 (41.6 to 86.9)	-7.3 (-20.3 to 5.7)
Metastatic phase of gallbladder and biliary tract cancer	37.0 (32.3 to 41.8)	49.6 (42.9 to 55.2)	35.0 (19.2 to 47.7)	-23.7 (-32.8 to -16.5)
Terminal phase of gallbladder and biliary tract cancer	10.6 (9.3 to 12.1)	14.3 (12.4 to 15.9)	35.0 (19.2 to 47.7)	-23.7 (-32.8 to -16.5)
Pancreatic cancer	191.5 (179.8 to 203.1)	384.3 (355.9 to 412.9)	100.5 (84.2 to 117.8)	14.3 (5.2 to 24.5)
Diagnosis and primary therapy phase of pancreatic cancer	42.0 (40.6 to 43.4)	81.1 (77.4 to 84.6)	92.7 (83.6 to 102.3)	9.7 (4.5 to 15.3)
Controlled phase of pancreatic cancer	96.8 (87.2 to 106.7)	202.7 (180.7 to 226.3)	109.2 (82.9 to 137.0)	19.7 (4.9 to 35.3)
Metastatic phase of pancreatic cancer	37.8 (36.6 to 39.0)	72.1 (69.3 to 74.9)	90.7 (83.0 to 98.5)	8.5 (3.9 to 13.1)
Terminal phase of pancreatic cancer	14.9 (14.4 to 15.3)	28.4 (27.3 to 29.5)	90.7 (83.0 to 98.5)	8.5 (3.9 to 13.1)
Malignant skin melanoma	1,248.1 (972.1 to 1,600.8)	2,341.5 (1,808.4 to 3,151.3)	87.9 (65.9 to 107.1)	13.9 (0.5 to 24.9)
Diagnosis and primary therapy phase of malignant skin melanoma	33.6 (26.0 to 43.2)	61.5 (47.2 to 82.3)	83.6 (62.0 to 101.4)	10.6 (-2.3 to 20.9)
Controlled phase of malignant skin melanoma	1,184.8 (923.6 to 1,517.4)	2,233.4 (1,725.4 to 3,008.9)	88.8 (66.4 to 108.2)	14.7 (1.2 to 26.0)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Metastatic phase of malignant skin melanoma	25.8 (20.1 to 34.2)	40.5 (30.5 to 54.7)	56.9 (37.5 to 70.0)	-8.6 (-20.1 to -0.5)
Terminal phase of malignant skin melanoma	3.9 (3.1 to 5.2)	6.1 (4.6 to 8.2)	55.8 (36.7 to 68.5)	-9.2 (-20.4 to -1.3)
Non-melanoma skin cancer	2,644.3 (2,400.3 to 2,916.5)	5,529.6 (4,962.1 to 6,204.9)	108.8 (78.8 to 141.7)	18.2 (0.3 to 36.9)
Diagnosis and primary therapy phase of cutaneous squamous cell carcinoma	9.0 (7.2 to 11.1)	29.6 (23.8 to 38.2)	228.4 (169.3 to 300.0)	85.9 (49.2 to 128.6)
Control phase of cutaneous squamous cell carcinoma	309.1 (249.4 to 379.0)	1,053.1 (843.5 to 1,345.9)	239.8 (182.0 to 311.4)	95.1 (60.0 to 136.6)
Metastatic phase of cutaneous squamous cell carcinoma	22.6 (17.7 to 28.1)	61.9 (47.4 to 82.3)	173.5 (110.6 to 255.9)	48.5 (12.6 to 94.8)
Terminal phase of cutaneous squamous cell carcinoma	1.7 (1.3 to 2.1)	4.5 (3.4 to 6.0)	170.3 (108.6 to 250.7)	47.3 (12.0 to 93.2)
Disfigurement due to basal cell carcinoma	2,302.0 (2,075.9 to 2,575.8)	4,380.5 (3,849.6 to 4,974.6)	90.0 (56.9 to 124.0)	7.5 (-11.8 to 27.4)
Ovarian cancer	625.8 (583.3 to 665.7)	1,053.8 (975.7 to 1,145.0)	68.3 (56.1 to 82.3)	-0.9 (-8.1 to 7.0)
Diagnosis and primary therapy phase of ovarian cancer	20.6 (19.3 to 22.0)	34.6 (32.0 to 37.6)	67.4 (55.5 to 81.2)	-1.7 (-8.9 to 5.9)
Controlled phase of ovarian cancer	471.4 (437.9 to 503.4)	801.1 (739.1 to 873.3)	69.9 (57.0 to 84.6)	0.3 (-7.1 to 8.4)
Metastatic phase of ovarian cancer	125.5 (117.8 to 134.1)	204.8 (190.6 to 220.7)	63.2 (52.2 to 74.9)	-4.9 (-11.5 to 1.4)
Terminal phase of ovarian cancer	8.2 (7.7 to 8.8)	13.3 (12.4 to 14.3)	62.4 (51.9 to 73.6)	-5.2 (-11.5 to 0.7)
Testicular cancer	348.0 (279.4 to 426.4)	556.0 (423.6 to 681.0)	60.8 (32.1 to 84.9)	9.4 (-9.7 to 25.6)
Diagnosis and primary therapy phase of testicular cancer	10.5 (8.4 to 12.8)	16.7 (12.7 to 20.4)	60.5 (32.1 to 84.5)	8.8 (-9.9 to 24.9)
Controlled phase of testicular cancer	330.4 (265.8 to 405.2)	529.4 (403.1 to 648.2)	61.3 (32.2 to 85.7)	9.9 (-9.5 to 26.4)
Metastatic phase of testicular cancer	6.6 (5.1 to 7.9)	9.2 (6.9 to 11.3)	38.1 (24.9 to 57.3)	-10.7 (-19.2 to 2.9)
Terminal phase of testicular cancer	0.5 (0.4 to 0.6)	0.7 (0.5 to 0.9)	34.2 (21.7 to 52.6)	-12.4 (-20.3 to 0.7)
Kidney cancer	900.9 (837.3 to 966.4)	1,960.6 (1,829.8 to 2,099.4)	117.3 (104.5 to 131.6)	31.8 (23.9 to 40.4)
Diagnosis and primary therapy phase of kidney cancer	47.2 (44.1 to 50.5)	101.5 (94.9 to 108.3)	114.9 (102.6 to 128.3)	28.8 (21.1 to 37.2)
Controlled phase of kidney cancer	815.4 (755.7 to 875.0)	1,784.4 (1,665.5 to 1,909.4)	118.4 (105.5 to 133.3)	32.9 (24.9 to 41.5)
Metastatic phase of kidney cancer	32.2 (30.5 to 34.5)	62.7 (59.0 to 66.5)	94.4 (83.8 to 106.6)	12.6 (5.9 to 20.8)
Terminal phase of kidney cancer	6.2 (5.9 to 6.6)	12.0 (11.3 to 12.8)	94.0 (83.3 to 106.0)	12.4 (5.7 to 20.5)
Bladder cancer	1,485.0 (1,317.1 to 1,622.1)	2,359.6 (2,077.2 to 2,563.2)	58.5 (49.8 to 69.1)	-8.8 (-14.2 to -2.8)
Diagnosis and primary therapy phase of bladder cancer	88.2 (78.2 to 96.5)	137.7 (120.7 to 149.4)	55.9 (47.0 to 65.9)	-11.0 (-16.4 to -5.0)
Controlled phase of bladder cancer	1,272.1 (1,122.8 to 1,394.8)	2,056.2 (1,801.9 to 2,233.4)	61.3 (52.1 to 72.4)	-7.0 (-12.7 to -0.6)
Metastatic phase of bladder cancer	69.8 (62.0 to 76.4)	99.7 (88.2 to 108.0)	42.6 (35.3 to 50.8)	-19.9 (-24.3 to -15.1)
Terminal phase of bladder cancer	12.7 (11.3 to 13.9)	18.1 (16.0 to 19.6)	42.4 (35.2 to 50.6)	-20.0 (-24.3 to -15.2)
Urinary incontinence due to bladder cancer	42.2 (40.3 to 44.5)	48.0 (45.5 to 51.0)	13.7 (6.6 to 22.2)	-36.7 (-40.4 to -32.3)
Brain and nervous system cancer	787.6 (658.4 to 914.2)	1,193.2 (1,010.6 to 1,373.3)	52.2 (28.6 to 70.9)	7.2 (-7.2 to 18.9)
Diagnosis and primary therapy phase of brain and nervous system cancers	44.1 (37.1 to 50.7)	69.2 (58.7 to 79.6)	57.2 (35.1 to 74.9)	7.8 (-5.1 to 18.4)
Controlled phase of brain and nervous system cancers	666.7 (551.4 to 780.4)	999.0 (844.7 to 1,149.2)	50.7 (26.6 to 70.5)	7.5 (-7.7 to 19.7)
Metastatic phase of brain and nervous system cancers	65.3 (55.7 to 74.7)	106.4 (89.5 to 123.1)	63.1 (46.3 to 75.9)	5.4 (-4.4 to 12.9)
Terminal phase of brain and nervous system cancers	11.5 (9.8 to 13.1)	18.6 (15.6 to 21.5)	62.2 (45.8 to 74.4)	4.9 (-4.8 to 12.5)
Thyroid cancer	1,091.5 (909.1 to 1,220.0)	2,179.4 (1,815.3 to 2,509.2)	100.2 (74.8 to 129.9)	24.4 (9.6 to 41.3)
Diagnosis and primary therapy phase of thyroid cancer	26.9 (22.5 to 30.1)	53.5 (44.7 to 61.6)	99.1 (74.0 to 128.1)	23.2 (8.7 to 39.8)
Controlled phase of thyroid cancer	1,042.7 (867.9 to 1,166.3)	2,089.9 (1,737.7 to 2,406.4)	101.1 (75.3 to 131.0)	25.2 (10.2 to 42.3)
Metastatic phase of thyroid cancer	20.5 (17.6 to 22.7)	33.7 (29.1 to 37.8)	64.1 (51.4 to 80.3)	-5.3 (-12.8 to 3.9)
Terminal phase of thyroid cancer	1.4 (1.2 to 1.6)	2.3 (2.0 to 2.6)	59.0 (46.8 to 75.7)	-7.2 (-14.2 to 2.5)
Mesothelioma	26.1 (23.3 to 30.4)	50.4 (44.2 to 57.6)	94.7 (65.9 to 110.9)	12.9 (-4.3 to 22.0)
Diagnosis and primary therapy phase of mesothelioma	2.0 (1.8 to 2.4)	4.0 (3.5 to 4.6)	100.6 (70.4 to 117.7)	16.4 (-1.9 to 26.3)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Controlled phase of mesothelioma	14.6 (12.9 to 17.1)	27.6 (24.3 to 31.3)	89.4 (62.4 to 108.3)	10.2 (-6.0 to 20.2)
Metastatic phase of mesothelioma	8.0 (7.2 to 9.6)	16.1 (14.0 to 18.5)	101.3 (69.7 to 116.3)	16.6 (-2.3 to 25.2)
Terminal phase of mesothelioma	1.4 (1.2 to 1.6)	2.7 (2.4 to 3.1)	101.0 (70.1 to 116.1)	16.4 (-2.4 to 25.1)
Hodgkin lymphoma	785.9 (568.1 to 965.0)	725.3 (625.0 to 997.2)	-12.7 (-30.9 to 59.0)	-34.7 (-46.7 to 16.7)
Diagnosis and primary therapy phase of Hodgkin disease	24.4 (17.7 to 29.8)	22.8 (19.7 to 31.4)	-11.9 (-29.7 to 59.4)	-34.7 (-46.1 to 16.3)
Controlled phase of Hodgkin disease	716.3 (516.5 to 886.6)	658.4 (565.3 to 902.9)	-12.9 (-32.0 to 59.5)	-34.3 (-47.1 to 18.2)
Metastatic phase of Hodgkin disease	42.2 (30.9 to 47.1)	41.4 (37.0 to 54.2)	-8.2 (-17.6 to 49.7)	-39.3 (-45.3 to -1.1)
Terminal phase of Hodgkin disease	3.0 (2.2 to 3.4)	2.7 (2.4 to 3.6)	-16.3 (-24.1 to 36.5)	-43.8 (-48.9 to -8.7)
Non-Hodgkin lymphoma	1,348.3 (1,144.6 to 1,621.1)	2,956.4 (2,448.0 to 3,253.1)	121.7 (82.7 to 142.0)	38.4 (12.3 to 50.7)
Diagnosis and primary therapy phase of non-Hodgkin lymphoma	50.0 (42.7 to 60.2)	108.3 (89.5 to 118.9)	119.5 (80.1 to 138.1)	35.2 (9.5 to 47.2)
Controlled phase of non-Hodgkin lymphoma	1,220.3 (1,033.0 to 1,467.7)	2,696.2 (2,233.7 to 2,966.7)	123.4 (84.3 to 144.1)	39.7 (13.7 to 52.5)
Metastatic phase of non-Hodgkin lymphoma	67.4 (58.6 to 81.2)	131.5 (108.2 to 143.8)	99.4 (61.7 to 113.7)	19.9 (-5.5 to 28.7)
Terminal phase of non-Hodgkin lymphoma	10.6 (9.3 to 12.8)	20.4 (16.8 to 22.3)	96.3 (59.4 to 110.0)	18.3 (-6.4 to 26.7)
Multiple myeloma	206.4 (164.3 to 262.6)	427.4 (349.3 to 528.8)	107.8 (78.1 to 137.1)	19.0 (1.3 to 36.9)
Diagnosis and primary therapy phase of multiple myeloma	12.8 (10.2 to 16.4)	27.0 (22.0 to 33.5)	111.0 (79.7 to 143.6)	20.8 (2.4 to 40.3)
Controlled phase of multiple myeloma	105.7 (83.7 to 135.7)	229.4 (186.7 to 287.1)	117.5 (85.3 to 153.0)	25.3 (6.1 to 46.1)
Metastatic phase of multiple myeloma	83.3 (66.7 to 105.4)	162.7 (133.8 to 199.3)	96.4 (69.1 to 120.7)	11.7 (-4.6 to 26.2)
Terminal phase of multiple myeloma	4.6 (3.8 to 5.8)	8.4 (6.9 to 10.1)	83.6 (60.3 to 99.5)	4.5 (-9.6 to 14.0)
Leukemia	1,476.9 (1,339.0 to 1,672.1)	2,117.3 (1,978.7 to 2,248.2)	44.3 (24.8 to 58.6)	6.7 (-4.6 to 15.6)
Diagnosis and primary therapy phase of leukemia	56.9 (51.3 to 64.7)	82.7 (77.1 to 88.0)	46.5 (26.0 to 61.5)	8.6 (-3.4 to 18.0)
Controlled phase of leukemia	1,200.4 (1,071.9 to 1,381.6)	1,671.3 (1,551.7 to 1,787.2)	40.4 (19.0 to 56.2)	7.5 (-6.0 to 17.8)
Metastatic phase of leukemia	204.4 (196.0 to 213.1)	341.7 (324.1 to 358.1)	67.2 (57.0 to 76.8)	4.2 (-2.0 to 10.1)
Terminal phase of leukemia	15.3 (14.7 to 16.0)	21.6 (20.6 to 22.7)	41.2 (34.0 to 48.3)	-9.3 (-13.8 to -4.9)
Other neoplasms	2,458.2 (2,170.5 to 3,118.2)	6,785.0 (5,938.1 to 7,417.5)	185.5 (104.5 to 215.4)	93.2 (47.0 to 113.0)
Diagnosis and primary therapy phase of other neoplasms	47.4 (42.4 to 58.9)	130.7 (114.5 to 142.1)	183.9 (109.3 to 211.9)	86.3 (44.9 to 105.9)
Controlled phase of other neoplasms	2,294.8 (2,017.0 to 2,924.6)	6,366.3 (5,569.5 to 6,973.4)	187.4 (104.2 to 218.5)	96.0 (48.2 to 116.3)
Metastatic phase of other neoplasms	99.7 (93.4 to 115.3)	248.5 (219.7 to 268.3)	151.8 (109.7 to 174.0)	50.8 (25.0 to 65.2)
Terminal phase of other neoplasms	16.3 (15.2 to 18.7)	39.5 (35.0 to 42.7)	145.7 (104.8 to 167.0)	47.6 (22.7 to 61.6)
Cardiovascular diseases	-	-	-	-
Rheumatic heart disease	20,218.5 (19,156.9 to 21,224.0)	32,903.9 (31,608.5 to 34,023.7)	62.8 (51.3 to 72.0)	13.5 (6.0 to 19.7)
Rheumatic heart disease, without heart failure	17,387.5 (16,166.3 to 18,453.4)	28,633.6 (26,843.2 to 30,447.5)	65.0 (49.2 to 79.4)	18.7 (6.7 to 29.8)
Mild heart failure due to rheumatic heart disease	698.9 (446.0 to 960.9)	1,054.5 (581.7 to 1,590.4)	51.1 (-1.6 to 109.2)	-8.9 (-40.0 to 24.2)
Moderate heart failure due to rheumatic heart disease	577.9 (412.7 to 780.8)	872.3 (531.6 to 1,283.8)	51.1 (-1.6 to 109.2)	-8.9 (-40.0 to 24.2)
Severe heart failure due to rheumatic heart disease	1,554.2 (1,249.7 to 1,914.4)	2,343.5 (1,521.0 to 3,177.2)	51.1 (-1.6 to 109.2)	-8.9 (-40.0 to 24.2)
Ischemic heart disease	56,401.0 (54,289.1 to 58,731.7)	92,936.7 (90,091.9 to 95,860.8)	64.7 (57.0 to 72.2)	-5.2 (-9.6 to -1.0)
Asymptomatic ischemic heart disease following myocardial infarction	10,117.1 (9,662.1 to 10,544.2)	17,484.9 (16,401.6 to 18,405.4)	72.5 (60.7 to 84.4)	-0.8 (-7.6 to 6.2)
Acute myocardial infarction first 2 days	17.2 (16.0 to 18.6)	29.7 (27.7 to 32.0)	72.7 (71.2 to 74.3)	-2.9 (-3.7 to -2.1)
Acute myocardial infarction 3 to 28 days	223.3 (215.3 to 231.9)	385.9 (372.3 to 400.1)	72.7 (71.2 to 74.3)	-2.9 (-3.7 to -2.1)
Asymptomatic angina due to ischemic heart disease	10,904.0 (9,465.7 to 12,480.7)	16,674.2 (14,702.3 to 18,909.5)	52.8 (41.8 to 65.0)	-10.8 (-17.2 to -3.8)
Mild angina due to ischemic heart disease	8,602.1 (6,573.4 to 10,849.1)	13,157.0 (9,988.1 to 16,474.1)	52.8 (41.8 to 65.0)	-10.8 (-17.2 to -3.8)
Moderate angina due to ischemic heart disease	4,521.1 (3,244.8 to 5,890.9)	6,914.0 (4,943.5 to 9,055.6)	52.8 (41.8 to 65.0)	-10.8 (-17.2 to -3.8)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Severe angina due to ischemic heart disease	11,732.8 (9,999.7 to 13,631.9)	17,945.6 (15,367.3 to 20,749.4)	52.8 (41.8 to 65.0)	-10.8 (-17.2 to -3.8)
Mild heart failure due to ischemic heart disease	2,551.5 (1,701.0 to 3,465.3)	5,048.5 (3,322.7 to 6,805.0)	97.3 (87.5 to 108.7)	8.2 (2.9 to 14.0)
Moderate heart failure due to ischemic heart disease	2,085.3 (1,502.7 to 2,726.6)	4,125.8 (2,993.0 to 5,419.2)	97.3 (87.5 to 108.7)	8.2 (2.9 to 14.0)
Severe heart failure due to ischemic heart disease	5,646.7 (4,898.1 to 6,504.4)	11,171.1 (9,670.5 to 12,845.0)	97.3 (87.5 to 108.7)	8.2 (2.9 to 14.0)
Cerebrovascular disease	-	-	-	-
Ischemic stroke	10,045.2 (9,643.5 to 10,453.4)	18,305.5 (17,767.4 to 18,920.7)	81.5 (72.6 to 92.7)	2.4 (-2.8 to 9.1)
Asymptomatic chronic ischemic stroke	2,337.2 (2,043.5 to 2,647.2)	4,272.5 (3,754.2 to 4,821.1)	82.1 (72.9 to 93.6)	2.7 (-2.7 to 9.6)
Chronic ischemic stroke severity level 1	1,753.5 (1,186.3 to 2,366.7)	3,205.2 (2,201.3 to 4,300.3)	82.1 (72.9 to 93.6)	2.7 (-2.7 to 9.6)
Chronic ischemic stroke severity level 2	2,512.9 (1,997.0 to 3,030.5)	4,594.0 (3,658.2 to 5,514.2)	82.1 (72.9 to 93.6)	2.7 (-2.7 to 9.6)
Chronic ischemic stroke severity level 4	595.3 (407.0 to 814.4)	1,088.0 (740.3 to 1,486.6)	82.1 (72.9 to 93.6)	2.7 (-2.7 to 9.6)
Chronic ischemic stroke severity level 3	1,582.1 (1,249.1 to 1,906.0)	2,891.8 (2,295.5 to 3,474.7)	82.1 (72.9 to 93.6)	2.7 (-2.7 to 9.6)
Chronic ischemic stroke severity level 5	1,014.1 (519.6 to 1,688.8)	1,854.0 (966.4 to 3,036.7)	82.1 (72.9 to 93.6)	2.7 (-2.7 to 9.6)
Acute ischemic stroke severity level 1	58.2 (39.9 to 77.8)	93.1 (63.7 to 122.8)	60.3 (48.4 to 71.7)	-9.8 (-16.9 to -2.8)
Acute ischemic stroke severity level 2	84.9 (67.6 to 102.4)	135.8 (107.9 to 163.9)	60.3 (48.4 to 71.7)	-9.8 (-16.9 to -2.8)
Acute ischemic stroke severity level 4	19.9 (14.0 to 27.2)	31.8 (22.1 to 43.3)	60.3 (48.4 to 71.7)	-9.8 (-16.9 to -2.8)
Acute ischemic stroke severity level 3	53.3 (42.9 to 64.4)	85.2 (68.3 to 102.4)	60.3 (48.4 to 71.7)	-9.8 (-16.9 to -2.8)
Acute ischemic stroke severity level 5	33.8 (17.5 to 53.2)	54.2 (28.3 to 86.3)	60.3 (48.4 to 71.7)	-9.8 (-16.9 to -2.8)
Hemorrhagic stroke	3,891.2 (3,769.5 to 4,019.0)	7,363.5 (7,139.7 to 7,616.1)	88.9 (80.6 to 98.6)	10.2 (5.4 to 16.1)
Asymptomatic chronic hemorrhagic stroke	908.8 (795.1 to 1,027.7)	1,722.3 (1,516.6 to 1,944.3)	89.2 (80.7 to 99.1)	10.4 (5.5 to 16.5)
Chronic hemorrhagic stroke severity level 1	678.9 (466.3 to 903.8)	1,286.4 (888.2 to 1,704.6)	89.2 (80.7 to 99.1)	10.4 (5.5 to 16.5)
Chronic hemorrhagic stroke severity level 2	984.5 (793.7 to 1,183.9)	1,865.9 (1,503.1 to 2,262.6)	89.2 (80.7 to 99.1)	10.4 (5.5 to 16.5)
Chronic hemorrhagic stroke severity level 4	230.9 (163.6 to 311.2)	437.5 (310.2 to 594.8)	89.2 (80.7 to 99.1)	10.4 (5.5 to 16.5)
Chronic hemorrhagic stroke severity level 3	615.5 (493.8 to 735.2)	1,166.4 (934.7 to 1,397.9)	89.2 (80.7 to 99.1)	10.4 (5.5 to 16.5)
Chronic hemorrhagic stroke severity level 5	395.8 (206.5 to 648.1)	750.1 (388.1 to 1,241.3)	89.2 (80.7 to 99.1)	10.4 (5.5 to 16.5)
Acute hemorrhagic stroke severity level 1	17.9 (12.7 to 24.1)	31.5 (22.0 to 42.3)	76.4 (61.4 to 87.2)	1.8 (-6.7 to 8.5)
Acute hemorrhagic stroke severity level 2	26.1 (20.9 to 31.4)	45.8 (36.6 to 55.1)	76.4 (61.4 to 87.2)	1.8 (-6.7 to 8.5)
Acute hemorrhagic stroke severity level 4	6.1 (4.2 to 8.4)	10.8 (7.2 to 14.7)	76.4 (61.4 to 87.2)	1.8 (-6.7 to 8.5)
Acute hemorrhagic stroke severity level 3	16.4 (13.3 to 19.9)	28.8 (23.2 to 35.4)	76.4 (61.4 to 87.2)	1.8 (-6.7 to 8.5)
Acute hemorrhagic stroke severity level 5	10.3 (5.3 to 16.5)	18.0 (9.3 to 29.0)	76.4 (61.4 to 87.2)	1.8 (-6.7 to 8.5)
Hypertensive heart disease	5,119.4 (4,925.0 to 5,340.4)	10,893.7 (10,526.7 to 11,246.4)	112.8 (101.6 to 123.9)	19.1 (12.7 to 25.4)
Mild heart failure due to hypertensive heart disease	1,270.7 (849.4 to 1,714.0)	2,704.0 (1,800.8 to 3,636.0)	112.8 (101.6 to 123.9)	19.1 (12.7 to 25.4)
Moderate heart failure due to hypertensive heart disease	1,040.0 (768.9 to 1,370.2)	2,213.1 (1,641.2 to 2,889.7)	112.8 (101.6 to 123.9)	19.1 (12.7 to 25.4)
Severe heart failure due to hypertensive heart disease	2,808.7 (2,423.3 to 3,229.7)	5,976.5 (5,142.1 to 6,858.5)	112.8 (101.6 to 123.9)	19.1 (12.7 to 25.4)
Cardiomyopathy and myocarditis	4,311.9 (4,154.4 to 4,461.4)	7,993.0 (7,738.3 to 8,269.3)	85.0 (77.9 to 93.0)	8.5 (4.3 to 13.4)
Acute myocarditis	240.1 (227.3 to 257.8)	370.3 (344.4 to 397.9)	53.5 (41.6 to 69.4)	-3.6 (-11.4 to 6.0)
Mild heart failure due to cardiomyopathy and myocarditis	1,003.2 (673.1 to 1,347.2)	1,878.3 (1,246.2 to 2,501.8)	86.8 (79.5 to 95.2)	9.1 (4.7 to 14.2)
Moderate heart failure due to cardiomyopathy and myocarditis	829.1 (598.1 to 1,077.7)	1,552.3 (1,122.7 to 2,018.0)	86.8 (79.5 to 95.2)	9.1 (4.7 to 14.2)
Severe heart failure due to cardiomyopathy and myocarditis	2,239.4 (1,923.5 to 2,549.8)	4,192.1 (3,621.5 to 4,774.9)	86.8 (79.5 to 95.2)	9.1 (4.7 to 14.2)
Atrial fibrillation and flutter	6,841.1 (6,602.8 to 7,114.7)	11,178.6 (10,655.1 to 11,683.7)	63.6 (53.9 to 71.4)	-10.3 (-15.6 to -5.8)
Asymptomatic atrial fibrillation and flutter	4,113.1 (3,867.1 to 4,362.7)	6,719.8 (6,298.2 to 7,173.9)	63.6 (53.9 to 71.4)	-10.4 (-15.6 to -5.8)
Symptomatic atrial fibrillation and flutter	2,728.0 (2,519.3 to 2,953.9)	4,458.9 (4,076.8 to 4,807.7)	63.7 (54.0 to 71.5)	-10.3 (-15.6 to -5.7)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Peripheral vascular disease	104,475.8 (99,440.3 to 109,950.1)	185,137.2 (172,555.7 to 196,597.2)	78.0 (59.9 to 91.2)	-0.1 (-9.9 to 6.7)
Asymptomatic peripheral vascular disease	97,747.0 (92,848.7 to 103,083.8)	175,165.0 (163,035.6 to 186,082.5)	80.1 (61.2 to 93.9)	1.6 (-8.5 to 8.6)
Symptomatic claudication due to peripheral vascular disease	6,728.7 (6,333.4 to 7,425.9)	9,972.3 (9,168.3 to 10,778.1)	49.0 (31.2 to 63.9)	-20.2 (-29.9 to -12.4)
Endocarditis	180.6 (149.8 to 213.0)	310.3 (252.1 to 361.0)	71.7 (55.9 to 86.2)	4.6 (-5.1 to 13.6)
Moderate endocarditis	39.8 (36.3 to 43.1)	55.0 (48.1 to 63.7)	37.9 (19.3 to 55.6)	-5.2 (-17.7 to 5.8)
Severe endocarditis	4.7 (4.0 to 5.4)	5.1 (4.4 to 6.0)	9.5 (-16.3 to 33.6)	-25.7 (-42.3 to -9.2)
Mild heart failure due to endocarditis	33.5 (20.8 to 48.6)	61.6 (38.8 to 87.3)	83.7 (63.0 to 104.7)	7.7 (-3.9 to 20.0)
Moderate heart failure due to endocarditis	27.7 (18.7 to 38.1)	50.9 (35.0 to 70.0)	83.7 (63.0 to 104.7)	7.7 (-3.9 to 20.0)
Severe heart failure due to endocarditis	74.9 (55.7 to 96.8)	137.6 (101.7 to 172.6)	83.7 (63.0 to 104.7)	7.7 (-3.9 to 20.0)
Other cardiovascular and circulatory diseases	41,600.0 (29,939.1 to 54,543.3)	95,225.2 (67,433.2 to 121,733.8)	130.2 (53.9 to 234.7)	36.4 (-8.6 to 98.7)
Mild heart failure due to other cardiovascular diseases	1,016.7 (577.7 to 1,549.2)	2,354.4 (1,396.7 to 3,442.7)	133.4 (53.9 to 252.0)	31.9 (-13.5 to 100.8)
Moderate heart failure due to other cardiovascular diseases	836.9 (530.6 to 1,205.4)	1,944.4 (1,196.4 to 2,862.6)	133.4 (53.9 to 252.0)	31.9 (-13.5 to 100.8)
Severe heart failure due to other cardiovascular diseases	2,257.6 (1,549.0 to 3,066.8)	5,236.6 (3,624.8 to 6,825.8)	133.4 (53.9 to 252.0)	31.9 (-13.5 to 100.8)
Asymptomatic other cardiovascular diseases	10,350.6 (7,386.3 to 13,770.5)	23,654.4 (16,510.6 to 30,884.7)	129.8 (53.4 to 234.2)	37.1 (-8.1 to 98.3)
Mild other cardiovascular diseases	11,279.0 (7,688.8 to 15,623.9)	25,755.1 (17,450.4 to 35,431.4)	129.8 (53.4 to 234.2)	37.1 (-8.1 to 98.3)
Moderate other cardiovascular diseases	5,532.7 (3,526.0 to 8,089.5)	12,666.1 (7,971.3 to 18,563.4)	129.8 (53.4 to 234.2)	37.1 (-8.1 to 98.3)
Severe other cardiovascular diseases	10,326.5 (7,127.9 to 14,014.8)	23,614.4 (16,154.1 to 31,894.3)	129.8 (53.4 to 234.2)	37.1 (-8.1 to 98.3)
Chronic respiratory diseases	-	-	-	-
Chronic obstructive pulmonary disease	198,729.4 (192,134.3 to 205,570.2)	328,503.6 (317,289.1 to 339,461.0)	65.1 (63.8 to 66.3)	0.5 (-0.2 to 1.2)
Asymptomatic chronic obstructive pulmonary disease	72,349.4 (61,401.7 to 85,792.6)	113,733.4 (96,108.6 to 135,225.3)	57.1 (48.4 to 66.2)	-5.1 (-10.2 to 0.4)
Mild chronic obstructive pulmonary disease	80,939.6 (66,535.5 to 93,331.9)	136,697.7 (114,646.1 to 157,188.3)	68.4 (63.0 to 75.9)	3.2 (-0.1 to 7.5)
Moderate chronic obstructive pulmonary disease	18,933.4 (14,675.6 to 23,102.8)	31,976.0 (24,914.5 to 38,823.2)	68.4 (63.0 to 75.9)	3.2 (-0.1 to 7.5)
Severe chronic obstructive pulmonary disease without heart failure	23,477.2 (14,173.7 to 34,279.4)	40,263.5 (24,153.0 to 59,167.1)	71.0 (62.9 to 81.0)	5.7 (0.6 to 11.4)
Mild heart failure due to severe chronic obstructive pulmonary disease	745.5 (494.5 to 1,018.0)	1,434.9 (947.1 to 1,951.9)	92.5 (83.9 to 101.6)	5.9 (1.1 to 10.9)
Moderate heart failure due to severe chronic obstructive pulmonary disease	622.6 (448.3 to 816.4)	1,198.7 (858.3 to 1,563.6)	92.5 (83.9 to 101.6)	5.9 (1.1 to 10.9)
Severe heart failure due to severe chronic obstructive pulmonary disease	1,661.8 (1,389.8 to 1,920.0)	3,199.4 (2,680.2 to 3,709.1)	92.5 (83.9 to 101.6)	5.9 (1.1 to 10.9)
Pneumoconiosis	-	-	-	-
Silicosis	37.5 (35.0 to 39.9)	56.2 (52.6 to 59.6)	49.8 (47.3 to 52.3)	-11.8 (-13.3 to -10.5)
Asymptomatic silicosis	8.4 (5.7 to 11.6)	12.7 (8.6 to 17.6)	49.8 (47.3 to 52.3)	-11.9 (-13.3 to -10.5)
Mild silicosis	12.0 (8.5 to 15.5)	17.9 (12.7 to 23.2)	49.8 (47.3 to 52.3)	-11.9 (-13.3 to -10.5)
Moderate silicosis	4.6 (1.9 to 8.0)	6.9 (2.9 to 12.0)	49.8 (47.3 to 52.3)	-11.9 (-13.3 to -10.5)
Severe silicosis without heart failure	1.6 (0.7 to 3.0)	2.5 (1.0 to 4.7)	51.2 (24.8 to 84.0)	-6.9 (-23.2 to 12.1)
Mild heart failure due to severe silicosis	2.7 (1.5 to 4.1)	4.0 (2.3 to 6.1)	49.4 (44.0 to 54.0)	-12.5 (-15.7 to -10.0)
Moderate heart failure due to severe silicosis	2.2 (1.4 to 3.2)	3.3 (2.1 to 4.7)	49.4 (44.0 to 53.9)	-12.5 (-15.7 to -10.0)
Severe heart failure due to severe silicosis	5.9 (4.1 to 8.0)	8.9 (6.1 to 11.9)	49.4 (44.0 to 54.0)	-12.5 (-15.7 to -10.0)
Asbestosis	8.8 (8.3 to 9.2)	14.8 (14.0 to 15.5)	67.5 (64.0 to 71.4)	-0.7 (-2.8 to 1.7)
Asymptomatic asbestosis	2.0 (1.3 to 2.8)	3.3 (2.2 to 4.7)	67.5 (64.0 to 71.4)	-0.7 (-2.8 to 1.7)
Mild asbestosis	2.8 (2.0 to 3.7)	4.7 (3.3 to 6.1)	67.5 (64.0 to 71.4)	-0.7 (-2.8 to 1.7)
Moderate asbestosis	1.1 (0.5 to 1.9)	1.9 (0.8 to 3.2)	67.5 (64.0 to 71.4)	-0.7 (-2.8 to 1.7)
Severe asbestosis without heart failure	0.6 (0.3 to 0.9)	0.8 (0.3 to 1.4)	39.3 (13.3 to 73.0)	-15.9 (-31.0 to 2.8)
Mild heart failure due to severe asbestosis	0.6 (0.3 to 0.9)	1.0 (0.6 to 1.6)	73.7 (65.2 to 81.2)	2.4 (-2.0 to 6.3)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Moderate heart failure due to severe asbestosis	0.5 (0.3 to 0.7)	0.8 (0.5 to 1.2)	73.7 (65.3 to 81.2)	2.4 (-2.0 to 6.3)
Severe heart failure due to severe asbestosis	1.3 (0.9 to 1.7)	2.2 (1.5 to 3.0)	73.7 (65.3 to 81.2)	2.3 (-2.0 to 6.3)
Coal workers pneumoconiosis	23.5 (22.3 to 24.6)	36.4 (34.6 to 38.1)	55.1 (53.1 to 56.8)	-6.9 (-8.0 to -5.9)
Asymptomatic coal workers pneumoconiosis	5.3 (3.3 to 7.4)	8.2 (5.2 to 11.6)	55.1 (53.1 to 56.8)	-6.9 (-8.0 to -5.9)
Mild coal workers pneumoconiosis	7.5 (5.4 to 9.9)	11.6 (8.4 to 15.4)	55.1 (53.1 to 56.8)	-6.9 (-8.0 to -5.9)
Moderate coal workers pneumoconiosis	2.9 (1.2 to 5.1)	4.5 (1.8 to 7.9)	55.1 (53.1 to 56.8)	-6.9 (-8.0 to -5.9)
Severe coal workers pneumoconiosis without heart failure	2.0 (1.0 to 3.3)	3.1 (1.6 to 5.0)	54.3 (38.1 to 74.3)	-3.4 (-14.0 to 9.3)
Mild heart failure due to severe coal workers pneumoconiosis	1.4 (0.8 to 2.1)	2.2 (1.3 to 3.2)	55.2 (49.2 to 62.5)	-8.0 (-11.6 to -4.0)
Moderate heart failure due to severe coal workers pneumoconiosis	1.2 (0.8 to 1.6)	1.8 (1.2 to 2.6)	55.2 (49.1 to 62.5)	-8.0 (-11.6 to -4.0)
Severe heart failure due to severe coal workers pneumoconiosis	3.2 (2.3 to 4.1)	4.9 (3.6 to 6.5)	55.2 (49.2 to 62.4)	-8.0 (-11.6 to -4.0)
Other pneumoconiosis	67.5 (62.8 to 72.0)	164.9 (154.0 to 174.3)	144.2 (137.9 to 150.3)	47.4 (44.0 to 51.1)
Asymptomatic other pneumoconiosis	15.1 (9.9 to 21.6)	36.9 (24.2 to 52.4)	144.2 (137.9 to 150.3)	47.4 (44.0 to 51.1)
Mild other pneumoconiosis	21.6 (15.0 to 28.7)	52.9 (36.8 to 70.1)	144.2 (137.9 to 150.3)	47.4 (44.0 to 51.1)
Moderate other pneumoconiosis	8.4 (3.5 to 14.8)	20.6 (8.7 to 35.7)	144.2 (137.9 to 150.3)	47.4 (44.0 to 51.1)
Severe other pneumoconiosis without heart failure	6.1 (2.9 to 10.1)	16.9 (8.4 to 26.8)	176.0 (150.3 to 203.8)	73.5 (55.7 to 91.6)
Mild heart failure due to severe other pneumoconiosis	4.0 (2.3 to 5.9)	9.3 (5.4 to 13.7)	132.7 (122.6 to 143.8)	38.7 (32.1 to 45.2)
Moderate heart failure due to severe other pneumoconiosis	3.3 (2.1 to 4.8)	7.7 (5.0 to 11.1)	132.7 (122.6 to 143.8)	38.7 (32.1 to 45.1)
Severe heart failure due to severe other pneumoconiosis	8.9 (6.3 to 11.6)	20.6 (14.8 to 27.2)	132.7 (122.6 to 143.8)	38.7 (32.1 to 45.2)
Asthma	182,776.4 (180,097.7 to 185,614.6)	241,694.7 (238,151.1 to 245,464.6)	32.1 (29.5 to 34.9)	-5.5 (-7.2 to -3.5)
Asymptomatic asthma	55,549.7 (49,334.9 to 62,666.3)	73,456.1 (65,198.8 to 83,231.7)	32.1 (29.5 to 34.9)	-5.5 (-7.2 to -3.5)
Controlled asthma	37,621.9 (26,539.0 to 48,581.0)	49,749.9 (35,163.3 to 64,519.4)	32.1 (29.5 to 34.9)	-5.5 (-7.2 to -3.5)
Partially controlled asthma	40,829.2 (32,447.7 to 49,596.0)	53,992.8 (42,849.0 to 65,624.6)	32.1 (29.5 to 34.9)	-5.5 (-7.2 to -3.5)
Uncontrolled asthma	48,775.6 (39,107.2 to 58,507.3)	64,495.9 (51,696.7 to 77,323.7)	32.1 (29.5 to 34.9)	-5.5 (-7.2 to -3.5)
Interstitial lung disease and pulmonary sarcoidosis	350.8 (337.5 to 363.7)	595.0 (569.1 to 622.5)	69.8 (58.9 to 78.9)	5.1 (-1.5 to 10.6)
Asymptomatic interstitial lung disease and pulmonary sarcoidosis	69.5 (45.6 to 94.3)	117.9 (77.7 to 160.1)	69.8 (58.9 to 78.9)	5.1 (-1.5 to 10.6)
Mild interstitial lung disease and pulmonary sarcoidosis	159.8 (128.9 to 190.2)	271.0 (219.2 to 322.4)	69.8 (58.9 to 78.9)	5.1 (-1.5 to 10.6)
Moderate interstitial lung disease and pulmonary sarcoidosis	46.5 (23.8 to 74.2)	79.0 (40.8 to 124.4)	69.8 (58.9 to 78.9)	5.1 (-1.5 to 10.6)
Severe interstitial lung disease and pulmonary sarcoidosis without heart failure	23.7 (10.9 to 40.5)	25.2 (10.0 to 45.2)	5.0 (-17.0 to 32.6)	-27.6 (-42.1 to -6.6)
Mild heart failure due to severe interstitial lung disease and pulmonary sarcoidosis	12.6 (7.3 to 19.6)	25.1 (14.2 to 40.6)	99.5 (79.2 to 119.1)	16.0 (5.5 to 26.7)
Moderate heart failure due to severe interstitial lung disease and pulmonary sarcoidosis	10.4 (6.3 to 15.4)	20.7 (12.4 to 30.9)	99.5 (79.2 to 119.2)	16.0 (5.5 to 26.7)
Severe heart failure due to severe interstitial lung disease and pulmonary sarcoidosis	28.2 (17.9 to 38.6)	56.1 (34.9 to 79.2)	99.5 (79.2 to 119.1)	16.0 (5.5 to 26.7)
Other chronic respiratory diseases	-	-	-	-
Cirrhosis	-	-	-	-
Cirrhosis due to hepatitis B	716.1 (682.5 to 753.6)	869.0 (813.2 to 923.0)	21.6 (11.4 to 30.2)	-20.8 (-27.2 to -15.3)
Cirrhosis due to hepatitis C	547.4 (521.5 to 574.8)	884.9 (837.2 to 947.7)	60.5 (52.0 to 74.4)	1.6 (-3.6 to 10.5)
Cirrhosis due to alcohol use	726.7 (680.9 to 764.5)	801.5 (746.6 to 864.3)	10.0 (1.1 to 21.4)	-33.4 (-38.6 to -27.1)
Cirrhosis due to other causes	553.0 (519.0 to 583.7)	742.0 (693.9 to 789.5)	33.6 (24.4 to 46.3)	3.6 (-3.5 to 13.2)
Digestive diseases	-	-	-	-
Peptic ulcer disease	37,523.2 (36,320.0 to 38,335.2)	35,515.2 (33,962.5 to 36,907.1)	-5.4 (-7.9 to -2.5)	-45.8 (-47.1 to -44.1)
Peptic ulcer disease, symptomatic episodes	2,944.5 (2,881.0 to 3,014.1)	2,845.3 (2,758.2 to 2,944.3)	-3.6 (-7.2 to 0.9)	-44.3 (-46.4 to -41.8)
Mild anemia due to peptic ulcer disease	17,343.3 (16,100.7 to 17,728.7)	14,964.1 (13,491.2 to 15,424.0)	-13.5 (-17.6 to -9.7)	-50.4 (-52.6 to -48.4)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Moderate anemia due to peptic ulcer disease	16,001.7 (15,720.8 to 16,783.2)	16,693.0 (16,254.8 to 18,026.9)	3.9 (1.1 to 13.1)	-40.5 (-41.9 to -35.4)
Severe anemia due to peptic ulcer disease	1,233.8 (1,098.4 to 1,680.1)	1,012.7 (918.0 to 1,339.0)	-17.1 (-39.9 to 5.3)	-52.9 (-64.5 to -42.0)
Gastritis and duodenitis	58,113.1 (56,520.3 to 59,640.5)	64,799.9 (63,317.5 to 66,212.6)	11.4 (7.8 to 14.9)	-26.7 (-28.7 to -24.7)
Gastritis and duodenitis, symptomatic episodes	1,441.5 (1,424.3 to 1,459.9)	1,703.3 (1,685.9 to 1,722.8)	18.0 (16.1 to 19.9)	-23.2 (-24.3 to -22.0)
Mild anemia due to gastritis and duodenitis	21,376.4 (20,036.8 to 22,055.6)	24,701.4 (23,397.6 to 25,280.5)	15.1 (7.5 to 24.6)	-27.2 (-31.4 to -22.4)
Moderate anemia due to gastritis and duodenitis	32,020.3 (31,500.0 to 33,246.5)	35,567.0 (35,020.5 to 36,882.2)	11.1 (6.0 to 15.3)	-25.3 (-28.3 to -22.7)
Severe anemia due to gastritis and duodenitis	3,274.9 (3,059.5 to 3,634.8)	2,828.2 (2,579.1 to 3,204.0)	-13.3 (-24.3 to -0.9)	-39.1 (-46.1 to -31.0)
Appendicitis	532.6 (488.7 to 589.1)	621.7 (546.4 to 699.6)	17.0 (1.0 to 37.2)	-14.6 (-25.4 to 0.0)
Paralytic ileus and intestinal obstruction	76.1 (73.6 to 78.7)	114.6 (111.4 to 117.6)	50.4 (44.7 to 56.3)	4.6 (1.2 to 8.0)
Inguinal, femoral, and abdominal hernia	17,440.0 (16,843.0 to 18,128.0)	25,393.4 (24,084.5 to 26,361.0)	45.7 (36.0 to 53.1)	-10.5 (-16.1 to -5.9)
Inflammatory bowel disease	6,012.7 (5,912.3 to 6,109.3)	10,575.9 (10,410.1 to 10,737.6)	75.7 (72.7 to 78.6)	9.6 (7.7 to 11.4)
Ulcerative colitis	3,755.8 (3,678.0 to 3,838.6)	5,746.8 (5,622.8 to 5,879.0)	52.9 (49.5 to 56.2)	-5.3 (-7.4 to -3.1)
Crohn's disease	2,256.9 (2,205.8 to 2,310.7)	4,829.2 (4,722.4 to 4,940.1)	113.8 (108.4 to 119.2)	35.3 (32.0 to 38.7)
Vascular intestinal disorders	20.8 (19.7 to 22.1)	35.3 (33.2 to 38.6)	69.9 (58.7 to 81.6)	-0.7 (-7.6 to 6.5)
Gallbladder and biliary diseases	4,286.3 (4,176.7 to 4,403.2)	5,893.8 (5,737.7 to 6,119.0)	37.0 (32.6 to 43.9)	-18.2 (-20.8 to -14.3)
Pancreatitis	1,153.7 (1,142.7 to 1,166.0)	1,972.8 (1,951.7 to 1,997.4)	70.8 (68.4 to 73.3)	6.9 (5.5 to 8.4)
Other digestive diseases	-	-	-	-
Neurological disorders	-	-	-	-
Alzheimer disease and other dementias	28,139.2 (27,574.5 to 28,720.5)	53,050.5 (51,663.7 to 54,359.8)	88.5 (82.1 to 95.0)	-0.7 (-4.0 to 2.8)
Mild Alzheimer disease and other dementias	19,244.6 (18,294.5 to 20,182.9)	35,946.8 (34,081.8 to 37,847.7)	86.7 (80.7 to 93.3)	-0.4 (-3.8 to 2.9)
Moderate Alzheimer disease and other dementias	6,229.9 (5,508.6 to 6,991.2)	11,944.0 (10,562.0 to 13,404.7)	91.6 (84.8 to 99.1)	-1.0 (-4.6 to 2.8)
Severe Alzheimer disease and other dementias	2,664.6 (1,972.6 to 3,354.2)	5,159.7 (3,812.1 to 6,585.4)	93.7 (85.3 to 101.9)	-1.1 (-4.9 to 2.6)
Parkinson disease	3,240.3 (2,632.0 to 3,834.0)	5,866.3 (4,777.2 to 6,950.0)	80.9 (77.7 to 83.6)	2.1 (0.4 to 3.5)
Mild Parkinson disease	1,883.3 (1,484.2 to 2,279.7)	3,409.6 (2,677.2 to 4,144.4)	80.9 (77.7 to 83.6)	2.1 (0.4 to 3.5)
Moderate Parkinson disease	1,158.4 (886.3 to 1,421.4)	2,097.2 (1,605.0 to 2,583.1)	80.9 (77.7 to 83.6)	2.1 (0.4 to 3.5)
Severe Parkinson disease	198.6 (122.1 to 300.5)	359.5 (220.1 to 544.2)	80.9 (77.7 to 83.6)	2.1 (0.4 to 3.5)
Epilepsy	16,488.3 (15,473.0 to 17,486.9)	21,712.0 (20,160.3 to 23,108.4)	31.6 (20.2 to 43.8)	-2.5 (-10.8 to 6.7)
Seizure-free, treated epilepsy	1,904.2 (1,538.5 to 2,304.2)	2,505.0 (1,995.7 to 3,058.4)	31.6 (15.6 to 48.4)	-2.1 (-14.3 to 10.4)
Less severe epilepsy	8,242.6 (7,697.6 to 8,812.8)	8,952.7 (8,246.6 to 9,622.9)	8.6 (-2.4 to 20.1)	-18.7 (-27.1 to -10.3)
Severe epilepsy	6,341.6 (5,716.9 to 7,002.3)	10,254.3 (9,336.6 to 11,235.6)	61.0 (43.9 to 83.5)	17.5 (5.2 to 33.8)
Multiple sclerosis	1,055.2 (1,031.8 to 1,078.3)	2,293.6 (2,238.9 to 2,345.6)	117.2 (110.0 to 124.0)	35.4 (30.7 to 39.5)
Mild multiple sclerosis	564.2 (504.5 to 619.6)	1,226.3 (1,097.7 to 1,352.5)	117.2 (110.0 to 124.0)	35.4 (30.7 to 39.5)
Moderate multiple sclerosis	288.0 (241.9 to 335.4)	626.1 (521.4 to 731.6)	117.2 (110.0 to 124.0)	35.4 (30.7 to 39.5)
Severe multiple sclerosis	203.0 (153.8 to 253.9)	441.3 (330.7 to 554.0)	117.2 (110.0 to 124.0)	35.4 (30.7 to 39.5)
Migraine	581,025.2 (569,050.5 to 594,687.5)	848,366.5 (831,034.6 to 864,852.1)	46.1 (41.4 to 50.1)	0.3 (-2.8 to 3.0)
Asymptomatic migraine	532,296.2 (514,838.4 to 550,920.3)	777,215.7 (751,256.3 to 802,156.8)	46.1 (41.4 to 50.1)	0.3 (-2.8 to 3.0)
Symptomatic migraine	48,729.0 (36,093.7 to 63,450.8)	71,150.7 (52,308.2 to 92,043.8)	46.1 (41.4 to 50.1)	0.3 (-2.8 to 3.0)
Tension-type headache	1,072,423.0 (1,050,262.7 to 1,095,165.3)	1,561,446.5 (1,537,571.4 to 1,585,765.8)	45.5 (41.9 to 49.4)	-0.0 (-2.4 to 2.6)
Asymptomatic tension-type headache	1,026,989.1 (995,470.5 to 1,058,647.1)	1,495,286.5 (1,457,104.0 to 1,530,224.4)	45.5 (41.9 to 49.4)	-0.0 (-2.4 to 2.6)
Symptomatic tension-type headache	45,433.9 (26,818.3 to 67,734.4)	66,160.0 (38,950.5 to 99,061.1)	45.5 (41.9 to 49.4)	-0.0 (-2.4 to 2.6)
Medication overuse headache	28,482.5 (19,594.2 to 36,622.3)	62,899.3 (43,143.0 to 80,656.0)	120.2 (109.5 to 133.8)	42.8 (35.9 to 51.9)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Asymptomatic medication overuse headache	6,839.0 (4,705.8 to 8,969.4)	15,104.1 (10,343.1 to 19,809.3)	120.2 (109.5 to 133.8)	42.8 (35.9 to 51.9)
Symptomatic medication overuse headache	21,643.5 (14,876.3 to 27,922.1)	47,795.3 (32,332.6 to 61,950.9)	120.2 (109.5 to 133.8)	42.8 (35.9 to 51.9)
Other neurological disorders	7.9 (6.9 to 9.1)	11.6 (10.0 to 13.3)	45.9 (36.0 to 56.3)	0.9 (-5.6 to 7.9)
Other neurological disorders	-	-	-	-
Guillain-Barré syndrome due to other neurological disorders	7.9 (6.9 to 9.1)	11.6 (10.0 to 13.3)	45.9 (36.0 to 56.3)	0.9 (-5.6 to 7.9)
Mental and substance use disorders	-	-	-	-
Schizophrenia	15,503.0 (14,595.8 to 16,434.2)	23,600.6 (22,170.6 to 25,038.7)	52.1 (50.3 to 53.6)	-1.5 (-2.4 to -0.6)
Schizophrenia residual state	5,616.4 (2,628.9 to 9,534.6)	8,550.4 (3,976.6 to 14,472.8)	52.1 (50.3 to 53.6)	-1.5 (-2.4 to -0.6)
Schizophrenia acute state	9,886.7 (6,115.2 to 13,132.6)	15,050.3 (9,233.7 to 19,969.2)	52.1 (50.3 to 53.6)	-1.5 (-2.4 to -0.6)
Alcohol use disorders	57,161.2 (54,423.2 to 60,106.6)	76,896.6 (73,454.0 to 80,491.9)	34.4 (32.3 to 36.4)	-7.6 (-8.8 to -6.5)
Asymptomatic alcohol dependence	17,867.6 (14,831.5 to 21,069.4)	24,023.5 (19,991.0 to 28,231.4)	34.3 (32.2 to 36.4)	-7.8 (-9.0 to -6.7)
Very mild alcohol dependence	32,908.2 (29,330.3 to 36,526.5)	44,243.8 (39,544.1 to 48,889.5)	34.3 (32.2 to 36.4)	-7.8 (-9.0 to -6.7)
Mild alcohol dependence	2,104.8 (971.1 to 3,592.7)	2,829.7 (1,322.5 to 4,863.9)	34.3 (32.2 to 36.4)	-7.8 (-9.0 to -6.7)
Moderate alcohol dependence	1,806.9 (692.8 to 3,515.2)	2,429.8 (925.1 to 4,720.9)	34.3 (32.2 to 36.4)	-7.8 (-9.0 to -6.7)
Severe alcohol dependence	1,354.3 (263.4 to 2,990.7)	1,821.1 (357.1 to 4,038.9)	34.3 (32.2 to 36.4)	-7.8 (-9.0 to -6.7)
Asymptomatic fetal alcohol syndrome	120.4 (86.8 to 157.6)	167.2 (120.4 to 218.5)	38.7 (37.1 to 40.3)	6.4 (5.1 to 7.5)
Mild fetal alcohol syndrome	275.7 (209.1 to 346.8)	382.9 (290.8 to 481.3)	38.7 (37.1 to 40.3)	6.4 (5.1 to 7.5)
Moderate fetal alcohol syndrome	572.7 (472.4 to 664.4)	790.7 (651.6 to 917.9)	37.9 (35.8 to 40.2)	5.5 (3.9 to 7.2)
Severe fetal alcohol syndrome	150.6 (106.6 to 202.6)	207.9 (147.5 to 279.2)	37.9 (35.8 to 40.2)	5.5 (3.9 to 7.2)
Drug use disorders	-	-	-	-
Opioid use disorders	8,842.5 (7,084.6 to 11,274.2)	14,071.8 (11,103.0 to 18,139.2)	58.9 (54.4 to 62.8)	6.4 (3.0 to 9.5)
Asymptomatic opioid dependence	1,431.4 (975.3 to 2,041.7)	2,278.1 (1,532.8 to 3,270.3)	58.9 (54.4 to 62.8)	6.4 (3.0 to 9.5)
Mild opioid dependence	3,227.9 (1,919.0 to 4,665.1)	5,136.7 (3,048.8 to 7,429.6)	58.9 (54.4 to 62.8)	6.4 (3.0 to 9.5)
Severe opioid dependence	4,183.2 (2,904.6 to 5,845.1)	6,657.0 (4,559.1 to 9,381.7)	58.9 (54.4 to 62.8)	6.4 (3.0 to 9.5)
Cocaine use disorders	5,587.1 (5,483.3 to 5,694.6)	7,384.6 (7,216.3 to 7,549.3)	32.1 (28.4 to 35.8)	-5.9 (-8.5 to -3.3)
Asymptomatic cocaine dependence	2,797.4 (2,300.9 to 3,246.6)	3,697.5 (3,017.3 to 4,314.7)	32.1 (28.4 to 35.8)	-5.9 (-8.5 to -3.3)
Mild cocaine dependence	1,416.0 (1,053.4 to 1,853.6)	1,871.4 (1,384.8 to 2,418.2)	32.1 (28.4 to 35.8)	-5.9 (-8.5 to -3.3)
Severe cocaine dependence	1,373.8 (1,013.3 to 1,809.7)	1,815.6 (1,330.6 to 2,381.4)	32.1 (28.4 to 35.8)	-5.9 (-8.5 to -3.3)
Amphetamine use disorders	11,786.0 (11,431.5 to 12,120.0)	14,922.9 (14,490.6 to 15,370.7)	26.4 (21.2 to 31.3)	-4.1 (-8.0 to -0.6)
Asymptomatic amphetamine dependence	6,472.1 (5,319.4 to 7,505.4)	8,195.0 (6,725.3 to 9,545.2)	26.4 (21.2 to 31.3)	-4.1 (-8.0 to -0.6)
Mild amphetamine dependence	2,296.9 (1,534.1 to 3,156.3)	2,908.1 (1,949.0 to 3,965.9)	26.4 (21.2 to 31.3)	-4.1 (-8.0 to -0.6)
Severe amphetamine dependence	3,017.1 (2,147.9 to 4,011.5)	3,819.8 (2,694.3 to 5,082.5)	26.4 (21.2 to 31.3)	-4.1 (-8.0 to -0.6)
Cannabis use disorders	11,122.2 (10,133.0 to 12,266.4)	13,625.0 (12,429.2 to 14,938.0)	22.4 (20.6 to 24.0)	-6.5 (-7.6 to -5.5)
Asymptomatic cannabis dependence	6,437.7 (5,660.5 to 7,273.8)	7,886.4 (6,968.9 to 8,904.2)	22.4 (20.6 to 24.0)	-6.5 (-7.6 to -5.5)
Mild cannabis dependence	4,015.6 (3,402.5 to 4,664.0)	4,919.2 (4,184.2 to 5,697.5)	22.4 (20.6 to 24.0)	-6.5 (-7.6 to -5.5)
Severe cannabis dependence	668.9 (434.7 to 952.6)	819.4 (534.0 to 1,152.5)	22.4 (20.6 to 24.0)	-6.5 (-7.6 to -5.5)
Other drug use disorders	-	-	-	-
Depressive disorders	-	-	-	-
Major depressive disorder	164,642.9 (136,031.1 to 195,432.2)	253,314.2 (208,457.2 to 299,691.3)	53.4 (49.0 to 58.9)	4.2 (2.4 to 6.2)
Major depressive disorder, currently without symptoms	21,418.9 (15,123.3 to 28,793.3)	32,953.2 (23,122.9 to 44,456.3)	53.4 (49.0 to 58.9)	4.2 (2.4 to 6.2)
Mild major depressive disorder	98,103.8 (78,512.7 to 120,317.4)	150,935.8 (120,622.0 to 183,384.4)	53.4 (49.0 to 58.9)	4.2 (2.4 to 6.2)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Moderate major depressive disorder	28,533.2 (20,208.4 to 38,235.6)	43,901.1 (30,544.7 to 59,123.3)	53.4 (49.0 to 58.9)	4.2 (2.4 to 6.2)
Severe major depressive disorder	16,587.0 (6,700.6 to 30,611.2)	25,524.1 (10,156.8 to 47,404.5)	53.4 (49.0 to 58.9)	4.2 (2.4 to 6.2)
Dysthymia	66,141.3 (58,828.5 to 73,599.6)	102,409.6 (91,246.2 to 113,441.2)	54.6 (52.4 to 57.2)	-0.3 (-1.2 to 0.7)
Dysthymia, currently without symptoms	19,263.4 (15,257.5 to 23,377.0)	29,827.0 (23,609.4 to 36,142.9)	54.6 (52.4 to 57.2)	-0.3 (-1.2 to 0.7)
Symptomatic dysthymia	46,877.9 (40,627.8 to 53,175.2)	72,582.6 (62,961.7 to 82,268.3)	54.6 (52.4 to 57.2)	-0.3 (-1.2 to 0.7)
Bipolar disorder	32,657.1 (28,847.1 to 36,522.3)	48,778.4 (43,498.9 to 54,371.2)	49.1 (46.7 to 52.2)	0.9 (-0.4 to 2.4)
Bipolar disorder residual state	17,643.9 (12,509.1 to 22,612.0)	26,356.4 (18,718.3 to 33,792.7)	49.1 (46.7 to 52.2)	0.9 (-0.4 to 2.4)
Bipolar disorder depressive state	7,847.2 (3,899.2 to 12,413.1)	11,719.8 (5,886.5 to 18,493.1)	49.1 (46.7 to 52.2)	0.9 (-0.4 to 2.4)
Bipolar disorder manic state	7,166.0 (4,143.4 to 10,988.7)	10,702.2 (6,169.6 to 16,469.4)	49.1 (46.7 to 52.2)	0.9 (-0.4 to 2.4)
Anxiety disorders	186,837.3 (148,567.3 to 228,275.3)	265,610.1 (213,015.1 to 318,817.0)	42.4 (36.6 to 46.8)	-0.5 (-1.7 to 0.8)
Anxiety disorders, currently without symptoms	37,627.2 (29,029.5 to 47,489.3)	53,490.3 (41,461.0 to 66,404.4)	42.4 (36.6 to 46.8)	-0.5 (-1.7 to 0.8)
Mild anxiety disorders	92,595.6 (73,116.1 to 114,606.6)	131,635.3 (104,096.4 to 161,273.7)	42.4 (36.6 to 46.8)	-0.5 (-1.7 to 0.8)
Moderate anxiety disorders	35,834.6 (25,728.2 to 47,779.8)	50,943.3 (37,219.7 to 67,769.2)	42.4 (36.6 to 46.8)	-0.5 (-1.7 to 0.8)
Severe anxiety disorders	20,780.0 (12,527.7 to 31,470.9)	29,541.2 (17,881.0 to 44,261.6)	42.4 (36.6 to 46.8)	-0.5 (-1.7 to 0.8)
Eating disorders	-	-	-	-
Anorexia nervosa	1,520.1 (1,266.2 to 1,831.0)	2,063.6 (1,683.5 to 2,535.0)	35.4 (31.1 to 40.7)	5.5 (2.2 to 9.2)
Bulimia nervosa	5,223.9 (4,054.0 to 6,915.5)	6,537.9 (4,917.2 to 8,857.6)	24.8 (20.4 to 29.2)	-3.7 (-6.9 to -0.8)
Autistic spectrum disorders	-	-	-	-
Autism	16,175.4 (15,434.8 to 16,925.0)	21,716.7 (20,731.8 to 22,713.5)	34.1 (33.5 to 34.8)	0.3 (0.1 to 0.6)
Asperger syndrome	23,229.2 (21,869.4 to 24,521.8)	31,100.1 (29,251.7 to 32,905.1)	33.7 (32.9 to 34.5)	0.4 (0.3 to 0.5)
Attention-deficit/hyperactivity disorder	34,557.3 (31,958.4 to 37,160.9)	39,343.5 (36,574.2 to 42,093.6)	13.8 (12.8 to 14.9)	-0.5 (-1.3 to 0.5)
Attention-deficit/hyperactivity disorder, currently without symptoms	24,883.7 (22,366.3 to 27,524.1)	28,330.0 (25,496.7 to 31,226.3)	13.8 (12.8 to 14.9)	-0.5 (-1.3 to 0.5)
Symptomatic attention-deficit/hyperactivity disorder	9,673.6 (7,590.8 to 11,457.5)	11,013.5 (8,633.4 to 13,039.6)	13.8 (12.8 to 14.9)	-0.5 (-1.3 to 0.5)
Conduct disorder	43,950.9 (40,995.8 to 47,195.4)	51,109.7 (48,006.9 to 54,557.0)	16.3 (15.4 to 17.2)	2.2 (1.4 to 3.1)
Conduct disorder, currently without symptoms	21,110.5 (17,158.4 to 25,192.4)	24,549.1 (20,047.1 to 29,302.1)	16.3 (15.4 to 17.2)	2.2 (1.4 to 3.1)
Symptomatic conduct disorder	22,840.3 (18,478.0 to 27,023.2)	26,560.6 (21,518.1 to 31,347.6)	16.3 (15.4 to 17.2)	2.2 (1.4 to 3.1)
Idiopathic intellectual disability	76,995.5 (59,711.8 to 95,120.1)	94,672.8 (75,906.5 to 116,664.7)	22.6 (12.7 to 35.8)	-5.8 (-13.5 to 4.4)
Borderline idiopathic intellectual disability	26,790.0 (15,754.8 to 41,388.7)	32,935.4 (19,538.7 to 50,760.0)	22.6 (12.7 to 35.7)	-5.8 (-13.5 to 4.4)
Mild idiopathic intellectual disability	31,350.9 (25,268.0 to 36,721.0)	38,869.8 (32,406.5 to 44,381.7)	23.7 (13.6 to 37.0)	-4.8 (-12.6 to 5.9)
Moderate idiopathic intellectual disability	12,214.7 (9,582.4 to 14,986.8)	14,803.4 (11,844.2 to 17,812.5)	21.0 (11.1 to 33.2)	-7.4 (-15.1 to 2.0)
Severe idiopathic intellectual disability	4,895.3 (3,859.7 to 5,949.4)	5,945.8 (4,829.3 to 7,041.8)	21.3 (11.4 to 33.7)	-7.3 (-14.9 to 2.1)
Profound idiopathic intellectual disability	1,744.6 (585.4 to 3,169.7)	2,118.4 (713.8 to 3,820.8)	21.3 (11.4 to 34.2)	-7.3 (-14.9 to 2.5)
Other mental and substance use disorders	81,356.0 (76,311.2 to 86,284.4)	124,042.9 (116,741.4 to 131,001.8)	52.3 (50.9 to 53.8)	0.2 (0.1 to 0.3)
Other mental disorders, currently without symptoms	11,163.7 (8,640.1 to 13,885.6)	17,020.7 (13,196.3 to 21,138.8)	52.3 (50.9 to 53.8)	0.2 (0.1 to 0.3)
Mild other mental disorders	51,350.0 (46,802.2 to 55,812.3)	78,292.8 (71,508.6 to 84,945.7)	52.3 (50.9 to 53.8)	0.2 (0.1 to 0.3)
Moderate other mental disorders	12,449.2 (9,988.1 to 15,104.9)	18,981.8 (15,259.9 to 23,064.5)	52.3 (50.9 to 53.8)	0.2 (0.1 to 0.3)
Severe other mental disorders	6,393.1 (3,875.3 to 9,386.9)	9,747.7 (5,877.0 to 14,279.0)	52.3 (50.9 to 53.8)	0.2 (0.1 to 0.3)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-
Diabetes mellitus	175,850.7 (159,923.5 to 187,156.3)	409,967.0 (381,806.3 to 432,038.4)	132.9 (123.7 to 142.4)	44.8 (38.5 to 51.3)
Uncomplicated diabetes mellitus	123,339.7 (109,234.1 to 134,162.4)	284,620.6 (259,839.7 to 304,103.9)	130.6 (119.6 to 142.1)	47.7 (39.5 to 56.8)
Diabetic neuropathy	37,652.1 (35,663.5 to 39,155.6)	90,628.7 (86,382.3 to 95,206.1)	140.8 (127.7 to 151.2)	42.0 (34.2 to 48.7)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Diabetic foot due to neuropathy	9,818.3 (9,429.4 to 10,336.7)	24,610.4 (23,390.1 to 25,843.6)	151.1 (131.7 to 168.8)	42.0 (31.2 to 51.7)
Diabetic neuropathy and amputation with treatment	1,056.9 (876.3 to 1,216.1)	2,712.8 (2,233.5 to 3,156.4)	156.4 (140.2 to 172.9)	47.6 (38.0 to 57.9)
Diabetic neuropathy and amputation without treatment	1,355.3 (1,184.7 to 1,541.7)	3,578.2 (3,127.3 to 4,068.8)	164.3 (142.3 to 185.5)	53.3 (40.4 to 65.4)
Moderate vision impairment due to diabetes mellitus	771.3 (335.0 to 1,247.8)	1,098.3 (467.9 to 1,742.8)	42.2 (32.5 to 50.8)	-20.8 (-25.6 to -15.1)
Severe vision impairment due to diabetes mellitus	106.5 (45.9 to 177.3)	163.6 (72.4 to 265.3)	54.2 (41.0 to 65.3)	-14.5 (-21.2 to -6.7)
Blindness due to diabetes mellitus	1,750.6 (1,140.4 to 2,320.7)	2,554.4 (1,680.4 to 3,345.6)	45.6 (37.0 to 57.0)	-17.4 (-22.7 to -11.5)
Acute glomerulonephritis	39.0 (36.3 to 41.8)	37.7 (35.1 to 40.5)	-3.4 (-6.0 to -1.2)	-22.2 (-24.2 to -20.6)
Chronic kidney disease	-	-	-	-
Chronic kidney disease due to diabetes mellitus	49,339.3 (38,328.3 to 65,278.0)	88,710.9 (71,150.1 to 111,417.2)	82.4 (58.6 to 96.8)	11.9 (-3.6 to 21.2)
Stage III chronic kidney disease without anemia due to diabetes mellitus	40,193.1 (29,164.1 to 56,032.9)	71,742.6 (54,452.3 to 94,047.0)	81.7 (54.6 to 99.0)	11.2 (-6.5 to 22.5)
Stage III chronic kidney disease and mild anemia due to diabetes mellitus	3,451.8 (3,373.5 to 3,522.5)	6,582.2 (6,483.5 to 6,669.2)	90.4 (86.6 to 95.4)	17.4 (15.2 to 20.4)
Stage III chronic kidney disease and moderate anemia due to diabetes mellitus	835.8 (787.2 to 885.6)	1,475.3 (1,419.3 to 1,533.7)	76.5 (64.4 to 88.0)	14.0 (5.4 to 21.7)
Stage III chronic kidney disease and severe anemia due to diabetes mellitus	330.2 (303.0 to 357.1)	413.3 (376.8 to 460.0)	25.2 (12.3 to 38.9)	-12.7 (-22.6 to -3.0)
Stage IV chronic kidney disease without anemia due to diabetes mellitus	578.5 (449.9 to 752.6)	1,215.8 (908.2 to 1,489.9)	111.7 (54.8 to 179.6)	26.2 (-7.5 to 64.0)
Stage IV chronic kidney disease and mild anemia due to diabetes mellitus	768.5 (694.5 to 866.6)	1,440.4 (1,311.7 to 1,589.1)	87.9 (62.5 to 114.1)	11.2 (-3.7 to 27.1)
Stage IV chronic kidney disease and moderate anemia due to diabetes mellitus	1,043.6 (939.3 to 1,138.8)	2,069.7 (1,915.2 to 2,230.5)	97.5 (76.4 to 124.2)	18.0 (5.5 to 33.8)
Stage IV chronic kidney disease and severe anemia due to diabetes mellitus	132.8 (114.7 to 153.7)	132.7 (115.6 to 150.4)	0.0 (-16.2 to 20.2)	-28.7 (-41.8 to -13.8)
Stage V chronic kidney disease untreated due to diabetes mellitus	1,688.9 (1,348.4 to 2,082.7)	2,858.4 (2,150.5 to 3,562.9)	70.3 (49.2 to 84.2)	3.0 (-8.5 to 11.6)
End-stage renal disease after transplant due to diabetes mellitus	50.1 (40.6 to 62.0)	108.0 (90.5 to 123.1)	116.5 (86.4 to 144.1)	32.3 (12.7 to 49.2)
End-stage renal disease on dialysis due to diabetes mellitus	265.8 (229.8 to 308.1)	672.3 (570.0 to 780.6)	151.7 (132.4 to 176.5)	50.8 (39.1 to 66.5)
Chronic kidney disease due to hypertension	79,945.0 (61,412.1 to 104,028.9)	101,253.4 (81,410.4 to 129,993.0)	26.8 (18.3 to 34.9)	-10.7 (-17.6 to -5.3)
Stage III chronic kidney disease without anemia due to hypertension	65,390.8 (47,188.2 to 89,905.2)	82,333.2 (62,702.0 to 111,347.8)	26.2 (16.2 to 35.9)	-9.1 (-17.5 to -1.8)
Stage III chronic kidney disease and mild anemia due to hypertension	4,597.3 (4,462.8 to 4,755.4)	6,375.2 (6,161.3 to 6,604.7)	38.5 (32.7 to 45.4)	-12.4 (-15.7 to -8.4)
Stage III chronic kidney disease and moderate anemia due to hypertension	2,949.2 (2,795.4 to 3,089.2)	3,548.7 (3,333.8 to 3,773.7)	20.3 (10.7 to 29.5)	-16.8 (-23.2 to -11.0)
Stage III chronic kidney disease and severe anemia due to hypertension	254.8 (221.0 to 290.3)	213.8 (164.6 to 260.4)	-15.9 (-35.1 to 0.9)	-37.4 (-50.9 to -24.8)
Stage IV chronic kidney disease without anemia due to hypertension	733.8 (529.9 to 968.4)	1,202.7 (905.4 to 1,558.5)	63.7 (14.3 to 125.2)	5.8 (-24.5 to 43.8)
Stage IV chronic kidney disease and mild anemia due to hypertension	1,210.3 (1,116.9 to 1,311.2)	1,607.0 (1,429.7 to 1,776.7)	32.8 (15.8 to 49.6)	-19.2 (-29.0 to -8.9)
Stage IV chronic kidney disease and moderate anemia due to hypertension	1,608.0 (1,511.1 to 1,718.7)	2,185.6 (2,042.6 to 2,381.7)	35.5 (22.9 to 51.1)	-18.1 (-25.5 to -8.5)
Stage IV chronic kidney disease and severe anemia due to hypertension	218.5 (188.7 to 256.8)	204.6 (174.9 to 234.2)	-6.0 (-23.6 to 12.8)	-29.5 (-43.6 to -14.4)
Stage V chronic kidney disease untreated due to hypertension	2,575.8 (2,114.6 to 3,232.7)	3,042.7 (2,449.4 to 3,817.0)	17.6 (6.7 to 31.8)	-27.1 (-34.3 to -18.9)
End-stage renal disease after transplant due to hypertension	67.2 (49.0 to 88.6)	69.7 (59.7 to 79.0)	4.6 (-12.4 to 24.6)	-33.7 (-45.2 to -20.6)
End-stage renal disease on dialysis due to hypertension	339.3 (292.5 to 391.0)	470.2 (395.4 to 566.6)	38.9 (24.9 to 51.4)	-16.3 (-25.3 to -8.9)
Chronic kidney disease due to glomerulonephritis	82,919.6 (65,066.5 to 102,663.4)	108,860.9 (88,330.3 to 135,481.9)	32.7 (17.3 to 41.3)	-13.5 (-25.6 to -6.6)
Stage III chronic kidney disease without anemia due to glomerulonephritis	68,580.3 (50,857.9 to 88,086.1)	90,050.7 (69,821.7 to 116,387.3)	32.9 (15.4 to 44.0)	-15.3 (-28.5 to -7.3)
Stage III chronic kidney disease and mild anemia due to glomerulonephritis	4,101.8 (3,944.8 to 4,292.9)	5,643.4 (5,405.7 to 5,939.4)	37.4 (28.7 to 46.4)	-2.0 (-6.9 to 4.0)
Stage III chronic kidney disease and moderate anemia due to glomerulonephritis	4,244.9 (3,989.0 to 4,447.6)	4,663.8 (4,342.6 to 4,925.4)	10.0 (1.7 to 18.7)	-9.4 (-15.9 to -2.8)
Stage III chronic kidney disease and severe anemia due to glomerulonephritis	349.2 (309.7 to 391.9)	370.3 (313.4 to 439.4)	5.3 (-8.1 to 21.7)	-12.2 (-23.2 to 2.1)
Stage IV chronic kidney disease without anemia due to glomerulonephritis	875.1 (750.8 to 1,040.4)	1,551.3 (1,238.9 to 1,886.8)	78.7 (34.4 to 119.2)	8.7 (-16.7 to 33.9)
Stage IV chronic kidney disease and mild anemia due to glomerulonephritis	885.0 (807.6 to 965.7)	1,280.2 (1,072.6 to 1,438.4)	45.6 (16.7 to 69.7)	-4.3 (-22.5 to 11.2)
Stage IV chronic kidney disease and moderate anemia due to glomerulonephritis	1,294.5 (1,210.8 to 1,387.9)	1,893.0 (1,722.2 to 2,076.8)	45.7 (29.9 to 63.8)	-2.2 (-12.1 to 9.4)
Stage IV chronic kidney disease and severe anemia due to glomerulonephritis	288.4 (246.8 to 323.8)	208.0 (165.8 to 265.1)	-28.6 (-45.0 to -2.4)	-44.3 (-57.2 to -22.8)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Stage V chronic kidney disease untreated due to glomerulonephritis	2,014.5 (1,657.7 to 2,429.0)	2,810.2 (2,302.9 to 3,393.4)	39.3 (27.7 to 52.4)	-4.9 (-12.0 to 2.6)
End-stage renal disease after transplant due to glomerulonephritis	42.7 (35.6 to 52.2)	80.0 (67.4 to 93.1)	87.7 (69.7 to 107.0)	24.3 (12.0 to 37.6)
End-stage renal disease on dialysis due to glomerulonephritis	243.3 (207.5 to 286.8)	309.9 (268.4 to 354.8)	26.6 (16.3 to 43.5)	-21.4 (-28.3 to -10.4)
Chronic kidney disease due to other causes	112,460.5 (89,217.8 to 141,834.6)	173,090.7 (142,395.9 to 213,010.4)	53.9 (43.5 to 63.6)	3.1 (-5.9 to 10.1)
Stage III chronic kidney disease without anemia due to other causes	91,143.6 (67,855.6 to 120,529.0)	138,667.7 (108,472.1 to 178,746.8)	52.2 (40.6 to 63.4)	1.7 (-8.8 to 10.0)
Stage III chronic kidney disease and mild anemia due to other causes	6,588.4 (6,327.3 to 6,851.2)	10,771.5 (10,487.1 to 11,129.5)	63.3 (56.8 to 70.3)	10.4 (6.7 to 14.7)
Stage III chronic kidney disease and moderate anemia due to other causes	5,627.3 (5,257.7 to 5,928.1)	8,265.5 (7,875.2 to 8,592.9)	46.7 (39.2 to 55.2)	11.5 (5.8 to 17.1)
Stage III chronic kidney disease and severe anemia due to other causes	393.2 (339.8 to 446.9)	489.2 (424.6 to 569.5)	23.9 (7.6 to 45.0)	-1.1 (-13.3 to 15.0)
Stage IV chronic kidney disease without anemia due to other causes	967.2 (795.4 to 1,228.6)	1,948.5 (1,599.2 to 2,349.4)	102.9 (85.4 to 157.5)	26.0 (-3.1 to 59.5)
Stage IV chronic kidney disease and mild anemia due to other causes	1,431.6 (1,311.5 to 1,574.7)	2,375.6 (2,145.1 to 2,598.7)	66.8 (43.8 to 88.3)	0.9 (-12.2 to 13.6)
Stage IV chronic kidney disease and moderate anemia due to other causes	2,082.9 (1,943.7 to 2,219.5)	3,866.9 (3,613.9 to 4,096.7)	85.7 (68.6 to 102.7)	15.9 (5.4 to 26.6)
Stage IV chronic kidney disease and severe anemia due to other causes	314.0 (271.8 to 354.5)	222.8 (188.1 to 270.4)	-29.8 (-42.2 to -10.4)	-43.4 (-53.5 to -29.3)
Stage V chronic kidney disease untreated due to other causes	3,343.6 (2,796.3 to 4,066.7)	5,377.4 (4,408.9 to 6,552.0)	60.5 (51.4 to 71.8)	2.7 (-4.3 to 11.2)
End-stage renal disease after transplant due to other causes	87.4 (67.5 to 110.8)	159.1 (135.8 to 183.1)	83.4 (54.6 to 111.1)	17.3 (-2.2 to 36.7)
End-stage renal disease on dialysis due to other causes	481.1 (404.9 to 579.4)	946.5 (803.1 to 1,146.5)	96.4 (85.3 to 107.6)	18.5 (11.7 to 25.8)
Urinary diseases and male infertility	-	-	-	-
Interstitial nephritis and urinary tract infections	1,045.5 (1,030.8 to 1,059.6)	1,753.7 (1,730.2 to 1,775.3)	67.5 (64.6 to 70.9)	16.2 (14.3 to 18.4)
Mild interstitial nephritis and urinary tract infections	367.5 (282.6 to 447.3)	616.5 (473.9 to 748.0)	67.5 (64.6 to 70.9)	16.2 (14.3 to 18.4)
Moderate interstitial nephritis and urinary tract infections	678.0 (597.6 to 765.6)	1,137.3 (1,002.5 to 1,281.4)	67.5 (64.6 to 70.9)	16.2 (14.3 to 18.4)
Urolithiasis	39,857.8 (31,797.3 to 48,384.4)	80,622.5 (61,562.7 to 103,069.9)	101.9 (89.6 to 113.3)	20.0 (12.9 to 26.1)
Acute urolithiasis	1,260.1 (1,139.6 to 1,393.0)	1,842.8 (1,646.6 to 2,058.3)	46.0 (42.5 to 49.8)	-7.3 (-9.2 to -5.1)
Chronic urolithiasis	38,597.7 (30,507.4 to 47,158.2)	78,779.7 (59,732.3 to 101,142.1)	103.8 (91.2 to 115.2)	20.8 (13.5 to 26.9)
Benign prostatic hyperplasia	55,229.5 (54,318.2 to 56,058.3)	99,148.4 (97,356.1 to 100,911.6)	79.3 (75.4 to 83.7)	3.0 (0.8 to 5.6)
Asymptomatic benign prostatic hyperplasia	22,895.0 (21,754.8 to 24,145.4)	41,100.9 (38,912.7 to 43,125.9)	79.3 (75.4 to 83.7)	3.0 (0.8 to 5.6)
Symptomatic benign prostatic hyperplasia	32,334.5 (31,071.1 to 33,621.9)	58,047.5 (55,736.1 to 60,469.0)	79.3 (75.4 to 83.7)	3.0 (0.8 to 5.6)
Male infertility due to other causes	27,259.8 (25,929.0 to 28,669.3)	39,276.2 (36,950.6 to 41,618.7)	44.0 (33.3 to 55.3)	2.9 (-4.8 to 11.0)
Primary male infertility	17,909.9 (16,629.6 to 19,348.9)	25,440.0 (23,194.0 to 27,559.5)	42.0 (27.3 to 59.5)	2.9 (-7.5 to 15.5)
Secondary male infertility	9,350.0 (8,799.4 to 9,887.8)	13,836.2 (13,075.7 to 14,599.6)	47.7 (37.1 to 59.8)	2.4 (-4.9 to 10.7)
Other urinary diseases	-	-	-	-
Gynecological diseases	-	-	-	-
Uterine fibroids	105,090.0 (97,076.2 to 112,366.8)	171,005.4 (158,155.9 to 182,513.5)	62.5 (61.2 to 63.8)	-1.8 (-2.3 to -1.2)
Asymptomatic uterine fibroids	33,026.1 (27,762.4 to 38,282.8)	53,740.4 (45,122.0 to 62,202.9)	62.5 (61.2 to 63.8)	-1.8 (-2.3 to -1.2)
Mild abdominal pain due to uterine fibroids, without anemia	44,082.7 (38,475.0 to 50,182.9)	80,490.9 (70,910.6 to 90,566.5)	82.3 (79.6 to 85.1)	5.8 (4.4 to 7.2)
Mild abdominal pain due to uterine fibroids, with mild anemia	14,272.4 (13,382.8 to 15,001.2)	21,288.5 (20,218.6 to 22,306.4)	48.5 (45.9 to 54.8)	-4.0 (-5.7 to 0.2)
Mild abdominal pain due to uterine fibroids, with moderate anemia	12,654.5 (11,795.9 to 13,515.9)	14,521.8 (13,558.5 to 15,436.5)	14.8 (9.8 to 18.7)	-25.5 (-29.0 to -23.1)
Mild abdominal pain due to uterine fibroids, with severe anemia	1,054.3 (977.8 to 1,128.3)	963.7 (819.8 to 1,038.1)	-8.3 (-21.8 to -1.9)	-41.1 (-49.7 to -36.8)
Polycystic ovarian syndrome	80,815.4 (79,285.9 to 82,411.6)	122,310.6 (119,572.7 to 124,929.3)	51.1 (46.6 to 55.6)	2.3 (-0.6 to 5.2)
Asymptomatic polycystic ovarian syndrome	12,928.4 (10,104.0 to 16,097.5)	19,483.3 (15,224.9 to 24,242.5)	50.5 (44.1 to 56.8)	1.6 (-1.6 to 4.6)
Hirsutism due to polycystic ovarian syndrome	53,360.8 (50,176.1 to 56,425.4)	80,483.8 (75,481.5 to 85,006.8)	50.7 (45.8 to 55.4)	1.6 (-1.4 to 4.5)
Hirsutism and primary infertility due to polycystic ovarian syndrome	5,108.4 (4,566.5 to 5,701.3)	7,900.3 (7,048.6 to 8,812.2)	54.4 (46.9 to 62.1)	9.2 (4.1 to 14.8)
Primary infertility due to polycystic ovarian syndrome	1,189.6 (622.3 to 1,870.2)	1,838.9 (995.8 to 2,868.1)	54.6 (44.0 to 66.7)	9.3 (3.7 to 15.1)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Hirsutism and secondary infertility due to polycystic ovarian syndrome	1,583.9 (827.3 to 2,553.0)	2,426.5 (1,264.4 to 3,938.9)	52.8 (43.7 to 63.6)	3.6 (-0.2 to 8.7)
Secondary infertility due to polycystic ovarian syndrome	6,644.4 (5,881.4 to 7,455.1)	10,177.9 (8,989.5 to 11,445.3)	53.0 (47.8 to 58.5)	3.6 (0.2 to 7.5)
Female infertility due to other causes	21,937.8 (19,637.7 to 24,037.5)	34,678.6 (31,103.9 to 38,009.3)	58.3 (44.8 to 72.4)	10.7 (1.7 to 20.3)
Idiopathic primary female infertility	5,067.7 (4,261.9 to 6,027.2)	7,213.9 (5,767.0 to 8,541.4)	43.0 (12.3 to 75.3)	12.9 (-11.6 to 38.1)
Idiopathic secondary female infertility	16,870.1 (14,874.6 to 18,585.4)	27,464.7 (24,634.3 to 30,139.4)	62.4 (48.4 to 79.6)	9.8 (0.7 to 21.2)
Endometriosis	9,899.0 (9,601.4 to 10,214.1)	14,661.2 (14,230.8 to 15,094.4)	47.9 (41.9 to 53.5)	-1.6 (-5.6 to 2.1)
Asymptomatic endometriosis	2,873.9 (2,082.2 to 3,682.8)	4,253.7 (3,079.0 to 5,484.3)	47.8 (41.7 to 53.3)	-1.8 (-5.7 to 1.9)
Mild abdominal pain due to endometriosis	540.7 (356.9 to 755.7)	800.3 (526.7 to 1,120.4)	47.8 (41.7 to 53.3)	-1.8 (-5.7 to 1.9)
Moderate abdominal pain due to endometriosis	4,889.7 (3,894.2 to 5,769.0)	7,236.3 (5,743.8 to 8,598.9)	47.8 (41.7 to 53.3)	-1.8 (-5.7 to 1.9)
Severe endometriosis	1,105.1 (764.3 to 1,485.2)	1,635.3 (1,129.1 to 2,175.9)	47.8 (41.7 to 53.3)	-1.8 (-5.7 to 1.9)
Primary infertility due to endometriosis	63.4 (41.9 to 90.9)	95.9 (63.5 to 138.1)	51.0 (41.8 to 61.7)	5.2 (-1.2 to 12.6)
Mild abdominal pain and primary infertility due to endometriosis	12.1 (7.6 to 17.4)	18.2 (11.3 to 26.2)	51.0 (41.8 to 61.7)	5.2 (-1.2 to 12.6)
Moderate abdominal pain and primary infertility due to endometriosis	109.0 (73.2 to 151.3)	164.9 (110.6 to 228.1)	51.0 (41.8 to 61.7)	5.2 (-1.2 to 12.6)
Severe abdominal pain and primary infertility due to endometriosis	24.4 (16.0 to 34.8)	36.9 (24.1 to 53.1)	51.0 (41.8 to 61.7)	5.2 (-1.2 to 12.6)
Secondary infertility due to endometriosis	85.2 (56.7 to 120.3)	127.4 (85.2 to 179.0)	49.3 (42.4 to 56.5)	-0.5 (-5.1 to 4.5)
Mild abdominal pain and secondary infertility due to endometriosis	16.2 (10.2 to 23.3)	24.2 (15.3 to 34.7)	49.3 (42.4 to 56.5)	-0.5 (-5.1 to 4.5)
Moderate abdominal pain and secondary infertility due to endometriosis	146.5 (98.8 to 202.7)	219.0 (148.1 to 301.8)	49.3 (42.4 to 56.5)	-0.5 (-5.1 to 4.5)
Severe abdominal pain and secondary infertility due to endometriosis	32.8 (21.4 to 45.9)	49.0 (32.4 to 69.3)	49.3 (42.4 to 56.5)	-0.5 (-5.1 to 4.5)
Genital prolapse	218,568.9 (214,601.1 to 222,616.2)	343,707.8 (336,958.8 to 350,327.4)	57.0 (53.0 to 61.5)	-0.9 (-3.3 to 1.7)
Asymptomatic genital prolapse	176,481.6 (158,761.1 to 191,001.6)	277,528.3 (249,622.7 to 301,180.7)	57.0 (53.0 to 61.5)	-0.9 (-3.3 to 1.7)
Abdominal pain due to genital prolapse	15,737.7 (4,017.4 to 32,704.3)	24,742.6 (6,281.4 to 51,494.0)	57.0 (53.0 to 61.5)	-0.9 (-3.3 to 1.7)
Stress incontinence due to genital prolapse	24,178.3 (14,909.2 to 34,945.8)	38,020.5 (23,494.6 to 55,537.8)	57.0 (53.0 to 61.5)	-0.9 (-3.3 to 1.7)
Abdominal pain and stress incontinence due to genital prolapse	2,171.3 (481.4 to 5,024.0)	3,416.4 (753.1 to 7,881.8)	57.0 (53.0 to 61.5)	-0.9 (-3.3 to 1.7)
Premenstrual syndrome	196,514.0 (185,655.6 to 207,308.9)	302,731.7 (284,373.1 to 321,829.6)	53.8 (40.3 to 67.9)	9.2 (-0.1 to 19.4)
Asymptomatic premenstrual syndrome	174,715.5 (164,239.7 to 185,275.3)	269,148.3 (251,882.0 to 287,500.8)	53.8 (40.3 to 67.9)	9.2 (-0.1 to 19.4)
Abdominal pain and depression due to premenstrual syndrome	7,885.2 (5,764.2 to 10,131.3)	12,147.8 (8,866.8 to 15,724.1)	53.8 (40.3 to 67.9)	9.2 (-0.1 to 19.4)
Abdominal pain due to premenstrual syndrome	11,166.7 (8,058.6 to 14,850.8)	17,203.0 (12,399.1 to 22,971.0)	53.8 (40.3 to 67.9)	9.2 (-0.1 to 19.4)
Depression due to premenstrual syndrome	2,746.6 (840.8 to 5,678.6)	4,232.6 (1,291.1 to 8,719.6)	53.8 (40.3 to 67.9)	9.2 (-0.1 to 19.4)
Other gynecological diseases	17,916.7 (16,719.9 to 19,057.9)	20,758.0 (19,699.4 to 21,792.8)	15.7 (6.9 to 26.4)	-19.3 (-25.6 to -11.8)
Asymptomatic other gynecological disorders	812.6 (730.5 to 897.2)	1,165.3 (1,048.7 to 1,301.3)	43.2 (33.8 to 52.4)	-8.1 (-14.0 to -2.1)
Mild other gynecological disorders	1,088.1 (964.3 to 1,203.1)	1,560.4 (1,391.8 to 1,735.3)	43.2 (33.8 to 52.4)	-8.1 (-14.0 to -2.1)
Moderate other gynecological disorders	311.3 (201.1 to 439.4)	446.3 (289.0 to 629.1)	43.2 (33.8 to 52.4)	-8.1 (-14.0 to -2.1)
Severe other gynecological disorders	156.9 (110.7 to 211.2)	225.0 (159.9 to 304.1)	43.2 (33.8 to 52.4)	-8.1 (-14.0 to -2.1)
Mild anemia due to other gynecological diseases	7,882.4 (7,417.4 to 9,078.5)	9,827.1 (9,281.2 to 10,877.3)	25.3 (4.4 to 39.1)	-11.8 (-27.0 to -2.1)
Moderate anemia due to other gynecological diseases	7,069.3 (5,762.7 to 7,615.1)	7,101.9 (6,083.8 to 7,626.2)	-0.3 (-14.7 to 26.1)	-29.1 (-39.5 to -9.8)
Severe anemia due to other gynecological diseases	596.2 (508.3 to 626.2)	432.1 (326.1 to 472.4)	-26.9 (-45.9 to -12.3)	-48.3 (-61.7 to -39.1)
Hemoglobinopathies and hemolytic anemias	-	-	-	-
Thalassemias	683.0 (606.3 to 769.4)	766.7 (691.8 to 849.8)	11.6 (8.5 to 19.1)	-2.5 (-5.1 to 3.8)
Beta-thalassemia major, with mild anemia	14.6 (11.5 to 17.4)	16.8 (13.4 to 20.1)	14.8 (-10.2 to 52.6)	-5.0 (-25.6 to 25.9)
Beta-thalassemia major, with moderate anemia	181.2 (154.2 to 203.4)	207.9 (177.1 to 232.8)	14.9 (0.9 to 30.6)	4.8 (-8.0 to 19.0)
Beta-thalassemia major, with severe anemia	74.0 (59.6 to 88.0)	74.1 (58.8 to 91.4)	-0.3 (-23.8 to 27.9)	-12.1 (-32.5 to 12.1)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Beta-thalassemia major, severe infection with severe anemia	3.1 (1.0 to 6.3)	3.5 (1.2 to 7.0)	12.8 (6.5 to 18.3)	0.9 (-4.8 to 5.7)
Hemoglobin E/beta-thalassemia, with mild anemia	12.8 (8.2 to 15.9)	12.0 (7.4 to 15.7)	-6.5 (-45.3 to 64.3)	-25.8 (-56.3 to 28.9)
Hemoglobin E/beta-thalassemia, with moderate anemia	133.3 (117.1 to 146.1)	142.3 (120.5 to 159.3)	7.1 (-9.3 to 21.8)	-4.6 (-19.5 to 8.4)
Hemoglobin E/beta-thalassemia, with severe anemia	40.1 (34.0 to 49.9)	44.5 (35.0 to 58.6)	9.6 (-16.3 to 51.8)	-5.6 (-27.6 to 29.8)
Hemoglobin E/beta-thalassemia, severe infection with severe anemia	2.0 (0.7 to 3.9)	2.2 (0.8 to 4.3)	12.4 (8.4 to 16.8)	-2.1 (-5.4 to 1.6)
Hemoglobin H disease, with mild anemia	3.3 (1.7 to 4.8)	2.5 (1.3 to 3.4)	-26.2 (-62.7 to 52.8)	-38.6 (-68.7 to 24.8)
Hemoglobin H disease, with moderate anemia	33.5 (29.1 to 37.5)	25.2 (19.7 to 29.4)	-24.0 (-40.5 to -11.1)	-31.0 (-46.0 to -19.1)
Hemoglobin H disease, with severe anemia	11.0 (7.6 to 14.8)	12.8 (9.1 to 17.6)	15.0 (-13.3 to 60.6)	-0.2 (-24.6 to 40.1)
Hemoglobin H disease, severe infection with severe anemia	0.5 (0.2 to 1.1)	0.5 (0.2 to 1.0)	-8.1 (-12.9 to -2.2)	-18.5 (-22.8 to -13.6)
Mild heart failure due to thalassemias	23.9 (14.4 to 35.0)	29.3 (18.4 to 42.6)	20.7 (0.4 to 66.4)	-2.1 (-18.0 to 31.8)
Moderate heart failure due to thalassemias	19.4 (11.7 to 28.3)	23.8 (15.4 to 33.3)	20.7 (0.4 to 66.4)	-2.1 (-18.0 to 31.8)
Severe heart failure due to thalassemias	52.8 (34.7 to 71.2)	64.6 (46.2 to 81.4)	20.7 (0.4 to 66.4)	-2.1 (-18.0 to 31.8)
Hemoglobin H disease, without anemia	7.2 (2.8 to 13.8)	10.1 (4.9 to 17.7)	44.3 (-28.0 to 186.2)	19.7 (-37.3 to 134.5)
Beta-thalassemia major, without anemia	49.4 (8.8 to 110.1)	60.3 (19.9 to 112.9)	23.5 (-14.9 to 147.5)	7.5 (-25.5 to 101.4)
Hemoglobin E/Beta-thalassemia, without anemia	21.1 (6.4 to 41.2)	34.5 (16.9 to 58.8)	64.5 (-12.4 to 276.8)	35.3 (-25.7 to 196.9)
Thalassemia trait	151,186.5 (138,147.1 to 169,165.6)	207,561.8 (192,411.3 to 228,437.6)	37.3 (34.7 to 39.6)	2.7 (0.5 to 4.5)
Asymptomatic B-thalassemia trait	52,482.9 (39,757.2 to 69,997.3)	71,598.7 (56,811.6 to 91,872.3)	36.5 (29.5 to 45.6)	-1.1 (-5.8 to 5.5)
Mild anemia due to B-thalassemia trait	25,655.3 (24,567.9 to 26,368.9)	35,161.7 (33,380.2 to 36,206.5)	36.9 (29.2 to 44.9)	0.9 (-4.9 to 6.7)
Moderate anemia due to B-thalassemia trait	39,962.4 (39,334.8 to 41,002.1)	55,935.2 (54,902.9 to 57,927.3)	39.7 (35.9 to 45.2)	8.3 (5.3 to 12.7)
Severe anemia due to B-thalassemia trait	3,752.0 (3,561.5 to 4,012.4)	4,306.4 (4,144.2 to 4,466.1)	14.9 (7.2 to 23.0)	-5.7 (-12.6 to 1.0)
Asymptomatic hemoglobin E trait	23,656.7 (22,028.8 to 25,276.3)	31,808.9 (29,538.8 to 33,963.5)	34.2 (31.2 to 37.9)	0.6 (-1.7 to 3.4)
Mild anemia due to hemoglobin E trait	2,659.6 (2,531.7 to 2,863.0)	4,593.6 (4,472.0 to 4,842.1)	73.1 (58.4 to 83.7)	26.6 (16.6 to 33.8)
Moderate anemia due to hemoglobin E trait	2,839.6 (2,630.4 to 2,953.8)	3,948.8 (3,682.0 to 4,067.6)	38.4 (29.9 to 51.5)	10.8 (3.9 to 21.6)
Severe anemia due to hemoglobin E trait	177.9 (149.3 to 310.5)	208.4 (180.9 to 223.8)	21.3 (-31.0 to 40.8)	-2.6 (-45.0 to 12.6)
Sickle cell disorders	1,826.5 (1,728.9 to 1,913.0)	3,250.4 (3,091.7 to 3,400.5)	77.6 (69.9 to 86.1)	52.3 (45.8 to 59.6)
Homozygous sickle cell and severe sickle cell/beta-thalassemia, without anemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.6 (-89.0 to 1,894.9)	7.0 (-91.6 to 1,272.4)
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with vaso-occlusive crisis, without anemia	7.5 (3.2 to 12.6)	20.6 (10.5 to 35.3)	174.0 (58.4 to 401.9)	122.3 (26.9 to 309.6)
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with stroke, without anemia	9.9 (4.2 to 17.0)	27.1 (14.1 to 48.0)	173.2 (51.4 to 423.1)	120.0 (22.8 to 327.4)
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with vaso-occlusive crisis and stroke, without anemia	1.0 (0.4 to 2.0)	3.0 (1.4 to 5.9)	182.9 (44.6 to 489.4)	122.9 (11.7 to 369.1)
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with mild anemia	153.4 (94.3 to 188.5)	309.4 (198.7 to 356.2)	96.7 (28.6 to 256.4)	57.7 (2.3 to 183.4)
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with moderate anemia	962.8 (871.1 to 1,034.7)	1,743.1 (1,628.8 to 1,848.3)	80.3 (66.2 to 98.4)	59.3 (46.9 to 75.4)
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with severe anemia	139.4 (98.7 to 213.2)	175.3 (132.4 to 265.7)	27.3 (-25.4 to 129.3)	14.5 (-33.1 to 104.5)
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with vaso-occlusive crisis and severe anemia	81.7 (57.7 to 106.6)	152.2 (110.8 to 198.2)	86.3 (68.5 to 106.4)	54.2 (39.4 to 69.4)
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with stroke and severe anemia	54.1 (38.6 to 72.9)	109.1 (78.2 to 145.7)	102.5 (69.2 to 138.5)	52.0 (28.3 to 77.9)
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with vaso-occlusive crisis, stroke, and severe anemia	7.0 (4.1 to 10.6)	14.4 (8.6 to 21.6)	106.6 (73.4 to 141.3)	49.8 (26.2 to 75.9)
Hemoglobin SC disease, without anemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.4 (-86.4 to 0.0)	44.3 (-89.3 to 0.0)
Hemoglobin SC disease, with vaso-occlusive crisis, without anemia	3.1 (1.4 to 5.7)	5.5 (2.4 to 10.4)	73.3 (-13.9 to 258.2)	37.4 (-32.0 to 185.7)
Hemoglobin SC disease, with stroke, without anemia	3.8 (1.7 to 6.5)	6.8 (2.9 to 11.8)	71.8 (-13.4 to 270.2)	34.5 (-32.1 to 183.0)
Hemoglobin SC disease, with vaso-occlusive crisis and stroke, without anemia	0.4 (0.2 to 0.8)	0.8 (0.3 to 1.6)	67.2 (-11.6 to 260.9)	27.0 (-31.7 to 173.3)
Hemoglobin SC disease, with mild anemia	68.1 (44.8 to 83.1)	121.5 (72.0 to 145.7)	79.3 (1.1 to 199.5)	49.1 (-16.6 to 150.5)
Hemoglobin SC disease, with moderate anemia	236.4 (223.5 to 253.2)	399.1 (375.6 to 426.8)	68.6 (56.8 to 82.2)	42.1 (32.2 to 53.3)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Hemoglobin SC disease, with severe anemia	25.0 (17.6 to 38.0)	36.8 (24.5 to 74.6)	40.6 (-23.1 to 230.9)	25.6 (-31.9 to 197.4)
Hemoglobin SC disease, with vaso-occlusive crisis and severe anemia	21.8 (16.6 to 26.9)	37.7 (28.5 to 47.1)	72.3 (55.2 to 91.2)	38.0 (23.6 to 52.9)
Hemoglobin SC disease, with stroke and severe anemia	16.3 (12.2 to 20.8)	29.3 (21.6 to 37.9)	80.0 (51.6 to 110.7)	30.0 (10.2 to 53.1)
Hemoglobin SC disease, with vaso-occlusive crisis, stroke, and severe anemia	2.2 (1.4 to 3.3)	4.1 (2.5 to 6.1)	82.3 (54.5 to 109.8)	26.4 (7.7 to 46.9)
Mild sickle cell/beta-thalassemia, without anemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.7 (-95.8 to 0.0)	52.4 (-96.4 to 0.0)
Mild sickle cell/beta-thalassemia, with vaso-occlusive crisis, without anemia	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.3)	290.4 (140.1 to 511.6)	190.5 (78.2 to 355.5)
Mild sickle cell/beta-thalassemia, with stroke, without anemia	0.1 (0.0 to 0.1)	0.2 (0.0 to 0.4)	290.2 (138.8 to 511.4)	189.0 (78.9 to 354.9)
Mild sickle cell/beta-thalassemia, with vaso-occlusive crisis and stroke, without anemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	295.7 (143.1 to 511.1)	189.2 (79.6 to 348.0)
Mild sickle cell/beta-thalassemia, with mild anemia	2.7 (1.9 to 3.3)	3.7 (2.6 to 4.7)	36.9 (-7.0 to 115.0)	12.7 (-22.9 to 77.8)
Mild sickle cell/beta-thalassemia, with moderate anemia	18.6 (15.5 to 20.7)	35.0 (31.6 to 37.6)	86.3 (62.6 to 122.3)	67.6 (46.3 to 98.3)
Mild sickle cell/beta-thalassemia, with severe anemia	8.2 (6.9 to 10.6)	10.9 (9.3 to 13.8)	31.4 (2.4 to 86.7)	16.1 (-9.1 to 65.0)
Mild sickle cell/beta-thalassemia, with vaso-occlusive crisis and severe anemia	1.4 (1.0 to 1.8)	2.3 (1.7 to 3.0)	70.3 (58.1 to 86.8)	37.7 (28.2 to 50.7)
Mild sickle cell/beta-thalassemia, with stroke and severe anemia	1.3 (0.9 to 1.8)	2.3 (1.7 to 3.1)	73.5 (61.7 to 91.5)	34.4 (25.0 to 48.2)
Mild sickle cell/beta-thalassemia, with vaso-occlusive crisis, stroke, and severe anemia	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	75.0 (62.9 to 91.4)	31.5 (22.1 to 45.7)
Sickle cell trait	166,447.6 (158,185.1 to 174,094.2)	261,740.7 (249,515.4 to 272,735.9)	57.0 (54.2 to 59.7)	19.3 (17.1 to 21.3)
Asymptomatic sickle cell trait	136,607.4 (128,176.4 to 144,335.9)	218,376.7 (206,248.2 to 229,323.5)	59.6 (55.8 to 63.1)	20.5 (17.7 to 23.1)
Mild anemia due to sickle cell trait	13,199.5 (12,762.9 to 14,599.0)	20,046.8 (19,463.1 to 21,286.1)	51.9 (36.1 to 62.8)	12.3 (0.5 to 20.2)
Moderate anemia due to sickle cell trait	15,286.7 (13,919.9 to 15,730.1)	21,568.3 (20,445.5 to 22,094.3)	40.7 (31.4 to 55.6)	14.6 (7.1 to 28.4)
Severe anemia due to sickle cell trait	1,354.0 (1,207.4 to 1,460.6)	1,748.9 (1,615.8 to 1,838.3)	28.4 (16.4 to 47.4)	8.0 (-2.1 to 26.0)
G6PD deficiency	229,333.9 (223,528.4 to 234,741.5)	337,628.8 (329,360.6 to 345,753.7)	47.1 (42.1 to 51.9)	11.4 (7.6 to 15.1)
Mild anemia due to G6PD deficiency	263.5 (253.8 to 276.1)	389.5 (374.0 to 408.5)	47.6 (39.1 to 56.8)	17.1 (10.8 to 24.5)
Moderate anemia due to G6PD deficiency	142.4 (131.5 to 151.1)	205.2 (187.6 to 218.7)	44.2 (28.2 to 59.5)	17.9 (5.2 to 29.5)
Severe anemia due to G6PD deficiency	112.6 (109.0 to 117.1)	148.4 (142.1 to 155.2)	31.5 (23.5 to 40.0)	3.8 (-2.4 to 10.2)
Mild heart failure due to G6PD deficiency	2.0 (1.2 to 3.0)	5.0 (3.1 to 7.2)	150.7 (100.0 to 229.3)	75.0 (39.1 to 130.0)
Moderate heart failure due to G6PD deficiency	1.6 (1.0 to 2.4)	4.1 (2.6 to 5.8)	150.6 (100.0 to 229.3)	75.0 (39.1 to 130.0)
Severe heart failure due to G6PD deficiency	4.5 (2.8 to 6.1)	11.2 (7.7 to 14.5)	150.7 (100.0 to 229.3)	75.0 (39.1 to 130.0)
Asymptomatic G6PD deficiency	228,807.3 (223,003.4 to 234,222.3)	336,865.4 (328,601.1 to 344,961.8)	47.1 (42.1 to 52.0)	11.3 (7.6 to 15.1)
G6PD trait	851,394.7 (846,057.9 to 855,868.5)	1,181,972.5 (1,174,352.1 to 1,188,844.0)	38.6 (37.6 to 39.9)	3.0 (2.2 to 3.9)
Asymptomatic hemizygous G6PD deficiency	850,142.9 (844,802.5 to 854,615.6)	1,179,990.9 (1,172,372.0 to 1,186,819.6)	38.6 (37.6 to 39.8)	2.9 (2.2 to 3.9)
Mild anemia due to hemizygous G6PD deficiency	676.1 (630.1 to 756.7)	1,194.9 (1,108.6 to 1,352.4)	75.9 (55.2 to 106.5)	22.8 (10.1 to 43.0)
Moderate anemia due to hemizygous G6PD deficiency	487.4 (433.1 to 526.3)	732.1 (582.8 to 819.8)	52.0 (18.0 to 77.3)	23.5 (-3.9 to 43.5)
Severe anemia due to hemizygous G6PD deficiency	88.3 (50.8 to 100.1)	54.5 (36.4 to 70.9)	-37.0 (-61.0 to 21.9)	-50.0 (-69.0 to -2.7)
Other hemoglobinopathies and hemolytic anemias	57,238.4 (55,380.4 to 58,772.9)	56,010.1 (54,470.2 to 57,258.6)	-2.3 (-5.5 to 1.3)	-26.6 (-29.0 to -24.0)
Other hemoglobinopathies and hemolytic anemias	-	-	-	-
Mild anemia due to other hemoglobinopathies and hemolytic anemias	32,245.6 (31,699.4 to 33,944.3)	34,613.8 (34,021.3 to 35,839.8)	7.3 (1.0 to 11.3)	-22.2 (-26.2 to -19.3)
Moderate anemia due to other hemoglobinopathies and hemolytic anemias	22,593.3 (20,591.7 to 23,200.7)	19,591.7 (18,029.5 to 20,274.5)	-13.3 (-19.4 to -3.9)	-31.9 (-36.6 to -24.8)
Severe anemia due to other hemoglobinopathies and hemolytic anemias	2,306.7 (1,990.1 to 2,648.9)	1,588.7 (1,411.9 to 1,899.1)	-31.4 (-42.6 to -18.7)	-45.5 (-53.9 to -35.4)
Mild heart failure due to other hemoglobinopathies and hemolytic anemias	22.7 (12.8 to 34.1)	52.7 (32.1 to 77.7)	131.0 (72.7 to 195.6)	39.2 (3.8 to 76.7)
Moderate heart failure due to other hemoglobinopathies and hemolytic anemias	19.0 (11.6 to 27.5)	44.1 (28.2 to 62.7)	131.0 (72.7 to 195.6)	39.2 (3.8 to 76.7)
Severe heart failure due to other hemoglobinopathies and hemolytic anemias	51.1 (34.3 to 67.8)	119.0 (82.5 to 154.2)	131.0 (72.7 to 195.6)	39.2 (3.8 to 76.7)
Endocrine, metabolic, blood, and immune disorders	72,089.8 (70,251.3 to 73,865.6)	79,556.0 (77,363.2 to 81,282.3)	10.3 (6.9 to 13.8)	-16.2 (-18.8 to -13.7)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Asymptomatic endocrine, metabolic, blood, and immune disorders	7,856.0 (7,283.1 to 8,449.1)	10,539.9 (9,751.8 to 11,384.4)	34.1 (31.5 to 36.3)	-6.1 (-7.9 to -4.4)
Mild endocrine, metabolic, blood, and immune disorders	9,327.2 (8,456.4 to 10,107.8)	12,513.5 (11,370.8 to 13,571.3)	34.1 (31.5 to 36.3)	-6.1 (-7.9 to -4.4)
Moderate endocrine, metabolic, blood, and immune disorders	1,480.5 (857.1 to 2,217.4)	1,986.2 (1,160.7 to 2,973.4)	34.1 (31.5 to 36.3)	-6.1 (-7.9 to -4.4)
Severe endocrine, metabolic, blood, and immune disorders	3,245.2 (2,688.4 to 3,800.1)	4,353.8 (3,614.8 to 5,132.4)	34.1 (31.5 to 36.3)	-6.1 (-7.9 to -4.4)
Mild anemia due to endocrine, metabolic, blood, and immune disorders	24,919.0 (24,095.0 to 26,609.0)	27,192.2 (26,457.7 to 28,824.2)	9.3 (1.6 to 15.1)	-17.9 (-24.0 to -13.7)
Moderate anemia due to endocrine, metabolic, blood, and immune disorders	22,619.6 (20,845.9 to 23,391.4)	20,274.6 (18,029.6 to 21,149.2)	-10.4 (-20.5 to -1.9)	-25.9 (-33.8 to -17.6)
Severe anemia due to endocrine, metabolic, blood, and immune disorders	2,304.5 (1,926.4 to 2,722.5)	1,844.5 (1,674.2 to 2,286.9)	-21.1 (-33.1 to -0.9)	-34.1 (-45.2 to -17.6)
Mild heart failure due to endocrine, metabolic, blood, and immune disorders	82.4 (53.9 to 115.7)	207.9 (135.2 to 288.0)	152.3 (128.1 to 173.7)	58.3 (42.5 to 71.7)
Moderate heart failure due to endocrine, metabolic, blood, and immune disorders	69.0 (48.5 to 91.6)	174.0 (122.8 to 228.5)	152.3 (128.1 to 173.7)	58.3 (42.5 to 71.7)
Severe heart failure due to endocrine, metabolic, blood, and immune disorders	186.3 (145.0 to 221.8)	469.6 (374.2 to 560.7)	152.3 (128.1 to 173.7)	58.3 (42.5 to 71.7)
Musculoskeletal disorders	-	-	-	-
Rheumatoid arthritis	10,732.8 (10,617.6 to 10,852.7)	16,863.2 (16,714.4 to 17,035.8)	57.0 (54.7 to 59.1)	-5.1 (-6.5 to -3.8)
Mild rheumatoid arthritis	4,973.7 (4,330.8 to 5,574.8)	7,814.8 (6,817.4 to 8,761.8)	57.0 (54.7 to 59.1)	-5.1 (-6.5 to -3.8)
Moderate rheumatoid arthritis	4,233.8 (3,753.2 to 4,769.1)	6,652.0 (5,859.6 to 7,458.4)	57.0 (54.7 to 59.1)	-5.1 (-6.5 to -3.8)
Severe rheumatoid arthritis	1,525.3 (1,025.1 to 2,122.4)	2,396.5 (1,627.4 to 3,346.5)	57.0 (54.7 to 59.1)	-5.1 (-6.5 to -3.8)
Osteoarthritis	140,494.8 (139,147.1 to 141,801.6)	241,825.0 (239,655.8 to 243,896.7)	71.9 (69.8 to 74.3)	-2.6 (-3.8 to -1.2)
Mild osteoarthritis of the hip	15,849.2 (14,918.3 to 16,781.1)	26,289.1 (24,808.0 to 27,751.4)	65.8 (61.4 to 69.8)	-6.7 (-9.2 to -4.3)
Moderate osteoarthritis of the hip	7,633.1 (6,705.2 to 8,563.0)	13,105.8 (11,648.1 to 14,528.2)	71.5 (67.4 to 75.9)	-3.2 (-5.5 to -0.6)
Severe osteoarthritis of the hip	2,205.0 (1,962.9 to 2,478.0)	4,006.1 (3,569.0 to 4,492.1)	81.3 (76.0 to 87.6)	2.8 (-0.1 to 6.5)
Mild osteoarthritis of the knee	63,542.7 (60,659.7 to 66,202.3)	107,979.2 (103,270.9 to 112,287.8)	69.8 (66.7 to 73.2)	-3.9 (-5.6 to -1.8)
Moderate osteoarthritis of the knee	37,246.7 (34,554.6 to 40,031.9)	65,164.0 (60,860.5 to 69,736.8)	74.8 (71.8 to 77.9)	-0.7 (-2.4 to 1.1)
Severe osteoarthritis of the knee	14,018.1 (12,580.8 to 15,475.7)	25,280.8 (22,704.6 to 27,888.8)	80.1 (76.4 to 84.1)	2.7 (0.6 to 5.0)
Low back and neck pain	-	-	-	-
Low back pain	414,049.0 (408,101.7 to 420,024.2)	651,008.8 (641,143.4 to 662,885.1)	56.8 (53.6 to 61.4)	-0.4 (-2.4 to 2.5)
Mild low back pain without leg pain	127,523.9 (98,330.6 to 158,420.2)	200,495.0 (155,537.1 to 249,894.2)	56.8 (53.6 to 61.4)	-0.4 (-2.4 to 2.5)
Mild low back pain with leg pain	22,855.4 (3,809.6 to 53,082.8)	35,934.6 (6,003.1 to 83,447.7)	56.8 (53.6 to 61.4)	-0.4 (-2.4 to 2.5)
Moderate low back pain without leg pain	116,815.8 (90,546.5 to 145,200.5)	183,663.9 (141,367.6 to 227,950.8)	56.8 (53.6 to 61.4)	-0.4 (-2.4 to 2.5)
Moderate low back pain with leg pain	31,276.6 (12,309.4 to 58,527.7)	49,191.1 (19,089.6 to 92,212.1)	56.8 (53.6 to 61.4)	-0.4 (-2.4 to 2.5)
Severe low back pain without leg pain	35,456.2 (28,160.8 to 44,253.1)	55,748.1 (44,070.0 to 69,532.5)	56.8 (53.6 to 61.4)	-0.4 (-2.4 to 2.5)
Severe low back pain with leg pain	11,372.2 (3,899.8 to 22,435.7)	17,883.4 (6,076.6 to 35,580.8)	56.8 (53.6 to 61.4)	-0.4 (-2.4 to 2.5)
Most severe low back pain without leg pain	48,372.0 (32,023.3 to 67,357.6)	76,053.4 (49,978.8 to 106,204.9)	56.8 (53.6 to 61.4)	-0.4 (-2.4 to 2.5)
Most severe low back pain with leg pain	20,376.9 (3,720.2 to 47,738.8)	32,039.3 (5,874.5 to 74,771.7)	56.8 (53.6 to 61.4)	-0.4 (-2.4 to 2.5)
Neck pain	226,306.1 (221,678.0 to 230,966.4)	349,305.2 (341,160.3 to 359,767.4)	54.1 (49.1 to 59.9)	-1.5 (-4.6 to 2.2)
Mild neck pain	155,254.8 (140,489.3 to 168,960.6)	239,646.1 (215,816.9 to 261,148.0)	54.1 (49.1 to 59.9)	-1.5 (-4.6 to 2.2)
Moderate neck pain	25,754.3 (14,713.9 to 37,958.6)	39,750.3 (22,647.2 to 57,536.4)	54.1 (49.1 to 59.9)	-1.5 (-4.6 to 2.2)
Severe neck pain	13,557.5 (8,912.5 to 18,935.9)	20,925.6 (13,711.2 to 29,344.2)	54.1 (49.1 to 59.9)	-1.5 (-4.6 to 2.2)
Most severe neck pain	31,739.5 (21,740.6 to 43,386.3)	48,983.2 (33,625.6 to 66,583.3)	54.1 (49.1 to 59.9)	-1.5 (-4.6 to 2.2)
Gout	3,471.8 (3,420.7 to 3,518.7)	5,825.6 (5,750.0 to 5,904.8)	67.5 (64.6 to 70.8)	-2.3 (-4.0 to -0.3)
Asymptomatic gout	3,102.4 (3,040.2 to 3,162.7)	5,205.8 (5,100.8 to 5,315.4)	67.5 (64.6 to 70.8)	-2.3 (-4.0 to -0.3)
Symptomatic episodes of gout	321.7 (278.7 to 367.2)	539.9 (465.7 to 613.8)	67.5 (64.6 to 70.8)	-2.3 (-4.0 to -0.3)
Polyarticular gout	47.6 (46.4 to 48.9)	79.9 (78.0 to 82.0)	67.5 (64.6 to 70.8)	-2.3 (-4.0 to -0.3)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Other musculoskeletal disorders	138,897.7 (121,127.2 to 157,325.4)	248,188.2 (216,691.1 to 281,933.6)	78.4 (75.0 to 82.5)	6.6 (5.0 to 8.9)
Asymptomatic other musculoskeletal disorders	34,640.4 (28,856.7 to 40,839.2)	61,896.9 (51,444.2 to 73,146.3)	78.4 (75.0 to 82.5)	6.6 (5.0 to 8.9)
Other musculoskeletal disorders severity level 2	29,490.2 (22,386.4 to 37,631.7)	52,694.8 (40,040.9 to 67,748.6)	78.4 (75.0 to 82.5)	6.6 (5.0 to 8.9)
Other musculoskeletal disorders severity level 3	15,018.3 (9,223.0 to 22,175.7)	26,835.3 (16,566.8 to 39,623.2)	78.4 (75.0 to 82.5)	6.6 (5.0 to 8.9)
Other musculoskeletal disorders severity level 5	11,118.4 (8,723.9 to 13,952.4)	19,865.9 (15,484.5 to 24,814.1)	78.4 (75.0 to 82.5)	6.6 (5.0 to 8.9)
Other musculoskeletal disorders severity level 6	9,973.7 (5,181.8 to 15,569.7)	17,820.6 (9,278.6 to 27,901.8)	78.4 (75.0 to 82.5)	6.6 (5.0 to 8.9)
Other musculoskeletal disorders severity level 1	30,088.3 (20,367.5 to 39,907.8)	53,763.6 (36,310.2 to 71,602.6)	78.4 (75.0 to 82.5)	6.6 (5.0 to 8.9)
Other musculoskeletal disorders severity level 4	8,568.3 (6,083.3 to 11,341.4)	15,311.1 (10,880.6 to 20,184.4)	78.4 (75.0 to 82.5)	6.6 (5.0 to 8.9)
Other non-communicable diseases	-	-	-	-
Congenital anomalies	-	-	-	-
Neural tube defects	923.0 (901.9 to 947.5)	1,470.2 (1,434.6 to 1,508.2)	59.2 (53.8 to 64.4)	25.4 (21.2 to 29.6)
Moderate motor impairment due to moderate neural tube defects	369.7 (357.4 to 383.4)	568.8 (549.1 to 592.6)	53.5 (46.6 to 62.7)	20.6 (15.1 to 27.8)
Severe motor impairment due to severe neural tube defects	150.0 (104.6 to 195.9)	244.3 (169.2 to 318.9)	62.7 (55.4 to 70.5)	28.6 (22.6 to 34.8)
Severe motor plus cognitive impairments due to severe neural tube defects	293.2 (244.3 to 340.3)	477.7 (395.5 to 556.5)	62.7 (55.4 to 70.5)	28.6 (22.6 to 34.8)
Severe motor impairment with incontinence due to severe neural tube defects	110.1 (69.6 to 156.1)	179.4 (114.5 to 251.6)	62.7 (55.4 to 70.5)	28.6 (22.6 to 34.8)
Congenital heart anomalies	18,199.0 (17,593.7 to 18,865.3)	34,315.9 (33,178.0 to 35,691.2)	88.0 (80.3 to 98.5)	40.0 (34.5 to 47.8)
Asymptomatic less severe congenital heart anomalies	7,547.6 (6,942.5 to 8,161.1)	13,965.4 (12,852.3 to 15,123.8)	84.5 (76.4 to 95.5)	37.0 (30.9 to 45.2)
Symptomatic less severe congenital heart anomalies	9,205.2 (8,560.8 to 9,834.5)	17,032.1 (15,821.5 to 18,325.1)	84.5 (76.4 to 95.5)	37.0 (30.9 to 45.2)
Severe congenital heart anomalies	923.7 (869.2 to 1,000.8)	2,598.7 (2,520.0 to 2,704.8)	182.1 (159.0 to 200.9)	108.8 (91.6 to 123.1)
Critical congenital heart anomalies	27.9 (25.4 to 30.8)	98.9 (93.6 to 104.9)	254.4 (215.0 to 297.1)	197.6 (164.5 to 233.7)
Mild heart failure due to congenital heart anomalies	121.1 (80.0 to 163.8)	152.0 (98.2 to 206.7)	25.7 (11.2 to 38.4)	7.0 (-5.1 to 17.0)
Moderate heart failure due to congenital heart anomalies	100.9 (72.0 to 133.3)	126.6 (90.8 to 167.9)	25.7 (11.2 to 38.4)	7.0 (-5.1 to 17.0)
Severe heart failure due to congenital heart anomalies	272.6 (228.2 to 317.5)	342.2 (286.2 to 399.5)	25.7 (11.2 to 38.4)	7.0 (-5.1 to 17.0)
Orofacial clefts	2,978.0 (2,863.3 to 3,082.2)	5,807.6 (5,621.9 to 5,988.1)	94.4 (86.1 to 105.9)	47.9 (41.2 to 56.6)
Asymptomatic orofacial clefts	2,356.0 (2,265.3 to 2,442.6)	4,705.1 (4,559.0 to 4,846.5)	99.1 (90.7 to 110.8)	50.7 (44.0 to 59.6)
Disfigurement level 1 due to orofacial clefts	207.3 (198.9 to 214.8)	367.5 (352.0 to 383.5)	76.9 (67.1 to 88.5)	37.2 (29.5 to 46.3)
Disfigurement level 2 due to orofacial clefts	207.3 (199.4 to 215.0)	367.4 (351.9 to 382.5)	77.0 (67.0 to 88.3)	37.3 (29.6 to 46.1)
Disfigurement level 2 and speech problems due to orofacial clefts	207.4 (198.7 to 215.0)	367.6 (351.9 to 382.7)	77.0 (67.1 to 88.5)	37.3 (29.6 to 46.1)
Down syndrome	4,752.1 (4,560.8 to 4,959.0)	8,538.5 (8,185.7 to 8,897.8)	79.5 (70.1 to 88.2)	32.8 (26.0 to 39.2)
Asymptomatic Down syndrome	124.2 (73.0 to 202.1)	208.9 (129.4 to 330.3)	68.7 (57.3 to 81.9)	29.3 (22.4 to 36.1)
Intellectual disability due to Down syndrome	2,093.2 (1,469.4 to 2,630.7)	3,368.3 (2,362.5 to 4,225.0)	61.0 (51.8 to 70.1)	26.6 (19.9 to 33.0)
Intellectual disability with congenital heart disease due to Down syndrome	1,559.5 (1,027.2 to 2,161.6)	2,505.6 (1,699.2 to 3,404.2)	60.7 (51.4 to 70.1)	26.5 (19.7 to 33.3)
Intellectual disability with dementia due to Down syndrome	511.5 (359.6 to 649.8)	1,331.1 (940.0 to 1,682.0)	160.6 (146.5 to 172.2)	50.6 (42.6 to 57.7)
Intellectual disability with congenital heart disease and dementia due to Down syndrome	374.0 (232.4 to 508.2)	973.6 (610.2 to 1,314.0)	160.5 (147.0 to 173.8)	50.5 (42.5 to 58.4)
Isolated congenital heart disease due to Down syndrome	89.7 (52.3 to 147.4)	150.9 (92.6 to 234.3)	68.8 (56.7 to 82.2)	29.3 (21.9 to 36.3)
Tumer syndrome	170.1 (161.5 to 178.5)	257.5 (246.6 to 271.2)	51.2 (42.6 to 62.3)	14.8 (8.4 to 23.3)
Asymptomatic Tumer syndrome	54.8 (51.8 to 58.1)	78.2 (74.3 to 83.0)	42.6 (33.9 to 53.3)	17.1 (10.1 to 25.7)
Congenital heart disease due to Tumer syndrome	16.2 (14.4 to 18.0)	23.1 (20.9 to 25.4)	42.6 (33.5 to 52.9)	17.0 (10.0 to 25.7)
Primary infertility due to Tumer syndrome	80.7 (76.9 to 84.5)	127.1 (122.2 to 133.7)	57.2 (48.7 to 68.8)	13.3 (7.2 to 21.6)
Congenital heart disease with infertility due to Tumer syndrome	18.4 (16.1 to 20.7)	29.0 (25.4 to 32.7)	57.2 (48.7 to 68.8)	13.3 (7.2 to 21.6)
Klinefelter syndrome	152.0 (143.9 to 159.2)	216.3 (207.1 to 226.7)	42.0 (33.2 to 52.7)	6.5 (0.0 to 14.5)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Asymptomatic Klinefelter syndrome	70.3 (63.8 to 76.3)	95.0 (87.5 to 102.8)	34.8 (26.4 to 45.5)	8.0 (1.4 to 16.2)
Borderline intellectual disability due to Klinefelter syndrome	16.8 (11.8 to 22.3)	22.7 (16.4 to 29.5)	35.3 (23.8 to 49.3)	8.1 (1.1 to 16.3)
Borderline intellectual disability with infertility due to Klinefelter syndrome	12.0 (7.5 to 17.1)	18.3 (11.3 to 25.6)	51.9 (42.5 to 63.4)	4.5 (-1.9 to 12.4)
Mild intellectual disability due to Klinefelter syndrome	1.4 (0.9 to 2.1)	1.9 (1.2 to 2.7)	35.1 (22.2 to 51.1)	8.0 (1.1 to 16.4)
Mild intellectual disability with infertility due to Klinefelter syndrome	1.0 (0.6 to 1.7)	1.5 (0.9 to 2.5)	51.9 (42.5 to 63.4)	4.5 (-1.9 to 12.4)
Primary infertility due to Klinefelter syndrome	50.4 (45.0 to 55.8)	76.7 (69.3 to 84.3)	51.9 (42.5 to 63.4)	4.5 (-1.9 to 12.4)
Chromosomal unbalanced rearrangements	6,683.3 (6,415.3 to 6,919.1)	11,649.3 (11,154.1 to 12,235.1)	74.0 (66.0 to 83.0)	27.5 (21.7 to 34.0)
Asymptomatic chromosomal unbalanced rearrangements	171.0 (103.1 to 269.0)	280.2 (179.0 to 422.9)	64.2 (54.2 to 77.3)	24.7 (18.7 to 31.5)
Intellectual disability due to chromosomal unbalanced rearrangements	2,918.3 (1,997.3 to 3,682.6)	4,564.5 (3,189.1 to 5,710.5)	56.2 (48.0 to 66.3)	22.3 (16.2 to 29.3)
Intellectual disability with congenital heart disease due to chromosomal unbalanced rearrangements	2,127.0 (1,385.6 to 3,062.7)	3,328.2 (2,206.4 to 4,659.6)	56.5 (47.8 to 65.9)	22.4 (16.4 to 29.5)
Intellectual disability with dementia due to chromosomal unbalanced rearrangements	772.7 (529.3 to 1,001.4)	1,884.5 (1,295.0 to 2,458.8)	143.8 (132.9 to 155.8)	40.8 (34.7 to 47.7)
Intellectual disability with congenital heart disease and dementia due to chromosomal unbalanced rearrangements	568.7 (367.1 to 779.5)	1,386.5 (902.6 to 1,895.8)	143.4 (132.7 to 156.7)	40.7 (34.5 to 48.3)
Isolated congenital heart disease due to chromosomal unbalanced rearrangements	125.5 (74.6 to 201.1)	205.3 (128.3 to 318.1)	64.1 (53.4 to 76.5)	24.7 (18.6 to 31.6)
Other congenital anomalies	20,979.3 (18,202.1 to 23,437.9)	25,840.0 (22,170.5 to 29,283.1)	22.9 (17.2 to 28.7)	-10.6 (-14.7 to -6.5)
Mild hearing loss due to other congenital anomalies	4,260.3 (3,769.5 to 4,637.3)	6,049.0 (5,388.5 to 6,643.4)	41.6 (35.0 to 50.1)	-1.8 (-6.5 to 3.8)
Mild hearing loss with ringing due to other congenital anomalies	1,126.8 (990.5 to 1,232.1)	1,600.0 (1,419.0 to 1,764.6)	41.7 (34.9 to 49.9)	-1.8 (-6.6 to 3.8)
Moderate hearing loss due to other congenital anomalies	3,624.7 (3,009.5 to 4,247.4)	4,743.7 (3,776.9 to 5,726.7)	29.8 (10.2 to 52.6)	-6.8 (-20.8 to 10.0)
Moderate hearing loss with ringing due to other congenital anomalies	1,570.0 (1,292.0 to 1,848.3)	2,054.9 (1,611.2 to 2,485.9)	30.0 (10.4 to 53.0)	-6.7 (-20.8 to 10.0)
Moderately severe hearing loss due to other congenital anomalies	2,835.1 (2,058.5 to 3,556.6)	3,129.4 (2,237.8 to 3,981.1)	10.3 (-11.6 to 38.1)	-18.2 (-34.5 to 1.9)
Moderately severe hearing loss with ringing due to other congenital anomalies	1,361.2 (990.4 to 1,732.7)	1,502.5 (1,074.9 to 1,923.2)	10.2 (-11.5 to 37.8)	-18.3 (-34.5 to 2.0)
Severe hearing loss with ringing due to other congenital anomalies	1,162.9 (910.7 to 1,453.8)	1,389.9 (1,116.5 to 1,715.7)	19.4 (4.7 to 35.2)	-11.7 (-22.0 to -0.5)
Severe hearing loss due to other congenital anomalies	2,053.1 (1,624.9 to 2,541.2)	2,454.2 (2,007.4 to 3,049.2)	19.5 (5.2 to 35.6)	-11.7 (-22.0 to -0.4)
Profound hearing loss due to other congenital anomalies	506.2 (361.2 to 682.5)	444.4 (303.8 to 592.4)	-12.0 (-23.2 to -2.8)	-24.9 (-34.5 to -17.5)
Profound hearing loss with ringing due to other congenital anomalies	895.5 (679.8 to 1,152.3)	786.8 (565.7 to 1,018.8)	-12.0 (-23.2 to -3.0)	-24.8 (-34.4 to -17.7)
Complete hearing loss due to other congenital anomalies	721.5 (531.3 to 955.1)	768.1 (576.2 to 1,022.9)	6.3 (-0.3 to 13.4)	-22.6 (-26.7 to -18.5)
Complete hearing loss with ringing due to other congenital anomalies	862.1 (668.2 to 1,104.1)	917.1 (714.3 to 1,181.2)	6.4 (0.1 to 12.7)	-22.7 (-26.8 to -18.5)
Other congenital anomalies	-	-	-	-
Skin and subcutaneous diseases	-	-	-	-
Dermatitis	240,442.0 (208,169.8 to 274,870.0)	333,785.4 (289,927.3 to 381,312.4)	38.7 (36.2 to 41.1)	-1.7 (-2.4 to -0.9)
Mild eczema	39,245.9 (32,059.4 to 47,263.2)	50,890.5 (41,525.4 to 61,464.6)	29.6 (26.3 to 32.4)	0.4 (-0.8 to 2.0)
Moderate eczema	4,418.6 (2,651.4 to 6,467.0)	5,730.2 (3,406.7 to 8,383.8)	29.6 (26.3 to 32.4)	0.4 (-0.8 to 2.0)
Severe eczema	1,870.2 (981.1 to 2,986.2)	2,425.3 (1,262.9 to 3,913.8)	29.6 (26.3 to 32.4)	0.4 (-0.8 to 2.0)
Asymptomatic contact dermatitis	36,610.7 (31,922.9 to 41,283.4)	53,697.5 (46,888.7 to 60,271.4)	46.4 (44.1 to 49.7)	-0.5 (-1.0 to -0.0)
Mild contact dermatitis	43,954.0 (38,739.0 to 49,174.0)	64,468.3 (57,125.1 to 71,908.1)	46.4 (44.1 to 49.7)	-0.5 (-1.0 to -0.0)
Severe contact dermatitis	7,022.2 (4,473.0 to 10,197.5)	10,299.3 (6,557.1 to 14,808.6)	46.4 (44.1 to 49.7)	-0.5 (-1.0 to -0.0)
Asymptomatic seborrhoeic dermatitis	44,878.9 (32,272.5 to 58,265.7)	61,168.2 (44,547.3 to 79,649.1)	36.2 (31.7 to 40.6)	-3.6 (-4.6 to -2.3)
Symptomatic seborrhoeic dermatitis	62,441.4 (45,173.5 to 80,478.8)	85,106.1 (61,700.6 to 109,996.4)	36.2 (31.7 to 40.6)	-3.6 (-4.6 to -2.3)
Psoriasis	39,830.9 (35,635.8 to 44,008.3)	58,264.1 (51,720.2 to 64,609.4)	46.0 (44.0 to 48.8)	-2.2 (-3.0 to -1.6)
Mild psoriasis	32,302.6 (28,265.5 to 36,251.1)	47,251.5 (41,230.9 to 53,209.9)	46.0 (44.0 to 48.8)	-2.2 (-3.0 to -1.6)
Moderate psoriasis	4,389.7 (2,801.4 to 6,420.7)	6,421.3 (4,057.8 to 9,416.5)	46.0 (44.0 to 48.8)	-2.2 (-3.0 to -1.6)
Severe psoriasis	3,138.6 (1,937.1 to 4,621.5)	4,591.3 (2,864.8 to 6,753.6)	46.0 (44.0 to 48.8)	-2.2 (-3.0 to -1.6)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Cellulitis	1,429.7 (1,221.3 to 1,663.3)	1,705.9 (1,429.7 to 2,040.3)	19.1 (13.2 to 25.1)	-18.2 (-21.2 to -15.9)
Mild cellulitis	1,000.4 (837.8 to 1,189.8)	1,193.7 (988.0 to 1,442.9)	19.1 (13.2 to 25.1)	-18.2 (-21.2 to -15.9)
Severe cellulitis	429.3 (329.3 to 543.8)	512.2 (390.3 to 653.0)	19.1 (13.2 to 25.1)	-18.2 (-21.2 to -15.9)
Pyoderma	6,172.6 (4,779.0 to 7,778.1)	5,759.7 (4,693.5 to 7,278.2)	-6.7 (-16.2 to 3.7)	-23.8 (-29.9 to -17.6)
Impetigo	4,456.5 (3,115.1 to 5,897.6)	3,147.8 (2,286.9 to 4,056.2)	-29.5 (-34.5 to -23.4)	-38.6 (-42.7 to -34.0)
Abscess and other bacterial skin diseases	1,716.0 (1,276.1 to 2,359.2)	2,611.8 (1,947.4 to 3,605.5)	51.9 (43.0 to 61.5)	4.9 (1.1 to 10.0)
Scabies	52,625.3 (49,093.1 to 56,164.8)	66,107.5 (62,430.1 to 70,635.9)	24.8 (15.0 to 40.1)	-4.0 (-11.3 to 7.3)
Fungal skin diseases	473,166.9 (410,058.4 to 543,735.8)	683,713.8 (597,898.2 to 780,963.4)	44.2 (41.2 to 47.9)	3.0 (1.9 to 3.8)
Tinea capitis	133,477.1 (110,346.7 to 155,321.9)	182,154.8 (151,710.2 to 210,560.2)	36.3 (33.5 to 39.7)	10.0 (8.4 to 11.7)
Other fungal skin diseases	339,689.8 (282,957.5 to 404,291.7)	501,559.0 (421,144.2 to 590,657.8)	47.4 (43.3 to 52.0)	0.7 (-0.4 to 1.6)
Viral skin diseases	105,924.3 (87,145.0 to 124,492.3)	127,923.6 (105,593.4 to 151,635.9)	20.5 (17.9 to 24.3)	-1.8 (-3.1 to -0.3)
Mild molluscum contagiosum	8,635.8 (7,352.8 to 9,869.9)	10,465.6 (8,899.7 to 12,018.2)	21.0 (15.3 to 26.8)	1.7 (-3.0 to 6.5)
Severe molluscum contagiosum	6,400.5 (5,116.1 to 7,661.9)	7,754.3 (6,243.0 to 9,319.1)	21.0 (15.3 to 26.8)	1.7 (-3.0 to 6.5)
Mild viral warts	52,137.1 (39,932.4 to 65,983.0)	62,929.9 (48,537.3 to 80,120.1)	20.3 (17.6 to 24.8)	-2.5 (-3.6 to -1.0)
Severe viral warts	38,750.8 (28,437.5 to 50,383.9)	46,773.7 (34,255.1 to 61,547.3)	20.3 (17.6 to 24.8)	-2.5 (-3.6 to -1.0)
Acne vulgaris	537,177.2 (507,604.6 to 567,911.7)	661,634.9 (622,842.5 to 700,241.7)	23.2 (13.9 to 32.6)	-0.4 (-7.8 to 7.3)
Alopecia areata	6,003.8 (5,901.9 to 6,116.4)	8,775.5 (8,614.4 to 8,937.9)	46.1 (42.5 to 49.4)	-1.1 (-3.4 to 1.2)
Mild alopecia areata	3,418.8 (2,817.7 to 4,071.3)	4,997.2 (4,127.6 to 5,928.3)	46.1 (42.5 to 49.4)	-1.1 (-3.4 to 1.2)
Severe alopecia areata	2,585.0 (1,921.1 to 3,165.7)	3,778.2 (2,810.6 to 4,609.7)	46.1 (42.5 to 49.4)	-1.1 (-3.4 to 1.2)
Pruritus	659.5 (639.1 to 687.1)	1,024.6 (988.1 to 1,074.1)	55.3 (46.3 to 63.1)	-0.2 (-5.9 to 5.3)
Urticaria	49,676.0 (47,216.6 to 52,480.2)	79,582.8 (72,812.3 to 86,296.3)	60.5 (44.2 to 75.0)	7.3 (-3.8 to 16.6)
Mild urticaria	38,417.7 (34,127.7 to 42,381.3)	61,548.8 (53,944.8 to 69,717.8)	60.5 (44.2 to 75.0)	7.3 (-3.8 to 16.6)
Severe urticaria	11,258.3 (7,797.7 to 15,023.3)	18,034.0 (12,540.4 to 24,225.2)	60.5 (44.2 to 75.0)	7.3 (-3.8 to 16.6)
Decubitus ulcer	1,204.6 (1,170.0 to 1,246.2)	1,921.4 (1,853.0 to 2,001.2)	59.5 (51.8 to 67.1)	-8.1 (-13.1 to -3.3)
Mild decubitus ulcer	324.4 (249.3 to 407.7)	517.5 (390.6 to 652.5)	59.5 (51.8 to 67.1)	-8.1 (-13.1 to -3.3)
Moderate decubitus ulcer	471.1 (388.2 to 559.3)	751.4 (616.9 to 887.8)	59.5 (51.8 to 67.1)	-8.1 (-13.1 to -3.3)
Severe decubitus ulcer	409.1 (329.9 to 492.1)	652.5 (522.2 to 788.8)	59.5 (51.8 to 67.1)	-8.1 (-13.1 to -3.3)
Other skin and subcutaneous diseases	314,508.9 (207,789.6 to 470,451.6)	495,327.6 (319,462.3 to 761,255.5)	57.1 (48.5 to 64.4)	0.0 (-0.9 to 0.9)
Asymptomatic other skin and subcutaneous diseases	140,325.4 (93,418.6 to 209,905.0)	221,002.7 (142,617.9 to 338,268.3)	57.1 (48.5 to 64.4)	0.0 (-0.9 to 0.9)
Symptomatic other skin and subcutaneous diseases	174,183.4 (115,239.0 to 264,531.7)	274,324.9 (175,372.2 to 422,597.4)	57.1 (48.5 to 64.4)	0.0 (-0.9 to 0.9)
Sense organ diseases	-	-	-	-
Glaucoma	6,687.0 (6,026.0 to 7,426.7)	10,899.9 (9,853.2 to 12,002.8)	63.0 (50.2 to 74.7)	-3.5 (-10.6 to 2.9)
Moderate vision impairment due to glaucoma	4,464.0 (4,029.2 to 4,979.9)	7,276.6 (6,540.4 to 8,066.8)	62.8 (44.9 to 79.3)	-2.1 (-12.4 to 7.4)
Severe vision impairment due to glaucoma	557.4 (481.8 to 637.6)	984.5 (853.0 to 1,110.2)	77.1 (54.4 to 95.4)	3.4 (-8.9 to 14.8)
Blindness due to glaucoma	1,665.6 (1,460.2 to 1,897.1)	2,638.7 (2,306.8 to 3,031.5)	58.3 (50.8 to 66.3)	-9.3 (-13.8 to -4.5)
Cataract	29,892.4 (26,555.6 to 32,788.6)	44,221.6 (39,326.0 to 48,603.1)	47.5 (41.3 to 56.4)	-17.6 (-20.8 to -13.0)
Moderate vision impairment due to cataract	22,169.2 (19,657.6 to 24,327.4)	31,639.3 (28,166.8 to 34,874.6)	42.3 (35.3 to 52.9)	-20.4 (-24.0 to -14.8)
Severe vision impairment due to cataract	3,101.1 (2,709.8 to 3,467.0)	4,858.4 (4,227.5 to 5,437.9)	56.3 (46.9 to 68.6)	-12.6 (-17.7 to -6.4)
Blindness due to cataract	4,622.1 (4,042.9 to 5,298.1)	7,723.9 (6,690.8 to 8,769.5)	66.9 (58.8 to 76.0)	-7.9 (-12.2 to -3.3)
Macular degeneration	7,835.5 (6,763.8 to 8,926.4)	13,873.8 (12,176.5 to 15,562.6)	76.3 (69.4 to 89.3)	-1.6 (-5.6 to 5.1)
Moderate vision impairment due to macular degeneration	6,384.5 (5,476.7 to 7,288.4)	11,363.1 (9,945.6 to 12,736.8)	77.3 (69.8 to 90.5)	0.3 (-4.2 to 7.4)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Severe vision impairment due to macular degeneration	786.1 (661.7 to 913.9)	1,497.4 (1,279.6 to 1,710.6)	89.9 (80.7 to 104.7)	6.6 (1.2 to 14.3)
Blindness due to macular degeneration	664.9 (505.8 to 829.4)	1,013.2 (769.0 to 1,272.9)	52.8 (41.0 to 62.7)	-23.3 (-29.7 to -18.2)
Uncorrected refractive error	433,574.9 (425,242.4 to 442,348.1)	659,847.2 (648,298.7 to 671,446.7)	52.0 (49.0 to 55.0)	-5.2 (-7.0 to -3.4)
Moderate vision impairment due to uncorrected refractive error	63,530.7 (59,324.5 to 68,202.2)	80,456.4 (74,751.2 to 86,444.5)	26.5 (24.4 to 28.5)	-17.2 (-18.4 to -16.2)
Severe vision impairment due to uncorrected refractive error	7,097.1 (6,458.4 to 7,784.1)	9,944.6 (9,022.6 to 10,908.0)	39.9 (37.7 to 42.5)	-13.5 (-14.8 to -11.9)
Blindness due to uncorrected refractive error	7,037.0 (6,476.4 to 7,679.2)	9,481.5 (8,732.5 to 10,344.6)	34.6 (32.6 to 36.9)	-12.8 (-13.9 to -11.5)
Near vision impairment due to presbyopia due to uncorrected refractive error	355,910.0 (349,759.3 to 362,087.3)	559,964.7 (551,150.5 to 568,509.5)	57.1 (53.6 to 60.9)	-3.0 (-5.1 to -0.6)
Age-related and other hearing loss	724,591.8 (676,905.3 to 767,910.0)	1,128,939.1 (1,055,657.5 to 1,200,476.4)	55.7 (52.7 to 58.4)	-6.5 (-7.9 to -5.2)
Mild hearing loss due to age-related and other hearing loss	375,772.7 (346,022.4 to 404,557.1)	582,948.6 (537,335.7 to 628,928.1)	54.8 (51.4 to 59.1)	-6.9 (-8.7 to -4.6)
Mild hearing loss with ringing due to age-related and other hearing loss	99,451.1 (91,229.7 to 107,536.9)	154,275.3 (141,490.1 to 167,222.0)	54.8 (51.4 to 59.1)	-6.9 (-8.7 to -4.7)
Moderate hearing loss due to age-related and other hearing loss	123,183.8 (112,082.6 to 133,953.1)	199,856.9 (181,070.0 to 216,323.5)	62.2 (57.5 to 66.9)	-3.5 (-6.0 to -1.0)
Moderate hearing loss with ringing due to age-related and other hearing loss	53,355.8 (48,550.1 to 58,028.2)	86,563.0 (78,442.5 to 94,883.5)	62.2 (57.3 to 66.8)	-3.5 (-5.9 to -1.0)
Moderately severe hearing loss due to age-related and other hearing loss	36,909.4 (31,461.6 to 42,100.5)	55,086.1 (47,716.1 to 63,317.7)	49.2 (39.9 to 58.7)	-11.9 (-16.5 to -7.4)
Moderately severe hearing loss with ringing due to age-related and other hearing loss	17,808.3 (14,999.4 to 20,388.5)	26,587.9 (22,533.9 to 30,703.5)	49.1 (39.4 to 58.8)	-11.9 (-16.5 to -7.4)
Severe hearing loss with ringing due to age-related and other hearing loss	3,894.4 (3,197.3 to 4,808.0)	5,591.8 (4,487.9 to 7,076.8)	42.9 (26.8 to 64.9)	-7.3 (-16.7 to 6.6)
Severe hearing loss due to age-related and other hearing loss	6,851.0 (5,600.3 to 8,302.5)	9,812.1 (7,921.4 to 12,102.7)	42.8 (27.2 to 63.3)	-7.5 (-17.2 to 6.9)
Profound hearing loss due to age-related and other hearing loss	832.7 (510.9 to 1,308.1)	702.3 (429.2 to 1,087.7)	-15.7 (-29.8 to -1.0)	-26.1 (-38.0 to -13.8)
Profound hearing loss with ringing due to age-related and other hearing loss	1,470.0 (933.1 to 2,182.9)	1,239.3 (774.3 to 1,915.6)	-15.7 (-29.4 to -2.1)	-26.1 (-37.8 to -14.1)
Complete hearing loss due to age-related and other hearing loss	2,304.6 (1,729.1 to 2,949.6)	2,856.7 (2,134.3 to 3,589.4)	23.7 (13.6 to 36.5)	-18.7 (-23.1 to -12.6)
Complete hearing loss with ringing due to age-related and other hearing loss	2,758.1 (2,069.1 to 3,465.3)	3,419.1 (2,607.5 to 4,277.8)	23.9 (13.3 to 35.0)	-18.5 (-23.1 to -13.3)
Other vision loss	22,332.7 (20,238.0 to 24,730.9)	26,806.0 (24,116.0 to 29,696.9)	19.9 (16.0 to 23.8)	-22.2 (-25.0 to -19.9)
Moderate vision impairment due to other vision loss	16,624.9 (15,018.4 to 18,490.1)	19,532.8 (17,402.2 to 21,710.2)	17.3 (13.1 to 21.8)	-22.7 (-26.1 to -19.9)
Severe vision impairment due to other vision loss	1,660.7 (1,446.8 to 1,904.9)	2,178.1 (1,879.1 to 2,498.1)	30.8 (23.8 to 38.5)	-18.8 (-24.4 to -14.1)
Blindness due to other vision loss	4,047.0 (3,435.5 to 4,674.9)	5,095.1 (4,296.4 to 5,990.8)	25.7 (20.4 to 31.1)	-21.5 (-24.4 to -19.0)
Other sense organ diseases	122,518.2 (121,315.0 to 123,724.1)	164,612.2 (163,116.9 to 166,389.9)	34.2 (32.5 to 36.2)	-0.2 (-1.4 to 1.2)
Asymptomatic other sense organ diseases	47,861.8 (42,471.5 to 53,112.5)	64,306.0 (57,208.4 to 71,543.7)	34.2 (32.5 to 36.2)	-0.2 (-1.4 to 1.2)
Mild other sense organ diseases	13,977.4 (7,556.6 to 21,392.8)	18,778.4 (10,272.3 to 28,745.5)	34.2 (32.5 to 36.2)	-0.2 (-1.4 to 1.2)
Moderate other sense organ diseases	34,747.7 (28,702.8 to 41,272.4)	46,685.8 (38,602.5 to 55,592.0)	34.2 (32.5 to 36.2)	-0.2 (-1.4 to 1.2)
Severe other sense organ diseases	25,931.3 (19,354.0 to 32,831.3)	34,842.0 (25,976.7 to 44,022.9)	34.2 (32.5 to 36.2)	-0.2 (-1.4 to 1.2)
Oral disorders	-	-	-	-
Deciduous caries	471,320.1 (468,466.9 to 474,136.8)	492,920.5 (490,657.1 to 495,385.2)	4.4 (3.6 to 5.2)	-2.1 (-2.8 to -1.4)
Asymptomatic deciduous caries	454,347.9 (450,942.4 to 457,845.6)	474,970.4 (471,628.1 to 478,339.9)	4.4 (3.6 to 5.1)	-2.1 (-2.9 to -1.4)
Tooth pain due to deciduous caries	16,972.2 (14,674.2 to 19,233.8)	17,950.1 (15,483.2 to 20,362.1)	5.6 (4.7 to 6.5)	-1.0 (-1.8 to -0.1)
Permanent caries	1,913,245.6 (1,895,228.8 to 1,930,655.6)	2,633,328.8 (2,607,931.9 to 2,658,749.5)	37.4 (35.8 to 39.6)	-1.2 (-2.3 to 0.4)
Asymptomatic permanent caries	1,740,088.2 (1,710,611.8 to 1,766,915.7)	2,389,516.8 (2,349,585.1 to 2,428,950.7)	37.1 (35.5 to 39.3)	-1.5 (-2.6 to 0.1)
Tooth pain due to permanent caries	173,157.4 (151,726.0 to 195,106.7)	243,812.0 (212,074.3 to 276,401.9)	40.6 (38.5 to 43.1)	1.7 (0.1 to 3.5)
Periodontal diseases	301,875.9 (298,122.2 to 305,411.9)	503,967.2 (496,870.4 to 511,448.4)	66.7 (63.7 to 70.1)	1.4 (-0.4 to 3.4)
Edentulism and severe tooth loss	171,997.7 (169,933.8 to 174,084.9)	250,683.6 (247,512.3 to 253,463.0)	45.6 (43.4 to 47.9)	-16.4 (-17.7 to -15.1)
Asymptomatic edentulism and severe tooth loss	95,625.0 (94,030.6 to 97,326.1)	139,371.8 (137,013.7 to 141,871.9)	45.6 (43.4 to 47.9)	-16.4 (-17.7 to -15.1)
Difficulty eating due to edentulism and severe tooth loss	76,372.7 (74,928.0 to 77,804.3)	111,311.8 (109,207.9 to 113,419.4)	45.6 (43.4 to 47.9)	-16.4 (-17.7 to -15.1)
Other oral disorders	87,601.7 (86,773.2 to 88,584.0)	126,945.5 (125,452.3 to 128,568.2)	44.7 (42.5 to 46.9)	-0.5 (-2.0 to 0.9)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Mild other oral disorders	39,206.6 (31,989.6 to 46,004.2)	56,816.5 (46,254.2 to 66,802.2)	44.7 (42.5 to 46.9)	-0.5 (-2.0 to 0.9)
Severe other oral disorders	48,395.1 (41,401.3 to 55,558.1)	70,129.0 (60,116.1 to 80,184.8)	44.7 (42.5 to 46.9)	-0.5 (-2.0 to 0.9)
Injuries	-	-	-	-
Transport injuries	-	-	-	-
Road injuries	-	-	-	-
Pedestrian road injuries	-	-	-	-
Cyclist road injuries	-	-	-	-
Amputations	165.4 (161.2 to 170.0)	193.4 (188.5 to 198.7)	17.0 (12.8 to 21.9)	-18.2 (-21.0 to -14.9)
Burns	32.5 (31.6 to 33.3)	44.3 (43.3 to 45.7)	36.5 (32.1 to 41.2)	-6.5 (-9.6 to -3.4)
Fractures	7,114.3 (6,998.1 to 7,245.8)	9,185.6 (9,002.7 to 9,369.4)	29.1 (26.6 to 31.8)	-12.9 (-14.7 to -10.8)
Head Injury	507.9 (485.0 to 531.2)	611.9 (583.4 to 639.8)	20.5 (17.2 to 23.9)	-16.4 (-18.9 to -14.1)
Minor Injury	2,499.0 (2,312.1 to 2,727.9)	2,816.4 (2,649.8 to 3,007.1)	12.8 (7.9 to 17.6)	-20.1 (-23.0 to -17.1)
Other Injury	638.9 (619.8 to 659.8)	754.6 (730.8 to 779.3)	18.1 (14.8 to 21.5)	-18.1 (-20.3 to -15.9)
Spinal Lesions	60.9 (59.7 to 62.1)	72.4 (71.0 to 74.1)	18.8 (15.6 to 22.5)	-17.5 (-19.8 to -14.9)
Motorcyclist road injuries	-	-	-	-
Amputations	773.4 (760.7 to 785.6)	987.8 (968.4 to 1,011.4)	27.7 (24.5 to 31.4)	-16.2 (-18.4 to -13.8)
Burns	277.1 (268.8 to 284.4)	359.4 (348.1 to 375.8)	29.7 (24.4 to 35.6)	-16.4 (-20.0 to -12.2)
Fractures	13,700.0 (13,500.0 to 13,900.0)	18,100.0 (17,800.0 to 18,400.0)	32.0 (29.4 to 34.8)	-15.6 (-17.5 to -13.7)
Head Injury	849.4 (827.4 to 874.0)	1,020.3 (994.5 to 1,046.0)	20.1 (15.9 to 24.4)	-20.4 (-23.3 to -17.6)
Minor Injury	6,926.2 (6,560.3 to 7,365.9)	8,619.5 (8,196.5 to 9,015.2)	24.5 (18.9 to 29.8)	-18.7 (-22.1 to -15.4)
Other Injury	2,654.6 (2,596.2 to 2,715.7)	3,182.1 (3,097.0 to 3,277.5)	19.9 (16.2 to 24.0)	-20.7 (-23.1 to -18.0)
Spinal Lesions	177.2 (173.6 to 180.5)	204.2 (200.2 to 208.3)	15.3 (12.1 to 18.4)	-22.8 (-24.8 to -20.7)
Motor vehicle road injuries	-	-	-	-
Amputations	428.6 (420.8 to 437.4)	641.6 (629.6 to 653.7)	49.7 (45.6 to 53.9)	3.1 (0.5 to 5.9)
Burns	216.2 (210.2 to 222.5)	317.4 (308.1 to 327.9)	46.8 (40.5 to 52.7)	1.2 (-2.9 to 5.5)
Fractures	23,900.0 (23,500.0 to 24,200.0)	34,900.0 (34,400.0 to 35,400.0)	46.0 (43.8 to 48.5)	-0.5 (-2.3 to 1.3)
Head Injury	1,726.7 (1,692.8 to 1,765.0)	2,317.1 (2,269.3 to 2,374.3)	34.2 (30.8 to 37.6)	-5.7 (-8.1 to -3.4)
Minor Injury	10,700.0 (10,100.0 to 11,300.0)	13,900.0 (13,100.0 to 14,600.0)	29.8 (26.8 to 32.7)	-7.6 (-9.5 to -5.4)
Other Injury	5,656.7 (5,548.5 to 5,787.5)	8,070.5 (7,899.2 to 8,267.4)	42.7 (38.7 to 46.7)	-1.9 (-4.5 to 0.6)
Spinal Lesions	574.3 (565.9 to 582.2)	676.2 (666.7 to 685.2)	17.8 (15.4 to 20.1)	-17.5 (-19.1 to -15.9)
Other road injuries	-	-	-	-
Amputations	19.9 (19.4 to 20.4)	23.5 (22.8 to 24.3)	18.5 (13.3 to 23.6)	-21.0 (-24.2 to -17.9)
Burns	3.6 (3.5 to 3.8)	4.5 (4.3 to 4.7)	24.1 (16.8 to 30.7)	-19.5 (-24.3 to -15.4)
Fractures	734.3 (721.3 to 747.6)	870.5 (853.9 to 889.6)	18.6 (15.9 to 21.1)	-23.0 (-24.8 to -21.2)
Head Injury	53.9 (52.4 to 55.6)	63.2 (61.2 to 65.4)	17.3 (12.2 to 22.1)	-21.4 (-24.7 to -18.2)
Minor Injury	262.2 (253.5 to 272.4)	305.4 (295.5 to 316.3)	16.5 (12.2 to 21.7)	-23.0 (-25.7 to -19.8)
Other Injury	77.3 (75.5 to 79.5)	90.0 (87.7 to 92.5)	16.5 (12.5 to 20.6)	-22.0 (-24.6 to -19.4)
Spinal Lesions	12.0 (11.8 to 12.3)	14.3 (13.9 to 14.7)	18.7 (14.2 to 23.3)	-21.0 (-24.2 to -17.7)
Other transport injuries	-	-	-	-
Amputations	2,015.1 (1,976.5 to 2,057.2)	2,390.2 (2,349.2 to 2,435.6)	18.6 (15.0 to 22.5)	-23.1 (-25.5 to -20.6)
Burns	694.1 (662.8 to 727.2)	801.0 (766.3 to 843.0)	15.5 (8.2 to 23.5)	-25.3 (-30.6 to -19.5)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Fractures	13,300.0 (13,000.0 to 13,600.0)	16,600.0 (16,200.0 to 17,000.0)	25.3 (21.7 to 28.6)	-21.3 (-23.8 to -18.8)
Head Injury	414.8 (402.1 to 427.9)	489.2 (475.7 to 502.8)	18.0 (13.9 to 22.3)	-22.0 (-24.7 to -19.1)
Minor Injury	3,425.3 (3,259.0 to 3,610.3)	4,094.9 (3,927.1 to 4,279.1)	19.6 (14.7 to 24.5)	-22.2 (-25.3 to -19.0)
Other Injury	1,472.0 (1,419.4 to 1,527.8)	1,772.4 (1,718.3 to 1,827.9)	20.4 (17.2 to 23.9)	-21.2 (-23.3 to -18.9)
Spinal Lesions	114.8 (109.5 to 120.9)	129.8 (124.8 to 135.4)	13.1 (6.4 to 19.9)	-23.4 (-27.9 to -18.5)
Unintentional injuries	-	-	-	-
Falls	-	-	-	-
Amputations	1,866.9 (1,833.5 to 1,905.5)	2,911.9 (2,851.4 to 2,970.1)	56.0 (51.4 to 60.2)	2.3 (-0.8 to 5.0)
Burns	711.8 (695.6 to 730.8)	1,106.8 (1,078.2 to 1,135.5)	55.5 (49.9 to 61.0)	0.8 (-3.0 to 4.2)
Fractures	98,200.0 (97,300.0 to 99,100.0)	163,000.0 (162,000.0 to 165,000.0)	66.4 (64.3 to 68.4)	1.5 (0.2 to 2.7)
Head Injury	5,140.3 (5,046.2 to 5,244.6)	7,784.2 (7,646.7 to 7,925.6)	51.5 (47.6 to 55.1)	2.2 (-0.3 to 4.8)
Minor Injury	40,400.0 (38,900.0 to 41,900.0)	61,200.0 (59,300.0 to 62,900.0)	51.5 (48.5 to 54.3)	-1.3 (-3.1 to 0.5)
Other Injury	7,520.2 (7,313.0 to 7,717.6)	11,800.0 (11,400.0 to 12,100.0)	56.3 (53.5 to 59.2)	2.8 (1.0 to 4.6)
Spinal Lesions	1,161.1 (1,145.1 to 1,178.5)	1,843.8 (1,819.3 to 1,868.2)	58.8 (55.8 to 61.9)	4.1 (2.2 to 6.1)
Drowning	-	-	-	-
Amputations	370.8 (355.9 to 388.1)	355.1 (339.2 to 371.2)	-4.2 (-10.3 to 1.5)	-33.0 (-37.2 to -29.1)
Burns	104.3 (97.7 to 111.1)	102.4 (95.7 to 110.3)	-1.8 (-10.4 to 7.1)	-31.4 (-37.3 to -25.3)
Fractures	2,064.8 (2,021.1 to 2,108.4)	2,535.2 (2,476.4 to 2,597.7)	22.8 (19.0 to 26.6)	-19.6 (-22.1 to -17.0)
Head Injury	75.3 (72.2 to 79.5)	82.4 (78.5 to 86.3)	9.5 (2.7 to 15.8)	-24.8 (-29.3 to -20.3)
Minor Injury	957.3 (920.6 to 994.7)	1,161.5 (1,113.0 to 1,217.9)	21.4 (14.9 to 29.0)	-21.2 (-25.3 to -16.4)
Other Injury	1,771.1 (1,693.4 to 1,849.9)	1,847.6 (1,742.3 to 1,947.1)	4.4 (-2.4 to 11.2)	-28.4 (-33.5 to -23.5)
Spinal Lesions	63.1 (61.0 to 65.6)	64.8 (62.1 to 68.1)	2.8 (-4.0 to 9.0)	-27.3 (-31.9 to -23.0)
Fire, heat, and hot substances	-	-	-	-
Amputations	940.1 (889.6 to 1,001.4)	1,032.4 (971.9 to 1,107.2)	9.9 (1.5 to 20.7)	-26.6 (-32.1 to -19.3)
Burns	21,600.0 (20,800.0 to 22,500.0)	23,800.0 (23,000.0 to 24,600.0)	10.1 (4.3 to 16.6)	-28.1 (-32.0 to -23.3)
Fractures	1,654.8 (1,606.5 to 1,704.1)	1,813.8 (1,766.2 to 1,864.9)	9.6 (4.7 to 14.4)	-29.8 (-32.9 to -26.7)
Head Injury	109.6 (105.0 to 114.6)	121.2 (116.8 to 126.6)	10.7 (4.2 to 17.9)	-27.4 (-31.6 to -23.0)
Minor Injury	5,485.4 (4,572.3 to 6,368.0)	5,359.0 (4,562.9 to 6,162.4)	-2.2 (-6.8 to 2.7)	-30.5 (-33.9 to -27.1)
Other Injury	3,103.6 (2,712.2 to 3,482.2)	3,228.6 (2,869.8 to 3,581.0)	4.1 (-0.1 to 8.6)	-29.4 (-32.2 to -26.6)
Spinal Lesions	14.0 (13.2 to 14.8)	15.5 (14.8 to 16.2)	10.7 (2.1 to 18.7)	-23.2 (-29.1 to -18.1)
Poisonings	-	-	-	-
Amputations	27.2 (26.6 to 27.9)	28.9 (28.2 to 29.6)	6.2 (2.1 to 9.7)	-28.5 (-31.1 to -26.2)
Burns	137.1 (132.9 to 141.9)	151.2 (146.6 to 156.1)	10.3 (5.7 to 15.7)	-28.0 (-30.7 to -24.8)
Fractures	113.9 (112.5 to 115.3)	132.5 (130.5 to 134.5)	16.3 (14.1 to 18.8)	-24.3 (-25.8 to -22.8)
Head Injury	9.5 (9.3 to 9.6)	11.7 (11.5 to 12.0)	23.7 (20.5 to 27.2)	-21.1 (-23.1 to -18.9)
Minor Injury	121.8 (119.4 to 124.4)	146.8 (144.0 to 149.8)	20.5 (16.8 to 24.0)	-23.4 (-25.7 to -21.3)
Other Injury	469.4 (456.0 to 482.5)	452.3 (438.0 to 466.9)	-3.6 (-7.3 to -0.5)	-32.8 (-35.4 to -30.6)
Spinal Lesions	1.7 (1.6 to 1.7)	1.8 (1.7 to 1.8)	6.6 (2.0 to 12.0)	-26.1 (-29.2 to -22.4)
Exposure to mechanical forces	-	-	-	-
Unintentional firearm injuries	-	-	-	-
Amputations	78.6 (76.8 to 80.8)	103.7 (101.0 to 107.0)	31.9 (27.2 to 36.9)	-12.2 (-15.3 to -9.0)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Burns	36.1 (34.9 to 37.5)	48.1 (46.8 to 49.7)	33.2 (28.5 to 38.4)	-12.0 (-15.0 to -8.6)
Fractures	886.7 (872.4 to 902.6)	1,172.4 (1,154.1 to 1,194.5)	32.2 (29.5 to 35.1)	-13.1 (-14.7 to -11.3)
Head Injury	26.4 (25.6 to 27.2)	34.3 (33.4 to 35.3)	30.2 (26.0 to 34.5)	-11.6 (-14.2 to -8.7)
Minor Injury	1,555.6 (1,495.1 to 1,624.3)	2,015.9 (1,942.8 to 2,088.0)	29.6 (23.7 to 36.1)	-13.4 (-17.2 to -9.3)
Other Injury	245.6 (203.1 to 288.8)	305.1 (255.8 to 357.0)	24.3 (21.4 to 27.3)	-13.0 (-14.7 to -11.1)
Spinal Lesions	41.2 (39.9 to 42.5)	49.6 (48.1 to 50.9)	20.3 (15.2 to 25.9)	-15.9 (-19.2 to -12.1)
Unintentional suffocation	-	-	-	-
Amputations	7.3 (7.1 to 7.6)	11.9 (11.6 to 12.3)	63.0 (55.8 to 72.5)	11.6 (6.9 to 17.6)
Burns	5.0 (4.8 to 5.1)	9.2 (8.9 to 9.5)	85.2 (78.7 to 93.7)	19.8 (15.6 to 25.2)
Fractures	312.5 (303.1 to 324.7)	536.5 (524.9 to 550.5)	71.7 (68.0 to 75.5)	14.4 (12.2 to 16.7)
Head Injury	9.7 (9.4 to 10.2)	17.0 (16.4 to 17.6)	74.4 (67.4 to 80.6)	18.4 (14.0 to 22.5)
Minor Injury	159.8 (142.7 to 179.2)	254.3 (233.3 to 276.9)	59.3 (52.3 to 65.6)	13.3 (9.5 to 16.7)
Other Injury	67.9 (64.1 to 72.6)	107.1 (101.3 to 113.4)	57.7 (53.7 to 61.9)	7.1 (4.6 to 9.9)
Spinal Lesions	8.2 (7.8 to 8.6)	13.6 (13.0 to 14.3)	66.5 (57.0 to 77.5)	133.0 (120.8 to 147.1)
Other exposure to mechanical forces	-	-	-	-
Amputations	6,181.7 (6,103.1 to 6,268.5)	7,773.7 (7,660.9 to 7,882.6)	25.8 (23.1 to 28.2)	-14.1 (-15.9 to -12.5)
Burns	1,321.4 (1,286.1 to 1,363.6)	1,661.1 (1,615.8 to 1,715.1)	25.7 (20.5 to 30.6)	-15.6 (-19.3 to -12.2)
Fractures	31,900.0 (31,400.0 to 32,400.0)	38,000.0 (37,400.0 to 38,600.0)	18.9 (17.2 to 20.9)	-19.2 (-20.3 to -18.0)
Head Injury	1,139.8 (1,098.2 to 1,179.0)	1,252.8 (1,215.9 to 1,290.6)	9.9 (7.4 to 12.7)	-22.9 (-24.5 to -21.2)
Minor Injury	50,100.0 (43,200.0 to 57,400.0)	56,200.0 (48,900.0 to 63,400.0)	12.3 (7.6 to 16.6)	-17.9 (-21.1 to -14.9)
Other Injury	6,908.6 (5,465.7 to 8,355.6)	8,036.1 (6,492.1 to 9,548.9)	16.4 (13.8 to 19.4)	-16.8 (-18.3 to -15.5)
Spinal Lesions	180.0 (175.6 to 184.2)	187.3 (183.5 to 191.6)	4.1 (1.0 to 7.9)	-26.5 (-28.6 to -23.8)
Adverse effects of medical treatment	-	-	-	-
Animal contact	-	-	-	-
Venomous animal contact	-	-	-	-
Amputations	95.1 (87.9 to 101.6)	98.5 (93.0 to 104.5)	3.8 (-5.1 to 13.2)	-30.7 (-36.5 to -24.4)
Burns	74.2 (69.4 to 79.7)	77.4 (73.2 to 82.2)	4.4 (4.9 to 13.9)	-30.3 (-36.3 to -24.0)
Fractures	365.7 (351.3 to 381.2)	384.9 (371.8 to 400.4)	5.3 (-0.4 to 10.9)	-30.5 (-34.1 to -26.8)
Head Injury	21.3 (19.7 to 23.5)	22.1 (20.5 to 24.0)	3.9 (-8.3 to 16.1)	-29.3 (-37.1 to -21.8)
Minor Injury	856.2 (785.4 to 936.2)	901.4 (841.4 to 965.0)	5.4 (-3.9 to 15.8)	-29.9 (-36.0 to -23.3)
Other Injury	799.9 (762.2 to 838.3)	785.8 (754.3 to 818.9)	-1.7 (-7.2 to 4.0)	-32.8 (-36.4 to -28.9)
Spinal Lesions	3.9 (3.5 to 4.4)	4.0 (3.8 to 4.4)	4.6 (-12.6 to 21.2)	-27.2 (-38.6 to -15.7)
Non-venomous animal contact	-	-	-	-
Amputations	281.5 (266.9 to 296.7)	286.8 (276.0 to 299.3)	1.9 (-4.6 to 8.5)	-32.5 (-36.7 to -28.2)
Burns	23.9 (22.5 to 25.5)	26.2 (24.8 to 27.2)	9.4 (1.4 to 17.4)	-29.7 (-34.5 to -24.5)
Fractures	1,330.9 (1,300.4 to 1,366.4)	1,581.8 (1,551.6 to 1,617.6)	18.9 (15.4 to 22.3)	-25.2 (-27.4 to -22.9)
Head Injury	85.0 (79.8 to 90.4)	87.2 (83.4 to 91.2)	2.7 (-5.3 to 10.8)	-29.3 (-34.6 to -24.0)
Minor Injury	10,600.0 (8,383.8 to 13,000.0)	9,546.7 (7,966.0 to 11,200.0)	-9.4 (-15.2 to -2.9)	-34.1 (-37.8 to -30.1)
Other Injury	533.8 (508.6 to 562.1)	553.3 (529.2 to 578.1)	3.7 (-0.7 to 7.5)	-30.5 (-33.5 to -28.1)
Spinal Lesions	7.1 (6.5 to 7.7)	7.9 (7.5 to 8.3)	11.9 (1.0 to 24.3)	-21.9 (-29.7 to -13.5)
Foreign body	-	-	-	-

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Pulmonary aspiration and foreign body in airway	-	-	-	-
Amputations	45.2 (43.9 to 46.7)	59.3 (57.7 to 61.3)	31.1 (26.8 to 36.5)	-8.2 (-11.2 to -4.6)
Burns	13.5 (13.1 to 13.9)	19.7 (19.1 to 20.3)	46.1 (40.2 to 51.7)	-2.8 (-6.7 to 1.3)
Fractures	224.3 (221.4 to 227.3)	349.9 (346.2 to 353.9)	56.0 (53.4 to 58.4)	-0.0 (-1.7 to 1.5)
Head Injury	8.0 (7.9 to 8.1)	12.0 (11.8 to 12.2)	50.3 (47.1 to 53.8)	-2.1 (-4.7 to 0.3)
Minor Injury	233.9 (227.3 to 241.3)	324.6 (315.4 to 335.3)	38.8 (32.9 to 44.9)	-5.8 (-9.4 to -1.9)
Other Injury	85.9 (74.1 to 99.7)	105.5 (95.3 to 116.3)	22.9 (15.7 to 29.4)	-13.2 (-17.3 to -9.4)
Spinal Lesions	12.4 (12.0 to 12.8)	16.8 (16.4 to 17.3)	36.2 (30.3 to 42.4)	-6.5 (-10.7 to -1.8)
Foreign body in eyes	-	-	-	-
Minor Injury	177.6 (171.7 to 183.1)	270.7 (263.5 to 277.7)	52.5 (47.2 to 58.9)	-0.2 (-3.4 to 3.7)
Other Injury	576.8 (256.5 to 893.3)	784.7 (357.7 to 1,206.8)	36.4 (32.7 to 40.8)	0.5 (-1.8 to 3.0)
Foreign body in other body part	-	-	-	-
Amputations	41.3 (40.0 to 42.7)	66.3 (64.5 to 68.7)	60.7 (53.3 to 67.8)	4.6 (-0.3 to 9.2)
Burns	38.5 (37.4 to 39.6)	60.8 (59.0 to 62.9)	57.9 (51.5 to 64.8)	0.7 (-3.8 to 5.8)
Fractures	202.8 (192.4 to 222.0)	320.0 (306.7 to 342.9)	57.9 (52.4 to 62.3)	2.0 (-1.1 to 4.8)
Head Injury	7.7 (7.3 to 8.2)	12.3 (11.7 to 13.0)	59.6 (52.7 to 65.8)	3.9 (-0.4 to 8.1)
Minor Injury	1,791.4 (1,389.1 to 2,247.0)	2,495.5 (2,068.9 to 2,937.2)	39.9 (29.1 to 51.1)	-5.0 (-11.2 to 1.1)
Other Injury	673.7 (536.4 to 805.3)	949.0 (783.4 to 1,104.4)	41.1 (35.6 to 47.7)	-3.9 (-6.8 to -0.5)
Spinal Lesions	5.6 (5.5 to 5.8)	8.5 (8.3 to 8.7)	52.0 (46.7 to 57.4)	4.0 (0.2 to 7.9)
Other unintentional injuries	-	-	-	-
Amputations	695.9 (681.4 to 710.8)	997.9 (979.5 to 1,019.9)	43.4 (39.3 to 47.6)	-3.7 (-6.3 to -1.0)
Burns	1,684.8 (1,630.8 to 1,741.2)	2,448.2 (2,380.4 to 2,523.2)	45.3 (39.0 to 51.4)	-4.1 (-8.3 to -0.2)
Fractures	19,700.0 (19,400.0 to 20,100.0)	29,300.0 (28,700.0 to 29,900.0)	48.4 (45.4 to 52.2)	-4.2 (-6.3 to -2.0)
Head Injury	273.3 (265.5 to 281.9)	395.0 (384.5 to 406.8)	44.5 (41.1 to 47.8)	-2.3 (-4.4 to -0.2)
Minor Injury	8,729.7 (7,472.2 to 9,916.2)	12,000.0 (10,300.0 to 13,500.0)	37.3 (33.6 to 41.1)	-3.9 (-6.2 to -1.6)
Other Injury	4,057.8 (3,583.3 to 4,521.3)	5,956.7 (5,297.1 to 6,590.1)	46.8 (42.6 to 51.4)	-2.6 (-5.0 to 0.2)
Spinal Lesions	58.0 (57.1 to 59.0)	92.0 (90.4 to 93.6)	58.6 (54.7 to 62.5)	4.9 (2.3 to 7.4)
Selfharm and interpersonal violence	-	-	-	-
Selfharm	-	-	-	-
Amputations	310.4 (306.9 to 314.2)	365.8 (361.9 to 369.4)	17.8 (15.9 to 19.7)	-26.5 (-27.6 to -25.5)
Burns	173.5 (170.4 to 176.8)	207.7 (204.5 to 211.2)	19.7 (17.0 to 22.7)	-27.4 (-29.1 to -25.6)
Fractures	638.7 (632.1 to 645.9)	782.8 (774.5 to 792.1)	22.6 (20.9 to 24.4)	-25.6 (-26.5 to -24.6)
Head Injury	51.9 (51.0 to 52.7)	65.6 (64.7 to 66.6)	26.6 (24.1 to 29.2)	-21.8 (-23.2 to -20.3)
Minor Injury	2,852.9 (2,787.5 to 2,930.3)	3,520.9 (3,426.5 to 3,629.7)	23.4 (18.6 to 27.8)	-23.6 (-26.3 to -21.1)
Other Injury	839.1 (826.4 to 852.4)	969.9 (955.8 to 986.1)	15.6 (13.4 to 18.2)	-26.8 (-28.2 to -25.3)
Spinal Lesions	22.2 (21.9 to 22.5)	28.1 (27.8 to 28.4)	26.7 (24.6 to 28.9)	-18.5 (-19.8 to -17.1)
Interpersonal violence	-	-	-	-
Assault by firearm	-	-	-	-
Amputations	30.8 (29.9 to 31.6)	51.2 (49.4 to 52.8)	66.1 (59.4 to 73.3)	8.5 (4.1 to 13.1)
Burns	12.5 (12.1 to 13.3)	20.0 (19.3 to 21.2)	60.4 (52.2 to 68.0)	2.8 (-2.4 to 7.6)
Fractures	861.2 (842.8 to 881.5)	1,249.8 (1,225.3 to 1,273.5)	45.1 (41.4 to 49.0)	-5.0 (-7.3 to -2.9)

Appendix Table G.1: Prevalence numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013
Head Injury	39.1 (35.5 to 42.5)	62.9 (57.1 to 68.4)	61.1 (55.7 to 67.1)	5.3 (1.7 to 9.2)
Minor Injury	1,397.3 (1,327.5 to 1,470.4)	2,060.9 (1,966.0 to 2,158.7)	47.5 (40.6 to 55.1)	-2.5 (-7.0 to 2.2)
Other Injury	240.1 (223.8 to 259.7)	345.1 (322.0 to 373.5)	43.7 (40.1 to 47.5)	-4.0 (-6.3 to -1.5)
Spinal Lesions	58.1 (55.6 to 61.2)	80.2 (76.9 to 84.1)	38.2 (28.1 to 47.2)	-4.4 (-10.8 to 1.6)
Assault by sharp object	-	-	-	-
Amputations	157.6 (154.1 to 161.1)	230.9 (226.6 to 235.9)	46.5 (42.1 to 51.0)	-3.7 (-6.6 to -0.7)
Burns	26.0 (25.1 to 27.4)	37.0 (35.9 to 38.5)	42.2 (35.7 to 48.5)	-4.9 (-8.7 to -0.6)
Fractures	411.3 (404.4 to 418.9)	598.6 (587.9 to 609.1)	45.6 (42.6 to 48.6)	-6.2 (-8.3 to -4.3)
Head Injury	34.6 (33.6 to 35.7)	54.8 (53.4 to 56.7)	58.3 (53.5 to 63.3)	2.3 (-0.8 to 5.5)
Minor Injury	3,212.0 (3,007.7 to 3,453.6)	4,523.6 (4,315.0 to 4,751.0)	40.9 (33.9 to 47.8)	-7.5 (-11.8 to -3.1)
Other Injury	418.2 (404.4 to 434.9)	597.9 (580.6 to 618.4)	43.0 (40.0 to 45.9)	-6.6 (-8.4 to -4.8)
Spinal Lesions	24.6 (23.5 to 25.9)	35.7 (34.3 to 37.7)	45.5 (35.8 to 55.1)	-3.3 (-9.5 to 3.0)
Assault by other means	-	-	-	-
Amputations	247.0 (241.6 to 252.6)	308.8 (302.2 to 316.3)	25.0 (21.0 to 28.8)	-15.8 (-18.4 to -13.4)
Burns	489.3 (474.2 to 506.3)	618.7 (599.2 to 641.4)	26.5 (21.1 to 33.2)	-15.9 (-19.4 to -11.5)
Fractures	2,474.5 (2,441.3 to 2,510.4)	3,153.7 (3,111.7 to 3,204.7)	27.4 (25.5 to 29.9)	-16.2 (-17.5 to -14.7)
Head Injury	420.9 (409.8 to 432.0)	536.3 (522.8 to 550.0)	27.4 (24.7 to 29.9)	-14.7 (-16.4 to -13.2)
Minor Injury	3,673.2 (3,341.5 to 4,066.3)	4,218.2 (3,941.8 to 4,508.9)	14.9 (10.3 to 19.3)	-20.7 (-23.6 to -18.1)
Other Injury	989.3 (913.5 to 1,066.0)	1,224.1 (1,138.0 to 1,312.3)	23.8 (20.8 to 26.6)	-15.2 (-16.9 to -13.5)
Spinal Lesions	56.3 (54.7 to 57.9)	73.6 (71.7 to 76.1)	30.8 (25.8 to 36.2)	-12.5 (-15.7 to -8.9)
Forces of nature, war, and legal intervention	-	-	-	-
Exposure to forces of nature	-	-	-	-
Amputations	1,218.4 (132.3 to 3,809.6)	1,197.9 (159.8 to 3,764.9)	4.5 (-12.7 to 33.1)	-37.0 (-48.0 to -20.2)
Burns	4,464.6 (2,085.1 to 8,534.3)	4,547.6 (1,939.3 to 9,476.5)	0.4 (-13.2 to 25.6)	-41.7 (-50.6 to -27.3)
Fractures	1,768.8 (799.6 to 3,514.7)	1,664.6 (786.4 to 3,348.3)	-5.3 (-20.0 to 15.5)	-47.4 (-56.5 to -35.0)
Head Injury	107.9 (54.3 to 226.2)	118.2 (60.9 to 249.3)	10.4 (5.8 to 28.4)	-34.0 (-46.1 to -20.7)
Minor Injury	1,293.5 (565.7 to 2,650.8)	1,521.9 (598.0 to 3,229.0)	16.9 (0.2 to 34.9)	-31.0 (-41.8 to -18.8)
Other Injury	4,288.8 (2,339.8 to 8,206.7)	5,247.2 (2,733.7 to 10,700.0)	21.6 (8.8 to 40.4)	-29.8 (-38.6 to -17.2)
Spinal Lesions	32.9 (12.4 to 70.6)	38.1 (15.1 to 80.0)	17.0 (-0.4 to 37.1)	-31.7 (-43.0 to -19.2)
Collective violence and legal intervention	-	-	-	-
Amputations	2,359.6 (1,275.0 to 4,095.8)	2,182.9 (1,230.4 to 3,625.7)	-6.9 (-12.7 to 0.7)	-27.1 (-33.1 to -20.7)
Burns	2,589.6 (396.1 to 6,770.1)	1,793.6 (299.4 to 4,769.4)	-30.3 (-35.2 to -19.4)	-50.7 (-55.5 to -43.1)
Fractures	23,300.0 (9,047.4 to 50,100.0)	16,500.0 (6,439.2 to 35,400.0)	-29.2 (-34.1 to -20.8)	-49.1 (-53.3 to -43.9)
Head Injury	1,111.6 (545.2 to 2,105.5)	772.6 (400.0 to 1,390.6)	-29.9 (-36.4 to -21.0)	-51.0 (-56.5 to -44.3)
Minor Injury	15,200.0 (7,892.3 to 27,700.0)	11,600.0 (5,444.5 to 21,000.0)	-24.1 (-35.5 to -9.5)	-42.4 (-51.8 to -32.0)
Other Injury	14,000.0 (6,744.0 to 25,500.0)	9,811.3 (4,660.5 to 18,300.0)	-30.1 (-34.9 to -21.2)	-49.6 (-53.7 to -44.3)
Spinal Lesions	984.7 (553.3 to 1,709.9)	851.4 (503.1 to 1,394.1)	-12.8 (-19.8 to -5.4)	-32.5 (-38.9 to -25.8)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	537,597.0 (400,064.9 to 698,084.4)	764,804.4 (572,379.6 to 990,467.0)	42.3 (40.2 to 44.3)	-3.9 (-5.1 to -3.0)
Communicable, maternal, neonatal, and nutritional diseases	94,398.4 (65,927.6 to 131,136.5)	101,495.1 (71,533.1 to 138,458.0)	7.6 (4.0 to 11.8)	-15.2 (-18.0 to -12.2)
HIV/AIDS and tuberculosis	3,427.9 (2,394.5 to 4,496.2)	7,733.3 (5,494.4 to 10,077.9)	125.4 (113.7 to 141.0)	47.1 (39.5 to 57.4)
Tuberculosis	2,417.7 (1,658.4 to 3,224.2)	3,669.7 (2,519.7 to 4,889.1)	51.9 (48.6 to 55.2)	-1.3 (-3.4 to 0.7)
HIV/AIDS	1,010.2 (715.2 to 1,306.6)	4,063.7 (2,918.9 to 5,327.4)	301.7 (259.4 to 354.3)	171.5 (142.0 to 208.7)
HIV/AIDS resulting in mycobacterial infection	72.0 (41.1 to 108.4)	268.3 (162.5 to 388.6)	275.5 (218.1 to 335.1)	144.6 (104.9 to 185.4)
HIV/AIDS resulting in other diseases	938.2 (666.6 to 1,220.1)	3,795.3 (2,726.7 to 4,974.6)	304.1 (257.2 to 361.0)	174.0 (140.9 to 214.3)
Early HIV	69.9 (35.4 to 127.9)	143.9 (71.5 to 265.4)	104.8 (92.2 to 126.3)	43.9 (35.0 to 59.3)
Symptomatic HIV	501.1 (339.2 to 686.7)	1,059.7 (719.9 to 1,489.8)	110.2 (97.4 to 131.0)	47.3 (38.5 to 62.7)
AIDS with antiretroviral treatment	0.0 (0.0 to 0.0)	633.6 (429.3 to 883.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
AIDS without antiretroviral treatment	367.2 (245.8 to 501.3)	1,958.1 (1,344.0 to 2,659.1)	434.6 (316.4 to 582.5)	238.9 (162.8 to 333.0)
Diarrhea, lower respiratory, and other common infectious diseases	14,272.1 (10,126.0 to 19,264.1)	14,339.7 (10,108.4 to 19,541.9)	0.2 (-2.8 to 4.6)	-16.5 (-18.5 to -13.6)
Diarrheal diseases	7,361.6 (5,060.7 to 10,165.5)	6,854.2 (4,701.9 to 9,415.3)	-6.9 (-9.2 to -4.7)	-18.0 (-19.9 to -16.0)
Mild diarrheal diseases	787.9 (525.2 to 1,129.7)	733.9 (483.8 to 1,044.4)	-6.9 (-9.4 to -4.1)	-18.0 (-20.1 to -15.7)
Moderate diarrheal diseases	5,065.9 (3,382.3 to 7,024.5)	4,715.7 (3,163.5 to 6,615.2)	-7.0 (-9.1 to -4.5)	-18.0 (-19.9 to -15.9)
Severe diarrheal diseases	1,506.9 (1,008.9 to 2,098.1)	1,403.2 (940.2 to 1,955.0)	-6.8 (-9.8 to -4.1)	-17.9 (-20.3 to -15.5)
Guillain-Barré syndrome due to diarrheal diseases	0.9 (0.5 to 1.3)	1.3 (0.8 to 1.9)	45.0 (35.2 to 55.3)	0.9 (-5.6 to 7.8)
Intestinal infectious diseases	265.9 (180.0 to 367.8)	203.7 (138.5 to 281.4)	-23.3 (-32.2 to -12.9)	-35.7 (-43.1 to -27.3)
Typhoid fever	195.9 (129.9 to 274.2)	158.6 (109.0 to 223.3)	-19.0 (-30.5 to -4.2)	-32.3 (-41.8 to -20.5)
Acute typhoid infection	25.8 (15.1 to 39.6)	20.6 (11.9 to 31.2)	-19.4 (-32.8 to -3.7)	-32.8 (-43.5 to -20.0)
Severe typhoid fever	91.3 (58.3 to 133.6)	73.4 (47.3 to 109.7)	-19.4 (-32.1 to -3.9)	-32.6 (-43.2 to -19.9)
Intestinal perforation due to typhoid	77.5 (41.9 to 122.8)	63.5 (34.4 to 101.3)	-18.2 (-32.0 to 1.1)	-31.8 (-43.2 to -16.2)
Gastrointestinal bleeding due to typhoid	1.4 (0.0 to 9.1)	1.1 (0.0 to 7.2)	-19.9 (-30.7 to -6.5)	-33.3 (-41.9 to -22.3)
Paratyphoid fever	52.6 (32.9 to 77.6)	38.3 (24.0 to 57.6)	-27.1 (-41.6 to -9.7)	-38.4 (-50.3 to -23.9)
Acute paratyphoid infection	1.7 (0.6 to 3.8)	1.2 (0.4 to 2.8)	-27.6 (-44.4 to -9.0)	-38.7 (-52.8 to -23.5)
Moderate paratyphoid fever	25.9 (14.1 to 41.3)	18.8 (10.4 to 30.3)	-27.6 (-42.7 to -8.6)	-38.6 (-51.6 to -22.1)
Severe paratyphoid fever	19.1 (9.0 to 33.3)	14.0 (6.4 to 25.3)	-27.0 (-44.6 to -3.1)	-38.3 (-52.9 to -18.4)
Intestinal perforation due to paratyphoid	5.9 (2.6 to 11.2)	4.3 (2.0 to 7.9)	-26.8 (-45.3 to 0.2)	-38.5 (-53.4 to -17.3)
Other intestinal infectious diseases	17.4 (8.3 to 33.3)	6.8 (3.2 to 13.4)	-61.0 (-67.6 to -51.8)	-67.4 (-72.9 to -59.7)
Lower respiratory infections	537.5 (362.8 to 754.1)	460.9 (310.5 to 642.7)	-14.1 (-17.4 to -11.7)	-26.1 (-28.9 to -24.2)
Moderate lower respiratory infections	75.1 (45.0 to 116.5)	64.6 (38.5 to 99.6)	-14.0 (-17.2 to -10.7)	-26.1 (-28.8 to -23.2)
Severe lower respiratory infections	461.4 (306.0 to 652.8)	395.0 (264.2 to 555.4)	-14.3 (-17.7 to -11.8)	-26.2 (-28.9 to -24.2)
Guillain-Barré syndrome due to lower respiratory infections	0.9 (0.5 to 1.5)	1.3 (0.6 to 2.2)	45.0 (35.2 to 55.3)	0.9 (-5.6 to 7.8)
Upper respiratory infections	2,068.0 (1,152.6 to 3,412.8)	2,863.1 (1,597.9 to 4,763.5)	38.4 (35.4 to 41.6)	6.6 (4.4 to 9.0)
Mild upper respiratory infections	859.4 (344.7 to 1,796.4)	1,189.8 (478.5 to 2,495.1)	38.4 (35.6 to 41.6)	6.6 (4.5 to 8.9)
Moderate upper respiratory infections	1,206.2 (777.7 to 1,753.7)	1,669.6 (1,075.9 to 2,430.0)	38.4 (35.3 to 41.9)	6.7 (4.3 to 9.2)
Guillain-Barré syndrome due to upper respiratory infections	2.5 (1.6 to 3.5)	3.6 (2.4 to 5.1)	45.0 (35.2 to 55.3)	0.9 (-5.6 to 7.8)
Otitis media	1,482.0 (880.2 to 2,377.7)	1,696.4 (1,017.6 to 2,697.9)	14.4 (11.4 to 17.6)	-10.1 (-12.2 to -7.7)
Acute otitis media	237.5 (122.6 to 417.1)	234.9 (121.9 to 417.4)	-1.2 (-4.5 to 2.4)	-12.5 (-15.4 to -9.4)
Severe infectious complications due to chronic otitis media	0.6 (0.0 to 2.2)	0.6 (0.0 to 2.5)	9.7 (7.0 to 12.8)	-9.7 (-11.8 to -7.1)
Vertigo with mild hearing loss due to chronic otitis media	71.4 (43.4 to 103.5)	78.7 (47.9 to 116.0)	10.2 (2.8 to 18.0)	-9.1 (-14.9 to -3.0)
Vertigo with mild hearing loss and ringing due to chronic otitis media	77.4 (46.8 to 112.1)	85.5 (52.8 to 125.0)	10.2 (3.4 to 18.6)	-9.0 (-14.5 to -2.4)
Mild hearing loss due to chronic otitis media	322.6 (143.6 to 634.4)	386.0 (171.8 to 755.9)	19.7 (16.8 to 22.8)	-10.8 (-12.9 to -8.5)
Mild hearing loss with ringing due to chronic otitis media	181.3 (99.8 to 300.7)	217.9 (119.9 to 363.0)	20.2 (16.6 to 23.9)	-10.9 (-13.3 to -8.3)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Vertigo with moderate hearing loss due to chronic otitis media	79.1 (48.7 to 115.7)	87.1 (54.2 to 126.0)	10.2 (3.0 to 17.8)	-9.2 (-15.1 to -2.9)
Vertigo with moderate hearing loss and ringing due to chronic otitis media	100.5 (61.5 to 146.2)	110.8 (68.8 to 161.0)	10.4 (3.3 to 17.7)	-9.5 (-15.2 to -3.5)
Moderate hearing loss due to chronic otitis media	198.3 (114.0 to 328.3)	237.5 (136.2 to 394.4)	19.6 (14.8 to 25.8)	-8.8 (-12.4 to -4.5)
Moderate hearing loss with ringing due to chronic otitis media	213.1 (136.2 to 314.8)	257.4 (165.1 to 390.1)	20.6 (14.2 to 27.2)	-8.7 (-13.0 to -4.1)
Meningitis	1,902.7 (1,323.2 to 2,550.8)	1,679.1 (1,165.8 to 2,259.6)	-11.7 (-15.5 to -7.9)	-31.4 (-34.4 to -27.8)
Pneumococcal meningitis	736.2 (520.3 to 982.0)	698.1 (494.1 to 917.8)	-5.2 (-11.5 to 3.4)	-27.6 (-32.1 to -20.9)
Acute pneumococcal meningitis	8.6 (5.8 to 12.2)	7.1 (4.7 to 10.1)	-17.3 (-25.8 to -8.7)	-26.0 (-33.5 to -18.7)
Mild behavioral problems due to pneumococcal meningitis	18.6 (7.4 to 37.0)	17.4 (6.7 to 35.2)	-7.0 (-18.0 to 3.8)	-32.4 (-40.2 to -24.5)
Mild motor impairment due to long term due to pneumococcal meningitis	12.1 (3.8 to 28.3)	12.0 (3.7 to 28.3)	-1.3 (-12.1 to 10.6)	-28.6 (-36.4 to -19.9)
Mild motor plus cognitive impairments due to pneumococcal meningitis	20.9 (8.1 to 40.7)	18.6 (6.8 to 37.5)	-11.4 (-20.9 to -0.8)	-35.3 (-42.1 to -27.7)
Borderline intellectual disability due to pneumococcal meningitis	8.9 (3.0 to 20.7)	7.9 (2.6 to 18.1)	-11.6 (-21.0 to -0.9)	-35.4 (-42.3 to -27.6)
Monocular distance vision loss due to pneumococcal meningitis	12.4 (4.5 to 26.7)	11.6 (4.1 to 25.9)	-7.2 (-16.2 to 3.3)	-32.5 (-38.9 to -25.0)
Mild intellectual disability due to pneumococcal meningitis	27.2 (16.0 to 41.0)	24.5 (14.6 to 37.4)	-9.9 (-18.5 to 1.2)	-30.3 (-36.8 to -21.9)
Moderate motor impairment due to pneumococcal meningitis	23.7 (14.6 to 35.7)	26.7 (16.7 to 39.5)	12.5 (-2.1 to 31.9)	-13.5 (-24.8 to 1.0)
Severe motor impairment due to pneumococcal meningitis	144.1 (93.5 to 208.3)	144.0 (94.9 to 208.1)	-0.2 (-11.7 to 15.0)	-23.0 (-31.9 to -11.5)
Moderate motor plus cognitive impairments due to pneumococcal meningitis	90.2 (55.7 to 134.5)	81.4 (51.4 to 121.8)	-10.1 (-20.0 to 2.0)	-30.3 (-37.9 to -21.1)
Severe motor plus cognitive impairments due to pneumococcal meningitis	235.0 (153.2 to 328.0)	212.4 (135.1 to 297.3)	-9.7 (-19.2 to 2.4)	-29.9 (-37.4 to -20.5)
Epilepsy due to pneumococcal meningitis	39.9 (26.9 to 54.1)	59.1 (39.8 to 79.6)	48.7 (20.1 to 81.0)	16.9 (-5.1 to 41.2)
Blindness due to pneumococcal meningitis	30.0 (15.9 to 49.9)	23.9 (11.7 to 41.4)	-21.2 (-33.6 to -6.5)	-46.9 (-54.9 to -37.9)
Mild hearing loss due to pneumococcal meningitis	6.4 (0.4 to 15.2)	6.4 (0.4 to 15.7)	-1.6 (-12.8 to 10.2)	-33.1 (-40.5 to -24.9)
Mild hearing loss with ringing due to pneumococcal meningitis	3.8 (0.3 to 8.2)	3.8 (0.3 to 8.4)	-1.5 (-14.5 to 10.8)	-33.0 (-41.8 to -24.6)
Moderate hearing loss due to pneumococcal meningitis	6.9 (0.5 to 14.8)	7.1 (0.5 to 15.1)	2.2 (-14.6 to 24.5)	-27.0 (-38.7 to -11.9)
Moderate hearing loss with ringing due to pneumococcal meningitis	8.4 (0.7 to 16.5)	8.6 (0.6 to 17.3)	2.7 (-12.6 to 19.8)	-26.6 (-36.8 to -14.9)
Moderately severe hearing loss due to pneumococcal meningitis	8.4 (0.6 to 16.4)	6.5 (0.4 to 12.8)	-22.9 (-37.0 to -6.8)	-42.1 (-51.9 to -31.1)
Moderately severe hearing loss with ringing due to pneumococcal meningitis	7.3 (0.6 to 14.1)	5.7 (0.4 to 11.5)	-22.7 (-37.8 to -7.0)	-42.0 (-51.9 to -31.1)
Severe hearing loss due to pneumococcal meningitis	2.8 (0.2 to 5.6)	1.9 (0.1 to 3.9)	-30.3 (-41.3 to -17.8)	-42.3 (-51.4 to -32.1)
Severe hearing loss with ringing due to pneumococcal meningitis	8.0 (0.6 to 15.6)	5.6 (0.4 to 11.3)	-30.3 (-41.0 to -17.1)	-42.3 (-51.1 to -31.4)
Profound hearing loss due to pneumococcal meningitis	2.4 (0.2 to 5.1)	1.0 (0.1 to 2.3)	-57.8 (-71.0 to -43.2)	-61.1 (-73.1 to -47.8)
Profound hearing loss with ringing due to pneumococcal meningitis	5.9 (0.4 to 11.7)	2.5 (0.2 to 5.5)	-57.9 (-72.4 to -41.2)	-61.1 (-74.4 to -45.5)
Complete hearing loss due to pneumococcal meningitis	1.5 (0.1 to 3.1)	0.8 (0.1 to 1.7)	-45.7 (-51.3 to -38.3)	-54.7 (-59.0 to -49.6)
Complete hearing loss with ringing due to pneumococcal meningitis	2.6 (0.2 to 5.3)	1.4 (0.1 to 3.0)	-45.6 (-51.5 to -38.7)	-54.5 (-59.0 to -49.5)
H influenzae type B meningitis	432.8 (297.3 to 598.7)	375.5 (258.8 to 510.3)	-13.7 (-20.5 to -3.3)	-31.0 (-36.3 to -22.3)
Acute H influenzae type B meningitis	9.3 (6.3 to 13.4)	6.1 (4.1 to 8.9)	-34.2 (-41.9 to -25.7)	-37.9 (-45.1 to -30.1)
Mild behavioral problems due to H influenzae type B meningitis	4.1 (0.3 to 11.3)	3.2 (0.1 to 9.0)	-24.6 (-61.3 to -12.2)	-43.8 (-71.3 to -34.8)
Mild motor impairment due to long term due to H influenzae type B meningitis	3.7 (0.2 to 12.1)	3.1 (0.1 to 9.8)	-19.2 (-59.6 to -1.8)	-40.2 (-70.3 to -27.5)
Mild motor plus cognitive impairments due to H influenzae type B meningitis	6.2 (0.3 to 17.9)	4.6 (0.1 to 13.7)	-27.2 (-62.4 to -17.0)	-45.5 (-71.7 to -38.0)
Borderline intellectual disability due to H influenzae type B meningitis	6.3 (0.4 to 18.9)	4.7 (0.1 to 14.7)	-28.0 (-61.3 to -16.4)	-46.2 (-71.1 to -37.8)
Monocular distance vision loss due to H influenzae type B meningitis	6.1 (0.4 to 17.2)	4.6 (0.1 to 13.8)	-24.9 (-60.8 to -12.9)	-43.9 (-70.9 to -35.1)
Mild intellectual disability due to H influenzae type B meningitis	8.8 (5.1 to 13.6)	7.5 (4.3 to 11.8)	-15.7 (-24.4 to -2.0)	-32.4 (-39.4 to -21.2)
Moderate motor impairment due to H influenzae type B meningitis	12.9 (7.7 to 19.9)	13.1 (7.9 to 20.4)	1.5 (-13.1 to 17.6)	-19.0 (-30.4 to -6.0)
Severe motor impairment due to H influenzae type B meningitis	80.6 (50.2 to 116.7)	73.9 (46.4 to 105.1)	-8.3 (-19.4 to 5.0)	-26.8 (-35.4 to -16.0)
Moderate motor plus cognitive impairments due to H influenzae type B meningitis	61.9 (38.7 to 91.4)	52.7 (32.5 to 78.3)	-15.5 (-26.3 to 0.6)	-32.2 (-40.9 to -19.6)
Severe motor plus cognitive impairments due to H influenzae type B meningitis	161.2 (102.8 to 224.4)	137.3 (87.5 to 194.2)	-15.1 (-26.0 to -0.4)	-31.9 (-40.4 to -20.0)
Epilepsy due to H influenzae type B meningitis	26.6 (17.8 to 35.7)	35.6 (24.4 to 47.5)	33.9 (7.7 to 64.3)	13.7 (-7.9 to 39.0)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Blindness due to H influenzae type B meningitis	3.6 (0.4 to 7.4)	2.2 (0.1 to 4.9)	-39.9 (-73.6 to -28.7)	-58.6 (-81.5 to -51.5)
Mild hearing loss due to H influenzae type B meningitis	3.7 (0.1 to 10.8)	3.0 (0.0 to 8.9)	-22.5 (-62.4 to -8.4)	-46.4 (-74.1 to -36.5)
Mild hearing loss with ringing due to H influenzae type B meningitis	2.2 (0.0 to 5.8)	1.8 (0.0 to 5.0)	-22.2 (-62.2 to -9.1)	-46.1 (-74.2 to -37.6)
Moderate hearing loss due to H influenzae type B meningitis	4.2 (0.1 to 10.5)	3.5 (0.1 to 9.3)	-18.1 (-61.2 to 1.5)	-40.1 (-71.4 to -27.1)
Moderate hearing loss with ringing due to H influenzae type B meningitis	5.1 (0.1 to 11.9)	4.3 (0.1 to 10.6)	-17.7 (-62.4 to -1.6)	-40.2 (-71.9 to -28.9)
Moderately severe hearing loss due to H influenzae type B meningitis	5.2 (0.1 to 12.4)	3.3 (0.0 to 8.5)	-38.0 (-72.5 to -21.5)	-52.2 (-78.8 to -40.5)
Moderately severe hearing loss with ringing due to H influenzae type B meningitis	4.6 (0.1 to 11.0)	2.9 (0.0 to 7.2)	-38.5 (-73.0 to -22.1)	-52.7 (-79.0 to -40.2)
Severe hearing loss due to H influenzae type B meningitis	2.0 (0.0 to 4.9)	1.2 (0.0 to 3.1)	-41.5 (-64.7 to -27.6)	-50.4 (-70.4 to -38.9)
Severe hearing loss with ringing due to H influenzae type B meningitis	5.7 (0.1 to 14.0)	3.4 (0.1 to 8.7)	-41.5 (-64.5 to -27.8)	-50.3 (-70.2 to -38.7)
Profound hearing loss due to H influenzae type B meningitis	1.7 (0.0 to 4.2)	0.7 (0.0 to 1.8)	-63.3 (-82.4 to -50.1)	-66.2 (-83.6 to -54.0)
Profound hearing loss with ringing due to H influenzae type B meningitis	4.1 (0.1 to 10.1)	1.6 (0.0 to 4.3)	-63.1 (-82.4 to -49.5)	-65.9 (-83.8 to -53.4)
Complete hearing loss due to H influenzae type B meningitis	1.0 (0.0 to 2.5)	0.5 (0.0 to 1.3)	-53.5 (-64.8 to -45.6)	-60.5 (-70.2 to -54.4)
Complete hearing loss with ringing due to H influenzae type B meningitis	1.8 (0.1 to 4.7)	0.9 (0.0 to 2.3)	-53.5 (-64.8 to -45.9)	-60.4 (-69.8 to -54.3)
Meningococcal meningitis	202.2 (126.9 to 300.6)	167.3 (106.3 to 251.6)	-17.1 (-25.0 to -8.0)	-37.2 (-42.5 to -29.3)
Acute meningococcal meningitis	7.0 (4.7 to 9.8)	5.2 (3.5 to 7.4)	-25.3 (-33.4 to -16.6)	-32.1 (-39.3 to -24.3)
Mild behavioral problems due to meningococcal meningitis	1.1 (0.0 to 5.1)	0.9 (0.0 to 4.2)	-23.1 (-56.0 to -9.3)	-43.5 (-67.9 to -33.9)
Mild motor impairment due to long term due to meningococcal meningitis	1.0 (0.0 to 4.5)	0.8 (0.0 to 3.7)	-20.0 (-56.9 to -2.7)	-41.6 (-68.4 to -29.4)
Mild motor plus cognitive impairments due to meningococcal meningitis	1.8 (0.0 to 8.4)	1.3 (0.0 to 6.4)	-25.9 (-56.2 to -8.9)	-45.6 (-67.9 to -33.8)
Borderline intellectual disability due to meningococcal meningitis	1.8 (0.0 to 8.6)	1.4 (0.0 to 6.4)	-26.0 (-56.4 to -13.3)	-45.5 (-67.9 to -36.5)
Monocular distance vision loss due to meningococcal meningitis	1.7 (0.0 to 7.7)	1.3 (0.0 to 6.1)	-23.9 (-56.6 to -9.2)	-44.1 (-68.2 to -33.7)
Mild intellectual disability due to meningococcal meningitis	3.2 (1.8 to 5.1)	2.7 (1.5 to 4.4)	-16.4 (-28.1 to -3.4)	-34.1 (-43.1 to -24.2)
Moderate motor impairment due to meningococcal meningitis	4.5 (2.8 to 6.9)	4.2 (2.6 to 6.6)	-7.2 (-20.3 to 8.4)	-27.3 (-37.1 to -15.3)
Severe motor impairment due to meningococcal meningitis	29.0 (18.2 to 42.2)	25.6 (16.2 to 37.5)	-11.7 (-24.0 to 3.4)	-30.7 (-40.0 to -19.3)
Moderate motor plus cognitive impairments due to meningococcal meningitis	22.9 (14.2 to 34.5)	19.1 (12.1 to 29.0)	-16.2 (-27.8 to -3.7)	-34.0 (-43.0 to -24.3)
Severe motor plus cognitive impairments due to meningococcal meningitis	60.7 (39.0 to 86.8)	50.8 (33.5 to 71.7)	-16.0 (-27.3 to -2.7)	-33.9 (-42.4 to -23.7)
Epilepsy due to meningococcal meningitis	6.0 (4.2 to 7.8)	9.2 (6.4 to 12.1)	53.8 (35.2 to 72.3)	21.4 (7.3 to 35.6)
Blindness due to meningococcal meningitis	44.3 (5.2 to 89.2)	33.1 (1.8 to 73.0)	-27.1 (-63.9 to -13.2)	-50.1 (-74.9 to -41.7)
Mild hearing loss due to meningococcal meningitis	1.8 (0.0 to 5.2)	1.5 (0.0 to 4.4)	-19.4 (-56.1 to -8.6)	-45.0 (-70.2 to -37.9)
Mild hearing loss with ringing due to meningococcal meningitis	1.1 (0.0 to 2.8)	0.9 (0.0 to 2.4)	-19.3 (-53.6 to -8.3)	-45.0 (-68.6 to -37.4)
Moderate hearing loss due to meningococcal meningitis	1.7 (0.0 to 4.4)	1.5 (0.0 to 3.9)	-16.3 (-57.1 to 0.6)	-39.9 (-69.2 to -29.0)
Moderate hearing loss with ringing due to meningococcal meningitis	2.1 (0.0 to 4.9)	1.8 (0.0 to 4.6)	-15.6 (-56.7 to -0.0)	-39.5 (-69.4 to -29.0)
Moderately severe hearing loss due to meningococcal meningitis	2.1 (0.0 to 5.1)	1.4 (0.0 to 3.5)	-37.4 (-67.6 to -22.4)	-52.0 (-75.1 to -41.9)
Moderately severe hearing loss with ringing due to meningococcal meningitis	1.8 (0.0 to 4.4)	1.2 (0.0 to 3.0)	-37.5 (-66.8 to -23.1)	-52.3 (-75.1 to -42.5)
Severe hearing loss due to meningococcal meningitis	0.7 (0.0 to 1.9)	0.5 (0.0 to 1.3)	-37.0 (-58.6 to -25.7)	-48.2 (-65.8 to -39.2)
Severe hearing loss with ringing due to meningococcal meningitis	2.1 (0.0 to 5.2)	1.4 (0.0 to 3.5)	-36.6 (-58.2 to -24.4)	-48.0 (-65.6 to -38.5)
Profound hearing loss due to meningococcal meningitis	0.8 (0.0 to 1.9)	0.3 (0.0 to 1.0)	-56.3 (-74.3 to -40.4)	-59.2 (-76.2 to -44.4)
Profound hearing loss with ringing due to meningococcal meningitis	1.8 (0.0 to 4.4)	0.8 (0.0 to 2.2)	-54.9 (-74.8 to -37.0)	-58.1 (-76.8 to -41.6)
Complete hearing loss due to meningococcal meningitis	0.4 (0.0 to 1.0)	0.2 (0.0 to 0.5)	-52.6 (-67.2 to -43.5)	-60.4 (-71.9 to -53.5)
Complete hearing loss with ringing due to meningococcal meningitis	0.7 (0.0 to 1.8)	0.3 (0.0 to 0.9)	-52.7 (-67.4 to -43.3)	-60.4 (-71.8 to -53.5)
Other meningitis	531.5 (362.5 to 727.8)	438.3 (299.2 to 604.2)	-17.4 (-23.3 to -11.9)	-35.2 (-39.7 to -30.7)
Acute viral meningitis	108.4 (72.4 to 152.4)	100.2 (67.2 to 143.4)	-7.5 (-14.4 to -0.6)	-19.9 (-26.0 to -14.0)
Other acute bacterial meningitis	9.9 (6.6 to 14.0)	7.4 (4.9 to 10.6)	-25.7 (-34.0 to -15.7)	-33.5 (-40.6 to -24.5)
Mild behavioral problems due to other bacterial meningitis	3.3 (0.2 to 10.6)	2.5 (0.0 to 8.6)	-27.1 (-72.2 to -13.5)	-46.9 (-79.6 to -37.1)
Mild motor impairment due to long term due to other bacterial meningitis	2.9 (0.1 to 9.8)	2.3 (0.0 to 8.1)	-21.7 (-67.4 to -2.6)	-43.3 (-77.0 to -29.9)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Mild motor plus cognitive impairments due to other bacterial meningitis	5.0 (0.2 to 16.2)	3.6 (0.1 to 12.2)	-29.7 (-71.8 to -15.4)	-48.7 (-79.6 to -38.3)
Borderline intellectual disability due to other bacterial meningitis	5.1 (0.3 to 16.6)	3.6 (0.1 to 12.7)	-29.9 (-72.7 to -15.2)	-48.8 (-80.5 to -38.2)
Monocular distance vision loss due to other bacterial meningitis	4.8 (0.2 to 15.9)	3.6 (0.1 to 12.6)	-27.6 (-72.1 to -12.2)	-47.2 (-79.5 to -36.2)
Mild intellectual disability due to other bacterial meningitis	8.1 (4.7 to 12.7)	6.3 (3.6 to 10.1)	-22.2 (-30.9 to -11.0)	-39.2 (-46.0 to -30.8)
Moderate motor impairment due to other bacterial meningitis	11.6 (7.2 to 17.9)	10.7 (6.5 to 16.4)	-8.1 (-19.3 to 5.7)	-28.4 (-37.1 to -17.6)
Severe motor impairment due to other bacterial meningitis	72.4 (45.1 to 104.2)	61.3 (38.4 to 88.2)	-15.5 (-25.3 to -3.1)	-34.1 (-41.8 to -24.7)
Moderate motor plus cognitive impairments due to other bacterial meningitis	55.8 (34.2 to 82.0)	43.6 (26.6 to 64.7)	-22.0 (-31.6 to -10.0)	-39.0 (-46.5 to -30.0)
Severe motor plus cognitive impairments due to other bacterial meningitis	147.0 (96.3 to 207.3)	115.1 (73.0 to 162.6)	-21.8 (-31.4 to -9.7)	-38.8 (-46.2 to -29.5)
Epilepsy due to other meningitis	21.5 (14.9 to 27.9)	28.2 (19.3 to 37.2)	31.2 (12.9 to 50.6)	2.8 (-11.6 to 17.4)
Blindness due to other bacterial meningitis	39.4 (4.1 to 78.1)	27.2 (1.1 to 61.6)	-32.8 (-75.2 to -16.1)	-54.7 (-83.0 to -43.9)
Mild hearing loss due to other bacterial meningitis	3.6 (0.1 to 10.4)	2.8 (0.0 to 8.4)	-26.0 (-73.3 to -9.4)	-49.4 (-81.5 to -38.5)
Mild hearing loss due with ringing to other bacterial meningitis	2.2 (0.1 to 5.6)	1.7 (0.0 to 4.7)	-25.9 (-75.2 to -10.6)	-49.2 (-83.1 to -39.0)
Moderate hearing loss due to other bacterial meningitis	3.7 (0.1 to 9.4)	3.2 (0.0 to 8.5)	-18.1 (-70.0 to 1.4)	-41.8 (-78.6 to -28.1)
Moderate hearing loss with ringing due to other bacterial meningitis	4.6 (0.1 to 10.6)	3.9 (0.1 to 9.8)	-17.9 (-68.7 to 1.0)	-41.8 (-77.3 to -28.9)
Moderately severe hearing loss due to other bacterial meningitis	4.3 (0.1 to 10.3)	2.8 (0.0 to 7.3)	-36.6 (-77.9 to -18.3)	-52.6 (-83.5 to -39.7)
Moderately severe hearing loss with ringing due to other bacterial meningitis	3.7 (0.1 to 8.9)	2.5 (0.0 to 6.3)	-36.3 (-78.6 to -19.0)	-52.4 (-84.2 to -40.2)
Severe hearing loss due to other bacterial meningitis	1.7 (0.0 to 4.1)	0.9 (0.0 to 2.4)	-48.9 (-76.7 to -36.6)	-57.5 (-81.1 to -47.3)
Severe hearing loss with ringing due to other bacterial meningitis	4.9 (0.1 to 11.7)	2.6 (0.0 to 6.6)	-48.7 (-76.5 to -36.8)	-57.4 (-80.6 to -47.5)
Profound hearing loss due to other bacterial meningitis	1.3 (0.0 to 3.2)	0.4 (0.0 to 1.1)	-71.9 (-90.6 to -61.3)	-74.2 (-91.3 to -64.5)
Profound hearing loss with ringing due to other bacterial meningitis	3.3 (0.1 to 8.0)	1.0 (0.0 to 2.6)	-72.0 (-90.4 to -61.5)	-74.2 (-91.3 to -64.5)
Complete hearing loss due to other bacterial meningitis	1.2 (0.0 to 2.9)	0.4 (0.0 to 1.2)	-62.1 (-78.4 to -51.8)	-68.1 (-81.6 to -60.1)
Complete hearing loss with ringing due to other bacterial meningitis	2.0 (0.1 to 5.1)	0.8 (0.0 to 2.1)	-61.9 (-78.0 to -51.7)	-67.9 (-81.0 to -60.2)
Encephalitis	206.5 (145.2 to 274.6)	229.1 (159.9 to 305.7)	10.8 (4.7 to 17.9)	-20.6 (-25.0 to -15.4)
Acute encephalitis	5.8 (3.9 to 8.3)	6.1 (4.1 to 8.7)	5.1 (0.2 to 9.9)	-16.2 (-19.5 to -12.7)
Mild behavioral problems due to encephalitis	2.4 (0.1 to 8.1)	2.4 (0.0 to 8.7)	-4.3 (-84.5 to 14.1)	-34.1 (-89.4 to -21.8)
Mild motor impairment due to long term due to encephalitis	2.1 (0.1 to 7.4)	2.1 (0.0 to 8.0)	-1.0 (-82.9 to 20.9)	-32.0 (-88.1 to -17.0)
Mild motor plus cognitive impairments due to encephalitis	3.7 (0.2 to 12.1)	3.6 (0.0 to 12.7)	-5.3 (-84.6 to 14.1)	-34.4 (-89.4 to -21.4)
Borderline intellectual disability due to encephalitis	3.7 (0.1 to 13.0)	3.6 (0.0 to 13.6)	-5.8 (-85.1 to 14.2)	-34.9 (-89.6 to -21.4)
Monocular distance vision loss due to encephalitis	3.5 (0.1 to 12.0)	3.4 (0.0 to 13.1)	-4.5 (-84.6 to 16.9)	-33.9 (-89.5 to -19.6)
Mild intellectual disability due to encephalitis	4.3 (2.5 to 6.6)	4.6 (2.7 to 7.2)	8.2 (1.3 to 16.3)	-22.6 (-27.4 to -16.7)
Moderate motor impairment due to encephalitis	6.0 (3.7 to 9.3)	6.8 (4.2 to 10.6)	13.0 (5.0 to 22.1)	-19.2 (-25.1 to -12.8)
Severe motor impairment due to encephalitis	39.2 (24.5 to 56.0)	43.9 (27.7 to 63.2)	12.1 (4.8 to 20.3)	-19.7 (-24.8 to -13.6)
Moderate motor plus cognitive impairments due to encephalitis	30.0 (18.4 to 46.0)	32.7 (19.9 to 50.6)	9.1 (0.6 to 18.5)	-21.5 (-27.7 to -14.7)
Severe motor plus cognitive impairments due to encephalitis	79.0 (52.5 to 109.1)	86.8 (57.1 to 121.3)	9.6 (0.7 to 20.0)	-20.9 (-27.7 to -13.7)
Epilepsy due to encephalitis	21.0 (14.5 to 27.7)	28.4 (19.3 to 37.3)	35.4 (16.6 to 55.0)	-0.8 (-14.1 to 13.1)
Blindness due to encephalitis	5.8 (0.4 to 12.6)	4.7 (0.1 to 11.3)	-20.8 (-85.1 to -2.6)	-48.9 (-90.6 to -37.5)
Diphtheria	0.2 (0.1 to 0.5)	0.1 (0.0 to 0.2)	-62.1 (-83.5 to -14.8)	-65.8 (-84.6 to -25.0)
Moderate diphtheria	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-62.1 (-83.4 to -15.5)	-65.8 (-84.6 to -25.0)
Severe diphtheria	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-62.1 (-83.4 to -15.5)	-65.8 (-84.6 to -25.0)
Whooping cough	179.2 (106.3 to 287.7)	125.5 (73.0 to 200.7)	-30.0 (-31.9 to -27.7)	-32.4 (-34.3 to -30.2)
Tetanus	59.4 (39.2 to 86.0)	13.2 (8.5 to 21.3)	-78.2 (-85.4 to -64.5)	-82.2 (-88.2 to -71.0)
Severe tetanus	8.8 (5.0 to 15.8)	1.5 (0.8 to 2.4)	-82.2 (-92.5 to -73.0)	-84.1 (-93.1 to -75.5)
Mild motor impairment due to neonatal tetanus	6.5 (2.6 to 14.1)	0.7 (0.3 to 1.6)	-88.8 (-94.1 to -79.4)	-91.4 (-95.5 to -84.3)
Mild motor plus cognitive impairments due to neonatal tetanus	16.8 (7.2 to 32.4)	2.0 (0.8 to 4.1)	-88.2 (-93.9 to -77.1)	-91.0 (-95.4 to -82.7)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Moderate motor impairment due to neonatal tetanus	1.6 (0.9 to 2.9)	0.7 (0.3 to 1.4)	-61.9 (-82.8 to -7.9)	-66.8 (-84.8 to -19.9)
Moderate motor impairment with blindness due to neonatal tetanus	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-72.2 (-89.0 to -40.1)	-78.3 (-91.4 to -53.8)
Moderate motor impairment with epilepsy due to neonatal tetanus	1.7 (1.0 to 2.6)	0.5 (0.3 to 0.9)	-71.0 (-85.3 to -44.5)	-75.5 (-87.5 to -53.3)
Moderate motor impairment with blindness and epilepsy due to neonatal tetanus	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.1)	-71.9 (-85.7 to -47.3)	-76.3 (-87.9 to -55.7)
Moderate motor plus cognitive impairment with blindness due to neonatal tetanus	0.6 (0.3 to 0.9)	0.2 (0.1 to 0.3)	-68.4 (-83.2 to -39.6)	-73.3 (-85.8 to -49.5)
Moderate motor plus cognitive impairment with epilepsy due to neonatal tetanus	3.9 (2.3 to 6.1)	1.1 (0.6 to 2.0)	-71.8 (-85.6 to -46.9)	-76.2 (-87.8 to -55.4)
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal tetanus	0.5 (0.3 to 0.7)	0.1 (0.1 to 0.2)	-72.3 (-85.9 to -48.3)	-76.6 (-88.0 to -56.6)
Severe motor impairment due to neonatal tetanus	8.8 (4.7 to 15.4)	3.6 (1.5 to 7.6)	-61.5 (-83.1 to -3.5)	-66.5 (-85.3 to -16.8)
Severe motor impairment with blindness due to neonatal tetanus	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-72.2 (-89.0 to -40.1)	-78.3 (-91.4 to -53.8)
Severe motor impairment with epilepsy due to neonatal tetanus	0.9 (0.6 to 1.4)	0.3 (0.1 to 0.4)	-72.4 (-85.9 to -48.7)	-76.7 (-88.1 to -57.1)
Severe motor impairment with blindness and epilepsy due to neonatal tetanus	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.0)	-72.7 (-86.1 to -49.4)	-76.9 (-88.3 to -57.7)
Severe motor plus cognitive impairment with blindness due to neonatal tetanus	1.2 (0.7 to 1.9)	0.4 (0.2 to 0.7)	-68.4 (-83.2 to -39.6)	-73.3 (-85.8 to -49.5)
Severe motor plus cognitive impairment with epilepsy due to neonatal tetanus	7.0 (4.2 to 10.5)	1.9 (1.0 to 3.3)	-72.8 (-86.2 to -49.5)	-77.0 (-88.3 to -57.8)
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal tetanus	0.7 (0.4 to 1.1)	0.2 (0.1 to 0.3)	-72.9 (-86.3 to -50.0)	-77.1 (-88.4 to -58.2)
Measles	75.4 (46.3 to 118.2)	17.3 (10.2 to 26.7)	-77.1 (-80.0 to -73.8)	-78.0 (-80.8 to -74.8)
Moderate measles	20.9 (12.1 to 32.8)	4.8 (2.8 to 7.7)	-77.1 (-80.4 to -73.0)	-78.0 (-81.2 to -74.0)
Severe measles	54.5 (33.0 to 84.6)	12.5 (7.2 to 19.8)	-77.1 (-80.6 to -73.1)	-78.0 (-81.3 to -74.2)
Varicella and herpes zoster	133.8 (83.6 to 202.9)	197.2 (122.1 to 299.2)	47.6 (41.1 to 54.5)	-1.8 (-5.7 to 2.7)
Chickenpox	12.8 (5.1 to 27.1)	13.4 (5.4 to 28.1)	4.7 (1.2 to 8.3)	-3.0 (-6.1 to 0.4)
Herpes zoster	121.0 (75.8 to 181.1)	183.8 (114.1 to 276.1)	51.9 (45.1 to 59.4)	-1.7 (-6.0 to 3.1)
Neglected tropical diseases and malaria	20,755.3 (13,818.4 to 30,144.3)	20,100.7 (13,202.4 to 28,946.1)	-3.3 (-10.2 to 6.7)	-28.7 (-33.1 to -23.0)
Malaria	2,440.3 (1,618.6 to 3,497.2)	3,170.5 (2,132.3 to 4,591.9)	30.1 (25.2 to 35.0)	7.8 (3.7 to 11.9)
Asymptomatic malaria parasitemia (PfPR)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild malaria	37.5 (11.7 to 93.7)	31.8 (9.8 to 80.5)	-16.4 (-34.8 to 12.5)	-29.6 (-44.8 to -6.4)
Moderate malaria	161.9 (72.4 to 303.9)	137.3 (57.8 to 289.6)	-16.5 (-34.6 to 12.6)	-29.5 (-44.8 to -6.1)
Severe malaria	6.5 (0.6 to 21.8)	5.6 (0.5 to 18.7)	-16.0 (-36.4 to 13.6)	-29.3 (-45.7 to -5.0)
Moderate motor impairment due to malaria	1.2 (0.7 to 1.8)	2.3 (1.4 to 3.7)	96.5 (39.2 to 204.0)	64.4 (16.4 to 155.4)
Moderate motor impairment with blindness due to malaria	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	3.9 (-24.1 to 47.9)	-19.0 (-41.1 to 16.3)
Moderate motor impairment with epilepsy due to malaria	3.0 (2.0 to 4.1)	4.6 (3.2 to 6.3)	50.3 (18.5 to 101.7)	24.6 (-1.8 to 68.0)
Moderate motor impairment with blindness and epilepsy due to malaria	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	47.6 (17.7 to 96.5)	22.4 (-2.5 to 63.8)
Moderate motor plus cognitive impairment with blindness due to malaria	1.0 (0.7 to 1.5)	1.6 (1.1 to 2.2)	53.1 (24.4 to 98.9)	27.2 (3.0 to 65.6)
Moderate motor plus cognitive impairment with epilepsy due to malaria	7.1 (4.9 to 9.7)	10.6 (7.3 to 14.6)	48.9 (16.3 to 96.9)	23.3 (-3.8 to 64.0)
Moderate motor plus cognitive impairment with blindness and epilepsy due to malaria	0.8 (0.6 to 1.1)	1.2 (0.8 to 1.6)	46.6 (16.9 to 94.3)	21.6 (-2.8 to 62.0)
Severe motor impairment due to malaria	6.2 (3.9 to 9.0)	12.5 (7.6 to 19.4)	96.5 (37.1 to 207.0)	63.7 (14.1 to 156.4)
Severe motor impairment with blindness due to malaria	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	3.9 (-24.1 to 47.9)	-19.0 (-41.1 to 16.3)
Severe motor impairment with epilepsy due to malaria	1.7 (1.2 to 2.3)	2.5 (1.8 to 3.4)	46.2 (16.9 to 94.1)	21.2 (-2.9 to 61.6)
Severe motor impairment with blindness and epilepsy due to malaria	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	45.6 (16.5 to 92.7)	20.7 (-3.3 to 60.5)
Severe motor plus cognitive impairment with blindness due to malaria	2.1 (1.5 to 2.9)	3.3 (2.3 to 4.4)	53.1 (24.4 to 98.9)	27.2 (3.0 to 65.6)
Severe motor plus cognitive impairment with epilepsy due to malaria	12.9 (8.8 to 17.0)	19.0 (13.3 to 24.7)	46.0 (15.6 to 93.5)	20.9 (-4.2 to 61.2)
Severe motor plus cognitive impairment with blindness and epilepsy due to malaria	1.3 (0.9 to 1.7)	1.9 (1.4 to 2.5)	45.0 (16.1 to 91.6)	20.3 (-3.7 to 59.7)
Mild anemia due to malaria parasitemia (PfPR)	80.3 (28.9 to 174.4)	117.1 (41.6 to 255.8)	45.9 (39.8 to 51.3)	13.4 (9.0 to 17.3)
Moderate anemia due to malaria parasitemia (PfPR)	1,596.4 (1,058.5 to 2,296.9)	2,193.5 (1,453.6 to 3,184.2)	37.1 (33.6 to 43.2)	13.4 (10.4 to 18.1)
Severe anemia due to malaria parasitemia (PfPR)	519.3 (356.4 to 713.7)	624.5 (426.5 to 872.2)	20.2 (6.4 to 32.7)	1.1 (-10.6 to 11.9)
Chagas disease	73.0 (48.8 to 102.0)	97.5 (64.9 to 137.0)	33.6 (28.8 to 39.1)	-17.4 (-20.2 to -14.2)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Acute Chagas disease	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-9.2 (-26.4 to 13.6)	-21.6 (-36.3 to -2.0)
Mild chronic digestive disease due to Chagas disease	3.9 (1.9 to 7.4)	4.9 (2.3 to 9.3)	24.8 (20.0 to 29.9)	-18.3 (-21.3 to -14.9)
Moderate chronic digestive disease due to Chagas disease	26.5 (16.9 to 37.7)	33.1 (21.1 to 47.3)	25.0 (19.6 to 30.6)	-18.2 (-21.6 to -14.4)
Asymptomatic Chagas disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Atrial fibrillation and flutter due to Chagas disease	11.1 (7.2 to 16.3)	16.6 (10.7 to 24.2)	49.6 (40.3 to 59.7)	-13.6 (-18.5 to -8.4)
Mild heart failure due to Chagas disease	2.7 (1.3 to 4.9)	3.7 (1.8 to 6.8)	36.6 (28.4 to 45.8)	-18.1 (-22.9 to -12.6)
Moderate heart failure due to Chagas disease	3.8 (1.9 to 6.7)	5.2 (2.6 to 9.2)	36.8 (28.2 to 47.2)	-18.0 (-22.9 to -12.0)
Severe heart failure due to Chagas disease	24.9 (13.8 to 39.1)	34.0 (19.1 to 54.0)	36.5 (29.8 to 44.3)	-18.1 (-22.0 to -13.7)
Leishmaniasis	21.1 (11.6 to 37.5)	49.7 (25.5 to 90.4)	134.7 (107.8 to 165.0)	75.8 (58.0 to 97.3)
Visceral leishmaniasis	5.9 (3.7 to 9.1)	8.0 (5.2 to 12.3)	35.8 (14.6 to 61.8)	15.2 (-2.5 to 36.7)
Moderate visceral leishmaniasis	3.1 (1.9 to 5.0)	4.3 (2.6 to 6.8)	36.6 (7.3 to 74.8)	15.3 (-8.5 to 45.5)
Severe visceral leishmaniasis	2.8 (1.8 to 4.3)	3.8 (2.4 to 5.6)	35.3 (16.9 to 57.2)	14.8 (-0.3 to 31.7)
Cutaneous and mucocutaneous leishmaniasis	15.1 (7.1 to 28.7)	41.7 (19.0 to 80.1)	175.1 (146.0 to 210.9)	97.1 (76.6 to 122.4)
African trypanosomiasis	18.8 (7.7 to 37.1)	5.4 (2.6 to 9.5)	-70.7 (-75.3 to -64.5)	-79.1 (-82.3 to -74.7)
Disfigurement due to African trypanosomiasis	2.3 (1.0 to 4.7)	0.7 (0.3 to 1.2)	-70.4 (-75.5 to -61.9)	-78.9 (-82.5 to -73.0)
Severe motor plus cognitive impairments due to African trypanosomiasis	16.5 (6.7 to 32.4)	4.7 (2.2 to 8.3)	-70.9 (-75.5 to -64.6)	-79.2 (-82.4 to -74.8)
Schistosomiasis	2,110.2 (1,112.2 to 3,901.6)	2,861.7 (1,483.6 to 5,467.2)	34.1 (26.4 to 55.4)	0.3 (-5.6 to 16.3)
Mild schistosomiasis	668.2 (270.5 to 1,390.2)	849.2 (342.0 to 1,775.7)	25.9 (17.0 to 40.5)	-9.0 (-15.8 to 1.7)
Mild diarrhea due to schistosomiasis	11.6 (4.3 to 27.4)	17.5 (6.3 to 43.1)	54.4 (3.3 to 81.1)	17.7 (-22.1 to 39.6)
Hematemesis due to schistosomiasis	1.3 (0.8 to 1.9)	2.3 (1.5 to 3.4)	76.9 (71.0 to 81.3)	17.5 (7.0 to 27.3)
Hepatomegaly due to schistosomiasis	97.7 (46.5 to 195.6)	178.1 (84.2 to 353.7)	82.4 (75.5 to 88.3)	34.7 (27.7 to 41.6)
Ascites due to schistosomiasis	31.0 (20.9 to 44.3)	54.8 (36.7 to 78.5)	77.0 (69.5 to 84.0)	17.9 (7.4 to 27.8)
Dysuria due to schistosomiasis	65.6 (27.7 to 140.3)	82.5 (31.6 to 189.2)	21.5 (-6.3 to 75.8)	-7.4 (-28.9 to 32.8)
Bladder pathology due to schistosomiasis	634.2 (302.0 to 1,274.6)	848.9 (395.3 to 1,787.6)	30.4 (15.9 to 76.7)	-0.9 (-12.5 to 34.8)
Hydronephrosis due to schistosomiasis	115.4 (56.1 to 224.3)	157.3 (74.2 to 328.8)	32.5 (19.3 to 78.4)	0.8 (-9.6 to 34.4)
Mild anemia due to schistosomiasis	23.3 (8.4 to 51.5)	34.3 (12.4 to 74.9)	46.6 (37.2 to 63.5)	6.2 (0.0 to 18.2)
Moderate anemia due to schistosomiasis	359.4 (234.5 to 518.9)	504.2 (332.1 to 728.5)	40.7 (27.3 to 51.3)	8.5 (-1.8 to 16.9)
Severe anemia due to schistosomiasis	102.6 (70.7 to 143.4)	132.5 (90.1 to 182.0)	28.6 (16.4 to 46.7)	1.0 (-8.5 to 14.9)
Cysticercosis	391.3 (272.4 to 510.5)	310.4 (212.2 to 409.5)	-20.9 (-33.9 to -3.0)	-46.5 (-55.1 to -34.4)
Cystic echinococcosis	93.4 (63.6 to 130.6)	79.2 (54.9 to 110.3)	-15.3 (-18.9 to -11.0)	-42.0 (-44.3 to -39.2)
Abdominal problems due to cystic echinococcosis	87.3 (59.0 to 122.1)	74.0 (50.3 to 103.6)	-15.3 (-19.1 to -10.8)	-42.1 (-44.4 to -39.2)
Chronic respiratory disease due to cystic echinococcosis	3.5 (1.8 to 5.9)	2.9 (1.5 to 5.1)	-14.9 (-18.9 to -11.0)	-41.8 (-44.7 to -38.9)
Epilepsy due to echinococcosis	2.6 (0.8 to 5.8)	2.3 (0.6 to 5.0)	-13.3 (-19.5 to -6.3)	-41.2 (-45.2 to -36.6)
Lymphatic filariasis	1,927.6 (984.4 to 3,273.4)	2,022.1 (1,096.3 to 3,294.4)	5.9 (-15.7 to 26.4)	-32.3 (-46.0 to -19.3)
Prevalence of detectable microfilaria due to lymphatic filariasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Lymphedema due to lymphatic filariasis	655.3 (353.0 to 1,018.8)	924.5 (502.2 to 1,455.7)	41.1 (34.7 to 47.4)	-9.4 (-13.6 to -5.5)
Hydrocele due to lymphatic filariasis	1,272.3 (498.2 to 2,500.7)	1,097.6 (428.7 to 2,189.0)	-13.3 (-38.4 to 13.4)	-44.7 (-60.6 to -27.6)
Onchocerciasis	1,555.2 (817.7 to 2,456.5)	1,179.8 (556.6 to 1,992.7)	-25.4 (-37.0 to -10.9)	-48.9 (-57.7 to -38.4)
Asymptomatic onchocerciasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild skin disease due to onchocerciasis	43.7 (15.2 to 88.7)	38.7 (10.6 to 83.5)	-13.4 (-35.1 to 9.0)	-30.7 (-47.2 to -13.8)
Mild skin disease without itch due to onchocerciasis	61.2 (24.0 to 127.9)	56.8 (19.4 to 126.4)	-7.7 (-22.7 to 3.6)	-34.2 (-45.6 to -24.6)
Moderate skin disease due to onchocerciasis	901.1 (400.9 to 1,570.4)	677.1 (249.0 to 1,268.9)	-27.0 (-43.9 to -3.5)	-49.6 (-62.7 to -32.5)
Severe skin disease due to onchocerciasis	403.5 (124.3 to 774.3)	312.9 (77.4 to 638.1)	-23.2 (-40.7 to -11.4)	-47.1 (-59.6 to -36.8)
Severe skin disease without itch due to onchocerciasis	18.4 (1.8 to 43.5)	16.0 (1.5 to 38.6)	-12.7 (-24.0 to -2.6)	-47.9 (-54.4 to -37.3)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Moderate vision impairment due to onchocerciasis	39.5 (22.5 to 63.1)	24.5 (11.3 to 45.0)	-38.9 (-54.6 to -23.0)	-62.4 (-71.9 to -52.2)
Severe vision impairment due to onchocerciasis	37.2 (23.6 to 54.8)	23.4 (11.4 to 39.7)	-38.2 (-54.0 to -20.6)	-62.6 (-72.3 to -51.9)
Blindness due to onchocerciasis	50.6 (30.6 to 78.0)	30.5 (15.3 to 54.4)	-40.9 (-54.8 to -25.8)	-64.9 (-73.3 to -55.7)
Trachoma	271.6 (182.7 to 377.9)	171.2 (115.3 to 241.7)	-37.2 (-43.0 to -30.4)	-64.2 (-67.5 to -60.5)
Moderate vision impairment due to trachoma	78.3 (45.8 to 123.1)	47.0 (27.4 to 73.8)	-40.3 (-49.0 to -28.7)	-65.9 (-71.0 to -59.5)
Severe vision impairment due to trachoma	87.0 (56.8 to 123.4)	53.1 (34.6 to 75.9)	-38.8 (-48.2 to -29.8)	-65.2 (-70.6 to -60.0)
Blindness due to trachoma	106.3 (68.5 to 151.3)	71.1 (46.3 to 102.7)	-33.2 (-41.5 to -23.0)	-62.2 (-66.8 to -56.8)
Dengue	80.0 (26.5 to 202.0)	565.9 (186.4 to 1,414.6)	607.2 (558.4 to 659.5)	446.8 (411.3 to 486.8)
Moderate dengue	6.3 (2.1 to 14.2)	44.2 (14.8 to 98.1)	601.5 (532.4 to 681.2)	440.6 (390.8 to 496.9)
Severe dengue	2.3 (0.8 to 5.5)	16.3 (5.6 to 38.7)	600.3 (570.8 to 634.0)	439.0 (416.5 to 464.9)
Post-dengue chronic fatigue syndrome	71.4 (22.9 to 184.8)	505.4 (158.5 to 1,287.7)	608.3 (555.5 to 668.1)	448.2 (409.0 to 492.5)
Yellow fever	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.2)	-59.8 (-63.7 to -54.3)	-68.3 (-71.4 to -64.0)
Asymptomatic yellow fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Moderate yellow fever	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-59.8 (-63.7 to -54.3)	-68.3 (-71.4 to -64.0)
Severe yellow fever	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-59.8 (-63.7 to -54.3)	-68.3 (-71.4 to -64.0)
Rabies	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-39.8 (-54.3 to -27.2)	-55.2 (-65.1 to -46.1)
Intestinal nematode infections	6,872.0 (3,931.9 to 11,213.1)	3,691.6 (2,185.8 to 5,801.7)	-46.0 (-50.6 to -41.4)	-58.8 (-62.3 to -55.3)
Ascariasis	3,629.1 (1,946.2 to 6,310.0)	933.9 (516.6 to 1,576.1)	-74.2 (-77.4 to -70.6)	-80.1 (-82.5 to -77.3)
Heavy infestation of ascariasis	1,813.1 (993.1 to 2,931.4)	647.4 (354.9 to 1,087.8)	-64.3 (-69.4 to -58.1)	-73.9 (-77.8 to -69.2)
Mild abdominopelvic problems due to ascariasis	1,800.4 (877.1 to 3,423.4)	276.9 (136.7 to 513.3)	-84.7 (-86.1 to -82.8)	-87.4 (-88.6 to -85.9)
Severe wasting due to ascariasis	15.6 (9.2 to 24.4)	9.6 (5.3 to 15.5)	-38.9 (-56.8 to -12.0)	-40.7 (-58.1 to -14.5)
Asymptomatic ascariasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Trichuriasis	790.6 (442.0 to 1,299.9)	576.0 (310.1 to 972.6)	-27.6 (-39.4 to -10.4)	-45.9 (-55.0 to -32.8)
Heavy infestation of trichuriasis	623.8 (349.3 to 1,006.3)	456.5 (242.4 to 748.0)	-27.5 (-41.4 to -7.5)	-45.9 (-56.6 to -30.6)
Mild abdominopelvic problems due to trichuriasis	162.0 (78.8 to 309.5)	116.8 (56.1 to 218.7)	-27.8 (-39.4 to -14.1)	-46.2 (-55.1 to -35.7)
Severe wasting due to trichuriasis	4.8 (2.7 to 7.4)	2.7 (1.5 to 4.4)	-44.9 (-62.8 to -16.4)	-46.5 (-63.9 to -18.9)
Asymptomatic trichuriasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Hookworm disease	2,452.3 (1,507.3 to 3,798.8)	2,181.7 (1,338.6 to 3,354.5)	-10.9 (-17.3 to -4.4)	-32.9 (-38.0 to -27.7)
Heavy infestation of hookworm	1,193.2 (655.4 to 1,981.0)	957.8 (527.1 to 1,566.8)	-19.7 (-29.8 to -7.8)	-41.3 (-49.0 to -32.4)
Mild abdominopelvic problems due to hookworm disease	227.2 (112.3 to 430.6)	212.7 (104.1 to 401.7)	-6.5 (-13.6 to 1.1)	-31.1 (-36.7 to -25.1)
Severe wasting due to hookworm disease	10.1 (5.9 to 15.8)	7.3 (4.2 to 11.4)	-28.5 (-47.3 to -2.7)	-30.7 (-48.9 to -5.5)
Mild anemia due to hookworm disease	54.9 (19.5 to 121.4)	65.0 (23.1 to 144.1)	18.2 (11.4 to 28.4)	-12.5 (-17.3 to -5.0)
Moderate anemia due to hookworm disease	771.8 (506.9 to 1,131.9)	763.5 (487.9 to 1,133.7)	-0.7 (-11.4 to 5.7)	-22.1 (-30.5 to -17.1)
Severe anemia due to hookworm disease	195.1 (130.4 to 272.0)	175.4 (115.5 to 246.8)	-9.7 (-26.4 to 9.7)	-28.0 (-41.6 to -11.9)
Asymptomatic hookworm disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Food-borne trematodiasis	2,434.0 (734.9 to 5,188.2)	3,634.8 (1,160.2 to 7,692.4)	50.1 (40.6 to 60.0)	-1.8 (-8.1 to 4.9)
Asymptomatic clonorchiasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Asymptomatic fascioliasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Asymptomatic intestinal fluke infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Asymptomatic opisthorchiasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Asymptomatic paragonimiasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Heavy opisthorchiasis due to food-borne trematodiasis	126.0 (59.3 to 218.0)	207.1 (95.2 to 356.9)	64.4 (31.2 to 102.8)	3.8 (-13.7 to 24.5)
Heavy clonorchiasis due to food-borne trematodiasis	386.4 (243.8 to 550.4)	625.3 (400.9 to 901.0)	61.4 (46.9 to 80.6)	7.7 (1.3 to 20.5)
Heavy intestinal fluke infection due to food-borne trematodiasis	19.3 (9.2 to 33.1)	31.2 (14.1 to 59.0)	61.2 (27.9 to 99.7)	1.2 (-16.9 to 22.7)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Heavy fascioliasis due to food-borne trematodiasis	23.5 (5.8 to 54.7)	37.9 (9.0 to 88.3)	60.5 (36.5 to 90.3)	4.7 (-11.1 to 24.1)
Heavy paragonimiasis due to food-borne trematodiasis	1,846.1 (220.4 to 4,590.0)	2,699.3 (328.0 to 6,686.6)	46.0 (35.7 to 56.9)	-5.0 (-11.7 to 2.1)
Cerebral paragonimiasis	32.7 (8.5 to 68.6)	33.9 (9.2 to 72.9)	3.4 (-21.0 to 37.8)	-22.0 (-40.4 to 3.8)
Other neglected tropical diseases	2,466.5 (1,581.9 to 3,602.5)	2,260.7 (1,473.6 to 3,358.6)	-8.9 (-13.4 to -0.1)	-20.6 (-25.0 to -12.8)
Acute infection due to other neglected tropical diseases	221.4 (94.7 to 412.8)	212.1 (97.5 to 400.1)	-5.5 (-27.8 to 38.3)	-31.6 (-50.3 to 10.1)
Mild anemia due to other neglected tropical diseases	96.0 (34.5 to 218.9)	94.6 (33.6 to 205.9)	-0.5 (-14.8 to 5.3)	-17.8 (-28.9 to -13.2)
Moderate anemia due to other neglected tropical diseases	1,659.8 (1,055.4 to 2,445.7)	1,562.7 (1,026.6 to 2,276.3)	-6.7 (-10.4 to 7.0)	-17.2 (-20.5 to -5.2)
Severe anemia due to other neglected tropical diseases	489.0 (333.0 to 679.8)	391.2 (260.0 to 552.0)	-19.7 (-33.0 to -9.0)	-27.9 (-39.7 to -18.3)
Maternal disorders	1,136.9 (773.8 to 1,549.9)	1,341.8 (924.5 to 1,824.3)	18.4 (8.2 to 27.4)	-15.0 (-21.9 to -8.4)
Maternal hemorrhage	62.7 (43.2 to 87.1)	69.5 (47.4 to 97.5)	11.2 (-0.7 to 22.5)	-16.4 (-25.2 to -8.1)
Maternal hemorrhage (< 1L blood lost)	15.4 (10.0 to 21.9)	16.1 (10.6 to 23.1)	5.0 (-12.9 to 25.7)	-21.3 (-34.2 to -6.3)
Maternal hemorrhage (> 1L blood lost)	7.9 (4.4 to 12.3)	8.3 (4.8 to 12.5)	6.3 (-12.4 to 26.6)	-20.3 (-33.8 to -6.1)
Mild anemia due to maternal hemorrhage	2.6 (0.9 to 5.7)	4.0 (1.4 to 8.9)	56.1 (36.4 to 72.6)	16.7 (2.8 to 28.6)
Moderate anemia due to maternal hemorrhage	32.3 (21.5 to 46.6)	36.2 (22.7 to 53.0)	12.5 (-1.6 to 28.7)	-15.1 (-25.6 to -3.1)
Severe anemia due to maternal hemorrhage	4.6 (2.8 to 7.4)	5.0 (2.8 to 7.9)	8.8 (-41.7 to 81.1)	-20.1 (-55.8 to 32.2)
Maternal sepsis and other maternal infections	27.6 (15.4 to 46.4)	21.4 (11.6 to 36.3)	-22.4 (-35.3 to -9.7)	-43.2 (-51.8 to -34.5)
Puerperal sepsis	17.6 (8.3 to 30.0)	12.6 (6.1 to 21.7)	-28.5 (-43.6 to -9.8)	-45.1 (-56.4 to -30.9)
Other maternal infections	0.4 (0.2 to 0.7)	0.4 (0.2 to 0.7)	-4.0 (-16.0 to 13.4)	-25.3 (-34.4 to -12.5)
Infertility due to puerperal sepsis	9.6 (3.4 to 21.9)	8.4 (3.1 to 19.6)	-12.2 (-23.1 to -2.4)	-41.4 (-47.9 to -34.5)
Maternal hypertensive disorders	62.8 (31.0 to 109.4)	64.7 (31.5 to 112.8)	2.9 (-2.8 to 9.7)	-21.8 (-25.6 to -17.3)
Other hypertensive disorders of pregnancy	51.7 (23.9 to 93.9)	54.5 (25.1 to 97.9)	5.5 (-0.2 to 13.7)	-20.1 (-24.1 to -14.8)
Severe pre-eclampsia	0.6 (0.2 to 1.5)	0.6 (0.2 to 1.6)	5.4 (0.7 to 12.8)	-20.2 (-23.0 to -15.3)
Long term sequelae of severe pre-eclampsia	1.9 (0.5 to 4.6)	2.0 (0.5 to 4.9)	5.6 (-14.2 to 33.3)	-20.2 (-33.6 to -0.1)
Eclampsia	1.7 (0.6 to 3.4)	1.5 (0.5 to 3.0)	-12.1 (-17.2 to -4.5)	-31.7 (-35.1 to -27.3)
Long term sequelae of eclampsia	7.0 (3.8 to 11.8)	6.2 (3.3 to 10.1)	-12.3 (-28.2 to 8.1)	-31.9 (-44.2 to -17.1)
Obstructed labor	787.9 (526.1 to 1,076.3)	951.5 (641.5 to 1,304.0)	20.9 (12.3 to 30.3)	-14.3 (-20.1 to -8.0)
Obstructed labor, acute event	22.4 (12.6 to 37.7)	21.6 (12.3 to 35.5)	-3.5 (-26.6 to 24.2)	-27.4 (-44.1 to -7.2)
Rectovaginal fistula	98.2 (47.3 to 162.3)	119.1 (58.2 to 193.2)	21.1 (3.7 to 42.8)	-14.0 (-26.2 to 0.1)
Vesicovaginal fistula	667.4 (448.3 to 923.9)	810.8 (540.9 to 1,118.5)	21.6 (12.8 to 30.9)	-13.9 (-19.6 to -7.4)
Complications of abortion	2.2 (1.3 to 3.5)	2.5 (1.4 to 4.0)	12.0 (2.0 to 22.3)	-16.6 (-23.8 to -9.1)
Other maternal disorders	193.6 (122.7 to 278.6)	232.2 (155.8 to 343.7)	22.1 (-14.3 to 62.2)	-10.5 (-37.3 to 18.5)
Neonatal disorders	5,466.7 (4,054.2 to 7,030.8)	12,648.8 (9,291.4 to 16,262.6)	130.9 (108.5 to 158.7)	80.5 (63.1 to 101.7)
Preterm birth complications	2,324.3 (1,687.8 to 2,984.3)	6,689.7 (4,914.1 to 8,643.6)	187.6 (166.9 to 210.3)	119.4 (104.2 to 136.9)
Asymptomatic retinopathy of prematurity	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild vision impairment due to retinopathy of prematurity	0.5 (0.1 to 1.6)	1.4 (0.2 to 4.3)	160.8 (126.1 to 197.5)	88.2 (61.8 to 116.4)
Moderate vision impairment due to retinopathy of prematurity	15.2 (6.8 to 28.4)	30.4 (13.5 to 56.9)	101.1 (69.2 to 136.7)	42.0 (18.4 to 68.2)
Severe vision impairment due to retinopathy of prematurity	46.4 (27.3 to 73.2)	97.4 (56.2 to 153.6)	109.8 (84.9 to 139.3)	43.2 (24.7 to 65.5)
Blindness due to retinopathy of prematurity	30.0 (9.4 to 56.3)	70.9 (21.8 to 134.0)	137.2 (101.9 to 179.5)	56.6 (33.9 to 84.4)
Mild motor impairment due to neonatal preterm birth complications <28wks	10.0 (4.4 to 20.2)	34.9 (15.8 to 69.6)	248.6 (208.1 to 314.4)	158.2 (127.5 to 207.6)
Mild motor plus cognitive impairments due to neonatal preterm birth complications <28wks	23.5 (11.1 to 43.1)	69.0 (33.8 to 124.7)	194.8 (171.3 to 220.9)	115.2 (98.2 to 135.0)
Mild motor impairment due to neonatal preterm birth complications 28-32wks	32.5 (13.1 to 64.6)	77.5 (32.9 to 153.3)	136.8 (88.9 to 214.0)	77.8 (42.9 to 135.1)
Mild motor plus cognitive impairments due to neonatal preterm birth complications 28-32wks	77.8 (36.3 to 136.5)	162.2 (80.4 to 281.0)	108.6 (75.8 to 153.0)	54.4 (30.9 to 85.5)
Mild motor impairment due to neonatal preterm birth complications 32-36wks	22.4 (9.8 to 44.3)	54.7 (23.9 to 104.5)	143.4 (111.8 to 188.5)	82.9 (59.2 to 117.4)
Mild motor plus cognitive impairments due to neonatal preterm birth complications 32-36wks	53.4 (25.7 to 91.1)	114.0 (56.4 to 192.8)	113.0 (96.0 to 134.3)	58.2 (45.5 to 74.1)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Moderate motor impairment due to neonatal preterm birth complications <28wks	36.8 (21.6 to 56.9)	146.3 (87.1 to 225.3)	297.9 (235.8 to 382.2)	207.2 (159.0 to 273.8)
Moderate motor impairment with blindness due to neonatal preterm birth complications <28wks	4.0 (1.9 to 7.0)	12.5 (6.0 to 21.3)	210.3 (161.3 to 272.5)	118.6 (86.3 to 158.8)
Moderate motor impairment with epilepsy due to neonatal preterm birth complications <28wks	44.0 (24.4 to 68.9)	150.0 (84.0 to 230.9)	240.9 (199.3 to 293.6)	156.2 (125.6 to 194.9)
Moderate motor impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks	10.6 (4.5 to 19.3)	36.7 (15.5 to 67.6)	245.9 (209.7 to 294.5)	160.3 (133.3 to 196.1)
Moderate motor plus cognitive impairment with blindness due to neonatal preterm birth complications <28wks	11.8 (5.5 to 20.7)	41.5 (19.4 to 72.4)	251.3 (214.7 to 300.3)	165.1 (138.3 to 202.2)
Moderate motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications <28wks	21.4 (10.9 to 34.6)	73.5 (36.2 to 118.4)	242.2 (203.8 to 290.7)	157.8 (129.2 to 193.5)
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks	4.8 (2.1 to 9.2)	16.5 (7.2 to 31.4)	243.6 (207.2 to 291.6)	158.9 (131.7 to 194.6)
Severe motor impairment due to neonatal preterm birth complications <28wks	149.6 (87.2 to 230.8)	592.0 (350.8 to 901.1)	296.1 (230.3 to 376.0)	206.2 (156.6 to 270.3)
Severe motor impairment with blindness due to neonatal preterm birth complications <28wks	5.5 (2.6 to 9.6)	17.1 (8.4 to 29.7)	211.9 (163.3 to 273.0)	119.4 (86.9 to 159.4)
Severe motor impairment with epilepsy due to neonatal preterm birth complications <28wks	44.7 (24.4 to 71.3)	149.1 (81.0 to 231.9)	233.0 (194.4 to 282.2)	150.9 (122.5 to 188.5)
Severe motor impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks	9.2 (4.3 to 15.9)	31.5 (14.9 to 54.2)	241.5 (204.2 to 289.4)	157.4 (129.8 to 193.1)
Severe motor plus cognitive impairment with blindness due to neonatal preterm birth complications <28wks	13.4 (6.2 to 23.9)	47.2 (21.1 to 84.4)	251.3 (214.7 to 300.3)	165.0 (138.4 to 202.2)
Severe motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications <28wks	19.9 (10.2 to 33.4)	68.1 (35.3 to 113.1)	241.1 (203.8 to 289.0)	157.2 (129.3 to 192.8)
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks	3.9 (1.8 to 7.6)	13.4 (6.1 to 25.7)	240.2 (202.8 to 288.0)	156.9 (128.9 to 192.3)
Moderate motor impairment due to neonatal preterm birth complications 28-32wks	99.2 (58.7 to 156.8)	298.5 (179.9 to 469.2)	199.5 (146.7 to 274.6)	136.1 (95.6 to 196.6)
Moderate motor impairment with blindness due to neonatal preterm birth complications 28-32wks	12.7 (6.3 to 22.3)	29.8 (15.0 to 53.1)	134.5 (91.9 to 196.4)	66.6 (37.1 to 110.0)
Moderate motor impairment with epilepsy due to neonatal preterm birth complications 28-32wks	113.8 (65.7 to 174.7)	281.8 (157.0 to 437.1)	147.9 (109.6 to 194.6)	89.8 (60.9 to 125.3)
Moderate motor impairment with blindness and epilepsy due to neonatal preterm birth complications 28-32wks	28.7 (12.1 to 50.7)	71.2 (29.9 to 125.9)	148.0 (111.5 to 191.0)	90.0 (61.8 to 122.7)
Moderate motor plus cognitive impairment with blindness due to neonatal preterm birth complications 28-32wks	32.2 (14.8 to 57.7)	82.8 (38.0 to 147.1)	156.2 (126.1 to 196.1)	96.7 (73.3 to 127.1)
Moderate motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications 28-32wks	57.7 (29.6 to 95.6)	141.2 (71.8 to 237.4)	144.4 (107.0 to 190.6)	87.3 (58.2 to 121.8)
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications 28-32wks	12.8 (5.4 to 23.2)	31.5 (13.4 to 58.6)	146.3 (109.7 to 188.8)	88.6 (61.1 to 121.2)
Severe motor impairment due to neonatal preterm birth complications 28-32wks	406.2 (233.0 to 631.0)	1,220.8 (729.4 to 1,860.3)	199.2 (148.3 to 271.4)	136.5 (95.7 to 192.7)
Severe motor impairment with blindness due to neonatal preterm birth complications 28-32wks	17.3 (8.6 to 29.4)	41.3 (20.5 to 70.1)	137.9 (94.9 to 196.4)	69.0 (40.2 to 110.3)
Severe motor impairment with epilepsy due to neonatal preterm birth complications 28-32wks	119.2 (68.4 to 190.3)	284.3 (161.0 to 459.6)	138.1 (101.0 to 183.2)	82.6 (55.3 to 116.7)
Severe motor impairment with blindness and epilepsy due to neonatal preterm birth complications 28-32wks	25.3 (10.9 to 45.3)	61.8 (26.9 to 114.5)	144.4 (108.5 to 186.7)	87.3 (60.5 to 119.5)
Severe motor plus cognitive impairment with blindness due to neonatal preterm birth complications 28-32wks	37.1 (17.6 to 63.8)	96.2 (46.4 to 167.6)	158.4 (129.7 to 195.8)	98.4 (76.4 to 126.9)
Severe motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications 28-32wks	55.7 (29.4 to 90.1)	136.1 (69.8 to 221.2)	144.0 (107.9 to 186.0)	86.9 (59.5 to 118.3)
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications 28-32wks	10.8 (4.5 to 19.8)	26.5 (11.4 to 49.2)	143.3 (107.9 to 185.9)	86.7 (60.0 to 118.2)
Moderate motor impairment due to neonatal preterm birth complications 32-36wks	57.8 (33.5 to 91.8)	187.7 (110.9 to 296.3)	224.0 (174.2 to 296.2)	153.4 (115.1 to 210.3)
Moderate motor impairment with blindness due to neonatal preterm birth complications 32-36wks	7.2 (3.4 to 12.7)	18.2 (8.8 to 33.9)	151.5 (102.5 to 208.2)	79.0 (45.8 to 116.7)
Moderate motor impairment with epilepsy due to neonatal preterm birth complications 32-36wks	69.5 (39.7 to 107.9)	184.5 (102.4 to 287.3)	165.6 (131.2 to 207.5)	101.9 (76.4 to 133.0)
Moderate motor impairment with blindness and epilepsy due to neonatal preterm birth complications 32-36wks	16.7 (7.1 to 30.0)	45.0 (19.0 to 80.3)	169.9 (137.2 to 206.0)	105.2 (80.6 to 132.4)
Moderate motor plus cognitive impairment with blindness due to neonatal preterm birth complications 32-36wks	19.0 (8.9 to 33.9)	53.2 (25.6 to 92.8)	180.1 (152.9 to 211.4)	113.6 (93.6 to 137.3)
Moderate motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications 32-36wks	34.6 (17.1 to 59.2)	93.1 (45.7 to 162.5)	169.0 (137.0 to 207.1)	104.8 (80.6 to 133.2)
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications 32-36wks	7.6 (3.2 to 13.8)	20.3 (9.2 to 37.5)	168.3 (135.7 to 204.8)	104.1 (80.3 to 131.6)
Severe motor impairment due to neonatal preterm birth complications 32-36wks	235.5 (134.3 to 355.0)	761.2 (444.5 to 1,138.1)	222.0 (174.3 to 291.3)	152.5 (116.4 to 206.0)
Severe motor impairment with blindness due to neonatal preterm birth complications 32-36wks	9.7 (4.7 to 16.8)	24.6 (12.1 to 44.2)	153.1 (104.0 to 209.2)	79.7 (46.4 to 117.1)
Severe motor impairment with epilepsy due to neonatal preterm birth complications 32-36wks	71.5 (42.2 to 112.4)	187.0 (108.9 to 284.6)	161.7 (129.2 to 200.5)	99.4 (74.9 to 129.0)
Severe motor impairment with blindness and epilepsy due to neonatal preterm birth complications 32-36wks	14.7 (6.3 to 27.0)	39.2 (16.8 to 69.6)	166.4 (134.4 to 202.4)	103.1 (79.4 to 129.8)
Severe motor plus cognitive impairment with blindness due to neonatal preterm birth complications 32-36wks	21.4 (10.0 to 37.2)	60.0 (27.6 to 103.4)	180.1 (152.9 to 211.4)	113.6 (93.6 to 137.3)
Severe motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications 32-36wks	32.7 (17.2 to 55.9)	86.8 (46.0 to 144.8)	166.1 (134.0 to 201.3)	102.9 (79.2 to 129.4)
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications 32-36wks	6.6 (2.7 to 12.1)	17.5 (7.3 to 32.5)	165.5 (133.5 to 200.1)	102.3 (78.5 to 128.9)
Neonatal encephalopathy due to birth asphyxia and trauma	1,533.3 (1,085.8 to 2,127.3)	2,388.1 (1,783.6 to 3,153.0)	57.1 (32.4 to 84.0)	25.6 (5.4 to 48.1)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Mild motor plus cognitive impairments due to neonatal encephalopathy due to birth asphyxia and trauma	251.6 (64.0 to 550.3)	215.0 (58.2 to 477.0)	-15.6 (-37.8 to 25.5)	-35.6 (-52.6 to -4.5)
Mild motor impairment due to neonatal encephalopathy due to birth asphyxia and trauma	103.1 (22.7 to 260.1)	91.8 (22.2 to 217.8)	-11.4 (-36.3 to 44.5)	-32.1 (-51.5 to 10.0)
Moderate motor impairment due to neonatal encephalopathy due to birth asphyxia and trauma	63.9 (39.3 to 97.0)	133.9 (79.9 to 203.0)	109.3 (52.6 to 184.3)	74.8 (27.6 to 137.3)
Moderate motor impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma	2.0 (1.2 to 3.0)	3.3 (2.1 to 4.9)	68.5 (31.1 to 101.1)	26.0 (-0.2 to 50.8)
Moderate motor impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	80.4 (57.3 to 106.7)	129.5 (92.0 to 170.2)	61.2 (33.5 to 92.2)	28.9 (7.6 to 53.8)
Moderate motor impairment with blindness and epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	10.3 (7.3 to 13.5)	16.3 (11.8 to 21.2)	59.1 (35.6 to 86.5)	27.5 (8.9 to 49.1)
Moderate motor plus cognitive impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma	27.1 (18.0 to 37.6)	45.7 (30.8 to 62.1)	67.9 (48.1 to 93.7)	35.0 (19.4 to 55.3)
Moderate motor plus cognitive impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	181.9 (130.4 to 243.1)	288.0 (208.8 to 374.3)	58.6 (32.4 to 88.2)	27.6 (6.8 to 51.1)
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	21.8 (15.5 to 28.4)	34.4 (24.5 to 44.5)	57.8 (34.3 to 84.7)	26.6 (8.2 to 48.2)
Severe motor impairment due to neonatal encephalopathy due to birth asphyxia and trauma	330.3 (212.8 to 478.5)	704.7 (445.3 to 1,049.9)	112.2 (51.6 to 193.0)	77.7 (26.9 to 144.8)
Severe motor impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma	1.4 (0.9 to 2.1)	2.4 (1.6 to 3.4)	68.6 (30.8 to 100.5)	25.9 (-0.2 to 51.0)
Severe motor impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	44.8 (31.6 to 58.1)	70.5 (49.6 to 90.7)	57.4 (33.9 to 84.1)	26.4 (8.1 to 48.1)
Severe motor impairment with blindness and epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	4.7 (3.5 to 6.0)	7.4 (5.5 to 9.4)	56.5 (33.2 to 83.4)	25.7 (7.6 to 47.4)
Severe motor plus cognitive impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma	57.0 (39.8 to 75.0)	95.8 (67.8 to 124.2)	67.5 (46.6 to 93.7)	34.4 (18.0 to 55.1)
Severe motor plus cognitive impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	318.9 (228.9 to 400.5)	496.1 (365.4 to 628.3)	55.5 (32.0 to 83.5)	25.1 (6.4 to 47.6)
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma	34.2 (25.4 to 43.8)	53.4 (39.1 to 67.9)	55.7 (33.0 to 82.3)	25.1 (7.4 to 46.8)
Neonatal sepsis and other neonatal infections	3.1 (1.0 to 6.8)	6.6 (2.0 to 15.0)	110.3 (97.4 to 128.1)	108.1 (95.3 to 125.7)
Hemolytic disease and other neonatal jaundice	747.9 (511.9 to 1,018.6)	1,606.8 (1,122.3 to 2,234.6)	112.4 (61.1 to 220.9)	66.7 (28.2 to 151.9)
Moderate motor impairment due to hemolytic disease and other neonatal jaundice	36.8 (22.0 to 57.2)	103.5 (60.6 to 176.3)	175.7 (76.0 to 391.1)	122.6 (44.2 to 290.8)
Moderate motor impairment with blindness due to hemolytic disease and other neonatal jaundice	1.8 (1.1 to 2.7)	3.1 (1.9 to 4.8)	78.0 (20.7 to 163.4)	28.8 (-13.2 to 93.9)
Moderate motor impairment with epilepsy due to hemolytic disease and other neonatal jaundice	53.8 (36.2 to 73.4)	99.1 (67.3 to 134.8)	82.5 (44.6 to 158.8)	41.8 (13.3 to 101.6)
Moderate motor impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice	6.8 (4.7 to 9.2)	12.5 (8.7 to 16.8)	83.3 (45.6 to 155.4)	42.6 (13.5 to 98.0)
Moderate motor plus cognitive impairment with blindness due to hemolytic disease and other neonatal jaundice	18.0 (11.6 to 25.8)	35.2 (23.2 to 51.4)	95.2 (53.5 to 181.0)	52.6 (20.7 to 119.1)
Moderate motor plus cognitive impairment with epilepsy due to hemolytic disease and other neonatal jaundice	120.6 (82.0 to 163.2)	221.7 (153.8 to 298.4)	82.1 (44.0 to 152.6)	41.6 (12.5 to 96.5)
Moderate motor plus cognitive impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice	14.4 (9.9 to 19.6)	26.4 (17.8 to 35.9)	81.8 (44.7 to 153.0)	41.6 (13.1 to 96.1)
Severe motor impairment severe due to hemolytic disease and other neonatal jaundice	189.4 (112.5 to 290.4)	544.8 (323.7 to 908.0)	183.7 (73.2 to 410.1)	128.5 (42.9 to 307.3)
Severe motor impairment with blindness due to hemolytic disease and other neonatal jaundice	1.3 (0.8 to 1.9)	2.3 (1.4 to 3.4)	78.0 (20.7 to 163.4)	28.8 (-13.2 to 93.9)
Severe motor impairment with epilepsy due to hemolytic disease and other neonatal jaundice	29.5 (19.9 to 39.5)	54.0 (37.5 to 72.2)	81.2 (43.7 to 152.6)	41.2 (12.7 to 95.5)
Severe motor impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice	3.1 (2.2 to 4.2)	5.7 (4.0 to 7.6)	80.0 (43.0 to 150.4)	40.5 (12.1 to 94.3)
Severe motor plus cognitive impairment with blindness due to hemolytic disease and other neonatal jaundice	37.7 (25.2 to 51.7)	74.8 (51.2 to 101.8)	95.2 (53.3 to 181.2)	52.6 (20.5 to 119.2)
Severe motor plus cognitive impairment with epilepsy due to hemolytic disease and other neonatal jaundice	212.1 (150.4 to 277.0)	382.1 (270.7 to 503.3)	78.1 (41.0 to 144.5)	39.2 (10.6 to 89.0)
Severe motor plus cognitive impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice	22.7 (16.0 to 30.2)	41.2 (29.1 to 53.8)	79.2 (42.6 to 149.1)	39.9 (11.6 to 93.4)
Other neonatal disorders	858.1 (573.6 to 1,219.0)	1,957.6 (1,334.4 to 2,698.5)	128.8 (82.2 to 189.1)	80.3 (43.8 to 126.6)
Nutritional deficiencies	46,100.7 (30,899.5 to 65,931.0)	41,765.3 (27,678.6 to 60,351.7)	-9.4 (-12.0 to -7.0)	-26.1 (-27.8 to -24.5)
Protein-energy malnutrition	2,948.7 (1,748.3 to 4,389.3)	2,574.3 (1,588.3 to 3,920.3)	-13.0 (-34.9 to 16.9)	-16.3 (-37.0 to 12.3)
Kwashiorkor due to protein-energy malnutrition	2.8 (1.3 to 5.0)	1.8 (0.9 to 3.3)	-35.8 (-49.6 to -18.0)	-37.7 (-51.1 to -20.3)
Marasmus due to protein-energy malnutrition	164.6 (83.4 to 286.1)	150.7 (75.5 to 255.0)	-8.6 (-23.0 to 6.6)	-22.8 (-34.2 to -11.4)
Severe wasting due to protein-energy malnutrition	2,781.4 (1,660.6 to 4,204.7)	2,421.9 (1,482.8 to 3,718.1)	-13.3 (-36.1 to 18.7)	-15.8 (-38.0 to 15.4)
Iodine deficiency	2,341.8 (1,457.4 to 3,669.6)	2,075.0 (1,294.6 to 3,291.9)	-11.4 (-17.1 to -5.4)	-36.7 (-40.8 to -32.3)
Visible goiter without symptoms	709.6 (479.5 to 1,006.6)	629.6 (425.9 to 901.2)	-11.3 (-17.1 to -5.1)	-36.7 (-40.9 to -32.2)
Visible goiter without heart failure due to iodine deficiency	1,257.2 (601.1 to 2,324.0)	1,114.6 (530.6 to 2,077.7)	-11.4 (-16.7 to -5.4)	-36.8 (-40.6 to -32.4)
Visible goiter with mild heart failure due to iodine deficiency	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	56.0 (5.3 to 175.3)	1.1 (-33.8 to 81.7)
Visible goiter with moderate heart failure due to iodine deficiency	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	56.0 (5.2 to 175.2)	1.1 (-33.8 to 81.8)
Visible goiter with severe heart failure due to iodine deficiency	0.4 (0.2 to 0.7)	0.7 (0.4 to 1.3)	56.0 (5.1 to 175.0)	1.2 (-33.4 to 81.4)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Visible goiter with signs and symptoms	364.5 (247.1 to 506.5)	323.5 (215.6 to 451.7)	-11.3 (-17.6 to -4.0)	-36.6 (-41.2 to -31.4)
Severe intellectual disability due to iodine deficiency	6.9 (4.0 to 12.4)	4.4 (2.7 to 7.0)	-33.1 (-64.6 to -2.6)	-35.3 (-65.8 to -5.9)
Profound intellectual disability due to iodine deficiency	3.0 (1.0 to 5.9)	2.0 (0.7 to 3.6)	-32.7 (-63.1 to -3.7)	-35.0 (-64.4 to -7.0)
Vitamin A deficiency	199.3 (129.5 to 293.6)	153.7 (99.0 to 224.9)	-22.9 (-28.7 to -16.9)	-39.1 (-44.1 to -33.5)
Moderate vision impairment loss due to vitamin A deficiency	110.2 (65.1 to 175.4)	90.5 (52.4 to 144.9)	-17.9 (-23.7 to -11.5)	-32.8 (-37.9 to -28.0)
Severe vision impairment loss due to vitamin A deficiency	46.0 (29.5 to 67.0)	35.8 (21.9 to 53.5)	-22.1 (-34.8 to -8.6)	-39.0 (-48.4 to -28.5)
Blindness due to vitamin A deficiency	43.0 (26.5 to 65.7)	27.4 (16.3 to 42.1)	-36.3 (-46.7 to -25.0)	-53.1 (-60.1 to -43.9)
Iron-deficiency anemia	40,078.7 (26,808.5 to 57,971.0)	36,663.5 (24,371.0 to 53,084.7)	-8.6 (-9.8 to -7.1)	-25.8 (-26.7 to -24.9)
Mild iron-deficiency anemia	2,026.9 (725.3 to 4,431.9)	2,198.2 (785.8 to 4,808.6)	8.4 (7.8 to 9.3)	-18.3 (-18.7 to -17.7)
Moderate iron-deficiency anemia	29,764.1 (19,689.2 to 43,266.8)	27,817.1 (18,406.6 to 40,441.9)	-6.5 (-7.2 to -6.0)	-24.0 (-24.6 to -23.6)
Severe iron-deficiency anemia	8,244.6 (5,693.0 to 11,458.1)	6,597.1 (4,523.7 to 9,153.5)	-20.0 (-21.1 to -18.7)	-34.1 (-35.0 to -32.8)
Mild heart failure due to iron-deficiency anemia	3.7 (1.8 to 6.3)	4.4 (2.3 to 7.5)	19.6 (19.8)	-22.3 (-35.2 to -9.9)
Moderate heart failure due to iron-deficiency anemia	5.2 (3.0 to 8.6)	6.2 (3.5 to 10.2)	19.8 (0.3 to 37.0)	-22.3 (-34.9 to -10.6)
Severe heart failure due to iron-deficiency anemia	34.2 (21.3 to 51.9)	40.6 (24.6 to 61.3)	19.1 (0.1 to 35.4)	-22.4 (-35.4 to -11.7)
Other nutritional deficiencies	532.2 (257.2 to 970.3)	298.8 (157.9 to 535.4)	-43.8 (-63.9 to -10.0)	-45.7 (-65.2 to -13.1)
Other communicable, maternal, neonatal, and nutritional diseases	3,238.8 (2,097.5 to 4,867.8)	3,565.4 (2,282.3 to 5,460.0)	9.7 (5.6 to 15.8)	-13.4 (-15.8 to -9.9)
Sexually transmitted diseases excluding HIV	1,001.7 (603.1 to 1,712.5)	1,383.8 (830.1 to 2,404.6)	38.0 (33.1 to 42.5)	-2.6 (-5.6 to 0.5)
Syphilis	57.5 (38.8 to 80.0)	58.4 (39.6 to 81.8)	1.5 (-5.3 to 9.9)	-36.9 (-40.8 to -32.0)
Chlamydial infection	472.4 (298.5 to 751.4)	646.5 (411.0 to 1,019.4)	37.1 (31.0 to 43.3)	0.4 (-4.2 to 4.8)
Asymptomatic chlamydial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild chlamydial infection	189.3 (75.3 to 397.5)	250.3 (99.9 to 521.2)	32.5 (28.2 to 36.0)	-3.2 (-6.2 to -0.7)
Epididymo-orchitis due to chlamydial infection	268.0 (176.1 to 384.0)	382.1 (250.3 to 545.2)	42.6 (34.1 to 51.5)	4.7 (-1.3 to 11.3)
Moderate pelvic inflammatory diseases due to chlamydial infection	6.3 (4.2 to 8.8)	5.6 (3.8 to 7.8)	-10.2 (-18.6 to -1.8)	-35.8 (-41.6 to -30.0)
Severe pelvic inflammatory diseases due to chlamydial infection	2.2 (1.5 to 3.2)	2.0 (1.3 to 2.8)	-10.1 (-17.9 to -2.7)	-35.7 (-41.2 to -30.6)
Primary infertility due to chlamydial infection	3.3 (1.4 to 7.0)	3.3 (1.4 to 6.9)	-0.2 (-8.3 to 11.5)	-31.8 (-37.4 to -24.0)
Secondary infertility due to chlamydial infection	3.3 (1.2 to 7.1)	3.2 (1.2 to 6.9)	-1.3 (-9.1 to 8.6)	-35.6 (-40.7 to -29.5)
Gonococcal infection	157.1 (100.3 to 247.5)	225.4 (144.8 to 344.1)	43.4 (29.1 to 61.0)	7.9 (-2.6 to 20.9)
Asymptomatic gonococcal infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild gonococcal infection	54.1 (22.1 to 114.1)	76.6 (30.2 to 159.3)	41.5 (30.5 to 53.2)	7.9 (-0.4 to 16.5)
Epididymo-orchitis due to gonococcal infection	84.5 (55.4 to 124.0)	129.0 (83.4 to 184.1)	52.5 (31.3 to 79.5)	16.5 (0.8 to 36.5)
Moderate pelvic inflammatory diseases due to gonococcal infection	7.6 (5.0 to 10.7)	7.9 (5.2 to 11.0)	3.1 (-18.1 to 28.1)	-26.7 (-41.1 to -9.6)
Severe pelvic inflammatory diseases due to gonococcal infection	2.8 (1.8 to 3.9)	2.8 (1.8 to 4.0)	2.3 (-12.0 to 18.4)	-27.2 (-37.3 to -16.0)
Primary infertility due to gonococcal infection	4.1 (1.8 to 8.7)	4.8 (2.0 to 10.2)	16.7 (4.5 to 31.2)	-20.9 (-29.1 to -10.9)
Secondary infertility due to gonococcal infection	3.9 (1.5 to 8.7)	4.3 (1.7 to 9.6)	10.5 (2.5 to 19.9)	-28.1 (-33.2 to -22.1)
Trichomoniasis	78.0 (30.9 to 167.4)	113.9 (45.1 to 242.9)	45.5 (32.3 to 64.1)	4.2 (-4.9 to 16.9)
Asymptomatic trichomoniasis infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Acute trichomoniasis infection	88.2 (35.0 to 185.9)	129.1 (51.4 to 276.3)	45.9 (33.5 to 62.7)	4.3 (-4.2 to 15.7)
Genital herpes	213.5 (68.2 to 516.5)	311.6 (98.3 to 748.5)	45.7 (40.8 to 49.6)	-4.8 (-6.8 to -2.6)
Asymptomatic genital herpes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Symptomatic genital herpes	195.9 (56.7 to 478.6)	289.3 (84.2 to 708.8)	47.7 (44.6 to 50.7)	-5.0 (-7.0 to -3.2)
Moderate infection due to initial genital herpes episode	17.6 (3.6 to 43.6)	22.3 (4.7 to 55.6)	26.2 (16.1 to 38.8)	-1.9 (-9.6 to 7.4)
Other sexually transmitted diseases	23.3 (15.7 to 33.9)	27.9 (19.0 to 40.2)	20.0 (9.2 to 32.4)	-16.9 (-24.3 to -8.1)
Moderate pelvic inflammatory diseases due to other sexually transmitted diseases	12.2 (8.3 to 17.1)	15.6 (10.5 to 21.9)	27.7 (10.6 to 46.0)	-9.9 (-21.4 to 2.8)
Severe pelvic inflammatory diseases due to other sexually transmitted diseases	4.5 (2.9 to 6.3)	5.7 (3.7 to 8.0)	27.6 (17.8 to 37.6)	-10.1 (-16.9 to -3.3)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Primary infertility due to other sexually transmitted diseases	3.3 (1.4 to 6.9)	3.3 (1.4 to 6.9)	0.1 (-9.0 to 11.3)	-31.7 (-37.9 to -24.4)
Secondary infertility due to other sexually transmitted diseases	3.3 (1.2 to 7.1)	3.2 (1.2 to 7.0)	-1.4 (-9.2 to 8.3)	-35.5 (-40.7 to -29.4)
Hepatitis	386.8 (250.8 to 559.8)	444.1 (290.5 to 641.1)	14.9 (12.1 to 17.5)	-17.3 (-19.4 to -15.3)
Hepatitis A	157.2 (101.3 to 228.1)	198.0 (128.3 to 287.8)	25.9 (22.9 to 29.1)	-0.9 (-3.5 to 2.0)
Asymptomatic acute hepatitis A	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild acute hepatitis A	2.9 (1.2 to 6.2)	3.7 (1.5 to 7.7)	26.0 (18.4 to 33.5)	-0.9 (-6.8 to 4.7)
Moderate acute hepatitis A	150.8 (97.7 to 217.9)	189.9 (123.5 to 275.0)	26.0 (22.8 to 29.2)	-0.9 (-3.6 to 2.0)
Severe acute hepatitis A	3.5 (2.3 to 4.9)	4.4 (2.9 to 6.2)	26.1 (25.5 to 27.1)	-0.9 (-2.2 to 0.6)
Hepatitis B	169.0 (109.4 to 243.6)	172.6 (112.0 to 247.4)	2.2 (-2.3 to 6.7)	-31.8 (-35.0 to -28.6)
Asymptomatic acute hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Moderate acute hepatitis B	161.5 (104.7 to 233.7)	164.9 (106.7 to 236.9)	2.2 (-2.3 to 6.8)	-31.8 (-35.1 to -28.6)
Severe acute hepatitis B	7.5 (5.0 to 10.7)	7.7 (5.1 to 11.0)	2.8 (-1.8 to 7.3)	-31.5 (-34.8 to -28.4)
Chronic Hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Hepatitis C	14.6 (9.5 to 21.1)	16.9 (11.0 to 24.3)	15.5 (10.0 to 21.4)	-21.2 (-25.1 to -17.1)
Asymptomatic acute hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Moderate acute hepatitis C	13.1 (8.4 to 19.1)	15.1 (9.9 to 22.0)	15.5 (9.8 to 21.7)	-21.1 (-25.3 to -16.7)
Severe acute hepatitis C	1.5 (1.0 to 2.2)	1.8 (1.2 to 2.5)	15.6 (10.9 to 21.0)	-21.5 (-24.9 to -17.7)
Chronic Hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Hepatitis E	46.0 (29.8 to 66.3)	56.6 (36.3 to 82.1)	22.9 (12.1 to 34.4)	-8.6 (-16.4 to -0.0)
Asymptomatic acute hepatitis E	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Moderate acute hepatitis E	42.1 (27.0 to 60.7)	51.7 (33.0 to 75.5)	23.0 (11.9 to 34.6)	-8.6 (-16.5 to 0.4)
Severe acute hepatitis E	4.0 (2.6 to 5.6)	4.9 (3.2 to 6.9)	22.5 (13.6 to 32.0)	-8.9 (-15.4 to -1.6)
Leprosy	22.9 (15.2 to 32.3)	39.7 (26.6 to 56.0)	73.4 (61.0 to 86.6)	5.7 (-1.5 to 13.4)
Disfigurement level 1 due to leprosy	0.5 (0.2 to 0.9)	0.2 (0.1 to 0.4)	-55.4 (-63.3 to -44.9)	-72.4 (-77.4 to -65.5)
Disfigurement level 2 due to leprosy	22.4 (14.9 to 31.4)	39.5 (26.4 to 55.6)	76.2 (63.7 to 89.3)	7.4 (0.2 to 15.0)
Other infectious diseases	1,827.5 (1,219.4 to 2,633.3)	1,697.9 (1,130.0 to 2,469.8)	-7.5 (-11.7 to -1.1)	-19.8 (-23.4 to -14.6)
Acute other infectious diseases	84.2 (52.0 to 125.6)	154.4 (83.2 to 247.8)	82.6 (37.9 to 141.9)	40.3 (2.5 to 94.2)
Mild anemia due to other infectious diseases	86.8 (30.9 to 188.5)	88.9 (31.8 to 194.8)	2.4 (-2.4 to 8.0)	-18.5 (-21.9 to -14.1)
Moderate anemia due to other infectious diseases	1,302.0 (852.0 to 1,899.8)	1,173.6 (771.9 to 1,710.2)	-9.8 (-14.5 to -5.7)	-21.5 (-25.4 to -17.9)
Severe anemia due to other infectious diseases	353.7 (234.1 to 496.7)	279.9 (190.7 to 389.3)	-21.4 (-28.5 to -5.9)	-29.8 (-36.2 to -15.8)
Guillain-Barré syndrome due to other infectious diseases	0.6 (0.3 to 0.8)	0.8 (0.5 to 1.2)	45.0 (35.2 to 55.3)	0.9 (-5.6 to 7.8)
Non-communicable diseases	406,227.5 (302,750.0 to 523,257.8)	626,477.7 (465,287.7 to 806,573.8)	54.2 (53.0 to 55.8)	1.4 (0.7 to 2.2)
Neoplasms	3,703.9 (2,745.5 to 4,779.5)	6,763.9 (4,989.2 to 8,715.9)	82.5 (75.4 to 90.8)	8.5 (4.4 to 13.5)
Esophageal cancer	84.1 (59.5 to 109.4)	125.7 (88.9 to 167.2)	49.6 (30.2 to 72.8)	-13.6 (-24.4 to -0.3)
Diagnosis and primary therapy phase of esophageal cancer	12.6 (8.4 to 17.6)	19.6 (13.0 to 28.0)	55.8 (29.7 to 88.9)	-9.8 (-24.9 to 9.4)
Controlled phase of esophageal cancer	16.3 (10.1 to 24.4)	26.2 (16.7 to 39.3)	61.0 (29.3 to 103.4)	-6.3 (-24.7 to 18.6)
Metastatic phase of esophageal cancer	43.3 (30.1 to 57.3)	62.5 (42.5 to 85.1)	43.9 (28.1 to 63.4)	-16.8 (-25.9 to -5.6)
Terminal phase of esophageal cancer	12.0 (8.4 to 15.5)	17.4 (12.1 to 23.1)	45.3 (29.8 to 63.9)	-15.9 (-25.0 to -5.3)
Stomach cancer	226.5 (165.4 to 291.2)	290.4 (209.4 to 368.1)	28.2 (19.1 to 38.3)	-25.7 (-30.9 to -20.0)
Diagnosis and primary therapy phase of stomach cancer	45.1 (31.1 to 60.8)	58.9 (40.0 to 79.7)	30.5 (20.1 to 41.9)	-24.4 (-30.3 to -18.0)
Controlled phase of stomach cancer	63.2 (40.4 to 91.2)	88.5 (57.4 to 127.5)	40.3 (28.9 to 53.4)	-18.3 (-24.8 to -10.8)
Metastatic phase of stomach cancer	89.7 (62.5 to 117.5)	108.3 (74.7 to 140.0)	21.0 (12.1 to 29.6)	-30.0 (-35.1 to -25.1)
Terminal phase of stomach cancer	28.5 (20.1 to 36.3)	34.6 (24.4 to 44.2)	21.3 (11.7 to 31.0)	-29.8 (-35.3 to -24.1)
Liver cancer	107.9 (76.6 to 143.6)	190.6 (133.3 to 253.2)	76.9 (55.6 to 102.0)	4.5 (-7.6 to 19.0)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Liver cancer due to hepatitis B	39.3 (27.7 to 52.1)	67.0 (46.3 to 89.9)	70.7 (44.5 to 102.0)	2.0 (-13.6 to 20.5)
Diagnosis and primary therapy phase of liver cancer due to hepatitis B	10.8 (7.3 to 15.0)	18.0 (11.7 to 25.2)	67.3 (43.0 to 95.7)	-0.1 (-14.1 to 16.7)
Controlled phase of liver cancer due to hepatitis B	6.9 (3.9 to 10.7)	14.3 (8.6 to 21.7)	108.2 (49.2 to 199.5)	24.8 (-10.1 to 78.1)
Metastatic phase of liver cancer due to hepatitis B	14.5 (9.9 to 19.5)	23.2 (15.5 to 30.8)	60.3 (39.4 to 84.0)	-4.0 (-17.0 to 9.6)
Terminal phase of liver cancer due to hepatitis B	7.1 (5.0 to 9.4)	11.5 (7.8 to 15.0)	60.7 (40.6 to 84.4)	-4.1 (-15.8 to 9.6)
Liver cancer due to hepatitis C	18.1 (12.8 to 24.1)	74.6 (52.6 to 99.9)	310.5 (256.5 to 378.5)	135.7 (106.8 to 174.3)
Diagnosis and primary therapy phase of liver cancer due to hepatitis C	5.0 (3.3 to 7.0)	20.0 (13.5 to 28.0)	302.4 (247.1 to 368.5)	131.2 (100.2 to 167.1)
Controlled phase of liver cancer due to hepatitis C	3.2 (2.0 to 4.9)	16.0 (9.9 to 23.6)	394.7 (277.3 to 547.5)	185.9 (120.6 to 272.3)
Metastatic phase of liver cancer due to hepatitis C	6.7 (4.5 to 9.0)	25.8 (17.6 to 34.5)	286.7 (240.5 to 347.1)	122.0 (97.0 to 155.4)
Terminal phase of liver cancer due to hepatitis C	3.3 (2.2 to 4.3)	12.8 (9.0 to 17.0)	293.1 (246.8 to 350.5)	125.5 (99.4 to 159.0)
Liver cancer due to alcohol use	29.3 (20.7 to 38.6)	29.9 (20.7 to 40.1)	2.0 (-10.3 to 16.3)	-40.4 (-47.6 to -32.1)
Diagnosis and primary therapy phase of liver cancer due to alcohol use	8.0 (5.4 to 11.1)	8.1 (5.3 to 11.4)	0.8 (-11.3 to 14.8)	-41.2 (-48.1 to -33.1)
Controlled phase of liver cancer due to alcohol use	5.2 (3.1 to 7.9)	6.1 (3.8 to 9.2)	18.3 (-8.3 to 54.2)	-30.8 (-46.2 to -10.8)
Metastatic phase of liver cancer due to alcohol use	10.7 (7.2 to 14.2)	10.5 (7.2 to 14.0)	-2.2 (-12.4 to 9.7)	-42.9 (-48.7 to -35.9)
Terminal phase of liver cancer due to alcohol use	5.4 (3.8 to 7.0)	5.2 (3.6 to 6.8)	-3.4 (-13.5 to 7.5)	-43.6 (-49.3 to -37.4)
Liver cancer due to other causes	21.2 (14.8 to 28.5)	19.1 (13.1 to 25.6)	-9.8 (-24.0 to 4.4)	-45.8 (-54.2 to -37.5)
Diagnosis and primary therapy phase of liver cancer due to other causes	5.8 (3.9 to 8.1)	5.2 (3.4 to 7.3)	-10.5 (-24.1 to 2.7)	-46.3 (-54.2 to -38.4)
Controlled phase of liver cancer due to other causes	3.7 (2.2 to 5.7)	3.9 (2.4 to 6.0)	6.4 (-22.9 to 40.1)	-36.0 (-53.6 to -15.3)
Metastatic phase of liver cancer due to other causes	7.9 (5.3 to 10.6)	6.7 (4.5 to 9.1)	-14.0 (-25.7 to -2.1)	-48.5 (-55.0 to -41.3)
Terminal phase of liver cancer due to other causes	3.8 (2.6 to 4.9)	3.2 (2.2 to 4.2)	-14.8 (-26.2 to -3.1)	-49.0 (-55.5 to -42.1)
Larynx cancer	64.3 (45.5 to 87.7)	86.0 (60.0 to 115.2)	32.8 (22.0 to 49.6)	-22.0 (-28.3 to -12.4)
Diagnosis and primary therapy phase of larynx cancer	12.4 (7.9 to 17.5)	16.2 (10.5 to 23.2)	30.3 (17.4 to 49.4)	-23.6 (-31.1 to -12.2)
Controlled phase of larynx cancer	21.3 (13.3 to 31.9)	32.0 (20.0 to 48.2)	49.3 (35.9 to 69.2)	-11.8 (-19.9 to -0.4)
Metastatic phase of larynx cancer	24.0 (15.6 to 33.0)	30.0 (19.9 to 41.6)	24.8 (11.7 to 42.0)	-27.0 (-34.5 to -17.5)
Terminal phase of larynx cancer	4.2 (2.8 to 5.7)	5.2 (3.4 to 7.0)	23.6 (15.1 to 38.5)	-27.8 (-32.7 to -19.5)
Laryngectomy due to larynx cancer	2.5 (1.6 to 3.7)	2.6 (1.7 to 4.0)	6.2 (-12.5 to 23.3)	-37.1 (-48.7 to -26.7)
Tracheal, bronchus and lung cancer	284.4 (208.8 to 358.4)	467.4 (338.5 to 593.2)	64.6 (54.9 to 72.9)	-3.7 (-9.3 to 1.2)
Diagnosis and primary therapy phase of lung, bronchus, and trachea cancer	31.8 (21.9 to 43.0)	53.6 (36.5 to 72.1)	68.5 (55.9 to 80.8)	-1.3 (-8.6 to 5.7)
Controlled phase of lung, bronchus, and trachea cancer	57.3 (37.4 to 82.9)	101.4 (65.1 to 146.2)	77.2 (64.6 to 89.6)	4.1 (-3.3 to 11.1)
Metastatic phase of lung, bronchus, and trachea cancer	153.9 (107.5 to 199.6)	246.0 (170.7 to 320.3)	60.0 (50.5 to 68.7)	-6.3 (-11.7 to -1.6)
Terminal phase of lung, bronchus, and trachea cancer	41.4 (29.3 to 52.4)	66.3 (47.3 to 83.9)	59.9 (48.0 to 71.5)	-6.5 (-13.5 to 0.1)
Breast cancer	532.7 (388.4 to 697.8)	1,068.2 (760.8 to 1,428.1)	100.7 (86.6 to 114.3)	15.7 (7.8 to 23.2)
Diagnosis and primary therapy phase of breast cancer	49.1 (33.1 to 68.1)	102.7 (69.8 to 140.4)	109.4 (92.6 to 126.8)	21.3 (11.7 to 31.1)
Controlled phase of breast cancer	156.1 (101.5 to 228.5)	286.1 (184.8 to 420.8)	83.2 (65.9 to 104.0)	6.6 (-3.2 to 18.5)
Metastatic phase of breast cancer	180.6 (123.6 to 236.4)	295.5 (203.0 to 385.3)	63.9 (52.7 to 75.9)	-5.6 (-12.1 to 1.3)
Terminal phase of breast cancer	15.5 (10.6 to 20.1)	24.7 (17.1 to 31.9)	60.4 (45.3 to 74.9)	-7.8 (-16.6 to 0.9)
Mastectomy due to breast cancer	131.5 (77.4 to 204.1)	359.2 (210.7 to 557.2)	173.9 (159.0 to 186.8)	52.5 (44.3 to 59.8)
Cervical cancer	225.1 (159.1 to 303.0)	243.8 (169.8 to 333.0)	8.3 (-3.5 to 22.3)	-34.6 (-41.7 to -26.6)
Diagnosis and primary therapy phase of cervical cancer	38.1 (24.8 to 52.9)	41.4 (26.7 to 58.5)	8.5 (-5.8 to 24.5)	-34.4 (-42.6 to -25.0)
Controlled phase of cervical cancer	123.2 (77.2 to 181.6)	131.8 (83.3 to 193.6)	7.0 (-6.1 to 22.2)	-35.2 (-43.2 to -26.5)
Metastatic phase of cervical cancer	54.3 (36.0 to 72.3)	60.2 (39.2 to 81.1)	10.5 (-2.2 to 26.0)	-33.8 (-41.2 to -24.9)
Terminal phase of cervical cancer	9.5 (6.4 to 12.4)	10.5 (6.9 to 13.8)	10.3 (0.3 to 21.2)	-34.1 (-40.0 to -27.8)
Uterine cancer	119.0 (80.2 to 166.6)	193.7 (123.7 to 273.6)	62.9 (36.4 to 92.1)	-6.0 (-20.6 to 9.8)
Diagnosis and primary therapy phase of uterine cancer	19.6 (12.8 to 27.6)	32.0 (20.4 to 45.5)	63.9 (36.7 to 95.2)	-5.3 (-20.6 to 11.8)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Controlled phase of uterine cancer	75.7 (45.4 to 113.0)	126.1 (74.7 to 191.1)	66.7 (38.2 to 98.2)	-3.4 (-19.3 to 13.8)
Metastatic phase of uterine cancer	20.9 (13.5 to 28.7)	31.2 (20.3 to 42.5)	49.8 (26.8 to 72.8)	-14.6 (-27.5 to -1.7)
Terminal phase of uterine cancer	3.0 (1.9 to 4.0)	4.4 (2.9 to 5.9)	49.7 (28.8 to 71.0)	-15.0 (-26.3 to -3.3)
Prostate cancer	333.0 (242.4 to 430.0)	893.7 (656.7 to 1,192.5)	164.2 (142.0 to 208.3)	48.2 (35.8 to 72.9)
Diagnosis and primary therapy phase of prostate cancer	28.1 (18.2 to 39.9)	100.9 (67.0 to 146.5)	251.1 (202.6 to 339.8)	99.6 (72.2 to 148.9)
Controlled phase of prostate cancer	65.2 (40.6 to 98.6)	250.5 (156.3 to 379.0)	278.6 (230.6 to 362.2)	115.3 (88.4 to 163.7)
Metastatic phase of prostate cancer	151.4 (100.9 to 201.6)	356.2 (238.5 to 494.0)	131.0 (109.1 to 178.9)	29.4 (17.1 to 57.1)
Terminal phase of prostate cancer	8.3 (5.6 to 11.0)	18.2 (12.7 to 24.9)	116.9 (88.0 to 165.6)	22.0 (5.6 to 49.6)
Impotence due to prostate cancer	23.1 (12.3 to 39.3)	48.4 (25.3 to 81.8)	109.7 (95.4 to 125.3)	17.7 (9.6 to 27.0)
Incontinence due to prostate cancer	56.9 (39.8 to 78.6)	119.5 (83.5 to 166.3)	109.7 (95.7 to 126.4)	17.8 (9.5 to 27.3)
Colon and rectum cancer	359.0 (266.4 to 460.0)	701.9 (512.7 to 899.1)	95.5 (86.5 to 104.1)	11.5 (6.3 to 16.5)
Diagnosis and primary therapy phase of colon and rectum cancers	49.4 (34.3 to 66.7)	100.6 (69.1 to 134.9)	103.5 (92.7 to 115.3)	16.2 (10.3 to 23.3)
Controlled phase of colon and rectum cancers	156.7 (103.2 to 225.7)	333.5 (217.9 to 487.3)	112.9 (102.7 to 122.2)	22.3 (16.6 to 27.8)
Metastatic phase of colon and rectum cancers	124.0 (86.9 to 160.2)	220.8 (154.1 to 285.1)	78.1 (70.3 to 86.7)	0.8 (-3.9 to 5.5)
Terminal phase of colon and rectum cancers	20.4 (14.6 to 25.6)	35.6 (25.1 to 45.1)	74.4 (62.4 to 86.1)	-1.1 (-8.0 to 5.7)
Stoma due to colon and rectum cancer	8.5 (5.8 to 11.6)	11.4 (7.9 to 15.5)	33.1 (25.4 to 41.5)	-25.3 (-29.8 to -20.3)
Lip and oral cavity cancer	119.6 (86.6 to 161.3)	206.9 (145.2 to 278.3)	72.3 (52.9 to 98.2)	0.0 (-11.1 to 14.6)
Diagnosis and primary therapy phase of mouth cancer	21.4 (14.1 to 30.4)	37.3 (24.4 to 53.6)	73.5 (49.2 to 103.9)	0.8 (-12.9 to 18.2)
Controlled phase of mouth cancer	53.1 (33.9 to 78.8)	95.1 (59.8 to 139.9)	77.9 (56.6 to 107.0)	3.8 (-8.2 to 20.6)
Metastatic phase of mouth cancer	38.5 (26.1 to 52.4)	63.7 (41.8 to 86.3)	65.3 (44.6 to 90.4)	-4.6 (-16.8 to 9.4)
Terminal phase of mouth cancer	6.5 (4.5 to 8.8)	10.8 (7.2 to 14.6)	64.8 (46.4 to 87.3)	-5.0 (-15.9 to 7.8)
Nasopharynx cancer	38.1 (26.8 to 52.1)	47.9 (33.1 to 64.3)	25.9 (5.6 to 49.6)	-23.5 (-36.0 to -9.4)
Diagnosis and primary therapy phase of nasopharynx cancer	6.2 (3.9 to 8.8)	7.9 (5.0 to 11.2)	27.7 (5.4 to 54.1)	-22.5 (-36.1 to -7.1)
Controlled phase of nasopharynx cancer	15.3 (9.5 to 23.5)	20.1 (12.4 to 30.2)	31.2 (5.3 to 62.6)	-19.7 (-35.5 to -0.7)
Metastatic phase of nasopharynx cancer	14.8 (9.8 to 20.2)	17.8 (11.6 to 24.3)	20.4 (3.9 to 38.8)	-27.5 (-37.1 to -16.4)
Terminal phase of nasopharynx cancer	1.8 (1.2 to 2.4)	2.2 (1.4 to 2.9)	18.6 (3.9 to 34.3)	-28.6 (-37.4 to -19.1)
Other pharynx cancer	37.5 (26.7 to 49.5)	66.0 (45.5 to 88.5)	75.5 (51.3 to 101.5)	1.4 (-12.6 to 16.3)
Diagnosis and primary therapy phase of other pharynx cancer	6.8 (4.5 to 9.4)	12.0 (7.7 to 16.9)	77.5 (46.5 to 112.5)	2.3 (-15.4 to 22.5)
Controlled phase of other pharynx cancer	16.3 (10.4 to 23.9)	29.8 (18.5 to 44.2)	82.7 (54.4 to 113.2)	5.8 (-10.8 to 23.0)
Metastatic phase of other pharynx cancer	12.1 (8.1 to 15.9)	20.2 (13.2 to 27.6)	67.4 (42.1 to 97.3)	-3.7 (-18.1 to 12.8)
Terminal phase of other pharynx cancer	2.4 (1.6 to 3.1)	4.0 (2.6 to 5.2)	66.8 (47.4 to 87.0)	-3.9 (-15.3 to 7.3)
Gallbladder and biliary tract cancer	28.1 (20.0 to 36.6)	39.1 (27.0 to 52.1)	39.8 (22.7 to 54.9)	-20.5 (-30.6 to -11.5)
Diagnosis and primary therapy phase of gallbladder and biliary tract cancer	5.7 (3.9 to 7.8)	8.1 (5.4 to 11.2)	42.9 (24.7 to 59.8)	-18.9 (-29.4 to -8.7)
Controlled phase of gallbladder and biliary tract cancer	1.8 (1.1 to 2.7)	3.0 (1.9 to 4.3)	64.2 (40.5 to 88.9)	-7.1 (-20.7 to 7.4)
Metastatic phase of gallbladder and biliary tract cancer	15.1 (10.4 to 19.8)	20.5 (13.6 to 27.7)	36.9 (19.5 to 52.9)	-22.2 (-32.3 to -12.5)
Terminal phase of gallbladder and biliary tract cancer	5.5 (3.9 to 7.1)	7.5 (5.1 to 9.9)	36.2 (18.5 to 52.2)	-22.5 (-33.1 to -12.8)
Pancreatic cancer	38.3 (27.3 to 49.4)	73.6 (52.1 to 96.2)	92.1 (80.6 to 103.7)	9.9 (3.1 to 16.8)
Diagnosis and primary therapy phase of pancreatic cancer	10.9 (7.5 to 14.9)	21.0 (14.1 to 28.5)	91.9 (77.2 to 107.4)	9.6 (1.1 to 18.8)
Controlled phase of pancreatic cancer	4.4 (2.8 to 6.5)	9.2 (5.9 to 13.7)	108.2 (81.4 to 139.3)	19.3 (4.1 to 37.1)
Metastatic phase of pancreatic cancer	15.4 (10.6 to 20.2)	29.1 (20.3 to 37.9)	89.5 (75.7 to 102.9)	8.4 (0.4 to 16.5)
Terminal phase of pancreatic cancer	7.6 (5.3 to 9.8)	14.4 (10.0 to 18.5)	88.8 (75.6 to 103.8)	7.9 (-0.6 to 17.8)
Malignant skin melanoma	76.4 (50.3 to 110.8)	137.9 (91.7 to 205.0)	80.8 (59.5 to 99.7)	9.1 (-3.8 to 20.2)
Diagnosis and primary therapy phase of malignant skin melanoma	9.2 (5.7 to 13.1)	16.4 (10.6 to 24.7)	79.6 (53.6 to 104.8)	8.7 (-7.2 to 23.9)
Controlled phase of malignant skin melanoma	54.3 (33.7 to 83.0)	101.7 (62.7 to 157.8)	87.4 (64.5 to 108.8)	14.4 (0.8 to 26.7)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Metastatic phase of malignant skin melanoma	10.8 (7.1 to 15.2)	16.6 (10.7 to 23.7)	54.3 (35.5 to 71.1)	-9.5 (-21.4 to 1.2)
Terminal phase of malignant skin melanoma	2.1 (1.4 to 2.9)	3.2 (2.1 to 4.5)	53.6 (34.2 to 67.6)	-10.5 (-22.4 to -1.6)
Non-melanoma skin cancer	49.9 (32.2 to 76.3)	126.2 (82.5 to 188.1)	152.8 (116.5 to 200.2)	42.5 (21.3 to 70.3)
Diagnosis and primary therapy phase of cutaneous squamous cell carcinoma	2.5 (1.6 to 3.6)	8.0 (5.1 to 11.5)	215.3 (158.1 to 286.9)	78.8 (44.4 to 120.9)
Control phase of cutaneous squamous cell carcinoma	13.9 (8.5 to 21.4)	47.2 (29.3 to 72.3)	236.6 (180.5 to 311.1)	94.7 (59.7 to 137.8)
Metastatic phase of cutaneous squamous cell carcinoma	9.0 (5.9 to 12.5)	24.1 (15.6 to 34.8)	166.9 (107.8 to 246.5)	46.3 (13.2 to 92.1)
Terminal phase of cutaneous squamous cell carcinoma	0.9 (0.6 to 1.2)	2.4 (1.5 to 3.5)	169.6 (109.0 to 250.3)	46.7 (11.7 to 92.4)
Disfigurement due to basal cell carcinoma	23.5 (11.0 to 42.9)	44.6 (20.9 to 80.2)	89.3 (56.7 to 124.0)	7.4 (-11.8 to 27.6)
Ovarian cancer	81.8 (58.8 to 104.7)	134.9 (97.0 to 174.6)	65.1 (52.0 to 79.7)	-2.9 (-10.7 to 4.8)
Diagnosis and primary therapy phase of ovarian cancer	5.6 (3.8 to 7.8)	9.6 (6.4 to 13.5)	69.5 (52.7 to 87.3)	-0.2 (-10.6 to 10.6)
Controlled phase of ovarian cancer	21.6 (13.8 to 31.2)	36.6 (23.7 to 54.1)	69.3 (54.8 to 84.9)	0.2 (-8.1 to 9.0)
Metastatic phase of ovarian cancer	50.1 (34.7 to 65.0)	81.5 (56.3 to 107.4)	62.9 (48.6 to 78.3)	-4.6 (-12.8 to 4.2)
Terminal phase of ovarian cancer	4.4 (3.1 to 5.7)	7.2 (4.9 to 9.3)	62.5 (51.7 to 73.6)	-5.1 (-11.3 to 0.9)
Testicular cancer	21.9 (14.5 to 31.1)	34.3 (22.2 to 49.0)	57.6 (30.8 to 80.5)	6.6 (-10.8 to 21.9)
Diagnosis and primary therapy phase of testicular cancer	3.0 (2.0 to 4.3)	4.8 (3.1 to 6.8)	60.5 (31.6 to 84.3)	8.9 (-10.1 to 24.5)
Controlled phase of testicular cancer	15.6 (9.7 to 23.5)	25.0 (14.9 to 37.8)	61.4 (31.2 to 87.0)	10.2 (-9.7 to 27.0)
Metastatic phase of testicular cancer	3.0 (2.0 to 4.1)	4.1 (2.7 to 5.7)	38.1 (24.8 to 57.5)	-10.7 (-19.1 to 2.9)
Terminal phase of testicular cancer	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	34.2 (21.6 to 52.6)	-12.4 (-20.3 to 0.7)
Kidney cancer	66.3 (47.5 to 89.4)	139.2 (99.2 to 185.8)	109.7 (97.0 to 123.5)	26.1 (18.2 to 34.3)
Diagnosis and primary therapy phase of kidney cancer	12.5 (8.4 to 17.0)	26.5 (17.9 to 36.5)	112.1 (94.9 to 132.1)	27.9 (17.7 to 40.6)
Controlled phase of kidney cancer	37.2 (23.9 to 54.1)	80.9 (53.1 to 116.6)	117.5 (103.1 to 133.7)	32.7 (24.3 to 41.7)
Metastatic phase of kidney cancer	13.3 (9.1 to 17.6)	25.5 (17.3 to 33.5)	92.2 (75.7 to 109.1)	11.8 (1.9 to 22.4)
Terminal phase of kidney cancer	3.3 (2.3 to 4.3)	6.4 (4.4 to 8.2)	90.8 (79.1 to 103.8)	10.3 (3.0 to 18.8)
Bladder cancer	117.7 (86.4 to 154.4)	179.8 (132.1 to 235.5)	52.5 (44.1 to 62.5)	-12.8 (-17.8 to -6.9)
Diagnosis and primary therapy phase of bladder cancer	22.2 (15.3 to 30.1)	34.6 (23.7 to 47.5)	55.7 (43.9 to 68.9)	-10.9 (-17.7 to -3.6)
Controlled phase of bladder cancer	56.8 (37.0 to 82.5)	91.3 (60.1 to 132.1)	60.6 (50.8 to 72.3)	-7.3 (-13.0 to -0.6)
Metastatic phase of bladder cancer	27.1 (18.5 to 35.5)	38.7 (26.5 to 50.9)	42.8 (33.0 to 54.5)	-19.4 (-25.3 to -12.8)
Terminal phase of bladder cancer	6.3 (4.4 to 8.1)	9.0 (6.3 to 11.6)	43.3 (31.0 to 56.1)	-19.2 (-26.5 to -11.6)
Urinary incontinence due to bladder cancer	5.3 (3.7 to 7.4)	6.1 (4.2 to 8.7)	15.2 (6.0 to 25.4)	-35.6 (-40.5 to -29.7)
Brain and nervous system cancer	78.8 (55.0 to 107.1)	121.9 (87.1 to 165.1)	55.4 (34.3 to 71.8)	5.6 (-6.7 to 15.9)
Diagnosis and primary therapy phase of brain and nervous system cancers	12.6 (8.3 to 18.0)	19.6 (12.9 to 27.8)	56.1 (33.8 to 74.2)	7.0 (-6.5 to 18.8)
Controlled phase of brain and nervous system cancers	31.5 (19.1 to 48.0)	46.5 (29.5 to 69.4)	49.4 (24.6 to 70.3)	7.0 (-8.7 to 20.9)
Metastatic phase of brain and nervous system cancers	28.5 (18.8 to 38.7)	45.7 (30.7 to 61.5)	60.9 (43.7 to 74.4)	4.3 (-6.7 to 12.6)
Terminal phase of brain and nervous system cancers	6.2 (4.2 to 8.2)	10.0 (6.9 to 13.2)	62.1 (45.7 to 74.5)	4.9 (-4.9 to 12.5)
Thyroid cancer	65.7 (44.0 to 91.2)	127.6 (85.7 to 180.9)	94.9 (71.3 to 122.4)	19.7 (6.6 to 35.6)
Diagnosis and primary therapy phase of thyroid cancer	7.7 (5.0 to 10.7)	15.1 (9.7 to 21.4)	96.4 (72.0 to 126.1)	21.5 (7.0 to 39.4)
Controlled phase of thyroid cancer	48.4 (30.0 to 72.1)	96.8 (60.7 to 145.0)	100.8 (74.2 to 130.7)	25.3 (9.9 to 42.8)
Metastatic phase of thyroid cancer	8.8 (5.8 to 11.7)	14.5 (9.6 to 19.4)	64.3 (49.3 to 82.1)	-4.1 (-13.2 to 6.3)
Terminal phase of thyroid cancer	0.8 (0.5 to 1.0)	1.2 (0.8 to 1.6)	60.5 (47.6 to 77.5)	-5.9 (-13.5 to 3.4)
Mesothelioma	5.6 (3.9 to 7.4)	10.8 (7.4 to 14.4)	96.6 (66.5 to 113.0)	14.1 (-4.4 to 23.5)
Diagnosis and primary therapy phase of mesothelioma	0.6 (0.4 to 0.8)	1.2 (0.7 to 1.6)	100.4 (71.1 to 117.8)	16.2 (-2.0 to 26.4)
Controlled phase of mesothelioma	0.7 (0.4 to 1.1)	1.3 (0.8 to 2.0)	87.0 (57.8 to 108.1)	8.7 (-8.3 to 21.0)
Metastatic phase of mesothelioma	3.5 (2.4 to 4.8)	6.9 (4.6 to 9.3)	97.0 (66.2 to 115.4)	14.2 (-4.6 to 25.2)
Terminal phase of mesothelioma	0.7 (0.5 to 1.0)	1.5 (1.0 to 1.9)	101.3 (70.3 to 116.4)	16.6 (-2.3 to 25.4)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Hodgkin lymphoma	61.5 (39.4 to 87.4)	57.5 (38.7 to 82.1)	-12.0 (-26.8 to 56.4)	-36.2 (-45.7 to 11.0)
Diagnosis and primary therapy phase of Hodgkin disease	7.0 (4.1 to 10.3)	6.5 (4.2 to 9.7)	-11.4 (-29.8 to 60.1)	-34.5 (-46.2 to 16.5)
Controlled phase of Hodgkin disease	34.0 (19.7 to 51.9)	31.0 (18.8 to 47.9)	-13.3 (-32.9 to 60.5)	-34.4 (-47.5 to 19.6)
Metastatic phase of Hodgkin disease	18.9 (12.0 to 25.8)	18.5 (12.1 to 25.7)	-7.8 (-17.6 to 50.2)	-38.7 (-45.3 to -0.7)
Terminal phase of Hodgkin disease	1.6 (1.0 to 2.2)	1.5 (1.0 to 2.0)	-16.3 (-24.2 to 36.5)	-43.8 (-48.9 to -8.7)
Non-Hodgkin lymphoma	103.2 (72.9 to 141.0)	216.2 (151.6 to 292.6)	112.2 (75.7 to 131.1)	31.4 (6.4 to 43.3)
Diagnosis and primary therapy phase of non-Hodgkin lymphoma	13.5 (8.8 to 19.2)	29.0 (19.3 to 40.5)	115.7 (77.9 to 139.2)	33.8 (7.6 to 49.2)
Controlled phase of non-Hodgkin lymphoma	56.1 (35.7 to 86.0)	122.9 (77.1 to 179.8)	121.7 (84.2 to 142.2)	39.6 (14.2 to 52.3)
Metastatic phase of non-Hodgkin lymphoma	27.9 (18.5 to 37.1)	53.6 (35.8 to 72.1)	95.3 (59.8 to 114.0)	17.8 (-5.8 to 30.1)
Terminal phase of non-Hodgkin lymphoma	5.7 (3.9 to 7.5)	10.8 (7.3 to 14.2)	93.1 (56.9 to 109.1)	16.1 (-7.9 to 26.6)
Multiple myeloma	43.8 (29.7 to 61.1)	86.3 (59.7 to 114.9)	98.6 (68.9 to 124.1)	13.4 (-4.5 to 28.6)
Diagnosis and primary therapy phase of multiple myeloma	3.5 (2.2 to 5.1)	7.3 (4.7 to 10.4)	109.4 (75.0 to 145.5)	20.2 (0.6 to 41.4)
Controlled phase of multiple myeloma	4.8 (2.9 to 7.5)	10.4 (6.4 to 15.8)	116.4 (82.2 to 154.5)	25.3 (4.4 to 47.3)
Metastatic phase of multiple myeloma	33.0 (22.0 to 46.2)	64.1 (42.5 to 86.2)	95.9 (66.2 to 121.9)	11.8 (-6.3 to 27.0)
Terminal phase of multiple myeloma	2.5 (1.7 to 3.4)	4.5 (3.0 to 6.0)	83.5 (60.3 to 99.7)	4.5 (-9.6 to 14.0)
Leukemia	164.7 (119.3 to 213.8)	249.6 (182.7 to 320.2)	52.1 (38.4 to 63.8)	4.1 (-4.0 to 11.4)
Diagnosis and primary therapy phase of leukemia	16.0 (10.6 to 22.5)	22.9 (15.4 to 31.8)	44.7 (24.3 to 62.0)	7.7 (-5.3 to 19.3)
Controlled phase of leukemia	56.7 (35.6 to 85.2)	77.7 (49.9 to 112.5)	38.4 (16.9 to 55.1)	6.8 (-7.2 to 17.6)
Metastatic phase of leukemia	83.8 (58.6 to 109.6)	137.5 (95.1 to 179.3)	63.9 (52.6 to 75.0)	3.6 (-3.4 to 10.7)
Terminal phase of leukemia	8.2 (5.7 to 10.6)	11.5 (8.1 to 14.7)	40.5 (32.0 to 48.3)	-9.5 (-14.9 to -4.2)
Other neoplasms	168.8 (116.5 to 236.0)	446.8 (312.5 to 596.4)	172.3 (102.3 to 199.0)	78.3 (39.6 to 97.0)
Diagnosis and primary therapy phase of other neoplasms	13.1 (8.6 to 18.8)	35.1 (23.5 to 48.0)	175.4 (103.7 to 206.4)	82.5 (41.6 to 104.4)
Controlled phase of other neoplasms	106.6 (65.3 to 162.3)	292.5 (186.3 to 422.8)	184.7 (101.4 to 216.2)	96.1 (46.9 to 115.7)
Metastatic phase of other neoplasms	40.6 (27.9 to 54.8)	99.2 (66.2 to 130.0)	146.8 (104.7 to 171.8)	49.2 (23.2 to 65.8)
Terminal phase of other neoplasms	8.5 (5.9 to 11.3)	20.1 (13.8 to 25.9)	138.0 (98.7 to 162.4)	42.9 (19.7 to 59.3)
Cardiovascular diseases	11,213.4 (8,044.6 to 14,820.1)	21,177.0 (14,947.8 to 28,436.7)	89.2 (69.1 to 108.7)	10.3 (-1.0 to 21.3)
Rheumatic heart disease	1,134.4 (764.1 to 1,596.5)	1,821.3 (1,211.3 to 2,530.8)	60.8 (47.5 to 73.7)	9.5 (-0.3 to 18.1)
Rheumatic heart disease, without heart failure	818.2 (528.2 to 1,207.3)	1,348.1 (863.3 to 1,961.3)	65.3 (49.8 to 79.3)	19.3 (7.4 to 30.4)
Mild heart failure due to rheumatic heart disease	27.1 (14.3 to 44.0)	40.6 (19.4 to 69.7)	50.4 (-3.1 to 109.7)	-9.0 (-40.0 to 24.7)
Moderate heart failure due to rheumatic heart disease	38.3 (22.6 to 59.1)	57.5 (31.1 to 93.0)	50.9 (-3.4 to 107.2)	-8.6 (-40.7 to 23.4)
Severe heart failure due to rheumatic heart disease	250.8 (167.8 to 359.0)	375.2 (223.6 to 570.5)	50.7 (-2.6 to 109.7)	-8.8 (-40.0 to 25.2)
Ischemic heart disease	3,464.4 (2,413.0 to 4,721.8)	5,804.1 (4,055.2 to 7,902.3)	67.5 (58.8 to 76.6)	-4.0 (-8.8 to 1.2)
Asymptomatic ischemic heart disease following myocardial infarction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Acute myocardial infarction first 2 days	7.2 (4.7 to 9.6)	12.3 (8.2 to 16.7)	72.3 (64.7 to 80.4)	-2.4 (-7.8 to 2.9)
Acute myocardial infarction 3 to 28 days	15.0 (10.2 to 21.0)	26.0 (17.5 to 36.2)	72.9 (65.1 to 81.6)	-2.5 (-6.7 to 2.1)
Asymptomatic angina due to ischemic heart disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild angina due to ischemic heart disease	263.0 (153.5 to 423.3)	401.0 (235.8 to 629.8)	52.5 (41.2 to 64.3)	-10.8 (-17.4 to -3.9)
Moderate angina due to ischemic heart disease	326.5 (196.4 to 490.5)	497.7 (292.9 to 743.6)	52.6 (41.3 to 64.7)	-10.7 (-17.5 to -3.8)
Severe angina due to ischemic heart disease	1,738.4 (1,153.8 to 2,484.6)	2,651.1 (1,764.9 to 3,794.9)	52.5 (41.3 to 64.6)	-10.8 (-17.3 to -3.8)
Mild heart failure due to ischemic heart disease	96.1 (51.9 to 157.2)	191.1 (104.0 to 312.5)	98.3 (88.3 to 110.3)	9.2 (3.6 to 15.3)
Moderate heart failure due to ischemic heart disease	134.3 (81.4 to 207.5)	267.1 (161.8 to 408.0)	98.7 (88.4 to 109.7)	9.4 (3.8 to 15.3)
Severe heart failure due to ischemic heart disease	883.8 (591.8 to 1,228.6)	1,757.9 (1,180.0 to 2,435.3)	98.4 (89.1 to 110.7)	9.3 (3.9 to 15.6)
Cerebrovascular disease	2,034.0 (1,456.5 to 2,657.0)	3,743.6 (2,669.9 to 4,843.9)	83.5 (75.9 to 93.5)	5.0 (0.5 to 11.2)
Ischemic stroke	1,454.0 (1,015.9 to 1,929.3)	2,650.1 (1,875.1 to 3,492.3)	81.8 (72.6 to 93.3)	3.0 (-2.2 to 9.9)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Asymptomatic chronic ischemic stroke	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Chronic ischemic stroke severity level 1	30.8 (15.7 to 56.6)	56.4 (29.2 to 101.7)	82.6 (73.1 to 94.6)	3.3 (-2.4 to 10.4)
Chronic ischemic stroke severity level 2	159.6 (99.9 to 229.6)	292.0 (182.2 to 418.6)	82.4 (73.2 to 94.5)	3.3 (-2.4 to 10.4)
Chronic ischemic stroke severity level 4	278.9 (161.0 to 409.2)	510.5 (297.8 to 753.9)	82.5 (72.8 to 95.3)	3.6 (-2.1 to 11.0)
Chronic ischemic stroke severity level 3	432.6 (276.1 to 617.5)	791.5 (502.4 to 1,125.1)	82.6 (72.4 to 94.5)	3.6 (-2.4 to 10.5)
Chronic ischemic stroke severity level 5	502.0 (233.2 to 830.9)	919.2 (427.4 to 1,519.8)	82.8 (72.7 to 95.4)	3.7 (-2.5 to 11.2)
Acute ischemic stroke severity level 1	1.0 (0.5 to 1.8)	1.7 (0.8 to 3.0)	60.7 (46.0 to 75.6)	-9.3 (-17.7 to -0.2)
Acute ischemic stroke severity level 2	5.5 (3.6 to 8.0)	8.8 (5.6 to 12.9)	60.8 (45.6 to 74.5)	-9.4 (-18.0 to -1.1)
Acute ischemic stroke severity level 4	10.3 (6.3 to 15.7)	16.6 (10.0 to 25.0)	60.5 (46.5 to 76.3)	-9.1 (-17.4 to 0.9)
Acute ischemic stroke severity level 3	15.2 (9.2 to 21.5)	24.4 (15.1 to 34.3)	61.0 (46.6 to 75.9)	-9.0 (-17.4 to 0.1)
Acute ischemic stroke severity level 5	18.1 (8.5 to 30.3)	29.2 (13.8 to 48.9)	61.2 (46.3 to 75.5)	-8.6 (-17.4 to 0.2)
Hemorrhagic stroke	580.0 (401.3 to 767.1)	1,093.5 (759.0 to 1,438.1)	88.5 (79.7 to 99.0)	10.6 (5.6 to 17.1)
Asymptomatic chronic hemorrhagic stroke	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Chronic hemorrhagic stroke severity level 1	12.1 (5.9 to 22.6)	23.0 (11.0 to 42.5)	89.3 (79.3 to 100.8)	10.9 (5.1 to 18.0)
Chronic hemorrhagic stroke severity level 2	63.6 (41.3 to 92.0)	120.5 (77.7 to 175.0)	89.4 (79.9 to 100.2)	11.0 (5.4 to 17.3)
Chronic hemorrhagic stroke severity level 4	112.1 (69.5 to 164.9)	211.4 (129.2 to 307.9)	88.7 (77.2 to 101.7)	11.0 (4.3 to 18.7)
Chronic hemorrhagic stroke severity level 3	172.6 (107.7 to 247.3)	326.4 (205.6 to 472.8)	89.1 (79.1 to 101.1)	11.0 (5.3 to 18.0)
Chronic hemorrhagic stroke severity level 5	203.0 (95.3 to 346.6)	383.0 (176.1 to 653.2)	88.6 (78.0 to 101.0)	11.0 (4.8 to 18.4)
Acute hemorrhagic stroke severity level 1	0.3 (0.2 to 0.6)	0.6 (0.3 to 1.1)	75.6 (59.8 to 88.5)	1.5 (-7.6 to 9.4)
Acute hemorrhagic stroke severity level 2	1.8 (1.1 to 2.7)	3.1 (2.0 to 4.8)	75.8 (59.8 to 88.8)	1.7 (-7.6 to 9.9)
Acute hemorrhagic stroke severity level 4	3.4 (2.0 to 5.1)	5.9 (3.5 to 8.9)	76.2 (61.2 to 87.0)	1.7 (-6.7 to 8.3)
Acute hemorrhagic stroke severity level 3	5.1 (3.1 to 7.4)	8.9 (5.3 to 12.8)	75.5 (59.4 to 87.5)	1.6 (-7.4 to 8.8)
Acute hemorrhagic stroke severity level 5	6.0 (2.8 to 10.2)	10.5 (4.9 to 17.5)	75.7 (60.2 to 87.2)	1.6 (-7.3 to 8.5)
Hypertensive heart disease	559.1 (393.8 to 768.1)	1,193.9 (844.9 to 1,633.9)	113.8 (102.8 to 124.9)	20.0 (13.7 to 26.3)
Mild heart failure due to hypertensive heart disease	48.1 (26.9 to 73.3)	102.7 (58.2 to 155.7)	113.4 (101.9 to 125.2)	19.9 (13.3 to 26.3)
Moderate heart failure due to hypertensive heart disease	67.6 (40.9 to 105.1)	144.2 (87.3 to 223.0)	113.5 (101.9 to 125.7)	19.9 (13.2 to 26.8)
Severe heart failure due to hypertensive heart disease	443.4 (302.0 to 628.9)	947.0 (651.4 to 1,324.3)	113.8 (102.9 to 124.7)	20.1 (13.8 to 26.2)
Cardiomyopathy and myocarditis	463.5 (319.2 to 624.0)	865.7 (591.5 to 1,159.6)	86.8 (79.0 to 95.1)	9.8 (5.2 to 14.8)
Acute myocarditis	11.6 (7.4 to 16.8)	17.8 (11.4 to 25.8)	53.3 (39.7 to 70.0)	-3.2 (-12.2 to 7.2)
Mild heart failure due to cardiomyopathy and myocarditis	38.5 (21.3 to 62.8)	72.3 (40.6 to 116.8)	87.6 (79.4 to 97.1)	10.0 (5.0 to 15.6)
Moderate heart failure due to cardiomyopathy and myocarditis	54.6 (33.3 to 83.4)	102.4 (62.2 to 159.5)	87.3 (79.2 to 96.8)	9.9 (5.1 to 15.6)
Severe heart failure due to cardiomyopathy and myocarditis	358.8 (241.1 to 494.6)	673.3 (450.3 to 929.4)	87.6 (79.6 to 96.2)	10.1 (5.2 to 15.3)
Atrial fibrillation and flutter	524.1 (368.4 to 716.5)	857.8 (603.7 to 1,177.4)	64.2 (54.3 to 71.9)	-9.7 (-15.1 to -5.2)
Asymptomatic atrial fibrillation and flutter	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Symptomatic atrial fibrillation and flutter	524.1 (368.5 to 714.4)	857.8 (608.0 to 1,173.3)	64.2 (54.3 to 71.9)	-9.7 (-15.1 to -5.2)
Peripheral vascular disease	85.9 (41.6 to 151.1)	127.7 (62.4 to 223.8)	49.6 (31.2 to 64.3)	-19.7 (-29.5 to -12.0)
Asymptomatic peripheral vascular disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Symptomatic claudication due to peripheral vascular disease	85.9 (41.6 to 149.9)	127.7 (62.6 to 223.2)	49.6 (31.3 to 64.3)	-19.7 (-29.4 to -12.0)
Endocarditis	18.3 (12.0 to 26.1)	32.5 (21.2 to 46.7)	77.4 (59.7 to 96.2)	7.0 (-3.9 to 18.4)
Moderate endocarditis	2.0 (1.2 to 2.9)	2.7 (1.7 to 4.1)	37.2 (16.6 to 56.2)	-5.3 (-18.2 to 6.7)
Severe endocarditis	0.6 (0.4 to 0.9)	0.7 (0.5 to 1.0)	9.5 (-16.3 to 33.7)	-25.7 (-42.3 to -9.1)
Mild heart failure due to endocarditis	1.3 (0.7 to 2.3)	2.5 (1.3 to 4.1)	85.5 (61.8 to 109.8)	9.3 (-4.3 to 24.4)
Moderate heart failure due to endocarditis	1.9 (1.0 to 3.1)	3.5 (2.0 to 5.5)	84.8 (61.5 to 112.1)	9.3 (-4.9 to 25.4)
Severe heart failure due to endocarditis	12.4 (7.7 to 18.7)	23.0 (14.4 to 34.6)	85.3 (63.7 to 110.0)	9.3 (-3.1 to 24.0)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other cardiovascular and circulatory diseases	2,929.8 (1,791.8 to 4,290.1)	6,730.4 (3,926.1 to 10,097.9)	131.2 (53.7 to 236.5)	37.1 (-8.4 to 99.7)
Mild heart failure due to other cardiovascular diseases	38.5 (19.3 to 66.2)	89.3 (46.4 to 157.8)	134.1 (53.3 to 250.0)	32.8 (-13.0 to 100.6)
Moderate heart failure due to other cardiovascular diseases	54.3 (30.9 to 89.7)	126.2 (66.9 to 210.0)	134.0 (53.7 to 249.0)	32.9 (-13.6 to 100.6)
Severe heart failure due to other cardiovascular diseases	356.1 (207.0 to 540.7)	827.0 (471.0 to 1,272.6)	134.1 (54.5 to 250.6)	33.1 (-12.1 to 101.0)
Asymptomatic other cardiovascular diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild other cardiovascular diseases	436.9 (242.0 to 704.3)	1,000.5 (540.1 to 1,654.6)	130.6 (53.4 to 234.8)	38.0 (-7.7 to 98.9)
Moderate other cardiovascular diseases	367.6 (202.9 to 608.2)	843.1 (455.8 to 1,394.9)	130.4 (52.6 to 234.3)	37.9 (-8.1 to 99.5)
Severe other cardiovascular diseases	1,676.4 (984.2 to 2,522.7)	3,844.1 (2,152.1 to 5,872.0)	130.4 (53.4 to 233.6)	38.1 (-7.8 to 99.6)
Chronic respiratory diseases	24,888.7 (17,534.2 to 33,184.9)	38,618.7 (26,864.7 to 51,458.3)	55.1 (50.3 to 60.6)	-0.0 (-2.5 to 2.8)
Chronic obstructive pulmonary disease	15,150.7 (10,288.3 to 20,649.5)	26,131.3 (17,785.3 to 35,786.9)	72.3 (67.4 to 78.6)	5.5 (2.7 to 9.3)
Asymptomatic chronic obstructive pulmonary disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild chronic obstructive pulmonary disease	1,487.1 (785.0 to 2,514.8)	2,510.8 (1,336.6 to 4,271.6)	68.5 (63.2 to 76.2)	3.7 (0.2 to 7.9)
Moderate chronic obstructive pulmonary disease	3,869.0 (2,516.1 to 5,619.2)	6,534.3 (4,264.3 to 9,453.2)	68.6 (63.0 to 76.5)	3.9 (0.3 to 8.3)
Severe chronic obstructive pulmonary disease without heart failure	8,572.7 (4,585.8 to 13,597.9)	14,719.8 (7,828.2 to 23,519.9)	71.5 (62.9 to 81.5)	6.5 (1.3 to 12.4)
Mild heart failure due to severe chronic obstructive pulmonary disease	272.2 (164.3 to 398.9)	526.8 (322.6 to 774.6)	93.6 (84.2 to 103.4)	7.2 (1.9 to 12.8)
Moderate heart failure due to severe chronic obstructive pulmonary disease	236.2 (152.1 to 338.9)	457.2 (292.3 to 654.3)	93.7 (83.8 to 103.9)	7.2 (1.7 to 12.8)
Severe heart failure due to severe chronic obstructive pulmonary disease	713.6 (509.8 to 919.3)	1,382.5 (983.2 to 1,797.5)	93.8 (84.6 to 103.5)	7.3 (2.1 to 12.6)
Pneumoconiosis	25.8 (18.2 to 35.1)	50.8 (36.0 to 69.0)	96.9 (89.2 to 103.3)	17.3 (12.5 to 21.3)
Silicosis	7.1 (4.6 to 10.1)	10.7 (6.9 to 15.1)	49.9 (47.2 to 52.3)	-11.8 (-13.3 to -10.5)
Asymptomatic silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild silicosis	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.6)	50.9 (44.6 to 56.3)	-10.9 (-15.2 to -7.3)
Moderate silicosis	1.0 (0.4 to 2.0)	1.6 (0.6 to 3.0)	49.8 (47.4 to 52.3)	-11.8 (-13.2 to -10.4)
Severe silicosis without heart failure	0.7 (0.3 to 1.3)	1.0 (0.4 to 2.0)	51.2 (24.9 to 84.0)	-6.8 (-23.2 to 12.2)
Mild heart failure due to severe silicosis	1.2 (0.6 to 1.9)	1.7 (0.9 to 2.8)	49.5 (44.1 to 54.1)	-12.4 (-15.7 to -9.9)
Moderate heart failure due to severe silicosis	1.0 (0.6 to 1.5)	1.5 (0.9 to 2.3)	49.5 (44.1 to 54.0)	-12.4 (-15.6 to -9.9)
Severe heart failure due to severe silicosis	3.1 (1.8 to 4.5)	4.6 (2.8 to 6.7)	49.6 (44.2 to 54.1)	-12.4 (-15.7 to -9.9)
Asbestosis	1.7 (1.1 to 2.3)	2.8 (1.8 to 3.9)	68.1 (64.6 to 72.1)	-0.4 (-2.5 to 2.0)
Asymptomatic asbestosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild asbestosis	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	67.5 (64.0 to 71.4)	-0.7 (-2.8 to 1.7)
Moderate asbestosis	0.3 (0.1 to 0.5)	0.4 (0.2 to 0.8)	67.5 (64.0 to 71.4)	-0.7 (-2.8 to 1.7)
Severe asbestosis without heart failure	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.6)	39.4 (13.4 to 73.0)	-15.9 (-31.0 to 2.8)
Mild heart failure due to severe asbestosis	0.3 (0.1 to 0.4)	0.4 (0.2 to 0.7)	73.7 (65.3 to 81.2)	2.4 (-2.0 to 6.4)
Moderate heart failure due to severe asbestosis	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	73.7 (65.3 to 81.3)	2.4 (-2.0 to 6.3)
Severe heart failure due to severe asbestosis	0.7 (0.4 to 1.0)	1.2 (0.7 to 1.7)	73.7 (65.3 to 81.2)	2.4 (-2.0 to 6.3)
Coal workers pneumoconiosis	4.4 (2.9 to 6.3)	6.8 (4.6 to 9.8)	55.1 (53.0 to 56.9)	-6.9 (-8.1 to -5.9)
Asymptomatic coal workers pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild coal workers pneumoconiosis	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.4)	55.1 (53.1 to 56.8)	-6.8 (-7.9 to -5.9)
Moderate coal workers pneumoconiosis	0.7 (0.2 to 1.2)	1.0 (0.4 to 1.9)	55.1 (53.1 to 56.8)	-6.8 (-7.9 to -5.9)
Severe coal workers pneumoconiosis without heart failure	0.8 (0.4 to 1.5)	1.3 (0.6 to 2.2)	54.4 (38.2 to 74.5)	-3.3 (-13.9 to 9.3)
Mild heart failure due to severe coal workers pneumoconiosis	0.6 (0.3 to 1.0)	1.0 (0.5 to 1.6)	55.2 (49.2 to 62.5)	-8.0 (-11.6 to -3.9)
Moderate heart failure due to severe coal workers pneumoconiosis	0.5 (0.3 to 0.8)	0.8 (0.5 to 1.3)	55.2 (49.1 to 62.5)	-8.0 (-11.6 to -4.0)
Severe heart failure due to severe coal workers pneumoconiosis	1.6 (1.1 to 2.4)	2.5 (1.6 to 3.7)	55.2 (49.2 to 62.5)	-8.0 (-11.6 to -4.0)
Other pneumoconiosis	12.6 (8.2 to 18.2)	30.5 (19.9 to 43.9)	141.8 (136.0 to 148.2)	45.7 (42.3 to 49.7)
Asymptomatic other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Mild other pneumoconiosis	0.4 (0.2 to 0.7)	1.0 (0.5 to 1.8)	141.6 (134.0 to 149.7)	45.8 (41.0 to 51.1)
Moderate other pneumoconiosis	1.9 (0.7 to 3.6)	4.7 (1.8 to 8.8)	144.5 (138.2 to 150.6)	47.7 (44.2 to 51.3)
Severe other pneumoconiosis without heart failure	2.5 (1.1 to 4.5)	6.8 (3.0 to 11.9)	173.0 (147.9 to 201.8)	71.2 (53.6 to 89.8)
Mild heart failure due to severe other pneumoconiosis	1.7 (0.9 to 2.8)	4.0 (2.2 to 6.5)	132.9 (122.9 to 144.1)	38.8 (32.3 to 45.4)
Moderate heart failure due to severe other pneumoconiosis	1.5 (0.8 to 2.3)	3.5 (2.0 to 5.5)	132.9 (122.9 to 144.1)	38.8 (32.3 to 45.4)
Severe heart failure due to severe other pneumoconiosis	4.5 (2.8 to 6.8)	10.5 (6.5 to 15.5)	131.1 (120.6 to 142.9)	37.6 (30.8 to 44.4)
Asthma	8,048.5 (5,283.4 to 11,388.7)	10,595.8 (6,924.6 to 15,102.0)	31.6 (28.9 to 34.6)	-5.3 (-7.2 to -3.2)
Asymptomatic asthma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Controlled asthma	532.7 (254.2 to 961.5)	701.8 (333.7 to 1,265.8)	31.8 (28.9 to 34.7)	-5.4 (-7.2 to -3.2)
Partially controlled asthma	1,396.8 (814.9 to 2,206.8)	1,840.1 (1,076.2 to 2,892.6)	31.7 (29.0 to 34.8)	-5.4 (-7.2 to -3.2)
Uncontrolled asthma	6,118.9 (3,874.5 to 9,056.2)	8,053.9 (5,096.8 to 11,883.8)	31.6 (28.9 to 34.6)	-5.3 (-7.2 to -3.2)
Interstitial lung disease and pulmonary sarcoidosis	47.3 (30.6 to 68.8)	80.7 (50.7 to 117.9)	70.9 (59.5 to 80.2)	5.4 (-1.5 to 11.2)
Asymptomatic interstitial lung disease and pulmonary sarcoidosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild interstitial lung disease and pulmonary sarcoidosis	3.0 (1.6 to 5.0)	5.0 (2.7 to 8.2)	68.7 (56.3 to 81.6)	5.0 (-3.0 to 13.1)
Moderate interstitial lung disease and pulmonary sarcoidosis	10.3 (4.9 to 17.7)	17.3 (8.2 to 29.7)	67.9 (56.5 to 78.2)	4.1 (-3.2 to 10.5)
Severe interstitial lung disease and pulmonary sarcoidosis without heart failure	9.7 (4.0 to 17.9)	10.2 (3.8 to 19.9)	4.7 (-16.8 to 32.4)	-27.8 (-42.3 to -6.9)
Mild heart failure due to severe interstitial lung disease and pulmonary sarcoidosis	5.5 (2.8 to 9.2)	10.9 (5.7 to 18.5)	99.6 (79.2 to 119.3)	16.1 (5.5 to 26.9)
Moderate heart failure due to severe interstitial lung disease and pulmonary sarcoidosis	4.7 (2.6 to 7.7)	9.3 (5.0 to 15.4)	99.7 (79.3 to 119.4)	16.1 (5.6 to 26.9)
Severe heart failure due to severe interstitial lung disease and pulmonary sarcoidosis	14.2 (8.6 to 21.9)	27.9 (16.5 to 42.5)	97.3 (76.1 to 117.5)	15.0 (3.7 to 26.0)
Other chronic respiratory diseases	1,616.3 (1,005.4 to 2,447.2)	1,760.0 (1,150.0 to 2,617.9)	8.4 (-4.6 to 26.4)	-32.8 (-40.7 to -21.8)
Cirrhosis	421.6 (293.8 to 580.9)	544.6 (381.1 to 750.4)	29.2 (25.5 to 33.2)	-14.9 (-17.2 to -12.6)
Cirrhosis due to hepatitis B	118.6 (81.8 to 165.6)	143.2 (98.8 to 197.7)	20.9 (9.1 to 31.6)	-21.0 (-28.1 to -13.9)
Cirrhosis due to hepatitis C	90.2 (62.7 to 125.4)	144.9 (100.8 to 201.3)	59.9 (49.8 to 75.3)	1.6 (-4.2 to 11.4)
Cirrhosis due to alcohol use	118.9 (83.0 to 164.7)	131.2 (89.3 to 180.1)	10.3 (-0.2 to 22.7)	-33.1 (-39.2 to -26.0)
Cirrhosis due to other causes	93.9 (64.4 to 132.2)	125.3 (85.6 to 175.1)	33.3 (20.7 to 50.5)	3.5 (-6.3 to 16.4)
Digestive diseases	6,804.9 (4,830.8 to 9,166.0)	8,457.9 (6,066.5 to 11,283.9)	24.4 (19.9 to 28.8)	-21.9 (-24.7 to -19.2)
Peptic ulcer disease	1,285.3 (888.1 to 1,795.0)	1,268.6 (873.2 to 1,774.5)	-1.4 (-5.9 to 3.7)	-43.2 (-45.5 to -40.3)
Peptic ulcer disease, symptomatic episodes	304.6 (212.7 to 410.8)	294.0 (206.9 to 397.8)	-3.6 (-7.5 to 1.1)	-44.1 (-46.4 to -41.6)
Mild anemia due to peptic ulcer disease	60.0 (21.7 to 129.2)	51.7 (18.8 to 111.5)	-13.6 (-18.1 to -9.9)	-50.3 (-52.7 to -48.3)
Moderate anemia due to peptic ulcer disease	756.9 (509.2 to 1,085.3)	788.1 (529.0 to 1,136.8)	3.8 (1.0 to 12.7)	-40.3 (-41.8 to -35.2)
Severe anemia due to peptic ulcer disease	163.7 (110.4 to 252.4)	134.8 (92.3 to 191.4)	-16.8 (-40.3 to 5.6)	-52.6 (-64.5 to -40.9)
Gastritis and duodenitis	2,245.6 (1,517.8 to 3,151.5)	2,384.2 (1,617.0 to 3,388.7)	6.3 (1.7 to 10.3)	-27.6 (-30.4 to -25.2)
Gastritis and duodenitis, symptomatic episodes	153.2 (106.4 to 207.7)	179.9 (124.9 to 243.4)	17.5 (13.1 to 21.7)	-23.0 (-25.6 to -20.7)
Mild anemia due to gastritis and duodenitis	75.5 (27.2 to 164.6)	86.7 (30.7 to 187.5)	14.6 (7.1 to 24.3)	-27.2 (-31.4 to -22.3)
Moderate anemia due to gastritis and duodenitis	1,561.8 (1,039.0 to 2,242.7)	1,724.4 (1,161.8 to 2,483.5)	10.6 (5.5 to 14.7)	-25.2 (-28.3 to -22.4)
Severe anemia due to gastritis and duodenitis	455.1 (312.1 to 638.5)	393.3 (269.6 to 549.1)	-13.3 (-24.8 to 0.4)	-38.5 (-45.6 to -29.5)
Appendicitis	162.3 (106.8 to 225.9)	190.2 (126.9 to 263.1)	17.4 (-1.0 to 39.2)	-13.6 (-26.7 to 1.8)
Paralytic ileus and intestinal obstruction	23.6 (16.1 to 31.7)	35.1 (23.8 to 47.5)	49.2 (41.2 to 57.4)	4.7 (-0.6 to 10.6)
Inguinal, femoral, and abdominal hernia	180.4 (88.9 to 336.5)	262.3 (129.4 to 490.8)	45.7 (35.8 to 53.1)	-9.9 (-15.6 to -5.3)
Inflammatory bowel disease	1,266.3 (875.1 to 1,720.2)	2,223.2 (1,544.1 to 3,028.2)	75.6 (71.5 to 79.5)	10.1 (7.6 to 12.5)
Ulcerative colitis	789.3 (550.4 to 1,067.6)	1,205.7 (836.1 to 1,631.8)	52.8 (48.3 to 57.0)	-4.9 (-7.6 to -2.3)
Crohn's disease	477.0 (328.3 to 653.1)	1,017.5 (702.9 to 1,387.2)	113.3 (106.0 to 120.7)	35.7 (31.2 to 40.2)
Vascular intestinal disorders	6.4 (4.3 to 8.7)	10.8 (7.2 to 14.6)	68.8 (54.1 to 83.7)	-0.2 (-9.7 to 9.8)
Gallbladder and biliary diseases	448.8 (312.9 to 609.5)	614.9 (428.8 to 826.8)	36.9 (31.5 to 43.6)	-17.9 (-21.0 to -14.3)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pancreatitis	340.2 (234.2 to 453.1)	579.8 (398.9 to 771.6)	70.5 (65.1 to 75.8)	7.3 (4.1 to 10.5)
Other digestive diseases	846.0 (581.4 to 1,179.0)	888.8 (612.7 to 1,228.4)	5.9 (-8.5 to 17.1)	-34.2 (-43.3 to -27.2)
Neurological disorders	37,187.6 (25,668.6 to 50,918.8)	59,360.1 (41,036.0 to 80,871.8)	59.6 (54.8 to 64.5)	5.0 (2.4 to 7.9)
Alzheimer disease and other dementias	4,052.5 (3,000.9 to 5,135.6)	7,773.6 (5,703.1 to 9,867.3)	91.8 (85.3 to 98.5)	-0.0 (-3.5 to 3.8)
Mild Alzheimer disease and other dementias	1,175.3 (807.2 to 1,623.4)	2,201.7 (1,503.8 to 3,034.5)	87.3 (81.2 to 93.8)	0.2 (-3.1 to 3.6)
Moderate Alzheimer disease and other dementias	1,918.7 (1,334.2 to 2,538.6)	3,701.7 (2,576.8 to 4,892.6)	92.8 (86.0 to 100.4)	0.0 (-3.7 to 3.7)
Severe Alzheimer disease and other dementias	958.5 (599.5 to 1,336.0)	1,870.2 (1,168.0 to 2,637.3)	95.0 (87.0 to 103.7)	-0.1 (-3.9 to 3.8)
Parkinson disease	383.4 (257.6 to 533.5)	694.8 (468.5 to 964.1)	81.2 (77.3 to 85.2)	2.7 (0.6 to 4.6)
Mild Parkinson disease	17.4 (8.3 to 32.6)	31.5 (14.9 to 58.8)	81.2 (77.4 to 85.1)	2.6 (0.5 to 4.4)
Moderate Parkinson disease	268.8 (170.2 to 383.4)	487.2 (311.3 to 698.0)	81.2 (77.0 to 85.4)	2.6 (0.4 to 4.8)
Severe Parkinson disease	97.1 (53.4 to 156.4)	176.1 (96.4 to 281.0)	81.3 (74.1 to 88.1)	2.8 (-1.2 to 6.4)
Epilepsy	5,364.9 (3,656.5 to 7,116.3)	7,544.2 (5,164.1 to 9,925.9)	40.5 (28.5 to 56.5)	4.4 (-4.5 to 15.9)
Seizure-free, treated epilepsy	90.0 (54.6 to 136.9)	118.3 (72.7 to 181.4)	31.9 (15.6 to 48.6)	-1.6 (-14.0 to 10.7)
Less severe epilepsy	2,036.0 (1,361.6 to 2,821.3)	2,206.4 (1,481.2 to 3,071.4)	8.5 (-2.6 to 20.6)	-18.3 (-26.7 to -9.2)
Severe epilepsy	3,238.9 (2,213.4 to 4,264.0)	5,219.5 (3,567.8 to 6,753.8)	60.6 (43.3 to 83.0)	18.2 (5.7 to 34.4)
Multiple sclerosis	349.1 (250.5 to 438.9)	754.6 (547.6 to 951.0)	116.1 (106.3 to 125.7)	35.1 (29.0 to 41.1)
Mild multiple sclerosis	95.5 (64.7 to 132.4)	206.9 (140.4 to 286.2)	116.8 (105.3 to 127.9)	35.4 (28.3 to 42.2)
Moderate multiple sclerosis	121.3 (79.7 to 165.0)	262.5 (176.3 to 358.5)	116.6 (102.5 to 129.3)	35.5 (26.9 to 43.3)
Severe multiple sclerosis	132.3 (90.5 to 176.9)	285.3 (195.4 to 380.8)	115.9 (101.0 to 131.1)	35.2 (26.1 to 44.2)
Migraine	19,805.0 (11,989.4 to 29,074.0)	28,898.1 (17,585.8 to 42,420.1)	46.1 (41.4 to 50.5)	0.8 (-2.4 to 3.7)
Asymptomatic migraine	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Symptomatic migraine	19,805.0 (12,053.4 to 28,990.7)	28,898.1 (17,616.3 to 42,315.8)	46.1 (41.4 to 50.4)	0.8 (-2.4 to 3.6)
Tension-type headache	1,624.5 (787.8 to 2,842.0)	2,363.2 (1,151.9 to 4,155.0)	45.5 (41.7 to 49.5)	0.3 (-2.1 to 2.9)
Asymptomatic tension-type headache	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Symptomatic tension-type headache	1,624.5 (792.1 to 2,837.3)	2,363.2 (1,154.0 to 4,148.7)	45.5 (41.7 to 49.5)	0.3 (-2.1 to 2.9)
Medication overuse headache	4,463.2 (2,617.2 to 6,764.5)	9,845.7 (5,777.9 to 15,100.3)	120.2 (109.3 to 133.7)	43.3 (36.2 to 52.4)
Asymptomatic medication overuse headache	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Symptomatic medication overuse headache	4,463.2 (2,617.6 to 6,761.7)	9,845.7 (5,800.1 to 15,072.9)	120.2 (109.3 to 133.7)	43.3 (36.3 to 52.4)
Other neurological disorders	1,145.0 (826.1 to 1,535.5)	1,485.8 (1,056.6 to 1,918.6)	31.4 (12.7 to 40.4)	-29.6 (-39.2 to -24.8)
Other neurological disorders	1,140.6 (851.0 to 1,433.1)	1,479.9 (1,122.1 to 1,837.2)	31.4 (14.4 to 38.7)	-29.7 (-39.2 to -24.9)
Guillain-Barré syndrome due to other neurological disorders	2.4 (1.6 to 3.4)	3.4 (2.3 to 4.9)	45.9 (36.0 to 56.3)	1.0 (-5.6 to 7.9)
Mental and substance use disorders	111,598.0 (80,379.5 to 146,084.9)	161,811.9 (116,057.8 to 210,256.0)	45.0 (42.9 to 47.2)	1.0 (0.3 to 1.9)
Schizophrenia	9,995.0 (7,330.1 to 12,011.8)	15,204.4 (11,169.3 to 18,188.6)	52.1 (50.3 to 54.1)	-1.1 (-2.2 to 0.1)
Schizophrenia residual state	3,011.5 (1,298.4 to 5,252.2)	4,580.5 (1,962.2 to 8,037.9)	52.1 (49.6 to 54.7)	-1.1 (-2.7 to 0.5)
Schizophrenia acute state	6,983.5 (4,230.8 to 9,665.4)	10,623.9 (6,464.5 to 14,699.2)	52.2 (50.0 to 54.3)	-1.1 (-2.3 to 0.3)
Alcohol use disorders	5,698.5 (3,807.5 to 8,095.7)	7,653.6 (5,150.7 to 10,952.3)	34.3 (32.0 to 36.6)	-7.5 (-8.8 to -6.1)
Asymptomatic alcohol dependence	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Very mild alcohol dependence	3,837.1 (2,564.3 to 5,573.6)	5,151.8 (3,448.3 to 7,472.4)	34.3 (31.9 to 36.7)	-7.6 (-8.9 to -6.3)
Mild alcohol dependence	463.0 (196.2 to 852.1)	621.3 (265.7 to 1,153.7)	34.1 (29.9 to 38.6)	-7.7 (-10.3 to -4.7)
Moderate alcohol dependence	625.6 (235.9 to 1,288.7)	840.5 (318.5 to 1,735.2)	34.2 (30.2 to 39.1)	-7.5 (-10.2 to -4.4)
Severe alcohol dependence	710.6 (132.2 to 1,637.7)	954.2 (179.0 to 2,237.9)	34.2 (28.4 to 39.7)	-7.5 (-11.3 to -3.9)
Asymptomatic fetal alcohol syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild fetal alcohol syndrome	4.5 (2.1 to 8.4)	6.2 (2.9 to 11.6)	38.9 (31.7 to 46.0)	6.6 (1.2 to 11.8)
Moderate fetal alcohol syndrome	31.0 (18.9 to 46.6)	42.7 (25.9 to 65.2)	37.7 (30.4 to 45.6)	5.6 (0.2 to 11.6)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Severe fetal alcohol syndrome	26.8 (15.8 to 43.5)	36.9 (22.1 to 59.4)	37.6 (33.9 to 41.7)	5.2 (2.5 to 8.2)
Drug use disorders	8,653.0 (6,028.4 to 11,432.8)	12,222.4 (8,513.1 to 16,172.8)	41.3 (36.3 to 46.3)	0.6 (-2.4 to 3.8)
Opioid use disorders	3,675.1 (2,473.4 to 5,083.3)	5,849.5 (3,907.9 to 8,184.0)	59.1 (54.0 to 63.6)	6.7 (3.2 to 10.2)
Asymptomatic opioid dependence	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild opioid dependence	1,003.2 (518.7 to 1,638.5)	1,596.3 (837.1 to 2,591.6)	59.0 (53.8 to 64.0)	6.7 (3.1 to 10.3)
Severe opioid dependence	2,671.9 (1,688.6 to 3,942.3)	4,253.3 (2,646.0 to 6,314.9)	59.1 (54.0 to 63.7)	6.8 (3.1 to 10.5)
Cocaine use disorders	766.9 (506.1 to 1,079.9)	1,012.9 (666.9 to 1,430.2)	32.1 (27.2 to 37.1)	-5.7 (-9.2 to -2.3)
Asymptomatic cocaine dependence	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild cocaine dependence	156.1 (95.8 to 231.5)	206.1 (126.5 to 305.2)	32.0 (26.5 to 37.7)	-5.8 (-9.7 to -1.9)
Severe cocaine dependence	610.8 (388.5 to 890.3)	806.8 (506.7 to 1,176.5)	32.2 (26.7 to 37.6)	-5.6 (-9.5 to -1.7)
Amphetamine use disorders	1,549.4 (967.5 to 2,241.9)	1,961.0 (1,233.0 to 2,832.9)	26.6 (20.8 to 32.2)	-3.8 (-8.1 to 0.3)
Asymptomatic amphetamine dependence	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild amphetamine dependence	174.9 (101.5 to 269.6)	221.3 (130.1 to 344.5)	26.5 (20.4 to 32.6)	-3.9 (-8.5 to 0.5)
Severe amphetamine dependence	1,374.6 (822.4 to 2,075.2)	1,739.7 (1,034.7 to 2,611.1)	26.6 (20.7 to 32.3)	-3.8 (-8.2 to 0.4)
Cannabis use disorders	323.1 (213.3 to 470.3)	395.6 (261.2 to 576.2)	22.4 (19.0 to 26.1)	-6.4 (-8.9 to -3.7)
Asymptomatic cannabis dependence	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild cannabis dependence	154.0 (93.5 to 235.5)	188.4 (115.2 to 286.9)	22.4 (19.2 to 25.4)	-6.4 (-8.6 to -4.4)
Severe cannabis dependence	169.1 (95.4 to 270.2)	207.2 (115.4 to 332.4)	22.5 (16.9 to 28.7)	-6.4 (-10.5 to -2.0)
Other drug use disorders	2,338.4 (1,554.1 to 3,250.4)	3,003.3 (1,998.9 to 4,164.5)	28.5 (21.5 to 36.5)	-4.4 (-9.7 to 1.4)
Depressive disorders	40,079.3 (27,064.4 to 55,703.7)	61,632.8 (41,353.8 to 85,621.4)	53.6 (49.6 to 58.4)	4.0 (2.2 to 5.6)
Major depressive disorder	33,711.1 (21,946.0 to 47,650.6)	51,783.9 (33,888.2 to 73,665.8)	53.4 (48.8 to 59.2)	4.7 (2.7 to 6.7)
Major depressive disorder, currently without symptoms	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild major depressive disorder	13,415.7 (8,464.1 to 19,394.7)	20,616.7 (13,022.9 to 29,630.0)	53.5 (49.0 to 59.1)	4.7 (2.6 to 6.6)
Moderate major depressive disorder	10,388.2 (6,265.3 to 15,585.7)	15,954.0 (9,700.4 to 23,966.9)	53.3 (48.7 to 59.2)	4.8 (2.6 to 6.8)
Severe major depressive disorder	9,907.2 (3,898.0 to 18,949.2)	15,213.1 (5,984.7 to 28,891.7)	53.3 (48.4 to 59.4)	4.8 (2.7 to 6.9)
Dysthymia	6,368.2 (4,238.3 to 9,150.4)	9,848.9 (6,586.6 to 14,166.0)	54.6 (52.1 to 57.2)	0.1 (-1.0 to 1.2)
Dysthymia, currently without symptoms	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Symptomatic dysthymia	6,368.2 (4,270.5 to 9,147.0)	9,848.9 (6,603.5 to 14,163.1)	54.6 (52.1 to 57.2)	0.1 (-1.0 to 1.2)
Bipolar disorder	6,643.0 (4,153.6 to 9,927.8)	9,911.1 (6,260.6 to 14,791.0)	49.2 (46.4 to 52.5)	1.3 (-0.4 to 2.9)
Bipolar disorder residual state	542.6 (291.4 to 928.2)	809.9 (435.5 to 1,375.5)	49.2 (46.7 to 52.6)	1.1 (-0.5 to 2.9)
Bipolar disorder depressive state	2,862.5 (1,304.6 to 5,001.0)	4,271.6 (1,933.5 to 7,387.8)	49.2 (46.3 to 53.0)	1.3 (-0.6 to 3.3)
Bipolar disorder manic state	3,237.8 (1,667.7 to 5,430.7)	4,829.5 (2,485.8 to 8,091.7)	49.2 (45.9 to 52.9)	1.3 (-0.7 to 3.3)
Anxiety disorders	17,180.4 (11,209.6 to 24,981.2)	24,355.8 (16,148.6 to 35,139.0)	42.1 (36.4 to 46.5)	-0.2 (-1.6 to 1.3)
Anxiety disorders, currently without symptoms	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild anxiety disorders	2,648.0 (1,490.5 to 4,225.1)	3,757.5 (2,129.1 to 6,020.2)	42.3 (36.5 to 46.7)	-0.3 (-1.6 to 1.1)
Moderate anxiety disorders	4,525.7 (2,694.7 to 7,174.8)	6,419.0 (3,797.0 to 9,986.9)	42.2 (36.3 to 46.7)	-0.2 (-1.6 to 1.3)
Severe anxiety disorders	10,006.6 (5,320.0 to 16,229.7)	14,179.3 (7,567.2 to 22,704.5)	42.1 (36.2 to 46.6)	-0.1 (-1.7 to 1.4)
Eating disorders	1,424.5 (919.3 to 2,112.5)	1,820.0 (1,154.5 to 2,720.3)	27.6 (23.7 to 32.1)	-1.2 (-4.2 to 1.7)
Anorexia nervosa	323.8 (210.2 to 472.7)	440.4 (285.5 to 648.3)	35.9 (30.2 to 41.8)	6.0 (1.7 to 10.3)
Bulimia nervosa	1,100.8 (683.8 to 1,681.9)	1,379.7 (850.7 to 2,136.6)	25.1 (20.2 to 30.2)	-3.4 (-7.1 to 0.1)
Autistic spectrum disorders	6,316.2 (4,382.1 to 8,573.3)	8,449.0 (5,888.1 to 11,458.7)	33.8 (32.7 to 34.9)	0.7 (-0.0 to 1.5)
Autism	3,992.7 (2,689.3 to 5,471.0)	5,345.0 (3,583.6 to 7,309.9)	33.9 (32.4 to 35.5)	0.7 (-0.3 to 1.8)
Asperger syndrome	2,323.5 (1,620.8 to 3,226.9)	3,104.0 (2,169.6 to 4,325.0)	33.6 (32.3 to 35.0)	0.7 (-0.1 to 1.5)
Attention-deficit/hyperactivity disorder	421.2 (254.3 to 654.1)	479.9 (287.4 to 745.8)	13.9 (12.1 to 16.0)	-0.3 (-1.9 to 1.5)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Attention-deficit/hyperactivity disorder, currently without symptoms	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Symptomatic attention-deficit/hyperactivity disorder	421.2 (254.8 to 653.6)	479.9 (287.9 to 744.7)	13.9 (12.1 to 16.0)	-0.4 (-2.0 to 1.4)
Conduct disorder	5,288.2 (3,325.9 to 7,691.5)	6,159.0 (3,868.2 to 8,911.6)	16.5 (15.0 to 18.0)	2.4 (1.1 to 3.8)
Conduct disorder, currently without symptoms	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Symptomatic conduct disorder	5,288.2 (3,341.5 to 7,675.5)	6,159.0 (3,890.5 to 8,893.0)	16.5 (15.0 to 18.0)	2.3 (1.0 to 3.7)
Idiopathic intellectual disability	3,822.3 (2,489.8 to 5,516.3)	4,666.7 (3,084.8 to 6,640.0)	22.0 (12.1 to 35.0)	-6.1 (-13.9 to 3.8)
Borderline idiopathic intellectual disability	282.9 (113.3 to 613.7)	347.0 (140.0 to 744.5)	22.6 (12.6 to 35.4)	-5.6 (-13.5 to 4.2)
Mild idiopathic intellectual disability	1,292.8 (759.9 to 2,017.2)	1,600.0 (952.7 to 2,470.1)	23.7 (13.4 to 37.3)	-4.5 (-12.5 to 6.4)
Moderate idiopathic intellectual disability	1,170.4 (748.8 to 1,727.2)	1,415.8 (919.2 to 2,046.5)	20.9 (10.7 to 33.0)	-7.2 (-15.2 to 2.5)
Severe idiopathic intellectual disability	745.1 (462.7 to 1,111.6)	902.7 (577.1 to 1,316.4)	21.1 (11.2 to 33.1)	-7.1 (-14.9 to 2.4)
Profound idiopathic intellectual disability	331.1 (100.6 to 664.1)	401.3 (124.8 to 798.8)	21.2 (10.5 to 35.0)	-7.0 (-15.2 to 3.8)
Other mental and substance use disorders	6,076.4 (4,106.7 to 8,149.8)	9,257.2 (6,277.9 to 12,411.5)	52.3 (50.5 to 54.1)	0.6 (-0.1 to 1.3)
Other mental disorders, currently without symptoms	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild other mental disorders	1,462.8 (887.1 to 2,229.3)	2,228.0 (1,349.0 to 3,387.8)	52.3 (50.7 to 54.0)	0.4 (-0.0 to 0.9)
Moderate other mental disorders	1,561.2 (1,032.5 to 2,258.3)	2,378.6 (1,565.2 to 3,452.1)	52.4 (50.4 to 54.5)	0.5 (-0.4 to 1.5)
Severe other mental disorders	3,052.4 (1,597.2 to 4,846.3)	4,650.6 (2,463.1 to 7,387.9)	52.4 (49.7 to 54.8)	0.7 (-0.8 to 2.1)
Diabetes, urogenital, blood, and endocrine diseases	37,947.8 (26,888.3 to 51,077.1)	65,561.4 (46,201.5 to 87,834.5)	72.7 (69.2 to 76.6)	14.1 (11.9 to 16.4)
Diabetes mellitus	12,533.0 (8,657.1 to 17,049.5)	29,518.1 (20,419.1 to 40,169.3)	135.7 (127.2 to 143.7)	43.4 (37.9 to 48.5)
Uncomplicated diabetes mellitus	5,756.0 (3,650.1 to 8,375.1)	13,258.2 (8,500.7 to 19,225.4)	130.6 (119.5 to 141.8)	48.0 (40.0 to 57.0)
Diabetic neuropathy	4,639.8 (3,131.7 to 6,381.8)	11,176.1 (7,657.6 to 15,360.7)	141.3 (127.8 to 152.2)	42.6 (34.7 to 49.3)
Diabetic foot due to neuropathy	1,313.9 (918.6 to 1,762.7)	3,302.8 (2,311.9 to 4,424.5)	152.1 (132.8 to 169.5)	42.8 (32.3 to 52.6)
Diabetic neuropathy and amputation with treatment	158.2 (109.0 to 216.4)	405.8 (279.5 to 546.5)	156.5 (139.4 to 175.2)	48.1 (37.9 to 59.0)
Diabetic neuropathy and amputation without treatment	339.3 (239.2 to 456.9)	898.2 (616.5 to 1,204.9)	165.3 (142.1 to 186.8)	54.3 (40.8 to 66.5)
Moderate vision impairment due to diabetes mellitus	21.9 (8.6 to 42.0)	31.3 (11.8 to 61.4)	42.7 (32.4 to 52.6)	-20.5 (-25.6 to -14.3)
Severe vision impairment due to diabetes mellitus	17.4 (6.5 to 31.9)	26.8 (10.4 to 48.4)	54.9 (40.0 to 71.4)	-13.7 (-22.0 to -4.7)
Blindness due to diabetes mellitus	286.5 (163.8 to 427.2)	418.8 (237.5 to 624.5)	46.1 (36.7 to 57.9)	-16.8 (-22.8 to -10.6)
Acute glomerulonephritis	2.0 (1.2 to 2.9)	1.9 (1.2 to 2.8)	-3.3 (-6.0 to -1.1)	-22.2 (-24.2 to -20.6)
Chronic kidney disease	8,277.0 (6,080.3 to 10,616.1)	12,347.3 (9,101.6 to 15,814.9)	49.5 (43.4 to 53.9)	-2.8 (-6.4 to -0.4)
Chronic kidney disease due to diabetes mellitus	1,385.5 (1,007.4 to 1,810.9)	2,491.8 (1,802.9 to 3,220.7)	80.5 (65.7 to 92.6)	10.6 (2.0 to 17.7)
Stage III chronic kidney disease without anemia due to diabetes mellitus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Stage III chronic kidney disease and mild anemia due to diabetes mellitus	12.2 (4.4 to 26.7)	23.2 (8.3 to 50.5)	89.9 (85.6 to 95.3)	17.5 (15.0 to 20.6)
Stage III chronic kidney disease and moderate anemia due to diabetes mellitus	40.8 (26.8 to 58.7)	71.5 (47.7 to 101.9)	75.4 (63.7 to 88.8)	13.7 (5.5 to 22.5)
Stage III chronic kidney disease and severe anemia due to diabetes mellitus	46.6 (31.8 to 65.2)	58.4 (38.8 to 81.6)	25.2 (12.0 to 40.6)	-12.1 (-22.1 to -1.1)
Stage IV chronic kidney disease without anemia due to diabetes mellitus	55.6 (34.7 to 82.3)	116.6 (73.5 to 169.1)	111.2 (56.3 to 178.1)	26.8 (-5.9 to 65.2)
Stage IV chronic kidney disease and mild anemia due to diabetes mellitus	75.6 (51.9 to 104.9)	141.0 (98.2 to 195.0)	87.2 (61.3 to 114.3)	11.3 (-3.9 to 27.3)
Stage IV chronic kidney disease and moderate anemia due to diabetes mellitus	142.7 (98.0 to 194.6)	282.2 (198.2 to 380.1)	97.3 (75.8 to 125.3)	18.2 (5.8 to 34.9)
Stage IV chronic kidney disease and severe anemia due to diabetes mellitus	30.1 (20.7 to 41.0)	30.3 (20.8 to 42.7)	0.5 (-18.0 to 23.5)	-28.1 (-42.7 to -11.8)
Stage V chronic kidney disease untreated due to diabetes mellitus	846.4 (566.5 to 1,169.6)	1,429.5 (937.8 to 1,988.8)	70.1 (48.7 to 85.4)	3.3 (-8.4 to 12.5)
End-stage renal disease after transplant due to diabetes mellitus	1.2 (0.6 to 2.0)	2.5 (1.4 to 4.1)	114.4 (81.2 to 150.9)	31.2 (9.8 to 54.2)
End-stage renal disease on dialysis due to diabetes mellitus	134.3 (92.6 to 174.3)	336.6 (229.8 to 448.5)	149.8 (129.7 to 176.3)	50.0 (37.6 to 66.6)
Chronic kidney disease due to hypertension	2,133.9 (1,570.6 to 2,775.1)	2,635.3 (1,915.3 to 3,415.5)	23.1 (16.3 to 33.2)	-22.4 (-26.9 to -16.3)
Stage III chronic kidney disease without anemia due to hypertension	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Stage III chronic kidney disease and mild anemia due to hypertension	16.3 (5.8 to 35.6)	22.6 (8.1 to 49.6)	38.5 (32.5 to 46.1)	-11.9 (-15.4 to -7.6)
Stage III chronic kidney disease and moderate anemia due to hypertension	144.9 (94.0 to 210.0)	174.6 (112.4 to 253.8)	20.5 (11.0 to 30.3)	-16.1 (-22.4 to -9.6)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Stage III chronic kidney disease and severe anemia due to hypertension	36.1 (23.7 to 50.9)	30.4 (18.9 to 43.6)	-15.8 (-35.5 to 4.1)	-36.7 (-50.6 to -21.7)
Stage IV chronic kidney disease without anemia due to hypertension	71.8 (43.9 to 106.9)	117.5 (73.1 to 179.7)	63.5 (12.6 to 127.8)	6.1 (-23.9 to 45.8)
Stage IV chronic kidney disease and mild anemia due to hypertension	120.1 (82.3 to 164.9)	159.5 (109.7 to 224.0)	33.2 (15.4 to 50.6)	-18.5 (-28.8 to -7.9)
Stage IV chronic kidney disease and moderate anemia due to hypertension	220.7 (152.6 to 303.6)	300.0 (207.1 to 408.2)	36.0 (21.9 to 51.3)	-17.3 (-25.7 to -8.1)
Stage IV chronic kidney disease and severe anemia due to hypertension	49.5 (33.4 to 70.4)	46.7 (31.7 to 65.3)	-5.5 (-25.8 to 19.1)	-28.5 (-44.6 to -9.4)
Stage V chronic kidney disease untreated due to hypertension	1,301.4 (878.5 to 1,783.9)	1,545.6 (1,020.4 to 2,158.7)	18.4 (7.5 to 32.8)	-26.1 (-33.1 to -17.8)
End-stage renal disease after transplant due to hypertension	1.6 (0.8 to 2.7)	1.6 (0.9 to 2.8)	4.1 (-14.5 to 26.4)	-33.9 (-46.9 to -19.5)
End-stage renal disease on dialysis due to hypertension	171.6 (119.8 to 224.0)	236.6 (162.6 to 316.0)	38.1 (23.7 to 52.7)	-16.5 (-25.4 to -7.9)
Chronic kidney disease due to glomerulonephritis	1,864.8 (1,367.4 to 2,442.3)	2,495.9 (1,809.0 to 3,252.0)	33.9 (25.6 to 43.3)	-6.9 (-11.9 to -0.5)
Stage III chronic kidney disease without anemia due to glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Stage III chronic kidney disease and mild anemia due to glomerulonephritis	14.7 (5.3 to 32.1)	20.2 (7.2 to 44.3)	36.8 (28.3 to 45.8)	-1.9 (-7.2 to 4.3)
Stage III chronic kidney disease and moderate anemia due to glomerulonephritis	212.7 (138.4 to 312.9)	232.8 (151.3 to 340.9)	9.7 (1.5 to 18.0)	-9.4 (-15.9 to -2.5)
Stage III chronic kidney disease and severe anemia due to glomerulonephritis	50.0 (33.6 to 70.6)	53.2 (34.1 to 75.6)	5.8 (-8.4 to 24.5)	-11.4 (-23.4 to 4.4)
Stage IV chronic kidney disease without anemia due to glomerulonephritis	84.6 (56.9 to 119.5)	150.4 (97.6 to 217.4)	79.4 (35.4 to 121.3)	10.3 (-16.2 to 35.3)
Stage IV chronic kidney disease and mild anemia due to glomerulonephritis	89.3 (60.4 to 126.4)	128.5 (84.6 to 179.7)	45.0 (15.9 to 70.0)	-4.1 (-22.4 to 12.0)
Stage IV chronic kidney disease and moderate anemia due to glomerulonephritis	181.4 (125.5 to 249.6)	263.6 (179.8 to 356.7)	44.9 (29.0 to 64.0)	-2.0 (-12.2 to 10.2)
Stage IV chronic kidney disease and severe anemia due to glomerulonephritis	65.2 (44.5 to 89.5)	47.7 (30.4 to 70.9)	-27.9 (-45.1 to 0.0)	-43.0 (-56.8 to -20.7)
Stage V chronic kidney disease untreated due to glomerulonephritis	1,040.0 (701.3 to 1,421.8)	1,439.2 (983.5 to 1,963.5)	38.4 (25.9 to 52.6)	-4.9 (-12.7 to 3.3)
End-stage renal disease after transplant due to glomerulonephritis	1.0 (0.5 to 1.7)	1.9 (1.0 to 3.2)	85.5 (61.7 to 113.5)	22.8 (6.7 to 42.5)
End-stage renal disease on dialysis due to glomerulonephritis	125.8 (87.3 to 166.4)	158.5 (107.5 to 208.5)	25.5 (14.0 to 42.5)	-21.8 (-29.5 to -10.3)
Chronic kidney disease due to other causes	2,892.9 (2,128.5 to 3,725.2)	4,724.3 (3,503.0 to 6,063.2)	63.4 (55.9 to 71.9)	6.9 (0.9 to 12.7)
Stage III chronic kidney disease without anemia due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Stage III chronic kidney disease and mild anemia due to other causes	23.5 (8.3 to 51.5)	38.3 (13.4 to 82.5)	62.9 (56.3 to 70.1)	10.8 (6.9 to 15.4)
Stage III chronic kidney disease and moderate anemia due to other causes	279.0 (180.7 to 409.2)	407.9 (267.6 to 597.9)	46.1 (38.5 to 54.7)	12.0 (6.4 to 17.8)
Stage III chronic kidney disease and severe anemia due to other causes	55.9 (37.2 to 78.7)	69.4 (45.2 to 98.4)	24.0 (6.4 to 47.0)	-0.5 (-13.5 to 16.6)
Stage IV chronic kidney disease without anemia due to other causes	93.7 (61.1 to 140.0)	188.8 (123.3 to 269.8)	103.6 (55.4 to 158.8)	27.0 (-2.4 to 60.4)
Stage IV chronic kidney disease and mild anemia due to other causes	141.7 (94.4 to 194.1)	235.5 (160.9 to 329.1)	67.2 (44.3 to 88.9)	2.0 (-11.4 to 15.3)
Stage IV chronic kidney disease and moderate anemia due to other causes	286.4 (199.2 to 390.1)	529.6 (373.4 to 707.4)	85.3 (67.7 to 102.8)	16.5 (5.8 to 27.5)
Stage IV chronic kidney disease and severe anemia due to other causes	70.7 (48.3 to 97.0)	49.8 (32.9 to 69.8)	-30.4 (-43.6 to -9.5)	-43.5 (-54.4 to -27.1)
Stage V chronic kidney disease untreated due to other causes	1,696.7 (1,154.7 to 2,311.1)	2,726.2 (1,876.7 to 3,679.2)	60.5 (51.3 to 71.6)	3.8 (-3.4 to 11.9)
End-stage renal disease after transplant due to other causes	2.1 (1.1 to 3.5)	3.7 (2.1 to 6.1)	82.3 (52.9 to 113.9)	17.0 (-2.3 to 39.5)
End-stage renal disease on dialysis due to other causes	243.2 (169.3 to 323.1)	475.0 (328.3 to 633.4)	95.4 (82.6 to 107.3)	18.5 (10.6 to 26.1)
Urinary diseases and male infertility	2,650.9 (1,759.4 to 3,772.1)	4,880.3 (3,212.9 to 7,017.1)	83.8 (77.8 to 91.1)	8.5 (5.1 to 12.4)
Interstitial nephritis and urinary tract infections	34.8 (21.8 to 51.7)	58.1 (36.4 to 85.6)	66.8 (59.9 to 74.7)	16.4 (11.8 to 21.3)
Mild interstitial nephritis and urinary tract infections	2.1 (0.8 to 4.5)	3.5 (1.3 to 7.2)	66.9 (58.6 to 76.1)	16.3 (10.8 to 22.4)
Moderate interstitial nephritis and urinary tract infections	32.8 (20.5 to 48.8)	54.7 (34.6 to 80.7)	66.7 (59.6 to 75.0)	16.4 (11.8 to 21.4)
Urolithiasis	336.9 (218.1 to 486.1)	661.8 (411.4 to 984.0)	95.8 (83.0 to 109.3)	20.4 (13.0 to 27.6)
Acute urolithiasis	135.4 (90.5 to 189.2)	197.7 (131.5 to 275.1)	45.9 (40.4 to 51.4)	-7.0 (-10.4 to -3.6)
Chronic urolithiasis	201.5 (116.9 to 310.9)	464.0 (268.1 to 739.6)	130.1 (115.1 to 144.4)	36.3 (27.8 to 44.0)
Benign prostatic hyperplasia	1,973.3 (1,292.0 to 2,761.0)	3,552.9 (2,316.5 to 4,993.7)	80.0 (75.9 to 84.5)	3.6 (1.3 to 6.3)
Asymptomatic benign prostatic hyperplasia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Symptomatic benign prostatic hyperplasia	1,973.3 (1,292.7 to 2,759.5)	3,552.9 (2,319.3 to 4,990.6)	80.0 (76.0 to 84.5)	3.6 (1.3 to 6.3)
Male infertility due to other causes	180.0 (78.0 to 354.5)	258.6 (111.8 to 531.4)	43.6 (32.3 to 56.6)	3.0 (-5.1 to 12.0)
Primary male infertility	132.8 (59.9 to 253.0)	188.8 (84.1 to 387.4)	42.2 (27.4 to 59.9)	3.1 (-7.5 to 15.9)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Secondary male infertility	47.2 (18.2 to 98.4)	69.8 (27.0 to 149.0)	47.9 (37.3 to 59.8)	2.5 (-5.0 to 10.8)
Other urinary diseases	125.9 (77.7 to 188.9)	348.9 (175.8 to 544.0)	195.7 (94.2 to 241.5)	86.0 (23.4 to 114.7)
Gynecological diseases	6,306.9 (4,134.8 to 9,277.6)	9,131.4 (5,982.5 to 13,595.8)	44.5 (40.3 to 49.3)	-3.5 (-6.1 to -0.5)
Uterine fibroids	1,577.4 (940.5 to 2,583.2)	2,164.7 (1,242.3 to 3,677.9)	36.6 (29.4 to 43.6)	-14.3 (-18.3 to -10.6)
Asymptomatic uterine fibroids	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild abdominal pain due to uterine fibroids, without anemia	470.7 (224.1 to 869.3)	859.8 (411.1 to 1,583.5)	82.7 (79.8 to 85.6)	6.2 (4.8 to 7.6)
Mild abdominal pain due to uterine fibroids, with mild anemia	202.8 (93.6 to 392.4)	302.8 (140.4 to 590.2)	48.8 (45.8 to 55.1)	-3.7 (-5.8 to 0.5)
Mild abdominal pain due to uterine fibroids, with moderate anemia	748.1 (480.2 to 1,103.6)	859.6 (553.9 to 1,276.6)	15.0 (9.9 to 19.0)	-25.3 (-28.6 to -22.7)
Mild abdominal pain due to uterine fibroids, with severe anemia	155.7 (107.7 to 213.5)	142.5 (96.3 to 193.7)	-8.1 (-21.2 to -0.7)	-40.8 (-49.4 to -36.0)
Polycystic ovarian syndrome	784.9 (369.0 to 1,470.9)	1,191.2 (562.3 to 2,227.4)	51.7 (47.1 to 56.4)	3.0 (0.1 to 6.1)
Asymptomatic polycystic ovarian syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Hirsutism due to polycystic ovarian syndrome	572.6 (271.9 to 1,070.6)	864.2 (411.6 to 1,618.8)	51.0 (46.1 to 55.7)	1.9 (-1.3 to 4.9)
Hirsutism and primary infertility due to polycystic ovarian syndrome	91.7 (42.1 to 172.0)	141.9 (66.2 to 268.0)	54.7 (46.7 to 62.9)	9.5 (4.0 to 15.4)
Primary infertility due to polycystic ovarian syndrome	8.8 (3.2 to 19.9)	13.7 (4.9 to 31.4)	55.0 (43.6 to 67.9)	9.6 (2.9 to 16.6)
Hirsutism and secondary infertility due to polycystic ovarian syndrome	8.0 (2.6 to 20.2)	12.3 (4.0 to 31.2)	53.0 (42.5 to 64.9)	4.0 (-0.9 to 10.0)
Secondary infertility due to polycystic ovarian syndrome	103.8 (46.3 to 197.5)	159.1 (71.8 to 303.3)	53.2 (48.0 to 59.1)	3.9 (0.4 to 7.9)
Female infertility due to other causes	122.3 (47.9 to 255.4)	191.9 (75.2 to 399.1)	56.9 (42.4 to 71.6)	11.0 (1.0 to 21.0)
Idiopathic primary female infertility	37.5 (16.0 to 73.0)	53.6 (22.4 to 102.3)	43.2 (12.0 to 76.5)	13.0 (-11.7 to 38.6)
Idiopathic secondary female infertility	84.8 (31.9 to 179.9)	138.3 (52.8 to 299.1)	62.8 (48.6 to 79.8)	10.1 (0.6 to 21.7)
Endometriosis	917.5 (613.2 to 1,243.1)	1,359.6 (906.4 to 1,861.5)	48.1 (42.1 to 54.3)	-1.3 (-5.3 to 2.8)
Asymptomatic endometriosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild abdominal pain due to endometriosis	5.8 (2.5 to 11.5)	8.6 (3.6 to 17.1)	48.3 (39.0 to 56.8)	-1.2 (-7.4 to 4.4)
Moderate abdominal pain due to endometriosis	530.2 (340.0 to 752.0)	785.0 (503.0 to 1,122.4)	48.1 (42.1 to 54.0)	-1.4 (-5.3 to 2.5)
Severe endometriosis	332.3 (193.9 to 494.3)	492.0 (288.3 to 734.9)	48.1 (41.0 to 56.2)	-1.4 (-6.0 to 4.0)
Primary infertility due to endometriosis	0.5 (0.2 to 1.0)	0.7 (0.3 to 1.5)	51.2 (30.4 to 75.5)	5.2 (-9.5 to 23.0)
Mild abdominal pain and primary infertility due to endometriosis	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.7)	51.1 (41.9 to 61.8)	5.4 (-1.1 to 12.8)
Moderate abdominal pain and primary infertility due to endometriosis	12.5 (7.0 to 20.1)	19.0 (10.3 to 30.4)	51.4 (32.9 to 74.2)	5.8 (-7.3 to 21.7)
Severe abdominal pain and primary infertility due to endometriosis	8.0 (4.7 to 12.9)	12.2 (7.0 to 19.8)	51.3 (42.0 to 62.3)	5.5 (-1.3 to 13.0)
Secondary infertility due to endometriosis	0.4 (0.2 to 0.9)	0.6 (0.2 to 1.4)	49.2 (30.9 to 69.6)	-0.4 (-12.5 to 13.4)
Mild abdominal pain and secondary infertility due to endometriosis	0.3 (0.1 to 0.6)	0.4 (0.2 to 0.8)	49.4 (42.6 to 56.6)	-0.3 (-4.9 to 4.7)
Moderate abdominal pain and secondary infertility due to endometriosis	16.5 (9.1 to 26.5)	24.7 (13.7 to 40.0)	50.1 (35.1 to 65.5)	0.2 (-9.6 to 10.9)
Severe abdominal pain and secondary infertility due to endometriosis	10.7 (6.2 to 17.3)	16.0 (9.2 to 26.0)	49.9 (41.6 to 59.1)	0.1 (-5.8 to 6.6)
Genital prolapse	696.1 (342.0 to 1,310.5)	1,094.2 (534.5 to 2,041.0)	57.1 (52.9 to 61.7)	-0.7 (-3.3 to 2.1)
Asymptomatic genital prolapse	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Abdominal pain due to genital prolapse	167.4 (32.9 to 432.4)	263.0 (50.4 to 681.3)	57.1 (52.9 to 61.8)	-0.7 (-3.3 to 2.1)
Stress incontinence due to genital prolapse	464.8 (205.1 to 878.7)	730.5 (322.5 to 1,392.7)	57.1 (53.0 to 61.6)	-0.7 (-3.2 to 2.0)
Abdominal pain and stress incontinence due to genital prolapse	64.0 (12.5 to 160.1)	100.6 (19.8 to 252.5)	57.3 (51.4 to 63.0)	-0.6 (-4.1 to 3.1)
Premenstrual syndrome	1,653.5 (1,032.5 to 2,500.2)	2,548.6 (1,581.3 to 3,777.0)	54.0 (40.7 to 67.9)	9.5 (0.1 to 19.5)
Asymptomatic premenstrual syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Abdominal pain and depression due to premenstrual syndrome	1,156.1 (716.5 to 1,737.6)	1,781.9 (1,094.7 to 2,666.4)	54.0 (40.8 to 67.7)	9.6 (0.3 to 19.6)
Abdominal pain due to premenstrual syndrome	120.0 (54.0 to 233.0)	185.0 (82.2 to 364.2)	53.9 (41.0 to 68.0)	9.5 (0.3 to 19.3)
Depression due to premenstrual syndrome	377.4 (115.5 to 822.9)	581.7 (176.8 to 1,254.7)	53.8 (40.4 to 68.8)	9.5 (0.2 to 20.2)
Other gynecological diseases	555.3 (375.7 to 790.1)	581.3 (395.7 to 826.6)	4.2 (-4.6 to 21.3)	-27.2 (-33.5 to -14.7)
Asymptomatic other gynecological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Mild other gynecological disorders	11.6 (5.5 to 21.7)	16.7 (7.9 to 30.8)	43.5 (33.5 to 53.7)	-7.8 (-14.1 to -1.1)
Moderate other gynecological disorders	33.7 (18.4 to 55.3)	48.3 (26.3 to 79.0)	43.2 (31.7 to 57.3)	-7.9 (-15.1 to 1.2)
Severe other gynecological disorders	47.1 (26.9 to 72.0)	67.6 (39.3 to 103.8)	43.7 (29.3 to 59.3)	-7.5 (-16.7 to 2.1)
Mild anemia due to other gynecological diseases	28.5 (10.2 to 63.2)	35.6 (12.7 to 80.6)	25.4 (5.4 to 39.1)	-11.6 (-26.2 to -1.9)
Moderate anemia due to other gynecological diseases	350.6 (223.4 to 510.3)	352.3 (228.9 to 521.7)	-0.2 (-14.7 to 25.8)	-29.0 (-39.4 to -8.8)
Severe anemia due to other gynecological diseases	83.7 (56.0 to 117.2)	60.7 (39.1 to 86.2)	-26.9 (-45.8 to -10.8)	-48.2 (-61.6 to -37.9)
Hemoglobinopathies and hemolytic anemias	5,736.7 (3,855.0 to 8,245.1)	7,071.9 (4,730.8 to 10,107.0)	23.2 (20.7 to 26.5)	-2.3 (-4.2 to 0.3)
Thalassemias	56.1 (37.7 to 78.7)	61.9 (42.1 to 88.0)	10.2 (1.8 to 22.1)	-4.2 (-11.3 to 5.8)
Beta-thalassemia major, with mild anemia	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.5)	14.6 (-11.6 to 55.4)	-5.1 (-26.9 to 28.6)
Beta-thalassemia major, with moderate anemia	11.3 (7.0 to 16.9)	12.9 (8.1 to 19.5)	14.7 (-0.4 to 32.1)	4.7 (-8.8 to 20.6)
Beta-thalassemia major, with severe anemia	11.6 (7.6 to 16.8)	11.7 (7.4 to 17.1)	-0.2 (-26.5 to 36.5)	-12.1 (-34.7 to 20.0)
Beta-thalassemia major, severe infection with severe anemia	0.8 (0.3 to 1.8)	0.9 (0.3 to 2.0)	12.8 (6.5 to 18.2)	0.9 (-4.8 to 5.7)
Hemoglobin E/beta-thalassemia, with mild anemia	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	-6.3 (-45.9 to 64.5)	-25.8 (-56.9 to 29.7)
Hemoglobin E/beta-thalassemia, with moderate anemia	8.2 (5.2 to 12.5)	8.8 (5.5 to 13.5)	7.3 (-10.9 to 24.6)	-4.4 (-20.6 to 10.6)
Hemoglobin E/beta-thalassemia, with severe anemia	6.3 (4.1 to 9.2)	7.0 (4.4 to 10.9)	9.9 (-17.8 to 54.1)	-5.4 (-29.0 to 31.9)
Hemoglobin E/beta-thalassemia, severe infection with severe anemia	0.5 (0.2 to 1.1)	0.6 (0.2 to 1.2)	12.4 (8.4 to 16.9)	-2.1 (-5.4 to 1.7)
Hemoglobin H disease, with mild anemia	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-24.6 (-63.1 to 70.7)	-37.5 (-69.0 to 38.8)
Hemoglobin H disease, with moderate anemia	2.1 (1.3 to 3.2)	1.6 (0.9 to 2.4)	-24.3 (-42.1 to -7.0)	-31.2 (-47.8 to -15.5)
Hemoglobin H disease, with severe anemia	1.7 (1.0 to 2.8)	2.0 (1.2 to 3.3)	15.9 (-13.8 to 65.5)	0.8 (-25.0 to 42.3)
Hemoglobin H disease, severe infection with severe anemia	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.3)	-8.1 (-12.9 to -2.2)	-18.5 (-22.7 to -13.6)
Mild heart failure due to thalassemias	1.0 (0.5 to 1.8)	1.2 (0.6 to 2.1)	20.8 (0.4 to 66.2)	-2.1 (-17.9 to 31.9)
Moderate heart failure due to thalassemias	1.4 (0.7 to 2.3)	1.7 (0.9 to 2.8)	20.7 (0.5 to 66.4)	-2.1 (-18.0 to 31.7)
Severe heart failure due to thalassemias	9.5 (5.4 to 14.6)	11.6 (6.9 to 17.4)	20.8 (0.1 to 66.6)	-2.3 (-18.1 to 32.1)
Hemoglobin H disease, without anemia	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	44.5 (-27.9 to 194.2)	21.6 (-38.7 to 142.5)
Beta-thalassemia major, without anemia	0.6 (0.1 to 1.6)	0.7 (0.2 to 1.7)	23.8 (-16.1 to 152.6)	7.3 (-26.3 to 101.8)
Hemoglobin E/Beta-thalassemia, without anemia	0.3 (0.1 to 0.7)	0.4 (0.2 to 0.9)	64.9 (-14.3 to 291.0)	35.9 (-28.0 to 207.5)
Thalassemia trait	2,799.6 (1,875.8 to 4,015.6)	3,769.6 (2,508.9 to 5,442.2)	34.6 (31.0 to 38.8)	5.9 (3.1 to 9.3)
Asymptomatic B-thalassemia trait	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild anemia due to B-thalassemia trait	92.8 (33.3 to 202.3)	126.8 (45.7 to 279.0)	36.7 (28.7 to 44.3)	1.0 (-4.7 to 6.7)
Moderate anemia due to B-thalassemia trait	1,994.4 (1,320.5 to 2,880.5)	2,783.8 (1,840.2 to 4,036.6)	39.4 (35.5 to 45.2)	8.6 (5.5 to 13.0)
Severe anemia due to B-thalassemia trait	535.4 (366.9 to 745.5)	615.1 (420.8 to 850.8)	15.1 (7.1 to 23.4)	-5.1 (-11.9 to 1.5)
Asymptomatic hemoglobin E trait	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild anemia due to hemoglobin E trait	9.6 (3.5 to 21.3)	16.6 (5.9 to 36.7)	73.1 (58.0 to 85.5)	27.0 (16.4 to 35.2)
Moderate anemia due to hemoglobin E trait	141.8 (94.5 to 208.9)	197.4 (131.0 to 284.5)	38.7 (29.6 to 52.3)	11.4 (4.4 to 22.4)
Severe anemia due to hemoglobin E trait	25.6 (16.6 to 41.8)	29.9 (19.8 to 41.6)	21.1 (-31.9 to 41.6)	-2.4 (-45.6 to 14.0)
Sickle cell disorders	190.9 (136.3 to 258.3)	342.1 (246.2 to 455.9)	79.4 (68.1 to 90.9)	49.7 (40.1 to 59.0)
Homozygous sickle cell and severe sickle cell/beta-thalassemia, without anemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.6 (-89.0 to 1,892.7)	6.9 (-91.7 to 1,272.1)
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with vaso-occlusive crisis, without anemia	2.3 (0.9 to 4.5)	6.5 (2.8 to 12.3)	177.2 (47.5 to 440.2)	123.6 (19.0 to 332.4)
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with stroke, without anemia	3.0 (1.2 to 5.5)	8.3 (3.9 to 15.3)	174.5 (49.0 to 443.4)	122.2 (18.4 to 338.4)
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with vaso-occlusive crisis and stroke, without anemia	0.6 (0.2 to 1.1)	1.6 (0.6 to 3.3)	183.3 (28.4 to 491.9)	120.4 (1.6 to 367.9)
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with mild anemia	2.4 (1.0 to 5.0)	4.9 (2.1 to 9.6)	98.5 (29.8 to 256.4)	59.1 (3.4 to 183.0)
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with moderate anemia	59.1 (37.1 to 88.7)	107.1 (67.8 to 158.4)	81.1 (64.8 to 101.4)	60.0 (45.7 to 78.2)
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with severe anemia	21.5 (12.4 to 35.3)	27.0 (16.1 to 45.2)	26.9 (-26.8 to 134.4)	14.3 (-34.1 to 110.3)
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with vaso-occlusive crisis and severe anemia	33.8 (21.3 to 50.3)	62.6 (39.3 to 91.3)	85.4 (59.5 to 116.9)	53.2 (32.3 to 77.8)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with stroke and severe anemia	21.8 (13.9 to 32.5)	43.7 (27.0 to 67.0)	102.0 (60.9 to 148.1)	51.8 (22.1 to 85.6)
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with vaso-occlusive crisis, stroke, and severe anemia	4.2 (2.3 to 6.8)	8.6 (4.8 to 13.7)	106.9 (68.7 to 151.4)	49.6 (24.3 to 84.1)
Hemoglobin SC disease, without anemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.4 (-86.4 to 0.0)	44.4 (-89.4 to 0.0)
Hemoglobin SC disease, with vaso-occlusive crisis, without anemia	1.0 (0.4 to 2.0)	1.8 (0.7 to 3.6)	76.2 (-19.2 to 281.2)	39.9 (-35.7 to 205.1)
Hemoglobin SC disease, with stroke, without anemia	1.2 (0.5 to 2.1)	2.1 (0.8 to 4.2)	72.1 (-15.3 to 290.4)	35.0 (-32.7 to 198.3)
Hemoglobin SC disease, with vaso-occlusive crisis and stroke, without anemia	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.9)	69.0 (-14.3 to 270.0)	28.4 (-35.0 to 179.9)
Hemoglobin SC disease, with mild anemia	1.1 (0.5 to 2.2)	1.9 (0.8 to 3.7)	80.0 (-2.0 to 203.5)	49.5 (-19.1 to 150.4)
Hemoglobin SC disease, with moderate anemia	14.4 (9.2 to 21.4)	24.4 (15.6 to 36.3)	69.1 (55.0 to 85.9)	42.8 (31.0 to 56.9)
Hemoglobin SC disease, with severe anemia	3.9 (2.2 to 6.6)	5.7 (3.1 to 11.6)	40.7 (-26.9 to 237.8)	25.4 (-34.8 to 197.4)
Hemoglobin SC disease, with vaso-occlusive crisis and severe anemia	8.9 (5.8 to 12.7)	15.4 (10.1 to 21.7)	73.5 (41.9 to 109.5)	38.3 (13.7 to 67.0)
Hemoglobin SC disease, with stroke and severe anemia	6.5 (4.1 to 9.3)	11.7 (7.4 to 16.7)	80.7 (45.8 to 119.8)	30.5 (5.5 to 59.5)
Hemoglobin SC disease, with vaso-occlusive crisis, stroke, and severe anemia	1.4 (0.8 to 2.2)	2.5 (1.5 to 3.9)	82.0 (53.7 to 109.8)	26.3 (6.8 to 46.5)
Mild sickle cell/beta-thalassemia, without anemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.7 (-95.8 to 0.0)	52.3 (-96.4 to 0.0)
Mild sickle cell/beta-thalassemia, with vaso-occlusive crisis, without anemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	290.1 (140.0 to 511.1)	190.4 (78.2 to 355.1)
Mild sickle cell/beta-thalassemia, with stroke, without anemia	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	289.9 (138.7 to 511.3)	188.6 (78.9 to 355.2)
Mild sickle cell/beta-thalassemia, with vaso-occlusive crisis and stroke, without anemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	295.5 (142.9 to 511.1)	189.2 (79.3 to 347.4)
Mild sickle cell/beta-thalassemia, with mild anemia	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	36.6 (-8.1 to 118.4)	12.5 (-23.3 to 80.0)
Mild sickle cell/beta-thalassemia, with moderate anemia	1.2 (0.7 to 1.7)	2.2 (1.4 to 3.3)	87.9 (50.9 to 135.3)	68.7 (36.1 to 109.7)
Mild sickle cell/beta-thalassemia, with severe anemia	1.3 (0.9 to 1.9)	1.7 (1.1 to 2.6)	31.0 (1.5 to 87.2)	15.7 (-9.4 to 64.9)
Mild sickle cell/beta-thalassemia, with vaso-occlusive crisis and severe anemia	0.6 (0.4 to 0.9)	1.0 (0.7 to 1.5)	70.3 (58.1 to 86.9)	37.7 (28.3 to 50.7)
Mild sickle cell/beta-thalassemia, with stroke and severe anemia	0.6 (0.3 to 0.8)	1.0 (0.6 to 1.5)	73.6 (61.9 to 91.5)	34.5 (25.1 to 47.6)
Mild sickle cell/beta-thalassemia, with vaso-occlusive crisis, stroke, and severe anemia	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	75.1 (62.9 to 91.4)	31.6 (22.3 to 45.7)
Sickle cell trait	1,003.5 (670.7 to 1,453.7)	1,396.6 (929.4 to 2,004.9)	39.0 (32.0 to 49.0)	13.8 (8.0 to 23.6)
Asymptomatic sickle cell trait	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild anemia due to sickle cell trait	47.6 (17.2 to 103.2)	72.2 (25.7 to 157.5)	51.8 (36.0 to 62.9)	12.7 (0.9 to 20.5)
Moderate anemia due to sickle cell trait	763.4 (500.1 to 1,113.9)	1,075.2 (713.2 to 1,562.7)	40.5 (31.3 to 55.2)	14.9 (7.3 to 28.6)
Severe anemia due to sickle cell trait	192.5 (131.4 to 267.6)	249.2 (168.3 to 344.4)	29.0 (15.5 to 48.1)	8.9 (-2.7 to 26.4)
G6PD deficiency	25.9 (17.7 to 36.0)	36.3 (24.8 to 50.4)	40.5 (31.7 to 49.5)	11.4 (4.8 to 18.1)
Mild anemia due to G6PD deficiency	1.0 (0.3 to 2.1)	1.4 (0.5 to 3.1)	47.5 (36.1 to 59.7)	17.4 (8.3 to 26.8)
Moderate anemia due to G6PD deficiency	7.3 (4.8 to 10.7)	10.5 (6.7 to 15.6)	44.2 (27.2 to 61.2)	18.0 (4.6 to 30.8)
Severe anemia due to G6PD deficiency	16.6 (11.1 to 23.2)	21.9 (14.8 to 30.7)	31.5 (21.5 to 43.2)	3.8 (-3.6 to 12.2)
Mild heart failure due to G6PD deficiency	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	151.1 (100.2 to 229.9)	75.4 (39.3 to 130.5)
Moderate heart failure due to G6PD deficiency	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	151.1 (100.1 to 229.9)	75.4 (39.2 to 130.4)
Severe heart failure due to G6PD deficiency	0.8 (0.4 to 1.3)	2.0 (1.2 to 3.1)	151.1 (100.2 to 229.9)	75.3 (39.3 to 130.4)
Asymptomatic G6PD deficiency	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
G6PD trait	39.5 (25.9 to 56.5)	48.8 (30.1 to 73.3)	23.6 (-1.0 to 50.9)	-0.7 (-20.6 to 20.4)
Asymptomatic hemizygous G6PD deficiency	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild anemia due to hemizygous G6PD deficiency	2.4 (0.9 to 5.4)	4.3 (1.5 to 9.3)	76.2 (54.7 to 107.1)	23.2 (10.2 to 44.3)
Moderate anemia due to hemizygous G6PD deficiency	24.5 (15.7 to 36.3)	36.7 (22.1 to 53.9)	51.6 (16.6 to 80.1)	23.5 (-4.9 to 45.8)
Severe anemia due to hemizygous G6PD deficiency	12.6 (6.8 to 18.8)	7.9 (4.5 to 12.4)	-38.5 (-62.2 to 22.3)	-51.1 (-70.0 to -2.9)
Other hemoglobinopathies and hemolytic anemias	1,621.3 (1,079.3 to 2,356.7)	1,416.5 (936.5 to 2,051.7)	-12.7 (-17.5 to -6.4)	-31.4 (-35.1 to -26.4)
Other hemoglobinopathies and hemolytic anemias	43.5 (32.3 to 57.3)	65.8 (49.0 to 84.6)	53.6 (34.1 to 64.3)	24.8 (6.7 to 35.0)
Mild anemia due to other hemoglobinopathies and hemolytic anemias	116.3 (41.6 to 251.8)	124.3 (44.8 to 274.5)	6.9 (0.8 to 11.2)	-22.2 (-26.3 to -19.1)
Moderate anemia due to other hemoglobinopathies and hemolytic anemias	1,124.2 (734.5 to 1,631.7)	975.1 (645.4 to 1,423.4)	-13.3 (-19.1 to -3.8)	-31.5 (-36.2 to -24.3)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Severe anemia due to other hemoglobinopathies and hemolytic anemias	326.2 (214.8 to 453.1)	226.0 (154.2 to 331.1)	-30.9 (-42.5 to -17.4)	-44.7 (-53.8 to -34.7)
Mild heart failure due to other hemoglobinopathies and hemolytic anemias	0.9 (0.4 to 1.7)	2.1 (1.0 to 3.7)	129.0 (67.3 to 193.5)	38.1 (0.7 to 75.8)
Moderate heart failure due to other hemoglobinopathies and hemolytic anemias	1.3 (0.7 to 2.3)	3.1 (1.7 to 5.2)	128.0 (67.4 to 193.3)	37.8 (0.5 to 76.6)
Severe heart failure due to other hemoglobinopathies and hemolytic anemias	8.7 (5.1 to 13.3)	19.9 (12.4 to 30.3)	128.1 (75.3 to 192.3)	38.7 (6.1 to 77.0)
Endocrine, metabolic, blood, and immune disorders	2,441.2 (1,676.0 to 3,414.8)	2,610.6 (1,797.9 to 3,629.0)	6.9 (2.2 to 12.8)	-16.7 (-20.2 to -12.3)
Asymptomatic endocrine, metabolic, blood, and immune disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild endocrine, metabolic, blood, and immune disorders	167.6 (88.3 to 284.8)	223.9 (119.2 to 377.8)	33.6 (30.7 to 36.4)	-5.9 (-7.9 to -3.8)
Moderate endocrine, metabolic, blood, and immune disorders	201.8 (105.1 to 333.8)	269.3 (139.5 to 447.5)	33.6 (29.2 to 37.8)	-5.8 (-8.7 to -2.8)
Severe endocrine, metabolic, blood, and immune disorders	482.9 (307.0 to 702.7)	644.2 (411.2 to 935.0)	33.5 (29.8 to 36.9)	-5.8 (-8.2 to -3.4)
Mild anemia due to endocrine, metabolic, blood, and immune disorders	90.2 (32.1 to 197.7)	98.0 (35.6 to 214.8)	9.1 (1.2 to 15.1)	-17.7 (-24.1 to -13.5)
Moderate anemia due to endocrine, metabolic, blood, and immune disorders	1,131.6 (740.6 to 1,643.8)	1,014.9 (664.0 to 1,479.3)	-10.3 (-20.0 to -1.4)	-25.5 (-33.3 to -16.9)
Severe anemia due to endocrine, metabolic, blood, and immune disorders	327.9 (219.2 to 462.9)	263.1 (176.2 to 375.5)	-20.6 (-32.9 to 0.2)	-33.5 (-44.2 to -16.4)
Mild heart failure due to endocrine, metabolic, blood, and immune disorders	3.3 (1.7 to 5.3)	8.2 (4.4 to 13.1)	149.3 (122.7 to 175.3)	57.5 (41.3 to 73.6)
Moderate heart failure due to endocrine, metabolic, blood, and immune disorders	4.8 (2.7 to 7.7)	11.8 (7.0 to 18.4)	148.6 (123.5 to 172.8)	57.3 (40.6 to 73.1)
Severe heart failure due to endocrine, metabolic, blood, and immune disorders	31.1 (19.9 to 44.6)	77.3 (50.3 to 112.0)	149.0 (122.4 to 173.7)	58.3 (41.9 to 73.7)
Musculoskeletal disorders	90,956.7 (64,737.0 to 120,920.5)	146,231.3 (103,763.1 to 194,304.6)	60.7 (58.6 to 63.6)	0.6 (-0.5 to 2.3)
Rheumatoid arthritis	2,504.8 (1,800.6 to 3,293.2)	3,925.6 (2,818.6 to 5,178.5)	56.8 (53.9 to 59.4)	-4.6 (-6.3 to -3.1)
Mild rheumatoid arthritis	533.8 (367.0 to 737.5)	837.2 (573.8 to 1,153.4)	56.9 (54.0 to 59.5)	-4.7 (-6.4 to -3.1)
Moderate rheumatoid arthritis	1,196.7 (803.3 to 1,669.7)	1,875.0 (1,266.6 to 2,614.4)	56.8 (53.5 to 59.8)	-4.6 (-6.5 to -2.9)
Severe rheumatoid arthritis	774.2 (469.5 to 1,117.6)	1,213.4 (731.7 to 1,744.4)	56.8 (52.6 to 60.9)	-4.5 (-7.0 to -2.2)
Osteoarthritis	7,306.6 (5,157.2 to 9,917.1)	12,811.1 (9,030.0 to 17,281.2)	75.4 (72.9 to 77.8)	-0.2 (-1.6 to 1.2)
Mild osteoarthritis of the hip	332.6 (192.8 to 528.2)	551.2 (322.0 to 880.8)	65.8 (61.4 to 69.8)	-6.4 (-8.9 to -4.1)
Moderate osteoarthritis of the hip	545.5 (368.0 to 746.4)	937.2 (635.9 to 1,288.4)	71.9 (67.3 to 76.8)	-2.8 (-5.3 to 0.0)
Severe osteoarthritis of the hip	323.8 (226.2 to 445.9)	590.2 (409.9 to 815.3)	82.1 (75.8 to 89.6)	3.5 (0.1 to 7.5)
Mild osteoarthritis of the knee	1,342.0 (773.4 to 2,150.5)	2,279.4 (1,307.0 to 3,630.0)	69.8 (66.8 to 73.3)	-3.6 (-5.3 to -1.6)
Moderate osteoarthritis of the knee	2,683.6 (1,864.5 to 3,721.5)	4,697.6 (3,262.8 to 6,483.9)	75.1 (71.9 to 78.3)	-0.4 (-2.2 to 1.5)
Severe osteoarthritis of the knee	2,079.0 (1,418.4 to 2,862.5)	3,755.6 (2,555.3 to 5,171.8)	80.6 (76.7 to 84.9)	3.2 (1.0 to 5.6)
Low back and neck pain	68,362.5 (47,692.6 to 92,110.2)	106,665.5 (74,116.9 to 142,959.7)	55.8 (53.3 to 59.6)	-0.4 (-1.9 to 1.9)
Low back pain	46,068.1 (31,609.5 to 63,500.9)	72,317.6 (49,051.0 to 99,738.5)	56.7 (53.5 to 61.5)	0.0 (-2.0 to 2.9)
Mild low back pain without leg pain	2,440.2 (1,257.9 to 4,335.3)	3,832.1 (1,978.2 to 6,915.7)	56.8 (53.4 to 61.4)	-0.1 (-2.2 to 2.8)
Mild low back pain with leg pain	436.7 (64.0 to 1,141.5)	685.8 (99.4 to 1,804.0)	56.8 (53.3 to 61.4)	-0.1 (-2.2 to 2.7)
Moderate low back pain without leg pain	5,973.9 (3,493.4 to 8,929.0)	9,381.5 (5,563.9 to 13,977.9)	56.8 (53.5 to 61.5)	-0.1 (-2.1 to 2.8)
Moderate low back pain with leg pain	1,598.8 (568.4 to 3,279.1)	2,511.5 (887.7 to 5,161.6)	56.8 (53.3 to 61.4)	-0.0 (-2.2 to 2.8)
Severe low back pain without leg pain	8,824.6 (5,676.8 to 12,964.5)	13,853.1 (8,874.2 to 20,589.0)	56.8 (53.3 to 61.5)	0.1 (-2.1 to 3.1)
Severe low back pain with leg pain	3,355.5 (1,067.9 to 6,838.2)	5,266.6 (1,654.9 to 10,748.2)	56.7 (53.1 to 61.6)	0.1 (-2.2 to 3.0)
Most severe low back pain without leg pain	16,335.2 (9,464.9 to 24,770.9)	25,639.3 (14,924.7 to 38,738.3)	56.7 (53.4 to 61.4)	0.1 (-2.0 to 3.0)
Most severe low back pain with leg pain	7,103.2 (1,281.9 to 16,926.5)	11,147.7 (1,940.1 to 26,549.4)	56.8 (53.2 to 61.7)	0.1 (-2.1 to 3.0)
Neck pain	22,294.4 (15,436.0 to 30,514.5)	34,347.9 (23,792.0 to 47,418.5)	54.0 (49.0 to 59.9)	-1.2 (-4.3 to 2.6)
Mild neck pain	7,802.5 (5,046.0 to 11,425.1)	12,026.1 (7,813.8 to 17,567.2)	54.0 (49.0 to 59.9)	-1.2 (-4.4 to 2.5)
Moderate neck pain	2,765.4 (1,367.3 to 4,657.0)	4,261.1 (2,097.4 to 7,217.3)	54.0 (48.9 to 60.0)	-1.1 (-4.4 to 2.6)
Severe neck pain	2,873.6 (1,687.2 to 4,550.6)	4,426.4 (2,608.4 to 6,935.2)	54.0 (48.9 to 60.0)	-1.1 (-4.4 to 2.7)
Most severe neck pain	8,853.0 (5,116.0 to 13,616.5)	13,634.3 (7,982.6 to 20,734.4)	53.9 (48.9 to 59.9)	-1.1 (-4.3 to 2.6)
Gout	110.6 (76.9 to 148.4)	185.5 (129.0 to 249.2)	67.7 (62.6 to 73.3)	-1.8 (-4.7 to 1.4)
Asymptomatic gout	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Symptomatic episodes of gout	84.9 (57.3 to 117.3)	142.6 (95.8 to 196.1)	67.8 (62.2 to 74.2)	-1.8 (-4.9 to 1.9)
Polyarticular gout	25.7 (18.1 to 32.3)	43.0 (30.4 to 54.2)	67.3 (58.6 to 76.9)	-2.0 (-7.1 to 3.7)
Other musculoskeletal disorders	12,672.4 (8,593.8 to 17,641.9)	22,643.6 (15,253.8 to 31,684.6)	78.6 (75.0 to 82.9)	7.0 (5.3 to 9.3)
Asymptomatic other musculoskeletal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Other musculoskeletal disorders severity level 2	792.8 (439.6 to 1,306.8)	1,416.2 (789.5 to 2,326.7)	78.5 (75.0 to 82.7)	6.9 (5.3 to 9.1)
Other musculoskeletal disorders severity level 3	1,625.5 (891.6 to 2,669.4)	2,903.8 (1,591.3 to 4,781.9)	78.6 (75.1 to 83.1)	6.9 (5.2 to 9.3)
Other musculoskeletal disorders severity level 5	3,173.8 (2,085.4 to 4,582.6)	5,670.5 (3,726.5 to 8,238.4)	78.6 (74.8 to 82.9)	7.0 (5.1 to 9.4)
Other musculoskeletal disorders severity level 6	5,135.3 (2,564.8 to 8,673.0)	9,178.6 (4,589.6 to 15,453.2)	78.6 (74.8 to 83.2)	7.1 (5.3 to 9.6)
Other musculoskeletal disorders severity level 1	647.4 (327.8 to 1,116.9)	1,156.5 (582.2 to 1,994.5)	78.5 (75.1 to 82.9)	6.9 (5.2 to 9.3)
Other musculoskeletal disorders severity level 4	1,297.4 (755.1 to 1,955.6)	2,318.0 (1,345.6 to 3,503.6)	78.6 (74.8 to 83.1)	6.9 (5.1 to 9.5)
Other non-communicable diseases	81,505.0 (54,391.7 to 118,179.4)	117,951.0 (78,473.3 to 170,905.6)	44.8 (42.8 to 46.7)	-4.1 (-5.4 to -3.0)
Congenital anomalies	4,967.5 (3,677.0 to 6,353.8)	8,022.5 (5,922.6 to 10,168.4)	61.4 (52.5 to 72.8)	19.7 (13.2 to 28.2)
Neural tube defects	285.0 (201.9 to 366.6)	461.2 (325.4 to 599.6)	61.6 (53.7 to 70.7)	27.9 (21.4 to 35.1)
Moderate motor impairment due to moderate neural tube defects	22.0 (14.3 to 31.9)	33.6 (22.0 to 48.4)	52.9 (42.1 to 64.9)	20.2 (11.8 to 29.8)
Severe motor impairment due to severe neural tube defects	58.8 (33.4 to 88.0)	95.9 (54.0 to 142.6)	63.0 (53.3 to 73.6)	29.0 (21.2 to 37.7)
Severe motor plus cognitive impairments due to severe neural tube defects	151.8 (100.3 to 204.5)	246.1 (160.5 to 333.5)	62.0 (51.5 to 73.9)	28.4 (20.1 to 37.7)
Severe motor impairment with incontinence due to severe neural tube defects	52.3 (29.5 to 79.1)	85.6 (48.0 to 128.3)	63.2 (54.7 to 73.3)	29.0 (22.1 to 36.8)
Congenital heart anomalies	656.5 (301.9 to 1,110.4)	1,230.4 (540.8 to 2,079.5)	86.8 (77.3 to 97.6)	40.7 (34.5 to 48.5)
Asymptomatic less severe congenital heart anomalies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Symptomatic less severe congenital heart anomalies	540.4 (215.7 to 947.4)	996.8 (402.8 to 1,715.4)	84.2 (76.0 to 95.4)	37.2 (31.1 to 45.6)
Severe congenital heart anomalies	54.4 (21.5 to 96.3)	152.9 (61.3 to 267.0)	182.0 (159.2 to 203.5)	109.5 (92.5 to 125.3)
Critical congenital heart anomalies	1.7 (0.7 to 3.0)	5.9 (2.4 to 10.4)	253.0 (206.2 to 305.4)	196.2 (157.8 to 240.5)
Mild heart failure due to congenital heart anomalies	5.0 (2.7 to 8.3)	6.3 (3.4 to 10.3)	25.9 (10.2 to 40.4)	7.0 (-5.4 to 18.1)
Moderate heart failure due to congenital heart anomalies	7.2 (4.2 to 11.2)	9.0 (5.2 to 14.4)	25.8 (10.8 to 39.4)	7.0 (-5.5 to 18.1)
Severe heart failure due to congenital heart anomalies	47.8 (31.8 to 69.1)	59.5 (39.1 to 85.5)	24.8 (10.5 to 38.5)	6.2 (-6.0 to 17.6)
Orofacial clefts	39.0 (25.8 to 56.3)	68.8 (45.6 to 98.8)	76.3 (65.2 to 89.5)	37.1 (28.4 to 47.3)
Asymptomatic orofacial clefts	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Disfigurement level 1 due to orofacial clefts	2.3 (1.1 to 4.2)	4.0 (1.9 to 7.3)	76.6 (63.1 to 90.8)	37.1 (26.6 to 47.8)
Disfigurement level 2 due to orofacial clefts	13.6 (9.2 to 19.4)	24.0 (16.1 to 33.8)	76.5 (63.3 to 91.1)	37.1 (26.4 to 48.6)
Disfigurement level 2 and speech problems due to orofacial clefts	23.1 (15.3 to 33.0)	40.8 (26.6 to 57.6)	76.5 (62.9 to 92.2)	37.2 (26.7 to 49.3)
Down syndrome	611.0 (455.2 to 774.0)	1,167.1 (894.8 to 1,459.7)	91.3 (80.5 to 101.4)	36.4 (29.3 to 42.9)
Asymptomatic Down syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Intellectual disability due to Down syndrome	180.6 (108.9 to 264.5)	289.9 (175.6 to 432.2)	60.6 (51.0 to 70.7)	26.6 (19.5 to 34.2)
Intellectual disability with congenital heart disease due to Down syndrome	238.3 (144.1 to 363.9)	381.5 (234.4 to 570.1)	60.6 (50.0 to 71.0)	26.6 (19.2 to 34.3)
Intellectual disability with dementia due to Down syndrome	95.0 (58.7 to 134.9)	248.0 (155.9 to 347.7)	161.5 (146.3 to 175.3)	51.0 (42.4 to 59.1)
Intellectual disability with congenital heart disease and dementia due to Down syndrome	91.6 (54.4 to 130.9)	238.6 (143.7 to 338.5)	160.9 (146.1 to 177.0)	50.7 (41.7 to 59.8)
Isolated congenital heart disease due to Down syndrome	5.5 (1.9 to 11.0)	9.2 (3.3 to 18.4)	68.8 (56.7 to 82.3)	29.3 (21.9 to 36.3)
Turner syndrome	2.8 (1.4 to 4.5)	4.3 (2.2 to 6.9)	52.1 (42.9 to 64.8)	14.5 (7.5 to 23.8)
Asymptomatic Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Congenital heart disease due to Turner syndrome	1.0 (0.4 to 1.8)	1.4 (0.6 to 2.5)	42.5 (33.4 to 52.8)	17.0 (10.0 to 25.6)
Primary infertility due to Turner syndrome	0.6 (0.3 to 1.2)	0.9 (0.4 to 1.9)	56.8 (39.6 to 78.8)	13.0 (0.8 to 28.1)
Congenital heart disease with infertility due to Turner syndrome	1.3 (0.6 to 2.1)	2.0 (0.9 to 3.3)	57.3 (48.9 to 69.0)	13.4 (7.4 to 21.8)
Klinefelter syndrome	0.9 (0.4 to 1.7)	1.3 (0.6 to 2.4)	47.2 (37.0 to 58.8)	5.5 (-1.8 to 13.9)
Asymptomatic Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Borderline intellectual disability due to Klinefelter syndrome	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.5)	35.3 (23.8 to 49.3)	8.1 (1.1 to 16.3)
Borderline intellectual disability with infertility due to Klinefelter syndrome	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.7)	51.9 (42.5 to 63.3)	4.6 (-1.8 to 12.4)
Mild intellectual disability due to Klinefelter syndrome	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	35.1 (22.2 to 51.1)	8.0 (1.1 to 16.4)
Mild intellectual disability with infertility due to Klinefelter syndrome	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	51.9 (42.5 to 63.3)	4.6 (-1.8 to 12.4)
Primary infertility due to Klinefelter syndrome	0.4 (0.2 to 0.8)	0.6 (0.3 to 1.1)	51.9 (39.4 to 66.7)	4.7 (-4.1 to 14.7)
Chromosomal unbalanced rearrangements	866.7 (648.5 to 1,103.0)	1,602.9 (1,203.6 to 2,038.4)	85.1 (75.6 to 95.0)	30.6 (24.8 to 37.1)
Asymptomatic chromosomal unbalanced rearrangements	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Intellectual disability due to chromosomal unbalanced rearrangements	251.8 (153.7 to 382.8)	392.8 (241.4 to 592.4)	56.2 (47.7 to 65.8)	22.5 (16.0 to 29.8)
Intellectual disability with congenital heart disease due to chromosomal unbalanced rearrangements	325.3 (185.7 to 495.4)	507.7 (292.7 to 760.1)	56.3 (46.9 to 66.5)	22.5 (15.8 to 30.0)
Intellectual disability with dementia due to chromosomal unbalanced rearrangements	143.2 (89.6 to 207.1)	350.7 (219.8 to 505.0)	144.8 (133.0 to 158.3)	41.3 (34.7 to 49.3)
Intellectual disability with congenital heart disease and dementia due to chromosomal unbalanced rearrangements	138.8 (85.3 to 203.3)	339.2 (214.3 to 493.0)	144.7 (132.0 to 159.9)	41.3 (34.0 to 49.8)
Isolated congenital heart disease due to chromosomal unbalanced rearrangements	7.6 (2.5 to 15.9)	12.5 (4.3 to 25.1)	64.1 (53.4 to 76.6)	24.7 (18.7 to 31.6)
Other congenital anomalies	2,505.6 (1,778.6 to 3,413.4)	3,486.4 (2,436.6 to 4,641.2)	38.7 (26.5 to 56.4)	4.3 (-4.6 to 17.4)
Mild hearing loss due to other congenital anomalies	39.6 (17.9 to 77.8)	56.1 (25.1 to 109.6)	41.7 (34.8 to 49.9)	-1.5 (-6.6 to 4.1)
Mild hearing loss with ringing due to other congenital anomalies	23.3 (12.6 to 37.8)	33.1 (17.8 to 53.6)	41.7 (33.8 to 51.3)	-1.5 (-7.1 to 5.2)
Moderate hearing loss due to other congenital anomalies	93.1 (53.1 to 152.0)	121.9 (70.0 to 201.8)	30.3 (10.6 to 53.7)	-6.4 (-20.4 to 10.5)
Moderate hearing loss with ringing due to other congenital anomalies	110.9 (69.8 to 163.6)	145.1 (89.7 to 215.5)	30.2 (10.8 to 53.8)	-6.3 (-20.9 to 10.8)
Moderately severe hearing loss due to other congenital anomalies	250.1 (152.1 to 373.9)	275.8 (165.4 to 416.0)	10.3 (-11.7 to 38.0)	-17.9 (-34.3 to 2.8)
Moderately severe hearing loss with ringing due to other congenital anomalies	215.2 (131.7 to 314.0)	237.3 (143.0 to 357.6)	10.1 (-12.1 to 38.8)	-18.0 (-34.4 to 2.8)
Severe hearing loss with ringing due to other congenital anomalies	284.1 (177.7 to 418.8)	339.2 (214.4 to 501.7)	19.6 (4.0 to 36.9)	-11.0 (-21.7 to 1.1)
Severe hearing loss due to other congenital anomalies	307.3 (193.4 to 447.1)	366.3 (234.1 to 539.0)	19.2 (4.4 to 36.8)	-11.5 (-22.1 to 1.4)
Profound hearing loss due to other congenital anomalies	100.1 (59.4 to 155.5)	88.0 (50.6 to 136.1)	-11.6 (-23.1 to -1.8)	-24.6 (-34.2 to -16.6)
Profound hearing loss with ringing due to other congenital anomalies	239.3 (145.9 to 365.8)	210.5 (126.6 to 320.2)	-11.6 (-23.1 to -2.5)	-24.5 (-34.3 to -17.0)
Complete hearing loss due to other congenital anomalies	146.6 (87.3 to 226.7)	155.4 (95.0 to 243.5)	6.2 (-1.4 to 13.5)	-22.2 (-26.9 to -17.6)
Complete hearing loss with ringing due to other congenital anomalies	255.9 (157.7 to 385.7)	270.9 (169.3 to 411.4)	5.9 (-0.7 to 13.1)	-22.3 (-26.8 to -17.7)
Other congenital anomalies	439.5 (271.8 to 632.1)	1,185.0 (720.3 to 1,715.9)	169.3 (139.4 to 205.5)	103.3 (76.9 to 136.5)
Skin and subcutaneous diseases	28,468.2 (18,179.1 to 43,741.2)	39,051.0 (25,044.5 to 60,125.8)	37.3 (33.8 to 40.3)	0.3 (-2.0 to 2.3)
Dermatitis	6,780.1 (4,422.6 to 9,744.8)	9,278.4 (6,029.0 to 13,326.7)	36.8 (34.7 to 39.2)	-0.6 (-1.4 to 0.3)
Mild eczema	1,013.8 (558.4 to 1,646.7)	1,312.2 (724.8 to 2,143.1)	29.4 (26.1 to 32.4)	0.6 (-0.7 to 2.3)
Moderate eczema	790.4 (389.7 to 1,312.0)	1,022.5 (503.0 to 1,692.8)	29.5 (25.7 to 32.4)	0.8 (-1.2 to 3.0)
Severe eczema	1,006.8 (490.2 to 1,676.6)	1,300.1 (627.7 to 2,179.2)	29.1 (24.8 to 33.4)	0.9 (-2.0 to 3.4)
Asymptomatic contact dermatitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild contact dermatitis	1,124.7 (624.1 to 1,838.3)	1,646.5 (911.8 to 2,696.8)	46.3 (43.9 to 49.7)	-0.3 (-1.0 to 0.4)
Severe contact dermatitis	1,235.8 (660.0 to 1,995.9)	1,807.9 (958.1 to 2,920.7)	46.2 (43.1 to 50.1)	-0.2 (-1.5 to 1.2)
Asymptomatic seborrhoeic dermatitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Symptomatic seborrhoeic dermatitis	1,608.5 (844.8 to 2,740.6)	2,189.2 (1,151.8 to 3,728.4)	36.2 (31.6 to 40.5)	-3.4 (-4.5 to -2.0)
Psoriasis	3,238.8 (2,241.2 to 4,538.5)	4,726.7 (3,254.7 to 6,621.9)	45.9 (43.2 to 48.8)	-1.9 (-3.0 to -0.6)
Mild psoriasis	823.7 (463.7 to 1,305.9)	1,202.9 (678.1 to 1,901.5)	45.9 (43.7 to 49.0)	-2.0 (-2.9 to -1.1)
Moderate psoriasis	770.8 (421.7 to 1,283.4)	1,125.0 (626.1 to 1,883.3)	45.9 (42.5 to 49.2)	-1.9 (-3.6 to -0.3)
Severe psoriasis	1,644.3 (934.8 to 2,577.6)	2,398.8 (1,362.1 to 3,797.3)	45.9 (42.4 to 49.6)	-1.8 (-3.6 to 0.2)
Cellulitis	101.3 (66.0 to 143.8)	120.2 (78.6 to 170.2)	18.6 (11.3 to 26.6)	-18.0 (-21.9 to -13.8)
Mild cellulitis	25.5 (14.2 to 41.3)	30.2 (16.8 to 49.9)	18.8 (10.6 to 26.5)	-18.1 (-22.2 to -14.3)
Severe cellulitis	75.8 (47.4 to 111.4)	90.0 (56.4 to 132.3)	18.6 (10.4 to 27.6)	-17.9 (-22.7 to -13.0)
Pyoderma	35.1 (13.5 to 78.2)	32.6 (12.4 to 72.1)	-7.1 (-16.3 to 2.9)	-24.0 (-29.8 to -17.7)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Impetigo	25.5 (9.8 to 57.3)	18.0 (6.9 to 39.1)	-29.5 (-34.9 to -23.3)	-38.5 (-42.9 to -33.4)
Abscess and other bacterial skin diseases	9.6 (3.6 to 20.3)	14.6 (5.3 to 31.7)	51.5 (41.4 to 62.6)	5.1 (0.8 to 10.7)
Scabies	1,358.2 (773.6 to 2,213.9)	1,705.4 (967.2 to 2,711.6)	24.8 (14.8 to 40.3)	-3.7 (-11.2 to 7.8)
Fungal skin diseases	2,666.6 (1,080.6 to 5,642.5)	3,847.2 (1,574.5 to 8,139.8)	44.1 (41.1 to 47.9)	3.3 (2.2 to 4.1)
Tinea capitis	758.6 (306.8 to 1,600.4)	1,034.8 (416.8 to 2,171.9)	36.4 (33.4 to 39.8)	10.2 (8.5 to 12.0)
Other fungal skin diseases	1,907.9 (778.8 to 4,144.4)	2,812.4 (1,148.0 to 6,049.9)	47.2 (43.2 to 52.1)	1.0 (-0.2 to 1.8)
Viral skin diseases	3,281.0 (1,988.2 to 5,074.6)	3,955.0 (2,398.4 to 6,150.9)	20.4 (17.8 to 24.1)	-1.7 (-3.0 to 0.0)
Mild molluscum contagiosum	49.2 (19.4 to 102.4)	59.5 (23.7 to 124.2)	21.0 (15.2 to 27.0)	1.9 (-2.9 to 7.0)
Severe molluscum contagiosum	416.7 (262.5 to 626.6)	503.8 (315.7 to 749.9)	21.0 (14.9 to 27.4)	2.0 (-3.0 to 7.2)
Mild viral warts	297.5 (115.2 to 643.9)	358.3 (138.8 to 790.8)	20.3 (17.4 to 24.9)	-2.3 (-3.5 to -0.6)
Severe viral warts	2,517.6 (1,466.8 to 3,897.6)	3,033.4 (1,758.8 to 4,687.1)	20.2 (17.3 to 24.8)	-2.2 (-3.4 to -0.6)
Acne vulgaris	5,827.3 (2,751.2 to 10,849.4)	7,180.8 (3,451.6 to 13,214.1)	23.2 (13.7 to 32.7)	-0.3 (-7.7 to 7.4)
Alopecia areata	200.9 (128.6 to 296.8)	292.4 (186.8 to 435.2)	45.6 (41.2 to 50.0)	-0.9 (-3.6 to 1.8)
Mild alopecia areata	36.4 (16.9 to 67.7)	53.1 (24.7 to 100.1)	45.8 (41.4 to 50.2)	-0.8 (-3.7 to 2.0)
Severe alopecia areata	164.4 (104.1 to 246.3)	239.4 (149.6 to 359.6)	45.6 (41.1 to 50.2)	-0.9 (-3.7 to 2.1)
Pruritus	7.0 (3.3 to 13.0)	10.8 (5.1 to 20.0)	54.8 (44.9 to 64.9)	0.0 (-6.4 to 6.5)
Urticaria	2,950.6 (1,942.6 to 4,156.5)	4,720.7 (3,036.5 to 6,737.2)	60.7 (43.4 to 75.5)	7.7 (-3.5 to 17.6)
Mild urticaria	979.4 (568.6 to 1,571.7)	1,567.6 (872.5 to 2,521.6)	60.6 (43.5 to 75.4)	7.7 (-3.7 to 17.2)
Severe urticaria	1,971.3 (1,130.7 to 3,031.7)	3,153.1 (1,819.7 to 4,933.3)	60.6 (43.5 to 75.5)	7.8 (-3.3 to 17.6)
Decubitus ulcer	175.5 (123.2 to 236.8)	277.5 (196.0 to 371.2)	58.1 (49.8 to 66.8)	-7.7 (-12.9 to -2.5)
Mild decubitus ulcer	3.3 (1.6 to 6.2)	5.3 (2.5 to 10.0)	59.0 (49.9 to 68.1)	-7.8 (-13.3 to -2.1)
Moderate decubitus ulcer	28.8 (18.7 to 41.6)	45.7 (29.5 to 66.1)	58.6 (50.3 to 67.6)	-7.8 (-13.0 to -2.3)
Severe decubitus ulcer	143.4 (94.2 to 200.1)	226.6 (150.9 to 316.6)	58.0 (49.4 to 66.8)	-7.8 (-13.1 to -2.3)
Other skin and subcutaneous diseases	1,845.9 (813.2 to 3,788.1)	2,903.1 (1,274.1 to 6,123.6)	57.0 (48.5 to 64.5)	0.4 (-0.6 to 1.3)
Asymptomatic other skin and subcutaneous diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Symptomatic other skin and subcutaneous diseases	1,845.9 (817.2 to 3,773.3)	2,903.1 (1,278.8 to 6,111.5)	57.0 (48.5 to 64.3)	0.4 (-0.6 to 1.2)
Sense organ diseases	36,935.8 (24,931.1 to 51,451.4)	54,428.1 (36,458.4 to 76,075.4)	47.4 (44.1 to 50.1)	-8.2 (-9.7 to -6.7)
Glaucoma	495.7 (350.7 to 676.5)	807.5 (571.6 to 1,102.8)	63.1 (54.8 to 70.9)	-4.6 (-9.7 to -0.2)
Moderate vision impairment due to glaucoma	129.0 (79.9 to 199.0)	210.5 (126.3 to 323.7)	63.0 (45.7 to 79.7)	-1.4 (-11.6 to 8.3)
Severe vision impairment due to glaucoma	91.8 (63.5 to 127.6)	162.1 (111.5 to 225.2)	77.3 (54.3 to 98.2)	4.2 (-8.7 to 16.7)
Blindness due to glaucoma	274.9 (187.2 to 380.6)	434.9 (298.3 to 606.5)	58.2 (50.2 to 66.5)	-8.7 (-13.5 to -4.0)
Cataract	1,860.6 (1,314.9 to 2,546.8)	2,916.7 (2,055.1 to 3,962.2)	56.7 (50.6 to 63.9)	-12.5 (-15.7 to -8.6)
Moderate vision impairment due to cataract	622.5 (379.5 to 951.4)	890.9 (553.1 to 1,352.9)	42.8 (35.7 to 53.6)	-19.9 (-23.7 to -14.2)
Severe vision impairment due to cataract	492.5 (337.9 to 679.1)	774.9 (532.9 to 1,067.5)	57.3 (47.4 to 69.7)	-11.8 (-16.9 to -5.3)
Blindness due to cataract	745.6 (516.2 to 1,026.4)	1,250.8 (864.0 to 1,716.6)	67.6 (59.4 to 77.0)	-7.1 (-11.6 to -2.3)
Macular degeneration	412.9 (288.5 to 568.2)	725.6 (509.4 to 985.1)	75.0 (69.0 to 87.8)	-4.4 (-8.6 to 1.4)
Moderate vision impairment due to macular degeneration	182.3 (111.2 to 279.6)	324.1 (198.6 to 496.3)	77.3 (69.7 to 90.8)	0.5 (-4.0 to 7.9)
Severe vision impairment due to macular degeneration	127.4 (85.6 to 177.6)	242.6 (165.0 to 337.6)	90.1 (80.1 to 105.0)	7.1 (1.1 to 14.9)
Blindness due to macular degeneration	103.2 (67.4 to 146.0)	158.8 (103.1 to 224.4)	54.2 (41.3 to 65.0)	-22.4 (-29.1 to -17.1)
Uncorrected refractive error	7,831.1 (5,020.3 to 11,995.7)	11,257.2 (7,149.8 to 17,452.3)	43.5 (40.4 to 47.2)	-8.9 (-10.6 to -7.0)
Moderate vision impairment due to uncorrected refractive error	1,855.0 (1,135.4 to 2,835.6)	2,344.4 (1,422.3 to 3,591.7)	26.3 (24.3 to 28.5)	-16.8 (-18.1 to -15.7)
Severe vision impairment due to uncorrected refractive error	1,176.0 (826.9 to 1,639.9)	1,646.8 (1,149.0 to 2,300.2)	40.1 (36.7 to 43.5)	-12.8 (-14.7 to -10.9)
Blindness due to uncorrected refractive error	1,202.2 (830.5 to 1,636.0)	1,615.4 (1,119.9 to 2,197.0)	34.4 (31.5 to 37.5)	-12.2 (-13.8 to -10.4)
Near vision impairment due to presbyopia due to uncorrected refractive error	3,597.9 (1,707.8 to 6,569.1)	5,650.6 (2,674.7 to 10,512.5)	57.0 (53.4 to 60.9)	-2.6 (-4.7 to -0.2)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Age-related and other hearing loss	21,632.6 (14,573.0 to 30,119.1)	32,579.7 (22,083.7 to 45,846.1)	50.7 (45.4 to 54.8)	-7.9 (-10.2 to -5.4)
Mild hearing loss due to age-related and other hearing loss	3,428.9 (1,539.6 to 6,572.1)	5,317.5 (2,382.3 to 10,158.4)	54.9 (51.5 to 59.3)	-6.6 (-8.4 to -4.3)
Mild hearing loss with ringing due to age-related and other hearing loss	2,021.7 (1,121.9 to 3,316.4)	3,135.0 (1,738.6 to 5,139.0)	54.9 (51.4 to 59.2)	-6.6 (-8.5 to -4.3)
Moderate hearing loss due to age-related and other hearing loss	3,068.5 (1,781.4 to 4,778.7)	4,974.4 (2,895.7 to 7,815.0)	62.2 (57.4 to 66.9)	-3.1 (-5.6 to -0.5)
Moderate hearing loss with ringing due to age-related and other hearing loss	3,637.2 (2,352.2 to 5,275.7)	5,895.8 (3,851.9 to 8,492.0)	62.2 (57.2 to 67.1)	-3.1 (-5.5 to -0.5)
Moderately severe hearing loss due to age-related and other hearing loss	3,100.2 (2,102.2 to 4,251.3)	4,601.4 (3,148.5 to 6,376.9)	48.5 (39.0 to 58.2)	-11.8 (-16.3 to -7.2)
Moderately severe hearing loss with ringing due to age-related and other hearing loss	2,659.7 (1,801.8 to 3,689.5)	3,945.5 (2,674.2 to 5,482.3)	48.5 (38.4 to 58.2)	-11.7 (-16.6 to -7.2)
Severe hearing loss with ringing due to age-related and other hearing loss	920.1 (602.8 to 1,316.6)	1,304.5 (846.8 to 1,910.9)	41.4 (25.5 to 62.1)	-7.2 (-16.6 to 6.1)
Severe hearing loss due to age-related and other hearing loss	997.1 (638.0 to 1,445.5)	1,412.6 (889.3 to 2,103.4)	41.4 (26.0 to 60.0)	-7.4 (-17.0 to 6.6)
Profound hearing loss due to age-related and other hearing loss	163.7 (84.2 to 280.0)	138.1 (71.0 to 240.8)	-15.5 (-30.4 to -0.3)	-25.8 (-38.1 to -13.0)
Profound hearing loss with ringing due to age-related and other hearing loss	390.6 (210.5 to 635.2)	329.0 (179.0 to 531.9)	-15.6 (-29.1 to -1.6)	-25.9 (-37.6 to -13.2)
Complete hearing loss due to age-related and other hearing loss	454.3 (282.8 to 691.3)	557.2 (341.1 to 853.2)	22.6 (12.3 to 35.1)	-18.6 (-23.5 to -12.6)
Complete hearing loss with ringing due to age-related and other hearing loss	790.5 (489.3 to 1,169.6)	968.6 (607.5 to 1,440.7)	22.9 (11.9 to 34.0)	-18.5 (-23.2 to -13.2)
Other vision loss	1,450.4 (1,013.3 to 1,978.1)	1,793.5 (1,260.4 to 2,452.0)	23.7 (19.4 to 27.6)	-21.1 (-23.5 to -19.0)
Moderate vision impairment due to other vision loss	487.6 (300.7 to 755.1)	571.9 (349.2 to 885.3)	17.3 (12.7 to 21.9)	-22.3 (-25.8 to -19.3)
Severe vision impairment due to other vision loss	276.8 (191.4 to 383.2)	362.7 (252.4 to 506.0)	30.9 (23.0 to 39.4)	-18.3 (-23.9 to -13.2)
Blindness due to other vision loss	686.0 (457.1 to 974.4)	858.9 (570.3 to 1,218.8)	25.3 (19.2 to 31.1)	-21.3 (-24.5 to -18.5)
Other sense organ diseases	3,252.5 (2,022.4 to 4,819.0)	4,348.0 (2,704.3 to 6,435.1)	33.7 (31.7 to 35.8)	0.1 (-1.3 to 1.6)
Asymptomatic other sense organ diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Mild other sense organ diseases	78.9 (25.7 to 181.9)	105.6 (34.6 to 242.6)	33.8 (31.6 to 36.1)	0.1 (-1.4 to 1.7)
Moderate other sense organ diseases	372.8 (178.2 to 722.2)	498.8 (238.1 to 959.0)	33.8 (31.9 to 36.0)	0.0 (-1.3 to 1.5)
Severe other sense organ diseases	2,800.8 (1,656.5 to 4,181.6)	3,743.6 (2,223.7 to 5,623.2)	33.7 (31.6 to 35.9)	0.1 (-1.2 to 1.7)
Oral disorders	11,133.6 (6,772.8 to 17,128.8)	16,449.5 (10,022.3 to 25,506.3)	47.6 (45.8 to 49.7)	-7.7 (-9.7 to -5.5)
Deciduous caries	171.2 (75.0 to 333.8)	181.1 (79.0 to 350.9)	5.7 (4.1 to 7.5)	-0.9 (-2.3 to 0.8)
Asymptomatic deciduous caries	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Tooth pain due to deciduous caries	171.2 (75.0 to 333.3)	181.1 (79.1 to 349.7)	5.7 (4.1 to 7.4)	-0.8 (-2.3 to 0.9)
Permanent caries	1,715.4 (795.3 to 3,288.8)	2,411.0 (1,102.6 to 4,664.5)	40.5 (38.3 to 43.0)	1.8 (0.1 to 3.7)
Asymptomatic permanent caries	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Tooth pain due to permanent caries	1,715.4 (798.1 to 3,284.2)	2,411.0 (1,111.0 to 4,661.5)	40.5 (38.3 to 43.0)	1.8 (0.1 to 3.7)
Periodontal diseases	1,969.0 (794.1 to 4,043.2)	3,286.0 (1,318.3 to 6,750.3)	66.8 (63.8 to 70.3)	1.7 (-0.2 to 3.7)
Edentulism and severe tooth loss	4,709.5 (3,198.8 to 6,503.1)	6,855.6 (4,647.2 to 9,420.4)	45.6 (43.3 to 47.9)	-16.2 (-17.6 to -14.9)
Asymptomatic edentulism and severe tooth loss	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Difficulty eating due to edentulism and severe tooth loss	4,709.5 (3,203.5 to 6,499.0)	6,855.6 (4,652.3 to 9,418.0)	45.6 (43.3 to 47.9)	-16.2 (-17.5 to -14.9)
Other oral disorders	2,568.5 (1,626.5 to 3,812.4)	3,715.7 (2,347.5 to 5,558.6)	44.6 (42.2 to 46.9)	-0.3 (-1.9 to 1.2)
Mild other oral disorders	220.9 (86.9 to 472.1)	319.5 (126.2 to 682.2)	44.7 (42.3 to 47.1)	-0.3 (-1.9 to 1.2)
Severe other oral disorders	2,347.6 (1,486.6 to 3,491.9)	3,396.2 (2,153.7 to 5,056.7)	44.7 (42.3 to 46.9)	-0.3 (-1.9 to 1.2)
Injuries	36,971.0 (27,321.3 to 49,304.4)	36,831.5 (26,895.7 to 48,748.0)	0.3 (-13.7 to 11.3)	-37.0 (-45.4 to -30.0)
Transport injuries	9,576.2 (7,215.2 to 12,357.8)	10,194.9 (7,477.9 to 13,437.8)	6.2 (-1.0 to 14.5)	-31.7 (-36.2 to -26.8)
Road injuries	8,012.3 (6,024.4 to 10,315.8)	8,593.4 (6,305.9 to 11,313.7)	6.9 (-0.7 to 15.8)	-31.0 (-35.8 to -25.8)
Pedestrian road injuries	1,931.8 (1,452.8 to 2,485.6)	2,271.8 (1,657.1 to 2,993.5)	17.2 (8.9 to 27.0)	-23.6 (-28.5 to -17.8)
Cyclist road injuries	789.2 (591.6 to 1,025.0)	812.4 (594.6 to 1,074.2)	2.8 (-3.5 to 9.9)	-33.9 (-37.9 to -29.5)
Amputations	5.5 (5.4 to 5.6)	4.1 (3.9 to 4.2)	-0.3 (-0.3 to -0.2)	-0.5 (-0.5 to -0.4)
Burns	4.1 (3.8 to 4.5)	4.0 (3.7 to 4.3)	-0.0 (-0.1 to 0.0)	-0.3 (-0.3 to -0.3)
Fractures	518.8 (503.2 to 538.7)	581.3 (562.9 to 605.0)	0.1 (0.1 to 0.1)	-0.2 (-0.2 to -0.2)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Head Injury	72.0 (69.0 to 76.1)	86.4 (82.7 to 91.3)	0.2 (0.2 to 0.2)	-0.2 (-0.2 to -0.1)
Minor Injury	21.2 (19.2 to 25.4)	24.2 (22.3 to 27.7)	0.1 (0.1 to 0.2)	-0.2 (-0.2 to -0.2)
Other Injury	140.7 (135.3 to 147.2)	87.5 (82.6 to 93.2)	-0.4 (-0.4 to -0.4)	-0.6 (-0.6 to -0.5)
Spinal Lesions	25.7 (25.2 to 26.1)	24.0 (23.3 to 24.6)	-0.1 (-0.1 to -0.0)	-0.3 (-0.4 to -0.3)
Motorcyclist road injuries	1,718.1 (1,288.4 to 2,238.3)	1,649.2 (1,201.7 to 2,204.5)	-4.2 (-12.2 to 5.1)	-38.2 (-43.1 to -32.5)
Amputations	53.0 (51.7 to 54.3)	39.5 (38.1 to 40.8)	-0.3 (-0.3 to -0.2)	-0.5 (-0.5 to -0.4)
Burns	11.1 (10.5 to 11.9)	11.3 (10.7 to 12.0)	0.0 (-0.0 to 0.1)	-0.3 (-0.3 to -0.2)
Fractures	796.9 (775.9 to 821.8)	951.3 (927.0 to 979.3)	0.2 (0.2 to 0.2)	-0.2 (-0.2 to -0.1)
Head Injury	125.9 (122.1 to 130.4)	150.7 (146.2 to 155.7)	0.2 (0.2 to 0.2)	-0.2 (-0.2 to -0.1)
Minor Injury	59.9 (56.1 to 66.7)	75.3 (71.2 to 81.7)	0.3 (0.2 to 0.3)	-0.1 (-0.1 to -0.1)
Other Injury	598.1 (578.3 to 621.7)	357.0 (339.4 to 377.9)	-0.4 (-0.4 to -0.4)	-0.6 (-0.6 to -0.6)
Spinal Lesions	71.4 (69.9 to 72.8)	61.6 (59.8 to 63.3)	-0.1 (-0.2 to -0.1)	-0.4 (-0.4 to -0.4)
Motor vehicle road injuries	3,486.2 (2,627.7 to 4,470.0)	3,777.8 (2,811.0 to 4,946.9)	8.1 (0.3 to 16.7)	-30.9 (-35.6 to -25.8)
Amputations	28.5 (28.1 to 28.9)	25.1 (24.5 to 25.6)	-0.1 (-0.1 to -0.1)	-0.3 (-0.4 to -0.3)
Burns	7.9 (7.5 to 8.6)	9.7 (9.1 to 10.4)	0.2 (0.2 to 0.3)	-0.1 (-0.2 to -0.1)
Fractures	1,658.7 (1,613.8 to 1,713.9)	2,118.2 (2,063.4 to 2,189.3)	0.3 (0.3 to 0.3)	-0.1 (-0.1 to -0.1)
Head Injury	245.4 (238.2 to 254.7)	332.7 (322.7 to 344.3)	0.4 (0.3 to 0.4)	-0.0 (-0.0 to 0.0)
Minor Injury	86.0 (75.7 to 106.9)	113.1 (99.8 to 137.8)	0.3 (0.3 to 0.4)	-0.0 (-0.1 to -0.0)
Other Injury	1,222.6 (1,176.5 to 1,279.5)	969.0 (924.2 to 1,024.6)	-0.2 (-0.2 to -0.2)	-0.4 (-0.4 to -0.4)
Spinal Lesions	230.4 (226.6 to 233.9)	203.5 (199.3 to 207.7)	-0.1 (-0.1 to -0.1)	-0.4 (-0.4 to -0.3)
Other road injuries	87.1 (65.5 to 112.3)	82.3 (61.0 to 107.3)	-5.7 (-11.4 to 1.0)	-40.1 (-43.4 to -36.1)
Amputations	0.9 (0.9 to 1.0)	0.7 (0.7 to 0.8)	-0.2 (-0.2 to -0.2)	-0.4 (-0.4 to -0.4)
Burns	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	0.0 (-0.0 to 0.1)	-0.2 (-0.3 to -0.2)
Fractures	54.4 (52.9 to 56.5)	54.0 (52.3 to 56.0)	-0.0 (-0.0 to 0.0)	-0.3 (-0.3 to -0.3)
Head Injury	7.9 (7.6 to 8.2)	9.3 (8.9 to 9.6)	0.2 (0.1 to 0.2)	-0.1 (-0.2 to -0.1)
Minor Injury	2.2 (2.1 to 2.4)	2.6 (2.4 to 2.8)	0.2 (0.1 to 0.2)	-0.1 (-0.2 to -0.1)
Other Injury	16.5 (15.8 to 17.3)	10.9 (10.3 to 11.5)	-0.3 (-0.4 to -0.3)	-0.5 (-0.5 to -0.5)
Spinal Lesions	4.8 (4.7 to 4.9)	4.5 (4.3 to 4.6)	-0.1 (-0.1 to -0.0)	-0.3 (-0.4 to -0.3)
Other transport injuries	1,563.8 (1,179.0 to 2,037.5)	1,601.5 (1,173.2 to 2,118.5)	2.2 (-3.1 to 8.5)	-35.1 (-38.5 to -31.2)
Amputations	262.9 (256.3 to 269.4)	186.1 (180.0 to 192.3)	-0.3 (-0.3 to -0.3)	-0.5 (-0.5 to -0.5)
Burns	14.1 (13.2 to 15.3)	14.9 (14.0 to 15.9)	0.1 (-0.0 to 0.1)	-0.3 (-0.3 to -0.2)
Fractures	920.2 (885.4 to 959.5)	1,069.2 (1,029.1 to 1,116.6)	0.2 (0.1 to 0.2)	-0.2 (-0.2 to -0.2)
Head Injury	59.1 (57.0 to 62.0)	69.9 (67.5 to 72.7)	0.2 (0.1 to 0.2)	-0.2 (-0.2 to -0.1)
Minor Injury	29.7 (27.0 to 35.1)	35.7 (33.0 to 40.7)	0.2 (0.1 to 0.3)	-0.1 (-0.2 to -0.1)
Other Injury	234.0 (221.2 to 247.8)	191.3 (179.7 to 204.5)	-0.2 (-0.2 to -0.2)	-0.4 (-0.4 to -0.4)
Spinal Lesions	43.0 (41.5 to 44.4)	33.8 (32.8 to 35.0)	-0.2 (-0.3 to -0.2)	-0.4 (-0.5 to -0.4)
Unintentional injuries	18,321.2 (13,949.7 to 23,599.0)	21,649.4 (16,036.0 to 28,726.9)	17.9 (10.5 to 25.8)	-28.0 (-32.8 to -22.7)
Falls	10,337.1 (7,869.5 to 13,263.5)	12,818.1 (9,356.9 to 16,996.8)	23.5 (13.6 to 35.0)	-28.3 (-34.5 to -21.1)
Amputations	99.1 (97.4 to 101.1)	87.3 (85.0 to 89.6)	-0.1 (-0.1 to -0.1)	-0.3 (-0.4 to -0.3)
Burns	23.2 (22.0 to 24.8)	29.3 (28.0 to 31.0)	0.3 (0.2 to 0.3)	-0.1 (-0.1 to -0.1)
Fractures	7,431.8 (7,206.9 to 7,700.5)	9,411.9 (9,104.1 to 9,770.7)	0.3 (0.2 to 0.3)	-0.0 (-0.1 to -0.0)
Head Injury	745.6 (726.0 to 769.7)	1,121.6 (1,093.5 to 1,152.9)	0.5 (0.5 to 0.5)	0.1 (0.0 to 0.1)
Minor Injury	322.1 (296.9 to 368.4)	489.5 (455.6 to 551.8)	0.5 (0.5 to 0.6)	0.1 (0.0 to 0.1)
Other Injury	1,246.3 (1,195.9 to 1,305.8)	1,152.0 (1,099.0 to 1,220.6)	-0.1 (-0.1 to -0.1)	-0.4 (-0.4 to -0.3)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Spinal Lesions	456.5 (450.1 to 462.6)	515.5 (506.7 to 525.4)	0.1 (0.1 to 0.2)	-0.2 (-0.2 to -0.2)
Drowning	407.9 (301.2 to 529.5)	373.6 (273.4 to 485.1)	-8.6 (-13.5 to -2.4)	-37.9 (-40.9 to -34.1)
Amputations	29.4 (28.3 to 30.5)	18.6 (17.7 to 19.5)	-0.4 (-0.4 to -0.3)	-0.6 (-0.6 to -0.5)
Burns	3.0 (2.9 to 3.2)	2.7 (2.5 to 2.9)	-0.1 (-0.2 to -0.1)	-0.4 (-0.4 to -0.4)
Fractures	186.3 (181.3 to 191.5)	169.5 (164.5 to 174.9)	-0.1 (-0.1 to -0.1)	-0.4 (-0.4 to -0.4)
Head Injury	11.1 (10.7 to 11.6)	12.1 (11.6 to 12.5)	0.1 (0.0 to 0.1)	-0.2 (-0.3 to -0.2)
Minor Injury	7.9 (7.6 to 8.3)	9.6 (9.1 to 10.1)	0.2 (0.1 to 0.3)	-0.1 (-0.2 to -0.1)
Other Injury	142.9 (139.0 to 147.1)	138.0 (133.7 to 142.4)	-0.0 (-0.1 to 0.0)	-0.3 (-0.4 to -0.3)
Spinal Lesions	27.3 (26.6 to 28.1)	23.2 (22.3 to 24.1)	-0.2 (-0.2 to -0.1)	-0.4 (-0.4 to -0.4)
Fire, heat, and hot substances	1,227.6 (936.6 to 1,580.8)	1,172.2 (867.1 to 1,551.4)	-4.7 (-10.0 to 0.6)	-36.8 (-39.8 to -33.8)
Amputations	41.6 (40.0 to 43.2)	31.5 (30.2 to 32.7)	-0.2 (-0.3 to -0.2)	-0.4 (-0.5 to -0.4)
Burns	715.3 (675.4 to 766.8)	671.7 (637.3 to 709.5)	-0.1 (-0.1 to -0.0)	-0.3 (-0.4 to -0.3)
Fractures	92.5 (89.7 to 95.7)	93.2 (90.4 to 96.2)	0.0 (-0.0 to 0.0)	-0.3 (-0.3 to -0.2)
Head Injury	15.9 (15.2 to 16.7)	17.6 (16.8 to 18.3)	0.1 (0.1 to 0.2)	-0.2 (-0.2 to -0.1)
Minor Injury	43.8 (31.3 to 65.7)	43.5 (32.6 to 62.6)	-0.0 (-0.1 to 0.1)	-0.3 (-0.3 to -0.2)
Other Injury	312.5 (276.6 to 358.6)	309.2 (276.4 to 349.8)	-0.0 (-0.1 to 0.0)	-0.3 (-0.3 to -0.3)
Spinal Lesions	5.7 (5.4 to 5.9)	5.0 (4.8 to 5.2)	-0.1 (-0.2 to -0.1)	-0.4 (-0.4 to -0.3)
Poisonings	83.9 (59.9 to 112.5)	78.7 (56.2 to 104.5)	-6.3 (-9.8 to -2.7)	-36.7 (-39.0 to -34.4)
Amputations	1.3 (1.3 to 1.4)	0.8 (0.7 to 0.8)	-0.4 (-0.5 to -0.4)	-0.6 (-0.6 to -0.6)
Burns	3.0 (2.8 to 3.2)	2.8 (2.7 to 3.0)	-0.0 (-0.1 to 0.0)	-0.3 (-0.4 to -0.3)
Fractures	7.7 (7.5 to 7.9)	6.9 (6.8 to 7.1)	-0.1 (-0.1 to -0.1)	-0.4 (-0.4 to -0.4)
Head Injury	1.3 (1.3 to 1.4)	1.7 (1.6 to 1.7)	0.2 (0.2 to 0.3)	-0.1 (-0.1 to -0.1)
Minor Injury	1.0 (1.0 to 1.1)	1.2 (1.2 to 1.3)	0.2 (0.1 to 0.3)	-0.1 (-0.2 to -0.1)
Other Injury	68.9 (66.7 to 71.6)	64.7 (62.3 to 67.2)	-0.1 (-0.1 to -0.0)	-0.3 (-0.4 to -0.3)
Spinal Lesions	0.7 (0.7 to 0.7)	0.5 (0.5 to 0.6)	-0.2 (-0.2 to -0.2)	-0.4 (-0.5 to -0.4)
Exposure to mechanical forces	3,564.0 (2,696.1 to 4,652.9)	3,758.0 (2,748.6 to 4,985.4)	5.2 (0.3 to 10.4)	-30.1 (-33.0 to -26.9)
Unintentional firearm injuries	137.4 (104.8 to 174.6)	146.6 (109.0 to 194.3)	6.4 (-0.3 to 14.2)	-29.8 (-34.0 to -25.1)
Amputations	13.3 (12.9 to 13.7)	9.3 (8.9 to 9.8)	-0.3 (-0.3 to -0.3)	-0.5 (-0.5 to -0.4)
Burns	0.9 (0.9 to 1.1)	1.1 (1.0 to 1.2)	0.2 (0.1 to 0.2)	-0.2 (-0.2 to -0.1)
Fractures	58.6 (57.1 to 60.8)	65.6 (63.9 to 67.6)	0.1 (0.1 to 0.1)	-0.2 (-0.2 to -0.2)
Head Injury	4.0 (3.8 to 4.1)	5.1 (5.0 to 5.3)	0.3 (0.3 to 0.3)	-0.1 (-0.1 to -0.0)
Minor Injury	15.4 (14.6 to 16.6)	20.1 (19.2 to 21.4)	0.3 (0.2 to 0.4)	-0.1 (-0.1 to -0.0)
Other Injury	28.0 (24.6 to 32.7)	29.9 (26.2 to 34.9)	0.1 (0.0 to 0.1)	-0.2 (-0.2 to -0.2)
Spinal Lesions	16.8 (16.4 to 17.2)	14.9 (14.5 to 15.3)	-0.1 (-0.1 to -0.1)	-0.3 (-0.4 to -0.3)
Unintentional suffocation	38.1 (29.1 to 48.9)	54.2 (40.2 to 71.6)	42.2 (34.7 to 50.1)	-3.3 (-8.1 to 1.6)
Amputations	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	-0.1 (-0.2 to -0.1)
Burns	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	0.8 (0.7 to 0.9)	0.3 (0.2 to 0.3)
Fractures	26.8 (25.2 to 30.1)	36.7 (34.8 to 40.3)	0.4 (0.3 to 0.4)	-0.1 (-0.1 to -0.0)
Head Injury	1.4 (1.4 to 1.5)	2.5 (2.4 to 2.6)	0.7 (0.7 to 0.8)	0.2 (0.2 to 0.3)
Minor Injury	1.3 (1.0 to 1.7)	2.1 (1.7 to 2.7)	0.6 (0.6 to 0.7)	0.2 (0.1 to 0.2)
Other Injury	4.4 (4.0 to 5.0)	7.0 (6.4 to 7.7)	0.6 (0.5 to 0.6)	0.1 (0.1 to 0.1)
Spinal Lesions	3.9 (3.8 to 4.0)	5.6 (5.4 to 5.8)	0.4 (0.4 to 0.5)	0.0 (-0.0 to 0.1)
Other exposure to mechanical forces	3,388.5 (2,566.4 to 4,423.9)	3,557.2 (2,597.7 to 4,726.4)	4.7 (-0.1 to 9.8)	-30.4 (-33.3 to -27.3)
Amputations	155.2 (152.6 to 157.8)	124.3 (121.6 to 127.4)	-0.2 (-0.2 to -0.2)	-0.4 (-0.4 to -0.4)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Burns	36.3 (34.2 to 39.4)	39.6 (37.5 to 42.1)	0.1 (0.1 to 0.1)	-0.2 (-0.2 to -0.2)
Fractures	1,804.9 (1,739.2 to 1,878.6)	1,968.9 (1,906.2 to 2,047.8)	0.1 (0.1 to 0.1)	-0.2 (-0.2 to -0.2)
Head Injury	149.8 (142.6 to 160.0)	166.0 (159.4 to 175.2)	0.1 (0.1 to 0.1)	-0.2 (-0.2 to -0.2)
Minor Injury	396.4 (275.2 to 617.5)	452.1 (325.8 to 686.2)	0.1 (0.1 to 0.2)	-0.2 (-0.2 to -0.1)
Other Injury	764.3 (673.2 to 885.7)	741.9 (648.5 to 865.8)	-0.0 (-0.1 to -0.0)	-0.3 (-0.3 to -0.3)
Spinal Lesions	74.9 (73.5 to 76.3)	58.3 (57.1 to 59.4)	-0.2 (-0.2 to -0.2)	-0.4 (-0.5 to -0.4)
Adverse effects of medical treatment	135.4 (85.9 to 199.2)	201.0 (127.1 to 295.2)	48.4 (46.1 to 50.7)	-5.7 (-7.2 to -4.0)
Animal contact	430.1 (321.0 to 562.1)	403.5 (299.5 to 527.6)	-6.3 (-10.6 to -1.4)	-36.4 (-39.0 to -33.5)
Venomous animal contact	165.5 (120.9 to 220.0)	153.1 (110.5 to 201.1)	-7.5 (-12.6 to -2.2)	-37.1 (-40.5 to -33.6)
Amputations	5.5 (5.2 to 5.8)	3.9 (3.7 to 4.1)	-0.3 (-0.3 to -0.2)	-0.5 (-0.5 to -0.4)
Burns	3.2 (3.0 to 3.5)	2.8 (2.7 to 3.0)	-0.1 (-0.2 to -0.1)	-0.4 (-0.4 to -0.3)
Fractures	19.3 (18.6 to 20.0)	18.5 (18.0 to 19.1)	-0.0 (-0.1 to -0.0)	-0.3 (-0.3 to -0.3)
Head Injury	3.1 (2.9 to 3.3)	3.2 (3.1 to 3.4)	0.0 (-0.0 to 0.1)	-0.3 (-0.3 to -0.2)
Minor Injury	7.9 (7.2 to 8.8)	8.5 (7.9 to 9.2)	0.1 (-0.0 to 0.2)	-0.2 (-0.3 to -0.2)
Other Injury	124.7 (118.6 to 131.4)	114.8 (109.3 to 120.3)	-0.1 (-0.1 to -0.0)	-0.3 (-0.4 to -0.3)
Spinal Lesions	1.6 (1.5 to 1.7)	1.4 (1.3 to 1.5)	-0.1 (-0.2 to -0.0)	-0.4 (-0.4 to -0.3)
Non-venomous animal contact	264.6 (195.9 to 352.9)	250.5 (183.9 to 337.8)	-5.4 (-10.9 to 0.6)	-36.0 (-38.9 to -32.8)
Amputations	8.2 (7.8 to 8.5)	5.7 (5.5 to 6.0)	-0.3 (-0.3 to -0.3)	-0.5 (-0.5 to -0.5)
Burns	1.1 (1.0 to 1.2)	0.9 (0.9 to 1.0)	-0.1 (-0.2 to -0.1)	-0.4 (-0.4 to -0.3)
Fractures	70.0 (67.7 to 72.5)	78.5 (76.3 to 80.9)	0.1 (0.1 to 0.2)	-0.2 (-0.2 to -0.2)
Head Injury	12.5 (11.8 to 13.1)	12.6 (12.1 to 13.2)	0.0 (-0.0 to 0.1)	-0.3 (-0.3 to -0.2)
Minor Injury	82.8 (56.5 to 135.0)	78.1 (57.5 to 117.6)	-0.0 (-0.1 to 0.0)	-0.3 (-0.4 to -0.3)
Other Injury	86.9 (82.2 to 92.6)	71.8 (68.6 to 76.2)	-0.2 (-0.2 to -0.1)	-0.4 (-0.4 to -0.4)
Spinal Lesions	3.1 (2.9 to 3.3)	2.8 (2.6 to 2.9)	-0.1 (-0.2 to -0.0)	-0.4 (-0.4 to -0.3)
Foreign body	208.4 (154.9 to 264.3)	254.8 (186.8 to 325.0)	22.1 (16.2 to 29.0)	-19.4 (-23.3 to -15.0)
Pulmonary aspiration and foreign body in airway	51.4 (39.1 to 64.4)	50.2 (38.4 to 64.6)	-2.7 (-10.5 to 7.4)	-33.7 (-38.6 to -27.2)
Amputations	1.9 (1.9 to 1.9)	1.3 (1.2 to 1.3)	-0.3 (-0.4 to -0.3)	-0.5 (-0.5 to -0.5)
Burns	0.5 (0.5 to 0.5)	0.5 (0.5 to 0.6)	0.1 (0.0 to 0.1)	-0.3 (-0.3 to -0.2)
Fractures	22.7 (22.2 to 23.3)	21.2 (20.7 to 21.9)	-0.1 (-0.1 to -0.0)	-0.4 (-0.4 to -0.4)
Head Injury	1.1 (1.1 to 1.2)	1.7 (1.6 to 1.7)	0.5 (0.5 to 0.5)	0.0 (0.0 to 0.1)
Minor Injury	1.8 (1.8 to 1.9)	2.5 (2.5 to 2.6)	0.4 (0.3 to 0.4)	-0.0 (-0.1 to 0.0)
Other Injury	18.1 (13.4 to 24.4)	17.6 (13.5 to 22.9)	-0.0 (-0.1 to 0.0)	-0.3 (-0.4 to -0.3)
Spinal Lesions	5.2 (5.1 to 5.3)	5.2 (5.1 to 5.4)	0.0 (-0.0 to 0.0)	-0.3 (-0.3 to -0.3)
Foreign body in eyes	46.2 (27.5 to 69.8)	60.3 (35.0 to 91.7)	30.6 (26.0 to 34.9)	-10.4 (-15.4 to -6.9)
Minor Injury	1.7 (1.6 to 1.7)	2.6 (2.5 to 2.6)	0.5 (0.5 to 0.6)	0.1 (0.1 to 0.2)
Other Injury	36.1 (18.6 to 59.4)	48.9 (25.7 to 80.6)	0.4 (0.3 to 0.4)	-0.0 (-0.0 to 0.0)
Foreign body in other body part	110.8 (84.5 to 140.5)	144.3 (108.0 to 186.5)	30.1 (23.9 to 36.9)	-16.5 (-20.1 to -12.7)
Amputations	0.6 (0.6 to 0.6)	0.6 (0.6 to 0.7)	0.1 (0.1 to 0.2)	-0.2 (-0.2 to -0.1)
Burns	0.8 (0.7 to 0.8)	1.1 (1.0 to 1.2)	0.5 (0.4 to 0.5)	0.0 (-0.0 to 0.1)
Fractures	24.2 (21.8 to 29.4)	24.1 (21.2 to 30.4)	-0.0 (-0.0 to 0.0)	-0.3 (-0.3 to -0.2)
Head Injury	1.1 (1.0 to 1.2)	1.8 (1.7 to 1.9)	0.6 (0.5 to 0.6)	0.2 (0.1 to 0.2)
Minor Injury	14.3 (10.6 to 21.6)	20.7 (16.6 to 28.6)	0.5 (0.3 to 0.6)	0.1 (-0.1 to 0.2)
Other Injury	67.6 (56.7 to 81.8)	93.4 (80.3 to 109.9)	0.4 (0.3 to 0.4)	-0.0 (-0.1 to 0.0)
Spinal Lesions	2.2 (2.2 to 2.3)	2.5 (2.4 to 2.5)	0.1 (0.1 to 0.1)	-0.2 (-0.2 to -0.2)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other unintentional injuries	1,926.9 (1,441.9 to 2,543.0)	2,589.5 (1,905.1 to 3,445.3)	34.2 (29.7 to 39.1)	-16.0 (-18.5 to -13.3)
Amputations	36.4 (35.7 to 37.1)	32.6 (31.9 to 33.4)	-0.1 (-0.1 to -0.1)	-0.3 (-0.4 to -0.3)
Burns	46.1 (43.6 to 49.2)	58.3 (55.5 to 61.7)	0.3 (0.2 to 0.3)	-0.1 (-0.1 to -0.1)
Fractures	1,415.0 (1,371.1 to 1,467.6)	1,924.5 (1,867.2 to 1,995.8)	0.4 (0.3 to 0.4)	-0.0 (-0.1 to -0.0)
Head Injury	37.9 (36.4 to 39.8)	54.6 (52.6 to 57.2)	0.4 (0.4 to 0.5)	0.0 (0.0 to 0.1)
Minor Injury	66.7 (45.9 to 105.5)	92.7 (65.6 to 143.8)	0.4 (0.3 to 0.5)	-0.0 (-0.0 to 0.0)
Other Injury	298.4 (261.0 to 347.6)	392.8 (344.4 to 460.6)	0.3 (0.3 to 0.3)	-0.1 (-0.1 to -0.0)
Spinal Lesions	23.8 (23.3 to 24.3)	29.4 (28.7 to 30.1)	0.2 (0.2 to 0.3)	-0.1 (-0.1 to -0.1)
Self-harm and interpersonal violence	1,030.3 (783.5 to 1,318.9)	1,053.5 (778.0 to 1,388.0)	1.8 (-5.0 to 10.5)	-34.4 (-38.5 to -29.2)
Self-harm	234.7 (173.8 to 304.1)	231.6 (167.0 to 307.3)	-1.7 (-6.9 to 5.4)	-39.0 (-42.2 to -34.8)
Amputations	26.0 (25.6 to 26.4)	13.2 (13.0 to 13.4)	-0.5 (-0.5 to -0.5)	-0.6 (-0.6 to -0.6)
Burns	9.2 (8.7 to 9.9)	7.2 (6.8 to 7.6)	-0.2 (-0.2 to -0.2)	-0.4 (-0.5 to -0.4)
Fractures	34.1 (33.5 to 34.8)	34.4 (33.8 to 35.1)	0.0 (-0.0 to 0.0)	-0.3 (-0.3 to -0.2)
Head Injury	7.6 (7.4 to 7.9)	9.6 (9.4 to 9.9)	0.3 (0.2 to 0.3)	-0.1 (-0.1 to -0.1)
Minor Injury	27.6 (26.8 to 28.5)	34.2 (33.0 to 35.4)	0.2 (0.2 to 0.3)	-0.1 (-0.2 to -0.1)
Other Injury	121.0 (118.2 to 124.3)	125.3 (122.3 to 128.8)	0.0 (0.0 to 0.1)	-0.3 (-0.3 to -0.2)
Spinal Lesions	8.7 (8.6 to 8.8)	7.5 (7.4 to 7.6)	-0.1 (-0.2 to -0.1)	-0.4 (-0.4 to -0.4)
Interpersonal violence	795.6 (608.6 to 1,010.3)	821.9 (610.4 to 1,077.7)	2.8 (-4.5 to 12.0)	-33.0 (-37.4 to -27.3)
Assault by firearm	133.5 (101.8 to 172.0)	163.1 (120.0 to 216.6)	21.9 (14.8 to 29.8)	-21.1 (-25.4 to -16.5)
Amputations	1.8 (1.8 to 1.8)	1.6 (1.5 to 1.6)	-0.1 (-0.2 to -0.1)	-0.4 (-0.4 to -0.3)
Burns	0.3 (0.3 to 0.4)	0.4 (0.4 to 0.5)	0.4 (0.3 to 0.5)	0.0 (-0.1 to 0.1)
Fractures	54.7 (53.2 to 56.6)	73.1 (71.0 to 75.7)	0.3 (0.3 to 0.4)	-0.0 (-0.1 to -0.0)
Head Injury	5.4 (5.0 to 5.9)	8.6 (8.0 to 9.4)	0.6 (0.6 to 0.6)	0.2 (0.1 to 0.2)
Minor Injury	13.8 (12.9 to 15.1)	20.5 (19.4 to 22.0)	0.5 (0.4 to 0.6)	0.1 (0.0 to 0.2)
Other Injury	35.6 (33.1 to 38.8)	38.0 (35.3 to 41.6)	0.1 (0.0 to 0.1)	-0.2 (-0.3 to -0.2)
Spinal Lesions	21.6 (21.0 to 22.2)	20.4 (19.8 to 20.9)	-0.1 (-0.1 to -0.0)	-0.3 (-0.3 to -0.3)
Assault by sharp object	144.8 (109.7 to 187.8)	172.3 (124.9 to 233.2)	18.5 (10.8 to 28.0)	-22.9 (-27.6 to -17.2)
Amputations	12.9 (12.7 to 13.2)	10.1 (9.8 to 10.4)	-0.2 (-0.2 to -0.2)	-0.4 (-0.4 to -0.4)
Burns	0.7 (0.6 to 0.8)	0.9 (0.8 to 1.0)	0.3 (0.2 to 0.3)	-0.1 (-0.1 to -0.1)
Fractures	22.9 (22.1 to 23.9)	30.3 (29.3 to 31.6)	0.3 (0.3 to 0.3)	-0.0 (-0.1 to -0.0)
Head Injury	4.9 (4.7 to 5.1)	7.8 (7.5 to 8.2)	0.6 (0.5 to 0.6)	0.1 (0.1 to 0.2)
Minor Injury	30.4 (28.1 to 34.4)	43.5 (40.9 to 47.8)	0.4 (0.4 to 0.5)	0.0 (-0.0 to 0.1)
Other Injury	63.3 (59.2 to 68.4)	69.6 (65.2 to 75.3)	0.1 (0.1 to 0.1)	-0.2 (-0.2 to -0.2)
Spinal Lesions	9.4 (9.1 to 9.6)	9.8 (9.5 to 10.1)	0.0 (0.0 to 0.1)	-0.2 (-0.3 to -0.2)
Assault by other means	517.4 (394.6 to 658.9)	486.5 (364.2 to 635.7)	-6.4 (-12.9 to 2.4)	-38.8 (-42.9 to -33.4)
Amputations	15.5 (15.2 to 15.8)	11.3 (11.0 to 11.6)	-0.3 (-0.3 to -0.2)	-0.5 (-0.5 to -0.4)
Burns	14.8 (14.0 to 16.1)	15.3 (14.5 to 16.4)	0.0 (-0.0 to 0.1)	-0.3 (-0.3 to -0.2)
Fractures	169.1 (162.9 to 176.3)	184.6 (177.6 to 192.4)	0.1 (0.1 to 0.1)	-0.2 (-0.2 to -0.2)
Head Injury	57.6 (55.4 to 60.7)	73.3 (70.6 to 76.8)	0.3 (0.2 to 0.3)	-0.1 (-0.1 to -0.1)
Minor Injury	31.1 (27.2 to 39.0)	36.5 (32.6 to 43.8)	0.2 (0.1 to 0.2)	-0.2 (-0.2 to -0.1)
Other Injury	206.5 (196.2 to 219.9)	144.0 (134.5 to 155.7)	-0.3 (-0.3 to -0.3)	-0.5 (-0.5 to -0.5)
Spinal Lesions	22.0 (21.5 to 22.5)	21.1 (20.5 to 21.7)	-0.0 (-0.1 to -0.0)	-0.3 (-0.3 to -0.3)
Forces of nature, war, and legal intervention	8,043.3 (3,543.7 to 16,294.9)	3,933.7 (1,860.7 to 7,821.0)	-50.7 (-57.7 to -40.2)	-67.9 (-72.6 to -61.0)
Exposure to forces of nature	552.1 (300.0 to 1,019.7)	556.8 (280.6 to 1,117.0)	-0.7 (-15.1 to 22.3)	-36.7 (-45.8 to -22.0)

Appendix Table G.2: YLD numbers and age-standardized rates with percent change between 1990 and 2013 for all causes and sequelae (statistically significant % change shown in bold)

	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Amputations	21.3 (18.5 to 24.3)	19.0 (17.4 to 20.8)	-0.1 (-0.2 to 0.1)	-0.4 (-0.5 to -0.3)
Burns	94.7 (85.8 to 104.6)	89.6 (83.3 to 95.9)	-0.1 (-0.2 to 0.1)	-0.3 (-0.4 to -0.2)
Fractures	140.5 (127.7 to 153.6)	110.1 (104.4 to 115.9)	-0.2 (-0.3 to -0.1)	-0.4 (-0.5 to -0.4)
Head Injury	15.0 (13.3 to 16.9)	17.3 (16.0 to 18.6)	0.2 (-0.0 to 0.3)	-0.2 (-0.3 to -0.0)
Minor Injury	11.3 (10.0 to 12.6)	13.7 (12.7 to 14.7)	0.2 (0.1 to 0.4)	-0.1 (-0.3 to -0.0)
Other Injury	271.8 (233.7 to 339.3)	299.9 (269.3 to 353.4)	0.1 (-0.1 to 0.3)	-0.2 (-0.3 to -0.1)
Spinal Lesions	12.6 (11.3 to 14.0)	12.0 (11.1 to 12.9)	-0.0 (-0.2 to 0.1)	-0.3 (-0.4 to -0.2)
Collective violence and legal intervention	7,491.1 (3,161.9 to 15,524.8)	3,376.9 (1,547.3 to 6,784.6)	-54.6 (-60.2 to -46.1)	-70.3 (-74.2 to -64.5)
Amputations	176.1 (158.2 to 195.0)	93.8 (86.5 to 100.9)	-0.5 (-0.5 to -0.4)	-0.7 (-0.7 to -0.6)
Burns	64.5 (57.4 to 72.2)	38.7 (34.3 to 43.8)	-0.4 (-0.5 to -0.3)	-0.6 (-0.7 to -0.6)
Fractures	3,604.1 (3,241.9 to 4,132.0)	1,658.4 (1,525.0 to 1,811.6)	-0.5 (-0.6 to -0.5)	-0.7 (-0.7 to -0.7)
Head Injury	148.6 (134.4 to 164.4)	106.9 (95.9 to 119.1)	-0.3 (-0.4 to -0.2)	-0.5 (-0.6 to -0.5)
Minor Injury	134.9 (116.4 to 163.7)	106.2 (95.2 to 120.1)	-0.2 (-0.3 to -0.1)	-0.5 (-0.6 to -0.4)
Other Injury	3,344.4 (3,050.2 to 3,630.1)	1,309.5 (1,224.7 to 1,412.9)	-0.6 (-0.6 to -0.6)	-0.7 (-0.8 to -0.7)
Spinal Lesions	358.6 (321.0 to 395.5)	224.2 (202.5 to 244.4)	-0.4 (-0.5 to -0.3)	-0.6 (-0.7 to -0.5)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (0-6 days)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
All causes	-	-	-	120.1 (84.1 to 163.0)	111.7 (78.5 to 153.5)	-7.0 (-12.1 to -1.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	98.7 (67.9 to 135.6)	92.7 (63.4 to 129.2)	-6.1 (-12.3 to 1.0)
HIV/AIDS and tuberculosis	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.3 (-2.0 to 4.7)
Tuberculosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.3 (-2.0 to 4.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.3 (-2.0 to 4.7)
HIV/AIDS	-	-	-	-	-	-
HIV/AIDS resulting in mycobacterial infection	-	-	-	-	-	-
HIV/AIDS resulting in other diseases	-	-	-	-	-	-
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	20.4 (13.9 to 28.6)	15.2 (10.2 to 20.8)	-25.0 (-34.6 to -20.4)
Diarrheal diseases	90.1 (87.5 to 92.6)	78.9 (75.9 to 81.9)	-12.4 (-16.4 to -8.1)	14.8 (10.1 to 20.4)	13.0 (8.7 to 17.9)	-12.3 (-16.2 to -7.9)
Intestinal infectious diseases	-	-	-	-	-	-
Typhoid fever	-	-	-	-	-	-
Paratyphoid fever	-	-	-	-	-	-
Other intestinal infectious diseases	-	-	-	-	-	-
Lower respiratory infections	30.9 (30.0 to 31.8)	16.7 (16.2 to 17.3)	-46.0 (-48.3 to -43.5)	3.3 (2.2 to 4.7)	1.8 (1.2 to 2.5)	-46.0 (-48.4 to -43.1)
Upper respiratory infections	1.2 (1.2 to 1.3)	1.3 (1.2 to 1.3)	7.4 (1.7 to 14.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.1 (-11.3 to 27.9)
Otitis media	0.8 (0.7 to 0.8)	0.7 (0.7 to 0.7)	-11.6 (-14.8 to -7.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.3 (-18.3 to -3.5)
Meningitis	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.9 (-55.1 to -40.7)
Pneumococcal meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.4 (-50.9 to -42.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.6 (-49.2 to -40.0)
H influenzae type B meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.6 (-50.9 to -40.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.3 (-48.5 to -38.0)
Meningococcal meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.9 (-54.3 to -42.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.5 (-54.1 to -42.3)
Other meningitis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-50.0 (-52.8 to -47.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.9 (-57.6 to -39.6)
Encephalitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.8 (-40.8 to -33.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.4 (-35.8 to -31.3)
Diphtheria	-	-	-	-	-	-
Whooping cough	-	-	-	-	-	-
Tetanus	17.0 (11.0 to 34.6)	2.5 (0.9 to 4.8)	-84.9 (-96.6 to -65.4)	2.2 (1.2 to 4.7)	0.3 (0.1 to 0.6)	-84.9 (-96.7 to -64.4)
Measles	-	-	-	-	-	-
Varicella and herpes zoster	7.9 (7.4 to 8.4)	7.4 (7.0 to 7.9)	-5.4 (-13.7 to 2.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-5.3 (-14.4 to 3.8)
Neglected tropical diseases and malaria	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.2 (3.3 to 75.5)
Malaria	19.4 (17.7 to 21.5)	23.6 (21.1 to 26.5)	21.7 (3.2 to 39.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.2 (3.3 to 75.5)
Chagas disease	-	-	-	-	-	-
Leishmaniasis	-	-	-	-	-	-
Visceral leishmaniasis	-	-	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	-	-	-	-
African trypanosomiasis	-	-	-	-	-	-
Schistosomiasis	-	-	-	-	-	-
Cysticercosis	-	-	-	-	-	-
Cystic echinococcosis	-	-	-	-	-	-
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	-	-	-
Onchocerciasis	-	-	-	-	-	-
Trachoma	-	-	-	-	-	-
Dengue	-	-	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	-	-	-
Rabies	-	-	-	-	-	-
Intestinal nematode infections	-	-	-	-	-	-
Ascariasis	-	-	-	-	-	-
Trichuriasis	-	-	-	-	-	-
Hookworm disease	-	-	-	-	-	-
Food-borne trematodiasis	-	-	-	-	-	-
Other neglected tropical diseases	-	-	0.0 (0.0 to 0.0)	-	-	-
Maternal disorders	-	-	-	-	-	-
Maternal hemorrhage	-	-	-	-	-	-
Maternal sepsis and other maternal infections	-	-	-	-	-	-
Maternal hypertensive disorders	-	-	-	-	-	-
Obstructed labor	-	-	-	-	-	-
Complications of abortion	-	-	-	-	-	-
Other maternal disorders	-	-	-	-	-	-
Neonatal disorders	-	-	-	16.0 (10.8 to 22.9)	19.7 (12.2 to 31.1)	22.8 (3.3 to 41.9)
Preterm birth complications	27.9 (23.9 to 32.6)	48.5 (42.0 to 56.0)	74.2 (60.3 to 90.6)	2.9 (2.0 to 3.9)	4.8 (3.4 to 6.4)	65.7 (50.6 to 84.8)
Neonatal encephalopathy due to birth asphyxia and trauma	49.6 (28.5 to 81.6)	33.4 (19.6 to 59.1)	-33.4 (-44.7 to -15.9)	5.7 (4.0 to 7.4)	4.0 (2.9 to 5.1)	-30.3 (-37.4 to -22.8)
Neonatal sepsis and other neonatal infections	23.7 (7.9 to 48.0)	50.3 (16.5 to 106.6)	110.0 (100.0 to 127.5)	3.1 (1.0 to 6.8)	6.6 (2.0 to 15.0)	110.3 (97.4 to 128.1)
Hemolytic disease and other neonatal jaundice	5.9 (4.5 to 7.5)	6.1 (4.8 to 7.5)	3.1 (-28.6 to 53.3)	1.5 (1.0 to 2.1)	1.6 (1.1 to 2.2)	5.8 (-24.4 to 51.9)
Other neonatal disorders	-	-	-	2.8 (1.7 to 4.4)	2.8 (1.6 to 4.4)	-0.8 (-30.2 to 33.7)
Nutritional deficiencies	-	-	-	60.5 (40.3 to 84.5)	55.9 (37.8 to 78.3)	-7.6 (-14.1 to -0.4)
Protein-energy malnutrition	259.3 (237.2 to 285.6)	229.9 (207.6 to 255.8)	-11.6 (-22.7 to 2.0)	32.5 (20.8 to 46.6)	28.9 (18.2 to 42.0)	-11.6 (-22.5 to 1.9)
Iodine deficiency	-	-	-	-	-	-

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (0-6 days)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Vitamin A deficiency	-	-	-	-	-	-
Iron-deficiency anemia	850.3 (848.7 to 852.7)	817.6 (816.0 to 819.3)	-3.9 (-4.1 to -3.6)	27.9 (18.7 to 40.3)	27.1 (18.1 to 39.1)	-3.0 (-3.8 to -2.3)
Other nutritional deficiencies	-	-	-	-	-	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	1.9 (1.2 to 2.7)	1.9 (1.3 to 2.8)	1.6 (-7.6 to 18.5)
Sexually transmitted diseases excluding HIV	-	-	-	-	-	-
Syphilis	-	-	0.0 (0.0 to 0.0)	-	-	-
Chlamydial infection	-	-	-	-	-	-
Gonococcal infection	-	-	-	-	-	-
Trichomoniasis	-	-	-	-	-	-
Genital herpes	-	-	-	-	-	-
Other sexually transmitted diseases	-	-	-	-	-	-
Hepatitis	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.8 (-39.1 to -25.1)
Hepatitis A	-	-	0.0 (0.0 to 0.0)	-	-	-
Hepatitis B	89.1 (85.4 to 93.6)	65.9 (62.6 to 69.4)	-26.0 (-30.6 to -21.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.8 (-39.1 to -25.1)
Hepatitis C	-	-	-	-	-	-
Hepatitis E	-	-	-	-	-	-
Leprosy	-	-	-	-	-	-
Other infectious diseases	53.6 (51.6 to 55.0)	51.5 (50.5 to 52.7)	-3.9 (-7.0 to -0.1)	1.9 (1.2 to 2.7)	1.9 (1.3 to 2.8)	1.6 (-7.6 to 18.5)
Non-communicable diseases	-	-	-	17.3 (12.7 to 22.7)	16.9 (12.4 to 22.2)	-2.2 (-4.7 to 0.4)
Neoplasms	-	-	-	-	-	-
Esophageal cancer	-	-	-	-	-	-
Stomach cancer	-	-	-	-	-	-
Liver cancer	-	-	-	-	-	-
Liver cancer due to hepatitis B	-	-	-	-	-	-
Liver cancer due to hepatitis C	-	-	-	-	-	-
Liver cancer due to alcohol use	-	-	-	-	-	-
Liver cancer due to other causes	-	-	-	-	-	-
Larynx cancer	-	-	-	-	-	-
Tracheal, bronchus and lung cancer	-	-	-	-	-	-
Breast cancer	-	-	-	-	-	-
Cervical cancer	-	-	-	-	-	-
Uterine cancer	-	-	-	-	-	-
Prostate cancer	-	-	-	-	-	-
Colon and rectum cancer	-	-	-	-	-	-
Lip and oral cavity cancer	-	-	-	-	-	-
Nasopharynx cancer	-	-	-	-	-	-
Other pharynx cancer	-	-	-	-	-	-
Gallbladder and biliary tract cancer	-	-	-	-	-	-
Pancreatic cancer	-	-	-	-	-	-
Malignant skin melanoma	-	-	-	-	-	-
Non-melanoma skin cancer	-	-	-	-	-	-
Ovarian cancer	-	-	-	-	-	-
Testicular cancer	-	-	-	-	-	-
Kidney cancer	-	-	-	-	-	-
Bladder cancer	-	-	-	-	-	-
Brain and nervous system cancer	-	-	-	-	-	-
Thyroid cancer	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-
Hodgkin lymphoma	-	-	0.0 (0.0 to 0.0)	-	-	-
Non-Hodgkin lymphoma	-	-	-	-	-	-
Multiple myeloma	-	-	-	-	-	-
Leukemia	-	-	-	-	-	-
Other neoplasms	-	-	0.0 (0.0 to 0.0)	-	-	-
Cardiovascular diseases	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.7 (-64.0 to -10.1)
Rheumatic heart disease	-	-	-	-	-	-
Ischemic heart disease	-	-	-	-	-	-
Cerebrovascular disease	-	-	-	-	-	-
Ischemic stroke	-	-	-	-	-	-
Hemorrhagic stroke	-	-	0.0 (0.0 to 0.0)	-	-	-
Hypertensive heart disease	-	-	-	-	-	-
Cardiomyopathy and myocarditis	-	-	0.0 (0.0 to 0.0)	-	-	-
Atrial fibrillation and flutter	-	-	-	-	-	-
Peripheral vascular disease	-	-	-	-	-	-
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.6 (-63.6 to -10.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.7 (-64.0 to -10.1)
Other cardiovascular and circulatory diseases	-	-	0.0 (0.0 to 0.0)	-	-	-
Chronic respiratory diseases	-	-	-	-	-	-
Chronic obstructive pulmonary disease	-	-	-	-	-	-
Pneumoconiosis	-	-	-	-	-	-
Silicosis	-	-	-	-	-	-
Asbestosis	-	-	-	-	-	-
Coal workers pneumoconiosis	-	-	-	-	-	-
Other pneumoconiosis	-	-	-	-	-	-

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (0-6 days)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Asthma	-	-	-	-	-	-
Interstitial lung disease and pulmonary sarcoidosis	-	-	-	-	-	-
Other chronic respiratory diseases	-	-	-	-	-	-
Cirrhosis	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.5 (-46.5 to -40.2)
Cirrhosis due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.4 (-79.2 to -43.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.4 (-79.2 to -43.0)
Cirrhosis due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.6 (-72.3 to -25.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.6 (-72.4 to -25.2)
Cirrhosis due to alcohol use	-	-	-	-	-	-
Cirrhosis due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.5 (-46.5 to -40.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.5 (-46.5 to -40.2)
Digestive diseases	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	7.4 (-9.8 to 24.6)
Peptic ulcer disease	-	-	-	-	-	-
Gastritis and duodenitis	-	-	-	-	-	-
Appendicitis	-	-	-	-	-	-
Paralytic ileus and intestinal obstruction	0.9 (0.8 to 1.0)	1.0 (0.8 to 1.1)	7.8 (-8.4 to 21.7)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	7.4 (-9.8 to 24.6)
Inguinal, femoral, and abdominal hernia	-	-	-	-	-	-
Inflammatory bowel disease	-	-	-	-	-	-
Vascular intestinal disorders	-	-	-	-	-	-
Gallbladder and biliary diseases	-	-	-	-	-	-
Pancreatitis	-	-	-	-	-	-
Other digestive diseases	-	-	-	-	-	-
Neurological disorders	-	-	-	2.3 (1.5 to 3.0)	2.3 (1.5 to 3.0)	0.6 (-11.1 to 14.9)
Alzheimer disease and other dementias	-	-	-	-	-	-
Parkinson disease	-	-	-	-	-	-
Epilepsy	6.8 (6.3 to 7.3)	6.3 (5.9 to 6.8)	-6.6 (-16.3 to 4.0)	2.3 (1.5 to 3.0)	2.3 (1.5 to 3.0)	0.6 (-11.1 to 14.9)
Multiple sclerosis	-	-	-	-	-	-
Migraine	-	-	-	-	-	-
Tension-type headache	-	-	-	-	-	-
Medication overuse headache	-	-	-	-	-	-
Other neurological disorders	-	-	-	-	-	-
Mental and substance use disorders	-	-	-	2.1 (1.5 to 2.9)	2.1 (1.5 to 2.9)	0.9 (-2.6 to 4.5)
Schizophrenia	-	-	-	-	-	-
Alcohol use disorders	0.3 (0.3 to 0.4)	0.3 (0.3 to 0.4)	-0.5 (-11.1 to 8.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.5 (-36.2 to 16.2)
Drug use disorders	-	-	-	-	-	-
Opioid use disorders	-	-	0.0 (0.0 to 0.0)	-	-	-
Cocaine use disorders	-	-	0.0 (0.0 to 0.0)	-	-	-
Amphetamine use disorders	-	-	0.0 (0.0 to 0.0)	-	-	-
Cannabis use disorders	-	-	-	-	-	-
Other drug use disorders	-	-	-	-	-	-
Depressive disorders	-	-	-	-	-	-
Major depressive disorder	-	-	-	-	-	-
Dysthymia	-	-	-	-	-	-
Bipolar disorder	-	-	-	-	-	-
Anxiety disorders	-	-	-	-	-	-
Eating disorders	-	-	-	-	-	-
Anorexia nervosa	-	-	-	-	-	-
Bulimia nervosa	-	-	-	-	-	-
Autistic spectrum disorders	-	-	-	2.1 (1.4 to 2.9)	2.1 (1.4 to 2.9)	1.4 (-2.0 to 4.9)
Autism	4.6 (3.9 to 5.2)	4.6 (4.0 to 5.2)	1.2 (0.8 to 1.5)	1.2 (0.8 to 1.7)	1.2 (0.8 to 1.7)	1.3 (-3.8 to 6.9)
Asperger syndrome	8.8 (7.8 to 9.8)	9.0 (7.9 to 9.9)	1.2 (1.2 to 1.2)	0.9 (0.6 to 1.3)	0.9 (0.6 to 1.3)	1.4 (-2.4 to 5.3)
Attention-deficit/hyperactivity disorder	-	-	-	-	-	-
Conduct disorder	-	-	-	-	-	-
Idiopathic intellectual disability	0.8 (0.6 to 1.2)	0.7 (0.5 to 0.8)	-18.8 (-41.5 to 13.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-18.5 (-42.6 to 14.5)
Other mental and substance use disorders	-	-	-	-	-	-
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	7.1 (5.0 to 10.0)	6.9 (4.9 to 9.6)	-2.8 (-5.2 to -0.4)
Diabetes mellitus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.5 (18.4 to 60.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.5 (18.4 to 60.2)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.5 (-35.1 to -27.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.5 (-35.2 to -27.5)
Chronic kidney disease	-	-	-	1.7 (1.0 to 2.4)	1.7 (1.0 to 2.4)	-2.0 (-8.0 to 4.3)
Chronic kidney disease due to diabetes mellitus	2.9 (1.2 to 5.8)	3.5 (1.5 to 7.0)	20.0 (2.3 to 39.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	13.5 (-1.8 to 31.2)
Chronic kidney disease due to hypertension	48.7 (17.5 to 107.2)	55.1 (21.3 to 119.4)	14.3 (-2.8 to 31.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	4.8 (-14.4 to 26.5)
Chronic kidney disease due to glomerulonephritis	18.9 (10.7 to 33.1)	21.0 (11.3 to 38.4)	9.3 (-5.2 to 32.7)	0.7 (0.4 to 1.0)	0.6 (0.4 to 0.9)	-11.4 (-21.7 to -0.8)
Chronic kidney disease due to other causes	56.2 (22.9 to 116.8)	63.8 (26.2 to 130.2)	13.6 (3.2 to 25.2)	0.8 (0.5 to 1.1)	0.8 (0.5 to 1.2)	3.5 (-7.2 to 16.4)
Urinary diseases and male infertility	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.4 (8.6 to 25.3)
Interstitial nephritis and urinary tract infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.8 (5.7 to 18.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.8 (5.6 to 18.5)
Urolithiasis	-	-	-	-	-	-
Benign prostatic hyperplasia	-	-	-	-	-	-
Male infertility due to other causes	-	-	-	-	-	-
Other urinary diseases	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.5 (8.2 to 54.0)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (0-6 days)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Gynecological diseases	-	-	-	-	-	-
Uterine fibroids	-	-	-	-	-	-
Polycystic ovarian syndrome	-	-	-	-	-	-
Female infertility due to other causes	-	-	-	-	-	-
Endometriosis	-	-	-	-	-	-
Genital prolapse	-	-	-	-	-	-
Premenstrual syndrome	-	-	-	-	-	-
Other gynecological diseases	-	-	-	-	-	-
Hemoglobinopathies and hemolytic anemias	-	-	-	3.2 (2.1 to 4.6)	3.1 (2.1 to 4.5)	-2.4 (-5.5 to 0.7)
Thalassemias	1.0 (0.9 to 1.1)	0.9 (0.8 to 1.0)	-10.9 (-13.9 to -6.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-14.2 (-25.9 to 0.1)
Thalassemia trait	76.7 (69.7 to 84.8)	73.7 (68.3 to 79.9)	-3.9 (-6.3 to -1.5)	1.3 (0.9 to 1.9)	1.2 (0.8 to 1.7)	-7.6 (-11.6 to -3.6)
Sickle cell disorders	2.2 (2.1 to 2.4)	3.3 (3.1 to 3.5)	47.8 (36.3 to 60.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	40.7 (19.9 to 64.2)
Sickle cell trait	107.1 (101.8 to 111.9)	139.6 (133.4 to 145.1)	30.3 (28.2 to 32.4)	0.6 (0.4 to 0.9)	0.6 (0.4 to 0.9)	3.6 (-3.6 to 11.3)
G6PD deficiency	136.3 (132.7 to 139.6)	161.0 (157.2 to 164.8)	18.1 (14.3 to 21.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.8 (-3.5 to 32.4)
G6PD trait	438.9 (435.8 to 441.5)	457.7 (454.3 to 460.8)	4.3 (3.3 to 5.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.4 (-27.7 to 27.6)
Other hemoglobinopathies and hemolytic anemias	30.9 (29.5 to 32.0)	29.7 (28.5 to 30.6)	-3.9 (-8.2 to 1.3)	1.0 (0.7 to 1.5)	1.0 (0.7 to 1.4)	-3.3 (-10.3 to 3.9)
Endocrine, metabolic, blood, and immune disorders	62.0 (60.7 to 63.3)	59.8 (58.6 to 61.0)	-3.6 (-6.4 to -0.6)	2.2 (1.5 to 3.1)	2.1 (1.5 to 3.0)	-4.0 (-9.2 to 0.4)
Musculoskeletal disorders	-	-	-	-	-	-
Rheumatoid arthritis	-	-	-	-	-	-
Osteoarthritis	-	-	-	-	-	-
Low back and neck pain	-	-	-	-	-	-
Low back pain	-	-	-	-	-	-
Neck pain	-	-	-	-	-	-
Gout	-	-	-	-	-	-
Other musculoskeletal disorders	-	-	-	-	-	-
Other non-communicable diseases	-	-	-	5.5 (4.1 to 7.3)	5.3 (3.8 to 6.9)	-4.2 (-9.1 to 0.6)
Congenital anomalies	-	-	-	3.9 (2.8 to 5.3)	3.9 (2.7 to 5.1)	-1.6 (-8.3 to 4.2)
Neural tube defects	1.4 (1.4 to 1.4)	1.3 (1.2 to 1.3)	-9.1 (-12.3 to -5.7)	0.5 (0.3 to 0.6)	0.4 (0.3 to 0.5)	-9.9 (-19.9 to 1.8)
Congenital heart anomalies	23.1 (22.3 to 24.1)	22.5 (21.8 to 23.4)	-2.6 (-7.5 to 2.9)	1.0 (0.5 to 1.6)	0.9 (0.4 to 1.5)	-7.8 (-17.5 to -1.6)
Orofacial clefts	3.9 (3.8 to 4.1)	3.6 (3.5 to 3.8)	-6.9 (-11.5 to -1.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-17.3 (-29.9 to -3.1)
Down syndrome	3.2 (3.0 to 3.4)	3.2 (3.1 to 3.4)	2.0 (-3.9 to 8.1)	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	2.1 (-6.7 to 11.7)
Turner syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	1.4 (-5.8 to 10.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.4 (-5.8 to 10.0)
Klinefelter syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	3.0 (-4.0 to 11.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.0 (-4.0 to 11.8)
Chromosomal unbalanced rearrangements	4.3 (4.1 to 4.4)	4.4 (4.2 to 4.6)	3.0 (-2.2 to 8.6)	0.5 (0.3 to 0.6)	0.5 (0.4 to 0.6)	3.1 (-4.8 to 11.0)
Other congenital anomalies	9.1 (7.4 to 10.7)	8.3 (6.7 to 9.9)	-8.5 (-13.4 to -3.9)	1.6 (1.0 to 2.4)	1.6 (1.1 to 2.4)	3.1 (-11.2 to 17.2)
Skin and subcutaneous diseases	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	1.8 (-5.1 to 8.7)
Dermatitis	-	-	-	-	-	-
Psoriasis	-	-	-	-	-	-
Cellulitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.4 (-22.5 to -3.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.4 (-22.6 to -3.1)
Pyoderma	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-31.3 (-35.3 to -20.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.4 (-35.3 to -20.9)
Scabies	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	2.1 (-19.1 to 27.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.7 (-29.5 to 49.0)
Fungal skin diseases	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	23.7 (15.3 to 36.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.6 (6.1 to 53.6)
Viral skin diseases	-	-	-	-	-	-
Acne vulgaris	-	-	-	-	-	-
Alopecia areata	-	-	-	-	-	-
Pruritus	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-4.9 (-17.2 to 12.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.4 (-22.4 to 18.2)
Urticaria	-	-	0.0 (0.0 to 0.0)	-	-	-
Decubitus ulcer	-	-	-	-	-	-
Other skin and subcutaneous diseases	10.8 (2.3 to 25.7)	11.1 (2.4 to 26.2)	2.1 (0.1 to 4.3)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	2.0 (-3.9 to 8.2)
Sense organ diseases	-	-	-	1.5 (1.0 to 2.2)	1.3 (0.9 to 2.0)	-11.3 (-15.7 to -6.0)
Glaucoma	-	-	-	-	-	-
Cataract	-	-	-	-	-	-
Macular degeneration	-	-	-	-	-	-
Uncorrected refractive error	49.4 (45.3 to 53.5)	48.0 (44.2 to 51.5)	-3.0 (-9.7 to 4.6)	1.0 (0.6 to 1.5)	0.9 (0.6 to 1.4)	-8.0 (-13.5 to -2.0)
Age-related and other hearing loss	3.3 (2.7 to 3.9)	3.1 (2.5 to 3.7)	-5.4 (-12.0 to 1.7)	0.4 (0.2 to 0.6)	0.3 (0.2 to 0.5)	-11.2 (-20.9 to -0.6)
Other vision loss	3.4 (2.2 to 4.7)	2.4 (1.5 to 3.3)	-30.9 (-35.6 to -25.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-34.2 (-41.3 to -26.2)
Other sense organ diseases	-	-	-	-	-	-
Oral disorders	-	-	-	-	-	-
Deciduous caries	-	-	-	-	-	-
Permanent caries	-	-	-	-	-	-
Periodontal diseases	-	-	-	-	-	-
Edentulism and severe tooth loss	-	-	-	-	-	-
Other oral disorders	-	-	-	-	-	-
Injuries	-	-	-	4.1 (1.8 to 7.3)	2.0 (1.1 to 3.3)	-52.0 (-72.9 to 3.7)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (0-6 days)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Transport injuries	-	-	-	0-1 (0-1 to 0-2)	0-1 (0-0 to 0-1)	-46.4 (-50.4 to -41.0)
Road injuries	-	-	-	0-1 (0-1 to 0-1)	0-0 (0-0 to 0-1)	-46.8 (-52.0 to -39.9)
Pedestrian road injuries	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-35.3 (-43.3 to -25.3)
Cyclist road injuries	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-38.7 (-46.3 to -27.3)
Motorcyclist road injuries	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-74.1 (-77.5 to -70.0)
Motor vehicle road injuries	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-35.7 (-42.1 to -28.0)
Other road injuries	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-39.5 (-47.5 to -29.7)
Other transport injuries	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-45.7 (-51.4 to -37.8)
Unintentional injuries	-	-	-	0-9 (0-6 to 1-2)	0-7 (0-5 to 1-0)	-17.5 (-21.2 to -13.1)
Falls	-	-	-	0-3 (0-2 to 0-4)	0-2 (0-2 to 0-3)	-6.9 (-12.7 to -0.7)
Drowning	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-52.0 (-59.4 to -46.1)
Fire, heat, and hot substances	-	-	-	0-2 (0-2 to 0-3)	0-2 (0-1 to 0-3)	-27.8 (-38.0 to -16.2)
Poisonings	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-37.2 (-44.0 to -29.4)
Exposure to mechanical forces	-	-	-	0-1 (0-1 to 0-2)	0-1 (0-1 to 0-2)	-11.2 (-16.8 to -6.0)
Unintentional firearm injuries	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-28.3 (-35.6 to -22.2)
Unintentional suffocation	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-16.0 (-23.6 to -9.7)
Other exposure to mechanical forces	-	-	-	0-1 (0-1 to 0-2)	0-1 (0-1 to 0-2)	-10.3 (-16.3 to -5.1)
Adverse effects of medical treatment	-	-	-	0-1 (0-0 to 0-1)	0-1 (0-0 to 0-1)	-6.5 (-10.7 to -1.4)
Animal contact	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-23.3 (-32.2 to -14.1)
Venomous animal contact	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-21.7 (-30.3 to -12.0)
Non-venomous animal contact	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-23.6 (-32.7 to -14.4)
Foreign body	-	-	-	0-1 (0-0 to 0-1)	0-0 (0-0 to 0-1)	-22.0 (-29.9 to -14.6)
Pulmonary aspiration and foreign body in airway	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-33.9 (-41.5 to -25.3)
Foreign body in eyes	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	2.6 (-4.5 to 9.6)
Foreign body in other body part	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-21.4 (-28.2 to -14.4)
Other unintentional injuries	-	-	-	0-1 (0-1 to 0-2)	0-1 (0-1 to 0-1)	-22.8 (-27.0 to -18.7)
Self-harm and interpersonal violence	-	-	-	0-0 (0-0 to 0-1)	0-0 (0-0 to 0-0)	-20.3 (-31.3 to -5.9)
Self-harm	-	-	-	-	-	-
Interpersonal violence	-	-	-	0-0 (0-0 to 0-1)	0-0 (0-0 to 0-0)	-20.3 (-31.3 to -5.9)
Assault by firearm	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-
Assault by sharp object	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-10.5 (-27.7 to 8.1)
Assault by other means	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-21.1 (-31.8 to -7.0)
Forces of nature, war, and legal intervention	-	-	-	3.0 (0.9 to 6.1)	1.2 (0.5 to 2.4)	-64.5 (-83.9 to 25.0)
Exposure to forces of nature	-	-	-	1-1 (0-1 to 2-6)	0-3 (0-0 to 0-9)	-89.9 (-97.5 to 139.0)
Collective violence and legal intervention	-	-	-	1-9 (0-6 to 4-4)	0-9 (0-4 to 1-9)	-49.0 (-78.9 to 39.9)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (7-27 days)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
All causes	-	-	-	419.6 (294.3 to 565.4)	384.9 (270.7 to 521.2)	-8.3 (-11.4 to -5.2)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	360.0 (250.7 to 486.7)	328.8 (230.6 to 448.5)	-8.7 (-12.3 to -5.2)
HIV/AIDS and tuberculosis	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.2 (-8.1 to 14.6)
Tuberculosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.1 (-1.3 to 5.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.2 (-8.1 to 14.6)
HIV/AIDS	-	-	-	-	-	-
HIV/AIDS resulting in mycobacterial infection	-	-	-	-	-	-
HIV/AIDS resulting in other diseases	-	-	-	-	-	-
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	112.6 (76.8 to 155.4)	94.0 (63.6 to 129.1)	-16.5 (-20.1 to -12.8)
Diarrheal diseases	605.4 (589.2 to 620.5)	533.7 (514.7 to 553.2)	-11.8 (-15.5 to -7.9)	98.9 (67.4 to 136.4)	87.4 (58.8 to 120.8)	-11.6 (-15.4 to -7.6)
Intestinal infectious diseases	-	-	-	-	-	-
Typhoid fever	-	-	-	-	-	-
Paratyphoid fever	-	-	-	-	-	-
Other intestinal infectious diseases	-	-	-	-	-	-
Lower respiratory infections	87.5 (85.0 to 89.7)	48.9 (47.5 to 50.5)	-44.1 (-46.4 to -41.6)	9.3 (6.2 to 13.0)	5.2 (3.5 to 7.3)	-44.0 (-46.5 to -41.2)
Upper respiratory infections	39.1 (37.4 to 40.7)	42.3 (40.7 to 44.0)	8.3 (2.5 to 14.8)	0.5 (0.3 to 0.8)	0.5 (0.3 to 0.8)	8.4 (0.8 to 18.1)
Otitis media	19.4 (18.8 to 20.1)	17.4 (16.7 to 18.1)	-10.2 (-14.0 to -5.9)	0.4 (0.2 to 0.6)	0.3 (0.2 to 0.5)	-9.7 (-14.6 to -4.5)
Meningitis	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-45.3 (-49.0 to -41.4)
Pneumococcal meningitis	0.4 (0.4 to 0.5)	0.2 (0.2 to 0.3)	-45.2 (-49.9 to -41.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-42.7 (-48.6 to -37.1)
H influenzae type B meningitis	0.5 (0.4 to 0.6)	0.3 (0.2 to 0.3)	-45.5 (-49.7 to -39.6)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-42.7 (-49.6 to -34.6)
Meningococcal meningitis	0.3 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-47.9 (-53.6 to -41.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.4 (-58.0 to -34.4)
Other meningitis	0.4 (0.3 to 0.5)	0.2 (0.2 to 0.2)	-51.1 (-56.1 to -46.5)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-49.7 (-55.9 to -42.7)
Encephalitis	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-35.2 (-37.8 to -32.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.6 (-34.9 to -30.5)
Diphtheria	-	-	-	-	-	-
Whooping cough	-	-	-	-	-	-
Tetanus	26.8 (18.9 to 40.7)	2.4 (1.2 to 4.0)	-91.1 (-96.3 to -83.0)	3.3 (1.9 to 5.7)	0.3 (0.1 to 0.5)	-91.0 (-96.3 to -82.8)
Measles	-	-	-	-	-	-
Varicella and herpes zoster	23.1 (21.8 to 24.5)	21.9 (20.7 to 23.3)	-4.8 (-12.9 to 2.6)	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.3)	-4.8 (-13.0 to 3.9)
Neglected tropical diseases and malaria	-	-	-	1.7 (0.8 to 3.7)	1.4 (0.7 to 2.8)	-15.8 (-31.7 to 3.3)
Malaria	115.8 (88.2 to 169.8)	108.5 (88.6 to 142.4)	-5.8 (-21.7 to 13.5)	1.7 (0.8 to 3.7)	1.4 (0.7 to 2.8)	-15.8 (-31.7 to 3.3)
Chagas disease	-	-	-	-	-	-
Leishmaniasis	-	-	-	-	-	-
Visceral leishmaniasis	-	-	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	-	-	-	-
African trypanosomiasis	-	-	-	-	-	-
Schistosomiasis	-	-	-	-	-	-
Cysticercosis	-	-	-	-	-	-
Cystic echinococcosis	-	-	-	-	-	-
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	-	-	-
Onchocerciasis	-	-	-	-	-	-
Trachoma	-	-	-	-	-	-
Dengue	-	-	-	-	-	-
Yellow fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-65.7 (-74.1 to -50.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-65.7 (-74.1 to -50.2)
Rabies	-	-	-	-	-	-
Intestinal nematode infections	-	-	-	-	-	-
Ascariasis	-	-	-	-	-	-
Trichuriasis	-	-	-	-	-	-
Hookworm disease	-	-	-	-	-	-
Food-borne trematodiasis	-	-	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-82.8 (-89.0 to -64.7)
Maternal disorders	-	-	-	-	-	-
Maternal hemorrhage	-	-	-	-	-	-
Maternal sepsis and other maternal infections	-	-	-	-	-	-
Maternal hypertensive disorders	-	-	-	-	-	-
Obstructed labor	-	-	-	-	-	-
Complications of abortion	-	-	-	-	-	-
Other maternal disorders	-	-	-	-	-	-
Neonatal disorders	-	-	-	31.6 (22.4 to 40.9)	32.8 (23.7 to 42.6)	3.2 (-5.4 to 17.7)
Preterm birth complications	77.2 (65.7 to 91.0)	137.8 (118.9 to 159.3)	78.4 (63.4 to 95.4)	7.8 (5.5 to 10.3)	13.4 (9.6 to 17.6)	71.5 (56.6 to 91.3)
Neonatal encephalopathy due to birth asphyxia and trauma	134.5 (73.4 to 227.3)	92.2 (51.9 to 167.5)	-32.3 (-43.9 to -13.3)	14.4 (10.2 to 18.6)	10.4 (7.5 to 13.3)	-28.1 (-35.4 to -20.0)
Neonatal sepsis and other neonatal infections	-	-	0.0 (0.0 to 0.0)	-	-	-
Hemolytic disease and other neonatal jaundice	15.0 (11.6 to 19.3)	16.2 (12.8 to 20.1)	7.9 (-25.1 to 61.7)	3.9 (2.6 to 5.5)	4.3 (2.9 to 6.0)	10.6 (-20.5 to 54.7)
Other neonatal disorders	-	-	-	5.6 (3.4 to 8.5)	4.8 (3.2 to 6.6)	-13.5 (-33.5 to 15.8)
Nutritional deficiencies	-	-	-	206.9 (138.8 to 289.5)	193.7 (131.7 to 271.0)	-6.4 (-11.9 to -0.4)
Protein-energy malnutrition	761.6 (696.8 to 838.7)	680.9 (614.9 to 757.4)	-10.9 (-22.0 to 2.8)	94.9 (60.7 to 136.1)	85.1 (53.8 to 123.5)	-10.7 (-21.8 to 3.1)
Iodine deficiency	-	-	-	-	-	-

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (7-27 days)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Vitamin A deficiency	-	-	-	-	-	-
Iron-deficiency anemia	3,370.0 (3,363.2 to 3,379.2)	3,265.7 (3,259.6 to 3,272.4)	-3.1 (-3.4 to -2.9)	112.0 (75.0 to 161.7)	108.6 (72.5 to 156.9)	-3.0 (-3.8 to -2.4)
Other nutritional deficiencies	-	-	-	-	-	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	7.1 (4.7 to 10.3)	6.9 (4.6 to 9.9)	-3.3 (-8.2 to 5.1)
Sexually transmitted diseases excluding HIV	-	-	-	-	-	-
Syphilis	-	-	0.0 (0.0 to 0.0)	-	-	-
Chlamydial infection	-	-	-	-	-	-
Gonococcal infection	-	-	-	-	-	-
Trichomoniasis	-	-	-	-	-	-
Genital herpes	-	-	-	-	-	-
Other sexually transmitted diseases	-	-	-	-	-	-
Hepatitis	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.9 (-41.9 to -20.9)
Hepatitis A	-	-	0.0 (0.0 to 0.0)	-	-	-
Hepatitis B	263.3 (252.6 to 276.6)	195.9 (186.2 to 206.3)	-25.6 (-30.2 to -20.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.9 (-41.9 to -20.9)
Hepatitis C	-	-	-	-	-	-
Hepatitis E	-	-	-	-	-	-
Leprosy	-	-	-	-	-	-
Other infectious diseases	212.4 (204.1 to 218.5)	205.7 (201.3 to 210.9)	-3.2 (-6.1 to 0.6)	7.1 (4.7 to 10.3)	6.9 (4.6 to 9.9)	-3.3 (-8.1 to 5.2)
Non-communicable diseases	-	-	-	55.7 (40.6 to 73.7)	55.1 (40.5 to 72.7)	-1.1 (-3.4 to 1.3)
Neoplasms	-	-	-	-	-	-
Esophageal cancer	-	-	-	-	-	-
Stomach cancer	-	-	-	-	-	-
Liver cancer	-	-	-	-	-	-
Liver cancer due to hepatitis B	-	-	-	-	-	-
Liver cancer due to hepatitis C	-	-	-	-	-	-
Liver cancer due to alcohol use	-	-	-	-	-	-
Liver cancer due to other causes	-	-	-	-	-	-
Larynx cancer	-	-	-	-	-	-
Tracheal, bronchus and lung cancer	-	-	-	-	-	-
Breast cancer	-	-	-	-	-	-
Cervical cancer	-	-	-	-	-	-
Uterine cancer	-	-	-	-	-	-
Prostate cancer	-	-	-	-	-	-
Colon and rectum cancer	-	-	-	-	-	-
Lip and oral cavity cancer	-	-	-	-	-	-
Nasopharynx cancer	-	-	-	-	-	-
Other pharynx cancer	-	-	-	-	-	-
Gallbladder and biliary tract cancer	-	-	-	-	-	-
Pancreatic cancer	-	-	-	-	-	-
Malignant skin melanoma	-	-	-	-	-	-
Non-melanoma skin cancer	-	-	-	-	-	-
Ovarian cancer	-	-	-	-	-	-
Testicular cancer	-	-	-	-	-	-
Kidney cancer	-	-	-	-	-	-
Bladder cancer	-	-	-	-	-	-
Brain and nervous system cancer	-	-	-	-	-	-
Thyroid cancer	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-
Hodgkin lymphoma	-	-	0.0 (0.0 to 0.0)	-	-	-
Non-Hodgkin lymphoma	-	-	-	-	-	-
Multiple myeloma	-	-	-	-	-	-
Leukemia	-	-	-	-	-	-
Other neoplasms	-	-	0.0 (0.0 to 0.0)	-	-	-
Cardiovascular diseases	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.9 (-62.0 to -10.9)
Rheumatic heart disease	-	-	-	-	-	-
Ischemic heart disease	-	-	-	-	-	-
Cerebrovascular disease	-	-	-	-	-	-
Ischemic stroke	-	-	-	-	-	-
Hemorrhagic stroke	-	-	0.0 (0.0 to 0.0)	-	-	-
Hypertensive heart disease	-	-	-	-	-	-
Cardiomyopathy and myocarditis	-	-	0.0 (0.0 to 0.0)	-	-	-
Atrial fibrillation and flutter	-	-	-	-	-	-
Peripheral vascular disease	-	-	-	-	-	-
Endocarditis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-39.0 (-60.0 to -12.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.9 (-62.0 to -10.9)
Other cardiovascular and circulatory diseases	-	-	0.0 (0.0 to 0.0)	-	-	-
Chronic respiratory diseases	-	-	-	-	-	-
Chronic obstructive pulmonary disease	-	-	-	-	-	-
Pneumoconiosis	-	-	-	-	-	-
Silicosis	-	-	-	-	-	-
Asbestosis	-	-	-	-	-	-
Coal workers pneumoconiosis	-	-	-	-	-	-
Other pneumoconiosis	-	-	-	-	-	-
Asthma	-	-	-	-	-	-

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (7-27 days)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Interstitial lung disease and pulmonary sarcoidosis	-	-	-	-	-	-
Other chronic respiratory diseases	-	-	-	-	-	-
Cirrhosis	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.0 (-46.0 to -39.7)
Cirrhosis due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.1 (-79.0 to -42.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.2 (-79.0 to -42.7)
Cirrhosis due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.1 (-71.9 to -24.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.1 (-71.9 to -24.9)
Cirrhosis due to alcohol use	-	-	-	-	-	-
Cirrhosis due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.0 (-46.0 to -39.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.0 (-46.0 to -39.7)
Digestive diseases	-	-	-	0.8 (0.5 to 1.1)	0.9 (0.6 to 1.2)	9.2 (-9.2 to 25.0)
Peptic ulcer disease	-	-	-	-	-	-
Gastritis and duodenitis	-	-	-	-	-	-
Appendicitis	-	-	-	-	-	-
Paralytic ileus and intestinal obstruction	2.5 (2.3 to 2.8)	2.7 (2.4 to 3.0)	8.3 (-7.9 to 22.4)	0.8 (0.5 to 1.1)	0.9 (0.6 to 1.2)	9.2 (-9.2 to 25.0)
Inguinal, femoral, and abdominal hernia	-	-	-	-	-	-
Inflammatory bowel disease	-	-	-	-	-	-
Vascular intestinal disorders	-	-	-	-	-	-
Gallbladder and biliary diseases	-	-	-	-	-	-
Pancreatitis	-	-	-	-	-	-
Other digestive diseases	-	-	-	-	-	-
Neurological disorders	-	-	-	6.6 (4.4 to 8.9)	6.7 (4.6 to 9.0)	1.6 (-9.1 to 14.9)
Alzheimer disease and other dementias	-	-	-	-	-	-
Parkinson disease	-	-	-	-	-	-
Epilepsy	20.1 (18.6 to 21.6)	18.9 (17.5 to 20.2)	-5.8 (-15.4 to 4.8)	6.6 (4.4 to 8.9)	6.7 (4.6 to 9.0)	1.6 (-9.1 to 14.9)
Multiple sclerosis	-	-	-	-	-	-
Migraine	-	-	-	-	-	-
Tension-type headache	-	-	-	-	-	-
Medication overuse headache	-	-	-	-	-	-
Other neurological disorders	-	-	-	-	-	-
Mental and substance use disorders	-	-	-	6.3 (4.3 to 8.6)	6.4 (4.4 to 8.8)	1.7 (-1.5 to 4.9)
Schizophrenia	-	-	-	-	-	-
Alcohol use disorders	1.1 (0.9 to 1.3)	1.1 (0.9 to 1.3)	-0.3 (-10.2 to 8.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-11.5 (-31.9 to 14.3)
Drug use disorders	-	-	-	-	-	-
Opioid use disorders	-	-	0.0 (0.0 to 0.0)	-	-	-
Cocaine use disorders	-	-	0.0 (0.0 to 0.0)	-	-	-
Amphetamine use disorders	-	-	0.0 (0.0 to 0.0)	-	-	-
Cannabis use disorders	-	-	-	-	-	-
Other drug use disorders	-	-	-	-	-	-
Depressive disorders	-	-	-	-	-	-
Major depressive disorder	-	-	-	-	-	-
Dysthymia	-	-	-	-	-	-
Bipolar disorder	-	-	-	-	-	-
Anxiety disorders	-	-	-	-	-	-
Eating disorders	-	-	-	-	-	-
Anorexia nervosa	-	-	-	-	-	-
Bulimia nervosa	-	-	-	-	-	-
Autistic spectrum disorders	-	-	-	6.1 (4.2 to 8.4)	6.2 (4.2 to 8.6)	2.3 (-1.0 to 5.4)
Autism	13.5 (11.7 to 15.3)	13.8 (11.9 to 15.6)	1.9 (1.6 to 2.3)	3.4 (2.2 to 4.8)	3.5 (2.3 to 5.0)	2.3 (-2.8 to 7.1)
Asperger syndrome	26.2 (23.0 to 28.9)	26.7 (23.4 to 29.5)	1.9 (1.9 to 2.0)	2.7 (1.8 to 3.8)	2.7 (1.8 to 3.9)	2.3 (-1.3 to 5.7)
Attention-deficit/hyperactivity disorder	-	-	-	-	-	-
Conduct disorder	-	-	-	-	-	-
Idiopathic intellectual disability	2.9 (2.1 to 4.1)	2.4 (1.8 to 3.0)	-18.1 (-38.8 to 9.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-18.0 (-39.3 to 9.9)
Other mental and substance use disorders	-	-	-	-	-	-
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	26.3 (18.4 to 37.0)	25.7 (18.0 to 36.1)	-2.2 (-4.5 to 0.1)
Diabetes mellitus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.4 (19.3 to 61.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.5 (19.4 to 61.1)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.9 (-34.6 to -26.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.9 (-34.6 to -26.9)
Chronic kidney disease	-	-	-	5.6 (3.5 to 7.8)	5.5 (3.4 to 7.8)	-1.3 (-6.0 to 4.7)
Chronic kidney disease due to diabetes mellitus	8.7 (3.6 to 17.2)	10.5 (4.5 to 20.9)	20.7 (3.0 to 40.3)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	13.9 (-0.9 to 32.6)
Chronic kidney disease due to hypertension	139.3 (48.0 to 311.3)	158.8 (59.5 to 348.9)	15.4 (-2.4 to 34.2)	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.9)	6.1 (-9.9 to 24.5)
Chronic kidney disease due to glomerulonephritis	60.1 (35.6 to 102.1)	66.3 (37.1 to 117.9)	9.0 (-4.9 to 31.0)	2.2 (1.4 to 3.2)	2.0 (1.2 to 2.8)	-10.8 (-20.4 to -1.0)
Chronic kidney disease due to other causes	165.9 (68.0 to 344.4)	189.3 (77.7 to 386.7)	14.3 (4.1 to 25.8)	2.6 (1.6 to 3.7)	2.7 (1.7 to 3.8)	5.0 (-4.8 to 16.1)
Urinary diseases and male infertility	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.1 (9.3 to 26.0)
Interstitial nephritis and urinary tract infections	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	12.6 (6.5 to 19.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.6 (6.4 to 19.2)
Urolithiasis	-	-	-	-	-	-
Benign prostatic hyperplasia	-	-	-	-	-	-
Male infertility due to other causes	-	-	-	-	-	-
Other urinary diseases	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.4 (8.9 to 54.8)
Gynecological diseases	-	-	-	-	-	-

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (7-27 days)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Uterine fibroids	-	-	-	-	-	-
Polycystic ovarian syndrome	-	-	-	-	-	-
Female infertility due to other causes	-	-	-	-	-	-
Endometriosis	-	-	-	-	-	-
Genital prolapse	-	-	-	-	-	-
Premenstrual syndrome	-	-	-	-	-	-
Other gynecological diseases	-	-	-	-	-	-
Hemoglobinopathies and hemolytic anemias	-	-	-	12.9 (8.7 to 18.6)	12.7 (8.4 to 18.3)	-1.9 (-4.7 to 1.1)
Thalassemias	2.9 (2.6 to 3.3)	2.7 (2.4 to 3.0)	-10.2 (-13.2 to -5.4)	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-13.8 (-26.3 to 1.2)
Thalassemia trait	228.6 (211.8 to 250.5)	221.1 (207.9 to 237.6)	-3.2 (-5.6 to -1.2)	5.3 (3.6 to 7.7)	5.0 (3.3 to 7.2)	-5.8 (-9.8 to -2.1)
Sickle cell disorders	6.8 (6.5 to 7.1)	10.4 (9.8 to 10.8)	51.6 (42.8 to 59.5)	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.9)	42.5 (25.8 to 61.0)
Sickle cell trait	314.2 (299.3 to 328.0)	412.8 (395.1 to 429.1)	31.4 (29.2 to 33.4)	2.5 (1.7 to 3.7)	2.6 (1.8 to 3.8)	3.7 (-3.0 to 10.8)
G6PD deficiency	400.5 (390.0 to 410.1)	476.6 (465.5 to 487.8)	19.0 (15.1 to 22.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	12.4 (-11.4 to 40.3)
G6PD trait	1,295.3 (1,286.1 to 1,303.0)	1,359.9 (1,349.8 to 1,368.9)	5.0 (4.0 to 6.1)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-6.4 (-26.3 to 16.6)
Other hemoglobinopathies and hemolytic anemias	122.6 (116.7 to 126.7)	118.7 (114.0 to 122.6)	-3.2 (-7.5 to 2.2)	4.2 (2.8 to 6.0)	4.0 (2.7 to 5.8)	-4.2 (-10.7 to 3.4)
Endocrine, metabolic, blood, and immune disorders	222.3 (218.0 to 226.7)	215.6 (211.8 to 219.5)	-3.0 (-5.6 to -0.2)	7.8 (5.3 to 11.0)	7.5 (5.2 to 10.6)	-3.7 (-9.0 to 1.2)
Musculoskeletal disorders	-	-	-	-	-	-
Rheumatoid arthritis	-	-	-	-	-	-
Osteoarthritis	-	-	-	-	-	-
Low back and neck pain	-	-	-	-	-	-
Low back pain	-	-	-	-	-	-
Neck pain	-	-	-	-	-	-
Gout	-	-	-	-	-	-
Other musculoskeletal disorders	-	-	-	-	-	-
Other non-communicable diseases	-	-	-	15.7 (11.6 to 20.6)	15.4 (11.2 to 19.8)	-2.1 (-7.3 to 3.1)
Congenital anomalies	-	-	-	10.8 (7.7 to 14.3)	10.9 (7.7 to 14.3)	1.5 (-5.9 to 7.5)
Neural tube defects	3.9 (3.8 to 4.0)	3.6 (3.5 to 3.7)	-6.1 (-9.5 to -2.6)	1.3 (0.9 to 1.6)	1.2 (0.8 to 1.5)	-6.4 (-16.0 to 4.0)
Congenital heart anomalies	60.0 (57.8 to 62.7)	61.7 (59.7 to 64.3)	2.8 (-2.4 to 8.6)	2.5 (1.2 to 4.1)	2.4 (1.1 to 4.0)	-3.1 (-14.3 to 4.2)
Orofacial clefts	10.8 (10.4 to 11.2)	10.5 (10.1 to 10.9)	-3.0 (-7.4 to 2.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-14.1 (-23.7 to -1.6)
Down syndrome	9.3 (8.8 to 9.8)	9.6 (9.2 to 10.0)	3.6 (-2.3 to 9.9)	1.0 (0.7 to 1.4)	1.1 (0.8 to 1.4)	4.0 (-3.7 to 12.4)
Turner syndrome	0.3 (0.3 to 0.3)	0.3 (0.3 to 0.3)	2.5 (-4.6 to 11.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.5 (-4.6 to 11.0)
Klinefelter syndrome	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.3)	3.9 (-3.2 to 12.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.9 (-3.2 to 12.7)
Chromosomal unbalanced rearrangements	12.4 (12.0 to 12.8)	13.0 (12.4 to 13.6)	4.6 (-0.7 to 10.4)	1.4 (1.0 to 1.8)	1.4 (1.0 to 1.9)	4.8 (-1.9 to 12.3)
Other congenital anomalies	22.6 (18.1 to 27.3)	20.7 (16.1 to 25.1)	-8.7 (-14.2 to -3.6)	4.4 (2.9 to 6.6)	5.3 (3.1 to 6.6)	5.3 (-9.5 to 19.2)
Skin and subcutaneous diseases	-	-	-	0.4 (0.2 to 0.9)	0.5 (0.2 to 0.9)	2.1 (-10.1 to 14.2)
Dermatitis	-	-	-	-	-	-
Psoriasis	-	-	-	-	-	-
Cellulitis	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-9.8 (-21.9 to -2.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.0 (-22.1 to -2.5)
Pyoderma	2.0 (1.1 to 3.1)	1.4 (0.8 to 2.1)	-30.9 (-34.9 to -20.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.1 (-40.9 to -15.5)
Scabies	7.2 (6.1 to 8.5)	7.4 (6.3 to 8.6)	3.0 (-18.3 to 28.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	3.5 (-19.8 to 29.3)
Fungal skin diseases	3.1 (1.8 to 4.6)	3.8 (2.4 to 5.5)	24.8 (16.1 to 37.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.5 (11.1 to 43.2)
Viral skin diseases	-	-	-	-	-	-
Acne vulgaris	-	-	-	-	-	-
Alopecia areata	-	-	-	-	-	-
Pruritus	0.4 (0.3 to 0.4)	0.4 (0.3 to 0.4)	-4.3 (-16.5 to 13.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.7 (-21.1 to 19.4)
Urticaria	-	-	0.0 (0.0 to 0.0)	-	-	-
Decubitus ulcer	-	-	-	-	-	-
Other skin and subcutaneous diseases	34.8 (7.5 to 81.5)	35.5 (7.7 to 83.1)	2.1 (0.0 to 4.0)	0.2 (0.0 to 0.6)	0.2 (0.0 to 0.6)	2.1 (-2.4 to 6.9)
Sense organ diseases	-	-	-	4.5 (3.0 to 6.6)	4.1 (2.7 to 6.0)	-10.6 (-15.4 to -5.5)
Glaucoma	-	-	-	-	-	-
Cataract	-	-	-	-	-	-
Macular degeneration	-	-	-	-	-	-
Uncorrected refractive error	147.0 (136.1 to 158.9)	143.7 (133.0 to 154.0)	-2.3 (-9.2 to 5.1)	3.0 (1.9 to 4.7)	2.8 (1.7 to 4.3)	-7.2 (-12.7 to -1.5)
Age-related and other hearing loss	8.7 (7.0 to 10.4)	8.3 (6.5 to 10.0)	-4.9 (-13.5 to 2.5)	1.1 (0.7 to 1.7)	1.0 (0.6 to 1.5)	-10.6 (-22.5 to 1.1)
Other vision loss	10.5 (7.0 to 14.2)	7.3 (5.0 to 10.0)	-30.5 (-35.0 to -25.4)	0.4 (0.2 to 0.7)	0.3 (0.2 to 0.5)	-33.6 (-40.9 to -26.1)
Other sense organ diseases	-	-	-	-	-	-
Oral disorders	-	-	-	-	-	-
Deciduous caries	-	-	-	-	-	-
Permanent caries	-	-	-	-	-	-
Periodontal diseases	-	-	-	-	-	-
Edentulism and severe tooth loss	-	-	-	-	-	-
Other oral disorders	-	-	-	-	-	-
Injuries	-	-	-	3.9 (2.0 to 6.8)	1.0 (0.4 to 1.9)	-77.2 (-86.8 to -43.2)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (7-27 days)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Transport injuries	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-51.6 (-54.6 to -48.3)
Road injuries	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-52.2 (-55.5 to -48.5)
Pedestrian road injuries	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-37.8 (-45.6 to -29.4)
Cyclist road injuries	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-37.9 (-46.5 to -27.7)
Motorcyclist road injuries	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-76.6 (-79.5 to -73.8)
Motor vehicle road injuries	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-41.5 (-46.8 to -35.1)
Other road injuries	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-44.6 (-52.2 to -36.5)
Other transport injuries	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-49.8 (-53.3 to -45.4)
Unintentional injuries	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-17.7 (-23.2 to -12.1)
Falls	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-4.3 (-14.2 to 4.9)
Drowning	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-56.0 (-62.8 to -47.1)
Fire, heat, and hot substances	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-29.7 (-42.6 to -15.1)
Poisonings	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-34.1 (-44.5 to -16.0)
Exposure to mechanical forces	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-13.6 (-19.5 to -6.5)
Unintentional firearm injuries	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-33.8 (-38.9 to -26.8)
Unintentional suffocation	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-11.4 (-18.1 to -3.3)
Other exposure to mechanical forces	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-12.2 (-19.2 to -3.7)
Adverse effects of medical treatment	-	-	-	0-0 (0-0 to 0-0)	-	-100.0 (-100.0 to -100.0)
Animal contact	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-23.8 (-35.4 to -11.5)
Venomous animal contact	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-20.3 (-38.7 to 3.7)
Non-venomous animal contact	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-26.9 (-37.8 to -17.5)
Foreign body	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-39.0 (-45.9 to -31.2)
Pulmonary aspiration and foreign body in airway	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-43.2 (-50.4 to -34.6)
Foreign body in eyes	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-12.9 (-21.6 to -2.9)
Foreign body in other body part	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-20.7 (-29.8 to -10.9)
Other unintentional injuries	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-24.7 (-31.6 to -16.1)
Self-harm and interpersonal violence	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-16.1 (-22.1 to -9.6)
Self-harm	-	-	-	-	-	-
Interpersonal violence	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-16.1 (-22.1 to -9.6)
Assault by firearm	-	-	-	-	-	-
Assault by sharp object	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-15.3 (-22.3 to -7.5)
Assault by other means	-	-	-	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-16.3 (-22.5 to -9.1)
Forces of nature, war, and legal intervention	-	-	-	3.8 (1.9 to 6.7)	0.9 (0.4 to 1.9)	-77.7 (-87.4 to -43.5)
Exposure to forces of nature	-	-	-	1.5 (0.7 to 2.8)	0.2 (0.1 to 0.9)	-91.2 (-96.3 to -27.0)
Collective violence and legal intervention	-	-	-	2.3 (1.0 to 4.5)	0.7 (0.3 to 1.5)	-69.2 (-82.8 to -31.4)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (28-364 days)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
All causes	-	-	-	7,234.5 (5,054.8 to 9,737.1)	6,603.2 (4,635.2 to 8,987.6)	-8.7 (-12.3 to -5.2)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	6,144.3 (4,254.7 to 8,318.2)	5,519.4 (3,854.4 to 7,522.9)	-10.2 (-14.2 to -6.0)
HIV/AIDS and tuberculosis	-	-	-	6.3 (4.4 to 8.3)	15.9 (11.3 to 20.9)	153.7 (124.9 to 186.1)
Tuberculosis	4.9 (4.6 to 5.3)	5.1 (4.8 to 5.4)	3.0 (-0.4 to 6.5)	1.6 (1.1 to 2.2)	1.7 (1.1 to 2.3)	2.8 (-7.0 to 12.6)
HIV/AIDS	-	-	-	4.7 (3.3 to 6.2)	14.3 (10.2 to 18.9)	206.7 (165.1 to 250.8)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	216.2 (174.4 to 264.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	216.3 (174.2 to 264.5)
HIV/AIDS resulting in other diseases	43.4 (39.5 to 47.4)	147.1 (137.7 to 158.2)	238.2 (213.1 to 267.3)	4.7 (3.3 to 6.2)	14.3 (10.1 to 18.8)	206.6 (165.0 to 250.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	1,840.5 (1,270.3 to 2,508.3)	1,536.9 (1,069.6 to 2,085.2)	-16.5 (-18.6 to -14.3)
Diarrheal diseases	9,282.5 (9,108.7 to 9,440.8)	7,954.8 (7,791.2 to 8,140.8)	-14.5 (-16.7 to -11.9)	1,507.7 (1,031.1 to 2,073.5)	1,295.1 (885.0 to 1,783.1)	-14.1 (-16.6 to -11.3)
Intestinal infectious diseases	-	-	-	10.1 (6.8 to 14.4)	6.3 (4.2 to 9.0)	-37.9 (-48.9 to -22.6)
Typhoid fever	54.2 (48.1 to 60.7)	35.6 (31.2 to 40.0)	-35.2 (-43.7 to -19.7)	7.1 (4.7 to 10.2)	4.7 (3.1 to 6.9)	-33.5 (-48.6 to -11.1)
Paratyphoid fever	44.7 (38.8 to 50.2)	26.1 (22.8 to 30.4)	-41.6 (-53.6 to -28.6)	2.3 (1.4 to 3.5)	1.4 (0.8 to 2.1)	-40.7 (-56.7 to -19.2)
Other intestinal infectious diseases	-	-	-	0.7 (0.3 to 1.3)	0.2 (0.1 to 0.4)	-69.6 (-75.5 to -62.0)
Lower respiratory infections	950.0 (919.9 to 983.9)	643.7 (617.5 to 674.6)	-32.3 (-36.2 to -28.9)	100.2 (67.5 to 141.1)	68.0 (45.6 to 95.1)	-32.1 (-36.7 to -28.3)
Upper respiratory infections	4,598.5 (4,450.3 to 4,755.0)	5,050.0 (4,900.6 to 5,207.9)	9.6 (4.8 to 14.9)	54.5 (30.3 to 91.1)	59.9 (33.5 to 100.0)	9.9 (4.5 to 15.8)
Otitis media	1,666.7 (1,618.4 to 1,718.7)	1,494.5 (1,440.1 to 1,547.3)	-10.5 (-14.4 to -6.2)	30.8 (18.2 to 49.9)	27.9 (16.1 to 45.5)	-9.4 (-13.7 to -5.1)
Meningitis	-	-	-	24.4 (17.0 to 33.0)	13.8 (9.5 to 18.7)	-43.3 (-46.5 to -39.6)
Pneumococcal meningitis	58.0 (46.6 to 73.1)	32.3 (26.4 to 40.3)	-44.3 (-48.7 to -40.3)	7.2 (5.0 to 9.7)	4.2 (3.0 to 5.6)	-41.0 (-46.9 to -34.9)
H influenzae type B meningitis	54.8 (43.0 to 72.1)	30.9 (24.4 to 40.6)	-43.9 (-47.9 to -38.5)	7.4 (5.2 to 10.2)	4.4 (3.0 to 6.1)	-40.1 (-46.5 to -32.2)
Meningococcal meningitis	27.3 (22.7 to 36.7)	14.5 (12.0 to 19.3)	-47.0 (-52.0 to -41.0)	3.8 (2.6 to 5.3)	2.1 (1.4 to 2.9)	-45.2 (-52.1 to -38.1)
Other meningitis	44.3 (35.6 to 58.9)	21.7 (17.8 to 28.7)	-51.0 (-55.3 to -46.6)	6.0 (4.2 to 8.3)	3.1 (2.1 to 4.3)	-49.0 (-54.0 to -42.5)
Encephalitis	15.0 (11.9 to 21.4)	9.7 (7.9 to 13.8)	-35.5 (-38.9 to -32.9)	2.1 (1.4 to 2.9)	1.4 (1.0 to 2.0)	-31.9 (-41.8 to -20.7)
Diphtheria	0.7 (0.3 to 1.6)	0.2 (0.1 to 0.7)	-71.3 (-92.4 to 38.2)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-71.3 (-92.4 to 38.1)
Whooping cough	1,708.7 (1,323.5 to 2,193.6)	1,179.2 (915.3 to 1,508.5)	-31.1 (-31.7 to -30.4)	84.4 (50.3 to 136.5)	58.2 (34.1 to 92.1)	-31.0 (-32.8 to -29.3)
Tetanus	91.9 (65.3 to 130.9)	8.4 (5.9 to 12.2)	-91.1 (-94.4 to -85.6)	7.0 (4.5 to 11.7)	0.7 (0.5 to 1.2)	-89.5 (-93.8 to -81.4)
Measles	195.5 (149.5 to 251.5)	42.6 (33.3 to 53.9)	-78.2 (-80.3 to -76.1)	17.4 (10.6 to 27.7)	3.8 (2.3 to 5.9)	-78.3 (-81.6 to -74.1)
Varicella and herpes zoster	332.5 (319.4 to 344.5)	316.8 (303.1 to 331.6)	-4.7 (-10.4 to 0.7)	1.9 (0.8 to 4.0)	1.8 (0.7 to 3.8)	-5.0 (-11.3 to 1.4)
Neglected tropical diseases and malaria	-	-	-	410.6 (273.6 to 590.8)	377.4 (253.3 to 539.0)	-8.3 (-12.2 to -1.6)
Malaria	4,761.5 (4,378.7 to 5,301.9)	5,367.4 (5,080.3 to 5,705.6)	13.0 (1.6 to 22.5)	105.8 (69.5 to 153.4)	114.2 (76.4 to 164.0)	8.3 (-0.5 to 15.6)
Chagas disease	21.7 (21.1 to 22.4)	20.4 (19.8 to 21.1)	-6.3 (-10.8 to -1.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.1 (-34.4 to 2.5)
Leishmaniasis	-	-	-	0.7 (0.4 to 1.1)	0.8 (0.5 to 1.3)	14.7 (-21.4 to 66.4)
Visceral leishmaniasis	7.9 (5.8 to 10.8)	8.8 (6.6 to 11.7)	11.9 (-18.4 to 44.3)	0.5 (0.3 to 0.9)	0.6 (0.3 to 1.0)	13.4 (-29.7 to 79.4)
Cutaneous and mucocutaneous leishmaniasis	13.2 (11.9 to 14.7)	15.9 (14.2 to 17.8)	20.5 (8.5 to 33.5)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.3)	20.4 (4.7 to 38.5)
African trypanosomiasis	-	-	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	-	-	-
Cysticercosis	-	-	-	-	-	-
Cystic echinococcosis	-	-	-	-	-	-
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	-	-	-
Onchocerciasis	-	-	-	-	-	-
Trachoma	-	-	-	-	-	-
Dengue	11.1 (4.1 to 24.9)	58.1 (21.4 to 130.3)	423.2 (422.0 to 424.7)	1.8 (0.6 to 4.8)	9.6 (3.2 to 24.2)	423.1 (309.6 to 590.1)
Yellow fever	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-64.7 (-73.2 to -49.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-64.7 (-73.2 to -49.8)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-65.5 (-79.2 to -36.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-65.5 (-79.2 to -36.4)
Intestinal nematode infections	-	-	-	101.5 (63.2 to 154.5)	60.8 (38.0 to 91.4)	-40.1 (-44.5 to -35.3)
Ascariasis	15,919.7 (13,281.3 to 19,546.6)	10,124.3 (8,803.4 to 11,615.9)	-36.2 (-49.9 to -20.0)	34.1 (20.1 to 55.8)	16.9 (9.9 to 27.2)	-50.6 (-58.3 to -41.2)
Trichuriasis	8,742.5 (7,442.1 to 10,489.3)	6,522.8 (5,911.0 to 7,172.2)	-25.0 (-39.3 to -10.1)	9.1 (5.1 to 14.6)	5.7 (3.2 to 9.5)	-37.6 (-50.8 to -17.3)
Hookworm disease	7,228.7 (6,195.2 to 8,683.2)	5,420.3 (4,955.3 to 5,960.2)	-24.7 (-38.6 to -10.6)	58.3 (38.4 to 85.0)	38.2 (24.3 to 55.8)	-34.7 (-39.5 to -28.7)
Food-borne trematodiasis	-	-	-	-	-	-
Other neglected tropical diseases	5,034.1 (4,650.6 to 5,429.7)	4,923.8 (4,822.6 to 5,059.4)	-2.3 (-9.5 to 5.5)	200.8 (133.2 to 289.0)	192.0 (128.5 to 274.8)	-5.0 (-9.3 to 5.5)
Maternal disorders	-	-	-	-	-	-
Maternal hemorrhage	-	-	-	-	-	-
Maternal sepsis and other maternal infections	-	-	-	-	-	-
Maternal hypertensive disorders	-	-	-	-	-	-
Obstructed labor	-	-	-	-	-	-
Complications of abortion	-	-	-	-	-	-
Other maternal disorders	-	-	-	-	-	-
Neonatal disorders	-	-	-	344.1 (248.2 to 448.4)	426.3 (308.2 to 548.6)	23.4 (11.6 to 40.4)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (28-364 days)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Preterm birth complications	931.5 (776.9 to 1,110.7)	1,764.7 (1,522.3 to 2,056.1)	88.9 (71.2 to 110.5)	97.9 (69.5 to 128.5)	185.6 (133.4 to 243.8)	89.3 (73.3 to 109.5)
Neonatal encephalopathy due to birth asphyxia and trauma	1,466.1 (687.9 to 2,692.1)	1,075.6 (576.9 to 2,044.8)	-26.7 (-42.3 to -0.6)	141.7 (101.3 to 186.9)	121.2 (88.0 to 156.9)	-14.3 (-24.9 to -2.6)
Neonatal sepsis and other neonatal infections	-	-	0.0 (0.0 to 0.0)	-	-	-
Hemolytic disease and other neonatal jaundice	161.7 (119.0 to 217.4)	204.5 (160.1 to 261.2)	26.8 (-16.5 to 102.4)	45.1 (29.4 to 63.8)	56.7 (38.3 to 79.6)	25.2 (-11.9 to 90.6)
Other neonatal disorders	-	-	-	59.5 (36.5 to 90.8)	62.8 (41.9 to 87.2)	5.7 (-19.6 to 42.1)
Nutritional deficiencies	-	-	-	3,397.7 (2,292.2 to 4,792.0)	3,026.3 (2,051.0 to 4,269.5)	-11.0 (-18.1 to -3.3)
Protein-energy malnutrition	7,535.6 (6,357.9 to 9,122.4)	6,480.5 (5,347.3 to 7,931.6)	-14.5 (-33.5 to 11.5)	928.6 (562.3 to 1,368.2)	801.1 (500.7 to 1,212.0)	-14.3 (-33.6 to 12.1)
Iodine deficiency	-	-	0.0 (0.0 to 0.0)	-	-	-
Vitamin A deficiency	-	-	-	-	-	-
Iron-deficiency anemia	56,883.9 (56,485.3 to 57,273.4)	55,370.0 (55,203.1 to 55,526.6)	-2.8 (-3.5 to -2.1)	2,288.4 (1,530.9 to 3,285.1)	2,125.7 (1,419.7 to 3,057.1)	-7.1 (-8.3 to -6.0)
Other nutritional deficiencies	-	-	-	180.7 (87.5 to 327.4)	99.5 (53.2 to 175.2)	-44.6 (-64.1 to -14.4)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	145.0 (96.9 to 207.8)	136.5 (91.7 to 197.3)	-6.1 (-9.5 to -0.2)
Sexually transmitted diseases excluding HIV	-	-	-	-	-	-
Syphilis	-	-	0.0 (0.0 to 0.0)	-	-	-
Chlamydial infection	-	-	-	-	-	-
Gonococcal infection	-	-	-	-	-	-
Trichomoniasis	-	-	-	-	-	-
Genital herpes	-	-	-	-	-	-
Other sexually transmitted diseases	-	-	-	-	-	-
Hepatitis	-	-	-	0.8 (0.5 to 1.2)	0.6 (0.4 to 0.9)	-23.9 (-32.2 to -14.3)
Hepatitis A	400.9 (356.3 to 451.8)	337.6 (304.4 to 375.1)	-15.9 (-17.1 to -14.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-15.9 (-17.1 to -14.7)
Hepatitis B	4,319.6 (4,156.9 to 4,529.5)	3,222.1 (3,078.5 to 3,382.1)	-25.5 (-29.8 to -21.1)	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-32.7 (-42.6 to -19.8)
Hepatitis C	176.5 (172.2 to 181.7)	149.2 (144.8 to 154.1)	-15.6 (-19.1 to -12.4)	0.4 (0.2 to 0.5)	0.3 (0.2 to 0.5)	-16.2 (-30.3 to 0.5)
Hepatitis E	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-2.9 (-24.8 to 26.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.4 (-25.6 to 35.2)
Leprosy	-	-	-	-	-	-
Other infectious diseases	3,591.2 (3,420.2 to 3,792.2)	3,490.6 (3,421.9 to 3,563.3)	-2.9 (-6.9 to 0.9)	144.2 (96.3 to 206.6)	135.9 (91.3 to 196.5)	-6.0 (-9.4 to -0.1)
Non-communicable diseases	-	-	-	1,066.6 (768.5 to 1,424.8)	1,074.4 (778.5 to 1,438.4)	0.8 (-2.0 to 3.4)
Neoplasms	-	-	-	16.6 (9.1 to 28.7)	23.5 (13.6 to 37.3)	47.5 (-22.6 to 131.1)
Esophageal cancer	-	-	-	-	-	-
Stomach cancer	-	-	-	-	-	-
Liver cancer	-	-	-	-	-	-
Liver cancer due to hepatitis B	-	-	-	-	-	-
Liver cancer due to hepatitis C	-	-	-	-	-	-
Liver cancer due to alcohol use	-	-	-	-	-	-
Liver cancer due to other causes	-	-	-	-	-	-
Larynx cancer	-	-	-	-	-	-
Tracheal, bronchus and lung cancer	-	-	-	-	-	-
Breast cancer	-	-	-	-	-	-
Cervical cancer	-	-	-	-	-	-
Uterine cancer	-	-	-	-	-	-
Prostate cancer	-	-	-	-	-	-
Colon and rectum cancer	-	-	-	-	-	-
Lip and oral cavity cancer	-	-	-	-	-	-
Nasopharynx cancer	-	-	-	-	-	-
Other pharynx cancer	-	-	-	-	-	-
Gallbladder and biliary tract cancer	-	-	-	-	-	-
Pancreatic cancer	-	-	-	-	-	-
Malignant skin melanoma	-	-	-	-	-	-
Non-melanoma skin cancer	-	-	-	-	-	-
Ovarian cancer	-	-	-	-	-	-
Testicular cancer	-	-	-	-	-	-
Kidney cancer	-	-	0.0 (0.0 to 0.0)	-	-	-
Bladder cancer	-	-	-	-	-	-
Brain and nervous system cancer	-	-	-	-	-	-
Thyroid cancer	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-
Hodgkin lymphoma	76.9 (36.2 to 179.4)	46.0 (18.8 to 111.6)	-41.6 (-83.7 to 135.0)	4.2 (1.6 to 10.1)	2.5 (0.9 to 6.2)	-42.6 (-84.3 to 127.0)
Non-Hodgkin lymphoma	-	-	0.0 (0.0 to 0.0)	-	-	-
Multiple myeloma	-	-	-	-	-	-
Leukemia	-	-	0.0 (0.0 to 0.0)	-	-	-
Other neoplasms	240.5 (169.8 to 386.9)	406.7 (285.3 to 575.5)	80.8 (-16.9 to 172.6)	12.4 (6.7 to 21.5)	21.0 (11.9 to 33.9)	80.7 (-17.9 to 171.4)
Cardiovascular diseases	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-32.0 (-50.1 to -15.5)
Rheumatic heart disease	-	-	-	-	-	-
Ischemic heart disease	-	-	0.0 (0.0 to 0.0)	-	-	-
Cerebrovascular disease	-	-	-	-	-	-
Ischemic stroke	-	-	0.0 (0.0 to 0.0)	-	-	-

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (28-364 days)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Hemorrhagic stroke	-	-	0.0 (0.0 to 0.0)	-	-	-
Hypertensive heart disease	-	-	0.0 (0.0 to 0.0)	-	-	-
Cardiomyopathy and myocarditis	-	-	0.0 (0.0 to 0.0)	-	-	-
Atrial fibrillation and flutter	-	-	-	-	-	-
Peripheral vascular disease	-	-	-	-	-	-
Endocarditis	1.6 (1.4 to 2.0)	1.1 (1.0 to 1.2)	-31.2 (-44.4 to -19.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-32.0 (-50.1 to -15.5)
Other cardiovascular and circulatory diseases	-	-	0.0 (0.0 to 0.0)	-	-	-
Chronic respiratory diseases	-	-	-	-	-	-
Chronic obstructive pulmonary disease	-	-	0.0 (0.0 to 0.0)	-	-	-
Pneumoconiosis	-	-	-	-	-	-
Silicosis	-	-	-	-	-	-
Asbestosis	-	-	-	-	-	-
Coal workers pneumoconiosis	-	-	-	-	-	-
Other pneumoconiosis	-	-	-	-	-	-
Asthma	-	-	-	-	-	-
Interstitial lung disease and pulmonary sarcoidosis	-	-	-	-	-	-
Other chronic respiratory diseases	-	-	-	-	-	-
Cirrhosis	-	-	-	1.2 (0.8 to 1.8)	0.7 (0.4 to 1.1)	-41.5 (-56.0 to -18.1)
Cirrhosis due to hepatitis B	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-66.9 (-78.7 to -42.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-66.9 (-78.8 to -42.4)
Cirrhosis due to hepatitis C	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-51.4 (-70.8 to -23.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.4 (-70.8 to -23.3)
Cirrhosis due to alcohol use	-	-	-	-	-	-
Cirrhosis due to other causes	6.9 (6.6 to 7.2)	4.0 (3.9 to 4.2)	-42.2 (-45.2 to -38.6)	1.2 (0.7 to 1.7)	0.7 (0.4 to 1.0)	-41.1 (-56.2 to -16.7)
Digestive diseases	-	-	-	6.3 (4.2 to 8.8)	6.7 (4.4 to 9.4)	7.8 (-9.6 to 26.0)
Peptic ulcer disease	-	-	-	-	-	-
Gastritis and duodenitis	-	-	-	-	-	-
Appendicitis	-	-	-	-	-	-
Paralytic ileus and intestinal obstruction	20.0 (18.4 to 22.1)	21.4 (18.9 to 23.6)	7.9 (-7.8 to 21.3)	6.3 (4.2 to 8.8)	6.7 (4.4 to 9.4)	7.8 (-9.6 to 26.0)
Inguinal, femoral, and abdominal hernia	-	-	-	-	-	-
Inflammatory bowel disease	-	-	-	-	-	-
Vascular intestinal disorders	-	-	-	-	-	-
Gallbladder and biliary diseases	-	-	-	-	-	-
Pancreatitis	-	-	-	-	-	-
Other digestive diseases	-	-	-	-	-	-
Neurological disorders	-	-	-	105.4 (71.5 to 141.9)	109.4 (74.6 to 145.5)	3.5 (-7.9 to 17.4)
Alzheimer disease and other dementias	-	-	-	-	-	-
Parkinson disease	-	-	-	-	-	-
Epilepsy	322.3 (299.0 to 345.2)	309.5 (287.2 to 330.2)	-4.1 (-13.2 to 6.2)	105.4 (71.5 to 141.9)	109.4 (74.6 to 145.5)	3.5 (-7.9 to 17.4)
Multiple sclerosis	-	-	-	-	-	-
Migraine	-	-	-	-	-	-
Tension-type headache	-	-	-	-	-	-
Medication overuse headache	-	-	-	-	-	-
Other neurological disorders	-	-	0.0 (0.0 to 0.0)	-	-	-
Mental and substance use disorders	-	-	-	112.4 (78.5 to 153.3)	114.4 (78.4 to 156.4)	1.8 (-1.6 to 5.3)
Schizophrenia	-	-	-	-	-	-
Alcohol use disorders	26.3 (22.0 to 30.1)	28.1 (23.6 to 31.7)	6.7 (-1.1 to 14.4)	1.3 (0.8 to 2.0)	1.4 (0.8 to 2.0)	5.6 (-10.8 to 24.4)
Drug use disorders	-	-	-	-	-	-
Opioid use disorders	-	-	0.0 (0.0 to 0.0)	-	-	-
Cocaine use disorders	-	-	0.0 (0.0 to 0.0)	-	-	-
Amphetamine use disorders	-	-	0.0 (0.0 to 0.0)	-	-	-
Cannabis use disorders	-	-	-	-	-	-
Other drug use disorders	-	-	-	-	-	-
Depressive disorders	-	-	-	-	-	-
Major depressive disorder	-	-	-	-	-	-
Dysthymia	-	-	-	-	-	-
Bipolar disorder	-	-	-	-	-	-
Anxiety disorders	-	-	-	-	-	-
Eating disorders	-	-	-	-	-	-
Anorexia nervosa	-	-	-	-	-	-
Bulimia nervosa	-	-	-	-	-	-
Autistic spectrum disorders	-	-	-	101.4 (70.1 to 139.3)	104.5 (71.3 to 143.2)	3.0 (0.0 to 6.4)
Autism	232.2 (206.2 to 257.6)	238.7 (211.9 to 264.9)	2.6 (2.3 to 2.9)	58.4 (39.3 to 82.6)	60.1 (39.9 to 84.6)	3.0 (-1.7 to 8.0)
Asperger syndrome	424.9 (377.1 to 468.1)	436.8 (387.5 to 481.2)	2.6 (2.6 to 2.7)	43.0 (29.0 to 61.0)	44.3 (29.7 to 62.4)	3.0 (-0.8 to 6.7)
Attention-deficit/hyperactivity disorder	-	-	-	-	-	-
Conduct disorder	-	-	-	-	-	-
Idiopathic intellectual disability	200.0 (128.7 to 290.0)	175.1 (115.9 to 249.9)	-12.0 (-30.1 to 5.8)	9.7 (5.5 to 15.2)	8.5 (5.0 to 13.3)	-11.5 (-29.4 to 7.6)
Other mental and substance use disorders	-	-	-	-	-	-
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	568.5 (397.7 to 801.6)	555.3 (386.2 to 779.7)	-2.3 (-4.8 to 0.1)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (28-364 days)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Diabetes mellitus	0.4 (0.3 to 0.4)	0.5 (0.4 to 0.6)	36.1 (20.1 to 61.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.2 (20.1 to 61.8)
Acute glomerulonephritis	2.0 (1.6 to 2.3)	1.4 (1.1 to 1.7)	-29.3 (-34.0 to -26.2)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-29.3 (-34.0 to -26.2)
Chronic kidney disease	-	-	-	105.6 (70.1 to 144.6)	107.4 (70.9 to 147.3)	1.6 (-3.4 to 7.2)
Chronic kidney disease due to diabetes mellitus	139.3 (61.2 to 278.0)	170.1 (76.2 to 333.2)	21.4 (4.9 to 40.1)	3.0 (2.0 to 4.2)	3.4 (2.3 to 4.8)	14.5 (1.3 to 29.3)
Chronic kidney disease due to hypertension	2,026.2 (679.1 to 4,611.0)	2,327.5 (859.8 to 5,190.5)	16.2 (-1.4 to 36.4)	11.0 (7.1 to 15.5)	12.1 (7.8 to 17.0)	9.9 (-6.7 to 28.9)
Chronic kidney disease due to glomerulonephritis	1,081.7 (673.0 to 1,760.0)	1,182.0 (699.9 to 1,982.7)	8.2 (-3.8 to 25.6)	42.9 (28.7 to 58.8)	39.9 (26.5 to 54.4)	-7.0 (-16.3 to 2.1)
Chronic kidney disease due to other causes	2,565.7 (1,085.0 to 5,260.1)	2,962.6 (1,249.2 to 5,978.4)	15.5 (6.4 to 25.8)	48.7 (31.9 to 66.7)	52.0 (33.8 to 72.0)	6.5 (-2.0 to 17.5)
Urinary diseases and male infertility	-	-	-	0.8 (0.5 to 1.2)	0.9 (0.6 to 1.4)	16.8 (-3.5 to 43.5)
Interstitial nephritis and urinary tract infections	17.4 (16.6 to 18.4)	19.7 (18.8 to 20.6)	12.9 (6.8 to 19.5)	0.6 (0.4 to 0.9)	0.7 (0.4 to 1.0)	12.2 (-7.8 to 38.1)
Urolithiasis	-	-	-	-	-	-
Benign prostatic hyperplasia	-	-	-	-	-	-
Male infertility due to other causes	-	-	-	-	-	-
Other urinary diseases	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	32.2 (3.3 to 72.2)
Gynecological diseases	-	-	-	-	-	-
Uterine fibroids	-	-	-	-	-	-
Polycystic ovarian syndrome	-	-	-	-	-	-
Female infertility due to other causes	-	-	-	-	-	-
Endometriosis	-	-	-	-	-	-
Genital prolapse	-	-	-	-	-	-
Premenstrual syndrome	-	-	-	-	-	-
Other gynecological diseases	-	-	-	-	-	-
Hemoglobinopathies and hemolytic anemias	-	-	-	319.3 (214.3 to 459.5)	313.2 (210.1 to 449.2)	-2.0 (-5.0 to 1.1)
Thalassemias	44.6 (39.1 to 50.3)	40.7 (36.6 to 45.4)	-9.1 (-12.2 to -4.1)	3.6 (2.4 to 5.3)	3.2 (2.0 to 4.7)	-12.8 (-28.7 to 7.9)
Thalassemia trait	3,689.6 (3,509.4 to 3,994.7)	3,602.4 (3,446.4 to 3,834.2)	-2.4 (-4.7 to -0.4)	149.2 (99.8 to 214.7)	137.4 (91.6 to 196.5)	-8.0 (-11.8 to -4.1)
Sickle cell disorders	103.8 (95.0 to 109.9)	161.7 (150.2 to 169.7)	55.0 (43.7 to 70.8)	9.9 (6.7 to 13.8)	14.1 (9.8 to 19.9)	43.1 (25.5 to 62.1)
Sickle cell trait	4,885.4 (4,659.4 to 5,105.1)	6,502.1 (6,224.4 to 6,760.6)	32.9 (30.7 to 34.9)	71.0 (47.4 to 103.1)	78.0 (51.9 to 111.0)	10.2 (-0.3 to 17.4)
G6PD deficiency	6,258.0 (6,095.6 to 6,410.1)	7,521.7 (7,346.0 to 7,699.0)	20.0 (16.1 to 23.9)	1.7 (1.1 to 2.4)	1.8 (1.2 to 2.6)	6.7 (-16.1 to 32.3)
G6PD trait	20,448.7 (20,303.2 to 20,568.4)	21,590.1 (21,432.1 to 21,734.1)	5.4 (4.4 to 6.5)	1.8 (1.1 to 2.6)	1.6 (0.9 to 2.3)	-13.8 (-38.7 to 13.3)
Other hemoglobinopathies and hemolytic anemias	2,068.0 (1,955.2 to 2,160.7)	2,011.4 (1,926.9 to 2,074.1)	-3.0 (-7.4 to 2.7)	82.1 (55.2 to 116.2)	77.2 (51.6 to 111.4)	-6.2 (-11.6 to 2.3)
Endocrine, metabolic, blood, and immune disorders	3,599.5 (3,520.4 to 3,681.2)	3,507.1 (3,361.2 to 3,625.6)	-2.7 (-7.4 to 1.8)	142.6 (98.3 to 200.8)	133.7 (90.6 to 189.7)	-6.1 (-12.8 to -0.1)
Musculoskeletal disorders	-	-	-	-	-	-
Rheumatoid arthritis	-	-	-	-	-	-
Osteoarthritis	-	-	-	-	-	-
Low back and neck pain	-	-	-	-	-	-
Low back pain	-	-	-	-	-	-
Neck pain	-	-	-	-	-	-
Gout	-	-	-	-	-	-
Other musculoskeletal disorders	-	-	-	-	-	-
Other non-communicable diseases	-	-	-	255.9 (185.8 to 339.0)	264.3 (193.1 to 344.9)	3.3 (-2.3 to 9.5)
Congenital anomalies	-	-	-	131.7 (96.4 to 171.1)	146.7 (105.9 to 190.5)	11.3 (3.6 to 20.1)
Neural tube defects	42.0 (40.9 to 43.2)	46.4 (45.1 to 47.7)	10.2 (6.3 to 14.1)	13.4 (9.4 to 17.3)	14.8 (10.5 to 19.2)	10.6 (-1.8 to 24.3)
Congenital heart anomalies	585.1 (564.2 to 609.7)	738.1 (712.2 to 770.8)	25.9 (19.4 to 34.2)	24.8 (13.5 to 38.5)	28.4 (13.4 to 47.3)	14.0 (-4.6 to 26.3)
Orofacial clefts	116.4 (111.9 to 121.3)	138.7 (133.0 to 144.3)	19.1 (12.3 to 26.0)	1.8 (1.2 to 2.7)	1.9 (1.2 to 2.9)	6.6 (-1.1 to 27.2)
Down syndrome	129.9 (124.0 to 136.5)	144.9 (139.3 to 151.3)	11.4 (5.0 to 18.0)	14.4 (10.4 to 18.7)	16.1 (11.9 to 21.0)	11.8 (1.8 to 22.4)
Turner syndrome	4.5 (4.3 to 4.8)	4.8 (4.6 to 5.1)	7.0 (-0.2 to 15.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	7.1 (-0.1 to 15.6)
Klinefelter syndrome	3.7 (3.5 to 3.9)	3.9 (3.7 to 4.1)	5.4 (-1.6 to 14.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.4 (-1.7 to 14.4)
Chromosomal unbalanced rearrangements	173.8 (167.8 to 178.9)	195.3 (186.3 to 205.9)	12.1 (6.3 to 18.5)	19.3 (13.8 to 25.4)	21.7 (15.6 to 28.3)	12.4 (3.9 to 21.6)
Other congenital anomalies	273.2 (222.3 to 327.7)	245.4 (196.1 to 298.0)	-10.3 (-16.4 to -4.6)	58.0 (39.6 to 83.0)	63.7 (43.9 to 87.4)	9.9 (-1.8 to 25.1)
Skin and subcutaneous diseases	-	-	-	42.1 (22.8 to 70.2)	43.3 (22.9 to 74.8)	3.0 (-13.7 to 20.6)
Dermatitis	-	-	-	-	-	-
Psoriasis	-	-	-	-	-	-
Cellulitis	33.4 (19.9 to 53.5)	30.1 (16.7 to 49.3)	-9.6 (-21.7 to -2.2)	2.4 (1.2 to 4.2)	2.2 (1.0 to 4.0)	-10.0 (-27.8 to 9.8)
Pyoderma	317.4 (176.7 to 491.2)	221.4 (134.6 to 332.3)	-30.7 (-34.7 to -20.0)	1.8 (0.6 to 4.4)	1.3 (0.4 to 3.0)	-30.5 (-35.5 to -19.2)
Scabies	1,121.0 (953.4 to 1,337.3)	1,168.5 (1,006.1 to 1,368.2)	4.1 (-17.4 to 29.4)	29.1 (16.2 to 47.4)	30.4 (16.6 to 50.2)	4.4 (-17.1 to 30.3)
Fungal skin diseases	475.1 (277.6 to 721.7)	602.7 (379.2 to 872.8)	26.3 (17.0 to 39.4)	2.7 (0.9 to 6.4)	3.4 (1.2 to 7.8)	27.1 (16.6 to 40.6)
Viral skin diseases	-	-	-	-	-	-
Acne vulgaris	-	-	-	-	-	-
Alopecia areata	-	-	-	-	-	-
Pruritus	5.7 (5.3 to 6.3)	5.6 (5.0 to 6.1)	-3.8 (-15.6 to 12.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-4.1 (-22.1 to 18.6)
Urticaria	-	-	0.0 (0.0 to 0.0)	-	-	-
Decubitus ulcer	-	-	-	-	-	-

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (28-364 days)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Other skin and subcutaneous diseases	988.7 (219.1 to 2,313.2)	983.2 (215.9 to 2,316.0)	-0.6 (-3.9 to 2.4)	5.9 (1.1 to 16.2)	5.9 (1.1 to 16.2)	-0.5 (-5.4 to 4.3)
Sense organ diseases	-	-	-	82.1 (56.1 to 119.2)	74.4 (49.7 to 108.7)	-9.4 (-14.5 to -4.2)
Glaucoma	-	-	-	-	-	-
Cataract	-	-	-	-	-	-
Macular degeneration	-	-	-	-	-	-
Uncorrected refractive error	2,526.0 (2,367.8 to 2,689.8)	2,473.1 (2,315.9 to 2,627.6)	-2.4 (-8.5 to 4.3)	54.8 (35.9 to 83.9)	51.0 (32.5 to 78.9)	-7.1 (-11.9 to -2.1)
Age-related and other hearing loss	142.6 (111.2 to 184.4)	131.5 (101.3 to 168.8)	-7.6 (-17.7 to 2.3)	21.7 (13.6 to 32.8)	19.3 (12.0 to 29.5)	-10.8 (-24.0 to 2.8)
Other vision loss	132.9 (97.8 to 173.3)	103.9 (76.4 to 133.4)	-21.9 (-26.8 to -17.4)	5.6 (3.3 to 8.8)	4.1 (2.4 to 6.6)	-26.6 (-35.3 to -18.9)
Other sense organ diseases	-	-	-	-	-	-
Oral disorders	-	-	-	-	-	-
Deciduous caries	-	-	-	-	-	-
Permanent caries	-	-	-	-	-	-
Periodontal diseases	-	-	-	-	-	-
Edentulism and severe tooth loss	-	-	-	-	-	-
Other oral disorders	-	-	-	-	-	-
Injuries	-	-	-	23.7 (14.8 to 39.2)	9.3 (6.0 to 18.6)	-62.9 (-74.7 to -23.9)
Transport injuries	-	-	-	1.2 (0.8 to 1.5)	0.6 (0.4 to 0.8)	-50.8 (-54.7 to -46.1)
Road injuries	-	-	-	0.9 (0.6 to 1.2)	0.4 (0.3 to 0.6)	-51.0 (-55.1 to -46.1)
Pedestrian road injuries	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-37.9 (-44.6 to -30.3)
Cyclist road injuries	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-39.0 (-47.1 to -29.5)
Motorcyclist road injuries	-	-	-	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.1)	-74.6 (-77.4 to -71.6)
Motor vehicle road injuries	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-40.5 (-46.4 to -33.5)
Other road injuries	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.4 (-50.7 to -35.6)
Other transport injuries	-	-	-	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-50.3 (-54.1 to -45.9)
Unintentional injuries	-	-	-	4.7 (3.3 to 6.2)	3.8 (2.7 to 5.2)	-17.5 (-24.7 to -9.8)
Falls	-	-	-	2.2 (1.6 to 3.0)	2.1 (1.5 to 3.0)	-3.4 (-16.8 to 10.4)
Drowning	-	-	-	0.4 (0.3 to 0.5)	0.2 (0.1 to 0.2)	-55.6 (-60.2 to -50.5)
Fire, heat, and hot substances	-	-	-	1.1 (0.8 to 1.4)	0.8 (0.5 to 1.1)	-28.5 (-38.1 to -17.5)
Poisonings	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-34.4 (-41.8 to -24.0)
Exposure to mechanical forces	-	-	-	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-13.5 (-20.6 to -6.0)
Unintentional firearm injuries	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.7 (-38.3 to -25.8)
Unintentional suffocation	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.8 (-19.8 to -3.1)
Other exposure to mechanical forces	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-12.2 (-20.1 to -4.1)
Adverse effects of medical treatment	-	-	-	0.0 (0.0 to 0.0)	-	-100.0 (-100.0 to -100.0)
Animal contact	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-22.1 (-29.8 to -13.6)
Venomous animal contact	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-19.5 (-30.9 to -3.6)
Non-venomous animal contact	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-24.5 (-32.9 to -14.8)
Foreign body	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-35.4 (-41.2 to -27.8)
Pulmonary aspiration and foreign body in airway	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-40.2 (-46.4 to -32.0)
Foreign body in eyes	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.7 (-17.7 to -4.5)
Foreign body in other body part	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.6 (-25.5 to -10.7)
Other unintentional injuries	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-24.3 (-29.9 to -17.8)
Self-harm and interpersonal violence	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-17.6 (-25.8 to -8.1)
Self-harm	-	-	-	-	-	-
Interpersonal violence	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-17.6 (-25.8 to -8.1)
Assault by firearm	-	-	-	-	-	-
Assault by sharp object	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.7 (-23.2 to -9.4)
Assault by other means	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-17.7 (-26.3 to -7.4)
Forces of nature, war, and legal intervention	-	-	-	17.6 (9.1 to 32.9)	4.8 (1.9 to 14.5)	-77.7 (-86.9 to -24.5)
Exposure to forces of nature	-	-	-	6.5 (3.0 to 12.2)	1.4 (0.2 to 8.5)	-90.6 (-96.0 to 33.0)
Collective violence and legal intervention	-	-	-	11.1 (4.9 to 23.3)	3.4 (1.4 to 7.4)	-70.4 (-83.1 to -35.1)

Appendix Table F.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (1-4 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
All causes	-	-	-	20,319.7 (14,234.4 to 27,777.8)	19,291.0 (13,567.8 to 26,326.7)	-5.0 (-8.4 to -1.8)
Communicable to maternal to neonatal to and nutritional diseases	-	-	-	13,811.1 (9,570.8 to 19,107.5)	12,748.6 (8,901.4 to 17,563.6)	-7.6 (-12.4 to -2.9)
HIV/AIDS and tuberculosis	-	-	-	36.4 (25.4 to 49.5)	76.0 (53.2 to 100.8)	109.8 (83.2 to 140.5)
Tuberculosis	56.2 (52.2 to 60.9)	56.4 (53.0 to 60.2)	0.3 (-3.0 to 3.5)	18.2 (11.7 to 26.0)	18.3 (11.9 to 26.0)	0.9 (-17.9 to 20.9)
HIV/AIDS	-	-	-	18.1 (12.7 to 23.9)	57.7 (40.8 to 76.3)	219.4 (173.6 to 267.6)
HIV/AIDS resulting in mycobacterial infection	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	228.3 (184.2 to 277.9)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	228.2 (183.8 to 277.9)
HIV/AIDS resulting in other diseases	166.4 (151.1 to 181.8)	586.8 (549.7 to 632.4)	252.4 (226.6 to 282.9)	18.1 (12.7 to 23.8)	57.6 (40.7 to 76.1)	219.4 (173.4 to 267.6)
Diarrhea to lower respiratory to and other common infectious diseases	-	-	-	4,248.3 (2,961.8 to 5,771.1)	3,570.9 (2,474.8 to 4,858.9)	-16.0 (-18.6 to -13.4)
Diarrheal diseases	18,615.6 (18,105.9 to 19,106.2)	16,170.9 (15,768.3 to 16,592.8)	-13.2 (-16.3 to -9.7)	3,052.9 (2,087.9 to 4,225.0)	2,661.1 (1,813.3 to 3,682.1)	-12.9 (-16.1 to -9.4)
Intestinal infectious diseases	-	-	-	61.5 (41.0 to 86.9)	39.3 (26.2 to 56.6)	-36.0 (-47.9 to -20.1)
Typhoid fever	331.1 (282.8 to 377.6)	223.6 (192.1 to 251.0)	-32.4 (-44.4 to -14.3)	43.9 (28.3 to 63.4)	29.9 (19.8 to 43.2)	-32.5 (-47.8 to -8.8)
Paratyphoid fever	263.0 (223.5 to 309.5)	156.1 (133.0 to 179.5)	-40.1 (-53.9 to -27.4)	13.6 (8.2 to 20.9)	8.2 (4.8 to 12.8)	-39.7 (-55.9 to -19.1)
Other intestinal infectious diseases	-	-	-	4.0 (1.9 to 7.8)	1.3 (0.6 to 2.5)	-68.5 (-74.4 to -60.7)
Lower respiratory infections	2,195.2 (2,132.0 to 2,250.5)	1,131.3 (1,062.7 to 1,186.6)	-48.5 (-51.8 to -45.3)	234.7 (157.9 to 331.7)	120.8 (81.2 to 172.0)	-48.5 (-52.2 to -44.7)
Upper respiratory infections	22,552.4 (22,065.4 to 23,030.7)	25,484.1 (24,855.1 to 26,153.0)	13.1 (9.2 to 16.9)	268.8 (147.7 to 448.4)	304.2 (169.5 to 507.7)	13.2 (8.9 to 17.3)
Otitis media	11,032.2 (10,189.4 to 11,797.2)	10,236.4 (9,505.0 to 11,042.5)	-7.3 (-10.9 to -3.1)	224.5 (132.9 to 360.9)	210.3 (124.8 to 335.6)	-6.4 (-10.2 to -2.1)
Meningitis	-	-	-	244.1 (170.4 to 327.0)	147.5 (104.0 to 195.9)	-39.6 (-43.0 to -35.8)
Pneumococcal meningitis	543.5 (393.3 to 729.8)	326.0 (242.1 to 433.4)	-40.1 (-44.0 to -35.8)	69.8 (48.5 to 94.4)	44.1 (30.8 to 58.2)	-36.7 (-43.9 to -28.6)
H influenzae type B meningitis	357.0 (210.8 to 567.5)	222.1 (142.4 to 344.8)	-37.7 (-42.4 to -31.2)	55.0 (37.5 to 74.6)	36.9 (25.5 to 49.9)	-33.0 (-40.7 to -23.3)
Meningococcal meningitis	129.7 (78.6 to 247.9)	73.1 (47.2 to 137.0)	-43.3 (-49.2 to -36.7)	21.2 (14.5 to 29.7)	12.5 (8.5 to 17.2)	-41.4 (-49.4 to -30.8)
Other meningitis	694.8 (588.5 to 870.6)	375.5 (323.5 to 464.5)	-46.0 (-48.7 to -42.9)	98.0 (68.0 to 135.8)	53.9 (37.0 to 74.4)	-45.0 (-48.8 to -41.1)
Encephalitis	92.7 (57.0 to 165.9)	59.6 (38.8 to 107.0)	-35.4 (-41.9 to -30.3)	14.5 (10.2 to 19.1)	10.1 (7.0 to 13.2)	-30.6 (-36.4 to -25.2)
Diphtheria	1.4 (0.5 to 4.1)	0.4 (0.1 to 1.1)	-74.1 (-94.3 to 18.9)	0.1 (0.0 to 0.3)	0.0 (0.0 to 0.1)	-74.1 (-94.3 to 20.4)
Whooping cough	1,679.0 (1,300.9 to 2,154.5)	1,178.3 (914.6 to 1,507.1)	-29.8 (-30.4 to -29.2)	83.5 (49.2 to 134.6)	58.6 (34.0 to 95.1)	-29.9 (-33.1 to -26.0)
Tetanus	154.0 (113.2 to 220.2)	17.3 (12.5 to 25.6)	-88.9 (-93.2 to -81.9)	8.8 (5.8 to 14.0)	1.7 (1.0 to 2.9)	-80.6 (-88.6 to -65.9)
Measles	534.9 (410.7 to 686.8)	121.3 (94.8 to 153.2)	-77.3 (-79.4 to -75.1)	48.0 (29.6 to 74.2)	10.9 (6.3 to 16.8)	-77.3 (-81.1 to -73.1)
Varicella and herpes zoster	963.7 (925.7 to 1,002.9)	919.2 (878.3 to 971.0)	-4.6 (-10.3 to 1.5)	6.9 (3.2 to 13.4)	6.4 (3.0 to 12.4)	-7.1 (-13.9 to 0.7)
Neglected tropical diseases and malaria	-	-	-	1,286.6 (841.2 to 1,876.6)	1,234.7 (804.1 to 1,809.6)	-4.2 (-8.0 to 2.4)
Malaria	35,560.9 (34,590.9 to 36,550.2)	47,313.6 (46,061.7 to 48,626.3)	33.0 (29.2 to 37.2)	444.6 (291.2 to 639.7)	531.0 (352.0 to 763.3)	19.3 (14.1 to 29.0)
Chagas disease	255.8 (248.1 to 263.2)	246.6 (239.0 to 254.9)	-3.5 (-7.5 to 0.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.6 (-26.3 to -3.5)
Leishmaniasis	-	-	-	2.6 (1.5 to 4.0)	3.4 (2.0 to 5.5)	32.5 (3.3 to 67.4)
Visceral leishmaniasis	24.6 (18.8 to 32.0)	28.6 (22.6 to 36.3)	16.1 (-4.3 to 43.9)	1.7 (1.0 to 2.8)	2.0 (1.2 to 3.3)	17.6 (-16.8 to 66.6)
Cutaneous and mucocutaneous leishmaniasis	76.1 (67.0 to 87.5)	123.1 (104.4 to 147.0)	61.1 (43.0 to 84.6)	0.8 (0.4 to 1.6)	1.3 (0.6 to 2.6)	60.9 (39.6 to 88.2)
African trypanosomiasis	4.9 (2.2 to 9.9)	1.3 (0.7 to 2.3)	-72.6 (-76.7 to -67.7)	1.4 (0.6 to 2.8)	0.4 (0.2 to 0.7)	-72.3 (-78.0 to -61.3)
Schistosomiasis	6,045.3 (5,456.4 to 6,624.4)	7,230.8 (6,255.1 to 8,387.5)	18.6 (10.6 to 33.5)	51.8 (27.1 to 94.4)	59.0 (30.4 to 111.5)	13.3 (3.6 to 25.1)
Cysticercosis	-	-	0.0 (0.0 to 0.0)	-	-	-
Cystic echinococcosis	52.9 (49.8 to 56.3)	26.7 (25.4 to 28.2)	-49.5 (-52.7 to -46.1)	5.1 (3.4 to 7.1)	2.6 (1.7 to 3.7)	-49.5 (-55.6 to -42.4)
Lymphatic filariasis	-	-	-52.4 (-64.2 to -30.9)	-	-	-
Onchocerciasis	-	-	-	-	-	-
Trachoma	-	-	-	-	-	-
Dengue	36.8 (13.5 to 82.5)	198.1 (72.9 to 444.3)	438.5 (437.0 to 440.4)	6.1 (1.9 to 15.2)	33.1 (10.5 to 84.9)	441.4 (306.6 to 632.7)
Yellow fever	0.5 (0.2 to 1.2)	0.2 (0.1 to 0.5)	-63.0 (-72.4 to -45.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.1 (-72.5 to -45.6)
Rabies	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.1)	-56.2 (-76.0 to -23.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.2 (-76.1 to -23.9)
Intestinal nematode infections	-	-	-	317.5 (191.1 to 503.3)	187.7 (114.0 to 298.3)	-40.9 (-45.7 to -35.5)
Ascariasis	65,848.8 (54,575.5 to 81,258.4)	42,146.2 (36,604.9 to 48,523.1)	-35.6 (-49.9 to -19.1)	133.3 (77.1 to 220.9)	65.2 (37.2 to 108.3)	-51.1 (-58.6 to -41.6)
Trichuriasis	36,000.9 (30,462.3 to 43,533.9)	27,207.6 (24,657.8 to 29,937.3)	-23.8 (-38.7 to -8.2)	34.8 (19.1 to 57.4)	22.4 (12.6 to 38.2)	-36.0 (-49.4 to -15.7)
Hookworm disease	29,538.6 (25,166.9 to 35,773.3)	22,389.9 (20,447.4 to 24,645.9)	-23.7 (-38.3 to -8.5)	149.4 (93.3 to 229.1)	100.1 (62.0 to 153.3)	-33.0 (-38.8 to -27.0)
Food-borne trematodiasis	179.0 (144.3 to 219.3)	102.7 (76.8 to 133.2)	-42.6 (-51.3 to -34.5)	7.2 (3.1 to 13.5)	3.1 (1.4 to 5.6)	-57.2 (-73.0 to -37.1)
Other neglected tropical diseases	14,087.4 (13,404.3 to 14,829.2)	13,294.9 (13,104.7 to 13,502.0)	-5.6 (-10.3 to -0.7)	450.3 (294.5 to 664.9)	414.5 (271.3 to 610.1)	-8.4 (-12.2 to 0.5)
Maternal disorders	-	-	-	-	-	-
Maternal hemorrhage	-	-	-	-	-	-
Maternal sepsis and other maternal infections	-	-	-	-	-	-
Maternal hypertensive disorders	-	-	-	-	-	-
Obstructed labor	-	-	-	-	-	-
Complications of abortion	-	-	-	-	-	-
Other maternal disorders	-	-	-	-	-	-

Appendix Table F.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (1-4 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Neonatal disorders	-	-	-	742.1 (540.8 to 969.7)	1,329.2 (959.6 to 1,739.3)	79.4 (57.5 to 106.1)
Preterm birth complications	2,320.4 (2,009.5 to 2,714.2)	5,078.0 (4,482.6 to 5,758.7)	118.7 (98.0 to 143.2)	277.5 (199.5 to 364.7)	638.8 (459.0 to 841.1)	129.6 (109.2 to 155.0)
Neonatal encephalopathy due to birth asphyxia and trauma	2,721.3 (1,158.6 to 5,001.0)	2,437.1 (1,387.2 to 4,188.2)	-9.5 (-30.6 to 34.0)	234.9 (168.8 to 324.9)	310.4 (224.4 to 409.4)	32.8 (9.1 to 61.3)
Neonatal sepsis and other neonatal infections	-	-	0.0 (0.0 to 0.0)	-	-	-
Hemolytic disease and other neonatal jaundice	319.4 (237.2 to 465.1)	608.5 (466.6 to 819.2)	91.8 (18.5 to 221.9)	107.4 (70.0 to 155.8)	181.8 (122.6 to 259.1)	69.1 (15.9 to 162.1)
Other neonatal disorders	-	-	-	122.4 (79.7 to 178.6)	198.1 (133.9 to 273.7)	61.8 (25.9 to 114.6)
Nutritional deficiencies	-	-	-	7,171.6 (4,737.3 to 10,147.5)	6,241.0 (4,185.9 to 8,892.8)	-13.1 (-21.1 to -4.2)
Protein-energy malnutrition	14,822.3 (11,935.2 to 18,913.6)	12,678.0 (10,042.7 to 16,291.3)	-15.0 (-38.5 to 18.5)	1,843.9 (1,078.8 to 2,808.7)	1,582.3 (962.6 to 2,457.4)	-14.7 (-38.2 to 19.4)
Iodine deficiency	1,610.3 (1,483.7 to 1,734.9)	935.1 (848.8 to 1,014.1)	-42.1 (-47.3 to -34.9)	38.0 (24.5 to 56.4)	22.7 (14.5 to 33.7)	-40.3 (-47.6 to -30.8)
Vitamin A deficiency	744.7 (568.3 to 947.0)	554.1 (409.1 to 707.9)	-25.7 (-30.4 to -21.0)	32.1 (19.6 to 48.2)	21.9 (13.0 to 33.8)	-31.9 (-41.1 to -22.3)
Iron-deficiency anemia	155,957.4 (155,163.2 to 156,743.9)	146,625.5 (146,257.9 to 146,947.7)	-6.0 (-6.5 to -5.5)	4,910.8 (3,248.2 to 7,173.8)	4,420.6 (2,912.2 to 6,496.3)	-10.0 (-11.1 to -9.0)
Other nutritional deficiencies	-	-	-	346.7 (167.2 to 630.0)	193.5 (101.0 to 350.5)	-44.1 (-64.9 to -8.9)
Other communicable to maternal to neonatal to and nutritional diseases	-	-	-	326.1 (214.6 to 470.3)	296.8 (197.6 to 433.3)	-9.3 (-13.4 to -2.4)
Sexually transmitted diseases excluding HIV	-	-	-	-	-	-
Syphilis	-	-	0.0 (0.0 to 0.0)	-	-	-
Chlamydial infection	-	-	-	-	-	-
Gonococcal infection	-	-	-	-	-	-
Trichomoniasis	-	-	-	-	-	-
Genital herpes	-	-	-	-	-	-
Other sexually transmitted diseases	-	-	-	-	-	-
Hepatitis	-	-	-	9.4 (6.0 to 13.9)	7.6 (4.8 to 11.3)	-18.6 (-26.8 to -10.1)
Hepatitis A	1,469.8 (1,326.0 to 1,629.5)	1,272.6 (1,160.6 to 1,396.4)	-13.4 (-14.3 to -12.5)	5.3 (3.3 to 8.0)	4.6 (2.8 to 6.9)	-12.9 (-25.2 to 2.2)
Hepatitis B	20,936.5 (20,313.2 to 21,816.0)	15,470.9 (14,980.9 to 16,094.7)	-26.1 (-29.5 to -22.6)	2.8 (1.8 to 4.0)	1.9 (1.2 to 2.8)	-31.8 (-40.2 to -21.7)
Hepatitis C	2,349.0 (2,261.2 to 2,440.3)	1,995.9 (1,918.3 to 2,070.5)	-15.0 (-19.4 to -10.9)	1.3 (0.8 to 1.9)	1.1 (0.7 to 1.6)	-16.0 (-30.6 to -0.3)
Hepatitis E	26.3 (21.9 to 31.7)	25.4 (21.4 to 29.5)	-3.3 (-27.3 to 25.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-1.2 (-27.5 to 30.8)
Leprosy	0.4 (0.3 to 0.5)	0.2 (0.1 to 0.2)	-52.6 (-61.9 to -41.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.9 (-61.5 to -41.2)
Other infectious diseases	9,826.2 (9,383.7 to 10,303.1)	9,242.8 (9,031.6 to 9,456.5)	-6.0 (-9.4 to -2.4)	316.7 (208.6 to 457.7)	289.2 (192.7 to 423.8)	-9.0 (-13.3 to -1.9)
Non-communicable diseases	-	-	-	6,162.1 (4,325.4 to 8,329.4)	6,301.7 (4,474.2 to 8,453.6)	2.3 (0.2 to 4.5)
Neoplasms	-	-	-	72.8 (44.3 to 115.1)	68.1 (43.4 to 99.9)	-4.5 (-31.7 to 19.9)
Esophageal cancer	-	-	-	-	-	-
Stomach cancer	-	-	-	-	-	-
Liver cancer	-	-	-	-	-	-
Liver cancer due to hepatitis B	-	-	-	-	-	-
Liver cancer due to hepatitis C	-	-	-	-	-	-
Liver cancer due to alcohol use	-	-	-	-	-	-
Liver cancer due to other causes	-	-	-	-	-	-
Larynx cancer	-	-	-	-	-	-
Tracheal to bronchus and lung cancer	-	-	-	-	-	-
Breast cancer	-	-	-	-	-	-
Cervical cancer	-	-	-	-	-	-
Uterine cancer	-	-	-	-	-	-
Prostate cancer	-	-	-	-	-	-
Colon and rectum cancer	-	-	-	-	-	-
Lip and oral cavity cancer	-	-	-	-	-	-
Nasopharynx cancer	-	-	-	-	-	-
Other pharynx cancer	-	-	-	-	-	-
Gallbladder and biliary tract cancer	-	-	-	-	-	-
Pancreatic cancer	-	-	-	-	-	-
Malignant skin melanoma	-	-	-	-	-	-
Non-melanoma skin cancer	-	-	-	-	-	-
Ovarian cancer	-	-	-	-	-	-
Testicular cancer	-	-	-	-	-	-
Kidney cancer	67.0 (44.1 to 90.2)	54.1 (45.0 to 66.6)	-22.5 (-43.8 to 34.1)	3.9 (2.1 to 6.4)	3.2 (2.0 to 4.8)	-22.7 (-45.2 to 36.7)
Bladder cancer	-	-	-	-	-	-
Brain and nervous system cancer	152.6 (106.8 to 223.6)	110.4 (88.2 to 137.5)	-25.6 (-51.5 to 3.2)	8.9 (4.9 to 14.9)	6.4 (3.9 to 9.8)	-25.7 (-51.7 to 2.5)
Thyroid cancer	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-
Hodgkin lymphoma	106.8 (56.8 to 172.2)	43.6 (26.1 to 90.5)	-62.3 (-81.1 to 21.3)	5.9 (2.7 to 10.8)	2.4 (1.1 to 5.2)	-62.1 (-82.5 to 17.1)
Non-Hodgkin lymphoma	63.8 (40.9 to 89.5)	70.9 (53.8 to 89.8)	16.1 (-29.9 to 63.7)	3.5 (1.8 to 6.0)	3.9 (2.4 to 6.0)	15.6 (-31.6 to 68.9)
Multiple myeloma	-	-	-	-	-	-
Leukemia	500.6 (390.7 to 646.2)	321.2 (264.0 to 389.3)	-34.7 (-53.8 to -18.4)	29.0 (17.4 to 44.6)	18.6 (11.8 to 27.7)	-34.5 (-53.7 to -18.1)
Other neoplasms	412.8 (283.0 to 713.7)	642.7 (484.6 to 832.5)	70.7 (-19.7 to 142.8)	21.6 (11.2 to 40.9)	33.5 (19.7 to 51.5)	69.9 (-19.8 to 145.0)
Cardiovascular diseases	-	-	-	54.9 (36.9 to 77.1)	48.2 (32.0 to 67.8)	-12.4 (-25.7 to 2.8)
Rheumatic heart disease	564.5 (500.2 to 622.7)	682.0 (615.4 to 765.3)	20.7 (2.5 to 42.1)	29.0 (19.0 to 42.5)	33.9 (21.3 to 50.1)	16.6 (-1.7 to 37.8)

Appendix Table F.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (1-4 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Ischemic heart disease	1.8 (1.6 to 2.0)	1.6 (1.4 to 1.8)	-10.6 (-25.7 to 3.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-10.9 (-26.1 to 3.1)
Cerebrovascular disease	-	-	-	1.2 (0.8 to 1.6)	1.3 (0.9 to 1.7)	7.8 (-1.3 to 16.0)
Ischemic stroke	3.1 (2.8 to 3.5)	3.6 (3.4 to 4.0)	15.7 (0.7 to 31.0)	0.5 (0.4 to 0.7)	0.6 (0.4 to 0.9)	15.3 (0.6 to 30.3)
Hemorrhagic stroke	4.0 (3.7 to 4.4)	4.0 (3.8 to 4.4)	1.5 (-9.7 to 13.0)	0.7 (0.5 to 0.9)	0.7 (0.5 to 1.0)	1.4 (-9.8 to 12.7)
Hypertensive heart disease	6.0 (5.6 to 6.4)	4.2 (3.9 to 4.4)	-30.0 (-35.8 to -23.7)	0.7 (0.5 to 1.0)	0.5 (0.3 to 0.7)	-30.1 (-35.9 to -23.7)
Cardiomyopathy and myocarditis	63.1 (58.6 to 67.5)	42.9 (40.7 to 45.1)	-31.9 (-36.6 to -26.3)	7.2 (4.9 to 10.2)	4.8 (3.2 to 6.8)	-33.2 (-41.1 to -24.9)
Atrial fibrillation and flutter	-	-	-	-	-	-
Peripheral vascular disease	-	-	-	-	-	-
Endocarditis	8.4 (7.5 to 9.6)	6.4 (5.8 to 7.3)	-23.3 (-34.2 to -11.3)	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.7)	-20.5 (-37.1 to -4.3)
Other cardiovascular and circulatory diseases	200.0 (137.9 to 292.1)	85.9 (45.6 to 141.0)	-57.0 (-76.8 to -27.9)	15.9 (8.9 to 26.2)	7.0 (3.2 to 12.3)	-56.5 (-76.8 to -27.0)
Chronic respiratory diseases	-	-	-	104.9 (68.7 to 149.9)	117.3 (76.9 to 167.2)	11.7 (1.3 to 23.8)
Chronic obstructive pulmonary disease	861.3 (758.8 to 958.5)	914.0 (809.0 to 1,010.7)	6.2 (4.0 to 9.0)	74.1 (46.3 to 110.8)	81.2 (50.2 to 119.0)	9.4 (-2.7 to 24.8)
Pneumoconiosis	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.1 (24.8 to 37.0)
Silicosis	-	-	0.0 (0.0 to 0.0)	-	-	-
Asbestosis	-	-	0.0 (0.0 to 0.0)	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	-	-	-
Other pneumoconiosis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	31.3 (25.7 to 37.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.1 (24.8 to 37.0)
Asthma	441.6 (372.0 to 489.1)	598.7 (524.6 to 673.1)	34.7 (13.2 to 66.3)	20.2 (12.7 to 29.6)	27.5 (17.5 to 40.5)	35.6 (10.2 to 70.4)
Interstitial lung disease and pulmonary sarcoidosis	1.3 (1.2 to 1.5)	1.3 (1.2 to 1.4)	-3.9 (-18.8 to 13.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-4.0 (-17.9 to 13.8)
Other chronic respiratory diseases	-	-	-	10.4 (6.1 to 16.7)	8.5 (5.0 to 13.3)	-18.9 (-30.7 to -2.3)
Cirrhosis	-	-	-	17.0 (11.3 to 24.3)	10.7 (7.0 to 15.8)	-37.1 (-49.2 to -21.9)
Cirrhosis due to hepatitis B	7.5 (6.5 to 8.6)	2.8 (2.4 to 3.3)	-62.7 (-69.1 to -55.3)	1.3 (0.9 to 1.9)	0.5 (0.3 to 0.7)	-62.6 (-69.4 to -55.2)
Cirrhosis due to hepatitis C	6.8 (5.6 to 8.3)	3.7 (3.3 to 4.4)	-45.0 (-58.1 to -28.1)	1.2 (0.8 to 1.8)	0.7 (0.4 to 1.0)	-44.9 (-58.1 to -27.3)
Cirrhosis due to alcohol use	-	-	-	-	-	-
Cirrhosis due to other causes	83.3 (79.8 to 86.7)	54.8 (53.0 to 56.8)	-34.2 (-37.3 to -30.7)	14.5 (9.5 to 20.8)	9.5 (6.1 to 14.2)	-33.8 (-48.6 to -16.5)
Digestive diseases	-	-	-	94.7 (62.7 to 138.4)	71.5 (47.6 to 106.5)	-24.2 (-34.3 to -13.4)
Peptic ulcer disease	-	-	0.0 (0.0 to 0.0)	-	-	-
Gastritis and duodenitis	1,166.9 (1,087.7 to 1,245.4)	725.1 (677.4 to 771.6)	-38.0 (-43.6 to -30.9)	48.8 (31.9 to 72.1)	29.5 (19.1 to 44.2)	-39.4 (-51.1 to -25.2)
Appendicitis	16.6 (14.2 to 18.4)	14.0 (12.2 to 16.3)	-15.9 (-30.0 to 2.2)	5.2 (3.0 to 8.1)	4.5 (2.7 to 7.1)	-13.2 (-45.8 to 40.7)
Paralytic ileus and intestinal obstruction	3.9 (3.8 to 4.1)	4.1 (3.9 to 4.2)	3.1 (-2.4 to 9.1)	1.3 (0.9 to 1.7)	1.3 (0.9 to 1.8)	3.1 (-2.4 to 9.2)
Inguinal to femoral to and abdominal hernia	1,546.1 (1,329.7 to 1,907.9)	1,522.5 (1,176.9 to 1,894.3)	1.4 (-29.9 to 37.0)	16.9 (8.3 to 32.8)	16.6 (7.5 to 32.8)	1.1 (-30.0 to 37.6)
Inflammatory bowel disease	6.6 (6.3 to 6.9)	8.8 (8.4 to 9.2)	33.4 (25.6 to 42.1)	1.5 (1.0 to 2.1)	2.0 (1.3 to 2.8)	33.5 (25.5 to 42.0)
Vascular intestinal disorders	0.6 (0.5 to 0.6)	0.6 (0.6 to 0.8)	16.0 (-5.6 to 38.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	16.0 (-5.8 to 38.9)
Gallbladder and biliary diseases	44.6 (41.7 to 47.8)	38.2 (35.4 to 41.1)	-14.2 (-23.4 to -5.4)	5.0 (3.3 to 7.2)	4.3 (2.7 to 6.2)	-13.7 (-30.9 to 7.2)
Pancreatitis	13.8 (12.6 to 14.9)	15.8 (15.2 to 16.5)	14.3 (5.3 to 27.1)	4.5 (3.0 to 6.1)	5.1 (3.4 to 7.0)	14.2 (4.5 to 27.6)
Other digestive diseases	-	-	-	11.4 (7.3 to 17.4)	7.9 (5.1 to 12.0)	-31.0 (-40.5 to -19.1)
Neurological disorders	-	-	-	465.2 (310.1 to 623.6)	501.6 (340.4 to 669.8)	7.8 (-3.3 to 21.3)
Alzheimer disease and other dementias	-	-	-	-	-	-
Parkinson disease	-	-	-	-	-	-
Epilepsy	1,403.6 (1,311.6 to 1,492.6)	1,404.4 (1,310.0 to 1,494.4)	-0.1 (-8.9 to 10.6)	465.0 (309.9 to 623.3)	501.3 (340.2 to 669.4)	7.8 (-3.3 to 21.3)
Multiple sclerosis	-	-	-	-	-	-
Migraine	-	-	-	-	-	-
Tension-type headache	-	-	-	-	-	-
Medication overuse headache	-	-	-	-	-	-
Other neurological disorders	0.8 (0.7 to 1.0)	0.9 (0.8 to 1.0)	4.1 (-5.5 to 13.2)	0.2 (0.2 to 0.4)	0.3 (0.2 to 0.4)	4.1 (-5.6 to 13.3)
Mental and substance use disorders	-	-	-	952.7 (656.5 to 1,305.0)	991.3 (686.4 to 1,362.7)	4.1 (-0.6 to 9.0)
Schizophrenia	-	-	-	-	-	-
Alcohol use disorders	134.2 (125.3 to 142.7)	145.9 (136.5 to 155.2)	8.7 (6.9 to 10.9)	7.5 (4.9 to 11.0)	8.1 (5.3 to 11.6)	8.0 (-2.9 to 19.7)
Drug use disorders	-	-	-	-	-	-
Opioid use disorders	-	-	-	-	-	-
Cocaine use disorders	-	-	-	-	-	-
Amphetamine use disorders	-	-	-	-	-	-
Cannabis use disorders	-	-	-	-	-	-
Other drug use disorders	-	-	-	-	-	-
Depressive disorders	-	-	-	60.4 (32.7 to 94.7)	68.7 (39.4 to 104.3)	13.4 (1.6 to 35.4)
Major depressive disorder	279.2 (174.3 to 403.8)	318.0 (215.6 to 437.5)	13.6 (7.3 to 30.7)	60.2 (32.6 to 94.5)	68.5 (39.2 to 104.2)	13.5 (1.6 to 35.6)
Dysthymia	2.0 (1.2 to 2.7)	2.0 (1.3 to 2.8)	2.3 (1.0 to 3.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	2.4 (1.0 to 3.4)
Bipolar disorder	-	-	-	-	-	-

Appendix Table F.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (1-4 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Anxiety disorders	551.3 (329.5 to 862.9)	584.4 (354.8 to 892.7)	6.4 (3.3 to 9.2)	53.1 (26.0 to 91.2)	56.4 (28.2 to 95.8)	5.9 (-5.0 to 20.2)
Eating disorders	-	-	-	-	-	-
Anorexia nervosa	-	-	-	-	-	-
Bulimia nervosa	-	-	-	-	-	-
Autistic spectrum disorders	-	-	-	535.6 (369.8 to 732.4)	556.9 (384.7 to 761.2)	3.9 (1.0 to 7.2)
Autism	1,292.8 (1,201.1 to 1,380.6)	1,342.5 (1,248.0 to 1,434.3)	3.8 (3.6 to 4.0)	330.0 (221.2 to 457.0)	343.1 (230.6 to 472.9)	3.9 (-0.2 to 8.6)
Asperger syndrome	2,007.8 (1,836.5 to 2,172.2)	2,085.7 (1,907.2 to 2,256.3)	3.9 (3.8 to 3.9)	205.7 (140.6 to 291.3)	213.8 (146.0 to 302.5)	3.9 (0.5 to 7.8)
Attention-deficit/hyperactivity disorder	828.1 (767.5 to 890.8)	854.3 (795.7 to 914.0)	3.1 (2.1 to 4.5)	10.2 (5.9 to 15.7)	10.5 (6.2 to 16.3)	3.4 (-5.8 to 13.2)
Conduct disorder	-	-	-	-	-	-
Idiopathic intellectual disability	5,769.8 (3,984.0 to 7,384.0)	5,853.4 (4,347.9 to 7,428.9)	1.6 (-11.5 to 18.8)	285.8 (177.5 to 422.3)	290.7 (186.7 to 425.8)	1.8 (-11.5 to 18.5)
Other mental and substance use disorders	-	-	0.0 (0.0 to 0.0)	-	-	-
Diabetes to urogenital to blood to and endocrine diseases	-	-	-	1,416.5 (981.6 to 2,003.2)	1,386.9 (962.7 to 1,955.4)	-2.1 (-4.4 to 0.5)
Diabetes mellitus	905.6 (822.5 to 992.4)	1,253.3 (1,124.7 to 1,371.1)	38.0 (22.2 to 58.1)	43.8 (27.5 to 66.7)	60.7 (38.6 to 91.8)	38.6 (21.8 to 60.0)
Acute glomerulonephritis	10.8 (9.3 to 12.3)	7.9 (6.7 to 9.2)	-26.6 (-30.9 to -23.6)	0.5 (0.3 to 0.8)	0.4 (0.2 to 0.6)	-26.6 (-30.9 to -23.6)
Chronic kidney disease	-	-	-	330.5 (216.9 to 451.2)	335.3 (220.4 to 461.0)	1.4 (-4.4 to 7.9)
Chronic kidney disease due to diabetes mellitus	638.1 (329.5 to 1,218.6)	779.7 (408.1 to 1,478.1)	21.5 (8.5 to 38.2)	11.9 (7.9 to 16.2)	13.4 (8.9 to 18.7)	12.8 (-0.9 to 26.2)
Chronic kidney disease due to hypertension	8,063.1 (3,586.1 to 16,793.9)	9,042.5 (4,227.0 to 17,982.9)	13.3 (-0.4 to 26.3)	42.0 (27.5 to 58.6)	45.2 (29.7 to 63.2)	7.9 (-9.8 to 27.4)
Chronic kidney disease due to glomerulonephritis	4,108.8 (2,655.7 to 6,825.1)	4,474.8 (2,798.1 to 7,440.0)	7.8 (-2.0 to 21.8)	132.2 (86.9 to 182.1)	120.0 (79.8 to 165.3)	-9.4 (-17.9 to 1.1)
Chronic kidney disease due to other causes	9,546.1 (4,758.0 to 18,517.8)	11,285.1 (5,568.3 to 21,817.5)	18.5 (10.2 to 27.1)	144.4 (94.6 to 198.4)	156.7 (100.4 to 216.0)	8.5 (-2.2 to 20.6)
Urinary diseases and male infertility	-	-	-	5.1 (3.2 to 7.5)	5.9 (3.7 to 8.7)	14.1 (-2.1 to 33.7)
Interstitial nephritis and urinary tract infections	80.4 (76.9 to 84.4)	91.3 (87.4 to 95.2)	13.5 (8.0 to 19.5)	2.8 (1.7 to 4.2)	3.1 (1.9 to 4.8)	13.5 (-6.6 to 38.2)
Urolithiasis	24.5 (18.2 to 32.4)	21.9 (14.1 to 30.3)	-9.7 (-29.0 to 0.9)	1.1 (0.6 to 1.6)	1.0 (0.6 to 1.6)	-3.7 (-14.2 to 4.6)
Benign prostatic hyperplasia	-	-	-	-	-	-
Male infertility due to other causes	-	-	-	-	-	-
Other urinary diseases	-	-	-	1.3 (0.8 to 2.1)	1.7 (1.0 to 2.7)	31.7 (2.5 to 65.4)
Gynecological diseases	-	-	-	-	-	-
Uterine fibroids	-	-	-	-	-	-
Polycystic ovarian syndrome	-	-	-	-	-	-
Female infertility due to other causes	-	-	-	-	-	-
Endometriosis	-	-	-	-	-	-
Genital prolapse	-	-	-	-	-	-
Premenstrual syndrome	-	-	-	-	-	-
Other gynecological diseases	-	-	-	-	-	-
Hemoglobinopathies and hemolytic anemias	-	-	-	705.3 (464.2 to 1,029.9)	678.3 (448.5 to 990.6)	-3.9 (-6.8 to -0.8)
Thalassemias	155.7 (135.8 to 176.6)	146.3 (131.1 to 162.6)	-6.3 (-9.3 to -0.9)	12.0 (7.9 to 17.5)	11.0 (7.2 to 16.1)	-8.6 (-23.3 to 8.5)
Thalassemia trait	15,082.1 (13,992.1 to 16,555.2)	14,878.7 (13,941.3 to 16,053.4)	-1.1 (-3.6 to 0.2)	336.3 (221.7 to 493.5)	287.9 (186.9 to 421.4)	-14.5 (-17.8 to -10.7)
Sickle cell disorders	368.4 (345.1 to 387.8)	602.0 (574.4 to 625.3)	63.1 (55.0 to 74.2)	26.7 (17.7 to 38.7)	41.6 (27.8 to 60.4)	55.8 (36.7 to 75.4)
Sickle cell trait	19,222.9 (18,255.2 to 20,103.3)	26,263.0 (25,098.4 to 27,324.6)	36.6 (34.2 to 38.8)	143.9 (93.1 to 212.1)	164.4 (108.5 to 239.0)	14.4 (4.3 to 23.2)
G6PD deficiency	25,195.0 (24,528.2 to 25,804.8)	30,766.9 (30,033.6 to 31,502.5)	22.1 (18.0 to 26.1)	4.5 (3.0 to 6.4)	4.8 (3.2 to 7.0)	7.2 (-15.4 to 35.3)
G6PD trait	84,375.3 (83,790.1 to 84,862.0)	89,953.6 (89,297.5 to 90,561.3)	6.6 (5.6 to 7.7)	4.3 (2.6 to 6.3)	4.1 (2.5 to 6.2)	-4.7 (-35.3 to 38.2)
Other hemoglobinopathies and hemolytic anemias	5,668.7 (5,402.2 to 5,927.4)	5,330.8 (5,166.6 to 5,479.3)	-6.0 (-10.6 to -1.4)	177.6 (116.5 to 260.1)	164.5 (109.2 to 242.6)	-7.6 (-13.4 to 0.7)
Endocrine to metabolic to blood to and immune disorders	9,847.6 (9,610.2 to 10,055.3)	9,369.0 (9,105.7 to 9,590.5)	-4.8 (-8.2 to -1.6)	331.2 (225.9 to 468.2)	306.3 (206.3 to 438.3)	-7.4 (-14.4 to -2.0)
Musculoskeletal disorders	-	-	-	-	-	-
Rheumatoid arthritis	-	-	-	-	-	-
Osteoarthritis	-	-	-	-	-	-
Low back and neck pain	-	-	-	-	-	-
Low back pain	-	-	-	-	-	-
Neck pain	-	-	-	-	-	-
Gout	-	-	-	-	-	-
Other musculoskeletal disorders	-	-	-	-	-	-
Other non-communicable diseases	-	-	-	2,983.4 (2,032.5 to 4,134.7)	3,106.1 (2,127.4 to 4,304.2)	4.1 (1.3 to 7.3)
Congenital anomalies	-	-	-	494.9 (360.5 to 642.0)	589.1 (426.7 to 760.0)	19.0 (9.9 to 30.2)
Neural tube defects	113.3 (110.5 to 116.4)	149.9 (145.7 to 153.9)	32.4 (27.6 to 36.8)	35.7 (25.0 to 46.3)	48.0 (33.9 to 63.4)	34.3 (21.8 to 49.6)
Congenital heart anomalies	1,760.9 (1,698.4 to 1,829.7)	2,616.8 (2,513.3 to 2,747.4)	48.5 (40.8 to 58.3)	76.0 (41.6 to 115.6)	102.5 (49.0 to 167.9)	34.0 (12.8 to 49.1)
Orofacial clefts	312.4 (298.5 to 324.0)	468.7 (448.7 to 487.5)	49.8 (41.3 to 60.2)	4.6 (3.1 to 6.8)	6.3 (4.1 to 9.1)	36.2 (15.4 to 61.4)
Down syndrome	460.5 (440.9 to 483.5)	569.4 (547.5 to 594.9)	23.7 (16.4 to 30.6)	51.6 (37.3 to 67.9)	64.0 (46.9 to 83.8)	23.9 (14.1 to 35.2)
Turner syndrome	16.3 (15.4 to 17.2)	18.8 (17.9 to 19.9)	15.4 (8.2 to 24.9)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.5)	15.7 (8.3 to 25.1)
Klinefelter syndrome	15.0 (14.1 to 15.7)	16.2 (15.5 to 17.0)	8.1 (0.8 to 17.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	7.9 (0.6 to 16.9)
Chromosomal unbalanced rearrangements	616.9 (594.8 to 636.4)	761.7 (726.9 to 802.6)	23.3 (16.7 to 31.1)	69.2 (49.5 to 91.0)	85.4 (61.2 to 111.3)	23.4 (14.0 to 33.9)
Other congenital anomalies	1,343.3 (1,067.6 to 1,607.2)	1,220.0 (949.9 to 1,475.5)	-9.1 (-15.9 to -2.2)	257.4 (174.0 to 362.9)	282.6 (194.6 to 385.1)	9.5 (-2.0 to 26.2)

Appendix Table F.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (1-4 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Skin and subcutaneous diseases	-	-	-	1,249.7 (767.4 to 1,893.7)	1,312.0 (809.7 to 1,965.7)	4.8 (1.8 to 9.2)
Dermatitis	8,911.2 (7,288.1 to 10,603.8)	9,424.6 (7,715.7 to 11,185.4)	5.8 (4.8 to 6.7)	386.1 (233.9 to 573.8)	413.3 (253.7 to 616.0)	7.1 (4.3 to 10.1)
Psoriasis	380.2 (299.3 to 462.6)	401.6 (316.1 to 488.9)	5.6 (4.5 to 6.8)	32.6 (21.3 to 47.8)	34.4 (22.0 to 50.3)	5.3 (-9.6 to 21.7)
Cellulitis	176.2 (122.5 to 253.7)	157.1 (103.1 to 226.8)	-10.6 (-20.4 to -4.4)	13.0 (7.1 to 21.4)	11.6 (6.2 to 19.2)	-10.9 (-26.9 to 6.0)
Pyoderma	1,789.8 (1,174.2 to 2,589.8)	1,251.2 (856.7 to 1,763.0)	-30.2 (-34.7 to -22.5)	10.3 (3.8 to 24.8)	7.2 (2.7 to 17.0)	-30.2 (-35.4 to -22.0)
Scabies	5,674.5 (4,933.2 to 6,627.7)	5,646.7 (4,859.5 to 6,569.3)	-0.6 (-17.9 to 22.6)	148.4 (82.7 to 245.7)	148.1 (80.8 to 237.9)	-0.6 (-18.4 to 23.2)
Fungal skin diseases	10,275.1 (5,919.4 to 15,763.9)	13,462.5 (8,415.0 to 19,552.4)	30.9 (19.8 to 46.1)	58.8 (19.8 to 140.3)	77.1 (27.2 to 175.2)	31.0 (19.6 to 46.2)
Viral skin diseases	16,801.6 (8,432.2 to 24,296.8)	17,138.8 (8,873.9 to 24,639.6)	2.0 (-0.9 to 6.9)	527.3 (249.3 to 873.3)	538.8 (254.6 to 894.6)	2.2 (-1.1 to 7.6)
Acne vulgaris	-	-	-	-	-	-
Alopecia areata	408.4 (372.8 to 450.8)	426.6 (387.6 to 468.1)	4.0 (-6.2 to 17.8)	14.1 (8.8 to 21.5)	14.8 (9.2 to 22.5)	4.1 (-8.3 to 21.6)
Pruritus	18.1 (16.9 to 19.4)	17.6 (16.2 to 19.2)	-2.9 (-12.8 to 9.8)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	-2.7 (-20.4 to 18.5)
Urticaria	499.0 (431.4 to 572.6)	602.9 (462.2 to 780.9)	18.3 (-9.1 to 61.7)	31.0 (19.3 to 45.7)	37.4 (22.1 to 58.9)	18.5 (-10.7 to 65.5)
Decubitus ulcer	16.8 (15.9 to 18.1)	14.5 (13.6 to 15.7)	-14.0 (-19.6 to -8.0)	2.8 (1.9 to 3.9)	2.4 (1.6 to 3.3)	-14.0 (-19.6 to -8.0)
Other skin and subcutaneous diseases	4,115.1 (908.0 to 9,232.5)	4,394.0 (964.6 to 9,884.7)	6.7 (3.3 to 10.5)	25.0 (4.8 to 70.6)	26.7 (5.1 to 73.6)	6.7 (1.2 to 12.4)
Sense organ diseases	-	-	-	1,175.6 (786.8 to 1,661.3)	1,141.7 (762.1 to 1,643.6)	-3.0 (-6.7 to 0.8)
Glaucoma	-	-	-	-	-	-
Cataract	-	-	-	-	-	-
Macular degeneration	-	-	-	-	-	-
Uncorrected refractive error	12,177.3 (11,525.4 to 12,812.9)	12,056.4 (11,459.3 to 12,704.1)	-1.1 (-6.2 to 4.5)	275.1 (176.3 to 417.9)	259.8 (161.9 to 404.6)	-5.8 (-9.5 to -1.4)
Age-related and other hearing loss	1,721.5 (1,110.3 to 2,355.8)	1,588.6 (1,008.5 to 2,212.4)	-7.9 (-17.6 to 3.3)	240.8 (133.4 to 385.5)	209.9 (115.9 to 341.9)	-12.9 (-24.3 to -0.0)
Other vision loss	632.1 (480.1 to 792.2)	493.1 (371.0 to 621.5)	-22.0 (-25.6 to -18.3)	30.2 (18.8 to 45.7)	21.2 (12.7 to 32.3)	-29.9 (-38.4 to -22.2)
Other sense organ diseases	23,051.6 (22,527.2 to 23,529.0)	23,797.5 (23,301.3 to 24,274.5)	3.3 (0.4 to 6.2)	629.4 (386.8 to 938.2)	650.9 (402.2 to 979.9)	3.4 (-0.0 to 7.0)
Oral disorders	-	-	-	63.2 (27.7 to 123.4)	63.3 (27.4 to 122.2)	0.2 (-2.2 to 2.7)
Deciduous caries	172,383.7 (170,587.5 to 174,180.1)	171,327.8 (169,563.0 to 173,100.3)	-0.6 (-2.0 to 0.9)	63.2 (27.7 to 123.4)	63.3 (27.4 to 122.2)	0.2 (-2.2 to 2.7)
Permanent caries	-	-	-	-	-	-
Periodontal diseases	-	-	-	-	-	-
Edentulism and severe tooth loss	-	-	-	-	-	-
Other oral disorders	-	-	-	-	-	-
Injuries	-	-	-	346.5 (265.2 to 445.1)	240.7 (182.1 to 320.2)	-30.2 (-39.0 to -23.7)
Transport injuries	-	-	-	53.9 (41.1 to 68.6)	31.5 (23.5 to 40.4)	-41.5 (-44.7 to -38.4)
Road injuries	-	-	-	44.2 (33.4 to 56.8)	26.5 (19.7 to 34.3)	-40.1 (-43.8 to -36.5)
Pedestrian road injuries	-	-	-	15.9 (11.4 to 21.3)	9.9 (7.2 to 13.2)	-37.8 (-42.6 to -32.9)
Cyclist road injuries	-	-	-	6.1 (4.6 to 8.3)	3.3 (2.4 to 4.3)	-46.2 (-50.4 to -42.1)
Motorcyclist road injuries	-	-	-	7.3 (5.6 to 9.3)	2.7 (2.0 to 3.4)	-63.3 (-66.3 to -60.3)
Motor vehicle road injuries	-	-	-	14.5 (10.8 to 18.7)	10.3 (7.6 to 13.3)	-28.5 (-33.0 to -24.0)
Other road injuries	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-31.2 (-37.8 to -25.1)
Other transport injuries	-	-	-	9.6 (7.4 to 12.4)	5.0 (3.8 to 6.4)	-47.8 (-51.5 to -44.6)
Unintentional injuries	-	-	-	226.1 (169.5 to 301.4)	187.6 (140.8 to 250.2)	-17.0 (-19.9 to -14.3)
Falls	-	-	-	74.0 (56.0 to 95.7)	69.9 (53.2 to 89.8)	-5.5 (-10.7 to 0.1)
Drowning	-	-	-	9.1 (7.0 to 11.7)	4.3 (3.2 to 5.6)	-52.2 (-57.4 to -45.9)
Fire to heat to and hot substances	-	-	-	48.6 (35.7 to 65.2)	36.2 (26.5 to 48.0)	-25.5 (-32.4 to -18.0)
Poisonings	-	-	-	2.4 (1.7 to 3.2)	1.5 (1.1 to 2.1)	-37.8 (-47.6 to -25.3)
Exposure to mechanical forces	-	-	-	47.9 (31.7 to 73.3)	40.7 (26.4 to 62.0)	-15.0 (-18.4 to -11.8)
Unintentional firearm injuries	-	-	-	0.8 (0.6 to 1.0)	0.6 (0.4 to 0.8)	-28.0 (-31.9 to -24.3)
Unintentional suffocation	-	-	-	1.0 (0.7 to 1.4)	0.8 (0.6 to 1.2)	-19.3 (-23.8 to -14.5)
Other exposure to mechanical forces	-	-	-	46.1 (30.3 to 70.9)	39.3 (25.3 to 60.3)	-14.7 (-18.2 to -11.4)
Adverse effects of medical treatment	-	-	-	5.8 (3.7 to 8.5)	5.2 (3.3 to 7.7)	-10.1 (-13.7 to -6.4)
Animal contact	-	-	-	8.4 (5.4 to 13.6)	6.0 (3.9 to 9.4)	-28.8 (-35.9 to -21.1)
Venomous animal contact	-	-	-	1.8 (1.3 to 2.4)	1.4 (1.0 to 1.8)	-24.6 (-39.3 to -4.9)
Non-venomous animal contact	-	-	-	6.6 (3.9 to 11.7)	4.6 (2.8 to 7.9)	-29.8 (-36.7 to -23.3)
Foreign body	-	-	-	10.1 (7.0 to 14.4)	8.5 (5.6 to 12.3)	-16.2 (-24.0 to -9.4)
Pulmonary aspiration and foreign body in airway	-	-	-	4.0 (2.6 to 5.9)	2.7 (1.8 to 3.9)	-31.4 (-36.9 to -25.1)
Foreign body in eyes	-	-	-	3.2 (1.3 to 5.9)	3.4 (1.4 to 6.2)	5.2 (-1.1 to 12.7)
Foreign body in other body part	-	-	-	2.9 (2.0 to 4.1)	2.3 (1.6 to 3.2)	-20.0 (-26.1 to -13.5)
Other unintentional injuries	-	-	-	19.8 (14.1 to 27.2)	15.3 (10.9 to 21.1)	-23.1 (-26.9 to -18.8)

Appendix Table F.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (1-4 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Self-harm and interpersonal violence	-	-	-	6.6 (5.0 to 8.5)	4.6 (3.5 to 5.9)	-30.2 (-34.1 to -26.0)
Self-harm	-	-	-	-	-	-
Interpersonal violence	-	-	-	6.6 (5.0 to 8.5)	4.6 (3.5 to 5.9)	-30.2 (-34.1 to -26.0)
Assault by firearm	-	-	-	0.9 (0.7 to 1.2)	0.6 (0.4 to 0.8)	-31.2 (-35.5 to -26.2)
Assault by sharp object	-	-	-	0.8 (0.6 to 1.1)	0.6 (0.5 to 0.8)	-28.1 (-33.1 to -22.5)
Assault by other means	-	-	-	4.9 (3.7 to 6.3)	3.4 (2.5 to 4.3)	-30.3 (-34.6 to -25.8)
Forces of nature to war to and legal intervention	-	-	-	60.0 (31.7 to 112.6)	17.1 (7.2 to 40.2)	-73.4 (-85.4 to -40.7)
Exposure to forces of nature	-	-	-	9.9 (4.9 to 17.2)	2.8 (0.9 to 14.3)	-82.3 (-92.3 to 18.9)
Collective violence and legal intervention	-	-	-	50.1 (23.4 to 99.0)	14.2 (5.4 to 30.7)	-71.7 (-86.6 to -41.0)

Appendix Table F.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (5-9 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
All causes	-	-	-	29,127.0 (20,622.4 to 39,256.0)	29,614.8 (21,128.0 to 39,810.4)	1.7 (0.6 to 2.9)
Communicable to maternal to neonatal to and nutritional diseases	-	-	-	14,381.7 (9,796.6 to 20,268.9)	14,020.2 (9,698.1 to 19,668.4)	-2.5 (-3.9 to -0.6)
HIV/AIDS and tuberculosis	-	-	-	21.1 (14.1 to 28.3)	109.6 (77.9 to 142.5)	418.7 (338.1 to 527.4)
Tuberculosis	48.2 (45.1 to 51.9)	46.0 (43.1 to 49.2)	-4.7 (-7.3 to -2.0)	15.5 (10.1 to 21.7)	14.8 (9.7 to 21.3)	-4.6 (-23.7 to 20.5)
HIV/AIDS	-	-	-	5.6 (3.6 to 8.0)	94.8 (67.8 to 123.6)	1,594.9 (1,190.9 to 2,194.7)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.5 (0.3 to 0.7)	1,698.7 (1,331.3 to 2,229.5)	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	1,704.7 (1,333.0 to 2,237.4)
HIV/AIDS resulting in other diseases	34.1 (26.3 to 41.6)	711.7 (669.2 to 761.7)	2,012.3 (1,584.0 to 2,577.7)	5.6 (3.6 to 8.0)	94.6 (67.6 to 123.4)	1,594.3 (1,190.3 to 2,195.8)
Diarrhea to lower respiratory to and other common infectious diseases	-	-	-	1,674.5 (1,183.9 to 2,251.5)	1,437.3 (1,001.3 to 1,968.9)	-14.3 (-18.5 to -9.3)
Diarrheal diseases	4,502.8 (4,346.7 to 4,655.9)	3,584.0 (3,442.6 to 3,722.2)	-20.5 (-24.8 to -16.1)	734.0 (499.8 to 1,013.9)	585.3 (397.6 to 812.6)	-20.3 (-25.4 to -14.8)
Intestinal infectious diseases	-	-	-	59.9 (40.4 to 85.0)	41.5 (27.9 to 59.1)	-30.8 (-44.7 to -12.6)
Typhoid fever	333.2 (276.3 to 383.2)	241.3 (207.9 to 273.7)	-27.2 (-42.3 to -9.2)	43.8 (27.7 to 64.9)	32.2 (21.0 to 47.0)	-26.7 (-45.8 to -1.0)
Paratyphoid fever	236.8 (189.8 to 291.8)	154.1 (126.1 to 182.1)	-34.7 (-52.5 to -15.5)	12.2 (7.4 to 19.0)	8.0 (4.8 to 12.5)	-34.7 (-55.0 to -6.8)
Other intestinal infectious diseases	-	-	-	3.8 (1.8 to 7.4)	1.3 (0.6 to 2.6)	-65.6 (-72.4 to -55.7)
Lower respiratory infections	292.4 (273.3 to 310.0)	228.1 (214.6 to 241.2)	-22.3 (-27.7 to -13.8)	31.0 (20.7 to 44.1)	24.2 (15.9 to 34.1)	-22.3 (-31.0 to -11.7)
Upper respiratory infections	23,362.4 (22,902.6 to 23,850.2)	27,268.2 (26,718.0 to 27,862.7)	16.5 (13.2 to 19.9)	277.4 (153.3 to 459.7)	324.3 (179.8 to 547.7)	16.9 (12.7 to 21.2)
Otitis media	11,527.4 (10,474.0 to 12,510.8)	11,378.0 (10,300.1 to 12,335.6)	-1.4 (-4.6 to 1.6)	246.5 (147.3 to 395.7)	244.4 (148.0 to 392.2)	-0.8 (-5.3 to 3.7)
Meningitis	-	-	-	277.4 (193.0 to 375.1)	186.7 (130.9 to 249.0)	-32.6 (-37.3 to -27.2)
Pneumococcal meningitis	889.7 (612.4 to 1,236.0)	578.6 (406.5 to 802.1)	-35.2 (-39.2 to -29.7)	104.0 (72.2 to 140.3)	71.5 (48.6 to 94.9)	-31.5 (-40.3 to -20.4)
H influenzae type B meningitis	529.5 (268.1 to 896.5)	348.9 (195.1 to 583.4)	-34.2 (-39.0 to -26.2)	75.9 (50.9 to 103.4)	54.6 (36.8 to 75.6)	-28.2 (-36.4 to -17.3)
Meningococcal meningitis	181.8 (89.6 to 382.7)	108.6 (57.6 to 222.7)	-40.1 (-46.2 to -30.4)	28.3 (18.7 to 40.4)	17.7 (12.3 to 25.0)	-37.6 (-46.0 to -24.2)
Other meningitis	472.9 (286.9 to 775.2)	280.4 (185.2 to 444.7)	-40.6 (-44.6 to -35.3)	69.2 (47.8 to 94.8)	42.9 (29.4 to 58.1)	-38.1 (-44.2 to -30.8)
Encephalitis	129.2 (69.7 to 252.2)	90.4 (52.6 to 176.7)	-29.8 (-38.0 to -22.4)	19.2 (13.5 to 25.5)	14.7 (10.4 to 19.5)	-23.2 (-30.5 to -16.2)
Diphtheria	0.4 (0.1 to 1.2)	0.2 (0.0 to 0.5)	-64.7 (-92.7 to 87.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-64.7 (-92.7 to 87.2)
Whooping cough	158.4 (122.8 to 203.3)	116.6 (90.5 to 149.2)	-26.5 (-27.1 to -25.9)	7.9 (4.5 to 12.9)	5.8 (3.3 to 9.4)	-26.0 (-38.4 to -12.1)
Tetanus	150.4 (108.0 to 225.8)	18.4 (12.8 to 27.9)	-87.9 (-92.9 to -79.1)	6.6 (4.3 to 9.9)	1.6 (1.0 to 2.8)	-75.9 (-85.0 to -57.3)
Measles	78.2 (60.1 to 100.2)	19.3 (15.1 to 24.4)	-75.3 (-77.5 to -72.9)	7.0 (4.1 to 11.1)	1.8 (1.1 to 2.8)	-74.9 (-79.5 to -68.6)
Varicella and herpes zoster	581.8 (532.5 to 633.5)	589.9 (546.1 to 635.1)	0.8 (-9.4 to 12.6)	7.5 (4.3 to 12.5)	7.1 (4.0 to 12.2)	-6.3 (-14.9 to 3.4)
Neglected tropical diseases and malaria	-	-	-	2,396.8 (1,578.5 to 3,499.8)	2,422.2 (1,597.2 to 3,534.6)	0.8 (-3.4 to 8.0)
Malaria	40,864.5 (39,969.8 to 41,764.0)	52,957.9 (51,374.1 to 54,611.2)	29.4 (25.3 to 33.6)	545.0 (361.2 to 787.0)	769.4 (516.9 to 1,099.2)	41.8 (31.8 to 49.5)
Chagas disease	477.7 (466.1 to 489.2)	507.6 (494.3 to 521.9)	6.0 (2.3 to 10.8)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	5.3 (-11.8 to 25.5)
Leishmaniasis	-	-	-	2.5 (1.5 to 4.2)	4.5 (2.5 to 7.9)	76.3 (42.4 to 120.5)
Visceral leishmaniasis	17.2 (13.1 to 22.3)	21.6 (17.2 to 27.8)	26.0 (0.6 to 54.7)	1.2 (0.7 to 2.0)	1.5 (0.9 to 2.4)	26.0 (-17.0 to 94.1)
Cutaneous and mucocutaneous leishmaniasis	121.1 (104.1 to 144.8)	271.8 (223.4 to 334.7)	123.5 (93.8 to 159.8)	1.3 (0.6 to 2.5)	3.0 (1.3 to 5.7)	124.0 (92.3 to 164.6)
African trypanosomiasis	4.9 (2.2 to 9.9)	1.4 (0.7 to 2.4)	-71.6 (-75.8 to -66.4)	1.4 (0.5 to 2.8)	0.4 (0.2 to 0.7)	-71.0 (-77.2 to -58.9)
Schistosomiasis	20,621.1 (18,585.4 to 22,576.9)	26,254.3 (22,798.7 to 30,289.0)	26.0 (18.1 to 42.9)	225.8 (123.8 to 405.1)	305.9 (171.1 to 556.7)	34.8 (26.4 to 50.7)
Cysticercosis	1.7 (1.1 to 2.4)	1.0 (0.8 to 1.3)	-39.7 (-60.2 to -14.6)	0.5 (0.3 to 0.8)	0.3 (0.2 to 0.5)	-38.6 (-60.8 to -12.4)
Cystic echinococcosis	67.7 (62.7 to 71.8)	38.9 (36.6 to 41.5)	-42.6 (-45.7 to -40.1)	6.5 (4.3 to 9.3)	3.8 (2.5 to 5.3)	-41.7 (-50.5 to -32.3)
Lymphatic filariasis	3,134.6 (2,799.5 to 3,444.3)	1,532.9 (1,328.1 to 1,737.0)	-51.4 (-58.4 to -42.9)	22.9 (11.5 to 39.0)	13.0 (6.9 to 21.2)	-42.8 (-61.2 to -18.7)
Onchocerciasis	1,832.5 (1,154.8 to 2,831.2)	1,186.8 (687.8 to 1,792.9)	-33.0 (-55.4 to -19.1)	129.2 (56.1 to 228.2)	86.7 (33.5 to 161.1)	-33.7 (-45.1 to -22.9)
Trachoma	-	-	-	-	-	-
Dengue	74.8 (27.4 to 167.8)	422.4 (155.3 to 947.6)	464.0 (462.3 to 466.1)	12.5 (4.0 to 30.8)	70.4 (22.6 to 177.1)	467.3 (357.1 to 625.4)
Yellow fever	1.0 (0.3 to 2.3)	0.4 (0.1 to 0.9)	-62.3 (-71.5 to -46.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-62.2 (-71.5 to -45.6)
Rabies	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-60.9 (-72.9 to -43.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-60.9 (-72.9 to -42.8)
Intestinal nematode infections	-	-	-	673.9 (401.4 to 1,069.6)	458.0 (279.6 to 706.8)	-31.9 (-37.3 to -25.8)
Ascariasis	108,993.4 (93,138.0 to 127,183.9)	74,278.8 (65,005.2 to 85,211.6)	-31.9 (-44.5 to -15.7)	245.7 (133.5 to 411.8)	119.9 (64.1 to 201.9)	-51.2 (-58.5 to -42.9)
Trichuriasis	60,967.2 (52,408.7 to 71,970.0)	47,859.1 (43,504.4 to 52,679.9)	-21.1 (-34.9 to -5.3)	108.3 (60.5 to 180.1)	61.1 (31.9 to 103.4)	-43.8 (-53.9 to -30.3)
Hookworm disease	47,760.0 (41,669.2 to 56,028.8)	37,200.4 (33,735.7 to 40,724.3)	-21.9 (-35.0 to -7.9)	319.9 (204.2 to 474.0)	277.0 (179.3 to 410.9)	-13.1 (-20.1 to -7.0)
Food-borne trematodiasis	914.4 (741.0 to 1,121.0)	562.5 (427.4 to 729.9)	-38.5 (-47.3 to -30.1)	24.2 (9.6 to 47.3)	9.7 (5.0 to 16.1)	-58.6 (-74.0 to -35.7)
Other neglected tropical diseases	15,649.9 (14,171.1 to 17,149.4)	14,720.3 (14,312.7 to 15,332.2)	-6.1 (-14.5 to 3.5)	751.9 (494.9 to 1,088.4)	699.7 (468.6 to 1,007.8)	-7.5 (-13.0 to 3.1)
Maternal disorders	-	-	-	-	-	-
Maternal hemorrhage	-	-	-	-	-	-
Maternal sepsis and other maternal infections	-	-	-	-	-	-
Maternal hypertensive disorders	-	-	-	-	-	-
Obstructed labor	-	-	-	-	-	-
Complications of abortion	-	-	-	-	-	-

Appendix Table F.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (5-9 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Other maternal disorders	-	-	-	-	-	-
Neonatal disorders	-	-	-	670.9 (494.3 to 870.5)	1,381.2 (1,000.9 to 1,805.5)	105.7 (82.1 to 135.9)
Preterm birth complications	2,259.6 (1,982.7 to 2,608.9)	5,290.7 (4,702.9 to 5,986.2)	133.8 (113.3 to 156.3)	270.3 (195.1 to 350.1)	686.8 (498.6 to 897.4)	153.2 (130.3 to 179.3)
Neonatal encephalopathy due to birth asphyxia and trauma	2,590.1 (1,041.1 to 4,750.3)	2,470.9 (1,346.1 to 4,284.2)	-4.7 (-25.2 to 43.1)	194.9 (138.1 to 279.3)	299.3 (219.1 to 398.2)	54.3 (25.8 to 88.2)
Neonatal sepsis and other neonatal infections	-	-	-	-	-	-
Hemolytic disease and other neonatal jaundice	265.3 (209.2 to 355.0)	606.9 (457.8 to 848.5)	125.6 (50.4 to 280.0)	97.1 (64.7 to 136.3)	188.4 (126.8 to 268.8)	92.1 (34.8 to 204.5)
Other neonatal disorders	-	-	-	108.5 (71.5 to 155.8)	206.7 (140.1 to 290.6)	90.0 (49.6 to 151.6)
Nutritional deficiencies	-	-	-	9,048.7 (6,066.1 to 13,023.1)	8,144.4 (5,448.1 to 11,683.3)	-10.0 (-11.0 to -9.0)
Protein-energy malnutrition	44.3 (26.2 to 68.5)	32.2 (17.9 to 50.4)	-27.2 (-44.3 to -9.1)	5.5 (2.6 to 9.7)	4.0 (1.8 to 7.4)	-27.1 (-47.3 to 1.5)
Iodine deficiency	5,477.4 (5,174.3 to 5,758.5)	3,495.6 (3,263.2 to 3,723.4)	-36.3 (-40.9 to -30.7)	100.1 (61.6 to 157.1)	64.1 (39.4 to 100.8)	-36.2 (-42.2 to -29.2)
Vitamin A deficiency	763.6 (568.1 to 983.3)	557.9 (408.4 to 731.8)	-27.1 (-32.3 to -21.8)	33.5 (20.7 to 49.7)	22.7 (13.5 to 34.7)	-32.5 (-42.1 to -23.1)
Iron-deficiency anemia	184,044.5 (182,461.6 to 185,592.3)	171,402.8 (170,709.2 to 172,117.1)	-7.0 (-7.8 to -6.2)	8,909.3 (5,975.8 to 12,821.6)	8,053.6 (5,384.5 to 11,548.9)	-9.6 (-10.6 to -8.6)
Other nutritional deficiencies	-	-	-	0.3 (0.1 to 0.6)	0.3 (0.0 to 0.3)	-53.7 (-75.6 to -9.2)
Other communicable to maternal to neonatal to and nutritional diseases	-	-	-	569.7 (380.7 to 813.2)	525.5 (352.8 to 752.0)	-8.0 (-11.5 to -2.2)
Sexually transmitted diseases excluding HIV	-	-	-	-	-	-
Syphilis	-	-	0.0 (0.0 to 0.0)	-	-	-
Chlamydial infection	-	-	-	-	-	-
Gonococcal infection	-	-	-	-	-	-
Trichomoniasis	-	-	-	-	-	-
Genital herpes	-	-	-	-	-	-
Other sexually transmitted diseases	-	-	-	-	-	-
Hepatitis	-	-	-	29.1 (18.5 to 43.0)	26.3 (16.8 to 38.7)	-9.8 (-15.3 to -3.3)
Hepatitis A	1,343.5 (1,243.3 to 1,448.6)	1,258.7 (1,170.3 to 1,352.6)	-6.5 (-6.8 to -6.0)	22.0 (14.1 to 32.6)	20.6 (13.1 to 30.8)	-6.1 (-13.1 to 1.5)
Hepatitis B	28,828.2 (28,175.8 to 29,678.7)	21,843.1 (21,218.7 to 22,474.5)	-24.4 (-27.1 to -21.3)	4.8 (3.1 to 7.0)	3.5 (2.2 to 5.1)	-28.2 (-37.2 to -17.5)
Hepatitis C	5,602.9 (5,380.1 to 5,820.9)	4,863.3 (4,675.7 to 5,038.1)	-13.4 (-17.6 to -9.1)	1.2 (0.8 to 1.8)	1.1 (0.7 to 1.6)	-13.6 (-27.0 to 1.5)
Hepatitis E	96.1 (79.9 to 115.0)	98.8 (83.3 to 114.3)	3.0 (-22.2 to 33.4)	1.0 (0.5 to 1.9)	1.1 (0.6 to 1.9)	5.1 (-46.8 to 106.0)
Leprosy	1.1 (0.9 to 1.3)	0.6 (0.5 to 0.7)	-43.4 (-51.3 to -31.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-38.4 (-46.5 to -26.2)
Other infectious diseases	11,612.9 (10,913.5 to 12,394.0)	10,834.6 (10,561.9 to 11,144.5)	-6.9 (-11.4 to -2.9)	540.6 (361.6 to 770.9)	499.2 (336.1 to 713.7)	-7.9 (-11.6 to -1.7)
Non-communicable diseases	-	-	-	14,062.1 (10,173.2 to 18,489.3)	15,147.7 (11,005.5 to 19,878.9)	7.7 (6.2 to 9.4)
Neoplasms	-	-	-	27.4 (18.6 to 38.3)	27.6 (18.4 to 38.2)	0.9 (-20.1 to 23.0)
Esophageal cancer	-	-	-	-	-	-
Stomach cancer	-	-	-	-	-	-
Liver cancer	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-22.2 (-53.6 to 11.5)
Liver cancer due to hepatitis B	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.6)	-0.2 (-41.9 to 51.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-5.1 (-45.1 to 38.3)
Liver cancer due to hepatitis C	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	166.1 (64.1 to 300.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	147.8 (51.7 to 274.0)
Liver cancer due to alcohol use	-	-	-	-	-	-
Liver cancer due to other causes	1.3 (0.9 to 2.0)	0.9 (0.7 to 1.1)	-33.2 (-61.0 to 3.2)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-36.9 (-62.9 to -6.7)
Larynx cancer	-	-	-	-	-	-
Tracheal to bronchus and lung cancer	-	-	-	-	-	-
Breast cancer	-	-	-	-	-	-
Cervical cancer	-	-	-	-	-	-
Uterine cancer	-	-	-	-	-	-
Prostate cancer	-	-	-	-	-	-
Colon and rectum cancer	-	-	-	-	-	-
Lip and oral cavity cancer	-	-	-	-	-	-
Nasopharynx cancer	2.8 (1.4 to 5.3)	1.5 (0.7 to 3.0)	-46.3 (-77.3 to 27.5)	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.2)	-47.5 (-78.1 to 30.7)
Other pharynx cancer	-	-	-	-	-	-
Gallbladder and biliary tract cancer	-	-	-	-	-	-
Pancreatic cancer	-	-	-	-	-	-
Malignant skin melanoma	-	-	-	-	-	-
Non-melanoma skin cancer	-	-	-	-	-	-
Ovarian cancer	-	-	-	-	-	-
Testicular cancer	-	-	-	-	-	-
Kidney cancer	9.5 (7.9 to 11.3)	9.2 (7.8 to 11.0)	-3.7 (-22.9 to 25.2)	0.6 (0.4 to 0.9)	0.6 (0.4 to 0.9)	-6.2 (-26.7 to 25.1)
Bladder cancer	-	-	-	-	-	-
Brain and nervous system cancer	54.4 (40.7 to 70.1)	47.5 (37.5 to 57.1)	-12.0 (-35.8 to 13.7)	4.9 (3.1 to 7.2)	4.2 (2.8 to 5.8)	-14.2 (-37.0 to 13.0)
Thyroid cancer	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-
Hodgkin lymphoma	64.6 (33.2 to 107.9)	34.0 (22.7 to 54.0)	-48.4 (-73.3 to 30.3)	3.9 (1.8 to 7.3)	2.0 (1.1 to 3.5)	-50.5 (-74.3 to 34.7)
Non-Hodgkin lymphoma	38.6 (27.3 to 47.5)	44.1 (34.9 to 53.6)	16.2 (-17.6 to 51.4)	2.6 (1.6 to 3.9)	2.8 (1.8 to 4.1)	12.6 (-23.5 to 49.2)
Multiple myeloma	-	-	-	-	-	-
Leukemia	108.0 (94.8 to 125.0)	105.8 (89.7 to 122.1)	-1.4 (-22.7 to 17.2)	9.5 (6.8 to 13.0)	8.1 (5.4 to 11.4)	-13.7 (-33.3 to 3.0)
Other neoplasms	84.0 (64.1 to 119.9)	160.5 (121.7 to 199.4)	100.2 (17.7 to 162.7)	5.4 (3.3 to 8.4)	9.5 (5.7 to 14.3)	84.8 (9.0 to 151.5)

Appendix Table F.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (5-9 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Cardiovascular diseases	-	-	-	120.7 (79.6 to 172.5)	141.9 (93.0 to 202.9)	17.9 (0.1 to 36.2)
Rheumatic heart disease	1,367.9 (1,248.9 to 1,476.1)	1,750.6 (1,623.1 to 1,883.1)	28.0 (13.9 to 43.4)	68.1 (43.3 to 99.6)	85.5 (54.2 to 125.8)	25.9 (11.0 to 41.1)
Ischemic heart disease	3.8 (3.5 to 4.2)	3.7 (3.4 to 4.2)	-3.9 (-16.7 to 10.6)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.7)	-3.8 (-16.7 to 10.9)
Cerebrovascular disease	-	-	-	4.3 (3.0 to 5.6)	4.9 (3.4 to 6.6)	15.6 (6.9 to 24.8)
Ischemic stroke	11.5 (10.4 to 12.6)	14.3 (13.2 to 15.5)	24.0 (10.4 to 41.1)	1.9 (1.3 to 2.7)	2.4 (1.6 to 3.3)	24.0 (10.4 to 40.8)
Hemorrhagic stroke	13.9 (12.9 to 15.1)	15.0 (14.0 to 16.2)	8.2 (-2.9 to 19.8)	2.3 (1.6 to 3.2)	2.5 (1.7 to 3.5)	8.3 (-2.7 to 19.9)
Hypertensive heart disease	6.2 (5.9 to 6.6)	6.5 (6.1 to 6.9)	4.4 (-4.2 to 14.7)	0.8 (0.5 to 1.1)	0.8 (0.5 to 1.1)	4.5 (-4.1 to 14.9)
Cardiomyopathy and myocarditis	56.1 (52.6 to 60.4)	59.0 (55.2 to 62.2)	5.1 (-2.6 to 12.5)	6.3 (4.3 to 8.9)	6.7 (4.5 to 9.4)	5.6 (-5.6 to 19.0)
Atrial fibrillation and flutter	-	-	-	-	-	-
Peripheral vascular disease	-	-	-	-	-	-
Endocarditis	6.3 (5.6 to 7.5)	6.3 (5.5 to 7.3)	-0.2 (-13.1 to 11.4)	0.5 (0.3 to 0.8)	0.6 (0.4 to 0.8)	10.3 (-8.4 to 27.9)
Other cardiovascular and circulatory diseases	547.4 (384.4 to 869.3)	579.9 (353.2 to 899.1)	5.4 (-36.1 to 58.4)	40.3 (23.5 to 68.6)	42.9 (22.2 to 73.0)	6.0 (-35.2 to 61.9)
Chronic respiratory diseases	-	-	-	964.8 (650.5 to 1,330.9)	936.7 (640.7 to 1,293.2)	-2.8 (-8.2 to 2.2)
Chronic obstructive pulmonary disease	2,529.0 (2,304.5 to 2,754.6)	2,826.6 (2,591.1 to 3,056.4)	11.6 (9.8 to 13.6)	214.4 (134.8 to 312.6)	250.4 (157.6 to 365.8)	16.8 (7.0 to 27.7)
Pneumoconiosis	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	38.1 (32.0 to 45.1)
Silicosis	-	-	0.0 (0.0 to 0.0)	-	-	-
Asbestosis	-	-	0.0 (0.0 to 0.0)	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	-	-	-
Other pneumoconiosis	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.7)	38.6 (32.3 to 45.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	38.1 (32.0 to 45.1)
Asthma	15,894.5 (15,211.2 to 16,555.4)	14,563.3 (13,903.8 to 15,176.2)	-8.4 (-13.8 to -3.3)	719.4 (462.9 to 1,030.8)	660.2 (428.5 to 945.8)	-8.1 (-13.9 to -3.0)
Interstitial lung disease and pulmonary sarcoidosis	5.3 (4.9 to 5.8)	5.7 (5.2 to 6.3)	7.7 (-5.5 to 21.6)	0.7 (0.4 to 1.0)	0.7 (0.5 to 1.1)	8.6 (-4.0 to 22.7)
Other chronic respiratory diseases	-	-	-	30.1 (17.5 to 47.0)	25.2 (15.3 to 39.2)	-16.4 (-27.1 to -1.3)
Cirrhosis	-	-	-	24.1 (15.9 to 34.8)	18.1 (11.8 to 26.1)	-25.0 (-37.3 to -10.5)
Cirrhosis due to hepatitis B	25.7 (22.7 to 29.4)	12.7 (11.0 to 14.6)	-50.9 (-58.9 to -41.4)	4.4 (2.8 to 6.8)	2.3 (1.5 to 3.3)	-48.5 (-61.8 to -32.5)
Cirrhosis due to hepatitis C	17.0 (15.1 to 19.5)	11.4 (9.8 to 12.9)	-33.8 (-43.9 to -18.5)	3.0 (1.9 to 4.3)	2.0 (1.3 to 2.9)	-32.3 (-46.1 to -13.3)
Cirrhosis due to alcohol use	-	-	-	-	-	-
Cirrhosis due to other causes	97.0 (92.3 to 101.6)	79.8 (76.1 to 83.6)	-17.8 (-23.2 to -12.6)	16.7 (11.0 to 24.0)	13.8 (8.7 to 20.1)	-17.0 (-34.9 to 5.2)
Digestive diseases	-	-	-	432.4 (295.6 to 602.9)	332.5 (230.2 to 463.7)	-23.1 (-27.5 to -17.8)
Peptic ulcer disease	121.6 (116.3 to 126.8)	57.2 (54.3 to 60.0)	-53.1 (-56.1 to -49.6)	8.1 (5.4 to 11.6)	4.6 (3.1 to 6.6)	-42.7 (-52.5 to -30.5)
Gastritis and duodenitis	5,656.4 (5,450.2 to 5,844.7)	3,891.5 (3,773.9 to 4,007.3)	-31.4 (-34.4 to -27.9)	330.7 (224.4 to 469.9)	246.5 (168.6 to 350.9)	-25.5 (-30.7 to -19.4)
Appendicitis	38.9 (34.1 to 45.2)	37.3 (29.7 to 43.0)	-2.6 (-25.5 to 15.5)	12.3 (7.4 to 18.2)	11.7 (7.0 to 17.6)	-4.7 (-35.9 to 39.0)
Paralytic ileus and intestinal obstruction	1.6 (1.5 to 1.6)	1.9 (1.8 to 2.0)	20.9 (15.0 to 26.7)	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.9)	21.1 (15.2 to 26.9)
Inguinal to femoral to and abdominal hernia	545.0 (509.7 to 592.4)	562.7 (526.3 to 600.0)	3.5 (-8.8 to 13.9)	5.9 (2.9 to 11.2)	6.1 (2.9 to 11.6)	3.7 (-10.2 to 17.5)
Inflammatory bowel disease	49.8 (47.6 to 52.0)	66.0 (63.3 to 68.9)	32.5 (24.7 to 41.0)	11.2 (7.2 to 15.9)	14.9 (9.7 to 21.3)	32.7 (6.6 to 72.6)
Vascular intestinal disorders	0.6 (0.5 to 0.6)	0.7 (0.6 to 0.8)	19.7 (2.4 to 39.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	19.8 (2.5 to 39.3)
Gallbladder and biliary diseases	46.5 (44.0 to 49.2)	45.9 (43.0 to 48.9)	-1.0 (-10.3 to 6.7)	5.2 (3.3 to 7.5)	5.2 (3.3 to 7.5)	-1.7 (-22.2 to 23.4)
Pancreatitis	17.8 (16.7 to 18.8)	22.6 (21.9 to 23.4)	26.4 (19.2 to 36.2)	5.8 (3.9 to 7.9)	7.3 (4.8 to 10.2)	25.7 (14.6 to 39.4)
Other digestive diseases	-	-	-	52.5 (34.8 to 76.1)	35.5 (23.6 to 50.6)	-32.4 (-40.5 to -23.7)
Neurological disorders	-	-	-	1,372.5 (927.0 to 1,892.8)	1,527.0 (1,028.8 to 2,080.9)	11.3 (2.6 to 20.3)
Alzheimer disease and other dementias	-	-	-	-	-	-
Parkinson disease	-	-	-	-	-	-
Epilepsy	1,779.5 (1,661.2 to 1,892.0)	1,863.5 (1,728.7 to 1,987.6)	4.7 (-5.0 to 15.7)	583.9 (391.1 to 786.6)	659.1 (449.3 to 875.0)	12.8 (1.9 to 27.2)
Multiple sclerosis	0.5 (0.5 to 0.6)	0.7 (0.7 to 0.8)	47.0 (26.1 to 69.8)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	47.1 (26.3 to 70.0)
Migraine	20,033.9 (18,669.6 to 21,610.6)	21,557.3 (19,571.6 to 23,205.5)	8.0 (-4.2 to 18.5)	712.1 (417.8 to 1,046.8)	768.3 (454.5 to 1,129.8)	8.1 (-5.4 to 20.5)
Tension-type headache	27,087.0 (24,035.6 to 30,342.1)	29,708.8 (25,972.3 to 32,870.9)	9.7 (-7.3 to 28.0)	41.9 (19.7 to 75.3)	46.0 (21.8 to 81.8)	10.4 (-8.0 to 29.8)
Medication overuse headache	208.9 (137.5 to 280.9)	322.5 (213.6 to 439.0)	52.9 (26.4 to 93.6)	34.2 (18.8 to 53.9)	53.0 (29.8 to 84.7)	54.0 (24.0 to 99.4)
Other neurological disorders	0.5 (0.4 to 0.6)	0.5 (0.5 to 0.6)	9.7 (-4.0 to 26.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	6.1 (-5.5 to 19.3)
Mental and substance use disorders	-	-	-	3,943.8 (2,668.7 to 5,360.4)	4,345.3 (2,947.9 to 5,869.4)	10.1 (7.5 to 13.6)
Schizophrenia	-	-	-	-	-	-
Alcohol use disorders	146.1 (137.2 to 154.8)	168.1 (157.3 to 178.0)	14.9 (13.4 to 16.4)	8.2 (5.3 to 11.8)	9.4 (6.1 to 13.6)	14.7 (3.3 to 26.4)
Drug use disorders	-	-	-	-	-	-
Opioid use disorders	-	-	-	-	-	-
Cocaine use disorders	-	-	-	-	-	-
Amphetamine use disorders	-	-	-	-	-	-
Cannabis use disorders	-	-	-	-	-	-
Other drug use disorders	-	-	-	-	-	-
Depressive disorders	-	-	-	998.0 (550.1 to 1,562.0)	1,169.4 (674.2 to 1,782.2)	16.7 (10.3 to 32.8)

Appendix Table F.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (5-9 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Major depressive disorder	4,617.0 (2,905.6 to 6,573.0)	5,405.7 (3,651.2 to 7,361.1)	16.6 (10.5 to 33.1)	985.0 (538.4 to 1,545.3)	1,155.5 (664.9 to 1,764.9)	16.9 (10.3 to 33.6)
Dysthymia	130.6 (101.9 to 156.9)	139.1 (108.2 to 167.2)	6.4 (5.6 to 7.0)	13.1 (8.0 to 19.8)	13.9 (8.6 to 21.6)	6.8 (-10.7 to 26.6)
Bipolar disorder	-	-	-	-	-	-
Anxiety disorders	7,389.3 (4,549.2 to 11,430.8)	8,078.7 (5,033.7 to 12,324.4)	9.2 (7.1 to 11.6)	704.8 (356.4 to 1,190.4)	771.0 (386.0 to 1,299.4)	9.5 (5.2 to 14.6)
Eating disorders	-	-	-	9.0 (5.3 to 14.0)	10.8 (6.3 to 16.4)	19.6 (-2.1 to 43.3)
Anorexia nervosa	37.2 (25.7 to 47.4)	44.7 (31.2 to 56.9)	20.2 (16.7 to 23.5)	8.2 (4.6 to 12.6)	9.8 (5.5 to 15.0)	20.4 (-3.8 to 47.3)
Bulimia nervosa	4.0 (2.2 to 7.2)	4.5 (2.5 to 8.2)	13.0 (7.6 to 14.8)	0.9 (0.4 to 1.7)	1.0 (0.5 to 2.0)	13.1 (1.5 to 22.2)
Autistic spectrum disorders	-	-	-	742.9 (518.8 to 1,023.2)	805.5 (558.4 to 1,106.2)	8.4 (5.6 to 11.4)
Autism	1,866.7 (1,765.0 to 1,969.5)	2,018.8 (1,908.7 to 2,130.2)	8.0 (7.8 to 8.1)	472.5 (319.9 to 655.5)	512.2 (343.3 to 712.9)	8.4 (4.4 to 12.6)
Asperger syndrome	2,657.9 (2,471.3 to 2,822.1)	2,876.3 (2,674.4 to 3,054.7)	8.0 (8.0 to 8.1)	270.5 (185.1 to 379.0)	293.3 (199.5 to 413.3)	8.4 (5.1 to 12.3)
Attention-deficit/hyperactivity disorder	8,036.5 (7,468.9 to 8,625.1)	8,630.3 (8,051.2 to 9,218.7)	7.2 (6.3 to 8.3)	98.3 (59.4 to 152.5)	105.7 (63.1 to 162.9)	7.6 (4.0 to 11.2)
Conduct disorder	6,443.1 (5,635.6 to 7,233.6)	7,081.3 (6,241.9 to 7,916.3)	9.7 (8.7 to 11.0)	779.9 (477.3 to 1,154.9)	859.3 (527.9 to 1,271.5)	10.2 (7.5 to 13.2)
Idiopathic intellectual disability	12,038.1 (9,493.5 to 14,726.9)	12,285.9 (10,097.3 to 14,907.8)	1.8 (-5.3 to 10.8)	602.6 (392.7 to 861.2)	614.0 (404.7 to 878.3)	1.9 (-5.7 to 11.1)
Other mental and substance use disorders	-	-	0.0 (0.0 to 0.0)	-	-	-
Diabetes to urogenital to blood to and endocrine diseases	-	-	-	2,153.1 (1,498.7 to 2,995.3)	2,431.1 (1,683.9 to 3,398.1)	12.9 (10.2 to 15.8)
Diabetes mellitus	2,559.3 (2,370.7 to 2,758.6)	3,703.0 (3,400.5 to 3,990.4)	44.9 (29.2 to 58.6)	123.3 (78.0 to 183.6)	178.7 (112.7 to 270.5)	45.5 (29.3 to 61.1)
Acute glomerulonephritis	6.5 (5.7 to 7.3)	5.3 (4.5 to 6.1)	-18.5 (-22.9 to -15.1)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-18.4 (-22.8 to -15.0)
Chronic kidney disease	-	-	-	439.1 (312.3 to 593.1)	514.7 (360.7 to 695.2)	17.2 (11.1 to 24.1)
Chronic kidney disease due to diabetes mellitus	856.7 (480.9 to 1,524.1)	1,059.8 (596.0 to 1,885.7)	23.4 (10.4 to 37.9)	17.2 (11.8 to 23.8)	21.8 (15.2 to 30.1)	27.3 (9.9 to 43.7)
Chronic kidney disease due to hypertension	7,551.3 (3,825.9 to 14,121.6)	8,269.8 (4,269.7 to 15,110.6)	9.4 (-1.4 to 24.8)	69.8 (49.1 to 95.7)	81.2 (56.6 to 113.6)	16.7 (1.3 to 33.9)
Chronic kidney disease due to glomerulonephritis	4,697.6 (2,991.1 to 7,519.4)	5,541.8 (3,554.2 to 8,872.2)	17.7 (7.1 to 28.7)	164.7 (114.9 to 222.9)	171.8 (120.9 to 233.7)	4.5 (-5.9 to 16.0)
Chronic kidney disease due to other causes	9,011.9 (5,044.7 to 16,320.1)	11,147.4 (6,123.4 to 20,148.5)	23.5 (13.9 to 32.5)	187.4 (134.0 to 258.9)	239.9 (167.4 to 326.3)	28.2 (16.8 to 39.9)
Urinary diseases and male infertility	-	-	-	3.5 (2.2 to 5.0)	4.2 (2.6 to 6.3)	20.0 (2.2 to 36.9)
Interstitial nephritis and urinary tract infections	33.9 (33.0 to 34.8)	40.6 (39.5 to 41.7)	19.5 (14.8 to 24.3)	1.2 (0.7 to 1.8)	1.4 (0.8 to 2.2)	19.3 (-9.3 to 53.7)
Urolithiasis	109.6 (72.3 to 163.1)	98.8 (59.3 to 160.0)	-9.6 (-31.9 to 5.8)	1.4 (0.9 to 2.1)	1.5 (0.9 to 2.3)	5.5 (-7.0 to 14.4)
Benign prostatic hyperplasia	-	-	-	-	-	-
Male infertility due to other causes	-	-	-	-	-	-
Other urinary diseases	-	-	-	0.9 (0.5 to 1.4)	1.3 (0.7 to 2.1)	48.8 (5.2 to 79.3)
Gynecological diseases	-	-	-	-	-	-
Uterine fibroids	-	-	-	-	-	-
Polycystic ovarian syndrome	-	-	-	-	-	-
Female infertility due to other causes	-	-	-	-	-	-
Endometriosis	-	-	-	-	-	-
Genital prolapse	-	-	-	-	-	-
Premenstrual syndrome	-	-	-	-	-	-
Other gynecological diseases	-	-	-	-	-	-
Hemoglobinopathies and hemolytic anemias	-	-	-	1,129.0 (760.7 to 1,605.7)	1,309.4 (879.8 to 1,866.6)	15.9 (12.8 to 19.3)
Thalassemias	150.6 (132.6 to 169.0)	148.9 (134.1 to 165.2)	-1.7 (-4.7 to 4.5)	12.7 (8.5 to 18.0)	12.7 (8.5 to 18.2)	-1.0 (-12.5 to 15.0)
Thalassemia trait	17,287.3 (16,009.0 to 18,916.5)	17,981.7 (16,971.1 to 19,305.3)	3.9 (1.4 to 6.3)	531.9 (360.4 to 758.9)	632.2 (423.1 to 896.2)	18.9 (14.9 to 22.8)
Sickle cell disorders	366.9 (347.0 to 386.0)	618.4 (588.2 to 646.3)	68.1 (60.9 to 76.7)	35.8 (23.9 to 50.4)	59.7 (41.1 to 82.5)	66.7 (49.2 to 88.1)
Sickle cell trait	21,476.8 (20,399.0 to 22,459.4)	29,895.7 (28,578.6 to 31,109.3)	38.9 (36.5 to 41.2)	222.2 (147.6 to 319.5)	306.5 (205.7 to 435.8)	38.1 (27.3 to 47.7)
G6PD deficiency	28,209.5 (27,465.2 to 28,903.9)	35,455.9 (34,572.6 to 36,334.3)	25.5 (21.1 to 29.7)	3.9 (2.6 to 5.5)	5.3 (3.6 to 7.6)	34.7 (17.4 to 53.2)
G6PD trait	95,503.0 (94,862.6 to 96,046.4)	106,234.6 (105,422.0 to 106,960.3)	11.0 (10.0 to 12.2)	7.1 (4.3 to 10.4)	8.7 (5.2 to 12.8)	23.8 (-7.5 to 62.1)
Other hemoglobinopathies and hemolytic anemias	6,687.4 (6,137.3 to 7,116.8)	6,239.1 (5,860.9 to 6,510.3)	-7.0 (-12.5 to -0.1)	315.5 (211.4 to 448.5)	284.4 (189.3 to 408.1)	-10.0 (-16.6 to -1.3)
Endocrine to metabolic to blood to and immune disorders	10,249.1 (9,990.1 to 10,523.2)	9,675.4 (8,885.7 to 10,290.0)	-5.6 (-14.1 to 0.9)	457.9 (313.4 to 645.9)	423.8 (286.3 to 608.9)	-7.5 (-17.4 to 1.3)
Musculoskeletal disorders	-	-	-	347.8 (234.8 to 483.8)	382.1 (255.5 to 537.9)	9.7 (0.1 to 20.7)
Rheumatoid arthritis	63.4 (62.3 to 64.6)	71.4 (70.2 to 72.5)	12.3 (9.8 to 14.9)	16.4 (11.4 to 22.2)	18.5 (12.9 to 25.0)	12.5 (5.4 to 19.6)
Osteoarthritis	-	-	-	-	-	-
Low back and neck pain	-	-	-	331.4 (222.4 to 464.5)	363.6 (241.8 to 512.3)	9.6 (-0.7 to 21.1)
Low back pain	2,765.5 (2,608.3 to 2,934.9)	3,031.1 (2,822.6 to 3,220.1)	9.4 (0.1 to 19.4)	324.3 (217.3 to 456.8)	356.0 (235.6 to 502.1)	9.7 (-0.8 to 21.5)
Neck pain	67.2 (57.3 to 76.8)	72.1 (62.9 to 84.3)	7.7 (-13.1 to 29.3)	7.1 (4.7 to 10.2)	7.3 (5.0 to 10.9)	7.3 (-14.6 to 32.2)
Gout	-	-	-	-	-	-
Other musculoskeletal disorders	-	-	0.0 (0.0 to 0.0)	-	-	-
Other non-communicable diseases	-	-	-	4,675.5 (3,206.1 to 6,611.1)	5,005.4 (3,431.3 to 7,091.3)	7.1 (3.7 to 10.2)
Congenital anomalies	-	-	-	582.8 (422.2 to 763.2)	714.5 (513.9 to 929.9)	22.6 (13.3 to 34.0)
Neural tube defects	117.6 (114.7 to 121.1)	165.4 (160.9 to 169.9)	40.6 (35.4 to 45.3)	36.7 (25.8 to 47.6)	52.6 (36.7 to 69.8)	42.6 (28.6 to 61.1)
Congenital heart anomalies	1,847.4 (1,784.4 to 1,917.9)	2,978.9 (2,854.8 to 3,133.3)	60.7 (52.8 to 71.3)	68.6 (31.8 to 114.2)	109.7 (49.0 to 184.4)	59.3 (47.8 to 71.2)

Appendix Table F.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (5-9 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Orofacial clefts	327.8 (314.2 to 339.1)	528.7 (506.7 to 550.8)	60.7 (52.0 to 71.4)	4.7 (3.0 to 6.8)	7.0 (4.5 to 10.1)	48.8 (27.4 to 75.5)
Down syndrome	501.9 (480.9 to 526.6)	664.4 (638.0 to 694.4)	32.1 (24.5 to 39.9)	55.8 (41.0 to 72.9)	74.0 (54.3 to 97.2)	32.9 (20.2 to 45.7)
Turner syndrome	17.8 (16.9 to 18.8)	21.8 (20.8 to 23.1)	21.9 (14.3 to 32.2)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.5)	22.0 (14.2 to 32.2)
Klinefelter syndrome	17.0 (16.0 to 17.9)	19.2 (18.3 to 20.2)	12.2 (4.7 to 21.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	12.5 (4.8 to 22.0)
Chromosomal unbalanced rearrangements	673.7 (648.7 to 695.0)	884.6 (843.0 to 934.6)	30.9 (24.0 to 39.5)	74.9 (53.8 to 98.4)	98.5 (71.1 to 129.0)	31.5 (20.9 to 43.2)
Other congenital anomalies	2,199.9 (1,786.2 to 2,600.7)	2,087.6 (1,627.4 to 2,496.0)	-5.3 (-12.0 to 0.9)	341.8 (230.0 to 483.0)	372.4 (254.2 to 513.5)	9.0 (-1.2 to 24.1)
Skin and subcutaneous diseases	-	-	-	2,093.6 (1,333.2 to 3,147.7)	2,329.1 (1,486.0 to 3,525.0)	11.3 (7.3 to 14.8)
Dermatitis	15,848.1 (13,394.5 to 18,894.4)	17,368.4 (14,662.5 to 20,711.7)	9.4 (7.9 to 10.9)	620.0 (395.9 to 898.5)	692.6 (439.6 to 1,004.3)	11.7 (8.9 to 14.6)
Psoriasis	1,303.2 (1,123.2 to 1,477.4)	1,414.7 (1,217.1 to 1,600.4)	8.4 (7.8 to 8.9)	110.5 (75.2 to 153.4)	120.2 (80.7 to 168.5)	8.7 (-0.3 to 19.2)
Cellulitis	98.5 (73.6 to 130.7)	91.3 (68.6 to 122.2)	-7.4 (-13.5 to -2.7)	7.3 (4.1 to 11.2)	6.8 (3.9 to 10.7)	-6.6 (-25.0 to 15.2)
Pyoderma	1,020.4 (655.4 to 1,485.7)	744.6 (512.2 to 1,024.7)	-27.0 (-32.7 to -18.1)	5.9 (2.1 to 13.8)	4.3 (1.6 to 9.6)	-26.8 (-33.6 to -16.4)
Scabies	4,603.3 (4,055.5 to 5,217.9)	4,399.7 (3,948.7 to 4,888.1)	-4.6 (-19.1 to 13.9)	120.1 (66.8 to 196.7)	115.0 (66.4 to 188.3)	-4.4 (-18.8 to 14.6)
Fungal skin diseases	43,569.4 (32,391.2 to 54,592.1)	52,153.9 (39,775.1 to 64,854.4)	19.6 (15.6 to 23.5)	249.4 (99.7 to 538.5)	298.8 (120.1 to 638.8)	19.9 (15.8 to 23.9)
Viral skin diseases	19,140.0 (15,247.4 to 23,007.8)	20,463.8 (16,551.1 to 24,421.6)	6.7 (4.4 to 9.6)	598.1 (357.5 to 933.0)	640.1 (383.3 to 996.9)	7.0 (4.2 to 10.5)
Acne vulgaris	17,654.7 (15,522.8 to 19,664.6)	20,617.3 (18,197.3 to 23,399.5)	15.9 (-1.5 to 40.6)	192.5 (90.5 to 359.8)	224.9 (105.7 to 406.2)	16.0 (-1.6 to 41.0)
Alopecia areata	376.9 (364.3 to 389.8)	411.3 (396.9 to 425.1)	8.8 (4.4 to 13.8)	13.0 (8.1 to 19.7)	14.2 (8.9 to 21.6)	9.2 (-1.0 to 22.9)
Pruritus	21.3 (19.9 to 22.5)	20.9 (19.3 to 22.3)	-1.6 (-10.6 to 6.4)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	-1.4 (-17.9 to 17.2)
Urticaria	1,883.6 (1,626.4 to 2,157.9)	2,349.8 (1,783.8 to 3,074.5)	21.7 (-7.2 to 68.1)	116.2 (73.5 to 174.1)	144.7 (86.0 to 228.9)	21.7 (-7.6 to 70.1)
Decubitus ulcer	15.7 (14.9 to 16.5)	14.0 (13.2 to 14.8)	-11.0 (-16.0 to -5.6)	2.6 (1.8 to 3.6)	2.3 (1.6 to 3.2)	-10.9 (-15.9 to -5.5)
Other skin and subcutaneous diseases	9,546.4 (2,071.7 to 22,143.9)	10,694.2 (2,301.7 to 24,700.4)	11.8 (9.5 to 14.2)	57.9 (10.7 to 161.5)	65.0 (11.8 to 182.3)	12.2 (8.4 to 15.9)
Sense organ diseases	-	-	-	1,618.4 (1,084.9 to 2,273.8)	1,557.1 (1,041.0 to 2,209.5)	-3.8 (-8.6 to 1.2)
Glaucoma	-	-	-	-	-	-
Cataract	-	-	-	-	-	-
Macular degeneration	-	-	-	-	-	-
Uncorrected refractive error	16,411.1 (15,580.7 to 17,228.9)	16,947.8 (16,237.3 to 17,807.5)	3.0 (-1.3 to 7.7)	360.5 (231.7 to 542.0)	355.4 (225.5 to 539.3)	-1.5 (-5.3 to 2.4)
Age-related and other hearing loss	7,139.0 (5,117.9 to 9,538.8)	6,860.8 (4,817.2 to 9,440.9)	-4.4 (-11.6 to 4.7)	698.8 (406.5 to 1,093.6)	621.8 (354.4 to 993.7)	-11.2 (-20.8 to -0.8)
Other vision loss	1,021.2 (802.0 to 1,262.2)	810.7 (630.7 to 1,011.7)	-20.8 (-24.2 to -17.1)	51.4 (33.1 to 74.8)	36.8 (23.3 to 54.8)	-28.5 (-36.2 to -21.0)
Other sense organ diseases	18,697.6 (18,286.7 to 19,111.8)	19,976.3 (19,515.9 to 20,445.8)	6.7 (3.3 to 10.2)	507.7 (314.3 to 757.2)	543.1 (334.9 to 812.4)	7.0 (2.6 to 11.2)
Oral disorders	-	-	-	380.6 (208.7 to 634.5)	404.8 (222.5 to 674.7)	6.4 (3.8 to 8.7)
Deciduous caries	247,861.4 (246,305.1 to 249,374.0)	263,692.6 (262,103.9 to 265,220.8)	6.2 (5.3 to 7.2)	89.7 (39.0 to 174.3)	96.8 (42.1 to 187.9)	7.8 (5.6 to 10.1)
Permanent caries	124,313.1 (122,424.7 to 126,415.7)	126,143.1 (124,037.2 to 128,209.4)	1.3 (-1.2 to 3.7)	116.6 (53.3 to 226.0)	120.4 (54.6 to 233.3)	3.3 (0.2 to 6.5)
Periodontal diseases	-	-	-	-	-	-
Edentulism and severe tooth loss	-	-	-	-	-	-
Other oral disorders	5,812.2 (5,679.8 to 5,954.3)	6,248.0 (6,066.7 to 6,402.8)	7.4 (3.7 to 11.2)	174.3 (108.8 to 260.5)	187.6 (116.4 to 280.9)	7.7 (3.0 to 12.5)
Injuries	-	-	-	683.3 (524.2 to 863.3)	447.0 (343.9 to 571.8)	-33.9 (-45.5 to -26.9)
Transport injuries	-	-	-	142.2 (110.5 to 180.0)	83.0 (64.3 to 105.1)	-41.7 (-45.1 to -38.0)
Road injuries	-	-	-	122.2 (95.0 to 154.6)	72.0 (55.9 to 91.1)	-41.1 (-44.8 to -37.0)
Pedestrian road injuries	-	-	-	50.7 (38.5 to 64.6)	31.0 (23.8 to 39.4)	-38.8 (-44.1 to -33.3)
Cyclist road injuries	-	-	-	16.3 (12.6 to 21.0)	8.2 (6.3 to 10.6)	-49.7 (-53.1 to -46.4)
Motorcyclist road injuries	-	-	-	15.3 (11.8 to 19.5)	5.7 (4.4 to 7.2)	-63.1 (-65.7 to -60.1)
Motor vehicle road injuries	-	-	-	38.7 (29.9 to 48.7)	26.3 (20.3 to 33.3)	-32.0 (-36.7 to -27.2)
Other road injuries	-	-	-	1.2 (0.9 to 1.5)	0.9 (0.7 to 1.1)	-29.8 (-34.6 to -24.3)
Other transport injuries	-	-	-	20.0 (15.5 to 25.3)	11.0 (8.4 to 14.1)	-45.3 (-48.2 to -42.0)
Unintentional injuries	-	-	-	409.4 (311.3 to 525.3)	333.1 (251.8 to 434.7)	-18.7 (-21.9 to -15.2)
Falls	-	-	-	141.2 (107.9 to 179.9)	128.8 (97.1 to 165.8)	-8.8 (-14.8 to -2.6)
Drowning	-	-	-	19.4 (14.2 to 25.5)	9.5 (6.9 to 12.6)	-51.3 (-55.9 to -46.0)
Fire to heat to and hot substances	-	-	-	48.9 (37.5 to 62.8)	37.4 (27.9 to 49.7)	-23.5 (-32.0 to -14.1)
Poisonings	-	-	-	4.0 (2.7 to 5.4)	2.4 (1.6 to 3.3)	-39.4 (-48.3 to -29.4)
Exposure to mechanical forces	-	-	-	129.3 (90.5 to 184.0)	102.0 (70.8 to 146.9)	-21.2 (-24.2 to -18.0)
Unintentional firearm injuries	-	-	-	2.4 (1.8 to 3.0)	1.7 (1.3 to 2.2)	-28.4 (-32.6 to -24.1)
Unintentional suffocation	-	-	-	1.7 (1.3 to 2.3)	1.4 (1.1 to 2.0)	-16.4 (-20.5 to -12.4)
Other exposure to mechanical forces	-	-	-	125.2 (87.3 to 178.8)	98.9 (68.4 to 142.9)	-21.1 (-24.1 to -17.9)
Adverse effects of medical treatment	-	-	-	3.8 (2.4 to 5.6)	3.8 (2.4 to 5.6)	-0.6 (-6.6 to 6.0)
Animal contact	-	-	-	20.0 (14.2 to 29.0)	13.5 (9.7 to 19.0)	-32.4 (-37.9 to -26.3)

Appendix Table F.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (5-9 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Venomous animal contact	-	-	-	6.1 (4.5 to 8.1)	4.4 (3.2 to 5.9)	-28.5 (-39.8 to -14.5)
Non-venomous animal contact	-	-	-	13.9 (9.0 to 22.2)	9.1 (6.0 to 14.1)	-34.0 (-39.3 to -29.1)
Foreign body	-	-	-	8.5 (6.2 to 11.5)	7.4 (5.1 to 10.4)	-13.5 (-20.8 to -7.1)
Pulmonary aspiration and foreign body in airway	-	-	-	3.2 (2.4 to 4.0)	2.1 (1.6 to 2.7)	-33.2 (-38.8 to -26.5)
Foreign body in eyes	-	-	-	2.8 (1.3 to 4.8)	2.9 (1.3 to 5.1)	6.7 (-0.9 to 14.9)
Foreign body in other body part	-	-	-	2.6 (1.9 to 3.5)	2.3 (1.7 to 3.1)	-10.9 (-16.0 to -5.7)
Other unintentional injuries	-	-	-	34.3 (25.8 to 44.9)	28.4 (21.5 to 37.2)	-17.3 (-21.8 to -13.1)
Self-harm and interpersonal violence	-	-	-	14.3 (11.1 to 17.9)	10.2 (7.9 to 12.9)	-28.5 (-31.9 to -24.7)
Self-harm	-	-	-	-	-	-
Interpersonal violence	-	-	-	14.3 (11.1 to 17.9)	10.2 (7.9 to 12.9)	-28.5 (-31.9 to -24.7)
Assault by firearm	-	-	-	2.5 (2.0 to 3.2)	1.9 (1.5 to 2.5)	-24.6 (-27.8 to -20.9)
Assault by sharp object	-	-	-	1.9 (1.5 to 2.4)	1.4 (1.1 to 1.8)	-23.0 (-27.0 to -18.5)
Assault by other means	-	-	-	9.8 (7.6 to 12.4)	6.8 (5.3 to 8.7)	-30.5 (-34.4 to -26.5)
Forces of nature to war to and legal intervention	-	-	-	117.4 (53.7 to 245.1)	20.6 (10.7 to 38.5)	-82.4 (-90.9 to -62.1)
Exposure to forces of nature	-	-	-	8.3 (5.7 to 11.7)	8.7 (3.7 to 18.1)	-6.2 (-50.8 to 103.5)
Collective violence and legal intervention	-	-	-	109.2 (46.0 to 235.1)	11.9 (6.2 to 24.7)	-89.2 (-94.0 to -69.8)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (10-14 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
All causes	-	-	-	35,489.2 (25,588.4 to 47,526.4)	37,487.6 (27,267.3 to 49,816.4)	5.8 (2.8 to 8.1)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	12,746.7 (8,579.8 to 18,395.2)	11,903.3 (8,242.3 to 16,741.3)	-6.1 (-12.2 to -1.3)
HIV/AIDS and tuberculosis	-	-	-	34.6 (22.7 to 48.9)	137.1 (95.6 to 178.4)	297.9 (234.8 to 378.7)
Tuberculosis	106.4 (99.0 to 112.9)	112.3 (105.7 to 118.1)	5.6 (3.1 to 9.0)	33.7 (22.2 to 47.7)	35.7 (23.5 to 49.5)	6.1 (-11.0 to 26.3)
HIV/AIDS	-	-	-	0.9 (0.5 to 1.3)	101.4 (72.0 to 131.1)	11,803.9 (8,122.5 to 17,234.1)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	1.2 (0.8 to 1.7)	8,380.8 (5,696.7 to 13,613.2)	0.0 (0.0 to 0.0)	0.5 (0.3 to 0.8)	8,118.6 (5,394.2 to 13,980.1)
HIV/AIDS resulting in other diseases	3.3 (2.6 to 4.1)	563.1 (528.3 to 607.6)	17,018.9 (13,462.4 to 21,819.8)	0.9 (0.5 to 1.3)	100.9 (71.6 to 130.5)	11,823.8 (8,112.4 to 17,319.0)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	1,089.5 (774.2 to 1,491.4)	1,061.5 (735.7 to 1,480.3)	-2.7 (-7.9 to 3.0)
Diarrheal diseases	2,111.4 (1,990.9 to 2,236.8)	2,017.8 (1,881.4 to 2,151.6)	-4.2 (-13.0 to 5.0)	340.9 (232.3 to 472.5)	326.7 (223.1 to 453.5)	-4.3 (-13.5 to 6.4)
Intestinal infectious diseases	-	-	-	31.8 (20.9 to 46.7)	24.1 (15.6 to 35.5)	-23.8 (-42.8 to 0.4)
Typhoid fever	180.3 (154.5 to 211.1)	141.6 (122.9 to 164.5)	-21.6 (-36.1 to -0.7)	23.8 (15.2 to 35.5)	18.9 (11.9 to 27.6)	-20.6 (-43.7 to 10.4)
Paratyphoid fever	116.7 (91.4 to 145.6)	85.7 (66.5 to 107.1)	-26.1 (-46.3 to 2.6)	6.0 (3.6 to 9.5)	4.5 (2.5 to 7.2)	-25.9 (-52.4 to 16.9)
Other intestinal infectious diseases	-	-	-	2.0 (1.0 to 4.0)	0.8 (0.4 to 1.5)	-61.9 (-70.1 to -50.9)
Lower respiratory infections	183.8 (172.9 to 194.3)	157.6 (148.2 to 167.2)	-14.3 (-20.3 to -4.9)	19.4 (13.0 to 28.0)	16.6 (11.2 to 23.4)	-14.4 (-25.3 to 0.1)
Upper respiratory infections	20,065.3 (19,613.9 to 20,510.7)	24,635.8 (24,143.0 to 25,158.6)	22.9 (19.3 to 27.2)	236.9 (132.0 to 389.5)	291.6 (162.0 to 486.2)	23.0 (18.7 to 28.1)
Otitis media	8,843.5 (7,999.9 to 9,617.5)	9,067.1 (8,170.8 to 9,950.8)	2.6 (-1.0 to 6.6)	190.3 (114.6 to 304.0)	197.1 (119.5 to 313.7)	3.6 (-2.5 to 9.7)
Meningitis	-	-	-	235.8 (163.8 to 316.4)	179.2 (126.1 to 239.1)	-23.9 (-29.8 to -17.5)
Pneumococcal meningitis	885.4 (589.5 to 1,249.0)	647.7 (441.5 to 912.9)	-26.9 (-31.2 to -20.3)	93.1 (64.5 to 124.1)	72.5 (50.1 to 96.9)	-22.1 (-32.5 to -8.4)
H influenzae type B meningitis	484.5 (218.5 to 850.5)	347.3 (178.1 to 598.2)	-28.2 (-33.5 to -18.8)	61.2 (41.7 to 84.4)	48.9 (33.2 to 65.9)	-20.5 (-31.2 to -5.6)
Meningococcal meningitis	172.2 (74.5 to 370.4)	112.2 (54.5 to 231.2)	-34.4 (-40.6 to -23.1)	24.1 (16.1 to 34.3)	16.8 (11.3 to 23.7)	-30.5 (-39.9 to -15.9)
Other meningitis	427.1 (231.0 to 729.2)	287.4 (177.9 to 468.9)	-32.3 (-37.9 to -23.3)	57.4 (38.5 to 78.6)	41.0 (28.0 to 55.4)	-28.7 (-36.2 to -18.1)
Encephalitis	131.9 (66.6 to 267.5)	101.9 (56.1 to 207.0)	-22.2 (-31.2 to -13.2)	18.4 (12.9 to 24.5)	15.8 (11.2 to 21.1)	-14.2 (-22.0 to -6.3)
Diphtheria	0.1 (0.1 to 0.4)	0.1 (0.0 to 0.2)	-55.1 (-89.1 to 136.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-55.2 (-89.2 to 136.7)
Whooping cough	28.4 (22.0 to 36.4)	22.1 (17.2 to 28.3)	-22.0 (-22.6 to -21.3)	1.4 (0.8 to 2.3)	1.1 (0.6 to 1.9)	-23.8 (-49.3 to 15.1)
Tetanus	133.6 (94.9 to 202.4)	17.1 (11.6 to 26.4)	-87.3 (-92.7 to -77.7)	5.2 (3.4 to 7.7)	1.4 (0.9 to 2.4)	-73.9 (-84.0 to -53.1)
Measles	18.7 (14.4 to 23.9)	5.0 (3.9 to 6.3)	-73.2 (-75.6 to -70.8)	1.7 (1.0 to 2.7)	0.5 (0.3 to 0.7)	-73.1 (-75.9 to -70.4)
Varicella and herpes zoster	301.4 (279.1 to 327.1)	328.2 (292.3 to 366.6)	8.4 (-2.6 to 24.5)	7.5 (4.6 to 11.4)	7.2 (4.4 to 11.3)	-3.0 (-12.1 to 6.2)
Neglected tropical diseases and malaria	-	-	-	3,499.5 (2,131.9 to 5,602.0)	2,314.9 (1,520.8 to 3,443.1)	-33.0 (-42.4 to -23.7)
Malaria	39,066.4 (38,155.3 to 40,122.1)	47,259.4 (46,026.0 to 48,431.2)	21.2 (17.8 to 24.5)	421.9 (279.9 to 601.2)	575.6 (388.5 to 823.9)	36.5 (29.6 to 44.4)
Chagas disease	547.3 (534.6 to 558.6)	631.6 (614.9 to 650.8)	15.5 (11.1 to 20.5)	1.3 (0.8 to 2.0)	1.5 (1.0 to 2.2)	15.3 (-1.6 to 35.1)
Leishmaniasis	-	-	-	2.1 (1.2 to 3.7)	4.9 (2.5 to 8.9)	128.2 (96.8 to 163.0)
Visceral leishmaniasis	8.8 (6.8 to 11.1)	12.0 (9.7 to 15.2)	37.4 (14.5 to 68.8)	0.6 (0.4 to 1.0)	0.9 (0.5 to 1.3)	36.8 (13.3 to 69.3)
Cutaneous and mucocutaneous leishmaniasis	138.6 (116.4 to 168.3)	370.0 (302.2 to 458.5)	166.3 (130.5 to 212.9)	1.5 (0.7 to 2.9)	4.0 (1.8 to 7.7)	167.6 (128.6 to 216.3)
African trypanosomiasis	4.1 (1.8 to 8.2)	1.2 (0.6 to 2.1)	-70.2 (-74.6 to -64.8)	1.2 (0.4 to 2.3)	0.3 (0.2 to 0.6)	-69.5 (-76.1 to -57.5)
Schistosomiasis	30,574.0 (27,511.9 to 33,450.4)	39,670.9 (34,387.0 to 46,066.5)	28.7 (20.7 to 48.1)	333.9 (180.3 to 594.6)	453.0 (244.1 to 830.8)	34.9 (26.6 to 54.1)
Cysticercosis	50.6 (42.5 to 59.6)	29.7 (24.0 to 35.5)	-41.6 (-52.2 to -26.6)	14.8 (9.7 to 20.4)	9.1 (6.0 to 12.5)	-38.4 (-53.2 to -18.5)
Cystic echinococcosis	63.2 (58.0 to 67.8)	41.0 (37.9 to 43.8)	-34.6 (-38.5 to -32.1)	6.0 (3.9 to 8.7)	4.0 (2.7 to 5.6)	-34.2 (-43.1 to -22.8)
Lymphatic filariasis	5,684.2 (5,194.5 to 6,143.5)	2,905.3 (2,560.2 to 3,253.8)	-48.8 (-55.0 to -41.7)	53.5 (27.9 to 89.3)	39.5 (21.6 to 66.3)	-25.8 (-47.1 to 0.0)
Onchocerciasis	2,821.0 (1,720.7 to 4,581.7)	1,652.7 (1,064.3 to 2,568.8)	-41.7 (-51.8 to -23.6)	148.6 (68.2 to 255.4)	107.1 (45.2 to 192.7)	-28.7 (-39.0 to -17.4)
Trachoma	-	-	-	-	-	-
Dengue	69.2 (25.3 to 155.2)	417.4 (153.8 to 936.3)	504.9 (501.2 to 508.9)	11.5 (3.7 to 29.1)	69.0 (22.3 to 171.1)	504.1 (387.2 to 656.1)
Yellow fever	0.8 (0.3 to 1.9)	0.3 (0.1 to 0.7)	-61.6 (-71.6 to -44.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-61.7 (-71.7 to -44.7)
Rabies	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-57.8 (-68.9 to -42.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.9 (-68.9 to -42.6)
Intestinal nematode infections	-	-	-	1,863.8 (1,009.4 to 3,293.2)	442.4 (271.6 to 676.9)	-75.7 (-80.7 to -69.6)
Ascariasis	137,756.4 (131,493.6 to 144,417.7)	75,898.9 (66,624.5 to 86,703.2)	-44.9 (-52.5 to -35.8)	1,439.4 (729.6 to 2,656.6)	96.0 (52.5 to 162.5)	-93.3 (-94.7 to -91.2)
Trichuriasis	60,665.6 (51,910.6 to 72,395.1)	48,124.6 (43,761.7 to 53,432.1)	-20.3 (-35.2 to -2.5)	103.4 (57.4 to 174.4)	61.3 (31.8 to 103.8)	-41.2 (-53.3 to -23.9)
Hookworm disease	51,299.0 (44,298.1 to 60,334.2)	41,932.7 (37,973.2 to 46,127.3)	-17.5 (-32.8 to -3.0)	321.0 (203.7 to 479.9)	285.1 (181.3 to 424.0)	-11.0 (-17.5 to -4.6)
Food-borne trematodiasis	1,786.4 (1,463.0 to 2,148.8)	1,410.1 (1,091.4 to 1,727.5)	-20.8 (-31.1 to -12.5)	59.5 (20.4 to 120.0)	34.4 (15.2 to 67.0)	-39.9 (-58.3 to -18.5)
Other neglected tropical diseases	12,257.4 (11,094.3 to 13,412.8)	12,202.0 (11,907.9 to 12,621.9)	-0.3 (-8.9 to 10.0)	581.4 (380.8 to 840.5)	574.0 (379.5 to 830.6)	-1.9 (-7.4 to 9.3)
Maternal disorders	-	-	-	50.1 (28.1 to 79.9)	47.9 (27.7 to 75.7)	-3.8 (-23.9 to 21.1)
Maternal hemorrhage	10.5 (9.1 to 11.9)	9.4 (8.8 to 10.1)	-9.8 (-21.0 to 4.1)	0.8 (0.5 to 1.1)	0.7 (0.5 to 1.0)	-9.0 (-20.0 to 2.9)
Maternal sepsis and other maternal infections	5.2 (2.8 to 8.3)	2.4 (1.4 to 3.5)	-54.6 (-66.9 to -39.7)	0.7 (0.3 to 1.2)	0.3 (0.1 to 0.5)	-55.7 (-68.4 to -37.7)
Maternal hypertensive disorders	9.4 (4.7 to 15.8)	6.0 (3.2 to 9.9)	-35.8 (-40.9 to -27.9)	0.6 (0.2 to 1.3)	0.4 (0.2 to 0.8)	-33.1 (-57.7 to 1.9)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (10-14 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Obstructed labor	115-0 (77-8 to 155-3)	110-1 (78-0 to 144-3)	-3-8 (-12-0 to 5-1)	38-7 (21-4 to 62-1)	37-3 (21-0 to 58-9)	-3-3 (-24-9 to 22-3)
Complications of abortion	0-1 (0-1 to 0-2)	0-1 (0-1 to 0-2)	-19-3 (-32-6 to -7-2)	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-19-5 (-32-9 to -7-4)
Other maternal disorders	-	-	-	9-3 (4-7 to 15-5)	9-1 (5-0 to 15-4)	-0-5 (-31-8 to 43-6)
Neonatal disorders	-	-	-	560-9 (411-2 to 727-4)	1,233-7 (909-0 to 1,596-6)	119-2 (95-0 to 150-8)
Preterm birth complications	2,007-5 (1,760-2 to 2,323-2)	4,902-7 (4,342-6 to 5,565-1)	144-6 (123-5 to 168-0)	232-8 (166-7 to 299-4)	625-9 (452-9 to 819-4)	169-0 (143-9 to 195-9)
Neonatal encephalopathy due to birth asphyxia and trauma	2,272-9 (886-7 to 4,166-7)	2,243-8 (1,178-7 to 3,902-8)	-1-0 (-21-9 to 50-2)	158-0 (110-2 to 223-8)	255-7 (186-4 to 336-9)	62-5 (32-9 to 98-5)
Neonatal sepsis and other neonatal infections	-	-	-	-	-	-
Hemolytic disease and other neonatal jaundice	216-4 (174-3 to 276-9)	524-2 (393-5 to 737-7)	138-5 (68-4 to 305-9)	80-5 (54-8 to 112-0)	168-0 (114-2 to 239-3)	105-7 (52-4 to 224-5)
Other neonatal disorders	-	-	-	89-6 (60-1 to 126-5)	184-2 (125-7 to 255-4)	104-8 (61-7 to 169-2)
Nutritional deficiencies	-	-	-	7,025-5 (4,724-6 to 10,077-8)	6,629-7 (4,430-6 to 9,505-9)	-5-7 (-6-7 to -4-7)
Protein-energy malnutrition	16-3 (9-2 to 25-6)	13-2 (7-4 to 20-6)	-18-6 (-33-9 to 0-0)	2-0 (0-9 to 3-8)	1-7 (0-8 to 3-0)	-18-0 (-38-0 to 5-6)
Iodine deficiency	9,408-0 (9,055-8 to 9,755-5)	6,893-5 (6,582-2 to 7,245-7)	-26-6 (-30-8 to -21-8)	170-5 (105-3 to 268-3)	125-3 (77-1 to 201-7)	-26-7 (-31-6 to -21-0)
Vitamin A deficiency	595-6 (435-7 to 768-9)	439-4 (311-8 to 573-3)	-26-2 (-31-5 to -20-1)	26-5 (15-5 to 40-0)	18-3 (10-6 to 29-4)	-31-3 (-41-6 to -19-9)
Iron-deficiency anemia	146,088-9 (144,947-0 to 147,208-1)	142,369-9 (141,833-8 to 142,833-8)	-2-4 (-3-2 to -1-6)	6,826-3 (4,591-6 to 9,789-4)	6,484-4 (4,340-3 to 9,284-0)	-5-0 (-6-1 to -4-0)
Other nutritional deficiencies	-	-	-	0-1 (0-0 to 0-3)	0-1 (0-0 to 0-1)	-42-2 (-61-1 to -6-6)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	486-8 (326-2 to 693-9)	478-6 (319-2 to 688-5)	-1-9 (-5-8 to 4-2)
Sexually transmitted diseases excluding HIV	-	-	-	26-0 (16-1 to 41-8)	30-2 (18-8 to 48-3)	16-2 (4-5 to 29-4)
Syphilis	-	-	0-0 (0-0 to 0-0)	-	-	-
Chlamydial infection	3,361-8 (3,232-7 to 3,487-6)	3,528-2 (3,394-4 to 3,678-3)	5-1 (-1-1 to 11-8)	14-2 (8-9 to 22-5)	16-0 (9-9 to 24-9)	12-1 (-0-0 to 27-0)
Gonococcal infection	1,032-1 (952-2 to 1,122-3)	1,253-0 (1,152-1 to 1,350-6)	21-9 (7-7 to 35-4)	6-8 (4-2 to 10-7)	8-6 (5-3 to 13-5)	26-2 (-4-7 to 65-9)
Trichomoniasis	950-8 (786-3 to 1,144-0)	1,164-6 (916-6 to 1,471-3)	21-7 (-5-9 to 60-9)	1-7 (0-7 to 3-6)	2-1 (0-8 to 4-6)	23-8 (-9-3 to 68-0)
Genital herpes	5,208-2 (4,993-0 to 5,431-8)	5,670-8 (5,426-0 to 5,882-8)	9-3 (2-8 to 14-8)	2-9 (1-1 to 6-3)	3-1 (1-1 to 6-9)	9-2 (-6-6 to 26-0)
Other sexually transmitted diseases	2-8 (2-3 to 3-3)	2-8 (2-3 to 3-3)	0-4 (-17-3 to 24-9)	0-4 (0-2 to 0-5)	0-2 (0-2 to 0-6)	0-2 (-17-5 to 24-7)
Hepatitis	-	-	-	39-2 (25-3 to 57-5)	38-3 (24-8 to 56-4)	-2-0 (-8-0 to 4-2)
Hepatitis A	969-7 (921-2 to 1,016-0)	992-8 (941-2 to 1,044-8)	2-5 (2-3 to 3-0)	28-2 (18-0 to 41-7)	28-9 (18-7 to 42-9)	2-4 (-4-6 to 10-1)
Hepatitis B	30,418-9 (29,773-3 to 31,181-6)	23,674-1 (23,009-8 to 24,285-4)	-22-1 (-24-8 to -19-2)	6-1 (3-9 to 9-0)	4-6 (2-9 to 6-7)	-25-2 (-34-8 to -14-0)
Hepatitis C	7,502-8 (7,247-0 to 7,763-2)	6,729-7 (6,503-1 to 6,951-3)	-10-2 (-14-0 to -6-2)	0-9 (0-6 to 1-3)	0-8 (0-5 to 1-2)	-9-7 (-24-2 to 7-3)
Hepatitis E	195-8 (180-7 to 211-8)	198-3 (183-4 to 214-9)	1-4 (-9-5 to 13-4)	4-0 (2-4 to 6-1)	4-1 (2-5 to 6-3)	3-2 (-22-9 to 35-7)
Leprosy	3-5 (3-0 to 4-0)	2-3 (2-1 to 2-5)	-33-7 (-43-2 to -23-3)	0-2 (0-1 to 0-2)	0-1 (0-1 to 0-2)	-25-9 (-35-4 to -15-4)
Other infectious diseases	9,223-6 (8,726-2 to 9,683-3)	9,006-8 (8,795-6 to 9,266-0)	-2-2 (-6-2 to 2-0)	421-4 (282-2 to 599-2)	409-9 (273-7 to 589-3)	-2-9 (-7-2 to 3-9)
Non-communicable diseases	-	-	-	21,763-2 (15,744-8 to 28,632-7)	24,909-3 (18,048-1 to 32,774-8)	14-4 (12-9 to 16-2)
Neoplasms	-	-	-	25-7 (18-2 to 34-8)	33-6 (24-0 to 45-2)	30-5 (11-7 to 52-8)
Esophageal cancer	-	-	-	-	-	-
Stomach cancer	-	-	-	-	-	-
Liver cancer	-	-	-	0-3 (0-2 to 0-4)	0-2 (0-1 to 0-3)	-13-5 (-38-6 to 7-5)
Liver cancer due to hepatitis B	0-6 (0-4 to 0-7)	0-6 (0-5 to 0-7)	4-6 (-29-6 to 36-2)	0-1 (0-1 to 0-1)	0-1 (0-1 to 0-1)	-1-3 (-32-1 to 23-1)
Liver cancer due to hepatitis C	0-1 (0-0 to 0-1)	0-2 (0-1 to 0-2)	208-9 (123-3 to 316-5)	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	191-7 (113-0 to 282-9)
Liver cancer due to alcohol use	-	-	-	-	-	-
Liver cancer due to other causes	0-9 (0-7 to 1-1)	0-6 (0-5 to 0-7)	-32-2 (-52-8 to -10-5)	0-1 (0-1 to 0-2)	0-1 (0-1 to 0-1)	-36-1 (-54-2 to -18-9)
Larynx cancer	-	-	-	-	-	-
Tracheal, bronchus and lung cancer	-	-	-	-	-	-
Breast cancer	-	-	-	-	-	-
Cervical cancer	-	-	-	-	-	-
Uterine cancer	-	-	-	-	-	-
Prostate cancer	-	-	-	-	-	-
Colon and rectum cancer	-	-	-	-	-	-
Lip and oral cavity cancer	-	-	-	-	-	-
Nasopharynx cancer	3-2 (1-7 to 5-2)	3-3 (1-7 to 6-6)	0-7 (-53-7 to 133-0)	0-3 (0-1 to 0-5)	0-3 (0-1 to 0-6)	-2-2 (-55-1 to 124-0)
Other pharynx cancer	-	-	-	-	-	-
Gallbladder and biliary tract cancer	-	-	-	-	-	-
Pancreatic cancer	-	-	-	-	-	-
Malignant skin melanoma	-	-	-	-	-	-
Non-melanoma skin cancer	-	-	-	-	-	-
Ovarian cancer	-	-	-	-	-	-
Testicular cancer	-	-	-	-	-	-
Kidney cancer	2-3 (2-0 to 2-7)	2-8 (2-4 to 3-2)	23-1 (1-8 to 48-0)	0-2 (0-1 to 0-3)	0-2 (0-1 to 0-3)	18-0 (-3-1 to 42-1)
Bladder cancer	-	-	-	-	-	-
Brain and nervous system cancer	36-2 (28-6 to 44-4)	38-3 (30-2 to 47-0)	6-4 (-17-5 to 30-1)	4-0 (2-6 to 5-7)	4-1 (2-7 to 5-8)	3-3 (-20-2 to 25-6)
Thyroid cancer	8-5 (5-4 to 13-5)	8-1 (6-5 to 9-9)	0-4 (-42-2 to 39-0)	0-5 (0-3 to 0-9)	0-5 (0-3 to 0-7)	-1-5 (-43-2 to 36-9)
Mesothelioma	-	-	-	-	-	-

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (10-14 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Hodgkin lymphoma	37.9 (23.5 to 58.8)	31.1 (23.6 to 43.4)	-18.1 (-48.5 to 47.3)	3.2 (1.9 to 5.3)	2.5 (1.6 to 3.9)	-22.2 (-50.7 to 36.6)
Non-Hodgkin lymphoma	25.2 (19.0 to 30.0)	32.7 (27.1 to 39.5)	29.8 (2.2 to 63.9)	2.1 (1.3 to 2.9)	2.5 (1.7 to 3.7)	24.0 (-2.8 to 58.7)
Multiple myeloma	-	-	-	-	-	-
Leukemia	59.8 (52.4 to 67.9)	71.9 (62.2 to 81.9)	20.7 (-0.6 to 40.9)	8.6 (6.0 to 11.6)	9.3 (6.5 to 12.7)	8.1 (-9.4 to 28.3)
Other neoplasms	86.6 (71.2 to 113.7)	199.1 (158.4 to 244.0)	134.2 (53.8 to 200.3)	6.6 (4.3 to 9.8)	13.9 (9.3 to 19.9)	114.3 (43.1 to 182.2)
Cardiovascular diseases	-	-	-	147.6 (98.7 to 206.5)	206.3 (135.1 to 291.6)	39.5 (17.1 to 64.3)
Rheumatic heart disease	1,767.2 (1,638.9 to 1,898.7)	2,345.1 (2,221.1 to 2,460.7)	32.9 (20.9 to 46.9)	86.9 (55.9 to 127.7)	113.9 (73.4 to 167.3)	30.9 (17.9 to 46.1)
Ischemic heart disease	5.3 (4.9 to 6.0)	5.9 (5.3 to 6.7)	10.2 (-7.2 to 28.3)	0.7 (0.4 to 0.9)	0.7 (0.5 to 1.0)	9.9 (-7.5 to 28.1)
Cerebrovascular disease	-	-	-	7.9 (5.5 to 10.5)	9.9 (6.9 to 13.2)	24.5 (15.1 to 37.2)
Ischemic stroke	22.0 (20.2 to 23.7)	29.7 (27.5 to 32.2)	34.9 (21.6 to 51.5)	3.7 (2.5 to 5.1)	5.0 (3.3 to 6.9)	33.4 (19.3 to 54.0)
Hemorrhagic stroke	25.1 (23.4 to 26.9)	29.3 (27.3 to 31.4)	16.9 (6.2 to 29.0)	4.2 (2.8 to 5.7)	4.9 (3.4 to 6.7)	16.6 (6.1 to 28.8)
Hypertensive heart disease	6.3 (5.9 to 6.7)	8.1 (7.5 to 8.7)	29.0 (16.2 to 42.3)	0.8 (0.5 to 1.1)	1.0 (0.7 to 1.4)	28.7 (15.9 to 42.2)
Cardiomyopathy and myocarditis	46.4 (43.5 to 49.4)	58.2 (54.7 to 61.2)	25.7 (17.4 to 33.5)	5.1 (3.4 to 7.1)	6.5 (4.3 to 9.2)	27.8 (14.6 to 41.3)
Atrial fibrillation and flutter	-	-	-	-	-	-
Peripheral vascular disease	-	-	-	-	-	-
Endocarditis	2.4 (1.9 to 3.2)	3.3 (2.6 to 4.1)	41.3 (12.1 to 70.4)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	48.4 (14.3 to 85.9)
Other cardiovascular and circulatory diseases	639.3 (438.0 to 923.5)	1,021.0 (619.8 to 1,491.6)	60.9 (-7.1 to 151.7)	46.0 (26.4 to 74.4)	73.8 (38.7 to 121.4)	60.8 (-6.3 to 152.4)
Chronic respiratory diseases	-	-	-	1,734.1 (1,177.8 to 2,413.5)	1,800.0 (1,241.5 to 2,465.5)	3.8 (-0.6 to 8.4)
Chronic obstructive pulmonary disease	3,957.2 (3,687.9 to 4,237.6)	4,703.8 (4,407.2 to 5,031.9)	19.1 (17.2 to 21.1)	331.8 (212.2 to 483.3)	414.9 (269.5 to 600.5)	25.1 (16.9 to 34.5)
Pneumoconiosis	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	40.8 (35.0 to 47.0)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.8 (-8.2 to 4.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.6 (-10.0 to 3.9)
Asbestosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.2 (-8.6 to 10.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.6 (-9.8 to 10.7)
Coal workers pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.4 (-13.1 to -4.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.3 (-13.9 to -5.5)
Other pneumoconiosis	1.0 (0.7 to 1.2)	1.5 (1.0 to 1.8)	47.0 (41.3 to 53.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	45.2 (39.4 to 51.9)
Asthma	30,179.8 (29,305.7 to 31,105.0)	29,867.3 (28,856.3 to 30,863.3)	-0.8 (-5.1 to 3.5)	1,355.2 (875.9 to 1,933.2)	1,343.7 (872.2 to 1,921.7)	-0.7 (-5.5 to 3.6)
Interstitial lung disease and pulmonary sarcoidosis	7.9 (7.4 to 8.7)	9.4 (8.6 to 10.4)	19.4 (4.4 to 34.4)	1.0 (0.6 to 1.5)	1.2 (0.8 to 1.8)	20.8 (6.3 to 35.2)
Other chronic respiratory diseases	-	-	-	45.8 (26.8 to 71.3)	39.8 (24.1 to 60.6)	-13.2 (-24.3 to 2.2)
Cirrhosis	-	-	-	23.1 (15.5 to 32.4)	20.6 (13.9 to 29.4)	-10.2 (-25.8 to 6.6)
Cirrhosis due to hepatitis B	37.1 (33.0 to 41.8)	23.8 (20.6 to 27.2)	-35.7 (-47.7 to -24.1)	6.4 (4.1 to 9.4)	4.1 (2.5 to 6.2)	-35.8 (-55.7 to -5.9)
Cirrhosis due to hepatitis C	22.5 (19.8 to 25.4)	18.3 (15.6 to 21.0)	-19.5 (-32.6 to 1.2)	3.9 (2.6 to 5.9)	3.2 (2.0 to 5.0)	-18.7 (-42.6 to 21.4)
Cirrhosis due to alcohol use	-	-	-	-	-	-
Cirrhosis due to other causes	74.4 (69.2 to 79.6)	77.6 (71.6 to 83.4)	4.5 (-5.9 to 14.6)	12.8 (8.3 to 18.2)	13.3 (8.6 to 19.6)	4.2 (-20.5 to 37.7)
Digestive diseases	-	-	-	434.4 (298.5 to 598.7)	368.1 (255.5 to 517.3)	-15.2 (-20.5 to -9.8)
Peptic ulcer disease	253.0 (239.5 to 267.9)	144.2 (133.0 to 155.9)	-42.9 (-47.9 to -37.5)	15.4 (10.1 to 21.6)	9.2 (6.0 to 13.3)	-40.5 (-49.8 to -26.3)
Gastritis and duodenitis	5,411.1 (5,232.3 to 5,574.2)	4,071.1 (3,945.1 to 4,205.7)	-24.7 (-28.1 to -20.8)	304.0 (205.8 to 428.3)	242.7 (165.8 to 347.4)	-20.2 (-25.6 to -14.2)
Appendicitis	57.7 (50.8 to 66.6)	60.2 (46.4 to 71.2)	6.7 (-20.7 to 26.4)	17.8 (11.3 to 25.5)	18.8 (11.3 to 28.4)	6.1 (-28.4 to 46.1)
Paralytic ileus and intestinal obstruction	1.2 (1.2 to 1.3)	1.5 (1.5 to 1.6)	25.6 (19.3 to 33.3)	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.7)	25.3 (19.1 to 33.1)
Inguinal, femoral, and abdominal hernia	479.7 (452.0 to 507.6)	567.0 (537.5 to 600.4)	18.2 (9.6 to 29.2)	5.2 (2.5 to 9.9)	6.2 (3.0 to 11.7)	18.7 (6.5 to 32.3)
Inflammatory bowel disease	127.4 (122.6 to 132.3)	175.5 (168.8 to 182.4)	38.0 (30.7 to 45.9)	28.2 (18.5 to 39.3)	38.9 (26.0 to 54.6)	37.9 (17.5 to 62.7)
Vascular intestinal disorders	0.5 (0.4 to 0.5)	0.6 (0.5 to 0.7)	26.0 (11.2 to 45.3)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	25.7 (10.9 to 44.9)
Gallbladder and biliary diseases	40.9 (39.1 to 43.0)	46.2 (43.3 to 48.9)	13.4 (3.1 to 21.3)	4.6 (3.0 to 6.5)	5.2 (3.4 to 7.4)	13.7 (-10.5 to 41.9)
Pancreatitis	18.3 (17.6 to 19.1)	25.8 (25.1 to 26.6)	40.8 (34.1 to 49.0)	5.9 (3.9 to 8.0)	8.2 (5.5 to 11.2)	38.6 (25.5 to 53.2)
Other digestive diseases	-	-	-	52.8 (35.3 to 75.4)	38.3 (25.8 to 54.5)	-27.2 (-36.5 to -18.5)
Neurological disorders	-	-	-	2,363.4 (1,582.9 to 3,319.3)	2,801.1 (1,870.7 to 3,899.0)	18.8 (11.2 to 25.0)
Alzheimer disease and other dementias	-	-	-	-	-	-
Parkinson disease	-	-	-	-	-	-
Epilepsy	1,746.4 (1,629.8 to 1,857.3)	1,927.5 (1,786.9 to 2,062.0)	10.4 (0.2 to 22.0)	568.3 (382.2 to 761.5)	677.5 (459.4 to 899.9)	19.1 (6.7 to 34.9)
Multiple sclerosis	5.1 (4.9 to 5.4)	8.1 (7.7 to 8.5)	59.4 (46.9 to 72.4)	1.9 (1.3 to 2.4)	3.0 (2.1 to 3.8)	59.0 (46.3 to 71.7)
Migraine	43,384.4 (41,374.1 to 45,624.9)	49,498.2 (46,575.5 to 52,084.2)	14.5 (5.8 to 21.8)	1,524.9 (898.6 to 2,246.8)	1,746.7 (1,028.3 to 2,581.5)	14.8 (5.1 to 23.2)
Tension-type headache	73,722.4 (69,611.0 to 78,546.4)	86,486.5 (80,825.4 to 91,404.4)	17.6 (6.9 to 27.8)	113.4 (54.4 to 200.5)	133.5 (64.9 to 237.6)	17.6 (6.5 to 28.7)
Medication overuse headache	949.7 (644.0 to 1,245.8)	1,471.6 (1,001.9 to 1,941.3)	54.9 (39.0 to 75.8)	154.2 (87.7 to 237.4)	239.6 (137.1 to 368.3)	55.0 (37.6 to 77.1)
Other neurological disorders	0.5 (0.4 to 0.6)	0.6 (0.5 to 0.7)	15.7 (-3.1 to 34.7)	0.8 (0.5 to 1.1)	0.8 (0.6 to 1.1)	10.2 (-7.3 to 27.1)
Mental and substance use disorders	-	-	-	7,820.3 (5,398.5 to 10,625.2)	9,112.3 (6,262.0 to 12,386.2)	16.4 (14.7 to 19.0)
Schizophrenia	50.5 (45.4 to 54.9)	54.6 (48.7 to 59.1)	8.1 (6.2 to 10.1)	34.7 (25.1 to 42.8)	37.6 (27.1 to 46.8)	8.2 (-0.9 to 18.7)
Alcohol use disorders	781.2 (677.3 to 887.2)	793.2 (695.6 to 896.7)	1.8 (-0.4 to 3.8)	74.9 (49.4 to 107.4)	75.0 (49.2 to 107.9)	0.1 (-4.8 to 5.6)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (10-14 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Drug use disorders	-	-	-	27.9 (18.7 to 38.9)	29.0 (19.6 to 40.2)	3.7 (-4.8 to 14.8)
Opioid use disorders	-	-	-	-	-	-
Cocaine use disorders	-	-	-	-	-	-
Amphetamine use disorders	61.7 (57.7 to 65.8)	64.3 (60.4 to 67.9)	4.0 (-3.1 to 14.1)	8.5 (5.3 to 12.6)	8.9 (5.5 to 12.9)	4.5 (-8.7 to 21.3)
Cannabis use disorders	364.7 (292.1 to 442.5)	374.7 (293.2 to 463.8)	2.9 (-1.2 to 6.3)	10.8 (6.7 to 16.2)	11.1 (6.8 to 16.8)	3.0 (-7.3 to 13.3)
Other drug use disorders	-	-	-	8.6 (5.3 to 12.9)	9.0 (5.6 to 13.2)	4.0 (-10.0 to 21.2)
Depressive disorders	-	-	-	2,275.6 (1,379.7 to 3,297.3)	2,773.5 (1,725.1 to 4,009.0)	21.5 (16.7 to 31.4)
Major depressive disorder	10,260.9 (7,300.2 to 13,051.4)	12,507.0 (9,490.8 to 15,504.2)	21.8 (17.3 to 32.4)	2,169.5 (1,297.0 to 3,177.1)	2,653.8 (1,633.9 to 3,865.4)	22.0 (16.9 to 32.6)
Dysthymia	1,069.1 (817.0 to 1,350.7)	1,202.7 (917.8 to 1,520.8)	12.7 (11.7 to 13.7)	106.1 (65.5 to 160.5)	119.7 (72.9 to 182.5)	12.7 (6.6 to 19.7)
Bipolar disorder	564.6 (293.9 to 877.3)	641.8 (323.3 to 1,009.4)	13.1 (5.5 to 26.9)	119.5 (54.6 to 227.5)	136.0 (60.4 to 264.5)	13.2 (0.5 to 28.9)
Anxiety disorders	17,057.8 (11,462.8 to 25,104.9)	19,691.9 (13,341.9 to 28,525.8)	15.9 (13.1 to 18.3)	1,610.4 (890.0 to 2,646.9)	1,863.2 (1,023.1 to 3,029.7)	15.8 (12.0 to 19.8)
Eating disorders	-	-	-	110.9 (66.6 to 179.1)	131.1 (77.8 to 211.7)	18.2 (9.8 to 26.3)
Anorexia nervosa	160.7 (126.4 to 195.3)	198.6 (155.9 to 240.9)	23.8 (21.0 to 26.6)	34.7 (21.7 to 50.9)	42.9 (27.3 to 62.6)	23.7 (11.1 to 38.6)
Bulimia nervosa	357.0 (225.6 to 604.1)	412.2 (251.4 to 709.1)	15.7 (8.8 to 18.6)	76.3 (41.7 to 136.6)	88.2 (45.5 to 163.3)	15.6 (3.8 to 25.7)
Autistic spectrum disorders	-	-	-	717.7 (497.9 to 976.7)	819.9 (568.9 to 1,111.9)	14.1 (11.2 to 17.4)
Autism	1,822.4 (1,731.5 to 1,912.2)	2,072.1 (1,968.9 to 2,174.6)	13.9 (13.7 to 14.1)	456.2 (305.9 to 629.2)	521.1 (348.4 to 722.1)	14.4 (9.9 to 18.7)
Asperger syndrome	2,590.5 (2,425.9 to 2,744.4)	2,948.1 (2,758.6 to 3,125.4)	14.0 (13.9 to 14.1)	261.6 (181.1 to 365.4)	298.8 (205.7 to 417.3)	14.2 (10.7 to 18.0)
Attention-deficit/hyperactivity disorder	10,696.1 (9,945.4 to 11,470.5)	12,059.1 (11,263.5 to 12,881.2)	12.9 (12.1 to 13.9)	130.1 (78.8 to 199.8)	147.1 (87.7 to 226.5)	13.0 (9.7 to 16.3)
Conduct disorder	18,087.2 (16,367.3 to 19,656.1)	20,872.8 (19,035.6 to 22,558.0)	15.6 (14.7 to 16.6)	2,173.7 (1,372.2 to 3,163.5)	2,516.4 (1,579.2 to 3,668.1)	15.8 (13.6 to 18.0)
Idiopathic intellectual disability	10,938.1 (8,702.6 to 13,298.9)	11,742.4 (9,645.5 to 14,361.1)	7.5 (-0.7 to 17.1)	544.7 (354.8 to 782.4)	583.7 (387.4 to 833.9)	7.2 (-1.4 to 17.3)
Other mental and substance use disorders	-	-	0.0 (0.0 to 0.0)	-	-	-
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	1,818.3 (1,257.5 to 2,524.9)	2,185.9 (1,519.6 to 3,033.4)	20.2 (17.1 to 23.5)
Diabetes mellitus	4,012.0 (3,766.9 to 4,270.0)	6,114.6 (5,689.7 to 6,617.9)	53.2 (37.5 to 66.0)	193.4 (122.1 to 287.0)	295.4 (186.2 to 441.5)	53.3 (37.2 to 67.3)
Acute glomerulonephritis	4.3 (3.7 to 4.8)	3.8 (3.2 to 4.3)	-11.1 (-14.9 to -7.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-11.3 (-15.2 to -7.7)
Chronic kidney disease	-	-	-	384.4 (269.2 to 524.3)	462.4 (330.0 to 617.8)	20.3 (13.1 to 27.3)
Chronic kidney disease due to diabetes mellitus	940.3 (563.0 to 1,548.7)	1,190.9 (693.4 to 1,961.8)	26.9 (13.7 to 41.5)	21.1 (14.6 to 29.0)	27.3 (19.2 to 37.7)	28.7 (13.6 to 45.9)
Chronic kidney disease due to hypertension	5,985.1 (3,305.5 to 10,213.0)	6,703.2 (3,767.1 to 11,347.1)	12.3 (0.7 to 26.7)	75.4 (52.3 to 103.2)	89.4 (62.7 to 121.5)	18.8 (3.0 to 36.8)
Chronic kidney disease due to glomerulonephritis	4,290.3 (2,753.5 to 6,709.5)	5,169.4 (3,310.6 to 8,283.5)	20.5 (8.2 to 31.8)	132.5 (93.1 to 179.6)	143.7 (101.9 to 192.5)	8.4 (-3.2 to 23.6)
Chronic kidney disease due to other causes	7,148.9 (4,220.7 to 11,813.9)	9,119.2 (5,405.9 to 15,347.7)	28.0 (12.5 to 39.8)	155.4 (108.3 to 211.8)	202.1 (139.6 to 275.4)	30.6 (15.8 to 43.7)
Urinary diseases and male infertility	-	-	-	7.2 (4.8 to 10.5)	8.9 (5.6 to 13.2)	24.1 (3.8 to 41.5)
Interstitial nephritis and urinary tract infections	62.8 (60.8 to 64.6)	78.5 (76.1 to 80.9)	25.2 (20.0 to 30.7)	2.1 (1.3 to 3.3)	2.7 (1.6 to 4.1)	24.7 (2.4 to 51.0)
Urolithiasis	270.5 (193.5 to 392.1)	256.8 (160.8 to 402.4)	-3.4 (-27.2 to 10.1)	3.1 (2.0 to 4.7)	3.4 (2.0 to 5.1)	7.8 (-7.1 to 19.6)
Benign prostatic hyperplasia	-	-	-	-	-	-
Male infertility due to other causes	-	-	-	-	-	-
Other urinary diseases	-	-	-	1.9 (1.2 to 3.0)	2.9 (1.6 to 4.5)	53.6 (4.9 to 92.8)
Gynecological diseases	-	-	-	-	-	-
Uterine fibroids	-	-	-	-	-	-
Polycystic ovarian syndrome	-	-	-	-	-	-
Female infertility due to other causes	-	-	-	-	-	-
Endometriosis	-	-	-	-	-	-
Genital prolapse	-	-	-	-	-	-
Premenstrual syndrome	-	-	-	-	-	-
Other gynecological diseases	-	-	-	-	-	-
Hemoglobinopathies and hemolytic anemias	-	-	-	875.3 (590.6 to 1,249.3)	1,072.4 (722.0 to 1,540.9)	22.4 (19.2 to 26.0)
Thalassemias	105.3 (92.6 to 117.9)	114.1 (102.5 to 126.2)	8.0 (4.6 to 15.0)	8.7 (5.8 to 12.2)	9.7 (6.5 to 13.8)	12.6 (-0.1 to 30.1)
Thalassemia trait	15,679.8 (14,493.5 to 17,194.6)	17,392.6 (16,383.2 to 18,692.7)	11.3 (8.4 to 13.7)	417.1 (280.3 to 592.3)	527.5 (354.7 to 756.2)	26.5 (22.3 to 31.1)
Sickle cell disorders	271.7 (255.2 to 287.1)	483.3 (455.7 to 508.7)	78.1 (69.5 to 87.8)	25.6 (17.9 to 35.2)	44.4 (30.3 to 62.1)	73.2 (54.3 to 96.5)
Sickle cell trait	18,943.6 (17,985.8 to 19,819.3)	27,404.8 (26,177.1 to 28,531.8)	44.9 (42.3 to 47.2)	171.9 (114.9 to 245.7)	245.5 (162.7 to 351.5)	42.7 (33.7 to 53.5)
G6PD deficiency	25,079.4 (24,421.5 to 25,705.5)	32,868.6 (32,006.7 to 33,697.9)	31.3 (26.7 to 35.9)	3.1 (2.1 to 4.3)	4.5 (3.0 to 6.4)	46.0 (27.6 to 66.4)
G6PD trait	86,398.6 (85,829.6 to 86,878.4)	101,239.3 (100,441.1 to 101,928.0)	17.4 (16.3 to 18.6)	5.9 (3.7 to 8.9)	7.6 (4.5 to 11.4)	27.8 (-6.6 to 63.4)
Other hemoglobinopathies and hemolytic anemias	5,309.3 (4,840.5 to 5,647.6)	5,181.2 (4,895.3 to 5,385.7)	-2.4 (-8.3 to 6.0)	243.1 (163.5 to 346.5)	233.2 (156.9 to 336.6)	-3.9 (-12.1 to 5.9)
Endocrine, metabolic, blood, and immune disorders	8,151.0 (7,938.7 to 8,370.3)	8,028.0 (7,484.6 to 8,482.0)	-1.2 (-9.4 to 5.4)	357.7 (242.3 to 507.1)	346.6 (235.7 to 496.0)	-3.1 (-12.3 to 5.9)
Musculoskeletal disorders	-	-	-	1,756.6 (1,200.3 to 2,393.6)	2,001.6 (1,364.5 to 2,743.4)	13.9 (8.9 to 19.0)
Rheumatoid arthritis	308.1 (302.6 to 313.9)	364.1 (358.1 to 370.5)	18.4 (15.7 to 21.2)	77.2 (53.3 to 104.0)	91.4 (64.2 to 122.1)	18.3 (8.0 to 30.1)
Osteoarthritis	-	-	-	-	-	-
Low back and neck pain	-	-	-	1,653.8 (1,136.6 to 2,269.6)	1,873.9 (1,272.1 to 2,582.0)	13.3 (7.9 to 18.6)
Low back pain	11,120.9 (10,764.2 to 11,535.3)	12,705.0 (12,264.2 to 13,142.7)	14.3 (9.3 to 20.1)	1,291.7 (870.4 to 1,810.3)	1,479.5 (985.1 to 2,062.3)	14.5 (8.6 to 20.6)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (10-14 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Neck pain	3,556.3 (3,321.8 to 3,883.9)	3,866.4 (3,538.8 to 4,309.5)	8.9 (-3.8 to 23.2)	362.1 (245.1 to 507.3)	394.4 (269.7 to 550.9)	9.0 (-3.8 to 23.7)
Gout	-	-	-	-	-	-
Other musculoskeletal disorders	261.2 (163.7 to 382.2)	372.6 (239.1 to 545.4)	42.1 (27.5 to 62.1)	25.5 (13.8 to 41.9)	36.3 (20.3 to 60.9)	41.8 (17.3 to 77.7)
Other non-communicable diseases	-	-	-	5,639.8 (3,624.1 to 8,485.4)	6,379.8 (4,103.5 to 9,535.8)	13.2 (8.7 to 17.6)
Congenital anomalies	-	-	-	514.7 (371.3 to 686.3)	667.8 (482.3 to 868.6)	29.7 (20.5 to 41.1)
Neural tube defects	105.4 (102.9 to 108.6)	155.1 (150.9 to 159.5)	47.5 (42.1 to 52.6)	32.7 (23.1 to 42.8)	49.0 (34.2 to 64.6)	50.0 (34.6 to 67.3)
Congenital heart anomalies	1,710.8 (1,652.1 to 1,775.0)	2,865.2 (2,743.8 to 3,015.4)	67.5 (59.5 to 78.4)	61.9 (28.3 to 105.4)	104.3 (46.1 to 175.9)	68.2 (58.3 to 80.0)
Orofacial clefts	298.8 (286.8 to 308.9)	505.8 (485.1 to 527.4)	69.4 (60.6 to 80.3)	4.1 (2.7 to 6.1)	6.6 (4.2 to 9.6)	58.3 (34.9 to 90.3)
Down syndrome	452.4 (433.3 to 474.7)	636.3 (610.4 to 665.8)	40.8 (32.8 to 49.2)	50.1 (36.5 to 65.8)	70.5 (51.5 to 92.5)	40.9 (28.9 to 54.9)
Turner syndrome	16.2 (15.4 to 17.1)	20.9 (19.9 to 22.1)	28.6 (20.5 to 39.8)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.5)	28.2 (20.1 to 39.4)
Klinefelter syndrome	15.5 (14.6 to 16.3)	18.4 (17.6 to 19.4)	18.5 (10.6 to 28.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	18.3 (10.3 to 28.5)
Chromosomal unbalanced rearrangements	610.8 (588.3 to 629.6)	844.4 (802.2 to 893.6)	38.3 (30.8 to 47.7)	67.5 (48.7 to 88.1)	93.4 (67.8 to 122.1)	37.9 (27.2 to 51.0)
Other congenital anomalies	2,216.4 (1,795.7 to 2,609.2)	2,236.9 (1,780.8 to 2,665.7)	1.0 (-6.0 to 7.9)	298.1 (199.2 to 424.5)	343.7 (230.2 to 476.0)	15.3 (3.6 to 30.4)
Skin and subcutaneous diseases	-	-	-	3,253.9 (1,983.8 to 5,145.4)	3,789.1 (2,288.4 to 6,007.2)	16.5 (10.8 to 23.0)
Dermatitis	20,121.1 (16,386.5 to 24,264.1)	22,829.4 (18,619.8 to 27,490.9)	13.7 (12.0 to 15.3)	685.7 (429.6 to 998.6)	794.7 (498.6 to 1,150.5)	15.9 (13.1 to 18.6)
Psoriasis	2,222.2 (1,935.3 to 2,523.1)	2,515.8 (2,188.7 to 2,867.9)	13.4 (12.7 to 14.0)	186.9 (126.1 to 265.9)	212.1 (143.5 to 297.7)	13.4 (6.0 to 21.3)
Cellulitis	76.2 (53.3 to 114.7)	77.4 (54.1 to 117.2)	2.1 (-3.9 to 6.5)	5.6 (3.2 to 9.4)	5.7 (3.2 to 9.6)	2.5 (-13.2 to 21.5)
Pyoderma	552.1 (359.6 to 844.1)	435.5 (299.0 to 636.1)	-21.1 (-28.0 to -9.1)	3.1 (1.1 to 7.5)	2.5 (0.9 to 5.5)	-21.0 (-30.2 to -8.1)
Scabies	8,214.9 (7,314.4 to 9,370.9)	8,639.4 (7,830.0 to 9,795.2)	5.2 (-12.3 to 26.7)	213.4 (120.4 to 353.3)	224.9 (129.1 to 362.9)	5.2 (-12.5 to 27.2)
Fungal skin diseases	58,385.2 (44,220.9 to 73,039.2)	70,164.2 (53,954.6 to 87,889.3)	20.5 (17.8 to 22.8)	332.8 (127.7 to 717.6)	400.7 (154.9 to 864.4)	20.4 (17.6 to 23.1)
Viral skin diseases	16,346.6 (14,375.2 to 18,405.8)	18,077.4 (15,978.5 to 20,332.4)	10.7 (8.9 to 12.9)	508.0 (320.5 to 772.2)	563.0 (355.3 to 863.4)	10.8 (8.4 to 13.7)
Acne vulgaris	94,403.6 (86,323.8 to 101,946.5)	112,151.1 (100,406.5 to 123,455.5)	18.5 (3.7 to 37.4)	1,025.6 (490.4 to 1,922.0)	1,221.1 (576.2 to 2,237.5)	18.4 (3.7 to 37.4)
Alopecia areata	391.2 (375.2 to 408.9)	439.8 (423.2 to 457.7)	12.7 (6.9 to 19.0)	13.4 (8.5 to 20.4)	15.1 (9.6 to 22.7)	12.5 (0.8 to 25.6)
Pruritus	26.0 (24.2 to 27.5)	26.7 (24.6 to 28.5)	3.1 (-7.7 to 12.1)	0.3 (0.1 to 0.5)	0.3 (0.1 to 0.6)	3.0 (-14.5 to 22.3)
Urticaria	3,072.8 (2,812.9 to 3,371.3)	3,984.8 (3,341.9 to 4,743.6)	27.8 (9.2 to 58.0)	187.9 (119.1 to 274.6)	244.0 (150.8 to 361.4)	27.9 (8.7 to 58.3)
Decubitus ulcer	15.5 (14.8 to 16.2)	14.4 (13.7 to 15.3)	-6.6 (-11.4 to -1.4)	2.6 (1.8 to 3.6)	2.4 (1.6 to 3.3)	-6.9 (-11.7 to -1.7)
Other skin and subcutaneous diseases	14,658.8 (3,186.4 to 35,603.3)	16,949.9 (3,697.1 to 40,649.9)	15.8 (13.8 to 18.0)	88.6 (17.1 to 259.0)	102.6 (20.1 to 298.0)	15.7 (12.7 to 19.1)
Sense organ diseases	-	-	-	1,485.8 (978.4 to 2,123.8)	1,493.5 (975.4 to 2,173.8)	0.5 (-4.7 to 5.7)
Glaucoma	-	-	-	-	-	-
Cataract	-	-	-	-	-	-
Macular degeneration	-	-	-	-	-	-
Uncorrected refractive error	17,179.0 (16,410.0 to 17,969.5)	18,837.5 (18,118.0 to 19,669.5)	9.8 (5.8 to 14.0)	361.1 (229.0 to 544.0)	379.9 (239.9 to 580.3)	5.0 (1.2 to 9.3)
Age-related and other hearing loss	11,539.0 (8,505.4 to 15,017.5)	11,885.5 (8,641.6 to 15,802.9)	2.9 (-2.9 to 9.7)	768.2 (445.3 to 1,234.7)	733.4 (415.4 to 1,170.4)	-4.7 (-12.5 to 4.9)
Other vision loss	1,169.4 (939.2 to 1,422.7)	982.7 (777.3 to 1,196.5)	-15.8 (-19.6 to -12.1)	61.0 (39.7 to 89.7)	46.6 (29.5 to 70.3)	-23.4 (-31.0 to -16.4)
Other sense organ diseases	10,963.3 (10,671.2 to 11,267.4)	12,345.6 (11,978.9 to 12,720.0)	12.8 (8.4 to 17.4)	295.5 (184.3 to 438.4)	333.6 (206.7 to 492.5)	12.9 (7.4 to 18.6)
Oral disorders	-	-	-	385.3 (211.1 to 656.5)	429.4 (234.0 to 731.0)	11.5 (8.8 to 14.0)
Deciduous caries	51,354.7 (51,046.8 to 51,679.5)	57,728.7 (57,326.9 to 58,085.3)	12.6 (11.7 to 13.5)	18.3 (8.0 to 35.8)	21.0 (9.2 to 40.8)	14.6 (10.0 to 19.5)
Permanent caries	233,361.9 (229,722.6 to 236,712.2)	250,653.6 (246,803.1 to 254,477.4)	7.6 (5.4 to 10.0)	217.4 (99.1 to 419.9)	239.2 (107.5 to 463.6)	10.0 (7.1 to 13.0)
Periodontal diseases	-	-	-	-	-	-
Edentulism and severe tooth loss	-	-	-	-	-	-
Other oral disorders	5,022.9 (4,912.5 to 5,138.6)	5,658.7 (5,509.2 to 5,818.3)	12.8 (9.3 to 16.7)	149.6 (93.9 to 222.9)	169.2 (105.3 to 255.1)	13.0 (8.4 to 18.0)
Injuries	-	-	-	979.3 (751.2 to 1,254.9)	675.0 (520.5 to 855.9)	-30.5 (-40.5 to -23.7)
Transport injuries	-	-	-	233.3 (181.9 to 297.4)	152.9 (118.5 to 194.0)	-34.4 (-38.6 to -30.2)
Road injuries	-	-	-	199.5 (154.5 to 253.5)	132.2 (102.4 to 168.5)	-33.7 (-38.1 to -29.1)
Pedestrian road injuries	-	-	-	77.6 (58.2 to 99.4)	53.8 (40.9 to 69.3)	-30.6 (-36.6 to -24.1)
Cyclist road injuries	-	-	-	27.5 (21.4 to 35.1)	15.7 (12.1 to 20.3)	-42.7 (-46.7 to -39.1)
Motorcyclist road injuries	-	-	-	26.2 (20.5 to 33.4)	11.8 (9.2 to 15.1)	-54.9 (-58.6 to -51.2)
Motor vehicle road injuries	-	-	-	65.4 (50.7 to 82.6)	48.9 (38.2 to 61.4)	-25.3 (-30.9 to -19.4)
Other road injuries	-	-	-	2.7 (2.1 to 3.4)	2.0 (1.5 to 2.5)	-25.5 (-30.9 to -19.8)
Other transport injuries	-	-	-	33.8 (26.1 to 42.8)	20.7 (16.0 to 26.3)	-38.9 (-42.2 to -35.3)
Unintentional injuries	-	-	-	552.5 (427.9 to 700.0)	466.8 (358.4 to 599.8)	-15.6 (-18.8 to -12.1)
Falls	-	-	-	187.9 (143.2 to 240.2)	177.0 (132.5 to 229.4)	-5.8 (-12.0 to 0.3)
Drowning	-	-	-	23.7 (17.1 to 30.8)	12.3 (9.0 to 16.2)	-47.9 (-52.6 to -42.4)
Fire, heat, and hot substances	-	-	-	53.5 (40.7 to 68.4)	42.3 (31.7 to 56.0)	-20.9 (-29.9 to -11.5)
Poisonings	-	-	-	4.8 (3.4 to 6.5)	3.1 (2.1 to 4.2)	-36.3 (-44.1 to -28.1)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (10-14 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Exposure to mechanical forces	-	-	-	189.9 (140.4 to 259.7)	152.0 (110.3 to 214.0)	-20.0 (-22.9 to -17.0)
Unintentional firearm injuries	-	-	-	4.6 (3.6 to 5.8)	3.5 (2.7 to 4.5)	-23.5 (-28.4 to -18.9)
Unintentional suffocation	-	-	-	2.5 (1.9 to 3.4)	2.4 (1.8 to 3.2)	-5.9 (-11.0 to -0.9)
Other exposure to mechanical forces	-	-	-	182.7 (134.2 to 251.1)	146.1 (105.3 to 207.0)	-20.2 (-23.1 to -17.1)
Adverse effects of medical treatment	-	-	-	3.2 (2.0 to 4.6)	3.4 (2.2 to 5.1)	8.5 (4.5 to 12.6)
Animal contact	-	-	-	27.4 (20.3 to 36.5)	18.9 (14.0 to 25.4)	-31.1 (-36.5 to -24.5)
Venomous animal contact	-	-	-	10.4 (7.5 to 13.8)	7.5 (5.4 to 10.1)	-27.8 (-37.8 to -15.7)
Non-venomous animal contact	-	-	-	17.1 (11.9 to 24.8)	11.4 (7.9 to 16.5)	-33.1 (-38.2 to -27.3)
Foreign body	-	-	-	8.1 (6.0 to 10.4)	7.2 (5.2 to 9.6)	-10.9 (-17.6 to -4.9)
Pulmonary aspiration and foreign body in airway	-	-	-	3.0 (2.3 to 3.8)	2.1 (1.6 to 2.6)	-31.0 (-36.2 to -24.2)
Foreign body in eyes	-	-	-	2.0 (1.0 to 3.2)	2.2 (1.1 to 3.6)	8.8 (1.1 to 16.4)
Foreign body in other body part	-	-	-	3.1 (2.3 to 4.1)	3.0 (2.2 to 4.0)	-4.1 (-8.6 to 0.6)
Other unintentional injuries	-	-	-	54.1 (41.3 to 69.4)	50.5 (38.2 to 66.0)	-6.7 (-11.4 to -2.4)
Self-harm and interpersonal violence	-	-	-	28.2 (22.0 to 35.3)	21.2 (16.3 to 26.7)	-25.0 (-28.5 to -20.8)
Self-harm	-	-	-	0.9 (0.7 to 1.2)	0.7 (0.5 to 0.8)	-29.8 (-34.2 to -25.1)
Interpersonal violence	-	-	-	27.3 (21.3 to 34.1)	20.5 (15.8 to 25.9)	-24.9 (-28.4 to -20.5)
Assault by firearm	-	-	-	4.2 (3.2 to 5.3)	3.4 (2.6 to 4.3)	-19.8 (-23.4 to -16.0)
Assault by sharp object	-	-	-	4.1 (3.2 to 5.2)	3.3 (2.6 to 4.3)	-18.7 (-23.7 to -13.9)
Assault by other means	-	-	-	19.0 (14.8 to 23.8)	13.8 (10.6 to 17.5)	-27.3 (-31.3 to -22.8)
Forces of nature, war, and legal intervention	-	-	-	165.2 (81.0 to 332.1)	34.1 (17.8 to 68.3)	-80.0 (-86.7 to -61.1)
Exposure to forces of nature	-	-	-	15.2 (8.3 to 30.4)	10.1 (5.9 to 19.1)	-31.7 (-57.5 to 2.4)
Collective violence and legal intervention	-	-	-	150.0 (69.3 to 312.7)	24.0 (10.9 to 54.4)	-84.9 (-90.1 to -66.4)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (15-19 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
All causes	-	-	-	38,075.1 (27,842.9 to 49,978.5)	42,093.8 (30,950.7 to 55,059.7)	10.6 (8.6 to 12.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	7,325.0 (5,033.0 to 10,407.7)	6,834.9 (4,818.7 to 9,569.5)	-6.7 (-9.6 to -2.9)
HIV/AIDS and tuberculosis	-	-	-	150.9 (100.4 to 202.7)	218.3 (152.1 to 290.0)	44.8 (32.0 to 60.2)
Tuberculosis	398.1 (366.0 to 425.0)	418.2 (390.0 to 443.1)	4.9 (2.3 to 8.7)	125.9 (82.3 to 172.8)	132.9 (88.9 to 184.8)	5.7 (-4.1 to 15.5)
HIV/AIDS	-	-	-	25.0 (17.2 to 34.3)	85.5 (60.0 to 114.7)	242.6 (183.9 to 325.1)
HIV/AIDS resulting in mycobacterial infection	1.3 (0.7 to 2.0)	4.9 (2.8 to 7.1)	270.1 (202.9 to 352.4)	0.5 (0.3 to 0.9)	1.9 (1.0 to 3.1)	263.0 (168.8 to 386.1)
HIV/AIDS resulting in other diseases	321.5 (285.8 to 364.1)	637.9 (583.2 to 695.7)	99.1 (75.7 to 121.7)	24.4 (16.8 to 33.7)	83.6 (58.5 to 112.1)	242.3 (183.4 to 325.5)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	941.4 (666.2 to 1,279.1)	953.2 (660.1 to 1,322.1)	1.1 (-3.6 to 6.3)
Diarrheal diseases	1,801.3 (1,713.6 to 1,882.8)	1,759.7 (1,665.9 to 1,862.0)	-2.3 (-9.2 to 5.5)	291.0 (199.5 to 402.2)	284.3 (193.0 to 390.3)	-2.3 (-11.0 to 6.5)
Intestinal infectious diseases	-	-	-	24.6 (16.1 to 35.3)	19.0 (12.0 to 27.5)	-23.0 (-42.9 to 4.8)
Typhoid fever	141.0 (119.6 to 162.7)	113.2 (96.6 to 132.0)	-19.8 (-37.7 to 2.7)	18.5 (11.7 to 27.5)	14.9 (9.3 to 22.1)	-20.2 (-43.1 to 15.5)
Paratyphoid fever	86.8 (69.3 to 105.0)	66.5 (52.8 to 81.6)	-23.3 (-44.5 to 4.9)	4.5 (2.6 to 7.0)	3.5 (2.0 to 5.5)	-22.8 (-50.2 to 20.9)
Other intestinal infectious diseases	-	-	-	1.6 (0.8 to 3.2)	0.6 (0.3 to 1.3)	-61.3 (-69.9 to -48.8)
Lower respiratory infections	142.6 (137.1 to 147.8)	115.9 (109.7 to 122.0)	-19.0 (-23.7 to -12.1)	15.1 (9.9 to 21.3)	12.2 (8.0 to 17.4)	-18.9 (-29.0 to -6.1)
Upper respiratory infections	18,039.5 (17,657.7 to 18,429.4)	23,047.1 (22,561.7 to 23,529.4)	27.8 (24.0 to 32.0)	212.9 (118.1 to 350.8)	272.5 (151.7 to 454.9)	27.8 (23.5 to 33.2)
Otitis media	7,644.8 (6,935.7 to 8,292.9)	7,990.3 (7,224.9 to 8,720.5)	4.5 (0.2 to 8.8)	155.8 (92.6 to 249.3)	164.4 (98.1 to 261.7)	5.6 (-0.9 to 11.8)
Meningitis	-	-	-	208.8 (147.8 to 276.8)	174.0 (121.9 to 228.8)	-16.7 (-22.8 to -9.3)
Pneumococcal meningitis	860.6 (560.9 to 1,229.5)	698.1 (468.4 to 1,002.3)	-19.0 (-23.9 to -11.9)	83.9 (59.8 to 111.9)	72.9 (50.9 to 96.5)	-13.2 (-23.6 to 1.0)
H influenzae type B meningitis	439.2 (184.5 to 786.6)	335.6 (160.9 to 589.2)	-23.5 (-29.5 to -13.3)	50.6 (34.9 to 68.9)	43.5 (29.6 to 59.9)	-14.3 (-26.0 to 1.4)
Meningococcal meningitis	161.6 (63.9 to 354.7)	113.3 (51.6 to 234.7)	-29.4 (-35.8 to -16.9)	21.0 (13.8 to 30.1)	15.9 (10.5 to 22.5)	-24.1 (-34.1 to -10.9)
Other meningitis	423.9 (215.5 to 741.9)	307.7 (188.1 to 509.4)	-26.9 (-33.8 to -13.8)	53.3 (36.7 to 73.5)	41.8 (28.6 to 57.2)	-21.5 (-31.2 to -10.9)
Encephalitis	144.4 (69.3 to 298.5)	115.3 (61.0 to 240.7)	-19.6 (-30.4 to -10.4)	19.4 (13.5 to 25.7)	17.3 (12.2 to 23.2)	-10.6 (-17.7 to -2.4)
Diphtheria	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-51.6 (-86.5 to 172.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.6 (-86.5 to 173.4)
Whooping cough	10.7 (8.3 to 13.7)	8.4 (6.5 to 10.8)	-21.3 (-21.8 to -20.8)	0.5 (0.3 to 0.9)	0.4 (0.2 to 0.7)	-21.2 (-23.9 to -18.6)
Tetanus	127.0 (92.0 to 188.1)	15.9 (10.5 to 24.6)	-87.6 (-92.9 to -78.5)	4.8 (3.2 to 7.2)	1.2 (0.8 to 2.1)	-75.2 (-84.6 to -57.1)
Measles	6.4 (4.9 to 8.1)	1.7 (1.4 to 2.2)	-72.7 (-75.1 to -70.3)	0.6 (0.4 to 0.9)	0.2 (0.1 to 0.2)	-72.7 (-75.1 to -70.3)
Varicella and herpes zoster	218.7 (200.7 to 240.1)	243.1 (218.5 to 268.8)	10.7 (-1.5 to 26.6)	7.9 (4.8 to 12.0)	7.9 (4.7 to 11.6)	-3.4 (-14.2 to 8.3)
Neglected tropical diseases and malaria	-	-	-	1,701.1 (1,105.0 to 2,580.7)	1,460.7 (941.8 to 2,247.7)	-14.4 (-20.9 to -5.7)
Malaria	30,745.1 (30,050.2 to 31,517.3)	38,649.6 (37,740.4 to 39,599.9)	25.7 (22.5 to 28.8)	203.4 (138.2 to 290.9)	241.4 (160.7 to 347.3)	18.6 (11.9 to 26.1)
Chagas disease	575.9 (563.7 to 588.3)	709.7 (691.8 to 729.6)	23.2 (18.8 to 27.6)	2.4 (1.6 to 3.5)	3.0 (1.9 to 4.3)	22.8 (9.3 to 37.4)
Leishmaniasis	-	-	-	1.8 (1.0 to 3.3)	4.8 (2.4 to 9.0)	160.3 (127.8 to 200.6)
Visceral leishmaniasis	4.7 (3.5 to 6.1)	7.0 (5.5 to 9.0)	50.5 (15.2 to 97.5)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	50.3 (13.4 to 99.9)
Cutaneous and mucocutaneous leishmaniasis	140.2 (116.6 to 169.6)	401.7 (329.8 to 494.6)	185.9 (148.6 to 232.2)	1.5 (0.7 to 2.9)	4.3 (2.0 to 8.4)	186.6 (148.2 to 237.4)
African trypanosomiasis	3.4 (1.5 to 6.8)	1.0 (0.6 to 1.8)	-69.3 (-73.8 to -63.7)	1.0 (0.4 to 1.9)	0.3 (0.1 to 0.5)	-68.5 (-75.4 to -56.5)
Schistosomiasis	30,988.8 (27,876.9 to 33,961.9)	40,814.3 (35,281.1 to 47,705.4)	30.2 (21.7 to 50.1)	304.8 (154.4 to 574.6)	406.3 (206.1 to 788.0)	31.5 (23.7 to 53.5)
Cysticercosis	154.6 (130.2 to 183.2)	97.7 (79.0 to 120.6)	-37.5 (-49.6 to -19.1)	44.9 (30.1 to 61.0)	29.9 (19.3 to 41.8)	-33.7 (-49.2 to -10.8)
Cystic echinococcosis	71.8 (66.3 to 77.9)	47.4 (44.6 to 50.7)	-34.1 (-36.9 to -29.7)	6.9 (4.5 to 9.8)	4.6 (3.0 to 6.6)	-33.2 (-43.5 to -20.9)
Lymphatic filariasis	6,295.2 (5,856.5 to 6,848.5)	3,423.9 (3,003.1 to 3,864.5)	-45.5 (-51.8 to -39.3)	93.2 (45.1 to 165.9)	74.8 (39.1 to 130.8)	-18.9 (-44.9 to 13.8)
Onchocerciasis	2,979.5 (1,827.9 to 4,719.9)	1,921.9 (1,242.8 to 3,133.8)	-35.5 (-45.3 to -22.7)	150.2 (71.2 to 253.6)	117.2 (50.5 to 212.0)	-23.0 (-34.0 to -9.8)
Trachoma	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-14.8 (-30.5 to 6.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.5 (-28.5 to 5.5)
Dengue	57.4 (21.0 to 128.8)	367.5 (135.6 to 824.4)	541.2 (535.0 to 547.8)	9.4 (2.9 to 24.4)	60.7 (20.1 to 151.4)	549.5 (420.3 to 718.1)
Yellow fever	0.6 (0.2 to 1.4)	0.2 (0.1 to 0.6)	-60.2 (-69.8 to -40.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-60.2 (-69.8 to -40.2)
Rabies	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-45.2 (-57.6 to -31.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.2 (-57.7 to -31.8)
Intestinal nematode infections	-	-	-	646.2 (372.4 to 1,039.2)	365.1 (212.1 to 582.0)	-43.3 (-48.1 to -37.9)
Ascariasis	119,259.2 (100,670.2 to 143,417.2)	78,547.9 (68,379.2 to 90,999.5)	-34.0 (-47.4 to -16.8)	280.9 (153.9 to 468.2)	88.6 (48.5 to 151.5)	-68.5 (-73.3 to -62.7)
Trichuriasis	61,325.3 (50,221.1 to 76,880.0)	46,595.2 (42,190.1 to 51,584.3)	-23.3 (-41.4 to -4.5)	89.8 (49.6 to 149.3)	60.8 (32.1 to 104.6)	-33.2 (-47.1 to -9.9)
Hookworm disease	59,054.8 (50,140.4 to 70,988.8)	49,511.1 (45,137.7 to 54,550.6)	-15.6 (-31.1 to 1.6)	275.5 (165.3 to 439.6)	215.7 (128.9 to 336.7)	-21.4 (-28.7 to -13.9)
Food-borne trematodiasis	3,658.5 (2,873.3 to 4,706.9)	2,839.2 (2,129.9 to 3,659.5)	-21.9 (-33.5 to -13.2)	137.9 (38.0 to 294.5)	83.5 (28.7 to 175.5)	-36.9 (-57.6 to -18.9)
Other neglected tropical diseases	3,212.2 (3,110.1 to 3,310.5)	2,483.5 (2,396.8 to 2,566.3)	-22.7 (-25.9 to -19.3)	99.0 (59.0 to 164.8)	69.1 (39.0 to 119.5)	-31.0 (-40.8 to -17.3)
Maternal disorders	-	-	-	198.3 (128.4 to 285.2)	205.5 (131.3 to 294.7)	3.7 (-9.9 to 19.1)
Maternal hemorrhage	112.2 (87.5 to 139.6)	92.8 (86.2 to 100.7)	-17.3 (-34.6 to 7.0)	5.6 (3.4 to 8.6)	4.7 (3.0 to 6.7)	-15.5 (-42.3 to 20.4)
Maternal sepsis and other maternal infections	49.0 (29.8 to 73.7)	27.9 (16.3 to 43.5)	-43.3 (-53.6 to -29.5)	3.1 (1.4 to 5.3)	1.4 (0.7 to 2.4)	-53.2 (-68.0 to -30.4)
Maternal hypertensive disorders	142.0 (83.4 to 212.7)	100.8 (57.2 to 155.5)	-29.4 (-36.0 to -22.6)	7.8 (3.8 to 13.2)	5.4 (2.6 to 9.4)	-30.6 (-42.3 to -16.7)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (15-19 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Obstructed labor	435-2 (337-4 to 530-3)	460-4 (369-8 to 552-6)	5-9 (-2-0 to 14-6)	145-4 (92-4 to 212-6)	155-0 (97-0 to 223-5)	6-6 (-6-4 to 23-2)
Complications of abortion	1-6 (1-0 to 2-2)	1-3 (0-9 to 1-9)	-12-9 (-27-7 to -0-1)	0-2 (0-1 to 0-3)	0-2 (0-1 to 0-2)	-12-8 (-27-6 to 0-1)
Other maternal disorders	-	-	-	36-3 (22-3 to 55-6)	38-8 (24-1 to 59-9)	8-6 (-26-1 to 49-9)
Neonatal disorders	-	-	-	526-2 (388-0 to 679-8)	1,165-7 (853-1 to 1,500-8)	120-9 (97-4 to 150-0)
Preterm birth complications	1,964-5 (1,725-5 to 2,265-2)	4,796-5 (4,256-2 to 5,436-4)	144-3 (123-2 to 167-4)	227-2 (165-1 to 293-3)	604-8 (439-7 to 781-9)	165-6 (144-9 to 192-4)
Neonatal encephalopathy due to birth asphyxia and trauma	2,129-6 (839-9 to 3,840-0)	2,101-4 (1,093-1 to 3,635-1)	-0-7 (-21-7 to 49-2)	144-6 (100-8 to 202-8)	231-1 (169-4 to 307-6)	60-5 (32-5 to 95-9)
Neonatal sepsis and other neonatal infections	-	-	-	-	-	-
Hemolytic disease and other neonatal jaundice	198-8 (161-1 to 250-3)	477-1 (361-6 to 666-6)	135-0 (71-7 to 289-0)	73-0 (50-3 to 100-7)	155-4 (107-4 to 217-3)	109-7 (56-8 to 221-5)
Other neonatal disorders	-	-	-	81-4 (54-7 to 115-2)	174-5 (120-3 to 242-7)	113-7 (71-4 to 179-9)
Nutritional deficiencies	-	-	-	3,546-6 (2,338-9 to 5,215-3)	2,569-9 (1,689-2 to 3,797-6)	-27-7 (-29-4 to -25-5)
Protein-energy malnutrition	10-1 (5-3 to 16-8)	10-6 (5-8 to 18-0)	4-7 (-16-8 to 39-2)	1-3 (0-6 to 2-4)	1-3 (0-6 to 2-5)	5-7 (-16-7 to 41-9)
Iodine deficiency	16,004-9 (15,293-0 to 16,783-2)	12,100-4 (11,588-6 to 12,679-8)	-24-5 (-28-9 to -19-2)	290-2 (180-8 to 457-4)	219-6 (137-1 to 347-0)	-24-4 (-29-4 to -18-3)
Vitamin A deficiency	449-1 (329-3 to 587-6)	346-7 (245-2 to 455-9)	-22-8 (-29-0 to -16-8)	20-3 (12-1 to 31-7)	14-6 (8-4 to 22-7)	-27-8 (-39-3 to -14-8)
Iron-deficiency anemia	120,584-3 (120,306-0 to 120,878-2)	99,332-1 (99,083-3 to 99,583-6)	-17-6 (-17-9 to -17-3)	3,234-7 (2,135-9 to 4,713-1)	2,334-3 (1,532-4 to 3,461-5)	-27-9 (-29-8 to -25-8)
Other nutritional deficiencies	-	-	-	0-1 (0-0 to 0-3)	0-1 (0-0 to 0-2)	-28-0 (-52-4 to 26-2)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	260-7 (167-5 to 404-8)	261-6 (165-8 to 412-0)	0-0 (-5-4 to 6-6)
Sexually transmitted diseases excluding HIV	-	-	-	132-0 (82-7 to 215-0)	156-3 (97-1 to 252-8)	18-3 (10-4 to 27-7)
Syphilis	1-7 (1-6 to 1-8)	1-1 (1-0 to 1-2)	-37-2 (-41-5 to -32-2)	0-4 (0-2 to 0-5)	0-2 (0-1 to 0-3)	-37-2 (-41-6 to -32-2)
Chlamydial infection	18,353-1 (17,667-8 to 18,978-1)	19,626-6 (18,933-1 to 20,375-7)	7-0 (1-0 to 13-3)	77-4 (48-8 to 123-0)	88-4 (54-9 to 139-6)	14-2 (6-3 to 24-5)
Gonococcal infection	4,730-9 (4,392-8 to 5,101-4)	5,909-6 (5,451-9 to 6,337-2)	25-3 (11-3 to 38-1)	31-0 (19-2 to 48-6)	40-3 (25-2 to 62-3)	30-3 (7-1 to 58-3)
Trichomoniasis	4,898-6 (4,077-2 to 5,826-1)	6,317-0 (5,011-5 to 7,913-5)	28-1 (0-5 to 66-7)	8-8 (3-4 to 18-6)	11-6 (4-3 to 25-1)	30-4 (-1-4 to 72-1)
Genital herpes	32,851-2 (31,667-5 to 34,068-8)	36,276-1 (34,820-0 to 37,536-7)	10-6 (4-7 to 15-5)	12-6 (4-6 to 28-2)	14-0 (5-1 to 30-9)	10-5 (1-0 to 20-0)
Other sexually transmitted diseases	27-8 (19-0 to 39-3)	26-1 (18-8 to 33-9)	-6-0 (-16-2 to 9-6)	1-8 (1-1 to 2-7)	1-9 (1-2 to 2-6)	3-8 (-22-7 to 34-9)
Hepatitis	-	-	-	44-3 (28-7 to 64-3)	43-6 (28-1 to 64-0)	-1-4 (-7-1 to 4-3)
Hepatitis A	758-1 (737-7 to 773-5)	812-6 (783-3 to 839-8)	7-1 (6-2 to 8-6)	26-7 (17-2 to 38-9)	28-6 (18-4 to 41-5)	7-1 (0-2 to 14-7)
Hepatitis B	34,061-4 (33,390-2 to 34,774-8)	25,823-5 (25,161-6 to 26,441-8)	-24-1 (-26-7 to -21-7)	8-4 (5-4 to 12-1)	6-2 (3-9 to 9-0)	-26-8 (-34-3 to -18-1)
Hepatitis C	9,057-1 (8,808-0 to 9,304-9)	8,305-5 (8,063-4 to 8,546-7)	-8-3 (-11-6 to -4-9)	0-7 (0-4 to 1-0)	0-6 (0-4 to 1-0)	-7-2 (-24-6 to 10-2)
Hepatitis E	329-2 (302-2 to 356-1)	315-9 (294-0 to 351-5)	-4-7 (-13-1 to 9-4)	8-5 (5-4 to 12-4)	8-3 (5-3 to 12-5)	-2-9 (-20-6 to 18-4)
Leprosy	7-1 (6-4 to 8-1)	5-3 (4-9 to 5-8)	-24-9 (-35-7 to -15-4)	0-4 (0-2 to 0-6)	0-3 (0-2 to 0-5)	-16-7 (-28-3 to -6-2)
Other infectious diseases	3,466-0 (3,390-9 to 3,547-6)	2,697-0 (2,618-3 to 2,788-6)	-22-2 (-25-2 to -18-8)	84-0 (54-9 to 125-0)	61-3 (38-2 to 96-0)	-27-5 (-37-1 to -15-3)
Non-communicable diseases	-	-	-	29,103-0 (21,388-5 to 37,996-7)	34,190-6 (25,067-3 to 44,822-3)	17-5 (15-8 to 19-4)
Neoplasms	-	-	-	38-3 (26-8 to 51-0)	46-9 (32-8 to 63-5)	21-2 (7-1 to 43-1)
Esophageal cancer	1-0 (0-7 to 1-4)	0-9 (0-6 to 1-4)	-8-7 (-30-6 to 21-6)	0-2 (0-1 to 0-3)	0-1 (0-1 to 0-2)	-12-4 (-31-7 to 13-2)
Stomach cancer	4-6 (3-9 to 5-4)	3-1 (2-7 to 3-8)	-32-0 (-44-6 to -16-1)	0-6 (0-4 to 0-8)	0-4 (0-3 to 0-5)	-35-9 (-48-0 to -20-0)
Liver cancer	-	-	-	0-5 (0-3 to 0-7)	0-4 (0-3 to 0-5)	-14-4 (-32-7 to 4-2)
Liver cancer due to hepatitis B	1-3 (1-1 to 1-6)	1-3 (1-1 to 1-6)	2-3 (-22-4 to 35-7)	0-2 (0-1 to 0-3)	0-2 (0-1 to 0-3)	-5-1 (-26-2 to 18-3)
Liver cancer due to hepatitis C	0-1 (0-1 to 0-1)	0-4 (0-3 to 0-4)	224-9 (143-8 to 330-3)	0-0 (0-0 to 0-0)	0-1 (0-0 to 0-1)	198-8 (130-9 to 291-3)
Liver cancer due to alcohol use	0-2 (0-1 to 0-2)	0-1 (0-1 to 0-1)	-36-3 (-52-0 to -6-0)	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	-39-9 (-54-1 to -13-0)
Liver cancer due to other causes	1-2 (1-0 to 1-5)	0-7 (0-6 to 0-9)	-37-2 (-52-9 to -17-6)	0-2 (0-1 to 0-3)	0-1 (0-1 to 0-2)	-41-6 (-55-1 to -27-2)
Larynx cancer	1-6 (1-3 to 2-1)	1-1 (0-8 to 1-3)	-36-4 (-46-1 to -23-0)	0-2 (0-1 to 0-2)	0-1 (0-1 to 0-2)	-31-6 (-41-5 to -17-7)
Tracheal, bronchus and lung cancer	3-2 (2-7 to 3-6)	2-8 (2-4 to 3-3)	-13-6 (-25-1 to 9-2)	0-6 (0-4 to 0-7)	0-5 (0-3 to 0-6)	-18-2 (-28-7 to 2-8)
Breast cancer	16-6 (13-7 to 20-8)	28-9 (21-5 to 41-5)	70-7 (28-1 to 143-0)	1-4 (0-9 to 2-0)	2-1 (1-3 to 3-4)	54-7 (13-9 to 126-8)
Cervical cancer	8-6 (5-8 to 12-3)	5-5 (3-5 to 7-6)	-36-7 (-59-6 to 2-1)	0-7 (0-4 to 1-0)	0-4 (0-2 to 0-7)	-35-3 (-60-9 to 7-3)
Uterine cancer	1-5 (1-0 to 2-2)	1-2 (0-8 to 1-6)	-21-9 (-43-8 to 14-8)	0-1 (0-1 to 0-2)	0-1 (0-0 to 0-1)	-22-3 (-44-1 to 14-7)
Prostate cancer	0-7 (0-4 to 0-9)	1-4 (1-0 to 2-0)	115-9 (80-5 to 151-7)	0-1 (0-0 to 0-1)	0-1 (0-1 to 0-2)	74-5 (47-6 to 105-4)
Colon and rectum cancer	9-0 (8-2 to 9-9)	13-2 (11-8 to 14-9)	47-7 (30-9 to 65-8)	0-8 (0-6 to 1-1)	1-1 (0-8 to 1-6)	36-4 (20-0 to 55-6)
Lip and oral cavity cancer	9-3 (7-0 to 13-5)	9-9 (7-5 to 14-6)	5-0 (-20-9 to 44-6)	0-8 (0-5 to 1-3)	0-8 (0-5 to 1-4)	3-1 (-22-1 to 42-2)
Nasopharynx cancer	9-9 (6-0 to 14-4)	8-0 (4-9 to 11-4)	-18-0 (-53-3 to 44-5)	0-9 (0-5 to 1-5)	0-8 (0-4 to 1-2)	-20-3 (-53-7 to 41-4)
Other pharynx cancer	1-0 (0-8 to 1-1)	1-1 (0-9 to 1-2)	6-2 (-11-4 to 26-7)	0-1 (0-1 to 0-1)	0-1 (0-1 to 0-1)	3-6 (-13-1 to 23-9)
Gallbladder and biliary tract cancer	0-2 (0-1 to 0-2)	0-2 (0-1 to 0-2)	-0-8 (-32-2 to 54-0)	0-0 (0-0 to 0-1)	0-0 (0-0 to 0-1)	-6-8 (-35-5 to 45-7)
Pancreatic cancer	0-4 (0-4 to 0-5)	0-6 (0-5 to 0-7)	31-0 (12-7 to 50-9)	0-1 (0-1 to 0-1)	0-1 (0-1 to 0-2)	26-2 (10-7 to 43-3)
Malignant skin melanoma	19-4 (15-0 to 23-4)	25-8 (19-8 to 31-9)	33-7 (4-9 to 63-8)	1-2 (0-7 to 1-7)	1-5 (0-9 to 2-4)	30-2 (-5-5 to 71-2)
Non-melanoma skin cancer	5-5 (4-5 to 6-8)	8-3 (6-1 to 10-8)	49-1 (14-1 to 102-6)	0-2 (0-1 to 0-4)	0-4 (0-2 to 0-6)	58-0 (2-3 to 150-4)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (15-19 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Ovarian cancer	8.7 (7.3 to 10.2)	10.4 (8.7 to 12.5)	21.2 (-3.7 to 48.0)	1.2 (0.8 to 1.6)	1.4 (1.0 to 2.0)	19.2 (-6.3 to 49.5)
Testicular cancer	16.1 (11.6 to 21.0)	21.3 (14.5 to 29.2)	32.4 (-6.4 to 83.8)	1.0 (0.6 to 1.5)	1.3 (0.7 to 2.0)	29.2 (-13.2 to 84.6)
Kidney cancer	2.9 (2.6 to 3.3)	4.1 (3.6 to 4.6)	40.4 (23.1 to 62.0)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	34.3 (17.1 to 55.2)
Bladder cancer	1.8 (1.5 to 2.0)	1.7 (1.5 to 2.0)	-1.6 (-11.4 to 8.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-4.5 (-13.5 to 6.1)
Brain and nervous system cancer	35.7 (27.9 to 44.7)	40.4 (31.8 to 49.9)	13.6 (-9.5 to 38.5)	3.9 (2.6 to 5.5)	4.3 (2.9 to 6.2)	10.7 (-12.2 to 33.9)
Thyroid cancer	43.0 (25.6 to 75.3)	41.6 (27.2 to 75.4)	-9.5 (-57.7 to 130.4)	2.5 (1.2 to 4.5)	2.3 (1.2 to 4.6)	-10.0 (-59.0 to 144.7)
Mesothelioma	0.2 (0.2 to 0.2)	0.1 (0.1 to 0.2)	-18.9 (-27.1 to -6.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.4 (-25.5 to -5.1)
Hodgkin lymphoma	59.6 (40.2 to 76.4)	48.8 (40.0 to 62.9)	-20.4 (-39.6 to 30.7)	5.0 (3.1 to 7.4)	3.9 (2.5 to 5.7)	-23.9 (-43.5 to 22.8)
Non-Hodgkin lymphoma	30.4 (23.9 to 36.1)	42.5 (35.9 to 51.1)	39.5 (14.8 to 73.7)	2.4 (1.6 to 3.4)	3.3 (2.2 to 4.5)	33.0 (8.1 to 66.8)
Multiple myeloma	0.9 (0.7 to 1.2)	1.2 (0.9 to 1.5)	29.0 (-1.0 to 55.5)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	24.8 (-3.3 to 48.7)
Leukemia	59.2 (51.3 to 67.7)	78.2 (68.7 to 89.3)	31.9 (12.1 to 55.9)	8.6 (6.1 to 11.5)	10.1 (7.0 to 13.6)	17.4 (-0.8 to 40.2)
Other neoplasms	62.6 (52.6 to 82.9)	149.0 (122.1 to 188.4)	139.4 (78.1 to 206.1)	4.7 (3.2 to 6.8)	10.4 (6.8 to 15.1)	120.0 (62.4 to 187.5)
Cardiovascular diseases	-	-	-	250.9 (165.8 to 363.8)	408.1 (261.3 to 592.6)	63.5 (26.4 to 101.5)
Rheumatic heart disease	2,016.6 (1,884.0 to 2,152.9)	2,706.0 (2,582.7 to 2,818.9)	33.8 (23.6 to 46.8)	99.9 (64.5 to 145.7)	131.5 (84.4 to 191.3)	31.5 (20.2 to 44.2)
Ischemic heart disease	8.0 (7.2 to 9.1)	9.5 (8.5 to 11.0)	18.8 (-2.2 to 39.3)	1.0 (0.6 to 1.4)	1.2 (0.8 to 1.7)	18.7 (-2.4 to 39.3)
Cerebrovascular disease	-	-	-	12.6 (8.7 to 16.7)	16.2 (11.1 to 21.8)	28.8 (16.8 to 42.8)
Ischemic stroke	35.1 (32.4 to 37.6)	50.0 (46.0 to 54.6)	42.6 (28.1 to 59.9)	5.9 (4.1 to 8.1)	8.3 (5.5 to 11.6)	40.2 (20.5 to 61.5)
Hemorrhagic stroke	39.8 (37.2 to 42.2)	47.5 (44.0 to 51.1)	18.9 (8.5 to 32.4)	6.7 (4.5 to 9.1)	8.0 (5.3 to 10.9)	18.5 (8.3 to 32.6)
Hypertensive heart disease	8.6 (8.0 to 9.3)	11.7 (10.8 to 12.7)	36.3 (21.1 to 51.6)	1.1 (0.7 to 1.5)	1.4 (1.0 to 2.0)	36.2 (21.0 to 51.4)
Cardiomyopathy and myocarditis	55.5 (52.1 to 58.9)	76.3 (70.3 to 80.7)	37.4 (28.5 to 46.6)	6.1 (4.1 to 8.6)	8.6 (5.6 to 11.9)	39.9 (25.0 to 55.9)
Atrial fibrillation and flutter	-	-	-	-	-	-
Peripheral vascular disease	-	-	-	-	-	-
Endocarditis	4.4 (3.5 to 5.5)	6.1 (4.7 to 7.5)	39.7 (20.3 to 58.1)	0.5 (0.3 to 0.7)	0.7 (0.4 to 1.0)	44.3 (22.7 to 66.4)
Other cardiovascular and circulatory diseases	1,827.4 (1,317.1 to 2,570.7)	3,497.6 (2,272.9 to 4,843.0)	94.9 (17.0 to 180.1)	129.8 (77.3 to 205.3)	248.5 (138.3 to 394.9)	94.6 (17.9 to 181.4)
Chronic respiratory diseases	-	-	-	1,561.9 (1,071.5 to 2,158.6)	1,798.2 (1,238.6 to 2,467.4)	15.2 (10.3 to 20.0)
Chronic obstructive pulmonary disease	5,493.8 (5,151.5 to 5,834.2)	6,703.9 (6,320.5 to 7,093.2)	22.1 (20.2 to 23.8)	454.2 (292.5 to 656.6)	588.0 (378.4 to 850.0)	29.3 (21.8 to 38.1)
Pneumoconiosis	-	-	-	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.9)	35.7 (30.9 to 40.6)
Silicosis	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.3)	0.4 (-6.0 to 7.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.6 (-6.0 to 7.4)
Asbestosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	7.4 (-3.7 to 15.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.1 (-3.3 to 17.4)
Coal workers pneumoconiosis	0.3 (0.3 to 0.3)	0.3 (0.2 to 0.3)	-10.1 (-14.4 to -6.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-9.6 (-14.0 to -5.6)
Other pneumoconiosis	1.9 (1.5 to 2.2)	2.8 (2.3 to 3.3)	50.3 (46.1 to 55.0)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	49.1 (44.6 to 54.2)
Asthma	23,356.2 (22,745.9 to 24,057.2)	25,711.1 (24,859.6 to 26,594.7)	10.1 (5.3 to 14.9)	1,046.7 (676.7 to 1,485.9)	1,154.2 (750.5 to 1,662.2)	10.3 (5.0 to 15.6)
Interstitial lung disease and pulmonary sarcoidosis	11.4 (10.7 to 12.3)	13.8 (12.4 to 15.2)	20.7 (5.6 to 37.0)	1.5 (0.9 to 2.2)	1.8 (1.1 to 2.7)	22.3 (7.3 to 37.6)
Other chronic respiratory diseases	-	-	-	59.0 (34.9 to 91.5)	53.5 (33.0 to 82.3)	-9.4 (-21.2 to 6.9)
Cirrhosis	-	-	-	23.3 (15.6 to 33.1)	23.4 (15.3 to 33.1)	0.5 (-14.6 to 18.2)
Cirrhosis due to hepatitis B	44.7 (40.4 to 49.5)	34.2 (29.4 to 38.9)	-23.2 (-37.7 to -11.5)	7.7 (4.9 to 11.0)	5.9 (3.5 to 8.9)	-23.4 (-45.5 to 5.7)
Cirrhosis due to hepatitis C	24.2 (21.2 to 27.5)	24.4 (20.9 to 28.3)	-0.3 (-17.1 to 24.7)	4.2 (2.7 to 6.4)	4.2 (2.7 to 6.3)	-0.6 (-25.7 to 39.5)
Cirrhosis due to alcohol use	16.5 (13.7 to 20.5)	11.5 (8.1 to 15.4)	-29.5 (-50.5 to -7.9)	2.9 (1.7 to 4.5)	2.0 (1.0 to 3.5)	-33.0 (-60.4 to 23.9)
Cirrhosis due to other causes	49.3 (43.5 to 53.9)	33.3 (58.4 to 72.9)	8.5 (15.6 to 53.4)	8.5 (5.5 to 12.6)	11.2 (7.1 to 16.4)	32.9 (-3.8 to 80.5)
Digestive diseases	-	-	-	230.1 (161.5 to 311.3)	221.2 (155.2 to 302.3)	-3.9 (-12.7 to 5.5)
Peptic ulcer disease	305.1 (270.3 to 342.9)	172.3 (149.4 to 197.7)	-43.3 (-53.7 to -32.0)	12.8 (8.2 to 19.6)	8.4 (5.3 to 12.4)	-34.2 (-52.6 to -8.8)
Gastritis and duodenitis	2,606.4 (2,433.3 to 2,766.2)	1,807.5 (1,662.8 to 1,950.9)	-30.6 (-37.2 to -24.0)	103.0 (68.8 to 147.6)	72.8 (48.7 to 106.5)	-29.6 (-38.2 to -17.0)
Appendicitis	67.4 (58.9 to 80.2)	75.3 (58.0 to 93.2)	10.1 (-12.7 to 46.6)	20.8 (13.0 to 30.6)	23.3 (14.4 to 34.6)	12.0 (-19.2 to 55.0)
Paralytic ileus and intestinal obstruction	1.3 (1.2 to 1.3)	1.6 (1.5 to 1.7)	22.4 (16.6 to 29.4)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	22.4 (16.5 to 29.4)
Inguinal, femoral, and abdominal hernia	490.8 (465.1 to 517.8)	587.0 (552.5 to 624.4)	19.3 (10.5 to 29.7)	5.3 (2.6 to 10.2)	6.4 (3.1 to 12.2)	19.7 (6.9 to 33.6)
Inflammatory bowel disease	224.6 (218.1 to 231.1)	324.5 (314.6 to 333.6)	44.3 (39.0 to 50.1)	49.5 (33.4 to 68.7)	71.8 (49.3 to 99.4)	44.8 (30.0 to 61.3)
Vascular intestinal disorders	0.4 (0.4 to 0.5)	0.5 (0.5 to 0.6)	27.2 (12.4 to 49.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	27.1 (12.3 to 49.7)
Gallbladder and biliary diseases	39.6 (37.7 to 41.8)	49.4 (46.5 to 52.4)	25.0 (13.1 to 35.6)	4.4 (2.8 to 6.2)	5.5 (3.5 to 7.9)	24.8 (-2.1 to 59.5)
Pancreatitis	19.9 (19.3 to 20.5)	30.5 (29.6 to 31.6)	53.5 (46.2 to 61.0)	6.4 (4.2 to 9.2)	9.7 (6.3 to 13.8)	51.5 (18.7 to 91.9)
Other digestive diseases	-	-	-	27.4 (18.5 to 38.4)	22.7 (15.4 to 31.8)	-16.6 (-28.8 to -5.7)
Neurological disorders	-	-	-	2,951.8 (1,963.6 to 4,151.3)	3,704.6 (2,501.3 to 5,213.2)	25.5 (19.5 to 31.4)
Alzheimer disease and other dementias	-	-	-	-	-	-
Parkinson disease	-	-	-	-	-	-
Epilepsy	1,708.4 (1,595.1 to 1,818.3)	1,966.2 (1,821.7 to 2,102.4)	15.1 (4.0 to 27.6)	558.8 (375.4 to 748.4)	691.8 (468.8 to 911.2)	23.7 (10.8 to 38.8)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (15-19 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Multiple sclerosis	20.7 (19.7 to 21.7)	35.6 (33.9 to 37.3)	71.8 (61.8 to 84.6)	7.4 (5.3 to 9.5)	12.7 (8.9 to 16.5)	70.3 (54.6 to 88.2)
Migraine	53,511.0 (51,292.9 to 55,610.5)	64,320.6 (61,308.1 to 67,094.1)	20.2 (13.1 to 27.4)	1,877.0 (1,115.3 to 2,745.8)	2,262.4 (1,358.1 to 3,344.3)	20.6 (13.0 to 28.7)
Tension-type headache	117,622.7 (112,163.6 to 122,452.4)	142,325.7 (137,646.2 to 146,329.7)	21.0 (14.4 to 28.1)	181.1 (86.6 to 319.1)	219.4 (107.1 to 382.5)	21.2 (14.1 to 29.2)
Medication overuse headache	2,005.1 (1,354.9 to 2,640.2)	3,174.2 (2,157.2 to 4,190.4)	58.2 (37.4 to 83.7)	324.9 (185.8 to 501.4)	515.4 (294.3 to 793.4)	58.6 (38.0 to 86.8)
Other neurological disorders	0.6 (0.5 to 0.7)	0.7 (0.6 to 0.8)	15.7 (-1.2 to 32.3)	2.5 (1.7 to 3.7)	3.0 (2.0 to 3.9)	18.8 (-2.9 to 36.2)
Mental and substance use disorders	-	-	-	11,968.8 (8,274.7 to 15,996.7)	14,039.0 (9,730.5 to 18,757.2)	17.3 (15.3 to 19.4)
Schizophrenia	488.5 (435.3 to 533.4)	522.4 (466.3 to 568.8)	6.9 (5.0 to 8.9)	328.4 (242.3 to 403.5)	352.1 (256.1 to 434.0)	7.2 (0.6 to 14.1)
Alcohol use disorders	5,543.9 (4,966.2 to 6,159.7)	5,455.6 (4,912.9 to 6,049.3)	-1.6 (-3.6 to 0.6)	564.3 (376.9 to 811.9)	554.1 (368.7 to 797.6)	-1.8 (-4.8 to 1.6)
Drug use disorders	-	-	-	1,096.0 (746.3 to 1,504.7)	1,142.2 (763.1 to 1,563.3)	4.0 (-1.4 to 10.7)
Opioid use disorders	118.8 (66.3 to 204.0)	122.7 (66.2 to 220.0)	2.7 (-2.2 to 9.8)	51.3 (24.7 to 91.1)	53.2 (25.3 to 95.7)	3.5 (-6.3 to 13.3)
Cocaine use disorders	765.5 (740.8 to 790.4)	787.8 (760.2 to 816.9)	3.0 (-1.5 to 7.4)	107.4 (70.6 to 153.5)	110.8 (72.4 to 157.9)	3.0 (-3.7 to 10.5)
Amphetamine use disorders	2,723.6 (2,579.8 to 2,864.4)	2,841.6 (2,710.1 to 2,970.2)	4.2 (-2.0 to 11.8)	363.2 (226.3 to 530.8)	379.8 (235.5 to 551.1)	4.5 (-2.9 to 13.6)
Cannabis use disorders	3,391.0 (2,841.4 to 3,993.8)	3,519.1 (2,917.2 to 4,197.8)	3.7 (1.1 to 6.2)	99.1 (63.1 to 145.4)	103.0 (65.5 to 151.2)	3.9 (-2.4 to 10.1)
Other drug use disorders	-	-	-	475.1 (310.3 to 667.3)	495.4 (323.7 to 689.7)	4.1 (-3.2 to 13.5)
Depressive disorders	-	-	-	3,765.4 (2,288.4 to 5,554.0)	4,709.3 (2,906.1 to 6,898.0)	25.0 (20.2 to 30.8)
Major depressive disorder	16,170.5 (11,858.9 to 21,086.1)	20,337.9 (15,240.8 to 26,074.0)	25.6 (20.5 to 32.2)	3,415.3 (2,012.7 to 5,122.3)	4,305.3 (2,586.4 to 6,416.7)	26.0 (20.6 to 32.8)
Dysthymia	3,531.1 (2,658.9 to 4,447.1)	4,065.7 (3,042.4 to 5,138.9)	15.1 (13.5 to 16.6)	350.1 (218.2 to 528.2)	404.0 (250.0 to 613.8)	15.3 (11.6 to 18.9)
Bipolar disorder	2,544.8 (1,771.3 to 3,475.1)	2,958.1 (1,989.6 to 4,097.4)	15.7 (11.2 to 25.8)	535.8 (296.5 to 922.1)	623.8 (341.3 to 1,087.8)	16.1 (9.0 to 27.1)
Anxiety disorders	21,995.3 (16,049.7 to 31,508.6)	26,007.0 (19,357.3 to 35,891.9)	18.6 (13.8 to 22.9)	2,070.5 (1,256.4 to 3,267.6)	2,451.6 (1,504.7 to 3,778.8)	18.7 (13.8 to 23.7)
Eating disorders	-	-	-	302.4 (191.4 to 442.5)	362.3 (227.2 to 535.2)	19.8 (14.5 to 25.3)
Anorexia nervosa	346.7 (269.8 to 443.2)	426.8 (330.6 to 546.5)	23.1 (18.9 to 27.2)	74.4 (46.8 to 111.7)	91.8 (58.1 to 137.4)	23.4 (13.6 to 33.7)
Bulimia nervosa	1,071.2 (773.3 to 1,407.4)	1,268.2 (899.1 to 1,671.6)	18.3 (14.5 to 21.5)	228.0 (137.8 to 344.9)	270.5 (161.6 to 413.3)	18.5 (12.1 to 25.0)
Autistic spectrum disorders	-	-	-	706.8 (493.3 to 964.0)	817.0 (563.7 to 1,118.6)	15.6 (12.7 to 18.5)
Autism	1,792.2 (1,705.3 to 1,879.2)	2,066.9 (1,966.8 to 2,169.0)	15.3 (15.1 to 15.5)	449.4 (300.5 to 618.5)	519.3 (343.8 to 710.9)	15.5 (11.7 to 19.8)
Asperger syndrome	2,544.1 (2,382.7 to 2,695.6)	2,937.2 (2,751.6 to 3,113.6)	15.5 (15.3 to 15.6)	257.4 (178.1 to 358.4)	297.7 (204.4 to 415.5)	15.6 (12.1 to 19.1)
Attention-deficit/hyperactivity disorder	9,935.1 (9,187.4 to 10,715.6)	11,329.9 (10,550.4 to 12,139.1)	14.0 (12.8 to 15.4)	121.0 (72.8 to 186.2)	138.2 (82.7 to 215.2)	14.2 (11.0 to 17.9)
Conduct disorder	16,722.0 (15,007.0 to 18,418.1)	19,641.3 (17,855.0 to 21,423.3)	17.5 (15.9 to 19.3)	2,010.0 (1,249.4 to 2,918.2)	2,365.5 (1,474.0 to 3,441.6)	17.6 (15.4 to 20.5)
Idiopathic intellectual disability	9,383.0 (7,436.6 to 11,507.0)	10,527.7 (8,616.9 to 12,902.5)	12.1 (3.4 to 23.0)	468.2 (305.3 to 671.4)	522.8 (347.2 to 739.3)	11.5 (2.8 to 22.6)
Other mental and substance use disorders	-	-	0.0 (0.0 to 0.0)	-	-	-
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	1,649.2 (1,136.0 to 2,266.7)	1,925.8 (1,329.9 to 2,651.6)	16.9 (12.8 to 20.6)
Diabetes mellitus	6,002.8 (5,719.9 to 6,314.8)	9,403.0 (8,842.0 to 10,011.3)	56.8 (44.7 to 67.7)	293.7 (188.7 to 433.1)	459.2 (291.6 to 674.3)	56.6 (44.4 to 68.0)
Acute glomerulonephritis	2.3 (2.0 to 2.6)	2.1 (1.8 to 2.5)	-7.9 (-11.8 to -4.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-8.0 (-11.9 to -4.9)
Chronic kidney disease	-	-	-	312.9 (216.2 to 416.4)	371.4 (256.2 to 494.9)	18.7 (11.2 to 26.8)
Chronic kidney disease due to diabetes mellitus	1,072.7 (671.3 to 1,592.9)	1,376.6 (871.8 to 2,037.3)	28.5 (13.3 to 45.6)	22.8 (15.5 to 31.4)	29.4 (20.1 to 40.8)	29.4 (6.7 to 59.0)
Chronic kidney disease due to hypertension	5,534.1 (3,398.9 to 8,368.0)	6,030.6 (3,723.4 to 9,049.3)	9.4 (-3.1 to 23.0)	71.0 (48.0 to 96.6)	83.5 (58.5 to 111.9)	17.8 (1.2 to 37.5)
Chronic kidney disease due to glomerulonephritis	4,197.8 (2,728.9 to 6,245.1)	5,031.5 (3,270.6 to 7,478.4)	19.7 (8.5 to 33.4)	101.1 (70.6 to 134.8)	104.0 (71.7 to 140.8)	2.7 (-10.9 to 20.3)
Chronic kidney disease due to other causes	6,428.8 (4,028.9 to 9,726.4)	8,394.2 (5,393.4 to 12,585.8)	31.1 (18.4 to 42.3)	118.0 (81.1 to 159.6)	154.4 (103.5 to 212.3)	30.9 (14.4 to 48.1)
Urinary diseases and male infertility	-	-	-	14.3 (9.4 to 20.6)	17.5 (10.9 to 26.0)	23.4 (2.5 to 42.6)
Interstitial nephritis and urinary tract infections	91.5 (87.8 to 94.9)	121.5 (116.5 to 126.0)	32.9 (26.9 to 40.9)	3.1 (1.9 to 4.7)	4.1 (2.5 to 6.3)	33.3 (11.0 to 57.9)
Urolithiasis	531.9 (417.0 to 745.5)	537.3 (355.7 to 808.0)	4.2 (-21.1 to 14.2)	7.3 (4.6 to 10.6)	7.7 (4.6 to 11.5)	5.4 (-12.3 to 23.7)
Benign prostatic hyperplasia	-	-	-	-	-	-
Male infertility due to other causes	-	-	-	-	-	-
Other urinary diseases	-	-	-	3.9 (2.4 to 6.0)	5.7 (3.0 to 8.9)	53.5 (3.1 to 90.0)
Gynecological diseases	-	-	-	404.5 (264.7 to 582.3)	451.9 (293.2 to 658.8)	11.4 (3.6 to 21.7)
Uterine fibroids	591.6 (436.7 to 736.7)	667.2 (489.1 to 841.8)	12.7 (10.7 to 15.0)	16.0 (8.9 to 26.5)	16.9 (9.3 to 28.0)	5.5 (-5.3 to 14.9)
Polycystic ovarian syndrome	5,159.6 (4,895.6 to 5,447.6)	6,263.2 (5,937.2 to 6,607.5)	21.2 (13.2 to 30.0)	50.5 (23.9 to 94.3)	61.7 (28.7 to 117.3)	22.0 (13.4 to 31.2)
Female infertility due to other causes	1,691.0 (1,266.6 to 2,239.2)	2,329.8 (1,640.8 to 3,068.7)	36.9 (-9.9 to 108.3)	11.9 (4.9 to 24.7)	16.2 (6.5 to 33.9)	35.5 (-12.8 to 108.5)
Endometriosis	191.6 (182.6 to 201.3)	209.4 (199.5 to 219.5)	9.2 (2.5 to 17.8)	18.1 (12.0 to 25.3)	19.9 (13.2 to 27.4)	9.7 (-6.6 to 27.9)
Genital prolapse	3,755.8 (3,493.4 to 4,027.2)	4,510.2 (4,175.5 to 4,911.7)	19.5 (8.0 to 34.7)	12.2 (6.0 to 22.5)	14.6 (7.1 to 27.3)	19.6 (6.1 to 37.2)
Premenstrual syndrome	23,566.7 (20,711.8 to 26,580.7)	28,501.3 (25,637.2 to 31,339.9)	20.5 (7.4 to 38.5)	200.9 (123.8 to 303.4)	243.2 (151.3 to 364.1)	20.5 (6.7 to 39.8)
Other gynecological diseases	3,027.5 (2,841.9 to 3,204.1)	2,742.8 (2,601.4 to 2,901.8)	-9.6 (-16.2 to -0.7)	94.9 (62.4 to 135.8)	79.4 (52.6 to 115.3)	-16.8 (-25.3 to -2.1)
Hemoglobinopathies and hemolytic anemias	-	-	-	473.6 (317.8 to 691.5)	506.4 (336.5 to 732.7)	6.9 (2.5 to 12.1)
Thalassemias	78.1 (68.8 to 89.5)	91.7 (81.9 to 102.4)	17.2 (12.5 to 24.2)	6.2 (4.1 to 8.7)	6.7 (4.5 to 9.5)	8.7 (-3.1 to 23.4)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (15-19 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Thalassemia trait	15,037.3 (13,678.2 to 16,897.0)	17,454.5 (16,306.7 to 18,914.5)	16.5 (11.6 to 19.7)	216.5 (145.3 to 315.9)	255.2 (168.6 to 373.0)	17.9 (11.3 to 24.4)
Sickle cell disorders	222.9 (203.8 to 240.2)	408.8 (379.0 to 439.6)	83.1 (71.6 to 99.0)	26.4 (18.2 to 35.8)	48.0 (33.8 to 64.2)	82.2 (59.9 to 107.0)
Sickle cell trait	16,528.2 (15,688.3 to 17,297.6)	25,032.2 (23,849.3 to 26,100.6)	51.4 (48.7 to 54.0)	70.2 (45.6 to 101.8)	95.0 (62.3 to 137.4)	35.5 (23.0 to 50.8)
G6PD deficiency	23,242.3 (22,656.2 to 23,799.2)	30,894.9 (30,080.2 to 31,688.0)	32.9 (28.3 to 37.6)	2.3 (1.5 to 3.2)	2.7 (1.8 to 3.8)	20.0 (7.1 to 35.9)
G6PD trait	83,168.6 (82,615.2 to 83,609.6)	99,193.5 (98,451.2 to 99,836.9)	19.2 (18.3 to 20.5)	4.0 (2.5 to 6.0)	4.7 (2.7 to 7.6)	17.4 (-24.9 to 74.0)
Other hemoglobinopathies and hemolytic anemias	6,491.9 (6,351.6 to 6,651.9)	4,985.1 (4,799.4 to 5,134.6)	-23.1 (-26.7 to -20.3)	148.2 (96.7 to 217.9)	94.1 (60.5 to 141.6)	-36.8 (-44.4 to -29.3)
Endocrine, metabolic, blood, and immune disorders	5,427.7 (5,207.3 to 5,645.3)	4,625.7 (4,521.4 to 4,732.8)	-14.8 (-18.7 to -11.0)	150.2 (101.8 to 214.2)	119.3 (80.2 to 171.7)	-20.6 (-28.0 to -12.2)
Musculoskeletal disorders	-	-	-	3,979.1 (2,718.1 to 5,402.2)	4,593.1 (3,155.4 to 6,244.8)	15.3 (10.0 to 21.5)
Rheumatoid arthritis	463.3 (455.5 to 471.3)	555.4 (546.3 to 564.8)	19.9 (17.3 to 22.6)	115.8 (79.9 to 154.7)	138.9 (96.9 to 186.7)	19.9 (11.4 to 29.3)
Osteoarthritis	-	-	-	-	-	-
Low back and neck pain	-	-	-	3,704.7 (2,547.0 to 5,052.2)	4,210.6 (2,870.4 to 5,784.1)	13.5 (8.0 to 19.7)
Low back pain	22,492.7 (21,641.6 to 23,452.8)	26,276.1 (25,283.6 to 27,247.1)	16.7 (10.0 to 23.8)	2,609.6 (1,774.0 to 3,635.0)	3,053.0 (2,051.8 to 4,255.7)	17.0 (9.8 to 24.0)
Neck pain	10,757.3 (10,093.3 to 11,691.2)	11,372.8 (10,447.9 to 12,732.3)	5.5 (-6.2 to 19.9)	1,095.2 (746.8 to 1,531.9)	1,157.6 (793.4 to 1,628.7)	5.5 (-6.1 to 19.9)
Gout	4.4 (4.2 to 4.6)	4.4 (4.2 to 4.6)	0.7 (-5.5 to 6.7)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	0.6 (-5.6 to 6.6)
Other musculoskeletal disorders	1,651.1 (1,058.9 to 2,555.0)	2,527.0 (1,475.6 to 4,001.4)	51.0 (27.5 to 84.4)	158.4 (88.5 to 266.1)	243.5 (122.6 to 426.5)	51.8 (25.4 to 87.3)
Other non-communicable diseases	-	-	-	6,449.5 (4,012.7 to 9,878.4)	7,430.4 (4,657.2 to 11,358.3)	15.3 (10.3 to 19.7)
Congenital anomalies	-	-	-	448.8 (330.9 to 582.4)	613.5 (442.6 to 795.0)	36.8 (26.6 to 48.3)
Neural tube defects	101.7 (99.4 to 104.5)	149.5 (145.7 to 153.7)	47.1 (42.0 to 51.9)	31.6 (22.3 to 41.1)	47.3 (33.1 to 62.3)	49.1 (35.0 to 68.0)
Congenital heart anomalies	1,715.1 (1,658.0 to 1,777.0)	2,862.4 (2,750.0 to 3,003.6)	66.6 (58.9 to 76.9)	60.5 (25.7 to 104.3)	102.3 (43.7 to 174.6)	68.7 (59.9 to 80.8)
Orofacial clefts	298.3 (287.2 to 308.0)	504.1 (484.4 to 524.0)	68.8 (60.3 to 79.1)	4.1 (2.7 to 5.9)	6.4 (4.2 to 9.3)	58.2 (36.0 to 83.5)
Down syndrome	436.2 (419.6 to 455.2)	629.5 (604.5 to 657.4)	44.2 (36.6 to 52.3)	48.3 (34.7 to 63.2)	69.6 (51.1 to 90.2)	44.3 (32.3 to 56.8)
Turner syndrome	19.5 (18.5 to 20.6)	25.4 (24.1 to 27.0)	30.0 (22.3 to 40.7)	0.4 (0.2 to 0.6)	0.5 (0.2 to 0.8)	30.2 (14.6 to 49.6)
Klinefelter syndrome	15.1 (14.2 to 15.8)	18.3 (17.4 to 19.2)	21.0 (13.1 to 31.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	20.9 (13.0 to 31.0)
Chromosomal unbalanced rearrangements	596.6 (575.6 to 614.3)	835.9 (795.8 to 883.7)	39.9 (32.6 to 49.0)	65.8 (47.8 to 85.7)	92.3 (66.7 to 120.5)	40.1 (29.6 to 51.4)
Other congenital anomalies	1,996.8 (1,691.3 to 2,282.5)	2,112.8 (1,768.3 to 2,441.7)	5.6 (-1.0 to 13.0)	238.1 (164.2 to 328.3)	295.0 (205.1 to 404.2)	23.7 (11.5 to 40.4)
Skin and subcutaneous diseases	-	-	-	4,180.5 (2,473.9 to 6,801.2)	4,869.3 (2,863.5 to 7,940.8)	16.5 (10.0 to 23.0)
Dermatitis	23,306.0 (18,430.0 to 28,867.7)	26,443.1 (21,015.3 to 32,498.5)	13.6 (11.3 to 15.5)	715.1 (452.8 to 1,041.8)	826.4 (524.4 to 1,190.6)	15.6 (12.9 to 18.3)
Psoriasis	3,114.0 (2,709.8 to 3,539.1)	3,576.9 (3,108.0 to 4,077.9)	14.9 (14.1 to 15.5)	261.4 (175.3 to 370.6)	300.8 (203.1 to 431.8)	14.8 (9.5 to 21.0)
Cellulitis	73.6 (50.0 to 109.5)	77.4 (52.7 to 112.0)	5.6 (-1.1 to 11.3)	5.5 (3.0 to 9.3)	5.7 (3.2 to 9.4)	5.5 (-6.3 to 19.0)
Pyoderma	423.3 (299.4 to 599.8)	358.8 (249.6 to 524.0)	-15.5 (-26.0 to -2.1)	2.4 (0.9 to 5.5)	2.0 (0.7 to 4.6)	-15.2 (-28.3 to -0.1)
Scabies	6,542.7 (5,956.4 to 7,304.5)	7,168.8 (6,509.4 to 8,147.7)	8.4 (-5.8 to 31.2)	169.8 (96.6 to 273.8)	186.5 (105.1 to 303.9)	8.3 (-6.2 to 32.1)
Fungal skin diseases	51,694.1 (39,574.7 to 65,145.7)	60,876.0 (47,196.5 to 76,590.4)	17.8 (14.3 to 20.9)	294.5 (113.5 to 658.2)	346.9 (133.1 to 773.3)	17.8 (14.2 to 20.9)
Viral skin diseases	15,875.4 (13,122.9 to 18,716.1)	17,909.9 (14,782.3 to 21,112.8)	12.8 (10.8 to 15.0)	493.1 (299.9 to 735.2)	557.0 (339.8 to 828.5)	12.9 (10.5 to 15.9)
Acne vulgaris	171,409.4 (158,186.5 to 186,918.1)	199,256.1 (179,751.6 to 218,626.7)	16.4 (3.5 to 30.8)	1,864.5 (889.0 to 3,467.6)	2,170.6 (1,030.9 to 4,054.1)	16.5 (3.5 to 30.8)
Alopecia areata	375.5 (365.0 to 385.9)	427.3 (413.6 to 441.1)	13.8 (9.5 to 18.4)	12.9 (8.2 to 19.6)	14.6 (9.1 to 22.1)	13.9 (2.5 to 26.2)
Pruritus	27.9 (26.2 to 29.8)	29.5 (27.1 to 32.3)	5.9 (-6.1 to 17.7)	0.3 (0.1 to 0.6)	0.3 (0.2 to 0.6)	4.8 (-18.5 to 39.4)
Urticaria	4,303.8 (3,941.8 to 4,685.6)	5,656.4 (4,902.1 to 6,514.0)	29.9 (14.6 to 55.1)	263.2 (168.2 to 379.5)	346.1 (212.1 to 508.8)	30.3 (13.2 to 55.6)
Decubitus ulcer	22.6 (21.8 to 23.6)	20.8 (19.8 to 21.9)	-7.8 (-12.3 to -3.5)	3.8 (2.5 to 5.1)	3.5 (2.4 to 4.8)	-7.8 (-12.4 to -3.4)
Other skin and subcutaneous diseases	15,736.1 (2,789.5 to 36,224.0)	18,199.0 (3,263.6 to 41,836.7)	15.6 (13.1 to 17.9)	94.1 (15.2 to 267.8)	108.9 (17.6 to 308.7)	15.7 (12.2 to 18.8)
Sense organ diseases	-	-	-	1,300.9 (847.4 to 1,884.3)	1,351.9 (892.8 to 1,946.9)	4.0 (-1.8 to 8.9)
Glaucoma	-	-	-	-	-	-
Cataract	-	-	-	-	-	-
Macular degeneration	-	-	-	-	-	-
Uncorrected refractive error	18,305.0 (17,571.2 to 19,061.4)	20,747.0 (19,988.2 to 21,600.0)	13.3 (9.5 to 17.1)	364.6 (228.5 to 552.3)	401.4 (250.2 to 619.2)	10.0 (6.2 to 13.7)
Age-related and other hearing loss	13,774.7 (10,790.5 to 17,633.9)	14,697.3 (11,373.6 to 18,671.4)	6.5 (0.9 to 13.2)	658.9 (402.8 to 1,021.7)	655.7 (395.7 to 1,014.4)	-0.5 (-9.7 to 8.9)
Other vision loss	1,278.6 (1,019.0 to 1,581.9)	1,136.8 (902.5 to 1,405.9)	-11.1 (-15.0 to -7.0)	68.8 (43.8 to 101.2)	55.8 (34.9 to 83.7)	-18.9 (-26.5 to -11.4)
Other sense organ diseases	7,740.1 (7,584.3 to 7,893.7)	8,857.6 (8,657.7 to 9,056.9)	14.4 (11.2 to 18.0)	208.6 (128.6 to 310.2)	238.9 (147.7 to 356.4)	14.5 (9.8 to 19.7)
Oral disorders	-	-	-	519.3 (289.8 to 857.9)	595.7 (331.3 to 979.0)	14.7 (11.7 to 17.4)
Deciduous caries	-	-	-	-	-	-
Permanent caries	255,773.5 (252,169.6 to 259,406.6)	284,691.1 (279,802.0 to 289,502.2)	11.3 (8.8 to 13.8)	237.7 (109.6 to 460.1)	270.7 (123.0 to 523.3)	13.8 (10.9 to 16.8)
Periodontal diseases	4,457.1 (4,354.4 to 4,566.4)	5,691.8 (5,524.8 to 5,846.8)	27.8 (22.8 to 32.5)	29.8 (11.9 to 61.1)	38.1 (15.3 to 78.1)	27.9 (22.1 to 33.6)
Edentulism and severe tooth loss	-	-	-	-	-	-
Other oral disorders	8,449.0 (8,244.0 to 8,691.1)	9,618.1 (9,298.6 to 9,954.1)	13.8 (9.2 to 18.5)	251.8 (156.7 to 377.4)	286.9 (178.0 to 433.9)	13.9 (8.9 to 18.8)
Injuries	-	-	-	1,647.1 (1,223.7 to 2,214.6)	1,068.3 (828.4 to 1,359.1)	-34.2 (-47.8 to -24.9)
Transport injuries	-	-	-	420.4 (327.2 to 532.2)	308.9 (239.7 to 394.4)	-26.6 (-30.7 to -21.7)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (15-19 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Road injuries	-	-	-	360.2 (280.7 to 456.7)	268.7 (208.1 to 343.8)	-25.5 (-30.0 to -20.4)
Pedestrian road injuries	-	-	-	110.0 (83.6 to 142.1)	85.7 (64.6 to 110.9)	-22.2 (-28.3 to -14.9)
Cyclist road injuries	-	-	-	37.5 (28.5 to 48.9)	24.2 (18.3 to 31.7)	-35.6 (-39.7 to -31.2)
Motorcyclist road injuries	-	-	-	62.5 (48.8 to 79.3)	34.4 (26.6 to 44.0)	-45.0 (-49.3 to -40.6)
Motor vehicle road injuries	-	-	-	146.1 (114.3 to 183.1)	121.2 (94.1 to 153.3)	-17.2 (-22.4 to -11.4)
Other road injuries	-	-	-	4.1 (3.1 to 5.3)	3.2 (2.4 to 4.1)	-23.0 (-28.6 to -16.8)
Other transport injuries	-	-	-	60.2 (46.2 to 76.6)	40.2 (30.9 to 51.4)	-33.2 (-37.3 to -28.9)
Unintentional injuries	-	-	-	749.2 (577.7 to 952.7)	660.1 (503.5 to 855.8)	-11.9 (-15.3 to -8.4)
Falls	-	-	-	263.0 (200.5 to 338.1)	251.5 (186.5 to 329.1)	-4.4 (-10.0 to 2.2)
Drowning	-	-	-	30.0 (21.8 to 39.0)	16.7 (12.4 to 22.0)	-44.1 (-48.4 to -39.4)
Fire, heat, and hot substances	-	-	-	67.6 (51.9 to 86.6)	53.7 (40.9 to 69.6)	-20.6 (-29.2 to -11.9)
Poisonings	-	-	-	6.2 (4.3 to 8.3)	4.1 (2.9 to 5.6)	-32.7 (-38.8 to -26.7)
Exposure to mechanical forces	-	-	-	245.1 (185.4 to 321.5)	203.6 (152.7 to 273.3)	-17.1 (-20.4 to -13.6)
Unintentional firearm injuries	-	-	-	8.5 (6.6 to 10.6)	7.1 (5.4 to 9.0)	-16.9 (-22.1 to -12.0)
Unintentional suffocation	-	-	-	3.0 (2.3 to 3.9)	3.1 (2.4 to 4.0)	2.3 (-3.3 to 8.2)
Other exposure to mechanical forces	-	-	-	233.6 (175.9 to 306.9)	193.4 (144.6 to 259.6)	-17.3 (-20.7 to -13.7)
Adverse effects of medical treatment	-	-	-	5.6 (3.6 to 8.2)	6.0 (3.8 to 8.8)	7.4 (3.3 to 11.7)
Animal contact	-	-	-	32.7 (24.4 to 42.5)	23.5 (17.3 to 30.9)	-28.2 (-33.7 to -22.2)
Venomous animal contact	-	-	-	13.7 (9.9 to 18.4)	10.2 (7.3 to 13.9)	-25.4 (-33.9 to -14.3)
Non-venomous animal contact	-	-	-	19.1 (13.9 to 26.2)	13.3 (9.6 to 18.1)	-30.4 (-35.0 to -24.9)
Foreign body	-	-	-	10.4 (7.5 to 13.7)	9.8 (6.9 to 13.3)	-5.3 (-11.6 to 0.2)
Pulmonary aspiration and foreign body in airway	-	-	-	3.2 (2.4 to 4.0)	2.2 (1.7 to 2.9)	-29.4 (-34.9 to -22.6)
Foreign body in eyes	-	-	-	2.9 (1.5 to 4.7)	3.2 (1.6 to 5.3)	11.6 (4.7 to 18.0)
Foreign body in other body part	-	-	-	4.3 (3.2 to 5.7)	4.4 (3.2 to 5.8)	1.1 (-3.5 to 6.6)
Other unintentional injuries	-	-	-	88.5 (67.7 to 113.8)	91.1 (69.0 to 117.4)	2.9 (-2.1 to 7.5)
Self-harm and interpersonal violence	-	-	-	48.7 (37.5 to 62.0)	37.4 (29.0 to 47.5)	-23.2 (-27.2 to -18.4)
Self-harm	-	-	-	5.8 (4.4 to 7.5)	3.9 (3.0 to 5.1)	-32.1 (-35.9 to -28.0)
Interpersonal violence	-	-	-	42.9 (33.3 to 54.3)	33.5 (26.0 to 42.2)	-22.0 (-26.4 to -16.9)
Assault by firearm	-	-	-	6.4 (4.9 to 8.1)	5.7 (4.3 to 7.3)	-11.3 (-16.2 to -6.1)
Assault by sharp object	-	-	-	7.8 (6.1 to 9.8)	6.8 (5.2 to 8.7)	-12.9 (-18.4 to -7.4)
Assault by other means	-	-	-	28.7 (22.1 to 36.4)	21.0 (16.2 to 26.7)	-26.9 (-31.4 to -21.5)
Forces of nature, war, and legal intervention	-	-	-	428.9 (191.8 to 872.6)	61.9 (32.5 to 116.5)	-85.5 (-90.4 to -75.6)
Exposure to forces of nature	-	-	-	21.8 (12.8 to 41.1)	20.7 (10.6 to 45.9)	-7.9 (-29.1 to 26.3)
Collective violence and legal intervention	-	-	-	407.1 (174.4 to 838.2)	41.2 (19.8 to 84.2)	-89.9 (-93.1 to -83.0)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (20-24 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
All causes	-	-	-	42,295.9 (31,206.6 to 55,046.9)	51,278.1 (37,854.5 to 66,955.3)	21.2 (19.4 to 23.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	6,736.0 (4,665.8 to 9,469.8)	6,918.4 (4,915.3 to 9,539.3)	2.7 (-0.8 to 7.2)
HIV/AIDS and tuberculosis	-	-	-	331.1 (225.5 to 448.5)	445.7 (308.4 to 590.1)	34.5 (27.0 to 43.3)
Tuberculosis	703.4 (656.5 to 752.0)	812.4 (766.2 to 859.3)	15.6 (13.2 to 18.9)	220.8 (147.0 to 306.2)	255.9 (172.5 to 351.4)	16.0 (8.5 to 24.3)
HIV/AIDS	-	-	-	110.3 (77.3 to 145.1)	189.8 (133.4 to 255.2)	71.9 (56.3 to 89.8)
HIV/AIDS resulting in mycobacterial infection	12.8 (8.0 to 18.0)	28.9 (18.5 to 38.6)	128.1 (97.9 to 156.0)	5.0 (2.7 to 7.8)	11.1 (6.3 to 17.3)	124.4 (89.3 to 162.9)
HIV/AIDS resulting in other diseases	1,312.1 (1,202.9 to 1,434.8)	2,020.0 (1,899.1 to 2,215.2)	54.2 (42.1 to 67.5)	105.3 (73.6 to 139.8)	178.7 (124.8 to 240.2)	69.3 (53.8 to 88.5)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	808.9 (572.0 to 1,097.3)	882.2 (609.1 to 1,218.7)	8.9 (3.6 to 14.6)
Diarrheal diseases	1,530.5 (1,439.6 to 1,620.9)	1,564.2 (1,457.4 to 1,665.4)	2.4 (-5.7 to 11.5)	245.4 (166.1 to 339.0)	251.8 (170.4 to 348.2)	2.7 (-7.3 to 13.5)
Intestinal infectious diseases	-	-	-	19.2 (12.1 to 27.8)	15.2 (9.7 to 22.1)	-20.8 (-45.5 to 11.2)
Typhoid fever	111.1 (91.2 to 133.4)	90.8 (74.7 to 108.4)	-18.0 (-40.4 to 10.4)	14.5 (8.9 to 21.7)	11.9 (7.3 to 17.9)	-17.5 (-46.6 to 20.9)
Paratyphoid fever	66.6 (51.4 to 82.7)	53.0 (39.9 to 66.6)	-20.6 (-43.5 to 15.0)	3.4 (2.0 to 5.3)	2.8 (1.6 to 4.5)	-19.3 (-47.8 to 34.4)
Other intestinal infectious diseases	-	-	-	1.3 (0.6 to 2.5)	0.5 (0.2 to 1.0)	-59.3 (-69.4 to -45.8)
Lower respiratory infections	111.6 (107.2 to 115.4)	97.2 (92.3 to 102.2)	-13.1 (-17.8 to -6.9)	11.7 (7.8 to 16.6)	10.2 (6.8 to 14.6)	-12.6 (-24.7 to 0.9)
Upper respiratory infections	16,083.6 (15,743.2 to 16,444.8)	22,040.2 (21,564.0 to 22,453.9)	37.4 (33.4 to 41.7)	189.1 (105.2 to 312.0)	260.1 (145.0 to 434.2)	37.4 (32.5 to 42.5)
Otitis media	6,439.2 (6,029.8 to 6,874.9)	7,352.2 (6,802.0 to 7,889.6)	14.4 (9.2 to 19.6)	125.7 (74.7 to 201.1)	144.6 (84.2 to 226.2)	15.0 (7.9 to 22.2)
Meningitis	-	-	-	185.9 (130.8 to 248.4)	170.7 (120.3 to 226.7)	-8.1 (-15.4 to 0.1)
Pneumococcal meningitis	826.2 (526.3 to 1,188.3)	744.3 (490.3 to 1,080.6)	-9.9 (-15.5 to -1.8)	75.7 (53.5 to 100.9)	73.0 (51.4 to 97.4)	-3.8 (-15.5 to 11.5)
H influenzae type B meningitis	402.4 (159.6 to 724.6)	326.8 (147.2 to 584.9)	-18.4 (-25.2 to -8.3)	43.0 (29.5 to 59.4)	39.7 (26.9 to 54.0)	-8.2 (-20.9 to 11.4)
Meningococcal meningitis	150.5 (55.7 to 326.8)	116.0 (49.6 to 242.6)	-22.3 (-29.3 to -10.4)	18.4 (12.2 to 26.7)	15.3 (10.4 to 21.8)	-16.6 (-26.0 to -1.7)
Other meningitis	410.8 (197.1 to 727.5)	327.7 (192.7 to 550.5)	-19.4 (-27.2 to -4.2)	48.9 (33.5 to 67.7)	42.8 (29.6 to 58.1)	-12.7 (-24.7 to 2.6)
Encephalitis	148.8 (68.7 to 311.9)	131.3 (67.3 to 281.5)	-10.7 (-24.8 to 0.8)	19.1 (13.1 to 26.1)	19.2 (13.5 to 25.6)	0.6 (-12.2 to 14.7)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-41.8 (-81.4 to 143.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.0 (-81.5 to 143.6)
Whooping cough	8.1 (6.3 to 10.4)	6.6 (5.1 to 8.4)	-18.5 (-19.1 to -17.9)	0.4 (0.2 to 0.7)	0.3 (0.2 to 0.5)	-18.5 (-20.8 to -16.7)
Tetanus	117.1 (84.8 to 173.9)	14.9 (9.6 to 22.9)	-87.4 (-92.8 to -78.0)	4.3 (2.8 to 6.4)	1.1 (0.7 to 1.9)	-75.3 (-84.2 to -57.4)
Measles	3.3 (2.5 to 4.2)	0.9 (0.7 to 1.2)	-71.5 (-73.9 to -69.0)	0.3 (0.2 to 0.5)	0.1 (0.1 to 0.1)	-71.6 (-74.0 to -69.1)
Varicella and herpes zoster	186.0 (172.8 to 203.0)	228.6 (213.7 to 250.9)	23.6 (9.8 to 37.1)	7.8 (4.7 to 11.7)	8.8 (5.4 to 13.5)	13.3 (-0.9 to 28.6)
Neglected tropical diseases and malaria	-	-	-	1,657.6 (1,079.0 to 2,447.2)	1,467.7 (966.9 to 2,206.4)	-11.7 (-17.5 to -3.2)
Malaria	24,727.7 (24,108.3 to 25,366.5)	32,324.1 (31,471.9 to 33,171.6)	31.1 (27.3 to 34.8)	146.3 (96.6 to 212.0)	181.6 (121.3 to 260.3)	24.0 (17.4 to 32.1)
Chagas disease	601.6 (587.0 to 616.5)	746.9 (728.0 to 766.5)	24.5 (19.9 to 28.6)	3.4 (2.2 to 4.8)	4.2 (2.7 to 6.0)	24.6 (12.3 to 38.2)
Leishmaniasis	-	-	-	1.7 (0.9 to 3.1)	4.6 (2.3 to 8.5)	163.2 (132.2 to 201.4)
Visceral leishmaniasis	4.0 (3.1 to 5.2)	6.3 (5.0 to 8.1)	57.9 (20.0 to 108.3)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.7)	57.6 (19.7 to 106.5)
Cutaneous and mucocutaneous leishmaniasis	134.2 (111.7 to 162.0)	381.6 (317.8 to 461.1)	184.1 (149.1 to 226.2)	1.4 (0.7 to 2.8)	4.1 (1.9 to 8.0)	184.9 (148.4 to 229.9)
African trypanosomiasis	10.4 (4.6 to 20.7)	3.0 (1.6 to 5.3)	-70.0 (-74.4 to -64.6)	2.9 (1.2 to 5.7)	0.8 (0.3 to 1.6)	-70.9 (-80.5 to -55.3)
Schistosomiasis	25,533.6 (22,892.2 to 28,059.5)	34,762.6 (29,978.7 to 40,897.0)	34.7 (25.9 to 57.8)	250.5 (127.1 to 471.2)	347.7 (173.6 to 681.1)	36.9 (28.3 to 61.3)
Cysticercosis	198.7 (168.0 to 234.5)	142.6 (117.0 to 174.4)	-28.7 (-42.6 to -8.4)	57.3 (39.0 to 77.3)	43.6 (29.0 to 59.8)	-24.3 (-41.4 to -1.0)
Cystic echinococcosis	77.5 (70.9 to 84.4)	57.9 (55.3 to 62.0)	-25.5 (-28.9 to -18.8)	7.4 (4.8 to 10.5)	5.6 (3.7 to 7.9)	-24.7 (-36.9 to -8.1)
Lymphatic filariasis	6,520.5 (5,978.5 to 7,225.9)	3,733.5 (3,246.7 to 4,329.3)	-42.6 (-49.2 to -35.8)	135.0 (65.2 to 238.7)	114.7 (60.5 to 195.9)	-13.9 (-37.5 to 12.9)
Onchocerciasis	2,835.7 (1,766.3 to 4,427.2)	2,089.0 (1,283.1 to 3,479.4)	-26.3 (-36.7 to -15.5)	144.5 (69.6 to 242.6)	120.0 (52.4 to 209.3)	-18.1 (-30.2 to -3.5)
Trachoma	1.8 (1.2 to 2.5)	1.6 (1.1 to 2.4)	-9.4 (-30.2 to 14.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	10.7 (-19.9 to 55.7)
Dengue	48.3 (17.7 to 108.4)	327.4 (120.9 to 734.4)	580.0 (572.6 to 587.8)	7.9 (2.5 to 20.0)	53.8 (18.2 to 134.4)	580.2 (436.3 to 767.5)
Yellow fever	0.5 (0.2 to 1.1)	0.2 (0.1 to 0.5)	-57.6 (-69.1 to -37.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.7 (-69.2 to -37.7)
Rabies	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-34.4 (-49.2 to -17.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.5 (-49.3 to -17.1)
Intestinal nematode infections	-	-	-	601.7 (345.0 to 970.3)	341.8 (198.4 to 547.1)	-43.0 (-48.0 to -37.1)
Ascariasis	114,274.9 (95,262.1 to 138,708.0)	77,631.2 (66,761.2 to 91,340.4)	-31.8 (-46.6 to -13.0)	273.5 (149.8 to 456.3)	85.9 (47.1 to 147.7)	-68.6 (-73.6 to -62.8)
Trichuriasis	57,777.2 (46,562.9 to 73,375.5)	45,521.1 (41,070.0 to 50,555.0)	-19.9 (-39.7 to 0.9)	83.3 (46.2 to 138.6)	58.5 (30.8 to 100.1)	-30.5 (-45.2 to -6.5)
Hookworm disease	55,389.9 (46,278.5 to 67,355.3)	48,143.5 (43,789.9 to 53,234.1)	-12.2 (-29.7 to 6.6)	245.0 (146.8 to 392.1)	197.3 (118.4 to 310.0)	-19.3 (-27.4 to -10.1)
Food-borne trematodiasis	5,255.8 (4,031.1 to 6,613.6)	5,111.8 (3,878.7 to 6,387.1)	-1.9 (-14.2 to 6.3)	230.8 (72.6 to 481.8)	197.4 (73.3 to 396.9)	-11.8 (-31.6 to 5.1)
Other neglected tropical diseases	2,379.0 (2,300.1 to 2,458.0)	1,842.2 (1,769.6 to 1,913.1)	-22.4 (-26.0 to -18.7)	68.3 (39.4 to 118.1)	51.8 (27.7 to 93.1)	-25.1 (-36.0 to -9.8)
Maternal disorders	-	-	-	219.8 (147.5 to 306.0)	237.4 (160.0 to 328.0)	8.3 (-4.6 to 21.0)
Maternal hemorrhage	492.2 (464.6 to 525.1)	530.4 (496.8 to 566.5)	8.0 (-1.1 to 18.1)	19.9 (13.4 to 28.3)	19.2 (13.0 to 27.2)	-3.2 (-18.4 to 12.0)
Maternal sepsis and other maternal infections	200.8 (119.3 to 323.1)	145.3 (86.0 to 238.2)	-27.4 (-39.1 to -14.4)	7.5 (3.8 to 12.6)	5.3 (2.7 to 8.8)	-28.9 (-49.6 to 0.9)
Maternal hypertensive disorders	481.8 (231.6 to 812.2)	455.5 (229.9 to 764.3)	-5.8 (-10.3 to 5.5)	24.2 (10.2 to 44.4)	23.0 (10.1 to 40.8)	-5.3 (-13.6 to 7.7)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (20-24 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Obstructed labor	387.3 (304.2 to 478.8)	435.8 (359.2 to 516.7)	12.8 (3.3 to 23.2)	127.8 (82.5 to 183.9)	145.1 (94.6 to 204.0)	13.6 (-1.6 to 31.1)
Complications of abortion	6.1 (4.1 to 8.3)	5.9 (3.9 to 8.1)	-0.7 (-17.7 to 11.0)	0.7 (0.4 to 1.1)	0.7 (0.4 to 1.1)	-0.2 (-19.6 to 14.4)
Other maternal disorders	-	-	-	39.6 (24.9 to 57.9)	44.2 (29.1 to 66.6)	13.9 (-19.9 to 49.7)
Neonatal disorders	-	-	-	487.8 (357.6 to 628.9)	1,164.7 (854.8 to 1,493.4)	138.3 (113.9 to 168.8)
Preterm birth complications	1,879.3 (1,649.1 to 2,156.1)	4,905.0 (4,331.5 to 5,584.2)	161.6 (139.3 to 186.2)	215.8 (156.2 to 276.4)	616.5 (450.8 to 798.1)	185.3 (164.0 to 212.2)
Neonatal encephalopathy due to birth asphyxia and trauma	1,960.1 (775.2 to 3,511.5)	2,014.1 (1,054.4 to 3,386.8)	3.8 (-18.6 to 56.5)	131.6 (92.3 to 183.7)	219.8 (162.3 to 287.9)	67.7 (37.7 to 101.3)
Neonatal sepsis and other neonatal infections	-	-	-	-	-	-
Hemolytic disease and other neonatal jaundice	183.6 (148.7 to 230.4)	456.2 (353.8 to 624.7)	143.4 (81.8 to 296.3)	66.2 (45.3 to 90.9)	149.8 (103.5 to 210.0)	122.9 (70.5 to 236.9)
Other neonatal disorders	-	-	-	74.2 (49.3 to 104.6)	178.6 (122.5 to 249.8)	141.2 (92.1 to 207.2)
Nutritional deficiencies	-	-	-	2,938.6 (1,935.3 to 4,324.0)	2,381.2 (1,566.7 to 3,506.7)	-19.1 (-20.6 to -17.3)
Protein-energy malnutrition	10.2 (5.2 to 16.5)	13.7 (7.2 to 23.3)	32.2 (0.9 to 88.6)	1.3 (0.5 to 2.4)	1.7 (0.7 to 3.5)	30.3 (-20.1 to 110.0)
Iodine deficiency	19,725.9 (18,689.4 to 20,802.9)	15,950.1 (15,079.7 to 16,840.5)	-19.0 (-24.7 to -12.9)	356.1 (219.7 to 566.3)	288.9 (180.3 to 457.8)	-18.9 (-24.7 to -12.6)
Vitamin A deficiency	363.5 (245.7 to 482.5)	295.0 (196.2 to 397.9)	-18.9 (-26.0 to -11.6)	16.9 (10.0 to 26.2)	12.9 (7.1 to 20.2)	-23.8 (-37.7 to -7.7)
Iron-deficiency anemia	97,990.9 (97,764.0 to 98,244.0)	86,634.3 (86,414.5 to 86,827.4)	-11.4 (-11.7 to -11.1)	2,564.2 (1,698.1 to 3,743.6)	2,077.6 (1,368.1 to 3,065.9)	-19.1 (-20.7 to -17.2)
Other nutritional deficiencies	-	-	-	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.3)	-25.6 (-60.6 to 79.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	292.2 (185.8 to 457.7)	339.5 (213.4 to 534.4)	16.1 (10.7 to 21.7)
Sexually transmitted diseases excluding HIV	-	-	-	191.3 (118.1 to 317.6)	246.2 (152.1 to 404.7)	28.6 (21.3 to 36.6)
Syphilis	9.4 (8.9 to 10.0)	6.2 (5.9 to 6.6)	-34.0 (-38.6 to -28.5)	1.9 (1.2 to 2.7)	1.3 (0.8 to 1.8)	-33.2 (-39.1 to -26.0)
Chlamydial infection	26,250.0 (25,394.5 to 27,038.7)	31,258.9 (30,312.9 to 32,273.9)	19.4 (13.9 to 25.3)	110.0 (69.7 to 175.2)	138.6 (87.6 to 218.8)	26.0 (18.0 to 34.9)
Gonococcal infection	6,096.4 (5,700.4 to 6,501.3)	8,304.7 (7,768.6 to 8,791.8)	37.0 (23.8 to 49.2)	39.9 (25.4 to 62.3)	56.1 (35.3 to 86.5)	40.6 (18.6 to 67.6)
Trichomoniasis	7,742.1 (6,804.0 to 8,910.0)	10,758.6 (9,142.5 to 12,660.1)	38.8 (15.4 to 70.6)	13.7 (5.4 to 29.0)	19.2 (7.3 to 40.6)	39.8 (13.9 to 74.5)
Genital herpes	71,651.0 (69,527.4 to 73,817.5)	86,347.5 (83,258.5 to 88,810.8)	21.0 (15.6 to 25.4)	22.6 (7.8 to 53.0)	27.5 (9.6 to 62.8)	21.3 (14.7 to 28.4)
Other sexually transmitted diseases	105.8 (58.2 to 165.3)	100.2 (59.2 to 147.0)	-4.6 (-13.4 to 7.7)	3.2 (2.1 to 4.6)	3.5 (2.3 to 5.0)	10.2 (-13.1 to 42.8)
Hepatitis	-	-	-	42.8 (27.7 to 62.0)	46.0 (29.8 to 67.3)	7.5 (1.5 to 13.6)
Hepatitis A	575.0 (570.7 to 576.0)	698.8 (682.9 to 711.9)	21.7 (19.7 to 24.5)	21.1 (13.4 to 30.8)	25.7 (16.5 to 37.7)	21.9 (13.6 to 31.0)
Hepatitis B	35,002.8 (34,244.4 to 35,744.9)	29,021.5 (28,302.2 to 29,829.5)	-16.8 (-19.7 to -14.2)	11.7 (7.6 to 16.9)	9.5 (6.1 to 13.9)	-18.4 (-25.5 to -10.1)
Hepatitis C	9,881.0 (9,648.6 to 10,122.1)	9,879.5 (9,629.6 to 10,132.1)	0.1 (-3.0 to 3.5)	0.7 (0.4 to 1.0)	0.7 (0.5 to 1.1)	2.0 (-13.7 to 18.8)
Hepatitis E	336.2 (310.5 to 360.3)	356.3 (332.5 to 394.9)	5.8 (-3.2 to 18.7)	9.4 (6.0 to 13.7)	10.1 (6.4 to 14.9)	7.7 (-8.8 to 27.8)
Leprosy	13.8 (12.3 to 15.4)	11.0 (10.1 to 11.9)	-19.3 (-29.6 to -9.5)	0.7 (0.4 to 1.2)	0.7 (0.4 to 1.0)	-9.3 (-37.4 to 28.9)
Other infectious diseases	2,561.0 (2,493.1 to 2,634.9)	2,009.5 (1,942.1 to 2,082.8)	-21.4 (-24.5 to -17.9)	57.3 (37.0 to 86.5)	46.7 (28.1 to 75.6)	-19.1 (-30.2 to -5.0)
Non-communicable diseases	-	-	-	33,403.1 (24,610.0 to 43,596.5)	42,814.2 (31,523.0 to 55,667.7)	28.1 (26.6 to 29.8)
Neoplasms	-	-	-	49.0 (34.9 to 65.9)	65.0 (45.4 to 87.2)	31.6 (18.5 to 52.0)
Esophageal cancer	1.8 (1.4 to 2.4)	2.0 (1.6 to 2.7)	8.4 (-14.0 to 37.8)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	3.5 (-16.8 to 28.7)
Stomach cancer	8.8 (7.8 to 10.0)	6.7 (6.0 to 7.6)	-23.3 (-33.7 to -10.4)	1.2 (0.8 to 1.6)	0.8 (0.6 to 1.1)	-28.1 (-37.3 to -16.2)
Liver cancer	-	-	-	0.9 (0.6 to 1.3)	0.9 (0.6 to 1.3)	-0.5 (-23.1 to 24.5)
Liver cancer due to hepatitis B	2.6 (2.0 to 3.4)	3.1 (2.5 to 3.7)	17.6 (-14.9 to 58.8)	0.5 (0.3 to 0.6)	0.5 (0.3 to 0.7)	8.6 (-17.7 to 39.1)
Liver cancer due to hepatitis C	0.3 (0.2 to 0.3)	1.0 (0.8 to 1.2)	258.6 (163.2 to 382.1)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	230.7 (148.7 to 331.5)
Liver cancer due to alcohol use	0.6 (0.5 to 0.8)	0.4 (0.3 to 0.6)	-26.0 (-47.0 to 9.2)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-31.0 (-48.1 to 1.5)
Liver cancer due to other causes	1.9 (1.5 to 2.4)	1.3 (1.0 to 1.5)	-32.2 (-50.6 to -10.5)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-36.9 (-52.3 to -19.7)
Larynx cancer	2.7 (2.1 to 3.7)	2.1 (1.7 to 2.9)	-21.5 (-36.1 to -0.5)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-18.8 (-33.2 to 2.2)
Tracheal, bronchus and lung cancer	5.3 (4.6 to 6.1)	5.2 (4.6 to 6.0)	-3.9 (-15.9 to 20.7)	0.9 (0.6 to 1.2)	0.9 (0.6 to 1.2)	-9.1 (-19.8 to 14.3)
Breast cancer	26.1 (22.3 to 29.7)	45.5 (37.2 to 54.2)	75.6 (41.7 to 110.1)	2.1 (1.5 to 2.9)	3.4 (2.3 to 4.9)	62.5 (29.3 to 104.2)
Cervical cancer	39.4 (29.3 to 51.2)	28.1 (21.7 to 35.6)	-28.5 (-45.6 to -6.7)	3.0 (1.9 to 4.4)	2.2 (1.4 to 3.2)	-26.8 (-46.7 to -2.3)
Uterine cancer	8.0 (5.3 to 12.8)	6.6 (4.4 to 9.6)	-17.5 (-46.4 to 34.9)	0.5 (0.3 to 0.9)	0.4 (0.2 to 0.7)	-17.3 (-48.1 to 35.6)
Prostate cancer	0.7 (0.5 to 0.9)	1.7 (1.2 to 2.5)	145.5 (109.5 to 184.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	101.0 (71.8 to 132.2)
Colon and rectum cancer	20.2 (18.7 to 22.1)	35.3 (32.0 to 39.0)	75.1 (57.9 to 94.6)	1.9 (1.3 to 2.5)	3.0 (2.1 to 4.1)	61.3 (43.2 to 85.8)
Lip and oral cavity cancer	13.2 (10.0 to 16.2)	16.3 (12.5 to 20.1)	24.0 (-1.9 to 58.9)	1.2 (0.7 to 1.7)	1.4 (0.9 to 2.0)	21.4 (-5.4 to 54.6)
Nasopharynx cancer	12.4 (7.7 to 18.4)	10.9 (6.8 to 15.7)	-11.4 (-50.1 to 53.6)	1.2 (0.7 to 1.9)	1.0 (0.6 to 1.6)	-14.1 (-52.3 to 51.1)
Other pharynx cancer	1.2 (1.0 to 1.4)	1.5 (1.2 to 1.8)	22.5 (0.9 to 52.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	19.9 (-1.1 to 48.8)
Gallbladder and biliary tract cancer	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	34.3 (-5.7 to 90.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	26.0 (-10.8 to 80.1)
Pancreatic cancer	0.8 (0.7 to 0.9)	1.1 (1.0 to 1.3)	43.7 (22.1 to 70.8)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	37.8 (18.6 to 60.5)
Malignant skin melanoma	52.4 (39.3 to 74.2)	86.3 (57.1 to 132.0)	65.4 (1.5 to 159.2)	3.1 (1.8 to 5.1)	5.1 (2.7 to 8.7)	63.4 (-4.9 to 168.4)
Non-melanoma skin cancer	20.9 (16.6 to 30.9)	40.7 (27.8 to 70.6)	87.4 (31.6 to 199.8)	0.7 (0.4 to 1.4)	1.8 (0.8 to 4.0)	126.3 (25.2 to 367.7)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (20-24 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Ovarian cancer	13.3 (11.5 to 15.4)	17.8 (15.0 to 21.4)	32.9 (6.6 to 66.6)	1.8 (1.3 to 2.5)	2.4 (1.6 to 3.3)	31.0 (4.1 to 64.8)
Testicular cancer	39.2 (29.4 to 50.9)	56.7 (39.9 to 74.9)	44.1 (4.9 to 90.1)	2.4 (1.5 to 3.5)	3.4 (2.0 to 5.3)	41.9 (2.7 to 94.3)
Kidney cancer	4.1 (3.6 to 4.6)	6.7 (5.8 to 7.7)	62.5 (40.7 to 91.9)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	54.4 (33.7 to 83.0)
Bladder cancer	2.8 (2.4 to 3.2)	3.3 (2.8 to 3.8)	14.1 (0.1 to 36.6)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	10.5 (-2.6 to 32.1)
Brain and nervous system cancer	34.9 (26.6 to 43.6)	44.2 (34.8 to 55.1)	27.2 (1.7 to 61.9)	3.8 (2.4 to 5.5)	4.7 (3.2 to 6.6)	23.2 (-1.5 to 57.8)
Thyroid cancer	50.8 (36.1 to 68.5)	68.3 (52.5 to 83.7)	35.6 (-5.0 to 87.7)	2.9 (1.7 to 4.8)	3.8 (2.4 to 5.9)	33.6 (-9.0 to 90.2)
Mesothelioma	0.3 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-13.3 (-27.4 to 8.5)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-11.6 (-26.4 to 12.3)
Hodgkin lymphoma	66.5 (44.0 to 89.0)	60.5 (47.8 to 82.2)	-10.3 (-38.9 to 47.9)	5.5 (3.4 to 8.4)	4.8 (3.1 to 7.2)	-14.8 (-42.0 to 44.2)
Non-Hodgkin lymphoma	35.4 (28.0 to 42.6)	57.0 (47.8 to 69.2)	60.7 (31.2 to 101.6)	2.8 (1.9 to 4.0)	4.3 (2.9 to 6.1)	52.5 (24.0 to 92.1)
Multiple myeloma	1.0 (0.8 to 1.4)	1.6 (1.2 to 2.0)	55.1 (15.5 to 92.0)	0.2 (0.2 to 0.3)	0.4 (0.2 to 0.5)	50.9 (13.4 to 83.7)
Leukemia	48.2 (42.2 to 55.3)	69.3 (61.1 to 78.5)	44.1 (21.8 to 72.5)	7.0 (4.9 to 9.4)	9.0 (6.3 to 12.1)	27.5 (6.6 to 52.5)
Other neoplasms	53.5 (45.2 to 64.3)	133.0 (111.0 to 159.7)	151.4 (91.5 to 205.8)	4.0 (2.7 to 5.7)	9.2 (6.1 to 13.2)	131.4 (73.6 to 186.4)
Cardiovascular diseases	-	-	-	236.2 (158.9 to 330.1)	422.8 (272.8 to 623.5)	79.9 (39.9 to 119.7)
Rheumatic heart disease	2,066.5 (1,928.5 to 2,181.7)	2,945.0 (2,824.1 to 3,060.0)	42.7 (32.3 to 55.5)	102.6 (66.6 to 149.1)	143.5 (92.1 to 207.7)	39.8 (29.0 to 52.6)
Ischemic heart disease	15.2 (13.7 to 16.9)	20.7 (18.8 to 23.4)	36.0 (16.5 to 61.5)	1.9 (1.2 to 2.7)	2.5 (1.7 to 3.6)	35.8 (16.2 to 61.4)
Cerebrovascular disease	-	-	-	18.8 (13.0 to 24.7)	26.7 (18.2 to 35.8)	42.3 (29.3 to 56.8)
Ischemic stroke	54.0 (50.4 to 57.4)	83.9 (78.1 to 90.7)	55.7 (41.7 to 73.0)	9.0 (6.2 to 12.4)	13.8 (9.2 to 19.1)	52.6 (33.3 to 77.0)
Hemorrhagic stroke	58.0 (54.7 to 61.0)	77.4 (72.6 to 82.5)	33.4 (22.9 to 46.1)	9.7 (6.6 to 13.4)	12.9 (8.7 to 17.7)	31.8 (19.6 to 47.7)
Hypertensive heart disease	12.4 (11.6 to 13.3)	18.7 (17.4 to 20.2)	52.2 (35.8 to 67.5)	1.5 (1.0 to 2.2)	2.3 (1.6 to 3.3)	52.0 (35.6 to 67.3)
Cardiomyopathy and myocarditis	65.0 (61.5 to 68.6)	98.3 (91.5 to 103.9)	51.8 (42.6 to 61.9)	7.1 (4.8 to 10.0)	10.9 (7.3 to 15.4)	53.6 (35.4 to 76.2)
Atrial fibrillation and flutter	-	-	-	-	-	-
Peripheral vascular disease	-	-	-	-	-	-
Endocarditis	4.9 (4.0 to 6.0)	7.1 (5.6 to 8.6)	45.9 (24.5 to 64.0)	0.5 (0.3 to 0.8)	0.8 (0.5 to 1.2)	52.7 (28.6 to 75.8)
Other cardiovascular and circulatory diseases	1,464.4 (1,000.8 to 2,209.6)	3,320.6 (2,119.7 to 4,917.0)	132.3 (35.4 to 247.5)	103.8 (60.2 to 175.4)	236.1 (128.3 to 389.2)	130.6 (33.1 to 245.1)
Chronic respiratory diseases	-	-	-	1,376.9 (949.7 to 1,879.8)	1,762.3 (1,203.0 to 2,417.3)	27.9 (23.2 to 33.2)
Chronic obstructive pulmonary disease	7,150.1 (6,745.6 to 7,507.8)	9,456.4 (8,945.4 to 9,933.8)	32.6 (31.0 to 33.9)	582.1 (378.5 to 842.5)	813.9 (528.3 to 1,168.8)	39.7 (32.8 to 48.1)
Pneumoconiosis	-	-	-	0.8 (0.5 to 1.1)	1.2 (0.8 to 1.7)	49.8 (43.5 to 55.6)
Silicosis	0.6 (0.5 to 0.8)	0.7 (0.5 to 0.8)	11.2 (5.3 to 17.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	10.6 (4.7 to 17.0)
Asbestosis	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.2)	22.4 (12.6 to 30.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	21.8 (11.3 to 30.8)
Coal workers pneumoconiosis	0.8 (0.7 to 0.8)	0.8 (0.7 to 0.9)	2.4 (-1.1 to 5.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	2.4 (-1.5 to 6.0)
Other pneumoconiosis	2.8 (2.4 to 3.1)	4.9 (4.2 to 5.5)	75.5 (70.4 to 80.1)	0.5 (0.3 to 0.7)	0.9 (0.6 to 1.3)	73.8 (68.7 to 78.8)
Asthma	16,164.9 (15,771.7 to 16,566.1)	19,588.0 (19,045.6 to 20,192.3)	21.3 (16.8 to 26.3)	720.2 (466.0 to 1,017.3)	875.4 (568.7 to 1,262.8)	21.4 (16.6 to 26.8)
Interstitial lung disease and pulmonary sarcoidosis	15.2 (14.2 to 16.3)	20.0 (18.0 to 22.0)	32.4 (16.9 to 49.6)	2.0 (1.2 to 2.9)	2.6 (1.6 to 3.9)	33.7 (18.8 to 50.7)
Other chronic respiratory diseases	-	-	-	71.8 (41.8 to 111.5)	69.2 (42.6 to 105.5)	-3.8 (-16.0 to 13.4)
Cirrhosis	-	-	-	23.3 (15.4 to 33.1)	27.0 (17.8 to 38.1)	16.2 (-1.1 to 35.8)
Cirrhosis due to hepatitis B	46.8 (42.8 to 51.4)	43.1 (37.9 to 48.5)	-7.3 (-21.9 to 5.1)	8.0 (5.3 to 11.5)	7.4 (4.6 to 11.1)	-8.2 (-30.3 to 22.5)
Cirrhosis due to hepatitis C	25.0 (22.3 to 28.1)	31.2 (27.7 to 35.2)	24.1 (6.7 to 48.2)	4.3 (2.8 to 6.6)	5.4 (3.4 to 7.9)	24.7 (-6.5 to 72.0)
Cirrhosis due to alcohol use	28.6 (24.5 to 33.3)	24.9 (19.4 to 32.0)	-12.5 (-32.2 to 9.5)	4.9 (3.1 to 7.5)	4.3 (2.6 to 7.3)	-13.6 (-43.0 to 33.2)
Cirrhosis due to other causes	35.8 (30.7 to 39.7)	57.8 (51.1 to 65.1)	61.7 (38.4 to 94.5)	6.1 (3.7 to 9.0)	9.9 (6.1 to 14.7)	63.0 (15.6 to 125.7)
Digestive diseases	-	-	-	223.1 (156.9 to 301.3)	264.1 (186.3 to 355.4)	18.3 (9.3 to 29.1)
Peptic ulcer disease	420.5 (381.4 to 457.8)	269.7 (237.1 to 301.3)	-35.6 (-45.7 to -26.1)	15.9 (10.4 to 23.5)	11.6 (7.6 to 17.5)	-26.8 (-45.1 to -4.0)
Gastritis and duodenitis	1,530.6 (1,415.5 to 1,635.7)	1,277.9 (1,169.6 to 1,375.4)	-16.4 (-24.7 to -7.9)	59.4 (39.9 to 85.5)	50.3 (32.7 to 74.2)	-15.3 (-26.8 to -0.7)
Appendicitis	70.3 (59.8 to 82.9)	83.2 (66.1 to 103.3)	16.7 (-5.7 to 64.0)	21.6 (13.7 to 32.0)	25.7 (15.7 to 38.6)	18.4 (-15.9 to 70.5)
Paralytic ileus and intestinal obstruction	1.5 (1.5 to 1.6)	2.0 (1.9 to 2.1)	34.2 (27.3 to 41.2)	0.5 (0.3 to 0.7)	0.7 (0.4 to 0.9)	34.0 (27.1 to 41.0)
Inguinal, femoral, and abdominal hernia	462.3 (436.2 to 490.5)	549.4 (515.8 to 592.4)	18.9 (9.1 to 31.0)	5.0 (2.4 to 9.6)	6.0 (2.9 to 11.4)	19.4 (6.3 to 34.2)
Inflammatory bowel disease	333.3 (324.1 to 341.8)	515.7 (502.8 to 528.5)	55.0 (49.8 to 60.2)	72.8 (49.6 to 99.6)	113.0 (75.6 to 155.6)	55.2 (42.2 to 69.4)
Vascular intestinal disorders	0.4 (0.4 to 0.4)	0.6 (0.5 to 0.6)	37.5 (21.5 to 59.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	37.4 (21.3 to 59.1)
Gallbladder and biliary diseases	77.0 (72.2 to 83.0)	92.4 (86.2 to 99.5)	20.0 (8.3 to 35.8)	8.4 (5.7 to 11.7)	10.2 (6.8 to 14.5)	20.4 (-0.2 to 46.5)
Pancreatitis	43.3 (42.4 to 44.3)	62.0 (60.5 to 63.5)	43.4 (39.0 to 48.1)	13.3 (8.9 to 18.9)	19.2 (12.5 to 27.0)	44.4 (18.1 to 82.0)
Other digestive diseases	-	-	-	26.1 (17.9 to 36.0)	27.3 (18.7 to 38.3)	4.7 (-9.0 to 17.0)
Neurological disorders	-	-	-	3,305.7 (2,212.2 to 4,631.4)	4,562.4 (3,067.4 to 6,396.3)	38.0 (31.9 to 44.4)
Alzheimer disease and other dementias	-	-	-	-	-	-
Parkinson disease	0.6 (0.3 to 1.1)	0.7 (0.4 to 1.2)	13.4 (-4.5 to 44.5)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	13.2 (-4.7 to 44.6)
Epilepsy	1,597.3 (1,488.9 to 1,707.1)	2,002.5 (1,845.8 to 2,146.5)	25.7 (13.7 to 39.0)	521.3 (353.4 to 696.2)	703.2 (482.2 to 924.5)	34.8 (20.7 to 52.9)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (20-24 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Multiple sclerosis	47.4 (45.0 to 49.5)	89.2 (85.4 to 92.9)	88.4 (77.8 to 101.0)	16.6 (11.7 to 21.3)	31.0 (22.1 to 40.4)	86.6 (62.0 to 113.2)
Migraine	62,342.4 (60,170.1 to 64,387.8)	81,518.6 (78,255.8 to 84,345.4)	30.7 (25.0 to 38.0)	2,167.2 (1,297.3 to 3,183.4)	2,847.2 (1,718.4 to 4,193.0)	31.2 (24.7 to 39.0)
Tension-type headache	133,402.5 (127,737.0 to 137,951.3)	174,262.2 (169,701.8 to 178,160.4)	30.8 (25.2 to 37.2)	204.4 (99.7 to 357.5)	267.8 (131.0 to 471.0)	31.0 (24.8 to 37.8)
Medication overuse headache	2,432.4 (1,665.3 to 3,175.0)	4,377.4 (3,009.2 to 5,714.4)	80.2 (59.9 to 105.4)	390.9 (221.0 to 599.2)	706.5 (407.8 to 1,071.1)	80.5 (59.8 to 105.4)
Other neurological disorders	0.6 (0.5 to 0.7)	0.8 (0.7 to 0.9)	26.5 (8.6 to 45.0)	5.2 (3.5 to 7.5)	6.6 (4.5 to 8.8)	26.7 (1.5 to 51.3)
Mental and substance use disorders	-	-	-	14,476.2 (10,390.1 to 18,988.7)	18,375.8 (13,153.8 to 24,265.3)	26.9 (25.3 to 28.8)
Schizophrenia	1,280.9 (1,151.8 to 1,393.3)	1,534.5 (1,377.3 to 1,669.8)	20.0 (18.2 to 21.9)	852.7 (617.9 to 1,039.1)	1,025.3 (741.8 to 1,239.9)	20.3 (15.7 to 25.0)
Alcohol use disorders	9,703.8 (8,579.5 to 10,886.9)	10,963.6 (9,766.8 to 12,330.2)	13.2 (10.2 to 16.5)	984.8 (641.7 to 1,431.8)	1,114.9 (724.5 to 1,614.5)	13.2 (9.3 to 17.0)
Drug use disorders	-	-	-	1,676.1 (1,143.8 to 2,255.3)	1,954.0 (1,324.6 to 2,657.8)	16.5 (10.8 to 22.0)
Opioid use disorders	703.3 (472.1 to 1,062.2)	847.8 (557.8 to 1,321.1)	20.4 (15.1 to 28.0)	298.7 (175.3 to 472.9)	361.6 (208.0 to 583.9)	20.6 (13.0 to 30.4)
Cocaine use disorders	1,134.6 (1,106.3 to 1,167.9)	1,322.8 (1,272.7 to 1,365.8)	17.1 (10.7 to 22.0)	157.4 (104.0 to 223.2)	184.1 (121.7 to 261.1)	17.1 (8.4 to 25.5)
Amphetamine use disorders	3,701.2 (3,569.7 to 3,832.0)	4,231.5 (4,079.5 to 4,394.1)	14.5 (8.8 to 19.9)	488.9 (307.1 to 711.6)	561.6 (353.4 to 814.7)	14.9 (7.9 to 22.0)
Cannabis use disorders	2,713.2 (2,391.4 to 3,127.8)	3,216.5 (2,824.8 to 3,697.2)	18.7 (16.7 to 21.0)	78.7 (51.5 to 115.6)	93.6 (61.1 to 136.2)	18.7 (11.5 to 26.7)
Other drug use disorders	-	-	-	652.4 (429.4 to 919.8)	753.1 (493.6 to 1,045.9)	15.4 (7.7 to 23.9)
Depressive disorders	-	-	-	4,574.3 (2,863.9 to 6,699.9)	6,187.4 (3,870.2 to 9,028.1)	35.2 (30.8 to 40.3)
Major depressive disorder	19,033.7 (13,898.6 to 24,917.6)	25,873.6 (19,052.6 to 33,414.5)	36.1 (31.3 to 42.3)	3,986.7 (2,370.4 to 5,983.4)	5,443.5 (3,240.6 to 8,167.6)	36.6 (31.3 to 43.1)
Dysthymia	5,964.6 (4,358.5 to 7,491.6)	7,521.8 (5,394.8 to 9,568.4)	26.4 (23.1 to 28.5)	587.6 (353.9 to 885.4)	743.9 (443.4 to 1,122.2)	26.5 (22.4 to 30.3)
Bipolar disorder	4,613.5 (3,629.9 to 5,560.2)	5,891.0 (4,602.5 to 7,100.8)	27.8 (23.9 to 32.9)	959.7 (571.1 to 1,499.7)	1,232.1 (734.0 to 1,943.4)	28.3 (23.0 to 34.2)
Anxiety disorders	23,226.3 (16,000.3 to 32,955.5)	29,299.8 (20,466.5 to 41,298.9)	26.6 (22.5 to 30.9)	2,169.1 (1,262.6 to 3,475.9)	2,745.3 (1,623.2 to 4,355.9)	26.7 (22.0 to 31.9)
Eating disorders	-	-	-	362.1 (202.8 to 583.2)	461.2 (251.5 to 763.3)	27.2 (19.6 to 33.7)
Anorexia nervosa	346.6 (277.4 to 437.2)	467.0 (365.7 to 592.9)	34.9 (30.0 to 40.2)	73.7 (47.4 to 110.8)	99.9 (64.2 to 150.6)	35.6 (25.7 to 45.1)
Bulimia nervosa	1,367.7 (787.9 to 2,103.6)	1,705.7 (922.4 to 2,698.6)	24.6 (15.9 to 30.4)	288.4 (144.9 to 493.7)	361.3 (177.9 to 641.6)	24.9 (15.5 to 32.6)
Autistic spectrum disorders	-	-	-	645.9 (449.5 to 874.2)	819.9 (569.9 to 1,109.6)	26.9 (24.0 to 30.2)
Autism	1,649.0 (1,568.7 to 1,730.8)	2,085.7 (1,985.1 to 2,188.9)	26.7 (26.5 to 27.0)	410.2 (273.5 to 564.3)	520.9 (345.5 to 710.3)	27.0 (22.8 to 31.3)
Asperger syndrome	2,341.5 (2,188.3 to 2,486.6)	2,962.1 (2,765.7 to 3,146.7)	26.8 (26.6 to 26.9)	235.7 (163.5 to 329.0)	299.0 (206.7 to 416.8)	26.9 (23.2 to 30.8)
Attention-deficit/hyperactivity disorder	3,990.3 (3,612.9 to 4,345.7)	4,983.3 (4,538.0 to 5,421.3)	25.1 (24.0 to 26.4)	48.4 (28.8 to 74.0)	60.6 (35.7 to 93.0)	25.3 (19.9 to 30.8)
Conduct disorder	2,724.7 (2,081.9 to 3,564.5)	3,496.5 (2,703.4 to 4,488.4)	28.7 (26.1 to 31.1)	324.6 (184.4 to 501.7)	417.9 (239.9 to 638.6)	28.8 (23.7 to 34.5)
Idiopathic intellectual disability	7,908.3 (6,199.9 to 9,768.9)	9,582.0 (7,792.4 to 11,734.3)	21.2 (11.5 to 34.3)	393.6 (255.0 to 566.3)	474.8 (313.8 to 675.9)	20.6 (10.3 to 33.7)
Other mental and substance use disorders	19,408.5 (16,573.0 to 22,482.3)	24,510.3 (20,930.6 to 28,384.2)	26.5 (26.5 to 26.6)	1,485.0 (972.8 to 2,054.8)	1,882.5 (1,223.4 to 2,628.0)	26.8 (24.0 to 29.4)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	2,159.6 (1,489.1 to 2,983.9)	2,907.3 (2,005.4 to 4,021.1)	34.5 (30.5 to 38.6)
Diabetes mellitus	8,055.8 (7,672.4 to 8,412.7)	14,235.9 (13,540.5 to 14,951.4)	77.3 (66.0 to 88.4)	421.2 (276.5 to 610.4)	742.8 (482.5 to 1,082.7)	76.6 (65.2 to 87.7)
Acute glomerulonephritis	1.7 (1.5 to 2.0)	1.7 (1.5 to 1.9)	-2.0 (-6.4 to 1.9)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-2.1 (-6.6 to 1.8)
Chronic kidney disease	-	-	-	374.7 (260.6 to 522.0)	480.8 (335.2 to 659.5)	28.6 (19.6 to 38.2)
Chronic kidney disease due to diabetes mellitus	1,377.8 (849.3 to 2,067.9)	1,881.7 (1,185.5 to 2,789.1)	38.5 (12.8 to 55.2)	33.0 (22.1 to 47.4)	44.8 (30.2 to 62.3)	36.2 (13.1 to 62.8)
Chronic kidney disease due to hypertension	5,330.4 (3,191.5 to 8,015.0)	6,112.9 (3,753.8 to 9,229.0)	16.2 (-1.4 to 30.2)	93.9 (64.6 to 130.4)	113.5 (78.8 to 158.3)	21.0 (5.1 to 38.5)
Chronic kidney disease due to glomerulonephritis	4,613.2 (2,822.6 to 6,909.5)	5,813.3 (3,753.5 to 8,611.0)	27.3 (8.7 to 41.6)	113.8 (77.0 to 160.5)	129.1 (89.6 to 176.2)	13.4 (-1.6 to 32.7)
Chronic kidney disease due to other causes	6,103.4 (3,752.0 to 9,172.5)	8,834.3 (5,547.5 to 13,072.5)	45.2 (32.4 to 61.0)	134.0 (89.7 to 187.8)	193.4 (132.5 to 269.6)	44.3 (28.8 to 65.5)
Urinary diseases and male infertility	-	-	-	68.2 (36.8 to 117.9)	91.2 (49.1 to 160.3)	33.9 (17.8 to 49.9)
Interstitial nephritis and urinary tract infections	102.6 (98.8 to 106.5)	150.5 (144.8 to 155.6)	46.9 (40.6 to 54.8)	3.5 (2.1 to 5.2)	5.1 (3.2 to 7.7)	47.4 (25.8 to 72.4)
Urolithiasis	861.5 (645.3 to 1,203.1)	1,020.6 (681.5 to 1,541.2)	21.6 (-3.8 to 34.0)	12.7 (8.2 to 18.4)	19.5 (9.5 to 22.7)	19.5 (1.5 to 35.8)
Benign prostatic hyperplasia	-	-	-	-	-	-
Male infertility due to other causes	6,472.3 (5,819.7 to 7,142.7)	8,579.8 (7,520.6 to 9,638.3)	33.0 (13.1 to 53.2)	45.8 (20.4 to 88.4)	60.9 (26.6 to 124.0)	33.1 (12.3 to 54.7)
Other urinary diseases	-	-	-	6.2 (3.8 to 9.4)	10.0 (5.5 to 15.7)	66.9 (15.9 to 105.3)
Gynecological diseases	-	-	-	813.9 (539.6 to 1,184.1)	1,051.9 (690.5 to 1,528.7)	29.0 (22.5 to 36.6)
Uterine fibroids	3,152.3 (2,404.9 to 3,872.6)	3,929.1 (2,949.5 to 4,862.1)	24.9 (22.4 to 26.8)	84.0 (47.9 to 137.9)	98.7 (56.2 to 161.9)	17.5 (11.8 to 23.6)
Polycystic ovarian syndrome	10,420.6 (9,997.4 to 10,905.6)	14,404.4 (13,734.3 to 15,014.5)	38.5 (30.5 to 46.3)	103.5 (48.6 to 195.5)	144.0 (68.9 to 269.8)	39.2 (31.2 to 47.5)
Female infertility due to other causes	3,377.2 (2,688.8 to 4,054.3)	4,591.0 (3,623.2 to 5,606.6)	36.1 (16.7 to 55.9)	22.1 (9.1 to 44.8)	30.1 (12.2 to 60.4)	36.0 (14.6 to 59.2)
Endometriosis	1,103.3 (1,055.7 to 1,155.9)	1,381.9 (1,323.4 to 1,440.8)	25.2 (18.6 to 33.8)	103.7 (69.5 to 142.0)	130.2 (86.7 to 176.8)	25.7 (15.7 to 36.2)
Genital prolapse	17,750.2 (16,715.8 to 18,791.0)	23,433.5 (22,016.7 to 25,112.7)	32.0 (21.2 to 45.4)	57.3 (27.7 to 107.2)	75.9 (36.1 to 142.2)	32.0 (21.3 to 47.1)
Premenstrual syndrome	41,646.7 (38,062.6 to 44,622.4)	57,131.9 (52,459.8 to 62,294.5)	37.1 (24.1 to 54.5)	352.8 (219.8 to 529.0)	485.9 (299.4 to 728.5)	37.4 (23.9 to 54.5)
Other gynecological diseases	2,908.6 (2,769.3 to 3,051.1)	2,965.9 (2,850.3 to 3,096.2)	2.0 (-3.9 to 9.9)	90.6 (60.2 to 129.9)	87.0 (58.1 to 126.4)	-4.4 (-12.0 to 10.4)
Hemoglobinopathies and hemolytic anemias	-	-	-	364.4 (244.2 to 532.3)	434.5 (287.3 to 626.5)	19.2 (14.1 to 24.7)
Thalassemias	56.8 (49.8 to 65.5)	75.1 (66.5 to 85.0)	31.9 (26.3 to 41.0)	4.5 (3.0 to 6.4)	5.5 (3.7 to 7.8)	21.8 (6.6 to 39.3)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (20-24 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Thalassemia trait	13,988.5 (12,560.1 to 15,898.9)	18,077.8 (16,721.3 to 19,913.4)	29.7 (25.1 to 33.9)	177.7 (118.2 to 258.5)	235.7 (156.1 to 345.3)	32.8 (25.1 to 40.2)
Sickle cell disorders	160.9 (144.4 to 174.9)	308.2 (284.9 to 333.0)	91.1 (78.6 to 110.1)	20.5 (14.4 to 27.9)	40.5 (27.3 to 55.7)	96.8 (72.8 to 124.5)
Sickle cell trait	14,708.2 (13,969.9 to 15,395.6)	23,196.3 (22,096.5 to 24,177.4)	58.0 (55.1 to 60.7)	57.4 (37.1 to 83.8)	80.1 (52.0 to 116.2)	39.2 (26.7 to 54.3)
G6PD deficiency	21,230.6 (20,703.5 to 21,728.4)	29,852.1 (29,094.7 to 30,596.4)	40.9 (36.0 to 45.7)	1.7 (1.2 to 2.4)	2.2 (1.5 to 3.1)	27.2 (16.1 to 40.8)
G6PD trait	77,751.0 (77,232.5 to 78,163.0)	101,263.2 (100,550.4 to 101,879.9)	30.5 (29.5 to 31.7)	3.8 (2.5 to 5.6)	4.6 (2.6 to 7.4)	19.3 (-17.7 to 81.3)
Other hemoglobinopathies and hemolytic anemias	4,712.0 (4,603.2 to 4,807.3)	3,604.3 (3,503.7 to 3,700.9)	-23.3 (-25.8 to -20.7)	98.7 (63.4 to 146.2)	65.9 (42.0 to 100.5)	-33.6 (-40.3 to -24.7)
Endocrine, metabolic, blood, and immune disorders	4,347.2 (4,172.8 to 4,524.1)	3,986.6 (3,897.0 to 4,075.9)	-8.1 (-12.4 to -4.1)	117.2 (79.5 to 167.5)	106.0 (71.5 to 149.9)	-9.4 (-17.3 to 0.4)
Musculoskeletal disorders	-	-	-	5,745.2 (3,950.3 to 7,754.7)	7,217.6 (4,927.3 to 9,724.6)	25.6 (21.0 to 30.8)
Rheumatoid arthritis	466.4 (459.1 to 474.0)	611.4 (601.9 to 621.6)	31.4 (28.5 to 34.4)	115.5 (81.4 to 152.7)	152.0 (106.2 to 204.3)	31.7 (22.1 to 41.5)
Osteoarthritis	-	-	-	-	-	-
Low back and neck pain	-	-	-	5,329.8 (3,678.7 to 7,217.2)	6,611.8 (4,547.9 to 8,984.2)	24.0 (19.1 to 29.6)
Low back pain	30,791.2 (29,781.7 to 31,885.8)	38,995.7 (37,773.3 to 40,211.5)	26.8 (21.0 to 33.6)	3,545.4 (2,398.6 to 4,963.1)	4,507.2 (3,028.0 to 6,322.4)	27.1 (20.9 to 34.1)
Neck pain	17,645.4 (16,945.3 to 18,533.0)	20,758.3 (19,684.6 to 22,313.3)	17.6 (9.9 to 28.3)	1,784.4 (1,232.4 to 2,473.8)	2,104.6 (1,442.3 to 2,916.9)	17.7 (9.9 to 28.8)
Gout	30.8 (29.8 to 31.8)	34.6 (33.4 to 35.6)	12.4 (7.2 to 17.3)	1.1 (0.7 to 1.5)	1.2 (0.8 to 1.7)	12.2 (6.8 to 17.1)
Other musculoskeletal disorders	3,140.5 (2,254.5 to 4,248.4)	4,736.6 (3,266.1 to 6,435.8)	50.0 (35.3 to 71.7)	298.8 (183.2 to 463.6)	452.5 (273.2 to 724.7)	50.6 (34.6 to 73.3)
Other non-communicable diseases	-	-	-	5,807.9 (3,710.4 to 8,904.0)	7,209.9 (4,610.8 to 11,003.7)	24.2 (20.1 to 28.5)
Congenital anomalies	-	-	-	404.4 (298.2 to 524.7)	617.5 (447.5 to 796.8)	52.4 (41.3 to 65.6)
Neural tube defects	93.6 (91.5 to 96.0)	148.4 (144.7 to 152.4)	58.9 (53.3 to 64.1)	28.9 (20.2 to 37.5)	46.7 (32.7 to 61.2)	61.4 (45.2 to 80.4)
Congenital heart anomalies	1,671.7 (1,618.0 to 1,730.8)	3,064.9 (2,954.5 to 3,194.4)	83.4 (75.4 to 93.9)	58.9 (25.4 to 100.9)	110.2 (47.4 to 186.7)	87.0 (77.8 to 98.0)
Orofacial clefts	283.8 (273.0 to 293.6)	526.7 (507.4 to 545.1)	85.6 (77.1 to 97.0)	3.8 (2.5 to 5.4)	6.4 (4.2 to 9.4)	70.5 (48.2 to 95.6)
Down syndrome	406.3 (391.4 to 423.5)	647.3 (622.8 to 673.9)	59.7 (51.4 to 68.0)	44.7 (32.4 to 58.7)	71.3 (52.1 to 93.9)	59.9 (47.0 to 73.9)
Turner syndrome	18.4 (17.4 to 19.4)	26.3 (25.1 to 27.9)	43.5 (35.4 to 54.6)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	43.4 (28.7 to 61.4)
Klinefelter syndrome	14.2 (13.5 to 14.9)	18.9 (18.1 to 19.8)	32.6 (24.4 to 43.4)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.4)	32.6 (20.7 to 47.9)
Chromosomal unbalanced rearrangements	560.8 (542.0 to 577.1)	863.8 (826.6 to 910.0)	54.2 (46.4 to 63.4)	61.6 (44.0 to 80.8)	95.0 (67.9 to 124.8)	54.1 (43.2 to 66.6)
Other congenital anomalies	1,922.8 (1,660.5 to 2,162.8)	2,237.1 (1,904.4 to 2,544.4)	16.4 (9.8 to 23.6)	206.2 (146.2 to 286.5)	287.1 (200.9 to 390.0)	39.3 (24.0 to 59.6)
Skin and subcutaneous diseases	-	-	-	3,482.2 (2,087.6 to 5,618.5)	4,327.5 (2,579.2 to 6,923.6)	24.5 (18.1 to 30.5)
Dermatitis	24,968.6 (19,587.2 to 30,616.5)	30,892.5 (24,392.0 to 37,603.0)	24.1 (22.3 to 25.4)	695.0 (431.4 to 1,013.5)	871.4 (547.6 to 1,265.4)	25.4 (22.7 to 28.1)
Psoriasis	3,741.7 (3,142.7 to 4,447.2)	4,678.8 (3,919.4 to 5,569.7)	25.3 (24.3 to 26.3)	311.6 (208.2 to 446.1)	390.7 (261.1 to 558.4)	25.4 (19.3 to 31.6)
Cellulitis	74.9 (50.7 to 107.3)	85.8 (59.2 to 120.1)	15.2 (6.8 to 23.3)	5.5 (3.0 to 9.3)	6.3 (3.4 to 10.1)	13.1 (-4.8 to 37.2)
Pyoderma	335.3 (208.0 to 527.6)	334.5 (202.7 to 537.7)	-0.3 (-17.3 to 21.5)	1.9 (0.7 to 4.4)	1.9 (0.7 to 4.5)	-0.4 (-19.5 to 23.0)
Scabies	5,426.6 (4,852.1 to 6,166.9)	6,538.4 (5,846.0 to 7,500.5)	19.4 (2.5 to 47.6)	140.3 (80.4 to 225.0)	169.7 (94.9 to 276.7)	19.4 (1.8 to 47.0)
Fungal skin diseases	46,254.4 (36,917.4 to 55,750.8)	58,828.2 (46,434.4 to 71,462.2)	27.5 (24.3 to 29.8)	262.7 (106.5 to 575.9)	334.7 (135.1 to 735.9)	27.5 (24.2 to 29.9)
Viral skin diseases	10,178.6 (4,590.4 to 16,882.2)	12,643.0 (5,972.7 to 20,359.4)	24.5 (20.1 to 32.6)	315.6 (119.9 to 611.9)	393.1 (156.7 to 750.8)	24.7 (20.0 to 33.9)
Acne vulgaris	123,078.2 (113,826.5 to 132,528.2)	145,475.0 (133,380.0 to 158,798.5)	18.4 (5.6 to 32.6)	1,334.3 (632.6 to 2,533.5)	1,581.3 (764.2 to 2,936.7)	18.5 (5.5 to 33.0)
Alopecia areata	392.3 (379.6 to 404.2)	488.4 (470.9 to 505.3)	24.7 (19.3 to 30.2)	13.4 (8.5 to 20.2)	16.7 (10.5 to 24.9)	24.8 (13.6 to 37.0)
Pruritus	32.7 (30.5 to 35.1)	38.9 (35.9 to 42.3)	19.6 (6.2 to 31.0)	0.4 (0.2 to 0.7)	0.4 (0.2 to 0.8)	19.3 (-6.2 to 50.3)
Urticaria	4,837.8 (4,429.9 to 5,235.7)	6,988.4 (6,016.4 to 7,982.9)	43.7 (26.8 to 69.2)	293.8 (189.7 to 424.0)	425.9 (261.8 to 632.4)	43.8 (26.2 to 70.8)
Decubitus ulcer	29.2 (28.1 to 30.6)	29.5 (28.1 to 31.0)	1.2 (-3.5 to 6.1)	4.8 (3.3 to 6.8)	4.9 (3.3 to 6.8)	0.9 (-8.8 to 11.9)
Other skin and subcutaneous diseases	17,092.5 (4,118.0 to 37,776.6)	21,619.9 (5,205.2 to 48,063.3)	26.7 (24.3 to 29.1)	102.9 (20.3 to 289.3)	130.5 (25.5 to 366.9)	26.7 (23.6 to 30.0)
Sense organ diseases	-	-	-	1,309.7 (866.4 to 1,889.3)	1,487.2 (972.6 to 2,176.6)	13.7 (7.8 to 18.4)
Glaucoma	418.4 (343.1 to 507.3)	530.5 (427.0 to 630.5)	27.3 (15.4 to 38.9)	22.9 (14.9 to 33.1)	27.1 (17.3 to 39.9)	18.2 (3.7 to 35.3)
Cataract	-	-	0.0 (0.0 to 0.0)	-	-	-
Macular degeneration	-	-	-	-	-	-
Uncorrected refractive error	18,966.6 (18,260.4 to 19,705.3)	23,245.5 (22,373.0 to 24,087.7)	22.8 (18.8 to 26.8)	365.7 (232.4 to 569.9)	437.5 (275.3 to 683.9)	19.6 (15.5 to 23.6)
Age-related and other hearing loss	19,047.4 (15,378.0 to 23,134.7)	21,906.2 (17,612.6 to 26,476.2)	15.3 (9.6 to 22.0)	675.3 (428.2 to 1,022.2)	738.4 (460.1 to 1,110.8)	9.5 (0.1 to 18.0)
Other vision loss	1,362.2 (1,109.2 to 1,632.9)	1,342.6 (1,090.1 to 1,602.2)	-1.2 (-5.3 to 2.4)	75.9 (50.6 to 108.0)	69.3 (45.2 to 100.0)	-8.7 (-16.4 to -1.4)
Other sense organ diseases	6,344.8 (6,217.4 to 6,468.8)	8,001.6 (7,814.4 to 8,181.1)	26.3 (22.3 to 30.4)	169.9 (104.0 to 250.6)	214.9 (131.9 to 320.2)	26.4 (20.7 to 32.7)
Oral disorders	-	-	-	611.5 (344.4 to 997.5)	777.7 (431.8 to 1,281.0)	27.2 (23.9 to 29.9)
Deciduous caries	-	-	-	-	-	-
Permanent caries	245,368.2 (241,699.2 to 248,971.2)	304,091.3 (298,476.3 to 309,492.3)	24.2 (21.6 to 27.0)	226.2 (104.7 to 435.4)	286.9 (131.0 to 556.2)	26.7 (23.6 to 30.0)
Periodontal diseases	12,373.2 (12,109.5 to 12,650.9)	16,738.9 (16,305.3 to 17,147.8)	35.7 (30.6 to 40.0)	82.6 (33.0 to 169.5)	112.0 (45.1 to 230.5)	35.6 (30.6 to 40.2)
Edentulism and severe tooth loss	364.0 (343.3 to 384.3)	407.5 (384.7 to 432.8)	12.1 (3.9 to 21.4)	10.5 (6.9 to 15.1)	11.8 (7.9 to 16.9)	12.3 (-2.2 to 28.5)
Other oral disorders	9,844.0 (9,649.3 to 10,075.0)	12,333.2 (11,999.2 to 12,673.5)	25.5 (21.1 to 29.8)	292.1 (184.6 to 434.3)	367.0 (228.5 to 557.2)	25.5 (20.6 to 30.3)
Injuries	-	-	-	2,156.8 (1,590.1 to 2,921.5)	1,545.6 (1,180.9 to 1,987.8)	-27.3 (-41.5 to -17.3)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (20-24 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Transport injuries	-	-	-	641.1 (490.1 to 819.1)	517.6 (397.5 to 669.0)	-19.4 (-24.4 to -13.7)
Road injuries	-	-	-	549.1 (419.9 to 701.3)	448.7 (344.4 to 580.3)	-18.3 (-23.7 to -12.3)
Pedestrian road injuries	-	-	-	141.9 (107.4 to 182.5)	124.9 (93.1 to 163.5)	-12.2 (-18.9 to -3.9)
Cyclist road injuries	-	-	-	47.9 (36.1 to 62.1)	36.3 (27.2 to 47.5)	-24.4 (-29.3 to -18.6)
Motorcyclist road injuries	-	-	-	116.8 (90.0 to 148.5)	73.9 (57.0 to 94.7)	-36.8 (-42.0 to -30.8)
Motor vehicle road injuries	-	-	-	237.1 (182.7 to 299.9)	209.2 (161.6 to 267.3)	-11.8 (-17.7 to -5.3)
Other road injuries	-	-	-	5.4 (4.1 to 7.0)	4.5 (3.4 to 5.8)	-17.4 (-23.1 to -10.1)
Other transport injuries	-	-	-	92.0 (69.9 to 118.5)	68.9 (52.3 to 88.9)	-25.1 (-29.8 to -20.2)
Unintentional injuries	-	-	-	926.3 (704.7 to 1,185.1)	885.2 (672.1 to 1,157.4)	-4.6 (-8.7 to 0.2)
Falls	-	-	-	350.1 (265.6 to 450.7)	357.4 (262.4 to 472.3)	1.8 (-4.4 to 9.0)
Drowning	-	-	-	35.4 (26.0 to 46.0)	23.2 (17.2 to 30.1)	-34.1 (-39.3 to -28.6)
Fire, heat, and hot substances	-	-	-	84.9 (65.5 to 107.1)	68.7 (51.7 to 89.3)	-19.1 (-27.2 to -10.5)
Poisonings	-	-	-	7.1 (4.9 to 9.5)	5.5 (3.9 to 7.5)	-21.6 (-28.9 to -14.8)
Exposure to mechanical forces	-	-	-	279.2 (213.5 to 362.7)	253.9 (188.0 to 336.9)	-9.2 (-13.2 to -4.6)
Unintentional firearm injuries	-	-	-	11.9 (9.3 to 14.9)	10.6 (8.2 to 13.7)	-11.1 (-16.8 to -5.1)
Unintentional suffocation	-	-	-	3.2 (2.4 to 4.2)	3.7 (2.8 to 4.8)	13.6 (7.0 to 20.3)
Other exposure to mechanical forces	-	-	-	264.1 (201.1 to 342.9)	239.6 (177.0 to 318.9)	-9.4 (-13.4 to -4.8)
Adverse effects of medical treatment	-	-	-	8.0 (5.0 to 11.7)	9.2 (5.8 to 13.5)	15.6 (12.1 to 18.7)
Animal contact	-	-	-	37.1 (27.6 to 48.7)	28.3 (20.8 to 37.2)	-23.8 (-29.2 to -17.7)
Venomous animal contact	-	-	-	15.9 (11.3 to 21.5)	12.5 (8.9 to 16.8)	-21.5 (-30.1 to -10.7)
Non-venomous animal contact	-	-	-	21.2 (15.7 to 28.4)	15.8 (11.6 to 21.5)	-25.5 (-30.3 to -20.5)
Foreign body	-	-	-	13.8 (10.0 to 18.2)	14.3 (10.1 to 19.4)	3.9 (-1.8 to 9.4)
Pulmonary aspiration and foreign body in airway	-	-	-	3.5 (2.6 to 4.4)	2.8 (2.1 to 3.6)	-19.7 (-26.1 to -11.5)
Foreign body in eyes	-	-	-	3.7 (2.0 to 6.1)	4.5 (2.3 to 7.4)	20.1 (13.0 to 26.5)
Foreign body in other body part	-	-	-	6.6 (4.9 to 8.6)	7.0 (5.2 to 9.2)	7.3 (2.6 to 13.2)
Other unintentional injuries	-	-	-	110.7 (84.8 to 142.0)	124.6 (94.6 to 161.5)	12.6 (7.4 to 17.7)
Self-harm and interpersonal violence	-	-	-	73.1 (56.0 to 92.6)	60.4 (46.1 to 77.7)	-17.6 (-22.2 to -11.6)
Self-harm	-	-	-	13.1 (9.7 to 17.0)	9.7 (7.1 to 12.7)	-25.7 (-30.2 to -20.6)
Interpersonal violence	-	-	-	60.1 (46.6 to 75.7)	50.7 (39.0 to 64.6)	-15.8 (-20.9 to -9.4)
Assault by firearm	-	-	-	9.5 (7.3 to 12.0)	9.3 (7.1 to 12.2)	-1.6 (-7.8 to 4.7)
Assault by sharp object	-	-	-	11.7 (9.1 to 14.8)	11.0 (8.4 to 14.3)	-5.9 (-11.7 to 0.6)
Assault by other means	-	-	-	38.9 (30.0 to 49.3)	30.4 (23.3 to 38.5)	-22.1 (-27.3 to -15.8)
Forces of nature, war, and legal intervention	-	-	-	516.3 (234.0 to 1,076.8)	82.3 (42.8 to 148.8)	-83.9 (-88.5 to -75.3)
Exposure to forces of nature	-	-	-	27.5 (15.7 to 46.5)	25.9 (13.2 to 55.9)	-8.4 (-37.3 to 37.2)
Collective violence and legal intervention	-	-	-	488.7 (216.2 to 1,032.9)	56.4 (27.4 to 111.1)	-88.4 (-91.4 to -82.8)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (25-29 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
All causes	-	-	-	42,007.4 (30,978.3 to 54,237.4)	54,897.7 (40,705.5 to 71,462.5)	30.7 (28.4 to 32.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	6,024.1 (4,190.9 to 8,439.6)	6,866.9 (4,909.8 to 9,402.0)	14.1 (9.4 to 19.8)
HIV/AIDS and tuberculosis	-	-	-	445.0 (308.4 to 589.2)	791.7 (558.5 to 1,046.2)	77.7 (68.5 to 89.6)
Tuberculosis	867.9 (818.8 to 921.2)	1,194.8 (1,133.3 to 1,255.5)	37.1 (33.5 to 40.8)	271.1 (182.2 to 365.7)	374.0 (254.5 to 507.4)	38.1 (30.8 to 45.5)
HIV/AIDS	-	-	-	173.9 (122.8 to 228.6)	417.7 (300.7 to 558.4)	139.4 (118.2 to 168.5)
HIV/AIDS resulting in mycobacterial infection	30.8 (20.0 to 41.8)	94.5 (64.5 to 121.1)	208.0 (170.7 to 243.3)	11.6 (6.5 to 17.9)	35.8 (21.4 to 53.1)	211.0 (156.1 to 267.2)
HIV/AIDS resulting in other diseases	1,699.3 (1,565.0 to 1,824.6)	3,534.4 (3,345.0 to 3,847.7)	106.4 (93.2 to 124.9)	162.2 (114.3 to 214.1)	381.9 (274.5 to 513.5)	134.8 (112.9 to 165.0)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	681.4 (478.1 to 927.5)	800.6 (556.2 to 1,103.2)	17.3 (12.3 to 23.1)
Diarrheal diseases	1,269.1 (1,210.5 to 1,328.5)	1,410.1 (1,335.6 to 1,482.9)	10.7 (3.5 to 18.7)	202.8 (136.9 to 277.9)	225.8 (153.3 to 310.0)	11.3 (2.3 to 21.3)
Intestinal infectious diseases	-	-	-	14.8 (9.5 to 21.6)	12.6 (8.0 to 18.3)	-14.9 (-39.7 to 18.7)
Typhoid fever	85.8 (69.6 to 102.8)	74.9 (61.5 to 87.9)	-13.2 (-34.8 to 15.3)	11.2 (6.8 to 16.7)	9.8 (5.9 to 14.9)	-12.3 (-41.6 to 32.3)
Paratyphoid fever	51.9 (40.5 to 63.3)	44.5 (33.9 to 56.3)	-15.9 (-38.3 to 24.6)	2.6 (1.5 to 4.2)	2.3 (1.3 to 3.8)	-12.6 (-43.8 to 38.2)
Other intestinal infectious diseases	-	-	-	1.0 (0.5 to 1.9)	0.4 (0.2 to 0.8)	-55.4 (-65.7 to -40.2)
Lower respiratory infections	96.0 (93.1 to 98.6)	98.4 (95.2 to 101.8)	1.9 (-2.3 to 6.9)	10.1 (6.8 to 14.1)	10.4 (7.0 to 14.8)	2.9 (-9.8 to 17.0)
Upper respiratory infections	14,099.9 (13,804.8 to 14,429.1)	20,398.5 (20,009.5 to 20,797.9)	44.1 (40.5 to 48.6)	165.7 (92.2 to 272.8)	240.0 (134.3 to 398.1)	44.8 (39.7 to 50.3)
Otitis media	5,231.6 (4,771.2 to 5,542.8)	6,383.5 (5,790.0 to 6,772.7)	21.5 (15.8 to 26.8)	99.3 (58.2 to 157.8)	122.0 (72.3 to 194.3)	22.8 (16.0 to 30.4)
Meningitis	-	-	-	160.1 (112.8 to 214.3)	160.1 (113.4 to 214.5)	-0.0 (-7.7 to 8.8)
Pneumococcal meningitis	754.7 (473.0 to 1,097.6)	749.6 (483.7 to 1,093.7)	-1.3 (-7.7 to 7.0)	65.0 (46.4 to 86.3)	68.9 (49.0 to 91.6)	5.9 (-7.2 to 23.7)
H influenzae type B meningitis	357.4 (135.3 to 651.4)	310.3 (132.7 to 569.6)	-13.5 (-20.7 to -3.6)	36.2 (24.7 to 49.2)	35.6 (24.4 to 48.1)	-1.7 (-15.9 to 17.0)
Meningococcal meningitis	136.2 (46.4 to 297.5)	114.8 (44.9 to 245.4)	-15.6 (-23.1 to -4.1)	15.7 (10.1 to 23.0)	14.3 (9.5 to 20.7)	-9.1 (-19.0 to 4.8)
Other meningitis	374.8 (174.7 to 669.7)	327.0 (183.0 to 561.0)	-12.5 (-20.7 to 2.0)	43.3 (29.8 to 60.1)	41.4 (28.0 to 56.7)	-4.3 (-18.2 to 10.3)
Encephalitis	139.3 (60.6 to 299.7)	135.7 (64.7 to 303.1)	-1.9 (-19.2 to 8.1)	17.0 (11.7 to 23.0)	18.7 (13.0 to 24.8)	10.2 (-4.2 to 26.5)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-31.8 (-79.1 to 162.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.7 (-79.3 to 165.4)
Whooping cough	5.2 (4.0 to 6.6)	4.4 (3.4 to 5.6)	-15.4 (-16.1 to -14.7)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.4)	-15.3 (-15.9 to -14.5)
Tetanus	101.1 (72.5 to 151.6)	13.7 (8.6 to 21.0)	-86.8 (-92.5 to -76.3)	3.6 (2.3 to 5.4)	1.0 (0.6 to 1.6)	-73.9 (-83.3 to -55.0)
Measles	1.6 (1.3 to 2.1)	0.5 (0.4 to 0.6)	-69.2 (-71.8 to -66.5)	0.2 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-69.1 (-71.7 to -66.5)
Varicella and herpes zoster	173.6 (163.3 to 186.1)	230.7 (214.6 to 245.8)	32.8 (20.2 to 44.4)	7.7 (4.7 to 11.8)	9.8 (5.9 to 14.9)	27.2 (12.4 to 44.5)
Neglected tropical diseases and malaria	-	-	-	1,540.6 (1,000.6 to 2,245.0)	1,490.7 (968.7 to 2,212.1)	-3.5 (-9.7 to 5.2)
Malaria	20,405.1 (19,924.3 to 20,899.9)	27,743.2 (27,081.3 to 28,405.8)	35.5 (31.8 to 39.2)	121.9 (80.6 to 176.8)	159.1 (106.1 to 229.7)	30.4 (23.1 to 39.6)
Chagas disease	658.4 (642.2 to 675.0)	758.7 (739.5 to 781.6)	14.7 (10.9 to 19.1)	4.5 (2.9 to 6.5)	5.2 (3.3 to 7.5)	15.7 (4.5 to 29.4)
Leishmaniasis	-	-	-	1.6 (0.8 to 2.9)	4.3 (2.1 to 8.0)	168.1 (137.3 to 209.0)
Visceral leishmaniasis	3.4 (2.4 to 4.6)	5.6 (4.3 to 7.2)	64.7 (20.9 to 134.5)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.6)	65.1 (20.0 to 136.1)
Cutaneous and mucocutaneous leishmaniasis	124.7 (104.1 to 150.3)	359.5 (301.9 to 429.6)	186.5 (152.9 to 227.7)	1.3 (0.6 to 2.6)	3.9 (1.8 to 7.5)	187.4 (153.3 to 232.6)
African trypanosomiasis	8.6 (3.8 to 17.1)	2.5 (1.3 to 4.4)	-70.4 (-74.7 to -65.1)	2.3 (0.9 to 4.6)	0.7 (0.3 to 1.3)	-70.9 (-79.9 to -56.1)
Schistosomiasis	21,208.3 (19,045.9 to 23,379.3)	29,868.7 (25,807.5 to 35,115.3)	38.5 (29.6 to 62.0)	209.0 (105.8 to 396.7)	299.7 (151.4 to 572.0)	41.3 (32.9 to 66.2)
Cysticercosis	174.1 (149.3 to 203.8)	128.3 (108.0 to 154.9)	-27.1 (-40.8 to -8.6)	50.1 (34.1 to 67.1)	39.2 (26.5 to 53.5)	-22.3 (-39.0 to 0.7)
Cystic echinococcosis	76.0 (70.2 to 82.5)	63.2 (60.6 to 67.2)	-17.3 (-20.6 to -11.9)	7.2 (4.8 to 10.3)	6.0 (4.0 to 8.5)	-16.6 (-29.7 to -0.4)
Lymphatic filariasis	6,310.4 (5,683.0 to 7,108.6)	3,935.6 (3,370.7 to 4,654.5)	-37.9 (-44.5 to -30.8)	171.4 (85.0 to 299.7)	156.7 (84.9 to 262.5)	-7.1 (-30.2 to 15.5)
Onchocerciasis	2,516.7 (1,624.0 to 3,869.8)	1,977.5 (1,203.7 to 3,322.5)	-22.3 (-33.3 to -10.6)	134.1 (65.6 to 220.1)	115.0 (50.5 to 197.3)	-15.8 (-28.9 to 1.3)
Trachoma	4.6 (3.0 to 6.6)	4.4 (2.8 to 6.4)	-3.7 (-24.9 to 22.1)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.6)	17.7 (-21.9 to 80.0)
Dengue	40.6 (14.8 to 91.1)	297.6 (109.7 to 667.6)	631.3 (624.5 to 638.2)	6.6 (2.1 to 16.5)	48.7 (16.0 to 122.1)	636.9 (480.0 to 833.7)
Yellow fever	0.4 (0.1 to 0.9)	0.2 (0.1 to 0.4)	-57.3 (-68.2 to -36.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.2 (-68.2 to -35.3)
Rabies	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-27.4 (-43.5 to -7.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.2 (-43.6 to -7.5)
Intestinal nematode infections	-	-	-	521.2 (299.6 to 838.8)	320.6 (186.3 to 516.3)	-38.3 (-43.6 to -32.1)
Ascariasis	98,608.2 (82,408.8 to 119,588.3)	73,296.1 (62,662.0 to 86,958.9)	-25.8 (-42.0 to -5.5)	236.4 (129.9 to 392.6)	79.8 (43.9 to 137.5)	-66.2 (-71.7 to -59.8)
Trichuriasis	49,861.0 (40,277.6 to 63,182.4)	42,650.6 (38,398.3 to 47,435.0)	-13.7 (-35.1 to 8.4)	72.3 (40.0 to 120.2)	54.3 (28.9 to 92.9)	-25.8 (-41.2 to -0.2)
Hookworm disease	47,777.8 (39,995.4 to 58,020.7)	44,876.5 (40,719.1 to 49,541.9)	-5.8 (-24.3 to 14.5)	212.6 (126.8 to 339.6)	186.5 (111.7 to 294.7)	-12.1 (-20.9 to -2.5)
Food-borne trematodiasis	5,689.4 (4,470.2 to 7,020.2)	7,167.5 (5,626.5 to 8,732.4)	26.1 (12.2 to 36.0)	253.7 (76.8 to 536.3)	290.9 (103.1 to 593.0)	17.5 (-4.0 to 36.4)
Other neglected tropical diseases	1,987.6 (1,915.8 to 2,054.0)	1,650.3 (1,579.7 to 1,718.1)	-17.3 (-21.3 to -13.0)	56.6 (32.6 to 94.6)	44.5 (24.0 to 79.0)	-22.5 (-35.1 to -4.7)
Maternal disorders	-	-	-	172.0 (114.0 to 238.5)	201.4 (136.6 to 272.2)	17.6 (3.0 to 31.8)
Maternal hemorrhage	463.4 (444.8 to 482.1)	597.1 (560.5 to 632.9)	28.4 (19.7 to 37.3)	17.9 (12.2 to 25.2)	20.4 (13.8 to 28.8)	14.0 (1.3 to 27.7)
Maternal sepsis and other maternal infections	322.9 (200.5 to 492.5)	256.1 (167.8 to 399.2)	-20.7 (-31.8 to -10.8)	5.0 (2.7 to 8.3)	4.1 (2.1 to 7.1)	-18.2 (-38.2 to 9.0)
Maternal hypertensive disorders	250.7 (134.3 to 408.8)	277.8 (150.3 to 450.4)	10.1 (7.0 to 16.2)	12.6 (6.0 to 23.2)	13.9 (6.5 to 25.6)	10.7 (0.8 to 24.5)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (25-29 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Obstructed labor	317.8 (252.8 to 390.1)	378.6 (309.7 to 452.3)	18.9 (9.2 to 29.6)	104.7 (68.8 to 149.7)	124.9 (81.9 to 175.5)	19.6 (2.6 to 37.5)
Complications of abortion	4.9 (3.3 to 6.6)	5.6 (3.8 to 7.7)	13.5 (1.0 to 25.4)	0.6 (0.3 to 0.9)	14.0 (0.4 to 1.0)	14.0 (0.8 to 26.9)
Other maternal disorders	-	-	-	31.1 (20.1 to 45.2)	37.4 (24.8 to 54.4)	22.2 (-13.8 to 58.3)
Neonatal disorders	-	-	-	436.0 (321.7 to 560.3)	1,095.8 (805.2 to 1,414.2)	150.9 (125.4 to 180.4)
Preterm birth complications	1,717.2 (1,511.1 to 1,961.5)	4,698.2 (4,162.1 to 5,350.9)	172.3 (149.0 to 198.3)	196.1 (142.8 to 250.8)	585.9 (431.1 to 760.6)	197.8 (174.5 to 225.6)
Neonatal encephalopathy due to birth asphyxia and trauma	1,715.2 (690.0 to 3,058.3)	1,864.9 (972.5 to 3,106.4)	9.2 (-14.5 to 62.6)	115.2 (81.6 to 160.3)	199.9 (147.7 to 264.9)	74.2 (44.6 to 108.3)
Neonatal sepsis and other neonatal infections	-	-	-	-	-	-
Hemolytic disease and other neonatal jaundice	162.9 (132.2 to 204.2)	422.1 (329.5 to 576.0)	152.1 (88.8 to 305.5)	58.9 (40.4 to 80.2)	139.0 (96.5 to 191.8)	132.0 (78.1 to 250.2)
Other neonatal disorders	-	-	-	65.7 (43.9 to 92.6)	171.1 (116.6 to 236.1)	160.8 (108.3 to 229.6)
Nutritional deficiencies	-	-	-	2,492.5 (1,645.0 to 3,688.2)	2,170.0 (1,428.7 to 3,204.4)	-13.0 (-14.9 to -11.1)
Protein-energy malnutrition	10.6 (5.5 to 17.7)	16.1 (8.7 to 26.5)	50.4 (20.3 to 93.8)	1.3 (0.5 to 2.4)	2.0 (0.7 to 4.0)	48.6 (-14.9 to 157.4)
Iodine deficiency	17,277.2 (16,330.1 to 18,275.6)	15,063.7 (14,228.7 to 15,937.7)	-13.2 (-19.8 to -6.5)	311.6 (193.3 to 492.8)	271.8 (169.1 to 428.8)	-12.7 (-19.7 to -5.7)
Vitamin A deficiency	301.3 (211.2 to 397.4)	257.5 (171.5 to 344.7)	-15.1 (-23.2 to -7.0)	14.5 (8.5 to 22.0)	11.7 (6.6 to 18.5)	-19.3 (-34.0 to -1.8)
Iron-deficiency anemia	83,551.0 (83,354.9 to 83,761.3)	79,798.0 (79,594.4 to 80,015.3)	-4.9 (-5.2 to -4.5)	2,165.0 (1,432.7 to 3,174.2)	1,884.4 (1,239.7 to 2,785.8)	-13.0 (-15.0 to -11.0)
Other nutritional deficiencies	-	-	-	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.3)	-6.3 (-61.6 to 118.9)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	256.7 (161.0 to 405.7)	316.6 (197.8 to 510.6)	23.1 (18.1 to 28.1)
Sexually transmitted diseases excluding HIV	-	-	-	166.9 (101.0 to 281.7)	228.2 (139.6 to 387.2)	36.6 (31.0 to 43.4)
Syphilis	20.2 (19.1 to 21.5)	14.0 (13.3 to 14.9)	-31.0 (-35.7 to -25.3)	4.0 (2.5 to 5.9)	2.8 (1.8 to 4.0)	-29.1 (-45.2 to -9.2)
Chlamydial infection	21,143.5 (20,565.0 to 21,762.9)	27,332.0 (26,558.9 to 28,118.9)	28.8 (23.6 to 33.5)	87.8 (55.6 to 139.6)	120.2 (75.8 to 189.3)	36.9 (29.3 to 44.8)
Gonococcal infection	4,494.0 (4,263.4 to 4,731.6)	6,486.9 (6,186.3 to 6,769.5)	44.1 (33.5 to 54.1)	30.0 (19.0 to 47.0)	44.4 (28.3 to 67.8)	47.9 (29.3 to 71.6)
Trichomoniasis	8,747.7 (8,033.5 to 9,416.0)	12,771.7 (11,759.5 to 13,916.7)	45.1 (30.3 to 64.5)	14.9 (5.9 to 32.0)	21.7 (8.5 to 46.6)	44.4 (28.2 to 66.7)
Genital herpes	92,013.7 (90,118.1 to 94,091.5)	120,735.5 (117,613.4 to 123,235.7)	30.9 (26.4 to 34.6)	26.0 (8.4 to 63.2)	34.4 (11.2 to 81.3)	32.3 (26.8 to 38.7)
Other sexually transmitted diseases	188.4 (125.8 to 263.9)	182.7 (128.4 to 248.6)	-3.7 (-10.3 to 6.8)	4.1 (2.7 to 6.1)	4.8 (3.2 to 6.9)	14.8 (-5.5 to 45.4)
Hepatitis	-	-	-	40.6 (26.1 to 58.7)	46.3 (30.0 to 67.1)	14.0 (8.5 to 20.1)
Hepatitis A	419.6 (409.6 to 425.1)	574.9 (568.9 to 577.8)	36.4 (33.3 to 40.5)	15.5 (9.9 to 22.8)	21.3 (13.8 to 31.1)	37.2 (27.3 to 48.0)
Hepatitis B	32,704.0 (31,987.8 to 33,406.5)	29,679.5 (28,975.1 to 30,520.2)	-9.5 (-12.6 to -6.8)	17.4 (11.3 to 25.3)	15.7 (10.1 to 22.8)	-9.8 (-16.5 to -3.1)
Hepatitis C	10,124.9 (9,909.3 to 10,353.6)	10,900.0 (10,639.4 to 11,165.1)	7.2 (3.9 to 10.8)	0.7 (0.4 to 1.0)	0.8 (0.5 to 1.1)	10.6 (-6.5 to 30.4)
Hepatitis E	249.4 (233.1 to 263.8)	298.8 (280.7 to 320.7)	19.5 (9.9 to 29.6)	7.0 (4.5 to 10.1)	8.5 (5.5 to 12.6)	22.6 (4.8 to 44.1)
Leprosy	19.4 (17.5 to 21.6)	18.8 (17.5 to 20.2)	-3.8 (-14.3 to 7.4)	1.1 (0.7 to 1.7)	1.1 (0.7 to 1.8)	3.9 (-31.3 to 58.6)
Other infectious diseases	2,162.7 (2,106.5 to 2,225.0)	1,818.9 (1,752.9 to 1,887.5)	-16.3 (-19.9 to -12.5)	48.1 (30.1 to 73.2)	41.0 (24.9 to 66.1)	-15.6 (-27.8 to 0.8)
Non-communicable diseases	-	-	-	33,379.1 (24,611.5 to 43,512.6)	46,025.0 (33,962.3 to 59,856.9)	37.9 (36.2 to 39.7)
Neoplasms	-	-	-	71.7 (51.0 to 95.7)	97.4 (68.6 to 130.8)	35.6 (23.2 to 50.0)
Esophageal cancer	2.4 (1.9 to 3.0)	3.2 (2.5 to 4.0)	30.1 (4.7 to 65.4)	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.7)	25.8 (1.7 to 53.8)
Stomach cancer	16.7 (14.9 to 18.7)	14.2 (12.7 to 15.8)	-15.4 (-25.8 to -3.5)	2.2 (1.5 to 3.0)	1.8 (1.2 to 2.4)	-20.0 (-29.8 to -8.2)
Liver cancer	-	-	-	1.8 (1.2 to 2.5)	2.0 (1.3 to 2.7)	10.2 (-13.2 to 36.3)
Liver cancer due to hepatitis B	5.1 (3.9 to 6.6)	6.4 (5.3 to 7.8)	25.6 (-8.0 to 67.5)	0.9 (0.6 to 1.2)	1.0 (0.7 to 1.4)	15.4 (-10.5 to 45.3)
Liver cancer due to hepatitis C	0.7 (0.6 to 0.9)	2.6 (2.1 to 3.1)	265.0 (162.9 to 388.6)	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.6)	235.5 (154.9 to 335.0)
Liver cancer due to alcohol use	1.3 (1.0 to 1.7)	1.0 (0.8 to 1.3)	-24.0 (-44.0 to 6.8)	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-29.0 (-45.0 to -4.3)
Liver cancer due to other causes	3.3 (2.6 to 4.1)	2.4 (2.0 to 2.9)	-26.3 (-44.7 to -3.9)	0.6 (0.4 to 0.8)	0.4 (0.3 to 0.5)	-31.5 (-46.9 to -14.7)
Larynx cancer	5.6 (4.2 to 7.1)	5.0 (3.6 to 6.5)	-12.0 (-28.0 to 8.7)	0.6 (0.4 to 0.8)	0.5 (0.3 to 0.7)	-11.0 (-26.9 to 9.8)
Tracheal, bronchus and lung cancer	8.2 (7.1 to 9.2)	8.5 (7.6 to 9.7)	2.0 (-10.8 to 28.0)	1.4 (1.0 to 1.9)	1.4 (1.0 to 1.8)	-4.1 (-15.6 to 20.2)
Breast cancer	81.5 (71.1 to 93.8)	143.9 (119.5 to 170.3)	76.3 (41.6 to 111.8)	6.7 (4.6 to 9.1)	10.9 (7.1 to 14.9)	62.4 (30.7 to 99.3)
Cervical cancer	126.3 (97.1 to 155.4)	99.5 (76.6 to 120.8)	-21.4 (-39.2 to -0.5)	9.6 (6.3 to 13.9)	7.8 (5.0 to 11.0)	-19.4 (-38.6 to 2.7)
Uterine cancer	19.1 (11.7 to 29.8)	18.0 (11.4 to 25.4)	-6.2 (-41.9 to 57.8)	1.3 (0.7 to 2.2)	1.2 (0.7 to 1.9)	-6.0 (-43.7 to 57.5)
Prostate cancer	1.0 (0.7 to 1.4)	2.6 (1.8 to 3.6)	155.0 (116.3 to 194.3)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	115.6 (81.7 to 152.3)
Colon and rectum cancer	33.0 (30.7 to 35.3)	60.1 (54.9 to 65.6)	81.2 (65.7 to 99.5)	3.0 (2.1 to 4.0)	5.0 (3.5 to 6.8)	68.4 (49.8 to 91.6)
Lip and oral cavity cancer	21.6 (17.2 to 26.9)	32.4 (25.2 to 41.8)	49.7 (15.2 to 96.7)	1.9 (1.2 to 2.8)	2.8 (1.8 to 4.1)	46.7 (8.1 to 97.5)
Nasopharynx cancer	17.9 (11.6 to 25.9)	15.9 (10.0 to 23.4)	-12.4 (-48.1 to 48.9)	1.7 (1.0 to 2.7)	1.5 (0.8 to 2.4)	-14.4 (-48.4 to 45.1)
Other pharynx cancer	2.0 (1.6 to 2.4)	2.9 (2.2 to 3.7)	44.9 (11.3 to 92.3)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	42.5 (9.6 to 87.6)
Gallbladder and biliary tract cancer	0.5 (0.4 to 0.6)	0.6 (0.5 to 0.8)	29.6 (0.2 to 62.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	22.1 (-5.5 to 52.9)
Pancreatic cancer	1.1 (1.0 to 1.2)	1.6 (1.4 to 1.9)	51.3 (31.5 to 74.0)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.5)	45.6 (28.2 to 64.0)
Malignant skin melanoma	65.7 (52.0 to 86.6)	94.8 (71.7 to 142.9)	42.0 (8.7 to 93.9)	3.9 (2.4 to 6.0)	5.6 (3.4 to 9.4)	39.5 (1.2 to 98.6)
Non-melanoma skin cancer	28.6 (24.8 to 33.7)	44.3 (36.7 to 53.9)	53.1 (24.2 to 93.0)	0.7 (0.4 to 1.1)	1.4 (0.8 to 2.3)	97.8 (35.0 to 200.8)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (25-29 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Ovarian cancer	16.8 (14.4 to 19.4)	23.8 (19.4 to 28.4)	41.1 (12.0 to 74.5)	2.3 (1.6 to 3.1)	3.2 (2.2 to 4.3)	39.6 (10.3 to 74.7)
Testicular cancer	63.1 (48.4 to 82.4)	90.5 (65.8 to 117.6)	42.4 (3.7 to 88.9)	3.9 (2.4 to 5.9)	5.4 (3.2 to 8.1)	40.7 (1.6 to 91.3)
Kidney cancer	7.5 (6.7 to 8.4)	13.2 (11.7 to 15.1)	75.1 (54.0 to 102.0)	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.4)	67.9 (47.0 to 94.4)
Bladder cancer	5.4 (4.5 to 6.0)	6.1 (5.3 to 7.1)	13.2 (-2.0 to 35.7)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	10.9 (-4.1 to 34.1)
Brain and nervous system cancer	37.7 (29.8 to 45.2)	53.0 (43.0 to 63.8)	39.4 (14.3 to 74.3)	4.2 (2.8 to 5.9)	5.7 (3.9 to 8.0)	36.0 (11.0 to 68.6)
Thyroid cancer	84.7 (66.9 to 105.0)	134.1 (104.9 to 163.2)	58.2 (21.4 to 102.8)	4.8 (3.1 to 7.0)	7.5 (4.6 to 11.2)	55.5 (18.1 to 105.6)
Mesothelioma	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.3)	-3.4 (-19.4 to 15.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-1.7 (-17.9 to 17.0)
Hodgkin lymphoma	59.7 (40.8 to 79.3)	60.1 (46.7 to 83.1)	-1.1 (-31.1 to 63.1)	5.0 (3.0 to 7.6)	4.7 (3.1 to 6.9)	-5.7 (-34.3 to 57.6)
Non-Hodgkin lymphoma	44.6 (36.1 to 53.1)	75.0 (62.4 to 91.9)	67.3 (37.7 to 107.3)	3.5 (2.3 to 4.9)	5.7 (3.8 to 8.1)	61.7 (30.0 to 101.6)
Multiple myeloma	1.1 (0.8 to 1.5)	1.9 (1.4 to 2.5)	75.4 (30.7 to 125.5)	0.2 (0.2 to 0.4)	0.4 (0.3 to 0.6)	70.7 (28.0 to 116.8)
Leukemia	44.0 (38.3 to 50.9)	72.8 (63.2 to 83.7)	65.2 (36.3 to 98.3)	6.4 (4.5 to 8.5)	9.4 (6.6 to 12.5)	47.1 (22.1 to 77.4)
Other neoplasms	59.9 (51.8 to 73.5)	153.2 (127.7 to 189.5)	155.4 (103.3 to 218.6)	4.5 (3.0 to 6.2)	10.6 (7.1 to 15.0)	137.8 (84.6 to 201.7)
Cardiovascular diseases	-	-	-	253.5 (172.2 to 352.8)	459.0 (296.2 to 665.7)	81.6 (44.7 to 118.7)
Rheumatic heart disease	1,945.9 (1,813.6 to 2,052.1)	3,001.4 (2,878.1 to 3,129.9)	53.6 (41.8 to 65.4)	97.2 (62.8 to 140.2)	146.9 (94.4 to 216.3)	50.9 (38.7 to 63.7)
Ischemic heart disease	29.2 (26.5 to 32.1)	43.5 (39.5 to 48.3)	47.6 (30.3 to 74.0)	3.5 (2.4 to 5.1)	5.3 (3.5 to 7.5)	48.1 (26.4 to 80.5)
Cerebrovascular disease	-	-	-	30.0 (20.8 to 40.0)	44.9 (31.4 to 59.3)	49.3 (37.3 to 63.7)
Ischemic stroke	91.6 (86.0 to 96.7)	143.5 (134.8 to 153.1)	55.6 (43.8 to 71.5)	15.1 (10.2 to 20.8)	23.5 (15.9 to 32.6)	55.4 (37.5 to 76.7)
Hemorrhagic stroke	89.3 (85.0 to 93.7)	129.3 (121.8 to 137.1)	44.0 (33.9 to 56.7)	14.9 (10.0 to 20.4)	21.3 (14.4 to 29.1)	43.3 (29.4 to 57.8)
Hypertensive heart disease	17.8 (16.9 to 18.9)	29.1 (27.4 to 31.4)	63.4 (49.1 to 77.6)	2.2 (1.5 to 3.1)	3.6 (2.4 to 5.0)	63.1 (47.0 to 78.1)
Cardiomyopathy and myocarditis	79.5 (75.4 to 83.5)	130.2 (121.5 to 137.0)	63.3 (53.0 to 73.5)	8.7 (5.9 to 12.3)	14.5 (9.6 to 20.3)	66.3 (45.5 to 90.2)
Atrial fibrillation and flutter	-	-	-	-	-	-
Peripheral vascular disease	-	-	-	-	-	-
Endocarditis	6.7 (5.4 to 8.0)	9.9 (7.7 to 11.9)	49.0 (27.6 to 67.5)	0.7 (0.4 to 1.0)	1.1 (0.7 to 1.6)	57.3 (33.0 to 81.7)
Other cardiovascular and circulatory diseases	1,562.5 (1,113.4 to 2,234.9)	3,412.9 (2,229.4 to 5,026.5)	120.1 (36.3 to 222.6)	111.1 (65.5 to 174.3)	242.8 (128.6 to 395.0)	120.9 (36.3 to 224.4)
Chronic respiratory diseases	-	-	-	1,457.5 (998.4 to 1,959.7)	2,001.2 (1,378.1 to 2,683.1)	37.1 (32.0 to 43.2)
Chronic obstructive pulmonary disease	9,540.0 (9,073.4 to 9,979.7)	13,465.9 (12,863.3 to 14,070.8)	40.6 (39.3 to 42.0)	771.2 (504.6 to 1,106.2)	1,144.5 (753.8 to 1,625.2)	48.2 (40.7 to 57.1)
Pneumoconiosis	-	-	-	1.1 (0.8 to 1.5)	1.8 (1.2 to 2.5)	61.8 (55.1 to 68.2)
Silicosis	1.0 (0.8 to 1.2)	1.3 (1.0 to 1.4)	19.8 (15.0 to 24.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	19.0 (13.9 to 23.4)
Asbestosis	0.3 (0.3 to 0.3)	0.4 (0.3 to 0.4)	28.5 (21.9 to 34.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	27.6 (20.3 to 34.8)
Coal workers pneumoconiosis	1.2 (1.1 to 1.3)	1.4 (1.2 to 1.5)	14.7 (11.8 to 17.3)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.4)	14.1 (11.0 to 17.3)
Other pneumoconiosis	3.5 (3.1 to 3.9)	6.9 (6.1 to 7.7)	95.4 (90.2 to 100.0)	0.6 (0.4 to 0.9)	1.2 (0.8 to 1.8)	93.8 (89.1 to 98.4)
Asthma	13,284.8 (12,970.3 to 13,628.4)	17,018.9 (16,600.5 to 17,500.1)	27.5 (23.0 to 32.8)	590.9 (383.9 to 836.3)	757.9 (491.3 to 1,095.8)	28.2 (23.0 to 34.0)
Interstitial lung disease and pulmonary sarcoidosis	19.4 (18.2 to 20.8)	27.0 (24.6 to 29.5)	38.1 (24.4 to 54.9)	2.5 (1.6 to 3.7)	3.5 (2.2 to 5.2)	39.8 (26.2 to 56.1)
Other chronic respiratory diseases	-	-	-	91.8 (54.3 to 140.0)	93.5 (58.3 to 140.0)	1.7 (-12.0 to 19.1)
Cirrhosis	-	-	-	24.5 (16.8 to 34.4)	31.3 (21.2 to 44.2)	27.2 (10.7 to 45.8)
Cirrhosis due to hepatitis B	47.9 (44.4 to 51.7)	51.2 (46.5 to 56.6)	6.6 (-6.8 to 18.5)	8.1 (5.4 to 11.9)	8.7 (5.6 to 13.0)	7.0 (-17.9 to 36.0)
Cirrhosis due to hepatitis C	28.2 (26.2 to 30.7)	40.1 (36.6 to 44.0)	41.4 (26.5 to 57.5)	4.8 (3.2 to 7.1)	6.9 (4.4 to 10.2)	42.3 (8.2 to 85.5)
Cirrhosis due to alcohol use	36.4 (32.2 to 40.6)	35.4 (30.6 to 42.3)	-3.9 (-18.1 to 15.9)	6.2 (3.9 to 9.0)	6.0 (3.7 to 9.4)	-3.6 (-32.4 to 37.4)
Cirrhosis due to other causes	31.7 (27.4 to 34.8)	56.6 (51.3 to 62.9)	78.3 (56.3 to 107.1)	5.4 (3.4 to 7.7)	9.6 (6.3 to 14.3)	78.1 (29.4 to 152.4)
Digestive diseases	-	-	-	299.5 (211.9 to 399.4)	365.3 (260.5 to 491.7)	22.1 (14.6 to 30.0)
Peptic ulcer disease	592.2 (560.0 to 629.8)	431.7 (394.3 to 472.2)	-27.5 (-34.3 to -20.0)	23.1 (15.4 to 33.9)	18.4 (12.0 to 26.7)	-20.8 (-34.5 to -1.1)
Gastritis and duodenitis	1,902.2 (1,775.2 to 2,022.8)	1,745.2 (1,615.7 to 1,864.3)	-8.6 (-16.6 to -0.5)	74.5 (50.1 to 107.4)	69.0 (46.4 to 99.8)	-7.2 (-17.5 to 3.8)
Appendicitis	64.0 (55.3 to 74.5)	75.6 (63.7 to 89.9)	17.0 (-6.7 to 52.4)	19.6 (12.2 to 28.6)	23.2 (15.0 to 33.4)	19.2 (-13.1 to 60.7)
Paralytic ileus and intestinal obstruction	1.8 (1.8 to 1.9)	2.6 (2.5 to 2.7)	42.7 (35.0 to 48.5)	0.6 (0.4 to 0.8)	0.9 (0.6 to 1.2)	43.0 (35.3 to 48.9)
Inguinal, femoral, and abdominal hernia	378.0 (357.5 to 398.8)	448.9 (421.8 to 481.9)	18.0 (8.4 to 29.5)	4.1 (2.0 to 7.7)	4.8 (2.4 to 9.3)	19.0 (5.0 to 33.8)
Inflammatory bowel disease	447.4 (437.4 to 457.5)	705.9 (691.2 to 720.6)	57.3 (52.9 to 61.3)	97.6 (65.8 to 134.3)	154.1 (105.5 to 212.3)	57.8 (47.2 to 69.0)
Vascular intestinal disorders	0.4 (0.4 to 0.5)	0.6 (0.6 to 0.7)	34.2 (17.4 to 54.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	34.5 (17.6 to 54.7)
Gallbladder and biliary diseases	161.3 (151.3 to 173.1)	181.6 (170.4 to 196.8)	11.7 (1.6 to 25.6)	17.7 (11.8 to 24.2)	19.9 (13.4 to 27.7)	12.8 (-3.2 to 31.0)
Pancreatitis	90.0 (87.8 to 92.6)	121.7 (118.2 to 125.2)	34.6 (29.5 to 40.4)	27.5 (18.3 to 37.2)	37.3 (24.6 to 51.4)	34.6 (17.0 to 59.1)
Other digestive diseases	-	-	-	34.7 (23.8 to 47.7)	37.6 (26.0 to 52.5)	9.0 (-4.1 to 19.9)
Neurological disorders	-	-	-	3,444.9 (2,289.8 to 4,808.6)	5,056.2 (3,360.4 to 7,057.2)	46.9 (39.7 to 54.1)
Alzheimer disease and other dementias	-	-	-	-	-	-
Parkinson disease	4.0 (2.0 to 6.6)	5.1 (2.9 to 8.2)	27.8 (7.9 to 55.8)	0.5 (0.2 to 1.0)	0.7 (0.3 to 1.2)	28.1 (8.0 to 56.7)
Epilepsy	1,413.1 (1,322.3 to 1,509.0)	1,906.4 (1,760.4 to 2,041.1)	34.5 (21.6 to 47.8)	463.8 (316.8 to 615.8)	667.8 (459.7 to 878.4)	43.7 (29.7 to 61.5)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (25-29 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Multiple sclerosis	82.8 (79.6 to 85.6)	155.8 (150.8 to 160.7)	87.5 (78.4 to 96.9)	28.3 (19.8 to 36.7)	53.4 (37.2 to 68.7)	88.7 (62.9 to 117.4)
Migraine	68,960.6 (66,142.1 to 71,968.4)	95,783.8 (91,767.5 to 99,540.7)	38.5 (30.6 to 45.9)	2,386.7 (1,438.6 to 3,512.6)	3,325.8 (1,995.5 to 4,848.3)	39.5 (30.9 to 47.6)
Tension-type headache	122,224.1 (116,662.8 to 127,561.3)	168,180.5 (163,178.0 to 173,328.8)	37.0 (31.0 to 44.2)	187.2 (89.8 to 325.5)	257.8 (125.0 to 451.3)	37.7 (30.9 to 45.3)
Medication overuse headache	2,307.2 (1,579.3 to 2,971.3)	4,609.0 (3,157.4 to 5,961.0)	99.4 (80.6 to 119.8)	370.0 (216.5 to 567.1)	739.9 (433.9 to 1,147.7)	100.3 (80.6 to 121.8)
Other neurological disorders	0.6 (0.5 to 0.7)	0.8 (0.7 to 0.9)	40.3 (21.3 to 59.8)	8.4 (5.6 to 12.1)	10.8 (7.3 to 14.3)	30.2 (2.0 to 60.2)
Mental and substance use disorders	-	-	-	13,351.2 (9,546.8 to 17,682.1)	18,196.4 (12,963.0 to 23,985.7)	36.3 (34.6 to 38.0)
Schizophrenia	1,918.8 (1,759.1 to 2,061.6)	2,522.6 (2,313.0 to 2,702.4)	30.9 (29.4 to 32.6)	1,270.6 (922.9 to 1,550.5)	1,673.8 (1,213.9 to 2,023.2)	31.8 (27.9 to 35.8)
Alcohol use disorders	9,146.6 (8,506.4 to 9,924.1)	11,404.8 (10,614.5 to 12,381.2)	24.2 (21.6 to 26.9)	926.3 (611.1 to 1,317.1)	1,155.9 (763.6 to 1,650.8)	24.7 (21.1 to 28.5)
Drug use disorders	-	-	-	1,638.8 (1,123.7 to 2,207.0)	2,196.6 (1,487.7 to 2,950.3)	34.1 (27.6 to 40.1)
Opioid use disorders	1,527.1 (1,105.6 to 2,053.2)	2,189.4 (1,536.1 to 3,037.0)	42.5 (35.1 to 49.3)	645.2 (404.5 to 936.2)	927.4 (565.5 to 1,382.7)	43.4 (34.7 to 51.6)
Cocaine use disorders	1,053.2 (1,023.9 to 1,083.5)	1,324.5 (1,280.3 to 1,370.9)	25.5 (19.3 to 30.7)	145.5 (95.4 to 206.9)	183.3 (120.0 to 258.8)	25.9 (16.6 to 35.2)
Amphetamine use disorders	2,454.4 (2,378.3 to 2,538.5)	3,145.7 (3,025.6 to 3,276.2)	27.7 (20.8 to 34.0)	322.6 (203.1 to 465.8)	414.8 (261.6 to 596.5)	28.7 (20.2 to 37.5)
Cannabis use disorders	1,820.2 (1,582.9 to 2,070.5)	2,314.6 (2,001.7 to 2,646.3)	26.7 (24.4 to 28.7)	52.8 (34.6 to 79.3)	67.2 (43.0 to 101.8)	27.1 (18.3 to 37.4)
Other drug use disorders	-	-	-	472.6 (314.8 to 659.4)	604.0 (399.9 to 836.5)	27.9 (18.8 to 37.4)
Depressive disorders	-	-	-	4,483.8 (2,902.4 to 6,334.4)	6,391.7 (4,122.6 to 9,064.1)	42.5 (39.3 to 46.0)
Major depressive disorder	18,098.4 (13,674.8 to 22,534.3)	26,029.0 (19,715.2 to 32,185.4)	43.2 (39.6 to 47.3)	3,777.9 (2,353.7 to 5,472.3)	5,443.5 (3,408.9 to 7,909.0)	44.0 (40.1 to 48.5)
Dysthymia	7,175.1 (5,453.7 to 8,994.1)	9,629.5 (7,206.6 to 12,172.5)	33.7 (30.0 to 36.5)	705.9 (436.4 to 1,054.3)	948.2 (582.5 to 1,424.0)	34.4 (29.6 to 37.9)
Bipolar disorder	5,131.8 (4,167.2 to 6,254.3)	7,037.7 (5,642.1 to 8,648.7)	36.5 (32.9 to 40.7)	1,062.9 (630.6 to 1,613.7)	1,460.9 (879.3 to 2,240.3)	37.3 (32.2 to 43.0)
Anxiety disorders	21,745.7 (14,278.7 to 30,454.0)	29,026.8 (18,973.0 to 40,623.4)	33.0 (29.3 to 36.1)	2,025.1 (1,165.9 to 3,266.6)	2,705.9 (1,558.3 to 4,359.3)	33.6 (29.5 to 37.6)
Eating disorders	-	-	-	289.2 (172.7 to 462.9)	377.6 (219.9 to 618.0)	30.3 (23.0 to 37.3)
Anorexia nervosa	270.9 (222.0 to 333.7)	381.6 (302.5 to 484.1)	40.1 (34.0 to 47.1)	57.4 (36.7 to 85.1)	81.2 (52.1 to 121.6)	41.0 (30.5 to 53.0)
Bulimia nervosa	1,101.6 (722.0 to 1,644.8)	1,406.3 (880.5 to 2,164.8)	26.7 (18.2 to 33.9)	231.8 (131.0 to 386.3)	296.3 (160.0 to 509.8)	27.3 (18.3 to 35.8)
Autistic spectrum disorders	-	-	-	562.6 (392.7 to 763.9)	768.3 (537.9 to 1,042.3)	36.6 (33.3 to 40.1)
Autism	1,440.1 (1,374.5 to 1,509.8)	1,963.8 (1,873.7 to 2,060.2)	35.8 (35.5 to 36.1)	357.1 (240.2 to 489.3)	487.8 (328.9 to 666.2)	36.6 (31.6 to 41.4)
Asperger syndrome	2,045.7 (1,906.3 to 2,175.5)	2,788.9 (2,592.7 to 2,969.7)	35.8 (35.4 to 36.1)	205.5 (142.8 to 286.6)	280.5 (194.7 to 392.5)	36.5 (32.7 to 40.6)
Attention-deficit/hyperactivity disorder	881.3 (737.9 to 1,001.6)	1,183.8 (993.1 to 1,344.7)	33.8 (32.4 to 35.2)	10.7 (6.2 to 16.5)	14.3 (8.3 to 22.4)	34.3 (23.7 to 46.5)
Conduct disorder	-	-	-	-	-	-
Idiopathic intellectual disability	6,659.2 (5,232.5 to 8,235.1)	8,649.5 (6,983.9 to 10,643.6)	29.2 (18.8 to 43.2)	331.6 (216.5 to 479.3)	427.3 (282.5 to 610.5)	28.8 (18.0 to 43.4)
Other mental and substance use disorders	9,809.6 (7,817.2 to 11,969.4)	13,366.9 (10,652.1 to 16,309.9)	35.7 (35.7 to 35.7)	749.8 (474.5 to 1,075.4)	1,024.0 (648.8 to 1,475.0)	36.6 (32.9 to 40.2)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	2,498.2 (1,722.0 to 3,450.0)	3,690.8 (2,530.3 to 5,074.9)	47.7 (43.4 to 52.5)
Diabetes mellitus	9,896.7 (9,428.4 to 10,313.0)	18,878.8 (18,108.2 to 19,681.9)	90.0 (78.4 to 101.4)	590.4 (394.3 to 836.1)	1,111.9 (743.8 to 1,566.9)	88.2 (77.2 to 100.1)
Acute glomerulonephritis	1.4 (1.3 to 1.6)	1.5 (1.4 to 1.7)	7.8 (3.6 to 11.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	8.0 (3.8 to 11.4)
Chronic kidney disease	-	-	-	487.2 (308.4 to 742.0)	652.9 (423.7 to 988.6)	34.6 (23.3 to 45.4)
Chronic kidney disease due to diabetes mellitus	1,882.3 (992.7 to 3,749.1)	2,687.0 (1,543.7 to 4,599.4)	46.3 (11.3 to 70.6)	52.6 (33.4 to 80.0)	72.2 (46.9 to 108.8)	37.8 (16.0 to 65.7)
Chronic kidney disease due to hypertension	5,356.0 (2,924.7 to 10,274.6)	6,562.1 (3,663.7 to 11,866.7)	23.2 (5.6 to 40.1)	134.4 (86.0 to 201.5)	163.4 (105.6 to 245.0)	21.9 (6.7 to 41.8)
Chronic kidney disease due to glomerulonephritis	5,393.2 (2,949.1 to 10,095.8)	7,090.6 (4,064.5 to 11,151.7)	35.6 (4.8 to 49.4)	136.4 (85.7 to 212.0)	168.1 (105.8 to 259.0)	23.1 (6.0 to 43.1)
Chronic kidney disease due to other causes	6,039.3 (3,385.4 to 11,252.4)	9,513.5 (5,564.1 to 15,856.6)	58.7 (36.8 to 80.8)	163.8 (102.4 to 256.5)	249.2 (160.0 to 382.6)	52.2 (35.3 to 76.6)
Urinary diseases and male infertility	-	-	-	70.4 (40.0 to 119.1)	102.1 (57.1 to 174.1)	45.3 (32.6 to 57.0)
Interstitial nephritis and urinary tract infections	93.8 (91.3 to 96.3)	143.6 (139.6 to 147.3)	52.6 (47.5 to 58.3)	3.2 (1.9 to 4.9)	4.8 (3.0 to 7.2)	53.3 (30.8 to 79.7)
Urolithiasis	1,276.8 (943.6 to 1,744.0)	1,698.1 (1,143.5 to 2,488.9)	33.6 (12.5 to 47.0)	18.9 (12.2 to 27.7)	25.2 (15.7 to 38.7)	33.0 (18.7 to 49.0)
Benign prostatic hyperplasia	-	-	-	-	-	-
Male infertility due to other causes	5,853.7 (5,518.8 to 6,227.7)	8,347.2 (7,762.7 to 8,942.4)	42.2 (29.0 to 55.3)	39.7 (17.4 to 78.1)	56.6 (24.7 to 115.6)	42.6 (28.0 to 57.0)
Other urinary diseases	-	-	-	8.6 (5.2 to 13.0)	15.5 (8.3 to 24.5)	84.4 (29.4 to 129.8)
Gynecological diseases	-	-	-	920.2 (610.8 to 1,327.3)	1,296.9 (854.6 to 1,884.5)	40.8 (33.5 to 48.8)
Uterine fibroids	5,776.0 (4,761.3 to 6,802.2)	7,766.5 (6,304.9 to 9,242.6)	33.9 (31.5 to 35.9)	146.0 (86.9 to 230.0)	184.9 (108.4 to 295.5)	26.6 (21.7 to 31.5)
Polycystic ovarian syndrome	12,620.3 (12,193.7 to 13,121.3)	18,406.1 (17,696.4 to 19,175.8)	45.2 (37.1 to 53.2)	125.3 (58.3 to 238.0)	183.2 (85.6 to 345.5)	46.2 (38.0 to 54.2)
Female infertility due to other causes	3,345.8 (2,560.0 to 4,047.4)	5,137.5 (4,007.7 to 6,215.4)	53.0 (34.5 to 76.2)	19.1 (7.4 to 39.1)	29.4 (11.5 to 60.1)	53.4 (32.5 to 75.7)
Endometriosis	1,668.3 (1,610.5 to 1,735.8)	2,247.6 (2,161.5 to 2,334.4)	34.2 (26.9 to 41.7)	156.2 (103.9 to 213.9)	210.8 (139.7 to 288.4)	35.1 (26.1 to 44.4)
Genital prolapse	25,233.0 (24,203.8 to 26,211.7)	35,234.0 (33,849.7 to 36,719.0)	39.1 (31.5 to 47.8)	81.4 (39.4 to 152.9)	113.8 (54.6 to 215.4)	39.6 (31.8 to 48.4)
Premenstrual syndrome	36,776.8 (33,588.9 to 40,662.7)	57,968.6 (52,625.1 to 64,143.2)	57.1 (36.9 to 77.9)	310.6 (192.9 to 467.6)	490.6 (300.3 to 737.0)	57.9 (37.1 to 78.9)
Other gynecological diseases	2,617.1 (2,486.5 to 2,756.4)	2,902.4 (2,775.0 to 3,064.4)	10.3 (2.3 to 20.1)	81.6 (55.4 to 115.4)	84.2 (57.3 to 122.3)	3.1 (-7.0 to 18.0)
Hemoglobinopathies and hemolytic anemias	-	-	-	326.1 (218.8 to 471.0)	424.6 (286.0 to 610.7)	30.2 (24.9 to 36.8)
Thalassemias	35.6 (31.1 to 40.8)	52.7 (46.8 to 60.4)	47.0 (39.0 to 57.5)	3.0 (2.0 to 4.2)	4.1 (2.7 to 5.8)	37.0 (21.4 to 55.7)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (25-29 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Thalassemia trait	12,500.2 (11,296.4 to 14,126.1)	17,740.3 (16,376.7 to 19,574.2)	41.6 (37.8 to 44.9)	167.5 (112.0 to 242.3)	247.4 (164.2 to 358.5)	47.7 (39.5 to 55.7)
Sickle cell disorders	118.1 (105.7 to 128.6)	235.4 (214.3 to 255.6)	97.8 (81.6 to 119.7)	16.0 (11.2 to 21.8)	32.5 (22.8 to 44.5)	103.0 (78.4 to 133.5)
Sickle cell trait	13,042.6 (12,390.5 to 13,643.0)	21,334.9 (20,329.3 to 22,247.4)	62.9 (60.0 to 65.7)	52.9 (33.9 to 77.7)	76.0 (50.2 to 109.6)	43.5 (30.5 to 62.0)
G6PD deficiency	18,619.2 (18,154.6 to 19,061.7)	28,081.1 (27,365.2 to 28,770.6)	50.2 (45.1 to 55.3)	1.5 (1.0 to 2.1)	2.1 (1.4 to 2.9)	40.3 (28.5 to 52.5)
G6PD trait	69,448.6 (69,010.1 to 69,807.8)	98,286.3 (97,624.7 to 98,865.2)	41.0 (39.9 to 42.2)	3.2 (1.9 to 4.8)	4.2 (2.4 to 6.7)	30.1 (-12.5 to 97.0)
Other hemoglobinopathies and hemolytic anemias	3,973.4 (3,880.8 to 4,053.5)	3,247.2 (3,154.4 to 3,337.6)	-18.6 (-21.3 to -15.8)	82.1 (53.8 to 121.8)	58.2 (37.0 to 86.4)	-29.5 (-37.3 to -20.3)
Endocrine, metabolic, blood, and immune disorders	3,821.4 (3,664.3 to 3,979.2)	3,825.6 (3,733.7 to 3,908.9)	-0.3 (-5.0 to 4.4)	103.8 (70.5 to 147.2)	102.2 (69.3 to 145.0)	-1.5 (-10.1 to 8.4)
Musculoskeletal disorders	-	-	-	6,900.5 (4,775.0 to 9,390.5)	9,341.4 (6,469.7 to 12,504.0)	35.4 (30.4 to 40.2)
Rheumatoid arthritis	438.4 (431.4 to 445.9)	619.6 (609.6 to 629.6)	40.8 (37.4 to 43.8)	108.2 (75.9 to 143.7)	153.1 (108.4 to 206.2)	41.6 (31.6 to 51.9)
Osteoarthritis	-	-	-	-	-	-
Low back and neck pain	-	-	-	6,300.1 (4,360.5 to 8,538.0)	8,445.9 (5,810.2 to 11,296.9)	34.1 (28.7 to 39.4)
Low back pain	35,057.0 (33,931.4 to 36,277.9)	47,352.0 (45,860.4 to 48,847.4)	34.5 (28.6 to 41.0)	4,026.5 (2,735.4 to 5,633.4)	5,448.7 (3,660.5 to 7,605.6)	35.3 (29.2 to 42.0)
Neck pain	22,513.6 (21,742.8 to 23,272.6)	29,664.9 (28,281.7 to 30,960.5)	31.6 (23.4 to 38.7)	2,273.6 (1,571.3 to 3,138.0)	2,997.2 (2,073.5 to 4,130.7)	32.1 (23.8 to 39.4)
Gout	81.2 (79.1 to 83.1)	97.5 (95.0 to 99.6)	19.7 (15.3 to 24.1)	2.8 (1.9 to 4.0)	3.4 (2.3 to 4.7)	20.9 (9.9 to 30.7)
Other musculoskeletal disorders	5,132.5 (3,642.6 to 6,605.2)	7,744.8 (5,616.9 to 9,955.2)	50.0 (44.1 to 58.3)	489.4 (297.8 to 757.7)	739.0 (453.3 to 1,143.8)	50.9 (43.2 to 61.1)
Other non-communicable diseases	-	-	-	5,077.6 (3,267.0 to 7,677.4)	6,786.1 (4,368.8 to 10,255.2)	33.8 (29.8 to 37.5)
Congenital anomalies	-	-	-	365.1 (269.5 to 471.6)	593.2 (430.0 to 763.5)	62.1 (51.0 to 75.9)
Neural tube defects	82.9 (81.0 to 85.1)	137.2 (133.9 to 141.0)	64.8 (59.2 to 70.5)	25.6 (18.0 to 33.1)	43.1 (30.2 to 56.1)	68.6 (52.3 to 87.0)
Congenital heart anomalies	1,568.6 (1,514.0 to 1,624.9)	3,005.7 (2,902.7 to 3,127.7)	90.6 (82.6 to 101.5)	54.5 (22.7 to 94.6)	107.1 (45.2 to 181.9)	96.3 (86.5 to 108.4)
Orofacial clefts	258.6 (248.5 to 267.9)	508.1 (490.9 to 524.5)	95.4 (87.0 to 107.0)	3.3 (2.2 to 4.9)	6.1 (4.0 to 8.7)	81.5 (62.1 to 102.9)
Down syndrome	361.9 (348.9 to 376.7)	623.5 (600.3 to 648.0)	71.6 (62.9 to 80.6)	39.7 (28.9 to 51.4)	68.4 (50.2 to 88.9)	72.4 (58.5 to 88.3)
Turner syndrome	16.6 (15.7 to 17.5)	25.5 (24.3 to 26.9)	52.7 (44.4 to 64.3)	0.3 (0.2 to 0.5)	0.5 (0.2 to 0.8)	52.1 (37.3 to 70.9)
Klinefelter syndrome	12.9 (12.2 to 13.5)	18.3 (17.5 to 19.2)	40.9 (32.2 to 52.0)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.4)	41.7 (26.7 to 56.9)
Chromosomal unbalanced rearrangements	504.3 (487.6 to 519.1)	833.0 (798.9 to 874.8)	64.4 (56.3 to 74.0)	55.2 (39.7 to 71.5)	91.3 (65.3 to 118.1)	65.7 (52.8 to 78.5)
Other congenital anomalies	1,822.7 (1,568.8 to 2,042.8)	2,281.9 (1,939.5 to 2,582.8)	24.5 (18.3 to 31.9)	186.3 (132.6 to 254.5)	276.5 (191.2 to 370.0)	48.1 (32.5 to 69.3)
Skin and subcutaneous diseases	-	-	-	2,655.3 (1,664.1 to 4,218.8)	3,598.6 (2,272.8 to 5,688.5)	35.7 (30.3 to 40.4)
Dermatitis	25,217.5 (20,143.3 to 30,441.2)	33,403.8 (26,745.3 to 40,248.2)	32.0 (30.7 to 33.3)	653.8 (412.2 to 952.4)	870.9 (554.1 to 1,264.1)	33.2 (30.9 to 35.8)
Psoriasis	3,933.7 (3,262.4 to 4,755.8)	5,249.0 (4,322.7 to 6,373.4)	32.9 (31.5 to 34.3)	326.5 (218.1 to 466.7)	436.6 (290.1 to 629.9)	33.7 (28.1 to 39.2)
Cellulitis	80.8 (59.4 to 109.7)	93.7 (69.8 to 126.9)	15.6 (7.4 to 22.8)	5.9 (3.5 to 9.5)	6.8 (4.1 to 10.6)	16.3 (-5.1 to 41.0)
Pyoderma	276.7 (185.8 to 398.2)	303.5 (201.7 to 444.9)	8.8 (-7.0 to 26.5)	1.6 (0.6 to 3.5)	1.7 (0.6 to 3.9)	9.7 (-9.5 to 29.9)
Scabies	4,507.3 (4,038.3 to 4,988.5)	5,955.4 (5,432.2 to 6,660.8)	30.4 (15.2 to 55.9)	116.4 (66.2 to 185.2)	154.2 (86.0 to 251.8)	31.1 (15.7 to 57.0)
Fungal skin diseases	40,962.9 (32,108.1 to 51,789.1)	56,485.8 (43,941.9 to 71,914.8)	37.3 (34.6 to 39.5)	232.6 (94.6 to 501.8)	320.8 (130.3 to 695.4)	37.9 (35.1 to 40.2)
Viral skin diseases	7,391.7 (3,347.9 to 12,453.3)	9,880.9 (4,725.6 to 16,364.6)	33.2 (28.6 to 41.7)	229.0 (87.8 to 447.0)	306.3 (124.1 to 595.7)	33.9 (28.6 to 43.8)
Acne vulgaris	62,521.7 (58,317.2 to 67,007.7)	82,112.8 (74,538.5 to 89,629.2)	31.6 (16.8 to 45.3)	677.1 (324.1 to 1,274.7)	890.1 (426.9 to 1,659.6)	32.2 (17.0 to 45.7)
Alopecia areata	444.8 (431.1 to 457.5)	594.0 (574.1 to 614.3)	33.1 (27.8 to 38.1)	15.1 (9.7 to 22.8)	20.2 (12.9 to 30.1)	33.4 (22.5 to 45.0)
Pruritus	38.7 (36.5 to 41.4)	50.3 (46.0 to 54.1)	29.8 (15.1 to 41.4)	0.4 (0.2 to 0.8)	0.5 (0.3 to 1.1)	30.2 (7.0 to 57.4)
Urticaria	4,678.7 (4,365.8 to 5,058.3)	7,190.7 (6,414.2 to 7,963.2)	53.3 (31.5 to 74.2)	283.4 (183.2 to 397.4)	436.6 (275.1 to 638.0)	54.4 (31.7 to 75.6)
Decubitus ulcer	33.7 (32.4 to 35.1)	37.3 (35.9 to 39.2)	10.5 (5.8 to 15.3)	5.6 (3.7 to 7.8)	6.2 (4.2 to 8.6)	11.2 (-1.3 to 24.1)
Other skin and subcutaneous diseases	18,042.3 (4,538.5 to 39,480.1)	24,681.1 (6,126.7 to 54,499.2)	36.3 (33.9 to 38.6)	107.8 (23.8 to 287.8)	147.5 (31.9 to 395.0)	36.8 (33.6 to 39.6)
Sense organ diseases	-	-	-	1,429.0 (923.3 to 2,099.2)	1,737.2 (1,115.3 to 2,543.1)	21.8 (15.2 to 26.3)
Glaucoma	441.9 (368.2 to 535.1)	607.4 (499.4 to 730.8)	37.4 (24.7 to 49.3)	25.2 (16.6 to 36.9)	32.6 (21.0 to 47.5)	29.5 (14.8 to 46.3)
Cataract	-	-	0.0 (0.0 to 0.0)	-	-	-
Macular degeneration	-	-	-	-	-	-
Uncorrected refractive error	18,908.3 (18,164.8 to 19,628.9)	24,793.4 (23,836.3 to 25,774.0)	30.5 (26.3 to 34.9)	360.5 (229.4 to 568.3)	461.4 (291.8 to 728.5)	27.9 (23.9 to 31.9)
Age-related and other hearing loss	26,148.6 (18,291.1 to 32,300.0)	32,179.8 (22,583.5 to 40,217.4)	22.4 (16.6 to 28.3)	786.0 (455.8 to 1,242.5)	920.3 (526.7 to 1,446.7)	17.4 (6.9 to 25.0)
Other vision loss	1,426.2 (1,162.5 to 1,736.8)	1,523.2 (1,241.0 to 1,874.8)	6.3 (2.2 to 10.6)	82.4 (54.7 to 118.8)	83.9 (55.3 to 121.1)	1.8 (-6.2 to 9.6)
Other sense organ diseases	6,541.4 (6,394.9 to 6,697.6)	8,931.6 (8,700.3 to 9,147.4)	35.9 (31.6 to 40.4)	174.9 (106.8 to 261.7)	239.0 (146.9 to 354.8)	36.6 (30.9 to 42.6)
Oral disorders	-	-	-	628.3 (354.6 to 1,024.6)	857.2 (479.1 to 1,416.5)	36.4 (33.5 to 39.2)
Deciduous caries	-	-	-	-	-	-
Permanent caries	200,641.2 (198,140.7 to 203,184.5)	270,077.7 (266,149.0 to 273,713.3)	34.0 (31.5 to 36.7)	182.9 (84.9 to 350.6)	252.8 (115.3 to 492.9)	38.2 (34.8 to 41.6)
Periodontal diseases	19,076.3 (18,718.5 to 19,421.7)	27,033.4 (26,496.0 to 27,590.3)	41.1 (37.0 to 45.1)	127.3 (50.9 to 261.8)	180.5 (72.4 to 372.0)	41.8 (37.6 to 46.1)
Edentulism and severe tooth loss	1,513.6 (1,455.1 to 1,567.1)	1,762.9 (1,696.0 to 1,834.7)	16.2 (10.1 to 22.7)	43.8 (29.0 to 61.2)	51.0 (33.7 to 71.9)	16.6 (7.6 to 25.7)
Other oral disorders	9,248.0 (9,053.9 to 9,459.4)	12,565.4 (12,244.9 to 12,858.7)	35.4 (30.8 to 39.7)	274.3 (172.2 to 410.7)	378.8 (233.3 to 558.8)	35.9 (31.2 to 40.8)
Injuries	-	-	-	2,604.2 (1,895.0 to 3,559.6)	2,005.8 (1,496.9 to 2,597.6)	-21.9 (-37.4 to -11.4)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (25-29 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Transport injuries	-	-	-	820.2 (618.1 to 1,054.5)	706.4 (532.6 to 924.1)	-14.1 (-19.8 to -7.2)
Road injuries	-	-	-	699.2 (526.4 to 896.4)	608.5 (455.7 to 796.7)	-13.2 (-19.3 to -6.0)
Pedestrian road injuries	-	-	-	158.6 (118.7 to 204.4)	151.5 (111.1 to 200.8)	-4.6 (-12.3 to 4.3)
Cyclist road injuries	-	-	-	57.8 (43.3 to 74.8)	48.3 (35.8 to 63.7)	-16.5 (-21.8 to -9.9)
Motorcyclist road injuries	-	-	-	169.1 (128.6 to 218.0)	123.7 (92.4 to 162.3)	-26.9 (-33.3 to -19.5)
Motor vehicle road injuries	-	-	-	306.9 (230.9 to 391.2)	279.2 (210.4 to 364.7)	-9.2 (-15.7 to -1.9)
Other road injuries	-	-	-	6.7 (5.0 to 8.7)	5.8 (4.3 to 7.5)	-14.3 (-20.0 to -7.5)
Other transport injuries	-	-	-	121.0 (91.1 to 157.0)	97.9 (74.1 to 127.2)	-19.2 (-23.9 to -13.7)
Unintentional injuries	-	-	-	1,070.3 (814.3 to 1,380.1)	1,073.3 (802.8 to 1,408.9)	0.1 (-4.8 to 5.4)
Falls	-	-	-	425.0 (320.0 to 549.1)	455.5 (330.5 to 606.5)	6.9 (0.0 to 14.4)
Drowning	-	-	-	37.1 (27.2 to 48.7)	27.9 (20.4 to 36.5)	-24.9 (-30.8 to -18.2)
Fire, heat, and hot substances	-	-	-	98.2 (76.2 to 125.5)	81.9 (61.6 to 105.8)	-16.7 (-24.6 to -9.0)
Poisonings	-	-	-	7.7 (5.4 to 10.3)	6.5 (4.6 to 8.7)	-14.9 (-20.8 to -8.2)
Exposure to mechanical forces	-	-	-	312.8 (238.7 to 408.6)	296.7 (219.8 to 395.3)	-5.4 (-10.0 to -0.3)
Unintentional firearm injuries	-	-	-	14.4 (11.1 to 18.2)	13.3 (10.1 to 17.4)	-7.2 (-13.4 to -1.0)
Unintentional suffocation	-	-	-	3.4 (2.5 to 4.4)	4.2 (3.1 to 5.4)	22.9 (15.5 to 30.2)
Other exposure to mechanical forces	-	-	-	295.1 (225.0 to 386.2)	279.2 (206.0 to 373.4)	-5.6 (-10.2 to -0.6)
Adverse effects of medical treatment	-	-	-	8.7 (5.5 to 13.0)	10.6 (6.7 to 15.6)	21.2 (17.1 to 25.2)
Animal contact	-	-	-	39.9 (29.7 to 51.8)	32.3 (23.4 to 42.3)	-18.9 (-24.7 to -13.6)
Venomous animal contact	-	-	-	17.1 (12.4 to 22.7)	14.2 (10.1 to 18.8)	-16.9 (-26.1 to -7.7)
Non-venomous animal contact	-	-	-	22.8 (16.9 to 30.1)	18.1 (13.2 to 24.4)	-20.6 (-25.9 to -15.8)
Foreign body	-	-	-	16.6 (12.1 to 21.7)	18.3 (13.0 to 24.5)	9.6 (4.0 to 15.6)
Pulmonary aspiration and foreign body in airway	-	-	-	3.6 (2.7 to 4.5)	3.0 (2.3 to 3.9)	-14.4 (-21.8 to -4.9)
Foreign body in eyes	-	-	-	4.5 (2.4 to 7.1)	5.6 (2.9 to 9.2)	24.1 (16.4 to 31.9)
Foreign body in other body part	-	-	-	8.6 (6.4 to 11.1)	9.6 (7.2 to 12.4)	11.8 (6.3 to 18.5)
Other unintentional injuries	-	-	-	124.2 (93.7 to 161.3)	143.6 (106.5 to 188.3)	15.6 (10.7 to 20.7)
Self-harm and interpersonal violence	-	-	-	91.1 (69.6 to 115.9)	79.0 (59.4 to 102.0)	-13.5 (-18.9 to -6.9)
Self-harm	-	-	-	18.4 (13.5 to 24.0)	14.5 (10.4 to 19.2)	-21.0 (-25.3 to -15.7)
Interpersonal violence	-	-	-	72.7 (56.0 to 91.8)	64.5 (49.0 to 83.3)	-11.7 (-17.7 to -4.1)
Assault by firearm	-	-	-	11.9 (9.1 to 15.1)	12.3 (9.2 to 15.8)	3.3 (-3.8 to 10.3)
Assault by sharp object	-	-	-	14.0 (10.7 to 18.0)	14.1 (10.5 to 18.4)	0.2 (-6.3 to 7.9)
Assault by other means	-	-	-	46.8 (35.8 to 59.6)	38.1 (29.2 to 48.8)	-18.8 (-24.5 to -11.6)
Forces of nature, war, and legal intervention	-	-	-	622.6 (267.4 to 1,346.4)	147.1 (75.2 to 273.3)	-75.3 (-82.4 to -66.9)
Exposure to forces of nature	-	-	-	21.8 (11.1 to 44.8)	29.5 (14.9 to 63.1)	34.5 (14.7 to 61.0)
Collective violence and legal intervention	-	-	-	600.8 (253.4 to 1,311.9)	117.6 (56.4 to 228.2)	-79.7 (-86.5 to -72.1)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (30-34 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
All causes	-	-	-	41,085.2 (30,442.0 to 52,995.0)	54,778.4 (40,656.7 to 70,437.1)	33.4 (30.8 to 35.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	5,289.3 (3,692.9 to 7,373.9)	6,349.7 (4,574.9 to 8,593.6)	20.2 (14.7 to 26.9)
HIV/AIDS and tuberculosis	-	-	-	436.0 (305.3 to 574.8)	977.9 (692.3 to 1,287.6)	124.1 (110.3 to 143.3)
Tuberculosis	864.4 (808.0 to 923.2)	1,267.7 (1,190.8 to 1,346.5)	46.8 (42.4 to 51.0)	267.7 (181.6 to 363.8)	393.4 (265.8 to 529.2)	47.0 (39.4 to 55.1)
HIV/AIDS	-	-	-	168.3 (118.1 to 222.0)	584.5 (422.1 to 777.9)	246.2 (204.8 to 296.0)
HIV/AIDS resulting in mycobacterial infection	34.6 (22.8 to 46.8)	138.5 (98.1 to 173.3)	303.8 (253.8 to 357.8)	12.9 (7.5 to 19.6)	51.9 (32.1 to 75.9)	304.8 (237.8 to 377.7)
HIV/AIDS resulting in other diseases	1,519.8 (1,397.3 to 1,639.7)	4,329.0 (4,131.6 to 4,716.5)	183.8 (165.9 to 211.6)	155.4 (108.4 to 206.0)	532.6 (382.6 to 708.3)	241.8 (198.4 to 296.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	560.1 (394.7 to 766.7)	685.5 (477.0 to 950.8)	22.3 (17.2 to 27.8)
Diarrheal diseases	1,030.4 (987.9 to 1,071.7)	1,212.8 (1,159.3 to 1,267.3)	17.8 (9.9 to 25.0)	163.8 (111.1 to 226.8)	193.1 (133.4 to 264.9)	17.9 (8.3 to 28.7)
Intestinal infectious diseases	-	-	-	11.1 (7.3 to 16.1)	10.1 (6.6 to 14.7)	-10.1 (-33.6 to 25.5)
Typhoid fever	64.3 (53.1 to 75.6)	59.3 (47.7 to 69.7)	-8.1 (-28.0 to 25.4)	8.4 (5.2 to 12.4)	7.9 (5.0 to 12.0)	-6.6 (-36.6 to 42.1)
Paratyphoid fever	39.3 (30.2 to 49.5)	35.0 (26.8 to 45.7)	-10.4 (-37.7 to 28.8)	2.0 (1.1 to 3.3)	1.8 (1.0 to 2.9)	-8.7 (-44.2 to 52.4)
Other intestinal infectious diseases	-	-	-	0.7 (0.3 to 1.4)	0.4 (0.2 to 0.7)	-51.9 (-63.9 to -34.3)
Lower respiratory infections	79.5 (77.2 to 81.4)	89.2 (86.9 to 91.7)	12.1 (8.3 to 17.0)	8.3 (5.6 to 11.7)	9.4 (6.3 to 13.3)	12.8 (-1.2 to 30.1)
Upper respiratory infections	12,066.8 (11,809.4 to 12,347.4)	17,826.2 (17,452.1 to 18,176.6)	47.6 (44.1 to 52.4)	141.2 (79.0 to 232.4)	209.2 (116.1 to 348.3)	48.0 (43.0 to 53.9)
Otitis media	4,135.8 (3,943.5 to 4,313.7)	5,072.3 (4,789.6 to 5,330.6)	22.7 (16.5 to 30.1)	77.4 (44.9 to 124.6)	95.7 (55.4 to 153.5)	23.8 (15.8 to 32.4)
Meningitis	-	-	-	132.8 (93.5 to 178.4)	140.8 (98.3 to 187.1)	6.0 (-2.0 to 14.8)
Pneumococcal meningitis	656.6 (403.2 to 967.7)	701.4 (439.7 to 1,040.7)	6.7 (-0.4 to 15.0)	53.0 (37.5 to 70.2)	59.9 (42.7 to 79.8)	12.8 (-0.4 to 30.7)
H influenzae type B meningitis	304.2 (109.7 to 563.8)	278.1 (111.4 to 518.6)	-8.6 (-16.2 to 1.1)	29.2 (20.1 to 40.5)	30.3 (20.6 to 41.5)	3.2 (-10.9 to 22.5)
Meningococcal meningitis	120.8 (37.6 to 262.5)	109.0 (37.3 to 235.0)	-9.5 (-17.7 to 1.5)	13.2 (8.2 to 20.2)	12.8 (8.2 to 19.3)	-3.0 (-13.2 to 10.3)
Other meningitis	330.2 (148.2 to 595.9)	306.7 (161.7 to 540.5)	-6.7 (-15.5 to 7.4)	37.4 (25.4 to 52.6)	37.8 (25.8 to 52.4)	1.1 (-13.0 to 17.3)
Encephalitis	125.6 (50.6 to 279.1)	125.5 (54.0 to 293.6)	1.1 (-18.0 to 10.4)	14.3 (9.9 to 19.5)	15.9 (11.0 to 21.4)	10.9 (-0.3 to 23.4)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-27.6 (-77.0 to 179.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.7 (-77.2 to 183.8)
Whooping cough	3.9 (3.0 to 5.0)	3.4 (2.6 to 4.3)	-13.4 (-14.1 to -12.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-13.4 (-14.1 to -12.6)
Tetanus	85.5 (60.7 to 130.0)	12.1 (7.5 to 18.8)	-86.1 (-92.3 to -74.7)	2.9 (1.9 to 4.4)	0.8 (0.5 to 1.3)	-72.6 (-83.0 to -52.7)
Measles	1.0 (0.8 to 1.2)	0.3 (0.3 to 0.4)	-66.7 (-69.4 to -63.9)	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-66.7 (-69.5 to -63.9)
Varicella and herpes zoster	167.0 (158.4 to 176.9)	222.2 (208.1 to 233.7)	33.4 (23.3 to 42.9)	7.9 (4.8 to 12.1)	10.3 (6.5 to 15.8)	30.5 (16.6 to 47.0)
Neglected tropical diseases and malaria	-	-	-	1,383.4 (904.2 to 2,019.2)	1,380.0 (898.5 to 2,016.1)	-0.4 (-6.7 to 7.5)
Malaria	16,763.2 (16,358.3 to 17,170.7)	23,341.6 (22,814.8 to 23,895.4)	39.2 (35.4 to 43.2)	103.4 (68.7 to 150.1)	139.9 (92.9 to 201.4)	35.3 (27.1 to 43.9)
Chagas disease	694.1 (676.8 to 710.5)	759.7 (734.9 to 784.6)	9.5 (4.6 to 14.0)	5.4 (3.5 to 7.9)	6.0 (3.9 to 8.8)	10.2 (-1.4 to 21.9)
Leishmaniasis	-	-	-	1.4 (0.7 to 2.7)	3.9 (2.0 to 7.3)	174.0 (142.9 to 213.7)
Visceral leishmaniasis	2.9 (2.2 to 3.9)	4.9 (3.8 to 6.4)	66.7 (26.3 to 121.2)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	65.9 (24.9 to 122.6)
Cutaneous and mucocutaneous leishmaniasis	114.4 (95.5 to 138.0)	335.5 (282.1 to 400.2)	192.6 (158.4 to 232.7)	1.2 (0.6 to 2.4)	3.6 (1.6 to 6.9)	194.2 (158.7 to 237.2)
African trypanosomiasis	7.1 (3.2 to 14.1)	2.0 (1.1 to 3.5)	-70.6 (-74.8 to -65.3)	1.9 (0.8 to 3.8)	0.6 (0.2 to 1.0)	-70.6 (-80.2 to -55.9)
Schistosomiasis	17,497.4 (15,697.0 to 19,214.5)	25,008.7 (21,656.5 to 29,387.4)	41.2 (31.9 to 64.5)	168.8 (86.6 to 319.0)	245.8 (124.3 to 473.1)	43.6 (34.9 to 69.1)
Cysticercosis	144.5 (125.2 to 167.2)	105.5 (88.7 to 125.3)	-27.4 (-39.7 to -10.8)	41.3 (28.6 to 54.2)	32.2 (21.6 to 43.6)	-22.5 (-38.9 to -0.2)
Cystic echinococcosis	71.9 (67.2 to 78.0)	60.8 (58.3 to 64.8)	-15.3 (-18.1 to -12.0)	6.8 (4.5 to 9.7)	5.8 (3.9 to 8.0)	-15.2 (-29.5 to -0.3)
Lymphatic filariasis	5,936.9 (5,260.3 to 6,822.9)	4,044.3 (3,410.8 to 4,854.9)	-32.0 (-39.3 to -23.8)	191.1 (96.6 to 326.5)	188.4 (100.8 to 311.3)	-0.3 (-23.0 to 22.5)
Onchocerciasis	2,141.0 (1,409.5 to 3,267.9)	1,630.5 (1,026.9 to 2,684.7)	-24.2 (-35.2 to -12.8)	121.7 (60.5 to 196.8)	102.7 (45.8 to 175.2)	-17.1 (-31.3 to 0.5)
Trachoma	28.2 (19.0 to 40.7)	20.7 (14.0 to 29.9)	-26.3 (-39.2 to -10.5)	1.7 (1.0 to 2.7)	1.4 (0.8 to 2.3)	-19.9 (-36.4 to 0.3)
Dengue	32.4 (11.9 to 72.7)	256.3 (94.3 to 574.8)	691.1 (685.3 to 696.4)	5.3 (1.6 to 13.0)	41.6 (13.4 to 103.5)	690.7 (513.7 to 936.0)
Yellow fever	0.3 (0.1 to 0.7)	0.1 (0.0 to 0.3)	-57.1 (-67.5 to -37.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.2 (-67.5 to -37.0)
Rabies	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-20.0 (-37.7 to 1.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.1 (-37.7 to 1.7)
Intestinal nematode infections	-	-	-	432.2 (248.2 to 693.0)	286.8 (167.2 to 456.1)	-33.3 (-39.2 to -27.0)
Ascariasis	81,484.4 (68,466.3 to 98,517.2)	64,187.5 (55,162.4 to 75,493.9)	-20.9 (-37.9 to 0.3)	193.2 (106.0 to 321.1)	70.7 (38.4 to 122.3)	-63.4 (-69.0 to -56.6)
Trichuriasis	41,253.6 (33,517.0 to 52,031.5)	37,297.1 (33,621.7 to 41,555.4)	-8.5 (-30.9 to 15.1)	59.9 (33.3 to 99.7)	47.6 (25.1 to 81.2)	-21.4 (-37.5 to 4.5)
Hookworm disease	39,635.7 (33,295.9 to 48,029.2)	39,160.3 (35,491.6 to 43,409.5)	-0.6 (-19.4 to 20.6)	179.1 (107.4 to 285.3)	168.5 (101.3 to 264.3)	-5.7 (-15.4 to 3.7)
Food-borne trematodiasis	5,339.7 (4,234.1 to 6,581.1)	6,396.2 (5,035.8 to 7,786.9)	19.8 (9.9 to 29.2)	252.5 (80.7 to 523.1)	285.1 (99.8 to 571.3)	14.6 (0.0 to 29.4)
Other neglected tropical diseases	1,729.4 (1,670.5 to 1,787.4)	1,489.0 (1,414.7 to 1,559.2)	-13.9 (-18.8 to -9.3)	49.8 (28.8 to 82.0)	39.8 (21.8 to 71.3)	-21.1 (-33.5 to -3.8)
Maternal disorders	-	-	-	138.0 (94.2 to 188.8)	171.4 (117.5 to 235.2)	24.5 (7.9 to 41.8)
Maternal hemorrhage	267.4 (248.5 to 287.2)	422.0 (395.6 to 449.4)	57.8 (43.2 to 73.4)	10.1 (6.9 to 14.4)	13.8 (9.2 to 19.8)	36.6 (16.5 to 60.4)
Maternal sepsis and other maternal infections	440.1 (280.4 to 617.2)	356.8 (236.2 to 518.8)	-18.5 (-27.3 to -11.2)	4.2 (2.3 to 7.7)	3.5 (1.9 to 6.4)	-16.7 (-33.8 to 7.2)
Maternal hypertensive disorders	160.6 (85.4 to 258.2)	200.3 (107.6 to 323.2)	25.0 (20.3 to 29.6)	8.1 (3.6 to 14.4)	10.1 (4.7 to 17.9)	24.7 (13.0 to 37.1)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (30-34 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Obstructed labor	276.5 (230.3 to 333.5)	339.4 (287.4 to 405.3)	23.2 (12.9 to 33.0)	90.1 (59.0 to 127.1)	111.6 (73.5 to 156.4)	24.1 (6.3 to 45.1)
Complications of abortion	3.3 (2.2 to 4.5)	4.2 (2.9 to 5.8)	27.8 (15.5 to 38.6)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.8)	28.4 (15.5 to 40.3)
Other maternal disorders	-	-	-	25.1 (16.0 to 37.0)	31.9 (20.7 to 46.3)	29.0 (-8.5 to 70.9)
Neonatal disorders	-	-	-	377.3 (279.4 to 480.8)	938.6 (691.9 to 1,206.7)	148.6 (123.6 to 177.7)
Preterm birth complications	1,519.0 (1,337.0 to 1,729.2)	4,133.8 (3,641.6 to 4,717.2)	171.9 (149.0 to 197.8)	171.4 (123.7 to 221.8)	504.0 (370.2 to 652.2)	193.6 (172.1 to 219.2)
Neonatal encephalopathy due to birth asphyxia and trauma	1,459.6 (588.7 to 2,613.3)	1,626.5 (840.2 to 2,719.1)	12.1 (-11.1 to 64.7)	97.2 (68.6 to 135.9)	167.3 (123.6 to 222.5)	72.7 (43.8 to 107.0)
Neonatal sepsis and other neonatal infections	-	-	-	-	-	-
Hemolytic disease and other neonatal jaundice	141.2 (115.2 to 176.9)	365.2 (284.1 to 507.3)	153.0 (89.1 to 306.5)	51.2 (35.1 to 68.6)	119.8 (82.6 to 164.9)	130.9 (80.4 to 248.4)
Other neonatal disorders	-	-	-	57.5 (38.4 to 81.1)	147.5 (100.9 to 203.3)	157.3 (104.6 to 221.5)
Nutritional deficiencies	-	-	-	2,175.2 (1,433.0 to 3,196.2)	1,929.2 (1,271.0 to 2,827.6)	-11.4 (-13.3 to -9.3)
Protein-energy malnutrition	11.7 (6.2 to 18.6)	17.3 (9.3 to 28.2)	48.3 (16.9 to 87.1)	1.4 (0.6 to 2.8)	2.1 (0.8 to 4.1)	47.0 (-13.7 to 134.8)
Iodine deficiency	14,093.0 (13,312.8 to 14,930.2)	12,487.3 (11,793.6 to 13,197.4)	-11.3 (-18.3 to -4.5)	253.2 (156.5 to 400.5)	224.7 (140.8 to 355.1)	-11.1 (-18.4 to -3.5)
Vitamin A deficiency	252.0 (180.9 to 327.2)	217.4 (148.2 to 289.5)	-14.0 (-23.7 to -5.0)	13.0 (7.7 to 20.3)	10.7 (6.2 to 16.9)	-18.1 (-34.3 to 1.4)
Iron-deficiency anemia	73,468.7 (73,204.1 to 73,677.0)	71,827.4 (71,590.6 to 72,039.7)	-2.2 (-2.7 to -1.8)	1,907.5 (1,266.0 to 2,782.8)	1,691.5 (1,110.3 to 2,486.1)	-11.4 (-13.4 to -9.2)
Other nutritional deficiencies	-	-	-	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.3)	-1.8 (-55.7 to 115.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	219.2 (136.3 to 351.5)	267.1 (164.5 to 434.5)	21.7 (16.5 to 26.8)
Sexually transmitted diseases excluding HIV	-	-	-	135.7 (79.9 to 231.6)	184.5 (110.8 to 319.9)	35.9 (29.9 to 42.6)
Syphilis	30.2 (28.4 to 32.2)	21.8 (20.7 to 23.0)	-28.0 (-33.1 to -22.1)	5.8 (3.7 to 8.5)	4.2 (2.7 to 6.2)	-27.1 (-43.9 to -4.6)
Chlamydial infection	15,726.3 (15,215.7 to 16,243.4)	20,535.7 (19,894.8 to 21,176.4)	30.7 (25.0 to 35.9)	64.7 (40.3 to 103.2)	89.8 (57.0 to 142.1)	39.0 (30.5 to 47.8)
Gonococcal infection	3,130.7 (2,956.0 to 3,321.3)	4,455.0 (4,211.0 to 4,721.4)	42.1 (31.6 to 53.6)	21.3 (13.5 to 33.2)	31.2 (19.6 to 47.1)	46.2 (26.4 to 72.7)
Trichomoniasis	8,413.5 (7,795.9 to 9,065.8)	11,994.1 (11,106.7 to 12,942.6)	42.6 (29.1 to 58.0)	14.0 (5.6 to 29.7)	19.8 (7.8 to 42.5)	41.0 (25.3 to 58.1)
Genital herpes	95,451.6 (93,817.4 to 97,218.5)	127,927.3 (125,274.3 to 130,446.4)	34.1 (30.3 to 37.7)	25.6 (8.1 to 61.9)	34.6 (10.9 to 83.6)	35.0 (29.6 to 41.0)
Other sexually transmitted diseases	240.5 (170.0 to 326.6)	229.0 (169.1 to 311.5)	-5.0 (-10.7 to 3.5)	4.3 (2.8 to 6.4)	4.8 (3.2 to 7.1)	12.6 (-6.1 to 37.1)
Hepatitis	-	-	-	39.9 (25.7 to 57.7)	44.2 (28.7 to 64.1)	11.0 (5.6 to 16.4)
Hepatitis A	301.9 (289.7 to 310.8)	433.5 (429.9 to 434.7)	43.6 (39.8 to 48.4)	11.1 (7.1 to 16.2)	16.0 (10.3 to 23.3)	43.8 (32.0 to 56.4)
Hepatitis B	29,084.6 (28,481.4 to 29,709.6)	26,670.2 (26,117.9 to 27,311.0)	-8.3 (-10.9 to -5.8)	23.0 (14.8 to 33.7)	21.1 (13.7 to 30.5)	-8.3 (-14.1 to -1.4)
Hepatitis C	10,002.0 (9,786.3 to 10,219.8)	10,760.1 (10,523.9 to 10,997.2)	7.6 (4.3 to 11.1)	0.7 (0.5 to 1.1)	0.8 (0.5 to 1.2)	10.2 (-6.8 to 31.8)
Hepatitis E	181.8 (170.6 to 192.9)	224.4 (211.8 to 237.7)	23.5 (13.4 to 33.4)	5.0 (3.1 to 7.3)	6.3 (4.1 to 9.3)	26.7 (6.0 to 49.6)
Leprosy	24.0 (21.6 to 26.8)	27.8 (25.9 to 29.9)	15.6 (3.3 to 30.9)	1.4 (0.9 to 2.1)	1.7 (1.0 to 2.6)	23.1 (-12.3 to 76.4)
Other infectious diseases	1,914.5 (1,868.3 to 1,965.0)	1,667.4 (1,604.9 to 1,730.0)	-12.9 (-16.5 to -9.1)	42.2 (26.9 to 63.9)	36.6 (21.7 to 59.7)	-14.0 (-26.3 to 1.5)
Non-communicable diseases	-	-	-	32,870.4 (24,345.9 to 42,523.6)	46,159.3 (34,148.9 to 59,927.1)	40.4 (38.8 to 42.2)
Neoplasms	-	-	-	103.2 (74.0 to 137.0)	134.2 (94.9 to 177.5)	29.7 (18.3 to 43.2)
Esophageal cancer	4.7 (3.6 to 5.8)	6.1 (4.7 to 8.0)	30.7 (-2.3 to 76.5)	0.8 (0.5 to 1.1)	1.0 (0.6 to 1.4)	24.6 (-5.5 to 65.2)
Stomach cancer	29.0 (25.8 to 32.6)	23.8 (21.5 to 26.2)	-17.6 (-27.7 to -6.3)	3.8 (2.6 to 5.1)	2.9 (2.1 to 3.9)	-22.2 (-31.5 to -11.2)
Liver cancer	-	-	-	3.0 (2.0 to 4.3)	3.2 (2.2 to 4.3)	5.8 (-17.1 to 34.8)
Liver cancer due to hepatitis B	8.7 (6.5 to 11.4)	10.3 (8.3 to 12.6)	20.0 (-13.2 to 65.4)	1.5 (1.0 to 2.1)	1.6 (1.1 to 2.2)	7.6 (-17.0 to 40.0)
Liver cancer due to hepatitis C	1.4 (1.1 to 1.8)	5.0 (4.0 to 6.1)	243.8 (155.4 to 368.2)	0.2 (0.2 to 0.4)	0.8 (0.5 to 1.1)	212.5 (140.5 to 302.6)
Liver cancer due to alcohol use	2.6 (2.0 to 3.5)	1.8 (1.4 to 2.3)	-30.3 (-49.1 to -5.6)	0.5 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-35.9 (-51.6 to -15.8)
Liver cancer due to other causes	4.9 (3.9 to 6.2)	3.4 (2.7 to 4.0)	-30.7 (-48.0 to -8.0)	0.8 (0.6 to 1.2)	0.5 (0.4 to 0.7)	-36.5 (-50.2 to -20.1)
Larynx cancer	8.5 (6.6 to 11.1)	8.0 (6.2 to 12.4)	-8.2 (-29.9 to 37.1)	0.8 (0.5 to 1.2)	0.8 (0.5 to 1.3)	-10.1 (-31.5 to 34.5)
Tracheal, bronchus and lung cancer	14.2 (12.6 to 15.7)	14.2 (12.8 to 16.1)	-1.5 (-12.8 to 20.9)	2.4 (1.7 to 3.3)	2.3 (1.6 to 3.0)	-7.0 (-17.4 to 13.7)
Breast cancer	192.5 (170.5 to 217.3)	311.6 (269.5 to 354.9)	62.1 (38.1 to 89.0)	15.6 (10.8 to 21.2)	23.4 (16.3 to 32.2)	50.6 (25.7 to 77.4)
Cervical cancer	253.5 (196.6 to 310.5)	207.7 (156.9 to 254.8)	-17.5 (-37.2 to 5.0)	19.0 (12.3 to 26.7)	16.0 (10.4 to 22.4)	-15.4 (-37.0 to 8.3)
Uterine cancer	38.9 (26.3 to 56.1)	37.1 (25.7 to 49.6)	-4.9 (-33.5 to 41.0)	2.6 (1.5 to 4.2)	2.4 (1.4 to 3.7)	-4.7 (-34.3 to 39.9)
Prostate cancer	1.5 (1.2 to 1.9)	3.5 (2.6 to 4.9)	124.1 (89.5 to 167.9)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	100.6 (67.7 to 141.4)
Colon and rectum cancer	56.0 (52.3 to 60.4)	96.5 (88.7 to 105.0)	72.1 (57.0 to 88.7)	5.0 (3.5 to 6.7)	8.0 (5.7 to 10.8)	59.9 (43.1 to 81.2)
Lip and oral cavity cancer	34.0 (26.8 to 43.3)	55.1 (41.4 to 73.6)	60.5 (18.5 to 123.4)	2.9 (2.0 to 4.3)	4.7 (2.9 to 7.0)	58.7 (14.6 to 131.5)
Nasopharynx cancer	25.6 (17.0 to 36.0)	25.5 (15.9 to 36.8)	-1.3 (-41.6 to 67.8)	2.5 (1.4 to 3.8)	2.4 (1.4 to 3.7)	-3.5 (-41.6 to 60.4)
Other pharynx cancer	3.7 (3.0 to 4.6)	5.6 (4.1 to 7.5)	52.1 (10.2 to 114.5)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	48.7 (7.5 to 106.1)
Gallbladder and biliary tract cancer	0.8 (0.7 to 1.0)	1.0 (0.8 to 1.2)	20.9 (-3.0 to 50.0)	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.4)	13.9 (-8.7 to 40.7)
Pancreatic cancer	1.6 (1.4 to 1.8)	2.4 (2.1 to 2.6)	45.4 (24.6 to 69.1)	0.4 (0.2 to 0.5)	0.5 (0.3 to 0.6)	39.1 (20.9 to 60.4)
Malignant skin melanoma	73.9 (55.1 to 92.0)	91.5 (73.1 to 120.6)	24.1 (-4.4 to 59.3)	4.4 (2.7 to 6.4)	5.3 (3.4 to 8.3)	21.7 (-9.1 to 60.5)
Non-melanoma skin cancer	38.7 (33.5 to 45.9)	57.3 (46.2 to 71.3)	48.6 (11.6 to 86.3)	0.8 (0.5 to 1.4)	1.7 (0.9 to 2.8)	96.8 (18.7 to 225.8)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (30-34 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Ovarian cancer	21.9 (19.1 to 25.1)	30.1 (25.5 to 35.6)	37.2 (14.6 to 67.7)	2.9 (2.0 to 3.9)	4.0 (2.7 to 5.5)	35.9 (11.7 to 66.7)
Testicular cancer	72.0 (54.6 to 98.9)	98.9 (69.8 to 128.1)	37.8 (-2.2 to 85.2)	4.4 (2.8 to 6.7)	5.9 (3.5 to 8.9)	35.5 (-4.5 to 85.2)
Kidney cancer	12.3 (11.1 to 13.6)	20.1 (17.8 to 22.7)	62.9 (44.4 to 85.3)	0.9 (0.6 to 1.3)	1.5 (1.0 to 2.1)	56.4 (34.9 to 83.1)
Bladder cancer	8.2 (6.9 to 9.2)	9.2 (7.8 to 11.0)	12.7 (-3.8 to 35.6)	0.7 (0.5 to 0.9)	0.8 (0.5 to 1.1)	11.7 (-7.5 to 35.4)
Brain and nervous system cancer	38.4 (30.9 to 46.8)	55.7 (45.1 to 68.6)	45.5 (17.8 to 77.8)	4.2 (2.9 to 5.8)	6.0 (4.0 to 8.5)	40.8 (13.1 to 75.3)
Thyroid cancer	93.3 (74.5 to 111.3)	143.8 (114.7 to 180.1)	53.7 (21.3 to 95.5)	5.3 (3.4 to 7.9)	8.0 (5.0 to 12.0)	52.5 (17.1 to 93.8)
Mesothelioma	0.4 (0.3 to 0.4)	0.3 (0.3 to 0.4)	-9.0 (-22.9 to 10.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-7.1 (-21.1 to 13.0)
Hodgkin lymphoma	50.5 (34.0 to 65.9)	51.2 (40.0 to 74.0)	-1.6 (-30.3 to 67.3)	4.2 (2.6 to 6.1)	4.1 (2.5 to 6.3)	-6.7 (-35.0 to 63.5)
Non-Hodgkin lymphoma	53.8 (42.6 to 64.3)	87.4 (74.4 to 105.4)	62.2 (32.3 to 101.2)	4.2 (2.8 to 5.9)	6.6 (4.4 to 9.3)	56.8 (27.2 to 98.2)
Multiple myeloma	2.1 (1.6 to 2.6)	3.6 (2.8 to 4.5)	73.7 (39.3 to 110.1)	0.5 (0.3 to 0.6)	0.8 (0.5 to 1.1)	68.4 (36.2 to 102.8)
Leukemia	40.9 (36.1 to 46.4)	65.7 (58.1 to 73.9)	60.9 (37.2 to 85.4)	5.9 (4.2 to 7.8)	8.5 (6.0 to 11.4)	44.0 (21.9 to 68.4)
Other neoplasms	71.2 (61.6 to 83.5)	180.3 (151.6 to 214.0)	152.5 (104.9 to 206.8)	5.3 (3.6 to 7.2)	12.5 (8.2 to 17.0)	135.9 (89.9 to 189.1)
Cardiovascular diseases	-	-	-	238.2 (163.7 to 335.6)	439.2 (291.8 to 617.5)	85.0 (50.1 to 117.7)
Rheumatic heart disease	1,755.4 (1,638.1 to 1,853.0)	2,821.7 (2,693.1 to 2,957.5)	61.0 (47.9 to 72.8)	88.7 (58.5 to 128.3)	138.8 (88.4 to 202.0)	56.1 (43.0 to 70.1)
Ischemic heart disease	55.9 (51.8 to 60.0)	81.8 (76.2 to 88.0)	46.0 (33.2 to 65.2)	6.6 (4.4 to 9.4)	9.7 (6.4 to 13.6)	46.1 (20.3 to 79.0)
Cerebrovascular disease	-	-	-	43.3 (30.1 to 57.6)	65.9 (45.7 to 88.1)	52.0 (37.6 to 68.8)
Ischemic stroke	144.0 (135.6 to 151.9)	225.2 (212.8 to 238.5)	56.2 (44.9 to 70.4)	23.3 (15.5 to 31.9)	36.2 (23.8 to 50.0)	55.4 (33.2 to 81.4)
Hemorrhagic stroke	122.6 (116.1 to 128.5)	182.7 (172.9 to 193.2)	49.0 (38.9 to 60.7)	20.1 (13.5 to 27.4)	29.7 (19.7 to 40.6)	48.1 (30.9 to 67.7)
Hypertensive heart disease	27.5 (26.1 to 29.2)	44.6 (42.1 to 47.7)	62.3 (48.6 to 77.6)	3.3 (2.3 to 4.7)	5.4 (3.6 to 7.6)	61.1 (45.0 to 80.7)
Cardiomyopathy and myocarditis	99.0 (94.4 to 103.5)	157.8 (149.0 to 164.9)	59.5 (50.6 to 68.2)	10.8 (7.2 to 15.0)	17.5 (11.7 to 24.0)	62.7 (42.9 to 83.3)
Atrial fibrillation and flutter	15.1 (13.9 to 16.3)	20.4 (19.3 to 21.9)	35.7 (22.7 to 47.6)	1.3 (0.9 to 1.9)	1.8 (1.2 to 2.6)	36.5 (19.0 to 52.8)
Peripheral vascular disease	-	-	-	-	-	-
Endocarditis	7.2 (5.8 to 8.5)	10.2 (8.0 to 12.4)	44.0 (19.9 to 62.2)	0.7 (0.5 to 1.1)	1.1 (0.7 to 1.6)	53.9 (28.7 to 76.6)
Other cardiovascular and circulatory diseases	1,168.5 (784.8 to 1,857.6)	2,788.4 (1,706.2 to 4,262.9)	141.6 (44.4 to 261.4)	83.4 (47.1 to 138.9)	199.1 (105.7 to 325.0)	141.9 (41.8 to 263.6)
Chronic respiratory diseases	-	-	-	1,642.5 (1,128.4 to 2,198.8)	2,318.5 (1,593.4 to 3,124.0)	41.0 (35.1 to 47.2)
Chronic obstructive pulmonary disease	12,256.7 (11,556.7 to 12,919.3)	17,510.7 (16,539.8 to 18,413.9)	42.9 (41.3 to 44.5)	983.5 (644.1 to 1,385.8)	1,479.5 (980.6 to 2,075.2)	50.3 (42.8 to 59.3)
Pneumoconiosis	-	-	-	1.4 (1.0 to 1.9)	2.2 (1.5 to 3.0)	58.1 (51.3 to 64.4)
Silicosis	1.4 (1.2 to 1.7)	1.7 (1.5 to 2.0)	20.6 (16.3 to 24.8)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	19.1 (14.2 to 23.4)
Asbestosis	0.4 (0.4 to 0.5)	0.5 (0.5 to 0.6)	26.1 (21.3 to 32.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	24.7 (18.0 to 31.6)
Coal workers pneumoconiosis	1.5 (1.4 to 1.6)	1.8 (1.6 to 1.9)	15.5 (13.0 to 17.9)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	14.4 (11.3 to 17.2)
Other pneumoconiosis	4.1 (3.6 to 4.6)	8.0 (7.0 to 8.8)	93.9 (89.0 to 98.7)	0.8 (0.5 to 1.1)	1.5 (0.9 to 2.1)	91.7 (87.0 to 96.3)
Asthma	12,231.8 (11,946.2 to 12,542.4)	16,102.5 (15,754.6 to 16,520.0)	31.5 (27.0 to 36.7)	541.5 (354.1 to 764.0)	714.2 (465.2 to 1,025.8)	31.8 (27.0 to 37.4)
Interstitial lung disease and pulmonary sarcoidosis	23.5 (21.9 to 25.3)	31.7 (28.9 to 34.5)	34.7 (19.4 to 50.7)	3.1 (2.0 to 4.5)	4.2 (2.6 to 6.1)	36.3 (21.1 to 52.0)
Other chronic respiratory diseases	-	-	-	113.1 (67.8 to 171.3)	118.5 (73.9 to 177.5)	4.6 (-8.8 to 22.1)
Cirrhosis	-	-	-	26.5 (18.1 to 36.9)	33.6 (22.8 to 46.9)	26.6 (12.8 to 40.8)
Cirrhosis due to hepatitis B	49.2 (46.2 to 52.9)	54.7 (50.2 to 59.8)	11.2 (-0.8 to 22.7)	8.4 (5.6 to 11.8)	9.2 (6.2 to 13.5)	10.6 (-11.1 to 38.3)
Cirrhosis due to hepatitis C	32.4 (30.3 to 34.9)	46.5 (42.6 to 51.0)	43.0 (29.6 to 58.1)	5.5 (3.7 to 7.8)	7.9 (5.3 to 11.3)	42.4 (16.1 to 80.0)
Cirrhosis due to alcohol use	45.8 (41.1 to 49.8)	45.0 (40.1 to 51.7)	-2.4 (-14.8 to 16.5)	7.8 (5.1 to 11.2)	7.7 (4.9 to 11.3)	-2.1 (-24.0 to 29.7)
Cirrhosis due to other causes	28.7 (25.4 to 31.6)	51.4 (46.7 to 57.0)	78.9 (58.4 to 103.6)	4.9 (3.1 to 7.2)	8.8 (5.6 to 13.0)	79.7 (33.9 to 135.1)
Digestive diseases	-	-	-	353.5 (249.0 to 471.4)	432.1 (306.1 to 579.1)	22.3 (15.6 to 29.0)
Peptic ulcer disease	816.8 (765.0 to 860.0)	595.2 (553.7 to 641.4)	-27.1 (-33.2 to -20.6)	31.8 (21.4 to 46.2)	25.3 (16.9 to 36.3)	-20.4 (-32.5 to -6.8)
Gastritis and duodenitis	2,130.0 (1,993.9 to 2,268.5)	1,968.3 (1,842.0 to 2,092.3)	-7.6 (-14.8 to -0.0)	82.7 (55.7 to 117.4)	78.1 (52.7 to 113.9)	-5.5 (-15.1 to 5.4)
Appendicitis	53.7 (46.3 to 62.8)	61.3 (53.2 to 73.0)	13.7 (-8.7 to 42.9)	16.4 (10.2 to 23.7)	18.7 (12.3 to 27.6)	13.5 (-17.7 to 58.8)
Paralytic ileus and intestinal obstruction	2.0 (2.0 to 2.1)	2.9 (2.8 to 3.1)	42.7 (34.5 to 50.2)	0.7 (0.4 to 0.9)	0.9 (0.6 to 1.3)	42.6 (34.3 to 50.1)
Inguinal, femoral, and abdominal hernia	359.4 (340.0 to 381.1)	435.8 (410.0 to 468.6)	20.8 (11.0 to 33.6)	3.9 (1.9 to 7.3)	4.7 (2.3 to 9.0)	20.9 (7.8 to 36.6)
Inflammatory bowel disease	541.1 (529.8 to 551.7)	850.4 (832.5 to 868.4)	57.3 (53.1 to 60.7)	117.1 (79.8 to 160.8)	184.6 (126.2 to 252.3)	57.6 (47.9 to 67.7)
Vascular intestinal disorders	0.5 (0.4 to 0.5)	0.6 (0.6 to 0.7)	28.0 (12.1 to 47.2)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	27.9 (12.0 to 47.1)
Gallbladder and biliary diseases	232.7 (219.2 to 247.4)	252.1 (235.9 to 272.5)	8.2 (-1.0 to 19.5)	25.3 (17.2 to 35.3)	27.5 (19.0 to 38.3)	8.9 (-5.1 to 23.7)
Pancreatitis	114.9 (112.3 to 117.3)	155.5 (151.6 to 159.6)	35.3 (31.2 to 40.3)	34.9 (23.3 to 47.1)	47.2 (31.8 to 64.1)	35.3 (19.5 to 53.3)
Other digestive diseases	-	-	-	40.7 (27.8 to 56.0)	45.0 (30.8 to 63.1)	10.9 (-1.9 to 21.5)
Neurological disorders	-	-	-	3,391.0 (2,256.8 to 4,728.6)	5,117.3 (3,385.2 to 7,157.6)	51.1 (43.6 to 58.3)
Alzheimer disease and other dementias	-	-	-	-	-	-
Parkinson disease	11.2 (6.6 to 16.5)	14.3 (9.1 to 20.2)	28.1 (14.0 to 47.4)	1.5 (0.8 to 2.5)	2.0 (1.1 to 3.1)	27.9 (13.7 to 47.5)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (30-34 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Epilepsy	1,205.2 (1,131.0 to 1,283.7)	1,661.8 (1,543.8 to 1,779.4)	37.8 (25.8 to 51.5)	395.0 (269.7 to 521.8)	580.5 (400.5 to 765.9)	46.8 (32.7 to 65.9)
Multiple sclerosis	118.3 (114.3 to 122.2)	217.4 (210.5 to 224.7)	83.7 (75.3 to 92.4)	39.9 (28.6 to 51.4)	73.3 (51.7 to 93.2)	83.6 (61.2 to 109.7)
Migraine	68,236.5 (65,483.7 to 71,118.6)	96,516.1 (92,806.1 to 100,087.4)	41.4 (33.8 to 49.1)	2,342.7 (1,415.0 to 3,448.8)	3,329.0 (2,009.9 to 4,880.1)	42.0 (33.8 to 50.4)
Tension-type headache	112,360.7 (107,439.3 to 116,736.7)	154,600.6 (149,850.9 to 159,498.1)	37.5 (31.2 to 45.2)	171.4 (82.7 to 300.4)	236.4 (115.0 to 415.3)	37.9 (30.8 to 45.7)
Medication overuse headache	2,695.8 (1,848.9 to 3,467.2)	5,522.1 (3,778.5 to 7,141.5)	104.0 (87.2 to 126.9)	429.1 (246.5 to 650.8)	881.6 (509.9 to 1,363.8)	104.9 (87.9 to 130.0)
Other neurological disorders	0.5 (0.4 to 0.6)	0.7 (0.6 to 0.9)	44.8 (23.5 to 71.2)	11.4 (7.7 to 16.3)	14.5 (9.9 to 18.9)	28.8 (0.9 to 56.3)
Mental and substance use disorders	-	-	-	12,099.8 (8,653.0 to 15,842.3)	16,862.3 (12,032.8 to 22,213.4)	39.3 (37.7 to 41.1)
Schizophrenia	2,254.4 (2,078.1 to 2,441.2)	2,973.2 (2,745.2 to 3,219.4)	31.9 (30.3 to 33.6)	1,479.9 (1,076.6 to 1,801.2)	1,957.1 (1,421.5 to 2,367.3)	32.2 (28.8 to 35.9)
Alcohol use disorders	7,549.8 (7,027.2 to 8,058.9)	9,630.4 (8,876.1 to 10,312.7)	27.6 (24.2 to 31.0)	761.0 (498.3 to 1,072.5)	970.5 (642.1 to 1,370.1)	27.6 (23.1 to 32.1)
Drug use disorders	-	-	-	1,403.7 (938.7 to 1,939.4)	2,064.0 (1,360.5 to 2,911.8)	47.0 (40.2 to 53.3)
Opioid use disorders	1,999.5 (1,391.5 to 2,878.8)	3,097.8 (2,070.8 to 4,548.1)	54.8 (46.9 to 60.2)	838.8 (508.6 to 1,295.4)	1,300.6 (781.1 to 2,054.4)	55.0 (46.4 to 61.8)
Cocaine use disorders	844.4 (813.9 to 871.0)	1,092.6 (1,054.3 to 1,131.5)	29.3 (24.1 to 34.8)	115.9 (74.9 to 162.5)	150.3 (100.3 to 211.6)	29.9 (19.5 to 41.1)
Amphetamine use disorders	1,146.0 (1,112.6 to 1,181.3)	1,599.3 (1,543.4 to 1,653.1)	39.5 (33.3 to 46.2)	149.5 (95.0 to 216.6)	209.3 (131.3 to 303.1)	39.9 (29.2 to 51.3)
Cannabis use disorders	1,100.7 (946.1 to 1,255.3)	1,411.1 (1,200.7 to 1,622.5)	28.2 (25.7 to 30.3)	31.8 (20.5 to 46.8)	40.7 (26.0 to 60.5)	28.1 (17.6 to 39.4)
Other drug use disorders	-	-	-	267.8 (178.3 to 370.2)	363.1 (242.8 to 497.6)	35.4 (26.1 to 46.4)
Depressive disorders	-	-	-	4,151.6 (2,679.1 to 5,883.1)	5,972.3 (3,844.9 to 8,488.4)	43.7 (40.8 to 47.1)
Major depressive disorder	16,541.3 (12,630.9 to 20,986.9)	23,986.4 (18,234.8 to 30,303.2)	44.9 (42.0 to 48.3)	3,426.8 (2,134.7 to 5,005.5)	4,985.5 (3,091.5 to 7,277.7)	45.4 (41.8 to 49.3)
Dysthymia	7,404.9 (6,080.2 to 8,796.5)	10,055.1 (8,112.6 to 12,008.4)	35.8 (32.5 to 38.4)	724.8 (458.9 to 1,062.5)	986.9 (620.0 to 1,458.2)	36.2 (32.1 to 40.0)
Bipolar disorder	4,495.5 (3,787.0 to 5,216.5)	6,261.2 (5,257.2 to 7,299.3)	39.3 (36.2 to 42.5)	923.8 (564.1 to 1,389.6)	1,290.2 (789.3 to 1,934.1)	39.7 (35.0 to 44.2)
Anxiety disorders	18,946.1 (13,042.6 to 25,248.1)	25,810.4 (17,553.9 to 34,372.1)	36.3 (33.0 to 39.3)	1,751.6 (1,062.8 to 2,707.0)	2,392.7 (1,439.0 to 3,730.7)	36.5 (32.5 to 40.5)
Eating disorders	-	-	-	188.1 (117.2 to 286.6)	246.1 (148.4 to 382.8)	30.4 (22.7 to 39.4)
Anorexia nervosa	176.2 (136.1 to 235.1)	249.4 (188.0 to 345.4)	41.0 (34.0 to 49.1)	37.1 (23.4 to 57.1)	52.8 (32.5 to 81.1)	41.7 (28.3 to 56.6)
Bulimia nervosa	723.4 (479.5 to 1,015.9)	922.6 (585.9 to 1,343.5)	27.1 (19.3 to 34.8)	150.9 (88.8 to 238.0)	193.3 (111.1 to 315.9)	27.5 (18.0 to 38.0)
Autistic spectrum disorders	-	-	-	476.9 (334.1 to 646.1)	656.6 (456.5 to 886.1)	37.7 (34.2 to 41.2)
Autism	1,226.7 (1,167.7 to 1,284.1)	1,687.1 (1,603.6 to 1,766.4)	37.5 (37.2 to 37.9)	302.5 (203.4 to 410.8)	416.6 (280.3 to 566.0)	37.7 (33.0 to 42.9)
Asperger syndrome	1,742.7 (1,626.4 to 1,857.2)	2,396.8 (2,232.8 to 2,557.5)	37.5 (37.1 to 37.9)	174.4 (120.9 to 243.0)	240.0 (166.2 to 337.4)	37.7 (33.1 to 42.1)
Attention-deficit/hyperactivity disorder	172.6 (131.6 to 209.6)	234.7 (180.4 to 284.5)	36.1 (33.4 to 38.5)	2.1 (1.1 to 3.3)	2.8 (1.5 to 4.6)	36.8 (14.0 to 62.3)
Conduct disorder	-	-	-	-	-	-
Idiopathic intellectual disability	5,469.7 (4,271.0 to 6,766.5)	7,249.5 (5,814.0 to 8,955.5)	32.4 (21.5 to 46.6)	271.8 (178.5 to 389.5)	357.6 (235.4 to 509.5)	31.5 (20.1 to 46.1)
Other mental and substance use disorders	9,108.8 (7,608.4 to 10,705.9)	12,548.3 (10,479.7 to 14,746.1)	37.8 (37.7 to 37.9)	689.3 (458.3 to 977.0)	952.4 (634.6 to 1,349.6)	38.1 (34.8 to 41.8)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	2,740.6 (1,895.7 to 3,761.9)	4,076.3 (2,814.6 to 5,571.7)	48.6 (44.2 to 53.8)
Diabetes mellitus	11,707.1 (11,127.7 to 12,307.0)	21,966.4 (21,057.2 to 22,884.8)	87.9 (76.2 to 99.6)	748.2 (505.7 to 1,044.9)	1,378.1 (928.5 to 1,921.7)	84.2 (73.0 to 96.7)
Acute glomerulonephritis	1.1 (1.0 to 1.3)	1.3 (1.1 to 1.4)	11.2 (7.0 to 14.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	11.1 (6.9 to 14.0)
Chronic kidney disease	-	-	-	573.5 (380.0 to 830.0)	769.2 (510.9 to 1,092.0)	34.5 (24.1 to 44.5)
Chronic kidney disease due to diabetes mellitus	2,343.0 (1,253.3 to 4,840.6)	3,376.2 (1,987.8 to 6,006.3)	48.6 (16.4 to 75.1)	75.2 (49.7 to 114.2)	101.9 (68.2 to 143.4)	36.2 (15.5 to 61.5)
Chronic kidney disease due to hypertension	4,994.8 (2,875.3 to 9,799.7)	6,387.7 (3,829.5 to 11,845.2)	29.6 (10.8 to 46.0)	173.6 (115.0 to 252.7)	207.0 (136.9 to 294.5)	19.2 (5.3 to 38.6)
Chronic kidney disease due to glomerulonephritis	5,786.1 (3,102.5 to 11,603.5)	7,669.6 (4,468.6 to 12,283.2)	37.6 (4.4 to 52.5)	144.3 (96.4 to 208.7)	186.1 (122.0 to 274.1)	29.1 (11.2 to 47.6)
Chronic kidney disease due to other causes	5,554.1 (3,250.7 to 10,790.9)	8,772.7 (5,090.9 to 15,450.3)	59.7 (37.0 to 84.6)	180.4 (116.3 to 260.4)	274.3 (180.2 to 395.2)	51.7 (34.2 to 78.4)
Urinary diseases and male infertility	-	-	-	72.3 (42.4 to 120.7)	107.7 (61.7 to 180.2)	49.4 (35.7 to 61.8)
Interstitial nephritis and urinary tract infections	81.0 (78.8 to 83.3)	126.3 (122.5 to 130.1)	55.9 (49.9 to 61.6)	2.7 (1.7 to 4.1)	4.3 (2.7 to 6.3)	56.0 (31.1 to 83.5)
Urolithiasis	1,749.8 (1,308.2 to 2,337.6)	2,457.8 (1,659.3 to 3,431.6)	41.1 (21.3 to 54.0)	23.2 (15.2 to 34.2)	32.4 (20.3 to 49.3)	39.0 (24.8 to 53.7)
Benign prostatic hyperplasia	-	-	-	-	-	-
Male infertility due to other causes	5,644.7 (5,337.9 to 5,947.4)	8,055.2 (7,584.9 to 8,531.0)	42.6 (32.1 to 53.4)	36.4 (15.6 to 72.3)	51.9 (22.3 to 107.2)	42.5 (30.6 to 54.7)
Other urinary diseases	-	-	-	9.9 (5.9 to 15.1)	19.1 (10.0 to 30.5)	101.9 (39.2 to 145.2)
Gynecological diseases	-	-	-	960.4 (639.7 to 1,404.9)	1,328.8 (875.5 to 1,945.2)	38.1 (31.7 to 45.7)
Uterine fibroids	9,481.5 (7,715.5 to 10,849.1)	12,911.6 (10,325.2 to 14,877.6)	36.2 (34.2 to 37.7)	213.3 (129.7 to 330.5)	257.7 (155.1 to 406.7)	20.7 (14.9 to 26.4)
Polycystic ovarian syndrome	13,974.0 (13,579.5 to 14,331.2)	19,637.8 (18,912.7 to 20,295.2)	40.6 (34.4 to 46.8)	137.2 (63.8 to 267.5)	194.0 (90.6 to 374.1)	41.4 (35.0 to 47.8)
Female infertility due to other causes	4,297.3 (3,504.5 to 5,020.6)	6,683.1 (5,450.2 to 7,776.5)	55.4 (38.4 to 77.4)	22.3 (8.2 to 46.2)	35.1 (13.0 to 73.9)	57.1 (39.5 to 79.5)
Endometriosis	1,834.1 (1,744.0 to 1,937.7)	2,482.7 (2,352.4 to 2,622.3)	35.4 (26.0 to 45.9)	170.4 (113.8 to 233.7)	231.8 (154.3 to 319.0)	36.1 (25.2 to 48.4)
Genital prolapse	26,027.2 (24,888.3 to 27,064.9)	35,663.1 (34,214.2 to 36,978.1)	37.2 (29.6 to 44.8)	83.6 (40.5 to 159.3)	115.0 (55.9 to 214.5)	37.7 (29.4 to 45.6)
Premenstrual syndrome	30,859.3 (27,570.3 to 34,303.3)	49,556.9 (44,995.8 to 55,321.7)	61.0 (38.6 to 87.9)	258.9 (160.5 to 386.5)	417.7 (253.5 to 631.0)	61.4 (38.1 to 89.5)
Other gynecological diseases	2,401.0 (2,232.6 to 2,549.2)	2,708.1 (2,600.3 to 2,826.6)	12.6 (4.9 to 23.7)	74.8 (50.8 to 106.2)	77.4 (52.6 to 110.1)	3.1 (-6.1 to 22.0)
Hemoglobinopathies and hemolytic anemias	-	-	-	290.5 (194.0 to 417.4)	395.7 (263.4 to 568.1)	36.2 (30.0 to 42.4)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (30-34 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Thalassemias	23-0 (19.9 to 26.3)	35.7 (31.4 to 40.9)	54.9 (44.3 to 70.4)	2-1 (1.4 to 3.1)	3-1 (2.1 to 4.4)	46.9 (29.1 to 72.4)
Thalassemia trait	10,862.1 (9,898.7 to 12,185.6)	15,929.9 (14,816.4 to 17,411.7)	46.9 (42.7 to 50.3)	153.8 (102.8 to 222.5)	240.4 (159.7 to 347.5)	56.2 (48.1 to 64.4)
Sickle cell disorders	81.4 (73.4 to 88.9)	165.7 (150.6 to 179.5)	103.4 (86.3 to 126.9)	11.2 (8.0 to 15.2)	23.2 (16.1 to 31.6)	106.0 (84.3 to 133.1)
Sickle cell trait	11,341.6 (10,775.2 to 11,859.0)	19,030.1 (18,132.1 to 19,839.3)	67.7 (64.7 to 70.7)	46.7 (29.7 to 68.0)	71.4 (47.1 to 103.4)	52.5 (36.5 to 79.4)
G6PD deficiency	15,975.4 (15,563.4 to 16,366.7)	24,799.1 (24,151.2 to 25,432.9)	55.3 (49.8 to 60.6)	1.3 (0.9 to 1.9)	1.9 (1.3 to 2.6)	41.0 (28.7 to 51.4)
G6PD trait	60,270.4 (59,902.9 to 60,577.5)	87,021.8 (86,446.1 to 87,522.5)	44.4 (43.3 to 45.6)	2.6 (1.6 to 3.9)	3.4 (1.9 to 5.2)	32.8 (-13.8 to 89.3)
Other hemoglobinopathies and hemolytic anemias	3,521.6 (3,437.4 to 3,598.0)	2,990.2 (2,890.4 to 3,090.0)	-15.1 (-18.1 to -11.7)	72.7 (47.2 to 107.1)	52.4 (33.6 to 78.6)	-28.0 (-36.5 to -17.9)
Endocrine, metabolic, blood, and immune disorders	3,504.9 (3,347.3 to 3,666.0)	3,609.3 (3,521.4 to 3,692.6)	3.1 (-2.1 to 8.4)	95.7 (64.6 to 134.8)	96.7 (65.7 to 135.2)	1.0 (-8.1 to 11.1)
Musculoskeletal disorders	-	-	-	7,647.6 (5,303.0 to 10,285.2)	10,507.6 (7,286.7 to 14,081.0)	37.3 (33.2 to 41.9)
Rheumatoid arthritis	428.8 (421.1 to 437.1)	604.8 (594.2 to 615.0)	41.1 (37.4 to 44.4)	104.9 (74.2 to 140.1)	148.4 (105.5 to 198.4)	41.4 (31.5 to 51.4)
Osteoarthritis	1,469.2 (1,440.8 to 1,495.6)	2,017.2 (1,979.9 to 2,055.4)	37.2 (33.6 to 41.1)	86.2 (60.4 to 117.2)	121.8 (84.2 to 166.8)	41.2 (34.2 to 48.3)
Low back and neck pain	-	-	-	6,677.9 (4,658.3 to 9,014.7)	9,068.1 (6,263.0 to 12,124.3)	35.6 (31.2 to 40.9)
Low back pain	36,891.1 (35,864.1 to 37,972.0)	50,399.6 (48,946.7 to 51,887.3)	36.6 (31.1 to 42.5)	4,210.1 (2,870.4 to 5,884.9)	5,766.2 (3,854.1 to 8,026.5)	36.9 (31.3 to 42.9)
Neck pain	24,590.0 (23,907.7 to 25,324.6)	32,829.7 (31,680.7 to 34,081.9)	33.6 (27.1 to 40.1)	2,467.7 (1,701.4 to 3,399.7)	3,301.9 (2,270.3 to 4,558.4)	33.9 (27.2 to 40.7)
Gout	140.7 (137.2 to 144.1)	170.0 (165.8 to 174.0)	20.9 (16.8 to 25.1)	5.9 (3.3 to 6.7)	5.9 (4.0 to 8.1)	21.5 (5.1 to 38.7)
Other musculoskeletal disorders	8,180.5 (6,368.0 to 10,016.1)	12,268.3 (9,599.7 to 15,034.2)	49.9 (44.9 to 55.5)	773.7 (498.8 to 1,159.8)	1,163.5 (747.6 to 1,728.7)	50.3 (44.3 to 57.4)
Other non-communicable diseases	-	-	-	4,627.2 (3,026.2 to 6,891.2)	6,238.2 (4,054.4 to 9,251.2)	35.0 (31.3 to 38.1)
Congenital anomalies	-	-	-	322.1 (237.8 to 420.1)	522.2 (376.3 to 675.9)	61.8 (51.2 to 74.7)
Neural tube defects	70.7 (68.9 to 72.6)	115.0 (112.2 to 118.3)	62.7 (56.9 to 68.5)	21.7 (15.3 to 28.3)	36.0 (25.6 to 46.8)	66.0 (49.7 to 85.1)
Congenital heart anomalies	1,423.8 (1,375.0 to 1,476.6)	2,634.5 (2,544.7 to 2,743.2)	84.7 (76.9 to 95.5)	49.5 (20.8 to 85.7)	93.5 (39.4 to 158.7)	88.9 (79.4 to 101.0)
Orofacial clefts	226.5 (217.8 to 235.2)	435.4 (421.1 to 449.5)	91.8 (83.4 to 103.6)	2.9 (1.9 to 4.1)	5.1 (3.4 to 7.4)	79.2 (58.3 to 103.0)
Down syndrome	311.4 (300.1 to 324.5)	543.3 (522.4 to 565.6)	74.5 (65.4 to 83.6)	34.0 (24.8 to 44.8)	59.4 (43.6 to 77.1)	74.9 (60.3 to 91.2)
Turner syndrome	14.4 (13.6 to 15.1)	22.3 (21.2 to 23.5)	54.5 (46.0 to 65.9)	0.3 (0.1 to 0.4)	0.4 (0.2 to 0.7)	54.9 (37.6 to 75.1)
Klinefelter syndrome	11.4 (10.7 to 11.9)	16.3 (15.6 to 17.1)	43.4 (34.5 to 54.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	43.2 (28.5 to 60.5)
Chromosomal unbalanced rearrangements	438.2 (423.5 to 451.6)	726.2 (696.0 to 762.7)	65.5 (57.4 to 75.4)	47.8 (34.3 to 62.0)	79.3 (57.1 to 102.6)	65.6 (55.2 to 79.1)
Other congenital anomalies	1,658.8 (1,435.3 to 1,853.0)	2,097.8 (1,811.0 to 2,362.8)	26.3 (20.0 to 34.2)	165.9 (116.0 to 226.8)	248.4 (172.5 to 333.7)	49.6 (34.3 to 70.9)
Skin and subcutaneous diseases	-	-	-	2,101.6 (1,352.3 to 3,255.5)	2,900.1 (1,859.4 to 4,467.1)	38.0 (32.4 to 42.9)
Dermatitis	24,653.5 (19,339.3 to 30,800.0)	32,958.1 (26,181.8 to 41,100.1)	33.7 (32.3 to 35.4)	603.8 (375.1 to 882.4)	812.2 (507.7 to 1,182.5)	34.5 (32.0 to 37.4)
Psoriasis	3,802.8 (3,205.0 to 4,500.6)	5,151.9 (4,298.5 to 6,137.8)	35.5 (33.9 to 36.9)	313.7 (209.0 to 445.0)	426.4 (282.1 to 609.3)	35.9 (30.6 to 41.5)
Cellulitis	83.7 (61.7 to 114.2)	94.4 (68.1 to 131.0)	12.9 (5.3 to 18.9)	6.1 (3.6 to 9.6)	6.8 (4.2 to 10.7)	12.8 (-6.4 to 37.9)
Pyoderma	225.3 (157.5 to 318.8)	255.1 (173.7 to 372.2)	12.7 (-2.2 to 29.3)	1.3 (0.5 to 2.7)	1.4 (0.5 to 3.1)	12.8 (-4.7 to 33.2)
Scabies	3,699.1 (3,281.1 to 4,115.5)	5,000.4 (4,563.2 to 5,582.3)	34.7 (17.2 to 58.4)	95.2 (53.3 to 153.5)	129.2 (71.9 to 207.4)	35.1 (17.9 to 59.1)
Fungal skin diseases	36,050.4 (28,058.4 to 46,709.2)	49,990.3 (38,634.7 to 65,264.3)	38.7 (35.7 to 41.3)	204.2 (81.8 to 446.1)	283.4 (113.2 to 624.5)	38.8 (35.5 to 41.6)
Viral skin diseases	4,956.1 (2,650.8 to 7,826.8)	6,622.4 (3,624.4 to 10,425.6)	33.5 (28.5 to 41.3)	152.8 (65.4 to 281.0)	204.5 (89.6 to 377.8)	33.8 (28.3 to 43.0)
Acne vulgaris	29,944.9 (26,815.9 to 32,882.8)	41,380.4 (36,569.9 to 45,730.1)	38.1 (18.1 to 60.8)	322.9 (154.4 to 589.2)	447.2 (208.9 to 841.4)	38.3 (17.6 to 61.0)
Alopecia areata	472.9 (457.7 to 487.3)	639.7 (619.7 to 661.2)	35.4 (30.0 to 40.6)	16.0 (10.1 to 23.9)	21.7 (13.6 to 32.6)	35.3 (25.4 to 47.4)
Pruritus	41.9 (39.2 to 45.4)	55.0 (49.5 to 59.1)	31.6 (14.2 to 45.8)	0.5 (0.2 to 0.9)	0.6 (0.3 to 1.2)	30.8 (6.8 to 60.8)
Urticaria	4,411.6 (4,061.5 to 4,951.1)	6,675.0 (5,837.9 to 7,483.6)	52.6 (23.9 to 75.7)	265.8 (171.3 to 377.8)	403.1 (256.8 to 589.1)	53.1 (24.3 to 76.9)
Decubitus ulcer	36.4 (34.9 to 37.9)	41.7 (39.7 to 44.0)	14.4 (9.4 to 19.9)	6.0 (4.0 to 8.4)	6.9 (4.6 to 9.5)	14.5 (0.1 to 31.0)
Other skin and subcutaneous diseases	19,019.1 (4,032.4 to 45,463.6)	26,250.3 (5,513.8 to 63,778.0)	38.0 (35.3 to 40.5)	113.4 (20.3 to 320.4)	156.6 (27.9 to 445.6)	38.0 (34.8 to 41.3)
Sense organ diseases	-	-	-	1,545.3 (993.9 to 2,300.1)	1,913.7 (1,230.8 to 2,832.9)	24.1 (18.1 to 28.7)
Glaucoma	476.4 (399.2 to 568.7)	673.4 (561.0 to 802.7)	41.4 (29.3 to 53.8)	29.0 (19.5 to 41.9)	39.5 (26.0 to 57.8)	36.3 (21.6 to 53.7)
Cataract	-	-	0.0 (0.0 to 0.0)	-	-	-
Macular degeneration	-	-	-	-	-	-
Uncorrected refractive error	18,301.8 (17,619.8 to 19,018.8)	24,536.8 (23,550.8 to 25,523.9)	34.0 (29.5 to 38.9)	356.4 (222.5 to 559.1)	465.6 (289.8 to 730.0)	30.6 (26.2 to 34.7)
Age-related and other hearing loss	33,109.0 (25,911.6 to 39,288.1)	41,180.7 (32,112.5 to 49,116.1)	24.2 (19.2 to 30.2)	904.1 (521.5 to 1,405.6)	1,082.8 (622.9 to 1,682.4)	19.9 (10.8 to 27.8)
Other vision loss	1,516.9 (1,259.8 to 1,813.8)	1,644.5 (1,369.0 to 1,976.0)	8.5 (4.1 to 12.5)	93.0 (62.9 to 131.7)	100.3 (68.2 to 143.5)	7.9 (0.4 to 14.9)
Other sense organ diseases	6,119.0 (5,985.2 to 6,263.5)	8,449.4 (8,247.7 to 8,643.7)	38.1 (33.9 to 42.2)	162.8 (100.7 to 241.7)	225.5 (138.6 to 332.4)	38.5 (32.5 to 44.6)
Oral disorders	-	-	-	658.2 (374.4 to 1,076.1)	902.2 (502.6 to 1,477.5)	36.9 (33.8 to 40.0)
Deciduous caries	-	-	-	-	-	-
Permanent caries	171,625.4 (169,033.1 to 174,028.8)	232,576.1 (228,900.0 to 236,422.7)	35.4 (32.6 to 39.0)	154.2 (71.2 to 295.2)	215.9 (98.7 to 416.2)	39.9 (36.1 to 44.1)
Periodontal diseases	23,996.2 (23,530.4 to 24,473.8)	34,437.2 (33,679.5 to 35,196.9)	43.6 (39.3 to 48.0)	159.7 (64.1 to 328.5)	229.4 (91.9 to 472.6)	43.7 (39.0 to 48.3)
Edentulism and severe tooth loss	3,240.0 (3,131.1 to 3,345.7)	3,869.4 (3,750.9 to 3,994.0)	19.5 (13.7 to 25.2)	93.2 (62.7 to 130.4)	111.6 (74.8 to 157.7)	19.7 (12.4 to 27.2)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (30-34 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Other oral disorders	8,504.1 (8,342.0 to 8,692.7)	11,672.8 (11,405.0 to 11,932.0)	37.3 (32.8 to 41.8)	251.1 (157.8 to 375.0)	345.3 (215.8 to 515.8)	37.5 (32.9 to 42.5)
Injuries	-	-	-	2,925.6 (2,094.2 to 4,072.7)	2,269.4 (1,683.0 to 2,980.5)	-21.1 (-37.4 to -10.5)
Transport injuries	-	-	-	907.4 (678.6 to 1,168.8)	788.8 (590.8 to 1,035.0)	-13.2 (-19.0 to -6.3)
Road injuries	-	-	-	762.1 (570.7 to 977.5)	669.1 (497.1 to 879.3)	-12.4 (-18.7 to -5.1)
Pedestrian road injuries	-	-	-	162.7 (121.8 to 209.6)	157.3 (115.6 to 207.5)	-3.5 (-11.0 to 5.5)
Cyclist road injuries	-	-	-	63.0 (47.3 to 81.9)	53.4 (39.2 to 70.4)	-15.4 (-20.8 to -8.7)
Motorcyclist road injuries	-	-	-	187.5 (140.0 to 242.8)	142.5 (105.0 to 188.1)	-24.1 (-30.6 to -16.3)
Motor vehicle road injuries	-	-	-	341.5 (255.3 to 436.7)	309.6 (232.0 to 402.7)	-9.5 (-16.1 to -1.9)
Other road injuries	-	-	-	7.4 (5.5 to 9.5)	6.2 (4.6 to 8.1)	-15.8 (-21.4 to -9.1)
Other transport injuries	-	-	-	145.2 (109.7 to 189.6)	119.8 (88.7 to 157.7)	-17.5 (-22.5 to -12.3)
Unintentional injuries	-	-	-	1,172.3 (883.4 to 1,518.9)	1,179.0 (873.5 to 1,562.0)	0.4 (-4.7 to 5.6)
Falls	-	-	-	488.2 (367.3 to 635.8)	520.8 (375.9 to 697.6)	6.4 (-0.1 to 13.8)
Drowning	-	-	-	36.6 (26.9 to 47.5)	29.9 (21.6 to 38.7)	-18.4 (-24.5 to -11.5)
Fire, heat, and hot substances	-	-	-	108.5 (83.0 to 138.2)	91.3 (68.8 to 118.8)	-15.8 (-23.5 to -8.9)
Poisonings	-	-	-	7.9 (5.6 to 10.7)	6.6 (4.6 to 8.9)	-17.1 (-23.4 to -10.9)
Exposure to mechanical forces	-	-	-	329.3 (247.2 to 430.6)	311.1 (228.7 to 415.5)	-5.7 (-10.3 to -0.7)
Unintentional firearm injuries	-	-	-	15.4 (11.8 to 19.7)	14.8 (11.1 to 19.6)	-4.2 (-10.5 to 2.6)
Unintentional suffocation	-	-	-	3.4 (2.6 to 4.4)	4.3 (3.3 to 5.7)	27.8 (19.9 to 35.8)
Other exposure to mechanical forces	-	-	-	310.5 (233.1 to 406.7)	291.9 (214.2 to 390.3)	-6.1 (-10.8 to -1.1)
Adverse effects of medical treatment	-	-	-	8.7 (5.5 to 12.9)	10.7 (6.7 to 15.7)	22.7 (18.5 to 27.2)
Animal contact	-	-	-	40.5 (29.9 to 52.5)	33.6 (24.7 to 44.2)	-17.0 (-22.5 to -11.7)
Venomous animal contact	-	-	-	17.4 (12.5 to 23.2)	14.8 (10.6 to 19.8)	-14.9 (-23.3 to -5.5)
Non-venomous animal contact	-	-	-	23.1 (17.1 to 30.7)	18.8 (13.7 to 25.2)	-18.8 (-23.6 to -13.6)
Foreign body	-	-	-	17.9 (13.1 to 23.1)	19.7 (14.1 to 25.8)	10.1 (4.9 to 16.3)
Pulmonary aspiration and foreign body in airway	-	-	-	3.5 (2.6 to 4.5)	3.0 (2.2 to 3.8)	-15.9 (-22.6 to -6.7)
Foreign body in eyes	-	-	-	4.6 (2.6 to 7.2)	5.6 (3.1 to 9.0)	21.4 (13.9 to 29.0)
Foreign body in other body part	-	-	-	9.7 (7.4 to 12.5)	11.1 (8.3 to 14.4)	14.2 (8.3 to 21.0)
Other unintentional injuries	-	-	-	134.8 (101.5 to 176.1)	155.5 (115.8 to 205.8)	15.2 (10.4 to 20.4)
Self-harm and interpersonal violence	-	-	-	102.6 (77.8 to 131.0)	89.9 (67.4 to 117.2)	-12.6 (-18.3 to -5.2)
Self-harm	-	-	-	21.6 (15.9 to 28.2)	17.1 (12.4 to 22.8)	-21.0 (-25.3 to -15.6)
Interpersonal violence	-	-	-	81.0 (61.7 to 103.1)	72.8 (54.8 to 94.8)	-10.4 (-16.6 to -2.2)
Assault by firearm	-	-	-	13.5 (10.3 to 17.3)	14.6 (10.8 to 19.2)	7.9 (0.8 to 15.9)
Assault by sharp object	-	-	-	15.2 (11.5 to 19.7)	15.9 (11.6 to 21.3)	4.0 (-3.1 to 12.7)
Assault by other means	-	-	-	52.3 (39.6 to 66.5)	42.4 (32.0 to 54.4)	-19.2 (-24.9 to -11.8)
Forces of nature, war, and legal intervention	-	-	-	743.3 (298.6 to 1,621.4)	211.7 (105.4 to 410.2)	-70.6 (-79.4 to -58.0)
Exposure to forces of nature	-	-	-	36.9 (17.2 to 79.5)	29.9 (14.3 to 62.3)	-18.0 (-37.6 to 9.7)
Collective violence and legal intervention	-	-	-	706.4 (281.3 to 1,558.3)	181.8 (86.3 to 353.7)	-73.4 (-82.5 to -61.2)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (35-39 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
All causes	-	-	-	40,746.9 (30,157.2 to 52,312.9)	56,062.0 (41,502.8 to 72,185.6)	37.6 (35.1 to 39.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	4,738.8 (3,320.1 to 6,545.2)	5,929.1 (4,296.3 to 7,960.5)	25.3 (18.6 to 33.1)
HIV/AIDS and tuberculosis	-	-	-	400.2 (278.8 to 527.5)	1,057.6 (761.4 to 1,391.7)	164.4 (144.9 to 188.9)
Tuberculosis	806.3 (759.7 to 854.8)	1,183.7 (1,117.0 to 1,247.3)	47.3 (43.5 to 50.9)	247.4 (168.7 to 334.6)	364.7 (248.0 to 491.3)	47.5 (40.0 to 55.3)
HIV/AIDS	-	-	-	152.9 (109.2 to 200.8)	692.9 (501.8 to 915.0)	354.6 (295.5 to 420.0)
HIV/AIDS resulting in mycobacterial infection	31.9 (21.3 to 43.7)	133.8 (96.2 to 168.2)	324.8 (262.6 to 393.1)	11.9 (6.7 to 18.1)	49.7 (31.2 to 70.9)	320.9 (242.7 to 411.8)
HIV/AIDS resulting in other diseases	1,191.2 (1,086.0 to 1,292.1)	4,443.8 (4,262.1 to 4,873.4)	273.3 (246.2 to 314.1)	141.0 (100.1 to 187.1)	643.2 (462.3 to 847.8)	358.0 (292.7 to 428.3)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	471.0 (334.7 to 646.2)	590.9 (412.7 to 814.6)	25.5 (20.4 to 30.9)
Diarrheal diseases	853.4 (819.6 to 888.1)	1,015.8 (963.6 to 1,066.6)	19.6 (11.0 to 27.1)	134.5 (92.0 to 184.9)	160.8 (109.0 to 222.5)	19.5 (9.4 to 30.2)
Intestinal infectious diseases	-	-	-	7.9 (4.9 to 11.6)	7.6 (4.8 to 11.4)	-4.5 (-33.3 to 37.9)
Typhoid fever	46.3 (38.3 to 54.5)	45.0 (36.2 to 55.0)	-3.4 (-25.1 to 28.5)	5.9 (3.6 to 9.1)	6.0 (3.7 to 9.2)	-0.3 (-33.8 to 55.7)
Paratyphoid fever	28.2 (21.5 to 36.0)	25.9 (19.7 to 34.2)	-6.9 (-40.0 to 32.2)	1.5 (0.8 to 2.4)	1.4 (0.8 to 2.2)	-6.4 (-45.9 to 46.2)
Other intestinal infectious diseases	-	-	-	0.5 (0.2 to 1.0)	0.3 (0.1 to 0.5)	-48.3 (-61.8 to -28.1)
Lower respiratory infections	72.5 (70.5 to 74.4)	89.0 (86.9 to 91.4)	23.1 (18.9 to 28.7)	7.5 (5.1 to 10.6)	9.3 (6.2 to 13.2)	23.3 (8.1 to 40.2)
Upper respiratory infections	10,253.3 (10,033.3 to 10,461.2)	15,539.0 (15,191.7 to 15,879.8)	51.8 (48.3 to 57.0)	119.3 (67.1 to 195.8)	181.6 (100.7 to 302.7)	52.1 (46.9 to 57.9)
Otitis media	3,526.0 (3,370.9 to 3,672.2)	4,415.5 (4,183.7 to 4,618.0)	25.5 (20.0 to 31.3)	65.4 (37.8 to 105.8)	82.9 (48.7 to 133.6)	26.8 (19.8 to 34.4)
Meningitis	-	-	-	111.5 (77.2 to 153.1)	121.1 (84.3 to 163.5)	8.7 (0.4 to 18.4)
Pneumococcal meningitis	570.8 (345.7 to 848.1)	635.2 (391.3 to 953.5)	11.3 (4.2 to 19.7)	44.0 (31.5 to 59.0)	51.6 (36.0 to 68.5)	17.2 (4.6 to 33.6)
H influenzae type B meningitis	254.0 (85.4 to 481.7)	237.0 (88.5 to 452.1)	-6.5 (-14.8 to 3.2)	22.9 (15.6 to 31.3)	24.0 (16.5 to 33.1)	4.5 (-9.9 to 25.0)
Meningococcal meningitis	109.7 (31.3 to 236.1)	101.1 (30.8 to 220.7)	-7.4 (-17.0 to 2.9)	11.7 (6.7 to 18.7)	11.6 (6.9 to 18.2)	-0.4 (-11.7 to 13.5)
Other meningitis	299.0 (125.9 to 549.7)	279.7 (137.3 to 504.3)	-6.0 (-15.3 to 7.8)	32.9 (21.8 to 46.2)	33.9 (22.7 to 47.1)	2.4 (-11.7 to 21.8)
Encephalitis	123.2 (47.9 to 278.0)	125.6 (51.6 to 299.4)	3.1 (-18.6 to 13.0)	13.6 (9.4 to 18.8)	15.4 (10.6 to 20.8)	13.4 (2.5 to 24.4)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-27.4 (-77.5 to 198.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.6 (-77.8 to 197.8)
Whooping cough	2.9 (2.2 to 3.7)	2.5 (2.0 to 3.2)	-12.7 (-13.3 to -11.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-12.9 (-13.5 to -12.1)
Tetanus	76.1 (54.4 to 113.8)	10.6 (6.5 to 16.6)	-86.2 (-92.3 to -75.1)	2.5 (1.6 to 3.9)	0.7 (0.4 to 1.1)	-73.4 (-83.6 to -55.4)
Measles	0.6 (0.5 to 0.8)	0.2 (0.2 to 0.3)	-66.3 (-69.0 to -63.6)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-66.4 (-69.1 to -63.7)
Varicella and herpes zoster	164.7 (156.8 to 173.4)	223.9 (212.3 to 235.6)	36.4 (28.3 to 45.2)	8.4 (5.1 to 12.8)	11.4 (7.0 to 17.5)	36.4 (21.3 to 50.1)
Neglected tropical diseases and malaria	-	-	-	1,300.4 (839.0 to 1,899.7)	1,293.7 (831.5 to 1,906.2)	-0.7 (-7.8 to 7.6)
Malaria	13,647.1 (13,268.7 to 14,023.7)	19,113.6 (18,617.8 to 19,652.1)	40.4 (35.9 to 45.1)	86.0 (58.1 to 124.2)	117.9 (78.4 to 171.2)	37.1 (28.6 to 47.0)
Chagas disease	690.5 (672.4 to 708.0)	746.7 (718.9 to 772.6)	8.5 (2.9 to 13.3)	6.1 (4.0 to 8.8)	6.6 (4.3 to 9.5)	8.6 (-1.6 to 19.1)
Leishmaniasis	-	-	-	1.3 (0.7 to 2.4)	3.5 (1.8 to 6.6)	171.7 (141.5 to 211.0)
Visceral leishmaniasis	2.7 (2.0 to 3.6)	4.3 (3.1 to 5.8)	64.8 (15.7 to 122.6)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	64.3 (15.1 to 124.7)
Cutaneous and mucocutaneous leishmaniasis	104.2 (86.9 to 125.5)	301.8 (253.8 to 360.7)	189.9 (156.7 to 230.0)	1.1 (0.5 to 2.1)	3.2 (1.5 to 6.2)	192.5 (158.2 to 234.3)
African trypanosomiasis	5.8 (2.6 to 11.7)	1.7 (0.9 to 2.9)	-71.0 (-75.2 to -65.7)	1.6 (0.6 to 3.1)	0.4 (0.2 to 0.8)	-71.0 (-80.2 to -56.7)
Schistosomiasis	14,625.9 (13,122.4 to 16,110.6)	20,269.4 (17,547.5 to 23,562.6)	37.5 (28.2 to 59.2)	133.2 (68.9 to 249.8)	188.7 (96.4 to 364.8)	39.9 (31.7 to 63.5)
Cysticercosis	125.8 (110.7 to 143.1)	89.9 (76.4 to 105.3)	-28.7 (-40.5 to -11.8)	35.6 (24.9 to 47.1)	27.3 (18.2 to 37.4)	-23.5 (-39.8 to -1.4)
Cystic echinococcosis	72.1 (68.1 to 77.5)	60.4 (57.5 to 64.1)	-15.9 (-18.8 to -13.5)	6.8 (4.5 to 9.6)	5.7 (3.7 to 8.2)	-15.9 (-28.5 to -0.5)
Lymphatic filariasis	5,437.5 (4,738.4 to 6,346.5)	3,922.3 (3,255.0 to 4,764.7)	-27.9 (-35.8 to -18.5)	196.6 (99.0 to 336.5)	203.2 (109.3 to 336.4)	4.2 (-19.1 to 29.7)
Onchocerciasis	1,822.5 (1,227.4 to 2,756.9)	1,308.9 (852.8 to 2,098.5)	-28.1 (-38.4 to -17.2)	112.0 (56.9 to 180.5)	88.8 (40.5 to 151.5)	-22.1 (-35.7 to -5.2)
Trachoma	73.6 (46.7 to 111.2)	51.8 (31.4 to 78.3)	-29.7 (-42.4 to -15.7)	4.9 (2.6 to 8.4)	3.5 (1.7 to 6.0)	-28.6 (-42.8 to -13.6)
Dengue	26.6 (9.7 to 59.6)	224.8 (82.7 to 504.3)	748.9 (744.8 to 751.9)	4.3 (1.4 to 10.6)	36.2 (11.3 to 90.8)	745.3 (561.4 to 1,039.0)
Yellow fever	0.2 (0.1 to 0.6)	0.1 (0.0 to 0.3)	-57.3 (-68.3 to -34.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.4 (-68.4 to -34.7)
Rabies	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-21.6 (-42.7 to 4.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.7 (-43.0 to 4.0)
Intestinal nematode infections	-	-	-	395.2 (227.3 to 634.1)	253.3 (147.3 to 403.5)	-35.7 (-41.6 to -29.1)
Ascariasis	75,284.0 (62,011.9 to 92,189.7)	57,796.8 (49,236.6 to 68,738.8)	-22.7 (-40.3 to -0.5)	181.1 (99.5 to 300.5)	62.0 (33.8 to 107.4)	-65.7 (-71.4 to -59.2)
Trichuriasis	37,417.5 (29,593.4 to 48,264.3)	33,297.8 (29,892.9 to 37,218.5)	-9.5 (-33.0 to 16.4)	53.0 (29.5 to 88.2)	40.9 (21.6 to 69.8)	-23.0 (-40.1 to 3.0)
Hookworm disease	35,804.6 (29,381.2 to 44,039.2)	34,860.8 (31,521.9 to 38,613.8)	-1.5 (-22.3 to 21.0)	161.1 (97.5 to 257.2)	150.4 (90.4 to 233.3)	-6.3 (-16.8 to 3.8)
Food-borne trematodiasis	5,614.1 (4,383.4 to 6,899.2)	6,995.3 (5,486.4 to 8,613.8)	24.7 (15.1 to 36.2)	271.3 (81.4 to 578.2)	322.7 (106.1 to 667.9)	20.2 (6.4 to 35.4)
Other neglected tropical diseases	1,539.3 (1,483.4 to 1,600.7)	1,363.0 (1,295.1 to 1,423.1)	-11.2 (-16.1 to -6.5)	45.6 (25.7 to 77.3)	35.8 (19.5 to 64.4)	-22.6 (-35.3 to -5.1)
Maternal disorders	-	-	-	121.3 (81.8 to 164.7)	154.9 (106.5 to 213.2)	27.8 (11.1 to 44.5)
Maternal hemorrhage	134.9 (126.7 to 144.7)	247.5 (229.6 to 266.9)	84.3 (65.7 to 102.2)	5.3 (3.6 to 7.6)	7.2 (4.8 to 10.2)	35.1 (8.7 to 68.8)
Maternal sepsis and other maternal infections	465.7 (303.4 to 657.1)	396.0 (265.9 to 569.0)	-14.6 (-22.4 to -7.3)	3.8 (2.0 to 7.4)	3.3 (1.7 to 6.2)	-13.2 (-30.9 to 10.8)
Maternal hypertensive disorders	140.1 (59.5 to 237.9)	181.5 (77.3 to 308.7)	30.6 (23.4 to 38.0)	7.0 (2.8 to 13.2)	9.1 (3.7 to 17.2)	28.9 (16.4 to 43.3)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (35-39 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Obstructed labor	256.8 (218.5 to 299.5)	326.4 (279.7 to 378.3)	27.8 (18.1 to 37.7)	82.9 (53.7 to 116.1)	106.1 (71.6 to 150.0)	28.1 (11.2 to 46.8)
Complications of abortion	2.2 (1.5 to 3.1)	3.1 (2.0 to 4.2)	37.7 (21.0 to 56.2)	0.3 (0.1 to 0.4)	38.0 (0.2 to 0.6)	38.0 (20.6 to 57.2)
Other maternal disorders	-	-	-	22.0 (13.9 to 32.1)	28.8 (18.9 to 42.4)	33.3 (-8.5 to 77.9)
Neonatal disorders	-	-	-	328.4 (244.2 to 417.7)	832.5 (614.6 to 1,060.8)	153.7 (129.1 to 181.9)
Preterm birth complications	1,357.5 (1,195.7 to 1,552.5)	3,749.0 (3,292.0 to 4,293.7)	176.6 (153.8 to 204.3)	152.0 (110.6 to 194.6)	453.5 (333.2 to 584.3)	198.2 (176.0 to 222.8)
Neonatal encephalopathy due to birth asphyxia and trauma	1,276.9 (523.9 to 2,302.4)	1,433.1 (736.6 to 2,413.4)	13.2 (-10.4 to 66.9)	83.1 (58.5 to 115.8)	143.6 (105.8 to 189.2)	74.0 (45.6 to 107.7)
Neonatal sepsis and other neonatal infections	-	-	-	-	-	-
Hemolytic disease and other neonatal jaundice	121.8 (99.9 to 150.1)	321.0 (250.7 to 441.0)	159.5 (95.7 to 308.9)	43.9 (30.7 to 58.9)	104.7 (73.2 to 146.8)	133.5 (83.0 to 248.9)
Other neonatal disorders	-	-	-	49.3 (32.9 to 69.6)	130.8 (89.9 to 177.7)	165.9 (112.3 to 228.5)
Nutritional deficiencies	-	-	-	1,930.7 (1,276.9 to 2,826.4)	1,771.7 (1,168.3 to 2,586.3)	-8.3 (-10.3 to -6.1)
Protein-energy malnutrition	12.3 (6.7 to 19.9)	17.2 (9.3 to 28.5)	39.8 (8.4 to 82.5)	1.5 (0.6 to 2.9)	2.1 (0.9 to 4.2)	39.8 (-14.9 to 121.9)
Iodine deficiency	11,615.0 (10,984.7 to 12,298.9)	10,648.1 (10,042.7 to 11,225.6)	-8.1 (-15.0 to -0.4)	207.4 (128.2 to 326.5)	190.7 (118.7 to 300.0)	-8.2 (-15.3 to -0.1)
Vitamin A deficiency	210.4 (143.4 to 279.0)	183.5 (123.5 to 244.6)	-12.4 (-22.5 to -3.0)	11.9 (6.9 to 18.8)	10.0 (5.6 to 16.1)	-15.9 (-33.1 to 5.7)
Iron-deficiency anemia	66,171.6 (65,949.2 to 66,365.6)	66,801.6 (66,534.8 to 67,038.0)	1.2 (0.8 to 1.7)	1,709.8 (1,133.5 to 2,488.9)	1,568.8 (1,038.5 to 2,293.9)	-8.3 (-10.3 to -6.2)
Other nutritional deficiencies	-	-	-	0.1 (0.1 to 0.3)	0.1 (0.0 to 0.3)	-9.2 (-58.4 to 97.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	186.8 (115.6 to 299.5)	227.9 (139.2 to 375.2)	21.8 (16.2 to 26.9)
Sexually transmitted diseases excluding HIV	-	-	-	110.4 (65.1 to 193.8)	150.9 (87.4 to 265.2)	36.6 (30.9 to 42.7)
Syphilis	35.1 (33.2 to 37.4)	26.4 (25.2 to 27.7)	-24.8 (-29.7 to -18.9)	6.7 (4.4 to 9.7)	5.1 (3.2 to 7.3)	-25.0 (-42.1 to -2.8)
Chlamydial infection	11,969.2 (11,573.8 to 12,349.3)	16,076.0 (15,591.8 to 16,496.1)	34.8 (29.6 to 39.6)	48.9 (30.6 to 78.1)	69.5 (44.0 to 111.4)	42.3 (33.5 to 51.8)
Gonococcal infection	2,183.1 (2,038.4 to 2,324.5)	3,104.5 (2,893.7 to 3,336.2)	42.6 (31.6 to 54.1)	14.7 (9.2 to 23.2)	21.8 (13.6 to 33.7)	48.1 (26.8 to 74.0)
Trichomoniasis	7,099.1 (6,597.1 to 7,526.4)	10,077.0 (9,385.5 to 10,718.1)	42.3 (30.4 to 54.9)	11.7 (4.7 to 24.7)	16.6 (6.6 to 35.4)	41.6 (28.1 to 56.7)
Genital herpes	94,043.4 (92,683.8 to 95,434.6)	128,256.8 (126,100.3 to 130,698.8)	36.8 (33.6 to 40.0)	24.6 (7.7 to 59.5)	33.6 (10.5 to 80.8)	36.7 (32.6 to 41.1)
Other sexually transmitted diseases	268.1 (197.5 to 355.7)	257.2 (197.9 to 337.7)	-3.7 (-10.0 to 3.5)	3.8 (2.4 to 5.8)	4.3 (2.8 to 6.6)	14.0 (-4.3 to 37.7)
Hepatitis	-	-	-	37.8 (24.4 to 54.9)	42.0 (27.2 to 60.0)	11.3 (4.8 to 17.4)
Hepatitis A	225.7 (212.8 to 236.2)	344.7 (337.9 to 348.9)	53.1 (48.2 to 59.2)	8.3 (5.3 to 12.1)	12.7 (8.1 to 18.4)	53.5 (40.0 to 67.9)
Hepatitis B	27,876.3 (27,269.6 to 28,507.1)	25,928.4 (25,406.0 to 26,473.9)	-6.7 (-9.2 to -4.1)	24.8 (16.0 to 36.1)	23.3 (15.1 to 33.3)	-6.2 (-12.7 to 1.3)
Hepatitis C	10,050.9 (9,851.9 to 10,262.3)	10,960.2 (10,728.2 to 11,194.1)	9.4 (6.2 to 12.7)	0.8 (0.5 to 1.1)	0.9 (0.6 to 1.3)	13.6 (-1.2 to 32.2)
Hepatitis E	142.9 (132.6 to 152.5)	181.7 (170.0 to 194.3)	27.0 (16.3 to 40.7)	3.9 (2.5 to 5.7)	5.1 (3.2 to 7.4)	31.4 (8.5 to 61.9)
Leprosy	27.3 (24.2 to 30.8)	36.7 (33.9 to 39.5)	34.9 (20.0 to 52.9)	1.6 (1.0 to 2.4)	2.3 (1.4 to 3.4)	45.1 (3.5 to 103.2)
Other infectious diseases	1,721.6 (1,676.0 to 1,768.5)	1,546.7 (1,497.5 to 1,601.4)	-9.9 (-13.5 to -6.1)	37.0 (23.6 to 55.9)	32.3 (19.8 to 53.4)	-12.3 (-25.0 to 3.3)
Non-communicable diseases	-	-	-	32,980.9 (24,463.2 to 42,516.5)	47,667.5 (35,177.2 to 61,556.3)	44.5 (42.8 to 46.4)
Neoplasms	-	-	-	152.7 (109.3 to 201.7)	196.8 (139.3 to 264.9)	28.7 (16.8 to 42.7)
Esophageal cancer	8.2 (6.6 to 10.0)	10.0 (7.8 to 12.6)	21.4 (-4.9 to 54.9)	1.3 (0.9 to 1.9)	1.6 (1.0 to 2.2)	15.8 (-7.1 to 45.2)
Stomach cancer	50.1 (44.7 to 55.5)	42.1 (38.0 to 46.9)	-15.9 (-25.2 to -4.7)	6.4 (4.6 to 8.6)	5.1 (3.6 to 6.7)	-20.6 (-30.6 to -8.3)
Liver cancer	-	-	-	5.2 (3.6 to 7.4)	5.2 (3.5 to 7.1)	-0.6 (-22.4 to 27.4)
Liver cancer due to hepatitis B	15.0 (11.3 to 19.4)	16.6 (13.2 to 20.8)	11.4 (-19.9 to 57.0)	2.6 (1.7 to 3.7)	2.5 (1.7 to 3.5)	-1.6 (-24.5 to 29.7)
Liver cancer due to hepatitis C	2.9 (2.3 to 3.6)	9.4 (7.5 to 11.9)	224.7 (139.6 to 350.3)	0.5 (0.3 to 0.7)	1.4 (1.0 to 2.0)	190.0 (124.2 to 276.9)
Liver cancer due to alcohol use	5.0 (3.8 to 6.4)	3.1 (2.5 to 3.9)	-37.1 (-53.6 to -11.3)	0.9 (0.6 to 1.2)	0.5 (0.3 to 0.7)	-43.0 (-56.4 to -25.8)
Liver cancer due to other causes	7.6 (5.9 to 9.6)	4.6 (3.7 to 5.7)	-38.2 (-55.2 to -16.7)	1.3 (0.9 to 1.8)	0.7 (0.5 to 1.0)	-44.2 (-57.0 to -28.4)
Larynx cancer	18.1 (13.6 to 23.0)	15.0 (11.8 to 21.3)	-18.0 (-35.2 to 12.8)	1.8 (1.1 to 2.6)	1.4 (0.9 to 2.2)	-21.1 (-40.8 to 13.0)
Tracheal, bronchus and lung cancer	30.1 (27.2 to 33.3)	27.7 (25.1 to 31.3)	-8.5 (-19.0 to 9.7)	5.1 (3.6 to 6.7)	4.4 (3.1 to 6.0)	-13.4 (-23.9 to 4.5)
Breast cancer	375.7 (335.0 to 418.0)	601.6 (530.6 to 674.2)	61.0 (37.9 to 83.1)	29.5 (20.7 to 39.7)	43.2 (29.4 to 58.4)	46.1 (23.2 to 71.8)
Cervical cancer	371.0 (286.6 to 462.2)	312.0 (231.6 to 383.2)	-15.9 (-37.6 to 11.2)	27.6 (17.9 to 39.6)	23.8 (15.2 to 34.5)	-14.7 (-36.0 to 15.6)
Uterine cancer	79.0 (51.0 to 121.7)	76.3 (48.8 to 106.8)	-2.8 (-38.6 to 55.7)	5.2 (2.8 to 9.1)	5.0 (2.8 to 7.7)	-3.3 (-39.7 to 54.5)
Prostate cancer	3.3 (2.5 to 4.2)	8.4 (6.2 to 11.4)	154.9 (115.7 to 206.0)	0.3 (0.2 to 0.4)	0.6 (0.4 to 1.0)	120.4 (81.0 to 171.7)
Colon and rectum cancer	92.6 (86.6 to 99.5)	153.6 (141.9 to 166.5)	66.2 (51.4 to 82.4)	8.2 (5.9 to 10.8)	12.7 (8.8 to 17.0)	54.8 (39.1 to 73.6)
Lip and oral cavity cancer	54.1 (43.4 to 70.2)	89.4 (65.8 to 120.7)	65.0 (19.3 to 136.4)	4.7 (3.1 to 6.8)	7.6 (4.7 to 11.6)	61.4 (14.2 to 132.9)
Nasopharynx cancer	36.9 (24.8 to 50.9)	35.3 (24.7 to 48.2)	-3.3 (-37.1 to 48.0)	3.5 (2.2 to 5.3)	3.3 (2.0 to 4.9)	-6.3 (-39.0 to 42.7)
Other pharynx cancer	10.2 (7.4 to 13.5)	15.2 (10.1 to 22.4)	47.3 (-3.4 to 135.5)	0.9 (0.6 to 1.4)	1.4 (0.8 to 2.2)	42.7 (-10.3 to 136.2)
Gallbladder and biliary tract cancer	1.5 (1.3 to 1.8)	1.8 (1.4 to 2.2)	19.4 (-3.8 to 48.0)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	11.7 (-10.0 to 38.3)
Pancreatic cancer	3.1 (2.7 to 3.4)	4.3 (3.7 to 4.8)	40.9 (19.0 to 65.9)	0.7 (0.5 to 0.9)	0.9 (0.6 to 1.2)	34.6 (16.0 to 55.5)
Malignant skin melanoma	93.3 (70.6 to 116.3)	119.4 (93.1 to 169.9)	27.6 (-2.6 to 69.5)	5.5 (3.5 to 8.3)	6.9 (4.3 to 10.8)	24.6 (-6.2 to 65.3)
Non-melanoma skin cancer	56.3 (46.1 to 72.5)	97.8 (72.1 to 149.5)	71.1 (23.1 to 155.6)	1.6 (0.9 to 2.7)	3.5 (1.8 to 7.1)	120.6 (19.7 to 323.4)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (35-39 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Ovarian cancer	33-8 (29-1 to 38-7)	48-4 (40-6 to 57-3)	43-7 (17-0 to 75-8)	4-4 (3-1 to 5-9)	6-3 (4-3 to 8-7)	43-3 (12-0 to 82-4)
Testicular cancer	58-3 (45-4 to 79-1)	87-2 (65-8 to 116-8)	50-2 (9-2 to 98-0)	5-3 (2-2 to 5-4)	5-3 (3-2 to 8-1)	47-0 (6-8 to 97-1)
Kidney cancer	21-3 (19-1 to 23-8)	33-9 (30-0 to 38-4)	59-3 (38-8 to 84-7)	1-6 (1-1 to 2-2)	2-5 (1-7 to 3-3)	52-9 (29-2 to 83-3)
Bladder cancer	17-1 (14-8 to 19-2)	19-7 (17-1 to 22-5)	15-4 (0-6 to 34-1)	1-4 (1-0 to 1-9)	1-6 (1-1 to 2-2)	14-4 (-1-8 to 35-2)
Brain and nervous system cancer	42-4 (34-7 to 51-0)	61-6 (48-9 to 73-6)	45-7 (17-5 to 79-4)	4-7 (3-1 to 6-4)	6-6 (4-4 to 9-2)	41-1 (13-5 to 75-1)
Thyroid cancer	110-0 (86-9 to 131-7)	176-5 (140-3 to 217-3)	60-8 (27-4 to 102-8)	6-2 (4-0 to 9-1)	9-8 (6-3 to 14-3)	56-9 (22-8 to 102-4)
Mesothelioma	0-6 (0-5 to 0-6)	0-5 (0-4 to 0-6)	-14-0 (-28-0 to 7-4)	0-1 (0-1 to 0-2)	0-1 (0-1 to 0-1)	-12-2 (-26-6 to 9-1)
Hodgkin lymphoma	51-5 (35-5 to 70-2)	46-6 (36-4 to 65-5)	-10-9 (-39-8 to 59-3)	4-3 (2-6 to 6-7)	3-7 (2-3 to 5-6)	-16-1 (-43-3 to 47-6)
Non-Hodgkin lymphoma	65-4 (51-6 to 78-9)	109-0 (91-5 to 130-1)	67-3 (35-5 to 103-7)	5-1 (3-3 to 7-2)	8-1 (5-4 to 11-3)	60-9 (30-4 to 99-0)
Multiple myeloma	3-5 (2-7 to 4-4)	5-6 (4-5 to 6-8)	62-6 (32-4 to 99-3)	0-8 (0-5 to 1-1)	1-2 (0-8 to 1-6)	56-8 (28-8 to 90-4)
Leukemia	43-2 (38-4 to 49-0)	71-7 (63-5 to 80-6)	66-7 (42-1 to 93-6)	6-2 (4-3 to 8-3)	9-3 (6-4 to 12-3)	49-5 (27-6 to 75-2)
Other neoplasms	85-9 (73-9 to 102-9)	220-1 (184-9 to 262-5)	157-9 (104-9 to 215-3)	6-3 (4-3 to 8-8)	15-2 (10-1 to 21-2)	140-0 (87-3 to 193-8)
Cardiovascular diseases	-	-	-	311-8 (210-7 to 434-4)	569-2 (373-4 to 813-1)	82-7 (47-3 to 121-1)
Rheumatic heart disease	1,582-3 (1,491-0 to 1,668-2)	2,647-3 (2,522-0 to 2,785-9)	68-3 (55-2 to 79-1)	82-4 (54-1 to 118-2)	132-8 (84-6 to 190-3)	61-1 (46-8 to 74-9)
Ischemic heart disease	246-8 (239-2 to 256-9)	355-4 (346-9 to 365-8)	44-2 (37-9 to 51-7)	14-4 (9-6 to 20-3)	21-5 (14-4 to 30-4)	49-0 (28-8 to 72-4)
Cerebrovascular disease	-	-	-	57-0 (39-3 to 76-0)	88-9 (61-1 to 119-1)	56-2 (39-1 to 75-2)
Ischemic stroke	197-7 (185-0 to 210-0)	312-1 (293-7 to 332-4)	58-3 (46-0 to 72-5)	31-3 (21-6 to 42-8)	49-5 (33-5 to 68-3)	58-4 (36-4 to 82-6)
Hemorrhagic stroke	160-2 (150-5 to 169-4)	247-0 (233-1 to 262-5)	54-6 (43-1 to 67-1)	25-7 (17-1 to 35-1)	39-4 (26-5 to 54-1)	54-5 (32-9 to 77-0)
Hypertensive heart disease	52-6 (49-6 to 56-2)	85-5 (80-6 to 90-5)	63-0 (50-6 to 78-1)	6-2 (4-1 to 8-6)	10-0 (6-8 to 14-0)	62-7 (37-6 to 93-1)
Cardiomyopathy and myocarditis	148-7 (141-8 to 155-3)	238-0 (228-2 to 246-3)	60-5 (52-0 to 70-0)	16-2 (11-1 to 22-3)	26-5 (17-9 to 36-6)	63-0 (47-4 to 80-3)
Atrial fibrillation and flutter	58-3 (53-9 to 63-1)	80-0 (75-3 to 85-8)	38-0 (24-4 to 50-8)	5-0 (3-2 to 7-2)	6-8 (4-5 to 9-5)	37-3 (15-8 to 62-1)
Peripheral vascular disease	-	-	-	-	-	-
Endocarditis	7-7 (6-3 to 9-0)	11-4 (8-9 to 13-4)	49-4 (28-6 to 65-3)	0-8 (0-5 to 1-1)	1-2 (0-8 to 1-8)	58-3 (34-5 to 80-1)
Other cardiovascular and circulatory diseases	1,837-0 (1,239-6 to 2,759-5)	3,969-7 (2,440-4 to 5,900-5)	118-1 (31-3 to 235-4)	129-9 (73-7 to 211-7)	281-5 (152-1 to 459-2)	116-4 (30-6 to 237-9)
Chronic respiratory diseases	-	-	-	1,838-9 (1,271-3 to 2,485-3)	2,681-0 (1,847-0 to 3,651-1)	45-7 (40-2 to 51-6)
Chronic obstructive pulmonary disease	15,141-6 (14,260-2 to 15,956-8)	22,014-3 (20,788-8 to 23,159-7)	45-8 (44-3 to 47-4)	1,198-0 (797-5 to 1,659-4)	1,840-6 (1,233-7 to 2,581-3)	53-5 (46-3 to 61-7)
Pneumoconiosis	-	-	-	1-8 (1-2 to 2-4)	2-9 (2-0 to 4-0)	63-6 (56-0 to 70-3)
Silicosis	1-9 (1-7 to 2-2)	2-4 (2-1 to 2-7)	24-1 (20-0 to 28-0)	0-4 (0-2 to 0-5)	0-4 (0-3 to 0-6)	22-4 (17-8 to 27-1)
Asbestosis	0-5 (0-5 to 0-6)	0-7 (0-6 to 0-7)	28-1 (23-6 to 33-7)	0-1 (0-1 to 0-1)	0-1 (0-1 to 0-2)	26-3 (20-6 to 33-0)
Coal workers pneumoconiosis	2-0 (1-8 to 2-1)	2-3 (2-2 to 2-5)	19-3 (16-7 to 21-3)	0-4 (0-2 to 0-5)	0-4 (0-3 to 0-6)	18-1 (15-3 to 20-6)
Other pneumoconiosis	5-0 (4-4 to 5-5)	10-1 (9-0 to 11-1)	104-5 (99-5 to 110-1)	0-9 (0-6 to 1-3)	1-9 (1-2 to 2-7)	102-5 (97-4 to 107-9)
Asthma	11,491-7 (11,210-8 to 11,768-9)	15,692-7 (15,403-6 to 16,023-0)	37-0 (32-8 to 41-6)	505-7 (330-4 to 714-9)	692-3 (453-0 to 991-1)	36-8 (32-3 to 41-9)
Interstitial lung disease and pulmonary sarcoidosis	26-6 (24-8 to 28-6)	36-6 (33-6 to 39-5)	38-0 (22-5 to 53-1)	3-5 (2-3 to 5-1)	4-9 (3-1 to 7-2)	39-7 (24-8 to 54-4)
Other chronic respiratory diseases	-	-	-	130-0 (79-4 to 195-9)	140-4 (88-4 to 212-6)	7-7 (-5-6 to 25-9)
Cirrhosis	-	-	-	29-9 (20-5 to 42-0)	37-2 (25-8 to 52-4)	24-5 (12-5 to 37-5)
Cirrhosis due to hepatitis B	55-8 (53-1 to 59-3)	61-8 (57-3 to 66-3)	11-2 (0-8 to 21-1)	9-4 (6-4 to 13-2)	10-5 (7-0 to 15-0)	10-9 (-8-2 to 34-0)
Cirrhosis due to hepatitis C	38-2 (35-7 to 40-7)	55-2 (51-2 to 60-5)	44-4 (32-5 to 59-4)	6-4 (4-3 to 9-1)	9-3 (6-2 to 13-3)	45-6 (21-6 to 75-1)
Cirrhosis due to alcohol use	57-5 (52-3 to 61-5)	55-5 (50-1 to 62-2)	-3-3 (-14-5 to 11-1)	9-6 (6-5 to 13-8)	9-4 (6-1 to 13-6)	-3-1 (-22-9 to 21-8)
Cirrhosis due to other causes	26-7 (24-3 to 29-6)	47-6 (43-4 to 52-0)	78-1 (61-6 to 101-8)	4-5 (2-9 to 6-6)	8-0 (5-3 to 11-7)	79-0 (38-1 to 130-1)
Digestive diseases	-	-	-	397-8 (283-6 to 530-1)	479-0 (340-6 to 641-9)	20-4 (14-3 to 26-7)
Peptic ulcer disease	1,130-4 (1,063-3 to 1,187-0)	805-7 (748-9 to 862-1)	-28-4 (-33-6 to -23-4)	43-5 (29-5 to 62-8)	34-5 (23-3 to 49-6)	-20-8 (-30-2 to -9-4)
Gastritis and duodenitis	2,367-4 (2,211-0 to 2,530-7)	2,130-2 (1,983-0 to 2,275-9)	-9-7 (-17-2 to -2-7)	92-2 (62-2 to 130-7)	84-4 (56-9 to 122-7)	-8-5 (-16-9 to 1-1)
Appendicitis	43-2 (37-3 to 50-2)	48-4 (42-3 to 55-9)	12-1 (-6-0 to 36-7)	13-0 (8-1 to 18-7)	14-6 (9-3 to 21-4)	12-8 (-17-6 to 54-9)
Paralytic ileus and intestinal obstruction	2-2 (2-2 to 2-3)	3-3 (3-1 to 3-4)	46-4 (37-4 to 55-0)	0-7 (0-5 to 1-0)	1-1 (0-7 to 1-4)	46-1 (37-0 to 54-7)
Inguinal, femoral, and abdominal hernia	437-6 (410-1 to 466-9)	565-8 (530-8 to 604-9)	29-6 (19-2 to 42-7)	4-7 (2-3 to 8-8)	6-1 (2-9 to 11-6)	29-8 (15-6 to 44-8)
Inflammatory bowel disease	585-6 (574-2 to 597-3)	932-6 (913-9 to 951-9)	59-7 (56-0 to 63-2)	126-0 (87-4 to 173-8)	201-0 (138-4 to 275-0)	59-6 (51-0 to 68-8)
Vascular intestinal disorders	0-5 (0-5 to 0-6)	0-7 (0-6 to 0-8)	31-7 (16-5 to 49-8)	0-2 (0-1 to 0-2)	0-2 (0-1 to 0-3)	31-4 (16-3 to 49-5)
Gallbladder and biliary diseases	293-5 (273-1 to 310-4)	320-2 (297-9 to 342-9)	9-3 (0-1 to 20-5)	31-8 (21-8 to 43-7)	34-7 (23-6 to 48-5)	8-8 (-2-2 to 23-6)
Pancreatitis	124-2 (121-6 to 126-4)	174-5 (170-4 to 178-3)	40-8 (37-2 to 45-1)	37-4 (25-2 to 50-6)	52-6 (35-4 to 71-3)	40-7 (25-7 to 57-0)
Other digestive diseases	-	-	-	48-4 (33-4 to 66-4)	49-8 (34-5 to 69-1)	3-6 (-10-5 to 14-8)
Neurological disorders	-	-	-	3,270-8 (2,180-8 to 4,558-4)	5,160-0 (3,447-6 to 7,232-2)	57-7 (49-6 to 67-3)
Alzheimer disease and other dementias	-	-	-	-	-	-
Parkinson disease	28-9 (17-9 to 40-0)	37-9 (24-5 to 51-6)	31-6 (23-5 to 43-4)	3-9 (2-1 to 6-0)	5-1 (2-8 to 7-8)	31-4 (19-2 to 48-7)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (35-39 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Epilepsy	1,041.5 (974.6 to 1,108.0)	1,467.8 (1,363.6 to 1,573.1)	41.2 (28.5 to 56.6)	339.5 (232.0 to 445.8)	510.4 (349.6 to 670.3)	50.1 (35.3 to 69.1)
Multiple sclerosis	138.3 (134.3 to 142.4)	254.2 (247.1 to 262.4)	84.4 (77.0 to 92.3)	46.2 (33.1 to 59.4)	85.2 (61.2 to 109.1)	84.8 (65.4 to 107.1)
Migraine	63,250.7 (60,126.0 to 66,468.7)	91,884.4 (88,851.6 to 95,058.2)	45.8 (36.5 to 55.2)	2,151.8 (1,281.8 to 3,168.1)	3,140.9 (1,900.3 to 4,624.5)	46.1 (35.9 to 56.2)
Tension-type headache	108,031.2 (103,431.2 to 112,435.6)	150,286.1 (145,781.4 to 154,926.7)	39.6 (32.3 to 46.9)	163.9 (79.6 to 288.2)	228.8 (110.3 to 400.6)	39.7 (31.8 to 47.4)
Medication overuse headache	3,494.5 (2,401.1 to 4,520.8)	7,391.9 (5,035.6 to 9,593.1)	112.3 (91.0 to 137.9)	552.4 (324.6 to 833.7)	1,172.7 (681.9 to 1,810.7)	112.4 (91.2 to 138.3)
Other neurological disorders	0.5 (0.4 to 0.5)	0.7 (0.6 to 0.8)	48.8 (30.2 to 71.7)	13.2 (9.0 to 18.4)	16.9 (11.8 to 22.2)	28.4 (3.5 to 51.7)
Mental and substance use disorders	-	-	-	10,853.2 (7,790.4 to 14,265.7)	15,520.6 (11,100.1 to 20,453.5)	43.0 (41.2 to 44.7)
Schizophrenia	2,328.5 (2,148.7 to 2,521.8)	3,156.4 (2,911.4 to 3,417.2)	35.9 (34.4 to 37.6)	1,512.5 (1,109.1 to 1,837.6)	2,058.9 (1,504.9 to 2,496.5)	36.1 (32.9 to 39.7)
Alcohol use disorders	6,477.0 (6,102.3 to 6,871.1)	8,510.1 (8,006.1 to 9,005.7)	31.8 (29.0 to 34.5)	647.1 (432.6 to 901.5)	853.0 (568.0 to 1,191.4)	31.8 (27.6 to 35.6)
Drug use disorders	-	-	-	1,092.5 (754.2 to 1,476.5)	1,675.6 (1,146.6 to 2,310.3)	53.3 (47.4 to 58.5)
Opioid use disorders	1,782.9 (1,356.7 to 2,388.0)	2,812.2 (2,085.8 to 3,849.8)	58.1 (52.3 to 62.4)	739.4 (489.8 to 1,068.8)	1,171.3 (761.4 to 1,713.2)	58.4 (51.3 to 64.0)
Cocaine use disorders	651.3 (632.1 to 670.0)	877.9 (846.2 to 908.7)	35.2 (29.8 to 41.2)	88.4 (58.9 to 123.4)	119.7 (78.4 to 169.9)	35.4 (24.1 to 47.7)
Amphetamine use disorders	601.6 (582.1 to 621.4)	913.7 (880.6 to 945.8)	52.5 (45.7 to 58.5)	77.8 (48.9 to 111.6)	118.5 (75.3 to 172.6)	52.5 (38.9 to 67.0)
Cannabis use disorders	664.7 (585.9 to 754.1)	885.0 (770.8 to 1,006.7)	33.4 (30.8 to 36.2)	19.1 (12.5 to 27.8)	25.4 (16.3 to 36.9)	33.4 (20.2 to 47.7)
Other drug use disorders	-	-	-	167.8 (112.8 to 231.3)	240.6 (159.6 to 322.8)	43.4 (32.4 to 56.1)
Depressive disorders	-	-	-	3,848.4 (2,452.0 to 5,581.6)	5,662.0 (3,572.1 to 8,284.8)	47.0 (43.6 to 50.4)
Major depressive disorder	15,244.5 (10,928.1 to 20,251.7)	22,581.9 (16,072.8 to 30,099.4)	48.4 (45.1 to 52.4)	3,131.1 (1,898.6 to 4,674.6)	4,655.1 (2,831.7 to 6,967.5)	48.6 (44.5 to 52.7)
Dysthymia	7,376.1 (6,234.6 to 8,517.0)	10,319.8 (8,578.2 to 12,014.2)	40.3 (37.2 to 42.8)	717.3 (465.0 to 1,042.5)	1,006.9 (646.5 to 1,462.6)	40.3 (36.5 to 43.8)
Bipolar disorder	3,765.4 (3,226.6 to 4,280.0)	5,392.9 (4,611.7 to 6,136.7)	43.7 (40.8 to 46.0)	767.1 (471.9 to 1,156.2)	1,102.7 (679.6 to 1,644.4)	43.8 (39.0 to 48.6)
Anxiety disorders	16,662.0 (11,795.6 to 21,231.4)	23,194.6 (16,254.0 to 29,614.3)	39.6 (36.9 to 42.3)	1,529.0 (927.4 to 2,310.8)	2,134.3 (1,302.4 to 3,216.2)	39.6 (36.1 to 42.9)
Eating disorders	-	-	-	105.7 (64.4 to 161.1)	142.2 (83.4 to 223.0)	34.2 (22.8 to 45.1)
Anorexia nervosa	106.3 (79.6 to 143.0)	157.3 (114.9 to 218.7)	47.9 (40.3 to 56.7)	22.3 (13.7 to 34.8)	33.1 (19.9 to 52.7)	48.3 (32.0 to 63.9)
Bulimia nervosa	402.4 (251.9 to 590.5)	525.3 (311.3 to 800.7)	30.7 (18.6 to 39.7)	83.4 (47.2 to 137.1)	109.1 (59.4 to 185.9)	30.3 (16.9 to 43.1)
Autistic spectrum disorders	-	-	-	415.6 (290.2 to 564.8)	586.3 (408.3 to 796.1)	41.0 (37.5 to 44.9)
Autism	1,077.8 (1,024.2 to 1,129.4)	1,515.1 (1,439.6 to 1,589.2)	41.0 (40.6 to 41.4)	263.3 (176.6 to 358.1)	371.7 (251.6 to 506.4)	41.1 (36.2 to 46.3)
Asperger syndrome	1,532.1 (1,430.2 to 1,638.3)	2,151.6 (2,005.5 to 2,300.7)	40.8 (40.4 to 41.2)	152.2 (106.3 to 212.2)	214.6 (147.7 to 299.2)	40.9 (36.6 to 45.5)
Attention-deficit/hyperactivity disorder	32.0 (21.7 to 43.2)	44.6 (30.2 to 60.0)	39.6 (35.5 to 43.6)	0.4 (0.2 to 0.7)	0.6 (0.3 to 0.9)	39.4 (31.7 to 46.9)
Conduct disorder	-	-	-	-	-	-
Idiopathic intellectual disability	4,535.3 (3,500.2 to 5,630.6)	6,084.9 (4,856.2 to 7,572.0)	34.4 (22.7 to 50.2)	224.2 (146.0 to 323.6)	299.1 (196.3 to 428.0)	33.5 (20.8 to 49.0)
Other mental and substance use disorders	9,464.0 (7,928.5 to 11,088.1)	13,334.5 (11,170.9 to 15,614.5)	41.3 (41.1 to 41.6)	710.8 (472.4 to 996.5)	1,005.9 (665.1 to 1,410.5)	41.5 (38.1 to 44.7)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	2,998.5 (2,088.9 to 4,128.4)	4,622.0 (3,223.5 to 6,315.3)	54.0 (49.9 to 59.3)
Diabetes mellitus	14,816.7 (14,182.1 to 15,555.1)	28,584.4 (27,503.4 to 29,805.6)	93.5 (82.9 to 106.0)	932.3 (632.4 to 1,312.1)	1,803.5 (1,221.5 to 2,513.7)	93.5 (83.8 to 106.1)
Acute glomerulonephritis	1.0 (0.8 to 1.1)	1.1 (1.0 to 1.3)	16.1 (11.3 to 19.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	15.9 (11.1 to 19.1)
Chronic kidney disease	-	-	-	646.3 (407.7 to 965.4)	885.8 (569.6 to 1,278.4)	37.2 (27.9 to 45.6)
Chronic kidney disease due to diabetes mellitus	2,734.9 (1,598.7 to 4,893.4)	4,109.5 (2,561.7 to 6,709.7)	52.0 (26.2 to 77.7)	97.9 (63.0 to 145.1)	138.9 (89.8 to 206.6)	41.6 (22.7 to 67.7)
Chronic kidney disease due to hypertension	4,569.9 (2,910.2 to 8,024.1)	6,155.7 (4,065.7 to 9,670.2)	37.1 (18.4 to 49.8)	211.5 (131.3 to 317.0)	253.9 (158.6 to 376.0)	19.8 (7.2 to 36.5)
Chronic kidney disease due to glomerulonephritis	5,929.6 (3,365.2 to 10,555.3)	8,117.9 (4,980.0 to 12,574.7)	41.3 (12.4 to 56.1)	144.3 (92.3 to 206.9)	196.9 (125.3 to 293.1)	36.3 (17.9 to 57.9)
Chronic kidney disease due to other causes	5,022.4 (3,076.9 to 8,698.6)	8,032.8 (4,924.5 to 13,280.4)	60.6 (42.2 to 84.4)	192.6 (121.8 to 295.1)	296.1 (188.1 to 437.9)	53.2 (37.4 to 77.9)
Urinary diseases and male infertility	-	-	-	74.4 (43.9 to 123.5)	115.0 (67.4 to 192.5)	55.4 (39.1 to 69.6)
Interstitial nephritis and urinary tract infections	70.7 (69.0 to 72.3)	115.2 (112.1 to 118.1)	63.4 (58.0 to 68.8)	2.4 (1.5 to 3.5)	3.9 (2.4 to 5.8)	64.3 (39.6 to 91.1)
Urolithiasis	2,301.7 (1,809.3 to 3,003.5)	3,358.2 (2,402.3 to 4,575.8)	47.0 (28.0 to 61.0)	26.9 (17.5 to 39.5)	39.3 (24.5 to 59.9)	45.4 (31.3 to 60.5)
Benign prostatic hyperplasia	-	-	-	-	-	-
Male infertility due to other causes	5,460.1 (5,158.9 to 5,787.8)	7,831.9 (7,343.4 to 8,374.9)	43.5 (32.9 to 56.3)	34.5 (14.6 to 69.1)	49.7 (20.9 to 100.2)	43.5 (32.1 to 57.8)
Other urinary diseases	-	-	-	10.6 (6.4 to 16.3)	22.2 (11.6 to 34.9)	123.4 (49.3 to 164.3)
Gynecological diseases	-	-	-	999.0 (652.1 to 1,477.9)	1,359.5 (890.7 to 2,029.6)	35.9 (31.2 to 41.3)
Uterine fibroids	18,912.6 (16,787.2 to 20,805.0)	26,640.2 (23,544.3 to 29,300.3)	41.3 (40.2 to 42.3)	301.2 (181.4 to 489.6)	355.5 (205.1 to 594.2)	17.6 (9.8 to 24.2)
Polycystic ovarian syndrome	14,884.3 (14,532.4 to 15,190.6)	21,233.3 (20,643.0 to 21,833.8)	43.1 (38.6 to 47.5)	144.1 (66.9 to 268.8)	207.1 (96.3 to 387.3)	43.7 (38.9 to 48.3)
Female infertility due to other causes	4,329.8 (3,531.3 to 5,113.4)	6,850.9 (5,728.9 to 7,943.4)	58.6 (42.8 to 78.5)	22.1 (8.5 to 46.3)	35.1 (13.8 to 73.9)	58.7 (42.5 to 79.1)
Endometriosis	1,861.2 (1,772.6 to 1,952.0)	2,636.5 (2,511.1 to 2,764.7)	42.0 (33.8 to 50.6)	171.8 (115.1 to 234.4)	244.0 (163.8 to 333.8)	42.1 (32.9 to 52.0)
Genital prolapse	26,590.8 (25,720.4 to 27,597.4)	36,886.0 (35,685.3 to 38,040.9)	39.3 (32.3 to 45.7)	85.2 (41.5 to 161.5)	118.4 (57.5 to 219.1)	39.3 (31.5 to 45.8)
Premenstrual syndrome	24,514.4 (22,157.8 to 26,915.0)	38,902.8 (35,100.9 to 42,699.0)	59.4 (40.4 to 83.8)	204.6 (126.8 to 311.9)	325.1 (201.3 to 488.2)	58.8 (40.2 to 82.8)
Other gynecological diseases	2,268.2 (2,059.4 to 2,468.0)	2,657.9 (2,521.4 to 2,804.2)	17.4 (6.9 to 30.0)	70.1 (47.9 to 99.5)	74.4 (50.9 to 104.8)	5.8 (-6.0 to 25.4)
Hemoglobinopathies and hemolytic anemias	-	-	-	254.8 (169.6 to 371.6)	360.5 (242.8 to 522.4)	41.4 (35.8 to 48.7)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (35-39 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Thalassemias	11.6 (10.0 to 13.2)	17.4 (15.4 to 19.5)	50.3 (40.0 to 65.1)	1.1 (0.7 to 1.5)	1.5 (1.0 to 2.1)	38.5 (19.8 to 63.3)
Thalassemia trait	9,604.7 (8,673.8 to 10,905.4)	14,641.4 (13,544.7 to 16,128.0)	53.2 (48.1 to 57.3)	138.5 (92.6 to 200.1)	229.3 (154.4 to 333.0)	65.7 (57.5 to 73.7)
Sickle cell disorders	53.2 (48.6 to 57.7)	108.2 (97.8 to 117.9)	104.0 (85.0 to 121.9)	7.5 (5.3 to 9.9)	15.4 (10.9 to 20.6)	105.4 (82.6 to 128.9)
Sickle cell trait	9,719.2 (9,237.6 to 10,164.0)	16,429.6 (15,641.4 to 17,138.5)	69.5 (66.3 to 72.6)	40.0 (25.6 to 59.3)	62.5 (41.5 to 91.9)	55.8 (38.9 to 83.6)
G6PD deficiency	14,002.6 (13,648.9 to 14,342.0)	21,948.7 (21,380.2 to 22,495.0)	57.2 (51.8 to 62.7)	1.2 (0.8 to 1.7)	1.8 (1.2 to 2.4)	48.3 (37.4 to 57.4)
G6PD trait	53,742.1 (53,412.9 to 54,016.6)	79,724.5 (79,222.4 to 80,181.0)	48.7 (47.7 to 50.1)	2.1 (1.3 to 3.1)	2.6 (1.4 to 4.4)	22.1 (-21.8 to 88.7)
Other hemoglobinopathies and hemolytic anemias	3,168.0 (3,102.5 to 3,232.7)	2,778.8 (2,684.1 to 2,876.5)	-12.0 (-15.5 to -8.6)	64.5 (42.0 to 95.2)	47.5 (30.6 to 72.5)	-26.6 (-35.7 to -17.7)
Endocrine, metabolic, blood, and immune disorders	3,337.6 (3,191.1 to 3,480.8)	3,605.8 (3,511.7 to 3,694.3)	8.4 (3.0 to 13.9)	91.7 (62.1 to 129.1)	97.7 (66.8 to 135.2)	6.5 (-2.6 to 17.1)
Musculoskeletal disorders	-	-	-	8,566.4 (5,994.6 to 11,471.6)	12,149.5 (8,503.7 to 16,239.9)	41.6 (38.4 to 46.0)
Rheumatoid arthritis	515.1 (506.5 to 523.6)	709.8 (698.0 to 720.9)	38.2 (35.1 to 41.2)	124.9 (88.2 to 166.7)	172.7 (121.8 to 229.8)	38.4 (30.5 to 46.7)
Osteoarthritis	5,001.1 (4,932.0 to 5,075.4)	7,009.8 (6,907.9 to 7,119.4)	40.6 (37.6 to 43.2)	290.2 (203.4 to 394.2)	417.2 (291.6 to 569.5)	43.8 (39.9 to 48.0)
Low back and neck pain	-	-	-	6,988.4 (4,865.3 to 9,412.8)	9,770.7 (6,785.8 to 13,074.1)	39.6 (35.8 to 44.7)
Low back pain	38,343.5 (37,357.2 to 39,318.9)	53,829.0 (52,145.3 to 55,419.9)	40.7 (35.0 to 46.5)	4,341.9 (2,961.6 to 6,039.5)	6,118.6 (4,092.7 to 8,508.4)	40.8 (34.9 to 46.7)
Neck pain	26,554.3 (25,659.7 to 27,422.7)	36,546.7 (35,149.5 to 38,023.5)	37.9 (31.0 to 46.1)	2,646.4 (1,820.1 to 3,649.8)	3,652.1 (2,534.8 to 5,064.7)	37.9 (30.8 to 46.0)
Gout	212.2 (207.6 to 216.5)	267.2 (262.2 to 272.2)	26.3 (22.7 to 29.9)	7.2 (4.9 to 9.8)	9.1 (6.2 to 12.5)	26.9 (12.6 to 41.3)
Other musculoskeletal disorders	12,314.3 (9,057.0 to 15,732.3)	18,920.6 (14,217.2 to 24,156.0)	54.1 (48.8 to 60.3)	1,155.8 (712.1 to 1,723.2)	1,779.8 (1,100.6 to 2,664.8)	53.9 (48.1 to 61.0)
Other non-communicable diseases	-	-	-	4,560.9 (2,956.0 to 6,740.7)	6,252.2 (4,075.7 to 9,254.5)	37.2 (33.8 to 40.1)
Congenital anomalies	-	-	-	284.5 (208.9 to 370.3)	471.8 (339.3 to 608.6)	65.7 (55.0 to 78.4)
Neural tube defects	59.5 (58.0 to 61.2)	98.7 (96.4 to 101.3)	66.4 (60.7 to 72.1)	18.1 (12.8 to 23.5)	30.8 (21.7 to 40.0)	70.5 (54.0 to 87.4)
Congenital heart anomalies	1,277.1 (1,234.9 to 1,324.2)	2,425.5 (2,348.2 to 2,519.1)	90.2 (82.5 to 100.7)	43.8 (17.9 to 75.7)	85.3 (35.3 to 145.6)	94.7 (84.8 to 105.8)
Orofacial clefts	198.5 (190.6 to 207.0)	399.3 (387.5 to 411.1)	101.3 (92.4 to 113.4)	2.4 (1.6 to 3.5)	4.5 (3.0 to 6.6)	86.2 (65.4 to 108.9)
Down syndrome	272.1 (262.9 to 283.0)	491.0 (472.9 to 510.4)	81.1 (71.9 to 89.9)	29.6 (21.5 to 38.7)	53.4 (39.4 to 70.0)	80.7 (66.4 to 95.7)
Turner syndrome	12.6 (11.9 to 13.3)	20.3 (19.4 to 21.4)	60.9 (52.4 to 72.8)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.6)	60.1 (43.9 to 80.5)
Klinefelter syndrome	10.2 (9.6 to 10.7)	15.1 (14.4 to 15.8)	48.4 (39.1 to 59.7)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	48.1 (32.9 to 66.2)
Chromosomal unbalanced rearrangements	386.2 (373.4 to 398.3)	660.7 (635.0 to 692.9)	71.4 (63.2 to 80.9)	41.8 (30.3 to 54.0)	71.7 (52.4 to 93.3)	71.6 (58.5 to 85.2)
Other congenital anomalies	1,504.9 (1,301.1 to 1,694.1)	1,939.2 (1,655.4 to 2,200.7)	29.1 (22.7 to 36.8)	148.4 (104.1 to 203.0)	225.5 (155.3 to 303.0)	51.6 (36.9 to 72.2)
Skin and subcutaneous diseases	-	-	-	1,854.0 (1,196.3 to 2,797.9)	2,617.7 (1,663.7 to 3,926.9)	41.3 (35.8 to 45.9)
Dermatitis	24,627.3 (18,637.4 to 32,569.9)	33,731.0 (25,775.8 to 44,269.3)	37.4 (36.1 to 39.2)	574.0 (353.4 to 848.8)	790.5 (488.9 to 1,165.9)	37.7 (35.4 to 40.3)
Psoriasis	3,639.0 (3,098.9 to 4,233.9)	5,073.3 (4,278.5 to 5,954.5)	39.8 (38.1 to 41.3)	297.8 (200.1 to 423.0)	416.8 (279.2 to 592.6)	39.9 (34.6 to 45.2)
Cellulitis	86.5 (61.7 to 129.1)	92.5 (66.3 to 135.6)	7.6 (1.4 to 12.6)	6.2 (3.6 to 9.9)	6.7 (4.0 to 10.8)	8.3 (-10.7 to 30.5)
Pyoderma	194.5 (120.8 to 293.1)	227.1 (140.2 to 364.5)	17.0 (-2.3 to 35.6)	1.1 (0.4 to 2.4)	1.3 (0.4 to 2.9)	17.1 (-5.7 to 40.7)
Scabies	3,241.6 (2,824.0 to 3,708.4)	4,499.5 (4,088.1 to 5,021.2)	39.6 (17.3 to 64.9)	83.1 (46.7 to 134.7)	115.9 (64.4 to 186.5)	39.4 (17.3 to 64.0)
Fungal skin diseases	34,184.5 (27,931.5 to 42,459.2)	48,404.4 (39,305.2 to 60,198.8)	42.0 (39.8 to 44.0)	192.8 (77.7 to 411.7)	273.7 (110.1 to 586.7)	41.9 (39.6 to 44.0)
Viral skin diseases	3,086.3 (1,755.0 to 4,528.3)	4,200.1 (2,414.6 to 6,162.7)	36.5 (31.5 to 42.3)	94.6 (44.4 to 169.1)	129.0 (61.7 to 231.4)	36.4 (30.1 to 43.3)
Acne vulgaris	18,982.7 (17,109.7 to 20,751.5)	26,870.6 (23,877.6 to 29,279.3)	42.1 (21.4 to 62.9)	203.6 (98.1 to 372.7)	289.2 (135.9 to 536.2)	41.9 (21.7 to 62.3)
Alopecia areata	501.9 (485.5 to 519.0)	698.5 (676.8 to 722.6)	39.7 (33.6 to 45.4)	16.9 (10.8 to 25.5)	23.6 (15.0 to 35.6)	39.4 (28.6 to 49.5)
Pruritus	46.1 (43.0 to 50.4)	62.2 (56.3 to 67.2)	35.4 (16.8 to 51.6)	0.5 (0.2 to 1.0)	0.7 (0.3 to 1.2)	34.9 (11.8 to 62.0)
Urticaria	4,238.9 (3,828.5 to 4,958.7)	6,463.8 (5,530.4 to 7,369.9)	53.9 (22.6 to 84.0)	253.5 (163.9 to 362.1)	388.3 (247.6 to 572.5)	54.1 (22.0 to 83.6)
Decubitus ulcer	38.9 (37.0 to 40.7)	45.8 (43.2 to 48.8)	18.2 (12.0 to 24.7)	6.3 (4.3 to 8.9)	7.5 (5.0 to 10.5)	18.2 (4.2 to 36.3)
Other skin and subcutaneous diseases	20,826.3 (4,784.0 to 48,732.9)	29,362.7 (6,712.6 to 68,430.3)	41.6 (38.7 to 44.1)	123.5 (23.1 to 352.4)	174.6 (32.5 to 500.6)	41.4 (38.3 to 44.5)
Sense organ diseases	-	-	-	1,712.0 (1,072.1 to 2,527.4)	2,175.6 (1,356.4 to 3,273.7)	27.1 (21.2 to 32.2)
Glaucoma	515.7 (420.1 to 632.0)	749.2 (597.6 to 925.5)	45.6 (33.4 to 58.5)	33.8 (21.6 to 49.8)	47.7 (30.1 to 71.2)	41.2 (27.1 to 56.7)
Cataract	-	-	0.0 (0.0 to 0.0)	-	-	-
Macular degeneration	-	-	-	-	-	-
Uncorrected refractive error	17,818.0 (17,071.5 to 18,636.7)	24,437.4 (23,329.1 to 25,479.9)	37.4 (32.8 to 42.7)	356.0 (223.4 to 553.2)	475.7 (297.1 to 744.1)	33.5 (29.4 to 38.0)
Age-related and other hearing loss	40,879.6 (32,556.2 to 49,932.6)	51,989.8 (41,170.1 to 64,532.2)	27.3 (21.5 to 33.2)	1,068.7 (613.8 to 1,656.2)	1,322.3 (754.6 to 2,098.3)	23.6 (15.0 to 31.6)
Other vision loss	1,614.3 (1,290.8 to 1,993.8)	1,813.2 (1,433.9 to 2,242.8)	12.8 (7.6 to 17.0)	106.4 (68.1 to 154.7)	120.7 (76.8 to 178.0)	13.4 (6.0 to 21.0)
Other sense organ diseases	5,568.2 (5,444.3 to 5,694.1)	7,888.0 (7,683.1 to 8,066.6)	42.0 (37.9 to 46.6)	147.1 (90.6 to 217.3)	209.2 (130.1 to 309.8)	42.2 (36.4 to 48.5)
Oral disorders	-	-	-	710.4 (407.9 to 1,148.7)	987.1 (563.3 to 1,601.9)	38.9 (35.6 to 41.9)
Deciduous caries	-	-	-	-	-	-
Permanent caries	152,940.3 (150,783.4 to 154,950.7)	213,168.5 (210,235.2 to 216,645.8)	39.7 (37.0 to 43.1)	136.1 (63.0 to 259.9)	196.0 (90.0 to 380.4)	43.9 (40.4 to 48.2)
Periodontal diseases	28,780.0 (28,213.6 to 29,342.9)	41,768.7 (40,723.0 to 42,924.8)	45.6 (40.9 to 50.4)	190.6 (76.2 to 393.3)	277.4 (110.8 to 572.4)	45.6 (41.0 to 50.7)
Edentulism and severe tooth loss	5,093.9 (4,923.4 to 5,272.9)	6,247.3 (6,058.2 to 6,447.9)	23.0 (17.4 to 28.2)	145.7 (97.1 to 204.3)	179.1 (119.6 to 250.2)	22.8 (16.5 to 29.4)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (35-39 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Other oral disorders	8,100.6 (7,918.0 to 8,285.0)	11,364.1 (11,120.3 to 11,622.0)	40.7 (36.5 to 45.4)	237.9 (148.9 to 355.1)	334.6 (210.9 to 499.5)	40.5 (36.1 to 45.9)
Injuries	-	-	-	3,027.1 (2,176.0 to 4,127.6)	2,465.4 (1,807.9 to 3,240.7)	-17.5 (-32.2 to -7.1)
Transport injuries	-	-	-	959.1 (714.8 to 1,234.8)	855.9 (633.8 to 1,121.1)	-11.0 (-17.1 to -3.7)
Road injuries	-	-	-	797.3 (592.6 to 1,023.0)	716.2 (528.4 to 941.8)	-10.4 (-17.1 to -2.6)
Pedestrian road injuries	-	-	-	166.4 (123.9 to 214.3)	164.1 (120.2 to 216.7)	-1.6 (-9.2 to 7.1)
Cyclist road injuries	-	-	-	66.5 (49.7 to 86.2)	57.8 (42.3 to 76.5)	-13.2 (-19.0 to -6.4)
Motorcyclist road injuries	-	-	-	199.2 (148.6 to 258.0)	160.3 (117.7 to 213.6)	-19.7 (-26.6 to -11.2)
Motor vehicle road injuries	-	-	-	357.5 (265.5 to 455.2)	327.5 (242.0 to 426.8)	-8.6 (-15.3 to -0.6)
Other road injuries	-	-	-	7.6 (5.7 to 9.8)	6.4 (4.7 to 8.4)	-16.3 (-22.3 to -9.6)
Other transport injuries	-	-	-	161.8 (121.2 to 212.1)	139.7 (103.8 to 182.9)	-13.7 (-18.5 to -8.4)
Unintentional injuries	-	-	-	1,244.4 (937.2 to 1,615.6)	1,286.1 (946.5 to 1,717.2)	3.2 (-1.9 to 8.8)
Falls	-	-	-	554.6 (415.2 to 722.6)	605.9 (438.7 to 810.9)	9.1 (2.1 to 16.5)
Drowning	-	-	-	35.6 (26.1 to 46.3)	31.1 (22.8 to 40.9)	-12.8 (-19.0 to -5.7)
Fire, heat, and hot substances	-	-	-	115.8 (88.2 to 147.7)	98.6 (73.6 to 128.3)	-14.8 (-22.2 to -8.1)
Poisonings	-	-	-	7.8 (5.5 to 10.6)	6.7 (4.7 to 9.0)	-15.0 (-21.2 to -9.2)
Exposure to mechanical forces	-	-	-	324.9 (241.2 to 427.6)	314.9 (230.9 to 425.7)	-3.3 (-8.3 to 2.1)
Unintentional firearm injuries	-	-	-	15.3 (11.6 to 19.6)	15.1 (11.1 to 20.1)	-1.5 (-8.5 to 5.6)
Unintentional suffocation	-	-	-	3.3 (2.5 to 4.3)	4.4 (3.3 to 5.9)	35.1 (27.1 to 43.7)
Other exposure to mechanical forces	-	-	-	306.3 (227.1 to 403.8)	295.3 (216.2 to 399.7)	-3.8 (-8.8 to 1.5)
Adverse effects of medical treatment	-	-	-	8.4 (5.3 to 12.3)	10.7 (6.7 to 15.9)	26.9 (22.6 to 31.0)
Animal contact	-	-	-	38.7 (28.7 to 50.3)	33.4 (24.5 to 43.7)	-14.0 (-19.0 to -8.2)
Venomous animal contact	-	-	-	16.7 (12.0 to 22.4)	14.8 (10.4 to 19.6)	-11.9 (-19.6 to -3.1)
Non-venomous animal contact	-	-	-	22.0 (16.3 to 28.9)	18.6 (13.5 to 25.1)	-15.6 (-20.4 to -10.0)
Foreign body	-	-	-	18.2 (13.5 to 23.2)	20.5 (15.0 to 26.5)	12.6 (6.8 to 19.1)
Pulmonary aspiration and foreign body in airway	-	-	-	3.5 (2.7 to 4.5)	3.0 (2.3 to 3.9)	-14.2 (-21.6 to -4.9)
Foreign body in eyes	-	-	-	4.2 (2.6 to 6.4)	5.1 (3.0 to 7.9)	21.8 (14.3 to 28.6)
Foreign body in other body part	-	-	-	10.5 (8.0 to 13.3)	12.3 (9.2 to 16.1)	17.9 (11.5 to 24.7)
Other unintentional injuries	-	-	-	140.4 (104.9 to 183.7)	164.3 (121.2 to 217.9)	16.8 (12.4 to 22.0)
Self-harm and interpersonal violence	-	-	-	110.1 (82.7 to 141.2)	96.8 (71.3 to 127.5)	-12.4 (-18.3 to -4.7)
Self-harm	-	-	-	25.3 (18.6 to 33.2)	20.4 (14.6 to 27.0)	-19.9 (-24.3 to -14.1)
Interpersonal violence	-	-	-	84.8 (64.3 to 107.8)	76.4 (56.9 to 100.5)	-10.1 (-16.8 to -1.5)
Assault by firearm	-	-	-	14.0 (10.6 to 17.9)	15.4 (11.3 to 20.4)	10.0 (2.1 to 18.6)
Assault by sharp object	-	-	-	15.9 (12.0 to 20.7)	17.0 (12.3 to 22.9)	6.3 (-1.1 to 14.9)
Assault by other means	-	-	-	54.9 (41.4 to 69.8)	44.1 (32.9 to 57.1)	-19.9 (-25.9 to -12.0)
Forces of nature, war, and legal intervention	-	-	-	713.5 (281.8 to 1,536.2)	226.7 (113.4 to 450.9)	-67.3 (-75.4 to -55.1)
Exposure to forces of nature	-	-	-	41.9 (18.8 to 93.1)	34.7 (17.9 to 67.6)	-15.5 (-39.0 to 12.5)
Collective violence and legal intervention	-	-	-	671.6 (259.3 to 1,480.2)	192.0 (91.2 to 395.2)	-70.7 (-78.2 to -59.2)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (40-44 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
All causes	-	-	-	35,883.4 (26,565.0 to 46,082.0)	58,931.6 (43,526.9 to 76,001.6)	64.2 (61.4 to 66.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	3,816.3 (2,675.7 to 5,249.4)	5,605.2 (4,037.8 to 7,531.1)	47.2 (39.3 to 56.8)
HIV/AIDS and tuberculosis	-	-	-	326.7 (229.9 to 432.0)	963.4 (683.2 to 1,271.2)	195.1 (169.8 to 225.3)
Tuberculosis	696.0 (646.0 to 747.8)	1,158.7 (1,080.8 to 1,237.6)	66.4 (61.4 to 72.1)	212.0 (145.9 to 288.7)	354.9 (241.5 to 486.2)	67.4 (58.2 to 77.5)
HIV/AIDS	-	-	-	114.8 (82.3 to 150.2)	608.5 (438.1 to 800.9)	429.0 (356.7 to 520.6)
HIV/AIDS resulting in mycobacterial infection	24.5 (15.9 to 34.2)	106.5 (75.7 to 136.4)	338.2 (267.2 to 421.3)	9.0 (5.2 to 14.0)	39.2 (24.3 to 56.6)	338.4 (247.3 to 459.3)
HIV/AIDS resulting in other diseases	809.4 (736.0 to 877.8)	3,750.0 (3,572.6 to 4,111.9)	361.2 (326.6 to 416.5)	105.8 (74.8 to 139.9)	569.3 (404.1 to 749.7)	437.3 (357.6 to 540.5)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	363.6 (257.9 to 499.0)	527.2 (369.5 to 731.2)	44.8 (38.7 to 51.5)
Diarrheal diseases	641.4 (614.6 to 668.1)	873.7 (824.9 to 922.2)	36.5 (26.1 to 45.7)	100.5 (69.2 to 138.2)	137.0 (92.5 to 188.4)	36.1 (24.3 to 50.2)
Intestinal infectious diseases	-	-	-	5.5 (3.4 to 8.1)	6.1 (3.9 to 9.1)	10.3 (-21.8 to 56.7)
Typhoid fever	32.0 (26.1 to 37.8)	36.1 (28.8 to 44.7)	12.0 (-15.7 to 50.2)	4.1 (2.5 to 6.2)	4.8 (3.0 to 7.4)	16.5 (-22.5 to 75.5)
Paratyphoid fever	19.3 (14.4 to 25.0)	20.3 (15.5 to 28.0)	5.0 (-32.0 to 57.1)	1.0 (0.5 to 1.6)	1.1 (0.6 to 1.8)	4.2 (-38.1 to 76.1)
Other intestinal infectious diseases	-	-	-	0.4 (0.2 to 0.7)	0.2 (0.1 to 0.4)	-40.6 (-55.5 to -19.9)
Lower respiratory infections	66.7 (65.0 to 68.5)	117.6 (115.4 to 120.1)	76.4 (70.8 to 83.1)	6.9 (4.6 to 9.7)	12.2 (8.3 to 17.2)	76.5 (58.6 to 95.9)
Upper respiratory infections	7,944.2 (7,775.9 to 8,094.3)	13,792.3 (13,457.6 to 14,108.8)	73.5 (69.0 to 79.0)	92.2 (52.0 to 152.3)	160.6 (89.6 to 266.9)	74.0 (68.3 to 80.7)
Otitis media	2,859.6 (2,729.1 to 2,981.8)	4,205.4 (4,011.2 to 4,391.1)	46.9 (40.5 to 54.7)	52.8 (31.0 to 86.0)	78.7 (46.9 to 126.9)	49.0 (40.4 to 58.5)
Meningitis	-	-	-	84.3 (58.6 to 115.8)	102.2 (71.1 to 140.6)	21.1 (12.8 to 30.6)
Pneumococcal meningitis	465.2 (278.8 to 697.1)	574.8 (348.2 to 869.8)	23.4 (14.7 to 32.2)	34.6 (24.9 to 46.6)	45.1 (32.1 to 60.6)	29.8 (15.1 to 47.2)
H influenzae type B meningitis	195.2 (60.0 to 378.1)	198.6 (66.7 to 391.9)	1.6 (-10.1 to 11.7)	16.0 (10.9 to 22.3)	18.5 (12.6 to 26.1)	14.9 (-0.8 to 35.5)
Meningococcal meningitis	90.8 (24.0 to 201.1)	90.5 (25.6 to 200.1)	-0.4 (-12.0 to 11.3)	9.4 (5.2 to 15.4)	10.1 (5.8 to 16.0)	7.7 (-4.0 to 23.0)
Other meningitis	231.4 (91.1 to 433.4)	248.1 (111.6 to 464.2)	7.2 (-4.7 to 21.6)	24.3 (16.3 to 34.2)	28.6 (19.0 to 39.7)	17.0 (1.7 to 35.8)
Encephalitis	104.2 (40.9 to 234.7)	133.3 (55.4 to 317.9)	29.0 (1.9 to 41.4)	11.6 (7.8 to 16.1)	16.5 (11.4 to 22.3)	42.7 (25.8 to 60.8)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-14.5 (-70.3 to 210.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.5 (-70.4 to 213.7)
Whooping cough	2.8 (2.2 to 3.6)	2.7 (2.1 to 3.5)	-1.9 (-2.8 to -0.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-2.0 (-2.9 to -0.9)
Tetanus	57.7 (41.5 to 86.5)	9.4 (5.8 to 14.6)	-84.0 (-91.1 to -71.2)	1.8 (1.1 to 2.8)	0.6 (0.4 to 0.9)	-68.6 (-80.2 to -49.4)
Measles	0.4 (0.3 to 0.5)	0.1 (0.1 to 0.2)	-62.1 (-65.2 to -58.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-62.1 (-65.3 to -59.0)
Varicella and herpes zoster	145.0 (137.3 to 155.5)	246.4 (231.4 to 262.1)	70.2 (57.6 to 82.1)	7.6 (4.7 to 11.7)	13.1 (8.0 to 20.0)	72.3 (53.7 to 92.9)
Neglected tropical diseases and malaria	-	-	-	1,079.0 (696.0 to 1,564.0)	1,314.3 (813.4 to 1,990.2)	20.8 (7.2 to 38.9)
Malaria	10,671.9 (10,378.8 to 10,970.0)	15,287.4 (14,889.8 to 15,743.0)	43.1 (38.4 to 48.3)	71.1 (47.4 to 101.6)	99.9 (66.8 to 143.7)	40.4 (31.7 to 50.4)
Chagas disease	619.6 (603.1 to 636.4)	709.6 (683.3 to 732.2)	14.6 (9.0 to 19.6)	6.1 (4.0 to 8.8)	7.0 (4.5 to 10.2)	14.5 (4.0 to 25.7)
Leishmaniasis	-	-	-	1.1 (0.6 to 2.1)	3.1 (1.5 to 5.8)	168.6 (139.2 to 206.3)
Visceral leishmaniasis	2.1 (1.5 to 2.8)	3.6 (2.4 to 5.1)	78.5 (10.6 to 163.4)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.4)	78.5 (11.1 to 165.6)
Cutaneous and mucocutaneous leishmaniasis	95.4 (79.3 to 115.0)	267.7 (225.1 to 319.3)	180.1 (147.9 to 218.0)	1.0 (0.5 to 1.9)	2.8 (1.3 to 5.5)	182.8 (149.4 to 224.9)
African trypanosomiasis	4.8 (2.1 to 9.6)	1.3 (0.7 to 2.3)	-71.3 (-75.5 to -66.0)	1.3 (0.5 to 2.6)	0.4 (0.1 to 0.7)	-71.5 (-80.7 to -55.7)
Schistosomiasis	12,235.1 (10,940.3 to 13,484.5)	16,253.4 (14,059.9 to 18,860.5)	31.2 (22.6 to 52.9)	108.7 (55.8 to 200.8)	146.6 (72.9 to 280.2)	33.2 (25.4 to 54.3)
Cysticercosis	98.1 (85.4 to 110.6)	80.7 (69.1 to 94.5)	-18.3 (-31.5 to 1.9)	27.6 (19.3 to 36.3)	24.5 (16.7 to 32.9)	-11.5 (-29.6 to 14.5)
Cystic echinococcosis	63.8 (60.5 to 68.2)	61.9 (58.5 to 65.6)	-3.1 (-7.2 to 0.4)	6.0 (4.0 to 8.4)	5.8 (3.9 to 8.3)	-2.6 (-15.8 to 13.9)
Lymphatic filariasis	4,664.6 (4,025.1 to 5,483.1)	3,728.3 (3,040.9 to 4,593.1)	-20.3 (-29.4 to -10.1)	180.5 (92.3 to 306.6)	208.5 (112.0 to 346.5)	16.6 (-8.5 to 41.7)
Onchocerciasis	1,535.7 (1,064.4 to 2,313.9)	1,074.0 (718.4 to 1,704.6)	-30.3 (-39.9 to -19.4)	102.4 (53.0 to 166.3)	78.1 (36.6 to 134.0)	-25.1 (-38.2 to -7.3)
Trachoma	113.6 (75.6 to 160.9)	77.3 (49.6 to 112.8)	-32.2 (-43.8 to -19.6)	7.6 (4.2 to 12.2)	5.3 (2.8 to 8.6)	-30.9 (-44.1 to -17.0)
Dengue	19.2 (7.0 to 43.1)	190.1 (69.8 to 426.3)	888.6 (885.1 to 890.4)	3.1 (0.9 to 7.8)	30.5 (9.8 to 77.1)	888.7 (653.1 to 1,208.5)
Yellow fever	0.2 (0.1 to 0.5)	0.1 (0.0 to 0.2)	-59.7 (-70.0 to -39.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-59.6 (-70.2 to -39.1)
Rabies	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-14.2 (-37.9 to 14.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.3 (-38.0 to 14.4)
Intestinal nematode infections	-	-	-	293.3 (169.7 to 468.5)	229.8 (135.3 to 365.5)	-21.2 (-28.4 to -13.4)
Ascariasis	55,986.8 (46,404.6 to 68,271.9)	53,917.9 (45,374.8 to 65,285.3)	-3.7 (-25.8 to 25.7)	131.7 (72.3 to 218.7)	55.5 (30.3 to 95.9)	-57.8 (-64.7 to -49.7)
Trichuriasis	27,909.2 (22,299.4 to 35,761.5)	30,749.4 (27,491.3 to 34,511.0)	11.6 (-17.0 to 42.1)	38.9 (21.5 to 64.6)	36.3 (19.1 to 61.5)	-7.7 (-27.2 to 24.0)
Hookworm disease	26,982.2 (22,326.1 to 33,001.1)	32,041.6 (28,941.0 to 35,608.5)	19.6 (-4.5 to 45.9)	122.7 (74.3 to 194.7)	138.0 (83.5 to 215.4)	12.8 (1.0 to 24.8)
Food-borne trematodiasis	4,650.2 (3,550.8 to 5,762.9)	8,990.1 (6,908.3 to 11,139.2)	93.1 (78.1 to 110.6)	232.5 (71.0 to 496.2)	442.0 (140.7 to 933.2)	91.1 (70.5 to 112.5)
Other neglected tropical diseases	1,217.9 (1,153.5 to 1,282.0)	1,365.2 (1,292.4 to 1,428.2)	12.1 (4.6 to 19.5)	37.7 (21.4 to 65.2)	32.8 (17.9 to 58.7)	-14.2 (-28.2 to 7.4)
Maternal disorders	-	-	-	96.6 (65.6 to 134.6)	131.1 (88.6 to 186.1)	35.8 (17.6 to 55.7)
Maternal hemorrhage	56.3 (52.6 to 59.8)	101.5 (95.1 to 107.5)	80.2 (66.3 to 96.0)	2.3 (1.6 to 3.3)	2.5 (1.7 to 3.5)	6.7 (-14.3 to 28.1)
Maternal sepsis and other maternal infections	383.5 (262.8 to 510.4)	377.8 (256.5 to 544.9)	-2.5 (-12.0 to 14.8)	2.4 (1.1 to 5.0)	2.3 (1.0 to 4.8)	-4.7 (-19.2 to 13.1)
Maternal hypertensive disorders	45.1 (16.7 to 79.5)	51.1 (19.0 to 88.9)	13.7 (6.8 to 20.1)	2.3 (0.8 to 4.4)	2.6 (0.9 to 4.9)	12.3 (-3.6 to 30.5)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (40-44 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Obstructed labor	223.3 (185.1 to 259.2)	307.1 (258.2 to 354.0)	37.7 (26.7 to 48.9)	71.9 (47.7 to 101.5)	99.3 (66.2 to 143.2)	38.2 (20.4 to 59.2)
Complications of abortion	1.0 (0.7 to 1.3)	1.2 (0.8 to 1.7)	26.8 (15.0 to 39.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	26.6 (14.0 to 40.5)
Other maternal disorders	-	-	-	17.6 (11.0 to 26.2)	24.3 (15.7 to 36.7)	41.1 (-7.2 to 91.3)
Neonatal disorders	-	-	-	253.3 (189.6 to 320.6)	773.8 (570.6 to 989.1)	205.3 (176.3 to 239.3)
Preterm birth complications	1,088.0 (958.5 to 1,244.4)	3,574.7 (3,130.0 to 4,103.0)	228.1 (201.2 to 262.2)	119.7 (86.7 to 152.8)	433.4 (318.2 to 557.3)	261.9 (233.9 to 292.4)
Neonatal encephalopathy due to birth asphyxia and trauma	988.8 (393.8 to 1,800.0)	1,288.3 (658.6 to 2,176.0)	30.5 (2.1 to 97.4)	62.2 (43.9 to 87.2)	127.2 (94.3 to 167.3)	106.0 (71.6 to 144.9)
Neonatal sepsis and other neonatal infections	-	-	-	-	-	-
Hemolytic disease and other neonatal jaundice	91.2 (75.8 to 111.3)	285.4 (226.2 to 382.5)	206.0 (136.7 to 377.4)	33.3 (23.0 to 44.5)	93.0 (65.3 to 128.0)	175.5 (118.2 to 304.5)
Other neonatal disorders	-	-	-	38.1 (25.8 to 53.5)	120.1 (82.9 to 163.3)	216.0 (157.9 to 289.3)
Nutritional deficiencies	-	-	-	1,560.9 (1,036.0 to 2,284.9)	1,700.3 (1,124.1 to 2,500.6)	8.8 (6.2 to 11.9)
Protein-energy malnutrition	9.9 (5.0 to 16.7)	12.1 (6.4 to 19.9)	21.6 (0.2 to 49.1)	1.2 (0.5 to 2.3)	1.5 (0.6 to 2.8)	21.9 (-5.8 to 57.7)
Iodine deficiency	8,696.8 (8,223.3 to 9,234.9)	9,396.1 (8,846.2 to 9,896.2)	7.9 (0.0 to 16.7)	155.0 (96.3 to 241.0)	167.5 (104.7 to 265.1)	8.0 (-0.4 to 17.7)
Vitamin A deficiency	137.8 (79.5 to 191.6)	136.9 (88.8 to 192.7)	-0.7 (-14.4 to 20.9)	8.3 (4.2 to 13.6)	7.9 (4.2 to 12.9)	-4.7 (-26.8 to 25.9)
Iron-deficiency anemia	53,628.4 (53,433.1 to 53,809.8)	65,836.2 (65,526.0 to 66,158.7)	22.8 (22.1 to 23.5)	1,396.3 (930.3 to 2,029.3)	1,523.3 (1,009.1 to 2,250.3)	8.9 (6.2 to 12.3)
Other nutritional deficiencies	-	-	-	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.2)	-19.5 (-50.4 to 21.5)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	136.2 (84.3 to 219.9)	195.1 (118.5 to 324.3)	43.0 (36.5 to 49.7)
Sexually transmitted diseases excluding HIV	-	-	-	77.2 (44.6 to 138.8)	123.2 (70.8 to 221.6)	59.7 (52.0 to 67.1)
Syphilis	33.3 (31.7 to 35.2)	29.4 (28.1 to 30.8)	-12.0 (-17.2 to -5.5)	6.3 (4.1 to 9.3)	5.6 (3.5 to 8.2)	-10.9 (-29.2 to 14.3)
Chlamydial infection	7,921.3 (7,616.9 to 8,206.4)	12,645.1 (12,204.3 to 13,041.7)	59.5 (52.7 to 67.7)	31.8 (19.8 to 50.6)	54.4 (34.0 to 86.9)	71.2 (59.9 to 84.5)
Gonococcal infection	1,249.5 (1,146.1 to 1,346.1)	2,010.6 (1,797.6 to 2,214.4)	61.0 (43.4 to 79.5)	8.3 (5.1 to 13.5)	14.0 (8.6 to 22.5)	69.6 (40.3 to 107.0)
Trichomoniasis	4,670.3 (4,244.8 to 5,066.4)	7,866.4 (7,215.1 to 8,529.9)	68.0 (51.4 to 90.6)	7.7 (3.1 to 16.3)	13.0 (5.2 to 27.7)	68.6 (50.2 to 96.9)
Genital herpes	79,710.8 (78,714.8 to 80,764.6)	127,089.1 (125,277.5 to 129,212.9)	59.4 (56.5 to 62.7)	20.4 (6.3 to 49.5)	32.5 (9.8 to 79.0)	59.3 (54.4 to 64.3)
Other sexually transmitted diseases	233.8 (175.7 to 296.1)	258.0 (203.1 to 324.4)	10.5 (3.3 to 18.6)	2.8 (1.7 to 4.5)	3.7 (2.4 to 5.7)	33.4 (13.9 to 62.8)
Hepatitis	-	-	-	27.3 (17.7 to 39.2)	38.4 (24.8 to 55.1)	40.4 (32.9 to 48.3)
Hepatitis A	151.7 (141.5 to 160.5)	288.1 (279.9 to 294.1)	89.9 (83.3 to 97.8)	5.5 (3.5 to 8.1)	10.5 (7.0 to 15.4)	90.0 (72.9 to 109.2)
Hepatitis B	22,207.9 (21,715.4 to 22,761.5)	26,547.6 (25,922.7 to 27,107.8)	19.6 (16.3 to 23.1)	18.7 (12.1 to 27.1)	22.8 (14.6 to 32.5)	21.8 (12.5 to 31.2)
Hepatitis C	9,023.2 (8,844.5 to 9,203.8)	11,780.1 (11,496.8 to 12,038.4)	30.6 (26.9 to 34.5)	0.7 (0.5 to 1.1)	1.0 (0.6 to 1.5)	35.7 (17.7 to 57.1)
Hepatitis E	88.0 (80.0 to 94.1)	143.7 (133.4 to 154.3)	62.8 (47.2 to 83.7)	2.3 (1.5 to 3.5)	4.0 (2.5 to 5.9)	72.2 (42.1 to 115.5)
Leprosy	30.9 (27.5 to 34.9)	47.7 (43.6 to 51.5)	54.2 (37.6 to 73.5)	1.7 (1.1 to 2.6)	3.0 (1.9 to 4.5)	68.3 (28.9 to 121.8)
Other infectious diseases	1,406.0 (1,358.4 to 1,454.4)	1,566.3 (1,517.3 to 1,616.0)	11.4 (6.6 to 16.4)	29.9 (19.0 to 45.0)	30.6 (18.5 to 49.8)	1.6 (-12.9 to 20.4)
Non-communicable diseases	-	-	-	29,255.5 (21,714.2 to 37,595.3)	50,478.2 (37,323.2 to 64,969.4)	72.5 (70.6 to 74.6)
Neoplasms	-	-	-	193.2 (139.8 to 254.7)	303.3 (214.9 to 404.2)	56.8 (44.2 to 72.1)
Esophageal cancer	16.6 (13.1 to 20.5)	21.4 (16.6 to 27.7)	29.8 (-2.7 to 66.9)	2.7 (1.8 to 3.7)	3.3 (2.2 to 4.7)	23.2 (-4.8 to 58.8)
Stomach cancer	69.7 (62.9 to 76.9)	74.6 (66.4 to 83.4)	7.3 (-6.2 to 22.1)	8.8 (6.2 to 11.7)	9.0 (6.3 to 12.0)	2.7 (-10.8 to 19.0)
Liver cancer	-	-	-	6.6 (4.3 to 9.2)	9.5 (6.3 to 13.3)	45.9 (10.0 to 91.9)
Liver cancer due to hepatitis B	18.4 (13.7 to 24.6)	30.2 (22.9 to 39.2)	65.6 (13.0 to 145.2)	3.1 (2.0 to 4.4)	4.5 (3.0 to 6.2)	47.9 (6.7 to 103.2)
Liver cancer due to hepatitis C	4.4 (3.4 to 5.5)	19.4 (14.8 to 25.1)	345.5 (215.0 to 529.3)	0.7 (0.5 to 1.0)	2.9 (1.9 to 4.1)	295.0 (196.0 to 424.3)
Liver cancer due to alcohol use	7.4 (5.6 to 9.7)	6.2 (4.8 to 7.9)	-15.3 (-41.2 to 19.3)	1.3 (0.8 to 1.8)	0.9 (0.6 to 1.3)	-24.4 (-43.3 to 0.5)
Liver cancer due to other causes	8.6 (6.6 to 11.0)	7.2 (5.7 to 9.1)	-15.2 (-39.1 to 17.0)	1.5 (1.0 to 2.0)	1.1 (0.7 to 1.6)	-23.4 (-41.5 to 1.0)
Larynx cancer	27.8 (21.3 to 33.1)	31.3 (25.5 to 40.2)	10.8 (-8.3 to 42.6)	2.8 (1.8 to 3.9)	3.0 (2.0 to 4.3)	3.7 (-16.2 to 37.4)
Tracheal, bronchus and lung cancer	52.4 (48.3 to 56.4)	64.3 (58.2 to 72.1)	22.1 (9.2 to 42.4)	8.5 (6.0 to 11.2)	10.1 (7.1 to 13.6)	18.9 (3.6 to 40.8)
Breast cancer	576.9 (519.6 to 626.8)	1,122.3 (1,019.6 to 1,237.5)	94.3 (72.2 to 120.8)	44.8 (31.5 to 59.4)	78.9 (55.0 to 106.9)	75.7 (52.8 to 103.2)
Cervical cancer	388.1 (298.0 to 479.4)	413.9 (291.1 to 523.2)	6.7 (-23.4 to 45.8)	28.9 (19.3 to 41.4)	31.1 (19.7 to 44.5)	8.3 (-23.1 to 47.8)
Uterine cancer	107.4 (75.6 to 157.8)	162.9 (106.2 to 235.7)	51.9 (-2.1 to 136.8)	7.1 (4.0 to 11.2)	10.6 (5.9 to 16.9)	50.4 (-2.4 to 134.9)
Prostate cancer	8.5 (6.6 to 10.4)	23.9 (18.6 to 31.9)	179.0 (133.4 to 236.3)	0.7 (0.5 to 1.1)	1.8 (1.1 to 2.7)	143.5 (96.2 to 208.7)
Colon and rectum cancer	135.8 (128.5 to 144.4)	258.2 (237.0 to 280.4)	90.3 (73.1 to 107.9)	11.8 (8.5 to 15.6)	21.1 (14.7 to 27.9)	78.8 (61.5 to 97.7)
Lip and oral cavity cancer	74.1 (59.0 to 94.2)	124.8 (88.8 to 167.0)	67.3 (23.3 to 134.5)	6.4 (4.3 to 9.2)	10.5 (6.5 to 15.7)	62.7 (18.7 to 131.1)
Nasopharynx cancer	41.4 (29.0 to 56.5)	54.3 (37.5 to 79.3)	30.0 (-16.6 to 108.8)	3.9 (2.4 to 6.0)	5.0 (3.0 to 8.0)	27.5 (-17.9 to 103.5)
Other pharynx cancer	22.4 (17.3 to 27.9)	34.9 (25.3 to 49.1)	54.1 (7.3 to 134.6)	2.0 (1.3 to 2.9)	3.1 (1.9 to 4.8)	53.3 (4.6 to 138.9)
Gallbladder and biliary tract cancer	2.6 (2.1 to 3.0)	3.6 (2.8 to 4.3)	37.8 (12.2 to 75.0)	0.7 (0.5 to 1.0)	1.0 (0.6 to 1.3)	29.0 (4.6 to 62.3)
Pancreatic cancer	5.2 (4.7 to 5.7)	8.4 (7.4 to 9.5)	62.5 (40.4 to 87.9)	1.1 (0.8 to 1.5)	1.7 (1.2 to 2.3)	56.4 (37.5 to 76.7)
Malignant skin melanoma	114.5 (85.3 to 142.0)	165.0 (130.9 to 225.4)	44.2 (11.0 to 85.7)	6.8 (4.2 to 10.0)	9.5 (6.1 to 14.6)	40.7 (5.2 to 81.8)
Non-melanoma skin cancer	76.0 (66.8 to 88.1)	130.7 (110.6 to 156.8)	73.1 (37.5 to 110.2)	1.6 (1.0 to 2.6)	3.8 (2.4 to 6.2)	132.6 (62.4 to 237.5)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (40-44 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Ovarian cancer	45.9 (39.6 to 52.2)	71.8 (60.1 to 85.3)	56.1 (27.9 to 91.1)	5.9 (4.1 to 8.0)	9.2 (6.3 to 12.5)	54.9 (20.8 to 102.6)
Testicular cancer	37.6 (28.7 to 48.7)	67.3 (47.8 to 88.5)	79.6 (34.3 to 129.1)	2.3 (1.4 to 3.4)	4.1 (2.5 to 6.0)	75.6 (31.5 to 132.5)
Kidney cancer	34.6 (31.3 to 38.5)	63.5 (55.9 to 72.7)	83.1 (59.2 to 110.3)	2.6 (1.8 to 3.6)	4.6 (3.1 to 6.3)	77.5 (51.1 to 108.9)
Bladder cancer	29.9 (25.0 to 33.7)	37.6 (32.9 to 43.8)	25.0 (7.2 to 49.5)	2.4 (1.6 to 3.2)	3.0 (2.0 to 4.1)	24.9 (5.6 to 51.0)
Brain and nervous system cancer	40.0 (32.5 to 47.1)	68.3 (55.0 to 83.5)	71.2 (34.6 to 110.9)	4.4 (3.1 to 6.1)	7.3 (4.9 to 10.1)	65.8 (31.5 to 104.4)
Thyroid cancer	116.8 (97.5 to 142.2)	239.7 (193.8 to 310.7)	105.6 (65.7 to 160.1)	6.6 (4.3 to 9.4)	13.3 (8.4 to 19.9)	101.1 (58.5 to 159.4)
Mesothelioma	0.7 (0.6 to 0.8)	0.8 (0.7 to 0.9)	4.1 (-9.7 to 32.7)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	6.2 (-8.9 to 35.6)
Hodgkin lymphoma	38.9 (25.4 to 54.8)	48.8 (36.9 to 68.7)	23.4 (-16.7 to 118.8)	3.3 (1.9 to 5.0)	3.9 (2.4 to 6.0)	15.8 (-22.6 to 105.2)
Non-Hodgkin lymphoma	75.6 (60.5 to 89.7)	151.1 (128.1 to 178.1)	100.3 (64.9 to 141.3)	5.8 (3.9 to 8.1)	11.2 (7.6 to 15.6)	92.1 (56.5 to 133.1)
Multiple myeloma	6.2 (4.8 to 8.1)	11.4 (9.2 to 14.7)	86.2 (47.3 to 133.8)	1.4 (0.9 to 2.0)	2.4 (1.6 to 3.4)	79.6 (43.9 to 124.7)
Leukemia	42.2 (37.9 to 46.7)	84.6 (74.3 to 95.0)	100.6 (72.4 to 129.8)	6.0 (4.2 to 8.1)	10.9 (7.6 to 14.6)	82.0 (54.9 to 110.7)
Other neoplasms	94.9 (82.8 to 110.8)	290.2 (243.1 to 352.9)	205.2 (149.2 to 283.4)	7.0 (4.9 to 9.5)	20.0 (13.2 to 28.3)	183.7 (129.3 to 260.8)
Cardiovascular diseases	-	-	-	398.1 (268.1 to 573.5)	930.0 (578.3 to 1,377.8)	132.2 (78.7 to 198.2)
Rheumatic heart disease	1,286.2 (1,212.0 to 1,362.8)	2,544.3 (2,421.4 to 2,680.9)	98.5 (82.9 to 110.6)	70.7 (47.4 to 100.0)	132.4 (84.9 to 188.3)	87.5 (68.2 to 104.8)
Ischemic heart disease	705.4 (656.7 to 791.7)	1,140.3 (1,106.7 to 1,181.4)	62.9 (43.8 to 77.0)	43.1 (29.0 to 59.4)	75.9 (51.2 to 103.8)	77.2 (52.9 to 98.6)
Cerebrovascular disease	-	-	-	68.8 (48.6 to 90.9)	127.3 (89.5 to 169.5)	84.8 (66.1 to 107.3)
Ischemic stroke	270.2 (254.7 to 286.9)	490.7 (464.9 to 520.0)	81.1 (68.6 to 97.5)	42.2 (29.3 to 56.6)	76.6 (52.5 to 104.9)	81.1 (59.4 to 107.2)
Hemorrhagic stroke	169.0 (159.7 to 178.3)	320.8 (303.1 to 338.5)	89.6 (77.3 to 103.4)	26.6 (18.0 to 35.4)	50.6 (33.8 to 68.3)	90.0 (67.1 to 120.2)
Hypertensive heart disease	107.4 (102.6 to 113.5)	219.4 (209.7 to 229.0)	104.2 (92.8 to 116.9)	12.5 (8.5 to 17.4)	25.4 (17.4 to 36.0)	104.7 (83.1 to 126.2)
Cardiomyopathy and myocarditis	195.6 (187.0 to 204.6)	379.5 (365.4 to 392.7)	93.9 (84.0 to 104.6)	21.5 (14.6 to 29.4)	42.4 (28.5 to 58.3)	96.8 (80.1 to 113.4)
Atrial fibrillation and flutter	91.7 (84.1 to 101.1)	139.1 (131.0 to 148.7)	52.5 (35.0 to 66.6)	7.7 (5.0 to 10.9)	11.6 (7.8 to 16.3)	52.1 (30.3 to 76.0)
Peripheral vascular disease	3,815.4 (3,405.2 to 4,360.8)	6,247.1 (5,426.4 to 7,598.7)	61.4 (29.5 to 119.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.2 (-10.6 to 120.6)
Endocarditis	7.7 (6.4 to 9.2)	14.2 (11.0 to 16.8)	84.5 (60.2 to 105.1)	0.8 (0.5 to 1.2)	1.6 (1.0 to 2.3)	94.8 (68.1 to 122.7)
Other cardiovascular and circulatory diseases	2,470.0 (1,503.3 to 4,158.1)	7,303.3 (4,290.0 to 11,901.6)	197.8 (67.3 to 397.0)	173.1 (92.1 to 308.9)	513.3 (259.3 to 888.6)	197.8 (66.8 to 395.8)
Chronic respiratory diseases	-	-	-	1,847.7 (1,280.5 to 2,483.0)	3,132.4 (2,163.0 to 4,228.0)	69.5 (62.8 to 76.2)
Chronic obstructive pulmonary disease	16,142.2 (15,327.4 to 16,958.5)	27,416.9 (25,958.4 to 28,805.3)	69.9 (67.9 to 71.8)	1,263.0 (848.1 to 1,739.4)	2,268.2 (1,530.4 to 3,132.0)	79.6 (70.7 to 88.2)
Pneumoconiosis	-	-	-	1.8 (1.3 to 2.5)	3.9 (2.7 to 5.4)	116.8 (105.5 to 126.2)
Silicosis	2.1 (1.9 to 2.4)	3.3 (2.9 to 3.7)	53.8 (48.6 to 58.0)	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.9)	53.7 (48.1 to 58.1)
Asbestosis	0.6 (0.5 to 0.6)	0.9 (0.8 to 0.9)	53.1 (48.1 to 59.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	53.4 (47.4 to 60.7)
Coal workers pneumoconiosis	1.9 (1.8 to 2.1)	3.2 (3.0 to 3.4)	63.4 (60.2 to 65.7)	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.9)	63.0 (59.5 to 65.6)
Other pneumoconiosis	4.9 (4.4 to 5.4)	13.5 (12.1 to 14.8)	174.9 (166.7 to 184.7)	0.9 (0.6 to 1.3)	2.5 (1.6 to 3.6)	173.9 (165.4 to 183.4)
Asthma	10,076.5 (9,836.1 to 10,301.0)	15,770.0 (15,446.9 to 16,089.0)	56.4 (51.8 to 61.7)	441.7 (290.5 to 623.0)	692.5 (451.5 to 985.3)	56.7 (51.6 to 62.4)
Interstitial lung disease and pulmonary sarcoidosis	25.0 (23.5 to 26.6)	42.6 (39.6 to 45.3)	70.6 (54.3 to 86.4)	3.4 (2.2 to 4.9)	5.8 (3.7 to 8.5)	73.9 (57.4 to 89.9)
Other chronic respiratory diseases	-	-	-	137.8 (85.9 to 207.9)	162.0 (103.4 to 241.2)	17.2 (3.0 to 36.2)
Cirrhosis	-	-	-	29.3 (20.3 to 40.3)	42.3 (29.1 to 58.1)	44.2 (32.2 to 57.6)
Cirrhosis due to hepatitis B	52.5 (50.0 to 55.5)	72.6 (67.8 to 77.1)	38.3 (26.1 to 49.9)	8.8 (6.0 to 12.1)	12.2 (8.2 to 17.3)	38.4 (15.0 to 66.8)
Cirrhosis due to hepatitis C	40.1 (37.5 to 42.6)	67.5 (62.9 to 73.9)	67.8 (53.6 to 85.3)	6.7 (4.5 to 9.4)	11.3 (7.6 to 15.8)	68.7 (43.0 to 104.4)
Cirrhosis due to alcohol use	60.9 (56.1 to 64.8)	67.4 (60.9 to 75.3)	11.0 (-1.4 to 23.8)	10.2 (7.0 to 14.3)	11.3 (7.5 to 16.0)	11.2 (-9.5 to 37.1)
Cirrhosis due to other causes	21.9 (20.2 to 24.3)	44.3 (40.3 to 48.8)	101.6 (81.5 to 127.7)	3.7 (2.4 to 5.3)	7.5 (4.9 to 10.8)	104.1 (54.6 to 166.9)
Digestive diseases	-	-	-	412.5 (294.4 to 551.1)	562.8 (404.5 to 751.8)	36.5 (30.1 to 43.4)
Peptic ulcer disease	1,490.6 (1,412.5 to 1,550.5)	1,310.8 (1,221.5 to 1,396.5)	-12.0 (-17.7 to -6.2)	58.1 (39.9 to 82.8)	55.5 (37.7 to 79.2)	-4.6 (-13.4 to 6.6)
Gastritis and duodenitis	2,518.0 (2,373.7 to 2,653.8)	2,756.4 (2,595.3 to 2,920.5)	9.6 (1.8 to 17.1)	98.9 (67.2 to 140.1)	111.4 (75.8 to 160.5)	12.8 (3.0 to 21.2)
Appendicitis	30.7 (26.0 to 36.5)	40.1 (34.7 to 45.9)	31.2 (6.8 to 57.3)	9.2 (5.8 to 13.6)	12.1 (7.7 to 17.2)	31.4 (-5.1 to 77.0)
Paralytic ileus and intestinal obstruction	2.4 (2.4 to 2.5)	4.2 (4.0 to 4.3)	71.5 (63.2 to 80.4)	0.8 (0.5 to 1.1)	1.4 (0.9 to 1.9)	71.5 (63.2 to 80.4)
Inguinal, femoral, and abdominal hernia	522.8 (488.2 to 563.4)	809.3 (755.5 to 876.9)	54.6 (40.6 to 72.1)	5.6 (2.8 to 10.5)	8.7 (4.2 to 16.4)	55.3 (39.4 to 73.7)
Inflammatory bowel disease	570.5 (560.0 to 581.1)	993.2 (975.7 to 1,012.4)	74.1 (70.4 to 77.8)	121.9 (84.2 to 165.8)	212.6 (143.7 to 288.8)	74.3 (66.0 to 83.2)
Vascular intestinal disorders	0.6 (0.5 to 0.6)	0.9 (0.9 to 1.0)	59.7 (44.7 to 81.9)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	59.7 (44.7 to 82.2)
Gallbladder and biliary diseases	312.3 (292.6 to 329.3)	402.4 (377.8 to 429.0)	28.6 (19.0 to 40.7)	33.6 (23.1 to 46.5)	43.4 (29.9 to 60.0)	28.9 (16.1 to 44.6)
Pancreatitis	113.1 (111.0 to 115.3)	195.2 (191.2 to 199.5)	72.6 (67.9 to 77.5)	33.8 (23.0 to 45.4)	58.6 (40.0 to 79.5)	73.1 (57.3 to 91.0)
Other digestive diseases	-	-	-	50.3 (34.4 to 69.6)	59.0 (40.9 to 81.1)	17.9 (2.8 to 30.5)
Neurological disorders	-	-	-	2,685.6 (1,798.9 to 3,738.5)	4,898.8 (3,290.3 to 6,858.3)	82.4 (73.5 to 92.5)
Alzheimer disease and other dementias	19.5 (18.5 to 20.6)	33.7 (32.1 to 35.4)	72.0 (61.4 to 85.2)	2.6 (1.8 to 3.6)	4.6 (3.1 to 6.2)	71.9 (58.2 to 89.2)
Parkinson disease	50.7 (32.8 to 67.7)	88.9 (54.5 to 119.8)	75.6 (65.0 to 82.8)	6.7 (3.8 to 10.3)	11.7 (6.4 to 18.1)	75.6 (56.3 to 92.6)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (40-44 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Epilepsy	820.3 (766.8 to 873.2)	1,360.2 (1,258.4 to 1,463.3)	65.7 (49.9 to 83.8)	267.9 (185.0 to 352.2)	471.8 (322.9 to 621.4)	75.9 (58.7 to 97.3)
Multiple sclerosis	139.6 (136.0 to 143.6)	281.1 (273.3 to 288.8)	101.3 (93.9 to 108.5)	46.4 (32.8 to 59.1)	93.3 (68.3 to 119.8)	101.3 (80.9 to 124.8)
Migraine	51,200.9 (48,948.7 to 53,860.9)	85,217.2 (82,248.0 to 88,335.8)	66.8 (56.1 to 77.2)	1,731.5 (1,036.8 to 2,558.4)	2,890.3 (1,767.1 to 4,245.3)	67.0 (55.9 to 78.5)
Tension-type headache	86,183.3 (82,673.8 to 89,709.4)	141,551.7 (137,194.7 to 145,809.5)	64.4 (55.2 to 72.8)	130.4 (63.2 to 230.2)	214.7 (104.2 to 375.6)	64.7 (55.3 to 73.9)
Medication overuse headache	3,087.7 (2,140.5 to 3,995.1)	7,564.1 (5,147.0 to 9,815.5)	145.0 (123.0 to 170.4)	485.6 (282.1 to 742.3)	1,192.9 (695.2 to 1,814.1)	145.8 (122.6 to 171.1)
Other neurological disorders	0.4 (0.3 to 0.5)	0.7 (0.6 to 0.8)	73.5 (51.1 to 103.4)	14.4 (9.9 to 19.8)	19.5 (13.6 to 25.7)	37.1 (12.7 to 58.6)
Mental and substance use disorders	-	-	-	8,339.8 (5,970.3 to 10,924.2)	14,222.5 (10,131.2 to 18,755.1)	70.5 (67.9 to 72.9)
Schizophrenia	1,846.8 (1,705.1 to 1,992.4)	3,139.4 (2,877.4 to 3,402.1)	69.9 (67.8 to 72.4)	1,189.6 (879.9 to 1,432.5)	2,032.1 (1,509.9 to 2,456.4)	70.8 (66.4 to 75.5)
Alcohol use disorders	4,943.9 (4,607.1 to 5,271.2)	7,814.1 (7,247.0 to 8,352.9)	58.2 (54.2 to 61.6)	490.6 (330.1 to 697.3)	778.5 (527.8 to 1,098.7)	58.7 (53.6 to 63.5)
Drug use disorders	-	-	-	690.0 (482.2 to 929.0)	1,228.4 (838.6 to 1,653.9)	77.9 (70.4 to 84.7)
Opioid use disorders	1,144.4 (861.3 to 1,453.1)	2,066.1 (1,527.8 to 2,657.8)	80.5 (74.1 to 85.8)	470.5 (311.5 to 659.6)	853.0 (547.9 to 1,221.1)	81.1 (72.9 to 88.9)
Cocaine use disorders	442.8 (431.3 to 455.1)	704.5 (685.7 to 724.1)	59.2 (53.0 to 65.5)	59.7 (39.1 to 84.2)	95.4 (62.9 to 134.1)	59.6 (45.4 to 75.0)
Amphetamine use disorders	339.3 (326.4 to 349.7)	632.5 (612.4 to 651.4)	86.4 (78.2 to 94.6)	43.6 (27.4 to 62.7)	81.6 (51.4 to 117.0)	87.0 (68.3 to 108.8)
Cannabis use disorders	418.9 (368.4 to 480.0)	688.5 (594.4 to 802.9)	64.4 (58.3 to 69.9)	12.0 (7.8 to 17.4)	19.7 (12.6 to 29.0)	64.1 (47.1 to 84.8)
Other drug use disorders	-	-	-	104.3 (69.9 to 140.5)	178.7 (121.6 to 241.4)	71.4 (56.0 to 88.8)
Depressive disorders	-	-	-	3,177.0 (2,003.2 to 4,616.3)	5,516.2 (3,405.3 to 8,075.3)	73.5 (68.2 to 78.4)
Major depressive disorder	12,525.6 (8,822.3 to 16,873.4)	21,831.2 (15,045.8 to 29,414.1)	74.1 (68.3 to 79.8)	2,558.0 (1,543.8 to 3,863.1)	4,471.1 (2,642.3 to 6,818.2)	74.6 (68.5 to 80.5)
Dysthymia	6,387.2 (5,377.9 to 7,461.5)	10,755.4 (8,976.9 to 12,640.2)	68.4 (64.4 to 71.8)	619.1 (402.1 to 904.2)	1,045.1 (673.1 to 1,537.0)	68.8 (64.1 to 73.1)
Bipolar disorder	2,779.5 (2,388.3 to 3,191.7)	4,716.7 (4,043.0 to 5,427.8)	69.7 (66.6 to 72.6)	562.4 (357.5 to 840.7)	957.8 (605.7 to 1,436.1)	70.2 (64.8 to 76.1)
Anxiety disorders	13,191.0 (9,358.4 to 17,106.2)	21,854.2 (14,626.7 to 29,352.6)	65.4 (57.3 to 71.8)	1,203.8 (716.6 to 1,799.3)	1,998.6 (1,151.3 to 3,034.8)	65.8 (57.2 to 72.6)
Eating disorders	-	-	-	42.4 (26.3 to 64.4)	62.9 (38.6 to 95.3)	47.8 (34.0 to 62.2)
Anorexia nervosa	54.9 (41.4 to 71.3)	93.8 (67.9 to 126.0)	70.6 (59.8 to 80.9)	11.5 (7.2 to 17.6)	19.7 (11.9 to 30.9)	70.8 (47.4 to 94.7)
Bulimia nervosa	150.1 (98.9 to 216.7)	209.7 (132.0 to 312.1)	39.2 (28.5 to 50.5)	30.9 (17.7 to 48.6)	43.2 (24.2 to 71.1)	39.2 (22.3 to 56.1)
Autistic spectrum disorders	-	-	-	319.8 (224.7 to 434.5)	545.9 (381.9 to 737.7)	70.6 (66.8 to 74.8)
Autism	834.7 (793.4 to 876.4)	1,418.9 (1,347.5 to 1,492.0)	70.0 (69.3 to 70.7)	202.6 (135.7 to 277.4)	345.9 (234.4 to 470.2)	70.7 (65.1 to 76.4)
Asperger syndrome	1,185.9 (1,103.1 to 1,267.9)	2,015.2 (1,871.3 to 2,156.6)	69.9 (69.3 to 70.5)	117.2 (81.7 to 160.9)	200.0 (138.4 to 276.5)	70.6 (65.8 to 75.9)
Attention-deficit/hyperactivity disorder	4.9 (2.9 to 7.3)	8.2 (4.8 to 12.4)	67.3 (59.9 to 72.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	67.5 (60.0 to 72.2)
Conduct disorder	-	-	-	-	-	-
Idiopathic intellectual disability	3,422.0 (2,628.3 to 4,275.1)	5,274.2 (4,170.0 to 6,595.9)	53.9 (40.3 to 72.5)	169.4 (110.1 to 245.0)	258.4 (170.4 to 368.5)	52.4 (38.7 to 70.6)
Other mental and substance use disorders	6,609.9 (5,458.5 to 7,791.3)	11,231.7 (9,274.3 to 13,244.6)	69.9 (69.8 to 70.0)	494.6 (315.7 to 704.8)	843.8 (539.9 to 1,200.7)	70.5 (66.6 to 74.6)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	3,026.2 (2,128.5 to 4,156.5)	5,694.7 (4,011.8 to 7,768.1)	87.8 (82.9 to 94.4)
Diabetes mellitus	15,940.2 (15,246.2 to 16,951.0)	38,080.0 (36,609.8 to 39,903.5)	138.8 (124.4 to 153.6)	1,057.0 (720.4 to 1,473.8)	2,553.4 (1,750.5 to 3,528.1)	141.5 (128.3 to 155.6)
Acute glomerulonephritis	0.8 (0.7 to 1.0)	1.3 (1.1 to 1.4)	49.4 (43.5 to 53.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	49.3 (43.4 to 53.5)
Chronic kidney disease	-	-	-	623.8 (397.2 to 893.5)	982.1 (636.4 to 1,422.2)	57.7 (48.4 to 65.6)
Chronic kidney disease due to diabetes mellitus	3,242.9 (2,107.3 to 5,259.8)	5,439.2 (3,693.0 to 8,501.3)	68.8 (40.1 to 97.2)	117.4 (74.8 to 166.6)	192.5 (126.0 to 280.8)	63.8 (42.8 to 89.1)
Chronic kidney disease due to hypertension	4,037.7 (2,748.5 to 6,262.8)	5,970.3 (4,320.6 to 9,116.5)	48.9 (32.2 to 65.0)	198.7 (125.2 to 285.1)	267.9 (170.2 to 389.0)	34.4 (21.5 to 51.5)
Chronic kidney disease due to glomerulonephritis	5,312.6 (3,372.8 to 8,950.8)	8,040.2 (5,352.1 to 12,778.8)	54.6 (29.3 to 71.5)	124.8 (80.3 to 173.6)	197.0 (127.1 to 281.3)	57.4 (40.1 to 82.3)
Chronic kidney disease due to other causes	4,584.6 (3,001.9 to 7,280.3)	8,153.2 (5,503.7 to 13,126.9)	79.3 (52.0 to 102.3)	183.0 (115.4 to 272.0)	324.7 (207.0 to 477.5)	77.4 (60.0 to 99.3)
Urinary diseases and male infertility	-	-	-	71.9 (44.5 to 113.1)	134.7 (82.4 to 213.8)	88.7 (68.0 to 104.4)
Interstitial nephritis and urinary tract infections	56.6 (55.1 to 57.9)	111.2 (108.1 to 114.1)	96.5 (90.2 to 103.2)	1.9 (1.2 to 2.9)	3.7 (2.3 to 5.6)	96.4 (68.2 to 130.3)
Urolithiasis	2,691.9 (2,065.1 to 3,548.5)	4,826.2 (3,409.8 to 6,839.1)	79.6 (58.9 to 98.3)	27.5 (18.1 to 40.1)	50.2 (31.4 to 75.1)	81.5 (65.4 to 98.9)
Benign prostatic hyperplasia	234.6 (225.0 to 243.6)	363.1 (347.9 to 377.4)	54.6 (46.3 to 63.8)	8.8 (5.6 to 12.7)	13.7 (8.6 to 20.2)	55.5 (40.0 to 72.1)
Male infertility due to other causes	3,845.2 (3,636.1 to 4,068.0)	6,448.5 (6,057.8 to 6,920.3)	67.2 (54.1 to 84.4)	23.6 (9.9 to 47.5)	39.6 (16.6 to 81.5)	67.8 (53.2 to 86.2)
Other urinary diseases	-	-	-	10.1 (6.1 to 15.4)	27.5 (14.1 to 42.9)	191.9 (90.8 to 240.4)
Gynecological diseases	-	-	-	981.5 (632.3 to 1,472.8)	1,569.4 (1,023.2 to 2,362.5)	59.6 (53.6 to 67.1)
Uterine fibroids	26,216.7 (23,872.8 to 28,645.4)	43,767.7 (39,699.9 to 48,034.2)	66.9 (65.3 to 68.4)	320.2 (185.3 to 543.0)	468.5 (259.4 to 815.1)	45.7 (37.4 to 52.8)
Polycystic ovarian syndrome	13,546.0 (13,295.9 to 13,791.5)	22,849.9 (22,376.2 to 23,364.9)	68.7 (64.2 to 73.7)	129.5 (59.2 to 246.1)	219.6 (101.4 to 416.9)	69.6 (64.9 to 74.9)
Female infertility due to other causes	3,721.4 (3,147.2 to 4,328.2)	7,021.8 (5,953.3 to 8,048.0)	88.8 (72.4 to 108.0)	18.9 (7.2 to 40.9)	35.6 (13.8 to 75.8)	88.7 (71.9 to 108.7)
Endometriosis	1,782.3 (1,710.2 to 1,848.7)	2,994.3 (2,874.9 to 3,118.1)	68.2 (58.7 to 77.2)	164.0 (109.7 to 222.5)	275.6 (184.4 to 373.1)	68.4 (57.7 to 79.1)
Genital prolapse	24,051.9 (23,153.8 to 25,050.6)	40,376.0 (38,951.8 to 41,954.8)	67.9 (59.8 to 75.8)	77.0 (37.5 to 144.4)	129.3 (62.3 to 238.8)	67.9 (59.5 to 76.4)
Premenstrual syndrome	25,778.4 (23,411.5 to 28,507.4)	44,485.5 (40,297.9 to 49,174.6)	71.2 (53.0 to 103.5)	214.5 (131.9 to 324.0)	370.2 (230.1 to 548.8)	71.2 (52.5 to 104.0)
Other gynecological diseases	1,880.2 (1,732.2 to 2,017.8)	2,627.1 (2,489.4 to 2,751.8)	39.6 (28.1 to 52.6)	57.5 (39.3 to 80.1)	70.8 (48.7 to 99.8)	22.8 (9.9 to 41.9)
Hemoglobinopathies and hemolytic anemias	-	-	-	210.5 (141.5 to 304.2)	349.0 (234.2 to 501.9)	65.7 (59.2 to 73.1)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (40-44 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Thalassemias	7.6 (6.2 to 8.9)	14.4 (12.4 to 16.7)	88.6 (72.2 to 119.8)	0.8 (0.5 to 1.1)	1.4 (0.9 to 2.0)	79.4 (54.6 to 121.3)
Thalassemia trait	7,564.8 (6,870.7 to 8,531.2)	13,955.1 (12,743.1 to 15,634.1)	84.4 (82.5 to 87.1)	116.4 (78.2 to 167.0)	230.9 (154.1 to 332.7)	98.2 (89.1 to 107.3)
Sickle cell disorders	32.6 (30.2 to 35.1)	67.0 (60.8 to 72.8)	105.5 (87.6 to 123.5)	4.8 (3.4 to 6.4)	9.8 (6.9 to 13.4)	106.6 (85.3 to 131.1)
Sickle cell trait	7,824.3 (7,438.3 to 8,178.6)	14,158.3 (13,478.6 to 14,773.8)	80.9 (77.7 to 84.1)	33.2 (21.7 to 48.6)	55.9 (36.4 to 80.2)	67.8 (51.3 to 96.8)
G6PD deficiency	11,014.2 (10,742.3 to 11,272.1)	20,105.4 (19,603.0 to 20,583.5)	82.5 (76.6 to 88.8)	1.0 (0.7 to 1.3)	1.8 (1.2 to 2.4)	84.4 (70.4 to 95.7)
G6PD trait	42,925.7 (42,684.1 to 43,144.5)	76,113.9 (75,658.9 to 76,544.5)	77.3 (76.0 to 78.8)	1.5 (0.8 to 2.3)	2.2 (1.2 to 3.9)	44.9 (-5.5 to 141.8)
Other hemoglobinopathies and hemolytic anemias	2,593.9 (2,536.6 to 2,659.6)	2,839.3 (2,726.7 to 2,944.7)	9.4 (4.5 to 14.2)	52.9 (34.4 to 77.3)	47.1 (30.6 to 71.9)	-11.1 (-23.0 to 1.7)
Endocrine, metabolic, blood, and immune disorders	2,908.8 (2,789.2 to 3,021.2)	3,873.7 (3,774.2 to 3,981.8)	33.2 (27.2 to 39.6)	81.5 (55.5 to 114.9)	106.0 (73.1 to 146.6)	30.1 (19.7 to 42.4)
Musculoskeletal disorders	-	-	-	8,114.7 (5,701.7 to 10,804.9)	13,882.8 (9,735.7 to 18,515.4)	71.0 (67.5 to 75.3)
Rheumatoid arthritis	592.2 (582.5 to 603.1)	933.4 (917.7 to 947.8)	57.7 (54.0 to 61.0)	142.8 (101.2 to 189.1)	225.8 (162.2 to 299.3)	58.1 (50.1 to 67.0)
Osteoarthritis	7,783.7 (7,680.3 to 7,903.2)	12,816.0 (12,646.5 to 12,999.7)	64.6 (61.6 to 67.8)	440.1 (308.1 to 600.7)	753.3 (524.3 to 1,026.0)	71.2 (67.0 to 75.4)
Low back and neck pain	-	-	-	6,276.9 (4,397.3 to 8,446.7)	10,619.4 (7,363.4 to 14,202.9)	69.1 (64.4 to 74.7)
Low back pain	35,254.5 (34,486.6 to 36,036.0)	59,154.6 (57,307.2 to 60,797.2)	67.7 (61.1 to 74.6)	3,969.9 (2,713.6 to 5,490.9)	6,685.6 (4,507.5 to 9,256.7)	68.2 (61.9 to 74.9)
Neck pain	23,253.2 (22,438.6 to 24,069.8)	39,563.6 (37,844.7 to 41,246.6)	70.0 (60.8 to 80.0)	2,307.0 (1,594.7 to 3,160.4)	3,933.8 (2,729.5 to 5,451.4)	70.5 (61.1 to 80.7)
Gout	251.3 (245.2 to 256.9)	409.3 (399.8 to 418.1)	62.9 (57.5 to 67.8)	8.4 (5.7 to 11.4)	13.8 (9.4 to 18.8)	64.0 (47.3 to 81.7)
Other musculoskeletal disorders	13,346.2 (10,342.8 to 16,375.7)	24,274.4 (18,915.6 to 29,741.4)	81.8 (77.3 to 87.5)	1,246.5 (799.2 to 1,799.5)	2,270.4 (1,451.4 to 3,278.9)	81.9 (76.7 to 88.4)
Other non-communicable diseases	-	-	-	4,208.5 (2,763.3 to 6,150.1)	6,808.7 (4,457.3 to 10,061.7)	61.8 (58.1 to 64.9)
Congenital anomalies	-	-	-	231.8 (170.1 to 300.8)	449.2 (323.4 to 582.7)	93.5 (81.0 to 107.5)
Neural tube defects	44.9 (43.7 to 46.4)	87.6 (85.6 to 89.8)	95.1 (87.7 to 101.7)	13.7 (9.7 to 17.7)	27.3 (19.2 to 35.3)	99.9 (78.8 to 123.8)
Congenital heart anomalies	1,068.3 (1,031.7 to 1,108.5)	2,349.6 (2,279.3 to 2,434.2)	119.6 (111.0 to 130.7)	36.7 (15.6 to 64.0)	83.2 (35.4 to 141.5)	126.8 (115.5 to 139.7)
Orofacial clefts	161.1 (154.1 to 168.7)	384.6 (373.9 to 395.8)	138.3 (126.5 to 152.8)	1.9 (1.2 to 2.8)	4.2 (2.8 to 6.1)	124.1 (95.4 to 155.2)
Down syndrome	210.6 (203.5 to 218.7)	461.9 (446.9 to 478.0)	119.5 (108.7 to 129.8)	22.8 (16.6 to 29.8)	50.0 (36.7 to 64.7)	119.7 (102.8 to 137.8)
Turner syndrome	10.0 (9.4 to 10.5)	19.2 (18.3 to 20.2)	91.5 (81.3 to 104.7)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	91.7 (70.5 to 113.7)
Klinefelter syndrome	8.2 (7.7 to 8.6)	14.5 (13.9 to 15.2)	77.2 (66.2 to 90.0)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	78.0 (57.6 to 98.0)
Chromosomal unbalanced rearrangements	304.1 (293.6 to 314.1)	628.2 (607.0 to 657.5)	106.5 (97.0 to 117.2)	32.7 (23.6 to 42.5)	67.9 (48.9 to 88.8)	107.6 (93.3 to 121.7)
Other congenital anomalies	1,219.8 (1,044.6 to 1,372.3)	1,856.8 (1,568.6 to 2,104.4)	52.0 (45.0 to 60.5)	123.8 (85.6 to 167.3)	216.1 (148.9 to 291.2)	74.1 (57.2 to 95.5)
Skin and subcutaneous diseases	-	-	-	1,455.1 (937.6 to 2,171.4)	2,452.9 (1,574.5 to 3,688.4)	68.7 (62.3 to 73.9)
Dermatitis	20,011.6 (14,876.5 to 25,627.8)	32,643.5 (24,692.0 to 41,590.6)	63.1 (61.5 to 65.8)	463.7 (284.5 to 688.1)	757.2 (466.0 to 1,119.6)	63.3 (60.2 to 66.4)
Psoriasis	3,135.9 (2,645.2 to 3,652.1)	5,079.2 (4,240.0 to 5,966.0)	61.9 (59.0 to 64.8)	255.5 (171.9 to 360.2)	414.7 (277.2 to 588.4)	62.3 (56.0 to 68.4)
Cellulitis	81.9 (54.5 to 129.8)	98.6 (65.6 to 154.4)	20.4 (13.7 to 28.2)	5.8 (3.2 to 9.9)	7.1 (3.9 to 12.1)	21.7 (0.5 to 47.9)
Pyoderma	155.4 (97.4 to 243.2)	221.5 (134.3 to 376.2)	42.6 (17.7 to 65.3)	0.9 (0.3 to 2.0)	1.2 (0.4 to 2.9)	42.0 (16.0 to 69.4)
Scabies	2,403.7 (2,090.2 to 2,752.7)	4,187.9 (3,799.4 to 4,664.3)	74.5 (46.0 to 103.9)	61.4 (34.3 to 99.4)	107.5 (60.4 to 173.2)	75.2 (46.9 to 105.5)
Fungal skin diseases	27,987.1 (23,653.9 to 33,181.8)	49,254.8 (41,559.4 to 58,185.3)	76.0 (74.8 to 77.5)	157.5 (63.6 to 333.6)	277.9 (112.0 to 588.3)	76.4 (74.8 to 78.2)
Viral skin diseases	1,869.4 (1,109.7 to 2,827.8)	2,978.6 (1,727.1 to 4,551.4)	59.3 (50.5 to 65.4)	57.1 (28.1 to 101.5)	91.1 (43.8 to 163.2)	59.5 (49.8 to 67.5)
Acne vulgaris	8,766.5 (8,060.4 to 9,517.2)	14,709.5 (13,226.1 to 15,948.6)	68.1 (46.3 to 85.7)	93.8 (45.3 to 171.0)	157.7 (75.4 to 291.9)	68.5 (46.6 to 86.4)
Alopecia areata	451.7 (438.7 to 466.0)	747.2 (724.0 to 772.2)	65.6 (58.3 to 72.1)	15.2 (9.7 to 22.6)	25.1 (16.2 to 37.9)	65.7 (53.5 to 77.9)
Pruritus	45.5 (42.9 to 49.4)	77.1 (72.1 to 82.0)	69.6 (51.5 to 84.5)	0.5 (0.2 to 0.9)	0.8 (0.4 to 1.6)	69.9 (43.6 to 101.9)
Urticaria	3,563.7 (3,227.9 to 4,156.4)	6,481.3 (5,609.0 to 7,335.7)	82.7 (48.0 to 116.1)	212.1 (137.8 to 299.8)	387.6 (248.4 to 567.3)	83.3 (48.2 to 118.7)
Decubitus ulcer	40.0 (38.2 to 41.8)	56.2 (53.0 to 59.6)	40.4 (33.1 to 47.8)	6.4 (4.3 to 8.9)	9.1 (6.2 to 12.7)	42.1 (23.3 to 64.6)
Other skin and subcutaneous diseases	21,026.3 (4,472.7 to 49,089.7)	36,159.9 (7,718.2 to 85,072.4)	72.0 (69.1 to 74.5)	125.2 (22.2 to 347.2)	215.8 (38.5 to 596.4)	72.4 (68.8 to 75.5)
Sense organ diseases	-	-	-	1,838.5 (1,167.2 to 2,735.7)	2,799.7 (1,756.1 to 4,235.1)	52.2 (46.3 to 57.6)
Glaucoma	441.7 (362.9 to 531.6)	735.1 (592.6 to 898.3)	66.1 (48.5 to 83.9)	30.5 (19.4 to 44.9)	49.5 (30.9 to 73.0)	62.3 (44.9 to 80.5)
Cataract	470.1 (357.0 to 612.0)	654.2 (503.4 to 841.6)	39.5 (13.8 to 85.8)	29.7 (19.1 to 45.6)	41.9 (26.6 to 62.6)	40.5 (16.7 to 77.8)
Macular degeneration	-	-	-	-	-	-
Uncorrected refractive error	22,611.9 (21,839.0 to 23,463.2)	36,798.4 (35,688.5 to 38,120.3)	62.6 (57.9 to 67.6)	401.4 (246.0 to 629.8)	627.1 (383.9 to 994.9)	56.1 (51.4 to 61.2)
Age-related and other hearing loss	45,912.4 (37,888.8 to 53,099.6)	71,097.3 (57,926.8 to 83,312.8)	54.7 (48.0 to 61.1)	1,159.7 (691.9 to 1,774.9)	1,744.8 (1,028.7 to 2,747.1)	50.3 (41.1 to 58.8)
Other vision loss	1,357.8 (1,090.8 to 1,654.4)	1,792.7 (1,420.3 to 2,208.1)	32.0 (25.1 to 38.7)	93.3 (59.4 to 132.8)	125.3 (78.7 to 180.6)	34.3 (25.7 to 43.7)
Other sense organ diseases	4,700.9 (4,603.6 to 4,807.0)	7,993.7 (7,816.8 to 8,159.3)	70.1 (64.6 to 75.0)	123.9 (76.2 to 183.5)	211.1 (131.0 to 311.6)	70.4 (63.8 to 77.4)
Oral disorders	-	-	-	683.0 (394.9 to 1,091.3)	1,106.9 (637.8 to 1,787.2)	61.8 (57.9 to 65.8)
Deciduous caries	-	-	-	-	-	-
Permanent caries	118,632.3 (116,984.3 to 120,362.5)	201,587.9 (198,963.5 to 204,513.6)	69.9 (66.4 to 73.5)	103.4 (48.1 to 197.2)	184.5 (84.8 to 356.2)	78.4 (73.3 to 83.4)
Periodontal diseases	30,325.1 (29,696.9 to 30,972.0)	50,134.7 (48,882.5 to 51,504.9)	65.2 (59.9 to 71.3)	200.4 (79.7 to 414.3)	331.9 (132.6 to 681.6)	65.6 (60.4 to 71.8)
Edentulism and severe tooth loss	6,446.7 (6,242.3 to 6,695.1)	9,097.3 (8,816.9 to 9,381.1)	41.1 (34.9 to 47.7)	183.8 (121.5 to 257.8)	259.6 (175.1 to 361.0)	41.2 (34.5 to 48.7)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (40-44 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Other oral disorders	6,674.6 (6,541.3 to 6,811.2)	11,279.5 (11,053.3 to 11,518.3)	69.0 (64.5 to 73.9)	195.5 (123.3 to 291.0)	330.9 (208.9 to 493.7)	69.4 (64.2 to 74.7)
Injuries	-	-	-	2,811.7 (2,027.9 to 3,850.3)	2,848.1 (2,076.2 to 3,780.2)	2.1 (-13.7 to 14.5)
Transport injuries	-	-	-	874.5 (647.8 to 1,133.9)	938.2 (688.2 to 1,241.4)	7.0 (-0.6 to 16.2)
Road injuries	-	-	-	728.2 (541.1 to 939.1)	780.8 (574.4 to 1,032.2)	6.9 (-1.4 to 16.9)
Pedestrian road injuries	-	-	-	148.7 (110.3 to 192.5)	179.0 (131.2 to 237.1)	20.0 (10.4 to 31.4)
Cyclist road injuries	-	-	-	62.7 (46.6 to 81.6)	64.1 (46.6 to 84.8)	2.1 (-4.9 to 10.4)
Motorcyclist road injuries	-	-	-	179.6 (132.5 to 233.6)	181.5 (132.3 to 242.5)	0.7 (-8.2 to 11.3)
Motor vehicle road injuries	-	-	-	330.0 (245.4 to 423.1)	349.7 (258.4 to 460.0)	5.7 (-2.5 to 15.6)
Other road injuries	-	-	-	7.2 (5.4 to 9.2)	6.6 (4.9 to 8.7)	-7.8 (-14.3 to -0.2)
Other transport injuries	-	-	-	146.3 (108.9 to 192.8)	157.4 (114.0 to 208.8)	7.5 (1.3 to 14.5)
Unintentional injuries	-	-	-	1,190.0 (892.8 to 1,551.2)	1,418.4 (1,031.7 to 1,897.3)	19.0 (12.8 to 25.7)
Falls	-	-	-	565.6 (422.6 to 737.7)	714.3 (513.8 to 959.6)	26.0 (17.8 to 34.9)
Drowning	-	-	-	30.2 (22.0 to 38.9)	32.3 (23.5 to 42.0)	7.1 (-0.3 to 15.6)
Fire, heat, and hot substances	-	-	-	106.4 (80.0 to 136.8)	102.8 (76.8 to 135.2)	-3.4 (-11.5 to 4.0)
Poisonings	-	-	-	6.6 (4.7 to 8.8)	6.9 (4.9 to 9.4)	5.8 (-1.1 to 13.1)
Exposure to mechanical forces	-	-	-	291.6 (215.2 to 386.6)	317.8 (229.7 to 436.7)	8.7 (2.8 to 15.0)
Unintentional firearm injuries	-	-	-	13.1 (9.8 to 16.9)	14.8 (10.7 to 19.9)	12.8 (4.8 to 21.7)
Unintentional suffocation	-	-	-	2.8 (2.1 to 3.7)	4.5 (3.3 to 6.0)	61.4 (51.5 to 72.2)
Other exposure to mechanical forces	-	-	-	275.7 (202.8 to 366.1)	298.5 (215.6 to 411.3)	8.0 (2.1 to 14.1)
Adverse effects of medical treatment	-	-	-	8.0 (5.1 to 11.8)	12.3 (7.7 to 18.1)	52.3 (47.8 to 56.9)
Animal contact	-	-	-	32.0 (23.7 to 41.9)	32.5 (23.5 to 43.0)	1.8 (-4.3 to 7.9)
Venomous animal contact	-	-	-	13.6 (9.8 to 18.1)	14.1 (9.9 to 18.7)	3.0 (-5.8 to 12.4)
Non-venomous animal contact	-	-	-	18.3 (13.6 to 24.4)	18.5 (13.4 to 25.1)	0.6 (-5.4 to 7.0)
Foreign body	-	-	-	15.5 (11.6 to 19.6)	20.2 (14.5 to 26.1)	29.5 (22.3 to 38.1)
Pulmonary aspiration and foreign body in airway	-	-	-	3.1 (2.4 to 4.0)	3.2 (2.4 to 4.1)	0.1 (-8.4 to 12.3)
Foreign body in eyes	-	-	-	3.5 (2.3 to 5.1)	4.9 (3.0 to 7.3)	40.6 (31.9 to 48.6)
Foreign body in other body part	-	-	-	8.9 (6.7 to 11.4)	12.1 (8.8 to 15.9)	35.7 (27.7 to 44.6)
Other unintentional injuries	-	-	-	134.2 (99.6 to 176.9)	179.3 (130.0 to 239.6)	33.4 (28.4 to 39.2)
Self-harm and interpersonal violence	-	-	-	100.0 (75.0 to 128.6)	103.7 (75.9 to 137.0)	3.4 (-3.9 to 12.5)
Self-harm	-	-	-	23.9 (17.3 to 31.2)	23.5 (16.8 to 31.2)	-2.0 (-7.5 to 4.2)
Interpersonal violence	-	-	-	76.1 (57.2 to 97.4)	80.2 (58.9 to 106.1)	5.1 (-3.3 to 15.5)
Assault by firearm	-	-	-	12.8 (9.7 to 16.6)	16.0 (11.7 to 21.4)	24.6 (16.0 to 33.8)
Assault by sharp object	-	-	-	14.1 (10.6 to 18.4)	18.0 (13.0 to 24.5)	27.2 (17.7 to 37.8)
Assault by other means	-	-	-	49.1 (36.9 to 62.7)	46.2 (34.4 to 60.4)	-6.2 (-13.8 to 3.4)
Forces of nature, war, and legal intervention	-	-	-	647.2 (263.2 to 1,349.2)	387.8 (189.1 to 740.2)	-38.6 (-57.1 to -4.4)
Exposure to forces of nature	-	-	-	46.5 (20.1 to 98.0)	43.5 (22.3 to 83.4)	-3.7 (-33.2 to 31.8)
Collective violence and legal intervention	-	-	-	600.7 (234.0 to 1,298.5)	344.3 (159.1 to 663.7)	-41.2 (-60.4 to -4.8)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (45-49 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
All causes	-	-	-	31,926.9 (23,826.3 to 41,168.2)	59,144.2 (43,940.4 to 76,418.6)	85.3 (82.1 to 88.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	3,138.7 (2,196.0 to 4,281.0)	4,945.6 (3,553.5 to 6,639.4)	57.7 (48.7 to 69.5)
HIV/AIDS and tuberculosis	-	-	-	272.8 (191.0 to 358.3)	805.3 (569.1 to 1,060.7)	194.9 (171.2 to 227.2)
Tuberculosis	632.3 (593.4 to 674.6)	1,109.1 (1,048.5 to 1,174.5)	74.7 (69.6 to 79.5)	190.9 (131.7 to 255.5)	337.1 (229.7 to 453.5)	76.7 (67.3 to 85.7)
HIV/AIDS	-	-	-	82.0 (58.4 to 107.9)	468.2 (333.6 to 620.3)	471.9 (379.5 to 585.1)
HIV/AIDS resulting in mycobacterial infection	18.1 (11.8 to 25.5)	77.6 (54.2 to 101.0)	328.2 (252.6 to 421.0)	6.6 (3.6 to 10.7)	28.4 (17.1 to 42.1)	333.0 (232.0 to 464.5)
HIV/AIDS resulting in other diseases	471.3 (429.2 to 522.0)	2,784.5 (2,635.2 to 3,047.5)	487.5 (435.5 to 548.5)	75.3 (53.6 to 99.8)	439.8 (313.7 to 583.6)	484.4 (383.0 to 611.3)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	304.7 (217.8 to 417.9)	478.4 (334.7 to 669.4)	56.7 (50.0 to 63.8)
Diarrheal diseases	550.3 (531.8 to 569.5)	785.5 (749.5 to 822.4)	42.2 (33.9 to 50.6)	85.5 (59.3 to 117.0)	122.3 (84.0 to 168.8)	43.3 (31.1 to 55.0)
Intestinal infectious diseases	-	-	-	4.5 (2.9 to 6.7)	5.2 (3.4 to 7.4)	14.3 (-17.2 to 54.4)
Typhoid fever	26.6 (21.9 to 31.5)	31.0 (25.1 to 37.7)	16.8 (-11.3 to 49.8)	3.4 (2.1 to 5.1)	4.1 (2.6 to 6.1)	21.8 (-18.1 to 80.2)
Paratyphoid fever	16.0 (11.8 to 20.7)	17.2 (13.2 to 23.4)	6.4 (-30.5 to 64.8)	0.8 (0.5 to 1.3)	0.9 (0.5 to 1.5)	6.3 (-35.0 to 76.5)
Other intestinal infectious diseases	-	-	-	0.3 (0.1 to 0.6)	0.2 (0.1 to 0.4)	-38.4 (-53.7 to -16.5)
Lower respiratory infections	76.8 (75.3 to 78.3)	158.6 (155.8 to 161.4)	105.7 (100.0 to 112.0)	7.9 (5.4 to 11.0)	16.4 (11.1 to 23.0)	106.8 (90.8 to 126.1)
Upper respiratory infections	6,387.7 (6,246.5 to 6,510.8)	12,136.7 (11,848.6 to 12,404.4)	89.1 (83.7 to 95.4)	73.7 (41.7 to 121.3)	140.6 (78.8 to 234.7)	90.6 (83.5 to 98.5)
Otitis media	2,624.1 (2,516.2 to 2,717.3)	4,284.8 (4,114.3 to 4,443.4)	62.6 (56.4 to 69.1)	48.5 (28.7 to 78.3)	80.2 (47.6 to 128.9)	65.1 (57.6 to 73.5)
Meningitis	-	-	-	64.5 (43.2 to 89.8)	81.0 (56.0 to 112.7)	25.3 (17.3 to 36.0)
Pneumococcal meningitis	402.7 (238.0 to 602.7)	515.0 (307.6 to 787.2)	27.1 (17.7 to 36.6)	28.9 (20.5 to 38.6)	38.8 (27.0 to 52.2)	34.0 (18.3 to 54.4)
H influenzae type B meningitis	157.9 (42.5 to 314.0)	163.5 (46.8 to 334.2)	2.7 (-11.8 to 14.4)	11.6 (7.7 to 16.6)	13.5 (9.0 to 19.3)	16.8 (5.7 to 33.4)
Meningococcal meningitis	76.7 (18.7 to 175.6)	79.1 (20.9 to 179.6)	2.6 (-10.5 to 15.5)	7.6 (4.0 to 12.7)	8.5 (4.8 to 14.4)	12.6 (-0.4 to 29.5)
Other meningitis	180.9 (59.6 to 354.9)	201.5 (74.1 to 406.5)	10.7 (-4.5 to 25.5)	16.4 (10.5 to 24.1)	20.1 (13.0 to 29.3)	22.4 (7.7 to 39.8)
Encephalitis	95.1 (38.1 to 212.3)	135.6 (57.4 to 323.4)	43.0 (12.3 to 57.8)	10.6 (7.4 to 14.7)	17.0 (11.8 to 22.9)	60.7 (42.6 to 81.1)
Diphtheria	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	10.9 (-65.9 to 320.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.3 (-66.0 to 322.8)
Whooping cough	2.3 (1.8 to 3.0)	2.5 (1.9 to 3.2)	4.6 (3.5 to 6.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	5.0 (3.8 to 6.4)
Tetanus	49.7 (35.5 to 75.2)	8.2 (5.0 to 12.8)	-83.8 (-91.1 to -70.6)	1.5 (0.9 to 2.4)	0.5 (0.3 to 0.7)	-68.3 (-80.7 to -49.1)
Measles	0.3 (0.2 to 0.3)	0.1 (0.1 to 0.1)	-60.4 (-63.7 to -57.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-60.3 (-63.6 to -56.9)
Varicella and herpes zoster	145.4 (137.9 to 156.9)	280.7 (264.1 to 297.7)	92.8 (77.5 to 107.2)	7.7 (4.7 to 11.5)	15.1 (9.2 to 23.0)	96.6 (76.7 to 117.1)
Neglected tropical diseases and malaria	-	-	-	946.9 (609.1 to 1,385.0)	1,275.5 (749.2 to 1,983.0)	33.1 (12.8 to 61.3)
Malaria	8,690.0 (8,472.1 to 8,922.4)	12,199.4 (11,898.4 to 12,523.5)	39.6 (35.6 to 44.5)	58.7 (39.3 to 84.5)	79.5 (53.1 to 115.8)	35.6 (26.8 to 44.6)
Chagas disease	535.5 (522.0 to 549.5)	683.4 (661.2 to 705.7)	27.0 (22.0 to 32.8)	5.9 (3.9 to 8.5)	7.6 (5.0 to 10.8)	27.2 (16.9 to 40.0)
Leishmaniasis	-	-	-	1.0 (0.5 to 1.8)	2.7 (1.4 to 5.1)	185.0 (153.6 to 222.1)
Visceral leishmaniasis	1.6 (1.2 to 2.2)	3.0 (2.1 to 4.1)	80.6 (23.7 to 153.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	81.7 (24.6 to 153.3)
Cutaneous and mucocutaneous leishmaniasis	80.0 (67.6 to 95.2)	238.6 (201.4 to 282.8)	196.6 (164.6 to 233.4)	0.8 (0.4 to 1.6)	2.5 (1.2 to 4.8)	200.5 (165.8 to 238.8)
African trypanosomiasis	4.0 (1.8 to 8.0)	1.1 (0.6 to 1.9)	-72.2 (-76.3 to -67.0)	1.0 (0.4 to 2.1)	0.3 (0.1 to 0.5)	-72.1 (-81.2 to -57.9)
Schistosomiasis	10,132.5 (9,059.9 to 11,189.8)	13,037.1 (11,246.7 to 15,166.4)	26.5 (18.2 to 47.1)	88.5 (45.3 to 162.7)	114.3 (57.5 to 218.0)	27.4 (20.0 to 47.7)
Cysticercosis	84.6 (73.0 to 96.8)	73.1 (61.7 to 85.9)	-14.2 (-29.6 to 8.7)	23.6 (16.4 to 31.5)	22.0 (15.0 to 29.6)	-7.1 (-27.1 to 24.5)
Cystic echinococcosis	60.6 (57.3 to 64.2)	63.2 (60.0 to 66.9)	4.1 (0.7 to 6.7)	5.6 (3.8 to 7.9)	5.9 (4.0 to 8.4)	5.1 (-9.5 to 20.2)
Lymphatic filariasis	4,322.4 (3,684.2 to 5,110.4)	3,480.4 (2,795.2 to 4,379.3)	-20.0 (-28.9 to -10.4)	176.3 (90.2 to 296.6)	206.8 (111.7 to 340.7)	18.5 (-6.4 to 42.7)
Onchocerciasis	1,340.9 (942.4 to 1,989.3)	899.0 (603.7 to 1,399.6)	-33.6 (-42.3 to -22.2)	96.6 (51.1 to 154.5)	69.8 (33.0 to 120.2)	-28.7 (-41.8 to -12.2)
Trachoma	163.0 (100.7 to 244.7)	105.4 (60.5 to 160.0)	-35.5 (-51.4 to -19.7)	10.4 (5.5 to 17.0)	6.8 (3.4 to 11.7)	-34.4 (-50.3 to -17.4)
Dengue	15.9 (5.8 to 35.6)	162.8 (59.8 to 365.1)	921.5 (917.9 to 924.1)	2.5 (0.7 to 6.3)	26.0 (8.6 to 65.2)	941.9 (684.0 to 1,274.4)
Yellow fever	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.2)	-61.6 (-71.7 to -38.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.4 (-71.7 to -37.8)
Rabies	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-14.0 (-34.2 to 14.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.7 (-34.1 to 15.3)
Intestinal nematode infections	-	-	-	233.7 (135.5 to 372.8)	198.7 (117.0 to 316.6)	-14.5 (-22.5 to -6.0)
Ascariasis	45,278.1 (37,901.0 to 54,925.4)	48,173.8 (40,369.1 to 58,690.9)	5.6 (-17.8 to 38.6)	104.5 (57.8 to 173.2)	49.1 (26.9 to 84.4)	-53.0 (-60.5 to -44.2)
Trichuriasis	22,654.8 (18,315.0 to 28,722.2)	27,305.8 (24,341.2 to 30,704.3)	21.3 (-8.9 to 52.5)	31.3 (17.3 to 52.0)	1.3 (17.0 to 54.2)	1.3 (-19.6 to 34.4)
Hookworm disease	21,997.0 (18,398.0 to 26,722.4)	28,446.9 (25,650.4 to 31,711.9)	29.5 (4.3 to 57.3)	97.9 (59.1 to 154.8)	117.6 (71.0 to 182.9)	20.5 (7.6 to 33.5)
Food-borne trematodiasis	4,163.8 (3,138.2 to 5,155.2)	9,967.0 (7,371.5 to 12,365.9)	138.5 (117.3 to 161.4)	211.2 (63.7 to 450.3)	506.9 (149.6 to 1,076.0)	139.0 (113.1 to 171.8)
Other neglected tropical diseases	1,023.1 (966.2 to 1,082.7)	1,231.0 (1,166.1 to 1,289.1)	19.7 (10.6 to 30.0)	31.9 (18.3 to 55.5)	28.2 (15.5 to 49.7)	-12.5 (-27.6 to 10.3)
Maternal disorders	-	-	-	69.4 (45.9 to 98.4)	96.2 (65.9 to 137.1)	38.3 (18.3 to 63.8)
Maternal hemorrhage	15.3 (14.5 to 16.1)	26.0 (24.4 to 27.5)	69.7 (56.2 to 82.5)	0.7 (0.5 to 0.9)	1.0 (0.7 to 1.4)	52.2 (30.2 to 79.4)
Maternal sepsis and other maternal infections	198.6 (137.0 to 272.0)	218.5 (151.7 to 292.0)	10.0 (-11.2 to 34.5)	1.0 (0.4 to 2.4)	1.1 (0.4 to 2.6)	9.6 (-11.0 to 35.8)
Maternal hypertensive disorders	3.6 (1.2 to 6.3)	4.2 (1.4 to 7.2)	16.5 (5.6 to 28.0)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	16.5 (-1.6 to 40.5)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (45-49 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Obstructed labor	172.3 (140.3 to 204.3)	236.6 (195.9 to 275.8)	36.6 (24.7 to 49.3)	54.8 (35.6 to 79.2)	76.0 (51.3 to 109.5)	38.7 (19.5 to 62.7)
Complications of abortion	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	0.0 (10.5 to 37.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	25.2 (11.1 to 38.7)
Other maternal disorders	-	-	-	12.7 (7.9 to 18.8)	17.8 (11.1 to 27.2)	42.6 (-7.6 to 98.1)
Neonatal disorders	-	-	-	189.6 (142.0 to 241.6)	672.8 (498.9 to 860.3)	255.1 (220.7 to 294.8)
Preterm birth complications	865.6 (760.8 to 995.8)	3,238.5 (2,828.6 to 3,728.8)	271.7 (239.9 to 311.3)	90.9 (66.7 to 115.7)	384.2 (283.6 to 494.4)	322.5 (293.1 to 356.9)
Neonatal encephalopathy due to birth asphyxia and trauma	817.6 (310.2 to 1,508.2)	1,110.9 (553.7 to 1,868.8)	35.7 (4.1 to 114.4)	45.3 (31.0 to 64.6)	103.7 (77.5 to 136.3)	131.0 (88.4 to 178.9)
Neonatal sepsis and other neonatal infections	-	-	-	-	-	-
Hemolytic disease and other neonatal jaundice	68.0 (57.2 to 82.6)	239.0 (189.5 to 316.9)	244.2 (166.2 to 418.3)	24.9 (17.2 to 33.5)	78.5 (54.6 to 108.1)	210.3 (146.6 to 349.7)
Other neonatal disorders	-	-	-	28.5 (19.4 to 40.3)	106.5 (73.1 to 143.6)	274.3 (203.2 to 358.9)
Nutritional deficiencies	-	-	-	1,257.3 (833.8 to 1,831.3)	1,465.1 (970.7 to 2,149.4)	16.3 (13.2 to 19.9)
Protein-energy malnutrition	10.6 (5.1 to 17.7)	12.7 (6.8 to 21.0)	19.0 (-4.0 to 50.1)	1.3 (0.5 to 2.4)	1.6 (0.7 to 2.8)	21.7 (-9.0 to 63.4)
Iodine deficiency	6,808.3 (6,410.4 to 7,247.7)	7,894.7 (7,422.3 to 8,334.8)	15.2 (6.8 to 25.1)	120.4 (75.0 to 187.1)	140.2 (87.3 to 222.6)	16.3 (7.4 to 27.0)
Vitamin A deficiency	98.7 (44.2 to 141.3)	101.7 (59.3 to 148.1)	2.3 (-1.6 to 40.7)	6.0 (2.7 to 10.1)	6.1 (3.0 to 10.3)	0.4 (-27.8 to 41.7)
Iron-deficiency anemia	43,872.2 (43,627.9 to 44,089.4)	58,712.0 (58,383.3 to 59,039.7)	33.2 (32.4 to 34.2)	1,129.4 (753.5 to 1,630.8)	1,317.2 (873.6 to 1,918.8)	16.4 (12.9 to 20.5)
Other nutritional deficiencies	-	-	-	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.2)	-14.5 (-45.7 to 36.4)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	98.0 (60.5 to 160.1)	152.1 (91.8 to 254.4)	54.8 (46.0 to 63.2)
Sexually transmitted diseases excluding HIV	-	-	-	51.5 (29.7 to 92.9)	90.2 (50.5 to 164.6)	74.8 (65.7 to 81.9)
Syphilis	31.1 (29.6 to 32.8)	31.1 (29.8 to 32.5)	-0.7 (-6.4 to 6.4)	5.8 (3.9 to 8.3)	5.9 (3.9 to 8.5)	1.8 (-18.7 to 26.0)
Chlamydial infection	5,045.5 (4,887.3 to 5,207.4)	9,183.4 (8,901.6 to 9,411.8)	81.2 (74.0 to 88.7)	20.1 (12.6 to 32.3)	38.6 (24.0 to 60.9)	92.2 (80.0 to 104.8)
Gonococcal infection	554.0 (497.3 to 605.2)	955.4 (860.2 to 1,045.0)	71.7 (56.3 to 89.1)	3.7 (2.3 to 6.3)	6.6 (4.0 to 10.8)	79.1 (47.8 to 119.3)
Trichomoniasis	2,188.5 (2,029.6 to 2,346.6)	4,159.2 (3,879.3 to 4,472.4)	88.7 (73.1 to 109.9)	3.6 (1.4 to 7.6)	6.8 (2.8 to 14.6)	91.5 (72.0 to 118.5)
Genital herpes	67,164.2 (66,254.8 to 68,033.8)	119,266.0 (117,587.0 to 121,228.6)	76.7 (73.6 to 80.6)	16.7 (4.9 to 40.9)	29.8 (8.8 to 73.1)	77.9 (73.1 to 82.7)
Other sexually transmitted diseases	144.1 (110.5 to 178.9)	175.9 (138.4 to 218.0)	21.6 (13.4 to 31.4)	1.6 (1.0 to 2.6)	2.4 (1.5 to 3.6)	50.5 (25.0 to 83.9)
Hepatitis	-	-	-	19.7 (12.6 to 28.4)	31.2 (20.0 to 44.9)	58.5 (49.9 to 67.5)
Hepatitis A	103.5 (94.9 to 111.1)	231.8 (223.3 to 238.5)	123.2 (113.8 to 134.2)	3.8 (2.4 to 5.5)	8.4 (5.4 to 12.1)	124.7 (102.6 to 152.1)
Hepatitis B	18,316.7 (17,910.9 to 18,815.1)	24,496.0 (23,846.7 to 25,001.4)	33.1 (29.4 to 37.2)	13.6 (8.7 to 19.6)	18.6 (11.9 to 26.7)	37.1 (27.0 to 47.2)
Hepatitis C	8,559.5 (8,411.9 to 8,714.7)	12,494.5 (12,250.2 to 12,741.9)	45.4 (41.7 to 49.3)	0.8 (0.5 to 1.2)	1.2 (0.8 to 1.8)	52.5 (24.5 to 87.4)
Hepatitis E	57.8 (51.6 to 63.1)	104.8 (96.1 to 114.7)	79.8 (58.1 to 108.9)	1.5 (1.0 to 2.3)	2.9 (1.8 to 4.3)	90.5 (47.8 to 144.4)
Leprosy	35.7 (32.1 to 39.8)	58.8 (53.6 to 64.2)	63.6 (49.4 to 82.4)	2.0 (1.3 to 3.0)	3.6 (2.3 to 5.3)	78.4 (38.5 to 132.4)
Other infectious diseases	1,179.2 (1,134.0 to 1,225.9)	1,442.5 (1,392.4 to 1,495.5)	21.8 (15.9 to 28.3)	24.7 (15.8 to 37.4)	27.2 (16.4 to 44.6)	9.0 (-7.6 to 28.6)
Non-communicable diseases	-	-	-	26,142.4 (19,447.2 to 33,691.1)	51,195.8 (37,942.3 to 66,241.6)	95.8 (93.8 to 98.0)
Neoplasms	-	-	-	230.7 (168.0 to 301.1)	435.1 (308.5 to 575.8)	88.5 (74.4 to 104.1)
Esophageal cancer	28.5 (22.4 to 34.4)	41.7 (33.4 to 52.6)	45.7 (14.7 to 89.8)	4.6 (3.1 to 6.3)	6.5 (4.3 to 9.2)	42.0 (12.7 to 79.7)
Stomach cancer	93.5 (84.3 to 103.9)	120.6 (107.2 to 134.5)	28.6 (11.8 to 46.3)	11.6 (8.2 to 15.7)	14.4 (10.0 to 18.9)	23.9 (6.5 to 43.0)
Liver cancer	-	-	-	8.3 (5.4 to 11.4)	14.5 (9.4 to 20.5)	75.0 (31.7 to 136.5)
Liver cancer due to hepatitis B	22.6 (16.4 to 30.8)	44.2 (33.2 to 60.1)	95.2 (28.7 to 197.2)	3.8 (2.4 to 5.3)	6.5 (4.1 to 9.3)	72.3 (22.9 to 144.3)
Liver cancer due to hepatitis C	6.5 (5.1 to 8.4)	33.3 (25.2 to 43.6)	404.0 (258.0 to 644.3)	1.1 (0.7 to 1.5)	5.0 (3.2 to 7.1)	347.5 (233.6 to 514.5)
Liver cancer due to alcohol use	10.6 (8.1 to 13.9)	10.5 (8.1 to 13.5)	-0.7 (-29.6 to 41.5)	1.8 (1.2 to 2.5)	1.6 (1.0 to 2.2)	-10.8 (-33.2 to 19.9)
Liver cancer due to other causes	9.7 (7.4 to 12.4)	9.7 (7.5 to 12.3)	0.4 (-29.7 to 37.7)	1.7 (1.1 to 2.3)	1.5 (1.0 to 2.1)	-9.5 (-32.3 to 18.2)
Larynx cancer	45.7 (35.7 to 53.9)	62.3 (50.6 to 78.9)	34.7 (11.9 to 68.6)	4.6 (3.0 to 6.4)	6.0 (4.0 to 8.5)	29.4 (4.8 to 65.8)
Tracheal, bronchus and lung cancer	84.1 (77.7 to 89.9)	131.7 (119.9 to 146.7)	55.2 (39.8 to 77.2)	13.2 (9.5 to 17.2)	20.1 (13.8 to 26.4)	51.0 (32.8 to 75.2)
Breast cancer	698.8 (640.8 to 751.2)	1,653.9 (1,515.9 to 1,807.3)	135.2 (112.8 to 162.0)	52.3 (37.1 to 68.3)	111.9 (78.6 to 150.7)	113.7 (89.8 to 140.2)
Cervical cancer	364.7 (287.5 to 448.0)	460.2 (336.5 to 573.4)	26.1 (-10.4 to 65.7)	27.1 (18.0 to 38.1)	34.6 (21.2 to 50.3)	28.2 (-8.8 to 74.4)
Uterine cancer	159.4 (109.1 to 240.7)	296.4 (188.5 to 454.9)	85.0 (11.2 to 215.2)	10.4 (5.9 to 17.3)	19.2 (10.2 to 32.5)	83.6 (11.7 to 215.0)
Prostate cancer	30.5 (23.9 to 36.9)	107.2 (81.2 to 140.4)	246.0 (182.5 to 338.7)	2.6 (1.7 to 3.7)	8.0 (5.1 to 11.7)	197.9 (135.8 to 291.8)
Colon and rectum cancer	184.8 (175.6 to 194.7)	404.4 (376.6 to 435.4)	117.5 (101.7 to 137.6)	15.6 (11.2 to 20.9)	32.4 (23.1 to 42.9)	107.4 (86.5 to 130.5)
Lip and oral cavity cancer	109.4 (88.3 to 136.6)	201.6 (149.7 to 262.9)	82.1 (38.0 to 146.7)	9.3 (6.3 to 13.4)	16.8 (10.7 to 24.5)	79.9 (34.3 to 143.0)
Nasopharynx cancer	48.3 (34.2 to 67.7)	76.5 (52.9 to 108.0)	57.1 (-2.0 to 146.2)	4.6 (3.0 to 6.8)	7.1 (4.3 to 10.8)	53.4 (-3.3 to 141.0)
Other pharynx cancer	41.3 (32.4 to 52.1)	73.3 (55.1 to 97.1)	75.6 (24.4 to 147.3)	3.6 (2.4 to 5.2)	6.4 (4.0 to 9.5)	73.3 (21.6 to 142.1)
Gallbladder and biliary tract cancer	3.9 (3.3 to 4.5)	6.0 (4.9 to 7.1)	51.8 (23.9 to 84.7)	1.1 (0.8 to 1.5)	1.6 (1.1 to 2.2)	42.6 (17.2 to 73.7)
Pancreatic cancer	7.5 (6.7 to 8.2)	14.8 (13.1 to 16.6)	96.8 (71.3 to 125.9)	1.6 (1.1 to 2.1)	3.0 (2.1 to 4.1)	90.5 (67.7 to 114.4)
Malignant skin melanoma	104.4 (75.8 to 131.7)	195.5 (150.7 to 276.5)	84.8 (50.6 to 136.7)	6.2 (3.9 to 9.1)	11.3 (7.0 to 17.7)	82.3 (45.1 to 132.7)
Non-melanoma skin cancer	116.4 (102.0 to 134.8)	222.7 (190.3 to 263.4)	90.8 (49.4 to 135.3)	2.0 (1.2 to 3.4)	5.0 (2.8 to 8.3)	143.8 (65.8 to 278.7)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (45-49 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Ovarian cancer	56.1 (49.3 to 62.9)	103.6 (88.8 to 122.8)	82.8 (53.9 to 120.5)	7.1 (4.9 to 9.5)	13.1 (8.8 to 18.3)	83.3 (44.9 to 131.8)
Testicular cancer	23.6 (17.6 to 31.0)	53.7 (37.5 to 69.7)	126.3 (71.9 to 197.0)	1.5 (0.9 to 2.2)	3.3 (2.0 to 5.0)	120.7 (63.7 to 191.6)
Kidney cancer	48.2 (43.4 to 53.4)	112.3 (99.0 to 129.2)	131.7 (99.7 to 172.7)	3.6 (2.5 to 5.0)	8.0 (5.5 to 11.0)	123.7 (88.4 to 168.6)
Bladder cancer	47.2 (40.8 to 53.0)	74.7 (64.1 to 86.9)	56.7 (34.3 to 88.9)	3.7 (2.6 to 5.1)	5.8 (4.0 to 8.0)	56.7 (31.9 to 90.0)
Brain and nervous system cancer	41.4 (33.9 to 49.6)	87.3 (71.3 to 106.6)	109.6 (71.0 to 163.3)	4.6 (3.2 to 6.3)	9.4 (6.4 to 13.2)	103.6 (66.1 to 156.9)
Thyroid cancer	100.6 (80.9 to 119.0)	244.0 (194.2 to 297.7)	141.4 (95.2 to 198.3)	5.7 (3.7 to 8.3)	13.6 (8.7 to 19.7)	137.1 (91.3 to 194.7)
Mesothelioma	1.1 (0.9 to 1.2)	1.4 (1.2 to 1.7)	28.5 (9.6 to 64.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	30.9 (12.2 to 68.0)
Hodgkin lymphoma	32.9 (22.3 to 44.6)	52.9 (39.5 to 75.8)	57.4 (6.3 to 167.3)	2.9 (1.7 to 4.3)	4.3 (2.7 to 6.6)	48.3 (0.5 to 154.0)
Non-Hodgkin lymphoma	81.3 (66.3 to 96.2)	196.8 (164.8 to 235.1)	139.8 (100.0 to 193.0)	6.2 (4.2 to 8.7)	14.5 (9.6 to 20.2)	131.2 (91.4 to 184.4)
Multiple myeloma	9.7 (7.5 to 12.6)	21.0 (16.6 to 26.6)	116.3 (72.5 to 173.4)	2.1 (1.4 to 3.0)	4.4 (2.9 to 6.2)	109.8 (61.7 to 169.8)
Leukemia	43.3 (39.0 to 47.7)	104.7 (92.0 to 117.6)	140.2 (109.9 to 173.9)	6.1 (4.4 to 8.0)	13.4 (9.2 to 17.8)	119.3 (85.5 to 156.8)
Other neoplasms	108.4 (93.9 to 124.3)	384.1 (332.5 to 457.7)	250.7 (195.7 to 328.7)	8.0 (5.6 to 11.0)	26.3 (18.0 to 36.4)	225.8 (174.0 to 300.2)
Cardiovascular diseases	-	-	-	521.8 (357.3 to 720.4)	1,222.9 (817.4 to 1,725.8)	134.3 (96.2 to 177.7)
Rheumatic heart disease	1,141.0 (1,070.4 to 1,214.5)	2,362.3 (2,251.9 to 2,486.8)	106.9 (90.4 to 120.3)	67.7 (46.1 to 94.3)	133.7 (88.7 to 185.3)	97.7 (73.2 to 121.8)
Ischemic heart disease	1,800.0 (1,637.2 to 2,054.4)	3,209.6 (3,072.8 to 3,343.9)	78.5 (53.8 to 98.1)	111.2 (75.8 to 156.7)	214.6 (146.1 to 297.2)	95.3 (62.5 to 118.5)
Cerebrovascular disease	-	-	-	91.1 (64.5 to 120.2)	193.1 (135.1 to 255.4)	111.8 (91.9 to 131.2)
Ischemic stroke	379.9 (359.4 to 403.8)	795.1 (756.4 to 836.5)	108.2 (93.2 to 124.2)	58.4 (40.9 to 78.8)	122.7 (84.7 to 165.9)	110.2 (88.1 to 134.5)
Hemorrhagic stroke	211.6 (200.3 to 223.0)	454.2 (429.5 to 481.1)	113.3 (97.4 to 132.5)	32.8 (22.4 to 44.0)	70.3 (47.6 to 95.6)	114.6 (89.7 to 142.1)
Hypertensive heart disease	237.3 (226.8 to 249.3)	571.4 (548.0 to 595.0)	140.0 (126.8 to 153.1)	27.3 (18.9 to 38.3)	65.9 (45.2 to 91.2)	141.5 (124.1 to 161.1)
Cardiomyopathy and myocarditis	266.7 (254.6 to 279.4)	570.7 (544.0 to 594.0)	113.3 (101.0 to 126.0)	29.5 (20.1 to 40.1)	63.6 (43.4 to 86.7)	115.9 (99.0 to 132.8)
Atrial fibrillation and flutter	115.7 (104.9 to 130.9)	189.1 (178.2 to 203.0)	64.2 (40.9 to 81.2)	9.6 (6.3 to 13.5)	15.7 (10.7 to 22.0)	65.0 (38.0 to 89.3)
Peripheral vascular disease	9,416.5 (8,298.9 to 10,800.6)	17,347.5 (15,130.1 to 20,986.5)	81.0 (44.5 to 145.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	89.4 (8.1 to 207.6)
Endocarditis	9.8 (8.0 to 11.9)	22.3 (16.9 to 26.2)	127.9 (94.6 to 165.7)	1.1 (0.7 to 1.6)	2.5 (1.5 to 3.7)	134.5 (94.1 to 185.6)
Other cardiovascular and circulatory diseases	2,597.8 (1,716.7 to 3,941.4)	7,492.2 (4,673.0 to 11,111.0)	188.2 (81.8 to 331.3)	184.3 (104.3 to 305.3)	533.7 (281.2 to 884.5)	189.7 (83.1 to 338.3)
Chronic respiratory diseases	-	-	-	1,840.8 (1,263.8 to 2,475.6)	3,465.6 (2,384.5 to 4,682.2)	88.3 (81.0 to 96.0)
Chronic obstructive pulmonary disease	16,619.4 (15,841.4 to 17,389.8)	31,502.4 (29,905.2 to 32,973.0)	88.7 (86.5 to 90.7)	1,310.0 (877.7 to 1,812.9)	2,589.4 (1,745.2 to 3,544.2)	97.7 (88.7 to 107.0)
Pneumoconiosis	-	-	-	1.9 (1.4 to 2.6)	4.7 (3.3 to 6.4)	143.3 (130.1 to 154.0)
Silicosis	2.5 (2.2 to 2.8)	4.2 (3.8 to 4.7)	69.1 (63.0 to 73.7)	0.5 (0.3 to 0.7)	0.8 (0.5 to 1.2)	69.5 (63.4 to 74.2)
Asbestosis	0.6 (0.6 to 0.6)	1.1 (1.0 to 1.2)	78.5 (71.9 to 84.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	79.3 (72.2 to 85.7)
Coal workers pneumoconiosis	2.0 (1.8 to 2.1)	3.7 (3.5 to 4.0)	87.0 (83.9 to 89.8)	0.4 (0.2 to 0.5)	0.7 (0.5 to 1.0)	87.7 (84.3 to 90.4)
Other pneumoconiosis	5.0 (4.5 to 5.6)	15.7 (14.2 to 17.2)	210.3 (200.2 to 221.5)	0.9 (0.6 to 1.4)	2.9 (1.9 to 4.2)	210.3 (199.8 to 222.0)
Asthma	8,713.1 (8,517.7 to 8,893.0)	15,783.7 (15,470.0 to 16,077.5)	80.2 (75.1 to 86.1)	379.3 (250.5 to 535.4)	689.3 (454.4 to 975.9)	81.7 (75.7 to 88.2)
Interstitial lung disease and pulmonary sarcoidosis	24.6 (23.2 to 25.9)	48.4 (45.7 to 51.1)	97.0 (79.0 to 112.3)	3.4 (2.2 to 4.9)	6.8 (4.2 to 10.0)	100.5 (81.7 to 116.9)
Other chronic respiratory diseases	-	-	-	146.2 (90.9 to 220.6)	175.4 (115.2 to 259.7)	19.5 (4.4 to 40.1)
Cirrhosis	-	-	-	30.9 (21.7 to 42.5)	50.0 (34.5 to 68.8)	62.0 (50.1 to 74.1)
Cirrhosis due to hepatitis B	55.2 (52.4 to 58.8)	85.5 (79.2 to 90.8)	54.3 (41.1 to 67.3)	9.1 (6.2 to 12.8)	14.2 (9.7 to 19.8)	55.6 (32.1 to 80.1)
Cirrhosis due to hepatitis C	43.9 (40.5 to 47.1)	87.6 (81.1 to 96.1)	98.1 (79.0 to 121.8)	7.2 (4.9 to 10.2)	14.5 (9.7 to 20.6)	100.1 (71.5 to 136.8)
Cirrhosis due to alcohol use	68.3 (62.9 to 72.4)	84.5 (76.4 to 93.0)	23.0 (10.0 to 37.1)	11.3 (7.8 to 15.9)	14.1 (9.2 to 19.9)	23.7 (6.0 to 50.1)
Cirrhosis due to other causes	19.5 (17.5 to 21.9)	43.3 (38.4 to 48.3)	120.9 (95.8 to 154.6)	3.2 (2.1 to 4.7)	7.2 (4.7 to 10.3)	123.7 (72.6 to 187.1)
Digestive diseases	-	-	-	428.1 (301.1 to 573.1)	647.4 (461.9 to 863.3)	51.2 (43.8 to 58.5)
Peptic ulcer disease	1,963.0 (1,850.7 to 2,053.0)	1,931.5 (1,803.6 to 2,033.2)	-2.0 (-7.5 to 3.2)	75.7 (52.1 to 107.2)	81.1 (55.9 to 115.2)	7.1 (-2.3 to 17.3)
Gastritis and duodenitis	2,910.2 (2,765.7 to 3,039.0)	3,501.8 (3,335.6 to 3,667.7)	20.0 (12.8 to 26.9)	112.6 (76.2 to 158.3)	139.1 (93.5 to 198.0)	23.6 (15.9 to 32.1)
Appendicitis	24.0 (20.8 to 28.3)	34.2 (29.9 to 38.4)	41.9 (18.1 to 65.6)	7.2 (4.5 to 10.4)	10.2 (6.5 to 14.6)	43.2 (5.8 to 94.6)
Paralytic ileus and intestinal obstruction	2.8 (2.8 to 2.9)	5.4 (5.3 to 5.6)	90.3 (83.1 to 99.7)	0.9 (0.6 to 1.3)	1.8 (1.2 to 2.4)	91.5 (83.3 to 101.2)
Inguinal, femoral, and abdominal hernia	668.6 (625.0 to 716.9)	1,117.6 (1,050.0 to 1,200.0)	66.7 (50.8 to 82.3)	7.1 (3.5 to 13.2)	11.9 (5.8 to 22.4)	68.1 (50.4 to 84.9)
Inflammatory bowel disease	518.0 (508.3 to 527.8)	1,046.2 (1,027.5 to 1,065.9)	101.1 (96.8 to 105.2)	109.8 (75.8 to 150.2)	222.5 (153.2 to 303.6)	102.6 (92.7 to 112.7)
Vascular intestinal disorders	0.7 (0.6 to 0.7)	1.2 (1.1 to 1.4)	84.8 (65.9 to 110.5)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	85.8 (66.6 to 111.6)
Gallbladder and biliary diseases	308.1 (292.3 to 327.0)	473.3 (449.7 to 503.8)	53.2 (40.8 to 65.9)	33.0 (22.7 to 45.3)	50.8 (34.8 to 69.9)	53.8 (39.7 to 69.5)
Pancreatitis	101.0 (99.0 to 103.3)	207.4 (202.9 to 212.2)	104.4 (98.1 to 110.7)	29.9 (20.3 to 40.2)	61.7 (42.0 to 84.0)	106.5 (88.1 to 126.6)
Other digestive diseases	-	-	-	51.7 (35.8 to 71.1)	67.9 (47.0 to 93.8)	32.2 (13.3 to 46.1)
Neurological disorders	-	-	-	2,086.3 (1,399.6 to 2,916.6)	4,269.8 (2,869.6 to 5,961.8)	104.7 (95.6 to 115.2)
Alzheimer disease and other dementias	109.3 (103.1 to 115.3)	215.4 (205.5 to 226.7)	95.7 (83.7 to 111.4)	14.0 (9.8 to 18.9)	27.7 (19.4 to 37.1)	97.9 (74.8 to 122.8)
Parkinson disease	84.8 (56.6 to 110.9)	173.2 (109.8 to 231.1)	103.3 (91.0 to 110.5)	11.0 (6.3 to 16.6)	22.5 (12.2 to 34.4)	105.2 (82.5 to 127.3)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (45-49 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Epilepsy	674.6 (631.2 to 718.4)	1,243.1 (1,150.4 to 1,336.7)	83.6 (66.1 to 104.4)	218.6 (149.9 to 286.3)	429.6 (295.1 to 559.6)	96.6 (76.3 to 122.8)
Multiple sclerosis	121.0 (117.8 to 124.4)	298.2 (290.0 to 306.2)	145.3 (136.5 to 154.0)	39.8 (28.8 to 50.8)	98.3 (70.3 to 125.0)	146.9 (123.7 to 172.7)
Migraine	40,258.4 (38,787.9 to 41,936.5)	74,804.8 (72,260.1 to 77,868.5)	85.0 (75.5 to 95.2)	1,346.5 (806.7 to 1,980.1)	2,516.9 (1,525.5 to 3,697.1)	87.0 (76.9 to 98.3)
Tension-type headache	63,694.0 (61,199.7 to 66,067.9)	120,859.7 (117,362.9 to 124,405.3)	89.0 (79.7 to 97.6)	95.7 (46.7 to 166.2)	182.4 (88.8 to 320.3)	90.8 (80.7 to 100.2)
Medication overuse headache	2,201.4 (1,509.7 to 2,849.7)	6,173.9 (4,149.6 to 8,073.3)	178.7 (151.6 to 208.8)	343.0 (200.5 to 524.0)	966.8 (558.7 to 1,461.6)	181.6 (154.1 to 212.0)
Other neurological disorders	0.4 (0.3 to 0.5)	0.8 (0.7 to 1.0)	97.1 (68.7 to 128.5)	17.6 (12.1 to 24.4)	25.7 (17.6 to 33.4)	47.2 (20.6 to 66.4)
Mental and substance use disorders	-	-	-	6,541.1 (4,707.2 to 8,537.6)	12,690.5 (9,070.5 to 16,685.2)	94.0 (91.6 to 96.2)
Schizophrenia	1,442.9 (1,328.4 to 1,555.0)	2,813.5 (2,583.6 to 3,042.9)	94.1 (91.7 to 96.8)	919.1 (682.1 to 1,104.5)	1,802.9 (1,333.6 to 2,164.0)	96.1 (91.2 to 101.1)
Alcohol use disorders	3,761.7 (3,530.0 to 3,985.9)	6,932.3 (6,490.1 to 7,337.1)	83.5 (80.1 to 86.9)	370.7 (251.3 to 521.5)	685.6 (461.8 to 969.5)	84.8 (80.1 to 90.2)
Drug use disorders	-	-	-	421.9 (293.1 to 567.7)	829.7 (573.4 to 1,121.9)	96.5 (88.5 to 104.9)
Opioid use disorders	692.1 (506.1 to 872.9)	1,360.4 (972.3 to 1,747.5)	95.4 (89.9 to 101.1)	281.6 (181.6 to 400.3)	556.0 (355.7 to 795.3)	97.4 (88.2 to 106.3)
Cocaine use disorders	284.8 (276.6 to 294.6)	524.1 (510.6 to 538.1)	83.5 (75.9 to 90.7)	38.0 (24.7 to 53.7)	70.4 (46.1 to 99.7)	85.1 (67.7 to 104.1)
Amphetamine use disorders	221.7 (213.1 to 228.6)	462.0 (448.0 to 474.7)	107.3 (99.4 to 117.5)	28.3 (17.8 to 40.6)	59.1 (37.3 to 85.8)	109.2 (86.5 to 132.8)
Cannabis use disorders	247.1 (211.8 to 291.6)	473.3 (401.7 to 566.8)	90.7 (85.5 to 95.1)	7.1 (4.6 to 10.3)	13.6 (8.7 to 20.0)	91.7 (71.3 to 116.9)
Other drug use disorders	-	-	-	66.9 (45.4 to 90.0)	130.7 (88.6 to 177.7)	95.4 (77.8 to 113.7)
Depressive disorders	-	-	-	2,613.4 (1,698.2 to 3,748.4)	5,143.9 (3,325.0 to 7,427.5)	96.8 (92.3 to 101.2)
Major depressive disorder	10,351.8 (7,702.7 to 13,387.0)	20,355.2 (15,068.1 to 26,243.7)	95.8 (90.4 to 100.6)	2,094.1 (1,303.0 to 3,055.9)	4,139.6 (2,566.9 to 6,069.7)	97.7 (92.2 to 103.2)
Dysthymia	5,397.9 (4,564.3 to 6,268.6)	10,399.6 (8,760.1 to 12,100.8)	91.8 (88.9 to 94.9)	519.3 (338.8 to 760.2)	1,004.3 (653.1 to 1,474.9)	93.4 (89.0 to 97.8)
Bipolar disorder	2,097.8 (1,832.2 to 2,430.5)	4,044.6 (3,522.7 to 4,693.9)	92.0 (88.7 to 95.1)	420.3 (265.4 to 619.2)	814.8 (512.6 to 1,203.0)	93.8 (88.0 to 99.9)
Anxiety disorders	10,420.2 (7,147.2 to 13,653.7)	19,799.5 (13,169.5 to 26,668.5)	88.7 (81.2 to 96.2)	942.5 (541.5 to 1,421.4)	1,798.3 (1,001.7 to 2,756.2)	90.4 (81.9 to 98.6)
Eating disorders	-	-	-	14.6 (8.9 to 22.2)	25.8 (15.7 to 39.3)	76.1 (58.6 to 96.0)
Anorexia nervosa	21.6 (16.7 to 26.9)	43.6 (32.8 to 55.6)	101.1 (87.9 to 111.9)	4.5 (2.8 to 6.7)	9.1 (5.6 to 13.9)	103.3 (71.3 to 138.6)
Bulimia nervosa	49.5 (30.6 to 74.3)	81.2 (48.4 to 122.6)	62.9 (56.1 to 71.4)	10.1 (5.5 to 16.9)	16.7 (8.9 to 28.0)	64.1 (42.3 to 87.9)
Autistic spectrum disorders	-	-	-	251.0 (174.2 to 338.5)	484.8 (338.7 to 654.1)	93.1 (88.5 to 98.1)
Autism	660.0 (625.9 to 695.3)	1,270.2 (1,203.4 to 1,341.0)	91.6 (91.0 to 92.4)	158.8 (106.0 to 216.2)	307.1 (206.4 to 417.7)	93.3 (86.4 to 100.2)
Asperger syndrome	937.4 (868.9 to 1,007.7)	1,803.7 (1,668.9 to 1,939.1)	91.6 (91.1 to 92.0)	92.1 (64.3 to 127.4)	177.7 (123.4 to 245.7)	92.9 (87.4 to 98.7)
Attention-deficit/hyperactivity disorder	0.7 (0.4 to 1.2)	1.4 (0.7 to 2.3)	88.8 (79.7 to 95.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.6 (80.3 to 96.5)
Conduct disorder	-	-	-	-	-	-
Idiopathic intellectual disability	2,657.8 (2,010.4 to 3,351.4)	4,538.8 (3,562.1 to 5,685.2)	69.5 (53.4 to 92.8)	130.8 (84.4 to 188.0)	221.8 (146.4 to 318.0)	69.5 (52.8 to 93.1)
Other mental and substance use disorders	6,159.0 (5,095.0 to 7,344.0)	11,849.3 (9,801.7 to 14,124.8)	91.5 (91.5 to 91.6)	456.9 (299.6 to 653.7)	882.9 (579.3 to 1,262.7)	93.3 (88.5 to 97.6)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	2,873.0 (2,041.2 to 3,872.6)	6,347.8 (4,445.5 to 8,582.5)	120.8 (114.0 to 128.6)
Diabetes mellitus	16,760.0 (15,751.6 to 17,916.7)	45,982.3 (43,946.4 to 48,235.5)	173.5 (155.9 to 190.1)	1,237.6 (842.5 to 1,697.2)	3,423.1 (2,372.3 to 4,667.2)	176.8 (160.7 to 191.6)
Acute glomerulonephritis	0.9 (0.8 to 1.0)	1.5 (1.3 to 1.6)	59.4 (54.2 to 64.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	60.2 (54.8 to 65.3)
Chronic kidney disease	-	-	-	565.9 (376.3 to 782.6)	1,015.1 (667.3 to 1,411.2)	79.6 (69.7 to 87.9)
Chronic kidney disease due to diabetes mellitus	4,145.3 (2,542.7 to 7,199.3)	7,465.1 (5,042.3 to 12,130.6)	83.7 (42.6 to 112.3)	139.1 (92.5 to 195.7)	258.7 (167.6 to 364.1)	86.6 (61.4 to 109.6)
Chronic kidney disease due to hypertension	3,644.8 (2,338.3 to 6,071.4)	5,674.2 (3,946.8 to 9,091.8)	55.4 (38.9 to 76.6)	152.4 (101.7 to 214.4)	225.5 (146.1 to 324.0)	47.5 (30.9 to 67.2)
Chronic kidney disease due to glomerulonephritis	4,498.5 (2,665.6 to 8,204.8)	7,187.0 (4,724.8 to 12,498.9)	63.7 (31.4 to 88.5)	104.3 (70.3 to 145.7)	187.0 (124.5 to 262.8)	78.2 (60.0 to 104.6)
Chronic kidney disease due to other causes	4,571.2 (2,887.7 to 7,741.9)	8,709.2 (5,618.3 to 14,418.3)	92.5 (62.2 to 115.3)	170.1 (110.0 to 240.6)	343.8 (225.2 to 482.0)	102.5 (81.8 to 124.7)
Urinary diseases and male infertility	-	-	-	68.1 (44.9 to 95.6)	148.0 (94.3 to 216.5)	118.2 (94.4 to 137.4)
Interstitial nephritis and urinary tract infections	47.0 (45.7 to 48.2)	104.7 (102.0 to 107.3)	121.9 (114.9 to 130.3)	1.6 (1.0 to 2.3)	3.5 (2.2 to 5.3)	123.3 (93.9 to 160.0)
Urolithiasis	2,949.1 (2,254.2 to 3,942.9)	6,453.2 (4,602.3 to 9,258.1)	117.9 (97.5 to 139.3)	27.7 (17.7 to 40.5)	60.6 (37.4 to 92.4)	117.2 (100.9 to 140.4)
Benign prostatic hyperplasia	769.2 (743.0 to 793.9)	1,374.4 (1,332.5 to 1,414.5)	77.8 (70.7 to 86.5)	28.8 (18.7 to 41.5)	51.5 (33.1 to 73.0)	78.7 (68.1 to 90.8)
Male infertility due to other causes	-	-	-	-	-	-
Other urinary diseases	-	-	-	10.1 (6.1 to 15.6)	32.4 (16.2 to 51.8)	244.7 (122.3 to 307.9)
Gynecological diseases	-	-	-	755.8 (484.5 to 1,160.3)	1,338.6 (843.4 to 2,061.9)	76.7 (69.0 to 84.8)
Uterine fibroids	26,301.4 (24,759.4 to 27,736.9)	49,576.7 (46,416.6 to 52,418.4)	87.7 (86.5 to 88.8)	290.0 (164.4 to 494.2)	481.4 (262.7 to 853.6)	65.4 (55.4 to 73.6)
Polycystic ovarian syndrome	10,258.6 (10,058.3 to 10,469.3)	19,473.3 (19,063.2 to 19,914.5)	89.0 (83.7 to 95.0)	94.9 (44.7 to 175.1)	181.7 (85.3 to 331.6)	91.4 (85.6 to 97.5)
Female infertility due to other causes	1,188.3 (964.3 to 1,425.5)	2,052.4 (1,642.7 to 2,495.6)	71.7 (47.6 to 103.8)	6.0 (2.3 to 13.1)	10.4 (4.0 to 23.2)	73.5 (49.4 to 105.6)
Endometriosis	1,464.0 (1,410.9 to 1,522.3)	2,703.7 (2,605.1 to 2,811.7)	83.9 (73.4 to 94.4)	133.2 (90.1 to 180.4)	247.4 (167.3 to 338.3)	85.7 (74.0 to 97.2)
Genital prolapse	22,721.8 (22,072.8 to 23,521.0)	43,611.3 (42,398.3 to 44,931.9)	91.4 (82.7 to 98.5)	72.2 (35.3 to 135.1)	139.1 (67.8 to 259.3)	92.9 (84.0 to 100.5)
Premenstrual syndrome	13,488.5 (11,751.3 to 15,618.4)	26,079.5 (22,999.0 to 30,016.6)	88.8 (57.6 to 139.6)	111.3 (67.0 to 167.1)	215.9 (131.4 to 326.3)	90.7 (58.3 to 142.6)
Other gynecological diseases	1,569.2 (1,387.6 to 1,764.3)	2,392.4 (2,267.5 to 2,604.2)	52.5 (33.5 to 73.1)	48.2 (32.0 to 68.4)	62.7 (42.1 to 90.0)	30.2 (8.6 to 61.5)
Hemoglobinopathies and hemolytic anemias	-	-	-	170.8 (114.1 to 247.7)	308.9 (205.0 to 445.7)	80.7 (72.3 to 89.4)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (45-49 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Thalassemias	3.7 (3.0 to 4.3)	8.6 (7.4 to 9.9)	131.1 (106.6 to 167.1)	0.4 (0.2 to 0.5)	0.8 (0.6 to 1.2)	130.9 (88.5 to 186.0)
Thalassemia trait	6,269.3 (5,710.8 to 7,050.2)	12,776.1 (11,637.8 to 14,356.6)	102.9 (99.8 to 106.0)	95.1 (63.8 to 136.8)	208.5 (138.4 to 300.6)	119.4 (107.0 to 129.9)
Sickle cell disorders	18.5 (16.9 to 20.0)	37.8 (34.2 to 41.1)	102.6 (84.4 to 125.6)	2.8 (2.0 to 3.8)	5.8 (4.1 to 7.9)	106.4 (83.8 to 131.5)
Sickle cell trait	6,573.4 (6,249.9 to 6,866.4)	12,371.8 (11,775.7 to 12,917.7)	87.3 (84.0 to 90.7)	25.6 (16.2 to 37.7)	46.6 (30.0 to 67.8)	81.2 (61.7 to 114.3)
G6PD deficiency	9,111.5 (8,874.0 to 9,337.9)	17,861.5 (17,415.9 to 18,283.8)	95.2 (88.8 to 102.0)	0.8 (0.6 to 1.2)	1.8 (1.2 to 2.5)	113.1 (97.1 to 130.3)
G6PD trait	35,460.1 (35,256.8 to 35,646.1)	69,839.1 (69,421.1 to 70,234.4)	96.1 (94.6 to 97.8)	1.0 (0.5 to 1.6)	1.7 (1.0 to 3.0)	81.5 (9.7 to 196.6)
Other hemoglobinopathies and hemolytic anemias	2,189.9 (2,143.6 to 2,242.3)	2,650.7 (2,548.4 to 2,753.1)	20.5 (15.6 to 25.3)	45.1 (29.8 to 65.9)	43.6 (28.5 to 65.4)	-3.4 (-15.8 to 8.9)
Endocrine, metabolic, blood, and immune disorders	2,594.0 (2,489.1 to 2,700.2)	3,940.3 (3,829.9 to 4,059.3)	51.2 (44.5 to 58.6)	74.7 (50.9 to 104.4)	114.2 (77.6 to 157.1)	52.7 (40.0 to 66.1)
Musculoskeletal disorders	-	-	-	(5,303.9 to 9,896.2)	(10,328.5 to 19,402.3)	(91.9 to 100.1)
Rheumatoid arthritis	679.6 (667.9 to 691.7)	1,187.1 (1,168.2 to 1,204.6)	73.9 (70.3 to 77.7)	162.3 (116.0 to 214.1)	284.9 (202.9 to 377.3)	75.5 (67.9 to 83.8)
Osteoarthritis	10,263.8 (10,125.6 to 10,400.1)	19,109.7 (18,869.2 to 19,336.9)	85.3 (82.3 to 88.8)	571.3 (400.5 to 779.8)	1,102.1 (773.6 to 1,495.0)	92.9 (88.7 to 97.4)
Low back and neck pain	-	-	-	(5,490.9 to 9,382.6)	(10,657.6 to 14,305.0)	(94.0 to 99.9)
Low back pain	32,103.6 (31,351.0 to 32,790.7)	61,721.5 (60,030.7 to 63,481.5)	91.3 (84.1 to 99.3)	3,585.7 (2,447.5 to 4,935.0)	6,927.1 (4,684.6 to 9,569.3)	93.0 (85.9 to 101.1)
Neck pain	19,363.4 (18,795.5 to 19,969.2)	37,743.3 (36,553.6 to 39,005.7)	94.1 (85.3 to 103.3)	1,905.2 (1,323.8 to 2,617.0)	3,730.5 (2,596.9 to 5,167.1)	95.8 (86.4 to 105.5)
Gout	287.2 (280.4 to 293.7)	550.8 (539.0 to 561.6)	91.0 (85.6 to 96.2)	9.5 (6.5 to 12.9)	18.4 (12.7 to 25.2)	93.2 (75.4 to 114.1)
Other musculoskeletal disorders	12,878.3 (9,658.1 to 16,538.8)	26,800.9 (19,907.2 to 34,242.2)	106.9 (100.1 to 115.4)	1,192.9 (741.7 to 1,771.1)	2,491.0 (1,548.5 to 3,691.7)	108.7 (101.5 to 117.0)
Other non-communicable diseases	-	-	-	(4,162.8 to 11,632.0)	(7,512.6 to 11,066.0)	(80.4 to 84.3)
Congenital anomalies	-	-	-	(201.4 to 258.2)	(454.9 to 588.8)	(125.9 to 143.1)
Neural tube defects	31.0 (30.2 to 32.1)	73.6 (71.8 to 75.5)	136.0 (126.5 to 144.5)	9.3 (6.5 to 12.2)	22.8 (16.1 to 29.6)	145.4 (118.5 to 172.3)
Congenital heart anomalies	827.6 (797.6 to 859.6)	2,161.8 (2,100.7 to 2,240.3)	159.7 (149.4 to 173.9)	28.3 (12.0 to 49.0)	76.6 (32.8 to 128.5)	171.1 (156.8 to 187.1)
Orofacial clefts	121.0 (115.3 to 127.0)	347.3 (337.8 to 357.1)	185.0 (170.2 to 203.3)	1.4 (0.9 to 2.0)	3.7 (2.4 to 5.3)	169.8 (136.4 to 210.0)
Down syndrome	184.7 (171.3 to 201.2)	478.0 (445.8 to 524.1)	157.8 (144.6 to 169.9)	24.2 (17.6 to 32.7)	62.6 (45.0 to 83.8)	158.8 (142.3 to 175.5)
Turner syndrome	7.6 (7.2 to 8.0)	17.2 (16.4 to 18.1)	123.5 (111.3 to 138.7)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	124.3 (102.4 to 151.3)
Klinefelter syndrome	6.6 (6.3 to 6.9)	13.5 (12.9 to 14.1)	102.6 (90.6 to 116.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	103.7 (79.9 to 129.4)
Chromosomal unbalanced rearrangements	268.7 (248.8 to 294.3)	658.8 (610.0 to 721.5)	144.1 (133.2 to 156.2)	34.9 (24.9 to 46.9)	85.6 (61.5 to 114.9)	145.2 (131.1 to 161.3)
Other congenital anomalies	1,017.4 (868.2 to 1,147.7)	1,711.6 (1,439.8 to 1,952.9)	67.7 (58.9 to 76.0)	103.1 (70.0 to 140.2)	203.2 (137.6 to 272.5)	96.8 (76.6 to 124.5)
Skin and subcutaneous diseases	-	-	-	(1,167.5 to 1,784.7)	(1,445.4 to 3,424.2)	(91.5 to 96.3)
Dermatitis	14,231.1 (10,961.8 to 17,659.5)	26,758.6 (20,710.0 to 33,223.5)	87.2 (85.8 to 88.9)	342.6 (212.8 to 498.4)	645.1 (400.6 to 934.8)	88.3 (84.7 to 91.8)
Psoriasis	2,697.8 (2,218.1 to 3,263.8)	4,937.5 (4,031.6 to 6,020.2)	82.1 (79.4 to 85.2)	217.6 (143.4 to 311.1)	400.3 (263.9 to 578.9)	83.8 (77.1 to 91.7)
Cellulitis	75.0 (54.1 to 108.0)	107.3 (77.2 to 153.8)	42.4 (34.8 to 51.1)	5.3 (3.0 to 8.5)	7.6 (4.3 to 12.1)	42.9 (20.7 to 71.0)
Pyoderma	136.9 (94.6 to 206.7)	223.2 (147.9 to 349.1)	62.2 (38.5 to 83.2)	0.8 (0.3 to 1.7)	1.2 (0.4 to 2.8)	63.3 (34.7 to 88.0)
Scabies	1,860.8 (1,663.8 to 2,082.6)	3,554.4 (3,253.1 to 3,887.3)	90.1 (64.8 to 119.5)	47.3 (26.6 to 76.3)	90.9 (51.2 to 145.1)	92.4 (66.7 to 122.6)
Fungal skin diseases	23,722.2 (20,395.9 to 27,346.7)	46,945.1 (40,348.3 to 54,050.0)	97.0 (95.5 to 98.7)	132.9 (54.1 to 272.6)	263.8 (107.5 to 541.5)	98.5 (96.6 to 100.5)
Viral skin diseases	1,674.4 (1,113.7 to 2,394.5)	3,116.5 (2,061.7 to 4,475.2)	85.4 (78.8 to 89.9)	50.8 (27.1 to 87.2)	94.7 (50.6 to 162.9)	86.8 (78.6 to 93.3)
Acne vulgaris	3,917.5 (3,582.9 to 4,309.4)	7,331.3 (6,588.5 to 8,131.2)	87.5 (62.5 to 109.6)	41.7 (20.2 to 76.8)	78.2 (37.2 to 145.4)	88.8 (63.2 to 110.8)
Alopecia areata	373.9 (364.2 to 384.0)	702.5 (684.7 to 721.4)	87.1 (80.1 to 93.9)	12.5 (7.9 to 18.5)	23.5 (15.0 to 35.1)	88.6 (76.8 to 101.3)
Pruritus	46.9 (44.8 to 50.0)	89.8 (85.8 to 94.5)	91.0 (76.5 to 102.2)	0.5 (0.2 to 0.9)	1.0 (0.5 to 1.8)	92.1 (65.6 to 118.9)
Urticaria	3,088.6 (2,846.7 to 3,508.9)	6,260.5 (5,597.3 to 6,902.6)	102.9 (71.7 to 131.9)	182.4 (118.1 to 257.1)	371.7 (240.4 to 534.3)	104.4 (74.0 to 133.7)
Decubitus ulcer	42.4 (40.7 to 44.3)	71.5 (68.2 to 75.0)	67.8 (58.7 to 75.8)	6.7 (4.5 to 9.2)	11.3 (7.6 to 15.7)	67.2 (44.4 to 101.0)
Other skin and subcutaneous diseases	21,536.6 (4,449.5 to 47,911.3)	41,707.6 (8,632.8 to 92,368.5)	92.8 (90.2 to 95.1)	126.6 (21.0 to 337.6)	245.9 (41.0 to 658.4)	94.3 (91.2 to 97.3)
Sense organ diseases	-	-	-	(2,107.4 to 3,150.2)	(3,589.3 to 5,430.0)	(70.1 to 76.4)
Glaucoma	396.3 (307.4 to 495.5)	724.2 (548.6 to 911.4)	81.9 (55.9 to 113.1)	28.1 (17.6 to 41.8)	49.9 (31.3 to 74.3)	77.7 (55.5 to 101.4)
Cataract	1,017.3 (753.0 to 1,327.2)	1,521.7 (1,137.4 to 1,981.2)	48.6 (25.1 to 91.2)	65.5 (40.6 to 98.7)	99.1 (60.0 to 149.6)	50.7 (30.1 to 82.9)
Macular degeneration	679.4 (525.4 to 852.9)	1,271.8 (989.2 to 1,589.0)	86.4 (76.5 to 97.3)	30.1 (18.8 to 44.7)	56.8 (35.8 to 84.3)	88.6 (76.3 to 103.6)
Uncorrected refractive error	31,309.4 (30,040.4 to 32,567.2)	57,352.6 (55,281.3 to 59,433.2)	82.3 (74.8 to 90.5)	496.2 (302.9 to 791.3)	863.5 (514.7 to 1,407.1)	73.6 (66.9 to 81.3)
Age-related and other hearing loss	51,931.8 (43,173.5 to 61,084.9)	90,169.7 (74,171.2 to 107,714.2)	73.1 (65.9 to 80.6)	1,294.4 (791.6 to 2,003.9)	2,184.5 (1,296.6 to 3,376.9)	68.5 (58.5 to 77.6)
Other vision loss	1,180.1 (925.9 to 1,478.5)	1,744.0 (1,330.9 to 2,207.7)	47.1 (35.4 to 59.9)	83.3 (52.6 to 122.3)	124.2 (77.5 to 187.1)	49.1 (37.7 to 61.4)
Other sense organ diseases	4,198.2 (4,101.9 to 4,302.3)	8,041.6 (7,877.3 to 8,238.2)	90.7 (84.5 to 97.7)	109.8 (68.4 to 162.1)	211.2 (131.7 to 312.8)	92.2 (84.4 to 100.8)
Oral disorders	-	-	-	(686.6 to 1,080.1)	(1,233.4 to 1,965.0)	(79.4 to 83.6)
Deciduous caries	-	-	-	-	-	-
Permanent caries	94,360.4 (93,165.5 to 95,638.4)	182,501.8 (180,401.1 to 184,675.3)	92.5 (89.0 to 96.2)	81.9 (38.0 to 156.5)	164.6 (76.0 to 316.1)	100.8 (96.2 to 105.5)
Periodontal diseases	31,866.8 (31,275.3 to 32,493.9)	58,951.6 (57,676.2 to 60,294.5)	84.1 (79.0 to 90.1)	209.5 (84.1 to 432.3)	388.6 (155.5 to 795.5)	85.5 (80.3 to 91.3)
Edentulism and severe tooth loss	8,325.7 (8,080.5 to 8,584.1)	13,144.2 (12,730.4 to 13,522.0)	57.2 (50.6 to 63.2)	235.9 (157.1 to 331.4)	373.2 (249.2 to 518.2)	58.3 (51.2 to 65.6)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (45-49 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Other oral disorders	5,472.8 (5,349.3 to 5,594.6)	10,512.5 (10,293.6 to 10,742.6)	91.2 (85.7 to 97.1)	159.3 (100.5 to 235.5)	307.0 (194.2 to 453.5)	92.7 (86.4 to 99.2)
Injuries	-	-	-	2,645.7 (1,892.2 to 3,564.4)	3,002.8 (2,182.8 to 3,988.7)	14.5 (-3.0 to 28.8)
Transport injuries	-	-	-	793.9 (588.3 to 1,027.7)	986.0 (719.5 to 1,303.8)	23.8 (14.5 to 34.5)
Road injuries	-	-	-	660.9 (491.3 to 854.3)	822.3 (602.2 to 1,086.7)	24.0 (14.4 to 35.4)
Pedestrian road injuries	-	-	-	138.7 (102.7 to 179.4)	193.0 (140.8 to 255.7)	38.9 (27.4 to 51.9)
Cyclist road injuries	-	-	-	58.3 (43.5 to 76.1)	69.6 (50.4 to 92.3)	19.0 (10.6 to 28.4)
Motorcyclist road injuries	-	-	-	159.7 (117.9 to 207.4)	187.0 (134.7 to 249.4)	16.7 (6.5 to 28.9)
Motor vehicle road injuries	-	-	-	297.2 (221.7 to 382.2)	365.8 (267.6 to 480.5)	22.8 (13.2 to 34.1)
Other road injuries	-	-	-	7.0 (5.2 to 8.9)	7.0 (5.2 to 9.3)	0.9 (-6.0 to 9.1)
Other transport injuries	-	-	-	133.0 (97.8 to 173.5)	163.6 (118.3 to 217.9)	22.8 (15.8 to 30.4)
Unintentional injuries	-	-	-	1,125.5 (842.7 to 1,469.8)	1,553.4 (1,126.0 to 2,085.5)	37.8 (30.1 to 45.5)
Falls	-	-	-	562.7 (420.8 to 735.5)	828.5 (597.1 to 1,114.6)	46.9 (37.0 to 57.4)
Drowning	-	-	-	27.4 (20.1 to 35.8)	32.9 (24.1 to 42.5)	19.9 (11.5 to 29.6)
Fire, heat, and hot substances	-	-	-	98.7 (74.9 to 126.8)	103.6 (75.5 to 136.5)	4.9 (-4.1 to 12.5)
Poisonings	-	-	-	5.3 (3.7 to 7.2)	6.8 (4.9 to 9.0)	27.5 (18.8 to 36.1)
Exposure to mechanical forces	-	-	-	253.6 (185.8 to 337.7)	318.1 (228.3 to 437.2)	25.0 (18.1 to 32.3)
Unintentional firearm injuries	-	-	-	10.9 (8.1 to 14.2)	13.9 (10.0 to 18.8)	27.0 (18.1 to 37.0)
Unintentional suffocation	-	-	-	2.4 (1.8 to 3.1)	4.4 (3.2 to 5.8)	82.6 (71.5 to 94.7)
Other exposure to mechanical forces	-	-	-	240.3 (175.9 to 320.4)	299.8 (215.0 to 413.0)	24.3 (17.7 to 31.7)
Adverse effects of medical treatment	-	-	-	8.0 (5.1 to 11.7)	14.2 (8.9 to 20.9)	78.3 (71.3 to 85.2)
Animal contact	-	-	-	28.4 (20.9 to 37.5)	31.9 (23.2 to 42.4)	12.1 (5.6 to 18.9)
Venomous animal contact	-	-	-	11.7 (8.4 to 15.8)	13.0 (9.3 to 17.0)	10.5 (1.5 to 20.1)
Non-venomous animal contact	-	-	-	16.7 (12.3 to 22.2)	18.9 (13.8 to 25.8)	13.3 (6.5 to 20.4)
Foreign body	-	-	-	13.8 (10.4 to 17.5)	20.3 (14.9 to 26.4)	47.4 (38.5 to 57.2)
Pulmonary aspiration and foreign body in airway	-	-	-	2.7 (2.1 to 3.5)	3.2 (2.4 to 4.2)	17.7 (6.9 to 31.7)
Foreign body in eyes	-	-	-	2.9 (1.9 to 4.0)	4.6 (3.0 to 6.6)	61.3 (50.9 to 70.7)
Foreign body in other body part	-	-	-	8.2 (6.1 to 10.5)	12.5 (9.2 to 16.4)	52.5 (43.6 to 61.9)
Other unintentional injuries	-	-	-	127.5 (94.4 to 168.1)	197.1 (141.9 to 264.0)	54.3 (48.6 to 61.0)
Self-harm and interpersonal violence	-	-	-	87.5 (65.6 to 112.6)	105.9 (77.1 to 140.2)	20.5 (11.5 to 31.8)
Self-harm	-	-	-	20.7 (15.2 to 27.0)	24.4 (17.3 to 32.6)	17.4 (10.1 to 26.2)
Interpersonal violence	-	-	-	66.8 (50.3 to 85.7)	81.6 (59.6 to 108.3)	21.4 (11.7 to 33.9)
Assault by firearm	-	-	-	11.4 (8.6 to 14.7)	16.3 (11.8 to 21.9)	42.8 (33.3 to 53.5)
Assault by sharp object	-	-	-	12.4 (9.2 to 16.3)	18.0 (12.8 to 24.6)	44.4 (33.6 to 57.2)
Assault by other means	-	-	-	43.0 (32.4 to 55.2)	47.3 (34.9 to 61.9)	9.3 (0.5 to 20.8)
Forces of nature, war, and legal intervention	-	-	-	638.9 (261.2 to 1,350.2)	357.5 (165.8 to 711.9)	-42.9 (-55.4 to -26.8)
Exposure to forces of nature	-	-	-	58.1 (26.2 to 123.8)	44.2 (21.4 to 89.8)	-21.8 (-46.8 to 6.7)
Collective violence and legal intervention	-	-	-	580.8 (230.7 to 1,257.9)	313.3 (144.7 to 652.3)	-45.1 (-58.0 to -26.9)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (50-54 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
All causes	-	-	-	32,106.9 (23,935.7 to 41,477.7)	55,992.3 (41,668.9 to 72,381.9)	74.4 (72.0 to 76.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	2,651.9 (1,848.9 to 3,611.6)	3,835.7 (2,741.9 to 5,200.5)	44.7 (36.5 to 54.9)
HIV/AIDS and tuberculosis	-	-	-	237.4 (165.0 to 311.6)	610.0 (432.3 to 799.0)	157.1 (136.4 to 186.3)
Tuberculosis	624.7 (580.0 to 671.4)	1,029.7 (956.1 to 1,102.5)	64.9 (59.1 to 70.5)	187.2 (129.0 to 250.9)	310.4 (211.7 to 415.0)	65.6 (56.6 to 75.3)
HIV/AIDS	-	-	-	50.2 (35.3 to 66.9)	299.6 (214.3 to 399.5)	494.7 (389.2 to 629.6)
HIV/AIDS resulting in mycobacterial infection	12.2 (7.4 to 17.9)	50.8 (33.8 to 68.5)	321.5 (229.3 to 423.2)	4.4 (2.3 to 7.1)	18.5 (10.8 to 27.8)	327.7 (206.3 to 475.5)
HIV/AIDS resulting in other diseases	292.2 (257.9 to 327.8)	1,896.5 (1,765.8 to 2,074.8)	547.1 (479.4 to 640.2)	45.8 (31.9 to 61.1)	281.2 (199.8 to 373.0)	514.8 (395.1 to 663.4)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	280.9 (197.1 to 387.8)	419.4 (292.8 to 586.5)	49.2 (42.6 to 56.1)
Diarrheal diseases	511.3 (494.6 to 528.5)	688.2 (654.7 to 719.7)	34.6 (26.7 to 42.2)	79.0 (54.1 to 107.9)	106.4 (72.9 to 145.8)	34.7 (23.8 to 46.3)
Intestinal infectious diseases	-	-	-	3.8 (2.3 to 5.5)	4.3 (2.8 to 6.4)	14.4 (-18.5 to 56.4)
Typhoid fever	22.4 (18.7 to 26.7)	25.9 (21.0 to 31.1)	16.7 (-11.6 to 46.5)	2.9 (1.7 to 4.4)	3.4 (2.1 to 5.2)	21.3 (-19.4 to 76.4)
Paratyphoid fever	13.3 (9.8 to 17.4)	13.8 (10.7 to 18.3)	4.4 (-31.6 to 63.0)	0.7 (0.4 to 1.1)	0.7 (0.4 to 1.2)	5.3 (-40.3 to 82.3)
Other intestinal infectious diseases	-	-	-	0.3 (0.1 to 0.5)	0.2 (0.1 to 0.3)	-39.8 (-55.6 to -18.5)
Lower respiratory infections	90.2 (88.7 to 91.9)	173.8 (170.3 to 177.1)	92.6 (87.3 to 98.3)	9.2 (6.3 to 12.8)	17.8 (11.9 to 25.0)	92.9 (77.9 to 108.8)
Upper respiratory infections	5,686.8 (5,547.3 to 5,802.4)	10,309.2 (10,053.0 to 10,540.7)	81.1 (75.7 to 87.6)	65.4 (36.8 to 107.9)	118.7 (66.5 to 196.2)	81.4 (74.5 to 89.2)
Otitis media	2,748.9 (2,650.2 to 2,851.3)	4,153.0 (4,017.5 to 4,313.8)	50.9 (45.0 to 57.6)	51.2 (30.8 to 82.2)	77.8 (46.3 to 124.3)	52.1 (44.5 to 60.1)
Meningitis	-	-	-	50.5 (33.0 to 72.5)	60.7 (41.0 to 87.3)	20.0 (11.4 to 31.6)
Pneumococcal meningitis	355.4 (207.4 to 537.2)	439.5 (256.7 to 682.5)	23.3 (13.8 to 32.9)	24.4 (17.1 to 32.5)	31.4 (22.1 to 42.8)	28.1 (13.0 to 47.9)
H influenzae type B meningitis	132.0 (30.0 to 270.1)	129.9 (30.0 to 277.8)	-2.3 (-18.9 to 9.4)	8.3 (5.4 to 12.3)	9.2 (5.9 to 13.5)	10.6 (-0.0 to 25.6)
Meningococcal meningitis	67.8 (15.0 to 156.9)	68.5 (16.3 to 156.7)	0.8 (-12.7 to 12.6)	6.5 (3.3 to 11.0)	7.0 (3.7 to 12.0)	9.1 (-5.3 to 27.0)
Other meningitis	149.6 (38.5 to 308.6)	158.2 (44.4 to 341.2)	5.2 (-13.2 to 20.9)	11.3 (6.7 to 17.7)	13.0 (7.8 to 20.2)	14.9 (1.9 to 30.7)
Encephalitis	98.7 (40.2 to 221.5)	129.8 (55.4 to 310.8)	32.3 (5.5 to 45.0)	11.1 (7.7 to 15.0)	16.2 (11.0 to 21.9)	45.3 (25.6 to 70.4)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-0.8 (-72.4 to 247.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.2 (-72.6 to 247.8)
Whooping cough	2.3 (1.8 to 2.9)	2.2 (1.7 to 2.8)	-3.5 (-4.6 to -2.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-3.7 (-4.8 to -2.5)
Tetanus	44.0 (31.4 to 66.4)	6.9 (4.1 to 10.7)	-84.6 (-91.5 to -71.9)	1.3 (0.8 to 2.0)	0.4 (0.2 to 0.5)	-71.6 (-82.5 to -53.6)
Measles	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.1)	-61.7 (-64.8 to -58.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.8 (-64.9 to -58.7)
Varicella and herpes zoster	172.4 (164.5 to 182.3)	315.5 (299.0 to 332.1)	82.7 (71.4 to 96.4)	9.2 (5.7 to 13.9)	17.0 (10.6 to 25.7)	84.7 (68.7 to 103.0)
Neglected tropical diseases and malaria	-	-	-	860.2 (544.5 to 1,274.5)	1,067.0 (620.0 to 1,678.9)	23.2 (4.7 to 45.5)
Malaria	6,997.3 (6,812.5 to 7,187.9)	9,631.5 (9,362.8 to 9,913.8)	37.6 (33.2 to 42.4)	39.1 (25.7 to 56.8)	50.4 (32.8 to 73.4)	29.0 (18.1 to 40.9)
Chagas disease	472.2 (460.2 to 484.2)	646.5 (625.5 to 672.4)	36.8 (31.3 to 44.4)	6.0 (3.9 to 8.6)	8.2 (5.3 to 11.8)	36.5 (26.0 to 49.3)
Leishmaniasis	-	-	-	0.8 (0.4 to 1.5)	2.4 (1.2 to 4.4)	189.1 (158.9 to 223.8)
Visceral leishmaniasis	1.3 (1.0 to 1.7)	2.3 (1.7 to 3.1)	78.0 (33.7 to 138.6)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	78.5 (33.3 to 140.6)
Cutaneous and mucocutaneous leishmaniasis	68.9 (59.2 to 80.6)	208.7 (177.2 to 245.2)	202.8 (170.3 to 239.3)	0.7 (0.3 to 1.4)	2.2 (1.0 to 4.2)	204.7 (170.1 to 243.6)
African trypanosomiasis	3.2 (1.4 to 6.4)	0.9 (0.5 to 1.5)	-71.9 (-76.1 to -66.7)	0.8 (0.3 to 1.7)	0.2 (0.1 to 0.5)	-72.7 (-81.3 to -58.2)
Schistosomiasis	8,292.8 (7,408.9 to 9,171.9)	10,541.5 (9,077.9 to 12,272.2)	25.5 (17.3 to 45.4)	67.9 (34.0 to 126.3)	86.8 (42.7 to 168.2)	26.1 (18.6 to 47.2)
Cysticercosis	81.6 (69.5 to 95.0)	66.1 (53.4 to 78.1)	-19.3 (-36.1 to 4.6)	22.6 (15.4 to 30.4)	19.9 (13.2 to 27.2)	-11.7 (-34.2 to 18.3)
Cystic echinococcosis	65.1 (61.6 to 68.4)	62.0 (59.2 to 65.6)	-4.5 (-7.5 to -2.7)	6.0 (4.1 to 8.5)	5.8 (3.9 to 8.0)	-4.4 (-15.8 to 10.0)
Lymphatic filariasis	3,973.7 (3,359.0 to 4,752.8)	3,167.8 (2,517.6 to 4,026.5)	-20.5 (-29.4 to -10.5)	168.9 (85.9 to 286.5)	195.3 (106.3 to 322.6)	16.7 (-8.0 to 41.2)
Onchocerciasis	1,166.2 (836.9 to 1,698.5)	759.9 (527.4 to 1,143.9)	-35.3 (-44.1 to -22.6)	90.3 (49.4 to 146.7)	63.3 (30.9 to 108.5)	-31.0 (-44.0 to -13.2)
Trachoma	278.8 (188.3 to 380.7)	171.7 (114.7 to 243.2)	-38.6 (-51.6 to -23.8)	16.9 (10.0 to 26.1)	10.4 (5.8 to 16.9)	-38.3 (-50.9 to -23.1)
Dengue	14.7 (5.4 to 32.9)	145.6 (53.5 to 326.7)	894.4 (889.3 to 899.0)	2.3 (0.7 to 5.7)	23.0 (7.5 to 59.1)	893.2 (652.4 to 1,208.5)
Yellow fever	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.1)	-61.8 (-71.6 to -41.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.9 (-71.8 to -41.4)
Rabies	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-24.5 (-42.1 to 1.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.6 (-42.3 to 1.3)
Intestinal nematode infections	-	-	-	203.5 (117.0 to 325.6)	156.7 (90.3 to 252.7)	-22.7 (-30.3 to -14.8)
Ascariasis	40,779.1 (33,875.9 to 49,627.3)	40,393.9 (33,985.5 to 48,940.2)	-1.1 (-23.4 to 28.8)	94.6 (52.1 to 156.4)	41.3 (22.7 to 70.7)	-56.4 (-63.4 to -47.6)
Trichuriasis	20,183.4 (16,169.8 to 25,804.4)	22,899.5 (20,445.5 to 25,756.9)	14.8 (-14.7 to 45.5)	27.2 (15.4 to 46.0)	27.2 (14.5 to 46.4)	-3.1 (-23.1 to 29.0)
Hookworm disease	19,552.9 (16,201.2 to 23,886.5)	23,893.5 (21,596.7 to 26,643.2)	22.9 (-1.2 to 50.1)	81.2 (48.4 to 129.3)	88.2 (51.9 to 138.7)	8.4 (-2.8 to 21.3)
Food-borne trematodiasis	4,206.6 (3,169.1 to 5,188.2)	8,516.4 (6,264.8 to 10,600.4)	102.4 (86.6 to 119.0)	207.6 (53.9 to 455.6)	421.2 (107.9 to 917.7)	102.0 (83.1 to 125.6)
Other neglected tropical diseases	891.6 (850.9 to 935.2)	1,012.0 (950.4 to 1,064.3)	13.5 (4.3 to 21.9)	27.4 (15.7 to 47.8)	23.5 (12.8 to 41.9)	-15.3 (-30.4 to 7.7)
Maternal disorders	-	-	-	33.4 (21.8 to 47.9)	44.8 (29.7 to 63.9)	33.8 (13.0 to 60.4)
Maternal hemorrhage	-	-	-	-	-	-
Maternal sepsis and other maternal infections	-	-	-	-	-	-
Maternal hypertensive disorders	-	-	-	-	-	-
Obstructed labor	105.6 (84.9 to 126.0)	141.2 (116.8 to 165.3)	33.8 (21.2 to 46.3)	33.4 (21.8 to 47.9)	44.8 (29.7 to 63.9)	33.8 (13.0 to 60.4)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (50-54 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Complications of abortion	-	-	-	-	-	-
Other maternal disorders	-	-	-	-	-	-
Neonatal disorders	-	-	-	164.4 (122.7 to 209.0)	537.9 (401.3 to 683.5)	227.6 (195.5 to 262.2)
Preterm birth complications	796.6 (695.9 to 921.7)	2,740.1 (2,388.8 to 3,167.1)	243.7 (213.7 to 280.7)	80.7 (59.2 to 102.7)	311.7 (232.0 to 395.8)	285.8 (258.0 to 318.2)
Neonatal encephalopathy due to birth asphyxia and trauma	714.3 (269.3 to 1,318.0)	898.3 (428.2 to 1,535.9)	26.1 (-3.4 to 98.0)	37.1 (24.8 to 53.5)	76.0 (55.4 to 101.0)	106.8 (68.3 to 150.8)
Neonatal sepsis and other neonatal infections	-	-	-	-	-	-
Hemolytic disease and other neonatal jaundice	59.2 (50.5 to 71.1)	181.6 (145.9 to 236.8)	201.0 (137.5 to 331.4)	21.8 (15.4 to 29.1)	61.4 (42.8 to 83.2)	176.6 (122.2 to 298.3)
Other neonatal disorders	-	-	-	24.7 (16.9 to 34.7)	88.8 (60.2 to 120.1)	261.7 (187.9 to 340.4)
Nutritional deficiencies	-	-	-	999.7 (665.1 to 1,450.5)	1,047.5 (690.4 to 1,544.5)	4.5 (1.3 to 8.6)
Protein-energy malnutrition	14.8 (8.0 to 24.0)	19.0 (10.4 to 31.0)	28.8 (4.6 to 61.9)	1.8 (0.8 to 3.3)	2.3 (1.0 to 4.2)	29.3 (-4.0 to 77.6)
Iodine deficiency	5,825.6 (5,450.9 to 6,219.2)	6,259.0 (5,869.1 to 6,631.2)	7.3 (-0.9 to 17.0)	102.7 (63.7 to 158.0)	110.6 (68.8 to 175.9)	7.5 (-1.1 to 18.3)
Vitamin A deficiency	83.6 (39.0 to 118.8)	87.0 (52.1 to 122.5)	3.7 (-13.1 to 38.0)	5.0 (2.3 to 8.1)	5.0 (2.6 to 8.1)	-0.9 (-27.1 to 44.5)
Iron-deficiency anemia	36,342.6 (36,153.4 to 36,522.9)	44,943.6 (44,724.1 to 45,167.0)	23.7 (22.9 to 24.5)	890.1 (595.0 to 1,285.0)	929.6 (616.2 to 1,358.2)	4.2 (0.7 to 8.6)
Other nutritional deficiencies	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.3)	-9.2 (-47.9 to 46.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	76.0 (47.6 to 122.8)	109.1 (66.0 to 184.7)	43.0 (34.1 to 52.7)
Sexually transmitted diseases excluding HIV	-	-	-	35.8 (20.0 to 65.9)	58.5 (31.9 to 109.2)	62.9 (52.9 to 71.0)
Syphilis	29.9 (28.4 to 31.3)	30.9 (29.7 to 32.4)	3.4 (-2.5 to 11.1)	5.5 (3.6 to 7.9)	5.8 (3.7 to 8.4)	5.3 (-15.8 to 32.0)
Chlamydial infection	3,150.7 (3,027.2 to 3,264.6)	5,459.0 (5,253.4 to 5,666.5)	73.2 (64.2 to 83.8)	12.2 (7.6 to 19.3)	22.1 (13.8 to 34.8)	80.6 (66.6 to 96.1)
Gonococcal infection	100.2 (88.0 to 114.8)	177.2 (162.7 to 197.4)	77.0 (52.9 to 100.8)	0.8 (0.5 to 1.3)	1.5 (0.9 to 2.2)	74.9 (39.5 to 124.9)
Trichomoniasis	833.4 (774.5 to 894.9)	1,429.3 (1,308.8 to 1,561.4)	70.6 (54.6 to 92.8)	1.3 (0.5 to 2.9)	2.3 (0.9 to 5.0)	71.1 (49.9 to 99.9)
Genital herpes	62,446.9 (61,608.2 to 63,245.9)	105,403.3 (103,934.9 to 107,122.7)	68.7 (65.7 to 72.3)	15.4 (4.5 to 37.7)	26.0 (7.5 to 63.6)	68.8 (64.3 to 73.9)
Other sexually transmitted diseases	3.8 (3.4 to 4.2)	6.0 (5.4 to 6.6)	57.4 (38.5 to 80.7)	0.5 (0.4 to 0.7)	0.8 (0.6 to 1.2)	57.7 (37.3 to 81.2)
Hepatitis	-	-	-	16.4 (10.6 to 23.5)	23.9 (15.3 to 34.5)	45.7 (36.8 to 54.8)
Hepatitis A	82.9 (75.4 to 89.7)	177.0 (169.2 to 183.4)	113.8 (104.5 to 124.3)	3.0 (1.9 to 4.4)	6.4 (4.1 to 9.2)	113.8 (90.9 to 137.2)
Hepatitis B	16,936.7 (16,555.4 to 17,463.3)	20,659.0 (20,116.7 to 21,105.8)	22.0 (18.4 to 25.6)	11.2 (7.2 to 16.1)	14.0 (8.9 to 20.3)	25.0 (15.2 to 35.3)
Hepatitis C	9,333.3 (9,190.9 to 9,495.9)	12,579.9 (12,376.8 to 12,814.2)	34.8 (31.8 to 37.9)	1.0 (0.6 to 1.5)	1.4 (0.9 to 2.1)	37.4 (13.3 to 67.5)
Hepatitis E	45.8 (41.4 to 49.6)	77.9 (71.4 to 85.7)	69.0 (50.0 to 96.4)	1.2 (0.7 to 1.7)	2.1 (1.3 to 3.1)	77.3 (37.5 to 135.4)
Leprosy	40.6 (36.5 to 44.5)	67.7 (61.7 to 74.2)	66.1 (52.9 to 83.3)	2.3 (1.5 to 3.3)	4.2 (2.7 to 6.1)	79.9 (44.9 to 126.0)
Other infectious diseases	1,040.4 (1,000.6 to 1,076.9)	1,220.3 (1,182.3 to 1,259.8)	17.3 (12.8 to 22.3)	21.4 (13.8 to 32.2)	22.5 (13.5 to 36.1)	4.3 (-10.4 to 23.4)
Non-communicable diseases	-	-	-	26,689.1 (19,809.7 to 34,498.5)	48,990.7 (36,297.9 to 63,447.5)	83.5 (81.8 to 85.4)
Neoplasms	-	-	-	309.7 (226.5 to 407.4)	559.7 (401.6 to 733.7)	80.3 (68.9 to 93.8)
Esophageal cancer	51.4 (40.8 to 63.0)	71.2 (55.4 to 90.5)	37.8 (6.3 to 77.7)	8.1 (5.5 to 11.1)	10.9 (7.4 to 15.3)	34.4 (4.2 to 72.5)
Stomach cancer	151.4 (138.4 to 168.1)	185.8 (163.7 to 212.1)	22.3 (6.4 to 41.1)	18.7 (13.3 to 24.6)	22.0 (15.5 to 29.7)	17.3 (0.5 to 38.4)
Liver cancer	-	-	-	11.4 (7.8 to 16.0)	19.4 (13.3 to 26.8)	70.0 (34.0 to 114.5)
Liver cancer due to hepatitis B	29.1 (22.3 to 38.1)	54.6 (43.1 to 69.5)	88.9 (34.2 to 170.1)	4.8 (3.3 to 6.9)	8.0 (5.4 to 11.1)	66.4 (24.7 to 121.0)
Liver cancer due to hepatitis C	10.3 (8.3 to 12.6)	47.9 (38.6 to 60.3)	366.7 (249.0 to 518.8)	1.7 (1.2 to 2.4)	7.1 (4.8 to 9.8)	307.8 (215.5 to 421.0)
Liver cancer due to alcohol use	16.4 (13.2 to 20.3)	16.3 (13.2 to 20.5)	-1.1 (-26.5 to 31.0)	2.7 (1.9 to 3.9)	2.4 (1.7 to 3.4)	-10.8 (-30.2 to 13.8)
Liver cancer due to other causes	12.6 (10.1 to 15.9)	12.2 (9.9 to 15.1)	-1.9 (-28.3 to 27.4)	2.1 (1.5 to 3.0)	1.9 (1.3 to 2.6)	-11.9 (-31.1 to 12.0)
Larynx cancer	75.4 (59.4 to 89.9)	100.8 (82.3 to 124.0)	32.5 (11.5 to 61.4)	7.6 (5.2 to 10.6)	9.6 (6.4 to 13.6)	26.6 (4.0 to 55.1)
Tracheal, bronchus and lung cancer	161.2 (149.2 to 171.9)	242.4 (222.4 to 267.8)	50.1 (36.2 to 67.4)	25.0 (18.1 to 32.5)	36.1 (25.8 to 47.2)	44.3 (27.3 to 65.0)
Breast cancer	793.7 (739.1 to 848.8)	1,892.1 (1,767.6 to 2,035.4)	138.5 (119.7 to 159.5)	56.4 (40.5 to 74.8)	118.4 (82.3 to 158.7)	109.2 (87.2 to 136.7)
Cervical cancer	343.4 (266.9 to 421.6)	392.2 (282.4 to 503.6)	14.5 (-17.4 to 54.0)	25.8 (16.7 to 36.4)	29.6 (18.1 to 43.4)	15.3 (-16.7 to 55.1)
Uterine cancer	283.2 (199.8 to 397.2)	501.8 (339.2 to 699.3)	77.0 (19.2 to 159.7)	18.5 (11.1 to 29.2)	32.2 (18.5 to 51.0)	74.3 (16.9 to 154.8)
Prostate cancer	103.9 (81.2 to 123.7)	359.9 (282.7 to 469.2)	244.5 (179.2 to 329.4)	8.9 (6.0 to 12.3)	26.9 (17.7 to 38.9)	201.5 (138.1 to 284.1)
Colon and rectum cancer	308.1 (293.6 to 323.4)	644.6 (600.8 to 693.2)	109.1 (93.0 to 126.8)	25.8 (18.6 to 33.9)	50.8 (35.8 to 67.3)	96.5 (78.0 to 116.5)
Lip and oral cavity cancer	151.8 (126.7 to 182.2)	268.0 (212.0 to 329.9)	75.4 (39.0 to 126.3)	12.9 (8.8 to 18.1)	22.3 (14.0 to 31.1)	71.1 (32.1 to 127.8)
Nasopharynx cancer	42.7 (31.4 to 57.8)	61.3 (43.6 to 84.8)	43.9 (-4.6 to 120.3)	4.1 (2.6 to 6.2)	5.7 (3.5 to 8.6)	37.9 (-9.0 to 106.9)
Other pharynx cancer	61.7 (49.7 to 76.7)	112.8 (85.7 to 147.3)	80.7 (36.3 to 145.1)	5.5 (3.7 to 7.6)	9.6 (6.0 to 14.2)	73.7 (26.8 to 140.8)
Gallbladder and biliary tract cancer	6.7 (5.6 to 7.7)	9.4 (7.7 to 10.9)	40.1 (17.4 to 64.6)	1.9 (1.3 to 2.6)	2.5 (1.7 to 3.4)	31.1 (10.9 to 53.7)
Pancreatic cancer	13.3 (12.1 to 14.5)	24.8 (22.2 to 27.6)	86.9 (64.2 to 113.5)	2.8 (2.0 to 3.8)	5.1 (3.5 to 6.8)	79.5 (60.0 to 101.3)
Malignant skin melanoma	114.9 (87.8 to 144.9)	221.1 (168.7 to 308.3)	91.9 (53.7 to 141.4)	6.9 (4.4 to 10.2)	12.8 (8.0 to 20.2)	86.6 (46.9 to 133.4)
Non-melanoma skin cancer	163.9 (141.7 to 190.5)	316.2 (267.9 to 370.6)	92.7 (57.0 to 137.4)	2.7 (1.5 to 4.5)	6.2 (3.5 to 10.4)	126.3 (65.1 to 217.1)
Ovarian cancer	72.9 (64.3 to 81.7)	127.6 (110.0 to 147.2)	75.6 (49.9 to 106.1)	9.3 (6.4 to 12.2)	16.0 (11.2 to 21.9)	72.3 (40.2 to 113.5)
Testicular cancer	11.5 (8.7 to 14.6)	25.3 (18.4 to 33.9)	117.1 (67.7 to 191.3)	0.7 (0.5 to 1.1)	1.6 (1.0 to 2.4)	108.6 (52.3 to 180.8)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (50-54 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Kidney cancer	84.0 (76.3 to 92.7)	181.5 (160.0 to 207.6)	115.9 (88.4 to 150.2)	6.2 (4.4 to 8.5)	12.9 (8.8 to 17.9)	107.6 (78.7 to 142.5)
Bladder cancer	92.0 (76.6 to 102.9)	138.9 (120.9 to 159.0)	50.5 (30.5 to 78.8)	7.1 (5.0 to 9.8)	10.7 (7.4 to 14.5)	49.3 (27.2 to 78.5)
Brain and nervous system cancer	45.7 (37.9 to 53.2)	92.1 (76.4 to 112.2)	101.4 (64.9 to 148.1)	5.1 (3.5 to 7.0)	9.9 (6.7 to 13.5)	93.6 (56.6 to 141.0)
Thyroid cancer	119.9 (95.4 to 141.9)	276.1 (216.1 to 343.7)	129.1 (88.3 to 187.3)	7.0 (4.6 to 9.9)	15.6 (10.0 to 23.1)	122.9 (83.0 to 178.2)
Mesothelioma	2.2 (1.9 to 2.5)	4.2 (3.6 to 4.9)	90.6 (63.7 to 128.1)	0.5 (0.3 to 0.6)	0.9 (0.6 to 1.2)	93.5 (67.2 to 131.2)
Hodgkin lymphoma	27.3 (19.0 to 35.4)	36.1 (27.7 to 56.5)	25.1 (10.9 to 143.5)	2.4 (1.4 to 3.5)	3.0 (1.9 to 4.7)	16.8 (-17.3 to 125.1)
Non-Hodgkin lymphoma	103.4 (84.2 to 124.8)	250.1 (207.1 to 298.6)	142.2 (100.9 to 189.6)	8.0 (5.5 to 11.2)	18.3 (12.2 to 25.6)	130.0 (90.0 to 176.7)
Multiple myeloma	15.3 (11.9 to 20.2)	33.5 (26.5 to 43.4)	118.5 (75.7 to 170.6)	3.3 (2.1 to 4.8)	6.9 (4.4 to 9.8)	108.9 (63.6 to 166.0)
Leukemia	56.9 (51.6 to 62.6)	120.9 (108.0 to 134.8)	7.9 (85.6 to 142.5)	7.9 (5.6 to 10.4)	15.3 (10.8 to 20.3)	95.2 (64.6 to 130.2)
Other neoplasms	122.3 (105.6 to 140.4)	418.4 (353.2 to 492.6)	241.8 (183.7 to 307.1)	9.1 (6.3 to 12.5)	28.4 (19.4 to 39.5)	211.8 (158.5 to 272.8)
Cardiovascular diseases	-	-	-	797.1 (559.4 to 1,084.2)	1,661.2 (1,134.5 to 2,349.4)	108.1 (80.2 to 141.2)
Rheumatic heart disease	1,063.3 (999.0 to 1,132.5)	2,100.3 (2,002.0 to 2,210.6)	97.9 (82.6 to 111.1)	68.8 (47.4 to 95.6)	127.2 (85.3 to 176.6)	85.6 (58.0 to 112.2)
Ischemic heart disease	4,242.2 (3,988.7 to 4,555.2)	6,563.2 (6,261.9 to 6,853.7)	55.1 (43.6 to 65.2)	257.8 (176.8 to 356.8)	419.8 (287.8 to 580.6)	63.4 (47.9 to 76.8)
Cerebrovascular disease	-	-	-	135.9 (94.9 to 179.0)	276.1 (194.5 to 364.6)	103.3 (86.6 to 120.1)
Ischemic stroke	597.2 (568.1 to 632.1)	1,212.4 (1,155.0 to 1,278.9)	102.9 (87.6 to 117.7)	91.2 (63.4 to 122.3)	184.8 (129.0 to 249.2)	102.9 (84.3 to 121.0)
Hemorrhagic stroke	291.6 (278.3 to 306.8)	593.7 (560.9 to 627.5)	103.7 (86.6 to 121.2)	44.7 (30.8 to 59.5)	91.3 (62.2 to 122.6)	103.9 (82.9 to 129.3)
Hypertensive heart disease	402.5 (384.5 to 422.1)	920.8 (882.6 to 959.5)	129.0 (115.9 to 142.6)	45.9 (32.0 to 63.6)	105.4 (72.6 to 144.1)	129.4 (114.1 to 146.2)
Cardiomyopathy and myocarditis	354.4 (337.8 to 371.1)	713.3 (678.3 to 749.6)	101.4 (88.8 to 114.5)	39.0 (26.4 to 53.3)	79.1 (53.7 to 108.7)	102.5 (87.5 to 119.5)
Atrial fibrillation and flutter	203.4 (187.1 to 225.3)	330.7 (315.8 to 349.6)	63.6 (43.8 to 81.5)	16.7 (11.4 to 23.4)	27.2 (18.7 to 38.4)	63.7 (41.6 to 85.7)
Peripheral vascular disease	12,272.5 (11,220.7 to 13,636.7)	21,870.7 (19,558.6 to 25,554.8)	77.0 (50.5 to 122.7)	0.7 (0.3 to 1.2)	1.1 (0.5 to 2.1)	61.6 (2.8 to 134.9)
Endocarditis	12.7 (10.3 to 15.8)	29.1 (21.8 to 34.0)	130.6 (93.3 to 175.2)	1.4 (0.9 to 2.1)	3.3 (2.0 to 4.8)	132.3 (89.0 to 188.0)
Other cardiovascular and circulatory diseases	3,248.3 (2,154.5 to 4,969.4)	8,739.4 (5,464.1 to 13,190.6)	171.4 (72.5 to 303.7)	230.8 (130.3 to 379.6)	622.0 (337.1 to 1,039.7)	171.0 (71.6 to 306.4)
Chronic respiratory diseases	-	-	-	1,950.5 (1,350.8 to 2,644.8)	3,541.0 (2,442.8 to 4,803.1)	81.5 (74.8 to 88.9)
Chronic obstructive pulmonary disease	18,258.0 (17,361.8 to 19,107.2)	33,133.4 (31,527.4 to 34,684.2)	81.5 (79.5 to 83.3)	1,421.9 (963.1 to 1,946.7)	2,699.9 (1,840.2 to 3,697.4)	89.9 (81.7 to 98.7)
Pneumoconiosis	-	-	-	2.3 (1.6 to 3.2)	5.0 (3.5 to 6.9)	117.1 (106.2 to 126.8)
Silicosis	3.2 (2.9 to 3.6)	5.0 (4.5 to 5.6)	55.6 (50.6 to 60.1)	0.6 (0.4 to 0.9)	1.0 (0.6 to 1.4)	55.7 (50.6 to 60.2)
Asbestosis	0.8 (0.7 to 0.8)	1.3 (1.2 to 1.4)	70.6 (63.6 to 76.6)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	71.3 (64.2 to 77.4)
Coal workers pneumoconiosis	2.3 (2.1 to 2.4)	3.9 (3.6 to 4.2)	70.5 (68.0 to 72.9)	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.1)	70.5 (67.8 to 72.9)
Other pneumoconiosis	5.9 (5.1 to 6.6)	16.3 (14.6 to 17.8)	175.7 (165.5 to 187.6)	1.1 (0.7 to 1.6)	3.1 (2.0 to 4.4)	175.1 (164.8 to 187.0)
Asthma	8,537.3 (8,350.2 to 8,719.4)	15,045.6 (14,729.8 to 15,355.4)	76.3 (70.6 to 81.5)	370.2 (244.3 to 521.5)	652.1 (427.6 to 921.9)	76.2 (70.0 to 82.3)
Interstitial lung disease and pulmonary sarcoidosis	28.5 (27.0 to 30.3)	52.5 (49.3 to 55.5)	84.1 (68.8 to 99.5)	4.0 (2.5 to 5.8)	7.4 (4.6 to 10.9)	85.5 (69.3 to 102.1)
Other chronic respiratory diseases	-	-	-	152.2 (95.9 to 229.3)	176.5 (116.6 to 260.9)	15.4 (1.1 to 35.7)
Cirrhosis	-	-	-	35.8 (25.1 to 49.1)	54.2 (37.6 to 74.4)	51.6 (40.5 to 63.4)
Cirrhosis due to hepatitis B	63.4 (60.2 to 67.4)	90.7 (84.0 to 96.1)	43.2 (31.0 to 55.6)	10.4 (7.2 to 14.5)	15.0 (10.2 to 20.8)	43.1 (23.3 to 68.3)
Cirrhosis due to hepatitis C	52.3 (48.2 to 56.2)	101.5 (93.8 to 111.0)	93.1 (74.7 to 118.1)	8.6 (5.8 to 12.0)	16.7 (11.2 to 23.5)	92.8 (67.1 to 128.3)
Cirrhosis due to alcohol use	82.3 (76.7 to 87.1)	96.9 (89.0 to 105.9)	17.8 (6.2 to 30.1)	13.5 (9.4 to 18.8)	15.9 (10.5 to 22.5)	17.6 (0.5 to 39.5)
Cirrhosis due to other causes	19.4 (17.4 to 22.0)	40.6 (35.4 to 46.1)	108.2 (84.9 to 141.5)	3.2 (2.1 to 4.7)	6.7 (4.3 to 9.7)	110.1 (61.7 to 175.2)
Digestive diseases	-	-	-	459.8 (325.4 to 615.2)	674.3 (481.7 to 898.3)	46.8 (39.5 to 53.3)
Peptic ulcer disease	2,536.6 (2,381.0 to 2,646.3)	2,322.4 (2,136.1 to 2,452.3)	-8.3 (-13.2 to -4.2)	88.6 (60.4 to 126.7)	89.6 (61.2 to 128.0)	1.0 (-5.5 to 10.0)
Gastritis and duodenitis	3,545.0 (3,347.9 to 3,752.3)	4,189.3 (4,014.0 to 4,349.4)	18.3 (10.6 to 25.4)	120.0 (81.2 to 172.0)	151.9 (101.2 to 218.3)	26.9 (18.0 to 34.5)
Appendicitis	20.1 (17.4 to 23.4)	27.6 (24.2 to 31.6)	37.8 (14.6 to 65.7)	5.9 (3.8 to 8.5)	8.2 (5.2 to 11.9)	38.0 (0.7 to 92.3)
Paralytic ileus and intestinal obstruction	3.4 (3.3 to 3.5)	6.2 (6.0 to 6.4)	82.2 (73.9 to 92.1)	1.1 (0.7 to 1.5)	2.0 (1.3 to 2.7)	81.8 (72.9 to 91.7)
Inguinal, femoral, and abdominal hernia	928.3 (866.8 to 996.0)	1,470.6 (1,369.4 to 1,576.8)	58.3 (41.4 to 74.6)	9.8 (4.8 to 18.1)	15.6 (7.6 to 29.0)	58.9 (41.7 to 76.0)
Inflammatory bowel disease	524.1 (514.5 to 533.5)	1,042.3 (1,023.9 to 1,061.5)	98.9 (94.8 to 103.0)	110.5 (76.1 to 150.0)	219.8 (151.1 to 300.7)	99.0 (90.1 to 108.6)
Vascular intestinal disorders	0.9 (0.9 to 1.0)	1.6 (1.5 to 1.8)	78.6 (58.6 to 98.7)	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	78.2 (58.1 to 98.7)
Gallbladder and biliary diseases	369.1 (349.8 to 390.6)	539.3 (511.5 to 572.6)	46.5 (34.9 to 59.0)	39.4 (26.9 to 53.9)	57.4 (39.6 to 78.6)	45.8 (33.3 to 60.0)
Pancreatitis	102.1 (100.0 to 104.5)	198.1 (193.9 to 202.5)	94.2 (88.2 to 100.3)	30.0 (20.8 to 40.4)	58.5 (39.5 to 78.4)	94.5 (78.5 to 113.1)
Other digestive diseases	-	-	-	54.3 (37.0 to 75.3)	70.8 (48.9 to 98.0)	31.5 (12.6 to 45.7)
Neurological disorders	-	-	-	1,921.6 (1,306.5 to 2,634.9)	3,667.2 (2,483.1 to 5,083.8)	90.8 (83.1 to 99.9)
Alzheimer disease and other dementias	355.5 (341.6 to 370.0)	657.4 (633.3 to 685.3)	84.7 (76.3 to 94.8)	44.6 (31.6 to 59.3)	82.7 (57.9 to 110.0)	85.3 (70.9 to 100.8)
Parkinson disease	152.4 (109.6 to 203.7)	283.9 (202.5 to 380.4)	86.2 (81.5 to 90.8)	19.3 (11.4 to 29.8)	35.8 (21.1 to 54.8)	85.8 (71.2 to 102.1)
Epilepsy	628.9 (588.0 to 668.5)	1,088.6 (1,008.0 to 1,167.4)	73.0 (57.1 to 92.4)	201.7 (138.5 to 263.9)	373.7 (259.1 to 485.9)	85.6 (66.6 to 108.0)
Multiple sclerosis	117.2 (113.8 to 120.5)	284.7 (276.4 to 292.4)	143.1 (133.3 to 152.9)	38.3 (27.5 to 48.1)	93.0 (67.3 to 117.9)	142.4 (120.7 to 166.9)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (50-54 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Migraine	34,931-0 (33,603-4 to 36,405-1)	60,781-9 (58,534-8 to 63,228-2)	74-1 (65-4 to 83-4)	1,161-1 (692-8 to 1,704-2)	2,024-4 (1,234-9 to 2,967-9)	74-5 (65-3 to 84-0)
Tension-type headache	56,464-3 (54,089-4 to 58,718-1)	101,267-2 (98,574-8 to 104,106-1)	79-3 (70-6 to 88-4)	84-6 (41-5 to 147-1)	151-9 (74-0 to 267-9)	79-6 (70-7 to 89-1)
Medication overuse headache	2,217-6 (1,523-4 to 2,875-2)	5,597-6 (3,800-4 to 7,271-5)	152-5 (130-4 to 178-8)	344-0 (200-1 to 521-1)	868-9 (505-3 to 1,327-1)	152-3 (130-5 to 180-5)
Other neurological disorders	0-5 (0-4 to 0-5)	0-9 (0-7 to 1-1)	84-5 (55-6 to 117-0)	27-9 (19-5 to 38-7)	36-7 (25-0 to 48-1)	33-0 (7-8 to 46-9)
Mental and substance use disorders	-	-	-	5,877-8 (4,233-3 to 7,620-5)	10,666-7 (7,663-2 to 13,790-5)	81-5 (79-6 to 83-3)
Schizophrenia	1,275-6 (1,175-7 to 1,379-5)	2,306-6 (2,124-9 to 2,491-4)	80-9 (78-6 to 83-2)	806-1 (599-1 to 962-3)	1,462-5 (1,085-2 to 1,750-7)	81-3 (76-8 to 86-5)
Alcohol use disorders	3,400-2 (3,168-4 to 3,615-3)	5,684-4 (5,305-4 to 6,016-4)	67-2 (63-9 to 70-7)	332-8 (225-2 to 472-7)	557-7 (375-4 to 794-9)	67-6 (62-5 to 72-6)
Drug use disorders	-	-	-	272-8 (193-3 to 354-6)	506-3 (355-4 to 661-1)	85-4 (77-8 to 94-7)
Opioid use disorders	424-7 (341-9 to 508-3)	783-8 (624-5 to 950-5)	84-5 (79-8 to 89-3)	171-2 (117-2 to 231-2)	316-3 (216-7 to 428-5)	84-7 (74-9 to 95-0)
Cocaine use disorders	195-0 (189-7 to 199-5)	352-4 (343-9 to 360-8)	80-6 (75-2 to 87-4)	25-8 (16-6 to 37-1)	46-9 (30-7 to 66-4)	81-3 (63-5 to 101-6)
Amphetamine use disorders	176-4 (172-1 to 180-6)	340-6 (332-8 to 348-5)	93-3 (86-8 to 99-3)	22-3 (14-2 to 32-2)	43-1 (26-8 to 62-8)	93-5 (71-8 to 119-3)
Cannabis use disorders	169-9 (142-5 to 199-0)	319-1 (267-4 to 374-8)	87-8 (82-6 to 92-7)	4-9 (3-1 to 7-2)	9-2 (5-7 to 13-6)	87-5 (69-3 to 107-9)
Other drug use disorders	-	-	-	48-6 (32-9 to 66-5)	90-9 (61-0 to 123-6)	87-1 (68-9 to 106-6)
Depressive disorders	-	-	-	2,461-6 (1,626-0 to 3,469-0)	4,525-2 (2,980-5 to 6,433-5)	83-9 (80-2 to 87-1)
Major depressive disorder	9,794-8 (7,470-0 to 12,301-4)	18,047-5 (13,863-0 to 22,658-9)	84-4 (79-9 to 88-1)	1,971-2 (1,250-7 to 2,847-2)	3,637-3 (2,297-8 to 5,265-6)	84-6 (80-1 to 88-8)
Dysthymia	5,122-4 (4,345-1 to 5,821-4)	9,261-5 (7,932-9 to 10,501-3)	80-8 (78-5 to 83-1)	490-4 (323-2 to 716-0)	887-9 (582-4 to 1,300-1)	81-0 (77-4 to 84-7)
Bipolar disorder	1,835-2 (1,602-7 to 2,076-5)	3,333-6 (2,907-5 to 3,765-0)	81-6 (79-3 to 84-1)	365-3 (230-1 to 538-3)	665-1 (420-0 to 983-9)	82-0 (76-4 to 88-1)
Anxiety disorders	9,231-4 (6,479-2 to 11,810-0)	16,873-2 (11,751-1 to 21,810-2)	82-7 (78-7 to 86-5)	830-3 (480-8 to 1,235-3)	1,517-7 (875-9 to 2,271-9)	82-7 (77-3 to 87-4)
Eating disorders	-	-	-	-	-	-
Anorexia nervosa	-	-	-	-	-	-
Bulimia nervosa	-	-	-	-	-	-
Autistic spectrum disorders	-	-	-	225-1 (156-9 to 304-8)	405-2 (281-1 to 546-1)	80-1 (75-8 to 84-4)
Autism	595-9 (564-0 to 631-4)	1,070-6 (1,012-3 to 1,134-5)	79-7 (79-1 to 80-2)	142-5 (96-0 to 194-6)	256-6 (173-3 to 351-9)	80-2 (74-0 to 86-7)
Asperger syndrome	846-1 (780-7 to 916-1)	1,517-9 (1,401-6 to 1,643-3)	79-4 (79-1 to 79-7)	82-7 (57-3 to 114-1)	148-6 (102-6 to 206-2)	79-6 (74-5 to 85-1)
Attention-deficit/hyperactivity disorder	0-1 (0-0 to 0-2)	0-2 (0-1 to 0-4)	76-0 (67-7 to 88-5)	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	75-7 (67-4 to 88-1)
Conduct disorder	-	-	-	-	-	-
Idiopathic intellectual disability	2,349-2 (1,784-1 to 2,970-2)	3,769-9 (2,936-9 to 4,705-7)	60-1 (44-6 to 82-2)	115-1 (74-2 to 166-8)	183-2 (120-5 to 262-0)	59-0 (43-3 to 80-1)
Other mental and substance use disorders	6,357-7 (5,250-7 to 7,475-2)	11,420-4 (9,431-2 to 13,428-0)	79-6 (79-5 to 79-7)	468-7 (306-0 to 674-7)	843-8 (553-9 to 1,216-9)	80-0 (76-2 to 83-8)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	2,659-1 (1,883-5 to 3,538-0)	5,761-3 (4,127-7 to 7,664-9)	117-0 (106-0 to 125-6)
Diabetes mellitus	18,403-4 (16,469-5 to 20,225-3)	48,212-3 (44,251-4 to 51,905-3)	162-3 (137-9 to 183-2)	1,442-8 (978-0 to 1,980-6)	3,754-6 (2,560-3 to 5,099-5)	161-1 (138-6 to 177-6)
Acute glomerulonephritis	1-1 (0-9 to 1-2)	1-5 (1-4 to 1-7)	41-7 (36-6 to 46-7)	0-1 (0-0 to 0-1)	0-1 (0-0 to 0-1)	41-6 (36-4 to 46-5)
Chronic kidney disease	-	-	-	615-0 (413-6 to 867-2)	1,027-3 (688-9 to 1,457-7)	67-3 (58-2 to 75-0)
Chronic kidney disease due to diabetes mellitus	4,933-5 (3,273-0 to 8,906-5)	8,728-3 (6,052-2 to 14,448-1)	81-0 (48-1 to 104-2)	164-9 (111-2 to 229-7)	296-8 (194-5 to 422-7)	80-2 (56-8 to 99-8)
Chronic kidney disease due to hypertension	3,722-8 (2,544-2 to 6,341-0)	5,365-6 (3,748-9 to 8,992-0)	45-1 (29-9 to 61-9)	150-6 (99-8 to 216-8)	199-3 (128-5 to 293-7)	31-6 (15-2 to 57-4)
Chronic kidney disease due to glomerulonephritis	4,480-5 (2,828-9 to 8,538-0)	6,621-3 (4,497-6 to 11,270-7)	50-8 (23-0 to 74-3)	108-0 (72-6 to 155-5)	176-4 (114-9 to 251-8)	62-7 (45-3 to 86-8)
Chronic kidney disease due to other causes	5,237-1 (3,520-8 to 9,332-4)	9,240-9 (6,342-7 to 15,309-2)	78-5 (56-1 to 98-7)	191-5 (126-7 to 272-4)	354-8 (244-7 to 498-2)	85-2 (67-2 to 111-7)
Urinary diseases and male infertility	-	-	-	121-2 (79-1 to 171-0)	239-0 (154-3 to 346-8)	97-2 (82-6 to 112-0)
Interstitial nephritis and urinary tract infections	46-5 (45-3 to 47-9)	98-5 (95-9 to 101-2)	111-8 (104-1 to 120-7)	1-5 (1-0 to 2-3)	3-3 (2-0 to 4-8)	112-9 (82-7 to 150-1)
Urolithiasis	3,530-6 (2,617-4 to 4,906-7)	7,863-2 (5,677-2 to 11,537-8)	123-1 (107-2 to 136-1)	30-7 (19-4 to 45-7)	67-0 (41-3 to 104-0)	116-9 (99-8 to 137-0)
Benign prostatic hyperplasia	2,101-6 (2,055-2 to 2,148-8)	3,582-8 (3,502-9 to 3,663-4)	70-4 (65-4 to 75-8)	78-1 (50-4 to 110-8)	133-4 (86-3 to 189-6)	70-9 (63-9 to 77-7)
Male infertility due to other causes	-	-	-	-	-	-
Other urinary diseases	-	-	-	10-8 (6-4 to 17-0)	35-3 (17-2 to 58-2)	246-5 (121-7 to 318-3)
Gynecological diseases	-	-	-	269-8 (162-1 to 447-3)	407-2 (236-3 to 703-2)	50-2 (41-0 to 58-9)
Uterine fibroids	11,816-8 (11,132-8 to 12,440-9)	20,762-0 (19,568-9 to 21,885-5)	75-7 (74-9 to 76-4)	156-2 (91-1 to 257-4)	226-6 (126-6 to 389-2)	44-6 (33-7 to 53-6)
Polycystic ovarian syndrome	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	77-7 (72-7 to 83-2)	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	77-3 (72-3 to 82-8)
Female infertility due to other causes	-	-	-	0-0 (0-0 to 0-0)	-	-
Endometriosis	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	48-9 (25-6 to 77-7)	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	48-6 (25-3 to 77-5)
Genital prolapse	23,923-3 (23,306-4 to 24,719-0)	42,647-9 (41,474-5 to 43,752-7)	78-4 (71-6 to 84-3)	75-9 (37-3 to 143-0)	135-3 (66-1 to 252-8)	78-3 (71-1 to 85-1)
Premenstrual syndrome	-	-	0-0 (0-0 to 0-0)	-	-	-
Other gynecological diseases	1,255-7 (1,133-7 to 1,395-0)	1,754-2 (1,665-8 to 1,868-5)	40-2 (24-6 to 56-2)	37-7 (25-4 to 53-9)	45-3 (31-0 to 62-9)	20-0 (1-4 to 46-9)
Hemoglobinopathies and hemolytic anemias	-	-	-	133-2 (88-4 to 193-6)	219-9 (147-4 to 319-2)	65-1 (57-2 to 73-5)
Thalassemias	3-6 (2-7 to 4-4)	8-2 (6-7 to 9-9)	124-6 (92-4 to 176-2)	0-4 (0-2 to 0-6)	0-9 (0-6 to 1-3)	128-1 (85-4 to 191-1)
Thalassemia trait	5,774-8 (5,199-5 to 6,522-6)	10,962-5 (9,996-1 to 12,255-7)	89-8 (87-0 to 93-7)	72-7 (48-6 to 105-0)	144-0 (95-9 to 209-4)	98-3 (86-3 to 110-2)
Sickle cell disorders	9-6 (8-6 to 10-4)	19-6 (18-0 to 21-2)	103-0 (86-6 to 131-4)	1-5 (1-1 to 2-1)	3-2 (2-2 to 4-3)	109-8 (85-6 to 137-7)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (50-54 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Sickle cell trait	5,667-1 (5,382-6 to 5,930-0)	10,609-2 (10,104-0 to 11,065-8)	87-2 (83-7 to 90-6)	17-1 (10-7 to 25-4)	30-6 (19-5 to 45-1)	78-9 (56-7 to 113-9)
G6PD deficiency	8,013-8 (7,800-4 to 8,215-3)	15,132-4 (14,749-3 to 15,494-5)	88-9 (82-6 to 95-4)	0-7 (0-5 to 1-0)	1-6 (1-1 to 2-2)	109-2 (91-9 to 129-3)
G6PD trait	32,741-6 (32,560-4 to 32,913-3)	60,775-8 (60,421-5 to 61,113-6)	85-6 (84-2 to 87-2)	0-6 (0-3 to 1-1)	1-1 (0-6 to 1-8)	73-9 (1-1 to 169-2)
Other hemoglobinopathies and hemolytic anemias	1,957-7 (1,915-4 to 1,996-8)	2,297-5 (2,169-3 to 2,415-5)	17-3 (11-3 to 23-0)	40-1 (26-5 to 58-0)	38-5 (25-1 to 57-5)	-3-8 (-18-6 to 8-8)
Endocrine, metabolic, blood, and immune disorders	2,571-8 (2,476-1 to 2,666-3)	3,720-1 (3,631-1 to 3,810-2)	44-7 (39-1 to 50-6)	77-1 (52-4 to 107-4)	113-2 (77-8 to 154-9)	46-9 (37-7 to 57-7)
Musculoskeletal disorders	-	-	-	7,900-4 (5,677-2 to 10,436-1)	14,358-0 (10,252-6 to 19,098-6)	81-7 (78-5 to 85-2)
Rheumatoid arthritis	872-6 (857-2 to 889-1)	1,414-2 (1,393-2 to 1,435-3)	62-0 (58-7 to 65-7)	207-6 (149-7 to 273-4)	336-6 (240-6 to 446-8)	62-2 (55-6 to 69-2)
Osteoarthritis	14,190-3 (13,997-5 to 14,380-7)	24,709-8 (24,412-2 to 24,999-8)	74-1 (71-1 to 77-2)	787-9 (552-5 to 1,074-5)	1,396-9 (977-3 to 1,896-7)	77-3 (73-7 to 81-0)
Low back and neck pain	-	-	-	5,538-3 (3,869-6 to 7,448-9)	9,934-3 (6,888-9 to 13,287-2)	79-3 (74-9 to 84-4)
Low back pain	33,425-5 (32,670-4 to 34,169-9)	59,749-1 (58,416-3 to 61,328-4)	78-6 (72-8 to 85-6)	3,713-1 (2,539-6 to 5,102-8)	6,649-5 (4,513-1 to 9,201-9)	78-9 (73-0 to 85-9)
Neck pain	18,633-8 (18,030-2 to 19,211-1)	33,502-8 (32,535-9 to 34,511-6)	79-9 (71-8 to 87-8)	1,825-2 (1,267-8 to 2,504-6)	3,284-8 (2,286-9 to 4,532-9)	80-0 (72-0 to 88-0)
Gout	361-8 (352-3 to 371-3)	649-8 (637-2 to 663-3)	79-6 (74-2 to 85-3)	11-9 (8-2 to 16-1)	21-4 (14-7 to 28-6)	80-2 (63-6 to 97-4)
Other musculoskeletal disorders	14,687-7 (11,185-1 to 18,610-8)	28,970-0 (22,309-2 to 36,266-0)	97-1 (91-0 to 105-7)	1,354-7 (853-4 to 1,989-6)	2,668-8 (1,686-5 to 3,896-3)	96-9 (90-4 to 105-2)
Other non-communicable diseases	-	-	-	4,777-4 (3,213-2 to 6,893-4)	8,047-2 (5,388-0 to 11,659-1)	68-5 (64-9 to 71-8)
Congenital anomalies	-	-	-	250-8 (188-6 to 315-4)	556-0 (414-3 to 698-1)	121-4 (110-1 to 134-3)
Neural tube defects	24-0 (23-3 to 24-8)	56-2 (54-7 to 57-8)	134-2 (124-6 to 144-6)	7-1 (4-8 to 9-3)	17-2 (12-0 to 22-2)	143-9 (113-3 to 176-6)
Congenital heart anomalies	748-7 (721-3 to 777-8)	1,854-9 (1,800-8 to 1,924-0)	147-3 (137-2 to 161-8)	25-7 (11-2 to 44-0)	66-2 (29-9 to 111-3)	158-0 (143-3 to 175-7)
Orofacial clefts	104-0 (99-3 to 109-3)	290-2 (282-1 to 298-6)	178-5 (163-5 to 196-1)	1-2 (0-8 to 1-7)	3-0 (2-0 to 4-4)	160-6 (122-9 to 199-0)
Down syndrome	271-0 (229-9 to 312-6)	673-3 (565-3 to 774-4)	148-5 (136-4 to 160-1)	49-1 (33-9 to 65-9)	122-0 (85-2 to 162-6)	148-2 (130-8 to 164-4)
Turner syndrome	5-4 (5-1 to 5-7)	11-5 (11-1 to 12-1)	114-9 (103-3 to 128-4)	0-1 (0-0 to 0-1)	0-2 (0-1 to 0-3)	114-5 (102-9 to 128-0)
Klinefelter syndrome	6-0 (5-7 to 6-3)	11-6 (11-2 to 12-2)	93-0 (81-3 to 106-2)	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-1)	92-7 (81-0 to 106-0)
Chromosomal unbalanced rearrangements	398-6 (331-5 to 457-7)	933-3 (777-5 to 1,077-9)	134-1 (124-0 to 145-5)	72-2 (49-3 to 97-5)	169-3 (116-5 to 230-1)	134-5 (120-8 to 149-1)
Other congenital anomalies	954-2 (819-0 to 1,066-3)	1,486-7 (1,257-7 to 1,668-6)	55-8 (48-1 to 63-9)	95-5 (66-5 to 128-9)	178-2 (123-0 to 236-3)	86-4 (66-3 to 113-5)
Skin and subcutaneous diseases	-	-	-	1,112-4 (722-3 to 1,684-6)	1,982-4 (1,292-5 to 2,980-6)	78-2 (73-6 to 82-3)
Dermatitis	11,361-6 (9,315-4 to 13,426-3)	20,221-1 (16,658-9 to 23,810-2)	78-0 (77-0 to 79-0)	288-3 (184-3 to 414-8)	513-9 (327-1 to 742-9)	78-2 (74-8 to 81-5)
Psoriasis	2,655-4 (2,206-5 to 3,209-4)	4,580-0 (3,790-1 to 5,537-0)	72-5 (70-3 to 74-8)	213-3 (140-7 to 306-8)	368-4 (245-1 to 533-9)	72-8 (66-7 to 78-7)
Cellulitis	79-0 (56-8 to 111-7)	112-3 (81-5 to 160-5)	42-3 (33-3 to 50-9)	5-5 (3-2 to 8-8)	7-8 (4-5 to 12-6)	42-0 (19-0 to 70-1)
Pyoderma	139-7 (95-7 to 210-2)	216-4 (138-2 to 340-3)	54-9 (34-6 to 72-4)	0-8 (0-3 to 1-8)	1-2 (0-4 to 2-8)	54-7 (32-3 to 77-3)
Scabies	1,594-7 (1,440-7 to 1,765-7)	2,847-4 (2,614-1 to 3,115-5)	78-5 (58-0 to 103-6)	40-4 (22-5 to 64-4)	72-3 (41-6 to 114-5)	78-9 (58-2 to 103-8)
Fungal skin diseases	23,066-3 (19,850-0 to 26,248-8)	41,936-3 (36,170-3 to 47,616-5)	81-8 (80-6 to 83-3)	128-8 (52-7 to 262-0)	234-5 (95-8 to 478-7)	82-0 (80-4 to 83-8)
Viral skin diseases	1,762-5 (1,262-2 to 2,395-1)	3,092-3 (2,203-1 to 4,218-3)	75-5 (71-9 to 78-6)	53-2 (30-2 to 88-5)	93-3 (53-2 to 155-7)	75-5 (70-0 to 81-5)
Acne vulgaris	2,656-3 (2,479-2 to 2,865-9)	4,720-5 (4,299-5 to 5,153-8)	78-6 (58-8 to 96-8)	28-2 (13-6 to 51-9)	50-1 (24-1 to 91-8)	78-6 (58-8 to 96-4)
Alopecia areata	352-1 (343-1 to 361-8)	625-5 (609-7 to 640-9)	77-7 (71-0 to 84-5)	11-7 (7-5 to 17-4)	20-8 (13-2 to 30-9)	77-8 (65-4 to 91-3)
Pruritus	51-1 (48-4 to 54-0)	93-3 (88-7 to 98-0)	82-9 (69-6 to 94-0)	0-5 (0-3 to 1-0)	1-0 (0-5 to 1-8)	81-8 (58-9 to 106-5)
Urticaria	3,116-0 (2,884-6 to 3,419-2)	5,695-8 (5,188-6 to 6,217-6)	83-6 (61-6 to 104-3)	183-3 (118-6 to 259-5)	335-7 (218-1 to 479-3)	83-8 (61-1 to 105-0)
Decubitus ulcer	48-2 (46-1 to 50-3)	81-8 (78-3 to 85-7)	70-0 (60-2 to 78-6)	7-4 (5-0 to 10-1)	12-5 (8-4 to 17-7)	70-1 (39-8 to 107-4)
Other skin and subcutaneous diseases	25,638-1 (6,018-7 to 58,203-3)	45,951-0 (10,796-3 to 104,418-1)	79-2 (77-1 to 81-1)	151-0 (28-4 to 400-2)	270-7 (51-2 to 716-9)	79-3 (76-9 to 81-7)
Sense organ diseases	-	-	-	2,619-2 (1,716-3 to 3,811-8)	4,175-9 (2,721-8 to 6,149-0)	59-4 (53-7 to 64-5)
Glaucoma	459-0 (367-1 to 564-1)	819-7 (659-2 to 1,004-1)	78-2 (53-6 to 107-2)	32-2 (20-8 to 46-9)	55-8 (36-3 to 80-6)	73-6 (53-6 to 97-9)
Cataract	1,828-5 (1,504-3 to 2,197-0)	2,573-1 (2,049-9 to 3,127-3)	41-1 (24-3 to 59-8)	111-6 (75-0 to 162-0)	162-5 (107-2 to 230-0)	45-1 (30-9 to 62-5)
Macular degeneration	876-1 (710-3 to 1,077-5)	1,494-4 (1,217-7 to 1,790-8)	70-4 (61-9 to 81-2)	38-7 (24-9 to 57-5)	67-2 (43-6 to 99-2)	73-4 (62-6 to 87-0)
Uncorrected refractive error	38,229-6 (36,866-1 to 39,628-5)	65,641-2 (63,486-3 to 67,734-5)	71-7 (65-6 to 78-2)	605-7 (364-5 to 963-6)	988-8 (587-1 to 1,580-8)	62-8 (57-3 to 69-2)
Age-related and other hearing loss	66,768-3 (58,126-6 to 75,849-1)	108,667-9 (94,922-0 to 124,661-3)	62-8 (57-0 to 68-7)	1,616-3 (1,029-0 to 2,434-7)	2,550-8 (1,604-0 to 3,843-7)	57-8 (49-2 to 65-2)
Other vision loss	1,358-1 (1,084-4 to 1,664-8)	1,907-5 (1,504-7 to 2,349-4)	40-2 (31-0 to 51-6)	93-0 (60-2 to 136-0)	132-6 (85-6 to 195-9)	42-7 (32-9 to 51-9)
Other sense organ diseases	4,669-8 (4,577-8 to 4,767-3)	8,367-3 (8,194-5 to 8,545-5)	78-9 (74-1 to 84-8)	121-7 (75-6 to 180-2)	218-1 (134-4 to 321-8)	79-1 (72-5 to 85-9)
Oral disorders	-	-	-	795-0 (478-9 to 1,229-1)	1,332-9 (792-0 to 2,091-8)	67-5 (62-5 to 71-7)
Deciduous caries	-	-	-	-	-	-
Permanent caries	86,898-2 (85,614-7 to 88,091-3)	154,885-5 (152,925-5 to 156,775-3)	78-3 (74-8 to 81-7)	73-9 (34-4 to 140-0)	137-0 (63-3 to 262-9)	85-3 (80-5 to 90-2)
Periodontal diseases	35,758-9 (35,175-0 to 36,334-5)	63,253-5 (62,080-9 to 64,508-5)	76-8 (72-7 to 81-5)	234-3 (94-4 to 481-7)	414-9 (166-3 to 851-0)	77-0 (72-8 to 81-8)
Edentulism and severe tooth loss	11,953-8 (11,580-7 to 12,352-0)	18,170-6 (17,546-5 to 18,733-1)	52-0 (45-4 to 59-4)	337-5 (224-9 to 466-7)	512-6 (343-5 to 706-7)	51-9 (45-1 to 59-0)
Other oral disorders	5,146-0 (5,029-7 to 5,262-6)	9,247-8 (9,058-0 to 9,447-8)	79-7 (74-6 to 84-9)	149-3 (94-1 to 221-6)	268-4 (170-2 to 397-4)	79-8 (73-8 to 85-8)
Injuries	-	-	-	2,765-9 (1,990-1 to 3,716-8)	3,166-0 (2,288-0 to 4,261-5)	15-0 (1-6 to 26-0)
Transport injuries	-	-	-	815-4 (604-6 to 1,056-0)	970-9 (706-8 to 1,288-7)	18-6 (10-4 to 28-4)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (50-54 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Road injuries	-	-	-	678.8 (503.7 to 878.5)	813.9 (592.4 to 1,079.6)	19.5 (10.7 to 29.9)
Pedestrian road injuries	-	-	-	148.6 (110.4 to 193.6)	197.3 (143.2 to 263.4)	32.4 (22.6 to 43.7)
Cyclist road injuries	-	-	-	64.5 (48.2 to 84.5)	72.2 (52.0 to 96.3)	11.6 (4.1 to 20.0)
Motorcyclist road injuries	-	-	-	152.9 (112.9 to 199.0)	175.0 (125.7 to 235.5)	14.0 (4.5 to 25.3)
Motor vehicle road injuries	-	-	-	305.2 (227.3 to 391.9)	362.1 (264.6 to 477.4)	18.3 (9.5 to 28.8)
Other road injuries	-	-	-	7.5 (5.7 to 9.7)	7.3 (5.4 to 9.6)	-2.9 (-9.7 to 4.6)
Other transport injuries	-	-	-	136.6 (100.7 to 179.4)	156.9 (112.2 to 210.3)	14.7 (8.4 to 21.6)
Unintentional injuries	-	-	-	1,249.2 (933.8 to 1,634.0)	1,636.9 (1,180.7 to 2,210.0)	30.8 (23.6 to 38.3)
Falls	-	-	-	665.3 (497.3 to 870.9)	917.8 (659.9 to 1,238.9)	37.7 (28.8 to 47.4)
Drowning	-	-	-	27.5 (20.4 to 35.8)	31.8 (23.2 to 41.7)	15.5 (8.1 to 24.4)
Fire, heat, and hot substances	-	-	-	95.4 (70.7 to 123.4)	98.4 (71.0 to 132.4)	3.1 (-5.5 to 10.4)
Poisonings	-	-	-	5.2 (3.7 to 6.9)	6.3 (4.5 to 8.3)	21.4 (13.8 to 29.9)
Exposure to mechanical forces	-	-	-	259.9 (189.4 to 348.4)	304.9 (216.4 to 420.4)	17.0 (11.1 to 23.5)
Unintentional firearm injuries	-	-	-	9.9 (7.4 to 12.8)	12.5 (8.9 to 17.0)	26.5 (17.5 to 36.5)
Unintentional suffocation	-	-	-	2.4 (1.8 to 3.1)	4.1 (3.0 to 5.4)	70.0 (60.1 to 80.6)
Other exposure to mechanical forces	-	-	-	247.6 (180.2 to 332.3)	288.3 (204.5 to 398.2)	16.1 (10.3 to 22.6)
Adverse effects of medical treatment	-	-	-	8.7 (5.5 to 12.9)	15.6 (9.8 to 22.8)	78.9 (72.2 to 85.0)
Animal contact	-	-	-	27.3 (20.3 to 35.8)	30.7 (22.5 to 40.8)	12.2 (6.2 to 18.9)
Venomous animal contact	-	-	-	10.7 (7.7 to 14.2)	11.6 (8.3 to 15.4)	8.8 (-0.3 to 17.9)
Non-venomous animal contact	-	-	-	16.6 (12.3 to 22.2)	19.0 (13.7 to 26.1)	14.5 (8.4 to 20.6)
Foreign body	-	-	-	14.4 (10.9 to 18.2)	19.8 (14.5 to 25.6)	37.5 (29.3 to 46.8)
Pulmonary aspiration and foreign body in airway	-	-	-	3.1 (2.3 to 3.9)	3.3 (2.4 to 4.2)	6.0 (-3.6 to 18.6)
Foreign body in eyes	-	-	-	2.7 (1.8 to 3.7)	4.2 (2.7 to 5.8)	54.6 (45.1 to 64.1)
Foreign body in other body part	-	-	-	8.7 (6.5 to 11.0)	12.4 (9.2 to 16.3)	43.0 (35.2 to 51.9)
Other unintentional injuries	-	-	-	145.5 (107.2 to 192.5)	211.5 (152.7 to 283.7)	45.1 (39.1 to 51.4)
Self-harm and interpersonal violence	-	-	-	86.0 (64.0 to 110.8)	101.9 (73.6 to 135.5)	18.0 (9.3 to 29.0)
Self-harm	-	-	-	22.0 (16.1 to 28.5)	24.1 (17.2 to 32.3)	9.3 (2.4 to 17.9)
Interpersonal violence	-	-	-	64.1 (48.2 to 82.3)	77.8 (56.6 to 104.2)	20.9 (11.3 to 33.1)
Assault by firearm	-	-	-	10.7 (8.0 to 13.8)	15.6 (11.2 to 21.0)	45.9 (37.0 to 55.6)
Assault by sharp object	-	-	-	11.7 (8.7 to 15.4)	16.6 (11.7 to 22.8)	40.9 (30.5 to 52.8)
Assault by other means	-	-	-	41.6 (31.2 to 53.3)	45.6 (33.3 to 60.5)	9.0 (0.2 to 20.7)
Forces of nature, war, and legal intervention	-	-	-	615.3 (257.5 to 1,285.0)	456.3 (198.4 to 968.4)	-25.6 (-41.2 to -2.0)
Exposure to forces of nature	-	-	-	50.6 (23.8 to 99.3)	48.1 (23.1 to 102.5)	-4.3 (-36.0 to 36.2)
Collective violence and legal intervention	-	-	-	564.6 (225.2 to 1,196.3)	408.2 (175.4 to 888.2)	-27.4 (-43.3 to -2.8)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (55-59 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
All causes	-	-	-	30,661.3 (22,993.9 to 39,376.9)	52,471.2 (39,347.9 to 67,606.7)	71.2 (68.6 to 73.4)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	2,225.3 (1,556.2 to 3,026.1)	3,042.8 (2,168.5 to 4,124.3)	36.8 (29.6 to 45.6)
HIV/AIDS and tuberculosis	-	-	-	214.7 (150.0 to 284.6)	474.9 (337.4 to 619.7)	121.0 (104.5 to 142.4)
Tuberculosis	604.1 (568.6 to 641.9)	980.6 (925.9 to 1,039.2)	62.7 (57.8 to 68.3)	178.1 (122.0 to 239.1)	292.0 (200.3 to 389.5)	63.8 (55.8 to 73.0)
HIV/AIDS	-	-	-	36.6 (25.4 to 48.6)	182.9 (130.1 to 243.9)	398.4 (305.6 to 519.5)
HIV/AIDS resulting in mycobacterial infection	9.8 (5.8 to 15.0)	32.5 (20.7 to 44.7)	236.4 (146.1 to 336.3)	3.5 (1.8 to 5.9)	11.7 (6.5 to 18.2)	238.6 (129.9 to 384.9)
HIV/AIDS resulting in other diseases	219.3 (193.0 to 247.0)	1,228.8 (1,130.7 to 1,357.8)	463.2 (393.5 to 555.0)	33.1 (23.1 to 44.6)	171.2 (120.8 to 226.9)	415.5 (314.4 to 548.6)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	236.5 (165.9 to 323.6)	348.0 (241.9 to 485.8)	47.0 (40.7 to 53.7)
Diarrheal diseases	450.6 (434.3 to 468.3)	581.4 (545.8 to 613.5)	29.4 (20.8 to 38.6)	68.5 (46.4 to 93.7)	88.8 (61.0 to 121.7)	29.3 (18.4 to 41.5)
Intestinal infectious diseases	-	-	-	3.0 (1.9 to 4.4)	3.4 (2.2 to 5.2)	16.0 (-19.6 to 60.1)
Typhoid fever	18.0 (14.7 to 21.8)	21.2 (17.2 to 26.1)	18.3 (-11.8 to 55.6)	2.3 (1.4 to 3.4)	2.8 (1.7 to 4.2)	24.6 (-19.5 to 82.9)
Paratyphoid fever	10.3 (7.8 to 13.2)	10.6 (8.2 to 14.1)	4.1 (-31.3 to 51.9)	0.5 (0.3 to 0.9)	0.5 (0.3 to 0.9)	3.2 (-39.1 to 68.8)
Other intestinal infectious diseases	-	-	-	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.2)	-40.1 (-56.1 to -19.1)
Lower respiratory infections	97.6 (95.9 to 99.4)	183.1 (179.1 to 186.8)	88.0 (83.1 to 93.4)	9.9 (6.8 to 13.6)	18.6 (12.6 to 26.0)	88.1 (74.4 to 102.4)
Upper respiratory infections	4,676.4 (4,557.5 to 4,777.3)	8,399.5 (8,185.6 to 8,599.2)	79.9 (74.4 to 87.1)	53.2 (29.9 to 87.4)	95.9 (53.5 to 160.5)	80.3 (73.2 to 88.5)
Otitis media	2,284.8 (2,208.5 to 2,360.6)	3,398.9 (3,301.7 to 3,519.7)	49.1 (43.2 to 55.3)	42.2 (25.7 to 67.8)	63.5 (37.8 to 101.0)	50.3 (43.2 to 58.3)
Meningitis	-	-	-	38.3 (24.3 to 56.9)	44.3 (28.6 to 64.9)	15.7 (7.5 to 26.5)
Pneumococcal meningitis	295.7 (166.6 to 455.1)	353.0 (197.4 to 560.3)	19.2 (9.8 to 29.1)	18.2 (12.9 to 25.2)	22.4 (15.5 to 30.9)	22.8 (6.9 to 42.2)
H influenzae type B meningitis	106.7 (20.6 to 224.4)	100.9 (18.8 to 221.9)	-6.2 (-25.8 to 5.9)	5.7 (3.5 to 8.9)	6.1 (3.8 to 9.4)	6.3 (-2.7 to 19.8)
Meningococcal meningitis	59.0 (12.0 to 136.4)	58.3 (12.4 to 137.7)	-1.6 (-16.2 to 9.8)	5.5 (2.5 to 9.6)	5.8 (2.9 to 10.3)	6.3 (-7.7 to 24.5)
Other meningitis	127.8 (28.9 to 269.5)	131.2 (31.3 to 294.0)	2.4 (-19.3 to 19.4)	8.8 (4.9 to 14.4)	10.0 (5.7 to 16.3)	13.0 (-0.3 to 30.7)
Encephalitis	92.4 (37.7 to 207.6)	120.3 (51.2 to 290.0)	31.1 (3.6 to 44.1)	10.2 (7.0 to 13.9)	14.9 (10.4 to 20.0)	45.6 (26.0 to 68.5)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.7 (-69.0 to 264.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.6 (-69.2 to 263.9)
Whooping cough	2.8 (2.2 to 3.6)	2.7 (2.1 to 3.4)	-4.1 (-5.1 to -3.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-4.0 (-6.2 to -2.2)
Tetanus	37.4 (26.8 to 56.2)	5.8 (3.4 to 9.0)	-84.9 (-91.7 to -72.0)	1.0 (0.6 to 1.7)	0.3 (0.2 to 0.4)	-73.4 (-83.5 to -57.2)
Measles	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.1)	-63.2 (-66.0 to -60.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.3 (-66.1 to -60.3)
Varicella and herpes zoster	187.4 (178.2 to 198.1)	334.7 (317.1 to 354.7)	78.7 (67.4 to 93.4)	10.0 (6.2 to 15.0)	18.1 (11.2 to 27.5)	79.6 (64.4 to 97.6)
Neglected tropical diseases and malaria	-	-	-	776.2 (492.7 to 1,143.8)	908.5 (532.9 to 1,417.7)	15.9 (-0.1 to 35.8)
Malaria	5,533.7 (5,371.3 to 5,699.0)	7,439.4 (7,190.2 to 7,703.1)	34.6 (29.2 to 40.7)	32.2 (21.2 to 46.6)	39.9 (26.2 to 59.0)	23.7 (14.2 to 34.7)
Chagas disease	414.2 (403.1 to 425.2)	579.4 (560.3 to 605.2)	40.0 (34.1 to 48.7)	6.0 (4.0 to 8.6)	8.4 (5.4 to 12.3)	40.2 (28.4 to 52.2)
Leishmaniasis	-	-	-	0.7 (0.3 to 1.2)	2.0 (1.0 to 3.8)	190.5 (160.2 to 224.0)
Visceral leishmaniasis	1.0 (0.8 to 1.3)	1.8 (1.3 to 2.4)	80.5 (36.6 to 138.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	80.2 (35.4 to 141.6)
Cutaneous and mucocutaneous leishmaniasis	59.6 (52.0 to 69.3)	180.0 (153.5 to 210.2)	202.3 (170.7 to 238.3)	0.6 (0.3 to 1.2)	1.9 (0.9 to 3.6)	204.3 (171.5 to 242.8)
African trypanosomiasis	2.7 (1.2 to 5.3)	0.7 (0.4 to 1.2)	-73.5 (-77.3 to -68.5)	0.7 (0.3 to 1.4)	0.2 (0.1 to 0.3)	-73.4 (-82.5 to -57.4)
Schistosomiasis	6,932.1 (6,209.6 to 7,651.5)	8,549.3 (7,369.1 to 9,932.1)	22.1 (13.9 to 41.8)	55.8 (28.1 to 103.8)	69.0 (34.3 to 132.8)	22.1 (14.6 to 41.3)
Cysticercosis	78.1 (65.8 to 91.8)	61.8 (47.9 to 74.3)	-21.0 (-39.3 to 5.9)	21.3 (14.7 to 28.4)	18.3 (12.1 to 25.3)	-14.3 (-36.4 to 18.3)
Cystic echinococcosis	64.2 (61.3 to 66.7)	59.2 (56.9 to 62.4)	-7.3 (-10.9 to -5.5)	5.8 (4.0 to 8.1)	5.4 (3.6 to 7.6)	-7.2 (-19.1 to 5.8)
Lymphatic filariasis	3,506.4 (2,946.1 to 4,229.2)	2,790.7 (2,211.0 to 3,576.0)	-20.4 (-29.8 to -10.1)	152.9 (77.2 to 263.5)	175.5 (95.5 to 289.2)	15.9 (-9.4 to 40.9)
Onchocerciasis	1,025.3 (748.4 to 1,457.7)	667.9 (469.2 to 963.6)	-35.0 (-44.2 to -22.1)	83.6 (47.4 to 135.8)	57.9 (29.5 to 99.2)	-31.9 (-44.2 to -13.6)
Trachoma	470.6 (294.2 to 645.7)	280.7 (173.0 to 397.8)	-40.7 (-52.2 to -27.2)	27.3 (15.6 to 41.9)	16.3 (8.8 to 25.7)	-40.1 (-52.3 to -27.8)
Dengue	12.6 (4.6 to 28.1)	121.7 (44.8 to 272.9)	872.8 (865.5 to 879.5)	2.0 (0.6 to 5.1)	19.0 (6.2 to 48.2)	869.5 (653.6 to 1,150.5)
Yellow fever	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-62.5 (-72.4 to -41.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-62.5 (-72.6 to -41.2)
Rabies	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-26.5 (-44.1 to -0.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.7 (-44.2 to -0.2)
Intestinal nematode infections	-	-	-	177.8 (102.3 to 285.1)	126.0 (72.4 to 204.5)	-29.0 (-35.8 to -21.4)
Ascariasis	35,919.3 (29,641.5 to 43,934.3)	33,456.8 (27,990.9 to 40,743.2)	-6.7 (-28.3 to 22.6)	83.9 (46.5 to 138.4)	33.2 (18.2 to 57.3)	-60.4 (-66.8 to -52.5)
Trichuriasis	17,702.0 (14,022.0 to 22,856.1)	18,958.6 (16,893.5 to 21,361.3)	8.7 (-20.2 to 38.5)	24.0 (13.4 to 39.6)	22.1 (11.7 to 37.4)	-8.7 (-28.3 to 21.5)
Hookworm disease	17,068.6 (14,033.8 to 20,985.5)	19,785.3 (17,881.5 to 22,091.5)	17.0 (-7.2 to 43.9)	69.8 (42.0 to 111.5)	70.7 (41.5 to 111.7)	1.1 (-9.6 to 13.8)
Food-borne trematodiasis	3,821.4 (2,826.1 to 4,795.9)	7,211.5 (5,294.4 to 8,955.1)	89.5 (73.3 to 104.4)	186.8 (49.0 to 409.6)	350.9 (91.3 to 767.8)	89.2 (68.5 to 107.7)
Other neglected tropical diseases	745.1 (712.9 to 777.9)	826.0 (779.6 to 866.5)	11.1 (3.2 to 20.2)	23.3 (13.2 to 40.0)	19.5 (10.6 to 34.8)	-17.3 (-31.6 to 5.6)
Maternal disorders	-	-	-	18.5 (11.7 to 26.7)	24.8 (15.7 to 35.6)	34.6 (8.1 to 68.6)
Maternal hemorrhage	-	-	-	-	-	-
Maternal sepsis and other maternal infections	-	-	-	-	-	-
Maternal hypertensive disorders	-	-	-	-	-	-
Obstructed labor	59.4 (47.4 to 71.5)	78.9 (64.7 to 93.5)	33.3 (19.8 to 47.3)	18.5 (11.7 to 26.7)	24.8 (15.7 to 35.6)	34.6 (8.1 to 68.6)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (55-59 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Complications of abortion	-	-	-	-	-	-
Other maternal disorders	-	-	-	-	-	-
Neonatal disorders	-	-	-	127.1 (95.4 to 162.1)	409.6 (308.2 to 517.5)	223.1 (191.0 to 254.6)
Preterm birth complications	677.5 (590.4 to 787.1)	2,242.4 (1,947.6 to 2,619.6)	231.7 (201.8 to 267.4)	64.7 (47.6 to 81.9)	243.1 (181.2 to 307.5)	275.9 (249.6 to 307.4)
Neonatal encephalopathy due to birth asphyxia and trauma	594.7 (220.6 to 1,111.6)	710.3 (323.0 to 1,237.0)	20.1 (-9.1 to 88.8)	27.4 (17.9 to 41.0)	53.3 (39.1 to 71.7)	97.2 (58.6 to 139.4)
Neonatal sepsis and other neonatal infections	-	-	-	-	-	-
Hemolytic disease and other neonatal jaundice	43.5 (37.3 to 51.0)	127.4 (103.9 to 162.0)	188.4 (133.4 to 294.9)	16.2 (11.3 to 21.5)	44.5 (31.3 to 60.1)	170.0 (122.4 to 280.1)
Other neonatal disorders	-	-	-	18.9 (12.9 to 26.7)	68.7 (46.7 to 92.1)	264.5 (191.4 to 343.8)
Nutritional deficiencies	-	-	-	795.1 (530.5 to 1,150.5)	798.4 (523.7 to 1,175.6)	0.2 (-3.1 to 4.5)
Protein-energy malnutrition	16.1 (8.3 to 25.6)	22.0 (12.0 to 35.0)	35.8 (12.5 to 72.9)	1.9 (0.9 to 3.4)	2.6 (1.1 to 4.7)	36.5 (4.1 to 85.7)
Iodine deficiency	4,621.7 (4,314.3 to 4,944.8)	4,862.6 (4,541.8 to 5,169.6)	5.4 (-3.3 to 15.5)	80.6 (49.8 to 124.2)	85.2 (52.7 to 135.7)	5.7 (-3.0 to 16.4)
Vitamin A deficiency	69.1 (32.9 to 98.6)	75.7 (44.5 to 106.7)	9.4 (-11.1 to 42.2)	3.9 (1.7 to 6.3)	4.1 (2.0 to 6.6)	4.6 (-22.3 to 50.3)
Iron-deficiency anemia	29,807.3 (29,656.4 to 29,958.8)	35,854.7 (35,651.8 to 36,049.3)	20.6 (19.7 to 21.4)	708.6 (475.3 to 1,022.7)	706.4 (466.7 to 1,036.7)	-0.6 (-4.1 to 3.9)
Other nutritional deficiencies	-	-	-	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-8.1 (-44.1 to 45.9)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	57.2 (35.7 to 92.5)	78.6 (47.9 to 132.6)	36.8 (26.9 to 47.2)
Sexually transmitted diseases excluding HIV	-	-	-	23.7 (12.7 to 45.7)	37.2 (18.8 to 72.9)	56.2 (43.2 to 64.9)
Syphilis	27.0 (26.0 to 28.1)	29.6 (28.5 to 30.8)	9.5 (3.8 to 16.1)	5.0 (3.3 to 6.9)	5.5 (3.6 to 7.8)	11.2 (-10.2 to 35.0)
Chlamydial infection	1,187.1 (1,140.2 to 1,230.1)	2,014.2 (1,936.9 to 2,090.7)	69.8 (60.9 to 80.1)	4.5 (2.8 to 7.2)	8.0 (4.9 to 12.5)	76.3 (58.4 to 96.4)
Gonococcal infection	31.6 (27.7 to 36.3)	54.5 (49.9 to 60.9)	73.3 (47.4 to 96.8)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	60.0 (32.3 to 97.7)
Trichomoniasis	282.2 (260.2 to 304.7)	477.6 (427.5 to 531.7)	68.3 (51.4 to 94.5)	0.5 (0.2 to 0.9)	0.8 (0.3 to 1.6)	69.3 (44.9 to 103.7)
Genital herpes	54,169.3 (53,467.9 to 54,838.7)	89,924.4 (88,693.4 to 91,378.5)	66.3 (63.3 to 69.8)	13.2 (3.8 to 32.4)	21.9 (6.3 to 54.0)	66.6 (62.4 to 71.0)
Other sexually transmitted diseases	2.2 (2.0 to 2.4)	3.4 (3.2 to 3.7)	55.9 (37.6 to 74.6)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	55.9 (37.5 to 74.6)
Hepatitis	-	-	-	12.9 (8.4 to 18.5)	18.4 (11.9 to 26.4)	42.5 (33.2 to 50.9)
Hepatitis A	61.8 (55.7 to 67.5)	132.7 (125.7 to 138.6)	115.4 (105.7 to 126.1)	2.2 (1.4 to 3.3)	4.8 (3.0 to 6.9)	114.8 (92.6 to 141.8)
Hepatitis B	14,767.2 (14,405.5 to 15,265.1)	17,491.0 (17,067.5 to 17,889.1)	18.8 (14.9 to 22.4)	8.8 (5.6 to 12.6)	10.6 (6.9 to 15.3)	21.4 (11.5 to 30.9)
Hepatitis C	9,063.6 (8,925.1 to 9,220.8)	11,830.0 (11,646.8 to 12,047.4)	30.9 (27.9 to 33.7)	1.1 (0.7 to 1.6)	1.4 (0.9 to 2.1)	32.7 (9.4 to 64.8)
Hepatitis E	34.6 (31.6 to 37.8)	57.9 (52.4 to 64.4)	66.6 (46.9 to 95.3)	0.9 (0.5 to 1.3)	1.5 (0.9 to 2.3)	76.5 (32.7 to 134.1)
Leprosy	42.6 (38.2 to 46.4)	74.8 (67.9 to 82.8)	75.6 (60.5 to 93.6)	2.4 (1.6 to 3.4)	4.6 (2.9 to 6.5)	89.7 (54.5 to 131.8)
Other infectious diseases	882.7 (842.5 to 918.3)	1,019.7 (990.4 to 1,050.5)	15.7 (10.7 to 22.0)	18.1 (11.6 to 27.2)	18.4 (11.1 to 29.4)	1.2 (-14.2 to 20.0)
Non-communicable diseases	-	-	-	25,714.7 (19,230.9 to 32,959.8)	46,311.6 (34,625.7 to 59,648.2)	80.1 (78.2 to 81.9)
Neoplasms	-	-	-	365.2 (265.2 to 474.4)	677.9 (491.8 to 887.3)	85.7 (74.8 to 97.3)
Esophageal cancer	72.9 (57.2 to 89.6)	107.4 (84.5 to 139.8)	47.4 (11.1 to 95.8)	11.2 (7.6 to 15.2)	15.9 (10.8 to 22.3)	41.7 (8.9 to 87.6)
Stomach cancer	200.8 (182.4 to 223.9)	256.2 (227.0 to 292.3)	27.9 (9.5 to 48.3)	24.3 (17.3 to 31.9)	29.8 (20.8 to 39.4)	22.1 (4.4 to 43.0)
Liver cancer	-	-	-	14.0 (9.3 to 19.6)	24.6 (16.5 to 33.7)	75.5 (37.3 to 127.2)
Liver cancer due to hepatitis B	33.3 (25.5 to 43.6)	65.5 (51.0 to 84.4)	97.7 (38.1 to 180.0)	5.5 (3.7 to 7.8)	9.6 (6.3 to 13.3)	75.9 (30.0 to 135.6)
Liver cancer due to hepatitis C	14.1 (11.3 to 17.7)	62.9 (50.7 to 78.8)	348.0 (238.1 to 507.7)	2.3 (1.5 to 3.3)	9.2 (6.1 to 12.6)	294.6 (202.9 to 412.4)
Liver cancer due to alcohol use	22.6 (17.9 to 28.4)	23.2 (18.7 to 28.9)	2.8 (-22.4 to 35.7)	3.7 (2.5 to 5.1)	3.5 (2.3 to 4.7)	-5.8 (-26.5 to 20.0)
Liver cancer due to other causes	15.0 (11.6 to 19.4)	15.5 (12.4 to 19.4)	4.9 (-25.3 to 39.6)	2.5 (1.7 to 3.6)	2.4 (1.6 to 3.3)	-5.6 (-27.6 to 22.6)
Larynx cancer	101.6 (82.9 to 122.0)	140.0 (111.9 to 174.9)	37.6 (16.7 to 64.6)	10.1 (6.8 to 13.9)	13.1 (8.8 to 18.7)	29.3 (6.4 to 60.2)
Tracheal, bronchus and lung cancer	233.5 (217.7 to 248.7)	362.9 (334.0 to 396.9)	55.6 (41.8 to 71.4)	35.6 (25.6 to 45.8)	53.3 (38.0 to 68.6)	49.7 (34.6 to 67.2)
Breast cancer	845.3 (783.0 to 905.8)	2,053.7 (1,935.8 to 2,186.1)	143.7 (125.6 to 162.2)	56.3 (40.4 to 75.4)	122.0 (86.9 to 164.8)	117.1 (94.1 to 138.4)
Cervical cancer	311.5 (243.5 to 381.8)	347.8 (252.9 to 450.6)	12.2 (-18.0 to 50.7)	23.4 (15.6 to 33.0)	26.4 (15.8 to 38.0)	11.7 (-18.9 to 52.0)
Uterine cancer	271.2 (207.0 to 357.5)	495.2 (346.0 to 658.3)	82.6 (35.3 to 146.7)	17.7 (10.9 to 26.3)	31.7 (18.9 to 47.3)	80.1 (32.1 to 139.4)
Prostate cancer	237.5 (193.5 to 284.2)	770.9 (614.2 to 1,006.2)	222.6 (169.5 to 299.2)	19.6 (13.5 to 26.7)	57.9 (38.8 to 82.1)	193.8 (138.9 to 272.6)
Colon and rectum cancer	410.1 (392.7 to 429.5)	842.6 (789.0 to 902.2)	105.4 (91.5 to 121.6)	34.1 (24.9 to 44.2)	66.4 (47.4 to 88.0)	94.4 (78.1 to 113.7)
Lip and oral cavity cancer	183.1 (152.0 to 222.1)	330.3 (258.2 to 410.2)	80.4 (42.3 to 129.4)	15.5 (10.9 to 21.5)	27.5 (18.0 to 38.7)	76.2 (36.1 to 127.7)
Nasopharynx cancer	43.3 (32.7 to 55.4)	62.3 (44.5 to 83.5)	43.5 (-3.2 to 119.5)	4.2 (2.7 to 6.0)	5.9 (3.7 to 8.7)	39.0 (-6.0 to 107.5)
Other pharynx cancer	70.0 (57.6 to 86.2)	129.7 (99.2 to 168.5)	85.1 (36.1 to 147.9)	6.1 (4.1 to 8.5)	11.0 (7.2 to 15.9)	79.5 (32.2 to 150.2)
Gallbladder and biliary tract cancer	10.0 (8.6 to 11.6)	13.9 (11.7 to 16.2)	38.9 (15.9 to 63.5)	2.8 (1.9 to 3.8)	3.7 (2.5 to 5.0)	31.4 (9.4 to 53.3)
Pancreatic cancer	18.7 (17.1 to 20.4)	36.4 (32.3 to 40.7)	94.8 (70.8 to 120.8)	3.9 (2.7 to 5.2)	7.4 (5.2 to 10.0)	87.9 (65.3 to 111.7)
Malignant skin melanoma	118.6 (91.9 to 158.2)	247.9 (189.0 to 340.1)	109.5 (66.7 to 156.7)	7.1 (4.6 to 10.8)	14.4 (8.8 to 22.5)	101.2 (59.7 to 150.6)
Non-melanoma skin cancer	205.6 (175.7 to 242.7)	395.5 (328.5 to 467.1)	93.5 (51.0 to 143.1)	3.4 (2.0 to 5.6)	8.1 (4.7 to 13.1)	134.7 (73.0 to 225.2)
Ovarian cancer	71.6 (64.0 to 79.0)	130.1 (114.3 to 150.6)	81.5 (59.3 to 110.4)	9.1 (6.5 to 11.9)	16.3 (11.4 to 21.6)	79.0 (49.5 to 117.4)
Testicular cancer	8.6 (6.4 to 10.9)	17.1 (12.4 to 22.4)	98.3 (52.8 to 152.6)	0.6 (0.4 to 0.8)	1.1 (0.7 to 1.7)	88.4 (40.9 to 153.9)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (55-59 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Kidney cancer	104.7 (95.0 to 114.5)	233.0 (205.4 to 264.2)	122.6 (94.6 to 154.9)	7.7 (5.4 to 10.4)	16.5 (11.5 to 22.4)	114.7 (87.5 to 149.1)
Bladder cancer	141.3 (122.4 to 159.1)	205.0 (177.3 to 237.3)	45.2 (24.6 to 70.9)	10.8 (7.5 to 14.7)	15.5 (10.8 to 21.0)	43.1 (21.3 to 69.9)
Brain and nervous system cancer	51.3 (42.7 to 61.2)	104.1 (84.8 to 125.8)	103.1 (67.0 to 144.0)	5.7 (3.9 to 7.8)	11.1 (7.6 to 15.2)	94.9 (59.4 to 134.4)
Thyroid cancer	95.3 (79.3 to 111.2)	227.9 (180.8 to 272.2)	139.7 (96.2 to 191.0)	5.7 (3.8 to 8.0)	13.1 (8.3 to 19.2)	130.9 (88.4 to 181.7)
Mesothelioma	3.1 (2.7 to 3.7)	6.4 (5.5 to 7.5)	107.5 (77.0 to 143.4)	0.7 (0.4 to 0.9)	1.4 (0.9 to 1.9)	110.7 (80.5 to 147.8)
Hodgkin lymphoma	24.1 (16.3 to 31.0)	35.4 (27.4 to 49.0)	41.5 (3.3 to 143.3)	2.2 (1.3 to 3.2)	3.0 (2.0 to 4.5)	32.2 (-5.1 to 126.2)
Non-Hodgkin lymphoma	119.2 (101.6 to 144.7)	290.9 (236.5 to 342.6)	146.0 (100.3 to 185.3)	9.1 (6.3 to 12.7)	21.2 (14.3 to 29.6)	133.3 (90.6 to 174.1)
Multiple myeloma	22.1 (16.8 to 28.8)	47.2 (35.9 to 62.0)	114.1 (69.7 to 170.0)	4.6 (2.9 to 6.8)	9.5 (6.2 to 13.3)	106.9 (59.5 to 167.5)
Leukemia	65.6 (59.5 to 71.9)	142.6 (126.2 to 159.0)	117.6 (91.6 to 149.4)	9.1 (6.5 to 12.0)	18.0 (12.7 to 23.8)	97.5 (67.6 to 133.1)
Other neoplasms	143.8 (124.9 to 166.7)	476.3 (404.7 to 561.2)	231.7 (178.5 to 297.3)	10.6 (7.4 to 14.2)	32.1 (22.3 to 45.0)	201.9 (153.2 to 265.3)
Cardiovascular diseases	-	-	-	1,169.0 (816.6 to 1,568.2)	2,167.2 (1,493.2 to 2,951.5)	85.2 (65.9 to 107.7)
Rheumatic heart disease	966.7 (913.2 to 1,024.9)	1,841.6 (1,757.5 to 1,929.8)	91.2 (76.3 to 103.9)	63.6 (43.9 to 88.4)	116.1 (78.5 to 161.1)	83.3 (54.3 to 109.3)
Ischemic heart disease	7,641.2 (7,185.2 to 8,165.6)	10,841.7 (10,278.5 to 11,548.8)	42.3 (32.3 to 52.3)	463.2 (316.4 to 639.6)	675.2 (467.6 to 929.9)	46.0 (34.2 to 57.3)
Cerebrovascular disease	-	-	-	191.4 (135.2 to 250.6)	371.6 (262.0 to 485.6)	94.4 (80.4 to 108.4)
Ischemic stroke	868.1 (831.2 to 908.4)	1,683.5 (1,612.3 to 1,769.8)	94.5 (81.5 to 107.4)	130.5 (89.5 to 174.1)	253.6 (175.1 to 341.6)	94.1 (79.9 to 111.0)
Hemorrhagic stroke	402.6 (384.0 to 424.0)	778.8 (732.6 to 817.4)	94.3 (76.4 to 109.3)	60.8 (41.7 to 80.8)	118.0 (81.3 to 158.2)	94.5 (74.4 to 113.4)
Hypertensive heart disease	504.6 (481.7 to 528.3)	1,105.0 (1,064.1 to 1,149.6)	119.7 (106.9 to 132.8)	56.8 (39.5 to 78.2)	125.2 (87.4 to 171.1)	120.3 (106.0 to 134.7)
Cardiomyopathy and myocarditis	410.9 (390.2 to 429.1)	820.7 (785.2 to 859.7)	100.1 (88.5 to 112.8)	44.7 (30.7 to 60.6)	90.3 (61.7 to 121.9)	102.0 (88.1 to 117.4)
Atrial fibrillation and flutter	386.9 (351.0 to 418.3)	645.3 (612.8 to 689.7)	66.2 (50.6 to 91.5)	31.3 (21.4 to 44.2)	52.4 (35.8 to 73.1)	67.0 (48.5 to 95.0)
Peripheral vascular disease	11,831.2 (10,803.8 to 12,948.8)	21,173.1 (19,147.7 to 23,909.8)	79.1 (57.1 to 106.1)	1.6 (0.8 to 3.1)	2.5 (1.2 to 4.8)	52.7 (0.2 to 120.8)
Endocarditis	13.4 (10.8 to 16.7)	29.6 (22.2 to 35.0)	123.6 (86.7 to 158.0)	1.5 (0.9 to 2.1)	3.2 (2.0 to 4.7)	124.5 (80.2 to 172.7)
Other cardiovascular and circulatory diseases	4,511.3 (3,094.4 to 6,652.2)	10,401.1 (7,353.7 to 15,343.1)	130.6 (62.1 to 227.9)	315.0 (184.1 to 501.2)	730.6 (436.0 to 1,121.7)	131.2 (63.4 to 228.7)
Chronic respiratory diseases	-	-	-	1,949.6 (1,348.3 to 2,649.2)	3,481.1 (2,383.4 to 4,721.4)	78.7 (71.6 to 85.5)
Chronic obstructive pulmonary disease	18,994.0 (18,104.0 to 19,903.1)	33,635.6 (32,065.3 to 35,215.7)	77.5 (75.7 to 79.2)	1,449.3 (992.2 to 1,997.7)	2,707.7 (1,832.5 to 3,722.2)	86.9 (78.7 to 95.3)
Pneumoconiosis	-	-	-	2.6 (1.8 to 3.6)	5.4 (3.8 to 7.5)	110.0 (100.1 to 118.9)
Silicosis	4.1 (3.6 to 4.5)	6.2 (5.5 to 6.8)	51.2 (47.5 to 55.4)	0.8 (0.5 to 1.1)	1.2 (0.8 to 1.7)	51.2 (47.4 to 55.3)
Asbestosis	0.9 (0.8 to 1.0)	1.5 (1.4 to 1.7)	75.3 (68.9 to 82.1)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	75.3 (69.2 to 83.0)
Coal workers pneumoconiosis	2.4 (2.2 to 2.5)	4.0 (3.7 to 4.3)	69.5 (67.2 to 71.7)	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.1)	69.3 (67.0 to 72.0)
Other pneumoconiosis	6.4 (5.6 to 7.1)	17.1 (15.4 to 18.8)	169.1 (159.0 to 179.7)	1.2 (0.8 to 1.7)	3.2 (2.1 to 4.7)	168.1 (157.7 to 178.8)
Asthma	7,960.1 (7,770.0 to 8,135.5)	13,718.1 (13,388.4 to 14,025.6)	72.9 (66.8 to 78.2)	340.7 (224.9 to 479.5)	589.0 (384.1 to 830.0)	72.9 (66.4 to 78.9)
Interstitial lung disease and pulmonary sarcoidosis	31.2 (29.5 to 33.0)	56.7 (52.8 to 60.0)	82.2 (67.4 to 96.8)	4.3 (2.8 to 6.3)	7.9 (4.9 to 11.6)	83.5 (67.7 to 98.7)
Other chronic respiratory diseases	-	-	-	152.7 (95.5 to 228.1)	171.1 (112.6 to 252.0)	11.9 (-2.5 to 30.7)
Cirrhosis	-	-	-	37.0 (25.7 to 50.7)	54.7 (38.1 to 74.6)	47.7 (38.8 to 57.5)
Cirrhosis due to hepatitis B	65.9 (62.7 to 69.8)	92.3 (86.6 to 97.5)	40.4 (30.5 to 51.4)	10.7 (7.2 to 14.6)	15.0 (10.3 to 20.5)	40.4 (21.2 to 62.1)
Cirrhosis due to hepatitis C	56.4 (52.7 to 60.2)	104.3 (97.9 to 112.7)	84.1 (70.2 to 106.6)	9.1 (6.2 to 12.7)	16.9 (11.6 to 23.5)	84.8 (63.3 to 112.2)
Cirrhosis due to alcohol use	87.8 (82.6 to 92.2)	101.8 (94.4 to 109.2)	16.2 (6.3 to 27.6)	14.2 (9.9 to 19.6)	16.6 (11.2 to 22.8)	16.6 (0.6 to 33.2)
Cirrhosis due to other causes	18.6 (16.7 to 20.9)	37.9 (33.3 to 42.8)	103.9 (82.7 to 132.3)	3.0 (2.0 to 4.3)	6.2 (4.1 to 8.8)	105.3 (59.9 to 167.7)
Digestive diseases	-	-	-	476.9 (339.8 to 640.0)	680.2 (488.3 to 903.4)	42.8 (36.5 to 48.8)
Peptic ulcer disease	2,814.1 (2,653.1 to 2,926.2)	2,548.6 (2,367.1 to 2,682.9)	-9.2 (-13.5 to -4.9)	95.9 (65.4 to 136.1)	95.2 (64.9 to 134.5)	-0.8 (-8.3 to 6.0)
Gastritis and duodenitis	4,099.4 (3,999.4 to 4,200.0)	4,967.7 (4,840.8 to 5,102.5)	21.5 (17.3 to 25.7)	132.0 (89.2 to 188.3)	173.3 (115.9 to 245.1)	30.5 (25.2 to 36.8)
Appendicitis	15.8 (13.3 to 18.8)	21.9 (18.7 to 25.8)	39.0 (9.3 to 79.1)	4.6 (2.9 to 6.8)	6.6 (4.0 to 9.6)	41.5 (0.4 to 105.3)
Paralytic ileus and intestinal obstruction	3.7 (3.5 to 3.8)	6.5 (6.3 to 6.7)	78.0 (69.3 to 89.3)	1.2 (0.8 to 1.6)	2.1 (1.4 to 2.9)	75.1 (58.5 to 99.8)
Inguinal, femoral, and abdominal hernia	1,240.1 (1,162.7 to 1,328.9)	1,952.7 (1,798.3 to 2,105.9)	57.7 (40.0 to 76.1)	12.9 (6.4 to 23.6)	20.5 (9.9 to 38.1)	58.1 (40.2 to 76.2)
Inflammatory bowel disease	489.2 (480.6 to 498.1)	955.3 (938.6 to 972.9)	95.7 (91.9 to 99.8)	101.7 (70.5 to 137.6)	198.9 (137.3 to 268.8)	95.6 (87.1 to 104.9)
Vascular intestinal disorders	1.2 (1.1 to 1.3)	2.1 (1.9 to 2.3)	79.8 (58.4 to 98.6)	0.4 (0.3 to 0.5)	0.7 (0.5 to 1.0)	79.7 (58.3 to 98.7)
Gallbladder and biliary diseases	413.8 (393.0 to 434.2)	597.4 (564.7 to 646.1)	44.4 (34.3 to 59.2)	43.6 (30.1 to 59.5)	63.0 (43.4 to 85.6)	44.2 (32.5 to 60.6)
Pancreatitis	89.0 (87.5 to 90.6)	169.9 (166.6 to 173.9)	91.1 (86.5 to 96.5)	25.8 (17.6 to 34.8)	49.5 (34.2 to 66.3)	92.0 (76.7 to 110.0)
Other digestive diseases	-	-	-	58.9 (40.5 to 82.4)	71.5 (49.8 to 98.4)	22.4 (4.9 to 36.8)
Neurological disorders	-	-	-	1,668.0 (1,148.8 to 2,245.3)	3,184.6 (2,174.5 to 4,319.9)	91.0 (81.7 to 99.7)
Alzheimer disease and other dementias	933.9 (900.7 to 963.1)	1,687.4 (1,621.3 to 1,751.1)	81.3 (71.5 to 89.3)	115.5 (81.4 to 152.6)	210.0 (147.7 to 278.9)	81.9 (70.6 to 92.4)
Parkinson disease	262.5 (196.3 to 336.1)	471.5 (351.3 to 608.9)	80.0 (76.1 to 83.8)	32.4 (20.2 to 47.6)	58.4 (37.0 to 86.8)	80.7 (68.3 to 92.7)
Epilepsy	561.6 (525.4 to 596.1)	944.7 (873.7 to 1,011.4)	68.3 (53.4 to 87.0)	177.9 (123.2 to 233.2)	320.5 (218.6 to 416.3)	80.2 (62.2 to 103.9)
Multiple sclerosis	91.5 (88.9 to 93.8)	229.7 (223.0 to 236.3)	151.5 (141.6 to 161.9)	29.6 (21.5 to 37.6)	74.2 (54.0 to 93.6)	151.2 (127.1 to 175.9)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (55-59 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Migraine	26,029.1 (25,041.1 to 27,010.0)	45,214.4 (43,359.7 to 46,792.7)	74.3 (64.9 to 82.6)	851.0 (516.0 to 1,247.4)	1,485.8 (896.5 to 2,175.8)	74.8 (64.5 to 83.4)
Tension-type headache	49,323.5 (47,666.3 to 51,111.1)	85,115.0 (82,322.7 to 87,839.5)	73.0 (64.9 to 80.9)	73.0 (35.9 to 126.9)	126.6 (62.7 to 220.7)	73.4 (64.5 to 82.7)
Medication overuse headache	2,214.1 (1,516.6 to 2,887.0)	5,519.9 (3,774.2 to 7,115.0)	149.2 (128.3 to 177.1)	338.6 (200.8 to 506.7)	848.6 (496.2 to 1,283.5)	149.5 (128.4 to 178.0)
Other neurological disorders	0.5 (0.4 to 0.6)	0.9 (0.7 to 1.0)	77.8 (53.2 to 109.7)	50.0 (34.6 to 69.8)	60.4 (41.3 to 79.1)	23.2 (-2.0 to 35.3)
Mental and substance use disorders	-	-	-	4,751.2 (3,425.2 to 6,131.1)	8,478.0 (6,083.4 to 10,958.8)	78.4 (76.4 to 80.2)
Schizophrenia	1,015.7 (937.0 to 1,102.2)	1,794.6 (1,655.6 to 1,946.0)	77.1 (74.8 to 79.3)	631.2 (465.6 to 762.2)	1,121.7 (827.7 to 1,348.3)	77.8 (72.8 to 82.2)
Alcohol use disorders	2,366.1 (2,223.5 to 2,503.0)	3,993.4 (3,754.7 to 4,214.7)	69.1 (66.1 to 72.2)	228.0 (153.7 to 321.7)	387.0 (261.8 to 548.6)	69.7 (64.8 to 75.1)
Drug use disorders	-	-	-	162.1 (114.2 to 209.0)	291.9 (206.8 to 377.6)	79.8 (70.7 to 89.1)
Opioid use disorders	239.0 (198.1 to 284.9)	420.5 (346.0 to 503.9)	76.4 (71.5 to 80.7)	94.5 (65.3 to 126.3)	167.4 (116.8 to 225.6)	77.1 (67.0 to 87.9)
Cocaine use disorders	118.1 (114.7 to 121.5)	211.5 (205.8 to 217.2)	79.4 (72.3 to 86.5)	15.4 (9.9 to 21.5)	27.8 (18.0 to 39.4)	80.8 (58.4 to 104.6)
Amphetamine use disorders	134.2 (130.5 to 137.8)	250.0 (243.4 to 255.8)	86.7 (79.6 to 93.9)	16.7 (10.6 to 24.2)	31.2 (20.0 to 45.5)	87.3 (65.1 to 113.0)
Cannabis use disorders	110.6 (90.4 to 133.5)	202.7 (166.5 to 244.4)	83.8 (78.3 to 88.6)	3.2 (2.0 to 4.8)	5.9 (3.6 to 8.9)	83.1 (65.8 to 102.2)
Other drug use disorders	-	-	-	32.4 (21.8 to 43.8)	59.6 (39.6 to 81.9)	84.5 (65.6 to 105.1)
Depressive disorders	-	-	-	2,132.2 (1,414.2 to 3,017.7)	3,849.7 (2,551.7 to 5,468.3)	80.5 (76.8 to 83.9)
Major depressive disorder	8,608.9 (6,706.7 to 10,578.6)	15,529.0 (12,094.7 to 19,086.5)	80.9 (77.0 to 84.4)	1,706.4 (1,081.0 to 2,462.5)	3,092.0 (1,955.0 to 4,489.3)	81.2 (76.5 to 85.2)
Dysthymia	4,505.7 (3,668.9 to 5,226.0)	7,982.0 (6,472.1 to 9,284.3)	77.6 (74.8 to 79.8)	425.8 (280.2 to 622.4)	757.7 (494.6 to 1,109.5)	77.9 (74.3 to 81.2)
Bipolar disorder	1,497.5 (1,279.2 to 1,699.1)	2,667.3 (2,292.8 to 3,012.3)	78.5 (76.0 to 80.9)	293.4 (184.5 to 439.3)	525.8 (333.2 to 785.8)	79.1 (73.4 to 85.0)
Anxiety disorders	7,761.6 (5,805.0 to 9,777.5)	13,828.5 (10,271.4 to 17,478.6)	78.5 (75.4 to 81.4)	687.3 (418.0 to 1,025.8)	1,229.0 (747.6 to 1,840.8)	78.8 (73.9 to 82.8)
Eating disorders	-	-	-	-	-	-
Anorexia nervosa	-	-	-	-	-	-
Bulimia nervosa	-	-	-	-	-	-
Autistic spectrum disorders	-	-	-	186.9 (129.7 to 251.8)	330.5 (229.0 to 444.9)	76.8 (72.4 to 81.3)
Autism	502.2 (473.7 to 534.5)	884.0 (833.4 to 941.8)	76.4 (75.8 to 77.0)	118.2 (79.8 to 162.1)	209.2 (142.2 to 287.1)	76.9 (70.7 to 82.9)
Asperger syndrome	712.2 (653.5 to 776.6)	1,252.2 (1,149.7 to 1,364.3)	76.2 (75.8 to 76.6)	68.6 (47.4 to 94.4)	121.4 (84.5 to 168.1)	76.8 (71.1 to 82.5)
Attention-deficit/hyperactivity disorder	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	69.2 (57.5 to 85.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.0 (57.2 to 85.5)
Conduct disorder	-	-	-	-	-	-
Idiopathic intellectual disability	1,899.6 (1,430.8 to 2,408.9)	3,016.0 (2,331.5 to 3,785.6)	58.9 (43.1 to 81.1)	92.1 (59.2 to 132.9)	145.3 (95.5 to 208.0)	57.7 (41.8 to 80.1)
Other mental and substance use disorders	4,655.5 (3,719.0 to 5,642.2)	8,182.4 (6,537.1 to 9,915.3)	76.1 (76.1 to 76.2)	337.9 (218.5 to 477.4)	597.1 (384.0 to 844.7)	76.7 (72.9 to 80.9)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	2,566.0 (1,823.2 to 3,431.9)	5,527.6 (3,938.0 to 7,391.9)	115.5 (105.7 to 125.8)
Diabetes mellitus	17,739.2 (14,681.0 to 19,785.3)	46,176.0 (40,296.3 to 50,394.9)	161.0 (139.0 to 183.8)	1,394.4 (961.7 to 1,906.6)	3,571.4 (2,442.1 to 4,844.2)	157.0 (138.2 to 173.8)
Acute glomerulonephritis	1.1 (0.9 to 1.3)	1.5 (1.3 to 1.7)	38.4 (32.6 to 43.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	38.3 (32.5 to 43.9)
Chronic kidney disease	-	-	-	623.8 (414.3 to 889.1)	1,031.5 (691.2 to 1,449.6)	65.2 (57.2 to 75.1)
Chronic kidney disease due to diabetes mellitus	4,837.5 (2,936.5 to 7,818.0)	8,893.1 (5,576.1 to 13,725.0)	86.6 (58.2 to 113.4)	161.5 (108.3 to 228.7)	302.0 (205.2 to 428.7)	86.1 (66.7 to 110.6)
Chronic kidney disease due to hypertension	3,704.5 (2,351.2 to 6,042.4)	5,036.2 (3,316.3 to 7,858.2)	37.8 (17.2 to 52.3)	154.5 (101.0 to 221.5)	195.4 (128.9 to 284.5)	24.9 (11.9 to 58.0)
Chronic kidney disease due to glomerulonephritis	4,570.8 (2,641.0 to 7,784.7)	6,392.9 (3,908.7 to 10,451.4)	42.5 (14.2 to 64.3)	104.4 (69.3 to 150.3)	164.9 (108.7 to 232.7)	58.7 (37.6 to 79.5)
Chronic kidney disease due to other causes	5,739.8 (3,402.7 to 9,852.2)	9,788.9 (6,130.7 to 15,505.3)	73.2 (48.6 to 91.3)	203.4 (131.3 to 295.0)	369.2 (251.9 to 517.0)	81.8 (60.9 to 108.7)
Urinary diseases and male infertility	-	-	-	256.4 (167.8 to 362.2)	470.0 (303.5 to 666.3)	83.2 (73.8 to 92.7)
Interstitial nephritis and urinary tract infections	45.4 (44.2 to 46.8)	95.1 (92.6 to 97.5)	110.0 (101.6 to 117.6)	1.5 (0.9 to 2.2)	3.1 (2.0 to 4.7)	110.4 (83.6 to 141.0)
Urolithiasis	4,104.3 (2,954.0 to 5,688.7)	8,878.3 (6,284.5 to 12,875.8)	116.8 (104.0 to 126.6)	31.9 (20.1 to 48.2)	69.6 (42.2 to 111.0)	117.2 (102.4 to 133.4)
Benign prostatic hyperplasia	5,770.9 (5,635.9 to 5,894.8)	9,765.8 (9,483.5 to 10,021.7)	69.6 (63.7 to 75.3)	211.8 (137.5 to 299.4)	360.4 (232.4 to 510.3)	70.1 (64.1 to 76.3)
Male infertility due to other causes	-	-	-	-	-	-
Other urinary diseases	-	-	-	11.2 (6.6 to 17.5)	36.8 (17.5 to 61.1)	247.7 (125.4 to 318.4)
Gynecological diseases	-	-	-	107.7 (61.2 to 185.8)	173.6 (94.7 to 304.6)	60.8 (53.5 to 67.5)
Uterine fibroids	2,338.8 (2,202.6 to 2,460.5)	3,982.2 (3,752.8 to 4,195.6)	70.7 (69.9 to 71.4)	46.5 (28.7 to 73.3)	67.8 (40.5 to 109.3)	45.4 (35.0 to 55.2)
Polycystic ovarian syndrome	-	-	-	-	-	-
Female infertility due to other causes	-	-	-	-	-	-
Endometriosis	-	-	-	-	-	-
Genital prolapse	19,489.3 (18,983.6 to 20,050.0)	33,617.0 (32,683.5 to 34,421.5)	73.2 (66.3 to 79.0)	61.2 (30.3 to 114.5)	105.8 (52.1 to 198.2)	73.1 (66.4 to 79.5)
Premenstrual syndrome	-	-	-	-	-	-
Other gynecological diseases	-	-	0.0 (0.0 to 0.0)	-	-	-
Hemoglobinopathies and hemolytic anemias	-	-	-	110.9 (74.3 to 160.9)	172.3 (114.8 to 249.3)	55.4 (45.9 to 64.5)
Thalassemias	1.5 (1.2 to 1.8)	4.0 (3.3 to 4.7)	176.6 (128.2 to 220.3)	0.1 (0.1 to 0.2)	0.5 (0.3 to 0.7)	205.5 (138.9 to 277.6)
Thalassemia trait	5,038.1 (4,513.9 to 5,721.7)	9,200.3 (8,373.6 to 10,323.3)	82.9 (80.3 to 87.1)	60.6 (40.7 to 87.6)	111.9 (75.1 to 161.2)	84.7 (70.4 to 97.3)
Sickle cell disorders	4.9 (4.5 to 5.3)	9.7 (8.9 to 10.3)	95.6 (83.9 to 108.9)	0.8 (0.6 to 1.1)	1.6 (1.1 to 2.2)	102.7 (86.3 to 122.3)
Sickle cell trait	4,794.5 (4,550.2 to 5,018.0)	8,819.7 (8,392.5 to 9,205.5)	84.3 (80.9 to 87.7)	14.5 (9.1 to 21.3)	24.9 (16.1 to 36.3)	71.5 (47.6 to 110.8)
G6PD deficiency	6,873.1 (6,692.5 to 7,038.9)	12,634.2 (12,311.1 to 12,935.6)	84.3 (78.2 to 90.7)	0.6 (0.4 to 0.8)	1.2 (0.8 to 1.7)	104.7 (87.7 to 119.3)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (55-59 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
G6PD trait	28,641-0 (28,488-5 to 28,792-3)	51,790-9 (51,491-4 to 52,075-4)	81-2 (79-9 to 82-7)	0-5 (0-2 to 0-8)	0-8 (0-5 to 1-4)	81-6 (7-4 to 165-4)
Other hemoglobinopathies and hemolytic anemias	1,671-3 (1,643-9 to 1,699-3)	1,937-3 (1,833-5 to 2,037-4)	16-2 (10-0 to 22-4)	33-8 (22-6 to 49-5)	31-5 (20-6 to 47-1)	-6-7 (-21-8 to 4-1)
Endocrine, metabolic, blood, and immune disorders	2,384-3 (2,313-4 to 2,453-5)	3,468-2 (3,366-4 to 3,567-7)	45-8 (39-7 to 52-0)	72-7 (49-5 to 100-3)	108-7 (74-5 to 147-7)	49-5 (39-3 to 60-2)
Musculoskeletal disorders	-	-	-	7,720-0 (5,572-9 to 10,154-2)	13,789-5 (9,904-5 to 18,234-0)	78-6 (75-0 to 81-8)
Rheumatoid arthritis	997-2 (982-0 to 1,013-3)	1,607-3 (1,585-1 to 1,629-1)	61-5 (58-4 to 64-7)	233-6 (167-3 to 307-1)	378-2 (271-9 to 497-6)	61-9 (56-1 to 67-7)
Osteoarthritis	16,632-7 (16,434-9 to 16,829-9)	28,456-6 (28,137-8 to 28,784-2)	71-5 (68-8 to 74-1)	902-6 (635-0 to 1,232-1)	1,583-7 (1,113-0 to 2,141-9)	75-4 (72-2 to 78-9)
Low back and neck pain	-	-	-	5,094-8 (3,580-7 to 6,847-1)	8,987-3 (6,237-1 to 12,049-3)	76-5 (71-5 to 81-0)
Low back pain	31,706-2 (30,867-9 to 32,441-2)	55,742-7 (54,472-4 to 57,308-6)	76-2 (70-7 to 82-0)	3,471-0 (2,377-5 to 4,758-9)	6,134-4 (4,166-7 to 8,459-9)	76-8 (70-8 to 82-7)
Neck pain	16,802-8 (16,179-5 to 17,378-9)	29,385-0 (28,370-0 to 30,391-6)	75-3 (67-1 to 84-0)	1,623-9 (1,133-2 to 2,217-7)	2,852-9 (1,993-7 to 3,914-0)	75-8 (67-3 to 84-5)
Gout	404-6 (395-3 to 414-0)	706-1 (692-7 to 720-2)	74-8 (70-3 to 79-9)	13-0 (8-9 to 17-7)	22-7 (15-8 to 30-8)	75-7 (60-8 to 91-6)
Other musculoskeletal disorders	16,237-4 (12,133-8 to 20,175-3)	30,908-0 (23,615-5 to 38,064-8)	90-6 (85-1 to 99-7)	1,476-0 (938-6 to 2,155-5)	2,817-6 (1,815-8 to 4,105-8)	90-5 (84-9 to 99-9)
Other non-communicable diseases	-	-	-	5,011-7 (3,316-9 to 7,249-8)	8,270-8 (5,443-7 to 12,039-9)	65-0 (61-8 to 67-9)
Congenital anomalies	-	-	-	234-1 (178-1 to 292-8)	522-8 (403-3 to 652-3)	123-1 (113-1 to 134-0)
Neural tube defects	15-9 (15-3 to 16-5)	38-2 (37-1 to 39-4)	141-2 (129-9 to 152-5)	4-5 (3-2 to 6-0)	11-4 (7-9 to 14-8)	152-0 (122-0 to 188-7)
Congenital heart anomalies	613-9 (589-7 to 639-4)	1,488-4 (1,443-7 to 1,545-5)	142-7 (131-9 to 157-0)	20-6 (8-7 to 35-3)	51-4 (22-1 to 87-3)	150-2 (137-5 to 166-0)
Orofacial clefts	83-1 (79-0 to 87-5)	234-6 (227-8 to 241-3)	182-4 (166-9 to 201-3)	0-9 (0-6 to 1-3)	2-4 (1-6 to 3-4)	171-2 (127-9 to 219-6)
Down syndrome	266-4 (235-0 to 290-2)	671-0 (592-8 to 731-0)	152-6 (140-4 to 164-5)	51-7 (38-9 to 65-5)	130-6 (98-6 to 165-3)	152-8 (137-0 to 168-7)
Turner syndrome	4-1 (3-9 to 4-4)	8-9 (8-6 to 9-3)	115-0 (102-4 to 129-1)	0-1 (0-0 to 0-1)	0-1 (0-0 to 0-2)	114-8 (102-2 to 128-9)
Klinefelter syndrome	5-1 (4-8 to 5-3)	9-7 (9-3 to 10-2)	90-8 (79-1 to 104-1)	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	90-8 (79-0 to 104-1)
Chromosomal unbalanced rearrangements	395-0 (347-9 to 432-2)	934-2 (825-8 to 1,021-5)	136-8 (127-1 to 147-7)	76-7 (55-4 to 97-9)	181-9 (133-2 to 233-2)	137-1 (124-5 to 151-1)
Other congenital anomalies	810-9 (699-6 to 905-2)	1,245-8 (1,054-9 to 1,397-0)	53-9 (46-1 to 62-1)	79-8 (56-4 to 107-7)	144-9 (101-3 to 192-8)	81-3 (63-0 to 107-8)
Skin and subcutaneous diseases	-	-	-	990-8 (629-2 to 1,521-8)	1,731-0 (1,090-4 to 2,648-8)	74-6 (70-8 to 79-0)
Dermatitis	8,281-3 (7,332-0 to 9,230-2)	14,467-7 (12,838-4 to 16,092-5)	75-1 (74-3 to 75-9)	224-8 (144-6 to 322-7)	393-8 (255-3 to 563-4)	75-2 (71-7 to 78-5)
Psoriasis	2,445-7 (2,088-4 to 2,892-8)	4,134-2 (3,538-5 to 4,910-0)	69-4 (67-5 to 71-4)	193-5 (129-7 to 273-7)	328-6 (218-7 to 467-8)	69-8 (64-4 to 75-8)
Cellulitis	77-3 (54-3 to 110-7)	108-7 (77-6 to 158-9)	41-3 (30-8 to 51-8)	5-3 (3-0 to 8-5)	7-5 (4-4 to 12-2)	41-4 (18-8 to 69-1)
Pyoderma	133-2 (83-6 to 211-2)	205-6 (117-7 to 348-7)	54-6 (29-6 to 73-4)	0-7 (0-3 to 1-8)	1-1 (0-4 to 2-7)	54-7 (29-3 to 77-5)
Scabies	1,325-7 (1,195-4 to 1,472-5)	2,314-7 (2,115-8 to 2,565-4)	75-3 (54-0 to 101-8)	33-2 (18-9 to 53-5)	58-3 (33-3 to 93-7)	76-0 (54-5 to 102-0)
Fungal skin diseases	20,981-8 (17,909-1 to 23,483-3)	37,113-1 (31,694-8 to 41,532-7)	77-3 (76-2 to 78-5)	77-3 (47-8 to 237-9)	205-9 (84-9 to 421-6)	77-6 (76-2 to 79-1)
Viral skin diseases	1,709-2 (1,254-2 to 2,280-8)	2,946-6 (2,164-3 to 3,941-9)	72-8 (70-1 to 75-6)	50-9 (30-0 to 82-6)	88-2 (51-6 to 143-5)	73-1 (67-8 to 78-4)
Acne vulgaris	1,535-6 (1,453-4 to 1,625-7)	2,577-7 (2,267-7 to 2,787-2)	68-2 (52-8 to 83-7)	16-1 (7-8 to 29-9)	27-1 (13-0 to 49-2)	68-3 (52-7 to 84-6)
Alopecia areata	313-0 (303-9 to 322-5)	541-6 (525-8 to 557-0)	73-5 (66-7 to 81-1)	10-3 (6-6 to 15-2)	17-9 (11-4 to 26-5)	73-6 (62-0 to 85-6)
Pruritus	53-1 (49-9 to 56-6)	93-7 (88-6 to 99-0)	77-0 (62-5 to 90-3)	0-6 (0-3 to 1-0)	1-0 (0-5 to 1-8)	76-5 (55-3 to 99-5)
Urticaria	2,831-5 (2,621-0 to 3,057-0)	5,060-5 (4,632-7 to 5,508-6)	79-5 (61-8 to 99-0)	164-3 (106-5 to 230-9)	295-3 (190-4 to 418-0)	79-9 (61-8 to 100-8)
Decubitus ulcer	51-7 (49-3 to 54-2)	86-4 (82-4 to 91-0)	67-6 (57-5 to 78-2)	7-7 (5-3 to 10-6)	13-1 (9-0 to 17-9)	68-7 (40-7 to 103-7)
Other skin and subcutaneous diseases	28,586-7 (5,866-6 to 69,684-9)	49,884-7 (10,312-2 to 121,257-1)	74-9 (73-1 to 76-7)	167-4 (29-2 to 480-6)	293-2 (51-1 to 838-8)	75-2 (73-0 to 77-5)
Sense organ diseases	-	-	-	2,904-6 (1,899-8 to 4,250-2)	4,592-5 (2,978-8 to 6,752-4)	58-1 (53-0 to 62-2)
Glaucoma	523-7 (418-4 to 645-7)	955-4 (751-2 to 1,192-7)	82-6 (55-9 to 117-3)	36-3 (24-2 to 52-4)	63-8 (40-8 to 93-2)	75-2 (54-0 to 100-3)
Cataract	2,579-0 (2,062-5 to 3,078-6)	3,626-4 (2,867-4 to 4,353-4)	41-6 (24-0 to 57-1)	152-5 (102-2 to 216-3)	222-4 (149-8 to 312-4)	46-1 (30-5 to 60-8)
Macular degeneration	1,023-6 (805-6 to 1,269-1)	1,760-3 (1,400-2 to 2,173-8)	72-2 (61-8 to 85-5)	45-6 (29-5 to 67-7)	79-1 (51-7 to 114-4)	73-2 (61-7 to 88-4)
Uncorrected refractive error	38,867-8 (37,484-2 to 40,341-2)	64,602-1 (62,464-4 to 66,786-4)	66-3 (61-4 to 72-3)	636-2 (382-3 to 1,001-6)	1,011-8 (600-2 to 1,607-5)	58-7 (53-5 to 64-2)
Age-related and other hearing loss	76,818-9 (67,316-1 to 85,622-1)	124,046-0 (107,861-0 to 139,607-7)	61-8 (57-3 to 66-7)	1,803-6 (1,143-4 to 2,678-8)	2,841-0 (1,766-3 to 4,281-5)	57-6 (49-6 to 63-5)
Other vision loss	1,480-0 (1,154-5 to 1,889-0)	2,124-6 (1,623-1 to 2,703-2)	43-8 (31-8 to 57-5)	99-3 (63-9 to 145-2)	143-1 (91-4 to 212-4)	44-0 (33-7 to 55-5)
Other sense organ diseases	5,089-9 (4,973-4 to 5,204-4)	8,953-2 (8,721-1 to 9,143-5)	76-3 (70-5 to 82-3)	130-9 (81-6 to 193-4)	231-4 (143-9 to 340-4)	76-7 (69-9 to 83-9)
Oral disorders	-	-	-	882-2 (546-7 to 1,334-4)	1,424-5 (869-1 to 2,186-6)	61-1 (56-2 to 66-3)
Deciduous caries	-	-	-	-	-	-
Permanent caries	72,693-9 (71,755-1 to 73,629-6)	127,876-4 (126,278-4 to 129,425-1)	76-3 (73-1 to 79-7)	60-9 (28-4 to 115-7)	111-4 (51-6 to 212-6)	82-9 (78-6 to 87-1)
Periodontal diseases	33,644-8 (33,151-5 to 34,145-8)	59,204-0 (58,163-5 to 60,329-7)	76-3 (72-5 to 80-6)	218-0 (88-1 to 447-9)	385-2 (154-6 to 790-8)	76-6 (72-6 to 81-0)
Edentulism and severe tooth loss	16,963-1 (16,457-1 to 17,399-9)	24,989-3 (24,315-3 to 25,693-0)	47-6 (42-5 to 53-5)	473-4 (318-4 to 651-9)	699-0 (474-8 to 966-7)	47-6 (42-3 to 53-7)
Other oral disorders	4,532-4 (4,435-8 to 4,626-1)	7,955-0 (7,771-2 to 8,142-1)	75-9 (70-5 to 81-3)	129-9 (81-9 to 191-6)	228-9 (145-1 to 339-5)	76-4 (70-0 to 82-0)
Injuries	-	-	-	2,721-2 (1,950-9 to 3,668-8)	3,116-8 (2,246-8 to 4,222-0)	15-1 (0-7 to 27-1)
Transport injuries	-	-	-	751-1 (556-9 to 974-0)	922-1 (669-1 to 1,231-9)	22-4 (14-0 to 31-9)
Road injuries	-	-	-	626-7 (465-2 to 812-1)	775-2 (562-5 to 1,034-1)	23-3 (14-4 to 33-4)
Pedestrian road injuries	-	-	-	143-7 (106-6 to 187-0)	198-3 (143-6 to 265-4)	37-6 (28-2 to 48-4)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (55-59 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Cyclist road injuries	-	-	-	64.2 (47.7 to 83.9)	74.4 (53.7 to 99.1)	15.6 (7.8 to 24.2)
Motorcyclist road injuries	-	-	-	134.7 (99.7 to 175.8)	156.5 (111.2 to 211.1)	15.9 (6.4 to 26.5)
Motor vehicle road injuries	-	-	-	276.8 (206.4 to 357.9)	338.5 (248.7 to 448.9)	21.9 (12.9 to 32.3)
Other road injuries	-	-	-	7.3 (5.5 to 9.4)	7.5 (5.5 to 9.9)	1.7 (-4.9 to 9.5)
Other transport injuries	-	-	-	124.4 (91.0 to 163.6)	146.9 (104.8 to 198.2)	17.9 (11.4 to 25.0)
Unintentional injuries	-	-	-	1,258.7 (933.9 to 1,650.9)	1,661.7 (1,191.7 to 2,242.3)	31.8 (24.2 to 39.3)
Falls	-	-	-	719.6 (536.9 to 940.6)	982.0 (704.3 to 1,322.6)	36.2 (26.7 to 46.2)
Drowning	-	-	-	25.2 (18.5 to 32.6)	29.9 (21.8 to 39.5)	18.8 (11.4 to 26.8)
Fire, heat, and hot substances	-	-	-	80.6 (59.2 to 105.9)	87.3 (61.9 to 117.9)	8.4 (0.7 to 15.5)
Poisonings	-	-	-	4.6 (3.3 to 6.1)	5.6 (4.0 to 7.5)	21.5 (14.0 to 29.4)
Exposure to mechanical forces	-	-	-	234.4 (169.6 to 313.9)	278.4 (196.7 to 384.3)	18.4 (12.9 to 24.5)
Unintentional firearm injuries	-	-	-	8.4 (6.3 to 11.0)	10.7 (7.6 to 14.6)	26.7 (18.3 to 36.2)
Unintentional suffocation	-	-	-	2.2 (1.6 to 2.8)	3.7 (2.7 to 5.0)	72.3 (62.9 to 82.1)
Other exposure to mechanical forces	-	-	-	223.8 (161.7 to 300.0)	264.0 (186.4 to 364.8)	17.6 (12.2 to 23.5)
Adverse effects of medical treatment	-	-	-	9.2 (5.9 to 13.5)	16.2 (10.3 to 23.8)	75.7 (68.9 to 82.7)
Animal contact	-	-	-	24.5 (18.2 to 32.2)	28.3 (20.9 to 37.8)	15.4 (9.2 to 20.9)
Venomous animal contact	-	-	-	9.1 (6.5 to 12.0)	10.1 (7.2 to 13.2)	11.3 (2.7 to 20.6)
Non-venomous animal contact	-	-	-	15.5 (11.4 to 20.8)	18.2 (13.1 to 25.2)	17.7 (11.9 to 23.7)
Foreign body	-	-	-	13.6 (10.3 to 17.2)	18.7 (13.7 to 24.2)	37.1 (29.2 to 45.8)
Pulmonary aspiration and foreign body in airway	-	-	-	2.9 (2.2 to 3.6)	3.2 (2.3 to 4.1)	9.1 (-0.9 to 22.3)
Foreign body in eyes	-	-	-	2.3 (1.6 to 3.2)	3.6 (2.4 to 4.9)	52.8 (43.4 to 60.6)
Foreign body in other body part	-	-	-	8.4 (6.3 to 10.7)	11.9 (8.8 to 15.5)	42.2 (34.6 to 50.6)
Other unintentional injuries	-	-	-	147.1 (107.9 to 195.3)	215.3 (154.9 to 289.3)	46.2 (40.5 to 52.0)
Self-harm and interpersonal violence	-	-	-	76.6 (57.2 to 98.7)	91.2 (65.8 to 122.3)	18.5 (10.4 to 28.9)
Self-harm	-	-	-	20.2 (14.7 to 26.3)	22.1 (15.8 to 29.8)	9.0 (2.8 to 17.5)
Interpersonal violence	-	-	-	56.4 (42.2 to 72.6)	69.1 (50.0 to 92.9)	22.0 (12.6 to 33.1)
Assault by firearm	-	-	-	9.7 (7.2 to 12.6)	14.1 (10.1 to 19.0)	45.8 (37.4 to 54.4)
Assault by sharp object	-	-	-	10.3 (7.5 to 13.5)	14.5 (10.2 to 20.1)	40.7 (31.1 to 51.5)
Assault by other means	-	-	-	36.5 (27.2 to 46.9)	40.5 (29.5 to 53.5)	10.5 (1.7 to 21.3)
Forces of nature, war, and legal intervention	-	-	-	634.8 (266.4 to 1,305.9)	441.7 (189.6 to 934.9)	-30.4 (-44.6 to -11.2)
Exposure to forces of nature	-	-	-	49.9 (23.7 to 96.3)	54.8 (25.1 to 118.6)	9.4 (-26.3 to 51.7)
Collective violence and legal intervention	-	-	-	584.9 (236.8 to 1,233.9)	386.9 (162.8 to 801.7)	-33.7 (-47.5 to -14.6)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (60-64 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
All causes	-	-	-	29,386.7 (22,074.8 to 37,849.2)	49,916.1 (37,424.7 to 64,240.5)	69.9 (67.6 to 72.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	1,796.4 (1,258.7 to 2,433.8)	2,413.4 (1,719.9 to 3,233.8)	34.3 (27.0 to 44.3)
HIV/AIDS and tuberculosis	-	-	-	185.9 (129.6 to 249.1)	375.5 (267.0 to 495.9)	101.8 (88.4 to 118.2)
Tuberculosis	545.4 (506.5 to 584.3)	885.1 (823.1 to 954.0)	61.7 (56.2 to 68.4)	159.0 (110.2 to 215.0)	260.7 (179.6 to 348.5)	63.8 (55.6 to 73.4)
HIV/AIDS	-	-	-	26.9 (19.0 to 35.7)	114.8 (82.3 to 153.0)	325.2 (249.2 to 428.6)
HIV/AIDS resulting in mycobacterial infection	7.5 (4.3 to 11.5)	21.1 (13.2 to 29.6)	186.9 (104.2 to 292.5)	2.6 (1.3 to 4.6)	7.6 (4.2 to 12.2)	195.4 (98.4 to 329.6)
HIV/AIDS resulting in other diseases	164.2 (141.8 to 186.9)	796.6 (729.7 to 882.8)	382.2 (321.4 to 466.6)	24.3 (17.0 to 32.4)	107.2 (76.6 to 143.6)	340.1 (255.3 to 456.9)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	199.2 (139.9 to 271.9)	289.1 (200.5 to 403.4)	44.8 (38.4 to 51.9)
Diarrheal diseases	412.6 (397.9 to 428.0)	514.7 (484.8 to 539.8)	24.5 (16.7 to 32.7)	62.3 (42.7 to 84.5)	77.7 (53.6 to 105.4)	24.7 (14.2 to 34.8)
Intestinal infectious diseases	-	-	-	2.5 (1.6 to 3.7)	2.8 (1.8 to 4.1)	12.1 (-21.0 to 54.3)
Typhoid fever	15.3 (12.7 to 18.4)	17.3 (14.2 to 21.2)	13.1 (-12.8 to 50.3)	1.9 (1.2 to 2.9)	2.3 (1.4 to 3.4)	20.7 (-18.9 to 79.9)
Paratyphoid fever	8.6 (6.7 to 10.9)	8.2 (6.3 to 10.7)	-4.0 (-35.8 to 41.6)	0.4 (0.3 to 0.7)	0.4 (0.2 to 0.7)	-3.7 (-40.4 to 57.6)
Other intestinal infectious diseases	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.2)	-42.3 (-57.1 to -22.6)
Lower respiratory infections	94.2 (92.5 to 96.0)	185.6 (181.5 to 189.7)	96.3 (91.2 to 102.1)	9.5 (6.5 to 13.0)	18.7 (12.6 to 25.5)	97.6 (84.5 to 109.9)
Upper respiratory infections	3,822.0 (3,721.9 to 3,909.1)	6,696.3 (6,529.6 to 6,861.2)	74.8 (69.0 to 81.4)	43.2 (24.5 to 69.9)	75.9 (43.0 to 126.1)	75.5 (68.5 to 83.6)
Otitis media	1,724.9 (1,662.8 to 1,793.3)	2,615.0 (2,522.9 to 2,729.0)	51.3 (43.4 to 59.6)	32.0 (19.3 to 50.6)	48.8 (29.0 to 78.2)	52.6 (43.7 to 62.2)
Meningitis	-	-	-	29.5 (17.4 to 45.5)	33.0 (19.7 to 51.3)	11.9 (4.2 to 22.0)
Pneumococcal meningitis	235.0 (127.7 to 368.9)	271.3 (144.5 to 440.2)	14.7 (5.1 to 24.5)	12.9 (8.9 to 18.5)	15.3 (10.4 to 22.1)	18.2 (4.4 to 33.9)
H influenzae type B meningitis	83.2 (13.8 to 178.9)	75.9 (11.2 to 171.3)	-10.0 (-31.9 to 1.6)	3.9 (2.2 to 6.5)	4.0 (2.4 to 6.6)	2.1 (-6.2 to 14.4)
Meningococcal meningitis	51.8 (9.5 to 118.1)	50.0 (9.4 to 119.5)	-4.2 (-20.1 to 7.0)	5.0 (2.0 to 8.8)	5.1 (2.2 to 9.3)	2.3 (-10.6 to 17.9)
Other meningitis	107.2 (23.1 to 225.3)	108.9 (24.0 to 247.5)	0.6 (-22.1 to 16.8)	7.6 (3.9 to 12.5)	8.6 (4.6 to 14.1)	12.4 (-2.6 to 28.4)
Encephalitis	83.3 (34.3 to 188.1)	107.5 (45.0 to 263.0)	29.3 (1.8 to 42.2)	9.1 (6.3 to 12.6)	13.2 (9.0 to 17.9)	45.0 (26.0 to 68.0)
Diphtheria	-	-	-	-	-	-
Whooping cough	-	-	-	-	-	-
Tetanus	30.2 (21.9 to 45.1)	4.7 (2.8 to 7.2)	-84.9 (-91.5 to -72.7)	0.9 (0.5 to 1.4)	0.2 (0.1 to 0.4)	-73.7 (-84.4 to -54.9)
Measles	-	-	-	-	-	-
Varicella and herpes zoster	190.6 (179.5 to 202.5)	349.1 (329.9 to 374.2)	82.5 (69.2 to 98.9)	10.2 (6.4 to 15.2)	18.7 (11.7 to 28.4)	82.6 (67.1 to 101.9)
Neglected tropical diseases and malaria	-	-	-	645.7 (412.2 to 935.8)	745.2 (441.2 to 1,156.3)	14.4 (-3.3 to 37.6)
Malaria	4,077.9 (3,942.0 to 4,205.4)	5,251.1 (5,050.1 to 5,455.9)	28.4 (22.6 to 34.7)	25.1 (16.6 to 36.6)	29.8 (19.3 to 43.5)	18.3 (8.3 to 29.8)
Chagas disease	363.8 (353.3 to 374.3)	494.4 (477.6 to 516.7)	35.4 (29.4 to 43.6)	6.2 (4.1 to 8.8)	8.4 (5.4 to 12.0)	35.5 (25.7 to 46.2)
Leishmaniasis	-	-	-	0.6 (0.3 to 1.1)	1.7 (0.8 to 3.1)	184.1 (154.6 to 216.7)
Visceral leishmaniasis	0.7 (0.5 to 1.0)	1.3 (0.9 to 1.7)	76.5 (26.8 to 149.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	77.0 (26.9 to 150.6)
Cutaneous and mucocutaneous leishmaniasis	51.7 (45.2 to 59.8)	152.0 (130.3 to 177.5)	193.0 (162.0 to 228.1)	0.5 (0.2 to 1.0)	1.6 (0.7 to 3.0)	195.4 (164.2 to 229.9)
African trypanosomiasis	2.1 (0.9 to 4.1)	0.5 (0.3 to 1.0)	-73.4 (-77.2 to -68.4)	0.5 (0.2 to 1.1)	0.1 (0.1 to 0.3)	-73.2 (-82.4 to -57.9)
Schistosomiasis	5,433.5 (4,876.0 to 5,999.1)	6,678.7 (5,754.5 to 7,757.2)	20.9 (12.5 to 41.0)	43.1 (21.9 to 79.9)	52.7 (26.6 to 101.4)	20.8 (13.0 to 39.7)
Cysticercosis	69.1 (58.2 to 80.8)	54.1 (42.2 to 64.8)	-21.9 (-39.6 to 4.8)	18.7 (12.8 to 24.9)	15.9 (10.3 to 21.8)	-15.5 (-36.4 to 16.8)
Cystic echinococcosis	60.3 (57.7 to 62.5)	56.2 (54.6 to 59.0)	-6.9 (-10.5 to -3.6)	5.5 (3.7 to 7.5)	5.1 (3.6 to 7.1)	-6.1 (-17.6 to 5.8)
Lymphatic filariasis	2,891.3 (2,410.6 to 3,492.6)	2,290.8 (1,810.3 to 2,935.3)	-21.2 (-30.2 to -11.2)	130.4 (66.4 to 222.9)	145.4 (80.3 to 238.8)	12.6 (-11.2 to 36.7)
Onchocerciasis	873.6 (657.5 to 1,216.4)	575.3 (406.8 to 809.9)	-34.8 (-43.6 to -22.0)	76.0 (43.7 to 121.9)	52.3 (28.1 to 87.1)	-32.3 (-43.9 to -15.0)
Trachoma	598.2 (399.1 to 811.7)	342.4 (224.4 to 464.1)	-43.4 (-52.8 to -31.8)	37.7 (22.8 to 55.3)	22.0 (12.8 to 33.9)	-41.8 (-51.0 to -30.6)
Dengue	10.5 (3.9 to 23.6)	97.6 (36.0 to 218.9)	824.6 (816.8 to 831.5)	1.6 (0.5 to 4.1)	15.0 (4.9 to 37.3)	828.9 (608.7 to 1,097.4)
Yellow fever	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-62.8 (-73.4 to -43.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-62.7 (-73.5 to -43.3)
Rabies	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-25.2 (-45.7 to 1.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.1 (-45.6 to 1.2)
Intestinal nematode infections	-	-	-	142.9 (82.6 to 228.4)	95.2 (54.7 to 154.4)	-33.2 (-39.7 to -26.3)
Ascariasis	28,819.3 (23,762.6 to 35,273.5)	26,187.3 (21,699.0 to 32,263.5)	-9.5 (-30.9 to 21.1)	67.4 (37.5 to 110.9)	24.8 (13.6 to 42.8)	-63.4 (-69.3 to -55.9)
Trichuriasis	14,152.1 (11,167.9 to 18,320.7)	14,866.4 (13,217.3 to 16,783.6)	6.4 (-22.3 to 36.0)	19.1 (10.6 to 31.7)	16.6 (8.9 to 27.9)	-14.0 (-32.4 to 15.5)
Hookworm disease	13,596.2 (11,144.6 to 16,733.2)	15,462.6 (13,938.5 to 17,374.1)	14.2 (-10.2 to 40.7)	56.3 (33.8 to 89.1)	53.8 (31.7 to 86.0)	-4.6 (-15.3 to 7.9)
Food-borne trematodiasis	2,946.4 (2,202.2 to 3,696.6)	5,990.2 (4,420.9 to 7,391.4)	103.0 (81.2 to 122.3)	140.2 (37.8 to 301.1)	287.3 (73.9 to 620.9)	105.7 (77.6 to 130.3)
Other neglected tropical diseases	453.9 (415.1 to 493.7)	542.9 (503.9 to 579.7)	19.2 (8.4 to 31.3)	17.3 (9.9 to 30.4)	14.3 (7.7 to 25.4)	-18.9 (-33.8 to 4.3)
Maternal disorders	-	-	-	10.0 (6.3 to 14.6)	13.3 (8.5 to 19.0)	32.7 (1.7 to 71.4)
Maternal hemorrhage	-	-	-	-	-	-
Maternal sepsis and other maternal infections	-	-	-	-	-	-
Maternal hypertensive disorders	-	-	-	-	-	-
Obstructed labor	32.7 (25.4 to 40.2)	42.9 (34.6 to 51.8)	31.1 (17.1 to 46.3)	10.0 (6.3 to 14.6)	13.3 (8.5 to 19.0)	32.7 (1.7 to 71.4)
Complications of abortion	-	-	-	-	-	-

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (60-64 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Other maternal disorders	-	-	-	-	-	-
Neonatal disorders	-	-	-	95.9 (71.6 to 123.3)	304.8 (229.9 to 385.5)	218.5 (185.8 to 250.4)
Preterm birth complications	570.2 (492.3 to 666.0)	1,808.3 (1,555.3 to 2,139.0)	216.2 (186.5 to 251.4)	50.9 (37.9 to 64.5)	185.2 (138.4 to 235.2)	264.0 (238.3 to 291.1)
Neonatal encephalopathy due to birth asphyxia and trauma	468.0 (167.2 to 880.8)	533.6 (231.5 to 950.5)	13.7 (-15.5 to 82.9)	19.1 (12.2 to 29.6)	35.3 (25.5 to 48.3)	87.4 (49.4 to 132.8)
Neonatal sepsis and other neonatal infections	-	-	-	-	-	-
Hemolytic disease and other neonatal jaundice	30.4 (26.3 to 35.5)	83.7 (68.9 to 101.7)	171.6 (121.9 to 256.2)	11.7 (8.2 to 15.5)	30.8 (21.8 to 40.9)	160.7 (118.3 to 247.4)
Other neonatal disorders	-	-	-	14.2 (9.7 to 20.3)	53.5 (35.9 to 71.7)	280.3 (189.0 to 362.1)
Nutritional deficiencies	-	-	-	617.2 (413.7 to 882.7)	627.7 (414.8 to 920.8)	1.4 (-2.4 to 6.1)
Protein-energy malnutrition	26.6 (14.5 to 43.2)	40.8 (20.8 to 66.6)	52.8 (13.7 to 104.4)	3.1 (1.4 to 5.7)	4.7 (2.1 to 8.7)	53.1 (9.1 to 118.5)
Iodine deficiency	3,533.3 (3,277.6 to 3,796.2)	3,707.6 (3,453.7 to 3,947.8)	4.6 (-4.6 to 15.4)	61.3 (38.0 to 95.0)	64.4 (40.3 to 102.4)	5.1 (-4.4 to 16.2)
Vitamin A deficiency	46.4 (19.2 to 72.3)	49.3 (25.0 to 74.9)	6.8 (-17.2 to 41.2)	2.9 (1.1 to 4.8)	3.0 (1.4 to 5.1)	3.0 (-26.1 to 56.3)
Iron-deficiency anemia	23,588.6 (23,419.8 to 23,776.4)	29,663.5 (29,435.2 to 29,856.1)	25.4 (24.2 to 26.7)	549.7 (370.8 to 786.8)	555.2 (370.3 to 816.0)	0.7 (-3.3 to 5.9)
Other nutritional deficiencies	-	-	-	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.7)	21.3 (-29.1 to 96.2)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	42.6 (26.7 to 69.2)	58.0 (35.1 to 98.3)	35.4 (24.8 to 47.5)
Sexually transmitted diseases excluding HIV	-	-	-	16.2 (8.1 to 32.9)	24.8 (11.6 to 52.4)	52.4 (37.6 to 61.7)
Syphilis	23.8 (23.0 to 24.6)	29.0 (28.0 to 30.1)	21.4 (15.5 to 27.5)	4.3 (2.9 to 6.1)	5.3 (3.6 to 7.7)	22.9 (3.3 to 49.2)
Chlamydial infection	78.9 (75.8 to 81.6)	133.3 (128.3 to 138.2)	68.5 (59.7 to 77.8)	0.4 (0.2 to 0.6)	0.6 (0.4 to 0.9)	60.8 (46.5 to 77.0)
Gonococcal infection	1.3 (1.1 to 1.4)	1.7 (1.6 to 1.9)	36.4 (22.0 to 57.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	10.1 (-10.7 to 41.4)
Trichomoniasis	21.8 (20.1 to 23.4)	36.6 (32.9 to 40.3)	67.1 (51.6 to 90.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	66.4 (20.6 to 133.0)
Genital herpes	46,282.7 (45,724.7 to 46,815.8)	76,176.9 (75,218.0 to 77,290.9)	64.1 (61.4 to 67.3)	11.2 (3.2 to 27.6)	18.4 (5.4 to 45.5)	64.5 (60.6 to 68.8)
Other sexually transmitted diseases	1.4 (1.2 to 1.5)	2.1 (2.0 to 2.3)	55.9 (38.0 to 73.4)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	55.5 (37.8 to 73.2)
Hepatitis	-	-	-	10.0 (6.6 to 14.3)	14.4 (9.4 to 20.7)	43.4 (32.9 to 52.9)
Hepatitis A	47.1 (42.4 to 51.5)	102.5 (96.7 to 107.5)	117.4 (108.1 to 127.4)	1.7 (1.1 to 2.5)	3.7 (2.3 to 5.3)	117.7 (94.0 to 145.5)
Hepatitis B	12,038.9 (11,722.6 to 12,459.0)	14,462.1 (14,097.5 to 14,831.6)	19.9 (15.8 to 23.6)	6.6 (4.3 to 9.4)	8.1 (5.3 to 11.8)	23.2 (11.8 to 34.3)
Hepatitis C	8,327.8 (8,199.4 to 8,474.9)	10,728.6 (10,566.7 to 10,900.4)	28.5 (25.5 to 31.4)	1.2 (0.8 to 1.7)	1.6 (1.0 to 2.3)	32.3 (10.8 to 61.3)
Hepatitis E	24.4 (22.1 to 26.9)	41.9 (37.4 to 47.1)	70.5 (46.3 to 102.0)	0.6 (0.4 to 0.9)	1.1 (0.7 to 1.6)	81.4 (38.5 to 146.1)
Leprosy	43.3 (38.8 to 46.9)	74.2 (67.2 to 83.1)	70.6 (55.2 to 90.2)	2.4 (1.6 to 3.5)	4.5 (2.9 to 6.4)	85.6 (53.9 to 123.3)
Other infectious diseases	572.2 (545.3 to 605.6)	725.6 (687.2 to 763.6)	26.6 (17.6 to 35.2)	13.9 (8.9 to 20.8)	14.3 (8.6 to 22.9)	2.2 (-15.3 to 24.3)
Non-communicable diseases	-	-	-	24,974.3 (18,749.3 to 32,190.8)	44,458.8 (33,225.2 to 57,406.9)	78.0 (76.2 to 79.9)
Neoplasms	-	-	-	443.3 (327.5 to 570.5)	837.0 (608.9 to 1,077.4)	88.6 (77.8 to 100.6)
Esophageal cancer	87.0 (68.9 to 107.4)	137.5 (107.5 to 182.0)	57.9 (18.4 to 110.6)	13.4 (9.3 to 18.2)	20.3 (14.0 to 28.1)	50.6 (17.6 to 98.0)
Stomach cancer	263.5 (240.8 to 287.2)	358.5 (317.8 to 405.5)	35.6 (16.6 to 56.3)	31.8 (22.5 to 41.8)	41.0 (29.1 to 53.6)	29.0 (9.7 to 49.2)
Liver cancer	-	-	-	15.0 (10.2 to 20.4)	27.6 (18.8 to 37.4)	83.8 (49.4 to 129.6)
Liver cancer due to hepatitis B	31.8 (24.8 to 40.9)	67.8 (53.1 to 86.3)	111.2 (55.4 to 195.2)	5.2 (3.5 to 7.3)	9.9 (6.7 to 13.8)	89.6 (45.1 to 147.3)
Liver cancer due to hepatitis C	16.4 (13.2 to 19.7)	74.2 (60.4 to 91.2)	349.9 (246.5 to 501.7)	2.7 (1.8 to 3.7)	10.8 (7.4 to 14.6)	297.8 (217.3 to 404.5)
Liver cancer due to alcohol use	26.8 (21.7 to 32.8)	28.9 (23.7 to 35.3)	7.1 (-16.2 to 40.4)	4.4 (3.0 to 5.9)	4.4 (2.9 to 5.9)	-0.1 (-18.9 to 24.5)
Liver cancer due to other causes	15.7 (12.8 to 19.7)	16.7 (13.4 to 20.7)	5.9 (-20.2 to 38.1)	2.7 (1.8 to 3.7)	2.6 (1.7 to 3.5)	-4.3 (-24.6 to 21.5)
Larynx cancer	112.9 (92.9 to 134.6)	162.2 (127.1 to 198.7)	42.6 (20.5 to 69.6)	11.4 (7.8 to 15.8)	15.2 (10.1 to 21.1)	33.6 (12.1 to 61.4)
Tracheal, bronchus and lung cancer	319.8 (300.3 to 338.1)	515.5 (475.6 to 560.6)	60.8 (47.6 to 75.3)	48.4 (35.1 to 61.9)	74.8 (53.6 to 96.1)	54.5 (40.5 to 69.8)
Breast cancer	931.4 (871.5 to 990.7)	2,280.6 (2,163.7 to 2,408.4)	144.5 (128.3 to 162.4)	60.6 (43.3 to 80.4)	129.3 (91.2 to 175.4)	114.0 (92.8 to 134.8)
Cervical cancer	270.2 (209.5 to 325.4)	309.8 (229.1 to 387.7)	14.5 (-14.9 to 47.2)	20.6 (13.9 to 28.6)	23.6 (15.3 to 33.4)	14.5 (-14.7 to 49.6)
Uterine cancer	248.6 (199.0 to 318.4)	451.7 (336.9 to 567.9)	81.1 (42.0 to 132.8)	16.4 (10.9 to 23.3)	29.0 (18.1 to 40.7)	77.2 (37.4 to 127.7)
Prostate cancer	471.7 (397.4 to 553.9)	1,435.1 (1,219.4 to 1,824.7)	199.4 (160.9 to 270.5)	39.1 (26.8 to 54.1)	109.8 (74.4 to 156.1)	177.8 (134.9 to 246.9)
Colon and rectum cancer	554.3 (530.7 to 579.0)	1,131.8 (1,064.0 to 1,208.1)	103.6 (89.4 to 119.5)	46.3 (33.9 to 60.3)	89.5 (64.8 to 117.1)	92.9 (77.0 to 110.5)
Lip and oral cavity cancer	204.5 (170.3 to 249.6)	361.3 (288.8 to 445.8)	76.1 (37.2 to 123.9)	17.7 (12.3 to 24.5)	30.4 (20.4 to 42.8)	72.3 (30.7 to 122.6)
Nasopharynx cancer	37.7 (28.9 to 48.5)	55.4 (39.8 to 75.6)	47.2 (1.0 to 115.5)	3.8 (2.4 to 5.4)	5.3 (3.3 to 8.0)	41.2 (-1.5 to 107.4)
Other pharynx cancer	71.2 (57.4 to 88.0)	131.1 (100.9 to 168.9)	83.0 (34.8 to 151.2)	6.3 (4.2 to 8.9)	11.3 (7.2 to 16.2)	78.7 (29.6 to 144.6)
Gallbladder and biliary tract cancer	13.5 (11.5 to 15.7)	18.7 (15.7 to 22.0)	38.0 (16.4 to 60.6)	3.7 (2.6 to 5.0)	4.9 (3.3 to 6.7)	31.3 (9.9 to 54.8)
Pancreatic cancer	25.9 (23.7 to 28.0)	51.6 (46.3 to 56.7)	98.7 (75.5 to 123.0)	5.3 (3.7 to 7.0)	10.2 (7.1 to 13.6)	91.9 (66.7 to 118.3)
Malignant skin melanoma	126.1 (95.6 to 166.4)	277.9 (196.0 to 383.5)	118.9 (76.4 to 172.2)	7.7 (5.0 to 11.5)	16.1 (9.8 to 25.0)	108.3 (65.7 to 159.4)
Non-melanoma skin cancer	272.2 (236.7 to 313.2)	558.5 (469.8 to 670.8)	104.8 (62.6 to 154.2)	4.5 (2.6 to 7.2)	10.9 (6.3 to 16.8)	138.9 (72.8 to 252.4)
Ovarian cancer	78.7 (70.5 to 87.2)	134.2 (117.4 to 152.6)	70.0 (47.2 to 96.4)	10.1 (7.2 to 13.1)	16.8 (11.8 to 22.1)	66.5 (40.1 to 99.3)
Testicular cancer	6.7 (4.8 to 8.2)	13.8 (10.2 to 17.7)	105.2 (64.1 to 171.7)	0.5 (0.3 to 0.7)	0.9 (0.6 to 1.4)	95.1 (46.7 to 166.4)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (60-64 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Kidney cancer	132.0 (118.8 to 146.3)	305.0 (267.2 to 348.0)	129.6 (101.7 to 163.8)	9.7 (6.9 to 13.1)	21.5 (14.9 to 29.2)	120.8 (91.2 to 157.0)
Bladder cancer	212.8 (180.1 to 237.4)	302.5 (265.5 to 348.4)	41.5 (23.8 to 64.9)	16.4 (11.7 to 22.2)	22.7 (16.2 to 31.3)	38.2 (20.1 to 61.9)
Brain and nervous system cancer	52.5 (44.4 to 60.9)	110.3 (89.7 to 131.7)	110.4 (75.6 to 147.8)	5.9 (4.1 to 7.9)	11.8 (7.9 to 15.8)	100.1 (65.3 to 138.4)
Thyroid cancer	83.0 (69.8 to 96.5)	199.9 (160.6 to 242.6)	138.7 (97.5 to 192.4)	5.2 (3.5 to 7.1)	11.8 (7.7 to 17.2)	128.2 (87.1 to 180.2)
Mesothelioma	3.8 (3.4 to 4.7)	9.0 (7.8 to 10.5)	135.7 (91.7 to 174.0)	0.8 (0.6 to 1.1)	1.9 (1.3 to 2.6)	136.6 (92.6 to 179.4)
Hodgkin lymphoma	25.2 (16.5 to 31.6)	35.4 (27.6 to 49.3)	35.2 (-1.2 to 133.0)	2.4 (1.5 to 3.4)	3.1 (2.0 to 4.6)	25.7 (-11.1 to 118.5)
Non-Hodgkin lymphoma	139.5 (117.4 to 176.6)	341.5 (272.1 to 407.0)	146.4 (98.1 to 186.1)	10.6 (7.3 to 14.7)	24.7 (16.7 to 33.9)	133.7 (86.3 to 174.3)
Multiple myeloma	29.4 (22.4 to 38.9)	62.6 (49.1 to 81.8)	112.8 (72.5 to 161.0)	6.1 (3.9 to 8.9)	12.5 (8.4 to 17.9)	104.4 (61.7 to 160.0)
Leukemia	78.4 (72.0 to 85.5)	168.5 (152.3 to 187.6)	113.9 (91.3 to 140.6)	10.8 (7.8 to 14.2)	21.4 (15.4 to 28.0)	97.7 (69.3 to 130.2)
Other neoplasms	171.6 (152.4 to 201.2)	575.0 (496.5 to 673.9)	235.7 (186.6 to 290.9)	12.8 (9.2 to 17.4)	38.7 (26.5 to 52.9)	204.4 (155.7 to 256.6)
Cardiovascular diseases	-	-	-	1,413.9 (997.5 to 1,880.3)	2,552.6 (1,793.1 to 3,451.1)	80.6 (62.9 to 98.8)
Rheumatic heart disease	826.5 (787.8 to 871.3)	1,531.1 (1,472.4 to 1,595.2)	84.8 (71.7 to 96.3)	58.1 (40.0 to 79.4)	102.0 (68.5 to 141.8)	76.7 (46.9 to 102.2)
Ischemic heart disease	10,023.5 (9,403.5 to 10,835.7)	14,343.2 (13,635.8 to 15,258.5)	43.1 (31.5 to 54.2)	605.9 (410.8 to 838.0)	882.8 (610.7 to 1,212.0)	46.0 (33.1 to 58.6)
Cerebrovascular disease	-	-	-	249.2 (177.6 to 324.7)	484.6 (343.2 to 627.4)	94.8 (81.9 to 107.6)
Ischemic stroke	1,196.4 (1,141.8 to 1,257.2)	2,311.9 (2,224.1 to 2,419.0)	93.3 (79.6 to 105.3)	178.1 (122.8 to 238.2)	343.9 (240.9 to 450.8)	93.3 (78.6 to 108.1)
Hemorrhagic stroke	475.1 (455.4 to 498.1)	941.4 (894.9 to 986.1)	98.3 (83.7 to 112.4)	71.1 (49.0 to 94.7)	140.7 (96.2 to 189.1)	98.7 (79.7 to 117.2)
Hypertensive heart disease	588.9 (561.7 to 616.8)	1,283.4 (1,237.4 to 1,332.4)	117.7 (104.6 to 130.7)	65.9 (46.2 to 90.7)	144.0 (101.5 to 198.8)	118.8 (105.3 to 133.1)
Cardiomyopathy and myocarditis	465.0 (442.2 to 484.3)	935.4 (898.7 to 976.1)	100.5 (90.6 to 112.3)	50.4 (34.8 to 67.6)	102.3 (69.6 to 138.1)	103.0 (90.9 to 116.8)
Atrial fibrillation and flutter	635.7 (577.2 to 686.4)	1,099.9 (1,028.4 to 1,185.7)	71.8 (55.3 to 96.2)	51.0 (34.8 to 71.5)	88.5 (60.6 to 120.8)	73.0 (55.3 to 98.2)
Peripheral vascular disease	13,638.6 (12,595.0 to 14,663.9)	23,872.0 (22,040.1 to 25,948.7)	74.5 (55.9 to 95.6)	4.7 (2.2 to 8.5)	6.7 (3.2 to 12.1)	40.5 (14.2 to 93.5)
Endocarditis	15.0 (11.9 to 18.6)	30.9 (23.9 to 37.0)	107.1 (76.7 to 131.8)	1.6 (1.0 to 2.4)	3.3 (2.0 to 4.8)	106.1 (66.8 to 146.7)
Other cardiovascular and circulatory diseases	4,703.2 (3,198.2 to 6,918.7)	10,573.5 (7,184.7 to 15,103.2)	124.2 (55.2 to 219.9)	327.2 (196.2 to 524.2)	738.3 (425.1 to 1,150.7)	125.2 (55.1 to 222.6)
Chronic respiratory diseases	-	-	-	1,892.4 (1,300.2 to 2,587.9)	3,330.9 (2,279.7 to 4,542.3)	76.2 (69.1 to 82.2)
Chronic obstructive pulmonary disease	19,175.6 (18,251.9 to 20,137.4)	33,594.7 (31,932.9 to 35,253.0)	74.7 (73.0 to 76.6)	1,428.4 (966.2 to 1,992.7)	2,618.0 (1,762.2 to 3,641.0)	83.4 (75.0 to 90.8)
Pneumoconiosis	-	-	-	2.8 (2.0 to 3.8)	5.8 (4.0 to 8.0)	105.8 (95.9 to 115.0)
Silicosis	4.9 (4.3 to 5.4)	7.2 (6.4 to 8.0)	48.4 (44.4 to 52.5)	0.9 (0.6 to 1.3)	1.4 (0.9 to 2.0)	49.0 (44.9 to 53.2)
Asbestosis	1.0 (0.9 to 1.1)	1.8 (1.6 to 2.0)	73.9 (68.1 to 81.7)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	75.2 (69.3 to 83.3)
Coal workers pneumoconiosis	2.3 (2.2 to 2.5)	4.0 (3.7 to 4.3)	70.7 (68.4 to 73.2)	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.1)	71.0 (68.5 to 73.7)
Other pneumoconiosis	6.6 (5.8 to 7.4)	17.5 (15.6 to 19.4)	166.6 (155.7 to 176.8)	1.2 (0.8 to 1.8)	3.3 (2.1 to 4.7)	165.9 (155.0 to 176.8)
Asthma	7,368.9 (7,181.1 to 7,541.8)	12,731.9 (12,439.4 to 13,004.0)	72.5 (66.2 to 77.9)	313.5 (207.5 to 439.4)	541.9 (356.8 to 762.3)	73.0 (66.7 to 78.8)
Interstitial lung disease and pulmonary sarcoidosis	32.9 (31.1 to 34.7)	60.9 (57.1 to 64.3)	84.9 (69.0 to 98.5)	4.6 (2.9 to 6.7)	8.5 (5.3 to 12.4)	86.1 (69.7 to 100.7)
Other chronic respiratory diseases	-	-	-	143.1 (90.4 to 216.8)	156.7 (102.5 to 231.7)	9.3 (-4.2 to 27.6)
Cirrhosis	-	-	-	35.0 (24.5 to 48.1)	51.3 (36.0 to 70.1)	46.7 (37.9 to 55.8)
Cirrhosis due to hepatitis B	60.5 (57.6 to 64.0)	85.8 (81.2 to 90.5)	41.3 (31.9 to 52.1)	9.7 (6.7 to 13.4)	13.8 (9.5 to 19.1)	41.7 (25.2 to 59.7)
Cirrhosis due to hepatitis C	55.5 (52.3 to 59.0)	101.9 (96.5 to 109.2)	82.4 (69.3 to 102.3)	8.9 (6.2 to 12.3)	16.4 (11.4 to 22.7)	83.9 (63.8 to 109.1)
Cirrhosis due to alcohol use	85.9 (81.4 to 89.8)	98.4 (92.7 to 104.7)	14.4 (5.5 to 24.9)	13.8 (9.6 to 18.9)	15.9 (10.8 to 21.7)	15.4 (1.5 to 31.0)
Cirrhosis due to other causes	16.2 (14.7 to 18.1)	32.4 (28.6 to 36.1)	98.8 (76.9 to 124.7)	2.6 (1.7 to 3.8)	5.2 (3.5 to 7.5)	100.5 (59.6 to 151.2)
Digestive diseases	-	-	-	551.4 (390.0 to 748.6)	762.1 (546.6 to 1,018.5)	38.1 (33.4 to 43.2)
Peptic ulcer disease	4,047.5 (3,896.5 to 4,159.5)	3,778.6 (3,492.0 to 4,018.9)	-6.9 (-11.6 to -1.3)	136.9 (94.0 to 192.5)	137.0 (93.7 to 194.3)	0.1 (-6.2 to 8.0)
Gastritis and duodenitis	4,762.9 (4,672.1 to 4,856.1)	6,331.7 (6,200.2 to 6,462.9)	32.6 (28.9 to 36.4)	154.8 (105.0 to 221.2)	214.2 (144.7 to 305.5)	38.3 (33.4 to 43.4)
Appendicitis	11.8 (9.8 to 14.2)	16.5 (14.1 to 19.4)	38.7 (5.8 to 83.7)	3.4 (2.2 to 5.0)	4.9 (3.0 to 7.3)	44.2 (-2.0 to 106.7)
Paralytic ileus and intestinal obstruction	4.1 (4.0 to 4.2)	7.6 (7.4 to 7.8)	82.2 (75.8 to 90.7)	1.3 (0.9 to 1.8)	2.4 (1.5 to 3.4)	80.2 (55.3 to 113.9)
Inguinal, femoral, and abdominal hernia	1,643.1 (1,545.7 to 1,751.6)	2,579.5 (2,382.8 to 2,765.1)	56.7 (40.0 to 73.6)	17.1 (8.4 to 31.6)	26.9 (13.1 to 50.3)	57.7 (40.4 to 76.0)
Inflammatory bowel disease	466.5 (458.2 to 474.8)	886.6 (871.5 to 902.3)	89.5 (86.1 to 93.3)	96.1 (66.3 to 129.9)	182.8 (128.3 to 247.1)	90.4 (82.9 to 97.7)
Vascular intestinal disorders	1.7 (1.6 to 1.8)	3.0 (2.8 to 3.4)	77.8 (60.4 to 97.5)	0.5 (0.4 to 0.8)	1.0 (0.6 to 1.4)	77.9 (60.4 to 97.6)
Gallbladder and biliary diseases	454.3 (432.4 to 475.5)	645.2 (609.7 to 690.2)	41.3 (31.7 to 54.1)	47.5 (32.8 to 65.1)	67.4 (46.5 to 91.4)	41.5 (30.8 to 55.6)
Pancreatitis	82.7 (81.2 to 84.2)	159.9 (156.4 to 163.5)	92.7 (87.8 to 98.7)	23.7 (16.4 to 32.0)	46.1 (31.5 to 62.1)	94.3 (79.0 to 110.4)
Other digestive diseases	-	-	-	70.1 (47.7 to 98.9)	79.5 (54.4 to 109.7)	14.3 (-2.3 to 27.6)
Neurological disorders	-	-	-	1,538.3 (1,074.1 to 2,052.4)	2,848.8 (1,968.4 to 3,800.5)	85.2 (76.4 to 93.9)
Alzheimer disease and other dementias	1,838.0 (1,777.3 to 1,888.4)	3,298.6 (3,177.7 to 3,406.3)	79.3 (69.7 to 87.0)	225.9 (160.1 to 299.4)	405.8 (286.8 to 538.3)	80.0 (69.6 to 88.7)
Parkinson disease	395.6 (300.0 to 507.9)	730.7 (545.7 to 952.4)	84.2 (79.1 to 88.4)	48.2 (30.4 to 68.8)	89.1 (56.1 to 128.9)	85.0 (73.8 to 95.6)
Epilepsy	501.8 (471.4 to 531.9)	821.3 (761.5 to 876.3)	63.0 (49.2 to 80.1)	158.5 (110.5 to 206.7)	277.2 (192.2 to 358.2)	74.8 (58.8 to 95.0)
Multiple sclerosis	72.1 (69.8 to 74.0)	184.2 (178.5 to 189.9)	154.9 (143.8 to 166.0)	23.2 (16.7 to 29.5)	58.9 (43.1 to 73.9)	154.0 (131.2 to 180.6)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (60-64 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Migraine	19,737.3 (18,939.9 to 20,682.6)	33,488.9 (31,870.1 to 34,840.3)	69.7 (57.9 to 79.3)	638.7 (388.3 to 933.0)	1,085.0 (656.8 to 1,582.2)	70.1 (58.2 to 80.5)
Tension-type headache	42,126.9 (40,599.8 to 43,975.0)	71,136.2 (68,412.6 to 73,963.7)	68.4 (59.3 to 77.8)	62.1 (30.5 to 108.2)	105.0 (52.1 to 183.5)	68.8 (59.2 to 78.7)
Medication overuse headache	1,977.7 (1,355.4 to 2,591.3)	4,812.2 (3,258.5 to 6,189.8)	142.3 (119.6 to 170.4)	300.3 (175.2 to 447.4)	731.5 (429.7 to 1,104.7)	143.0 (119.8 to 172.1)
Other neurological disorders	0.5 (0.4 to 0.6)	0.9 (0.7 to 1.0)	73.3 (49.7 to 102.4)	81.4 (56.2 to 113.4)	96.4 (66.0 to 127.2)	20.6 (-3.6 to 31.3)
Mental and substance use disorders	-	-	-	3,799.5 (2,718.4 to 4,949.5)	6,752.1 (4,810.2 to 8,783.9)	77.7 (75.6 to 79.6)
Schizophrenia	748.9 (692.8 to 812.2)	1,347.6 (1,248.9 to 1,461.5)	79.5 (77.1 to 82.1)	460.1 (339.3 to 555.3)	830.9 (609.8 to 1,001.7)	80.7 (75.6 to 85.5)
Alcohol use disorders	1,545.0 (1,442.1 to 1,645.0)	2,609.4 (2,439.5 to 2,780.1)	68.5 (64.9 to 72.1)	147.5 (100.2 to 208.1)	250.2 (168.5 to 351.4)	69.5 (63.3 to 75.8)
Drug use disorders	-	-	-	90.1 (63.7 to 116.5)	164.0 (116.0 to 209.5)	82.1 (71.6 to 93.3)
Opioid use disorders	121.6 (100.8 to 144.6)	213.5 (177.3 to 253.7)	75.3 (70.6 to 79.4)	47.6 (33.0 to 64.0)	83.8 (57.9 to 113.1)	76.2 (63.3 to 90.0)
Cocaine use disorders	62.8 (60.9 to 64.7)	116.9 (113.8 to 120.0)	85.6 (78.0 to 93.5)	8.2 (5.3 to 11.8)	15.3 (10.2 to 21.6)	86.9 (61.1 to 117.0)
Amphetamine use disorders	97.3 (94.6 to 100.0)	184.5 (180.1 to 188.8)	89.2 (82.1 to 97.0)	12.0 (7.7 to 17.2)	22.8 (14.5 to 32.5)	90.7 (67.6 to 113.5)
Cannabis use disorders	67.8 (57.9 to 78.0)	121.7 (103.4 to 140.5)	79.2 (74.0 to 84.2)	2.0 (1.2 to 3.0)	3.5 (2.2 to 5.3)	79.4 (62.2 to 98.0)
Other drug use disorders	-	-	-	20.4 (13.6 to 27.8)	38.5 (25.9 to 52.1)	89.3 (67.9 to 110.5)
Depressive disorders	-	-	-	1,840.0 (1,201.5 to 2,620.6)	3,296.4 (2,142.4 to 4,692.9)	79.3 (75.1 to 82.2)
Major depressive disorder	7,507.1 (5,668.8 to 9,258.1)	13,448.9 (10,063.6 to 16,653.0)	78.9 (74.0 to 81.9)	1,474.7 (936.1 to 2,137.3)	2,646.0 (1,670.5 to 3,825.9)	79.6 (74.3 to 83.2)
Dysthymia	3,890.3 (2,971.3 to 4,708.0)	6,921.5 (5,305.8 to 8,362.5)	77.5 (75.2 to 79.7)	365.3 (229.5 to 533.1)	650.4 (408.3 to 959.4)	78.2 (74.7 to 81.2)
Bipolar disorder	1,208.4 (989.7 to 1,449.4)	2,141.7 (1,761.6 to 2,550.9)	76.8 (73.9 to 79.7)	234.5 (144.8 to 350.5)	416.5 (257.3 to 624.7)	77.7 (72.1 to 83.7)
Anxiety disorders	6,492.5 (4,884.4 to 8,303.9)	11,394.8 (8,453.4 to 14,777.3)	75.0 (70.5 to 79.3)	569.9 (356.1 to 851.3)	999.9 (609.4 to 1,510.8)	75.3 (69.6 to 80.9)
Eating disorders	-	-	-	-	-	-
Anorexia nervosa	-	-	-	-	-	-
Bulimia nervosa	-	-	-	-	-	-
Autistic spectrum disorders	-	-	-	152.5 (105.8 to 204.7)	271.1 (188.4 to 364.3)	77.8 (73.6 to 82.2)
Autism	414.2 (389.1 to 443.0)	733.0 (689.3 to 784.2)	76.5 (75.9 to 77.2)	96.5 (65.3 to 130.5)	171.6 (115.6 to 234.2)	77.9 (71.6 to 84.0)
Asperger syndrome	585.0 (534.5 to 640.4)	1,035.3 (946.5 to 1,133.8)	76.5 (76.3 to 76.8)	56.0 (39.1 to 77.0)	99.5 (68.7 to 137.1)	77.6 (72.7 to 82.7)
Attention-deficit/hyperactivity disorder	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.0 (53.2 to 86.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.4 (53.5 to 87.2)
Conduct disorder	-	-	-	-	-	-
Idiopathic intellectual disability	1,511.5 (1,132.9 to 1,923.6)	2,343.4 (1,789.1 to 2,946.5)	54.4 (38.6 to 75.4)	73.2 (47.4 to 105.3)	112.6 (73.6 to 160.1)	53.7 (37.4 to 74.0)
Other mental and substance use disorders	3,224.7 (2,406.3 to 4,155.3)	5,689.8 (4,241.8 to 7,337.9)	76.0 (75.6 to 76.3)	231.9 (142.7 to 329.2)	410.6 (252.4 to 581.3)	77.1 (72.7 to 81.2)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	2,575.8 (1,846.6 to 3,440.8)	5,433.6 (3,869.1 to 7,263.5)	110.7 (101.9 to 121.1)
Diabetes mellitus	15,960.1 (11,951.2 to 18,532.6)	42,144.7 (34,953.5 to 47,496.0)	163.6 (140.2 to 196.5)	1,266.5 (868.7 to 1,741.3)	3,248.1 (2,203.4 to 4,430.5)	156.9 (137.5 to 176.4)
Acute glomerulonephritis	1.1 (0.9 to 1.2)	1.5 (1.4 to 1.7)	42.2 (37.1 to 47.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	42.4 (37.2 to 47.4)
Chronic kidney disease	-	-	-	620.8 (414.1 to 852.7)	1,031.5 (705.5 to 1,393.8)	66.2 (59.4 to 74.8)
Chronic kidney disease due to diabetes mellitus	5,112.4 (3,056.5 to 7,955.3)	9,800.7 (6,320.6 to 14,504.5)	92.3 (66.0 to 123.0)	154.7 (106.0 to 210.5)	302.6 (207.3 to 410.2)	95.6 (73.1 to 119.7)
Chronic kidney disease due to hypertension	3,805.2 (2,409.9 to 5,999.9)	5,121.7 (3,368.4 to 7,579.2)	35.5 (19.8 to 48.1)	159.2 (105.2 to 219.8)	190.2 (126.3 to 261.6)	18.9 (4.8 to 46.9)
Chronic kidney disease due to glomerulonephritis	5,012.0 (2,791.5 to 8,371.5)	6,577.9 (3,920.6 to 10,227.5)	33.5 (4.7 to 54.8)	98.6 (66.6 to 135.6)	156.1 (106.9 to 214.7)	58.8 (40.0 to 78.1)
Chronic kidney disease due to other causes	6,527.3 (3,757.0 to 10,876.7)	11,068.0 (6,939.9 to 16,918.2)	70.9 (45.4 to 92.4)	208.3 (136.1 to 297.3)	382.6 (259.4 to 523.3)	85.0 (63.6 to 104.7)
Urinary diseases and male infertility	-	-	-	418.5 (275.0 to 590.5)	763.0 (499.5 to 1,076.5)	82.2 (74.7 to 89.3)
Interstitial nephritis and urinary tract infections	47.3 (46.0 to 48.6)	99.9 (97.2 to 102.5)	110.7 (103.1 to 118.8)	1.5 (1.0 to 2.3)	3.3 (2.0 to 4.8)	110.6 (84.8 to 139.9)
Urolithiasis	4,489.9 (3,215.8 to 6,162.5)	9,916.8 (7,014.8 to 13,929.8)	120.3 (110.7 to 129.0)	32.5 (19.8 to 50.1)	73.3 (42.7 to 118.7)	124.4 (110.4 to 139.4)
Benign prostatic hyperplasia	10,231.9 (10,001.8 to 10,441.3)	17,698.5 (17,194.0 to 18,141.6)	72.5 (66.9 to 78.3)	373.5 (243.2 to 525.6)	650.1 (418.5 to 919.1)	74.1 (68.1 to 80.2)
Male infertility due to other causes	-	-	-	-	-	-
Other urinary diseases	-	-	-	10.9 (6.3 to 17.2)	36.3 (16.7 to 61.9)	248.3 (131.9 to 311.0)
Gynecological diseases	-	-	-	44.9 (22.7 to 83.5)	76.5 (38.3 to 141.2)	70.4 (64.6 to 76.8)
Uterine fibroids	462.8 (436.3 to 486.5)	793.4 (747.2 to 835.0)	71.0 (70.5 to 71.6)	3.3 (1.7 to 6.2)	5.7 (2.8 to 10.5)	71.0 (63.9 to 78.0)
Polycystic ovarian syndrome	-	-	-	-	-	-
Female infertility due to other causes	-	-	-	-	-	-
Endometriosis	-	-	-	-	-	-
Genital prolapse	13,282.5 (12,956.0 to 13,656.1)	22,724.3 (22,108.7 to 23,382.1)	70.5 (64.5 to 76.9)	41.6 (20.7 to 77.5)	70.9 (35.1 to 131.8)	70.3 (64.1 to 77.4)
Premenstrual syndrome	-	-	-	-	-	-
Other gynecological diseases	-	-	0.0 (0.0 to 0.0)	-	-	-
Hemoglobinopathies and hemolytic anemias	-	-	-	133.7 (89.7 to 192.3)	183.3 (122.0 to 266.1)	36.9 (28.5 to 44.7)
Thalassemias	1.0 (0.8 to 1.3)	2.9 (2.3 to 3.5)	176.7 (120.2 to 228.9)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	203.1 (128.8 to 274.5)
Thalassemia trait	4,230.5 (3,806.4 to 4,792.3)	7,604.3 (6,898.5 to 8,635.4)	79.3 (76.9 to 82.1)	53.7 (36.0 to 76.4)	93.7 (62.1 to 136.5)	74.4 (62.0 to 86.7)
Sickle cell disorders	2.6 (2.5 to 2.8)	4.9 (4.6 to 5.2)	84.9 (76.9 to 92.9)	0.4 (0.3 to 0.5)	0.8 (0.5 to 1.0)	92.4 (79.2 to 105.4)
Sickle cell trait	3,912.5 (3,718.7 to 4,091.9)	6,974.3 (6,644.2 to 7,275.4)	77.7 (74.6 to 80.9)	12.0 (7.6 to 17.5)	19.8 (12.7 to 28.5)	65.7 (40.2 to 96.1)
G6PD deficiency	5,574.9 (5,434.6 to 5,704.6)	10,137.2 (9,893.0 to 10,372.6)	81.4 (75.6 to 87.5)	0.5 (0.3 to 0.7)	1.1 (0.7 to 1.5)	108.7 (93.3 to 124.9)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (60-64 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
G6PD trait	24,611.8 (24,486.1 to 24,738.3)	44,047.5 (43,802.3 to 44,284.3)	78.5 (77.2 to 79.9)	0.4 (0.2 to 0.7)	0.7 (0.4 to 1.1)	72.0 (3.4 to 158.3)
Other hemoglobinopathies and hemolytic anemias	2,889.8 (2,773.2 to 2,972.2)	3,660.8 (3,507.8 to 3,827.1)	26.3 (20.5 to 33.4)	66.7 (44.1 to 95.8)	67.0 (44.1 to 98.9)	0.5 (-10.7 to 10.2)
Endocrine, metabolic, blood, and immune disorders	3,090.3 (2,989.9 to 3,196.8)	4,493.3 (4,374.6 to 4,611.2)	45.1 (39.0 to 50.5)	91.3 (63.4 to 125.3)	131.0 (90.2 to 179.1)	43.4 (34.8 to 53.7)
Musculoskeletal disorders	-	-	-	7,379.0 (5,340.5 to 9,674.3)	13,195.2 (9,506.5 to 17,384.9)	78.8 (75.5 to 81.7)
Rheumatoid arthritis	1,128.9 (1,110.9 to 1,147.4)	1,835.1 (1,808.7 to 1,861.6)	62.2 (58.6 to 65.4)	262.3 (188.1 to 344.7)	426.3 (306.9 to 564.1)	62.5 (56.6 to 68.3)
Osteoarthritis	18,580.0 (18,366.6 to 18,776.8)	31,942.0 (31,602.8 to 32,278.2)	71.4 (68.9 to 74.3)	992.1 (696.9 to 1,350.7)	1,723.7 (1,209.0 to 2,334.0)	73.7 (70.9 to 76.7)
Low back and neck pain	-	-	-	4,631.3 (3,271.7 to 6,209.5)	8,201.5 (5,720.7 to 10,934.4)	77.1 (72.7 to 81.6)
Low back pain	29,868.1 (29,109.9 to 30,575.0)	52,627.6 (51,508.8 to 54,334.0)	75.7 (70.7 to 81.5)	3,244.3 (2,228.7 to 4,430.1)	5,730.9 (3,904.2 to 7,859.5)	76.6 (71.4 to 82.5)
Neck pain	14,447.8 (13,943.0 to 14,914.7)	25,708.0 (24,875.2 to 26,600.3)	77.7 (69.7 to 85.8)	1,387.0 (972.0 to 1,889.0)	2,470.5 (1,728.1 to 3,391.6)	78.2 (70.2 to 86.5)
Gout	426.0 (415.3 to 436.4)	754.6 (738.1 to 771.3)	76.6 (71.5 to 82.5)	13.5 (9.3 to 18.2)	24.0 (16.6 to 32.3)	77.5 (62.8 to 93.2)
Other musculoskeletal disorders	16,401.3 (13,014.8 to 19,929.9)	31,302.9 (24,738.2 to 38,033.1)	90.3 (85.6 to 96.5)	1,479.7 (960.1 to 2,131.5)	2,819.7 (1,808.0 to 4,049.7)	90.5 (85.2 to 96.7)
Other non-communicable diseases	-	-	-	5,345.7 (3,548.2 to 7,698.0)	8,695.2 (5,748.3 to 12,489.4)	62.7 (59.7 to 65.3)
Congenital anomalies	-	-	-	187.5 (143.4 to 234.5)	426.1 (329.9 to 529.9)	127.3 (116.1 to 139.3)
Neural tube defects	9.6 (9.2 to 10.0)	25.5 (24.6 to 26.4)	164.3 (149.9 to 180.4)	2.7 (1.9 to 3.5)	7.5 (5.3 to 10.0)	181.3 (144.6 to 220.1)
Congenital heart anomalies	507.0 (484.8 to 530.5)	1,258.8 (1,219.3 to 1,309.1)	147.3 (135.5 to 163.4)	17.0 (7.4 to 29.1)	43.1 (18.7 to 72.7)	154.4 (139.5 to 171.4)
Orofacial clefts	66.8 (63.4 to 70.4)	201.7 (195.6 to 208.2)	200.8 (183.4 to 222.9)	0.7 (0.4 to 1.0)	2.0 (1.3 to 2.8)	192.3 (138.7 to 251.6)
Down syndrome	204.9 (181.1 to 223.7)	538.2 (475.6 to 584.7)	162.3 (148.9 to 174.1)	39.5 (29.8 to 50.3)	103.6 (79.1 to 131.4)	162.2 (146.0 to 178.9)
Turner syndrome	3.1 (2.9 to 3.3)	6.9 (6.6 to 7.2)	123.8 (108.5 to 138.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	123.2 (107.9 to 138.1)
Klinefelter syndrome	4.2 (4.0 to 4.4)	8.3 (7.9 to 8.7)	96.9 (84.7 to 110.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.6 (85.3 to 111.1)
Chromosomal unbalanced rearrangements	310.4 (272.1 to 340.3)	765.8 (678.1 to 835.5)	146.0 (135.1 to 158.0)	59.9 (43.5 to 76.6)	147.5 (108.1 to 189.0)	145.9 (132.6 to 161.4)
Other congenital anomalies	686.2 (594.6 to 765.4)	1,041.0 (885.1 to 1,171.1)	51.3 (44.1 to 58.6)	67.7 (48.0 to 91.3)	122.2 (86.5 to 161.2)	80.0 (61.3 to 107.6)
Skin and subcutaneous diseases	-	-	-	899.4 (581.7 to 1,427.6)	1,569.7 (1,004.5 to 2,520.6)	74.5 (70.6 to 78.6)
Dermatitis	6,463.0 (5,815.6 to 7,228.2)	11,400.4 (10,264.3 to 12,731.6)	75.9 (75.1 to 76.7)	183.3 (119.6 to 258.8)	322.9 (211.4 to 456.0)	76.2 (72.5 to 79.5)
Psoriasis	2,240.1 (1,922.4 to 2,617.5)	3,854.8 (3,307.9 to 4,519.8)	71.6 (70.1 to 73.5)	175.8 (118.9 to 253.3)	303.1 (206.7 to 434.1)	72.4 (67.1 to 77.6)
Cellulitis	78.5 (56.4 to 110.3)	111.7 (81.4 to 158.5)	42.0 (32.5 to 52.9)	5.4 (3.2 to 8.5)	7.7 (4.4 to 12.5)	42.8 (22.8 to 64.9)
Pyoderma	127.0 (78.6 to 193.3)	200.4 (115.7 to 326.9)	57.9 (32.1 to 74.4)	0.7 (0.3 to 1.7)	1.1 (0.4 to 2.7)	58.4 (30.8 to 78.9)
Scabies	935.9 (843.4 to 1,046.2)	1,622.3 (1,487.7 to 1,785.9)	72.5 (52.9 to 97.5)	23.3 (13.5 to 37.9)	40.6 (23.3 to 64.1)	73.6 (53.2 to 98.3)
Fungal skin diseases	18,612.0 (15,571.1 to 20,906.9)	33,051.3 (27,975.5 to 37,070.4)	77.2 (75.6 to 79.0)	102.4 (42.3 to 210.1)	182.1 (75.3 to 373.7)	77.9 (75.9 to 79.9)
Viral skin diseases	1,631.0 (1,202.3 to 2,199.0)	2,843.9 (2,095.3 to 3,846.6)	73.9 (71.7 to 76.5)	48.4 (28.8 to 77.3)	84.4 (49.8 to 136.1)	74.4 (69.8 to 79.0)
Acne vulgaris	940.1 (869.9 to 1,012.3)	1,565.5 (1,414.8 to 1,736.5)	65.8 (46.7 to 86.3)	9.8 (4.8 to 18.2)	16.4 (7.8 to 29.8)	66.3 (47.4 to 87.1)
Alopecia areata	288.6 (280.2 to 297.2)	502.5 (487.7 to 517.6)	73.7 (67.1 to 81.1)	9.4 (6.0 to 13.9)	16.4 (10.5 to 24.3)	74.3 (63.1 to 86.0)
Pruritus	56.2 (53.2 to 59.4)	103.1 (97.4 to 109.3)	82.9 (70.6 to 99.0)	0.6 (0.3 to 1.1)	1.1 (0.5 to 2.0)	83.9 (64.2 to 107.7)
Urticaria	2,574.1 (2,359.5 to 2,765.9)	4,473.9 (4,069.2 to 4,843.0)	73.4 (56.0 to 94.5)	148.5 (97.0 to 209.5)	258.5 (168.4 to 367.8)	74.1 (55.9 to 94.8)
Decubitus ulcer	72.4 (69.5 to 76.4)	122.7 (117.6 to 128.9)	69.1 (59.6 to 78.1)	10.7 (7.4 to 14.5)	18.1 (12.5 to 24.6)	68.7 (47.5 to 95.9)
Other skin and subcutaneous diseases	31,151.5 (7,737.8 to 75,098.2)	54,526.8 (13,555.2 to 131,213.2)	74.6 (72.6 to 76.6)	181.1 (38.1 to 508.8)	317.4 (66.4 to 897.0)	75.2 (73.0 to 77.4)
Sense organ diseases	-	-	-	3,263.6 (2,129.4 to 4,679.6)	5,146.0 (3,287.2 to 7,444.6)	57.7 (53.5 to 61.2)
Glaucoma	562.1 (457.8 to 679.2)	959.7 (781.6 to 1,154.4)	70.1 (46.3 to 95.3)	42.6 (28.7 to 59.3)	71.8 (47.8 to 101.2)	68.2 (50.3 to 88.8)
Cataract	3,813.1 (3,154.6 to 4,421.9)	5,347.3 (4,413.8 to 6,227.6)	39.4 (30.2 to 52.7)	227.3 (153.8 to 324.4)	333.9 (226.3 to 469.3)	46.9 (37.9 to 56.8)
Macular degeneration	1,178.8 (940.6 to 1,422.5)	1,998.6 (1,620.0 to 2,389.7)	69.1 (57.2 to 83.3)	54.0 (34.8 to 78.8)	92.6 (61.3 to 134.0)	71.2 (60.2 to 86.4)
Uncorrected refractive error	39,532.9 (38,060.4 to 40,874.4)	64,286.4 (62,262.6 to 66,369.3)	62.1 (57.3 to 67.1)	682.0 (424.3 to 1,045.3)	1,053.5 (647.0 to 1,631.8)	54.2 (49.6 to 59.2)
Age-related and other hearing loss	82,899.6 (75,531.5 to 88,630.9)	135,712.3 (123,990.2 to 145,681.9)	63.3 (59.7 to 67.0)	2,017.4 (1,297.1 to 2,941.1)	3,209.7 (2,030.4 to 4,717.0)	59.2 (53.1 to 64.4)
Other vision loss	1,531.4 (1,225.5 to 1,962.5)	2,086.9 (1,637.1 to 2,592.1)	36.7 (24.7 to 45.5)	109.6 (71.7 to 156.1)	153.1 (98.3 to 220.7)	39.8 (30.4 to 48.6)
Other sense organ diseases	5,111.9 (5,004.3 to 5,214.8)	9,038.8 (8,841.0 to 9,209.8)	76.4 (71.4 to 81.6)	130.7 (82.0 to 191.6)	231.4 (145.7 to 342.8)	77.0 (71.2 to 83.2)
Oral disorders	-	-	-	995.1 (632.0 to 1,469.0)	1,553.4 (977.8 to 2,310.5)	55.8 (51.4 to 61.0)
Deciduous caries	-	-	-	-	-	-
Permanent caries	58,610.1 (57,739.8 to 59,334.5)	104,865.0 (103,068.9 to 106,400.1)	78.3 (75.1 to 82.4)	47.7 (22.5 to 90.4)	88.5 (41.2 to 168.0)	85.2 (80.4 to 89.9)
Periodontal diseases	29,016.5 (28,619.6 to 29,421.2)	51,186.8 (50,343.9 to 52,037.1)	76.0 (72.3 to 79.8)	187.2 (75.9 to 383.2)	330.8 (132.9 to 678.6)	76.7 (73.0 to 80.6)
Edentulism and severe tooth loss	23,411.1 (22,887.5 to 23,887.8)	33,906.3 (33,220.0 to 34,664.2)	44.4 (40.6 to 49.2)	650.2 (439.6 to 897.2)	941.1 (639.0 to 1,300.4)	44.6 (40.6 to 49.6)
Other oral disorders	3,852.4 (3,774.5 to 3,934.5)	6,761.9 (6,598.5 to 6,925.5)	75.1 (69.2 to 80.8)	109.9 (69.7 to 161.9)	193.0 (123.0 to 285.4)	75.6 (69.5 to 81.8)
Injuries	-	-	-	2,616.0 (1,895.3 to 3,504.2)	3,043.8 (2,193.4 to 4,069.8)	16.8 (3.4 to 28.3)
Transport injuries	-	-	-	672.0 (499.5 to 873.6)	842.9 (609.5 to 1,126.6)	25.1 (16.9 to 33.7)
Road injuries	-	-	-	559.2 (415.0 to 725.9)	708.9 (513.1 to 943.1)	26.4 (17.9 to 35.7)
Pedestrian road injuries	-	-	-	132.1 (97.7 to 171.6)	188.8 (135.7 to 251.3)	42.6 (34.0 to 52.5)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (60-64 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Cyclist road injuries	-	-	-	63.3 (47.0 to 82.6)	74.7 (53.9 to 99.9)	17.8 (10.2 to 26.0)
Motorcyclist road injuries	-	-	-	110.7 (81.9 to 144.1)	133.6 (94.5 to 181.2)	20.3 (11.1 to 30.3)
Motor vehicle road injuries	-	-	-	246.2 (183.1 to 318.3)	304.6 (221.9 to 404.4)	23.5 (14.9 to 33.0)
Other road injuries	-	-	-	7.0 (5.3 to 9.1)	7.2 (5.3 to 9.5)	2.7 (-3.3 to 9.7)
Other transport injuries	-	-	-	112.8 (83.2 to 147.2)	133.9 (95.2 to 180.7)	18.5 (11.8 to 25.6)
Unintentional injuries	-	-	-	1,301.7 (964.9 to 1,710.8)	1,715.7 (1,229.9 to 2,310.2)	31.5 (23.8 to 39.4)
Falls	-	-	-	792.5 (591.6 to 1,034.5)	1,072.9 (767.4 to 1,443.9)	34.9 (25.0 to 45.6)
Drowning	-	-	-	22.2 (16.4 to 29.0)	26.5 (19.1 to 35.0)	18.8 (11.6 to 26.5)
Fire, heat, and hot substances	-	-	-	66.2 (47.9 to 88.5)	74.4 (51.7 to 104.0)	12.3 (5.5 to 19.4)
Poisonings	-	-	-	4.2 (3.0 to 5.6)	5.1 (3.7 to 6.8)	19.9 (12.2 to 27.9)
Exposure to mechanical forces	-	-	-	216.2 (155.4 to 290.5)	256.7 (181.1 to 355.0)	18.5 (13.5 to 23.8)
Unintentional firearm injuries	-	-	-	7.2 (5.4 to 9.3)	8.9 (6.3 to 12.1)	23.1 (15.0 to 31.5)
Unintentional suffocation	-	-	-	2.0 (1.5 to 2.6)	3.4 (2.5 to 4.6)	71.3 (62.5 to 80.4)
Other exposure to mechanical forces	-	-	-	207.0 (148.6 to 278.6)	244.4 (172.3 to 338.3)	17.8 (12.9 to 23.0)
Adverse effects of medical treatment	-	-	-	9.6 (6.1 to 14.3)	17.1 (10.8 to 25.2)	77.4 (71.8 to 82.9)
Animal contact	-	-	-	22.1 (16.4 to 29.0)	25.8 (18.8 to 34.6)	16.4 (10.8 to 22.1)
Venomous animal contact	-	-	-	7.5 (5.5 to 9.8)	8.3 (6.0 to 10.9)	10.3 (2.2 to 18.6)
Non-venomous animal contact	-	-	-	14.6 (10.7 to 19.5)	17.5 (12.5 to 24.1)	19.6 (13.9 to 25.5)
Foreign body	-	-	-	13.0 (9.9 to 16.5)	17.7 (13.1 to 22.9)	35.9 (28.6 to 44.2)
Pulmonary aspiration and foreign body in airway	-	-	-	2.9 (2.2 to 3.6)	3.2 (2.4 to 4.1)	9.8 (0.1 to 22.0)
Foreign body in eyes	-	-	-	2.1 (1.5 to 2.9)	3.2 (2.2 to 4.5)	52.0 (43.1 to 60.1)
Foreign body in other body part	-	-	-	8.0 (6.1 to 10.2)	11.3 (8.3 to 14.7)	41.0 (33.9 to 48.8)
Other unintentional injuries	-	-	-	155.6 (114.0 to 207.0)	219.6 (156.9 to 296.1)	41.1 (35.5 to 47.0)
Self-harm and interpersonal violence	-	-	-	67.0 (50.2 to 86.5)	79.9 (57.4 to 107.7)	18.9 (10.8 to 28.4)
Self-harm	-	-	-	18.7 (13.8 to 24.3)	21.1 (15.1 to 28.5)	12.2 (4.7 to 20.7)
Interpersonal violence	-	-	-	48.3 (36.2 to 62.3)	58.9 (42.5 to 79.4)	21.4 (12.7 to 31.4)
Assault by firearm	-	-	-	8.5 (6.3 to 11.2)	12.1 (8.7 to 16.4)	41.9 (34.6 to 49.6)
Assault by sharp object	-	-	-	8.7 (6.4 to 11.6)	12.1 (8.5 to 16.7)	39.2 (30.4 to 49.3)
Assault by other means	-	-	-	31.1 (23.2 to 40.0)	34.6 (25.2 to 45.9)	11.0 (2.5 to 21.0)
Forces of nature, war, and legal intervention	-	-	-	575.2 (245.9 to 1,173.8)	405.3 (175.0 to 817.7)	-29.3 (-42.8 to -10.5)
Exposure to forces of nature	-	-	-	45.9 (21.7 to 86.8)	52.7 (24.3 to 110.0)	14.4 (-23.2 to 64.2)
Collective violence and legal intervention	-	-	-	529.4 (219.0 to 1,113.8)	352.6 (148.5 to 722.9)	-32.9 (-45.8 to -15.6)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (65-69 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
All causes	-	-	-	25,259.2 (19,048.7 to 32,502.9)	37,104.4 (27,873.7 to 47,644.9)	46.9 (45.0 to 48.6)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	1,254.2 (885.5 to 1,684.3)	1,524.3 (1,100.5 to 2,030.5)	21.5 (15.8 to 28.4)
HIV/AIDS and tuberculosis	-	-	-	138.1 (96.8 to 183.4)	262.7 (186.5 to 346.5)	90.1 (79.6 to 103.7)
Tuberculosis	415.1 (393.7 to 440.0)	669.4 (631.6 to 709.1)	61.2 (56.3 to 67.4)	118.9 (82.1 to 160.0)	194.0 (133.9 to 258.4)	63.1 (55.7 to 71.3)
HIV/AIDS	-	-	-	19.2 (13.6 to 25.6)	68.7 (49.4 to 91.3)	257.9 (194.6 to 342.8)
HIV/AIDS resulting in mycobacterial infection	5.2 (3.0 to 8.1)	14.4 (9.1 to 20.3)	181.6 (106.9 to 280.5)	1.8 (0.9 to 3.2)	5.1 (2.8 to 8.1)	187.8 (97.0 to 330.2)
HIV/AIDS resulting in other diseases	118.0 (103.1 to 134.4)	472.3 (430.0 to 529.2)	300.4 (249.2 to 365.5)	17.4 (12.2 to 23.6)	63.6 (45.3 to 84.5)	266.6 (193.9 to 359.7)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	157.6 (112.0 to 213.1)	205.6 (143.8 to 279.4)	30.3 (25.4 to 36.1)
Diarrheal diseases	389.4 (379.0 to 400.1)	455.7 (437.8 to 471.2)	17.1 (11.9 to 22.4)	57.9 (40.2 to 78.0)	67.7 (46.9 to 91.0)	16.8 (9.4 to 25.0)
Intestinal infectious diseases	-	-	-	2.2 (1.4 to 3.1)	2.2 (1.4 to 3.3)	1.4 (-26.3 to 41.5)
Typhoid fever	13.4 (11.2 to 15.9)	14.1 (11.8 to 17.4)	4.8 (-17.6 to 40.7)	1.6 (1.0 to 2.4)	1.8 (1.1 to 2.7)	9.8 (-25.3 to 66.4)
Paratyphoid fever	7.4 (5.8 to 9.1)	6.4 (4.9 to 8.3)	-14.1 (-40.1 to 27.4)	0.4 (0.2 to 0.6)	0.3 (0.2 to 0.5)	-13.4 (-43.9 to 36.6)
Other intestinal infectious diseases	-	-	-	0.1 (0.1 to 0.3)	0.1 (0.0 to 0.2)	-46.9 (-59.2 to -29.9)
Lower respiratory infections	82.9 (81.4 to 84.4)	146.0 (142.6 to 149.5)	76.3 (71.5 to 81.5)	8.2 (5.6 to 11.2)	14.5 (9.9 to 20.0)	77.0 (65.9 to 88.0)
Upper respiratory infections	2,800.4 (2,731.0 to 2,868.9)	4,332.5 (4,218.9 to 4,443.4)	54.8 (49.1 to 60.7)	31.2 (17.7 to 50.8)	48.5 (27.4 to 79.7)	55.3 (49.1 to 62.0)
Otitis media	1,054.0 (1,020.9 to 1,088.6)	1,389.6 (1,342.2 to 1,442.1)	32.1 (25.7 to 38.4)	19.4 (11.8 to 30.4)	25.8 (15.3 to 40.7)	33.4 (26.0 to 40.6)
Meningitis	-	-	-	22.2 (12.0 to 35.3)	23.7 (13.1 to 38.8)	6.8 (-1.2 to 16.5)
Pneumococcal meningitis	177.1 (93.9 to 280.9)	198.3 (102.3 to 326.2)	11.6 (1.7 to 21.4)	9.1 (6.0 to 13.5)	10.3 (6.6 to 15.1)	12.9 (0.2 to 27.6)
H influenzae type B meningitis	60.6 (8.6 to 132.3)	53.5 (6.1 to 122.5)	-12.7 (-36.6 to -1.5)	2.6 (1.3 to 4.5)	2.5 (1.3 to 4.4)	-2.4 (-11.0 to 7.9)
Meningococcal meningitis	43.2 (7.1 to 96.8)	40.4 (6.5 to 94.7)	-7.3 (-23.2 to 3.6)	4.3 (1.4 to 7.8)	4.2 (1.5 to 7.9)	-2.9 (-16.3 to 12.1)
Other meningitis	84.9 (17.3 to 179.0)	83.0 (16.9 to 187.5)	-2.8 (-26.3 to 11.9)	6.3 (3.0 to 10.5)	6.8 (3.4 to 11.5)	7.5 (-6.0 to 24.5)
Encephalitis	65.4 (25.9 to 149.3)	73.7 (29.2 to 182.5)	13.2 (-11.1 to 23.9)	6.9 (4.8 to 9.4)	8.7 (5.9 to 11.8)	25.7 (10.4 to 45.0)
Diphtheria	-	-	-	-	-	-
Whooping cough	-	-	-	-	-	-
Tetanus	22.7 (16.7 to 33.5)	3.5 (2.2 to 5.3)	-84.5 (-91.6 to -71.9)	0.6 (0.4 to 1.1)	0.2 (0.1 to 0.3)	-71.8 (-85.0 to -46.8)
Measles	-	-	-	-	-	-
Varicella and herpes zoster	170.1 (160.8 to 179.9)	268.5 (253.7 to 287.4)	57.8 (46.4 to 71.6)	9.0 (5.6 to 13.5)	14.3 (8.9 to 21.7)	58.2 (45.4 to 74.5)
Neglected tropical diseases and malaria	-	-	-	499.7 (327.1 to 714.4)	506.9 (313.4 to 754.0)	0.8 (-11.9 to 17.0)
Malaria	2,783.3 (2,691.6 to 2,869.6)	3,378.8 (3,250.3 to 3,513.0)	21.5 (15.8 to 27.2)	15.7 (10.1 to 23.0)	17.5 (11.5 to 25.9)	11.4 (1.0 to 23.2)
Chagas disease	286.5 (277.6 to 295.0)	388.9 (375.5 to 405.5)	35.7 (29.9 to 43.1)	5.7 (3.8 to 8.0)	7.7 (5.1 to 11.1)	36.4 (27.0 to 46.3)
Leishmaniasis	-	-	-	0.5 (0.2 to 0.9)	1.3 (0.6 to 2.4)	173.3 (144.5 to 205.8)
Visceral leishmaniasis	0.6 (0.4 to 0.7)	0.9 (0.7 to 1.2)	66.4 (24.2 to 128.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	65.8 (24.5 to 129.1)
Cutaneous and mucocutaneous leishmaniasis	42.6 (37.2 to 49.3)	119.7 (102.7 to 139.2)	180.8 (150.8 to 215.8)	0.4 (0.2 to 0.8)	1.2 (0.6 to 2.3)	183.9 (152.9 to 220.8)
African trypanosomiasis	1.5 (0.7 to 3.0)	0.4 (0.2 to 0.7)	-72.4 (-76.4 to -67.2)	0.4 (0.1 to 0.7)	0.1 (0.0 to 0.2)	-72.3 (-81.0 to -57.5)
Schistosomiasis	4,040.3 (3,625.4 to 4,457.3)	4,903.2 (4,225.3 to 5,726.0)	19.9 (11.2 to 39.8)	30.5 (15.3 to 57.2)	36.7 (18.2 to 71.2)	19.0 (10.7 to 37.6)
Cysticercosis	53.8 (46.6 to 62.2)	39.3 (31.5 to 46.2)	-26.7 (-42.3 to -4.4)	14.3 (10.1 to 18.9)	11.3 (7.6 to 15.0)	-20.7 (-39.3 to 4.8)
Cystic echinococcosis	48.7 (46.8 to 50.3)	41.7 (40.5 to 43.6)	-14.2 (-17.8 to -11.5)	4.3 (3.0 to 6.0)	3.8 (2.6 to 5.2)	-13.4 (-22.6 to -3.4)
Lymphatic filariasis	2,232.5 (1,854.0 to 2,687.7)	1,787.5 (1,413.2 to 2,284.4)	-20.0 (-28.9 to -10.5)	102.5 (53.5 to 172.8)	112.9 (61.8 to 184.5)	11.3 (-11.4 to 34.4)
Onchocerciasis	715.4 (537.8 to 964.5)	473.3 (334.4 to 664.6)	-34.2 (-43.5 to -20.8)	65.5 (38.6 to 104.2)	45.1 (24.9 to 74.1)	-32.3 (-43.2 to -15.7)
Trachoma	678.8 (441.8 to 992.3)	370.5 (239.7 to 523.9)	-45.3 (-55.1 to -34.5)	47.2 (27.1 to 73.4)	26.9 (15.3 to 41.6)	-43.1 (-51.8 to -34.0)
Dengue	8.0 (2.9 to 18.0)	70.8 (26.1 to 158.7)	782.1 (773.8 to 788.5)	1.2 (0.4 to 3.1)	10.8 (3.5 to 26.9)	785.1 (587.5 to 1,054.3)
Yellow fever	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-62.7 (-72.5 to -38.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-62.7 (-72.5 to -37.8)
Rabies	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-27.5 (-47.8 to -4.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.5 (-47.8 to -4.6)
Intestinal nematode infections	-	-	-	106.2 (61.3 to 169.9)	63.3 (36.3 to 102.3)	-40.3 (-46.2 to -33.9)
Ascariasis	21,838.9 (17,966.6 to 26,772.8)	18,085.4 (15,100.5 to 22,082.6)	-17.1 (-36.4 to 9.5)	51.2 (28.5 to 84.1)	17.1 (9.5 to 29.3)	-66.6 (-72.1 to -59.8)
Trichuriasis	10,716.1 (8,426.6 to 13,910.4)	10,259.6 (9,149.8 to 11,535.8)	-2.6 (-29.0 to 25.0)	14.4 (8.0 to 23.6)	11.3 (6.1 to 18.8)	-21.8 (-38.1 to 3.9)
Hookworm disease	10,282.1 (8,432.1 to 12,681.6)	10,669.4 (9,618.2 to 11,932.3)	4.7 (-18.3 to 28.8)	40.7 (23.8 to 65.0)	34.8 (20.2 to 55.4)	-14.6 (-24.7 to -3.2)
Food-borne trematodiasis	1,990.5 (1,500.8 to 2,485.7)	3,405.1 (2,605.2 to 4,166.3)	71.6 (55.4 to 86.2)	94.7 (25.1 to 204.6)	160.8 (43.5 to 345.8)	71.4 (49.4 to 88.3)
Other neglected tropical diseases	271.8 (247.8 to 298.9)	292.6 (268.2 to 316.2)	7.8 (-3.4 to 20.6)	11.1 (6.0 to 19.8)	8.8 (4.4 to 16.3)	-22.2 (-39.5 to 4.0)
Maternal disorders	-	-	-	5.3 (3.3 to 7.9)	6.9 (4.1 to 10.4)	30.2 (-0.5 to 73.7)
Maternal hemorrhage	-	-	-	-	-	-
Maternal sepsis and other maternal infections	-	-	-	-	-	-
Maternal hypertensive disorders	-	-	-	-	-	-
Obstructed labor	17.5 (13.4 to 22.1)	22.8 (17.9 to 28.1)	30.5 (15.0 to 47.3)	5.3 (3.3 to 7.9)	6.9 (4.1 to 10.4)	30.2 (-0.5 to 73.7)
Complications of abortion	-	-	-	-	-	-

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (65-69 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Other maternal disorders	-	-	-	-	-	-
Neonatal disorders	-	-	-	58.8 (44.1 to 77.4)	157.7 (120.2 to 198.7)	169.5 (138.4 to 197.7)
Preterm birth complications	425.3 (361.6 to 503.9)	1,131.3 (961.9 to 1,349.8)	165.7 (139.6 to 197.0)	32.6 (24.3 to 41.4)	99.8 (74.5 to 126.1)	205.8 (184.0 to 229.2)
Neonatal encephalopathy due to birth asphyxia and trauma	342.3 (114.8 to 668.7)	349.3 (136.2 to 643.4)	1.8 (-24.8 to 62.0)	10.8 (6.1 to 17.9)	16.0 (10.9 to 23.8)	51.1 (19.5 to 96.8)
Neonatal sepsis and other neonatal infections	-	-	-	-	-	-
Hemolytic disease and other neonatal jaundice	16.9 (14.8 to 19.7)	39.1 (33.2 to 46.1)	129.4 (89.5 to 192.2)	6.7 (4.7 to 8.9)	15.4 (11.0 to 20.4)	125.5 (87.0 to 198.3)
Other neonatal disorders	-	-	-	8.7 (5.8 to 12.7)	26.6 (18.1 to 35.7)	208.3 (138.8 to 276.8)
Nutritional deficiencies	-	-	-	364.7 (244.6 to 525.3)	346.2 (229.0 to 504.2)	-5.3 (-9.0 to -1.0)
Protein-energy malnutrition	28.1 (16.0 to 44.1)	48.5 (26.2 to 77.8)	73.5 (27.6 to 122.2)	3.2 (1.5 to 5.8)	5.6 (2.4 to 10.0)	74.2 (27.0 to 133.6)
Iodine deficiency	2,495.0 (2,305.4 to 2,696.4)	2,355.6 (2,178.4 to 2,511.3)	-5.4 (-14.5 to 5.3)	42.7 (26.6 to 65.7)	40.5 (25.1 to 64.7)	-5.0 (-14.5 to 6.0)
Vitamin A deficiency	30.4 (11.1 to 51.7)	29.9 (13.7 to 48.4)	0.5 (-27.6 to 39.4)	2.1 (0.7 to 3.7)	2.1 (0.8 to 3.6)	0.0 (-31.6 to 55.8)
Iron-deficiency anemia	14,422.2 (14,256.6 to 14,597.0)	16,345.0 (16,157.8 to 16,500.9)	13.4 (11.8 to 15.0)	316.4 (215.0 to 448.8)	297.7 (196.4 to 436.2)	-6.2 (-10.5 to -1.0)
Other nutritional deficiencies	-	-	-	0.3 (0.1 to 0.6)	0.4 (0.2 to 0.7)	29.6 (-22.8 to 95.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	30.1 (18.9 to 48.2)	38.3 (23.8 to 64.2)	27.2 (17.3 to 36.9)
Sexually transmitted diseases excluding HIV	-	-	-	12.7 (6.5 to 25.3)	17.1 (8.1 to 35.4)	34.4 (21.8 to 42.3)
Syphilis	21.1 (20.4 to 21.8)	24.5 (23.6 to 25.4)	16.3 (10.4 to 21.7)	3.8 (2.5 to 5.2)	4.4 (3.0 to 6.1)	16.7 (-2.5 to 40.1)
Chlamydial infection	1.2 (1.2 to 1.3)	1.5 (1.4 to 1.6)	23.6 (16.7 to 30.6)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-5.3 (-14.7 to 4.7)
Gonococcal infection	0.5 (0.5 to 0.6)	0.5 (0.4 to 0.6)	-0.2 (-20.2 to 24.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-0.2 (-20.3 to 24.3)
Trichomoniasis	0.3 (0.3 to 0.3)	0.4 (0.4 to 0.5)	42.6 (25.5 to 61.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.7 (23.2 to 64.0)
Genital herpes	36,077.8 (35,658.2 to 36,480.3)	51,527.2 (50,844.7 to 52,306.3)	42.9 (40.6 to 45.6)	8.6 (2.5 to 21.3)	12.3 (3.6 to 30.3)	43.3 (39.9 to 47.2)
Other sexually transmitted diseases	1.1 (1.0 to 1.2)	1.4 (1.3 to 1.6)	32.5 (19.7 to 46.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	32.6 (19.7 to 46.4)
Hepatitis	-	-	-	7.2 (4.7 to 10.1)	9.0 (5.9 to 13.0)	26.2 (17.0 to 33.9)
Hepatitis A	32.5 (29.2 to 35.7)	60.1 (56.1 to 63.6)	85.3 (78.5 to 92.2)	1.1 (0.7 to 1.7)	2.1 (1.4 to 3.1)	85.7 (65.2 to 112.3)
Hepatitis B	8,966.0 (8,714.9 to 9,269.4)	9,512.4 (9,287.4 to 9,753.1)	6.2 (2.5 to 9.8)	4.6 (3.0 to 6.6)	5.0 (3.3 to 7.3)	9.1 (-0.9 to 18.2)
Hepatitis C	6,738.3 (6,638.2 to 6,854.7)	7,782.4 (7,662.5 to 7,900.5)	15.6 (12.9 to 18.2)	1.0 (0.6 to 1.5)	1.2 (0.8 to 1.7)	21.0 (1.2 to 43.2)
Hepatitis E	16.3 (14.7 to 18.0)	25.1 (21.9 to 28.4)	53.4 (29.2 to 84.0)	0.4 (0.2 to 0.6)	0.6 (0.4 to 1.0)	65.8 (22.5 to 131.1)
Leprosy	39.8 (36.1 to 42.8)	66.1 (60.2 to 73.5)	65.8 (52.9 to 84.2)	2.2 (1.5 to 3.2)	3.9 (2.6 to 5.7)	78.2 (50.5 to 110.7)
Other infectious diseases	353.2 (328.0 to 378.5)	399.2 (371.0 to 426.6)	13.2 (2.0 to 24.4)	8.0 (5.0 to 11.9)	8.3 (5.0 to 13.1)	2.9 (-18.9 to 28.0)
Non-communicable diseases	-	-	-	21,704.7 (16,332.3 to 27,954.9)	33,157.1 (24,892.6 to 42,702.3)	52.8 (51.2 to 54.3)
Neoplasms	-	-	-	462.6 (346.3 to 590.5)	752.5 (557.5 to 972.2)	62.4 (54.0 to 72.9)
Esophageal cancer	85.5 (69.2 to 102.9)	126.2 (101.0 to 156.9)	47.8 (17.4 to 85.3)	13.2 (9.2 to 17.7)	18.6 (12.8 to 25.5)	40.9 (12.3 to 71.0)
Stomach cancer	270.0 (246.6 to 294.7)	323.3 (287.8 to 361.8)	19.6 (5.7 to 36.8)	32.4 (23.6 to 41.9)	36.8 (26.0 to 48.0)	13.3 (-1.1 to 29.5)
Liver cancer	-	-	-	13.7 (9.7 to 18.4)	23.4 (16.0 to 31.7)	71.8 (41.6 to 103.9)
Liver cancer due to hepatitis B	26.4 (21.2 to 33.0)	52.5 (41.8 to 65.3)	99.2 (48.7 to 164.4)	4.4 (3.1 to 5.9)	7.7 (5.2 to 10.5)	77.1 (41.5 to 122.2)
Liver cancer due to hepatitis C	15.9 (13.2 to 19.1)	65.8 (54.6 to 78.9)	314.9 (222.5 to 425.4)	2.6 (1.8 to 3.5)	9.5 (6.5 to 13.0)	265.7 (197.6 to 356.8)
Liver cancer due to alcohol use	26.6 (22.2 to 31.9)	26.3 (22.0 to 31.6)	-0.7 (-21.6 to 23.7)	4.3 (3.0 to 5.8)	4.0 (2.7 to 5.4)	-7.4 (-23.4 to 10.5)
Liver cancer due to other causes	14.2 (11.3 to 17.7)	13.9 (11.0 to 17.4)	-1.9 (-29.4 to 32.2)	2.4 (1.7 to 3.3)	2.2 (1.4 to 3.0)	-9.7 (-31.0 to 14.8)
Larynx cancer	97.2 (80.4 to 116.5)	128.7 (101.2 to 155.3)	32.1 (12.5 to 56.0)	9.8 (6.8 to 13.2)	12.0 (8.1 to 16.6)	22.5 (2.4 to 48.8)
Tracheal, bronchus and lung cancer	328.9 (308.7 to 348.2)	480.3 (442.1 to 520.3)	46.1 (34.8 to 57.9)	48.8 (35.9 to 62.2)	68.6 (49.6 to 87.3)	40.7 (29.4 to 53.0)
Breast cancer	976.6 (913.5 to 1,031.4)	1,876.6 (1,793.5 to 1,961.0)	92.5 (81.4 to 104.6)	61.1 (43.8 to 81.7)	104.0 (72.8 to 140.8)	70.2 (53.8 to 86.5)
Cervical cancer	204.6 (163.1 to 240.7)	217.7 (164.0 to 272.6)	6.9 (-18.2 to 35.9)	15.8 (11.0 to 21.6)	16.9 (11.0 to 23.5)	6.6 (-18.7 to 38.9)
Uterine cancer	214.4 (174.9 to 261.1)	292.3 (228.0 to 365.6)	36.4 (6.9 to 69.8)	14.3 (9.6 to 19.7)	19.0 (12.4 to 27.6)	33.0 (4.1 to 65.9)
Prostate cancer	711.6 (601.4 to 826.6)	1,743.4 (1,494.2 to 2,260.0)	142.9 (112.4 to 195.1)	58.9 (40.9 to 82.2)	134.7 (94.9 to 190.9)	125.9 (90.5 to 182.7)
Colon and rectum cancer	634.6 (606.4 to 665.9)	1,067.6 (1,004.5 to 1,131.2)	68.2 (58.0 to 80.1)	53.3 (38.9 to 69.1)	84.8 (60.8 to 111.2)	59.1 (47.5 to 71.3)
Lip and oral cavity cancer	177.7 (146.3 to 219.6)	281.3 (223.3 to 352.4)	58.1 (25.5 to 102.5)	15.5 (10.8 to 21.8)	23.9 (16.3 to 33.4)	53.3 (19.4 to 98.9)
Nasopharynx cancer	27.7 (20.7 to 35.5)	36.2 (26.1 to 49.3)	29.6 (-11.7 to 93.4)	2.9 (1.9 to 4.1)	3.6 (2.2 to 5.2)	24.1 (-15.7 to 85.7)
Other pharynx cancer	58.7 (48.3 to 73.4)	95.3 (72.6 to 125.6)	61.8 (22.2 to 118.5)	5.2 (3.5 to 7.3)	8.3 (5.2 to 11.9)	55.3 (15.3 to 114.4)
Gallbladder and biliary tract cancer	15.7 (13.2 to 18.1)	18.3 (15.5 to 21.3)	16.5 (-0.8 to 36.8)	4.2 (2.9 to 5.6)	4.7 (3.1 to 6.4)	13.0 (-5.8 to 36.0)
Pancreatic cancer	29.8 (27.5 to 32.3)	49.0 (44.2 to 54.5)	64.8 (45.7 to 85.8)	5.9 (4.2 to 7.7)	9.4 (6.6 to 12.5)	58.8 (38.8 to 80.5)
Malignant skin melanoma	115.3 (83.4 to 158.5)	211.8 (144.3 to 290.1)	83.3 (44.4 to 126.6)	7.1 (4.5 to 10.6)	12.3 (7.6 to 19.0)	73.9 (37.0 to 116.1)
Non-melanoma skin cancer	351.5 (311.1 to 395.1)	612.0 (523.8 to 719.4)	74.2 (42.8 to 110.4)	5.8 (3.4 to 9.4)	11.5 (6.7 to 18.8)	96.2 (49.5 to 174.3)
Ovarian cancer	74.5 (66.0 to 83.6)	99.9 (87.2 to 115.3)	33.9 (14.5 to 56.8)	9.6 (7.0 to 12.5)	12.6 (8.9 to 16.5)	31.2 (8.7 to 57.0)
Testicular cancer	4.3 (3.1 to 5.5)	7.9 (5.8 to 10.5)	82.0 (39.6 to 146.4)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	69.2 (21.4 to 140.7)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (65-69 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Kidney cancer	132.0 (119.4 to 147.9)	248.3 (217.8 to 284.2)	87.7 (64.4 to 119.9)	9.7 (6.8 to 13.0)	17.4 (12.2 to 23.7)	79.8 (55.6 to 110.5)
Bladder cancer	252.6 (218.4 to 281.1)	299.3 (260.2 to 342.8)	18.5 (4.5 to 35.0)	19.4 (14.0 to 26.1)	22.4 (16.1 to 30.3)	15.5 (1.5 to 30.9)
Brain and nervous system cancer	48.4 (40.9 to 56.1)	87.0 (70.6 to 102.6)	80.2 (51.2 to 111.5)	5.4 (3.6 to 7.2)	9.3 (6.3 to 12.9)	72.4 (41.3 to 104.2)
Thyroid cancer	66.2 (55.9 to 77.4)	134.1 (104.3 to 160.2)	103.0 (65.4 to 145.9)	4.3 (3.0 to 6.0)	8.2 (5.4 to 11.6)	91.8 (55.1 to 136.4)
Mesothelioma	4.2 (3.6 to 5.2)	8.6 (7.2 to 9.8)	107.4 (65.5 to 139.1)	0.9 (0.6 to 1.2)	1.8 (1.2 to 2.5)	107.1 (65.1 to 145.2)
Hodgkin lymphoma	22.8 (15.2 to 28.8)	28.4 (22.1 to 38.5)	21.7 (-13.3 to 104.1)	2.2 (1.4 to 3.2)	2.6 (1.7 to 3.8)	12.0 (-20.8 to 87.6)
Non-Hodgkin lymphoma	146.3 (121.9 to 184.1)	298.7 (231.0 to 347.0)	107.4 (58.2 to 139.9)	11.1 (7.8 to 15.7)	21.6 (14.7 to 29.9)	96.2 (51.2 to 130.2)
Multiple myeloma	33.5 (25.2 to 45.4)	58.2 (44.3 to 75.9)	74.2 (37.4 to 118.3)	6.9 (4.4 to 10.1)	11.5 (7.4 to 16.1)	66.6 (28.8 to 112.7)
Leukemia	82.9 (76.4 to 90.6)	145.6 (130.6 to 160.1)	75.7 (56.4 to 97.6)	11.7 (8.3 to 15.0)	18.8 (13.5 to 24.3)	60.8 (38.9 to 86.3)
Other neoplasms	176.6 (154.1 to 211.1)	494.4 (422.1 to 578.3)	181.0 (131.7 to 234.3)	13.1 (9.3 to 17.7)	33.4 (22.9 to 45.2)	156.0 (109.1 to 206.7)
Cardiovascular diseases	-	-	-	1,448.5 (1,044.2 to 1,916.0)	2,273.3 (1,587.6 to 3,033.6)	57.2 (43.7 to 70.4)
Rheumatic heart disease	668.0 (641.1 to 698.9)	1,150.2 (1,107.5 to 1,194.6)	72.3 (63.4 to 82.9)	51.7 (36.2 to 70.1)	85.5 (59.7 to 116.9)	66.3 (42.1 to 87.2)
Ischemic heart disease	9,908.4 (9,349.1 to 10,552.5)	13,701.0 (13,047.6 to 14,512.7)	38.3 (28.6 to 50.4)	596.0 (411.8 to 817.5)	839.7 (577.6 to 1,146.1)	40.7 (29.7 to 54.8)
Cerebrovascular disease	-	-	-	286.1 (202.2 to 374.0)	466.0 (331.6 to 601.8)	63.2 (52.4 to 73.5)
Ischemic stroke	1,453.8 (1,379.5 to 1,534.8)	2,317.4 (2,234.6 to 2,411.7)	59.7 (48.7 to 70.3)	212.2 (147.0 to 281.7)	338.8 (237.8 to 444.0)	60.0 (47.9 to 72.1)
Hemorrhagic stroke	503.6 (476.8 to 533.3)	863.9 (825.6 to 908.8)	71.4 (59.8 to 84.6)	74.0 (51.3 to 98.5)	127.3 (87.2 to 169.4)	72.0 (58.8 to 86.9)
Hypertensive heart disease	753.2 (715.1 to 792.3)	1,390.9 (1,331.8 to 1,451.6)	85.0 (72.3 to 98.9)	82.9 (57.8 to 113.9)	154.0 (108.1 to 209.0)	85.7 (72.9 to 100.1)
Cardiomyopathy and myocarditis	569.4 (543.7 to 595.8)	959.2 (920.4 to 999.5)	68.6 (59.5 to 79.1)	61.2 (42.2 to 83.2)	104.2 (71.3 to 140.2)	70.2 (59.2 to 81.6)
Atrial fibrillation and flutter	918.1 (865.2 to 969.4)	1,217.6 (1,125.3 to 1,314.5)	32.7 (20.8 to 45.0)	72.2 (50.1 to 99.9)	96.3 (66.5 to 132.0)	33.6 (20.6 to 46.3)
Peripheral vascular disease	15,257.6 (13,972.2 to 16,715.3)	23,125.8 (20,754.7 to 25,691.8)	51.4 (32.2 to 74.5)	10.2 (4.9 to 18.1)	12.5 (6.0 to 22.9)	21.6 (-0.8 to 63.6)
Endocarditis	19.2 (15.2 to 23.8)	32.4 (25.2 to 39.1)	69.2 (47.1 to 89.7)	2.0 (1.3 to 3.0)	3.4 (2.2 to 5.0)	70.3 (37.2 to 108.1)
Other cardiovascular and circulatory diseases	4,063.5 (2,786.0 to 5,803.5)	7,203.0 (4,770.9 to 10,075.3)	78.4 (21.2 to 157.0)	286.4 (164.6 to 430.4)	511.7 (298.2 to 806.0)	79.1 (21.8 to 160.8)
Chronic respiratory diseases	-	-	-	1,632.5 (1,120.7 to 2,279.6)	2,546.9 (1,741.8 to 3,504.1)	56.1 (50.4 to 61.2)
Chronic obstructive pulmonary disease	17,160.2 (16,358.5 to 17,981.6)	26,279.1 (25,073.8 to 27,476.7)	53.3 (51.7 to 54.8)	1,245.8 (836.1 to 1,742.5)	2,023.4 (1,359.2 to 2,833.6)	62.5 (55.9 to 69.0)
Pneumoconiosis	-	-	-	2.7 (1.9 to 3.7)	4.7 (3.3 to 6.6)	77.0 (69.2 to 84.9)
Silicosis	5.0 (4.4 to 5.4)	6.6 (5.8 to 7.2)	32.6 (29.0 to 36.1)	0.9 (0.6 to 1.4)	1.3 (0.8 to 1.8)	32.8 (29.1 to 36.3)
Asbestosis	1.1 (0.9 to 1.1)	1.6 (1.4 to 1.7)	51.7 (46.2 to 58.0)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	52.9 (47.2 to 59.2)
Coal workers pneumoconiosis	2.2 (2.0 to 2.3)	3.2 (3.0 to 3.4)	46.7 (44.6 to 48.9)	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.9)	46.9 (44.6 to 49.2)
Other pneumoconiosis	6.1 (5.4 to 6.7)	13.9 (12.4 to 15.5)	130.2 (121.1 to 139.7)	1.1 (0.7 to 1.7)	2.6 (1.7 to 3.7)	129.1 (120.0 to 139.2)
Asthma	6,177.2 (6,019.3 to 6,328.3)	9,206.7 (9,013.8 to 9,399.2)	49.2 (44.7 to 53.9)	258.5 (170.7 to 362.2)	386.9 (255.2 to 540.6)	49.7 (45.0 to 54.4)
Interstitial lung disease and pulmonary sarcoidosis	31.4 (29.8 to 33.1)	50.9 (48.0 to 53.6)	62.5 (48.3 to 74.2)	4.4 (2.8 to 6.3)	7.1 (4.4 to 10.3)	63.3 (48.6 to 75.5)
Other chronic respiratory diseases	-	-	-	121.2 (76.2 to 188.4)	124.8 (80.5 to 189.7)	2.6 (-9.4 to 19.9)
Cirrhosis	-	-	-	26.5 (18.6 to 35.9)	33.9 (23.8 to 46.3)	27.8 (21.0 to 35.4)
Cirrhosis due to hepatitis B	45.5 (43.3 to 47.9)	59.1 (55.6 to 62.1)	29.8 (21.4 to 40.8)	7.2 (5.0 to 9.9)	9.4 (6.5 to 12.7)	29.9 (16.1 to 47.2)
Cirrhosis due to hepatitis C	44.3 (41.8 to 46.9)	69.2 (65.6 to 73.5)	55.7 (45.2 to 70.8)	7.0 (4.9 to 9.6)	10.9 (7.6 to 15.0)	56.1 (39.9 to 76.6)
Cirrhosis due to alcohol use	66.6 (63.8 to 69.6)	65.4 (62.3 to 69.4)	-1.8 (-8.1 to 5.8)	10.5 (7.3 to 14.4)	10.4 (7.0 to 14.2)	-1.6 (-12.1 to 11.7)
Cirrhosis due to other causes	11.5 (10.4 to 12.8)	20.4 (18.0 to 22.9)	77.2 (56.3 to 103.8)	1.8 (1.2 to 2.6)	3.3 (2.2 to 4.7)	76.7 (40.1 to 128.6)
Digestive diseases	-	-	-	552.3 (391.0 to 748.8)	630.4 (447.5 to 850.9)	14.2 (10.5 to 17.9)
Peptic ulcer disease	4,843.6 (4,695.6 to 4,958.7)	4,111.3 (3,944.6 to 4,308.2)	-15.1 (-17.7 to -10.6)	162.6 (112.4 to 227.1)	140.2 (96.2 to 197.7)	-13.8 (-18.5 to -8.6)
Gastritis and duodenitis	4,877.8 (4,795.4 to 4,962.8)	5,976.8 (5,844.1 to 6,105.2)	22.7 (19.9 to 25.6)	149.4 (101.0 to 211.8)	176.7 (119.6 to 248.8)	17.6 (13.5 to 21.9)
Appendicitis	8.2 (7.1 to 9.5)	10.5 (9.2 to 12.1)	26.4 (1.9 to 60.0)	2.3 (1.5 to 3.4)	3.1 (2.0 to 4.5)	32.6 (-5.3 to 85.6)
Paralytic ileus and intestinal obstruction	4.5 (4.4 to 4.6)	7.3 (7.1 to 7.6)	62.7 (56.2 to 70.6)	1.4 (0.9 to 1.9)	2.3 (1.5 to 3.1)	66.3 (33.9 to 101.6)
Inguinal, femoral, and abdominal hernia	1,821.7 (1,736.2 to 1,925.0)	2,614.1 (2,437.9 to 2,773.9)	43.5 (32.4 to 55.7)	18.6 (9.2 to 34.6)	26.9 (13.3 to 50.3)	44.0 (32.7 to 56.3)
Inflammatory bowel disease	396.2 (388.8 to 403.7)	632.7 (621.7 to 644.0)	59.8 (56.8 to 63.2)	80.1 (55.9 to 107.7)	128.3 (89.4 to 173.3)	60.3 (53.8 to 67.5)
Vascular intestinal disorders	2.2 (2.0 to 2.3)	3.3 (2.9 to 3.6)	50.5 (35.2 to 67.5)	0.7 (0.5 to 1.0)	1.1 (0.7 to 1.5)	50.5 (35.2 to 67.6)
Gallbladder and biliary diseases	430.6 (412.3 to 452.9)	504.8 (480.8 to 535.4)	17.3 (8.4 to 26.6)	44.3 (30.9 to 60.4)	52.1 (36.2 to 70.7)	17.5 (8.2 to 27.6)
Pancreatitis	73.6 (72.6 to 74.7)	119.9 (117.8 to 122.0)	63.0 (59.6 to 66.6)	20.8 (14.4 to 27.7)	34.0 (23.6 to 45.3)	63.6 (52.7 to 75.5)
Other digestive diseases	-	-	-	72.1 (49.1 to 101.3)	66.8 (45.9 to 92.2)	-6.5 (-20.0 to 4.1)
Neurological disorders	-	-	-	1,320.1 (941.0 to 1,733.5)	2,023.2 (1,430.0 to 2,667.9)	53.4 (47.5 to 59.0)
Alzheimer disease and other dementias	2,824.6 (2,750.4 to 2,897.5)	4,360.2 (4,217.4 to 4,493.3)	54.6 (47.9 to 61.6)	341.0 (242.5 to 450.7)	529.0 (377.0 to 701.3)	55.2 (47.9 to 62.1)
Parkinson disease	530.8 (398.7 to 668.6)	825.4 (610.1 to 1,044.4)	55.6 (51.4 to 59.2)	63.5 (40.4 to 91.9)	99.2 (62.3 to 144.2)	56.2 (48.7 to 62.7)
Epilepsy	409.7 (384.8 to 435.1)	586.8 (547.2 to 625.2)	43.5 (31.4 to 58.0)	128.8 (90.2 to 166.8)	196.0 (135.8 to 252.8)	52.1 (38.4 to 69.1)
Multiple sclerosis	47.5 (45.9 to 49.0)	100.1 (96.9 to 103.4)	110.9 (101.6 to 120.4)	15.0 (10.7 to 18.9)	31.6 (22.8 to 39.5)	110.8 (90.3 to 135.7)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (65-69 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Migraine	13,394.0 (12,914.9 to 13,961.5)	19,115.2 (18,281.7 to 19,831.5)	43.1 (34.8 to 50.1)	424.8 (258.2 to 618.6)	608.8 (369.0 to 883.7)	43.6 (34.7 to 51.8)
Tension-type headache	31,762.8 (30,701.8 to 33,054.1)	45,965.6 (44,486.4 to 47,524.1)	44.9 (37.5 to 51.7)	46.2 (22.9 to 80.2)	67.1 (33.2 to 116.5)	45.3 (37.5 to 52.7)
Medication overuse headache	1,266.8 (874.4 to 1,650.3)	2,482.8 (1,695.2 to 3,194.7)	95.9 (79.4 to 117.3)	189.0 (111.8 to 281.5)	372.0 (219.3 to 561.8)	96.5 (79.6 to 118.1)
Other neurological disorders	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.7)	44.7 (28.7 to 66.2)	111.9 (78.3 to 155.6)	119.6 (82.4 to 157.0)	8.4 (-10.6 to 17.1)
Mental and substance use disorders	-	-	-	2,710.9 (1,925.1 to 3,591.2)	4,140.3 (2,927.4 to 5,486.5)	52.7 (50.5 to 54.6)
Schizophrenia	469.4 (433.7 to 509.5)	724.9 (668.6 to 790.1)	54.6 (52.2 to 56.8)	282.4 (211.6 to 340.6)	439.2 (325.2 to 531.0)	55.5 (50.8 to 60.4)
Alcohol use disorders	831.3 (778.9 to 887.2)	1,192.4 (1,114.5 to 1,277.0)	43.6 (40.5 to 46.5)	77.7 (53.1 to 108.9)	112.1 (75.5 to 158.0)	44.3 (38.7 to 50.0)
Drug use disorders	-	-	-	45.6 (31.8 to 59.0)	73.3 (51.4 to 95.6)	61.0 (50.0 to 72.7)
Opioid use disorders	56.7 (47.8 to 66.7)	86.4 (71.8 to 102.2)	52.5 (47.8 to 57.1)	21.9 (15.1 to 29.2)	33.4 (23.3 to 45.0)	53.0 (37.5 to 67.6)
Cocaine use disorders	26.8 (26.0 to 27.7)	44.9 (43.7 to 46.1)	67.4 (60.3 to 74.8)	3.6 (2.3 to 5.0)	6.0 (3.9 to 8.5)	66.8 (40.8 to 97.4)
Amphetamine use disorders	63.9 (62.2 to 65.5)	107.6 (105.1 to 110.1)	68.7 (62.5 to 74.9)	7.7 (5.0 to 11.3)	13.1 (8.2 to 19.0)	69.0 (48.8 to 95.2)
Cannabis use disorders	37.1 (30.8 to 44.2)	55.4 (45.4 to 66.3)	49.4 (43.1 to 55.2)	1.1 (0.7 to 1.6)	1.6 (1.0 to 2.4)	48.6 (32.3 to 67.5)
Other drug use disorders	-	-	-	11.4 (7.7 to 15.7)	19.2 (12.8 to 26.8)	68.7 (50.9 to 91.8)
Depressive disorders	-	-	-	1,429.4 (934.4 to 2,052.2)	2,196.6 (1,430.3 to 3,146.5)	53.7 (49.6 to 56.5)
Major depressive disorder	5,939.3 (4,351.4 to 7,463.2)	9,091.9 (6,613.6 to 11,446.3)	53.4 (48.3 to 56.2)	1,145.7 (708.4 to 1,696.4)	1,762.2 (1,085.1 to 2,592.9)	53.9 (48.9 to 57.3)
Dysthymia	3,070.0 (2,396.6 to 3,677.8)	4,680.0 (3,621.4 to 5,593.3)	52.6 (49.9 to 55.0)	283.7 (182.0 to 417.0)	434.3 (275.3 to 639.5)	53.2 (49.7 to 56.4)
Bipolar disorder	884.7 (701.8 to 1,112.0)	1,352.3 (1,073.0 to 1,688.5)	52.9 (50.0 to 55.9)	168.3 (103.0 to 255.4)	258.9 (158.0 to 390.3)	53.8 (48.9 to 59.4)
Anxiety disorders	4,982.2 (3,726.1 to 6,407.9)	7,373.2 (5,408.6 to 9,665.8)	47.8 (42.8 to 53.0)	429.1 (266.7 to 642.7)	637.5 (388.9 to 969.5)	48.4 (41.8 to 54.1)
Eating disorders	-	-	-	-	-	-
Anorexia nervosa	-	-	-	-	-	-
Bulimia nervosa	-	-	-	-	-	-
Autistic spectrum disorders	-	-	-	110.6 (77.7 to 147.6)	172.4 (120.5 to 229.4)	55.8 (51.9 to 59.5)
Autism	306.5 (286.8 to 328.9)	473.9 (443.2 to 509.3)	54.7 (54.1 to 55.4)	70.2 (47.8 to 95.0)	109.1 (74.1 to 149.2)	55.5 (50.3 to 60.8)
Asperger syndrome	429.6 (391.3 to 472.5)	667.4 (608.1 to 732.9)	55.5 (55.2 to 55.8)	40.4 (28.1 to 55.7)	63.2 (43.6 to 87.2)	56.2 (51.8 to 61.1)
Attention-deficit/hyperactivity disorder	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.3 (24.2 to 59.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.4 (24.1 to 59.6)
Conduct disorder	-	-	-	-	-	-
Idiopathic intellectual disability	1,050.7 (774.8 to 1,356.5)	1,459.2 (1,097.9 to 1,860.5)	38.8 (24.6 to 56.8)	50.4 (32.0 to 73.1)	69.4 (45.1 to 98.8)	37.5 (23.2 to 55.9)
Other mental and substance use disorders	1,660.7 (1,181.4 to 2,300.0)	2,544.6 (1,803.4 to 3,516.8)	53.3 (51.4 to 55.1)	117.3 (71.1 to 180.8)	180.9 (108.3 to 278.0)	54.2 (49.3 to 59.2)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	2,202.7 (1,557.5 to 2,907.9)	4,016.1 (2,821.8 to 5,336.7)	82.1 (74.2 to 90.3)
Diabetes mellitus	13,270.5 (10,085.6 to 15,359.9)	30,225.4 (25,041.6 to 34,144.8)	128.0 (110.6 to 153.3)	1,044.3 (715.3 to 1,434.4)	2,302.5 (1,572.8 to 3,132.3)	120.6 (105.4 to 137.1)
Acute glomerulonephritis	1.0 (0.9 to 1.1)	1.3 (1.2 to 1.4)	32.4 (28.6 to 35.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	32.4 (28.6 to 35.9)
Chronic kidney disease	-	-	-	524.5 (351.1 to 746.5)	748.0 (511.2 to 1,044.2)	42.4 (35.7 to 52.4)
Chronic kidney disease due to diabetes mellitus	5,123.3 (3,150.2 to 8,756.6)	8,745.1 (5,675.1 to 12,851.8)	74.5 (43.4 to 99.0)	125.2 (84.4 to 175.8)	222.9 (150.4 to 311.1)	78.5 (59.0 to 97.9)
Chronic kidney disease due to hypertension	3,564.8 (2,340.6 to 5,593.3)	4,162.9 (2,825.5 to 6,214.4)	18.2 (5.1 to 28.5)	142.0 (96.5 to 200.8)	146.7 (97.9 to 208.9)	3.4 (-10.2 to 18.4)
Chronic kidney disease due to glomerulonephritis	5,320.1 (2,933.0 to 9,759.1)	5,897.9 (3,533.7 to 9,022.9)	14.0 (-11.3 to 36.5)	77.1 (52.7 to 107.7)	101.1 (69.1 to 143.6)	31.1 (16.5 to 46.2)
Chronic kidney disease due to other causes	6,919.8 (4,071.1 to 11,958.6)	9,881.1 (6,292.3 to 15,625.0)	45.5 (21.2 to 63.0)	180.1 (118.0 to 270.6)	277.3 (187.1 to 390.9)	54.5 (36.8 to 73.8)
Urinary diseases and male infertility	-	-	-	454.6 (299.0 to 636.7)	734.9 (478.2 to 1,036.1)	61.6 (56.2 to 67.3)
Interstitial nephritis and urinary tract infections	47.2 (45.9 to 48.6)	86.7 (84.4 to 89.3)	83.8 (76.8 to 91.5)	1.5 (1.0 to 2.2)	2.8 (1.7 to 4.1)	84.2 (64.1 to 107.6)
Urolithiasis	4,369.7 (3,222.3 to 6,058.9)	8,314.8 (6,039.0 to 11,550.8)	90.3 (82.2 to 97.2)	29.4 (17.8 to 45.4)	58.0 (34.1 to 91.9)	96.3 (84.5 to 107.2)
Benign prostatic hyperplasia	11,512.0 (11,278.7 to 11,755.3)	17,815.6 (17,407.3 to 18,211.9)	54.9 (50.3 to 59.7)	413.8 (269.8 to 580.0)	645.0 (421.2 to 910.1)	55.9 (51.0 to 60.7)
Male infertility due to other causes	-	-	-	-	-	-
Other urinary diseases	-	-	-	9.8 (5.7 to 15.3)	29.2 (14.0 to 48.1)	211.9 (111.3 to 266.7)
Gynecological diseases	-	-	-	25.4 (12.8 to 46.7)	36.4 (18.2 to 67.6)	43.2 (37.5 to 49.2)
Uterine fibroids	85.5 (80.7 to 89.9)	122.0 (115.1 to 128.3)	42.8 (42.2 to 43.5)	0.6 (0.3 to 1.1)	0.9 (0.4 to 1.6)	43.5 (31.8 to 56.2)
Polycystic ovarian syndrome	-	-	-	-	-	-
Female infertility due to other causes	-	-	-	-	-	-
Endometriosis	-	-	-	-	-	-
Genital prolapse	8,031.7 (7,835.9 to 8,244.6)	11,474.4 (11,149.4 to 11,817.6)	42.9 (37.7 to 48.6)	24.8 (12.5 to 45.6)	35.5 (17.7 to 66.1)	43.2 (37.3 to 49.4)
Premenstrual syndrome	-	-	-	-	-	-
Other gynecological diseases	-	-	-	0.0 (0.0 to 0.0)	-	-
Hemoglobinopathies and hemolytic anemias	-	-	-	84.9 (56.9 to 122.9)	103.1 (67.9 to 149.8)	21.4 (12.1 to 29.0)
Thalassemias	0.4 (0.4 to 0.5)	1.0 (0.9 to 1.2)	138.5 (106.4 to 172.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	159.1 (115.1 to 218.6)
Thalassemia trait	3,231.9 (2,884.2 to 3,678.4)	5,095.3 (4,568.6 to 5,808.8)	57.8 (55.9 to 59.5)	37.1 (24.7 to 53.9)	53.5 (35.1 to 77.9)	44.2 (33.1 to 56.1)
Sickle cell disorders	1.4 (1.3 to 1.5)	2.4 (2.2 to 2.6)	67.6 (60.7 to 74.6)	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	70.5 (57.4 to 85.7)
Sickle cell trait	3,017.6 (2,873.6 to 3,153.2)	4,916.9 (4,685.2 to 5,127.3)	63.0 (60.3 to 65.7)	8.2 (5.2 to 12.0)	12.0 (7.5 to 17.8)	46.7 (24.5 to 75.0)
G6PD deficiency	4,247.9 (4,143.3 to 4,341.1)	7,008.3 (6,842.2 to 7,167.1)	65.2 (60.0 to 70.5)	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.8)	68.0 (58.6 to 79.3)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (65-69 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
G6PD trait	19,832.6 (19,720.5 to 19,942.4)	30,399.8 (30,227.8 to 30,566.8)	53.4 (52.2 to 54.6)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	32.6 (-19.8 to 90.0)
Other hemoglobinopathies and hemolytic anemias	1,768.9 (1,715.4 to 1,829.7)	2,023.5 (1,912.3 to 2,145.1)	14.5 (8.0 to 22.4)	38.8 (26.0 to 55.4)	36.1 (23.8 to 53.0)	-6.4 (-20.5 to 3.3)
Endocrine, metabolic, blood, and immune disorders	2,265.7 (2,189.2 to 2,343.2)	2,940.0 (2,855.5 to 3,025.6)	29.9 (24.6 to 35.0)	68.9 (47.8 to 93.8)	91.2 (63.3 to 123.1)	32.2 (24.7 to 40.8)
Musculoskeletal disorders	-	-	-	6,204.2 (4,467.1 to 8,091.2)	9,422.8 (6,767.8 to 12,361.3)	51.9 (49.5 to 54.3)
Rheumatoid arthritis	1,104.8 (1,086.4 to 1,122.2)	1,531.2 (1,510.9 to 1,551.9)	38.8 (35.9 to 41.7)	252.0 (181.4 to 331.0)	350.9 (253.3 to 461.8)	39.3 (34.9 to 43.7)
Osteoarthritis	18,281.2 (18,076.1 to 18,474.4)	26,768.5 (26,498.8 to 27,019.0)	46.5 (44.4 to 48.9)	939.7 (662.9 to 1,277.6)	1,403.3 (990.3 to 1,895.0)	49.4 (46.7 to 52.0)
Low back and neck pain	-	-	-	3,728.9 (2,639.6 to 4,964.3)	5,631.5 (3,954.8 to 7,511.6)	50.9 (47.5 to 54.9)
Low back pain	25,183.7 (24,557.5 to 25,742.0)	37,777.1 (36,926.7 to 39,261.4)	50.0 (46.1 to 55.6)	2,688.2 (1,855.9 to 3,644.1)	4,055.3 (2,772.3 to 5,566.3)	50.6 (46.6 to 56.5)
Neck pain	11,022.2 (10,733.7 to 11,307.7)	16,610.7 (16,113.8 to 17,082.7)	50.9 (45.4 to 56.3)	1,040.7 (732.6 to 1,418.0)	1,576.2 (1,101.0 to 2,151.5)	51.5 (45.8 to 56.9)
Gout	403.7 (394.9 to 413.6)	601.3 (588.5 to 613.6)	49.1 (44.7 to 53.6)	12.5 (8.6 to 16.8)	18.7 (13.1 to 25.1)	49.7 (37.0 to 62.4)
Other musculoskeletal disorders	14,339.4 (11,330.1 to 17,267.3)	22,688.8 (17,740.4 to 27,108.5)	58.3 (53.3 to 62.7)	1,271.1 (818.2 to 1,820.0)	2,018.3 (1,301.6 to 2,903.1)	58.7 (53.4 to 63.4)
Other non-communicable diseases	-	-	-	5,144.4 (3,415.9 to 7,294.8)	7,317.7 (4,844.9 to 10,394.3)	42.2 (39.6 to 44.9)
Congenital anomalies	-	-	-	131.5 (99.6 to 164.4)	254.8 (195.9 to 317.7)	93.8 (84.0 to 103.7)
Neural tube defects	4.4 (4.1 to 4.7)	11.3 (10.9 to 11.8)	154.4 (137.5 to 176.6)	1.2 (0.8 to 1.5)	3.2 (2.2 to 4.2)	175.2 (144.8 to 213.7)
Congenital heart anomalies	372.3 (354.6 to 393.0)	759.0 (735.0 to 791.7)	103.8 (92.4 to 118.0)	12.3 (5.4 to 20.9)	25.6 (11.3 to 43.6)	108.9 (93.5 to 125.5)
Orofacial clefts	49.3 (46.7 to 52.1)	122.4 (118.1 to 126.6)	148.2 (134.0 to 165.5)	0.5 (0.3 to 0.7)	1.2 (0.8 to 1.7)	146.3 (106.2 to 196.7)
Down syndrome	136.9 (120.8 to 150.2)	317.7 (280.3 to 345.6)	132.8 (119.0 to 143.6)	26.0 (19.6 to 33.1)	60.4 (45.9 to 75.6)	132.1 (115.8 to 148.3)
Turner syndrome	1.9 (1.8 to 2.0)	3.8 (3.6 to 4.0)	96.8 (80.0 to 110.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	97.0 (80.1 to 110.6)
Klinefelter syndrome	3.0 (2.8 to 3.2)	5.4 (5.1 to 5.6)	77.9 (66.7 to 90.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.0 (66.8 to 90.8)
Chromosomal unbalanced rearrangements	213.4 (186.3 to 234.3)	455.9 (403.8 to 497.6)	113.9 (103.7 to 124.9)	40.5 (29.4 to 51.3)	86.7 (63.4 to 110.7)	114.4 (101.4 to 127.6)
Other congenital anomalies	519.1 (447.5 to 585.2)	684.8 (580.5 to 774.2)	32.1 (25.4 to 38.4)	51.1 (35.8 to 69.3)	77.5 (54.6 to 103.2)	51.6 (36.2 to 72.9)
Skin and subcutaneous diseases	-	-	-	718.9 (473.8 to 1,131.3)	1,083.0 (707.3 to 1,724.1)	50.6 (46.9 to 54.4)
Dermatitis	5,147.8 (4,580.8 to 5,861.9)	7,762.8 (6,905.0 to 8,809.9)	50.9 (49.8 to 51.9)	143.5 (94.5 to 204.5)	215.9 (142.4 to 305.7)	50.4 (47.3 to 53.6)
Psoriasis	1,840.3 (1,554.9 to 2,200.8)	2,731.8 (2,296.4 to 3,288.7)	48.4 (46.6 to 51.0)	141.6 (98.0 to 204.8)	211.6 (146.1 to 306.4)	49.3 (44.6 to 53.7)
Cellulitis	73.7 (54.8 to 97.8)	89.2 (66.5 to 120.4)	21.0 (14.1 to 28.5)	4.9 (3.0 to 7.7)	6.0 (3.7 to 9.5)	22.0 (5.9 to 39.0)
Pyoderma	111.1 (76.6 to 157.6)	147.0 (92.6 to 223.8)	32.9 (12.7 to 46.4)	0.6 (0.2 to 1.4)	0.8 (0.3 to 1.8)	33.2 (11.8 to 48.9)
Scabies	638.5 (587.5 to 708.3)	993.9 (915.7 to 1,087.9)	55.7 (38.6 to 74.3)	15.7 (9.2 to 25.6)	24.6 (14.1 to 39.1)	56.7 (39.4 to 75.9)
Fungal skin diseases	14,517.0 (12,207.2 to 16,266.1)	22,225.0 (18,815.5 to 24,816.7)	53.3 (51.5 to 55.2)	78.8 (32.6 to 160.2)	121.2 (50.0 to 247.2)	53.8 (51.8 to 55.8)
Viral skin diseases	1,392.9 (1,007.7 to 1,927.4)	2,068.1 (1,500.8 to 2,860.1)	48.6 (45.8 to 51.8)	40.7 (24.1 to 65.1)	60.6 (35.8 to 97.0)	49.0 (45.1 to 53.9)
Acne vulgaris	706.8 (655.6 to 758.9)	1,002.7 (906.8 to 1,110.6)	41.7 (26.2 to 58.7)	7.3 (3.6 to 13.4)	10.4 (5.0 to 18.9)	42.3 (26.6 to 59.4)
Alopecia areata	255.6 (248.1 to 262.9)	381.4 (368.8 to 393.5)	49.4 (43.7 to 55.3)	8.2 (5.3 to 12.1)	12.3 (7.9 to 18.2)	49.9 (40.4 to 59.4)
Pruritus	57.5 (54.2 to 60.9)	91.9 (85.0 to 100.5)	59.1 (45.0 to 80.6)	0.6 (0.3 to 1.1)	1.0 (0.4 to 1.8)	60.4 (40.4 to 85.0)
Urticaria	2,063.5 (1,872.4 to 2,247.3)	3,123.9 (2,798.3 to 3,426.2)	51.5 (34.2 to 71.5)	117.2 (76.1 to 165.9)	178.1 (117.4 to 252.9)	51.8 (34.5 to 73.4)
Decubitus ulcer	111.8 (107.0 to 118.1)	159.3 (150.7 to 168.4)	42.8 (32.7 to 50.0)	16.2 (11.3 to 21.6)	23.2 (16.0 to 31.4)	43.3 (28.1 to 59.0)
Other skin and subcutaneous diseases	25,036.9 (6,267.6 to 60,794.6)	37,758.5 (9,414.9 to 91,747.0)	50.9 (49.0 to 53.1)	143.5 (30.5 to 400.4)	217.4 (46.0 to 609.8)	51.4 (49.4 to 53.9)
Sense organ diseases	-	-	-	3,270.3 (2,151.0 to 4,608.2)	4,601.7 (3,005.2 to 6,495.9)	40.7 (37.1 to 44.5)
Glaucoma	561.8 (448.1 to 706.5)	842.4 (648.3 to 1,061.1)	50.1 (27.0 to 78.2)	46.8 (29.9 to 67.1)	71.2 (44.5 to 102.6)	51.5 (34.7 to 73.8)
Cataract	4,575.4 (3,601.3 to 5,491.1)	5,957.8 (4,700.5 to 7,181.2)	29.6 (22.0 to 42.5)	284.4 (184.1 to 406.3)	397.7 (259.6 to 566.3)	39.5 (31.8 to 50.7)
Macular degeneration	1,189.4 (907.0 to 1,502.0)	1,729.2 (1,342.7 to 2,150.1)	45.1 (33.3 to 61.0)	56.6 (35.6 to 83.6)	84.9 (54.5 to 123.9)	49.6 (39.2 to 64.7)
Uncorrected refractive error	36,598.0 (34,866.3 to 38,085.2)	52,142.3 (50,134.5 to 54,367.4)	42.6 (37.4 to 47.8)	655.0 (407.1 to 991.1)	907.0 (560.5 to 1,386.0)	38.3 (34.8 to 42.6)
Age-related and other hearing loss	78,659.0 (73,202.4 to 82,806.5)	113,219.7 (105,654.5 to 119,636.8)	44.1 (41.9 to 46.2)	2,004.9 (1,277.6 to 2,893.6)	2,830.1 (1,790.4 to 4,084.0)	41.2 (35.1 to 47.2)
Other vision loss	1,430.3 (1,083.7 to 1,935.5)	1,701.7 (1,289.6 to 2,175.9)	19.4 (7.9 to 30.3)	110.1 (69.1 to 161.0)	139.3 (87.7 to 200.3)	27.0 (16.7 to 35.7)
Other sense organ diseases	4,462.2 (4,366.9 to 4,556.3)	6,776.3 (6,629.2 to 6,925.7)	52.0 (47.5 to 56.4)	112.4 (70.8 to 165.0)	171.4 (108.4 to 252.9)	52.6 (47.3 to 57.9)
Oral disorders	-	-	-	1,023.7 (675.2 to 1,463.0)	1,378.3 (896.7 to 1,988.9)	34.4 (31.2 to 38.0)
Deciduous caries	-	-	-	-	-	-
Permanent caries	40,913.5 (40,307.7 to 41,422.4)	64,087.1 (63,170.5 to 65,159.6)	56.7 (53.9 to 60.1)	32.5 (15.4 to 61.4)	53.9 (25.2 to 101.8)	65.7 (60.7 to 70.4)
Periodontal diseases	21,249.3 (20,978.1 to 21,543.9)	33,296.4 (32,758.9 to 33,828.7)	56.8 (53.6 to 60.1)	135.1 (54.9 to 276.0)	212.7 (85.5 to 436.7)	57.4 (54.2 to 60.8)
Edentulism and severe tooth loss	18,275.8 (27,874.0 to 28,726.7)	36,015.2 (35,442.8 to 36,644.2)	27.5 (24.9 to 30.2)	774.4 (525.9 to 1,063.9)	988.4 (673.5 to 1,364.8)	27.6 (25.1 to 30.7)
Other oral disorders	2,907.8 (2,850.4 to 2,970.8)	4,365.9 (4,267.4 to 4,474.9)	50.3 (45.2 to 55.3)	81.7 (52.7 to 119.9)	123.3 (78.5 to 181.2)	50.8 (45.4 to 56.0)
Injuries	-	-	-	2,300.3 (1,670.7 to 3,063.1)	2,423.0 (1,733.0 to 3,258.4)	5.7 (-5.4 to 15.9)
Transport injuries	-	-	-	523.1 (388.6 to 683.2)	618.3 (445.2 to 825.9)	17.9 (11.4 to 24.9)
Road injuries	-	-	-	434.4 (322.7 to 566.2)	520.1 (375.2 to 693.4)	19.4 (12.6 to 26.5)
Pedestrian road injuries	-	-	-	107.4 (79.5 to 140.3)	145.6 (104.8 to 193.7)	35.4 (28.6 to 42.8)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (65-69 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Cyclist road injuries	-	-	-	52.1 (38.6 to 68.0)	58.0 (41.9 to 77.5)	11.3 (4.6 to 17.8)
Motorcyclist road injuries	-	-	-	80.7 (59.9 to 106.4)	91.1 (64.1 to 124.2)	12.6 (5.0 to 20.3)
Motor vehicle road injuries	-	-	-	188.6 (140.9 to 245.2)	219.8 (159.6 to 292.8)	16.3 (9.4 to 23.7)
Other road injuries	-	-	-	5.6 (4.2 to 7.3)	5.5 (4.1 to 7.3)	-1.9 (-7.1 to 4.1)
Other transport injuries	-	-	-	88.7 (65.6 to 115.7)	98.2 (70.4 to 131.2)	10.5 (4.7 to 16.7)
Unintentional injuries	-	-	-	1,217.1 (907.4 to 1,591.6)	1,405.2 (1,009.7 to 1,886.6)	15.2 (8.1 to 22.2)
Falls	-	-	-	800.1 (601.0 to 1,037.6)	918.6 (659.6 to 1,232.2)	14.5 (5.4 to 24.2)
Drowning	-	-	-	17.3 (12.7 to 22.4)	19.7 (14.3 to 26.2)	14.1 (7.6 to 20.9)
Fire, heat, and hot substances	-	-	-	50.5 (35.4 to 70.0)	53.5 (37.0 to 75.3)	5.8 (1.0 to 10.7)
Poisonings	-	-	-	3.4 (2.4 to 4.5)	3.4 (2.5 to 4.5)	0.4 (-6.4 to 7.4)
Exposure to mechanical forces	-	-	-	165.6 (118.8 to 223.4)	182.0 (128.8 to 250.9)	9.7 (5.7 to 13.6)
Unintentional firearm injuries	-	-	-	5.5 (4.1 to 7.2)	6.3 (4.5 to 8.6)	13.8 (7.2 to 20.8)
Unintentional suffocation	-	-	-	1.6 (1.2 to 2.1)	2.6 (1.9 to 3.5)	62.8 (54.8 to 70.3)
Other exposure to mechanical forces	-	-	-	158.5 (113.7 to 214.1)	173.1 (122.5 to 238.8)	9.0 (5.2 to 12.8)
Adverse effects of medical treatment	-	-	-	10.5 (6.6 to 15.6)	15.4 (9.7 to 22.7)	46.4 (39.0 to 52.9)
Animal contact	-	-	-	18.0 (13.3 to 23.5)	19.0 (13.9 to 25.7)	5.7 (1.2 to 10.3)
Venomous animal contact	-	-	-	5.6 (4.0 to 7.3)	5.7 (4.1 to 7.4)	1.5 (-5.7 to 8.6)
Non-venomous animal contact	-	-	-	12.4 (9.1 to 16.8)	13.4 (9.6 to 18.4)	7.8 (3.1 to 12.5)
Foreign body	-	-	-	10.7 (8.0 to 13.5)	13.2 (9.8 to 17.1)	23.9 (17.9 to 30.8)
Pulmonary aspiration and foreign body in airway	-	-	-	2.3 (1.8 to 2.9)	2.3 (1.7 to 3.0)	-1.7 (-8.9 to 7.3)
Foreign body in eyes	-	-	-	1.8 (1.2 to 2.4)	2.4 (1.6 to 3.3)	33.1 (26.4 to 39.5)
Foreign body in other body part	-	-	-	6.6 (5.0 to 8.3)	8.6 (6.4 to 11.1)	30.3 (24.4 to 37.2)
Other unintentional injuries	-	-	-	141.0 (102.7 to 188.8)	180.3 (129.2 to 243.0)	27.8 (23.4 to 32.5)
Self-harm and interpersonal violence	-	-	-	51.3 (38.3 to 66.7)	55.1 (39.4 to 74.4)	7.0 (0.8 to 14.4)
Self-harm	-	-	-	14.9 (11.0 to 19.5)	14.4 (10.2 to 19.3)	-3.9 (-9.4 to 2.6)
Interpersonal violence	-	-	-	36.4 (27.2 to 47.5)	40.7 (29.2 to 55.3)	11.4 (4.6 to 19.4)
Assault by firearm	-	-	-	6.7 (5.0 to 8.9)	8.8 (6.3 to 11.9)	30.5 (24.6 to 36.7)
Assault by sharp object	-	-	-	6.4 (4.6 to 8.6)	8.2 (5.7 to 11.4)	27.3 (20.0 to 35.0)
Assault by other means	-	-	-	23.3 (17.4 to 29.9)	23.7 (17.2 to 31.6)	1.7 (-5.1 to 9.7)
Forces of nature, war, and legal intervention	-	-	-	508.8 (219.3 to 1,040.6)	344.3 (151.3 to 711.2)	-32.4 (-44.6 to -13.8)
Exposure to forces of nature	-	-	-	39.9 (20.3 to 75.1)	51.4 (24.0 to 106.6)	27.9 (-14.9 to 83.3)
Collective violence and legal intervention	-	-	-	468.9 (189.0 to 976.3)	292.8 (122.0 to 619.4)	-37.5 (-48.7 to -20.8)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (70-74 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
All causes	-	-	-	19,716.5 (14,889.9 to 25,283.4)	33,449.8 (25,048.6 to 42,660.4)	69.7 (67.2 to 71.8)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	862.6 (614.6 to 1,149.9)	1,124.5 (812.8 to 1,490.7)	30.4 (24.9 to 36.6)
HIV/AIDS and tuberculosis	-	-	-	94.8 (66.0 to 125.9)	197.8 (140.0 to 260.3)	108.7 (97.1 to 122.9)
Tuberculosis	293.3 (276.5 to 311.0)	537.9 (505.6 to 568.9)	82.9 (76.2 to 92.1)	82.9 (57.8 to 111.0)	153.5 (105.9 to 204.1)	84.9 (75.8 to 96.1)
HIV/AIDS	-	-	-	11.9 (8.3 to 16.0)	44.3 (31.8 to 58.1)	271.6 (204.1 to 367.5)
HIV/AIDS resulting in mycobacterial infection	3.3 (2.0 to 5.1)	9.9 (6.1 to 14.2)	203.6 (121.5 to 302.8)	1.1 (0.6 to 1.9)	3.5 (1.8 to 5.5)	210.2 (113.2 to 340.9)
HIV/AIDS resulting in other diseases	73.8 (63.8 to 83.8)	307.8 (279.3 to 346.8)	315.5 (265.5 to 384.7)	10.8 (7.4 to 14.6)	40.8 (29.2 to 53.9)	278.3 (202.7 to 382.4)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	115.8 (82.9 to 154.9)	168.6 (119.7 to 227.1)	45.3 (40.1 to 51.6)
Diarrheal diseases	326.5 (318.9 to 333.8)	421.6 (409.5 to 432.2)	29.3 (24.5 to 33.9)	47.9 (33.6 to 64.3)	61.8 (43.3 to 83.1)	28.8 (22.4 to 35.6)
Intestinal infectious diseases	-	-	-	1.6 (1.1 to 2.4)	1.8 (1.1 to 2.6)	6.2 (-24.4 to 53.8)
Typhoid fever	10.3 (8.4 to 12.2)	11.7 (9.4 to 14.9)	11.8 (-12.9 to 60.0)	1.2 (0.8 to 1.9)	1.4 (0.8 to 2.2)	13.8 (-23.3 to 77.5)
Paratyphoid fever	5.7 (4.5 to 7.2)	5.2 (3.9 to 6.8)	-10.7 (-37.7 to 37.2)	0.3 (0.2 to 0.4)	0.3 (0.1 to 0.4)	-5.7 (-44.2 to 59.3)
Other intestinal infectious diseases	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-42.0 (-56.0 to -23.4)
Lower respiratory infections	89.8 (87.8 to 91.8)	165.9 (162.5 to 169.3)	85.0 (79.1 to 90.1)	8.7 (6.0 to 12.0)	16.2 (11.2 to 22.2)	85.7 (75.4 to 96.1)
Upper respiratory infections	1,841.1 (1,795.3 to 1,887.7)	3,291.1 (3,208.7 to 3,376.1)	78.9 (72.4 to 85.3)	20.3 (11.6 to 33.2)	36.5 (20.8 to 59.2)	79.6 (72.0 to 87.4)
Otitis media	564.8 (544.3 to 585.8)	884.4 (852.2 to 919.2)	56.5 (49.2 to 64.6)	10.3 (6.3 to 16.3)	16.3 (9.7 to 25.4)	58.1 (49.2 to 67.6)
Meningitis	-	-	-	15.2 (7.6 to 25.6)	17.5 (9.1 to 29.7)	15.0 (7.3 to 27.3)
Pneumococcal meningitis	121.4 (63.0 to 194.4)	148.8 (74.5 to 247.5)	21.9 (11.2 to 33.1)	6.0 (3.8 to 8.9)	7.3 (4.6 to 11.1)	22.5 (9.5 to 36.5)
H influenzae type B meningitis	40.4 (5.0 to 88.9)	38.9 (3.6 to 91.0)	-4.9 (-36.4 to 9.0)	1.6 (0.7 to 2.9)	1.6 (0.7 to 3.1)	5.0 (-6.2 to 17.6)
Meningococcal meningitis	31.0 (4.7 to 69.6)	31.2 (4.6 to 73.2)	-0.8 (-20.0 to 12.7)	3.1 (0.9 to 5.9)	3.2 (1.1 to 6.3)	3.5 (-10.7 to 21.1)
Other meningitis	60.8 (11.8 to 129.2)	63.9 (12.3 to 146.2)	4.2 (-23.3 to 21.6)	4.6 (2.0 to 8.0)	5.3 (2.5 to 9.2)	16.0 (0.5 to 36.5)
Encephalitis	46.9 (17.4 to 109.1)	62.4 (23.0 to 159.7)	32.9 (-0.9 to 49.4)	4.7 (3.2 to 6.6)	6.9 (4.7 to 9.7)	47.5 (29.9 to 69.2)
Diphtheria	-	-	-	-	-	-
Whooping cough	-	-	-	-	-	-
Tetanus	15.5 (11.5 to 22.9)	2.3 (1.4 to 3.5)	-85.6 (-91.8 to -73.8)	0.4 (0.2 to 0.7)	0.1 (0.1 to 0.2)	-76.2 (-85.8 to -57.9)
Measles	-	-	-	-	-	-
Varicella and herpes zoster	128.1 (122.5 to 133.9)	222.0 (212.1 to 234.5)	73.1 (63.7 to 85.3)	6.7 (4.2 to 10.1)	11.6 (7.3 to 17.3)	73.3 (61.6 to 88.1)
Neglected tropical diseases and malaria	-	-	-	363.2 (245.1 to 509.8)	368.7 (235.0 to 541.4)	0.9 (-10.0 to 14.4)
Malaria	1,689.6 (1,626.1 to 1,754.2)	2,053.4 (1,963.1 to 2,147.6)	21.6 (14.5 to 28.4)	10.4 (6.8 to 15.1)	11.9 (7.7 to 17.4)	14.3 (1.7 to 28.1)
Chagas disease	208.0 (201.2 to 214.2)	299.6 (289.1 to 310.8)	43.9 (37.6 to 51.1)	4.9 (3.3 to 6.9)	7.1 (4.8 to 10.0)	44.5 (35.2 to 54.5)
Leishmaniasis	-	-	-	0.3 (0.2 to 0.6)	0.9 (0.4 to 1.7)	177.9 (148.0 to 212.9)
Visceral leishmaniasis	0.4 (0.3 to 0.6)	0.8 (0.6 to 1.0)	73.1 (38.1 to 124.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	73.6 (38.3 to 126.2)
Cutaneous and mucocutaneous leishmaniasis	29.9 (26.3 to 34.2)	85.3 (74.0 to 97.9)	184.5 (154.9 to 221.2)	0.3 (0.1 to 0.6)	0.9 (0.4 to 1.6)	189.0 (158.3 to 227.8)
African trypanosomiasis	1.0 (0.5 to 2.0)	0.3 (0.2 to 0.5)	-71.6 (-75.6 to -66.3)	0.2 (0.1 to 0.5)	0.1 (0.0 to 0.1)	-71.6 (-80.9 to -57.4)
Schistosomiasis	2,699.6 (2,423.4 to 2,973.5)	3,317.4 (2,866.1 to 3,871.6)	21.3 (12.2 to 42.1)	20.2 (10.2 to 37.9)	24.7 (12.3 to 47.6)	20.6 (12.2 to 39.9)
Cysticercosis	37.3 (32.8 to 42.6)	28.8 (24.1 to 33.5)	-22.3 (-37.6 to -2.2)	9.8 (6.9 to 13.0)	8.2 (5.6 to 11.0)	-16.0 (-34.7 to 8.2)
Cystic echinococcosis	34.9 (33.7 to 36.0)	37.3 (36.3 to 39.0)	7.0 (2.9 to 9.8)	3.1 (2.1 to 4.2)	3.3 (2.3 to 4.5)	7.6 (-3.1 to 19.4)
Lymphatic filariasis	1,574.4 (1,305.5 to 1,902.3)	1,337.8 (1,055.8 to 1,711.9)	-15.1 (-24.8 to -5.1)	73.5 (39.2 to 124.1)	85.4 (47.9 to 138.9)	17.3 (-6.4 to 41.2)
Onchocerciasis	512.3 (387.1 to 680.4)	350.2 (250.1 to 496.6)	-32.2 (-41.4 to -18.4)	49.6 (30.0 to 78.4)	35.1 (20.0 to 58.8)	-30.4 (-40.9 to -13.9)
Trachoma	589.1 (407.6 to 823.5)	341.6 (232.0 to 472.2)	-42.0 (-52.1 to -31.0)	43.7 (26.7 to 65.8)	26.3 (16.0 to 39.2)	-39.9 (-47.9 to -31.3)
Dengue	5.7 (2.1 to 12.8)	53.5 (19.7 to 120.0)	842.8 (831.6 to 851.5)	0.9 (0.3 to 2.2)	8.0 (2.7 to 20.6)	841.0 (638.8 to 1,090.6)
Yellow fever	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-61.3 (-71.9 to -31.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.3 (-72.0 to -31.4)
Rabies	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-18.9 (-40.3 to 12.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.9 (-40.3 to 13.1)
Intestinal nematode infections	-	-	-	76.9 (44.6 to 122.7)	45.7 (26.5 to 74.0)	-40.3 (-46.4 to -34.1)
Ascariasis	15,906.8 (12,939.8 to 19,717.0)	13,082.5 (10,920.4 to 15,968.2)	-17.6 (-37.3 to 9.2)	37.4 (20.9 to 61.5)	12.3 (6.8 to 20.9)	-67.3 (-72.7 to -60.7)
Trichuriasis	7,765.7 (6,007.7 to 10,226.2)	7,401.7 (6,595.7 to 8,323.5)	-3.1 (-30.2 to 25.5)	10.3 (5.7 to 17.0)	8.0 (4.3 to 13.4)	-23.2 (-39.3 to 1.3)
Hookworm disease	7,395.2 (6,020.9 to 9,231.0)	7,728.3 (6,969.4 to 8,629.5)	5.4 (-18.6 to 31.5)	29.2 (17.3 to 46.7)	25.5 (15.2 to 40.7)	-12.6 (-23.0 to -0.7)
Food-borne trematodiasis	1,332.9 (1,012.6 to 1,657.4)	2,354.0 (1,835.2 to 2,883.2)	76.9 (60.5 to 91.1)	62.5 (16.8 to 135.9)	106.1 (31.6 to 225.9)	72.2 (48.6 to 93.5)
Other neglected tropical diseases	162.5 (142.9 to 183.9)	192.3 (177.0 to 208.9)	18.2 (7.3 to 31.4)	7.2 (3.8 to 13.1)	5.9 (2.9 to 11.3)	-20.2 (-37.4 to 8.3)
Maternal disorders	-	-	-	2.6 (1.5 to 4.0)	3.7 (2.1 to 5.8)	41.0 (3.7 to 103.0)
Maternal hemorrhage	-	-	-	-	-	-
Maternal sepsis and other maternal infections	-	-	-	-	-	-
Maternal hypertensive disorders	-	-	-	-	-	-
Obstructed labor	8.7 (6.5 to 11.2)	12.3 (9.4 to 15.8)	40.9 (22.6 to 61.7)	2.6 (1.5 to 4.0)	3.7 (2.1 to 5.8)	41.0 (3.7 to 103.0)
Complications of abortion	-	-	-	-	-	-

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (70-74 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Other maternal disorders	-	-	-	-	-	-
Neonatal disorders	-	-	-	29.8 (21.7 to 40.4)	94.1 (71.4 to 119.4)	219.0 (170.8 to 261.5)
Preterm birth complications	276.6 (231.7 to 332.4)	834.5 (697.1 to 1,020.2)	201.3 (169.1 to 239.7)	16.9 (12.5 to 21.8)	60.0 (45.3 to 75.6)	255.5 (227.0 to 284.7)
Neonatal encephalopathy due to birth asphyxia and trauma	234.3 (73.8 to 472.0)	247.3 (91.6 to 468.7)	5.5 (-25.4 to 76.1)	5.3 (2.3 to 10.2)	7.8 (4.6 to 13.0)	49.5 (10.8 to 118.8)
Neonatal sepsis and other neonatal infections	-	-	-	-	-	-
Hemolytic disease and other neonatal jaundice	7.4 (6.5 to 8.9)	22.2 (18.5 to 26.2)	198.0 (135.8 to 276.6)	3.1 (2.2 to 4.1)	9.1 (6.5 to 12.3)	193.8 (134.2 to 272.1)
Other neonatal disorders	-	-	-	4.4 (3.0 to 6.7)	17.2 (11.1 to 23.1)	294.1 (181.3 to 398.9)
Nutritional deficiencies	-	-	-	235.5 (159.2 to 333.0)	261.4 (174.8 to 379.5)	10.7 (6.0 to 16.5)
Protein-energy malnutrition	38.7 (20.4 to 61.8)	72.4 (37.8 to 114.1)	87.2 (41.2 to 141.0)	4.3 (1.9 to 7.8)	8.2 (3.7 to 14.2)	88.0 (39.1 to 150.3)
Iodine deficiency	1,549.4 (1,428.8 to 1,672.8)	1,708.9 (1,580.3 to 1,829.5)	10.4 (-0.8 to 22.7)	26.2 (16.4 to 40.0)	29.1 (17.9 to 46.2)	10.9 (-0.5 to 23.7)
Vitamin A deficiency	18.5 (7.3 to 31.9)	19.5 (9.6 to 30.9)	8.5 (-27.3 to 44.5)	1.4 (0.5 to 2.4)	1.5 (0.6 to 2.6)	7.4 (-23.1 to 60.8)
Iron-deficiency anemia	9,082.5 (8,959.6 to 9,203.3)	12,392.9 (12,189.1 to 12,574.4)	36.5 (34.1 to 38.9)	203.2 (137.4 to 288.3)	222.1 (148.4 to 326.3)	8.9 (3.5 to 15.7)
Other nutritional deficiencies	-	-	-	0.4 (0.2 to 0.9)	0.6 (0.3 to 1.1)	46.9 (-11.3 to 125.0)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	20.9 (13.4 to 33.3)	30.2 (18.8 to 50.0)	44.1 (32.1 to 54.9)
Sexually transmitted diseases excluding HIV	-	-	-	9.2 (5.0 to 18.2)	14.2 (7.2 to 28.8)	52.7 (38.1 to 62.3)
Syphilis	17.8 (17.0 to 18.6)	23.4 (22.6 to 24.3)	31.3 (23.9 to 39.2)	3.1 (2.1 to 4.3)	4.1 (2.8 to 5.8)	32.2 (13.4 to 55.2)
Chlamydial infection	0.4 (0.4 to 0.4)	0.4 (0.4 to 0.5)	9.0 (-2.5 to 20.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	8.1 (-3.6 to 19.6)
Gonococcal infection	0.4 (0.3 to 0.4)	0.4 (0.3 to 0.5)	6.5 (-14.7 to 30.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	6.5 (-14.8 to 30.5)
Trichomoniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.8 (52.3 to 96.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.9 (49.8 to 99.6)
Genital herpes	25,038.8 (24,750.9 to 25,309.4)	41,208.9 (40,688.2 to 41,772.6)	64.5 (62.0 to 67.4)	5.9 (1.7 to 14.5)	9.8 (2.8 to 24.1)	64.9 (61.2 to 68.8)
Other sexually transmitted diseases	0.8 (0.7 to 0.8)	1.2 (1.1 to 1.3)	57.1 (41.2 to 74.4)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	57.2 (41.2 to 74.4)
Hepatitis	-	-	-	4.6 (3.0 to 6.5)	6.4 (4.2 to 9.0)	38.3 (27.9 to 47.9)
Hepatitis A	19.5 (17.4 to 21.6)	43.9 (40.8 to 46.7)	125.6 (116.3 to 134.8)	0.7 (0.4 to 1.0)	1.5 (1.0 to 2.2)	125.6 (99.2 to 158.9)
Hepatitis B	6,254.6 (6,066.8 to 6,475.4)	7,053.7 (6,885.2 to 7,240.3)	12.8 (8.7 to 17.1)	3.0 (2.0 to 4.3)	3.5 (2.3 to 5.0)	15.8 (4.7 to 26.6)
Hepatitis C	4,898.3 (4,827.1 to 4,981.3)	6,379.6 (6,281.2 to 6,476.4)	30.3 (27.1 to 33.1)	0.7 (0.4 to 1.0)	0.9 (0.6 to 1.4)	38.9 (16.5 to 64.1)
Hepatitis E	10.3 (9.4 to 11.4)	17.3 (15.4 to 19.6)	67.0 (43.3 to 100.1)	0.2 (0.1 to 0.4)	0.4 (0.3 to 0.6)	67.7 (25.1 to 130.1)
Leprosy	33.8 (31.1 to 36.4)	60.1 (54.8 to 66.0)	77.3 (64.8 to 94.8)	1.9 (1.3 to 2.7)	3.6 (2.4 to 5.1)	90.0 (63.5 to 119.7)
Other infectious diseases	222.0 (202.8 to 243.3)	301.5 (283.8 to 320.2)	35.9 (23.2 to 48.0)	5.1 (3.2 to 7.6)	6.0 (3.7 to 9.3)	17.1 (-7.6 to 46.5)
Non-communicable diseases	-	-	-	16,990.0 (12,726.9 to 21,799.2)	30,061.0 (22,435.9 to 38,514.9)	76.9 (75.1 to 78.7)
Neoplasms	-	-	-	398.2 (299.4 to 505.2)	776.9 (573.9 to 983.6)	94.7 (85.4 to 106.0)
Esophageal cancer	74.6 (60.0 to 90.0)	113.8 (91.4 to 143.4)	51.7 (20.0 to 96.2)	11.7 (8.1 to 15.7)	16.9 (11.7 to 23.2)	44.0 (16.1 to 80.7)
Stomach cancer	248.8 (225.9 to 274.7)	342.2 (307.2 to 379.1)	37.2 (22.3 to 55.1)	30.2 (22.1 to 39.3)	38.9 (28.3 to 49.9)	28.6 (13.3 to 46.3)
Liver cancer	-	-	-	11.1 (7.6 to 14.9)	20.9 (14.6 to 28.0)	89.3 (57.4 to 128.5)
Liver cancer due to hepatitis B	19.4 (15.4 to 24.2)	41.1 (33.3 to 50.3)	112.2 (59.3 to 183.9)	3.3 (2.2 to 4.4)	6.2 (4.2 to 8.3)	88.6 (51.3 to 141.3)
Liver cancer due to hepatitis C	13.4 (11.0 to 16.2)	61.1 (50.9 to 72.7)	355.9 (263.3 to 468.6)	2.2 (1.5 to 3.0)	8.9 (6.2 to 12.0)	301.5 (231.9 to 396.1)
Liver cancer due to alcohol use	22.3 (18.6 to 27.0)	26.0 (21.7 to 30.7)	16.9 (-6.0 to 45.8)	3.6 (2.5 to 4.9)	4.0 (2.7 to 5.3)	9.1 (-9.7 to 33.1)
Liver cancer due to other causes	11.4 (9.1 to 14.5)	12.0 (9.4 to 15.0)	5.5 (-23.0 to 40.1)	2.0 (1.3 to 2.7)	1.9 (1.3 to 2.7)	-3.2 (-24.2 to 25.0)
Larynx cancer	64.6 (54.6 to 78.5)	102.5 (83.3 to 121.3)	58.7 (35.9 to 87.0)	6.6 (4.6 to 8.9)	9.8 (6.7 to 13.6)	48.6 (25.7 to 78.3)
Tracheal, bronchus and lung cancer	259.1 (242.6 to 276.3)	470.9 (433.5 to 505.2)	81.8 (67.0 to 97.2)	38.6 (28.5 to 48.4)	75.1 (48.8 to 85.9)	75.1 (60.8 to 89.4)
Breast cancer	784.0 (735.3 to 829.2)	1,821.5 (1,761.8 to 1,897.7)	132.3 (119.2 to 147.1)	46.7 (33.5 to 63.1)	95.4 (67.2 to 129.7)	104.3 (82.5 to 124.1)
Cervical cancer	125.6 (101.8 to 145.4)	159.6 (122.5 to 195.1)	27.8 (-2.3 to 57.9)	10.1 (6.9 to 13.5)	12.8 (8.6 to 18.0)	27.3 (-2.7 to 59.0)
Uterine cancer	149.9 (117.9 to 181.6)	237.3 (184.1 to 291.7)	59.0 (26.5 to 96.7)	10.3 (7.0 to 14.5)	15.8 (10.2 to 22.7)	53.3 (21.3 to 91.2)
Prostate cancer	781.4 (666.4 to 889.5)	2,109.8 (1,820.4 to 2,543.9)	167.5 (141.1 to 210.6)	66.4 (46.8 to 88.3)	170.9 (121.7 to 232.5)	154.4 (122.5 to 206.5)
Colon and rectum cancer	559.1 (534.5 to 589.9)	1,154.5 (1,089.3 to 1,218.8)	106.8 (92.6 to 119.2)	48.2 (35.4 to 62.4)	94.0 (69.0 to 121.2)	95.4 (81.1 to 108.6)
Lip and oral cavity cancer	137.6 (112.6 to 181.8)	250.4 (204.1 to 311.8)	82.1 (44.4 to 131.7)	12.5 (8.5 to 17.6)	22.0 (15.2 to 30.5)	77.1 (38.1 to 127.3)
Nasopharynx cancer	17.4 (12.7 to 23.4)	23.2 (16.9 to 30.5)	35.3 (-9.8 to 94.6)	1.9 (1.2 to 2.8)	2.4 (1.5 to 3.5)	28.6 (-13.0 to 83.3)
Other pharynx cancer	33.7 (27.8 to 40.5)	67.6 (52.1 to 84.6)	98.5 (55.2 to 163.2)	3.2 (2.2 to 4.3)	6.1 (4.1 to 8.8)	92.6 (48.1 to 163.7)
Gallbladder and biliary tract cancer	15.5 (13.3 to 18.1)	21.0 (18.1 to 24.5)	35.7 (15.6 to 58.6)	4.0 (2.8 to 5.3)	5.3 (3.6 to 7.2)	32.9 (9.9 to 56.6)
Pancreatic cancer	27.0 (24.9 to 29.2)	54.5 (49.4 to 59.4)	102.0 (81.3 to 125.1)	5.3 (3.8 to 6.9)	10.3 (7.2 to 13.5)	95.6 (71.7 to 122.4)
Malignant skin melanoma	89.7 (63.1 to 123.5)	192.8 (131.1 to 263.0)	115.3 (69.3 to 163.9)	5.7 (3.6 to 8.4)	11.5 (7.0 to 17.7)	103.1 (61.8 to 150.2)
Non-melanoma skin cancer	360.9 (310.8 to 414.7)	725.0 (613.6 to 866.1)	100.1 (64.6 to 150.2)	6.6 (4.0 to 10.1)	15.7 (9.4 to 24.4)	136.1 (71.6 to 235.5)
Ovarian cancer	49.5 (44.3 to 56.1)	87.0 (76.1 to 99.0)	75.7 (54.8 to 102.4)	6.5 (4.7 to 8.6)	11.2 (7.8 to 14.6)	70.2 (44.5 to 103.9)
Testicular cancer	2.7 (1.9 to 3.4)	5.9 (4.4 to 7.7)	114.6 (70.0 to 185.7)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	94.3 (47.4 to 165.3)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (70-74 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Kidney cancer	95.0 (85.0 to 108.7)	240.2 (213.8 to 271.8)	152.8 (122.3 to 189.1)	7.1 (5.1 to 9.4)	17.1 (12.2 to 22.4)	139.7 (108.1 to 176.3)
Bladder cancer	232.4 (203.2 to 259.9)	355.8 (308.8 to 404.4)	52.9 (35.7 to 74.6)	18.3 (13.3 to 24.2)	26.7 (19.2 to 35.4)	45.7 (28.6 to 66.0)
Brain and nervous system cancer	33.9 (28.7 to 39.0)	74.1 (60.6 to 85.8)	118.5 (84.9 to 156.8)	3.9 (2.7 to 5.2)	7.9 (5.6 to 10.7)	104.4 (69.8 to 146.4)
Thyroid cancer	48.1 (40.8 to 56.2)	113.3 (91.1 to 134.0)	135.1 (92.4 to 184.1)	3.4 (2.3 to 4.6)	7.4 (4.9 to 10.3)	120.0 (80.8 to 166.5)
Mesothelioma	3.1 (2.6 to 4.1)	5.7 (4.4 to 6.8)	86.3 (39.9 to 117.7)	0.7 (0.5 to 1.0)	1.3 (0.8 to 1.8)	88.0 (36.5 to 127.4)
Hodgkin lymphoma	16.6 (11.6 to 20.7)	24.6 (19.7 to 34.1)	44.3 (8.0 to 135.0)	1.8 (1.1 to 2.5)	2.4 (1.6 to 3.5)	33.0 (-1.9 to 116.9)
Non-Hodgkin lymphoma	122.6 (102.4 to 160.8)	293.1 (218.6 to 338.0)	146.4 (68.8 to 187.1)	9.5 (6.7 to 13.6)	21.4 (14.3 to 29.0)	131.0 (62.7 to 169.7)
Multiple myeloma	28.8 (21.5 to 40.0)	57.5 (44.2 to 78.3)	102.0 (57.6 to 143.0)	6.0 (4.0 to 9.0)	11.5 (7.5 to 16.0)	92.5 (49.2 to 135.6)
Leukemia	69.6 (64.1 to 76.0)	150.2 (134.7 to 165.6)	116.3 (90.2 to 141.1)	10.2 (7.5 to 13.1)	20.1 (14.3 to 25.8)	96.7 (71.4 to 125.7)
Other neoplasms	154.5 (134.1 to 186.0)	487.9 (404.4 to 563.1)	217.7 (152.0 to 279.7)	11.6 (8.2 to 15.6)	33.3 (23.2 to 45.4)	188.0 (131.0 to 246.8)
Cardiovascular diseases	-	-	-	1,311.6 (945.8 to 1,729.8)	2,360.8 (1,679.5 to 3,128.1)	79.9 (64.0 to 96.3)
Rheumatic heart disease	502.3 (484.4 to 522.3)	917.2 (885.1 to 957.7)	82.4 (73.8 to 92.6)	40.6 (28.8 to 54.3)	73.4 (51.3 to 98.3)	81.6 (57.4 to 101.4)
Ischemic heart disease	8,060.2 (7,574.9 to 8,595.9)	13,871.8 (13,230.0 to 14,589.6)	72.5 (58.5 to 87.0)	496.0 (345.4 to 682.5)	856.9 (593.0 to 1,162.6)	73.0 (57.9 to 88.7)
Cerebrovascular disease	-	-	-	275.8 (196.3 to 361.6)	489.7 (350.8 to 632.6)	77.4 (66.4 to 89.8)
Ischemic stroke	1,442.8 (1,361.9 to 1,536.5)	2,532.7 (2,432.6 to 2,637.9)	75.4 (63.2 to 88.0)	206.8 (143.6 to 277.1)	363.7 (256.2 to 477.7)	75.8 (63.0 to 89.1)
Hemorrhagic stroke	477.6 (451.7 to 504.6)	870.1 (835.7 to 907.0)	82.2 (70.5 to 95.4)	68.9 (47.7 to 91.9)	126.0 (87.0 to 166.2)	82.6 (69.1 to 97.9)
Hypertensive heart disease	747.8 (705.7 to 794.4)	1,541.9 (1,469.9 to 1,615.6)	106.2 (91.0 to 122.9)	81.2 (56.9 to 111.5)	168.2 (118.4 to 229.7)	107.4 (92.1 to 123.9)
Cardiomyopathy and myocarditis	530.7 (504.5 to 562.9)	1,000.1 (957.3 to 1,046.2)	88.5 (76.3 to 100.6)	56.5 (39.4 to 76.5)	107.2 (74.1 to 142.9)	89.4 (75.9 to 103.8)
Atrial fibrillation and flutter	1,064.8 (1,002.4 to 1,125.9)	1,554.5 (1,437.7 to 1,646.8)	46.8 (31.6 to 57.3)	82.5 (56.9 to 111.8)	121.0 (84.6 to 166.9)	47.3 (31.7 to 58.7)
Peripheral vascular disease	13,273.2 (12,360.6 to 14,202.3)	23,670.7 (21,614.5 to 25,607.4)	78.8 (59.0 to 99.6)	14.4 (7.0 to 25.9)	20.7 (9.9 to 36.5)	42.5 (25.5 to 67.9)
Endocarditis	19.1 (14.8 to 23.6)	33.1 (25.9 to 40.3)	74.4 (50.8 to 99.1)	2.0 (1.2 to 2.9)	3.4 (2.2 to 4.9)	73.4 (42.5 to 115.2)
Other cardiovascular and circulatory diseases	3,727.3 (2,490.0 to 5,356.4)	7,328.8 (4,873.5 to 10,530.4)	96.9 (32.2 to 195.2)	262.7 (148.9 to 409.3)	520.4 (286.4 to 812.9)	98.6 (31.9 to 196.8)
Chronic respiratory diseases	-	-	-	1,228.2 (832.0 to 1,690.4)	2,133.0 (1,450.6 to 2,951.2)	73.9 (67.7 to 79.4)
Chronic obstructive pulmonary disease	13,145.9 (12,471.7 to 13,840.7)	22,802.0 (21,641.1 to 24,019.9)	73.5 (71.5 to 75.4)	948.1 (632.1 to 1,327.6)	1,700.6 (1,131.6 to 2,416.3)	79.5 (72.6 to 85.4)
Pneumoconiosis	-	-	-	2.3 (1.6 to 3.1)	4.4 (3.1 to 6.1)	92.3 (83.9 to 100.8)
Silicosis	4.3 (3.8 to 4.8)	6.5 (5.8 to 7.2)	49.5 (45.2 to 54.0)	0.8 (0.5 to 1.2)	1.2 (0.8 to 1.8)	49.2 (44.6 to 53.6)
Asbestosis	0.9 (0.9 to 1.0)	1.7 (1.5 to 1.8)	74.8 (67.5 to 83.2)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	74.5 (67.0 to 83.1)
Coal workers pneumoconiosis	1.9 (1.8 to 2.0)	3.0 (2.8 to 3.2)	59.7 (56.7 to 62.4)	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.8)	59.3 (56.0 to 62.1)
Other pneumoconiosis	5.0 (4.4 to 5.7)	12.5 (10.9 to 14.1)	147.7 (137.7 to 158.6)	0.9 (0.6 to 1.4)	2.3 (1.5 to 3.4)	145.7 (136.2 to 157.1)
Asthma	4,455.1 (4,337.4 to 4,570.2)	7,776.0 (7,615.9 to 7,930.6)	74.5 (70.0 to 79.6)	184.2 (122.1 to 258.3)	322.5 (212.7 to 449.4)	75.0 (69.9 to 80.6)
Interstitial lung disease and pulmonary sarcoidosis	25.6 (24.1 to 27.0)	48.0 (45.5 to 50.7)	87.9 (72.4 to 104.4)	3.5 (2.3 to 5.1)	6.5 (4.1 to 9.5)	87.2 (68.5 to 105.9)
Other chronic respiratory diseases	-	-	-	90.0 (55.7 to 140.6)	98.9 (63.3 to 153.2)	9.6 (-3.5 to 28.3)
Cirrhosis	-	-	-	16.9 (11.9 to 22.9)	26.4 (18.5 to 36.3)	56.5 (47.0 to 65.4)
Cirrhosis due to hepatitis B	30.0 (28.5 to 31.6)	45.8 (43.1 to 48.3)	52.4 (42.3 to 65.2)	4.7 (3.2 to 6.4)	7.2 (5.0 to 9.9)	52.9 (35.8 to 75.1)
Cirrhosis due to hepatitis C	28.8 (27.4 to 30.3)	56.0 (52.9 to 59.9)	93.7 (80.1 to 112.5)	4.5 (3.1 to 6.2)	8.7 (6.1 to 11.9)	94.0 (73.7 to 118.6)
Cirrhosis due to alcohol use	43.0 (41.2 to 45.0)	52.9 (50.4 to 56.2)	22.9 (14.7 to 32.6)	6.7 (4.7 to 9.1)	8.3 (5.7 to 11.3)	24.0 (8.8 to 39.3)
Cirrhosis due to other causes	6.7 (6.0 to 7.5)	14.4 (12.8 to 16.0)	115.4 (85.8 to 148.3)	1.1 (0.7 to 1.5)	2.3 (1.5 to 3.4)	114.0 (66.1 to 179.2)
Digestive diseases	-	-	-	511.9 (358.7 to 697.3)	636.5 (452.3 to 862.8)	24.4 (20.7 to 28.6)
Peptic ulcer disease	4,986.3 (4,855.3 to 5,085.3)	4,666.4 (4,478.2 to 4,870.4)	-6.4 (-8.8 to -2.6)	162.4 (112.1 to 226.0)	155.2 (107.3 to 218.1)	-4.6 (-8.2 to 1.2)
Gastritis and duodenitis	5,117.2 (5,035.2 to 5,203.6)	6,859.2 (6,723.3 to 6,986.3)	34.1 (31.4 to 36.8)	150.6 (102.9 to 211.3)	188.7 (128.0 to 266.6)	25.2 (21.8 to 29.5)
Appendicitis	5.2 (4.6 to 5.9)	7.3 (6.5 to 8.3)	39.6 (17.9 to 67.1)	1.5 (1.0 to 2.1)	2.2 (1.4 to 3.1)	47.5 (5.9 to 101.4)
Paralytic ileus and intestinal obstruction	4.5 (4.3 to 4.6)	8.2 (8.0 to 8.4)	84.2 (77.1 to 91.6)	1.3 (0.9 to 1.9)	2.4 (1.6 to 3.4)	84.9 (44.8 to 129.3)
Inguinal, femoral, and abdominal hernia	1,772.1 (1,697.1 to 1,861.5)	2,881.3 (2,685.6 to 3,045.1)	62.7 (52.0 to 74.0)	17.9 (8.9 to 33.3)	29.3 (14.6 to 54.4)	63.3 (52.1 to 74.3)
Inflammatory bowel disease	283.3 (277.9 to 288.8)	541.1 (532.0 to 550.5)	91.0 (87.4 to 95.0)	56.4 (39.6 to 75.3)	108.0 (75.7 to 145.0)	91.4 (84.3 to 98.7)
Vascular intestinal disorders	2.4 (2.2 to 2.6)	4.2 (3.8 to 4.7)	76.1 (56.6 to 96.8)	0.8 (0.5 to 1.1)	1.4 (0.9 to 1.9)	73.9 (50.3 to 103.3)
Gallbladder and biliary diseases	342.2 (327.6 to 359.0)	510.4 (486.5 to 537.0)	49.3 (38.4 to 59.3)	34.8 (24.3 to 47.0)	52.0 (36.1 to 70.3)	49.5 (37.8 to 60.3)
Pancreatitis	58.2 (57.2 to 59.1)	115.5 (113.2 to 117.8)	98.6 (93.7 to 103.4)	16.1 (11.2 to 21.4)	32.2 (22.3 to 42.9)	99.8 (85.6 to 114.7)
Other digestive diseases	-	-	-	70.0 (47.4 to 99.2)	65.0 (44.5 to 89.1)	-6.1 (-20.3 to 4.8)
Neurological disorders	-	-	-	1,172.7 (855.9 to 1,528.0)	2,118.4 (1,542.6 to 2,755.1)	80.4 (74.3 to 87.4)
Alzheimer disease and other dementias	3,482.4 (3,382.4 to 3,591.8)	6,339.9 (6,140.3 to 6,547.8)	82.1 (74.8 to 90.7)	490.6 (356.7 to 638.8)	897.0 (651.5 to 1,166.8)	82.6 (75.4 to 92.0)
Parkinson disease	577.3 (417.3 to 733.0)	993.0 (725.6 to 1,248.9)	72.1 (67.8 to 76.4)	68.0 (41.6 to 99.4)	117.3 (73.1 to 170.5)	72.5 (66.6 to 79.8)
Epilepsy	286.8 (267.4 to 306.4)	481.8 (449.1 to 513.8)	68.2 (52.8 to 84.6)	89.1 (62.6 to 115.6)	158.7 (111.7 to 203.5)	78.0 (60.1 to 98.6)
Multiple sclerosis	24.5 (23.5 to 25.5)	71.9 (69.1 to 75.0)	192.9 (176.8 to 209.4)	7.7 (5.5 to 9.7)	22.3 (16.2 to 28.1)	191.2 (155.0 to 231.3)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (70-74 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Migraine	7,710-1 (7,407-4 to 8,026-6)	13,705-3 (13,168-3 to 14,235-7)	77-9 (68-8 to 86-6)	240-1 (145-9 to 349-6)	429-4 (263-3 to 617-7)	79-0 (68-9 to 88-8)
Tension-type headache	20,997-7 (20,284-0 to 21,754-8)	35,629-7 (34,519-0 to 36,741-8)	69-9 (61-7 to 76-7)	30-2 (15-0 to 52-1)	51-4 (25-4 to 89-2)	70-2 (61-6 to 77-7)
Medication overuse headache	672-4 (467-7 to 870-7)	1,796-6 (1,224-2 to 2,327-3)	166-4 (146-1 to 193-6)	98-9 (58-4 to 148-2)	265-5 (155-5 to 401-9)	167-6 (147-1 to 194-7)
Other neurological disorders	0-3 (0-2 to 0-3)	0-5 (0-4 to 0-6)	71-2 (48-7 to 99-5)	148-1 (103-1 to 202-4)	176-7 (123-8 to 233-8)	21-2 (1-3 to 30-4)
Mental and substance use disorders	-	-	-	1,791-3 (1,260-3 to 2,391-3)	3,174-1 (2,226-9 to 4,244-0)	77-2 (74-7 to 79-8)
Schizophrenia	244-4 (226-0 to 265-7)	428-2 (396-7 to 464-9)	75-3 (72-6 to 77-9)	144-3 (106-6 to 174-0)	254-0 (189-9 to 306-7)	76-2 (70-1 to 81-8)
Alcohol use disorders	392-6 (362-3 to 425-8)	709-5 (656-4 to 763-7)	80-7 (76-7 to 85-0)	36-2 (24-6 to 50-4)	65-7 (44-6 to 91-2)	81-3 (74-2 to 90-3)
Drug use disorders	-	-	-	20-7 (14-5 to 26-9)	38-0 (26-7 to 49-5)	83-9 (68-4 to 99-5)
Opioid use disorders	23-2 (19-6 to 27-0)	40-1 (33-3 to 47-3)	72-7 (67-9 to 77-3)	8-9 (6-1 to 11-8)	15-4 (10-4 to 20-8)	73-9 (55-1 to 94-3)
Cocaine use disorders	8-6 (8-3 to 8-9)	16-8 (16-3 to 17-3)	95-0 (85-8 to 105-0)	1-2 (0-8 to 1-7)	2-3 (1-5 to 3-4)	91-8 (62-7 to 128-1)
Amphetamine use disorders	37-3 (36-4 to 38-2)	71-5 (69-8 to 73-2)	91-8 (84-9 to 98-5)	4-4 (2-8 to 6-5)	8-6 (5-4 to 12-3)	93-2 (66-3 to 120-7)
Cannabis use disorders	15-3 (12-8 to 17-9)	25-5 (21-2 to 29-8)	66-6 (61-2 to 70-9)	0-4 (0-3 to 0-7)	0-7 (0-5 to 1-1)	66-3 (50-9 to 82-8)
Other drug use disorders	-	-	-	5-7 (3-8 to 8-1)	11-0 (7-3 to 15-2)	92-7 (67-4 to 118-0)
Depressive disorders	-	-	-	988-5 (632-7 to 1,447-5)	1,762-4 (1,125-1 to 2,595-1)	78-2 (74-0 to 82-3)
Major depressive disorder	4,160-0 (2,868-6 to 5,425-2)	7,403-9 (5,034-0 to 9,723-3)	77-9 (73-1 to 82-8)	790-2 (475-8 to 1,204-3)	1,412-7 (843-5 to 2,143-7)	78-6 (73-5 to 84-0)
Dysthymia	2,174-4 (1,787-6 to 2,524-7)	3,818-6 (3,129-7 to 4,425-6)	75-7 (73-1 to 77-6)	198-3 (131-4 to 290-2)	349-7 (230-0 to 512-2)	76-4 (73-1 to 79-3)
Bipolar disorder	576-1 (463-2 to 718-4)	1,032-9 (830-5 to 1,283-8)	79-3 (76-1 to 83-0)	107-9 (66-3 to 162-6)	194-4 (118-1 to 293-4)	80-1 (74-2 to 87-0)
Anxiety disorders	3,266-3 (2,551-0 to 4,144-7)	5,609-2 (4,352-1 to 7,119-7)	71-7 (68-1 to 75-3)	277-1 (177-8 to 412-4)	477-4 (306-6 to 709-1)	72-2 (67-8 to 77-0)
Eating disorders	-	-	-	-	-	-
Anorexia nervosa	-	-	-	-	-	-
Bulimia nervosa	-	-	-	-	-	-
Autistic spectrum disorders	-	-	-	72-2 (50-8 to 96-1)	129-6 (91-1 to 172-5)	79-5 (75-0 to 83-8)
Autism	203-4 (189-3 to 219-5)	362-6 (336-7 to 391-7)	78-3 (77-4 to 79-0)	45-9 (31-6 to 62-1)	82-2 (56-5 to 111-9)	79-3 (72-9 to 85-3)
Asperger syndrome	283-4 (257-0 to 312-9)	507-9 (459-4 to 561-2)	79-2 (78-4 to 79-8)	26-4 (18-3 to 36-4)	47-4 (33-0 to 65-9)	79-8 (74-7 to 85-1)
Attention-deficit/hyperactivity disorder	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	75-5 (38-6 to 95-9)	0-0 (0-0 to 0-0)	0-0 (0-0 to 0-0)	75-4 (38-4 to 96-2)
Conduct disorder	-	-	-	-	-	-
Idiopathic intellectual disability	634-2 (453-2 to 832-7)	1,050-2 (785-6 to 1,342-8)	65-3 (46-8 to 89-8)	30-2 (19-1 to 44-1)	49-4 (32-0 to 69-8)	63-6 (43-9 to 87-4)
Other mental and substance use disorders	1,640-6 (1,217-7 to 2,102-9)	2,900-6 (2,160-2 to 3,721-5)	76-8 (75-3 to 78-2)	114-2 (71-3 to 167-6)	203-0 (126-8 to 296-5)	77-8 (72-9 to 82-4)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	1,657-3 (1,174-4 to 2,196-1)	3,538-7 (2,498-3 to 4,705-7)	113-5 (105-2 to 122-7)
Diabetes mellitus	9,349-2 (7,449-0 to 11,173-8)	24,414-3 (20,202-1 to 27,830-4)	161-2 (139-1 to 188-5)	774-6 (525-3 to 1,063-7)	1,938-3 (1,332-6 to 2,669-1)	150-1 (132-9 to 171-5)
Acute glomerulonephritis	0-8 (0-7 to 0-9)	1-1 (1-0 to 1-2)	39-9 (35-8 to 43-5)	0-0 (0-0 to 0-1)	0-1 (0-0 to 0-1)	40-0 (35-8 to 43-6)
Chronic kidney disease	-	-	-	379-5 (262-2 to 548-1)	678-5 (469-3 to 976-3)	78-9 (70-8 to 86-8)
Chronic kidney disease due to diabetes mellitus	4,018-0 (2,769-2 to 6,236-0)	8,268-5 (5,894-7 to 11,262-2)	109-7 (70-7 to 131-7)	84-2 (57-9 to 118-4)	189-5 (132-7 to 270-7)	126-3 (98-1 to 148-0)
Chronic kidney disease due to hypertension	2,800-5 (2,076-0 to 3,803-0)	3,906-5 (2,952-4 to 5,433-1)	39-8 (27-5 to 51-8)	105-4 (72-6 to 148-7)	125-8 (85-9 to 185-2)	19-3 (6-1 to 33-4)
Chronic kidney disease due to glomerulonephritis	4,454-6 (2,858-6 to 7,232-8)	5,531-0 (3,805-2 to 7,718-9)	27-0 (2-8 to 47-0)	52-8 (36-8 to 73-8)	92-3 (62-8 to 134-7)	75-1 (53-3 to 96-1)
Chronic kidney disease due to other causes	6,052-6 (4,131-6 to 9,049-1)	10,450-5 (7,482-7 to 14,729-0)	75-7 (50-1 to 93-2)	137-1 (90-9 to 210-0)	271-0 (185-0 to 392-6)	98-3 (77-3 to 120-0)
Urinary diseases and male infertility	-	-	-	381-4 (250-4 to 532-2)	734-1 (480-3 to 1,029-7)	92-2 (85-7 to 100-4)
Interstitial nephritis and urinary tract infections	43-8 (42-7 to 45-0)	91-1 (88-9 to 93-4)	107-9 (100-0 to 115-7)	1-4 (0-9 to 2-0)	2-9 (1-9 to 4-3)	109-0 (89-1 to 131-4)
Urolithiasis	3,674-9 (2,748-9 to 5,023-3)	7,904-0 (5,712-0 to 10,830-2)	115-1 (104-4 to 124-7)	23-2 (14-4 to 35-1)	53-3 (31-7 to 82-3)	129-9 (113-2 to 141-3)
Benign prostatic hyperplasia	9,814-7 (9,575-4 to 10,055-5)	18,214-4 (17,724-9 to 18,754-2)	85-5 (79-1 to 93-3)	349-1 (228-3 to 487-6)	651-7 (426-6 to 920-5)	86-4 (80-3 to 94-5)
Male infertility due to other causes	-	-	-	-	-	-
Other urinary diseases	-	-	-	7-8 (4-5 to 12-2)	26-1 (12-6 to 42-0)	253-3 (136-0 to 319-1)
Gynecological diseases	-	-	-	12-9 (6-5 to 23-6)	22-0 (10-9 to 41-1)	70-1 (63-3 to 78-3)
Uterine fibroids	13-6 (12-8 to 14-3)	23-0 (21-7 to 24-2)	69-5 (68-8 to 70-2)	0-1 (0-0 to 0-2)	0-2 (0-1 to 0-3)	69-8 (43-4 to 99-8)
Polycystic ovarian syndrome	-	-	-	-	-	-
Female infertility due to other causes	-	-	-	-	-	-
Endometriosis	-	-	-	-	-	-
Genital prolapse	4,198-4 (4,080-1 to 4,314-5)	7,129-9 (6,914-6 to 7,345-1)	69-7 (62-9 to 77-2)	12-8 (6-4 to 23-4)	21-9 (10-9 to 40-9)	70-2 (63-3 to 78-5)
Premenstrual syndrome	-	-	-	-	-	-
Other gynecological diseases	-	-	0-0 (0-0 to 0-0)	-	-	-
Hemoglobinopathies and hemolytic anemias	-	-	-	58-8 (39-8 to 84-1)	84-8 (56-6 to 121-5)	44-3 (34-0 to 55-2)
Thalassemias	0-3 (0-2 to 0-3)	0-8 (0-6 to 0-9)	167-7 (126-3 to 216-3)	0-0 (0-0 to 0-0)	0-1 (0-1 to 0-1)	177-2 (132-2 to 233-8)
Thalassemia trait	2,212-3 (1,948-4 to 2,551-7)	4,013-0 (3,582-5 to 4,546-2)	81-5 (77-7 to 85-1)	26-8 (18-2 to 38-5)	46-6 (31-0 to 67-7)	73-4 (60-4 to 87-6)
Sickle cell disorders	0-8 (0-7 to 0-9)	1-3 (1-2 to 1-4)	68-8 (61-3 to 75-8)	0-1 (0-1 to 0-2)	0-2 (0-1 to 0-3)	71-4 (56-9 to 89-5)
Sickle cell trait	2,026-6 (1,931-6 to 2,116-2)	3,554-5 (3,385-6 to 3,708-6)	75-3 (72-5 to 78-2)	6-0 (3-9 to 8-9)	9-6 (6-3 to 13-9)	59-6 (32-1 to 97-0)
G6PD deficiency	2,918-6 (2,848-7 to 2,980-3)	5,107-1 (4,987-4 to 5,223-4)	75-0 (69-6 to 80-5)	0-3 (0-2 to 0-4)	0-5 (0-3 to 0-7)	79-9 (70-0 to 92-1)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (70-74 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
G6PD trait	14,122.2 (14,046.1 to 14,198.0)	24,395.9 (24,255.6 to 24,533.9)	72.7 (71.4 to 74.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	33.2 (-21.9 to 102.1)
Other hemoglobinopathies and hemolytic anemias	1,116.6 (1,055.5 to 1,173.1)	1,552.1 (1,484.0 to 1,632.5)	38.8 (31.2 to 48.4)	25.3 (16.9 to 36.0)	27.6 (18.3 to 40.4)	8.7 (-5.1 to 23.9)
Endocrine, metabolic, blood, and immune disorders	1,581.2 (1,531.8 to 1,631.6)	2,524.1 (2,456.4 to 2,594.9)	59.7 (53.8 to 65.4)	50.0 (35.1 to 67.2)	80.9 (56.6 to 107.8)	61.6 (53.5 to 71.3)
Musculoskeletal disorders	-	-	-	4,572.0 (3,326.7 to 5,874.8)	8,145.2 (5,931.3 to 10,542.3)	78.0 (75.4 to 81.2)
Rheumatoid arthritis	913.5 (899.5 to 927.0)	1,543.8 (1,523.7 to 1,565.6)	69.0 (65.7 to 72.4)	205.1 (148.0 to 267.0)	348.0 (252.4 to 452.5)	69.7 (64.6 to 74.8)
Osteoarthritis	15,462.4 (15,302.8 to 15,610.5)	26,926.0 (26,599.4 to 27,239.6)	74.1 (71.4 to 77.1)	777.8 (551.4 to 1,051.4)	1,394.1 (985.3 to 1,882.8)	79.3 (76.2 to 82.1)
Low back and neck pain	-	-	-	2,660.0 (1,873.5 to 3,524.1)	4,760.9 (3,359.4 to 6,320.3)	78.7 (75.1 to 83.9)
Low back pain	18,743.0 (18,214.7 to 19,187.3)	33,564.6 (32,843.7 to 34,828.0)	78.9 (74.1 to 85.1)	1,972.8 (1,366.3 to 2,667.3)	3,549.3 (2,434.9 to 4,843.1)	79.7 (74.8 to 86.0)
Neck pain	7,373.0 (7,190.4 to 7,553.1)	12,950.7 (12,557.3 to 13,318.2)	75.6 (69.4 to 81.9)	687.2 (483.6 to 933.6)	1,211.6 (855.7 to 1,648.2)	76.3 (69.8 to 82.8)
Gout	325.6 (318.3 to 333.3)	555.2 (542.5 to 567.5)	70.6 (65.1 to 76.2)	9.9 (6.9 to 13.3)	17.0 (11.7 to 22.7)	71.1 (58.0 to 85.8)
Other musculoskeletal disorders	10,515.4 (8,237.0 to 13,106.1)	18,546.2 (14,383.3 to 23,282.7)	76.2 (69.3 to 82.1)	919.1 (607.5 to 1,340.7)	1,625.1 (1,065.7 to 2,374.7)	76.8 (69.8 to 82.5)
Other non-communicable diseases	-	-	-	4,330.0 (2,985.4 to 6,003.2)	7,151.0 (4,900.0 to 9,952.6)	65.1 (62.7 to 67.9)
Congenital anomalies	-	-	-	82.0 (62.5 to 103.7)	198.4 (151.6 to 246.6)	142.0 (129.6 to 155.7)
Neural tube defects	1.4 (1.2 to 1.5)	5.1 (4.8 to 5.3)	268.1 (234.0 to 318.8)	0.3 (0.2 to 0.4)	1.3 (0.9 to 1.8)	321.3 (263.5 to 403.1)
Congenital heart anomalies	218.2 (206.3 to 232.4)	565.8 (547.3 to 589.0)	159.2 (141.9 to 177.8)	7.3 (3.4 to 12.1)	18.8 (8.6 to 31.5)	158.7 (137.6 to 181.9)
Orofacial clefts	29.3 (27.5 to 31.1)	91.6 (88.4 to 95.1)	212.7 (192.2 to 236.1)	0.3 (0.2 to 0.4)	0.9 (0.6 to 1.2)	210.6 (158.6 to 266.8)
Down syndrome	74.7 (65.9 to 82.5)	223.8 (197.8 to 245.2)	200.2 (180.5 to 217.1)	15.6 (11.6 to 19.7)	46.7 (34.9 to 58.9)	200.3 (176.9 to 222.9)
Turner syndrome	0.9 (0.8 to 0.9)	2.2 (2.1 to 2.4)	157.1 (129.9 to 182.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	157.1 (129.8 to 182.6)
Klinefelter syndrome	1.9 (1.8 to 2.0)	4.0 (3.8 to 4.2)	112.7 (99.3 to 127.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.6 (99.2 to 127.2)
Chromosomal unbalanced rearrangements	119.3 (104.9 to 131.6)	329.7 (292.1 to 359.6)	176.3 (160.7 to 194.5)	24.8 (18.4 to 31.5)	68.7 (51.6 to 86.9)	177.7 (158.4 to 198.6)
Other congenital anomalies	349.4 (298.8 to 394.6)	554.4 (469.7 to 630.2)	58.9 (50.7 to 66.7)	33.8 (23.9 to 45.7)	61.9 (43.6 to 82.2)	82.9 (64.2 to 107.0)
Skin and subcutaneous diseases	-	-	-	503.9 (334.6 to 787.1)	877.4 (581.5 to 1,378.2)	74.0 (70.2 to 78.4)
Dermatitis	3,461.3 (3,036.8 to 3,990.8)	6,015.1 (5,268.6 to 6,942.1)	73.8 (72.8 to 74.7)	94.8 (62.7 to 135.5)	164.0 (108.7 to 235.6)	73.0 (69.3 to 76.5)
Psoriasis	1,245.0 (1,025.1 to 1,528.5)	2,182.6 (1,789.8 to 2,686.6)	75.3 (73.1 to 77.4)	94.4 (65.7 to 138.4)	166.3 (115.0 to 244.9)	76.2 (70.6 to 81.6)
Cellulitis	60.3 (44.9 to 80.8)	84.0 (61.1 to 114.1)	39.1 (28.9 to 48.7)	4.0 (2.4 to 6.1)	5.6 (3.4 to 8.7)	39.6 (22.8 to 57.4)
Pyoderma	86.1 (58.0 to 130.1)	143.6 (91.8 to 225.5)	67.4 (43.9 to 85.9)	0.5 (0.2 to 1.1)	0.8 (0.3 to 1.8)	67.2 (42.9 to 89.1)
Scabies	427.3 (396.1 to 468.4)	701.7 (651.9 to 763.7)	63.8 (47.7 to 82.5)	10.4 (6.1 to 16.7)	17.2 (9.9 to 27.1)	64.7 (49.0 to 84.0)
Fungal skin diseases	9,838.2 (8,482.8 to 10,876.9)	17,369.5 (14,912.7 to 19,283.2)	76.6 (74.7 to 78.0)	52.9 (21.8 to 106.0)	93.7 (38.5 to 189.0)	77.1 (75.1 to 78.9)
Viral skin diseases	988.1 (696.2 to 1,359.0)	1,724.1 (1,213.3 to 2,369.4)	74.5 (71.9 to 77.1)	28.5 (16.5 to 45.4)	49.9 (28.8 to 79.7)	75.0 (70.4 to 79.7)
Acne vulgaris	448.5 (417.6 to 479.2)	725.5 (660.9 to 799.7)	61.7 (45.2 to 80.2)	4.6 (2.2 to 8.4)	7.4 (3.6 to 13.5)	62.0 (45.0 to 81.4)
Alopecia areata	196.9 (190.2 to 203.5)	339.4 (326.3 to 353.3)	72.5 (64.4 to 80.1)	6.3 (4.1 to 9.2)	10.8 (7.0 to 16.0)	73.3 (62.3 to 84.6)
Pruritus	43.5 (40.7 to 46.1)	75.0 (68.8 to 82.6)	71.7 (54.4 to 97.0)	0.4 (0.2 to 0.8)	0.8 (0.4 to 1.4)	72.7 (51.1 to 101.0)
Urticaria	1,580.0 (1,443.2 to 1,698.1)	2,799.6 (2,560.2 to 3,007.6)	77.0 (59.8 to 98.8)	88.6 (58.4 to 125.1)	157.4 (104.6 to 220.2)	77.3 (60.3 to 99.4)
Decubitus ulcer	134.4 (127.7 to 142.3)	212.8 (198.6 to 227.2)	58.7 (45.6 to 68.9)	19.2 (13.4 to 26.0)	30.5 (21.4 to 41.2)	59.3 (43.3 to 74.1)
Other skin and subcutaneous diseases	17,482.2 (4,358.7 to 42,358.7)	30,382.0 (7,550.2 to 73,724.8)	73.8 (71.3 to 76.5)	99.2 (21.1 to 273.9)	173.0 (36.6 to 480.0)	74.4 (71.8 to 77.2)
Sense organ diseases	-	-	-	2,918.7 (1,984.8 to 4,038.4)	4,804.2 (3,265.4 to 6,663.3)	64.5 (61.3 to 68.2)
Glaucoma	501.2 (392.3 to 613.8)	846.5 (683.6 to 1,011.7)	68.7 (45.7 to 96.6)	45.1 (30.2 to 62.9)	76.0 (50.5 to 106.5)	68.3 (53.6 to 87.2)
Cataract	4,667.7 (3,782.1 to 5,442.2)	7,155.5 (5,848.4 to 8,335.6)	52.7 (45.9 to 66.2)	297.5 (201.5 to 405.9)	470.4 (315.9 to 660.0)	57.7 (50.2 to 68.8)
Macular degeneration	865.8 (667.0 to 1,038.8)	1,635.2 (1,326.5 to 1,943.0)	88.6 (75.4 to 107.8)	43.9 (28.7 to 62.7)	80.9 (53.4 to 115.6)	84.5 (71.3 to 99.7)
Uncorrected refractive error	29,570.5 (28,216.0 to 30,631.7)	49,207.0 (47,466.7 to 50,989.8)	66.3 (61.1 to 71.6)	540.2 (343.8 to 803.4)	861.3 (545.2 to 1,310.7)	59.2 (54.7 to 64.3)
Age-related and other hearing loss	63,603.1 (60,961.6 to 65,592.6)	106,653.6 (101,400.1 to 110,928.4)	67.8 (65.2 to 69.8)	1,807.6 (1,212.3 to 2,548.9)	3,019.3 (2,005.8 to 4,284.5)	66.9 (61.5 to 73.7)
Other vision loss	1,178.7 (887.6 to 1,540.1)	1,653.5 (1,261.0 to 2,064.6)	40.8 (25.0 to 53.4)	95.8 (62.2 to 138.4)	138.9 (91.8 to 197.7)	45.9 (33.8 to 54.7)
Other sense organ diseases	3,564.9 (3,494.4 to 3,640.2)	6,292.4 (6,162.5 to 6,420.0)	76.5 (71.8 to 81.4)	88.7 (55.7 to 129.3)	157.3 (98.6 to 230.6)	77.2 (71.7 to 82.9)
Oral disorders	-	-	-	825.4 (551.8 to 1,167.7)	1,270.9 (842.8 to 1,811.1)	53.8 (50.1 to 58.1)
Deciduous caries	-	-	-	-	-	-
Permanent caries	25,942.9 (25,579.5 to 26,291.9)	49,036.3 (48,311.7 to 49,840.8)	88.9 (85.4 to 93.2)	20.6 (9.8 to 38.8)	39.4 (18.5 to 74.4)	90.9 (87.1 to 95.7)
Periodontal diseases	13,546.2 (13,357.5 to 13,738.7)	25,876.1 (25,479.3 to 26,257.1)	91.0 (87.3 to 94.9)	85.3 (34.7 to 173.5)	163.5 (66.1 to 334.7)	91.7 (87.7 to 95.6)
Edentulism and severe tooth loss	24,578.2 (24,228.1 to 24,916.6)	35,915.5 (35,445.8 to 36,392.2)	46.1 (43.6 to 48.8)	666.4 (453.8 to 914.6)	975.1 (667.5 to 1,336.8)	46.3 (43.7 to 49.3)
Other oral disorders	1,911.1 (1,872.9 to 1,951.2)	3,330.7 (3,253.3 to 3,401.5)	74.3 (68.7 to 79.5)	53.1 (34.3 to 77.8)	93.0 (59.6 to 136.3)	75.0 (69.0 to 80.6)
Injuries	-	-	-	1,863.8 (1,359.0 to 2,472.4)	2,264.4 (1,626.4 to 3,017.4)	22.2 (6.1 to 36.3)
Transport injuries	-	-	-	371.5 (276.2 to 484.1)	519.0 (372.7 to 692.7)	39.5 (32.8 to 46.2)
Road injuries	-	-	-	306.6 (228.0 to 399.1)	436.5 (312.8 to 582.1)	42.1 (35.4 to 48.7)
Pedestrian road injuries	-	-	-	82.1 (61.0 to 106.7)	130.3 (94.2 to 172.8)	58.5 (51.4 to 65.9)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (70-74 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Cyclist road injuries	-	-	-	38.4 (28.5 to 50.0)	51.9 (37.5 to 69.0)	34.8 (27.9 to 41.9)
Motorcyclist road injuries	-	-	-	52.6 (38.3 to 70.1)	68.7 (48.1 to 93.9)	30.2 (23.4 to 36.8)
Motor vehicle road injuries	-	-	-	129.5 (96.5 to 168.5)	181.2 (130.4 to 241.8)	39.7 (32.8 to 46.7)
Other road injuries	-	-	-	4.0 (3.0 to 5.2)	4.5 (3.2 to 5.9)	11.8 (6.2 to 17.9)
Other transport injuries	-	-	-	64.9 (48.2 to 84.5)	82.5 (59.1 to 110.3)	27.0 (20.0 to 34.5)
Unintentional injuries	-	-	-	1,026.7 (777.3 to 1,329.1)	1,419.7 (1,025.9 to 1,900.5)	37.9 (28.5 to 47.9)
Falls	-	-	-	718.6 (546.7 to 923.7)	981.0 (710.1 to 1,302.6)	36.0 (24.3 to 49.4)
Drowning	-	-	-	12.5 (9.2 to 16.2)	16.6 (11.9 to 22.1)	32.2 (25.2 to 39.8)
Fire, heat, and hot substances	-	-	-	36.2 (25.2 to 50.9)	45.5 (31.2 to 64.6)	25.3 (20.4 to 30.5)
Poisonings	-	-	-	2.5 (1.8 to 3.2)	2.8 (2.1 to 3.7)	13.1 (5.2 to 20.8)
Exposure to mechanical forces	-	-	-	110.7 (79.6 to 149.3)	153.3 (108.3 to 210.4)	38.3 (34.1 to 42.8)
Unintentional firearm injuries	-	-	-	3.8 (2.8 to 5.0)	4.8 (3.4 to 6.6)	27.6 (21.2 to 34.1)
Unintentional suffocation	-	-	-	1.1 (0.8 to 1.5)	2.2 (1.6 to 2.9)	95.8 (88.1 to 103.0)
Other exposure to mechanical forces	-	-	-	105.8 (76.0 to 142.9)	146.3 (103.3 to 200.9)	38.2 (33.8 to 42.5)
Adverse effects of medical treatment	-	-	-	10.1 (6.4 to 15.0)	16.2 (10.3 to 23.9)	60.1 (53.8 to 66.7)
Animal contact	-	-	-	13.2 (9.9 to 17.6)	16.4 (12.0 to 22.2)	23.6 (18.3 to 29.1)
Venomous animal contact	-	-	-	3.7 (2.7 to 4.9)	4.4 (3.2 to 5.8)	18.4 (11.1 to 26.3)
Non-venomous animal contact	-	-	-	9.5 (7.0 to 12.8)	12.0 (8.6 to 16.4)	25.8 (20.2 to 31.2)
Foreign body	-	-	-	8.3 (6.3 to 10.4)	12.4 (9.3 to 16.1)	50.2 (43.4 to 58.0)
Pulmonary aspiration and foreign body in airway	-	-	-	2.0 (1.5 to 2.4)	2.7 (2.1 to 3.5)	38.9 (29.0 to 51.4)
Foreign body in eyes	-	-	-	1.3 (0.9 to 1.8)	2.0 (1.3 to 2.8)	54.1 (47.0 to 61.0)
Foreign body in other body part	-	-	-	5.0 (3.8 to 6.4)	7.7 (5.8 to 10.0)	53.6 (47.0 to 61.0)
Other unintentional injuries	-	-	-	114.5 (83.0 to 154.3)	175.5 (126.1 to 237.2)	53.2 (48.1 to 58.8)
Self-harm and interpersonal violence	-	-	-	35.7 (26.5 to 46.6)	44.0 (31.3 to 59.5)	22.8 (15.9 to 30.5)
Self-harm	-	-	-	10.9 (8.0 to 14.2)	12.8 (9.2 to 17.2)	17.1 (9.6 to 25.5)
Interpersonal violence	-	-	-	24.8 (18.4 to 32.5)	31.2 (22.2 to 42.2)	25.3 (18.6 to 33.0)
Assault by firearm	-	-	-	4.7 (3.4 to 6.2)	6.6 (4.7 to 9.0)	41.9 (36.4 to 47.8)
Assault by sharp object	-	-	-	4.3 (3.1 to 5.9)	6.1 (4.3 to 8.5)	41.0 (33.8 to 48.4)
Assault by other means	-	-	-	15.8 (11.8 to 20.5)	18.5 (13.3 to 24.7)	16.2 (9.3 to 23.8)
Forces of nature, war, and legal intervention	-	-	-	430.0 (182.6 to 863.2)	281.7 (125.9 to 567.4)	-34.6 (-47.5 to -13.3)
Exposure to forces of nature	-	-	-	31.2 (15.6 to 56.8)	43.7 (20.8 to 85.2)	39.1 (-4.1 to 93.4)
Collective violence and legal intervention	-	-	-	398.8 (158.6 to 820.9)	238.0 (101.1 to 491.2)	-40.4 (-52.0 to -22.0)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (75-79 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
All causes	-	-	-	16,224.1 (12,305.1 to 20,683.7)	26,277.4 (19,866.9 to 33,661.5)	62.0 (59.5 to 64.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	542.1 (387.6 to 723.8)	743.3 (537.7 to 985.6)	37.0 (30.9 to 44.6)
HIV/AIDS and tuberculosis	-	-	-	57.2 (40.0 to 75.0)	122.6 (86.6 to 161.2)	114.3 (102.1 to 127.9)
Tuberculosis	181.8 (172.5 to 191.8)	352.6 (330.1 to 375.2)	92.8 (85.0 to 102.9)	50.5 (35.1 to 67.1)	98.6 (68.6 to 131.9)	94.7 (84.9 to 107.0)
HIV/AIDS	-	-	-	6.7 (4.7 to 8.9)	24.0 (17.3 to 31.5)	261.0 (183.6 to 355.2)
HIV/AIDS resulting in mycobacterial infection	1.8 (1.0 to 2.7)	5.8 (3.6 to 8.5)	233.9 (138.0 to 347.3)	0.6 (0.3 to 1.0)	2.0 (1.1 to 3.1)	242.5 (128.4 to 393.3)
HIV/AIDS resulting in other diseases	40.2 (34.7 to 47.4)	174.1 (157.0 to 195.7)	331.4 (271.2 to 406.8)	6.1 (4.2 to 8.2)	22.0 (15.7 to 29.1)	264.4 (179.4 to 365.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	84.1 (60.6 to 111.9)	125.0 (89.8 to 165.6)	48.7 (44.2 to 53.5)
Diarrheal diseases	246.6 (241.4 to 251.5)	331.2 (323.4 to 337.9)	33.8 (29.6 to 37.7)	35.6 (25.0 to 47.7)	47.6 (33.2 to 63.5)	33.6 (27.1 to 39.9)
Intestinal infectious diseases	-	-	-	1.1 (0.7 to 1.6)	1.2 (0.8 to 1.9)	12.8 (-20.5 to 61.4)
Typhoid fever	6.9 (5.6 to 8.2)	8.3 (6.4 to 10.7)	17.5 (-10.9 to 71.5)	0.8 (0.5 to 1.2)	1.0 (0.6 to 1.6)	19.4 (-19.9 to 83.2)
Paratyphoid fever	3.9 (3.0 to 4.9)	3.7 (2.8 to 4.9)	-5.9 (-35.3 to 49.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-1.1 (-39.3 to 70.2)
Other intestinal infectious diseases	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-39.4 (-55.0 to -20.4)
Lower respiratory infections	104.7 (100.8 to 109.6)	204.0 (198.8 to 209.6)	94.3 (84.3 to 102.3)	10.0 (7.0 to 13.6)	19.6 (13.5 to 26.6)	95.5 (84.4 to 107.4)
Upper respiratory infections	1,229.9 (1,203.5 to 1,259.2)	2,097.0 (2,049.1 to 2,152.0)	69.8 (64.2 to 75.7)	13.4 (7.7 to 21.9)	22.8 (13.1 to 37.0)	70.5 (63.7 to 78.0)
Otitis media	345.9 (334.4 to 356.8)	510.5 (494.7 to 527.7)	47.1 (40.7 to 53.5)	6.2 (3.8 to 10.0)	9.3 (5.6 to 14.4)	48.4 (40.7 to 56.9)
Meningitis	-	-	-	9.5 (4.4 to 16.7)	11.4 (5.7 to 19.8)	20.4 (12.0 to 33.3)
Pneumococcal meningitis	76.1 (38.7 to 123.7)	97.9 (48.5 to 164.2)	27.6 (16.8 to 38.6)	3.6 (2.2 to 5.5)	4.7 (2.9 to 7.3)	29.7 (17.4 to 44.4)
H influenzae type B meningitis	24.9 (2.7 to 56.0)	24.6 (1.8 to 58.8)	-2.6 (-36.7 to 11.1)	0.9 (0.3 to 1.8)	1.0 (0.4 to 2.0)	7.0 (-5.2 to 22.5)
Meningococcal meningitis	19.6 (2.8 to 45.0)	20.5 (2.8 to 48.5)	3.0 (-17.5 to 14.9)	2.0 (0.6 to 3.9)	2.1 (0.7 to 4.3)	6.3 (-7.6 to 26.4)
Other meningitis	39.0 (7.4 to 83.5)	43.1 (7.9 to 99.3)	9.4 (-18.8 to 26.1)	3.0 (1.3 to 5.3)	3.6 (1.7 to 6.6)	21.6 (6.5 to 41.3)
Encephalitis	31.6 (10.5 to 77.0)	41.1 (13.6 to 109.6)	29.3 (-4.3 to 43.9)	2.9 (2.0 to 4.1)	4.2 (2.9 to 6.0)	44.8 (30.6 to 59.3)
Diphtheria	-	-	-	-	-	-
Whooping cough	-	-	-	-	-	-
Tetanus	9.5 (7.0 to 13.9)	1.5 (0.9 to 2.4)	-84.7 (-91.2 to -72.6)	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.1)	-73.6 (-85.2 to -50.0)
Measles	-	-	-	-	-	-
Varicella and herpes zoster	98.4 (94.3 to 102.9)	171.4 (164.1 to 179.9)	73.2 (64.5 to 84.1)	5.1 (3.3 to 7.6)	8.8 (5.6 to 13.1)	73.6 (62.4 to 86.6)
Neglected tropical diseases and malaria	-	-	-	226.7 (154.7 to 311.1)	247.7 (159.6 to 359.1)	8.4 (-4.4 to 25.6)
Malaria	863.0 (823.7 to 905.2)	1,074.4 (1,010.6 to 1,135.2)	24.1 (15.4 to 33.6)	5.7 (3.7 to 8.3)	6.7 (4.3 to 10.1)	19.1 (4.7 to 33.6)
Chagas disease	144.8 (139.8 to 149.2)	222.3 (214.2 to 230.9)	53.0 (46.1 to 60.3)	4.1 (2.7 to 5.8)	6.3 (4.2 to 8.9)	54.0 (43.7 to 64.4)
Leishmaniasis	-	-	-	0.2 (0.1 to 0.4)	0.6 (0.3 to 1.1)	195.2 (164.1 to 233.6)
Visceral leishmaniasis	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	80.7 (37.1 to 147.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	80.4 (35.8 to 150.7)
Cutaneous and mucocutaneous leishmaniasis	18.3 (16.3 to 20.6)	55.9 (48.9 to 63.7)	203.7 (173.5 to 240.2)	0.2 (0.1 to 0.3)	0.6 (0.3 to 1.0)	209.8 (176.8 to 249.4)
African trypanosomiasis	0.6 (0.3 to 1.1)	0.2 (0.1 to 0.3)	-70.8 (-74.7 to -65.4)	0.1 (0.1 to 0.3)	0.0 (0.0 to 0.1)	-70.9 (-79.8 to -56.4)
Schistosomiasis	1,514.9 (1,362.9 to 1,659.3)	1,979.0 (1,722.1 to 2,302.1)	28.2 (18.7 to 51.4)	11.2 (5.7 to 21.2)	14.6 (7.2 to 28.4)	28.0 (19.0 to 48.5)
Cysticercosis	23.4 (20.8 to 26.5)	19.4 (16.5 to 22.2)	-17.6 (-32.6 to 1.8)	6.1 (4.3 to 7.9)	5.4 (3.8 to 7.2)	-10.6 (-29.1 to 13.4)
Cystic echinococcosis	26.2 (25.3 to 27.1)	28.8 (28.1 to 29.8)	9.8 (5.6 to 13.0)	2.3 (1.6 to 3.1)	2.5 (1.8 to 3.4)	10.7 (0.2 to 21.9)
Lymphatic filariasis	968.5 (805.5 to 1,171.8)	871.2 (684.2 to 1,113.3)	-10.4 (-20.5 to 0.2)	45.5 (24.6 to 75.6)	55.7 (31.8 to 89.0)	24.1 (-1.3 to 49.2)
Onchocerciasis	305.4 (233.6 to 400.5)	220.7 (156.0 to 317.3)	-28.7 (-39.2 to -15.1)	31.1 (19.2 to 48.2)	23.2 (13.4 to 38.6)	-26.7 (-37.8 to -9.5)
Trachoma	442.1 (293.5 to 626.1)	284.5 (188.8 to 389.8)	-35.1 (-50.4 to -21.0)	33.7 (20.7 to 51.1)	22.3 (13.4 to 33.7)	-33.4 (-45.5 to -23.2)
Dengue	3.9 (1.4 to 8.7)	38.7 (14.2 to 86.7)	900.1 (884.2 to 912.8)	0.6 (0.2 to 1.5)	5.7 (1.9 to 14.4)	896.7 (700.6 to 1,166.1)
Yellow fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.9 (-71.6 to -30.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.9 (-71.6 to -30.2)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.3 (-28.7 to 55.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.3 (-29.0 to 55.9)
Intestinal nematode infections	-	-	-	47.6 (27.8 to 75.3)	30.9 (18.0 to 49.3)	-34.9 (-41.4 to -28.1)
Ascariasis	9,909.9 (8,072.5 to 12,256.9)	8,878.7 (7,327.2 to 10,886.4)	-10.7 (-32.1 to 19.0)	23.3 (13.0 to 38.0)	8.2 (4.5 to 13.9)	-64.9 (-70.7 to -57.7)
Trichuriasis	4,851.1 (3,762.0 to 6,372.5)	5,040.1 (4,482.3 to 5,701.5)	5.2 (-24.3 to 36.7)	6.4 (3.5 to 10.4)	5.3 (2.9 to 8.8)	-17.8 (-34.6 to 7.1)
Hookworm disease	4,587.5 (3,736.5 to 5,720.9)	5,273.8 (4,756.6 to 5,889.2)	15.4 (-11.0 to 43.5)	18.0 (10.8 to 28.4)	17.4 (10.3 to 27.5)	-2.8 (-14.8 to 9.4)
Food-borne trematodiasis	792.3 (600.2 to 979.1)	1,605.9 (1,252.0 to 1,956.4)	102.1 (84.3 to 120.7)	34.8 (10.2 to 74.5)	70.4 (21.2 to 149.8)	102.8 (78.0 to 126.5)
Other neglected tropical diseases	83.9 (74.8 to 93.0)	118.9 (109.1 to 127.4)	41.5 (24.5 to 59.9)	3.8 (1.9 to 6.9)	3.4 (1.7 to 6.5)	-13.6 (-32.4 to 21.2)
Maternal disorders	-	-	-	1.1 (0.7 to 1.7)	1.7 (1.0 to 2.7)	53.7 (0.6 to 127.0)
Maternal hemorrhage	-	-	-	-	-	-
Maternal sepsis and other maternal infections	-	-	-	-	-	-
Maternal hypertensive disorders	-	-	-	-	-	-
Obstructed labor	3.9 (2.8 to 5.1)	5.9 (4.3 to 7.8)	52.0 (30.1 to 78.1)	1.1 (0.7 to 1.7)	1.7 (1.0 to 2.7)	53.7 (0.6 to 127.0)
Complications of abortion	-	-	-	-	-	-

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (75-79 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Other maternal disorders	-	-	-	-	-	-
Neonatal disorders	-	-	-	16.6 (11.8 to 23.1)	47.8 (36.0 to 61.3)	191.4 (140.7 to 235.2)
Preterm birth complications	204.0 (166.2 to 252.8)	557.0 (455.2 to 689.4)	171.8 (139.8 to 211.3)	10.0 (7.3 to 13.3)	31.7 (23.8 to 40.5)	218.0 (183.5 to 248.2)
Neonatal encephalopathy due to birth asphyxia and trauma	148.7 (45.4 to 306.1)	161.4 (57.3 to 314.6)	7.7 (-25.2 to 82.2)	2.8 (1.0 to 5.9)	3.7 (1.7 to 7.1)	33.0 (0.3 to 105.7)
Neonatal sepsis and other neonatal infections	-	-	-	-	-	-
Hemolytic disease and other neonatal jaundice	3.1 (2.7 to 3.7)	8.9 (7.2 to 10.7)	189.2 (120.3 to 262.2)	1.3 (0.9 to 1.8)	3.8 (2.7 to 5.1)	189.2 (121.0 to 264.9)
Other neonatal disorders	-	-	-	2.5 (1.6 to 3.9)	8.6 (5.6 to 11.8)	257.8 (149.2 to 358.9)
Nutritional deficiencies	-	-	-	142.4 (97.1 to 201.0)	177.3 (119.7 to 255.7)	24.4 (18.5 to 30.6)
Protein-energy malnutrition	42.8 (23.8 to 67.2)	83.5 (42.6 to 130.1)	95.6 (48.2 to 147.8)	4.7 (2.2 to 8.1)	9.2 (4.0 to 16.3)	96.5 (45.8 to 152.8)
Iodine deficiency	977.9 (889.1 to 1,069.1)	1,046.2 (960.9 to 1,126.7)	6.9 (-5.2 to 20.5)	16.4 (10.2 to 25.2)	17.5 (10.7 to 27.7)	7.1 (-5.1 to 21.3)
Vitamin A deficiency	10.1 (4.2 to 17.3)	11.7 (6.2 to 18.0)	22.1 (-27.9 to 60.2)	0.8 (0.3 to 1.3)	0.9 (0.4 to 1.5)	18.0 (-18.2 to 78.3)
Iron-deficiency anemia	5,652.9 (5,559.8 to 5,736.9)	8,480.3 (8,326.5 to 8,614.8)	49.4 (46.3 to 52.4)	120.1 (82.3 to 169.0)	149.0 (99.8 to 218.5)	23.9 (16.8 to 31.0)
Other nutritional deficiencies	-	-	-	0.5 (0.2 to 1.1)	0.7 (0.3 to 1.3)	45.6 (-12.3 to 105.0)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	14.0 (9.0 to 22.5)	21.1 (13.3 to 34.9)	50.3 (40.9 to 58.5)
Sexually transmitted diseases excluding HIV	-	-	-	6.8 (3.7 to 13.0)	10.2 (5.4 to 20.0)	51.1 (38.1 to 59.1)
Syphilis	13.9 (13.3 to 14.6)	19.5 (18.8 to 20.2)	39.6 (32.2 to 48.0)	2.4 (1.6 to 3.3)	3.4 (2.3 to 4.7)	40.7 (21.8 to 61.6)
Chlamydial infection	0.3 (0.3 to 0.3)	0.3 (0.3 to 0.3)	6.5 (-3.6 to 18.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	6.4 (-3.7 to 18.8)
Gonococcal infection	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.3)	5.2 (-13.6 to 27.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	5.1 (-13.7 to 27.9)
Trichomoniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.2 (39.9 to 82.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.6 (36.5 to 84.0)
Genital herpes	18,055.0 (17,871.8 to 18,234.6)	28,547.7 (28,192.1 to 28,932.9)	57.5 (55.1 to 60.1)	4.2 (1.2 to 10.4)	6.7 (1.9 to 16.4)	58.1 (54.4 to 61.7)
Other sexually transmitted diseases	0.5 (0.5 to 0.6)	0.8 (0.8 to 0.9)	50.2 (37.4 to 64.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	50.2 (37.3 to 64.4)
Hepatitis	-	-	-	2.8 (1.9 to 4.0)	4.0 (2.7 to 5.7)	42.1 (31.9 to 51.9)
Hepatitis A	13.8 (12.4 to 15.1)	28.3 (26.2 to 30.2)	105.2 (99.2 to 110.7)	0.5 (0.3 to 0.7)	1.0 (0.6 to 1.4)	105.9 (80.8 to 133.5)
Hepatitis B	4,012.5 (3,888.3 to 4,148.3)	4,817.7 (4,692.2 to 4,957.8)	19.5 (15.0 to 24.6)	1.8 (1.2 to 2.6)	2.3 (1.5 to 3.2)	23.6 (10.7 to 35.8)
Hepatitis C	3,519.4 (3,469.9 to 3,577.5)	4,618.7 (4,547.4 to 4,685.6)	30.8 (27.8 to 33.7)	0.4 (0.3 to 0.6)	0.5 (0.4 to 0.8)	35.4 (13.9 to 61.2)
Hepatitis E	6.2 (5.7 to 6.8)	11.0 (9.8 to 12.3)	75.0 (51.3 to 106.8)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	92.9 (45.2 to 161.6)
Leprosy	24.4 (22.4 to 26.3)	48.5 (44.5 to 52.7)	97.8 (82.8 to 116.9)	1.3 (0.9 to 1.9)	2.8 (1.9 to 4.0)	108.8 (84.6 to 140.5)
Other infectious diseases	137.7 (128.1 to 149.0)	206.4 (195.7 to 216.6)	49.4 (37.4 to 61.3)	3.1 (2.0 to 4.6)	4.0 (2.5 to 6.3)	30.4 (5.8 to 58.9)
Non-communicable diseases	-	-	-	13,880.1 (10,461.2 to 17,771.8)	23,492.2 (17,674.3 to 30,133.4)	69.2 (67.3 to 71.1)
Neoplasms	-	-	-	363.9 (275.4 to 457.5)	675.0 (506.4 to 848.2)	85.5 (76.6 to 94.7)
Esophageal cancer	53.0 (43.3 to 64.0)	89.8 (72.6 to 111.9)	68.6 (31.1 to 114.2)	8.5 (6.0 to 11.1)	13.5 (9.3 to 18.2)	59.3 (28.5 to 99.6)
Stomach cancer	222.7 (200.9 to 246.8)	305.5 (278.3 to 338.9)	36.6 (22.2 to 51.6)	27.1 (19.7 to 34.3)	34.8 (25.1 to 44.9)	28.4 (14.7 to 45.2)
Liver cancer	-	-	-	8.2 (5.7 to 11.0)	17.1 (11.9 to 22.8)	107.0 (71.3 to 147.1)
Liver cancer due to hepatitis B	12.1 (9.8 to 15.0)	30.2 (24.8 to 36.9)	149.6 (91.3 to 219.3)	2.1 (1.5 to 2.8)	4.6 (3.2 to 6.1)	118.9 (74.7 to 170.2)
Liver cancer due to hepatitis C	10.7 (8.9 to 13.1)	52.9 (44.2 to 63.1)	391.1 (292.8 to 509.3)	1.8 (1.2 to 2.4)	7.6 (5.3 to 10.2)	327.2 (239.7 to 424.1)
Liver cancer due to alcohol use	17.7 (14.7 to 21.1)	22.0 (18.4 to 26.3)	24.2 (0.5 to 52.2)	2.9 (2.0 to 3.9)	3.4 (2.3 to 4.6)	15.0 (-6.0 to 39.8)
Liver cancer due to other causes	8.1 (6.6 to 10.2)	9.1 (7.3 to 11.2)	12.1 (-18.0 to 49.4)	1.4 (1.0 to 1.9)	1.5 (1.0 to 2.1)	4.3 (-18.3 to 32.0)
Larynx cancer	41.9 (35.2 to 49.9)	71.5 (56.5 to 85.9)	70.3 (42.2 to 100.1)	4.6 (3.2 to 6.2)	7.0 (4.7 to 9.6)	53.9 (26.3 to 84.5)
Tracheal, bronchus and lung cancer	206.6 (195.3 to 220.5)	394.9 (364.1 to 423.5)	91.0 (73.2 to 105.3)	31.1 (23.0 to 39.2)	56.7 (41.4 to 71.4)	82.7 (66.3 to 97.2)
Breast cancer	772.6 (726.6 to 812.1)	1,575.0 (1,527.5 to 1,628.7)	103.2 (92.1 to 114.7)	44.5 (32.0 to 59.8)	79.7 (55.9 to 108.7)	79.8 (60.1 to 95.7)
Cervical cancer	85.4 (66.9 to 98.0)	96.8 (73.6 to 118.6)	12.9 (-12.3 to 40.8)	7.1 (4.9 to 9.4)	8.0 (5.2 to 11.0)	12.2 (-14.2 to 43.5)
Uterine cancer	112.2 (91.5 to 136.0)	167.5 (130.7 to 208.5)	48.8 (15.0 to 88.2)	8.1 (5.6 to 11.1)	11.5 (7.4 to 16.2)	41.8 (9.0 to 81.7)
Prostate cancer	790.9 (683.8 to 883.6)	1,862.6 (1,639.4 to 2,248.8)	132.8 (110.6 to 167.4)	67.6 (46.8 to 89.6)	155.9 (110.8 to 215.2)	127.2 (99.6 to 176.0)
Colon and rectum cancer	548.7 (525.8 to 576.8)	1,037.3 (974.6 to 1,096.6)	88.5 (75.9 to 100.7)	49.2 (36.5 to 62.8)	86.6 (64.0 to 110.2)	75.8 (63.0 to 89.1)
Lip and oral cavity cancer	95.3 (80.2 to 113.5)	165.3 (135.7 to 200.6)	72.4 (40.8 to 112.9)	9.0 (6.4 to 12.2)	15.0 (10.3 to 20.4)	65.7 (33.0 to 107.7)
Nasopharynx cancer	10.3 (7.4 to 13.6)	14.9 (10.3 to 20.8)	44.8 (-10.1 to 114.9)	1.2 (0.8 to 1.8)	1.7 (1.0 to 2.5)	38.0 (-13.7 to 106.0)
Other pharynx cancer	20.8 (16.9 to 25.6)	39.1 (29.8 to 48.7)	87.0 (38.5 to 146.6)	2.1 (1.4 to 2.8)	3.7 (2.4 to 5.2)	77.2 (31.1 to 139.9)
Gallbladder and biliary tract cancer	16.3 (13.5 to 19.4)	21.2 (17.6 to 24.6)	29.2 (9.8 to 53.0)	4.0 (2.8 to 5.3)	5.0 (3.4 to 6.8)	26.6 (2.6 to 52.7)
Pancreatic cancer	26.6 (24.7 to 28.7)	49.3 (44.9 to 53.8)	84.6 (66.7 to 103.0)	5.1 (3.6 to 6.6)	9.1 (6.6 to 11.8)	79.2 (58.8 to 102.8)
Malignant skin melanoma	79.2 (60.5 to 108.5)	157.9 (111.4 to 215.9)	98.5 (56.5 to 146.5)	5.3 (3.6 to 7.7)	9.8 (6.0 to 14.6)	84.4 (42.0 to 128.1)
Non-melanoma skin cancer	378.6 (318.7 to 438.9)	749.0 (625.2 to 910.3)	95.4 (57.7 to 152.0)	7.5 (4.8 to 11.3)	17.6 (11.0 to 26.7)	131.7 (70.6 to 238.2)
Ovarian cancer	41.9 (37.1 to 48.1)	66.0 (56.9 to 75.1)	57.7 (31.3 to 81.9)	5.8 (4.2 to 7.6)	8.7 (6.2 to 11.4)	50.5 (21.0 to 80.8)
Testicular cancer	2.1 (1.5 to 2.6)	4.4 (3.2 to 5.8)	100.2 (59.1 to 182.7)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	78.1 (39.0 to 154.4)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (75-79 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Kidney cancer	80.4 (70.6 to 93.3)	186.2 (161.8 to 210.6)	130.5 (98.9 to 168.9)	6.2 (4.5 to 8.2)	13.5 (9.5 to 17.9)	116.3 (85.9 to 154.7)
Bladder cancer	220.5 (190.8 to 252.0)	333.4 (279.2 to 379.5)	50.5 (31.9 to 70.7)	18.0 (13.1 to 23.6)	25.5 (18.1 to 34.5)	41.7 (23.7 to 60.2)
Brain and nervous system cancer	24.3 (20.8 to 29.5)	55.6 (44.7 to 65.7)	129.3 (85.3 to 172.2)	2.9 (2.1 to 3.9)	6.1 (4.1 to 8.3)	111.3 (65.5 to 158.3)
Thyroid cancer	36.4 (29.9 to 43.1)	74.0 (59.6 to 87.2)	102.3 (65.9 to 145.2)	2.8 (1.9 to 3.9)	5.2 (3.5 to 7.1)	85.7 (53.4 to 126.2)
Mesothelioma	3.1 (2.6 to 4.1)	5.2 (4.0 to 6.6)	73.6 (25.8 to 102.8)	0.7 (0.4 to 1.0)	1.1 (0.7 to 1.6)	73.5 (26.0 to 114.7)
Hodgkin lymphoma	13.2 (9.2 to 16.6)	18.5 (14.6 to 24.0)	36.6 (0.7 to 111.2)	1.5 (1.0 to 2.1)	1.9 (1.3 to 2.8)	25.6 (7.3 to 99.7)
Non-Hodgkin lymphoma	105.8 (88.7 to 142.0)	246.9 (181.0 to 291.9)	144.0 (62.3 to 187.4)	8.4 (6.0 to 12.1)	18.4 (12.0 to 25.1)	125.7 (50.6 to 171.1)
Multiple myeloma	26.6 (19.7 to 37.7)	50.2 (38.0 to 65.7)	89.6 (46.8 to 133.2)	5.7 (3.7 to 8.6)	10.2 (6.5 to 14.3)	79.6 (38.0 to 127.7)
Leukemia	64.0 (58.9 to 70.2)	129.9 (116.1 to 142.8)	102.6 (78.1 to 125.2)	10.0 (7.3 to 12.7)	18.2 (13.1 to 23.7)	82.2 (58.1 to 106.4)
Other neoplasms	147.0 (126.8 to 182.9)	474.6 (382.0 to 549.5)	228.1 (143.7 to 293.3)	11.4 (8.2 to 15.7)	33.1 (22.9 to 44.5)	194.0 (118.9 to 255.4)
Cardiovascular diseases	-	-	-	1,169.0 (842.0 to 1,527.6)	2,110.9 (1,502.9 to 2,805.5)	80.6 (64.8 to 97.6)
Rheumatic heart disease	345.9 (333.9 to 359.2)	684.0 (661.6 to 713.7)	97.0 (88.2 to 107.0)	28.6 (20.3 to 38.5)	55.4 (38.5 to 74.1)	94.9 (68.7 to 116.0)
Ischemic heart disease	6,818.4 (6,499.7 to 7,230.4)	11,978.7 (11,580.0 to 12,459.8)	75.5 (61.8 to 85.6)	408.4 (284.0 to 555.8)	715.8 (495.3 to 969.0)	75.5 (61.9 to 86.7)
Cerebrovascular disease	-	-	-	271.7 (193.3 to 354.5)	454.5 (326.8 to 583.8)	66.8 (57.3 to 80.1)
Ischemic stroke	1,507.3 (1,426.7 to 1,605.6)	2,424.9 (2,323.0 to 2,532.9)	59.9 (49.6 to 73.4)	211.1 (147.3 to 283.3)	339.8 (239.7 to 443.5)	60.6 (50.2 to 74.8)
Hemorrhagic stroke	429.0 (402.4 to 456.3)	809.8 (773.7 to 849.7)	88.0 (74.4 to 105.3)	60.7 (42.4 to 80.5)	114.8 (80.6 to 151.1)	88.9 (74.1 to 106.7)
Hypertensive heart disease	679.0 (640.4 to 720.4)	1,368.6 (1,309.1 to 1,432.6)	101.0 (87.0 to 115.8)	72.6 (51.4 to 99.2)	146.6 (103.6 to 198.8)	101.7 (88.3 to 117.4)
Cardiomyopathy and myocarditis	462.5 (439.4 to 490.9)	819.3 (784.9 to 855.4)	76.8 (65.0 to 87.2)	48.6 (34.2 to 65.3)	86.4 (59.5 to 115.7)	78.0 (65.4 to 90.0)
Atrial fibrillation and flutter	1,302.0 (1,231.6 to 1,385.2)	1,922.1 (1,800.9 to 2,042.8)	47.5 (35.0 to 59.4)	99.1 (69.2 to 135.6)	146.5 (102.7 to 201.7)	48.4 (35.5 to 61.1)
Peripheral vascular disease	11,466.4 (10,606.6 to 12,292.7)	19,228.7 (17,662.9 to 20,704.9)	67.1 (49.9 to 88.4)	19.6 (9.4 to 35.1)	25.1 (12.2 to 44.6)	28.1 (5.7 to 56.5)
Endocarditis	16.7 (12.3 to 20.5)	24.8 (19.4 to 30.8)	47.4 (25.2 to 80.6)	1.7 (1.1 to 2.5)	2.5 (1.6 to 3.6)	45.6 (16.9 to 88.7)
Other cardiovascular and circulatory diseases	3,089.2 (2,025.0 to 4,658.2)	6,713.6 (4,695.0 to 9,650.8)	117.5 (45.7 to 232.0)	218.8 (125.4 to 344.5)	478.2 (278.0 to 778.2)	119.4 (46.2 to 235.5)
Chronic respiratory diseases	-	-	-	919.0 (626.0 to 1,264.5)	1,576.0 (1,081.6 to 2,144.1)	71.5 (66.1 to 77.2)
Chronic obstructive pulmonary disease	10,426.4 (9,889.6 to 10,973.5)	17,549.4 (16,647.6 to 18,490.7)	67.7 (65.9 to 69.4)	712.3 (476.8 to 996.1)	1,263.6 (843.2 to 1,755.1)	77.3 (71.3 to 84.8)
Pneumoconiosis	-	-	-	1.8 (1.2 to 2.4)	3.5 (2.4 to 4.7)	96.6 (88.2 to 105.5)
Silicosis	3.2 (2.9 to 3.5)	5.1 (4.6 to 5.6)	57.9 (53.8 to 61.7)	0.6 (0.4 to 0.9)	1.0 (0.6 to 1.4)	58.3 (54.0 to 62.5)
Asbestosis	0.7 (0.7 to 0.8)	1.3 (1.2 to 1.4)	75.9 (69.7 to 82.9)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	77.3 (71.1 to 84.6)
Coal workers pneumoconiosis	1.4 (1.3 to 1.5)	2.3 (2.1 to 2.4)	64.1 (61.1 to 67.1)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	64.1 (60.7 to 67.3)
Other pneumoconiosis	4.0 (3.5 to 4.6)	10.0 (8.8 to 11.4)	147.5 (138.0 to 160.8)	0.7 (0.5 to 1.1)	1.8 (1.2 to 2.7)	143.3 (130.5 to 158.0)
Asthma	3,443.4 (3,351.4 to 3,520.0)	5,746.2 (5,619.9 to 5,867.0)	66.2 (61.8 to 71.3)	140.2 (93.3 to 195.0)	234.1 (156.4 to 323.5)	66.9 (62.1 to 72.0)
Interstitial lung disease and pulmonary sarcoidosis	20.1 (19.0 to 21.0)	38.7 (36.8 to 41.0)	91.6 (78.6 to 109.2)	2.7 (1.7 to 3.9)	5.1 (3.2 to 7.3)	86.7 (69.5 to 107.3)
Other chronic respiratory diseases	-	-	-	62.1 (38.3 to 96.2)	69.8 (44.9 to 106.4)	12.4 (-1.5 to 30.0)
Cirrhosis	-	-	-	11.1 (8.0 to 15.1)	16.9 (11.9 to 23.0)	51.4 (42.6 to 60.0)
Cirrhosis due to hepatitis B	18.7 (17.8 to 19.7)	30.7 (29.1 to 32.1)	63.2 (52.8 to 75.1)	2.9 (2.0 to 3.9)	4.7 (3.3 to 6.4)	64.1 (46.3 to 82.9)
Cirrhosis due to hepatitis C	20.2 (19.2 to 21.2)	36.5 (34.3 to 38.8)	80.2 (65.6 to 95.6)	3.1 (2.1 to 4.2)	5.6 (3.9 to 7.6)	80.8 (62.0 to 105.1)
Cirrhosis due to alcohol use	29.6 (28.6 to 30.9)	34.3 (32.8 to 36.0)	15.3 (8.3 to 22.5)	4.5 (3.2 to 6.2)	5.3 (3.7 to 7.2)	15.6 (3.7 to 29.7)
Cirrhosis due to other causes	4.0 (3.6 to 4.4)	8.3 (7.4 to 9.1)	109.6 (80.5 to 135.8)	0.6 (0.4 to 0.9)	1.3 (0.9 to 1.9)	105.2 (63.7 to 165.3)
Digestive diseases	-	-	-	434.8 (304.5 to 587.2)	544.2 (387.5 to 735.8)	25.2 (22.2 to 28.2)
Peptic ulcer disease	4,293.6 (4,223.1 to 4,351.5)	4,043.1 (3,906.2 to 4,209.6)	-6.2 (-9.5 to -2.5)	139.3 (96.9 to 192.5)	132.8 (92.4 to 184.9)	-4.9 (-7.9 to 0.7)
Gastritis and duodenitis	4,294.6 (4,252.9 to 4,335.0)	6,436.3 (6,340.7 to 6,526.9)	49.3 (47.2 to 51.3)	127.4 (87.3 to 178.2)	174.9 (119.9 to 246.4)	37.1 (33.9 to 40.9)
Appendicitis	3.1 (2.7 to 3.4)	4.5 (4.0 to 5.1)	45.5 (22.9 to 69.9)	0.9 (0.6 to 1.2)	1.3 (0.8 to 1.9)	51.1 (11.8 to 100.6)
Paralytic ileus and intestinal obstruction	4.6 (4.5 to 4.8)	8.4 (8.1 to 8.6)	79.9 (72.0 to 88.9)	1.3 (0.9 to 1.8)	2.3 (1.6 to 3.2)	79.0 (43.4 to 123.8)
Inguinal, femoral, and abdominal hernia	1,806.9 (1,725.7 to 1,899.3)	2,823.4 (2,628.4 to 2,985.2)	55.9 (45.7 to 66.1)	18.1 (8.9 to 33.4)	28.2 (14.2 to 52.2)	56.5 (46.1 to 66.9)
Inflammatory bowel disease	227.3 (223.0 to 231.8)	391.8 (385.1 to 398.5)	71.7 (68.3 to 75.2)	44.4 (31.3 to 59.3)	76.5 (53.9 to 102.6)	72.4 (66.0 to 79.1)
Vascular intestinal disorders	2.8 (2.6 to 3.1)	4.6 (4.2 to 5.4)	61.4 (41.8 to 84.9)	0.9 (0.6 to 1.2)	1.4 (0.9 to 1.9)	64.2 (27.2 to 109.0)
Gallbladder and biliary diseases	327.8 (313.8 to 341.6)	454.1 (436.4 to 474.9)	37.8 (30.7 to 46.5)	32.8 (23.2 to 43.8)	45.4 (31.7 to 60.8)	38.3 (30.2 to 47.5)
Pancreatitis	47.4 (46.5 to 48.4)	90.0 (88.1 to 92.1)	89.1 (83.5 to 94.3)	12.9 (9.1 to 17.0)	24.6 (17.1 to 32.4)	90.5 (77.5 to 103.3)
Other digestive diseases	-	-	-	56.9 (38.8 to 79.7)	56.7 (38.9 to 77.7)	0.7 (-14.1 to 11.4)
Neurological disorders	-	-	-	1,252.6 (919.4 to 1,610.2)	2,038.6 (1,497.6 to 2,632.7)	62.9 (56.9 to 68.8)
Alzheimer disease and other dementias	5,084.2 (4,921.2 to 5,253.4)	8,542.2 (8,206.6 to 8,838.7)	67.5 (59.9 to 75.1)	703.8 (513.0 to 908.2)	1,185.3 (862.5 to 1,547.9)	68.3 (60.8 to 76.4)
Parkinson disease	576.5 (438.6 to 720.8)	1,005.8 (750.3 to 1,272.5)	73.8 (69.4 to 78.0)	66.6 (42.6 to 95.9)	116.4 (73.4 to 166.9)	74.8 (68.2 to 81.4)
Epilepsy	213.4 (199.7 to 227.6)	341.8 (318.5 to 364.4)	59.6 (45.8 to 75.3)	66.0 (47.0 to 85.0)	111.2 (78.6 to 142.3)	68.5 (52.5 to 86.8)
Multiple sclerosis	16.6 (15.6 to 17.5)	41.9 (40.0 to 44.0)	151.9 (135.3 to 171.6)	5.1 (3.6 to 6.5)	12.8 (9.2 to 16.1)	152.1 (120.4 to 191.1)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (75-79 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Migraine	4,894.2 (4,636.6 to 5,125.5)	7,687.3 (7,325.8 to 8,085.4)	56.2 (46.6 to 67.4)	149.4 (91.8 to 216.3)	235.1 (143.4 to 338.1)	57.1 (46.5 to 69.5)
Tension-type headache	14,826.3 (14,193.9 to 15,525.0)	24,189.4 (23,347.0 to 25,064.3)	62.7 (52.9 to 72.0)	21.0 (10.5 to 36.5)	34.3 (16.9 to 59.7)	63.3 (52.9 to 72.7)
Medication overuse headache	393.6 (273.1 to 515.2)	887.1 (603.6 to 1,152.3)	125.0 (103.2 to 150.6)	56.9 (33.6 to 85.8)	125.6 (74.5 to 193.9)	125.6 (103.2 to 153.1)
Other neurological disorders	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.4)	61.8 (44.9 to 88.3)	183.9 (128.5 to 246.1)	215.0 (152.9 to 280.5)	18.3 (2.0 to 27.2)
Mental and substance use disorders	-	-	-	1,276.4 (888.7 to 1,714.2)	2,162.1 (1,512.7 to 2,927.3)	69.4 (66.3 to 72.0)
Schizophrenia	116.8 (107.6 to 127.0)	204.6 (188.0 to 222.4)	74.5 (71.4 to 77.7)	67.4 (50.8 to 81.0)	118.5 (89.3 to 142.5)	75.8 (68.8 to 83.6)
Alcohol use disorders	238.2 (218.7 to 258.1)	396.1 (364.0 to 429.9)	65.7 (62.4 to 68.9)	21.6 (14.8 to 30.3)	36.0 (24.9 to 50.1)	66.3 (59.4 to 74.2)
Drug use disorders	-	-	-	10.5 (7.2 to 13.9)	19.0 (13.0 to 25.2)	82.0 (65.7 to 99.0)
Opioid use disorders	10.8 (9.2 to 12.5)	17.9 (15.1 to 21.1)	66.0 (60.1 to 71.5)	4.2 (2.9 to 5.6)	6.9 (4.8 to 9.4)	66.3 (45.0 to 91.5)
Cocaine use disorders	2.3 (2.2 to 2.4)	4.7 (4.5 to 4.9)	101.0 (88.7 to 113.3)	0.3 (0.2 to 0.5)	0.7 (0.5 to 1.0)	101.1 (88.6 to 113.5)
Amphetamine use disorders	22.6 (22.0 to 23.1)	43.4 (42.4 to 44.4)	91.8 (85.4 to 98.3)	2.7 (1.7 to 3.9)	5.2 (3.3 to 7.5)	91.9 (65.1 to 121.6)
Cannabis use disorders	6.2 (5.1 to 7.3)	10.1 (8.2 to 12.0)	62.9 (55.7 to 69.8)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	63.8 (46.4 to 81.0)
Other drug use disorders	-	-	-	3.1 (2.0 to 4.4)	5.9 (3.8 to 8.4)	93.3 (67.1 to 121.3)
Depressive disorders	-	-	-	720.1 (449.6 to 1,066.2)	1,221.9 (759.8 to 1,806.1)	69.7 (64.6 to 73.8)
Major depressive disorder	3,083.8 (1,996.8 to 4,122.2)	5,218.2 (3,342.8 to 7,033.5)	68.6 (62.0 to 73.2)	575.3 (337.5 to 898.2)	975.1 (558.4 to 1,507.0)	69.4 (62.4 to 74.5)
Dysthymia	1,613.3 (1,393.1 to 1,835.1)	2,745.0 (2,367.2 to 3,132.0)	69.5 (67.2 to 71.6)	144.8 (97.7 to 209.9)	246.8 (167.1 to 358.8)	70.5 (67.1 to 73.3)
Bipolar disorder	402.9 (334.8 to 483.7)	691.1 (571.6 to 829.3)	70.9 (68.1 to 74.3)	74.0 (46.0 to 109.2)	127.3 (79.3 to 189.8)	71.9 (65.9 to 78.0)
Anxiety disorders	2,358.8 (1,921.2 to 2,853.2)	3,765.2 (2,994.7 to 4,622.7)	58.9 (54.5 to 63.1)	196.3 (131.3 to 279.6)	313.7 (207.2 to 451.4)	59.8 (53.9 to 65.2)
Eating disorders	-	-	-	-	-	-
Anorexia nervosa	-	-	-	-	-	-
Bulimia nervosa	-	-	-	-	-	-
Autistic spectrum disorders	-	-	-	48.7 (34.2 to 64.4)	85.9 (60.1 to 114.2)	76.4 (71.7 to 80.8)
Autism	140.2 (129.9 to 151.8)	245.4 (227.1 to 266.1)	74.3 (73.3 to 75.3)	31.0 (21.3 to 42.1)	54.5 (37.6 to 74.8)	75.7 (69.2 to 82.1)
Asperger syndrome	193.2 (174.2 to 213.6)	342.0 (307.2 to 378.8)	76.3 (75.5 to 77.0)	17.7 (12.3 to 24.0)	31.4 (21.9 to 43.4)	77.5 (72.0 to 82.8)
Attention-deficit/hyperactivity disorder	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.0 (22.1 to 81.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.2 (22.1 to 82.2)
Conduct disorder	-	-	-	-	-	-
Idiopathic intellectual disability	398.2 (286.1 to 521.1)	630.6 (466.8 to 818.9)	57.7 (40.5 to 77.2)	18.8 (11.8 to 27.3)	29.4 (18.8 to 41.7)	56.0 (38.2 to 75.0)
Other mental and substance use disorders	1,740.6 (1,282.3 to 2,230.2)	3,065.9 (2,255.9 to 3,951.3)	75.5 (72.6 to 77.9)	119.0 (72.1 to 171.6)	210.5 (128.0 to 302.1)	76.9 (72.4 to 81.1)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	1,256.1 (901.8 to 1,665.6)	2,576.4 (1,839.5 to 3,405.0)	105.1 (97.0 to 114.4)
Diabetes mellitus	6,122.2 (4,970.8 to 7,565.3)	15,740.4 (13,138.3 to 18,557.1)	156.5 (134.6 to 184.0)	554.3 (378.8 to 760.8)	1,370.1 (938.7 to 1,886.4)	147.4 (128.6 to 166.9)
Acute glomerulonephritis	0.6 (0.5 to 0.6)	0.9 (0.8 to 1.0)	53.1 (48.0 to 57.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	53.3 (48.2 to 57.7)
Chronic kidney disease	-	-	-	315.3 (212.7 to 463.2)	512.3 (344.8 to 746.8)	62.2 (56.2 to 72.2)
Chronic kidney disease due to diabetes mellitus	3,213.3 (2,284.7 to 4,509.2)	6,895.6 (4,978.4 to 9,423.0)	115.9 (84.7 to 136.6)	60.8 (42.1 to 87.6)	140.0 (96.6 to 204.5)	130.9 (105.0 to 156.9)
Chronic kidney disease due to hypertension	2,295.1 (1,741.3 to 3,115.5)	2,896.8 (2,189.8 to 3,802.7)	26.4 (15.1 to 36.1)	88.9 (59.7 to 129.9)	94.0 (62.4 to 135.4)	5.6 (-4.9 to 18.7)
Chronic kidney disease due to glomerulonephritis	3,963.1 (2,685.8 to 5,695.8)	4,575.5 (3,158.6 to 6,395.8)	15.5 (-2.0 to 33.9)	39.1 (26.3 to 56.2)	59.6 (39.6 to 86.3)	52.3 (36.0 to 69.8)
Chronic kidney disease due to other causes	5,963.3 (4,119.5 to 8,624.9)	9,362.8 (6,673.1 to 13,280.3)	57.3 (38.4 to 74.5)	126.5 (82.4 to 190.9)	218.8 (148.2 to 325.9)	73.3 (60.8 to 87.1)
Urinary diseases and male infertility	-	-	-	301.7 (199.4 to 420.5)	564.1 (371.7 to 788.9)	86.9 (80.5 to 93.2)
Interstitial nephritis and urinary tract infections	42.8 (41.4 to 44.1)	86.6 (84.0 to 89.4)	101.5 (92.6 to 112.4)	1.3 (0.8 to 1.9)	2.7 (1.7 to 3.9)	101.9 (85.0 to 123.2)
Urolithiasis	3,150.7 (2,377.1 to 4,193.8)	6,765.8 (4,980.7 to 8,946.0)	113.8 (104.1 to 121.1)	18.9 (11.8 to 28.3)	43.2 (26.2 to 66.5)	128.7 (114.4 to 137.4)
Benign prostatic hyperplasia	7,862.5 (7,694.4 to 8,032.5)	14,118.1 (13,797.0 to 14,522.0)	78.8 (72.7 to 85.4)	275.6 (181.2 to 384.1)	497.1 (326.7 to 696.6)	80.3 (74.3 to 86.9)
Male infertility due to other causes	-	-	-	-	-	-
Other urinary diseases	-	-	-	5.9 (3.5 to 9.2)	21.1 (10.3 to 34.0)	276.3 (156.2 to 343.4)
Gynecological diseases	-	-	-	7.4 (3.7 to 13.5)	11.7 (5.8 to 21.7)	58.4 (50.9 to 66.3)
Uterine fibroids	2.4 (2.3 to 2.6)	3.8 (3.6 to 4.0)	56.3 (55.5 to 57.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	56.2 (27.9 to 88.6)
Polycystic ovarian syndrome	-	-	-	-	-	-
Female infertility due to other causes	-	-	-	-	-	-
Endometriosis	-	-	-	-	-	-
Genital prolapse	2,442.6 (2,365.1 to 2,520.7)	3,869.3 (3,739.9 to 3,991.6)	57.6 (51.3 to 65.4)	7.4 (3.7 to 13.5)	11.7 (5.8 to 21.7)	58.4 (51.0 to 66.4)
Premenstrual syndrome	-	-	-	-	-	-
Other gynecological diseases	-	-	-	0.0 (0.0 to 0.0)	-	-
Hemoglobinopathies and hemolytic anemias	-	-	-	40.8 (27.3 to 57.7)	59.0 (39.9 to 84.8)	44.8 (35.1 to 55.2)
Thalassemias	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	130.2 (113.1 to 151.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	134.7 (115.5 to 155.1)
Thalassemia trait	1,573.7 (1,395.6 to 1,803.8)	2,850.7 (2,514.7 to 3,256.9)	80.5 (77.3 to 83.3)	20.9 (14.2 to 29.7)	33.5 (22.6 to 48.6)	60.1 (48.4 to 75.9)
Sickle cell disorders	0.4 (0.4 to 0.5)	0.7 (0.7 to 0.8)	72.0 (61.7 to 82.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	69.8 (52.2 to 88.7)
Sickle cell trait	1,329.1 (1,267.9 to 1,385.9)	2,341.0 (2,230.6 to 2,443.9)	75.4 (72.9 to 78.2)	4.1 (2.6 to 6.0)	6.7 (4.2 to 9.9)	63.7 (24.7 to 96.8)
G6PD deficiency	1,879.5 (1,837.8 to 1,917.4)	3,451.7 (3,371.8 to 3,527.6)	83.1 (77.6 to 88.4)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	80.9 (72.7 to 93.4)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (75-79 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
G6PD trait	10,567.6 (10,500.0 to 10,634.1)	17,539.7 (17,440.7 to 17,640.3)	65.3 (64.0 to 66.8)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	0.6 (-36.7 to 46.6)
Other hemoglobinopathies and hemolytic anemias	704.3 (672.3 to 753.2)	1,057.6 (1,017.8 to 1,104.8)	50.0 (38.8 to 59.2)	15.3 (10.2 to 21.9)	18.2 (12.2 to 26.3)	19.7 (0.6 to 35.1)
Endocrine, metabolic, blood, and immune disorders	1,156.8 (1,124.4 to 1,191.4)	1,862.8 (1,815.1 to 1,914.4)	60.3 (54.8 to 66.3)	36.6 (25.5 to 48.8)	59.0 (41.5 to 79.2)	61.1 (53.1 to 70.5)
Musculoskeletal disorders	-	-	-	3,444.8 (2,514.6 to 4,443.1)	5,773.2 (4,208.0 to 7,463.2)	67.6 (64.5 to 70.5)
Rheumatoid arthritis	806.7 (793.7 to 819.4)	1,269.6 (1,252.7 to 1,286.5)	56.8 (53.7 to 60.1)	177.8 (129.7 to 232.0)	280.1 (203.9 to 363.3)	57.5 (53.2 to 62.2)
Osteoarthritis	14,005.9 (13,838.7 to 14,161.6)	22,753.6 (22,475.6 to 23,010.1)	61.8 (58.9 to 65.1)	677.8 (478.8 to 917.7)	1,129.1 (802.1 to 1,517.7)	66.6 (63.6 to 69.8)
Low back and neck pain	-	-	-	2,047.5 (1,447.8 to 2,708.5)	3,462.9 (2,459.1 to 4,587.5)	69.0 (65.0 to 74.0)
Low back pain	15,100.6 (14,676.7 to 15,431.2)	25,460.3 (24,905.9 to 26,321.8)	67.8 (63.1 to 73.4)	1,561.9 (1,090.7 to 2,125.8)	2,640.0 (1,822.8 to 3,584.1)	68.8 (64.3 to 74.4)
Neck pain	5,297.7 (5,115.9 to 5,480.7)	8,960.5 (8,638.8 to 9,283.0)	68.4 (60.0 to 77.0)	485.7 (343.2 to 659.9)	822.9 (582.1 to 1,113.1)	69.3 (60.6 to 78.2)
Gout	270.3 (263.3 to 276.6)	446.4 (436.0 to 456.2)	64.4 (59.4 to 70.1)	8.0 (5.6 to 10.6)	13.3 (9.3 to 17.7)	65.8 (54.0 to 80.3)
Other musculoskeletal disorders	6,221.3 (4,304.9 to 8,033.2)	10,350.1 (7,004.1 to 13,542.1)	65.9 (58.7 to 72.0)	533.6 (330.6 to 798.3)	887.8 (537.5 to 1,333.1)	66.4 (59.0 to 72.7)
Other non-communicable diseases	-	-	-	3,752.4 (2,601.1 to 5,132.1)	6,018.8 (4,178.6 to 8,286.4)	60.3 (57.2 to 64.1)
Congenital anomalies	-	-	-	53.5 (40.2 to 67.6)	122.0 (92.7 to 151.6)	128.0 (114.8 to 141.6)
Neural tube defects	0.3 (0.3 to 0.4)	1.6 (1.5 to 1.7)	373.2 (306.5 to 452.1)	0.1 (0.0 to 0.1)	0.4 (0.3 to 0.5)	509.9 (376.4 to 655.5)
Congenital heart anomalies	146.1 (137.5 to 156.8)	357.1 (343.0 to 373.9)	143.7 (125.7 to 162.4)	4.7 (2.1 to 7.8)	11.5 (5.1 to 19.3)	146.2 (123.8 to 168.0)
Orofacial clefts	20.3 (19.0 to 21.6)	59.8 (57.4 to 62.3)	194.3 (173.7 to 217.1)	0.2 (0.1 to 0.3)	0.5 (0.4 to 0.8)	190.2 (139.0 to 253.4)
Down syndrome	44.3 (39.0 to 49.2)	134.1 (118.5 to 147.0)	201.9 (180.5 to 222.6)	9.1 (6.7 to 11.7)	27.5 (20.5 to 34.8)	202.2 (175.9 to 230.0)
Turner syndrome	0.4 (0.3 to 0.4)	1.0 (1.0 to 1.1)	188.5 (151.6 to 232.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	188.6 (151.1 to 232.6)
Klinefelter syndrome	1.2 (1.1 to 1.2)	2.6 (2.5 to 2.7)	117.5 (102.5 to 133.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.8 (102.8 to 134.0)
Chromosomal unbalanced rearrangements	73.0 (63.9 to 81.0)	201.3 (178.6 to 219.7)	174.3 (157.0 to 194.6)	14.9 (11.1 to 19.0)	41.1 (30.9 to 52.0)	177.0 (154.4 to 200.3)
Other congenital anomalies	251.8 (212.7 to 287.8)	375.5 (315.9 to 431.7)	48.6 (41.3 to 55.6)	24.7 (17.1 to 33.5)	41.0 (28.7 to 54.5)	66.0 (50.1 to 88.0)
Skin and subcutaneous diseases	-	-	-	376.0 (254.8 to 575.9)	627.6 (421.9 to 964.4)	66.9 (62.7 to 71.1)
Dermatitis	2,347.3 (2,007.5 to 2,726.6)	3,925.6 (3,354.3 to 4,557.8)	66.6 (65.2 to 68.0)	63.7 (41.9 to 91.6)	105.3 (69.5 to 152.6)	65.4 (61.4 to 69.5)
Psoriasis	881.3 (718.7 to 1,078.8)	1,465.2 (1,181.4 to 1,813.8)	65.4 (62.6 to 69.2)	65.6 (45.3 to 97.1)	109.3 (74.6 to 162.3)	66.6 (60.7 to 72.9)
Cellulitis	51.8 (36.8 to 72.6)	69.8 (48.5 to 102.1)	34.0 (24.6 to 44.1)	3.4 (2.0 to 5.4)	4.6 (2.6 to 7.4)	35.4 (18.3 to 52.5)
Pyoderma	73.4 (46.8 to 116.5)	113.9 (65.0 to 196.8)	53.4 (33.4 to 73.2)	0.4 (0.1 to 0.9)	0.6 (0.2 to 1.5)	54.2 (31.9 to 75.9)
Scabies	260.3 (239.9 to 284.5)	471.3 (434.4 to 517.8)	80.2 (60.6 to 103.2)	6.3 (3.7 to 9.8)	11.4 (6.5 to 17.9)	81.3 (62.0 to 105.2)
Fungal skin diseases	7,003.9 (6,100.5 to 7,796.1)	12,050.9 (10,508.4 to 13,394.2)	71.5 (69.7 to 72.9)	37.1 (15.3 to 74.7)	64.0 (26.3 to 128.3)	72.3 (70.4 to 74.0)
Viral skin diseases	688.2 (481.2 to 938.7)	1,141.6 (799.2 to 1,560.8)	65.3 (61.5 to 69.3)	19.6 (11.4 to 31.0)	32.5 (18.9 to 51.7)	66.1 (60.4 to 71.7)
Acne vulgaris	311.4 (290.1 to 331.8)	484.1 (441.7 to 533.5)	54.6 (39.6 to 73.7)	3.1 (1.5 to 5.7)	4.9 (2.3 to 8.7)	55.3 (38.8 to 74.0)
Alopecia areata	161.8 (155.0 to 168.8)	267.6 (255.8 to 278.7)	64.9 (55.7 to 73.0)	5.1 (3.2 to 7.4)	8.4 (5.4 to 12.4)	65.7 (53.8 to 77.7)
Pruritus	28.7 (26.9 to 30.4)	50.9 (46.6 to 56.0)	75.9 (58.1 to 100.8)	0.3 (0.1 to 0.5)	0.5 (0.2 to 1.0)	77.2 (54.7 to 107.7)
Urticaria	1,359.4 (1,264.9 to 1,447.2)	2,301.3 (2,151.4 to 2,450.6)	68.5 (53.0 to 85.9)	75.1 (50.2 to 105.5)	127.1 (84.4 to 177.3)	69.4 (53.4 to 87.1)
Decubitus ulcer	177.3 (166.0 to 190.1)	271.6 (252.0 to 293.7)	53.1 (38.8 to 65.4)	24.8 (17.6 to 33.5)	38.2 (26.9 to 51.5)	54.2 (37.5 to 69.0)
Other skin and subcutaneous diseases	12,783.7 (3,162.0 to 30,718.1)	21,572.7 (5,338.6 to 52,293.2)	68.1 (65.5 to 71.1)	71.6 (15.2 to 198.0)	120.9 (25.5 to 332.8)	68.9 (66.2 to 72.1)
Sense organ diseases	-	-	-	2,668.0 (1,862.5 to 3,676.6)	4,304.2 (2,983.6 to 5,924.3)	61.2 (56.8 to 66.7)
Glaucoma	486.6 (367.8 to 597.4)	783.6 (606.1 to 952.7)	61.3 (41.1 to 80.4)	44.7 (29.1 to 64.0)	72.0 (47.6 to 103.2)	61.3 (48.7 to 76.8)
Cataract	4,576.8 (3,605.8 to 5,451.5)	6,562.9 (5,282.1 to 7,709.0)	42.4 (35.7 to 54.4)	280.1 (187.7 to 391.7)	437.2 (297.4 to 615.2)	55.9 (48.2 to 67.3)
Macular degeneration	659.7 (475.7 to 811.7)	1,120.6 (821.6 to 1,388.1)	69.4 (53.8 to 86.8)	35.2 (22.7 to 51.0)	58.3 (38.5 to 84.3)	65.0 (51.2 to 83.2)
Uncorrected refractive error	24,879.0 (23,826.1 to 25,916.7)	39,842.5 (38,346.4 to 41,295.8)	59.6 (54.4 to 65.2)	439.7 (282.5 to 657.1)	683.5 (436.1 to 1,027.2)	55.3 (51.2 to 59.6)
Age-related and other hearing loss	52,501.8 (50,968.4 to 53,805.6)	86,818.3 (84,037.3 to 89,432.2)	64.8 (63.5 to 66.0)	1,705.6 (1,177.6 to 2,374.3)	2,801.4 (1,936.0 to 3,912.1)	64.2 (57.6 to 72.6)
Other vision loss	1,086.7 (805.8 to 1,452.8)	1,462.4 (1,088.4 to 1,881.6)	34.4 (18.6 to 47.5)	86.7 (55.5 to 129.2)	122.9 (79.9 to 179.0)	42.1 (30.7 to 53.0)
Other sense organ diseases	3,103.1 (3,030.5 to 3,178.8)	5,244.7 (5,135.9 to 5,345.8)	68.3 (63.7 to 73.9)	76.1 (48.0 to 110.6)	128.7 (80.8 to 186.1)	69.1 (64.3 to 75.1)
Oral disorders	-	-	-	654.8 (442.2 to 922.0)	965.1 (645.2 to 1,363.5)	47.3 (44.0 to 50.9)
Deciduous caries	-	-	-	-	-	-
Permanent caries	18,155.8 (17,877.5 to 18,436.9)	33,094.4 (32,623.7 to 33,563.1)	81.5 (77.9 to 85.6)	13.6 (6.4 to 25.4)	26.1 (12.4 to 49.4)	92.5 (86.6 to 97.8)
Periodontal diseases	9,790.9 (9,656.5 to 9,931.0)	17,623.1 (17,363.2 to 17,878.0)	79.4 (75.8 to 83.1)	60.8 (24.7 to 123.3)	109.5 (44.5 to 223.7)	80.1 (76.5 to 84.0)
Edentulism and severe tooth loss	20,361.6 (20,070.0 to 20,616.4)	28,818.3 (28,436.3 to 29,180.9)	41.0 (38.5 to 43.3)	544.5 (373.7 to 746.7)	769.1 (528.7 to 1,050.6)	41.3 (38.7 to 44.0)
Other oral disorders	1,314.0 (1,289.7 to 1,338.2)	2,200.2 (2,157.8 to 2,245.5)	66.7 (62.6 to 71.2)	36.0 (23.1 to 53.1)	60.4 (38.6 to 88.4)	67.5 (62.4 to 72.8)
Injuries	-	-	-	1,801.9 (1,358.0 to 2,321.6)	2,041.9 (1,496.1 to 2,700.3)	13.3 (0.3 to 26.6)
Transport injuries	-	-	-	286.7 (213.9 to 373.1)	403.5 (289.6 to 538.2)	40.6 (34.0 to 46.8)
Road injuries	-	-	-	235.1 (174.3 to 306.0)	339.4 (243.3 to 454.1)	44.3 (38.0 to 50.0)
Pedestrian road injuries	-	-	-	67.1 (50.1 to 86.9)	108.1 (78.3 to 143.4)	60.9 (54.3 to 68.1)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (75-79 years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Cyclist road injuries	-	-	-	31.0 (23.1 to 40.3)	42.4 (30.7 to 56.0)	36.6 (29.6 to 43.3)
Motorcyclist road injuries	-	-	-	34.3 (24.6 to 46.0)	48.6 (33.9 to 66.5)	41.4 (35.4 to 47.2)
Motor vehicle road injuries	-	-	-	99.7 (74.0 to 130.0)	137.0 (98.5 to 183.4)	37.3 (31.0 to 43.0)
Other road injuries	-	-	-	3.0 (2.2 to 3.9)	3.3 (2.4 to 4.4)	10.6 (5.9 to 16.1)
Other transport injuries	-	-	-	51.6 (38.8 to 66.7)	64.1 (46.1 to 84.9)	24.0 (15.6 to 32.6)
Unintentional injuries	-	-	-	1,175.2 (899.7 to 1,498.0)	1,389.9 (1,017.6 to 1,840.8)	17.8 (7.2 to 29.4)
Falls	-	-	-	914.6 (700.5 to 1,157.8)	1,034.4 (759.8 to 1,355.7)	12.5 (0.5 to 26.7)
Drowning	-	-	-	9.0 (6.6 to 11.7)	12.3 (8.7 to 16.3)	36.5 (29.9 to 43.0)
Fire, heat, and hot substances	-	-	-	28.4 (19.4 to 40.6)	35.1 (23.9 to 50.1)	23.3 (19.5 to 27.7)
Poisonings	-	-	-	2.0 (1.4 to 2.5)	2.1 (1.5 to 2.7)	7.4 (0.7 to 14.4)
Exposure to mechanical forces	-	-	-	87.7 (63.1 to 118.2)	114.9 (81.5 to 157.6)	30.9 (27.5 to 34.2)
Unintentional firearm injuries	-	-	-	2.7 (2.0 to 3.6)	3.5 (2.5 to 4.7)	29.0 (22.7 to 35.5)
Unintentional suffocation	-	-	-	0.9 (0.7 to 1.2)	1.8 (1.3 to 2.4)	94.7 (87.1 to 101.7)
Other exposure to mechanical forces	-	-	-	84.1 (60.5 to 113.5)	109.6 (77.8 to 150.4)	30.2 (26.9 to 33.5)
Adverse effects of medical treatment	-	-	-	10.1 (6.4 to 14.8)	15.7 (9.9 to 23.3)	56.3 (49.4 to 63.1)
Animal contact	-	-	-	9.8 (7.3 to 13.0)	12.3 (9.0 to 16.8)	26.2 (21.2 to 31.2)
Venomous animal contact	-	-	-	2.5 (1.8 to 3.2)	3.0 (2.2 to 3.9)	22.6 (15.7 to 30.2)
Non-venomous animal contact	-	-	-	7.3 (5.4 to 9.9)	9.3 (6.7 to 12.8)	27.5 (22.0 to 32.6)
Foreign body	-	-	-	7.3 (5.6 to 9.1)	10.8 (8.1 to 13.8)	48.4 (41.9 to 55.1)
Pulmonary aspiration and foreign body in airway	-	-	-	2.1 (1.6 to 2.6)	2.8 (2.1 to 3.6)	33.9 (25.2 to 44.1)
Foreign body in eyes	-	-	-	0.9 (0.7 to 1.3)	1.4 (1.0 to 2.0)	49.5 (43.0 to 55.2)
Foreign body in other body part	-	-	-	4.2 (3.2 to 5.4)	6.6 (4.9 to 8.4)	55.0 (48.2 to 61.6)
Other unintentional injuries	-	-	-	106.4 (77.3 to 142.9)	152.2 (109.7 to 204.6)	42.8 (38.8 to 47.6)
Self-harm and interpersonal violence	-	-	-	26.2 (19.4 to 34.1)	31.9 (22.8 to 43.0)	21.4 (15.0 to 28.1)
Self-harm	-	-	-	9.0 (6.6 to 11.5)	9.7 (7.0 to 13.1)	8.1 (1.3 to 15.7)
Interpersonal violence	-	-	-	17.2 (12.8 to 22.7)	22.2 (15.8 to 30.0)	28.3 (22.3 to 34.7)
Assault by firearm	-	-	-	3.2 (2.3 to 4.3)	4.7 (3.3 to 6.3)	45.0 (39.8 to 49.9)
Assault by sharp object	-	-	-	2.9 (2.1 to 3.9)	4.2 (2.9 to 5.8)	44.2 (37.6 to 51.0)
Assault by other means	-	-	-	11.1 (8.3 to 14.5)	13.3 (9.6 to 17.8)	19.5 (13.3 to 25.9)
Forces of nature, war, and legal intervention	-	-	-	313.8 (132.2 to 617.7)	216.6 (96.7 to 426.1)	-31.4 (-45.9 to -3.8)
Exposure to forces of nature	-	-	-	22.4 (11.6 to 39.5)	33.1 (16.6 to 60.3)	47.8 (-3.3 to 122.9)
Collective violence and legal intervention	-	-	-	291.4 (115.2 to 587.7)	183.5 (78.0 to 372.6)	-37.3 (-50.6 to -14.3)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (80+ years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
All causes	-	-	-	19,511.5 (14,938.8 to 24,400.4)	38,914.2 (29,464.4 to 49,079.2)	99.4 (95.9 to 102.8)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	455.1 (330.7 to 592.2)	748.2 (546.6 to 980.5)	64.4 (58.5 to 70.8)
HIV/AIDS and tuberculosis	-	-	-	38.6 (27.4 to 50.4)	91.3 (65.7 to 119.9)	136.4 (124.4 to 149.6)
Tuberculosis	137.6 (129.0 to 146.2)	287.9 (266.9 to 309.4)	109.8 (103.1 to 117.0)	36.3 (25.8 to 47.7)	77.2 (54.6 to 102.3)	112.7 (102.5 to 122.9)
HIV/AIDS	-	-	-	2.3 (1.6 to 3.4)	14.1 (10.1 to 18.7)	509.3 (341.2 to 740.3)
HIV/AIDS resulting in mycobacterial infection	0.6 (0.3 to 1.0)	3.0 (1.8 to 4.4)	436.0 (230.9 to 735.9)	0.2 (0.1 to 0.4)	1.0 (0.5 to 1.6)	453.1 (211.7 to 808.1)
HIV/AIDS resulting in other diseases	11.4 (8.7 to 14.7)	112.2 (97.3 to 128.3)	890.2 (677.7 to 1,178.2)	2.1 (1.4 to 3.2)	13.1 (9.3 to 17.5)	515.6 (334.0 to 777.6)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	81.3 (59.0 to 105.7)	150.4 (109.8 to 196.8)	85.0 (79.0 to 91.0)
Diarrheal diseases	270.3 (264.1 to 276.3)	440.3 (431.2 to 448.7)	63.2 (58.5 to 68.3)	37.3 (26.6 to 49.2)	60.7 (43.2 to 79.5)	62.5 (56.3 to 69.5)
Intestinal infectious diseases	-	-	-	0.8 (0.5 to 1.1)	1.0 (0.7 to 1.5)	33.4 (-2.7 to 77.0)
Typhoid fever	5.2 (4.2 to 6.2)	7.1 (6.0 to 8.3)	37.7 (10.1 to 86.1)	0.6 (0.4 to 0.9)	0.8 (0.5 to 1.2)	42.5 (-2.8 to 101.5)
Paratyphoid fever	3.0 (2.3 to 3.9)	3.4 (2.6 to 4.5)	9.8 (-21.9 to 70.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	17.4 (-25.9 to 96.9)
Other intestinal infectious diseases	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-22.3 (-39.3 to 1.3)
Lower respiratory infections	183.5 (172.4 to 196.8)	420.9 (404.9 to 439.1)	130.4 (114.5 to 144.7)	16.6 (11.7 to 22.4)	38.9 (27.4 to 52.3)	134.5 (117.3 to 150.6)
Upper respiratory infections	877.5 (855.1 to 902.3)	1,855.3 (1,812.3 to 1,902.7)	112.0 (104.8 to 120.2)	9.1 (5.3 to 14.8)	9.1 (11.2 to 31.6)	113.7 (104.3 to 123.6)
Otitis media	185.7 (179.9 to 192.2)	348.7 (337.1 to 361.9)	88.3 (79.7 to 97.2)	3.3 (2.0 to 5.2)	6.3 (3.8 to 9.8)	90.6 (79.2 to 102.4)
Meningitis	-	-	-	7.7 (3.6 to 13.8)	11.2 (5.5 to 19.9)	44.5 (34.9 to 61.6)
Pneumococcal meningitis	59.5 (29.8 to 98.1)	90.6 (44.6 to 154.4)	51.6 (39.3 to 65.3)	2.7 (1.6 to 4.5)	4.2 (2.4 to 6.8)	54.2 (40.0 to 68.6)
H influenzae type B meningitis	18.6 (1.9 to 42.4)	21.9 (1.8 to 53.1)	16.4 (-21.8 to 32.9)	0.8 (0.3 to 1.6)	1.0 (0.4 to 2.1)	33.4 (16.0 to 67.9)
Meningococcal meningitis	15.4 (2.3 to 36.5)	19.5 (3.2 to 46.4)	26.1 (6.0 to 42.5)	1.6 (0.5 to 3.2)	2.1 (0.7 to 4.3)	34.4 (17.4 to 63.3)
Other meningitis	31.9 (6.4 to 68.2)	41.8 (8.5 to 97.3)	29.7 (-1.2 to 49.0)	2.6 (1.2 to 4.7)	3.8 (1.8 to 6.8)	44.6 (24.7 to 71.2)
Encephalitis	25.1 (5.6 to 67.6)	40.3 (8.6 to 122.7)	59.8 (1.2 to 83.3)	1.7 (1.1 to 2.7)	3.0 (1.9 to 4.7)	74.5 (59.1 to 89.8)
Diphtheria	-	-	-	-	-	-
Whooping cough	-	-	-	-	-	-
Tetanus	8.7 (6.0 to 13.3)	1.5 (0.9 to 2.4)	-82.3 (-90.2 to -69.9)	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.2)	-70.7 (-88.0 to -29.1)
Measles	-	-	-	-	-	-
Varicella and herpes zoster	90.4 (86.3 to 95.1)	193.5 (184.5 to 203.6)	114.4 (100.9 to 128.7)	4.5 (2.8 to 6.5)	9.6 (6.2 to 14.3)	116.0 (100.3 to 132.8)
Neglected tropical diseases and malaria	-	-	-	179.5 (125.2 to 243.2)	223.5 (150.5 to 319.6)	23.6 (10.0 to 42.1)
Malaria	294.5 (281.5 to 311.0)	411.1 (385.1 to 435.6)	39.8 (30.9 to 51.0)	2.5 (1.6 to 3.8)	3.1 (1.9 to 4.9)	24.4 (6.8 to 43.2)
Chagas disease	130.5 (126.1 to 134.8)	278.6 (267.2 to 292.7)	114.0 (102.9 to 126.5)	4.7 (3.2 to 6.5)	10.2 (6.9 to 14.0)	114.6 (100.8 to 130.0)
Leishmaniasis	-	-	-	0.1 (0.1 to 0.2)	0.5 (0.2 to 0.8)	260.0 (223.8 to 305.4)
Visceral leishmaniasis	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	96.5 (50.5 to 159.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.1 (49.9 to 161.6)
Cutaneous and mucocutaneous leishmaniasis	11.9 (10.7 to 13.2)	44.7 (39.8 to 50.2)	275.6 (241.8 to 315.1)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.8)	282.9 (247.1 to 328.5)
African trypanosomiasis	0.3 (0.2 to 0.6)	0.1 (0.1 to 0.2)	-68.6 (-72.9 to -63.1)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-67.0 (-77.5 to -49.9)
Schistosomiasis	921.7 (830.9 to 1,010.5)	1,387.5 (1,211.3 to 1,640.6)	48.5 (36.4 to 78.0)	6.8 (3.5 to 12.8)	10.2 (5.2 to 19.9)	47.9 (37.3 to 72.7)
Cysticercosis	12.6 (11.0 to 14.3)	12.4 (10.4 to 14.5)	-1.4 (-19.7 to 20.5)	3.1 (2.2 to 4.1)	3.4 (2.4 to 4.5)	7.6 (-13.9 to 38.2)
Cystic echinococcosis	25.9 (24.9 to 27.0)	42.3 (41.1 to 43.5)	64.4 (54.4 to 73.0)	2.2 (1.5 to 2.9)	3.6 (2.5 to 4.8)	66.9 (50.1 to 86.3)
Lymphatic filariasis	715.6 (591.9 to 872.0)	728.4 (572.9 to 935.4)	2.1 (-10.9 to 14.9)	33.4 (18.3 to 54.0)	46.4 (27.0 to 74.6)	40.9 (11.6 to 69.6)
Onchocerciasis	193.8 (148.2 to 251.0)	162.8 (115.1 to 233.5)	-16.5 (-29.2 to -0.8)	19.8 (12.5 to 29.8)	17.5 (10.1 to 28.8)	-13.4 (-26.1 to 5.2)
Trachoma	540.6 (388.0 to 751.2)	375.3 (272.2 to 494.8)	-29.9 (-43.3 to -18.3)	40.2 (25.5 to 58.4)	29.5 (18.7 to 42.8)	-26.3 (-37.4 to -15.9)
Dengue	2.9 (1.0 to 6.5)	34.1 (12.5 to 76.4)	1,086.7 (1,067.2 to 1,100.3)	0.4 (0.1 to 1.0)	4.8 (1.6 to 12.4)	1,078.5 (873.4 to 1,374.2)
Yellow fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.3 (-67.5 to -0.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.3 (-67.5 to -0.4)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.4 (-8.2 to 82.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.5 (-8.2 to 83.2)
Intestinal nematode infections	-	-	-	36.9 (21.7 to 57.7)	28.8 (17.0 to 45.1)	-21.7 (-29.4 to -13.8)
Ascariasis	7,708.7 (6,253.1 to 9,549.2)	8,006.2 (6,604.3 to 9,861.3)	3.9 (-21.0 to 39.4)	17.6 (9.9 to 28.7)	7.4 (4.1 to 12.3)	-58.0 (-64.9 to -49.8)
Trichuriasis	3,779.2 (2,920.2 to 4,976.5)	4,651.4 (4,137.2 to 5,240.6)	25.5 (-10.0 to 63.6)	4.8 (2.6 to 7.9)	4.6 (2.6 to 7.6)	-2.7 (-22.4 to 23.8)
Hookworm disease	3,569.1 (2,904.9 to 4,458.6)	4,855.3 (4,365.4 to 5,395.7)	37.0 (5.8 to 72.3)	14.5 (8.9 to 22.6)	16.7 (10.1 to 25.8)	15.0 (1.6 to 30.7)
Food-borne trematodiasis	647.7 (499.5 to 792.6)	1,540.9 (1,199.3 to 1,897.2)	139.3 (116.4 to 158.0)	26.5 (8.4 to 54.6)	62.5 (20.5 to 130.0)	137.7 (109.4 to 164.4)
Other neglected tropical diseases	74.9 (66.5 to 83.6)	135.3 (120.0 to 146.0)	81.8 (53.1 to 109.7)	2.9 (1.6 to 5.0)	3.1 (1.6 to 5.9)	4.5 (-19.8 to 54.1)
Maternal disorders	-	-	-	0.4 (0.2 to 0.7)	0.8 (0.4 to 1.3)	67.6 (5.5 to 170.8)
Maternal hemorrhage	-	-	-	-	-	-
Maternal sepsis and other maternal infections	-	-	-	-	-	-
Maternal hypertensive disorders	-	-	-	-	-	-
Obstructed labor	1.6 (1.1 to 2.2)	2.6 (1.8 to 3.7)	67.8 (36.8 to 101.1)	0.4 (0.2 to 0.7)	0.8 (0.4 to 1.3)	67.6 (5.5 to 170.8)
Complications of abortion	-	-	-	-	-	-

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (80+ years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Other maternal disorders	-	-	-	-	-	-
Neonatal disorders	-	-	-	9.9 (6.4 to 15.0)	30.0 (20.7 to 42.2)	208.0 (148.4 to 274.4)
Preterm birth complications	192.0 (149.0 to 251.3)	620.7 (482.3 to 833.3)	222.9 (181.4 to 278.5)	6.2 (4.2 to 8.9)	20.8 (14.7 to 28.6)	234.2 (189.7 to 282.9)
Neonatal encephalopathy due to birth asphyxia and trauma	131.4 (37.3 to 284.6)	158.4 (51.0 to 324.8)	19.7 (-20.6 to 118.8)	1.9 (0.5 to 4.3)	2.5 (0.8 to 5.6)	30.3 (-7.2 to 122.4)
Neonatal sepsis and other neonatal infections	-	-	-	-	-	-
Hemolytic disease and other neonatal jaundice	0.5 (0.4 to 0.7)	2.3 (1.6 to 3.2)	382.8 (183.0 to 621.3)	0.2 (0.1 to 0.3)	1.0 (0.6 to 1.5)	381.6 (177.5 to 622.3)
Other neonatal disorders	-	-	-	1.5 (0.9 to 2.5)	5.7 (3.4 to 8.4)	292.0 (161.4 to 423.2)
Nutritional deficiencies	-	-	-	133.3 (92.9 to 183.1)	228.3 (155.1 to 320.2)	70.9 (60.2 to 82.8)
Protein-energy malnutrition	122.5 (67.7 to 188.6)	249.1 (135.9 to 389.3)	103.2 (69.1 to 145.2)	13.0 (6.2 to 22.1)	26.5 (12.2 to 46.3)	103.9 (69.0 to 148.5)
Iodine deficiency	580.0 (517.0 to 640.4)	757.6 (683.6 to 829.8)	31.2 (11.7 to 51.2)	9.3 (5.8 to 14.4)	12.3 (7.6 to 19.3)	32.5 (13.3 to 54.0)
Vitamin A deficiency	6.1 (2.9 to 9.4)	8.0 (4.2 to 11.9)	33.5 (-6.1 to 96.9)	0.5 (0.2 to 0.8)	0.6 (0.3 to 1.0)	33.0 (-13.4 to 111.6)
Iron-deficiency anemia	5,024.4 (4,942.3 to 5,109.3)	11,323.2 (11,107.7 to 11,546.3)	125.9 (120.3 to 131.4)	108.9 (75.6 to 150.5)	186.3 (126.0 to 268.2)	70.5 (58.1 to 85.0)
Other nutritional deficiencies	-	-	-	1.7 (0.8 to 3.7)	2.6 (1.3 to 4.9)	59.6 (-2.8 to 106.5)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	12.0 (7.9 to 19.2)	23.9 (15.6 to 37.7)	98.8 (85.9 to 112.4)
Sexually transmitted diseases excluding HIV	-	-	-	6.2 (3.5 to 11.5)	12.0 (6.8 to 22.5)	94.4 (81.5 to 105.0)
Syphilis	15.2 (14.5 to 15.9)	28.1 (27.0 to 29.2)	86.2 (75.4 to 96.2)	2.5 (1.7 to 3.4)	4.7 (3.3 to 6.5)	89.6 (65.4 to 114.2)
Chlamydial infection	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.4)	36.3 (21.8 to 57.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	36.5 (21.9 to 57.2)
Gonococcal infection	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.3)	15.3 (-4.9 to 53.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.4 (-4.9 to 53.3)
Trichomoniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.6 (80.0 to 138.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.5 (76.8 to 139.3)
Genital herpes	16,137.6 (15,980.0 to 16,296.1)	31,728.0 (31,389.8 to 32,108.3)	97.1 (94.1 to 100.0)	3.6 (1.1 to 8.9)	7.1 (2.1 to 17.7)	98.8 (93.7 to 103.5)
Other sexually transmitted diseases	0.4 (0.4 to 0.5)	0.8 (0.8 to 0.9)	90.7 (67.7 to 116.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	91.0 (67.9 to 117.3)
Hepatitis	-	-	-	1.9 (1.3 to 2.7)	3.3 (2.2 to 4.7)	76.9 (62.1 to 91.6)
Hepatitis A	11.9 (10.7 to 12.9)	30.7 (28.5 to 32.6)	160.0 (152.8 to 166.7)	0.4 (0.2 to 0.6)	1.0 (0.7 to 1.5)	161.6 (123.3 to 210.2)
Hepatitis B	3,002.2 (2,892.8 to 3,108.5)	4,287.3 (4,160.0 to 4,442.6)	43.0 (36.3 to 51.2)	1.2 (0.8 to 1.7)	1.7 (1.1 to 2.5)	48.3 (30.7 to 64.9)
Hepatitis C	3,149.1 (3,096.6 to 3,208.3)	5,037.7 (4,958.5 to 5,122.4)	60.3 (56.7 to 64.2)	0.2 (0.2 to 0.4)	0.4 (0.3 to 0.6)	65.3 (37.8 to 99.5)
Hepatitis E	3.9 (3.6 to 4.4)	8.2 (7.2 to 9.3)	108.4 (70.5 to 154.3)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	124.9 (60.2 to 204.9)
Leprosy	20.8 (19.1 to 22.5)	57.8 (52.9 to 61.9)	177.9 (157.5 to 201.1)	1.1 (0.8 to 1.6)	3.3 (2.2 to 4.5)	189.1 (154.7 to 227.0)
Other infectious diseases	127.9 (117.7 to 138.5)	289.3 (272.1 to 306.4)	127.1 (106.0 to 150.3)	2.8 (1.9 to 4.1)	5.3 (3.4 to 7.9)	88.4 (47.2 to 135.4)
Non-communicable diseases	-	-	-	16,013.5 (12,121.9 to 20,135.8)	33,970.6 (25,658.9 to 42,648.6)	112.0 (109.6 to 114.8)
Neoplasms	-	-	-	379.8 (292.4 to 465.5)	1,053.6 (808.8 to 1,300.8)	177.5 (162.6 to 191.0)
Esophageal cancer	48.5 (40.1 to 57.7)	109.0 (90.7 to 131.3)	125.8 (80.0 to 179.9)	7.8 (5.5 to 10.0)	16.4 (11.8 to 21.6)	110.7 (72.3 to 157.0)
Stomach cancer	229.6 (203.6 to 260.4)	474.6 (424.8 to 537.2)	107.2 (86.7 to 129.8)	27.5 (20.6 to 35.0)	92.0 (38.8 to 67.5)	92.0 (72.1 to 115.1)
Liver cancer	-	-	-	7.7 (5.4 to 10.2)	21.5 (15.3 to 28.5)	179.4 (132.9 to 238.9)
Liver cancer due to hepatitis B	8.1 (6.4 to 10.2)	25.9 (20.8 to 31.7)	222.0 (139.4 to 330.0)	1.4 (1.0 to 1.9)	4.0 (2.8 to 5.4)	182.5 (122.0 to 265.6)
Liver cancer due to hepatitis C	12.1 (9.9 to 14.9)	76.2 (61.3 to 93.8)	532.7 (377.1 to 722.3)	2.0 (1.4 to 2.7)	10.8 (7.7 to 14.5)	447.8 (325.6 to 582.5)
Liver cancer due to alcohol use	18.2 (15.2 to 21.6)	31.1 (25.8 to 37.4)	71.6 (38.4 to 114.9)	3.0 (2.1 to 4.0)	4.8 (3.4 to 6.5)	60.8 (32.9 to 97.0)
Liver cancer due to other causes	7.4 (5.7 to 9.7)	11.2 (8.5 to 14.2)	50.7 (6.1 to 112.0)	1.3 (0.9 to 1.8)	1.9 (1.2 to 2.6)	42.9 (11.2 to 89.6)
Larynx cancer	27.6 (22.8 to 33.7)	69.0 (56.3 to 82.7)	150.4 (118.0 to 189.0)	3.3 (2.3 to 4.4)	7.2 (5.1 to 9.7)	118.5 (84.4 to 158.0)
Tracheal, bronchus and lung cancer	165.7 (156.6 to 180.6)	504.8 (448.1 to 549.3)	209.3 (160.3 to 235.2)	24.7 (18.5 to 30.8)	70.7 (52.2 to 88.5)	188.4 (151.9 to 215.8)
Breast cancer	1,041.3 (974.1 to 1,096.1)	3,005.4 (2,895.5 to 3,111.7)	188.9 (173.2 to 208.7)	54.7 (39.8 to 73.2)	145.4 (104.2 to 195.5)	166.2 (141.0 to 188.3)
Cervical cancer	75.1 (59.3 to 87.0)	129.1 (105.4 to 157.0)	71.6 (37.0 to 117.4)	6.4 (4.6 to 8.5)	10.8 (7.7 to 14.6)	67.7 (30.0 to 113.4)
Uterine cancer	87.9 (70.8 to 103.3)	215.4 (170.1 to 265.3)	145.4 (98.0 to 200.9)	6.7 (4.6 to 8.9)	15.5 (10.5 to 21.4)	130.9 (83.5 to 184.6)
Prostate cancer	816.3 (714.2 to 917.0)	2,701.8 (2,366.5 to 3,206.2)	231.0 (196.2 to 275.2)	68.4 (48.0 to 89.6)	226.4 (164.4 to 306.1)	228.7 (184.2 to 289.8)
Colon and rectum cancer	600.8 (569.9 to 638.1)	1,688.9 (1,565.6 to 1,818.8)	181.5 (159.2 to 207.8)	55.9 (42.7 to 69.1)	146.3 (110.3 to 184.2)	161.2 (140.3 to 185.6)
Lip and oral cavity cancer	95.5 (79.4 to 116.8)	229.5 (188.3 to 274.7)	141.8 (93.6 to 194.7)	9.3 (6.7 to 12.6)	21.2 (15.2 to 27.6)	128.8 (81.5 to 180.5)
Nasopharynx cancer	9.7 (6.7 to 13.4)	16.4 (11.8 to 23.4)	70.5 (7.4 to 164.1)	1.2 (0.7 to 1.7)	1.9 (1.2 to 2.9)	65.7 (10.0 to 153.2)
Other pharynx cancer	18.1 (14.3 to 22.2)	42.1 (32.7 to 52.1)	132.4 (74.0 to 210.9)	1.9 (1.3 to 2.5)	4.2 (2.9 to 5.7)	120.4 (64.8 to 196.1)
Gallbladder and biliary tract cancer	20.6 (16.9 to 25.2)	42.2 (31.9 to 50.3)	106.3 (64.9 to 145.6)	4.7 (3.2 to 6.1)	9.3 (6.1 to 12.8)	98.6 (53.4 to 145.7)
Pancreatic cancer	30.8 (28.3 to 33.4)	85.4 (77.0 to 95.1)	177.3 (148.9 to 213.3)	5.7 (4.1 to 7.3)	15.2 (11.0 to 19.7)	167.1 (130.3 to 211.4)
Malignant skin melanoma	81.3 (62.4 to 106.9)	252.9 (169.5 to 329.6)	207.7 (149.5 to 298.1)	5.6 (3.8 to 7.8)	15.9 (9.8 to 23.1)	181.3 (125.1 to 264.4)
Non-melanoma skin cancer	570.9 (473.0 to 663.9)	1,569.5 (1,291.9 to 1,854.5)	177.1 (113.1 to 242.3)	11.5 (7.7 to 17.2)	38.6 (24.8 to 57.4)	233.8 (142.9 to 367.8)
Ovarian cancer	40.6 (35.7 to 47.6)	102.6 (85.2 to 120.2)	153.7 (103.9 to 205.3)	5.8 (4.1 to 7.5)	13.8 (9.7 to 18.0)	138.4 (91.6 to 199.3)
Testicular cancer	2.2 (1.5 to 2.8)	5.9 (4.3 to 7.5)	162.0 (103.7 to 245.9)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	124.3 (71.2 to 207.6)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (80+ years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Kidney cancer	63.6 (55.1 to 75.7)	246.0 (198.9 to 299.3)	281.1 (208.5 to 395.8)	5.1 (3.7 to 6.7)	17.9 (12.4 to 24.4)	247.0 (178.6 to 359.1)
Bladder cancer	222.0 (192.4 to 258.5)	571.6 (455.2 to 663.8)	158.4 (118.5 to 198.6)	18.8 (13.8 to 24.4)	44.3 (31.6 to 58.2)	135.8 (101.5 to 173.9)
Brain and nervous system cancer	18.0 (15.3 to 21.7)	62.8 (47.9 to 74.5)	252.4 (170.0 to 333.5)	2.2 (1.6 to 3.0)	7.0 (4.7 to 9.4)	216.4 (136.0 to 297.8)
Thyroid cancer	35.5 (27.9 to 41.7)	97.2 (79.7 to 117.2)	175.4 (126.4 to 237.7)	3.0 (2.1 to 3.9)	7.3 (5.1 to 10.0)	147.1 (97.8 to 208.5)
Mesothelioma	3.2 (2.6 to 4.1)	7.6 (5.7 to 9.3)	144.0 (81.0 to 189.5)	0.7 (0.5 to 1.0)	1.6 (1.1 to 2.3)	145.2 (77.7 to 202.7)
Hodgkin lymphoma	11.5 (7.4 to 14.9)	23.0 (18.3 to 29.8)	96.3 (47.9 to 214.4)	1.5 (0.9 to 2.1)	2.6 (1.7 to 3.7)	75.5 (30.4 to 194.2)
Non-Hodgkin lymphoma	98.2 (81.5 to 136.1)	367.6 (244.5 to 448.8)	307.5 (150.5 to 388.1)	8.0 (5.7 to 11.5)	27.6 (16.7 to 38.5)	268.1 (130.2 to 351.3)
Multiple myeloma	26.3 (19.2 to 38.0)	71.6 (51.9 to 95.8)	176.2 (100.9 to 253.4)	5.7 (3.7 to 8.4)	14.5 (9.3 to 20.4)	157.9 (87.3 to 234.2)
Leukemia	70.8 (64.3 to 78.2)	213.0 (188.3 to 237.7)	202.0 (162.6 to 240.9)	11.6 (8.5 to 14.4)	31.1 (23.0 to 39.1)	169.0 (132.6 to 210.1)
Other neoplasms	183.6 (152.8 to 243.8)	937.0 (712.0 to 1,130.6)	436.9 (241.6 to 585.4)	14.5 (10.2 to 20.3)	65.8 (44.2 to 90.0)	376.6 (209.2 to 512.1)
Cardiovascular diseases	-	-	-	1,370.4 (1,006.1 to 1,778.8)	3,203.4 (2,327.4 to 4,166.3)	134.0 (110.4 to 157.1)
Rheumatic heart disease	364.5 (348.4 to 383.4)	862.2 (830.1 to 896.6)	137.4 (125.6 to 150.2)	29.9 (21.7 to 39.7)	69.0 (48.9 to 92.2)	131.9 (101.3 to 155.4)
Ischemic heart disease	6,869.1 (6,639.0 to 7,159.8)	16,732.9 (16,169.2 to 17,313.0)	144.3 (132.1 to 157.4)	454.0 (323.9 to 599.0)	1,081.9 (766.7 to 1,438.7)	138.1 (124.2 to 152.4)
Cerebrovascular disease	-	-	-	288.9 (208.4 to 373.9)	621.9 (454.1 to 794.5)	114.7 (94.6 to 138.9)
Ischemic stroke	1,776.3 (1,622.3 to 1,911.3)	3,668.0 (3,452.4 to 3,910.3)	106.2 (86.4 to 132.5)	232.7 (165.6 to 307.4)	487.0 (351.7 to 635.1)	108.8 (88.2 to 135.8)
Hemorrhagic stroke	420.5 (388.5 to 451.2)	995.9 (927.3 to 1,076.5)	136.2 (111.6 to 166.4)	56.2 (39.9 to 74.2)	135.0 (96.8 to 175.9)	139.0 (114.8 to 170.3)
Hypertensive heart disease	964.5 (920.9 to 1,016.8)	2,280.1 (2,193.8 to 2,374.7)	137.4 (121.3 to 152.1)	97.6 (70.4 to 130.7)	234.2 (169.8 to 313.1)	140.4 (123.6 to 155.4)
Cardiomyopathy and myocarditis	446.0 (425.3 to 470.7)	931.3 (892.6 to 975.1)	109.7 (96.2 to 122.4)	44.4 (31.8 to 58.9)	94.2 (66.1 to 124.4)	112.1 (97.7 to 126.7)
Atrial fibrillation and flutter	2,053.6 (1,918.5 to 2,187.5)	3,975.9 (3,727.7 to 4,281.3)	93.5 (79.1 to 113.7)	147.8 (104.3 to 200.2)	289.8 (204.4 to 395.8)	95.4 (80.4 to 116.8)
Peripheral vascular disease	13,566.4 (12,902.2 to 14,303.6)	28,537.3 (27,105.6 to 30,155.6)	111.1 (96.5 to 125.9)	34.7 (17.1 to 60.1)	59.0 (29.1 to 103.0)	69.4 (49.9 to 97.4)
Endocarditis	17.6 (12.9 to 21.3)	31.8 (25.3 to 40.5)	1.6 (51.0 to 127.3)	1.6 (1.0 to 2.4)	2.9 (1.9 to 4.3)	77.7 (40.5 to 142.4)
Other cardiovascular and circulatory diseases	3,967.7 (2,341.0 to 6,453.0)	10,761.1 (7,002.8 to 16,991.5)	173.7 (74.8 to 345.0)	271.4 (150.5 to 442.3)	750.4 (437.1 to 1,216.9)	178.3 (77.0 to 357.4)
Chronic respiratory diseases	-	-	-	946.3 (660.0 to 1,276.2)	1,996.5 (1,402.4 to 2,697.9)	111.0 (103.5 to 119.1)
Chronic obstructive pulmonary disease	11,995.9 (11,360.1 to 12,583.3)	24,880.2 (23,566.4 to 26,101.6)	107.9 (106.1 to 110.0)	762.4 (521.0 to 1,057.4)	1,647.6 (1,132.6 to 2,284.5)	116.2 (107.0 to 125.9)
Pneumoconiosis	-	-	-	1.8 (1.3 to 2.5)	4.3 (3.0 to 5.8)	132.1 (122.4 to 141.5)
Silicosis	2.8 (2.5 to 3.0)	5.6 (5.1 to 6.1)	102.2 (97.4 to 107.1)	0.5 (0.3 to 0.7)	1.1 (0.7 to 1.5)	102.9 (97.8 to 107.7)
Asbestosis	0.7 (0.7 to 0.8)	1.8 (1.6 to 1.9)	136.8 (129.1 to 144.7)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	138.4 (130.8 to 146.6)
Coal workers pneumoconiosis	1.3 (1.2 to 1.4)	2.6 (2.4 to 2.7)	93.3 (90.4 to 96.4)	0.3 (0.2 to 0.4)	0.3 (0.3 to 0.7)	92.7 (89.6 to 96.0)
Other pneumoconiosis	4.9 (4.2 to 5.6)	13.5 (11.8 to 15.2)	177.0 (165.7 to 188.7)	0.9 (0.6 to 1.3)	2.4 (1.5 to 3.4)	159.0 (140.9 to 177.3)
Asthma	3,108.1 (3,025.5 to 3,185.6)	6,689.9 (6,532.7 to 6,867.9)	115.8 (108.6 to 122.6)	120.3 (81.2 to 164.0)	262.1 (178.1 to 358.4)	117.9 (110.1 to 125.4)
Interstitial lung disease and pulmonary sarcoidosis	20.9 (20.1 to 21.9)	50.5 (47.3 to 53.0)	142.1 (128.1 to 157.2)	2.7 (1.7 to 4.0)	6.4 (4.1 to 9.3)	137.0 (108.2 to 168.0)
Other chronic respiratory diseases	-	-	-	59.1 (37.2 to 92.2)	76.2 (49.3 to 115.3)	28.7 (12.1 to 45.7)
Cirrhosis	-	-	-	6.1 (4.4 to 8.2)	12.4 (8.9 to 16.6)	101.7 (88.6 to 116.1)
Cirrhosis due to hepatitis B	10.0 (9.4 to 10.6)	22.0 (20.8 to 23.3)	119.7 (103.1 to 137.9)	1.5 (1.0 to 2.0)	3.3 (2.3 to 4.5)	121.9 (92.1 to 154.5)
Cirrhosis due to hepatitis C	11.8 (11.1 to 12.4)	29.3 (26.9 to 31.5)	149.4 (127.6 to 173.7)	1.7 (1.2 to 2.3)	4.3 (3.0 to 5.8)	151.1 (115.9 to 190.6)
Cirrhosis due to alcohol use	18.2 (17.4 to 18.9)	27.3 (25.9 to 28.8)	50.5 (40.9 to 60.2)	2.6 (1.9 to 3.5)	4.0 (2.8 to 5.5)	52.9 (34.4 to 72.2)
Cirrhosis due to other causes	1.7 (1.5 to 1.9)	4.6 (4.1 to 5.2)	170.9 (126.8 to 211.7)	0.3 (0.2 to 0.4)	0.7 (0.5 to 1.1)	161.4 (102.7 to 224.7)
Digestive diseases	-	-	-	504.4 (357.5 to 677.6)	778.2 (556.4 to 1,040.3)	54.4 (50.1 to 58.4)
Peptic ulcer disease	6,930.5 (6,867.0 to 6,987.1)	8,314.3 (8,177.8 to 8,440.6)	20.2 (18.0 to 22.4)	215.3 (151.8 to 294.4)	269.9 (189.5 to 371.3)	25.3 (22.4 to 28.4)
Gastritis and duodenitis	3,251.3 (3,214.3 to 3,288.3)	6,141.4 (6,058.9 to 6,226.9)	89.4 (86.2 to 92.5)	104.8 (73.4 to 144.0)	182.6 (126.3 to 254.8)	74.1 (69.2 to 79.1)
Appendicitis	2.1 (1.9 to 2.4)	3.5 (3.2 to 3.8)	65.9 (39.8 to 90.1)	0.6 (0.4 to 0.9)	1.0 (0.7 to 1.4)	68.0 (25.8 to 121.0)
Paralytic ileus and intestinal obstruction	6.9 (6.7 to 7.2)	15.8 (15.3 to 16.2)	128.1 (117.8 to 138.5)	1.8 (1.2 to 2.4)	4.1 (2.8 to 5.4)	130.4 (91.3 to 181.9)
Inguinal, femoral, and abdominal hernia	2,347.6 (2,239.9 to 2,471.4)	3,897.0 (3,659.2 to 4,137.7)	66.2 (55.5 to 79.9)	22.4 (11.1 to 41.1)	37.6 (19.2 to 68.5)	67.6 (56.7 to 81.1)
Inflammatory bowel disease	225.6 (220.9 to 230.5)	503.9 (494.7 to 513.1)	123.9 (118.7 to 129.3)	41.5 (29.9 to 54.5)	93.8 (66.5 to 123.1)	125.9 (117.0 to 135.6)
Vascular intestinal disorders	4.5 (4.1 to 5.3)	9.3 (8.2 to 11.5)	107.6 (82.8 to 140.2)	1.2 (0.8 to 1.6)	2.5 (1.6 to 3.5)	110.2 (62.7 to 180.4)
Gallbladder and biliary diseases	394.6 (377.5 to 412.6)	738.8 (707.5 to 769.8)	87.7 (77.9 to 97.6)	37.5 (26.6 to 49.6)	71.0 (50.3 to 94.2)	89.4 (78.2 to 100.5)
Pancreatitis	45.0 (44.2 to 45.7)	107.7 (105.9 to 109.5)	140.2 (134.6 to 145.9)	11.6 (8.1 to 15.0)	28.1 (19.9 to 36.6)	143.2 (126.8 to 162.2)
Other digestive diseases	-	-	-	67.8 (46.7 to 93.8)	87.5 (60.6 to 119.3)	30.9 (10.6 to 44.6)
Neurological disorders	-	-	-	2,862.7 (2,095.1 to 3,642.5)	5,762.2 (4,136.5 to 7,409.4)	101.4 (92.6 to 110.3)
Alzheimer disease and other dementias	13,508.4 (13,095.6 to 13,980.3)	27,897.4 (26,801.0 to 28,818.5)	107.2 (97.1 to 116.5)	2,114.3 (1,542.6 to 2,694.2)	4,431.4 (3,193.7 to 5,712.6)	109.5 (99.7 to 119.2)
Parkinson disease	566.9 (462.5 to 662.1)	1,233.7 (1,005.9 to 1,442.3)	118.2 (113.4 to 122.8)	61.8 (41.9 to 84.7)	136.5 (93.2 to 185.6)	120.7 (113.2 to 128.8)
Epilepsy	157.0 (146.3 to 168.0)	301.1 (281.5 to 322.0)	92.3 (75.1 to 112.0)	46.5 (33.8 to 59.6)	95.2 (68.5 to 119.5)	104.0 (83.1 to 129.7)
Multiple sclerosis	12.7 (11.8 to 13.6)	40.0 (37.3 to 42.6)	214.9 (189.4 to 248.1)	3.6 (2.6 to 4.7)	11.5 (8.5 to 14.6)	216.6 (162.0 to 286.8)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (80+ years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Migraine	3,495.5 (3,313.7 to 3,711.4)	6,977.5 (6,607.0 to 7,477.0)	100.0 (84.1 to 119.9)	99.7 (62.0 to 141.6)	202.0 (124.4 to 288.6)	102.8 (85.5 to 122.6)
Tension-type headache	13,230.1 (12,642.6 to 13,879.2)	29,338.6 (28,070.2 to 30,511.4)	122.4 (108.9 to 135.9)	17.9 (9.0 to 30.8)	40.1 (20.1 to 69.4)	123.5 (109.4 to 137.4)
Medication overuse headache	374.4 (258.6 to 496.5)	1,174.6 (799.8 to 1,516.9)	214.5 (180.0 to 250.2)	51.1 (30.7 to 76.2)	162.6 (97.1 to 243.6)	217.5 (182.9 to 257.4)
Other neurological disorders	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.5)	108.0 (85.2 to 130.3)	467.7 (337.7 to 616.2)	682.7 (487.2 to 884.6)	46.9 (30.5 to 58.8)
Mental and substance use disorders	-	-	-	923.2 (673.5 to 1,220.0)	1,959.7 (1,425.9 to 2,605.8)	112.3 (108.6 to 115.5)
Schizophrenia	30.1 (27.7 to 32.8)	69.3 (64.3 to 75.3)	131.1 (126.5 to 136.1)	16.1 (12.2 to 19.6)	37.9 (28.7 to 45.8)	134.2 (114.8 to 155.8)
Alcohol use disorders	205.6 (185.9 to 225.4)	436.8 (393.6 to 480.6)	113.0 (109.2 to 116.6)	17.9 (12.4 to 25.4)	38.5 (26.1 to 54.4)	114.7 (105.5 to 124.3)
Drug use disorders	-	-	-	4.3 (3.0 to 5.8)	10.2 (7.0 to 13.9)	137.0 (106.6 to 168.9)
Opioid use disorders	3.8 (3.3 to 4.3)	8.2 (7.1 to 9.5)	118.4 (110.5 to 125.9)	1.4 (1.0 to 1.9)	3.1 (2.1 to 4.1)	117.9 (77.5 to 169.5)
Cocaine use disorders	0.2 (0.2 to 0.2)	0.6 (0.5 to 0.6)	199.4 (166.2 to 233.2)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	199.7 (166.3 to 233.6)
Amphetamine use disorders	11.9 (11.6 to 12.1)	29.4 (28.7 to 30.2)	148.8 (140.6 to 158.0)	1.4 (0.9 to 2.0)	3.4 (2.2 to 5.0)	145.9 (107.5 to 189.4)
Cannabis use disorders	1.4 (1.1 to 1.7)	2.9 (2.3 to 3.5)	108.7 (98.8 to 119.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	108.9 (99.0 to 119.4)
Other drug use disorders	-	-	-	1.4 (0.9 to 2.1)	3.6 (2.3 to 5.1)	146.8 (107.8 to 193.2)
Depressive disorders	-	-	-	559.6 (385.3 to 787.8)	1,186.1 (818.0 to 1,675.5)	111.9 (106.6 to 116.4)
Major depressive disorder	2,523.8 (1,978.8 to 3,117.5)	5,261.0 (4,065.0 to 6,581.6)	109.0 (102.3 to 114.0)	443.0 (292.9 to 637.0)	937.3 (609.5 to 1,356.3)	111.6 (104.6 to 117.2)
Dysthymia	1,365.9 (1,173.4 to 1,555.5)	2,874.7 (2,468.1 to 3,277.1)	111.1 (107.2 to 114.1)	116.6 (79.9 to 164.3)	248.8 (170.6 to 351.2)	113.4 (108.2 to 117.6)
Bipolar disorder	278.9 (233.1 to 333.0)	598.6 (500.8 to 707.4)	115.3 (110.8 to 119.9)	48.1 (30.3 to 71.3)	104.9 (66.4 to 156.1)	118.1 (109.2 to 127.6)
Anxiety disorders	1,670.4 (1,312.5 to 2,043.4)	3,326.3 (2,597.1 to 4,106.2)	99.6 (94.3 to 104.9)	130.4 (89.7 to 182.5)	263.5 (177.3 to 372.4)	101.9 (94.6 to 108.7)
Eating disorders	-	-	-	-	-	-
Anorexia nervosa	-	-	-	-	-	-
Bulimia nervosa	-	-	-	-	-	-
Autistic spectrum disorders	-	-	-	35.9 (25.7 to 47.3)	80.3 (57.1 to 105.4)	123.7 (117.2 to 130.0)
Autism	109.9 (101.0 to 120.0)	241.4 (222.0 to 263.3)	120.3 (118.7 to 121.7)	23.0 (16.4 to 31.0)	51.3 (35.8 to 69.3)	122.8 (114.1 to 132.0)
Asperger syndrome	147.9 (130.7 to 165.3)	328.8 (290.2 to 367.6)	122.8 (122.1 to 123.5)	12.9 (9.1 to 17.6)	29.1 (20.6 to 39.4)	124.8 (117.9 to 132.8)
Attention-deficit/hyperactivity disorder	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.3 (58.5 to 142.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.4 (58.4 to 142.9)
Conduct disorder	-	-	-	-	-	-
Idiopathic intellectual disability	212.7 (150.4 to 289.8)	404.1 (287.0 to 541.8)	91.0 (68.1 to 114.6)	9.7 (5.9 to 14.2)	18.4 (11.5 to 26.5)	90.3 (67.0 to 115.3)
Other mental and substance use disorders	1,564.8 (1,189.4 to 1,964.2)	3,355.2 (2,556.8 to 4,249.8)	114.8 (111.0 to 119.1)	101.1 (66.9 to 144.6)	220.0 (144.7 to 313.4)	117.6 (111.6 to 123.7)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	1,095.7 (801.8 to 1,409.7)	2,851.3 (2,059.5 to 3,722.2)	160.3 (149.1 to 170.2)
Diabetes mellitus	4,454.0 (3,791.8 to 5,511.5)	14,709.0 (12,335.4 to 17,876.5)	231.2 (200.6 to 263.7)	415.1 (289.5 to 559.8)	1,326.3 (915.6 to 1,787.8)	220.0 (193.1 to 244.3)
Acute glomerulonephritis	0.5 (0.4 to 0.6)	0.9 (0.8 to 1.0)	90.4 (85.3 to 94.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	90.8 (85.7 to 95.2)
Chronic kidney disease	-	-	-	347.0 (257.6 to 451.6)	733.6 (546.4 to 947.7)	111.7 (103.0 to 119.8)
Chronic kidney disease due to diabetes mellitus	2,745.8 (1,799.4 to 3,764.0)	7,798.7 (5,726.9 to 10,386.5)	185.3 (153.4 to 228.6)	43.0 (31.1 to 56.9)	133.4 (98.1 to 173.4)	210.8 (176.3 to 252.9)
Chronic kidney disease due to hypertension	2,818.1 (2,060.0 to 3,716.4)	5,278.0 (3,763.8 to 6,890.3)	87.5 (70.6 to 108.3)	98.9 (73.2 to 129.0)	140.4 (105.0 to 181.4)	42.7 (26.6 to 55.4)
Chronic kidney disease due to glomerulonephritis	5,179.3 (3,355.9 to 7,280.4)	7,821.1 (5,148.2 to 10,515.4)	52.5 (28.5 to 78.1)	40.5 (29.7 to 52.7)	99.3 (72.0 to 129.3)	144.8 (117.5 to 176.0)
Chronic kidney disease due to other causes	9,288.8 (6,178.9 to 12,766.8)	18,061.1 (12,532.6 to 23,786.2)	96.1 (78.3 to 112.8)	164.7 (120.3 to 215.7)	360.5 (266.8 to 467.4)	119.1 (105.0 to 134.7)
Urinary diseases and male infertility	-	-	-	260.9 (174.3 to 359.8)	639.1 (424.6 to 887.1)	145.3 (135.5 to 152.7)
Interstitial nephritis and urinary tract infections	35.4 (34.2 to 36.6)	92.1 (88.8 to 95.5)	160.6 (147.0 to 175.4)	1.1 (0.7 to 1.5)	2.8 (1.8 to 4.1)	163.0 (135.5 to 192.4)
Urolithiasis	3,793.9 (2,946.4 to 4,648.1)	10,222.7 (7,957.2 to 12,491.8)	170.2 (159.6 to 180.5)	20.3 (13.2 to 29.6)	60.9 (38.9 to 89.9)	200.0 (186.4 to 209.8)
Benign prostatic hyperplasia	6,964.7 (6,733.7 to 7,196.9)	16,181.3 (15,799.7 to 16,586.7)	132.9 (123.1 to 142.5)	233.8 (155.4 to 322.7)	550.0 (365.2 to 760.4)	135.3 (124.9 to 145.3)
Male infertility due to other causes	-	-	-	-	-	-
Other urinary diseases	-	-	-	5.7 (3.4 to 8.9)	25.4 (13.3 to 39.4)	357.7 (233.3 to 450.4)
Gynecological diseases	-	-	-	3.4 (1.7 to 6.3)	7.0 (3.5 to 12.8)	104.0 (91.9 to 115.9)
Uterine fibroids	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.4)	99.3 (98.5 to 100.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.6 (98.8 to 100.5)
Polycystic ovarian syndrome	-	-	-	-	-	-
Female infertility due to other causes	-	-	-	-	-	-
Endometriosis	-	-	-	-	-	-
Genital prolapse	1,200.3 (1,158.8 to 1,243.6)	2,411.3 (2,329.2 to 2,489.1)	101.5 (91.6 to 111.5)	3.4 (1.7 to 6.3)	7.0 (3.5 to 12.8)	104.0 (91.9 to 115.9)
Premenstrual syndrome	-	-	-	-	-	-
Other gynecological diseases	-	-	0.0 (0.0 to 0.0)	-	-	-
Hemoglobinopathies and hemolytic anemias	-	-	-	38.8 (26.6 to 54.2)	80.8 (55.0 to 114.0)	108.1 (90.8 to 127.3)
Thalassemias	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	197.1 (168.5 to 234.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	198.8 (169.1 to 236.5)
Thalassemia trait	1,344.0 (1,194.0 to 1,540.7)	3,038.1 (2,715.8 to 3,434.7)	126.5 (122.3 to 132.9)	21.1 (14.6 to 29.1)	47.8 (33.0 to 68.0)	126.9 (111.1 to 142.6)
Sickle cell disorders	0.3 (0.3 to 0.3)	0.7 (0.6 to 0.7)	120.6 (102.1 to 135.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	110.3 (88.7 to 139.5)
Sickle cell trait	1,111.5 (1,059.6 to 1,157.6)	2,262.9 (2,161.2 to 2,354.4)	104.0 (101.5 to 106.9)	3.8 (2.5 to 5.5)	7.8 (5.0 to 11.3)	108.4 (62.2 to 145.1)
G6PD deficiency	1,487.7 (1,455.3 to 1,518.8)	3,246.9 (3,174.2 to 3,315.9)	118.9 (112.2 to 125.1)	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.6)	140.2 (106.9 to 161.5)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (80+ years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
G6PD trait	10,157.0 (10,086.8 to 10,230.7)	20,334.4 (20,214.0 to 20,456.7)	100.7 (98.9 to 102.6)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	14.7 (-30.9 to 90.9)
Other hemoglobinopathies and hemolytic anemias	626.0 (600.0 to 661.2)	1,455.2 (1,348.2 to 1,586.0)	132.6 (112.0 to 156.1)	13.5 (9.1 to 19.1)	24.6 (16.0 to 35.6)	80.2 (44.8 to 123.0)
Endocrine, metabolic, blood, and immune disorders	1,009.3 (980.2 to 1,041.4)	2,197.8 (2,128.7 to 2,271.9)	118.0 (109.1 to 128.6)	30.5 (22.0 to 40.6)	64.4 (46.3 to 84.5)	110.9 (100.0 to 124.2)
Musculoskeletal disorders	-	-	-	3,251.5 (2,419.1 to 4,161.5)	6,917.7 (5,129.3 to 8,870.4)	112.7 (108.4 to 117.4)
Rheumatoid arthritis	960.2 (939.9 to 979.0)	1,999.1 (1,961.3 to 2,034.0)	108.7 (103.6 to 114.2)	198.4 (146.9 to 253.6)	419.7 (309.2 to 534.2)	111.5 (104.9 to 118.6)
Osteoarthritis	18,908.1 (18,692.5 to 19,125.7)	39,231.8 (38,748.9 to 39,665.7)	108.0 (104.4 to 111.8)	840.9 (597.7 to 1,124.5)	1,785.8 (1,273.5 to 2,387.1)	112.4 (109.0 to 115.6)
Low back and neck pain	-	-	-	1,907.5 (1,357.7 to 2,499.3)	4,065.6 (2,922.4 to 5,303.6)	112.8 (107.1 to 120.4)
Low back pain	15,447.8 (15,050.0 to 15,782.6)	32,396.6 (31,631.2 to 33,256.5)	110.1 (103.4 to 117.2)	1,511.6 (1,069.3 to 2,025.1)	3,216.3 (2,250.5 to 4,332.5)	112.5 (105.8 to 120.1)
Neck pain	4,562.3 (4,367.1 to 4,765.1)	9,648.0 (9,298.8 to 9,998.2)	112.0 (99.9 to 125.4)	396.0 (283.2 to 536.3)	849.3 (612.4 to 1,125.9)	114.4 (102.5 to 127.9)
Gout	274.0 (267.6 to 281.1)	576.3 (564.2 to 590.4)	110.8 (104.5 to 117.8)	7.7 (5.4 to 10.0)	16.3 (11.4 to 21.5)	113.1 (95.6 to 132.0)
Other musculoskeletal disorders	3,672.9 (2,525.1 to 5,110.4)	7,690.9 (4,979.7 to 10,744.9)	109.6 (91.8 to 125.5)	297.1 (177.3 to 459.2)	630.3 (366.0 to 977.5)	111.8 (94.0 to 127.9)
Other non-communicable diseases	-	-	-	4,673.3 (3,380.2 to 6,201.3)	9,435.7 (6,882.0 to 12,583.5)	101.9 (98.3 to 105.6)
Congenital anomalies	-	-	-	31.0 (23.3 to 40.2)	87.3 (66.6 to 108.8)	182.2 (155.9 to 209.0)
Neural tube defects	0.0 (0.0 to 0.0)	0.2 (0.2 to 0.2)	844.6 (531.5 to 1,253.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	1,251.2 (710.0 to 2,032.8)
Congenital heart anomalies	64.0 (57.0 to 72.5)	232.4 (209.5 to 255.9)	266.0 (209.9 to 321.7)	2.0 (1.0 to 3.3)	7.3 (3.3 to 12.3)	256.0 (198.8 to 324.1)
Orofacial clefts	9.1 (8.2 to 9.9)	43.6 (41.0 to 46.3)	382.6 (330.6 to 442.9)	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.6)	375.6 (299.9 to 463.1)
Down syndrome	16.3 (13.8 to 18.8)	74.9 (64.3 to 83.8)	360.4 (298.8 to 434.2)	3.4 (2.4 to 4.4)	15.6 (11.7 to 19.8)	366.3 (287.9 to 454.3)
Turner syndrome	0.0 (0.0 to 0.1)	0.3 (0.2 to 0.3)	450.7 (303.0 to 671.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	451.6 (303.5 to 675.1)
Klinefelter syndrome	0.5 (0.5 to 0.6)	1.7 (1.6 to 1.8)	209.7 (177.3 to 245.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	209.8 (177.4 to 245.7)
Chromosomal unbalanced rearrangements	26.7 (22.3 to 32.0)	115.1 (100.5 to 127.6)	333.8 (266.7 to 412.2)	5.5 (4.0 to 7.2)	23.8 (17.5 to 30.1)	336.0 (261.8 to 423.5)
Other congenital anomalies	212.5 (178.7 to 246.1)	386.7 (323.5 to 449.4)	82.6 (72.6 to 91.4)	20.1 (14.0 to 27.5)	40.1 (28.5 to 53.6)	99.9 (81.3 to 121.7)
Skin and subcutaneous diseases	-	-	-	330.8 (226.8 to 493.6)	704.7 (484.7 to 1,054.1)	112.9 (105.9 to 120.8)
Dermatitis	1,626.4 (1,199.3 to 1,993.6)	3,423.6 (2,494.7 to 4,196.2)	110.9 (108.4 to 113.1)	41.9 (26.0 to 62.5)	88.5 (55.3 to 131.6)	111.3 (104.0 to 117.8)
Psoriasis	576.2 (473.8 to 689.1)	1,216.7 (989.5 to 1,471.1)	111.7 (107.2 to 115.7)	40.3 (27.7 to 57.5)	86.5 (59.0 to 124.8)	114.4 (104.8 to 123.7)
Cellulitis	69.0 (48.8 to 92.3)	123.9 (87.7 to 166.8)	80.2 (72.0 to 87.4)	4.3 (2.6 to 6.5)	7.7 (4.7 to 11.9)	80.9 (63.2 to 101.9)
Pyoderma	76.7 (46.8 to 114.5)	152.7 (92.1 to 239.2)	99.5 (78.4 to 119.0)	0.4 (0.1 to 0.9)	0.8 (0.3 to 1.7)	100.5 (76.0 to 122.6)
Scabies	171.2 (160.9 to 183.3)	366.5 (345.5 to 390.3)	115.3 (93.7 to 135.5)	4.0 (2.3 to 6.2)	8.6 (5.1 to 13.5)	117.5 (95.5 to 139.9)
Fungal skin diseases	5,864.7 (4,737.7 to 6,856.3)	12,558.2 (10,222.8 to 14,654.2)	114.7 (111.7 to 117.8)	29.8 (12.1 to 62.4)	64.5 (26.3 to 134.7)	116.7 (113.4 to 120.2)
Viral skin diseases	495.1 (333.7 to 666.4)	1,031.1 (690.0 to 1,394.5)	108.6 (105.0 to 113.1)	13.4 (7.6 to 21.9)	28.3 (16.1 to 45.8)	110.9 (103.6 to 118.8)
Acne vulgaris	218.0 (201.0 to 233.9)	424.7 (381.8 to 476.3)	94.7 (74.4 to 128.0)	2.1 (1.0 to 3.9)	4.1 (2.0 to 7.4)	96.1 (74.8 to 130.9)
Alopecia areata	249.9 (234.6 to 267.0)	539.1 (483.4 to 584.0)	116.7 (94.2 to 137.8)	7.5 (4.9 to 11.0)	16.3 (10.7 to 24.0)	118.5 (94.0 to 142.1)
Pruritus	18.5 (17.2 to 19.8)	42.2 (38.8 to 47.2)	127.5 (104.1 to 161.6)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.8)	130.0 (98.7 to 169.5)
Urticaria	1,602.4 (1,466.0 to 1,752.7)	3,446.7 (3,166.3 to 3,724.8)	116.0 (91.6 to 141.8)	84.2 (55.9 to 117.2)	183.3 (120.9 to 255.7)	117.5 (94.4 to 143.9)
Decubitus ulcer	318.4 (302.5 to 336.4)	640.5 (602.7 to 678.6)	102.2 (83.2 to 118.0)	41.9 (29.9 to 54.4)	85.5 (61.1 to 112.9)	104.3 (85.0 to 122.9)
Other skin and subcutaneous diseases	11,382.4 (2,815.0 to 27,431.5)	24,031.3 (5,975.3 to 58,026.2)	111.7 (107.1 to 116.0)	60.9 (12.8 to 171.2)	130.1 (27.1 to 362.4)	113.6 (108.9 to 118.1)
Sense organ diseases	-	-	-	3,680.5 (2,677.5 to 4,871.0)	7,477.1 (5,465.8 to 9,942.4)	103.1 (98.8 to 107.7)
Glaucoma	906.1 (735.7 to 1,103.2)	1,669.0 (1,357.8 to 1,957.1)	85.7 (66.4 to 104.9)	78.7 (53.6 to 111.2)	150.5 (100.7 to 208.1)	92.0 (73.9 to 108.3)
Cataract	6,382.2 (5,357.6 to 7,248.2)	10,807.2 (9,059.6 to 12,267.0)	69.5 (62.9 to 78.9)	411.9 (284.8 to 558.3)	751.5 (519.6 to 1,022.1)	82.1 (75.5 to 89.9)
Macular degeneration	1,367.4 (1,099.0 to 1,643.0)	2,858.8 (2,310.2 to 3,393.8)	110.1 (94.4 to 123.4)	108.8 (73.3 to 151.6)	205.7 (139.5 to 286.4)	89.6 (76.3 to 102.7)
Uncorrected refractive error	31,443.8 (30,392.2 to 32,531.3)	61,478.8 (59,459.2 to 63,352.7)	95.9 (89.8 to 103.2)	515.8 (338.1 to 764.2)	969.4 (632.7 to 1,470.6)	87.6 (82.8 to 93.1)
Age-related and other hearing loss	52,413.7 (51,601.1 to 52,900.3)	109,730.2 (107,769.1 to 110,924.9)	109.9 (108.9 to 110.6)	2,398.9 (1,733.6 to 3,193.1)	5,092.9 (3,673.1 to 6,759.1)	112.2 (105.5 to 119.8)
Other vision loss	1,575.2 (1,192.3 to 2,051.7)	2,462.9 (1,898.1 to 3,216.0)	57.2 (45.4 to 68.0)	104.2 (68.2 to 146.6)	174.7 (116.9 to 248.5)	67.6 (58.7 to 76.8)
Other sense organ diseases	2,664.2 (2,589.2 to 2,743.7)	5,599.5 (5,460.5 to 5,758.7)	110.8 (103.1 to 118.4)	62.2 (39.6 to 89.2)	132.4 (83.1 to 189.7)	112.8 (104.3 to 121.6)
Oral disorders	-	-	-	631.0 (432.3 to 866.7)	1,166.6 (796.6 to 1,615.7)	84.7 (81.0 to 88.8)
Deciduous caries	-	-	-	-	-	-
Permanent caries	14,150.4 (13,915.1 to 14,384.6)	33,077.4 (32,431.1 to 33,605.0)	134.5 (128.8 to 139.9)	9.8 (4.6 to 18.2)	23.8 (11.2 to 44.5)	143.3 (137.1 to 149.4)
Periodontal diseases	8,173.9 (8,026.8 to 8,317.5)	18,595.8 (18,286.0 to 18,936.3)	127.9 (122.8 to 134.0)	48.4 (19.7 to 97.0)	111.5 (45.4 to 227.7)	130.1 (124.8 to 136.3)
Edentulism and severe tooth loss	21,572.3 (21,272.0 to 21,858.5)	38,252.6 (37,780.9 to 38,727.0)	77.7 (74.7 to 81.1)	550.3 (381.7 to 743.8)	984.0 (682.7 to 1,325.8)	78.8 (75.6 to 82.2)
Other oral disorders	861.7 (835.6 to 885.4)	1,787.7 (1,725.9 to 1,842.9)	107.9 (99.8 to 116.8)	22.6 (14.6 to 32.7)	47.3 (30.5 to 68.5)	109.6 (101.2 to 119.9)
Injuries	-	-	-	3,043.0 (2,349.1 to 3,781.4)	4,195.4 (3,101.7 to 5,447.2)	37.4 (21.7 to 55.1)
Transport injuries	-	-	-	309.2 (231.9 to 401.6)	548.4 (395.1 to 726.6)	77.1 (69.2 to 84.5)
Road injuries	-	-	-	247.7 (181.6 to 323.7)	453.8 (325.6 to 603.7)	83.1 (76.8 to 88.7)
Pedestrian road injuries	-	-	-	79.3 (59.2 to 102.8)	153.0 (110.1 to 203.9)	92.5 (84.6 to 100.5)

Appendix Table G.3: Prevalence and YLDs with percent change between 1990 and 2013 by age for all causes (80+ years)

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013
Cyclist road injuries	-	-	-	31.9 (23.8 to 41.5)	57.8 (41.4 to 76.1)	80.8 (72.3 to 89.3)
Motorcyclist road injuries	-	-	-	28.4 (20.4 to 38.2)	52.1 (36.7 to 71.0)	83.1 (78.0 to 88.0)
Motor vehicle road injuries	-	-	-	105.0 (76.5 to 137.6)	186.7 (134.1 to 248.4)	77.8 (72.2 to 82.8)
Other road injuries	-	-	-	3.0 (2.2 to 3.9)	4.2 (3.0 to 5.6)	40.2 (35.7 to 45.2)
Other transport injuries	-	-	-	61.6 (47.1 to 77.6)	94.6 (68.8 to 123.2)	53.4 (38.2 to 69.5)
Unintentional injuries	-	-	-	2,421.0 (1,875.7 to 3,018.9)	3,372.7 (2,493.0 to 4,410.4)	38.6 (23.7 to 57.2)
Falls	-	-	-	2,111.8 (1,641.2 to 2,618.7)	2,799.3 (2,079.2 to 3,623.9)	31.8 (16.0 to 51.7)
Drowning	-	-	-	9.5 (7.0 to 12.3)	16.4 (11.8 to 21.8)	73.0 (64.3 to 81.1)
Fire, heat, and hot substances	-	-	-	37.7 (25.6 to 53.5)	60.6 (40.4 to 87.6)	60.8 (54.2 to 67.4)
Poisonings	-	-	-	2.1 (1.6 to 2.7)	3.1 (2.3 to 3.9)	43.3 (33.3 to 53.8)
Exposure to mechanical forces	-	-	-	85.3 (61.8 to 114.1)	156.6 (112.1 to 212.5)	83.4 (78.7 to 87.8)
Unintentional firearm injuries	-	-	-	2.5 (1.9 to 3.4)	4.4 (3.1 to 6.1)	74.0 (66.8 to 80.9)
Unintentional suffocation	-	-	-	1.1 (0.8 to 1.5)	3.2 (2.2 to 4.2)	174.4 (162.4 to 184.1)
Other exposure to mechanical forces	-	-	-	81.6 (59.1 to 109.2)	149.0 (106.6 to 202.1)	82.3 (77.8 to 86.9)
Adverse effects of medical treatment	-	-	-	9.0 (5.7 to 13.1)	18.8 (11.9 to 27.8)	109.7 (100.5 to 119.0)
Animal contact	-	-	-	10.0 (7.3 to 13.3)	17.0 (12.2 to 23.0)	70.6 (63.5 to 77.0)
Venomous animal contact	-	-	-	2.0 (1.5 to 2.6)	3.2 (2.3 to 4.2)	58.3 (50.1 to 66.3)
Non-venomous animal contact	-	-	-	7.9 (5.8 to 10.6)	13.8 (9.8 to 18.9)	73.8 (65.9 to 80.7)
Foreign body	-	-	-	8.2 (6.4 to 10.2)	15.8 (12.2 to 20.1)	93.8 (84.4 to 102.4)
Pulmonary aspiration and foreign body in airway	-	-	-	2.8 (2.2 to 3.6)	5.3 (4.0 to 6.8)	87.8 (73.8 to 101.5)
Foreign body in eyes	-	-	-	0.7 (0.5 to 0.9)	1.4 (1.0 to 1.9)	96.4 (89.4 to 103.4)
Foreign body in other body part	-	-	-	4.6 (3.5 to 5.8)	9.1 (6.8 to 11.6)	97.1 (88.4 to 105.8)
Other unintentional injuries	-	-	-	147.6 (106.8 to 196.8)	285.1 (204.6 to 382.9)	92.9 (85.5 to 101.0)
Self-harm and interpersonal violence	-	-	-	25.1 (18.5 to 32.7)	40.1 (28.8 to 54.2)	59.3 (51.7 to 66.8)
Self-harm	-	-	-	9.4 (7.0 to 12.1)	13.4 (9.6 to 18.0)	41.8 (32.2 to 51.7)
Interpersonal violence	-	-	-	15.7 (11.5 to 20.6)	26.8 (19.2 to 36.1)	69.8 (63.2 to 76.2)
Assault by firearm	-	-	-	2.9 (2.1 to 3.9)	5.6 (4.0 to 7.6)	90.4 (85.2 to 94.9)
Assault by sharp object	-	-	-	2.5 (1.8 to 3.4)	4.6 (3.2 to 6.4)	81.2 (73.9 to 89.0)
Assault by other means	-	-	-	10.3 (7.6 to 13.4)	16.6 (12.0 to 22.0)	61.1 (54.2 to 68.0)
Forces of nature, war, and legal intervention	-	-	-	287.6 (126.9 to 510.5)	234.3 (106.5 to 431.6)	-19.3 (-37.7 to 14.6)
Exposure to forces of nature	-	-	-	15.2 (8.0 to 25.5)	21.1 (10.8 to 37.4)	38.0 (-12.0 to 122.2)
Collective violence and legal intervention	-	-	-	272.4 (115.8 to 491.9)	213.1 (94.1 to 404.7)	-22.6 (-40.5 to 9.9)

Appendix Table G.4 - Afghanistan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,257.0 (890.6 to 1,700.3)	2,902.6 (2,115.8 to 3,806.0)	132.5 (105.6 to 152.5)	-9.4 (-18.2 to -3.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	355.1 (241.5 to 496.4)	761.4 (525.3 to 1,071.7)	114.5 (99.8 to 130.1)	-14.5 (-18.9 to -10.1)
HIV/AIDS and tuberculosis	-	-	-	-	1.8 (1.2 to 2.6)	5.9 (3.9 to 8.8)	217.8 (175.5 to 271.8)	20.6 (7.4 to 39.4)
Tuberculosis	5.8 (5.5 to 6.1)	17.9 (17.4 to 18.3)	207.1 (193.7 to 223.7)	16.0 (11.2 to 21.1)	1.8 (1.2 to 2.4)	5.5 (3.7 to 7.4)	210.4 (170.8 to 250.0)	17.3 (6.5 to 28.1)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.5)	0.4 (0.1 to 0.7)	109.0 (52.2 to 1,746.8)	131.8 (52.2 to 1,746.8)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	606.8 (54.0 to 4,263.3)	172.0 (-40.8 to 1,641.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	606.8 (53.4 to 4,267.3)	172.0 (-42.0 to 1,644.7)
HIV/AIDS resulting in other diseases	0.7 (0.0 to 3.6)	3.2 (0.5 to 15.0)	577.6 (63.2 to 3,796.3)	167.2 (-36.4 to 1,455.1)	0.1 (0.0 to 0.5)	0.4 (0.0 to 2.3)	552.8 (43.8 to 5,585.7)	153.2 (-45.9 to 2,029.7)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	57.7 (40.9 to 78.5)	108.8 (77.0 to 147.8)	88.5 (74.8 to 102.5)	-13.8 (-19.7 to -7.6)
Diarrheal diseases	209.9 (200.5 to 219.1)	437.6 (404.7 to 467.4)	108.3 (91.1 to 125.7)	-0.9 (-8.4 to 7.5)	33.9 (23.9 to 46.9)	70.5 (48.0 to 98.5)	109.0 (90.6 to 127.7)	-42.2 (-8.7 to 8.5)
Intestinal infectious diseases	-	-	-	-	0.9 (0.6 to 1.4)	1.5 (1.0 to 2.2)	60.2 (21.3 to 115.2)	33.3 (-48.1 to -11.7)
Typhoid fever	4.9 (4.2 to 5.8)	8.6 (7.2 to 10.1)	75.2 (40.9 to 121.4)	-26.8 (-41.2 to -8.3)	0.6 (0.4 to 0.9)	1.1 (0.7 to 1.7)	76.5 (29.5 to 141.2)	-26.3 (-43.5 to -2.6)
Paratyphoid fever	2.6 (2.2 to 3.1)	4.7 (3.8 to 5.5)	78.4 (40.0 to 129.0)	-26.6 (-42.5 to -5.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	80.1 (28.2 to 153.5)	26.1 (-44.6 to 3.3)
Other intestinal infectious diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.3)	-21.8 (-83.7 to 37.8)	-88.9 (-83.7 to 37.8)
Lower respiratory infections	63.4 (54.3 to 71.3)	114.2 (91.9 to 132.8)	78.9 (47.5 to 118.4)	-7.8 (-21.9 to 10.3)	6.7 (4.3 to 9.4)	11.9 (7.7 to 17.2)	78.4 (60.4 to 120.0)	8.5 (-23.0 to 10.2)
Upper respiratory infections	254.7 (228.6 to 279.2)	634.9 (560.2 to 703.0)	148.9 (112.7 to 189.1)	0.2 (-14.3 to 15.1)	3.0 (1.7 to 5.0)	7.5 (4.1 to 12.8)	149.1 (113.3 to 190.7)	0.8 (-14.2 to 16.2)
Otitis media	161.6 (149.6 to 172.6)	359.9 (333.1 to 392.3)	122.5 (101.8 to 144.5)	-9.9 (-18.4 to -0.5)	3.0 (1.8 to 4.8)	6.5 (3.8 to 10.8)	120.7 (98.5 to 143.7)	-10.4 (-19.5 to -1.5)
Meningitis	-	-	-	-	6.6 (4.4 to 9.0)	7.2 (4.9 to 10.0)	10.6 (-15.2 to 35.0)	-53.8 (-62.5 to -44.7)
Pneumococcal meningitis	23.3 (14.3 to 34.1)	25.0 (15.5 to 37.0)	7.2 (-18.0 to 42.4)	-55.9 (-65.1 to -41.0)	2.4 (1.4 to 2.9)	2.4 (1.5 to 3.4)	13.5 (-23.3 to 59.0)	-52.3 (-64.8 to -36.8)
H influenzae type B meningitis	16.7 (6.8 to 30.7)	17.9 (8.4 to 31.3)	7.5 (-22.8 to 62.0)	-58.4 (-68.8 to -37.8)	1.8 (1.1 to 2.9)	2.3 (1.2 to 3.8)	27.3 (-34.4 to 105.2)	-49.6 (-72.6 to -21.1)
Meningococcal meningitis	9.8 (3.5 to 20.0)	8.4 (3.3 to 17.5)	-13.9 (-38.2 to 23.9)	-63.3 (-73.0 to -49.6)	1.2 (0.6 to 2.0)	1.1 (0.7 to 1.6)	-13.0 (-40.1 to 43.6)	-63.3 (-73.8 to -43.4)
Other meningitis	11.2 (7.0 to 17.6)	12.1 (7.3 to 19.3)	8.5 (-14.6 to 31.6)	-50.7 (-61.4 to -39.8)	1.4 (0.9 to 2.0)	1.5 (1.0 to 2.1)	5.5 (-20.7 to 44.5)	-51.4 (-63.2 to -35.0)
Encephalitis	9.6 (1.7 to 7.4)	7.5 (3.6 to 14.9)	-21.6 (-87.0 to 135.8)	-91.1 (-93.9 to -88.3)	0.5 (0.3 to 0.6)	1.0 (0.7 to 1.3)	113.6 (83.9 to 152.4)	-44.5 (-26.4 to -1.1)
Diphtheria	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-49.5 (-96.2 to 838.8)	-74.0 (-97.4 to 178.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.5 (-96.2 to 845.3)	-74.0 (-97.4 to 182.0)
Whooping cough	41.2 (31.4 to 53.9)	34.2 (26.5 to 43.9)	-16.9 (-21.2 to -12.4)	-55.7 (-58.0 to -53.3)	2.0 (1.2 to 3.3)	1.7 (1.0 to 2.8)	-16.7 (-23.9 to -8.9)	-55.5 (-93.3 to -51.4)
Tetanus	1.5 (0.9 to 3.0)	1.3 (0.7 to 1.9)	-8.8 (-72.2 to 64.7)	-58.1 (-89.3 to -20.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-7.8 (-55.0 to 71.6)	-52.0 (-79.9 to -8.2)
Measles	10.4 (7.2 to 14.3)	0.7 (0.4 to 1.0)	-93.7 (-95.7 to -91.1)	-95.8 (-97.8 to -95.5)	0.9 (0.5 to 1.5)	0.1 (0.0 to 0.1)	99.8 (-96.8 to -88.8)	-96.9 (-98.4 to -94.4)
Varicella and herpes zoster	11.1 (10.1 to 11.9)	25.4 (23.6 to 27.3)	127.9 (106.8 to 158.3)	3.5 (-15.9 to 23.5)	0.4 (0.1 to 0.3)	0.4 (0.2 to 0.7)	176.3 (103.2 to 280.9)	6.4 (-26.1 to 47.1)
Neglected tropical diseases and malaria	-	-	-	-	40.0 (23.2 to 64.6)	75.0 (45.2 to 120.2)	87.2 (58.8 to 123.5)	-27.6 (-39.8 to -12.1)
Malaria	52.2 (40.2 to 68.3)	87.4 (68.7 to 115.0)	67.2 (32.6 to 106.2)	-41.5 (-55.1 to -26.2)	0.6 (0.3 to 0.9)	1.1 (0.7 to 1.7)	100.0 (44.9 to 170.3)	-22.8 (-39.8 to 1.1)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	6.2 (2.7 to 12.6)	19.5 (8.3 to 39.7)	212.6 (156.7 to 279.4)	14.6 (-3.7 to 36.2)
Visceral leishmaniasis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-0.4 (-42.6 to 119.3)	-55.4 (-71.2 to -9.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.4 (-42.7 to 119.4)	-55.4 (-71.2 to -9.8)
Cutaneous and mucocutaneous leishmaniasis	588.2 (402.7 to 834.0)	1,836.7 (1,297.0 to 2,572.5)	211.3 (156.2 to 277.5)	13.8 (-3.8 to 35.1)	6.2 (2.7 to 12.6)	19.5 (8.3 to 39.7)	212.7 (156.8 to 279.5)	14.6 (-3.7 to 36.2)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	245.0 (-30.4 to 981.0)	14.5 (-75.0 to 258.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	259.9 (-27.6 to 1,035.5)	19.3 (-74.5 to 278.1)
Cystic echinococcosis	0.8 (0.7 to 0.9)	0.9 (0.9 to 1.1)	17.1 (8.1 to 33.9)	-56.6 (-60.3 to -50.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	19.3 (-6.1 to 52.1)	55.7 (-66.1 to -42.2)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	21.5 (9.4 to 40.4)	19.3 (8.0 to 34.3)	-9.7 (-38.3 to 33.8)	-73.3 (-81.5 to -57.5)	1.5 (0.6 to 3.0)	1.3 (0.5 to 2.4)	-10.5 (-39.4 to 28.4)	-73.4 (-81.5 to -57.5)
Dengue	0.5 (0.2 to 1.4)	6.2 (1.9 to 16.6)	1,110.7 (1,095.9 to 1,127.9)	365.5 (359.8 to 372.1)	0.1 (0.0 to 0.2)	1.0 (0.3 to 2.8)	1,049.1 (840.3 to 1,314.1)	332.5 (270.9 to 416.5)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.5 (-9.8 to 132.8)	-40.0 (-59.1 to -12.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.5 (-9.9 to 133.2)	-40.0 (-59.1 to -12.1)
Intestinal nematode infections	-	-	-	-	18.5 (9.7 to 32.7)	23.1 (11.8 to 42.9)	23.9 (-14.6 to 85.5)	43.7 (-64.2 to -9.3)
Ascariasis	4,569.8 (3,681.3 to 5,752.0)	11,377.7 (8,255.9 to 15,415.0)	148.0 (69.6 to 262.3)	-3.4 (-40.3 to 59.1)	18.0 (9.4 to 32.1)	21.9 (11.0 to 51.5)	20.7 (-18.2 to 83.1)	45.3 (-65.8 to -9.9)
Trichuriasis	1,122.6 (761.3 to 1,648.9)	2,887.1 (1,932.1 to 4,163.4)	157.7 (49.3 to 337.7)	-1.4 (-50.3 to 93.4)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.8)	169.8 (26.1 to 482.4)	4.7 (-56.7 to 160.0)
Hookworm disease	88.8 (60.0 to 131.1)	223.7 (154.3 to 318.3)	151.7 (54.6 to 324.4)	43.5 (-48.3 to 82.8)	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.1)	146.1 (56.9 to 262.0)	4.4 (-41.1 to 51.9)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	334.1 (257.1 to 411.7)	740.8 (697.3 to 800.7)	120.8 (78.8 to 188.0)	-11.1 (-25.8 to 11.1)	13.1 (8.1 to 19.2)	28.9 (19.4 to 41.8)	116.3 (88.5 to 206.1)	-15.4 (-26.0 to 14.9)
Maternal disorders	-	-	-	-	6.2 (4.2 to 8.4)	11.7 (8.1 to 16.0)	89.7 (66.2 to 116.5)	-29.4 (-37.7 to -20.2)
Maternal hemorrhage	2.6 (2.0 to 3.4)	6.5 (3.7 to 9.4)	149.5 (32.9 to 315.4)	-10.8 (-54.0 to 48.9)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	134.0 (17.6 to 326.6)	-15.5 (-57.3 to 53.0)
Maternal sepsis and other maternal infections	10.9 (4.7 to 16.7)	10.5 (4.9 to 15.3)	-3.3 (-58.2 to 123.7)	-63.6 (-84.8 to -9.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-7.4 (-49.2 to 59.2)	-65.6 (-80.7 to -44.5)
Maternal hypertensive disorders	13.2 (5.0 to 23.9)	19.9 (7.3 to 36.6)	50.8 (28.7 to 65.5)	-42.5 (-50.8 to -37.3)	0.7 (0.2 to 1.4)	1.0 (0.3 to 2.1)	50.6 (26.5 to 71.4)	-42.8 (-51.7 to -35.2)
Obstructed labor	13.3 (12.2 to 14.5)	26.2 (23.6 to 29.0)	95.8 (82.3 to 109.3)	-27.7 (-32.3 to -23.1)	4.3 (3.0 to 5.9)	8.6 (5.8 to 11.7)	97.6 (76.7 to 118.6)	27.2 (-34.1 to -19.9)
Complications of abortion	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	69.7 (-25.2 to 229.2)	-38.4 (-70.3 to 14.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.6 (-25.2 to 230.0)	-36.2 (-70.7 to 17.6)
Other maternal disorders	-	-	-	-	0.9 (0.5 to 1.4)	1.7 (1.0 to 2.7)	98.6 (1.9 to 255.7)	25.3 (-62.2 to 33.0)
Neonatal disorders	-	-	-	-	8.9 (4.4 to 17.9)	57.2 (31.8 to 103.1)	577.7 (256.0 to 956.3)	211.1 (68.8 to 397.1)
Preterm birth complications	39.3 (18.6 to 77.0)	250.9 (147.4 to 435.3)	543.3 (402.6 to 834.4)	145.5 (97.4 to 245.7)	2.6 (1.4 to 4.1)	25.9 (15.0 to 41.7)	897.5 (482.5 to 1,592.7)	311.9 (144.4 to 605.1)
Neonatal encephalopathy due to birth asphyxia and trauma	18.1 (5.4 to 57.0)	45.4 (19.9 to 102.6)	167.7 (58.8 to 335.0)	6.6 (-38.8 to 190.3)	1.8 (0.8 to 3.4)	7.6 (3.7 to 14.2)	317.3 (109.4 to 859.7)	115.6 (0.7 to 463.3)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.3)	319.5 (299.5 to 349.1)	157.8 (145.5 to 176.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	157.8 (247.1 to 430.0)	163.5 (113.3 to 225.8)
Hemolytic disease and other neonatal jaundice	3.7 (1.6 to 7.6)	27.1 (11.9 to 51.0)	610.8 (176.5 to 2,272.9)	256.3 (37.0 to 1,124.2)	1.2 (0.5 to 2.5)	7.9 (3.6 to 14.4)	554.5 (180.8 to 1,945.1)	212.3 (32.9 to 917.1)
Other neonatal disorders	-	-	-	-	3.3 (0.4 to 10.7)	15.8 (3.0 to 49.2)	432.2 (127.2 to 1,155.7)	146.5 (7.5 to 471.1)
Nutritional deficiencies	-	-	-	-	228.2 (152.8 to 322.5)	475.6 (317.7 to 686.7)	109.0 (90.4 to 127.2)	-18.1 (-22.7 to -13.7)
Protein-energy malnutrition	137.8 (60.5 to 265.5)	187.1 (68.7 to 392.6)	32.5 (-56.9 to 333.9)	-28.7 (-75.7 to 128.6)	17.1 (6.9 to 35.8)	22.2 (9.0 to 53.7)	32.8 (-56.5 to 332.9)	-28.4 (-75.8 to 128.8)
Iodine deficiency	394.7 (204.3 to 600.8)	657.9 (360.8 to 989.1)	63.3 (-11.0 to 249.4)	-40.3 (-70.0 to 39.8)	7.0 (3.1 to 13.3)	11.8 (8.4 to 21.5)	64.3 (-11.2 to 242.4)	-39.9 (-11.2 to 41.7)
Vitamin A deficiency	14.0 (8.3 to 21.6)	18.5 (11.0 to 28.3)	32.7 (-0.8 to 68.2)	-46.2 (-57.4 to -33.3)	0.8 (0.4 to 1.3)	1.0 (0.5 to 1.7)	27.1 (8.1 to 67.4)	47.5 (-61.0 to -33.4)

Appendix Table G.4 - Afghanistan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	5,280.1 (5,206.9 to 5,352.8)	12,055.0 (11,970.2 to 12,161.8)	127.9 (124.7 to 131.2)	-1.0 (-1.9 to -0.0)	201.0 (135.3 to 287.8)	437.8 (294.0 to 631.2)	117.9 (113.0 to 121.5)	-16.6 (-18.3 to -14.9)
Other nutritional deficiencies	-	-	-	-	2.3 (0.5 to 6.4)	1.8 (0.4 to 5.9)	-23.5 (-81.8 to 240.1)	-5.1 (-90.0 to 79.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	12.3 (8.1 to 17.6)	27.3 (18.1 to 38.8)	121.8 (97.9 to 150.6)	-14.5 (-24.0 to -4.5)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.8 (1.1 to 3.1)	4.7 (2.5 to 8.2)	164.0 (69.5 to 247.2)	-3.1 (-33.5 to 24.6)
Syphilis	0.2 (0.2 to 0.3)	0.4 (0.4 to 0.5)	69.1 (45.2 to 99.7)	-38.6 (-45.8 to -30.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	75.3 (29.9 to 137.2)	-3.7 (-52.4 to -17.2)
Chlamydial infection	204.4 (142.6 to 271.8)	544.6 (306.3 to 804.9)	164.8 (34.8 to 350.2)	-1.0 (-4.9 to 68.9)	1.0 (0.5 to 1.8)	2.5 (1.0 to 4.6)	167.6 (7.9 to 356.1)	-1.3 (-59.5 to 66.3)
Gonococcal infection	60.3 (45.4 to 74.5)	154.9 (112.8 to 199.4)	155.3 (70.6 to 273.6)	-3.9 (-33.4 to 36.4)	0.4 (0.2 to 0.7)	1.0 (0.6 to 1.7)	144.5 (76.4 to 255.7)	-8.6 (-33.0 to 27.5)
Trichomoniasis	36.5 (16.2 to 57.6)	125.9 (79.8 to 203.6)	233.3 (84.5 to 660.0)	19.3 (-30.3 to 153.9)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.5)	263.1 (80.0 to 1,108.5)	28.9 (-34.4 to 267.7)
Genital herpes	1,243.2 (1,170.0 to 1,308.1)	3,241.8 (3,042 to 3,429.3)	160.2 (139.1 to 182.7)	-3.5 (-11.1 to 4.9)	0.0 (0.1 to 0.8)	0.0 (0.3 to 2.1)	151.4 (134.2 to 188.4)	-3.7 (-12.2 to 6.0)
Other sexually transmitted diseases	2.0 (1.5 to 2.6)	4.0 (2.9 to 5.3)	102.0 (58.0 to 156.2)	-22.5 (-41.6 to 1.5)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	164.9 (79.7 to 323.2)	-0.9 (-30.5 to 52.4)
Hepatitis	-	-	-	-	0.9 (0.6 to 1.3)	2.1 (1.4 to 3.1)	132.8 (95.4 to 175.5)	-18.0 (-32.4 to 1.9)
Hepatitis A	22.9 (21.6 to 24.3)	55.0 (52.1 to 57.9)	139.6 (137.6 to 141.3)	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.6)	1.1 (0.7 to 1.5)	168.6 (137.0 to 204.6)	0.2 (-10.2 to 12.2)
Hepatitis B	951.5 (714.8 to 1,168.7)	1,518.5 (1,156.5 to 1,902.0)	65.8 (16.2 to 130.2)	-34.4 (-54.1 to -13.8)	0.0 (0.2 to 0.6)	0.7 (0.4 to 1.1)	70.8 (16.6 to 162.0)	-36.9 (-56.8 to -0.4)
Hepatitis C	448.8 (394.4 to 506.2)	878.5 (773.6 to 992.5)	95.0 (65.2 to 131.9)	-29.8 (-39.3 to -18.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	94.3 (40.0 to 152.1)	-24.2 (-43.9 to 1.3)
Hepatitis E	2.5 (1.5 to 3.3)	9.9 (6.7 to 14.1)	299.2 (170.1 to 668.2)	51.3 (4.4 to 178.4)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.5)	304.9 (147.8 to 737.6)	52.5 (-2.3 to 198.8)
Leprosy	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	118.0 (42.0 to 320.9)	-18.8 (-43.9 to 50.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.6 (40.0 to 335.6)	-18.9 (-46.1 to 61.1)
Other infectious diseases	246.6 (201.3 to 292.8)	545.1 (501.5 to 605.6)	120.9 (89.9 to 150.2)	-11.9 (-23.0 to -0.8)	9.5 (6.2 to 13.8)	20.4 (13.3 to 29.1)	113.7 (84.3 to 145.2)	-17.1 (-29.4 to -3.7)
Non-communicable diseases	-	-	-	-	177.4 (495.6 to 865.7)	1,866.4 (1,369.5 to 2,408.9)	177.4 (165.4 to 189.2)	2.1 (-2.3 to 6.1)
Neoplasms	-	-	-	-	3.0 (1.9 to 4.7)	9.9 (6.2 to 15.7)	229.2 (143.2 to 354.6)	15.6 (-11.2 to 56.3)
Esophageal cancer	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	163.8 (64.1 to 316.6)	-13.3 (-44.8 to 35.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	165.6 (77.4 to 306.7)	-12.4 (-42.7 to 33.7)
Stomach cancer	2.2 (1.6 to 3.0)	6.5 (4.3 to 9.2)	189.6 (103.7 to 317.2)	-2.1 (-29.9 to 35.6)	0.3 (0.2 to 0.4)	0.9 (0.5 to 1.3)	192.5 (106.4 to 318.9)	-2.0 (-28.2 to 37.2)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.5)	47.9 (25.3 to 65.2)	73.5 (19.2 to 150.8)
Liver cancer due to hepatitis B	0.1 (0.0 to 0.2)	0.4 (0.1 to 0.8)	417.2 (136.3 to 1,048.3)	76.2 (-19.5 to 306.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	407.6 (144.1 to 926.9)	73.4 (-18.2 to 259.4)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.1)	0.5 (0.2 to 1.4)	1,149.2 (498.2 to 2,456.9)	298.2 (97.6 to 674.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	1,082.7 (494.4 to 2,138.2)	263.3 (92.2 to 540.4)
Liver cancer due to alcohol use	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	123.1 (-14.3 to 438.7)	-22.3 (-69.9 to 75.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.8 (-4.7 to 373.5)	-22.9 (-67.8 to 53.8)
Liver cancer due to other causes	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.5)	196.1 (39.1 to 608.2)	-4.4 (-53.2 to 165.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	186.1 (49.2 to 543.4)	-0.8 (-49.2 to 129.0)
Larynx cancer	0.7 (0.4 to 1.1)	1.9 (1.1 to 3.1)	181.2 (80.6 to 332.1)	-6.5 (-39.7 to 42.2)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	151.3 (80.0 to 331.7)	-6.0 (-39.0 to 42.5)
Tracheal, bronchus and lung cancer	1.3 (0.4 to 1.8)	4.0 (1.2 to 5.9)	212.9 (124.2 to 348.2)	2.3 (-25.7 to 43.6)	0.2 (0.1 to 0.4)	0.7 (0.2 to 1.2)	213.1 (117.8 to 361.6)	3.2 (-27.0 to 46.0)
Breast cancer	3.1 (1.7 to 7.6)	13.9 (6.8 to 38.3)	324.8 (164.1 to 657.2)	49.3 (-3.6 to 162.1)	0.3 (0.2 to 0.8)	1.4 (0.7 to 3.9)	297.0 (149.5 to 599.5)	38.7 (-9.6 to 143.0)
Cervical cancer	5.5 (3.0 to 10.1)	14.7 (8.2 to 26.1)	162.8 (46.7 to 378.1)	4.2 (-44.9 to 70.7)	0.4 (0.2 to 0.8)	1.1 (0.6 to 2.1)	153.2 (76.2 to 307.3)	-3.1 (-44.7 to 68.8)
Uterine cancer	1.2 (0.3 to 2.5)	3.9 (1.0 to 8.1)	230.9 (69.8 to 532.5)	10.5 (-42.4 to 108.7)	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.6)	234.9 (70.7 to 551.6)	11.8 (-40.9 to 109.7)
Prostate cancer	0.6 (0.3 to 1.1)	4.5 (2.2 to 8.1)	631.5 (319.0 to 1,237.1)	104.6 (18.8 to 253.5)	0.1 (0.0 to 0.1)	0.5 (0.2 to 0.9)	535.4 (285.4 to 1,019.5)	78.0 (-6.6 to 199.4)
Colon and rectum cancer	0.9 (0.7 to 1.1)	3.5 (2.5 to 4.6)	287.0 (178.6 to 423.5)	24.7 (-7.1 to 62.6)	0.1 (0.1 to 0.1)	0.4 (0.2 to 0.5)	272.4 (168.0 to 415.0)	19.9 (-10.3 to 61.8)
Lip and oral cavity cancer	0.9 (0.3 to 1.6)	2.7 (0.9 to 4.9)	200.3 (95.5 to 360.5)	2.9 (-32.8 to 61.7)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.5)	200.4 (97.5 to 361.6)	3.3 (-33.4 to 56.7)
Nasopharynx cancer	0.6 (0.3 to 1.1)	1.5 (0.7 to 2.7)	125.8 (23.7 to 315.6)	-17.3 (-51.5 to 46.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	124.4 (30.2 to 294.9)	-19.5 (-51.1 to 37.9)
Other pharynx cancer	0.2 (0.1 to 0.4)	0.5 (0.2 to 0.9)	133.1 (30.1 to 333.6)	-21.2 (-55.9 to 44.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	132.7 (36.5 to 313.8)	-22.5 (-53.2 to 35.3)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	242.0 (119.0 to 418.4)	7.2 (-30.6 to 62.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	229.7 (118.0 to 382.3)	3.1 (-30.3 to 52.1)
Pancreatic cancer	0.1 (0.0 to 0.1)	0.2 (0.2 to 0.3)	258.4 (145.2 to 433.0)	14.4 (-19.9 to 62.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	255.4 (158.5 to 390.7)	13.0 (-15.8 to 51.9)
Malignant skin melanoma	0.4 (0.2 to 1.2)	1.3 (0.6 to 3.6)	304.8 (95.3 to 381.8)	1.3 (-28.6 to 67.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	198.3 (32.5 to 60.5)	2.5 (-32.5 to 60.5)
Non-melanoma skin cancer	0.9 (0.6 to 1.3)	3.5 (2.4 to 5.1)	290.0 (157.6 to 480.8)	24.9 (-18.5 to 105.8)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	363.6 (223.0 to 572.6)	50.5 (-2.6 to 119.9)
Ovarian cancer	0.2 (0.1 to 0.4)	0.8 (0.3 to 1.6)	226.4 (94.5 to 463.0)	10.6 (-33.9 to 96.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.3)	223.2 (73.0 to 482.6)	11.1 (-42.9 to 105.5)
Testicular cancer	0.1 (0.1 to 0.3)	0.5 (0.3 to 0.9)	263.3 (85.2 to 593.1)	37.0 (-25.8 to 161.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	253.7 (81.9 to 607.4)	32.1 (-29.1 to 143.6)
Kidney cancer	0.4 (0.2 to 0.8)	1.2 (0.5 to 2.0)	192.0 (78.6 to 354.9)	13.9 (-24.7 to 68.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	303.3 (95.0 to 364.9)	12.7 (-21.7 to 62.8)
Bladder cancer	1.1 (0.7 to 1.5)	3.2 (2.2 to 4.5)	197.6 (99.7 to 345.6)	-3.8 (-34.0 to 38.8)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	200.1 (100.6 to 341.9)	-3.4 (-33.1 to 39.1)
Brain and nervous system cancer	1.5 (0.6 to 5.2)	4.7 (2.4 to 12.8)	279.2 (74.1 to 532.8)	43.4 (-8.3 to 101.8)	0.1 (0.1 to 0.4)	0.1 (0.2 to 1.2)	271.6 (103.6 to 468.1)	36.2 (-5.7 to 91.6)
Thyroid cancer	1.0 (0.3 to 2.9)	3.7 (1.2 to 10.5)	253.3 (121.3 to 478.6)	21.3 (-22.1 to 97.1)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.7)	246.2 (110.1 to 472.8)	16.1 (-27.3 to 87.0)
Mesothelioma	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	93.7 (23.2 to 234.2)	34.7 (-57.6 to 7.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	303.3 (26.8 to 228.5)	12.7 (-56.1 to 6.3)
Hodgkin lymphoma	2.4 (0.7 to 4.4)	7.4 (2.3 to 12.5)	204.9 (67.4 to 486.2)	24.9 (-27.4 to 123.7)	0.2 (0.1 to 0.4)	0.6 (0.2 to 1.1)	197.3 (66.1 to 445.9)	18.1 (-29.8 to 101.5)
Non-Hodgkin lymphoma	0.9 (0.4 to 2.8)	3.5 (1.5 to 9.5)	282.9 (148.5 to 515.1)	39.4 (-10.8 to 129.2)	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.8)	277.3 (146.1 to 493.0)	33.5 (-13.7 to 123.5)
Multiple myeloma	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.9)	279.7 (134.9 to 546.8)	26.2 (-20.9 to 109.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	265.0 (123.0 to 498.3)	21.6 (-25.2 to 100.6)
Leukemia	1.5 (0.8 to 3.8)	4.8 (3.1 to 8.7)	223.2 (80.5 to 509.2)	35.2 (-11.1 to 109.0)	0.2 (0.1 to 0.4)	0.6 (0.4 to 1.0)	221.9 (117.3 to 408.9)	25.8 (-12.0 to 83.3)
Other neoplasms	1.9 (1.0 to 6.3)	6.7 (3.8 to 16.6)	280.2 (128.2 to 473.2)	23.4 (-15.5 to 78.7)	0.1 (0.1 to 0.4)	0.5 (0.3 to 1.1)	266.3 (131.3 to 448.3)	17.8 (-18.5 to 66.4)
Cardiovascular diseases	-	-	-	-	11.7 (7.7 to 16.3)	33.9 (21.8 to 48.1)	192.7 (128.5 to 264.2)	7.2 (-13.0 to 32.9)
Rheumatic heart disease	26.1 (19.8 to 33.8)	70.9 (51.2 to 99.4)	165.3 (84.5 to 280.6)	4.7 (-22.4 to 38.4)	1.3 (0.8 to 2.0)	3.8 (2.2 to 6.0)	179.3 (97.0 to 297.6)	14.2 (-14.6 to 56.9)
Ischemic heart disease	44.1 (35.9 to 53.0)	111.5 (95.4 to 133.0)	152.4 (96.4 to 234.1)	-14.7 (-30.9 to 8.3)	2.5 (1.6 to 3.6)	6.4 (4.2 to 9.1)	156.1 (86.5 to 268.4)	-10.0 (-33.1 to 24.8)
Cerebrovascular disease	-	-	-	-	0.4 (0.3 to 0.6)	1.2 (0.8 to 1.7)	201.8 (138.1 to 283.6)	3.2 (-18.9 to 31.3)
Ischemic stroke	2.2 (1.8 to 2.6)	6.7 (5.9 to 7.7)	207.2 (147.8 to 302.8)	2.5 (-18.4 to 33.6)	0.3 (0.2 to 0.5)	1.0 (0.7 to 1.4)	208.7 (140.8 to 305.0)	3.7 (-18.2 to 35.3)
Hemorrhagic stroke	0.4 (0.3 to 0.5)	1.0 (0.8 to 1.3)	160.1 (85.0 to 254.3)	-5.4 (-33.2 to 28.0)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	161.7 (86.8 to 257.1)	-4.8 (-33.9 to 28.7)
Hypertensive heart disease	4.6 (3.1 to 6.1)	18.7 (14.3 to 23.5)	309.6 (167.3 to 534.3)	52.9 (-3.6 to 136.6)	0.5 (0.3 to 0.8)	2.0 (1.3 to 3.1)	307.1 (164.8 to 522.4)	51.6 (-4.1 to 136.4)
Cardiomyopathy and myocarditis	4.7 (3.9 to 5.7)	16.9 (12.0 to 22.0)	255.1 (159.9 to 379.7)	37.3 (-7.0 to 99.4)	0.5 (0.3 to 0.7)	1.9 (1.1 to 2.8)	263.4 (151.9 to 404.8)	40.2 (-7.1 to 107.6)
Atrial fibrillation and flutter	3.9 (2.6 to 5.9)	17.4 (12.2 to 26.7)	342.0 (152.3 to 795.3)	34.3 (-21.8 to 169.1)	0.3 (0.2 to 0.5)	1.3 (0.8 to 2.2)	340.7 (161.3 to 830.3)	35.1 (-20.9 to 171.2)
Peripheral vascular disease	82.9 (52.8 to 113.5)	288.6 (200.3 to 374.0)	248.4 (157.3 to 389.5)	11.4 (-11.9 to 49.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	247.2 (61.7 to 619.2)	-7.9 (-55.3 to 57.1)
Endocarditis	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.7)	154.6 (82.6 to 245.3)	24.3 (-24.0 to 74.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	191.4 (114.3 to 296.4)	26.1 (-16.3 to 85.5)
Other cardiovascular and circulatory diseases	87.8 (56.3 to 122.4)	347.0 (139.1 to 349.0)	183.1 (74.0 to 325.8)	6.1 (-34.1 to 54.8)	17.2 (3.4 to 9.			

Appendix Table G.4 - Afghanistan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	0.0	0.1	150.0	-13.3	0.0	0.1	170.6	-5.1
Silicosis	(0.0 to 0.0)	(0.1 to 0.1)	(137.1 to 163.2)	(-18.0 to -8.2)	(0.0 to 0.0)	(0.0 to 0.1)	(161.3 to 180.1)	(-8.5 to -1.6)
Asbestosis	-	-	0.0	0.0	-	-	150.1	-13.2
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.1	0.2	179.6	-1.3	0.0	0.0	180.6	-0.5
Asthma	(0.1 to 0.1)	(0.2 to 0.2)	(169.2 to 190.7)	(-5.1 to 2.8)	(0.0 to 0.0)	(0.0 to 0.1)	(169.8 to 192.3)	(-4.4 to 3.7)
Interstitial lung disease and pulmonary sarcoidosis	121.2	333.5	163.2	3.0	5.2	14.3	163.4	2.8
Other chronic respiratory diseases	(78.7 to 168.3)	(222.0 to 510.0)	(68.0 to 381.6)	(-32.8 to 58.0)	(2.8 to 8.5)	(8.1 to 24.1)	(69.6 to 389.7)	(-32.6 to 60.0)
Cirrhosis	0.5	1.5	180.5	0.5	0.1	0.2	184.0	1.6
Cirrhosis due to hepatitis B	(0.4 to 0.7)	(1.2 to 1.8)	(105.1 to 290.9)	(-26.0 to 35.3)	(0.0 to 0.1)	(0.1 to 0.3)	(110.3 to 295.4)	(-24.7 to 35.9)
Cirrhosis due to hepatitis C	-	-	-	-	1.1	2.4	141.8	-12.0
Cirrhosis due to alcohol use	1.3	2.4	77.4	-29.3	(0.3 to 2.5)	(1.0 to 4.8)	(43.9 to 292.5)	(-47.7 to 41.4)
Cirrhosis due to other causes	(0.8 to 2.1)	(1.1 to 3.5)	(-12.7 to 224.7)	(66.0 to 23.3)	(0.5 to 1.1)	(1.0 to 2.1)	(68.8 to 126.6)	(-24.1 to -5.5)
Digestive diseases	1.6	3.6	131.8	4.7	0.3	0.6	130.9	5.3
Peptic ulcer disease	(0.9 to 2.1)	(2.6 to 4.9)	(40.0 to 272.7)	(-31.4 to 87.8)	(0.1 to 0.4)	(0.3 to 0.9)	(32.2 to 293.7)	(-32.4 to 92.1)
Gastritis and duodenitis	0.3	0.5	37.9	-47.7	0.1	0.1	41.6	-47.1
Appendicitis	(0.2 to 0.5)	(0.3 to 0.8)	(-34.0 to 188.6)	(-73.3 to -6.1)	(0.0 to 0.1)	(0.0 to 0.1)	(-35.3 to 195.1)	(-74.4 to 0.7)
Paralytic ileus and intestinal obstruction	1.4	2.6	85.0	-13.7	0.2	0.4	84.5	-14.4
Inguinal, femoral, and abdominal hernia	(1.1 to 1.8)	(2.0 to 3.2)	(25.1 to 153.2)	(-42.6 to 25.9)	(0.1 to 0.4)	(0.2 to 0.7)	(5.5 to 191.5)	(-47.5 to 36.4)
Inflammatory bowel disease	-	-	-	-	7.0	17.6	152.6	-11.4
Vascular intestinal disorders	34.3	70.2	104.6	-29.3	(4.8 to 9.7)	(12.4 to 23.9)	(117.6 to 185.1)	(-24.3 to -0.2)
Galbladder and biliary diseases	(27.6 to 39.2)	(55.8 to 83.1)	(66.7 to 145.3)	(-41.8 to -15.4)	1.5	3.2	119.0	-25.4
Pancreatitis	31.4	46.7	48.6	-43.9	(0.9 to 2.1)	(2.1 to 4.6)	(58.8 to 170.7)	(-45.0 to -7.8)
Other digestive diseases	(26.5 to 35.9)	(39.7 to 53.2)	(21.5 to 84.0)	(-52.4 to -31.6)	1.5	2.2	46.6	-42.0
Neurological disorders	0.8	1.6	99.0	-22.5	(1.0 to 2.2)	(1.4 to 3.2)	(7.7 to 99.8)	(-54.7 to -26.0)
Alzheimer disease and other dementias	(0.6 to 1.0)	(1.2 to 2.3)	(33.7 to 234.1)	(-45.6 to 11.8)	0.2	0.5	106.7	-20.8
Parkinson disease	0.1	0.4	214.5	8.2	(0.1 to 0.4)	(0.3 to 0.9)	(20.3 to 280.8)	(-49.6 to 31.7)
Epilepsy	(0.1 to 0.2)	(0.3 to 0.5)	(88.9 to 361.0)	(-14.1 to 40.4)	0.0	0.1	217.1	11.0
Multiple sclerosis	51.6	130.8	148.2	-11.4	(0.1 to 0.1)	(0.1 to 0.2)	(69.8 to 456.3)	(-19.2 to 55.1)
Migraine	(45.1 to 60.1)	(110.5 to 166.1)	(102.7 to 233.1)	(-29.1 to 11.7)	0.5	1.4	148.4	-10.5
Tension-type headache	7.1	28.4	301.7	46.9	(0.3 to 1.0)	(0.7 to 2.6)	(100.2 to 236.7)	(-28.9 to 12.2)
Medication overuse headache	(6.5 to 7.6)	(26.0 to 31.0)	(257.7 to 349.8)	(-31.2 to 65.0)	1.5	6.0	305.9	48.4
Other neurological disorders	0.0	0.1	197.4	-7.5	(1.0 to 2.1)	(4.0 to 8.4)	(249.1 to 372.8)	(-29.7 to 70.6)
Mental and substance use disorders	20.4	75.0	260.5	3.2	0.0	0.0	197.4	-3.9
Schizophrenia	(16.1 to 23.6)	(64.8 to 85.9)	(203.2 to 387.8)	(-13.7 to 30.6)	(0.0 to 0.0)	(0.0 to 0.0)	(117.6 to 317.2)	(-99.1 to 58.9)
Alcohol use disorders	2.3	7.5	224.9	0.7	0.3	0.9	197.5	-6.4
Drug use disorders	(1.2 to 3.3)	(3.9 to 10.8)	(197.5 to 243.6)	(-6.5 to 5.9)	(0.1 to 0.4)	(0.5 to 1.1)	(103.9 to 250.0)	(-27.5 to 21.0)
Opioid use disorders	54.3	143.4	163.7	0.9	0.2	0.2	151.8	-7.3
Cocaine use disorders	(45.9 to 62.3)	(120.7 to 167.1)	(112.1 to 230.0)	(-18.0 to 25.6)	(0.3 to 0.7)	(0.8 to 1.7)	(104.5 to 209.9)	(-21.9 to 8.7)
Amphetamine use disorders	1.4	7.3	402.2	8.2	1.0	2.2	133.8	-17.7
Other drug use disorders	(1.0 to 1.9)	(4.9 to 10.2)	(208.9 to 708.3)	(-21.6 to 182.0)	(0.4 to 1.9)	(1.1 to 3.6)	(48.7 to 215.8)	(-46.7 to 10.9)
Migraine	1,003.9	2,883.1	182.8	-4.9	67.5	207.6	209.4	8.8
Tension-type headache	(717.5 to 1,371.5)	(2,040.3 to 3,882.9)	(801.0 to 1,331.8)	(-31.5 to 42.0)	(44.9 to 96.5)	(137.5 to 293.0)	(142.8 to 284.0)	(-14.5 to 26.0)
Medication overuse headache	1,720.0	4,514.2	160.9	-0.7	2.7	10.0	288.5	-3.9
Other neurological disorders	(1,582.0 to 1,849.3)	(3,242.8 to 5,768.2)	(84.1 to 243.9)	(-26.0 to 22.3)	1.4	6.3	302.8	49.5
Schizophrenia	73.3	295.6	299.6	47.9	11.4	46.3	302.8	49.5
Alcohol use disorders	(47.9 to 98.7)	(195.7 to 401.8)	(215.5 to 434.4)	(-17.6 to 93.9)	(6.3 to 17.8)	(26.1 to 71.3)	(218.4 to 437.5)	(-17.8 to 93.4)
Drug use disorders	0.0	0.1	152.2	1.4	1.8	3.9	129.8	-36.4
Opioid use disorders	(0.0 to 0.0)	(0.0 to 0.1)	(69.9 to 280.5)	(-32.8 to 44.1)	(0.8 to 4.8)	(2.3 to 6.8)	(9.6 to 351.1)	(-68.9 to 23.7)
Cocaine use disorders	22.8	60.3	164.0	-0.0	232.2	648.4	178.5	5.3
Amphetamine use disorders	(20.7 to 24.8)	(54.8 to 65.4)	(152.6 to 177.1)	(-3.9 to 4.2)	(161.7 to 316.3)	(458.2 to 878.6)	(167.3 to 195.7)	(-13.1 to 22.5)
Other drug use disorders	59.0	146.6	147.9	-4.8	14.3	38.2	167.7	1.5
Schizophrenia	(52.6 to 67.1)	(129.5 to 167.7)	(131.6 to 166.4)	(-10.8 to 1.7)	(3.8 to 8.0)	(9.4 to 20.8)	(132.0 to 173.6)	(-11.0 to 4.4)
Alcohol use disorders	-	-	-	-	29.1	104.7	252.7	37.0
Drug use disorders	-	-	-	-	(17.4 to 44.9)	(66.1 to 152.8)	(187.0 to 395.4)	(-12.1 to 90.3)
Opioid use disorders	55.7	214.4	277.2	43.6	22.4	88.1	286.7	47.0
Cocaine use disorders	(32.1 to 87.4)	(143.1 to 294.3)	(194.2 to 493.8)	(-13.8 to 122.0)	(11.8 to 36.9)	(52.5 to 132.9)	(197.8 to 508.6)	(-15.4 to 126.6)
Amphetamine use disorders	8.1	30.5	152.1	1.1	15.2	2.8	155.7	-0.9
Other drug use disorders	(5.4 to 11.0)	(16.6 to 24.9)	(78.3 to 317.3)	(-28.6 to 47.4)	(0.6 to 1.7)	(1.7 to 4.2)	(69.6 to 332.3)	(-30.9 to 51.0)
Schizophrenia	15.9	37.0	132.7	-11.5	2.1	4.8	134.4	-10.7
Alcohol use disorders	(12.2 to 19.3)	(30.1 to 45.1)	(68.1 to 217.2)	(-32.8 to 17.9)	(1.2 to 3.1)	(2.8 to 7.4)	(67.4 to 226.1)	(-35.0 to 21.9)
Drug use disorders	16.8	45.4	168.8	-0.6	0.5	1.3	172.2	0.2
Opioid use disorders	(12.8 to 20.6)	(34.1 to 55.7)	(165.7 to 171.5)	(-0.7 to -0.4)	(0.3 to 0.7)	(0.8 to 2.0)	(127.4 to 223.9)	(-14.9 to 17.7)
Other drug use disorders	-	-	-	-	3.2	7.7	144.0	-6.4
Schizophrenia	-	-	-	-	(1.8 to 4.8)	(4.6 to 11.2)	(67.8 to 262.6)	(-34.9 to 35.9)
Alcohol use disorders	-	-	-	-	14.0	36.2	158.0	0.4
Drug use disorders	-	-	-	-	(33.1 to 110.6)	(90.6 to 292.5)	(151.8 to 192.0)	(-5.6 to 8.2)
Opioid use disorders	272.0	728.3	167.4	-0.7	55.1	148.5	169.7	0.4
Cocaine use disorders	(143.2 to 440.0)	(393.2 to 1,155.4)	(145.3 to 192.2)	(-7.7 to 7.8)	(25.7 to 99.9)	(71.5 to 265.9)	(148.2 to 195.4)	(-6.9 to 9.7)
Amphetamine use disorders	91.3	248.3	171.3	-0.2	8.7	23.8	173.0	0.6
Other drug use disorders	(73.0 to 108.9)	(200.7 to 294.6)	(168.0 to 175.7)	(-0.5 to 0.1)	(5.5 to 12.8)	(15.2 to 34.6)	(163.7 to 183.4)	(-2.2 to 3.2)
Schizophrenia	64.1	168.3	162.2	-0.7	12.9	34.0	164.3	0.1
Alcohol use disorders	(54.7 to 73.1)	(142.5 to 192.7)	(143.7 to 182.3)	(-6.6 to 5.1)	(7.8 to 19.3)	(21.1 to 51.6)	(142.8 to 187.8)	(-6.6 to 7.6)
Drug use disorders	425.9	1,183.5	172.3	0.2	39.0	106.9	174.2	1.9
Opioid use disorders	(177.4 to 625.9)	(490.4 to 1,712.3)	(168.9 to 176.3)	(-0.4 to 0.9)	(14.9 to 64.2)	(41.4 to 176.9)	(165.7 to 183.4)	(-1.4 to 3.7)
Other drug use disorders	-	-	-	-	0.9 to 2.2	(2.4 to 6.2)	(145.9 to 213.9)	(-8.0 to 15.6)
Schizophrenia	1.2	3.4	191.8	6.7	0.2	0.7	192.2	6.8
Alcohol use disorders	(0.7 to 1.7)	(2.1 to 5.0)	(157.5 to 219.8)	(-5.3 to 17.1)	(0.1 to 0.4)	(0.4 to 1.2)	(114.5 to 285.0)	(-22.2 to 40.3)
Drug use disorders	5.6	15.5	173.3	2.1	1.2	3.3	175.5	2.9
Opioid use disorders	(3.9 to 7.9)	(10.6 to 21.7)	(170.2 to 176.8)	(-1.8 to 2.4)	(0.7 to 1.9)	(1.9 to 5.2)	(142.2 to 215.0)	(-9.1 to 16.8)
Other drug use disorders	-	-	-	-	14.0	36.2	158.0	0.5
Schizophrenia	35.4	91.2	157.1	-0.2	(8.8 to 19.0)	(24.9 to 48.9)	(147.7 to 168.9)	(-2.6 to 4.3)
Alcohol use disorders	(33.5 to 37.4)	(86.3 to 96.4)	(156.3 to 158.0)	(-0.2 to -0.1)	(9.2 to 11.6)	(26.2 to 33.2)	(151.8 to 192.0)	(-5.6 to 8.2)
Drug use disorders	53.8	137.2	154.8	-0.2	5.3	13.7	155.9	0.5
Opioid use disorders	(50.4 to 56.9)	(128.6 to 145.3)	(153.8 to 155.8)	(-0.3 to -0.1)	(3.7 to 7.4)	(9.5 to 19.1)	(143.8 to 169.2)	(-3.5 to 4.9)
Other drug use disorders	90.4	247.1	173.0	-0.9	1.1	3.0	173.5	-0.6
Schizophrenia	(74.5 to 106.6)	(203.8 to 291.3)	(172.7 to 173.2)	(-0.9 to -0.8)	(0.6 to 1.7)	(1.7 to 4.7)	(153.9 to 196.2)	(-7.5 to 7.4)
Alcohol use disorders	165.1	465.2	180.0	0.8	19.7	55.6	182.6	0.2
Drug use disorders	(137.4 to 191.3)	(385.0 to 536.5)	(179.0 to 181.0)	(-0.9 to -0.7)	(12.2 to 29.5)	(34.1 to 83.4)	(173.7 to 194.3)	(-3.6 to 4.5)
Opioid use disorders	40.9	1,083.4	144.8	-3.3	21.5	53.0	146.1	-2.6
Other drug use disorders	(37.0 to 526.5)	(884.5 to 1,311.0)	(123.2 to 170.4)	(-12.1 to 7.0)	(14.1 to 30.3)	(34.9 to 76.1)	(123.1 to 174.5)	(-11.6 to 8.3)
Schizophrenia	132.0	350.0	164.6	-0.0	9.7	26.0	167.4	1.3
Alcohol use disorders	(122.8 to 140.8)	(326.0 to 372.4)	(163.3 to 165.9)	(-0.3 to 0.3)	(6.6 to 13.0)	(17.9 to 34.8)	(155.7 to 181.2)	(-2.4 to 5.3)
Drug use disorders	-	-	-	-	76.2	199.4	161.0	0.1
Opioid use disorders	-	-	-	-	(52.7 to 103.5)	(137.6 to 275.6)	(138.1 to 189.7)	(-13.6 to 14.7)
Other drug use disorders	249.9	755.7	199.5	10.0	20.1	61.2	202.5	8.3
Schizophrenia	(210.6 to 290.9)	(608.2 to 943.6)	(139.7 to 281.3)	(-17.6 to 40.9)	(13.5 to 28.8)	(38.8 to 90.1)	(128.4 to 295.5)	(-24.2 to 46.0)
Alcohol use disorders	0.1	0.2	97.0	-15.9	0.0	0.0	157.0	-9.0
Drug use disorders	(0.1 to 0.1)	(0.2 to 0.2)	(85.3 to 110.5)	(-19.2 to -11.8)	(0.0 to 0.0)	(0.0 to 0.0)	(85.3 to 110.6)	(-19.3 to -11.8)
Opioid use disorders	-	-	-	-	9.7	25.9	168.0	0.0
Other drug use disorders	-	-	-	-	(6.8 to 13.1)	(18.3 to 35.5)	(139.1 to 196.9)	(-7.9 to 8.4)
Schizophrenia	61.8	196.8	214.0	12.3	1.7	5.1	206.7	12.1
Alcohol use disorders	(44.0 to 88.0)	(130.9 to 290.1)	(144.2 to 317.9)	(-11.7 to 48.2)	(1.1 to 2.4)	(3.5 to 7.3)	(141.2 to 294.6)	(-8.9 to 50.5)
Drug use disorders	59.3	121.3	101.0	-23.4	2.			

Appendix Table G.4 - Afghanistan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	2.2 (2.0 to 2.3)	5.9 (5.5 to 6.3)	173.3 (149.0 to 206.5)	0.1 (-4.5 to 13.7)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	173.2 (105.8 to 257.3)	3.5 (-15.4 to 24.3)
Urolithiasis	53.8 (33.8 to 90.1)	184.7 (116.9 to 311.0)	244.4 (201.8 to 305.9)	0.2 (5.6 to 35.2)	0.9 (0.2 to 0.4)	0.9 (0.5 to 1.4)	270.1 (218.3 to 325.0)	39.9 (23.7 to 57.4)
Benign prostatic hyperplasia	41.0 (36.8 to 44.7)	141.9 (130.3 to 153.9)	244.4 (206.9 to 289.8)	1.4 (-7.5 to 14.9)	2.9 (1.0 to 2.0)	5.0 (3.2 to 6.9)	245.5 (207.1 to 293.9)	3.5 (-7.1 to 17.2)
Male infertility due to other causes	77.6 (52.4 to 111.4)	191.9 (117.1 to 268.9)	151.8 (33.9 to 306.5)	-0.1 (47.6 to 55.9)	0.5 (0.2 to 1.1)	1.3 (0.5 to 2.8)	152.9 (31.3 to 319.7)	0.2 (-48.2 to 65.2)
Other urinary diseases	-	-	-	-	-	-	-	-
Gynecological diseases	-	-	-	-	-	-	-	-
Uterine fibroids	159.6 (144.0 to 174.1)	415.9 (375.4 to 453.5)	160.1 (159.2 to 160.9)	0.5 (0.3 to 0.7)	4.0 (2.6 to 5.9)	9.5 (6.0 to 14.5)	141.1 (127.1 to 151.4)	-7.7 (-12.9 to -4.0)
Polycystic ovarian syndrome	202.6 (184.6 to 221.0)	519.2 (468.3 to 572.3)	155.4 (124.0 to 192.7)	-0.2 (-11.7 to 13.0)	2.0 (0.9 to 3.6)	5.1 (2.3 to 9.6)	156.6 (125.1 to 195.7)	0.1 (-10.9 to 14.6)
Female infertility due to other causes	25.3 (7.3 to 53.5)	75.9 (32.3 to 147.9)	222.2 (-6.7 to 1,037.9)	26.2 (-68.8 to 381.1)	0.2 (0.0 to 0.4)	0.5 (0.1 to 1.1)	215.7 (4.0 to 888.8)	22.9 (-65.6 to 327.7)
Endometriosis	16.3 (13.7 to 19.1)	45.2 (38.7 to 52.4)	174.1 (118.8 to 253.7)	7.5 (-14.2 to 39.4)	1.5 (1.0 to 2.1)	4.1 (2.8 to 5.7)	175.3 (115.9 to 266.4)	7.8 (-15.4 to 42.1)
Genital prolapse	430.0 (335.7 to 514.5)	1,142.7 (891.0 to 1,368.8)	165.0 (99.7 to 252.9)	-3.1 (-25.7 to 23.2)	1.4 (0.6 to 2.6)	3.6 (1.7 to 7.0)	165.0 (100.6 to 253.6)	-3.0 (-25.5 to 23.6)
Premenstrual syndrome	381.1 (204.1 to 560.0)	1,132.5 (665.8 to 1,801.1)	199.6 (34.5 to 488.6)	3.2 (-52.2 to 119.8)	10.0 (1.5 to 5.7)	9.5 (4.4 to 16.8)	200.7 (35.7 to 493.6)	11.5 (-52.5 to 125.6)
Other gynecological diseases	55.6 (47.1 to 63.4)	141.3 (130.2 to 151.7)	153.6 (117.9 to 199.3)	-4.9 (-18.3 to 11.6)	2.1 (1.2 to 3.0)	5.0 (3.4 to 7.3)	142.4 (110.5 to 229.2)	-9.1 (-22.0 to 21.6)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	-	-	-	-
Thalassemias	3.9 (3.1 to 4.7)	9.5 (7.6 to 11.2)	143.0 (120.8 to 170.5)	-1.6 (-11.2 to 10.8)	0.3 (0.2 to 0.5)	0.8 (0.5 to 1.2)	143.6 (80.1 to 226.6)	-3.1 (-26.2 to 26.8)
Thalassemia trait	527.7 (472.4 to 582.6)	1,365.5 (1,251.4 to 1,474.3)	158.4 (146.4 to 170.1)	1.6 (-3.2 to 6.2)	10.2 (6.7 to 14.7)	25.0 (16.4 to 36.3)	144.7 (113.8 to 182.4)	-1.9 (-14.4 to 11.6)
Sickle cell disorders	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.4)	103.7 (62.1 to 117.5)	-15.8 (-33.4 to -0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	110.9 (64.2 to 129.5)	-13.3 (-33.8 to -4.3)
Sickle cell trait	199.8 (91.5 to 137.4)	248.8 (206.2 to 312.0)	124.0 (99.2 to 138.0)	-11.9 (-21.8 to -4.4)	0.4 (0.2 to 0.6)	0.8 (0.4 to 1.3)	111.3 (-0.5 to 338.7)	33.8 (-60.2 to 82.6)
G6PD deficiency	431.7 (341.8 to 534.4)	1,064.6 (736.1 to 1,370.5)	148.4 (59.0 to 249.2)	-2.4 (-37.6 to 37.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	130.1 (113.8 to 147.5)	-5.1 (-9.3 to -0.6)
G6PD trait	1,982.9 (1,723.3 to 2,229.3)	5,072.6 (4,104.7 to 5,840.0)	155.6 (103.1 to 213.2)	-0.7 (-21.1 to 21.7)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.4)	150.7 (17.1 to 276.3)	-5.5 (-50.6 to 32.5)
Other hemoglobinopathies and hemolytic anemias	257.4 (219.5 to 285.6)	578.2 (511.5 to 631.2)	124.8 (96.3 to 163.3)	-13.6 (-22.5 to -4.3)	8.8 (5.8 to 12.9)	18.4 (11.4 to 28.1)	108.1 (66.5 to 185.7)	-22.8 (-34.0 to -2.3)
Endocrine, metabolic, blood, and immune disorders	265.9 (236.2 to 290.8)	598.9 (521.6 to 667.1)	124.3 (95.1 to 157.7)	-11.5 (-20.2 to -2.6)	9.9 (6.6 to 13.9)	21.4 (14.4 to 30.8)	115.6 (78.4 to 156.0)	-8.4 (-27.9 to 4.6)
Musculoskeletal disorders	-	-	-	-	-	-	-	-
Rheumatoid arthritis	18.7 (17.6 to 19.8)	47.1 (45.0 to 49.5)	152.2 (135.3 to 171.2)	-11.3 (-18.2 to -4.8)	4.4 (3.1 to 6.0)	11.2 (8.0 to 15.1)	154.2 (129.2 to 182.5)	-10.6 (-18.4 to -2.5)
Osteoarthritis	149.7 (140.2 to 159.6)	449.6 (422.4 to 474.2)	200.0 (174.4 to 226.1)	-0.8 (-8.3 to 6.9)	9.0 (6.3 to 12.2)	27.2 (19.2 to 37.7)	200.5 (175.3 to 227.0)	-0.4 (-8.0 to 7.7)
Low back and neck pain	-	-	-	-	-	-	-	-
Low back pain	605.4 (463.5 to 745.9)	1,624.9 (1,321.7 to 2,002.7)	164.0 (97.6 to 301.6)	-0.1 (-24.8 to 32.2)	66.7 (42.1 to 99.1)	179.8 (115.9 to 265.3)	164.9 (99.0 to 305.5)	0.5 (-23.9 to 35.2)
Neck pain	302.1 (255.4 to 347.0)	836.5 (689.8 to 955.2)	176.3 (125.9 to 241.1)	0.9 (-17.2 to 22.9)	29.3 (19.5 to 40.9)	81.3 (54.8 to 114.3)	178.8 (124.1 to 242.8)	1.8 (-15.9 to 23.5)
Gout	2.8 (2.4 to 3.2)	8.1 (6.8 to 9.2)	195.2 (133.8 to 264.8)	3.2 (-17.7 to 27.3)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	193.1 (121.6 to 295.3)	3.4 (-20.1 to 37.6)
Other musculoskeletal disorders	75.3 (50.1 to 113.5)	288.1 (166.9 to 398.4)	282.5 (203.1 to 370.2)	30.1 (5.6 to 60.9)	6.8 (3.8 to 11.5)	26.6 (13.9 to 42.8)	31.4 (204.8 to 378.3)	1.1 (6.8 to 63.9)
Other non-communicable diseases	-	-	-	-	-	-	-	-
Congenital anomalies	-	-	-	-	-	-	-	-
Neural tube defects	0.8 (0.6 to 1.0)	4.9 (3.9 to 6.0)	527.5 (362.2 to 810.5)	194.3 (115.2 to 334.4)	0.2 (0.1 to 0.3)	1.3 (0.8 to 1.8)	620.9 (370.1 to 1,022.3)	252.7 (130.4 to 438.6)
Congenital heart anomalies	7.5 (5.5 to 10.0)	52.1 (39.3 to 66.2)	596.4 (365.5 to 955.8)	243.1 (115.5 to 446.7)	0.4 (0.2 to 0.6)	2.0 (0.9 to 3.4)	408.8 (215.2 to 687.1)	156.9 (60.6 to 308.1)
Orofacial clefts	1.0 (0.6 to 1.7)	8.6 (5.4 to 12.0)	719.5 (345.7 to 1,538.9)	337.0 (132.7 to 817.8)	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	689.2 (302.8 to 1,534.3)	321.5 (111.1 to 784.4)
Down syndrome	7.1 (5.2 to 9.5)	31.2 (24.9 to 41.5)	345.5 (192.2 to 561.0)	94.4 (26.4 to 187.1)	0.8 (0.5 to 1.2)	3.5 (2.4 to 5.2)	351.9 (191.7 to 588.3)	97.0 (28.7 to 202.3)
Turner syndrome	0.2 (0.2 to 0.3)	0.8 (0.6 to 1.1)	238.2 (126.1 to 402.7)	39.3 (-7.9 to 110.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	241.8 (122.9 to 433.7)	39.6 (8.8 to 116.1)
Klinefelter syndrome	0.4 (0.3 to 0.5)	0.9 (0.7 to 1.2)	161.2 (70.7 to 281.0)	5.0 (-31.6 to 52.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	161.4 (70.9 to 281.7)	3.8 (-32.3 to 51.5)
Chromosomal unbalanced rearrangements	630.0 (5.4 to 8.8)	1,642.2 (22.8 to 35.0)	172.1 (204.6 to 473.1)	77.6 (31.1 to 149.0)	0.8 (0.5 to 1.1)	3.2 (2.2 to 4.5)	80.1 (197.3 to 498.0)	31.1 (29.7 to 160.7)
Other congenital anomalies	29.5 (25.0 to 34.1)	69.8 (58.0 to 82.1)	134.6 (101.3 to 178.4)	-10.3 (-22.8 to 5.3)	2.5 (1.6 to 3.6)	6.8 (4.5 to 10.3)	171.9 (122.0 to 255.1)	1.2 (-10.2 to 29.3)
Skin and subcutaneous diseases	-	-	-	-	-	-	-	-
Dermatitis	625.3 (496.0 to 765.0)	1,647.4 (1,295.1 to 2,026.6)	163.0 (159.6 to 165.4)	-0.2 (-4.3 to -0.1)	21.4 (12.6 to 32.4)	56.5 (32.9 to 84.3)	163.5 (153.0 to 174.4)	0.6 (-1.9 to 3.4)
Psoriasis	55.5 (43.9 to 68.9)	159.2 (119.6 to 186.3)	170.2 (168.1 to 172.2)	0.0 (-0.1 to 0.2)	4.5 (2.9 to 6.6)	12.2 (7.9 to 18.1)	172.5 (152.3 to 196.1)	0.9 (-5.2 to 6.7)
Cellulitis	2.4 (1.9 to 3.1)	4.9 (3.8 to 6.4)	105.1 (74.9 to 133.0)	-15.6 (-26.3 to -4.3)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	108.8 (54.1 to 176.4)	-14.5 (-31.1 to 6.5)
Pyoderma	10.9 (8.5 to 14.0)	22.9 (18.2 to 28.7)	108.6 (94.6 to 125.5)	-7.6 (-13.1 to -1.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.3)	109.0 (82.6 to 141.6)	-7.1 (-17.5 to 4.7)
Scabies	51.6 (40.4 to 67.8)	130.0 (102.7 to 162.4)	153.1 (63.4 to 257.5)	-1.0 (-35.1 to 45.2)	1.3 (0.7 to 2.3)	3.3 (1.8 to 5.6)	153.4 (63.1 to 258.2)	-0.5 (-35.0 to 47.4)
Fungal skin diseases	603.0 (446.0 to 767.5)	1,642.2 (1,212.2 to 2,088.0)	172.1 (169.3 to 175.1)	77.6 (-0.3 to 0.2)	0.8 (1.3 to 7.3)	3.2 (1.3 to 7.3)	80.1 (169.2 to 178.5)	0.5 (-0.5 to 1.6)
Viral skin diseases	292.8 (223.0 to 359.1)	750.1 (590.1 to 897.0)	155.7 (145.2 to 168.3)	0.2 (-1.9 to 2.2)	9.0 (5.3 to 14.0)	23.2 (13.6 to 36.1)	156.8 (143.4 to 171.3)	0.7 (-2.8 to 4.2)
Acne vulgaris	1,214.8 (840.3 to 1,572.2)	3,043.4 (1,989.8 to 3,959.3)	152.9 (54.2 to 282.9)	-8.2 (-44.0 to 32.5)	13.1 (5.8 to 25.3)	33.0 (14.4 to 65.0)	154.4 (55.0 to 286.0)	-7.9 (-43.4 to 34.0)
Alopecia areata	14.2 (12.1 to 16.6)	37.6 (32.3 to 42.6)	165.9 (118.2 to 223.0)	2.1 (-14.6 to 21.4)	0.5 (0.3 to 0.7)	1.3 (0.8 to 1.9)	167.5 (112.2 to 234.3)	3.1 (-15.8 to 25.1)
Pruritus	1.6 (0.9 to 2.5)	6.4 (4.6 to 9.1)	295.4 (106.4 to 629.5)	61.8 (-7.8 to 183.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	291.1 (101.4 to 680.7)	61.8 (-10.3 to 192.1)
Urticaria	77.7 (48.4 to 116.9)	214.6 (152.3 to 278.5)	178.2 (61.5 to 385.8)	1.6 (-34.3 to 64.5)	4.6 (2.5 to 7.7)	12.7 (7.4 to 19.4)	179.5 (59.5 to 395.6)	1.8 (-34.2 to 66.9)
Decubitus ulcer	0.9 (0.7 to 1.1)	2.2 (1.8 to 2.8)	135.6 (86.5 to 230.0)	-21.6 (-49.1 to 32.8)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	133.4 (81.3 to 224.4)	-21.3 (-49.3 to 31.6)
Other skin and subcutaneous diseases	424.3 (299.9 to 592.8)	1,170.1 (807.7 to 1,656.0)	175.2 (158.8 to 192.4)	-0.0 (-3.5 to 3.5)	2.5 (1.1 to 5.0)	6.8 (3.0 to 14.0)	175.8 (158.9 to 193.5)	0.4 (-3.3 to 4.3)
Sense organ diseases	-	-	-	-	-	-	-	-
Glaucoma	18.3 (12.8 to 24.2)	54.8 (40.8 to 78.8)	395.8 (132.5 to 308.1)	6.4 (-15.6 to 42.6)	1.4 (0.9 to 2.1)	4.0 (2.4 to 6.3)	181.9 (134.9 to 261.6)	0.7 (-17.9 to 33.4)
Cataract	45.2 (31.5 to 61.6)	116.3 (78.3 to 161.0)	159.9 (89.7 to 230.9)	-16.5 (-37.7 to 4.9)	3.4 (2.1 to 5.0)	9.1 (5.5 to 13.7)	169.6 (113.3 to 242.9)	-14.3 (-32.4 to 7.9)
Macular degeneration	9.5 (5.2 to 15.9)	30.0 (16.0 to 47.3)	214.9 (101.9 to 425.2)	-2.3 (-33.7 to 51.5)	0.6 (0.3 to 1.0)	1.8 (0.9 to 3.2)	221.6 (111.6 to 392.8)	-2.7 (-33.2 to 41.4)
Uncorrected refractive error	894.9 (697.1 to 956.0)	2,244.9 (1,934.2 to 2,592.9)	168.1 (124.3 to 226.3)	-2.4 (-16.2 to 14.6)	18.9 (12.3 to 28.2)	45.4 (29.2 to 69.6)	139.0 (117.0 to 170.5)	-12.6 (-19.8 to -2.5)
Age-related and other hearing loss	611.9 (561.4 to 668.0)	1,575.1 (1,455.9 to 1,716.3)	157.3 (142.5 to 171.8)	-9.1 (-12.4 to -6.0)	15.6 (10.3 to 22.5)	39.2 (25.7 to 56.4)	152.0 (128.7 to 175.1)	-10.1 (-14.8 to -5.1)
Other vision loss	66.2 (52.5 to 84.4)	145.7 (113.0 to 182.9)	120.2 (93.2 to 147.3)	-13.1 (-22.8 to 0.8)	5.1 (3.2 to 7.5)	10.9 (6.8 to 16.1)	113.7 (87.9 to 142.8)	-16.1 (-25.0 to -1.8)
Other sense organ diseases	286.8 (269.1 to 304.4)	718.0 (679.1 to 756.2)	150.1 (128.5 to 171.7)	-0.0 (-6.6 to 6.8)	7.6 (4.7 to 11.4)	19.1 (11.7 to 28.3)	150.8 (126.9 to 175.3)	0.6 (-7.1 to 8.2)
Oral disorders	-	-	-	-	-	-	-	-
Deciduous caries	1,564.6 (1,481.2 to 1,643.1)	3,721.5 (3,559.8 to 3,891.2)	137.5 (123.0 to 153.2)	-0.3 (-6.2 to 6.5)	0.3 (0.2 to 1.1)	0.6 (0.6 to 2.7)	176.9 (160.2 to 193.5)	-3.6 (-10.2 to 2.8)
Permanent caries	3,254.0 (2,925.6 to 3,651.2)	8,967.6 (7,877.5 to 10,458.8)	173.4 (136.1 to 224.5)	1.2 (-12.1 to 19.0)	1.2 (1.4 to 6.1)	8.9 (4.1 to 17.6)	174.7 (136.3 to 225.9)	1.9 (-12.0 to 20.2)
Periodontal diseases	368.1 (337.4 to 400.7)	1,045.6 (960.5 to 1,151.1)	182.3 (155.1 to 221.1)	2.8 (-8.6 to 18.1)	2.4 (1.0 to 4			

Appendix Table G.4 - Afghanistan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	250.5 (229.9 to 270.7)	706.0 (654.2 to 760.5)	182.3 (149.6 to 212.7)	-7.2 (-17.3 to 1.6)	6.8 (4.6 to 9.6)	19.2 (13.1 to 26.7)	182.9 (149.6 to 213.8)	-6.8 (-16.9 to 2.2)
Other oral disorders	160.1 (150.4 to 171.0)	432.3 (406.4 to 456.3)	169.3 (152.0 to 188.9)	-0.6 (-6.2 to 5.6)	4.7 (2.9 to 7.0)	12.7 (8.0 to 18.9)	170.9 (151.5 to 193.6)	0.2 (-6.1 to 7.2)
Injuries	-	-	-	-	229.1 (95.5 to 491.7)	274.8 (149.2 to 501.5)	24.4 (0.9 to 59.3)	-40.2 (-47.4 to -30.3)
Transport injuries	-	-	-	-	22.3 (17.0 to 28.8)	53.8 (40.5 to 69.2)	141.2 (129.9 to 153.4)	-4.9 (-8.0 to -1.2)
Road injuries	-	-	-	-	10.3 (5.3 to 25.9)	46.5 (34.9 to 59.7)	131.3 (119.1 to 144.6)	-8.9 (-12.4 to -4.8)
Pedestrian road injuries	-	-	-	-	5.1 (3.8 to 6.6)	10.7 (8.0 to 13.9)	109.5 (91.0 to 127.5)	-14.8 (-20.0 to -9.8)
Cyclist road injuries	-	-	-	-	1.8 (1.4 to 2.4)	4.7 (3.5 to 6.0)	152.9 (137.5 to 170.7)	-0.7 (-6.4 to 6.4)
Motorcyclist road injuries	-	-	-	-	2.7 (2.0 to 3.4)	4.9 (3.7 to 6.3)	82.6 (70.6 to 96.4)	-26.7 (-31.0 to -21.9)
Motor vehicle road injuries	-	-	-	-	10.3 (7.8 to 13.2)	26.0 (19.5 to 33.7)	152.1 (132.4 to 175.9)	-2.5 (-8.5 to 5.1)
Other road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	40.2 (29.8 to 50.7)	-49.0 (-52.2 to -45.9)
Other transport injuries	-	-	-	-	2.2 (1.7 to 2.8)	7.3 (5.5 to 9.4)	231.0 (211.9 to 251.5)	28.7 (21.2 to 36.5)
Unintentional injuries	-	-	-	-	21.3 (16.2 to 27.3)	53.3 (41.0 to 68.5)	150.4 (141.7 to 158.2)	-5.9 (-8.6 to -3.3)
Falls	-	-	-	-	6.5 (4.9 to 8.4)	18.0 (13.6 to 23.2)	176.7 (163.2 to 190.6)	1.1 (-3.1 to 5.3)
Drowning	-	-	-	-	0.5 (0.4 to 0.6)	0.9 (0.7 to 1.2)	84.9 (67.9 to 110.1)	-25.3 (-32.0 to -18.4)
Fire, heat, and hot substances	-	-	-	-	1.9 (1.5 to 2.5)	3.3 (2.6 to 4.2)	70.5 (54.0 to 86.3)	-33.5 (-38.5 to -28.2)
Poisonings	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	69.2 (34.9 to 110.1)	-34.8 (-46.2 to -22.4)
Exposure to mechanical forces	-	-	-	-	5.9 (4.5 to 7.8)	15.0 (11.2 to 19.6)	153.9 (138.2 to 169.9)	-4.4 (-9.3 to 1.0)
Unintentional firearm injuries	-	-	-	-	0.3 (0.2 to 0.3)	0.6 (0.5 to 0.8)	124.6 (106.0 to 145.0)	-15.5 (-21.6 to -8.8)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	247.6 (214.4 to 288.0)	33.2 (22.4 to 45.6)
Other exposure to mechanical forces	-	-	-	-	5.6 (4.2 to 7.4)	14.2 (10.7 to 18.6)	154.7 (138.3 to 171.1)	-4.1 (-9.2 to 1.5)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	190.0 (170.0 to 211.1)	13.8 (5.3 to 23.0)
Animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.9 (0.6 to 1.1)	170.5 (148.4 to 194.4)	2.3 (-3.9 to 8.8)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.5)	163.2 (126.9 to 201.6)	-0.7 (-11.9 to 10.3)
Non-venomous animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.5 (0.4 to 0.7)	176.1 (154.2 to 200.9)	4.4 (-0.5 to 11.0)
Foreign body	-	-	-	-	0.3 (0.2 to 0.4)	0.8 (0.6 to 1.1)	158.3 (142.7 to 174.0)	-0.9 (-5.6 to 4.0)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	117.0 (89.7 to 154.4)	-11.5 (-19.9 to -1.1)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	160.3 (130.5 to 194.4)	0.9 (-8.5 to 11.1)
Foreign body in other body part	-	-	-	-	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.6)	176.8 (159.6 to 193.6)	2.3 (-4.5 to 8.4)
Other unintentional injuries	-	-	-	-	5.5 (4.2 to 7.1)	13.7 (10.4 to 17.7)	148.7 (133.1 to 167.1)	-8.0 (-13.5 to -1.4)
Self-harm and interpersonal violence	-	-	-	-	2.8 (2.1 to 3.5)	7.2 (5.5 to 9.1)	159.3 (145.6 to 172.6)	-0.3 (-5.1 to 4.0)
Self-harm	-	-	-	-	0.3 (0.2 to 0.4)	0.9 (0.7 to 1.2)	187.7 (164.2 to 215.4)	7.8 (-0.3 to 17.0)
Interpersonal violence	-	-	-	-	2.4 (1.9 to 3.1)	6.2 (4.8 to 7.9)	155.6 (141.0 to 170.3)	-1.6 (-6.7 to 3.3)
Assault by firearm	-	-	-	-	0.5 (0.4 to 0.6)	1.2 (0.9 to 1.6)	154.9 (137.0 to 178.6)	1.0 (-5.6 to 9.8)
Assault by sharp object	-	-	-	-	0.5 (0.4 to 0.7)	1.4 (1.0 to 1.8)	165.1 (144.5 to 188.6)	3.7 (-3.8 to 12.5)
Assault by other means	-	-	-	-	1.4 (1.1 to 1.8)	3.6 (2.8 to 4.6)	152.3 (132.0 to 171.6)	-4.5 (-11.7 to 1.9)
Forces of nature, war, and legal intervention	-	-	-	-	182.7 (53.0 to 444.1)	160.6 (47.7 to 381.1)	-11.6 (-17.2 to -5.5)	-51.4 (-55.4 to -47.1)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.1)	0.5 (0.2 to 1.0)	1,700.3 (755.5 to 4,113.2)	379.2 (141.6 to 980.1)
Collective violence and legal intervention	-	-	-	-	182.7 (53.0 to 444.1)	160.1 (47.4 to 380.1)	-11.9 (-17.5 to -5.8)	-51.5 (-55.5 to -47.2)

Appendix Table G.4 - Albania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	320.8 (239.8 to 417.5)	360.0 (268.8 to 468.0)	11.2 (9.1 to 15.6)	12.2 (-6.0 to 1.1)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	38.4 (26.6 to 53.6)	30.4 (21.2 to 41.5)	-21.1 (-30.0 to -9.5)	-0.9 (-11.8 to 13.5)
HIV/AIDS and tuberculosis	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	0.3 (2.4 to 36.3)	-3.9 (-16.5 to 9.4)
Tuberculosis	1.0 (0.9 to 1.0)	1.1 (1.1 to 1.2)	17.7 (11.8 to 24.7)	-5.4 (-9.9 to -0.0)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	16.3 (1.0 to 35.5)	-4.8 (-17.4 to 8.6)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	324.7 (42.1 to 1,405.0)	295.6 (29.1 to 3,78.4)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	280.1 (21.2 to 1,313.0)	212.3 (-3.7 to 1,121.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	280.1 (21.2 to 1,316.2)	212.3 (-3.8 to 1,122.9)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	279.6 (34.7 to 1,297.0)	275.3 (29.9 to 1,290.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	325.6 (41.8 to 1,453.4)	297.3 (28.4 to 1,459.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	4.2 (3.0 to 5.7)	2.5 (1.8 to 3.4)	-40.1 (-44.2 to -35.8)	-20.6 (-25.4 to -15.7)
Diarrheal diseases	11.7 (10.8 to 12.6)	7.5 (7.1 to 7.9)	-35.6 (-41.3 to -28.9)	-8.6 (-16.6 to 0.6)	1.9 (1.3 to 2.6)	1.2 (0.8 to 1.6)	-36.6 (-43.3 to -29.2)	-8.5 (-17.4 to 1.8)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-82.6 to -33.0)	0.0 (-78.6 to -16.8)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.4 (-56.8 to -15.7)	-30.8 (-47.9 to 2.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.4 (-57.1 to -15.7)	-30.8 (-48.0 to 2.7)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.8 (-57.3 to -18.8)	-29.1 (-46.4 to 3.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.8 (-57.3 to -18.7)	-29.1 (-46.4 to 3.5)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-95.7 (-99.8 to -88.4)	-94.7 (-99.8 to -14.1)
Lower respiratory infections	1.0 (0.8 to 1.1)	0.4 (0.4 to 0.5)	-55.3 (-63.9 to -43.7)	-38.5 (-48.5 to -22.9)	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-55.6 (-66.1 to -40.7)	-37.2 (-51.0 to -16.3)
Upper respiratory infections	35.6 (34.1 to 36.9)	30.5 (29.1 to 31.7)	-14.6 (-19.1 to -9.4)	-1.6 (-6.5 to 4.1)	0.4 (0.2 to 0.7)	0.4 (0.2 to 0.6)	-14.9 (-20.8 to -8.7)	-1.3 (-8.0 to 5.9)
Otitis media	39.5 (36.2 to 43.0)	31.4 (29.2 to 34.1)	-20.6 (-27.1 to -14.3)	-6.5 (-13.6 to 1.1)	0.8 (0.5 to 1.3)	0.6 (0.4 to 1.0)	-23.9 (-30.9 to -16.7)	-8.2 (-16.2 to 0.4)
Meningitis	-	-	-	-	0.4 (0.2 to 0.5)	0.1 (0.1 to 0.2)	-61.8 (-69.2 to -49.7)	-55.2 (-63.7 to -40.2)
Pneumococcal meningitis	1.3 (0.8 to 2.0)	0.6 (0.3 to 0.9)	-56.4 (-68.3 to -46.0)	-55.8 (-67.2 to -45.3)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-60.1 (-70.8 to -45.1)	-55.3 (-67.0 to -38.8)
H influenzae type B meningitis	0.7 (0.3 to 1.4)	0.2 (0.1 to 0.5)	-68.5 (-81.4 to -49.7)	-64.5 (-78.2 to -41.4)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-68.9 (-84.1 to -43.0)	-61.5 (-80.3 to -29.0)
Meningococcal meningitis	0.4 (0.1 to 0.8)	0.1 (0.0 to 0.3)	-64.5 (-78.7 to -32.3)	-62.6 (-76.0 to -25.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-59.8 (-79.1 to -15.5)	-53.9 (-76.0 to 0.9)
Other meningitis	0.7 (0.4 to 1.3)	0.3 (0.1 to 0.6)	-59.0 (-69.4 to -46.6)	-54.5 (-65.8 to -40.3)	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-58.8 (-71.8 to -38.8)	-50.4 (-65.8 to -25.7)
Encephalitis	0.9 (0.4 to 2.1)	0.7 (0.3 to 1.7)	-22.7 (-37.8 to -8.7)	-25.5 (-39.0 to -12.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-20.7 (-35.4 to -2.2)	-20.6 (-34.8 to -3.7)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.6 (-96.0 to 387.9)	-41.0 (-94.7 to 646.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.6 (-96.0 to 390.7)	-41.0 (-94.7 to 649.8)
Whooping cough	1.8 (1.4 to 2.3)	0.1 (0.1 to 0.1)	-93.9 (-94.7 to -93.1)	-87.6 (-89.2 to -85.9)	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-93.9 (-95.3 to -92.4)	-87.5 (-90.5 to -84.5)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-91.0 (-94.8 to -82.4)	-90.4 (-94.4 to -81.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-88.1 (-92.6 to -80.0)	-87.2 (-91.9 to -78.1)
Measles	3.7 (3.7 to 3.8)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.3 (0.2 to 0.5)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	2.2 (2.1 to 2.3)	1.6 (1.5 to 1.8)	-26.0 (-32.2 to -17.8)	-2.8 (-10.8 to 7.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-15.5 to 37.8)	-2.7 (-22.3 to 23.2)
Neglected tropical diseases and malaria	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-32.3 to 27.4)	0.0 (-35.5 to 23.3)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.0 (-76.0 to 263.2)	34.4 (-70.2 to 351.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.0 (-75.6 to 267.4)	36.4 (-70.1 to 354.8)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.4 (-44.1 to -0.4)	-6.5 (-28.2 to 26.5)
Visceral leishmaniasis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-27.2 (-44.4 to 0.8)	-5.7 (-28.3 to 28.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.2 (-44.5 to 0.8)	-5.7 (-28.4 to 28.2)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.3 (-55.7 to -7.2)	-27.1 (-49.3 to 4.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.3 (-55.7 to -7.0)	-27.1 (-49.3 to 4.2)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-85.2 (-94.2 to -60.1)	-87.8 (-95.2 to -68.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-84.3 (-93.9 to -57.2)	-87.2 (-95.1 to -66.0)
Cystic echinococcosis	0.3 (0.3 to 0.3)	0.4 (0.4 to 0.4)	36.5 (20.6 to 47.7)	30.7 (19.7 to 37.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	32.9 (1.2 to 75.9)	29.3 (1.1 to 65.3)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.9 (-73.5 to -31.6)	-47.1 (-71.1 to -22.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.9 (-73.5 to -31.3)	-47.1 (-71.3 to -22.4)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.5 (-44.1 to 5.1)	-1.9 (-29.9 to 34.3)
Maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-57.5 (-67.7 to -43.9)	47.1 (-59.6 to -30.2)
Maternal hemorrhage	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-41.3 (-64.7 to 4.1)	-23.2 (-54.7 to 33.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.1 (-75.7 to 9.7)	-32.0 (-69.9 to 37.6)
Maternal sepsis and other maternal infections	1.3 (0.8 to 1.8)	0.3 (0.2 to 0.4)	-77.4 (-85.8 to -67.6)	-75.6 (-85.6 to -64.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-80.7 (-88.9 to -64.4)	-77.1 (-86.2 to -58.6)
Maternal hypertensive disorders	0.8 (0.4 to 1.3)	0.4 (0.2 to 0.6)	-53.5 (-60.1 to -41.2)	-41.2 (-49.8 to -25.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-53.3 (-64.9 to -35.6)	-41.0 (-55.9 to -18.4)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.9 (-78.7 to 86.1)	-32.6 (-72.2 to 133.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.9 (-78.8 to 87.1)	-32.6 (-72.4 to 133.1)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.1 (-52.1 to 76.1)	17.1 (-39.7 to 119.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.1 (-52.2 to 76.6)	17.1 (-39.8 to 119.3)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-55.5 (-73.2 to -30.1)	-44.4 (-66.5 to -12.7)
Neonatal disorders	-	-	-	-	4.5 (2.9 to 6.8)	8.2 (5.0 to 11.9)	83.9 (5.0 to 188.8)	118.1 (25.3 to 242.6)
Preterm birth complications	12.1 (8.7 to 16.3)	14.8 (11.3 to 19.4)	22.5 (6.0 to 43.6)	36.6 (18.3 to 60.3)	1.2 (0.8 to 1.6)	1.7 (1.1 to 2.3)	44.3 (9.7 to 94.0)	67.6 (27.6 to 125.2)
Neonatal encephalopathy due to birth asphyxia and trauma	2.8 (1.3 to 6.7)	1.9 (0.8 to 4.7)	-32.9 (-60.1 to 12.2)	-20.6 (-51.7 to 38.1)	0.6 (0.3 to 1.0)	0.4 (0.2 to 0.7)	-26.1 (-62.8 to 45.7)	-7.2 (-53.6 to 82.8)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.5 (1.3 to 58.8)	131.1 (109.9 to 229.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.9 (-69.7 to 272.5)	134.1 (-37.1 to 672.1)
Hemolytic disease and other neonatal jaundice	2.5 (1.1 to 4.8)	2.6 (1.4 to 4.5)	10.1 (-59.8 to 211.5)	29.9 (-52.5 to 271.7)	0.9 (0.4 to 1.9)	1.0 (0.5 to 1.8)	9.8 (-60.6 to 210.4)	30.7 (-53.2 to 271.9)
Other neonatal disorders	-	-	-	-	1.8 (1.0 to 3.1)	5.0 (2.5 to 8.1)	194.8 (19.7 to 400.4)	249.3 (41.5 to 493.6)
Nutritional deficiencies	-	-	-	-	27.4 (18.3 to 39.4)	17.9 (11.9 to 25.9)	-34.7 (-38.0 to -31.9)	-16.4 (-20.2 to -13.0)
Protein-energy malnutrition	13.5 (9.5 to 18.3)	5.5 (4.0 to 7.4)	-58.8 (-73.7 to -37.0)	-34.4 (-45.4 to 30.8)	1.7 (1.0 to 2.7)	0.7 (0.4 to 1.1)	-58.9 (-73.9 to -36.4)	-14.5 (-45.8 to 32.1)
Iodine deficiency	35.2 (17.0 to 66.4)	22.2 (9.9 to 37.9)	-36.7 (-74.5 to 61.3)	-34.8 (-73.8 to 61.2)	0.4 (0.3 to 1.3)	0.4 (0.2 to 0.8)	-37.2 (-74.8 to 58.7)	-35.6 (-73.8 to 63.3)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-

Appendix Table G.4 - Albania prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	836.1 (823.9 to 850.6)	630.4 (617.5 to 643.6)	-24.6 (-26.5 to -22.7)	-14.6 (-16.8 to -12.5)	25.0 (16.7 to 36.4)	16.8 (11.2 to 24.4)	-33.0 (-36.0 to -30.9)	-16.1 (-19.7 to -13.4)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-13.5 (-63.9 to 88.1)	79.8 (-25.0 to 290.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.9 (1.2 to 2.9)	1.4 (0.8 to 2.1)	-29.2 (-40.0 to -13.7)	-11.4 (-25.5 to 6.7)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.6 (0.3 to 1.1)	0.5 (0.3 to 1.0)	-8.9 (-20.5 to 4.4)	-5.9 (-16.1 to 7.3)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	30.2 (8.1 to 54.1)	-11.4 (-25.9 to 3.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.5 (-4.9 to 74.9)	-12.3 (-34.5 to 20.8)
Chlamydial infection	86.0 (75.3 to 97.5)	74.8 (65.9 to 84.2)	-13.0 (-28.5 to 3.8)	-2.6 (-20.1 to 15.4)	0.3 (0.1 to 0.5)	0.2 (0.1 to 0.4)	-15.3 (-31.0 to 4.9)	5.4 (-2.6 to 15.0)
Gonococcal infection	21.7 (17.0 to 27.2)	16.1 (12.4 to 19.2)	-26.2 (-46.0 to 5.4)	-12.9 (-35.9 to 24.1)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-29.3 (-51.8 to 0.9)	-17.5 (-43.1 to 17.0)
Trichomoniasis	42.5 (29.2 to 60.6)	44.4 (32.2 to 59.2)	2.2 (-35.2 to 75.5)	12.2 (-25.3 to 83.7)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	2.1 (-39.0 to 89.5)	12.3 (-28.5 to 98.4)
Genital herpes	481.7 (437.7 to 529.9)	599.1 (486.3 to 596.7)	22.0 (-2.0 to 29.0)	8.4 (-19.5 to 5.6)	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.3)	-2.9 (-7.5 to 25.5)	-8.7 (-19.9 to 6.8)
Other sexually transmitted diseases	0.8 (0.6 to 1.1)	0.7 (0.5 to 0.8)	-20.9 (-32.3 to -6.5)	-18.1 (-29.2 to -3.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-40.9 to 29.5)	-11.7 (-38.6 to 30.9)
Hepatitis	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-21.2 (-31.3 to -8.8)	-14.0 (-25.5 to -0.2)
Hepatitis A	4.5 (4.3 to 4.7)	3.0 (3.0 to 3.1)	-32.7 (-33.5 to -31.8)	-7.8 (-8.0 to -7.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-18.7 (-27.4 to -9.2)	-2.5 (-12.5 to 8.5)
Hepatitis B	84.5 (69.1 to 104.6)	51.9 (42.8 to 60.5)	-37.6 (-53.3 to -21.9)	-39.0 (-53.5 to -23.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-29.3 (-54.1 to -11.2)	-36.2 (-58.0 to 1.0)
Hepatitis C	44.2 (39.5 to 49.2)	41.3 (37.4 to 45.8)	-6.6 (-19.0 to 9.2)	-6.6 (-33.6 to -11.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.5 (-35.2 to 24.2)	-25.7 (-47.9 to 6.3)
Hepatitis E	-	-	-	-	-	-	-	-
Leprosy	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-
Other infectious diseases	36.8 (30.5 to 41.7)	24.9 (21.5 to 28.4)	-32.5 (-43.0 to -18.4)	-13.9 (-28.0 to 3.5)	1.2 (0.7 to 1.7)	0.7 (0.4 to 1.1)	-39.8 (-55.7 to -16.7)	-14.0 (-37.6 to 17.2)
Non-communicable diseases	-	-	-	-	-	-	-	-
Neoplasms	-	-	-	-	(189.9 to 327.5)	(225.3 to 391.7)	(15.4 to 23.3)	(-3.1 to 2.8)
Esophageal cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	17.9 (-19.0 to 78.5)	-32.8 (-53.9 to 1.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.8 (-15.3 to 78.2)	-31.3 (-51.8 to 1.9)
Stomach cancer	0.8 (0.7 to 0.9)	1.1 (0.8 to 1.5)	47.5 (8.0 to 94.9)	-16.2 (-38.6 to 11.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	44.8 (5.5 to 92.1)	-17.2 (-39.6 to 10.7)
Liver cancer	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	86.3 (12.8 to 185.5)	3.4 (-32.7 to 58.9)
Liver cancer due to hepatitis B	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	40.8 (-36.8 to 214.0)	-20.3 (-64.3 to 78.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.7 (-29.3 to 178.9)	-18.5 (-59.1 to 60.1)
Liver cancer due to hepatitis C	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	293.0 (75.8 to 706.2)	114.0 (-4.5 to 331.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	268.2 (77.7 to 590.0)	98.8 (-2.8 to 270.9)
Liver cancer due to alcohol use	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	70.4 (-5.5 to 215.9)	-7.3 (-48.8 to 71.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	66.6 (-3.8 to 174.8)	-9.3 (-48.2 to 52.0)
Liver cancer due to other causes	0.1 (0.0 to 0.1)	0.7 (0.0 to 1.1)	408.0 (-49.0 to 91.2)	0.7 (-70.1 to 14.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.4 (-44.5 to 65.6)	42.9 (-67.3 to -2.4)
Larynx cancer	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	35.0 (-16.8 to 129.7)	-21.2 (-51.1 to 36.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	41.1 (-7.7 to 115.2)	-17.5 (-45.1 to 24.8)
Tracheal, bronchus and lung cancer	0.7 (0.6 to 0.9)	1.5 (1.2 to 2.0)	107.4 (54.0 to 175.8)	17.5 (-12.5 to 56.4)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	97.3 (47.1 to 161.8)	12.3 (-16.2 to 50.0)
Breast cancer	0.8 (0.7 to 1.1)	5.2 (4.0 to 6.3)	513.7 (343.2 to 703.7)	310.7 (196.4 to 438.1)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.5)	246.3 (134.3 to 396.1)	128.5 (56.1 to 227.6)
Cervical cancer	0.7 (0.8 to 1.2)	1.2 (0.8 to 1.7)	72.0 (-23.6 to 73.9)	-56.8 (-43.1 to 27.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	13.3 (-21.4 to 76.4)	-15.9 (-43.7 to 30.2)
Uterine cancer	0.7 (0.5 to 0.9)	1.3 (0.8 to 2.0)	85.6 (14.3 to 228.1)	22.1 (-24.2 to 114.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	83.7 (-11.1 to 227.5)	20.7 (-26.2 to 110.9)
Prostate cancer	2.0 (1.6 to 2.5)	5.6 (4.2 to 7.8)	175.2 (93.6 to 289.3)	45.2 (0.8 to 105.8)	0.2 (0.1 to 0.2)	0.5 (0.3 to 0.8)	195.5 (102.9 to 351.4)	55.5 (7.7 to 141.7)
Colon and rectum cancer	0.8 (0.7 to 0.9)	1.6 (1.3 to 1.9)	106.1 (62.7 to 168.9)	21.8 (-6.8 to 60.8)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	92.6 (48.4 to 151.8)	13.9 (-13.9 to 51.2)
Lip and oral cavity cancer	0.5 (0.4 to 0.6)	0.6 (0.4 to 0.8)	24.0 (-15.1 to 94.5)	-26.9 (-49.6 to 14.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	22.4 (-15.6 to 89.7)	-27.8 (-51.2 to 11.3)
Nasopharynx cancer	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-49.2 (-50.9 to 35.0)	-49.2 (-68.2 to -11.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-49.3 to 36.9)	-21.4 (-67.4 to -12.5)
Other pharynx cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	32.7 (-25.6 to 163.2)	-24.6 (-56.7 to 46.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.9 (-18.0 to 151.5)	-25.8 (-53.9 to 43.0)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.2 (-29.0 to 91.7)	-34.7 (-58.5 to 12.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.7 (-32.0 to 75.9)	-39.0 (-60.4 to 2.8)
Pancreatic cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	177.9 (103.6 to 278.5)	56.4 (14.5 to 112.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	158.5 (95.1 to 226.8)	45.4 (10.5 to 89.3)
Malignant skin melanoma	0.4 (0.2 to 0.5)	0.7 (0.4 to 1.1)	75.1 (23.2 to 190.2)	19.4 (-16.0 to 98.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	19.0 (-22.3 to 92.2)	15.4 (-22.3 to 92.2)
Non-melanoma skin cancer	1.6 (1.1 to 2.0)	4.1 (2.9 to 5.3)	163.7 (77.4 to 291.6)	46.6 (-3.0 to 113.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	230.0 (113.8 to 372.7)	76.5 (11.4 to 161.5)
Ovarian cancer	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	84.4 (22.5 to 171.0)	36.1 (-8.7 to 101.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	71.6 (9.0 to 172.0)	26.4 (-18.6 to 99.6)
Testicular cancer	0.3 (0.2 to 0.5)	0.3 (0.1 to 0.4)	-18.4 (-55.4 to 75.3)	-15.2 (-53.5 to 82.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.7 (-58.2 to 85.8)	-18.2 (-57.8 to 86.6)
Kidney cancer	0.2 (0.2 to 0.3)	0.8 (0.6 to 1.0)	304.8 (112.8 to 350.6)	81.3 (26.9 to 167.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	183.7 (96.1 to 324.5)	97.9 (15.5 to 149.7)
Bladder cancer	3.2 (2.4 to 3.8)	1.1 (0.9 to 1.3)	-67.0 (-74.1 to -50.9)	-83.3 (-87.0 to -75.0)	0.4 (0.2 to 0.6)	0.1 (0.1 to 0.2)	-68.7 (-75.8 to -53.2)	-84.1 (-87.7 to -76.0)
Brain and nervous system cancer	0.5 (0.4 to 0.7)	0.9 (0.7 to 1.2)	66.7 (25.5 to 127.0)	39.4 (3.6 to 85.9)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.1)	65.5 (19.2 to 127.9)	31.9 (-6.1 to 79.9)
Thyroid cancer	0.5 (0.4 to 0.7)	0.8 (0.6 to 1.3)	65.5 (10.8 to 152.9)	30.3 (-12.1 to 100.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	64.6 (8.4 to 153.6)	26.5 (-16.8 to 93.8)
Mesothelioma	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	52.8 (10.3 to 171.1)	81.0 (33.9 to 30.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.6 (8.7 to 120.0)	8.3 (-35.1 to 30.5)
Hodgkin lymphoma	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	13.0 (-22.8 to 71.9)	14.2 (-21.9 to 71.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	10.4 (-23.8 to 65.0)	6.3 (-26.1 to 56.2)
Non-Hodgkin lymphoma	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.8)	33.3 (-12.5 to 255.3)	6.8 (-29.1 to 183.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	29.8 (-14.7 to 252.1)	1.1 (-32.6 to 170.7)
Multiple myeloma	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	83.0 (10.2 to 216.7)	16.3 (-30.5 to 97.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.3 (9.8 to 194.3)	12.5 (-31.1 to 82.7)
Leukemia	0.8 (0.6 to 1.0)	1.1 (0.9 to 1.5)	49.7 (1.5 to 105.7)	47.5 (6.0 to 116.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	60.3 (16.3 to 121.4)	42.4 (6.3 to 96.5)
Other neoplasms	4.3 (2.6 to 6.3)	4.0 (2.6 to 7.0)	-14.9 (-52.1 to 119.6)	5.7 (-41.3 to 194.3)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.4)	-9.9 (-43.8 to 120.8)	9.9 (-35.1 to 166.2)
Cardiovascular diseases	-	-	-	-	3.9 (2.7 to 5.4)	7.2 (5.2 to 9.8)	86.9 (49.1 to 127.2)	4.5 (-15.8 to 26.7)
Rheumatic heart disease	0.3 (0.2 to 0.3)	0.5 (0.4 to 0.5)	62.9 (25.4 to 116.0)	0.5 (-22.7 to 34.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	60.6 (14.8 to 117.4)	0.4 (-29.6 to 36.5)
Ischemic heart disease	26.6 (22.9 to 33.5)	44.5 (39.8 to 50.7)	69.2 (25.4 to 104.2)	-8.2 (-31.0 to 9.5)	1.4 (0.9 to 2.1)	2.4 (1.6 to 3.1)	68.6 (17.0 to 111.0)	-9.8 (-35.1 to 11.0)
Cerebrovascular disease	-	-	-	-	0.5 (0.4 to 0.7)	0.9 (0.6 to 1.2)	67.3 (34.6 to 102.6)	6.4 (-14.5 to 27.8)
Ischemic stroke	2.6 (2.2 to 3.1)	4.6 (3.8 to 5.4)	74.9 (39.3 to 109.8)	6.1 (-14.2 to 26.3)	0.4 (0.3 to 0.5)	0.7 (0.5 to 1.0)	72.4 (36.6 to 110.9)	6.2 (-14.8 to 29.8)
Hemorrhagic stroke	0.7 (0.6 to 0.9)	1.1 (0.9 to 1.4)	51.8 (12.0 to 103.7)	6.6 (-21.2 to 39.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	49.4 (7.1 to 100.0)	6.4 (-23.4 to 41.0)
Hypertensive heart disease	3.7 (3.3 to 4.1)	7.8 (7.1 to 8.6)	109.5 (81.5 to 142.0)	8.2 (-6.5 to 24.8)	0.4 (0.3 to 0.6)	0.8 (0.6 to 1.2)	110.2 (80.4 to 143.9)	8.9 (-6.5 to 26.0)
Cardiomyopathy and myocarditis	4.1 (3.6 to 4.6)	5.2 (4.7 to 5.7)	26.2 (6.7 to 47.8)	-32.4 (-42.8 to -20.5)	0.4 (0.3 to 0.6)	0.5 (0.4 to 0.8)	25.8 (5.3 to 48.7)	-32.3 (-43.3 to -19.9)
Atrial fibrillation and flutter	0.1 (0.1 to 0.1)	0.7 (0.4 to 1.0)	708.1 (465.0 to 1,316.2)	410.4 (259.2 to 788.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	667.7 (380.6 to 1,298.9)	382.9 (208.4 to 815.8)
Peripheral vascular disease	60.7 (47.3 to 76.6)	104.1 (77.4 to 126.8)	73.3 (21.2 to 139.5)	-6.5 (-34.4 to 26.0)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-5.0 (-43.2 to 97.8)	-52.3 (-71.6 to -5.7)
Endocarditis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	36.7 (0.1 to 144.2)	-5.1 (-29.5 to 70.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.0 (1.9 to 107.1)	-2.0 (-31.7 to 41.3)
Other cardiovascular and circulatory diseases	13.9 (8.6 to 24.4)	34.4 (22.4 to 46.6)	159.3 (24.3 to 324.3)	55.5 (-26.6 to 159.2)	1.0 (0.5 to 1.8)	2.4 (1.4 to 3.7)	169.8 (22.7 to 329.3)	56.7 (-27.4 to 165.8)
Chronic respiratory diseases	-	-	-	-	12.6 (8.7 to 17.0)	13.8 (9.4 to 19.0)	9.0 (-4.3 to 27.3)	-15.3 (-25.8 to -3.2)
Chronic obstructive pulmonary disease	120.7 (115.4 to 125.7)	168.2 (160.8 to 175.3)	39.3 (35.3 to 43.9)	-2.3 (-5.3 to 0.7)	7.0 (4.7 to 9.8)	9.8 (6.6 to 13.8)	40.3 (20.5 to 63.3)	-0.9 (-15.7 to 14.5)

Appendix Table G.4 - Albania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.1 (20.0 to 37.8)	29.1 (-21.2 to -11.2)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.9 (43.2 to 60.5)	-5.1 (-9.8 to 0.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.5 (43.4 to 60.8)	-5.0 (-9.7 to 0.7)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.5 (36.7 to 55.1)	-5.3 (-10.2 to 0.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.1 (37.2 to 55.7)	-5.2 (-10.1 to 0.8)
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.1 (-6.2 to 15.8)	0.0 (-36.3 to -33.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.1 (5.5 to 16.4)	30.1 (-36.2 to -22.8)
Asthma	85.4 (75.5 to 96.6)	67.0 (56.1 to 78.4)	-21.8 (-35.4 to -3.0)	-21.7 (-34.7 to -4.5)	3.8 (2.4 to 5.4)	2.9 (1.8 to 4.3)	-23.3 (-37.1 to -4.0)	-23.3 (-35.9 to -4.2)
Interstitial lung disease and pulmonary sarcoidosis	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	31.2 (-9.5 to 103.1)	-1.0 (-32.0 to 49.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	33.4 (-8.1 to 103.0)	-0.9 (-31.7 to 47.9)
Other chronic respiratory diseases	-	-	-	-	1.7 (1.1 to 2.7)	0.9 (0.5 to 1.6)	-45.8 (-64.2 to -15.0)	-61.9 (-74.4 to -39.9)
Cirrhosis	-	-	-	-	0.2 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-76.1 (-79.8 to -71.6)	-76.1 (-82.0 to -74.9)
Cirrhosis due to hepatitis B	0.2 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-72.8 (-83.3 to -56.6)	-78.3 (-87.3 to -65.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-71.9 (-84.0 to -53.4)	-71.9 (-87.4 to -62.7)
Cirrhosis due to hepatitis C	0.2 (0.2 to 0.3)	0.1 (0.0 to 0.1)	-77.7 (-83.9 to -66.3)	-83.0 (-87.7 to -73.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-76.3 (-84.4 to -63.0)	-81.8 (-88.0 to -71.5)
Cirrhosis due to alcohol use	0.2 (0.1 to 0.2)	0.0 (0.0 to 0.0)	-82.7 (-89.9 to -73.2)	-88.7 (-93.1 to -82.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-87.9 (-90.1 to -69.6)	-87.9 (-93.2 to -80.4)
Cirrhosis due to other causes	0.3 (0.3 to 0.4)	0.1 (0.1 to 0.1)	-76.1 (-80.9 to -70.6)	-70.4 (-76.3 to -63.2)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-75.2 (-82.7 to -65.0)	-69.1 (-78.8 to -56.2)
Digestive diseases	-	-	-	-	2.7 (1.9 to 3.6)	3.6 (2.6 to 4.9)	34.4 (20.5 to 48.3)	-6.0 (-16.5 to 4.1)
Peptic ulcer disease	10.1 (8.3 to 11.6)	8.3 (6.3 to 9.9)	-17.9 (-37.0 to 2.7)	-54.8 (-64.6 to -44.2)	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.5)	-12.6 (-37.1 to 15.7)	-51.9 (-64.0 to -37.3)
Gastritis and duodenitis	1.6 (1.5 to 1.8)	1.9 (1.7 to 2.2)	19.5 (1.5 to 42.0)	6.1 (-8.7 to 25.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	11.2 (-15.8 to 52.7)	-2.9 (-23.1 to 31.3)
Appendicitis	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-34.1 (-52.9 to 6.9)	-20.8 (-44.6 to 21.3)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-32.7 (-59.9 to 18.5)	-19.4 (-52.5 to 36.8)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	12.2 (-48.2 to 54.7)	18.7 (-36.3 to 50.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.3 (-51.3 to 70.2)	17.3 (-38.9 to 65.3)
Inguinal, femoral, and abdominal hernia	12.8 (10.8 to 15.3)	17.0 (14.0 to 20.2)	32.7 (2.5 to 72.4)	-12.3 (-33.9 to 13.9)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-12.0 (-1.9 to 70.7)	-12.0 (-33.9 to 15.0)
Inflammatory bowel disease	3.7 (3.5 to 3.9)	6.5 (6.2 to 6.8)	73.9 (64.3 to 84.7)	35.3 (27.8 to 43.6)	0.8 (0.5 to 1.1)	1.4 (0.9 to 1.9)	72.4 (57.2 to 87.9)	35.6 (24.8 to 47.1)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.4 (30.1 to 148.4)	14.6 (-21.5 to 57.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.0 (15.8 to 150.9)	5.7 (-32.8 to 60.3)
Gallbladder and biliary diseases	6.8 (4.1 to 5.4)	4.8 (5.9 to 7.9)	-44.5 (-16.7 to 74.6)	45.5 (-26.2 to 10.7)	0.5 (0.3 to 0.7)	0.7 (0.5 to 1.0)	49.7 (16.6 to 76.3)	-4.3 (-26.0 to 12.3)
Pancreatitis	0.8 (0.7 to 0.8)	1.3 (1.3 to 1.4)	74.8 (61.6 to 91.4)	30.0 (20.0 to 41.9)	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.5)	73.6 (48.7 to 102.0)	30.9 (13.1 to 50.8)
Other digestive diseases	-	-	-	-	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.7)	3.5 (-35.9 to 31.4)	-27.7 (-55.4 to -7.3)
Neurological disorders	-	-	-	-	32.3 (21.7 to 44.5)	37.1 (25.8 to 51.2)	15.4 (-0.3 to 34.0)	0.8 (-11.6 to 15.9)
Alzheimer disease and other dementias	14.5 (12.8 to 16.3)	29.9 (26.5 to 33.5)	106.8 (73.7 to 145.9)	-9.9 (-17.0 to 17.8)	2.0 (1.5 to 2.7)	4.3 (3.1 to 5.6)	111.2 (77.0 to 151.6)	0.1 (-16.1 to 19.2)
Parkinson disease	1.2 (0.8 to 1.6)	2.3 (1.6 to 3.1)	90.1 (76.6 to 109.2)	-0.5 (-6.5 to 8.4)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	89.7 (66.9 to 119.0)	0.3 (-11.2 to 14.5)
Epilepsy	26.8 (18.2 to 36.5)	21.2 (14.2 to 28.9)	-17.9 (-51.9 to 31.9)	-17.9 (-49.4 to 36.3)	7.7 (4.4 to 11.9)	6.3 (3.6 to 9.7)	-17.8 (-51.6 to 43.2)	-12.9 (-48.6 to 51.4)
Multiple sclerosis	1.5 (1.2 to 1.8)	2.2 (1.7 to 2.7)	46.5 (9.9 to 92.7)	20.2 (-10.2 to 57.6)	0.5 (0.3 to 0.7)	0.7 (0.5 to 1.0)	46.1 (7.9 to 99.3)	20.4 (-10.8 to 64.4)
Migraine	453.8 (403.5 to 497.3)	471.7 (437.2 to 510.8)	4.1 (-9.0 to 17.5)	15.6 (-11.4 to 13.9)	15.1 (9.2 to 23.3)	16.1 (9.6 to 23.8)	6.3 (-9.9 to 17.5)	6.3 (-11.4 to 14.3)
Tension-type headache	584.8 (519.9 to 643.6)	619.9 (566.7 to 671.1)	6.0 (-7.2 to 21.0)	1.7 (-10.6 to 15.1)	0.9 (0.4 to 1.6)	0.9 (0.5 to 1.7)	5.6 (-7.7 to 20.9)	2.1 (-14.0 to 16.3)
Medication overuse headache	25.3 (15.5 to 36.5)	47.3 (30.5 to 66.5)	90.1 (39.4 to 146.2)	58.9 (15.5 to 102.7)	4.0 (2.1 to 6.4)	7.4 (4.1 to 11.7)	88.8 (37.7 to 147.1)	60.3 (15.1 to 106.4)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.6 (-13.7 to 56.0)	8.3 (-20.5 to 42.0)	1.4 (0.9 to 2.0)	1.1 (0.7 to 1.7)	-25.5 (-49.8 to 14.4)	-61.6 (-74.0 to -40.6)
Mental and substance use disorders	-	-	-	-	65.1 (47.1 to 84.4)	66.3 (48.3 to 86.6)	1.9 (-1.0 to 4.5)	0.2 (-1.9 to 2.4)
Schizophrenia	9.0 (8.2 to 9.8)	10.2 (9.4 to 11.0)	13.5 (8.1 to 20.1)	-0.9 (-5.2 to 3.6)	5.8 (4.3 to 7.1)	6.6 (4.8 to 8.0)	5.8 (5.2 to 21.6)	6.6 (6.5 to 5.7)
Alcohol use disorders	3.2 (2.3 to 4.7)	10.5 (8.3 to 12.9)	229.0 (145.4 to 314.6)	0.3 (-113.3 to 285.0)	1.0 (0.2 to 0.5)	1.0 (0.6 to 1.5)	234.9 (144.5 to 330.8)	216.5 (115.9 to 306.3)
Drug use disorders	-	-	-	-	3.9 (2.5 to 5.6)	3.3 (2.1 to 4.8)	-14.2 (-27.0 to 1.9)	-6.8 (-20.1 to 9.2)
Opioid use disorders	3.4 (1.7 to 6.0)	3.1 (1.4 to 5.4)	-8.7 (-23.9 to 2.8)	-7.6 (-20.8 to 3.3)	1.4 (0.7 to 2.6)	1.3 (0.5 to 2.3)	-9.5 (-26.0 to 6.3)	-7.4 (-22.2 to 7.7)
Cocaine use disorders	2.1 (1.6 to 2.7)	2.1 (1.7 to 2.5)	-0.8 (-28.2 to 34.4)	0.3 (-21.9 to 41.4)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	6.0 (-30.2 to 41.7)	6.0 (-23.8 to 48.7)
Amphetamine use disorders	6.4 (5.2 to 7.7)	4.9 (4.0 to 5.9)	-22.3 (-41.2 to -0.2)	-11.8 (-33.0 to 12.3)	0.8 (0.5 to 1.2)	0.6 (0.4 to 1.0)	-22.6 (-44.0 to 1.9)	-12.1 (-35.5 to 15.1)
Cannabis use disorders	6.9 (5.3 to 8.5)	6.0 (4.7 to 7.3)	-12.7 (-14.4 to -10.7)	-0.3 (-0.5 to -0.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-12.7 (-24.4 to 2.5)	-0.2 (-13.0 to 16.0)
Other drug use disorders	-	-	-	-	1.1 (0.7 to 1.7)	0.9 (0.6 to 1.4)	-16.9 (-42.4 to 19.5)	-6.9 (-35.0 to 32.7)
Depressive disorders	-	-	-	-	24.0 (16.5 to 33.3)	26.0 (17.7 to 35.7)	6.0 (1.8 to 14.2)	0.4 (-3.8 to 5.2)
Major depressive disorder	97.7 (84.7 to 109.4)	104.6 (90.8 to 118.2)	7.2 (0.3 to 14.2)	-0.0 (-5.0 to 5.6)	20.2 (13.6 to 28.2)	21.4 (14.4 to 29.9)	6.0 (-1.0 to 13.2)	0.2 (-5.0 to 6.0)
Dysthymia	39.9 (33.1 to 47.1)	47.4 (39.4 to 55.3)	18.9 (11.9 to 27.3)	0.7 (0.5 to 1.0)	3.9 (2.5 to 5.6)	4.6 (3.0 to 6.6)	18.0 (10.3 to 26.7)	1.0 (-1.4 to 3.5)
Bipolar disorder	21.5 (17.0 to 25.9)	22.9 (18.4 to 27.1)	6.4 (0.1 to 13.6)	-1.6 (-6.4 to 3.4)	4.4 (2.6 to 6.8)	4.6 (2.8 to 7.1)	5.5 (-1.9 to 14.2)	-1.1 (-7.2 to 5.0)
Anxiety disorders	113.9 (94.6 to 135.3)	162.2 (97.9 to 134.4)	43.2 (-2.5 to 7.2)	21.1 (0.5 to 1.1)	10.5 (7.0 to 15.1)	10.7 (7.2 to 15.2)	6.2 (-3.9 to 7.2)	0.9 (-1.4 to 3.6)
Eating disorders	-	-	-	-	0.9 (0.6 to 1.5)	0.8 (0.5 to 1.2)	-16.0 (-23.1 to -8.7)	2.9 (-5.3 to 11.7)
Anorexia nervosa	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	4.9 (-5.1 to 17.6)	29.5 (17.1 to 44.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	5.9 (-22.0 to 44.4)	30.1 (-4.0 to 75.4)
Bulimia nervosa	4.1 (2.9 to 5.6)	3.4 (2.4 to 4.6)	-17.8 (-48.9 to -16.5)	0.6 (0.1 to 1.3)	0.9 (0.5 to 1.4)	0.7 (0.4 to 1.1)	-17.7 (-24.5 to -10.5)	0.7 (-7.6 to 9.7)
Autistic spectrum disorders	-	-	-	-	4.2 (2.9 to 5.7)	4.0 (2.6 to 5.0)	3.7 (-14.3 to -8.2)	-0.5 (-3.6 to 2.9)
Autism	10.7 (10.2 to 11.3)	9.6 (9.1 to 10.1)	-10.3 (-11.2 to -9.3)	-0.7 (-0.7 to -0.6)	2.7 (1.8 to 3.7)	2.4 (1.6 to 3.2)	-11.2 (-15.5 to -6.3)	-0.4 (-4.8 to 4.6)
Asperger syndrome	15.4 (14.4 to 16.3)	13.7 (12.8 to 14.6)	-11.0 (-12.1 to -9.8)	-1.0 (-1.0 to -0.8)	1.5 (1.1 to 2.2)	1.4 (0.9 to 1.9)	-11.7 (-15.3 to -7.9)	-0.7 (-4.7 to 3.0)
Attention-deficit/hyperactivity disorder	22.7 (20.9 to 24.5)	16.3 (15.0 to 17.5)	-28.3 (-28.5 to -28.1)	0.4 (0.3 to 0.4)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-28.4 (-33.3 to -22.6)	0.3 (-6.4 to 8.2)
Conduct disorder	33.3 (31.4 to 35.4)	24.5 (23.0 to 26.0)	-26.6 (-27.1 to -25.9)	2.5 (0.2 to 0.2)	4.0 (2.5 to 5.8)	3.0 (1.9 to 4.3)	-29.3 (-29.7 to -22.8)	0.6 (-4.0 to 5.2)
Idiopathic intellectual disability	55.3 (46.2 to 67.6)	41.8 (34.5 to 50.6)	-24.5 (-32.3 to -16.5)	-16.9 (-25.5 to -8.1)	2.7 (1.8 to 3.8)	2.0 (1.3 to 2.9)	-24.9 (-32.8 to -16.9)	-16.6 (-25.4 to -7.5)
Other mental and substance use disorders	52.0 (48.7 to 55.2)	58.7 (55.2 to 62.1)	12.8 (10.7 to 15.0)	-0.6 (-0.9 to -0.3)	3.9 (2.6 to 5.3)	4.4 (3.0 to 5.9)	11.9 (7.3 to 16.9)	-0.3 (-4.0 to 3.4)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	29.3 (20.7 to 39.5)	37.4 (26.1 to 50.6)	27.6 (13.5 to 44.6)	7.9 (-3.8 to 21.8)
Diabetes mellitus	146.5 (124.1 to 168.1)	212.5 (171.8 to 255.1)	44.4 (14.7 to 82.9)	12.1 (-8.9 to 44.0)	9.6 (6.3 to 13.7)	15.7 (10.2 to 23.0)	62.7 (23.9 to 119.3)	17.9 (-10.3 to 58.6)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.4 (-57.7 to -50.9)	-44.5 (-48.5 to -40.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.4 (-57.7 to -50.9)	-44.5 (-48.5 to -40.6)
Chronic kidney disease	-	-	-	-	7.1 (5.2 to 9.3)	8.9 (6.6 to 11.4)	25.9 (12.5 to 40.0)	2.6 (-7.9 to 11.5)
Chronic kidney disease due to diabetes mellitus	31.4 (21.6 to 46.8)	33.0 (22.1 to 47.3)	4.0 (-21.1 to 44.2)	-29.8 (-45.3 to -7.8)	0.8 (0.5 to 1.1)	0.8 (0.6 to 1.2)	4.3 (-23.6 to 37.1)	-27.9 (-47.9 to -5.5)
Chronic kidney disease due to hypertension	92.1 (57.7 to 141.2)	84.0 (50.8 to 137.8)	-10.4 (-28.1 to 25.5)	-13.4 (-30.3 to 14.8)	1.3 (0.9 to 1.9)	0.4 (0.3 to 0.7)	-67.7 (-78.5 to -47.7)	-73.7 (-83.8 to -59.6)
Chronic kidney disease due to glomerulonephritis	61.9 (41.4 to 87.3)	24.4 (20.4 to 29.1)	-60.6 (-69.3 to -46.7)	-55.2 (-74.6 to -15.3)	2.1 (1.5 to 2.9)	2.1 (1.5 to 2.9)	9.4 (-18.3 to 23.6)	9.4 (-24.9 to 12.5)
Chronic kidney disease due to other causes	135.4 (93.8 to 205.9)	226.6 (165.6 to 303.8)	68.3 (28.9 to 115.9)	47.7 (25.5 to 72.6)	2.9 (2.0 to 3.7)	5.5 (4.0 to 7.2)	93.6 (64.8 to 128.1)	55.8 (34.2 to 83.5)
Urinary diseases and male infertility	-	-	-	-	1.5 (1.0 to 2.2)	2.8 (1.8 to 4.0)	84.9 (60.3 to 112.7)	8.7 (6.3 to 25.8)

Appendix Table G.4 - Albania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.5 (0.4 to 0.6)	0.5 (0.4 to 0.6)	-6.7 (-23.1 to 18.0)	0.0 (-17.7 to 20.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.4 (-31.5 to 27.7)	-0.9 (-24.8 to 33.4)
Urolithiasis	22.9 (15.4 to 32.9)	29.6 (21.5 to 39.4)	33.0 (2.1 to 60.7)	-15.3 (-33.4 to -2.7)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	40.0 (18.3 to 66.0)	-2.1 (-17.7 to 11.7)
Benign prostatic hyperplasia	29.4 (25.4 to 33.6)	60.0 (53.5 to 67.6)	105.1 (71.1 to 143.6)	8.4 (-10.3 to 28.8)	1.0 (0.7 to 1.5)	2.1 (1.4 to 3.0)	105.7 (71.3 to 143.9)	8.9 (9.5 to 29.5)
Male infertility due to other causes	12.3 (8.8 to 15.9)	11.0 (8.5 to 14.0)	-10.5 (-37.7 to 31.5)	5.0 (-27.2 to 51.9)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-10.2 (-38.0 to 36.3)	5.8 (-27.0 to 60.2)
Other urinary diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	69.9 (20.0 to 126.8)	21.2 (-13.4 to 60.8)
Gynecological diseases	-	-	-	-	3.9 (2.5 to 6.0)	4.0 (2.6 to 6.0)	2.3 (-12.0 to 17.4)	1.6 (-12.0 to 15.9)
Uterine fibroids	58.6 (52.9 to 63.9)	75.6 (69.3 to 81.7)	28.9 (26.0 to 32.1)	7.6 (7.4 to 7.9)	0.9 (0.5 to 1.5)	1.0 (0.6 to 1.6)	7.9 (1.0 to 14.2)	-3.4 (-8.4 to 1.0)
Polycystic ovarian syndrome	56.3 (49.3 to 63.1)	56.4 (50.7 to 62.3)	0.1 (-14.3 to 17.6)	4.1 (-10.9 to 21.6)	0.5 (0.3 to 1.0)	0.5 (0.2 to 1.0)	-0.2 (-14.6 to 17.1)	4.8 (-10.2 to 21.6)
Female infertility due to other causes	3.6 (1.1 to 6.5)	4.4 (2.0 to 7.1)	21.3 (-54.1 to 332.4)	45.3 (-45.1 to 430.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	48.3 (-54.5 to 268.0)	41.5 (-45.1 to 362.5)
Endometriosis	5.9 (4.9 to 6.9)	6.4 (5.5 to 7.3)	8.4 (-12.3 to 37.4)	11.7 (-9.8 to 40.3)	0.5 (0.3 to 0.8)	0.6 (0.4 to 0.8)	8.5 (-16.0 to 39.7)	12.6 (-11.9 to 43.9)
Genital prolapse	142.4 (123.1 to 162.1)	176.5 (156.5 to 196.7)	23.7 (5.3 to 49.2)	4.3 (-11.5 to 23.1)	0.5 (0.2 to 0.9)	0.6 (0.3 to 1.1)	23.4 (4.2 to 48.5)	4.4 (-11.9 to 23.6)
Premenstrual syndrome	128.3 (82.3 to 180.1)	118.0 (73.6 to 157.7)	-6.7 (-46.3 to 45.1)	2.3 (-45.3 to 57.2)	1.1 (0.6 to 1.8)	1.0 (0.5 to 1.6)	-7.2 (-46.9 to 44.2)	2.2 (-45.0 to 58.4)
Other gynecological diseases	11.9 (9.9 to 14.3)	10.9 (9.0 to 12.6)	-8.3 (-27.5 to 12.7)	-7.6 (-27.3 to 13.0)	0.4 (0.2 to 0.5)	0.3 (0.2 to 0.5)	-10.6 (-33.4 to 25.9)	-10.1 (-33.9 to 25.0)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	5.5 (3.6 to 8.1)	4.5 (3.0 to 6.5)	-17.4 (-26.0 to -3.8)	0.9 (-10.0 to 16.7)
Thalassemias	0.7 (0.7 to 0.8)	0.5 (0.4 to 0.5)	-36.9 (-40.9 to -31.5)	0.4 (-5.8 to 9.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-37.1 (-57.8 to -5.0)	-0.2 (-32.5 to 49.9)
Thalassemia trait	172.2 (162.6 to 182.2)	160.5 (154.5 to 170.6)	-7.0 (-10.5 to -1.2)	1.1 (-2.3 to 7.5)	3.8 (2.5 to 5.6)	3.3 (2.1 to 4.9)	-13.5 (-27.1 to 3.9)	7.6 (-10.7 to 27.5)
Sickle cell disorders	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-29.5 (-39.5 to -16.0)	-3.2 (-17.5 to 14.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.3 (-33.4 to -14.1)	-2.0 (-13.3 to 11.9)
Sickle cell trait	79.9 (76.4 to 82.8)	69.6 (67.2 to 71.9)	-12.8 (-15.1 to -10.7)	5.4 (-7.9 to -3.0)	0.4 (0.2 to 0.7)	0.3 (0.2 to 0.5)	-22.6 (-34.9 to 58.8)	1.4 (-15.7 to 115.1)
G6PD deficiency	42.7 (31.5 to 53.4)	37.2 (20.9 to 54.1)	-13.5 (-52.3 to 42.0)	-5.8 (-48.1 to 54.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.7 (-31.3 to 17.8)	5.2 (-12.2 to 39.8)
G6PD trait	454.4 (416.4 to 489.3)	427.9 (390.2 to 459.9)	-5.8 (-15.9 to 5.0)	1.5 (-9.4 to 13.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.5 (-90.9 to 488.9)	20.5 (-88.2 to 580.0)
Other hemoglobinopathies and hemolytic anemias	45.9 (41.4 to 50.7)	38.9 (35.0 to 41.9)	-16.9 (-25.4 to -2.9)	-16.9 (-26.5 to -5.2)	1.1 (0.7 to 1.7)	0.8 (0.5 to 1.2)	-27.6 (-42.1 to -3.0)	-20.0 (-37.8 to 4.6)
Endocrine, metabolic, blood, and immune disorders	50.5 (45.3 to 55.0)	44.5 (42.1 to 46.6)	-11.7 (-19.8 to -2.0)	4.7 (-12.2 to 3.9)	1.6 (-1.2 to 3.9)	1.3 (0.9 to 1.9)	-18.2 (-27.7 to -2.5)	-4.3 (-14.9 to 11.4)
Musculoskeletal disorders	-	-	-	-	61.3 (43.5 to 82.2)	82.0 (58.0 to 109.3)	33.7 (23.1 to 45.0)	2.3 (-4.9 to 9.9)
Rheumatoid arthritis	3.1 (2.7 to 3.5)	7.6 (7.1 to 8.1)	140.9 (109.5 to 186.2)	67.4 (44.0 to 105.0)	0.7 (0.5 to 1.0)	1.8 (1.3 to 2.3)	137.8 (105.1 to 186.1)	68.3 (42.5 to 107.6)
Osteoarthritis	96.7 (92.6 to 100.1)	173.8 (166.8 to 180.5)	80.0 (69.5 to 90.7)	1.9 (-3.8 to 7.8)	5.9 (4.1 to 8.1)	10.6 (7.4 to 14.3)	79.6 (68.9 to 91.0)	2.4 (-3.6 to 8.5)
Low back and neck pain	-	-	-	-	49.9 (34.9 to 68.3)	62.0 (42.7 to 84.8)	24.3 (12.5 to 38.0)	1.4 (-8.7 to 10.2)
Low back pain	337.5 (312.8 to 365.4)	425.7 (392.6 to 459.6)	26.1 (12.6 to 40.8)	-0.0 (-10.0 to 10.9)	37.8 (25.6 to 53.5)	47.2 (31.9 to 65.6)	24.8 (11.1 to 39.5)	0.4 (-10.0 to 11.6)
Neck pain	122.3 (99.7 to 147.2)	151.7 (129.7 to 176.4)	24.7 (1.8 to 50.8)	0.8 (-15.6 to 19.6)	12.1 (7.8 to 17.0)	14.8 (10.2 to 20.7)	23.8 (1.4 to 50.2)	1.0 (-15.5 to 20.8)
Gout	1.1 (1.1 to 1.2)	1.8 (1.7 to 1.9)	55.7 (41.3 to 70.8)	-2.5 (-11.3 to 7.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	54.2 (22.1 to 94.2)	-2.3 (-21.9 to 21.8)
Other musculoskeletal disorders	52.4 (38.9 to 65.4)	83.2 (64.1 to 103.0)	58.4 (44.7 to 75.5)	8.1 (-0.5 to 17.8)	4.8 (3.1 to 7.1)	7.6 (4.9 to 11.1)	57.9 (41.0 to 76.2)	8.8 (-0.4 to 18.8)
Other non-communicable diseases	-	-	-	-	44.1 (29.2 to 63.4)	51.4 (34.1 to 74.3)	16.7 (11.5 to 21.1)	-6.1 (-9.6 to -2.7)
Congenital anomalies	-	-	-	-	3.4 (2.5 to 4.5)	3.9 (2.8 to 5.1)	14.1 (-0.6 to 34.5)	18.3 (2.5 to 40.8)
Neural tube defects	0.8 (0.6 to 1.0)	1.0 (0.8 to 1.2)	24.7 (-4.4 to 73.4)	53.7 (18.0 to 113.5)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	25.2 (-19.9 to 99.9)	56.6 (0.2 to 151.1)
Congenital heart anomalies	21.6 (17.8 to 26.7)	24.3 (19.4 to 30.1)	11.4 (-14.2 to 52.0)	26.8 (-2.2 to 73.3)	0.7 (0.3 to 1.3)	0.8 (0.3 to 1.5)	14.4 (-11.2 to 53.7)	31.7 (2.5 to 76.9)
Orofacial clefts	4.0 (3.1 to 5.3)	4.0 (3.0 to 5.4)	2.9 (-34.7 to 49.5)	19.1 (-24.4 to 73.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-17.4 (-48.6 to 25.7)	-4.3 (-40.0 to 45.0)
Down syndrome	3.2 (2.5 to 4.2)	3.5 (2.8 to 4.6)	10.3 (-27.0 to 64.8)	9.7 (-27.4 to 63.5)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	24.0 (-18.6 to 88.7)	11.4 (-26.7 to 69.2)
Turner syndrome	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-4.8 (-40.4 to 41.9)	10.4 (-30.7 to 65.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.2 (-40.3 to 52.0)	11.6 (-31.0 to 75.4)
Klinefelter syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	11.6 (-23.1 to 47.1)	23.6 (-14.9 to 62.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.0 (-23.4 to 48.7)	22.4 (-16.0 to 61.3)
Chromosomal unbalanced rearrangements	5.8 (4.6 to 7.2)	6.3 (5.2 to 7.7)	9.5 (-18.3 to 45.5)	0.7 (-18.7 to 45.2)	0.9 (0.5 to 1.0)	0.9 (0.6 to 1.3)	11.5 (-8.3 to 67.5)	11.5 (-17.8 to 49.7)
Other congenital anomalies	11.1 (8.9 to 13.0)	9.9 (8.0 to 11.7)	-11.2 (-19.4 to -1.6)	-11.0 (-19.4 to -0.6)	1.2 (0.8 to 1.8)	1.3 (0.9 to 1.7)	4.0 (-11.5 to 29.4)	13.1 (-4.1 to 40.0)
Skin and subcutaneous diseases	-	-	-	-	15.2 (9.9 to 22.6)	14.4 (9.4 to 21.3)	-5.4 (-12.5 to 3.9)	-5.3 (-12.9 to 4.1)
Dermatitis	142.8 (119.6 to 168.1)	142.7 (120.6 to 165.8)	-0.1 (-3.2 to 4.1)	-0.0 (-0.2 to 0.2)	3.6 (2.2 to 5.2)	3.5 (2.2 to 5.1)	-2.0 (-6.5 to 3.1)	0.4 (-2.6 to 3.2)
Psoriasis	25.3 (22.3 to 28.5)	28.0 (24.6 to 31.3)	10.5 (6.7 to 15.5)	10.5 (-0.2 to 0.2)	2.1 (1.4 to 2.9)	2.3 (1.5 to 3.2)	9.7 (2.5 to 16.9)	0.4 (-4.5 to 5.7)
Cellulitis	0.5 (0.4 to 0.7)	0.5 (0.4 to 0.6)	-9.6 (-22.6 to 14.2)	-4.7 (-14.4 to 7.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-9.8 (-30.5 to 18.9)	-3.8 (-22.3 to 20.4)
Pyoderma	4.7 (3.8 to 5.9)	3.3 (2.6 to 4.1)	-30.8 (-38.6 to -23.1)	-20.3 (-24.1 to -15.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-31.4 (-40.2 to -21.9)	-19.9 (-26.4 to -12.7)
Scabies	7.5 (6.8 to 8.2)	5.5 (5.0 to 6.1)	-26.7 (-35.0 to -15.3)	-17.4 (-27.0 to -5.1)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-26.9 (-36.9 to -14.9)	-17.0 (-28.1 to 0.8)
Fungal skin diseases	249.9 (190.2 to 320.0)	263.3 (205.2 to 343.2)	5.3 (-15.5 to 14.6)	5.3 (-0.5 to 10.5)	1.5 (0.6 to 3.1)	1.5 (0.6 to 3.2)	4.6 (-2.0 to 14.0)	-0.1 (-1.2 to 0.8)
Viral skin diseases	82.6 (62.9 to 100.4)	64.7 (49.8 to 79.9)	-21.8 (-26.1 to -16.6)	0.1 (-1.6 to 1.9)	2.6 (1.5 to 4.0)	2.0 (1.2 to 3.1)	-22.1 (-27.0 to -17.0)	3.2 (-3.0 to 3.2)
Acne vulgaris	91.4 (65.7 to 115.1)	79.6 (61.4 to 101.9)	-15.1 (-40.2 to 39.4)	1.8 (-26.7 to 67.8)	1.0 (0.4 to 1.9)	0.9 (0.4 to 1.7)	-15.3 (-40.3 to 40.4)	1.8 (-26.8 to 69.6)
Alopecia areata	3.6 (3.1 to 4.0)	3.9 (3.4 to 4.5)	10.7 (-3.8 to 26.0)	0.8 (-11.5 to 14.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	9.4 (-7.6 to 27.4)	1.1 (-13.7 to 16.4)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.0 (-7.0 to 51.1)	-2.6 (-22.8 to 24.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.0 (-7.2 to 51.3)	-2.6 (-22.9 to 24.7)
Urticaria	52.8 (38.9 to 68.0)	43.4 (35.0 to 53.3)	-18.2 (-39.0 to 19.3)	-24.9 (-43.6 to 8.2)	3.2 (1.9 to 4.9)	2.6 (1.6 to 3.9)	-18.5 (-39.8 to 17.2)	-24.3 (-43.0 to 8.5)
Decubitus ulcer	0.4 (0.3 to 0.4)	0.6 (0.5 to 0.8)	78.2 (41.2 to 130.6)	14.8 (-10.6 to 54.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	73.6 (28.1 to 129.2)	15.2 (-15.6 to 56.2)
Other skin and subcutaneous diseases	172.7 (114.7 to 260.3)	224.6 (136.8 to 370.9)	28.7 (10.0 to 48.5)	-3.9 (-8.0 to 0.3)	1.0 (0.4 to 2.1)	1.3 (0.5 to 2.9)	28.0 (9.3 to 47.2)	-3.6 (-9.9 to 0.7)
Sense organ diseases	-	-	-	-	18.9 (12.3 to 27.6)	24.5 (16.0 to 36.1)	29.4 (21.8 to 38.1)	-10.4 (-14.6 to -4.9)
Glaucoma	2.9 (2.4 to 3.4)	3.2 (2.6 to 3.8)	10.8 (-9.1 to 33.6)	-20.1 (-34.5 to -3.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	17.4 (2.4 to 39.6)	-20.4 (-32.9 to -5.5)
Cataract	21.0 (16.5 to 26.1)	31.7 (25.3 to 38.5)	53.5 (23.5 to 78.5)	-23.0 (-37.5 to -10.5)	0.7 (0.4 to 1.1)	1.1 (0.7 to 1.7)	55.3 (26.8 to 80.2)	-22.0 (-35.8 to -10.1)
Macular degeneration	6.6 (5.0 to 8.6)	11.9 (9.2 to 15.1)	77.8 (34.9 to 140.5)	1.2 (-23.0 to 37.4)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	80.2 (36.7 to 137.8)	0.9 (-23.3 to 34.0)
Uncorrected refractive error	249.6 (207.6 to 294.4)	309.6 (255.1 to 374.5)	22.6 (-2.0 to 68.0)	-9.3 (-27.0 to 19.4)	3.8 (2.3 to 6.4)	4.4 (2.5 to 7.3)	14.0 (-3.3 to 39.6)	-12.8 (-25.2 to 6.1)
Age-related and other hearing loss	419.5 (368.4 to 466.7)	593.0 (526.7 to 652.4)	41.1 (33.2 to 50.6)	-8.5 (-11.7 to -4.4)	11.2 (7.4 to 16.2)	15.9 (10.5 to 22.8)	9.7 (30.4 to 54.3)	41.7 (-14.8 to 31.5)
Other vision loss	18.6 (16.2 to 21.2)	14.5 (12.5 to 17.0)	-22.3 (-31.6 to -11.2)	-33.6 (-41.2 to -24.0)	0.7 (0.5 to 1.1)	0.6 (0.4 to 0.9)	-14.5 (-24.3 to -0.9)	-31.6 (-37.8 to -21.8)
Other sense organ diseases	78.0 (74.5 to 81.8)	73.5 (70.2 to 76.7)	-5.7 (-11.8 to 0.0)	0.5 (-5.6 to 6.6)	2.1 (1.3 to 3.1)	1.9 (1.2 to 2.9)	-7.2 (-13.7 to -0.4)	-2.4 (-6.0 to 7.6)
Oral disorders	-	-	-	-	6.5 (3.9 to 10.1)	8.5 (5.1 to 13.1)	30.6 (24.0 to 37.1)	-5.2 (-9.8 to -0.4)
Deciduous caries	330.3 (314.7 to 344.1)	173.3 (166.4 to 180.6)	-47.8 (-50.5 to 43.7)	-0.4 (-5.8 to 6.9)	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	47.6 (52.0 to 42.4)	0.2 (-8.5 to 9.7)
Permanent caries	1,328.7 (1,172.2 to 1,498.6)	1,353.1 (1,234.3 to 1,483.6)	2.3 (-12.6 to 17.7)	4.2 (-10.7 to 19.5)	0.8 (0.3 to 1.6)	0.8 (0.4 to 1.5)	1.7 (-13.3 to 17.4)	4.5 (-10.6 to 20.0)
Periodontal diseases	263.7 (241.3 to 283.9)	366.0 (333.5 to 404.2						

Appendix Table G.4 - Albania prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	82.4 (78.1 to 86.7)	128.6 (122.3 to 134.3)	56.2 (45.7 to 67.5)	-12.7 (-18.5 to -6.5)	2.3 (1.5 to 3.1)	3.5 (2.4 to 4.9)	55.9 (45.0 to 67.8)	-23 (-18.3 to -5.8)
Other oral disorders	56.4 (53.4 to 59.5)	59.7 (56.7 to 62.6)	5.7 (-1.0 to 13.7)	-0.2 (-6.5 to 7.1)	1.7 (1.0 to 2.5)	1.7 (1.1 to 2.6)	5.2 (-2.3 to 13.7)	0.0 (-7.0 to 7.5)
Injuries	-	-	-	-	29.2 (22.2 to 37.4)	28.0 (20.1 to 37.9)	-4.5 (-14.5 to 7.9)	-31.2 (-38.5 to -22.1)
Transport injuries	-	-	-	-	3.7 (2.7 to 4.7)	2.4 (1.7 to 3.3)	-33.5 (-42.1 to -23.3)	-48.1 (-54.5 to -40.7)
Road injuries	-	-	-	-	2.7 (2.0 to 3.5)	1.7 (1.2 to 2.3)	-38.7 (-47.2 to -29.1)	-51.7 (-58.1 to -44.6)
Pedestrian road injuries	-	-	-	-	0.6 (0.4 to 0.7)	0.3 (0.2 to 0.5)	-41.0 (-50.8 to -29.7)	-52.4 (-59.7 to -43.8)
Cyclist road injuries	-	-	-	-	0.6 (0.4 to 0.7)	0.4 (0.3 to 0.5)	-30.1 (-38.8 to -21.2)	-47.0 (-53.2 to -40.4)
Motorcyclist road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.2)	-46.7 (-54.9 to -36.9)	-57.2 (-63.6 to -50.0)
Motor vehicle road injuries	-	-	-	-	1.2 (0.9 to 1.5)	0.7 (0.5 to 1.0)	-37.5 (-47.2 to -25.5)	-50.6 (-57.8 to -41.6)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-65.3 (-69.9 to -59.5)	-73.5 (-76.8 to -69.4)
Other transport injuries	-	-	-	-	0.9 (0.7 to 1.2)	0.8 (0.5 to 1.0)	-18.0 (-27.7 to -6.5)	-37.7 (-45.1 to -29.1)
Unintentional injuries	-	-	-	-	25.2 (19.1 to 32.3)	25.2 (18.2 to 34.1)	-0.2 (-10.5 to 12.3)	-29.0 (-36.6 to -19.8)
Falls	-	-	-	-	21.6 (16.8 to 27.7)	22.1 (15.8 to 30.0)	2.1 (-9.1 to 15.8)	-29.1 (-37.1 to -19.3)
Drowning	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-45.7 (-53.8 to -35.1)	-52.4 (-59.0 to -43.8)
Fire, heat, and hot substances	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-25.4 (-36.6 to -12.3)	-34.6 (-43.6 to -23.8)
Poisonings	-	-	-	-	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.0)	-79.8 (-82.7 to -76.5)	-80.8 (-83.5 to -77.8)
Exposure to mechanical forces	-	-	-	-	1.7 (1.3 to 2.2)	1.5 (1.1 to 2.0)	-12.9 (-19.8 to -6.4)	-26.9 (-31.9 to -22.1)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.4 (-56.9 to -38.0)	-56.7 (-63.8 to -45.5)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.2 (-50.0 to -35.5)	-51.5 (-56.9 to -45.3)
Other exposure to mechanical forces	-	-	-	-	1.7 (1.3 to 2.2)	1.5 (1.1 to 2.0)	-12.0 (-19.0 to -5.5)	-26.2 (-31.2 to -21.3)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	33.5 (22.7 to 46.3)	8.0 (-0.9 to 18.8)
Animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-13.3 (-22.6 to -2.1)	-20.9 (-28.2 to -12.0)
Venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-9.9 (-21.7 to 5.3)	-18.4 (-28.6 to -5.1)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-15.5 (-25.5 to -2.9)	-22.6 (-30.4 to -12.4)
Foreign body	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-16.7 (-25.6 to -6.4)	-27.2 (-34.5 to -19.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-40.9 (-51.6 to -27.9)	-45.6 (-54.8 to -34.0)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-4.9 (-11.3 to 2.0)	-10.3 (-16.6 to -4.1)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-3.5 (-15.4 to 9.4)	-20.5 (-29.5 to -11.3)
Other unintentional injuries	-	-	-	-	0.8 (0.6 to 1.0)	0.8 (0.6 to 1.1)	5.7 (-2.9 to 14.7)	-19.0 (-25.0 to -12.6)
Self-harm and interpersonal violence	-	-	-	-	1.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-24.9 (-33.6 to -14.4)	-28.9 (-33.6 to -13.5)
Self-harm	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	34.8 (18.9 to 55.1)	-0.2 (-12.0 to 13.9)
Interpersonal violence	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-23.0 (-33.3 to -9.5)	-40.4 (-48.1 to -30.6)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.7 (-12.2 to 10.2)	-25.0 (-32.2 to -16.7)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.2 (-23.7 to 4.9)	-30.0 (-39.0 to -18.5)
Assault by other means	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-30.8 (-40.8 to -18.1)	-46.6 (-53.9 to -36.6)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.8 (-57.0 to -42.6)	-65.3 (-71.0 to -59.1)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.8 (-57.0 to -42.6)	-65.3 (-71.0 to -59.1)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Algeria prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	2,253.0 (1,655.5 to 2,947.9)	3,924.7 (2,879.0 to 5,102.9)	74.2 (67.2 to 81.8)	74.2 (5.4 to 1.8)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	399.4 (274.0 to 567.1)	457.5 (313.7 to 643.0)	14.3 (6.2 to 24.7)	-12.3 (-18.2 to -4.5)
HIV/AIDS and tuberculosis	-	-	-	-	4.1 (2.7 to 5.6)	7.8 (5.3 to 10.6)	91.4 (70.7 to 117.0)	0.6 (-9.1 to 11.2)
Tuberculosis	13.2 (12.5 to 13.8)	24.0 (23.1 to 24.8)	81.4 (74.2 to 90.1)	-4.8 (-7.8 to -0.7)	4.1 (2.7 to 5.6)	7.4 (4.9 to 10.0)	80.5 (60.9 to 104.3)	-4.8 (-13.5 to 5.2)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.5 (0.2 to 1.0)	3,752.2 (798.8 to 180,576.7)	1,785.2 (335.6 to 83,295.5)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,262.7 (410.4 to 173,288.2)	975.6 (130.4 to 79,289.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,262.7 (406.7 to nan)	975.6 (128.2 to nan)
HIV/AIDS resulting in other diseases	0.1 (0.0 to 0.3)	5.9 (3.3 to 10.5)	5,373.9 (1,365.8 to 380,320.4)	2,771.6 (687.0 to 195,004.3)	0.0 (0.0 to 0.0)	0.5 (0.2 to 1.0)	3,812.0 (795.0 to nan)	1,805.2 (334.5 to nan)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	81.8 (57.5 to 110.3)	82.9 (58.2 to 112.3)	1.2 (-6.0 to 9.5)	-20.2 (-25.8 to -13.6)
Diarrheal diseases	344.4 (325.1 to 362.1)	354.8 (332.2 to 377.1)	3.0 (-5.2 to 12.3)	-15.0 (-21.5 to -7.5)	56.2 (37.9 to 77.7)	57.7 (39.0 to 81.0)	2.6 (-6.1 to 12.8)	-15.0 (-21.9 to -6.6)
Intestinal infectious diseases	-	-	-	-	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.6)	-0.1 (-0.6 to 0.1)	-17.5 (-49.2 to -18.6)
Typhoid fever	2.6 (2.2 to 3.0)	2.4 (2.0 to 2.7)	-8.3 (-24.5 to 11.2)	-28.3 (-40.9 to -9.5)	0.4 (0.2 to 0.5)	0.3 (0.2 to 0.5)	-0.6 (-28.7 to 16.7)	-27.8 (-43.3 to -8.1)
Paratyphoid fever	1.3 (1.1 to 1.6)	1.2 (1.0 to 1.5)	-6.0 (-24.9 to 18.1)	-26.2 (-40.9 to -6.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-0.6 (-26.4 to 22.7)	-26.1 (-41.5 to -4.7)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-0.4 (-83.2 to -47.5)	-76.9 (-86.7 to -58.8)
Lower respiratory infections	15.9 (10.6 to 21.3)	13.0 (9.2 to 19.4)	-20.7 (-53.7 to 45.8)	-37.5 (-60.9 to 2.8)	1.7 (0.9 to 2.6)	1.9 (0.7 to 2.3)	-1.8 (-56.3 to 47.9)	-37.3 (-62.5 to 4.3)
Upper respiratory infections	541.6 (477.8 to 613.1)	747.8 (655.2 to 841.8)	38.3 (18.5 to 60.2)	-0.8 (-14.9 to 14.5)	6.4 (3.6 to 10.6)	8.8 (5.0 to 15.0)	37.7 (17.7 to 61.3)	-0.5 (-15.4 to 15.4)
Otitis media	341.9 (315.8 to 369.8)	400.9 (370.6 to 431.9)	17.3 (6.7 to 27.7)	-10.5 (-18.7 to -3.0)	6.3 (3.7 to 10.3)	7.3 (4.3 to 12.1)	16.0 (5.6 to 28.1)	-11.2 (-19.4 to -2.5)
Meningitis	-	-	-	-	8.6 (5.5 to 12.8)	5.1 (3.4 to 7.3)	-39.8 (-53.5 to -27.2)	-59.0 (-66.9 to -50.7)
Pneumococcal meningitis	32.8 (20.1 to 49.7)	21.5 (12.9 to 35.6)	-34.7 (-49.3 to -14.4)	-59.5 (-67.9 to -46.8)	3.1 (2.0 to 4.8)	1.9 (1.3 to 2.7)	-17.0 (-55.5 to 14.7)	-58.3 (-68.7 to -45.1)
H influenzae type B meningitis	19.6 (6.3 to 41.3)	10.4 (3.4 to 22.2)	-46.8 (-63.2 to -22.2)	-64.7 (-74.0 to -46.5)	2.2 (1.2 to 3.7)	1.2 (0.7 to 1.8)	-1.2 (-68.4 to -5.1)	-59.3 (-76.8 to -31.6)
Meningococcal meningitis	11.6 (3.2 to 26.5)	6.7 (1.9 to 16.2)	-43.7 (-59.9 to -21.9)	-63.9 (-72.3 to -50.9)	1.6 (0.8 to 2.9)	0.8 (0.4 to 1.5)	-0.8 (-64.0 to -15.3)	-64.3 (-74.2 to -44.1)
Other meningitis	13.6 (7.5 to 24.1)	9.3 (4.6 to 17.7)	-33.5 (-48.5 to -12.3)	-54.4 (-64.5 to -42.2)	1.7 (1.1 to 2.6)	1.1 (0.7 to 1.7)	-1.1 (-50.7 to -11.0)	-53.8 (-64.3 to -37.2)
Encephalitis	2.9 (2.9 to 16.0)	8.9 (3.8 to 21.4)	31.5 (10.2 to 50.0)	-34.2 (-31.4 to -9.9)	0.9 (0.6 to 1.2)	1.2 (0.8 to 1.7)	34.2 (6.4 to 63.1)	-47.9 (-32.9 to -1.2)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.2 (-95.9 to 571.5)	-53.1 (-95.8 to 327.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.2 (-95.8 to 594.3)	-53.1 (-95.8 to 327.4)
Whooping cough	9.4 (7.3 to 12.0)	2.3 (1.7 to 3.0)	-75.8 (-78.0 to -73.5)	-77.8 (-79.8 to -75.7)	0.5 (0.3 to 0.8)	0.1 (0.1 to 0.2)	-7.5 (-81.2 to -69.1)	-77.7 (-82.7 to -71.7)
Tetanus	0.3 (0.2 to 0.5)	0.0 (0.0 to 0.1)	-89.0 (-95.9 to -70.4)	-92.3 (-97.1 to -79.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-84.3 (-94.6 to -62.2)	-87.9 (-95.9 to -70.0)
Measles	4.0 (3.1 to 4.9)	1.0 (0.7 to 1.3)	-75.8 (-80.8 to -69.3)	-77.2 (-81.9 to -71.1)	0.4 (0.2 to 0.5)	0.1 (0.0 to 0.1)	-35.9 (-85.9 to -42.0)	-77.4 (-86.6 to -64.4)
Varicella and herpes zoster	21.1 (19.7 to 22.6)	28.9 (25.6 to 32.6)	36.8 (18.2 to 56.4)	6.5 (-12.8 to 32.5)	0.4 (0.2 to 0.6)	0.8 (0.4 to 1.2)	110.7 (49.6 to 196.9)	12.0 (-21.2 to 66.2)
Neglected tropical diseases and malaria	-	-	-	-	44.5 (23.5 to 85.8)	47.3 (23.5 to 95.2)	4.8 (-11.6 to 26.9)	-32.5 (-44.7 to -19.1)
Malaria	3.2 (2.2 to 4.7)	4.5 (2.8 to 6.1)	42.2 (-12.8 to 91.0)	10.1 (-30.4 to 52.9)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	0.1 (-29.3 to 53.9)	17.6 (6.8 to 28.5)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	23.1 (5.0 to 63.0)	-6.6 (-28.1 to 21.7)
Visceral leishmaniasis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	27.7 (-5.1 to 64.9)	6.1 (-19.9 to 33.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.7 (-5.4 to 64.9)	6.1 (-20.1 to 34.0)
Cutaneous and mucocutaneous leishmaniasis	5.4 (4.0 to 7.0)	6.7 (5.0 to 9.0)	24.4 (1.6 to 49.2)	-7.0 (-24.9 to 11.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	22.8 (-7.4 to 68.3)	-7.8 (-30.3 to 22.6)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	2,008.3 (792.4 to 4,186.8)	3,329.1 (1,310.9 to 6,934.3)	65.4 (60.6 to 72.2)	0.9 (-1.8 to 4.5)	16.3 (6.7 to 37.7)	26.5 (10.4 to 62.0)	62.6 (35.3 to 88.6)	2.1 (-13.1 to 17.9)
Cysticercosis	0.2 (0.0 to 0.5)	0.0 (0.0 to 0.0)	-91.4 (-98.0 to -33.2)	-95.2 (-98.7 to -63.2)	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.0)	0.0 (-97.7 to -23.7)	-90.4 (-98.5 to -59.1)
Cystic echinococcosis	2.6 (2.1 to 3.1)	3.1 (2.7 to 3.6)	22.6 (12.2 to 33.5)	-34.8 (-39.7 to -29.3)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.4)	21.8 (-3.8 to 55.4)	-34.4 (-47.3 to -17.7)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	59.8 (32.4 to 97.1)	37.6 (19.0 to 62.0)	-37.0 (-58.1 to -4.6)	-73.9 (-83.5 to -59.0)	4.2 (2.1 to 7.5)	2.7 (1.3 to 4.7)	-37.2 (-56.4 to -7.3)	-73.8 (-82.9 to -59.2)
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.9 (-60.2 to -15.7)	-59.9 (-72.3 to -41.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.9 (-60.3 to -15.7)	-59.9 (-72.3 to -41.7)
Intestinal nematode infections	-	-	-	-	3.1 (0.8 to 8.1)	0.6 (0.2 to 1.7)	0.6 (-94.1 to -21.7)	-80.7 (-94.0 to -26.6)
Ascariasis	1,572.9 (1,276.0 to 1,968.4)	2,406.3 (1,961.7 to 2,954.9)	53.6 (13.9 to 105.7)	-3.1 (-27.4 to 31.0)	3.0 (0.7 to 8.1)	0.5 (0.1 to 1.6)	0.5 (-96.5 to -28.2)	-85.8 (-96.6 to -28.3)
Trichuriasis	651.7 (542.9 to 783.1)	1,043.0 (867.8 to 1,260.0)	59.6 (22.6 to 109.2)	-1.0 (-26.0 to 33.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	61.4 (-83.0 to 1,200.7)	2.4 (-90.8 to 790.9)
Hookworm disease	14.5 (11.7 to 17.9)	27.8 (22.6 to 34.0)	91.9 (41.1 to 161.2)	0.1 (-26.4 to 36.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	166.3 (58.3 to 144.0)	7.4 (-16.7 to 26.6)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	383.3 (292.7 to 479.6)	370.4 (339.4 to 401.5)	-2.8 (-22.6 to 25.8)	-11.2 (-27.8 to 11.8)	20.4 (10.8 to 37.9)	17.0 (9.9 to 30.0)	-16.3 (-34.9 to 16.7)	-29.2 (-51.4 to -1.2)
Maternal disorders	-	-	-	-	1.6 (0.8 to 2.7)	1.8 (1.0 to 3.1)	13.9 (-9.3 to 41.7)	-41.5 (-53.5 to -27.8)
Maternal hemorrhage	5.6 (4.4 to 6.6)	10.1 (6.5 to 13.7)	78.5 (11.2 to 362.3)	-11.6 (-43.8 to 31.4)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.6)	58.5 (-25.7 to 163.1)	-18.6 (-59.8 to 38.6)
Maternal sepsis and other maternal infections	15.8 (10.5 to 22.3)	13.1 (8.1 to 19.9)	-16.0 (-43.5 to 15.1)	-62.7 (-75.1 to -46.0)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-2.3 (-55.4 to 30.1)	-63.3 (-77.0 to -36.2)
Maternal hypertensive disorders	15.0 (5.6 to 27.2)	17.6 (7.0 to 31.4)	17.3 (0.4 to 41.1)	-38.9 (-49.2 to -29.0)	0.7 (0.2 to 1.5)	0.9 (0.3 to 1.7)	16.6 (-4.4 to 45.1)	-39.1 (-50.8 to -26.1)
Obstructed labor	0.7 (0.4 to 1.0)	0.7 (0.4 to 1.1)	3.8 (-26.9 to 50.4)	-46.8 (-61.7 to -24.0)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	4.1 (-54.0 to 102.5)	-46.7 (-78.8 to 3.8)
Complications of abortion	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	25.7 (-22.7 to 103.0)	-39.8 (-62.9 to -4.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.7 (-22.9 to 104.4)	-39.8 (-62.9 to -4.4)
Other maternal disorders	-	-	-	-	0.2 (0.1 to 0.5)	0.2 (0.1 to 0.5)	5.2 (-46.8 to 109.0)	-46.1 (-72.4 to 5.4)
Neonatal disorders	-	-	-	-	28.9 (17.1 to 45.5)	72.8 (45.8 to 110.1)	152.9 (57.2 to 323.2)	90.5 (20.3 to 210.6)
Preterm birth complications	59.8 (41.1 to 85.5)	209.2 (150.7 to 280.2)	251.3 (173.2 to 354.1)	145.3 (91.5 to 215.9)	7.0 (4.4 to 10.1)	26.0 (17.2 to 36.0)	273.0 (154.1 to 437.7)	170.1 (87.5 to 288.7)
Neonatal encephalopathy due to birth asphyxia and trauma	45.6 (19.6 to 95.4)	76.5 (40.3 to 128.1)	69.1 (-19.2 to 301.0)	28.1 (-38.8 to 200.8)	10.5 (4.7 to 19.4)	19.2 (10.7 to 30.7)	85.6 (-9.6 to 314.0)	44.5 (-29.2 to 220.7)
Neonatal sepsis and other neonatal infections	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.7)	58.5 (66.1 to 88.6)	0.0 (-47.2 to 67.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-8.4 to 102.5)	78.9 (40.3 to 79.2)
Hemolytic disease and other neonatal jaundice	25.0 (9.7 to 64.0)	69.4 (24.4 to 146.2)	107.2 (-14.8 to 781.4)	176.3 (-36.5 to 554.0)	8.0 (3.2 to 17.3)	20.0 (7.9 to 41.2)	139.7 (-9.8 to 568.0)	75.1 (-33.3 to 385.4)
Other neonatal disorders	-	-	-	-	3.3 (1.5 to 6.2)	7.6 (3.8 to 14.1)	131.3 (7.8 to 414.4)	73.6 (-18.9 to 283.6)
Nutritional deficiencies	-	-	-	-	222.4 (147.0 to 324.0)	225.7 (150.9 to 332.2)	1.7 (-8.5 to 12.1)	-17.4 (-25.6 to -9.4)
Protein-energy malnutrition	130.6 (63.6 to 240.7)	94.2 (33.9 to 204.5)	-31.6 (-77.7 to 105.8)	37.5 (-78.4 to 80.2)	16.3 (6.9 to 33.3)	11.7 (3.7 to 26.9)	11.7 (-77.5 to 108.1)	-31.2 (-78.9 to 82.0)
Iodine deficiency	663.9 (278.7 to 1,145.2)	779.6 (258.9 to 1,381.0)	23.8 (-71.6 to 238.3)	-27.3 (-83.0 to 124.4)	12.1 (4.3 to 24.7)	14.0 (4.6 to 28.5)	22.6 (-71.9 to 232.8)	-27.2 (-83.3 to 121.4)
Vitamin A deficiency	26.9 (15.4 to 40.2)	17.8 (10.1 to 27.5)	-32.6 (-54.0 to -9.9)	-47.6 (-63.2 to -32.9)	1.5 (0.8 to 2.6)	1.0 (0.5 to 1.7)	-32.7 (-54.8 to -7.4)	-49.5 (-64.9 to -34.6)

Appendix Table G.4 - Algeria prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	5,831.3 (5,739.5 to 5,922.4)	6,785.2 (6,685.2 to 6,883.4)	16.3 (13.7 to 18.9)	-14.1 (-16.1 to -12.2)	192.0 (127.9 to 277.7)	198.7 (131.7 to 288.7)	3.6 (-0.3 to 6.6)	-15.1 (-18.1 to -12.6)
Other nutritional deficiencies	-	-	-	-	0.4 (0.1 to 1.6)	0.2 (0.0 to 0.8)	-40.7 (-85.7 to 139.0)	-46.1 (-86.4 to 108.8)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	16.2 (10.1 to 24.1)	19.1 (11.7 to 29.9)	17.1 (-0.7 to 44.0)	-12.6 (-25.3 to 3.2)
Sexually transmitted diseases excluding HIV	-	-	-	-	4.6 (2.4 to 7.9)	7.5 (4.1 to 13.5)	61.5 (18.4 to 151.5)	-11.0 (-31.7 to 29.0)
Syphilis	0.7 (0.6 to 0.7)	0.8 (0.7 to 0.9)	26.0 (7.0 to 80.8)	-42.9 (-51.0 to -33.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	41.3 (-3.6 to 73.9)	-41.3 (-55.7 to -20.2)
Chlamydial infection	483.1 (340.3 to 634.6)	772.6 (557.6 to 1,020.6)	60.1 (0.0 to 155.1)	-8.4 (-42.4 to 41.0)	2.4 (1.1 to 4.4)	3.7 (1.6 to 7.1)	48.1 (-10.9 to 214.6)	-13.6 (-47.8 to 78.0)
Gonococcal infection	151.3 (107.6 to 195.5)	224.3 (164.2 to 281.2)	47.5 (5.7 to 127.5)	-12.8 (-36.8 to 30.8)	1.0 (0.5 to 1.7)	1.5 (0.8 to 2.5)	46.8 (-5.3 to 133.6)	-13.3 (-43.8 to 33.4)
Trichomoniasis	95.7 (45.7 to 185.6)	225.4 (146.6 to 306.0)	153.6 (19.1 to 362.9)	23.4 (-32.7 to 117.2)	0.2 (0.0 to 0.4)	0.4 (0.1 to 0.9)	172.6 (16.8 to 482.6)	31.8 (-33.9 to 155.8)
Genital herpes	3,046.6 (2,867.4 to 3,206.6)	6,185.6 (5,835.7 to 6,560.0)	103.2 (87.4 to 120.7)	-9.8 (-11.6 to -4.6)	0.8 (0.3 to 2.0)	1.6 (0.5 to 4.0)	97.0 (77.2 to 117.7)	-3.6 (-11.8 to 6.2)
Other sexually transmitted diseases	4.7 (3.2 to 6.3)	7.6 (5.8 to 10.2)	64.5 (34.9 to 95.1)	-25.3 (-38.7 to -10.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	97.2 (29.6 to 216.8)	3.2 (-33.7 to 47.4)
Hepatitis	-	-	-	-	2.1 (1.3 to 3.0)	2.7 (1.6 to 4.0)	31.2 (-3.6 to 66.0)	-24.1 (-45.1 to 0.8)
Hepatitis A	38.6 (36.9 to 40.4)	45.9 (44.4 to 47.4)	18.9 (17.2 to 20.5)	-2.5 (-2.5 to -2.4)	0.8 (0.5 to 1.2)	1.1 (0.7 to 1.7)	36.4 (21.1 to 54.3)	-0.6 (-11.1 to 11.0)
Hepatitis B	1,986.9 (1,481.9 to 2,418.9)	2,193.8 (1,673.1 to 2,736.1)	9.8 (-19.8 to 58.4)	-35.3 (-52.5 to -8.2)	1.0 (0.6 to 1.5)	1.1 (0.5 to 2.0)	20.1 (43.2 to 102.2)	-39.6 (-71.8 to 8.5)
Hepatitis C	1,155.7 (1,039.0 to 1,278.2)	1,659.0 (1,469.2 to 1,849.7)	43.4 (23.0 to 68.0)	-24.4 (-34.1 to -11.5)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.3)	25.7 (9.0 to 66.3)	-29.2 (-49.0 to -2.8)
Hepatitis E	3.8 (2.6 to 5.1)	6.9 (4.1 to 9.9)	76.6 (46.4 to 141.7)	5.1 (-12.5 to 39.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	84.2 (27.9 to 175.1)	5.0 (-25.8 to 51.8)
Leprosy	-	-	0.0 (0.0 to 0.0)	-	-	-	-	-
Other infectious diseases	271.4 (209.3 to 335.1)	274.8 (228.6 to 327.2)	1.2 (-18.4 to 29.5)	-12.6 (-27.8 to 7.7)	9.6 (5.7 to 14.1)	9.0 (5.5 to 13.4)	-6.5 (-31.0 to 32.6)	-9.5 (-32.6 to 25.8)
Non-communicable diseases	-	-	-	-	-	-	-	-
Neoplasms	-	-	-	-	5.2 (1,302.8 to 2,301.2)	10.7 (2,496.4 to 4,382.0)	104.6 (81.8 to 98.8)	-4.4 (-2.7 to 5.4)
Esophageal cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	93.6 (31.0 to 181.8)	-15.9 (-42.1 to 22.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	91.3 (44.8 to 155.0)	-16.9 (-37.2 to 11.6)
Stomach cancer	2.1 (1.7 to 2.6)	3.3 (2.7 to 4.0)	56.3 (18.5 to 106.0)	-29.6 (-45.7 to -8.0)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	55.9 (16.8 to 107.8)	-29.7 (-47.4 to -5.9)
Liver cancer	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	86.3 (39.2 to 156.2)	-15.8 (-40.3 to 15.9)
Liver cancer due to hepatitis B	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	132.0 (29.0 to 332.1)	4.8 (-42.1 to 94.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	126.9 (39.2 to 276.7)	1.8 (-37.4 to 70.6)
Liver cancer due to hepatitis C	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.5)	293.8 (120.6 to 625.0)	78.3 (-0.0 to 235.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	268.8 (134.7 to 525.1)	67.1 (6.0 to 184.2)
Liver cancer due to alcohol use	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-31.0 (-63.2 to 23.8)	-68.0 (-83.1 to -43.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.0 (-59.2 to 9.6)	-69.0 (-81.0 to -48.1)
Liver cancer due to other causes	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	10.1 (-58.3 to 74.3)	-60.2 (-81.4 to -20.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.7 (-58.7 to 51.5)	-42.4 (-81.4 to -29.5)
Larynx cancer	1.4 (0.8 to 1.9)	1.7 (1.3 to 2.4)	23.1 (-19.0 to 121.2)	-46.4 (-64.6 to -2.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	23.3 (-19.7 to 117.9)	-46.6 (-65.2 to -2.1)
Tracheal, bronchus and lung cancer	1.8 (1.4 to 2.3)	2.7 (2.2 to 3.4)	47.6 (6.2 to 107.5)	-34.7 (-52.2 to -9.6)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.6)	47.2 (4.8 to 114.3)	-34.9 (-53.4 to -6.7)
Breast cancer	7.9 (5.9 to 10.3)	27.4 (21.0 to 35.2)	247.2 (146.9 to 401.2)	44.8 (4.2 to 104.0)	0.7 (0.4 to 1.0)	2.2 (1.5 to 3.1)	226.7 (125.2 to 368.4)	35.8 (-3.2 to 94.0)
Cervical cancer	5.2 (3.5 to 6.9)	6.3 (4.5 to 8.9)	22.3 (-19.7 to 92.3)	-49.2 (-66.3 to -20.2)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.7)	48.8 (-20.7 to 103.8)	-48.8 (-66.3 to -15.9)
Uterine cancer	0.9 (0.6 to 1.5)	2.0 (1.2 to 3.1)	138.8 (32.8 to 307.1)	3.0 (-41.6 to 73.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	132.7 (28.2 to 315.3)	-0.2 (-43.4 to 74.2)
Prostate cancer	1.2 (0.6 to 1.9)	4.8 (2.9 to 7.1)	307.5 (135.2 to 624.4)	73.0 (0.1 to 208.6)	0.1 (0.1 to 0.2)	0.5 (0.3 to 0.7)	21.9 (89.2 to 477.5)	35.4 (-19.5 to 143.1)
Colon and rectum cancer	4.2 (3.5 to 4.9)	10.0 (8.5 to 11.6)	139.4 (88.2 to 204.2)	6.4 (-15.5 to 33.9)	0.4 (0.3 to 0.5)	0.8 (0.6 to 1.2)	127.6 (78.7 to 191.5)	0.8 (-21.4 to 28.1)
Lip and oral cavity cancer	0.9 (0.7 to 1.2)	1.5 (1.1 to 2.0)	54.9 (9.4 to 131.6)	-29.4 (-52.0 to 38.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	52.6 (6.0 to 129.5)	-31.0 (-5.3 to 51.6)
Nasopharynx cancer	0.4 (2.1 to 4.1)	3.0 (3.0 to 6.2)	41.9 (-9.8 to 120.5)	-29.5 (-54.7 to 9.1)	0.4 (0.2 to 0.4)	0.4 (0.2 to 0.6)	41.9 (-9.5 to 116.7)	-30.7 (-55.8 to 7.3)
Other pharynx cancer	1.0 (0.5 to 1.5)	0.7 (0.5 to 1.0)	-39.7 (-62.1 to 83.6)	-73.6 (-83.6 to -16.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-39.5 (-61.5 to 91.1)	-73.6 (-83.2 to -17.5)
Gallbladder and biliary tract cancer	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.9)	17.1 (-27.5 to 95.0)	-48.2 (-68.0 to -14.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	18.2 (-28.2 to 104.0)	47.6 (-68.6 to -10.1)
Pancreatic cancer	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	168.2 (99.0 to 264.1)	18.6 (-10.8 to 60.2)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	164.8 (105.5 to 243.4)	16.6 (-8.5 to 49.1)
Malignant skin melanoma	0.4 (0.3 to 0.5)	1.0 (0.8 to 1.4)	151.5 (76.8 to 258.0)	12.4 (-22.3 to 64.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	137.9 (64.0 to 247.9)	5.1 (-30.1 to 60.0)
Non-melanoma skin cancer	2.0 (1.7 to 2.4)	6.1 (5.1 to 7.7)	204.9 (145.9 to 278.2)	31.6 (4.1 to 64.9)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	266.2 (162.8 to 410.2)	60.2 (9.2 to 128.8)
Ovarian cancer	0.7 (0.5 to 1.0)	1.6 (1.2 to 2.2)	127.2 (50.9 to 245.9)	-1.2 (-32.7 to 47.1)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	123.5 (47.0 to 235.2)	-3.6 (-36.5 to 49.0)
Testicular cancer	0.4 (0.2 to 0.6)	1.0 (0.6 to 1.5)	155.5 (46.7 to 339.3)	20.8 (-28.7 to 105.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	146.3 (31.8 to 360.1)	15.0 (-37.5 to 100.8)
Kidney cancer	0.7 (0.6 to 1.0)	1.2 (1.0 to 1.5)	65.3 (10.5 to 135.4)	1.3 (-23.6 to 43.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	75.6 (23.2 to 147.7)	5.0 (-23.8 to 44.7)
Bladder cancer	1.8 (1.3 to 2.4)	2.6 (2.0 to 3.3)	42.0 (-3.3 to 124.0)	-36.6 (-57.1 to -1.1)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	40.1 (-2.8 to 122.5)	-37.8 (-56.6 to -15.1)
Brain and nervous system cancer	1.4 (1.1 to 2.0)	3.3 (2.4 to 4.1)	140.5 (48.7 to 237.8)	52.2 (0.2 to 104.1)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	148.9 (56.9 to 247.5)	47.2 (-3.6 to 99.1)
Thyroid cancer	3.1 (1.9 to 4.2)	5.5 (3.9 to 7.8)	76.4 (14.0 to 213.6)	-20.0 (-48.4 to 38.1)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	71.6 (9.1 to 214.3)	-23.4 (-50.2 to 34.2)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	71.2 (12.6 to 155.0)	-21.2 (-47.8 to 37.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.8 (12.9 to 160.3)	21.9 (-48.1 to 18.5)
Hodgkin lymphoma	2.7 (1.8 to 3.7)	4.4 (3.2 to 5.9)	61.6 (5.0 to 170.2)	3.6 (-31.8 to 67.9)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	56.9 (11.1 to 160.1)	-3.6 (-36.3 to 54.7)
Non-Hodgkin lymphoma	3.5 (2.3 to 4.6)	7.5 (5.9 to 9.8)	107.4 (47.2 to 272.2)	11.2 (-20.4 to 98.2)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	104.4 (46.7 to 263.7)	6.3 (-23.9 to 89.9)
Multiple myeloma	0.3 (0.2 to 0.5)	1.1 (0.8 to 1.5)	256.5 (124.7 to 515.4)	57.4 (-0.7 to 165.8)	0.1 (0.0 to 0.1)	0.3 (0.1 to 0.3)	232.4 (104.4 to 467.2)	46.4 (-11.2 to 148.8)
Leukemia	3.4 (2.6 to 4.4)	6.6 (5.4 to 7.9)	92.3 (41.1 to 161.0)	30.5 (1.4 to 71.6)	0.4 (0.3 to 0.5)	0.8 (0.5 to 1.1)	88.4 (52.8 to 165.7)	22.4 (-5.4 to 63.3)
Other neoplasms	7.5 (4.7 to 13.5)	15.7 (12.5 to 21.5)	140.2 (10.8 to 264.7)	60.2 (-7.5 to 123.2)	0.2 (0.3 to 0.9)	1.1 (0.7 to 1.6)	136.5 (17.7 to 249.0)	46.3 (-10.7 to 101.0)
Cardiovascular diseases	-	-	-	-	34.8 (22.8 to 48.4)	74.4 (50.3 to 103.7)	115.4 (62.5 to 173.4)	4.8 (-20.0 to 32.7)
Rheumatic heart disease	53.7 (49.3 to 58.1)	94.4 (87.1 to 103.0)	75.2 (56.2 to 100.5)	2.4 (-8.0 to 15.5)	2.9 (1.8 to 4.2)	5.7 (3.7 to 8.1)	97.0 (64.4 to 147.8)	16.1 (-3.5 to 53.9)
Ischemic heart disease	171.4 (139.6 to 214.1)	316.9 (264.9 to 371.9)	86.1 (39.9 to 146.7)	-15.3 (-35.7 to 11.9)	9.6 (6.1 to 14.2)	18.5 (11.9 to 26.1)	87.6 (35.6 to 168.0)	-13.5 (-37.2 to 23.9)
Cerebrovascular disease	-	-	-	-	1.2 (0.8 to 1.6)	2.8 (1.9 to 3.8)	129.8 (89.1 to 187.5)	2.6 (-15.0 to 27.9)
Ischemic stroke	6.5 (5.7 to 7.6)	15.5 (13.5 to 18.0)	135.6 (97.6 to 186.5)	3.1 (-13.0 to 26.0)	1.0 (0.7 to 1.4)	2.4 (1.6 to 3.3)	135.6 (91.9 to 199.7)	4.3 (-14.4 to 31.7)
Hemorrhagic stroke	1.1 (0.9 to 1.4)	2.1 (1.6 to 2.8)	92.5 (47.3 to 176.5)	-8.6 (-30.4 to 30.4)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	92.3 (47.6 to 176.1)	-8.9 (-30.9 to 30.2)
Hypertensive heart disease	17.6 (14.2 to 21.8)	56.6 (47.4 to 65.3)	221.6 (142.3 to 322.8)	59.3 (10.4 to 101.1)	2.0 (1.3 to 2.8)	6.3 (4.1 to 9.3)	221.6 (134.8 to 321.2)	49.7 (8.4 to 100.8)
Cardiomyopathy and myocarditis	15.5 (12.9 to 18.0)	39.2 (33.8 to 44.0)	152.9 (104.7 to 219.7)	33.2 (4.0 to 71.8)	1.7 (1.1 to 2.4)	4.3 (2.8 to 6.1)	153.9 (98.3 to 222.5)	33.5 (1.2 to 74.4)
Atrial fibrillation and flutter	3.7 (2.1 to 5.3)	6.8 (4.6 to 9.5)	77.4 (14.7 to 305.3)	-28.1 (-57.5 to 61.8)	0.3 (0.1 to 0.5)	0.5 (0.3 to 0.9)	83.7 (11.3 to 323.0)	-26.8 (-57.7 to 67.3)
Peripheral vascular disease	260.4 (198.8 to 341.8)	719.0 (543.2 to 885.1)	181.4 (91.7 to 291.5)	18.0 (-17.1 to 58.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.7)	117.7 (2.4 to 332.1)	-7.4 (-58.9 to 70.1)
Endocarditis	0.4 (0.3 to 0.6)	0.9 (0.7 to 1.2)	101.3 (53.4 to 168.1)	25.1 (-4.6 to 81.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	118.0 (64.4 to 185.5)	0.9 (-1.6 to 7.5)
Other cardiovascular and circulatory diseases	239.6 (173.4 to 332.4)	512.2 (316.3 to 671.3)	120.9 (29.6 to 225.4)	11.5 (-36.0 to 65.1)	16.9 (10.1 to 26.2)	36.2 (20.8 to 54.5)	118.7 (77.5 to 229.4)	11.1 (-35.6 to 66.5)
Chronic respiratory diseases	-	-	-	-	79.8 (54.5 to 110.0)	142.5 (95.3 to 196.1)	79.2 (48.1 to 116.5)	-4.8 (-22.4 to 13.9)
Chronic obstructive pulmonary disease	691.8 (649.8 to 736.6)	1,469.5 (1,372.2 to 1,560.7)	112.5 (105					

Appendix Table G.4 - Algeria prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	109.0 (102.2 to 115.6)	-5.1 (-8.6 to -2.0)
Silicosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	100.1 (91.3 to 110.1)	-12.0 (-16.5 to -7.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	100.0 (91.1 to 110.4)	-12.1 (-16.5 to -7.6)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.2 (0.2 to 0.2)	0.4 (0.4 to 0.5)	113.8 (104.5 to 122.1)	-0.7 (-4.8 to 3.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	114.3 (104.8 to 122.7)	-0.3 (-4.5 to 3.7)
Asthma	647.2 (496.4 to 770.0)	756.5 (616.2 to 889.1)	17.5 (9.8 to 56.2)	-21.6 (-37.7 to -3.9)	28.7 (17.7 to 43.1)	33.2 (21.4 to 49.7)	16.0 (-11.2 to 55.9)	-22.1 (-38.8 to -3.1)
Interstitial lung disease and pulmonary sarcoidosis	1.6 (1.2 to 1.9)	3.4 (2.7 to 4.3)	117.2 (56.6 to 207.9)	3.0 (-24.8 to 49.0)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	118.4 (56.0 to 210.8)	2.8 (-25.5 to 50.9)
Other chronic respiratory diseases	-	-	-	-	4.1 (2.4 to 6.5)	5.1 (3.1 to 8.0)	25.0 (-19.6 to 86.5)	-41.2 (-62.2 to -11.6)
Cirrhosis	-	-	-	-	1.5 (1.0 to 2.1)	1.8 (1.3 to 2.6)	21.2 (2.9 to 42.5)	-24.3 (-34.6 to -11.9)
Cirrhosis due to hepatitis B	2.6 (1.4 to 3.8)	3.7 (1.6 to 5.3)	47.8 (-40.7 to 193.2)	-15.3 (-67.4 to 43.5)	0.4 (0.2 to 0.7)	0.6 (0.2 to 1.0)	46.5 (-42.8 to 218.2)	-15.9 (-69.9 to 53.1)
Cirrhosis due to hepatitis C	3.3 (2.2 to 4.3)	4.4 (2.7 to 6.7)	27.8 (-11.3 to 139.7)	-25.7 (-49.2 to 50.3)	0.5 (0.3 to 0.9)	0.7 (0.4 to 1.2)	27.0 (-19.1 to 151.6)	-26.5 (-52.9 to 54.6)
Cirrhosis due to alcohol use	0.7 (0.4 to 1.0)	0.7 (0.4 to 1.1)	10.7 (-45.0 to 123.2)	-46.6 (-73.8 to 4.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	8.3 (-48.0 to 145.0)	46.7 (-75.2 to 12.4)
Cirrhosis due to other causes	2.6 (1.9 to 3.1)	2.2 (1.7 to 2.8)	-12.7 (-37.9 to 21.1)	-22.1 (-45.8 to 8.2)	0.4 (0.3 to 0.7)	0.4 (0.2 to 0.6)	-13.4 (-45.0 to 38.9)	-22.9 (-52.1 to 20.1)
Digestive diseases	-	-	-	-	15.0 (11.2 to 21.8)	26.9 (19.0 to 35.7)	68.0 (49.8 to 88.6)	-15.6 (-24.1 to -6.4)
Peptic ulcer disease	71.4 (60.5 to 81.8)	80.1 (66.4 to 92.7)	12.2 (-11.3 to 40.7)	-45.8 (-57.3 to -33.5)	2.7 (1.8 to 4.0)	3.4 (2.3 to 4.9)	26.2 (1.7 to 60.1)	-40.0 (-49.2 to -26.1)
Gastritis and duodenitis	76.7 (68.0 to 86.7)	60.8 (53.6 to 67.3)	-20.6 (-32.0 to -8.1)	-48.9 (-55.8 to -40.6)	3.6 (2.4 to 5.3)	3.0 (1.9 to 4.4)	-18.0 (-35.4 to 6.9)	-42.8 (-52.0 to -29.5)
Appendicitis	2.0 (1.5 to 2.6)	2.6 (2.0 to 3.2)	27.7 (-7.6 to 88.1)	-24.2 (-42.8 to 6.4)	0.6 (0.4 to 1.0)	0.8 (0.5 to 1.2)	27.3 (-19.0 to 113.2)	-23.5 (-47.9 to 22.5)
Paralytic ileus and intestinal obstruction	0.3 (0.2 to 0.6)	0.4 (0.3 to 0.5)	66.6 (-44.8 to 148.8)	-3.4 (-44.0 to 18.1)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	63.0 (-45.5 to 162.6)	-3.2 (-46.7 to 33.1)
Inguinal, femoral, and abdominal hernia	62.0 (52.9 to 70.6)	109.9 (95.1 to 129.9)	77.0 (44.7 to 118.1)	-11.6 (-30.5 to 10.3)	0.6 (0.3 to 1.2)	1.1 (0.5 to 2.2)	76.5 (42.7 to 118.1)	-11.3 (-30.4 to 10.9)
Inflammatory bowel disease	17.4 (16.1 to 18.9)	53.2 (49.0 to 57.8)	205.5 (171.5 to 240.9)	46.8 (30.9 to 63.2)	3.7 (2.5 to 5.2)	11.4 (7.7 to 15.5)	204.1 (162.0 to 248.1)	47.1 (28.0 to 66.3)
Vascular intestinal disorders	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	91.5 (29.8 to 170.2)	-6.7 (-43.8 to 27.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.8 (32.8 to 182.4)	-0.8 (-40.8 to 50.3)
Gallbladder and biliary diseases	7.8 (6.8 to 8.9)	15.4 (12.9 to 17.6)	97.9 (56.2 to 143.7)	-6.3 (-25.1 to 16.9)	0.8 (0.5 to 1.2)	1.6 (1.1 to 2.3)	97.3 (51.1 to 146.7)	-6.3 (-25.4 to 18.4)
Pancreatitis	4.2 (3.9 to 4.4)	8.0 (7.4 to 8.6)	90.6 (73.0 to 111.1)	-8.1 (-15.1 to 1.1)	1.2 (0.8 to 1.7)	2.4 (1.6 to 3.3)	88.5 (55.6 to 128.5)	-8.1 (-21.8 to 7.7)
Other digestive diseases	-	-	-	-	2.5 (1.6 to 3.8)	3.1 (2.0 to 4.6)	24.6 (8.0 to 72.8)	-37.2 (-53.2 to -13.9)
Neurological disorders	-	-	-	-	179.7 (123.1 to 246.9)	362.0 (236.6 to 497.3)	101.7 (72.3 to 137.6)	5.7 (-6.4 to 21.2)
Alzheimer disease and other dementias	92.5 (81.9 to 106.3)	218.7 (187.5 to 249.5)	136.4 (96.1 to 189.6)	-0.3 (-18.5 to 23.1)	12.9 (9.1 to 17.0)	30.9 (21.4 to 40.6)	138.5 (97.5 to 193.3)	0.1 (-18.5 to 24.6)
Parkinson disease	8.5 (4.4 to 12.0)	20.0 (10.8 to 28.0)	135.4 (121.4 to 150.6)	1.7 (-3.5 to 7.6)	1.0 (0.5 to 1.6)	2.4 (1.2 to 3.7)	136.4 (110.4 to 166.2)	2.3 (-7.9 to 13.4)
Epilepsy	123.6 (100.7 to 144.7)	183.3 (152.4 to 215.0)	47.4 (14.6 to 98.6)	-0.4 (-22.3 to 31.3)	38.3 (25.0 to 53.6)	62.2 (41.0 to 87.0)	62.6 (22.6 to 120.9)	11.1 (-16.3 to 47.7)
Multiple sclerosis	2.9 (2.0 to 3.9)	11.8 (8.2 to 16.0)	303.1 (155.0 to 557.2)	82.8 (16.1 to 182.8)	1.0 (0.6 to 1.5)	3.9 (2.3 to 5.9)	293.1 (139.6 to 568.8)	78.5 (9.6 to 189.8)
Migraine	2,482.5 (1,886.6 to 3,231.0)	4,988.2 (3,630.1 to 5,581.3)	100.3 (88.9 to 112.2)	85.3 (-22.7 to 35.5)	8.3 (47.4 to 244.4)	157.5 (89.4 to 244.4)	68.3 (37.8 to 115.1)	8.3 (-22.9 to 37.0)
Tension-type headache	4,111.0 (3,802.9 to 4,398.1)	6,971.2 (5,041.9 to 9,142.5)	69.3 (22.7 to 121.9)	-3.7 (-28.5 to 23.4)	6.3 (3.4 to 13.9)	10.6 (4.7 to 19.9)	68.6 (31.4 to 121.7)	-3.7 (-22.9 to 23.5)
Medication overuse headache	179.0 (117.2 to 241.4)	546.7 (368.9 to 737.3)	205.8 (139.6 to 288.4)	50.7 (18.1 to 91.9)	28.2 (15.7 to 43.8)	86.1 (49.4 to 132.0)	206.1 (138.0 to 289.3)	50.9 (18.6 to 93.0)
Other neurological disorders	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	62.3 (9.6 to 144.7)	2.6 (-32.4 to 47.6)	6.7 (4.2 to 10.2)	8.4 (5.5 to 11.9)	26.4 (-16.8 to 96.6)	-47.6 (-65.6 to -18.0)
Mental and substance use disorders	-	-	-	-	608.8 (422.3 to 835.0)	1,070.4 (736.4 to 1,469.9)	79.9 (66.0 to 85.3)	-0.5 (-4.3 to 4.0)
Schizophrenia	54.8 (49.7 to 59.3)	117.7 (107.3 to 127.2)	114.7 (105.7 to 125.9)	-0.4 (-4.1 to 3.8)	35.3 (26.3 to 43.0)	75.8 (55.6 to 92.7)	114.2 (100.5 to 131.3)	-0.2 (-5.9 to 6.2)
Alcohol use disorders	65.5 (55.1 to 78.2)	142.5 (122.2 to 169.5)	117.9 (102.2 to 132.8)	8.3 (0.9 to 15.2)	6.3 (4.1 to 9.1)	13.9 (9.0 to 20.1)	120.4 (98.6 to 142.2)	8.9 (-1.1 to 17.5)
Drug use disorders	-	-	-	-	84.9 (51.8 to 128.3)	176.8 (108.0 to 268.6)	108.4 (83.8 to 138.2)	1.4 (-9.4 to 15.3)
Opioid use disorders	164.9 (97.0 to 252.2)	362.3 (224.8 to 541.7)	120.1 (96.0 to 158.2)	2.7 (-8.5 to 19.1)	68.9 (37.7 to 110.1)	151.5 (87.2 to 237.7)	120.5 (93.5 to 158.7)	3.0 (-8.8 to 20.6)
Cocaine use disorders	19.8 (16.2 to 23.8)	34.3 (28.0 to 41.2)	74.2 (29.5 to 129.8)	4.7 (-28.9 to 23.6)	2.7 (1.7 to 4.1)	4.7 (3.0 to 7.0)	75.8 (22.6 to 140.5)	-6.2 (-31.8 to 28.2)
Amphetamine use disorders	35.7 (28.2 to 43.1)	52.9 (43.3 to 63.6)	47.8 (11.2 to 104.6)	-1.1 (-31.8 to 21.3)	4.7 (2.7 to 7.1)	7.0 (4.2 to 10.6)	47.9 (6.5 to 110.5)	-11.1 (-34.9 to 26.0)
Cannabis use disorders	39.7 (30.3 to 48.5)	63.6 (50.5 to 76.3)	60.3 (52.6 to 70.3)	-0.0 (-0.1 to 0.0)	1.2 (0.7 to 1.8)	1.8 (1.1 to 2.8)	59.9 (35.8 to 93.2)	-0.1 (-14.8 to 16.9)
Other drug use disorders	-	-	-	-	7.5 (4.6 to 10.9)	11.8 (7.1 to 17.3)	57.4 (11.3 to 131.7)	-9.0 (-34.5 to 33.5)
Depressive disorders	-	-	-	-	120.9 (120.9 to 329.5)	211.2 (211.2 to 609.7)	90.5 (56.8 to 99.5)	-1.4 (-8.2 to 10.3)
Major depressive disorder	911.1 (554.3 to 1,266.3)	1,631.9 (921.8 to 2,356.2)	78.6 (49.2 to 100.0)	-1.7 (-9.3 to 12.2)	188.6 (102.6 to 299.8)	336.2 (169.4 to 560.1)	77.7 (47.3 to 99.1)	-1.6 (-9.3 to 12.2)
Dysthymia	227.4 (184.6 to 270.7)	465.3 (374.6 to 554.7)	104.4 (97.9 to 112.7)	-0.5 (-0.7 to -0.4)	22.0 (13.9 to 32.3)	44.9 (28.2 to 65.8)	104.0 (95.2 to 114.6)	-0.3 (-2.8 to 2.3)
Bipolar disorder	159.1 (137.8 to 180.9)	310.1 (271.2 to 351.3)	94.9 (82.6 to 108.8)	-1.2 (-6.3 to 3.8)	32.6 (19.7 to 49.4)	63.2 (38.8 to 95.0)	93.8 (80.5 to 110.8)	-1.3 (-7.2 to 5.1)
Anxiety disorders	1,018.7 (445.4 to 1,483.7)	1,725.1 (880.1 to 2,457.3)	70.3 (48.4 to 95.3)	0.4 (-0.7 to -0.1)	70.3 (37.9 to 156.0)	94.5 (71.7 to 254.1)	69.9 (46.9 to 95.7)	-0.2 (-2.5 to 2.1)
Eating disorders	-	-	-	-	3.8 (2.2 to 5.7)	6.1 (3.7 to 9.7)	63.1 (42.1 to 86.8)	4.3 (-7.9 to 18.1)
Anorexia nervosa	4.1 (2.6 to 5.9)	6.9 (4.5 to 10.3)	68.5 (45.7 to 96.8)	14.9 (1.6 to 34.3)	0.9 (0.5 to 1.4)	1.5 (0.8 to 2.4)	68.9 (26.1 to 127.0)	15.3 (-11.6 to 53.9)
Bulimia nervosa	13.7 (9.3 to 19.4)	22.0 (14.9 to 31.5)	60.7 (50.8 to 69.5)	0.3 (0.3 to 0.4)	2.9 (1.7 to 4.5)	4.7 (2.7 to 7.5)	61.7 (38.5 to 85.6)	1.1 (-11.9 to 14.8)
Autistic spectrum disorders	-	-	-	-	31.2 (21.7 to 42.6)	45.8 (31.9 to 62.0)	46.7 (41.2 to 52.8)	0.7 (-2.6 to 4.2)
Autism	78.1 (73.9 to 82.5)	115.4 (109.5 to 121.9)	47.9 (46.7 to 49.2)	0.5 (0.5 to 0.5)	19.4 (13.1 to 26.6)	28.5 (19.2 to 39.1)	47.1 (39.1 to 55.6)	0.7 (-3.9 to 5.8)
Asperger syndrome	117.3 (110.0 to 124.2)	172.5 (161.7 to 183.1)	47.1 (45.4 to 48.8)	0.7 (0.6 to 0.7)	11.8 (8.2 to 16.6)	17.3 (11.9 to 24.2)	46.3 (40.3 to 52.9)	0.7 (-2.8 to 4.5)
Attention-deficit/hyperactivity disorder	199.7 (164.7 to 235.4)	206.1 (170.1 to 243.3)	3.3 (2.2 to 3.9)	-0.0 (-0.0 to -0.0)	2.4 (1.4 to 3.8)	2.5 (1.4 to 3.9)	3.4 (-3.7 to 11.4)	0.4 (-6.8 to 8.1)
Conduct disorder	368.9 (306.3 to 427.5)	366.4 (304.3 to 428.6)	-0.8 (-2.9 to 2.3)	0.0 (-0.0 to -0.0)	44.5 (27.6 to 67.3)	44.2 (27.2 to 67.5)	0.5 (-5.0 to 4.5)	0.1 (-3.9 to 4.3)
Idiopathic intellectual disability	78.2 (66.4 to 92.0)	1,051.5 (896.0 to 1,247.7)	35.1 (24.2 to 46.4)	6.1 (-13.5 to 1.8)	38.2 (25.3 to 54.2)	51.4 (34.3 to 72.9)	34.7 (23.3 to 46.4)	-5.9 (-13.8 to 2.2)
Other mental and substance use disorders	324.9 (303.0 to 346.4)	671.5 (628.3 to 711.5)	106.7 (104.1 to 109.5)	0.5 (0.3 to 0.7)	24.4 (16.6 to 32.7)	50.3 (34.0 to 67.7)	106.5 (97.8 to 115.8)	0.7 (-2.7 to 4.6)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	177.1 (123.0 to 243.2)	374.5 (258.2 to 516.8)	111.2 (84.2 to 138.9)	14.4 (-2.7 to 32.9)
Diabetes mellitus	764.3 (599.2 to 938.3)	2,182.1 (1,817.9 to 2,536.0)	186.0 (116.3 to 263.4)	33.6 (-1.9 to 75.1)	65.4 (43.2 to 93.0)	182.8 (122.2 to 259.3)	180.7 (107.2 to 266.8)	25.7 (-7.0 to 66.8)
Acute glomerulonephritis	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-13.8 (-20.2 to -6.0)	-29.7 (-34.4 to -24.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.8 (-20.2 to -6.9)	-29.7 (-34.4 to -24.2)
Chronic kidney disease	-	-	-	-	22.0 (15.5 to 30.1)	39.3 (27.7 to 54.5)	79.0 (60.8 to 99.2)	-0.7 (-8.2 to 8.1)
Chronic kidney disease due to diabetes mellitus	172.6 (114.5 to 246.3)	399.9 (255.7 to 680.8)	128.3 (74.1 to 232.0)	7.8 (-19.2 to 56.7)	4.0 (2.6 to 5.8)	9.0 (6.1 to 12.9)	122.5 (76.7 to 208.5)	9.7 (-15.2 to 52.2)
Chronic kidney disease due to hypertension	141.6 (96.2 to 208.2)	185.9 (136.5 to 266.2)	32.0 (-4.7 to 80.9)	-21.6 (-38.4 to 2.6)	6.3 (4.4 to 8.9)	9.9 (6.7 to 14.0)	54.9 (24.3 to 98.4)	-19.8 (-37.3 to -0.8)
Chronic kidney disease due to glomerulonephritis	227.9 (163.8 to 330.4)	365.3 (239.5 to 525.5)	62.3 (16.2 to 99.6)	52.2 (-45.7 to -1.1)	3.9 (2.4 to 5.5)	4.6 (2.8 to 7.2)	22.6 (-12.8 to 66.0)	-22.9 (-43.4 to 3.8)
Chronic kidney disease due to other causes	308.5 (209.5 to 432.0)	635.5 (461.4 to 833.1)	108.9 (61.4 to 164.0)	14.2 (-11.3 to 45.2)	7.8 (5.4 to 10.9)	15.9 (10.5 to 23.1)	103.4 (57.4 to 155.7)	17.7 (8.8 to 47.1)
Urinary diseases and male infertility	-	-	-	-	10.1 (6.4 to 14.6)	28.8 (17.7 to 42.6)	184.6 (142.8 to 244.8)	28.0 (11.1 to 50.4)

Appendix Table G.4 - Algeria prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	5.0 (4.7 to 5.4)	9.0 (8.4 to 9.5)	78.3 (62.7 to 97.3)	0.2 (-4.4 to 12.9)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	76.5 (37.7 to 125.8)	3.6 (-15.3 to 27.0)
Urolithiasis	236.5 (142.9 to 365.2)	686.2 (418.3 to 1,020.7)	189.2 (144.7 to 265.5)	1.4 (12.4 to 59.5)	1.4 (0.8 to 2.2)	4.5 (2.5 to 7.5)	227.8 (181.0 to 299.2)	52.9 (33.7 to 85.5)
Benign prostatic hyperplasia	155.0 (142.1 to 169.1)	378.6 (347.4 to 407.9)	145.1 (115.2 to 176.4)	7.9 (5.1 to 21.6)	5.6 (3.6 to 7.8)	13.6 (8.8 to 19.3)	145.5 (116.0 to 176.9)	8.2 (-4.9 to 22.0)
Male infertility due to other causes	157.1 (103.1 to 212.8)	316.8 (207.6 to 434.2)	108.9 (8.6 to 241.2)	5.9 (4.4 to 73.9)	1.1 (0.4 to 2.3)	2.1 (0.8 to 4.5)	108.1 (3.2 to 252.8)	6.3 (-46.1 to 80.0)
Other urinary diseases	-	-	-	-	1.9 (0.9 to 3.3)	1.9 (0.9 to 3.3)	105.6 (150.5 to 685.7)	105.6 (23.2 to 270.5)
Gynecological diseases	-	-	-	-	31.2 (20.1 to 46.5)	63.6 (40.7 to 96.9)	104.6 (66.0 to 144.6)	-0.1 (-16.8 to 17.3)
Uterine fibroids	359.4 (322.5 to 392.3)	859.7 (778.3 to 934.3)	139.2 (136.6 to 142.0)	-1.4 (-1.6 to -1.3)	5.9 (3.5 to 9.6)	12.3 (7.1 to 20.3)	108.8 (92.1 to 122.6)	-9.1 (-16.2 to -3.9)
Polycystic ovarian syndrome	471.2 (426.5 to 515.6)	946.2 (857.1 to 1,032.6)	100.7 (74.4 to 128.6)	-1.9 (-14.8 to 11.4)	4.6 (2.2 to 8.5)	9.7 (4.3 to 17.1)	100.2 (73.6 to 128.6)	-1.9 (-14.0 to 10.6)
Female infertility due to other causes	54.5 (21.3 to 97.9)	148.3 (63.8 to 236.2)	172.2 (-2.2 to 662.2)	35.9 (52.2 to 390.0)	0.3 (0.1 to 0.8)	0.8 (0.2 to 1.8)	154.1 (-2.6 to 566.4)	29.8 (-52.2 to 294.7)
Endometriosis	38.0 (32.0 to 45.1)	86.1 (72.4 to 100.5)	127.7 (76.0 to 185.2)	5.2 (17.9 to 30.2)	3.5 (2.3 to 5.0)	8.0 (5.1 to 11.1)	127.4 (74.9 to 184.8)	5.5 (-18.6 to 32.7)
Genital prolapse	1,075.9 (884.4 to 1,288.2)	2,235.7 (1,699.0 to 2,675.7)	108.5 (52.3 to 172.4)	-5.5 (-28.9 to 20.7)	3.4 (1.6 to 6.7)	7.1 (3.3 to 13.2)	108.3 (50.9 to 173.5)	-5.7 (-28.9 to 21.4)
Premenstrual syndrome	1,344.6 (947.4 to 1,933.3)	2,711.8 (1,725.1 to 3,843.3)	106.9 (10.4 to 218.6)	11.3 (-37.1 to 66.3)	11.3 (6.3 to 18.7)	22.9 (11.7 to 40.2)	105.9 (10.2 to 219.3)	11.2 (-36.9 to 68.3)
Other gynecological diseases	71.2 (56.2 to 86.8)	116.1 (106.1 to 125.7)	63.6 (33.1 to 102.0)	-14.0 (-29.7 to 6.9)	2.1 (1.2 to 3.0)	3.3 (2.2 to 4.8)	61.9 (30.7 to 155.5)	-14.9 (-29.9 to 34.1)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	37.2 (24.9 to 53.8)	47.2 (31.4 to 68.2)	26.8 (17.4 to 40.9)	1.8 (-7.8 to 13.3)
Thalassemias	6.5 (5.3 to 7.7)	7.5 (6.3 to 8.6)	14.5 (3.2 to 29.3)	0.0 (-9.9 to 12.4)	0.5 (0.3 to 0.8)	0.6 (0.4 to 0.9)	16.0 (-19.9 to 70.9)	-2.0 (-31.7 to 42.8)
Thalassemia trait	1,142.6 (1,022.1 to 1,273.8)	1,696.6 (1,573.2 to 1,824.8)	48.6 (40.8 to 57.2)	-0.1 (-5.1 to 6.1)	25.3 (16.9 to 36.8)	33.9 (22.6 to 49.2)	34.0 (18.9 to 52.4)	7.7 (-8.4 to 22.4)
Sickle cell disorders	2.0 (1.6 to 2.3)	2.7 (2.2 to 3.0)	36.2 (14.9 to 66.0)	9.3 (-6.2 to 30.0)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	47.5 (24.6 to 80.9)	9.6 (-5.9 to 30.2)
Sickle cell trait	725.9 (659.4 to 794.6)	1,050.9 (943.8 to 1,140.3)	44.8 (39.6 to 51.4)	-2.8 (-6.3 to 1.7)	3.9 (2.4 to 5.7)	5.0 (3.0 to 7.4)	29.6 (5.7 to 63.9)	5.4 (-12.5 to 35.0)
G6PD deficiency	321.5 (255.2 to 395.9)	548.7 (454.7 to 632.3)	71.0 (31.4 to 120.0)	15.3 (-11.1 to 48.2)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	50.4 (46.6 to 53.6)	16.9 (13.5 to 19.6)
G6PD trait	2,087.7 (1,974.8 to 2,191.6)	3,410.0 (3,231.2 to 3,575.7)	63.2 (52.4 to 76.6)	8.1 (1.0 to 17.0)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	14.6 (-65.3 to 85.4)	-44.4 (-78.0 to 17.2)
Other hemoglobinopathies and hemolytic anemias	248.3 (205.2 to 277.2)	298.9 (260.3 to 328.3)	20.4 (2.4 to 47.5)	-16.6 (-27.7 to -2.6)	7.1 (4.0 to 10.7)	7.1 (4.4 to 10.8)	1.6 (-30.0 to 48.8)	-18.5 (-41.2 to 15.4)
Endocrine, metabolic, blood, and immune disorders	335.4 (285.6 to 372.1)	409.1 (370.8 to 428.2)	20.2 (6.6 to 40.3)	11.4 (-21.1 to 2.5)	20.2 (7.6 to 16.5)	12.7 (8.5 to 17.9)	11.9 (-9.7 to 31.4)	-10.5 (-23.2 to 6.4)
Musculoskeletal disorders	-	-	-	-	328.6 (229.5 to 445.9)	724.9 (501.4 to 980.6)	118.5 (42.3 to 157.4)	2.9 (-7.6 to 2.8)
Rheumatoid arthritis	46.1 (43.5 to 49.1)	77.2 (73.0 to 81.4)	67.4 (54.3 to 81.9)	-17.0 (-23.8 to -9.6)	11.0 (7.8 to 14.7)	18.3 (13.0 to 24.5)	66.5 (49.7 to 84.6)	-16.9 (-24.9 to -8.6)
Osteoarthritis	453.8 (427.9 to 478.7)	1,070.0 (1,012.9 to 1,126.7)	136.6 (118.5 to 136.1)	-1.1 (-8.1 to 6.8)	27.7 (19.4 to 37.8)	65.5 (45.4 to 89.9)	136.1 (118.9 to 157.4)	-0.8 (-7.7 to 7.4)
Low back and neck pain	-	-	-	-	248.9 (168.1 to 349.9)	536.8 (366.1 to 749.8)	112.9 (79.1 to 165.2)	3.2 (-1.1 to 25.2)
Low back pain	1,545.7 (1,269.0 to 1,868.3)	3,376.1 (2,804.8 to 3,967.7)	116.4 (72.5 to 189.4)	5.4 (-14.6 to 36.8)	173.1 (112.3 to 250.1)	377.0 (246.9 to 560.4)	116.3 (71.5 to 189.5)	5.8 (-14.3 to 37.1)
Neck pain	769.5 (652.3 to 876.8)	1,628.7 (1,353.3 to 1,884.1)	113.6 (67.0 to 158.0)	-0.5 (-20.8 to 18.3)	75.6 (51.2 to 105.1)	159.8 (105.6 to 221.7)	112.8 (65.7 to 159.0)	-0.4 (-20.9 to 18.7)
Gout	8.6 (7.1 to 10.0)	20.5 (17.3 to 23.5)	135.2 (85.4 to 213.1)	1.9 (-18.9 to 30.3)	0.3 (0.2 to 0.4)	0.7 (0.4 to 0.9)	138.0 (78.3 to 231.6)	2.6 (-22.6 to 40.6)
Other musculoskeletal disorders	447.5 (334.1 to 562.9)	1,132.9 (876.1 to 1,403.8)	153.2 (132.1 to 176.9)	9.4 (1.4 to 18.9)	40.9 (25.8 to 60.5)	103.6 (66.9 to 152.7)	97.6 (132.1 to 178.9)	9.7 (-11.1 to 20.5)
Other non-communicable diseases	-	-	-	-	343.7 (231.0 to 501.2)	588.7 (398.4 to 838.3)	71.5 (37.4 to 67.7)	-4.5 (-8.6 to -0.5)
Congenital anomalies	-	-	-	-	22.1 (16.2 to 28.9)	48.5 (33.8 to 65.3)	118.7 (78.4 to 176.2)	49.9 (22.4 to 88.0)
Neural tube defects	6.9 (5.7 to 8.4)	14.0 (11.3 to 16.9)	101.4 (52.9 to 173.4)	5.4 (15.7 to 107.1)	2.0 (1.2 to 2.8)	4.1 (2.6 to 6.0)	109.2 (35.8 to 221.1)	61.1 (5.3 to 143.7)
Congenital heart anomalies	87.0 (66.1 to 107.2)	217.3 (186.4 to 262.5)	148.7 (94.9 to 232.9)	82.2 (42.6 to 145.1)	3.0 (1.3 to 5.2)	7.5 (3.1 to 13.0)	146.6 (90.8 to 228.1)	83.7 (43.7 to 145.9)
Orofacial clefts	15.7 (11.5 to 21.6)	38.7 (28.5 to 49.4)	147.3 (68.3 to 268.3)	0.5 (31.8 to 188.4)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.8)	93.7 (25.4 to 237.1)	61.7 (-2.2 to 156.9)
Down syndrome	34.2 (26.9 to 45.5)	62.8 (49.7 to 82.3)	85.2 (22.7 to 165.3)	27.5 (-15.2 to 82.6)	4.1 (2.8 to 5.9)	8.1 (5.6 to 11.7)	98.1 (29.3 to 187.7)	31.7 (-13.5 to 90.1)
Turner syndrome	0.9 (0.6 to 1.2)	1.5 (1.1 to 2.0)	67.9 (11.8 to 154.1)	15.2 (-23.1 to 74.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.2 (12.2 to 175.0)	14.9 (-26.6 to 80.4)
Klinefelter syndrome	0.8 (0.6 to 1.1)	1.2 (0.9 to 1.6)	47.2 (1.8 to 125.9)	0.9 (-30.3 to 54.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.4 (20.4 to 170.7)	0.1 (-30.9 to 53.8)
Chromosomal unbalanced rearrangements	447.5 (25.6 to 36.9)	1,132.9 (44.8 to 71.9)	153.2 (41.7 to 139.4)	9.4 (-3.1 to 64.3)	40.9 (2.6 to 4.0)	103.6 (5.0 to 10.0)	97.6 (47.8 to 157.9)	9.7 (-1.7 to 70.2)
Other congenital anomalies	68.5 (57.1 to 80.8)	100.0 (85.6 to 117.1)	46.5 (23.5 to 69.6)	-9.4 (-23.4 to 5.2)	9.0 (6.0 to 13.2)	21.1 (13.1 to 31.1)	130.5 (54.8 to 267.9)	57.4 (8.2 to 147.0)
Skin and subcutaneous diseases	-	-	-	-	131.3 (81.6 to 206.1)	199.9 (126.9 to 305.8)	53.2 (37.4 to 67.7)	1.1 (-8.3 to 9.2)
Dermatitis	1,197.8 (1,015.5 to 1,380.7)	2,015.6 (1,669.2 to 2,336.5)	68.0 (61.0 to 77.3)	-0.1 (-0.1 to 0.0)	34.4 (21.8 to 50.7)	54.5 (34.9 to 80.3)	58.5 (47.2 to 69.8)	2.8 (-2.8 to 8.1)
Psoriasis	134.3 (106.9 to 166.7)	349.5 (194.0 to 312.0)	85.5 (78.1 to 94.1)	0.0 (-0.1 to 0.2)	11.0 (7.1 to 16.3)	20.4 (13.0 to 30.4)	84.9 (70.4 to 99.6)	0.2 (-5.4 to 6.2)
Cellulitis	5.4 (4.5 to 6.6)	7.0 (5.6 to 9.0)	30.3 (13.1 to 51.5)	-16.9 (-25.4 to -2.6)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.8)	29.9 (31.0 to 66.1)	-16.1 (-32.0 to 4.6)
Pyoderma	21.8 (17.2 to 27.6)	25.4 (20.5 to 33.3)	16.9 (5.5 to 30.1)	-7.4 (-12.9 to -0.9)	0.1 (0.0 to 0.3)	0.1 (0.1 to 0.3)	16.6 (-0.7 to 35.8)	-7.3 (-17.8 to 4.4)
Scabies	103.5 (84.7 to 129.3)	137.9 (113.1 to 168.3)	34.0 (0.8 to 72.3)	-8.8 (-3.4 to 19.3)	2.7 (1.5 to 4.5)	3.6 (1.9 to 5.9)	33.8 (-0.6 to 72.0)	-8.2 (-33.8 to 20.0)
Fungal skin diseases	1,448.0 (1,080.0 to 1,833.2)	2,538.9 (1,971.0 to 3,157.3)	75.4 (62.8 to 90.7)	75.4 (0.0 to 0.5)	8.2 (3.2 to 17.5)	14.3 (5.8 to 30.6)	75.1 (62.2 to 90.4)	0.3 (-0.6 to 1.3)
Viral skin diseases	628.8 (484.5 to 761.6)	769.1 (568.0 to 974.0)	21.8 (11.9 to 31.6)	0.1 (-2.0 to 2.2)	19.5 (11.4 to 30.6)	23.9 (13.5 to 37.9)	21.7 (11.2 to 32.1)	0.3 (-3.1 to 3.7)
Acne vulgaris	3,253.3 (2,614.1 to 3,983.7)	4,273.4 (3,315.1 to 5,327.0)	30.5 (-6.3 to 87.0)	2.1 (-26.5 to 45.0)	35.3 (16.2 to 68.4)	46.4 (21.3 to 91.8)	30.3 (-6.2 to 86.7)	2.2 (-26.8 to 45.3)
Alopecia areata	33.0 (29.1 to 36.8)	55.4 (47.4 to 64.2)	68.5 (36.1 to 104.7)	-1.0 (-19.3 to 19.6)	1.1 (0.7 to 1.7)	1.9 (1.1 to 2.8)	67.6 (32.8 to 110.0)	-0.8 (-20.2 to 22.2)
Pruritus	5.4 (3.3 to 8.1)	9.8 (5.7 to 14.3)	79.0 (-3.1 to 251.2)	-3.1 (-57.8 to 90.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	78.0 (-6.7 to 254.8)	-3.0 (-56.5 to 94.1)
Urticaria	199.6 (123.2 to 274.1)	358.2 (238.1 to 496.5)	78.8 (1.5 to 219.5)	4.8 (-41.3 to 26.2)	12.0 (6.4 to 19.0)	21.3 (12.1 to 33.8)	76.5 (0.0 to 223.0)	3.9 (-42.8 to 67.4)
Decubitus ulcer	3.0 (2.1 to 3.8)	5.5 (4.2 to 7.2)	78.4 (36.4 to 220.0)	-16.2 (-39.2 to 84.8)	0.4 (0.3 to 0.7)	0.8 (0.5 to 1.2)	80.0 (32.4 to 210.8)	-15.2 (-40.6 to 80.9)
Other skin and subcutaneous diseases	1,051.5 (719.1 to 1,498.6)	2,096.5 (1,392.0 to 3,103.8)	99.3 (78.2 to 118.6)	0.9 (-3.7 to 4.7)	6.2 (2.7 to 12.8)	12.3 (5.4 to 25.3)	98.7 (76.9 to 119.4)	1.1 (-3.8 to 4.8)
Sense organ diseases	-	-	-	-	143.8 (98.2 to 203.7)	248.1 (168.6 to 349.4)	72.3 (10.7 to 100.7)	-11.9 (-16.4 to -8.0)
Glaucoma	57.4 (40.2 to 75.6)	112.3 (82.1 to 146.2)	98.2 (40.2 to 172.1)	-7.1 (-34.6 to 27.5)	2.7 (2.7 to 6.8)	8.9 (5.5 to 13.4)	100.7 (54.4 to 160.7)	-6.7 (-31.0 to 18.0)
Cataract	176.2 (121.0 to 249.6)	337.5 (229.1 to 458.3)	95.4 (39.3 to 155.2)	-16.5 (-36.5 to 6.4)	13.8 (8.1 to 21.6)	27.0 (16.0 to 39.9)	100.5 (42.6 to 145.7)	-14.3 (-35.4 to 4.3)
Macular degeneration	30.2 (17.4 to 44.4)	68.0 (40.1 to 101.3)	121.7 (46.7 to 267.8)	-4.4 (-36.2 to 48.4)	2.0 (1.0 to 3.0)	4.4 (2.4 to 7.5)	119.8 (56.3 to 246.6)	-7.2 (-32.9 to 37.3)
Uncorrected refractive error	1,988.5 (1,685.6 to 2,260.1)	3,656.0 (3,231.4 to 4,133.6)	83.7 (55.5 to 124.7)	6.0 (-18.6 to 12.6)	47.5 (30.4 to 70.3)	77.5 (49.6 to 118.0)	62.5 (47.7 to 83.2)	-14.7 (-22.0 to -5.0)
Age-related and other hearing loss	1,745.4 (1,617.1 to 1,879.2)	3,463.6 (3,218.5 to 3,731.5)	98.6 (89.0 to 107.2)	-9.2 (-12.6 to -6.1)	8.2 (3.2 to 17.5)	14.3 (5.7 to 12.5)	88.2 (75.1 to 103.0)	-10.3 (-15.2 to -5.1)
Other vision loss	163.0 (132.5 to 198.1)	243.2 (187.3 to 316.7)	46.7 (23.1 to 83.8)	-16.1 (-27.5 to 0.5)	12.9 (8.4 to 18.9)	19.1 (11.8 to 28.9)	47.3 (23.9 to 78.8)	-18.8 (-29.8 to -6.6)
Other sense organ diseases	618.6 (586.0 to 648.4)	864.8 (825.4 to 906.2)	39.9 (30.9 to 49.4)	-0.6 (-6.5 to 5.8)	16.6 (10.4 to 24.6)	23.0 (14.0 to 33.7)	38.7 (28.4 to 50.2)	-0.6 (-7.2 to 6.8)
Oral disorders								

Appendix Table G.4 - Algeria prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	726.6 (670.8 to 787.4)	1,584.7 (1,448.4 to 1,702.4)	118.6 (94.2 to 141.1)	-5.1 (-14.5 to 4.0)	20.0 (13.3 to 28.4)	43.7 (28.8 to 60.6)	119.0 (94.1 to 142.1)	-4.9 (-14.7 to 4.6)
Other oral disorders	385.6 (362.6 to 408.6)	679.5 (636.2 to 722.5)	76.3 (65.0 to 88.9)	-0.5 (-6.2 to 5.9)	11.4 (7.1 to 17.0)	19.9 (12.3 to 29.7)	75.9 (63.6 to 89.5)	-0.3 (-6.4 to 6.7)
Injuries	-	-	-	-	78.3 (59.4 to 100.0)	90.3 (64.8 to 121.6)	14.7 (2.0 to 30.7)	-38.7 (-45.2 to -30.8)
Transport injuries	-	-	-	-	41.3 (31.1 to 52.7)	39.0 (27.8 to 53.0)	-6.3 (-18.1 to 9.0)	-49.6 (-55.4 to -42.3)
Road injuries	-	-	-	-	36.5 (27.8 to 46.6)	33.6 (23.9 to 45.7)	-8.5 (-20.6 to 7.6)	-90.4 (-56.2 to -43.0)
Pedestrian road injuries	-	-	-	-	9.2 (6.8 to 11.8)	7.1 (5.0 to 9.6)	-23.3 (-35.5 to -9.3)	-54.8 (-60.8 to -47.7)
Cyclist road injuries	-	-	-	-	3.6 (2.7 to 4.7)	4.3 (3.0 to 5.8)	17.7 (4.4 to 32.8)	-38.4 (-45.2 to -30.5)
Motorcyclist road injuries	-	-	-	-	4.3 (3.2 to 5.5)	3.5 (2.4 to 4.9)	-19.6 (-30.9 to -4.9)	-58.4 (-63.7 to -51.5)
Motor vehicle road injuries	-	-	-	-	19.1 (14.4 to 24.5)	18.6 (13.4 to 25.1)	-2.8 (-16.9 to 15.5)	-48.6 (-55.4 to -39.9)
Other road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-52.5 (-58.8 to -44.0)	-75.1 (-78.1 to -71.1)
Other transport injuries	-	-	-	-	4.8 (3.6 to 6.3)	5.4 (3.9 to 7.3)	11.1 (-1.6 to 26.9)	-44.3 (-50.3 to -36.7)
Unintentional injuries	-	-	-	-	34.3 (26.1 to 44.2)	43.9 (31.9 to 59.0)	27.7 (16.2 to 39.9)	-33.3 (-39.3 to -26.9)
Falls	-	-	-	-	13.2 (10.0 to 17.0)	19.5 (14.0 to 27.2)	50.7 (33.1 to 70.8)	-28.4 (-37.1 to -18.5)
Drowning	-	-	-	-	0.9 (0.6 to 1.1)	0.8 (0.5 to 1.0)	-12.7 (-25.6 to 4.4)	-51.2 (-57.9 to -42.7)
Fire, heat, and hot substances	-	-	-	-	4.2 (3.3 to 5.4)	3.4 (2.5 to 4.7)	-19.1 (-30.5 to -6.3)	-55.1 (-60.7 to -48.5)
Poisonings	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-11.4 (-28.9 to 9.7)	-47.3 (-56.3 to -36.0)
Exposure to mechanical forces	-	-	-	-	6.8 (5.1 to 9.0)	7.5 (5.5 to 10.0)	8.7 (-1.1 to 18.9)	-38.1 (-42.4 to -33.4)
Unintentional firearm injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-14.3 (-25.0 to -1.1)	-55.7 (-60.8 to -49.3)
Unintentional suffocation	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	38.3 (19.6 to 57.2)	-21.9 (-30.2 to -12.3)
Other exposure to mechanical forces	-	-	-	-	6.5 (4.9 to 8.5)	7.1 (5.2 to 9.6)	9.5 (0.5 to 19.7)	-37.5 (-41.8 to -32.7)
Adverse effects of medical treatment	-	-	-	-	0.4 (0.2 to 0.5)	0.7 (0.5 to 1.1)	108.4 (95.1 to 121.7)	11.0 (4.0 to 17.8)
Animal contact	-	-	-	-	1.1 (0.8 to 1.4)	1.3 (0.9 to 1.8)	22.1 (8.4 to 37.5)	-28.2 (-35.3 to -20.8)
Venomous animal contact	-	-	-	-	0.5 (0.4 to 0.7)	0.6 (0.5 to 0.9)	27.7 (9.0 to 47.0)	-26.9 (-36.9 to -16.8)
Non-venomous animal contact	-	-	-	-	0.6 (0.4 to 0.8)	0.7 (0.5 to 0.9)	34.9 (1.0 to 34.7)	-29.8 (-37.2 to -20.8)
Foreign body	-	-	-	-	0.8 (0.6 to 1.0)	1.1 (0.8 to 1.4)	34.9 (22.3 to 49.2)	-25.1 (-31.3 to -18.5)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-28.3 (-41.4 to -10.7)	-52.1 (-59.7 to -41.7)
Foreign body in eyes	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	58.9 (43.7 to 76.1)	-9.5 (-17.9 to 0.2)
Foreign body in other body part	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.8)	50.7 (34.1 to 68.3)	-21.9 (-29.2 to -14.4)
Other unintentional injuries	-	-	-	-	6.7 (5.0 to 8.7)	8.9 (6.6 to 11.9)	33.8 (20.9 to 47.7)	-30.6 (-36.3 to -23.7)
Self-harm and interpersonal violence	-	-	-	-	1.9 (1.5 to 2.4)	2.0 (1.4 to 2.7)	0.5 (-12.3 to 17.0)	-46.6 (-52.8 to -38.3)
Self-harm	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	35.9 (18.7 to 55.0)	-37.6 (-45.3 to -29.4)
Interpersonal violence	-	-	-	-	1.7 (1.3 to 2.1)	1.6 (1.1 to 2.2)	-5.2 (-18.3 to 11.1)	-48.4 (-55.1 to -39.8)
Assault by firearm	-	-	-	-	0.3 (0.3 to 0.4)	0.4 (0.3 to 0.5)	8.4 (-6.2 to 23.3)	-40.1 (-47.3 to -32.8)
Assault by sharp object	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	10.2 (-5.6 to 31.3)	-41.8 (-49.6 to -31.4)
Assault by other means	-	-	-	-	1.0 (0.7 to 1.3)	0.8 (0.6 to 1.1)	-14.7 (-27.9 to 2.1)	-53.4 (-60.0 to -44.7)
Forces of nature, war, and legal intervention	-	-	-	-	0.7 (0.3 to 1.4)	5.4 (2.4 to 11.1)	709.7 (431.6 to 1,293.3)	326.8 (175.5 to 655.6)
Exposure to forces of nature	-	-	-	-	0.7 (0.3 to 1.4)	0.9 (0.4 to 1.9)	29.9 (6.9 to 60.4)	-29.5 (-43.3 to -11.5)
Collective violence and legal intervention	-	-	-	-	-	4.6 (2.0 to 9.6)	-	-

Appendix Table G.4 - Andorra prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	6.4 (4.8 to 8.2)	10.8 (8.1 to 14.0)	69.2 (61.9 to 75.3)	2.5 (5.6 to 1.3)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	56.2 (33.2 to 83.8)	2.5 (-10.9 to 19.1)
HIV/AIDS and tuberculosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	237.2 (44.7 to 665.5)	95.0 (-16.1 to 343.5)
Tuberculosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.5 (71.4 to 87.4)	6.5 (1.9 to 11.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (50.0 to 111.4)	5.7 (-10.8 to 27.7)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	322.7 (35.2 to 1,691.1)	346.1 (-23.3 to 926.9)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	197.9 (-8.7 to 1,143.3)	80.5 (-46.9 to 651.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	197.9 (-8.9 to 1,145.7)	80.5 (-47.0 to 652.9)
HIV/AIDS resulting in other diseases	0.1 (0.0 to 0.1)	0.4 (0.1 to 0.8)	619.2 (140.6 to 2,224.7)	310.9 (31.0 to 1,250.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	323.5 (35.1 to 1,722.1)	146.8 (-23.3 to 961.6)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	37.3 (26.3 to 51.7)	-15.0 (-21.8 to -6.2)
Diarrheal diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.1 (21.4 to 61.7)	-16.5 (-29.7 to -0.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.4 (15.2 to 68.4)	-16.6 (-32.3 to 3.5)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.3 (55.7 to 23.5)	-46.1 (-72.1 to -17.4)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.0 (-34.6 to 38.1)	-35.3 (-59.0 to -5.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.1 (-34.6 to 38.6)	-35.3 (-59.0 to -5.2)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.0 (-13.8 to 97.9)	-3.6 (-44.7 to 34.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.0 (-13.8 to 98.2)	-3.6 (-44.3 to 35.2)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.7 (-80.9 to -4.3)	-71.2 (-88.0 to -36.3)
Lower respiratory infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.4 (0.9 to 200.8)	-15.4 (-47.5 to 43.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.8 (-0.3 to 221.3)	-14.7 (-47.7 to 51.8)
Upper respiratory infections	0.8 (0.7 to 0.8)	1.2 (1.1 to 1.2)	54.7 (44.9 to 65.3)	0.2 (-6.6 to 6.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.1 (43.8 to 65.8)	0.2 (-7.4 to 7.8)
Otitis media	0.6 (0.5 to 0.7)	0.9 (0.7 to 1.0)	40.7 (19.0 to 65.4)	-10.9 (-23.7 to 2.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.2 (17.2 to 61.6)	-12.2 (-25.5 to 0.6)
Meningitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.8 (-27.4 to 42.1)	-38.7 (-54.5 to -6.3)
Pneumococcal meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.9 (-24.9 to 31.2)	-40.5 (-56.3 to -23.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.7 (-27.4 to 53.5)	36.1 (-57.1 to -5.0)
H influenzae type B meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.1 (-55.6 to 64.0)	-47.0 (-71.8 to 5.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.5 (-58.3 to 90.3)	-42.0 (-73.3 to 22.8)
Meningococcal meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.3 (-36.5 to 157.5)	-37.0 (-62.3 to 74.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.1 (-37.0 to 189.4)	-30.4 (-63.0 to 103.5)
Other meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.1 (-43.0 to 58.5)	-43.7 (-63.9 to -3.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.5 (-48.2 to 94.1)	-39.3 (-67.2 to 18.0)
Encephalitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.7 (36.5 to 143.3)	6.1 (-23.5 to 47.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.5 (50.1 to 149.5)	13.1 (-14.3 to 51.6)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.1 (-94.7 to 499.7)	-68.4 (-97.0 to 222.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.1 (-94.7 to 504.2)	-68.4 (-97.0 to 229.0)
Whooping cough	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-92.9 (-94.2 to -91.4)	-94.7 (-95.7 to -93.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-93.0 (-95.5 to -89.7)	-94.8 (-96.6 to -92.3)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.0 (-73.2 to 14.4)	-56.2 (-83.9 to -27.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.2 (-75.2 to 21.9)	-52.3 (-85.4 to -16.4)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -99.6)	-100.0 (-100.0 to -99.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -99.6)	-100.0 (-100.0 to -99.7)
Varicella and herpes zoster	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	65.5 (36.0 to 105.6)	0.7 (-15.0 to 20.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.4 (31.6 to 135.4)	1.8 (-23.0 to 37.0)
Neglected tropical diseases and malaria	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.2 (-48.3 to -30.6)	-60.6 (-67.3 to -54.3)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.3 (-67.8 to 549.8)	5.7 (-79.1 to 322.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.7 (-67.6 to 567.3)	7.0 (-79.0 to 333.0)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-74.6 (-90.3 to 28.3)	-85.7 (-94.7 to -27.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-72.8 (-90.2 to 34.3)	-84.7 (-94.6 to -23.5)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.5 (-43.9 to -34.7)	-60.7 (-64.3 to -58.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.9 (-46.2 to -29.2)	-59.9 (-65.7 to -53.6)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.9 (-45.6 to 98.8)	-37.5 (-68.2 to 21.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.9 (-45.6 to 99.2)	-37.5 (-68.2 to 22.2)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.4 (-27.5 to 156.1)	-6.8 (-57.4 to 59.5)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.7 (-36.3 to 45.9)	-29.2 (-54.4 to 4.5)
Maternal hemorrhage	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.0 (-54.6 to 22.6)	-45.0 (-68.3 to -13.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.0 (-67.7 to 27.9)	-49.1 (-77.2 to -7.9)
Maternal sepsis and other maternal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.9 (-85.8 to 400.9)	6.3 (-84.4 to 219.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.6 (-43.4 to 226.3)	2.0 (-58.6 to 128.3)
Maternal hypertensive disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.7 (29.5 to 66.6)	5.0 (-2.9 to 18.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.9 (6.6 to 94.4)	4.8 (-20.7 to 37.3)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.7 (-13.4 to 325.3)	17.0 (-38.5 to 205.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.7 (-13.5 to 325.8)	17.0 (-38.6 to 205.9)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.8 (-24.6 to 103.6)	-3.6 (-46.2 to 44.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.8 (-25.1 to 104.4)	-3.6 (-46.4 to 44.7)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-46.7 to 89.2)	0.0 (-61.8 to 36.5)
Neonatal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	93.7 (13.1 to 216.6)	24.5 (-27.0 to 103.8)
Preterm birth complications	0.3 (0.2 to 0.5)	0.5 (0.3 to 1.0)	105.2 (44.5 to 191.6)	30.5 (-8.5 to 87.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	103.1 (17.3 to 253.6)	31.0 (-24.4 to 128.4)
Neonatal encephalopathy due to birth asphyxia and trauma	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-15.4 (-45.6 to 38.9)	-45.4 (-64.6 to -10.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.6 (-42.1 to 55.3)	-41.2 (-62.4 to 2.3)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.5 (39.3 to 64.5)	20.9 (15.4 to 36.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.5 (-3.1 to 144.0)	21.4 (-19.7 to 102.2)
Hemolytic disease and other neonatal jaundice	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.3 (-72.7 to 489.2)	8.4 (-82.2 to 272.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.9 (-72.2 to 505.6)	-8.1 (-82.1 to 285.6)
Other neonatal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	224.6 (65.7 to 734.9)	109.6 (6.5 to 438.4)
Nutritional deficiencies	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	38.9 (11.5 to 53.7)	-4.2 (-22.4 to 4.2)
Protein-energy malnutrition	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.5 (-7.4 to 346.8)	-15.6 (-57.1 to 78.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.4 (-48.5 to 524.8)	-16.3 (-73.4 to 135.3)
Iodine deficiency	1.0 (0.4 to 2.0)	0.9 (0.4 to 1.5)	-11.2 (-67.8 to 151.3)	-43.9 (-79.1 to 60.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.1 (-67.3 to 148.5)	-43.3 (-79.1 to 56.3)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron-deficiency anemia	5.6 (5.4 to 5.7)	8.4 (7.6 to 8.7)	51.1 (36.9 to 57.1)	-1.4 (-12.1 to 2.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	44.8 (14.3 to 52.3)	-0.6 (-20.6 to 4.3)

Appendix Table G.4 - Andorra prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.0	0.0	29.4	-43.8
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.0	0.0	45.0	-3.0
Sexually transmitted diseases excluding HIV	-	-	-	-	0.0	0.0	56.7	1.2
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	146.2 (92.3 to 213.5)	32.4 (-1.6 to 73.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	143.6 (65.2 to 259.9)	32.8 (-13.9 to 98.2)
Chlamydial infection	1.5 (0.6 to 1.3)	1.5 (1.0 to 2.0)	47.5 (8.3 to 175.5)	1.7 (-24.8 to 96.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.5 (8.8 to 130.0)	42.3 (-36.4 to 63.2)
Gonococcal infection	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	28.4 (-42.8 to 119.4)	-3.4 (-59.2 to 67.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.1 (-21.0 to 92.5)	-4.8 (-42.2 to 42.9)
Trichomoniasis	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	46.0 (-8.9 to 171.2)	-3.5 (-42.0 to 74.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.5 (-17.2 to 236.8)	-2.3 (-48.4 to 117.0)
Genital herpes	5.8 (5.0 to 6.6)	10.0 (8.7 to 11.2)	72.4 (43.9 to 110.2)	-0.4 (-17.5 to 22.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.0 (40.5 to 108.3)	0.0 (-17.8 to 23.2)
Other sexually transmitted diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.5 (-21.0 to 75.6)	-21.1 (-46.9 to 14.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.1 (-14.7 to 130.9)	-1.1 (-44.8 to 61.2)
Hepatitis	-	-	-	-	0.0	0.0	36.3	-14.0
Hepatitis A	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	43.8 (42.9 to 44.5)	-5.9 (-7.0 to -4.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.7 (29.5 to 67.0)	-4.6 (-16.6 to 8.1)
Hepatitis B	0.7 (0.6 to 0.9)	0.8 (0.7 to 1.0)	12.2 (-12.6 to 57.4)	0.0 (-47.8 to -4.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.9 (-17.0 to 87.9)	-30.9 (50.3 to 11.4)
Hepatitis C	1.2 (1.0 to 1.3)	1.4 (1.3 to 1.6)	22.7 (5.2 to 41.6)	-29.7 (-39.8 to -18.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.1 (-21.7 to 80.4)	-32.4 (-51.8 to -1.2)
Hepatitis E	-	-	60.4 (1.7 to 127.3)	6.2 (-34.3 to 49.1)	-	-	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.5)	44.7 (20.9 to 136.1)	-1.1 (-19.4 to 73.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.7 (10.7 to 234.9)	-4.2 (-19.4 to 148.2)
Non-communicable diseases	-	-	-	-	5.6	9.7	74.9	0.8
Neoplasms	-	-	-	-	4.1 (4.1 to 7.2)	7.2 (7.2 to 12.5)	81.1 (65.6 to 81.9)	5.0 (-3.3 to 4.9)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.8 (12.0 to 180.8)	-10.8 (-46.8 to 37.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.7 (9.1 to 165.0)	-14.1 (-46.7 to 29.9)
Stomach cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	68.9 (17.0 to 133.5)	-20.5 (-44.5 to 8.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.0 (10.8 to 125.2)	-23.2 (-47.1 to 7.8)
Liver cancer	-	-	-	-	0.0	0.0	142.3	20.7
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	186.2 (14.1 to 915.2)	48.2 (-42.7 to 426.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	174.1 (10.7 to 826.5)	41.5 (-42.9 to 376.1)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	394.9 (120.3 to 1,134.8)	145.8 (6.3 to 509.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	376.1 (117.0 to 1,054.0)	137.1 (6.9 to 477.2)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.5 (-23.4 to 236.9)	-19.2 (-62.7 to 66.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.2 (-24.6 to 203.9)	-24.4 (-63.3 to 48.5)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.0 (-61.6 to 147.5)	-52.6 (-79.6 to 18.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.0 (-62.5 to 130.9)	-53.8 (-79.9 to 6.3)
Larynx cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	303.5 (5.0 to 59.8)	-34.7 (-47.7 to -19.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.6 (4.2 to 61.8)	-33.7 (-47.7 to -17.8)
Tracheal, bronchus and lung cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	100.1 (41.7 to 173.1)	-0.0 (-30.3 to 36.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.4 (36.3 to 163.9)	-3.5 (-32.2 to 32.9)
Breast cancer	0.3 (0.2 to 0.3)	0.6 (0.5 to 0.7)	113.4 (75.2 to 165.0)	5.7 (-13.1 to 31.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.4 (54.6 to 144.7)	-1.8 (-23.7 to 21.2)
Cervical cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.1 (-28.4 to 103.5)	-35.8 (-62.4 to 12.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.8 (-29.1 to 98.7)	-35.6 (-62.7 to 10.7)
Uterine cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	78.0 (0.4 to 201.2)	-10.7 (-50.5 to 53.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.3 (-4.2 to 200.2)	-12.1 (-53.1 to 53.5)
Prostate cancer	0.2 (0.2 to 0.3)	0.7 (0.6 to 0.9)	212.6 (148.5 to 295.9)	53.3 (21.8 to 94.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	217.3 (135.0 to 329.8)	54.7 (14.2 to 107.4)
Colon and rectum cancer	0.8 (0.7 to 0.8)	1.3 (1.2 to 1.4)	72.2 (54.7 to 91.0)	-17.2 (-26.0 to -8.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	69.3 (53.0 to 87.8)	-18.4 (-26.5 to -9.5)
Lip and oral cavity cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	90.8 (21.2 to 189.4)	-2.9 (-38.8 to 49.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.9 (16.9 to 187.6)	-5.5 (-40.6 to 47.3)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.0)	9.7 (-34.9 to 94.4)	-41.4 (-65.6 to 22.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.2 (-36.2 to 93.7)	-42.4 (-65.4 to 3.0)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.3 (0.6 to 184.7)	-8.7 (-47.4 to 48.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.4 (-0.5 to 175.9)	-9.7 (-48.3 to 43.9)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.2 (-12.5 to 140.9)	-32.9 (-58.0 to 9.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.1 (-15.6 to 142.0)	-34.1 (-58.7 to 8.9)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	138.1 (69.7 to 249.1)	17.0 (-16.7 to 71.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.7 (61.1 to 223.9)	13.7 (-20.3 to 60.1)
Malignant skin melanoma	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	135.4 (62.4 to 244.8)	22.7 (-16.0 to 79.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	131.0 (56.2 to 231.6)	20.7 (-19.3 to 76.1)
Non-melanoma skin cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	167.5 (47.5 to 365.6)	29.8 (-29.3 to 129.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	239.3 (98.8 to 472.9)	54.2 (-6.7 to 159.8)
Ovarian cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	95.8 (18.6 to 220.1)	0.1 (-40.1 to 64.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.6 (16.8 to 213.4)	-0.7 (-42.0 to 62.3)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.5 (-27.5 to 167.8)	-9.0 (-53.6 to 75.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.2 (-29.4 to 174.5)	-10.0 (-55.8 to 78.3)
Kidney cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	143.7 (66.2 to 263.9)	22.7 (-17.2 to 82.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	136.7 (56.4 to 257.3)	19.1 (-21.6 to 79.4)
Bladder cancer	0.0 (0.2 to 0.3)	0.3 (0.4 to 0.5)	55.5 (35.4 to 76.4)	-25.5 (-35.1 to -14.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	49.6 (32.5 to 67.3)	-28.1 (-36.3 to -19.5)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	110.2 (51.0 to 195.2)	12.6 (-20.4 to 59.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.5 (44.1 to 192.4)	10.2 (-22.0 to 55.9)
Thyroid cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	101.0 (29.2 to 217.2)	9.9 (-28.9 to 75.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.5 (23.6 to 200.7)	7.8 (-31.9 to 68.7)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	159.4 (26.7 to 361.6)	28.8 (-34.0 to 128.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	159.8 (23.2 to 369.9)	29.9 (-36.9 to 138.0)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.3 (-0.4 to 154.3)	0.9 (-41.3 to 57.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.8 (-0.3 to 137.1)	-7.9 (-41.6 to 45.7)
Non-Hodgkin lymphoma	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	141.9 (40.3 to 259.2)	21.8 (-31.3 to 81.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	133.4 (15.0 to 255.5)	17.7 (-35.7 to 80.3)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	136.3 (30.4 to 316.0)	17.2 (-35.3 to 108.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	128.6 (23.8 to 294.1)	12.8 (-38.8 to 95.7)
Leukemia	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	121.0 (60.5 to 202.6)	6.9 (-24.1 to 46.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	116.5 (52.4 to 194.6)	4.9 (-26.4 to 42.3)
Other neoplasms	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	278.1 (156.2 to 474.1)	87.1 (27.1 to 177.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	258.2 (142.5 to 434.4)	77.4 (21.5 to 159.8)
Cardiovascular diseases	-	-	-	-	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.6)	87.2 (47.0 to 134.9)	-6.2 (-25.7 to 16.6)
Rheumatic heart disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.5 (31.1 to 161.1)	-1.0 (-29.4 to 35.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.1 (18.5 to 202.6)	-2.5 (-38.2 to 55.5)
Ischemic heart disease	1.4 (1.1 to 1.7)	2.4 (2.1 to 2.7)	73.4 (34.6 to 118.6)	-15.2 (-34.1 to 6.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	62.6 (20.0 to 116.2)	-20.8 (-42.0 to 3.7)
Cerebrovascular disease	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	85.7 (56.6 to 122.6)	-4.6 (-19.8 to 12.3)
Ischemic stroke	0.4 (0.3 to 0.4)	0.7 (0.6 to 0.8)	82.0 (53.3 to 118.7)	-7.1 (-21.6 to 9.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	82.4 (52.5 to 119.4)	6.1 (-21.5 to 10.6)
Hemorrhagic stroke	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	96.6 (23.2 to 218.5)	1.3 (-35.9 to 59.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.4 (24.6 to 218.1)	1.5 (-36.5 to 60.3)
Hypertensive heart disease	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	110.0 (18.2 to 307.8)	2.2 (-41.3 to 96.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.4 (16.7 to 308.5)	3.6 (-40.2 to 95.9)
Cardiomyopathy and myocarditis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	56.3 (2.7 to 131.1)	-19.6 (-46.6 to 16.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.1 (3.0 to 132.1)	-19.4 (-46.3 to 18.5)
Atrial fibrillation and flutter	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.5)	88.8 (13.9 to 194.4)	-5.2 (-41.1 to 44.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.7 (15.1 to 197.5)	-3.5 (-41.3 to 45.3)
Peripheral vascular disease	1.9 (1.4 to 2.5)	3.9 (2.8 to 5.1)	107.5 (41.1 to 210.6)	2.8 (-35.8 to 64.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	153.9 (-13.1 to 552.5)	20.0 (-62.7 to 213.7)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.7 (13.6 to 194.0)	-4.3 (-39.4 to 52.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.5 (3.0 to 213.0)	-4.6 (-44.0 to 58.0)
Other cardiovascular and circulatory diseases	0.9 (0.5 to 1.4)	2.0 (1.2 to 2.8)	120.4 (15.3 to 306.5)	11.5 (-40.6 to 107.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	120.7 (15.2 to 313.2)	12.4 (-40.5 to 110.0)
Chronic respiratory diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	87.2 (37.4 to 118.7)	-4.8 (-24.8 to 20.4)
Chronic obstructive pulmonary disease	3.7 (3.0 to 4.4)	7.0 (5.7 to 8.4)	88.0 (65.3 to 108.3)	0.5 (-11.9 to 10.9)	0.2 (0.0 to 0.3)	0.3 (0.2 to 0.5)	82.9 (38.9 to 137.1)	-1.5 (-24.5 to 27.0)
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.3 (37.4 to 65.5)	-21.9 (-31.1 to -14.5)

Appendix Table G.4 - Andorra prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.9 (22.2 to 37.4)	-34.0 (-36.9 to -29.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.0 (22.4 to 37.6)	30.0 (-36.7 to -29.1)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.1 (41.1 to 83.1)	-15.1 (-30.6 to -5.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.3 (42.7 to 85.0)	-14.7 (-29.9 to -5.3)
Asthma	2.3 (1.8 to 2.7)	3.8 (2.9 to 4.6)	67.4 (21.2 to 131.5)	6.5 (-34.8 to 31.9)	0.2 (0.1 to 0.1)	0.2 (0.1 to 0.2)	67.1 (19.7 to 133.6)	67.1 (-34.8 to 33.7)
Interstitial lung disease and pulmonary sarcoidosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.0 (22.6 to 180.1)	0.0 (-35.7 to 46.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.6 (21.5 to 181.2)	0.4 (-35.6 to 46.5)
Other chronic respiratory diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.7 (-50.5 to 19.3)	-58.3 (-73.2 to -35.8)
Cirrhosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.8 (39.0 to 106.7)	-6.5 (-23.6 to 13.2)
Cirrhosis due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.7 (-19.6 to 268.7)	-7.4 (-57.7 to 113.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.3 (-20.6 to 289.8)	68.3 (-57.8 to 121.0)
Cirrhosis due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.3 (35.9 to 359.6)	8.3 (-27.1 to 142.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.8 (27.2 to 354.1)	7.3 (-32.0 to 146.1)
Cirrhosis due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.5 (-27.9 to 128.1)	-30.5 (-61.8 to 23.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.4 (-30.0 to 140.3)	-29.6 (-62.8 to 30.5)
Cirrhosis due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	110.9 (10.1 to 278.9)	22.1 (-31.5 to 110.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.6 (2.4 to 298.6)	18.5 (-37.0 to 115.7)
Digestive diseases	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	94.0 (61.0 to 130.6)	7.5 (-11.3 to 30.8)
Peptic ulcer disease	0.4 (0.4 to 0.4)	0.4 (0.3 to 0.5)	2.4 (-8.0 to 14.5)	-54.1 (-59.6 to -48.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.1 (-6.6 to 22.8)	-51.9 (-57.0 to -42.6)
Gastritis and duodenitis	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.3)	70.3 (56.3 to 85.5)	-12.4 (-20.6 to -4.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.5 (64.7 to 105.9)	-3.2 (-17.2 to 12.7)
Appendicitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.9 (9.8 to 69.7)	-14.7 (-43.2 to 22.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.2 (-16.5 to 85.3)	-14.7 (-46.6 to 34.9)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	124.8 (68.6 to 242.1)	19.7 (-19.1 to 84.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	121.2 (48.7 to 255.7)	19.7 (-23.4 to 94.8)
Inguinal, femoral, and abdominal hernia	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	83.9 (22.5 to 194.2)	7.9 (-37.7 to 44.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.9 (22.3 to 197.6)	-7.2 (-38.0 to 46.8)
Inflammatory bowel disease	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.5)	109.6 (58.4 to 170.9)	18.1 (-10.6 to 54.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	110.4 (57.5 to 171.6)	18.8 (-10.3 to 55.3)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	125.4 (48.7 to 269.5)	13.7 (-23.2 to 75.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.4 (27.2 to 312.4)	14.9 (-28.5 to 97.1)
Gallbladder and biliary diseases	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	85.6 (25.7 to 149.7)	-1.9 (-33.9 to 33.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.8 (25.9 to 152.1)	-1.7 (-34.0 to 37.1)
Pancreatitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	122.2 (100.8 to 142.7)	22.2 (12.4 to 35.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	119.8 (85.3 to 160.1)	23.6 (3.4 to 46.3)
Other digestive diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	144.5 (54.7 to 280.3)	36.3 (-13.6 to 112.8)
Neurological disorders	-	-	-	-	0.5 (0.4 to 0.7)	1.0 (0.7 to 1.4)	89.6 (57.7 to 118.2)	7.8 (-7.8 to 25.4)
Alzheimer disease and other dementias	0.9 (0.7 to 1.0)	1.8 (1.3 to 2.2)	111.0 (38.4 to 188.4)	-4.3 (-34.0 to 28.4)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	115.9 (40.6 to 192.8)	-2.9 (-34.4 to 30.2)
Parkinson disease	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	104.6 (89.6 to 129.6)	0.0 (-6.1 to 12.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.8 (83.6 to 137.7)	1.9 (-8.9 to 17.3)
Epilepsy	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	40.5 (-25.8 to 140.8)	-13.5 (-53.9 to 48.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	46.3 (-22.4 to 156.9)	-9.3 (-51.6 to 59.3)
Multiple sclerosis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	179.0 (81.6 to 310.3)	58.6 (2.5 to 137.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	181.4 (74.5 to 316.5)	61.0 (-0.3 to 140.6)
Migraine	7.2 (5.7 to 8.8)	11.8 (9.3 to 14.2)	64.2 (28.7 to 115.1)	3.5 (-19.9 to 33.9)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.6)	63.6 (28.2 to 114.7)	3.7 (-19.9 to 34.7)
Tension-type headache	10.6 (8.1 to 13.3)	21.4 (17.9 to 25.0)	98.3 (51.5 to 182.1)	22.8 (-9.6 to 76.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	96.4 (48.7 to 183.6)	23.0 (-9.3 to 77.3)
Medication overuse headache	0.4 (0.2 to 0.5)	1.0 (0.6 to 1.3)	162.1 (93.1 to 266.7)	54.9 (15.6 to 120.3)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	161.2 (94.2 to 268.8)	55.3 (16.7 to 122.3)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.4 (4.0 to 142.5)	-3.5 (-38.2 to 42.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	82.0 (11.0 to 165.2)	-14.9 (-48.6 to 23.4)
Mental and substance use disorders	-	-	-	-	1.3 (0.9 to 1.7)	2.0 (1.4 to 2.7)	54.2 (48.1 to 59.3)	-2.0 (-5.8 to 1.0)
Schizophrenia	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	66.2 (56.4 to 79.6)	-0.9 (-6.9 to 6.0)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	66.3 (54.0 to 81.7)	-0.6 (-8.0 to 8.2)
Alcohol use disorders	0.6 (0.6 to 0.7)	1.0 (0.9 to 1.1)	59.4 (50.1 to 70.4)	4.8 (-0.6 to 12.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	59.5 (48.5 to 71.1)	5.1 (-1.6 to 12.7)
Drug use disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	43.0 (26.3 to 64.2)	-6.0 (-16.6 to 8.6)
Opioid use disorders	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	41.9 (25.1 to 62.5)	-10.5 (-21.0 to 1.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	41.7 (23.9 to 64.2)	-10.5 (-22.1 to 3.8)
Cocaine use disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	37.1 (-1.3 to 101.7)	-8.9 (-35.9 to 38.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.0 (-4.0 to 105.0)	-8.8 (-36.9 to 40.5)
Amphetamine use disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	52.7 (26.7 to 88.9)	6.2 (-12.3 to 33.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.6 (22.1 to 91.8)	6.7 (-14.9 to 35.5)
Cannabis use disorders	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	35.7 (33.1 to 38.7)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.7 (21.1 to 52.2)	0.2 (-10.9 to 12.9)
Other drug use disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.4 (3.3 to 108.5)	-0.1 (-29.6 to 42.6)
Depressive disorders	-	-	-	-	0.5 (0.3 to 0.7)	0.7 (0.4 to 1.1)	54.1 (38.9 to 65.3)	-4.6 (-13.9 to 2.0)
Major depressive disorder	1.9 (1.1 to 2.7)	2.9 (1.5 to 4.2)	52.2 (32.8 to 65.1)	-5.7 (-17.8 to 2.3)	0.6 (0.2 to 0.6)	0.6 (0.3 to 1.0)	51.6 (31.8 to 65.2)	-5.3 (-17.7 to 2.6)
Dysthymia	0.8 (0.7 to 1.0)	1.4 (1.2 to 1.6)	66.0 (62.1 to 69.9)	-0.3 (-0.5 to -0.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	65.1 (60.2 to 71.2)	-0.1 (-2.6 to 2.5)
Bipolar disorder	0.4 (0.3 to 0.4)	0.6 (0.5 to 0.7)	58.2 (48.4 to 66.9)	-0.8 (-6.8 to 5.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	57.7 (46.2 to 68.6)	-0.5 (-7.6 to 6.8)
Anxiety disorders	2.6 (1.5 to 3.7)	4.1 (2.5 to 5.8)	58.4 (47.1 to 72.0)	-0.3 (-0.7 to -0.2)	0.2 (0.1 to 0.4)	0.2 (0.2 to 0.6)	58.0 (46.2 to 71.4)	-0.1 (-2.2 to 2.0)
Eating disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-5.3 to 9.4)
Anorexia nervosa	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	46.0 (18.6 to 79.0)	6.7 (-12.1 to 30.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.6 (17.7 to 83.3)	7.3 (-12.4 to 31.8)
Bulimia nervosa	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	31.6 (27.6 to 39.2)	-0.1 (-0.1 to -0.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	31.8 (23.5 to 42.5)	0.1 (-5.3 to 5.5)
Autistic spectrum disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	56.2 (51.1 to 61.2)	0.7 (-2.9 to 4.1)
Autism	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.2)	56.5 (55.4 to 57.7)	0.4 (0.4 to 0.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	56.0 (48.5 to 63.5)	0.7 (-4.3 to 5.8)
Asperger syndrome	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.3)	56.8 (55.6 to 57.8)	0.6 (0.5 to 0.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.5 (50.7 to 62.6)	0.9 (-2.9 to 4.8)
Attention-deficit/hyperactivity disorder	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.4)	29.2 (29.1 to 29.2)	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.2 (20.6 to 38.8)	0.1 (-6.7 to 7.7)
Conduct disorder	0.4 (0.3 to 0.4)	0.5 (0.4 to 0.6)	28.4 (27.7 to 29.1)	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	28.6 (23.5 to 34.3)	0.3 (-3.8 to 4.4)
Idiopathic intellectual disability	0.3 (0.1 to 0.4)	0.4 (0.2 to 0.6)	31.0 (-25.7 to 125.1)	-16.0 (-51.3 to 44.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.7 (-26.3 to 126.9)	-15.9 (-52.2 to 46.1)
Other mental and substance use disorders	1.0 (0.9 to 1.0)	1.6 (1.5 to 1.7)	67.1 (65.0 to 69.1)	0.4 (0.3 to 0.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	66.3 (60.5 to 72.2)	0.7 (-2.9 to 4.3)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	0.5 (0.3 to 0.6)	0.9 (0.7 to 1.2)	89.9 (75.5 to 114.7)	7.1 (-0.2 to 19.2)
Diabetes mellitus	1.4 (1.0 to 1.7)	3.2 (2.5 to 4.3)	134.3 (68.5 to 256.4)	27.0 (-7.3 to 90.0)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	134.2 (72.6 to 248.6)	27.0 (-6.8 to 85.6)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.2 (15.1 to 34.1)	-16.3 (-23.6 to -9.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.2 (15.0 to 34.1)	-16.3 (-23.7 to -9.4)
Chronic kidney disease	-	-	-	-	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	78.0 (67.7 to 86.2)	-0.6 (-4.6 to 3.3)
Chronic kidney disease due to diabetes mellitus	0.6 (0.3 to 0.8)	1.4 (0.9 to 2.1)	144.8 (69.7 to 370.8)	27.6 (-13.8 to 137.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	115.6 (50.4 to 337.7)	15.9 (-22.4 to 131.7)
Chronic kidney disease due to hypertension	0.6 (0.4 to 0.7)	0.9 (0.6 to 1.4)	65.3 (17.5 to 131.9)	-10.9 (-39.1 to 21.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	36.9 (-56.1 to -10.4)	-64.7 (-75.0 to -51.3)
Chronic kidney disease due to glomerulonephritis	0.9 (0.5 to 1.2)	0.9 (0.6 to 1.2)	0.2 (-33.7 to 50.3)	-39.6 (-58.2 to -16.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	225.2 (139.0 to 343.5)	84.3 (34.0 to 147.6)
Chronic kidney disease due to other causes	1.9 (1.3 to 2.8)	3.9 (2.7 to 5.3)	100.5 (54.6 to 161.5)	0.1 (-16.0 to 38.4)	0.2 (0.1 to 0.1)	0.2 (0.1 to 0.2)	102.6 (51.9 to 158.2)	12.7 (-15.6 to 42.0)
Urinary diseases and male infertility	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	116.7 (84.9 to 184.3)	13.2 (-3.1 to 45.4)
Interstitial nephritis and urinary tract infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.7 (23.6 to 144.4)	-6.9 (-32.9 to 30.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.2 (10.0 to 155.6)	-6.9 (-39.9 to 39.3)

Appendix Table G.4 - Andorra prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Urolithiasis	0.6 (0.4 to 0.9)	2.0 (1.4 to 3.1)	219.0 (169.0 to 295.9)	0.0 (40.2 to 109.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	235.4 (179.1 to 304.0)	76.8 (47.4 to 113.1)
Benign prostatic hyperplasia	1.2 (1.0 to 1.4)	2.4 (2.0 to 2.8)	103.3 (66.4 to 177.5)	3.6 (-14.4 to 38.4)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	103.4 (66.6 to 176.2)	4.2 (-13.9 to 39.1)
Male infertility due to other causes	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	50.9 (-4.3 to 133.0)	2.0 (-35.6 to 56.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.7 (-6.1 to 142.2)	1.4 (-36.5 to 63.0)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	254.1 (97.9 to 657.6)	87.4 (2.7 to 300.7)
Gynecological diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	58.7 (37.2 to 84.6)	-2.5 (-15.6 to 14.0)
Uterine fibroids	1.9 (1.6 to 2.2)	3.4 (2.9 to 4.0)	77.1 (75.5 to 78.8)	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	75.2 (61.9 to 148.1)	0.6 (-7.2 to 41.3)
Polycystic ovarian syndrome	0.8 (0.7 to 1.0)	1.4 (1.1 to 1.6)	65.5 (26.8 to 103.2)	4.7 (-20.0 to 29.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.4 (26.5 to 101.0)	4.7 (-19.9 to 28.5)
Female infertility due to other causes	0.1 (0.0 to 0.2)	0.2 (0.0 to 0.2)	32.8 (-78.2 to 651.4)	-9.7 (-86.2 to 409.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.6 (-79.9 to 728.5)	-8.1 (-86.4 to 464.8)
Endometriosis	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	43.9 (-2.6 to 104.2)	-9.6 (-37.6 to 28.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.8 (-2.9 to 105.0)	-9.6 (-38.0 to 29.1)
Genital prolapse	3.2 (2.9 to 3.5)	5.3 (4.8 to 5.8)	65.2 (45.8 to 88.7)	-2.7 (-14.6 to 11.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.2 (45.9 to 89.2)	-2.5 (-14.7 to 11.5)
Premenstrual syndrome	1.3 (0.8 to 1.8)	1.9 (1.3 to 2.6)	46.9 (-14.8 to 161.6)	-1.8 (-42.9 to 67.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.1 (-16.8 to 157.1)	-1.8 (-43.5 to 70.8)
Other gynecological diseases	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	47.9 (-15.0 to 117.3)	-5.9 (-46.1 to 35.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.9 (-47.6 to 282.1)	1.4 (-68.0 to 124.6)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	70.3 (44.7 to 92.7)	12.3 (5.4 to 26.5)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.7 (15.7 to 54.8)	0.2 (-13.6 to 15.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.9 (-1.7 to 77.9)	0.0 (-27.1 to 33.5)
Thalassemia trait	1.1 (0.7 to 2.5)	1.8 (1.1 to 4.1)	61.6 (48.5 to 74.4)	1.9 (-6.7 to 8.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	54.4 (34.6 to 71.8)	-0.2 (-11.7 to 7.3)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	126.5 (58.6 to 193.7)	56.2 (11.7 to 100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.2 (44.6 to 197.4)	42.6 (0.7 to 99.6)
Sickle cell trait	0.8 (0.5 to 1.1)	1.6 (1.1 to 2.2)	103.0 (59.3 to 182.9)	30.1 (3.5 to 80.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	135.9 (94.9 to 259.4)	65.1 (34.6 to 146.5)
G6PD deficiency	0.9 (0.6 to 1.3)	1.6 (1.0 to 2.2)	73.8 (-6.3 to 196.1)	1.6 (-41.4 to 86.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.9 (6.5 to 175.3)	10.1 (-32.6 to 62.9)
G6PD trait	7.4 (6.7 to 8.1)	11.4 (10.2 to 12.4)	54.3 (34.5 to 77.1)	-3.4 (-15.8 to 10.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.9 (-43.2 to 127.2)	-9.2 (-65.0 to 69.6)
Other hemoglobinopathies and hemolytic anemias	0.3 (0.3 to 0.3)	0.5 (0.4 to 0.6)	70.2 (48.1 to 120.3)	3.3 (-12.3 to 43.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.4 (31.6 to 196.0)	5.6 (-16.9 to 105.2)
Endocrine, metabolic, blood, and immune disorders	0.7 (0.6 to 0.7)	1.1 (1.0 to 1.3)	68.2 (48.8 to 93.1)	1.2 (-9.8 to 20.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	70.3 (45.2 to 107.5)	2.7 (-10.8 to 35.0)
Musculoskeletal disorders	-	-	-	-	1.5 (1.0 to 2.0)	2.7 (1.8 to 3.6)	89.9 (60.2 to 104.6)	4.9 (8.8 to 18.0)
Rheumatoid arthritis	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.3)	155.4 (106.4 to 210.3)	36.4 (11.1 to 65.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	157.6 (103.3 to 214.0)	38.2 (9.9 to 67.1)
Osteoarthritis	3.0 (2.5 to 3.4)	5.6 (4.7 to 6.3)	90.8 (48.0 to 137.9)	-3.7 (-26.0 to 21.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	91.2 (46.3 to 139.2)	-3.4 (-26.3 to 21.8)
Low back and neck pain	-	-	-	-	1.2 (0.8 to 1.6)	2.1 (1.4 to 2.9)	76.3 (51.8 to 106.3)	3.0 (-12.3 to 20.4)
Low back pain	7.1 (6.1 to 8.0)	12.9 (11.4 to 14.5)	83.2 (51.7 to 119.3)	5.9 (-13.7 to 28.0)	0.8 (0.5 to 1.1)	1.4 (0.9 to 2.0)	82.6 (50.5 to 119.9)	6.1 (-13.7 to 28.6)
Neck pain	4.1 (3.3 to 4.8)	6.8 (5.5 to 8.0)	65.6 (41.1 to 105.9)	-2.9 (-17.5 to 18.5)	0.4 (0.3 to 0.6)	0.7 (0.4 to 0.9)	65.3 (41.3 to 104.7)	-2.6 (-17.3 to 18.4)
Gout	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	85.2 (62.5 to 121.2)	-3.1 (-15.4 to 16.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.8 (52.0 to 129.7)	-2.6 (-19.8 to 21.8)
Other musculoskeletal disorders	1.9 (1.6 to 2.3)	3.8 (3.0 to 4.5)	96.2 (84.1 to 106.2)	10.9 (4.3 to 16.4)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	96.1 (83.3 to 107.6)	11.2 (4.6 to 17.2)
Other non-communicable diseases	-	-	-	-	0.8 (0.7 to 1.5)	1.7 (1.2 to 2.5)	61.3 (60.2 to 76.7)	-3.9 (-8.7 to 0.9)
Congenital anomalies	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	69.7 (44.7 to 102.0)	4.6 (-10.8 to 25.6)
Neural tube defects	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.2 (-6.4 to 63.8)	-19.7 (-39.0 to 6.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.6 (-15.2 to 88.8)	-17.5 (-44.9 to 23.2)
Congenital heart anomalies	0.4 (0.4 to 0.5)	0.6 (0.5 to 0.8)	37.1 (6.1 to 79.1)	-12.5 (-32.1 to 14.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.6 (10.1 to 76.4)	-10.6 (-28.7 to 13.6)
Crofacial clefts	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	36.5 (0.4 to 90.0)	-13.3 (-36.3 to 20.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.9 (-5.3 to 107.1)	-14.0 (-40.2 to 32.6)
Down syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	62.9 (11.8 to 154.7)	-1.7 (-32.7 to 53.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.3 (17.1 to 164.8)	-1.3 (-31.9 to 53.5)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.3 (12.5 to 146.1)	4.4 (-27.1 to 59.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.3 (9.9 to 147.5)	5.0 (-28.1 to 60.1)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.4 (23.4 to 183.0)	21.6 (-21.6 to 80.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.3 (8.5 to 201.3)	21.4 (-29.5 to 94.9)
Chromosomal unbalanced rearrangements	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	71.0 (12.1 to 126.9)	3.2 (-32.4 to 37.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	78.6 (17.0 to 138.4)	3.9 (-32.5 to 37.8)
Other congenital anomalies	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	37.5 (-1.0 to 70.1)	-5.2 (-38.9 to 4.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	37.5 (42.2 to 169.9)	19.6 (-9.5 to 74.7)
Skin and subcutaneous diseases	-	-	-	-	0.4 (0.2 to 0.6)	0.6 (0.4 to 0.8)	51.4 (37.2 to 62.8)	-2.4 (-12.4 to 6.7)
Dermatitis	3.6 (2.7 to 4.5)	5.6 (4.2 to 6.9)	55.9 (51.8 to 59.2)	-0.1 (-0.1 to -0.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	53.0 (47.1 to 57.9)	-0.0 (-2.4 to 2.4)
Psoriasis	0.7 (0.6 to 0.9)	1.2 (1.1 to 1.4)	66.4 (63.4 to 69.9)	0.1 (-0.1 to 0.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	66.1 (59.2 to 72.9)	4.3 (-3.8 to 4.3)
Cellulitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	71.2 (50.7 to 104.5)	1.1 (-15.7 to 14.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.6 (40.1 to 116.3)	2.0 (-20.3 to 27.1)
Pyoderma	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	100.1 (77.5 to 123.1)	16.2 (5.5 to 26.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.1 (71.3 to 128.6)	16.0 (1.7 to 32.2)
Scabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.4 (-10.3 to 64.8)	-22.4 (-40.4 to 5.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.6 (-12.7 to 69.5)	-22.3 (-41.9 to 9.2)
Fungal skin diseases	3.7 (3.3 to 4.1)	6.3 (5.5 to 6.9)	68.6 (65.9 to 71.5)	0.4 (0.2 to 0.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	68.3 (65.1 to 71.5)	0.5 (-0.4 to 1.5)
Viral skin diseases	1.0 (0.8 to 1.3)	1.5 (1.2 to 1.8)	48.1 (42.4 to 54.8)	0.5 (-1.9 to 3.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	47.7 (40.7 to 55.1)	0.6 (-2.7 to 4.1)
Acne vulgaris	7.8 (5.9 to 9.7)	9.2 (7.0 to 11.4)	18.7 (-19.3 to 70.4)	-11.3 (-40.3 to 27.2)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	18.5 (-19.5 to 70.2)	-11.3 (-40.5 to 27.7)
Alopecia areata	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	70.1 (53.5 to 91.7)	-1.5 (-10.9 to 9.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.3 (49.6 to 93.5)	-1.5 (-13.3 to 12.2)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.4 (-11.0 to 166.8)	-13.6 (-50.4 to 47.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.9 (-14.7 to 181.0)	-12.7 (-50.7 to 51.1)
Urticaria	0.4 (0.2 to 0.6)	0.7 (0.4 to 0.9)	62.6 (-5.1 to 237.1)	6.7 (-38.0 to 102.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	62.7 (-4.8 to 236.9)	1.1 (-37.5 to 103.6)
Decubitus ulcer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	90.6 (37.9 to 155.3)	-7.7 (-31.4 to 21.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.8 (36.6 to 157.4)	-7.4 (-31.4 to 24.0)
Other skin and subcutaneous diseases	4.3 (2.4 to 7.4)	7.6 (4.2 to 13.6)	77.9 (65.4 to 88.8)	0.0 (-3.3 to 3.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	77.6 (65.4 to 88.8)	0.2 (-3.4 to 3.8)
Sense organ diseases	-	-	-	-	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.0)	83.7 (70.9 to 100.0)	-6.5 (-12.8 to 0.7)
Glaucoma	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	53.9 (13.8 to 105.3)	-23.5 (-40.1 to -0.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.5 (6.1 to 105.6)	-2.7 (-43.9 to -0.8)
Cataract	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.4)	52.2 (2.3 to 115.7)	-30.1 (-51.9 to -4.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.1 (2.5 to 90.6)	-32.9 (-55.3 to -14.2)
Macular degeneration	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	85.2 (52.3 to 152.2)	-10.1 (-25.5 to 18.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.3 (53.8 to 150.9)	-11.6 (-25.9 to 16.4)
Uncorrected refractive error	5.9 (4.9 to 6.9)	10.8 (8.6 to 12.9)	83.3 (40.0 to 137.7)	-1.5 (-26.2 to 30.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	72.8 (39.5 to 113.3)	-6.5 (-24.9 to 15.7)
Age-related and other hearing loss	8.3 (7.1 to 9.3)	14.9 (12.9 to 16.9)	80.1 (72.3 to 86.9)	-8.4 (-13.1 to -4.5)	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.7)	94.0 (78.3 to 122.3)	-4.7 (-11.8 to 6.1)
Other vision loss	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	37.6 (-2.3 to 46.6)	-0.0 (-48.1 to 25.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.1 (10.4 to 55.0)	-29.9 (-42.8 to -18.3)
Other sense organ diseases	1.2 (1.1 to 1.3)	2.0 (1.9 to 2.1)	65.9 (54.8 to 75.7)	-0.5 (-6.7 to 5.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	65.1 (53.3 to 76.1)	-0.2 (-6.9 to 6.4)
Oral disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	67.1 (55.3 to 81.3)	-8.2 (-14.4 to -0.4)
Deciduous caries	1.8 (1.6 to 1.9)	2.4 (2.2 to 2.6)	37.0 (24.0 to 51.6)	-0.6 (-10.0 to 9.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.7 (26.6 to 56.0)	-0.2 (-12.7 to 12.9)
Permanent caries	19.4 (17.3 to 21.7)	31.3 (28.2 to 34.8)	59.4 (44.0 to 91.7)	1.5 (-8.0 to 21.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.9 (43.0 to 91.1)	1.6 (-8.3 to 21.5)
Periodontal diseases	5.0 (4.3 to 5.6)	9.4 (8.3 to 10.6)	87.2 (55.7 to 124.9)	3.1 (-13.8 to 25.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	86.6 (55.2 to 125.1)	3.2 (-13.9 to 25.3)
Edentulism and severe tooth loss	3.8 (3.4 to 4.2)	6.3 (5.6 to 6.9)	64.2 (45.7 to 81.5)	-16.3 (-25.5 to -7.4)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	64.1 (45.4 to 81.9)	-15.8 (-25.4 to -6.8)

Appendix Table G.4 - Andorra prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	1.0 (0.9 to 1.0)	1.6 (1.5 to 1.6)	63.0 (52.0 to 75.3)	-0.2 (-6.9 to 7.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	62.7 (51.4 to 75.4)	-0.1 (-7.1 to 8.0)
Injuries	-	-	-	-	0.6 (0.4 to 0.8)	0.7 (0.5 to 1.0)	22.6 (9.3 to 37.7)	-35.1 (-41.6 to -27.6)
Transport injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-12.4 (-22.0 to -1.6)	-51.9 (-57.2 to -45.8)
Road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-23.1 (-31.3 to -13.2)	-57.6 (-62.2 to -52.0)
Pedestrian road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.8 (-29.2 to -9.2)	-57.7 (-62.1 to -51.1)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.2 (-15.2 to 13.7)	-45.0 (-52.8 to -36.7)
Motorcyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.2 (-37.1 to -8.5)	-58.0 (-64.7 to -48.5)
Motor vehicle road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-26.0 (-33.8 to -17.5)	-59.2 (-63.6 to -54.3)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.8 (-61.2 to -47.2)	-75.2 (-78.8 to -70.8)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	100.1 (77.4 to 122.2)	9.7 (-2.7 to 21.6)
Unintentional injuries	-	-	-	-	0.5 (0.4 to 0.6)	0.6 (0.5 to 0.9)	29.1 (14.9 to 45.3)	-31.8 (-38.8 to -23.8)
Falls	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	36.9 (19.7 to 57.6)	-28.4 (-37.0 to -18.3)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.2 (2.2 to 28.4)	-36.3 (-43.7 to -28.9)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.0 (6.4 to 44.7)	-32.6 (-41.4 to -20.1)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.6 (-30.4 to 2.3)	-51.7 (-60.8 to -41.8)
Exposure to mechanical forces	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-10.9 (-19.6 to 0.4)	-47.4 (-52.7 to -40.7)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.6 (-21.1 to -1.6)	-47.4 (-54.4 to -40.0)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.7 (47.3 to 94.2)	-1.1 (-15.3 to 12.8)
Other exposure to mechanical forces	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-11.3 (-20.0 to 0.0)	-47.6 (-53.0 to -40.9)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.0 (62.9 to 98.0)	-0.2 (-9.0 to 9.3)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.3 (57.4 to 92.3)	-3.4 (-12.2 to 7.3)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.6 (37.8 to 92.2)	-3.7 (-19.1 to 13.6)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.1 (57.7 to 94.9)	-3.4 (-12.7 to 8.5)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.1 (20.5 to 52.8)	-17.3 (-28.9 to -6.7)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.8 (9.1 to 44.6)	-29.4 (-39.6 to -16.6)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.1 (23.9 to 52.9)	-13.8 (-23.9 to -3.4)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.6 (19.2 to 60.4)	-15.3 (-29.6 to -1.8)
Other unintentional injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	9.2 (-2.4 to 22.5)	-41.2 (-47.8 to -34.3)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.7 (0.6 to 21.8)	-38.5 (-44.1 to -32.5)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.3 (18.9 to 53.1)	-24.9 (-35.0 to -15.6)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.3 (-16.1 to 3.0)	-47.9 (-52.9 to -41.9)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.5 (-11.1 to 9.2)	-45.6 (-50.9 to -39.7)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.1 (16.4 to 38.3)	-29.8 (-35.2 to -22.9)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.7 (-22.2 to -1.8)	-50.7 (-55.9 to -44.3)
Forces of nature, war, and legal intervention	-	-	-	-	-	-	-	-
Exposure to forces of nature	-	-	-	-	-	-	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Angola prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,113.3 (806.3 to 1,465.2)	2,006.2 (1,474.5 to 2,642.1)	80.8 (69.8 to 89.2)	-10.8 (-16.6 to -5.6)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	-	-	-	-
HIV/AIDS and tuberculosis	-	-	-	-	14.3 (9.8 to 19.2)	60.7 (40.3 to 85.4)	322.5 (248.1 to 428.2)	103.8 (65.6 to 159.5)
Tuberculosis	34.5 (32.3 to 36.8)	64.0 (59.8 to 68.8)	85.4 (75.6 to 94.6)	-8.5 (-12.6 to -4.3)	10.4 (7.1 to 14.1)	19.5 (13.2 to 26.6)	87.2 (75.3 to 100.1)	-7.6 (-12.8 to -2.2)
HIV/AIDS	-	-	-	-	3.3 (2.2 to 5.8)	41.1 (25.5 to 61.5)	382.0 (441.9 to 3,600.4)	431.7 (269.0 to 751.0)
HIV/AIDS resulting in mycobacterial infection	1.1 (0.6 to 1.7)	7.2 (4.3 to 10.6)	594.4 (375.8 to 909.7)	247.4 (140.3 to 405.4)	0.4 (0.2 to 0.7)	2.7 (1.4 to 4.3)	601.2 (368.2 to 987.0)	251.6 (135.4 to 437.3)
HIV/AIDS resulting in other diseases	35.4 (22.9 to 50.2)	296.0 (245.0 to 357.5)	735.2 (494.8 to 1,174.6)	316.5 (197.5 to 542.8)	3.5 (1.8 to 5.4)	38.5 (23.2 to 58.5)	1,006.8 (650.7 to 1,763.4)	452.4 (272.9 to 835.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	63.0 (44.9 to 84.4)	93.4 (66.4 to 125.6)	48.4 (37.3 to 59.2)	-24.0 (-30.1 to -18.2)
Diarrheal diseases	242.2 (230.6 to 253.3)	379.7 (361.8 to 397.2)	56.4 (46.8 to 66.5)	-17.4 (-22.4 to -12.6)	39.4 (26.8 to 54.5)	62.0 (42.1 to 86.3)	57.4 (46.6 to 68.8)	-17.0 (-22.5 to -11.8)
Intestinal infectious diseases	-	-	-	-	0.8 (0.5 to 1.2)	0.8 (0.5 to 1.2)	1.7 (24.8 to 35.2)	-49.8 (-62.0 to -33.3)
Typhoid fever	3.4 (2.9 to 4.0)	4.0 (3.4 to 4.7)	17.8 (-3.6 to 41.6)	-42.2 (-53.6 to -28.2)	0.4 (0.3 to 0.7)	0.5 (0.3 to 0.8)	19.9 (9.8 to 58.8)	-40.8 (-55.4 to -23.1)
Paratyphoid fever	1.7 (1.4 to 2.0)	2.5 (2.0 to 3.1)	46.4 (12.2 to 90.4)	-27.4 (-44.6 to -6.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	48.4 (7.7 to 100.0)	26.5 (-45.8 to -2.3)
Other intestinal infectious diseases	-	-	-	-	-	0.2 (0.1 to 0.5)	-54.2 (-72.7 to -36.1)	-77.3 (-86.4 to -59.2)
Lower respiratory infections	18.9 (12.9 to 24.6)	20.9 (16.0 to 26.0)	9.5 (-24.4 to 74.4)	-5.4 (-59.3 to -29.2)	2.0 (1.1 to 3.1)	2.2 (1.3 to 3.3)	9.7 (-24.4 to 78.4)	-44.9 (-59.1 to -25.9)
Upper respiratory infections	267.8 (241.8 to 290.6)	537.6 (480.5 to 594.0)	100.2 (76.1 to 132.5)	-2.9 (-15.3 to 13.1)	3.1 (1.8 to 5.2)	6.3 (3.5 to 10.7)	100.6 (75.5 to 133.2)	-2.3 (-15.0 to 13.7)
Otitis media	169.1 (155.4 to 186.0)	322.5 (293.6 to 355.9)	90.4 (73.9 to 108.3)	-8.5 (-16.2 to -1.0)	3.0 (1.7 to 4.8)	5.6 (3.2 to 9.3)	89.5 (72.2 to 109.2)	-8.5 (-16.7 to 0.0)
Meningitis	-	-	-	-	11.9 (8.2 to 16.4)	14.7 (9.9 to 20.5)	23.8 (-11.6 to 60.2)	-38.1 (-54.7 to -22.4)
Pneumococcal meningitis	56.1 (34.6 to 85.7)	69.5 (44.2 to 105.1)	23.6 (-0.3 to 53.5)	-38.5 (-49.6 to -25.4)	4.9 (3.4 to 6.8)	6.7 (4.4 to 9.9)	31.2 (-3.0 to 101.7)	35.6 (-52.2 to -6.2)
H influenzae type B meningitis	29.4 (12.2 to 57.0)	30.9 (12.0 to 61.5)	6.9 (-37.7 to 36.6)	-48.2 (-69.2 to -34.8)	3.4 (2.0 to 5.8)	3.7 (2.3 to 5.5)	15.9 (-47.2 to 77.9)	-44.3 (-74.0 to -14.7)
Meningococcal meningitis	4.8 (1.7 to 10.7)	6.2 (2.3 to 14.0)	28.4 (-10.4 to 76.5)	-37.1 (-55.3 to -13.4)	0.6 (0.4 to 1.0)	0.8 (0.5 to 1.3)	35.8 (-12.3 to 93.3)	-34.7 (-53.6 to -9.5)
Other meningitis	23.8 (14.4 to 39.8)	26.5 (15.4 to 44.4)	10.5 (-12.2 to 36.4)	-44.0 (-55.4 to -30.0)	2.9 (2.0 to 4.2)	3.5 (2.3 to 5.1)	20.5 (-12.8 to 72.7)	-39.1 (-55.4 to -12.0)
Encephalitis	1.8 (0.8 to 3.8)	3.0 (1.3 to 6.9)	67.4 (34.0 to 92.9)	-18.3 (-35.1 to -7.9)	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	13.2 (37.8 to 114.8)	-16.7 (-30.7 to 0.0)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Whooping cough	34.3 (26.2 to 44.9)	18.7 (14.6 to 23.8)	-45.5 (-49.6 to -41.1)	-70.8 (-73.0 to -68.5)	1.7 (1.0 to 2.8)	0.9 (0.5 to 1.5)	-45.3 (-51.1 to -38.7)	-70.7 (-73.8 to -67.1)
Tetanus	0.8 (0.4 to 1.6)	0.7 (0.1 to 0.4)	-75.2 (-92.7 to -45.5)	-87.4 (-96.7 to -68.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-77.0 (-89.5 to -51.9)	-88.4 (-94.7 to -76.8)
Measles	8.9 (6.2 to 12.2)	0.7 (0.5 to 0.9)	-92.5 (-94.6 to -89.8)	-96.1 (-97.2 to -94.7)	0.8 (0.4 to 1.3)	0.1 (0.0 to 0.1)	29.5 (-95.7 to -87.6)	35.5 (-97.7 to -93.6)
Varicella and herpes zoster	6.6 (6.1 to 7.1)	14.3 (13.2 to 15.4)	117.7 (94.4 to 142.3)	6.6 (-12.0 to 26.6)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	115.5 (55.4 to 186.5)	8.6 (-21.5 to 45.5)
Neglected tropical diseases and malaria	-	-	-	-	150.2 (88.4 to 253.9)	252.7 (147.6 to 439.0)	69.3 (39.5 to 99.9)	-20.0 (-35.3 to -7.3)
Malaria	4,111.6 (3,789.7 to 4,455.6)	6,890.5 (6,313.2 to 7,509.4)	67.3 (54.5 to 80.0)	-23.1 (-29.5 to -16.6)	36.0 (24.3 to 52.5)	57.2 (38.9 to 83.0)	60.4 (47.5 to 74.3)	29.2 (-34.8 to -22.0)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	88.6 (40.9 to 156.6)	-12.5 (-35.7 to 18.5)
Visceral leishmaniasis	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.7)	115.9 (32.1 to 230.2)	5.3 (-29.8 to 54.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	115.9 (32.1 to 230.6)	5.3 (-30.0 to 55.6)
Cutaneous and mucocutaneous leishmaniasis	1.6 (1.0 to 2.5)	2.6 (1.6 to 4.0)	63.0 (14.8 to 135.9)	-22.4 (-45.0 to 11.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	66.3 (8.9 to 156.4)	21.8 (-27.4 to 18.7)
African trypanosomiasis	8.3 (4.1 to 14.4)	0.2 (0.1 to 0.3)	-98.0 (-98.3 to -97.7)	-99.0 (-99.2 to -98.9)	2.3 (1.0 to 4.0)	0.1 (0.0 to 0.1)	-97.9 (-98.2 to -98.8)	-99.0 (-99.3 to -98.2)
Schistosomiasis	4,946.9 (2,703.6 to 7,377.2)	10,412.2 (5,753.7 to 15,533.2)	110.2 (106.0 to 114.7)	0.2 (-1.6 to 2.0)	0.2 (22.1 to 102.1)	0.7 (43.9 to 212.8)	108.2 (82.9 to 116.3)	2.1 (-11.8 to 0.8)
Cysticercosis	4.2 (2.0 to 7.2)	4.0 (1.6 to 7.6)	-6.6 (-65.0 to 136.5)	-53.1 (-80.8 to 22.6)	1.0 (0.5 to 2.0)	1.1 (0.4 to 2.2)	1.1 (-63.4 to 169.0)	-48.6 (-80.1 to 34.3)
Cystic echinococcosis	2.9 (2.5 to 3.2)	2.9 (2.6 to 3.2)	-0.3 (-15.6 to 18.8)	-63.3 (-66.5 to -56.3)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	1.6 (-24.3 to 36.2)	-62.1 (-69.1 to -52.1)
Lymphatic filariasis	536.4 (444.3 to 639.1)	897.5 (739.4 to 1,059.1)	66.6 (33.4 to 108.1)	-15.8 (-30.8 to 1.2)	14.5 (7.1 to 23.8)	24.7 (12.5 to 41.8)	72.5 (32.3 to 106.0)	-11.7 (-36.3 to 10.6)
Onchocerciasis	107.3 (48.4 to 233.3)	122.3 (69.4 to 214.2)	20.3 (-7.2 to 45.6)	-42.0 (-55.0 to -30.5)	6.2 (2.5 to 11.8)	7.7 (3.5 to 13.1)	27.0 (6.2 to 51.4)	38.5 (-48.7 to -26.7)
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.6 (0.2 to 1.4)	5.8 (1.9 to 14.1)	905.1 (892.9 to 919.3)	382.9 (377.1 to 389.7)	0.1 (0.0 to 0.3)	0.9 (0.3 to 2.5)	853.7 (679.3 to 1,059.5)	351.3 (283.3 to 426.2)
Yellow fever	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-36.8 (-67.9 to 31.1)	-69.6 (-82.7 to -40.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.8 (-67.9 to 31.1)	-69.6 (-82.8 to -40.5)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Intestinal nematode infections	-	-	-	-	8.8 (5.4 to 13.5)	18.0 (10.9 to 27.9)	104.8 (85.6 to 128.2)	-3.3 (-13.7 to 8.7)
Ascariasis	1,638.5 (1,217.3 to 2,184.4)	3,403.3 (2,547.2 to 4,576.5)	107.9 (34.4 to 215.8)	-0.1 (-40.1 to 68.7)	1.1 (0.6 to 1.9)	2.2 (1.2 to 3.7)	106.3 (76.5 to 141.7)	0.4 (-17.7 to 19.9)
Trichuriasis	1,467.5 (1,087.3 to 2,018.2)	3,075.2 (2,238.6 to 4,280.6)	110.6 (28.9 to 230.7)	0.4 (-44.2 to 78.1)	0.6 (0.3 to 1.0)	1.2 (0.6 to 2.0)	110.9 (60.7 to 170.8)	1.3 (-26.3 to 36.1)
Hookworm disease	1,696.4 (1,316.1 to 2,201.6)	3,553.5 (2,746.0 to 4,624.4)	108.1 (48.8 to 198.6)	0.2 (-34.2 to 53.2)	0.2 (4.5 to 10.8)	0.2 (9.0 to 22.5)	183.7 (81.6 to 133.9)	4.2 (-16.2 to 10.3)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	197.3 (154.8 to 239.7)	269.8 (251.3 to 293.5)	37.0 (11.5 to 79.5)	-37.6 (-47.9 to -22.9)	31.6 (10.3 to 77.9)	39.6 (14.8 to 94.5)	31.1 (-32.5 to 154.1)	-38.4 (-70.0 to 31.3)
Maternal disorders	-	-	-	-	2.5 (1.7 to 3.4)	3.6 (2.4 to 4.9)	43.2 (21.6 to 67.4)	-32.7 (-42.2 to -21.8)
Maternal hemorrhage	2.9 (2.0 to 3.7)	6.7 (4.6 to 8.8)	127.0 (42.9 to 244.9)	1.7 (-34.9 to 54.0)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.5)	15.2 (13.7 to 275.6)	6.5 (-49.4 to 64.9)
Maternal sepsis and other maternal infections	5.6 (3.7 to 8.3)	7.2 (4.7 to 10.7)	27.6 (13.4 to 47.5)	-39.2 (-45.6 to -29.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	26.2 (-19.1 to 107.4)	-39.9 (-59.8 to -8.1)
Maternal hypertensive disorders	3.5 (1.8 to 5.6)	5.5 (2.7 to 8.9)	56.1 (34.3 to 65.4)	-27.3 (-37.4 to -22.3)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.5)	55.0 (28.9 to 82.6)	-27.7 (-40.0 to -15.5)
Obstructed labor	5.2 (4.6 to 5.8)	6.9 (6.0 to 7.8)	31.8 (20.6 to 43.1)	-37.2 (-42.2 to -32.6)	1.7 (1.1 to 2.3)	2.2 (1.5 to 3.2)	32.9 (13.9 to 55.5)	-36.7 (-45.2 to -26.9)
Complications of abortion	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	70.9 (-5.8 to 217.8)	-20.3 (-53.0 to 43.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.9 (-6.4 to 218.4)	-20.0 (-53.1 to 43.6)
Other maternal disorders	-	-	-	-	0.4 (0.3 to 0.6)	0.7 (0.4 to 1.0)	55.1 (4.0 to 167.3)	-27.2 (-54.7 to 24.9)
Neonatal disorders	-	-	-	-	8.0 (4.3 to 14.0)	30.1 (19.4 to 44.0)	290.5 (118.9 to 543.4)	105.8 (10.6 to 251.7)
Preterm birth complications	34.6 (16.3 to 67.2)	153.9 (83.1 to 271.4)	347.8 (250.9 to 502.7)	114.3 (71.6 to 180.2)	2.1 (1.2 to 3.6)	14.0 (8.3 to 21.8)	576.8 (261.3 to 1,053.5)	243.3 (95.5 to 490.4)
Neonatal encephalopathy due to birth asphyxia and trauma	60.2 (5.8 to 193.2)	88.7 (15.2 to 271.8)	57.8 (11.5 to 202.3)	-26.1 (-47.5 to 50.0)	2.2 (0.8 to 5.1)	5.9 (3.0 to 11.0)	184.0 (70.6 to 473.9)	46.9 (-19.8 to 261.2)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.2)	0.5 (0.2 to 1.1)	180.1 (362.1 to 446.9)	0.0 (-166.2 to 215.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	180.1 (337.8 to 457.3)	399.9 (152.2 to 221.1)
Hemolytic disease and other neonatal jaundice	2.3 (0.8 to 4.5)	10.6 (4.7 to 20.3)	326.0 (69.0 to 2,202.6)	152.2 (-5.3 to 1,480.5)	0.9 (0.3 to 1.7)	4.0 (1.6 to 8.0)	340.5 (74.2 to 2,434.5)	156.6 (-5.1 to 1,500.2)
Other neonatal disorders	-	-	-	-	2.9 (0.9 to 6.2)	6.1 (3.3 to 10.9)	117.9 (-10.8 to 501.0)	17.6 (-54.6 to 223.1)
Nutritional deficiencies	-	-	-	-	156.2 (104.8 to 225.8)	180.1 (119.3 to 263.5)	-	-
Protein-energy malnutrition	101.1 (37.7 to 228.2)	121.5 (42.8 to 262.6)	17.9 (-65.1 to 346.5)	33.0 (-76.3 to 99.8)	3.0 (4.2 to 31.0)	12.5 (4.7 to 33.9)	19.3 (-65.5 to 358.6)	-32.7 (-77.1 to 108.9)
Iodine deficiency	1,114.8 (729.2 to 1,630.7)	964.3 (427.2 to 1,485.4)	-13.2 (-70.1 to 66.7)	-59.6 (-85.9 to -19.1)	20.0 (10.5 to 35.4)	17.4 (6.9 to 32.4)	-12.7 (-69.6 to 65.3)	-59.5 (-85.9 to -19.5)
Vitamin A deficiency	46.4 (38.5 to 54.2)	58.7 (48.2 to 68.3)	26.2 (13.0 to 40.5)	-43.1 (-50.0 to -35.3)	2.0 (1.2 to 2.9)	2.3 (1.4 to 3.4)	14.5 (-0.2 to 30.0)	-46.8 (-53.6 to -39.2)

Appendix Table G.4 - Angola prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	3,256.9 (3,160.9 to 3,373.4)	4,318.2 (4,129.0 to 4,519.5)	32.3 (26.0 to 38.8)	-39.6 (-42.7 to -36.3)	121.2 (82.2 to 172.6)	144.8 (95.9 to 209.7)	19.0 (13.0 to 28.4)	19.0 (-50.6 to -43.2)
Other nutritional deficiencies	-	-	-	-	0.6 (0.1 to 2.7)	0.5 (0.1 to 2.3)	-13.8 (-80.4 to 271.3)	-52.9 (-86.8 to 69.3)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	9.2 (5.8 to 13.6)	14.0 (9.0 to 21.4)	51.8 (33.2 to 79.7)	-24.9 (-34.2 to -12.3)
Sexually transmitted diseases excluding HIV	-	-	-	-	2.4 (1.4 to 4.0)	4.8 (2.7 to 8.3)	101.3 (60.5 to 140.1)	-5.3 (-21.8 to 10.5)
Syphilis	1.2 (1.0 to 1.3)	1.3 (1.1 to 1.4)	7.9 (-10.2 to 30.3)	-44.7 (-53.3 to -45.7)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.4)	44.3 (-18.1 to 47.2)	44.3 (-55.3 to -29.1)
Chlamydial infection	195.6 (159.5 to 233.9)	421.3 (353.5 to 493.0)	116.9 (61.7 to 175.3)	3.3 (-20.1 to 30.3)	1.1 (0.6 to 1.9)	2.4 (1.3 to 4.0)	113.7 (57.2 to 196.2)	1.7 (-23.6 to 36.7)
Gonococcal infection	57.8 (42.5 to 73.8)	114.1 (84.9 to 149.7)	97.8 (30.0 to 200.1)	-7.2 (-37.0 to 35.1)	0.4 (0.2 to 0.7)	0.6 (0.3 to 1.1)	78.2 (1.2 to 224.2)	-15.4 (-48.5 to 44.5)
Trichomoniasis	105.2 (60.0 to 146.2)	232.7 (153.1 to 315.7)	119.9 (30.4 to 304.1)	6.3 (-34.0 to 83.3)	0.2 (0.1 to 0.4)	0.4 (0.1 to 0.9)	125.5 (9.4 to 380.9)	8.3 (-39.9 to 110.2)
Genital herpes	1,743.4 (1,564.5 to 1,940.4)	3,786.3 (3,346.0 to 4,223.7)	117.4 (84.0 to 156.4)	0.5 (-8.0 to 23.5)	0.4 (0.2 to 1.1)	1.0 (0.3 to 2.4)	120.0 (85.6 to 162.9)	7.3 (-7.3 to 24.7)
Other sexually transmitted diseases	3.7 (2.5 to 4.9)	6.8 (4.3 to 9.8)	81.7 (44.0 to 140.3)	-14.5 (-33.4 to 14.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	87.6 (24.9 to 204.8)	-12.8 (-38.8 to 33.6)
Hepatitis	-	-	-	-	1.0 (0.6 to 1.4)	1.6 (1.0 to 2.3)	62.7 (39.6 to 94.5)	-23.4 (-36.9 to -8.2)
Hepatitis A	18.8 (17.7 to 19.9)	35.5 (33.7 to 37.4)	88.5 (87.5 to 89.6)	-3.9 (-4.0 to -3.7)	0.3 (0.2 to 0.5)	0.6 (0.4 to 1.0)	107.0 (83.4 to 133.9)	1.6 (-8.6 to 13.0)
Hepatitis B	1,267.2 (1,079.3 to 1,479.2)	1,406.6 (1,133.7 to 1,639.7)	10.5 (-10.7 to 40.1)	-46.0 (-55.8 to -32.2)	0.5 (0.3 to 0.9)	0.6 (0.4 to 0.9)	19.6 (15.8 to 24.0)	-39.1 (-56.8 to -14.0)
Hepatitis C	331.8 (300.5 to 365.8)	497.3 (447.0 to 550.4)	49.4 (29.8 to 73.5)	-26.9 (-35.2 to -17.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	53.5 (13.5 to 106.7)	-23.0 (-43.6 to 4.4)
Hepatitis E	2.3 (2.0 to 2.6)	6.3 (5.7 to 6.9)	176.4 (138.3 to 225.7)	30.4 (12.7 to 51.4)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	176.9 (117.9 to 269.3)	31.1 (3.6 to 68.9)
Leprosy	0.7 (0.6 to 0.9)	2.5 (2.2 to 2.8)	250.0 (183.1 to 328.3)	72.3 (46.0 to 108.2)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	254.1 (167.5 to 364.0)	75.0 (39.5 to 124.6)
Other infectious diseases	146.6 (120.0 to 174.0)	197.0 (171.8 to 221.7)	33.9 (14.0 to 59.8)	-39.4 (-46.5 to -31.2)	5.8 (3.6 to 8.5)	7.5 (4.7 to 11.1)	28.4 (6.5 to 67.2)	-41.2 (-52.2 to -20.5)
Non-communicable diseases	-	-	-	-	602.3 (441.6 to 775.1)	1,267.4 (928.7 to 1,640.4)	110.5 (104.5 to 116.1)	1.9 (-1.5 to 4.3)
Neoplasms	-	-	-	-	3.2 (1.8 to 5.2)	8.9 (5.6 to 13.8)	176.3 (86.9 to 325.1)	42.7 (5.4 to 128.2)
Esophageal cancer	0.4 (0.2 to 0.7)	0.8 (0.5 to 1.3)	89.5 (13.3 to 237.2)	-0.3 (-39.0 to 77.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	83.5 (6.3 to 226.4)	-4.0 (-42.9 to 70.6)
Stomach cancer	1.2 (0.8 to 1.9)	2.1 (1.4 to 3.2)	62.4 (3.3 to 187.4)	-13.4 (-44.4 to 49.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	55.3 (-2.2 to 175.3)	-17.7 (-47.2 to 40.2)
Liver cancer	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	140.4 (33.8 to 315.4)	22.4 (-29.5 to 111.4)
Liver cancer due to hepatitis B	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.6)	213.0 (56.2 to 642.0)	63.5 (-18.9 to 287.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	178.7 (48.4 to 523.7)	45.9 (-24.2 to 224.6)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.1)	0.3 (0.1 to 0.5)	749.5 (275.0 to 2,066.1)	334.9 (103.9 to 973.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	649.8 (249.2 to 1,679.0)	275.3 (80.8 to 783.4)
Liver cancer due to alcohol use	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.3)	29.0 (-44.3 to 178.7)	-32.0 (-68.5 to 45.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	17.4 (-46.2 to 139.6)	-37.9 (-70.0 to 23.7)
Liver cancer due to other causes	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	91.6 (-10.6 to 317.7)	-5.0 (-55.8 to 108.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.6 (-14.6 to 243.7)	-16.3 (-58.8 to 75.4)
Larynx cancer	0.5 (0.3 to 0.8)	0.9 (0.6 to 1.4)	67.8 (1.5 to 187.1)	-10.9 (-45.1 to 50.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	12.9 (-1.5 to 194.7)	-12.9 (-46.8 to 56.5)
Tracheal, bronchus and lung cancer	0.6 (0.4 to 1.0)	1.1 (0.8 to 1.8)	74.4 (5.8 to 198.7)	-7.1 (-42.7 to 54.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	68.8 (2.8 to 183.7)	-10.3 (-44.5 to 50.4)
Breast cancer	5.2 (3.2 to 8.1)	20.0 (12.9 to 32.6)	278.1 (119.8 to 574.0)	88.9 (11.9 to 232.3)	0.5 (0.2 to 0.8)	1.6 (0.9 to 2.7)	240.8 (102.6 to 511.7)	72.3 (3.9 to 199.0)
Cervical cancer	0.6 (3.7 to 10.8)	10.7 (6.6 to 17.5)	63.0 (-6.3 to 194.3)	-9.7 (-54.0 to 46.3)	0.5 (0.3 to 0.9)	0.9 (0.5 to 1.4)	64.4 (-6.2 to 193.6)	-20.7 (-54.1 to 45.6)
Uterine cancer	1.5 (0.7 to 2.8)	3.0 (1.5 to 5.9)	105.0 (3.4 to 333.1)	5.8 (-45.2 to 121.7)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	101.6 (-0.2 to 343.6)	2.8 (-14.7 to 123.7)
Prostate cancer	2.2 (1.2 to 3.7)	13.1 (7.8 to 22.0)	492.7 (234.4 to 975.9)	213.1 (84.8 to 442.7)	0.2 (0.1 to 0.4)	1.2 (0.7 to 2.1)	382.9 (181.1 to 737.4)	156.1 (53.8 to 325.4)
Colon and rectum cancer	2.0 (1.3 to 3.0)	7.6 (5.4 to 11.8)	270.4 (137.4 to 524.6)	90.4 (26.1 to 210.9)	0.2 (0.1 to 0.3)	0.6 (0.4 to 1.1)	239.9 (115.8 to 476.2)	73.7 (13.4 to 188.2)
Lip and oral cavity cancer	1.1 (0.6 to 1.9)	2.3 (1.4 to 3.7)	103.7 (15.7 to 274.1)	5.9 (-39.4 to 91.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	99.4 (13.6 to 263.5)	3.0 (-41.6 to 85.2)
Nasopharynx cancer	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	111.7 (21.1 to 309.8)	5.2 (-42.3 to 105.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	102.6 (16.6 to 278.8)	0.7 (-43.5 to 89.7)
Other pharynx cancer	0.3 (0.1 to 0.4)	0.6 (0.3 to 1.1)	125.4 (7.2 to 374.4)	17.4 (-43.2 to 141.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	111.3 (3.7 to 333.7)	8.8 (-46.5 to 115.8)
Gallbladder and biliary tract cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	141.5 (36.8 to 342.9)	24.1 (-27.3 to 119.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	122.6 (26.3 to 307.3)	15.0 (-34.4 to 108.4)
Pancreatic cancer	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	186.5 (75.8 to 387.6)	45.5 (-8.6 to 145.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	166.2 (70.5 to 346.9)	35.6 (-13.3 to 119.1)
Malignant skin melanoma	0.9 (0.4 to 1.1)	2.7 (1.2 to 3.1)	210.7 (62.1 to 413.9)	58.4 (-17.8 to 151.7)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	174.4 (50.2 to 403.5)	33.9 (-23.1 to 141.4)
Non-melanoma skin cancer	0.6 (0.5 to 0.8)	1.9 (1.4 to 2.7)	209.6 (122.6 to 335.4)	50.1 (7.2 to 114.4)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	249.3 (113.3 to 469.4)	69.3 (1.1 to 188.7)
Ovarian cancer	0.4 (0.2 to 0.6)	1.1 (0.6 to 1.9)	205.0 (78.0 to 441.5)	51.4 (-13.2 to 172.7)	0.1 (0.0 to 0.1)	0.3 (0.1 to 0.3)	192.0 (65.7 to 460.8)	43.8 (-18.7 to 180.4)
Testicular cancer	0.3 (0.2 to 0.5)	1.1 (0.6 to 1.8)	259.4 (83.1 to 586.0)	72.5 (-7.8 to 225.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	243.4 (65.5 to 551.2)	61.4 (-15.0 to 202.5)
Kidney cancer	0.9 (0.4 to 1.7)	2.9 (1.4 to 3.8)	160.5 (36.7 to 383.8)	55.5 (-1.7 to 168.8)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	160.0 (37.7 to 373.1)	46.8 (-8.5 to 153.4)
Bladder cancer	0.8 (0.5 to 1.2)	1.7 (1.2 to 2.7)	127.1 (41.3 to 285.4)	17.9 (-25.8 to 95.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	112.5 (31.4 to 261.6)	10.2 (-31.7 to 82.4)
Brain and nervous system cancer	0.7 (0.3 to 2.0)	1.8 (1.1 to 3.0)	199.8 (1.1 to 360.1)	40.9 (-29.4 to 110.9)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	181.7 (17.4 to 329.0)	29.9 (-22.4 to 102.5)
Thyroid cancer	0.7 (0.4 to 1.2)	2.0 (1.2 to 3.3)	193.0 (66.7 to 426.2)	40.2 (-21.4 to 156.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	175.7 (55.1 to 395.3)	30.3 (-26.8 to 138.5)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	57.5 (-8.8 to 182.4)	-27.1 (-52.4 to 44.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.7 (-68.8 to 187.3)	-16.2 (-51.3 to 47.7)
Hodgkin lymphoma	0.9 (0.3 to 1.6)	2.1 (1.1 to 2.4)	138.7 (36.2 to 318.5)	27.2 (-21.8 to 115.8)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	130.3 (65.3 to 290.8)	18.1 (-26.1 to 97.1)
Non-Hodgkin lymphoma	1.5 (0.9 to 2.5)	4.6 (3.1 to 6.8)	210.4 (85.7 to 405.5)	63.9 (1.1 to 169.8)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.6)	197.2 (79.2 to 370.9)	53.9 (-6.2 to 152.1)
Multiple myeloma	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.7)	188.0 (50.1 to 439.3)	0.0 (-21.3 to 172.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	168.4 (35.8 to 421.8)	38.2 (-28.4 to 159.0)
Leukemia	0.9 (0.5 to 2.3)	2.7 (1.6 to 4.4)	210.7 (35.9 to 467.9)	58.4 (-6.9 to 143.3)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	191.1 (56.8 to 352.3)	39.4 (-9.6 to 115.5)
Other neoplasms	5.7 (2.4 to 19.2)	22.6 (14.1 to 44.1)	404.2 (73.6 to 695.8)	145.9 (18.7 to 290.4)	0.4 (0.1 to 1.1)	1.4 (0.7 to 2.7)	369.1 (84.6 to 615.8)	114.1 (16.6 to 245.6)
Cardiovascular diseases	-	-	-	-	11.7 (7.9 to 16.1)	28.5 (19.2 to 39.0)	144.5 (98.2 to 196.9)	19.8 (-3.4 to 47.3)
Rheumatic heart disease	80.7 (76.1 to 85.1)	200.5 (188.3 to 213.1)	148.1 (128.6 to 169.9)	21.3 (12.5 to 30.9)	4.0 (2.6 to 5.8)	9.8 (6.4 to 14.5)	146.1 (125.1 to 172.2)	19.7 (6.3 to 34.9)
Ischemic heart disease	45.6 (37.8 to 54.0)	83.1 (70.7 to 100.6)	81.9 (44.0 to 131.2)	-6.6 (-24.0 to 16.4)	2.1 (1.2 to 2.9)	3.5 (2.2 to 5.3)	75.8 (20.3 to 159.4)	-8.8 (-34.1 to 26.8)
Cerebrovascular disease	-	-	-	-	0.7 (0.5 to 0.9)	1.4 (1.0 to 1.9)	113.6 (70.6 to 166.3)	6.3 (-14.7 to 31.2)
Ischemic stroke	3.4 (2.9 to 4.0)	7.2 (6.2 to 8.2)	112.2 (71.3 to 165.8)	6.1 (-14.9 to 31.8)	0.3 (0.3 to 0.7)	1.1 (0.7 to 1.5)	113.4 (69.5 to 171.6)	6.8 (-15.0 to 34.0)
Hemorrhagic stroke	1.0 (0.8 to 1.1)	2.0 (1.7 to 2.4)	109.0 (63.2 to 170.2)	2.9 (-20.1 to 29.7)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	110.3 (63.9 to 174.8)	3.2 (-20.9 to 34.1)
Hypertensive heart disease	10.3 (7.3 to 13.8)	24.7 (19.5 to 30.5)	142.2 (54.6 to 253.9)	17.4 (-23.8 to 73.9)	1.1 (0.7 to 1.7)	2.7 (1.7 to 3.9)	143.6 (53.2 to 256.6)	19.1 (-22.8 to 75.6)
Cardiomyopathy and myocarditis	7.9 (6.4 to 9.8)	17.7 (14.6 to 21.5)	125.7 (62.2 to 200.2)	15.9 (-20.6 to 62.6)	0.9 (0.5 to 1.2)	1.9 (1.3 to 2.8)	127.3 (64.6 to 210.4)	16.9 (-20.3 to 66.0)
Atrial fibrillation and flutter	4.2 (3.3 to 5.3)	12.8 (9.8 to 16.8)	202.0 (109.4 to 316.9)	47.9 (-7.7 to 112.2)	0.3 (0.2 to 0.5)	1.0 (0.6 to 1.5)	205.5 (110.1 to 326.8)	50.5 (-5.1 to 112.2)
Peripheral vascular disease	86.3 (66.5 to 106.3)	161.5 (109.6 to 210.3)	89.4 (14.9 to 164.2)	-3.0 (-31.6 to 26.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	68.4 (-28.5 to 251.1)	-19.5 (-61.9 to 65.6)
Endocarditis	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	103.2 (35.7 to 215.3)	8.4 (-35.2 to 85.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	123.1 (41.9 to 250.2)	15.9 (-36.8 to 112.1)
Other cardiovascular and circulatory diseases	38.7 (21.4 to 64.2)	115.5 (58.0 to 166.3)	206.0 (31.7 to 505.7)	48.7 (-39.8 to 209.4)	2.7 (1.3 to 4.6)	8.1 (3.8 to 13.1)	209.1 (31.9 to 510.0)	50.6 (-39.7 to 2

Appendix Table G.4 - Angola prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumococcosis	0.0	0.1	83.7	-7.9	0.0	0.0	94.4	-3.8
Silicosis	(0.0 to 0.0)	(0.1 to 0.1)	(75.4 to 92.0)	(-12.2 to -3.5)	(0.0 to 0.0)	(0.0 to 0.0)	(87.8 to 101.8)	(-7.1 to -0.5)
Asbestosis	-	-	0.0	0.0	0.0	0.0	83.5	-7.9
Coal workers pneumococcosis	-	-	0.0	0.0	-	-	-	-
Other pneumococcosis	0.0	0.1	104.2	0.5	0.0	0.0	104.4	0.8
Asthma	(0.0 to 0.0)	(0.1 to 0.1)	(95.9 to 113.2)	(-3.1 to 4.5)	(0.0 to 0.0)	(0.0 to 0.0)	(95.9 to 114.2)	(-3.3 to 4.7)
Interstitial lung disease and pulmonary sarcoidosis	192.1	434.5	126.1	9.7	8.4	19.1	127.6	10.6
Other chronic respiratory diseases	(136.2 to 236.0)	(333.7 to 515.3)	(65.5 to 207.5)	(-11.8 to 35.5)	(5.2 to 12.5)	(12.0 to 28.1)	(65.8 to 212.1)	(-12.1 to 36.8)
Cirrhosis	0.2	0.5	131.4	8.0	0.0	0.1	133.2	8.7
Cirrhosis due to hepatitis B	(0.2 to 0.3)	(0.4 to 0.6)	(65.2 to 231.9)	(-18.8 to 46.9)	(0.0 to 0.0)	(0.0 to 0.1)	(67.6 to 231.2)	(-17.7 to 46.6)
Cirrhosis due to hepatitis C	-	-	-	-	8.5	13.2	59.0	-22.6
Cirrhosis due to alcohol use	-	-	-	-	(3.8 to 16.4)	(6.4 to 23.3)	(-15.6 to 191.6)	(-58.2 to 41.1)
Cirrhosis due to other causes	-	-	-	-	0.8	1.4	69.6	-15.4
Digestive diseases	1.7	1.5	-18.2	-51.6	(0.6 to 1.1)	(0.9 to 1.9)	(49.1 to 92.0)	(-23.3 to -7.1)
Peptic ulcer disease	(1.3 to 2.1)	(0.7 to 2.4)	(-56.8 to 53.8)	(-71.0 to -20.3)	0.3	0.2	-17.8	-51.3
Gastritis and duodenitis	0.9	2.7	201.0	39.6	0.2	0.4	202.8	40.4
Appendicitis	(0.6 to 1.2)	(1.6 to 3.7)	(52.4 to 355.5)	(-19.3 to 96.7)	(0.1 to 0.2)	(0.2 to 0.7)	(46.1 to 389.1)	(-21.2 to 108.6)
Paralytic ileus and intestinal obstruction	1.1	1.4	34.6	-31.4	0.2	0.2	35.4	-30.7
Inguinal, femoral, and abdominal hernia	(0.9 to 1.3)	(1.1 to 1.9)	(-4.5 to 100.2)	(-49.6 to -4.4)	(0.1 to 0.3)	(0.1 to 0.4)	(-8.0 to 100.3)	(-50.5 to -1.8)
Inflammatory bowel disease	1.2	2.7	117.6	18.6	0.2	0.5	113.1	19.1
Vascular intestinal disorders	(1.0 to 1.5)	(2.3 to 3.3)	(67.2 to 178.7)	(-11.2 to 57.5)	(0.1 to 0.3)	(0.3 to 0.7)	(48.2 to 224.8)	(-18.4 to 72.2)
Peptic ulcer disease	72.8	87.0	19.6	-35.6	13.5	24.9	84.7	-15.2
Gastritis and duodenitis	(61.5 to 82.2)	(72.0 to 100.6)	(-3.0 to 46.6)	(-46.4 to -23.2)	(9.2 to 19.0)	(13.7 to 34.0)	(58.0 to 110.8)	(-26.9 to -5.6)
Appendicitis	103.9	201.2	93.2	-5.1	3.0	3.4	14.8	-41.3
Paralytic ileus and intestinal obstruction	(89.5 to 116.4)	(175.2 to 223.4)	(65.2 to 131.5)	(-18.2 to 11.5)	(2.0 to 4.3)	(2.3 to 4.9)	(-10.6 to 40.1)	(-52.2 to -30.1)
Inguinal, femoral, and abdominal hernia	1.2	2.4	103.3	-4.3	4.8	8.8	86.4	-12.9
Inflammatory bowel disease	(1.0 to 1.5)	(1.9 to 3.0)	(41.2 to 175.9)	(-32.1 to 28.7)	(3.2 to 6.8)	(5.9 to 12.8)	(49.8 to 129.4)	(-26.7 to 0.4)
Vascular intestinal disorders	0.1	0.3	93.9	-0.9	0.4	0.7	104.3	-4.8
Peptic ulcer disease	48.1	78.3	59.0	-18.1	(0.2 to 0.5)	(0.4 to 1.1)	(27.5 to 213.4)	(-38.2 to 44.4)
Gastritis and duodenitis	(39.5 to 61.8)	(64.0 to 113.8)	(14.4 to 164.8)	(-36.1 to 8.9)	(0.0 to 0.1)	(0.0 to 0.1)	(15.5 to 242.6)	(-23.9 to 30.1)
Appendicitis	8.9	22.9	158.4	26.0	0.5	0.8	59.6	-17.3
Paralytic ileus and intestinal obstruction	(8.4 to 9.3)	(21.9 to 23.9)	(141.3 to 175.1)	(-19.0 to 33.7)	(0.2 to 1.0)	(0.4 to 1.7)	(14.5 to 170.8)	(-35.9 to 9.8)
Inguinal, femoral, and abdominal hernia	0.0	0.0	105.2	-4.5	1.9	4.9	161.3	27.5
Inflammatory bowel disease	(0.0 to 0.0)	(0.0 to 0.1)	(52.4 to 211.9)	(-37.5 to 35.1)	(1.3 to 2.6)	(3.3 to 6.7)	(136.5 to 185.7)	(-17.6 to 37.8)
Vascular intestinal disorders	2.8	6.1	119.5	0.3	0.0	0.0	121.3	10.1
Gallbladder and biliary diseases	(2.4 to 3.2)	(5.5 to 6.9)	(86.3 to 151.3)	(-6.5 to 27.5)	(0.0 to 0.4)	(0.4 to 0.9)	(83.1 to 169.3)	(-6.2 to 31.6)
Pancreatitis	1.6	3.5	117.6	4.0	0.2	1.0	120.9	5.5
Other digestive diseases	(1.5 to 1.7)	(3.3 to 3.7)	(99.3 to 134.7)	(-3.9 to 12.6)	(0.3 to 0.6)	(0.7 to 1.4)	(87.1 to 159.6)	(-10.3 to 22.8)
Neurological disorders	-	-	-	-	2.3	4.5	102.3	-7.2
Alzheimer disease and other dementias	-	-	-	-	(1.1 to 3.9)	(2.7 to 7.1)	(25.8 to 238.9)	(-41.6 to 55.9)
Parkinson disease	16.8	34.5	103.8	0.1	39.5	89.8	128.1	8.1
Epilepsy	(14.3 to 19.1)	(29.6 to 39.0)	(66.9 to 151.6)	(-17.4 to 24.2)	(26.3 to 55.6)	(60.2 to 125.1)	(102.2 to 156.0)	(-8.7 to 23.4)
Multiple sclerosis	0.6	1.1	96.3	-0.7	2.3	4.8	109.4	1.5
Migraine	(0.5 to 0.7)	(0.9 to 1.3)	(82.4 to 109.5)	(-5.8 to 5.0)	(1.6 to 3.0)	(3.4 to 6.2)	(70.8 to 161.4)	(-16.6 to 26.4)
Tension-type headache	12.5	25.6	104.8	-0.7	0.1	0.1	99.1	1.1
Medication overuse headache	(7.1 to 19.8)	(14.6 to 39.9)	(2.5 to 323.7)	(-49.8 to 105.5)	(0.0 to 0.1)	(0.1 to 0.2)	(66.1 to 139.3)	(-15.2 to 21.0)
Other neurological disorders	0.4	1.0	133.4	13.8	3.5	7.9	125.7	10.7
Alzheimer disease and other dementias	(0.4 to 0.5)	(0.9 to 1.1)	(93.2 to 177.9)	(-3.8 to 33.9)	(1.7 to 6.1)	(4.0 to 13.5)	(11.5 to 381.9)	(-45.5 to 135.3)
Parkinson disease	675.3	1,411.0	108.1	1.1	0.2	0.5	(87.1 to 186.9)	(-8.7 to 39.3)
Epilepsy	(613.8 to 738.0)	(1,298.0 to 1,534.3)	(84.6 to 137.1)	(-11.4 to 12.8)	22.9	48.2	116.6	0.2
Multiple sclerosis	1,174.8	2,263.7	123.6	3.6	(13.7 to 34.1)	(28.7 to 72.0)	(85.1 to 161.7)	(-10.8 to 14.7)
Migraine	(1,074.2 to 1,281.3)	(2,379.5 to 2,393.8)	(95.7 to 154.1)	(-7.0 to 15.4)	1.8	1.1	125.0	4.4
Tension-type headache	42.5	126.9	200.3	44.3	(0.9 to 3.1)	(0.9 to 7.0)	(95.8 to 157.7)	(-6.8 to 17.0)
Medication overuse headache	(27.1 to 57.8)	(82.0 to 177.8)	(116.0 to 288.6)	(-7.7 to 84.0)	6.6	19.9	203.1	45.5
Other neurological disorders	0.0	0.0	93.5	-6.1	2.3	4.6	112.9	2.6
Neurological disorders	(0.0 to 0.0)	(0.0 to 0.0)	(45.2 to 161.6)	(-27.5 to 32.1)	(1.3 to 5.0)	(2.9 to 7.5)	(10.8 to 249.7)	(-46.3 to 69.0)
Mental and substance use disorders	-	-	-	-	213.2	452.4	112.4	1.5
Schizophrenia	19.6	40.6	106.2	0.4	(151.0 to 281.8)	(317.7 to 598.3)	(105.9 to 118.6)	(-1.3 to 41.1)
Alcohol use disorders	(17.8 to 21.3)	(37.0 to 43.9)	(96.9 to 116.9)	(-3.6 to 5.3)	12.4	25.9	109.4	1.8
Drug use disorders	110.7	205.5	85.3	-11.4	10.8	20.2	87.0	-10.6
Opioid use disorders	(102.3 to 120.0)	(190.0 to 222.0)	(75.3 to 95.3)	(-15.4 to -6.8)	(7.3 to 15.3)	(13.5 to 28.6)	(75.2 to 99.5)	(-15.8 to -5.0)
Cocaine use disorders	-	-	-	-	11.7	25.0	114.9	3.1
Amphetamine use disorders	14.6	31.8	115.8	4.1	(7.7 to 16.4)	(16.4 to 34.7)	(89.4 to 142.0)	(-7.8 to 14.8)
Cannabis use disorders	(9.5 to 21.9)	(20.3 to 46.6)	(93.8 to 145.4)	(-6.1 to 15.8)	5.9	13.0	119.0	5.3
Other drug use disorders	4.7	10.2	116.0	0.6	(3.5 to 9.6)	(7.5 to 20.5)	(54.3 to 154.2)	(-6.1 to 20.1)
Depressive disorders	(3.9 to 5.8)	(8.5 to 12.0)	(61.1 to 177.8)	(-17.6 to 26.5)	(0.4 to 0.9)	(0.9 to 2.0)	(94.3 to 194.4)	(-21.3 to 35.3)
Major depressive disorder	16.1	32.6	102.0	-3.7	2.1	4.3	104.0	-2.7
Dysthymia	(14.7 to 17.3)	(29.8 to 35.0)	(80.2 to 126.1)	(-13.2 to 7.1)	(1.3 to 3.1)	(2.7 to 6.2)	(73.5 to 142.7)	(-17.0 to 14.2)
Bipolar disorder	11.3	24.1	112.3	0.1	0.3	0.7	114.0	0.9
Anxiety disorders	(9.5 to 13.1)	(20.3 to 27.9)	(111.8 to 112.9)	(-0.1 to 0.1)	(0.2 to 0.5)	(0.4 to 1.0)	(76.4 to 159.1)	(-15.3 to 21.2)
Eating disorders	-	-	-	-	2.7	5.7	109.0	0.3
Anorexia nervosa	-	-	-	-	(1.7 to 4.1)	(3.5 to 8.5)	(50.8 to 192.5)	(-28.2 to 37.6)
Bulimia nervosa	-	-	-	-	12.4	25.9	116.0	2.5
Autistic spectrum disorders	31.7	66.2	108.3	0.3	(58.0 to 128.4)	(125.3 to 281.3)	(104.0 to 130.7)	(-2.3 to 8.0)
Autism	(30.1 to 33.4)	(62.8 to 69.7)	(108.1 to 108.5)	(-0.3 to 0.3)	80.4	174.5	117.0	2.7
Asperger syndrome	45.8	95.3	108.0	0.4	(51.3 to 118.4)	(111.0 to 256.2)	(103.6 to 133.7)	(-2.8 to 9.2)
Attention-deficit/hyperactivity disorder	(42.9 to 48.5)	(89.4 to 100.9)	(107.7 to 108.3)	(-0.4 to 0.4)	9.0	18.6	107.7	0.8
Conduct disorder	75.4	163.0	115.7	0.2	(5.9 to 13.0)	(12.1 to 27.1)	(102.2 to 113.8)	(-1.5 to 3.2)
Idiopathic intellectual disability	(69.6 to 81.6)	(150.5 to 176.2)	(115.7 to 115.8)	(-0.2 to 0.2)	10.8	22.7	110.6	1.1
Other mental and substance use disorders	256.3	536.1	108.7	0.2	(6.7 to 16.4)	(13.8 to 34.3)	(95.8 to 128.5)	(-5.2 to 8.3)
Diabetes, urogenital, blood, and endocrine diseases	(102.9 to 115.6)	(223.7 to 251.4)	(117.0 to 117.2)	(-0.2 to 0.2)	31.3	69.2	110.5	0.8
Diabetes mellitus	355.5	744.3	108.8	3.4	(10.3 to 37.5)	(21.0 to 79.6)	(103.3 to 117.8)	(-1.8 to 3.4)
Acute glomerulonephritis	(241.6 to 459.0)	(557.1 to 942.1)	(78.6 to 158.1)	(-12.0 to 30.6)	2.4	5.3	114.7	1.1
Idiopathic intellectual disability	118.6	246.1	107.2	0.2	(1.5 to 3.8)	(3.1 to 8.2)	(97.2 to 134.0)	(-6.9 to 9.9)
Other mental and substance use disorders	(110.5 to 126.2)	(229.3 to 262.0)	(106.8 to 107.5)	(-0.1 to 0.3)	4.3	8.8	123.8	4.4
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	(0.2 to 0.5)	(0.5 to 1.2)	(73.6 to 194.5)	(-17.4 to 36.4)
Diabetes mellitus	26.5	80.2	203.9	40.8	2.1	4.5	112.7	0.3
Acute glomerulonephritis	(21.4 to 33.1)	(65.7 to 99.1)	(138.7 to 279.0)	(-12.2 to 28.9)	(1.2 to 3.4)	(2.5 to 7.2)	(94.8 to 133.6)	(-8.2 to 10.0)
Chronic kidney disease	0.1	0.2	52.4	-0.7	(1.2 to 3.4)	(2.5 to 7.2)	(94.8 to 133.6)	(-8.2 to 10.0)
Chronic kidney disease due to diabetes mellitus	(0.1 to 0.1)	(0.2 to 0.2)	(34.5 to 65.6)	(-31.3 to -19.1)	(8.6 to 16.8)	(18.0 to 35.3)	(102.2 to 118.1)	(-1.8 to 4.6)
Chronic kidney disease due to hypertension	-	-	-	-	7.8	16.4	109.9	1.3
Chronic kidney disease due to glomerulonephritis	-	-	-	-	0.3	0.6	116.5	0.6
Chronic kidney disease due to other causes	-	-	-	-	0.9	2.0	116.5	0.6
Urinary diseases and male infertility	31.7	66.2	108.3	0.3	(0.5 to 1.4)	(1.2 to 3.0)	(101.8 to 132.8)	(-6.2 to 8.2)
Diabetes mellitus	(30.1 to 33.4)	(62.8 to 69.7)	(108.1 to 108.5)	(-0.3 to 0.3)	0.2	0.5	116.7	1.1
Acute glomerulonephritis	45.8	95.3	108.0	0.4	(8.3 to 18.6)	(18.0 to 41.4)	(100.0 to 129.0)	(-3.4 to 5.6)
Chronic kidney disease	(42.9 to 48.5)	(89.4 to 100.9)	(107.7 to 108.3)	(-0.4 to 0.4)	3.4	7.3	110.0	4.0
Chronic kidney disease due to diabetes mellitus	75.4	163.0	115.7	0.2	(10.3 to 25.3)	(21.0 to 51.8)	(79.9 to 159.0)	(-11.4 to 31.1)
Chronic kidney disease due to hypertension	(69.6 to 81.6)	(150.5 to 176.2)	(115.7 to 115.8)	(-0.2 to 0.2)	8.8	18.3	109.2	1.2
Chronic kidney disease due to glomerulonephritis	256.3	536.1	108.7	0.2	(5.9 to 11.8)	(12.5 to 24.7)	(100.6 to 118.5)	(-2.1 to 4.9)
Chronic kidney disease due to other causes	118.6	246.1	107.2	0.2	53.7	100.3	86.8	-7.9
Urinary diseases and male infertility	(110.5 to 126.2)	(229.3 to 262.0)	(106.8 to 107.5)	(-0.1 to 0.3)	(37.1 to 72.9)	(71.0 to 136.7)	(75.3 to 97.8)	(-12.7 to -2.3)
Diabetes mellitus	26.5	80.2	203.9	40.8	1.9	5.9	205.8	43.4
Acute glomerulonephritis	(21.4 to 33.1)	(65.7 to 99.1)	(138.7 to 279.0)	(-12.2 to 28.9)	(1.3 to 2.7)	(3.8 to 8.8)	(135.5 to 287.3)	

Appendix Table G.4 - Angola prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.9 (1.8 to 2.1)	4.2 (3.9 to 4.5)	117.9 (98.4 to 140.3)	117.9 (-0.9 to 17.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	120.7 (66.7 to 186.4)	120.7 (-11.7 to 32.5)
Urolithiasis	18.5 (14.7 to 23.1)	32.1 (24.5 to 39.7)	72.8 (55.0 to 93.0)	-12.4 (-21.7 to -3.2)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	123.3 (94.0 to 157.1)	123.3 (0.6 to 26.0)
Benign prostatic hyperplasia	51.6 (47.0 to 56.3)	104.9 (96.4 to 113.1)	103.0 (79.3 to 128.2)	5.8 (-6.3 to 18.5)	1.8 (1.2 to 2.6)	3.7 (2.4 to 5.4)	105.5 (81.1 to 132.6)	105.5 (5.4 to 20.2)
Male infertility due to other causes	68.7 (50.6 to 89.5)	142.5 (102.7 to 189.4)	104.7 (42.3 to 206.0)	-1.7 (-32.2 to 45.1)	0.4 (0.2 to 0.9)	0.9 (0.3 to 1.9)	107.2 (41.3 to 206.0)	107.2 (-31.5 to 47.5)
Other urinary diseases	-	-	-	-	-	-	-	-
Gynecological diseases	-	-	-	-	10.9 (7.2 to 16.1)	20.8 (13.3 to 31.9)	90.9 (64.2 to 119.6)	-11.1 (-22.5 to 1.1)
Uterine fibroids	144.5 (130.4 to 157.5)	298.4 (269.3 to 325.3)	106.2 (106.1 to 106.4)	-0.8 (-0.9 to -0.8)	3.2 (2.0 to 4.8)	4.9 (2.9 to 7.9)	53.5 (36.3 to 83.1)	-27.8 (-36.1 to -12.9)
Polycystic ovarian syndrome	137.3 (122.0 to 153.2)	300.4 (269.6 to 329.6)	118.3 (88.4 to 151.1)	2.8 (-10.4 to 17.0)	1.3 (0.6 to 2.5)	2.9 (1.3 to 5.3)	119.2 (88.6 to 152.8)	3.1 (-10.5 to 18.0)
Female infertility due to other causes	94.0 (58.8 to 133.5)	204.0 (117.2 to 307.6)	117.8 (17.1 to 254.9)	4.5 (-4.6 to 89.5)	0.2 (0.0 to 0.2)	0.2 (0.2 to 1.1)	125.3 (20.5 to 302.3)	125.3 (-46.1 to 90.3)
Endometriosis	13.6 (11.5 to 15.8)	26.9 (22.6 to 31.5)	97.3 (54.6 to 146.0)	-6.4 (-25.4 to 14.9)	1.2 (0.8 to 1.8)	2.5 (1.6 to 3.5)	99.7 (53.8 to 153.2)	5.7 (-26.4 to 18.1)
Genital prolapse	285.3 (238.1 to 334.1)	602.5 (464.7 to 719.4)	110.6 (64.3 to 172.8)	3.7 (-16.5 to 26.8)	0.9 (0.4 to 1.7)	1.9 (0.9 to 3.6)	111.9 (64.7 to 174.1)	4.4 (-16.0 to 28.6)
Premenstrual syndrome	278.7 (181.4 to 378.1)	700.0 (470.9 to 951.8)	151.4 (58.5 to 284.9)	2.3 (-26.4 to 73.3)	15.3 (1.2 to 3.8)	2.3 (3.2 to 9.5)	154.2 (59.3 to 297.5)	16.9 (-26.3 to 76.9)
Other gynecological diseases	37.9 (20.5 to 54.9)	53.8 (33.3 to 73.2)	42.7 (-12.6 to 157.8)	-32.6 (-57.9 to 21.1)	1.5 (0.6 to 2.1)	1.7 (0.6 to 2.5)	15.8 (-54.9 to 163.3)	45.9 (-77.8 to 20.0)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	18.3 (12.3 to 26.1)	32.1 (21.7 to 45.9)	75.1 (54.9 to 90.7)	-22.7 (-31.8 to -14.7)
Thalassemias	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	101.0 (67.2 to 125.5)	-1.7 (-18.3 to 9.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.2 (85.7 to 129.8)	5.7 (-7.3 to 12.7)
Thalassemia trait	54.1 (46.9 to 61.8)	111.2 (96.1 to 126.8)	106.2 (88.1 to 119.5)	0.0 (-8.6 to 6.6)	0.9 (0.6 to 1.3)	1.9 (1.3 to 2.9)	116.2 (69.2 to 159.0)	4.6 (-19.7 to 26.7)
Sickle cell disorders	30.3 (26.9 to 33.5)	67.6 (60.8 to 73.8)	121.9 (103.1 to 149.3)	9.7 (-2.7 to 25.2)	3.0 (2.0 to 4.1)	6.6 (4.5 to 9.0)	124.8 (89.1 to 160.4)	11.0 (5.8 to 29.9)
Sickle cell trait	1,956.0 (1,772.5 to 2,015.4)	3,934.0 (3,671.5 to 4,124.1)	105.4 (97.4 to 113.1)	-0.4 (-4.3 to 3.2)	9.2 (6.0 to 13.2)	18.1 (12.0 to 26.1)	95.4 (58.6 to 126.7)	-10.2 (-25.0 to 4.8)
G6PD deficiency	758.8 (702.3 to 815.6)	1,565.5 (1,462.8 to 1,665.6)	106.3 (86.4 to 127.8)	-0.1 (-9.6 to 10.2)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	71.5 (40.8 to 120.7)	-9.6 (-19.1 to 3.6)
G6PD trait	2,500.0 (2,482.6 to 2,511.6)	5,195.6 (5,169.9 to 5,220.2)	107.4 (105.9 to 109.1)	0.4 (-0.4 to 1.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.3)	78.6 (-78.4 to 368.9)	-18.7 (85.2 to 117.5)
Other hemoglobinopathies and hemolytic anemias	161.1 (138.5 to 181.3)	193.9 (169.8 to 217.8)	20.1 (9.9 to 41.7)	-44.8 (-51.7 to -37.2)	5.1 (3.2 to 7.5)	5.2 (3.4 to 7.7)	3.3 (-18.6 to 34.4)	-58.2 (-67.4 to -47.6)
Endocrine, metabolic, blood, and immune disorders	157.7 (143.8 to 188.9)	237.4 (199.4 to 273.6)	41.5 (9.3 to 73.0)	7.9 (-44.5 to -21.8)	6.4 (3.5 to 8.7)	7.9 (4.9 to 11.6)	40.2 (-3.8 to 76.0)	40.2 (-52.7 to -23.2)
Musculoskeletal disorders	-	-	-	-	103.9 (74.0 to 137.6)	225.7 (161.2 to 301.6)	117.7 (95.5 to 139.2)	5.1 (-4.0 to 14.4)
Rheumatoid arthritis	21.4 (20.6 to 22.3)	41.1 (39.5 to 42.9)	91.4 (80.0 to 104.8)	-9.4 (-14.5 to -3.4)	5.0 (3.6 to 6.7)	9.8 (7.0 to 13.1)	94.1 (78.9 to 114.3)	-8.1 (-14.4 to -0.9)
Osteoarthritis	168.8 (161.2 to 175.5)	340.0 (325.6 to 353.5)	101.6 (90.1 to 112.3)	1.2 (-4.3 to 6.1)	10.2 (7.1 to 13.7)	28.7 (14.5 to 20.0)	103.6 (91.6 to 114.7)	2.3 (-3.1 to 7.6)
Low back and neck pain	-	-	-	-	90.2 (56.8 to 107.8)	172.2 (119.1 to 231.6)	115.3 (86.6 to 144.9)	2.9 (-9.4 to 15.2)
Low back pain	438.0 (412.0 to 463.7)	898.9 (844.2 to 951.5)	105.2 (88.8 to 123.4)	-0.7 (-8.0 to 7.8)	48.3 (32.8 to 66.1)	100.0 (67.6 to 137.1)	107.5 (89.9 to 125.6)	0.5 (-7.1 to 8.8)
Neck pain	329.1 (253.3 to 407.8)	735.8 (602.2 to 852.4)	125.8 (70.1 to 198.2)	5.8 (-19.2 to 33.4)	32.0 (20.4 to 45.8)	72.2 (49.3 to 102.3)	128.5 (71.2 to 204.1)	7.2 (-18.8 to 35.9)
Gout	1.2 (1.0 to 1.3)	2.4 (2.1 to 2.7)	101.6 (67.8 to 138.0)	0.5 (-15.8 to 17.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	102.1 (55.7 to 165.5)	1.3 (-22.5 to 33.4)
Other musculoskeletal disorders	94.1 (53.9 to 135.9)	253.1 (166.2 to 325.0)	467.4 (122.4 to 265.3)	29.7 (10.1 to 76.0)	8.4 (4.4 to 13.4)	22.5 (13.7 to 34.5)	32.0 (12.4 to 78.5)	32.0 (11.3 to 78.5)
Other non-communicable diseases	-	-	-	-	120.4 (75.1 to 182.9)	250.0 (157.7 to 379.2)	107.7 (100.4 to 114.9)	-2.5 (-5.0 to 0.4)
Congenital anomalies	-	-	-	-	2.8 (2.1 to 3.7)	10.6 (7.8 to 13.7)	277.0 (218.0 to 345.6)	86.7 (57.4 to 121.3)
Neural tube defects	0.8 (0.7 to 1.0)	5.1 (4.4 to 5.9)	509.4 (375.1 to 687.1)	253.0 (173.9 to 364.7)	0.2 (0.1 to 0.3)	1.4 (0.9 to 1.9)	600.8 (363.6 to 893.3)	321.2 (182.9 to 502.6)
Congenital heart anomalies	6.4 (4.7 to 8.6)	45.9 (33.8 to 60.0)	626.7 (338.0 to 909.1)	319.4 (142.1 to 562.8)	0.2 (0.1 to 0.4)	1.6 (0.7 to 2.8)	554.3 (311.8 to 852.6)	278.4 (131.4 to 457.9)
Orofacial clefts	0.6 (0.4 to 0.9)	5.8 (3.9 to 8.3)	900.0 (459.6 to 1,413.0)	500.0 (259.2 to 952.9)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	726.4 (391.1 to 1,443.2)	448.6 (213.6 to 927.1)
Down syndrome	4.6 (3.7 to 5.6)	17.0 (14.1 to 21.0)	267.3 (180.4 to 406.2)	100.9 (51.6 to 176.7)	0.5 (0.4 to 0.7)	2.0 (1.3 to 2.7)	273.8 (171.9 to 426.6)	108.7 (54.1 to 194.0)
Turner syndrome	0.2 (0.1 to 0.2)	0.6 (0.5 to 0.8)	221.2 (116.7 to 344.8)	64.1 (9.6 to 130.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	223.5 (113.4 to 359.6)	63.1 (8.5 to 135.8)
Klinefelter syndrome	0.3 (0.2 to 0.4)	0.6 (0.5 to 0.7)	100.7 (37.9 to 197.4)	-1.3 (-32.6 to 46.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.7 (38.8 to 201.7)	-1.5 (-32.8 to 47.0)
Chromosomal unbalanced rearrangements	65.8 (5.5 to 8.4)	25.3 (21.4 to 30.4)	107.6 (186.1 to 389.0)	107.6 (54.6 to 171.2)	0.9 (0.5 to 1.1)	2.9 (2.0 to 4.0)	377.0 (183.0 to 412.9)	112.2 (57.0 to 192.7)
Other congenital anomalies	14.1 (11.5 to 16.6)	26.7 (22.2 to 31.1)	88.7 (73.6 to 106.1)	-9.3 (-15.5 to -1.7)	1.1 (0.7 to 1.6)	2.7 (1.7 to 4.2)	148.8 (96.5 to 231.5)	11.0 (-9.3 to 43.3)
Skin and subcutaneous diseases	-	-	-	-	57.9 (36.3 to 88.4)	126.4 (80.1 to 193.6)	117.9 (107.0 to 130.5)	4.0 (-0.9 to 9.7)
Dermatitis	607.7 (511.6 to 701.4)	1,273.0 (1,068.4 to 1,469.8)	109.1 (108.8 to 109.9)	0.0 (-0.0 to 0.0)	22.1 (13.9 to 31.9)	46.5 (29.3 to 67.4)	110.8 (104.0 to 117.7)	0.8 (-1.7 to 3.3)
Psoriasis	63.3 (54.2 to 72.6)	131.7 (112.5 to 151.0)	107.6 (106.7 to 108.2)	0.0 (-0.0 to 0.0)	5.1 (3.4 to 7.3)	10.7 (7.2 to 15.4)	107.8 (97.2 to 125.2)	1.2 (-3.6 to 6.5)
Cellulitis	2.2 (1.8 to 2.8)	4.5 (3.4 to 5.6)	100.8 (69.9 to 135.9)	-2.0 (-21.0 to 15.9)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	101.5 (48.5 to 169.2)	-0.9 (-24.5 to 25.1)
Pyoderma	19.1 (14.0 to 24.9)	35.9 (26.7 to 46.4)	87.6 (75.6 to 101.6)	-4.2 (-10.5 to 3.0)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.5)	87.9 (70.2 to 108.9)	-3.7 (-12.2 to 6.3)
Scabies	119.9 (104.1 to 137.4)	234.0 (204.9 to 268.0)	94.7 (59.9 to 137.2)	-8.0 (-23.3 to 10.9)	3.1 (1.7 to 4.9)	6.0 (3.4 to 9.8)	95.6 (60.3 to 138.5)	-7.4 (-24.6 to 11.0)
Fungal skin diseases	1,628.2 (1,309.1 to 2,073.9)	3,420.8 (2,742.5 to 4,364.6)	109.7 (108.4 to 111.5)	109.7 (0.1 to 0.1)	0.9 (0.6 to 1.9)	0.9 (0.5 to 1.9)	107.7 (105.5 to 110.0)	0.9 (-0.0 to 1.3)
Viral skin diseases	214.1 (163.0 to 261.5)	459.7 (355.4 to 553.9)	114.3 (108.6 to 121.4)	2.6 (0.7 to 4.8)	6.6 (3.8 to 10.3)	14.2 (8.2 to 22.0)	115.3 (106.0 to 126.4)	3.2 (-0.3 to 7.0)
Acne vulgaris	468.0 (344.9 to 608.0)	1,257.7 (981.6 to 1,625.2)	165.4 (85.1 to 308.2)	22.3 (-12.9 to 86.6)	5.1 (2.1 to 10.0)	13.6 (6.2 to 25.5)	167.2 (86.4 to 310.3)	22.9 (-12.7 to 88.4)
Alopecia areata	9.1 (8.1 to 10.3)	18.9 (16.8 to 21.3)	107.9 (75.7 to 147.3)	1.1 (-12.9 to 18.5)	0.3 (0.2 to 0.5)	0.6 (0.4 to 1.0)	108.5 (68.8 to 157.3)	1.6 (-14.4 to 23.3)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	107.7 (65.5 to 166.4)	0.9 (-21.3 to 32.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.7 (65.3 to 166.8)	0.9 (-21.3 to 32.2)
Urticaria	43.1 (29.9 to 57.3)	120.9 (81.1 to 164.6)	183.2 (70.7 to 339.1)	26.5 (-15.4 to 81.8)	2.5 (1.4 to 4.0)	7.2 (4.0 to 11.4)	185.7 (72.7 to 348.9)	29.0 (-14.7 to 85.0)
Decubitus ulcer	1.0 (0.9 to 1.1)	2.2 (1.9 to 2.5)	116.9 (76.4 to 167.0)	4.5 (-16.9 to 34.1)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	118.8 (72.0 to 176.2)	6.3 (-18.4 to 38.5)
Other skin and subcutaneous diseases	599.4 (415.9 to 827.1)	1,212.4 (841.5 to 1,657.8)	102.1 (95.8 to 107.2)	-1.9 (-4.6 to 0.3)	3.5 (1.6 to 7.1)	7.2 (3.3 to 14.6)	103.1 (96.4 to 109.2)	-1.2 (-3.0 to 1.2)
Sense organ diseases	-	-	-	-	46.9 (27.8 to 69.5)	82.7 (51.3 to 127.5)	94.3 (76.9 to 92.9)	-9.9 (-12.9 to -6.6)
Glaucoma	14.1 (11.5 to 17.0)	20.9 (16.8 to 25.3)	48.7 (27.7 to 73.5)	-26.6 (-39.8 to -13.5)	0.9 (0.6 to 1.2)	1.5 (1.0 to 2.1)	63.4 (42.9 to 89.2)	-17.6 (-20.2 to -2.5)
Cataract	38.5 (30.6 to 47.3)	60.6 (49.1 to 74.4)	57.5 (33.2 to 83.2)	-20.9 (-31.5 to -11.5)	2.4 (1.6 to 3.4)	3.9 (2.7 to 5.4)	58.5 (41.7 to 80.6)	-20.8 (-28.5 to -11.6)
Macular degeneration	10.4 (7.9 to 13.6)	24.5 (18.9 to 31.3)	133.5 (71.5 to 210.1)	16.1 (-12.1 to 58.5)	0.5 (0.3 to 0.7)	1.1 (0.7 to 1.6)	131.0 (72.8 to 197.9)	12.1 (-13.6 to 45.9)
Uncorrected refractive error	1,401.9 (1,304.1 to 1,495.6)	2,634.3 (2,420.8 to 2,846.1)	87.5 (68.6 to 108.6)	-8.5 (-11.1 to 0.6)	19.3 (11.1 to 32.3)	35.2 (19.6 to 60.3)	81.5 (67.2 to 98.8)	-11.4 (-16.9 to -4.5)
Age-related and other hearing loss	956.4 (849.6 to 1,066.3)	1,768.6 (1,554.5 to 1,970.4)	84.4 (78.1 to 92.6)	-6.6 (-9.1 to -3.4)	13.3 (7.6 to 22.4)			

Appendix Table G.4 - Angola prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	152.6 (142.8 to 163.4)	287.8 (269.2 to 306.4)	88.2 (72.3 to 107.1)	-5.4 (-12.8 to 3.8)	4.2 (2.8 to 5.7)	7.9 (5.3 to 11.0)	98.2 (73.4 to 109.7)	-4.1 (-12.1 to 5.0)
Other oral disorders	142.5 (133.6 to 151.3)	298.2 (281.3 to 316.2)	108.6 (92.8 to 127.6)	0.1 (-7.2 to 8.5)	4.2 (2.6 to 6.2)	8.7 (5.4 to 13.0)	110.1 (93.0 to 130.4)	1.0 (-7.1 to 9.8)
Injuries	-	-	-	-	106.6 (62.2 to 182.6)	104.4 (72.8 to 147.7)	1.7 (-24.9 to 26.1)	-44.4 (-57.0 to -32.8)
Transport injuries	-	-	-	-	16.5 (12.6 to 21.2)	26.9 (20.2 to 34.9)	63.3 (57.0 to 70.2)	-16.0 (-18.9 to -13.1)
Road injuries	-	-	-	-	13.9 (10.6 to 17.9)	23.1 (17.4 to 29.8)	66.2 (58.1 to 72.8)	-15.0 (-18.1 to -11.6)
Pedestrian road injuries	-	-	-	-	3.9 (2.9 to 5.0)	6.2 (4.6 to 8.1)	61.0 (47.6 to 75.5)	-16.7 (-21.9 to -10.8)
Cyclist road injuries	-	-	-	-	1.6 (1.2 to 2.0)	2.2 (1.7 to 2.9)	41.2 (32.5 to 52.3)	-25.2 (-29.3 to -19.5)
Motorcyclist road injuries	-	-	-	-	2.7 (2.0 to 3.5)	3.8 (2.8 to 4.9)	39.9 (30.2 to 51.8)	-27.9 (-32.7 to -22.4)
Motor vehicle road injuries	-	-	-	-	5.6 (4.3 to 7.1)	10.6 (8.0 to 13.7)	88.5 (76.1 to 102.1)	-3.8 (-9.6 to 1.9)
Other road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	14.3 (6.1 to 21.8)	-46.0 (-49.4 to -42.7)
Other transport injuries	-	-	-	-	2.5 (1.9 to 3.3)	3.9 (2.9 to 5.1)	52.9 (44.9 to 61.8)	-21.5 (-25.7 to -17.0)
Unintentional injuries	-	-	-	-	22.5 (17.2 to 28.9)	41.1 (31.1 to 53.2)	82.3 (77.0 to 87.9)	-7.8 (-10.8 to -5.0)
Falls	-	-	-	-	8.9 (6.7 to 11.4)	16.5 (12.7 to 22.1)	91.2 (81.5 to 101.1)	-4.3 (-9.0 to 0.9)
Drowning	-	-	-	-	0.6 (0.4 to 0.8)	0.9 (0.6 to 1.1)	50.7 (36.3 to 66.3)	-23.4 (-30.0 to -16.8)
Fire, heat, and hot substances	-	-	-	-	2.8 (2.2 to 3.6)	4.0 (3.0 to 5.2)	42.6 (31.1 to 55.0)	-26.6 (-31.4 to -22.0)
Poisonings	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	60.5 (35.4 to 90.2)	-21.8 (-31.3 to -10.8)
Exposure to mechanical forces	-	-	-	-	6.2 (4.7 to 8.0)	12.1 (9.1 to 15.6)	95.0 (85.3 to 103.7)	-3.3 (-7.4 to 0.9)
Unintentional firearm injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.6)	107.8 (92.9 to 125.0)	4.6 (-2.5 to 12.9)
Unintentional suffocation	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	136.9 (112.9 to 166.5)	19.6 (10.3 to 32.2)
Other exposure to mechanical forces	-	-	-	-	5.9 (4.5 to 7.7)	11.5 (8.6 to 14.9)	94.0 (84.8 to 103.0)	-3.8 (-8.2 to 0.6)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	122.3 (107.0 to 136.3)	13.3 (6.2 to 21.3)
Animal contact	-	-	-	-	0.7 (0.5 to 0.9)	1.1 (0.8 to 1.4)	59.4 (49.8 to 68.9)	-20.4 (-24.4 to -16.5)
Venomous animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.6)	63.3 (47.0 to 81.5)	-19.7 (-26.5 to -12.1)
Non-venomous animal contact	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	56.4 (46.6 to 65.8)	-21.1 (-24.9 to -16.7)
Foreign body	-	-	-	-	0.4 (0.3 to 0.6)	0.8 (0.6 to 1.0)	89.8 (78.0 to 101.7)	-4.5 (-9.4 to 0.7)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	71.3 (47.4 to 91.3)	-9.4 (-18.9 to -1.8)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	104.7 (85.0 to 128.7)	-0.5 (-8.3 to 9.7)
Foreign body in other body part	-	-	-	-	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.6)	94.4 (82.1 to 108.7)	-3.7 (-9.7 to 3.3)
Other unintentional injuries	-	-	-	-	2.8 (2.1 to 3.6)	4.9 (3.7 to 6.4)	75.3 (65.3 to 88.1)	-10.9 (-15.8 to -4.6)
Self-harm and interpersonal violence	-	-	-	-	2.2 (1.7 to 2.8)	3.8 (2.9 to 4.8)	69.1 (60.4 to 76.6)	-15.0 (-18.8 to -11.6)
Self-harm	-	-	-	-	0.4 (0.3 to 0.5)	0.7 (0.5 to 0.9)	94.6 (81.4 to 111.1)	-3.3 (-9.5 to 3.9)
Interpersonal violence	-	-	-	-	1.9 (1.4 to 2.4)	3.0 (2.3 to 3.9)	64.1 (54.7 to 72.4)	-17.9 (-22.1 to -14.0)
Assault by firearm	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	70.0 (58.8 to 80.1)	-16.6 (-21.8 to -12.1)
Assault by sharp object	-	-	-	-	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.7)	80.4 (68.9 to 93.0)	-11.2 (-16.7 to -5.0)
Assault by other means	-	-	-	-	1.2 (0.9 to 1.6)	2.0 (1.5 to 2.5)	58.4 (47.1 to 69.4)	-20.2 (-25.3 to -15.0)
Forces of nature, war, and legal intervention	-	-	-	-	65.3 (26.4 to 145.5)	32.6 (13.6 to 71.4)	-49.9 (-54.7 to -44.2)	-65.9 (-69.9 to -61.5)
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.1)	-	-
Collective violence and legal intervention	-	-	-	-	65.3 (26.4 to 145.5)	32.5 (13.5 to 71.4)	-49.9 (-54.8 to -44.3)	-65.9 (-69.9 to -61.5)

Appendix Table G.4 - Antigua and Barbuda prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	5.9 (4.4 to 7.6)	9.2 (6.9 to 12.0)	56.6 (52.7 to 60.6)	0.2 (-2.4 to 2.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.5 (0.5 to 0.9)	0.9 (0.6 to 1.2)	36.6 (30.3 to 42.8)	-1.4 (-6.0 to 3.2)
HIV/AIDS and tuberculosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	108.4 (51.7 to 175.4)	30.7 (-4.1 to 73.3)
Tuberculosis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	61.2 (54.7 to 68.1)	1.9 (-1.8 to 5.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.3 (44.9 to 78.7)	2.2 (-7.0 to 13.0)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	184.4 (44.8 to 527.2)	79.3 (-10.4 to 296.2)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	158.6 (30.7 to 476.3)	54.7 (-22.9 to 251.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	158.6 (30.4 to 477.2)	54.7 (-23.0 to 251.6)
HIV/AIDS resulting in other diseases	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	153.7 (30.3 to 545.6)	68.1 (-13.8 to 328.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	184.8 (43.6 to 528.3)	79.4 (-10.5 to 301.0)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	28.6 (19.0 to 38.1)	-6.1 (-13.1 to 0.2)
Diarrheal diseases	0.4 (0.3 to 0.4)	0.5 (0.5 to 0.5)	33.6 (20.9 to 46.0)	1.5 (-7.7 to 10.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	32.7 (20.2 to 45.3)	1.1 (-8.0 to 10.8)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.3 (-27.8 to 21.3)	-28.9 (-46.7 to -10.7)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.4 (-12.5 to 26.8)	-23.2 (-35.2 to -7.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.4 (-12.6 to 26.8)	-23.2 (-35.3 to -7.7)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.6 (-20.3 to 28.2)	-24.0 (-41.3 to -6.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.6 (-20.5 to 28.3)	-24.0 (-41.2 to -6.0)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.9 (-89.0 to 10.7)	-68.4 (-91.9 to -18.2)
Lower respiratory infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.0 (5.7 to 80.6)	-1.1 (-25.5 to 25.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.1 (4.8 to 89.1)	-0.2 (-25.4 to 29.7)
Upper respiratory infections	3.1 (2.8 to 3.4)	4.3 (3.9 to 4.7)	40.9 (21.9 to 60.8)	-1.5 (-14.6 to 12.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	40.6 (22.0 to 61.1)	-1.5 (-14.4 to 13.0)
Otitis media	0.7 (0.6 to 0.7)	0.9 (0.8 to 0.9)	24.9 (16.7 to 34.1)	-11.3 (-17.0 to -5.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.2 (12.8 to 34.8)	-12.5 (-19.7 to -4.7)
Meningitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.0 (-50.0 to -19.0)	-57.5 (-65.6 to -44.9)
Pneumococcal meningitis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-40.8 (-51.7 to -24.5)	-61.3 (-68.6 to -50.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.3 (-49.6 to -12.4)	-56.0 (-65.7 to -41.6)
H influenzae type B meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.2 (-68.4 to -22.7)	-65.2 (-77.7 to -46.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.3 (-71.3 to -9.9)	-61.9 (-79.4 to -36.2)
Meningococcal meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.1 (-53.1 to 6.3)	-58.6 (-68.9 to -30.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.5 (-50.3 to 35.0)	-54.3 (-66.2 to -11.0)
Other meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.7 (-55.4 to -2.0)	-60.9 (-69.7 to -34.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.7 (-56.8 to 14.4)	-57.7 (-69.7 to -23.0)
Encephalitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.3 (-3.2 to 46.8)	-25.2 (-38.3 to -6.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.0 (0.1 to 65.6)	18.4 (-3.5 to 5.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.4 (-89.2 to 838.1)	-31.3 (-93.0 to 487.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.4 (-89.4 to 843.1)	-31.3 (-93.1 to 489.6)
Whooping cough	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	125.2 (116.9 to 134.3)	81.6 (74.8 to 88.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	124.0 (53.9 to 239.6)	80.6 (23.7 to 173.7)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-66.0 (-82.3 to -25.2)	-76.7 (-87.8 to -49.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-64.9 (-82.7 to -31.0)	-75.5 (-87.5 to -51.9)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to 0.0)	-100.0 (-100.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.3 (-100.0 to nan)	-99.4 (-100.0 to nan)
Varicella and herpes zoster	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	40.1 (16.5 to 68.9)	-0.6 (-18.1 to 21.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.0 (12.6 to 127.6)	0.7 (-31.3 to 42.2)
Neglected tropical diseases and malaria	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	17.1 (-15.9 to 65.1)	-13.9 (-39.0 to 19.4)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.0 (-23.5 to 188.5)	-6.2 (-45.7 to 102.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.2 (-20.9 to 190.2)	-4.2 (-44.0 to 103.4)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.9 (-11.0 to 123.7)	-0.9 (-39.5 to 49.8)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.6 (-28.3 to 138.8)	-4.5 (-44.1 to 75.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.6 (-28.4 to 139.0)	-4.5 (-44.6 to 76.0)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.3 (-7.9 to 122.6)	-0.8 (-40.2 to 50.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.6 (-13.7 to 131.0)	-0.4 (-41.7 to 55.6)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	52.0 (48.8 to 55.6)	0.1 (-1.7 to 2.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.6 (17.3 to 60.1)	-2.6 (-18.6 to 6.2)
Cysticercosis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-33.3 (-78.4 to 37.5)	-54.6 (-85.2 to -5.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.5 (-77.6 to 45.7)	-53.6 (-84.8 to -12.1)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.6 (-52.2 to -42.1)	-67.5 (-70.6 to -65.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.2 (-56.2 to -31.2)	-66.8 (-73.2 to -58.4)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	316.2 (282.4 to 358.5)	188.4 (165.0 to 217.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	311.5 (224.2 to 516.4)	186.3 (128.9 to 324.9)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.3 (-31.9 to 47.2)	-28.7 (-51.3 to 0.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.3 (-31.9 to 47.7)	28.7 (-51.4 to 0.8)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.1 (-11.5 to 152.6)	1.4 (-41.4 to 69.1)
Ascariasis	-	-	-	-	1.7 (-35.9 to 262.5)	0.0 (0.0 to 0.0)	-	-
Trichuriasis	-	-	-	-	60.0 (-37.7 to 329.3)	3.2 (-59.9 to 176.8)	-	-
Hookworm disease	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	56.1 (-28.9 to 248.6)	0.7 (-54.2 to 124.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.1 (-11.5 to 152.6)	1.4 (-41.4 to 69.1)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	0.6 (0.5 to 0.8)	0.8 (0.8 to 0.9)	29.2 (3.3 to 69.9)	-2.6 (-21.7 to 26.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.0 (9.4 to 92.4)	-2.6 (-14.7 to 48.2)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.9 (-0.4 to 48.6)	-1.0 (-19.1 to 18.8)
Maternal hemorrhage	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.8 (16.7 to 61.5)	8.1 (-8.1 to 30.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.1 (4.0 to 61.9)	8.3 (-18.1 to 28.6)
Maternal sepsis and other maternal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.5 (-6.0 to 72.8)	-16.5 (-41.7 to 4.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.7 (-13.8 to 48.5)	-20.3 (-38.8 to 0.9)
Maternal hypertensive disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.2 (10.0 to 31.9)	-2.5 (-11.1 to 5.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.2 (-12.3 to 64.2)	-2.2 (-28.2 to 33.3)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.0 (-34.5 to 89.1)	-0.5 (-44.9 to 55.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.0 (-34.6 to 89.2)	-0.5 (-44.9 to 55.1)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.6 (-12.0 to 134.7)	13.0 (-28.4 to 82.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.6 (-12.1 to 134.7)	13.0 (-28.4 to 82.3)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.5 (-22.1 to 99.5)	-0.2 (-37.0 to 58.6)
Neonatal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	82.8 (30.4 to 134.9)	28.6 (-8.0 to 64.5)
Preterm birth complications	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.5)	182.8 (135.2 to 237.7)	94.6 (62.0 to 132.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	171.2 (107.6 to 241.0)	88.3 (44.3 to 136.4)
Neonatal encephalopathy due to birth asphyxia and trauma	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.7)	26.6 (-9.3 to 64.7)	-12.5 (-36.6 to 13.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.3 (-29.7 to 113.2)	-11.4 (-49.5 to 51.2)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	179.9 (142.7 to 234.7)	124.7 (94.8 to 168.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	184.1 (132.3 to 245.2)	128.1 (86.5 to 177.1)
Hemolytic disease and other neonatal jaundice	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	34.3 (-57.6 to 320.6)	-6.9 (-70.3 to 192.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.7 (-58.0 to 347.3)	-6.1 (-70.6 to 208.7)
Other neonatal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	159.6 (31.8 to 394.7)	83.7 (-7.0 to 247.9)
Nutritional deficiencies	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.7)	32.0 (25.6 to 37.6)	-3.8 (-8.3 to 0.5)
Protein-energy malnutrition	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-7.2 (-58.6 to 105.6)	-26.1 (-66.8 to 61.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.3 (-59.4 to 110.4)	26.0 (-67.2 to 65.5)
Iodine deficiency	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-4.7 (-34.2 to 43.6)	-36.6 (-56.1 to -3.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.0 (-36.1 to 42.8)	-36.5 (-56.9 to -3.8)
Vitamin A deficiency	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.0 (-44.7 to -22.4)	-51.7 (-58.8 to -42.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.3 (-46.6 to -19.5)	-51.9 (-60.6 to -41.5)

Appendix Table G.4 - Antigua and Barbuda prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	11.5 (11.4 to 11.6)	15.9 (15.8 to 16.1)	38.5 (36.4 to 40.5)	2.4 (-3.9 to -0.9)	0.4 (0.2 to 0.5)	0.5 (0.3 to 0.7)	34.5 (30.7 to 36.9)	34.5 (-4.9 to -0.6)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.3 (-57.0 to 300.1)	14.7 (-65.3 to 213.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	30.7 (20.9 to 43.6)	-5.9 (-12.8 to 2.7)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.3 (18.3 to 48.9)	-9.1 (-18.3 to 0.9)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.1 (28.0 to 82.6)	-12.3 (-25.4 to 3.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.4 (6.5 to 115.8)	-13.0 (-37.7 to 24.7)
Chlamydial infection	1.8 (1.5 to 2.1)	2.4 (1.9 to 2.7)	29.0 (2.1 to 69.3)	-7.3 (-26.3 to 20.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.0 (8.4 to 59.0)	-8.0 (-22.5 to 11.7)
Gonococcal infection	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.3)	27.8 (-11.1 to 92.5)	-4.8 (-33.3 to 42.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.6 (-27.5 to 79.6)	-21.5 (-46.0 to 31.5)
Trichomoniasis	0.5 (0.4 to 0.7)	0.5 (0.4 to 0.7)	12.6 (-29.1 to 69.2)	-21.2 (-49.2 to 15.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.0 (-37.1 to 72.8)	-23.8 (-54.2 to 18.3)
Genital herpes	15.1 (14.4 to 15.8)	23.5 (21.9 to 24.7)	55.7 (42.8 to 67.1)	-4.9 (-12.8 to 2.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.4 (36.4 to 65.8)	-5.0 (-13.6 to 3.0)
Other sexually transmitted diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.6 (19.1 to 67.1)	0.0 (-27.5 to -0.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.8 (16.3 to 112.2)	2.4 (-23.4 to 39.7)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.7 (8.4 to 37.2)	-27.0 (-40.5 to -9.9)
Hepatitis A	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	28.3 (27.9 to 28.6)	-6.5 (-7.1 to -5.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.0 (21.5 to 52.9)	-4.5 (-14.7 to 6.8)
Hepatitis B	3.2 (2.4 to 3.7)	2.5 (1.9 to 3.0)	-22.5 (-46.2 to 7.2)	-49.5 (-65.1 to -30.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.0 (-46.1 to 35.2)	-47.5 (-67.7 to -16.1)
Hepatitis C	1.1 (0.9 to 1.2)	1.2 (1.1 to 1.3)	13.2 (-1.2 to 31.2)	-30.2 (-38.8 to -19.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.1 (-10.4 to 55.7)	-24.5 (-45.6 to 1.6)
Hepatitis E	-	-	25.8 (14.6 to 41.8)	-10.6 (-18.0 to -0.1)	-	-	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	0.5 (0.4 to 0.6)	0.6 (0.6 to 0.7)	31.3 (17.7 to 44.8)	-3.0 (-12.5 to 6.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.4 (16.7 to 55.8)	1.8 (-9.9 to 19.4)
Non-communicable diseases	-	-	-	-	4.9 (3.6 to 6.3)	7.9 (5.9 to 10.2)	62.2 (57.4 to 66.8)	2.5 (-0.6 to 5.3)
Neoplasms	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	87.1 (54.8 to 127.8)	21.9 (1.0 to 46.6)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.0 (-16.5 to 69.9)	-23.2 (-46.1 to 10.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.4 (-17.5 to 60.0)	-25.2 (-46.6 to 3.8)
Stomach cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.3 (-33.8 to 14.3)	-42.4 (-56.2 to -24.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.9 (-38.6 to 10.6)	-45.1 (-59.4 to -27.3)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	497.1 (269.5 to 599.5)	227.1 (138.5 to 349.6)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	584.0 (215.4 to 1,246.3)	320.8 (89.9 to 743.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	536.6 (212.6 to 1,024.0)	292.3 (191.9 to 599.3)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,749.2 (904.1 to 3,928.4)	1,096.0 (549.1 to 2,500.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,583.5 (923.6 to 3,148.5)	993.8 (573.8 to 2,010.7)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	145.4 (35.2 to 331.2)	62.1 (-10.8 to 183.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	125.9 (38.1 to 250.2)	49.6 (-7.9 to 128.9)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	136.4 (27.1 to 352.3)	46.8 (-22.1 to 190.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	120.5 (34.5 to 271.8)	37.0 (-16.9 to 135.8)
Larynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.9 (-64.9 to -34.2)	-70.1 (-77.7 to -58.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.9 (-55.8 to -8.6)	-60.3 (-72.4 to -42.4)
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.7 (3.1 to 85.7)	-12.5 (-34.4 to 16.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.0 (-2.2 to 80.1)	-16.9 (-38.4 to 12.9)
Breast cancer	0.4 (0.3 to 0.5)	0.2 (0.1 to 0.3)	-42.7 (-64.5 to -7.3)	-68.3 (-80.3 to -49.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.1 (-39.4 to 54.1)	-45.4 (-65.6 to -14.3)
Cervical cancer	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	3.8 (-34.0 to 69.6)	-41.4 (-63.0 to -5.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.3 (-34.7 to 66.3)	-42.1 (-63.1 to -8.0)
Uterine cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	142.5 (7.5 to 333.2)	42.7 (-37.0 to 151.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	130.7 (2.2 to 319.7)	37.3 (-39.1 to 150.0)
Prostate cancer	0.1 (0.1 to 0.2)	0.5 (0.3 to 0.8)	257.9 (133.7 to 436.3)	156.6 (68.1 to 278.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	198.8 (104.7 to 326.5)	116.6 (47.5 to 209.4)
Colon and rectum cancer	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.5)	97.0 (72.1 to 128.1)	30.0 (13.2 to 50.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	94.1 (69.1 to 124.8)	28.2 (11.3 to 47.8)
Lip and oral cavity cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.0)	43.1 (1.4 to 97.0)	-12.5 (-37.6 to 20.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.2 (-3.8 to 91.7)	-16.2 (-41.3 to 17.4)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.3 (-20.5 to 84.9)	-32.5 (-54.8 to 2.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.4 (-22.7 to 71.9)	-34.7 (-55.3 to -4.4)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.6 (8.5 to 119.9)	-22.8 (-48.2 to 23.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.1 (-10.0 to 110.5)	-23.7 (-48.7 to 17.8)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.3 (-72.1 to 34.9)	-68.9 (-81.6 to -8.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.7 (-72.5 to 38.0)	-68.9 (-81.8 to -8.2)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	521.6 (352.7 to 747.4)	307.8 (196.8 to 454.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	455.2 (306.6 to 640.9)	262.4 (164.0 to 385.4)
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.9 (-15.2 to 86.7)	-29.2 (-49.4 to 9.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.6 (-20.5 to 82.1)	-30.9 (-51.1 to 7.7)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	146.5 (78.5 to 251.6)	53.7 (11.5 to 120.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	188.0 (88.1 to 337.7)	84.5 (18.9 to 189.7)
Ovarian cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	418.5 (249.3 to 690.2)	224.4 (118.9 to 390.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	387.2 (203.4 to 683.0)	207.8 (92.5 to 390.4)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	473.1 (18.7 to 1,150.6)	267.4 (-22.9 to 686.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	434.9 (15.5 to 1,154.3)	239.5 (-26.5 to 688.7)
Kidney cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.4 (5.5 to 82.3)	-13.7 (-34.2 to 14.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.8 (-0.3 to 77.8)	-16.7 (-37.9 to 11.7)
Bladder cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	184.7 (89.1 to 325.6)	91.1 (26.2 to 182.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	198.2 (94.3 to 357.5)	100.6 (28.8 to 207.1)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	489.3 (81.7 to 799.1)	296.3 (20.7 to 485.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	474.4 (69.0 to 725.6)	276.8 (8.9 to 433.9)
Thyroid cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	147.8 (66.0 to 288.1)	42.2 (-3.7 to 119.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	139.5 (61.4 to 273.4)	38.4 (-5.6 to 111.3)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	160.8 (93.9 to 244.5)	75.3 (29.4 to 125.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	166.4 (103.1 to 245.3)	78.5 (35.6 to 130.3)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,012.6 (55.1 to 1,723.1)	670.1 (7.4 to 1,148.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	977.8 (41.3 to 1,625.1)	642.3 (4.4 to 1,071.1)
Non-Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	118.6 (49.2 to 208.1)	31.4 (-9.8 to 84.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.3 (42.7 to 186.7)	23.7 (-13.4 to 71.3)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	121.0 (33.9 to 255.6)	35.8 (-17.2 to 119.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.6 (22.6 to 253.3)	30.7 (-24.4 to 117.2)
Leukemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.0 (35.2 to 170.5)	28.3 (-6.3 to 80.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.5 (33.7 to 148.6)	18.7 (-11.8 to 61.4)
Other neoplasms	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	184.4 (110.7 to 305.1)	82.4 (38.8 to 152.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	167.9 (99.1 to 274.7)	71.3 (29.1 to 134.7)
Cardiovascular diseases	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	99.5 (66.6 to 137.8)	29.3 (8.5 to 54.7)
Rheumatic heart disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.8 (40.8 to 89.4)	-6.0 (-17.8 to 9.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.0 (41.2 to 95.6)	-5.9 (-17.7 to 13.1)
Ischemic heart disease	0.5 (0.4 to 0.5)	1.3 (1.1 to 1.6)	179.6 (114.8 to 259.5)	83.6 (40.6 to 139.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	220.2 (121.8 to 348.9)	110.7 (44.8 to 201.6)
Cerebrovascular disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.4 (20.4 to 94.5)	3.6 (-23.2 to 26.6)
Ischemic stroke	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	45.7 (15.8 to 91.8)	-3.6 (-24.1 to 28.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.3 (14.1 to 91.2)	-4.1 (-24.8 to 27.1)
Hemorrhagic stroke	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	61.1 (14.1 to 118.2)	-1.2 (-30.9 to 35.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.4 (12.4 to 122.9)	-0.7 (-32.8 to 39.1)
Hypertensive heart disease	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	35.6 (20.2 to 54.1)	-12.3 (-22.4 to -0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.4 (18.7 to 55.5)	-12.3 (-23.6 to 0.8)
Cardiomyopathy and myocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.7 (50.0 to 118.0)	10.1 (-8.2 to 35.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.5 (46.7 to 125.0)	10.0 (-10.3 to 38.4)
Atrial fibrillation and flutter	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.4)	77.0 (34.8 to 138.8)	20.5 (-8.0 to 64.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.5 (31.3 to 139.7)	20.8 (-10.2 to 64.9)
Peripheral vascular disease	1.9 (1.6 to 2.2)	3.3 (2.5 to 3.9)	75.3 (28.9 to 124.9)	-1.9 (-27.5 to 25.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.5 (-40.2 to 116.2)	-13.6 (-57.8 to 53.5)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.7 (1.1 to 67.0)	-18.6 (-36.5 to 6.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.1 (15.5 to 88.9)	-16.1 (-36.3 to 5.8)
Other cardiovascular and circulatory diseases	0.2 (0.1 to 0.4)	0.3 (0.3 to 0.4)	77.2 (6.6 to 256.0)	11.2 (-45.5 to 102.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.3 (-5.7 to 259.1)	2.0 (-4.5 to 104.5)
Chronic respiratory diseases	-	-	-	-	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.8)	65.3 (29.4 to 109.0)	1.1 (-21.1 to 27.3)
Chronic obstructive pulmonary disease	2.8 (2.6 to 2.9)	4.7 (4.5 to 4.9)	69.5 (64.2 to 75.3)	-0.4 (-3.6 to 2.9)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	87.0 (38.4 to 121.2)	10.2 (-18.3 to 30.6)

Appendix Table G.4 - Antigua and Barbuda prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	57.8	-3.5
Silicosis	0.0	0.0	44.3	-10.4	0.0	0.0	43.9	-10.7
Asbestosis	-	-	0.0	0.0	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	49.3	-	0.0	0.0	68.4	1.7
Asthma	3.8	5.8	49.5	-4.4	0.2	0.3	49.6	-4.5
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	65.4	4.9	0.0	0.0	65.8	5.1
Other chronic respiratory diseases	-	-	-	-	0.0	0.0	33.0	-21.4
Cirrhosis	-	-	-	-	0.0	0.0	69.4	-15.3
Cirrhosis due to hepatitis B	0.0	0.0	107.5	19.4	0.0	0.0	105.4	19.7
Cirrhosis due to hepatitis C	0.0	0.0	100.2	19.7	0.0	0.0	95.9	17.7
Cirrhosis due to alcohol use	0.0	0.0	24.3	-30.6	0.0	0.0	24.0	-30.9
Cirrhosis due to other causes	0.0	0.0	91.3	23.3	0.0	0.0	88.2	22.2
Digestive diseases	-	-	-	-	0.0	0.0	205.7	207.0
Peptic ulcer disease	0.6	0.4	-26.4	-52.3	0.0	0.0	-12.5	-45.5
Gastritis and duodenitis	1.3	1.9	53.8	3.6	0.0	0.1	48.3	-1.4
Appendicitis	0.0	0.0	30.4	-8.0	0.0	0.0	31.2	-8.1
Paralytic ileus and intestinal obstruction	0.0	0.0	50.4	7.6	0.0	0.0	50.1	7.2
Inguinal, femoral, and abdominal hernia	0.2	0.1	-27.5	-53.0	0.0	0.0	-26.8	-52.6
Inflammatory bowel disease	0.1	0.2	108.2	22.7	0.0	0.0	107.9	22.6
Vascular intestinal disorders	0.0	0.0	28.8	-14.6	0.0	0.0	28.8	-14.6
Gallbladder and biliary diseases	0.0	0.0	16.7	-30.2	0.0	0.0	16.3	-30.8
Pancreatitis	0.0	0.0	146.4	51.2	0.0	0.0	145.9	51.1
Other digestive diseases	-	-	-	-	0.0	0.0	641.8	365.6
Neurological disorders	-	-	-	-	0.4	0.7	63.3	6.1
Alzheimer disease and other dementias	0.5	0.7	43.5	1.3	0.1	0.1	40.9	1.3
Parkinson disease	0.0	0.0	44.3	-1.3	0.0	0.0	46.0	-1.1
Epilepsy	0.1	0.2	76.9	18.8	0.0	0.1	80.0	21.7
Multiple sclerosis	0.0	0.0	234.0	87.3	0.0	0.0	222.9	82.2
Migraine	6.3	9.6	54.3	1.2	0.3	0.5	48.3	-1.1
Tension-type headache	12.5	20.1	60.3	2.8	0.0	0.0	60.2	3.1
Medication overuse headache	0.3	0.6	132.1	38.1	0.0	0.1	132.1	38.3
Other neurological disorders	0.0	0.0	54.4	1.1	0.0	0.0	34.6	-5.7
Mental and substance use disorders	-	-	-	-	1.5	2.3	53.5	0.4
Schizophrenia	0.2	0.3	69.2	-0.5	0.1	0.2	69.0	-0.3
Alcohol use disorders	0.4	0.6	66.7	3.6	0.0	0.1	66.8	3.8
Drug use disorders	-	-	-	-	0.1	0.1	50.7	4.0
Opioid use disorders	0.0	0.1	91.2	2.9	0.0	0.0	88.6	3.3
Cocaine use disorders	0.1	0.2	64.2	12.4	0.0	0.0	64.0	13.1
Amphetamine use disorders	0.1	0.1	22.5	-4.4	0.0	0.0	22.5	-4.4
Cannabis use disorders	0.1	0.2	33.9	-0.5	0.0	0.0	34.3	-0.1
Other drug use disorders	-	-	-	-	0.0	0.0	42.7	4.9
Depressive disorders	-	-	-	-	0.6	0.9	54.7	0.0
Major depressive disorder	2.4	3.7	53.7	-0.1	0.5	0.8	53.1	-0.1
Dysthymia	0.8	1.3	65.1	0.3	0.1	0.1	65.1	0.3
Bipolar disorder	0.5	0.7	52.2	-0.0	0.1	0.1	51.9	0.1
Anxiety disorders	3.7	5.7	53.1	0.3	0.5	0.7	52.6	0.7
Eating disorders	-	-	-	-	0.2	0.0	27.4	2.3
Anorexia nervosa	0.0	0.0	38.1	6.7	0.0	0.0	38.3	6.9
Bulimia nervosa	0.1	0.1	25.1	1.4	0.0	0.0	25.3	1.4
Autistic spectrum disorders	-	-	-	-	0.1	0.1	48.8	-0.3
Autism	0.2	0.3	45.3	-0.3	0.0	0.1	45.0	-0.2
Asperger syndrome	0.3	0.4	44.7	-0.4	0.0	0.0	44.2	-0.5
Attention-deficit/hyperactivity disorder	0.4	0.6	32.7	0.5	0.0	0.0	32.8	0.6
Conduct disorder	0.6	0.8	40.0	0.6	0.0	0.0	40.2	0.7
Idiopathic intellectual disability	0.3	0.3	30.5	-10.1	0.0	0.0	30.1	-10.2
Other mental and substance use disorders	1.0	1.6	53.9	-0.7	0.1	0.1	53.5	-0.6
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	0.5	0.9	86.0	11.7
Diabetes mellitus	3.0	6.8	123.7	24.1	0.2	0.5	121.0	21.3
Acute glomerulonephritis	0.0	0.0	41.9	3.9	0.0	0.0	41.9	3.9
Chronic kidney disease	1.7	2.8	63.0	-3.5	0.0	0.0	62.3	-4.6
Chronic kidney disease due to diabetes mellitus	1.0	1.6	68.2	9.2	0.0	0.0	67.0	0.4
Chronic kidney disease due to hypertension	0.7	1.2	56.3	-12.3	0.0	0.0	55.3	-14.1
Chronic kidney disease due to glomerulonephritis	2.3	3.6	56.3	0.0	0.0	0.0	56.3	0.0
Chronic kidney disease due to other causes	2.1	3.3	54.4	0.7	0.0	0.0	53.8	0.8
Urinary diseases and male infertility	-	-	-	-	0.0	0.0	46.4	0.6

Appendix Table G.4 - Antigua and Barbuda prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.4 (79.6 to 121.3)	0.0 (21.1 to 46.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.4 (61.1 to 142.3)	32.8 (9.4 to 60.1)
Urolithiasis	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.1)	67.1 (39.4 to 99.0)	3.6 (-17.2 to 25.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.4 (44.5 to 100.1)	5.5 (-12.9 to 26.2)
Benign prostatic hyperplasia	0.4 (0.4 to 0.5)	0.6 (0.6 to 0.7)	45.2 (31.3 to 64.9)	2.8 (-7.0 to 16.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.6 (30.9 to 66.1)	2.9 (-7.4 to 16.6)
Male infertility due to other causes	0.5 (0.4 to 0.6)	0.7 (0.5 to 0.8)	31.4 (5.2 to 84.1)	-3.7 (-30.1 to 34.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.5 (6.7 to 83.6)	-3.6 (-30.1 to 36.6)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Gynecological diseases	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	68.8 (46.5 to 92.0)	4.7 (-9.0 to 19.4)
Uterine fibroids	1.1 (1.0 to 1.2)	2.5 (2.3 to 2.7)	128.4 (122.8 to 135.0)	6.1 (6.0 to 6.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	93.3 (73.4 to 114.6)	3.8 (-5.6 to 14.2)
Polycystic ovarian syndrome	1.2 (1.1 to 1.4)	2.1 (1.9 to 2.3)	69.6 (45.1 to 102.6)	4.1 (-9.8 to 23.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.7 (44.7 to 101.8)	4.3 (-9.6 to 24.0)
Female infertility due to other causes	0.5 (0.2 to 0.7)	0.8 (0.4 to 1.3)	68.5 (-16.5 to 236.7)	9.9 (-45.0 to 120.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.7 (-17.8 to 235.4)	10.6 (-43.5 to 119.7)
Endometriosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	80.7 (45.8 to 125.8)	10.3 (-10.5 to 38.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.7 (43.3 to 127.4)	10.9 (-12.1 to 39.2)
Genital prolapse	3.3 (2.7 to 3.9)	6.1 (5.1 to 7.0)	82.6 (44.1 to 134.9)	3.0 (-16.7 to 29.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.4 (44.5 to 136.1)	3.2 (-16.7 to 29.9)
Premenstrual syndrome	3.2 (2.4 to 4.1)	4.7 (3.5 to 5.9)	50.7 (-1.6 to 107.4)	5.6 (-31.8 to 49.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.3 (-2.7 to 107.3)	5.2 (-3.2 to 50.6)
Other gynecological diseases	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.3)	55.3 (25.6 to 98.9)	1.1 (-17.5 to 26.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.9 (22.1 to 144.3)	1.7 (-17.6 to 59.9)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	49.6 (32.6 to 54.4)	0.8 (-4.7 to 10.3)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.5 (4.6 to 39.1)	2.2 (-16.1 to 11.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.5 (0.0 to 38.0)	-0.9 (-19.6 to 11.5)
Thalassemia trait	0.6 (0.3 to 1.0)	0.8 (0.5 to 1.5)	46.4 (36.2 to 54.3)	-0.3 (-6.9 to 4.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.3 (26.5 to 62.2)	0.3 (-12.4 to 11.7)
Sickle cell disorders	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	49.8 (33.4 to 82.1)	8.8 (-3.1 to 30.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.2 (31.5 to 79.2)	9.5 (-6.2 to 26.6)
Sickle cell trait	5.1 (4.5 to 5.6)	7.7 (6.9 to 8.4)	52.8 (47.6 to 59.3)	4.0 (0.4 to 8.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	44.7 (29.5 to 74.7)	4.2 (-6.6 to 26.7)
G6PD deficiency	2.5 (2.0 to 3.1)	3.8 (2.9 to 4.7)	49.5 (6.6 to 109.9)	1.9 (-27.4 to 43.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.9 (19.0 to 89.6)	4.6 (-16.5 to 32.0)
G6PD trait	9.8 (9.2 to 10.5)	14.8 (13.8 to 15.8)	51.2 (38.1 to 65.1)	2.5 (-6.4 to 11.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.4 (-70.9 to 756.3)	2.3 (-78.2 to 462.0)
Other hemoglobinopathies and hemolytic anemias	0.5 (0.4 to 0.5)	0.7 (0.6 to 0.7)	36.8 (23.0 to 51.0)	-4.1 (-13.6 to 5.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.2 (4.2 to 41.5)	-8.3 (-21.9 to 5.5)
Endocrine, metabolic, blood, and immune disorders	0.5 (0.5 to 0.6)	0.7 (0.7 to 0.8)	39.5 (24.8 to 57.4)	0.7 (-11.3 to 10.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.2 (12.5 to 67.6)	-2.7 (-17.7 to 21.7)
Musculoskeletal disorders	-	-	-	-	0.8 (0.6 to 1.1)	1.4 (1.0 to 1.8)	74.0 (61.0 to 88.5)	3.1 (-3.8 to 10.5)
Rheumatoid arthritis	0.1 (0.1 to 0.2)	0.3 (0.3 to 0.3)	111.8 (98.6 to 127.0)	33.6 (24.9 to 43.7)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	110.9 (95.4 to 130.1)	32.9 (22.8 to 44.8)
Osteoarthritis	2.2 (2.1 to 2.2)	3.7 (3.6 to 3.9)	72.9 (63.3 to 82.2)	1.4 (-4.3 to 6.9)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	73.9 (64.1 to 83.9)	1.2 (-4.5 to 6.9)
Low back and neck pain	-	-	-	-	0.5 (0.3 to 0.7)	0.8 (0.5 to 1.1)	69.9 (45.3 to 86.7)	-0.8 (-11.4 to 12.0)
Low back pain	2.7 (2.4 to 3.0)	4.3 (3.9 to 4.8)	58.7 (38.1 to 90.0)	-2.6 (-15.1 to 16.2)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	58.6 (37.7 to 90.6)	-2.6 (-15.0 to 16.6)
Neck pain	1.9 (1.6 to 2.1)	3.3 (2.8 to 3.7)	72.4 (40.5 to 108.8)	1.8 (-17.2 to 22.7)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	72.2 (40.3 to 109.3)	1.7 (-17.0 to 22.8)
Gout	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.1 (46.0 to 88.7)	-3.8 (-15.1 to 9.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.1 (31.2 to 112.4)	-2.6 (-24.5 to 20.2)
Other musculoskeletal disorders	1.6 (1.3 to 1.9)	3.2 (2.6 to 3.8)	98.8 (80.3 to 117.3)	10.2 (1.6 to 18.6)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	99.3 (79.7 to 118.2)	18.2 (1.0 to 18.5)
Other non-communicable diseases	-	-	-	-	1.1 (0.7 to 1.6)	1.6 (1.1 to 2.3)	47.4 (42.2 to 53.2)	-5.3 (-8.0 to -1.9)
Congenital anomalies	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	74.8 (54.8 to 103.9)	17.9 (3.9 to 37.2)
Neural tube defects	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.9 (3.3 to 56.1)	-7.1 (-26.2 to 11.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.8 (-3.8 to 76.0)	-5.4 (-30.4 to 25.8)
Congenital heart anomalies	0.3 (0.3 to 0.4)	0.5 (0.5 to 0.6)	64.9 (27.8 to 106.7)	14.7 (-11.2 to 44.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.7 (32.9 to 111.0)	17.3 (-7.6 to 46.8)
Orofacial clefts	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	49.3 (16.0 to 85.5)	5.8 (-17.6 to 31.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.8 (-4.7 to 87.2)	5.7 (-31.7 to 31.7)
Down syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	59.0 (22.3 to 124.9)	6.0 (-18.8 to 50.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.2 (28.6 to 142.4)	9.3 (-17.4 to 56.8)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.0 (0.4 to 116.6)	2.6 (-30.6 to 50.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.2 (-3.8 to 117.9)	2.4 (-33.1 to 51.2)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.7 (-10.4 to 114.5)	-1.0 (-38.6 to 46.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.7 (-12.3 to 110.6)	-3.0 (-40.1 to 43.8)
Chromosomal unbalanced rearrangements	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	61.5 (27.3 to 105.0)	1.5 (-15.4 to 37.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.6 (33.0 to 124.8)	12.4 (-14.3 to 43.7)
Other congenital anomalies	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.4)	32.1 (21.8 to 44.6)	-1.8 (-18.5 to -4.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	90.7 (53.6 to 159.2)	29.1 (-3.8 to 73.7)
Skin and subcutaneous diseases	-	-	-	-	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.7)	46.6 (33.5 to 60.2)	-1.3 (-9.6 to 7.9)
Dermatitis	3.0 (2.4 to 3.5)	4.5 (3.7 to 5.4)	54.3 (48.1 to 60.1)	-0.1 (-0.2 to 0.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	50.9 (45.1 to 56.6)	0.1 (-2.6 to 2.7)
Psoriasis	0.0 (0.4 to 0.6)	0.0 (0.7 to 0.9)	57.7 (52.6 to 64.7)	0.0 (-0.1 to 0.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	57.5 (47.7 to 68.8)	0.1 (-4.5 to 5.1)
Cellulitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.7 (14.9 to 49.9)	-14.6 (-24.9 to -5.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.1 (8.6 to 58.7)	-14.6 (-29.0 to 1.0)
Pyoderma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.3 (69.0 to 91.5)	22.4 (16.9 to 28.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.0 (55.2 to 107.6)	22.9 (7.5 to 38.7)
Scabies	0.8 (0.7 to 0.9)	1.1 (0.9 to 1.3)	41.4 (16.5 to 79.1)	-1.9 (-19.5 to 23.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.1 (15.2 to 77.7)	-2.1 (-19.9 to 22.1)
Fungal skin diseases	4.6 (3.5 to 6.0)	7.1 (5.5 to 9.3)	55.2 (50.2 to 61.3)	0.2 (-0.3 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.8 (49.8 to 61.3)	-0.2 (-1.0 to 0.7)
Viral skin diseases	1.2 (0.9 to 1.6)	1.7 (1.2 to 2.1)	34.2 (27.5 to 45.5)	-0.0 (-1.8 to 2.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	33.9 (26.4 to 45.7)	0.0 (-3.1 to 3.2)
Acne vulgaris	4.5 (3.2 to 5.7)	5.8 (3.6 to 7.4)	29.9 (-17.4 to 86.5)	-1.9 (-36.9 to 40.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	29.6 (-18.3 to 87.5)	-2.0 (-37.1 to 40.5)
Alopecia areata	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	54.1 (34.8 to 76.0)	-1.7 (-14.3 to 12.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.4 (29.6 to 80.8)	-1.4 (-16.8 to 14.7)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.5 (24.1 to 104.0)	1.5 (-24.0 to 29.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.5 (24.0 to 104.4)	1.5 (-24.1 to 29.7)
Urticaria	0.7 (0.5 to 0.9)	1.0 (0.6 to 1.4)	52.3 (-15.7 to 135.9)	-2.8 (-46.9 to 54.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	51.9 (-16.1 to 133.1)	-3.2 (-46.7 to 54.0)
Decubitus ulcer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.2 (8.6 to 44.8)	-26.8 (-42.7 to -6.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.3 (-14.0 to 55.4)	-26.9 (-45.2 to -0.4)
Other skin and subcutaneous diseases	3.8 (2.4 to 6.2)	6.2 (4.0 to 9.6)	62.5 (41.1 to 90.4)	-1.1 (-6.4 to 3.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	62.3 (41.2 to 89.8)	-1.2 (-6.2 to 3.2)
Sense organ diseases	-	-	-	-	0.5 (0.3 to 0.7)	0.7 (0.5 to 1.0)	40.9 (32.4 to 48.4)	-10.8 (-14.3 to -7.0)
Glaucoma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	28.6 (12.4 to 44.9)	-18.1 (-27.2 to -6.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.1 (10.0 to 52.3)	-15.9 (-28.1 to 0.2)
Cataract	0.6 (0.4 to 0.7)	0.6 (0.4 to 0.7)	4.4 (-9.4 to 18.3)	-28.6 (-37.0 to -20.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.7 (-5.7 to 17.3)	-27.8 (-35.2 to -20.7)
Macular degeneration	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	92.7 (55.5 to 153.9)	11.7 (-10.3 to 42.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.6 (52.2 to 149.0)	10.5 (-12.6 to 39.4)
Uncorrected refractive error	5.9 (5.6 to 6.2)	9.4 (8.8 to 9.9)	58.6 (45.1 to 72.2)	4.7 (-22.3 to 3.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	44.6 (33.3 to 55.9)	-10.5 (-16.6 to -4.3)
Age-related and other hearing loss	9.5 (8.9 to 10.0)	14.1 (13.1 to 15.1)	48.4 (43.2 to 55.6)	-9.5 (-12.2 to -6.0)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	43.8 (32.0 to 53.5)	-9.6 (-14.6 to -3.8)
Other vision loss	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.3)	5.2 (-4.4 to 17.1)	-31.5 (-36.9 to -24.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.7 (-0.4 to 25.3)	-28.6 (-34.9 to -21.0)
Other sense organ diseases	1.4 (1.3 to 1.5)	2.0 (1.9 to 2.1)	43.7 (34.6 to 53.1)	-0.6 (-6.8 to 5.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	43.4 (32.8 to 53.6)	-0.7 (-7.4 to 6.2)
Oral disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	54.3 (48.5 to 59.8)	-4.2 (-7.3 to -1.0)
Deciduous caries	2.8 (2.7 to 2.9)	3.3 (3.2 to 3.4)	19.5 (13.9 to 25.4)	0.5 (-4.1 to 5.5)	0.0 (0.0 to 0.0)</			

Appendix Table G.4 - Antigua and Barbuda prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	4.2 (4.0 to 4.3)	6.2 (6.0 to 6.4)	48.1 (40.3 to 55.8)	-4.2 (-11.0 to -1.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	48.5 (40.4 to 56.6)	-6.4 (-11.4 to -1.3)
Other oral disorders	1.1 (1.0 to 1.1)	1.6 (1.5 to 1.7)	54.0 (42.4 to 65.6)	-0.8 (-8.0 to 6.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	53.5 (41.2 to 66.1)	-0.9 (-8.2 to 6.8)
Injuries	-	-	-	-	0.3 (0.3 to 0.4)	0.4 (0.3 to 0.5)	16.1 (4.8 to 28.7)	28.1 (-34.8 to -20.4)
Transport injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	18.3 (3.8 to 36.3)	-27.6 (-36.3 to -17.1)
Road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	14.0 (-0.1 to 31.6)	-30.1 (-38.6 to -19.8)
Pedestrian road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.4 (-13.3 to 17.2)	-37.1 (-45.4 to -27.3)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.1 (11.9 to 40.3)	-22.3 (-30.5 to -12.9)
Motorcyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.2 (9.0 to 21.6)	-37.0 (-45.1 to -27.3)
Motor vehicle road injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	22.3 (5.9 to 43.0)	-25.5 (-35.3 to -13.0)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.6 (-11.3 to 16.2)	-38.1 (-46.0 to -29.5)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.9 (62.1 to 107.0)	9.3 (-3.0 to 23.8)
Unintentional injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	15.2 (5.7 to 25.7)	-27.7 (-33.7 to -21.1)
Falls	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	9.9 (-2.8 to 24.6)	-30.9 (-38.8 to -21.7)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.6 (-16.7 to 11.5)	-39.6 (-47.6 to -30.6)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.0 (-24.3 to 0.7)	-44.2 (-51.7 to -36.5)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.3 (-10.5 to 22.0)	-32.4 (-41.7 to -21.5)
Exposure to mechanical forces	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	6.1 (-1.4 to 14.7)	-32.6 (-37.2 to -27.6)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.9 (53.8 to 98.2)	6.9 (-5.0 to 21.1)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.7 (37.0 to 73.9)	-3.4 (-13.5 to 9.0)
Other exposure to mechanical forces	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	0.8 (-6.4 to 9.0)	-35.8 (-40.2 to -31.0)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.8 (85.9 to 109.5)	23.0 (15.6 to 30.8)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.7 (64.7 to 99.3)	14.2 (3.8 to 24.5)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.0 (64.9 to 110.1)	16.1 (3.6 to 29.3)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.1 (60.0 to 97.7)	12.7 (1.5 to 24.4)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.5 (8.1 to 33.2)	-22.8 (-30.3 to -15.3)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.7 (-21.8 to 9.0)	-39.1 (-48.2 to -28.7)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.4 (21.6 to 58.7)	-10.9 (-22.1 to 1.9)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.2 (20.7 to 48.1)	-15.1 (-22.9 to -7.0)
Other unintentional injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	65.5 (53.3 to 78.8)	-1.7 (-9.1 to 6.1)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.6 (4.4 to 36.1)	-29.2 (-37.4 to -19.1)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.0 (-4.2 to 19.7)	-36.8 (-43.3 to -29.3)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.3 (5.6 to 40.8)	-27.3 (-36.5 to -16.1)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.9 (50.6 to 85.6)	-0.2 (-9.9 to 9.6)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.3 (9.7 to 51.6)	-23.5 (-34.2 to -9.8)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.5 (-19.3 to 11.7)	-42.9 (-51.3 to -32.9)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.5 (-33.2 to 22.5)	-43.4 (-58.7 to -24.2)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.5 (-33.2 to 22.5)	-43.4 (-58.7 to -24.2)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Argentina prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	3,188.8 (2,372.5 to 4,117.6)	4,312.3 (3,212.0 to 5,546.7)	35.3 (31.8 to 38.5)	35.3 (4.1 to 0.9)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	256.7 (178.0 to 355.7)	305.6 (219.5 to 417.5)	18.8 (8.8 to 33.2)	-0.7 (-9.0 to 11.0)
HIV/AIDS and tuberculosis	-	-	-	-	7.5 (5.0 to 10.5)	13.7 (9.3 to 19.0)	82.8 (46.2 to 124.4)	33.6 (6.9 to 64.4)
Tuberculosis	15.5 (14.9 to 16.2)	18.2 (17.5 to 19.0)	17.2 (12.8 to 22.0)	-14.1 (-17.5 to -10.7)	4.8 (3.2 to 6.5)	5.6 (3.8 to 7.6)	17.2 (3.5 to 33.5)	-13.9 (-23.7 to -2.0)
HIV/AIDS	-	-	-	-	2.3 (1.2 to 4.8)	8.1 (5.1 to 12.2)	199.0 (87.5 to 420.0)	115.9 (35.7 to 278.4)
HIV/AIDS resulting in mycobacterial infection	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	56.2 (-4.1 to 164.6)	11.7 (-31.3 to 89.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	56.2 (-4.2 to 165.2)	11.7 (-31.5 to 90.0)
HIV/AIDS resulting in other diseases	21.6 (12.3 to 31.0)	86.1 (71.9 to 102.0)	300.7 (188.3 to 536.4)	191.3 (109.9 to 364.0)	2.7 (1.2 to 4.8)	8.1 (5.1 to 12.2)	199.3 (87.5 to 426.0)	116.9 (35.7 to 283.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	28.2 (19.2 to 39.9)	28.1 (18.9 to 40.6)	-0.3 (-6.1 to 5.5)	-20.2 (-25.0 to -15.2)
Diarrheal diseases	6.8 (6.1 to 7.5)	7.6 (6.8 to 8.4)	12.2 (-3.6 to 28.6)	-9.8 (-22.4 to 3.3)	1.1 (0.7 to 1.6)	1.2 (0.8 to 1.7)	11.2 (9.5 to 35.3)	-10.0 (-26.4 to 10.1)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (45.2 to 14.9)	-25.6 (-55.0 to -5.5)
Typhoid fever	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-25.6 (-42.6 to -8.2)	-39.3 (-53.1 to -24.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-42.6 to -8.1)	-39.3 (-53.1 to -24.5)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.9 (-11.2 to 56.6)	-3.0 (-26.5 to 28.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.9 (-11.6 to 56.7)	-3.0 (-26.5 to 28.9)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.4 (-80.3 to 139.6)	-42.3 (-84.2 to 96.6)
Lower respiratory infections	79.2 (75.8 to 82.3)	76.1 (71.3 to 80.6)	-4.0 (-11.9 to 3.5)	-26.4 (-32.1 to -20.6)	8.2 (5.5 to 11.4)	7.7 (5.3 to 10.7)	-5.4 (-14.4 to 3.6)	-25.3 (-32.8 to -19.4)
Upper respiratory infections	527.1 (502.0 to 549.6)	650.0 (622.1 to 679.2)	22.9 (16.0 to 31.4)	-0.8 (-6.3 to 6.1)	6.2 (3.5 to 10.3)	7.6 (4.3 to 12.6)	22.8 (15.2 to 31.8)	-0.6 (-6.9 to 6.8)
Otitis media	392.3 (368.1 to 417.4)	412.4 (388.1 to 442.1)	4.8 (-2.7 to 13.6)	-14.0 (-20.3 to -6.8)	7.0 (4.1 to 11.4)	7.4 (4.3 to 12.1)	4.7 (-3.3 to 14.5)	-14.1 (-20.6 to -6.1)
Meningitis	-	-	-	-	2.7 (2.5 to 5.2)	2.2 (1.5 to 3.1)	-39.6 (-53.0 to -27.8)	-52.3 (-62.7 to -42.7)
Pneumococcal meningitis	13.8 (8.6 to 22.0)	8.1 (5.1 to 13.1)	-41.3 (-52.1 to -28.2)	-55.3 (-63.4 to -45.2)	1.4 (0.9 to 1.9)	0.8 (0.5 to 1.2)	-39.1 (-58.4 to -19.3)	-52.1 (-67.2 to -36.7)
H influenzae type B meningitis	5.4 (2.0 to 11.1)	2.7 (1.0 to 5.9)	-49.6 (-67.6 to -22.9)	-60.4 (-74.1 to -39.2)	0.7 (0.4 to 1.1)	0.4 (0.2 to 0.6)	-46.4 (-68.7 to 9.3)	-56.5 (-74.6 to -11.5)
Meningococcal meningitis	5.9 (2.0 to 14.1)	3.3 (1.1 to 8.3)	-44.8 (-62.6 to -8.9)	-57.8 (-70.7 to -27.0)	0.8 (0.4 to 1.3)	0.5 (0.2 to 0.8)	-43.2 (-61.5 to -1.4)	-55.6 (-69.6 to -23.4)
Other meningitis	6.9 (3.3 to 13.3)	4.3 (2.2 to 8.5)	-37.8 (-50.6 to -20.9)	-51.9 (-61.8 to -37.4)	0.9 (0.6 to 1.3)	0.6 (0.4 to 0.9)	-33.8 (-55.9 to -7.6)	-48.0 (-65.2 to -26.7)
Encephalitis	1.4 (1.4 to 7.8)	2.2 (1.5 to 8.6)	4.2 (-16.8 to 28.5)	-22.2 (-37.2 to -2.3)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	11.7 (-10.1 to 44.0)	-15.0 (-31.4 to 9.4)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.2 (-94.2 to 306.0)	-57.4 (-94.7 to 253.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.2 (-94.3 to 306.2)	-57.4 (-95.1 to 254.5)
Whooping cough	12.1 (9.5 to 15.5)	4.5 (3.5 to 5.8)	-62.7 (-65.0 to -60.3)	-63.0 (-65.3 to -60.6)	0.6 (0.3 to 1.0)	0.2 (0.1 to 0.4)	-62.8 (-68.8 to -56.4)	-63.2 (-69.1 to -56.8)
Tetanus	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-57.7 (-78.5 to -8.3)	-66.0 (-82.7 to -26.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.9 (-79.1 to 4.6)	-64.7 (-82.9 to -14.6)
Measles	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -95.9)	-100.0 (-100.0 to -96.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -95.9)	-100.0 (-100.0 to -96.0)
Varicella and herpes zoster	28.5 (26.1 to 31.5)	34.7 (31.4 to 38.3)	21.8 (6.3 to 37.7)	0.5 (-12.1 to 14.3)	0.9 (0.5 to 1.4)	1.2 (0.7 to 1.9)	35.8 (7.3 to 71.2)	1.1 (-20.3 to 27.7)
Neglected tropical diseases and malaria	-	-	-	-	50.1 (33.6 to 72.5)	45.4 (30.8 to 62.4)	-8.6 (-23.5 to 5.0)	-27.2 (-38.7 to -17.9)
Malaria	3.3 (3.3 to 3.4)	4.1 (4.0 to 4.3)	23.8 (18.9 to 28.6)	0.5 (-3.4 to 4.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-16.5 (-46.8 to 20.0)	-31.8 (-55.9 to -2.7)
Chagas disease	1,628.8 (1,552.5 to 1,705.7)	1,906.3 (1,797.1 to 2,021.3)	16.6 (8.1 to 26.4)	-13.1 (-19.5 to -5.7)	17.8 (11.9 to 25.2)	22.4 (14.9 to 31.3)	24.7 (14.7 to 38.9)	-13.9 (-21.4 to -5.0)
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (17.8 to 35.0)	0.7 (-6.4 to 7.2)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.6 (2.5 to 112.2)	19.4 (-15.1 to 77.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.6 (2.4 to 112.5)	19.4 (-15.2 to 78.4)
Cutaneous and mucocutaneous leishmaniasis	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.4)	25.7 (16.7 to 34.2)	-0.5 (-7.5 to 6.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.7 (16.7 to 34.2)	-0.5 (-7.6 to 6.0)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	1.3 (0.5 to 2.4)	0.5 (0.3 to 0.9)	-59.0 (-81.1 to -4.0)	-70.7 (-86.4 to -31.2)	0.5 (0.2 to 0.9)	0.2 (0.1 to 0.4)	-53.6 (-78.3 to 12.5)	-66.8 (-84.5 to -18.7)
Cystic echinococcosis	18.4 (16.9 to 19.1)	14.0 (13.2 to 14.6)	-23.9 (-28.6 to -14.2)	-43.9 (-47.0 to -37.5)	1.7 (1.2 to 2.4)	1.3 (0.9 to 1.8)	-24.2 (-33.7 to -12.6)	-43.7 (-50.8 to -35.6)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	1.5 (0.4 to 3.8)	9.0 (2.8 to 23.5)	519.0 (511.4 to 527.7)	389.6 (383.6 to 396.5)	0.3 (0.1 to 0.7)	1.5 (0.4 to 4.0)	483.5 (402.0 to 581.9)	362.3 (299.8 to 442.6)
Yellow fever	0.3 (0.1 to 0.7)	0.1 (0.0 to 0.3)	-67.8 (-84.6 to -28.3)	-74.5 (-87.8 to -43.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.8 (-84.7 to -27.6)	-74.5 (-87.8 to -42.6)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.7 (-42.0 to 3.0)	-34.4 (-53.9 to -18.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.7 (-42.0 to 3.0)	-34.4 (-53.9 to -18.3)
Intestinal nematode infections	-	-	-	-	22.8 (13.2 to 38.7)	12.8 (7.8 to 19.7)	-42.7 (-60.8 to -25.8)	-49.9 (-65.9 to -35.3)
Ascariasis	3,842.7 (3,312.7 to 4,460.0)	3,158.3 (2,647.1 to 3,760.0)	-17.8 (-35.5 to 2.9)	-35.6 (-49.4 to -19.2)	11.5 (5.8 to 22.0)	0.6 (0.2 to 1.5)	-95.1 (-97.8 to -88.3)	-95.8 (-98.1 to -89.9)
Trichuriasis	1,247.3 (1,034.7 to 1,496.0)	975.2 (792.4 to 1,186.6)	-22.0 (-39.7 to 1.9)	-39.1 (-52.9 to -19.8)	0.4 (0.2 to 1.1)	0.0 (0.0 to 0.0)	-98.9 (-99.7 to -96.1)	-99.0 (-99.2 to -96.7)
Hookworm disease	1,291.2 (1,089.9 to 1,422.4)	1,468.3 (1,255.4 to 1,727.9)	18.1 (-5.0 to 45.4)	10.8 (-26.8 to 12.0)	10.8 (6.6 to 16.5)	12.3 (7.3 to 18.7)	13.3 (-21.8 to 48.3)	-2.2 (-32.6 to 27.3)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	205.3 (145.8 to 268.6)	210.7 (174.0 to 245.3)	2.5 (-20.4 to 45.4)	-2.1 (-23.6 to 38.0)	7.0 (3.9 to 10.3)	7.0 (4.4 to 10.3)	-0.6 (-26.3 to 67.7)	-2.1 (-27.5 to 65.1)
Maternal disorders	-	-	-	-	0.9 (0.5 to 1.4)	1.6 (0.6 to 1.6)	11.2 (-16.4 to 36.1)	-19.9 (-39.5 to -1.8)
Maternal hemorrhage	11.8 (10.8 to 12.9)	14.9 (10.9 to 18.5)	26.9 (-10.5 to 59.3)	-9.0 (-35.7 to 14.3)	0.4 (0.2 to 0.5)	0.4 (0.2 to 0.7)	23.2 (-38.0 to 70.6)	-11.2 (-55.0 to 22.9)
Maternal sepsis and other maternal infections	3.7 (1.2 to 6.9)	3.2 (1.0 to 5.6)	-12.6 (-76.4 to 148.2)	-38.6 (83.4 to 77.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-16.3 (-52.6 to 49.2)	-38.7 (-65.3 to 9.5)
Maternal hypertensive disorders	6.9 (3.1 to 11.9)	7.1 (3.3 to 12.3)	1.7 (-4.9 to 14.4)	-26.5 (-32.2 to -18.0)	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.7)	3.0 (-18.0 to 27.0)	-25.8 (-40.8 to -8.6)
Obstructed labor	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	5.0 (-51.2 to 87.7)	-24.0 (-64.4 to 35.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	5.0 (-51.2 to 87.9)	-24.0 (-64.5 to 36.0)
Complications of abortion	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-1.9 (-37.0 to 36.3)	-28.5 (-54.0 to -0.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.9 (-37.0 to 36.4)	-28.5 (-54.1 to -0.5)
Other maternal disorders	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	20.4 (-24.2 to 85.8)	-12.9 (-45.2 to 33.5)
Neonatal disorders	-	-	-	-	47.3 (30.8 to 72.3)	81.5 (50.9 to 118.5)	73.2 (15.4 to 150.5)	41.9 (-5.7 to 105.2)
Preterm birth complications	136.9 (101.4 to 182.7)	361.2 (272.6 to 479.7)	163.3 (112.1 to 226.2)	111.7 (70.5 to 162.3)	15.5 (10.7 to 21.4)	37.4 (25.2 to 50.4)	142.0 (81.7 to 214.2)	96.2 (47.8 to 155.6)
Neonatal encephalopathy due to birth asphyxia and trauma	72.4 (38.8 to 137.0)	73.4 (40.1 to 137.3)	1.9 (-35.7 to 64.7)	-16.6 (-47.0 to 35.1)	12.6 (8.4 to 18.6)	13.5 (8.9 to 19.7)	6.7 (-30.8 to 63.5)	-11.4 (-42.3 to 35.9)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	59.0 (25.7 to 103.0)	9.0 (-27.9 to 106.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	61.7 (-20.3 to 105.9)	58.5 (-22.3 to 109.4)
Hemolytic disease and other neonatal jaundice	44.0 (16.3 to 104.4)	64.5 (21.5 to 137.3)	44.2 (-52.6 to 372.0)	19.4 (-60.9 to 289.9)	14.1 (5.8 to 31.1)	19.8 (7.2 to 39.2)	38.1 (-47.0 to 262.6)	12.6 (-56.9 to 197.3)
Other neonatal disorders	-	-	-	-	5.1 (2.7 to 9.1)	10.9 (5.8 to 18.1)	112.2 (17.9 to 291.7)	73.7 (-3.4 to 220.9)
Nutritional deficiencies	-	-	-	-	111.0 (73.0 to 163.6)	122.5 (80.4 to 178.3)	10.4 (-6.8 to 14.1)	-2.5 (-5.3 to 0.9)
Protein-energy malnutrition	5.2 (3.0 to 7.9)	4.0 (2.3 to 6.3)	-24.1 (-38.0 to -1.0)	50.1 (-58.7 to -34.3)	0.5 (0.3 to 1.0)	0.5 (0.2 to 0.8)	0.5 (-4.0 to -1.3)	51.0 (-6.1 to -34.2)
Iodine deficiency	82.1 (68.4 to 96.3)	72.7 (57.4 to 89.2)	-11.7 (-33.7 to 17.1)	34.5 (-50.7 to -13.3)	1.5 (0.9 to 2.3)	1.3 (0.7 to 2.1)	-11.1 (-33.6 to 19.2)	-33.9 (-50.7 to -11.5)
Vitamin A deficiency	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-

Appendix Table G.4 - Argentina prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	3,536.3 (3,472.2 to 3,601.6)	4,068.7 (4,004.9 to 4,136.3)	14.9 (12.1 to 17.9)	2.5 (-4.9 to 0.1)	108.9 (72.0 to 160.0)	120.7 (79.3 to 176.1)	10.8 (7.2 to 14.7)	10.8 (4.8 to 1.9)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	5.5 (-30.6 to 52.3)	5.5 (-53.6 to 0.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	11.7 (7.4 to 17.9)	13.4 (8.3 to 21.1)	14.6 (-2.1 to 38.0)	-5.9 (20.0 to 11.9)
Sexually transmitted diseases excluding HIV	-	-	-	-	5.5 (3.2 to 9.0)	7.1 (4.0 to 12.7)	29.9 (10.4 to 67.8)	-5.2 (-26.8 to 21.6)
Syphilis	2.3 (2.0 to 2.5)	3.4 (2.9 to 3.9)	52.9 (26.7 to 83.8)	4.9 (-13.1 to 26.7)	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.9)	52.7 (12.8 to 106.0)	5.7 (-22.4 to 42.3)
Chlamydial infection	625.4 (518.4 to 753.6)	812.6 (655.0 to 978.0)	30.9 (-6.3 to 72.3)	-3.5 (30.4 to 26.8)	2.9 (1.6 to 4.9)	3.7 (1.8 to 6.9)	28.0 (-21.0 to 104.4)	-5.3 (-41.7 to 51.1)
Gonococcal infection	82.8 (62.3 to 108.5)	88.0 (64.1 to 123.6)	4.3 (-29.2 to 66.3)	-22.4 (-47.1 to 23.4)	0.7 (0.4 to 1.1)	0.8 (0.5 to 1.4)	18.7 (-20.2 to 72.3)	-11.9 (-40.6 to 27.7)
Trichomoniasis	165.6 (111.4 to 230.2)	210.9 (156.7 to 263.3)	30.4 (-24.9 to 91.6)	-6.4 (-45.7 to 37.0)	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.7)	24.5 (-35.9 to 106.5)	-11.0 (-53.6 to 47.0)
Genital herpes	4,135.6 (3,915.9 to 4,388.9)	5,714.5 (5,410.6 to 6,011.7)	38.6 (25.6 to 49.0)	-2.0 (-11.0 to 5.3)	1.1 (0.3 to 2.6)	1.5 (0.5 to 3.6)	37.6 (24.5 to 48.8)	2.2 (-11.3 to 6.0)
Other sexually transmitted diseases	6.6 (4.0 to 9.2)	6.3 (4.1 to 9.4)	-4.8 (-40.3 to 53.2)	-32.8 (-57.9 to 8.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	0.1 (-16.8 to 91.8)	-10.0 (-40.2 to 38.3)
Hepatitis	-	-	-	-	1.0 (0.7 to 1.5)	1.2 (0.7 to 1.8)	14.2 (2.9 to 27.2)	-10.0 (-18.8 to -0.0)
Hepatitis A	35.1 (34.0 to 36.3)	38.0 (36.6 to 39.3)	7.9 (7.7 to 8.1)	-8.8 (-9.4 to -8.1)	0.9 (0.6 to 1.3)	1.1 (0.7 to 1.6)	19.0 (6.5 to 33.4)	-5.2 (-14.9 to 6.3)
Hepatitis B	202.9 (189.9 to 215.5)	145.4 (134.8 to 156.7)	-28.5 (-35.3 to -21.0)	-45.5 (-50.5 to -39.9)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-21.5 (-46.4 to 13.3)	-42.9 (-61.3 to -17.0)
Hepatitis C	263.7 (242.5 to 286.2)	275.3 (252.9 to 297.5)	4.1 (-7.4 to 16.7)	-24.8 (-33.1 to -15.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.7 (-26.5 to 34.7)	-25.2 (-45.2 to -0.7)
Hepatitis E	-	-	-	-	-	-	-	-
Leprosy	1.2 (0.8 to 1.6)	1.3 (1.1 to 1.6)	12.9 (-7.9 to 42.8)	-23.2 (-37.4 to -2.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	12.4 (-19.4 to 66.4)	-23.3 (-45.1 to 14.2)
Other infectious diseases	143.5 (106.6 to 178.6)	149.4 (116.9 to 182.6)	3.8 (-21.6 to 39.5)	-2.6 (-26.3 to 30.6)	5.1 (3.0 to 7.6)	5.0 (3.0 to 7.4)	-0.9 (-36.5 to 48.5)	-5.0 (-39.3 to 41.8)
Non-communicable diseases	-	-	-	-	-	-	-	-
Neoplasms	-	-	-	-	(1,956.7 to 3,408.9)	(2,784.9 to 4,843.4)	(39.3 to 46.6)	(8.8 to 5.9)
Esophageal cancer	2.9 (2.3 to 3.7)	3.7 (2.8 to 5.2)	25.3 (8.5 to 75.2)	-17.9 (-40.2 to 15.0)	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.9)	0.6 (-6.6 to 72.4)	-17.9 (-38.5 to 13.0)
Stomach cancer	9.2 (8.3 to 10.2)	13.7 (12.0 to 15.9)	48.1 (27.4 to 80.9)	-2.6 (-16.5 to 18.7)	1.1 (0.8 to 1.5)	1.6 (1.1 to 2.1)	6.7 (-18.1 to 72.9)	-6.7 (-22.1 to 12.9)
Liver cancer	-	-	-	-	-	-	-	-
Liver cancer due to hepatitis B	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	147.5 (13.3 to 496.4)	70.1 (-22.5 to 307.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (-16.5 to 467.5)	64.5 (-19.7 to 285.7)
Liver cancer due to hepatitis C	0.3 (0.2 to 0.4)	1.4 (0.9 to 1.8)	361.0 (157.7 to 661.0)	196.4 (68.6 to 386.9)	0.1 (0.0 to 0.1)	0.2 (0.2 to 0.3)	329.3 (177.7 to 532.8)	175.5 (77.4 to 309.1)
Liver cancer due to alcohol use	1.1 (0.8 to 1.4)	0.8 (0.5 to 1.1)	-27.9 (-56.3 to 13.0)	-53.3 (-71.6 to -27.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-27.5 (-49.4 to 1.7)	-53.0 (-67.2 to -33.4)
Liver cancer due to other causes	0.4 (0.2 to 0.6)	0.3 (0.2 to 0.5)	-25.0 (-60.3 to 45.8)	-49.9 (-73.9 to -4.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-27.1 (-57.4 to 21.3)	-51.5 (-71.6 to -19.6)
Larynx cancer	4.5 (3.1 to 6.2)	7.8 (5.6 to 11.1)	68.2 (12.5 to 168.1)	18.2 (-20.9 to 87.8)	0.6 (0.4 to 0.9)	0.8 (0.5 to 1.2)	31.2 (-5.9 to 85.3)	-8.1 (-34.1 to 30.3)
Tracheal, bronchus and lung cancer	14.5 (13.1 to 15.8)	18.0 (15.8 to 20.6)	24.3 (6.5 to 44.3)	-15.0 (-27.1 to -1.2)	2.3 (1.7 to 3.0)	2.8 (1.9 to 3.7)	20.6 (1.2 to 41.3)	-17.4 (-30.7 to -3.0)
Breast cancer	81.3 (70.8 to 91.4)	225.3 (203.6 to 249.6)	177.4 (136.6 to 228.1)	87.4 (59.8 to 121.7)	6.7 (4.9 to 8.8)	12.8 (9.2 to 17.4)	90.6 (56.1 to 131.8)	28.8 (5.7 to 56.5)
Cervical cancer	38.2 (29.6 to 44.4)	35.6 (27.0 to 43.4)	-6.8 (-25.3 to 14.5)	-48.2 (-47.5 to -49.4)	2.9 (1.8 to 3.8)	2.6 (1.7 to 3.8)	9.9 (-26.2 to 17.2)	-33.6 (-48.0 to -17.2)
Uterine cancer	25.8 (18.1 to 37.3)	38.0 (23.6 to 52.3)	48.5 (-0.8 to 110.6)	3.2 (-30.5 to 47.8)	1.7 (1.0 to 2.7)	2.5 (1.4 to 3.9)	46.9 (-18.0 to 113.1)	1.1 (-31.4 to 46.7)
Prostate cancer	32.0 (24.6 to 40.8)	84.3 (64.2 to 114.2)	161.3 (101.9 to 255.8)	75.0 (34.9 to 139.2)	3.5 (2.3 to 5.0)	9.4 (5.8 to 13.8)	164.9 (100.5 to 279.9)	73.9 (31.4 to 149.7)
Colon and rectum cancer	33.3 (31.1 to 35.6)	75.3 (67.8 to 82.8)	125.3 (99.9 to 154.2)	49.9 (33.1 to 68.8)	3.1 (2.3 to 4.1)	6.6 (4.8 to 8.8)	111.3 (84.0 to 143.3)	39.6 (20.8 to 59.7)
Lip and oral cavity cancer	8.2 (6.1 to 10.7)	12.0 (9.0 to 15.5)	46.8 (10.9 to 94.0)	0.6 (-24.4 to 32.9)	0.7 (0.5 to 1.1)	1.1 (0.7 to 1.5)	44.9 (6.9 to 91.9)	-1.4 (-27.0 to 30.3)
Nasopharynx cancer	1.5 (1.1 to 1.9)	1.2 (0.9 to 1.6)	-24.2 (-46.5 to 21.8)	-46.3 (-62.6 to -33.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-25.5 (-47.1 to 18.6)	-47.7 (-63.0 to -16.5)
Other pharynx cancer	3.6 (2.3 to 4.6)	3.2 (2.2 to 4.8)	-13.3 (-42.2 to 64.9)	-38.7 (-59.0 to 17.2)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-11.6 (-39.8 to 69.5)	-38.0 (-57.5 to 19.8)
Gallbladder and biliary tract cancer	2.5 (1.8 to 3.0)	2.2 (1.7 to 2.9)	-13.9 (-36.7 to 40.8)	-44.4 (-59.2 to -9.6)	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.8)	-16.1 (-38.9 to 39.3)	-45.1 (-60.1 to -11.4)
Pancreatic cancer	0.5 (0.4 to 0.5)	3.9 (3.2 to 4.6)	758.1 (579.2 to 959.9)	457.1 (341.3 to 585.5)	0.1 (0.1 to 0.1)	0.8 (0.6 to 1.1)	663.9 (523.6 to 821.4)	395.7 (307.5 to 496.6)
Malignant skin melanoma	11.1 (9.3 to 13.5)	17.6 (13.8 to 22.4)	57.9 (26.7 to 95.6)	37.9 (-12.2 to 35.9)	0.9 (0.5 to 1.0)	1.1 (0.7 to 1.6)	63.7 (24.3 to 95.7)	8.0 (-15.2 to 35.0)
Non-melanoma skin cancer	29.3 (24.9 to 34.2)	41.7 (34.8 to 49.7)	41.4 (11.8 to 78.6)	-8.9 (-28.3 to 14.4)	0.4 (0.3 to 0.7)	0.7 (0.4 to 1.1)	57.8 (23.8 to 107.4)	-0.9 (-21.8 to 28.9)
Ovarian cancer	2.2 (2.0 to 2.6)	9.6 (8.1 to 11.2)	326.3 (243.8 to 427.4)	194.3 (136.3 to 263.7)	0.3 (0.2 to 0.4)	1.2 (0.8 to 1.7)	316.8 (206.0 to 467.6)	186.2 (110.0 to 289.9)
Testicular cancer	1.8 (0.7 to 4.2)	11.8 (3.2 to 21.9)	1,230.8 (40.5 to 2,539.9)	849.8 (0.9 to 1,778.7)	0.1 (0.0 to 0.3)	1.7 (0.2 to 1.4)	1,187.0 (35.4 to 2,804.9)	826.5 (-2.5 to 1,969.7)
Kidney cancer	15.3 (10.4 to 13.2)	22.1 (19.8 to 25.9)	41.8 (63.2 to 133.6)	-5.1 (13.1 to 63.0)	1.2 (0.6 to 1.2)	1.7 (1.2 to 2.3)	37.2 (58.0 to 133.6)	-9.0 (9.9 to 62.1)
Bladder cancer	15.3 (13.1 to 17.9)	22.1 (18.3 to 28.4)	41.8 (15.3 to 91.1)	-5.1 (-23.0 to 27.6)	1.2 (0.9 to 1.7)	1.7 (1.2 to 2.5)	37.2 (9.1 to 85.1)	-9.0 (-27.3 to 22.6)
Brain and nervous system cancer	3.8 (3.2 to 5.1)	7.3 (6.0 to 8.9)	91.7 (50.1 to 128.8)	44.6 (13.8 to 72.4)	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.1)	84.5 (44.5 to 123.4)	36.1 (7.1 to 64.4)
Thyroid cancer	9.3 (6.8 to 11.4)	13.8 (10.7 to 19.6)	43.5 (9.7 to 128.5)	1.8 (-22.8 to 62.8)	0.6 (0.4 to 0.8)	0.8 (0.5 to 1.3)	41.0 (7.4 to 124.8)	-1.3 (-24.7 to 57.1)
Mesothelioma	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	52.2 (46.1 to 130.3)	24.8 (-0.0 to 57.6)	0.1 (0.0 to 0.0)	0.1 (0.0 to 0.1)	89.9 (48.4 to 127.5)	32.2 (0.6 to 55.3)
Hodgkin lymphoma	0.5 (0.3 to 1.5)	5.3 (1.9 to 7.5)	1,647.4 (49.7 to 2,351.1)	1,234.2 (13.8 to 1,765.0)	0.0 (0.0 to 0.1)	0.4 (0.1 to 0.7)	1,614.9 (40.1 to 2,246.5)	1,185.6 (3.6 to 1,639.0)
Non-Hodgkin lymphoma	13.2 (11.0 to 16.3)	26.9 (21.8 to 33.5)	102.4 (68.9 to 143.8)	42.9 (19.0 to 72.3)	1.0 (0.7 to 1.4)	2.0 (1.3 to 2.8)	96.1 (59.2 to 140.8)	37.3 (12.2 to 68.3)
Multiple myeloma	1.9 (1.5 to 2.5)	3.7 (2.7 to 4.8)	95.2 (40.4 to 166.5)	33.5 (-3.9 to 82.3)	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.1)	87.8 (29.8 to 174.7)	27.9 (-11.3 to 86.9)
Leukemia	7.6 (6.3 to 9.1)	11.9 (9.8 to 14.5)	55.2 (22.1 to 95.0)	19.8 (-5.5 to 51.1)	0.9 (0.7 to 1.3)	1.5 (1.0 to 2.0)	61.9 (27.1 to 97.5)	17.1 (-7.3 to 42.8)
Other neoplasms	31.4 (26.6 to 38.3)	89.4 (73.8 to 106.6)	184.0 (121.8 to 252.7)	107.7 (61.9 to 159.2)	2.2 (1.5 to 3.0)	5.9 (4.0 to 8.2)	173.7 (114.5 to 239.0)	96.4 (51.6 to 143.9)
Cardiovascular diseases	-	-	-	-	-	-	-	-
Rheumatic heart disease	6.9 (5.6 to 8.2)	10.1 (8.1 to 12.1)	47.0 (14.4 to 91.1)	-0.3 (-22.1 to 28.7)	0.7 (0.5 to 1.1)	1.0 (0.7 to 1.5)	44.8 (3.3 to 101.4)	-1.7 (-30.2 to 36.8)
Ischemic heart disease	411.1 (345.8 to 493.5)	661.9 (558.0 to 786.5)	60.1 (26.8 to 109.3)	5.1 (-16.4 to 37.5)	25.6 (16.9 to 36.4)	40.5 (27.1 to 57.9)	56.8 (23.5 to 107.6)	1.9 (-20.2 to 34.0)
Cerebrovascular disease	-	-	-	-	-	-	-	-
Ischemic stroke	60.3 (54.4 to 67.9)	69.1 (57.3 to 81.3)	15.1 (-9.5 to 43.0)	-22.5 (-38.7 to -4.0)	8.9 (6.0 to 11.8)	10.2 (6.7 to 14.4)	15.4 (-9.2 to 45.0)	-21.7 (-38.0 to -2.1)
Hemorrhagic stroke	18.6 (15.8 to 21.4)	26.1 (21.9 to 31.2)	39.0 (9.9 to 77.3)	-3.9 (-23.9 to 21.9)	2.8 (1.8 to 3.8)	3.9 (2.7 to 5.5)	40.2 (7.4 to 80.7)	-2.6 (-25.4 to 25.6)
Hypertensive heart disease	71.8 (60.8 to 82.3)	117.2 (99.4 to 134.6)	62.4 (34.4 to 100.8)	1.2 (-18.4 to 22.2)	7.8 (5.2 to 10.9)	12.7 (8.5 to 17.7)	62.8 (34.0 to 100.6)	-0.3 (-17.5 to 23.1)
Cardiomyopathy and myocarditis	22.4 (17.8 to 27.2)	50.3 (43.4 to 57.5)	125.4 (78.1 to 184.1)	48.5 (17.0 to 86.8)	2.4 (1.5 to 3.4)	5.4 (3.6 to 7.6)	129.1 (79.2 to 192.2)	51.7 (18.1 to 94.1)
Atrial fibrillation and flutter	47.7 (36.9 to 57.7)	74.7 (56.0 to 94.7)	56.9 (16.8 to 106.8)	-0.6 (-26.2 to 30.1)	3.6 (2.4 to 5.1)	5.7 (3.5 to 8.6)	59.4 (17.4 to 112.7)	1.3 (-25.2 to 35.0)
Peripheral vascular disease	630.4 (452.9 to 772.1)	928.2 (708.6 to 1,157.6)	44.8 (0.4 to 126.1)	-4.0 (-33.5 to 48.2)	0.4 (0.2 to 0.9)	0.6 (0.2 to 1.2)	43.4 (-50.3 to 240.3)	-17.3 (-71.8 to 88.3)
Endocarditis	1.8 (1.4 to 2.6)	2.9 (2.2 to 3.8)	67.4 (5.7 to 115.1)	11.6 (-29.3 to 43.2)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	70.1 (3.1 to 143.9)	15.0 (-30.9 to 64.4)
Other cardiovascular and circulatory diseases	193.6 (86.5 to 363.3)	451.9 (200.0 to 706.9)	142.9 (-9.6 to 464.5)	-9.8 (-40.6 to 271.8)	13.7 (5.3 to 27.6)	22.2 (12.9 to 53.3)	163.4 (-9.5 to 470.0)	59.8 (-40.5 to 280.0)
Chronic respiratory diseases	-	-	-	-	-	-	-	-
Chronic obstructive pulmonary disease	2,108.2 (1,998.5 to 2,209.8)	3,075.5 (2,926.1 to 3,231.8)	45.6 (40.6 to 50.6)	1.3 (-2.2 to 4.7)	115.4 (75.8 to 163.8)	208.5 (119.0 to 256.4)	39.7 (30.4 to 83.0)	3.1 (-9.0 to 27.7)

Appendix Table G.4 - Argentina prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumonia	-	-	-	-	0.1	0.2	49.4	-
Silicosis	0.2	0.4	42.9	-3.9	0.0	0.1	43.2	-3.8
Asbestosis	0.1	0.2	57.0	5.7	0.0	0.0	57.6	6.0
Coal workers pneumoconiosis	0.1	0.1	50.2	2.7	0.0	0.0	51.4	3.2
Other pneumoconiosis	0.2	0.3	50.7	5.8	0.1	0.1	46.4	5.0
Asthma	2,110.4	2,561.4	21.0	-4.0	93.5	113.2	20.8	-3.9
Interstitial lung disease and pulmonary sarcoidosis	2.6	3.8	45.2	0.1	0.4	0.5	45.2	0.2
Other chronic respiratory diseases	-	-	-	-	4.2	4.5	5.3	-26.9
Cirrhosis	-	-	-	-	1.6	2.3	46.6	-
Cirrhosis due to hepatitis B	1.0	1.6	55.0	9.8	0.2	0.3	54.2	10.3
Cirrhosis due to hepatitis C	3.4	6.4	88.1	35.1	1.0	1.0	89.1	36.4
Cirrhosis due to alcohol use	4.2	4.1	-2.5	-31.2	0.7	0.7	-2.8	-31.1
Cirrhosis due to other causes	1.1	2.0	90.3	46.9	0.4	0.3	83.3	41.5
Digestive diseases	-	-	-	-	37.3	55.5	49.1	-
Peptic ulcer disease	176.2	169.6	-4.0	-40.3	5.5	5.2	-4.2	-41.0
Gastritis and duodenitis	105.0	91.5	-13.0	-38.9	4.0	3.6	-9.5	-33.8
Appendicitis	2.1	2.0	-1.7	-21.0	0.6	0.6	0.5	-19.2
Paralytic ileus and intestinal obstruction	0.3	0.3	113.0	51.3	0.1	0.2	106.0	49.4
Inguinal, femoral, and abdominal hernia	169.9	134.3	-21.7	-50.6	1.7	1.4	-20.8	-49.8
Inflammatory bowel disease	71.0	116.6	63.5	16.0	15.0	24.6	63.4	16.2
Vascular intestinal disorders	0.2	0.3	56.1	0.1	0.1	0.1	55.4	1.5
Gallbladder and biliary diseases	59.8	40.5	-31.9	-36.5	6.2	8.5	36.7	5.6
Pancreatitis	8.8	13.8	57.7	11.1	2.6	4.1	57.5	11.5
Other digestive diseases	-	-	-	-	1.5	7.2	417.6	259.4
Neurological disorders	-	-	-	-	160.0	257.3	60.7	-
Alzheimer disease and other dementias	195.2	349.9	79.1	-3.1	28.6	52.8	85.0	-0.8
Parkinson disease	50.8	77.5	52.6	-1.3	6.0	9.1	53.1	-0.3
Epilepsy	93.5	107.3	14.1	-11.0	36.5	43.7	18.9	-7.0
Multiple sclerosis	9.2	20.7	124.8	61.1	3.1	6.9	124.0	60.4
Migraine	1,323.1	2,114.9	58.1	45.1	16.8	72.1	58.8	17.0
Tension-type headache	5,432.7	6,200.6	12.5	8.8	8.8	12.2	38.3	2.0
Medication overuse headache	159.1	324.5	101.5	46.4	24.9	50.9	101.9	47.0
Other neurological disorders	0.1	0.1	31.9	-1.2	7.0	9.5	36.4	-22.1
Mental and substance use disorders	-	-	-	-	792.5	1,054.0	32.9	-0.5
Schizophrenia	90.4	124.9	38.0	-0.9	58.2	80.5	38.2	-0.7
Alcohol use disorders	415.5	565.8	36.1	-1.2	41.5	56.6	36.5	-0.9
Drug use disorders	-	-	-	-	102.7	102.7	33.8	-2.1
Opioid use disorders	69.4	95.7	38.1	-1.2	29.0	40.0	38.3	-1.1
Cocaine use disorders	46.1	55.4	20.4	-1.1	18.9	26.2	38.6	-1.2
Amphetamine use disorders	121.4	154.4	26.8	-5.8	15.9	20.3	27.0	-5.6
Cannabis use disorders	53.0	69.6	31.2	0.2	1.5	2.0	31.3	0.4
Other drug use disorders	-	-	-	-	23.2	30.5	30.8	-3.0
Depressive disorders	-	-	-	-	148.8	187.7	26.2	-
Major depressive disorder	973.8	1,322.9	35.7	-0.2	200.4	271.4	35.4	-0.1
Dysthymia	479.7	669.8	40.1	-0.1	46.4	64.7	39.3	0.0
Bipolar disorder	240.3	331.3	37.6	-0.0	49.1	67.6	37.7	0.1
Anxiety disorders	1,947.9	2,555.5	31.0	31.0	179.8	235.1	30.8	-0.1
Eating disorders	-	-	-	-	18.0	24.6	37.1	4.3
Anorexia nervosa	12.9	21.9	70.0	31.5	2.7	4.7	70.5	32.0
Bulimia nervosa	71.6	94.0	31.1	-0.7	15.2	19.9	30.9	-0.7
Autistic spectrum disorders	-	-	-	-	38.6	48.7	26.2	-
Autism	100.5	127.2	26.4	0.2	24.8	31.3	26.3	0.5
Asperger syndrome	137.8	174.3	26.3	0.3	13.8	17.4	26.3	0.6
Attention-deficit/hyperactivity disorder	230.2	255.5	10.8	0.3	2.8	3.1	11.0	0.5
Conduct disorder	274.3	300.1	9.3	0.2	1.7	1.8	4.0	0.2
Idiopathic intellectual disability	163.1	140.3	-13.5	-31.6	9.8	8.4	-14.2	-31.9
Other mental and substance use disorders	512.5	728.2	41.8	0.1	38.2	54.3	42.0	0.4
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	226.5	335.8	48.0	-
Diabetes mellitus	951.4	1,696.6	76.2	25.8	66.1	117.1	76.5	24.6
Acute glomerulonephritis	0.1	0.0	-75.0	-31.4	0.0	0.0	-17.5	-31.4
Chronic kidney disease	160.6	400.0	149.8	75.0	8.8	21.5	149.7	76.9
Chronic kidney disease due to diabetes mellitus	300.5	321.4	7.2	-22.2	12.7	19.3	53.3	9.0
Chronic kidney disease due to hypertension	290.0	368.5	24.5	-19.2	18.6	24.5	31.5	34.3
Chronic kidney disease due to glomerulonephritis	63.3	75.6	18.9	-15.5	30.1	37.9	25.5	-8.6
Chronic kidney disease due to other causes	460.5	891.5	93.8	32.4	22.2	33.6	51.1	2.0
Urinary diseases and male infertility	-	-	-	-	14.8	21.7	47.3	10.6

Appendix Table G.4 - Argentina prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	7.4 (6.7 to 8.1)	12.9 (11.6 to 14.1)	74.9 (51.3 to 103.3)	28.7 (11.6 to 48.7)	0.2 (0.1 to 0.4)	0.4 (0.3 to 0.6)	75.0 (40.4 to 119.8)	29.2 (3.6 to 61.9)
Urolithiasis	244.2 (106.4 to 365.9)	494.7 (212.5 to 754.4)	100.7 (78.8 to 128.6)	35.5 (21.6 to 55.7)	1.7 (0.7 to 2.8)	3.5 (1.4 to 5.9)	105.9 (79.9 to 138.0)	41.1 (22.9 to 64.0)
Benign prostatic hyperplasia	533.8 (473.0 to 587.9)	768.7 (680.1 to 863.0)	43.4 (22.4 to 70.7)	-4.3 (-18.1 to 13.6)	19.1 (12.4 to 27.0)	27.5 (17.6 to 39.1)	43.6 (22.9 to 72.4)	-3.6 (-17.4 to 14.9)
Male infertility due to other causes	76.9 (51.8 to 106.0)	113.1 (84.2 to 144.9)	48.1 (-5.7 to 142.1)	5.0 (-33.1 to 71.7)	0.5 (0.2 to 1.1)	0.8 (0.3 to 1.7)	51.6 (-7.3 to 149.2)	7.8 (-34.3 to 77.7)
Other urinary diseases	-	-	-	-	-	-	-	-
Gynecological diseases	-	-	-	-	-	-	-	-
Uterine fibroids	807.7 (717.4 to 907.1)	1,115.1 (990.4 to 1,252.1)	37.8 (37.6 to 38.0)	-0.7 (-0.7 to -0.6)	9.1 (4.9 to 16.1)	11.9 (6.6 to 20.8)	30.4 (19.4 to 40.0)	-6.1 (-14.0 to 0.7)
Polycystic ovarian syndrome	490.7 (438.0 to 539.7)	663.2 (589.5 to 741.8)	34.5 (15.7 to 57.9)	-2.7 (-16.0 to 14.1)	4.6 (2.1 to 8.9)	6.2 (2.9 to 11.8)	34.8 (16.4 to 57.3)	-2.7 (-15.7 to 13.3)
Female infertility due to other causes	6.0 (2.5 to 11.8)	8.5 (3.4 to 26.4)	41.7 (-68.0 to 580.5)	-7.3 (-78.0 to 369.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	35.8 (-64.9 to 549.7)	-3.9 (-75.4 to 354.2)
Endometriosis	86.0 (67.2 to 103.6)	109.8 (87.8 to 131.1)	26.9 (4.7 to 70.5)	-9.1 (-31.1 to 22.4)	2.9 (5.1 to 11.4)	3.4 (6.5 to 14.2)	10.2 (-4.5 to 73.4)	9.0 (-31.5 to 24.1)
Genital prolapse	1,314.1 (1,129.2 to 1,510.2)	1,790.2 (1,517.2 to 2,078.0)	36.4 (9.0 to 71.4)	-2.3 (-21.9 to 22.7)	4.2 (2.0 to 8.0)	5.7 (2.7 to 10.8)	36.3 (8.4 to 71.4)	-2.3 (-22.3 to 23.1)
Premenstrual syndrome	1,069.9 (661.5 to 1,437.3)	1,450.3 (995.4 to 2,003.8)	36.1 (-18.6 to 154.5)	-1.6 (-41.1 to 83.9)	9.0 (4.5 to 15.0)	12.2 (6.6 to 20.4)	20.0 (-18.0 to 164.4)	-2.0 (-40.4 to 90.3)
Other gynecological diseases	91.4 (80.0 to 102.8)	119.6 (110.5 to 128.9)	30.7 (14.4 to 50.5)	-4.8 (-16.7 to 9.5)	2.6 (1.7 to 3.7)	3.0 (2.0 to 4.3)	18.3 (-1.2 to 53.6)	-13.9 (-27.9 to 11.6)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	-	-	-	-
Thalassemias	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.6)	27.0 (14.2 to 40.5)	14.1 (2.6 to 26.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	32.7 (3.2 to 83.9)	17.3 (-8.2 to 61.3)
Thalassemia trait	379.5 (362.9 to 401.1)	477.0 (455.0 to 505.2)	25.6 (21.2 to 29.9)	-1.1 (-4.7 to 2.2)	14.5 (9.7 to 20.6)	17.1 (11.5 to 24.5)	17.7 (9.8 to 28.5)	-0.1 (-6.7 to 8.7)
Sickle cell disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	12.0 (0.3 to 18.2)	-5.3 (-15.3 to -0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.4 (-2.2 to 22.4)	2.1 (-18.2 to 4.4)
Sickle cell trait	101.9 (91.5 to 114.4)	127.7 (115.3 to 139.6)	26.7 (5.2 to 36.3)	1.6 (-17.0 to 8.1)	2.0 (0.9 to 2.5)	2.0 (1.2 to 3.0)	24.3 (-5.8 to 88.4)	12.6 (-14.8 to 73.3)
G6PD deficiency	576.1 (513.2 to 641.8)	771.5 (699.9 to 840.1)	33.5 (14.9 to 54.9)	5.3 (-9.4 to 22.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	18.8 (-24.2 to 75.6)	3.3 (-33.9 to 46.7)
G6PD trait	4,028.3 (3,903.3 to 4,154.6)	4,973.7 (4,814.8 to 5,117.9)	23.4 (18.3 to 28.5)	-3.5 (-7.5 to 0.5)	0.3 (0.1 to 0.5)	0.4 (0.1 to 0.6)	27.3 (-46.6 to 426.0)	10.5 (-54.9 to 341.1)
Other hemoglobinopathies and hemolytic anemias	122.6 (92.5 to 150.3)	151.0 (127.4 to 173.4)	22.9 (4.2 to 62.0)	3.2 (-18.8 to 33.5)	3.7 (2.2 to 5.5)	4.4 (2.7 to 6.4)	17.9 (-14.6 to 91.1)	5.9 (-23.7 to 70.7)
Endocrine, metabolic, blood, and immune disorders	289.4 (258.8 to 318.3)	404.7 (380.2 to 426.9)	40.7 (26.2 to 56.6)	10.2 (2.5 to 26.2)	14.0 (6.8 to 14.4)	14.0 (9.6 to 19.3)	22.2 (23.4 to 62.4)	11.2 (1.4 to 31.8)
Musculoskeletal disorders	-	-	-	-	-	-	-	-
Rheumatoid arthritis	120.5 (114.0 to 126.2)	169.0 (161.5 to 176.2)	39.9 (31.9 to 50.0)	-2.8 (-8.4 to 4.2)	28.4 (20.2 to 37.6)	39.6 (28.1 to 52.3)	39.7 (30.4 to 50.7)	-2.6 (-9.1 to 5.3)
Osteoarthritis	1,298.2 (1,233.8 to 1,355.8)	1,971.2 (1,880.9 to 2,057.7)	51.4 (41.8 to 62.8)	0.0 (-6.4 to 7.5)	45.1 (68.3 to 64.8)	66.3 (45.2 to 99.9)	51.2 (41.3 to 62.8)	0.5 (-6.1 to 8.0)
Low back and neck pain	-	-	-	-	-	-	-	-
Low back pain	1,799.4 (1,694.6 to 1,897.8)	2,495.8 (2,332.5 to 2,638.6)	38.8 (26.8 to 49.3)	-0.5 (-9.1 to 6.8)	201.0 (136.8 to 280.2)	278.5 (190.0 to 387.5)	39.0 (26.8 to 49.9)	-0.1 (-8.9 to 7.7)
Neck pain	1,671.6 (1,353.9 to 2,023.4)	2,530.7 (2,264.2 to 2,813.9)	50.9 (24.4 to 88.0)	7.5 (-11.4 to 33.2)	249.2 (106.1 to 234.8)	292.4 (168.5 to 343.4)	50.9 (24.8 to 89.0)	7.9 (-11.0 to 33.9)
Gout	55.7 (45.4 to 63.6)	84.4 (72.0 to 96.2)	52.0 (21.0 to 85.4)	4.5 (-17.0 to 27.6)	1.7 (1.2 to 2.4)	2.7 (1.7 to 3.8)	52.1 (16.6 to 95.2)	5.1 (-19.6 to 34.4)
Other musculoskeletal disorders	1,281.2 (1,100.2 to 1,451.2)	2,272.1 (1,996.5 to 2,538.9)	76.1 (65.1 to 96.0)	25.9 (17.9 to 40.5)	10.7 (7.6 to 165.9)	16.6 (14.1 to 288.7)	26.3 (64.8 to 96.2)	6.3 (-17.9 to 40.7)
Other non-communicable diseases	-	-	-	-	-	-	-	-
Congenital anomalies	-	-	-	-	-	-	-	-
Neural tube defects	12.1 (10.3 to 14.5)	14.8 (13.0 to 17.3)	22.7 (0.5 to 53.2)	0.9 (-17.3 to 26.1)	3.6 (2.3 to 5.2)	4.5 (3.0 to 6.2)	22.5 (8.4 to 70.6)	1.2 (-23.8 to 41.2)
Congenital heart anomalies	193.4 (160.5 to 231.4)	326.7 (272.3 to 420.4)	67.2 (31.2 to 136.6)	35.6 (6.3 to 91.7)	6.6 (2.7 to 11.7)	11.6 (4.8 to 20.3)	73.9 (36.7 to 136.7)	12.6 (4.2 to 24.0)
Orofacial clefts	30.8 (22.2 to 39.8)	48.2 (39.0 to 59.1)	57.2 (7.6 to 131.1)	29.2 (-11.6 to 89.7)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.8)	2.5 (-25.3 to 87.2)	-2.2 (-38.1 to 54.8)
Down syndrome	62.9 (52.5 to 78.9)	96.4 (77.6 to 115.6)	54.0 (9.8 to 99.9)	21.5 (-13.2 to 57.7)	8.4 (5.8 to 11.4)	13.6 (9.5 to 18.1)	63.9 (16.1 to 115.3)	27.0 (-10.1 to 66.4)
Turner syndrome	1.5 (1.2 to 1.8)	2.0 (1.6 to 2.6)	32.5 (-1.3 to 78.8)	5.8 (-21.0 to 43.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	34.1 (-1.4 to 86.7)	5.8 (-22.5 to 47.4)
Klinefelter syndrome	1.3 (1.0 to 1.7)	1.7 (1.3 to 2.0)	28.3 (-6.2 to 67.5)	2.4 (-25.2 to 33.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.0 (-13.3 to 111.0)	2.0 (-34.7 to 59.0)
Chromosomal unbalanced rearrangements	69.4 (57.8 to 81.4)	110.3 (88.9 to 140.4)	59.3 (18.1 to 120.7)	9.2 (-6.8 to 74.2)	9.2 (6.5 to 12.3)	15.7 (10.9 to 21.2)	83.7 (34.8 to 135.5)	29.5 (-3.7 to 82.8)
Other congenital anomalies	74.3 (57.6 to 89.2)	81.0 (57.3 to 98.6)	9.7 (-11.9 to 26.3)	-16.2 (-32.1 to -3.5)	13.6 (9.2 to 19.0)	25.1 (15.7 to 36.3)	82.1 (38.3 to 150.1)	46.1 (10.9 to 100.2)
Skin and subcutaneous diseases	-	-	-	-	-	-	-	-
Dermatitis	1,854.8 (1,537.2 to 2,165.5)	2,440.8 (2,012.1 to 2,865.2)	31.4 (29.5 to 32.9)	0.0 (-0.0 to 0.1)	50.3 (32.7 to 73.5)	64.6 (41.3 to 94.3)	28.7 (24.4 to 32.5)	0.2 (-2.3 to 2.7)
Psoriasis	403.6 (355.5 to 450.2)	549.6 (482.6 to 613.9)	36.0 (35.1 to 36.8)	0.0 (-0.0 to 0.0)	36.0 (22.4 to 46.2)	32.9 (30.3 to 62.8)	32.9 (29.8 to 42.0)	0.2 (-4.3 to 4.7)
Cellulitis	15.7 (13.0 to 19.3)	21.8 (17.9 to 26.8)	38.1 (27.8 to 49.2)	1.0 (-6.3 to 9.0)	1.1 (0.7 to 1.6)	1.5 (0.9 to 2.2)	38.2 (16.5 to 61.8)	1.5 (-13.5 to 19.9)
Pyoderma	37.3 (30.2 to 47.4)	39.7 (31.0 to 51.7)	6.3 (-4.1 to 15.8)	-14.2 (-20.6 to -7.8)	0.2 (0.1 to 0.5)	0.2 (0.1 to 0.5)	5.9 (-6.9 to 18.6)	-14.1 (-23.2 to -5.2)
Scabies	19.5 (16.6 to 22.8)	19.4 (16.7 to 22.8)	-0.5 (-20.9 to 24.0)	-21.8 (-37.7 to -2.2)	0.5 (0.3 to 0.8)	0.5 (0.3 to 0.8)	-0.8 (-23.5 to 28.1)	-21.7 (-39.9 to 0.6)
Fungal skin diseases	1,894.5 (1,544.7 to 2,268.5)	2,540.1 (2,081.3 to 3,026.4)	33.3 (30.9 to 36.3)	0.1 (-0.0 to 0.2)	0.1 (0.3 to 0.8)	0.1 (0.8 to 29.9)	35.9 (30.5 to 36.6)	0.3 (-0.6 to 1.2)
Viral skin diseases	787.7 (630.4 to 931.2)	937.3 (741.0 to 1,137.0)	18.7 (14.5 to 22.8)	0.1 (-2.1 to 2.1)	24.4 (14.3 to 38.4)	29.0 (17.0 to 45.4)	18.6 (13.8 to 23.6)	0.2 (-9.9 to 3.4)
Acne vulgaris	3,676.2 (2,898.9 to 4,539.2)	4,932.7 (3,894.9 to 6,184.1)	34.2 (-3.7 to 92.9)	8.4 (-22.2 to 54.5)	40.0 (17.7 to 75.9)	53.6 (24.2 to 102.2)	34.4 (-3.8 to 93.1)	8.5 (-22.4 to 55.3)
Alopecia areata	49.3 (45.8 to 52.6)	66.1 (61.6 to 70.9)	33.4 (21.1 to 47.8)	-1.7 (-11.0 to 8.8)	1.7 (1.1 to 2.5)	2.2 (1.4 to 3.3)	33.3 (16.4 to 50.1)	-1.3 (-13.5 to 10.8)
Pruritus	11.8 (8.3 to 15.1)	15.5 (11.2 to 20.2)	29.5 (-7.8 to 117.9)	9.1 (-33.6 to 56.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	29.5 (-10.5 to 122.5)	6.4 (-35.2 to 60.9)
Urticaria	222.7 (171.7 to 290.5)	298.8 (229.0 to 371.2)	32.1 (-2.4 to 87.5)	-3.4 (-28.7 to 37.9)	13.2 (8.1 to 20.1)	17.6 (10.7 to 26.2)	31.1 (-3.2 to 90.2)	-3.2 (-28.9 to 40.7)
Decubitus ulcer	15.5 (12.4 to 19.2)	23.2 (19.1 to 27.7)	50.1 (9.7 to 99.8)	-6.2 (-31.7 to 25.8)	2.2 (1.5 to 3.2)	3.3 (2.2 to 4.7)	48.5 (8.4 to 101.3)	-6.4 (-31.3 to 27.0)
Other skin and subcutaneous diseases	1,989.0 (1,214.6 to 3,242.3)	2,801.1 (1,670.3 to 4,639.0)	40.3 (35.3 to 45.2)	0.6 (-1.4 to 2.9)	11.6 (4.9 to 26.0)	16.4 (6.8 to 37.1)	40.3 (34.6 to 45.2)	0.9 (-1.0 to 3.5)
Sense organ diseases	-	-	-	-	-	-	-	-
Glaucoma	53.9 (45.7 to 63.5)	65.0 (53.4 to 78.9)	20.0 (4.3 to 39.9)	-26.0 (-35.8 to -13.9)	4.8 (3.2 to 6.8)	6.2 (4.1 to 8.9)	27.8 (9.7 to 54.9)	-27.8 (-32.0 to -5.8)
Cataract	57.6 (43.3 to 72.7)	67.1 (50.9 to 88.7)	15.3 (-18.6 to 56.1)	32.7 (-51.9 to -8.6)	3.8 (2.5 to 5.4)	4.7 (3.2 to 6.7)	23.4 (-6.6 to 60.8)	-29.2 (-45.6 to -6.5)
Macular degeneration	69.3 (56.0 to 84.8)	125.3 (97.2 to 150.9)	79.1 (51.1 to 120.4)	7.7 (-9.6 to 32.1)	4.6 (3.1 to 6.4)	8.0 (5.3 to 11.2)	75.2 (51.4 to 108.7)	0.1 (-14.0 to 18.7)
Uncorrected refractive error	2,520.3 (2,359.0 to 2,673.0)	3,473.9 (3,250.0 to 3,682.8)	37.9 (25.6 to 49.7)	3.8 (-12.3 to 4.4)	37.1 (22.0 to 59.9)	48.9 (29.0 to 80.2)	31.6 (23.1 to 40.9)	-8.0 (-14.0 to -1.4)
Age-related and other hearing loss	3,969.8 (3,733.9 to 4,202.6)	5,399.8 (5,096.9 to 5,708.2)	35.9 (31.2 to 40.0)	-8.7 (-12.0 to -6.0)	4.7 (68.5 to 145.5)	10.2 (96.3 to 206.8)	40.0 (30.9 to 54.1)	-1.4 (-16.1 to -2.2)
Other vision loss	139.6 (119.9 to 159.4)	135.2 (112.3 to 158.1)	-3.6 (-13.4 to 7.7)	-35.4 (-41.6 to -28.0)	8.4 (5.7 to 11.7)	8.4 (5.6 to 11.8)	0.2 (-11.6 to 12.5)	-33.4 (-40.8 to -25.7)
Other sense organ diseases	775.0 (741.9 to 811.4)	978.9 (938.2 to 1,024.3)	26.0 (18.6 to 34.4)	-0.1 (-5.7 to 6.5)	20.6 (12.7 to 30.2)	25.8 (15.9 to 38.4)	25.6 (17.3 to 34.8)	0.1 (-6.3 to 7.5)
Oral disorders	-	-	-	-	-	-	-	-
Deciduous caries	2,216.2 (2,139.3 to 2,313.0)	2,268.3 (2,193.0 to 2,346.8)	1.7 (-3.6 to 6.9)	0.8 (-4.5 to 5.9)	0.8 (0.4 to 1.7)	0.9 (0.4 to 1.7)	1.7 (-6.0 to 9.8)	0.9 (-9.9 to 8.8)
Permanent caries	16,217.0 (15,618.8 to 16,647.3)	21,146.2 (20,508.3 to 21,800.8)	30.1 (25.3 to 36.0)	0.2 (-3.4 to 4.8)	16.1 (7.3 to 30.7)	20.9 (9.6 to 40.2)	30.0 (25.0 to 35.8)	0.3 (-3.5 to 4.9)
Periodontal diseases	5,138.0 (4,922.4 to 5,347.4)	7,503.5 (7,207.2 to 7,802.6)	45.8 (37.9 to 54.2)	3.4 (-2.1 to 9.6)	33.7 (13.4 to 69.5)	49.1 (19.7 to 99.8)	45.7 (37.6 to 54.4)	3.5 (-2.3 to 9.7)

Appendix Table G.4 - Argentina prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	2 430.1 (2,288.7 to 2,588.3)	3 164.2 (2,945.1 to 3,393.8)	29.7 (18.8 to 42.1)	-13.1 (-20.5 to -4.9)	67.1 (45.5 to 93.4)	87.2 (58.3 to 121.6)	29.8 (18.5 to 41.9)	29.8 (-20.4 to -4.6)
Other oral disorders	556.6 (528.8 to 585.5)	751.0 (708.4 to 796.1)	34.7 (23.6 to 46.1)	0.2 (-8.0 to 8.8)	16.3 (10.4 to 24.4)	22.0 (13.7 to 32.8)	34.7 (23.2 to 46.6)	0.4 (-8.2 to 9.4)
Injuries	-	-	-	-	295.6 (216.7 to 391.6)	236.7 (169.0 to 317.8)	-19.2 (-36.3 to -6.2)	-44.5 (-56.8 to -35.3)
Transport injuries	-	-	-	-	67.7 (51.0 to 86.6)	42.0 (30.4 to 56.1)	-38.1 (-44.2 to -31.2)	-56.5 (-60.7 to -51.6)
Road injuries	-	-	-	-	59.6 (44.7 to 76.1)	32.1 (23.3 to 42.9)	-46.4 (-51.4 to -40.1)	-62.2 (-65.7 to -57.8)
Pedestrian road injuries	-	-	-	-	10.5 (7.8 to 13.7)	6.3 (4.5 to 8.6)	-40.1 (-46.0 to -33.8)	-58.2 (-62.2 to -53.8)
Cyclist road injuries	-	-	-	-	7.7 (5.7 to 9.8)	3.9 (2.9 to 5.2)	-49.8 (-56.4 to -42.6)	-64.3 (-69.0 to -59.2)
Motorcyclist road injuries	-	-	-	-	10.2 (7.6 to 13.1)	4.4 (3.1 to 6.0)	-57.1 (-63.1 to -49.4)	-69.5 (-73.7 to -64.0)
Motor vehicle road injuries	-	-	-	-	30.7 (23.1 to 38.9)	17.5 (12.6 to 22.8)	-43.7 (-48.7 to -38.0)	-60.4 (-63.8 to -56.3)
Other road injuries	-	-	-	-	0.6 (0.4 to 0.7)	0.2 (0.2 to 0.3)	-62.9 (-67.6 to -57.2)	-73.8 (-77.1 to -69.8)
Other transport injuries	-	-	-	-	8.1 (6.1 to 10.6)	9.9 (7.0 to 13.5)	22.2 (11.8 to 33.7)	-14.7 (-22.2 to -6.7)
Unintentional injuries	-	-	-	-	175.1 (132.3 to 225.9)	181.2 (129.4 to 244.0)	3.2 (-6.2 to 13.0)	29.4 (-35.9 to -22.6)
Falls	-	-	-	-	92.1 (69.5 to 118.5)	100.1 (71.1 to 135.5)	8.1 (-3.3 to 22.3)	-29.7 (-37.8 to -20.3)
Drowning	-	-	-	-	1.1 (0.8 to 1.4)	0.9 (0.6 to 1.1)	-19.5 (-29.7 to -7.1)	-42.2 (-49.6 to -33.4)
Fire, heat, and hot substances	-	-	-	-	6.5 (4.2 to 10.0)	7.1 (4.2 to 11.2)	8.0 (-4.2 to 23.6)	-22.8 (-31.1 to -11.7)
Poisonings	-	-	-	-	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.6)	-16.4 (-29.5 to -0.8)	-38.0 (-47.8 to -26.5)
Exposure to mechanical forces	-	-	-	-	67.6 (51.0 to 88.3)	53.1 (38.1 to 71.8)	-21.5 (-28.6 to -14.6)	-42.7 (-47.8 to -37.7)
Unintentional firearm injuries	-	-	-	-	1.2 (0.9 to 1.5)	2.1 (1.5 to 2.9)	81.5 (60.6 to 104.0)	29.8 (15.2 to 45.5)
Unintentional suffocation	-	-	-	-	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	15.8 (1.8 to 32.0)	-17.9 (-27.3 to -7.0)
Other exposure to mechanical forces	-	-	-	-	66.0 (49.8 to 86.2)	50.5 (36.2 to 68.5)	-23.6 (-30.5 to -16.7)	-44.2 (-49.1 to -39.2)
Adverse effects of medical treatment	-	-	-	-	1.4 (0.9 to 2.1)	2.0 (1.2 to 2.9)	42.6 (32.7 to 54.0)	0.4 (-6.5 to 8.4)
Animal contact	-	-	-	-	1.5 (1.1 to 2.0)	2.0 (1.4 to 2.9)	37.9 (27.5 to 49.3)	0.2 (-7.0 to 8.1)
Venomous animal contact	-	-	-	-	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.5)	28.2 (14.7 to 44.2)	-5.7 (-15.8 to 6.0)
Non-venomous animal contact	-	-	-	-	1.2 (0.9 to 1.6)	1.7 (1.2 to 2.4)	40.0 (28.9 to 52.5)	1.4 (-5.9 to 10.1)
Foreign body	-	-	-	-	1.5 (1.0 to 2.1)	1.6 (1.0 to 2.3)	6.3 (-4.8 to 15.4)	-20.7 (-29.2 to -13.8)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.3)	-4.6 (-16.0 to 8.5)	-29.7 (-38.0 to -20.2)
Foreign body in eyes	-	-	-	-	0.4 (0.2 to 0.7)	0.5 (0.3 to 0.8)	16.7 (3.4 to 32.0)	-11.9 (-22.2 to -0.1)
Foreign body in other body part	-	-	-	-	0.8 (0.5 to 1.1)	0.8 (0.5 to 1.2)	4.7 (-8.2 to 15.3)	-22.2 (-31.9 to -14.1)
Other unintentional injuries	-	-	-	-	2.9 (2.0 to 3.9)	14.0 (9.9 to 19.5)	389.3 (342.6 to 449.8)	230.9 (199.3 to 271.4)
Self-harm and interpersonal violence	-	-	-	-	10.9 (8.2 to 14.0)	9.3 (6.8 to 12.5)	-14.9 (-21.9 to -7.5)	-39.0 (-43.8 to -33.7)
Self-harm	-	-	-	-	2.0 (1.4 to 2.6)	2.3 (1.6 to 3.1)	18.1 (6.0 to 30.9)	-16.8 (-25.2 to -7.6)
Interpersonal violence	-	-	-	-	9.0 (6.8 to 11.5)	7.0 (5.1 to 9.3)	-22.1 (-29.3 to -14.3)	-43.9 (-49.0 to -38.3)
Assault by firearm	-	-	-	-	3.1 (2.3 to 3.9)	2.4 (1.7 to 3.2)	-22.4 (-29.1 to -15.1)	-44.2 (-49.0 to -39.1)
Assault by sharp object	-	-	-	-	1.4 (1.1 to 1.9)	1.5 (1.0 to 2.0)	2.2 (-6.4 to 12.3)	-26.7 (-32.9 to -19.5)
Assault by other means	-	-	-	-	4.5 (3.4 to 5.7)	3.1 (2.3 to 4.2)	-29.9 (-38.0 to -20.6)	-49.3 (-55.1 to -42.5)
Forces of nature, war, and legal intervention	-	-	-	-	41.9 (11.7 to 110.6)	4.2 (1.6 to 9.1)	-89.4 (-93.9 to -79.0)	-93.3 (-96.2 to -86.4)
Exposure to forces of nature	-	-	-	-	0.4 (0.2 to 0.8)	0.5 (0.2 to 1.6)	-16.6 (-51.4 to 526.6)	-30.3 (-58.2 to 409.9)
Collective violence and legal intervention	-	-	-	-	41.4 (11.5 to 110.1)	3.7 (1.2 to 8.7)	-90.8 (-94.4 to -84.5)	-94.2 (-96.5 to -90.1)

Appendix Table G.4 - Armenia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	327.3 (243.3 to 426.9)	316.6 (235.7 to 409.7)	-3.3 (-5.8 to 0.6)	-3.3 (-4.1 to 1.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	31.9 (22.1 to 44.2)	24.2 (17.4 to 33.0)	-24.1 (-30.5 to -14.9)	2.4 (-6.1 to 14.7)
HIV/AIDS and tuberculosis	-	-	-	-	1.0 (0.7 to 1.3)	1.0 (0.7 to 1.4)	1.5 (8.5 to 13.9)	7.7 (-2.8 to 20.5)
Tuberculosis	3.2 (2.9 to 3.5)	3.2 (2.9 to 3.5)	-0.4 (-7.0 to 7.3)	5.1 (-1.2 to 12.4)	1.0 (0.7 to 1.3)	1.0 (0.7 to 1.3)	-1.1 (-10.8 to 11.1)	5.0 (-4.8 to 17.6)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	1,703,323.0 (116,760.5 to 408,178,697.7)	1,914,921.1 (125,858.0 to 472,915,250.0)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	973,093.7 (58,833.7 to 0.0)	1,103,670.9 (63,350.7 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	973,093.7 (58,795.5 to nan)	1,103,670.9 (62,807.3 to nan)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.3 (0.2 to 0.6)	2,047,895.9 (183,249.0 to 0.0)	2,334,147.1 (208,881.5 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	1,769,928.0 (113,048.2 to nan)	1,979,324.6 (123,262.0 to nan)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	5.1 (3.6 to 7.0)	3.5 (2.4 to 4.7)	-32.5 (-36.2 to -28.5)	-10.8 (-15.5 to -5.8)
Diarrheal diseases	13.9 (13.1 to 14.8)	9.0 (8.5 to 9.5)	-35.5 (-40.7 to -30.4)	-8.7 (-15.9 to -1.4)	2.3 (1.5 to 3.1)	1.4 (1.0 to 2.0)	-36.3 (-41.9 to -30.0)	-8.5 (-16.7 to -0.0)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-60.5 (-79.4 to -18.7)	-50.0 (-73.9 to 2.9)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.3 (-57.5 to -38.9)	-36.3 (-45.9 to -23.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.3 (-57.5 to -38.9)	-36.3 (-46.1 to -23.6)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.8 (-56.9 to -38.0)	-31.7 (-43.5 to -19.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.8 (-56.9 to -38.0)	-31.7 (-43.8 to -19.9)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.0 (-99.6 to 134.0)	88.6 (-99.5 to 195.1)
Lower respiratory infections	0.8 (0.5 to 1.1)	0.5 (0.4 to 0.6)	-35.0 (-56.6 to 1.0)	-5.7 (-37.0 to 39.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-35.2 (-58.4 to 6.1)	-5.1 (-38.3 to 46.3)
Upper respiratory infections	84.5 (80.7 to 87.9)	67.8 (64.9 to 70.7)	-19.7 (-25.0 to -14.2)	-0.8 (-7.1 to 5.6)	1.0 (0.6 to 1.7)	1.0 (0.5 to 1.4)	-20.1 (-26.0 to -14.1)	-0.8 (-8.0 to 6.5)
Otitis media	44.4 (41.0 to 48.0)	31.9 (29.4 to 34.4)	-28.3 (-34.1 to -21.3)	-10.6 (-17.5 to -2.0)	0.9 (0.5 to 1.5)	0.6 (0.4 to 1.0)	-29.8 (-36.0 to -22.6)	-10.9 (-18.2 to -1.7)
Meningitis	-	-	-	-	0.6 (0.4 to 0.8)	0.3 (0.2 to 0.4)	-49.4 (-59.7 to -37.1)	-40.0 (-51.6 to -24.7)
Pneumococcal meningitis	2.6 (1.6 to 3.9)	1.4 (0.8 to 2.1)	-47.5 (-56.5 to -37.4)	-43.0 (-52.6 to -32.1)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-46.7 (-57.9 to -34.4)	-38.7 (-51.2 to -24.4)
H influenzae type B meningitis	1.7 (0.5 to 3.4)	0.8 (0.2 to 1.5)	-56.1 (-67.5 to -38.5)	-48.7 (-61.0 to -25.4)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.1)	-50.9 (-67.8 to -13.0)	-38.7 (-59.3 to 10.1)
Meningococcal meningitis	0.6 (0.2 to 1.3)	0.3 (0.1 to 0.6)	-51.0 (-70.1 to -36.7)	-51.0 (-65.1 to -28.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-56.6 (-73.6 to -26.6)	-50.0 (-68.9 to -15.5)
Other meningitis	0.8 (0.4 to 1.6)	0.4 (0.2 to 0.8)	-50.0 (-61.4 to -39.6)	-44.1 (-54.1 to -31.8)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-50.4 (-64.8 to -36.3)	-41.4 (-57.6 to -23.8)
Encephalitis	1.5 (0.7 to 3.3)	1.2 (0.5 to 2.8)	-20.6 (-33.5 to -8.8)	-15.7 (-28.6 to -3.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-17.7 (-32.0 to -1.2)	-9.3 (-24.8 to 8.8)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.9 (-97.4 to 249.1)	-49.7 (-96.5 to 322.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.9 (-97.4 to 251.1)	-49.7 (-96.5 to 323.8)
Whooping cough	0.7 (0.5 to 0.8)	0.5 (0.4 to 0.6)	-28.4 (-29.7 to -27.1)	-28.0 (-25.8 to -30.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-28.0 (-38.8 to -15.0)	28.1 (9.7 to 51.7)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.4 (-72.0 to -31.5)	-44.1 (-67.1 to -22.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.2 (-72.6 to -30.9)	-49.2 (-67.4 to -21.0)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-98.7 (-99.5 to -98.0)	-97.7 (-99.1 to -96.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-98.7 (-99.1 to -96.5)	-97.7 (-99.1 to -96.5)
Varicella and herpes zoster	2.2 (2.1 to 2.4)	1.6 (1.5 to 1.8)	-26.3 (-33.1 to -19.2)	-1.8 (-11.9 to 7.6)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-8.0 (-27.3 to 17.1)	-2.8 (-23.1 to 22.8)
Neglected tropical diseases and malaria	-	-	-	-	1.3 (0.8 to 1.9)	0.8 (0.5 to 1.1)	-42.4 (-55.2 to -11.9)	-13.0 (-32.3 to 29.4)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-92.3 (-98.6 to -79.4)	-90.9 (-98.3 to -75.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.0 (-80.2 to 206.8)	37.2 (-76.3 to 278.7)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.8 (-55.1 to 25.6)	-3.8 (-42.7 to 62.6)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.5 (-33.7 to 30.7)	29.9 (-6.7 to 80.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.5 (-33.7 to 31.5)	29.9 (-6.8 to 81.0)
Cutaneous and mucocutaneous leishmaniasis	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-27.9 (-59.5 to 22.9)	-10.4 (-48.7 to 56.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.0 (-60.4 to 31.2)	-9.8 (-50.3 to 66.9)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.6 (0.2 to 1.4)	0.5 (0.2 to 1.2)	-15.7 (-69.8 to 275.1)	-10.5 (-67.7 to 278.8)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	-11.4 (-68.7 to 298.5)	-6.0 (-66.1 to 304.8)
Cystic echinococcosis	1.2 (1.1 to 1.3)	0.6 (0.6 to 0.7)	-48.9 (-52.3 to -44.4)	-49.4 (-54.2 to -44.0)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-48.1 (-56.7 to -38.5)	-48.3 (-57.4 to -38.7)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-71.8 (-83.7 to -43.3)	-63.5 (-78.2 to -22.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-71.8 (-83.8 to -43.3)	-63.5 (-78.3 to -22.8)
Intestinal nematode infections	-	-	-	-	0.1 (0.0 to 0.3)	0.0 (0.0 to 0.0)	-84.5 (-97.6 to -36.4)	-82.0 (-97.2 to -29.5)
Ascariasis	24.4 (13.4 to 45.8)	16.8 (10.2 to 27.7)	-29.0 (-70.2 to 50.2)	-14.0 (-63.0 to 79.9)	0.1 (0.0 to 0.3)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -99.7)	-100.0 (-100.0 to -99.6)
Trichuriasis	-	-	-	-	0.9 (-57.5 to 62.2)	0.9 (-48.7 to 90.8)	-	-
Hookworm disease	2.7 (1.5 to 4.5)	2.6 (1.4 to 4.4)	-2.4 (-56.0 to 117.9)	1.8 (-54.1 to 127.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.5 (-74.7 to 99.5)	-16.2 (-72.9 to 107.5)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	28.3 (19.3 to 37.9)	16.5 (15.3 to 17.9)	-41.6 (-56.2 to -15.2)	-4.3 (-28.0 to 38.3)	0.9 (0.5 to 1.4)	0.5 (0.4 to 0.8)	-44.1 (-51.2 to 2.0)	-4.8 (-16.7 to 75.2)
Maternal disorders	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-52.6 (-64.7 to -36.5)	-45.9 (-59.5 to -27.3)
Maternal hemorrhage	0.6 (0.4 to 0.7)	0.4 (0.3 to 0.5)	-38.4 (-57.2 to -6.0)	-28.6 (-50.2 to 8.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.7 (-69.9 to -2.3)	-36.3 (-64.3 to 9.8)
Maternal sepsis and other maternal infections	2.5 (1.3 to 4.3)	1.0 (0.6 to 1.7)	-58.2 (-65.4 to -47.4)	-51.6 (-60.1 to -39.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-63.3 (-77.4 to -42.1)	-57.8 (-73.8 to -34.0)
Maternal hypertensive disorders	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-40.8 (-53.2 to -33.4)	-33.7 (-47.3 to -25.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.4 (-64.6 to -14.8)	-35.3 (-59.5 to -4.1)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.4 (-59.5 to -9.8)	-31.5 (-53.9 to 2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.4 (-59.6 to -9.8)	-31.5 (-54.0 to 3.4)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.3 (-51.8 to -30.1)	-41.1 (-45.2 to -20.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.7 (-71.6 to 23.5)	-34.6 (-67.2 to 41.5)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.5 (-72.8 to -10.0)	-43.6 (-69.0 to 2.6)
Neonatal disorders	-	-	-	-	3.9 (2.5 to 5.6)	5.7 (3.8 to 8.0)	44.5 (-6.6 to 115.5)	85.4 (18.7 to 177.3)
Preterm birth complications	10.5 (6.2 to 18.2)	18.5 (11.6 to 29.9)	79.1 (34.7 to 129.5)	119.7 (65.6 to 184.8)	1.3 (0.8 to 2.1)	2.5 (1.5 to 3.6)	93.3 (17.5 to 197.2)	144.4 (48.8 to 273.7)
Neonatal encephalopathy due to birth asphyxia and trauma	6.2 (2.6 to 15.5)	3.7 (1.9 to 7.6)	-39.5 (-65.1 to 20.7)	-38.5 (-65.6 to 57.7)	1.2 (0.6 to 2.0)	1.0 (0.6 to 1.7)	-22.4 (-59.1 to 65.8)	2.5 (-46.0 to 117.1)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.2 (-42.6 to -27.5)	17.6 (4.3 to 31.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.6 (-45.1 to -21.5)	16.9 (-0.2 to 42.6)
Hemolytic disease and other neonatal jaundice	1.8 (0.7 to 3.3)	2.5 (1.4 to 4.2)	35.4 (-42.2 to 290.5)	72.2 (-26.6 to 401.4)	0.7 (0.3 to 1.3)	1.0 (0.5 to 1.7)	37.8 (-42.9 to 298.1)	76.0 (-27.9 to 405.9)
Other neonatal disorders	-	-	-	-	1.3 (0.3 to 1.3)	0.7 (0.6 to 2.4)	87.9 (-15.0 to 325.3)	142.6 (9.2 to 450.4)
Nutritional deficiencies	-	-	-	-	18.6 (12.2 to 27.1)	11.5 (7.8 to 17.1)	-18.6 (-41.1 to -30.6)	9.8 (-16.7 to -1.4)
Protein-energy malnutrition	4.0 (1.5 to 8.3)	2.6 (1.0 to 5.6)	-33.9 (-79.4 to 109.0)	19.2 (-62.8 to 275.7)	0.5 (0.2 to 1.2)	0.3 (0.1 to 0.7)	-33.6 (-80.4 to 111.4)	19.8 (-64.6 to 280.3)
Iodine deficiency	73.8 (50.9 to 99.3)	33.8 (18.6 to 51.5)	-55.4 (-75.0 to -18.2)	-49.9 (-71.6 to -9.0)	1.3 (0.7 to 2.3)	0.6 (0.3 to 1.1)	-55.9 (-75.4 to -18.4)	-50.2 (-71.8 to -8.4)

Appendix Table G.4 - Armenia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron-deficiency anemia	505.5 (497.8 to 513.7)	352.2 (347.8 to 356.3)	-30.3 (-31.8 to -28.8)	-6.7 (-8.5 to -4.8)	16.2 (10.7 to 23.6)	10.6 (7.0 to 15.5)	-34.3 (-36.5 to -32.6)	-7.5 (-10.4 to -5.2)
Other nutritional deficiencies	-	-	-	-	0.6 (0.2 to 1.5)	0.3 (0.1 to 0.8)	-41.8 (-83.6 to 107.6)	5.1 (-70.4 to 273.8)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.9 (1.2 to 2.9)	1.4 (0.9 to 2.2)	-25.4 (-32.9 to -16.4)	-4.8 (-13.9 to 5.7)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.3 (0.5 to 1.6)	0.8 (0.5 to 1.3)	-13.0 (-23.8 to 0.7)	-1.3 (-13.4 to 13.8)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-28.9 (-41.2 to -14.8)	-34.2 (-45.1 to -22.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.2 (-48.4 to -1.1)	-31.7 (-51.1 to -9.1)
Chlamydial infection	112.8 (98.1 to 128.6)	96.7 (83.0 to 108.7)	-14.2 (-28.8 to 2.7)	-0.7 (-17.5 to 18.7)	0.5 (0.3 to 0.8)	0.4 (0.2 to 0.7)	-8.5 (-25.8 to 12.6)	5.7 (-14.0 to 29.3)
Gonococcal infection	22.7 (17.4 to 27.9)	17.5 (13.9 to 20.5)	-22.2 (-43.2 to 2.6)	-7.1 (-31.6 to 22.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-19.3 (-45.5 to 20.3)	-3.3 (-34.8 to 44.7)
Trichomoniasis	52.2 (37.2 to 71.9)	37.3 (28.5 to 49.9)	-28.4 (-56.4 to 18.4)	-6.9 (-48.7 to 37.9)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-31.4 (-59.4 to 18.9)	-19.2 (-52.6 to 39.1)
Genital herpes	564.8 (547.6 to 581.4)	551.5 (534.0 to 568.6)	-2.3 (-6.4 to 1.6)	-0.9 (-6.9 to 1.0)	0.1 (0.0 to 0.4)	0.1 (0.0 to 0.3)	-2.0 (-10.5 to 1.9)	-2.8 (-8.6 to 3.2)
Other sexually transmitted diseases	1.0 (0.8 to 1.3)	0.7 (0.6 to 0.9)	-30.2 (-39.0 to -17.4)	-21.8 (-31.2 to -7.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.1 (-42.4 to 6.0)	-10.9 (-33.8 to 18.7)
Hepatitis	-	-	-	-	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-29.1 (-41.7 to -12.9)	-20.1 (-34.4 to -8.8)
Hepatitis A	4.2 (4.1 to 4.4)	2.8 (2.8 to 2.9)	-32.9 (-33.5 to -32.4)	-7.1 (-7.1 to -6.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-22.4 (-30.5 to -13.6)	-2.4 (-12.7 to 8.6)
Hepatitis B	368.7 (324.3 to 414.0)	229.7 (191.0 to 266.3)	-37.9 (-50.3 to -26.2)	-30.2 (-44.4 to -17.5)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-33.9 (-54.2 to -4.2)	-29.3 (-51.2 to 3.7)
Hepatitis C	268.2 (243.1 to 292.9)	199.8 (180.7 to 220.0)	-25.3 (-35.0 to -15.3)	-25.5 (-35.1 to -15.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.2 (-45.9 to -4.8)	-24.9 (-44.0 to -1.3)
Hepatitis E	0.4 (0.3 to 0.4)	0.3 (0.3 to 0.4)	-11.1 (-22.2 to 3.1)	1.1 (-11.8 to 18.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.3 (-37.0 to 28.7)	0.6 (-27.7 to 42.5)
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	19.6 (16.2 to 23.7)	11.8 (10.2 to 13.6)	-39.9 (-49.9 to -29.4)	-4.5 (-20.9 to 12.5)	0.6 (0.4 to 1.0)	0.4 (0.2 to 0.6)	-40.3 (-52.1 to -29.6)	-1.0 (-20.4 to 16.7)
Non-communicable diseases	-	-	-	-	265.1 (197.4 to 345.7)	269.6 (200.2 to 349.0)	1.7 (-1.3 to 4.9)	1.5 (-1.4 to 4.6)
Neoplasms	-	-	-	-	2.2 (1.5 to 2.9)	3.4 (2.5 to 4.5)	60.8 (33.1 to 83.5)	44.6 (20.7 to 63.6)
Esophageal cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-7.9 (-36.0 to 40.3)	-27.0 (-48.5 to 10.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.6 (-33.7 to 37.5)	-27.5 (-48.8 to 11.2)
Stomach cancer	1.1 (0.9 to 1.2)	0.9 (0.8 to 1.1)	-14.3 (-29.1 to 6.0)	-30.2 (-42.0 to -14.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-13.2 (-29.5 to 6.6)	-29.8 (-42.8 to -13.8)
Liver cancer	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	33.0 (-4.9 to 83.7)	1.8 (-26.5 to 42.0)
Liver cancer due to hepatitis B	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	11.2 (-34.3 to 87.7)	-10.8 (-47.9 to 50.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.6 (-26.5 to 60.8)	-12.5 (-41.9 to 29.5)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	245.5 (99.5 to 485.9)	159.6 (50.2 to 334.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	220.6 (108.8 to 385.0)	137.2 (45.4 to 265.7)
Liver cancer due to alcohol use	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	26.2 (-26.5 to 112.0)	26.2 (-45.8 to 56.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.2 (-19.1 to 81.4)	-9.0 (-39.6 to 35.7)
Liver cancer due to other causes	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-37.6 (-67.2 to 18.5)	-50.1 (-74.0 to -1.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.4 (-62.8 to 2.7)	-51.9 (-70.6 to -16.2)
Larynx cancer	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.6)	5.5 (-30.0 to 56.7)	-3.8 (-35.1 to 41.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-0.4 (-28.8 to 41.4)	-9.6 (-34.2 to 25.3)
Tracheal, bronchus and lung cancer	1.1 (1.0 to 1.3)	1.7 (1.4 to 2.0)	54.5 (25.3 to 92.1)	36.9 (11.4 to 69.9)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	50.0 (23.0 to 83.5)	33.7 (11.1 to 61.1)
Breast cancer	4.4 (3.4 to 5.3)	14.1 (12.1 to 16.0)	223.7 (158.4 to 308.4)	186.0 (127.7 to 263.4)	0.1 (0.3 to 0.5)	0.4 (0.6 to 1.1)	186.7 (88.6 to 318.2)	108.0 (66.2 to 153.8)
Cervical cancer	2.3 (1.9 to 3.1)	2.0 (1.4 to 2.5)	-13.9 (-41.4 to 12.3)	-16.6 (-43.0 to 9.3)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-14.0 (-42.7 to 14.4)	-16.7 (-44.5 to 10.1)
Uterine cancer	1.0 (0.7 to 1.6)	1.3 (0.7 to 1.8)	26.9 (-23.8 to 85.8)	12.6 (-31.4 to 61.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	26.4 (-25.5 to 90.0)	10.9 (-33.0 to 63.0)
Prostate cancer	1.2 (0.9 to 1.6)	3.2 (1.9 to 4.5)	193.4 (56.9 to 324.0)	135.8 (27.3 to 241.3)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.5)	331.2 (75.1 to 544.2)	250.5 (40.5 to 408.2)
Colon and rectum cancer	1.8 (1.7 to 2.0)	3.3 (3.0 to 3.7)	83.5 (56.6 to 112.7)	55.2 (33.8 to 80.1)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	77.2 (49.5 to 110.1)	48.0 (25.8 to 74.3)
Lip and oral cavity cancer	0.5 (0.4 to 0.7)	0.6 (0.4 to 0.7)	12.8 (-25.7 to 72.7)	1.5 (-32.4 to 53.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	15.4 (-24.8 to 66.9)	2.0 (-33.0 to 50.3)
Nasopharynx cancer	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-17.4 (-55.4 to 33.7)	-15.1 (-53.1 to 34.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.2 (-53.5 to 26.2)	-16.4 (-52.1 to 27.1)
Other pharynx cancer	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	11.2 (-41.4 to 105.5)	-1.0 (-47.1 to 84.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.1 (-33.0 to 81.7)	-3.4 (-39.8 to 54.6)
Gallbladder and biliary tract cancer	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-34.4 (-51.8 to 54.7)	-38.5 (-65.5 to 10.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.9 (-51.8 to 52.1)	-38.8 (-65.0 to 11.7)
Pancreatic cancer	0.1 (0.1 to 0.2)	0.3 (0.3 to 0.4)	95.5 (48.1 to 155.1)	52.8 (14.9 to 99.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	91.7 (40.6 to 132.1)	42.9 (10.3 to 84.4)
Malignant skin melanoma	1.0 (0.8 to 1.3)	1.2 (1.0 to 1.5)	22.1 (-9.8 to 65.4)	21.2 (-10.0 to 62.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	20.4 (-11.6 to 64.3)	18.0 (-13.4 to 61.7)
Non-melanoma skin cancer	0.7 (0.6 to 1.0)	1.5 (1.1 to 1.9)	108.0 (40.9 to 211.3)	58.9 (6.9 to 137.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	171.5 (68.4 to 354.4)	107.6 (29.1 to 248.0)
Ovarian cancer	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.8)	58.0 (15.4 to 118.1)	37.6 (2.2 to 89.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	54.8 (8.2 to 127.7)	34.8 (6.1 to 94.5)
Testicular cancer	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	27.4 (-33.3 to 142.4)	15.5 (-26.1 to 160.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.4 (-38.8 to 150.9)	21.7 (-31.6 to 175.0)
Kidney cancer	0.4 (0.3 to 0.5)	1.0 (0.8 to 1.2)	133.2 (63.2 to 231.7)	94.5 (36.5 to 177.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	116.7 (52.4 to 214.6)	79.7 (25.3 to 157.4)
Bladder cancer	0.6 (0.5 to 0.8)	1.2 (1.0 to 1.5)	89.7 (35.7 to 157.2)	49.1 (8.3 to 100.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	83.1 (32.8 to 152.8)	41.6 (3.6 to 92.5)
Brain and nervous system cancer	1.2 (0.9 to 1.7)	1.2 (0.9 to 1.5)	5.0 (-29.5 to 38.4)	23.5 (-15.2 to 62.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	7.6 (-23.0 to 36.2)	20.2 (-13.1 to 51.6)
Thyroid cancer	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	75.2 (-15.6 to 164.7)	66.3 (-13.7 to 177.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.7 (-17.3 to 184.5)	29.6 (-16.4 to 184.3)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.7 (-31.7 to 53.3)	-20.7 (-45.0 to 17.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.5 (-29.2 to 56.8)	-19.1 (-44.0 to 22.0)
Hodgkin lymphoma	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-1.5 (-39.2 to 56.8)	16.7 (-27.7 to 82.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.4 (-36.6 to 60.9)	14.4 (-26.8 to 79.6)
Non-Hodgkin lymphoma	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.7)	119.5 (1.5 to 206.7)	114.6 (9.9 to 199.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	107.3 (-1.7 to 189.6)	99.3 (-2.4 to 179.9)
Multiple myeloma	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	58.9 (6.8 to 152.7)	45.3 (-2.6 to 127.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.8 (6.6 to 135.9)	38.7 (-2.3 to 112.4)
Leukemia	1.3 (1.0 to 1.8)	1.2 (1.0 to 1.5)	-7.0 (-34.0 to 22.8)	15.3 (-17.0 to 50.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	8.5 (-17.8 to 40.3)	23.8 (-4.7 to 57.2)
Other neoplasms	2.4 (1.8 to 3.2)	3.6 (2.8 to 4.4)	57.3 (1.8 to 111.7)	57.3 (11.4 to 111.8)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	45.5 (0.1 to 93.2)	43.8 (4.1 to 90.7)
Cardiovascular diseases	-	-	-	-	3.7 (2.5 to 5.1)	4.5 (3.1 to 6.2)	22.3 (-4.3 to 56.0)	-6.1 (-25.4 to 18.9)
Rheumatic heart disease	0.5 (0.4 to 0.5)	0.5 (0.4 to 0.6)	6.5 (-10.2 to 27.7)	-6.9 (-22.1 to 12.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.8 (-15.0 to 44.4)	-5.9 (-25.0 to 24.5)
Ischemic heart disease	32.5 (27.8 to 40.2)	39.7 (35.7 to 44.7)	22.3 (-3.5 to 51.6)	-5.2 (-22.3 to 15.2)	1.6 (1.0 to 2.4)	1.9 (1.3 to 2.6)	17.7 (-13.1 to 57.0)	9.9 (-30.1 to 16.8)
Cerebrovascular disease	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.6)	19.5 (-8.6 to 59.0)	3.3 (-21.7 to 34.9)
Ischemic stroke	1.4 (1.2 to 1.7)	1.8 (1.4 to 2.1)	25.3 (-8.4 to 66.5)	3.0 (-25.6 to 38.6)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	24.3 (-9.6 to 65.9)	3.0 (-24.8 to 37.5)
Hemorrhagic stroke	1.1 (0.9 to 1.3)	1.3 (1.1 to 1.6)	17.7 (-10.7 to 55.4)	5.7 (-20.8 to 36.8)	0.2 (0.1 to 0.2)	0.3 (0.1 to 0.3)	15.3 (-13.6 to 59.4)	5.0 (-21.1 to 43.3)
Hypertensive heart disease	3.8 (3.4 to 4.2)	5.7 (5.1 to 6.3)	48.0 (27.2 to 72.2)	14.4 (-13.4 to 19.3)	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.9)	18.5 (-24.1 to 75.2)	1.8 (-14.4 to 20.8)
Cardiomyopathy and myocarditis	2.4 (2.1 to 2.8)	3.4 (3.0 to 3.8)	42.8 (16.7 to 73.0)	7.0 (-13.3 to 31.8)	0.2 (0.2 to 0.4)	0.3 (0.2 to 0.5)	43.4 (16.7 to 78.9)	7.2 (-14.2 to 34.6)
Atrial fibrillation and flutter	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.5)	207.1 (85.2 to 330.9)	157.4 (60.0 to 260.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	194.4 (68.5 to 362.6)	148.8 (45.9 to 284.4)
Peripheral vascular disease	68.9 (50.4 to 86.3)	95.6 (75.3 to 122.0)	36.1 (-1.1 to 106.2)	1.6 (-25.0 to 50.4)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-3.7 (-48.8 to 115.7)	-45.9 (-71.6 to 21.2)
Endocarditis	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-61.3 (-93.1 to -43.3)	-34.0 (-57.9 to 1.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.8 (-43.0 to 51.4)	-33.2 (-60.3 to 9.4)
Other cardiovascular and circulatory diseases	12.3 (6.0 to 22.6)	14.1 (6.9 to 22.8)	12.6 (-55.2 to 174.3)	-10.5 (-64.1 to 121.3)	0.9 (0.4 to 1.6)	1.0 (0.4 to 1.8)	12.0 (-54.7 to 176.3)	-10.6 (-63.7 to 120.7)
Chronic respiratory diseases	-	-	-	-	10.0 (6.7 to 13.5)	10.6 (7.3 to 14.6)	6.7 (-7.0 to 21.7)	-0.7 (-13.4 to 12.6)

Appendix Table G.4 - Armenia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Chronic obstructive pulmonary disease	122.8 (116.9 to 128.8)	135.1 (128.7 to 141.0)	10.0 (6.6 to 13.0)	0.3 (-2.6 to 3.1)	7.2 (4.8 to 10.0)	7.9 (5.1 to 11.3)	10.7 (9.6 to 27.6)	10.7 (-17.1 to 15.6)
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.7 (-2.3 to 5.5)	-10.5 (-14.0 to -7.0)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.7 (8.7 to 19.3)	-0.1 (-4.4 to 4.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.4 (9.1 to 20.6)	0.2 (-4.3 to 5.1)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.9 (-10.3 to -1.3)	-16.7 (-20.4 to -12.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.1 (-9.7 to 0.4)	-16.1 (-20.0 to -12.3)
Asthma	56.9 (43.8 to 69.1)	58.3 (48.7 to 68.9)	2.0 (-22.2 to 43.3)	-2.4 (-24.3 to 35.6)	2.5 (1.5 to 3.7)	2.5 (1.6 to 3.7)	2.2 (-22.7 to 43.9)	-1.9 (-24.5 to 37.7)
Interstitial lung disease and pulmonary sarcoidosis	0.3 (0.3 to 0.4)	0.3 (0.2 to 0.4)	-2.5 (-31.2 to 38.9)	-2.6 (-31.5 to 39.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-1.5 (-30.1 to 40.2)	-2.2 (-31.1 to 40.0)
Other chronic respiratory diseases	-	-	-	-	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.2)	0.1 (-63.3 to -32.6)	0.1 (-66.7 to -39.2)
Cirrhosis	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	3.4 (14.7 to 50.1)	30.3 (16.7 to 52.2)
Cirrhosis due to hepatitis B	0.7 (0.6 to 0.9)	0.9 (0.7 to 1.1)	24.7 (9.4 to 70.7)	23.7 (-10.6 to 70.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	23.2 (-15.4 to 71.9)	23.3 (-14.5 to 74.8)
Cirrhosis due to hepatitis C	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.7)	30.9 (-28.1 to 170.2)	25.9 (-30.5 to 150.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	30.2 (-30.3 to 163.5)	26.0 (-30.5 to 151.6)
Cirrhosis due to alcohol use	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	54.3 (-0.0 to 159.1)	40.9 (-8.3 to 130.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	54.0 (-5.5 to 168.8)	42.2 (-12.1 to 140.1)
Cirrhosis due to other causes	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.5)	19.4 (-12.6 to 74.8)	48.7 (10.7 to 118.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	17.1 (-22.4 to 89.6)	48.4 (-11.2 to 138.2)
Digestive diseases	-	-	-	-	2.8 (2.0 to 3.8)	3.4 (2.4 to 4.5)	19.5 (11.7 to 26.6)	9.3 (1.9 to 16.4)
Peptic ulcer disease	23.1 (21.9 to 24.3)	25.5 (23.7 to 27.3)	10.7 (0.9 to 19.7)	-10.3 (-18.3 to -3.1)	0.6 (0.4 to 0.9)	0.7 (0.5 to 1.1)	19.1 (3.6 to 35.7)	-8.8 (-20.2 to 3.3)
Gastritis and duodenitis	5.0 (4.5 to 5.6)	5.3 (4.7 to 5.9)	5.6 (-7.5 to 20.1)	10.4 (-2.7 to 22.7)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-10.3 (-26.5 to 7.9)	2.6 (-14.2 to 24.2)
Appendicitis	0.3 (0.3 to 0.4)	0.3 (0.2 to 0.3)	21.5 (-39.2 to -3.6)	0.1 (-22.3 to 21.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	21.6 (-47.4 to 13.6)	0.1 (-32.4 to 46.0)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.4 (-12.1 to 28.9)	11.2 (-9.8 to 27.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.5 (-17.2 to 39.6)	10.9 (-15.2 to 39.4)
Inguinal, femoral, and abdominal hernia	11.8 (10.0 to 13.6)	10.8 (9.1 to 12.5)	-9.0 (-24.3 to 12.4)	-22.4 (-35.7 to -3.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-9.1 (-25.0 to 12.7)	-21.6 (-35.2 to -2.4)
Inflammatory bowel disease	4.2 (4.1 to 4.4)	5.9 (5.7 to 6.1)	39.9 (32.1 to 47.4)	35.7 (28.1 to 42.7)	0.9 (0.6 to 1.2)	1.3 (0.9 to 1.7)	38.9 (27.4 to 50.6)	35.8 (25.0 to 46.9)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.4 (-8.4 to 107.6)	0.7 (-32.5 to 52.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.5 (-21.0 to 119.8)	1.8 (-40.9 to 69.6)
Gallbladder and biliary diseases	3.6 (3.2 to 4.1)	3.4 (2.9 to 3.8)	-5.7 (-24.4 to 14.3)	-20.8 (-36.5 to -4.4)	0.4 (0.3 to 0.5)	0.4 (0.2 to 0.5)	-5.7 (-26.2 to 15.1)	-21.0 (-37.4 to -3.6)
Pancreatitis	0.8 (0.8 to 0.9)	1.3 (1.3 to 1.4)	57.7 (47.8 to 69.0)	48.8 (39.9 to 59.2)	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	56.8 (34.9 to 84.4)	49.7 (29.3 to 74.6)
Other digestive diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	16.4 (-10.8 to 55.8)	5.2 (-19.6 to 43.2)
Neurological disorders	-	-	-	-	30.4 (20.4 to 42.1)	31.0 (21.2 to 42.8)	2.1 (-9.7 to 15.0)	4.3 (-7.1 to 16.4)
Alzheimer disease and other dementias	18.4 (16.4 to 20.6)	30.9 (26.9 to 34.8)	67.8 (41.1 to 106.0)	1.2 (-15.0 to 24.9)	2.6 (1.9 to 3.5)	4.6 (3.3 to 6.1)	72.7 (44.5 to 112.1)	1.8 (-14.6 to 25.9)
Parkinson disease	1.2 (1.0 to 1.4)	1.8 (1.5 to 2.0)	41.5 (32.2 to 51.6)	1.0 (-3.9 to 5.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	41.1 (22.5 to 63.4)	1.7 (-10.1 to 15.6)
Epilepsy	14.3 (9.5 to 18.9)	12.5 (8.6 to 16.5)	-12.4 (-45.2 to 49.1)	2.7 (-35.8 to 74.5)	4.6 (2.6 to 7.0)	4.2 (2.5 to 6.3)	-9.3 (-44.0 to 53.9)	7.3 (-33.4 to 82.0)
Multiple sclerosis	0.7 (0.6 to 0.8)	0.8 (0.8 to 0.9)	14.1 (6.0 to 38.0)	23.3 (7.9 to 40.3)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	23.6 (-4.3 to 49.1)	25.6 (-7.0 to 52.0)
Migraine	520.3 (464.7 to 572.7)	461.1 (412.1 to 509.7)	-11.0 (-24.6 to 3.6)	-2.2 (-16.9 to 13.4)	17.9 (10.5 to 26.4)	15.8 (9.3 to 23.4)	-11.4 (-25.0 to 3.3)	-1.9 (-17.0 to 14.1)
Tension-type headache	783.6 (720.8 to 847.6)	719.9 (637.4 to 813.6)	-8.1 (-21.1 to 6.9)	-0.5 (-14.7 to 15.0)	1.2 (0.6 to 2.1)	1.1 (0.5 to 2.0)	-8.2 (-21.7 to 6.5)	-0.3 (-15.0 to 15.3)
Medication overuse headache	21.7 (14.5 to 28.7)	29.8 (19.9 to 39.7)	37.8 (13.3 to 65.1)	42.7 (17.2 to 70.3)	3.4 (2.0 to 5.3)	4.7 (2.6 to 7.1)	37.2 (12.1 to 64.9)	42.3 (16.7 to 71.0)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.5 (-25.3 to 35.5)	8.6 (-18.9 to 45.9)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-32.6 (-52.0 to -6)	-58.6 (-70.4 to -38.9)
Mental and substance use disorders	-	-	-	-	74.3 (53.4 to 97.4)	66.9 (48.1 to 87.2)	-9.9 (-12.6 to -7.4)	-0.4 (-3.2 to 2.2)
Schizophrenia	10.4 (9.5 to 11.2)	9.9 (9.1 to 10.6)	-4.8 (-8.5 to -0.9)	-0.1 (-4.0 to 3.6)	6.7 (4.9 to 8.1)	6.4 (4.7 to 7.7)	-4.9 (-10.8 to 1.1)	0.2 (-5.6 to 6.1)
Alcohol use disorders	29.9 (25.6 to 34.5)	32.5 (28.2 to 37.0)	8.9 (1.4 to 16.4)	19.4 (11.0 to 27.3)	3.0 (1.9 to 4.3)	3.3 (2.1 to 4.6)	8.8 (0.1 to 18.2)	19.6 (10.0 to 29.4)
Drug use disorders	-	-	-	-	4.6 (3.1 to 6.1)	4.0 (2.7 to 5.3)	-12.6 (-22.7 to -1.5)	1.2 (-10.6 to 14.1)
Opioid use disorders	4.5 (3.3 to 5.7)	4.0 (3.1 to 5.0)	-9.6 (-19.9 to 0.3)	4.1 (-6.4 to 13.7)	1.9 (1.2 to 2.7)	1.7 (1.1 to 2.4)	-9.5 (-21.9 to 4.1)	4.3 (-8.6 to 18.7)
Cocaine use disorders	2.8 (2.5 to 3.1)	2.4 (2.1 to 2.7)	-13.0 (-26.6 to 2.1)	-1.0 (-16.2 to 16.3)	0.4 (0.2 to 0.6)	0.3 (0.2 to 0.5)	-13.1 (-31.1 to 10.2)	-1.1 (-20.7 to 25.1)
Amphetamine use disorders	6.7 (6.1 to 7.3)	5.7 (5.3 to 6.0)	-15.4 (-24.5 to -5.0)	-1.9 (-12.3 to 10.7)	0.9 (0.5 to 1.3)	0.7 (0.5 to 1.1)	-15.3 (-27.6 to 0.7)	-1.6 (-15.4 to 16.9)
Cannabis use disorders	6.3 (5.8 to 6.8)	5.4 (5.0 to 5.8)	-14.2 (-14.9 to -13.5)	2.1 (1.7 to 2.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-14.0 (-26.0 to -1.2)	2.4 (-11.9 to 17.3)
Other drug use disorders	-	-	-	-	1.3 (0.8 to 1.9)	1.1 (0.7 to 1.6)	-14.1 (-37.4 to 14.9)	-0.7 (-27.7 to 32.3)
Depressive disorders	-	-	-	-	29.8 (19.6 to 41.6)	27.4 (18.2 to 38.1)	-8.2 (-13.6 to -2.5)	-2.0 (-7.3 to 3.6)
Major depressive disorder	121.5 (96.9 to 143.1)	111.3 (89.0 to 131.9)	-8.6 (-15.4 to -1.5)	-2.2 (-8.9 to 4.6)	25.1 (16.0 to 36.0)	22.8 (14.8 to 32.1)	-9.3 (-15.8 to -2.1)	-2.3 (-8.7 to 4.7)
Dysthymia	48.4 (39.8 to 56.5)	47.3 (39.3 to 54.8)	-2.2 (-4.7 to 1.0)	-1.5 (-1.7 to 1.2)	4.7 (3.0 to 6.9)	4.6 (3.0 to 6.7)	-2.6 (-5.9 to 1.2)	-1.3 (-3.5 to 1.0)
Bipolar disorder	24.2 (21.0 to 27.3)	22.5 (19.7 to 25.2)	-6.8 (-11.7 to -1.5)	-4.9 (-5.9 to 4.6)	4.9 (3.0 to 7.5)	4.6 (2.8 to 6.8)	-9.4 (-13.9 to -4.0)	4.7 (-7.4 to 6.2)
Anxiety disorders	105.1 (85.6 to 126.2)	92.1 (74.5 to 109.2)	-12.4 (-14.9 to -9.6)	-2.4 (-2.9 to -2.0)	9.7 (6.5 to 14.1)	8.8 (5.7 to 12.2)	-13.0 (-16.4 to -9.2)	-2.4 (-5.0 to 0.4)
Eating disorders	-	-	-	-	0.9 (0.6 to 1.4)	0.7 (0.4 to 1.1)	-23.0 (-29.9 to -15.8)	-4.9 (-12.8 to 3.9)
Anorexia nervosa	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-17.7 (-25.0 to -9.7)	3.4 (-6.3 to 13.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-17.1 (-39.9 to 15.6)	3.9 (-24.4 to 46.2)
Bulimia nervosa	4.0 (2.9 to 5.4)	3.1 (2.1 to 4.2)	-23.4 (-25.6 to -21.3)	5.5 (-4.4 to 4.8)	0.9 (0.5 to 1.4)	0.7 (0.4 to 1.0)	-23.4 (-30.6 to -16.2)	5.7 (-13.6 to 3.4)
Autistic spectrum disorders	-	-	-	-	4.2 (2.9 to 5.6)	3.5 (2.5 to 4.8)	-14.7 (-17.9 to -11.6)	4.3 (0.7 to 7.8)
Autism	10.6 (10.1 to 11.2)	9.1 (8.6 to 9.6)	-14.4 (-14.9 to -13.3)	3.7 (3.5 to 3.9)	2.6 (1.8 to 3.6)	2.2 (1.5 to 3.1)	-14.8 (-19.3 to -10.8)	4.1 (-1.3 to 8.8)
Asperger syndrome	15.1 (14.2 to 16.1)	13.0 (12.2 to 13.8)	-14.1 (-14.8 to -13.3)	4.7 (4.6 to 4.8)	1.5 (1.1 to 2.1)	1.3 (0.9 to 1.8)	-14.4 (-18.0 to -10.7)	4.9 (0.7 to 9.2)
Attention-deficit/hyperactivity disorder	19.6 (18.1 to 21.2)	14.0 (12.9 to 15.1)	-28.7 (-29.1 to -28.4)	5.2 (4.8 to 5.4)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-28.7 (-33.7 to -22.9)	5.2 (-2.1 to 13.3)
Conduct disorder	28.2 (26.5 to 29.9)	19.7 (18.5 to 21.0)	-30.6 (-30.6 to -29.1)	29.9 (4.6 to 5.0)	4.8 (2.2 to 5.0)	2.4 (1.5 to 3.5)	-29.8 (-33.0 to -26.5)	5.0 (3.0 to 9.8)
Idiopathic intellectual disability	53.6 (43.0 to 65.6)	36.4 (28.5 to 45.3)	-31.7 (-42.4 to -22.7)	-16.9 (-29.6 to -6.1)	2.6 (1.7 to 3.8)	1.8 (1.1 to 2.6)	-31.8 (-43.0 to -22.7)	-16.6 (-30.1 to -5.2)
Other mental and substance use disorders	56.7 (53.1 to 60.2)	57.5 (54.1 to 60.8)	1.5 (-0.0 to 3.0)	2.1 (1.7 to 2.6)	4.3 (2.9 to 5.7)	4.3 (2.9 to 5.8)	1.0 (-3.0 to 5.1)	2.3 (-1.4 to 6.2)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	33.1 (23.6 to 44.3)	37.6 (26.5 to 50.0)	13.2 (1.2 to 28.0)	13.3 (1.1 to 28.1)
Diabetes mellitus	192.1 (160.7 to 222.9)	257.9 (214.6 to 307.9)	33.5 (8.7 to 68.1)	29.7 (6.1 to 64.4)	15.1 (9.9 to 21.0)	20.5 (13.6 to 29.1)	35.1 (10.4 to 70.0)	28.0 (5.7 to 61.9)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.3 (-56.3 to -49.8)	-39.9 (-43.3 to -36.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.3 (-56.3 to -49.8)	-39.9 (-43.3 to -36.3)
Chronic kidney disease	-	-	-	-	7.8 (5.6 to 10.4)	7.7 (5.5 to 10.1)	-1.7 (-10.7 to 6.1)	0.9 (-7.9 to 8.1)
Chronic kidney disease due to diabetes mellitus	35.6 (24.4 to 53.8)	44.9 (31.0 to 73.1)	26.9 (-9.0 to 57.0)	9.6 (-19.5 to 45.0)	1.2 (0.8 to 1.7)	1.5 (1.0 to 2.2)	22.6 (-7.3 to 64.0)	10.6 (-16.0 to 47.9)
Chronic kidney disease due to hypertension	62.0 (37.6 to 101.7)	55.9 (32.8 to 92.8)	-11.2 (-30.9 to 22.3)	-11.2 (-22.8 to 36.6)	0.1 (1.5 to 2.9)	0.9 (0.6 to 1.4)	-11.2 (-47.5 to 42.2)	0.7 (-6.7 to 43.5)
Chronic kidney disease due to glomerulonephritis	65.8 (42.7 to 97.7)	37.0 (27.9 to 49.0)	-43.0 (-56.5 to -27.6)	-41.0 (-53.4 to -25.8)	2.0 (1.4 to 2.9)	2.0 (1.4 to 2.7)	-1.0 (-22.5 to 25.9)	11.8 (-11.8 to 43.9)
Chronic kidney disease due to other causes	83.5 (50.3 to 136.0)	101.8 (68.6 to 149.6)	21.5 (-11.6 to 61.6)	28.5 (-0.1 to 62.0)	2.4 (1.7 to 3.3)	3.2 (2.2 to 4.4)	33.4 (3.4 to 61.5)	37.1 (6.7 to 68.3)

Appendix Table G.4 - Armenia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Urinary diseases and male infertility	-	-	-	-	2.0	2.8	39.9	22.4
Interstitial nephritis and urinary tract infections	0.9 (0.8 to 1.0)	1.0 (0.9 to 1.1)	6.5 (-4.6 to 17.9)	21.4 (8.7 to 34.5)	1.3 to 2.8	1.8 to 3.9	(25.9 to 52.9)	(0.9 to 23.2)
Urolithiasis	21.9 (16.3 to 30.0)	28.3 (21.3 to 36.2)	30.2 (0.8 to 52.5)	4.8 (-18.2 to 20.9)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	10.7 (6.0 to 26.5)	-1.0 (-15.6 to 11.9)
Benign prostatic hyperplasia	44.5 (41.3 to 47.9)	66.0 (60.4 to 71.3)	48.7 (32.6 to 64.1)	1.6 (1.0 to 2.3)	2.4 (1.5 to 3.4)	48.4 (31.9 to 64.0)	14.2 (1.3 to 26.9)	
Male infertility due to other causes	14.9 (11.2 to 18.6)	13.5 (10.3 to 16.9)	-10.0 (-36.9 to 33.1)	0.1 (-23.2 to 64.4)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	0.0 (-38.4 to 40.0)	10.4 (-24.9 to 71.9)
Other urinary diseases	-	-	-	-	0.0	0.0	-20.9	-26.7
Gynecological diseases	-	-	-	-	4.4 (2.9 to 6.7)	3.9 (2.6 to 5.9)	-11.2 (-23.2 to 1.0)	-3.8 (-16.4 to 9.5)
Uterine fibroids	69.6 (62.7 to 75.8)	70.1 (64.1 to 75.8)	0.7 (-1.1 to 2.9)	-4.1 (-4.3 to -3.9)	1.0 (0.6 to 1.7)	0.9 (0.5 to 1.6)	-8.2 (-13.4 to -3.5)	-6.6 (-11.4 to -2.3)
Polycystic ovarian syndrome	62.8 (55.4 to 69.5)	53.0 (48.0 to 57.8)	-15.3 (-26.0 to -1.8)	6.7 (-17.8 to 7.1)	0.6 (0.3 to 1.1)	0.5 (0.2 to 0.9)	-16.5 (-27.1 to -1.1)	0.1 (-18.0 to 7.2)
Female infertility due to other causes	9.0 (5.2 to 13.5)	7.0 (4.1 to 10.6)	-22.3 (-58.3 to 54.9)	-1.7 (-47.6 to 95.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-23.2 (-58.3 to 50.0)	3.0 (-47.9 to 88.7)
Endometriosis	6.5 (5.4 to 7.6)	5.8 (5.0 to 6.7)	-9.6 (-27.7 to 12.6)	-1.8 (-20.8 to 21.1)	0.6 (0.4 to 0.9)	0.5 (0.4 to 0.8)	-9.7 (-29.2 to 14.0)	-1.8 (-21.5 to 23.4)
Genital prolapse	177.0 (153.9 to 198.7)	167.4 (148.2 to 187.6)	-6.0 (-19.8 to 11.9)	-4.3 (-18.5 to 12.9)	0.6 (0.3 to 1.0)	0.5 (0.3 to 1.0)	-6.0 (-20.6 to 11.5)	-4.1 (-18.8 to 12.9)
Premenstrual syndrome	146.6 (97.6 to 191.9)	123.2 (89.8 to 157.5)	-13.8 (-44.5 to 38.7)	4.7 (-35.1 to 59.1)	1.2 (0.6 to 2.0)	1.0 (0.6 to 1.7)	-14.1 (-46.0 to 59.7)	-0.9 (-36.0 to 59.7)
Other gynecological diseases	12.6 (11.1 to 14.3)	10.7 (9.9 to 11.6)	-15.1 (-25.7 to -2.8)	7.0 (-18.5 to 6.6)	0.4 (0.2 to 0.5)	0.3 (0.2 to 0.5)	-14.5 (-28.5 to 7.3)	5.9 (-21.3 to 16.4)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	2.2 (1.5 to 3.2)	1.6 (1.1 to 2.3)	-29.1 (-34.8 to -19.9)	-2.9 (-10.7 to 8.0)
Thalassemias	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-40.2 (-46.4 to -31.6)	-7.4 (-17.8 to 6.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.7 (-55.9 to -27.2)	-10.5 (-34.6 to 11.2)
Thalassemia trait	58.8 (50.2 to 73.2)	49.9 (42.3 to 60.8)	-15.1 (-19.1 to -10.6)	0.7 (-4.0 to 6.1)	1.7 (1.1 to 2.5)	1.3 (0.9 to 1.8)	-26.8 (-31.1 to -15.5)	-0.9 (-9.4 to 13.0)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-17.0 (-64.6 to -26.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.6 (-58.3 to -16.2)	-5.1 (-43.8 to 12.4)
Sickle cell trait	2.3 (1.6 to 2.8)	1.6 (1.3 to 2.1)	-26.3 (-46.6 to -18.1)	-1.7 (-36.0 to -1.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.4 (-53.9 to -13.2)	-14.7 (-39.8 to 15.2)
G6PD deficiency	7.2 (6.6 to 7.8)	7.3 (7.0 to 7.7)	1.6 (-6.1 to 11.6)	21.3 (12.1 to 33.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.1 (-27.9 to 19.2)	33.9 (4.3 to 66.2)
G6PD trait	405.6 (401.5 to 409.2)	325.8 (322.0 to 328.7)	-19.6 (-20.9 to -18.6)	-6.7 (-4.3 to -5.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.2 (-84.7 to 158.4)	-13.1 (-76.6 to 254.3)
Other hemoglobinopathies and hemolytic anemias	16.4 (13.1 to 19.5)	11.6 (10.1 to 12.6)	-29.4 (-41.9 to -11.2)	0.5 (-23.9 to 11.3)	0.5 (0.3 to 0.7)	0.3 (0.2 to 0.4)	-26.7 (-55.2 to -4.6)	9.4 (-35.3 to 29.0)
Endocrine, metabolic, blood, and immune disorders	44.2 (40.3 to 47.3)	31.3 (29.8 to 32.6)	-29.3 (-35.5 to -21.7)	-12.2 (-19.9 to -3.4)	1.5 (1.0 to 2.1)	1.1 (0.7 to 1.5)	-30.6 (-37.0 to -18.9)	-12.0 (-20.2 to 1.4)
Musculoskeletal disorders	-	-	-	-	55.0 (39.3 to 74.1)	59.2 (42.3 to 78.3)	8.1 (-2.9 to 17.9)	1.3 (-8.8 to 10.7)
Rheumatoid arthritis	5.2 (5.0 to 5.6)	6.3 (6.1 to 6.6)	20.8 (12.3 to 29.1)	15.5 (7.5 to 23.0)	1.3 (0.9 to 1.7)	1.5 (1.1 to 2.0)	18.5 (7.3 to 31.4)	15.0 (4.0 to 27.6)
Osteoarthritis	129.5 (124.3 to 134.9)	166.5 (158.8 to 171.0)	27.4 (19.9 to 34.5)	27.4 (-5.3 to 5.7)	0.2 (5.6 to 11.0)	0.2 (7.1 to 13.7)	26.5 (18.9 to 33.9)	0.3 (-5.3 to 6.1)
Low back and neck pain	-	-	-	-	38.9 (26.9 to 53.0)	39.9 (27.4 to 54.1)	3.1 (-11.4 to 16.8)	0.4 (-13.4 to 14.2)
Low back pain	222.1 (190.9 to 249.9)	234.6 (202.0 to 265.1)	5.6 (-12.3 to 27.3)	0.9 (-16.5 to 20.8)	24.8 (16.6 to 35.1)	26.0 (17.3 to 36.8)	4.9 (-13.5 to 26.9)	1.3 (-16.5 to 21.8)
Neck pain	143.6 (112.8 to 176.3)	141.5 (116.5 to 164.6)	-0.9 (-26.0 to 31.4)	-1.7 (-26.8 to 29.1)	14.1 (9.2 to 20.4)	13.9 (9.2 to 19.7)	-1.4 (-26.6 to 30.7)	-1.6 (-26.5 to 30.4)
Gout	2.2 (2.1 to 2.3)	2.7 (2.5 to 2.8)	21.7 (12.1 to 31.9)	0.1 (-2.6 to 3.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	5.9 (-1.0 to 48.5)	5.9 (-11.7 to 29.1)
Other musculoskeletal disorders	74.5 (56.8 to 92.2)	84.4 (66.7 to 103.0)	13.7 (3.3 to 23.0)	4.8 (-2.8 to 12.3)	6.8 (4.4 to 9.9)	7.7 (5.0 to 11.2)	13.3 (-2.0 to 23.6)	4.7 (-3.1 to 13.6)
Other non-communicable diseases	-	-	-	-	53.2 (35.5 to 76.3)	52.7 (35.9 to 75.1)	-0.9 (-4.1 to 2.6)	-4.9 (-7.9 to -2.1)
Congenital anomalies	-	-	-	-	3.4 (2.5 to 4.7)	3.8 (2.7 to 5.0)	11.1 (9.2 to 33.7)	35.9 (11.0 to 64.9)
Neural tube defects	0.8 (0.6 to 0.9)	0.9 (0.8 to 1.1)	15.5 (-5.3 to 45.8)	52.1 (24.7 to 91.9)	0.2 (0.2 to 0.4)	0.3 (0.2 to 0.4)	19.8 (-1.7 to 74.4)	58.7 (17.2 to 133.9)
Congenital heart anomalies	12.7 (9.8 to 16.3)	18.8 (16.7 to 21.9)	50.0 (13.8 to 97.4)	90.6 (44.4 to 151.3)	0.4 (0.2 to 0.8)	0.7 (0.3 to 1.1)	53.4 (16.1 to 98.9)	96.5 (47.8 to 155.1)
Orofacial clefts	1.8 (1.4 to 2.2)	2.8 (2.3 to 3.3)	53.5 (13.8 to 112.2)	100.9 (48.8 to 177.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	12.4 (-23.1 to 72.8)	47.3 (0.4 to 124.5)
Down syndrome	3.1 (2.7 to 3.8)	3.5 (2.9 to 4.3)	9.4 (-11.3 to 41.5)	30.4 (6.4 to 69.1)	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	19.5 (-5.1 to 59.0)	36.6 (9.0 to 80.0)
Turner syndrome	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-16.2 (-49.4 to 24.0)	3.7 (-37.3 to 53.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.3 (-51.6 to 30.3)	3.7 (-39.9 to 56.7)
Klinefelter syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-4.8 (-31.6 to 34.8)	17.2 (-15.8 to 65.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.1 (-27.7 to 42.7)	16.7 (-16.1 to 65.6)
Chromosomal unbalanced rearrangements	4.9 (3.7 to 6.2)	5.2 (4.5 to 6.0)	5.7 (-19.4 to 45.7)	26.2 (-4.0 to 74.7)	0.6 (0.4 to 0.9)	0.7 (0.5 to 1.0)	15.4 (-12.4 to 62.2)	32.2 (0.4 to 86.3)
Other congenital anomalies	12.2 (10.3 to 14.2)	10.0 (7.8 to 10.3)	-26.3 (-35.5 to -15.8)	-14.9 (-25.1 to -3.1)	1.7 (1.1 to 2.6)	1.6 (1.0 to 2.3)	-5.5 (-30.7 to 33.0)	18.6 (-13.4 to 65.8)
Skin and subcutaneous diseases	-	-	-	-	15.6 (10.2 to 23.0)	13.3 (8.6 to 19.6)	-14.7 (-22.4 to -8.0)	-4.3 (-13.0 to 2.9)
Dermatitis	141.3 (114.2 to 171.1)	126.0 (101.6 to 152.2)	-10.9 (-12.7 to -8.6)	-0.2 (-0.6 to 0.2)	0.2 (2.1 to 5.0)	0.3 (1.8 to 4.4)	19.8 (-15.2 to 8.7)	58.7 (-3.0 to 2.7)
Psoriasis	27.8 (24.6 to 31.1)	26.3 (23.3 to 29.4)	-5.4 (-7.2 to -3.2)	0.1 (-0.1 to 0.4)	2.3 (1.5 to 3.2)	2.1 (1.5 to 3.0)	-5.9 (-11.4 to -0.1)	0.4 (-4.7 to 5.8)
Cellulitis	1.2 (1.0 to 1.5)	1.0 (0.8 to 1.3)	-18.5 (-29.1 to -1.8)	-5.4 (-16.9 to 10.5)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-18.3 (-37.0 to 7.0)	-4.4 (-25.7 to 21.0)
Pyoderma	3.4 (2.9 to 4.1)	3.2 (2.6 to 3.9)	-6.5 (-13.4 to 0.5)	10.1 (5.5 to 15.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.2 (-17.5 to 3.1)	10.4 (0.1 to 20.1)
Scabies	8.2 (8.2 to 11.7)	9.8 (6.7 to 9.1)	21.6 (-37.7 to -2.1)	2.8 (-23.2 to 20.7)	0.1 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-21.8 (-38.9 to -1.7)	2.5 (-23.4 to 21.8)
Fungal skin diseases	263.6 (203.9 to 350.1)	244.2 (190.2 to 319.5)	-7.4 (-10.8 to -3.2)	1.4 (0.9 to 1.9)	1.5 (0.6 to 3.3)	1.4 (0.6 to 3.0)	-7.7 (-11.3 to -3.5)	1.5 (0.6 to 2.5)
Viral skin diseases	78.8 (60.1 to 97.5)	59.6 (44.4 to 75.6)	-24.5 (-27.9 to -21.0)	0.1 (-1.5 to 1.9)	2.4 (1.4 to 3.8)	1.8 (1.0 to 2.9)	-24.7 (-28.8 to -20.7)	0.1 (-2.9 to 3.1)
Acne vulgaris	85.2 (66.8 to 106.9)	69.0 (55.0 to 82.3)	-18.4 (-40.1 to 11.8)	2.8 (-25.8 to 40.9)	0.9 (0.4 to 1.8)	0.8 (0.3 to 1.5)	-8.3 (-40.4 to 11.6)	2.6 (-25.8 to 40.2)
Alopecia areata	3.9 (3.4 to 4.4)	3.8 (3.3 to 4.2)	-2.6 (-17.9 to 13.8)	2.8 (-13.2 to 19.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-3.3 (-20.9 to 15.2)	2.5 (-15.5 to 21.2)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.1 (-22.8 to 23.7)	1.5 (-20.2 to 26.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.1 (-22.8 to 23.7)	1.5 (-20.2 to 26.9)
Urticaria	56.0 (43.7 to 72.5)	42.3 (32.2 to 53.5)	-24.3 (-51.0 to 6.4)	-21.2 (-48.8 to 10.2)	3.4 (2.1 to 5.3)	2.5 (1.5 to 3.8)	-25.2 (-51.4 to 5.8)	-21.4 (-49.1 to 10.6)
Decubitus ulcer	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.3)	0.0 (-22.9 to 46.9)	1.8 (-24.5 to 40.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.9 (-24.3 to 51.3)	3.2 (-21.5 to 47.8)
Other skin and subcutaneous diseases	201.8 (130.3 to 316.9)	208.7 (128.5 to 337.7)	3.6 (-6.3 to 12.1)	-1.2 (-5.6 to 3.0)	1.2 (0.5 to 2.5)	1.2 (0.6 to 3.0)	2.7 (-6.7 to 12.0)	-1.1 (-5.7 to 3.2)
Sense organ diseases	-	-	-	-	25.8 (17.1 to 36.9)	27.0 (18.2 to 38.1)	4.6 (-0.1 to 9.6)	-10.0 (-13.7 to -6.7)
Glaucoma	4.9 (4.1 to 5.8)	4.8 (3.9 to 5.7)	-2.3 (-15.5 to 12.9)	-17.2 (-28.8 to -4.4)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.5)	9.6 (8.1 to 32.5)	-14.3 (-27.0 to -0.0)
Cataract	30.2 (23.9 to 36.6)	30.5 (24.3 to 36.9)	1.2 (-16.7 to 17.3)	-30.3 (-41.8 to -21.0)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.6)	2.7 (-14.8 to 19.2)	-30.1 (-40.2 to -21.0)
Macular degeneration	8.9 (6.6 to 12.0)	11.9 (9.1 to 15.1)	33.4 (-2.5 to 72.4)	7.2 (-2.0 to 39.3)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	32.4 (0.5 to 69.5)	4.3 (-20.2 to 34.6)
Uncorrected refractive error	315.8 (286.0 to 347.4)	327.9 (297.4 to 357.6)	3.9 (-7.6 to 17.6)	-7.2 (-17.4 to 4.2)	3.9 (2.9 to 7.9)	4.7 (2.7 to 7.9)	4.7 (-11.5 to 5.7)	-11.4 (-18.2 to -3.1)
Age-related and other hearing loss	509.7 (445.3 to 568.3)	550.5 (489.7 to 605.5)	7.8 (2.5 to 14.3)	-7.2 (-10.9 to -3.2)	16.1 (10.7 to 22.7)	17.9 (12.3 to 24.7)	11.5 (5.2 to 19.6)	-8.0 (-12.8 to -3.0)
Other vision loss	22.6 (19.9 to 26.2)	14.9 (12.9 to 17.3)	-34.0 (-41.6 to -26.4)	-33.4 (-40.9 to -25.5)	1.0 (0.7 to 1.5)	0.7 (0.5 to 1.0)	-29.9 (-37.6 to -20.9)	-32.4 (-38.8 to -24.7)
Other sense organ diseases	81.6 (77.5 to 85.2)	69.0 (65.7 to 72.3)	-14.5 (-20.6 to -9.4)	-1.0 (-6.8 to 5.8)	2.2 (1.3 to 3.2)	1.8 (1.1 to 2.7)	-16.4 (-22.2 to -9.5)	-1.0 (-7.7 to 6.3)
Oral disorders	-	-	-	-	8.4 (5.0 to 13.0)	8.7 (5.2 to 13.4)	3.7 (-0.2 to 9.8)	2.7 (-5.9 to 6.6)
Deciduous caries	313.5 (307.4 to 319.6)	177.2 (173.8 to 180.5)	-43.5 (-45.1 to -41.9)	0.4 (-2.4 to 3.1)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-43.5 (-46.7 to -40.0)	0.4 (-5.3 to 6.6)
Permanent caries	1,920.4 (1,859.9 to 1,967.9)	1,669.0 (1,619.0 to 1,713.2)	-13.1 (-16.4 to -9.5)	-0.8 (-4.5 to 3.1)	1.9 (0.9 to 3.7)	1.6 (0.8 to 3.2)	-13.5 (-16.7 to -9.7)	-0.8 (-4.6 to 3.3)

Appendix Table G.4 - Armenia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.								
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Periodontal diseases	241.6 (229.7 to 253.1)	261.7 (248.2 to 275.4)	8.4 (0.9 to 16.5)	2.1 (-5.0 to 9.8)	1.6 (0.6 to 3.3)	1.7 (0.7 to 3.5)	8.1 (0.4 to 16.5)	2.3 (-5.0 to 10.1)
Edentulism and severe tooth loss	107.6 (103.0 to 112.1)	131.6 (126.6 to 136.3)	22.2 (15.4 to 29.4)	-6.5 (-11.5 to -1.5)	3.0 (2.0 to 4.1)	3.6 (2.4 to 4.9)	21.5 (14.5 to 29.0)	-6.3 (-11.5 to -0.9)
Other oral disorders	61.1 (58.1 to 64.2)	55.8 (52.9 to 58.7)	-8.6 (-14.6 to -2.2)	-1.0 (-7.6 to 5.9)	1.8 (1.1 to 2.7)	1.6 (1.0 to 2.4)	-9.2 (-15.4 to -1.9)	-1.2 (-7.9 to 6.7)
Injuries	-	-	-	-	30.4 (22.9 to 39.1)	22.8 (16.2 to 30.8)	-25.2 (-32.7 to -17.4)	-30.9 (-37.7 to -23.4)
Transport injuries	-	-	-	-	5.2 (3.9 to 6.8)	2.6 (1.8 to 3.5)	-50.8 (-56.9 to -43.7)	-51.9 (-57.7 to -45.3)
Road injuries	-	-	-	-	4.6 (3.4 to 6.0)	2.1 (1.5 to 2.9)	-53.5 (-59.5 to -46.4)	-54.5 (-60.2 to -47.9)
Pedestrian road injuries	-	-	-	-	1.0 (0.7 to 1.2)	0.4 (0.3 to 0.6)	-54.4 (-60.7 to -46.5)	-56.3 (-62.0 to -49.1)
Cyclist road injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.3 (0.2 to 0.4)	-48.8 (-54.7 to -42.7)	-50.8 (-56.3 to -45.1)
Motorcyclist road injuries	-	-	-	-	0.4 (0.3 to 0.6)	0.2 (0.1 to 0.3)	-52.5 (-58.4 to -44.8)	-52.8 (-58.6 to -45.6)
Motor vehicle road injuries	-	-	-	-	2.6 (2.0 to 3.4)	1.2 (0.9 to 1.6)	-54.0 (-60.7 to -46.2)	-54.7 (-61.0 to -47.6)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-59.4 (-64.8 to -52.9)	-61.1 (-66.1 to -55.2)
Other transport injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.5 (0.3 to 0.6)	-33.1 (-40.5 to -24.3)	-35.0 (-41.9 to -26.3)
Unintentional injuries	-	-	-	-	24.7 (18.7 to 31.9)	19.5 (14.2 to 26.8)	-19.7 (-27.4 to -11.9)	-26.7 (-33.7 to -19.4)
Falls	-	-	-	-	16.8 (12.6 to 21.6)	13.9 (9.8 to 18.8)	-17.3 (-26.3 to -7.1)	-27.8 (-35.9 to -18.8)
Drowning	-	-	-	-	0.3 (0.2 to 0.3)	0.1 (0.1 to 0.1)	-61.8 (-67.2 to -54.9)	-60.5 (-65.8 to -53.8)
Fire, heat, and hot substances	-	-	-	-	0.7 (0.6 to 0.9)	0.4 (0.3 to 0.6)	-44.1 (-51.4 to -35.9)	-43.1 (-50.1 to -35.1)
Poisonings	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-46.5 (-53.7 to -37.9)	-41.8 (-49.4 to -32.2)
Exposure to mechanical forces	-	-	-	-	4.3 (3.2 to 5.6)	3.2 (2.3 to 4.3)	-25.4 (-30.7 to -19.4)	-22.4 (-27.4 to -15.8)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-41.2 (-50.0 to -30.5)	-40.1 (-48.8 to -29.9)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-24.8 (-33.7 to -15.7)	-22.2 (-31.3 to -13.8)
Other exposure to mechanical forces	-	-	-	-	4.1 (3.1 to 5.4)	3.1 (2.2 to 4.2)	-25.1 (-30.2 to -19.0)	-22.0 (-26.9 to -16.4)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	6.5 (0.3 to 13.1)	1.4 (-4.3 to 7.8)
Animal contact	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-19.0 (-26.6 to -10.3)	-14.0 (-21.6 to -5.6)
Venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-17.8 (-28.3 to -6.6)	-12.5 (-23.6 to -0.9)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-19.8 (-28.1 to -10.0)	-15.1 (-23.0 to -5.9)
Foreign body	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-28.8 (-35.7 to -21.1)	-26.5 (-33.4 to -19.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-46.3 (-55.1 to -34.4)	-43.9 (-52.6 to -32.1)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-15.9 (-21.1 to -10.8)	-8.8 (-15.3 to -2.2)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-20.3 (-28.1 to -11.9)	-20.4 (-27.7 to -12.9)
Other unintentional injuries	-	-	-	-	2.1 (1.6 to 2.7)	1.8 (1.3 to 2.5)	-12.9 (-20.0 to -4.6)	-16.7 (-23.1 to -8.9)
Self-harm and interpersonal violence	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-28.8 (-36.8 to -18.9)	-30.7 (-38.3 to -21.5)
Self-harm	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-1.3 (-11.5 to 12.1)	-5.9 (-15.4 to 6.6)
Interpersonal violence	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.2)	-43.1 (-50.5 to -34.0)	-44.1 (-51.0 to -35.5)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.1 (-38.4 to -24.4)	-33.6 (-39.8 to -25.8)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-35.4 (-43.1 to -23.5)	-36.6 (-44.2 to -25.6)
Assault by other means	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-46.3 (-53.5 to -36.8)	-47.1 (-54.0 to -38.1)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Australia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	2,131.2 (1,593.1 to 2,733.3)	3,226.2 (2,411.1 to 4,139.5)	51.5 (47.9 to 54.4)	2.2 (-2.2 to 1.9)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	97.4 (67.4 to 136.5)	134.3 (96.2 to 183.5)	38.2 (26.1 to 50.3)	6.9 (-2.0 to 15.7)
HIV/AIDS and tuberculosis	-	-	-	-	1.9 (1.2 to 2.9)	1.6 (1.1 to 2.3)	-13.3 (-39.2 to 17.4)	-40.1 (-58.6 to -19.3)
Tuberculosis	2.2 (2.1 to 2.4)	2.7 (2.6 to 2.9)	23.5 (17.7 to 29.9)	-13.2 (-17.2 to -9.0)	0.7 (0.4 to 1.0)	0.8 (0.6 to 1.1)	22.2 (-1.7 to 53.9)	-13.7 (-30.7 to 9.6)
HIV/AIDS	-	-	-	-	1.3 (0.7 to 2.1)	0.8 (0.4 to 1.4)	-33.2 (-62.7 to 55.8)	-95.5 (-75.5 to -28.9)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.8 (-85.6 to -52.4)	-79.5 (-90.1 to -66.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.8 (-85.7 to -52.3)	-79.5 (-90.1 to -66.5)
HIV/AIDS resulting in other diseases	7.4 (5.5 to 9.7)	10.6 (6.7 to 15.5)	44.2 (-2.9 to 93.0)	-3.7 (-37.0 to 30.4)	1.3 (0.7 to 2.1)	0.8 (0.4 to 1.4)	-33.1 (-62.7 to 6.0)	-55.5 (-75.5 to -28.7)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	10.8 (7.3 to 15.3)	12.0 (7.9 to 17.6)	11.1 (18.1 to 19.8)	-18.7 (-25.7 to -12.1)
Diarrheal diseases	9.0 (8.5 to 9.5)	12.3 (11.6 to 12.9)	36.2 (25.5 to 47.9)	-2.1 (-9.9 to 6.4)	1.4 (1.0 to 2.0)	1.9 (1.3 to 2.7)	35.4 (18.7 to 55.1)	-2.2 (-14.6 to 13.0)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.2 (58.0 to 15.5)	-42.5 (-68.0 to -14.2)
Typhoid fever	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-14.4 (-35.4 to 12.9)	-36.3 (-51.2 to -14.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.4 (-35.5 to 13.0)	-36.3 (-51.3 to -14.7)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.2 (-14.1 to 57.8)	-11.8 (-33.7 to 18.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.2 (-14.1 to 57.8)	-11.8 (-33.8 to 18.4)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-81.2 (-98.6 to 169.8)	85.9 (99.0 to 101.0)
Lower respiratory infections	3.2 (2.7 to 3.9)	3.9 (3.0 to 4.9)	22.9 (-14.7 to 73.2)	-28.6 (-48.9 to -1.8)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	21.3 (-18.6 to 75.0)	-28.1 (-50.8 to 1.5)
Upper respiratory infections	323.5 (303.7 to 340.7)	420.8 (396.6 to 442.7)	29.8 (19.8 to 40.8)	-3.0 (-10.3 to 5.2)	3.8 (2.1 to 6.3)	4.9 (2.8 to 8.2)	29.4 (19.3 to 40.9)	-3.0 (-10.6 to 5.7)
Otitis media	106.9 (102.0 to 111.4)	125.6 (119.5 to 131.4)	17.4 (10.7 to 24.2)	-12.4 (-17.1 to -7.5)	2.0 (1.2 to 3.2)	2.3 (1.4 to 3.7)	17.1 (9.0 to 25.0)	-13.0 (-18.9 to -6.6)
Meningitis	-	-	-	-	2.6 (1.7 to 3.6)	1.5 (1.0 to 2.1)	-42.3 (-58.3 to -27.8)	-57.8 (-69.9 to -46.5)
Pneumococcal meningitis	11.4 (7.3 to 18.4)	6.6 (4.1 to 11.2)	-42.6 (-52.9 to -28.6)	-60.4 (-67.2 to -50.8)	0.6 (0.7 to 1.6)	0.6 (0.4 to 0.8)	-45.3 (-59.4 to -28.7)	-60.6 (-71.1 to -48.6)
H influenzae type B meningitis	3.0 (1.0 to 7.1)	1.9 (0.6 to 4.5)	-36.3 (-67.5 to 34.6)	-53.5 (-75.8 to 4.7)	0.4 (0.2 to 0.7)	0.3 (0.1 to 0.5)	-28.3 (-69.7 to 54.8)	-45.1 (-77.2 to 20.2)
Meningococcal meningitis	2.3 (0.8 to 5.8)	1.1 (0.3 to 3.1)	-53.2 (-77.0 to -30.0)	-67.9 (-83.7 to -49.0)	0.3 (0.2 to 0.6)	0.1 (0.1 to 0.3)	-69.0 (-79.0 to -25.2)	-69.0 (-85.3 to -45.4)
Other meningitis	5.4 (2.6 to 11.4)	3.3 (1.5 to 7.3)	-39.7 (-57.0 to -21.5)	-56.7 (-68.7 to -43.9)	0.8 (0.5 to 1.1)	0.5 (0.3 to 0.7)	-38.2 (-59.6 to -14.1)	-54.8 (-70.7 to -35.7)
Encephalitis	0.9 (0.4 to 2.5)	1.3 (0.6 to 3.5)	40.5 (12.5 to 79.1)	-48.4 (-23.9 to 23.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	-1.0 (16.5 to 88.4)	-1.0 (-21.6 to 29.8)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.3 (-93.6 to 466.9)	-52.1 (-95.6 to 298.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.3 (-93.9 to 469.9)	-52.1 (-95.6 to 301.6)
Whooping cough	1.9 (1.5 to 2.4)	1.9 (1.5 to 2.4)	1.5 (0.4 to 2.7)	-16.1 (-17.1 to -15.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	1.4 (-11.6 to 16.4)	-16.2 (-27.0 to -3.8)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.1 (-41.8 to 67.5)	-5.2 (-58.8 to 23.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.6 (-39.9 to 65.1)	-6.2 (-57.6 to 20.3)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.5 (-85.6 to -79.4)	-85.4 (-88.0 to -82.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-82.5 (-85.6 to -79.4)	-85.4 (-88.0 to -82.9)
Varicella and herpes zoster	12.2 (11.0 to 13.6)	17.6 (15.8 to 19.9)	42.9 (28.8 to 62.9)	0.3 (-8.8 to 12.3)	0.4 (0.3 to 0.7)	0.7 (0.4 to 1.1)	57.0 (29.5 to 94.7)	1.4 (-16.4 to 25.6)
Neglected tropical diseases and malaria	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	20.2 (-17.7 to 96.2)	-21.3 (-46.6 to 28.8)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.3 (-47.3 to 673.3)	27.3 (-60.3 to 485.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.8 (-46.9 to 689.6)	30.2 (-60.1 to 494.5)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Visceral leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Cysticercosis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-57.3 (-82.3 to 85.7)	-71.1 (-88.4 to 25.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.5 (-81.0 to 96.0)	-69.4 (-87.6 to 32.7)
Cystic echinococcosis	2.0 (1.6 to 2.3)	2.2 (1.7 to 2.7)	4.6 (-14.7 to 63.6)	-34.7 (-45.3 to 1.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	8.1 (-22.2 to 77.0)	-31.7 (-50.2 to 10.8)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-77.3 (-87.6 to -58.0)	-99.0 (-93.8 to -79.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-74.1 (-86.5 to -50.7)	-87.5 (-93.4 to -76.6)
Dengue	0.1 (0.0 to 0.3)	0.3 (0.0 to 0.9)	298.7 (268.2 to 336.8)	188.5 (166.5 to 216.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.2)	298.7 (268.0 to 336.8)	188.5 (166.3 to 216.1)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.7 (-5.3 to 169.9)	-6.9 (-33.9 to 90.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.7 (-5.4 to 170.0)	-6.9 (-34.0 to 90.8)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Ascariasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trichuriasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Hookworm disease	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	573.7 (196.2 to 753.6)	388.8 (114.8 to 519.9)
Maternal disorders	-	-	-	-	0.6 (0.3 to 1.2)	0.7 (0.4 to 1.2)	15.6 (-33.2 to 59.0)	-9.3 (-47.4 to 24.2)
Maternal hemorrhage	13.1 (6.0 to 20.5)	16.9 (11.0 to 22.6)	29.3 (-13.3 to 163.8)	1.5 (-31.4 to 109.7)	0.2 (0.1 to 0.6)	0.2 (0.1 to 0.5)	5.1 (-61.5 to 95.3)	-17.3 (-69.9 to 53.0)
Maternal sepsis and other maternal infections	0.7 (0.3 to 1.4)	0.8 (0.3 to 1.5)	3.2 (-60.4 to 213.6)	-38.0 (-68.1 to 140.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.0 (-28.1 to 63.4)	-16.8 (-43.3 to 27.1)
Maternal hypertensive disorders	3.9 (2.1 to 6.2)	5.2 (2.6 to 8.3)	32.2 (12.2 to 51.3)	2.9 (-13.4 to 19.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.5)	31.8 (23.3 to 65.4)	2.6 (-21.0 to 29.7)
Obstructed labor	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	13.6 (-46.8 to 123.7)	-10.7 (-58.4 to 76.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.6 (-47.1 to 124.1)	-10.7 (-58.5 to 77.5)
Complications of abortion	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	27.6 (-13.6 to 74.2)	-0.1 (-32.0 to 36.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.6 (-13.6 to 74.9)	-0.1 (-32.1 to 37.1)
Other maternal disorders	-	-	-	-	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.3)	11.3 (-42.6 to 95.5)	-12.7 (-55.3 to 53.5)
Neonatal disorders	-	-	-	-	19.8 (13.9 to 28.2)	40.6 (27.8 to 54.7)	106.7 (44.3 to 170.4)	52.5 (6.7 to 99.5)
Preterm birth complications	110.6 (77.7 to 153.7)	225.3 (160.0 to 317.2)	102.7 (69.9 to 143.7)	47.4 (23.8 to 77.2)	11.9 (8.3 to 16.3)	24.4 (17.0 to 32.8)	106.9 (53.4 to 169.0)	52.8 (13.2 to 99.1)
Neonatal encephalopathy due to birth asphyxia and trauma	18.9 (10.1 to 39.2)	17.3 (7.9 to 42.8)	-13.1 (-39.5 to 32.2)	-35.9 (-55.0 to -2.3)	3.9 (2.6 to 5.8)	3.6 (2.3 to 5.3)	-10.0 (-39.8 to 47.8)	-32.8 (-54.8 to 9.8)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.0 (42.1 to 82.0)	33.8 (17.4 to 83.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.5 (9.4 to 145.5)	39.2 (-9.6 to 102.8)
Hemolytic disease and other neonatal jaundice	5.3 (2.1 to 12.2)	6.1 (2.7 to 14.3)	14.3 (-63.3 to 221.8)	-16.1 (-73.1 to 137.1)	2.1 (0.8 to 5.0)	2.5 (1.0 to 5.8)	14.6 (-63.3 to 232.9)	-15.5 (-73.0 to 143.4)
Other neonatal disorders	-	-	-	-	1.9 (1.1 to 3.5)	10.2 (4.6 to 16.0)	506.7 (88.1 to 868.9)	348.7 (38.5 to 616.2)
Nutritional deficiencies	-	-	-	-	58.3 (38.6 to 85.9)	71.7 (47.2 to 105.5)	22.8 (18.5 to 29.8)	-1.0 (-4.2 to 4.8)
Protein-energy malnutrition	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.5)	71.9 (4.3 to 144.2)	-20.0 (-51.0 to 10.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	63.8 (-15.2 to 183.6)	-22.1 (-58.7 to 32.7)
Iodine deficiency	185.3 (51.9 to 165.2)	96.2 (55.9 to 150.1)	-90.9 (-56.9 to 116.3)	-36.6 (-69.1 to 51.5)	1.9 (0.8 to 3.5)	1.7 (0.8 to 3.2)	-10.8 (-55.5 to 118.2)	-35.8 (-67.9 to 54.9)
Vitamin A deficiency	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Iron deficiency anemia	2,048.6 (1,999.1 to 2,094.7)	2,706.0 (2,656.0 to 2,764.4)	31.8 (29.1 to 35.6)	-0.1 (-2.6 to 3.0)	56.4 (37.3 to 82.6)	69.9 (46.1 to 102.3)	23.7 (20.1 to 30.5)	-0.0 (-2.8 to 5.8)

Appendix Table G.4 - Australia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.1 (-35.6 to 88.2)	47.0 (-68.1 to -12.3)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	5.7 (3.4 to 9.2)	7.5 (4.6 to 12.5)	31.0 (14.2 to 49.3)	-0.6 (-13.3 to 13.8)
Sexually transmitted diseases excluding HIV	-	-	-	-	2.5 (1.3 to 4.7)	3.6 (1.9 to 6.7)	42.4 (21.8 to 70.1)	2.5 (-12.6 to 23.6)
Syphilis	1.1 (0.9 to 1.3)	2.4 (2.0 to 2.7)	112.5 (73.3 to 161.7)	26.8 (2.9 to 57.6)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	111.2 (55.4 to 190.6)	27.0 (-7.3 to 75.8)
Chlamydial infection	385.3 (266.9 to 407.5)	453.4 (381.1 to 536.8)	17.3 (4.0 to 78.4)	30.7 (-20.5 to 37.4)	1.2 (0.4 to 1.7)	1.7 (0.6 to 2.3)	42.8 (-11.2 to 122.0)	1.2 (-31.8 to 72.3)
Gonococcal infection	90.5 (69.8 to 118.9)	122.3 (94.9 to 155.5)	35.2 (-4.5 to 92.8)	6.7 (-25.4 to 53.3)	0.4 (0.2 to 0.7)	0.5 (0.2 to 0.9)	21.3 (-8.7 to 57.9)	-4.4 (-28.7 to 25.0)
Trichomoniasis	107.4 (82.0 to 130.5)	141.9 (109.6 to 173.8)	31.2 (-2.9 to 87.2)	0.8 (-26.1 to 43.4)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.5)	30.8 (-6.3 to 95.0)	0.7 (-28.7 to 51.4)
Genital herpes	2,943.9 (2,869.6 to 3,014.9)	4,398.1 (4,292.1 to 4,494.7)	49.3 (44.3 to 54.4)	-0.7 (-4.1 to 2.8)	0.8 (0.2 to 1.9)	1.1 (0.4 to 2.7)	47.5 (39.5 to 54.9)	-0.6 (-5.8 to 4.9)
Other sexually transmitted diseases	2.3 (1.5 to 3.4)	2.9 (2.0 to 4.0)	22.7 (-21.6 to 99.0)	-3.8 (-38.9 to 53.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	65.3 (-0.9 to 108.1)	10.4 (-24.7 to 58.5)
Hepatitis	-	-	-	-	0.8 (0.5 to 1.2)	1.0 (0.6 to 1.4)	17.8 (2.2 to 37.0)	17.8 (-27.3 to -3.5)
Hepatitis A	13.5 (12.8 to 14.2)	16.1 (15.0 to 17.1)	18.7 (17.0 to 20.3)	-10.9 (-12.6 to -9.2)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	23.3 (9.3 to 39.5)	-9.3 (-19.7 to 2.4)
Hepatitis B	750.5 (675.3 to 819.6)	713.8 (646.0 to 792.5)	-5.3 (-16.4 to 9.2)	-33.8 (-41.5 to -24.1)	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.6)	11.5 (-17.2 to 53.8)	23.6 (-42.6 to 4.7)
Hepatitis C	478.2 (439.9 to 515.6)	535.4 (494.4 to 580.5)	11.6 (0.8 to 25.2)	-28.2 (-35.3 to -19.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	18.6 (-16.2 to 63.4)	-24.5 (-44.0 to 2.5)
Hepatitis E	-	-	-	-	0.5 (-2.3 to 19.7)	-	-	-
Leprosy	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	34.1 (-29.0 to 515.8)	-20.6 (-58.8 to 272.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.8 (-29.1 to 652.3)	-18.9 (-58.7 to 346.2)
Other infectious diseases	82.1 (70.9 to 95.9)	101.9 (91.2 to 114.3)	24.2 (6.2 to 43.6)	-0.5 (-16.3 to 14.2)	2.4 (1.5 to 3.7)	3.0 (1.8 to 4.6)	24.3 (-4.3 to 58.6)	1.3 (-20.2 to 28.7)
Non-communicable diseases	-	-	-	-	1,910.3 (1,422.0 to 2,452.7)	2,960.0 (2,223.4 to 3,807.0)	55.0 (51.2 to 58.4)	1.9 (-0.2 to 4.1)
Neoplasms	-	-	-	-	311.8 (23.4 to 41.1)	593.5 (44.0 to 77.0)	86.5 (74.1 to 99.3)	5.4 (-1.4 to 12.8)
Esophageal cancer	1.6 (1.3 to 1.9)	3.3 (2.4 to 4.1)	98.9 (45.0 to 168.6)	9.0 (-20.5 to 47.1)	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	88.3 (40.5 to 145.1)	3.6 (-22.3 to 32.6)
Stomach cancer	6.0 (5.3 to 6.9)	8.4 (7.2 to 9.9)	39.4 (18.4 to 64.1)	-24.0 (-34.9 to -11.4)	0.7 (0.5 to 0.9)	0.9 (0.6 to 1.2)	31.7 (9.7 to 58.7)	-28.1 (-39.9 to -13.1)
Liver cancer	-	-	-	-	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	221.6 (66.5 to 358.3)	81.4 (5.2 to 153.7)
Liver cancer due to hepatitis B	0.2 (0.1 to 0.3)	0.6 (0.3 to 1.0)	183.8 (25.6 to 567.5)	66.0 (-25.9 to 292.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	168.2 (20.9 to 318.1)	55.8 (-28.8 to 256.7)
Liver cancer due to hepatitis C	0.2 (0.1 to 0.2)	1.5 (0.8 to 2.3)	846.7 (405.2 to 1,844.9)	418.9 (182.5 to 967.3)	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	759.8 (382.5 to 1,610.2)	375.4 (166.7 to 850.9)
Liver cancer due to alcohol use	0.4 (0.2 to 0.5)	0.6 (0.3 to 1.0)	72.4 (-16.7 to 230.9)	-4.6 (-52.9 to 81.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	61.4 (-19.9 to 194.1)	-10.6 (-55.6 to 60.6)
Liver cancer due to other causes	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.3)	-35.3 (-50.8 to 172.1)	-22.7 (-71.4 to 52.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.4 (-52.4 to 151.8)	-25.2 (-72.6 to 40.4)
Larynx cancer	2.2 (1.4 to 2.8)	4.1 (3.3 to 4.9)	81.6 (41.3 to 155.6)	6.4 (-19.7 to 45.4)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	53.7 (12.7 to 102.3)	-13.5 (-36.3 to 13.8)
Tracheal, bronchus and lung cancer	13.7 (12.6 to 15.0)	22.5 (19.1 to 25.3)	64.9 (35.3 to 88.9)	-7.9 (-23.9 to 5.3)	1.9 (1.4 to 2.4)	2.9 (2.0 to 3.8)	53.1 (26.4 to 76.3)	-14.2 (-29.3 to -1.4)
Breast cancer	103.7 (98.3 to 108.9)	159.8 (146.4 to 173.5)	54.2 (39.0 to 68.7)	-14.1 (-22.6 to -5.9)	5.2 (3.6 to 7.3)	8.1 (5.7 to 11.4)	56.1 (39.4 to 71.8)	-12.1 (-21.1 to -2.7)
Cervical cancer	7.5 (5.6 to 8.9)	7.0 (5.5 to 8.8)	-7.3 (-27.5 to 19.4)	-41.2 (-54.2 to -24.4)	0.6 (0.4 to 0.8)	0.5 (0.3 to 0.7)	5.7 (-2.7 to 23.6)	-40.2 (-93.8 to -22.4)
Uterine cancer	12.7 (10.1 to 15.6)	22.5 (17.4 to 30.0)	74.1 (29.0 to 148.6)	19.8 (-27.4 to 42.2)	0.8 (0.5 to 1.1)	1.4 (0.9 to 2.1)	62.3 (24.3 to 148.0)	-4.3 (-30.7 to 40.8)
Prostate cancer	57.0 (46.7 to 64.3)	154.4 (122.7 to 188.6)	168.9 (116.8 to 250.3)	50.0 (23.2 to 96.3)	6.7 (3.3 to 10.2)	11.9 (8.4 to 16.7)	151.6 (102.2 to 232.0)	38.9 (12.5 to 85.0)
Colon and rectum cancer	52.3 (49.4 to 55.8)	95.5 (86.6 to 104.5)	82.5 (64.1 to 101.3)	1.2 (-8.5 to 11.8)	4.2 (3.1 to 5.4)	7.3 (5.3 to 9.5)	72.1 (53.4 to 92.3)	-5.0 (-15.0 to 5.7)
Lip and oral cavity cancer	6.2 (5.1 to 7.5)	9.0 (6.6 to 11.2)	44.5 (9.9 to 90.1)	-17.9 (-37.2 to 7.9)	0.5 (0.3 to 0.7)	0.7 (0.5 to 1.0)	41.4 (7.2 to 90.2)	-19.4 (-38.7 to 6.9)
Nasopharynx cancer	0.6 (0.4 to 0.8)	0.6 (0.5 to 0.9)	12.2 (-24.2 to 65.3)	-32.6 (-54.4 to 0.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	5.5 (-26.3 to 48.1)	-36.9 (-55.5 to -11.3)
Other pharynx cancer	1.9 (1.4 to 2.5)	4.1 (2.7 to 5.6)	112.0 (31.4 to 218.7)	19.5 (-25.2 to 78.9)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	96.8 (24.1 to 198.8)	10.8 (-30.3 to 67.6)
Gallbladder and biliary tract cancer	0.6 (0.4 to 0.7)	0.8 (0.5 to 1.0)	30.5 (-2.4 to 77.3)	-31.2 (-48.1 to -8.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	25.5 (8.2 to 72.1)	-33.0 (-50.1 to -10.1)
Pancreatic cancer	1.7 (1.5 to 1.9)	3.7 (3.1 to 4.3)	116.8 (75.0 to 173.9)	17.9 (-4.7 to 48.7)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	102.2 (64.9 to 151.5)	10.6 (-9.0 to 36.6)
Malignant skin melanoma	49.7 (34.4 to 69.5)	102.9 (67.6 to 150.9)	105.7 (68.8 to 151.8)	23.7 (1.8 to 51.7)	2.9 (1.7 to 4.5)	5.8 (3.5 to 9.1)	101.3 (64.0 to 145.4)	20.6 (-1.3 to 46.8)
Non-melanoma skin cancer	169.3 (134.3 to 205.4)	306.0 (241.9 to 369.2)	81.1 (33.4 to 140.6)	11.9 (-25.8 to 33.7)	3.6 (0.9 to 3.3)	9.5 (1.8 to 6.5)	90.5 (63.5 to 147.4)	4.9 (-20.5 to 37.2)
Ovarian cancer	4.8 (4.1 to 5.5)	7.7 (6.4 to 9.1)	60.6 (29.9 to 100.3)	-8.3 (-25.7 to 12.7)	0.6 (0.4 to 0.8)	0.9 (0.7 to 1.3)	57.4 (19.8 to 107.7)	-10.1 (-31.8 to 15.7)
Testicular cancer	4.1 (2.7 to 5.7)	5.3 (3.5 to 7.6)	25.9 (-21.1 to 108.0)	-6.7 (-42.0 to 54.4)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	24.0 (-24.0 to 112.0)	-8.8 (-44.5 to 58.3)
Kidney cancer	9.7 (8.5 to 11.0)	22.7 (19.6 to 26.4)	132.0 (95.7 to 176.2)	32.4 (12.0 to 57.9)	0.7 (0.5 to 0.9)	1.5 (1.1 to 2.1)	120.1 (82.1 to 168.2)	25.5 (4.6 to 52.4)
Bladder cancer	13.4 (11.6 to 15.5)	22.7 (18.0 to 27.0)	69.0 (38.9 to 105.3)	19.9 (-24.0 to 11.6)	1.6 (0.7 to 1.4)	3.6 (1.1 to 2.2)	69.9 (30.6 to 97.4)	-12.2 (-28.4 to 7.0)
Brain and nervous system cancer	4.1 (3.3 to 4.8)	7.1 (5.7 to 8.4)	72.8 (46.6 to 103.1)	7.3 (-8.9 to 26.4)	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.0)	66.9 (38.4 to 102.8)	3.5 (-13.0 to 24.8)
Thyroid cancer	6.3 (5.3 to 7.9)	11.4 (8.4 to 14.0)	82.7 (36.5 to 132.6)	14.4 (-13.4 to 45.7)	0.4 (0.2 to 0.5)	0.7 (0.4 to 1.0)	78.2 (32.5 to 129.7)	11.2 (-16.8 to 44.4)
Mesothelioma	0.4 (0.3 to 0.5)	1.0 (0.6 to 1.3)	187.7 (55.3 to 268.5)	57.9 (-11.6 to 101.7)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	175.0 (46.6 to 293.5)	0.8 (-17.0 to 112.9)
Hodgkin lymphoma	1.9 (1.2 to 2.4)	2.7 (2.0 to 4.0)	41.1 (2.0 to 128.0)	19.2 (-31.9 to 54.9)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	29.4 (-4.7 to 105.4)	-14.6 (-37.4 to 38.1)
Non-Hodgkin lymphoma	16.1 (12.0 to 23.2)	26.0 (17.1 to 35.3)	64.5 (15.7 to 101.5)	-5.4 (-33.2 to 18.8)	1.2 (0.8 to 1.8)	1.8 (1.1 to 2.7)	59.9 (10.9 to 97.7)	-7.9 (-35.1 to 14.9)
Multiple myeloma	2.8 (1.8 to 4.1)	7.0 (4.6 to 10.2)	155.0 (58.2 to 305.1)	40.8 (-12.8 to 121.9)	0.6 (0.3 to 0.9)	1.3 (0.7 to 2.0)	137.7 (41.9 to 275.1)	31.5 (-21.4 to 108.1)
Leukemia	8.1 (7.1 to 9.2)	16.1 (13.9 to 18.6)	97.7 (65.6 to 133.0)	12.5 (-5.7 to 32.6)	1.0 (0.7 to 1.3)	1.9 (1.4 to 2.5)	93.1 (59.2 to 136.7)	8.7 (-10.0 to 32.4)
Other neoplasms	13.2 (11.3 to 16.7)	38.9 (29.9 to 46.6)	199.6 (111.0 to 283.7)	76.1 (26.5 to 120.7)	2.5 (0.6 to 1.3)	5.5 (1.7 to 3.5)	184.0 (97.9 to 266.1)	66.8 (17.0 to 109.8)
Cardiovascular diseases	-	-	-	-	43.0 (30.4 to 57.8)	96.8 (66.2 to 129.2)	125.9 (78.1 to 176.4)	28.0 (0.4 to 56.9)
Rheumatic heart disease	22.8 (18.2 to 27.5)	35.8 (30.0 to 41.9)	56.4 (19.8 to 107.2)	-8.5 (-28.7 to 21.4)	2.0 (1.3 to 2.9)	3.1 (2.0 to 4.6)	55.0 (2.8 to 128.3)	-10.0 (-40.5 to 30.9)
Ischemic heart disease	336.6 (291.0 to 393.1)	644.9 (565.2 to 765.4)	90.5 (56.8 to 136.7)	3.6 (-15.0 to 30.1)	14.8 (9.9 to 20.9)	31.4 (21.2 to 44.1)	112.7 (61.7 to 176.4)	16.4 (-11.5 to 53.1)
Cerebrovascular disease	-	-	-	-	11.4 (8.0 to 15.4)	19.7 (13.8 to 25.8)	72.0 (45.0 to 111.8)	-0.9 (-16.2 to 21.9)
Ischemic stroke	62.0 (53.2 to 69.2)	108.4 (96.0 to 122.1)	73.0 (47.2 to 115.6)	-2.0 (-16.4 to 22.1)	9.0 (6.2 to 12.2)	15.5 (10.8 to 20.7)	72.2 (44.4 to 114.5)	-1.5 (-17.4 to 22.4)
Hemorrhagic stroke	16.5 (14.1 to 19.1)	28.5 (24.2 to 33.5)	72.3 (36.0 to 114.1)	1.6 (-19.1 to 25.9)	2.4 (1.7 to 3.4)	4.2 (2.8 to 5.6)	70.4 (34.3 to 117.2)	1.4 (-19.5 to 29.4)
Hypertensive heart disease	12.4 (10.6 to 14.1)	35.0 (30.4 to 39.6)	181.6 (130.0 to 244.2)	54.5 (26.7 to 88.3)	1.3 (0.9 to 1.9)	3.8 (2.5 to 5.3)	181.1 (125.6 to 248.8)	55.0 (24.8 to 92.5)
Cardiomyopathy and myocarditis	14.0 (12.0 to 16.4)	39.7 (36.0 to 44.0)	182.9 (134.6 to 244.5)	63.8 (36.5 to 98.2)	1.5 (1.0 to 2.1)	4.3 (2.9 to 5.9)	184.5 (135.1 to 246.6)	65.6 (37.1 to 101.3)
Atrial fibrillation and flutter	93.3 (75.6 to 118.3)	149.4 (110.1 to 193.7)	58.1 (1.6 to 134.7)	-12.7 (-44.7 to 30.0)	7.2 (4.6 to 10.6)	11.4 (7.1 to 17.0)	56.9 (-1.2 to 133.6)	-13.1 (-45.8 to 29.5)
Peripheral vascular disease	525.2 (430.5 to 620.2)	916.0 (753.6 to 1,077.5)	75.8 (33.8 to 128.2)	-2.7 (-26.0 to 25.9)	0.3 (0.1 to 0.7)	0.7 (0.3 to 1.5)	111.8 (12.6 to 403.1)	4.9 (-44.7 to 156.1)
Endocarditis	0.6 (0.4 to 0.7)	1.2 (0.9 to 1.6)	104.9 (56.5 to 193.6)	19.8 (-7.6 to 71.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	109.8 (46.2 to 233.2)	23.9 (-13.1 to 94.1)
Other cardiovascular and circulatory diseases	61.5 (31.3 to 143.9)	319.3 (114.3 to 506.8)	490.5 (52.8 to 1,145.2)	246.4 (-10.0 to 633.3)	4.3 (1.9 to 10.5)	22.3 (7.4 to 39.5)	489.0 (51.4 to 1,150.4)	246.3 (-11.7 to 640.0)
Chronic respiratory diseases	-	-	-	-	156.6 (108.2 to 208.6)	334.4 (164.1 to 312.1)	151.1 (40.0 to 68.8)	1.1 (-5.9 to 11.2)
Chronic obstructive pulmonary disease	1,133.4 (1,061.8 to 1,212.6)	1,839.2 (1,724.2 to 1,949.0)	62.1 (55.7 to 68.6)	-1.9 (-5.7 to 2.0)	66.3 (42.6 to 92.2)	117.5 (77.9 to 162.9)	75.0 (51.9 to	

Appendix Table G.4 - Australia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.3 (0.2 to 0.3)	0.4 (0.4 to 0.4)	52.2 (44.8 to 61.8)	-13.4 (-17.5 to -8.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	54.9 (40.7 to 68.2)	54.9 (-20.1 to -4.0)
Asbestosis	-	-	-	-	-	-	-	-
Coal workers pneumoconiosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	69.0 (63.1 to 74.9)	0.5 (-2.9 to 4.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.5 (62.5 to 74.5)	0.2 (-3.5 to 3.8)
Other pneumoconiosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	82.4 (71.1 to 95.6)	8.0 (1.5 to 15.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	82.0 (70.6 to 95.0)	7.7 (1.1 to 15.1)
Asthma	1,922.9 (1,830.5 to 2,007.1)	2,622.3 (2,505.9 to 2,736.2)	36.7 (28.2 to 45.3)	0.3 (-6.6 to 6.6)	84.7 (55.9 to 121.4)	114.8 (75.6 to 162.5)	13.6 (27.3 to 44.5)	-0.7 (-6.6 to 6.6)
Interstitial lung disease and pulmonary sarcoidosis	0.5 (0.4 to 0.6)	0.8 (0.6 to 0.9)	67.3 (9.3 to 127.2)	3.7 (-30.9 to 41.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	68.4 (47.3 to 128.4)	4.3 (-30.9 to 41.5)
Other chronic respiratory diseases	-	-	-	-	3.5 (2.2 to 5.4)	1.9 (1.1 to 3.0)	46.4 (-59.0 to -28.5)	67.7 (-75.1 to -56.8)
Cirrhosis	-	-	-	-	0.7 (0.5 to 1.0)	0.8 (0.5 to 1.1)	6.3 (-8.8 to 24.0)	34.0 (-43.2 to -23.1)
Cirrhosis due to hepatitis B	1.2 (0.7 to 1.6)	1.1 (0.7 to 1.5)	-8.8 (-47.5 to 81.9)	-44.4 (-67.2 to 10.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	10.0 (-52.5 to 88.5)	-44.2 (-70.0 to 15.3)
Cirrhosis due to hepatitis C	1.5 (1.1 to 1.9)	2.1 (1.5 to 2.7)	41.2 (-11.4 to 100.4)	-12.7 (-44.1 to 24.2)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	39.9 (-15.0 to 118.8)	-13.1 (-47.1 to 34.9)
Cirrhosis due to alcohol use	1.5 (1.3 to 1.8)	1.1 (0.6 to 1.5)	-24.0 (-60.1 to 7.5)	-54.5 (-75.9 to -34.8)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	25.4 (-62.0 to 16.7)	-55.0 (-77.2 to -30.0)
Cirrhosis due to other causes	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.7)	50.5 (-5.6 to 163.3)	-1.2 (-35.8 to 66.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	50.5 (-5.6 to 163.5)	-1.2 (-35.8 to 66.9)
Digestive diseases	-	-	-	-	27.1 (19.3 to 36.0)	51.1 (35.6 to 68.2)	88.2 (73.1 to 103.3)	19.1 (9.4 to 29.2)
Peptic ulcer disease	125.8 (112.5 to 140.6)	89.5 (79.7 to 97.9)	-28.5 (-39.5 to -18.4)	-65.1 (-70.6 to -60.3)	4.2 (2.8 to 5.9)	4.1 (2.7 to 5.7)	-2.4 (-19.5 to 21.1)	50.3 (-59.4 to -37.3)
Gastritis and duodenitis	18.1 (16.4 to 19.8)	17.1 (14.0 to 20.5)	-5.5 (-26.2 to 13.3)	-41.8 (-53.7 to -30.6)	1.0 (0.7 to 1.4)	1.1 (0.7 to 1.6)	11.2 (-10.5 to 52.8)	-30.0 (-43.6 to -5.9)
Appendicitis	0.6 (0.5 to 0.6)	0.6 (0.5 to 0.7)	1.8 (-14.8 to 23.2)	-21.4 (-35.0 to -3.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	3.4 (-26.2 to 51.1)	-20.4 (-44.5 to 19.7)
Paralytic ileus and intestinal obstruction	0.9 (0.7 to 1.0)	1.6 (1.3 to 1.9)	80.7 (42.8 to 133.7)	5.8 (-16.7 to 36.6)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.6)	76.2 (30.3 to 146.0)	5.0 (-21.0 to 47.2)
Inguinal, femoral, and abdominal hernia	58.1 (47.8 to 71.9)	96.2 (80.2 to 115.9)	64.9 (42.5 to 92.4)	7.8 (-19.9 to 6.7)	0.6 (0.3 to 1.1)	1.0 (0.5 to 1.8)	68.8 (41.8 to 92.2)	7.2 (-19.4 to 7.5)
Inflammatory bowel disease	63.5 (60.5 to 66.2)	146.1 (139.7 to 152.8)	129.6 (116.9 to 144.4)	49.4 (41.0 to 58.9)	13.4 (9.1 to 18.2)	30.6 (21.0 to 41.4)	128.9 (114.4 to 146.4)	49.8 (40.2 to 61.4)
Vascular intestinal disorders	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	89.6 (25.2 to 165.7)	5.9 (-30.1 to 47.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	91.1 (17.8 to 202.7)	8.4 (-31.2 to 67.7)
Gallbladder and biliary diseases	16.3 (15.0 to 17.9)	21.6 (19.2 to 23.5)	32.5 (17.1 to 48.6)	-22.3 (-31.3 to -12.7)	1.7 (1.1 to 2.4)	2.2 (1.5 to 3.0)	31.3 (13.7 to 51.1)	-22.5 (-32.6 to -10.9)
Pancreatitis	4.2 (4.0 to 4.4)	6.5 (6.2 to 6.8)	56.4 (46.3 to 67.0)	1.9 (-6.7 to 6.1)	1.9 (-6.7 to 6.1)	1.9 (-6.7 to 6.1)	54.8 (30.7 to 83.8)	-0.8 (-16.1 to 18.4)
Other digestive diseases	-	-	-	-	4.6 (3.2 to 6.3)	9.5 (6.3 to 13.3)	105.9 (66.7 to 149.3)	30.3 (5.0 to 57.8)
Neurological disorders	-	-	-	-	206.4 (141.0 to 277.7)	337.2 (231.2 to 453.3)	63.0 (43.1 to 87.5)	2.0 (-10.6 to 17.1)
Alzheimer disease and other dementias	242.9 (212.7 to 268.0)	537.5 (478.5 to 607.7)	119.5 (88.7 to 159.1)	3.6 (-10.3 to 22.5)	35.7 (25.6 to 46.5)	80.3 (57.9 to 105.7)	123.6 (91.2 to 164.8)	3.5 (-10.6 to 22.5)
Parkinson disease	47.6 (38.5 to 56.9)	82.9 (69.6 to 97.9)	74.8 (57.7 to 87.1)	2.9 (-12.7 to 3.1)	7.4 (3.7 to 7.7)	9.6 (6.5 to 13.4)	73.3 (54.1 to 87.7)	3.1 (-13.9 to 4.7)
Epilepsy	49.4 (35.9 to 62.4)	59.6 (39.9 to 80.3)	20.4 (-22.2 to 91.0)	-14.7 (-44.5 to 36.2)	19.6 (12.1 to 28.1)	24.8 (14.6 to 36.5)	25.8 (-20.7 to 102.7)	-9.8 (-43.1 to 45.5)
Multiple sclerosis	7.2 (6.8 to 7.6)	17.2 (16.1 to 18.3)	138.2 (117.6 to 159.1)	55.7 (42.5 to 69.0)	2.4 (1.7 to 3.0)	5.6 (4.0 to 7.1)	136.6 (105.4 to 174.2)	55.4 (35.4 to 80.1)
Migraine	3,242.1 (2,829.3 to 3,686.7)	4,757.7 (3,929.9 to 5,442.0)	46.7 (16.0 to 81.4)	2.9 (-18.4 to 26.9)	109.5 (64.5 to 163.3)	2.9 (-18.4 to 26.9)	160.0 (95.7 to 240.0)	2.9 (-18.9 to 27.9)
Tension-type headache	5,450.5 (4,897.7 to 6,056.6)	5,303.6 (3,199.1 to 8,004.2)	-3.9 (-44.3 to -25.9)	-50.0 (-61.0 to -47.8)	8.2 (4.0 to 14.5)	5.3 (2.5 to 9.2)	55.0 (30.7 to 83.8)	-55.0 (-60.8 to -47.5)
Medication overuse headache	93.0 (59.8 to 130.0)	201.1 (133.5 to 272.9)	115.7 (59.8 to 204.8)	43.6 (5.9 to 102.7)	14.4 (7.9 to 22.9)	31.1 (18.0 to 48.7)	115.4 (58.9 to 205.2)	44.2 (5.0 to 104.7)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	51.3 (18.0 to 87.7)	0.4 (-21.1 to 23.6)	11.0 (7.4 to 15.0)	20.6 (14.6 to 27.5)	86.1 (43.8 to 154.4)	-9.1 (-29.4 to 24.6)
Mental and substance use disorders	-	-	-	-	512.7 (373.5 to 662.7)	723.5 (531.2 to 935.4)	41.0 (37.5 to 45.4)	1.4 (-1.2 to 4.2)
Schizophrenia	67.4 (62.8 to 71.5)	98.1 (90.6 to 105.3)	45.1 (40.3 to 50.9)	-0.9 (-4.4 to 2.9)	42.9 (31.2 to 51.8)	62.1 (46.8 to 74.4)	44.9 (37.2 to 53.0)	-0.9 (-6.3 to 4.7)
Alcohol use disorders	188.8 (173.3 to 204.8)	270.0 (247.6 to 292.5)	42.8 (35.5 to 50.4)	3.2 (-1.9 to 8.8)	18.8 (12.6 to 26.3)	26.8 (18.1 to 38.0)	42.7 (34.1 to 52.0)	3.5 (-2.8 to 10.2)
Drug use disorders	-	-	-	-	67.2 (46.4 to 87.3)	87.4 (61.3 to 115.9)	30.2 (17.6 to 42.9)	-1.7 (-11.1 to 8.1)
Opioid use disorders	63.5 (56.8 to 70.3)	85.2 (75.8 to 93.2)	33.9 (25.8 to 42.9)	-0.1 (-6.3 to 6.3)	26.3 (18.7 to 34.2)	35.3 (25.1 to 45.6)	34.0 (23.5 to 45.6)	0.2 (-7.8 to 8.8)
Cocaine use disorders	42.8 (40.0 to 45.6)	56.7 (53.6 to 60.1)	32.2 (21.7 to 44.3)	0.5 (-7.6 to 9.4)	5.8 (3.8 to 8.3)	7.7 (5.1 to 11.0)	32.0 (18.4 to 49.1)	0.4 (-10.3 to 13.0)
Amphetamine use disorders	100.9 (95.4 to 107.0)	127.7 (120.2 to 137.3)	26.4 (16.2 to 37.4)	1.3 (-12.1 to 4.3)	16.5 (8.1 to 19.1)	16.5 (10.4 to 24.3)	4.2 (13.6 to 40.7)	3.7 (-3.7 to 7.0)
Cannabis use disorders	96.2 (89.3 to 102.5)	118.4 (108.0 to 127.6)	23.2 (16.3 to 29.4)	-3.8 (-9.6 to 1.2)	2.8 (1.8 to 4.0)	3.4 (2.3 to 4.9)	23.1 (10.9 to 36.3)	-3.7 (-13.3 to 6.4)
Other drug use disorders	-	-	-	-	19.1 (11.9 to 27.9)	24.4 (15.2 to 36.4)	27.9 (-3.6 to 72.1)	-2.8 (-27.1 to 30.8)
Depressive disorders	-	-	-	-	184.4 (126.6 to 255.9)	272.3 (186.9 to 371.7)	47.3 (40.2 to 57.5)	3.3 (-1.7 to 10.1)
Major depressive disorder	769.0 (640.7 to 894.5)	1,144.0 (983.7 to 1,310.9)	48.3 (40.0 to 59.3)	3.6 (-1.9 to 11.2)	316.3 (104.9 to 217.4)	331.3 (157.4 to 315.0)	47.6 (39.3 to 59.2)	3.9 (-2.1 to 11.3)
Dysthymia	292.6 (249.7 to 339.6)	429.6 (367.3 to 499.5)	46.8 (36.1 to 56.5)	0.2 (-6.4 to 6.3)	28.1 (18.3 to 39.8)	41.0 (27.4 to 58.7)	46.2 (35.5 to 57.0)	0.2 (-6.7 to 7.3)
Bipolar disorder	151.9 (131.0 to 173.2)	213.7 (186.3 to 240.6)	40.5 (33.4 to 48.0)	-0.5 (-4.9 to 4.4)	30.7 (18.9 to 45.5)	43.0 (26.6 to 63.3)	40.4 (31.9 to 49.5)	-0.2 (-6.0 to 6.1)
Anxiety disorders	1,009.0 (904.9 to 1,116.1)	1,431.6 (1,307.9 to 1,545.1)	41.7 (33.6 to 51.7)	2.3 (-3.3 to 9.0)	92.2 (62.7 to 127.6)	130.3 (89.5 to 180.5)	41.1 (33.2 to 52.3)	2.3 (-2.9 to 9.6)
Eating disorders	-	-	-	-	15.4 (9.1 to 23.6)	19.4 (11.6 to 29.6)	25.7 (20.3 to 31.9)	0.5 (-3.8 to 5.4)
Anorexia nervosa	8.0 (6.3 to 9.8)	10.9 (8.6 to 13.4)	35.9 (22.5 to 48.9)	8.7 (-2.2 to 19.0)	1.7 (1.1 to 2.5)	2.3 (1.5 to 3.4)	35.2 (15.4 to 58.6)	8.2 (-7.8 to 26.5)
Bulimia nervosa	65.4 (42.4 to 88.7)	81.5 (52.5 to 111.3)	24.5 (22.6 to 26.0)	-0.5 (-0.9 to 0.0)	13.7 (7.9 to 21.2)	17.1 (9.9 to 26.7)	24.3 (18.3 to 30.8)	-0.4 (-5.2 to 4.5)
Autistic spectrum disorders	-	-	-	-	20.7 (14.3 to 28.2)	28.2 (19.5 to 38.5)	36.4 (32.2 to 40.8)	0.3 (-2.9 to 3.5)
Autism	55.9 (53.1 to 58.9)	76.8 (72.8 to 80.9)	37.1 (36.4 to 37.8)	0.2 (0.2 to 0.2)	13.7 (9.3 to 18.8)	18.7 (12.5 to 25.7)	36.4 (30.8 to 42.6)	0.3 (-4.0 to 4.8)
Asperger syndrome	70.8 (66.4 to 75.3)	96.9 (90.7 to 103.5)	36.8 (35.9 to 37.8)	0.3 (0.2 to 0.3)	7.0 (4.8 to 9.8)	9.6 (6.6 to 13.3)	36.2 (30.6 to 42.1)	0.2 (-3.7 to 4.6)
Attention-deficit/hyperactivity disorder	105.3 (88.1 to 123.3)	122.8 (102.9 to 143.8)	16.5 (16.2 to 16.7)	0.2 (0.2 to 0.2)	1.3 (0.7 to 2.0)	1.5 (0.9 to 2.3)	16.5 (9.1 to 24.4)	0.3 (-6.3 to 6.7)
Conduct disorder	112.5 (96.1 to 129.9)	128.8 (109.8 to 149.3)	14.4 (13.9 to 15.1)	0.1 (0.1 to 0.2)	13.5 (8.1 to 19.9)	15.5 (9.4 to 23.1)	14.6 (9.6 to 19.7)	0.4 (-4.3 to 4.8)
Idiopathic intellectual disability	40.1 (30.7 to 69.3)	50 (32.1 to 74.9)	1.2 (-20.3 to 28.5)	-26.4 (-4.9 to -46.6)	2.1 (1.6 to 4.5)	2.9 (3.6 to 4.7)	1.0 (-21.6 to 27.2)	-26.3 (-42.4 to -7.1)
Other mental and substance use disorders	307.6 (289.7 to 325.0)	462.4 (435.0 to 488.7)	50.2 (48.5 to 51.9)	0.3 (0.1 to 0.6)	22.7 (15.5 to 30.5)	34.0 (23.1 to 45.6)	49.6 (44.3 to 55.5)	0.5 (-3.1 to 4.1)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	132.2 (92.2 to 176.7)	252.5 (179.9 to 332.6)	91.0 (75.5 to 106.4)	21.4 (11.9 to 30.7)
Diabetes mellitus	482.0 (391.3 to 572.4)	1,519.8 (1,270.0 to 1,803.5)	216.8 (148.1 to 292.3)	92.3 (51.9 to 139.0)	32.3 (20.6 to 46.5)	98.3 (65.5 to 138.2)	208.2 (136.2 to 274.2)	84.1 (41.7 to 124.5)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.1 (-3.0 to 9.5)	-22.8 (-27.3 to -17.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.1 (-0.9 to 9.5)	-22.8 (-27.3 to -17.4)
Chronic kidney disease	-	-	-	-	41.3 (29.3 to 55.3)	55.5 (47.6 to 87.6)	59.5 (48.2 to 69.5)	2.6 (-2.9 to 8.2)
Chronic kidney disease due to diabetes mellitus	349.7 (215.5 to 567.1)	1,146.2 (804.0 to 1,705.4)	232.7 (142.5 to 351.7)	98.9 (45.3 to 169.0)	10.0 (6.5 to 14.5)	25.5 (17.4 to 35.5)	156.8 (105.1 to 219.8)	56.0 (25.2 to 94.1)
Chronic kidney disease due to hypertension	303.5 (200.8 to 443.9)	471.7 (306.4 to 720.4)	54.8 (8.8 to 133.6)	1.2 (-29.2 to 47.5)	8.4 (5.7 to 12.1)	9.5 (6.7 to 13.3)	13.4 (-10.8 to 47.1)	-28.1 (-43.3 to -7.5)
Chronic kidney disease due to glomerulonephritis	364.1 (258.7 to 507.9)	489.1 (360.6 to 704.3)	34.0 (1.9 to 81.4)	-16.5 (-35.3 to 11.5)	8.0 (5.4 to 11.0)	12.0 (8.2 to 16.4)	49.3 (15.8 to 93.0)	1.0 (-20.5 to 25.4)
Chronic kidney disease due to other causes	637.6 (481.4 to 868.1)	885.0 (609.0 to 1,225.3)	39.2 (10.8 to 84.0)	11.9 (-27.1 to 15.5)	36.3 (10.6 to 19.9)	14.9 (13.4 to 25.1)	27.2 (8.3 to 45.5)	44.1 (-26.0 to -1.4)
Urinary diseases and male infertility	-	-	-	-	16.2 (10.6 to 23.1)	30.4 (19.3 to 43.4)	86.9 (57.8 to 124.0)	5.9 (-10.8 to 26.6)
Interstitial nephritis and urinary tract infections	3.9 (3.5 to 4.4)	7.1 (6.3 to 7.9)	81.1 (48.0 to 110.1)	21.8 (-1.2 to 42.5)	0.1 (0.1 to 0.2)	0.2		

Appendix Table G.4 - Australia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Urolithiasis	119.5 (75.7 to 158.7)	186.9 (86.4 to 295.1)	60.3 (-13.3 to 97.6)	48.0 (50.6 to 15.0)	1.2 (0.7 to 1.8)	1.6 (0.8 to 2.7)	37.0 (-6.6 to 63.0)	-18.0 (-43.9 to -2.5)
Benign prostatic hyperplasia	398.0 (341.2 to 448.4)	779.5 (675.9 to 885.8)	95.0 (60.0 to 139.1)	9.0 (-10.7 to 32.9)	14.2 (9.2 to 20.2)	27.6 (17.7 to 39.3)	8.7 (-11.4 to 32.6)	94.0 (59.1 to 137.4)
Male infertility due to other causes	35.9 (25.5 to 47.5)	55.2 (41.6 to 70.8)	53.5 (1.3 to 143.3)	20.9 (-20.1 to 92.0)	0.2 (0.1 to 0.5)	0.4 (0.2 to 0.8)	21.4 (-2.5 to 29.5)	54.2 (0.7 to 154.6)
Other urinary diseases	-	-	-	-	0.4 (0.2 to 0.7)	0.6 (0.2 to 1.0)	-21.5 (-16.6 to 82.2)	-
Gynecological diseases	-	-	-	-	24.7 (16.1 to 36.1)	38.1 (21.7 to 49.3)	40.8 (12.5 to 53.8)	40.8 (-16.9 to 14.1)
Uterine fibroids	479.6 (424.2 to 540.1)	707.9 (631.9 to 791.5)	47.5 (45.6 to 49.5)	1.9 (1.8 to 2.1)	4.9 (2.6 to 8.6)	7.6 (4.1 to 13.2)	54.6 (37.0 to 76.7)	9.0 (-3.6 to 24.8)
Polycystic ovarian syndrome	331.6 (304.9 to 357.7)	440.9 (403.7 to 475.3)	33.1 (17.2 to 48.2)	1.0 (-11.1 to 12.4)	3.0 (1.4 to 5.7)	4.0 (1.9 to 7.6)	33.3 (18.0 to 48.9)	1.2 (-10.3 to 12.8)
Female infertility due to other causes	2.0 (1.2 to 4.8)	2.9 (1.8 to 7.9)	35.7 (-45.2 to 304.3)	6.8 (-56.4 to 211.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.4 (-41.8 to 302.5)	8.9 (-53.3 to 214.0)
Endometriosis	61.9 (53.6 to 71.1)	75.5 (64.3 to 86.3)	22.1 (-1.4 to 47.1)	7.6 (-25.3 to 11.5)	5.7 (3.8 to 8.0)	6.9 (4.6 to 9.8)	6.9 (-3.5 to 50.0)	-7.5 (-26.9 to 13.5)
Genital prolapse	747.2 (640.3 to 855.1)	1,170.9 (997.2 to 1,338.2)	56.3 (25.7 to 94.0)	3.4 (-17.4 to 28.9)	2.4 (1.1 to 4.5)	3.7 (1.8 to 7.0)	56.3 (25.5 to 95.2)	3.3 (-17.8 to 29.5)
Premenstrual syndrome	907.3 (690.0 to 1,137.3)	1,119.3 (731.1 to 1,513.3)	23.5 (-30.6 to 88.7)	-4.4 (-45.3 to 46.0)	7.6 (4.5 to 12.1)	9.4 (5.2 to 14.9)	23.7 (-30.8 to 87.6)	-4.4 (-45.5 to 44.9)
Other gynecological diseases	49.3 (40.9 to 63.3)	62.3 (53.6 to 78.1)	31.0 (9.6 to 67.5)	-3.8 (-35.5 to 21.2)	1.2 (0.6 to 2.2)	1.5 (0.9 to 2.5)	37.7 (-35.1 to 134.8)	-1.3 (-54.9 to 69.7)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	12.0 (8.0 to 17.1)	16.1 (10.9 to 23.1)	35.4 (24.3 to 44.1)	0.2 (-7.5 to 6.5)
Thalassemias	0.7 (0.6 to 0.7)	0.8 (0.7 to 0.9)	21.1 (15.1 to 29.3)	-0.2 (-5.1 to 6.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	22.7 (94.0 to 48.7)	2.5 (-9.8 to 27.0)
Thalassemia trait	312.0 (302.8 to 323.8)	433.5 (422.2 to 454.5)	38.8 (34.4 to 43.6)	-0.4 (-3.4 to 2.9)	9.3 (6.3 to 13.3)	12.7 (8.6 to 18.1)	37.1 (25.7 to 46.9)	1.4 (-7.1 to 8.8)
Sickle cell disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	23.7 (0.4 to 46.1)	-1.3 (-22.0 to 16.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.0 (10.5 to 42.4)	-0.0 (-14.4 to 13.1)
Sickle cell trait	60.0 (55.5 to 65.3)	74.8 (70.3 to 80.1)	24.7 (12.5 to 36.3)	-10.4 (-19.3 to -1.8)	0.5 (0.3 to 0.9)	0.5 (0.3 to 0.7)	-10.3 (-40.0 to 38.1)	-33.6 (-55.0 to 4.6)
G6PD deficiency	112.5 (72.5 to 147.7)	162.2 (133.6 to 188.1)	42.9 (3.2 to 131.3)	0.0 (-25.9 to 66.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	70.4 (-1.9 to 152.0)	26.3 (-32.3 to 104.0)
G6PD trait	2,918.2 (2,727.9 to 3,097.5)	3,141.1 (2,847.3 to 3,402.8)	7.6 (-3.7 to 19.8)	-23.1 (-31.2 to -14.4)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-22.9 (-56.3 to 27.9)	-40.9 (-66.3 to -5.1)
Other hemoglobinopathies and hemolytic anemias	99.4 (94.2 to 107.7)	146.5 (135.9 to 160.6)	47.3 (31.4 to 62.0)	3.7 (-7.3 to 14.2)	1.8 (1.2 to 2.7)	2.7 (1.7 to 4.1)	6.6 (8.4 to 78.1)	6.6 (-18.4 to 30.2)
Endocrine, metabolic, blood, and immune disorders	185.8 (174.1 to 199.4)	265.0 (246.9 to 290.9)	42.1 (30.0 to 58.3)	-1.1 (-9.3 to 9.2)	5.7 (3.9 to 7.9)	8.6 (5.9 to 12.0)	51.0 (33.3 to 75.1)	4.7 (-7.8 to 18.7)
Musculoskeletal disorders	-	-	-	-	505.6 (359.9 to 662.2)	763.8 (543.0 to 1,000.1)	51.1 (43.1 to 59.7)	-2.3 (-7.5 to 3.2)
Rheumatoid arthritis	101.1 (96.3 to 105.6)	170.3 (162.7 to 178.1)	68.0 (58.2 to 80.4)	-1.4 (-7.1 to 5.9)	23.1 (16.5 to 30.3)	38.8 (27.6 to 50.9)	67.8 (56.7 to 81.1)	-0.6 (-7.2 to 7.4)
Osteoarthritis	624.4 (598.9 to 647.6)	1,151.0 (1,105.3 to 1,198.0)	83.9 (74.5 to 94.5)	2.3 (-2.8 to 8.3)	21.5 (14.2 to 30.7)	39.4 (26.0 to 56.3)	83.0 (73.9 to 93.9)	2.2 (-2.9 to 8.3)
Low back and neck pain	-	-	-	-	320.4 (226.5 to 427.3)	455.1 (318.9 to 614.1)	41.9 (29.6 to 55.1)	-5.5 (-16.6 to 3.3)
Low back pain	1,551.6 (1,464.9 to 1,637.4)	2,474.9 (2,350.3 to 2,618.6)	59.4 (47.9 to 73.4)	5.1 (-2.7 to 15.0)	171.9 (118.1 to 239.1)	272.3 (182.9 to 379.5)	58.3 (46.6 to 72.8)	5.2 (-2.7 to 15.4)
Neck pain	63.5 (58.8 to 68.3)	111.5 (103.9 to 119.4)	75.0 (59.4 to 94.2)	2.9 (-6.3 to 14.3)	2.0 (1.4 to 2.7)	3.4 (2.4 to 4.6)	73.6 (50.7 to 102.3)	2.7 (-11.0 to 19.4)
Other musculoskeletal disorders	1,523.6 (1,377.2 to 1,663.3)	2,505.2 (2,292.5 to 2,711.4)	64.6 (56.3 to 71.4)	4.0 (-1.1 to 8.2)	138.6 (94.6 to 192.0)	227.1 (155.7 to 311.8)	64.1 (55.3 to 71.5)	4.2 (-1.3 to 8.7)
Other non-communicable diseases	-	-	-	-	296.1 (202.0 to 416.8)	400.7 (300.6 to 621.8)	48.8 (44.3 to 53.4)	-4.8 (-7.8 to -2.0)
Congenital anomalies	-	-	-	-	27.9 (19.4 to 36.9)	40.2 (28.4 to 53.0)	43.2 (26.8 to 65.3)	1.2 (-10.4 to 16.7)
Neural tube defects	8.0 (6.9 to 9.3)	9.1 (7.9 to 10.8)	13.5 (7.5 to 41.6)	-15.0 (-30.8 to 6.2)	2.5 (1.7 to 3.4)	2.9 (2.0 to 4.1)	14.9 (-11.7 to 59.7)	-13.3 (-33.5 to 20.1)
Congenital heart anomalies	158.3 (137.4 to 178.8)	200.1 (173.2 to 229.5)	26.1 (4.2 to 53.6)	-7.9 (-23.9 to 12.2)	5.6 (2.4 to 9.8)	7.2 (3.0 to 12.4)	27.6 (8.4 to 54.3)	-6.2 (-20.2 to 13.7)
Crofacial clefts	23.5 (19.7 to 28.1)	29.2 (23.3 to 35.6)	24.3 (-6.3 to 58.0)	-9.7 (-31.1 to 19.1)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	20.4 (-16.1 to 74.3)	-12.3 (-39.3 to 26.9)
Down syndrome	24.4 (20.1 to 31.1)	35.3 (29.4 to 43.1)	45.1 (10.7 to 95.2)	-1.3 (-24.3 to 32.9)	3.5 (2.4 to 4.8)	5.3 (3.8 to 7.1)	0.2 (15.4 to 108.5)	53.6 (-25.0 to 35.8)
Turner syndrome	0.9 (0.9 to 1.0)	1.3 (1.0 to 1.7)	40.1 (13.5 to 79.5)	3.7 (-16.0 to 33.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.2 (8.6 to 81.1)	4.0 (-18.3 to 35.0)
Klinefelter syndrome	0.7 (0.5 to 0.9)	1.1 (0.8 to 1.5)	66.0 (8.2 to 164.9)	20.6 (-21.3 to 92.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.1 (-4.4 to 177.0)	21.3 (-2.8 to 102.8)
Chromosomal unbalanced rearrangements	38.2 (32.5 to 45.5)	57.6 (47.1 to 70.3)	49.9 (17.9 to 88.7)	2.2 (-19.7 to 28.7)	5.4 (3.9 to 7.3)	8.7 (6.3 to 11.6)	8.7 (23.9 to 103.4)	2.8 (-19.5 to 31.9)
Other congenital anomalies	35.4 (30.2 to 40.9)	43.1 (36.4 to 49.5)	49.9 (12.3 to 30.4)	-14.9 (-21.3 to -9.0)	10.7 (7.8 to 15.0)	15.9 (10.1 to 23.0)	49.2 (18.8 to 83.2)	1.0 (-12.8 to 35.0)
Skin and subcutaneous diseases	-	-	-	-	107.0 (72.2 to 156.5)	149.7 (101.2 to 216.4)	40.4 (32.7 to 46.6)	0.3 (-4.7 to 4.3)
Dermatitis	1,140.1 (953.3 to 1,334.8)	1,559.6 (1,306.4 to 1,808.7)	36.6 (34.9 to 38.7)	-0.0 (-0.1 to 0.0)	33.8 (22.1 to 49.1)	45.7 (29.9 to 66.0)	35.3 (31.8 to 39.1)	0.0 (-2.1 to 2.2)
Psoriasis	291.0 (268.6 to 314.4)	429.6 (397.0 to 464.5)	47.5 (45.9 to 49.1)	-0.2 (-0.3 to -0.1)	23.4 (16.2 to 32.6)	34.4 (23.9 to 47.7)	47.0 (41.5 to 52.5)	3.0 (-3.8 to 9.9)
Cellulitis	8.7 (7.1 to 11.0)	13.5 (10.9 to 16.9)	54.0 (39.4 to 68.7)	0.6 (-10.4 to 8.0)	0.9 (0.4 to 0.9)	0.9 (0.6 to 1.4)	53.2 (28.3 to 80.1)	-1.0 (-16.5 to 16.7)
Pyoderma	11.0 (8.5 to 14.3)	18.3 (13.6 to 24.4)	65.5 (52.6 to 79.8)	13.1 (6.4 to 20.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	64.0 (45.5 to 85.4)	12.7 (0.1 to 27.0)
Scabies	12.6 (10.5 to 15.7)	12.7 (10.5 to 15.5)	-0.0 (-22.7 to 27.9)	-26.9 (-42.7 to -8.8)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	-0.1 (-25.0 to 29.5)	-26.7 (-44.7 to -5.3)
Fungal skin diseases	1,133.3 (954.6 to 1,300.0)	1,681.9 (1,434.5 to 1,916.0)	48.2 (45.2 to 51.7)	0.2 (0.1 to 0.3)	6.3 (2.5 to 13.2)	9.4 (3.8 to 19.5)	47.6 (44.4 to 51.2)	0.2 (-0.7 to 1.1)
Viral skin diseases	375.0 (293.7 to 456.8)	483.1 (381.4 to 588.8)	28.6 (25.6 to 32.2)	-0.2 (-2.3 to 2.0)	11.6 (6.7 to 18.3)	14.8 (8.5 to 23.4)	28.3 (23.8 to 33.1)	-0.1 (-3.4 to 3.3)
Acne vulgaris	1,249.5 (1,003.3 to 1,482.2)	1,424.2 (1,203.1 to 1,650.5)	14.0 (-10.6 to 43.4)	-7.2 (-27.4 to 17.0)	13.5 (6.2 to 25.3)	15.4 (7.2 to 27.6)	14.0 (-10.5 to 43.5)	-7.0 (-27.2 to 17.3)
Alopecia areata	27.7 (25.6 to 29.8)	41.5 (38.0 to 44.9)	49.7 (33.0 to 68.7)	-0.5 (-11.3 to 11.5)	0.9 (0.6 to 1.4)	1.4 (0.9 to 2.1)	48.9 (29.9 to 70.8)	-0.6 (-13.2 to 13.3)
Pruritus	7.0 (5.1 to 8.6)	11.4 (8.6 to 14.6)	61.3 (31.1 to 150.4)	0.6 (-27.0 to 54.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	60.3 (12.3 to 152.3)	0.6 (-29.0 to 57.2)
Urticaria	132.0 (93.1 to 171.2)	222.0 (165.3 to 277.5)	70.9 (6.5 to 152.7)	15.6 (-28.4 to 69.4)	7.7 (4.4 to 12.2)	13.0 (7.7 to 19.7)	15.9 (5.3 to 153.4)	15.9 (-28.2 to 72.5)
Decubitus ulcer	8.9 (7.0 to 10.5)	16.8 (13.9 to 19.8)	88.3 (47.3 to 145.9)	0.8 (-19.8 to 30.7)	1.3 (0.8 to 1.8)	2.3 (1.6 to 3.2)	85.2 (42.3 to 147.3)	0.5 (-21.9 to 34.3)
Other skin and subcutaneous diseases	1,270.9 (753.7 to 2,121.5)	2,047.1 (1,173.9 to 3,557.1)	60.4 (49.3 to 69.8)	0.1 (-3.0 to 2.7)	7.4 (3.1 to 16.0)	11.9 (4.7 to 26.9)	59.7 (48.8 to 69.4)	0.2 (-3.2 to 2.9)
Sense organ diseases	-	-	-	-	96.9 (64.3 to 140.0)	157.1 (105.0 to 224.7)	62.4 (55.5 to 68.8)	-7.8 (-11.4 to -4.2)
Glaucoma	35.5 (30.1 to 41.4)	44.4 (37.7 to 51.9)	24.9 (8.8 to 43.2)	33.0 (-41.4 to 43.1)	2.2 (1.5 to 3.1)	3.0 (2.1 to 4.2)	34.9 (17.3 to 55.8)	-9.0 (-37.9 to -18.1)
Cataract	19.7 (14.5 to 24.7)	25.6 (18.9 to 32.0)	29.1 (6.7 to 70.3)	35.0 (-46.7 to -34.7)	1.2 (0.8 to 1.8)	1.7 (1.2 to 2.5)	40.2 (14.8 to 78.3)	-30.3 (-42.5 to -12.5)
Macular degeneration	22.8 (18.4 to 27.6)	68.9 (55.1 to 81.7)	202.4 (143.4 to 267.5)	53.4 (23.4 to 86.7)	1.6 (1.1 to 2.2)	4.0 (2.7 to 5.4)	143.2 (102.8 to 189.0)	18.7 (-1.8 to 41.7)
Uncorrected refractive error	1,299.6 (1,136.1 to 1,449.9)	2,148.7 (1,859.7 to 2,396.3)	64.8 (39.2 to 96.8)	-1.6 (-17.1 to 18.0)	17.5 (9.9 to 29.3)	27.4 (15.2 to 47.3)	55.3 (35.6 to 77.9)	-6.3 (-17.8 to 7.1)
Age-related and other hearing loss	2,404.3 (2,319.1 to 2,504.3)	3,896.6 (3,768.0 to 4,060.5)	61.7 (57.4 to 67.0)	-7.1 (-9.9 to -4.0)	60.8 (40.4 to 87.9)	103.0 (69.8 to 145.5)	70.0 (60.5 to 78.1)	-7.5 (-11.8 to -3.7)
Other vision loss	72.7 (63.9 to 80.8)	73.2 (64.0 to 84.8)	0.6 (-8.4 to 11.9)	41.1 (-46.0 to -35.6)	0.3 (2.2 to 4.4)	3.3 (2.2 to 4.6)	3.8 (-6.3 to 16.0)	-40.1 (-45.4 to -33.7)
Other sense organ diseases	393.2 (375.1 to 411.5)	566.0 (541.0 to 592.3)	44.0 (35.0 to 53.5)	-0.3 (-6.3 to 6.7)	10.3 (6.4 to 15.3)	14.7 (9.2 to 22.1)	42.5 (33.4 to 52.9)	-0.3 (-6.9 to 7.0)
Oral disorders	-	-	-	-	64.2 (41.7 to 93.4)	93.7 (60.2 to 136.9)	46.0 (37.1 to 54.0)	-11.9 (-17.2 to -6.6)
Deciduous caries	623.6 (611.4 to 634.6)	716.1 (701.6 to 730.5)	14.7 (11.6 to 17.9)	0.6 (-2.1 to 3.5)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.3)	14.5 (5.1 to 24.3)	0.5 (-7.8 to 9.0)
Permanent caries	3,731.5 (3,599.5 to 3,852.0)	5,347.7 (5,091.3 to 5,420.1)	40.5 (34.2 to 47.5)	40.5 (-2.7 to 7.0)	2.2 (1.0 to 4.3)	3.1 (1.4 to 6.0)	29.9 (32.0 to 47.8)	1.6 (-3.2 to 7.4)
Periodontal diseases	1,474.3 (1,391.2 to 1,560.7)	2,558.5 (2,423.5 to 2,709.0)	73.3 (60.8 to					

Appendix Table G.4 - Australia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	315.2 (299.1 to 333.0)	454.4 (429.6 to 479.0)	44.1 (33.5 to 54.7)	-4.0 (-7.3 to 7.2)	9.2 (5.7 to 13.7)	13.2 (8.2 to 19.5)	43.6 (32.5 to 55.4)	-0.0 (-7.6 to 8.3)
Injuries	-	-	-	-	123.6 (94.1 to 159.0)	131.8 (95.1 to 177.8)	6.2 (-4.2 to 17.6)	-35.7 (-41.9 to -28.8)
Transport injuries	-	-	-	-	35.2 (26.6 to 45.0)	26.1 (19.0 to 34.9)	-26.1 (-33.6 to -17.1)	-52.9 (-57.6 to -47.2)
Road injuries	-	-	-	-	30.7 (23.2 to 39.3)	21.2 (15.4 to 28.1)	-31.3 (-38.6 to -23.0)	-56.0 (-60.5 to -50.8)
Pedestrian road injuries	-	-	-	-	4.1 (3.1 to 5.4)	3.4 (2.4 to 4.6)	-18.3 (-27.3 to -8.9)	-49.4 (-54.9 to -43.5)
Cyclist road injuries	-	-	-	-	2.7 (2.0 to 3.5)	1.4 (1.0 to 1.9)	-48.2 (-55.4 to -39.6)	-65.5 (-70.2 to -59.9)
Motorcyclist road injuries	-	-	-	-	6.0 (4.4 to 7.7)	3.4 (2.4 to 4.6)	-43.7 (-52.7 to -32.5)	-63.1 (-69.1 to -55.9)
Motor vehicle road injuries	-	-	-	-	17.7 (13.5 to 22.5)	12.9 (9.5 to 17.0)	-27.7 (-34.7 to -19.4)	-53.8 (-58.2 to -48.7)
Other road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-27.5 (-36.5 to -16.0)	-93.5 (-92.2 to -46.1)
Other transport injuries	-	-	-	-	4.5 (3.3 to 5.9)	5.0 (3.5 to 6.7)	10.9 (0.1 to 22.3)	-31.1 (-37.8 to -24.0)
Unintentional injuries	-	-	-	-	86.4 (66.3 to 111.4)	103.6 (74.4 to 139.7)	19.6 (8.1 to 31.5)	-28.6 (-35.4 to -21.4)
Falls	-	-	-	-	53.8 (41.0 to 68.6)	68.4 (49.3 to 91.6)	26.4 (12.5 to 42.8)	-27.8 (-35.7 to -18.4)
Drowning	-	-	-	-	0.5 (0.3 to 0.6)	0.4 (0.3 to 0.5)	-5.8 (-16.7 to 7.2)	-39.7 (-46.7 to -31.4)
Fire, heat, and hot substances	-	-	-	-	3.1 (2.0 to 4.8)	3.9 (2.3 to 6.3)	23.3 (8.3 to 41.0)	-20.8 (-30.2 to -9.6)
Poisonings	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	2.3 (-12.3 to 19.8)	-30.4 (-40.4 to -17.8)
Exposure to mechanical forces	-	-	-	-	23.1 (17.1 to 30.3)	22.6 (16.1 to 30.7)	-2.4 (-11.9 to 9.0)	-35.9 (-41.9 to -28.7)
Unintentional firearm injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.3 to 0.5)	-3.4 (-14.2 to 9.5)	-35.4 (-42.3 to -27.0)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	60.6 (40.1 to 82.1)	4.4 (-9.3 to 17.8)
Other exposure to mechanical forces	-	-	-	-	22.6 (16.7 to 29.7)	22.0 (15.7 to 30.0)	-2.8 (-12.3 to 8.7)	-36.2 (-42.1 to -28.9)
Adverse effects of medical treatment	-	-	-	-	0.8 (0.5 to 1.2)	1.2 (0.8 to 1.9)	60.4 (47.2 to 76.1)	0.4 (-7.4 to 10.1)
Animal contact	-	-	-	-	1.0 (0.7 to 1.3)	1.4 (1.0 to 1.9)	37.1 (26.7 to 48.9)	-11.8 (-18.2 to -4.4)
Venomous animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	28.3 (14.5 to 42.4)	-14.5 (-23.9 to -5.2)
Non-venomous animal contact	-	-	-	-	0.8 (0.6 to 1.1)	1.1 (0.8 to 1.6)	39.1 (27.9 to 51.6)	-11.0 (-18.1 to -3.3)
Foreign body	-	-	-	-	0.8 (0.6 to 1.1)	1.0 (0.6 to 1.4)	18.3 (6.4 to 28.6)	-19.6 (-28.5 to -11.7)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	7.7 (-5.6 to 20.0)	-29.5 (-38.5 to -21.2)
Foreign body in eyes	-	-	-	-	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	26.6 (12.0 to 40.9)	-10.5 (-21.9 to 0.8)
Foreign body in other body part	-	-	-	-	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.8)	17.0 (3.0 to 29.4)	-21.1 (-31.5 to -12.2)
Other unintentional injuries	-	-	-	-	3.3 (2.3 to 4.4)	4.7 (3.2 to 6.4)	43.8 (33.9 to 54.9)	-14.1 (-20.1 to -7.8)
Self-harm and interpersonal violence	-	-	-	-	2.0 (1.5 to 2.6)	2.1 (1.5 to 2.8)	3.2 (-6.3 to 12.9)	-34.2 (-40.1 to -28.2)
Self-harm	-	-	-	-	1.1 (0.8 to 1.4)	1.4 (1.0 to 1.9)	32.6 (18.2 to 46.7)	-15.7 (-25.0 to -6.9)
Interpersonal violence	-	-	-	-	0.9 (0.7 to 1.2)	0.6 (0.5 to 0.9)	-31.0 (-37.6 to -23.2)	-55.5 (-59.7 to -50.5)
Assault by firearm	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-37.8 (-43.9 to -31.6)	-60.2 (-63.9 to -56.2)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-2.3 (-10.1 to 7.1)	-36.6 (-41.6 to -30.6)
Assault by other means	-	-	-	-	0.6 (0.5 to 0.8)	0.4 (0.3 to 0.6)	-35.1 (-42.5 to -26.4)	-58.3 (-62.9 to -52.7)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.6 (50.6 to 1,355.9)	42.1 (-70.8 to 1,296.5)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.6 (50.6 to 1,355.9)	42.1 (-70.8 to 1,296.5)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Austria prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	966.5 (725.7 to 1,245.9)	1,143.4 (854.0 to 1,473.3)	18.4 (15.4 to 22.3)	18.4 (4.9 to 0.9)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	41.2 (28.2 to 58.3)	45.6 (32.4 to 63.6)	10.9 (6.2 to 24.5)	6.2 (-4.3 to 18.4)
HIV/AIDS and tuberculosis	-	-	-	-	0.6 (0.4 to 0.9)	1.1 (0.6 to 1.8)	37.9 (9.0 to 170.3)	37.9 (6.5 to 129.0)
Tuberculosis	1.6 (1.5 to 1.7)	1.6 (1.5 to 1.6)	-1.7 (-5.4 to 2.1)	-14.6 (-17.9 to -11.1)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.7)	-2.3 (-18.0 to 17.2)	-14.8 (-28.3 to 3.6)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.3)	0.6 (0.2 to 1.3)	333.2 (59.2 to 809.7)	333.2 (29.8 to 681.7)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	147.7 (-11.2 to 387.4)	118.7 (-21.9 to 333.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	147.7 (-11.4 to 388.0)	118.7 (-22.1 to 336.3)
HIV/AIDS resulting in other diseases	0.9 (0.4 to 1.6)	7.2 (2.3 to 16.0)	690.2 (262.5 to 1,360.1)	564.6 (190.9 to 1,154.4)	0.1 (0.0 to 0.3)	0.6 (0.2 to 1.3)	334.3 (59.2 to 811.0)	268.6 (29.3 to 688.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	4.5 (3.0 to 6.6)	4.7 (3.1 to 6.8)	3.7 (-3.1 to 11.7)	-6.1 (-12.3 to 1.4)
Diarrheal diseases	2.9 (2.5 to 3.2)	2.8 (2.5 to 3.2)	-2.9 (-18.5 to 18.3)	-12.7 (-32.4 to 13.6)	0.2 (0.3 to 0.7)	0.2 (0.3 to 0.6)	-29.5 (-22.9 to 21.3)	-34.2 (-34.0 to 18.6)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.7 to 47.8	-70.7 to 40.8
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.2 (-38.6 to -8.9)	-27.4 (-38.2 to -15.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.2 (-33.6 to -8.9)	-27.4 (-38.3 to -15.4)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.1 (-18.5 to 47.5)	7.9 (-20.2 to 42.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.1 (-18.6 to 47.7)	7.9 (-20.3 to 42.3)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-66.6 (-98.9 to 577.5)	-68.7 (-98.9 to 536.3)
Lower respiratory infections	0.7 (0.7 to 0.8)	0.8 (0.7 to 0.8)	1.3 (-4.2 to 6.6)	-14.7 (-18.5 to -10.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	10.4 (-15.9 to 20.9)	4.2 (-28.0 to 2.6)
Upper respiratory infections	115.4 (110.2 to 120.4)	124.8 (119.9 to 130.1)	8.2 (1.5 to 14.7)	0.8 (-6.2 to 6.6)	1.3 (0.8 to 2.2)	1.5 (0.8 to 2.4)	7.9 (0.4 to 15.9)	0.9 (-6.7 to 8.2)
Otitis media	81.7 (73.1 to 89.8)	78.5 (71.1 to 87.7)	-3.5 (-15.4 to 8.3)	-13.2 (-23.7 to -2.6)	1.6 (0.9 to 2.5)	1.5 (0.9 to 2.4)	-4.1 (-17.1 to 8.8)	-13.8 (-24.3 to -3.1)
Meningitis	-	-	-	-	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.9)	8.7 (-15.8 to 38.7)	-3.0 (-26.7 to 28.0)
Pneumococcal meningitis	1.6 (1.0 to 2.7)	1.7 (1.1 to 3.0)	9.2 (-13.6 to 37.5)	-8.5 (-28.2 to 16.9)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	10.4 (-19.8 to 48.6)	3.3 (-31.6 to 31.1)
H influenzae type B meningitis	0.8 (0.3 to 1.8)	0.8 (0.3 to 1.9)	1.5 (-43.7 to 74.1)	-7.5 (-49.5 to 68.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	6.5 (-48.6 to 105.1)	2.4 (-51.9 to 97.4)
Meningococcal meningitis	0.8 (0.2 to 2.0)	0.9 (0.4 to 2.3)	22.3 (-23.8 to 122.9)	6.6 (-35.6 to 95.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	36.3 (-28.0 to 136.6)	19.8 (-38.8 to 113.0)
Other meningitis	1.4 (0.6 to 3.1)	1.4 (0.6 to 3.0)	-4.6 (-36.7 to 30.8)	-16.0 (-44.1 to 23.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-2.6 (-4.2 to 50.0)	-13.2 (-50.4 to 39.3)
Encephalitis	1.2 (0.5 to 3.3)	1.4 (0.6 to 3.9)	18.4 (-4.6 to 47.9)	-3.1 (-20.1 to 22.4)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	23.4 (-3.5 to 57.5)	3.3 (-20.2 to 30.4)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.2 (-90.3 to 663.8)	-30.1 (-91.1 to 571.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.2 (-90.3 to 675.6)	-30.1 (-91.1 to 575.4)
Whooping cough	0.8 (0.6 to 1.0)	1.2 (0.9 to 1.6)	52.2 (47.1 to 57.5)	68.7 (63.1 to 74.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	52.6 (31.7 to 77.5)	69.2 (45.7 to 96.9)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.5 (-47.0 to -31.2)	-49.7 (-71.1 to -34.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.9 (-69.4 to -29.5)	-50.5 (-73.5 to -31.5)
Measles	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-98.3 (-98.7 to -97.9)	-98.1 (-98.5 to -97.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-98.3 (-98.8 to -97.4)	-98.1 (-98.7 to -97.1)
Varicella and herpes zoster	6.3 (5.5 to 7.3)	7.4 (6.3 to 8.6)	15.8 (-5.6 to 44.1)	0.8 (-13.9 to 18.5)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	24.6 (-1.1 to 66.9)	0.7 (-23.4 to 33.4)
Neglected tropical diseases and malaria	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.0 (-72.5 to -2.4)	0.0 (-76.0 to -16.7)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.0 (-56.4 to 459.7)	16.8 (-59.4 to 442.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.9 (-56.6 to 467.4)	18.3 (-59.0 to 448.5)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-75.9 (-91.6 to 15.7)	-78.8 (-92.6 to 8.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-74.4 (-91.0 to 17.3)	-77.4 (-92.2 to 11.9)
Cystic echinococcosis	0.4 (0.4 to 0.4)	0.3 (0.2 to 0.3)	-30.7 (-34.6 to -14.8)	-43.8 (-47.3 to -30.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-27.6 (-42.4 to -7.2)	-41.1 (-51.2 to -24.6)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.1 (-47.8 to 16.7)	-10.3 (-54.7 to 4.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.1 (-47.8 to 17.0)	-10.3 (-54.8 to 5.0)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.5 (-29.6 to 60.4)	9.3 (-39.2 to 41.5)
Maternal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	0.3 (-38.0 to 53.8)	11.5 (-31.8 to 72.2)
Maternal hemorrhage	1.3 (0.9 to 1.8)	1.4 (0.5 to 2.4)	5.5 (-61.5 to 99.1)	17.3 (-57.8 to 123.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	9.5 (-63.5 to 132.9)	25.1 (-58.3 to 165.9)
Maternal sepsis and other maternal infections	0.6 (0.4 to 1.0)	0.5 (0.3 to 0.8)	-15.1 (-45.8 to 12.9)	-24.9 (-56.4 to -0.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.1 (-39.1 to 0.6)	-22.6 (-40.0 to -3.7)
Maternal hypertensive disorders	0.6 (0.4 to 0.9)	0.6 (0.4 to 0.8)	-9.9 (-17.4 to 0.6)	-1.1 (-9.3 to 10.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-10.5 (-35.0 to 22.2)	-1.9 (-28.5 to 34.3)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.3 (-17.3 to -0.6)	1.2 (-7.6 to 10.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.3 (-17.3 to -0.6)	1.2 (-7.6 to 10.9)
Complications of abortion	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-5.9 (-13.2 to 0.8)	3.3 (-4.8 to 10.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.9 (-13.2 to 0.9)	3.3 (-4.8 to 10.8)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.6 (-48.2 to 106.9)	21.4 (-42.4 to 130.1)
Neonatal disorders	-	-	-	-	9.1 (6.2 to 12.0)	12.8 (9.1 to 17.1)	43.3 (6.5 to 81.1)	32.0 (-2.2 to 67.6)
Preterm birth complications	52.8 (38.3 to 76.2)	83.9 (59.0 to 121.4)	60.0 (22.1 to 101.6)	45.3 (10.4 to 83.0)	6.2 (4.2 to 8.5)	9.6 (6.7 to 13.0)	56.5 (14.3 to 94.4)	44.7 (8.8 to 80.7)
Neonatal encephalopathy due to birth asphyxia and trauma	7.4 (4.0 to 15.3)	5.3 (2.4 to 13.7)	-31.0 (-53.7 to 7.4)	-36.3 (-56.7 to -2.2)	1.6 (1.1 to 2.3)	1.1 (0.7 to 1.7)	-29.5 (-52.2 to 2.8)	-34.3 (-55.3 to -4.4)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.4 (24.5 to 86.5)	60.1 (38.5 to 106.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.6 (-17.1 to 161.0)	60.4 (8.1 to 109.5)
Hemolytic disease and other neonatal jaundice	1.7 (0.6 to 4.2)	1.2 (0.3 to 3.0)	-21.3 (-90.2 to 204.4)	-27.8 (-91.2 to 178.2)	0.7 (0.2 to 1.7)	0.7 (0.1 to 1.3)	-18.4 (-89.6 to 206.0)	-25.7 (-90.7 to 183.2)
Other neonatal disorders	-	-	-	-	0.6 (0.4 to 0.9)	1.6 (0.8 to 2.4)	187.4 (42.6 to 362.1)	165.4 (30.5 to 326.2)
Nutritional deficiencies	-	-	-	-	24.8 (15.8 to 37.0)	24.7 (15.6 to 37.6)	-0.1 (-20.8 to 16.9)	-0.1 (-21.1 to 21.2)
Protein-energy malnutrition	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.0 (-66.0 to 19.4)	-30.8 (-72.5 to 11.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.7 (-65.8 to 19.4)	-30.6 (-72.4 to 11.8)
Iodine deficiency	188.1 (70.4 to 253.6)	121.4 (66.9 to 184.1)	-35.7 (-66.3 to 118.4)	-39.7 (-69.0 to 88.4)	2.6 (1.1 to 5.3)	2.2 (1.0 to 3.9)	-19.9 (-66.5 to 117.8)	-27.5 (-69.5 to 85.6)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron-deficiency anemia	879.4 (797.0 to 898.3)	959.0 (851.2 to 987.5)	9.4 (-3.6 to 19.7)	2.7 (-11.7 to 15.2)	22.1 (14.1 to 32.7)	22.5 (14.3 to 33.8)	2.5 (-23.8 to 28.0)	2.4 (-24.0 to 32.4)

Appendix Table G.4 - Austria prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.6 (-58.3 to 5.2)	-44.6 (-65.5 to -22.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.0 (1.2 to 3.3)	2.2 (1.3 to 4.0)	6.0 (-7.7 to 95.1)	2.9 (-11.5 to 134.8)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.9 (0.5 to 1.7)	1.0 (0.6 to 1.9)	9.8 (8.9 to 31.0)	1.2 (-17.3 to 22.4)
Syphilis	0.5 (0.4 to 0.5)	0.9 (0.8 to 1.0)	82.7 (55.0 to 116.7)	39.0 (15.4 to 67.5)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	82.3 (35.2 to 145.7)	39.1 (1.2 to 88.5)
Chlamydial infection	146.7 (132.4 to 218.8)	153.5 (101.4 to 189.2)	5.5 (-44.3 to 23.5)	0.4 (-3.8 to 26.9)	0.5 (0.2 to 0.8)	0.5 (0.2 to 0.8)	4.5 (-30.5 to 32.3)	4.6 (-30.7 to 35.3)
Gonococcal infection	25.5 (15.6 to 36.5)	23.9 (14.8 to 33.1)	-6.9 (-49.8 to 70.9)	2.4 (-48.9 to 90.0)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-9.7 (-42.4 to 39.0)	-2.7 (-39.1 to 52.0)
Trichomoniasis	24.0 (15.7 to 32.1)	23.9 (15.5 to 32.6)	-1.8 (-38.9 to 70.3)	-6.4 (-45.0 to 61.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-4.1 (-44.1 to 79.2)	-8.2 (-50.6 to 76.2)
Genital herpes	948.7 (792.2 to 1,114.1)	1,135.0 (1,001.6 to 1,279.0)	19.6 (0.1 to 45.8)	-1.4 (-18.5 to 20.4)	0.2 (0.1 to 0.6)	0.3 (0.1 to 0.7)	17.7 (-2.8 to 44.0)	-1.5 (-19.2 to 20.6)
Other sexually transmitted diseases	0.6 (0.4 to 0.7)	0.7 (0.6 to 0.9)	26.2 (11.3 to 48.0)	15.8 (3.3 to 34.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.3 (9.7 to 75.0)	33.4 (5.0 to 74.0)
Hepatitis	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-3.1 (-16.1 to 10.5)	-11.7 (-22.4 to -0.3)
Hepatitis A	6.2 (6.0 to 6.4)	6.1 (5.9 to 6.3)	-1.9 (-2.2 to -1.8)	-6.0 (-6.8 to -5.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	1.8 (-9.9 to 14.5)	-4.3 (-15.7 to 8.1)
Hepatitis B	112.4 (88.7 to 142.4)	85.5 (64.8 to 105.7)	-23.0 (-43.0 to -0.0)	-35.6 (-53.4 to -14.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-14.0 (-45.0 to 23.3)	-28.5 (-53.3 to 1.9)
Hepatitis C	163.9 (145.1 to 181.8)	146.9 (129.7 to 163.8)	-10.0 (-24.7 to 6.1)	-27.0 (-39.0 to -13.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.8 (-36.4 to 34.9)	-24.3 (-45.9 to 3.0)
Hepatitis E	-	-	-	-	38.3 (-21.8 to 137.3)	26.0 (-27.6 to 118.1)	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	34.4 (30.4 to 39.0)	36.5 (31.5 to 73.4)	3.0 (-11.4 to 110.0)	2.3 (-14.6 to 138.5)	0.8 (0.5 to 1.2)	0.9 (0.5 to 2.3)	4.6 (-19.1 to 241.1)	7.6 (-15.8 to 289.2)
Non-communicable diseases	-	-	-	-	819.4 (612.5 to 1,056.9)	1,017.4 (757.5 to 1,308.5)	24.0 (19.9 to 29.0)	1.9 (-1.8 to 5.7)
Neoplasms	-	-	-	-	16.2 (12.0 to 20.8)	22.7 (16.7 to 28.9)	40.0 (29.8 to 53.8)	0.5 (-7.7 to 9.7)
Esophageal cancer	0.5 (0.3 to 0.6)	0.7 (0.5 to 0.9)	59.3 (13.3 to 119.3)	14.4 (-18.5 to 59.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	54.3 (12.5 to 110.2)	11.1 (-18.4 to 52.6)
Stomach cancer	6.2 (5.2 to 7.2)	4.8 (4.0 to 5.8)	-21.9 (-34.4 to -5.9)	-45.8 (-54.0 to -35.5)	0.7 (0.5 to 0.9)	0.7 (0.3 to 0.7)	-26.3 (-40.0 to -10.9)	-48.4 (-57.4 to -38.9)
Liver cancer	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	74.9 (24.8 to 156.9)	26.5 (-9.3 to 81.7)
Liver cancer due to hepatitis B	0.2 (0.1 to 0.4)	0.5 (0.3 to 0.8)	96.9 (-10.4 to 302.7)	43.0 (-34.1 to 192.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	75.6 (-19.2 to 259.6)	29.5 (-37.9 to 161.4)
Liver cancer due to hepatitis C	0.2 (0.1 to 0.4)	1.0 (0.6 to 1.6)	365.8 (120.4 to 834.0)	235.1 (58.7 to 593.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	299.9 (84.7 to 678.1)	190.6 (36.5 to 458.6)
Liver cancer due to alcohol use	0.6 (0.4 to 0.8)	0.7 (0.4 to 1.1)	11.6 (-39.7 to 119.1)	-20.4 (-57.5 to 56.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	1.0 (-42.9 to 90.2)	-27.0 (-59.2 to 39.1)
Liver cancer due to other causes	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.2)	-21.7 (-69.4 to 121.0)	-43.0 (-78.0 to 62.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.7 (-69.9 to 97.3)	-46.2 (-77.8 to 45.6)
Larynx cancer	1.3 (0.9 to 1.7)	1.2 (1.0 to 1.8)	-3.2 (-32.4 to 40.6)	-5.3 (-51.7 to 1.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-15.8 (-40.6 to 27.7)	-39.1 (-57.2 to -7.5)
Tracheal, bronchus and lung cancer	6.4 (5.7 to 7.1)	9.0 (7.7 to 10.1)	41.7 (13.2 to 65.0)	2.7 (-18.0 to 19.9)	0.9 (0.7 to 1.2)	1.2 (0.9 to 1.6)	31.5 (6.5 to 53.2)	-4.3 (-23.6 to 11.5)
Breast cancer	46.3 (42.1 to 50.3)	65.1 (60.1 to 70.7)	40.7 (25.9 to 57.6)	-0.8 (-10.7 to 11.4)	2.7 (1.9 to 3.7)	3.4 (2.3 to 4.6)	26.7 (10.2 to 43.0)	-10.4 (-21.6 to 1.1)
Cervical cancer	7.9 (5.8 to 9.4)	4.9 (3.8 to 7.1)	-40.7 (-55.4 to -1.5)	-54.9 (-66.0 to -25.8)	0.6 (0.4 to 0.8)	0.4 (0.2 to 0.5)	0.4 (-5.6 to -1.9)	-55.0 (-66.6 to -26.5)
Uterine cancer	15.0 (10.5 to 16.8)	14.2 (10.9 to 20.0)	-9.3 (-30.5 to 64.9)	-9.3 (-49.5 to 19.6)	0.9 (0.6 to 1.4)	0.9 (0.6 to 1.4)	-1.1 (-31.9 to 29.2)	-36.8 (-51.0 to 15.7)
Prostate cancer	22.9 (19.4 to 27.5)	60.9 (52.0 to 74.7)	166.9 (106.2 to 232.7)	86.3 (46.5 to 132.5)	2.6 (1.4 to 2.6)	5.5 (3.1 to 6.3)	124.2 (71.0 to 205.5)	56.4 (20.9 to 114.3)
Colon and rectum cancer	25.0 (23.3 to 26.9)	31.1 (27.9 to 34.3)	24.7 (9.4 to 40.0)	-12.2 (-22.5 to -1.9)	2.2 (1.6 to 2.8)	2.5 (1.8 to 3.2)	16.9 (2.2 to 32.5)	-17.5 (-27.9 to -6.6)
Lip and oral cavity cancer	4.2 (3.9 to 4.6)	5.7 (4.4 to 7.2)	34.7 (4.1 to 73.2)	-3.2 (-25.0 to 24.1)	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.6)	29.9 (-2.5 to 68.3)	-6.6 (-29.5 to 21.4)
Nasopharynx cancer	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-30.2 (-52.3 to 7.1)	-48.6 (-64.4 to -22.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.7 (-57.3 to -10.0)	-49.8 (-65.3 to -25.8)
Other pharynx cancer	2.1 (1.5 to 2.8)	3.2 (2.1 to 4.5)	56.4 (-8.8 to 140.2)	12.8 (-34.0 to 75.2)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.4)	10.9 (-9.9 to 143.3)	10.9 (-35.9 to 75.9)
Gallbladder and biliary tract cancer	0.6 (0.4 to 0.7)	0.5 (0.4 to 0.7)	-23.2 (-39.7 to 25.3)	-46.4 (-57.8 to -13.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-23.9 (-44.8 to 32.5)	-46.5 (-60.1 to -10.7)
Pancreatic cancer	1.2 (1.0 to 1.3)	1.9 (1.6 to 2.3)	65.9 (32.4 to 110.0)	18.7 (-4.8 to 48.1)	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.5)	56.4 (24.5 to 96.7)	12.1 (-10.8 to 39.0)
Malignant skin melanoma	7.3 (5.1 to 10.0)	12.6 (8.7 to 17.9)	73.7 (37.5 to 113.6)	28.6 (3.2 to 58.5)	0.4 (0.3 to 0.7)	0.7 (0.4 to 1.2)	68.0 (32.3 to 107.9)	24.1 (-1.4 to 53.7)
Non-melanoma skin cancer	7.9 (5.2 to 11.3)	13.8 (8.1 to 20.0)	73.8 (-6.8 to 177.8)	30.0 (-32.5 to 98.4)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.5)	92.2 (28.8 to 183.1)	37.4 (-11.2 to 95.0)
Ovarian cancer	4.3 (3.6 to 5.1)	4.3 (3.5 to 5.7)	-1.6 (-22.9 to 40.5)	-29.3 (-44.1 to 1.4)	0.6 (0.4 to 0.7)	0.5 (0.4 to 0.7)	-4.1 (-26.4 to 37.5)	-30.8 (-46.9 to -1.1)
Testicular cancer	3.7 (2.5 to 5.5)	2.9 (1.8 to 4.3)	-21.1 (-53.3 to 32.6)	-27.5 (-57.9 to 25.0)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.2)	-21.9 (-54.7 to 31.5)	-28.2 (-59.1 to 25.6)
Kidney cancer	7.9 (6.5 to 9.0)	11.9 (10.0 to 14.3)	51.2 (23.0 to 92.4)	7.1 (-13.7 to 33.9)	0.6 (0.4 to 0.8)	0.8 (0.6 to 1.1)	44.1 (15.8 to 84.7)	2.7 (-18.1 to 29.9)
Bladder cancer	10.1 (8.5 to 11.7)	13.2 (10.9 to 15.0)	30.7 (7.3 to 57.5)	30.7 (-24.8 to 10.8)	0.7 (0.5 to 1.0)	0.9 (0.6 to 1.3)	49.9 (1.6 to 52.1)	12.9 (-17.7 to 5.9)
Brain and nervous system cancer	1.9 (1.6 to 2.4)	3.0 (2.4 to 3.6)	54.5 (26.9 to 85.5)	16.7 (-3.7 to 38.9)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	30.3 (19.1 to 84.7)	14.0 (-7.6 to 38.7)
Thyroid cancer	3.8 (2.9 to 4.6)	4.1 (3.1 to 6.5)	-0.5 (-25.3 to 89.3)	-23.4 (-42.4 to 44.0)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.4)	-4.2 (-29.5 to 80.4)	-26.2 (-46.0 to 37.6)
Mesothelioma	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	0.0 (-17.9 to 74.1)	-22.4 (-39.5 to 22.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	9.9 (-18.6 to 75.1)	-19.4 (-39.6 to 26.2)
Hodgkin lymphoma	2.4 (1.3 to 2.9)	1.3 (1.0 to 2.6)	-45.8 (-62.9 to 65.5)	-51.1 (-69.1 to 35.1)	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-59.5 (-64.9 to 58.3)	-41.5 (-71.3 to 25.3)
Non-Hodgkin lymphoma	6.5 (5.3 to 10.8)	15.3 (8.6 to 19.9)	179.1 (-8.2 to 250.9)	98.3 (-32.0 to 146.2)	0.5 (0.3 to 0.8)	1.1 (0.6 to 1.6)	163.0 (-13.6 to 239.2)	88.1 (-35.4 to 139.3)
Multiple myeloma	1.2 (0.8 to 1.7)	2.2 (1.4 to 3.1)	83.0 (19.5 to 166.4)	30.6 (-13.9 to 89.3)	0.2 (0.2 to 0.4)	0.4 (0.2 to 0.7)	72.7 (11.8 to 157.3)	24.1 (-19.3 to 86.8)
Leukemia	2.7 (2.2 to 3.1)	4.8 (4.0 to 5.7)	82.3 (41.7 to 125.9)	24.7 (-2.2 to 51.1)	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	70.1 (31.8 to 111.7)	17.9 (-7.4 to 43.7)
Other neoplasms	7.1 (6.4 to 8.5)	21.3 (16.2 to 26.6)	204.9 (113.0 to 282.7)	111.2 (55.0 to 157.1)	0.5 (0.4 to 0.7)	1.4 (0.9 to 1.9)	181.4 (97.9 to 262.2)	97.8 (44.9 to 144.2)
Cardiovascular diseases	-	-	-	-	37.9 (26.7 to 50.7)	51.5 (36.7 to 68.5)	35.5 (15.7 to 58.7)	-4.6 (-18.8 to 12.0)
Rheumatic heart disease	2.1 (2.0 to 2.2)	2.1 (2.0 to 2.3)	1.5 (-7.6 to 11.0)	-24.8 (-31.1 to -18.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-0.3 (-29.6 to 70.2)	-27.9 (-50.7 to 26.3)
Ischemic heart disease	193.9 (163.6 to 236.5)	250.3 (218.9 to 292.2)	30.2 (1.2 to 65.2)	-9.0 (-30.7 to 14.3)	12.4 (8.1 to 17.4)	14.5 (9.7 to 20.4)	17.7 (-9.9 to 50.3)	-19.0 (-39.6 to 3.8)
Cerebrovascular disease	-	-	-	-	9.2 (6.3 to 12.3)	13.6 (9.3 to 18.4)	48.2 (28.9 to 79.4)	7.4 (-12.4 to 28.6)
Ischemic stroke	53.8 (44.5 to 63.6)	80.3 (67.5 to 95.6)	49.7 (18.4 to 84.9)	7.9 (-14.3 to 30.8)	7.6 (5.2 to 10.5)	11.4 (7.7 to 15.7)	49.9 (17.8 to 85.7)	8.2 (-14.7 to 32.2)
Hemorrhagic stroke	10.6 (7.2 to 14.6)	15.0 (9.9 to 20.3)	42.5 (-8.0 to 115.8)	4.7 (-30.1 to 53.4)	1.5 (0.9 to 2.3)	2.2 (1.2 to 3.1)	4.4 (-8.7 to 115.2)	4.4 (-30.5 to 54.8)
Hypertensive heart disease	36.4 (33.8 to 39.2)	42.3 (39.2 to 45.6)	16.1 (5.2 to 28.1)	-19.1 (-26.5 to -10.6)	3.9 (2.7 to 5.3)	4.5 (3.2 to 6.1)	16.7 (4.7 to 29.7)	-18.5 (-26.2 to -9.2)
Cardiomyopathy and myocarditis	18.5 (16.2 to 21.3)	19.9 (18.1 to 23.0)	6.3 (-9.4 to 35.4)	-22.5 (-33.9 to -2.4)	1.9 (1.3 to 2.6)	2.0 (1.4 to 2.8)	7.2 (-10.7 to 38.2)	-21.9 (-34.6 to -0.3)
Atrial fibrillation and flutter	8.3 (5.4 to 13.9)	42.5 (32.8 to 56.0)	400.2 (176.3 to 830.0)	291.2 (95.0 to 573.4)	0.6 (0.4 to 1.1)	3.3 (2.1 to 4.9)	442.8 (175.3 to 835.3)	294.2 (95.3 to 576.2)
Peripheral vascular disease	316.3 (255.2 to 392.4)	424.2 (318.0 to 520.9)	33.6 (-0.0 to 81.7)	-5.9 (-30.0 to 32.8)	0.4 (0.1 to 0.8)	0.5 (0.1 to 1.0)	16.0 (-54.7 to 219.9)	-20.8 (-70.0 to 120.9)
Endocarditis	0.6 (0.4 to 0.8)	0.7 (0.5 to 1.0)	11.0 (-33.5 to 90.3)	-14.6 (-48.0 to 40.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-6.4 (-57.8 to 86.2)	-29.8 (-66.6 to 33.4)
Other cardiovascular and circulatory diseases	133.7 (81.1 to 191.1)	184.0 (115.7 to 242.5)	37.2 (-22.5 to 142.1)	-2.7 (-44.5 to 66.9)	9.4 (5.0 to 14.7)	13.0 (7.1 to 19.3)	37.9 (-22.3 to 144.5)	-2.4 (-44.5 to 69.4)
Chronic respiratory diseases	-	-	-	-	44.0 (29.7 to 61.4)	57.1 (37.6 to 78.9)	29.4 (19.4 to 42.2)	4.4 (-9.4 to 22.2)
Chronic obstructive pulmonary disease	716.1 (643.5 to 800.6)	954.9 (868.0 to 1,046.3)	33.2 (24.1 to 42.7)	1.0 (-5.6 to 8.1)	22.5 (13.2 to 34.6)	33.8 (20.6 to 49.9)	48.7 (13.6 to 110.4)	11.8 (-13.0 to 57.6)
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.0 (-19.8 to -14.3)	-38.1 (-40.1 to -35.9)

Appendix Table G.4 - Austria prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Silicosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-19.7 (-22.6 to -15.7)	-41.3 (-43.4 to -38.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.0 (-22.1 to -15.0)	-40.9 (-43.1 to -37.8)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-17.9 (-21.5 to -14.3)	-37.7 (-40.6 to -34.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.8 (-19.3 to -12.1)	-36.4 (-39.2 to -33.5)
Asthma	480.2 (446.9 to 513.3)	516 (481.4 to 549.0)	7.5 (-2.8 to 17.8)	3.0 (-12.6 to 5.6)	21.0 (13.7 to 29.8)	22.5 (14.7 to 32.4)	10.3 (3.1 to 17.7)	2.8 (-12.6 to 6.7)
Interstitial lung disease and pulmonary sarcoidosis	1.3 (1.2 to 1.3)	2.9 (2.8 to 3.0)	123.6 (110.5 to 136.3)	62.5 (53.2 to 71.6)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.5)	110.1 (81.9 to 135.9)	53.8 (37.9 to 71.1)
Other chronic respiratory diseases	-	-	-	-	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	19.2 (-15.8 to 73.1)	-10.5 (-35.7 to 29.5)
Cirrhosis	-	-	-	-	1.4 (1.0 to 1.9)	1.5 (1.0 to 2.0)	8.7 (-1.5 to 19.8)	-17.6 (-25.0 to -9.0)
Cirrhosis due to hepatitis B	0.8 (0.5 to 1.2)	0.9 (0.6 to 1.3)	18.7 (-32.4 to 139.7)	-10.5 (-49.9 to 82.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	18.3 (-36.8 to 156.9)	-10.3 (-52.6 to 92.0)
Cirrhosis due to hepatitis C	2.8 (1.8 to 4.1)	4.0 (2.4 to 5.5)	51.1 (-33.3 to 148.3)	12.0 (51.3 to 85.6)	0.5 (0.3 to 0.7)	0.6 (0.3 to 1.1)	49.2 (-36.1 to 150.2)	10.7 (-53.4 to 89.1)
Cirrhosis due to alcohol use	4.0 (3.1 to 5.0)	3.1 (1.9 to 4.3)	-25.3 (-54.0 to 29.7)	-44.7 (-66.7 to -3.0)	0.7 (0.4 to 1.0)	0.5 (0.3 to 0.8)	-25.6 (-55.2 to 29.8)	-44.7 (-66.8 to -3.3)
Cirrhosis due to other causes	0.7 (0.5 to 1.0)	1.1 (0.6 to 1.9)	44.4 (-19.1 to 167.8)	15.2 (-31.3 to 113.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	45.9 (-21.9 to 185.3)	18.3 (-33.1 to 127.2)
Digestive diseases	-	-	-	-	11.8 (8.5 to 15.6)	16.1 (11.6 to 21.4)	36.8 (25.0 to 48.1)	7.6 (-1.5 to 17.5)
Peptic ulcer disease	47.0 (43.9 to 50.5)	31.7 (26.1 to 37.1)	-32.5 (-45.5 to -19.6)	-54.9 (-62.9 to -47.1)	1.7 (1.2 to 2.3)	1.3 (0.9 to 1.9)	-21.7 (-32.8 to -6.1)	-47.6 (-54.8 to -36.8)
Gastritis and duodenitis	22.1 (20.2 to 24.3)	24.8 (22.5 to 27.8)	12.5 (-1.1 to 24.8)	-15.8 (-25.5 to -6.5)	1.0 (0.7 to 1.4)	1.2 (0.8 to 1.7)	18.2 (2.6 to 30.8)	-10.6 (-22.7 to 1.0)
Appendicitis	0.8 (0.8 to 0.9)	0.5 (0.5 to 0.5)	-38.9 (-43.0 to -34.2)	-39.9 (-44.2 to -35.0)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.2)	-38.4 (-52.1 to -20.1)	-39.6 (-55.1 to -20.1)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	106.0 (82.9 to 138.6)	68.5 (35.1 to 127.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	101.5 (48.1 to 163.4)	67.7 (20.7 to 131.7)
Inguinal, femoral, and abdominal hernia	87.7 (78.2 to 98.0)	107.0 (95.1 to 119.2)	22.5 (1.9 to 43.1)	-10.5 (-24.4 to 3.1)	0.9 (0.4 to 1.6)	1.1 (0.5 to 2.0)	23.4 (2.4 to 42.6)	9.3 (-23.1 to 41.1)
Inflammatory bowel disease	20.6 (18.8 to 22.4)	32.5 (29.9 to 35.4)	57.0 (42.6 to 80.2)	25.6 (13.7 to 44.4)	4.3 (2.9 to 5.9)	6.8 (4.7 to 9.3)	56.8 (41.2 to 80.9)	26.1 (12.8 to 45.7)
Vascular intestinal disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	49.1 (3.7 to 120.7)	6.7 (-23.5 to 51.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.1 (-9.8 to 141.4)	5.1 (-29.4 to 61.9)
Gallbladder and biliary diseases	17.1 (15.8 to 18.7)	21.1 (18.8 to 24.2)	22.8 (7.6 to 44.0)	-6.8 (-17.3 to 8.6)	1.8 (1.2 to 2.4)	2.2 (1.5 to 3.1)	22.9 (6.7 to 44.6)	-6.6 (-18.3 to 9.6)
Pancreatitis	2.3 (2.2 to 2.4)	3.3 (3.1 to 3.4)	41.4 (34.3 to 48.6)	0.7 (-4.9 to 16.7)	0.9 (0.4 to 0.9)	0.9 (0.6 to 1.3)	41.0 (21.5 to 63.1)	11.1 (-4.9 to 28.7)
Other digestive diseases	-	-	-	-	1.1 (0.8 to 1.5)	2.3 (1.5 to 3.2)	112.5 (50.4 to 160.3)	67.2 (17.9 to 104.8)
Neurological disorders	-	-	-	-	100.5 (69.1 to 136.0)	126.4 (87.2 to 169.0)	25.8 (12.9 to 42.2)	4.0 (-7.3 to 17.1)
Alzheimer disease and other dementias	135.9 (109.9 to 163.6)	196.5 (157.2 to 235.6)	44.1 (10.0 to 94.4)	-3.2 (-25.1 to 29.3)	19.9 (14.0 to 27.0)	29.4 (20.3 to 39.1)	47.1 (11.4 to 99.1)	-2.1 (-24.6 to 31.5)
Parkinson disease	5.7 (4.5 to 7.2)	7.9 (6.2 to 10.2)	37.2 (25.8 to 63.4)	0.9 (-10.5 to 15.7)	0.9 (0.4 to 1.0)	0.9 (0.6 to 1.4)	38.3 (17.1 to 67.4)	0.8 (-16.5 to 19.0)
Epilepsy	24.9 (17.7 to 32.6)	24.9 (17.0 to 33.2)	-1.1 (-39.1 to 57.6)	-11.4 (-46.2 to 38.7)	9.8 (5.9 to 14.0)	10.2 (6.1 to 15.2)	3.9 (-38.2 to 66.2)	-8.1 (-44.3 to 47.8)
Multiple sclerosis	5.3 (3.8 to 6.7)	9.9 (7.1 to 13.2)	89.7 (16.7 to 207.5)	52.7 (-5.5 to 146.6)	1.7 (1.0 to 2.5)	3.2 (2.0 to 4.8)	89.2 (15.1 to 209.9)	52.6 (-6.7 to 147.6)
Migraine	1,569.6 (1,391.0 to 1,755.1)	1,744.9 (1,589.2 to 1,900.7)	11.1 (-4.3 to 30.9)	-1.3 (-15.7 to 16.7)	53.3 (31.4 to 78.7)	59.1 (35.0 to 86.5)	10.5 (-4.8 to 30.6)	-1.1 (-16.1 to 17.2)
Tension-type headache	1,988.1 (1,399.3 to 2,622.8)	2,550.0 (2,371.4 to 2,681.9)	28.6 (-4.1 to 79.0)	15.5 (-15.3 to 62.7)	3.8 (1.3 to 5.5)	3.8 (1.9 to 6.7)	28.1 (-4.9 to 80.4)	15.9 (-11.7 to 64.6)
Medication overuse headache	61.6 (40.2 to 83.2)	104.5 (70.1 to 138.7)	69.3 (33.3 to 119.8)	41.4 (12.4 to 84.6)	9.6 (5.4 to 16.6)	16.2 (9.4 to 25.2)	69.4 (32.0 to 121.0)	41.7 (13.0 to 87.5)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.1 (-28.7 to 72.9)	-3.1 (-39.1 to 43.3)	2.5 (1.7 to 3.6)	3.5 (2.3 to 5.0)	38.3 (-4.1 to 107.1)	-4.9 (-33.5 to 42.6)
Mental and substance use disorders	-	-	-	-	193.9 (134.8 to 259.3)	214.5 (149.1 to 286.9)	10.6 (6.9 to 14.4)	0.3 (-2.5 to 2.6)
Schizophrenia	22.3 (17.3 to 26.7)	26.4 (20.8 to 31.7)	18.6 (10.0 to 28.5)	-0.4 (-6.2 to 9.9)	14.2 (9.6 to 18.7)	16.9 (11.5 to 21.8)	18.7 (8.6 to 30.5)	0.1 (-7.6 to 9.8)
Alcohol use disorders	128.5 (117.0 to 141.2)	148.2 (137.2 to 161.1)	15.8 (8.5 to 22.1)	8.1 (1.5 to 14.2)	12.9 (8.6 to 18.3)	14.8 (10.0 to 21.3)	15.3 (7.2 to 23.0)	15.3 (0.9 to 15.5)
Drug use disorders	-	-	-	-	19.1 (13.4 to 25.1)	19.5 (13.6 to 25.4)	1.8 (-7.3 to 13.5)	1.5 (-8.0 to 13.4)
Opioid use disorders	25.3 (21.7 to 28.6)	26.3 (22.6 to 29.9)	4.2 (-4.0 to 12.2)	1.5 (-6.3 to 9.2)	10.5 (7.4 to 13.9)	11.0 (7.7 to 14.5)	4.2 (-5.6 to 14.6)	2.2 (-7.5 to 12.0)
Cocaine use disorders	11.8 (9.6 to 14.5)	11.9 (10.0 to 13.9)	1.7 (-21.6 to 33.9)	2.0 (-22.3 to 35.7)	1.6 (1.0 to 2.4)	1.6 (1.0 to 2.4)	1.5 (-21.9 to 37.2)	2.1 (-23.0 to 39.3)
Amphetamine use disorders	18.7 (16.3 to 21.1)	18.5 (16.3 to 21.0)	-1.2 (-16.8 to 19.7)	-1.1 (-15.8 to 23.8)	2.4 (1.5 to 3.6)	2.4 (1.5 to 3.6)	0.9 (-19.6 to 22.3)	0.9 (-18.0 to 26.3)
Cannabis use disorders	14.0 (12.6 to 15.4)	13.3 (11.9 to 14.5)	-5.4 (-10.1 to 0.7)	-0.5 (-6.0 to 6.2)	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	-4.9 (-17.2 to 11.7)	0.1 (-13.5 to 17.7)
Other drug use disorders	-	-	-	-	4.1 (2.5 to 6.0)	4.1 (2.6 to 5.9)	-1.0 (-26.1 to 38.8)	1.0 (-25.6 to 40.8)
Depressive disorders	-	-	-	-	64.3 (34.0 to 102.8)	73.7 (38.6 to 117.7)	14.6 (6.3 to 21.8)	-0.8 (-8.2 to 4.7)
Major depressive disorder	255.1 (116.6 to 380.8)	292.5 (131.3 to 438.4)	14.5 (4.5 to 23.2)	-1.1 (-9.6 to 5.0)	51.8 (22.6 to 87.3)	59.2 (25.1 to 98.6)	14.3 (3.6 to 23.2)	0.8 (-10.0 to 6.0)
Dysthymia	130.3 (109.8 to 150.7)	151.5 (128.4 to 175.4)	16.3 (12.9 to 20.0)	-0.5 (-0.8 to -0.3)	12.5 (8.2 to 18.4)	14.5 (9.6 to 21.5)	16.1 (11.5 to 20.9)	-0.3 (-2.6 to 2.1)
Bipolar disorder	59.5 (50.2 to 69.8)	65.5 (55.7 to 75.1)	10.1 (3.6 to 16.3)	-1.0 (-6.4 to 4.5)	12.0 (7.4 to 18.4)	13.2 (8.1 to 19.8)	9.8 (2.3 to 17.9)	-0.7 (-7.6 to 6.2)
Anxiety disorders	408.1 (229.1 to 571.5)	450.2 (270.2 to 633.0)	11.0 (1.6 to 20.7)	-0.5 (-1.3 to -0.1)	37.1 (18.3 to 58.6)	40.9 (21.4 to 64.7)	10.7 (0.9 to 20.9)	-0.2 (-2.5 to 2.0)
Eating disorders	-	-	-	-	5.8 (2.9 to 10.0)	5.5 (2.8 to 9.3)	4.8 (-10.8 to 3.5)	4.8 (-1.0 to 12.2)
Anorexia nervosa	6.7 (3.2 to 11.9)	7.3 (3.8 to 12.3)	9.9 (-5.0 to 26.1)	17.6 (3.8 to 33.8)	1.4 (0.6 to 2.7)	1.6 (0.7 to 2.9)	9.9 (-7.5 to 29.8)	17.8 (0.7 to 37.6)
Bulimia nervosa	20.6 (10.8 to 37.9)	18.6 (10.0 to 33.5)	-9.7 (-12.7 to -4.8)	0.3 (0.1 to 0.5)	4.3 (2.1 to 8.0)	3.9 (1.9 to 7.2)	-9.5 (-15.2 to -2.1)	0.6 (-4.7 to 6.5)
Autistic spectrum disorders	-	-	-	-	8.4 (5.9 to 11.5)	9.2 (6.5 to 12.5)	9.7 (6.2 to 13.6)	1.0 (-2.2 to 4.5)
Autism	21.9 (20.6 to 23.1)	24.0 (22.6 to 25.5)	9.8 (8.9 to 10.9)	0.7 (0.6 to 0.7)	5.3 (3.5 to 7.3)	5.8 (3.9 to 8.0)	9.5 (4.7 to 15.2)	0.9 (-3.6 to 5.9)
Asperger syndrome	31.2 (29.2 to 33.4)	34.4 (32.0 to 37.0)	10.2 (9.2 to 11.2)	0.9 (0.8 to 1.0)	3.1 (2.1 to 4.3)	3.4 (2.4 to 4.7)	9.9 (5.5 to 14.4)	1.1 (-3.0 to 5.1)
Attention-deficit/hyperactivity disorder	38.3 (31.8 to 45.1)	34.7 (28.8 to 40.8)	-9.5 (-9.6 to -9.3)	0.0 (0.0 to 0.0)	0.5 (0.3 to 0.7)	0.4 (0.2 to 0.7)	-9.4 (-15.4 to -2.6)	0.2 (-6.5 to 7.6)
Conduct disorder	54.0 (45.4 to 63.3)	49.9 (42.0 to 58.3)	-7.7 (-8.2 to -7.2)	0.1 (0.1 to 0.1)	6.5 (3.9 to 9.8)	6.0 (3.7 to 9.2)	-7.5 (-11.3 to -3.5)	0.3 (-3.8 to 4.5)
Idiopathic intellectual disability	38.6 (20.6 to 56.2)	27.0 (12.7 to 45.4)	-26.7 (-64.0 to 36.5)	-31.2 (-66.6 to 36.5)	2.1 (1.2 to 3.0)	1.6 (0.7 to 2.8)	-28.8 (-61.1 to 27.2)	-33.2 (-66.6 to 27.2)
Other mental and substance use disorders	148.6 (139.7 to 156.9)	174.1 (163.9 to 183.8)	17.1 (15.2 to 19.2)	0.5 (0.3 to 0.9)	11.0 (7.4 to 14.7)	12.8 (8.7 to 17.2)	16.8 (12.3 to 21.5)	0.9 (-2.8 to 4.5)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	84.7 (61.0 to 111.6)	120.0 (85.9 to 157.8)	41.3 (30.4 to 56.7)	10.7 (2.5 to 21.5)
Diabetes mellitus	336.5 (275.9 to 410.0)	598.3 (477.5 to 722.7)	77.2 (36.9 to 136.7)	36.1 (5.3 to 75.4)	23.0 (15.0 to 32.7)	41.0 (26.3 to 58.4)	76.6 (38.6 to 136.9)	35.1 (5.3 to 75.8)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.7 (-8.5 to 2.7)	-9.5 (-14.8 to -3.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.7 (-6.6 to 2.8)	-9.5 (-14.8 to -3.8)
Chronic kidney disease	-	-	-	-	31.2 (20.6 to 42.6)	40.7 (27.1 to 54.8)	30.9 (22.6 to 38.6)	2.5 (-3.0 to 7.8)
Chronic kidney disease due to diabetes mellitus	106.7 (73.3 to 158.1)	165.0 (109.3 to 244.2)	54.4 (5.6 to 129.8)	13.2 (-19.0 to 57.3)	6.0 (3.7 to 8.7)	8.8 (5.6 to 12.1)	46.8 (10.3 to 102.9)	8.8 (-16.4 to 50.6)
Chronic kidney disease due to hypertension	84.6 (60.7 to 110.0)	93.3 (64.5 to 128.6)	9.3 (-15.6 to 52.8)	-14.7 (-32.2 to 13.2)	8.4 (5.0 to 12.1)	2.9 (1.8 to 4.1)	-66.1 (-73.8 to -52.9)	-73.0 (-79.0 to -63.1)
Chronic kidney disease due to glomerulonephritis	137.7 (85.3 to 208.8)	72.2 (55.7 to 92.8)	-47.3 (-63.6 to -33.0)	-54.9 (-68.8 to -37.3)	3.0 (1.8 to 4.5)	6.8 (4.4 to 9.7)	129.8 (66.7 to 212.6)	76.7 (32.7 to 136.8)
Chronic kidney disease due to other causes	295.9 (183.1 to 436.5)	453.2 (314.2 to 602.3)	53.3 (27.6 to 109.9)	13.8 (1.1 to 55.0)	13.8 (8.5 to 19.4)	22.7 (14.8 to 30.6)	60.0 (38.6 to 109.2)	25.8 (8.7 to 61.4)
Urinary diseases and male infertility	-	-	-	-	9.2 (6.0 to 13.0)	15.6 (10.2 to 22.2)	68.5 (58.7 to 83.3)	25.6 (17.8 to 37.1)
Interstitial nephritis and urinary tract infections	2.2 (2.2 to 2.3)	4.6 (4.4 to 4.7)	102.5 (93.0 to 111.2)	69.5 (60.7 to 77.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	100.0 (74.7 to 134.2)	68.7 (44.7 to 99.4)

Appendix Table G.4 - Austria prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Urolithiasis	75.7 (44.6 to 130.8)	205.0 (139.9 to 330.5)	163.3 (108.2 to 288.1)	96.4 (51.7 to 183.9)	0.8 (0.4 to 1.4)	1.8 (1.0 to 3.2)	132.5 (90.2 to 202.4)	72.8 (41.0 to 119.8)
Benign prostatic hyperplasia	219.8 (206.4 to 232.0)	353.3 (343.4 to 361.7)	60.3 (51.7 to 72.3)	17.3 (10.7 to 26.1)	7.8 (5.1 to 11.0)	12.6 (8.2 to 17.8)	61.6 (52.1 to 73.9)	18.4 (11.3 to 27.2)
Male infertility due to other causes	67.2 (49.0 to 85.3)	66.8 (51.4 to 85.3)	-2.1 (-28.3 to 46.2)	-1.7 (-28.1 to 46.3)	0.5 (0.2 to 0.9)	0.5 (0.2 to 0.9)	-0.7 (-29.5 to 47.8)	-0.7 (-29.1 to 48.5)
Other urinary diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.6 (0.2 to 1.3)	484.5 (58.8 to 746.3)	338.9 (16.9 to 528.4)
Gynecological diseases	-	-	-	-	10.4 (6.5 to 16.1)	11.5 (7.1 to 18.1)	10.3 (4.1 to 33.1)	-8.4 (-16.4 to 15.8)
Uterine fibroids	302.6 (258.7 to 350.0)	386.9 (332.2 to 446.8)	27.8 (26.2 to 29.5)	0.0 (-0.0 to 0.1)	2.6 (1.3 to 4.8)	3.3 (1.5 to 6.1)	21.0 (-1.7 to 89.1)	-2.8 (-21.1 to 52.4)
Polycystic ovarian syndrome	131.3 (113.4 to 150.9)	145.9 (124.5 to 169.2)	11.8 (-10.6 to 35.7)	2.4 (-17.9 to 25.5)	1.3 (0.6 to 2.4)	1.4 (0.7 to 2.7)	11.4 (-10.3 to 34.8)	2.4 (-17.5 to 25.5)
Female infertility due to other causes	41.8 (21.8 to 65.5)	44.5 (21.9 to 71.0)	4.0 (-48.3 to 141.0)	-2.9 (-51.0 to 126.7)	0.2 (0.1 to 0.5)	0.2 (0.1 to 0.6)	4.0 (-48.0 to 127.0)	-1.8 (-51.0 to 113.1)
Endometriosis	22.2 (15.8 to 28.1)	23.9 (17.2 to 30.6)	7.9 (-27.8 to 54.7)	-1.5 (-33.3 to 43.0)	2.1 (1.2 to 3.0)	2.2 (1.3 to 3.3)	7.7 (-28.0 to 57.3)	-1.6 (-32.9 to 43.8)
Genital prolapse	507.8 (460.0 to 554.3)	590.2 (532.7 to 647.1)	15.8 (1.1 to 32.7)	-4.5 (-16.4 to 10.8)	1.6 (0.8 to 3.0)	1.9 (0.9 to 3.6)	16.1 (1.3 to 33.0)	-4.4 (-16.3 to 11.5)
Premenstrual syndrome	212.6 (149.2 to 277.9)	201.3 (131.1 to 281.9)	-5.3 (-44.9 to 68.5)	-9.8 (-48.8 to 63.3)	1.8 (1.0 to 2.8)	1.7 (0.9 to 2.8)	-5.4 (-45.3 to 69.7)	-10.4 (-49.4 to 63.7)
Other gynecological diseases	27.9 (24.4 to 40.3)	29.8 (25.6 to 55.8)	6.8 (-27.8 to 109.8)	-1.9 (-32.9 to 72.4)	0.8 (0.5 to 1.5)	0.8 (0.5 to 1.9)	3.8 (-46.7 to 192.6)	-5.7 (-50.2 to 131.7)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	5.8 (3.9 to 8.5)	5.9 (3.9 to 8.6)	1.1 (-17.9 to 21.4)	-5.0 (-27.5 to 20.4)
Thalassemias	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-20.2 (-27.2 to -13.3)	-11.4 (-19.2 to -3.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.9 (-40.9 to 12.7)	-9.4 (-34.3 to 26.1)
Thalassemia trait	116.0 (104.9 to 131.1)	125.3 (112.3 to 141.9)	7.6 (0.6 to 16.9)	-3.2 (-10.7 to 3.5)	3.4 (2.3 to 4.8)	3.4 (2.3 to 5.0)	0.8 (-13.1 to 18.9)	-5.2 (-20.2 to 6.7)
Sickle cell disorders	0.2 (0.2 to 0.2)	0.2 (0.1 to 0.2)	-5.9 (-17.8 to 6.6)	-4.7 (-18.3 to 8.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.7 (-9.5 to 8.2)	-1.6 (-11.3 to 7.7)
Sickle cell trait	123.8 (114.2 to 135.8)	128.6 (119.4 to 137.8)	4.3 (-5.9 to 10.1)	-6.2 (-20.0 to 0.5)	1.4 (0.9 to 2.2)	1.3 (0.8 to 2.0)	-8.2 (-37.4 to 23.8)	-9.9 (-43.9 to 29.8)
G6PD deficiency	99.4 (66.0 to 133.5)	120.3 (82.3 to 164.9)	21.8 (-24.6 to 99.4)	0.7 (-33.2 to 80.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.4 (-43.3 to 53.8)	9.5 (-39.5 to 42.2)
G6PD trait	1,088.1 (972.4 to 1,185.7)	1,169.9 (1,045.2 to 1,264.1)	7.8 (-5.8 to 24.3)	-3.1 (-15.3 to 11.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	3.8 (-38.9 to 83.1)	5.2 (-42.1 to 77.3)
Other hemoglobinopathies and hemolytic anemias	47.3 (43.7 to 50.7)	57.0 (50.8 to 79.4)	18.3 (4.1 to 71.0)	3.1 (-10.3 to 71.0)	0.9 (0.6 to 1.4)	1.0 (0.6 to 2.0)	6.1 (-20.9 to 145.9)	-0.7 (-24.4 to 164.8)
Endocrine, metabolic, blood, and immune disorders	151.2 (147.0 to 155.7)	156.2 (148.1 to 164.7)	3.3 (-2.6 to 9.4)	-10.5 (-15.7 to -4.3)	5.0 (3.5 to 6.9)	5.3 (3.6 to 7.3)	-9.4 (-4.7 to 15.2)	-9.4 (-16.9 to 0.3)
Musculoskeletal disorders	-	-	-	-	175.6 (124.9 to 232.7)	225.8 (158.5 to 301.9)	28.9 (14.9 to 44.2)	4.2 (-7.3 to 16.9)
Rheumatoid arthritis	31.3 (28.3 to 34.8)	37.2 (32.9 to 42.1)	19.0 (0.6 to 39.3)	-9.6 (-22.8 to 4.6)	7.1 (5.1 to 9.5)	8.5 (5.9 to 11.4)	19.3 (0.6 to 40.3)	-8.6 (-22.7 to 5.8)
Osteoarthritis	440.6 (373.7 to 520.6)	607.0 (526.1 to 702.0)	37.1 (13.4 to 69.6)	-1.6 (-19.4 to 22.1)	15.0 (9.4 to 22.5)	20.8 (13.3 to 30.3)	37.5 (13.4 to 69.4)	-1.1 (-19.4 to 22.7)
Low back and neck pain	-	-	-	-	126.7 (87.4 to 171.7)	158.7 (109.2 to 217.4)	25.6 (5.8 to 46.3)	3.8 (-2.1 to 21.0)
Low back pain	429.3 (429.3 to 572.9)	709.7 (593.3 to 832.3)	43.4 (18.7 to 73.2)	18.3 (-3.4 to 44.1)	54.1 (35.9 to 77.2)	78.0 (51.9 to 109.7)	43.6 (18.5 to 73.4)	19.2 (-3.5 to 45.2)
Neck pain	744.5 (613.4 to 863.0)	829.4 (666.1 to 1,016.2)	11.1 (-11.7 to 45.3)	-9.0 (-28.3 to 19.4)	72.6 (48.1 to 103.2)	80.7 (52.1 to 118.2)	10.6 (-12.1 to 45.4)	-8.9 (-28.6 to 20.1)
Gout	16.4 (14.6 to 18.1)	23.3 (20.5 to 26.1)	42.6 (21.8 to 64.1)	4.6 (-10.7 to 20.9)	0.5 (0.3 to 0.7)	0.7 (0.5 to 1.0)	42.9 (15.0 to 71.7)	5.7 (-15.2 to 27.6)
Other musculoskeletal disorders	288.3 (238.0 to 339.7)	408.3 (323.2 to 490.0)	41.2 (31.2 to 53.6)	11.3 (3.7 to 20.5)	26.2 (17.3 to 36.9)	37.2 (24.2 to 52.9)	41.6 (30.8 to 54.4)	11.9 (3.3 to 21.3)
Other non-communicable diseases	-	-	-	-	155.5 (103.6 to 221.7)	181.5 (122.8 to 257.7)	18.6 (12.5 to 25.4)	4.3 (-8.9 to 2.5)
Congenital anomalies	-	-	-	-	14.2 (9.6 to 19.5)	16.8 (11.4 to 23.2)	18.2 (3.3 to 35.7)	3.8 (-9.7 to 20.4)
Neural tube defects	2.3 (2.0 to 2.9)	2.1 (1.7 to 2.3)	-10.5 (-29.1 to 9.0)	-16.2 (-33.6 to 2.6)	0.8 (0.5 to 1.1)	0.7 (0.5 to 1.0)	-10.2 (-37.2 to 24.1)	-15.4 (-40.9 to 16.6)
Congenital heart anomalies	88.2 (74.6 to 105.1)	90.7 (75.0 to 112.7)	3.5 (-20.7 to 32.3)	-5.8 (-27.7 to 19.7)	3.1 (1.3 to 5.4)	3.2 (1.3 to 5.7)	3.9 (-18.7 to 31.2)	-4.6 (-25.2 to 19.9)
Crofacial clefts	11.4 (9.8 to 13.4)	12.5 (10.0 to 15.9)	8.7 (-15.3 to 45.2)	2.2 (-23.8 to 30.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	3.6 (-25.1 to 49.1)	-7.2 (-33.5 to 32.4)
Down syndrome	8.8 (7.0 to 11.7)	11.4 (9.4 to 14.7)	30.7 (-4.3 to 75.1)	10.5 (-18.8 to 48.7)	1.3 (0.9 to 1.9)	1.8 (1.3 to 2.5)	29.9 (0.9 to 88.8)	12.9 (-18.1 to 52.6)
Turner syndrome	0.5 (0.3 to 0.6)	0.5 (0.4 to 0.7)	15.6 (-16.0 to 66.5)	7.1 (-22.1 to 54.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.5 (-19.6 to 69.3)	6.8 (-24.5 to 56.4)
Klinefelter syndrome	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.6)	36.1 (-5.9 to 108.2)	23.1 (-15.0 to 88.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.9 (-19.6 to 112.0)	20.9 (-23.6 to 97.8)
Chromosomal unbalanced rearrangements	18.2 (15.5 to 21.6)	22.1 (18.7 to 26.4)	21.1 (-1.5 to 51.2)	2.8 (-16.8 to 28.1)	2.7 (2.0 to 3.5)	3.5 (2.5 to 4.5)	29.0 (4.4 to 62.8)	4.2 (-16.1 to 30.5)
Other congenital anomalies	19.5 (12.7 to 26.7)	18.9 (11.6 to 26.4)	-2.6 (-23.6 to 18.9)	-5.1 (-33.8 to 2.2)	6.2 (3.8 to 9.1)	7.5 (4.5 to 11.3)	6.2 (-3.2 to 51.5)	9.6 (-12.1 to 38.0)
Skin and subcutaneous diseases	-	-	-	-	49.3 (30.6 to 76.1)	53.7 (34.3 to 82.4)	9.0 (-2.6 to 23.1)	-0.6 (-12.0 to 13.6)
Dermatitis	447.4 (346.8 to 550.6)	495.7 (385.1 to 606.4)	10.9 (7.4 to 14.7)	-0.1 (-0.2 to 0.1)	10.4 (6.4 to 15.2)	11.5 (7.1 to 16.9)	10.4 (6.6 to 14.3)	0.1 (-2.4 to 2.6)
Psoriasis	114.9 (99.2 to 132.5)	135.4 (116.0 to 156.2)	17.7 (15.0 to 20.8)	0.1 (-0.2 to 0.4)	9.2 (6.3 to 12.9)	10.9 (7.4 to 15.1)	17.6 (12.1 to 23.4)	0.5 (-3.4 to 4.6)
Cellulitis	4.5 (3.7 to 5.4)	2.7 (2.2 to 3.3)	-40.3 (-45.7 to -34.2)	-47.4 (-51.8 to -43.0)	0.2 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-46.7 (-50.4 to -27.3)	-46.7 (-56.4 to -36.1)
Pyoderma	12.1 (10.0 to 14.8)	14.5 (11.7 to 18.0)	19.4 (13.7 to 26.1)	1.4 (-1.0 to 4.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	19.0 (10.1 to 28.8)	1.7 (-5.0 to 8.4)
Scabies	5.2 (4.4 to 6.1)	4.2 (3.4 to 5.1)	-20.2 (-38.6 to 4.6)	-24.4 (-41.7 to -2.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-20.1 (-40.1 to 6.9)	-23.8 (-42.2 to 0.7)
Fungal skin diseases	569.6 (503.4 to 627.7)	681.2 (604.1 to 744.8)	19.6 (17.3 to 21.9)	0.6 (0.3 to 0.8)	3.2 (1.3 to 6.6)	3.8 (1.5 to 7.8)	19.4 (17.0 to 22.0)	-0.9 (-0.2 to 1.7)
Viral skin diseases	155.8 (121.2 to 193.4)	159.2 (126.8 to 193.0)	2.1 (-1.9 to 8.8)	-0.2 (-2.0 to 2.6)	4.9 (2.8 to 7.6)	4.9 (2.8 to 7.6)	0.3 (-3.0 to 8.8)	0.3 (-3.0 to 3.8)
Acne vulgaris	1,184.2 (810.5 to 1,591.5)	1,053.4 (809.9 to 1,301.4)	-12.1 (-39.2 to 42.8)	-6.3 (-33.5 to 52.3)	12.8 (5.6 to 25.3)	11.4 (5.2 to 21.6)	-12.2 (-39.1 to 43.2)	-6.2 (-33.6 to 52.7)
Alopecia areata	13.3 (12.2 to 14.3)	16.2 (14.8 to 17.7)	22.0 (8.5 to 36.7)	0.5 (-9.6 to 11.6)	0.5 (0.3 to 0.6)	0.5 (0.3 to 0.8)	21.5 (6.0 to 39.2)	0.7 (-11.7 to 14.7)
Pruritus	1.2 (0.8 to 1.6)	1.2 (0.7 to 2.0)	-6.6 (-39.3 to 113.6)	-25.6 (-51.6 to 60.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.8 (-41.7 to 110.0)	-24.2 (-53.4 to 60.7)
Urticaria	56.5 (37.7 to 77.0)	80.9 (48.9 to 107.1)	49.2 (-13.6 to 108.3)	28.4 (-25.3 to 72.4)	3.3 (1.8 to 5.4)	4.7 (2.4 to 7.3)	50.0 (-13.5 to 106.9)	4.7 (-28.5 to 73.4)
Decubitus ulcer	7.1 (6.3 to 8.1)	7.3 (5.8 to 9.1)	3.7 (-24.6 to 30.0)	-27.9 (-46.2 to -10.4)	1.0 (0.7 to 1.4)	1.0 (0.7 to 1.5)	2.4 (-26.3 to 33.6)	-28.1 (-47.0 to -8.4)
Other skin and subcutaneous diseases	623.0 (350.0 to 1,073.0)	803.3 (439.1 to 1,437.5)	28.5 (20.5 to 35.3)	1.0 (-2.2 to 4.2)	3.6 (1.4 to 8.2)	4.7 (1.8 to 10.8)	28.4 (20.2 to 35.2)	1.2 (-2.3 to 4.7)
Sense organ diseases	-	-	-	-	62.4 (42.1 to 90.7)	78.8 (52.5 to 111.7)	26.6 (17.2 to 36.2)	-7.6 (-13.9 to -1.3)
Glaucoma	10.8 (6.7 to 15.5)	11.2 (7.8 to 15.6)	2.6 (-26.1 to 56.8)	-37.0 (-46.7 to 8.6)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.5)	-7.7 (-28.6 to 40.3)	-9.0 (-47.7 to 1.3)
Cataract	28.3 (16.3 to 42.9)	26.6 (17.5 to 39.9)	-6.1 (-37.9 to 43.7)	-35.8 (-56.1 to -3.2)	1.8 (1.0 to 2.8)	1.8 (1.0 to 2.9)	2.3 (-27.4 to 32.1)	-33.7 (-49.0 to -9.1)
Macular degeneration	37.8 (25.3 to 51.9)	52.0 (32.0 to 72.5)	39.7 (-0.6 to 86.0)	-4.0 (-28.3 to 27.8)	2.4 (1.5 to 3.7)	3.2 (1.7 to 5.0)	34.8 (-0.5 to 68.0)	-8.0 (-29.6 to 16.4)
Uncorrected refractive error	963.8 (797.5 to 1,140.5)	1,169.0 (925.0 to 1,432.9)	21.8 (-8.4 to 59.8)	-7.7 (-30.5 to 21.1)	12.9 (7.5 to 22.3)	15.0 (8.4 to 26.4)	16.4 (-5.3 to 43.3)	-10.5 (-27.5 to 9.5)
Age-related and other hearing loss	1,296.3 (1,124.5 to 1,457.6)	1,644.7 (1,422.7 to 1,867.5)	27.1 (21.4 to 31.7)	-8.0 (-12.8 to -4.4)	8.0 (4.6 to 14.7)	8.0 (3.5 to 13.7)	34.0 (28.8 to 40.2)	-4.7 (-14.7 to 6.0)
Other vision loss	27.8 (20.9 to 35.6)	23.8 (16.5 to 33.5)	-15.2 (-32.4 to 6.6)	-37.3 (-48.2 to -23.4)	1.7 (1.1 to 2.7)	1.7 (1.0 to 2.7)	6.2 (-22.5 to 12.0)	1.7 (-4.8 to 16.2)
Other sense organ diseases	185.0 (176.6 to 193.6)	212.7 (202.3 to 223.7)	15.0 (7.8 to 22.8)	-0.7 (-6.6 to 5.4)	4.8 (3.0 to 7.1)	5.5 (3.4 to 8.2)	14.3 (7.3 to 22.5)	-0.5 (-6.6 to 6.3)
Oral disorders	-	-	-	-	27.6 (17.7 to 41.2)	32.6 (20.7 to 48.1)	17.6 (7.7 to 31.1)	-8.6 (-16.0 to 0.8)
Deciduous caries	264.3 (242.2 to 283.3)	228.1 (209.4 to 244.5)	-33.9 (-23.6 to -3.3)	-3.0 (-14.1 to 9.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-13.7 (-23.0 to -3.1)	-2.7 (-15.3 to 12.2)
Permanent caries	3,004.4 (2,671.0 to 3,306.0)	3,372.4 (3,050.5 to 3,674.0)	12.1 (-0.8 to 27.3)	12.1 (-11.1 to 14.6)	1.7 (0.8 to 3.4)	1.7 (0.9 to 3.8)	0.7 (-1.1 to 2.7)	0.7 (-1.1 to 15.0)
Periodontal diseases	756.7 (659.8 to 849.6)	1,054						

Appendix Table G.4 - Austria prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Other oral disorders	147.5 (139.8 to 155.6)	169.5 (160.3 to 178.4)	15.1 (6.4 to 24.2)	-4.0 (-7.3 to 7.9)	4.3 (2.7 to 6.4)	4.9 (3.1 to 7.4)	14.8 (5.6 to 24.2)	0.1 (-7.7 to 8.4)
Injuries	-	-	-	-	103.9 (78.7 to 134.0)	80.4 (58.0 to 107.6)	-23.0 (-31.2 to -13.5)	-41.6 (-47.6 to -34.9)
Transport injuries	-	-	-	-	19.1 (14.4 to 24.6)	8.9 (6.5 to 11.9)	-53.7 (-58.7 to -48.1)	-64.1 (-68.1 to -59.6)
Road injuries	-	-	-	-	17.5 (13.1 to 22.4)	6.8 (4.9 to 9.0)	-61.2 (-65.4 to -56.5)	-69.6 (-72.9 to -65.7)
Pedestrian road injuries	-	-	-	-	2.6 (1.9 to 3.3)	1.1 (0.8 to 1.5)	-56.0 (-60.9 to -50.9)	-46.0 (-70.1 to -41.9)
Cyclist road injuries	-	-	-	-	1.6 (1.2 to 2.1)	0.7 (0.5 to 1.0)	-55.6 (-61.2 to -48.6)	-64.8 (-69.3 to -59.1)
Motorcyclist road injuries	-	-	-	-	3.0 (2.2 to 3.9)	1.0 (0.7 to 1.4)	-66.9 (-72.8 to -60.1)	-73.9 (-78.6 to -68.4)
Motor vehicle road injuries	-	-	-	-	10.2 (7.7 to 13.0)	3.9 (2.9 to 5.2)	-61.6 (-65.3 to -57.2)	-69.9 (-72.9 to -66.3)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-71.0 (-74.5 to -66.8)	-77.0 (-79.8 to -73.6)
Other transport injuries	-	-	-	-	1.7 (1.2 to 2.2)	2.1 (1.5 to 2.8)	26.0 (14.6 to 40.5)	3.9 (-12.4 to 6.7)
Unintentional injuries	-	-	-	-	83.5 (63.2 to 107.7)	70.5 (50.8 to 94.6)	-15.9 (-25.0 to -5.3)	-35.9 (-42.3 to -28.5)
Falls	-	-	-	-	60.9 (46.3 to 77.8)	56.1 (40.8 to 75.2)	-8.1 (-20.4 to 6.0)	-29.9 (-38.6 to -19.8)
Drowning	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-25.8 (-31.1 to -16.6)	-43.2 (-48.8 to -35.4)
Fire, heat, and hot substances	-	-	-	-	1.3 (0.8 to 2.0)	1.1 (0.7 to 1.8)	-13.5 (-24.6 to -0.1)	-31.8 (-40.6 to -20.4)
Poisonings	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-49.3 (-57.6 to -40.2)	-58.9 (-65.7 to -51.0)
Exposure to mechanical forces	-	-	-	-	14.1 (10.4 to 18.5)	8.4 (6.0 to 11.7)	-40.5 (-46.6 to -33.3)	-51.8 (-56.8 to -45.7)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-66.8 (-71.4 to -61.7)	-71.5 (-75.3 to -67.2)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.8 (-25.8 to 0.8)	-27.5 (-37.7 to -15.0)
Other exposure to mechanical forces	-	-	-	-	14.0 (10.3 to 18.3)	8.4 (5.9 to 11.6)	-40.4 (-46.6 to -33.1)	-51.7 (-56.7 to -45.7)
Adverse effects of medical treatment	-	-	-	-	0.4 (0.3 to 0.6)	0.6 (0.3 to 0.8)	27.1 (13.6 to 41.3)	-0.1 (-10.3 to 9.3)
Animal contact	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	26.0 (15.9 to 38.4)	0.4 (-7.5 to 10.9)
Venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	14.9 (-2.5 to 33.5)	-4.1 (-18.9 to 12.1)
Non-venomous animal contact	-	-	-	-	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	27.9 (16.3 to 41.6)	1.2 (-8.0 to 12.5)
Foreign body	-	-	-	-	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	-4.9 (-15.3 to 6.4)	-18.8 (-28.5 to -7.6)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-8.7 (-19.7 to 3.0)	-26.9 (-37.1 to -16.0)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-4.1 (-9.7 to 10.9)	-10.6 (-20.3 to 0.5)
Foreign body in other body part	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-5.1 (-17.9 to 10.4)	-18.9 (-30.7 to -3.4)
Other unintentional injuries	-	-	-	-	5.8 (4.1 to 7.8)	3.2 (2.2 to 4.6)	-44.5 (-51.6 to -34.7)	-58.5 (-63.8 to -51.3)
Self-harm and interpersonal violence	-	-	-	-	1.3 (1.0 to 1.7)	1.0 (0.7 to 1.3)	-24.9 (-31.0 to -18.4)	-41.5 (-46.4 to -36.2)
Self-harm	-	-	-	-	0.6 (0.5 to 0.8)	0.5 (0.4 to 0.7)	-33.6 (-42.6 to -4.3)	-33.0 (-40.3 to -25.2)
Interpersonal violence	-	-	-	-	0.7 (0.5 to 0.8)	0.4 (0.3 to 0.6)	-35.9 (-41.9 to -28.9)	-49.4 (-54.1 to -43.8)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-35.9 (-41.6 to -29.5)	-50.4 (-54.8 to -45.5)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-21.4 (-27.6 to -14.2)	-38.8 (-43.6 to -33.5)
Assault by other means	-	-	-	-	0.5 (0.4 to 0.6)	0.3 (0.2 to 0.4)	-38.2 (-44.8 to -30.1)	-50.8 (-56.1 to -44.1)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.1 (-45.4 to 26.4)	-32.7 (-59.8 to -0.8)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.1 (-45.4 to 26.4)	-32.7 (-59.8 to -0.8)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Azerbaijan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	624.4 (460.8 to 815.9)	948.2 (706.5 to 1,231.4)	51.8 (47.8 to 56.7)	8.0 (-2.2 to 3.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	79.5 (55.0 to 111.2)	89.0 (61.9 to 121.8)	11.9 (4.0 to 22.6)	-8.0 (-14.3 to 0.6)
HIV/AIDS and tuberculosis	-	-	-	-	3.4 (2.3 to 4.6)	5.2 (3.5 to 7.3)	1.8 (37.9 to 81.9)	-0.5 (-9.8 to 18.0)
Tuberculosis	10.9 (10.3 to 11.5)	15.2 (14.4 to 16.2)	39.5 (32.9 to 47.3)	-9.3 (-13.5 to -4.7)	3.4 (2.3 to 4.6)	4.7 (3.2 to 6.3)	39.3 (28.4 to 51.6)	-9.0 (-15.5 to -1.6)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.5 (0.2 to 1.4)	2,955.4 (567.4 to 10,355.0)	4,714.1 (307.6 to 7,903.3)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	2,093.4 (418.2 to 8,950.8)	1,298.7 (221.8 to 5,686.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	2,093.4 (417.8 to 8,952.1)	1,298.7 (219.1 to 7,05.8)
HIV/AIDS resulting in other diseases	0.2 (0.0 to 0.6)	4.7 (2.0 to 9.1)	2,564.7 (718.1 to 10,913.9)	1,706.3 (455.8 to 7,322.4)	0.0 (0.0 to 0.1)	0.5 (0.1 to 1.4)	2,762.6 (557.5 to 11,406.9)	1,762.7 (302.1 to 7,733.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	11.2 (7.8 to 15.3)	11.0 (7.7 to 15.0)	-0.2 (-7.5 to 5.0)	-14.8 (-19.7 to -9.6)
Diarrheal diseases	30.0 (28.0 to 31.9)	29.8 (28.1 to 31.8)	-0.8 (-8.9 to 8.8)	-8.2 (-15.4 to 0.4)	4.9 (3.3 to 6.8)	4.8 (3.3 to 6.6)	-0.1 (-1.0 to 0.2)	-8.0 (-16.3 to 1.3)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (-86.9 to -49.9)	0.0 (-89.0 to -58.5)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.4 (-48.0 to -22.8)	-47.9 (-57.1 to -36.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-48.1 to -22.7)	-47.9 (-57.1 to -36.6)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.3 (-49.2 to -20.7)	-45.7 (-56.3 to -33.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-49.3 to -20.7)	-36.3 (-56.4 to -33.5)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-86.3 (-97.0 to -63.9)	-86.3 (-97.5 to -63.9)
Lower respiratory infections	3.7 (3.1 to 4.4)	1.6 (1.3 to 2.0)	-57.4 (-67.5 to -41.7)	-55.6 (-66.0 to -38.6)	0.4 (0.2 to 0.6)	0.2 (0.1 to 0.3)	-56.6 (-68.7 to -39.6)	-54.9 (-67.0 to -36.4)
Upper respiratory infections	105.1 (95.7 to 113.4)	137.5 (125.0 to 150.8)	30.7 (15.1 to 48.5)	3.6 (-8.9 to 17.4)	1.2 (0.7 to 2.1)	1.6 (0.9 to 2.7)	30.2 (14.4 to 48.5)	3.7 (-8.8 to 18.0)
Otitis media	92.6 (84.3 to 100.4)	106.0 (97.5 to 114.5)	14.4 (4.7 to 24.9)	-10.0 (-17.2 to -2.2)	1.9 (1.1 to 3.1)	2.1 (1.3 to 3.4)	11.5 (1.5 to 22.9)	-10.2 (-18.0 to -1.9)
Meningitis	-	-	-	-	1.6 (1.1 to 2.2)	1.4 (0.9 to 1.9)	-13.3 (-30.2 to 3.3)	-34.7 (-46.3 to -10.7)
Pneumococcal meningitis	6.5 (3.9 to 10.3)	5.9 (3.6 to 9.7)	-8.9 (-23.9 to 10.1)	-37.3 (-47.2 to -24.0)	0.5 (0.4 to 0.8)	0.5 (0.4 to 0.8)	-4.5 (-27.4 to 22.7)	-30.6 (-46.3 to -10.7)
H influenzae type B meningitis	4.4 (1.6 to 8.7)	3.3 (1.2 to 7.0)	-25.1 (-46.0 to 0.1)	-44.8 (-58.8 to -22.9)	0.5 (0.3 to 0.8)	0.4 (0.3 to 0.7)	-19.4 (-45.6 to 27.1)	-36.6 (-56.6 to 0.3)
Meningococcal meningitis	1.5 (0.5 to 3.3)	1.1 (0.3 to 2.8)	-27.5 (-55.0 to -1.1)	-48.5 (-66.2 to -28.7)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-32.5 (-55.3 to 12.9)	-49.4 (-65.6 to -17.2)
Other meningitis	2.2 (1.1 to 3.9)	1.9 (0.9 to 3.6)	-13.4 (-34.6 to 12.2)	-36.8 (-50.9 to -16.4)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-9.3 (-43.9 to 28.6)	-31.1 (-57.4 to -1.3)
Encephalitis	2.5 (1.1 to 5.5)	3.0 (1.4 to 7.2)	20.1 (-3.7 to 46.8)	-17.2 (-32.5 to 2.5)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	25.8 (2.9 to 60.5)	-11.0 (-26.6 to 13.5)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-82.5 (-98.5 to 94.6)	-84.5 (-98.5 to 50.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-82.5 (-98.5 to 100.9)	-84.5 (-98.6 to 51.5)
Whooping cough	13.2 (10.1 to 17.3)	6.1 (4.7 to 7.9)	-53.5 (-55.5 to -51.5)	-48.6 (-50.9 to -46.4)	0.7 (0.4 to 1.1)	0.3 (0.2 to 0.5)	-53.5 (-57.3 to -49.8)	-48.7 (-52.8 to -44.5)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.7 (-80.1 to -9.2)	-65.7 (-84.7 to -30.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.2 (-76.0 to -6.0)	-58.8 (-81.6 to -26.6)
Measles	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-91.9 (-93.1 to -90.7)	-91.2 (-92.5 to -89.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-91.9 (-93.1 to -90.7)	-91.2 (-92.5 to -89.8)
Varicella and herpes zoster	4.7 (4.5 to 5.0)	5.2 (4.9 to 5.6)	11.0 (1.6 to 21.1)	-1.2 (-10.5 to 8.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	40.7 (13.0 to 78.4)	-0.3 (-20.5 to 25.2)
Neglected tropical diseases and malaria	-	-	-	-	3.3 (1.8 to 5.3)	2.2 (1.4 to 3.2)	-31.6 (-51.0 to 5.5)	-30.5 (-49.6 to 5.8)
Malaria	0.8 (0.7 to 0.8)	1.0 (0.9 to 1.0)	24.7 (18.9 to 30.3)	-0.1 (-4.2 to 3.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.6 (-10.2 to 36.8)	-3.0 (-23.9 to 24.6)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.2 (-21.8 to 42.9)	-27.9 (-45.8 to -4.1)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.2 (-6.0 to 76.2)	14.4 (-15.3 to 54.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.2 (-6.3 to 77.6)	14.4 (-15.3 to 54.6)
Cutaneous and mucocutaneous leishmaniasis	1.0 (0.8 to 1.3)	1.1 (0.8 to 1.4)	3.0 (-16.8 to 28.9)	-31.4 (-44.4 to -14.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.0 (-26.2 to 44.4)	-31.1 (-49.1 to -5.2)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-75.6 (-90.2 to -23.5)	-83.5 (-92.8 to -44.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-73.6 (-89.8 to -15.7)	-82.2 (-92.4 to -40.5)
Cystic echinococcosis	2.5 (2.3 to 2.7)	2.0 (1.9 to 2.2)	-21.1 (-30.5 to -5.8)	-45.4 (-51.2 to -38.1)	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-21.9 (-37.0 to -1.1)	-45.6 (-54.9 to -33.9)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.8 (-69.6 to -21.5)	63.5 (-75.5 to -37.4)
Intestinal nematode infections	-	-	-	-	0.7 (0.2 to 1.8)	0.0 (0.0 to 0.1)	0.0 (-97.1 to -75.2)	0.0 (-97.5 to -79.4)
Ascariasis	327.8 (205.5 to 503.3)	309.2 (197.4 to 479.7)	-5.9 (-49.6 to 77.3)	-29.6 (-62.9 to 32.4)	0.7 (0.2 to 1.8)	0.0 (0.0 to 0.1)	0.0 (-99.2 to -85.9)	-97.2 (-99.2 to -88.0)
Trichuriasis	-	-	34.5 (-40.1 to 193.8)	-4.8 (-58.1 to 110.0)	-	-	-	-
Hookworm disease	5.1 (2.8 to 8.2)	7.9 (4.5 to 13.2)	52.9 (-27.9 to 246.1)	53.5 (-53.1 to 125.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.8 (12.4 to 93.2)	-2.6 (-25.7 to 25.3)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	65.1 (44.3 to 87.6)	57.1 (48.3 to 61.9)	-12.9 (-34.8 to 28.2)	-10.1 (-32.7 to 34.0)	2.3 (1.2 to 3.5)	1.9 (1.2 to 2.8)	-18.1 (-35.9 to 48.1)	-12.3 (-29.4 to 63.6)
Maternal disorders	-	-	-	-	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-24.7 (-47.5 to -2.5)	-45.6 (-61.3 to -30.0)
Maternal hemorrhage	1.2 (1.0 to 1.4)	1.1 (0.8 to 1.4)	-10.8 (-37.1 to 20.3)	-34.4 (-53.3 to -12.1)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-9.8 (-44.4 to 38.9)	-33.2 (-58.1 to 1.2)
Maternal sepsis and other maternal infections	5.5 (3.4 to 8.2)	3.9 (2.4 to 6.2)	-30.9 (-43.3 to -15.1)	-56.4 (-64.6 to -46.0)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-42.5 (-69.4 to -2.8)	-59.0 (-77.2 to -32.8)
Maternal hypertensive disorders	0.6 (0.3 to 1.0)	0.5 (0.2 to 0.9)	-11.6 (-24.5 to 8.3)	-35.4 (-44.8 to -21.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-11.8 (-42.9 to 27.3)	-35.4 (-58.4 to -7.7)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.7 (-43.5 to 17.1)	-39.6 (-58.3 to -15.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.7 (-43.5 to 17.2)	-39.6 (-58.3 to -14.8)
Complications of abortion	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-14.1 (-27.6 to 2.1)	-37.2 (-46.7 to -25.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.0 (-60.9 to 93.3)	-37.2 (-70.1 to 32.3)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-17.9 (-56.2 to 55.0)	-40.5 (-68.2 to 12.9)
Neonatal disorders	-	-	-	-	5.9 (3.6 to 9.3)	14.5 (9.6 to 20.6)	145.2 (52.8 to 319.4)	101.0 (24.8 to 243.9)
Preterm birth complications	9.2 (6.3 to 13.3)	25.9 (19.1 to 34.4)	185.3 (129.3 to 246.1)	121.6 (77.9 to 168.5)	0.9 (0.6 to 1.4)	3.2 (2.1 to 4.6)	247.5 (118.5 to 421.9)	177.8 (73.7 to 313.5)
Neonatal encephalopathy due to birth asphyxia and trauma	13.9 (4.7 to 39.1)	16.8 (8.4 to 35.5)	32.9 (-23.1 to 148.6)	6.6 (-39.5 to 103.8)	2.0 (0.9 to 3.3)	3.8 (2.2 to 5.7)	95.0 (6.9 to 314.3)	64.9 (-9.4 to 253.1)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.1 (87.0 to 110.0)	131.9 (120.0 to 147.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.9 (49.7 to 183.4)	134.0 (76.1 to 233.4)
Hemolytic disease and other neonatal jaundice	4.6 (2.0 to 9.3)	9.7 (5.0 to 16.9)	95.3 (-11.5 to 509.9)	59.0 (-28.0 to 394.8)	1.7 (0.7 to 3.9)	3.7 (1.8 to 6.5)	98.8 (-10.4 to 533.0)	59.9 (-27.1 to 414.9)
Other neonatal disorders	-	-	-	-	1.3 (0.5 to 3.2)	3.8 (1.4 to 7.8)	185.2 (18.0 to 776.1)	132.6 (-3.9 to 606.6)
Nutritional deficiencies	-	-	-	-	51.4 (34.0 to 74.3)	51.2 (33.9 to 73.9)	-0.3 (-8.1 to 8.1)	-17.4 (-23.7 to -10.5)
Protein-energy malnutrition	12.8 (5.0 to 27.4)	11.9 (4.6 to 24.5)	-6.0 (-27.7 to 196.5)	3.9 (-69.8 to 228.6)	1.5 (0.5 to 3.6)	1.5 (0.5 to 3.3)	4.1 (-72.6 to 201.7)	3.9 (-69.8 to 233.6)
Iodine deficiency	288.0 (136.5 to 412.1)	166.1 (95.3 to 248.2)	-41.6 (-72.9 to 11.7)	-59.5 (-81.2 to -21.5)	5.2 (2.2 to 9.1)	3.0 (1.4 to 5.2)	-41.9 (-73.2 to 11.2)	-59.5 (-81.1 to -22.2)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-

Appendix Table G.4 - Azerbaijan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	1,307.8 (1,287.9 to 1,328.7)	1,448.2 (1,417.7 to 1,478.5)	10.8 (7.2 to 13.9)	-11.2 (-14.0 to -8.6)	44.1 (29.6 to 63.8)	46.4 (30.8 to 67.5)	5.4 (0.4 to 7.6)	-12.4 (-16.6 to -10.6)
Other nutritional deficiencies	-	-	-	-	0.5 (0.1 to 1.6)	0.4 (0.1 to 1.5)	-0.4 (-1.4 to 0.6)	-10.7 (-24.5 to 3.2)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	4.1 (2.6 to 6.4)	4.7 (2.9 to 7.2)	13.2 (0.5 to 27.7)	-10.7 (-22.4 to -0.4)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.9 (1.0 to 3.1)	2.6 (1.5 to 4.4)	38.9 (21.4 to 59.1)	-4.9 (-16.0 to 7.8)
Syphilis	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	2.8 (-12.1 to 21.0)	-36.0 (-44.5 to -25.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-1.4 to 46.5)	34.1 (-49.9 to -9.6)
Chlamydial infection	233.1 (196.5 to 263.9)	338.5 (295.3 to 378.9)	44.8 (23.2 to 73.0)	0.7 (-13.9 to 20.2)	1.0 (0.5 to 1.7)	1.5 (0.8 to 2.4)	44.1 (18.4 to 77.1)	0.5 (-16.7 to 22.2)
Gonococcal infection	51.0 (41.3 to 60.7)	62.6 (50.7 to 74.5)	22.7 (5.4 to 63.6)	-10.6 (-30.9 to 18.1)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	24.2 (-13.2 to 77.3)	-9.6 (-36.1 to 29.6)
Trichomoniasis	105.0 (68.1 to 146.7)	122.1 (92.3 to 182.4)	11.0 (-20.0 to 160.3)	-22.7 (-43.7 to 69.0)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	6.3 (-29.6 to 161.9)	-25.8 (-49.8 to 71.0)
Genital herpes	1,022.4 (987.3 to 1,058.1)	1,644.3 (1,586.3 to 1,696.9)	61.0 (52.9 to 68.7)	-2.2 (-6.7 to 2.1)	0.3 (0.1 to 0.7)	0.4 (0.1 to 1.0)	57.5 (45.6 to 68.9)	-2.2 (-7.8 to 3.9)
Other sexually transmitted diseases	2.1 (1.5 to 2.9)	3.0 (2.2 to 4.0)	39.5 (19.8 to 57.7)	-13.5 (-25.8 to -1.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	41.2 (6.9 to 90.6)	6.4 (-28.1 to 23.2)
Hepatitis	-	-	-	-	0.7 (0.4 to 1.0)	0.7 (0.5 to 1.1)	12.2 (8.6 to 36.3)	-22.9 (-38.1 to -5.8)
Hepatitis A	9.5 (9.2 to 9.9)	9.8 (9.5 to 10.0)	2.6 (1.6 to 3.7)	-8.0 (-8.1 to -7.7)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	20.5 (7.3 to 34.0)	-2.5 (-13.1 to 7.8)
Hepatitis B	721.3 (620.5 to 806.7)	693.7 (602.7 to 787.9)	-4.5 (-20.3 to 20.4)	-32.1 (-43.5 to -15.8)	0.4 (0.2 to 0.5)	0.4 (0.2 to 0.6)	7.5 (-21.8 to 50.4)	-32.9 (-54.8 to -4.2)
Hepatitis C	487.7 (432.4 to 541.1)	573.7 (519.5 to 631.7)	17.4 (2.3 to 36.9)	-24.2 (-33.6 to -12.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	6.7 (-23.1 to 42.6)	-26.5 (-47.6 to -4.4)
Hepatitis E	0.9 (0.8 to 1.0)	1.1 (1.0 to 1.2)	24.2 (9.6 to 44.0)	-12.6 (-23.2 to 14.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	26.5 (-10.2 to 74.1)	-12.3 (-36.4 to 19.5)
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	46.3 (37.1 to 57.6)	41.4 (32.4 to 50.8)	-10.4 (-32.9 to 16.6)	-11.2 (-33.9 to 14.9)	1.6 (0.9 to 2.4)	1.4 (0.7 to 2.1)	-15.0 (-45.1 to 5.3)	-12.0 (-42.5 to 13.0)
Non-communicable diseases	-	-	-	-	492.2 (363.2 to 641.6)	778.5 (575.0 to 1,009.9)	58.9 (52.7 to 64.2)	21.1 (-1.3 to 5.9)
Neoplasms	-	-	-	-	3.2 (2.3 to 4.2)	6.0 (4.2 to 8.1)	85.6 (57.9 to 116.3)	14.4 (-2.1 to 33.1)
Esophageal cancer	0.7 (0.6 to 0.9)	0.9 (0.7 to 1.3)	25.3 (-14.2 to 84.7)	-26.2 (-49.5 to 9.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	24.0 (-15.9 to 81.2)	-27.0 (-50.8 to 7.7)
Stomach cancer	2.4 (2.1 to 2.7)	2.3 (1.9 to 2.9)	-2.5 (-24.4 to 23.9)	-42.8 (-55.3 to -27.2)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-5.5 (-28.2 to 20.1)	-44.9 (-57.2 to -29.7)
Liver cancer	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	0.1 (-0.1 to 0.9)
Liver cancer due to hepatitis B	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	52.2 (-5.7 to 141.9)	-10.8 (-43.8 to 42.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	47.1 (3.8 to 109.5)	-13.7 (-39.1 to 21.8)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.3)	315.7 (156.0 to 602.4)	142.7 (47.0 to 315.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	302.0 (176.6 to 496.4)	132.7 (59.6 to 241.0)
Liver cancer due to alcohol use	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	67.9 (-0.4 to 177.2)	-2.3 (-4.1 to 60.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	64.0 (7.7 to 140.2)	-4.8 (-37.4 to 39.1)
Liver cancer due to other causes	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-20.0 (-56.0 to 46.0)	-51.9 (-73.8 to -11.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.6 (-51.7 to 24.9)	54.1 (-71.3 to -22.3)
Larynx cancer	0.5 (0.4 to 0.7)	0.7 (0.5 to 1.0)	31.1 (-7.8 to 86.8)	-22.0 (-44.0 to 10.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	25.2 (-11.2 to 75.6)	-25.2 (-46.8 to 3.1)
Tracheal, bronchus and lung cancer	1.5 (1.3 to 1.7)	1.8 (1.4 to 2.4)	21.5 (-7.4 to 58.2)	-27.6 (-43.9 to -7.1)	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.4)	16.6 (-13.1 to 54.6)	-30.6 (-47.4 to -9.2)
Breast cancer	3.7 (3.1 to 4.4)	18.3 (15.7 to 20.9)	393.3 (285.5 to 516.9)	207.4 (141.7 to 283.8)	0.4 (0.3 to 0.5)	1.1 (0.7 to 1.5)	192.9 (119.4 to 283.8)	6.0 (-24.9 to 120.0)
Cervical cancer	2.5 (2.0 to 3.2)	3.2 (2.2 to 4.3)	30.3 (-10.3 to 81.3)	-26.9 (-48.2 to 11.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	27.3 (-13.4 to 83.7)	-27.3 (-49.5 to 10.1)
Uterine cancer	1.9 (1.3 to 2.9)	2.8 (1.7 to 4.9)	44.7 (-8.4 to 125.4)	-20.1 (-47.2 to 23.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	44.6 (-10.3 to 132.2)	-20.6 (-48.8 to 24.6)
Prostate cancer	2.1 (1.7 to 2.7)	6.3 (4.5 to 8.4)	197.3 (117.8 to 305.8)	83.1 (33.1 to 145.8)	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.9)	232.6 (125.5 to 374.9)	106.6 (41.6 to 188.8)
Colon and rectum cancer	2.9 (2.7 to 3.2)	5.4 (4.5 to 6.4)	85.7 (52.8 to 125.9)	8.6 (-9.6 to 31.2)	0.3 (0.2 to 0.3)	0.5 (0.3 to 0.6)	75.7 (38.8 to 118.3)	2.1 (-18.2 to 27.3)
Lip and oral cavity cancer	0.5 (0.4 to 0.6)	0.9 (0.6 to 1.2)	81.7 (9.6 to 172.2)	11.0 (-3.9 to 66.3)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	81.7 (8.8 to 165.2)	10.3 (-34.4 to 64.3)
Nasopharynx cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	123.7 (8.2 to 262.7)	44.9 (-28.8 to 126.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	125.5 (11.2 to 249.3)	44.8 (-28.8 to 116.3)
Other pharynx cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	121.8 (10.0 to 320.7)	34.1 (-36.1 to 145.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	116.1 (12.8 to 272.1)	29.5 (-32.1 to 120.5)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	60.0 (4.1 to 135.4)	-8.7 (-41.8 to 32.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	51.0 (1.2 to 114.8)	-13.8 (-42.8 to 21.3)
Pancreatic cancer	0.1 (0.1 to 0.1)	0.3 (0.3 to 0.4)	198.9 (126.3 to 291.1)	77.5 (36.3 to 130.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	180.6 (120.5 to 251.9)	63.4 (-29.8 to 107.1)
Malignant skin melanoma	0.8 (0.7 to 1.1)	1.8 (1.3 to 2.4)	109.6 (40.5 to 200.9)	30.8 (-13.0 to 88.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	105.8 (31.3 to 202.1)	28.1 (-17.1 to 86.4)
Non-melanoma skin cancer	1.6 (1.2 to 1.9)	3.4 (2.7 to 4.3)	121.1 (64.2 to 203.1)	23.2 (-7.5 to 69.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	157.2 (87.1 to 270.4)	42.6 (-7.3 to 105.2)
Ovarian cancer	0.5 (0.4 to 0.7)	1.2 (0.8 to 1.7)	125.5 (43.2 to 270.5)	29.2 (-17.1 to 108.7)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	121.9 (35.6 to 283.2)	26.3 (-21.0 to 114.8)
Testicular cancer	0.5 (0.3 to 0.8)	1.0 (0.6 to 1.6)	107.2 (10.8 to 312.4)	42.4 (-21.6 to 181.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	99.9 (2.6 to 314.0)	37.5 (-38.0 to 179.3)
Kidney cancer	1.9 (1.6 to 2.4)	3.9 (3.0 to 5.0)	98.7 (41.5 to 177.0)	34.4 (-1.1 to 84.6)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	96.6 (38.9 to 174.4)	30.0 (-5.4 to 77.2)
Bladder cancer	0.9 (0.7 to 1.2)	1.4 (1.1 to 1.9)	56.9 (10.8 to 124.3)	-5.6 (-32.8 to 31.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	51.2 (7.5 to 117.1)	-9.6 (-34.0 to 27.6)
Brain and nervous system cancer	1.3 (1.0 to 1.8)	2.4 (1.8 to 3.0)	84.1 (26.2 to 141.4)	31.0 (-7.1 to 70.0)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	83.8 (30.6 to 145.1)	26.4 (-8.1 to 66.7)
Thyroid cancer	3.0 (2.1 to 4.2)	5.1 (3.3 to 7.3)	68.5 (11.9 to 165.2)	8.9 (-26.2 to 65.3)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	66.1 (11.4 to 163.6)	7.0 (-27.1 to 63.9)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	585.0 (8.3 to 128.7)	-14.7 (-42.7 to 28.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.5 (10.6 to 132.2)	-12.6 (-41.9 to 28.0)
Hodgkin lymphoma	0.5 (0.3 to 0.7)	1.0 (0.5 to 1.6)	98.4 (4.6 to 294.0)	63.3 (-14.5 to 217.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	95.5 (2.2 to 279.9)	57.5 (-18.7 to 203.5)
Non-Hodgkin lymphoma	1.0 (0.8 to 1.3)	2.1 (1.5 to 2.7)	117.6 (46.1 to 204.3)	47.6 (-1.6 to 101.4)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	112.9 (41.1 to 199.9)	40.5 (-5.3 to 93.1)
Multiple myeloma	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	200.7 (72.1 to 388.8)	75.5 (-0.0 to 181.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	190.1 (68.7 to 356.1)	69.1 (-2.5 to 162.8)
Leukemia	2.3 (1.8 to 2.9)	3.9 (3.0 to 5.0)	74.1 (25.1 to 129.7)	58.5 (14.5 to 107.3)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	80.0 (32.4 to 133.8)	52.2 (12.3 to 91.5)
Other neoplasms	1.6 (1.1 to 2.2)	4.1 (2.9 to 5.4)	171.6 (48.6 to 314.4)	124.0 (25.5 to 239.5)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	160.5 (49.1 to 302.1)	108.7 (20.7 to 212.8)
Cardiovascular diseases	-	-	-	-	5.7 (3.9 to 7.8)	9.6 (6.6 to 13.3)	70.2 (33.0 to 114.3)	-2.0 (-21.9 to 21.6)
Rheumatic heart disease	0.8 (0.7 to 0.9)	1.3 (1.1 to 1.4)	54.8 (30.5 to 82.6)	-7.3 (-22.7 to 9.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	59.1 (23.6 to 108.6)	-5.5 (-25.9 to 21.9)
Ischemic heart disease	48.0 (40.9 to 57.6)	80.4 (72.0 to 92.5)	69.0 (33.3 to 102.8)	0.9 (-18.9 to 19.8)	2.3 (1.5 to 3.4)	3.7 (2.5 to 5.2)	61.2 (16.9 to 107.1)	-3.3 (-27.7 to 21.0)
Cerebrovascular disease	-	-	-	-	0.6 (0.5 to 0.9)	1.1 (0.8 to 1.6)	78.4 (37.8 to 120.8)	5.2 (-18.8 to 29.8)
Ischemic stroke	2.2 (1.8 to 2.6)	4.0 (3.3 to 4.7)	81.1 (39.0 to 126.7)	4.3 (-20.7 to 30.1)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.8)	80.0 (35.6 to 130.8)	4.3 (-21.8 to 32.6)
Hemorrhagic stroke	2.0 (1.7 to 2.4)	3.4 (2.9 to 4.0)	74.9 (34.9 to 122.7)	5.0 (-18.6 to 33.9)	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.8)	74.6 (31.0 to 128.6)	4.4 (-20.9 to 36.3)
Hypertensive heart disease	5.9 (5.2 to 6.5)	11.0 (10.0 to 12.1)	88.4 (62.2 to 122.0)	1.2 (-14.1 to 20.8)	0.6 (0.4 to 0.9)	1.2 (0.8 to 1.7)	87.3 (60.3 to 124.6)	1.2 (-14.4 to 20.9)
Cardiomyopathy and myocarditis	0.2 (3.1 to 4.2)	1.2 (6.1 to 7.4)	540.0 (55.6 to 118.9)	219.0 (-11.2 to 28.8)	0.0 (0.2 to 0.5)	0.1 (0.5 to 0.9)	528.4 (53.4 to 122.0)	215.4 (-12.3 to 30.0)
Atrial fibrillation and flutter	0.2 (0.1 to 0.2)	1.2 (1.0 to 1.4)	540.0 (362.9 to 850.8)	219.0 (132.7 to 355.3)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	528.4 (293.2 to 898.5)	215.4 (100.9 to 391.0)
Peripheral vascular disease	102.2 (78.8 to 128.8)	210.1 (163.7 to 259.4)	104.9 (55.6 to 190.6)	11.0 (-13.0 to 49.7)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	82.1 (5.6 to 282.6)	-14.4 (-50.3 to 91.4)
Endocarditis	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.6)	23.3 (4.0 to 66.2)	-31.7 (-48.0 to -6.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	25.1 (-10.7 to 79.1)	-31.6 (-52.6 to -8.8)
Other cardiovascular and circulatory diseases	20.4 (10.7 to 35.2)	35.1 (17.2 to 55.4)	71.5 (-23.3 to 277.4)	1.4 (-58.7 to 122.7)	2.5 (0.7 to 2.6)	4.3 (1.0 to 4.3)	71.1 (-22.0 to 285.1)	4.3 (-58.1 to 123.5)
Chronic respiratory diseases	-	-	-	-	18.8 (12.8 to 26.3)	31.2 (21.1 to 44.2)	67.0 (34.7 to 96.5)	-0.0 (-19.9 to 19.5)
Chronic obstructive pulmonary disease	212.0 (201.3 to 222.5)	356.5 (339.7 to 373.4)	68.3 (63.3 to 73.7)	0.2 (-2.6 to 3.1)	13.2 (8.6 to 19.0)	22.2 (14.4 to 31.7)	69.8	

Appendix Table G.4 - Azerbaijan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumococcosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.3 (43.9 to 54.4)	49.3 (-13.5 to -7.2)
Silicosis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	65.9 (58.4 to 73.6)	0.6 (-4.1 to 5.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.2 (58.4 to 74.3)	0.7 (-4.1 to 5.3)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumococcosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumococcosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	40.0 (34.4 to 46.1)	-5.5 (-19.8 to -13.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.6 (35.0 to 47.0)	40.6 (-19.2 to -12.7)
Asthma	90.8 (62.3 to 117.2)	153.9 (122.2 to 189.6)	67.1 (22.9 to 164.6)	-3.1 (-24.7 to 41.3)	3.9 (2.3 to 6.0)	6.7 (4.1 to 10.4)	67.1 (23.4 to 169.3)	-2.4 (-24.4 to 43.0)
Interstitial lung disease and pulmonary sarcoidosis	0.6 (0.5 to 0.8)	1.0 (0.7 to 1.2)	52.2 (7.5 to 130.5)	-3.7 (-31.7 to 43.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	54.8 (10.0 to 132.5)	-3.0 (-30.7 to 44.5)
Other chronic respiratory diseases	-	-	-	-	1.6 (1.0 to 2.6)	2.2 (1.3 to 3.3)	31.9 (-11.3 to 108.8)	-19.9 (-45.9 to 28.4)
Cirrhosis	-	-	-	-	0.8 (0.6 to 1.1)	1.3 (0.9 to 1.8)	57.1 (40.3 to 75.1)	4.9 (-5.0 to 15.3)
Cirrhosis due to hepatitis B	2.0 (1.6 to 2.3)	3.2 (2.5 to 3.9)	61.0 (19.4 to 117.9)	6.3 (-19.7 to 45.0)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	60.2 (16.5 to 124.7)	6.0 (-21.8 to 48.3)
Cirrhosis due to hepatitis C	1.2 (0.9 to 1.6)	1.9 (1.3 to 2.5)	54.6 (-3.3 to 128.8)	-3.8 (-38.6 to 40.4)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	55.7 (-6.1 to 147.9)	-2.8 (-39.7 to 49.1)
Cirrhosis due to alcohol use	0.8 (0.6 to 1.0)	1.3 (0.9 to 1.8)	60.6 (-0.7 to 176.7)	-1.5 (-36.0 to 62.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	59.9 (-6.8 to 192.7)	-2.0 (-37.9 to 69.0)
Cirrhosis due to other causes	0.9 (0.7 to 1.0)	1.3 (1.0 to 1.6)	47.3 (15.3 to 99.2)	21.0 (-5.3 to 61.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	46.6 (2.7 to 115.8)	21.1 (-14.8 to 75.0)
Digestive diseases	-	-	-	-	6.5 (4.6 to 8.8)	12.2 (8.7 to 16.4)	87.0 (68.9 to 104.9)	13.3 (2.7 to 24.1)
Peptic ulcer disease	37.8 (35.2 to 40.3)	41.7 (39.1 to 44.5)	10.4 (0.6 to 21.4)	-35.5 (-40.8 to -30.5)	1.0 (0.7 to 1.5)	1.2 (0.8 to 1.7)	11.8 (-11.9 to 37.9)	-34.0 (-46.9 to -22.9)
Gastritis and duodenitis	8.9 (7.8 to 9.9)	11.7 (10.3 to 13.2)	32.5 (10.2 to 57.5)	1.2 (-15.1 to 18.0)	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.9)	27.6 (-5.9 to 76.9)	4.3 (-19.2 to 42.2)
Appendicitis	0.7 (0.6 to 0.9)	0.8 (0.7 to 1.0)	20.8 (9.0 to 51.5)	-1.5 (-25.1 to 21.9)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	20.3 (-19.5 to 73.2)	-1.9 (-33.1 to 38.8)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	56.3 (1.7 to 125.4)	19.7 (-13.6 to 59.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	54.3 (-8.0 to 140.3)	19.6 (-22.0 to 70.4)
Inguinal, femoral, and abdominal hernia	42.4 (37.2 to 48.3)	59.7 (50.9 to 68.9)	40.0 (15.6 to 73.0)	-12.5 (-29.5 to 8.4)	0.4 (0.2 to 0.8)	0.6 (0.3 to 1.2)	39.8 (14.8 to 73.6)	-11.9 (-29.3 to 9.1)
Inflammatory bowel disease	7.6 (7.2 to 7.9)	16.9 (16.3 to 17.6)	124.0 (111.5 to 137.0)	35.8 (28.1 to 43.8)	1.6 (1.1 to 2.2)	3.6 (2.5 to 4.9)	123.1 (105.2 to 144.0)	35.7 (25.5 to 47.1)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (47.3 to 224.5)	0.0 (0.8 to 161.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (43.4 to 223.8)	0.0 (-6.1 to 157.1)
Gallbladder and biliary diseases	5.9 (5.2 to 6.7)	8.0 (7.0 to 9.1)	34.5 (11.7 to 62.4)	0.6 (-32.3 to -2.6)	0.6 (0.4 to 0.7)	0.8 (0.6 to 1.1)	34.5 (10.3 to 62.8)	19.7 (-33.2 to -3.0)
Pancreatitis	1.5 (1.4 to 1.6)	3.7 (3.5 to 3.9)	151.5 (133.1 to 166.8)	47.6 (37.1 to 56.1)	0.4 (0.3 to 0.6)	1.1 (0.8 to 1.5)	150.3 (114.9 to 189.0)	47.5 (28.1 to 68.2)
Other digestive diseases	-	-	-	-	1.6 (1.1 to 2.3)	4.0 (2.5 to 5.7)	142.7 (95.9 to 195.9)	45.6 (16.8 to 76.5)
Neurological disorders	-	-	-	-	56.0 (36.8 to 78.5)	89.6 (60.8 to 124.2)	60.1 (42.3 to 81.9)	5.2 (-6.2 to 17.8)
Alzheimer disease and other dementias	24.5 (21.9 to 27.2)	49.2 (43.2 to 55.5)	99.9 (68.5 to 138.5)	-3.0 (-18.8 to 18.5)	3.5 (2.5 to 4.5)	7.1 (5.1 to 9.2)	104.4 (71.7 to 147.3)	3.6 (-19.7 to 18.7)
Parkinson disease	1.9 (1.6 to 2.2)	3.4 (2.9 to 3.9)	81.4 (71.5 to 90.3)	1.2 (-4.0 to 6.1)	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	80.1 (57.6 to 107.3)	0.7 (-11.6 to 15.1)
Epilepsy	26.6 (18.6 to 36.2)	35.1 (23.9 to 47.2)	31.2 (-17.8 to 113.2)	-0.8 (-37.8 to 60.5)	7.7 (4.4 to 12.0)	10.9 (6.4 to 16.3)	41.4 (-11.8 to 129.1)	7.9 (-32.9 to 74.8)
Multiple sclerosis	1.3 (1.2 to 1.4)	2.7 (2.5 to 2.9)	111.2 (84.8 to 140.5)	25.5 (10.0 to 42.7)	0.4 (0.3 to 0.6)	0.9 (0.6 to 1.2)	109.4 (69.2 to 159.0)	24.3 (1.6 to 53.7)
Migraine	1,023.1 (893.6 to 1,143.8)	1,515.5 (1,354.9 to 1,673.5)	47.7 (22.3 to 75.6)	0.5 (-16.7 to 16.4)	35.2 (20.6 to 52.5)	51.7 (30.4 to 76.7)	46.6 (21.7 to 74.6)	5.5 (-17.3 to 16.6)
Tension-type headache	1,526.4 (1,403.0 to 1,662.7)	2,288.7 (2,023.8 to 2,568.0)	49.4 (31.2 to 72.0)	0.0 (-11.9 to 13.8)	2.3 (1.1 to 4.0)	3.0 (1.7 to 6.2)	48.9 (30.5 to 73.3)	0.2 (-11.7 to 15.1)
Medication overuse headache	40.6 (27.0 to 53.9)	93.5 (63.1 to 123.3)	130.3 (81.8 to 194.3)	44.0 (12.5 to 80.6)	6.4 (3.6 to 9.8)	14.7 (8.1 to 22.9)	130.9 (80.8 to 198.5)	44.1 (13.0 to 83.0)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.4 (9.7 to 108.6)	3.0 (-21.1 to 43.9)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	51.9 (14.3 to 98.0)	-24.7 (-44.4 to -1.3)
Mental and substance use disorders	-	-	-	-	145.9 (105.1 to 190.4)	213.2 (154.1 to 277.5)	46.0 (42.3 to 50.9)	-0.0 (-2.3 to 2.8)
Schizophrenia	19.0 (17.3 to 20.5)	31.1 (28.4 to 33.7)	63.4 (56.7 to 71.7)	-0.5 (-4.1 to 3.9)	12.3 (9.0 to 14.9)	20.0 (14.8 to 24.3)	63.1 (53.5 to 74.4)	0.5 (-5.8 to 5.7)
Alcohol use disorders	63.5 (55.6 to 72.9)	114.6 (100.4 to 131.0)	80.4 (68.3 to 94.5)	18.5 (11.1 to 27.2)	6.4 (4.1 to 9.1)	11.5 (7.5 to 16.6)	80.1 (67.0 to 95.7)	19.1 (10.3 to 28.9)
Drug use disorders	-	-	-	-	9.3 (6.3 to 12.5)	13.4 (9.2 to 18.0)	44.3 (27.2 to 63.0)	-0.6 (-11.7 to 12.1)
Opioid use disorders	8.3 (6.0 to 10.6)	13.2 (10.1 to 16.8)	60.3 (41.4 to 79.7)	2.4 (-9.2 to 12.1)	3.5 (2.2 to 5.0)	5.5 (3.6 to 7.9)	59.2 (36.6 to 84.9)	1.9 (-11.1 to 17.1)
Cocaine use disorders	5.5 (4.7 to 6.2)	7.9 (6.8 to 8.8)	42.3 (19.8 to 76.1)	0.8 (-17.6 to 17.3)	0.8 (0.5 to 1.1)	1.1 (0.7 to 1.6)	41.8 (30.0 to 84.6)	3.4 (-24.1 to 23.3)
Amphetamine use disorders	14.7 (13.5 to 15.8)	19.6 (18.2 to 21.3)	33.9 (19.4 to 48.1)	-1.6 (-11.9 to 8.6)	1.9 (1.2 to 2.9)	2.6 (1.6 to 3.8)	33.3 (14.0 to 56.2)	-1.7 (-14.9 to 14.0)
Cannabis use disorders	13.7 (12.6 to 14.9)	18.4 (17.0 to 19.9)	33.9 (32.7 to 35.1)	0.5 (0.4 to 0.5)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.8)	34.1 (16.7 to 53.4)	0.7 (-12.3 to 14.0)
Other drug use disorders	-	-	-	-	2.7 (1.7 to 4.0)	3.7 (2.2 to 5.5)	31.1 (-0.9 to 87.3)	-2.4 (-28.3 to 34.9)
Depressive disorders	-	-	-	-	8.6 (37.2 to 79.0)	11.2 (56.4 to 119.4)	31.1 (42.7 to 60.0)	1.7 (-5.5 to 5.0)
Major depressive disorder	231.4 (186.1 to 271.0)	345.9 (274.6 to 411.4)	49.1 (40.8 to 60.4)	-0.5 (-6.1 to 5.7)	47.9 (30.7 to 68.5)	71.2 (45.2 to 101.6)	48.3 (39.8 to 60.0)	-0.5 (-6.3 to 6.2)
Dysthymia	89.2 (72.4 to 104.5)	142.8 (118.6 to 166.6)	60.1 (55.2 to 66.3)	-0.8 (-1.0 to -0.6)	8.6 (5.6 to 12.6)	13.8 (8.9 to 20.2)	59.6 (53.1 to 66.4)	0.8 (-3.1 to 1.4)
Bipolar disorder	46.0 (39.4 to 52.1)	71.0 (62.0 to 79.9)	54.0 (46.7 to 63.2)	-0.4 (-5.2 to 4.5)	9.4 (5.8 to 14.2)	14.5 (8.7 to 21.8)	53.5 (43.7 to 65.7)	-0.4 (-6.5 to 6.4)
Anxiety disorders	208.3 (169.4 to 249.2)	294.5 (236.1 to 353.0)	41.5 (35.5 to 48.2)	-1.0 (-1.2 to -0.8)	19.3 (12.9 to 28.0)	27.1 (18.1 to 39.3)	40.6 (33.7 to 48.9)	-0.9 (-3.5 to 1.9)
Eating disorders	-	-	-	-	2.0 (1.2 to 3.0)	2.5 (1.5 to 4.0)	29.6 (18.8 to 42.1)	-0.9 (-8.8 to 8.1)
Anorexia nervosa	0.6 (0.5 to 0.8)	0.8 (0.6 to 1.1)	37.2 (24.0 to 54.6)	7.0 (-2.1 to 19.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	36.7 (-0.3 to 90.8)	7.0 (-21.7 to 47.0)
Bulimia nervosa	8.6 (6.2 to 11.7)	11.1 (7.9 to 15.1)	29.4 (26.2 to 32.3)	-1.4 (-1.9 to -1.1)	1.8 (1.1 to 2.9)	2.4 (1.4 to 3.8)	29.1 (18.2 to 41.4)	-1.5 (-9.4 to 7.5)
Autistic spectrum disorders	-	-	-	-	8.6 (5.9 to 11.7)	11.2 (7.8 to 15.3)	31.1 (26.7 to 35.6)	1.7 (-1.5 to 5.0)
Autism	21.8 (20.7 to 22.9)	28.8 (27.3 to 30.3)	32.0 (31.2 to 32.9)	1.5 (1.5 to 1.6)	5.4 (3.6 to 7.5)	7.1 (4.8 to 9.8)	31.2 (25.3 to 37.4)	1.6 (-2.9 to 6.0)
Asperger syndrome	31.1 (29.2 to 33.0)	41.0 (38.4 to 43.5)	31.8 (30.6 to 32.9)	2.0 (1.9 to 2.0)	3.1 (2.2 to 4.4)	4.1 (2.9 to 5.7)	31.0 (25.6 to 36.4)	1.9 (-2.2 to 5.8)
Attention-deficit/hyperactivity disorder	45.5 (41.9 to 49.1)	47.3 (43.5 to 51.1)	4.0 (3.2 to 4.4)	0.6 (1.4 to 1.5)	0.6 (0.3 to 0.9)	0.6 (0.3 to 0.9)	3.9 (-3.7 to 12.1)	1.4 (-5.5 to 9.5)
Conduct disorder	65.9 (62.1 to 69.9)	67.5 (63.4 to 71.9)	2.4 (1.5 to 3.6)	1.2 (1.2 to 1.3)	0.9 (5.1 to 11.6)	8.2 (5.1 to 11.9)	2.5 (-2.4 to 6.6)	1.4 (-5.6 to 5.3)
Idiopathic intellectual disability	114.1 (88.0 to 137.9)	121.4 (95.3 to 146.5)	6.2 (-4.2 to 20.2)	-17.4 (-25.3 to -5.8)	5.6 (3.6 to 8.1)	5.9 (3.9 to 8.4)	6.1 (5.2 to 20.0)	-17.1 (-25.7 to -5.4)
Other mental and substance use disorders	107.1 (100.1 to 113.8)	174.5 (163.5 to 184.5)	63.0 (61.0 to 65.1)	1.0 (0.7 to 1.4)	8.0 (5.4 to 10.8)	13.1 (8.8 to 17.5)	62.7 (55.3 to 69.5)	1.2 (-2.9 to 4.9)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	63.7 (45.6 to 86.6)	114.8 (79.9 to 154.7)	80.2 (63.1 to 100.6)	18.4 (6.3 to 31.7)
Diabetes mellitus	303.8 (248.2 to 361.2)	736.6 (642.5 to 840.0)	142.9 (92.6 to 207.6)	47.1 (16.1 to 84.9)	23.7 (15.5 to 33.7)	57.2 (38.6 to 79.6)	142.4 (92.7 to 208.3)	44.0 (13.5 to 81.7)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.2 (-40.3 to -33.7)	0.0 (-46.3 to -41.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.2 (-40.3 to -33.7)	-43.8 (-46.3 to -41.2)
Chronic kidney disease	-	-	-	-	13.5 (9.6 to 18.0)	21.0 (15.1 to 27.9)	54.9 (40.4 to 73.0)	1.3 (-7.9 to 11.9)
Chronic kidney disease due to diabetes mellitus	62.1 (38.7 to 90.7)	113.0 (69.0 to 179.6)	81.5 (32.4 to 156.5)	3.8 (-27.3 to 44.3)	2.1 (1.4 to 3.1)	4.0 (2.6 to 5.8)	89.7 (35.5 to 156.5)	6.2 (-22.2 to 41.4)
Chronic kidney disease due to hypertension	124.3 (71.4 to 204.7)	161.3 (96.8 to 290.0)	28.9 (-1.9 to 74.8)	-4.1 (-23.8 to 20.9)	3.7 (2.5 to 5.1)	2.7 (1.8 to 3.7)	-27.6 (-45.7 to -2.2)	-55.2 (-65.8 to -39.5)
Chronic kidney disease due to glomerulonephritis	112.9 (72.6 to 186.3)	98.3 (72.2 to 132.5)	-18.2 (-40.6 to 5.7)	4.8 (-57.4 to 28.3)	3.4 (2.3 to 4.8)	5.3 (3.6 to 7.2)	53.9 (20.1 to 102.5)	10.7 (-12.3 to 41.9)
Chronic kidney disease due to other causes	162.5 (100.5 to 290.6)	299.8 (197.1 to 430.2)	88.3 (36.0 to 144.4)	38.5 (7.7 to 67.8)	4.3 (2.9 to 5.6)	9.0 (6.3 to 12.4)	112.7 (66.4 to 165.5)	44.6 (12.7 to 79.0)
Urinary diseases and male infertility	-	-	-	-	3.1 (2.0 to 4.5)	5.8 (3.8 to 8.3)	86.4 (67.8 to 107.6)	17.0 (5.7 to 30.0)

Appendix Table G.4 - Azerbaijan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.9 (1.7 to 2.1)	3.1 (2.8 to 3.4)	62.7 (42.0 to 88.0)	23.4 (9.2 to 40.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	63.3 (29.6 to 107.5)	21.1 (-0.3 to 52.4)
Urolithiasis	39.2 (29.7 to 54.3)	69.3 (52.4 to 97.2)	75.7 (59.7 to 96.4)	3.2 (-6.6 to 14.8)	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.9)	62.2 (47.2 to 79.1)	-1.0 (-9.0 to 7.9)
Benign prostatic hyperplasia	64.3 (57.1 to 70.0)	127.3 (117.2 to 135.9)	98.2 (74.0 to 124.2)	21.0 (6.8 to 35.7)	2.3 (1.5 to 3.3)	4.6 (3.0 to 6.5)	97.0 (73.0 to 124.3)	20.9 (6.5 to 36.3)
Male infertility due to other causes	44.0 (36.4 to 52.3)	66.4 (52.7 to 81.0)	51.0 (13.5 to 96.9)	3.7 (-21.7 to 34.7)	0.3 (0.1 to 0.6)	0.4 (0.2 to 0.9)	50.2 (11.3 to 100.0)	3.8 (-23.7 to 37.2)
Other urinary diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	39.9 (-1.3 to 121.6)	-15.1 (-36.6 to 35.0)
Gynecological diseases	-	-	-	-	9.2 (5.9 to 13.7)	15.3 (9.8 to 22.7)	65.8 (44.0 to 91.9)	0.5 (-12.0 to 15.7)
Uterine fibroids	126.5 (114.3 to 137.7)	245.5 (224.5 to 265.3)	93.9 (90.3 to 97.9)	0.2 (0.1 to 0.3)	2.4 (1.5 to 3.8)	4.1 (2.5 to 6.7)	69.1 (59.8 to 77.4)	-6.2 (-10.9 to -2.9)
Polycystic ovarian syndrome	117.0 (104.3 to 130.1)	193.0 (171.7 to 214.8)	65.8 (37.5 to 92.8)	1.8 (-13.6 to 17.6)	1.1 (0.5 to 2.2)	1.9 (0.9 to 3.5)	64.9 (37.5 to 92.8)	2.0 (-13.7 to 18.0)
Female infertility due to other causes	24.0 (13.5 to 35.0)	36.7 (23.1 to 54.0)	54.2 (-12.4 to 168.8)	11.4 (-37.8 to 96.5)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.4)	30.8 (-14.1 to 154.9)	8.3 (-38.4 to 87.3)
Endometriosis	12.3 (10.2 to 14.4)	21.7 (18.5 to 24.8)	76.3 (41.2 to 118.7)	7.3 (14.4 to 31.1)	1.1 (0.7 to 1.7)	2.0 (1.3 to 2.8)	76.0 (40.3 to 121.3)	7.1 (-14.5 to 32.1)
Genital prolapse	325.3 (278.5 to 370.6)	535.7 (461.9 to 605.0)	65.3 (35.5 to 100.5)	-1.4 (-18.9 to 17.3)	1.0 (0.5 to 2.0)	1.7 (0.8 to 3.2)	65.1 (34.4 to 101.1)	-1.5 (-19.5 to 17.5)
Premenstrual syndrome	270.4 (144.6 to 381.8)	452.6 (287.4 to 612.5)	65.5 (-5.9 to 209.9)	2.3 (-38.3 to 97.1)	2.3 (1.1 to 3.9)	3.8 (2.0 to 6.3)	65.1 (-6.0 to 215.5)	6.6 (-37.5 to 103.2)
Other gynecological diseases	33.3 (25.8 to 40.7)	49.2 (46.1 to 52.5)	47.5 (24.5 to 88.5)	-4.4 (-21.0 to 19.0)	1.1 (0.6 to 1.5)	1.6 (1.0 to 2.2)	46.9 (26.5 to 129.1)	-6.9 (-20.2 to 43.4)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	10.6 (7.1 to 15.2)	11.8 (7.9 to 17.0)	11.1 (3.4 to 26.0)	-0.1 (-7.3 to 12.2)
Thalassemias	1.8 (1.5 to 2.0)	1.7 (1.5 to 2.0)	-1.9 (-8.6 to 5.8)	-1.5 (-8.4 to 6.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-1.6 (-29.2 to 36.8)	0.9 (-26.4 to 41.5)
Thalassemia trait	375.0 (347.2 to 406.2)	496.8 (461.2 to 534.7)	32.7 (27.7 to 37.2)	0.7 (-2.9 to 4.2)	8.8 (5.9 to 12.5)	10.0 (6.7 to 14.5)	14.0 (5.8 to 29.4)	3.0 (-5.0 to 15.5)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.4 (-2.8 to 14.2)	-9.5 (-15.4 to -1.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.4 (-4.9 to 16.3)	-9.7 (-17.5 to 0.1)
Sickle cell trait	51.1 (47.0 to 54.8)	59.5 (55.1 to 64.3)	16.1 (9.6 to 23.7)	-11.6 (-16.7 to -5.7)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	11.0 (-21.7 to 59.0)	10.7 (-23.0 to 56.6)
G6PD deficiency	14.4 (13.4 to 15.4)	22.4 (21.4 to 23.4)	55.9 (43.9 to 69.8)	18.7 (9.7 to 29.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (63.1 to 96.2)	52.9 (41.7 to 68.6)
G6PD trait	815.1 (807.0 to 822.5)	1,066.7 (1,059.4 to 1,079.1)	30.9 (29.2 to 32.6)	-2.7 (-4.0 to -1.4)	0.0 (0.0 to 1.1)	0.1 (0.0 to 0.1)	29.8 (-28.0 to 112.5)	-4.2 (-43.7 to 47.6)
Other hemoglobinopathies and hemolytic anemias	42.2 (28.7 to 52.0)	42.4 (38.3 to 46.8)	0.2 (-22.8 to 45.6)	1.3 (-35.4 to 18.7)	1.3 (0.7 to 2.1)	1.2 (0.7 to 1.8)	-7.0 (-37.0 to 88.8)	-18.9 (-42.1 to 61.5)
Endocrine, metabolic, blood, and immune disorders	98.1 (83.1 to 111.3)	105.3 (100.0 to 110.8)	7.4 (-5.6 to 25.5)	16.1 (-24.6 to 0.3)	3.6 (2.4 to 5.0)	3.7 (2.5 to 5.2)	3.6 (-6.3 to 28.1)	36.8 (-23.4 to 5.0)
Musculoskeletal disorders	-	-	-	-	97.7 (68.3 to 131.7)	164.2 (115.9 to 219.9)	68.1 (48.8 to 91.3)	0.4 (-10.1 to 13.1)
Rheumatoid arthritis	8.5 (8.0 to 9.1)	15.8 (14.8 to 17.0)	85.6 (68.0 to 104.5)	19.1 (7.7 to 30.7)	2.1 (1.4 to 2.8)	3.8 (2.7 to 5.1)	83.2 (62.5 to 107.3)	18.3 (5.1 to 31.8)
Osteoarthritis	206.1 (197.8 to 214.2)	374.2 (360.8 to 387.6)	81.5 (72.2 to 91.8)	-0.6 (-5.3 to 4.5)	12.7 (9.9 to 17.2)	23.0 (16.2 to 31.5)	81.3 (71.8 to 92.0)	-0.6 (-5.5 to 4.7)
Low back and neck pain	-	-	-	-	71.2 (48.2 to 97.8)	116.9 (80.7 to 160.4)	64.5 (38.8 to 95.9)	0.3 (-14.9 to 19.2)
Low back pain	398.1 (323.3 to 454.8)	670.1 (587.4 to 756.8)	68.9 (38.0 to 103.4)	3.4 (-14.7 to 22.6)	44.6 (29.3 to 63.7)	74.8 (49.7 to 106.0)	68.5 (37.1 to 103.0)	3.5 (-14.7 to 23.5)
Neck pain	269.8 (217.0 to 325.7)	427.9 (354.1 to 490.9)	59.1 (18.6 to 107.1)	-3.6 (-27.4 to 23.8)	26.6 (17.7 to 38.2)	42.1 (27.4 to 59.2)	58.7 (18.3 to 106.6)	-3.7 (-27.2 to 23.7)
Gout	3.6 (3.4 to 3.8)	6.7 (6.3 to 7.0)	86.9 (72.4 to 100.9)	7.3 (-0.7 to 15.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	85.1 (50.9 to 131.2)	6.5 (-11.9 to 30.4)
Other musculoskeletal disorders	127.0 (96.2 to 158.2)	222.3 (170.8 to 279.0)	75.8 (54.8 to 93.8)	0.4 (-11.4 to 10.0)	11.6 (7.5 to 17.0)	20.3 (13.0 to 30.1)	64.6 (53.6 to 94.6)	0.4 (-11.8 to 10.9)
Other non-communicable diseases	-	-	-	-	93.9 (61.7 to 136.3)	136.4 (91.1 to 197.9)	45.4 (40.1 to 51.3)	-5.4 (-8.4 to -2.1)
Congenital anomalies	-	-	-	-	5.0 (3.6 to 6.6)	8.5 (6.3 to 11.0)	70.0 (46.2 to 102.7)	33.0 (15.1 to 58.4)
Neural tube defects	1.0 (0.8 to 1.2)	2.4 (2.1 to 2.8)	141.3 (91.6 to 198.4)	105.1 (62.3 to 153.6)	0.3 (0.2 to 0.4)	0.8 (0.5 to 1.1)	160.0 (78.7 to 271.3)	123.6 (53.3 to 220.5)
Congenital heart anomalies	13.0 (8.5 to 17.9)	40.5 (34.4 to 48.7)	211.0 (116.0 to 405.6)	155.0 (76.2 to 317.8)	0.4 (0.2 to 0.6)	1.3 (0.6 to 2.4)	197.2 (107.5 to 375.2)	146.2 (70.3 to 297.3)
Orofacial clefts	1.8 (1.1 to 2.8)	5.8 (4.6 to 7.1)	222.2 (98.3 to 424.0)	179.9 (71.6 to 356.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	174.1 (63.4 to 354.7)	137.9 (41.3 to 293.6)
Down syndrome	5.3 (4.5 to 6.4)	9.4 (7.7 to 11.6)	79.0 (36.7 to 125.8)	39.5 (7.1 to 76.7)	0.7 (0.5 to 0.9)	1.3 (0.9 to 1.7)	91.7 (44.6 to 145.7)	45.0 (9.8 to 85.6)
Turner syndrome	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.5)	57.8 (1.2 to 130.3)	22.7 (-21.6 to 79.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.0 (1.9 to 148.0)	21.4 (-22.3 to 83.8)
Klinefelter syndrome	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	40.9 (0.7 to 98.8)	9.9 (-1.4 to 55.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.6 (11.6 to 118.5)	8.6 (-22.5 to 53.3)
Chromosomal unbalanced rearrangements	7.8 (6.7 to 8.9)	14.1 (11.4 to 17.0)	80.9 (40.6 to 129.1)	44.2 (9.7 to 78.1)	1.0 (0.7 to 1.3)	1.9 (1.3 to 2.5)	45.7 (48.6 to 147.3)	45.7 (12.4 to 86.4)
Other congenital anomalies	24.3 (20.3 to 28.3)	28.5 (24.6 to 32.9)	17.4 (3.7 to 32.8)	-14.4 (-24.1 to -3.6)	2.6 (1.7 to 3.8)	3.2 (2.2 to 4.6)	24.5 (-4.1 to 60.4)	-2.0 (-23.4 to 25.5)
Skin and subcutaneous diseases	-	-	-	-	30.0 (19.4 to 44.7)	40.9 (27.0 to 61.7)	35.8 (24.2 to 50.9)	-3.3 (-10.7 to 7.0)
Dermatitis	276.1 (224.0 to 332.9)	402.6 (321.9 to 488.4)	45.8 (40.7 to 50.8)	-0.1 (-4.3 to 0.0)	6.7 (4.1 to 10.0)	9.5 (5.8 to 14.1)	41.9 (36.4 to 47.7)	-0.2 (-2.8 to 2.4)
Psoriasis	52.9 (46.9 to 59.3)	79.8 (70.0 to 89.7)	50.6 (47.9 to 54.2)	0.1 (-0.1 to 0.3)	4.3 (2.9 to 6.1)	6.5 (4.4 to 9.2)	59.1 (41.7 to 59.5)	0.0 (-4.7 to 5.7)
Cellulitis	2.5 (2.0 to 3.1)	3.1 (2.4 to 4.0)	22.5 (5.3 to 48.1)	-5.7 (-16.2 to 11.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	21.8 (4.0 to 54.7)	-5.4 (-23.3 to 17.0)
Pyoderma	7.0 (5.8 to 8.4)	9.6 (7.9 to 11.8)	36.5 (27.0 to 46.4)	9.5 (5.0 to 14.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	9.5 (20.5 to 50.7)	9.5 (-0.3 to 18.7)
Scabies	21.3 (18.2 to 25.1)	25.5 (21.7 to 30.2)	19.4 (0.0 to 43.6)	-6.9 (-21.5 to 10.8)	0.6 (0.3 to 0.9)	0.7 (0.4 to 1.1)	19.1 (-1.6 to 44.0)	-6.9 (-22.4 to 11.4)
Fungal skin diseases	513.3 (389.1 to 681.5)	798.3 (564.8 to 985.5)	54.2 (35.8 to 51.8)	44.2 (0.2 to 88.0)	2.9 (1.2 to 6.5)	4.2 (1.7 to 9.3)	48.8 (35.2 to 51.4)	0.5 (-0.4 to 1.5)
Viral skin diseases	169.8 (130.1 to 208.1)	197.4 (146.2 to 249.5)	16.2 (9.6 to 22.1)	0.0 (-1.8 to 1.9)	5.3 (3.0 to 8.4)	6.1 (3.4 to 9.7)	15.8 (8.2 to 22.5)	0.0 (-3.0 to 3.3)
Acne vulgaris	185.8 (141.1 to 224.7)	243.1 (185.5 to 293.9)	31.3 (-4.2 to 78.6)	6.7 (-21.6 to 44.8)	2.0 (0.9 to 3.9)	2.6 (1.2 to 5.3)	31.1 (-3.9 to 79.7)	6.7 (-21.3 to 44.9)
Alopecia areata	7.5 (6.6 to 8.3)	11.1 (9.9 to 12.4)	48.7 (24.7 to 77.1)	1.2 (-14.9 to 19.6)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	48.9 (20.5 to 79.7)	1.8 (-16.5 to 22.7)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.1 (16.9 to 100.6)	0.5 (-21.2 to 32.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.1 (16.8 to 100.7)	0.6 (-21.3 to 33.2)
Urticaria	93.8 (67.7 to 117.4)	121.5 (84.8 to 168.2)	27.4 (-18.3 to 117.8)	-16.9 (-42.3 to 34.3)	5.6 (3.3 to 8.4)	7.2 (4.2 to 11.4)	27.4 (-19.3 to 119.3)	27.4 (-43.2 to 35.3)
Decubitus ulcer	0.3 (0.3 to 0.4)	0.6 (0.5 to 0.7)	67.5 (32.5 to 117.1)	14.4 (-10.5 to 53.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	69.0 (25.6 to 126.0)	14.8 (-14.6 to 61.4)
Other skin and subcutaneous diseases	356.0 (235.6 to 535.5)	558.6 (369.7 to 839.8)	56.6 (44.8 to 71.5)	-1.9 (-6.4 to 3.3)	2.1 (0.9 to 4.3)	3.3 (1.4 to 6.8)	56.1 (44.1 to 71.4)	-2.0 (-6.5 to 3.4)
Sense organ diseases	-	-	-	-	43.9 (28.9 to 63.2)	63.9 (42.4 to 91.9)	65.5 (37.9 to 92.6)	-10.2 (-13.7 to -6.8)
Glaucoma	8.3 (7.0 to 9.7)	12.2 (10.0 to 14.4)	46.3 (28.4 to 69.9)	-14.6 (-28.8 to -1.0)	0.6 (0.4 to 0.8)	0.9 (0.6 to 1.2)	57.9 (37.1 to 84.9)	-11.1 (-22.6 to 4.3)
Cataract	44.5 (35.3 to 54.5)	56.3 (44.9 to 67.9)	26.6 (5.9 to 49.1)	-31.4 (-40.3 to -21.3)	1.5 (0.9 to 2.3)	1.9 (1.2 to 2.9)	29.2 (9.0 to 52.4)	-30.6 (-39.7 to -20.7)
Macular degeneration	14.6 (11.0 to 18.8)	28.3 (20.7 to 35.2)	94.2 (55.1 to 133.6)	8.3 (-14.3 to 37.3)	0.5 (0.3 to 0.7)	0.9 (0.5 to 1.4)	93.1 (54.8 to 132.8)	6.2 (-16.3 to 33.0)
Uncorrected refractive error	534.8 (482.5 to 586.3)	797.4 (722.2 to 880.1)	49.1 (31.5 to 69.9)	-7.0 (-12.1 to 5.3)	8.5 (5.0 to 14.0)	11.8 (6.9 to 19.6)	37.7 (26.5 to 51.2)	-11.5 (-17.7 to -3.2)
Age-related and other hearing loss	851.5 (740.0 to 952.5)	1,340.0 (1,164.2 to 1,503.7)	57.0 (49.5 to 67.3)	-7.5 (-10.8 to -3.5)	26.5 (17.4 to 37.7)	40.8 (26.5 to 57.3)	48.5 (42.3 to 65.1)	8.5 (-13.8 to -3.9)
Other vision loss	42.9 (37.6 to 49.2)	43.5 (37.2 to 50.3)	0.8 (-6.9 to 13.4)	0.8 (-38.0 to 23.0)	2.0 (1.3 to 2.9)	2.1 (1.4 to 3.0)	6.4 (-3.1 to 19.7)	-29.2 (-34.9 to -21.3)
Other sense organ diseases	163.0 (154.9 to 171.3)	207.6 (198.1 to 217.1)	27.5 (18.9 to 36.1)	-0.3 (-7.0 to 6.2)	4.4 (2.7 to 6.4)	5.5 (3.4 to 8.2)	26.4 (16.8 to 36.4)	-0.3 (-7.6 to 7.2)
Oral disorders	-	-	-	-	14.9 (8.9 to 23.5)	23.1 (13.5 to 36.5)	54.8 (49.9 to 60.2)	-7.7 (-5.4 to 0.6)
Deciduous caries	704.0 (686.0 to 718.7)	608.7 (595.1 to 620.9)	-13.6 (-16.1 to -10.7)	0.5 (-2.3 to 3.8)	0.2 (0.1 to 0.5)	0.2 (0.1 to 0.5)	0.2 (-18.6 to -8.2)	0.7 (-5.4 to 6.8)
Permanent caries	3,801.2 (3,630.6 to 3,957.3)	5,354.3 (5,214.9 to 5,493.5)	40.9 (34.4 to 47.7)	1.1 (-3.2 to 5.5)	3.8 (1.7 to 7.2)			

Appendix Table G.4 - Azerbaijan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	168.4 (160.4 to 176.0)	280.3 (268.6 to 292.2)	66.3 (56.6 to 77.2)	-6.5 (-11.5 to -1.3)	4.7 (3.1 to 6.5)	7.7 (5.2 to 10.7)	65.6 (56.1 to 76.8)	-6.5 (-11.3 to -0.9)
Other oral disorders	118.2 (111.6 to 125.1)	171.7 (161.5 to 181.4)	45.7 (33.7 to 56.9)	-1.7 (-9.0 to 5.5)	3.5 (2.2 to 5.2)	5.0 (3.2 to 7.6)	45.1 (33.3 to 56.6)	-1.7 (-9.0 to 5.8)
Injuries	-	-	-	-	52.6 (39.6 to 67.8)	80.8 (60.0 to 105.2)	51.9 (42.7 to 73.7)	-6.3 (-11.9 to 8.5)
Transport injuries	-	-	-	-	8.8 (6.6 to 11.3)	8.7 (6.5 to 11.2)	-0.8 (-6.0 to 4.3)	-38.7 (-41.7 to -35.9)
Road injuries	-	-	-	-	8.2 (6.1 to 10.5)	8.0 (6.0 to 10.3)	-2.1 (-7.5 to 3.4)	-39.9 (-43.0 to -36.9)
Pedestrian road injuries	-	-	-	-	1.1 (0.8 to 1.4)	0.9 (0.6 to 1.1)	-20.1 (-28.2 to -12.0)	-47.1 (-51.6 to -42.8)
Cyclist road injuries	-	-	-	-	1.1 (0.8 to 1.4)	1.0 (0.8 to 1.4)	-4.2 (-10.3 to 2.5)	-40.7 (-44.3 to -36.8)
Motorcyclist road injuries	-	-	-	-	0.9 (0.7 to 1.2)	0.9 (0.6 to 1.2)	-2.2 (-10.3 to 7.3)	-41.3 (-46.0 to -35.7)
Motor vehicle road injuries	-	-	-	-	5.0 (3.8 to 6.5)	5.1 (3.8 to 6.7)	1.2 (-1.0 to 3.5)	-37.9 (-42.1 to -33.3)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-14.4 (-20.4 to -8.5)	-48.1 (-51.4 to -44.7)
Other transport injuries	-	-	-	-	0.6 (0.4 to 0.8)	0.7 (0.5 to 0.9)	16.2 (8.3 to 25.2)	-23.1 (-28.1 to -17.6)
Unintentional injuries	-	-	-	-	43.1 (32.6 to 55.6)	63.9 (47.8 to 83.4)	48.4 (42.7 to 53.6)	-9.9 (-13.4 to -6.6)
Falls	-	-	-	-	28.9 (21.7 to 37.1)	45.6 (34.1 to 59.4)	58.0 (50.1 to 64.9)	-7.7 (-12.4 to -3.3)
Drowning	-	-	-	-	0.5 (0.4 to 0.6)	0.4 (0.3 to 0.5)	-16.2 (-23.8 to -8.4)	-43.9 (-48.6 to -39.2)
Fire, heat, and hot substances	-	-	-	-	1.5 (1.2 to 1.9)	1.6 (1.2 to 2.1)	7.0 (-1.0 to 15.1)	-30.5 (-35.0 to -25.6)
Poisonings	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-9.2 (-20.7 to 4.5)	-37.6 (-45.3 to -28.7)
Exposure to mechanical forces	-	-	-	-	7.7 (5.8 to 10.0)	9.8 (7.3 to 12.9)	28.3 (20.8 to 34.5)	-14.3 (-18.4 to -10.7)
Unintentional firearm injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	25.3 (13.3 to 37.3)	-18.1 (-25.5 to -10.8)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	49.1 (32.4 to 63.9)	1.8 (-8.3 to 11.5)
Other exposure to mechanical forces	-	-	-	-	7.4 (5.6 to 9.8)	9.5 (7.1 to 12.5)	28.2 (20.5 to 34.4)	-14.4 (-18.7 to -10.7)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	56.9 (48.2 to 67.8)	2.1 (-3.8 to 9.3)
Animal contact	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.7)	46.7 (37.9 to 56.3)	1.7 (-3.6 to 7.2)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	43.4 (27.8 to 60.6)	-1.5 (-11.2 to 9.2)
Non-venomous animal contact	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	48.8 (39.0 to 59.0)	3.5 (-2.3 to 9.1)
Foreign body	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.7)	38.7 (31.1 to 46.2)	-6.5 (-11.0 to -2.3)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	27.9 (15.8 to 41.3)	-11.1 (-18.5 to -3.4)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	43.4 (34.2 to 53.1)	-1.5 (-6.8 to 4.1)
Foreign body in other body part	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	45.9 (34.9 to 57.0)	-4.9 (-11.3 to 1.7)
Other unintentional injuries	-	-	-	-	3.5 (2.6 to 4.5)	5.1 (3.8 to 6.7)	45.0 (36.2 to 54.4)	-9.9 (-15.3 to -4.1)
Self-harm and interpersonal violence	-	-	-	-	0.8 (0.6 to 1.0)	1.1 (0.8 to 1.4)	33.6 (27.0 to 40.0)	-19.4 (-23.0 to -16.0)
Self-harm	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	79.9 (66.1 to 93.7)	6.0 (-1.8 to 13.5)
Interpersonal violence	-	-	-	-	0.5 (0.4 to 0.7)	0.6 (0.5 to 0.8)	12.5 (6.4 to 18.2)	-31.5 (-34.9 to -28.2)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	46.7 (20.3 to 38.0)	1.7 (-25.6 to -15.7)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	29.2 (21.7 to 40.5)	-20.6 (-26.2 to -15.7)
Assault by other means	-	-	-	-	0.4 (0.3 to 0.4)	0.4 (0.3 to 0.5)	2.9 (-4.6 to 9.7)	-37.2 (-41.4 to -33.3)
Forces of nature, war, and legal intervention	-	-	-	-	7.1 (2.3 to 18.0)	7.1 (2.3 to 18.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.1 (0.0 to 0.1)	-	-
Collective violence and legal intervention	-	-	-	-	-	7.1 (2.3 to 17.9)	-	-

Appendix Table G.4 - Bahrain prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	47.7 (35.0 to 62.2)	147.5 (109.2 to 191.5)	209.3 (197.7 to 222.3)	-11.8 (-0.9 to 5.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	6.7 (4.7 to 9.4)	13.5 (9.4 to 18.5)	100.5 (84.2 to 119.2)	-11.8 (-18.2 to -4.7)
HIV/AIDS and tuberculosis	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	285.9 (219.1 to 368.9)	6.6 (-7.7 to 25.0)
Tuberculosis	0.2 (0.1 to 0.2)	0.5 (0.5 to 0.6)	221.5 (193.7 to 250.1)	-8.7 (-13.4 to -3.9)	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.2)	220.8 (170.1 to 286.7)	-8.4 (-19.3 to 4.3)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3,311.5 (1,125.5 to 6,660.1)	732.2 (280.3 to 2,046.1)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,555.3 (1,065.8 to 7,201.5)	619.3 (209.4 to 2,057.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,555.3 (1,055.1 to 7,230.2)	619.3 (207.3 to 2,060.7)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.4 (0.2 to 0.5)	2,835.2 (1,311.9 to 7,343.2)	887.3 (384.6 to 2,418.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	2,506.6 (1,121.3 to 6,738.2)	732.1 (280.3 to 2,073.5)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	1.0 (0.9 to 1.8)	1.5 (1.5 to 2.9)	62.9 (49.1 to 79.6)	-18.7 (-24.7 to -11.9)
Diarrheal diseases	6.1 (5.7 to 6.6)	9.3 (8.6 to 10.0)	51.6 (37.4 to 69.5)	-18.7 (-25.9 to -10.5)	1.0 (0.7 to 1.4)	1.5 (1.0 to 2.1)	60.4 (35.6 to 89.4)	-18.7 (-26.2 to -10.4)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.3 (21.3 to 126.1)	-23.7 (-45.1 to -3.4)
Typhoid fever	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	74.6 (29.8 to 119.5)	-23.5 (-39.3 to -4.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.6 (27.5 to 129.8)	-23.2 (-40.7 to -1.3)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.9 (28.8 to 145.5)	-20.9 (-41.0 to 6.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.9 (28.7 to 145.8)	-20.9 (-41.0 to 6.2)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.5 (-98.9 to 2,522.4)	-67.9 (-99.5 to 1,050.0)
Lower respiratory infections	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	22.0 (-31.8 to 286.3)	-30.9 (-58.6 to 105.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	21.0 (-35.9 to 284.4)	-32.6 (-59.6 to 102.4)
Upper respiratory infections	10.2 (9.0 to 11.1)	24.6 (21.7 to 27.4)	141.9 (105.2 to 183.6)	-3.0 (-16.9 to 12.4)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	140.7 (104.0 to 183.9)	-3.0 (-17.5 to 14.1)
Otitis media	6.0 (5.6 to 6.4)	12.5 (11.3 to 13.7)	110.6 (86.2 to 132.9)	-10.6 (-20.2 to -1.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	109.0 (86.5 to 133.0)	-11.5 (-20.0 to -2.2)
Meningitis	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	28.1 (5.9 to 77.9)	-52.8 (-64.9 to -35.8)
Pneumococcal meningitis	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	5.6 (-22.1 to 96.0)	-62.9 (-72.8 to -34.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-13.7 to 84.2)	-57.2 (-68.0 to -35.9)
H influenzae type B meningitis	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	10.7 (-35.3 to 149.3)	-59.2 (-76.0 to -4.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.1 (-22.9 to 230.9)	-49.3 (-69.2 to 30.5)
Meningococcal meningitis	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	63.5 (-47.8 to 74.6)	-63.5 (-79.3 to -38.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.5 (-44.8 to 82.4)	-60.8 (-78.5 to -34.1)
Other meningitis	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	33.2 (-10.1 to 94.3)	-51.7 (-67.6 to -30.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.9 (-1.7 to 116.1)	-46.0 (-61.6 to -20.8)
Encephalitis	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.6)	125.2 (85.9 to 187.7)	-25.2 (-33.6 to 2.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	141.9 (88.4 to 215.9)	-13.3 (-31.4 to 9.4)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.3 (-93.1 to 512.2)	-73.6 (-96.9 to 129.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.3 (-93.1 to 514.8)	-73.6 (-96.9 to 130.3)
Whooping cough	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-66.4 (-69.3 to -63.3)	-76.6 (-78.6 to -74.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-66.4 (-75.7 to -54.7)	-76.6 (-83.1 to -68.4)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.7 (-72.6 to 43.1)	-64.5 (-88.0 to -46.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.5 (-72.0 to 57.7)	-62.9 (-87.5 to -42.1)
Measles	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-91.4 (-94.6 to -86.3)	-94.1 (-96.3 to -90.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.2 (-94.6 to -85.3)	-93.9 (-96.3 to -90.0)
Varicella and herpes zoster	0.4 (0.3 to 0.4)	0.8 (0.7 to 0.9)	115.6 (80.2 to 151.5)	4.8 (-11.7 to 22.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	227.7 (120.4 to 353.8)	8.5 (-20.8 to 46.9)
Neglected tropical diseases and malaria	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	80.8 (48.8 to 185.4)	-5.0 (-21.5 to 51.0)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	205.8 (52.1 to 457.6)	19.6 (-39.8 to 115.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	235.9 (75.7 to 468.8)	29.7 (-32.1 to 116.2)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.5 (32.3 to 168.4)	-16.1 (-41.0 to 13.1)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.1 (-7.4 to 311.9)	-10.3 (50.8 to 72.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.0 (-9.2 to 327.9)	-10.7 (52.0 to 77.2)
Cutaneous and mucocutaneous leishmaniasis	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.9)	96.3 (26.3 to 185.8)	-17.8 (-46.5 to 20.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.3 (20.6 to 192.2)	-18.7 (-47.8 to 20.9)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.1 (-83.3 to 266.3)	-77.2 (-93.9 to -15.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.1 (-82.2 to 295.3)	-75.3 (-93.6 to -7.7)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	330.0 (282.5 to 378.4)	33.4 (19.6 to 48.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	322.3 (213.6 to 440.0)	33.4 (3.0 to 67.9)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.2 (-81.5 to 41.0)	-62.6 (-92.1 to -50.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.2 (-81.6 to 41.4)	62.6 (-92.1 to -50.7)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	193.3 (131.6 to 265.2)	-4.7 (-24.3 to 17.4)
Ascariasis	-	-	214.9 (87.6 to 427.5)	-0.2 (-40.6 to 67.2)	-	-	-	-
Trichuriasis	-	-	216.4 (80.4 to 461.2)	0.3 (-42.8 to 77.7)	-	-	-	-
Hookworm disease	0.3 (0.2 to 0.5)	1.1 (0.8 to 1.5)	217.8 (99.7 to 363.2)	0.7 (-36.7 to 46.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	193.3 (131.6 to 265.2)	4.7 (-24.3 to 17.4)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	5.5 (4.1 to 7.0)	10.4 (9.2 to 11.6)	88.2 (49.9 to 154.0)	-6.1 (-25.5 to 26.3)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	77.3 (44.2 to 185.9)	-5.1 (-22.6 to 55.6)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	45.7 (15.7 to 79.4)	-49.4 (-59.8 to -37.6)
Maternal hemorrhage	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	142.9 (23.8 to 276.1)	-17.5 (-56.5 to 26.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	127.6 (-7.5 to 325.7)	-22.5 (-65.9 to 40.7)
Maternal sepsis and other maternal infections	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	42.9 (-16.1 to 60.4)	-62.9 (-75.1 to -48.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.5 (-46.7 to 96.5)	65.3 (-81.0 to -35.3)
Maternal hypertensive disorders	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.6)	40.9 (19.4 to 56.3)	-50.1 (-57.9 to -45.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.0 (15.6 to 67.1)	-50.6 (-59.5 to -41.1)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.7 (-17.5 to 76.1)	-57.4 (-71.4 to -39.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.9 (-46.1 to 138.4)	-57.0 (-79.8 to -19.7)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.0 (-4.0 to 170.8)	44.1 (-68.0 to -10.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.0 (-4.6 to 170.8)	-44.1 (-68.0 to -10.4)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.2 (-15.9 to 252.4)	-45.4 (-70.6 to 21.6)
Neonatal disorders	-	-	-	-	0.9 (0.6 to 1.3)	2.4 (1.7 to 3.3)	169.8 (95.8 to 300.1)	8.4 (-20.5 to 57.9)
Preterm birth complications	3.5 (2.6 to 4.6)	10.7 (8.2 to 14.2)	204.9 (140.2 to 307.5)	17.3 (-7.2 to 54.3)	0.4 (0.3 to 0.6)	1.5 (1.0 to 2.1)	241.7 (163.8 to 423.7)	34.2 (4.2 to 101.6)
Neonatal encephalopathy due to birth asphyxia and trauma	1.0 (0.5 to 1.8)	1.2 (0.6 to 2.3)	25.6 (-47.6 to 187.2)	-48.6 (-78.2 to 13.7)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.5)	40.5 (-32.6 to 208.5)	-42.3 (-72.1 to 27.3)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	258.3 (207.5 to 300.4)	155.8 (119.5 to 185.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	155.8 (119.9 to 511.3)	163.2 (56.9 to 336.4)
Hemolytic disease and other neonatal jaundice	0.3 (0.1 to 0.7)	0.3 (0.1 to 0.6)	8.0 (-65.1 to 207.4)	-55.9 (-85.8 to 22.6)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	25.3 (-57.4 to 203.0)	-49.8 (-83.1 to 22.4)
Other neonatal disorders	-	-	-	-	0.1 (0.0 to 0.2)	0.4 (0.2 to 0.6)	383.8 (127.4 to 786.5)	94.0 (-8.6 to 254.1)
Nutritional deficiencies	-	-	-	-	4.0 (2.6 to 5.7)	7.7 (5.1 to 11.2)	94.0 (76.2 to 110.6)	-14.7 (-21.2 to -7.9)
Protein-energy malnutrition	1.9 (1.0 to 3.3)	2.0 (0.7 to 4.4)	3.2 (-66.5 to 193.2)	-26.1 (-75.6 to 106.6)	0.3 (0.1 to 0.5)	0.3 (0.1 to 0.6)	3.3 (-66.3 to 193.6)	-26.0 (-75.6 to 106.9)
Iodine deficiency	15.5 (7.0 to 25.1)	20.7 (7.5 to 38.4)	35.8 (-56.6 to 216.0)	-54.3 (-83.8 to 6.4)	0.3 (0.1 to 0.5)	0.4 (0.1 to 0.8)	35.2 (-57.1 to 217.7)	-54.2 (-83.9 to 6.3)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-

Appendix Table G.4 - Bahrain prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	103.3 (101.2 to 105.3)	231.8 (230.1 to 233.5)	124.4 (119.6 to 129.5)	-8.9 (-10.9 to -6.9)	3.3 (2.2 to 4.8)	7.0 (4.6 to 10.1)	109.5 (103.2 to 116.2)	-9.9 (-12.5 to -6.8)
Other nutritional deficiencies	-	-	-	-	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.2)	-38.5 (80.9 to 89.4)	-55.9 (86.1 to 34.2)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.7 (0.4 to 1.0)	125.1 (76.0 to 210.2)	-11.1 (28.9 to 17.3)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.6)	183.2 (82.9 to 453.9)	-5.7 (37.6 to 71.7)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.6 (65.7 to 173.2)	-39.1 (-47.5 to -27.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	118.7 (51.1 to 216.1)	-37.7 (-54.5 to -14.2)
Chlamydial infection	10.7 (6.2 to 15.9)	27.2 (19.5 to 40.0)	141.9 (36.7 to 475.9)	-17.4 (51.7 to 94.7)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	173.4 (36.0 to 1,007.7)	-6.8 (54.3 to 260.2)
Gonococcal infection	3.7 (2.5 to 4.9)	9.3 (6.6 to 11.9)	153.8 (70.2 to 280.2)	-9.5 (-40.3 to 36.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	189.1 (99.0 to 366.0)	-0.3 (30.0 to 58.5)
Trichomoniasis	2.4 (1.6 to 3.5)	6.6 (3.9 to 10.0)	179.2 (36.4 to 360.4)	-11.2 (-57.9 to 58.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	160.7 (6.9 to 412.5)	-16.1 (67.2 to 73.9)
Genital herpes	68.9 (65.0 to 72.7)	218.1 (203.4 to 230.9)	216.8 (191.0 to 245.2)	-4.0 (-12.1 to 4.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	210.4 (179.3 to 243.0)	-4.5 (-12.9 to 5.3)
Other sexually transmitted diseases	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	121.8 (84.0 to 162.4)	-31.0 (-42.9 to -18.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	169.1 (82.1 to 297.9)	-10.3 (37.0 to 26.9)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	120.6 (70.1 to 171.5)	-26.8 (-44.0 to -11.0)
Hepatitis A	0.5 (0.5 to 0.6)	1.2 (1.2 to 1.2)	122.1 (121.3 to 122.6)	-5.5 (-6.1 to -4.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	160.2 (127.5 to 195.8)	-3.9 (-14.7 to 8.2)
Hepatitis B	45.5 (34.5 to 57.0)	79.9 (54.8 to 102.7)	74.3 (12.9 to 351.2)	-40.8 (-60.4 to -16.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	83.5 (12.8 to 169.5)	-42.8 (-65.4 to -18.4)
Hepatitis C	23.5 (20.6 to 26.4)	63.0 (54.5 to 72.1)	168.2 (121.8 to 219.3)	-16.4 (-28.4 to -1.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.7 (58.7 to 219.0)	-23.2 (-46.0 to 7.6)
Hepatitis E	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	300.2 (162.5 to 463.6)	35.7 (-9.0 to 88.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	301.8 (136.5 to 551.6)	33.6 (-16.4 to 113.0)
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	567.3 (55.4 to 4,990.0)	79.1 (-50.7 to 1,488.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	545.9 (46.4 to 6,393.7)	73.2 (52.6 to 1,868.5)
Other infectious diseases	4.1 (3.0 to 5.2)	8.1 (6.9 to 9.4)	98.1 (55.7 to 168.4)	-6.9 (-26.2 to 22.3)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	80.8 (34.1 to 190.9)	-8.9 (30.8 to 42.3)
Non-communicable diseases	-	-	-	-	28.9 (28.9 to 51.0)	97.3 (97.3 to 169.9)	233.2 (218.6 to 247.8)	5.6 (1.9 to 9.4)
Neoplasms	-	-	-	-	0.3 (0.2 to 0.3)	0.7 (0.5 to 0.9)	152.5 (113.4 to 203.4)	-23.7 (-33.0 to -10.2)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.4 (-17.5 to 142.0)	-53.6 (-73.5 to -20.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.5 (5.4 to 138.5)	-52.1 (-70.9 to -18.8)
Stomach cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	36.2 (4.4 to 83.1)	-52.2 (-63.6 to -36.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.7 (0.6 to 85.4)	-54.1 (-66.3 to -37.2)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.1 (14.9 to 151.7)	43.1 (-61.9 to -19.3)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	118.7 (8.4 to 326.9)	-35.7 (-72.9 to 28.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.7 (-14.9 to 264.2)	-41.4 (-74.3 to 10.3)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	330.3 (105.9 to 874.1)	36.5 (-35.9 to 219.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	281.9 (106.0 to 763.1)	20.8 (-41.2 to 177.4)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.0 (-46.4 to 96.6)	-66.1 (-80.9 to -33.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.2 (-46.8 to 75.9)	-67.0 (-80.8 to -37.6)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.2 (-55.9 to 147.7)	-64.6 (-6.0 to -5.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.3 (-58.5 to 129.0)	-48.2 (-87.4 to -17.0)
Larynx cancer	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.4)	247.4 (194.9 to 294.8)	13.2 (-5.4 to 30.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	222.3 (162.2 to 287.2)	2.0 (-17.1 to 22.4)
Tracheal, bronchus and lung cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	33.1 (-5.6 to 113.5)	-55.0 (-67.9 to -30.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.1 (-9.1 to 102.5)	-57.6 (-69.3 to -34.0)
Breast cancer	1.0 (0.8 to 1.1)	1.6 (1.1 to 2.1)	62.1 (9.2 to 130.4)	-66.6 (-76.8 to -52.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	124.5 (47.2 to 229.2)	-46.5 (-63.3 to -21.9)
Cervical cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	14.7 (-32.4 to 71.8)	-42.9 (-77.2 to -44.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.3 (-28.6 to 86.1)	-61.0 (-77.2 to -41.3)
Uterine cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	254.2 (16.5 to 653.0)	7.4 (-65.3 to 107.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	240.8 (111.7 to 644.3)	1.5 (-67.1 to 108.1)
Prostate cancer	0.1 (0.1 to 0.1)	0.5 (0.3 to 0.8)	477.2 (207.8 to 923.3)	76.0 (-4.7 to 197.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	366.9 (156.9 to 657.9)	42.4 (-8.3 to 128.0)
Colon and rectum cancer	0.5 (0.5 to 0.6)	1.8 (1.6 to 1.9)	235.4 (199.9 to 272.5)	1.7 (-8.4 to 12.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	228.6 (189.7 to 267.1)	-0.4 (-11.1 to 10.2)
Lip and oral cavity cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	108.0 (30.5 to 315.4)	-37.6 (-61.0 to -21.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.6 (29.2 to 294.9)	-39.2 (-61.9 to 16.6)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.2 (24.3 to 271.0)	-37.8 (-61.8 to 4.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.7 (25.0 to 250.8)	-40.8 (-62.8 to -3.9)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.3 (-12.5 to 194.6)	-54.8 (-74.7 to -17.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.9 (-15.7 to 172.5)	-57.4 (-75.8 to -24.0)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	253.1 (51.4 to 450.1)	23.7 (-46.9 to 101.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	235.7 (43.5 to 421.6)	18.1 (-49.6 to 87.4)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	279.7 (169.9 to 444.7)	11.3 (-20.0 to 60.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	274.2 (180.6 to 413.4)	8.3 (-21.7 to 52.0)
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	370.5 (65.9 to 356.1)	-4.4 (-40.8 to 63.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	165.0 (57.8 to 352.0)	9.0 (-43.2 to 54.1)
Non-melanoma skin cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	165.3 (96.6 to 325.1)	-14.2 (-40.9 to 39.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	126.5 (39.8 to 379.5)	-24.4 (-58.6 to 64.5)
Ovarian cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	174.3 (59.7 to 362.1)	-15.1 (-46.6 to 35.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	160.5 (48.9 to 371.1)	-19.0 (-49.7 to 34.9)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	565.8 (136.6 to 1,465.2)	117.7 (-23.9 to 367.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	502.4 (86.6 to 1,753.9)	92.3 (-32.3 to 411.6)
Kidney cancer	0.1 (0.0 to 0.0)	0.1 (0.1 to 0.2)	394.2 (176.0 to 514.9)	32.2 (-6.4 to 99.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	279.4 (158.0 to 497.9)	22.7 (-15.5 to 83.3)
Bladder cancer	0.4 (0.3 to 0.4)	0.7 (0.6 to 0.8)	75.8 (41.7 to 113.3)	-43.3 (-54.1 to -29.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	74.3 (40.1 to 113.5)	-44.3 (-55.3 to -30.0)
Brain and nervous system cancer	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	109.3 (30.8 to 250.6)	-19.2 (-47.1 to 22.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	119.5 (39.0 to 257.0)	-20.8 (-48.3 to 18.2)
Thyroid cancer	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	286.5 (80.9 to 574.8)	19.0 (-43.3 to 97.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	266.7 (74.3 to 544.9)	11.3 (-45.5 to 84.7)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	541.0 (266.8 to 932.0)	137.8 (30.7 to 292.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	512.2 (247.3 to 915.2)	22.7 (19.6 to 284.5)
Hodgkin lymphoma	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	21.1 (-33.8 to 277.7)	-55.7 (-74.6 to 36.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.2 (-36.6 to 252.8)	-58.0 (-75.4 to 31.4)
Non-Hodgkin lymphoma	0.2 (0.1 to 0.2)	0.5 (0.4 to 0.7)	230.0 (119.9 to 392.8)	12.5 (-22.5 to 60.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	218.5 (110.9 to 375.4)	5.2 (-28.3 to 52.0)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	253.7 (77.2 to 642.2)	1.8 (-46.1 to 108.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	233.4 (70.2 to 641.4)	-5.8 (-50.6 to 101.4)
Leukemia	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	260.3 (138.6 to 411.2)	43.5 (-3.1 to 100.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	255.1 (139.3 to 388.7)	27.2 (-15.5 to 77.7)
Other neoplasms	0.1 (0.1 to 0.2)	0.6 (0.4 to 0.8)	359.0 (136.2 to 570.4)	79.4 (2.2 to 155.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	332.9 (128.1 to 536.9)	58.6 (9.8 to 128.6)
Cardiovascular diseases	-	-	-	-	0.7 (0.5 to 1.0)	2.4 (1.6 to 3.3)	256.0 (167.7 to 348.1)	20.7 (-3.3 to 43.6)
Rheumatic heart disease	1.3 (0.9 to 1.6)	3.9 (2.9 to 4.8)	206.0 (116.1 to 353.7)	0.1 (-23.8 to 36.0)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	230.0 (130.4 to 381.3)	13.2 (-13.9 to 57.7)
Ischemic heart disease	2.5 (2.1 to 2.9)	7.3 (6.3 to 8.7)	198.4 (140.3 to 266.8)	-4.5 (-23.7 to 12.3)	0.1 (0.1 to 0.2)	0.5 (0.3 to 0.7)	230.9 (153.5 to 325.2)	0.5 (-22.6 to 27.9)
Cerebrovascular disease	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	238.1 (164.3 to 347.2)	-4.2 (-27.0 to 24.2)
Ischemic stroke	0.1 (0.1 to 0.1)	0.4 (0.4 to 0.5)	243.2 (170.3 to 366.2)	-4.0 (-28.0 to 28.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	243.4 (164.2 to 375.3)	-4.1 (-27.1 to 28.9)
Hemorrhagic stroke	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	210.0 (115.9 to 359.2)	-8.3 (-33.6 to 34.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	210.6 (117.0 to 360.3)	-8.0 (-33.7 to 35.9)
Hypertensive heart disease	0.3 (0.2 to 0.3)	1.5 (1.3 to 1.8)	455.2 (343.4 to 650.3)	77.7 (34.1 to 134.5)	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.2)	454.5 (332.5 to 646.1)	70.8 (31.7 to 133.3)
Cardiomyopathy and myocarditis	0.3 (0.3 to 0.4)	1.3 (1.1 to 1.5)	338.8 (247.3 to 442.7)	45.2 (15.5 to 94.1)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	337.5 (239.7 to 462.8)	45.4 (14.2 to 94.0)
Atrial fibrillation and flutter	0.5 (0.4 to 0.6)	3.0 (2.6 to 3.4)	552.5 (392.4 to 742.2)	107.0 (53.9 to 177.1)	0.0 (0.0 to 0.1)	0.2 (0.2 to 0.3)	556.5 (398.9 to 753.8)	105.2 (52.8 to 177.6)
Peripheral vascular disease	4.2 (3.1 to 5.8)	18.1 (9.6 to 28.0)	321.9 (126.2 to 654.8)	18.6 (-23.5 to 71.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.5 (3.2 to 276.8)	-26.9 (-64.1 to 37.4)
Endocarditis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	538.9 (250.0 to 779.9)	101.8 (19.0 to 183.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	549.4 (242.6 to 866.1)	105.0 (12.0 to 226.1)
Other cardiovascular and circulatory diseases	5.0 (3.5 to 7.2)	15.4 (8.4 to 21.3)	219.7 (66.1 to 399.0)	3.3 (-47.1 to 55.2)	0.4 (0.2 to 0.6)	1.1 (0.6 to 1.6)	218.9 (64.5 to 401.7)	2.8 (-4.7 to 55.1)
Chronic respiratory diseases	-	-	-	-	1.9 (1.3 to 2.6)	6.6 (4.5 to 9.0)	240.5 (183.6 to 301.3)	2.5 (-10.2 to 18.0)

Appendix Table G.4 - Bahrain prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	228.3 (216.6 to 241.1)	-4.6 (-12.3 to -5.0)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	205.0 (191.0 to 223.4)	-18.2 (-22.3 to -13.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	205.8 (191.3 to 224.4)	-18.0 (-22.4 to -13.2)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	240.7 (225.6 to 256.4)	-1.9 (-6.2 to 1.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	242.2 (226.7 to 258.1)	-1.2 (-5.6 to 3.0)
Asthma	14.4 (11.8 to 17.5)	43.4 (33.3 to 55.9)	201.5 (119.7 to 306.2)	-5.6 (-26.3 to 22.1)	0.6 (0.4 to 0.9)	1.9 (1.2 to 2.9)	198.4 (116.8 to 304.9)	-6.3 (-27.2 to 20.2)
Interstitial lung disease and pulmonary sarcoidosis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	240.6 (124.4 to 422.3)	2.7 (-27.0 to 44.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	245.8 (129.1 to 423.3)	4.0 (-28.6 to 46.5)
Other chronic respiratory diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	136.3 (69.8 to 214.5)	-29.2 (-48.6 to -7.2)
Cirrhosis	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	97.1 (65.5 to 138.3)	-32.5 (-41.7 to -21.6)
Cirrhosis due to hepatitis B	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	57.9 (-20.1 to 348.3)	-46.3 (-70.6 to 25.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.0 (-24.0 to 355.0)	-46.9 (-72.0 to 28.5)
Cirrhosis due to hepatitis C	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	188.3 (32.4 to 524.8)	-0.7 (-54.4 to 100.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	185.7 (28.1 to 545.7)	-3.3 (-56.1 to 109.7)
Cirrhosis due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.0 (-39.9 to 126.7)	-59.9 (-80.0 to -30.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.3 (-39.5 to 152.4)	60.4 (-26.1 to -25.9)
Cirrhosis due to other causes	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	70.0 (9.9 to 168.3)	-26.2 (-50.8 to 9.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.3 (1.9 to 185.3)	-80.1 (-56.8 to 20.2)
Digestive diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.9 (0.6 to 1.2)	216.0 (175.9 to 260.1)	-7.4 (-18.2 to 3.1)
Peptic ulcer disease	0.9 (0.8 to 1.1)	1.4 (1.0 to 1.7)	44.3 (12.9 to 83.7)	-46.5 (-57.2 to -35.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	82.4 (30.8 to 142.7)	-35.4 (-50.0 to -20.7)
Gastritis and duodenitis	1.1 (1.0 to 1.3)	1.6 (1.3 to 1.9)	45.4 (17.7 to 77.3)	-45.6 (-53.1 to -36.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	42.0 (5.2 to 102.5)	-39.4 (-49.5 to -24.8)
Appendicitis	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	140.6 (49.9 to 309.3)	-21.4 (-46.6 to 29.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	136.4 (35.3 to 357.7)	-21.0 (-51.2 to 38.7)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	191.8 (128.5 to 251.1)	-0.9 (-18.1 to 18.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	193.6 (107.4 to 282.1)	0.2 (-25.8 to 33.8)
Inguinal, femoral, and abdominal hernia	0.5 (0.5 to 0.6)	1.6 (1.3 to 1.9)	185.9 (126.0 to 263.2)	-11.6 (-34.3 to 16.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	185.2 (124.1 to 270.7)	-11.6 (-34.8 to 16.3)
Inflammatory bowel disease	0.4 (0.4 to 0.4)	2.0 (1.8 to 2.2)	395.6 (341.0 to 460.2)	47.9 (32.1 to 64.6)	0.1 (0.1 to 0.1)	0.1 (0.3 to 0.6)	394.6 (325.7 to 473.9)	47.9 (29.8 to 68.2)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	221.8 (140.1 to 340.9)	1.6 (-28.8 to 45.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	228.1 (137.5 to 346.7)	3.7 (-33.2 to 56.3)
Gallbladder and biliary diseases	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.5)	217.7 (131.5 to 316.6)	-1.2 (-25.7 to 27.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	217.4 (128.8 to 320.7)	1.5 (-26.1 to 26.7)
Pancreatitis	0.1 (0.1 to 0.1)	0.3 (0.3 to 0.3)	214.6 (173.3 to 253.8)	-8.0 (-16.1 to 1.4)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	213.8 (146.0 to 301.1)	-8.4 (-22.8 to 9.1)
Other digestive diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	193.3 (119.4 to 314.0)	-14.6 (-34.9 to 18.5)
Neurological disorders	-	-	-	-	3.6 (2.4 to 5.1)	12.1 (7.9 to 17.0)	237.0 (182.2 to 297.2)	10.1 (-5.4 to 24.4)
Alzheimer disease and other dementias	1.2 (1.1 to 1.4)	3.6 (3.1 to 4.0)	389.9 (143.9 to 244.6)	1.4 (-16.4 to 22.2)	0.2 (0.1 to 0.2)	0.5 (0.3 to 0.6)	185.3 (139.6 to 240.5)	1.3 (-17.4 to 20.7)
Parkinson disease	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	224.5 (196.1 to 262.0)	-0.3 (-9.9 to 8.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	228.5 (181.6 to 286.0)	-0.7 (-12.5 to 12.1)
Epilepsy	2.2 (1.7 to 2.7)	5.8 (4.5 to 7.1)	163.7 (93.3 to 260.7)	-0.2 (-26.1 to 34.7)	0.8 (0.5 to 1.1)	2.2 (1.4 to 3.1)	179.5 (97.1 to 289.6)	6.9 (-23.7 to 48.1)
Multiple sclerosis	0.1 (0.0 to 0.1)	0.4 (0.3 to 0.6)	510.7 (280.9 to 1,047.6)	81.0 (19.3 to 214.2)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	496.6 (247.9 to 1,034.2)	75.3 (9.2 to 202.3)
Migraine	52.4 (39.3 to 67.7)	166.4 (136.9 to 201.9)	218.9 (132.4 to 338.3)	1.6 (-27.4 to 37.1)	1.8 (1.0 to 2.8)	5.7 (3.2 to 9.0)	217.5 (128.3 to 334.7)	1.3 (-27.1 to 35.3)
Tension-type headache	86.7 (80.4 to 93.4)	267.2 (201.5 to 324.5)	210.0 (128.0 to 283.0)	2.1 (-19.4 to 23.9)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.8)	209.6 (129.1 to 284.0)	2.2 (-12.0 to 24.6)
Medication overuse headache	3.9 (2.6 to 5.4)	18.9 (12.5 to 25.5)	386.5 (284.1 to 542.7)	53.6 (23.1 to 91.6)	0.6 (0.3 to 1.0)	3.0 (1.6 to 4.7)	385.9 (281.9 to 546.6)	53.4 (23.5 to 93.1)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	199.1 (73.3 to 395.0)	4.7 (-36.0 to 59.3)	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	202.3 (102.4 to 325.1)	-2.8 (-36.8 to 36.9)
Mental and substance use disorders	-	-	-	-	13.5 (9.3 to 18.6)	44.5 (31.0 to 60.3)	231.4 (210.3 to 251.1)	7.2 (-1.9 to 22.1)
Schizophrenia	1.4 (1.3 to 1.6)	4.9 (4.4 to 5.3)	234.9 (219.8 to 256.8)	-0.5 (-4.4 to 4.6)	0.9 (0.7 to 1.1)	3.1 (2.3 to 3.8)	233.4 (208.8 to 262.2)	0.8 (-6.9 to 6.4)
Alcohol use disorders	3.6 (3.2 to 4.1)	10.4 (9.3 to 11.7)	187.7 (163.6 to 209.7)	-10.7 (-17.0 to -4.8)	0.4 (0.2 to 0.5)	1.0 (0.7 to 1.5)	187.0 (160.9 to 213.8)	-10.8 (-18.3 to -2.9)
Drug use disorders	-	-	-	-	2.6 (1.4 to 4.1)	11.6 (7.5 to 16.3)	357.4 (252.6 to 479.1)	41.4 (11.8 to 74.3)
Opioid use disorders	5.4 (3.1 to 8.4)	25.6 (18.1 to 33.3)	395.2 (265.7 to 558.0)	51.4 (14.9 to 95.2)	2.2 (1.2 to 3.7)	10.7 (6.7 to 15.0)	396.0 (262.1 to 563.1)	51.8 (14.5 to 96.2)
Cocaine use disorders	0.4 (0.4 to 0.6)	1.5 (1.1 to 1.9)	220.8 (122.6 to 347.2)	0.1 (-24.7 to 44.5)	0.2 (0.0 to 0.1)	0.2 (0.1 to 0.3)	218.9 (115.5 to 368.6)	6.0 (-25.9 to 51.0)
Amphetamine use disorders	0.8 (0.6 to 1.0)	1.8 (1.4 to 2.2)	124.6 (65.1 to 210.2)	-21.6 (-41.8 to 7.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	122.0 (57.4 to 213.9)	-21.9 (-44.7 to 9.9)
Cannabis use disorders	0.8 (0.7 to 1.0)	2.4 (2.0 to 2.9)	188.9 (179.1 to 198.9)	1.7 (1.4 to 2.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	190.2 (141.1 to 248.9)	2.5 (-13.1 to 20.2)
Other drug use disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.7)	160.5 (77.3 to 287.6)	-10.8 (-38.6 to 31.4)
Depressive disorders	-	-	-	-	4.4 (2.3 to 7.0)	14.3 (7.4 to 23.1)	229.1 (187.8 to 259.7)	5.6 (-3.4 to 15.5)
Major depressive disorder	18.7 (10.3 to 27.6)	61.7 (31.6 to 90.2)	231.9 (183.9 to 266.1)	6.8 (-3.1 to 18.0)	3.9 (1.9 to 6.4)	12.7 (5.9 to 21.1)	230.0 (183.1 to 265.4)	6.7 (-3.7 to 18.4)
Dysthymia	5.1 (4.0 to 6.2)	16.4 (12.8 to 19.9)	223.2 (213.5 to 237.2)	-1.0 (-1.3 to -0.7)	0.5 (0.3 to 0.7)	1.6 (1.0 to 2.4)	222.6 (206.9 to 240.1)	-1.2 (-3.8 to 1.7)
Bipolar disorder	3.8 (3.3 to 4.4)	11.9 (10.3 to 13.4)	209.7 (193.3 to 230.7)	-2.0 (-6.3 to 3.6)	0.8 (0.5 to 1.2)	2.4 (1.5 to 3.6)	208.3 (186.5 to 236.3)	-2.2 (-8.1 to 4.5)
Anxiety disorders	20.0 (9.1 to 28.8)	57.3 (28.3 to 82.9)	187.0 (161.5 to 215.6)	1.9 (-2.8 to -1.0)	5.3 (0.8 to 3.0)	5.3 (2.4 to 8.5)	185.5 (159.0 to 215.3)	-2.1 (-4.7 to 0.5)
Eating disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	164.1 (131.5 to 197.8)	-1.0 (-11.9 to 11.8)
Anorexia nervosa	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	202.4 (169.6 to 256.0)	16.3 (4.7 to 41.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	202.6 (134.5 to 292.9)	17.0 (-8.5 to 50.9)
Bulimia nervosa	0.3 (0.2 to 0.4)	0.7 (0.4 to 1.0)	152.3 (142.8 to 161.8)	-6.4 (-9.1 to -4.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	151.5 (116.2 to 191.2)	-6.7 (-18.3 to 6.6)
Autistic spectrum disorders	-	-	-	-	0.6 (0.4 to 0.9)	1.7 (1.2 to 2.4)	175.4 (164.6 to 186.3)	1.7 (-1.7 to 5.0)
Autism	1.6 (1.5 to 1.7)	4.4 (4.1 to 4.6)	176.8 (174.9 to 178.8)	1.5 (1.5 to 1.6)	0.4 (0.3 to 0.5)	1.1 (0.7 to 1.5)	174.8 (159.2 to 191.6)	1.5 (-3.4 to 6.3)
Asperger syndrome	2.4 (2.2 to 2.5)	6.7 (6.2 to 7.1)	177.6 (175.0 to 180.3)	2.0 (1.9 to 2.0)	0.2 (0.2 to 0.3)	0.7 (0.5 to 0.9)	176.5 (163.7 to 189.8)	2.0 (-1.9 to 5.9)
Attention-deficit/hyperactivity disorder	2.8 (2.3 to 3.3)	5.8 (4.8 to 6.8)	107.1 (104.3 to 108.7)	1.2 (1.0 to 1.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	107.0 (91.6 to 124.2)	1.4 (-6.0 to 9.4)
Conduct disorder	4.8 (4.0 to 5.6)	9.6 (8.0 to 11.3)	96.7 (95.8 to 102.7)	0.7 (0.4 to 0.9)	0.6 (0.4 to 0.9)	1.2 (0.7 to 1.8)	98.9 (90.7 to 107.7)	0.9 (-2.9 to 4.9)
Idiopathic intellectual disability	12.7 (10.7 to 15.3)	30.4 (25.4 to 36.7)	139.6 (117.0 to 161.4)	-10.2 (-18.4 to -1.9)	0.6 (0.4 to 0.9)	1.5 (1.0 to 2.1)	138.4 (114.3 to 160.9)	-10.4 (-19.0 to -1.9)
Other mental and substance use disorders	8.4 (7.8 to 9.0)	28.3 (26.2 to 30.4)	237.7 (232.1 to 243.9)	1.9 (1.2 to 2.5)	0.6 (0.4 to 0.9)	2.1 (1.4 to 2.9)	236.8 (220.7 to 253.0)	1.8 (-2.1 to 5.7)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	5.3 (3.6 to 7.3)	19.9 (13.6 to 27.6)	277.0 (233.9 to 325.2)	21.1 (6.6 to 40.5)
Diabetes mellitus	34.4 (28.8 to 39.9)	164.1 (140.2 to 189.9)	375.2 (287.6 to 501.4)	36.8 (12.4 to 78.4)	2.5 (1.6 to 3.6)	12.6 (8.4 to 17.9)	397.5 (297.8 to 516.1)	36.3 (12.0 to 75.5)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.1 (30.4 to 53.1)	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.1 (30.3 to 53.2)	41.1 (-42.1 to -34.3)
Chronic kidney disease	-	-	-	-	0.5 (0.3 to 0.6)	1.4 (1.0 to 2.0)	204.0 (170.3 to 236.1)	0.2 (-6.8 to 7.9)
Chronic kidney disease due to diabetes mellitus	3.1 (2.1 to 4.4)	11.4 (7.7 to 16.5)	271.8 (159.4 to 398.0)	15.2 (-17.4 to 59.8)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.5)	281.2 (181.4 to 428.9)	17.8 (-11.2 to 59.3)
Chronic kidney disease due to hypertension	2.7 (1.8 to 4.1)	5.8 (4.0 to 7.9)	113.1 (49.2 to 203.7)	-27.0 (-43.2 to 3.2)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	165.7 (94.7 to 247.2)	-23.2 (-40.4 to -1.8)
Chronic kidney disease due to glomerulonephritis	4.8 (3.3 to 6.5)	12.3 (7.5 to 17.8)	155.8 (86.4 to 231.0)	-24.8 (-47.1 to -2.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	114.8 (45.8 to 228.3)	-21.4 (-42.5 to 15.1)
Chronic kidney disease due to other causes	5.6 (3.9 to 7.7)	19.2 (12.9 to 28.2)	247.2 (151.2 to 332.6)	18.5 (-6.0 to 43.3)	0.2 (0.1 to 0.2)	0.5 (0.4 to 0.8)	235.4 (158.6 to 343.9)	17.2 (-4.3 to 45.4)
Urinary diseases and male infertility	-	-	-	-	0.3 (0.2 to 0.4)	1.1 (0.6 to 1.9)	283.5 (198.3 to 466.9)	12.8 (-6.2 to 51.7)

Appendix Table G.4 - Bahrain prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.1 (0.1 to 0.1)	0.3 (0.3 to 0.3)	191.2 (167.9 to 222.5)	0.0 (-4.6 to 13.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	192.2 (124.6 to 272.5)	4.2 (-14.6 to 25.5)
Urolithiasis	3.1 (1.6 to 5.7)	12.5 (4.5 to 31.9)	258.2 (137.8 to 485.0)	13.7 (26.4 to 63.3)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.4)	295.5 (222.7 to 494.1)	29.3 (1.9 to 78.9)
Benign prostatic hyperplasia	2.7 (2.5 to 2.9)	8.4 (7.8 to 9.1)	217.0 (183.2 to 250.8)	-4.6 (-15.6 to 5.5)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	218.7 (184.0 to 254.9)	-4.3 (-15.4 to 6.1)
Male infertility due to other causes	5.8 (4.0 to 7.8)	20.6 (13.6 to 28.4)	260.0 (109.8 to 458.4)	16.8 (-32.1 to 84.7)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.3)	259.3 (104.9 to 483.2)	17.5 (-33.4 to 90.7)
Other urinary diseases	-	-	-	-	0.5 (0.1 to 0.1)	0.5 (0.2 to 1.1)	89.5 (142.3 to 786.6)	53.7 (-21.3 to 169.0)
Gynecological diseases	-	-	-	-	0.7 (0.4 to 1.0)	2.0 (1.2 to 2.9)	195.4 (134.5 to 258.1)	-8.3 (-26.0 to 11.2)
Uterine fibroids	7.0 (6.2 to 7.6)	25.5 (23.0 to 27.7)	266.4 (258.2 to 275.5)	-3.8 (-4.2 to -3.4)	0.1 (0.1 to 0.2)	0.5 (0.3 to 0.7)	225.7 (206.0 to 242.3)	-9.3 (-13.7 to -5.6)
Polycystic ovarian syndrome	9.4 (8.3 to 10.4)	27.6 (25.1 to 30.1)	195.3 (156.2 to 243.4)	-6.6 (-18.3 to 6.5)	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.5)	193.4 (154.7 to 240.4)	-6.6 (-17.9 to 6.5)
Female infertility due to other causes	1.5 (0.6 to 2.8)	4.3 (1.5 to 9.0)	181.4 (-18.7 to 745.9)	0.0 (-71.8 to 186.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	166.4 (-13.9 to 650.5)	-11.2 (-69.6 to 162.3)
Endometriosis	0.8 (0.7 to 0.9)	2.5 (2.1 to 2.8)	217.6 (154.4 to 296.6)	-2.0 (-19.9 to 20.3)	0.1 (0.0 to 0.1)	0.2 (0.2 to 0.3)	215.7 (152.2 to 301.4)	2.3 (-20.6 to 21.7)
Genital prolapse	20.1 (15.3 to 25.0)	62.8 (50.7 to 77.5)	209.6 (132.4 to 330.0)	-8.8 (-29.2 to 15.9)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	208.8 (131.3 to 330.4)	-9.0 (-29.5 to 16.4)
Premenstrual syndrome	26.1 (15.1 to 36.5)	71.7 (40.3 to 99.1)	171.8 (31.1 to 435.1)	-8.4 (-56.9 to 77.5)	0.2 (0.1 to 0.4)	0.6 (0.3 to 1.0)	172.7 (29.5 to 432.4)	-8.7 (-57.5 to 75.7)
Other gynecological diseases	1.9 (1.3 to 2.3)	5.0 (4.5 to 5.5)	172.3 (113.7 to 290.8)	-11.4 (-30.3 to 27.0)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	163.0 (105.9 to 390.2)	-35.1 (-34.0 to 53.8)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	1.2 (0.8 to 1.7)	2.5 (1.7 to 3.5)	113.3 (96.0 to 127.4)	5.1 (-13.6 to 1.2)
Thalassemias	0.2 (0.2 to 0.3)	0.5 (0.5 to 0.6)	133.0 (105.4 to 172.9)	11.1 (-0.8 to 28.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	139.5 (72.9 to 248.1)	10.8 (-20.1 to 60.7)
Thalassemia trait	33.0 (29.0 to 36.8)	89.0 (80.3 to 97.2)	168.0 (156.1 to 191.3)	1.1 (-3.4 to 10.0)	0.5 (0.4 to 0.8)	1.1 (0.8 to 1.7)	111.1 (76.6 to 131.9)	-3.5 (-21.2 to 5.5)
Sickle cell disorders	1.5 (1.4 to 1.6)	3.5 (3.2 to 3.7)	128.3 (109.0 to 151.7)	-1.7 (-9.6 to 8.3)	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.6)	157.4 (122.0 to 199.1)	2.2 (-10.3 to 17.9)
Sickle cell trait	76.3 (71.6 to 80.3)	192.6 (181.0 to 203.8)	152.0 (140.3 to 165.3)	0.3 (-9.9 to 4.7)	0.6 (0.2 to 0.5)	0.6 (0.4 to 0.9)	92.5 (64.2 to 128.4)	-10.6 (-24.2 to 4.6)
G6PD deficiency	71.0 (59.9 to 81.7)	208.8 (185.1 to 232.7)	194.6 (143.1 to 255.7)	8.6 (-10.3 to 31.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	121.2 (63.6 to 228.4)	0.5 (-27.9 to 41.7)
G6PD trait	103.7 (102.6 to 104.5)	245.2 (242.6 to 247.3)	136.5 (133.4 to 139.8)	-4.1 (-5.4 to -2.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	130.6 (92.7 to 219.5)	2.6 (-95.8 to 750.3)
Other hemoglobinopathies and hemolytic anemias	4.3 (3.4 to 4.9)	9.9 (8.8 to 11.0)	130.7 (92.9 to 194.2)	-7.7 (-22.2 to 15.1)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	108.3 (47.9 to 254.1)	-7.6 (-30.8 to 48.4)
Endocrine, metabolic, blood, and immune disorders	5.7 (4.7 to 6.5)	12.7 (11.8 to 13.6)	123.3 (95.5 to 169.1)	0.2 (-17.2 to 8.9)	0.4 (0.1 to 0.3)	0.6 (0.3 to 0.6)	122.1 (84.3 to 193.0)	4.7 (-17.7 to 22.2)
Musculoskeletal disorders	-	-	-	-	7.0 (4.7 to 9.4)	24.3 (16.8 to 32.7)	243.7 (192.5 to 355.8)	1.5 (-10.6 to 21.6)
Rheumatoid arthritis	1.0 (1.0 to 1.1)	2.6 (2.5 to 2.8)	154.2 (139.3 to 171.4)	-20.3 (-25.4 to -14.8)	0.2 (0.2 to 0.3)	0.6 (0.4 to 0.8)	153.4 (131.3 to 178.8)	-20.6 (-26.7 to -14.3)
Osteoarthritis	7.7 (7.2 to 8.2)	28.1 (26.5 to 29.9)	263.3 (235.4 to 297.8)	0.1 (-6.8 to 7.9)	0.5 (0.3 to 0.6)	2.4 (1.2 to 2.7)	264.7 (234.2 to 300.9)	-0.3 (-7.5 to 7.6)
Low back and neck pain	-	-	-	-	5.5 (3.6 to 7.6)	18.5 (12.5 to 25.9)	251.4 (171.6 to 380.5)	0.4 (-16.5 to 29.0)
Low back pain	33.7 (20.7 to 40.8)	114.9 (89.9 to 143.8)	238.4 (150.2 to 463.9)	0.6 (-21.1 to 42.6)	3.8 (2.3 to 5.5)	12.9 (8.1 to 18.9)	236.8 (148.0 to 466.8)	0.7 (-21.8 to 43.3)
Neck pain	17.2 (14.7 to 19.9)	57.8 (47.2 to 65.8)	237.8 (157.6 to 317.2)	-0.5 (-20.1 to 22.2)	1.7 (1.1 to 2.4)	5.7 (3.8 to 8.1)	236.9 (157.5 to 317.3)	-0.8 (-20.8 to 21.5)
Gout	0.2 (0.2 to 0.2)	0.8 (0.6 to 0.9)	294.2 (192.5 to 413.5)	7.0 (-15.8 to 31.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	291.7 (167.0 to 471.7)	6.1 (-19.7 to 42.7)
Other musculoskeletal disorders	9.0 (6.6 to 11.6)	37.7 (28.0 to 48.1)	316.5 (281.8 to 352.3)	16.4 (9.2 to 24.3)	0.8 (0.5 to 1.2)	3.4 (2.2 to 5.1)	166.7 (280.5 to 353.3)	16.0 (9.2 to 24.2)
Other non-communicable diseases	-	-	-	-	6.8 (4.6 to 9.7)	19.5 (13.5 to 28.3)	187.4 (169.5 to 203.9)	-4.4 (-9.0 to -0.1)
Congenital anomalies	-	-	-	-	0.5 (0.4 to 0.7)	2.0 (1.3 to 2.9)	287.6 (207.8 to 390.1)	51.5 (22.0 to 89.2)
Neural tube defects	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	156.5 (77.9 to 235.7)	5.6 (-26.6 to 37.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	156.0 (63.8 to 268.4)	6.3 (-30.7 to 50.6)
Congenital heart anomalies	3.2 (2.7 to 3.9)	10.9 (9.4 to 12.9)	238.0 (161.7 to 332.8)	37.5 (6.6 to 76.1)	0.1 (0.0 to 0.2)	0.4 (0.2 to 0.7)	254.4 (178.5 to 346.6)	45.1 (14.1 to 82.2)
Orofacial clefts	0.6 (0.5 to 0.8)	1.9 (1.4 to 2.4)	189.2 (97.1 to 320.0)	24.4 (-14.7 to 79.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.1 (27.1 to 213.0)	-15.3 (-45.0 to 31.3)
Down syndrome	0.6 (0.5 to 0.8)	2.0 (1.5 to 3.1)	220.7 (114.5 to 430.6)	28.1 (-14.4 to 107.3)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.4)	242.9 (123.5 to 468.3)	35.5 (-10.0 to 119.5)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	169.6 (106.4 to 266.0)	11.6 (-14.1 to 51.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	175.9 (100.0 to 287.7)	10.7 (-20.2 to 53.8)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	174.6 (90.6 to 289.9)	0.1 (-30.5 to 42.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	206.7 (111.7 to 334.2)	0.7 (-30.2 to 43.0)
Chromosomal unbalanced rearrangements	0.5 (0.5 to 0.7)	1.7 (1.3 to 2.1)	197.2 (117.1 to 275.4)	1.7 (-12.4 to 49.1)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	254.7 (127.7 to 310.0)	24.7 (-8.4 to 61.1)
Other congenital anomalies	1.4 (1.2 to 1.6)	3.6 (2.9 to 4.3)	158.8 (111.7 to 207.5)	-10.1 (-25.9 to 6.4)	0.2 (0.1 to 0.3)	1.0 (0.6 to 1.6)	376.7 (217.0 to 640.6)	81.5 (20.3 to 179.8)
Skin and subcutaneous diseases	-	-	-	-	2.8 (1.7 to 4.3)	7.7 (4.8 to 12.1)	180.8 (153.0 to 208.6)	3.9 (-6.2 to 14.0)
Dermatitis	29.9 (23.2 to 36.7)	86.2 (66.9 to 106.2)	188.7 (179.0 to 197.5)	0.3 (-0.0 to 0.5)	0.9 (0.5 to 1.4)	2.6 (1.5 to 3.9)	172.2 (152.4 to 185.8)	0.0 (-2.6 to 2.6)
Psoriasis	2.9 (2.3 to 3.7)	9.2 (7.0 to 11.7)	212.2 (203.3 to 225.3)	0.2 (-0.3 to 0.2)	0.2 (0.2 to 0.4)	0.7 (0.5 to 1.1)	215.5 (188.0 to 236.9)	-0.1 (-5.6 to 5.7)
Cellulitis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	121.0 (94.1 to 150.0)	-14.9 (-22.6 to -5.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	119.7 (62.2 to 192.4)	-14.7 (-30.7 to 4.7)
Pyoderma	0.4 (0.3 to 0.5)	0.8 (0.6 to 1.0)	103.5 (78.5 to 131.2)	-7.3 (-12.9 to -0.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.8 (70.5 to 142.9)	-7.1 (-17.4 to 4.4)
Scabies	1.8 (1.4 to 2.3)	4.7 (3.8 to 6.1)	157.5 (89.5 to 275.2)	-1.1 (-26.4 to 38.2)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	157.0 (86.3 to 277.4)	-1.0 (-26.8 to 39.1)
Fungal skin diseases	30.6 (22.7 to 38.8)	95.0 (71.7 to 120.6)	210.5 (198.5 to 223.9)	0.2 (0.5 to 1.0)	0.5 (0.3 to 0.4)	0.5 (0.2 to 1.2)	209.5 (197.3 to 223.7)	0.7 (-0.3 to 1.7)
Viral skin diseases	10.4 (7.5 to 13.3)	23.4 (15.9 to 31.4)	123.6 (105.4 to 141.8)	-0.1 (-2.1 to 2.0)	0.1 (0.2 to 0.5)	0.7 (0.4 to 1.2)	122.9 (103.1 to 143.2)	0.0 (-3.6 to 3.2)
Acne vulgaris	55.8 (43.1 to 72.0)	166.3 (125.1 to 213.6)	198.6 (100.9 to 331.7)	21.4 (-20.5 to 72.9)	0.6 (0.3 to 1.1)	1.8 (0.8 to 3.4)	198.7 (100.5 to 331.6)	21.4 (-20.8 to 72.7)
Alopecia areata	0.7 (0.6 to 0.8)	1.9 (1.4 to 2.3)	187.9 (116.5 to 257.9)	-2.3 (-22.2 to 18.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	186.9 (107.8 to 267.6)	-2.3 (-23.6 to 19.8)
Pruritus	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.6)	229.6 (88.2 to 787.8)	1.6 (-50.7 to 131.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	227.4 (76.7 to 809.2)	0.1 (-51.6 to 139.5)
Urticaria	4.2 (2.8 to 5.7)	11.6 (7.3 to 16.0)	180.0 (54.7 to 357.4)	0.7 (-47.7 to 52.8)	0.2 (0.1 to 0.4)	0.7 (0.4 to 1.1)	177.3 (52.3 to 353.9)	-0.6 (-48.0 to 51.7)
Decubitus ulcer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	163.2 (105.6 to 235.9)	-22.2 (-44.3 to 21.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	166.4 (101.0 to 248.2)	-21.6 (-43.9 to 21.8)
Other skin and subcutaneous diseases	22.4 (15.4 to 31.6)	73.7 (50.0 to 103.5)	227.8 (195.2 to 267.3)	1.3 (-2.6 to 4.7)	0.1 (0.1 to 0.3)	0.4 (0.2 to 0.9)	227.1 (193.2 to 266.3)	1.2 (-2.9 to 4.9)
Sense organ diseases	-	-	-	-	2.1 (1.8 to 3.8)	7.1 (4.8 to 10.2)	165.6 (149.5 to 184.6)	-13.9 (-19.2 to -10.5)
Glaucoma	1.4 (0.9 to 1.8)	3.6 (2.4 to 4.8)	158.3 (70.8 to 268.5)	-1.1 (-49.8 to 10.6)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	167.3 (96.4 to 255.8)	-16.8 (-41.2 to 7.9)
Cataract	2.9 (2.0 to 4.3)	7.7 (4.7 to 11.0)	158.8 (86.0 to 277.0)	-21.2 (-37.0 to -2.3)	0.2 (0.1 to 0.3)	0.6 (0.3 to 0.9)	147.2 (80.1 to 234.7)	-21.0 (-35.2 to -2.6)
Macular degeneration	0.6 (0.4 to 1.0)	1.7 (1.0 to 2.5)	182.6 (78.8 to 313.8)	-21.2 (-54.5 to 12.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	178.5 (88.1 to 294.9)	-19.0 (-47.6 to 10.2)
Uncorrected refractive error	35.4 (29.8 to 41.1)	106.9 (91.6 to 122.0)	203.1 (142.4 to 276.4)	5.0 (-22.0 to 11.9)	0.9 (0.6 to 1.3)	2.3 (1.5 to 3.4)	162.8 (133.6 to 203.9)	-14.3 (-24.2 to -5.7)
Age-related and other hearing loss	35.6 (32.7 to 38.9)	109.1 (99.1 to 121.0)	206.0 (189.9 to 224.2)	-9.3 (-12.5 to -6.2)	0.9 (0.6 to 1.3)	2.6 (1.6 to 3.8)	185.0 (161.1 to 211.2)	-11.4 (-16.6 to -6.7)
Other vision loss	3.5 (2.7 to 4.4)	8.5 (6.5 to 11.1)	144.9 (100.6 to 183.9)	-19.3 (-35.1 to -8.4)	0.3 (0.2 to 0.4)	0.7 (0.4 to 1.0)	152.3 (99.4 to 194.2)	-19.3 (-32.4 to -9.5)
Other sense organ diseases	10.7 (10.2 to 11.3)	25.9 (24.7 to 27.3)	142.1 (124.5 to 160.4)	-0.3 (-6.9 to 6.1)	0.3 (0.2 to 0.4)	0.7 (0.4 to 1.0)	140.5 (120.5 to 161.2)	-0.3 (-7.6 to 7.4)
Oral disorders	-	-	-	-	0.9 (0.5 to 1.3)	2.7 (1.6 to 4.1)	212.8 (194.1 to 231.8)	-3.5 (-10.1 to 3.2)
Deciduous caries	44.4 (41.7 to 46.6)	71.5 (68.1 to 74.9)	60.9 (51.3 to 72.5)	0.1 (-5.9 to 7.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	60.5 (48.1 to 75.7)	0.3 (-7.9 to 9.5)
Permanent caries	161.3 (142.8 to 183.9)	470.6 (413.7 to 521.4)	191.7 (156.7 to 228.9)	0.0 (-11.8 to 12.7)	0.2 (0.1 to 0.3)	0.5 (0.2		

Appendix Table G.4 - Bahrain prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Edentulism and severe tooth loss	10.4 (9.4 to 11.4)	32.8 (29.6 to 35.8)	215.1 (177.3 to 259.0)	-6.6 (-17.4 to 7.2)	0.3 (0.2 to 0.4)	0.9 (0.6 to 1.3)	215.7 (178.6 to 259.9)	-6.9 (-17.7 to 6.9)
Other oral disorders	8.0 (7.5 to 8.5)	24.3 (22.6 to 25.9)	201.9 (181.4 to 223.3)	-0.7 (-6.3 to 5.0)	0.2 (0.1 to 0.4)	0.7 (0.4 to 1.1)	201.3 (178.7 to 223.7)	-0.8 (-6.8 to 5.3)
Injuries	-	-	-	-	1.6 (1.2 to 2.1)	3.0 (2.2 to 4.0)	87.0 (65.6 to 112.1)	-38.9 (-44.9 to -31.8)
Transport injuries	-	-	-	-	0.8 (0.6 to 1.1)	1.3 (0.9 to 1.7)	55.6 (33.1 to 83.3)	-49.1 (-55.4 to -41.6)
Road injuries	-	-	-	-	0.7 (0.5 to 0.9)	1.1 (0.8 to 1.6)	54.8 (31.5 to 83.7)	-49.0 (-55.7 to -41.4)
Pedestrian road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	39.0 (16.6 to 65.1)	-52.1 (-58.6 to -44.7)
Cyclist road injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	50.2 (30.5 to 69.1)	-51.2 (-56.7 to -45.8)
Motorcyclist road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	26.0 (7.4 to 49.3)	-60.0 (-65.2 to -54.1)
Motor vehicle road injuries	-	-	-	-	0.5 (0.3 to 0.6)	0.8 (0.5 to 1.1)	65.3 (37.7 to 99.3)	-45.7 (-53.6 to -36.4)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.9 (-21.7 to 9.7)	-69.5 (-73.4 to -64.8)
Other transport injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	64.5 (43.3 to 88.6)	-48.7 (-54.6 to -41.7)
Unintentional injuries	-	-	-	-	0.7 (0.5 to 0.9)	1.6 (1.1 to 2.1)	119.9 (100.9 to 140.4)	-29.6 (-35.5 to -23.5)
Falls	-	-	-	-	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	116.4 (90.8 to 145.2)	-32.7 (-40.8 to -24.3)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.8 (5.9 to 49.2)	-58.2 (-64.0 to -51.5)
Fire, heat, and hot substances	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	51.4 (28.2 to 78.7)	-47.6 (-54.3 to -40.6)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.3 (-14.1 to 44.5)	-61.1 (-69.1 to -51.5)
Exposure to mechanical forces	-	-	-	-	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.6)	128.1 (105.1 to 148.4)	-25.0 (-30.1 to -19.5)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.1 (56.6 to 109.4)	-43.6 (-50.4 to -36.0)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	214.9 (173.5 to 254.2)	6.7 (-4.7 to 17.8)
Other exposure to mechanical forces	-	-	-	-	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.6)	129.5 (110.5 to 150.1)	-24.3 (-29.6 to -18.8)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	243.5 (215.0 to 273.2)	16.9 (9.0 to 24.5)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.2 (70.5 to 118.0)	-35.8 (-42.2 to -29.1)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.5 (67.9 to 134.3)	-35.0 (-44.1 to -25.1)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.3 (66.1 to 115.6)	-36.5 (-43.4 to -29.2)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	129.8 (107.6 to 155.3)	-24.4 (-30.7 to -16.8)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.3 (5.2 to 61.5)	-50.4 (-58.4 to -40.4)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	174.8 (140.7 to 211.9)	-7.7 (-16.9 to 2.8)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	145.6 (118.8 to 177.3)	-21.9 (-29.4 to -13.5)
Other unintentional injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	154.8 (128.3 to 185.2)	-18.8 (-26.1 to -12.1)
Self-harm and interpersonal violence	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	102.7 (77.1 to 132.5)	-34.5 (-42.1 to -26.2)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	188.2 (148.6 to 235.2)	-16.1 (-25.7 to -4.0)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	70.7 (46.3 to 98.1)	-42.3 (-49.7 to -34.3)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.9 (62.6 to 107.4)	-37.7 (-43.9 to -31.1)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.4 (59.7 to 120.3)	-39.5 (-47.0 to -30.1)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	61.5 (35.2 to 92.4)	-44.9 (-52.9 to -35.5)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	-	-	-
Collective violence and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-

Appendix Table G.4 - Bangladesh prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	11,571.4 (8,491.9 to 15,039.6)	17,132.4 (12,646.6 to 22,197.9)	48.1 (42.8 to 54.0)	48.1 (-10.9 to -5.8)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	3,487.4 (2,410.8 to 4,841.1)	3,348.8 (2,363.2 to 4,559.5)	-4.0 (-9.0 to 2.3)	-31.7 (-35.2 to -27.2)
HIV/AIDS and tuberculosis	-	-	-	-	40.9 (27.7 to 55.6)	77.3 (53.1 to 103.4)	77.3 (75.1 to 104.6)	5.2 (-2.0 to 13.2)
Tuberculosis	136.4 (128.6 to 144.0)	252.6 (242.9 to 262.2)	83.7 (75.7 to 94.0)	2.3 (-2.4 to 8.0)	40.8 (27.7 to 55.6)	75.6 (51.9 to 101.0)	85.2 (71.4 to 100.3)	3.3 (-3.8 to 11.0)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.2)	1.6 (0.7 to 3.1)	-	-
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	0.0 (-1,342.7 to 0.0)	0.0 (733.5 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-	-
HIV/AIDS resulting in other diseases	0.1 (0.0 to 0.2)	10.4 (7.0 to 15.5)	0.0 (396.5 to 0.0)	0.0 (191.9 to 0.0)	0.0 (0.0 to 0.2)	1.6 (0.7 to 3.1)	-	-
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	439.1 (311.9 to 587.1)	505.2 (356.1 to 675.6)	15.1 (7.2 to 23.3)	-11.6 (-17.3 to -5.4)
Diarrheal diseases	963.8 (900.7 to 1,024.6)	927.8 (867.1 to 985.8)	-4.0 (-12.8 to 5.3)	-13.1 (-20.2 to -5.3)	155.4 (103.5 to 216.1)	148.9 (101.3 to 205.5)	-4.0 (-13.5 to 5.4)	-12.7 (-20.4 to -4.8)
Intestinal infectious diseases	-	-	-	-	11.5 (7.7 to 16.4)	10.2 (6.8 to 14.4)	-11.5 (-29.3 to 10.3)	-28.7 (-42.6 to -12.0)
Typhoid fever	76.2 (63.9 to 86.4)	67.7 (57.7 to 78.5)	-11.9 (-27.3 to 9.5)	-29.4 (-41.9 to -13.5)	10.0 (6.6 to 14.3)	8.9 (5.8 to 12.8)	-10.7 (-30.8 to 16.5)	-28.1 (-43.1 to -7.4)
Paratyphoid fever	27.2 (21.5 to 33.4)	24.0 (16.3 to 31.2)	-12.6 (-42.2 to 22.9)	-27.7 (-50.9 to -1.4)	1.4 (0.8 to 2.2)	1.3 (0.7 to 1.9)	-10.3 (-44.5 to 32.5)	26.4 (-51.4 to 6.8)
Other intestinal infectious diseases	-	-	-	-	0.1 (0.1 to 0.3)	0.0 (0.0 to 0.0)	-87.6 (-94.2 to -75.1)	-90.0 (-95.3 to -80.0)
Lower respiratory infections	166.0 (152.9 to 179.8)	136.6 (125.4 to 146.9)	-17.8 (-27.5 to -8.5)	-25.1 (-33.7 to -17.2)	17.3 (11.5 to 24.3)	14.1 (9.3 to 19.8)	-18.0 (-29.5 to -6.3)	-24.9 (-34.3 to -15.2)
Upper respiratory infections	5,555.5 (5,289.5 to 5,796.1)	7,981.7 (7,597.1 to 8,373.4)	42.8 (33.4 to 51.8)	0.5 (-6.0 to 6.7)	65.1 (36.2 to 108.4)	93.1 (52.2 to 156.2)	43.0 (33.1 to 52.6)	1.0 (-5.8 to 7.2)
Otitis media	2,077.6 (1,867.0 to 2,284.3)	2,540.1 (2,292.7 to 2,852.6)	21.3 (10.8 to 34.4)	-11.4 (-19.3 to -1.4)	44.5 (26.6 to 71.5)	53.5 (31.4 to 85.8)	20.3 (7.2 to 34.6)	-10.6 (-20.2 to 0.1)
Meningitis	-	-	-	-	127.1 (87.7 to 177.4)	173.7 (119.7 to 236.8)	36.9 (15.7 to 63.6)	-9.7 (-24.0 to 7.0)
Pneumococcal meningitis	778.0 (468.2 to 1,166.6)	1,201.4 (723.8 to 1,822.1)	53.0 (16.0 to 100.5)	-4.8 (-29.3 to 25.7)	63.8 (44.3 to 87.1)	92.5 (63.7 to 128.8)	44.2 (13.5 to 87.4)	-6.5 (-25.7 to 19.2)
H influenzae type B meningitis	335.8 (133.4 to 631.6)	394.1 (145.3 to 763.5)	16.5 (-14.3 to 61.0)	-24.9 (-43.3 to 6.2)	32.8 (19.5 to 52.9)	36.1 (23.0 to 51.3)	14.0 (-23.6 to 48.4)	21.6 (-46.7 to 0.0)
Meningococcal meningitis	55.3 (21.7 to 125.2)	85.7 (31.5 to 188.4)	50.9 (8.2 to 121.1)	-9.9 (-34.8 to 36.9)	6.3 (3.9 to 9.2)	9.1 (5.5 to 13.8)	46.0 (0.5 to 96.9)	-9.8 (-35.6 to 22.8)
Other meningitis	214.6 (117.3 to 374.1)	345.3 (172.6 to 607.6)	58.3 (18.0 to 116.0)	0.1 (-25.7 to 35.0)	24.1 (15.9 to 35.0)	36.1 (22.7 to 51.6)	48.1 (12.9 to 102.1)	-2.7 (-25.4 to 31.9)
Encephalitis	62.4 (29.2 to 130.8)	72.4 (32.0 to 156.2)	15.0 (-4.2 to 29.3)	-28.2 (-39.3 to -19.9)	7.1 (4.9 to 9.8)	8.1 (5.6 to 11.0)	13.5 (-7.7 to 38.3)	25.9 (-38.1 to -10.4)
Diphtheria	0.0 (0.0 to 0.2)	0.0 (0.0 to 0.0)	86.8 (-99.1 to 127.5)	-87.2 (-99.1 to 127.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-86.8 (-99.1 to 132.0)	-87.2 (-99.1 to 65.1)
Whooping cough	108.2 (83.9 to 138.7)	11.7 (9.0 to 15.1)	-89.2 (-90.6 to -87.7)	-88.2 (-89.7 to -86.5)	5.3 (3.2 to 8.6)	0.6 (0.3 to 0.9)	-89.2 (-91.6 to -86.1)	-88.2 (-90.9 to -84.9)
Tetanus	34.3 (18.6 to 58.4)	0.3 (0.1 to 0.8)	-99.1 (-99.6 to -97.3)	-99.4 (-99.8 to -98.2)	1.1 (0.6 to 1.8)	0.0 (0.0 to 0.1)	-97.9 (-99.3 to -96.6)	-98.4 (-99.5 to -95.7)
Measles	33.7 (25.4 to 43.8)	3.3 (2.5 to 4.1)	-90.3 (-92.4 to -87.6)	-90.7 (-91.9 to -86.8)	3.0 (1.8 to 4.8)	0.3 (0.2 to 0.5)	-90.3 (-94.3 to -84.7)	-89.8 (-94.0 to -83.8)
Varicella and herpes zoster	87.2 (79.0 to 95.5)	103.4 (93.6 to 113.5)	18.3 (2.6 to 35.4)	-2.0 (-18.8 to 18.1)	1.6 (0.9 to 2.6)	2.6 (1.5 to 4.1)	60.7 (16.3 to 123.8)	-2.3 (-31.1 to 38.2)
Neglected tropical diseases and malaria	-	-	-	-	665.4 (419.5 to 1,018.7)	527.6 (334.9 to 776.0)	-20.8 (-31.7 to -7.0)	-44.9 (-52.7 to -34.6)
Malaria	750.1 (697.8 to 799.4)	1,136.2 (1,067.8 to 1,209.3)	50.4 (38.7 to 63.1)	-0.9 (-8.7 to 7.6)	4.8 (2.6 to 7.4)	7.7 (5.0 to 11.2)	56.1 (26.1 to 168.2)	5.5 (-13.2 to 94.1)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.6 (0.3 to 1.1)	0.8 (0.4 to 1.6)	41.4 (3.1 to 111.1)	0.0 (-34.0 to 43.8)
Visceral leishmaniasis	3.8 (2.5 to 5.5)	4.6 (3.1 to 6.7)	20.0 (-7.0 to 61.3)	-1.8 (-22.0 to 30.6)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.6)	20.7 (-14.1 to 70.0)	-1.2 (-26.7 to 32.5)
Cutaneous and mucocutaneous leishmaniasis	29.6 (17.2 to 47.9)	48.3 (25.6 to 74.0)	63.0 (-14.9 to 193.8)	-0.1 (-46.2 to 66.9)	0.3 (0.1 to 0.7)	0.5 (0.2 to 1.1)	62.8 (-16.8 to 204.9)	0.7 (-45.8 to 76.4)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	2.4 (1.1 to 4.5)	1.5 (0.6 to 2.7)	-39.1 (-77.6 to 79.1)	-62.0 (-86.0 to 12.1)	0.7 (0.3 to 1.3)	0.5 (0.2 to 1.0)	-30.8 (-74.7 to 109.8)	-56.6 (-84.0 to 28.3)
Cystic echinococcosis	16.2 (14.4 to 18.8)	13.4 (12.7 to 14.5)	-16.9 (-30.0 to -1.5)	-45.3 (-53.6 to -38.6)	1.5 (1.0 to 2.2)	1.2 (0.8 to 1.7)	-17.1 (-39.7 to 12.0)	-45.7 (-84.4 to -30.3)
Lymphatic filariasis	2,813.2 (2,310.4 to 3,403.6)	1,368.9 (977.5 to 1,961.8)	-52.1 (-63.9 to -37.8)	-69.9 (-77.2 to -61.1)	91.3 (41.8 to 165.5)	94.7 (47.7 to 169.0)	5.1 (-29.4 to 40.0)	-42.7 (-60.7 to -24.5)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	20.9 (8.4 to 46.0)	149.3 (60.8 to 327.4)	611.2 (606.6 to 616.6)	392.0 (388.8 to 395.7)	3.4 (1.2 to 8.1)	24.0 (8.5 to 57.4)	609.7 (480.0 to 780.7)	394.6 (316.2 to 478.9)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-97.2 (-98.1 to -66.9)	-97.7 (-98.4 to -74.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-97.2 (-98.1 to -66.9)	97.7 (-98.4 to -74.7)
Intestinal nematode infections	-	-	-	-	452.0 (257.1 to 756.6)	318.9 (181.9 to 500.7)	-29.5 (-42.5 to -13.6)	-49.7 (-60.1 to -37.3)
Ascariasis	53,061.1 (46,743.6 to 60,250.4)	56,043.6 (40,916.8 to 75,205.9)	3.8 (-26.3 to 46.3)	-29.4 (-51.0 to 1.4)	255.8 (140.7 to 453.5)	119.6 (62.8 to 204.4)	-53.8 (-66.3 to -32.7)	-64.9 (-75.4 to -47.5)
Trichuriasis	23,437.7 (18,663.8 to 29,196.7)	29,775.5 (19,857.6 to 44,205.6)	27.5 (-21.1 to 100.2)	-16.4 (-48.9 to 41.1)	35.5 (18.1 to 64.4)	32.4 (14.9 to 64.9)	-11.9 (-51.9 to 67.3)	-19.9 (-68.7 to 21.8)
Hookworm disease	28,492.1 (23,970.5 to 34,148.9)	35,086.6 (25,348.6 to 47,700.1)	23.2 (-15.5 to 76.6)	21.4 (-46.3 to 20.3)	160.8 (96.7 to 251.1)	166.9 (97.2 to 256.3)	3.3 (-19.4 to 35.0)	-32.4 (-48.6 to -10.6)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	2,752.6 (2,136.4 to 3,375.9)	2,284.8 (2,166.3 to 2,451.7)	-17.8 (-32.7 to 7.3)	-34.6 (-45.3 to -17.6)	111.1 (69.4 to 160.0)	79.8 (52.7 to 114.0)	-29.4 (-38.3 to -2.8)	-42.1 (-49.5 to -22.8)
Maternal disorders	-	-	-	-	77.3 (51.7 to 108.3)	96.0 (64.5 to 133.1)	24.8 (6.5 to 41.4)	-26.9 (-37.1 to -16.8)
Maternal hemorrhage	11.9 (8.5 to 16.9)	14.7 (9.1 to 20.6)	23.6 (-26.4 to 90.4)	26.9 (-55.2 to 10.8)	0.9 (0.5 to 1.5)	0.7 (0.3 to 1.2)	-26.8 (-64.1 to 44.6)	54.9 (-77.4 to 49.9)
Maternal sepsis and other maternal infections	75.8 (49.1 to 110.6)	51.7 (33.0 to 70.2)	-31.7 (-46.6 to 6.1)	-66.3 (-72.4 to -45.9)	1.1 (0.5 to 2.0)	0.6 (0.3 to 1.0)	-48.7 (-69.1 to -22.5)	-6.8 (-80.6 to -54.2)
Maternal hypertensive disorders	35.6 (14.4 to 64.2)	26.0 (10.1 to 49.3)	-28.5 (-39.8 to -12.6)	-56.7 (-63.4 to -46.2)	1.9 (0.7 to 3.8)	1.4 (0.5 to 2.8)	-30.6 (-47.7 to -10.6)	-57.4 (-67.6 to -44.1)
Obstructed labor	187.5 (158.4 to 216.9)	246.2 (209.8 to 282.3)	30.7 (19.4 to 41.1)	-24.2 (-30.9 to -18.0)	61.4 (40.2 to 85.5)	80.3 (53.8 to 110.9)	31.0 (16.7 to 45.3)	-23.7 (-31.9 to -15.3)
Complications of abortion	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	-	-2.3 (-40.3 to 82.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-	-45.9 (-65.2 to -5.1)
Other maternal disorders	-	-	-	-	11.9 (6.0 to 21.3)	13.1 (6.3 to 22.2)	13.0 (-48.9 to 107.9)	-33.3 (-70.3 to 23.3)
Neonatal disorders	-	-	-	-	120.4 (76.3 to 180.1)	500.5 (346.0 to 680.6)	320.5 (176.1 to 536.7)	217.9 (106.3 to 388.1)
Preterm birth complications	593.8 (371.9 to 886.7)	2,809.1 (2,014.4 to 3,915.6)	376.7 (262.1 to 518.6)	220.2 (144.8 to 322.2)	39.1 (24.1 to 59.8)	254.3 (167.4 to 361.7)	554.7 (326.8 to 855.6)	391.9 (224.2 to 613.8)
Neonatal encephalopathy due to birth asphyxia and trauma	1,475.6 (883.8 to 2,247.2)	1,647.1 (660.9 to 2,971.5)	15.0 (-22.1 to 176.6)	-25.1 (-49.4 to 87.6)	40.6 (18.3 to 73.9)	112.3 (72.7 to 161.3)	184.3 (66.3 to 444.4)	111.5 (17.2 to 341.8)
Neonatal sepsis and other neonatal infections	1.0 (0.3 to 2.2)	1.6 (0.5 to 3.2)	63.5 (41.8 to 76.5)	94.4 (68.6 to 109.8)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.5)	113.3 (38.5 to 84.5)	90.2 (64.6 to 119.4)
Hemolytic disease and other neonatal jaundice	51.4 (24.2 to 91.3)	322.3 (149.1 to 557.2)	527.0 (133.8 to 1,584.7)	408.3 (92.9 to 1,272.3)	16.8 (7.6 to 30.2)	83.1 (39.3 to 146.3)	401.3 (94.0 to 1,196.4)	294.2 (55.0 to 893.2)
Other neonatal disorders	-	-	-	-	23.7 (10.9 to 44.1)	50.6 (28.5 to 87.2)	112.7 (-2.4 to 500.1)	60.0 (-24.9 to 347.9)
Nutritional deficiencies	-	-	-	-	2,037.4 (1,375.3 to 2,890.6)	1,546.8 (1,033.1 to 2,225.5)	-24.2 (-47.2 to -20.3)	-45.8 (-47.9 to -43.3)
Protein-energy malnutrition	1,045.0 (796.5 to 1,342.2)	912.2 (608.8 to 1,282.5)	-13.9 (-45.6 to 36.2)	-4.4 (-38.4 to 48.2)	77.2 (77.2 to 196.4)	72.8 (60.7 to 180.8)	-7.9 (-46.2 to 37.6)	-42.9 (-39.3 to 48.7)
Iodine deficiency	4,052.9 (3,640.3 to 4,546.3)	3,763.0 (3,199.6 to 4,313.0)	-7.8 (-23.1 to 9.4)	-43.1 (-52.5 to -31.2)	72.8 (44.8 to 113.9)	67.2 (40.9 to 108.8)	-7.9 (-23.2 to 9.4)	-42.9 (-52.5 to -30.9)
Vitamin A deficiency	94.9 (67.5 to 120.3)	66.7 (46.0 to 85.4)	-29.9 (-42.3 to -19.7)	-45.7 (-54.4 to -37.9)	3.5 (2.0 to 5.7)	2.4 (1.3 to 3.9)	-33.2 (-45.4 to -19.9)	-49.3 (-58.6 to -39.3)

Appendix Table G.4 - Bangladesh prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	47,146.7 (46,522.6 to 47,722.6)	43,102.8 (42,856.3 to 43,346.6)	-9.1 (-10.3 to -7.9)	-7.8 (-8.4 to -7.2)	1,830.6 (1,239.2 to 2,601.2)	1,362.3 (909.8 to 1,969.4)	-25.8 (-28.1 to -22.9)	-47.9 (-49.6 to -45.8)
Other nutritional deficiencies	-	-	-	-	1.5 (0.5 to 4.1)	1.7 (0.7 to 3.3)	17.3 (-62.9 to 178.5)	19.7 (-59.0 to 208.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	106.9 (70.5 to 155.5)	93.5 (61.5 to 135.2)	-13.0 (-23.1 to -0.9)	-36.6 (-43.3 to -28.8)
Sexually transmitted diseases excluding HIV	-	-	-	-	17.4 (11.1 to 28.0)	25.7 (15.8 to 41.9)	48.2 (17.0 to 75.9)	-17.1 (-32.2 to -3.4)
Syphilis	11.0 (10.0 to 12.2)	6.9 (6.1 to 7.9)	-37.5 (-46.8 to -25.0)	-65.0 (-68.7 to -49.5)	2.1 (1.3 to 2.9)	1.3 (0.8 to 1.9)	-36.8 (-43.2 to -16.6)	-44.9 (-53.3 to -55.2)
Chlamydial infection	1,380.4 (1,232.9 to 1,525.1)	2,339.8 (2,109.2 to 2,573.1)	68.2 (46.9 to 92.9)	-1.2 (-12.6 to 11.2)	7.4 (4.2 to 12.6)	11.9 (6.8 to 20.0)	60.1 (30.0 to 95.0)	-6.0 (-22.3 to 11.8)
Gonococcal infection	542.2 (387.4 to 734.1)	826.1 (634.2 to 1,053.4)	52.6 (-0.1 to 115.9)	-7.5 (-37.2 to 31.4)	4.6 (2.3 to 8.2)	6.7 (3.5 to 11.6)	48.4 (-18.3 to 152.6)	-9.9 (-49.5 to 49.5)
Trichomoniasis	974.6 (513.7 to 1,405.7)	1,756.0 (1,202.8 to 2,311.9)	76.4 (2.1 to 284.3)	3.5 (-39.1 to 89.7)	1.6 (0.5 to 3.9)	3.0 (1.1 to 6.5)	78.8 (-4.2 to 358.2)	6.4 (-41.3 to 122.3)
Genital herpes	4,893.7 (3,960.7 to 5,343.0)	8,131.0 (6,752.0 to 9,467.0)	72.5 (38.9 to 110.8)	8.5 (-26.2 to 11.8)	2.2 (0.4 to 3.0)	2.2 (0.7 to 5.5)	71.8 (36.4 to 112.9)	8.0 (-26.3 to 13.9)
Other sexually transmitted diseases	26.1 (18.5 to 36.8)	27.8 (21.2 to 35.2)	8.0 (-15.0 to 29.5)	-45.8 (-56.2 to -34.3)	0.5 (0.3 to 0.7)	0.7 (0.4 to 1.1)	54.7 (1.0 to 159.3)	-17.2 (-44.1 to 29.9)
Hepatitis	-	-	-	-	6.9 (4.4 to 10.0)	8.9 (5.7 to 13.1)	29.9 (15.7 to 47.3)	-16.9 (-27.7 to -5.0)
Hepatitis A	172.5 (164.2 to 180.8)	187.9 (181.7 to 194.2)	8.4 (6.8 to 10.1)	-8.8 (-9.0 to -8.4)	3.5 (2.0 to 5.1)	4.8 (3.0 to 7.0)	36.4 (22.0 to 53.9)	0.0 (-10.3 to 12.8)
Hepatitis B	5,105.8 (4,511.6 to 5,713.2)	4,520.0 (3,764.6 to 5,316.9)	-12.3 (-27.4 to -7.4)	-42.5 (-51.2 to -29.7)	2.2 (1.2 to 3.1)	2.3 (1.4 to 3.7)	14.2 (-15.5 to 54.9)	-34.8 (-54.9 to -13.1)
Hepatitis C	555.0 (504.9 to 611.1)	702.4 (643.7 to 765.4)	26.2 (11.4 to 41.6)	-27.2 (-35.3 to -19.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	23.2 (10.4 to 47.9)	-19.8 (-36.9 to -2.8)
Hepatitis E	44.4 (35.9 to 52.4)	61.3 (52.4 to 72.1)	36.8 (11.1 to 78.0)	-16.9 (-32.4 to 8.3)	1.3 (0.7 to 1.9)	1.7 (1.1 to 2.7)	38.6 (2.9 to 87.1)	-17.2 (-38.1 to 9.7)
Leprosy	11.4 (9.2 to 13.8)	15.6 (13.7 to 17.9)	36.0 (18.7 to 59.9)	-25.8 (-34.0 to -15.6)	0.7 (0.4 to 1.0)	0.9 (0.6 to 1.4)	40.4 (14.0 to 78.7)	-23.3 (-36.8 to -6.4)
Other infectious diseases	2,096.1 (1,707.4 to 2,491.3)	1,741.4 (1,585.0 to 1,950.2)	-17.2 (-28.7 to -5.4)	-37.6 (-45.4 to -29.0)	82.0 (53.5 to 117.7)	57.9 (37.6 to 82.1)	-29.5 (-40.5 to -17.6)	-44.8 (-53.3 to -35.5)
Non-communicable diseases	-	-	-	-	5,767.6 to 10,030.8	9,868.5 to 17,309.5	71.8	71.8
Neoplasms	-	-	-	-	38.5 (27.1 to 51.9)	71.8 (48.9 to 99.9)	86.0 (45.1 to 138.8)	4.0 (-19.4 to 33.5)
Esophageal cancer	6.9 (5.0 to 9.3)	10.0 (6.7 to 15.1)	43.2 (-9.9 to 118.3)	-21.6 (-50.1 to 23.6)	1.1 (0.7 to 1.6)	1.6 (0.9 to 2.5)	40.4 (-8.3 to 111.3)	-23.0 (-51.0 to 16.1)
Stomach cancer	14.6 (11.5 to 18.1)	20.6 (15.7 to 26.4)	40.0 (8.0 to 96.0)	-24.7 (-45.9 to 6.3)	1.9 (1.3 to 2.7)	2.7 (1.8 to 3.8)	39.3 (-6.1 to 93.3)	-24.8 (-46.7 to 5.3)
Liver cancer	-	-	-	-	2.1 (1.3 to 3.1)	4.4 (2.8 to 6.3)	117.5 (36.1 to 211.5)	16.1 (-25.8 to 64.6)
Liver cancer due to hepatitis B	3.2 (1.8 to 5.3)	7.8 (3.7 to 13.3)	137.8 (6.6 to 457.4)	29.4 (-42.8 to 211.0)	0.6 (0.3 to 1.0)	1.3 (0.6 to 2.2)	127.7 (4.8 to 397.7)	22.3 (-43.2 to 182.7)
Liver cancer due to hepatitis C	3.9 (2.4 to 6.2)	12.8 (7.1 to 19.6)	226.7 (47.6 to 532.9)	71.5 (-21.3 to 222.9)	0.7 (0.4 to 1.1)	2.0 (1.1 to 3.2)	208.3 (48.0 to 477.8)	60.6 (-23.8 to 195.4)
Liver cancer due to alcohol use	2.2 (1.3 to 3.4)	2.2 (1.3 to 3.6)	0.1 (-49.1 to 95.3)	-45.7 (-71.8 to 6.2)	0.4 (0.2 to 0.6)	0.6 (0.2 to 0.6)	1.0 (-4.2 to 79.7)	-44.5 (-69.6 to -0.9)
Liver cancer due to other causes	2.6 (1.6 to 4.2)	4.0 (2.4 to 6.4)	56.3 (-29.6 to 201.9)	-11.3 (-60.2 to 71.8)	0.4 (0.3 to 0.7)	0.6 (0.4 to 1.1)	53.4 (-25.9 to 167.1)	-12.0 (-57.9 to 47.5)
Larynx cancer	8.6 (6.1 to 12.2)	12.3 (8.3 to 18.2)	41.4 (-6.7 to 115.9)	-23.1 (-48.3 to 18.0)	0.9 (0.5 to 1.4)	1.2 (0.7 to 1.9)	38.4 (-6.1 to 116.1)	-24.9 (-49.3 to 16.6)
Tracheal, bronchus and lung cancer	13.1 (10.1 to 16.8)	22.8 (17.0 to 29.6)	72.9 (20.6 to 152.6)	-8.3 (-35.5 to 33.3)	2.3 (1.5 to 3.3)	3.8 (2.4 to 5.3)	62.7 (14.1 to 139.2)	-13.3 (-38.8 to 25.7)
Breast cancer	30.5 (22.9 to 40.3)	119.1 (83.1 to 171.6)	283.6 (142.8 to 506.0)	101.1 (27.1 to 221.9)	2.6 (1.7 to 3.8)	9.2 (5.4 to 14.6)	244.3 (118.3 to 456.6)	82.1 (14.5 to 198.5)
Cervical cancer	48.7 (27.7 to 70.8)	54.0 (34.9 to 79.4)	9.0 (-35.3 to 102.9)	-42.6 (-65.6 to -9.0)	3.7 (2.0 to 5.8)	4.1 (2.4 to 6.6)	42.7 (-35.8 to 109.6)	-42.3 (-66.4 to 9.7)
Uterine cancer	10.6 (5.5 to 18.3)	17.1 (9.6 to 32.6)	59.5 (-24.3 to 262.4)	-14.8 (-59.3 to 83.9)	0.7 (0.3 to 1.4)	1.2 (0.6 to 2.3)	56.0 (-23.5 to 249.6)	-16.5 (-58.2 to 78.8)
Prostate cancer	8.7 (5.0 to 17.3)	38.7 (24.4 to 65.1)	351.5 (167.6 to 661.1)	136.3 (46.2 to 284.8)	1.0 (0.5 to 1.8)	3.5 (2.0 to 6.1)	272.8 (131.8 to 518.2)	94.2 (24.1 to 213.6)
Colon and rectum cancer	19.1 (15.9 to 22.9)	48.1 (37.2 to 61.7)	150.2 (84.2 to 243.7)	22.3 (-8.3 to 63.5)	1.8 (1.2 to 2.5)	4.1 (2.7 to 5.8)	124.5 (64.1 to 209.8)	9.5 (-18.2 to 49.8)
Lip and oral cavity cancer	67.3 (46.3 to 98.8)	123.8 (89.0 to 173.4)	83.8 (19.7 to 181.3)	-2.9 (-31.2 to 50.2)	5.8 (3.5 to 9.1)	10.4 (6.5 to 16.0)	81.5 (19.4 to 173.8)	-4.2 (-36.2 to 44.4)
Nasopharynx cancer	6.3 (3.8 to 11.6)	12.5 (8.7 to 17.9)	109.5 (9.7 to 266.5)	11.4 (-34.2 to 91.7)	0.6 (0.3 to 1.1)	1.2 (0.8 to 1.9)	10.1 (10.4 to 245.9)	5.2 (-36.3 to 78.0)
Other pharynx cancer	12.4 (7.2 to 18.7)	19.7 (12.6 to 29.7)	58.4 (-13.1 to 198.5)	-18.3 (-54.7 to 50.9)	1.2 (0.7 to 1.9)	1.8 (1.1 to 2.9)	54.0 (-11.8 to 168.6)	-21.3 (-54.1 to 35.2)
Gallbladder and biliary tract cancer	0.7 (0.5 to 1.1)	1.5 (1.1 to 2.2)	124.5 (49.7 to 222.3)	17.4 (-19.7 to 67.2)	0.2 (0.1 to 0.4)	0.4 (0.3 to 0.7)	110.7 (47.5 to 187.1)	10.3 (-21.3 to 49.9)
Pancreatic cancer	0.5 (0.4 to 0.6)	1.0 (0.7 to 1.3)	92.2 (34.0 to 172.1)	-2.7 (-31.3 to 35.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	77.2 (29.1 to 139.2)	-10.6 (-34.2 to 19.7)
Malignant skin melanoma	4.1 (2.6 to 5.7)	4.9 (3.5 to 7.8)	16.9 (-27.2 to 111.7)	4.9 (-61.1 to 12.6)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	11.0 (-29.5 to 105.9)	-42.2 (-63.4 to 7.6)
Non-melanoma skin cancer	4.7 (3.5 to 5.9)	9.4 (7.2 to 13.1)	95.7 (38.3 to 203.3)	-3.2 (-31.3 to 50.9)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	82.9 (5.4 to 276.2)	-14.2 (-53.6 to 88.6)
Ovarian cancer	8.1 (5.7 to 11.0)	19.1 (12.9 to 27.5)	129.8 (41.1 to 309.7)	22.7 (-25.3 to 118.3)	1.1 (0.7 to 1.7)	2.6 (1.5 to 4.1)	127.9 (33.5 to 308.6)	19.7 (-28.5 to 115.5)
Testicular cancer	5.0 (2.3 to 10.7)	10.2 (2.4 to 28.8)	53.7 (-48.3 to 394.5)	-26.6 (-73.7 to 132.2)	0.3 (0.1 to 0.7)	0.6 (0.1 to 1.8)	47.1 (-51.8 to 366.5)	-30.3 (-75.8 to 123.3)
Kidney cancer	8.0 (1.8 to 5.0)	3.6 (2.6 to 4.7)	26.3 (-34.3 to 118.4)	14.0 (-30.1 to 73.0)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	47.6 (-21.8 to 140.6)	16.8 (-26.5 to 76.0)
Bladder cancer	2.6 (1.4 to 5.2)	9.0 (6.4 to 12.2)	338.8 (60.3 to 616.0)	124.4 (-13.5 to 252.0)	0.2 (0.1 to 0.5)	0.8 (0.5 to 1.2)	310.3 (57.3 to 564.8)	107.2 (-16.3 to 239.1)
Brain and nervous system cancer	6.8 (4.6 to 13.0)	15.2 (10.4 to 22.7)	137.6 (21.7 to 257.6)	39.1 (-25.9 to 103.5)	0.7 (0.4 to 1.5)	1.6 (0.9 to 2.5)	131.6 (19.4 to 249.4)	32.7 (-29.6 to 93.1)
Thyroid cancer	1.3 (0.8 to 2.1)	2.3 (1.6 to 3.5)	91.2 (-9.7 to 247.7)	-3.0 (-51.1 to 99.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	72.6 (-16.3 to 232.8)	-16.9 (-56.2 to 82.3)
Mesothelioma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	12.7 (-25.0 to 74.8)	-37.2 (-58.6 to -9.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.0 (-22.2 to 79.6)	35.1 (-48.5 to 11.2)
Hodgkin lymphoma	17.8 (8.1 to 29.8)	9.3 (6.5 to 14.7)	-50.5 (-73.4 to 55.2)	-53.6 (-73.0 to 33.4)	1.2 (0.6 to 2.2)	0.7 (0.4 to 1.2)	-41.8 (-68.5 to 67.4)	107.2 (70.6 to 31.6)
Non-Hodgkin lymphoma	26.9 (13.2 to 43.4)	55.4 (26.5 to 81.6)	108.8 (25.3 to 197.3)	30.3 (-15.9 to 89.5)	2.3 (1.0 to 3.9)	4.6 (2.0 to 7.7)	102.5 (26.3 to 187.5)	21.1 (-21.1 to 78.7)
Multiple myeloma	0.5 (0.3 to 0.9)	1.1 (0.6 to 2.0)	107.1 (7.6 to 304.2)	7.1 (-42.6 to 104.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	90.9 (7.1 to 255.2)	-1.0 (-43.7 to 81.4)
Leukemia	34.3 (23.9 to 48.3)	38.9 (26.5 to 45.1)	2.2 (-33.3 to 54.6)	-12.3 (-38.9 to 26.7)	3.5 (2.4 to 5.0)	4.3 (2.9 to 6.3)	23.8 (-11.3 to 71.6)	8.6 (-33.7 to 25.3)
Other neoplasms	29.5 (16.0 to 72.5)	76.0 (57.6 to 98.4)	202.3 (-5.9 to 420.7)	20.2 (-18.0 to 229.4)	2.0 (1.0 to 4.7)	5.1 (3.3 to 7.6)	209.9 (8.8 to 408.8)	89.2 (-17.8 to 196.3)
Cardiovascular diseases	-	-	-	-	138.6 (87.8 to 198.6)	314.0 (174.7 to 483.7)	126.6 (38.1 to 236.1)	17.4 (-25.7 to 72.9)
Rheumatic heart disease	302.8 (251.0 to 364.5)	452.2 (394.9 to 513.7)	49.8 (18.4 to 77.3)	-11.6 (-27.6 to 4.3)	19.7 (13.1 to 27.8)	29.4 (19.7 to 41.8)	49.6 (16.1 to 85.8)	-13.1 (-31.3 to 8.0)
Ischemic heart disease	777.6 (610.4 to 1,010.0)	980.8 (859.4 to 1,120.4)	27.1 (-4.1 to 60.2)	-29.2 (-46.2 to -11.5)	43.3 (26.8 to 65.2)	54.4 (36.3 to 77.7)	28.2 (-11.8 to 85.6)	-28.2 (-50.6 to 2.4)
Cerebrovascular disease	-	-	-	-	21.4 (14.7 to 28.3)	41.1 (27.9 to 54.8)	92.9 (51.5 to 135.0)	17.4 (-19.9 to 27.7)
Ischemic stroke	95.2 (81.8 to 111.4)	186.2 (158.1 to 209.3)	96.1 (54.3 to 138.0)	5.0 (-19.1 to 28.2)	14.1 (9.6 to 18.9)	27.5 (18.4 to 37.7)	96.8 (53.1 to 143.5)	5.4 (-18.0 to 30.5)
Hemorrhagic stroke	49.0 (41.7 to 57.4)	90.1 (75.4 to 102.8)	83.3 (43.1 to 125.2)	-1.1 (-25.5 to 22.7)	7.3 (4.8 to 10.0)	13.6 (8.9 to 18.5)	85.5 (43.1 to 133.5)	-0.1 (-23.7 to 27.1)
Hypertensive heart disease	40.8 (25.8 to 56.3)	92.1 (56.0 to 130.3)	123.7 (33.9 to 271.9)	16.7 (-30.2 to 100.2)	4.4 (2.6 to 6.9)	10.7 (5.4 to 15.7)	125.3 (33.6 to 287.5)	18.1 (-29.5 to 104.0)
Cardiomyopathy and myocarditis	37.4 (30.4 to 45.8)	78.6 (65.1 to 97.8)	110.6 (60.5 to 168.4)	14.4 (-15.3 to 50.9)	3.9 (2.4 to 5.6)	8.3 (5.2 to 12.0)	113.2 (57.5 to 180.7)	16.2 (-16.4 to 57.4)
Atrial fibrillation and flutter	15.0 (12.1 to 18.3)	13.4 (10.3 to 16.9)	-11.7 (-36.9 to 29.5)	-49.6 (-64.4 to -25.1)	1.0 (0.8 to 1.7)	1.2 (0.6 to 1.6)	-11.4 (-41.1 to 31.9)	-49.2 (-66.0 to -24.7)
Peripheral vascular disease	2,108.9 (1,500.8 to 2,778.8)	3,608.2 (2,741.0 to 4,391.0)	70.3 (22.2 to 147.1)	-4.2 (-31.7 to 39.4)	1.0 (0.5 to 2.1)	1.9 (0.8 to 3.8)	76.7 (-0.2 to 242.3)	-11.4 (-47.5 to 81.0)
Endocarditis	1.8 (1.2 to 2.5)	4.1 (2.6 to 5.8)	127.8 (69.4 to 210.9)	27.6 (-7.5 to 86.5)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.8)	34.0 (7.7 to 257.7)	17.4 (-11.8 to 108.7)
Other cardiovascular and circulatory diseases	624.5 (202.4 to							

Appendix Table G.4 - Bangladesh prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	3,373.3 (3,207.9 to 3,528.0)	5,728.7 (5,457.9 to 5,991.8)	68.5 (58.7 to 80.7)	-10.1 (-14.7 to -4.3)	91.8 (61.5 to 127.6)	156.1 (105.1 to 214.2)	69.8 (59.4 to 83.0)	-9.4 (-14.1 to -3.3)
Other oral disorders	1,592.2 (1,500.8 to 1,687.5)	2,684.5 (2,526.4 to 2,850.7)	67.6 (54.3 to 81.3)	0.2 (-7.0 to 7.6)	46.5 (29.4 to 69.4)	78.2 (48.7 to 117.6)	67.9 (54.4 to 83.6)	0.8 (-6.8 to 9.3)
Injuries	-	-	-	-	303.8 (226.5 to 416.9)	405.2 (307.1 to 521.5)	35.1 (16.4 to 43.6)	-20.0 (-29.6 to -14.8)
Transport injuries	-	-	-	-	75.4 (57.4 to 97.4)	107.6 (81.0 to 139.2)	42.6 (36.9 to 48.2)	-17.0 (-20.0 to -13.8)
Road injuries	-	-	-	-	47.5 (36.0 to 61.2)	75.3 (57.0 to 97.9)	59.9 (52.7 to 67.2)	-6.2 (-9.7 to -2.1)
Pedestrian road injuries	-	-	-	-	15.2 (11.5 to 19.5)	28.3 (21.1 to 36.7)	85.3 (72.9 to 99.7)	10.5 (4.5 to 17.2)
Cyclist road injuries	-	-	-	-	5.2 (3.9 to 6.7)	7.4 (5.6 to 9.7)	42.0 (31.2 to 53.6)	-14.5 (-20.9 to -7.9)
Motorcyclist road injuries	-	-	-	-	9.0 (6.7 to 11.6)	6.8 (5.1 to 9.0)	-24.2 (-30.0 to -18.0)	-55.2 (-58.5 to -52.0)
Motor vehicle road injuries	-	-	-	-	17.1 (13.0 to 21.9)	32.2 (24.2 to 41.7)	88.1 (74.0 to 104.2)	8.3 (1.2 to 16.6)
Other road injuries	-	-	-	-	0.9 (0.7 to 1.1)	1.1 (0.8 to 1.5)	28.5 (20.7 to 38.2)	-27.7 (-31.6 to -23.0)
Other transport injuries	-	-	-	-	27.9 (21.1 to 36.2)	31.7 (23.9 to 41.0)	13.5 (5.5 to 21.6)	-34.3 (-39.3 to -29.4)
Unintentional injuries	-	-	-	-	162.7 (124.0 to 208.4)	252.9 (193.3 to 324.0)	55.4 (50.5 to 60.6)	-8.1 (-11.0 to -5.1)
Falls	-	-	-	-	80.9 (61.5 to 104.2)	144.4 (109.0 to 185.0)	78.3 (70.2 to 87.3)	1.7 (-3.0 to 6.9)
Drowning	-	-	-	-	22.4 (16.6 to 29.2)	25.9 (19.1 to 33.5)	15.7 (6.2 to 25.7)	-29.2 (-34.0 to -24.2)
Fire, heat, and hot substances	-	-	-	-	18.1 (14.0 to 23.0)	18.5 (14.3 to 23.2)	1.9 (-6.9 to 12.1)	-41.5 (-45.8 to -36.5)
Poisonings	-	-	-	-	0.7 (0.5 to 1.0)	0.5 (0.4 to 0.7)	-26.2 (-38.7 to -11.0)	-54.0 (-60.7 to -46.0)
Exposure to mechanical forces	-	-	-	-	12.4 (9.3 to 16.1)	23.3 (17.7 to 30.5)	88.4 (78.2 to 98.4)	10.0 (5.4 to 15.2)
Unintentional firearm injuries	-	-	-	-	0.5 (0.4 to 0.6)	1.0 (0.8 to 1.3)	106.6 (91.5 to 121.9)	14.3 (7.2 to 22.2)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	118.5 (94.6 to 146.6)	29.5 (17.8 to 43.0)
Other exposure to mechanical forces	-	-	-	-	11.8 (8.8 to 15.3)	22.0 (16.7 to 28.8)	87.4 (76.7 to 97.8)	9.6 (4.9 to 15.1)
Adverse effects of medical treatment	-	-	-	-	1.9 (1.2 to 2.8)	2.9 (1.8 to 4.3)	53.7 (44.9 to 62.8)	-9.4 (-14.8 to -3.7)
Animal contact	-	-	-	-	6.6 (4.9 to 8.4)	5.9 (4.4 to 7.7)	9.9 (-15.8 to -3.5)	-46.5 (-49.6 to -43.4)
Venomous animal contact	-	-	-	-	2.7 (1.9 to 3.6)	2.5 (1.8 to 3.3)	-8.7 (-19.4 to 2.9)	-46.9 (-52.6 to -41.3)
Non-venomous animal contact	-	-	-	-	3.9 (2.9 to 5.2)	3.4 (2.6 to 4.6)	-10.6 (-16.8 to -4.2)	-46.3 (-49.0 to -43.3)
Foreign body	-	-	-	-	4.2 (3.2 to 5.4)	6.8 (5.2 to 8.6)	59.6 (51.2 to 68.9)	-8.5 (-13.2 to -3.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.6 (0.5 to 0.8)	0.9 (0.7 to 1.2)	43.6 (28.0 to 60.0)	-7.6 (-14.6 to -0.0)
Foreign body in eyes	-	-	-	-	0.9 (0.5 to 1.3)	1.4 (0.9 to 2.2)	65.7 (48.1 to 85.0)	1.6 (-7.5 to 10.9)
Foreign body in other body part	-	-	-	-	2.7 (2.0 to 3.5)	4.4 (3.3 to 5.7)	61.8 (50.8 to 73.7)	-11.1 (-16.9 to -4.0)
Other unintentional injuries	-	-	-	-	15.5 (11.8 to 20.0)	24.7 (18.5 to 32.1)	59.8 (50.1 to 71.0)	-6.8 (-12.1 to -1.2)
Self-harm and interpersonal violence	-	-	-	-	6.5 (4.9 to 8.3)	10.0 (7.6 to 12.8)	55.1 (47.6 to 63.2)	-14.5 (-18.1 to -10.6)
Self-harm	-	-	-	-	1.6 (1.1 to 2.1)	1.9 (1.4 to 2.5)	18.9 (7.7 to 31.6)	-34.8 (-40.5 to -28.6)
Interpersonal violence	-	-	-	-	4.9 (3.7 to 6.2)	8.1 (6.2 to 10.3)	66.7 (57.4 to 77.0)	-7.9 (-12.6 to -3.1)
Assault by firearm	-	-	-	-	0.8 (0.6 to 1.0)	1.0 (0.8 to 1.3)	36.8 (27.8 to 46.8)	-23.1 (-27.7 to -18.3)
Assault by sharp object	-	-	-	-	1.2 (0.9 to 1.5)	1.9 (1.4 to 2.5)	64.8 (51.3 to 78.7)	-10.6 (-17.3 to -3.6)
Assault by other means	-	-	-	-	3.0 (2.3 to 3.7)	5.2 (3.9 to 6.6)	75.2 (63.4 to 88.8)	-2.7 (-8.6 to 4.1)
Forces of nature, war, and legal intervention	-	-	-	-	59.2 (23.3 to 145.3)	34.7 (13.8 to 81.8)	-41.4 (-47.0 to -36.7)	-62.0 (-67.1 to -57.6)
Exposure to forces of nature	-	-	-	-	59.2 (23.3 to 145.3)	34.7 (13.7 to 81.8)	-41.4 (-47.0 to -36.8)	-62.0 (-67.1 to -57.6)
Collective violence and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	3,782.4 (862.9 to 9,010.8)	5,526.0 (1,319.5 to 12,665.3)

Appendix Table G.4 - Barbados prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	27.1 (20.1 to 35.3)	33.3 (24.8 to 43.2)	22.7 (19.7 to 25.9)	0.2 (-1.9 to 2.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.6 (1.8 to 3.6)	2.6 (1.8 to 3.6)	-0.4 (-6.7 to 6.7)	-0.6 (-6.6 to 6.2)
HIV/AIDS and tuberculosis	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	61.3 (9.7 to 107.5)	31.8 (-11.9 to 69.7)
Tuberculosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	13.6 (7.3 to 19.9)	-8.2 (-12.9 to -3.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	12.4 (-0.9 to 27.6)	-8.6 (-19.3 to 3.5)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	112.0 (10.3 to 227.1)	74.6 (-11.9 to 175.7)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.2 (-53.1 to 51.7)	-23.7 (-63.2 to 23.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.2 (-53.2 to 51.9)	-23.7 (-63.2 to 23.1)
HIV/AIDS resulting in other diseases	0.4 (0.2 to 0.7)	1.2 (0.8 to 1.7)	225.1 (104.3 to 363.7)	180.5 (71.3 to 304.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	113.6 (10.3 to 231.8)	76.6 (-11.8 to 180.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.2 (0.3 to 0.7)	0.2 (0.3 to 0.6)	-6.7 (-13.3 to -0.1)	-8.5 (-15.2 to -2.0)
Diarrheal diseases	1.4 (1.3 to 1.5)	1.4 (1.3 to 1.5)	1.5 (-7.5 to 11.5)	1.4 (-7.7 to 11.5)	0.0 (0.1 to 0.3)	0.0 (0.2 to 0.3)	0.0 (-9.6 to 11.4)	0.0 (-8.9 to 11.7)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.7 (-60.2 to -7.2)	-24.3 (-60.6 to -8.0)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.7 (-36.5 to -8.1)	-24.3 (-36.4 to -9.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.7 (-36.5 to -8.1)	-24.3 (-36.5 to -9.7)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.8 (-36.9 to -2.7)	-22.1 (-36.0 to -3.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.9 (-37.0 to -2.7)	-22.1 (-36.1 to -3.0)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.1 (-98.5 to 169.0)	-52.5 (-98.5 to 169.0)
Lower respiratory infections	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-37.4 (-61.9 to 10.0)	-47.2 (-68.3 to -5.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.5 (-63.3 to 9.9)	-48.6 (-69.0 to -4.8)
Upper respiratory infections	12.8 (11.7 to 14.0)	13.0 (11.8 to 14.2)	0.9 (-11.6 to 15.8)	-3.9 (-15.6 to 9.4)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	0.7 (-12.0 to 14.9)	-3.9 (-15.5 to 9.4)
Otitis media	2.8 (2.6 to 2.9)	2.5 (2.4 to 2.7)	-8.8 (-15.0 to -2.3)	-11.4 (-17.2 to -5.2)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-9.9 (-17.1 to -2.5)	-12.4 (-19.1 to -5.6)
Meningitis	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-60.2 (-68.4 to -50.6)	-62.4 (-69.9 to -53.4)
Pneumococcal meningitis	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.1)	-63.0 (-70.1 to -48.7)	-67.9 (-73.9 to -55.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-62.2 (-72.4 to -43.0)	-63.4 (-74.4 to -47.2)
H influenzae type B meningitis	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-64.5 (-78.3 to -32.1)	-66.6 (-79.4 to -32.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.1 (-81.1 to -16.2)	-60.8 (-81.0 to -15.8)
Meningococcal meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.3 (-70.7 to -27.8)	-62.7 (-73.7 to -31.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-55.4 (-71.7 to -23.8)	-59.2 (-73.8 to -27.5)
Other meningitis	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-60.4 (-72.2 to -48.0)	-63.9 (-73.9 to -51.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-60.2 (-76.3 to -39.5)	-62.5 (-77.2 to -43.8)
Encephalitis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-71.1 (-22.2 to 18.2)	-71.1 (-35.0 to 0.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.5 (-23.5 to 32.4)	-2.1 (-36.2 to 13.0)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.5 (-92.0 to 509.7)	-35.4 (-93.0 to 511.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.5 (-92.1 to 510.8)	-35.4 (-92.1 to 513.9)
Whooping cough	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-23.3 (-23.8 to -22.7)	-12.3 (-12.9 to -11.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.6 (-33.8 to -12.4)	-12.7 (-24.3 to -0.0)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-78.8 (-90.2 to -56.6)	-80.7 (-91.1 to -60.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-75.6 (-89.6 to -49.7)	-77.1 (-90.2 to -53.8)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	11.2 (-12.1 to 39.2)	-2.1 (-19.3 to 20.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.7 (-11.7 to 88.3)	4.0 (-34.9 to 39.9)
Neglected tropical diseases and malaria	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-25.8 (-47.4 to 5.2)	-19.4 (-39.6 to 10.2)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.6 (-34.6 to 79.6)	11.4 (-35.7 to 77.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.8 (-35.3 to 81.3)	13.0 (-36.2 to 78.8)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.2 (-25.2 to 167.5)	6.9 (-30.8 to 139.2)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.6 (-48.1 to 103.9)	-1.9 (-49.1 to 117.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.6 (-48.4 to 104.5)	-1.9 (-49.1 to 119.0)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	18.5 (-22.5 to 187.0)	6.0 (-28.2 to 149.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.8 (-26.7 to 184.5)	7.2 (-33.3 to 156.2)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-78.9 (-93.7 to -42.8)	-81.9 (-94.7 to -52.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-78.1 (-93.5 to -41.9)	-81.1 (-94.3 to -50.9)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.1 (-35.4 to -27.0)	-46.6 (-49.2 to -43.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.1 (-41.6 to -12.9)	-44.7 (-54.3 to -31.1)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.4)	213.6 (188.0 to 245.7)	192.8 (169.0 to 222.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	206.1 (142.8 to 319.3)	188.6 (131.6 to 298.0)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.7 (-46.9 to 22.9)	-23.1 (-52.5 to 10.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.7 (-47.0 to 23.1)	-23.1 (-52.5 to 10.9)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.2 (-16.7 to 60.3)	5.8 (-29.1 to 37.0)
Ascariasis	-	-	-	-	17.1 (-28.9 to 90.7)	0.0 (-39.3 to 62.9)	-	-
Trichuriasis	-	-	-	-	18.1 (-31.1 to 94.4)	1.0 (-41.2 to 66.1)	-	-
Hookworm disease	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	15.5 (-25.4 to 82.1)	-1.3 (-36.2 to 55.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.2 (-16.7 to 60.3)	5.8 (-29.1 to 37.0)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	2.4 (1.9 to 3.0)	2.2 (2.1 to 2.3)	-9.3 (-26.2 to 16.1)	-2.5 (-20.8 to 24.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-14.0 (-22.9 to 26.9)	-2.6 (-12.5 to 44.1)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.1 (-18.5 to 23.2)	12.9 (-7.4 to 38.5)
Maternal hemorrhage	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.1 (20.9 to 59.1)	53.0 (34.1 to 75.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.9 (10.6 to 58.8)	52.6 (23.7 to 75.3)
Maternal sepsis and other maternal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.2 (-29.4 to 18.2)	-9.6 (-35.2 to 11.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.0 (-34.8 to 10.2)	-11.4 (-32.9 to 14.7)
Maternal hypertensive disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.9 (-14.1 to 9.7)	10.4 (-1.1 to 22.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.4 (-30.9 to 36.2)	9.1 (-21.2 to 53.5)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.9 (-42.4 to 36.3)	1.5 (-33.7 to 58.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.9 (-42.5 to 36.5)	1.5 (-33.9 to 58.9)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.2 (-37.8 to 82.3)	17.9 (-30.5 to 107.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.2 (-37.9 to 83.0)	17.9 (-30.6 to 108.3)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.1 (-38.7 to 62.7)	10.6 (-30.5 to 82.7)
Neonatal disorders	-	-	-	-	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.7)	42.5 (2.5 to 101.3)	37.0 (-1.2 to 94.1)
Preterm birth complications	1.2 (0.6 to 2.3)	2.5 (1.4 to 4.8)	112.0 (56.8 to 186.4)	97.4 (46.4 to 165.4)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	100.4 (14.6 to 227.7)	90.3 (9.6 to 212.2)
Neonatal encephalopathy due to birth asphyxia and trauma	1.3 (0.5 to 3.4)	1.1 (0.4 to 2.6)	-21.1 (-43.8 to 14.3)	-26.3 (-47.5 to 5.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-18.5 (-51.3 to 34.6)	-19.3 (-54.1 to 33.0)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.5 (47.2 to 107.0)	91.7 (67.4 to 135.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.8 (45.5 to 110.1)	92.8 (65.5 to 139.0)
Hemolytic disease and other neonatal jaundice	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.3)	3.4 (-55.0 to 153.6)	-1.3 (-56.6 to 141.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	4.7 (-55.5 to 156.6)	-0.1 (-57.7 to 145.8)
Other neonatal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	105.4 (2.8 to 315.5)	97.7 (-0.9 to 301.2)
Nutritional deficiencies	-	-	-	-	1.4 (1.0 to 2.1)	1.3 (0.9 to 1.9)	-9.0 (-12.3 to -6.5)	-6.2 (-9.2 to -3.3)
Protein-energy malnutrition	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-34.1 (-69.3 to 38.9)	-26.4 (-67.4 to 58.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-33.9 (-69.8 to 41.3)	-25.9 (-67.2 to 61.7)
Iodine deficiency	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-29.0 (-49.8 to -1.0)	-36.0 (-55.0 to -11.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.2 (-51.3 to -0.5)	-36.1 (-55.8 to -11.0)
Vitamin A deficiency	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.4 (-60.3 to -47.0)	-55.1 (-60.7 to -48.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.6 (-60.1 to -40.5)	-56.2 (-63.3 to -47.9)

Appendix Table G.4 - Barbados prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	46.3 (45.7 to 47.0)	45.0 (44.4 to 45.5)	-2.9 (-4.5 to -1.2)	-4.6 (-6.3 to -3.0)	1.4 (0.9 to 2.0)	1.3 (0.8 to 1.9)	-5.2 (-11.3 to -6.4)	-5.4 (-8.1 to -3.6)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-64.9 to 203.6)	25.6 (-62.4 to 244.6)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-5.6 (-13.3 to 4.4)	-4.9 (-11.7 to 4.9)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.0 to 0.1)	-1.3 (-11.8 to 9.6)	-7.0 (-16.3 to 3.1)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.9 (4.3 to 48.2)	-10.7 (-24.1 to 7.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.7 (-1.2 to 74.2)	-10.1 (-35.8 to 28.7)
Chlamydia infection	7.9 (6.7 to 9.2)	6.8 (5.7 to 7.9)	-12.9 (-32.9 to 8.4)	-9.6 (-30.3 to 11.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-5.7 (-21.2 to 12.5)	-3.3 (-19.1 to 15.8)
Gonococcal infection	1.0 (0.8 to 1.2)	0.8 (0.6 to 1.0)	-18.0 (-43.5 to 25.2)	-10.6 (-38.5 to 36.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.1 (-48.6 to 15.6)	-18.7 (-44.0 to 23.8)
Trichomoniasis	2.0 (1.4 to 2.8)	1.7 (1.2 to 2.2)	-14.4 (-51.9 to 33.3)	-16.2 (-53.1 to 29.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.8 (-58.7 to 33.8)	-19.7 (-59.8 to 32.3)
Genital herpes	69.1 (65.1 to 72.8)	82.9 (78.2 to 87.2)	20.1 (10.6 to 29.7)	-5.9 (-13.2 to 21.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	16.3 (4.3 to 27.3)	46.7 (-13.9 to 2.6)
Other sexually transmitted diseases	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-15.4 (-26.4 to -2.0)	-24.0 (-35.4 to -10.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-21.5 to 47.2)	-1.2 (-26.6 to 36.2)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.1 (-36.7 to -3.4)	-29.5 (-42.6 to -13.9)
Hepatitis A	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.2)	-6.1 (-6.2 to -6.0)	-5.3 (-5.9 to -4.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.0 (-13.6 to 10.0)	-4.3 (-15.4 to 7.5)
Hepatitis B	13.6 (10.6 to 16.6)	7.9 (6.0 to 10.1)	-41.6 (-62.0 to -17.8)	-49.6 (-66.6 to -30.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.2 (-62.2 to -7.2)	-51.6 (-72.2 to -25.3)
Hepatitis C	5.0 (4.5 to 5.6)	4.7 (4.3 to 5.1)	-5.3 (-17.9 to 10.0)	-26.3 (-36.0 to -14.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.7 (-34.9 to 29.1)	-30.5 (-49.7 to -3.3)
Hepatitis E	-	-	-	-	-	-	-	-
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.3 (-13.8 to 28.7)	-26.4 (-37.8 to -7.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.9 (-16.6 to 21.8)	-29.7 (-40.1 to -12.8)
Other infectious diseases	1.8 (1.5 to 1.9)	1.7 (1.6 to 1.8)	-7.0 (-13.0 to 0.8)	-2.7 (-8.8 to 5.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-6.3 (-17.1 to 14.9)	2.8 (-8.6 to 25.7)
Non-communicable diseases	-	-	-	-	22.9 (17.0 to 29.7)	29.1 (21.7 to 37.8)	27.3 (23.8 to 31.2)	2.2 (-0.3 to 4.9)
Neoplasms	-	-	-	-	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	91.6 (46.8 to 137.1)	41.2 (8.7 to 74.3)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.4 (-14.0 to 61.6)	-15.3 (-37.5 to 16.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.7 (-14.3 to 63.2)	-15.4 (-37.9 to 16.8)
Stomach cancer	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-22.8 (-39.4 to -1.1)	-42.0 (-54.5 to -25.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.9 (-42.0 to -1.5)	-43.3 (-56.0 to -25.2)
Liver cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	465.5 (170.1 to 909.8)	296.1 (93.1 to 603.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	352.5 (244.4 to 526.3)	237.0 (150.0 to 356.0)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,391.2 (704.6 to 2,742.8)	990.4 (491.6 to 1,953.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,303.4 (738.6 to 2,476.2)	933.1 (527.6 to 1,764.0)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	125.5 (26.4 to 287.8)	65.3 (-5.8 to 185.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.5 (30.7 to 233.2)	56.8 (-3.0 to 146.8)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.7 (17.7 to 318.7)	122.1 (-13.9 to 205.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.0 (24.6 to 257.5)	55.9 (-8.9 to 164.5)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	45.9 (4.6 to 99.3)	-3.3 (-30.5 to 31.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.4 (-6.5 to 101.8)	-3.7 (-33.5 to 33.7)
Larynx cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	27.9 (1.1 to 63.0)	-10.0 (-29.1 to 13.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.9 (-3.4 to 62.5)	-11.7 (-32.4 to 14.5)
Tracheal, bronchus and lung cancer	0.6 (0.6 to 0.8)	1.1 (0.8 to 1.5)	73.2 (24.0 to 138.3)	13.7 (-18.2 to 54.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	69.2 (21.5 to 130.6)	13.1 (-18.2 to 55.8)
Breast cancer	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.4)	-17.5 (-44.8 to 27.7)	49.5 (-62.3 to 12.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.0 (-45.5 to 26.6)	49.4 (-6.2 to -12.6)
Cervical cancer	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.4)	143.5 (4.5 to 290.3)	58.0 (-32.3 to 154.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	135.1 (1.4 to 282.4)	55.9 (-33.7 to 148.2)
Uterine cancer	0.7 (0.5 to 1.1)	2.5 (1.5 to 3.6)	240.2 (85.3 to 449.4)	163.0 (42.5 to 322.8)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	195.9 (62.5 to 358.0)	133.0 (28.4 to 264.1)
Prostate cancer	0.4 (0.3 to 0.4)	0.7 (0.6 to 0.8)	90.9 (49.5 to 139.4)	40.9 (10.0 to 76.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	84.1 (42.7 to 132.1)	37.3 (6.7 to 73.3)
Colon and rectum cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	31.0 (-8.1 to 78.7)	9.2 (-35.0 to 24.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.5 (-10.0 to 74.3)	-10.9 (-37.1 to 20.6)
Lip and oral cavity cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.5 (-25.5 to 47.6)	-28.5 (-48.6 to 2.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-28.5 to 39.0)	-30.2 (-49.7 to -3.5)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.3 (-9.6 to 94.2)	-17.2 (-42.2 to 22.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.1 (-10.3 to 89.9)	-17.7 (-41.8 to 19.9)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-60.3 (-74.4 to 4.1)	-69.9 (-80.8 to -21.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.7 (-74.9 to 9.0)	-69.3 (-81.1 to -18.9)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	406.5 (392.6 to 799.7)	406.5 (270.4 to 569.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	514.6 (344.5 to 705.1)	359.6 (230.3 to 505.1)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.6 (-28.9 to 51.1)	-2.6 (-48.7 to 6.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.5 (-31.2 to 48.0)	-30.9 (-50.2 to 6.0)
Malignant skin melanoma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	108.2 (44.4 to 205.0)	53.7 (6.9 to 129.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	136.6 (42.3 to 310.9)	83.7 (12.2 to 223.9)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	382.4 (242.9 to 579.3)	249.6 (148.5 to 391.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	362.9 (211.4 to 593.4)	237.1 (126.8 to 402.0)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	347.2 (-14.2 to 845.8)	297.7 (-22.8 to 723.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	322.9 (-17.3 to 825.8)	273.1 (-27.6 to 727.9)
Kidney cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	163.9 (-9.7 to 51.2)	-18.4 (-37.0 to 4.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.0 (-13.1 to 51.8)	19.8 (-38.8 to 6.0)
Bladder cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-11.2 (-35.0 to 36.2)	-32.7 (-50.8 to 4.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.8 (-36.1 to 34.1)	-33.6 (-51.3 to 2.0)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	354.1 (49.1 to 671.4)	354.1 (23.8 to 540.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	451.8 (39.7 to 628.1)	342.3 (14.2 to 491.6)
Thyroid cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	88.2 (31.5 to 161.2)	37.3 (-4.2 to 87.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.6 (25.6 to 153.0)	33.4 (-8.7 to 83.6)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	148.6 (88.4 to 221.5)	85.8 (41.0 to 141.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	156.5 (95.8 to 228.7)	94.4 (47.7 to 147.9)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	801.8 (16.7 to 1,308.1)	713.8 (7.5 to 1,244.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	815.6 (11.5 to 1,244.3)	712.7 (2.3 to 1,103.9)
Non-Hodgkin lymphoma	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	76.7 (28.6 to 138.9)	27.7 (-6.5 to 71.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.2 (19.8 to 129.2)	23.1 (-11.8 to 65.3)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	107.0 (25.5 to 251.9)	41.2 (-13.8 to 140.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.5 (21.0 to 245.8)	35.6 (-17.1 to 133.3)
Leukemia	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	48.3 (11.4 to 91.9)	20.7 (-9.9 to 60.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.0 (12.3 to 88.0)	37.0 (-9.4 to 51.2)
Other neoplasms	0.3 (0.2 to 0.3)	0.6 (0.5 to 0.8)	121.3 (69.7 to 192.4)	70.6 (31.2 to 128.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	112.3 (63.4 to 182.6)	63.4 (27.2 to 116.9)
Cardiovascular diseases	-	-	-	-	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.0)	75.9 (46.4 to 115.1)	30.9 (9.3 to 59.9)
Rheumatic heart disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.1 (15.3 to 59.2)	-4.8 (-18.3 to 10.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.4 (15.2 to 61.5)	-4.4 (-18.3 to 12.0)
Ischemic heart disease	2.3 (2.0 to 2.7)	6.0 (4.8 to 7.4)	153.5 (94.3 to 233.8)	82.5 (38.3 to 139.4)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	185.6 (103.3 to 306.3)	105.4 (44.7 to 191.7)
Cerebrovascular disease	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	35.3 (10.9 to 59.4)	1.0 (-16.9 to 18.6)
Ischemic stroke	0.6 (0.6 to 0.7)	0.9 (0.7 to 1.0)	31.7 (7.6 to 58.7)	-0.4 (-18.7 to 19.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	32.7 (8.0 to 61.0)	-0.5 (-18.7 to 20.8)
Hemorrhagic stroke	0.2 (0.2 to 0.2)	0.3 (0.2 to 0.3)	42.0 (3.2 to 88.1)	4.0 (-24.8 to 38.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	42.3 (5.0 to 89.5)	3.6 (-23.8 to 38.9)
Hypertensive heart disease	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.4)	19.5 (6.0 to 36.0)	-11.8 (-21.5 to 0.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.5 (5.6 to 38.4)	-11.6 (-22.4 to 1.5)
Cardiomyopathy and myocarditis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	56.3 (33.3 to 83.7)	12.5 (-4.0 to 31.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.4 (30.5 to 90.5)	12.8 (-6.3 to 36.3)
Atrial fibrillation and flutter	1.0 (0.8 to 1.2)	1.5 (1.2 to 1.9)	61.0 (18.9 to 108.3)	29.3 (-3.7 to 68.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	62.1 (16.8 to 111.1)	29.4 (-4.9 to 69.1)
Peripheral vascular disease	9.4 (7.1 to 11.9)	13.5 (10.1 to 16.4)	45.6 (0.5 to 98.4)	-4.0 (-33.6 to 29.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.3 (-47.0 to 296.3)	-0.6 (-55.4 to 233.3)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.2 (-16.5 to 43.3)	-10.0 (-34.3 to 11.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.1 (-18.6 to 51.8)	-7.0 (-37.2 to 16.7)
Other cardiovascular and circulatory diseases	1.1 (0.5 to 1.9)	1.4 (1.2 to 1.7)	34.7 (-29.0 to 179.6)	34.1 (-46.8 to 107.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	34.5 (-29.4 to 176.2)	0.2 (-46.8 to 105.0)
Chronic respiratory diseases	-	-	-	-	2.1 (1.5 to 2.9)	2.8 (1.9 to 3.8)	30.2 (15.1 to 49.1)	4.3 (-7.2 to 19.3)
Chronic obstructive pulmonary disease	13.3 (12.7 to 13.9)	18.6 (17.7 to 19.5)	39.6 (35.5 to 44.4)	0.4 (-2.5 to 3.8)	0.8 (0.5 to 1.1)	1.3 (0.8 to 1.8)	59.8 (35.7 to 95.0)	14.7 (-3.0 to 40.3)

Appendix Table G.4 - Barbados prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.3 (29.5 to 41.7)	-1.3 (-5.4 to 3.0)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.5 (21.0 to 30.1)	-7.8 (-11.0 to -4.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.2 (20.6 to 29.9)	-8.1 (-11.2 to -4.9)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.4 (33.6 to 54.6)	3.8 (-2.8 to 12.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.9 (32.9 to 54.0)	3.4 (-3.5 to 11.9)
Asthma	29.6 (26.4 to 32.6)	33.4 (30.4 to 37.0)	12.7 (-2.8 to 31.8)	-2.3 (-15.4 to 14.5)	1.3 (0.8 to 1.8)	1.5 (0.9 to 2.1)	12.0 (3.6 to 31.7)	-2.4 (-15.6 to 15.2)
Interstitial lung disease and pulmonary sarcoidosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.3 (-2.1 to 86.4)	3.2 (-25.5 to 39.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.6 (-2.0 to 86.9)	3.3 (-26.1 to 39.0)
Other chronic respiratory diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	35.8 (-14.2 to 122.2)	-1.9 (-38.6 to 59.4)
Cirrhosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.8 (22.0 to 57.9)	1.0 (-10.6 to 15.0)
Cirrhosis due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.5 (-34.0 to 100.1)	-14.7 (52.7 to 42.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.1 (-38.3 to 109.5)	-13.6 (-54.6 to 49.2)
Cirrhosis due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.5 (6.8 to 140.1)	19.9 (-26.1 to 70.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.4 (1.9 to 149.9)	20.8 (-28.6 to 81.1)
Cirrhosis due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.3 (-18.9 to 67.2)	-22.7 (-45.6 to 11.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.1 (-24.9 to 74.2)	22.4 (-49.6 to 17.7)
Cirrhosis due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.5 (15.3 to 103.5)	29.0 (-9.4 to 67.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.5 (2.4 to 113.5)	27.3 (-11.5 to 81.0)
Digestive diseases	-	-	-	-	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.8)	37.3 (27.8 to 48.5)	4.6 (-2.8 to 13.3)
Peptic ulcer disease	2.6 (2.4 to 2.8)	2.0 (1.7 to 2.2)	-25.5 (-33.8 to -16.5)	-44.2 (-50.9 to -37.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-16.1 (-26.6 to -5.9)	-39.0 (-46.9 to -31.4)
Gastritis and duodenitis	6.5 (6.2 to 6.8)	8.0 (7.6 to 8.3)	22.9 (14.7 to 30.6)	-3.3 (-10.3 to 3.5)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.4)	18.5 (10.4 to 29.2)	-7.1 (-14.5 to 1.9)
Appendicitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.0 (-26.7 to 28.0)	-6.9 (-27.2 to 28.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.9 (-29.6 to 35.5)	-6.6 (-29.5 to 32.6)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.8 (-7.7 to 92.5)	15.6 (-19.4 to 84.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.6 (-11.2 to 94.9)	15.2 (-23.9 to 88.0)
Inguinal, femoral, and abdominal hernia	1.1 (1.0 to 1.3)	0.8 (0.7 to 1.0)	-28.1 (-42.9 to -6.5)	-44.1 (-55.1 to -26.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.4 (-42.5 to -4.4)	-43.8 (-54.9 to -26.1)
Inflammatory bowel disease	0.3 (0.3 to 0.3)	0.6 (0.5 to 0.6)	69.4 (60.9 to 79.4)	27.3 (20.8 to 34.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	68.6 (54.8 to 84.2)	27.1 (16.4 to 38.6)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.3 (-29.3 to 107.7)	-4.2 (-44.1 to 57.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.3 (-29.3 to 108.6)	-4.2 (-44.3 to 57.7)
Gallbladder and biliary diseases	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	-2.0 (-17.3 to 14.2)	-3.5 (-43.5 to -22.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.2 (-18.3 to 16.4)	-33.7 (-44.7 to -21.5)
Pancreatitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.0 (83.2 to 110.9)	53.7 (43.2 to 64.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.8 (49.8 to 153.8)	52.8 (18.3 to 95.4)
Other digestive diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	529.7 (334.6 to 683.1)	380.1 (232.4 to 495.9)
Neurological disorders	-	-	-	-	1.9 (1.3 to 2.6)	2.3 (1.6 to 3.2)	23.3 (6.7 to 41.5)	4.4 (-9.5 to 19.5)
Alzheimer disease and other dementias	2.8 (2.5 to 3.1)	3.4 (3.0 to 3.8)	20.7 (1.9 to 42.8)	-1.7 (-17.0 to 16.4)	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.6)	20.0 (0.5 to 42.7)	-4.3 (-17.5 to 16.9)
Parkinson disease	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	28.8 (18.3 to 39.4)	-1.8 (-7.6 to 5.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.5 (7.7 to 57.2)	-1.9 (-18.3 to 18.4)
Epilepsy	0.5 (0.3 to 0.7)	0.7 (0.4 to 1.0)	35.5 (-22.7 to 148.3)	21.5 (-31.6 to 123.1)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.4)	37.2 (-24.7 to 154.9)	24.1 (-31.7 to 131.8)
Multiple sclerosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	147.5 (122.8 to 173.4)	81.8 (63.6 to 100.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	136.1 (94.2 to 185.9)	74.4 (43.0 to 111.8)
Migraine	28.2 (24.1 to 32.2)	31.9 (26.4 to 36.0)	9.9 (-13.6 to 39.9)	6.1 (-24.6 to 20.7)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.6)	6.9 (-14.4 to 38.6)	-6.0 (-25.0 to 20.6)
Tension-type headache	54.9 (44.2 to 65.0)	65.5 (61.1 to 69.8)	18.4 (-1.5 to 49.0)	3.7 (-14.4 to 28.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	17.9 (-2.5 to 50.5)	3.8 (-14.2 to 29.0)
Medication overuse headache	1.2 (0.8 to 1.8)	2.4 (1.5 to 3.3)	93.5 (31.5 to 173.3)	49.4 (1.4 to 107.7)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	91.0 (29.7 to 175.1)	49.0 (0.8 to 109.9)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.1 (-10.5 to 77.4)	1.2 (-25.0 to 44.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	5.1 (-26.2 to 49.3)	-14.1 (-39.5 to 21.9)
Mental and substance use disorders	-	-	-	-	6.5 (4.7 to 8.6)	7.4 (5.3 to 9.7)	12.6 (8.0 to 16.7)	-0.5 (-2.8 to 1.8)
Schizophrenia	0.8 (0.7 to 0.8)	1.0 (0.9 to 1.1)	28.8 (22.4 to 35.3)	-0.1 (-4.5 to 3.9)	0.6 (0.4 to 0.6)	0.7 (0.5 to 0.8)	27.9 (19.1 to 36.8)	0.1 (-6.3 to 6.1)
Alcohol use disorders	1.6 (1.5 to 1.7)	2.1 (1.9 to 2.2)	30.2 (23.9 to 37.8)	8.5 (3.7 to 13.6)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	29.7 (21.1 to 39.5)	8.6 (2.0 to 16.4)
Drug use disorders	-	-	-	-	0.4 (0.2 to 0.5)	0.6 (0.3 to 0.5)	5.9 (8.7 to 23.8)	3.5 (-10.2 to 19.4)
Opioid use disorders	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.4)	39.4 (13.3 to 70.4)	6.9 (-4.2 to 18.0)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	37.5 (9.6 to 74.3)	6.6 (-8.8 to 23.8)
Cocaine use disorders	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.5)	8.8 (-15.9 to 38.5)	8.9 (-16.1 to 35.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	9.0 (-18.4 to 41.8)	7.5 (-18.2 to 40.5)
Amphetamine use disorders	0.5 (0.5 to 0.5)	0.4 (0.4 to 0.5)	-11.9 (-19.9 to -3.0)	-2.6 (-11.5 to 6.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-11.9 (-25.1 to 3.2)	-2.4 (-17.2 to 14.2)
Cannabis use disorders	0.8 (0.7 to 0.9)	0.7 (0.6 to 0.8)	-7.9 (-13.8 to -1.7)	2.4 (-3.6 to 8.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.9 (-19.9 to 5.9)	2.7 (-10.8 to 17.5)
Other drug use disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-1.7 (-27.7 to 33.1)	3.2 (-23.8 to 40.5)
Depressive disorders	-	-	-	-	2.5 (1.7 to 3.6)	2.9 (1.9 to 4.1)	14.6 (6.9 to 21.7)	1.4 (-6.8 to 4.3)
Major depressive disorder	10.8 (8.4 to 12.8)	12.3 (9.2 to 14.9)	13.9 (5.1 to 21.5)	-1.4 (-7.5 to 5.3)	2.2 (1.4 to 3.1)	2.5 (1.6 to 3.6)	12.9 (4.4 to 20.9)	-1.4 (-7.7 to 5.2)
Dysthymia	3.6 (3.0 to 4.2)	4.5 (3.8 to 5.3)	25.9 (19.1 to 33.6)	-1.4 (-1.7 to -1.0)	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	25.2 (18.1 to 33.7)	-1.5 (-3.7 to 0.9)
Bipolar disorder	2.1 (1.8 to 2.5)	2.4 (2.1 to 2.8)	13.6 (6.6 to 20.8)	-1.1 (-6.6 to 4.0)	0.4 (0.3 to 0.7)	0.5 (0.3 to 0.7)	12.9 (5.3 to 21.0)	-1.1 (-7.3 to 5.2)
Anxiety disorders	16.4 (11.5 to 20.8)	18.1 (13.3 to 22.5)	11.3 (1.1 to 20.2)	2.0 (-2.4 to -1.7)	1.7 (0.9 to 2.2)	1.7 (1.1 to 2.4)	16.5 (0.5 to 19.4)	-2.0 (-3.9 to -0.1)
Eating disorders	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-1.7 (-23.0 to -8.9)	-2.0 (-9.0 to 6.9)
Anorexia nervosa	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-12.1 (-21.9 to -0.1)	2.7 (-8.2 to 15.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.3 (-30.0 to 9.5)	2.3 (-17.5 to 28.0)
Bulimia nervosa	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-17.7 (-49.5 to -14.9)	-2.6 (-3.0 to -2.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-17.6 (-24.5 to -9.6)	-2.7 (-10.5 to 6.5)
Autistic spectrum disorders	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	8.5 (5.0 to 12.5)	2.1 (-0.8 to 6.0)
Autism	0.8 (0.7 to 0.8)	0.8 (0.8 to 0.9)	9.1 (8.3 to 10.0)	2.1 (2.0 to 2.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	8.4 (3.2 to 13.9)	2.2 (-2.6 to 7.3)
Asperger syndrome	1.1 (1.0 to 1.2)	1.2 (1.1 to 1.3)	9.4 (8.2 to 10.4)	2.7 (2.6 to 2.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	8.6 (4.4 to 13.2)	2.6 (-1.1 to 6.7)
Attention-deficit/hyperactivity disorder	1.8 (1.6 to 1.9)	1.5 (1.3 to 1.6)	-16.8 (-16.9 to -16.7)	1.0 (1.0 to 1.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.9 (-22.0 to -10.5)	1.0 (-5.3 to 8.4)
Conduct disorder	2.3 (2.2 to 2.5)	1.3 (1.8 to 2.1)	-47.3 (-17.5 to -17.1)	1.2 (-1.1 to 1.2)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-17.2 (-20.7 to -13.5)	1.1 (-2.9 to 5.9)
Idiopathic intellectual disability	0.6 (0.3 to 1.1)	0.6 (0.3 to 1.1)	0.9 (-33.3 to 51.4)	0.9 (-37.5 to 41.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.7 (-34.0 to 50.4)	5.6 (-38.1 to 40.7)
Other mental and substance use disorders	4.5 (4.2 to 4.7)	5.5 (5.2 to 5.8)	22.8 (20.0 to 25.8)	1.6 (1.3 to 2.0)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	22.2 (17.2 to 27.6)	1.7 (-1.6 to 5.5)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	2.6 (1.8 to 3.6)	3.7 (2.5 to 5.1)	40.4 (21.0 to 63.9)	2.8 (-10.8 to 19.6)
Diabetes mellitus	20.3 (17.2 to 23.2)	31.9 (26.2 to 37.8)	56.6 (24.5 to 98.1)	5.9 (-14.9 to 34.4)	1.5 (1.0 to 2.1)	2.3 (1.5 to 3.3)	57.8 (24.9 to 101.0)	4.3 (-17.7 to 33.7)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.1 (3.8 to 16.2)	3.8 (-1.6 to 9.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.8 (3.8 to 16.2)	3.8 (-1.6 to 9.2)
Chronic kidney disease	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	29.7 (9.8 to 49.9)	1.3 (-10.1 to 15.6)
Chronic kidney disease due to diabetes mellitus	7.8 (5.3 to 10.9)	11.1 (7.0 to 16.7)	41.2 (0.9 to 83.9)	0.3 (-22.5 to 29.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	45.2 (11.5 to 90.1)	3.0 (-18.5 to 34.0)
Chronic kidney disease due to hypertension	4.0 (3.0 to 5.2)	5.2 (3.9 to 7.2)	30.1 (4.9 to 67.7)	9.9 (-13.0 to 39.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	24.4 (4.0 to 51.7)	-1.2 (-16.2 to 19.4)
Chronic kidney disease due to glomerulonephritis	11.3 (7.8 to 15.9)	14.1 (9.5 to 21.2)	24.8 (-0.7 to 51.1)	0.7 (-19.6 to 24.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	36.2 (-11.3 to 94.1)	14.6 (-22.2 to 61.9)
Chronic kidney disease due to other causes	9.3 (6.7 to 12.6)	10.9 (7.4 to 16.0)	17.0 (-6.9 to 43.3)	-4.2 (-23.4 to 16.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	20.1 (-4.3 to 52.8)	-2.1 (-21.4 to 22.3)
Urinary diseases and male infertility	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	42.8 (26.7 to 58.8)	8.9 (-1.9 to 19.5)

Appendix Table G.4 - Barbados prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	46.9 (32.3 to 60.7)	29.5 (17.4 to 41.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.8 (18.9 to 80.2)	28.3 (5.9 to 57.4)
Urolithiasis	2.3 (1.7 to 3.1)	3.6 (2.4 to 5.8)	50.6 (26.5 to 104.3)	7.4 (9.4 to 40.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	53.8 (30.9 to 105.0)	11.1 (-4.5 to 41.7)
Benign prostatic hyperplasia	2.0 (1.8 to 2.2)	2.9 (2.7 to 3.1)	49.4 (31.1 to 65.3)	10.1 (-3.3 to 21.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	50.3 (32.0 to 67.3)	10.2 (-3.1 to 22.3)
Male infertility due to other causes	2.2 (1.8 to 2.7)	2.2 (1.8 to 2.7)	0.2 (-25.9 to 32.4)	4.8 (-22.9 to 37.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.6 (-27.7 to 34.3)	4.0 (-23.6 to 41.6)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-24.8 to 40.8)	0.0 (-44.4 to 40.8)
Gynecological diseases	-	-	-	-	0.4 (0.2 to 0.6)	0.4 (0.3 to 0.6)	12.1 (-4.0 to 26.0)	-1.3 (-15.3 to 11.1)
Uterine fibroids	5.3 (4.7 to 5.7)	7.3 (6.7 to 7.9)	39.5 (36.4 to 43.1)	-6.0 (-6.1 to -5.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	24.2 (11.8 to 34.9)	-6.6 (-15.4 to 1.3)
Polycystic ovarian syndrome	5.4 (4.8 to 6.1)	5.9 (5.3 to 6.5)	8.7 (-9.4 to 26.6)	-2.1 (-17.7 to 13.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	8.3 (-9.8 to 26.8)	-1.6 (-17.6 to 14.5)
Female infertility due to other causes	1.9 (0.8 to 3.1)	2.2 (1.1 to 3.4)	13.8 (-44.1 to 181.5)	13.7 (-45.6 to 193.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-43.8 to 163.9)	0.0 (-45.7 to 172.0)
Endometriosis	0.5 (0.4 to 0.6)	0.6 (0.5 to 0.7)	11.8 (-10.8 to 43.1)	-0.3 (-21.2 to 25.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	11.4 (-12.9 to 45.4)	0.5 (-22.1 to 27.9)
Genital prolapse	15.2 (12.2 to 18.4)	20.5 (17.7 to 23.6)	34.6 (6.9 to 70.2)	-3.8 (-21.9 to 21.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	34.4 (7.1 to 69.9)	-4.1 (-22.1 to 21.4)
Premenstrual syndrome	13.2 (9.7 to 16.6)	13.1 (8.9 to 17.3)	1.1 (-41.6 to 47.5)	3.1 (-42.0 to 51.0)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	0.1 (-42.3 to 48.5)	3.8 (-4.3 to 52.2)
Other gynecological diseases	0.9 (0.7 to 1.0)	0.8 (0.8 to 0.9)	-3.1 (-20.1 to 21.5)	-9.6 (-25.4 to 11.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.5 (-28.6 to 48.4)	-8.7 (-31.3 to 43.5)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	0.7 (-5.1 to 9.5)	0.5 (-5.2 to 9.7)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.9 (-25.2 to -9.3)	-2.3 (-10.9 to 7.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.6 (-22.3 to -12.6)	-2.8 (-7.0 to 4.7)
Thalassemia trait	2.0 (1.5 to 2.5)	2.2 (1.7 to 2.6)	6.8 (1.2 to 12.0)	-2.5 (-7.7 to 2.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	4.0 (-8.8 to 17.6)	-5.1 (-15.8 to 7.4)
Sickle cell disorders	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	2.4 (-7.7 to 21.6)	6.6 (-3.5 to 26.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.1 (-4.9 to 27.0)	10.4 (4.5 to 26.7)
Sickle cell trait	21.5 (19.9 to 23.0)	24.8 (23.0 to 26.4)	15.2 (11.3 to 20.2)	5.2 (1.6 to 9.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	0.6 (-9.6 to 20.6)	3.2 (-7.5 to 21.8)
G6PD deficiency	14.2 (11.0 to 17.0)	16.3 (11.9 to 20.0)	15.0 (-18.6 to 55.9)	5.5 (-25.4 to 43.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.3 (-32.4 to 60.0)	-1.0 (-36.0 to 53.2)
G6PD trait	43.7 (40.8 to 46.3)	46.5 (42.4 to 49.8)	6.8 (-4.0 to 16.3)	-3.6 (-13.4 to 4.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.5 (-51.3 to 328.5)	52.5 (-55.0 to 400.1)
Other hemoglobinopathies and hemolytic anemias	2.0 (1.8 to 2.1)	2.1 (1.9 to 2.2)	4.0 (-6.7 to 15.5)	-2.6 (-12.6 to 7.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-9.1 (-23.2 to 10.7)	-5.6 (-19.8 to 14.1)
Endocrine, metabolic, blood, and immune disorders	2.1 (1.9 to 2.3)	3.5 (2.0 to 5.2)	65.5 (-6.7 to 17.7)	3.5 (-13.2 to 12.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	4.5 (-14.4 to 23.1)	2.2 (-16.5 to 22.2)
Musculoskeletal disorders	-	-	-	-	3.8 (2.7 to 5.0)	5.3 (3.8 to 7.0)	40.3 (31.5 to 49.2)	2.9 (-3.1 to 9.5)
Rheumatoid arthritis	0.7 (0.7 to 0.7)	1.2 (1.2 to 1.3)	76.5 (64.6 to 88.9)	34.7 (25.4 to 44.1)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	74.6 (61.1 to 90.2)	33.8 (22.9 to 45.8)
Osteoarthritis	11.0 (10.6 to 11.4)	16.2 (15.6 to 16.9)	46.8 (38.7 to 55.1)	0.2 (-5.3 to 5.8)	0.7 (0.5 to 0.9)	1.0 (0.7 to 1.3)	47.5 (39.1 to 56.2)	0.1 (-5.8 to 6.0)
Low back and neck pain	-	-	-	-	2.2 (1.6 to 3.0)	2.9 (2.0 to 4.0)	29.2 (15.1 to 44.5)	0.0 (-10.2 to 11.5)
Low back pain	12.4 (11.0 to 13.6)	16.0 (14.1 to 17.6)	28.1 (10.1 to 52.5)	-0.3 (-14.3 to 18.0)	1.4 (0.9 to 1.9)	1.8 (1.2 to 2.5)	27.5 (9.4 to 52.2)	-0.2 (-14.4 to 18.6)
Neck pain	8.9 (7.6 to 10.1)	11.7 (10.0 to 13.3)	32.5 (11.4 to 51.9)	0.8 (-13.6 to 13.9)	0.9 (0.6 to 1.2)	1.1 (0.8 to 1.6)	31.9 (10.8 to 52.0)	0.8 (-13.9 to 14.8)
Gout	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	42.6 (26.2 to 59.2)	-2.4 (-13.9 to 8.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.7 (12.8 to 81.0)	-2.3 (-22.7 to 23.6)
Other musculoskeletal disorders	7.8 (6.6 to 9.2)	12.6 (10.2 to 15.2)	60.4 (46.8 to 73.7)	7.1 (0.5 to 1.0)	0.7 (0.5 to 1.0)	1.1 (0.8 to 1.6)	60.0 (46.2 to 75.1)	7.1 (0.1 to 14.1)
Other non-communicable diseases	-	-	-	-	4.7 (3.2 to 6.7)	5.7 (3.8 to 8.2)	20.7 (16.5 to 24.7)	-2.8 (-6.1 to 0.5)
Congenital anomalies	-	-	-	-	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	42.8 (23.7 to 66.4)	27.4 (9.5 to 49.6)
Neural tube defects	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	1.6 (-15.6 to 23.4)	1.8 (-15.7 to 23.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.1 (-24.1 to 43.6)	4.0 (-22.8 to 45.2)
Congenital heart anomalies	1.1 (0.9 to 1.4)	1.6 (1.4 to 2.0)	46.6 (16.3 to 87.6)	39.1 (10.5 to 78.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	48.2 (17.7 to 88.8)	41.9 (13.0 to 81.3)
Orofacial clefts	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.3)	30.4 (-3.8 to 69.8)	28.9 (-5.2 to 67.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.9 (-24.0 to 57.1)	9.0 (-24.9 to 55.0)
Down syndrome	0.2 (0.2 to 0.2)	0.3 (0.2 to 0.3)	34.2 (2.0 to 70.5)	13.9 (-13.2 to 45.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.3 (13.8 to 92.2)	17.5 (-11.3 to 51.4)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.9 (-22.9 to 60.9)	1.6 (-26.6 to 52.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.9 (-25.4 to 66.9)	2.0 (-28.1 to 58.9)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.8 (-19.7 to 58.7)	5.8 (-25.4 to 47.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.1 (-2.4 to 54.0)	5.7 (-25.7 to 47.1)
Chromosomal unbalanced rearrangements	0.4 (0.4 to 0.5)	0.6 (0.5 to 0.7)	33.8 (4.0 to 70.0)	28.9 (-11.3 to 43.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	0.1 (-12.1 to 12.1)	0.1 (-10.3 to 49.5)
Other congenital anomalies	1.1 (0.9 to 1.3)	1.1 (0.9 to 1.3)	-1.1 (-10.1 to 6.6)	-11.2 (-19.0 to -4.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	45.2 (16.2 to 91.8)	35.6 (7.9 to 79.4)
Skin and subcutaneous diseases	-	-	-	-	1.4 (0.9 to 2.1)	1.5 (1.0 to 2.3)	11.6 (2.4 to 21.8)	1.1 (-6.6 to 10.0)
Dermatitis	12.9 (10.4 to 15.4)	14.6 (11.9 to 17.3)	13.0 (8.3 to 17.8)	-0.1 (-0.3 to 0.1)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.5)	10.4 (5.9 to 15.6)	-0.3 (-2.8 to 2.5)
Psoriasis	2.3 (2.0 to 2.6)	2.8 (2.4 to 3.2)	21.6 (17.3 to 27.1)	0.1 (-0.2 to 0.3)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	20.8 (13.4 to 29.0)	0.0 (-4.7 to 5.3)
Cellulitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.9 (-4.1 to 28.0)	-14.6 (-24.4 to -1.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.8 (-11.7 to 36.1)	-13.8 (-29.1 to 5.4)
Pyoderma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	43.0 (32.6 to 54.1)	23.7 (18.1 to 29.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.3 (23.3 to 63.4)	23.8 (9.4 to 39.5)
Scabies	3.2 (2.7 to 3.6)	3.3 (2.8 to 3.8)	3.6 (-16.7 to 30.2)	-0.4 (-19.2 to 24.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	2.9 (-1.4 to 30.4)	-0.4 (-19.6 to 14.2)
Fungal skin diseases	20.2 (15.6 to 26.7)	23.9 (18.8 to 31.1)	18.3 (11.6 to 26.9)	18.8 (0.4 to 13)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	19.9 (11.2 to 26.3)	0.8 (-0.1 to 1.7)
Viral skin diseases	5.0 (3.6 to 6.4)	4.8 (3.5 to 6.1)	-4.7 (-9.1 to 3.0)	0.1 (-2.1 to 2.6)	0.2 (0.1 to 0.2)	0.1 (-0.1 to 0.2)	-5.1 (-10.2 to 3.5)	2.9 (-3.2 to 3.9)
Acne vulgaris	17.5 (13.0 to 22.5)	16.0 (11.1 to 19.9)	-10.0 (-38.0 to 37.4)	6.0 (-25.5 to 58.2)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-9.9 (-37.6 to 37.9)	6.0 (-26.4 to 59.4)
Alopecia areata	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.3)	20.8 (9.9 to 36.8)	0.3 (-13.5 to 13.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.8 (-0.3 to 41.0)	-0.0 (-16.0 to 17.1)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.6 (3.6 to 70.5)	4.0 (-18.6 to 33.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.6 (3.6 to 70.6)	4.0 (-18.6 to 33.0)
Urticaria	3.1 (2.4 to 4.0)	3.9 (3.1 to 4.9)	29.0 (-11.4 to 69.8)	4.7 (-28.2 to 37.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	28.7 (-12.6 to 68.7)	4.4 (-29.0 to 38.7)
Decubitus ulcer	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-7.1 (-31.6 to 28.4)	-25.0 (-44.9 to 3.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.7 (-33.8 to 35.4)	-24.1 (-46.4 to 8.4)
Other skin and subcutaneous diseases	17.9 (10.9 to 29.8)	24.1 (14.4 to 39.6)	34.4 (19.7 to 52.2)	-0.7 (-4.9 to 3.5)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	34.3 (19.0 to 52.3)	-0.7 (-5.1 to 3.6)
Sense organ diseases	-	-	-	-	2.1 (1.4 to 2.9)	2.5 (1.7 to 3.4)	20.4 (12.9 to 26.6)	-8.4 (-13.0 to -4.0)
Glaucoma	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	2.7 (-12.2 to 22.7)	-20.2 (-31.6 to -5.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.9 (-14.8 to 26.4)	-20.2 (-33.9 to -2.5)
Cataract	0.7 (0.6 to 0.8)	0.6 (0.5 to 0.7)	-9.1 (-17.1 to 2.0)	-27.7 (-34.4 to -18.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-9.4 (-19.5 to 2.7)	-27.6 (-35.2 to -18.0)
Macular degeneration	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	68.9 (26.5 to 118.5)	9.9 (-17.3 to 42.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.3 (22.2 to 116.5)	9.0 (-19.7 to 41.5)
Uncorrected refractive error	23.8 (22.0 to 25.6)	33.1 (30.7 to 35.5)	38.8 (25.1 to 54.2)	0.1 (-9.6 to 11.6)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.5)	29.2 (18.0 to 42.0)	-4.7 (-12.4 to 4.5)
Age-related and other hearing loss	45.8 (43.3 to 48.3)	58.7 (55.4 to 62.1)	27.9 (23.8 to 33.3)	-8.7 (-11.5 to -5.1)	1.4 (1.0 to 2.0)	1.7 (1.2 to 2.4)	21.4 (12.3 to 29.0)	8.6 (-11.1 to -2.4)
Other vision loss	0.3 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-11.6 (-20.4 to -1.0)	-31.8 (-37.9 to -24.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.3 (-21.5 to 5.6)	-31.3 (-40.3 to -20.6)
Other sense organ diseases	6.0 (5.7 to 6.2)	6.6 (6.3 to 6.9)	11.1 (4.3 to 18.2)	-1.3 (-7.4 to 4.9)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	10.5 (3.3 to 18.2)	-1.3 (-8.1 to 5.8)
Oral disorders	-	-	-	-	1.0 (0.6 to 1.6)	1.3 (0.8 to 2.0)	27.5 (26.6 to 32.0)	-4.4 (-7.5 to -1.1)
Deciduous caries	13.7 (13.0 to 14.4)	11.9 (11.3 to 12.4)	-13.0 (-19.0 to -7.6)	1.4 (-5.5 to 7.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.3 (-20.7 to 5.3)	1.3 (-7.4 to 10.4)
Permanent caries	118.8 (114.0 to 123.5)	128.4 (122.7 to 133.3)	8.2 (1.6 to 14.3)	-0.1 (-6.3 to 5.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	7.7 (1.2 to 14.1)	-0.2 (-6.5 to 5.7)
Periodontal diseases	30.7 (29.2 to 32.1)	43.1 (41.0 to 45.3)	40.4 (31.3 to 51.3)	-1.3 (-7.6 to 6.2)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.6)	40.2 (31.0 to 50.8)	-1.4 (-7.9 to 6.0)

Appendix Table G.4 - Barbados prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	21.1 (20.4 to 21.8)	27.4 (26.5 to 28.4)	30.0 (24.0 to 36.3)	-4.7 (-11.0 to -2.1)	0.6 (0.4 to 0.8)	0.8 (0.5 to 1.0)	30.3 (24.0 to 36.8)	6.9 (-11.4 to -2.1)
Other oral disorders	4.7 (4.4 to 4.9)	5.5 (5.2 to 5.8)	16.8 (7.0 to 26.8)	-0.9 (-9.4 to 7.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	16.2 (6.1 to 26.7)	-1.0 (-9.8 to 7.6)
Injuries	-	-	-	-	1.6 (1.2 to 2.1)	1.5 (1.1 to 2.1)	-5.4 (-14.8 to 5.2)	-26.8 (-33.9 to -19.0)
Transport injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.5 (0.4 to 0.7)	-3.8 (-15.3 to 10.3)	-27.3 (-36.0 to -16.7)
Road injuries	-	-	-	-	0.5 (0.4 to 0.6)	0.5 (0.3 to 0.6)	-7.0 (-18.2 to 7.0)	-29.7 (-38.2 to -19.3)
Pedestrian road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-17.8 (-28.6 to -4.4)	-37.4 (-45.5 to -27.4)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.4 (-7.7 to 14.3)	-22.4 (-30.1 to -13.5)
Motorcyclist road injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-15.0 (-26.5 to -1.4)	-35.9 (-44.4 to -26.1)
Motor vehicle road injuries	-	-	-	-	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.4)	0.5 (-13.4 to 16.4)	-24.2 (-34.5 to -12.7)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.0 (-26.1 to -3.2)	-37.3 (-45.0 to -27.7)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	39.6 (21.8 to 59.4)	5.4 (-7.5 to 19.8)
Unintentional injuries	-	-	-	-	1.0 (0.8 to 1.3)	0.9 (0.7 to 1.3)	-6.5 (-14.6 to 2.2)	-26.6 (-32.8 to -19.9)
Falls	-	-	-	-	0.5 (0.3 to 0.6)	0.4 (0.3 to 0.6)	-9.9 (-20.4 to 3.0)	-30.4 (-38.5 to -20.9)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.0 (-31.5 to -7.2)	-38.3 (-46.9 to -28.6)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.0 (-37.7 to -18.7)	-44.1 (-50.8 to -36.2)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.8 (-32.7 to -7.3)	-33.3 (-42.6 to -20.8)
Exposure to mechanical forces	-	-	-	-	0.3 (0.3 to 0.4)	0.3 (0.2 to 0.4)	-16.3 (-22.6 to -9.6)	-30.9 (-35.6 to -25.9)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.6 (25.8 to 66.3)	13.5 (-0.2 to 30.2)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.3 (9.2 to 41.0)	0.0 (-12.5 to 11.9)
Other exposure to mechanical forces	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-21.0 (-26.8 to -14.9)	-34.5 (-38.9 to -29.8)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.3 (51.5 to 71.9)	23.7 (16.2 to 31.5)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.3 (27.2 to 53.4)	9.9 (0.8 to 20.4)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.6 (27.7 to 58.2)	13.2 (1.4 to 25.2)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.3 (23.2 to 53.1)	8.1 (-2.8 to 19.8)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.0 (-10.7 to 10.7)	-22.1 (-29.4 to -13.4)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.2 (-34.7 to -8.3)	-38.5 (-47.6 to -26.9)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.0 (-4.9 to 22.9)	-12.4 (-22.0 to 1.2)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.2 (0.7 to 23.7)	-14.1 (-21.8 to -5.0)
Other unintentional injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	36.5 (25.0 to 49.4)	1.3 (-7.1 to 10.8)
Self-harm and interpersonal violence	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-2.1 (-13.8 to 12.1)	-26.4 (-35.1 to -16.0)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.8 (-22.1 to -1.1)	-35.0 (-42.0 to -26.6)
Interpersonal violence	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.2 (-12.5 to 16.1)	-24.4 (-33.6 to -13.0)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.5 (24.4 to 54.2)	3.6 (-6.5 to 15.2)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.1 (-8.2 to 23.7)	-19.4 (-30.5 to -6.1)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.0 (-33.1 to -7.4)	-41.2 (-49.6 to -30.5)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.7 (-36.5 to 14.5)	-19.1 (-37.9 to 26.6)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.7 (-36.5 to 14.5)	-19.1 (-37.9 to 26.6)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Belarus prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,118.1 (828.9 to 1,452.7)	1,147.6 (851.0 to 1,498.7)	2.7 (-0.0 to 5.3)	-1.8 (-4.3 to 0.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	68.4 (47.5 to 96.4)	53.1 (37.1 to 74.5)	-22.4 (-28.6 to -16.0)	-5.3 (-12.6 to 1.6)
HIV/AIDS and tuberculosis	-	-	-	-	2.8 (1.9 to 3.7)	4.4 (3.0 to 6.1)	54.9 (33.6 to 93.5)	48.3 (27.9 to 84.4)
Tuberculosis	9.1 (8.5 to 9.7)	10.9 (10.3 to 11.5)	20.2 (13.1 to 27.0)	13.8 (7.1 to 20.2)	2.8 (1.9 to 3.7)	3.3 (2.3 to 4.5)	20.4 (9.1 to 33.2)	14.3 (3.2 to 26.8)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.1)	1.0 (0.5 to 2.1)	9,076.2 (2,266.4 to 103,518.0)	6,876.0 (2,211.6 to 100,559.0)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	10,096.8 (2,615.3 to 204,088.6)	9,751.6 (2,532.4 to 198,087.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	10,096.8 (2,610.8 to 205,073.7)	9,751.6 (2,526.4 to 198,219.7)
HIV/AIDS resulting in other diseases	0.1 (0.0 to 0.5)	9.8 (6.9 to 13.8)	8,943.7 (2,295.1 to 155,015.5)	8,753.3 (2,207.1 to 152,270.3)	0.0 (0.0 to 0.1)	1.0 (0.5 to 2.0)	9,033.1 (2,222.6 to 170,934.0)	8,843.4 (2,162.0 to 167,000.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	12.2 (8.3 to 17.4)	9.8 (6.5 to 14.1)	-20.1 (-24.9 to -14.7)	-8.3 (-13.5 to -2.5)
Diarrheal diseases	17.8 (16.6 to 19.2)	15.2 (14.0 to 16.2)	-14.7 (-23.2 to -5.8)	-0.9 (-11.1 to 9.7)	2.9 (1.9 to 4.0)	2.4 (1.7 to 3.4)	-35.4 (-51.1 to -4.7)	-1.0 (-12.7 to 12.0)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.5 (-62.8 to -9.5)	-32.8 (-57.2 to -1.6)
Typhoid fever	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-33.6 (-57.1 to -9.4)	-26.7 (-50.0 to -0.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.6 (-57.1 to -9.4)	-26.7 (-50.0 to -0.6)
Paratyphoid fever	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-34.0 (-58.9 to -5.3)	-25.1 (-48.5 to 7.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.0 (-58.9 to -5.2)	-25.1 (-48.9 to 7.1)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-85.9 (-99.6 to 161.0)	-84.1 (-99.6 to 180.3)
Lower respiratory infections	9.3 (8.0 to 10.4)	5.1 (5.1 to 6.1)	-38.8 (-47.6 to -27.3)	-15.4 (-27.9 to 1.8)	1.0 (0.6 to 1.4)	0.6 (0.4 to 0.8)	-39.1 (-48.6 to -26.5)	-15.2 (-29.2 to 3.0)
Upper respiratory infections	344.7 (314.8 to 374.9)	300.4 (271.6 to 329.8)	-12.5 (-21.0 to -3.1)	-1.0 (-10.9 to 9.2)	4.0 (2.3 to 6.6)	3.5 (1.9 to 5.8)	-12.8 (-22.0 to -3.0)	-1.0 (-11.3 to 9.4)
Otitis media	138.3 (128.7 to 149.4)	110.5 (101.9 to 119.0)	-19.7 (-25.9 to -13.1)	-10.7 (-16.6 to -4.1)	2.8 (1.7 to 4.5)	2.2 (1.3 to 3.4)	-21.9 (-28.1 to -15.0)	-11.1 (-18.3 to -3.8)
Meningitis	-	-	-	-	0.8 (0.5 to 1.4)	0.4 (0.3 to 0.6)	-45.9 (-66.4 to -30.4)	-41.0 (-63.3 to -22.4)
Pneumococcal meningitis	3.4 (2.0 to 5.5)	1.9 (1.1 to 3.3)	-42.4 (-52.7 to -29.8)	-42.1 (-52.8 to -29.6)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.2)	-42.4 (-58.3 to -26.8)	-38.4 (-55.5 to -20.4)
H influenzae type B meningitis	2.4 (0.6 to 5.0)	0.9 (0.3 to 2.2)	-60.6 (-80.7 to -45.2)	-57.4 (-78.2 to -36.5)	0.3 (0.1 to 0.8)	0.1 (0.1 to 0.2)	-60.0 (-84.9 to -31.5)	-53.8 (-82.3 to -19.5)
Meningococcal meningitis	0.9 (0.3 to 2.0)	0.4 (0.1 to 1.1)	-49.9 (-71.2 to -13.4)	-48.0 (-68.1 to -11.1)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-46.1 (-72.4 to 14.1)	-40.9 (-70.2 to 32.4)
Other meningitis	1.4 (0.6 to 2.8)	0.9 (0.4 to 1.8)	-39.1 (-53.9 to -12.2)	-36.9 (-51.7 to -3.5)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-31.2 (-55.2 to 14.7)	-26.3 (-52.6 to 26.3)
Encephalitis	4.2 (1.7 to 10.2)	3.8 (1.6 to 9.8)	-10.1 (-32.2 to 8.7)	-13.4 (-33.0 to 5.0)	0.5 (0.4 to 0.7)	0.5 (0.3 to 0.7)	-5.5 (-24.2 to 16.0)	-7.9 (-24.1 to 14.6)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.2 (-93.2 to 485.3)	-40.4 (-92.0 to 381.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.2 (-93.3 to 487.2)	-40.4 (-92.1 to 395.1)
Whooping cough	1.5 (1.2 to 1.9)	0.2 (0.1 to 0.3)	-86.8 (-88.0 to -85.4)	-80.5 (-82.4 to -78.5)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-86.8 (-90.1 to -82.3)	-80.6 (-85.4 to -74.0)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.4 (-62.6 to -16.8)	-45.3 (-57.3 to -20.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.5 (-63.0 to -15.6)	-45.2 (-57.4 to -17.6)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-92.7 (-96.4 to -89.2)	-89.9 (-94.5 to -83.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-92.7 (-96.4 to -89.2)	-89.0 (-94.5 to -83.7)
Varicella and herpes zoster	5.9 (5.5 to 6.5)	5.0 (4.5 to 5.5)	-15.9 (-26.5 to -4.8)	-18.8 (-10.1 to 8.7)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-0.6 (-24.0 to 27.9)	-0.6 (-22.5 to 24.4)
Neglected tropical diseases and malaria	-	-	-	-	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-9.2 (-53.1 to 43.6)	-9.0 (-55.4 to 36.0)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.9 (-74.5 to 184.9)	-5.7 (-69.3 to 241.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.0 (-73.5 to 188.3)	-3.6 (-68.3 to 249.1)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.6 (0.2 to 1.4)	0.1 (0.1 to 0.3)	-76.3 (-93.4 to -18.8)	-77.8 (-93.7 to -27.2)	0.2 (0.1 to 0.4)	0.0 (0.0 to 0.1)	-71.9 (-92.2 to -0.5)	-74.5 (-92.9 to -13.2)
Cystic echinococcosis	1.6 (1.5 to 1.7)	2.4 (2.1 to 2.7)	57.4 (36.3 to 72.3)	50.3 (29.3 to 66.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	56.1 (21.4 to 94.0)	49.7 (15.8 to 87.5)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.0 (-19.7 to 77.0)	30.6 (-19.7 to 76.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.0 (-19.7 to 77.7)	30.6 (-19.7 to 76.7)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.2 (-37.7 to 40.4)	-0.6 (-37.9 to 40.4)
Maternal disorders	-	-	-	-	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.4)	-31.7 (-49.0 to -11.5)	-32.3 (-49.3 to -12.1)
Maternal hemorrhage	4.4 (3.8 to 5.2)	3.5 (2.7 to 4.2)	-20.8 (-41.6 to 3.9)	-20.1 (-40.9 to 3.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-26.0 (-57.5 to 20.2)	-26.3 (-57.4 to 17.0)
Maternal sepsis and other maternal infections	5.1 (3.0 to 7.7)	2.5 (1.6 to 4.0)	-50.1 (-63.6 to -32.4)	-49.4 (-63.0 to -32.5)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-56.1 (-70.8 to -37.2)	-56.1 (-70.8 to -36.9)
Maternal hypertensive disorders	1.7 (1.0 to 2.5)	1.3 (0.8 to 1.9)	-24.3 (-33.3 to -13.8)	-25.8 (-34.9 to -14.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-25.0 (-41.4 to -3.3)	-26.4 (-42.8 to -4.6)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.6 (-52.6 to 19.0)	-25.6 (-53.0 to 21.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.6 (-52.8 to 19.3)	-25.6 (-53.1 to 21.1)
Complications of abortion	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-17.2 (-38.1 to 13.2)	-18.0 (-38.5 to 12.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.5 (-58.6 to 74.4)	-15.9 (-59.9 to 79.9)
Other maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-29.0 (-57.1 to 15.8)	-29.8 (-57.6 to 14.6)
Neonatal disorders	-	-	-	-	9.6 (6.4 to 13.7)	7.5 (5.2 to 10.0)	-21.4 (-49.7 to 6.1)	-8.9 (-41.7 to 23.4)
Preterm birth complications	30.8 (23.7 to 39.6)	30.9 (24.0 to 39.3)	0.7 (-12.8 to 15.6)	11.5 (-3.6 to 27.9)	3.5 (2.5 to 4.8)	3.8 (2.6 to 5.0)	7.5 (-15.5 to 32.7)	23.0 (-3.4 to 52.2)
Neonatal encephalopathy due to birth asphyxia and trauma	13.6 (6.9 to 28.7)	6.4 (3.1 to 14.3)	-53.3 (-74.2 to -17.6)	-45.2 (-70.5 to -3.2)	3.2 (1.8 to 5.3)	1.7 (0.9 to 2.5)	-50.0 (-73.3 to -1.3)	40.0 (-68.5 to 20.0)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.2 (-5.2 to 34.2)	58.4 (31.5 to 72.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.1 (-11.1 to 48.9)	51.5 (19.2 to 106.7)
Hemolytic disease and other neonatal jaundice	3.3 (1.0 to 7.5)	0.9 (0.4 to 1.7)	-71.6 (-90.1 to -1.8)	-67.1 (-88.5 to 14.3)	1.2 (0.4 to 2.8)	0.4 (0.2 to 0.7)	-69.6 (-89.3 to 2.9)	64.9 (-87.5 to 16.0)
Other neonatal disorders	-	-	-	-	1.6 (0.8 to 3.0)	1.7 (0.9 to 2.9)	3.8 (-53.1 to 109.1)	20.1 (-45.5 to 142.3)
Nutritional deficiencies	-	-	-	-	39.2 (26.0 to 57.4)	27.9 (18.5 to 40.6)	-28.9 (-34.2 to -22.1)	-6.2 (-12.3 to 1.4)
Protein-energy malnutrition	8.5 (3.3 to 17.4)	3.8 (1.6 to 8.0)	-54.6 (-85.6 to 45.8)	-33.6 (-79.0 to 114.5)	1.1 (0.4 to 2.3)	0.5 (0.2 to 1.0)	-54.6 (-85.7 to 48.5)	-33.7 (-79.2 to 118.8)
Iodine deficiency	184.3 (61.9 to 297.0)	102.5 (40.5 to 168.0)	-45.6 (-80.7 to 124.6)	-44.2 (-78.8 to 126.6)	3.3 (1.0 to 6.5)	1.9 (0.6 to 3.6)	-45.7 (-81.0 to 121.0)	-44.3 (-79.2 to 123.4)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron-deficiency anemia	1,174.1 (1,154.6 to 1,194.1)	941.4 (922.8 to 959.5)	-19.4 (-21.6 to -17.5)	-1.4 (-4.0 to 1.0)	34.6 (22.8 to 50.7)	25.4 (16.6 to 37.1)	-26.7 (-29.3 to -23.9)	-2.5 (-5.7 to 1.2)

Appendix Table G.4 - Belarus prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	7.9 (1.9 to 14.0)	0.0 (-10.2 to 0.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.5 (2.2 to 15.3)	-4.6 (-9.9 to 0.9)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.2 (0.2 to 0.2)	0.1 (0.1 to 0.2)	-30.3 (-38.8 to -26.8)	0.0 (-1.2 to -35.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-29.9 (-33.5 to -26.3)	-37.9 (-40.9 to -34.8)
Asthma	349.9 (309.7 to 389.7)	295.3 (264.3 to 331.0)	-15.3 (-27.8 to 11.1)	-8.9 (-23.2 to 12.7)	13.0 (9.9 to 22.2)	13.0 (8.2 to 18.8)	-8.7 (-28.0 to 0.8)	-15.6 (-23.3 to 13.7)
Interstitial lung disease and pulmonary sarcoidosis	0.8 (0.6 to 1.1)	0.9 (0.7 to 1.1)	5.3 (-27.2 to 49.8)	0.4 (-30.6 to 43.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	0.1 (-25.9 to 48.5)	0.8 (-29.5 to 41.6)
Other chronic respiratory diseases	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	25.2 (6.0 to 64.6)	12.2 (-16.7 to 47.0)
Cirrhosis	-	-	-	-	0.7 (0.5 to 1.0)	1.4 (1.0 to 2.0)	106.6 (80.6 to 138.7)	94.3 (70.1 to 123.0)
Cirrhosis due to hepatitis B	0.9 (0.7 to 1.1)	1.5 (1.0 to 2.1)	67.3 (13.2 to 158.2)	57.1 (5.4 to 137.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	6.1 (6.1 to 179.2)	-1.6 (-1.6 to 155.2)
Cirrhosis due to hepatitis C	0.8 (0.5 to 1.1)	3.2 (2.4 to 3.9)	327.1 (148.1 to 545.9)	295.8 (128.2 to 488.5)	0.1 (0.1 to 0.2)	0.5 (0.3 to 0.8)	323.3 (147.0 to 600.4)	290.3 (132.5 to 543.7)
Cirrhosis due to alcohol use	1.7 (1.4 to 2.1)	2.8 (2.0 to 3.4)	59.4 (13.5 to 109.4)	46.2 (4.4 to 92.3)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	61.7 (7.7 to 121.1)	47.8 (0.3 to 105.0)
Cirrhosis due to other causes	0.8 (0.7 to 1.0)	1.3 (0.8 to 1.8)	48.6 (0.1 to 112.9)	54.6 (8.2 to 118.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	45.8 (9.0 to 132.6)	51.6 (-2.7 to 137.4)
Digestive diseases	-	-	-	-	11.4 (8.2 to 15.1)	13.6 (9.8 to 17.9)	19.6 (13.0 to 25.7)	11.1 (5.5 to 17.0)
Peptic ulcer disease	61.9 (60.0 to 63.7)	56.2 (54.3 to 58.1)	-8.9 (-13.0 to -4.1)	-23.3 (-26.9 to -19.3)	1.8 (1.2 to 2.5)	1.7 (1.2 to 2.4)	4.6 (13.0 to 4.5)	-20.8 (-28.1 to -12.9)
Gastritis and duodenitis	15.9 (14.2 to 17.8)	19.2 (17.0 to 21.1)	21.3 (2.7 to 39.2)	22.7 (4.3 to 42.1)	0.9 (0.6 to 1.3)	0.9 (0.6 to 1.3)	-3.1 (-19.6 to 20.4)	12.7 (-6.4 to 36.3)
Appendicitis	0.7 (0.6 to 0.8)	0.5 (0.4 to 0.6)	-28.8 (-39.6 to -14.6)	-15.9 (-29.7 to 3.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-28.0 (-46.4 to -3.4)	-15.4 (-38.5 to 16.9)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	15.5 (-6.8 to 40.3)	8.1 (-15.1 to 34.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	13.3 (-12.2 to 46.0)	7.2 (-17.7 to 42.8)
Inguinal, femoral, and abdominal hernia	23.8 (20.1 to 28.1)	24.6 (20.5 to 29.0)	2.7 (-16.5 to 32.4)	-11.1 (-27.5 to 13.1)	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.5)	0.7 (-17.4 to 33.3)	-0.6 (-27.6 to 14.2)
Inflammatory bowel disease	20.9 (20.0 to 21.7)	27.1 (25.9 to 28.1)	30.4 (23.7 to 36.9)	20.8 (14.6 to 26.9)	4.4 (3.0 to 5.9)	5.7 (3.9 to 7.8)	28.2 (20.8 to 40.5)	21.0 (12.6 to 30.7)
Vascular intestinal disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	27.4 (-13.7 to 88.5)	4.1 (-28.1 to 51.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	26.5 (-30.0 to 114.0)	4.7 (-38.9 to 72.5)
Gallbladder and biliary diseases	17.5 (15.5 to 19.5)	17.4 (15.0 to 19.7)	-0.5 (-15.5 to 17.9)	-11.3 (-24.3 to 5.9)	1.8 (1.2 to 2.6)	1.8 (1.2 to 2.5)	-0.9 (-17.2 to 20.4)	-11.2 (-25.4 to 8.0)
Pancreatitis	5.6 (5.3 to 5.9)	8.1 (7.7 to 8.5)	45.1 (35.7 to 55.5)	45.1 (24.4 to 41.9)	1.6 (1.1 to 2.3)	2.4 (1.6 to 3.2)	44.5 (29.2 to 62.7)	32.8 (18.5 to 49.2)
Other digestive diseases	-	-	-	-	0.3 (0.2 to 0.5)	0.7 (0.4 to 0.9)	104.6 (50.0 to 158.5)	90.8 (39.6 to 140.3)
Neurological disorders	-	-	-	-	113.0 (76.2 to 156.0)	133.1 (90.9 to 184.7)	17.5 (6.1 to 31.7)	11.0 (0.6 to 24.4)
Alzheimer disease and other dementias	102.6 (90.0 to 116.5)	136.6 (115.8 to 156.5)	33.7 (7.7 to 62.1)	-0.0 (-19.4 to 21.2)	15.1 (10.7 to 19.7)	20.6 (14.5 to 27.9)	36.3 (9.8 to 66.2)	0.1 (-19.2 to 22.0)
Parkinson disease	5.8 (5.0 to 6.5)	7.0 (6.0 to 7.9)	22.2 (15.3 to 28.4)	0.1 (-4.9 to 5.0)	0.7 (0.5 to 0.9)	0.8 (0.6 to 1.1)	22.9 (5.1 to 38.8)	0.4 (-12.9 to 14.5)
Epilepsy	21.7 (14.7 to 28.9)	18.3 (11.8 to 24.8)	-15.3 (-47.5 to 36.4)	-10.0 (-44.2 to 45.6)	6.5 (3.7 to 9.9)	5.8 (3.2 to 9.1)	-10.8 (-48.2 to 52.5)	-4.1 (-44.2 to 63.4)
Multiple sclerosis	6.6 (6.0 to 7.3)	9.3 (8.3 to 10.3)	39.9 (21.8 to 61.5)	30.8 (13.6 to 50.5)	2.2 (1.5 to 2.8)	3.1 (2.2 to 3.9)	39.6 (16.5 to 70.5)	30.6 (8.8 to 59.0)
Migraine	1,709.7 (1,562.7 to 1,854.6)	1,705.0 (1,564.9 to 1,848.2)	0.1 (-10.4 to 12.9)	0.2 (-10.5 to 13.4)	57.7 (33.8 to 85.1)	57.7 (34.2 to 85.3)	-0.2 (-10.7 to 13.4)	0.5 (-10.3 to 14.1)
Tension-type headache	3,008.2 (2,805.2 to 3,199.1)	2,957.0 (2,618.9 to 3,296.0)	-1.7 (-13.2 to 13.0)	-1.3 (-13.3 to 15.1)	6.3 (2.2 to 7.9)	6.5 (2.1 to 8.0)	0.3 (-14.0 to 13.3)	0.3 (-13.6 to 16.4)
Medication overuse headache	155.0 (100.9 to 212.5)	247.9 (167.5 to 334.7)	58.9 (25.4 to 124.7)	51.7 (17.3 to 110.1)	24.1 (13.3 to 38.6)	38.8 (21.7 to 60.8)	59.1 (25.0 to 127.0)	16.9 (5.7 to 111.1)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.0 (-24.0 to 48.2)	2.6 (-24.3 to 42.5)	2.1 (1.4 to 2.9)	1.9 (1.3 to 2.7)	-8.5 (-32.1 to 18.5)	-29.8 (-47.3 to -10.0)
Mental and substance use disorders	-	-	-	-	254.2 (178.3 to 343.4)	253.0 (177.0 to 343.1)	-0.5 (-3.7 to 2.9)	0.2 (-2.5 to 3.3)
Schizophrenia	33.3 (30.5 to 35.9)	34.7 (31.8 to 37.3)	4.5 (0.2 to 9.4)	-0.0 (-4.2 to 4.6)	21.2 (15.4 to 25.7)	22.2 (16.3 to 27.0)	4.7 (-1.7 to 11.7)	0.5 (-5.9 to 6.9)
Alcohol use disorders	261.7 (238.9 to 287.7)	290.5 (264.7 to 317.9)	11.4 (5.2 to 18.6)	8.6 (2.4 to 15.7)	29.0 (17.3 to 36.7)	29.0 (19.2 to 41.1)	11.8 (4.9 to 19.6)	9.2 (2.3 to 16.8)
Drug use disorders	-	-	-	-	14.7 (10.2 to 19.1)	14.5 (10.0 to 19.3)	-1.4 (-14.1 to 12.1)	2.3 (-11.1 to 16.5)
Opioid use disorders	18.1 (15.6 to 20.5)	17.5 (14.9 to 19.9)	-3.4 (-10.1 to 4.5)	-0.8 (-7.1 to 7.1)	7.5 (5.2 to 9.9)	7.3 (5.0 to 9.8)	-3.1 (-12.5 to 8.3)	-0.4 (-9.6 to 10.7)
Cocaine use disorders	8.8 (6.8 to 10.6)	8.4 (6.7 to 10.3)	-5.6 (-29.7 to 35.0)	-5.2 (-30.3 to 39.2)	1.2 (0.7 to 1.8)	1.2 (0.7 to 1.7)	-0.2 (-33.1 to 43.6)	-4.6 (-33.4 to 48.9)
Amphetamine use disorders	15.2 (13.5 to 19.1)	15.7 (13.6 to 19.4)	3.6 (-19.4 to 31.2)	3.6 (-15.5 to 40.1)	2.1 (1.3 to 3.2)	2.1 (1.3 to 3.3)	9.9 (-21.6 to 34.4)	9.7 (-17.4 to 42.2)
Cannabis use disorders	15.9 (12.8 to 18.7)	14.5 (11.7 to 17.0)	-8.5 (-10.8 to -6.6)	0.5 (0.4 to 0.7)	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.6)	-8.6 (-21.3 to 6.5)	0.7 (-13.3 to 18.1)
Other drug use disorders	-	-	-	-	3.4 (2.0 to 5.0)	3.4 (2.0 to 5.0)	-0.2 (-28.7 to 45.5)	4.4 (-26.3 to 51.2)
Depressive disorders	-	-	-	-	108.5 (65.3 to 166.1)	108.8 (62.7 to 168.3)	0.3 (-6.6 to 7.8)	-1.3 (-7.5 to 5.6)
Major depressive disorder	454.9 (289.0 to 631.6)	451.1 (271.3 to 636.5)	-0.3 (-8.8 to 7.9)	-2.0 (-9.0 to 6.6)	92.4 (51.3 to 144.5)	91.5 (49.3 to 146.0)	-0.7 (-9.3 to 8.0)	-1.5 (-8.9 to 6.7)
Dysthymia	168.2 (138.9 to 196.0)	177.8 (147.9 to 207.5)	6.2 (4.4 to 8.1)	-0.3 (-0.4 to -0.1)	16.1 (10.4 to 23.3)	17.0 (11.1 to 25.0)	5.9 (3.1 to 9.2)	0.1 (-2.5 to 2.3)
Bipolar disorder	75.3 (66.0 to 84.2)	76.7 (67.9 to 86.3)	2.4 (-2.7 to 7.3)	-0.5 (-5.8 to 4.9)	15.2 (9.4 to 22.7)	15.5 (9.6 to 23.0)	2.2 (-4.4 to 8.8)	-0.3 (-7.0 to 5.8)
Anxiety disorders	271.8 (238.1 to 302.2)	261.7 (229.6 to 290.4)	-3.3 (-5.1 to -1.6)	-0.4 (-0.5 to -0.3)	24.8 (17.0 to 34.7)	23.8 (16.2 to 33.3)	-3.8 (-7.0 to -0.2)	-0.2 (-3.2 to 2.9)
Eating disorders	-	-	-	-	2.4 (1.5 to 3.7)	2.1 (1.3 to 3.3)	-0.3 (-18.7 to 4.3)	-0.3 (-8.2 to 8.2)
Anorexia nervosa	1.1 (0.9 to 1.4)	1.0 (0.8 to 1.3)	-7.4 (-17.1 to 1.3)	7.2 (-4.3 to 17.2)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-8.0 (-30.3 to 19.5)	7.5 (-19.3 to 38.3)
Bulimia nervosa	10.2 (7.4 to 13.6)	9.0 (6.3 to 12.2)	-11.7 (-15.1 to -8.3)	-1.0 (-1.4 to -0.6)	2.2 (1.3 to 3.3)	1.9 (1.1 to 3.0)	-12.0 (-19.2 to -3.3)	-1.0 (-8.8 to 7.6)
Autistic spectrum disorders	-	-	-	-	11.5 (8.0 to 15.6)	10.5 (7.3 to 14.2)	-8.7 (-11.8 to -5.7)	0.9 (-2.5 to 4.1)
Autism	29.9 (28.3 to 31.6)	27.3 (25.8 to 28.9)	-8.3 (-8.9 to -7.7)	0.5 (0.5 to 0.5)	7.3 (4.9 to 10.1)	6.7 (4.5 to 9.1)	-8.7 (-13.0 to -4.3)	0.9 (-3.8 to 5.4)
Asperger syndrome	42.3 (39.7 to 44.9)	38.5 (35.9 to 41.2)	-8.6 (-9.3 to -7.9)	0.6 (0.6 to 0.7)	4.2 (2.9 to 5.9)	3.8 (2.7 to 5.3)	0.4 (-1.4 to -5.3)	0.9 (-3.0 to 4.7)
Attention-deficit/hyperactivity disorder	46.7 (43.0 to 50.4)	31.5 (29.0 to 34.0)	-32.2 (-32.9 to -31.8)	0.7 (0.7 to 0.8)	0.6 (0.3 to 0.9)	0.4 (0.2 to 0.6)	-32.3 (-37.0 to -26.7)	0.8 (-6.4 to 8.8)
Conduct disorder	67.7 (63.8 to 71.7)	43.5 (40.7 to 46.3)	-35.5 (-36.3 to -34.4)	0.7 (0.7 to 0.8)	8.2 (5.1 to 12.0)	5.3 (3.3 to 7.7)	-35.5 (-38.5 to -32.2)	0.9 (-3.6 to 5.5)
Idiopathic intellectual disability	163.0 (136.2 to 196.8)	131.7 (109.7 to 157.7)	-18.9 (-26.0 to -11.5)	-9.8 (-17.6 to -1.6)	7.9 (5.2 to 11.2)	6.4 (4.3 to 9.1)	-11.1 (-26.3 to -10.9)	-9.6 (-17.5 to -0.6)
Other mental and substance use disorders	179.5 (168.8 to 190.4)	194.3 (183.2 to 205.7)	8.7 (7.5 to 9.9)	0.3 (0.2 to 0.5)	13.3 (8.9 to 17.8)	14.4 (9.8 to 19.4)	8.6 (4.6 to 12.7)	0.6 (-3.1 to 4.3)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	86.1 (61.2 to 115.0)	92.1 (63.9 to 124.4)	7.0 (-3.8 to 18.0)	2.4 (-7.3 to 11.6)
Diabetes mellitus	312.0 (250.3 to 380.9)	372.0 (277.9 to 480.4)	20.7 (-11.8 to 52.2)	12.7 (-14.9 to 39.0)	25.9 (17.2 to 36.4)	31.5 (20.0 to 47.0)	21.9 (9.2 to 53.7)	12.0 (-15.0 to 38.6)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.8 (-35.9 to -21.3)	-22.9 (-29.5 to -15.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.8 (-35.9 to -21.2)	-22.9 (-29.6 to -15.6)
Chronic kidney disease	-	-	-	-	26.7 (19.1 to 35.2)	27.2 (19.2 to 36.3)	2.0 (-7.7 to 12.6)	2.6 (-12.0 to 6.8)
Chronic kidney disease due to diabetes mellitus	132.2 (92.7 to 190.3)	145.5 (88.8 to 211.5)	12.4 (-26.3 to 50.7)	-1.6 (-35.3 to 28.7)	4.4 (3.0 to 6.3)	4.6 (2.9 to 6.7)	5.3 (-24.2 to 39.4)	-6.0 (-32.0 to 22.8)
Chronic kidney disease due to hypertension	197.9 (141.3 to 278.7)	204.1 (124.4 to 290.3)	4.0 (-25.5 to 39.7)	1.0 (-24.5 to 31.8)	7.0 (4.4 to 10.0)	2.5 (1.6 to 3.5)	-64.7 (-73.6 to -48.8)	-67.3 (-75.3 to -53.3)
Chronic kidney disease due to glomerulonephritis	205.4 (142.0 to 279.1)	126.5 (97.1 to 169.4)	-37.9 (-52.5 to -15.2)	-38.4 (-51.1 to -18.4)	6.9 (4.7 to 9.7)	8.3 (5.6 to 11.7)	20.0 (-5.5 to 47.1)	20.0 (-5.2 to 44.9)
Chronic kidney disease due to other causes	257.8 (180.8 to 358.3)	398.5 (250.8 to 531.1)	53.3 (6.6 to 92.6)	28.7 (4.5 to 72.2)	36.3 (5.8 to 11.1)	36.3 (7.7 to 16.3)	40.9 (5.1 to 85.5)	34.4 (2.3 to 71.0)
Urinary diseases and male infertility	-	-	-	-	9.0 (5.8 to 12.7)	10.9 (7.1 to 15.7)	21.4 (9.9 to 34.6)	5.2 (-4.5 to 16.7)
Interstitial nephritis and urinary tract infections	3.7 (3.5 to 4.0)	4.3 (4.1 to 4.6)	17.0 (6.3 to 28.6)	23.4 (11.5 to 36.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	15.7 (-1.8 to 39.3)	22.7 (3.9 to 48.3)

Appendix Table G.4 - Belarus prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Urolithiasis	66.3 (47.9 to 91.2)	77.0 (42.5 to 116.9)	14.1 (-14.8 to 52.2)		0.7 (0.5 to 1.1)	0.8 (0.4 to 1.3)	7.8 (-13.6 to 35.7)	-7.0 (-25.0 to 18.7)
Benign prostatic hyperplasia	213.8 (199.0 to 230.8)	234 (245.7 to 282.0)	23.4 (11.1 to 38.4)		5.1 (5.1 to 18.0)	7.7 (6.2 to 13.5)	9.5 (11.2 to 38.4)	5.6 (-4.9 to 18.3)
Male infertility due to other causes	68.7 (54.1 to 84.9)	63.9 (51.3 to 77.3)	-6.5 (-31.2 to 24.2)		-0.5 (-26.6 to 32.1)	0.4 (0.2 to 0.9)	-6.4 (-31.5 to 26.4)	-0.6 (-26.9 to 33.7)
Other urinary diseases	-	-	-		0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	121.7 (9.1 to 195.3)	98.9 (3.4 to 166.5)
Gynecological diseases	-	-	-		12.2 (7.6 to 18.9)	13.6 (8.4 to 19.7)	3.8 (-7.8 to 25.9)	7.3 (-9.1 to 24.0)
Uterine fibroids	227.3 (207.0 to 246.1)	254.5 (233.5 to 274.7)	12.4 (11.2 to 13.8)		2.7 (1.5 to 4.7)	2.9 (1.6 to 5.0)	6.3 (-2.2 to 13.3)	-1.2 (-6.4 to 4.8)
Polycystic ovarian syndrome	177.3 (159.8 to 194.3)	176.1 (159.2 to 191.7)	-0.4 (-12.2 to 13.7)		-0.3 (-12.2 to 13.1)	1.7 (0.8 to 3.3)	-0.5 (-12.2 to 13.6)	0.0 (-12.0 to 13.6)
Female infertility due to other causes	44.9 (25.8 to 67.3)	44.8 (26.2 to 64.0)	-0.2 (-47.9 to 93.3)		8.1 (-43.0 to 108.1)	0.2 (0.1 to 0.5)	-0.3 (-46.0 to 92.1)	7.3 (-41.8 to 103.6)
Endometriosis	18.8 (15.8 to 22.2)	20.4 (17.4 to 23.6)	8.4 (-13.5 to 37.2)		6.7 (-14.2 to 34.6)	1.9 (1.1 to 2.5)	1.9 (-14.9 to 41.4)	7.3 (-15.4 to 38.2)
Genital prolapse	599.0 (533.9 to 656.5)	637.6 (569.7 to 715.8)	7.0 (-8.1 to 24.9)		-0.8 (-15.3 to 16.7)	2.0 (0.9 to 3.6)	7.0 (8.4 to 25.2)	-0.7 (-15.2 to 16.6)
Premenstrual syndrome	368.5 (240.6 to 493.1)	404.6 (258.1 to 548.8)	8.1 (-33.1 to 96.2)		12.2 (-29.9 to 100.7)	3.1 (1.7 to 5.0)	7.9 (-34.5 to 99.2)	12.1 (-30.7 to 104.1)
Other gynecological diseases	30.6 (27.2 to 34.0)	30.0 (27.0 to 33.2)	-1.5 (-14.3 to 14.4)		-2.9 (-15.6 to 12.1)	0.8 (0.5 to 1.2)	-1.5 (-20.7 to 32.1)	-2.0 (-21.0 to 30.7)
Hemoglobinopathies and hemolytic anemias	-	-	-		7.1 (4.7 to 10.1)	5.9 (3.9 to 8.5)	-16.5 (-24.1 to -5.1)	0.7 (-8.3 to 13.6)
Thalassemias	0.2 (0.2 to 0.2)	0.1 (0.1 to 0.2)	-29.0 (-38.4 to -19.5)		6.1 (8.1 to 0.0)	0.0 (0.0 to 0.0)	-29.2 (-47.1 to -8.1)	3.7 (-23.0 to 35.2)
Thalassemia trait	173.1 (164.4 to 184.5)	166.1 (156.5 to 176.6)	-3.7 (-8.6 to 1.6)		3.2 (-1.7 to 8.1)	5.8 (3.9 to 8.3)	-15.4 (-22.4 to -5.7)	0.9 (-7.6 to 10.6)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.0 (-24.5 to 26.9)		1.5 (-6.6 to 54.2)	0.0 (0.0 to 0.0)	-12.5 (-21.8 to 41.8)	5.9 (-4.0 to 70.6)
Sickle cell trait	4.7 (4.2 to 5.3)	4.4 (3.9 to 4.9)	-6.6 (-11.5 to -3.8)		0.0 (-4.7 to 6.6)	0.0 (0.0 to 0.1)	-31.0 (-62.6 to 15.7)	-0.8 (-49.3 to 68.8)
G6PD deficiency	17.1 (14.9 to 19.4)	16.3 (15.0 to 17.4)	-4.8 (-18.9 to 9.9)		0.4 (-12.8 to 18.4)	0.0 (0.0 to 0.0)	-13.9 (-39.4 to 14.4)	5.7 (-19.2 to 36.3)
G6PD trait	1,087.2 (1,075.9 to 1,100.7)	1,017.4 (1,005.4 to 1,032.2)	-6.1 (-7.6 to -4.2)		-1.4 (-3.0 to 0.6)	0.1 (0.0 to 0.1)	-15.2 (-71.4 to 108.4)	3.0 (-75.0 to 186.5)
Other hemoglobinopathies and hemolytic anemias	43.3 (31.5 to 52.2)	36.7 (31.7 to 40.8)	-14.6 (-35.8 to 24.6)		-1.8 (-23.4 to 42.3)	1.1 (0.5 to 1.8)	-21.8 (-53.6 to 88.5)	-0.8 (-31.4 to 127.1)
Endocrine, metabolic, blood, and immune disorders	149.3 (137.9 to 160.2)	105.6 (100.7 to 110.9)	-29.0 (-34.4 to -21.6)		5.2 (-27.1 to -12.5)	3.6 (2.4 to 4.9)	-31.4 (-37.1 to -21.7)	-22.1 (-29.1 to -10.9)
Musculoskeletal disorders	-	-	-		255.2 (182.4 to 338.8)	253.2 (204.5 to 380.8)	12.7 (4.1 to 21.2)	2.3 (-5.9 to 10.5)
Rheumatoid arthritis	47.9 (45.4 to 50.3)	55.1 (52.7 to 57.6)	15.5 (8.4 to 23.9)		11.1 (8.0 to 14.6)	12.8 (9.2 to 17.0)	15.1 (6.9 to 24.6)	1.7 (-5.3 to 9.7)
Osteoarthritis	582.7 (559.5 to 608.8)	698.9 (672.7 to 725.5)	20.6 (13.9 to 26.8)		35.5 (-4.8 to 5.9)	42.7 (30.0 to 57.8)	20.4 (13.4 to 27.2)	1.0 (-4.8 to 6.7)
Low back and neck pain	-	-	-		178.3 (123.2 to 241.8)	195.5 (134.4 to 266.1)	10.1 (-1.6 to 22.6)	2.1 (-9.0 to 14.0)
Low back pain	1,191.4 (1,090.7 to 1,293.9)	1,298.2 (1,180.5 to 1,410.3)	9.2 (-2.0 to 23.1)		0.3 (-10.5 to 13.0)	0.3 (88.7 to 180.6)	0.3 (96.5 to 200.6)	0.6 (-2.3 to 10.0)
Neck pain	484.2 (408.3 to 563.8)	534.8 (446.9 to 623.4)	10.7 (-11.0 to 41.2)		2.9 (-16.9 to 33.2)	47.2 (31.2 to 66.0)	52.2 (-11.5 to 42.3)	3.4 (-16.7 to 34.0)
Gout	6.9 (6.4 to 7.4)	7.8 (7.3 to 8.3)	14.2 (3.7 to 25.8)		-0.2 (-9.2 to 9.5)	0.3 (0.1 to 0.3)	13.2 (8.6 to 43.9)	-0.5 (-18.6 to 27.4)
Other musculoskeletal disorders	332.9 (262.0 to 402.4)	393.5 (317.0 to 473.1)	18.7 (10.3 to 27.5)		6.4 (-0.3 to 13.5)	30.1 (19.9 to 43.5)	35.7 (23.5 to 51.5)	6.6 (-0.7 to 14.0)
Other non-communicable diseases	-	-	-		179.5 (120.5 to 256.7)	179.7 (121.2 to 256.6)	6.2 (-3.5 to 3.6)	6.4 (-10.1 to -3.1)
Congenital anomalies	-	-	-		12.2 (8.8 to 16.0)	12.4 (8.8 to 16.0)	0.9 (-11.0 to 15.2)	7.5 (-5.9 to 24.2)
Neural tube defects	2.7 (2.2 to 3.4)	1.9 (1.6 to 2.3)	-27.1 (-47.0 to -4.7)		-13.5 (-37.1 to 13.3)	0.8 (0.5 to 1.3)	-25.9 (-53.3 to 10.0)	-11.4 (-44.0 to 31.7)
Congenital heart anomalies	59.0 (50.3 to 70.4)	65.4 (57.4 to 77.0)	12.1 (-9.3 to 36.4)		23.1 (-0.1 to 49.3)	2.1 (0.9 to 3.6)	13.6 (-7.1 to 37.7)	27.5 (-4.4 to 53.8)
Crofacial clefts	7.9 (6.6 to 9.7)	9.0 (7.6 to 10.8)	14.6 (-4.8 to 44.3)		21.7 (-3.8 to 53.9)	0.1 (0.1 to 0.2)	-18.7 (-40.2 to 15.6)	-13.6 (-38.2 to 22.4)
Down syndrome	10.7 (8.8 to 12.8)	11.8 (10.1 to 14.1)	10.7 (-10.4 to 37.6)		14.0 (-7.7 to 41.8)	1.8 (1.0 to 1.9)	20.3 (-3.9 to 54.3)	3.1 (-4.8 to 51.1)
Turner syndrome	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.5)	-11.3 (-44.0 to 28.2)		0.0 (-36.2 to 43.9)	0.0 (0.0 to 0.0)	-9.4 (-44.0 to 32.4)	1.2 (-37.8 to 47.5)
Klinefelter syndrome	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	6.5 (-22.9 to 45.3)		18.2 (-14.6 to 61.2)	0.0 (0.0 to 0.0)	13.0 (-19.3 to 53.9)	17.8 (-14.9 to 60.6)
Chromosomal unbalanced rearrangements	15.5 (12.8 to 19.0)	16.7 (14.4 to 19.5)	9.2 (-14.5 to 32.6)		2.2 (-11.9 to 36.6)	2.5 (1.5 to 2.9)	18.5 (-8.8 to 47.6)	16.8 (-9.4 to 44.8)
Other congenital anomalies	48.2 (40.1 to 55.8)	39.4 (32.0 to 46.4)	-18.5 (-27.2 to -7.7)		5.6 (-25.1 to -5.0)	5.0 (3.9 to 7.7)	-10.5 (-24.6 to 11.9)	2.1 (-18.1 to 24.0)
Skin and subcutaneous diseases	-	-	-		50.4 (33.2 to 74.9)	45.2 (29.5 to 67.1)	-10.4 (-17.1 to -4.1)	-5.1 (-11.6 to 1.2)
Dermatitis	475.1 (390.2 to 567.0)	456.4 (374.9 to 544.1)	-3.5 (-5.4 to -1.7)		13.1 (8.1 to 18.8)	12.3 (7.7 to 17.7)	-6.2 (-9.8 to -2.9)	0.1 (-2.7 to 3.1)
Psoriasis	89.4 (79.1 to 99.6)	90.9 (79.8 to 101.5)	2.1 (-0.8 to 3.6)		7.2 (-0.0 to 0.1)	7.3 (4.9 to 10.1)	1.9 (-3.7 to 7.7)	0.2 (-5.3 to 5.7)
Cellulitis	5.5 (4.5 to 6.5)	5.0 (4.2 to 6.3)	-8.1 (-17.9 to 1.0)		0.4 (-8.7 to 8.5)	0.4 (0.2 to 0.6)	8.5 (-24.1 to 10.9)	0.9 (-16.3 to 20.3)
Pyoderma	8.4 (7.0 to 10.1)	8.7 (7.1 to 11.0)	3.8 (-5.2 to 12.2)		7.6 (0.0 to 15.1)	0.0 (0.0 to 0.1)	2.7 (-9.6 to 15.5)	7.1 (-4.1 to 19.8)
Scabies	30.3 (25.5 to 35.5)	26.8 (22.1 to 32.8)	-11.6 (-29.9 to 13.5)		-0.2 (-19.3 to 26.0)	0.7 (0.4 to 1.1)	-11.8 (-30.5 to 13.5)	-0.1 (-20.1 to 27.4)
Fungal skin diseases	823.2 (645.6 to 1,075.4)	811.7 (635.1 to 1,047.5)	-0.9 (-5.0 to 2.8)		0.2 (-0.1 to 0.3)	4.6 (1.9 to 10.0)	-1.1 (-5.3 to 2.8)	0.3 (-0.5 to 1.2)
Viral skin diseases	205.8 (158.2 to 254.8)	169.4 (123.5 to 216.3)	-17.4 (-22.0 to -13.7)		6.3 (-1.8 to 9.9)	6.3 (3.6 to 9.9)	0.2 (-2.8 to 3.3)	0.2 (-3.1 to 3.4)
Acne vulgaris	308.2 (239.4 to 369.0)	243.6 (199.9 to 291.6)	-21.2 (-39.4 to 6.2)		-4.6 (-26.3 to 29.0)	3.3 (1.5 to 6.2)	-21.4 (-39.6 to 6.0)	-4.8 (-26.5 to 29.2)
Alopecia areata	12.5 (11.1 to 14.1)	12.8 (11.2 to 14.6)	3.4 (-13.2 to 21.4)		0.8 (-14.6 to 18.7)	0.4 (0.3 to 0.6)	3.2 (-15.7 to 24.4)	1.5 (-1.6 to 22.1)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.9 (-20.5 to 38.2)		1.1 (-23.0 to 30.1)	0.0 (0.0 to 0.0)	4.9 (-20.5 to 38.2)	1.1 (-23.0 to 30.3)
Urticaria	164.2 (122.0 to 213.6)	114.5 (79.5 to 152.0)	-29.5 (-51.6 to 1.0)		-25.7 (-49.1 to 5.4)	9.7 (5.7 to 14.5)	-29.2 (-51.3 to 0.4)	-25.3 (-49.1 to 7.2)
Decubitus ulcer	1.3 (1.1 to 1.7)	2.3 (1.8 to 2.8)	71.2 (31.3 to 116.1)		0.2 (-9.8 to 79.6)	0.3 (0.1 to 0.3)	67.0 (20.4 to 127.8)	40.8 (2.6 to 89.8)
Other skin and subcutaneous diseases	754.8 (448.8 to 1,279.0)	775.7 (447.0 to 1,327.8)	3.0 (-3.7 to 9.6)		4.5 (-8.5 to 0.7)	4.4 (1.8 to 9.7)	2.9 (-3.6 to 9.6)	-4.3 (-8.3 to -0.3)
Sense organ diseases	-	-	-		93.4 (62.3 to 133.3)	96.9 (65.3 to 137.8)	3.9 (-2.3 to 9.4)	-10.2 (-15.4 to -5.4)
Glaucoma	15.1 (11.8 to 18.5)	15.2 (12.0 to 18.8)	0.6 (-16.5 to 20.8)		-13.3 (-6.6 to 7.6)	0.9 (0.1 to 0.3)	9.6 (-4.7 to 35.8)	-8.9 (-9.1 to 10.9)
Cataract	134.3 (105.1 to 162.5)	128.2 (97.8 to 156.2)	-4.1 (-20.8 to 12.3)		-24.7 (-38.0 to -10.9)	5.2 (3.2 to 7.7)	-2.6 (-19.2 to 12.3)	-24.2 (-37.7 to -11.3)
Macular degeneration	36.0 (25.6 to 48.5)	46.6 (33.6 to 63.5)	28.8 (-1.7 to 85.9)		6.7 (-17.2 to 60.7)	1.3 (0.8 to 2.1)	29.5 (1.4 to 82.9)	5.9 (-15.6 to 55.9)
Uncorrected refractive error	1,082.7 (908.7 to 1,245.5)	1,119.8 (959.7 to 1,276.6)	5.1 (-17.6 to 27.8)		-6.9 (-26.4 to 12.1)	16.7 (9.6 to 27.6)	-1.0 (-16.1 to 12.8)	-10.8 (-23.7 to 1.6)
Age-related and other hearing loss	2,022.1 (1,787.2 to 2,226.3)	2,151.7 (1,912.5 to 2,363.8)	6.7 (-2.7 to 11.7)		-7.6 (-11.2 to -3.5)	59.8 (39.9 to 83.3)	64.1 (43.1 to 90.7)	-9.7 (-31.0 to 15.0)
Other vision loss	68.3 (55.7 to 84.2)	51.1 (41.4 to 63.4)	-24.8 (-34.2 to -13.1)		3.1 (-37.3 to -38.3)	2.5 (2.1 to 4.6)	-18.2 (-27.5 to -8.1)	-23.8 (-31.5 to -15.0)
Other sense organ diseases	246.1 (233.1 to 258.9)	231.9 (221.0 to 244.1)	-5.5 (-11.9 to 1.5)		0.3 (-6.1 to 7.5)	6.5 (4.0 to 9.6)	6.1 (-12.8 to 1.0)	0.5 (-6.2 to 7.7)
Oral disorders	-	-	-		23.5 (14.5 to 35.7)	25.3 (15.6 to 37.9)	7.6 (3.6 to 11.8)	-2.0 (-5.8 to 1.7)
Deciduous caries	584.2 (555.0 to 614.7)	339.3 (320.4 to 357.4)	-41.6 (-46.0 to -37.6)		0.1 (-6.6 to 7.6)	0.1 (0.1 to 0.3)	0.1 (-4.7 to 35.8)	0.7 (-9.1 to 10.9)
Permanent caries	4,736.9 (4,344.0 to 5,101.0)	4,460.5 (4,120.9 to 4,798.5)	-5.7 (-14.2 to 5.7)		2.8 (-11.1 to 10.7)	2.6 (1.2 to 5.0)	1.8 (-34.1 to 5.9)	-1.8 (-10.6 to 11.2)
Periodontal diseases	695.2 (659.2 to 730.4)	769.6 (733.7 to 805.9)	11.1 (3.6 to 19.3)		0.6 (-6.0 to 7.8)	4.5 (1.8 to 9.2)	5.0 (3.4 to 19.0)	0.8 (1.2 to 8.0)
Edentulism and severe tooth loss	385.9 (370.1 to 401.9)	437.8 (421.3 to 455.2)	13.9 (7.5 to 20.5)		-5.2 (-10.4 to 0.3)	10.5 (7.2 to 14.6)	13.8 (7.2 to 20.5)	-5.0 (-10.2 to 0.7)

Appendix Table G.4 - Belarus prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Other oral disorders	190.6 (180.7 to 201.5)	191.0 (180.2 to 201.1)	0.6 (-6.9 to 8.1)	0.3 (-7.1 to 7.7)	5.5 (3.5 to 8.3)	5.6 (3.5 to 8.2)	0.6 (-7.3 to 8.4)	0.6 (-7.7 to 8.2)
Injuries	-	-	-	-	84.4 (63.2 to 109.7)	59.6 (42.4 to 80.5)	-29.8 (-36.2 to -22.4)	-36.9 (-42.7 to -30.2)
Transport injuries	-	-	-	-	29.4 (21.9 to 38.1)	16.3 (11.5 to 22.2)	-45.0 (-51.8 to -37.1)	-50.2 (-56.3 to -43.1)
Road injuries	-	-	-	-	24.7 (18.3 to 31.9)	13.3 (9.4 to 18.2)	-46.5 (-53.3 to -38.4)	-51.6 (-57.8 to -44.2)
Pedestrian road injuries	-	-	-	-	5.4 (3.9 to 6.9)	2.9 (2.1 to 4.0)	-45.2 (-52.1 to -36.8)	-51.6 (-57.7 to -44.1)
Cyclist road injuries	-	-	-	-	3.8 (2.8 to 4.9)	2.1 (1.5 to 2.9)	-43.2 (-49.6 to -36.7)	-48.4 (-54.0 to -42.3)
Motorcyclist road injuries	-	-	-	-	2.3 (1.7 to 3.0)	1.1 (0.8 to 1.6)	-51.0 (-57.4 to -43.0)	-55.0 (-60.8 to -47.8)
Motor vehicle road injuries	-	-	-	-	13.0 (9.7 to 16.7)	7.0 (4.9 to 9.5)	-46.7 (-54.2 to -37.3)	-51.5 (-58.4 to -43.0)
Other road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-63.0 (-67.8 to -57.7)	-66.4 (-70.8 to -61.4)
Other transport injuries	-	-	-	-	4.7 (3.5 to 6.3)	3.0 (2.1 to 4.1)	-37.6 (-44.2 to -30.0)	-43.2 (-49.2 to -36.4)
Unintentional injuries	-	-	-	-	52.6 (39.8 to 68.5)	41.7 (29.8 to 56.2)	-21.1 (-27.1 to -14.1)	-29.5 (-34.9 to -23.0)
Falls	-	-	-	-	22.8 (17.1 to 29.4)	18.7 (13.1 to 25.4)	-18.1 (-27.0 to -7.4)	-28.9 (-36.9 to -19.5)
Drowning	-	-	-	-	0.9 (0.7 to 1.2)	0.4 (0.3 to 0.6)	-53.0 (-59.2 to -45.8)	-56.7 (-62.2 to -50.0)
Fire, heat, and hot substances	-	-	-	-	2.4 (1.8 to 3.0)	1.7 (1.2 to 2.4)	-27.3 (-36.3 to -17.2)	-32.6 (-40.9 to -23.6)
Poisonings	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.2)	-42.8 (-49.9 to -34.2)	-42.4 (-49.8 to -33.2)
Exposure to mechanical forces	-	-	-	-	13.8 (10.3 to 18.3)	9.9 (7.2 to 13.5)	-28.5 (-33.2 to -23.3)	-33.1 (-37.0 to -28.4)
Unintentional firearm injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-54.0 (-61.4 to -45.9)	-55.4 (-62.4 to -47.7)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-31.4 (-38.5 to -23.2)	-35.4 (-41.8 to -27.9)
Other exposure to mechanical forces	-	-	-	-	13.5 (10.0 to 17.8)	9.7 (7.0 to 13.3)	-28.0 (-32.6 to -22.8)	-32.6 (-36.5 to -28.0)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	11.5 (3.0 to 20.6)	2.3 (-5.4 to 9.9)
Animal contact	-	-	-	-	0.7 (0.5 to 0.9)	0.6 (0.4 to 0.8)	-14.8 (-22.3 to -6.3)	-17.7 (-25.0 to -10.2)
Venomous animal contact	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-10.4 (-20.0 to 0.3)	-12.4 (-22.4 to -1.8)
Non-venomous animal contact	-	-	-	-	0.5 (0.4 to 0.6)	0.4 (0.3 to 0.5)	-16.8 (-25.1 to -7.4)	-20.4 (-27.9 to -11.5)
Foreign body	-	-	-	-	0.7 (0.6 to 0.9)	0.5 (0.4 to 0.7)	-24.6 (-31.6 to -16.5)	-28.8 (-35.4 to -21.3)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.2)	-38.6 (-48.5 to -26.7)	-42.7 (-51.7 to -32.2)
Foreign body in eyes	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-9.9 (-15.1 to -4.2)	-9.9 (-16.5 to -4.0)
Foreign body in other body part	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.3)	-16.5 (-24.5 to -7.7)	-22.9 (-30.0 to -15.0)
Other unintentional injuries	-	-	-	-	10.9 (8.1 to 14.3)	9.4 (6.8 to 12.5)	-14.0 (-20.3 to -6.9)	-23.7 (-29.1 to -17.2)
Self-harm and interpersonal violence	-	-	-	-	2.3 (1.8 to 3.0)	1.6 (1.1 to 2.2)	-31.0 (-38.7 to -21.9)	-37.3 (-44.1 to -29.2)
Self-harm	-	-	-	-	1.1 (0.8 to 1.4)	0.9 (0.6 to 1.2)	-19.2 (-27.8 to -9.0)	-26.3 (-34.0 to -17.1)
Interpersonal violence	-	-	-	-	1.3 (1.0 to 1.6)	0.7 (0.5 to 1.0)	-41.1 (-49.2 to -32.0)	-46.8 (-54.0 to -38.6)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-41.5 (-47.0 to -34.7)	-46.8 (-51.7 to -40.7)
Assault by sharp object	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-34.4 (-42.3 to -24.3)	-40.8 (-47.9 to -31.7)
Assault by other means	-	-	-	-	0.9 (0.7 to 1.2)	0.5 (0.4 to 0.7)	-42.6 (-51.0 to -33.3)	-48.2 (-55.6 to -40.0)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Belgium prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,341.9 (1,005.0 to 1,723.8)	1,566.2 (1,172.8 to 2,001.5)	16.7 (13.6 to 19.9)	16.7 (-4.9 to -0.2)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	50.6 (34.9 to 71.1)	54.6 (37.5 to 76.0)	7.9 (3.1 to 18.8)	0.7 (-8.6 to 9.6)
HIV/AIDS and tuberculosis	-	-	-	-	0.7 (0.5 to 1.1)	1.0 (0.7 to 1.5)	41.5 (12.4 to 78.1)	23.6 (-1.7 to 55.1)
Tuberculosis	2.0 (1.9 to 2.0)	2.0 (1.9 to 2.1)	2.0 (-1.8 to 6.0)	-7.3 (-10.8 to -3.5)	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.8)	2.0 (-15.1 to 23.6)	-6.5 (-22.5 to 13.6)
HIV/AIDS	-	-	-	-	0.1 (0.1 to 0.3)	0.4 (0.2 to 0.8)	216.4 (73.0 to 387.8)	183.5 (42.9 to 302.0)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.2 (-18.6 to 136.4)	41.5 (-26.5 to 113.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.2 (-18.8 to 136.9)	41.5 (-26.6 to 114.0)
HIV/AIDS resulting in other diseases	1.1 (0.6 to 1.9)	5.7 (2.3 to 9.6)	403.4 (218.5 to 604.4)	311.5 (157.4 to 479.7)	0.1 (0.1 to 0.3)	0.4 (0.2 to 0.8)	216.8 (73.0 to 390.4)	164.2 (42.9 to 302.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	5.9 (3.8 to 8.7)	5.8 (3.8 to 8.6)	-0.6 (-6.6 to 5.6)	-13.4 (-18.6 to -7.7)
Diarrheal diseases	3.4 (3.1 to 3.9)	3.6 (3.2 to 4.1)	4.1 (-11.3 to 26.2)	-11.1 (-26.8 to 14.4)	0.5 (0.4 to 0.8)	0.6 (0.4 to 0.8)	2.9 (-14.8 to 28.6)	-11.0 (-29.1 to 18.2)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (58.8 to 30.6)	-16.6 (-62.4 to 17.8)
Typhoid fever	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-12.2 (-26.3 to 3.8)	-20.6 (-33.2 to -5.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.2 (-26.5 to 3.8)	-20.6 (-33.3 to -5.5)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.5 (-4.5 to 51.8)	11.1 (-10.5 to 39.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.5 (-4.6 to 51.9)	11.1 (-10.6 to 39.3)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-65.7 (-99.1 to 720.9)	-88.7 (-99.2 to 641.7)
Lower respiratory infections	2.1 (2.1 to 2.2)	2.2 (2.1 to 2.2)	1.4 (-3.6 to 6.1)	-20.7 (-24.9 to -17.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	1.0 (-11.1 to 15.0)	-19.9 (-30.0 to -8.5)
Upper respiratory infections	150.2 (143.8 to 157.0)	163.9 (156.5 to 170.8)	9.4 (2.7 to 16.2)	0.4 (-5.7 to 6.7)	1.7 (1.0 to 2.9)	1.9 (1.1 to 3.1)	9.1 (1.9 to 16.8)	0.3 (-6.2 to 7.8)
Otitis media	118.4 (104.7 to 133.6)	119.5 (107.3 to 132.9)	1.4 (-11.8 to 15.9)	-10.1 (-20.8 to 1.9)	2.1 (1.2 to 3.3)	2.1 (1.2 to 3.4)	-0.2 (-13.5 to 14.3)	-11.4 (-22.1 to 0.9)
Meningitis	-	-	-	-	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.8)	-10.4 (-29.8 to 16.3)	-20.8 (-38.2 to 6.5)
Pneumococcal meningitis	1.6 (1.0 to 2.8)	1.6 (1.0 to 2.6)	-1.6 (-25.8 to 26.2)	-17.5 (-39.4 to 6.2)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	2.7 (-41.7 to 31.2)	-15.7 (-51.1 to 15.6)
H influenzae type B meningitis	1.1 (0.4 to 2.2)	0.8 (0.3 to 2.0)	-21.1 (-58.2 to 18.5)	-30.2 (-62.5 to 10.8)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-24.4 (-63.0 to 41.8)	-30.6 (-66.6 to 32.3)
Meningococcal meningitis	0.9 (0.3 to 2.1)	0.7 (0.2 to 1.9)	-18.0 (-54.1 to 31.3)	-29.7 (-60.1 to 21.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-24.3 (-55.7 to 40.9)	-34.5 (-62.1 to 31.3)
Other meningitis	1.0 (0.4 to 2.1)	1.1 (0.5 to 2.5)	15.6 (-29.9 to 57.7)	1.4 (-35.6 to 37.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	19.6 (-38.7 to 85.7)	6.1 (-44.4 to 62.4)
Encephalitis	0.4 (0.2 to 1.0)	0.4 (0.2 to 1.2)	13.1 (-7.2 to 44.7)	-2.2 (-20.8 to 23.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	21.8 (-2.3 to 54.4)	4.9 (-17.2 to 35.4)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.3 (-93.4 to 553.7)	-41.5 (-93.7 to 446.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.3 (-93.4 to 554.4)	-41.5 (-93.8 to 447.3)
Whooping cough	0.8 (0.6 to 1.1)	0.1 (0.1 to 0.1)	-90.8 (-92.2 to -89.3)	-91.5 (-92.7 to -90.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-90.9 (-94.7 to -85.9)	-91.5 (-95.1 to -86.9)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.3 (-63.4 to -31.9)	-50.8 (-68.6 to -33.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.7 (-64.3 to -32.5)	-51.3 (-68.8 to -34.6)
Measles	2.2 (2.2 to 2.2)	0.0 (0.0 to 0.0)	-99.9 (-100.0 to -99.9)	-99.9 (-100.0 to -99.9)	0.2 (0.1 to 0.3)	0.0 (0.0 to 0.0)	-99.9 (-100.0 to -99.9)	-99.9 (-100.0 to -99.9)
Varicella and herpes zoster	9.3 (8.3 to 10.4)	11.0 (9.7 to 12.4)	18.5 (0.2 to 38.2)	0.4 (-11.9 to 14.3)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.7)	21.3 (-3.9 to 50.8)	0.8 (-18.1 to 25.2)
Neglected tropical diseases and malaria	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-63.0 (-73.2 to -42.1)	-67.4 (-76.2 to -49.5)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.5 (-80.6 to 299.7)	24.8 (-82.2 to 280.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.9 (-80.2 to 314.2)	26.9 (-81.9 to 291.9)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-78.4 (-92.5 to -12.7)	-80.6 (-93.6 to -30.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-77.0 (-92.0 to -6.4)	-79.3 (-93.3 to -22.6)
Cystic echinococcosis	0.5 (0.5 to 0.6)	0.2 (0.2 to 0.2)	-63.2 (-66.2 to -59.0)	-67.8 (-70.1 to -62.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-59.9 (-66.8 to -51.9)	-65.4 (-70.6 to -58.5)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.6 (-54.6 to 13.0)	-17.3 (-61.5 to -1.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.6 (-54.6 to 13.0)	-17.3 (-61.6 to -1.9)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.9 (-24.8 to 151.5)	66.8 (-38.3 to 118.9)
Maternal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	13.8 (-29.2 to 54.8)	21.1 (-25.5 to 64.8)
Maternal hemorrhage	2.3 (1.3 to 3.4)	2.5 (0.9 to 3.9)	5.8 (-59.6 to 99.6)	13.0 (-57.6 to 117.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	16.6 (-63.2 to 123.2)	25.7 (-61.2 to 139.5)
Maternal sepsis and other maternal infections	1.0 (0.7 to 1.5)	1.1 (0.7 to 1.6)	11.3 (-17.4 to 47.8)	3.4 (-21.1 to 37.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.9 (-14.0 to 32.3)	6.9 (-13.7 to 29.1)
Maternal hypertensive disorders	1.3 (0.9 to 1.9)	1.5 (1.0 to 2.2)	12.5 (3.2 to 25.4)	18.2 (8.4 to 31.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	10.4 (-12.3 to 42.2)	16.4 (-7.7 to 49.7)
Obstructed labor	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	6.7 (-2.3 to 16.1)	14.0 (4.2 to 24.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.7 (-51.3 to 108.1)	14.4 (-48.6 to 117.6)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.9 (43.0 to 74.7)	65.9 (51.2 to 84.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.9 (42.7 to 74.7)	65.9 (51.0 to 84.7)
Other maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	17.1 (-38.9 to 134.1)	24.9 (-35.4 to 148.0)
Neonatal disorders	-	-	-	-	9.6 (6.6 to 12.9)	12.6 (8.7 to 17.7)	30.8 (5.0 to 85.2)	19.3 (-13.6 to 68.9)
Preterm birth complications	40.3 (29.2 to 55.5)	57.4 (41.6 to 83.5)	41.8 (11.9 to 82.4)	27.9 (1.2 to 64.2)	5.0 (3.5 to 6.9)	7.3 (5.0 to 9.9)	46.2 (8.2 to 93.9)	33.9 (-1.5 to 77.8)
Neonatal encephalopathy due to birth asphyxia and trauma	9.3 (5.3 to 18.0)	6.4 (3.2 to 15.1)	-33.3 (-54.1 to 0.7)	-38.8 (-57.8 to -8.7)	2.1 (1.5 to 2.9)	1.5 (1.0 to 2.3)	-28.6 (-51.7 to 8.7)	-34.3 (-55.5 to 0.5)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.9 (46.7 to 132.9)	52.1 (35.3 to 114.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.7 (21.5 to 133.9)	53.8 (12.0 to 115.8)
Hemolytic disease and other neonatal jaundice	3.4 (1.1 to 7.3)	2.2 (0.6 to 4.3)	-38.9 (-87.1 to 224.0)	-44.5 (-88.3 to 195.5)	1.4 (0.4 to 3.2)	1.0 (0.3 to 2.1)	-35.2 (-86.5 to 241.9)	-41.5 (-87.7 to 213.4)
Other neonatal disorders	-	-	-	-	0.9 (0.5 to 1.7)	2.8 (1.3 to 4.5)	222.6 (18.5 to 472.9)	194.0 (8.1 to 422.8)
Nutritional deficiencies	-	-	-	-	31.1 (20.3 to 46.1)	31.5 (20.5 to 46.6)	2.2 (-14.7 to 11.0)	-2.5 (-15.1 to 4.4)
Protein-energy malnutrition	0.2 (0.1 to 0.4)	0.5 (0.2 to 0.8)	178.5 (-19.1 to 357.7)	67.3 (-51.3 to 171.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	171.1 (-29.8 to 446.3)	63.7 (-57.1 to 221.9)
Iodine deficiency	179.9 (94.4 to 324.4)	85.4 (32.5 to 177.7)	-52.3 (-86.3 to 24.9)	-56.3 (-87.2 to 14.1)	3.2 (1.4 to 6.7)	1.5 (0.5 to 3.6)	-52.1 (-86.5 to 24.8)	-55.8 (-87.2 to 15.0)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron deficiency anemia	1,118.2 (1,078.0 to 1,143.1)	1,241.0 (1,150.4 to 1,279.4)	11.6 (2.6 to 15.7)	1.6 (-5.6 to 5.0)	27.9 (18.2 to 40.3)	29.9 (19.5 to 43.9)	8.1 (-9.9 to 14.9)	1.9 (-11.4 to 7.2)

Appendix Table G.4 - Belgium prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.0	0.0	-39.6	-43.4
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	3.1	3.3	5.9	0.4
Sexually transmitted diseases excluding HIV	-	-	-	-	1.6	1.7	4.9	-1.2
Syphilis	0.4	0.8	75.8	38.9	0.1	0.1	72.9	37.2
Chlamydia infection	387.1	367.4	-3.8	1.0	-3.8	-1.0	-4.1	-1.0
Gonococcal infection	27.7	30.7	10.3	14.3	0.1	0.1	18.5	22.6
Trichomoniasis	24.1	20.0	-17.2	-21.8	0.0	0.0	-21.8	-27.2
Genital herpes	1,415.6	1,517.2	7.1	-9.9	0.4	0.4	5.7	-9.9
Other sexually transmitted diseases	1.2	0.8	-28.2	-30.9	0.0	0.0	-13.6	-15.7
Hepatitis	(0.9 to 1.5)	(0.6 to 1.0)	(-41.2 to -13.8)	(-42.6 to -17.0)	(0.0 to 0.0)	(0.0 to 0.0)	(-36.3 to 10.1)	(-38.5 to 15.5)
Hepatitis A	7.3	7.3	0.6	-7.4	0.2	0.2	2.1	-6.1
Hepatitis B	101.1	75.4	-24.6	-34.4	0.1	0.0	-23.7	-33.1
Hepatitis C	122.5	113.6	-7.0	-22.9	0.0	0.0	-6.7	-24.1
Hepatitis E	-	-	-	-	20.2	-	-	-
Leprosy	-	-	0.0	0.0	-	-	-	-
Other infectious diseases	46.1	50.8	9.2	1.7	1.2	1.3	10.1	4.1
Non-communicable diseases	-	-	-	-	1,125.3	1,356.4	20.5	0.8
Neoplasms	-	-	-	-	(836.0 to 1,449.8)	(1,012.8 to 1,729.0)	(16.9 to 24.1)	(-2.1 to 3.6)
Esophageal cancer	1.2	2.0	79.2	33.0	0.2	0.3	67.5	24.7
Stomach cancer	6.3	5.4	-14.7	-39.9	0.7	0.5	-19.0	-42.4
Liver cancer	-	-	-	-	0.1	0.1	81.4	35.9
Liver cancer due to hepatitis B	0.1	0.2	117.4	66.0	0.0	0.0	(28.0 to 152.3)	(-4.6 to 87.7)
Liver cancer due to hepatitis C	0.1	0.5	323.1	215.0	0.0	0.1	(0.1 to 457.3)	(-22.4 to 330.2)
Liver cancer due to alcohol use	0.3	0.3	-4.0	-30.5	0.0	0.0	-5.1	-30.9
Liver cancer due to other causes	0.1	0.1	-27.4	-47.0	0.0	0.0	-28.5	-47.9
Larynx cancer	4.9	3.8	-23.4	-42.3	0.5	0.4	-29.4	-46.5
Tracheal, bronchus and lung cancer	16.0	18.0	13.7	-13.8	2.2	2.3	5.7	-19.6
Breast cancer	122.1	174.7	43.9	3.9	6.2	8.0	28.1	-6.6
Cervical cancer	7.3	5.2	-30.1	-42.3	0.5	0.4	-31.1	-43.1
Uterine cancer	8.6	12.8	49.4	15.5	0.8	1.0	45.2	7.8
Prostate cancer	67.0	138.9	105.5	48.8	4.9	9.3	76.6	28.7
Colon and rectum cancer	48.8	59.5	21.8	-11.1	4.0	4.6	15.4	-16.0
Lip and oral cavity cancer	5.7	7.4	29.1	-2.2	0.5	0.6	23.9	-5.4
Nasopharynx cancer	0.7	0.4	-45.9	-57.6	0.1	0.0	-46.9	-58.3
Other pharynx cancer	2.4	3.8	58.7	20.8	0.2	0.3	54.1	18.1
Gallbladder and biliary tract cancer	0.6	0.4	-35.1	-54.4	0.1	0.1	-35.7	-54.0
Pancreatic cancer	1.2	1.6	32.4	-2.2	0.2	0.2	29.8	-3.1
Malignant skin melanoma	9.2	16.6	80.2	42.7	0.5	1.0	72.8	37.0
Non-melanoma skin cancer	49.7	72.7	46.1	29.7	2.8	3.2	14.7	15.6
Ovarian cancer	5.9	5.7	-4.1	-28.4	0.7	0.7	-6.0	-30.1
Testicular cancer	2.5	2.2	-13.8	-18.7	0.2	0.2	-15.1	-20.4
Kidney cancer	8.6	14.4	67.1	25.8	0.6	1.0	60.1	20.7
Bladder cancer	21.8	23.2	5.9	-1.3	1.7	1.6	-9.5	-32.8
Brain and nervous system cancer	3.7	4.0	7.7	-16.5	0.4	0.4	1.7	-18.2
Thyroid cancer	4.4	4.9	11.4	-8.8	0.3	0.3	0.7	-15.1
Mesothelioma	0.2	0.4	126.6	70.7	0.0	0.1	126.1	70.1
Hodgkin lymphoma	1.7	1.9	11.6	0.1	0.2	0.2	9.6	-7.2
Non-Hodgkin lymphoma	7.4	13.8	94.8	45.6	0.5	1.0	85.5	38.5
Multiple myeloma	1.7	3.3	91.2	40.5	0.4	0.6	80.3	32.2
Leukemia	7.7	10.1	31.6	-4.1	1.0	1.2	24.5	-8.3
Other neoplasms	8.5	27.3	223.8	131.1	0.6	1.8	200.2	114.2
Cardiovascular diseases	-	-	-	-	43.8	60.4	38.1	1.4
Rheumatic heart disease	0.8	1.0	20.1	-6.9	0.1	0.1	19.1	-8.3
Ischemic heart disease	270.5	331.8	23.3	-11.2	14.8	12.9	16.8	-19.6
Cerebrovascular disease	-	-	-	-	11.6	15.4	33.1	-0.5
Ischemic stroke	68.6	92.2	34.9	-9.9	9.6	12.9	34.0	-0.6
Hemorrhagic stroke	13.6	17.7	28.1	-2.2	1.9	2.5	28.6	-1.3
Hypertensive heart disease	14.4	22.9	59.3	13.7	1.5	2.4	59.7	15.0
Cardiomyopathy and myocarditis	13.7	15.9	16.6	-13.0	1.4	1.7	16.7	-12.4
Atrial fibrillation and flutter	43.0	72.3	67.1	21.2	3.3	5.5	66.4	21.7
Peripheral vascular disease	396.7	564.2	42.5	2.0	0.5	0.7	30.0	-12.9
Endocarditis	0.6	0.9	51.0	27.6	0.1	0.1	30.8	7.6
Other cardiovascular and circulatory diseases	152.6	256.2	68.6	23.6	10.5	17.8	69.1	24.7
Chronic respiratory diseases	-	-	-	-	62.4	74.3	19.1	-1.3
Chronic obstructive pulmonary disease	884.5	1,090.8	23.3	-4.2	39.2	48.7	24.6	-3.0
Pneumoconiosis	-	-	-	-	0.0	0.0	-14.0	-33.8

Appendix Table G.4 - Belgium prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.3 (-2.2 to 9.7)	-2.9 (-25.9 to -17.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.7 (-1.8 to 10.2)	-21.6 (-25.6 to -17.0)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-27.7 (-32.3 to -23.5)	-43.0 (-46.5 to -39.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.0 (-31.5 to -22.7)	-42.3 (-45.7 to -38.8)
Asthma	514.8 (490.0 to 537.7)	575.0 (549.0 to 598.7)	11.1 (4.4 to 19.3)	1.6 (-5.3 to 9.6)	22.4 (14.7 to 32.0)	24.5 (16.3 to 35.3)	11.1 (4.4 to 18.8)	11.0 (5.3 to 9.7)
Interstitial lung disease and pulmonary sarcoidosis	0.7 (0.5 to 0.8)	0.9 (0.8 to 0.9)	27.6 (0.4 to 67.8)	4.7 (-17.6 to 37.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	28.3 (0.3 to 68.2)	5.0 (-17.3 to 38.5)
Other chronic respiratory diseases	-	-	-	-	0.7 (0.4 to 1.1)	0.5 (0.3 to 0.8)	-21.8 (-45.4 to 7.8)	-39.5 (-57.0 to -16.5)
Cirrhosis	-	-	-	-	0.7 (0.5 to 1.0)	0.8 (0.6 to 1.1)	15.4 (2.0 to 29.8)	-7.5 (-18.0 to 3.2)
Cirrhosis due to hepatitis B	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.7)	19.4 (-28.5 to 95.2)	-5.9 (-42.9 to 55.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	11.0 (-38.6 to 115.4)	-3.9 (-50.2 to 71.0)
Cirrhosis due to hepatitis C	1.3 (0.8 to 1.8)	2.4 (1.6 to 3.2)	92.0 (3.2 to 262.4)	50.7 (-19.3 to 197.7)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	91.8 (-18.8 to 265.4)	51.1 (-22.2 to 203.8)
Cirrhosis due to alcohol use	2.3 (1.9 to 2.8)	1.6 (1.0 to 2.2)	-32.1 (-61.6 to 0.5)	-47.2 (-70.5 to -20.2)	0.4 (0.2 to 0.5)	0.2 (0.1 to 0.4)	-32.9 (-63.8 to 6.3)	-47.7 (-71.8 to -16.5)
Cirrhosis due to other causes	0.5 (0.3 to 0.6)	0.7 (0.3 to 1.2)	59.8 (-40.6 to 189.7)	29.7 (-47.9 to 127.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	57.4 (-42.2 to 207.5)	28.2 (-49.9 to 137.0)
Digestive diseases	-	-	-	-	17.5 (12.3 to 23.8)	23.6 (16.7 to 31.7)	34.4 (16.7 to 54.6)	10.6 (-5.7 to 28.1)
Peptic ulcer disease	80.9 (75.0 to 86.3)	48.4 (42.1 to 54.5)	-40.0 (-46.7 to -34.0)	-61.8 (-66.7 to -57.7)	2.8 (1.9 to 3.9)	1.8 (1.2 to 2.5)	-36.1 (-42.0 to -28.5)	-58.5 (-62.5 to -53.2)
Gastritis and duodenitis	10.2 (8.0 to 12.5)	9.9 (8.5 to 11.3)	-2.4 (-21.1 to 20.6)	-23.4 (-38.8 to -5.6)	0.5 (0.3 to 0.7)	0.5 (0.4 to 0.8)	10.9 (-23.0 to 44.5)	-12.3 (-42.3 to 17.6)
Appendicitis	0.6 (0.5 to 0.7)	0.6 (0.5 to 0.6)	-7.9 (-17.2 to 4.3)	-10.4 (-20.0 to 2.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-7.4 (-31.0 to 26.1)	-10.4 (-35.5 to 26.0)
Paralytic ileus and intestinal obstruction	0.3 (0.3 to 0.3)	0.5 (0.4 to 0.5)	62.5 (41.9 to 78.9)	23.9 (-0.1 to 39.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	57.8 (19.2 to 106.2)	22.6 (-7.4 to 56.0)
Inguinal, femoral, and abdominal hernia	46.2 (39.8 to 52.5)	56.8 (49.2 to 64.7)	22.1 (2.7 to 53.9)	22.1 (-24.2 to 9.8)	0.5 (0.2 to 0.8)	0.6 (0.3 to 1.1)	22.4 (1.9 to 52.3)	9.5 (-23.6 to 9.8)
Inflammatory bowel disease	41.0 (32.9 to 50.9)	59.1 (50.7 to 67.2)	44.5 (15.5 to 87.6)	19.3 (-5.7 to 56.2)	8.5 (5.6 to 12.2)	12.2 (8.2 to 16.8)	44.0 (18.8 to 86.9)	19.5 (-5.6 to 56.8)
Vascular intestinal disorders	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	37.4 (-5.2 to 104.0)	0.9 (-29.0 to 44.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	36.0 (-17.7 to 139.1)	1.5 (-34.1 to 67.9)
Gallbladder and biliary diseases	27.2 (22.7 to 31.0)	36.4 (33.1 to 39.8)	32.7 (15.0 to 65.5)	6.7 (-7.3 to 33.0)	2.8 (1.9 to 3.9)	3.1 (2.5 to 5.2)	33.4 (15.8 to 67.0)	7.9 (-7.7 to 35.3)
Pancreatitis	2.6 (2.5 to 2.8)	4.0 (3.9 to 4.2)	52.1 (44.4 to 62.3)	4.0 (18.3 to 33.0)	0.8 (0.5 to 1.0)	1.1 (0.8 to 1.6)	51.9 (21.1 to 77.7)	25.2 (7.6 to 47.3)
Other digestive diseases	-	-	-	-	1.5 (1.0 to 2.1)	3.3 (2.1 to 4.6)	122.3 (56.1 to 171.5)	83.5 (27.1 to 125.4)
Neurological disorders	-	-	-	-	121.7 (83.4 to 164.8)	156.4 (109.2 to 208.2)	28.5 (11.3 to 48.9)	4.4 (-9.4 to 21.1)
Alzheimer disease and other dementias	217.1 (183.8 to 245.3)	321.8 (273.5 to 373.6)	48.0 (21.0 to 84.8)	-4.6 (-21.7 to 18.5)	31.2 (23.3 to 40.9)	47.2 (33.7 to 63.0)	50.8 (22.7 to 89.3)	-4.0 (-21.6 to 19.9)
Parkinson disease	12.7 (8.1 to 17.7)	18.0 (11.7 to 23.7)	42.2 (32.2 to 56.7)	2.9 (-4.5 to 10.8)	1.4 (0.8 to 2.2)	2.0 (1.2 to 3.0)	41.6 (24.9 to 60.0)	2.6 (-10.1 to 15.5)
Epilepsy	35.7 (25.6 to 46.0)	37.1 (25.6 to 50.2)	3.8 (-33.9 to 62.4)	-8.3 (-41.7 to 44.1)	14.0 (8.8 to 20.2)	15.4 (9.1 to 22.5)	9.8 (-31.5 to 73.2)	-2.3 (-39.0 to 53.4)
Multiple sclerosis	10.5 (9.3 to 11.9)	15.4 (11.5 to 18.8)	47.6 (9.7 to 87.6)	24.5 (-8.3 to 58.6)	3.4 (2.4 to 4.5)	5.0 (3.3 to 7.0)	47.6 (7.7 to 88.0)	24.5 (-9.3 to 60.7)
Migraine	1,494.6 (1,213.2 to 1,817.8)	1,636.9 (1,320.9 to 1,954.2)	10.3 (-14.3 to 45.0)	0.4 (-22.6 to 30.6)	50.3 (29.1 to 77.8)	55.1 (32.3 to 83.6)	9.9 (-14.8 to 44.6)	0.5 (-22.4 to 30.4)
Tension-type headache	2,250.0 (1,709.9 to 2,836.1)	2,958.8 (2,493.7 to 3,390.8)	33.7 (-1.4 to 81.3)	33.7 (-10.6 to 63.6)	8.4 (1.6 to 6.1)	8.6 (2.1 to 7.8)	32.6 (-1.3 to 81.0)	20.6 (-11.3 to 65.0)
Medication overuse headache	76.5 (50.5 to 105.7)	131.4 (84.9 to 182.3)	70.8 (28.7 to 131.9)	47.8 (13.4 to 99.7)	11.8 (6.8 to 18.4)	20.3 (11.3 to 32.4)	70.8 (28.0 to 133.4)	48.3 (14.1 to 99.1)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.0 (-20.8 to 92.5)	1.7 (-31.1 to 62.9)	6.2 (4.1 to 8.5)	6.9 (4.7 to 9.3)	12.3 (-18.9 to 52.2)	-24.9 (-44.9 to 1.8)
Mental and substance use disorders	-	-	-	-	226.0 (163.0 to 296.1)	245.5 (175.2 to 321.9)	8.8 (3.4 to 13.7)	-0.9 (-5.1 to 3.1)
Schizophrenia	29.1 (22.6 to 34.8)	32.8 (25.9 to 39.4)	12.8 (6.5 to 21.3)	-1.2 (-6.5 to 9.9)	18.3 (12.8 to 23.9)	20.8 (14.2 to 27.0)	13.1 (5.3 to 28.7)	-0.6 (-7.6 to 8.8)
Alcohol use disorders	141.7 (130.5 to 154.6)	161.2 (147.7 to 174.2)	14.1 (7.4 to 20.8)	5.9 (-0.3 to 12.2)	14.1 (9.5 to 20.1)	16.0 (10.8 to 22.8)	13.9 (6.8 to 22.1)	6.1 (-0.7 to 13.6)
Drug use disorders	-	-	-	-	19.9 (12.6 to 28.9)	19.7 (12.9 to 28.2)	-10.9 (-13.8 to 14.4)	-4.9 (-17.5 to 10.2)
Opioid use disorders	23.8 (13.3 to 38.4)	22.7 (12.7 to 37.1)	-4.8 (-17.9 to 8.0)	-11.6 (-25.4 to 0.2)	9.8 (4.9 to 16.7)	9.3 (4.8 to 16.1)	-4.5 (-18.7 to 12.1)	-11.4 (-26.9 to 1.8)
Cocaine use disorders	16.9 (12.2 to 21.4)	18.8 (16.1 to 21.5)	11.1 (-16.0 to 54.8)	9.4 (-18.5 to 55.2)	2.3 (1.3 to 3.6)	2.6 (1.6 to 3.7)	11.0 (-17.0 to 60.8)	9.0 (-19.9 to 61.4)
Amphetamine use disorders	18.7 (16.0 to 21.4)	17.6 (14.9 to 20.4)	-5.2 (-23.4 to 18.5)	-2.1 (-24.6 to 20.8)	5.2 (1.5 to 3.5)	5.3 (1.4 to 3.4)	2.9 (-26.7 to 21.2)	5.9 (-27.9 to 21.1)
Cannabis use disorders	22.8 (19.8 to 25.7)	22.3 (19.6 to 25.2)	-1.8 (-7.8 to 4.5)	-0.9 (-7.1 to 6.1)	0.7 (0.4 to 1.0)	0.6 (0.4 to 0.9)	-2.0 (-15.3 to 13.2)	-0.7 (-14.8 to 15.0)
Other drug use disorders	-	-	-	-	4.7 (2.9 to 6.9)	4.9 (3.0 to 7.4)	3.3 (-29.0 to 46.4)	2.3 (-29.8 to 43.9)
Depressive disorders	-	-	-	-	72.5 (47.6 to 103.8)	79.8 (51.9 to 115.5)	11.1 (-7.5 to 24.7)	-2.0 (-16.1 to 9.7)
Major depressive disorder	280.6 (207.4 to 348.4)	306.5 (212.6 to 408.1)	11.0 (-13.1 to 28.4)	-2.9 (-20.8 to 11.8)	56.3 (36.0 to 82.6)	61.4 (37.2 to 93.1)	10.4 (-13.2 to 27.5)	2.5 (-20.5 to 12.1)
Dysthymia	171.3 (145.1 to 199.9)	194.1 (165.1 to 226.7)	13.6 (11.0 to 16.7)	-0.2 (-0.3 to -0.0)	16.3 (11.0 to 23.2)	18.5 (12.4 to 26.2)	13.4 (9.6 to 17.5)	0.0 (-2.1 to 2.6)
Bipolar disorder	76.0 (63.7 to 89.1)	82.7 (69.9 to 96.5)	9.1 (3.0 to 15.7)	-0.7 (-6.6 to 5.3)	15.2 (9.3 to 22.9)	16.6 (10.2 to 24.8)	8.8 (1.5 to 16.7)	-0.6 (-7.5 to 7.1)
Anxiety disorders	458.7 (376.3 to 537.9)	502.9 (417.6 to 587.9)	9.9 (7.1 to 13.6)	-0.1 (-0.2 to 0.0)	41.5 (27.8 to 59.3)	45.5 (30.5 to 64.5)	9.7 (6.0 to 14.2)	0.2 (-2.0 to 2.7)
Eating disorders	-	-	-	-	7.1 (3.5 to 12.1)	7.1 (3.6 to 12.1)	0.7 (-4.7 to 6.9)	5.4 (-1.1 to 11.9)
Anorexia nervosa	8.1 (3.9 to 14.0)	9.3 (4.6 to 16.2)	15.2 (3.6 to 33.4)	19.3 (7.5 to 35.0)	1.7 (0.7 to 3.3)	2.0 (0.9 to 3.8)	15.9 (0.4 to 35.9)	19.8 (4.0 to 39.6)
Bulimia nervosa	25.5 (13.4 to 46.3)	24.3 (13.0 to 44.0)	-4.3 (-5.5 to -2.4)	0.8 (0.5 to 1.1)	5.4 (2.6 to 9.8)	5.1 (2.5 to 9.4)	-4.2 (-9.3 to 2.2)	1.0 (-4.0 to 6.9)
Autistic spectrum disorders	-	-	-	-	10.9 (7.6 to 14.8)	12.0 (8.4 to 16.3)	10.0 (6.2 to 13.5)	0.5 (-3.0 to 3.8)
Autism	28.5 (26.9 to 30.1)	31.4 (29.5 to 33.3)	10.2 (9.5 to 10.9)	0.1 (0.1 to 0.2)	6.9 (4.6 to 9.5)	7.6 (5.2 to 10.3)	10.0 (5.0 to 15.2)	15.0 (4.1 to 5.5)
Asperger syndrome	40.9 (38.1 to 43.6)	44.9 (41.8 to 48.1)	10.2 (9.5 to 10.9)	0.2 (0.1 to 0.3)	4.0 (2.8 to 5.5)	4.4 (3.1 to 6.1)	9.9 (5.8 to 14.3)	0.4 (-3.6 to 4.7)
Attention-deficit/hyperactivity disorder	49.5 (41.0 to 58.2)	48.4 (40.1 to 56.9)	-2.0 (-2.1 to -1.8)	-0.2 (-0.3 to -0.2)	0.6 (0.3 to 1.0)	0.6 (0.3 to 0.9)	-2.2 (-4.8 to 4.2)	-0.4 (-7.2 to 6.1)
Conduct disorder	70.7 (59.5 to 82.4)	69.4 (58.5 to 80.8)	-1.5 (-1.7 to -1.3)	-0.1 (-0.2 to -0.1)	8.5 (5.2 to 12.8)	8.4 (5.1 to 12.7)	-1.4 (-5.3 to 2.9)	-0.0 (-4.0 to 4.2)
Idiopathic intellectual disability	59.7 (31.1 to 87.8)	50.8 (27.7 to 74.4)	-15.0 (-50.8 to 14.1)	-3.7 (-55.2 to 30.8)	3.3 (1.9 to 5.6)	3.0 (1.5 to 4.8)	-15.9 (-50.4 to 44.0)	-23.3 (-55.4 to 10.8)
Other mental and substance use disorders	190.6 (179.3 to 201.7)	221.0 (208.1 to 233.7)	16.2 (14.7 to 17.8)	0.2 (0.0 to 0.4)	13.9 (9.5 to 18.6)	16.1 (11.0 to 21.6)	15.8 (11.7 to 20.1)	0.5 (-3.1 to 4.1)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	111.3 (78.9 to 146.4)	151.8 (107.5 to 200.2)	35.7 (23.9 to 55.6)	9.6 (0.1 to 23.8)
Diabetes mellitus	479.9 (372.5 to 586.6)	746.0 (600.0 to 894.8)	54.1 (15.9 to 125.8)	21.8 (-7.3 to 72.7)	34.8 (22.5 to 50.0)	55.1 (35.3 to 78.7)	56.8 (19.3 to 124.3)	23.8 (6.1 to 72.3)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.0 (-6.7 to 4.0)	-10.4 (-16.5 to -6.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.0 (-6.7 to 4.0)	-10.4 (-16.5 to -6.0)
Chronic kidney disease	-	-	-	-	39.5 (26.3 to 53.7)	50.7 (34.3 to 68.5)	28.6 (20.2 to 35.7)	3.9 (-0.6 to 8.7)
Chronic kidney disease due to diabetes mellitus	89.0 (57.7 to 122.5)	143.7 (93.0 to 245.3)	63.4 (6.9 to 137.7)	20.0 (-16.6 to 70.4)	6.1 (3.7 to 9.3)	7.7 (4.9 to 11.0)	27.4 (-3.9 to 73.3)	-1.3 (-25.3 to 33.3)
Chronic kidney disease due to hypertension	98.7 (77.6 to 138.3)	107.0 (74.7 to 171.5)	8.0 (-19.9 to 42.9)	-16.7 (-38.3 to 11.8)	11.0 (6.8 to 15.5)	4.9 (3.2 to 7.0)	-55.1 (-67.2 to -40.0)	-62.7 (-72.2 to -50.5)
Chronic kidney disease due to glomerulonephritis	149.7 (94.4 to 259.5)	105.7 (78.0 to 153.1)	-26.5 (-51.6 to 6.0)	-40.4 (-58.8 to -18.9)	4.0 (2.6 to 5.8)	7.2 (4.8 to 10.3)	81.3 (42.6 to 139.6)	47.8 (18.3 to 90.3)
Chronic kidney disease due to other causes	348.1 (250.7 to 538.0)	648.2 (449.7 to 997.2)	80.0 (45.4 to 146.8)	27.8 (9.8 to 79.8)	18.5 (12.0 to 25.4)	31.0 (20.9 to 41.7)	65.9 (45.0 to 98.8)	34.3 (16.6 to 59.1)
Urinary diseases and male infertility	-	-	-	-	11.1 (7.3 to 15.8)	17.7 (11.6 to 24.9)	59.2 (48.3 to 72.3)	22.7 (14.4 to 32.6)
Interstitial nephritis and urinary tract infections	2.6 (2.5 to 2.8)	4.1 (3.9 to 4.3)	57.4 (44.8 to 70.4)	38.1 (26.8 to 50.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	56.3 (31.0 to 87.9)	38.3 (15.1 to 68.9)

Appendix Table G.4 - Belgium prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Urolithiasis	123.5 (70.8 to 220.0)	274.2 (172.1 to 437.8)	121.9 (93.5 to 173.5)	69.8 (48.5 to 102.9)	1.0 (0.5 to 1.8)	2.1 (1.1 to 3.8)	117.9 (94.2 to 152.8)	117.9 (50.2 to 89.5)
Benign prostatic hyperplasia	257.6 (238.0 to 278.6)	408.9 (396.0 to 423.0)	59.4 (46.6 to 72.5)	20.7 (11.1 to 30.8)	9.0 (5.9 to 12.6)	14.4 (9.4 to 20.1)	58.9 (45.5 to 72.9)	21.0 (10.8 to 31.6)
Male infertility due to other causes	72.3 (54.9 to 90.2)	70.3 (53.1 to 90.3)	-2.3 (-32.9 to 42.7)	1.1 (-30.8 to 47.7)	0.5 (0.2 to 1.0)	0.5 (0.2 to 1.0)	-3.2 (-34.7 to 40.6)	0.5 (-32.5 to 46.0)
Other urinary diseases	-	-	-	-	0.5 (0.2 to 1.0)	0.6 (0.3 to 1.2)	-4.1 (-36.5 to 176.6)	-25.3 (-50.8 to 108.9)
Gynecological diseases	-	-	-	-	12.3 (7.7 to 18.8)	13.5 (8.4 to 21.3)	9.8 (4.6 to 32.5)	-1.4 (-13.7 to 19.5)
Uterine fibroids	380.7 (324.1 to 441.6)	459.8 (395.2 to 531.9)	21.1 (19.6 to 22.5)	0.2 (0.1 to 0.2)	3.3 (1.6 to 6.1)	3.9 (1.9 to 7.4)	16.2 (0.4 to 69.3)	-2.4 (-15.9 to 43.2)
Polycystic ovarian syndrome	151.2 (126.6 to 173.2)	185.8 (160.1 to 215.2)	22.9 (1.8 to 53.5)	16.0 (-4.2 to 44.6)	1.5 (0.7 to 2.8)	1.8 (0.9 to 3.3)	21.8 (1.2 to 51.9)	15.0 (-4.3 to 43.4)
Female infertility due to other causes	35.1 (19.3 to 54.8)	30.1 (11.9 to 52.4)	-16.5 (-66.8 to 101.4)	-18.6 (-66.4 to 90.6)	0.2 (0.1 to 0.4)	0.2 (0.0 to 0.4)	-16.2 (-66.1 to 99.6)	-18.6 (-66.7 to 88.3)
Endometriosis	27.6 (21.0 to 34.9)	79.2 (21.4 to 36.2)	6.6 (-25.3 to 53.1)	2.5 (-29.7 to 45.6)	2.7 (1.6 to 3.8)	2.7 (1.7 to 3.9)	9.9 (-26.8 to 54.1)	-1.4 (-30.5 to 46.1)
Genital prolapse	641.7 (579.7 to 700.4)	732.0 (667.2 to 797.2)	14.2 (0.0 to 30.5)	-1.8 (-14.7 to 13.3)	2.0 (1.0 to 3.8)	2.3 (1.1 to 4.4)	14.2 (0.4 to 30.6)	-1.6 (-14.9 to 14.0)
Premenstrual syndrome	256.1 (170.8 to 326.4)	233.3 (158.3 to 322.8)	-9.9 (-43.7 to 55.9)	-11.5 (-44.1 to 54.7)	2.1 (1.1 to 3.4)	2.0 (1.0 to 3.3)	-10.4 (-44.3 to 53.9)	-11.2 (-45.4 to 51.7)
Other gynecological diseases	25.3 (20.8 to 43.2)	26.7 (21.0 to 46.1)	6.2 (-39.4 to 94.3)	-1.1 (-44.5 to 84.3)	0.6 (0.3 to 1.5)	0.6 (0.3 to 1.7)	2.5 (-62.1 to 201.4)	-5.8 (-66.6 to 174.6)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	10.1 (6.7 to 14.7)	10.5 (7.0 to 15.1)	3.9 (-4.8 to 14.8)	-4.8 (-11.3 to 3.5)
Thalassemias	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	0.1 (-7.3 to 7.4)	1.1 (-6.4 to 8.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.0 (-27.3 to 29.6)	-
Thalassemia trait	140.4 (128.7 to 155.5)	151.5 (137.6 to 168.7)	8.4 (2.5 to 13.6)	-3.2 (-8.4 to 1.5)	4.3 (2.9 to 6.0)	4.3 (2.9 to 6.2)	2.0 (8.8 to 12.8)	-8.2 (-16.5 to 0.6)
Sickle cell disorders	0.9 (0.7 to 1.0)	1.0 (0.8 to 1.1)	9.9 (9.3 to 35.6)	6.9 (-11.4 to 30.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	14.8 (-1.1 to 34.0)	10.4 (-6.0 to 31.0)
Sickle cell trait	328.5 (313.3 to 343.0)	369.8 (353.4 to 385.5)	12.8 (8.8 to 16.6)	0.9 (-2.7 to 4.6)	4.3 (2.8 to 6.3)	4.5 (2.9 to 6.6)	3.9 (-7.8 to 17.2)	-2.7 (-13.6 to 9.0)
G6PD deficiency	95.1 (65.6 to 125.9)	118.9 (76.7 to 161.7)	23.0 (-22.5 to 99.4)	9.8 (-30.9 to 78.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.8 (-65.7 to 234.2)	-32.4 (-71.0 to 236.3)
G6PD trait	1,330.3 (1,178.0 to 1,446.1)	1,446.4 (1,294.5 to 1,568.6)	8.7 (-4.7 to 26.1)	-3.0 (-15.0 to 12.5)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-14.1 (-52.9 to 86.1)	-14.1 (-58.7 to 90.9)
Other hemoglobinopathies and hemolytic anemias	61.4 (56.5 to 67.1)	72.3 (65.5 to 80.9)	18.1 (3.3 to 35.5)	1.1 (-12.0 to 14.2)	1.2 (0.8 to 1.8)	1.4 (0.8 to 2.0)	12.5 (-13.5 to 52.6)	1.1 (-19.5 to 23.4)
Endocrine, metabolic, blood, and immune disorders	116.5 (110.9 to 123.1)	138.3 (131.6 to 147.3)	18.8 (12.4 to 27.4)	2.8 (-4.3 to 11.2)	3.5 (2.4 to 4.8)	4.3 (2.9 to 5.8)	20.8 (11.9 to 35.6)	5.3 (-2.8 to 19.1)
Musculoskeletal disorders	-	-	-	-	334.2 (236.8 to 438.6)	393.6 (283.3 to 524.1)	17.4 (11.1 to 25.5)	-0.5 (-5.7 to 6.3)
Rheumatoid arthritis	37.9 (34.7 to 41.6)	45.5 (40.2 to 50.6)	20.7 (1.1 to 37.8)	-6.4 (-19.9 to 5.8)	8.5 (6.1 to 11.3)	10.2 (7.1 to 13.7)	20.4 (1.6 to 38.4)	-5.8 (-19.1 to 7.6)
Osteoarthritis	602.9 (508.3 to 699.9)	777.9 (662.3 to 916.4)	28.5 (3.7 to 62.9)	-6.0 (-25.3 to 20.9)	20.4 (13.1 to 29.8)	26.3 (16.7 to 39.0)	27.9 (2.8 to 63.0)	-5.7 (-25.5 to 21.7)
Low back and neck pain	-	-	-	-	277.3 (193.6 to 371.1)	320.6 (223.0 to 434.1)	15.6 (7.9 to 24.4)	-0.8 (-7.1 to 7.0)
Low back pain	1,656.7 (1,566.0 to 1,740.4)	1,903.8 (1,773.3 to 2,022.9)	14.9 (6.4 to 26.8)	-1.6 (-9.3 to 8.4)	381.7 (122.8 to 253.4)	458.7 (142.5 to 288.7)	14.5 (6.2 to 26.3)	-1.4 (-9.0 to 9.0)
Neck pain	988.1 (908.4 to 1,063.8)	1,155.0 (1,071.1 to 1,245.4)	17.3 (5.4 to 30.0)	0.0 (-10.2 to 11.1)	95.7 (66.4 to 130.1)	112.0 (77.7 to 156.3)	16.9 (4.8 to 29.6)	0.3 (-10.1 to 11.1)
Gout	22.6 (20.3 to 24.8)	29.6 (26.3 to 32.8)	30.9 (13.6 to 51.8)	-0.9 (-13.4 to 15.3)	0.7 (0.5 to 1.0)	0.9 (0.6 to 1.2)	30.6 (7.6 to 62.8)	0.2 (-17.8 to 24.9)
Other musculoskeletal disorders	303.2 (239.1 to 360.0)	394.7 (316.5 to 469.7)	7.9 (21.7 to 40.6)	27.3 (1.0 to 15.8)	27.3 (18.0 to 38.7)	35.6 (23.6 to 50.5)	30.6 (20.9 to 41.4)	8.6 (0.9 to 17.1)
Other non-communicable diseases	-	-	-	-	179.6 (118.8 to 261.2)	211.7 (143.2 to 305.5)	14.5 (11.6 to 24.0)	-2.8 (-8.1 to 2.8)
Congenital anomalies	-	-	-	-	11.5 (8.3 to 15.0)	16.4 (11.2 to 21.9)	42.7 (21.7 to 65.3)	27.6 (7.9 to 48.6)
Neural tube defects	2.7 (2.3 to 3.2)	2.2 (2.0 to 2.6)	-16.4 (-32.0 to 1.0)	-22.7 (-37.2 to -6.6)	0.9 (0.6 to 1.3)	0.8 (0.5 to 1.0)	-16.2 (-37.6 to 10.6)	-22.5 (-41.9 to 3.2)
Congenital heart anomalies	80.4 (71.1 to 91.9)	76.5 (66.0 to 89.6)	-5.1 (-21.9 to 16.7)	-14.0 (-29.1 to 5.3)	2.9 (1.2 to 4.9)	2.8 (1.1 to 4.9)	-3.5 (-19.6 to 17.0)	-11.8 (-26.5 to 6.4)
Crofacial clefts	14.9 (12.2 to 18.7)	13.9 (11.6 to 16.9)	-6.6 (-29.9 to 25.3)	-16.5 (-37.3 to 11.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-13.3 (-40.7 to 27.0)	-22.6 (-47.3 to 13.9)
Down syndrome	9.2 (8.0 to 10.4)	10.9 (9.0 to 13.0)	20.5 (-6.2 to 44.1)	1.7 (-19.5 to 23.9)	1.4 (1.0 to 1.8)	1.7 (1.2 to 2.2)	26.4 (-1.9 to 54.2)	5.2 (-18.7 to 28.8)
Turner syndrome	0.6 (0.4 to 0.8)	0.7 (0.5 to 0.9)	14.9 (-31.6 to 82.6)	6.2 (-37.0 to 67.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.6 (-37.0 to 85.3)	6.6 (-41.2 to 72.2)
Klinefelter syndrome	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.7)	52.2 (6.6 to 101.7)	37.2 (-4.0 to 81.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.6 (-5.5 to 117.3)	34.7 (-11.6 to 102.4)
Chromosomal unbalanced rearrangements	22.2 (18.8 to 26.5)	26.6 (21.7 to 33.1)	20.0 (8.4 to 57.2)	3.1 (-21.0 to 35.2)	3.3 (2.4 to 4.3)	4.1 (2.9 to 5.6)	26.0 (9.5 to 65.3)	4.6 (-20.8 to 37.5)
Other congenital anomalies	17.0 (12.4 to 20.2)	17.1 (11.5 to 21.6)	0.7 (-25.3 to 25.4)	2.7 (-33.8 to 8.3)	2.7 (2.0 to 4.0)	2.7 (4.0 to 10.4)	6.9 (56.1 to 210.6)	115.2 (57.2 to 187.6)
Skin and subcutaneous diseases	-	-	-	-	63.6 (40.6 to 97.5)	70.3 (45.3 to 107.4)	10.5 (2.1 to 20.7)	0.5 (-8.1 to 10.7)
Dermatitis	583.3 (454.8 to 716.4)	635.6 (496.9 to 775.7)	9.3 (6.9 to 12.1)	-0.1 (-0.1 to -0.0)	13.7 (8.5 to 20.3)	15.0 (9.2 to 22.2)	9.5 (6.1 to 13.3)	0.1 (-2.5 to 2.7)
Psoriasis	149.5 (128.9 to 172.3)	171.3 (146.9 to 197.4)	14.8 (12.7 to 17.1)	0.1 (-0.1 to 0.2)	11.9 (8.4 to 16.7)	13.7 (9.3 to 19.0)	14.7 (9.5 to 20.0)	0.8 (-3.6 to 4.8)
Cellulitis	5.8 (4.8 to 7.3)	6.4 (5.3 to 7.7)	10.2 (-0.8 to 24.7)	0.4 (-10.6 to 13.3)	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	12.2 (-1.1 to 33.3)	2.6 (-15.1 to 22.9)
Pyoderma	7.6 (6.4 to 9.2)	8.8 (7.3 to 10.8)	16.2 (11.6 to 20.8)	-2.0 (-4.4 to 0.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	15.3 (5.2 to 25.9)	-2.0 (-10.8 to 6.2)
Scabies	10.4 (9.7 to 11.2)	8.4 (7.6 to 9.3)	-18.6 (-28.2 to -8.5)	0.3 (-33.1 to -14.3)	0.3 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-18.8 (-29.9 to -6.7)	-24.3 (-34.9 to -12.8)
Fungal skin diseases	746.2 (661.0 to 821.5)	869.8 (770.0 to 952.0)	16.8 (15.3 to 18.5)	0.2 (0.0 to 0.3)	4.1 (1.7 to 8.6)	4.8 (2.0 to 10.0)	16.5 (14.7 to 18.4)	0.3 (-0.6 to 1.2)
Viral skin diseases	201.0 (157.9 to 246.7)	244.4 (170.5 to 258.9)	7.9 (3.3 to 11.9)	7.0 (-1.4 to 3.1)	6.2 (3.5 to 9.7)	6.6 (3.8 to 10.3)	9.8 (2.5 to 12.0)	0.8 (-2.3 to 4.4)
Acne vulgaris	1,491.9 (1,168.5 to 1,815.0)	1,403.4 (1,078.2 to 1,767.0)	-4.5 (-32.2 to 25.1)	-2.0 (-32.0 to 29.4)	16.1 (7.4 to 30.5)	15.3 (6.8 to 29.9)	-4.5 (-32.3 to 25.2)	-1.8 (-32.3 to 29.5)
Alopecia areata	17.5 (16.2 to 19.0)	21.0 (19.2 to 22.7)	20.1 (5.4 to 35.6)	-0.0 (-10.9 to 12.1)	0.6 (0.4 to 0.8)	0.7 (0.4 to 1.0)	19.3 (4.4 to 36.7)	0.3 (-12.0 to 14.5)
Pruritus	1.6 (0.8 to 2.1)	1.7 (1.1 to 2.4)	1.7 (-35.8 to 124.9)	-18.3 (-45.9 to 86.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.6 (-38.4 to 130.2)	-18.2 (-48.2 to 85.4)
Urticaria	78.4 (59.6 to 104.8)	107.7 (78.8 to 141.6)	37.9 (-8.8 to 99.1)	15.4 (-28.2 to 65.9)	4.6 (2.8 to 11.0)	6.2 (3.5 to 9.8)	37.8 (-10.8 to 98.4)	19.5 (-29.5 to 63.9)
Decubitus ulcer	7.5 (6.3 to 9.1)	10.8 (9.0 to 12.6)	45.4 (11.1 to 85.0)	3.3 (-19.0 to 27.5)	1.0 (0.7 to 1.4)	1.5 (1.0 to 2.1)	46.0 (8.4 to 89.4)	4.0 (-20.1 to 32.7)
Other skin and subcutaneous diseases	823.7 (459.4 to 1,433.6)	1,024.1 (561.7 to 1,815.4)	24.3 (17.2 to 30.7)	1.2 (-1.9 to 4.3)	4.7 (1.9 to 10.7)	5.9 (2.3 to 13.5)	24.1 (16.4 to 30.5)	1.4 (-2.1 to 4.7)
Sense organ diseases	-	-	-	-	69.1 (45.5 to 98.8)	84.7 (56.4 to 120.8)	22.7 (12.9 to 31.3)	-10.0 (-16.8 to -3.7)
Glaucoma	14.3 (9.8 to 19.4)	13.6 (9.1 to 19.2)	-7.6 (-25.9 to 43.7)	-32.0 (-44.2 to 25.5)	1.1 (0.7 to 2.0)	1.3 (0.7 to 2.0)	9.1 (-26.1 to 43.2)	-92.6 (-44.1 to -60.9)
Cataract	38.5 (25.2 to 55.1)	39.9 (23.8 to 57.4)	3.8 (-22.7 to 50.0)	-32.8 (-49.2 to -6.6)	2.4 (1.4 to 3.8)	2.5 (1.4 to 3.8)	3.2 (-18.1 to 53.0)	-32.6 (-46.1 to 0.1)
Macular degeneration	47.2 (31.0 to 63.7)	66.2 (46.0 to 89.1)	40.2 (15.5 to 70.7)	-2.8 (-19.6 to 18.4)	3.0 (1.7 to 4.5)	4.2 (2.5 to 6.3)	40.3 (17.3 to 65.5)	-5.1 (-20.8 to 11.0)
Uncorrected refractive error	1,288.5 (1,048.0 to 1,566.8)	1,542.8 (1,276.8 to 1,843.7)	19.6 (9.9 to 55.6)	-7.5 (-29.6 to 21.9)	16.9 (9.5 to 28.7)	19.5 (11.0 to 32.7)	15.2 (7.2 to 41.1)	15.2 (-7.7 to 11.7)
Age-related and other hearing loss	1,577.4 (1,393.3 to 1,740.5)	1,911.1 (1,718.4 to 2,154.9)	22.8 (16.8 to 28.4)	-9.2 (-14.7 to -4.4)	36.8 (24.8 to 52.3)	47.7 (32.6 to 67.5)	29.6 (19.5 to 43.0)	-9.1 (-16.6 to -1.6)
Other vision loss	36.4 (28.0 to 46.5)	30.1 (21.4 to 40.7)	-19.6 (-28.8 to 1.8)	-38.3 (-45.6 to -24.2)	2.4 (1.5 to 3.5)	2.3 (1.4 to 3.4)	3.7 (-19.9 to 11.3)	-7.7 (-37.6 to -14.1)
Other sense organ diseases	241.1 (229.8 to 252.0)	279.3 (266.8 to 292.2)	16.1 (8.6 to 24.5)	-0.5 (-6.9 to 6.5)				

Appendix Table G.4 - Belgium prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	191.3 (181.2 to 201.9)	214.8 (204.4 to 225.9)	12.6 (4.3 to 21.9)	-0.4 (-7.7 to 7.9)	5.5 (3.5 to 8.2)	6.2 (3.9 to 9.2)	12.4 (3.6 to 22.2)	-0.1 (-7.9 to 8.7)
Injuries	-	-	-	-	165.9 (127.2 to 212.2)	155.3 (112.0 to 205.8)	-6.8 (-16.1 to 3.9)	-29.1 (-36.1 to -21.2)
Transport injuries	-	-	-	-	50.6 (38.3 to 64.7)	40.0 (29.1 to 53.1)	-21.0 (-28.6 to -11.9)	-37.3 (-43.4 to -29.8)
Road injuries	-	-	-	-	49.1 (37.2 to 62.7)	38.1 (27.7 to 50.5)	-22.6 (-30.0 to -13.6)	-38.6 (-44.6 to -31.1)
Pedestrian road injuries	-	-	-	-	5.2 (3.9 to 6.8)	4.7 (3.4 to 6.4)	-10.2 (-18.6 to -1.1)	-30.9 (-37.4 to -23.4)
Cyclist road injuries	-	-	-	-	7.1 (5.3 to 9.0)	5.0 (3.7 to 6.6)	-29.5 (-38.0 to -19.1)	-42.9 (-49.7 to -34.3)
Motorcyclist road injuries	-	-	-	-	12.8 (9.4 to 16.4)	8.9 (6.3 to 12.0)	-30.9 (-40.2 to -18.0)	-44.1 (-51.8 to -33.5)
Motor vehicle road injuries	-	-	-	-	23.7 (18.0 to 30.3)	19.3 (14.3 to 25.3)	-18.7 (-25.4 to -10.9)	-35.8 (-41.2 to -29.4)
Other road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.1)	-48.3 (-54.2 to -41.3)	-98.7 (-63.6 to -52.9)
Other transport injuries	-	-	-	-	1.5 (1.1 to 2.0)	2.0 (1.4 to 2.7)	30.7 (18.5 to 44.3)	7.3 (-2.5 to 17.7)
Unintentional injuries	-	-	-	-	113.1 (86.9 to 144.0)	112.8 (81.2 to 150.3)	-0.6 (-10.7 to 11.1)	-25.3 (-32.6 to -17.0)
Falls	-	-	-	-	87.4 (66.8 to 111.1)	85.9 (61.9 to 113.5)	-1.9 (-13.2 to 11.3)	-28.4 (-36.2 to -19.3)
Drowning	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-16.6 (-25.0 to -7.1)	-32.4 (-39.0 to -25.0)
Fire, heat, and hot substances	-	-	-	-	1.9 (1.2 to 2.9)	2.1 (1.2 to 3.4)	9.6 (-3.3 to 23.2)	-10.6 (-21.3 to 0.9)
Poisonings	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.3)	-28.0 (-37.2 to -18.4)	-40.3 (-48.1 to -31.3)
Exposure to mechanical forces	-	-	-	-	15.9 (12.0 to 20.8)	15.4 (11.1 to 21.0)	-3.6 (-12.0 to 4.9)	-20.5 (-27.5 to -13.6)
Unintentional firearm injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-16.7 (-26.2 to -6.9)	-28.9 (-36.9 to -20.5)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	43.3 (25.6 to 63.3)	12.0 (-2.0 to 29.2)
Other exposure to mechanical forces	-	-	-	-	15.7 (11.8 to 20.5)	15.2 (10.9 to 20.7)	-3.6 (-12.1 to 4.8)	-20.6 (-27.6 to -13.7)
Adverse effects of medical treatment	-	-	-	-	0.5 (0.3 to 0.7)	0.6 (0.4 to 1.0)	27.6 (17.8 to 36.1)	2.4 (-4.8 to 8.5)
Animal contact	-	-	-	-	0.8 (0.6 to 1.1)	0.9 (0.7 to 1.3)	18.3 (9.3 to 28.3)	-4.6 (-11.7 to 3.7)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	9.6 (-2.6 to 22.0)	-6.0 (-17.3 to 4.8)
Non-venomous animal contact	-	-	-	-	0.7 (0.5 to 1.0)	0.8 (0.6 to 1.2)	19.4 (10.0 to 30.8)	-4.4 (-12.1 to 4.9)
Foreign body	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-7.3 (-15.8 to -0.7)	-19.8 (-28.8 to -12.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-12.1 (-21.3 to -1.0)	-29.8 (-37.9 to -20.0)
Foreign body in eyes	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	2.3 (-6.9 to 10.0)	-9.3 (-19.0 to -1.8)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-14.1 (-23.3 to -6.2)	-25.7 (-34.8 to -18.2)
Other unintentional injuries	-	-	-	-	5.8 (4.2 to 7.9)	7.1 (5.0 to 9.8)	22.5 (12.4 to 31.8)	-4.6 (-12.4 to 2.6)
Self-harm and interpersonal violence	-	-	-	-	2.3 (1.7 to 2.9)	2.4 (1.8 to 3.3)	7.8 (-0.6 to 16.9)	-12.6 (-19.2 to -5.1)
Self-harm	-	-	-	-	1.3 (1.0 to 1.8)	1.8 (1.3 to 2.5)	38.7 (27.7 to 51.2)	13.7 (4.6 to 24.2)
Interpersonal violence	-	-	-	-	0.9 (0.7 to 1.2)	0.6 (0.4 to 0.8)	-36.0 (-42.1 to -29.0)	-47.8 (-52.8 to -42.0)
Assault by firearm	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-28.3 (-34.6 to -21.2)	-42.6 (-47.7 to -36.8)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-17.9 (-24.5 to -10.7)	-33.2 (-38.4 to -27.4)
Assault by other means	-	-	-	-	0.7 (0.5 to 0.9)	0.4 (0.3 to 0.5)	-41.0 (-47.6 to -33.1)	-51.6 (-57.1 to -44.9)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-94.2 (-97.5 to -86.4)	-95.6 (-98.1 to -89.6)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-94.2 (-97.5 to -86.4)	-95.6 (-98.1 to -89.6)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Belize prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	15.5 (11.4 to 20.3)	29.4 (21.7 to 38.5)	90.0 (85.6 to 94.5)	-0.6 (-2.6 to 1.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.8 (1.9 to 3.9)	4.2 (2.9 to 5.8)	52.9 (43.8 to 63.0)	-1.9 (-7.8 to 5.0)
HIV/AIDS and tuberculosis	-	-	-	-	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	572.5 (409.4 to 813.4)	218.9 (143.0 to 331.6)
Tuberculosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	149.5 (138.7 to 162.7)	22.8 (17.4 to 28.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	149.9 (122.5 to 181.2)	22.7 (11.6 to 35.7)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	3,101.0 (1,316.6 to 7,740.0)	1,516.4 (602.9 to 3,766.4)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,353.1 (983.8 to 5,494.9)	1,026.5 (400.7 to 2,466.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,306.0 (820.4 to 5,639.2)	1,009.7 (335.1 to 2,465.1)
HIV/AIDS resulting in other diseases	0.1 (0.0 to 0.2)	1.9 (1.3 to 2.5)	3,405.9 (1,357.0 to 8,275.1)	1,721.8 (657.0 to 4,193.3)	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	3,116.6 (1,307.4 to 7,901.3)	1,523.7 (601.6 to 3,841.0)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.5 (0.4 to 0.7)	0.6 (0.4 to 0.9)	21.8 (12.6 to 32.5)	-16.8 (-22.1 to -11.4)
Diarrheal diseases	1.7 (1.6 to 1.8)	2.0 (1.9 to 2.1)	17.3 (7.8 to 26.9)	-10.1 (-17.4 to -3.2)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	16.9 (6.3 to 27.0)	-10.2 (-17.8 to -3.3)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.8 (-81.1 to -3.1)	-58.7 (-88.2 to -39.8)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.0 (-27.6 to 4.0)	-45.0 (-53.9 to -35.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.0 (-27.7 to 4.0)	-45.0 (-53.9 to -35.4)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.0 (-29.5 to 8.1)	-44.3 (-54.9 to -30.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.0 (-29.5 to 8.3)	-44.3 (-54.9 to -30.4)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-97.1 (-99.7 to -13.5)	-98.2 (-99.8 to -46.0)
Lower respiratory infections	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	3.7 (-24.9 to 38.1)	-22.6 (-40.9 to -2.8)	0.0 (0.0 to 0.0)	0.0 (-29.4 to 43.0)	2.5 (-42.8 to -0.4)	-23.2 (-42.8 to -0.4)
Upper respiratory infections	10.0 (9.0 to 11.0)	16.5 (15.1 to 18.1)	66.1 (42.8 to 89.1)	-2.0 (-15.0 to 11.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	65.8 (42.4 to 88.6)	-2.1 (-15.3 to 11.3)
Otitis media	2.4 (2.2 to 2.5)	3.4 (3.2 to 3.6)	44.8 (34.9 to 55.3)	-11.0 (-16.7 to -4.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	42.4 (29.5 to 55.5)	-12.0 (-19.1 to -4.2)
Meningitis	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-43.2 (-52.5 to -24.0)	-66.2 (-71.2 to -56.0)
Pneumococcal meningitis	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.2)	-46.0 (-57.8 to -28.9)	-69.2 (-75.6 to -60.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.8 (-55.8 to -17.3)	-65.7 (-73.1 to -52.7)
H influenzae type B meningitis	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-56.5 (-69.3 to -37.7)	-75.5 (-82.2 to -65.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.9 (-69.7 to -12.0)	-72.3 (-82.0 to -49.9)
Meningococcal meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.3 (-66.0 to -12.3)	-67.8 (-79.2 to -48.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.7 (-68.6 to 6.8)	-62.7 (-80.0 to -39.6)
Other meningitis	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-42.7 (-56.4 to -19.2)	-60.0 (-73.6 to -50.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.4 (-56.7 to 15.3)	-60.4 (-72.7 to -33.5)
Encephalitis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	35.4 (10.6 to 63.3)	-41.1 (-41.1 to -34.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.4 (16.8 to 88.6)	-21.8 (-36.6 to -2.7)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.6 (-96.2 to 738.9)	-64.2 (-96.5 to 304.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.6 (-96.2 to 753.8)	-64.2 (-96.6 to 306.0)
Whooping cough	0.2 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-76.3 (-78.6 to -73.8)	-80.2 (-82.1 to -78.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-76.3 (-80.5 to -71.3)	-80.3 (-83.7 to -76.0)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.3 (-89.9 to -63.8)	-88.0 (-93.1 to -77.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-75.1 (-87.4 to -46.6)	-84.5 (-91.9 to -68.1)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.3)	40.3 (24.1 to 58.3)	-3.0 (-19.7 to 16.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.6 (33.1 to 144.3)	-3.3 (-32.2 to 32.9)
Neglected tropical diseases and malaria	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	13.1 (-15.5 to 51.5)	-28.4 (-45.3 to -5.4)
Malaria	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-30.3 (-49.7 to -1.8)	-60.2 (-74.1 to -43.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.8 (-65.1 to -9.4)	-67.7 (-80.7 to -50.0)
Chagas disease	0.9 (0.8 to 1.0)	1.8 (1.7 to 2.0)	97.1 (74.8 to 127.1)	1.1 (-9.3 to 13.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.0 (78.8 to 142.3)	-1.3 (-14.1 to 14.1)
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.8 (15.2 to 188.4)	7.7 (-28.5 to 79.5)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.6 (-33.2 to 241.6)	-10.6 (-50.9 to 106.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.6 (-33.5 to 245.7)	-10.6 (-51.0 to 107.2)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	81.0 (23.1 to 188.6)	8.3 (-23.5 to 79.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.8 (13.8 to 200.1)	8.6 (-28.6 to 85.3)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-87.4 (-95.8 to -63.7)	-92.6 (-97.2 to -79.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-86.1 (-95.8 to -59.1)	-91.9 (-97.2 to -76.9)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.3 (61.3 to 92.4)	-15.9 (-22.7 to -9.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.5 (38.3 to 121.4)	-16.1 (-34.4 to 7.5)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.0 (0.0 to 0.1)	0.3 (0.1 to 0.8)	756.1 (751.2 to 761.7)	392.0 (389.2 to 395.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	753.6 (613.1 to 946.8)	391.8 (321.3 to 481.1)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.0 (-29.0 to 39.6)	-36.8 (-55.4 to -13.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.0 (-29.0 to 39.9)	-36.8 (-55.4 to -13.2)
Intestinal nematode infections	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.2)	30.5 (59.0 to 13.1)	-30.5 (-72.0 to -24.3)
Ascariasis	18.5 (12.3 to 28.4)	13.8 (7.8 to 23.0)	-26.4 (-63.1 to 40.2)	-55.9 (-78.8 to -9.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	90.1 (97.1 to -66.3)	-91.4 (-97.5 to -70.9)
Trichuriasis	22.1 (15.0 to 31.4)	13.0 (7.6 to 21.3)	-41.8 (-69.9 to 10.5)	-66.7 (-83.9 to -31.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-74.5 (-94.3 to 8.1)	-84.9 (-96.9 to -27.6)
Hookworm disease	13.5 (9.3 to 19.1)	17.7 (10.8 to 27.0)	29.5 (-26.9 to 125.6)	0.1 (-59.2 to 36.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	9.2 (-29.9 to 70.4)	33.3 (-59.4 to 6.8)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	2.9 (2.3 to 3.6)	4.0 (3.8 to 4.3)	38.5 (11.7 to 77.5)	-4.9 (-21.7 to 18.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	36.3 (21.0 to 97.1)	-3.1 (-13.9 to 38.4)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.2 (0.5 to 53.1)	-37.2 (-48.9 to -23.9)
Maternal hemorrhage	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.1 (29.4 to 107.7)	-26.5 (-43.8 to -3.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.0 (37.8 to 155.2)	-21.2 (-36.5 to 21.4)
Maternal sepsis and other maternal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.6 (-4.0 to 59.5)	-47.1 (-60.1 to -32.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.2 (-16.7 to 30.0)	-50.3 (-59.6 to -38.1)
Maternal hypertensive disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	15.5 (6.4 to 27.3)	-40.9 (-45.4 to -35.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.9 (-11.9 to 50.3)	-40.7 (-54.9 to -23.1)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.1 (-29.0 to 125.0)	-37.2 (-60.7 to 13.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.6 (-36.7 to 208.1)	-32.6 (-64.6 to 44.1)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.9 (-26.3 to 125.1)	-35.4 (-60.3 to 2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.5 (-36.2 to 154.9)	-33.6 (-65.8 to 13.9)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	30.9 (-19.6 to 111.6)	-34.3 (-58.8 to 5.5)
Neonatal disorders	-	-	-	-	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	131.7 (56.9 to 215.9)	37.6 (-6.8 to 86.8)
Preterm birth complications	0.9 (0.5 to 1.5)	2.9 (1.6 to 5.4)	234.1 (146.2 to 340.0)	97.5 (45.0 to 157.0)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	221.5 (100.4 to 449.0)	87.4 (16.0 to 215.7)
Neonatal encephalopathy due to birth asphyxia and trauma	1.2 (0.4 to 2.9)	1.2 (0.5 to 2.9)	2.2 (-33.0 to 59.8)	-39.7 (-60.9 to -4.9)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	22.2 (-28.7 to 104.4)	-27.5 (-57.2 to 21.5)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.9 (83.8 to 193.6)	79.9 (58.3 to 152.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.5 (73.4 to 195.3)	82.1 (49.3 to 154.2)
Hemolytic disease and other neonatal jaundice	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.5)	102.6 (-13.9 to 413.5)	19.0 (-49.7 to 195.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	115.7 (-9.8 to 423.9)	24.4 (-47.8 to 201.9)
Other neonatal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	268.8 (53.8 to 577.1)	118.9 (-9.7 to 302.9)
Nutritional deficiencies	-	-	-	-	1.5 (1.0 to 2.2)	2.2 (1.5 to 3.2)	44.9 (38.8 to 49.6)	-7.6 (-10.6 to -5.0)
Protein-energy malnutrition	0.5 (0.3 to 0.8)	0.4 (0.2 to 0.7)	-14.6 (-63.2 to 87.1)	-28.7 (-67.3 to 47.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-14.9 (-63.2 to 92.5)	-28.8 (-67.3 to 51.0)
Iodine deficiency	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	27.5 (9.4 to 73.2)	-36.7 (-55.9 to -12.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.7 (-12.4 to 77.1)	-36.5 (-55.6 to -11.2)
Vitamin A deficiency	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-27.4 (-39.1 to -10.1)	-53.9 (-60.8 to -43.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.4 (-44.1 to -11.7)	-56.5 (-64.1 to -45.9)

Appendix Table G.4 - Belize prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	43.8 (43.1 to 44.5)	67.5 (67.0 to 68.1)	54.1 (51.6 to 56.8)	6.6 (-8.0 to -5.2)	1.5 (1.0 to 2.1)	2.1 (1.4 to 3.1)	47.6 (43.7 to 49.9)	47.6 (-9.1 to -4.9)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-44.9 to 373.1)	0.0 (-50.4 to 276.3)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	59.4 (47.9 to 80.4)	-4.9 (-11.3 to 4.4)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	91.1 (66.6 to 115.2)	-7.4 (-17.2 to 2.6)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.1 (69.7 to 143.7)	-10.2 (-23.7 to 4.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.4 (82.4 to 132.4)	-9.7 (-35.0 to 26.2)
Chlamydial infection	4.9 (3.9 to 6.0)	9.0 (7.6 to 10.6)	85.4 (42.2 to 146.4)	-7.5 (-27.4 to 18.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	91.4 (54.2 to 134.4)	-5.8 (-22.2 to 14.3)
Gonococcal infection	0.5 (0.4 to 0.6)	1.0 (0.7 to 1.2)	95.1 (40.2 to 158.9)	-1.3 (-28.0 to 27.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.9 (10.3 to 132.3)	-18.6 (-42.9 to 12.0)
Trichomoniasis	1.1 (0.8 to 1.6)	2.1 (1.2 to 3.1)	77.6 (-2.2 to 233.6)	-15.5 (-51.0 to 49.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.1 (-18.2 to 262.9)	-20.3 (-57.9 to 62.8)
Genital herpes	34.3 (32.7 to 36.0)	71.1 (67.0 to 75.0)	106.7 (92.1 to 122.6)	-5.4 (-11.7 to 1.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.5 (83.3 to 122.1)	5.6 (-12.9 to 2.6)
Other sexually transmitted diseases	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	88.8 (60.5 to 121.0)	-11.3 (-33.1 to -6.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.6 (56.0 to 221.5)	2.2 (-26.6 to 41.7)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.7 (17.1 to 57.0)	-30.1 (-42.2 to -17.1)
Hepatitis A	0.3 (0.3 to 0.3)	0.4 (0.3 to 0.4)	26.1 (25.5 to 26.8)	-14.6 (-15.2 to -14.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.5 (36.7 to 74.9)	-6.9 (-17.0 to 3.8)
Hepatitis B	13.3 (11.3 to 15.6)	13.2 (11.1 to 15.4)	-0.3 (-21.6 to 24.9)	-46.3 (-56.6 to -34.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.9 (-15.6 to 55.4)	-46.8 (-62.5 to -27.2)
Hepatitis C	2.5 (2.2 to 2.9)	3.7 (3.3 to 4.0)	44.1 (20.4 to 69.3)	-29.0 (-38.1 to -18.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.4 (5.3 to 69.4)	-28.2 (-48.0 to 0.3)
Hepatitis E	-	-	55.7 (37.0 to 78.9)	-15.0 (-24.0 to -3.2)	-	-	-	-
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.8 (-37.5 to -18.9)	-59.9 (-65.2 to -54.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.3 (-34.2 to -15.3)	-58.3 (-63.7 to -53.1)
Other infectious diseases	2.1 (1.6 to 2.5)	2.9 (2.7 to 3.1)	41.7 (32.5 to 55.9)	-5.7 (-11.1 to 1.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	47.6 (34.2 to 79.1)	4.4 (-5.7 to 25.6)
Non-communicable diseases	-	-	-	-	11.9 (8.8 to 15.5)	24.0 (17.8 to 31.3)	101.3 (96.2 to 107.0)	1.6 (-0.7 to 4.6)
Neoplasms	-	-	-	-	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.5)	255.8 (180.9 to 338.0)	88.2 (45.5 to 132.5)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	143.9 (72.8 to 253.4)	26.3 (-9.8 to 81.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	140.1 (70.1 to 239.2)	24.2 (-12.1 to 74.4)
Stomach cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	98.8 (57.1 to 163.1)	2.2 (-19.0 to 34.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.1 (47.8 to 150.1)	-2.8 (-24.3 to 27.7)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	797.7 (577.9 to 1,142.8)	368.3 (249.9 to 544.4)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	948.4 (426.0 to 1,975.1)	431.5 (168.2 to 974.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	930.0 (444.8 to 1,741.1)	423.4 (184.0 to 865.9)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3,294.8 (1,734.0 to 6,508.8)	1,665.2 (847.9 to 3,311.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3,087.9 (1,878.4 to 5,641.4)	1,550.5 (924.1 to 2,872.1)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	331.9 (128.0 to 666.5)	127.3 (20.0 to 305.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	324.8 (156.5 to 576.4)	126.3 (35.2 to 258.4)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	360.0 (148.7 to 795.1)	18.5 (16.5 to 356.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	353.2 (168.9 to 660.5)	118.0 (25.5 to 288.5)
Larynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.4 (46.1 to 232.9)	16.8 (-24.5 to 67.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	170.8 (86.1 to 290.6)	37.2 (-6.4 to 96.6)
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	200.2 (129.5 to 297.0)	51.8 (16.2 to 98.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	187.2 (113.6 to 276.4)	45.1 (8.6 to 89.5)
Breast cancer	0.2 (0.1 to 0.2)	0.5 (0.4 to 0.8)	221.7 (127.1 to 380.2)	44.7 (2.3 to 116.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	231.8 (135.3 to 397.2)	52.7 (11.2 to 128.7)
Cervical cancer	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	164.2 (73.2 to 333.6)	45.5 (-22.3 to 87.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	165.1 (71.0 to 332.9)	16.1 (-21.5 to 90.6)
Uterine cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	424.4 (118.0 to 812.1)	156.2 (8.5 to 336.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	423.2 (118.3 to 819.8)	156.7 (92.4 to 341.5)
Prostate cancer	0.2 (0.1 to 0.3)	1.1 (0.6 to 1.6)	505.4 (214.4 to 816.4)	238.0 (73.1 to 411.8)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	511.4 (210.0 to 784.2)	245.6 (74.5 to 401.4)
Colon and rectum cancer	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	85.8 (21.5 to 143.4)	-8.5 (-39.5 to 18.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.7 (20.4 to 139.4)	-8.2 (-39.8 to 19.9)
Lip and oral cavity cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	159.3 (82.1 to 258.5)	29.4 (-9.9 to 78.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	158.8 (83.3 to 259.0)	30.4 (-8.9 to 81.2)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.5 (56.0 to 242.4)	2.5 (-28.2 to 53.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	119.7 (56.7 to 230.6)	1.9 (-26.6 to 50.8)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	163.4 (69.2 to 315.8)	24.8 (-19.6 to 93.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	158.3 (68.8 to 302.2)	22.6 (-19.4 to 88.8)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.0 (-45.1 to 129.1)	-53.0 (-71.4 to 20.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.3 (-46.7 to 126.4)	-53.7 (-72.3 to 18.2)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,019.4 (762.6 to 1,379.0)	489.9 (353.6 to 674.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	891.0 (670.7 to 1,191.2)	413.3 (294.3 to 568.9)
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	94.5 (42.9 to 196.6)	97.4 (32.5 to 144.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.8 (42.1 to 210.0)	-5.6 (-31.8 to 54.9)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	282.2 (185.6 to 423.3)	86.2 (38.3 to 157.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	416.1 (233.4 to 641.4)	158.6 (61.4 to 274.7)
Ovarian cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	1,063.5 (668.1 to 1,738.4)	472.0 (280.1 to 780.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,014.0 (597.9 to 1,691.4)	455.3 (243.0 to 790.7)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,146.2 (95.1 to 2,613.4)	477.6 (-12.1 to 1,942.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,030.1 (80.1 to 2,593.3)	423.9 (-16.4 to 1,068.2)
Kidney cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	168.5 (104.0 to 258.1)	46.5 (10.4 to 97.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	160.0 (97.0 to 268.9)	39.8 (3.4 to 97.1)
Bladder cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.7 (-23.9 to 176.2)	-19.4 (-60.6 to 43.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.0 (-31.7 to 185.0)	-17.4 (-64.6 to 48.2)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	532.0 (88.6 to 852.4)	355.0 (25.1 to 528.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	623.9 (108.2 to 950.8)	384.5 (25.9 to 538.6)
Thyroid cancer	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	361.2 (172.2 to 585.1)	110.4 (19.5 to 211.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	359.7 (167.9 to 591.9)	112.0 (19.7 to 212.9)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.6 (298.2 to 541.1)	169.6 (109.7 to 238.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	424.6 (312.3 to 555.0)	179.7 (121.6 to 249.5)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,861.6 (130.2 to 2,881.6)	1,158.9 (34.8 to 1,749.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,965.7 (122.3 to 2,957.8)	1,193.8 (29.4 to 1,751.9)
Non-Hodgkin lymphoma	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	295.7 (152.0 to 516.2)	103.4 (25.2 to 216.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	274.6 (135.1 to 481.5)	89.1 (15.2 to 194.7)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	250.0 (87.4 to 536.6)	74.0 (-5.9 to 215.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	235.2 (84.5 to 498.6)	67.3 (-8.3 to 200.1)
Leukemia	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	105.4 (38.2 to 217.8)	52.9 (15.6 to 115.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	159.8 (78.0 to 257.9)	80.0 (24.9 to 114.0)
Other neoplasms	0.1 (0.1 to 0.2)	0.5 (0.4 to 0.7)	256.7 (160.3 to 397.9)	136.6 (79.8 to 219.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	260.4 (164.6 to 397.0)	130.4 (74.3 to 213.0)
Cardiovascular diseases	-	-	-	-	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	141.9 (95.3 to 191.7)	26.7 (3.4 to 51.2)
Rheumatic heart disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.2 (66.6 to 121.4)	-5.4 (-19.8 to 8.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.9 (66.9 to 129.2)	-5.2 (-19.8 to 11.7)
Ischemic heart disease	0.8 (0.7 to 1.0)	2.6 (2.1 to 3.2)	214.5 (130.2 to 305.0)	68.1 (23.3 to 117.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	262.2 (138.3 to 400.0)	94.7 (29.1 to 170.8)
Cerebrovascular disease	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	91.2 (47.0 to 133.3)	-1.9 (-25.8 to 22.4)
Ischemic stroke	0.2 (0.2 to 0.3)	0.4 (0.4 to 0.5)	87.6 (35.9 to 129.0)	-1.7 (-28.9 to 23.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	88.7 (35.8 to 133.2)	-1.4 (-29.1 to 24.2)
Hemorrhagic stroke	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	97.6 (48.8 to 165.6)	-3.9 (-29.4 to 34.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	100.8 (48.6 to 169.5)	-2.8 (-29.7 to 36.5)
Hypertensive heart disease	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	52.0 (31.5 to 72.8)	-20.0 (-30.8 to -8.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.8 (32.3 to 77.0)	-19.8 (-31.3 to -7.3)
Cardiomyopathy and myocarditis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	97.0 (67.3 to 129.5)	0.5 (-16.9 to 20.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.0 (60.7 to 136.5)	0.0 (-19.6 to 22.8)
Atrial fibrillation and flutter	0.3 (0.2 to 0.3)	0.7 (0.6 to 0.8)	159.0 (96.4 to 236.7)	39.2 (4.1 to 82.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	161.6 (96.2 to 240.5)	39.9 (4.4 to 83.3)
Peripheral vascular disease	3.3 (2.3 to 4.0)	6.8 (5.5 to 8.3)	108.2 (71.4 to 166.2)	0.0 (-18.0 to 28.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.2 (-12.3 to 281.3)	0.6 (-50.4 to 117.3)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.8 (-19.4 to 41.4)	-44.0 (-58.1 to -22.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.0 (-2.0 to 44.4)	-47.5 (-60.4 to -22.5)
Other cardiovascular and circulatory diseases	0.4 (0.2 to 0.8)	0.9 (0.7 to 1.1)	108.2 (6.3 to 320.7)	0.4 (-52.5 to 84.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	108.8 (8.4 to 329.1)	-9.2 (-21.6 to 86.6)
Chronic respiratory diseases	-	-	-	-	0.9 (0.6 to 1.3)	1.5 (1.0 to 2.1)	66.3 (39.7 to 92.3)	-15.2 (-27.5 to -1.7)
Chronic obstructive pulmonary disease	5.8 (5.5 to 6.0)	12.1 (11.5 to 12.7)	109.3 (103.8 to 115.8)	-1.5				

Appendix Table G.4 - Belize prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumococcal	-	-	-	-	0.0	0.0	-	-
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.5 (74.8 to 88.5)	-11.9 (-15.0 to -8.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.5 to 106.8	(-9.3 to -1.2)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	80.9	-12.3
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.1 (92.4 to 125.2)	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.3	0.5
Asthma	10.6 (8.8 to 12.7)	15.0 (12.0 to 17.7)	44.4 (0.1 to 81.0)	-22.0 (-43.9 to -3.3)	0.5 (0.3 to 0.7)	0.7 (0.4 to 1.0)	43.5	(-4.1 to -3.4)
Interstitial lung disease and pulmonary sarcoidosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.1 (47.3 to 169.7)	4.0 (-27.6 to 44.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.3	4.1
Other chronic respiratory diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.2)	-15.9	(-72.6 to -35.3)
Cirrhosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	128.1	17.2
Cirrhosis due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	138.4 (37.5 to 292.7)	20.7 (-32.6 to 105.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	135.2	19.5
Cirrhosis due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	143.3 (45.2 to 319.7)	24.2 (-25.8 to 115.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	140.2	23.9
Cirrhosis due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.4 (37.3 to 199.5)	-5.3 (-34.7 to 37.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.5	-4.9
Cirrhosis due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	135.8 (66.3 to 227.5)	47.4 (2.1 to 116.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	130.8	44.4
Digestive diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	115.0	9.5
Peptic ulcer disease	1.0 (0.9 to 1.1)	1.2 (1.0 to 1.3)	11.8 (2.6 to 28.3)	-41.7 (-48.4 to -33.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	25.4	-36.3
Gastritis and duodenitis	2.7 (2.6 to 2.9)	5.2 (4.9 to 5.5)	89.3 (77.2 to 102.9)	5.3 (-0.4 to 11.6)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	81.1	3.1
Appendicitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.4 (18.8 to 132.4)	-4.7 (-30.4 to 20.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.3	-4.1
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.9 (-0.7 to 178.2)	12.8 (-14.1 to 78.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.7	12.8
Inguinal, femoral, and abdominal hernia	0.5 (0.5 to 0.6)	0.6 (0.5 to 0.7)	21.0 (-3.0 to 48.1)	-36.6 (-50.2 to -19.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.9	-36.3
Inflammatory bowel disease	0.2 (0.2 to 0.2)	0.5 (0.5 to 0.5)	172.9 (159.9 to 188.5)	24.6 (18.6 to 31.6)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	174.0	24.8
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.1 (12.9 to 158.3)	-9.1 (-40.6 to 51.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.1	-9.1
Gallbladder and biliary diseases	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	32.9 (15.1 to 58.5)	32.6 (-41.6 to -19.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.7	33.9
Pancreatitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	218.4 (197.8 to 241.7)	48.6 (38.9 to 58.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	217.0	47.7
Other digestive diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	865.6	395.0
Neurological disorders	-	-	-	-	1.0 (0.7 to 1.4)	2.1 (1.4 to 3.0)	111.2	5.7
Alzheimer disease and other dementias	0.8 (0.7 to 0.9)	1.4 (1.3 to 1.6)	73.8 (45.6 to 107.6)	-1.6 (-17.6 to 17.9)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	73.8	-1.5
Parkinson disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.9 (71.2 to 91.2)	-1.8 (-6.5 to 3.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.6	-1.9
Epilepsy	0.4 (0.3 to 0.6)	1.0 (0.7 to 1.3)	120.7 (29.3 to 263.7)	24.1 (-26.8 to 101.6)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	137.9	34.1
Multiple sclerosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	336.3 (289.9 to 389.1)	86.5 (67.3 to 108.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	321.4	79.9
Migraine	16.1 (13.3 to 18.8)	31.5 (26.1 to 35.8)	95.4 (54.4 to 142.8)	1.1 (-22.0 to 17.2)	0.0 (0.3 to 0.9)	1.1 (0.6 to 1.6)	95.8	-9.2
Tension-type headache	31.9 (27.2 to 37.7)	68.9 (63.8 to 74.4)	117.8 (78.9 to 160.0)	4.9 (-12.9 to 23.3)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	118.8	5.1
Medication overuse headache	0.6 (0.4 to 0.9)	2.0 (1.3 to 2.7)	212.3 (128.5 to 354.4)	43.7 (7.7 to 92.8)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	212.7	43.7
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.9 (34.4 to 164.2)	2.8 (-24.6 to 48.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	52.7	-15.4
Mental and substance use disorders	-	-	-	-	3.9 (2.8 to 5.2)	7.8 (5.5 to 10.3)	99.2	0.2
Schizophrenia	0.4 (0.3 to 0.4)	0.8 (0.8 to 0.9)	128.0 (116.1 to 139.0)	-0.7 (-5.3 to 3.8)	0.2 (0.2 to 0.3)	0.2 (0.4 to 0.7)	93.2 to 106.2	(-2.1 to 2.6)
Alcohol use disorders	0.9 (0.8 to 1.0)	2.2 (2.0 to 2.3)	137.7 (125.4 to 150.9)	14.3 (9.0 to 19.9)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	139.4	14.6
Drug use disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.6)	119.0	4.8
Opioid use disorders	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	140.1 (109.6 to 163.4)	-2.6 (-14.0 to 7.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	139.7	-2.5
Cocaine use disorders	0.1 (0.1 to 0.3)	0.6 (0.4 to 0.8)	493.2 (54.4 to 298.7)	12.7 (-27.0 to 67.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	101.1 to 177.4	(-16.7 to 12.3)
Amphetamine use disorders	0.3 (0.3 to 0.4)	0.6 (0.6 to 0.7)	88.9 (71.0 to 113.3)	1.4 (-7.7 to 13.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	88.8	1.7
Cannabis use disorders	0.5 (0.4 to 0.5)	1.0 (0.7 to 1.0)	84.7 (81.8 to 88.5)	-0.2 (-0.2 to -0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.3	0.2
Other drug use disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	118.5	8.6
Depressive disorders	-	-	-	-	1.4 (1.0 to 2.1)	2.9 (1.9 to 4.1)	98.8	1.0
Major depressive disorder	6.2 (4.9 to 7.3)	12.1 (9.4 to 14.6)	96.7 (82.3 to 110.1)	-1.1 (-7.5 to 3.8)	1.3 (0.8 to 1.8)	2.5 (1.6 to 3.6)	96.1	-1.3
Dysthymia	1.7 (1.4 to 2.1)	3.8 (3.1 to 4.5)	118.4 (111.1 to 127.6)	0.5 (0.4 to 0.7)	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.5)	118.5	0.4
Bipolar disorder	1.1 (0.9 to 1.3)	2.4 (2.0 to 2.8)	108.3 (97.1 to 126.8)	-0.8 (-5.1 to 4.8)	0.2 (0.1 to 0.4)	0.5 (0.3 to 0.7)	108.0	-0.8
Anxiety disorders	9.6 (6.3 to 12.6)	19.2 (12.9 to 25.0)	101.2 (90.4 to 112.8)	0.7 (0.5 to 0.8)	0.9 (0.5 to 1.4)	1.8 (1.0 to 2.7)	100.8	0.7
Eating disorders	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	86.5	1.1
Anorexia nervosa	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	89.7 (68.8 to 111.9)	5.6 (-5.1 to 17.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.2	5.6
Bulimia nervosa	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	85.5 (79.0 to 96.2)	0.4 (0.2 to 0.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	86.1	0.4
Autistic spectrum disorders	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	75.2	-0.5
Autism	0.6 (0.5 to 0.6)	1.0 (0.9 to 1.0)	76.1 (75.2 to 77.1)	-0.6 (-0.6 to -0.6)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	68.7 to 82.5	(-3.8 to 3.0)
Asperger syndrome	0.8 (0.8 to 0.9)	1.5 (1.4 to 1.6)	74.6 (73.4 to 76.0)	-0.8 (-0.8 to -0.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	74.3	-0.6
Attention-deficit/hyperactivity disorder	1.8 (1.6 to 1.9)	2.7 (2.5 to 2.9)	54.8 (54.3 to 55.0)	0.2 (0.1 to 0.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	55.3	0.5
Conduct disorder	2.3 (2.2 to 2.5)	3.6 (3.4 to 3.9)	56.4 (55.7 to 57.1)	0.3 (0.2 to 0.2)	0.3 (0.2 to 0.4)	0.3 (0.3 to 0.6)	56.9	0.3
Idiopathic intellectual disability	0.6 (0.3 to 0.9)	1.1 (0.5 to 1.7)	90.9 (26.8 to 201.0)	5.6 (-29.3 to 68.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	90.9	6.4
Other mental and substance use disorders	2.3 (2.2 to 2.5)	5.0 (4.7 to 5.3)	114.3 (111.4 to 117.4)	-0.5 (-0.6 to -0.4)	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	114.8	-0.3
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	1.3 (0.9 to 1.8)	2.9 (2.0 to 4.0)	118.4	8.2
Diabetes mellitus	9.1 (7.7 to 10.5)	23.0 (19.6 to 26.5)	151.9 (104.0 to 207.5)	15.4 (-9.1 to 45.0)	0.6 (0.4 to 0.9)	1.6 (1.1 to 2.2)	149.4	13.9
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.0 (39.5 to 65.9)	0.0 (0.5 to 17.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.0	0.0
Chronic kidney disease	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	92.0	0.9
Chronic kidney disease due to diabetes mellitus	3.6 (2.3 to 5.0)	7.5 (5.0 to 11.5)	109.2 (59.8 to 163.1)	2.3 (-23.3 to 28.7)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	107.1	0.6
Chronic kidney disease due to hypertension	2.7 (1.8 to 4.1)	5.3 (3.6 to 7.9)	98.4 (44.6 to 168.2)	10.7 (-16.0 to 40.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	96.2	-0.6
Chronic kidney disease due to glomerulonephritis	5.6 (3.4 to 8.5)	10.6 (7.0 to 15.4)	88.5 (56.9 to 133.2)	0.0 (-22.2 to 21.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	100.4	12.8
Chronic kidney disease due to other causes	5.8 (3.9 to 8.9)	10.0 (6.4 to 15.4)	72.3 (33.9 to 132.7)	-2.9 (-26.7 to 28.3)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	74.3	-3.3
Urinary diseases and male infertility	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	95.5	2.5

Appendix Table G.4 - Belize prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	159.5 (133.4 to 192.8)	33.7 (22.0 to 48.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	159.9 (108.0 to 227.4)	33.9 (9.2 to 63.1)
Urolithiasis	0.8 (0.6 to 1.1)	2.4 (1.6 to 3.5)	171.4 (124.1 to 262.0)	32.5 (7.7 to 77.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	177.9 (135.8 to 260.3)	38.1 (15.5 to 81.1)
Benign prostatic hyperplasia	0.8 (0.7 to 0.8)	1.3 (1.2 to 1.4)	68.9 (49.3 to 90.9)	-4.9 (-16.4 to 7.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	69.3 (48.7 to 90.7)	-4.8 (-16.5 to 7.5)
Male infertility due to other causes	0.8 (0.6 to 1.0)	1.7 (1.3 to 2.1)	115.5 (48.3 to 202.9)	-2.4 (-32.8 to 35.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.0 (42.1 to 207.2)	-2.0 (-34.7 to 38.3)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	100.8 (45.7 to 497.4)	0.2 (-28.5 to 208.3)
Gynecological diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.7)	131.4 (101.9 to 163.5)	1.0 (-10.7 to 13.8)
Uterine fibroids	2.3 (2.1 to 2.6)	6.6 (5.9 to 7.1)	179.0 (175.3 to 183.0)	2.8 (2.8 to 2.9)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	145.8 (122.3 to 164.2)	-2.9 (-12.0 to 4.7)
Polycystic ovarian syndrome	2.8 (2.3 to 3.2)	6.9 (6.2 to 7.6)	152.7 (109.3 to 201.7)	7.3 (-8.6 to 25.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	152.6 (108.4 to 201.1)	7.8 (-8.4 to 26.3)
Female infertility due to other causes	0.4 (0.2 to 0.6)	1.0 (0.5 to 1.5)	144.9 (20.5 to 438.4)	6.0 (-47.4 to 124.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	135.7 (16.5 to 427.8)	4.5 (-48.1 to 122.1)
Endometriosis	0.3 (0.2 to 0.3)	0.7 (0.6 to 0.8)	160.0 (108.0 to 227.3)	9.3 (-11.9 to 36.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	160.3 (103.6 to 231.3)	9.5 (-13.3 to 37.6)
Genital prolapse	7.1 (5.8 to 8.7)	16.7 (13.8 to 19.3)	134.9 (75.8 to 202.9)	2.4 (-20.5 to 26.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	134.4 (74.9 to 205.3)	2.1 (-20.7 to 27.5)
Premenstrual syndrome	7.6 (6.0 to 9.4)	16.2 (11.6 to 20.5)	113.8 (46.6 to 202.2)	-0.8 (-33.5 to 39.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	113.3 (45.4 to 202.4)	-0.4 (-33.5 to 41.4)
Other gynecological diseases	0.5 (0.5 to 0.6)	1.1 (1.0 to 1.2)	99.9 (60.5 to 148.1)	-5.7 (-22.9 to 14.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.1 (55.1 to 190.1)	-6.2 (-26.4 to 34.6)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	69.3 (50.4 to 76.2)	0.7 (-5.8 to 9.3)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.9 (-22.7 to 43.8)	-9.2 (-46.0 to 0.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.5 (-19.1 to 45.1)	-10.2 (-42.5 to 1.2)
Thalassemia trait	2.9 (1.9 to 4.3)	4.6 (2.7 to 7.2)	68.7 (16.7 to 76.4)	-3.8 (-33.9 to 0.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	55.6 (33.5 to 78.7)	-3.3 (-16.6 to 10.8)
Sickle cell disorders	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	91.1 (67.1 to 133.2)	13.5 (1.0 to 33.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.2 (75.8 to 139.0)	13.8 (-0.3 to 29.9)
Sickle cell trait	10.5 (9.1 to 11.9)	20.2 (17.3 to 22.8)	91.4 (83.2 to 101.1)	9.1 (4.5 to 14.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	91.4 (48.8 to 133.1)	12.0 (-6.3 to 50.8)
G6PD deficiency	7.9 (6.4 to 9.5)	14.1 (10.9 to 17.7)	77.1 (30.5 to 138.2)	0.7 (-25.8 to 35.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.2 (19.1 to 142.4)	3.1 (-20.0 to 31.5)
G6PD trait	29.0 (27.0 to 30.8)	51.9 (48.0 to 55.3)	79.3 (61.9 to 97.2)	2.8 (-7.2 to 13.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.9 (-81.3 to 336.9)	-37.6 (-82.8 to 139.7)
Other hemoglobinopathies and hemolytic anemias	1.8 (1.6 to 2.0)	2.8 (2.6 to 3.1)	54.2 (36.4 to 72.7)	-8.6 (-16.9 to 0.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	41.8 (22.4 to 71.1)	-8.9 (-21.3 to 8.9)
Endocrine, metabolic, blood, and immune disorders	2.0 (1.6 to 2.2)	3.0 (2.8 to 3.3)	52.5 (31.6 to 80.4)	4.4 (-15.4 to 8.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	44.8 (20.1 to 98.8)	-3.9 (-18.0 to 26.1)
Musculoskeletal disorders	-	-	-	-	1.7 (1.2 to 2.3)	3.8 (2.7 to 5.1)	125.8 (106.3 to 146.2)	4.9 (-2.5 to 12.1)
Rheumatoid arthritis	0.3 (0.3 to 0.3)	0.9 (0.8 to 0.9)	180.9 (164.8 to 199.6)	45.8 (36.2 to 56.4)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	179.3 (156.9 to 207.6)	44.8 (33.9 to 57.8)
Osteoarthritis	3.8 (3.7 to 4.0)	8.1 (7.8 to 8.4)	111.6 (100.0 to 121.7)	2.6 (-2.8 to 7.3)	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.7)	112.4 (100.5 to 123.1)	2.4 (-3.2 to 7.4)
Low back and neck pain	-	-	-	-	1.1 (0.7 to 1.5)	2.4 (1.6 to 3.3)	117.3 (90.5 to 148.0)	11.3 (-10.6 to 12.0)
Low back pain	6.1 (5.0 to 7.0)	12.8 (11.4 to 14.2)	110.5 (80.0 to 151.5)	-1.2 (-14.5 to 14.4)	0.7 (0.4 to 1.0)	1.4 (1.0 to 2.0)	111.0 (80.2 to 153.9)	-1.0 (-15.0 to 15.2)
Neck pain	4.3 (3.5 to 4.9)	9.7 (8.5 to 11.0)	125.3 (86.4 to 178.5)	1.2 (-14.5 to 22.6)	0.4 (0.3 to 0.6)	1.0 (0.7 to 1.4)	125.5 (86.6 to 179.4)	1.1 (-14.5 to 22.9)
Gout	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	96.9 (75.5 to 124.8)	-8.4 (-18.1 to 4.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.8 (59.9 to 149.1)	-8.2 (-27.1 to 16.9)
Other musculoskeletal disorders	3.0 (2.5 to 3.6)	7.8 (6.4 to 9.3)	157.7 (139.1 to 176.7)	14.2 (5.6 to 22.8)	0.3 (0.2 to 0.4)	0.7 (0.5 to 1.0)	140.0 (138.1 to 178.6)	14.0 (5.2 to 22.8)
Other non-communicable diseases	-	-	-	-	2.6 (1.8 to 3.8)	4.7 (3.2 to 6.9)	80.1 (72.9 to 88.0)	-5.2 (-8.3 to -2.1)
Congenital anomalies	-	-	-	-	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	113.6 (83.2 to 157.3)	20.4 (3.9 to 44.1)
Neural tube defects	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	85.3 (43.8 to 141.2)	10.8 (-14.0 to 44.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.9 (28.9 to 180.7)	14.2 (-20.8 to 68.1)
Congenital heart anomalies	0.7 (0.6 to 0.9)	1.9 (1.5 to 2.3)	164.8 (90.0 to 244.2)	56.4 (12.5 to 104.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	164.4 (93.1 to 244.5)	58.0 (14.8 to 109.3)
Orofacial clefts	0.1 (0.1 to 0.2)	0.3 (0.3 to 0.4)	132.0 (67.3 to 207.0)	42.9 (3.8 to 89.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.2 (23.4 to 180.3)	14.8 (-23.0 to 69.4)
Down syndrome	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	94.4 (43.6 to 151.7)	11.4 (-17.9 to 45.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.7 (43.3 to 160.1)	11.8 (-19.3 to 48.1)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.5 (36.4 to 178.6)	5.1 (-24.0 to 56.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.9 (34.5 to 185.8)	5.8 (-26.3 to 57.2)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.7 (24.7 to 167.6)	1.1 (-29.3 to 50.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.9 (40.0 to 204.2)	1.2 (-29.3 to 52.0)
Chromosomal unbalanced rearrangements	0.0 (0.2 to 0.4)	0.6 (0.5 to 0.8)	88.5 (38.9 to 161.6)	0.1 (-20.5 to 50.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	91.1 (39.8 to 172.5)	8.1 (-20.4 to 53.9)
Other congenital anomalies	0.8 (0.6 to 0.9)	1.2 (1.0 to 1.4)	61.0 (45.6 to 76.6)	-11.1 (-19.3 to -3.1)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	118.4 (78.3 to 184.5)	20.4 (-0.0 to 55.4)
Skin and subcutaneous diseases	-	-	-	-	0.9 (0.6 to 1.4)	1.6 (1.0 to 2.5)	78.9 (64.1 to 99.7)	-1.2 (-8.7 to 8.6)
Dermatitis	8.0 (6.6 to 9.6)	15.8 (12.8 to 19.1)	97.3 (90.2 to 103.5)	0.0 (-0.1 to 0.1)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	87.7 (78.7 to 95.8)	0.7 (-2.0 to 2.9)
Psoriasis	1.3 (1.1 to 1.4)	2.6 (2.3 to 2.9)	101.9 (97.5 to 106.5)	0.0 (-0.1 to 0.1)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	101.9 (89.7 to 115.6)	0.0 (-4.5 to 5.3)
Cellulitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.9 (19.2 to 62.4)	-12.0 (-22.1 to -1.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.1 (10.6 to 75.3)	-11.6 (-25.5 to 4.8)
Pyoderma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	102.8 (86.2 to 117.4)	22.1 (16.7 to 27.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.5 (72.4 to 135.3)	22.1 (7.9 to 37.4)
Scabies	2.5 (2.2 to 2.9)	4.2 (3.6 to 4.7)	65.9 (34.7 to 106.4)	-2.2 (-20.1 to 21.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	66.1 (33.8 to 107.2)	-2.0 (-20.3 to 21.2)
Fungal skin diseases	12.5 (9.3 to 16.5)	23.9 (18.1 to 31.7)	91.4 (81.4 to 101.2)	0.1 (-0.4 to 0.1)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	91.3 (81.3 to 101.4)	-0.2 (-1.1 to 0.7)
Viral skin diseases	4.4 (3.3 to 5.4)	7.0 (5.2 to 8.8)	59.2 (49.6 to 67.1)	0.2 (-1.7 to 2.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	59.0 (48.5 to 68.4)	0.6 (-2.9 to 3.6)
Acne vulgaris	14.7 (11.5 to 18.7)	22.8 (15.0 to 33.8)	53.0 (-1.9 to 145.4)	-12.1 (-43.6 to 39.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.5)	52.7 (-2.3 to 145.3)	-11.9 (-43.7 to 39.5)
Alopecia areata	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.3)	88.2 (64.6 to 115.0)	-1.3 (-12.8 to 13.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.9 (56.8 to 129.2)	-1.6 (-15.7 to 16.4)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.1 (53.8 to 144.0)	0.6 (-21.0 to 28.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.1 (53.7 to 144.1)	-0.6 (-21.0 to 28.6)
Urticaria	1.5 (0.9 to 2.1)	3.0 (2.1 to 4.1)	98.2 (15.9 to 260.2)	6.5 (-32.9 to 76.9)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	97.9 (15.2 to 260.8)	5.8 (-34.0 to 76.9)
Decubitus ulcer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.2 (15.7 to 91.3)	-22.2 (-43.5 to -2.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.8 (14.2 to 103.1)	-21.4 (-44.7 to 2.9)
Other skin and subcutaneous diseases	8.6 (5.8 to 12.8)	17.0 (11.6 to 24.5)	99.7 (82.0 to 119.9)	-0.1 (-5.5 to 3.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	99.7 (81.9 to 120.5)	-0.1 (-5.7 to 3.8)
Sense organ diseases	-	-	-	-	1.1 (0.7 to 1.5)	1.8 (1.2 to 2.5)	68.2 (58.9 to 77.1)	-10.8 (-14.4 to -7.0)
Glaucoma	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.4)	60.5 (37.3 to 83.5)	-19.5 (-30.7 to -8.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.7 (31.9 to 85.7)	-18.5 (-32.0 to -4.8)
Cataract	0.9 (0.7 to 1.1)	1.2 (0.9 to 1.4)	29.5 (17.8 to 47.4)	-28.6 (-35.1 to -18.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	29.9 (18.6 to 47.2)	-28.2 (-34.7 to -19.3)
Macular degeneration	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	123.2 (78.0 to 172.8)	11.0 (-12.0 to 37.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	116.9 (75.5 to 163.1)	8.7 (-12.6 to 33.0)
Uncorrected refractive error	14.3 (13.3 to 15.3)	26.5 (24.7 to 28.3)	85.2 (68.0 to 102.5)	-6.6 (-12.1 to 11.4)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.6)	72.5 (59.7 to 85.4)	-10.9 (-16.0 to -5.6)
Age-related and other hearing loss	19.1 (17.8 to 20.4)	34.6 (32.0 to 37.4)	81.0 (73.8 to 90.2)	-9.6 (-12.3 to -6.1)	0.6 (0.4 to 0.9)	1.1 (0.7 to 1.5)	72.1 (58.9 to 86.6)	-9.2 (-14.1 to -2.6)
Other vision loss	0.5 (0.4 to 0.6)	0.6 (0.5 to 0.7)	24.4 (10.0 to 39.9)	-33.0 (-39.1 to -26.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	28.6 (11.3 to 47.4)	-31.6 (-38.2 to -24.5)
Other sense organ diseases	4.5 (4.2 to 4.7)	7.3 (7.0 to 7.7)	63.6 (52.1 to 76.2)	-0.4 (-6.3 to 6.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	63.0 (49.8 to 77.7)	-0.2 (-7.4 to 7.6)
Oral disorders	-	-	-	-	0.5 (0.3 to 0.7)	0.9 (0.5 to 1.4)	94.9 (88.4 to 101.7)	-4.0 (-6.9 to -1.1)
Deciduous caries	18.5 (17.6 to 19.5)	24.7 (23.7 to 25.8)	33.1 (25.5 to 42.4)	0.6 (-5.1 to 7.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.3 (22.8 to 45.6)	0.8 (-7.3 to 9.9)
Permanent caries	78.7 (75.4 to 81.8)	149.8 (143.9 to 156.9)	90.3 (80.8 to 101.4)	0.7 (-3.7 to 5.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	90.1 (79.9 to 101.4)	0.7 (-4.0 to 5.6)
Periodontal diseases	14.5 (13.8 to 15.2)	31.6 (30.1 to 33.2)	118.2 (103.9 to 133.2)	-3.2 (-9.2 to 3.3)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	118.2 (104.1 to 133.9)	-3.3 (-9.3 to 3.5)

Appendix Table G.4 - Belize prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes								
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	7.3 (7.1 to 7.6)	13.6 (13.2 to 14.1)	86.2 (77.4 to 94.2)	-4.0 (-10.1 to -2.1)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.5)	86.7 (78.1 to 95.0)	-6.1 (-10.3 to -2.0)
Other oral disorders	2.7 (2.6 to 2.9)	5.4 (5.1 to 5.7)	98.6 (83.7 to 114.8)	-0.0 (-6.8 to 7.4)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	98.6 (83.1 to 116.7)	-0.1 (-6.9 to 8.2)
Injuries	-	-	-	-	0.8 (0.6 to 1.0)	1.2 (0.9 to 1.6)	46.6 (32.6 to 63.0)	-27.8 (-34.6 to -20.1)
Transport injuries	-	-	-	-	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.6)	56.7 (36.7 to 82.0)	-22.8 (-32.3 to -11.3)
Road injuries	-	-	-	-	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	48.1 (28.7 to 72.5)	-26.8 (-36.0 to -15.5)
Pedestrian road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	23.9 (5.4 to 46.1)	-35.8 (-44.4 to -25.4)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.8 (41.7 to 78.2)	-18.7 (-27.1 to -9.4)
Motorcyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	37.6 (19.5 to 60.8)	-35.4 (-43.7 to -25.1)
Motor vehicle road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	69.3 (46.1 to 94.0)	-20.5 (-31.0 to -6.5)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.6 (5.9 to 41.9)	-40.4 (-48.0 to -31.4)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	179.1 (148.8 to 218.2)	32.8 (18.3 to 50.2)
Unintentional injuries	-	-	-	-	0.5 (0.4 to 0.6)	0.7 (0.5 to 0.9)	43.1 (31.7 to 56.3)	-28.6 (-34.5 to -22.1)
Falls	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	34.0 (18.7 to 51.8)	-33.2 (-40.8 to -25.1)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.8 (2.9 to 40.5)	-37.9 (-46.2 to -28.1)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.6 (5.9 to 24.6)	-42.7 (-49.7 to -34.7)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.8 (6.3 to 59.5)	-32.8 (-42.4 to -20.7)
Exposure to mechanical forces	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	32.6 (22.3 to 42.6)	-32.8 (-37.5 to -27.6)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	130.4 (101.0 to 166.7)	10.2 (-4.2 to 27.1)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.6 (71.5 to 123.8)	-2.6 (-14.2 to 9.9)
Other exposure to mechanical forces	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	25.8 (16.5 to 35.5)	-36.2 (-40.5 to -31.6)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	146.6 (134.5 to 159.4)	27.4 (20.5 to 35.3)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	135.2 (113.5 to 160.2)	19.8 (9.6 to 32.1)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	146.8 (114.7 to 182.9)	24.1 (10.7 to 39.2)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	127.9 (105.9 to 156.8)	17.2 (5.7 to 30.7)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.2 (31.3 to 63.3)	-22.8 (-30.4 to -14.8)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.5 (9.6 to 30.7)	-38.5 (-47.6 to -26.6)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.4 (46.5 to 98.8)	-10.2 (-20.9 to 4.1)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.5 (50.4 to 86.6)	-15.5 (-23.8 to -7.2)
Other unintentional injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	129.3 (110.1 to 151.2)	1.5 (-7.1 to 10.7)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	57.4 (38.8 to 80.9)	-25.8 (-34.5 to -15.0)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.5 (25.8 to 61.4)	-35.4 (-42.8 to -27.1)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	60.8 (40.7 to 87.3)	-23.5 (-33.1 to -11.3)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	126.3 (102.6 to 153.5)	6.1 (-4.3 to 18.4)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.3 (47.7 to 99.6)	-21.2 (-31.2 to -7.5)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.1 (6.2 to 47.3)	-40.2 (-48.3 to -28.5)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.1 (-75.6 to -55.1)	-83.5 (-87.8 to -78.3)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.1 (-75.6 to -55.1)	-83.5 (-87.8 to -78.3)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Benin prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	521.4 (378.3 to 689.4)	982.4 (717.6 to 1,299.9)	88.5 (82.6 to 94.3)	88.5 (-12.9 to -7.4)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	206.8 (140.3 to 291.9)	306.2 (210.0 to 439.0)	48.3 (36.0 to 59.9)	48.3 (-40.1 to -27.8)
HIV/AIDS and tuberculosis	-	-	-	-	3.5 (2.3 to 4.6)	14.2 (9.7 to 19.7)	307.0 (233.6 to 412.5)	81.1 (49.8 to 130.6)
Tuberculosis	8.9 (8.3 to 9.6)	17.0 (15.8 to 18.2)	89.2 (78.9 to 99.4)	-13.5 (-18.1 to -9.4)	2.7 (1.8 to 3.6)	5.2 (3.5 to 7.0)	91.7 (77.0 to 106.9)	-12.5 (-18.1 to -6.1)
HIV/AIDS	-	-	-	-	0.8 (0.4 to 1.3)	9.0 (5.9 to 13.4)	1,180.0 (572.0 to 1,939.7)	474.7 (215.1 to 857.3)
HIV/AIDS resulting in mycobacterial infection	0.1 (0.0 to 0.2)	0.7 (0.4 to 1.1)	628.1 (298.7 to 1,167.4)	236.1 (83.0 to 491.1)	0.0 (0.0 to 0.1)	0.3 (0.1 to 0.5)	613.7 (275.1 to 1,321.0)	231.3 (73.2 to 551.4)
HIV/AIDS resulting in other diseases	8.0 (5.1 to 12.9)	80.9 (72.0 to 90.0)	924.5 (520.0 to 1,525.9)	406.4 (202.5 to 698.6)	0.7 (0.4 to 1.2)	8.7 (5.7 to 13.1)	1,120.7 (573.4 to 2,024.8)	489.7 (217.4 to 947.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	25.3 (18.2 to 33.4)	36.8 (26.5 to 50.0)	45.7 (31.7 to 59.7)	-25.3 (-32.6 to -18.3)
Diarrheal diseases	57.5 (50.6 to 65.1)	95.3 (84.4 to 106.6)	64.4 (40.3 to 95.9)	-10.6 (-22.4 to 3.2)	9.2 (6.2 to 12.9)	15.3 (10.2 to 21.4)	65.3 (38.9 to 96.0)	-10.2 (-22.7 to 4.0)
Intestinal infectious diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-3.4 (-30.0 to 31.1)	52.1 (-64.7 to -35.8)
Typhoid fever	1.5 (1.3 to 1.7)	1.5 (1.2 to 1.8)	-3.2 (-28.3 to 27.1)	-52.2 (-64.2 to -37.8)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-1.5 (-30.2 to 36.9)	-50.7 (-64.8 to -32.8)
Paratyphoid fever	0.7 (0.6 to 0.8)	1.0 (0.8 to 1.3)	52.0 (15.1 to 105.4)	-24.5 (-44.5 to 4.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	52.7 (8.8 to 116.9)	23.8 (-47.0 to 7.7)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-62.9 (-83.1 to -39.8)	-81.5 (-91.6 to -60.3)
Lower respiratory infections	4.4 (3.7 to 5.4)	3.9 (3.0 to 5.3)	-11.0 (-41.5 to 25.1)	36.4 (-50.9 to 20.8)	0.5 (0.3 to 0.7)	0.4 (0.2 to 0.6)	-11.5 (-42.6 to 29.7)	-36.7 (-53.4 to -18.6)
Upper respiratory infections	333.3 (310.7 to 355.1)	655.8 (612.0 to 708.1)	95.6 (76.4 to 119.9)	-3.7 (-13.2 to 7.3)	3.9 (2.2 to 6.4)	7.6 (4.3 to 12.9)	96.5 (76.2 to 121.4)	-3.3 (-13.1 to 8.1)
Otitis media	109.5 (98.5 to 119.2)	210.2 (187.0 to 232.1)	91.1 (72.3 to 112.0)	-8.0 (-16.8 to 3.1)	2.3 (1.3 to 3.6)	4.3 (2.6 to 6.8)	91.9 (71.4 to 113.4)	-7.5 (-16.9 to 4.3)
Meningitis	-	-	-	-	8.3 (5.8 to 11.4)	8.3 (5.7 to 11.3)	0.8 (-20.4 to 19.4)	-48.5 (-59.7 to -38.9)
Pneumococcal meningitis	38.9 (23.2 to 61.5)	37.0 (22.9 to 55.0)	-7.2 (-29.2 to 31.3)	-52.0 (-64.7 to -34.4)	3.4 (2.2 to 5.0)	3.4 (2.3 to 4.8)	0.6 (-27.7 to 40.2)	-49.2 (-62.9 to -29.7)
H influenzae type B meningitis	16.1 (6.5 to 31.4)	1.8 (7.1 to 30.7)	-88.8 (-26.9 to 42.2)	-50.9 (-64.6 to -30.4)	1.6 (1.0 to 2.3)	2.0 (1.2 to 3.0)	20.8 (-17.2 to 83.9)	-40.9 (-58.7 to -14.0)
Meningococcal meningitis	17.9 (6.9 to 39.7)	15.4 (5.7 to 36.3)	-13.4 (-33.1 to 7.4)	-56.1 (-65.4 to -44.0)	2.0 (1.3 to 3.0)	1.7 (1.1 to 2.4)	-17.6 (-40.1 to 14.9)	-56.6 (-67.8 to -41.3)
Other meningitis	10.8 (7.0 to 16.9)	10.0 (6.5 to 15.4)	-9.9 (-32.5 to 16.2)	-49.3 (-64.2 to -36.0)	1.3 (0.9 to 1.9)	1.2 (0.8 to 1.8)	-5.5 (-33.5 to 28.6)	-44.0 (-64.2 to -28.5)
Encephalitis	0.0 (0.5 to 2.1)	1.0 (0.9 to 3.9)	100.0 (70.9 to 110.1)	-0.1 (-15.8 to 0.9)	0.1 (0.0 to 0.2)	0.2 (0.2 to 0.3)	96.4 (68.7 to 129.8)	-5.6 (-17.3 to 8.5)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-78.0 (-98.5 to 245.0)	0.0 (0.0 to 0.0)	-	-
Whooping cough	7.9 (6.1 to 10.2)	3.5 (2.7 to 4.5)	-55.6 (-59.3 to -51.5)	-74.9 (-77.0 to -72.7)	0.4 (0.2 to 0.6)	0.2 (0.1 to 0.3)	-55.5 (-61.5 to -48.6)	-74.9 (-78.3 to -71.0)
Tetanus	0.4 (0.2 to 0.8)	0.1 (0.1 to 0.6)	-75.0 (-82.7 to -143.5)	-74.7 (-91.7 to 26.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.0 (-63.9 to 71.2)	-64.1 (-80.8 to -7.3)
Measles	2.6 (1.9 to 3.5)	0.8 (0.6 to 1.0)	-69.2 (-75.7 to -63.4)	-59.9 (-86.7 to -79.9)	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.1)	0.1 (-79.5 to -56.2)	-43.6 (-88.7 to -76.0)
Varicella and herpes zoster	3.1 (2.9 to 3.4)	6.7 (6.0 to 7.3)	111.6 (83.9 to 138.6)	0.5 (-19.3 to 21.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	107.4 (42.3 to 180.0)	-1.6 (-34.3 to 37.4)
Neglected tropical diseases and malaria	-	-	-	-	100.1 (63.4 to 146.3)	113.7 (67.9 to 182.7)	13.0 (7.7 to 34.0)	-52.5 (-62.4 to -41.4)
Malaria	3,081.3 (2,902.8 to 3,281.8)	4,977.6 (4,634.6 to 5,329.6)	60.7 (52.3 to 70.0)	-23.4 (-28.4 to -18.5)	27.7 (18.7 to 39.8)	41.5 (28.2 to 59.4)	50.1 (37.7 to 59.8)	27.4 (-33.9 to -22.2)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	1,483.5 (635.6 to 2,904.3)	1,027.4 (450.9 to 2,019.6)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.8 (32.1 to 192.3)	0.1 (-29.0 to 43.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.8 (32.0 to 192.4)	0.1 (-29.0 to 43.4)
Cutaneous and mucocutaneous leishmaniasis	0.3 (0.2 to 0.5)	5.2 (2.7 to 8.4)	1,528.5 (711.0 to 2,707.9)	1,068.5 (449.2 to 2,863.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	1,492.8 (638.5 to 2,949.6)	1,034.3 (451.9 to 2,033.8)
African trypanosomiasis	0.0 (0.0 to 0.0)	-	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	-	-	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Schistosomiasis	2,341.5 (1,197.7 to 3,627.6)	4,452.6 (2,276.5 to 6,942.3)	88.7 (83.3 to 97.8)	-11.9 (-14.4 to -7.9)	24.3 (9.7 to 51.6)	45.7 (17.8 to 98.1)	88.1 (65.9 to 104.2)	-12.5 (-22.8 to -5.6)
Cysticercosis	5.6 (2.4 to 8.7)	12.4 (6.5 to 19.4)	124.0 (-6.1 to 471.7)	-7.8 (-55.4 to 122.8)	1.5 (0.6 to 2.5)	3.5 (1.7 to 6.0)	141.9 (1.1 to 514.2)	0.1 (-52.5 to 136.1)
Cystic echinococcosis	1.1 (1.0 to 1.3)	1.6 (1.5 to 1.7)	41.9 (20.8 to 61.8)	-13.4 (-27.0 to -5.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	40.6 (7.5 to 85.6)	-13.9 (-31.1 to 6.9)
Lymphatic filariasis	219.6 (178.9 to 260.1)	100.0 (75.7 to 130.7)	-55.1 (-64.9 to -41.1)	-76.3 (-81.7 to -49.6)	5.7 (3.0 to 9.6)	5.6 (2.9 to 9.6)	-0.0 (-31.2 to 30.4)	-53.7 (-68.8 to -36.3)
Onchocerciasis	657.8 (508.5 to 851.2)	83.5 (41.9 to 135.2)	-87.4 (-94.1 to -78.0)	87.4 (-96.2 to -47.7)	62.6 (19.3 to 52.9)	62.6 (2.1 to 12.6)	62.6 (-92.2 to -64.9)	90.5 (-95.1 to -82.2)
Trachoma	5.0 (2.9 to 7.8)	6.7 (3.8 to 10.0)	33.5 (-16.6 to 107.5)	-39.8 (-61.7 to 3.2)	0.3 (0.1 to 0.5)	0.3 (0.2 to 0.6)	23.7 (-20.1 to 91.3)	-43.6 (-62.6 to -6.1)
Dengue	0.7 (0.3 to 1.5)	6.8 (2.8 to 15.0)	905.9 (896.5 to 916.8)	384.3 (379.8 to 389.5)	0.1 (0.0 to 0.3)	1.1 (0.4 to 2.7)	918.6 (698.8 to 1,238.5)	390.0 (292.7 to 510.1)
Yellow fever	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	3.8 (5.8 to 71.0)	0.0 (0.0 to 0.0)	-	-
Intestinal nematode infections	-	-	-	-	1.0 (0.6 to 1.6)	2.1 (1.2 to 3.2)	104.4 (53.8 to 171.9)	-4.0 (-27.4 to 30.0)
Ascariasis	424.2 (303.5 to 601.3)	885.4 (606.8 to 1,309.1)	106.8 (22.8 to 243.9)	-1.7 (-47.0 to 87.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	102.0 (61.6 to 154.8)	-0.2 (-24.1 to 33.0)
Trichuriasis	116.2 (75.0 to 172.8)	242.2 (153.4 to 360.6)	109.2 (11.7 to 272.9)	1.3 (-52.5 to 103.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.2 (22.2 to 219.7)	-0.0 (-46.5 to 67.9)
Hookworm disease	289.4 (197.4 to 422.7)	513.2 (421.6 to 868.7)	77.1 (19.8 to 256.6)	112.2 (-48.0 to 82.6)	0.3 (0.5 to 1.4)	0.9 (1.1 to 2.9)	163.7 (48.8 to 181.0)	4.7 (-29.9 to 34.4)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	85.7 (62.8 to 109.4)	156.4 (145.0 to 170.2)	82.2 (41.0 to 145.3)	-9.7 (-29.4 to 19.6)	5.6 (3.1 to 9.9)	7.5 (4.7 to 11.4)	36.6 (2.0 to 85.6)	-42.7 (-60.5 to -19.3)
Maternal disorders	-	-	-	-	3.1 (2.1 to 4.3)	5.1 (3.4 to 7.2)	62.9 (43.1 to 84.4)	-27.8 (-36.1 to -18.6)
Maternal hemorrhage	1.3 (0.8 to 1.9)	2.1 (1.1 to 3.0)	56.6 (-20.3 to 167.4)	33.7 (-66.1 to 14.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	41.3 (-31.8 to 163.5)	-38.8 (-69.8 to 14.5)
Maternal sepsis and other maternal infections	1.9 (1.2 to 2.8)	1.7 (1.2 to 2.6)	-8.3 (-25.7 to 11.4)	-50.1 (-67.4 to -52.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-57.5 to 66.6)	-11.6 (-78.8 to -32.9)
Maternal hypertensive disorders	1.8 (0.6 to 3.2)	2.6 (0.8 to 4.9)	48.1 (33.7 to 71.0)	-36.4 (-44.2 to -26.9)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	47.8 (19.9 to 81.3)	-36.5 (-48.3 to -22.3)
Obstructed labor	7.5 (6.5 to 8.4)	12.2 (10.9 to 13.6)	62.4 (49.5 to 77.5)	-27.8 (-33.6 to -21.0)	2.4 (1.6 to 3.4)	4.0 (2.7 to 5.6)	63.4 (47.1 to 85.2)	27.2 (-34.3 to -18.2)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	26.0 (67.1 to 24.9)	0.0 (0.0 to 0.0)	-	-
Other maternal disorders	-	-	-	-	0.5 (0.3 to 0.8)	0.9 (0.5 to 1.3)	68.7 (8.4 to 168.3)	-25.0 (-51.8 to 18.6)
Neonatal disorders	-	-	-	-	2.4 (1.4 to 4.1)	15.8 (10.3 to 22.7)	582.3 (304.1 to 959.5)	266.0 (99.1 to 503.1)
Preterm birth complications	13.5 (8.6 to 20.5)	68.8 (49.8 to 93.7)	413.6 (315.5 to 551.8)	146.1 (100.1 to 212.2)	0.7 (0.5 to 1.1)	7.3 (4.8 to 10.2)	888.8 (562.8 to 1,379.9)	410.8 (244.0 to 675.1)
Neonatal encephalopathy due to birth asphyxia and trauma	29.0 (2.6 to 92.3)	41.5 (9.8 to 119.0)	60.3 (-0.6 to 340.0)	-25.8 (-53.9 to 124.8)	1.0 (0.3 to 2.4)	3.9 (2.2 to 6.3)	325.2 (106.5 to 837.7)	121.2 (-5.1 to 540.2)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	120.2 (109.2 to 153.4)	36.1 (29.3 to 56.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	123.5 (100.3 to 162.6)	38.1 (23.8 to 62.2)
Hemolytic disease and other neonatal jaundice	1.1 (0.5 to 2.3)	8.7 (3.7 to 19.0)	707.3 (141.1 to 2,091.2)	363.7 (29.8 to 1,224.2)	0.4 (0.2 to 0.8)	3.3 (1.3 to 7.5)	691.2 (140.3 to 2,128.3)	346.4 (25.8 to 1,197.2)
Other neonatal disorders	-	-	-	-	0.2 (0.1 to 0.4)	1.2 (0.5 to 2.3)	466.1 (147.1 to 1,127.9)	203.5 (25.5 to 585.1)
Nutritional deficiencies	-	-	-	-	68.2 (45.7 to 97.1)	113.4 (77.3 to 160.7)	66.7 (-43.4 to 85.2)	-19.3 (-26.2 to -11.8)
Protein-energy malnutrition	56.8 (29.4 to 98.1)	66.6 (32.1 to 124.1)	14.9 (-53.5 to 190.9)	-32.4 (-70.1 to 51.9)	3.2 (3.1 to 13.2)	3.7 (8.4 to 16.7)	14.4 (55.9 to 195.2)	-47.3 (-70.4 to 55.2)
Iodine deficiency	177.4 (73.6 to 277.5)	197.8 (64.2 to 367.6)	13.2 (-72.8 to 218.1)	-47.9 (-88.6 to 54.4)	3.2 (1.1 to 6.2)	3.5 (1.0 to 7.4)	14.4 (-72.5 to 217.4)	-47.3 (-88.3 to 54.8)
Vitamin A deficiency	9.5 (6.6 to 13.0)	12.7 (8.1 to 17.7)	31.6 (3.4 to 71.5)	-24.2 (-39.9 to 1.3)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.8)	29.8 (0.7 to 67.8)	-24.5 (-40.7 to -12.2)

Appendix Table G.4 - Benin prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	1,422.0 (1,365.9 to 1,465.8)	2,638.9 (2,549.9 to 2,733.5)	84.5 (77.4 to 92.9)	-12.6 (-16.5 to -8.5)	57.6 (39.2 to 82.4)	101.2 (68.1 to 144.9)	75.1 (68.6 to 86.0)	-16.6 (-19.8 to -10.8)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	151.9 (-33.4 to 767.7)	47.3 (-59.0 to 370.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	4.3 (2.8 to 6.2)	7.3 (4.7 to 10.7)	70.4 (55.7 to 99.2)	-20.4 (-27.3 to -11.4)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.9 (0.5 to 1.5)	1.7 (1.0 to 2.9)	94.2 (64.4 to 125.4)	-12.5 (-24.0 to -1.6)
Syphilis	0.5 (0.5 to 0.6)	0.6 (0.5 to 0.7)	15.4 (-1.7 to 39.9)	-44.1 (-51.3 to -34.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	15.5 (-12.4 to 36.0)	43.4 (-55.7 to -27.8)
Chlamydial infection	48.1 (38.1 to 57.5)	107.4 (92.0 to 123.4)	121.3 (80.1 to 176.0)	-0.4 (-17.9 to 22.2)	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.1)	123.4 (65.2 to 199.3)	0.2 (-23.8 to 32.2)
Gonococcal infection	21.6 (15.8 to 27.4)	42.2 (33.6 to 50.8)	92.8 (40.2 to 188.0)	-12.6 (-35.3 to 26.6)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.6)	95.6 (16.7 to 224.9)	-11.4 (-45.3 to 42.8)
Trichomoniasis	52.9 (31.5 to 71.4)	75.5 (44.1 to 132.5)	31.2 (-29.4 to 229.8)	-34.2 (-62.0 to 44.5)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	21.8 (-39.5 to 238.9)	-37.5 (-66.4 to 50.7)
Genital herpes	710.8 (673.3 to 749.1)	1,535.6 (1,447.9 to 1,616.4)	115.2 (99.2 to 131.5)	-2.0 (-8.9 to 5.3)	0.2 (0.1 to 0.5)	0.4 (0.1 to 1.0)	115.9 (97.4 to 136.9)	-1.2 (-9.1 to 7.0)
Other sexually transmitted diseases	1.8 (1.2 to 2.5)	3.1 (2.2 to 4.2)	67.5 (47.7 to 95.1)	-27.4 (-35.6 to -15.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	75.3 (21.5 to 167.3)	-23.0 (-44.9 to 12.8)
Hepatitis	-	-	-	-	0.7 (0.4 to 1.0)	1.0 (0.6 to 1.5)	45.7 (17.7 to 81.1)	-35.3 (-49.0 to -17.1)
Hepatitis A	8.9 (8.4 to 9.4)	17.1 (16.2 to 17.9)	90.2 (89.0 to 91.5)	-2.0 (-2.1 to -1.8)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	109.5 (84.2 to 137.7)	1.9 (-9.1 to 14.7)
Hepatitis B	987.4 (773.7 to 1,173.8)	1,220.2 (1,048.9 to 1,397.8)	26.1 (-4.4 to 50.3)	-42.1 (-54.3 to -27.1)	0.4 (0.3 to 0.7)	0.5 (0.3 to 0.7)	17.1 (15.9 to 67.5)	-46.5 (-61.8 to -22.6)
Hepatitis C	345.2 (307.7 to 388.4)	536.4 (471.4 to 602.8)	54.5 (30.4 to 81.6)	-26.5 (-36.8 to -14.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	51.6 (-1.9 to 95.8)	-24.7 (-41.9 to 0.0)
Hepatitis E	1.9 (1.6 to 2.3)	3.3 (1.7 to 4.5)	77.9 (-14.2 to 150.2)	-16.9 (-60.9 to 11.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	77.7 (-15.9 to 163.9)	-18.2 (-60.8 to 16.7)
Leprosy	2.1 (1.6 to 2.7)	2.6 (2.2 to 3.0)	23.3 (8.0 to 44.8)	-34.8 (-42.2 to -24.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	25.4 (7.3 to 52.8)	-33.7 (-42.5 to -20.9)
Other infectious diseases	62.2 (46.8 to 78.6)	113.3 (102.5 to 125.0)	81.0 (62.7 to 123.9)	-11.5 (-21.3 to 8.1)	2.6 (1.6 to 3.7)	4.4 (2.9 to 6.4)	70.8 (50.7 to 136.5)	-16.1 (-27.0 to 16.4)
Non-communicable diseases	-	-	-	-	298.3 (220.3 to 388.1)	649.6 (477.2 to 844.2)	117.6 (111.6 to 125.0)	1.9 (-1.1 to 5.4)
Neoplasms	-	-	-	-	1.1 (0.8 to 1.4)	2.8 (1.9 to 3.8)	150.9 (101.0 to 211.8)	28.9 (3.6 to 60.5)
Esophageal cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	128.9 (50.2 to 233.0)	15.4 (-22.4 to 64.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	129.0 (58.7 to 225.3)	15.5 (-19.9 to 63.7)
Stomach cancer	0.5 (0.4 to 0.6)	0.8 (0.6 to 1.1)	72.3 (30.0 to 131.7)	-12.3 (-33.8 to 17.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	76.0 (31.1 to 138.0)	-10.0 (-32.4 to 21.9)
Liver cancer	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	98.2 (13.9 to 147.4)	-11.1 (-35.0 to 23.1)
Liver cancer due to hepatitis B	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.1)	100.8 (4.3 to 316.8)	-6.5 (-52.9 to 101.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	98.3 (13.3 to 293.2)	-7.8 (-48.9 to 92.2)
Liver cancer due to hepatitis C	0.1 (0.0 to 0.2)	0.4 (0.2 to 0.7)	499.3 (91.8 to 2,538.0)	205.6 (6.7 to 1,146.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	464.1 (79.8 to 2,313.6)	179.5 (-0.5 to 1,054.3)
Liver cancer due to alcohol use	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-27.3 (-67.6 to 56.5)	-62.1 (-83.3 to -22.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-24.3 (-65.8 to 49.1)	-59.7 (-82.2 to -23.3)
Liver cancer due to other causes	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	114.6 (-45.8 to 114.5)	-65.5 (-74.1 to 5.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	91.1 (-38.4 to 86.2)	-47.2 (-71.0 to -5.1)
Larynx cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.3)	36.8 (-11.4 to 239.6)	-30.4 (-54.7 to 63.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.7 (-9.1 to 238.2)	-29.0 (-53.6 to 66.6)
Tracheal, bronchus and lung cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	84.9 (43.1 to 143.6)	-3.8 (-25.1 to 27.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	88.0 (40.0 to 153.4)	-1.5 (-27.0 to 33.1)
Breast cancer	1.6 (1.1 to 1.9)	5.1 (3.7 to 6.9)	229.4 (128.0 to 371.4)	50.1 (4.2 to 120.7)	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.6)	197.1 (103.9 to 334.8)	38.0 (-5.0 to 102.6)
Cervical cancer	2.4 (1.7 to 3.2)	4.5 (3.0 to 6.5)	83.7 (21.4 to 189.2)	9.7 (-40.4 to 40.9)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	46.4 (22.2 to 191.7)	-6.1 (-39.4 to 44.7)
Uterine cancer	0.5 (0.3 to 0.7)	1.2 (0.7 to 2.0)	151.7 (39.1 to 337.1)	22.5 (-27.9 to 108.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	150.9 (39.1 to 339.3)	22.4 (-29.4 to 111.0)
Prostate cancer	0.8 (0.5 to 1.4)	4.9 (2.9 to 8.4)	506.8 (251.4 to 1,029.3)	215.7 (82.9 to 470.3)	0.1 (0.0 to 0.1)	0.5 (0.3 to 0.8)	429.4 (215.6 to 848.9)	184.5 (69.0 to 403.7)
Colon and rectum cancer	0.5 (0.5 to 0.6)	1.5 (1.3 to 1.9)	191.3 (132.9 to 267.0)	39.1 (12.3 to 74.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	176.6 (119.2 to 255.7)	34.8 (6.5 to 73.7)
Lip and oral cavity cancer	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.6)	127.6 (61.3 to 223.1)	12.5 (-21.6 to 59.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	127.4 (61.0 to 218.2)	14.8 (-22.4 to 61.8)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	100.1 (29.6 to 216.7)	-7.0 (-38.8 to 43.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.6 (31.1 to 193.1)	-9.3 (-38.4 to 34.1)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	87.3 (10.0 to 238.3)	-7.7 (-45.4 to 67.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.9 (16.6 to 216.6)	-5.7 (-41.7 to 60.4)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	81.7 (13.8 to 192.2)	-12.3 (-46.9 to 41.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.7 (13.9 to 172.2)	-13.1 (-46.2 to 33.4)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	183.7 (106.6 to 295.5)	41.3 (-41.4 to 98.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	183.8 (120.9 to 270.4)	41.9 (6.4 to 89.2)
Malignant skin melanoma	0.2 (0.2 to 0.3)	0.4 (0.4 to 0.7)	146.0 (75.8 to 261.7)	13.4 (-19.3 to 67.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	188.1 (67.2 to 258.0)	12.1 (-21.6 to 69.2)
Non-melanoma skin cancer	0.3 (0.2 to 0.4)	0.7 (0.5 to 1.0)	153.3 (55.6 to 397.9)	24.6 (-19.7 to 155.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	226.9 (121.0 to 380.7)	62.0 (1.9 to 150.3)
Ovarian cancer	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.6)	135.3 (48.7 to 251.0)	12.8 (-29.4 to 67.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	138.2 (44.3 to 282.5)	15.0 (-30.8 to 89.4)
Testicular cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	221.3 (73.4 to 458.4)	41.9 (-23.3 to 145.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	215.2 (50.0 to 472.1)	40.0 (-27.2 to 144.8)
Kidney cancer	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	71.7 (2.6 to 198.0)	16.6 (-25.7 to 54.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.0 (8.4 to 207.9)	7.6 (-23.4 to 55.8)
Bladder cancer	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	90.4 (36.2 to 185.2)	-6.2 (-33.0 to 42.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	91.4 (34.7 to 188.1)	-3.9 (-32.0 to 49.4)
Brain and nervous system cancer	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	218.6 (95.0 to 398.7)	55.9 (13.7 to 113.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	227.4 (115.2 to 373.5)	51.6 (13.7 to 103.2)
Thyroid cancer	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	110.0 (24.5 to 266.4)	-2.7 (-45.4 to 70.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.8 (19.3 to 266.7)	-3.9 (-45.5 to 73.5)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.4 (43.9 to 189.1)	11.1 (-30.7 to 49.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	189.9 (42.4 to 191.7)	1.2 (-30.9 to 50.2)
Hodgkin lymphoma	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	166.5 (62.7 to 356.2)	55.1 (4.1 to 137.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	172.2 (70.3 to 341.8)	53.5 (0.9 to 131.7)
Non-Hodgkin lymphoma	0.5 (0.4 to 0.8)	1.3 (0.9 to 1.8)	138.9 (53.8 to 258.9)	31.1 (-3.8 to 89.9)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	146.4 (67.2 to 254.2)	29.6 (-4.2 to 89.3)
Multiple myeloma	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	163.5 (66.6 to 314.4)	29.4 (-22.3 to 109.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	151.6 (49.7 to 290.2)	23.2 (-29.4 to 102.0)
Leukemia	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	151.4 (38.7 to 344.8)	17.0 (-22.1 to 73.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	165.2 (63.1 to 259.2)	8.8 (-24.3 to 58.3)
Other neoplasms	1.7 (1.0 to 3.1)	4.2 (2.5 to 5.8)	173.6 (9.3 to 347.6)	32.5 (-21.1 to 105.3)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	168.5 (20.9 to 317.0)	26.8 (-20.5 to 93.0)
Cardiovascular diseases	-	-	-	-	8.6 (6.0 to 11.8)	17.3 (11.4 to 24.7)	101.1 (59.8 to 150.4)	-0.8 (-20.1 to 22.3)
Rheumatic heart disease	55.6 (42.9 to 68.2)	106.5 (83.2 to 134.5)	92.1 (37.4 to 154.9)	-11.5 (-34.7 to 15.8)	2.7 (1.7 to 4.1)	5.3 (3.2 to 8.0)	95.9 (41.5 to 161.5)	-5.4 (-30.2 to 23.2)
Ischemic heart disease	37.2 (31.0 to 45.4)	51.7 (43.0 to 64.6)	37.9 (3.9 to 85.5)	-25.5 (-42.4 to -2.1)	1.8 (1.1 to 2.6)	2.1 (1.3 to 3.2)	17.1 (-25.4 to 79.2)	-96.1 (-57.8 to -5.3)
Cerebrovascular disease	-	-	-	-	0.5 (0.3 to 0.5)	0.8 (0.5 to 1.1)	111.4 (62.2 to 166.9)	3.1 (-2.0 to 33.0)
Ischemic stroke	2.0 (1.7 to 2.3)	4.1 (3.5 to 4.9)	109.1 (62.8 to 161.7)	2.3 (-19.8 to 31.5)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	112.8 (60.4 to 169.5)	4.3 (-20.9 to 34.4)
Hemorrhagic stroke	0.6 (0.4 to 0.7)	1.2 (0.9 to 1.4)	103.2 (58.0 to 170.0)	-3.3 (-25.3 to 27.2)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	104.7 (59.8 to 177.5)	-2.6 (-26.4 to 33.5)
Hypertensive heart disease	7.6 (5.8 to 10.1)	14.3 (9.5 to 19.3)	88.2 (19.2 to 172.1)	0.2 (-37.4 to 45.9)	0.8 (0.5 to 1.2)	1.6 (0.9 to 2.4)	91.7 (19.4 to 179.9)	2.1 (-37.1 to 48.5)
Cardiomyopathy and myocarditis	5.0 (3.7 to 6.4)	9.7 (7.0 to 13.5)	92.0 (23.0 to 207.9)	-1.9 (-40.6 to 66.4)	0.5 (0.3 to 0.8)	1.1 (0.6 to 1.6)	95.4 (24.3 to 209.1)	0.4 (-40.2 to 67.0)
Atrial fibrillation and flutter	0.7 (0.4 to 0.9)	3.3 (2.3 to 4.3)	402.0 (193.5 to 786.3)	0.3 (-43.0 to 399.7)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.4)	398.0 (186.7 to 803.5)	175.5 (45.0 to 409.9)
Peripheral vascular disease	71.6 (52.1 to 92.6)	130.5 (95.8 to 178.5)	80.5 (24.8 to 165.5)	-6.9 (-31.5 to 29.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	54.9 (-18.1 to 212.6)	-10.5 (-54.9 to 71.7)
Endocarditis	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.9)	27.4 (-22.0 to 113.6)	-34.0 (-66.6 to 36.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	37.1 (-23.5 to 153.1)	-31.7 (-68.1 to 51.5)
Other cardiovascular and circulatory diseases	21.7 (21.6 to 45.0)	87.0 (43.1 to 133.6)	173.1 (28.9 to 384.8)	28.4 (-41.3 to 131.3)	2.2 (1.3 to 3.4)	6.1 (2.6 to 10.4)	175.8 (97.7 to 390.4)	30.2 (-4.7 to 136.8)
Chronic respiratory diseases	-	-	-	-	18.4 (12.4 to 25.6)	42.8 (29.1 to 59.4)	133.5 (82.0 to	

Appendix Table G.4 - Benin prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.1 (99.6 to 113.7)	-0.8 (-4.1 to 2.1)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.1 (87.9 to 108.1)	-4.3 (-9.2 to 0.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.8 (87.3 to 108.1)	-4.3 (-9.5 to 0.5)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	14.7 (106.2 to 122.9)	2.3 (-1.4 to 5.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.3 (106.0 to 124.8)	2.7 (-1.1 to 6.8)
Asthma	70.2 (51.7 to 105.9)	267.6 (197.5 to 323.1)	292.3 (122.6 to 461.4)	47.9 (-1.7 to 104.4)	3.0 (1.8 to 5.2)	11.6 (7.1 to 16.9)	298.9 (124.1 to 475.5)	50.9 (12.1 to 108.8)
Interstitial lung disease and pulmonary sarcoidosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	130.7 (46.7 to 242.2)	6.8 (-27.5 to 51.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	130.0 (47.6 to 238.3)	6.6 (-26.7 to 49.9)
Other chronic respiratory diseases	-	-	-	-	2.8 (1.6 to 4.4)	4.1 (2.5 to 6.4)	45.6 (-0.1 to 106.8)	-30.6 (-54.4 to -1.5)
Cirrhosis	-	-	-	-	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.0)	72.9 (51.2 to 95.7)	14.8 (-23.8 to -4.4)
Cirrhosis due to hepatitis B	1.0 (0.8 to 1.1)	1.2 (0.7 to 1.7)	20.8 (-30.7 to 91.9)	-36.8 (-45.1 to -8.8)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	21.0 (-33.8 to 105.9)	-36.8 (-65.6 to -2.5)
Cirrhosis due to hepatitis C	0.5 (0.3 to 0.6)	1.0 (0.6 to 1.6)	121.3 (16.8 to 288.9)	19.7 (-47.8 to 103.1)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	118.6 (17.1 to 295.5)	18.8 (-45.3 to 107.4)
Cirrhosis due to alcohol use	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.3)	59.0 (3.1 to 215.6)	-26.3 (-49.5 to 45.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	63.1 (-1.0 to 230.9)	-24.8 (-51.9 to 49.0)
Cirrhosis due to other causes	0.5 (0.5 to 0.7)	1.2 (0.9 to 1.5)	119.9 (59.3 to 187.1)	15.3 (-22.2 to 57.9)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	119.9 (36.5 to 235.4)	16.3 (-29.5 to 73.5)
Digestive diseases	-	-	-	-	6.1 (4.2 to 8.5)	12.2 (8.5 to 16.5)	98.7 (74.9 to 125.3)	-4.7 (-14.3 to 6.0)
Peptic ulcer disease	25.9 (22.1 to 29.1)	39.4 (29.9 to 46.8)	51.0 (17.7 to 82.8)	-21.5 (-36.3 to -7.9)	1.0 (0.7 to 1.4)	1.6 (1.1 to 2.2)	56.5 (24.4 to 109.6)	-20.1 (-33.4 to 0.2)
Gastritis and duodenitis	57.3 (49.1 to 63.8)	117.2 (100.4 to 130.8)	103.0 (71.9 to 149.6)	2.5 (-11.5 to 24.6)	2.5 (1.7 to 3.7)	4.9 (3.3 to 6.9)	92.8 (58.5 to 132.3)	-3.1 (-18.5 to 15.7)
Appendicitis	0.6 (0.4 to 0.7)	1.4 (1.1 to 1.8)	123.8 (62.8 to 274.7)	0.3 (-24.0 to 54.1)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	125.9 (49.5 to 308.0)	2.3 (-27.6 to 63.6)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	90.1 (45.4 to 221.3)	1.4 (-9.7 to 19.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	90.0 (34.3 to 237.3)	2.7 (-19.7 to 33.5)
Inguinal, femoral, and abdominal hernia	16.9 (13.5 to 22.6)	28.2 (23.9 to 33.1)	69.5 (15.9 to 129.6)	-8.9 (-29.5 to 15.1)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.5)	70.7 (14.9 to 131.8)	-7.8 (-28.7 to 17.2)
Inflammatory bowel disease	4.5 (4.3 to 4.7)	12.4 (11.8 to 12.9)	174.4 (158.0 to 193.3)	26.8 (19.6 to 34.4)	0.9 (0.6 to 1.3)	2.6 (1.8 to 3.6)	177.7 (153.2 to 207.0)	28.1 (18.4 to 39.5)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	175.0 (98.4 to 299.2)	10.4 (-27.7 to 95.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	178.9 (97.1 to 324.6)	14.0 (-33.5 to 113.2)
Gallbladder and biliary diseases	1.5 (1.3 to 1.6)	3.4 (3.1 to 3.8)	135.0 (97.7 to 174.2)	9.2 (-9.0 to 29.3)	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.5)	188.9 (95.2 to 191.1)	11.6 (-7.8 to 34.7)
Pancreatitis	0.8 (0.7 to 0.8)	1.9 (1.7 to 1.9)	139.8 (120.4 to 164.0)	10.6 (1.6 to 20.9)	0.2 (0.1 to 0.3)	0.5 (0.4 to 0.7)	141.5 (103.5 to 189.9)	12.1 (-4.6 to 31.2)
Other digestive diseases	-	-	-	-	0.9 (0.5 to 1.4)	1.4 (0.9 to 2.2)	61.7 (15.0 to 139.5)	-22.6 (-45.1 to 14.8)
Neurological disorders	-	-	-	-	20.5 (13.7 to 28.5)	46.6 (30.8 to 64.8)	127.3 (97.2 to 158.7)	5.5 (-8.2 to 18.5)
Alzheimer disease and other dementias	7.5 (6.5 to 8.4)	12.9 (11.6 to 14.3)	71.4 (47.4 to 104.7)	-3.7 (-18.4 to 18.1)	1.0 (0.7 to 1.3)	1.8 (1.3 to 2.4)	78.9 (49.4 to 106.0)	-1.8 (-17.4 to 20.1)
Parkinson disease	0.3 (0.3 to 0.4)	0.6 (0.5 to 0.7)	87.8 (76.1 to 100.0)	-0.6 (-5.7 to 5.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	92.4 (56.5 to 137.6)	1.5 (-15.8 to 23.9)
Epilepsy	8.5 (5.0 to 13.1)	17.0 (9.6 to 26.7)	100.9 (-2.5 to 314.1)	-5.2 (-53.2 to 95.4)	2.5 (1.2 to 4.2)	5.3 (2.7 to 8.5)	115.5 (6.6 to 351.2)	2.1 (-49.2 to 113.0)
Multiple sclerosis	0.3 (0.2 to 0.3)	0.7 (0.6 to 0.8)	148.8 (111.7 to 194.6)	11.2 (-4.3 to 29.2)	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	148.6 (98.7 to 205.4)	11.0 (-11.9 to 37.0)
Migraine	342.8 (315.6 to 372.0)	726.8 (663.6 to 790.7)	110.2 (86.5 to 139.7)	11.6 (-14.1 to 9.8)	9.1 (7.0 to 17.1)	24.7 (14.6 to 36.2)	111.8 (87.5 to 143.7)	-2.2 (-13.2 to 11.2)
Tension-type headache	589.6 (535.4 to 644.1)	1,334.8 (1,220.0 to 1,446.3)	125.3 (101.0 to 156.5)	0.9 (-7.2 to 14.1)	2.5 (0.4 to 1.5)	3.0 (1.0 to 3.5)	126.2 (100.8 to 160.3)	3.1 (-1.7 to 15.5)
Medication overuse headache	21.9 (14.2 to 29.9)	69.4 (44.3 to 98.5)	215.8 (121.5 to 328.9)	43.6 (2.6 to 92.3)	3.4 (2.0 to 5.3)	10.8 (5.9 to 17.4)	218.9 (120.3 to 337.0)	44.9 (3.5 to 97.4)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	100.4 (50.7 to 164.1)	-4.8 (-28.0 to 27.2)	1.0 (0.6 to 1.9)	1.7 (1.1 to 2.5)	69.5 (-5.9 to 157.3)	-7.5 (-49.2 to 38.3)
Mental and substance use disorders	-	-	-	-	98.2 (68.1 to 134.0)	218.7 (151.5 to 304.1)	122.6 (114.0 to 132.3)	2.6 (-1.0 to 6.9)
Schizophrenia	9.8 (8.9 to 10.6)	22.0 (20.0 to 23.9)	123.8 (113.4 to 136.6)	0.3 (-4.0 to 5.5)	6.2 (4.5 to 7.5)	14.0 (10.2 to 17.1)	127.1 (111.1 to 143.2)	1.9 (-4.5 to 8.7)
Alcohol use disorders	24.4 (22.9 to 26.2)	63.7 (59.7 to 67.9)	159.1 (147.7 to 172.9)	2.3 (14.3 to 25.1)	2.3 (1.6 to 3.3)	6.2 (4.1 to 8.6)	163.4 (145.9 to 184.3)	21.0 (13.2 to 29.4)
Drug use disorders	-	-	-	-	5.7 (3.8 to 8.0)	13.1 (8.6 to 18.5)	128.7 (104.8 to 155.0)	2.5 (-7.2 to 13.6)
Opioid use disorders	7.5 (4.9 to 11.0)	17.5 (11.7 to 25.1)	134.2 (115.3 to 159.1)	3.1 (-4.6 to 13.5)	3.0 (1.8 to 4.7)	7.2 (4.3 to 11.2)	136.8 (115.5 to 169.0)	4.4 (-5.9 to 17.7)
Cocaine use disorders	2.3 (1.9 to 2.7)	5.4 (4.7 to 6.3)	131.5 (86.4 to 200.3)	5.3 (-15.7 to 27.8)	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.1)	138.2 (75.9 to 220.2)	5.0 (-19.5 to 37.6)
Amphetamine use disorders	7.6 (7.0 to 8.2)	16.1 (14.9 to 17.2)	112.3 (92.3 to 133.2)	-2.9 (-11.6 to 6.2)	1.0 (0.6 to 1.4)	2.1 (1.3 to 3.1)	113.2 (82.0 to 154.4)	-2.2 (-16.0 to 15.3)
Cannabis use disorders	3.4 (2.6 to 4.1)	7.5 (5.9 to 9.1)	120.7 (119.3 to 122.1)	0.7 (0.5 to 0.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	121.5 (74.2 to 179.3)	1.0 (-18.7 to 25.2)
Other drug use disorders	-	-	-	-	1.3 (0.8 to 2.0)	2.9 (1.8 to 4.3)	118.8 (60.7 to 195.4)	-0.8 (-25.2 to 33.8)
Depressive disorders	-	-	-	-	43.2 (25.6 to 66.9)	97.6 (57.9 to 150.1)	125.9 (108.8 to 149.3)	2.7 (-4.5 to 11.9)
Major depressive disorder	190.3 (119.4 to 257.3)	429.5 (274.6 to 581.4)	124.6 (106.7 to 150.8)	1.9 (-5.7 to 12.8)	38.7 (22.1 to 61.0)	87.8 (49.9 to 138.3)	126.7 (107.7 to 153.8)	3.1 (-4.8 to 13.9)
Dysthymia	47.1 (38.2 to 56.7)	102.4 (82.6 to 123.7)	116.3 (113.7 to 118.3)	-1.2 (-1.6 to -0.9)	4.5 (2.9 to 6.5)	9.8 (6.3 to 14.4)	118.3 (111.7 to 124.9)	-0.3 (-2.9 to 2.3)
Bipolar disorder	26.5 (22.8 to 30.1)	58.7 (49.9 to 66.6)	120.0 (107.5 to 133.9)	-0.8 (-5.7 to 3.9)	5.3 (3.3 to 7.9)	11.9 (7.2 to 18.0)	122.8 (105.8 to 141.8)	0.3 (-6.4 to 7.5)
Anxiety disorders	113.8 (94.7 to 135.5)	243.7 (201.7 to 289.6)	113.2 (110.6 to 115.5)	-4.8 (-1.1 to -0.6)	10.4 (6.9 to 14.8)	22.4 (14.7 to 31.9)	114.6 (74.5 to 195.7)	-0.0 (-3.1 to 3.3)
Eating disorders	-	-	-	-	1.2 (0.7 to 1.9)	2.6 (1.6 to 4.2)	118.5 (99.5 to 138.9)	-0.1 (-8.7 to 8.6)
Anorexia nervosa	0.8 (0.6 to 1.1)	1.9 (1.5 to 2.5)	126.3 (105.5 to 150.0)	4.2 (-5.5 to 15.4)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	126.0 (75.1 to 187.5)	4.3 (-19.1 to 30.8)
Bulimia nervosa	4.9 (3.3 to 7.1)	10.6 (7.3 to 15.5)	116.8 (114.7 to 118.9)	-1.4 (-1.6 to -1.2)	1.0 (0.6 to 1.6)	2.2 (1.3 to 3.6)	117.6 (96.0 to 139.1)	-1.0 (-10.2 to 9.1)
Autistic spectrum disorders	-	-	-	-	5.8 (4.0 to 7.9)	12.4 (8.6 to 16.8)	112.9 (104.6 to 120.8)	2.9 (-0.6 to 6.3)
Autism	15.1 (14.3 to 15.8)	32.0 (30.3 to 33.6)	111.2 (110.8 to 111.6)	1.7 (1.7 to 1.8)	3.7 (2.5 to 5.1)	7.9 (5.3 to 10.8)	112.9 (101.2 to 124.5)	2.3 (-2.2 to 7.4)
Asperger syndrome	21.6 (20.3 to 22.9)	45.9 (43.0 to 48.6)	111.3 (110.8 to 112.0)	2.3 (2.2 to 2.4)	2.2 (1.5 to 3.0)	4.6 (3.2 to 6.4)	112.3 (103.0 to 122.9)	2.9 (-0.9 to 7.4)
Attention-deficit/hyperactivity disorder	36.3 (33.6 to 39.3)	76.0 (70.1 to 82.1)	108.2 (107.9 to 108.3)	0.9 (0.8 to 0.9)	0.9 (0.3 to 0.7)	0.9 (0.5 to 1.4)	108.3 (92.3 to 124.9)	1.0 (-6.6 to 9.0)
Conduct disorder	53.1 (50.0 to 56.2)	111.6 (105.3 to 118.3)	109.4 (109.0 to 109.8)	0.8 (0.8 to 0.9)	6.3 (4.0 to 9.2)	13.3 (8.4 to 19.3)	115.5 (103.3 to 120.4)	1.4 (-2.9 to 6.2)
Idiopathic intellectual disability	141.1 (83.9 to 190.1)	298.0 (218.4 to 374.5)	108.2 (75.2 to 191.9)	2.2 (-14.9 to 51.8)	6.9 (3.7 to 10.4)	14.5 (10.4 to 20.9)	108.8 (74.5 to 195.7)	2.9 (-14.8 to 51.1)
Other mental and substance use disorders	58.6 (54.6 to 62.2)	131.5 (122.6 to 139.9)	123.5 (122.6 to 124.4)	1.4 (1.1 to 1.8)	4.3 (2.9 to 5.8)	9.8 (6.6 to 13.2)	126.0 (116.4 to 135.7)	6.6 (-1.1 to 6.4)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	30.4 (21.4 to 41.0)	66.2 (46.3 to 89.3)	118.1 (105.6 to 130.0)	7.2 (1.4 to 13.4)
Diabetes mellitus	27.2 (20.5 to 33.0)	129.5 (107.4 to 148.7)	375.4 (267.6 to 516.3)	122.8 (70.4 to 192.3)	1.9 (1.2 to 2.8)	9.0 (5.9 to 12.7)	364.2 (257.7 to 494.6)	120.9 (66.5 to 188.9)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	27.8 (16.4 to 38.6)	-33.5 (-38.1 to -29.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.8 (16.4 to 38.6)	33.5 (-38.1 to -29.3)
Chronic kidney disease	-	-	-	-	8.2 (5.8 to 10.9)	16.6 (11.6 to 22.5)	103.8 (83.2 to 125.7)	-2.0 (-11.8 to 8.9)
Chronic kidney disease due to diabetes mellitus	43.5 (27.7 to 71.6)	94.6 (60.1 to 154.3)	113.5 (56.1 to 207.3)	5.8 (-25.8 to 55.1)	0.7 (0.5 to 1.0)	1.6 (1.0 to 2.3)	116.7 (59.5 to 186.3)	4.6 (-22.9 to 40.7)
Chronic kidney disease due to hypertension	224.6 (138.4 to 363.1)	458.9 (288.6 to 781.8)	100.3 (72.6 to 152.5)	2.2 (-16.7 to 24.0)	2.7 (1.8 to 3.7)	5.5 (3.7 to 7.8)	106.6 (68.8 to 146.5)	-3.0 (-19.1 to 17.2)
Chronic kidney disease due to glomerulonephritis	184.8 (128.8 to 291.8)	399.9 (266.6 to 567.4)	112.4 (80.6 to 153.2)	-4.9 (-17.4 to 20.2)	2.9 (2.0 to 3.9)	6.0 (4.1 to 8.5)	106.6 (69.0 to 151.9)	2.1 (-17.5 to 24.0)
Chronic kidney disease due to other causes	147.5 (90.1 to 242.4)	284.4 (178.9 to 488.4)	92.1 (49.5 to 142.3)	-7.1 (-29.4 to 20.4)	1.8 (1.3 to 2.5)	3.1 (2.4 to 4.9)	91.8 (49.1 to 149.5)	-9.3 (-31.9 to 19.9)
Urinary diseases and male infertility	-	-	-	-	1.4 (0.9 to 2.0)	2.9 (1.9 to 4.1)	104.5 (81.6 to 131.3)	5.3 (-5.4 to 17.5)

Appendix Table G.4 - Benin prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.0 (0.9 to 1.0)	2.2 (2.0 to 2.3)	123.8 (104.0 to 149.0)	0.0 (-3.1 to 14.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	125.0 (78.9 to 188.5)	12.5 (-11.8 to 28.4)
Urolithiasis	10.2 (7.7 to 13.6)	17.4 (13.7 to 23.0)	70.3 (46.4 to 89.8)	-12.3 (-23.3 to -2.9)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	124.3 (97.1 to 156.6)	8.1 (-2.1 to 19.9)
Benign prostatic hyperplasia	28.3 (26.0 to 30.9)	56.5 (51.6 to 61.1)	98.3 (74.7 to 124.0)	5.0 (-6.5 to 17.2)	1.0 (0.7 to 1.4)	2.0 (1.3 to 2.9)	101.7 (77.9 to 127.9)	6.8 (-5.2 to 19.4)
Male infertility due to other causes	40.2 (29.1 to 52.9)	82.9 (63.6 to 107.1)	103.8 (41.0 to 215.9)	-11.5 (-39.1 to 40.1)	0.2 (0.1 to 0.5)	0.5 (0.2 to 1.1)	107.4 (38.9 to 221.6)	-9.6 (-39.4 to 42.1)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.2 (16.1 to 238.8)	-4.0 (-44.3 to 61.8)
Gynecological diseases	-	-	-	-	5.7 (3.8 to 8.5)	12.9 (8.4 to 19.1)	124.4 (96.3 to 157.6)	-2.4 (-14.2 to 10.9)
Uterine fibroids	76.6 (69.4 to 83.2)	163.3 (147.6 to 177.8)	112.3 (111.4 to 113.2)	-7.2 (-7.4 to -7.0)	1.7 (1.1 to 2.6)	3.4 (2.1 to 5.2)	97.0 (81.0 to 155.2)	-14.4 (-21.3 to 11.2)
Polycystic ovarian syndrome	69.5 (62.3 to 76.6)	158.5 (138.5 to 177.7)	127.0 (92.1 to 165.3)	-1.7 (-15.4 to 13.4)	0.7 (0.3 to 1.2)	1.5 (0.7 to 2.8)	127.3 (92.9 to 163.8)	-1.2 (-15.0 to 12.8)
Female infertility due to other causes	38.2 (26.0 to 48.7)	70.4 (48.6 to 101.6)	81.6 (18.8 to 179.6)	-22.5 (-48.9 to 19.9)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.8)	80.7 (19.3 to 178.8)	-22.7 (-49.1 to 20.8)
Endometriosis	7.0 (6.0 to 8.0)	14.6 (12.4 to 16.7)	108.8 (70.6 to 152.6)	-9.6 (-26.3 to 9.6)	0.6 (0.4 to 0.9)	1.3 (0.8 to 1.9)	109.9 (65.8 to 159.4)	-8.7 (-27.8 to 12.5)
Genital prolapse	169.8 (147.9 to 191.7)	356.2 (311.4 to 405.3)	108.3 (75.4 to 155.8)	-5.1 (-18.4 to 13.5)	0.5 (0.3 to 1.0)	1.1 (0.5 to 2.1)	109.7 (75.8 to 157.5)	-4.4 (-18.4 to 14.4)
Premenstrual syndrome	149.5 (97.9 to 208.3)	442.3 (324.3 to 585.2)	197.8 (82.3 to 369.5)	33.0 (-22.7 to 102.1)	1.2 (0.6 to 2.1)	3.7 (2.1 to 6.1)	199.5 (80.3 to 373.9)	33.8 (-23.3 to 104.3)
Other gynecological diseases	19.6 (9.4 to 30.4)	40.2 (22.9 to 56.8)	103.8 (17.7 to 327.4)	-10.0 (-47.7 to 84.6)	0.8 (0.3 to 1.1)	1.5 (0.7 to 2.2)	96.3 (-12.6 to 124.0)	-13.5 (-60.5 to 127.6)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	10.3 (7.1 to 14.2)	19.9 (13.6 to 27.6)	93.0 (76.5 to 110.3)	-7.1 (-14.4 to 1.6)
Thalassemias	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	71.3 (19.9 to 133.9)	-16.0 (-41.9 to 15.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.8 (22.7 to 112.9)	-16.8 (-40.3 to 2.6)
Thalassemia trait	33.9 (19.1 to 48.6)	71.6 (41.7 to 101.2)	107.0 (91.8 to 165.2)	-0.0 (-7.3 to 27.4)	0.6 (0.4 to 0.9)	1.1 (0.7 to 1.7)	103.2 (60.2 to 144.8)	-0.9 (-21.8 to 20.1)
Sickle cell disorders	31.9 (29.7 to 33.9)	67.1 (61.7 to 71.5)	109.8 (92.4 to 127.3)	3.1 (-6.4 to 12.3)	3.2 (2.3 to 4.2)	6.8 (4.8 to 9.0)	112.4 (91.1 to 141.5)	4.2 (-6.8 to 18.2)
Sickle cell trait	912.8 (859.8 to 963.3)	1,917.1 (1,805.1 to 1,998.0)	108.2 (101.0 to 115.7)	0.6 (-2.8 to 4.4)	4.3 (2.9 to 6.2)	8.2 (5.3 to 11.9)	89.9 (54.1 to 122.7)	-7.2 (-23.5 to 9.5)
G6PD deficiency	628.9 (466.8 to 798.6)	1,295.5 (1,009.1 to 1,616.1)	106.0 (45.1 to 192.6)	-0.5 (-29.7 to 40.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	97.7 (40.2 to 186.1)	-2.9 (-26.8 to 28.0)
G6PD trait	1,201.9 (1,110.1 to 1,259.7)	2,449.3 (2,250.1 to 2,568.6)	102.9 (84.1 to 122.5)	-2.9 (-11.9 to 6.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	88.8 (-44.2 to 218.7)	-17.7 (-75.1 to 56.3)
Other hemoglobinopathies and hemolytic anemias	61.9 (51.8 to 73.8)	108.6 (96.2 to 121.6)	74.8 (45.5 to 116.8)	-17.0 (-31.2 to 1.7)	2.1 (1.4 to 3.1)	3.5 (2.3 to 5.2)	64.4 (35.9 to 121.6)	-22.0 (-35.4 to 9.2)
Endocrine, metabolic, blood, and immune disorders	73.1 (62.1 to 84.1)	132.6 (102.6 to 153.7)	81.6 (32.9 to 126.8)	-12.2 (-31.4 to 4.2)	2.8 (1.8 to 4.2)	5.0 (2.9 to 7.3)	76.4 (18.1 to 134.1)	-4.2 (-38.3 to 6.6)
Musculoskeletal disorders	-	-	-	-	56.4 (39.8 to 75.3)	119.5 (83.4 to 159.5)	111.1 (87.8 to 144.6)	-1.8 (-11.8 to 14.8)
Rheumatoid arthritis	6.5 (6.2 to 6.8)	9.5 (9.1 to 9.9)	44.9 (35.1 to 55.5)	-35.1 (-39.2 to -30.4)	1.5 (1.1 to 2.0)	2.2 (1.6 to 3.0)	47.9 (33.3 to 65.6)	-34.0 (-39.4 to -27.3)
Osteoarthritis	94.9 (91.1 to 98.5)	191.6 (183.1 to 200.2)	101.0 (88.9 to 112.8)	0.7 (-4.9 to 6.5)	5.7 (4.0 to 7.8)	11.7 (8.1 to 15.9)	103.7 (91.1 to 116.5)	1.9 (-4.0 to 7.8)
Low back and neck pain	-	-	-	-	41.7 (28.6 to 57.2)	89.3 (60.2 to 122.7)	112.9 (82.4 to 158.6)	-2.3 (-15.6 to 22.5)
Low back pain	238.0 (205.9 to 289.4)	509.4 (397.7 to 616.1)	113.1 (66.7 to 171.3)	-1.4 (-20.2 to 28.5)	26.2 (17.3 to 37.9)	56.5 (36.7 to 81.9)	115.9 (68.5 to 172.8)	0.1 (-19.5 to 29.6)
Neck pain	159.7 (132.2 to 187.1)	335.8 (289.3 to 383.9)	110.2 (67.7 to 156.8)	-5.1 (-23.1 to 15.2)	15.5 (10.3 to 22.0)	32.8 (22.3 to 46.3)	112.2 (69.5 to 161.2)	-4.3 (-22.2 to 17.4)
Gout	0.4 (0.3 to 0.4)	0.8 (0.7 to 0.9)	113.0 (80.3 to 152.9)	1.8 (-13.1 to 19.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	116.0 (70.8 to 171.3)	2.2 (-20.7 to 31.6)
Other musculoskeletal disorders	83.2 (64.5 to 103.2)	179.5 (136.0 to 223.6)	114.3 (98.6 to 133.0)	1.6 (-6.7 to 8.2)	7.4 (4.8 to 10.8)	46.2 (10.4 to 23.9)	117.1 (100.0 to 138.1)	2.8 (-5.9 to 10.4)
Other non-communicable diseases	-	-	-	-	58.2 (37.8 to 86.5)	122.9 (79.6 to 181.9)	111.4 (99.6 to 122.5)	0.6 (-3.8 to 5.4)
Congenital anomalies	-	-	-	-	3.0 (1.9 to 4.5)	9.1 (6.3 to 12.8)	203.8 (137.9 to 283.2)	49.4 (19.0 to 87.2)
Neural tube defects	0.3 (0.3 to 0.4)	3.0 (2.7 to 3.4)	762.8 (580.4 to 1,018.5)	394.7 (285.5 to 548.6)	0.1 (0.0 to 0.1)	0.8 (0.6 to 1.2)	983.3 (646.3 to 1,588.8)	555.7 (336.1 to 914.2)
Congenital heart anomalies	3.1 (2.2 to 4.3)	32.4 (26.0 to 40.4)	933.1 (610.5 to 1,407.2)	482.5 (295.6 to 836.9)	0.1 (0.1 to 0.1)	1.1 (0.4 to 2.2)	762.8 (446.2 to 1,232.2)	378.0 (206.6 to 641.6)
Orofacial clefts	0.3 (0.2 to 0.5)	4.6 (3.6 to 5.9)	1,336.7 (795.0 to 2,329.3)	850.5 (478.2 to 1,578.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	1,133.9 (611.1 to 2,347.4)	717.9 (359.4 to 1,504.0)
Down syndrome	2.2 (1.7 to 2.7)	8.7 (7.1 to 10.8)	299.4 (193.8 to 441.6)	108.7 (54.6 to 182.5)	0.2 (0.2 to 0.3)	1.0 (0.7 to 1.4)	304.5 (196.8 to 469.1)	112.1 (55.5 to 195.2)
Turner syndrome	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.5)	264.0 (122.8 to 460.2)	0.3 (8.1 to 173.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	272.5 (119.2 to 488.3)	80.4 (5.2 to 185.5)
Klinefelter syndrome	0.1 (0.1 to 0.2)	0.3 (0.3 to 0.3)	111.5 (57.6 to 160.1)	3.7 (-2.7 to 27.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.2 (64.9 to 174.6)	4.2 (-22.6 to 28.8)
Chromosomal unbalanced rearrangements	0.0 (2.9 to 4.2)	0.0 (1.7 to 17.4)	112.7 (202.3 to 441.7)	1.5 (56.3 to 183.8)	0.0 (0.3 to 0.6)	0.0 (1.1 to 2.3)	112.7 (202.9 to 469.4)	1.5 (58.4 to 201.0)
Other congenital anomalies	22.8 (16.6 to 30.3)	43.6 (32.4 to 56.7)	90.0 (61.4 to 128.3)	-8.6 (-22.7 to 11.8)	2.2 (1.2 to 3.5)	4.4 (2.6 to 7.4)	104.4 (52.3 to 179.3)	-0.8 (-27.7 to 34.2)
Skin and subcutaneous diseases	-	-	-	-	20.8 (13.1 to 32.7)	46.6 (29.2 to 73.0)	124.7 (106.6 to 141.6)	5.6 (-1.6 to 12.7)
Dermatitis	209.2 (165.2 to 261.0)	450.9 (352.1 to 566.8)	114.4 (112.1 to 116.7)	-0.3 (-0.5 to -0.0)	6.0 (3.7 to 8.7)	12.8 (7.9 to 18.5)	113.1 (104.5 to 121.3)	0.3 (-2.5 to 3.3)
Psoriasis	32.3 (25.5 to 38.6)	69.9 (54.9 to 84.2)	115.7 (113.3 to 117.8)	0.1 (-0.2 to 0.4)	2.6 (1.7 to 3.8)	5.7 (3.7 to 8.2)	117.5 (103.5 to 131.9)	1.2 (-4.3 to 6.2)
Cellulitis	0.9 (0.7 to 1.2)	1.9 (1.4 to 2.4)	101.3 (70.6 to 140.5)	-1.1 (-15.6 to 18.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	102.9 (48.2 to 172.9)	-0.0 (-24.0 to 30.7)
Pyoderma	8.7 (6.4 to 11.2)	16.0 (12.0 to 20.5)	83.7 (71.5 to 98.3)	-4.1 (-10.4 to 3.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	84.0 (66.6 to 103.1)	-3.7 (-12.1 to 5.4)
Scabies	51.9 (45.8 to 58.8)	89.9 (76.0 to 106.2)	71.8 (38.8 to 111.8)	-15.1 (-30.8 to 5.8)	1.3 (0.8 to 2.2)	2.3 (1.3 to 3.8)	72.1 (39.4 to 113.2)	-14.9 (-30.4 to 6.1)
Fungal skin diseases	586.7 (424.6 to 817.7)	1,258.6 (913.1 to 1,759.6)	113.3 (110.1 to 117.4)	0.5 (0.3 to 0.7)	3.3 (1.3 to 7.3)	7.1 (2.7 to 16.0)	114.1 (110.3 to 118.8)	1.0 (0.2 to 1.7)
Viral skin diseases	74.7 (57.5 to 92.2)	151.9 (118.2 to 189.1)	102.6 (89.1 to 117.3)	-1.0 (-5.7 to 4.6)	2.3 (1.4 to 3.6)	4.7 (2.8 to 7.4)	103.0 (87.4 to 121.0)	-0.4 (-6.7 to 6.7)
Acne vulgaris	212.0 (140.5 to 271.6)	653.7 (375.1 to 948.6)	206.7 (66.6 to 380.3)	44.8 (-19.9 to 123.3)	2.3 (1.0 to 4.2)	7.0 (2.8 to 14.3)	208.6 (66.3 to 382.4)	44.7 (-20.0 to 124.4)
Alopecia areata	4.3 (3.8 to 4.8)	9.3 (8.3 to 10.2)	115.3 (80.7 to 153.9)	1.5 (-13.2 to 18.9)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	118.6 (74.4 to 167.9)	2.6 (-15.2 to 25.3)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.7 (67.6 to 161.9)	1.5 (-19.5 to 27.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.7 (67.2 to 162.1)	1.5 (-19.5 to 27.5)
Urticaria	19.4 (11.7 to 26.7)	54.9 (40.2 to 73.1)	176.7 (79.6 to 404.6)	25.4 (-19.2 to 122.0)	1.1 (0.6 to 1.9)	3.2 (1.9 to 5.1)	179.4 (78.0 to 415.8)	25.6 (-18.1 to 124.1)
Decubitus ulcer	0.4 (0.3 to 0.5)	0.9 (0.7 to 1.0)	112.5 (66.8 to 173.9)	6.0 (-23.1 to 41.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	117.8 (65.7 to 191.4)	8.7 (-23.5 to 49.3)
Other skin and subcutaneous diseases	256.6 (174.7 to 370.5)	538.4 (364.7 to 772.6)	109.0 (99.8 to 116.8)	-0.7 (-3.6 to 2.2)	3.2 (0.7 to 3.1)	3.2 (1.4 to 6.5)	110.5 (101.0 to 119.1)	0.1 (-3.2 to 3.3)
Sense organ diseases	-	-	-	-	28.6 (18.3 to 43.3)	55.0 (34.7 to 82.8)	90.0 (74.5 to 111.0)	-4.5 (-17.0 to 2.4)
Glaucoma	1.4 (1.0 to 1.9)	9.2 (6.9 to 12.2)	552.7 (360.8 to 824.0)	160.6 (80.5 to 274.4)	0.1 (0.1 to 0.1)	0.5 (0.3 to 0.7)	474.3 (324.1 to 692.1)	131.2 (70.9 to 222.2)
Cataract	9.6 (6.3 to 13.7)	26.9 (17.3 to 35.8)	181.1 (68.8 to 354.4)	37.3 (-11.0 to 102.1)	0.6 (0.4 to 1.0)	1.7 (1.0 to 2.7)	164.0 (72.4 to 298.4)	28.4 (-9.8 to 82.8)
Macular degeneration	1.7 (1.1 to 2.6)	16.3 (10.7 to 23.6)	830.9 (508.5 to 1,385.6)	341.8 (191.6 to 605.8)	0.1 (0.1 to 0.2)	0.9 (0.5 to 1.4)	768.4 (465.6 to 1,225.2)	300.7 (162.4 to 506.1)
Uncorrected refractive error	416.5 (329.8 to 510.1)	832.2 (656.3 to 1,045.8)	97.3 (39.7 to 185.6)	3.4 (-26.5 to 29.0)	7.6 (4.7 to 11.8)	13.8 (8.4 to 22.1)	80.4 (49.8 to 125.8)	-12.4 (-24.3 to 5.9)
Age-related and other hearing loss	696.5 (512.5 to 683.5)	1,178.6 (997.0 to 1,344.9)	93.2 (83.0 to 104.7)	-5.7 (-9.6 to -2.1)	16.7 (9.9 to 25.6)	30.8 (18.4 to 47.8)	84.0 (63.0 to 106.9)	-9.6 (-17.3 to -2.7)
Other vision loss	5.3 (4.0 to 6.8)	16.0 (12.6 to 19.5)	199.6 (142.5 to 261.7)	71.0 (41.4 to 109.0)	0.3 (0.2 to 0.4)	0.9 (0.6 to 1.3)	181.0 (124.5 to 243.9)	0.9 (-38.8 to 90.1)
Other sense organ diseases	119.6 (113.5 to 126.2)	242.2 (228.9 to 255.3)	101.8 (87.5 to 117.1)	-0.6 (-6.6 to 5.8)	3.2 (1.9 to 4.7)	6.4 (3.9 to 9.6)	102.7 (86.6 to 120.2)	0.2 (-6.3 to 7.4)
Oral disorders	-	-	-	-	5.8 (3.1 to 9.6)	12.3 (6.7 to 20.4)	112.5 (98.7 to 128.2)	12.3 (-6.8 to 7.1)
Deciduous caries	497.4 (473.1 to 519.1)	970.7 (920.2 to						

Appendix Table G.4 - Benin prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.								
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	16.7 (15.3 to 18.1)	30.5 (28.1 to 32.8)	82.0 (62.4 to 104.6)	-7.9 (-16.9 to 1.9)	0.5 (0.3 to 0.6)	0.8 (0.6 to 1.2)	84.5 (63.2 to 108.2)	-6.9 (-16.4 to 3.8)
Other oral disorders	71.5 (67.0 to 75.9)	153.7 (144.9 to 163.2)	113.9 (96.4 to 134.7)	-0.7 (-8.4 to 7.8)	2.1 (1.3 to 3.1)	4.5 (2.8 to 6.7)	115.3 (96.4 to 137.3)	-0.1 (-8.0 to 8.9)
Injuries	-	-	-	-	16.3 (12.4 to 20.8)	26.6 (19.7 to 34.9)	63.0 (52.6 to 73.8)	-18.4 (-23.5 to -13.1)
Transport injuries	-	-	-	-	6.5 (4.9 to 8.4)	9.8 (7.2 to 12.8)	50.1 (38.1 to 63.5)	-21.6 (-27.5 to -15.3)
Road injuries	-	-	-	-	6.0 (4.5 to 7.7)	8.9 (6.5 to 11.7)	49.1 (36.6 to 62.7)	-22.3 (-28.4 to -15.6)
Pedestrian road injuries	-	-	-	-	1.5 (1.1 to 2.0)	2.0 (1.4 to 2.7)	29.6 (15.3 to 44.8)	-29.2 (-36.1 to -22.4)
Cyclist road injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.7 (0.5 to 0.9)	31.4 (20.4 to 42.0)	-27.6 (-33.7 to -22.0)
Motorcyclist road injuries	-	-	-	-	0.9 (0.7 to 1.2)	1.2 (0.9 to 1.6)	36.2 (23.0 to 51.1)	-31.7 (-38.0 to -24.7)
Motor vehicle road injuries	-	-	-	-	2.9 (2.2 to 3.8)	4.9 (3.6 to 6.4)	67.9 (50.7 to 85.8)	-24.1 (-22.0 to -4.8)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	14.6 (4.3 to 26.7)	-44.2 (-48.8 to -38.9)
Other transport injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.9 (0.6 to 1.2)	60.8 (46.5 to 76.2)	-14.4 (-21.4 to -6.8)
Unintentional injuries	-	-	-	-	9.4 (7.2 to 12.0)	16.2 (12.1 to 21.2)	72.1 (62.8 to 81.7)	-16.2 (-20.9 to -11.6)
Falls	-	-	-	-	3.7 (2.9 to 4.8)	6.7 (4.9 to 8.8)	77.9 (65.3 to 91.6)	-16.2 (-22.9 to -9.9)
Drowning	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	27.1 (12.7 to 42.8)	-36.1 (-42.3 to -28.9)
Fire, heat, and hot substances	-	-	-	-	0.6 (0.4 to 0.7)	0.8 (0.6 to 1.1)	43.6 (29.1 to 60.4)	-27.4 (-33.5 to -20.5)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	51.9 (24.8 to 83.8)	-27.6 (-38.7 to -15.5)
Exposure to mechanical forces	-	-	-	-	2.9 (2.2 to 3.8)	5.0 (3.7 to 6.7)	71.3 (61.6 to 82.2)	-15.5 (-20.0 to -10.4)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	63.2 (46.5 to 80.9)	-20.8 (-28.3 to -12.5)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	118.8 (96.8 to 142.8)	8.4 (-1.7 to 18.1)
Other exposure to mechanical forces	-	-	-	-	2.8 (2.1 to 3.7)	4.8 (3.5 to 6.4)	71.1 (61.0 to 82.3)	-15.6 (-20.1 to -10.4)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	127.7 (113.4 to 144.5)	16.9 (9.0 to 26.7)
Animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	63.0 (49.1 to 76.3)	-19.3 (-25.3 to -13.7)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	67.2 (45.6 to 90.1)	-18.8 (-28.1 to -9.8)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	59.2 (47.2 to 72.3)	-19.7 (-25.2 to -13.7)
Foreign body	-	-	-	-	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	78.7 (66.5 to 92.2)	-10.4 (-15.8 to -4.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	37.6 (18.3 to 58.0)	-24.8 (-32.7 to -15.4)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	102.9 (82.5 to 127.2)	-4.6 (-12.5 to 5.3)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	88.1 (72.7 to 104.4)	-7.5 (-14.6 to 0.2)
Other unintentional injuries	-	-	-	-	1.4 (1.1 to 1.9)	2.5 (1.9 to 3.3)	74.8 (60.6 to 87.6)	-12.8 (-19.4 to -6.7)
Self-harm and interpersonal violence	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.8)	57.8 (46.0 to 71.9)	-23.1 (-28.8 to -16.5)
Self-harm	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	92.9 (74.2 to 112.1)	-9.3 (-17.2 to -1.3)
Interpersonal violence	-	-	-	-	0.3 (0.3 to 0.4)	0.5 (0.4 to 0.7)	51.7 (39.8 to 66.3)	-26.4 (-32.0 to -19.3)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	69.3 (56.7 to 83.7)	-17.1 (-22.9 to -10.4)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	89.4 (73.1 to 109.3)	-9.9 (-17.7 to -0.3)
Assault by other means	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	38.2 (26.2 to 52.8)	-33.1 (-38.9 to -25.9)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	41.9 (23.0 to 64.7)	-24.2 (-33.6 to -13.5)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	41.9 (23.0 to 64.7)	-24.2 (-33.6 to -13.5)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Bhutan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	47.2 (34.6 to 61.4)	72.8 (54.2 to 94.6)	54.3 (49.2 to 60.0)	54.3 (-7.4 to -1.6)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	8.7 (6.1 to 12.0)	8.6 (6.2 to 11.7)	-1.8 (-8.3 to 11.0)	-20.2 (-25.4 to -9.9)
HIV/AIDS and tuberculosis	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 1.0)	47.9 (32.9 to 163.8)	-18.8 (-25.9 to 33.8)
Tuberculosis	1.0 (0.9 to 1.1)	1.3 (1.3 to 1.4)	33.4 (26.6 to 40.6)	-25.7 (-29.5 to -20.8)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	33.2 (24.1 to 43.4)	-25.6 (-30.4 to -20.2)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.5)	1,389.1 (210.3 to 6,458.8)	723.6 (66.8 to 3,474.7)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	844.7 (105.2 to 3,572.7)	499.0 (9.6 to 1,870.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	844.7 (103.5 to 3,601.5)	409.0 (7.0 to 1,876.8)
HIV/AIDS resulting in other diseases	0.1 (0.0 to 0.5)	0.7 (0.1 to 3.1)	1,233.0 (211.3 to 5,196.4)	632.3 (73.0 to 2,808.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.5)	1,476.5 (211.3 to 7,736.8)	782.8 (70.2 to 4,301.5)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	2.2 (1.6 to 3.0)	2.1 (1.5 to 2.8)	-6.7 (-14.0 to 1.4)	-19.0 (-25.4 to -12.2)
Diarrheal diseases	7.3 (6.7 to 7.9)	6.6 (6.1 to 7.2)	-9.4 (-19.3 to 1.9)	-9.4 (-19.1 to 0.9)	1.2 (0.8 to 1.7)	1.1 (0.7 to 1.5)	-9.8 (-20.2 to 1.7)	-9.4 (-19.3 to 1.5)
Intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-19.9 (-41.5 to 6.3)	-31.8 (-50.3 to -10.3)
Typhoid fever	0.4 (0.3 to 0.5)	0.3 (0.3 to 0.4)	-16.1 (-37.8 to 10.2)	-29.9 (-48.7 to -6.5)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-16.4 (-39.2 to 14.6)	-28.7 (-48.6 to -2.5)
Paratyphoid fever	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-28.6 (-52.7 to 3.3)	-37.0 (-57.0 to -10.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.5 (-52.6 to 10.9)	-37.0 (-58.0 to -5.5)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-95.3 (-99.6 to 449.7)	-96.0 (-99.7 to 342.3)
Lower respiratory infections	0.3 (0.3 to 0.4)	0.2 (0.2 to 0.3)	-38.5 (-52.8 to -15.1)	-36.7 (-50.5 to -14.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-38.6 (-55.0 to -12.2)	-36.5 (-51.1 to -12.3)
Upper respiratory infections	22.6 (20.3 to 25.1)	29.9 (26.7 to 33.2)	31.7 (12.4 to 56.3)	-2.7 (-16.0 to 14.1)	0.3 (0.1 to 0.5)	0.4 (0.2 to 0.6)	31.7 (12.4 to 55.8)	-2.3 (-16.2 to 14.7)
Otitis media	9.5 (8.6 to 10.5)	10.7 (9.7 to 11.9)	12.0 (0.7 to 25.2)	-15.0 (-23.5 to -4.8)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	9.8 (4.2 to 24.7)	-14.3 (-24.3 to -3.5)
Meningitis	-	-	-	-	0.4 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-23.7 (-39.6 to -8.8)	-46.3 (-56.9 to -31.4)
Pneumococcal meningitis	1.7 (1.0 to 2.6)	1.4 (0.9 to 2.2)	-16.4 (-41.9 to 16.9)	-4.4 (-62.2 to 23.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-10.7 (-33.2 to 18.5)	-39.3 (-53.1 to -22.0)
H influenzae type B meningitis	0.9 (0.4 to 1.7)	0.5 (0.2 to 1.0)	-47.3 (-67.7 to -14.1)	-64.1 (-77.3 to -42.0)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-41.5 (-70.0 to -10.5)	-57.5 (-78.6 to -36.0)
Meningococcal meningitis	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.3)	-19.8 (-53.7 to 36.3)	-48.2 (-69.8 to -13.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.3 (-50.9 to 49.7)	-43.7 (-65.0 to -3.9)
Other meningitis	0.8 (0.4 to 1.6)	0.6 (0.3 to 1.1)	-28.4 (-53.1 to 10.2)	-50.3 (-67.0 to -24.2)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-24.3 (-48.5 to 12.8)	-46.1 (-61.9 to -20.4)
Encephalitis	0.3 (0.1 to 0.5)	0.3 (0.1 to 0.6)	9.3 (-20.7 to 28.6)	-26.6 (-49.3 to -18.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	17.2 (5.1 to 45.4)	-22.9 (-37.0 to -5.9)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-68.5 (-98.2 to 607.0)	-65.8 (-98.0 to 546.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-68.5 (-98.2 to 617.6)	-65.8 (-98.0 to 554.8)
Whooping cough	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-87.0 (-88.4 to -85.5)	-83.9 (-85.7 to -82.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-87.0 (-92.2 to -78.8)	-83.9 (-90.4 to -73.9)
Tetanus	0.6 (0.3 to 1.1)	0.0 (0.0 to 0.0)	-98.0 (-99.2 to -95.7)	-98.5 (-99.4 to -96.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-95.1 (-98.2 to -84.8)	-95.9 (-98.5 to -87.5)
Measles	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-85.6 (-89.1 to -80.9)	-85.6 (-86.7 to -76.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-85.3 (-90.2 to -78.3)	-82.2 (-88.1 to -73.9)
Varicella and herpes zoster	0.4 (0.4 to 0.5)	0.5 (0.4 to 0.5)	8.7 (-3.9 to 23.8)	-3.8 (-19.2 to 15.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.3 (9.5 to 106.7)	-5.8 (-33.1 to 31.4)
Neglected tropical diseases and malaria	-	-	-	-	0.6 (0.4 to 1.0)	0.6 (0.4 to 0.9)	-7.4 (-28.4 to 16.4)	-17.7 (-35.8 to 1.6)
Malaria	13.3 (7.3 to 23.2)	21.9 (15.1 to 31.4)	69.2 (-23.8 to 194.6)	22.0 (-45.5 to 116.0)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	110.4 (39.5 to 145.2)	65.8 (9.7 to 93.3)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.6 (-58.0 to 18.3)	-55.6 (-73.1 to -24.9)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.4 (-19.0 to 80.8)	5.0 (-27.5 to 53.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.4 (-19.0 to 81.0)	5.0 (-27.8 to 53.5)
Cutaneous and mucocutaneous leishmaniasis	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-42.2 (-70.9 to 6.8)	-64.1 (-81.2 to -37.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.7 (-70.8 to 15.2)	-63.6 (-81.6 to -31.9)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	16.1 (-43.0 to 174.3)	-34.9 (-69.5 to 55.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	39.1 (-36.4 to 241.7)	-22.2 (-65.2 to 90.5)
Cystic echinococcosis	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-41.9 (-49.6 to -34.7)	-68.0 (-71.2 to -62.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.6 (-53.8 to -24.2)	-66.7 (-73.4 to -58.1)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.4)	595.9 (587.4 to 605.8)	394.2 (388.2 to 401.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	558.9 (444.8 to 679.8)	363.9 (291.3 to 441.4)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-77.3 (-86.2 to -59.9)	-81.3 (-88.2 to -69.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-77.3 (-86.2 to -59.8)	-81.3 (-88.2 to -69.4)
Intestinal nematode infections	-	-	-	-	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.1)	-66.9 (-82.7 to -37.0)	-69.1 (-83.6 to -41.9)
Ascariasis	67.3 (45.2 to 99.5)	93.6 (55.5 to 160.6)	37.3 (-27.3 to 180.6)	-4.3 (-52.4 to 94.4)	0.2 (0.1 to 0.4)	0.0 (0.0 to 0.1)	0.0 (-92.2 to -54.2)	-81.8 (-92.2 to -55.3)
Trichuriasis	28.3 (17.1 to 46.3)	43.0 (23.1 to 72.9)	53.6 (-28.3 to 211.9)	3.7 (-55.4 to 124.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.3 (-56.6 to 500.3)	1.8 (-73.9 to 340.8)
Hookworm disease	6.1 (4.1 to 9.9)	9.2 (5.4 to 14.9)	51.3 (-23.4 to 188.9)	49.1 (-50.8 to 101.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.6 (1.5 to 200.4)	35.3 (-24.8 to 119.5)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	8.2 (6.3 to 10.2)	5.5 (4.5 to 6.5)	-32.3 (-46.1 to -12.2)	-34.9 (-47.4 to -17.7)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-35.6 (-53.5 to -5.9)	-33.7 (-51.9 to -3.5)
Maternal disorders	-	-	-	-	0.0 (0.2 to 0.5)	0.0 (0.3 to 0.6)	-	-
Maternal hemorrhage	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	23.8 (-3.7 to 58.2)	-34.7 (-48.4 to -46.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.8 (-54.4 to 34.0)	-98.1 (-75.7 to -29.0)
Maternal sepsis and other maternal infections	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-44.0 (-57.6 to -9.9)	-69.9 (-77.8 to -49.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.2 (-74.1 to -31.1)	-74.7 (-85.4 to -62.7)
Maternal hypertensive disorders	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-31.0 (-40.9 to -22.4)	-63.6 (-68.1 to -59.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.9 (-47.7 to -17.9)	-64.6 (-71.7 to -56.6)
Obstructed labor	0.8 (0.7 to 1.0)	1.0 (0.8 to 1.1)	17.1 (8.4 to 28.5)	-32.1 (-37.2 to -26.0)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	17.6 (5.6 to 31.1)	-31.5 (-38.3 to -24.3)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.6 (-56.2 to 27.6)	-40.7 (-77.2 to -36.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.6 (-56.3 to 27.8)	-60.0 (-77.2 to -36.3)
Other maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	16.0 (-31.4 to 116.7)	-33.0 (-60.2 to 26.0)
Neonatal disorders	-	-	-	-	0.4 (0.3 to 0.7)	1.6 (1.1 to 2.6)	272.1 (134.8 to 516.9)	197.9 (85.0 to 400.9)
Preterm birth complications	1.7 (0.9 to 3.2)	6.6 (4.0 to 10.7)	286.9 (195.2 to 472.5)	180.8 (114.2 to 315.5)	0.1 (0.1 to 0.2)	0.8 (0.5 to 1.3)	505.2 (277.2 to 868.8)	373.7 (197.0 to 670.3)
Neonatal encephalopathy due to birth asphyxia and trauma	4.5 (1.2 to 8.6)	4.2 (1.7 to 7.2)	-8.1 (-29.2 to 83.2)	-34.3 (-49.6 to 33.9)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	117.9 (35.6 to 315.2)	72.3 (3.8 to 251.3)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.8 (58.8 to 87.6)	124.8 (109.0 to 146.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.7 (51.1 to 92.6)	126.0 (98.8 to 153.5)
Hemolytic disease and other neonatal jaundice	0.2 (0.1 to 0.4)	0.8 (0.4 to 1.8)	396.2 (53.0 to 1,425.4)	326.9 (33.5 to 1,231.6)	0.1 (0.0 to 0.1)	0.3 (0.1 to 0.6)	360.6 (52.5 to 1,143.8)	282.4 (25.7 to 951.4)
Other neonatal disorders	-	-	-	-	0.1 (0.0 to 0.2)	0.2 (0.0 to 0.5)	134.8 (-12.4 to 606.8)	88.1 (-31.0 to 474.0)
Nutritional deficiencies	-	-	-	-	4.4 (3.0 to 6.4)	3.1 (2.0 to 4.4)	-30.7 (-33.7 to -27.9)	-41.7 (-44.2 to -39.3)
Protein-energy malnutrition	1.2 (0.7 to 1.8)	1.4 (0.9 to 2.0)	18.9 (-37.8 to 117.4)	28.4 (-26.9 to 117.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	19.1 (-36.8 to 122.2)	30.7 (-26.7 to 126.6)
Iodine deficiency	4.8 (3.6 to 6.3)	4.1 (3.2 to 5.3)	-13.4 (-38.8 to 27.1)	-49.1 (-64.8 to -22.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-13.8 (-39.1 to 27.6)	-48.9 (-64.7 to -21.6)
Vitamin A deficiency	0.6 (0.4 to 0.8)	0.4 (0.2 to 0.5)	-38.8 (-50.1 to -25.1)	-52.0 (-58.2 to -39.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.4 (-52.8 to -27.1)	-54.8 (-61.8 to -43.5)

Appendix Table G.4 - Bhutan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	124.7 (122.9 to 126.5)	92.0 (90.2 to 93.5)	-26.2 (-28.0 to -24.5)	-42.7 (-44.0 to -41.3)	4.1 (2.8 to 6.0)	2.8 (1.8 to 4.1)	-32.7 (-35.5 to -30.9)	-43.5 (-45.8 to -42.1)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	1.1 (-15.5 to 18.4)	-24.0 (-34.7 to -14.1)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	64.6 (41.0 to 94.9)	-12.1 (-23.2 to 1.4)
Syphilis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-	-36.2 (-45.8 to -25.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	43.2 (-7.2 to -87.0)
Chlamydial infection	5.6 (6.0 to 7.2)	11.5 (10.4 to 12.6)	74.6 (53.1 to 103.6)	-2.6 (-14.0 to 11.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	77.2 (53.4 to 116.2)	-1.9 (-18.5 to 18.3)
Gonococcal infection	2.5 (1.9 to 3.1)	4.5 (3.5 to 5.6)	79.7 (33.5 to 160.2)	0.8 (-24.7 to 45.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	83.0 (13.9 to 236.0)	1.6 (-35.6 to 81.2)
Trichomoniasis	4.8 (3.6 to 6.1)	8.9 (6.7 to 11.1)	87.5 (28.6 to 171.2)	2.4 (-28.5 to 47.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.3 (23.0 to 195.3)	3.7 (-31.8 to 59.6)
Genital herpes	71.9 (64.1 to 78.2)	118.8 (108.5 to 128.0)	65.1 (44.6 to 87.2)	-10.2 (-20.6 to 0.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	64.6 (42.4 to 88.1)	-10.2 (-21.2 to 1.7)
Other sexually transmitted diseases	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-4.4 (-21.9 to 23.2)	-50.1 (-59.4 to -35.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-1.8 to 134.2)	48.0 (-46.1 to 18.9)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (11.4 to 53.5)	-17.1 (-32.2 to -0.3)
Hepatitis A	0.8 (0.8 to 0.9)	0.9 (0.8 to 0.9)	2.8 (1.3 to 4.4)	-10.1 (-10.3 to -9.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.5 (19.8 to 50.3)	-1.9 (-12.1 to 9.1)
Hepatitis B	29.1 (24.3 to 33.7)	34.4 (28.8 to 39.4)	17.4 (-4.7 to 46.8)	-23.7 (-37.0 to -5.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.9 (-12.2 to 62.2)	-29.5 (53.5 to 3.6)
Hepatitis C	3.3 (2.9 to 3.7)	4.0 (3.6 to 4.4)	20.7 (3.6 to 41.3)	-28.1 (-36.9 to -16.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.1 (9.5 to 37.2)	-25.5 (-43.7 to -1.7)
Hepatitis E	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	38.6 (10.6 to 69.3)	-16.5 (-33.0 to 3.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.4 (-4.4 to 123.4)	-15.9 (-43.9 to 29.5)
Leprosy	0.1 (0.0 to 0.3)	0.1 (0.1 to 0.2)	4.6 (-32.8 to 145.0)	-42.2 (-62.0 to 34.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.6 (-34.7 to 160.7)	-41.3 (-62.4 to 43.1)
Other infectious diseases	5.8 (4.6 to 7.2)	3.9 (3.2 to 4.7)	-32.3 (-46.7 to -15.8)	-38.2 (-50.6 to -24.4)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-32.6 (-53.0 to -17.5)	-33.4 (-53.3 to -18.4)
Non-communicable diseases	-	-	-	-	36.1 (26.3 to 46.8)	61.4 (45.5 to 79.1)	70.1 (64.5 to 76.8)	0.8 (-3.8 to 2.9)
Neoplasms	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.8)	86.8 (41.8 to 167.3)	0.2 (-21.4 to 36.3)
Esophageal cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	75.0 (2.1 to 213.3)	-6.0 (-42.5 to 61.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.4 (-0.5 to 193.9)	-11.3 (-45.3 to 51.5)
Stomach cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	74.2 (4.7 to 206.4)	-6.1 (-42.1 to 58.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.3 (-5.3 to 174.3)	-15.0 (-48.0 to 40.3)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	143.2 (5.3 to 330.5)	26.4 (-18.9 to 115.5)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	304.5 (24.9 to 887.6)	121.0 (-34.4 to 439.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	263.3 (15.8 to 754.7)	102.4 (-38.6 to 368.3)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	354.9 (75.8 to 1,184.5)	140.6 (-12.8 to 541.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	319.1 (66.5 to 1,023.6)	114.0 (-17.1 to 428.7)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.8 (-61.7 to 213.5)	-46.2 (-78.9 to 59.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.5 (-62.1 to 162.5)	-52.3 (-80.2 to 32.1)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.7 (-21.0 to 275.6)	-10.6 (-56.1 to 113.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.9 (-23.8 to 217.9)	-18.5 (-58.6 to 75.2)
Larynx cancer	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.5)	84.9 (51.0 to 128.5)	-3.6 (-20.5 to 18.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.9 (36.2 to 135.5)	-5.7 (-25.6 to 22.1)
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	101.6 (26.0 to 237.6)	10.5 (-29.3 to 79.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.1 (9.9 to 209.0)	1.7 (-37.8 to 65.8)
Breast cancer	1.1 (0.9 to 1.3)	1.3 (1.0 to 1.9)	-39.0 (-94.4 to 72.7)	-39.0 (-53.5 to -16.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	42.0 (-0.6 to 122.1)	-27.6 (-47.4 to 10.5)
Cervical cancer	0.3 (0.1 to 0.5)	0.3 (0.1 to 0.5)	-5.8 (-46.9 to 73.9)	-5.1 (-48.8 to -1.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.9 (-46.5 to 76.3)	-45.5 (-68.8 to -1.7)
Uterine cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	63.8 (-18.6 to 243.4)	-4.8 (-51.6 to 98.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.1 (-21.8 to 239.9)	-8.8 (-52.6 to 90.1)
Prostate cancer	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.4)	264.2 (124.0 to 564.8)	60.2 (2.1 to 186.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	267.2 (106.0 to 640.4)	61.0 (-6.9 to 221.9)
Colon and rectum cancer	0.5 (0.4 to 0.5)	1.1 (0.9 to 1.2)	116.2 (90.5 to 152.0)	2.9 (-7.5 to 19.2)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	111.2 (84.2 to 148.9)	1.7 (-10.1 to 17.8)
Lip and oral cavity cancer	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	112.5 (23.4 to 286.2)	16.8 (-28.6 to 100.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	107.7 (23.3 to 274.5)	12.5 (-30.4 to 93.2)
Nasopharynx cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	23.2 (-38.8 to 147.2)	-30.0 (-65.1 to 37.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.1 (-37.8 to 137.9)	32.2 (-63.4 to 30.1)
Other pharynx cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	147.7 (25.8 to 391.6)	37.9 (-28.5 to 164.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	132.3 (21.3 to 350.4)	27.7 (-31.3 to 144.8)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	118.0 (16.7 to 322.4)	15.6 (-36.7 to 115.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.2 (5.8 to 272.9)	3.8 (-41.9 to 89.7)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.4 (14.2 to 219.9)	-3.3 (-38.7 to 58.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.5 (10.3 to 187.6)	-13.1 (-42.7 to 39.0)
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	100.9 (17.2 to 273.8)	4.8 (-36.6 to 86.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.3 (14.2 to 264.1)	0.6 (-39.6 to 79.2)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	206.8 (117.0 to 347.0)	47.7 (0.9 to 116.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	248.6 (101.6 to 531.0)	57.3 (-12.2 to 184.1)
Ovarian cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	211.7 (65.0 to 494.4)	73.6 (-6.9 to 222.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	194.5 (53.4 to 489.7)	59.1 (-16.7 to 206.2)
Testicular cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	220.3 (41.5 to 668.5)	65.0 (-20.9 to 277.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	191.6 (31.1 to 598.9)	49.8 (-31.0 to 239.4)
Kidney cancer	0.1 (0.0 to 0.0)	0.1 (0.0 to 0.1)	127.5 (33.9 to 326.1)	65.4 (-6.7 to 195.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	127.2 (33.4 to 313.3)	52.1 (-13.2 to 176.3)
Bladder cancer	0.2 (0.2 to 0.2)	0.5 (0.4 to 0.5)	137.7 (109.3 to 175.3)	9.6 (-3.1 to 26.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	132.1 (102.9 to 171.6)	7.8 (-5.0 to 25.9)
Brain and nervous system cancer	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	47.8 (-21.5 to 185.5)	1.1 (-40.1 to 90.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.4 (-13.9 to 199.3)	-1.1 (-40.9 to 85.1)
Thyroid cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	144.6 (30.6 to 411.6)	28.7 (-29.2 to 166.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	132.1 (23.6 to 370.1)	18.8 (-34.7 to 136.9)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.4 (-18.4 to 162.6)	-24.1 (-54.6 to 37.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.6 (-15.6 to 164.8)	-23.1 (-47.4 to 39.9)
Hodgkin lymphoma	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	15.0 (-41.7 to 132.2)	-11.9 (-50.7 to 68.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.4 (-39.5 to 134.0)	-17.0 (-52.4 to 58.5)
Non-Hodgkin lymphoma	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	171.3 (50.2 to 464.6)	69.3 (8.2 to 251.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	151.7 (37.7 to 407.0)	49.0 (-19.4 to 199.9)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.8 (10.0 to 340.3)	14.4 (-38.1 to 123.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.1 (6.2 to 304.1)	6.0 (-42.5 to 111.2)
Leukemia	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	70.3 (-6.7 to 207.2)	38.6 (-15.0 to 132.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.1 (5.6 to 205.2)	22.1 (-23.1 to 104.8)
Other neoplasms	0.2 (0.1 to 0.4)	0.5 (0.3 to 0.9)	153.6 (-3.3 to 406.9)	103.6 (2.4 to 273.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	153.7 (5.8 to 382.9)	79.0 (0.7 to 219.0)
Cardiovascular diseases	-	-	-	-	0.7 (0.5 to 1.0)	1.6 (1.0 to 2.4)	134.1 (48.0 to 236.7)	21.5 (-20.6 to 72.9)
Rheumatic heart disease	2.6 (2.0 to 3.2)	4.3 (3.3 to 5.7)	65.7 (13.6 to 146.1)	1.1 (-26.6 to 48.6)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	63.1 (16.3 to 131.5)	-2.4 (-29.1 to 33.0)
Ischemic heart disease	3.2 (2.7 to 3.8)	5.0 (4.3 to 5.9)	53.1 (23.6 to 96.6)	-18.5 (-33.5 to 2.3)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	55.7 (13.7 to 120.7)	-16.5 (-38.8 to 18.3)
Cerebrovascular disease	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	81.5 (47.3 to 136.6)	0.9 (-19.0 to 30.3)
Ischemic stroke	0.5 (0.4 to 0.5)	0.9 (0.7 to 1.0)	83.5 (50.3 to 134.9)	1.4 (-19.3 to 29.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	83.6 (49.0 to 139.2)	1.8 (-18.8 to 31.1)
Hemorrhagic stroke	0.2 (0.2 to 0.3)	0.4 (0.4 to 0.5)	77.2 (41.8 to 129.3)	-0.7 (-21.7 to 29.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	76.8 (37.7 to 134.7)	-0.5 (-23.6 to 32.7)
Hypertensive heart disease	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.6)	141.6 (53.9 to 284.2)	12.2 (-30.0 to 82.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	138.8 (53.3 to 289.6)	12.7 (-30.8 to 86.1)
Cardiomyopathy and myocarditis	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.5)	114.0 (63.0 to 176.4)	13.7 (-15.1 to 55.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	116.3 (60.9 to 187.9)	15.6 (-15.6 to 59.5)
Atrial fibrillation and flutter	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	49.3 (-29.0 to 58.3)	-49.3 (-67.6 to -25.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.2 (-33.1 to 65.1)	49.1 (-68.3 to -22.2)
Peripheral vascular disease	9.4 (6.1 to 13.3)	18.7 (13.3 to 26.5)	92.4 (23.3 to 248.9)	2.3 (-31.2 to 63.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	237.5 (69.9 to 562.7)	23.4 (-38.4 to 139.1)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.2 (58.2 to 213.3)	22.7 (-18.3 to 88.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	133.3 (66.1 to 250.0)	29.4 (-15.8 to 115.0)
Other cardiovascular and circulatory diseases	0.0 (1.0 to 5.3)	0.2 (3.2 to 18.1)	279.0 (-10.0 to 1,113.9)	30.7 (-53.2 to 469.4)	0.0 (0.1 to 0.4)	0.2 (0.2 to 1.4)	28.1 (-8.6 to 113.9)	82.4 (-53.5 to 478.6)
Chronic respiratory diseases	-	-	-	-	2.8 (1.9 to 3.9)	4.9 (3.4 to 6.6)	73.3 (53.6 to 97.4)	-2.6 (-13.6 to 9.1)
Chronic obstructive pulmonary disease	19.1 (18.3 to 20.0)	34.1 (32.6 to 35.6)	78.0 (72.6 to 84.0)	-0.2 (-2.9 to 2.9)	2.1 (1.4 to 2.9)	3.7 (2.5 to 5.2)	79.1 (60.4 to 98.0)	1.1 (-9.4 to 11.

Appendix Table G.4 - Bhutan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	81.6	-1.6
Silicosis	0.0	0.0	60.2	-12.8	0.0	0.0	(73.9 to 89.8)	(6.0 to 2.9)
Asbestosis	-	-	0.0	0.0	-	-	59.9	-12.8
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	103.5	11.2	0.0	0.0	103.1	11.1
Asthma	9.6	19.6	103.1	11.7	0.4	0.9	105.1	12.5
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.1	89.3	8.3	0.0	0.0	90.1	8.3
Other chronic respiratory diseases	-	-	-	-	0.1	0.3	3.9	-41.2
Cirrhosis	-	-	-	-	0.1	0.1	40.4	-7.4
Cirrhosis due to hepatitis B	0.1	0.1	69.5	-0.8	0.0	0.0	71.6	-0.1
Cirrhosis due to hepatitis C	0.0	0.1	33.7	-6.7	0.0	0.0	32.6	-7.2
Cirrhosis due to alcohol use	0.1	0.1	42.7	-18.5	0.0	0.0	44.1	-17.2
Cirrhosis due to other causes	0.1	0.2	24.6	-2.7	0.0	0.0	22.4	-4.1
Digestive diseases	0.1	0.2	111.1	-33.4	0.7	0.9	22.3	-24.9
Peptic ulcer disease	2.1	2.4	18.2	-39.6	0.1	0.1	15.9	-41.7
Gastritis and duodenitis	9.6	7.4	-22.9	-48.9	0.4	0.4	-17.6	-43.2
Appendicitis	0.1	0.1	17.2	-28.5	0.0	0.0	17.6	-28.7
Paralytic ileus and intestinal obstruction	0.0	0.0	38.6	-12.8	0.0	0.0	37.2	-12.4
Inguinal, femoral, and abdominal hernia	1.9	3.1	67.2	-4.4	0.0	0.0	65.2	-4.4
Inflammatory bowel disease	0.6	1.2	108.7	18.4	0.1	0.3	109.2	19.1
Vascular intestinal disorders	0.0	0.0	93.6	2.9	0.0	0.0	95.6	6.7
Gallbladder and biliary diseases	0.2	0.3	71.4	-2.4	0.0	0.0	70.0	-2.1
Pancreatitis	0.1	0.2	74.0	-3.0	0.0	0.1	74.8	-2.1
Other digestive diseases	-	-	-	-	0.0	0.0	123.6	38.3
Neurological disorders	-	-	-	-	4.3	7.5	74.8	1.6
Alzheimer disease and other dementias	0.8	2.1	159.8	0.0	0.1	0.3	170.2	0.6
Parkinson disease	0.1	0.2	107.9	0.2	0.0	0.0	106.3	0.6
Epilepsy	1.9	2.8	44.3	-1.0	0.6	1.1	71.1	17.8
Multiple sclerosis	0.1	0.2	103.0	13.3	0.0	0.1	102.8	13.4
Migraine	80.9	134.9	67.0	0.8	4.6	6.1	-0.8	
Tension-type headache	135.0	225.9	67.9	-1.1	0.2	0.3	67.7	-0.9
Medication overuse headache	2.5	5.8	124.8	30.7	0.4	0.9	125.1	31.0
Other neurological disorders	0.0	0.0	56.1	4.0	0.1	0.1	23.6	-49.7
Mental and substance use disorders	-	-	-	-	9.8	16.5	68.2	0.4
Schizophrenia	0.8	1.5	82.2	-0.4	0.5	1.0	83.0	0.0
Alcohol use disorders	4.1	7.3	75.7	-3.0	0.4	0.7	76.4	-2.7
Drug use disorders	-	-	-	-	0.5	0.9	91.4	3.8
Opioid use disorders	0.4	0.8	98.0	6.7	0.2	0.4	98.9	6.9
Cocaine use disorders	0.2	0.5	89.0	0.1	0.0	0.1	89.4	-0.2
Amphetamine use disorders	0.8	1.4	86.4	2.6	0.1	0.2	86.9	2.9
Cannabis use disorders	0.8	1.3	73.6	0.9	0.0	0.0	73.7	1.1
Other drug use disorders	-	-	-	-	0.1	0.3	88.3	1.8
Depressive disorders	-	-	-	-	2.2	3.8	75.5	1.0
Major depressive disorder	16.4	28.3	74.6	0.7	3.4	5.9	74.7	1.3
Dysthymia	5.5	9.9	79.6	-1.1	0.5	1.0	80.0	-0.7
Bipolar disorder	2.9	5.4	85.0	0.1	0.6	1.1	85.6	0.6
Anxiety disorders	16.8	27.5	62.5	1.6	2.5	4.2	63.2	-0.8
Eating disorders	-	-	-	-	0.1	0.2	71.5	0.8
Anorexia nervosa	0.1	0.2	84.6	16.0	0.0	0.0	85.2	16.5
Bulimia nervosa	0.5	0.8	68.6	-2.4	0.1	0.2	69.1	-2.0
Autistic spectrum disorders	-	-	-	-	0.7	0.9	44.5	1.9
Autism	1.7	2.4	45.0	1.4	0.4	0.6	44.5	1.7
Asperger syndrome	2.4	3.5	44.6	1.8	0.2	0.3	44.6	2.2
Attention-deficit/hyperactivity disorder	3.7	4.3	18.6	0.4	0.0	0.1	19.0	0.8
Conduct disorder	5.0	3.6	28.1	0.2	0.7	0.5	18.2	0.5
Idiopathic intellectual disability	4.7	5.5	16.8	4.2	0.4	0.5	29.1	-4.3
Other mental and substance use disorders	6.8	12.9	89.6	1.2	0.5	1.0	90.1	1.6
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	3.3	5.4	61.9	0.1
Diabetes mellitus	21.0	36.5	74.5	1.6	1.3	2.2	75.3	1.2
Acute glomerulonephritis	0.0	0.0	32.5	-24.4	0.0	0.0	32.5	-24.4
Chronic kidney disease	-	-	-	-	0.7	1.2	68.9	3.5
Chronic kidney disease due to diabetes mellitus	6.9	11.4	69.7	-5.7	0.1	0.2	74.2	1.4
Chronic kidney disease due to hypertension	10.3	15.6	52.2	0.7	0.3	0.4	79.8	4.4
Chronic kidney disease due to glomerulonephritis	13.6	19.9	51.1	-4.6	0.2	0.4	61.5	0.8
Chronic kidney disease due to other causes	8.8	12.6	43.2	-24.4	0.2	0.2	43.2	-24.4
Urinary diseases and male infertility	-	-	-	-	0.2	0.5	116.5	8.4

Appendix Table G.4 - Bhutan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	58.1 (41.9 to 76.9)	0.0 (-9.0 to 9.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.3 (20.9 to 103.4)	0.9 (-19.5 to 22.7)
Urolithiasis	1.4 (0.9 to 1.8)	2.7 (2.1 to 3.6)	90.2 (49.2 to 148.6)	1.0 (-16.1 to 25.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	119.5 (93.4 to 155.7)	25.5 (11.9 to 44.1)
Benign prostatic hyperplasia	3.8 (3.5 to 4.1)	8.3 (7.6 to 8.9)	115.9 (93.2 to 142.8)	5.1 (-5.7 to 18.1)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	115.7 (91.2 to 142.4)	6.0 (-5.3 to 18.8)
Male infertility due to other causes	2.4 (1.8 to 3.1)	4.9 (3.2 to 6.4)	100.2 (72.8 to 202.5)	1.7 (-34.9 to 52.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	100.0 (20.1 to 203.1)	1.6 (-38.5 to 52.0)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-11.3 to 249.8)
Gynecological diseases	-	-	-	-	0.5 (0.3 to 0.7)	0.8 (0.5 to 1.2)	63.8 (36.9 to 92.9)	-12.4 (-26.4 to 1.5)
Uterine fibroids	8.0 (7.3 to 8.7)	13.6 (12.3 to 14.8)	69.5 (68.2 to 70.8)	-3.2 (-3.4 to -2.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	23.4 (5.6 to 38.3)	-31.7 (-41.5 to -23.1)
Polycystic ovarian syndrome	7.6 (6.9 to 8.4)	13.0 (11.7 to 14.5)	71.7 (47.7 to 96.5)	-7.5 (-19.8 to 4.9)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	73.5 (48.9 to 98.6)	-6.6 (-19.0 to 6.3)
Female infertility due to other causes	1.6 (0.5 to 2.7)	3.8 (2.2 to 5.6)	145.6 (21.2 to 342.8)	37.1 (-34.8 to 236.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	155.1 (17.8 to 531.4)	32.6 (-33.7 to 246.2)
Endometriosis	0.8 (0.6 to 0.9)	1.4 (1.2 to 1.7)	88.6 (49.4 to 135.6)	-0.2 (-20.8 to 24.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	90.0 (48.1 to 142.1)	0.6 (-21.7 to 27.6)
Genital prolapse	15.0 (12.5 to 17.2)	25.9 (22.3 to 30.1)	72.9 (40.6 to 115.8)	-6.1 (-23.7 to 14.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	73.7 (38.9 to 118.5)	-5.8 (-23.4 to 16.1)
Premenstrual syndrome	13.0 (7.7 to 20.3)	27.5 (17.4 to 37.8)	114.7 (20.0 to 270.3)	13.0 (-37.5 to 89.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	113.8 (19.6 to 271.7)	13.3 (-38.7 to 91.9)
Other gynecological diseases	1.6 (1.1 to 2.0)	1.6 (1.3 to 1.9)	1.0 (-22.7 to 41.3)	-43.4 (-56.7 to -21.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-25.9 (-56.4 to 57.0)	-59.4 (-75.6 to -18.8)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.5 (0.3 to 0.7)	0.7 (0.4 to 0.9)	33.8 (20.7 to 51.2)	9.4 (-2.2 to 25.0)
Thalassemias	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	3.7 (-7.3 to 23.3)	-5.4 (-15.1 to 10.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.5 (-26.7 to 22.0)	-13.4 (-33.3 to 9.1)
Thalassemia trait	16.0 (12.5 to 20.1)	23.2 (18.8 to 28.8)	44.5 (38.5 to 54.6)	2.4 (-1.9 to 9.6)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	72.2 (48.8 to 99.2)	37.5 (15.9 to 60.7)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.7 (-18.1 to 50.6)	-12.2 (-31.9 to 16.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.1 (-6.8 to 49.8)	-15.0 (-27.4 to 8.1)
Sickle cell trait	12.4 (10.6 to 14.2)	15.1 (13.0 to 17.2)	21.5 (15.1 to 27.8)	-13.9 (-18.5 to -9.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	52.9 (5.9 to 161.4)	26.7 (-18.5 to 137.3)
G6PD deficiency	9.8 (7.3 to 12.2)	13.8 (10.3 to 17.8)	42.2 (-7.4 to 106.8)	0.6 (-34.5 to 46.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.5 (53.5 to 82.9)	33.3 (24.1 to 45.4)
G6PD trait	83.9 (74.3 to 92.1)	110.0 (93.7 to 122.7)	32.4 (6.3 to 56.2)	-5.7 (-24.3 to 11.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.7 (-73.5 to 371.1)	32.6 (-73.3 to 293.1)
Other hemoglobinopathies and hemolytic anemias	5.1 (4.2 to 5.9)	3.4 (3.0 to 3.9)	-34.9 (-44.6 to -17.8)	-0.1 (-58.6 to 42.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-39.4 (-56.8 to -9.9)	-8.9 (-62.7 to 25.1)
Endocrine, metabolic, blood, and immune disorders	6.9 (6.3 to 7.6)	6.0 (5.5 to 6.6)	-12.9 (-25.0 to 2.7)	-20.2 (-38.4 to -19.8)	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	26.2 (30.2 to 859.8)	26.2 (-38.4 to -12.4)
Musculoskeletal disorders	-	-	-	-	6.7 (4.7 to 9.0)	12.3 (8.8 to 16.7)	85.8 (63.4 to 111.5)	2.6 (-8.5 to 15.1)
Rheumatoid arthritis	0.8 (0.7 to 0.8)	1.1 (1.0 to 1.2)	42.7 (30.0 to 56.4)	-20.7 (-28.0 to -12.6)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	42.3 (26.7 to 60.1)	-20.4 (-28.0 to -11.1)
Osteoarthritis	7.0 (6.7 to 7.3)	13.1 (12.5 to 13.7)	86.3 (74.7 to 98.3)	-2.1 (-8.2 to 4.1)	0.4 (0.3 to 0.6)	0.8 (0.6 to 1.1)	85.8 (74.1 to 98.5)	-1.6 (-7.8 to 4.8)
Low back and neck pain	-	-	-	-	5.3 (3.6 to 7.3)	9.7 (6.7 to 13.3)	80.0 (56.6 to 115.0)	1.5 (-12.0 to 18.7)
Low back pain	36.5 (30.5 to 42.8)	66.6 (57.9 to 74.7)	82.2 (49.6 to 125.9)	0.7 (-15.1 to 23.2)	4.1 (2.7 to 5.8)	7.5 (5.0 to 10.5)	82.6 (49.9 to 126.1)	1.3 (-14.5 to 23.7)
Neck pain	12.5 (10.8 to 14.2)	22.8 (19.6 to 25.8)	82.5 (50.5 to 117.4)	1.0 (-14.5 to 18.8)	1.2 (0.8 to 1.7)	2.3 (1.5 to 3.2)	83.1 (50.4 to 118.7)	1.3 (-14.7 to 19.6)
Gout	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	98.6 (67.1 to 134.3)	0.0 (-8.6 to 25.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.8 (51.7 to 159.1)	8.6 (-19.5 to 44.3)
Other musculoskeletal disorders	8.0 (6.2 to 10.3)	17.1 (13.0 to 21.1)	113.6 (94.7 to 135.1)	16.9 (6.8 to 27.2)	0.7 (0.5 to 1.1)	1.6 (1.0 to 2.3)	114.6 (95.6 to 136.6)	17.7 (7.4 to 28.2)
Other non-communicable diseases	-	-	-	-	7.4 (4.9 to 10.8)	11.7 (7.8 to 17.0)	57.7 (50.6 to 64.2)	-6.4 (-9.7 to -3.2)
Congenital anomalies	-	-	-	-	0.3 (0.2 to 0.5)	0.7 (0.5 to 1.0)	110.4 (71.4 to 165.6)	54.7 (27.1 to 94.3)
Neural tube defects	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	322.1 (237.1 to 432.0)	262.2 (189.1 to 358.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	410.3 (250.5 to 658.0)	353.1 (210.3 to 569.7)
Congenital heart anomalies	0.4 (0.2 to 0.5)	2.6 (2.1 to 3.2)	995.1 (359.5 to 2089.6)	477.7 (279.4 to 834.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	512.6 (305.2 to 859.8)	410.3 (241.3 to 704.0)
Orofacial clefts	0.0 (0.0 to 0.1)	0.4 (0.3 to 0.5)	844.7 (496.1 to 1,550.6)	785.2 (447.4 to 1,482.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	785.2 (369.4 to 1,460.5)	683.4 (338.6 to 1,374.0)
Down syndrome	0.4 (0.3 to 0.4)	1.0 (0.8 to 1.1)	157.9 (103.8 to 220.7)	105.4 (60.9 to 156.9)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	171.9 (109.8 to 247.2)	116.9 (69.1 to 178.7)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	116.6 (39.7 to 208.7)	62.4 (4.6 to 131.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	126.1 (48.9 to 234.8)	62.5 (5.1 to 134.3)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.1 (-3.9 to 115.0)	2.5 (-31.1 to 53.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.1 (15.2 to 157.5)	3.0 (-31.2 to 54.7)
Chromosomal unbalanced rearrangements	0.4 (0.3 to 0.5)	1.0 (0.8 to 1.2)	147.6 (90.7 to 229.5)	97.0 (50.5 to 161.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	161.7 (96.9 to 254.3)	108.9 (56.2 to 180.8)
Other congenital anomalies	2.3 (1.6 to 2.9)	3.1 (2.3 to 3.9)	32.2 (12.9 to 59.2)	-12.4 (-24.4 to 2.7)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	46.0 (12.2 to 105.8)	2.9 (-21.3 to 43.4)
Skin and subcutaneous diseases	-	-	-	-	2.5 (1.6 to 4.0)	4.0 (2.5 to 6.1)	56.4 (42.0 to 70.5)	2.8 (-6.6 to 10.8)
Dermatitis	14.8 (12.2 to 18.3)	23.2 (18.7 to 28.6)	56.0 (51.0 to 61.2)	-0.2 (-0.5 to -0.0)	0.4 (0.3 to 0.6)	0.7 (0.4 to 1.0)	51.9 (43.8 to 59.6)	0.0 (-3.1 to 3.6)
Psoriasis	3.2 (2.6 to 3.9)	5.4 (4.3 to 6.6)	68.5 (64.5 to 72.3)	0.3 (-0.2 to 0.3)	0.4 (0.2 to 0.4)	0.4 (0.3 to 0.6)	68.5 (56.7 to 80.7)	0.4 (-5.0 to 6.1)
Cellulitis	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	28.6 (7.3 to 58.5)	-14.1 (-28.9 to 5.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.9 (-3.1 to 71.6)	-12.7 (-34.4 to 12.0)
Pyoderma	0.8 (0.6 to 1.1)	0.7 (0.5 to 0.9)	-20.5 (-33.1 to -6.8)	-28.2 (-36.1 to -19.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.1 (-34.1 to -4.8)	-28.4 (-37.7 to -17.8)
Scabies	6.6 (5.6 to 7.8)	8.9 (7.4 to 10.7)	34.1 (4.7 to 69.2)	-3.0 (-21.7 to 22.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	33.9 (4.7 to 69.9)	-2.8 (-22.1 to 22.6)
Fungal skin diseases	34.7 (25.5 to 45.5)	53.2 (39.8 to 68.9)	53.9 (43.8 to 64.2)	9.8 (0.4 to 1.1)	0.3 (0.1 to 0.4)	0.3 (0.1 to 0.6)	58.8 (43.5 to 64.4)	1.0 (0.1 to 2.0)
Viral skin diseases	11.1 (8.4 to 13.7)	13.2 (9.7 to 17.2)	19.0 (6.7 to 31.3)	-0.5 (-4.2 to 3.0)	0.1 (0.2 to 0.5)	0.4 (0.2 to 0.7)	19.0 (6.4 to 31.7)	-0.2 (-4.0 to 4.4)
Acne vulgaris	58.3 (47.3 to 69.3)	92.8 (77.3 to 108.9)	58.4 (24.1 to 106.7)	7.3 (-16.7 to 38.9)	0.6 (0.3 to 1.2)	1.0 (0.5 to 1.9)	58.5 (23.9 to 107.9)	7.4 (-16.9 to 39.1)
Alopecia areata	0.4 (0.4 to 0.5)	0.7 (0.6 to 0.7)	56.7 (37.0 to 76.8)	-0.6 (-12.5 to 11.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.2 (30.9 to 84.1)	-0.0 (-14.2 to 16.5)
Pruritus	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	54.6 (12.2 to 118.1)	7.3 (-32.5 to 32.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.7 (2.0 to 139.4)	-6.5 (-36.0 to 45.2)
Urticaria	5.6 (4.1 to 7.3)	10.8 (8.0 to 13.8)	94.2 (26.7 to 177.8)	5.7 (-29.4 to 49.9)	0.3 (0.2 to 0.5)	0.6 (0.4 to 1.0)	95.2 (26.7 to 180.9)	6.2 (-28.9 to 51.1)
Decubitus ulcer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	110.3 (68.5 to 153.7)	7.6 (-19.5 to 34.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.9 (62.7 to 157.2)	7.0 (-19.0 to 38.6)
Other skin and subcutaneous diseases	21.7 (14.8 to 31.3)	36.8 (24.5 to 54.1)	69.1 (54.9 to 82.7)	-0.6 (-5.9 to 4.2)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.4)	69.1 (54.1 to 82.6)	-0.1 (-5.7 to 4.7)
Sense organ diseases	-	-	-	-	3.5 (2.4 to 5.1)	5.3 (3.6 to 7.5)	89.5 (48.7 to 58.7)	-13.5 (-17.3 to -10.1)
Glaucoma	0.8 (0.6 to 1.0)	1.2 (1.0 to 1.5)	51.2 (17.7 to 104.6)	-20.9 (-38.2 to 8.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	52.3 (21.1 to 97.0)	-19.2 (-35.8 to 5.7)
Cataract	4.6 (3.6 to 5.7)	7.2 (5.8 to 8.4)	56.2 (30.0 to 81.7)	-23.9 (-34.0 to -15.3)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	58.3 (36.7 to 87.1)	-24.2 (-31.9 to -14.2)
Macular degeneration	0.3 (0.2 to 0.4)	0.7 (0.5 to 1.1)	131.1 (44.8 to 263.0)	15.8 (-24.2 to 73.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	127.5 (59.6 to 221.3)	1.2 (-25.8 to 37.3)
Uncorrected refractive error	37.7 (34.2 to 41.5)	56.5 (51.5 to 62.3)	49.3 (31.3 to 70.0)	-12.7 (-23.0 to -0.2)	0.9 (0.6 to 1.4)	1.3 (0.9 to 2.0)	39.2 (38.5 to 50.4)	-18.0 (-23.2 to -12.1)
Age-related and other hearing loss	53.1 (44.4 to 61.1)	88.8 (74.7 to 101.5)	67.0 (58.2 to 77.4)	-7.3 (-10.4 to -2.8)	1.8 (1.1 to 2.7)	2.8 (1.8 to 4.2)	60.1 (43.9 to 78.1)	-9.0 (-15.1 to -3.2)
Other vision loss	2.6 (2.1 to 3.1)	3.0 (2.4 to 3.5)	15.3 (3.6 to 36.2)	-29.9 (-38.4 to -14.3)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	13.3 (1.1 to 31.0)	-31.0 (-39.4 to -20.0)
Other sense organ diseases	12.6 (11.9 to 13.3)	16.1 (15.4 to 16.9)	28.1 (19.1 to 37.1)	-0.9 (-7.0 to 5.4)	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	27.3 (17.0 to 38.0)	-0.7 (-7.1 to 6.7)
Oral disorders	-	-	-	-	1.0 (0.6 to 1.6)	1.7 (1.1 to 2.7)	70.9 (64.0 to 78.5)	4.7 (-8.6 to 0.6)
Deciduous caries	58.1 (55.7 to 60.8)	51.2 (49.0 to 53.3)	-12.0 (-16.6 to -6.5)	-0.6 (-5.8 to 5.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.3 (-18.4 to 4.6)	-0.3 (-7.8 to 7.7)
Permanent caries	167.7 (148.6 to 182.1)	275.0 (251.6 to 296.3)	63.1 (45.3 to 90.8)	2.3 (-8.2 to 19.4)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.5)	63.0 (44.7 to 90.8)	2.4 (-8.4 to 19.5)
Periodontal diseases	25.9 (24.1 to 27.7)	47.4 (43.8 to 50.7)	83.3 (65.7 to 100.7)	3.0 (-7.5 to 12.9)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.6)	83.6 (65.5 to 101.2)	3.3 (-7.2 to 13.4)

Appendix Table G.4 - Bhutan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	15.5 (14.7 to 16.3)	27.3 (26.1 to 28.4)	76.6 (64.6 to 89.4)	-9.7 (-14.8 to -3.9)	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.0)	76.0 (64.1 to 89.7)	-5.3 (-14.5 to -3.2)
Other oral disorders	7.8 (7.4 to 8.3)	13.0 (12.1 to 13.7)	65.5 (51.8 to 78.3)	-0.2 (-7.7 to 7.5)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	65.6 (51.6 to 79.7)	0.2 (-7.8 to 8.1)
Injuries	-	-	-	-	2.4 (1.8 to 3.0)	2.8 (2.1 to 3.7)	18.6 (10.9 to 27.7)	-29.8 (-34.3 to -24.8)
Transport injuries	-	-	-	-	0.9 (0.7 to 1.2)	1.0 (0.7 to 1.3)	6.5 (1.7 to 16.5)	-35.7 (-40.3 to -30.2)
Road injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.8 (0.6 to 1.0)	13.2 (3.8 to 24.6)	-30.3 (-35.6 to -23.8)
Pedestrian road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	12.8 (1.4 to 26.7)	-28.9 (-35.3 to -21.4)
Cyclist road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	10.6 (0.9 to 21.6)	-30.1 (-35.9 to -23.7)
Motorcyclist road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-3.5 (-14.2 to 8.9)	-42.0 (-48.0 to -35.2)
Motor vehicle road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	26.1 (13.0 to 41.6)	-23.5 (-30.9 to -15.1)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.1 (-19.1 to -0.3)	-47.2 (-51.9 to -41.9)
Other transport injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-14.8 (-22.4 to -6.6)	-50.8 (-54.9 to -46.2)
Unintentional injuries	-	-	-	-	1.4 (1.1 to 1.8)	1.7 (1.3 to 2.3)	24.7 (17.4 to 32.1)	-27.6 (-31.6 to -23.1)
Falls	-	-	-	-	0.5 (0.3 to 0.6)	0.6 (0.5 to 0.9)	43.5 (32.6 to 55.3)	-23.7 (-29.6 to -17.0)
Drowning	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-7.8 (-18.2 to 4.6)	-41.8 (-47.7 to -34.9)
Fire, heat, and hot substances	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-27.0 (-33.8 to -19.1)	-54.1 (-57.8 to -49.8)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.2 (4.3 to 48.0)	-22.1 (-33.9 to -9.8)
Exposure to mechanical forces	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	40.7 (31.8 to 50.1)	-17.6 (-22.5 to -12.8)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.6 (23.1 to 51.9)	-22.9 (-30.2 to -14.9)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.2 (21.4 to 53.1)	-17.8 (-25.6 to -9.3)
Other exposure to mechanical forces	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	41.0 (32.0 to 50.5)	-17.4 (-22.4 to -12.4)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.9 (50.3 to 69.9)	-5.4 (-11.1 to 0.9)
Animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-10.7 (-17.3 to -2.5)	-45.3 (-48.8 to -41.1)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-5.9 (-15.8 to 6.6)	-43.9 (-49.2 to -37.1)
Non-venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-13.8 (-21.5 to -5.1)	-46.2 (-50.2 to -41.4)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.1 (28.7 to 49.2)	-19.2 (-24.4 to -13.6)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.1 (-11.0 to 19.5)	-33.2 (-40.7 to -25.3)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.6 (37.8 to 66.6)	-5.0 (-12.6 to 4.3)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.5 (30.8 to 56.7)	-19.4 (-25.9 to -12.2)
Other unintentional injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.5)	59.1 (45.5 to 74.5)	-9.7 (-17.0 to -1.6)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-13.6 (-21.2 to -4.3)	-49.0 (-53.2 to -43.7)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.1 (-3.6 to 17.1)	-41.0 (-46.0 to -35.2)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-16.7 (-24.9 to -6.8)	-50.4 (-54.8 to -44.9)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.8 (-19.7 to -3.1)	-47.9 (-52.2 to -43.1)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.2 (-17.6 to 7.7)	-46.4 (-52.0 to -38.2)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.0 (-29.2 to -10.8)	-52.4 (-57.2 to -46.7)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.1)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.1)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Bolivia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	601.8 (445.6 to 790.6)	993.2 (733.9 to 1,296.6)	65.0 (61.5 to 69.2)	65.0 (3.3 to 1.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	122.9 (84.5 to 171.5)	165.3 (116.3 to 227.6)	34.3 (27.3 to 43.4)	-5.7 (-11.0 to 1.4)
HIV/AIDS and tuberculosis	-	-	-	-	3.3 (2.1 to 4.4)	6.1 (3.8 to 12.2)	71.1 (49.2 to 228.6)	0.7 (-11.2 to 94.9)
Tuberculosis	10.1 (9.6 to 10.6)	15.6 (14.9 to 16.4)	54.1 (47.2 to 62.3)	-9.1 (-12.8 to -4.5)	3.1 (2.1 to 4.2)	4.8 (3.3 to 6.5)	54.4 (41.9 to 67.4)	-8.8 (-15.3 to -2.8)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.6)	1.3 (0.2 to 7.1)	3,906.5 (388.2 to 93,306.3)	3,371.1 (-15.6 to 56,680.5)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.6)	3,009.2 (-23.4 to 59,888.1)	1,809.2 (53.2 to 36,975.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.3)	3,009.2 (25.2 to 60,262.7)	1,809.2 (-54.6 to 37,127.7)
HIV/AIDS resulting in other diseases	1.6 (0.0 to 5.5)	8.9 (2.0 to 39.6)	4,291.7 (34.2 to 53,438.0)	2,745.2 (-16.1 to 33,653.9)	0.1 (0.0 to 0.6)	1.2 (0.1 to 7.1)	5,070.4 (30.3 to 249,406.9)	3,237.7 (-22.6 to 154,689.6)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	26.7 (18.6 to 36.7)	30.4 (21.3 to 41.4)	13.8 (7.2 to 20.6)	-13.4 (-17.6 to -8.6)
Diarrheal diseases	124.2 (118.5 to 130.0)	136.8 (128.6 to 143.8)	9.9 (1.7 to 17.8)	-13.4 (-19.4 to -7.6)	20.1 (13.6 to 28.0)	22.1 (15.1 to 30.3)	9.6 (2.1 to 18.3)	13.6 (-19.6 to -6.8)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-47.8 to -10.1)	0.0 (-64.5 to -39.7)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.4 (-22.4 to 10.8)	-37.9 (-47.7 to -25.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.4 (-22.6 to 10.8)	-37.9 (-47.8 to -25.8)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.6 (-26.6 to 12.6)	-39.7 (-50.5 to -22.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.6 (-26.6 to 12.6)	-39.7 (-50.6 to -22.8)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.8 (-95.0 to -61.2)	-90.4 (-96.7 to -73.4)
Lower respiratory infections	10.9 (9.5 to 12.1)	9.6 (8.6 to 10.6)	-12.0 (-24.0 to 5.3)	-33.7 (-41.2 to -24.4)	1.1 (0.8 to 1.6)	1.0 (0.7 to 1.4)	-12.1 (-26.0 to 6.3)	-33.6 (-42.3 to -22.9)
Upper respiratory infections	238.8 (227.1 to 250.6)	371.6 (353.4 to 388.9)	55.4 (45.6 to 65.2)	0.6 (-5.7 to 7.0)	2.8 (1.6 to 4.8)	4.4 (2.5 to 7.3)	55.1 (45.4 to 66.3)	0.7 (-0.9 to 7.3)
Otitis media	83.9 (78.6 to 89.2)	113.9 (107.2 to 120.8)	35.5 (26.6 to 47.1)	-9.0 (-14.7 to -1.9)	1.6 (1.0 to 2.6)	2.2 (1.3 to 3.5)	33.1 (22.0 to 45.2)	-10.4 (-17.6 to -2.9)
Meningitis	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.4)	-6.9 (-25.1 to 22.2)	-38.6 (-50.2 to -21.2)
Pneumococcal meningitis	0.9 (0.5 to 1.4)	0.8 (0.5 to 1.3)	-7.9 (-26.0 to 20.3)	-42.8 (-53.1 to -27.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	0.1 (-33.5 to 53.1)	-38.0 (-56.0 to -5.1)
H influenzae type B meningitis	0.6 (0.2 to 1.1)	0.5 (0.2 to 0.9)	-17.6 (-41.9 to 23.5)	-47.3 (-62.1 to -21.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-13.0 (-43.9 to 70.3)	-42.5 (-62.7 to 9.6)
Meningococcal meningitis	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.3)	-18.6 (-45.0 to 17.1)	-48.7 (-63.6 to -24.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-50.1 to 36.7)	-45.5 (-66.3 to -12.5)
Other meningitis	0.6 (0.3 to 1.1)	0.5 (0.3 to 1.0)	-11.8 (-38.5 to 21.7)	-42.1 (-58.4 to -20.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-5.8 (-45.7 to 53.8)	-36.0 (-62.1 to 3.1)
Encephalitis	0.6 (0.3 to 1.3)	0.8 (0.4 to 1.8)	39.0 (22.5 to 58.5)	-55.8 (-24.2 to -4.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	0.1 (-1.1 to 1.3)	-39.0 (-21.3 to 6.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.0 (-99.3 to 122.9)	-86.6 (-99.2 to 31.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-86.0 (-99.3 to 125.6)	-86.6 (-99.2 to 32.6)
Whooping cough	11.3 (8.7 to 14.6)	4.9 (3.8 to 6.2)	-57.0 (-59.7 to -54.2)	-64.0 (-66.3 to -61.6)	0.6 (0.3 to 0.9)	0.2 (0.1 to 0.4)	-56.9 (-61.6 to -51.8)	-63.9 (-67.9 to -59.6)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.6 (-97.6 to -92.0)	-97.2 (-98.4 to -94.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-94.2 (-96.8 to -88.4)	-96.2 (-97.9 to -91.9)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	5.4 (5.0 to 5.8)	7.5 (6.7 to 8.4)	38.5 (20.0 to 58.1)	-3.7 (-22.0 to 18.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	62.6 (13.9 to 128.7)	-4.6 (-35.4 to 39.5)
Neglected tropical diseases and malaria	-	-	-	-	18.9 (12.4 to 27.9)	27.8 (18.2 to 40.6)	46.9 (22.5 to 73.4)	-8.0 (-21.4 to 9.3)
Malaria	8.4 (5.7 to 11.2)	12.2 (9.2 to 17.1)	45.5 (3.2 to 103.5)	-4.7 (-33.7 to 34.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	74.8 (-1.5 to 219.4)	20.0 (-32.6 to 109.1)
Chagas disease	515.8 (489.1 to 542.4)	796.1 (757.1 to 839.4)	54.3 (43.0 to 65.4)	-7.1 (-13.7 to 0.0)	3.9 (2.5 to 5.4)	6.5 (4.3 to 9.2)	69.7 (54.7 to 85.2)	-7.0 (-15.2 to 1.2)
Leishmaniasis	-	-	-	-	0.5 (0.2 to 1.0)	0.4 (0.2 to 0.8)	-17.4 (-31.7 to 1.2)	-54.1 (-61.1 to -44.4)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.7 (-49.8 to 292.4)	-3.1 (-58.9 to 144.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.7 (-50.3 to 293.8)	-3.1 (-59.5 to 145.2)
Cutaneous and mucocutaneous leishmaniasis	47.4 (34.7 to 63.3)	39.1 (30.0 to 50.7)	-17.6 (-31.6 to 0.6)	-54.2 (-61.1 to -44.9)	0.5 (0.2 to 1.0)	0.4 (0.2 to 0.8)	-17.5 (-31.7 to 1.2)	-54.1 (-61.1 to -44.4)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	8.7 (4.6 to 16.0)	4.9 (2.5 to 9.8)	-42.6 (-81.1 to 61.4)	-64.3 (-86.8 to -15.3)	2.3 (1.1 to 4.6)	1.4 (0.7 to 3.0)	-35.9 (-79.4 to 90.1)	-59.8 (-85.5 to 0.1)
Cystic echinococcosis	0.4 (0.3 to 0.4)	0.3 (0.2 to 0.3)	-26.5 (-43.0 to -12.6)	-56.6 (-66.3 to -49.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-25.5 (-48.6 to 0.4)	-56.6 (-70.2 to -40.7)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.3 (0.1 to 0.7)	2.0 (0.6 to 5.5)	664.1 (654.8 to 674.9)	386.4 (380.4 to 393.2)	0.0 (0.0 to 0.1)	0.3 (0.1 to 0.9)	623.1 (491.5 to 763.2)	357.1 (281.0 to 440.4)
Yellow fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.9 (-69.5 to -57.0)	-77.0 (-80.2 to -73.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.9 (-69.6 to -57.0)	-77.0 (-80.3 to -73.1)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.3 (-78.5 to 1.8)	-61.5 (-85.3 to -37.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.9 (-78.6 to 2.1)	-61.5 (-85.3 to -37.9)
Intestinal nematode infections	-	-	-	-	4.8 (2.6 to 8.8)	8.9 (5.2 to 14.8)	83.8 (20.7 to 193.2)	24.9 (-22.8 to 112.2)
Ascariasis	820.7 (600.2 to 1,119.7)	638.1 (436.0 to 881.7)	-22.5 (-50.6 to 24.3)	-50.9 (-70.5 to -16.1)	2.1 (0.9 to 4.6)	0.2 (0.1 to 0.5)	-91.4 (-96.7 to -76.6)	-93.4 (-97.5 to -80.3)
Trichuriasis	557.2 (393.8 to 775.1)	766.3 (524.2 to 1,092.6)	36.6 (-17.8 to 133.0)	-14.7 (-52.1 to 55.8)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.4)	108.4 (-51.0 to 796.8)	29.6 (-73.2 to 524.6)
Hookworm disease	556.2 (408.6 to 772.0)	1,437.0 (1,059.4 to 1,927.5)	160.3 (64.3 to 300.5)	62.2 (-2.9 to 157.2)	8.5 (1.5 to 4.8)	7.7 (5.1 to 14.2)	217.3 (89.9 to 434.1)	97.7 (3.4 to 262.0)
Food-borne trematodiasis	141.8 (101.8 to 186.6)	246.7 (171.1 to 338.1)	73.7 (28.1 to 127.8)	-1.5 (-27.4 to 28.9)	2.9 (0.7 to 6.7)	5.1 (1.2 to 12.1)	73.7 (23.3 to 127.2)	-1.1 (-27.3 to 29.0)
Other neglected tropical diseases	109.3 (76.4 to 143.7)	127.6 (120.3 to 136.0)	16.7 (-10.7 to 65.7)	-13.3 (-33.2 to 21.6)	4.4 (2.6 to 6.4)	5.0 (3.3 to 7.3)	12.6 (1.1 to 76.5)	-14.7 (-22.9 to 36.3)
Maternal disorders	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	35.0 (5.6 to 70.0)	-20.4 (-36.9 to 0.0)
Maternal hemorrhage	0.7 (0.5 to 0.8)	1.6 (1.2 to 2.0)	139.8 (61.0 to 260.3)	39.6 (-6.2 to 104.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	132.8 (1.2 to 397.9)	43.3 (-37.1 to 201.0)
Maternal sepsis and other maternal infections	1.0 (0.7 to 1.4)	1.0 (0.7 to 1.5)	-	-41.7 (-14.2 to 23.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.5 (-11.8 to 19.4)	-40.8 (-49.5 to -31.1)
Maternal hypertensive disorders	1.4 (1.0 to 2.0)	1.6 (1.1 to 2.2)	10.1 (1.3 to 16.6)	-35.7 (-41.4 to -31.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	10.2 (-10.8 to 35.4)	-35.6 (-47.3 to -21.1)
Obstructed labor	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	20.5 (8.1 to 33.8)	-28.9 (-35.8 to -21.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.8 (-20.4 to 92.5)	-25.2 (-51.1 to 5.9)
Complications of abortion	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	11.4 (2.9 to 20.6)	-35.0 (-39.6 to -29.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.8 (-46.4 to 114.2)	-34.1 (-66.3 to 23.1)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.5 (-15.8 to 106.9)	21.5 (-50.7 to 22.1)
Neonatal disorders	-	-	-	-	4.2 (2.7 to 6.4)	18.4 (11.7 to 25.5)	351.3 (130.6 to 621.0)	211.9 (60.4 to 404.2)
Preterm birth complications	17.9 (9.2 to 31.9)	75.1 (44.2 to 121.9)	321.9 (198.6 to 529.0)	175.1 (99.8 to 306.1)	1.6 (0.9 to 2.6)	9.5 (5.7 to 15.2)	507.2 (191.2 to 1,033.9)	315.0 (102.7 to 675.9)
Neonatal encephalopathy due to birth asphyxia and trauma	31.9 (7.5 to 74.6)	37.1 (14.1 to 90.8)	19.3 (-14.2 to 121.9)	-24.3 (-45.2 to 40.4)	1.3 (0.6 to 2.5)	3.9 (2.3 to 5.9)	199.1 (65.2 to 495.5)	108.7 (10.9 to 323.6)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.3)	113.4 (100.4 to 125.1)	93.2 (81.5 to 103.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.2 (91.4 to 137.2)	114.8 (73.3 to 114.7)
Hemolytic disease and other neonatal jaundice	2.6 (1.1 to 6.1)	9.2 (4.7 to 15.0)	179.8 (6.1 to 978.5)	297.4 (-25.5 to 673.9)	1.0 (0.4 to 2.1)	3.5 (1.7 to 6.1)	298.9 (9.1 to 1,044.2)	180.7 (-23.1 to 692.7)
Other neonatal disorders	-	-	-	-	0.3 (0.1 to 0.7)	1.4 (0.7 to 2.5)	389.9 (49.4 to 1,127.2)	238.4 (3.7 to 737.7)
Nutritional deficiencies	-	-	-	-	65.0 (43.0 to 93.0)	76.7 (51.1 to 110.0)	18.0 (14.6 to 20.3)	-16.9 (-18.7 to -15.4)
Protein-energy malnutrition	13.0 (9.5 to 17.4)	9.2 (6.2 to 13.3)	-29.7 (-55.8 to 11.6)	-41.7 (-60.3 to -17.2)	1.6 (0.9 to 2.5)	1.1 (0.6 to 1.9)	29.6 (56.9 to 14.2)	-42.1 (-60.9 to -17.8)
Iodine deficiency	1.7 (1.2 to 2.3)	1.5 (1.0 to 2.0)	-11.7 (-46.4 to 31.9)	-47.9 (-67.8 to -21.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-9.6 (-43.7 to 42.7)	-46.9 (-68.8 to -17.1)
Vitamin A deficiency	3.6 (2.6 to 4.6)	2.5 (1.8 to 3.3)	-30.4 (-41.6 to -16.1)	-52.4 (-59.9 to -42.4)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-34.5 (-46.9 to -19.6)	-55.6 (-63.3 to -46.1)

Appendix Table G.4 - Bolivia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	1,672.0 (1,640.4 to 1,703.4)	2,079.6 (2,060.8 to 2,099.2)	24.2 (21.9 to 26.9)	-15.3 (-16.6 to -13.8)	63.2 (42.3 to 91.1)	75.4 (50.3 to 108.7)	19.4 (16.1 to 21.3)	19.4 (-18.0 to -14.9)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-34.8 (-67.9 to 27.8)	-46.5 (-73.0 to -3.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	4.6 (3.0 to 6.8)	5.8 (3.6 to 8.7)	25.0 (13.9 to 37.8)	-13.5 (-20.2 to -6.3)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.2 (0.7 to 2.2)	1.9 (1.1 to 3.3)	53.9 (33.1 to 73.5)	-10.8 (-21.6 to -0.7)
Syphilis	0.3 (0.3 to 0.4)	0.3 (0.3 to 0.3)	-7.7 (-23.1 to 9.5)	-49.2 (-56.7 to -40.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-7.2 (-32.3 to 28.9)	-48.7 (-61.9 to -30.8)
Chlamydial infection	94.5 (69.0 to 123.6)	178.4 (139.1 to 222.6)	88.9 (28.9 to 188.0)	11.2 (-23.6 to 68.2)	0.6 (0.4 to 1.0)	1.0 (0.6 to 1.6)	66.7 (32.1 to 107.3)	-1.0 (-20.3 to 20.9)
Gonococcal infection	20.3 (16.7 to 24.3)	27.6 (22.9 to 33.6)	36.1 (4.3 to 74.4)	-18.9 (-37.1 to 1.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	17.3 (-23.6 to 63.5)	-31.0 (-53.9 to -4.0)
Trichomoniasis	68.7 (50.7 to 90.0)	104.6 (70.1 to 143.9)	50.9 (-4.7 to 139.3)	-8.5 (-40.4 to 41.1)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.4)	49.1 (-12.7 to 149.5)	-9.6 (-44.7 to 48.0)
Genital herpes	1,082.7 (1,050.6 to 1,116.9)	1,758.5 (1,700.2 to 1,815.3)	62.4 (54.8 to 69.3)	-8.8 (-12.6 to -5.1)	0.3 (0.1 to 0.7)	0.5 (0.1 to 1.1)	60.7 (49.2 to 69.7)	46.9 (-14.4 to 4.5)
Other sexually transmitted diseases	1.3 (1.0 to 1.7)	1.4 (1.1 to 1.8)	-39.9 (-7.1 to 25.4)	6.1 (-47.2 to 29.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.7 (4.7 to 103.2)	19.0 (-43.2 to 14.0)
Hepatitis	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	45.4 (29.7 to 60.9)	-9.6 (-18.9 to 0.2)
Hepatitis A	10.2 (9.7 to 10.6)	13.9 (13.4 to 14.4)	36.5 (35.4 to 37.5)	-3.6 (-3.6 to -3.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	53.1 (35.5 to 69.6)	-0.5 (-10.8 to 10.4)
Hepatitis B	161.2 (149.9 to 173.5)	167.5 (155.0 to 179.9)	3.5 (-6.9 to 14.2)	-33.3 (-41.0 to -28.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	23.9 (5.4 to 64.5)	-26.5 (-43.7 to -3.3)
Hepatitis C	97.3 (88.9 to 106.4)	119.6 (108.2 to 131.2)	22.6 (7.1 to 40.4)	-29.2 (-36.9 to -19.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.7 (6.8 to 54.8)	-28.2 (-50.1 to 0.2)
Hepatitis E	-	-	132.5 (100.3 to 167.9)	38.8 (18.9 to 59.9)	-	-	-	-
Leprosy	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	28.1 (9.9 to 52.2)	-30.0 (-39.3 to -18.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.1 (4.4 to 74.9)	-29.6 (-47.4 to -3.8)
Other infectious diseases	75.2 (70.7 to 95.2)	87.6 (78.4 to 98.5)	16.7 (-3.2 to 27.5)	-14.5 (-27.5 to -7.2)	3.0 (1.9 to 4.4)	3.4 (2.1 to 5.0)	11.7 (-3.0 to 25.2)	-15.7 (-27.2 to -5.5)
Non-communicable diseases	-	-	-	-	790.4 (332.6 to 577.9)	790.4 (586.8 to 1,022.4)	76.8 (72.5 to 81.5)	1.1 (-0.5 to 4.2)
Neoplasms	-	-	-	-	2.9 (2.1 to 4.0)	6.1 (4.0 to 8.6)	107.3 (56.5 to 171.7)	14.0 (-11.8 to 48.4)
Esophageal cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	72.8 (8.5 to 170.1)	-9.5 (-41.7 to 37.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.3 (9.3 to 160.2)	-11.4 (-41.5 to 32.6)
Stomach cancer	3.1 (2.6 to 3.7)	4.7 (3.5 to 6.1)	49.7 (7.5 to 108.4)	-21.1 (-42.1 to 9.1)	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	44.1 (6.4 to 101.6)	-24.1 (-43.7 to 5.5)
Liver cancer	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	27.4 (16.9 to 161.0)	9.1 (-39.8 to 34.7)
Liver cancer due to hepatitis B	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	152.7 (27.3 to 354.2)	33.4 (-33.1 to 142.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	141.1 (40.7 to 289.4)	26.9 (-26.9 to 101.1)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	631.1 (223.2 to 1,591.7)	253.3 (53.7 to 735.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	593.0 (250.2 to 1,372.0)	231.1 (66.8 to 602.3)
Liver cancer due to alcohol use	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	32.6 (-31.6 to 156.1)	-34.0 (-65.8 to 23.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.1 (-23.3 to 124.2)	-7.7 (-61.8 to 9.5)
Liver cancer due to other causes	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	4.1 (-56.8 to 119.6)	-4.1 (-77.4 to 9.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.6 (-51.4 to 89.7)	21.9 (-75.2 to 3.4)
Larynx cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	214.9 (50.1 to 368.2)	76.8 (-16.9 to 165.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	128.4 (31.5 to 259.3)	25.7 (-27.1 to 97.6)
Tracheal, bronchus and lung cancer	0.5 (0.4 to 0.6)	0.9 (0.7 to 1.2)	72.8 (26.6 to 143.2)	-10.1 (-33.7 to 25.1)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	70.0 (24.6 to 151.0)	-11.5 (-33.9 to 27.8)
Breast cancer	3.5 (2.8 to 4.4)	9.5 (6.2 to 13.9)	173.1 (65.7 to 313.3)	42.8 (9.6 to 111.9)	0.3 (0.2 to 0.4)	0.7 (0.4 to 1.1)	159.6 (59.7 to 297.1)	38.5 (-12.9 to 106.2)
Cervical cancer	7.0 (5.3 to 8.8)	8.1 (4.6 to 11.4)	13.3 (-36.0 to 86.3)	-85.3 (-62.9 to 2.8)	0.6 (0.3 to 0.8)	0.6 (0.3 to 1.0)	15.3 (-36.2 to 84.2)	-35.1 (-62.3 to 2.9)
Uterine cancer	1.9 (1.2 to 3.1)	3.3 (1.8 to 5.6)	73.7 (-6.1 to 227.1)	-5.5 (-47.2 to 73.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	71.0 (-7.3 to 222.1)	-7.6 (-48.4 to 70.2)
Prostate cancer	2.1 (1.3 to 3.3)	10.4 (6.7 to 17.3)	387.6 (168.4 to 873.1)	140.0 (37.3 to 379.4)	0.2 (0.1 to 0.3)	0.9 (0.5 to 1.5)	288.0 (123.5 to 680.4)	89.8 (13.7 to 276.9)
Colon and rectum cancer	1.8 (1.5 to 2.0)	4.9 (3.8 to 6.3)	178.7 (107.2 to 265.3)	40.8 (5.3 to 83.7)	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.6)	156.8 (90.7 to 245.0)	30.4 (-2.4 to 74.1)
Lip and oral cavity cancer	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	49.2 (-7.9 to 144.2)	-21.2 (-53.0 to 27.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	47.1 (-9.3 to 140.4)	-23.4 (-55.0 to 25.9)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.3 (-17.5 to 126.3)	-21.2 (-50.1 to 28.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.2 (-14.6 to 110.5)	-24.0 (-50.5 to 18.1)
Other pharynx cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	82.4 (-11.3 to 234.6)	-4.5 (-51.2 to 67.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.7 (-9.7 to 212.6)	-8.2 (-50.5 to 58.0)
Gallbladder and biliary tract cancer	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	108.3 (23.7 to 239.7)	4.5 (-38.3 to 69.1)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	94.4 (16.0 to 212.3)	-1.6 (-41.3 to 57.1)
Pancreatic cancer	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.3)	128.7 (62.9 to 216.5)	12.8 (-18.8 to 57.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	120.5 (58.6 to 203.7)	9.0 (-23.9 to 56.1)
Malignant skin melanoma	0.9 (0.7 to 1.2)	2.1 (1.4 to 2.9)	139.9 (39.4 to 263.9)	30.8 (-19.0 to 94.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	130.0 (41.8 to 247.3)	26.1 (-19.7 to 86.7)
Non-melanoma skin cancer	3.3 (2.3 to 4.3)	7.4 (5.6 to 9.4)	123.2 (51.6 to 258.3)	10.5 (-26.1 to 71.4)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	167.7 (79.3 to 296.6)	31.1 (-15.2 to 101.6)
Ovarian cancer	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.8)	144.9 (45.7 to 297.7)	32.4 (-19.9 to 113.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	142.1 (39.8 to 310.4)	30.2 (-24.8 to 116.3)
Testicular cancer	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.5)	145.6 (18.2 to 368.7)	41.4 (-31.0 to 165.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	134.8 (6.4 to 382.1)	34.2 (-35.5 to 179.0)
Kidney cancer	0.4 (0.3 to 0.5)	1.1 (0.8 to 1.4)	174.3 (87.6 to 303.4)	49.6 (2.2 to 110.8)	0.1 (0.0 to 0.0)	0.1 (0.1 to 0.1)	163.9 (86.3 to 278.1)	40.4 (-0.9 to 100.0)
Bladder cancer	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	43.9 (4.0 to 104.2)	-26.3 (-46.5 to 3.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	43.3 (4.6 to 99.2)	-26.8 (-47.5 to 0.9)
Brain and nervous system cancer	0.4 (0.3 to 0.6)	0.8 (0.6 to 1.1)	117.2 (33.3 to 217.8)	33.7 (-9.8 to 88.0)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	116.4 (38.8 to 211.0)	26.7 (-14.3 to 79.9)
Thyroid cancer	1.1 (0.7 to 1.6)	2.3 (1.3 to 4.0)	111.1 (6.2 to 294.6)	15.0 (-40.3 to 114.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	104.2 (5.5 to 273.8)	9.5 (-42.2 to 96.9)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.2 (-24.3 to 93.5)	25.2 (-59.9 to 3.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.9 (-21.1 to 91.6)	34.4 (-58.6 to 1.7)
Hodgkin lymphoma	0.6 (0.4 to 0.9)	0.9 (0.6 to 1.3)	51.8 (-14.4 to 200.2)	9.1 (-34.1 to 98.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	53.8 (-9.8 to 193.8)	6.5 (-32.0 to 84.4)
Non-Hodgkin lymphoma	0.8 (0.6 to 1.2)	1.6 (1.2 to 2.2)	98.8 (26.0 to 391.1)	24.4 (-19.4 to 78.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	96.2 (26.4 to 184.9)	18.1 (-21.3 to 71.3)
Multiple myeloma	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.5)	139.4 (46.8 to 298.3)	25.3 (-22.3 to 102.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	129.3 (40.6 to 272.0)	17.8 (-26.7 to 93.0)
Leukemia	1.5 (0.9 to 2.4)	2.7 (1.8 to 4.0)	89.3 (-7.4 to 227.3)	35.9 (-22.6 to 114.9)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	89.6 (18.1 to 195.9)	28.3 (-14.6 to 84.2)
Other neoplasms	4.9 (3.3 to 8.1)	13.4 (9.5 to 17.4)	196.5 (36.4 to 341.9)	96.8 (13.8 to 191.9)	0.3 (0.2 to 0.6)	0.8 (0.5 to 1.3)	190.7 (42.8 to 330.7)	81.7 (11.4 to 172.5)
Cardiovascular diseases	-	-	-	-	4.1 (2.8 to 5.8)	11.8 (8.0 to 16.6)	191.3 (133.5 to 253.8)	44.6 (18.3 to 75.0)
Rheumatic heart disease	3.9 (3.7 to 4.2)	8.1 (7.4 to 8.6)	104.4 (84.0 to 123.6)	14.3 (2.9 to 25.0)	0.2 (0.2 to 0.4)	0.5 (0.3 to 0.7)	99.9 (55.0 to 165.9)	9.9 (-17.4 to 50.0)
Ischemic heart disease	26.0 (22.8 to 29.8)	93.3 (74.7 to 115.1)	256.1 (177.7 to 366.0)	73.0 (35.3 to 125.9)	1.2 (0.8 to 1.8)	5.2 (3.3 to 7.7)	314.0 (204.7 to 481.5)	95.2 (45.8 to 170.0)
Cerebrovascular disease	-	-	-	-	0.6 (0.4 to 0.8)	1.1 (0.7 to 1.4)	77.9 (47.1 to 117.9)	8.3 (-23.3 to 12.8)
Ischemic stroke	2.8 (2.4 to 3.3)	4.8 (4.2 to 5.6)	72.6 (40.7 to 114.3)	-11.3 (-27.0 to 9.6)	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.0)	73.0 (39.8 to 117.4)	-10.7 (-27.3 to 12.3)
Hemorrhagic stroke	1.2 (1.0 to 1.4)	2.2 (1.8 to 2.6)	89.3 (41.9 to 143.4)	-1.3 (-25.7 to 25.8)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	90.3 (41.9 to 147.1)	0.1 (-26.1 to 29.8)
Hypertensive heart disease	3.3 (2.4 to 4.2)	7.5 (5.9 to 9.1)	124.5 (91.6 to 170.7)	7.3 (-8.2 to 25.6)	0.4 (0.2 to 0.5)	0.8 (0.5 to 1.2)	124.7 (88.7 to 173.8)	7.7 (-8.9 to 26.3)
Cardiomyopathy and myocarditis	1.4 (1.0 to 1.9)	3.7 (2.8 to 4.6)	160.2 (104.7 to 226.8)	38.7 (6.6 to 78.5)	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.6)	159.0 (99.6 to 232.4)	40.6 (5.8 to 82.2)
Atrial fibrillation and flutter	5.3 (4.1 to 6.5)	14.9 (12.0 to 17.7)	182.2 (106.9 to 287.5)	23.3 (-17.2 to 74.6)	0.4 (0.2 to 0.5)	1.0 (0.7 to 1.5)	182.6 (108.0 to 290.1)	24.1 (-16.2 to 77.3)
Peripheral vascular disease	107.0 (76.1 to 137.0)	215.8 (163.2 to 271.4)	101.4 (35.2 to 175.4)	1.5 (-26.8 to 33.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	77.1 (-10.3 to 226.1)	-19.6 (-63.2 to 44.4)
Endocarditis	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.6)	68.5 (30.9 to 119.6)	10.2 (-14.8 to 45.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	87.1 (35.2 to 164.6)	16.5 (-17.4 to 65.6)
Other cardiovascular and circulatory diseases	14.5 (7.2 to 25.7)	38.1 (18.3 to 64.3)	167.1 (21.9 to 391.0)	40.8 (-37.5 to 174.2)	1.0 (0.5 to 1.9)	2.7 (1.2 to 4.8)	166.6 (75.4 to 394.2)	41.5 (-38.7 to 177.8)
Chronic respiratory diseases	-	-	-	-	25.1 (16.9 to 35.4)	52.6 (36.2 to 72.8)	109.7 (74.5 to 157.3)	11.5 (-9.9 to 36.9)
Chronic obstructive pulmonary disease	219.0 (208.9 to 229.0)	404.4 (384.9 to 422.1)	84.5 (78.5 to 89.9)	0.4 (-2.5 to				

Appendix Table G.4 - Bolivia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.6 (1.5 to 1.7)	3.0 (2.8 to 3.2)	87.5 (69.3 to 108.2)	11.3 (1.9 to 22.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	87.6 (51.8 to 132.7)	11.9 (7.2 to 35.4)
Urolithiasis	27.2 (19.5 to 39.7)	73.6 (54.8 to 99.4)	179.0 (112.8 to 266.6)	38.7 (8.7 to 75.6)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	201.3 (142.7 to 287.6)	63.7 (35.6 to 104.4)
Benign prostatic hyperplasia	39.5 (36.9 to 42.0)	83.1 (76.7 to 88.0)	110.5 (89.9 to 129.3)	3.1 (6.5 to 12.7)	1.4 (0.9 to 2.0)	3.0 (1.9 to 4.2)	110.7 (90.6 to 129.8)	3.7 (5.9 to 13.1)
Male infertility due to other causes	16.5 (12.3 to 21.7)	24.9 (14.5 to 33.7)	51.9 (-14.0 to 123.7)	-11.2 (48.3 to 30.3)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	53.8 (-18.9 to 131.3)	-9.9 (51.3 to 34.8)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.4)	47.3 (192.1 to 839.1)	47.3 (66.2 to 432.8)
Gynecological diseases	-	-	-	-	8.2 (5.3 to 12.2)	14.4 (9.4 to 21.5)	74.8 (56.3 to 97.9)	-0.7 (-10.9 to 11.9)
Uterine fibroids	109.3 (98.5 to 119.0)	196.2 (177.2 to 213.3)	79.2 (78.6 to 80.0)	-1.0 (-1.0 to -0.9)	2.0 (1.2 to 3.2)	3.3 (1.9 to 5.3)	63.6 (52.6 to 72.1)	-8.3 (-14.7 to -3.7)
Polycystic ovarian syndrome	116.3 (101.8 to 130.6)	200.0 (178.2 to 221.6)	71.8 (45.7 to 102.4)	-1.1 (-14.8 to 14.9)	1.1 (0.5 to 2.1)	3.9 (0.9 to 3.5)	110.6 (46.5 to 102.6)	-1.4 (-14.7 to 14.3)
Female infertility due to other causes	11.5 (6.4 to 17.3)	12.6 (6.6 to 20.7)	6.7 (-48.3 to 147.0)	0.1 (-70.9 to 36.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	47.3 (-46.9 to 148.2)	-9.8 (-70.3 to 37.2)
Endometriosis	10.9 (9.3 to 12.7)	19.6 (16.7 to 22.7)	79.7 (44.1 to 122.4)	3.0 (17.3 to 26.0)	1.0 (0.7 to 1.4)	1.8 (1.2 to 2.6)	80.2 (41.8 to 124.4)	3.1 (-18.3 to 28.0)
Genital prolapse	299.0 (248.3 to 348.3)	544.8 (463.5 to 628.6)	82.3 (43.4 to 130.6)	1.8 (-17.6 to 25.7)	1.0 (0.5 to 1.8)	1.7 (0.8 to 3.2)	82.2 (43.2 to 130.4)	1.6 (-18.5 to 25.6)
Premenstrual syndrome	270.0 (207.8 to 332.8)	526.1 (385.8 to 647.6)	95.1 (29.8 to 179.5)	11.7 (-24.6 to 64.5)	2.3 (1.3 to 3.5)	4.4 (2.6 to 7.1)	96.6 (29.0 to 179.9)	12.3 (-25.1 to 64.2)
Other gynecological diseases	27.5 (24.8 to 30.6)	40.1 (37.4 to 42.7)	45.8 (28.2 to 62.0)	-14.1 (-24.2 to -5.7)	0.8 (0.5 to 1.2)	1.2 (0.8 to 1.7)	43.3 (25.4 to 71.3)	-15.8 (-26.1 to -1.9)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	5.5 (3.7 to 8.0)	8.0 (5.4 to 11.5)	45.5 (31.9 to 65.4)	0.3 (8.6 to 12.9)
Thalassemias	0.3 (0.3 to 0.4)	0.5 (0.4 to 0.6)	46.0 (29.9 to 73.8)	6.1 (-5.4 to 25.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	53.6 (7.8 to 121.3)	12.4 (-20.1 to 58.7)
Thalassemia trait	138.5 (127.5 to 150.4)	222.7 (207.6 to 239.7)	60.5 (53.9 to 67.8)	2.2 (-2.0 to 6.8)	3.4 (2.2 to 4.9)	5.6 (3.7 to 8.0)	65.3 (46.8 to 84.3)	10.8 (-1.3 to 22.1)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.1 (6.5 to 32.5)	-19.7 (-26.0 to -8.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.4 (54.0 to 39.2)	-19.6 (-28.2 to -4.4)
Sickle cell trait	9.3 (8.4 to 10.1)	11.5 (10.4 to 12.5)	23.7 (12.5 to 37.6)	-21.7 (-28.3 to -12.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	46.7 (-13.5 to 249.2)	-6.9 (-43.5 to 156.5)
G6PD deficiency	45.1 (39.7 to 50.4)	62.3 (52.6 to 71.1)	37.7 (15.3 to 65.3)	-12.3 (-26.6 to 5.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.5 (87.6 to 159.1)	37.2 (18.6 to 78.8)
G6PD trait	718.3 (690.6 to 745.6)	1,119.8 (1,078.3 to 1,161.0)	55.5 (47.6 to 64.7)	-1.1 (-6.1 to 4.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	27.1 (-33.2 to 123.7)	-26.0 (-62.1 to 26.0)
Other hemoglobinopathies and hemolytic anemias	56.1 (45.0 to 66.6)	66.5 (59.8 to 72.8)	18.5 (-0.2 to 49.0)	-19.0 (-30.9 to -1.1)	2.0 (1.2 to 3.0)	2.3 (1.5 to 3.3)	13.0 (9.6 to 58.0)	-18.1 (33.8 to 18.2)
Endocrine, metabolic, blood, and immune disorders	72.0 (65.4 to 78.8)	90.3 (81.0 to 97.3)	25.2 (8.7 to 43.1)	-22.8 (-23.2 to -0.5)	2.7 (1.8 to 3.9)	3.2 (2.1 to 4.6)	17.5 (0.3 to 40.0)	14.6 (-25.1 to 2.1)
Musculoskeletal disorders	-	-	-	-	79.9 (56.3 to 105.3)	149.7 (106.2 to 196.5)	87.2 (76.2 to 100.1)	9.7 (-1.1 to 9.6)
Rheumatoid arthritis	20.2 (19.5 to 21.0)	30.2 (29.1 to 31.4)	49.6 (41.8 to 57.4)	-17.1 (-21.7 to -12.4)	4.8 (3.4 to 6.3)	7.1 (5.0 to 9.4)	48.7 (38.1 to 59.3)	-17.1 (-22.8 to -11.3)
Osteoarthritis	146.0 (140.1 to 151.8)	291.1 (279.7 to 302.3)	99.1 (87.7 to 110.4)	1.6 (-4.0 to 6.9)	9.0 (6.3 to 12.2)	17.8 (12.5 to 24.3)	98.7 (87.2 to 110.7)	1.8 (-3.8 to 7.5)
Low back and neck pain	-	-	-	-	53.8 (37.2 to 73.2)	96.5 (66.9 to 128.8)	79.1 (65.4 to 97.6)	0.9 (-6.1 to 10.0)
Low back pain	331.8 (310.8 to 349.0)	587.8 (555.0 to 619.8)	76.5 (64.4 to 92.5)	0.1 (-6.7 to 8.3)	37.4 (25.2 to 51.9)	66.1 (44.6 to 91.7)	76.3 (64.3 to 92.6)	0.3 (-6.2 to 8.6)
Neck pain	166.4 (139.2 to 198.9)	309.1 (267.1 to 347.6)	87.1 (44.2 to 132.8)	2.3 (-17.2 to 24.6)	16.4 (10.5 to 23.0)	30.5 (20.4 to 42.3)	87.5 (45.0 to 132.3)	2.5 (-17.0 to 25.3)
Gout	1.8 (1.7 to 2.0)	3.6 (3.3 to 4.0)	95.3 (71.6 to 124.9)	2.0 (-9.7 to 16.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	95.0 (54.6 to 147.2)	2.6 (-17.8 to 29.4)
Other musculoskeletal disorders	134.7 (110.6 to 161.9)	307.1 (242.4 to 377.6)	127.5 (110.3 to 144.6)	12.5 (13.0 to 30.9)	12.3 (8.1 to 17.9)	28.1 (18.2 to 40.7)	117.7 (109.1 to 146.4)	17.7 (13.0 to 31.7)
Other non-communicable diseases	-	-	-	-	99.6 (66.1 to 145.8)	164.3 (109.3 to 237.9)	65.1 (59.9 to 69.9)	-5.8 (-8.3 to -3.4)
Congenital anomalies	-	-	-	-	5.4 (3.9 to 7.2)	12.4 (9.1 to 16.4)	130.5 (95.1 to 176.9)	50.6 (27.6 to 79.7)
Neural tube defects	0.7 (0.6 to 0.8)	2.3 (2.1 to 2.6)	250.4 (194.9 to 319.6)	158.5 (117.2 to 210.5)	0.2 (0.1 to 0.3)	0.7 (0.5 to 1.0)	299.8 (203.2 to 412.7)	199.9 (128.8 to 282.6)
Congenital heart anomalies	8.5 (6.6 to 11.0)	41.8 (35.0 to 49.7)	398.2 (270.3 to 547.7)	259.1 (165.1 to 372.3)	0.3 (0.1 to 0.5)	1.4 (0.6 to 2.5)	354.1 (235.1 to 497.1)	237.5 (151.9 to 346.6)
Orofacial clefts	1.4 (1.0 to 2.0)	8.4 (6.5 to 10.6)	511.6 (276.8 to 790.7)	373.0 (191.3 to 598.9)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	411.2 (197.4 to 697.9)	293.6 (128.3 to 510.0)
Down syndrome	5.2 (4.0 to 6.8)	12.3 (9.9 to 15.3)	137.6 (68.2 to 230.1)	63.1 (15.1 to 128.3)	0.6 (0.4 to 0.9)	1.5 (1.1 to 2.2)	151.1 (77.1 to 255.6)	71.9 (20.8 to 143.1)
Turner syndrome	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	115.8 (35.8 to 237.5)	44.3 (-9.4 to 125.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	118.2 (34.3 to 249.6)	43.6 (-12.0 to 128.4)
Klinefelter syndrome	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	56.1 (19.6 to 118.8)	0.9 (-22.5 to 41.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.5 (26.7 to 132.2)	1.1 (-22.5 to 42.0)
Chromosomal unbalanced rearrangements	7.4 (6.0 to 9.0)	17.4 (14.3 to 20.8)	132.1 (79.5 to 202.9)	22.1 (23.2 to 109.0)	0.2 (0.6 to 1.2)	2.2 (1.5 to 2.9)	149.9 (86.3 to 225.7)	68.0 (27.7 to 122.6)
Other congenital anomalies	25.8 (21.8 to 29.7)	37.9 (32.1 to 43.8)	45.7 (33.0 to 64.4)	-9.1 (-17.0 to 2.3)	3.4 (2.3 to 4.8)	6.4 (4.2 to 8.9)	90.5 (55.7 to 143.0)	20.1 (-0.9 to 52.1)
Skin and subcutaneous diseases	-	-	-	-	34.5 (21.9 to 52.2)	55.3 (35.4 to 83.8)	60.5 (51.9 to 68.9)	-0.4 (-6.6 to 4.6)
Dermatitis	353.4 (289.2 to 416.7)	580.3 (476.9 to 685.7)	64.0 (62.0 to 66.0)	0.0 (-0.1 to 0.1)	11.0 (6.8 to 16.2)	17.5 (11.0 to 25.9)	59.3 (53.1 to 65.0)	0.1 (-2.3 to 2.7)
Psoriasis	48.1 (42.2 to 54.2)	82.6 (72.0 to 93.1)	71.3 (69.9 to 72.9)	0.0 (-0.0 to 0.1)	5.9 (2.6 to 5.5)	6.8 (4.6 to 9.5)	70.9 (61.6 to 81.3)	0.0 (-4.6 to 5.6)
Cellulitis	0.6 (0.5 to 0.7)	1.0 (0.9 to 1.2)	57.7 (44.7 to 75.8)	1.0 (-7.1 to 10.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	58.0 (27.6 to 92.8)	1.1 (-15.8 to 20.5)
Pyoderma	2.6 (2.2 to 3.2)	4.2 (3.5 to 5.2)	60.7 (53.2 to 68.1)	4.0 (0.5 to 8.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	60.1 (39.3 to 83.1)	4.2 (-6.9 to 17.0)
Scabies	89.4 (77.6 to 102.7)	132.4 (114.5 to 150.8)	48.1 (23.3 to 79.3)	-3.9 (-20.8 to 15.5)	2.3 (1.3 to 3.7)	3.4 (1.9 to 5.5)	47.8 (23.3 to 80.0)	-3.9 (-21.6 to 16.1)
Fungal skin diseases	460.1 (346.8 to 607.3)	771.4 (584.9 to 1,017.9)	67.4 (63.5 to 71.6)	0.2 (0.2 to 0.3)	2.6 (1.0 to 5.7)	4.3 (1.7 to 9.7)	69.5 (63.2 to 71.8)	0.4 (-0.5 to 1.2)
Viral skin diseases	178.8 (137.5 to 216.4)	268.2 (204.4 to 329.2)	49.7 (44.2 to 55.2)	-0.0 (-1.6 to 1.9)	5.6 (3.2 to 8.7)	8.3 (4.7 to 13.3)	49.7 (43.0 to 56.5)	3.2 (-2.9 to 3.0)
Acne vulgaris	330.1 (265.8 to 396.9)	508.0 (414.2 to 596.1)	55.0 (16.4 to 97.2)	-3.2 (27.0 to 22.0)	3.6 (1.7 to 6.8)	5.5 (2.5 to 10.6)	55.0 (15.6 to 97.2)	-3.1 (-27.1 to 22.0)
Alopecia areata	5.7 (5.1 to 6.2)	9.3 (8.5 to 10.1)	62.5 (44.5 to 84.1)	-2.3 (-12.7 to 10.9)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	62.3 (37.7 to 94.3)	-2.5 (-15.4 to 14.4)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.6 (36.4 to 112.6)	0.9 (-21.9 to 25.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.6 (36.4 to 112.6)	-0.9 (-21.9 to 25.7)
Urticaria	52.8 (33.4 to 70.4)	91.4 (63.3 to 123.3)	70.8 (12.9 to 190.5)	0.4 (-34.7 to 67.2)	3.1 (1.7 to 4.9)	5.4 (3.1 to 8.8)	70.7 (12.5 to 185.5)	1.0 (-34.7 to 68.0)
Decubitus ulcer	0.5 (0.4 to 0.7)	0.9 (0.7 to 1.0)	61.0 (13.0 to 117.4)	-20.9 (-47.5 to 11.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	61.3 (13.8 to 121.1)	-20.1 (-48.5 to 17.1)
Other skin and subcutaneous diseases	339.5 (230.9 to 499.7)	593.2 (395.8 to 882.1)	74.2 (64.7 to 83.6)	-1.7 (-6.4 to 2.1)	2.0 (0.9 to 2.1)	3.5 (1.5 to 7.3)	74.4 (64.1 to 83.9)	-1.6 (-6.3 to 2.5)
Sense organ diseases	-	-	-	-	42.5 (28.9 to 59.9)	66.7 (45.1 to 95.2)	56.7 (48.4 to 64.3)	-12.7 (-16.3 to -9.4)
Glaucoma	8.7 (7.3 to 10.4)	12.5 (10.5 to 14.7)	44.9 (26.2 to 62.7)	-22.0 (-32.2 to -12.7)	0.6 (0.4 to 0.9)	0.9 (0.6 to 1.3)	48.8 (25.9 to 71.5)	-21.1 (-34.1 to -8.7)
Cataract	44.3 (36.4 to 52.2)	68.7 (56.3 to 81.8)	54.6 (41.9 to 68.3)	-26.3 (-31.3 to -20.3)	2.7 (1.8 to 3.8)	4.3 (2.9 to 6.0)	58.6 (46.2 to 72.9)	-25.0 (-30.0 to -18.7)
Macular degeneration	9.9 (7.6 to 12.3)	20.7 (16.5 to 25.6)	108.8 (71.9 to 163.7)	10.0 (-11.3 to 37.2)	0.5 (0.3 to 0.7)	1.0 (0.6 to 1.4)	108.3 (71.4 to 160.5)	8.4 (-12.3 to 34.6)
Uncorrected refractive error	691.7 (647.0 to 738.1)	1,174.5 (1,107.0 to 1,253.2)	69.6 (55.1 to 85.4)	5.0 (-11.9 to 2.6)	10.9 (6.6 to 17.4)	17.4 (10.3 to 28.5)	58.6 (48.6 to 71.1)	-11.1 (-16.1 to -4.8)
Age-related and other hearing loss	717.7 (669.0 to 773.6)	1,198.1 (1,110.3 to 1,277.2)	65.2 (59.0 to 73.1)	-9.6 (-12.3 to -6.1)	21.7 (14.7 to 30.6)	34.7 (23.2 to 48.6)	59.4 (46.1 to 71.8)	-11.0 (-16.5 to -5.9)
Other vision loss	24.5 (21.4 to 28.0)	26.3 (22.9 to 30.2)	7.4 (-3.7 to 18.1)	-35.6 (-40.8 to -30.0)	1.8 (1.3 to 2.6)	1.9 (1.3 to 2.7)	4.2 (-7.2 to 15.5)	-3.1 (-42.6 to -30.4)
Other sense organ diseases	158.9 (150.4 to 166.1)	243.7 (231.1 to 256.1)	53.0 (43.2 to 64.6)	-0.4 (-6.2 to 5.9)	4.2 (2.7 to 6.2)	6.5 (4.0 to 9.6)	52.7 (41.5 to 65.6)	-0.4 (-6.8 to 7.1)
Oral disorders	-	-	-	-	17.2 (10.4 to 26.5)	29.9 (18.0 to 46.6)	73.5 (68.1 to 78.8)	-5.2 (-8.4 to -2.0)
Deciduous caries	589.4 (571.5 to 608.2)	786.7 (763.1 to 811.7)	33.4 (28.4 to 37.7)	0.8 (-2.9 to 4.1)	0.8 (0.1 to 0.4)	0.3 (0.1 to 0.6)	33.2 (24.5 to 42.9)	0.7 (-5.8 to 8.1)
Permanent caries	2,620.6 (2,498.0 to 2,736.9)	4,252.8 (4,033.0 to 4,452						

Appendix Table G.4 - Bolivia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	271.4 (261.4 to 282.2)	482.0 (466.5 to 499.1)	77.3 (69.2 to 85.6)	-9.1 (-12.9 to -5.0)	7.5 (5.0 to 10.5)	13.3 (9.0 to 18.4)	76.9 (68.1 to 85.9)	76.9 (-13.1 to -4.8)
Other oral disorders	103.0 (97.1 to 108.9)	173.2 (162.8 to 182.3)	68.1 (54.6 to 82.7)	-0.6 (-7.6 to 7.4)	3.0 (1.9 to 4.5)	5.1 (3.2 to 7.7)	68.0 (53.9 to 83.4)	-0.4 (-8.2 to 7.8)
Injuries	-	-	-	-	31.8 (24.3 to 40.7)	37.6 (28.1 to 49.1)	18.1 (12.5 to 23.4)	-30.9 (-34.0 to -27.9)
Transport injuries	-	-	-	-	11.0 (8.2 to 14.2)	11.2 (8.3 to 14.6)	1.4 (-5.1 to 8.5)	-40.9 (-44.3 to -37.3)
Road injuries	-	-	-	-	10.3 (7.7 to 13.3)	10.4 (7.7 to 13.6)	0.8 (-5.9 to 8.2)	-41.4 (-44.8 to -37.7)
Pedestrian road injuries	-	-	-	-	4.8 (3.5 to 6.2)	4.1 (3.0 to 5.4)	-15.3 (-23.4 to -7.7)	-50.1 (-54.1 to -46.3)
Cyclist road injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.8 (0.6 to 1.0)	10.5 (2.8 to 19.3)	-36.1 (-40.3 to -31.5)
Motorcyclist road injuries	-	-	-	-	1.0 (0.7 to 1.3)	0.9 (0.6 to 1.2)	-9.0 (-16.3 to -0.7)	-47.1 (-51.1 to -42.6)
Motor vehicle road injuries	-	-	-	-	3.7 (2.7 to 4.7)	4.5 (3.4 to 5.9)	23.2 (12.2 to 34.4)	-29.8 (-35.3 to -23.9)
Other road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-6.2 (-13.4 to 1.3)	-46.5 (-50.1 to -42.7)
Other transport injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.8 (0.6 to 1.0)	10.6 (3.4 to 18.7)	-34.3 (-38.9 to -29.7)
Unintentional injuries	-	-	-	-	19.4 (14.8 to 24.9)	24.4 (18.3 to 32.0)	25.9 (20.1 to 30.9)	-26.2 (-29.4 to -23.4)
Falls	-	-	-	-	6.5 (5.0 to 8.4)	10.8 (7.9 to 14.1)	64.6 (53.8 to 75.8)	-13.3 (-19.2 to -7.6)
Drowning	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	4.1 (5.0 to 15.5)	-37.4 (-42.1 to -31.3)
Fire, heat, and hot substances	-	-	-	-	0.8 (0.6 to 1.0)	0.7 (0.5 to 0.9)	-11.8 (-20.6 to -3.5)	-45.7 (-50.1 to -41.5)
Poisonings	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	15.0 (2.6 to 38.1)	-30.7 (-39.6 to -19.2)
Exposure to mechanical forces	-	-	-	-	8.7 (6.6 to 11.3)	7.4 (5.6 to 9.7)	-14.6 (-19.6 to -9.5)	-48.3 (-51.3 to -45.6)
Unintentional firearm injuries	-	-	-	-	0.6 (0.4 to 0.7)	0.7 (0.5 to 0.9)	25.3 (15.9 to 38.5)	-25.3 (-31.0 to -18.6)
Unintentional suffocation	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	48.8 (30.9 to 66.4)	-6.2 (-16.5 to 3.7)
Other exposure to mechanical forces	-	-	-	-	8.0 (6.0 to 10.4)	6.5 (4.8 to 8.6)	-18.7 (-23.8 to -14.0)	-50.8 (-53.9 to -48.1)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	97.0 (86.8 to 108.1)	15.2 (8.6 to 22.6)
Animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	60.2 (48.5 to 72.3)	-6.7 (-12.3 to -1.1)
Venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	57.6 (39.2 to 77.7)	-7.3 (-16.2 to 2.0)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	62.0 (51.0 to 74.2)	-6.7 (-11.6 to -0.5)
Foreign body	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	38.3 (29.2 to 48.4)	-19.5 (-24.4 to -14.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	28.5 (16.6 to 41.1)	-24.4 (-30.6 to -18.1)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	56.4 (36.3 to 80.7)	-6.0 (-16.2 to 7.2)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	50.2 (39.7 to 62.2)	-14.3 (-20.4 to -7.9)
Other unintentional injuries	-	-	-	-	2.7 (2.0 to 3.5)	4.6 (3.4 to 6.0)	69.3 (58.8 to 83.4)	-5.8 (-11.6 to 2.1)
Self-harm and interpersonal violence	-	-	-	-	1.3 (1.0 to 1.6)	1.6 (1.2 to 2.1)	28.3 (20.0 to 37.9)	-27.9 (-32.2 to -23.0)
Self-harm	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	22.5 (10.5 to 34.4)	-32.7 (-38.6 to -26.7)
Interpersonal violence	-	-	-	-	1.0 (0.8 to 1.3)	1.3 (1.0 to 1.7)	29.7 (20.7 to 40.1)	-26.8 (-31.4 to -21.3)
Assault by firearm	-	-	-	-	0.3 (0.2 to 0.3)	0.5 (0.3 to 0.6)	85.1 (70.4 to 102.8)	2.2 (-5.3 to 11.9)
Assault by sharp object	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-39.6 (-43.9 to -33.9)	-64.1 (-66.2 to -60.9)
Assault by other means	-	-	-	-	0.6 (0.5 to 0.8)	0.8 (0.6 to 1.0)	26.4 (15.6 to 38.5)	-28.1 (-33.9 to -21.5)
Forces of nature, war, and legal intervention	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.6)	201.4 (131.9 to 339.2)	68.9 (32.7 to 135.7)
Exposure to forces of nature	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.5)	151.7 (91.6 to 286.4)	39.6 (9.7 to 104.3)
Collective violence and legal intervention	-	-	-	-	-	0.1 (0.0 to 0.1)	-	-

Appendix Table G.4 - Bosnia and Herzegovina prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	463.6 (343.7 to 602.3)	472.5 (352.9 to 609.5)	1.9 (-1.2 to 5.6)	1.9 (-4.6 to 1.3)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	47.9 (33.2 to 67.4)	25.9 (18.2 to 36.1)	-45.8 (-52.1 to -40.2)	-26.7 (-35.1 to -19.6)
HIV/AIDS and tuberculosis	-	-	-	-	0.6 (0.4 to 0.9)	0.7 (0.5 to 0.9)	5.6 (-5.3 to 18.6)	2.8 (-7.6 to 15.3)
Tuberculosis	2.1 (2.0 to 2.2)	2.3 (2.2 to 2.4)	7.4 (3.2 to 11.6)	2.8 (-0.8 to 6.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-5.5 to 18.2)	0.0 (-7.9 to 14.9)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	4,588.3 (4,539.6 to 4,637.0)	1,757.7 to 548,087.8	2,019.7 to 523,479.3
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4,539.6 (1,657.5 to 0.0)	4,848.6 (1,790.6 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4,539.6 (1,655.0 to nan)	4,848.6 (1,771.4 to nan)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4,019.5 (1,634.2 to 0.0)	4,815.8 (2,002.3 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4,588.9 (1,747.8 to nan)	5,307.5 (2,014.5 to nan)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	4.2 (2.9 to 5.8)	2.7 (1.9 to 3.7)	-35.3 (-39.3 to -31.2)	-14.2 (-19.3 to -8.6)
Diarrheal diseases	12.3 (11.4 to 13.2)	8.3 (7.8 to 8.8)	-32.6 (-38.6 to -25.5)	-8.1 (-16.6 to 1.8)	2.0 (1.3 to 2.8)	1.3 (0.9 to 1.8)	-40.4 to -26.4	-17.3 to 2.3
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-88.3 to -54.7	-84.8 to -45.5
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.2 (-66.2 to -26.2)	-37.6 (-56.6 to -13.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.2 (-66.2 to -26.2)	-37.6 (-56.6 to -13.4)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.9 (-66.1 to -30.0)	-36.3 (-54.7 to -16.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.9 (-66.2 to -29.9)	-36.3 (-54.7 to -16.0)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.4 (-99.9 to -77.1)	-99.3 (-99.9 to -71.9)
Lower respiratory infections	1.9 (1.6 to 2.3)	0.8 (0.7 to 0.9)	-59.5 (-66.8 to -50.2)	-43.1 (-54.1 to -30.3)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.1)	-60.0 (-68.4 to -49.8)	-42.7 (-55.2 to -28.3)
Upper respiratory infections	45.1 (43.1 to 47.6)	35.7 (34.1 to 37.4)	-20.6 (-26.2 to -15.8)	-1.1 (-8.1 to 5.2)	0.5 (0.3 to 0.9)	0.4 (0.2 to 0.7)	-21.2 (-27.2 to -15.2)	-1.2 (-8.7 to 6.3)
Otitis media	48.6 (45.1 to 52.1)	35.8 (33.3 to 38.1)	-26.6 (-32.1 to -20.0)	-5.7 (-12.6 to 1.6)	1.0 (0.6 to 1.6)	0.7 (0.4 to 1.1)	-28.9 (-35.4 to -22.1)	-7.6 (-16.1 to 0.6)
Meningitis	-	-	-	-	0.3 (0.2 to 0.3)	0.1 (0.0 to 0.1)	-72.3 (-78.0 to -63.4)	-65.7 (-72.3 to -53.7)
Pneumococcal meningitis	1.0 (0.6 to 1.6)	0.3 (0.2 to 0.5)	-70.5 (-77.8 to -60.4)	-67.8 (-75.6 to -56.7)	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-68.6 (-78.0 to -56.6)	-62.6 (-73.5 to -48.0)
H influenzae type B meningitis	0.5 (0.2 to 1.0)	0.1 (0.0 to 0.2)	-77.2 (-87.4 to -65.8)	-72.6 (-83.2 to -56.7)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-75.4 (-85.8 to -38.2)	-67.3 (-81.0 to -18.6)
Meningococcal meningitis	0.3 (0.1 to 0.8)	0.1 (0.0 to 0.2)	-80.5 (-88.7 to -69.4)	-77.6 (-86.4 to -65.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-77.3 (-86.1 to -59.3)	-72.8 (-82.9 to -50.0)
Other meningitis	0.6 (0.2 to 1.0)	0.2 (0.1 to 0.3)	-69.1 (-82.6 to -62.0)	-69.1 (-77.8 to -56.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-71.7 (-82.3 to -58.6)	-64.5 (-77.3 to -47.8)
Encephalitis	0.6 (0.3 to 1.3)	0.4 (0.2 to 0.9)	-37.1 (-56.2 to -21.8)	-37.1 (-57.4 to -25.7)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-31.7 (-44.0 to -14.6)	-32.4 (-44.4 to -15.6)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.7 (-96.1 to 136.6)	-64.2 (-95.1 to 152.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.7 (-96.2 to 138.7)	-64.2 (-95.2 to 153.2)
Whooping cough	1.5 (1.2 to 1.9)	0.2 (0.2 to 0.3)	-84.6 (-85.6 to -83.5)	-68.7 (-70.8 to -66.6)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-84.5 (-86.9 to -81.8)	-68.6 (-73.5 to -63.0)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.6 (-81.3 to -39.4)	-48.2 (-80.5 to -31.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.8 (-82.1 to -37.9)	-49.2 (-81.2 to -29.7)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-95.7 (-97.3 to -93.8)	-91.1 (-94.5 to -87.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-95.7 (-97.3 to -93.8)	-91.1 (-94.5 to -87.2)
Varicella and herpes zoster	2.4 (2.3 to 2.6)	1.9 (1.7 to 2.1)	-23.3 (-32.1 to -13.8)	-3.5 (-10.7 to 7.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-0.4 (-22.5 to 29.5)	-3.4 (-23.3 to 22.8)
Neglected tropical diseases and malaria	-	-	-	-	0.3 (0.2 to 0.5)	0.1 (0.1 to 0.2)	-55.0 (-69.5 to -40.0)	-57.2 (-70.6 to -43.1)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.2 (-87.4 to 63.5)	-15.7 (-83.1 to 118.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.7 (-87.0 to 68.2)	-13.6 (-82.6 to 124.8)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.1 (-63.3 to -6.4)	-17.4 (-50.6 to 27.5)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.1 (-63.3 to -6.4)	-17.4 (-50.5 to 27.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.1 (-63.3 to -6.3)	-17.4 (-50.6 to 27.6)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.1 (-74.7 to -19.5)	-51.4 (-68.1 to -34.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.1 (-74.7 to -19.5)	-51.4 (-68.1 to -13.9)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.4 (0.1 to 0.8)	0.1 (0.0 to 0.2)	-78.6 (-94.6 to 27.8)	-81.5 (-94.9 to 10.6)	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-75.9 (-94.2 to 47.9)	-78.8 (-94.5 to 34.8)
Cystic echinococcosis	2.5 (2.4 to 2.7)	1.3 (1.2 to 1.4)	-46.5 (-50.9 to -43.6)	-49.5 (-53.3 to -46.8)	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-47.5 (-54.8 to -39.5)	-49.9 (-56.3 to -42.3)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.0 (-71.7 to -41.9)	-49.4 (-69.0 to -30.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.0 (-71.7 to -41.8)	-49.4 (-69.0 to -30.9)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.8 (-50.4 to 5.2)	-3.4 (-34.2 to 45.4)
Maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-49.6 (-60.9 to -35.2)	-27.0 (-43.1 to -5.2)
Maternal hemorrhage	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	72.2 (25.0 to 117.2)	155.8 (85.6 to 222.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.0 (-77.3 to -5.8)	-25.0 (-66.7 to 39.3)
Maternal sepsis and other maternal infections	0.9 (0.5 to 1.4)	0.3 (0.2 to 0.5)	-65.3 (-78.9 to -51.3)	-54.2 (-71.7 to -34.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.1 (-81.2 to -46.8)	-57.2 (-74.0 to -25.5)
Maternal hypertensive disorders	0.5 (0.3 to 0.9)	0.3 (0.2 to 0.5)	-43.1 (-49.8 to -32.2)	-16.4 (-27.3 to 1.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-43.1 (-57.0 to -21.9)	-16.4 (-37.3 to 16.2)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.2 (-74.5 to 118.1)	0.3 (-62.5 to 225.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.2 (-74.5 to 120.0)	0.3 (-62.5 to 227.5)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.4 (-68.8 to -5.1)	-23.0 (-54.5 to 38.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.4 (-68.8 to -5.0)	-23.0 (-54.5 to 39.8)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.0 (-72.5 to -1.3)	-26.1 (-59.9 to 44.6)
Neonatal disorders	-	-	-	-	6.8 (4.6 to 9.6)	5.2 (3.4 to 7.4)	-24.8 (-48.5 to 11.9)	-2.6 (-33.8 to 44.4)
Preterm birth complications	20.1 (15.6 to 25.7)	18.0 (14.1 to 23.1)	-10.8 (-22.6 to 5.5)	9.6 (-5.0 to 29.6)	2.4 (1.6 to 3.3)	3.0 (1.6 to 3.1)	-2.2 (-22.9 to 24.2)	24.2 (-1.3 to 60.2)
Neonatal encephalopathy due to birth asphyxia and trauma	8.6 (4.7 to 15.6)	2.9 (1.4 to 6.2)	-66.5 (-82.8 to -33.2)	-56.3 (-77.6 to -33.9)	2.2 (1.3 to 3.3)	0.8 (0.4 to 1.3)	-8.2 (-42.8 to 21.8)	-53.4 (-76.9 to 4.3)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.4 (-34.5 to -3.5)	-47.0 (-22.4 to 80.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.0 (-42.5 to 16.0)	-47.6 (-75.5 to -39.5)
Hemolytic disease and other neonatal jaundice	4.3 (2.4 to 7.0)	3.3 (1.7 to 6.7)	-28.5 (-68.0 to 95.8)	-8.0 (-59.1 to 150.3)	1.6 (0.8 to 2.7)	1.2 (0.6 to 2.6)	-27.4 (-67.2 to 97.9)	-6.2 (-57.8 to 153.3)
Other neonatal disorders	-	-	-	-	0.6 (0.2 to 1.2)	0.8 (0.4 to 1.4)	41.2 (-36.0 to 217.7)	82.3 (-17.1 to 311.7)
Nutritional deficiencies	-	-	-	-	33.8 (22.6 to 49.4)	15.8 (10.4 to 23.1)	-52.9 (-60.0 to -48.1)	-34.0 (-43.9 to -26.1)
Protein-energy malnutrition	12.2 (8.6 to 16.5)	2.2 (1.5 to 3.0)	-82.1 (-89.3 to -71.5)	-62.5 (-77.2 to -40.2)	1.5 (0.9 to 2.5)	0.3 (0.2 to 0.4)	-82.2 (-89.2 to -71.0)	-62.7 (-77.3 to -39.5)
Iodine deficiency	120.3 (84.1 to 157.2)	64.0 (44.4 to 87.3)	-46.7 (-66.2 to -18.0)	-37.5 (-60.0 to -3.8)	2.2 (1.2 to 3.7)	1.1 (0.6 to 1.9)	-47.1 (-66.7 to -17.5)	-37.6 (-60.5 to -3.7)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-

Appendix Table G.4 - Bosnia and Herzegovina prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	870.8 (863.2 to 882.1)	563.0 (552.4 to 573.6)	-35.3 (-36.6 to -34.0)	-16.4 (-18.2 to -14.7)	24.6 (16.4 to 35.8)	14.0 (9.3 to 20.6)	-43.1 (-45.4 to -41.3)	-43.1 (-21.3 to -15.7)
Other nutritional deficiencies	-	-	-	-	5.5 (2.6 to 11.2)	0.3 (0.1 to 1.6)	-62.2 (-98.0 to -77.7)	-92.0 (-95.8 to -52.8)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.1 (1.3 to 3.3)	1.4 (0.8 to 2.2)	-34.9 (-43.8 to -23.0)	-10.8 (-24.4 to 5.8)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.8 (0.4 to 1.6)	0.6 (0.3 to 1.2)	-25.0 (-33.7 to -14.8)	-7.9 (-18.0 to 4.1)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	14.3 (4.0 to 49.5)	-8.5 (-22.7 to 16.7)	0.1 (0.0 to 0.0)	0.1 (0.0 to 0.0)	11.4 (-20.8 to 56.1)	8.1 (-34.4 to 24.4)
Chlamydial infection	115.7 (103.0 to 130.1)	85.4 (75.9 to 95.1)	-26.1 (-37.9 to -14.0)	-1.5 (-16.7 to 14.5)	0.3 (0.2 to 0.6)	0.2 (0.1 to 0.4)	-26.4 (-37.9 to -12.4)	-1.8 (-17.6 to 16.7)
Gonococcal infection	27.5 (21.7 to 32.8)	18.3 (14.9 to 22.1)	-34.2 (-48.5 to -9.7)	-7.6 (-28.7 to 27.4)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-38.1 (-55.2 to -11.7)	-13.6 (-37.9 to 22.8)
Trichomoniasis	63.2 (46.1 to 82.0)	43.5 (31.3 to 61.5)	-32.5 (-51.6 to 3.2)	-9.2 (-36.0 to 38.1)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-11.1 (-55.9 to 5.5)	-11.1 (-40.8 to 41.0)
Genital herpes	813.1 (719.8 to 899.6)	796.5 (667.4 to 811.4)	-9.4 (-21.8 to 5.8)	-10.7 (-22.8 to 4.4)	0.2 (0.1 to 0.5)	0.2 (0.1 to 0.5)	-12.6 (-25.7 to 3.1)	-11.7 (-23.8 to 4.6)
Other sexually transmitted diseases	1.2 (0.8 to 1.6)	0.7 (0.5 to 0.9)	-41.7 (-53.4 to -26.9)	-27.2 (-41.4 to -7.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.9 (-61.4 to -2.9)	-23.9 (-52.3 to 17.9)
Hepatitis	-	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-30.6 (-40.4 to -20.0)	-16.7 (-28.8 to -3.9)
Hepatitis A	5.2 (5.1 to 5.3)	3.1 (3.0 to 3.2)	-40.9 (-41.1 to -40.7)	-19.8 (-20.5 to -18.8)	0.1 (0.1 to 0.2)	0.0 (0.1 to 0.1)	-27.4 (-35.9 to -19.2)	-8.0 (-18.8 to 3.3)
Hepatitis B	113.0 (87.0 to 141.0)	69.7 (55.8 to 82.8)	-37.9 (-57.2 to -14.5)	-31.1 (-52.1 to -6.6)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-38.8 (-61.4 to -8.9)	-33.1 (-58.4 to -1.2)
Hepatitis C	74.8 (66.9 to 82.6)	58.2 (52.6 to 63.9)	-22.2 (-32.7 to -9.9)	-26.3 (-35.2 to -15.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.5 (-41.4 to 21.8)	-11.9 (-44.4 to 8.3)
Hepatitis E	-	-	-24.2 (-31.5 to -16.2)	-7.3 (-16.1 to 1.8)	-	-	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	34.7 (28.9 to 39.6)	20.9 (17.9 to 24.1)	-40.2 (-47.6 to -27.1)	-14.4 (-25.3 to 6.1)	1.0 (0.8 to 1.6)	0.5 (0.4 to 0.9)	-43.5 (-57.2 to -21.2)	-11.8 (-34.5 to 22.4)
Non-communicable diseases	-	-	-	-	4.3 (277.1 to 484.5)	5.0 (290.9 to 503.7)	16.4 (1.3 to 7.5)	16.4 (-3.3 to 2.3)
Neoplasms	-	-	-	-	2.5 (1.8 to 3.2)	5.0 (3.7 to 6.6)	101.8 (72.4 to 125.2)	46.4 (25.8 to 63.2)
Esophageal cancer	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	48.2 (7.2 to 101.0)	3.3 (-25.8 to 40.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.9 (4.7 to 87.0)	-2.6 (-28.5 to 28.3)
Stomach cancer	1.1 (0.9 to 1.3)	1.2 (1.0 to 1.4)	13.2 (-8.8 to 41.5)	-26.4 (-40.7 to -8.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	7.5 (-14.5 to 34.4)	-30.1 (-44.1 to -12.5)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-0.8 to 0.8)	0.0 (-2.7 to 2.7)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	9,896.3 (48.0 to 38,687.3)	7,671.9 (46.0 to 30,357.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6,945.5 (49.9 to 38,365.7)	7,265.5 (-49.9 to 29,781.9)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	73,587.5 (127.1 to 208,437.2)	53,103.7 (86.6 to 146,756.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79,341.2 (111.1 to 215,043.3)	55,510.3 (71.8 to 149,040.6)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	28,443.5 (3.2 to 95,556.1)	20,264.6 (26.1 to 69,107.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24,804.6 (7.8 to 89,014.7)	17,335.6 (-31.2 to 117,174.4)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	5,866.3 (70.8 to 13,554.5)	4,626.8 (-63.9 to 10,942.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6,494.5 (-70.5 to 13,381.4)	5,011.1 (-64.6 to 10,683.0)
Larynx cancer	0.5 (0.4 to 0.7)	0.6 (0.5 to 0.9)	27.2 (-14.6 to 96.1)	-8.2 (-38.1 to 38.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	11.3 (-22.7 to 58.0)	-21.1 (-44.2 to 10.4)
Tracheal, bronchus and lung cancer	1.8 (1.6 to 2.1)	3.1 (2.7 to 3.6)	70.8 (40.9 to 107.3)	18.2 (-2.2 to 42.9)	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	50.0 (28.0 to 79.9)	4.1 (-10.4 to 24.1)
Breast cancer	2.2 (1.8 to 2.8)	11.2 (9.4 to 12.5)	404.0 (284.7 to 505.3)	292.0 (198.9 to 372.8)	0.3 (0.2 to 0.4)	0.7 (0.5 to 0.9)	158.9 (81.3 to 231.1)	103.1 (42.8 to 157.3)
Cervical cancer	2.3 (1.8 to 2.8)	1.9 (1.4 to 2.4)	-17.0 (-38.9 to 10.2)	6.6 (-46.3 to -1.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-18.6 (-40.7 to -9.2)	7.5 (-48.0 to -3.5)
Uterine cancer	0.5 (0.4 to 0.8)	2.1 (0.8 to 3.1)	315.7 (31.0 to 564.4)	233.8 (4.4 to 422.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	290.1 (24.5 to 530.5)	208.1 (-2.0 to 392.0)
Prostate cancer	2.1 (1.7 to 2.5)	7.2 (5.6 to 10.2)	244.4 (161.4 to 419.1)	92.0 (45.8 to 199.4)	0.2 (0.1 to 0.3)	0.7 (0.5 to 1.1)	233.3 (148.3 to 457.9)	81.9 (35.2 to 209.8)
Colon and rectum cancer	2.1 (1.9 to 2.3)	7.7 (6.9 to 8.6)	271.7 (226.7 to 325.3)	149.8 (120.6 to 186.8)	0.2 (0.2 to 0.3)	0.7 (0.5 to 0.9)	216.4 (174.8 to 267.4)	109.6 (82.5 to 144.6)
Lip and oral cavity cancer	0.8 (0.6 to 0.9)	1.2 (0.9 to 1.5)	58.0 (13.7 to 118.1)	12.9 (-18.4 to 56.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	51.8 (7.1 to 108.3)	6.3 (-23.4 to 45.2)
Nasopharynx cancer	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-37.1 (-57.8 to -4.6)	-46.9 (-64.3 to -20.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.5 (-55.4 to -7.3)	-48.0 (-63.0 to -24.1)
Other pharynx cancer	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	79.2 (4.6 to 230.0)	34.8 (-26.1 to 145.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.9 (-0.9 to 160.5)	20.9 (-25.5 to 93.9)
Gallbladder and biliary tract cancer	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.4)	-32.3 (-52.0 to 66.3)	-59.1 (-71.1 to -1.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-38.2 (-57.0 to 49.4)	-61.9 (-73.5 to -9.3)
Pancreatic cancer	0.2 (0.2 to 0.3)	0.4 (0.4 to 0.5)	90.6 (50.7 to 140.1)	21.6 (-3.9 to 53.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	69.6 (37.5 to 110.8)	10.1 (-10.7 to 38.7)
Malignant skin melanoma	1.4 (1.1 to 2.0)	2.1 (1.5 to 3.2)	41.7 (13.2 to 85.4)	24.7 (-0.3 to 63.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	41.7 (87.8 to 77.8)	19.0 (-6.5 to 55.4)
Non-melanoma skin cancer	1.7 (1.3 to 2.3)	4.3 (3.0 to 6.1)	148.9 (61.8 to 279.4)	50.8 (-0.6 to 131.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	241.9 (110.3 to 408.0)	101.6 (24.2 to 207.0)
Ovarian cancer	0.5 (0.4 to 0.6)	0.9 (0.7 to 1.1)	73.2 (33.8 to 125.1)	39.4 (9.0 to 81.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	60.5 (12.9 to 123.4)	29.0 (-8.3 to 78.9)
Testicular cancer	0.2 (0.1 to 0.3)	0.4 (0.1 to 0.7)	134.5 (-47.6 to 400.8)	194.7 (-35.5 to 532.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	109.9 (-53.1 to 385.6)	157.4 (-44.0 to 473.8)
Kidney cancer	0.8 (0.3 to 0.4)	1.7 (1.4 to 2.0)	109.5 (293.6 to 576.7)	66.5 (183.1 to 387.2)	0.1 (0.0 to 0.0)	0.1 (0.1 to 0.2)	91.8 (223.5 to 447.1)	29.9 (131.7 to 285.7)
Bladder cancer	0.6 (0.5 to 0.7)	1.7 (1.4 to 2.0)	184.6 (124.8 to 267.5)	66.5 (30.9 to 118.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	144.4 (94.5 to 214.8)	42.0 (11.9 to 84.8)
Brain and nervous system cancer	1.2 (1.0 to 1.4)	1.5 (1.1 to 1.8)	28.9 (-0.2 to 58.1)	26.7 (-0.2 to 56.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	30.5 (2.6 to 61.6)	25.2 (-3.7 to 52.8)
Thyroid cancer	0.6 (0.5 to 0.8)	1.4 (0.8 to 1.9)	151.3 (26.1 to 248.9)	155.7 (31.2 to 258.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	140.3 (20.8 to 247.4)	135.8 (17.8 to 243.1)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	7.6 (-21.2 to 140.6)	25.1 (-44.3 to 64.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-17.5 to 158.6)	0.0 (-42.6 to 75.3)
Hodgkin lymphoma	0.5 (0.3 to 0.7)	0.6 (0.3 to 0.8)	28.4 (-32.4 to 90.4)	41.3 (-25.4 to 112.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	23.9 (-36.0 to 72.7)	32.0 (-31.1 to 85.9)
Non-Hodgkin lymphoma	0.4 (0.3 to 0.6)	1.5 (0.7 to 2.1)	330.2 (60.7 to 492.9)	279.6 (50.0 to 424.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	283.2 (40.6 to 414.7)	232.9 (28.0 to 346.0)
Multiple myeloma	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	182.5 (27.1 to 446.3)	110.3 (-0.9 to 301.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	143.9 (13.2 to 361.2)	81.7 (-14.1 to 234.2)
Leukemia	0.8 (0.6 to 1.0)	1.2 (1.0 to 1.4)	61.7 (21.3 to 111.2)	48.1 (9.9 to 95.0)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	64.0 (29.5 to 107.6)	29.9 (10.9 to 77.9)
Other neoplasms	1.7 (1.4 to 2.0)	4.1 (3.2 to 5.6)	136.8 (81.1 to 237.7)	90.5 (44.4 to 173.8)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	107.7 (58.0 to 191.2)	63.8 (24.6 to 131.0)
Cardiovascular diseases	-	-	-	-	6.2 (4.2 to 8.6)	11.0 (7.8 to 15.1)	80.8 (36.3 to 117.5)	13.9 (-12.2 to 36.4)
Rheumatic heart disease	0.5 (0.4 to 0.6)	0.7 (0.6 to 0.9)	44.1 (10.5 to 85.8)	4.0 (-19.3 to 35.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	40.8 (0.5 to 98.5)	2.3 (-25.6 to 41.9)
Ischemic heart disease	44.6 (37.7 to 55.2)	68.6 (61.7 to 76.1)	55.8 (16.5 to 93.1)	-2.5 (-22.7 to 17.7)	2.3 (1.5 to 3.5)	3.6 (2.5 to 5.0)	55.8 (9.8 to 105.3)	-4.5 (-28.7 to 20.4)
Cerebrovascular disease	-	-	-	-	0.8 (0.6 to 1.1)	1.3 (0.8 to 1.7)	49.2 (21.6 to 84.3)	13.6 (-5.4 to 36.9)
Ischemic stroke	4.4 (3.8 to 5.1)	7.0 (5.9 to 8.2)	57.7 (30.8 to 89.5)	15.4 (-4.4 to 36.5)	0.7 (0.5 to 0.9)	1.0 (0.7 to 1.4)	54.9 (24.6 to 90.4)	14.5 (-6.7 to 37.6)
Hemorrhagic stroke	1.1 (0.8 to 1.3)	1.4 (1.1 to 1.8)	32.9 (-3.8 to 98.8)	11.9 (-17.0 to 68.4)	0.2 (0.1 to 0.2)	0.3 (0.1 to 0.3)	29.5 (-7.3 to 93.7)	10.4 (-18.2 to 62.9)
Hypertensive heart disease	6.9 (6.1 to 7.8)	13.7 (12.2 to 15.3)	98.2 (67.4 to 135.5)	8.4 (-2.2 to 28.7)	0.8 (0.5 to 1.0)	1.5 (1.0 to 2.1)	96.0 (65.2 to 135.4)	8.0 (-9.2 to 29.2)
Cardiomyopathy and myocarditis	1.7 (1.5 to 2.0)	10.1 (7.6 to 12.6)	500.7 (336.8 to 670.6)	246.5 (155.0 to 355.1)	0.1 (0.1 to 0.2)	0.8 (0.5 to 1.2)	501.0 (322.7 to 687.7)	251.7 (153.4 to 364.0)
Atrial fibrillation and flutter	95.9 (71.8 to 127.3)	171.2 (131.2 to 215.0)	80.6 (7.0 to 167.3)	9.3 (-31.1 to 56.6)	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.3)	-14.9 (-52.8 to 69.3)	-57.3 (-75.9 to -17.1)
Endocarditis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	23.6 (-15.3 to 113.6)	4.4 (-28.7 to 93.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.5 (-16.1 to 85.3)	5.3 (-28.9 to 67.4)
Other cardiovascular and circulatory diseases	15.0 (7.5 to 34.2)	37.0 (18.0 to 55.1)	149.5 (-20.4 to 447.9)	77.8 (-44.6 to 296.2)	1.1 (0.5 to 2.4)	2.6 (1.0 to 4.3)	148.1 (-21.0 to 443.9)	77.6 (-45.0 to 301.9)
Chronic respiratory diseases	-	-	-	-	15.5 (10.4 to 21.3)	18.5 (12.5 to 25.4)	19.5 (3.0 to 38.7)	3.0 (-11.2 to 18.2)
Chronic obstructive pulmonary disease	201.0 (191.4 to 210.2)	241.6 (230.6 to 252.3)	20.1 (16.7 to 24.2)	-0.3 (-2.9 to 2.6)	11.9 (7.9 to 16.3)	14.7 (9.6 to 20.5)	24.8 (3.0 to 49.9)	4.2 (-13.0 to 26.2)

Appendix Table G.4 - Bosnia and Herzegovina prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumococcal	-	-	-	-	0.0	0.0	10.7	-4.5
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.8 (26.5 to 41.4)	0.4 (-4.7 to 5.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.2 (26.7 to 42.0)	0.7 (-4.5 to 6.0)
Asbestosis	-	-	-	-	0.0	0.0	-	-
Coal workers pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.6 (13.5 to 30.6)	-2.1 (-8.4 to 3.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.1 (14.1 to 31.3)	-1.7 (-8.1 to 3.6)
Other pneumoconiosis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	11.2 (23.0 to 0.6)	-0.9 (-39.0 to -34.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.6 (-38.6 to -24.5)	-0.6 (-3.3 to 2.1)
Asthma	70.5 (53.3 to 89.8)	78.7 (56.9 to 95.4)	15.2 (-27.6 to 58.9)	6.6 (-32.5 to 45.3)	3.1 (1.8 to 4.7)	3.4 (2.1 to 5.0)	13.3 (-28.9 to 55.6)	5.8 (-33.3 to 47.3)
Interstitial lung disease and pulmonary sarcoidosis	0.5 (0.4 to 0.7)	0.6 (0.4 to 0.7)	17.2 (-24.1 to 65.3)	7.3 (-30.1 to 51.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	20.0 (-22.9 to 68.3)	7.8 (-28.9 to 51.9)
Other chronic respiratory diseases	-	-	-	-	0.4	0.3	-29.1	-41.9
Cirrhosis	-	-	-	-	0.3	0.5	-52.2 to -1.0	-30.7
Cirrhosis due to hepatitis B	0.6 (0.4 to 0.8)	0.5 (0.4 to 0.7)	-14.3 (-41.2 to 39.7)	-22.6 (-47.8 to 26.0)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-15.9 (-45.5 to 39.0)	23.1 (-50.6 to 26.4)
Cirrhosis due to hepatitis C	0.8 (0.5 to 1.1)	0.5 (0.3 to 0.7)	-35.2 (-62.4 to 42.7)	-43.5 (-67.0 to 23.6)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-36.1 (-64.7 to 46.1)	-43.7 (-69.1 to 27.3)
Cirrhosis due to alcohol use	0.7 (0.4 to 1.0)	0.4 (0.1 to 0.5)	-50.3 (-78.7 to -13.4)	0.1 (-82.8 to -29.7)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-51.6 (-79.1 to -13.5)	-59.1 (-82.6 to -27.7)
Cirrhosis due to other causes	0.6 (0.5 to 0.7)	0.5 (0.4 to 0.7)	-12.3 (-42.2 to 18.8)	-1.5 (-33.5 to 30.9)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-15.2 (-46.7 to 24.2)	-3.3 (-38.0 to 38.8)
Digestive diseases	-	-	-	-	4.6	5.0	10.3	-12.1
Peptic ulcer disease	31.1 (28.6 to 33.1)	18.8 (16.0 to 22.8)	-39.6 (-46.9 to -29.0)	-64.7 (-69.2 to -58.7)	1.1 (0.7 to 1.5)	0.8 (0.5 to 1.1)	-31.7 (-39.4 to -17.5)	-59.8 (-63.7 to -51.3)
Gastritis and duodenitis	2.6 (2.3 to 2.8)	2.0 (1.7 to 2.3)	-22.6 (-35.5 to -9.4)	-28.8 (-41.7 to -15.3)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-22.3 (-37.8 to 5.0)	-26.4 (-41.7 to 4.0)
Appendicitis	0.4 (0.3 to 0.6)	0.2 (0.1 to 0.2)	-60.4 (-76.2 to -37.7)	-49.5 (-70.7 to -19.0)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-59.8 (-77.2 to -30.3)	-48.7 (-72.0 to -8.0)
Paralytic ileus and intestinal obstruction	0.0	0.1	41.6	22.3	0.0	0.0	25.1	25.1
Inguinal, femoral, and abdominal hernia	20.0 (16.7 to 23.7)	26.3 (21.7 to 30.3)	32.0 (4.5 to 63.6)	-9.3 (-27.4 to 12.9)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.5)	29.9 (-2.8 to 63.4)	-9.4 (-27.6 to 13.4)
Inflammatory bowel disease	6.1 (5.9 to 6.4)	8.9 (8.6 to 9.3)	45.9 (37.1 to 53.8)	36.1 (28.1 to 43.5)	1.3 (0.9 to 1.8)	1.9 (1.3 to 2.5)	43.4 (32.1 to 55.6)	35.6 (24.8 to 46.5)
Vascular intestinal disorders	0.0	0.0	53.6	-4.7	0.0	0.0	56.8	-1.0
Gallbladder and biliary diseases	10.5 (9.0 to 12.0)	10.5 (9.2 to 11.9)	0.2 (-18.3 to 21.0)	-31.0 (-35.6 to -5.1)	0.2 (0.1 to 0.5)	0.1 (0.1 to 0.5)	1.1 (-19.9 to 22.0)	-21.3 (-36.4 to -4.3)
Pancreatitis	1.3 (1.2 to 1.3)	1.8 (1.7 to 1.9)	38.6 (28.7 to 50.3)	23.1 (14.8 to 33.6)	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.7)	35.8 (17.5 to 57.7)	22.9 (7.0 to 41.9)
Other digestive diseases	-	-	-	-	0.2	0.3	93.9	53.7
Neurological disorders	-	-	-	-	42.5	44.9	19.4 to 150.3	6.0
Alzheimer disease and other dementias	25.7 (22.4 to 28.9)	50.4 (44.0 to 56.9)	95.5 (63.1 to 139.8)	-1.4 (-17.8 to 22.8)	3.7 (2.6 to 4.8)	7.2 (5.2 to 9.4)	95.7 (62.5 to 142.4)	6.0 (-18.6 to 22.5)
Parkinson disease	2.1 (1.4 to 2.9)	3.7 (2.5 to 4.9)	76.6 (55.4 to 94.9)	0.5 (-7.7 to 8.2)	0.3 (0.1 to 0.4)	0.4 (0.3 to 0.6)	73.8 (46.8 to 102.8)	0.0 (-12.3 to 14.3)
Epilepsy	25.2 (16.1 to 35.5)	18.2 (11.7 to 24.6)	-27.4 (-59.3 to 26.0)	-15.5 (-52.4 to 45.0)	7.1 (3.9 to 11.1)	5.4 (2.9 to 8.7)	-23.9 (-59.7 to 36.7)	-10.3 (-52.3 to 61.5)
Multiple sclerosis	1.0 (0.9 to 1.1)	1.9 (1.7 to 2.0)	82.3 (62.2 to 105.9)	86.6 (66.2 to 110.9)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	79.2 (47.6 to 116.0)	84.8 (50.8 to 121.0)
Migraine	667.1 (602.4 to 728.6)	591.6 (545.3 to 638.5)	-11.3 (-21.4 to -0.4)	-21.9 (-11.3 to 12.0)	22.9 (13.7 to 34.1)	20.2 (12.1 to 29.2)	-12.1 (-23.3 to -1.2)	-2.1 (-11.7 to 12.4)
Tension-type headache	89.2 (77.5 to 942.9)	77.2 (708.9 to 828.4)	-10.0 (-20.1 to 1.5)	1.2 (-10.4 to 13.5)	1.3 (0.6 to 2.3)	1.2 (0.6 to 2.1)	-0.8 (-20.8 to 1.6)	0.9 (-10.5 to 14.3)
Medication overuse headache	43.3 (27.8 to 60.3)	63.1 (42.0 to 87.7)	45.1 (7.2 to 111.5)	50.9 (11.6 to 116.0)	6.8 (3.7 to 10.9)	9.8 (5.6 to 15.2)	43.4 (6.1 to 108.4)	51.0 (10.8 to 115.1)
Other neurological disorders	0.0	0.0	5.4	6.3	0.2	0.2	1.2	-45.8
Mental and substance use disorders	-	-	-	-	98.8	84.7	-14.3	-3.0
Schizophrenia	14.7 (13.5 to 15.9)	13.4 (12.3 to 14.4)	-9.1 (-13.1 to -5.0)	-1.1 (-4.8 to 3.2)	71.6 to 128.7	64.7 (61.6 to 109.8)	-11.9 (-16.9 to -11.9)	-1.3 (-5.0 to -1.0)
Alcohol use disorders	55.5 (50.8 to 60.4)	33.1 (29.8 to 36.8)	-40.4 (-44.9 to -35.5)	-33.5 (-38.4 to -28.0)	5.6 (3.8 to 7.9)	3.3 (2.2 to 4.6)	-41.2 (-45.9 to -35.8)	-33.8 (-39.3 to -27.7)
Drug use disorders	-	-	-	-	5.6	4.1	-27.4	-5.4
Opioid use disorders	5.2 (2.5 to 8.7)	4.0 (2.0 to 6.6)	-23.1 (-31.9 to -12.1)	-1.7 (-14.4 to 10.7)	2.2 (1.0 to 3.9)	1.7 (0.8 to 2.9)	-23.4 (-34.7 to -9.3)	-2.1 (-17.3 to 13.7)
Cocaine use disorders	2.5 (2.5 to 3.9)	3.2 (2.2 to 3.2)	28.1 (-38.6 to 14.2)	5.3 (-21.1 to 48.6)	0.4 (0.3 to 0.7)	0.4 (0.2 to 0.5)	-17.6 (-40.8 to 18.8)	7.1 (-23.3 to 53.8)
Amphetamine use disorders	8.7 (7.1 to 10.5)	5.6 (4.7 to 6.6)	-35.0 (-50.2 to -16.8)	-15.2 (-35.0 to 9.2)	1.1 (0.7 to 1.7)	0.7 (0.5 to 1.1)	-35.2 (-51.7 to -14.8)	-14.9 (-37.1 to 11.4)
Cannabis use disorders	8.7 (6.9 to 10.5)	6.6 (5.2 to 7.8)	-25.0 (-26.4 to -23.2)	0.0 (-0.0 to 0.1)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-25.0 (-36.0 to -13.0)	0.1 (-14.3 to 15.4)
Other drug use disorders	-	-	-	-	1.6	1.1	-29.7	-7.7
Depressive disorders	-	-	-	-	36.1	33.4	-7.5	0.4
Major depressive disorder	145.3 (125.7 to 163.1)	134.5 (114.6 to 154.0)	-7.3 (-13.3 to -2.0)	-0.1 (-6.2 to 4.0)	29.9 (19.9 to 42.0)	27.3 (17.9 to 38.2)	-8.6 (-14.7 to -3.2)	-0.4 (-6.4 to 4.4)
Dysthymia	64.3 (53.3 to 75.8)	63.6 (53.0 to 73.7)	-1.2 (-6.3 to 4.7)	-0.5 (-0.7 to -0.4)	6.2 (4.0 to 9.2)	6.1 (3.9 to 8.9)	-2.4 (-7.9 to 4.4)	-0.6 (-3.1 to 1.7)
Bipolar disorder	33.2 (26.7 to 39.7)	29.8 (24.5 to 35.1)	-10.2 (-15.3 to -4.4)	-1.0 (-5.7 to 4.6)	6.8 (4.0 to 10.3)	6.0 (3.6 to 9.0)	-11.4 (-17.4 to -4.5)	-1.1 (-7.3 to 5.9)
Anxiety disorders	151.6 (134.6 to 188.8)	146.6 (121.9 to 166.4)	-3.4 (-14.0 to -6.4)	-0.5 (-0.7 to -0.4)	14.9 (10.1 to 21.5)	13.2 (8.9 to 18.8)	-11.5 (-15.8 to -7.1)	-0.5 (-2.9 to 2.1)
Eating disorders	-	-	-	-	1.2	0.9	-27.4	4.3
Anorexia nervosa	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.4)	23.4 (6.1 to 63.5)	74.2 (49.9 to 131.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	22.5 (-12.9 to 87.7)	72.7 (23.4 to 163.8)
Bulimia nervosa	5.3 (3.8 to 7.2)	3.7 (2.6 to 5.0)	-30.2 (-31.1 to -29.3)	0.2 (0.1 to 0.4)	1.1 (0.7 to 1.8)	0.8 (0.5 to 1.2)	-30.2 (-36.1 to -23.7)	0.2 (-8.3 to 9.2)
Autistic spectrum disorders	-	-	-	-	5.3	4.3	-18.8	0.4
Autism	13.7 (13.0 to 14.5)	11.3 (10.7 to 12.0)	-17.7 (-18.5 to -16.8)	0.4 (0.4 to 0.5)	3.4 (2.3 to 4.6)	2.8 (1.9 to 3.8)	-18.7 (-22.4 to -14.8)	0.5 (-4.3 to 5.3)
Asperger syndrome	19.6 (18.3 to 20.8)	16.0 (15.0 to 17.2)	-18.0 (-19.0 to -17.0)	0.6 (0.5 to 0.6)	2.0 (1.4 to 2.7)	1.6 (1.1 to 2.2)	-19.0 (-22.1 to -15.2)	0.3 (-3.3 to 4.7)
Attention-deficit/hyperactivity disorder	23.1 (21.2 to 24.9)	15.6 (14.3 to 16.8)	-32.5 (-32.6 to -32.5)	-0.1 (-0.2 to -0.1)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-32.5 (-37.5 to -27.1)	-0.1 (-7.6 to 8.0)
Conduct disorder	33.2 (31.3 to 35.3)	23.4 (22.0 to 24.9)	-29.6 (-30.1 to -29.2)	0.2 (-0.2 to -0.1)	4.0 (2.5 to 5.8)	2.8 (1.8 to 4.1)	-29.6 (-34.6 to -25.3)	0.1 (-4.0 to 4.3)
Idiopathic intellectual disability	70.3 (58.1 to 85.0)	50.6 (41.8 to 61.4)	-27.9 (-35.4 to -19.6)	-12.8 (-22.0 to -2.8)	3.4 (2.2 to 4.8)	2.4 (1.6 to 3.4)	-28.6 (-36.4 to -19.9)	-12.9 (-22.6 to -2.2)
Other mental and substance use disorders	81.0 (76.2 to 85.9)	75.5 (71.1 to 79.7)	-6.8 (-8.8 to -4.8)	0.4 (0.1 to 0.7)	6.1 (4.1 to 8.2)	5.6 (3.8 to 7.5)	-8.1 (-11.9 to -4.1)	0.2 (-3.3 to 4.1)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	43.6	50.6	16.2	9.0
Diabetes mellitus	232.5 (202.1 to 269.6)	296.2 (244.2 to 350.4)	27.2 (2.7 to 57.5)	19.1 (-4.9 to 47.0)	16.5 (10.7 to 24.2)	22.5 (14.9 to 32.1)	36.2 (5.1 to 83.2)	19.4 (-7.3 to 56.3)
Acute glomerulonephritis	0.0	0.0	67.0	53.1	0.0	0.0	67.0	53.1
Chronic kidney disease	0.0 to 0.0	0.0 to 0.0	-70.5 to -63.4	-58.2 to -48.0	0.0 to 0.0	0.0 to 0.0	-70.5 to -63.3	-58.3 to -48.0
Chronic kidney disease due to diabetes mellitus	71.1 (46.2 to 106.7)	90.8 (62.4 to 131.8)	27.9 (-3.8 to 79.7)	2.8 (-19.8 to 38.3)	2.2 (1.5 to 3.1)	2.6 (1.8 to 3.6)	19.2 (-4.4 to 59.5)	-0.3 (-2.8 to 28.9)
Chronic kidney disease due to hypertension	107.4 (71.7 to 153.2)	72.4 (48.4 to 105.3)	-33.0 (-47.7 to -9.0)	-28.4 (-44.5 to -11.0)	3.0 (2.0 to 4.2)	1.3 (0.9 to 1.7)	-56.9 (-65.2 to -40.6)	-59.1 (-67.3 to -43.8)
Chronic kidney disease due to glomerulonephritis	101.0 (66.2 to 145.9)	49.0 (36.2 to 65.6)	-51.9 (-61.8 to -33.1)	-21.9 (-31.9 to -11.9)	2.5 (2.1 to 2.9)	2.2 (1.6 to 2.9)	-25.0 (-39.1 to -5.6)	-22.6 (-37.8 to -2.8)
Chronic kidney disease due to other causes	185.8 (125.7 to 284.2)	290.5 (216.3 to 388.6)	58.5 (27.1 to 99.9)	44.4 (24.1 to 73.1)	5.0 (3.6 to 6.9)	8.5 (6.2 to 11.0)	68.1 (39.3 to 104.4)	52.5 (30.3 to 79.0)
Urinary diseases and male infertility	-	-	-	-	2.1	3.7	81.5	15.0
	-	-	-	-	1.3 to 2.9	2.4 to 5.3	53.8 to 111.6	-1.9 to 33.4

Appendix Table G.4 - Bosnia and Herzegovina prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.9 (0.8 to 1.0)	0.8 (0.7 to 0.9)	-7.5 (-22.6 to 10.0)	-1.5 (15.6 to 19.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.8 (-29.0 to 19.2)	1.4 (-21.5 to 30.1)
Urolithiasis	34.0 (25.2 to 49.4)	47.3 (32.8 to 62.6)	39.7 (0.2 to 81.0)	0.4 (-23.8 to 34.3)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	38.4 (10.3 to 72.2)	9.4 (-10.1 to 36.3)
Benign prostatic hyperplasia	45.2 (37.6 to 51.3)	88.8 (77.1 to 100.1)	97.1 (61.3 to 143.1)	1.6 (-6.4 to 41.7)	1.0 (1.0 to 2.4)	3.1 (2.0 to 4.5)	94.1 (58.0 to 140.7)	13.3 (-7.7 to 40.9)
Male infertility due to other causes	19.0 (13.7 to 24.3)	13.4 (10.0 to 18.4)	-30.2 (-51.3 to 10.9)	1.3 (-29.2 to 59.4)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-30.0 (-51.1 to 11.8)	1.7 (-31.5 to 61.9)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	67.5 (10.2 to 104.9)	89.3 (-26.7 to 87.6)
Gynecological diseases	-	-	-	-	6.2 (3.9 to 9.2)	4.9 (3.1 to 7.3)	-20.6 (-30.6 to -9.0)	-4.3 (-15.9 to 10.0)
Uterine fibroids	102.6 (93.1 to 111.3)	97.5 (89.5 to 105.3)	-5.0 (-6.6 to -3.2)	-1.4 (-1.7 to -1.3)	1.4 (0.8 to 2.4)	1.1 (0.6 to 1.9)	-21.9 (-27.4 to -17.1)	-12.6 (-17.5 to -8.4)
Polycystic ovarian syndrome	86.2 (76.4 to 96.8)	69.0 (62.8 to 75.1)	-20.0 (-30.2 to -6.9)	0.2 (-12.5 to 16.5)	0.8 (0.4 to 1.6)	1.7 (0.3 to 1.2)	-20.0 (-30.4 to -7.4)	0.7 (-12.1 to 17.0)
Female infertility due to other causes	11.3 (3.1 to 23.1)	8.5 (2.2 to 16.7)	-22.1 (-42.4 to 183.0)	15.2 (-73.8 to 307.6)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	32.1 (-81.5 to 172.6)	14.0 (-71.8 to 299.7)
Endometriosis	9.1 (7.8 to 10.6)	7.8 (6.7 to 8.9)	-14.9 (-32.1 to 5.3)	5.0 (15.6 to 29.3)	0.8 (0.6 to 1.2)	0.7 (0.5 to 1.0)	0.8 (-32.8 to 7.8)	5.4 (-17.1 to 32.3)
Genital prolapse	253.0 (222.1 to 286.1)	237.5 (213.2 to 264.4)	-6.2 (-21.2 to 10.5)	-2.6 (-17.7 to 14.2)	0.8 (0.4 to 1.5)	0.8 (0.4 to 1.4)	-6.4 (-21.7 to 9.9)	-2.4 (-17.7 to 14.1)
Premenstrual syndrome	195.0 (118.0 to 275.3)	145.1 (101.9 to 194.3)	-26.0 (-53.4 to 31.6)	1.7 (-36.9 to 73.1)	1.2 (0.8 to 2.9)	1.2 (0.7 to 1.9)	-26.1 (-53.5 to 30.7)	-0.3 (-37.5 to 72.7)
Other gynecological diseases	17.7 (14.9 to 20.7)	12.5 (10.4 to 14.7)	-29.2 (-44.7 to -12.7)	-14.9 (-32.8 to 5.0)	0.5 (0.4 to 0.8)	0.3 (0.2 to 0.5)	-35.0 (-53.0 to -7.7)	-22.2 (-44.2 to 9.6)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	3.8 (2.5 to 5.5)	3.3 (2.1 to 4.7)	-12.9 (-19.8 to -0.8)	8.9 (1.0 to 22.5)
Thalassemias	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-38.9 (-44.0 to -32.4)	1.7 (-6.7 to 12.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.5 (-57.7 to -17.4)	-2.8 (-30.9 to 39.7)
Thalassemia trait	118.9 (103.8 to 138.8)	102.3 (89.4 to 120.4)	-14.0 (-18.3 to -8.3)	2.6 (-3.4 to 7.4)	1.3 (1.7 to 3.8)	2.5 (1.7 to 3.7)	-4.1 (-14.6 to 12.9)	18.9 (7.1 to 36.6)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.1 (-50.9 to -30.9)	-6.4 (-25.9 to 2.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.2 (-51.4 to -24.7)	-4.8 (-28.8 to 9.1)
Sickle cell trait	15.8 (11.2 to 22.4)	12.5 (8.9 to 17.8)	-19.0 (-38.0 to -14.1)	1.4 (-27.0 to 2.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-15.8 (-45.4 to 31.9)	13.9 (-29.4 to 81.3)
G6PD deficiency	45.0 (33.1 to 56.9)	32.8 (18.9 to 47.4)	-27.5 (-56.9 to 12.9)	-13.3 (-48.5 to 35.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.7 (-29.8 to -10.9)	-1.6 (-11.9 to 17.0)
G6PD trait	599.5 (557.3 to 637.6)	512.6 (472.9 to 546.8)	-14.6 (-22.6 to -5.3)	-1.7 (-10.9 to 9.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.9 (-55.5 to 787.4)	57.6 (-40.5 to 956.7)
Other hemoglobinopathies and hemolytic anemias	43.9 (39.3 to 49.1)	32.5 (29.4 to 35.1)	-26.0 (-35.0 to -16.7)	-17.6 (-28.3 to -6.2)	1.0 (0.6 to 1.5)	0.6 (0.4 to 1.0)	-35.5 (-51.4 to -19.3)	-17.1 (-35.3 to 12.8)
Endocrine, metabolic, blood, and immune disorders	62.8 (58.7 to 66.4)	50.2 (47.5 to 52.8)	-20.2 (-25.0 to -13.8)	2.0 (-14.0 to 0.4)	1.5 (1.3 to 2.8)	1.5 (1.0 to 2.1)	-23.2 (-31.2 to -13.7)	-6.8 (-15.8 to 4.1)
Musculoskeletal disorders	-	-	-	-	89.8 (63.2 to 119.8)	71.1 (68.9 to 126.3)	-15.5 (-0.5 to 15.2)	-1.5 (-9.8 to 4.0)
Rheumatoid arthritis	6.1 (5.5 to 6.6)	8.5 (7.7 to 9.2)	39.2 (22.6 to 59.6)	6.7 (-6.1 to 21.9)	1.4 (1.0 to 1.9)	1.9 (1.4 to 2.6)	36.3 (18.0 to 58.3)	6.1 (-7.6 to 22.9)
Osteoarthritis	181.7 (174.4 to 188.9)	270.5 (261.0 to 281.0)	48.7 (40.9 to 57.1)	0.7 (-4.7 to 6.0)	11.2 (7.9 to 15.1)	16.4 (11.5 to 22.3)	46.9 (39.3 to 55.2)	6.4 (-0.9 to 6.0)
Low back and neck pain	-	-	-	-	57.3 (46.7 to 91.6)	68.6 (47.8 to 91.8)	19.1 (-5.5 to 12.9)	1.5 (-9.8 to 8.5)
Low back pain	424.0 (393.7 to 455.9)	441.5 (415.1 to 468.2)	4.2 (-4.8 to 13.7)	-2.4 (-10.6 to 6.8)	47.4 (31.7 to 66.2)	48.5 (33.2 to 66.5)	2.5 (-6.4 to 12.3)	-2.5 (-11.1 to 6.9)
Neck pain	201.8 (165.7 to 235.5)	207.9 (171.7 to 245.3)	4.1 (-20.9 to 30.9)	2.5 (-21.3 to 29.0)	19.9 (13.1 to 28.3)	20.3 (13.6 to 28.6)	3.1 (-22.3 to 29.7)	2.3 (-21.5 to 29.2)
Gout	1.9 (1.8 to 2.0)	2.6 (2.4 to 2.7)	34.7 (23.6 to 47.2)	4.4 (-4.3 to 13.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	32.0 (54.0 to 65.9)	3.7 (-16.6 to 29.1)
Other musculoskeletal disorders	107.2 (81.1 to 133.0)	99.0 (62.0 to 133.4)	-6.3 (-36.7 to 10.7)	-20.5 (-47.6 to -7.0)	9.8 (6.3 to 14.3)	9.0 (5.1 to 14.1)	-7.7 (-38.4 to 10.5)	-20.7 (-48.4 to -6.1)
Other non-communicable diseases	-	-	-	-	70.0 (45.9 to 102.5)	73.7 (48.5 to 106.9)	5.2 (-1.2 to 10.3)	-6.6 (-10.0 to -2.7)
Congenital anomalies	-	-	-	-	4.6 (3.4 to 6.0)	5.1 (3.7 to 6.7)	10.1 (3.7 to 29.3)	27.6 (11.3 to 49.8)
Neural tube defects	1.4 (1.1 to 1.7)	1.0 (0.9 to 1.2)	-25.5 (-41.7 to -2.9)	0.0 (-21.5 to 30.7)	0.5 (0.3 to 0.7)	0.4 (0.2 to 0.5)	-23.8 (-44.7 to 7.4)	3.2 (-25.6 to 45.4)
Congenital heart anomalies	27.7 (21.8 to 34.7)	26.8 (20.5 to 33.8)	-3.2 (-29.3 to 28.3)	20.9 (-11.4 to 59.8)	0.9 (0.4 to 1.6)	0.9 (0.4 to 1.6)	-0.6 (-2.8 to 30.4)	25.7 (-5.3 to 64.9)
Orofacial clefts	4.2 (3.5 to 5.2)	4.2 (3.3 to 5.4)	0.3 (-23.6 to 37.1)	0.3 (-5.3 to 70.6)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-54.6 to -1.0)	-18.9 (-43.1 to 22.6)
Down syndrome	4.3 (3.3 to 5.4)	4.6 (3.7 to 5.7)	7.3 (-20.4 to 46.4)	19.1 (-11.4 to 63.4)	0.6 (0.4 to 0.8)	0.7 (0.5 to 1.0)	22.2 (-12.2 to 68.3)	25.0 (-9.8 to 71.3)
Turner syndrome	0.2 (0.2 to 0.2)	0.2 (0.1 to 0.2)	-14.3 (-46.4 to 27.3)	9.5 (-31.3 to 62.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.3 (-47.3 to 27.7)	8.8 (-32.1 to 62.4)
Klinefelter syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	-3.4 (-31.8 to 53.5)	18.9 (-15.5 to 88.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.4 (-34.2 to 48.2)	18.1 (-16.3 to 88.0)
Chromosomal unbalanced rearrangements	7.8 (6.3 to 9.9)	7.8 (7.2 to 11.2)	0.0 (-17.2 to 46.9)	8.9 (-7.7 to 63.7)	1.3 (0.7 to 1.4)	1.3 (0.9 to 1.8)	23.9 (-6.2 to 70.0)	26.9 (-3.9 to 73.7)
Other congenital anomalies	15.1 (12.4 to 17.8)	12.2 (10.1 to 14.2)	-19.9 (-27.0 to -11.2)	-10.1 (-18.1 to -0.2)	1.5 (1.0 to 2.2)	1.8 (1.2 to 2.5)	15.4 (-6.7 to 51.7)	39.3 (10.9 to 85.3)
Skin and subcutaneous diseases	-	-	-	-	21.4 (13.7 to 31.5)	18.0 (11.8 to 26.9)	-16.0 (-23.3 to -7.3)	-5.3 (-13.7 to 5.3)
Dermatitis	214.3 (179.1 to 255.4)	184.3 (155.6 to 215.8)	-13.9 (-16.6 to -11.1)	-0.1 (-0.2 to -0.0)	5.6 (3.5 to 8.1)	4.7 (3.0 to 6.9)	-15.6 (-19.1 to -11.6)	-0.1 (-2.7 to 2.8)
Psoriasis	38.0 (33.3 to 42.8)	36.4 (32.0 to 40.8)	-4.3 (-7.7 to 0.4)	4.3 (-0.1 to 0.2)	0.0 (2.1 to 4.3)	2.9 (2.0 to 4.1)	0.1 (-11.2 to 10.0)	0.1 (5.0 to 5.5)
Cellulitis	0.7 (0.5 to 0.8)	0.6 (0.5 to 0.8)	-8.8 (-26.4 to 15.6)	2.1 (-12.7 to 15.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-6.9 (-30.3 to 19.7)	2.0 (-20.0 to 26.8)
Pyoderma	6.3 (4.8 to 7.9)	4.2 (3.3 to 5.3)	-33.8 (-45.3 to -21.6)	-24.2 (-32.5 to -15.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-35.1 (-46.6 to -21.6)	-24.8 (-33.7 to -13.8)
Scabies	9.8 (8.8 to 10.8)	6.2 (5.6 to 6.7)	-36.5 (-44.4 to -27.6)	-21.8 (-31.4 to -10.3)	0.3 (0.1 to 0.4)	0.2 (0.1 to 0.5)	-37.1 (-45.6 to -26.5)	-1.3 (-32.4 to -9.6)
Fungal skin diseases	354.9 (272.4 to 472.0)	333.3 (264.2 to 427.9)	-6.3 (-11.7 to 1.0)	5.1 (-0.1 to 0.4)	0.1 (0.8 to 4.5)	1.9 (0.7 to 4.0)	-6.9 (-12.4 to -1.1)	0.1 (-0.9 to 1.0)
Viral skin diseases	95.7 (71.1 to 120.1)	70.8 (54.5 to 88.7)	-26.2 (-29.9 to -20.6)	0.0 (-1.6 to 1.9)	3.0 (1.7 to 4.7)	2.2 (1.3 to 3.4)	-26.7 (-30.7 to -21.2)	0.0 (-2.9 to 3.2)
Acne vulgaris	86.4 (59.8 to 114.9)	73.0 (58.2 to 88.6)	-16.1 (-39.4 to 27.6)	16.0 (-17.1 to 77.2)	0.9 (0.4 to 2.0)	0.8 (0.4 to 1.5)	-16.2 (-39.3 to 27.2)	16.1 (-17.1 to 77.1)
Alopecia areata	5.3 (4.6 to 5.9)	5.2 (4.4 to 5.8)	-1.3 (-20.2 to 18.9)	-0.3 (-17.5 to 21.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-2.9 (-23.0 to 20.4)	-0.7 (-19.1 to 23.4)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	5.1 (2.2 to 9.2)	0.0 (0.0 to 0.0)	5.1 (-22.9 to 36.3)	-14 (-25.2 to 26.5)
Urticaria	76.6 (50.9 to 95.5)	53.4 (42.0 to 65.6)	-30.8 (-52.5 to 14.3)	-26.0 (-48.3 to 26.6)	4.6 (2.5 to 6.9)	3.1 (1.9 to 4.7)	-11.7 (-53.2 to 12.6)	26.1 (-49.4 to 26.5)
Decubitus ulcer	0.6 (0.5 to 0.6)	1.1 (0.8 to 1.4)	99.3 (53.6 to 159.3)	34.5 (5.4 to 73.8)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	90.5 (39.7 to 158.1)	32.6 (-0.9 to 76.3)
Other skin and subcutaneous diseases	283.9 (180.6 to 447.1)	316.2 (182.1 to 545.6)	9.6 (-8.2 to 31.2)	-3.6 (-8.3 to 3.0)	1.7 (0.7 to 3.5)	1.8 (0.7 to 4.2)	8.3 (-6.6 to 29.9)	-3.7 (-8.7 to 3.3)
Sense organ diseases	-	-	-	-	32.9 (21.2 to 49.2)	38.1 (24.7 to 56.1)	15.8 (9.7 to 23.6)	-11.9 (-15.5 to -7.1)
Glaucoma	4.9 (4.1 to 5.8)	4.8 (3.7 to 6.0)	-2.1 (-21.6 to 22.7)	-17.3 (-33.4 to 1.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-0.5 (-13.5 to 30.3)	-1.7 (-32.8 to -1.7)
Cataract	38.0 (29.4 to 46.8)	50.5 (38.6 to 62.1)	33.6 (5.2 to 59.3)	-26.6 (-40.9 to -13.9)	1.3 (0.8 to 2.0)	1.7 (1.1 to 2.7)	34.9 (8.4 to 59.6)	-26.1 (-39.7 to -13.8)
Macular degeneration	12.4 (9.7 to 15.8)	18.9 (13.9 to 26.0)	48.6 (14.1 to 108.8)	5.0 (-19.8 to 50.0)	0.4 (0.3 to 0.6)	0.6 (0.4 to 1.0)	50.7 (15.7 to 110.0)	4.1 (-20.0 to 46.9)
Uncorrected refractive error	624.5 (542.5 to 712.0)	652.6 (584.3 to 731.0)	4.5 (-12.4 to 24.6)	-15.3 (-28.0 to 0.6)	8.3 (4.6 to 14.0)	8.3 (4.5 to 14.3)	0.3 (-15.5 to 16.0)	-16.6 (-26.7 to -4.9)
Age-related and other hearing loss	727.1 (635.7 to 809.8)	882.4 (788.5 to 965.4)	21.2 (14.7 to 29.1)	8.0 (-11.3 to -3.4)	18.9 (12.3 to 27.7)	23.9 (15.9 to 34.1)	25.9 (17.7 to 37.1)	-9.5 (-14.9 to -3.8)
Other vision loss	27.3 (23.6 to 31.3)	20.0 (16.7 to 24.3)	-27.2 (-35.9 to -13.5)	-31.3 (-38.7 to -19.7)	1.1 (0.7 to 1.6)	0.9 (0.6 to 1.3)	-16.0 (-27.4 to -2.1)	-2.0 (-36.1 to -18.1)
Other sense organ diseases	101.6 (96.6 to 106.5)	92.4 (87.5 to 97.2)	-9.0 (-15.3 to -2.6)	-0.5 (-7.0 to 6.2)	2.7 (1.7 to 4.0)	2.4 (1.5 to 3.6)	-2.4 (-17.2 to -3.4)	-0.5 (-7.6 to 7.1)
Oral disorders	-	-	-	-	11.0 (6.7 to 17.4)	12.4 (7.6 to 19.1)	-5.3 (-6.2 to 20.8)	13.0 (-10.3 to 0.3)
Deciduous caries	278.1 (268.9 to 286.8)	144.5 (140.2 to 149.5)	-48.1 (-50.2 to -45.7)	1.2 (-3.0 to 6.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.1 (-52.1 to -43.3)	1.3 (-6.7 to 10.6)
Permanent caries	2557.2 (2,419.5 to 2,667.3)	2,237.6 (2,153.7 to 2,307.6)	-12.5 (-17.2 to -7.6)	1.5 (-4.6 to 7.5)	1.5 (0.7 to 2.9)	1.3 (0.6 to 2.5)	-13.2 (-18.0 to -7.8)	1.4 (-4.7 to 7.7)
Periodontal diseases	450.5 (409.5 to 491.4)	510.5 (463.0 to 554.7)	13.					

Appendix Table G.4 - Bosnia and Herzegovina prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	148.6 (136.2 to 160.3)	205.8 (195.4 to 216.5)	38.2 (27.2 to 52.7)	-12.5 (-19.9 to -3.6)	4.1 (2.7 to 5.8)	5.6 (3.8 to 7.7)	36.2 (24.6 to 51.1)	36.2 (-20.4 to -3.9)
Other oral disorders	82.9 (78.6 to 87.2)	75.9 (71.7 to 79.6)	-8.6 (-14.9 to -1.0)	-0.4 (-7.2 to 7.4)	2.4 (1.5 to 3.6)	2.2 (1.4 to 3.3)	-9.4 (-15.8 to -1.7)	-0.5 (-7.4 to 7.8)
Injuries	-	-	-	-	41.8 (31.4 to 54.1)	56.7 (38.6 to 81.5)	33.5 (9.1 to 76.4)	12.2 (-8.3 to 48.6)
Transport injuries	-	-	-	-	2.8 (2.1 to 3.7)	1.6 (1.2 to 2.2)	-42.1 (-48.5 to -34.8)	-48.3 (-53.8 to -41.7)
Road injuries	-	-	-	-	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.0)	66.7 (47.2 to 94.3)	46.0 (28.5 to 66.1)
Pedestrian road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	68.0 (44.0 to 94.5)	36.3 (18.2 to 56.0)
Cyclist road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	36.7 (21.2 to 53.0)	14.6 (2.1 to 28.1)
Motorcyclist road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	51.1 (27.8 to 75.8)	42.8 (21.9 to 64.7)
Motor vehicle road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	84.9 (58.9 to 118.2)	64.8 (43.4 to 91.8)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.5 (-26.4 to -2.8)	-26.8 (-35.6 to -16.4)
Other transport injuries	-	-	-	-	2.4 (1.8 to 3.1)	0.9 (0.6 to 1.2)	-62.9 (-67.0 to -58.2)	-66.5 (-70.2 to -62.3)
Unintentional injuries	-	-	-	-	38.3 (28.8 to 49.4)	38.0 (27.3 to 51.3)	-1.0 (-11.1 to 10.4)	-17.7 (-26.1 to -8.0)
Falls	-	-	-	-	33.3 (25.0 to 43.0)	31.8 (22.7 to 42.8)	-4.9 (-15.3 to 6.9)	-22.9 (-31.4 to -13.1)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,826.6 (1,534.9 to 2,175.6)	1,714.6 (1,451.7 to 2,025.3)
Fire, heat, and hot substances	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.5)	46.4 (22.1 to 71.0)	52.4 (28.7 to 77.3)
Poisonings	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.0 to 0.1)	-74.0 (-77.2 to -69.8)	-71.8 (-75.4 to -66.8)
Exposure to mechanical forces	-	-	-	-	2.4 (1.8 to 3.2)	4.1 (2.9 to 5.5)	67.9 (47.4 to 85.5)	72.1 (51.7 to 90.7)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	24.1 (23.1 to 83.4)	17.1 (25.4 to 84.5)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.7 (9.6 to 42.2)	73.0 (4.5 to 33.5)
Other exposure to mechanical forces	-	-	-	-	2.4 (1.7 to 3.1)	4.0 (2.9 to 5.4)	68.7 (47.8 to 86.5)	73.0 (52.4 to 91.8)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	11.2 (1.9 to 20.9)	-1.7 (-9.5 to 6.3)
Animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-25.1 (-32.3 to -17.1)	-23.1 (-30.1 to -15.6)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-24.4 (-35.2 to -12.6)	-20.8 (-32.6 to -8.9)
Non-venomous animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-25.7 (-34.2 to -15.3)	-24.6 (-32.6 to -15.1)
Foreign body	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-25.3 (-32.9 to -16.8)	-26.9 (-34.1 to -19.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-45.1 (-54.6 to -33.2)	-44.8 (-54.0 to -33.7)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-15.3 (-20.8 to -9.4)	-9.5 (-16.3 to -3.1)
Foreign body in other body part	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-15.0 (-24.2 to -5.8)	-20.5 (-28.4 to -12.6)
Other unintentional injuries	-	-	-	-	1.5 (1.1 to 1.9)	1.3 (0.9 to 1.7)	-12.9 (-21.3 to -4.3)	-27.8 (-34.1 to -20.8)
Self-harm and interpersonal violence	-	-	-	-	0.7 (0.5 to 0.9)	0.4 (0.3 to 0.5)	-43.4 (-50.3 to -35.6)	-47.4 (-53.5 to -40.4)
Self-harm	-	-	-	-	0.5 (0.3 to 0.6)	0.2 (0.2 to 0.3)	-53.4 (-59.5 to -47.2)	-56.7 (-62.2 to -51.4)
Interpersonal violence	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-19.3 (-29.9 to -6.2)	-24.5 (-34.2 to -12.8)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	5.7 (-4.0 to 16.4)	-5.8 (-13.8 to 3.3)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.8 (-5.2 to 25.3)	1.3 (-10.9 to 15.8)
Assault by other means	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-33.0 (-42.7 to -20.8)	-36.0 (-44.8 to -25.2)
Forces of nature, war, and legal intervention	-	-	-	-	-	16.7 (7.1 to 34.2)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	16.7 (7.1 to 34.2)	-	-

Appendix Table G.4 - Botswana prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	130.4 (95.2 to 171.2)	215.5 (158.5 to 280.9)	65.3 (59.1 to 70.7)	65.3 (-0.3 to 5.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	37.0 (25.5 to 52.9)	61.8 (44.0 to 86.1)	67.9 (48.9 to 84.2)	24.4 (7.4 to 36.0)
HIV/AIDS and tuberculosis	-	-	-	-	6.1 (4.2 to 8.1)	23.3 (16.6 to 30.9)	284.4 (236.2 to 343.4)	136.1 (105.5 to 175.6)
Tuberculosis	13.4 (12.6 to 14.3)	20.6 (19.2 to 22.2)	53.7 (45.8 to 62.1)	-11.7 (-15.8 to -7.6)	4.1 (2.8 to 5.6)	6.3 (4.3 to 8.5)	52.9 (43.6 to 61.8)	-12.3 (-17.0 to -7.9)
HIV/AIDS	-	-	-	-	2.2 (1.3 to 2.7)	2.4 (1.2 to 2.7)	75.2 (61.9 to 94.5)	497.4 (391.2 to 619.9)
HIV/AIDS resulting in mycobacterial infection	1.7 (1.0 to 2.3)	6.1 (3.8 to 8.1)	264.2 (197.7 to 342.2)	123.9 (82.0 to 170.3)	0.6 (0.4 to 1.0)	2.3 (1.3 to 3.4)	258.9 (191.2 to 339.9)	120.8 (79.2 to 168.6)
HIV/AIDS resulting in other diseases	18.1 (15.4 to 20.5)	175.6 (165.5 to 189.7)	866.6 (762.1 to 1,009.2)	596.0 (519.2 to 693.3)	1.3 (0.9 to 1.8)	14.8 (10.4 to 20.0)	1,015.0 (827.6 to 1,248.7)	699.6 (559.8 to 869.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	3.9 (2.8 to 5.3)	4.4 (3.1 to 6.0)	11.9 (3.3 to 20.8)	-12.1 (-19.0 to -5.8)
Diarrheal diseases	13.5 (12.5 to 14.4)	14.6 (13.6 to 15.6)	8.4 (-1.9 to 18.8)	-6.2 (-14.5 to 2.4)	2.2 (1.5 to 3.0)	2.4 (1.6 to 3.3)	7.8 (-2.9 to 19.3)	4.5 (-15.2 to 3.1)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-	-14.9 (-37.2 to 12.5)
Typhoid fever	0.2 (0.2 to 0.2)	0.2 (0.1 to 0.2)	-15.6 (-32.7 to 4.6)	-37.9 (-50.6 to -20.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.5 (-36.2 to 12.5)	-37.2 (-52.1 to -17.7)
Paratyphoid fever	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	3.4 (-20.4 to 38.4)	-23.9 (-41.6 to 1.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.1 (-23.1 to 41.7)	-24.2 (-43.4 to 3.3)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-94.5 (-99.7 to 272.8)	-96.0 (-99.8 to 165.2)
Lower respiratory infections	0.5 (0.4 to 0.8)	0.6 (0.5 to 0.7)	11.2 (-28.0 to 62.3)	-28.1 (-54.5 to -6.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	10.5 (-30.9 to 62.9)	-27.8 (-43.9 to -3.5)
Upper respiratory infections	36.6 (33.0 to 40.0)	50.5 (45.0 to 55.7)	38.7 (19.8 to 56.4)	-1.8 (-15.1 to 11.7)	0.4 (0.2 to 0.7)	0.6 (0.3 to 1.0)	38.2 (19.4 to 56.6)	-1.9 (-15.2 to 11.5)
Otitis media	26.1 (23.6 to 28.6)	34.9 (31.9 to 38.4)	33.5 (23.0 to 46.2)	-5.1 (-13.3 to 4.2)	0.5 (0.3 to 0.8)	0.6 (0.4 to 1.0)	33.2 (21.0 to 46.5)	-4.5 (-13.0 to 5.1)
Meningitis	-	-	-	-	0.6 (0.4 to 0.9)	0.6 (0.4 to 0.9)	1.6 (-2.3 to 28.6)	-30.6 (-47.4 to -13.3)
Pneumococcal meningitis	1.3 (0.7 to 2.0)	1.4 (0.9 to 2.4)	13.9 (-9.8 to 45.7)	-34.9 (-40.6 to -3.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	16.8 (4.4 to 48.9)	21.5 (-38.4 to -1.8)
H influenzae type B meningitis	1.4 (0.5 to 3.0)	1.4 (0.5 to 3.0)	-1.2 (-43.3 to 32.5)	-34.4 (-60.8 to -8.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	7.2 (-45.2 to 61.9)	-24.7 (-61.1 to 10.6)
Meningococcal meningitis	1.0 (0.3 to 2.2)	0.9 (0.3 to 2.3)	-0.9 (-37.0 to 33.3)	-37.4 (-59.8 to -11.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-1.8 (-30.8 to 42.3)	-35.0 (-53.7 to -6.8)
Other meningitis	1.5 (0.8 to 2.6)	1.5 (0.8 to 2.7)	-1.8 (-29.9 to 26.5)	-33.7 (-52.3 to -12.8)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-7.0 (-41.0 to 37.6)	-7.0 (-58.2 to -5.0)
Encephalitis	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.7)	48.3 (12.0 to 75.9)	98.3 (-28.5 to 11.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	52.6 (-19.0 to 90.6)	-1.1 (-19.0 to 19.6)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.4 (-94.2 to 76.1)	-46.5 (-94.3 to 42.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.4 (-94.3 to 76.7)	-46.5 (-94.4 to 423.9)
Whooping cough	0.6 (0.4 to 0.7)	0.0 (0.0 to 0.0)	-97.0 (-97.6 to -96.3)	-97.1 (-97.7 to -96.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-97.0 (-97.9 to -95.8)	-97.1 (-97.9 to -95.9)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.4 (-92.4 to -59.6)	-88.1 (-94.7 to -72.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-76.3 (-88.3 to -41.5)	-84.5 (-91.9 to -64.6)
Measles	0.3 (0.2 to 0.4)	0.0 (0.0 to 0.0)	-90.0 (-92.6 to -86.5)	-90.3 (-92.9 to -87.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.1 (-94.8 to -82.9)	-90.4 (-95.0 to -83.5)
Varicella and herpes zoster	0.9 (0.8 to 0.9)	1.3 (1.2 to 1.5)	52.0 (33.6 to 76.9)	0.8 (-16.5 to 27.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.3 (21.7 to 136.5)	-1.7 (-28.6 to 47.4)
Neglected tropical diseases and malaria	-	-	-	-	8.1 (4.0 to 17.2)	12.2 (5.8 to 25.1)	52.4 (8.4 to 98.6)	-7.1 (-33.9 to 24.6)
Malaria	76.8 (44.0 to 126.5)	88.0 (49.6 to 168.6)	14.9 (-28.9 to 76.8)	-22.4 (-50.6 to 26.0)	0.7 (0.5 to 1.0)	0.9 (0.6 to 1.3)	27.1 (0.4 to 38.3)	-7.1 (-25.9 to 0.2)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.3 (-11.7 to 192.4)	6.1 (-28.1 to 106.1)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.3 (-11.5 to 191.2)	6.1 (-28.0 to 105.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.3 (-11.7 to 192.4)	6.1 (-28.1 to 106.1)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.9 (-17.6 to 103.1)	2.4 (-41.8 to 47.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.9 (-17.8 to 103.1)	2.4 (-41.9 to 47.9)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	140.9 (57.8 to 278.3)	227.7 (95.0 to 446.7)	61.7 (57.5 to 67.2)	1.4 (-0.7 to 4.6)	1.2 (0.5 to 2.7)	1.9 (0.7 to 4.3)	64.0 (38.0 to 87.7)	3.7 (-9.1 to 17.2)
Cysticercosis	1.6 (0.8 to 2.7)	2.4 (1.2 to 3.7)	47.7 (-19.5 to 209.7)	-24.7 (-57.6 to 47.2)	0.5 (0.2 to 0.8)	0.7 (0.3 to 1.2)	60.2 (-15.7 to 243.0)	-18.5 (-54.9 to 61.5)
Cystic echinococcosis	0.4 (0.3 to 0.4)	0.5 (0.4 to 0.5)	35.2 (1.6 to 47.4)	-34.8 (-52.7 to -25.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	34.7 (-1.5 to 69.3)	-34.2 (-52.8 to -16.9)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	5.1 (4.0 to 6.3)	3.6 (2.7 to 4.8)	-29.3 (-40.6 to -12.4)	-64.5 (-70.1 to -55.3)	0.4 (0.2 to 0.6)	0.3 (0.2 to 0.5)	-26.4 (-38.1 to -8.8)	-63.0 (-69.2 to -54.1)
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.7 (-64.8 to -10.4)	-59.2 (-76.1 to -34.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.7 (-64.9 to -10.4)	-59.2 (-76.1 to -33.9)
Intestinal nematode infections	-	-	-	-	1.5 (0.9 to 2.3)	2.3 (1.4 to 3.5)	53.5 (27.9 to 86.8)	4.5 (-16.2 to 31.1)
Ascariasis	85.4 (64.3 to 108.7)	124.2 (90.1 to 169.6)	44.4 (-1.9 to 120.9)	-0.9 (-36.5 to 62.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.8 (-23.9 to 142.3)	1.0 (-46.3 to 95.1)
Trichuriasis	257.4 (198.9 to 328.9)	374.3 (282.3 to 487.3)	44.4 (-0.7 to 113.6)	-1.0 (-35.7 to 54.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	39.7 (-17.3 to 133.7)	0.1 (-45.9 to 88.0)
Hookworm disease	277.0 (222.4 to 345.0)	425.3 (328.6 to 543.5)	52.0 (10.5 to 113.5)	0.6 (-31.3 to 47.1)	1.3 (0.8 to 2.0)	2.0 (1.2 to 3.1)	55.2 (27.9 to 94.0)	4.9 (-17.6 to 35.2)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	23.4 (17.8 to 29.0)	22.0 (20.3 to 24.0)	-5.8 (-24.7 to 24.3)	-21.7 (-35.9 to -0.7)	3.8 (1.2 to 11.4)	6.0 (1.8 to 15.6)	65.2 (-12.9 to 173.2)	18.0 (-43.3 to 98.3)
Maternal disorders	-	-	-	-	0.5 (0.3 to 0.7)	0.5 (0.4 to 0.7)	6.9 (-6.2 to 20.3)	-38.3 (-44.9 to -31.4)
Maternal hemorrhage	1.1 (1.0 to 1.3)	1.5 (1.2 to 1.9)	36.5 (-0.3 to 69.7)	-28.3 (-46.4 to -10.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	14.9 (-34.2 to 76.4)	40.5 (-60.5 to -9.2)
Maternal sepsis and other maternal infections	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-42.3 (-13.2 to 22.9)	-42.3 (-50.5 to -30.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.5 (-28.3 to 49.7)	-43.2 (-58.5 to -19.1)
Maternal hypertensive disorders	0.3 (0.1 to 0.5)	0.3 (0.1 to 0.5)	-48.3 (-10.6 to 4.3)	-48.3 (-51.7 to -44.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.1 (-23.2 to 20.0)	-4.1 (-57.8 to -36.2)
Obstructed labor	1.2 (1.1 to 1.3)	1.2 (1.1 to 1.4)	6.7 (-0.0 to 13.8)	-37.5 (-41.4 to -33.8)	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	6.3 (-6.3 to 20.6)	37.8 (-44.5 to -30.5)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.7 (-40.3 to 109.6)	-39.9 (-66.7 to 1.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.7 (-40.9 to 110.1)	-39.9 (-66.7 to 1.3)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	8.3 (-29.7 to 65.0)	37.7 (-59.7 to -5.3)
Neonatal disorders	-	-	-	-	3.4 (2.0 to 5.2)	7.8 (5.1 to 11.4)	130.6 (54.8 to 226.9)	63.3 (10.1 to 130.0)
Preterm birth complications	11.0 (8.0 to 15.6)	33.0 (24.8 to 44.2)	201.0 (150.7 to 255.3)	109.5 (75.0 to 147.0)	1.3 (0.9 to 1.8)	3.8 (2.7 to 5.2)	209.6 (120.7 to 305.9)	117.5 (57.1 to 181.4)
Neonatal encephalopathy due to birth asphyxia and trauma	5.7 (1.5 to 15.8)	6.9 (2.1 to 18.4)	23.7 (-7.7 to 106.4)	-16.0 (-35.8 to 39.3)	0.6 (0.4 to 1.0)	1.0 (0.5 to 1.5)	56.6 (-11.9 to 177.6)	10.7 (-38.4 to 97.6)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	145.8 (128.8 to 165.2)	145.8 (129.0 to 165.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	143.3 (118.5 to 189.2)	143.5 (118.6 to 189.4)
Hemolytic disease and other neonatal jaundice	0.6 (0.3 to 1.0)	1.1 (0.5 to 2.0)	68.0 (-25.8 to 337.2)	15.3 (-49.5 to 200.1)	0.2 (0.1 to 0.4)	0.2 (0.2 to 0.8)	67.4 (-28.8 to 327.4)	15.4 (-49.8 to 196.9)
Other neonatal disorders	-	-	-	-	1.3 (0.3 to 2.7)	2.6 (0.8 to 5.0)	106.7 (-7.8 to 348.1)	46.1 (-34.5 to 212.7)
Nutritional deficiencies	-	-	-	-	13.7 (9.0 to 19.8)	11.9 (7.9 to 17.1)	-13.1 (-25.8 to -3.2)	-33.3 (-40.9 to -26.3)
Protein-energy malnutrition	11.3 (3.5 to 25.3)	5.8 (1.9 to 14.7)	-48.7 (-87.6 to 99.2)	-49.9 (-87.7 to 84.3)	1.4 (0.4 to 3.5)	0.7 (0.2 to 1.8)	-48.8 (-87.7 to 96.8)	-49.8 (-87.8 to 85.1)
Iodine deficiency	22.2 (14.5 to 29.5)	18.5 (12.5 to 25.1)	-17.3 (-48.8 to 41.0)	-50.0 (-70.2 to -13.3)	0.4 (0.2 to 0.7)	0.3 (0.2 to 0.6)	-17.3 (-48.9 to 42.2)	-50.1 (-70.3 to -12.6)
Vitamin A deficiency	1.4 (1.0 to 1.8)	0.9 (0.6 to 1.1)	-37.1 (-48.8 to -26.2)	-52.2 (-60.6 to -44.6)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-43.2 (-56.4 to -31.3)	-56.9 (-66.0 to -48.7)

Appendix Table G.4 - Botswana prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	347.3 (341.9 to 352.2)	340.8 (332.1 to 348.1)	-1.8 (-4.5 to 0.4)	-29.5 (-31.4 to -27.9)	11.8 (7.9 to 17.1)	10.7 (7.2 to 15.5)	-9.4 (-11.9 to -5.8)	-31.3 (-32.9 to -28.6)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.3 (0.8 to 2.0)	1.8 (1.1 to 2.8)	1.8 (12.3 to 70.9)	-9.0 (-23.2 to 14.0)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.5 (0.3 to 1.0)	1.0 (0.5 to 1.7)	81.0 (30.6 to 184.8)	1.8 (-23.3 to 51.4)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	20.9 (0.7 to 46.7)	-32.7 (-43.0 to -20.5)	0.0 (0.0 to 0.0)	18.9 (0.0 to 0.0)	18.9 (-11.7 to 63.6)	-39.4 (-47.6 to -13.5)
Chlamydial infection	55.3 (38.4 to 76.0)	109.4 (89.3 to 133.8)	99.6 (39.0 to 193.3)	13.3 (-19.1 to 60.3)	0.2 (0.1 to 0.5)	0.5 (0.3 to 0.9)	122.2 (15.8 to 386.4)	27.4 (30.4 to 163.2)
Gonococcal infection	17.6 (13.6 to 22.1)	31.4 (23.9 to 37.9)	78.2 (31.0 to 137.7)	2.0 (-22.9 to 32.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	62.0 (-14.6 to 160.1)	-6.2 (-47.8 to 42.4)
Trichomoniasis	34.2 (22.2 to 49.5)	56.0 (39.3 to 73.4)	67.7 (-8.8 to 179.4)	-5.6 (-43.5 to 46.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	62.6 (-15.7 to 183.2)	-8.2 (-48.4 to 50.1)
Genital herpes	291.5 (274.0 to 309.3)	469.6 (439.9 to 500.2)	61.5 (46.9 to 76.5)	8.8 (-16.6 to 0.8)	0.1 (0.0 to 0.2)	0.3 (0.0 to 0.3)	59.3 (43.0 to 75.3)	91.1 (-17.7 to 4.1)
Other sexually transmitted diseases	0.5 (0.3 to 0.6)	0.6 (0.4 to 0.8)	27.5 (7.2 to 50.6)	-26.5 (-37.6 to -14.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-10.8 to 111.5)	0.0 (-45.5 to 11.2)
Hepatitis	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	13.1 (-11.3 to 41.6)	-31.8 (-46.6 to -14.1)
Hepatitis A	2.0 (1.9 to 2.0)	2.3 (2.2 to 2.4)	15.9 (15.5 to 16.3)	-9.5 (-9.9 to -9.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	37.1 (21.2 to 53.5)	-5.1 (-15.5 to 5.3)
Hepatitis B	180.0 (140.3 to 218.0)	175.5 (139.5 to 223.0)	-3.8 (-30.3 to 38.7)	-39.0 (-54.5 to -15.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-0.8 (-35.4 to 43.4)	-41.4 (-60.1 to -17.3)
Hepatitis C	34.5 (30.9 to 38.0)	39.7 (35.3 to 44.3)	14.6 (0.2 to 34.6)	-30.4 (-38.0 to -20.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.7 (-16.8 to 44.2)	-30.5 (-49.7 to -7.9)
Hepatitis E	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.4)	37.1 (9.8 to 76.6)	-18.2 (-33.4 to 4.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.1 (2.7 to 101.6)	-17.0 (-37.9 to 14.5)
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.7 (-17.4 to 457.5)	-15.0 (-50.5 to 218.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.6 (-21.4 to 467.1)	-13.5 (-54.3 to 231.3)
Other infectious diseases	16.5 (12.8 to 20.2)	15.7 (14.1 to 17.5)	-5.1 (-19.1 to 14.4)	-24.1 (-34.1 to -13.5)	0.6 (0.4 to 1.0)	0.6 (0.4 to 1.0)	-0.3 (-14.6 to 33.2)	-15.0 (-29.4 to 8.7)
Non-communicable diseases	-	-	-	-	87.4 (64.4 to 113.2)	145.9 (108.1 to 188.1)	66.9 (63.0 to 71.3)	-0.7 (-2.9 to 1.7)
Neoplasms	-	-	-	-	0.4 (0.2 to 0.5)	0.8 (0.5 to 1.2)	116.9 (49.6 to 263.9)	14.8 (-22.5 to 92.6)
Esophageal cancer	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	29.5 (-26.4 to 183.0)	-32.7 (-60.7 to 44.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.0 (-25.9 to 163.8)	-32.6 (-61.0 to 34.6)
Stomach cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	46.6 (8.6 to 149.9)	-27.8 (-55.6 to 22.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.8 (-13.3 to 138.3)	-32.5 (-58.5 to 14.6)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.4 (9.7 to 207.0)	-9.9 (-44.6 to 62.1)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	185.7 (33.4 to 522.3)	53.8 (-28.6 to 252.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	145.5 (21.3 to 407.4)	30.9 (-36.9 to 179.8)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	300.6 (79.6 to 828.5)	95.7 (-9.9 to 356.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	239.1 (63.3 to 648.2)	65.5 (-22.5 to 271.8)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.2 (-35.2 to 184.9)	-28.6 (-65.2 to 44.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.5 (-41.2 to 134.6)	-39.0 (-68.5 to 24.9)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.2 (-41.1 to 135.4)	-44.7 (-72.8 to 32.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.8 (-45.8 to 98.6)	-52.5 (-75.9 to 6.9)
Larynx cancer	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-2.5 (-51.0 to 126.1)	-49.6 (-75.6 to 13.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.0 (-36.0 to 143.7)	-40.2 (-66.9 to 24.5)
Tracheal, bronchus and lung cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	41.9 (-12.2 to 155.2)	-27.5 (-53.8 to 27.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.6 (-17.0 to 134.8)	-31.3 (-56.7 to 18.7)
Breast cancer	0.6 (0.2 to 1.0)	1.2 (0.5 to 2.9)	83.1 (-8.7 to 467.3)	-2.4 (-51.3 to 219.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	65.2 (-17.9 to 402.1)	-14.7 (-56.1 to 175.0)
Cervical cancer	0.3 (0.1 to 0.4)	0.3 (0.2 to 0.6)	27.9 (-35.9 to 213.7)	9.1 (-74.5 to 32.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	28.1 (-38.1 to 213.5)	-62.1 (-76.0 to 30.4)
Uterine cancer	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.4)	-14.1 (-66.8 to 246.0)	-56.7 (-82.6 to 83.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.2 (-67.4 to 232.6)	-58.6 (-83.2 to 73.7)
Prostate cancer	0.5 (0.2 to 1.0)	2.5 (1.2 to 4.6)	399.5 (164.7 to 963.5)	144.2 (36.8 to 401.6)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	322.4 (136.5 to 756.1)	104.2 (18.0 to 317.1)
Colon and rectum cancer	0.4 (0.3 to 0.5)	1.0 (0.6 to 1.8)	151.0 (57.7 to 436.1)	35.0 (-15.8 to 189.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	135.6 (48.2 to 390.0)	23.6 (-22.3 to 146.7)
Lip and oral cavity cancer	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	58.2 (-10.3 to 194.1)	-17.5 (-51.6 to 56.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.9 (-8.7 to 183.4)	-18.2 (-53.9 to 52.5)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.9 (-27.0 to 141.9)	-28.7 (-60.4 to 30.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.6 (-25.8 to 143.5)	30.6 (-60.9 to 27.3)
Other pharynx cancer	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	63.8 (-19.4 to 245.0)	-11.7 (-56.5 to 86.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.1 (-22.1 to 244.6)	-14.8 (-59.2 to 83.3)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.5 (-36.4 to 203.8)	-32.7 (-67.5 to 67.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.2 (-39.7 to 186.4)	-35.0 (-68.3 to 53.5)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	66.7 (-9.0 to 273.1)	-13.6 (-47.5 to 90.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.9 (-5.5 to 252.6)	-17.9 (-48.9 to 84.7)
Malignant skin melanoma	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	76.9 (6.1 to 254.7)	-10.6 (-45.8 to 91.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.8 (6.9 to 240.4)	-13.6 (-47.3 to 79.1)
Non-melanoma skin cancer	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	238.3 (107.9 to 455.5)	44.8 (-9.2 to 133.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	258.9 (93.2 to 558.6)	40.1 (-25.7 to 162.9)
Ovarian cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	76.4 (-24.7 to 395.0)	-24.2 (-65.0 to 137.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.9 (-28.5 to 369.1)	-29.2 (-67.9 to 121.2)
Testicular cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	150.2 (24.6 to 412.8)	37.3 (-27.1 to 172.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	145.6 (23.8 to 409.9)	33.0 (-29.3 to 163.0)
Kidney cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	91.9 (23.8 to 221.6)	19.9 (-29.2 to 91.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.8 (19.9 to 211.9)	5.9 (-34.6 to 80.2)
Bladder cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	145.7 (59.2 to 310.4)	18.4 (-24.0 to 97.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	131.4 (50.8 to 274.5)	9.4 (-29.9 to 75.9)
Brain and nervous system cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	55.2 (1.0 to 139.8)	-1.8 (-32.5 to 70.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.4 (3.7 to 146.1)	-9.3 (-38.2 to 64.0)
Thyroid cancer	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	103.2 (6.4 to 358.6)	-4.8 (-47.4 to 120.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.4 (7.7 to 343.0)	-7.5 (-48.9 to 108.8)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.1 (-17.6 to 142.7)	22.0 (-58.0 to 25.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.3 (-16.3 to 149.5)	6.1 (-57.3 to 28.5)
Hodgkin lymphoma	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	134.1 (28.9 to 345.3)	43.9 (-13.7 to 155.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.5 (18.5 to 318.0)	27.6 (-21.5 to 121.7)
Non-Hodgkin lymphoma	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.8)	146.0 (49.4 to 378.4)	35.8 (-20.4 to 160.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	134.6 (40.9 to 348.2)	24.6 (-27.1 to 137.7)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	76.0 (-9.9 to 296.3)	-6.9 (-52.4 to 106.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.3 (-15.8 to 274.3)	-12.2 (-55.9 to 96.1)
Leukemia	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	79.2 (10.2 to 190.8)	22.0 (-21.0 to 101.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.3 (16.4 to 184.2)	6.1 (-31.1 to 78.7)
Other neoplasms	0.5 (0.3 to 0.7)	1.5 (0.9 to 2.3)	196.4 (89.0 to 366.8)	96.3 (29.7 to 233.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	183.0 (83.2 to 348.5)	74.2 (15.1 to 196.7)
Cardiovascular diseases	-	-	-	-	1.4 (1.0 to 1.9)	3.0 (2.0 to 4.2)	114.0 (62.1 to 179.5)	8.8 (-13.4 to 40.8)
Rheumatic heart disease	1.0 (0.9 to 1.0)	1.5 (1.4 to 1.6)	57.5 (43.8 to 71.8)	-0.9 (-7.9 to 6.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	54.7 (23.3 to 90.3)	-4.4 (-24.8 to 16.8)
Ischemic heart disease	8.9 (7.1 to 11.1)	17.5 (14.8 to 21.5)	96.9 (45.4 to 181.3)	0.6 (-23.6 to 38.0)	0.5 (0.3 to 0.8)	0.9 (0.6 to 1.2)	63.3 (16.9 to 161.2)	-16.0 (-38.0 to 29.2)
Cerebrovascular disease	-	-	-	-	0.3 (0.1 to 0.2)	0.3 (0.2 to 0.3)	87.3 (51.1 to 129.5)	0.1 (-19.1 to 25.3)
Ischemic stroke	0.7 (0.6 to 0.8)	1.3 (1.1 to 1.5)	90.5 (56.2 to 132.4)	0.0 (-18.8 to 25.7)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	90.0 (52.0 to 133.6)	-0.2 (-20.2 to 26.3)
Hemorrhagic stroke	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.4)	82.7 (44.9 to 140.5)	-1.2 (-21.6 to 31.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	81.4 (40.3 to 143.1)	-1.3 (-24.4 to 33.8)
Hypertensive heart disease	0.9 (0.7 to 1.2)	2.6 (1.8 to 3.2)	173.8 (87.4 to 302.8)	36.0 (-9.9 to 105.1)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	171.0 (84.3 to 304.0)	35.4 (-9.7 to 105.6)
Cardiomyopathy and myocarditis	1.1 (0.8 to 1.4)	2.1 (1.8 to 2.4)	99.4 (45.4 to 182.0)	18.9 (-19.2 to 76.9)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	98.5 (41.5 to 182.1)	17.8 (-21.1 to 79.2)
Atrial fibrillation and flutter	1.4 (0.9 to 1.9)	4.0 (3.1 to 5.4)	184.4 (81.7 to 383.4)	21.9 (-26.9 to 142.6)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	182.8 (80.5 to 379.6)	22.6 (-26.5 to 135.7)
Peripheral vascular disease	28.5 (18.7 to 40.6)	56.8 (41.9 to 69.4)	100.6 (24.1 to 215.5)	-0.5 (-32.8 to 50.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	115.4 (6.5 to 432.9)	-5.7 (-52.6 to 120.7)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	37.6 (5.0 to 92.9)	-2.6 (-34.3 to 41.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.4 (-8.1 to 113.5)	-2.2 (-39.9 to 61.1)
Other cardiovascular and circulatory diseases	4.8 (2.7 to 8.6)	13.5 (4.7 to 21.7)	189.2 (-9.7 to 510.2)	49.8 (-54.2 to 228.4)	0.3 (0.2 to 0.6)	0.9 (0.3 to 1.7)	186.8 (-9.4 to 514.3)	49.1 (-54.1 to 231.4)
Chronic respiratory diseases	-	-	-	-	6.2 (4.2 to 8.8)	10.4 (7.2 to 14.1)	68.0 (42.3 to 97.2)	-3.4 (-15.8 to 8.8)
Chronic obstructive pulmonary disease	46.8 (44.8 to 49.0)	82.1 (78.8 to 85.9)	75.3 (69.4 to 81.3)	-1.0				

Appendix Table G.4 - Botswana prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	79.5	-3.5
Silicosis	0.0	0.0	76.3	-7.9	0.0	0.0	(73.9 to 85.2)	(-6.7 to -0.1)
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	76.5	-7.8
Coal workers pneumoconiosis	0.0	0.0	0.0	0.0	0.0	0.0	76.5	-7.8
Other pneumoconiosis	0.0	0.0	0.0	0.0	0.0	0.0	76.5	-7.8
Asthma	41.8	61.3	49.4	-15.2	1.8	2.7	49.3	-15.1
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.1	90.5	10.4	0.0	0.0	90.5	10.2
Other chronic respiratory diseases	0.0	0.0	0.0	0.0	0.0	0.0	90.5	10.2
Cirrhosis	0.1	0.1	76.8	-1.5	0.0	0.0	82.2	0.9
Cirrhosis due to hepatitis B	0.0	0.0	0.0	0.0	0.0	0.0	82.2	0.9
Cirrhosis due to hepatitis C	0.1	0.1	76.8	-1.5	0.0	0.0	82.2	0.9
Cirrhosis due to alcohol use	0.1	0.2	54.9	-16.9	0.0	0.0	82.2	0.9
Cirrhosis due to other causes	0.2	0.3	67.4	23.4	0.0	0.0	82.2	0.9
Digestive diseases	5.7	7.3	28.7	-40.3	0.2	0.3	83.3	-38.3
Peptic ulcer disease	5.2 to 6.1	(6.6 to 8.0)	(12.1 to 47.4)	(-47.2 to -32.9)	(0.1 to 0.3)	(0.2 to 0.4)	(13.2 to 66.0)	(-45.8 to -27.6)
Gastritis and duodenitis	12.8	20.9	62.7	-0.3	0.6	0.9	57.5	0.1
Appendicitis	0.1	0.3	95.9	17.5	0.0	0.1	94.6	17.0
Paralytic ileus and intestinal obstruction	0.0	0.0	0.0	0.0	0.0	0.0	94.6	17.0
Inguinal, femoral, and abdominal hernia	2.0	3.0	48.7	-20.8	0.0	0.0	47.8	-20.6
Inflammatory bowel disease	1.2	2.7	120.0	0.3	0.0	0.1	118.8	25.4
Vascular intestinal disorders	0.0	0.0	0.0	0.0	0.0	0.0	118.8	25.4
Gallbladder and biliary diseases	0.3	0.8	140.5	19.2	0.0	0.1	140.4	20.2
Pancreatitis	0.2	0.4	91.6	6.5	0.1	0.1	90.6	6.6
Other digestive diseases	0.0	0.0	0.0	0.0	0.0	0.0	90.6	6.6
Neurological disorders	1.9	4.7	142.9	10.2	0.3	0.7	147.6	10.9
Alzheimer disease and other dementias	0.1	0.2	102.8	-0.4	0.0	0.0	102.7	-0.7
Parkinson disease	1.9	2.6	39.1	-6.4	0.6	0.9	47.8	0.2
Epilepsy	0.1	0.2	84.1	3.4	0.0	0.1	83.3	2.9
Multiple sclerosis	0.1	0.2	57.2 to 114.0	(-10.1 to 19.3)	(0.0 to 0.1)	(0.0 to 0.1)	(47.9 to 126.9)	(-17.1 to 27.3)
Migraine	95.3	151.5	59.4	3.2	3.1	5.2	3.5	-3.5
Tension-type headache	165.2	295.9	79.7	3.9	0.3	0.4	78.6	3.7
Medication overuse headache	6.4	15.0	132.9	39.8	1.0	2.3	131.1	38.7
Other neurological disorders	0.0	0.0	45.2	-4.5	0.2	0.3	66.4	-23.4
Mental and substance use disorders	2.8	4.8	73.5	-3.4	32.7	52.8	61.6	-1.8
Schizophrenia	15.1	37.5	148.6	38.5	1.8	3.1	72.8	3.8
Alcohol use disorders	13.1 to 17.1	(33.0 to 43.1)	(129.0 to 170.3)	(28.8 to 49.6)	(1.0 to 2.1)	(2.5 to 5.4)	(129.3 to 174.2)	(28.6 to 50.9)
Drug use disorders	2.3	4.0	72.0	-0.7	1.0	1.6	70.7	-1.8
Opioid use disorders	1.5 to 2.4	(2.6 to 6.1)	(52.2 to 95.5)	(-11.3 to 9.4)	(0.6 to 1.5)	(1.0 to 2.6)	(43.3 to 96.3)	(-13.7 to 10.6)
Cocaine use disorders	0.6 to 0.8	(1.0 to 1.5)	(39.3 to 135.3)	(-19.3 to 23.3)	(0.1 to 0.1)	(0.1 to 0.3)	(28.7 to 153.1)	(-24.5 to 32.4)
Amphetamine use disorders	2.2	4.0	84.6	3.8	0.3	0.5	83.0	3.3
Cannabis use disorders	2.0	3.4	70.0	1.1	0.1	0.1	68.9	0.3
Other drug use disorders	0.0	0.0	0.0	0.0	0.0	0.0	68.9	0.3
Depressive disorders	54.8	89.2	62.4	-2.7	11.3	18.3	61.4	-3.1
Major depressive disorder	40.8 to 69.8	(63.5 to 113.6)	(50.3 to 77.6)	(-8.2 to 4.9)	(7.0 to 17.0)	(11.0 to 27.6)	(48.6 to 76.8)	(-8.4 to 4.5)
Dysthymia	13.3	23.3	75.3	-0.9	1.3	2.2	74.5	-1.3
Bipolar disorder	7.6	13.6	78.4	-0.6	1.5	2.8	77.7	-1.1
Anxiety disorders	54.2	87.3	61.3	-0.7	12.6	20.5	62.7	-2.8
Eating disorders	0.3	0.4	62.7	0.4	0.1	0.1	61.1	-0.5
Anorexia nervosa	0.2 to 0.3	(0.3 to 0.5)	(44.7 to 80.6)	(-9.6 to 10.6)	(0.0 to 0.1)	(0.1 to 0.1)	(28.1 to 111.3)	(-20.3 to 27.9)
Bulimia nervosa	1.4	2.4	68.4	-1.7	0.3	0.5	68.8	-1.8
Autistic spectrum disorders	4.3	6.3	48.2	1.3	1.7	2.5	47.9	1.2
Autism	4.0 to 4.5	(6.0 to 6.6)	(47.5 to 48.9)	(1.2 to 1.3)	(0.7 to 1.5)	(1.0 to 2.1)	(39.8 to 55.7)	(-3.8 to 6.0)
Asperger syndrome	6.1	9.0	47.8	1.7	0.6	0.9	47.0	1.4
Attention-deficit/hyperactivity disorder	10.5	13.8	31.2	0.2	0.1	0.2	31.3	0.4
Conduct disorder	15.5	20.1	30.3	0.2	0.1	0.2	21.7 to 41.3	(-7.0 to 7.8)
Idiopathic intellectual disability	66.1	74.5	12.6	-25.1	3.2	3.6	12.4	-25.0
Other mental and substance use disorders	16.7	30.5	82.8	0.9	1.2	2.3	81.9	0.6
Diabetes, urogenital, blood, and endocrine diseases	27.4	53.8	96.3	17.7	1.8	3.6	96.5	15.8
Diabetes mellitus	23.6 to 31.6	(44.9 to 63.1)	(59.4 to 140.8)	(-5.8 to 50.3)	(1.2 to 2.6)	(2.4 to 5.1)	(56.8 to 137.9)	(-9.2 to 45.2)
Acute glomerulonephritis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Chronic kidney disease	17.9	28.4	59.2	-7.2	0.3	0.4	59.5	-7.9
Chronic kidney disease due to diabetes mellitus	35.2 to 89.9	(52.6 to 131.9)	(17.5 to 84.9)	(-20.6 to 22.0)	(0.5 to 0.9)	(0.8 to 1.6)	(48.6 to 114.8)	(-13.3 to 21.9)
Chronic kidney disease due to hypertension	47.1	79.4	70.7	0.8	1.2	1.2	51.4	-3.0
Chronic kidney disease due to glomerulonephritis	31.0 to 69.1	(55.3 to 112.2)	(34.2 to 113.0)	(-19.5 to 29.0)	(0.6 to 1.1)	(0.8 to 1.6)	(24.9 to 81.5)	(-22.0 to 13.2)
Chronic kidney disease due to other causes	23.1 to 61.3	(33.3 to 96.1)	(14.7 to 104.4)	(-26.2 to 30.1)	(0.3 to 0.7)	(0.5 to 1.0)	(21.4 to 111.5)	(-25.0 to 28.7)
Urinary diseases and male infertility	0.0	0.0	0.0	0.0	0.0	0.0	109.4	4.9

Appendix Table G.4 - Botswana prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	24.2 (22.8 to 25.7)	36.1 (33.7 to 38.6)	48.9 (36.0 to 63.1)	-21.9 (-28.3 to -15.0)	0.7 (0.5 to 0.9)	1.0 (0.7 to 1.4)	47.9 (34.0 to 62.3)	-22.1 (-28.7 to -15.0)
Other oral disorders	20.2 (19.0 to 21.4)	33.0 (31.0 to 35.0)	63.3 (50.0 to 77.5)	-0.9 (-8.0 to 6.6)	6.0 (4.5 to 7.7)	7.7 (5.6 to 10.4)	28.9 (48.7 to 77.8)	-24.5 (-8.6 to 6.9)
Injuries	-	-	-	-	6.0 (4.5 to 7.7)	7.7 (5.6 to 10.4)	28.9 (9.3 to 47.2)	-24.5 (-33.8 to -14.7)
Transport injuries	-	-	-	-	1.4 (1.0 to 1.8)	2.0 (1.4 to 2.7)	43.4 (24.4 to 67.2)	-11.1 (-22.2 to 2.2)
Road injuries	-	-	-	-	1.2 (0.9 to 1.6)	1.7 (1.2 to 2.4)	40.8 (21.5 to 65.2)	-12.3 (-23.3 to 1.2)
Pedestrian road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	15.5 (-1.8 to 38.5)	-25.4 (-35.7 to -13.4)
Cyclist road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	39.7 (24.6 to 57.7)	-13.8 (-22.8 to -3.8)
Motorcyclist road injuries	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	40.9 (20.1 to 65.7)	-13.5 (-25.5 to -0.1)
Motor vehicle road injuries	-	-	-	-	0.6 (0.5 to 0.8)	0.9 (0.7 to 1.3)	54.5 (30.3 to 82.5)	-3.6 (-17.4 to 12.4)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.6 (-19.3 to 10.0)	-45.0 (-51.9 to -36.3)
Other transport injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	66.2 (46.2 to 89.1)	-2.0 (-13.7 to 10.9)
Unintentional injuries	-	-	-	-	3.7 (2.9 to 4.8)	5.0 (3.6 to 6.6)	32.1 (20.3 to 45.8)	-26.8 (-33.7 to -18.9)
Falls	-	-	-	-	2.1 (1.6 to 2.6)	2.4 (1.7 to 3.2)	14.6 (2.2 to 29.0)	-39.0 (-45.9 to -30.7)
Drowning	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-19.8 (-31.9 to -4.9)	-46.8 (-54.1 to -37.9)
Fire, heat, and hot substances	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	33.2 (15.3 to 52.6)	-14.7 (-25.1 to -3.3)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.2 (-1.3 to 39.5)	-24.9 (-34.7 to -14.0)
Exposure to mechanical forces	-	-	-	-	0.8 (0.6 to 1.0)	1.4 (1.0 to 1.9)	74.2 (61.5 to 90.1)	9.9 (2.5 to 18.6)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	116.1 (87.8 to 150.3)	30.2 (13.7 to 50.1)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.8 (60.8 to 108.0)	14.9 (1.8 to 28.0)
Other exposure to mechanical forces	-	-	-	-	0.7 (0.6 to 1.0)	1.3 (0.9 to 1.7)	72.3 (60.3 to 87.9)	8.8 (1.6 to 17.3)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	112.4 (102.0 to 124.6)	25.2 (19.6 to 33.2)
Animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	20.4 (9.7 to 32.7)	-24.4 (-30.5 to -17.3)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	29.0 (12.9 to 47.5)	-19.2 (-28.3 to -9.2)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	14.3 (2.6 to 28.4)	-27.8 (-35.0 to -19.9)
Foreign body	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	29.5 (16.9 to 43.7)	-19.3 (-26.8 to -10.8)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.2 (-23.9 to 11.0)	-35.9 (-45.8 to -24.4)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.4 (30.9 to 62.8)	-8.8 (-18.1 to 1.3)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	43.6 (28.8 to 62.8)	-14.9 (-23.4 to -4.3)
Other unintentional injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	47.4 (35.0 to 59.1)	-14.1 (-20.5 to -7.9)
Self-harm and interpersonal violence	-	-	-	-	0.4 (0.3 to 0.5)	0.7 (0.5 to 1.0)	109.1 (83.5 to 141.8)	32.0 (15.4 to 50.9)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	136.7 (110.6 to 169.7)	32.3 (17.9 to 49.5)
Interpersonal violence	-	-	-	-	0.3 (0.2 to 0.4)	0.7 (0.5 to 0.9)	106.5 (78.7 to 140.4)	31.9 (14.3 to 51.9)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	141.9 (116.5 to 170.3)	53.4 (38.2 to 70.5)
Assault by sharp object	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	155.7 (124.6 to 199.6)	57.3 (38.1 to 83.5)
Assault by other means	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	84.5 (57.4 to 118.3)	19.1 (2.0 to 39.9)
Forces of nature, war, and legal intervention	-	-	-	-	0.5 (0.1 to 1.3)	0.0 (0.0 to 0.1)	-91.9 (-96.2 to -80.9)	-92.8 (-96.5 to -83.7)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.3 (9.9 to 168.1)	-10.4 (-31.3 to 78.1)
Collective violence and legal intervention	-	-	-	-	0.5 (0.1 to 1.3)	0.0 (0.0 to 0.1)	-93.0 (-96.6 to -84.6)	-93.7 (-96.9 to -86.4)

Appendix Table G.4 - Brazil prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	7,782.6 (7,563.7 to 7,982.1)	15,076.2 (14,729.1 to 15,464.0)	94.4 (87.3 to 101.4)	-8.6 (-11.9 to -5.4)	214.8 (144.6 to 296.0)	414.9 (282.0 to 570.9)	93.1 (86.2 to 100.7)	43.9 (-12.1 to -5.5)
Other oral disorders	2,433.2 (2,285.0 to 2,567.8)	3,644.5 (3,435.1 to 3,833.2)	50.5 (39.0 to 62.8)	-0.3 (-7.7 to 7.0)	71.2 (44.7 to 106.0)	106.6 (66.1 to 159.4)	49.8 (37.8 to 62.2)	-0.4 (-7.9 to 7.2)
Injuries	-	-	-	-	674.4 (510.7 to 874.7)	777.2 (559.9 to 1,049.2)	14.6 (4.7 to 26.4)	-34.4 (-40.0 to -28.0)
Transport injuries	-	-	-	-	173.2 (130.0 to 226.0)	150.4 (106.5 to 203.1)	-13.7 (-24.6 to -1.0)	-50.3 (-56.2 to -43.7)
Road injuries	-	-	-	-	162.5 (122.1 to 211.5)	142.5 (101.0 to 192.8)	-12.8 (-24.0 to 0.3)	-49.8 (-55.8 to -43.0)
Pedestrian road injuries	-	-	-	-	50.0 (37.4 to 65.0)	39.9 (28.1 to 53.8)	-20.7 (-31.0 to -8.5)	-54.6 (-60.1 to -48.6)
Cyclist road injuries	-	-	-	-	8.2 (6.1 to 10.7)	9.4 (6.7 to 12.7)	14.9 (0.9 to 29.8)	-36.3 (-43.5 to -28.6)
Motorcyclist road injuries	-	-	-	-	27.2 (20.0 to 35.2)	26.2 (18.0 to 35.9)	-4.3 (-16.7 to 11.5)	-43.3 (-50.3 to -34.6)
Motor vehicle road injuries	-	-	-	-	74.6 (56.0 to 97.1)	64.4 (45.7 to 87.4)	-13.0 (-26.0 to 0.4)	-50.4 (-56.8 to -42.8)
Other road injuries	-	-	-	-	2.6 (1.9 to 3.3)	2.6 (1.9 to 3.6)	0.8 (-12.2 to 15.7)	-44.5 (-51.2 to -36.9)
Other transport injuries	-	-	-	-	10.7 (8.0 to 13.9)	7.9 (5.6 to 10.6)	-26.5 (-34.8 to -17.2)	-57.8 (-62.6 to -52.6)
Unintentional injuries	-	-	-	-	458.3 (348.7 to 593.7)	579.5 (419.8 to 781.3)	26.0 (16.3 to 36.7)	-28.5 (-34.0 to -22.5)
Falls	-	-	-	-	203.8 (154.2 to 264.8)	291.1 (207.2 to 394.5)	42.0 (27.2 to 58.5)	-26.6 (-34.3 to -17.7)
Drowning	-	-	-	-	4.0 (2.9 to 5.3)	2.5 (1.8 to 3.5)	-35.6 (-44.7 to -24.4)	-59.7 (-65.0 to -53.3)
Fire, heat, and hot substances	-	-	-	-	15.8 (12.0 to 20.0)	12.3 (8.8 to 16.7)	-22.9 (-32.9 to -11.8)	-51.5 (-57.3 to -45.1)
Poisonings	-	-	-	-	0.9 (0.6 to 1.3)	0.9 (0.6 to 1.2)	-7.0 (-22.9 to 13.7)	-37.9 (-47.3 to -25.2)
Exposure to mechanical forces	-	-	-	-	136.6 (103.8 to 178.9)	119.0 (86.8 to 161.9)	-13.0 (-19.4 to -6.3)	-43.5 (-47.2 to -39.8)
Unintentional firearm injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	75.9 (50.8 to 104.1)	15.5 (0.3 to 32.5)
Unintentional suffocation	-	-	-	-	127.4 (96.5 to 167.0)	108.5 (79.2 to 147.1)	-14.9 (-21.2 to -8.3)	-44.6 (-48.2 to -41.0)
Adverse effects of medical treatment	-	-	-	-	1.2 (0.8 to 1.8)	2.2 (1.4 to 3.2)	76.6 (67.0 to 87.0)	-0.4 (-5.7 to 5.5)
Animal contact	-	-	-	-	1.2 (0.9 to 1.6)	1.4 (1.0 to 1.8)	10.4 (-0.2 to 22.8)	-32.1 (-37.7 to -25.3)
Venomous animal contact	-	-	-	-	0.7 (0.5 to 0.9)	0.7 (0.5 to 1.0)	6.3 (-6.0 to 20.1)	-34.0 (-40.8 to -26.3)
Non-venomous animal contact	-	-	-	-	0.5 (0.4 to 0.7)	0.6 (0.4 to 0.9)	15.8 (3.0 to 30.1)	-29.6 (-36.3 to -22.4)
Foreign body	-	-	-	-	2.5 (1.9 to 3.2)	2.9 (2.2 to 3.8)	15.5 (4.4 to 28.1)	-30.3 (-36.6 to -23.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.9 (0.7 to 1.2)	0.8 (0.6 to 1.1)	-13.7 (-27.2 to 3.8)	-48.1 (-55.5 to -38.8)
Foreign body in eyes	-	-	-	-	0.4 (0.2 to 0.5)	0.4 (0.2 to 0.6)	20.8 (10.8 to 31.6)	-20.1 (-27.1 to -13.0)
Foreign body in other body part	-	-	-	-	1.3 (0.9 to 1.6)	1.7 (1.2 to 2.3)	35.1 (21.5 to 48.7)	-20.0 (-27.0 to -12.8)
Other unintentional injuries	-	-	-	-	92.1 (69.0 to 119.2)	147.2 (106.3 to 196.8)	59.2 (48.8 to 72.6)	-10.4 (-16.1 to -3.4)
Self-harm and interpersonal violence	-	-	-	-	42.7 (32.5 to 54.5)	47.1 (34.0 to 63.8)	9.4 (-1.1 to 24.4)	-36.7 (-43.5 to -28.6)
Self-harm	-	-	-	-	5.9 (4.3 to 7.7)	6.7 (4.8 to 9.2)	14.4 (2.5 to 30.1)	-37.7 (-43.9 to -29.8)
Interpersonal violence	-	-	-	-	36.9 (28.2 to 46.9)	40.3 (29.0 to 54.7)	8.7 (-4.3 to 24.3)	-36.5 (-43.6 to -27.9)
Assault by firearm	-	-	-	-	9.1 (6.9 to 11.8)	15.1 (10.8 to 20.3)	65.3 (47.7 to 84.0)	-5.4 (-14.7 to 3.7)
Assault by sharp object	-	-	-	-	8.1 (6.1 to 10.4)	10.2 (7.1 to 14.3)	24.8 (9.4 to 44.5)	-28.3 (-36.8 to -17.4)
Assault by other means	-	-	-	-	19.7 (15.0 to 25.2)	15.1 (11.0 to 20.2)	-23.7 (-33.9 to -10.2)	-54.5 (-60.2 to -47.0)
Forces of nature, war, and legal intervention	-	-	-	-	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.5)	71.3 (24.5 to 117.2)	5.3 (-20.4 to 37.3)
Exposure to forces of nature	-	-	-	-	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.5)	70.9 (24.3 to 116.6)	5.2 (-20.7 to 37.1)
Collective violence and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-

Appendix Table G.4 - Brunei prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	18.6 (13.6 to 24.2)	35.8 (26.3 to 46.4)	93.3 (84.2 to 100.6)	40.0 (3.3 to 3.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.3 (1.6 to 3.2)	3.7 (2.5 to 5.2)	58.7 (42.5 to 78.4)	12.0 (0.8 to 25.5)
HIV/AIDS and tuberculosis	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.0)	463.3 (264.7 to 766.7)	168.1 (80.8 to 301.7)
Tuberculosis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	70.2 (61.4 to 78.6)	-18.1 (-21.4 to -14.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.7 (36.7 to 110.2)	-17.6 (-30.8 to -2.4)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	823.1 (346.2 to 1,908.9)	397.3 (137.4 to 1,026.1)
HIV/AIDS resulting in mycobacterial infection	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
HIV/AIDS resulting in other diseases	0.1 (0.0 to 0.2)	0.7 (0.6 to 1.0)	706.1 (242.1 to 1,386.4)	367.3 (98.0 to 771.9)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	823.1 (346.2 to 1,908.9)	397.3 (137.4 to 1,026.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.0 (0.1 to 0.3)	0.2 (0.2 to 0.4)	44.9 (33.0 to 56.7)	-7.7 (-14.6 to -0.7)
Diarrheal diseases	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	38.2 (17.2 to 63.9)	0.3 (-14.3 to 17.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.1 (10.5 to 70.4)	0.4 (-18.2 to 23.8)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.7 (66.6 to 68.4)	22.6 (-76.1 to 18.8)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.7 (-18.2 to 38.4)	-23.1 (-40.7 to -3.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.7 (-18.2 to 38.4)	-23.1 (-40.7 to -3.0)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.1 (-10.3 to 70.5)	-11.2 (-34.7 to 23.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.1 (-10.3 to 70.9)	-11.2 (-34.7 to 23.5)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.1 (-95.8 to 907.3)	-29.6 (-97.0 to 624.6)
Lower respiratory infections	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-24.4 (-38.8 to 1.1)	-55.6 (-64.3 to -42.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.4 (-42.7 to 5.7)	-55.6 (-64.9 to -41.5)
Upper respiratory infections	5.5 (5.2 to 5.8)	8.0 (7.6 to 8.5)	46.3 (34.9 to 58.8)	-1.0 (-8.6 to 7.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	45.7 (34.0 to 59.2)	-0.9 (-9.0 to 7.7)
Otitis media	2.7 (2.5 to 2.9)	3.9 (3.6 to 4.1)	43.9 (34.6 to 54.7)	-12.4 (-18.2 to -6.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	41.3 (29.9 to 53.9)	-13.0 (-19.0 to -5.8)
Meningitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	81.2 (13.0 to 165.8)	16.9 (-25.6 to 71.2)
Pneumococcal meningitis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	86.6 (47.2 to 132.9)	6.4 (-14.2 to 32.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.8 (26.5 to 155.6)	9.2 (-19.8 to 52.5)
H influenzae type B meningitis	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	109.3 (4.6 to 362.8)	30.3 (-28.4 to 220.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.2 (-7.1 to 381.4)	46.0 (-36.3 to 225.0)
Meningococcal meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.0 (7.5 to 223.8)	11.4 (-31.6 to 69.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.2 (-5.3 to 218.3)	6.7 (-40.5 to 66.0)
Other meningitis	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	67.1 (-2.7 to 157.1)	7.3 (-32.8 to 77.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.9 (-18.1 to 194.2)	4.7 (-44.2 to 94.2)
Encephalitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.7 (50.3 to 145.7)	-4.4 (-14.2 to 31.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.1 (39.4 to 143.5)	2.1 (-22.5 to 28.0)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.1 (-91.5 to 632.6)	-49.9 (-93.7 to 363.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.1 (-91.6 to 637.5)	-49.9 (-93.8 to 364.6)
Whooping cough	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.5 (-14.8 to -14.1)	-2.9 (-3.3 to -2.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.5 (-33.1 to 9.6)	-3.1 (-24.0 to 24.1)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.9 (-73.1 to 75.0)	-57.2 (-82.4 to -16.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.6 (-67.9 to 83.5)	-49.0 (-77.5 to 23.6)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.9 (-100.0 to -92.4)	-99.9 (-100.0 to -91.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.9 (-100.0 to -92.3)	-99.9 (-100.0 to -91.7)
Varicella and herpes zoster	0.2 (0.2 to 0.2)	0.3 (0.2 to 0.3)	52.0 (32.7 to 74.0)	-6.0 (-17.6 to 8.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.3 (52.5 to 156.1)	-1.5 (-20.9 to 24.4)
Neglected tropical diseases and malaria	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	134.2 (96.0 to 195.7)	-1.9 (-28.6 to 38.2)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.2 (-61.1 to 808.8)	-6.7 (-72.9 to 522.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.2 (-66.3 to 653.6)	-20.1 (-77.2 to 402.7)
Chagas disease	-	-	0.0 (0.0 to 0.0)	-	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.6 (87.6 to 4.2)	-82.4 (-94.2 to -60.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-60.7 (-88.5 to 1.3)	-82.6 (-94.3 to -61.4)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.5 (29.5 to 69.1)	-26.2 (-31.0 to -19.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.6 (6.3 to 94.1)	-26.4 (-41.7 to -6.6)
Lymphatic filariasis	0.5 (0.4 to 0.6)	1.0 (0.8 to 1.2)	90.2 (60.8 to 129.2)	-9.6 (-23.7 to 10.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	116.3 (80.4 to 175.9)	-14.6 (-38.0 to 19.8)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	357.9 (316.4 to 410.4)	188.8 (162.6 to 221.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	339.8 (241.7 to 530.9)	175.6 (120.8 to 286.6)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.9 (-79.5 to 179.6)	0.5 (-87.2 to 78.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.9 (-79.5 to 180.0)	0.5 (-87.3 to 78.4)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	308.5 (138.8 to 1,396.0)	157.9 (51.3 to 841.0)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.5 (-28.0 to 24.9)	-28.3 (-46.3 to -8.2)
Maternal hemorrhage	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	36.7 (-1.4 to 82.4)	-0.2 (-28.4 to 34.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.2 (-24.0 to 109.0)	-0.7 (-43.1 to 57.3)
Maternal sepsis and other maternal infections	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	1.6 (-35.7 to 57.3)	-44.2 (-64.7 to -16.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.0 (-47.1 to 24.8)	47.5 (-63.7 to -22.4)
Maternal hypertensive disorders	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-20.2 (-30.8 to -0.2)	-41.2 (-47.7 to -26.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.8 (-37.0 to 5.9)	-40.7 (-52.9 to -22.3)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.5 (-44.9 to 74.0)	-31.9 (-58.4 to 30.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.5 (-45.0 to 74.5)	-31.9 (-58.4 to 30.6)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.4 (-35.6 to 19.6)	-35.7 (-52.6 to -12.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.4 (-35.6 to 19.6)	-35.7 (-52.7 to -12.2)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.8 (-50.8 to 79.9)	-29.8 (-63.6 to 31.7)
Neonatal disorders	-	-	-	-	0.4 (0.2 to 0.6)	0.5 (0.5 to 1.4)	135.9 (37.3 to 252.7)	59.4 (-6.7 to 137.1)
Preterm birth complications	1.7 (1.0 to 2.9)	4.9 (2.7 to 8.5)	191.7 (81.6 to 316.5)	91.5 (22.8 to 172.9)	0.2 (0.1 to 0.3)	0.6 (0.3 to 0.9)	159.7 (41.0 to 319.6)	73.3 (-5.6 to 178.5)
Neonatal encephalopathy due to birth asphyxia and trauma	0.3 (0.2 to 0.6)	0.6 (0.3 to 1.1)	64.3 (5.0 to 142.9)	12.1 (-26.3 to 67.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	48.4 (-4.5 to 136.1)	3.6 (-33.0 to 64.7)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.1 (26.2 to 44.4)	77.7 (51.9 to 80.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.7 (17.1 to 71.6)	77.2 (46.5 to 114.7)
Hemolytic disease and other neonatal jaundice	0.1 (0.0 to 0.2)	0.2 (0.0 to 0.7)	27.9 (-57.9 to 886.6)	-12.2 (-71.0 to 578.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	27.5 (-60.1 to 653.3)	82.5 (-73.0 to 401.5)
Other neonatal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	169.1 (21.5 to 543.3)	81.8 (-17.9 to 332.1)
Nutritional deficiencies	-	-	-	-	1.6 (1.0 to 2.3)	2.2 (1.4 to 3.2)	37.6 (33.9 to 40.9)	1.8 (-1.0 to 4.3)
Protein-energy malnutrition	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.8 (-36.9 to 38.7)	-54.3 (-72.6 to -25.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.0 (-40.9 to 44.7)	-54.7 (-75.0 to -16.7)
Iodine deficiency	1.5 (0.8 to 2.3)	1.7 (1.0 to 2.6)	13.4 (-47.2 to 119.0)	-33.3 (-69.2 to 25.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	13.7 (-47.7 to 119.9)	-32.7 (-68.9 to 25.9)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron-deficiency anemia	50.5 (50.0 to 51.0)	74.1 (73.3 to 75.0)	46.8 (44.1 to 49.2)	3.5 (1.5 to 5.4)	1.5 (1.0 to 2.2)	2.1 (1.4 to 3.1)	38.0 (34.5 to 40.8)	2.6 (-0.0 to 4.6)

Appendix Table G.4 - Brunei prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.6 (-37.8 to 44.3)	-54.1 (-76.6 to -15.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	42.0 (15.5 to 75.4)	-0.0 (-17.9 to 21.3)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	53.1 (21.9 to 81.8)	-5.5 (-22.8 to 11.0)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	146.4 (86.3 to 230.1)	3.2 (-15.3 to 30.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	145.3 (58.1 to 283.5)	3.1 (-26.6 to 51.7)
Chlamydial infection	14.7 (8.3 to 12.8)	14.7 (11.6 to 17.7)	42.9 (0.1 to 89.8)	-7.3 (-34.7 to 22.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	40.8 (4.4 to 80.9)	-9.0 (-32.1 to 15.7)
Gonococcal infection	0.8 (0.5 to 1.0)	1.0 (0.7 to 1.3)	24.7 (-22.5 to 129.3)	-1.8 (-46.6 to 57.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.7 (-13.5 to 105.5)	-10.1 (-40.0 to 41.1)
Trichomoniasis	1.0 (0.6 to 1.4)	1.9 (1.4 to 2.7)	96.3 (24.1 to 239.8)	19.8 (-23.3 to 98.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.3 (18.5 to 312.6)	29.5 (-26.6 to 136.1)
Genital herpes	22.8 (20.7 to 25.1)	45.4 (40.8 to 50.1)	98.3 (75.0 to 127.8)	-1.5 (-13.3 to 12.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.2 (63.5 to 124.6)	-1.7 (-14.3 to 13.2)
Other sexually transmitted diseases	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	50.7 (22.3 to 84.4)	-12.2 (-28.8 to 5.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.9 (2.8 to 144.6)	0.5 (-33.0 to 50.8)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.8 (15.5 to 71.3)	-20.1 (-35.3 to -4.6)
Hepatitis A	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.3)	45.6 (44.1 to 46.9)	-0.2 (-0.3 to -0.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.9 (41.3 to 85.8)	-0.4 (-12.2 to 13.0)
Hepatitis B	12.5 (11.0 to 14.5)	12.6 (10.9 to 14.2)	0.6 (-17.5 to 21.1)	-41.9 (-51.9 to -29.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.0 (-17.7 to 77.0)	35.7 (-57.1 to -10.1)
Hepatitis C	1.8 (1.6 to 2.0)	3.0 (2.7 to 3.2)	60.8 (42.2 to 86.2)	-28.9 (-36.7 to -19.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.0 (26.7 to 132.2)	-26.7 (-49.8 to 8.4)
Hepatitis E	-	-	60.6 (15.2 to 129.9)	3.9 (-28.7 to 35.7)	-	-	-	-
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	252.3 (-1.2 to 2,677.2)	40.4 (-57.5 to 1,125.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	249.4 (-4.8 to 3,214.2)	41.4 (-59.7 to 1,408.6)
Other infectious diseases	2.3 (1.8 to 2.7)	3.0 (2.5 to 3.5)	31.2 (2.7 to 69.0)	1.1 (-20.2 to 27.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	35.8 (-6.2 to 101.8)	8.3 (-24.6 to 58.6)
Non-communicable diseases	-	-	-	-	15.2 (11.1 to 19.8)	30.7 (22.6 to 39.8)	102.1 (92.2 to 112.1)	2.0 (-2.0 to 6.2)
Neoplasms	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	89.5 (63.8 to 119.7)	-31.5 (-40.1 to -21.3)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.8 (-53.1 to 69.6)	-75.4 (-84.4 to -41.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.2 (-48.3 to 72.3)	-75.0 (-82.3 to -40.6)
Stomach cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	63.1 (32.1 to 105.6)	-37.4 (-50.4 to -19.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.0 (28.7 to 109.6)	-38.0 (-51.7 to -20.9)
Liver cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	188.1 (20.4 to 674.8)	-11.0 (-61.1 to 135.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	122.4 (43.3 to 242.2)	-29.7 (-54.7 to 10.3)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	409.4 (133.3 to 1,115.7)	60.6 (-20.3 to 265.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	402.3 (140.7 to 1,091.4)	-55.3 (-19.5 to 250.1)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.9 (-73.4 to 55.5)	-80.6 (-90.8 to -54.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.7 (-71.0 to 55.0)	-79.1 (-90.1 to -54.4)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.0 (-86.5 to 12.1)	-84.5 (-95.5 to -63.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.3 (-85.2 to 12.6)	-84.3 (-95.4 to -64.0)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	275.9 (186.0 to 451.9)	30.5 (-0.0 to 95.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	188.5 (127.0 to 323.9)	1.7 (-23.1 to 46.6)
Larynx cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	159.6 (100.2 to 227.2)	-7.3 (-28.9 to 15.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	159.8 (99.9 to 227.3)	-7.4 (-28.2 to 15.7)
Tracheal, bronchus and lung cancer	0.5 (0.4 to 0.5)	1.1 (1.0 to 1.2)	149.6 (108.3 to 203.6)	-17.0 (-30.4 to -0.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	136.6 (86.3 to 199.8)	-20.3 (-35.2 to -2.3)
Breast cancer	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	148.7 (-5.4 to 352.5)	0.7 (-59.9 to 78.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	147.3 (-6.3 to 354.6)	-0.4 (-60.0 to 75.9)
Cervical cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	157.8 (39.7 to 335.8)	8.8 (-50.2 to 50.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	152.2 (35.6 to 330.9)	-10.6 (-53.2 to 49.5)
Uterine cancer	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	300.5 (160.6 to 449.9)	32.0 (-15.2 to 81.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	349.3 (144.1 to 606.6)	58.6 (-17.1 to 152.8)
Prostate cancer	0.9 (0.8 to 0.9)	1.1 (1.0 to 1.2)	27.8 (8.4 to 52.4)	-56.9 (-64.0 to -47.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	23.0 (3.3 to 46.6)	-57.9 (-65.3 to -48.9)
Colon and rectum cancer	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	0.9 (-53.8 to 102.0)	-61.6 (-81.3 to -23.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.4 (-53.3 to 98.4)	-63.6 (-82.1 to -26.3)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.0)	72.2 (-2.7 to 189.4)	-28.8 (-60.3 to 22.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.7 (14.4 to 185.3)	-29.5 (-60.2 to 17.0)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-32.8 (-61.4 to 196.0)	-77.7 (-87.4 to -5.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.0 (-62.5 to 199.5)	-77.4 (-87.4 to -3.0)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.1 (32.2 to 170.0)	-32.3 (-52.3 to 0.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.5 (34.6 to 174.0)	-31.8 (-54.3 to 3.4)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	131.5 (71.8 to 210.6)	-19.4 (-40.2 to 8.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	142.8 (87.4 to 215.9)	-16.2 (-36.3 to 10.3)
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	357.6 (150.0 to 739.6)	82.2 (-4.0 to 290.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	332.4 (130.0 to 751.6)	67.9 (-10.9 to 284.3)
Non-melanoma skin cancer	0.3 (0.2 to 0.4)	0.7 (0.5 to 1.0)	137.4 (50.3 to 290.3)	-17.4 (-47.6 to 29.7)	0.0 (0.0 to 0.0)	0.4 (0.0 to 0.0)	142.4 (65.6 to 266.3)	-21.9 (-42.2 to 28.4)
Ovarian cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	102.0 (41.0 to 202.2)	-12.3 (-38.9 to 24.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.1 (32.3 to 211.0)	-14.3 (-41.4 to 29.2)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	165.5 (-15.3 to 513.5)	54.9 (-48.9 to 242.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	147.2 (-27.3 to 636.6)	44.0 (-55.1 to 259.8)
Kidney cancer	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	105.4 (37.3 to 189.4)	-10.8 (-38.3 to 20.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.5 (38.9 to 184.1)	-14.0 (-39.8 to 17.5)
Bladder cancer	0.2 (0.2 to 0.3)	0.4 (0.4 to 0.4)	67.4 (49.0 to 91.5)	-40.0 (-46.4 to -31.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	68.2 (50.1 to 91.6)	-39.6 (-45.8 to -32.0)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	66.1 (17.2 to 130.1)	3.7 (-23.8 to 44.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.1 (22.2 to 139.5)	-3.2 (-28.9 to 39.0)
Thyroid cancer	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	164.7 (28.8 to 351.5)	31.9 (-33.1 to 114.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	162.1 (28.7 to 342.3)	27.3 (-34.6 to 107.7)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.7 (14.6 to 164.3)	-13.7 (-49.7 to 41.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.3 (14.3 to 160.3)	-15.4 (-51.8 to 37.6)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	215.5 (6.5 to 468.4)	18.9 (-27.6 to 274.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	227.2 (3.3 to 476.0)	-11.4 (-30.9 to 25.1)
Non-Hodgkin lymphoma	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	224.4 (105.7 to 432.4)	19.6 (-22.1 to 97.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	217.4 (100.7 to 415.1)	16.1 (-24.6 to 89.4)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	368.7 (98.2 to 1,025.6)	67.8 (-32.4 to 361.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	343.1 (92.6 to 975.9)	57.6 (-38.2 to 348.7)
Leukemia	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	20.4 (-16.2 to 60.8)	-27.1 (-45.7 to -6.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.5 (-6.3 to 75.2)	-29.3 (-46.1 to -7.7)
Other neoplasms	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	299.2 (108.0 to 533.4)	156.1 (25.3 to 287.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	307.7 (107.5 to 549.5)	441.8 (17.8 to 267.5)
Cardiovascular diseases	-	-	-	-	0.3 (0.2 to 0.5)	1.0 (0.6 to 1.3)	203.8 (121.8 to 293.1)	7.1 (-19.8 to 37.4)
Rheumatic heart disease	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	157.5 (99.4 to 234.6)	5.5 (-19.5 to 41.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	147.7 (67.5 to 249.2)	2.9 (-28.0 to 46.7)
Ischemic heart disease	1.4 (1.1 to 1.8)	4.0 (3.3 to 5.2)	182.9 (112.8 to 319.2)	-5.3 (-30.5 to 42.1)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	188.2 (118.1 to 319.8)	-2.7 (-27.4 to 41.3)
Cerebrovascular disease	-	-	-	-	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	168.2 (115.9 to 245.1)	-8.6 (-25.6 to 27.9)
Ischemic stroke	0.5 (0.4 to 0.5)	1.3 (1.1 to 1.5)	167.1 (108.0 to 240.3)	-5.5 (-29.2 to 24.1)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	168.3 (109.5 to 244.6)	5.4 (-28.8 to 25.9)
Hemorrhagic stroke	0.2 (0.2 to 0.2)	0.5 (0.5 to 0.6)	171.2 (113.1 to 262.0)	1.6 (-22.6 to 44.5)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	171.2 (107.6 to 262.5)	2.3 (-23.1 to 43.2)
Hypertensive heart disease	0.1 (0.1 to 0.2)	0.5 (0.4 to 0.6)	246.8 (170.5 to 322.6)	20.1 (-8.1 to 48.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	249.7 (172.7 to 335.0)	21.0 (-7.7 to 51.1)
Cardiomyopathy and myocarditis	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.4)	165.1 (112.2 to 232.6)	3.1 (-21.0 to 34.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	165.5 (108.5 to 234.3)	3.2 (-21.4 to 36.5)
Atrial fibrillation and flutter	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	143.5 (50.7 to 304.1)	4.2 (-40.3 to 115.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	149.1 (52.0 to 312.9)	6.8 (-41.9 to 119.4)
Peripheral vascular disease	1.2 (0.7 to 1.6)	2.7 (1.3 to 4.3)	125.5 (15.8 to 267.6)	-21.3 (-51.7 to 19.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	192.4 (36.5 to 772.1)	14.4 (-50.1 to 212.1)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	174.7 (86.7 to 323.3)	6.3 (-31.3 to 65.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	175.2 (75.9 to 340.8)	5.2 (-34.2 to 77.6)
Other cardiovascular and circulatory diseases	1.2 (0.5 to 2.3)	4.1 (1.6 to 6.5)	265.0 (18.0 to 774.8)	34.5 (-53.6 to 215.3)	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.5)	265.6 (161.0 to 781.8)	35.3 (-53.7 to 214.1)
Chronic respiratory diseases	-	-	-	-	0.6 (0.4 to 0.9)	1.3 (0.9 to 1.8)	100.7 (71.5 to 137.2)	3.8 (-15.1 to 10.1)
Chronic obstructive pulmonary disease	4.9 (4.5 to 5.4)	11.2 (10.2 to 12.3)	126.2 (114.0 to 137.2)	-3.4 (-8.1 to 0.7)	0.3 (0.2 to 0.4)	0.7 (0.4 to 0.9)	135.1 (96.6 to 173.6)	0.3 (-15.7 to 18.0)
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.7 (77.8 to 101.2)	-25.1 (-30.5 to -20.7)

Appendix Table G.4 - Brunei prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.0 (64.4 to 83.8)	-35.9 (-39.8 to -32.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.5 (61.3 to 93.1)	-33.4 (-43.5 to -25.2)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.7 (77.4 to 108.4)	-21.0 (-25.9 to -16.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.1 (78.7 to 110.2)	-20.1 (-24.9 to -15.0)
Asthma	7.3 (5.9 to 8.9)	13.0 (10.8 to 15.2)	77.9 (32.8 to 134.3)	3.3 (-2.7 to 10.7)	0.6 (0.2 to 0.5)	0.6 (0.4 to 0.9)	6.6 (31.3 to 132.6)	-4.6 (-25.6 to 21.2)
Interstitial lung disease and pulmonary sarcoidosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	125.3 (48.4 to 214.9)	-4.0 (-38.8 to 34.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.3 (51.8 to 217.5)	-3.1 (-37.5 to 35.9)
Other chronic respiratory diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	64.9 (18.4 to 125.8)	-28.6 (-49.9 to -1.5)
Cirrhosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.9 (31.6 to 97.5)	-35.6 (-46.1 to -22.7)
Cirrhosis due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.6 (8.4 to 245.3)	37.0 (-64.6 to 24.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.9 (-14.0 to 268.1)	-37.7 (-66.0 to 29.2)
Cirrhosis due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.1 (-6.7 to 241.6)	-14.0 (-60.4 to 72.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.6 (-12.5 to 257.3)	-14.6 (-63.4 to 79.1)
Cirrhosis due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.9 (-70.2 to 108.3)	-88.0 (-33.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.0 (-70.9 to 131.2)	-63.9 (-87.8 to -29.1)
Cirrhosis due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	125.1 (-14.1 to 385.0)	14.5 (-58.2 to 136.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.0 (-21.4 to 396.6)	11.7 (-61.4 to 143.6)
Digestive diseases	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	70.4 (52.4 to 89.3)	-34.6 (-41.2 to -27.1)
Peptic ulcer disease	0.7 (0.7 to 0.7)	0.5 (0.4 to 0.5)	-31.9 (-39.5 to -23.2)	-74.1 (-77.3 to -70.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.9 (-18.3 to 17.5)	-66.0 (-70.4 to -58.5)
Gastritis and duodenitis	0.3 (0.2 to 0.3)	0.2 (0.2 to 0.2)	-24.9 (-37.8 to -10.9)	-67.2 (-72.4 to -61.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.8 (-38.2 to 20.5)	-61.0 (-68.0 to -47.8)
Appendicitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.7 (-12.3 to 28.5)	-30.3 (-41.7 to -16.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.6 (-20.3 to 49.4)	-28.2 (-46.6 to -3.8)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.7 (8.2 to 113.2)	-5.8 (-21.8 to 16.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.7 (-0.3 to 123.3)	-4.7 (-30.4 to 25.6)
Inguinal, femoral, and abdominal hernia	0.2 (0.2 to 0.3)	0.5 (0.5 to 0.6)	126.6 (83.8 to 175.6)	-14.1 (-31.7 to 11.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	126.8 (84.8 to 181.4)	-13.7 (-31.7 to 13.0)
Inflammatory bowel disease	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	120.9 (69.3 to 189.9)	5.6 (-17.3 to 34.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	119.4 (62.6 to 200.4)	6.2 (-19.5 to 37.9)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	128.8 (81.1 to 195.7)	2.8 (-25.6 to 35.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	127.0 (73.6 to 208.5)	2.5 (-32.5 to 50.6)
Gallbladder and biliary diseases	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.4)	108.9 (61.4 to 157.9)	-16.6 (-32.5 to -0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.5 (56.5 to 161.1)	-16.7 (-33.6 to 0.5)
Pancreatitis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	159.4 (143.3 to 176.7)	17.6 (10.5 to 24.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	160.0 (114.4 to 208.7)	18.5 (1.0 to 36.6)
Other digestive diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	116.6 (61.1 to 190.2)	-17.1 (-37.4 to 10.3)
Neurological disorders	-	-	-	-	1.2 (0.7 to 1.8)	2.4 (1.6 to 3.5)	99.5 (54.4 to 168.3)	3.2 (-14.6 to 29.5)
Alzheimer disease and other dementias	0.5 (0.4 to 0.5)	1.2 (1.1 to 1.4)	158.8 (116.8 to 217.1)	2.6 (-15.4 to 27.3)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	155.7 (114.2 to 213.9)	3.9 (-14.9 to 28.8)
Parkinson disease	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	184.7 (167.5 to 203.0)	2.6 (-7.9 to 2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	187.9 (156.3 to 224.7)	-2.1 (-11.4 to 8.8)
Epilepsy	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	90.0 (5.8 to 234.5)	17.0 (-34.9 to 105.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	84.8 (3.0 to 230.0)	15.1 (-35.9 to 105.1)
Multiple sclerosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	256.9 (197.9 to 325.5)	69.8 (44.5 to 99.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	256.9 (197.7 to 325.5)	69.8 (44.5 to 99.2)
Migraine	24.4 (16.9 to 30.5)	43.1 (29.1 to 54.9)	77.3 (21.0 to 169.2)	-0.3 (-29.5 to 53.2)	0.8 (0.4 to 1.3)	1.5 (0.8 to 2.4)	75.5 (18.5 to 166.1)	-0.3 (-29.9 to 52.9)
Tension-type headache	27.3 (22.7 to 31.9)	34.9 (32.5 to 109.7)	247.5 (181.6 to 337.6)	0.1 (-60.3 to 42.3)	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.3)	248.6 (179.2 to 339.0)	34.8 (59.0 to 142.6)
Medication overuse headache	0.8 (0.5 to 1.0)	2.4 (1.6 to 3.3)	211.3 (131.4 to 293.9)	51.9 (18.0 to 86.8)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	207.6 (128.6 to 293.1)	52.1 (-16.7 to 88.6)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.4 (51.6 to 187.4)	10.6 (-16.7 to 49.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	48.9 (3.6 to 121.6)	-40.7 (-58.9 to -11.0)
Mental and substance use disorders	-	-	-	-	5.0 (3.5 to 6.9)	8.7 (6.0 to 11.9)	73.0 (64.8 to 82.1)	-0.5 (-4.3 to 2.3)
Schizophrenia	0.7 (0.6 to 0.7)	1.4 (1.3 to 1.5)	97.3 (87.0 to 107.2)	-2.2 (-6.2 to 2.0)	0.5 (0.3 to 0.6)	0.9 (0.7 to 1.1)	95.8 (81.5 to 109.3)	-2.3 (-7.9 to 3.9)
Alcohol use disorders	2.3 (1.9 to 2.6)	4.2 (3.6 to 4.8)	84.5 (67.4 to 106.6)	8.7 (0.3 to 19.0)	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	84.0 (66.1 to 108.4)	9.2 (-0.4 to 20.7)
Drug use disorders	-	-	-	-	0.6 (0.4 to 0.8)	0.9 (0.6 to 1.2)	55.7 (37.9 to 75.0)	-2.4 (-13.5 to 9.2)
Opioid use disorders	0.7 (0.5 to 0.9)	1.1 (0.9 to 1.3)	61.4 (42.5 to 84.2)	-2.4 (-13.1 to 7.5)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.6)	60.5 (41.0 to 87.4)	-2.7 (-14.6 to 9.1)
Cocaine use disorders	0.4 (0.4 to 0.5)	0.7 (0.6 to 0.8)	55.2 (26.3 to 91.1)	-3.9 (-20.9 to 17.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	54.7 (18.6 to 99.0)	-4.0 (-24.5 to 20.8)
Amphetamine use disorders	0.5 (0.5 to 0.7)	0.9 (0.8 to 1.0)	50.7 (23.1 to 82.6)	0.1 (-17.9 to 20.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	50.0 (18.9 to 85.4)	-0.1 (-20.0 to 22.3)
Cannabis use disorders	0.6 (0.5 to 0.7)	0.9 (0.8 to 1.0)	46.4 (44.3 to 49.0)	-0.6 (-0.8 to -0.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.8 (26.8 to 69.0)	-0.5 (-13.6 to 14.0)
Other drug use disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	51.6 (9.7 to 108.0)	-1.9 (-28.9 to 34.6)
Depressive disorders	-	-	-	-	1.7 (0.9 to 2.8)	3.1 (1.6 to 5.0)	81.3 (59.4 to 103.7)	-0.3 (-9.0 to 6.1)
Major depressive disorder	6.6 (3.1 to 9.9)	11.8 (5.4 to 18.1)	79.7 (54.4 to 108.9)	-0.5 (-11.2 to 7.6)	1.4 (0.6 to 2.4)	2.5 (1.0 to 4.2)	78.1 (53.7 to 106.9)	-0.9 (-11.6 to 7.7)
Dysthymia	3.4 (2.7 to 4.0)	6.5 (5.4 to 7.6)	92.3 (80.6 to 108.2)	1.7 (1.2 to 2.1)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	91.2 (78.7 to 108.1)	1.7 (-0.9 to 3.9)
Bipolar disorder	1.5 (1.2 to 1.9)	2.7 (2.2 to 3.2)	74.7 (63.4 to 90.3)	-0.4 (-5.4 to 5.9)	0.3 (0.2 to 0.5)	0.6 (0.3 to 0.9)	74.0 (60.7 to 90.8)	-0.1 (-7.0 to 7.0)
Anxiety disorders	6.8 (3.1 to 9.5)	12.0 (6.1 to 16.5)	77.8 (56.4 to 101.9)	2.0 (1.4 to 2.6)	0.6 (0.3 to 1.0)	1.1 (0.5 to 1.8)	76.6 (55.6 to 101.4)	2.1 (-1.0 to 5.0)
Eating disorders	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	42.2 (27.1 to 60.1)	3.8 (-6.7 to 15.6)
Anorexia nervosa	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	48.9 (18.9 to 83.3)	6.3 (-14.6 to 30.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	48.8 (15.4 to 87.9)	6.6 (-16.8 to 34.7)
Bulimia nervosa	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	38.9 (33.7 to 45.5)	2.6 (1.5 to 4.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	38.9 (25.7 to 53.4)	2.6 (-6.8 to 12.6)
Autistic spectrum disorders	-	-	-	-	0.3 (0.2 to 0.5)	0.5 (0.4 to 0.7)	54.1 (48.5 to 59.8)	-2.1 (-5.2 to 1.0)
Autism	0.9 (0.8 to 0.9)	1.3 (1.3 to 1.4)	55.5 (54.2 to 57.0)	-4.9 (-2.0 to 4.8)	0.1 (0.1 to 0.3)	0.1 (0.2 to 0.5)	54.6 (46.1 to 62.6)	-1.7 (-6.3 to 2.9)
Asperger syndrome	1.2 (1.1 to 1.3)	1.9 (1.7 to 2.0)	54.3 (52.5 to 56.2)	-2.6 (-2.7 to -2.4)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	53.4 (47.2 to 60.0)	-2.6 (-6.1 to 1.2)
Attention-deficit/hyperactivity disorder	1.7 (1.6 to 1.9)	2.3 (2.2 to 2.5)	36.8 (36.7 to 37.0)	-0.1 (-0.1 to -0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.5 (26.9 to 47.3)	-0.2 (-7.3 to 7.7)
Conduct disorder	2.3 (2.1 to 2.5)	3.2 (2.9 to 3.5)	42.3 (41.5 to 43.1)	-0.0 (-0.0 to -0.0)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	42.2 (36.0 to 48.8)	0.1 (-4.4 to 4.4)
Idiopathic intellectual disability	0.8 (0.4 to 1.1)	1.0 (0.5 to 1.5)	10.8 (-13.4 to 40.7)	-31.5 (-46.2 to -13.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	10.4 (-15.5 to 42.5)	-31.5 (-47.1 to -12.1)
Other mental and substance use disorders	4.0 (3.7 to 4.3)	7.4 (7.0 to 7.9)	84.5 (79.5 to 89.7)	4.7 (-2.2 to 1.2)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	83.4 (74.5 to 92.5)	-1.8 (-5.2 to 2.2)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	1.3 (0.9 to 1.8)	2.9 (2.1 to 4.0)	127.7 (107.1 to 144.7)	12.1 (3.0 to 20.6)
Diabetes mellitus	5.0 (4.2 to 5.9)	15.4 (12.8 to 18.4)	208.9 (143.5 to 280.4)	34.5 (8.5 to 64.5)	0.3 (0.2 to 0.5)	1.0 (0.7 to 1.4)	220.3 (144.7 to 296.7)	30.9 (3.7 to 60.7)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.0 (-9.9 to 7.4)	-43.3 (-48.0 to -38.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.0 (-10.0 to 7.4)	-43.3 (-48.0 to -38.9)
Chronic kidney disease	-	-	-	-	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.6)	112.1 (86.5 to 137.6)	1.6 (-4.2 to 9.3)
Chronic kidney disease due to diabetes mellitus	1.6 (1.0 to 2.5)	5.9 (3.4 to 9.9)	264.6 (158.6 to 439.8)	41.1 (5.7 to 107.7)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	245.8 (145.3 to 358.9)	40.4 (3.4 to 87.9)
Chronic kidney disease due to hypertension	2.4 (1.5 to 3.9)	4.3 (2.7 to 6.6)	80.5 (22.8 to 140.9)	-9.4 (-33.3 to 17.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	92.4 (41.7 to 167.3)	-15.5 (-39.1 to 15.1)
Chronic kidney disease due to glomerulonephritis	1.6 (1.2 to 2.3)	3.2 (2.1 to 4.9)	91.8 (39.6 to 177.0)	-13.1 (-39.9 to 11.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	76.0 (41.3 to 120.3)	-6.7 (-25.1 to 15.7)
Chronic kidney disease due to other causes	2.8 (1.8 to 4.3)	4.9 (3.3 to 7.0)	72.3 (35.0 to 128.9)	0.1 (-32.5 to 21.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	72.3 (29.4 to 135.7)	-0.8 (-31.3 to 24.9)
Urinary diseases and male infertility	-	-	-	-	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	187.3 (150.7 to 235.4)	-5.1 (-18.2 to 11.2)
Interstitial nephritis and urinary tract infections	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	118.2 (85.7 to 158.4)	25.7 (9.5 to 43.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.8 (66.3 to 184.6)	26.8 (0.5 to 57.3)

Appendix Table G.4 - Brunei prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Urolithiasis	0.8 (0.5 to 1.2)	2.2 (1.3 to 3.9)	181.9 (99.2 to 234.7)	0.0 (-21.9 to 18.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	138.5 (85.0 to 191.0)	<-1 (-22.0 to 10.5)
Benign prostatic hyperplasia	2.3 (2.0 to 2.6)	6.8 (5.9 to 7.6)	193.0 (149.1 to 248.8)	-7.6 (-22.4 to 9.5)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	196.2 (151.9 to 254.3)	-7.1 (-22.1 to 10.5)
Male infertility due to other causes	0.8 (0.6 to 1.0)	1.1 (0.7 to 1.4)	40.5 (-6.6 to 107.1)	-5.3 (-36.5 to 40.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.2 (-9.6 to 112.9)	-4.9 (-37.8 to 45.0)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,291.2 (21.0 to 2,641.9)	538.9 (-49.1 to 1,058.8)
Gynecological diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	184.6 (77.4 to 134.2)	13.0 (0.2 to 28.5)
Uterine fibroids	5.6 (4.8 to 6.5)	14.8 (13.0 to 16.8)	163.6 (154.4 to 174.1)	13.5 (13.2 to 13.8)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	135.5 (119.8 to 150.2)	14.9 (9.2 to 19.8)
Polycystic ovarian syndrome	3.4 (3.1 to 3.8)	6.7 (6.1 to 7.2)	93.5 (72.0 to 121.9)	14.4 (2.5 to 30.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	92.2 (70.5 to 119.7)	14.3 (1.8 to 29.8)
Female infertility due to other causes	0.1 (0.0 to 0.3)	0.3 (0.1 to 0.7)	103.5 (-66.1 to 872.7)	-1.0 (-82.9 to 411.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.1 (-63.3 to 775.7)	-0.9 (-81.8 to 390.4)
Endometriosis	0.7 (0.6 to 0.9)	1.3 (1.1 to 1.6)	79.7 (37.9 to 153.0)	0.1 (-17.0 to 48.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	80.2 (35.9 to 161.3)	5.9 (-18.3 to 53.4)
Genital prolapse	8.0 (6.3 to 9.7)	19.2 (15.5 to 22.4)	143.6 (82.8 to 216.9)	10.9 (-12.3 to 37.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	142.4 (82.2 to 217.0)	10.6 (-12.3 to 37.8)
Premenstrual syndrome	7.0 (4.6 to 9.6)	13.4 (8.5 to 19.2)	96.5 (7.6 to 220.2)	23.4 (-31.5 to 97.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	95.3 (7.3 to 218.9)	23.1 (-30.7 to 93.8)
Other gynecological diseases	0.9 (0.7 to 1.0)	1.6 (1.5 to 1.7)	83.6 (59.6 to 111.3)	8.6 (-5.1 to 23.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	81.3 (56.1 to 138.9)	9.1 (-6.0 to 43.4)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.2 to 0.5)	54.7 (41.4 to 77.0)	6.9 (-2.3 to 20.5)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.2 (14.3 to 43.7)	-4.1 (-11.1 to 13.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.5 (-2.9 to 51.5)	-9.2 (-26.8 to 14.7)
Thalassemia trait	8.6 (8.2 to 9.2)	13.9 (13.2 to 14.7)	61.0 (54.8 to 67.8)	0.4 (-3.3 to 4.9)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	60.4 (47.9 to 82.0)	8.6 (-0.9 to 23.1)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.2 (12.0 to 38.5)	-7.3 (-16.2 to 3.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.6 (13.6 to 50.8)	-5.7 (-17.2 to 8.3)
Sickle cell trait	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.2)	14.7 (10.7 to 29.5)	-28.4 (-30.9 to -19.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.3 (-20.1 to 48.3)	-22.3 (-38.9 to 11.5)
G6PD deficiency	0.4 (7.6 to 11.3)	14.0 (10.2 to 17.8)	482.7 (3.6 to 108.8)	7.1 (-35.3 to 30.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.2 (-26.5 to 105.8)	-8.3 (-49.2 to 33.4)
G6PD trait	32.1 (31.6 to 32.6)	53.6 (52.7 to 54.6)	66.9 (62.9 to 71.4)	4.9 (2.3 to 7.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.2 (71.2 to 1,561.5)	0.4 (-79.2 to 834.7)
Other hemoglobinopathies and hemolytic anemias	2.1 (1.8 to 2.4)	3.4 (3.0 to 3.8)	59.8 (36.5 to 92.6)	5.9 (-8.7 to 22.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	43.4 (6.3 to 109.6)	5.0 (-22.8 to 47.9)
Endocrine, metabolic, blood, and immune disorders	3.6 (3.2 to 3.9)	6.0 (5.7 to 6.2)	63.6 (52.5 to 84.2)	5.6 (-1.2 to 16.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	65.1 (48.4 to 95.3)	9.5 (-1.1 to 25.8)
Musculoskeletal disorders	-	-	-	-	3.4 (2.3 to 4.6)	8.6 (6.1 to 11.6)	153.0 (110.5 to 200.4)	11.6 (-2.1 to 27.9)
Rheumatoid arthritis	0.2 (0.2 to 0.2)	0.6 (0.6 to 0.6)	164.8 (150.3 to 181.3)	2.7 (-3.4 to 9.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	164.6 (140.2 to 191.4)	3.1 (-4.9 to 12.5)
Osteoarthritis	5.1 (4.9 to 5.4)	15.3 (14.7 to 16.0)	197.5 (180.9 to 217.2)	-1.9 (-6.8 to 3.9)	0.2 (0.1 to 0.3)	0.5 (0.4 to 0.8)	198.3 (180.9 to 219.4)	-1.6 (-6.8 to 4.5)
Low back and neck pain	-	-	-	-	2.5 (1.6 to 3.5)	5.9 (4.0 to 8.1)	139.3 (84.7 to 200.3)	14.5 (-7.0 to 39.6)
Low back pain	13.9 (11.2 to 17.7)	31.2 (25.1 to 37.8)	130.6 (53.1 to 207.1)	7.7 (-22.8 to 40.8)	1.6 (1.0 to 2.4)	3.5 (2.2 to 5.2)	129.2 (51.0 to 205.3)	8.2 (-22.8 to 41.8)
Neck pain	8.9 (7.5 to 10.2)	23.3 (21.0 to 25.9)	162.9 (120.0 to 218.0)	27.7 (9.0 to 52.6)	0.9 (0.6 to 1.3)	2.3 (1.6 to 3.2)	161.9 (117.9 to 218.5)	28.0 (8.7 to 53.7)
Gout	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.4)	168.1 (105.4 to 246.6)	-2.9 (-25.4 to 27.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	167.5 (89.4 to 277.9)	-2.4 (-28.6 to 36.4)
Other musculoskeletal disorders	7.4 (5.8 to 8.9)	21.8 (17.8 to 25.9)	192.6 (168.1 to 221.7)	10.4 (4.7 to 16.6)	0.7 (0.4 to 1.0)	2.0 (1.3 to 2.9)	192.0 (167.3 to 222.3)	10.8 (5.0 to 17.4)
Other non-communicable diseases	-	-	-	-	2.3 (0.4 to 4.2)	5.2 (3.5 to 7.5)	67.9 (67.0 to 84.7)	4.7 (-0.2 to 11.8)
Congenital anomalies	-	-	-	-	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.8)	66.4 (37.1 to 98.0)	2.9 (-14.4 to 21.6)
Neural tube defects	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	44.3 (21.4 to 73.4)	-1.1 (-16.8 to 19.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	44.4 (10.0 to 90.4)	0.0 (-23.3 to 31.0)
Congenital heart anomalies	2.6 (2.3 to 3.1)	3.5 (3.0 to 4.2)	33.0 (8.2 to 64.8)	-14.2 (-30.6 to 6.1)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	34.1 (10.3 to 62.6)	-11.7 (-27.7 to 7.3)
Crofacial clefts	0.5 (0.5 to 0.7)	0.8 (0.7 to 1.0)	49.1 (18.0 to 88.1)	-5.2 (-24.9 to 19.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.5 (8.2 to 100.6)	-4.6 (-30.0 to 27.6)
Down syndrome	0.2 (0.2 to 0.3)	0.2 (0.4 to 0.6)	86.1 (52.5 to 140.2)	7.0 (-11.8 to 37.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	108.7 (67.3 to 169.6)	8.4 (-11.9 to 40.0)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.9 (13.9 to 151.4)	9.0 (-24.7 to 67.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.1 (13.1 to 161.0)	9.3 (-25.0 to 70.8)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.0 (49.5 to 174.0)	28.0 (-5.7 to 72.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.0 (27.1 to 200.1)	25.0 (-20.2 to 80.7)
Chromosomal unbalanced rearrangements	0.4 (0.4 to 0.5)	0.8 (0.6 to 0.9)	83.3 (38.7 to 137.2)	5.3 (-19.7 to 36.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	105.9 (49.4 to 168.6)	6.6 (-20.6 to 39.3)
Other congenital anomalies	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.7)	48.2 (16.4 to 89.3)	-5.0 (-33.1 to 8.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	67.7 (14.3 to 144.4)	9.4 (-25.3 to 56.7)
Skin and subcutaneous diseases	-	-	-	-	1.5 (1.0 to 2.3)	2.5 (1.6 to 3.7)	62.8 (47.6 to 77.7)	-1.5 (-9.3 to 6.4)
Dermatitis	15.8 (12.8 to 19.1)	26.4 (21.6 to 31.9)	67.3 (60.9 to 73.8)	-0.2 (-0.5 to 0.2)	0.4 (0.3 to 0.6)	0.7 (0.4 to 1.0)	61.4 (54.8 to 68.6)	0.1 (-2.2 to 2.6)
Psoriasis	2.9 (2.5 to 3.2)	5.5 (4.8 to 6.2)	91.6 (82.3 to 101.9)	-0.3 (-0.6 to 0.0)	0.2 (0.2 to 0.3)	0.2 (0.3 to 0.6)	90.2 (76.7 to 104.5)	-0.3 (-4.6 to 4.0)
Cellulitis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	84.2 (63.8 to 110.9)	0.0 (-8.2 to 9.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.0)	89.3 (47.4 to 128.4)	0.1 (-14.8 to 20.1)
Pyoderma	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.3)	27.9 (15.3 to 42.0)	-12.4 (-16.1 to -7.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.5 (8.2 to 47.1)	-12.5 (-21.6 to -3.0)
Scabies	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	25.4 (-1.6 to 64.6)	-21.8 (-38.0 to 1.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.3 (-4.5 to 68.5)	-22.1 (-39.2 to 4.5)
Fungal skin diseases	13.2 (10.3 to 16.5)	24.8 (20.1 to 29.9)	88.0 (77.8 to 101.5)	-1.3 (-2.0 to -0.6)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	87.5 (77.1 to 100.5)	-1.2 (-2.3 to -0.1)
Viral skin diseases	6.9 (5.2 to 8.4)	9.6 (7.6 to 11.6)	39.2 (33.3 to 51.2)	0.2 (-2.6 to 4.7)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	39.0 (31.3 to 52.1)	-0.4 (-3.5 to 2.7)
Acne vulgaris	31.6 (22.9 to 39.0)	43.7 (33.3 to 55.9)	35.8 (-2.6 to 104.8)	-5.3 (-31.8 to 40.7)	0.3 (0.2 to 0.7)	0.5 (0.2 to 1.0)	35.7 (-2.6 to 104.9)	-5.5 (-32.0 to 41.2)
Alopecia areata	0.4 (0.3 to 0.4)	0.6 (0.6 to 0.7)	79.9 (61.0 to 99.8)	-2.8 (-12.1 to 8.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.7 (55.2 to 105.0)	-2.6 (-14.2 to 10.5)
Pruritus	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	121.5 (52.9 to 228.6)	0.5 (-33.0 to 56.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	121.9 (48.2 to 236.3)	0.7 (-34.1 to 60.1)
Urticaria	1.5 (1.0 to 2.2)	2.7 (1.5 to 4.0)	69.0 (-9.3 to 242.5)	8.1 (-47.3 to 94.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	66.7 (-11.4 to 241.8)	-8.6 (-49.1 to 95.0)
Decubitus ulcer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	99.4 (55.1 to 148.3)	-8.5 (-30.7 to 26.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.0 (44.6 to 154.8)	-8.4 (-33.6 to 25.1)
Other skin and subcutaneous diseases	10.7 (7.5 to 14.8)	24.5 (15.9 to 36.4)	128.1 (94.0 to 165.0)	-0.7 (-3.7 to 3.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	127.1 (92.2 to 164.0)	-0.5 (-3.8 to 3.5)
Sense organ diseases	-	-	-	-	0.8 (0.5 to 1.1)	1.5 (1.0 to 2.1)	91.0 (76.7 to 103.9)	-12.6 (-16.7 to -8.2)
Glaucoma	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	45.2 (19.7 to 76.5)	-36.3 (-48.1 to -23.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	60.9 (34.7 to 92.1)	-32.5 (-42.3 to -20.9)
Cataract	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	79.7 (10.3 to 142.1)	-33.8 (-58.0 to -35.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.2 (21.8 to 127.7)	-33.5 (-52.1 to -13.8)
Macular degeneration	0.2 (0.1 to 0.3)	0.8 (0.5 to 1.1)	266.2 (171.4 to 399.9)	19.3 (-12.3 to 63.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	233.9 (152.6 to 335.4)	11.7 (-13.9 to 48.2)
Uncorrected refractive error	6.9 (6.1 to 7.6)	13.9 (12.5 to 15.3)	101.1 (79.0 to 127.7)	-9.5 (-17.4 to 0.0)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	17.4 (53.8 to 89.4)	-17.6 (-22.6 to -11.8)
Age-related and other hearing loss	14.4 (13.1 to 15.7)	34.8 (31.6 to 37.8)	142.3 (125.8 to 155.2)	-9.2 (-12.5 to -6.3)	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.0)	129.6 (102.4 to 151.3)	-7.8 (-14.7 to -0.0)
Other vision loss	1.4 (1.1 to 1.7)	1.8 (1.3 to 2.4)	34.5 (14.3 to 56.9)	-32.6 (-39.6 to -24.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	31.3 (25.3 to 65.4)	-31.3 (-37.6 to -24.3)
Other sense organ diseases	5.7 (5.4 to 6.0)	9.1 (8.7 to 9.5)	59.8 (49.3 to 71.8)	1.1 (-5.0 to 7.7)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.4)	58.5 (47.3 to 71.8)	1.1 (-5.2 to 8.3)
Oral disorders	-	-	-	-	0.3 (0.2 to 0.5)	0.6 (0.4 to 1.0)	117.4 (105.5 to 129.9)	4.1 (-0.6 to 9.2)
Deciduous caries	26.2 (24.9 to 27.6)	29.3 (28.1 to 30.3)	11.7 (4.4 to 18.8)	0.7 (-6.1 to 7.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.0 (1.7 to 22.7)	0.9 (-6.5 to 10.6)
Permanent caries	96.3 (88.6 to 106.3)	163.1 (149.7 to 178.4)	69.8 (50.2 to 89.5)	17.1 (-12.0 to 9.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	69.1 (49.6 to 89.3)	1.5 (-12.2 to 9.7)
Periodontal diseases	7.8 (7.2 to 8.3)	20.0 (18.7 to 21.3)	156.2 (133.2 to 183.7)	1.0 (-6.8 to 9.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	156.0 (132.1 to 182.9)	1.2 (-6.7 to 10.0)
Edentulism and severe tooth loss	2.0 (1.9 to 2.2)	6.4 (6.0 to 6.8)	211.9 (184.3 to 248.1)	10.7 (1.8 to 22.2)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	213.8 (183.1 to 250.0)	11.4 (2.2 to 23.0)

Appendix Table G.4 - Brunei prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	4.1 (3.9 to 4.4)	7.6 (7.1 to 8.0)	84.0 (69.2 to 99.7)	0.4 (-7.2 to 7.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	83.2 (67.2 to 99.5)	0.5 (-7.2 to 8.6)
Injuries	-	-	-	-	1.1 (0.8 to 1.4)	1.4 (1.0 to 1.9)	27.4 (14.9 to 42.1)	-38.2 (-44.3 to -31.5)
Transport injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-26.9 (-35.2 to -18.0)	-63.0 (-66.8 to -59.0)
Road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-33.2 (-40.7 to -24.6)	-65.9 (-69.3 to -62.0)
Pedestrian road injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-24.6 (-33.2 to -14.5)	-62.2 (-65.9 to -58.0)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-47.1 (-54.6 to -38.5)	-72.7 (-76.2 to -68.7)
Motorcyclist road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-51.4 (-59.1 to -42.9)	-74.4 (-78.0 to -70.4)
Motor vehicle road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-21.5 (-29.8 to -11.9)	-60.5 (-64.1 to -56.4)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.5 (-56.3 to -41.7)	-74.5 (-77.6 to -71.2)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	39.5 (25.2 to 54.1)	-38.6 (-44.8 to -32.1)
Unintentional injuries	-	-	-	-	0.7 (0.5 to 0.9)	1.1 (0.8 to 1.5)	56.2 (42.7 to 71.2)	-27.6 (-34.3 to -20.0)
Falls	-	-	-	-	0.4 (0.3 to 0.5)	0.7 (0.5 to 1.0)	75.8 (58.8 to 94.8)	-25.8 (-33.7 to -16.8)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.8 (2.0 to 35.1)	-39.8 (-46.9 to -32.3)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	52.6 (30.8 to 81.7)	-23.7 (-32.9 to -12.6)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.7 (-46.6 to -15.2)	-63.7 (-70.4 to -55.4)
Exposure to mechanical forces	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	14.0 (2.6 to 27.4)	-40.8 (-46.2 to -34.7)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.8 (-2.9 to 30.0)	-37.8 (-46.0 to -29.8)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.9 (25.0 to 70.4)	-16.2 (-27.1 to -4.3)
Other exposure to mechanical forces	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	14.0 (2.4 to 27.3)	-40.9 (-46.4 to -34.8)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.5 (87.2 to 120.0)	1.2 (-6.4 to 10.4)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.7 (48.5 to 80.0)	-13.4 (-20.2 to -6.1)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.3 (37.6 to 85.3)	-13.4 (-23.7 to -1.7)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.5 (48.9 to 82.7)	-13.4 (-20.6 to -5.3)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.6 (24.9 to 50.4)	-21.8 (-29.8 to -14.4)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.8 (2.5 to 43.5)	-32.3 (-40.9 to -21.7)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.2 (35.0 to 70.3)	-12.1 (-21.7 to 0.1)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.5 (19.5 to 50.4)	-23.4 (-32.5 to -15.3)
Other unintentional injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	338.8 (289.1 to 388.3)	93.4 (72.4 to 114.7)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.4 (-6.8 to 15.0)	-51.1 (-55.0 to -46.6)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.2 (63.1 to 111.4)	-26.8 (-34.7 to -18.1)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.3 (-31.5 to -14.2)	-60.9 (-64.5 to -57.0)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.3 (-39.5 to -23.0)	-64.3 (-68.0 to -60.5)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.4 (-37.4 to -22.5)	-63.6 (-66.7 to -60.2)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.0 (-29.5 to -9.5)	-59.6 (-63.9 to -55.0)
Forces of nature, war, and legal intervention	-	-	-	-	-	-	-	-
Exposure to forces of nature	-	-	-	-	-	-	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Bulgaria prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,085.6 (813.8 to 1,404.2)	988.7 (740.6 to 1,274.5)	-9.9 (-11.5 to -6.4)	-3.3 (-6.2 to -0.6)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	64.8 (45.1 to 89.8)	45.9 (32.0 to 63.6)	-29.4 (-42.3 to -10.7)	-1.6 (-18.9 to 22.1)
HIV/AIDS and tuberculosis	-	-	-	-	1.2 (0.9 to 1.7)	1.6 (1.1 to 2.3)	29.6 (12.0 to 59.4)	43.8 (22.7 to 77.2)
Tuberculosis	3.9 (3.7 to 4.1)	4.4 (4.2 to 4.6)	12.8 (7.8 to 18.5)	22.4 (17.2 to 28.3)	0.1 (0.8 to 1.6)	0.3 (0.9 to 1.8)	305.0 (0.9 to 26.8)	305.0 (9.7 to 39.4)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.7)	379.3 (104.3 to 626.5)	429.2 (129.5 to 721.9)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	379.3 (138.8 to 678.1)	429.2 (165.3 to 762.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	379.3 (138.5 to 678.4)	429.2 (164.6 to 763.1)
HIV/AIDS resulting in other diseases	0.5 (0.2 to 1.1)	2.4 (1.4 to 4.1)	362.3 (156.0 to 681.5)	416.8 (186.5 to 768.6)	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.7)	303.6 (101.8 to 633.6)	356.0 (127.3 to 731.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	7.2 (5.0 to 9.8)	5.1 (3.6 to 7.1)	-28.4 (-32.5 to -23.7)	-8.6 (-14.6 to -2.7)
Diarrheal diseases	21.0 (19.3 to 22.5)	15.5 (14.5 to 16.6)	-26.0 (-33.4 to -17.3)	-6.9 (-16.3 to 4.7)	3.3 (2.3 to 4.6)	2.4 (1.6 to 3.4)	-27.1 (-35.1 to -18.1)	-6.6 (-17.2 to 4.9)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-71.6 (-71.6 to -11.2)	8.1 (61.2 to 8.1)
Typhoid fever	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-41.1 (-63.9 to 1.3)	-25.1 (-48.8 to 19.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.1 (-64.0 to 1.5)	-25.1 (-48.9 to 19.9)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.1 (-62.4 to 4.2)	-23.1 (-48.4 to 26.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.1 (-62.5 to 4.7)	-23.1 (-48.4 to 27.4)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-90.2 (-99.6 to 41.4)	87.0 (99.5 to 78.0)
Lower respiratory infections	1.3 (1.1 to 1.6)	0.7 (0.5 to 1.0)	-43.9 (-64.9 to -19.9)	-5.7 (-70.2 to -32.8)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-45.1 (-66.8 to -19.4)	-52.4 (-70.8 to -31.7)
Upper respiratory infections	84.6 (80.3 to 88.3)	66.6 (63.7 to 70.1)	-21.3 (-26.5 to -14.6)	0.2 (-6.4 to 9.4)	1.0 (0.6 to 1.7)	0.8 (0.4 to 1.3)	-21.7 (-27.3 to -14.7)	0.4 (-7.1 to 9.4)
Otitis media	89.9 (84.3 to 95.6)	65.2 (61.0 to 70.2)	-27.6 (-33.3 to -20.5)	-5.1 (-12.1 to 3.3)	1.8 (1.1 to 2.8)	1.3 (0.8 to 2.0)	-29.5 (-35.9 to -22.3)	-7.0 (-15.0 to 2.2)
Meningitis	-	-	-	-	0.6 (0.4 to 0.8)	0.3 (0.2 to 0.4)	-54.6 (-64.3 to -36.7)	-44.6 (-57.2 to -21.3)
Pneumococcal meningitis	2.6 (1.5 to 4.2)	1.2 (0.7 to 2.0)	-53.2 (-62.6 to -36.7)	-47.5 (-58.5 to -27.1)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-91.1 (-63.2 to -27.6)	-40.9 (-57.1 to -10.2)
H influenzae type B meningitis	0.9 (0.3 to 1.9)	0.4 (0.1 to 0.8)	-59.4 (-74.4 to -18.1)	-49.7 (-68.0 to 11.2)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-59.3 (-78.7 to 25.8)	-46.9 (-73.6 to 72.2)
Meningococcal meningitis	0.7 (0.2 to 1.7)	0.3 (0.1 to 0.7)	-59.8 (-73.2 to -34.0)	-52.9 (-68.2 to -21.8)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-58.0 (-74.2 to -25.1)	-48.9 (-69.5 to -7.4)
Other meningitis	1.2 (0.5 to 2.5)	0.5 (0.2 to 1.1)	-55.9 (-66.5 to -43.4)	-48.3 (-60.1 to -31.4)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-55.6 (-72.5 to -35.1)	-45.8 (-66.9 to -19.3)
Encephalitis	1.3 (0.5 to 3.2)	1.2 (0.5 to 3.1)	-5.9 (-23.1 to 12.6)	-5.9 (-10.9 to 31.8)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-48.8 (-21.8 to 19.5)	11.5 (8.1 to 42.5)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.8 (-93.9 to 413.9)	-23.0 (-91.4 to 545.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.8 (-93.9 to 415.1)	-23.0 (-91.4 to 556.3)
Whooping cough	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.4)	108.6 (92.9 to 125.9)	232.4 (207.4 to 260.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.0 (50.0 to 198.0)	228.0 (139.9 to 372.5)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.5 (-77.2 to -18.2)	-58.5 (-67.7 to -18.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.1 (-77.1 to -15.0)	-57.4 (-67.7 to -15.1)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-90.5 (-95.5 to -84.9)	-84.4 (-92.7 to -75.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-90.5 (-95.6 to -84.9)	-84.4 (-92.8 to -75.2)
Varicella and herpes zoster	4.7 (4.4 to 5.2)	3.6 (3.2 to 4.1)	-23.1 (-34.3 to -11.1)	-1.4 (-11.7 to 8.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-9.2 (-32.4 to 20.0)	-1.3 (-23.5 to 26.0)
Neglected tropical diseases and malaria	-	-	-	-	0.9 (0.6 to 1.2)	0.3 (0.2 to 0.5)	-60.4 (-67.4 to -53.5)	-51.1 (-60.2 to -42.7)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.4 (-81.4 to 255.6)	-15.8 (-75.2 to 386.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.2 (-81.5 to 257.3)	-16.6 (-75.0 to 389.3)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.4 (0.2 to 0.7)	0.1 (0.0 to 0.2)	-82.5 (-93.8 to -25.8)	-82.7 (-94.1 to -37.9)	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-81.3 (-93.5 to -18.5)	-81.5 (-93.9 to -33.4)
Cystic echinococcosis	8.4 (7.7 to 8.9)	3.5 (3.2 to 3.9)	-57.8 (-61.0 to -53.5)	-47.9 (-51.6 to -42.8)	0.8 (0.5 to 1.1)	0.3 (0.2 to 0.4)	-57.9 (-63.1 to -52.0)	-47.2 (-53.6 to -39.7)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.7 (-42.4 to -7.5)	-7.3 (-32.1 to 15.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.7 (-42.4 to -7.4)	-7.3 (-32.2 to 15.3)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	124.7 (-7.1 to 191.6)	172.3 (13.2 to 254.2)
Maternal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-35.3 (-49.0 to -12.4)	-20.5 (-37.3 to 7.1)
Maternal hemorrhage	0.5 (0.4 to 0.6)	0.3 (0.2 to 0.4)	-34.7 (-51.7 to -10.7)	-23.5 (-44.1 to 6.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.1 (-80.3 to 29.7)	-48.6 (-76.4 to 67.0)
Maternal sepsis and other maternal infections	1.4 (0.8 to 2.5)	0.9 (0.5 to 1.5)	-34.5 (-50.9 to -4.1)	-22.4 (-41.4 to 13.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.2 (-74.4 to -21.6)	-36.7 (-68.8 to 23.7)
Maternal hypertensive disorders	0.9 (0.4 to 1.5)	0.6 (0.3 to 1.0)	-27.1 (-43.2 to 7.1)	-11.2 (-29.5 to 26.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-27.1 (-48.3 to 18.0)	-10.7 (-36.3 to 41.8)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.3 (-79.8 to 347.8)	-14.5 (-75.5 to 472.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.3 (-79.9 to 348.1)	-14.5 (-75.6 to 473.8)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.6 (-32.7 to 177.9)	50.7 (-18.1 to 253.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.6 (-32.8 to 178.6)	50.7 (-18.3 to 253.5)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.6 (-54.6 to 22.7)	-12.6 (-44.5 to 49.2)
Neonatal disorders	-	-	-	-	16.4 (9.7 to 25.4)	12.6 (7.1 to 21.7)	-24.0 (-66.0 to 69.5)	-0.3 (-55.4 to 121.5)
Preterm birth complications	50.3 (29.2 to 82.2)	53.1 (33.2 to 84.8)	7.4 (-30.6 to 50.1)	36.7 (-13.3 to 94.8)	6.6 (3.8 to 10.8)	7.6 (4.5 to 11.8)	19.2 (-46.7 to 118.0)	55.6 (-30.6 to 185.5)
Neonatal encephalopathy due to birth asphyxia and trauma	10.8 (5.8 to 21.5)	5.5 (2.7 to 12.1)	-50.4 (-70.2 to -9.6)	-34.8 (-60.5 to 21.8)	2.7 (1.6 to 4.5)	1.4 (0.8 to 2.4)	-50.0 (-72.8 to 9.3)	-32.6 (-62.6 to 48.1)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.6 (40.0 to 65.4)	138.1 (117.7 to 149.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.0 (8.9 to 129.1)	132.8 (64.8 to 246.3)
Hemolytic disease and other neonatal jaundice	3.6 (1.6 to 9.5)	2.9 (0.7 to 8.6)	-11.3 (-79.2 to 102.9)	-11.3 (-73.3 to 174.4)	1.1 (0.6 to 3.4)	1.1 (0.3 to 3.2)	-11.5 (-79.1 to 107.2)	15.7 (-72.6 to 174.6)
Other neonatal disorders	-	-	-	-	5.8 (2.1 to 9.6)	2.5 (0.9 to 7.9)	-72.0 (-88.6 to 137.4)	-63.4 (-85.1 to 212.6)
Nutritional deficiencies	-	-	-	-	35.7 (23.4 to 51.7)	23.8 (15.7 to 34.8)	-33.3 (-37.1 to -29.4)	-1.0 (-5.7 to 4.6)
Protein-energy malnutrition	7.2 (5.0 to 9.8)	3.4 (2.4 to 4.6)	-52.6 (-70.0 to -25.6)	-24.8 (-52.3 to 18.2)	0.9 (0.5 to 1.4)	0.4 (0.2 to 0.7)	-52.8 (-70.0 to -24.3)	-25.1 (-52.3 to 19.9)
Iodine deficiency	52.5 (26.3 to 81.3)	38.0 (13.4 to 42.8)	-27.9 (-75.7 to 20.1)	-48.1 (-69.2 to 42.6)	0.9 (0.4 to 1.8)	0.5 (0.2 to 0.9)	-48.4 (-75.2 to 19.6)	-37.8 (-68.9 to 42.3)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron deficiency anemia	1,267.4 (1,243.5 to 1,289.6)	969.2 (946.6 to 990.7)	-23.5 (-25.9 to -21.2)	1.4 (-1.5 to 4.3)	32.9 (21.8 to 48.3)	22.4 (14.8 to 32.7)	-31.8 (-35.3 to -28.1)	1.6 (-2.1 to 6.7)

Appendix Table G.4 - Bulgaria prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-4.7 (-9.9 to 0.9)	-10.5 (-15.5 to -5.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.5 (-8.9 to 2.4)	-14.8 to -4.7
Asbestosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	2.1 (-2.8 to 7.2)	-4.4 (-9.1 to -0.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.8 (-0.2 to 10.4)	-2.2 (-7.2 to 2.0)
Coal workers pneumoconiosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-1.9 (-6.7 to 2.6)	-6.6 (-10.2 to -1.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.3 (-5.5 to 4.4)	-4.2 (-8.9 to 0.2)
Other pneumoconiosis	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-35.4 (-43.6 to -27.5)	-38.7 (-45.7 to -33.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.6 (-42.4 to -25.3)	-37.2 (-44.6 to -31.2)
Asthma	258.9 (214.7 to 300.1)	294.9 (206.4 to 265.6)	13.5 (-25.1 to 13.7)	15.1 (-19.0 to 47.3)	11.1 (6.9 to 16.2)	10.1 (6.6 to 14.3)	-9.1 (-23.3 to 14.0)	-8.6 (-18.5 to 28.8)
Interstitial lung disease and pulmonary sarcoidosis	1.3 (0.9 to 1.6)	1.2 (0.9 to 1.6)	-6.3 (-35.9 to 38.5)	-3.5 (-33.1 to 43.7)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-5.1 (-35.1 to 40.4)	-2.9 (-32.5 to 45.4)
Other chronic respiratory diseases	-	-	-	-	0.7 (0.4 to 1.1)	1.2 (0.7 to 1.9)	68.9 (13.8 to 157.9)	66.7 (11.7 to 149.0)
Cirrhosis	-	-	-	-	1.1 (0.7 to 1.5)	1.0 (0.7 to 1.4)	-8.8 (-16.1 to 8.2)	4.0 (-7.9 to 17.5)
Cirrhosis due to hepatitis B	1.4 (1.1 to 1.8)	1.7 (1.1 to 2.2)	20.9 (-27.4 to 69.8)	26.5 (-24.0 to 80.0)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	19.7 (-37.7 to 76.4)	26.0 (-27.2 to 85.4)
Cirrhosis due to hepatitis C	1.7 (1.1 to 2.3)	1.7 (1.2 to 2.4)	-0.7 (-31.0 to 63.7)	3.1 (-27.2 to 70.5)	0.3 (0.1 to 0.4)	0.3 (0.2 to 0.4)	0.5 (-33.5 to 71.4)	3.8 (-30.3 to 77.8)
Cirrhosis due to alcohol use	2.1 (1.6 to 2.6)	1.2 (0.9 to 1.6)	-40.0 (-58.2 to -11.2)	-39.7 (-58.5 to -9.8)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-40.8 (-60.0 to -10.7)	-39.9 (-59.7 to -9.7)
Cirrhosis due to other causes	1.3 (0.9 to 1.6)	1.5 (1.2 to 1.9)	18.6 (-13.3 to 69.4)	37.4 (4.5 to 89.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	18.4 (-16.9 to 74.6)	38.3 (-0.0 to 100.1)
Digestive diseases	-	-	-	-	11.0 (7.8 to 14.7)	11.0 (7.9 to 14.6)	0.2 (-6.0 to 7.5)	-0.0 (-7.4 to 8.1)
Peptic ulcer disease	80.4 (74.7 to 84.9)	47.3 (39.4 to 53.8)	-41.1 (-49.9 to -32.2)	-53.0 (-60.4 to -46.5)	2.7 (1.8 to 3.7)	1.8 (1.2 to 2.5)	-33.1 (-41.2 to -21.3)	-45.3 (-52.2 to -35.5)
Gastritis and duodenitis	15.3 (13.7 to 17.0)	23.7 (21.3 to 26.7)	55.9 (32.4 to 79.3)	50.9 (27.5 to 72.4)	0.8 (0.5 to 1.1)	1.1 (0.7 to 1.5)	41.4 (15.4 to 62.3)	41.4 (14.6 to 65.3)
Appendicitis	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.3)	-31.7 (-46.8 to -10.4)	-8.8 (-29.6 to 26.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-31.0 (-51.3 to 0.5)	-4.7 (-37.5 to 46.9)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	29.3 (4.9 to 68.9)	47.2 (9.2 to 136.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	25.9 (-5.0 to 72.8)	48.3 (-14.0 to 146.0)
Inguinal, femoral, and abdominal hernia	34.1 (27.7 to 40.3)	35.6 (29.9 to 41.8)	4.4 (-16.9 to 32.9)	6.1 (-24.4 to 17.7)	0.3 (0.2 to 0.7)	0.4 (0.2 to 0.7)	4.2 (-16.9 to 34.6)	5.0 (-23.7 to 20.3)
Inflammatory bowel disease	13.5 (12.9 to 14.1)	18.2 (17.4 to 18.9)	34.6 (26.8 to 43.3)	40.7 (32.6 to 49.2)	2.8 (1.9 to 3.8)	3.8 (2.6 to 5.1)	34.3 (23.8 to 45.3)	41.6 (30.4 to 52.7)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (-7.8 to 83.7)	7.7 (-21.1 to 51.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-8.0 to 83.8)	7.7 (-21.3 to 51.9)
Gallbladder and biliary diseases	27.1 (23.1 to 31.1)	20.8 (18.1 to 24.0)	-23.1 (-36.7 to -8.5)	-25.5 (-38.5 to -10.9)	2.8 (1.8 to 4.0)	2.2 (1.5 to 3.0)	-23.3 (-37.6 to -8.0)	-25.2 (-38.8 to -10.0)
Pancreatitis	3.6 (3.4 to 3.7)	3.7 (3.5 to 4.0)	1.0 (-2.9 to 13.9)	5.2 (-0.2 to 16.2)	1.0 (0.7 to 1.4)	1.1 (0.8 to 1.5)	1.7 (-1.5 to 4.9)	8.4 (-5.5 to 24.0)
Other digestive diseases	-	-	-	-	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.0)	56.2 (28.0 to 96.9)	55.7 (27.4 to 96.5)
Neurological disorders	-	-	-	-	90.0 (61.7 to 123.0)	90.6 (62.9 to 123.9)	0.8 (-10.6 to 13.3)	7.1 (-5.8 to 20.9)
Alzheimer disease and other dementias	95.1 (82.9 to 106.6)	130.9 (113.7 to 148.0)	37.4 (15.7 to 64.1)	0.8 (-15.2 to 20.8)	13.4 (9.8 to 17.7)	19.0 (13.3 to 24.8)	40.9 (17.8 to 69.7)	1.6 (-14.7 to 22.4)
Parkinson disease	9.9 (8.0 to 11.8)	11.5 (9.2 to 13.9)	15.4 (8.1 to 25.2)	1.2 (-9.2 to 6.8)	1.2 (0.8 to 1.6)	1.3 (0.9 to 1.9)	15.0 (3.1 to 30.3)	-1.3 (-11.8 to 11.7)
Epilepsy	42.6 (27.7 to 60.7)	30.8 (20.2 to 43.0)	-27.8 (-59.8 to 25.8)	-12.7 (-51.4 to 54.1)	12.9 (7.4 to 20.2)	9.3 (5.5 to 14.6)	-27.6 (-60.5 to 30.7)	-12.4 (-51.9 to 59.9)
Multiple sclerosis	2.3 (2.1 to 2.5)	4.0 (3.6 to 4.3)	75.5 (52.7 to 99.3)	91.9 (67.2 to 118.3)	0.7 (0.5 to 1.0)	1.3 (0.9 to 1.7)	72.7 (43.2 to 109.7)	88.7 (56.9 to 130.2)
Migraine	1,304.1 (1,202.2 to 1,405.1)	1,099.4 (1,007.3 to 1,188.2)	-15.7 (-24.4 to -5.4)	-0.2 (-10.8 to 12.3)	44.1 (26.5 to 64.7)	37.0 (21.9 to 53.4)	-16.3 (-25.1 to -6.2)	0.1 (-10.9 to 13.3)
Tension-type headache	1,718.4 (1,567.0 to 1,885.3)	1,493.0 (1,324.1 to 1,586.2)	-13.3 (-26.6 to -4.1)	-1.1 (-14.4 to 12.7)	2.3 (1.3 to 4.5)	2.2 (1.1 to 3.8)	-4.5 (-26.8 to -4.2)	0.2 (-14.3 to 13.5)
Medication overuse headache	92.8 (58.1 to 129.3)	127.9 (79.7 to 178.9)	37.0 (-2.0 to 98.2)	50.6 (10.6 to 115.1)	14.4 (7.8 to 22.8)	19.8 (10.6 to 31.1)	36.3 (4.0 to 98.2)	51.2 (11.2 to 115.5)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.1 (-30.4 to 39.1)	5.9 (-20.8 to 41.4)	0.8 (0.5 to 1.1)	0.7 (0.5 to 1.0)	0.2 (-25.7 to 32.3)	-23.8 (-43.7 to 0.9)
Mental and substance use disorders	-	-	-	-	192.2 (139.7 to 248.5)	159.0 (115.9 to 205.7)	-17.2 (-19.3 to -15.1)	-2.7 (-4.9 to -0.5)
Schizophrenia	29.8 (27.5 to 32.0)	26.4 (24.8 to 28.4)	-11.4 (-14.4 to -8.0)	-0.6 (-4.2 to 3.5)	18.9 (13.9 to 22.9)	16.8 (12.5 to 20.4)	-11.3 (-16.2 to -6.6)	-0.1 (-5.7 to 5.5)
Alcohol use disorders	87.9 (78.8 to 96.0)	57.1 (50.5 to 63.9)	-34.9 (-40.3 to -29.6)	-25.7 (-32.2 to -19.5)	8.7 (5.7 to 12.4)	5.7 (3.7 to 8.1)	-34.9 (-40.7 to -28.9)	-25.5 (-32.4 to -18.4)
Drug use disorders	-	-	-	-	10.4 (6.5 to 14.8)	7.4 (4.8 to 10.5)	-28.6 (-39.6 to -17.0)	-13.2 (-26.7 to 1.1)
Opioid use disorders	9.0 (4.4 to 15.0)	7.7 (3.7 to 12.9)	-14.3 (-23.3 to -3.0)	0.3 (-10.8 to 13.9)	3.7 (1.7 to 6.6)	3.2 (1.4 to 5.7)	-13.7 (-26.6 to 1.8)	1.2 (-14.4 to 20.1)
Cocaine use disorders	7.9 (6.8 to 8.9)	6.2 (5.4 to 7.0)	-21.8 (-34.5 to -6.2)	-1.6 (-8.1 to 18.7)	1.1 (0.7 to 1.6)	0.8 (0.5 to 1.2)	-22.3 (-37.5 to -2.4)	-2.0 (-22.0 to 24.5)
Amphetamine use disorders	15.8 (13.2 to 18.5)	8.6 (7.1 to 9.8)	-45.6 (-57.9 to -30.1)	-21.9 (-48.4 to -3.2)	2.3 (1.2 to 3.0)	1.1 (0.7 to 1.7)	-46.0 (-59.0 to -29.9)	-2.9 (-9.3 to 11.6)
Cannabis use disorders	12.2 (10.6 to 13.7)	8.8 (7.7 to 9.9)	-27.6 (-32.0 to -23.4)	-0.4 (-6.4 to 5.4)	0.4 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-27.1 (-38.4 to -13.5)	0.3 (-15.3 to 18.3)
Other drug use disorders	-	-	-	-	3.2 (2.0 to 4.7)	2.0 (1.3 to 2.9)	-37.3 (-55.4 to -10.9)	-22.0 (-45.0 to 11.5)
Depressive disorders	-	-	-	-	73.0 (49.8 to 100.8)	64.3 (44.2 to 89.4)	-12.0 (-15.9 to -7.4)	-0.2 (-4.6 to 4.9)
Major depressive disorder	294.7 (253.7 to 334.5)	258.7 (219.1 to 295.2)	-12.3 (-16.7 to -7.0)	-0.5 (-5.1 to 4.9)	59.7 (39.6 to 82.6)	52.0 (34.9 to 72.3)	-12.9 (-17.6 to -7.4)	-0.1 (-5.3 to 5.7)
Dysthymia	139.9 (115.1 to 168.4)	129.3 (107.3 to 154.2)	-7.6 (-13.1 to -0.3)	-0.7 (-5.6 to 6.5)	13.3 (8.7 to 19.5)	12.3 (8.1 to 17.9)	-8.0 (-14.1 to -0.2)	0.4 (-6.0 to 7.4)
Bipolar disorder	61.8 (51.0 to 73.5)	54.0 (44.4 to 63.7)	-12.6 (-17.0 to -8.2)	-2.1 (-6.5 to 2.4)	12.4 (7.6 to 18.2)	10.8 (6.6 to 16.0)	-12.8 (-18.5 to -7.2)	-2.0 (-8.0 to 4.0)
Anxiety disorders	338.7 (294.4 to 382.4)	283.6 (247.8 to 320.1)	-16.2 (-18.6 to -14.1)	-0.3 (-0.4 to -0.1)	30.8 (21.1 to 43.3)	25.6 (17.6 to 36.1)	-16.8 (-20.0 to -13.7)	-0.1 (-2.6 to 2.5)
Eating disorders	-	-	-	-	1.9 (1.2 to 3.0)	1.4 (0.9 to 2.2)	-26.9 (-33.4 to -19.9)	0.4 (-7.5 to 9.5)
Anorexia nervosa	0.9 (0.7 to 1.0)	0.7 (0.6 to 0.9)	-18.7 (-26.2 to -11.2)	15.3 (5.0 to 25.9)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-18.8 (-38.6 to 8.1)	15.3 (-12.1 to 54.1)
Bulimia nervosa	8.3 (6.1 to 11.1)	6.0 (4.3 to 8.3)	-27.8 (-30.9 to -25.3)	-1.3 (-1.6 to -1.2)	1.8 (1.0 to 2.8)	1.3 (0.8 to 2.1)	-27.9 (-34.9 to -21.2)	-1.1 (-9.4 to 7.8)
Autistic spectrum disorders	-	-	-	-	10.1 (7.0 to 13.6)	8.0 (5.5 to 10.8)	-20.6 (-23.0 to -18.0)	0.7 (-2.5 to 4.1)
Autism	26.2 (24.9 to 27.7)	21.0 (19.8 to 22.2)	-20.0 (-20.6 to -19.5)	0.4 (0.4 to 0.5)	6.4 (4.3 to 8.7)	5.1 (3.4 to 6.9)	-20.6 (-23.9 to -16.7)	0.7 (-3.7 to 5.8)
Asperger syndrome	37.3 (34.9 to 39.8)	29.8 (27.7 to 32.0)	-20.2 (-20.9 to -19.5)	0.5 (0.5 to 0.6)	3.7 (2.6 to 5.1)	2.9 (2.0 to 4.1)	-20.6 (-23.8 to -17.5)	0.7 (-3.2 to 4.8)
Attention-deficit/hyperactivity disorder	39.0 (35.9 to 42.1)	21.3 (19.6 to 23.0)	-45.2 (-45.8 to -44.9)	0.2 (0.2 to 0.2)	0.5 (0.3 to 0.7)	0.3 (0.2 to 0.4)	-45.5 (-49.3 to -40.7)	-0.1 (-7.2 to 8.9)
Conduct disorder	58.1 (54.7 to 61.6)	29.7 (27.8 to 31.6)	-48.9 (-49.5 to -48.3)	0.1 (0.1 to 0.2)	7.0 (4.4 to 10.3)	3.6 (2.3 to 5.2)	-48.9 (-51.1 to -46.6)	0.2 (-4.1 to 4.4)
Idiopathic intellectual disability	135.8 (109.2 to 166.9)	87.7 (63.6 to 109.7)	-35.2 (-44.8 to -27.5)	-19.1 (-31.4 to -9.6)	6.6 (4.3 to 9.4)	4.2 (2.6 to 6.1)	-38.6 (-45.3 to -27.3)	-19.2 (-30.8 to -8.8)
Other mental and substance use disorders	161.8 (152.3 to 171.1)	150.4 (141.6 to 159.1)	-7.1 (-8.0 to -6.2)	0.3 (0.1 to 0.5)	11.9 (8.1 to 16.1)	11.0 (7.6 to 14.8)	-3.3 (-10.4 to 4.2)	0.9 (-2.7 to 4.4)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	115.2 (81.8 to 155.2)	117.2 (82.3 to 158.3)	1.7 (-10.3 to 16.6)	7.2 (-5.0 to 20.7)
Diabetes mellitus	535.5 (433.0 to 640.2)	595.4 (482.5 to 723.3)	10.8 (-12.1 to 42.9)	16.6 (-6.4 to 48.3)	56.6 (37.0 to 80.6)	64.2 (42.4 to 91.5)	13.2 (-10.3 to 46.7)	16.8 (-7.1 to 48.6)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Chronic kidney disease	-	-	-	-	27.9 (20.4 to 36.0)	26.7 (19.7 to 34.5)	-4.3 (-12.7 to 4.8)	-0.2 (-7.4 to 8.4)
Chronic kidney disease due to diabetes mellitus	191.7 (111.3 to 296.3)	212.3 (146.6 to 301.5)	14.2 (-24.8 to 51.0)	11.1 (-23.3 to 41.8)	5.0 (3.4 to 6.9)	5.3 (3.5 to 7.6)	6.5 (-19.5 to 38.6)	7.6 (-16.8 to 35.3)
Chronic kidney disease due to hypertension	242.7 (172.8 to 361.7)	186.7 (125.7 to 259.8)	-23.2 (-38.9 to -0.3)	-13.8 (-29.9 to 7.7)	6.9 (4.9 to 9.2)	4.9 (3.4 to 6.7)	-29.7 (-42.0 to -11.8)	-27.3 (-39.6 to -9.8)
Chronic kidney disease due to glomerulonephritis	262.9 (193.5 to 371.8)	190.0 (136.5 to 258.2)	-28.0 (-41.9 to -8.3)	-25.6 (-38.5 to -7.2)	6.1 (4.2 to 8.3)	4.7 (3.3 to 6.7)	-23.6 (-36.6 to 3.9)	-23.6 (-26.8 to 10.3)
Chronic kidney disease due to other causes	389.7 (278.2 to 550.6)	481.1 (319.5 to 682.8)	20.0 (-4.9 to 49.2)	17.9 (2.7 to 49.0)	9.0 (7.0 to 13.0)	9.9 (8.4 to 15.4)	11.9 (4.5 to 31.2)	21.5 (2.6 to 52.7)
Urinary diseases and male infertility	-	-	-	-	7.4 (4.8 to 10.5)	8.2 (5.4 to 11.6)	9.9 (-8.3 to 35.8)	-2.5 (-18.1 to 19.7)
Interstitial nephritis and urinary tract infections	1.9 (1.7 to 2.1)	1.6 (1.5 to 1.8)	-15.3 (-26.2 to -3.2)	-1.5 (-15.8 to 13.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-16.0 (-32.0 to 5.1)	-2.0 (-21.8 to 25.5)

Appendix Table G.4 - Bulgaria prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	168.7 (160.4 to 177.5)	146.2 (138.8 to 154.2)	-13.3 (-20.0 to -6.7)	-0.4 (-7.6 to 7.3)	4.9 (3.0 to 7.3)	4.2 (2.7 to 6.3)	-13.7 (-20.5 to -6.7)	-0.4 (-7.7 to 7.9)
Injuries	-	-	-	-	140.2 (105.7 to 181.0)	99.2 (70.7 to 133.7)	-29.4 (-37.2 to -21.7)	-32.9 (-40.3 to -25.6)
Transport injuries	-	-	-	-	20.6 (15.4 to 26.6)	7.9 (5.6 to 10.8)	-61.2 (-66.1 to -56.6)	-61.2 (-65.8 to -56.0)
Road injuries	-	-	-	-	16.2 (12.1 to 20.8)	5.9 (4.2 to 8.1)	-63.6 (-68.2 to -58.5)	-63.1 (-67.8 to -57.9)
Pedestrian road injuries	-	-	-	-	3.4 (2.5 to 4.4)	1.4 (1.0 to 1.9)	-60.0 (-65.4 to -53.9)	-60.0 (-66.4 to -54.6)
Cyclist road injuries	-	-	-	-	3.2 (2.4 to 4.2)	1.0 (0.7 to 1.3)	-69.9 (-73.0 to -66.5)	-69.3 (-72.6 to -65.8)
Motorcyclist road injuries	-	-	-	-	1.8 (1.3 to 2.4)	0.5 (0.4 to 0.7)	-70.8 (-75.0 to -66.3)	-69.5 (-74.1 to -64.6)
Motor vehicle road injuries	-	-	-	-	7.3 (5.4 to 9.4)	3.0 (2.1 to 4.1)	-59.3 (-65.3 to -53.0)	-58.5 (-64.6 to -51.8)
Other road injuries	-	-	-	-	0.4 (0.3 to 0.6)	0.1 (0.0 to 0.1)	-85.0 (-86.8 to -82.8)	-85.0 (-86.8 to -82.7)
Other transport injuries	-	-	-	-	4.4 (3.3 to 5.7)	2.0 (1.4 to 2.8)	-54.5 (-59.5 to -48.9)	-54.1 (-59.2 to -48.3)
Unintentional injuries	-	-	-	-	118.0 (89.1 to 152.5)	90.5 (64.6 to 121.7)	-23.5 (-31.8 to -15.5)	-27.7 (-35.5 to -19.8)
Falls	-	-	-	-	93.1 (69.6 to 120.1)	72.7 (51.7 to 97.6)	-22.2 (-31.4 to -13.0)	-28.6 (-37.2 to -19.9)
Drowning	-	-	-	-	0.4 (0.3 to 0.5)	0.2 (0.1 to 0.3)	-48.4 (-55.5 to -40.6)	-47.5 (-54.6 to -39.4)
Fire, heat, and hot substances	-	-	-	-	1.3 (1.0 to 1.7)	0.8 (0.6 to 1.1)	-36.8 (-45.5 to -27.3)	-34.2 (-43.0 to -23.7)
Poisonings	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.1)	-47.9 (-55.9 to -38.7)	-40.6 (-50.3 to -28.8)
Exposure to mechanical forces	-	-	-	-	17.1 (12.7 to 22.4)	11.6 (8.4 to 15.7)	-32.5 (-37.3 to -27.3)	-27.9 (-33.1 to -22.3)
Unintentional firearm injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-50.6 (-59.2 to -41.2)	-46.4 (-55.3 to -36.2)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-49.0 (-54.3 to -43.0)	-46.1 (-52.0 to -39.3)
Other exposure to mechanical forces	-	-	-	-	16.7 (12.3 to 21.9)	11.4 (8.2 to 15.4)	-32.0 (-36.9 to -26.8)	-27.4 (-32.6 to -21.8)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	8.2 (-2.2 to 18.8)	6.5 (-2.7 to 16.4)
Animal contact	-	-	-	-	0.6 (0.4 to 0.7)	0.4 (0.3 to 0.6)	-21.7 (-29.0 to -13.3)	-14.2 (-22.1 to -4.9)
Venomous animal contact	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-18.7 (-30.4 to -6.7)	-9.4 (-23.1 to 5.6)
Non-venomous animal contact	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-23.1 (-31.3 to -13.4)	-16.8 (-25.7 to -6.5)
Foreign body	-	-	-	-	0.7 (0.6 to 1.0)	0.5 (0.4 to 0.7)	-31.9 (-38.4 to -24.6)	-28.3 (-35.2 to -20.5)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-49.2 (-57.9 to -37.7)	-46.1 (-55.8 to -34.2)
Foreign body in eyes	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-19.7 (-24.6 to -14.2)	-9.7 (-16.0 to -2.8)
Foreign body in other body part	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-25.0 (-32.2 to -17.0)	-22.8 (-29.8 to -14.6)
Other unintentional injuries	-	-	-	-	4.5 (3.3 to 5.9)	4.0 (2.9 to 5.4)	-9.9 (-18.0 to -0.2)	-9.5 (-17.7 to 0.4)
Self-harm and interpersonal violence	-	-	-	-	1.6 (1.2 to 2.1)	0.8 (0.6 to 1.1)	-50.5 (-55.7 to -43.7)	-50.1 (-55.3 to -43.4)
Self-harm	-	-	-	-	1.0 (0.7 to 1.2)	0.5 (0.3 to 0.6)	-50.8 (-55.7 to -44.8)	-51.1 (-55.8 to -44.9)
Interpersonal violence	-	-	-	-	0.7 (0.5 to 0.9)	0.3 (0.2 to 0.5)	-50.0 (-56.3 to -42.5)	-48.9 (-55.3 to -41.2)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-41.5 (-46.9 to -35.5)	-40.7 (-46.4 to -34.7)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-42.2 (-49.2 to -33.3)	-40.4 (-47.4 to -31.4)
Assault by other means	-	-	-	-	0.5 (0.4 to 0.6)	0.2 (0.2 to 0.3)	-53.3 (-59.8 to -45.6)	-52.3 (-58.9 to -44.4)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.3 (48.7 to 70.9)	51.1 (32.8 to 177.1)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.3 (48.7 to 70.9)	51.1 (32.8 to 177.1)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Burkina Faso prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	939.7 (679.2 to 1,239.5)	1,541.3 (1,120.2 to 2,030.0)	64.0 (55.6 to 72.2)	64.0 (-18.3 to -9.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	387.2 (266.3 to 531.0)	468.9 (329.0 to 653.1)	20.6 (7.1 to 36.9)	-48.0 (-55.4 to -38.0)
HIV/AIDS and tuberculosis	-	-	-	-	19.5 (13.3 to 27.2)	17.6 (11.8 to 25.5)	-10.9 (-23.5 to 10.5)	-52.2 (-58.8 to -39.8)
Tuberculosis	14.4 (13.4 to 15.5)	21.3 (19.8 to 22.9)	47.7 (40.2 to 57.5)	-19.8 (-23.9 to -15.2)	4.3 (3.0 to 5.9)	6.5 (4.4 to 8.8)	50.0 (38.2 to 63.9)	-18.9 (-24.5 to -12.9)
HIV/AIDS	-	-	-	-	15.2 (10.1 to 21.7)	11.1 (6.9 to 17.9)	-28.8 (-43.5 to 0.1)	-42.3 (-70.8 to -46.0)
HIV/AIDS resulting in mycobacterial infection	2.0 (1.2 to 2.7)	0.8 (0.4 to 1.4)	-59.3 (-70.3 to -41.2)	-78.0 (-84.1 to -66.7)	0.7 (0.4 to 1.1)	0.3 (0.1 to 0.6)	-58.9 (-72.3 to -36.3)	-77.6 (-84.9 to -63.8)
HIV/AIDS resulting in other diseases	139.4 (118.4 to 165.8)	98.7 (85.0 to 115.1)	-29.4 (-40.0 to -15.4)	-61.1 (-66.7 to -53.3)	14.5 (9.6 to 20.7)	10.8 (6.7 to 17.5)	-27.4 (-42.7 to 2.2)	-62.0 (-70.4 to -44.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	54.9 (39.1 to 73.5)	69.3 (48.8 to 93.7)	26.4 (16.9 to 36.7)	-28.4 (-33.6 to -22.3)
Diarrheal diseases	213.2 (200.6 to 226.1)	221.6 (205.8 to 237.7)	4.1 (-5.5 to 14.2)	-43.3 (-48.2 to -38.0)	34.0 (23.2 to 46.7)	35.6 (24.3 to 49.1)	5.4 (-5.9 to 15.5)	43.1 (-48.1 to -37.3)
Intestinal infectious diseases	-	-	-	-	0.9 (0.6 to 1.3)	0.4 (0.3 to 0.6)	0.4 (-63.9 to 36.3)	-74.8 (-80.9 to -66.4)
Typhoid fever	4.0 (3.5 to 4.7)	2.2 (1.8 to 2.6)	-45.6 (-58.1 to -31.5)	-71.2 (-77.9 to -63.0)	0.5 (0.3 to 0.8)	0.3 (0.2 to 0.4)	0.3 (-59.0 to -24.3)	-70.0 (-77.8 to -59.8)
Paratyphoid fever	2.7 (2.3 to 3.1)	1.9 (1.5 to 2.2)	-30.8 (-46.0 to -11.6)	-64.5 (-72.9 to -53.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	0.1 (-48.6 to -2.7)	-63.5 (-73.6 to -50.4)
Other intestinal infectious diseases	-	-	-	-	0.2 (0.1 to 0.4)	0.0 (0.0 to 0.1)	-88.1 (-93.7 to -88.3)	-93.7 (-96.5 to -88.3)
Lower respiratory infections	3.8 (3.3 to 4.2)	5.4 (4.5 to 6.2)	40.9 (14.8 to 74.6)	-12.7 (-24.1 to 0.4)	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.8)	52.0 (93.3 to 87.3)	-11.9 (-26.7 to 6.6)
Upper respiratory infections	611.8 (572.8 to 645.4)	1,183.6 (1,121.8 to 1,250.7)	93.4 (79.8 to 110.1)	0.9 (-5.8 to 8.9)	7.1 (4.0 to 11.9)	13.9 (7.8 to 23.1)	94.7 (80.3 to 111.9)	1.8 (-5.5 to 9.7)
Otitis media	197.4 (179.0 to 217.8)	348.2 (316.9 to 380.2)	76.9 (60.1 to 93.5)	-9.2 (-18.9 to 1.2)	4.1 (2.4 to 6.4)	7.2 (4.3 to 11.8)	78.2 (59.3 to 99.2)	-8.2 (-18.5 to 3.1)
Meningitis	-	-	-	-	6.9 (4.6 to 9.6)	10.9 (7.4 to 14.9)	58.6 (21.7 to 101.2)	-11.6 (30.5 to 12.0)
Pneumococcal meningitis	31.2 (18.8 to 46.8)	54.7 (34.9 to 77.4)	78.7 (34.0 to 120.7)	-0.9 (-23.0 to 20.5)	5.4 (1.9 to 4.7)	5.4 (3.7 to 7.4)	78.7 (15.6 to 162.8)	-1.4 (-34.5 to 41.7)
H influenzae type B meningitis	9.8 (4.7 to 17.3)	9.9 (4.7 to 17.4)	-2.8 (-25.1 to 70.6)	-48.5 (-61.6 to -11.3)	1.2 (0.7 to 1.7)	1.4 (0.9 to 2.5)	10.1 (-21.7 to 144.2)	-42.9 (59.3 to 30.2)
Meningococcal meningitis	13.6 (6.1 to 27.5)	21.6 (8.9 to 42.6)	56.6 (27.3 to 111.3)	-10.0 (-28.6 to 16.5)	1.7 (1.1 to 2.6)	2.9 (1.7 to 4.7)	66.9 (28.4 to 132.8)	-2.1 (-30.2 to 29.6)
Other meningitis	7.0 (5.2 to 9.8)	9.1 (6.8 to 12.9)	27.9 (6.8 to 60.7)	-31.2 (-44.1 to -13.5)	1.0 (0.6 to 1.4)	1.2 (0.8 to 1.8)	30.3 (22.2 to 70.0)	-30.2 (-46.3 to -9.7)
Encephalitis	1.9 (0.9 to 3.9)	3.2 (1.5 to 6.5)	67.4 (49.4 to 88.9)	-19.6 (-21.1 to -0.8)	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	78.1 (52.8 to 107.1)	-6.6 (-18.9 to 6.4)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-	-	0.0 (99.4 to 359.2)	0.0 (0.0 to 0.0)	-	-
Whooping cough	14.8 (11.4 to 19.1)	0.9 (0.7 to 1.2)	-94.0 (-95.2 to -92.6)	-96.7 (-97.3 to -95.9)	0.7 (0.4 to 1.2)	0.0 (0.0 to 0.1)	-94.0 (-95.8 to -91.4)	-96.7 (-97.7 to -95.2)
Tetanus	0.7 (0.4 to 1.4)	0.5 (0.2 to 1.0)	-36.1 (-75.7 to 64.1)	-65.8 (-88.6 to -8.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-40.1 (-65.5 to 33.0)	-68.6 (-81.6 to -31.5)
Measles	4.1 (3.0 to 5.4)	0.1 (0.1 to 0.2)	-96.5 (-97.7 to -94.9)	-98.1 (-98.7 to -97.2)	0.4 (0.2 to 0.6)	0.0 (0.0 to 0.0)	-96.4 (-97.6 to -94.7)	-98.0 (-98.7 to -97.1)
Varicella and herpes zoster	5.4 (5.0 to 5.9)	10.9 (9.9 to 12.0)	101.5 (75.1 to 130.7)	4.6 (-18.3 to 31.3)	4.6 (0.1 to 0.2)	0.2 (0.1 to 0.4)	90.5 (35.3 to 180.2)	5.2 (-30.8 to 56.3)
Neglected tropical diseases and malaria	-	-	-	-	183.9 (115.0 to 270.0)	146.2 (97.8 to 209.3)	-21.5 (-36.9 to 7.7)	-69.9 (-76.7 to -57.1)
Malaria	5,796.4 (5,502.1 to 6,083.5)	11,103.8 (10,492.8 to 11,688.8)	91.6 (83.1 to 100.2)	-5.2 (-10.1 to 0.1)	53.6 (36.2 to 77.3)	101.4 (68.2 to 145.7)	89.8 (75.4 to 102.2)	-4.9 (-13.0 to 0.3)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.4 (0.2 to 0.7)	0.6 (0.3 to 1.2)	57.7 (26.0 to 102.1)	-16.9 (-34.3 to 5.2)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.2 (18.4 to 163.4)	-6.1 (-32.2 to 32.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.2 (18.4 to 163.9)	-6.1 (-32.2 to 32.2)
Cutaneous and mucocutaneous leishmaniasis	33.9 (23.1 to 49.4)	53.2 (37.0 to 77.4)	56.3 (26.2 to 99.5)	-17.9 (-34.7 to 3.6)	0.4 (0.2 to 0.7)	0.6 (0.3 to 1.2)	57.7 (26.0 to 102.1)	-16.9 (-34.3 to 5.2)
African trypanosomiasis	0.1 (0.1 to 0.3)	-	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Schistosomiasis	4,535.6 (3,076.3 to 5,949.4)	581.6 (75.6 to 2,984.5)	-94.8 (-97.9 to -28.9)	-97.4 (-98.9 to -68.5)	47.5 (22.7 to 90.9)	6.9 (1.1 to 34.1)	-93.2 (-97.0 to -25.8)	-96.4 (-98.4 to -64.8)
Cysticercosis	14.9 (9.7 to 22.9)	29.3 (16.8 to 44.7)	97.5 (2.1 to 251.6)	-3.2 (-48.8 to 71.5)	3.8 (2.2 to 6.5)	8.3 (4.5 to 13.7)	119.2 (10.0 to 292.1)	6.5 (-44.1 to 90.5)
Cystic echinococcosis	2.3 (2.2 to 2.6)	1.9 (1.7 to 2.3)	-16.3 (-31.9 to -1.4)	-58.4 (-64.7 to -53.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-16.2 (-39.8 to 12.6)	-57.9 (-67.1 to -47.0)
Lymphatic filariasis	382.4 (301.7 to 472.7)	116.4 (66.8 to 185.0)	-69.8 (-81.5 to -56.6)	-80.4 (-87.9 to -72.7)	13.0 (5.6 to 24.5)	10.5 (4.5 to 20.6)	-15.5 (-60.1 to 25.3)	-55.3 (-77.8 to -30.7)
Onchocerciasis	571.8 (318.0 to 874.7)	0.0	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	53.7 (21.1 to 99.1)	0.0	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Trachoma	7.4 (3.0 to 13.8)	16.8 (7.7 to 31.6)	124.9 (17.1 to 387.5)	15.5 (-35.7 to 166.1)	0.5 (0.2 to 0.9)	1.0 (0.4 to 1.9)	106.8 (3.2 to 322.6)	7.4 (-43.8 to 122.6)
Dengue	0.6 (0.2 to 1.4)	5.7 (2.0 to 13.0)	839.6 (828.4 to 852.6)	386.8 (381.0 to 393.5)	0.1 (0.0 to 0.3)	0.9 (0.3 to 2.3)	816.8 (597.4 to 1,148.3)	367.2 (281.6 to 483.4)
Yellow fever	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.2)	-48.2 (-59.1 to -33.3)	-73.2 (-78.1 to -66.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.2 (-59.1 to -33.2)	-73.2 (-78.1 to -66.8)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-35.5 to 77.0)	0.0 (0.0 to 0.0)	-	-
Intestinal nematode infections	-	-	-	-	2.1 (1.3 to 3.3)	3.7 (2.2 to 5.7)	73.0 (36.4 to 118.4)	-12.4 (-29.9 to 13.6)
Ascariasis	162.7 (109.8 to 242.4)	253.7 (170.9 to 384.7)	55.9 (-11.4 to 182.7)	-19.3 (-60.8 to 68.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.8 (0.5 to 140.4)	-17.9 (-51.2 to 38.4)
Trichuriasis	174.2 (109.5 to 272.4)	273.2 (173.6 to 415.1)	54.1 (-17.2 to 199.5)	-19.0 (-63.4 to 79.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.6 (-11.6 to 174.2)	-18.5 (-57.7 to 58.7)
Hookworm disease	615.3 (423.5 to 898.1)	1,097.7 (754.4 to 1,586.4)	77.8 (31.1 to 200.6)	77.8 (51.9 to 73.7)	4.7 (1.3 to 3.3)	3.7 (2.2 to 5.7)	3.7 (36.4 to 118.5)	-22.4 (-29.9 to 13.6)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	150.6 (111.6 to 191.1)	276.0 (254.5 to 302.4)	83.2 (45.3 to 146.9)	-0.8 (-19.2 to 27.8)	8.9 (5.5 to 13.6)	12.7 (8.4 to 18.4)	43.6 (5.2 to 97.0)	-39.1 (-58.2 to -13.6)
Maternal disorders	-	-	-	-	1.7 (1.1 to 2.3)	2.4 (1.7 to 3.4)	47.6 (24.2 to 72.7)	29.5 (-40.2 to -18.7)
Maternal hemorrhage	3.4 (2.0 to 4.9)	7.9 (5.1 to 10.8)	133.7 (49.8 to 279.5)	-0.6 (-36.0 to 62.1)	0.3 (0.1 to 0.2)	0.3 (0.2 to 0.6)	151.4 (22.2 to 376.8)	-1.8 (-47.9 to 99.9)
Maternal sepsis and other maternal infections	3.0 (1.9 to 4.5)	5.5 (3.6 to 7.8)	83.8 (56.6 to 124.5)	-13.5 (-26.0 to 5.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.0 (-4.4 to 22.5)	-10.8 (-52.6 to 48.3)
Maternal hypertensive disorders	3.2 (1.2 to 5.9)	5.2 (1.9 to 9.5)	60.8 (48.3 to 72.8)	-26.2 (-32.5 to -18.6)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.5)	60.9 (36.2 to 91.3)	-25.7 (-36.8 to -10.9)
Obstructed labor	3.3 (2.8 to 3.9)	4.2 (3.5 to 5.0)	27.9 (17.6 to 39.7)	-37.2 (-42.2 to -31.6)	1.1 (0.7 to 1.5)	1.4 (0.9 to 2.0)	30.0 (8.0 to 53.6)	-36.3 (-46.1 to -25.6)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-	-	72.4 (-7.0 to 168.7)	0.0 (0.0 to 0.0)	72.4 (-7.8 to 168.8)	-22.9 (-59.0 to 16.6)
Other maternal disorders	-	-	-	-	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.6)	61.1 (5.4 to 174.7)	-24.3 (-55.6 to 29.2)
Neonatal disorders	-	-	-	-	4.2 (2.3 to 7.7)	18.5 (12.5 to 26.4)	358.6 (175.0 to 605.1)	159.4 (43.3 to 322.7)
Preterm birth complications	24.9 (15.3 to 39.0)	108.4 (74.6 to 155.4)	338.8 (263.8 to 438.5)	126.7 (89.9 to 177.1)	1.2 (0.7 to 1.8)	8.9 (5.8 to 13.3)	665.4 (361.9 to 1,026.5)	320.9 (160.2 to 532.3)
Neonatal encephalopathy due to birth asphyxia and trauma	54.9 (4.2 to 175.8)	75.7 (10.2 to 233.4)	44.5 (5.4 to 178.0)	-26.5 (-46.1 to 38.6)	1.7 (0.6 to 4.4)	4.2 (1.8 to 8.0)	155.6 (42.6 to 482.5)	36.8 (-24.8 to 267.3)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.3)	0.3 (0.1 to 0.7)	140.0 (120.1 to 159.3)	44.4 (32.4 to 56.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (113.2 to 171.4)	44.2 (28.2 to 63.3)
Hemolytic disease and other neonatal jaundice	1.6 (0.7 to 3.4)	8.0 (3.6 to 13.3)	425.5 (93.5 to 1,273.3)	231.2 (12.0 to 788.1)	0.6 (0.2 to 1.5)	3.1 (1.4 to 5.6)	437.8 (89.9 to 1,323.2)	239.1 (12.2 to 827.0)
Other neonatal disorders	-	-	-	-	0.7 (0.3 to 1.4)	2.3 (1.1 to 4.3)	248.8 (38.9 to 681.8)	95.1 (-26.9 to 365.6)
Nutritional deficiencies	-	-	-	-	115.0 (78.4 to 162.2)	200.9 (138.0 to 283.8)	74.6 (58.2 to 90.4)	-0.9 (-12.6 to 0.9)
Protein-energy malnutrition	116.1 (64.2 to 186.2)	182.1 (103.9 to 301.0)	53.1 (-21.0 to 208.2)	-13.5 (-53.3 to 68.3)	3.9 (7.0 to 25.3)	4.4 (10.9 to 40.6)	13.5 (-21.2 to 214.7)	43.1 (-53.6 to 69.9)
Iodine deficiency	219.0 (162.4 to 285.1)	243.4 (149.1 to 322.7)	12.8 (-37.2 to 69.7)	-43.3 (-68.6 to -10.9)	3.9 (2.2 to 7.4)	4.4 (2.2 to 6.5)	13.5 (-35.5 to 69.6)	-43.1 (-68.2 to -11.6)
Vitamin A deficiency	19.0 (13.2 to 26.5)	23.5 (15.1 to 32.5)	23.2 (-5.8 to 61.6)	-21.0 (-39.8 to 5.7)	0.9 (0.5 to 1.4)	1.1 (0.6 to 1.8)	23.0 (6.7 to 56.6)	-19.4 (-38.6 to 3.3)

Appendix Table G.4 - Burkina Faso prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumonia	-	-	-	-	0.0	0.0	73.9	-5.3
Silicosis	0.0	0.1	59.8	-11.1	0.0	0.0	59.8	-11.1
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Coal workers pneumoconiosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Other pneumoconiosis	0.0	0.1	86.4	0.4	0.0	0.0	86.3	0.7
Asthma	158.2	332.0	114.1	0.5	6.9	14.7	116.1	1.7
Interstitial lung disease and pulmonary sarcoidosis	0.2	0.4	118.1	13.3	0.0	0.0	117.3	13.4
Other chronic respiratory diseases	-	-	-	-	7.8	11.6	51.0	-19.0
Cirrhosis	-	-	-	-	0.7	1.0	52.7	-45.9
Cirrhosis due to hepatitis B	1.6	1.8	13.5	-33.0	0.3	0.3	14.8	-32.1
Cirrhosis due to hepatitis C	0.7	1.4	104.6	9.6	0.1	0.2	103.1	11.5
Cirrhosis due to alcohol use	0.9	1.1	35.0	-26.0	0.1	0.2	36.2	-24.8
Cirrhosis due to other causes	1.0	1.9	87.5	10.6	0.2	0.3	89.3	11.7
Digestive diseases	-	-	-	-	11.3	20.6	83.1	-0.9
Peptic ulcer disease	54.6	70.6	29.2	-22.9	1.9	2.6	35.6	-17.8
Gastritis and duodenitis	109.8	186.5	69.5	-5.0	4.6	8.1	78.3	1.0
Appendicitis	1.0	2.2	128.1	5.1	0.3	0.7	128.5	6.5
Paralytic ileus and intestinal obstruction	0.1	0.2	69.2	-1.8	0.0	0.1	68.6	-0.1
Inguinal, femoral, and abdominal hernia	35.9	57.7	64.1	-14.6	0.4	0.6	66.8	-12.8
Inflammatory bowel disease	7.6	18.6	145.4	26.9	1.6	4.0	150.6	29.5
Vascular intestinal disorders	0.0	0.0	0.0	14.3	0.0	0.0	175.9	20.8
Gallbladder and biliary diseases	2.5	5.2	109.2	0.3	0.5	1.1	113.6	16.2
Pancreatitis	1.3	2.7	114.9	10.3	0.4	0.8	117.9	12.5
Other digestive diseases	-	-	-	-	1.8	3.1	71.0	-8.1
Neurological disorders	-	-	-	-	39.4	83.7	113.3	10.4
Alzheimer disease and other dementias	11.5	17.6	53.2	1.4	1.5	2.4	57.9	4.1
Parkinson disease	0.5	0.9	56.1	0.2	0.1	0.1	59.3	2.3
Epilepsy	28.3	53.3	90.2	-4.5	8.0	16.6	112.0	5.6
Multiple sclerosis	0.5	1.1	123.5	11.9	0.2	0.4	122.8	11.7
Migraine	59.7	144.6	94.4	-2.2	20.1	39.4	96.1	-0.9
Tension-type headache	1,018.5	2,129.4	109.1	3.0	1.5	3.2	111.1	4.2
Medication overuse headache	37.4	112.5	201.7	54.0	5.8	17.8	207.3	56.5
Other neurological disorders	0.0	0.0	79.3	-7.5	2.2	3.7	76.1	11.1
Mental and substance use disorders	-	-	-	-	168.1	340.2	101.9	2.6
Schizophrenia	16.5	33.3	102.6	0.6	10.4	21.5	106.6	2.4
Alcohol use disorders	41.7	91.0	118.3	9.0	4.0	8.8	122.2	10.6
Drug use disorders	-	-	-	-	9.7	20.4	110.5	2.8
Opioid use disorders	12.2	26.3	115.1	3.0	5.0	10.9	118.8	4.8
Cocaine use disorders	3.2	6.8	112.5	0.5	1.1	2.4	112.7	3.5
Amphetamine use disorders	13.4	26.3	95.8	-3.0	1.7	3.5	98.9	-1.4
Cannabis use disorders	5.8	11.8	103.7	0.7	0.2	0.3	106.1	1.8
Other drug use disorders	-	-	-	-	2.3	4.6	101.5	-0.6
Depressive disorders	-	-	-	-	1.4	2.8	105.0	5.4
Major depressive disorder	303.5	631.8	107.5	4.3	61.9	130.7	110.3	6.0
Dysthymia	80.4	157.1	95.5	-0.5	7.7	15.2	98.2	0.8
Bipolar disorder	45.2	91.3	102.7	0.2	9.1	18.7	105.8	1.7
Anxiety disorders	199.2	390.7	96.2	0.3	18.3	36.3	98.8	1.1
Eating disorders	-	-	-	-	2.1	4.3	104.0	0.1
Anorexia nervosa	1.5	3.0	108.2	3.1	0.3	0.6	110.8	4.6
Bulimia nervosa	8.6	17.2	100.9	-1.7	1.8	3.6	103.2	-0.5
Autistic spectrum disorders	-	-	-	-	10.3	20.4	97.5	2.1
Autism	26.7	52.2	95.6	0.8	6.5	12.9	97.4	2.0
Asperger syndrome	38.3	75.1	95.8	1.1	3.8	7.5	97.1	2.1
Attention-deficit/hyperactivity disorder	66.7	128.8	93.2	0.3	0.8	1.6	94.7	0.9
Conduct disorder	97.7	188.7	93.3	0.2	0.7	1.2	95.0	1.1
Idiopathic intellectual disability	305.4	498.1	62.8	-15.1	14.8	24.4	64.0	-14.3
Other mental and substance use disorders	99.8	201.4	102.0	0.6	7.4	15.1	105.2	2.2
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	51.5	106.2	105.5	12.6
Diabetes mellitus	83.4	291.5	248.0	83.5	5.9	20.3	236.7	83.0
Acute glomerulonephritis	0.1	0.1	25.3	-32.0	0.0	0.0	25.3	-32.9
Chronic kidney disease	-	-	-	-	13.9	26.3	90.1	0.9
Chronic kidney disease due to diabetes mellitus	79.6	136.9	72.9	-2.6	1.3	2.3	78.7	-1.2
Chronic kidney disease due to hypertension	392.2	722.9	86.5	1.2	4.4	8.9	100.2	8.6
Chronic kidney disease due to glomerulonephritis	318.1	625.8	98.1	-1.1	5.0	9.5	98.6	-0.2
Chronic kidney disease due to other causes	254.9	474.9	83.7	-10.0	3.1	5.7	82.6	-10.7
Urinary diseases and male infertility	-	-	-	-	2.4	3.9	62.8	-3.4

Appendix Table G.4 - Burkina Faso prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.								
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	32.8 (29.7 to 35.5)	45.8 (42.0 to 49.4)	40.0 (24.5 to 56.5)	-15.8 (-24.3 to -6.8)	0.9 (0.6 to 1.2)	1.3 (0.8 to 1.8)	42.4 (26.3 to 60.9)	-14.4 (-23.5 to -4.5)
Other oral disorders	123.9 (117.1 to 130.4)	241.8 (226.2 to 257.6)	95.0 (79.6 to 114.1)	-0.6 (-7.6 to 7.7)	3.5 (2.2 to 5.3)	7.1 (4.4 to 10.9)	96.8 (80.7 to 117.6)	0.4 (-7.1 to 9.3)
Injuries	-	-	-	-	25.7 (19.7 to 32.9)	43.1 (32.7 to 56.0)	67.7 (62.1 to 73.7)	-6.8 (-10.0 to -3.6)
Transport injuries	-	-	-	-	8.1 (6.2 to 10.5)	14.8 (11.1 to 19.2)	82.4 (73.2 to 90.8)	3.5 (-1.1 to 8.2)
Road injuries	-	-	-	-	7.3 (5.3 to 9.0)	13.5 (9.8 to 17.0)	88.9 (78.0 to 97.7)	6.7 (1.7 to 11.7)
Pedestrian road injuries	-	-	-	-	1.9 (1.5 to 2.5)	3.3 (2.4 to 4.3)	68.6 (54.7 to 82.6)	-0.9 (-7.8 to 5.3)
Cyclist road injuries	-	-	-	-	0.6 (0.5 to 0.8)	0.9 (0.7 to 1.2)	50.8 (41.3 to 60.8)	-7.4 (-12.9 to -1.6)
Motorcyclist road injuries	-	-	-	-	1.0 (0.7 to 1.2)	1.5 (1.1 to 2.0)	54.5 (42.8 to 67.6)	-14.9 (-20.6 to -8.4)
Motor vehicle road injuries	-	-	-	-	3.3 (2.6 to 4.3)	7.3 (5.4 to 9.3)	117.8 (101.6 to 132.7)	21.2 (13.2 to 28.6)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	48.0 (38.1 to 58.5)	21.4 (-25.8 to -16.3)
Other transport injuries	-	-	-	-	1.2 (0.9 to 1.5)	1.7 (1.3 to 2.2)	45.8 (36.0 to 57.2)	-15.7 (-21.4 to -9.5)
Unintentional injuries	-	-	-	-	16.6 (12.7 to 21.3)	27.2 (20.6 to 35.3)	63.8 (57.9 to 69.8)	-9.9 (-13.4 to -6.6)
Falls	-	-	-	-	6.4 (4.9 to 8.3)	11.1 (8.4 to 14.5)	73.3 (60.9 to 82.7)	-6.4 (-11.4 to -0.8)
Drowning	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	32.8 (19.0 to 46.7)	-26.8 (-33.0 to -21.1)
Fire, heat, and hot substances	-	-	-	-	1.1 (0.8 to 1.4)	1.5 (1.1 to 1.9)	35.9 (24.0 to 48.9)	-24.7 (-30.0 to -18.5)
Poisonings	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	41.4 (16.6 to 71.3)	-26.4 (-37.3 to -13.4)
Exposure to mechanical forces	-	-	-	-	5.2 (4.0 to 6.8)	8.4 (6.4 to 11.1)	61.1 (53.4 to 70.3)	-13.2 (-16.8 to -9.0)
Unintentional firearm injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	61.1 (48.6 to 74.1)	-14.2 (-20.0 to -7.9)
Unintentional suffocation	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	110.5 (84.7 to 135.2)	14.3 (2.9 to 25.8)
Other exposure to mechanical forces	-	-	-	-	5.0 (3.8 to 6.4)	8.0 (6.0 to 10.6)	60.6 (52.5 to 69.9)	-13.4 (-17.2 to -9.0)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	98.0 (85.8 to 111.4)	13.7 (6.5 to 22.5)
Animal contact	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	53.0 (43.0 to 65.1)	-16.6 (-21.1 to -11.1)
Venomous animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	57.3 (39.1 to 79.1)	-16.0 (-24.2 to -6.7)
Non-venomous animal contact	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	49.5 (41.4 to 59.9)	-17.1 (-21.2 to -12.1)
Foreign body	-	-	-	-	0.3 (0.3 to 0.4)	0.6 (0.4 to 0.8)	76.1 (65.0 to 85.7)	-3.7 (-9.2 to 1.4)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	54.3 (32.7 to 82.0)	-9.1 (-18.5 to 0.8)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	90.8 (70.8 to 112.5)	-2.7 (-10.9 to 6.5)
Foreign body in other body part	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.4)	80.2 (68.2 to 93.3)	-2.5 (-8.8 to 4.6)
Other unintentional injuries	-	-	-	-	2.6 (1.9 to 3.3)	4.1 (3.1 to 5.4)	61.6 (50.6 to 72.4)	-9.5 (-15.8 to -3.9)
Self-harm and interpersonal violence	-	-	-	-	0.7 (0.5 to 0.9)	1.0 (0.7 to 1.3)	42.1 (35.5 to 50.0)	-24.1 (-27.5 to -20.3)
Self-harm	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	79.1 (64.8 to 94.4)	-6.0 (-12.5 to 0.9)
Interpersonal violence	-	-	-	-	0.6 (0.4 to 0.7)	0.8 (0.6 to 1.0)	34.4 (27.8 to 42.2)	-29.2 (-32.5 to -25.5)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	40.8 (30.5 to 50.5)	-25.8 (-30.4 to -21.2)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	58.2 (48.5 to 70.7)	-18.2 (-23.1 to -11.5)
Assault by other means	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.6)	27.3 (19.4 to 36.2)	-32.8 (-36.6 to -28.4)
Forces of nature, war, and legal intervention	-	-	-	-	0.3 (0.1 to 0.8)	0.1 (0.0 to 0.3)	-58.2 (-64.9 to -44.8)	-68.4 (-73.4 to -59.8)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	318.3 (247.7 to 385.8)	148.0 (108.1 to 189.2)
Collective violence and legal intervention	-	-	-	-	0.3 (0.1 to 0.8)	0.1 (0.0 to 0.3)	-63.8 (-67.9 to -58.3)	-71.6 (-75.1 to -67.2)

Appendix Table G.4 – Burundi prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	505.7 (369.3 to 666.2)	917.1 (666.9 to 1,203.5)	80.5 (67.4 to 101.3)	88.5 (6.6 to 15.3)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	147.5 (98.4 to 212.6)	205.8 (146.4 to 283.6)	41.2 (18.0 to 59.3)	-26.8 (-41.4 to -14.8)
HIV/AIDS and tuberculosis	-	-	-	-	10.0 (6.8 to 13.4)	18.2 (12.0 to 28.4)	77.0 (52.3 to 160.0)	0.2 (-15.1 to 53.6)
Tuberculosis	16.6 (15.3 to 18.0)	22.8 (21.1 to 24.4)	37.9 (31.1 to 46.3)	-23.3 (-27.0 to -19.0)	5.1 (3.4 to 6.9)	7.0 (4.8 to 9.4)	37.5 (28.7 to 48.0)	-23.7 (-28.6 to -18.8)
HIV/AIDS	-	-	-	-	4.9 (3.2 to 6.8)	11.3 (6.7 to 20.1)	118.5 (71.9 to 271.1)	28.2 (2.3 to 130.2)
HIV/AIDS resulting in mycobacterial infection	1.2 (0.7 to 1.7)	1.4 (0.7 to 2.4)	17.7 (-14.2 to 85.4)	-26.7 (-46.7 to 19.9)	0.4 (0.2 to 0.7)	0.5 (0.2 to 1.0)	16.9 (-19.5 to 89.0)	-26.8 (-49.2 to 21.4)
HIV/AIDS resulting in other diseases	49.7 (41.0 to 60.5)	83.7 (66.9 to 108.3)	67.6 (37.3 to 113.8)	1.0 (-16.9 to 30.9)	4.4 (2.9 to 6.2)	10.7 (6.3 to 19.5)	128.8 (76.0 to 290.8)	34.0 (0.2 to 146.5)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	27.7 (19.7 to 37.4)	38.4 (27.1 to 52.3)	38.9 (28.0 to 50.4)	-21.5 (-27.1 to -15.5)
Diarrheal diseases	98.7 (90.0 to 107.4)	145.9 (135.7 to 155.6)	48.5 (33.9 to 66.2)	-13.5 (-21.9 to -4.6)	16.0 (10.8 to 22.7)	23.8 (16.3 to 33.5)	48.4 (32.9 to 67.4)	-21.6 (-22.0 to -4.1)
Intestinal infectious diseases	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	0.2 (-4.1 to 54.8)	0.2 (-44.5 to -16.0)
Typhoid fever	1.0 (0.8 to 1.1)	1.2 (1.1 to 1.4)	26.4 (6.0 to 47.4)	-28.9 (-40.5 to -17.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	26.4 (-1.0 to 60.2)	-28.4 (-41.9 to -12.2)
Paratyphoid fever	0.4 (0.3 to 0.4)	0.6 (0.5 to 0.6)	55.1 (22.4 to 89.5)	-12.7 (-31.3 to 8.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (14.7 to 107.6)	-12.6 (-32.3 to 11.0)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.9 (-72.2 to 39.7)	-63.0 (-84.3 to -19.5)
Lower respiratory infections	7.5 (6.1 to 9.0)	14.7 (11.6 to 19.5)	91.7 (48.2 to 171.8)	14.3 (-6.7 to 44.2)	0.8 (0.5 to 1.1)	1.6 (1.0 to 2.4)	93.1 (42.9 to 175.5)	14.3 (-2.9 to 46.9)
Upper respiratory infections	196.0 (186.4 to 205.5)	350.2 (333.4 to 366.8)	79.2 (68.1 to 91.5)	-1.2 (-7.2 to 5.2)	2.3 (1.3 to 3.9)	4.1 (2.3 to 6.8)	79.6 (67.6 to 93.6)	-1.2 (-7.5 to 5.7)
Otitis media	98.7 (90.2 to 107.2)	159.8 (147.5 to 173.2)	62.7 (45.5 to 80.6)	-11.4 (-20.2 to -1.6)	2.0 (1.2 to 3.3)	3.3 (1.9 to 5.2)	61.9 (43.1 to 81.6)	-11.5 (-21.6 to -1.0)
Meningitis	-	-	-	-	5.7 (4.0 to 7.6)	5.0 (3.5 to 6.7)	-11.7 (-24.3 to 2.4)	-49.0 (-56.2 to -41.5)
Pneumococcal meningitis	19.8 (12.4 to 29.7)	19.1 (12.4 to 27.7)	-4.2 (-22.1 to 30.8)	-44.0 (-53.7 to -25.1)	1.9 (1.2 to 2.5)	1.9 (1.2 to 2.5)	3.0 (-20.3 to 43.1)	-40.7 (-52.5 to -20.4)
H influenzae type B meningitis	12.6 (5.4 to 22.8)	10.4 (4.9 to 18.0)	-17.3 (-35.0 to 11.8)	-54.2 (-63.6 to -38.3)	1.3 (0.8 to 1.9)	1.2 (0.8 to 1.7)	-12.7 (-36.2 to 29.9)	-52.0 (-63.9 to -30.4)
Meningococcal meningitis	2.6 (1.2 to 5.5)	2.4 (1.1 to 5.1)	-8.3 (-35.6 to 24.5)	-45.7 (-61.0 to -27.3)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-8.8 (-38.3 to 28.8)	-46.3 (-63.1 to -28.4)
Other meningitis	17.8 (9.9 to 30.1)	14.4 (8.4 to 24.2)	-17.3 (-38.2 to 3.7)	-51.4 (-63.3 to -36.9)	2.3 (1.4 to 3.3)	1.7 (1.2 to 2.4)	-21.7 (-46.6 to 3.4)	-54.3 (-68.9 to -40.1)
Encephalitis	0.0 (0.5 to 2.0)	1.7 (0.8 to 3.4)	71.9 (55.5 to 92.5)	0.1 (-11.0 to 6.4)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	75.1 (50.1 to 105.4)	0.2 (-14.1 to 11.2)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-98.1 to 867.8)	0.0 (0.0 to 0.0)	-	-
Whooping cough	5.7 (4.5 to 7.3)	0.8 (0.6 to 1.0)	-86.8 (-88.7 to -84.5)	-92.2 (-93.3 to -90.8)	0.3 (0.2 to 0.4)	0.0 (0.0 to 0.1)	-86.6 (-90.4 to -82.6)	-92.1 (-94.3 to -89.7)
Tetanus	0.7 (0.4 to 1.3)	0.3 (0.1 to 0.5)	-63.5 (-81.6 to -7.4)	-79.8 (-90.2 to -46.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.0 (-76.9 to -20.5)	-77.2 (-86.1 to -54.9)
Measles	1.5 (1.2 to 1.8)	0.0 (0.0 to 0.1)	-97.0 (-97.9 to -95.6)	-98.2 (-98.7 to -97.4)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.0)	-98.9 (-97.9 to -95.4)	-98.2 (-98.8 to -97.3)
Varicella and herpes zoster	3.6 (3.2 to 3.9)	6.7 (6.2 to 7.3)	90.2 (69.8 to 113.4)	3.6 (-15.2 to 27.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	87.3 (31.1 to 159.9)	2.6 (-28.1 to 47.6)
Neglected tropical diseases and malaria	-	-	-	-	68.6 (38.8 to 112.9)	58.5 (37.7 to 90.2)	-13.1 (-35.1 to 8.0)	-55.3 (-67.3 to -42.8)
Malaria	1,034.4 (985.4 to 1,084.2)	1,115.7 (1,062.8 to 1,169.7)	8.3 (3.9 to 12.5)	-41.2 (-43.5 to -39.0)	12.3 (8.0 to 18.0)	15.9 (10.7 to 22.9)	29.2 (14.5 to 41.2)	-23.6 (-32.7 to -16.3)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	67.2 (4.0 to 165.0)	-9.9 (-43.3 to 34.6)
Visceral leishmaniasis	0.4 (0.3 to 0.7)	0.8 (0.4 to 1.3)	77.8 (-12.3 to 189.8)	0.4 (-48.3 to 65.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	78.7 (-12.3 to 212.3)	1.5 (-48.9 to 68.6)
Cutaneous and mucocutaneous leishmaniasis	0.7 (0.4 to 1.1)	1.0 (0.6 to 1.5)	40.3 (-20.7 to 122.4)	-27.9 (-56.6 to 13.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.0 (-23.0 to 141.2)	-27.9 (-57.4 to 22.6)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	2,406.9 (776.5 to 4,599.3)	614.4 (134.2 to 2,061.6)	-74.5 (-88.3 to -26.2)	-89.8 (-94.0 to -60.4)	24.2 (7.0 to 60.8)	7.3 (1.8 to 24.2)	-75.0 (-83.0 to -19.5)	-86.5 (-90.8 to -55.4)
Cysticercosis	2.2 (1.2 to 4.5)	2.8 (0.9 to 5.0)	32.8 (-47.8 to 226.2)	-37.1 (-69.8 to 32.4)	0.6 (0.3 to 1.2)	0.8 (0.2 to 1.5)	42.7 (-43.4 to 264.2)	-32.3 (-68.4 to 41.5)
Cystic echinococcosis	1.9 (1.6 to 2.2)	2.7 (2.5 to 3.1)	42.0 (21.3 to 66.2)	-20.7 (-27.0 to -11.4)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.4)	42.6 (14.8 to 80.4)	-20.3 (-31.5 to -4.7)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	256.8 (130.9 to 522.7)	176.1 (125.8 to 270.9)	-31.2 (-50.2 to 5.3)	-59.7 (-72.2 to -41.4)	15.5 (6.6 to 28.0)	13.1 (6.4 to 21.5)	-14.2 (-32.8 to 13.2)	51.4 (-62.8 to -34.9)
Trachoma	0.8 (0.4 to 1.5)	0.2 (0.1 to 0.6)	-72.7 (-83.4 to -46.5)	-82.3 (-89.9 to -67.1)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-70.8 (-83.8 to -36.4)	-81.8 (-90.1 to -62.4)
Dengue	0.2 (0.1 to 0.6)	1.9 (0.5 to 5.1)	788.1 (777.3 to 800.7)	386.8 (380.9 to 393.7)	0.0 (0.0 to 0.1)	0.3 (0.1 to 0.8)	745.5 (579.1 to 938.6)	356.1 (277.5 to 434.5)
Yellow fever	0.1 (0.1 to 0.3)	0.1 (0.0 to 0.2)	-52.1 (-70.2 to -17.6)	-73.2 (-83.2 to -48.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.1 (-70.2 to -17.3)	-73.2 (-82.2 to -58.0)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-60.3 to 32.8)	0.0 (0.0 to 0.0)	-	-
Intestinal nematode infections	-	-	-	-	13.2 (8.0 to 20.6)	15.9 (9.8 to 24.3)	20.4 (9.5 to 31.6)	-38.3 (-43.9 to -32.2)
Ascariasis	1,220.7 (960.8 to 1,565.5)	1,081.0 (865.4 to 1,339.5)	-10.5 (-36.0 to 21.4)	-53.4 (-69.8 to -31.7)	0.7 (0.4 to 1.2)	0.6 (0.3 to 1.1)	-9.3 (-21.1 to 4.8)	-51.7 (-59.4 to -43.1)
Trichuriasis	1,161.8 (925.7 to 1,460.1)	1,034.2 (821.9 to 1,295.7)	-10.7 (-35.2 to 23.0)	-53.8 (-69.0 to -30.8)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	-6.4 (-22.1 to 12.7)	-51.2 (-60.3 to -38.9)
Hookworm disease	2,253.7 (2,138.2 to 2,968.0)	2,599.9 (2,196.9 to 3,084.0)	15.5 (-16.8 to 32.6)	-46.9 (-58.9 to -28.6)	3.3 (7.4 to 19.0)	3.3 (9.3 to 22.7)	15.5 (10.9 to 35.1)	-37.3 (-43.3 to -31.0)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	60.3 (49.4 to 77.1)	133.9 (122.3 to 149.7)	122.0 (73.9 to 172.7)	38.5 (9.9 to 67.3)	2.4 (1.5 to 3.7)	4.9 (3.2 to 7.2)	99.6 (64.3 to 164.1)	5.1 (-21.2 to 40.6)
Maternal disorders	-	-	-	-	2.2 (1.5 to 3.0)	3.2 (2.1 to 4.6)	47.0 (24.3 to 73.7)	-25.3 (-36.3 to -13.3)
Maternal hemorrhage	1.9 (1.5 to 2.3)	4.3 (3.2 to 5.4)	124.6 (54.1 to 208.5)	14.5 (-17.6 to 53.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	93.0 (-8.3 to 244.7)	-3.9 (-50.6 to 70.9)
Maternal sepsis and other maternal infections	2.8 (1.9 to 4.1)	2.8 (1.8 to 4.0)	-0.4 (-16.2 to 16.7)	-46.4 (-54.9 to -37.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	6.7 (-33.7 to 60.8)	-46.5 (-64.4 to -21.1)
Maternal hypertensive disorders	2.8 (1.3 to 4.6)	4.1 (2.1 to 6.7)	50.0 (32.6 to 76.3)	-26.3 (-32.4 to -12.1)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.4)	49.0 (24.2 to 82.1)	-26.5 (-37.3 to -11.3)
Obstructed labor	4.2 (3.4 to 5.1)	6.1 (5.0 to 7.5)	45.0 (28.2 to 60.6)	-25.9 (-34.1 to -17.6)	1.4 (0.9 to 2.0)	2.0 (1.3 to 3.0)	45.6 (26.0 to 69.1)	-25.7 (-35.1 to -13.3)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-	-	0.0 (-6.3 to 235.8)	0.0 (0.0 to 0.0)	-	-
Other maternal disorders	-	-	-	-	0.5 (0.3 to 0.8)	0.8 (0.5 to 1.2)	46.4 (-4.2 to 116.4)	25.5 (-51.5 to 10.5)
Neonatal disorders	-	-	-	-	3.6 (2.1 to 6.3)	13.9 (8.7 to 20.8)	283.3 (143.1 to 585.4)	136.2 (38.5 to 336.8)
Preterm birth complications	18.5 (9.3 to 35.6)	71.4 (40.5 to 124.5)	287.8 (217.6 to 428.3)	114.6 (76.0 to 183.5)	1.3 (0.7 to 2.3)	6.7 (4.1 to 10.8)	435.0 (214.3 to 946.2)	222.8 (95.6 to 521.5)
Neonatal encephalopathy due to birth asphyxia and trauma	33.9 (2.8 to 112.6)	44.7 (6.6 to 138.0)	42.3 (4.2 to 172.9)	-23.4 (-46.9 to 50.8)	1.2 (0.8 to 2.2)	2.9 (1.3 to 5.2)	157.3 (53.3 to 482.2)	49.9 (-18.0 to 311.9)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	125.0 (109.5 to 139.0)	0.0 (-27.3 to 45.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	36.8 (104.1 to 155.5)	129.3 (24.0 to 55.3)
Hemolytic disease and other neonatal jaundice	1.1 (0.5 to 2.2)	4.9 (2.3 to 9.1)	369.0 (57.8 to 1,089.0)	213.2 (0.9 to 753.0)	0.4 (0.2 to 0.9)	1.9 (0.8 to 3.6)	369.6 (52.4 to 1,131.9)	212.0 (-3.4 to 757.1)
Other neonatal disorders	-	-	-	-	0.8 (0.3 to 1.6)	2.4 (0.7 to 6.4)	174.7 (9.3 to 751.6)	65.2 (-35.8 to 413.7)
Nutritional deficiencies	-	-	-	-	32.1 (20.9 to 46.1)	66.7 (45.0 to 95.6)	107.8 (82.8 to 132.5)	24.0 (12.3 to 36.1)
Protein-energy malnutrition	41.3 (23.9 to 68.6)	56.7 (32.3 to 94.8)	37.5 (-35.0 to 186.6)	-17.8 (-55.3 to 53.4)	5.1 (2.5 to 9.4)	7.0 (3.4 to 12.9)	38.6 (-35.2 to 190.3)	-17.6 (-56.3 to 56.4)
Iodine deficiency	134.4 (121.2 to 148.9)	154.6 (129.4 to 184.4)	15.3 (-4.6 to 43.6)	-40.4 (-52.1 to -22.6)	2.5 (1.7 to 3.9)	2.8 (1.7 to 4.5)	14.4 (-5.8 to 42.4)	-40.5 (-52.5 to -23.1)
Vitamin A deficiency	2.0 (1.4 to 2.9)	2.1 (1.4 to 3.1)	6.0 (-25.0 to 31.8)	-41.0 (-58.8 to -27.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-7.0 (-32.8 to 22.9)	-45.6 (-61.3 to -29.9)

Appendix Table G.4 - Burundi prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumococcal	-	-	-	-	0.0	0.0	75.1	-1.2
Silicosis	0.0	0.0	67.5	-4.0	0.0	0.0	(69.4 to 81.0)	(-4.4 to 1.5)
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	67.2	-4.1
Coal workers pneumoconiosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Other pneumoconiosis	0.0	0.0	83.3	2.0	0.0	0.0	83.3	1.7
Asthma	67.5	105.6	(75.8 to 91.3)	-9.1	2.9	4.6	54.7	-9.6
Interstitial lung disease and pulmonary sarcoidosis	0.1	0.2	95.6	3.2	0.0	0.0	96.2	3.3
Other chronic respiratory diseases	0.1	0.2	(37.0 to 192.7)	(-24.9 to 44.9)	0.0	0.0	(38.6 to 188.6)	(-24.1 to 42.7)
Cirrhosis	0.7	1.0	33.1	-20.7	8.1	9.7	20.3	-33.4
Cirrhosis due to hepatitis B	0.4	0.7	(-21.3 to 138.1)	(53.2 to 39.5)	(4.5 to 13.3)	(5.3 to 15.8)	(-25.2 to 87.6)	(-58.3 to 3.9)
Cirrhosis due to hepatitis C	0.4	0.7	60.8	-11.2	0.1	0.1	63.6	-10.5
Cirrhosis due to alcohol use	0.7	0.8	19.9	-31.6	0.1	0.1	19.4	-32.1
Cirrhosis due to other causes	0.9	1.3	52.3	-4.3	0.1	0.2	52.4	-3.3
Digestive diseases	0.1	0.2	(19.4 to 109.4)	(-27.5 to 39.0)	6.8	12.8	(6.5 to 124.6)	(-31.7 to 45.3)
Peptic ulcer disease	37.8	53.7	42.7	-11.4	1.3	1.9	44.9	-13.2
Gastritis and duodenitis	60.1	107.4	78.9	12.7	2.7	5.2	95.6	20.9
Appendicitis	0.7	1.3	85.3	-1.5	0.2	0.4	86.6	-1.8
Paralytic ileus and intestinal obstruction	0.1	0.2	(35.5 to 345.0)	(-25.8 to 30.9)	0.0	0.0	(26.2 to 166.0)	(-31.0 to 39.1)
Inguinal, femoral, and abdominal hernia	15.1	35.7	137.8	149.6	0.2	0.4	132.4	145.4
Inflammatory bowel disease	4.9	11.3	132.2	25.9	1.0	2.4	132.4	25.8
Vascular intestinal disorders	0.0	0.0	59.2	-4.9	0.0	0.0	58.4	-6.5
Gallbladder and biliary diseases	1.7	3.2	88.7	0.2	0.3	0.3	89.2	0.9
Pancreatitis	0.9	1.7	96.8	5.1	0.3	0.5	96.9	4.9
Other digestive diseases	0.0	0.0	81.8 to 114.3	(-2.8 to 14.4)	1.0	1.6	63.4	-4.2
Neurological disorders	8.1	13.2	64.6	1.2	21.0	42.7	(21.7 to 189.1)	(-29.5 to 67.8)
Alzheimer disease and other dementias	0.4	0.7	69.0	3.9	0.1	0.1	68.0	3.0
Parkinson disease	11.9	27.3	128.2	26.0	3.5	8.6	146.4	34.7
Epilepsy	0.2	0.5	109.9	12.4	0.1	0.2	109.7	12.2
Multiple sclerosis	0.2	0.5	(81.6 to 348.6)	(-2.6 to 31.5)	0.1	0.1	(71.4 to 158.4)	(-8.5 to 38.0)
Migraine	395.7	535.5	72.5	8.0	10.4	18.4	78.4	-8.1
Tension-type headache	621.2	1,263.2	103.5	4.1	0.9	1.9	104.5	4.3
Medication overuse headache	25.3	63.7	158.0	35.9	4.0	10.1	158.8	36.1
Other neurological disorders	0.0	0.0	73.5	-7.2	1.0	1.6	67.8	1.0
Mental and substance use disorders	11.1	20.9	88.6	1.1	121.6	232.9	91.5	1.1
Schizophrenia	56.7	95.6	69.6	-11.9	7.1	13.4	88.2	0.5
Alcohol use disorders	52.5 to 61.2	(88.8 to 103.2)	(60.4 to 78.5)	(-16.3 to -7.7)	(3.7 to 7.8)	(6.3 to 13.4)	(58.3 to 80.2)	(-17.7 to -7.1)
Drug use disorders	8.1	15.6	93.1	4.0	6.5	12.7	95.4	1.9
Opioid use disorders	5.3 to 12.3	(10.3 to 22.5)	(73.6 to 120.7)	(-5.1 to 17.2)	(4.3 to 9.2)	(8.4 to 17.6)	(75.1 to 120.1)	(-7.6 to 13.8)
Cocaine use disorders	2.1 to 3.1	(4.4 to 6.2)	(58.4 to 163.0)	(-15.5 to 30.7)	(2.0 to 5.4)	(3.8 to 10.0)	(70.2 to 124.0)	(-7.7 to 19.7)
Amphetamine use disorders	8.5	16.6	95.1	-4.0	1.1	2.2	96.8	-3.1
Cannabis use disorders	6.6	13.3	101.4	0.0	0.2	0.4	102.8	0.5
Other drug use disorders	5.0 to 8.1	(9.9 to 16.2)	(99.5 to 103.3)	(-0.1 to 0.1)	1.5	2.9	98.4	-1.1
Depressive disorders	250.5	482.9	93.3	2.1	56.7	109.7	91.1	1.8
Major depressive disorder	52.6	97.7	86.7	-0.9	5.1	9.5	87.1	-1.1
Dysthymia	29.4	56.2	91.8	-0.4	6.0	11.5	92.1	-0.6
Bipolar disorder	25.2 to 33.4	(47.1 to 64.3)	(79.9 to 105.8)	(-5.1 to 5.3)	(3.7 to 9.0)	(6.9 to 17.3)	(76.8 to 110.0)	(-6.8 to 7.1)
Anxiety disorders	180.9	304.5	89.6	-1.1	14.8	28.2	89.9	-1.1
Eating disorders	0.9	1.8	108.2	5.4	1.3	2.7	103.3	1.3
Anorexia nervosa	0.7 to 1.2	(1.4 to 2.4)	(87.2 to 128.6)	(-4.9 to 15.4)	(0.8 to 2.1)	(1.6 to 4.2)	(85.1 to 122.1)	(-7.6 to 10.6)
Bulimia nervosa	5.3	10.7	102.0	0.4	1.1	2.3	102.2	0.5
Autistic spectrum disorders	17.0	31.0	83.5	0.9	6.6	12.2	89.9	1.1
Autism	24.5	44.7	83.3	1.2	4.2	7.7	84.0	1.0
Asperger syndrome	22.9 to 25.9	(41.8 to 47.3)	(82.9 to 83.7)	(1.1 to 1.3)	(1.7 to 3.4)	(3.1 to 6.3)	(74.9 to 91.6)	(-3.0 to 4.9)
Attention-deficit/hyperactivity disorder	39.6	72.3	83.1	-0.5	0.5	0.9	83.9	0.0
Conduct disorder	56.7	107.7	89.7	0.4	6.8	12.6	94.5	0.1
Idiopathic intellectual disability	98.1	207.4	109.8	21.0	4.8	10.2	109.7	20.5
Other mental and substance use disorders	64.8	125.5	94.5	0.8	4.8	9.4	94.9	0.8
Diabetes, urogenital, blood, and endocrine diseases	34.2	81.0	135.6	31.0	23.1	46.2	99.4	10.8
Diabetes mellitus	0.1	0.1	33.8	-21.6	0.0	0.0	22.9 to 43.9	(-26.5 to -16.4)
Acute glomerulonephritis	0.1	0.1	23.0 to 43.9	(-26.5 to -16.5)	0.0	0.0	(22.9 to 43.9)	(-26.5 to -16.4)
Chronic kidney disease	73.4	118.6	62.5	-7.7	8.6	16.3	88.5	3.4
Chronic kidney disease due to diabetes mellitus	221.0	413.2	85.0	2.9	2.5	4.9	90.9	4.9
Chronic kidney disease due to hypertension	194.3	352.1	82.9	9.5	3.1	6.1	95.3	8.9
Chronic kidney disease due to glomerulonephritis	145.6	256.5	79.6	-3.9	1.9	3.5	87.3	2.7
Chronic kidney disease due to other causes	86.7 to 249.8	(156.4 to 443.3)	(17.9 to 150.0)	(-25.1 to 36.3)	1.4	2.5	75.9	7.1
Urinary diseases and male infertility	-	-	-	-	0.9 to 2.0	1.6 to 3.5	(55.9 to 98.4)	(-4.4 to 20.1)

Appendix Table G.4 - Burundi prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Edentulism and severe tooth loss	88.9 (82.1 to 95.5)	130.5 (130.3 to 148.9)	57.6 (42.5 to 71.5)	-4.7 (-14.9 to 1.0)	2.4 (1.6 to 3.4)	3.9 (2.6 to 5.4)	57.9 (41.7 to 72.4)	-6.9 (-15.6 to 1.4)
Other oral disorders	78.4 (73.8 to 82.9)	144.4 (134.8 to 154.1)	85.2 (68.5 to 102.7)	-1.5 (-8.6 to 7.4)	2.3 (1.4 to 3.5)	4.3 (2.7 to 6.5)	85.5 (67.9 to 104.0)	-1.5 (-9.5 to 7.9)
Injuries	-	-	-	-	20.3 (15.5 to 26.3)	91.4 (43.1 to 197.6)	309.9 (129.3 to 836.2)	136.3 (30.7 to 444.6)
Transport injuries	-	-	-	-	8.6 (6.5 to 11.0)	8.9 (6.7 to 11.7)	4.4 (-1.0 to 9.8)	-39.1 (-41.8 to -36.4)
Road injuries	-	-	-	-	7.6 (5.7 to 9.7)	7.9 (5.9 to 10.4)	5.0 (-1.0 to 10.7)	-38.9 (-41.6 to -36.0)
Pedestrian road injuries	-	-	-	-	2.6 (1.9 to 3.3)	2.6 (1.9 to 3.4)	-0.0 (-7.7 to 7.7)	-41.2 (-44.7 to -37.8)
Cyclist road injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.7 (0.5 to 0.9)	-3.2 (-10.1 to 4.6)	-41.6 (-45.6 to -36.8)
Motorcyclist road injuries	-	-	-	-	0.9 (0.7 to 1.1)	0.8 (0.6 to 1.0)	-11.3 (-18.1 to -4.5)	-48.4 (-52.1 to -45.1)
Motor vehicle road injuries	-	-	-	-	3.3 (2.5 to 4.2)	3.8 (2.9 to 5.0)	16.0 (6.9 to 25.3)	-33.0 (-37.5 to -28.8)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-34.3 (-38.3 to -29.9)	-62.2 (-64.3 to -60.1)
Other transport injuries	-	-	-	-	1.0 (0.8 to 1.3)	1.0 (0.8 to 1.3)	0.1 (-5.9 to 7.2)	-41.0 (-44.3 to -36.8)
Unintentional injuries	-	-	-	-	11.3 (8.7 to 14.6)	17.4 (13.2 to 22.8)	54.3 (48.5 to 60.3)	-12.8 (-16.0 to -9.8)
Falls	-	-	-	-	4.5 (3.5 to 5.9)	8.0 (6.0 to 10.5)	76.0 (65.4 to 87.3)	-5.1 (-10.8 to 0.1)
Drowning	-	-	-	-	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.4)	19.1 (6.7 to 31.3)	-30.0 (-36.3 to -23.8)
Fire, heat, and hot substances	-	-	-	-	1.4 (1.1 to 1.8)	1.8 (1.4 to 2.3)	31.2 (19.6 to 44.3)	-24.7 (-30.0 to -19.0)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	28.3 (9.9 to 48.5)	-28.5 (-36.9 to -19.1)
Exposure to mechanical forces	-	-	-	-	2.6 (1.9 to 3.4)	3.9 (2.9 to 5.2)	53.1 (46.5 to 60.0)	-12.9 (-16.3 to -9.6)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	79.5 (64.3 to 95.7)	1.2 (-6.5 to 9.9)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	104.3 (85.1 to 123.1)	16.4 (7.4 to 26.6)
Other exposure to mechanical forces	-	-	-	-	2.4 (1.8 to 3.2)	3.7 (2.8 to 4.9)	51.5 (44.6 to 58.5)	-13.9 (-17.4 to -10.4)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	87.6 (76.8 to 98.6)	8.5 (1.6 to 15.4)
Animal contact	-	-	-	-	0.6 (0.5 to 0.8)	0.8 (0.6 to 1.0)	18.8 (9.8 to 27.9)	-32.6 (-37.0 to -28.6)
Venomous animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.3 to 0.5)	22.2 (7.6 to 36.1)	-32.5 (-39.7 to -25.8)
Non-venomous animal contact	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	16.0 (6.5 to 27.2)	-32.8 (-37.3 to -28.4)
Foreign body	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	63.2 (53.6 to 73.9)	-5.9 (-10.9 to -0.8)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	45.6 (27.1 to 65.7)	-10.6 (-18.9 to -1.9)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	78.0 (59.8 to 103.4)	-2.4 (-11.0 to 7.0)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	64.2 (53.0 to 76.1)	-5.6 (-12.0 to 1.0)
Other unintentional injuries	-	-	-	-	1.6 (1.2 to 2.1)	2.1 (1.6 to 2.8)	32.0 (21.6 to 43.4)	-23.6 (-29.6 to -17.6)
Self-harm and interpersonal violence	-	-	-	-	0.5 (0.4 to 0.6)	0.6 (0.4 to 0.8)	26.5 (19.0 to 34.2)	-27.0 (-30.6 to -23.0)
Self-harm	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	67.8 (54.6 to 82.3)	-5.8 (-12.8 to 1.5)
Interpersonal violence	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	15.0 (7.3 to 22.7)	-35.0 (-38.8 to -31.2)
Assault by firearm	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	23.8 (12.7 to 33.6)	-30.0 (-35.5 to -25.1)
Assault by sharp object	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	34.9 (24.0 to 47.5)	-25.2 (-30.9 to -18.1)
Assault by other means	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.3)	8.3 (-0.3 to 17.4)	-38.7 (-42.9 to -34.1)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	64.4 (18.9 to 170.5)	2,784,166.5 (1,095,853.9 to 6,274,716.8)	1,765,996.9 (665,577.5 to 4,085,315.6)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	208.0 (85.1 to 639.9)	5.5 (-20.1 to 96.2)
Collective violence and legal intervention	-	-	-	-	-	64.4 (18.9 to 170.5)	-	-

Appendix Table G.4 - Cambodia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,541.8 (967.8 to 2,326.9)	1,648.2 (1,169.5 to 2,187.8)	9.0 -44.7	-53.8 to -32.0 (-53.8 to -32.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	277.6	270.9	-2.5	-36.2
HIV/AIDS and tuberculosis	-	-	-	-	(192.9 to 389.9)	(191.9 to 374.6)	(-9.9 to 6.6)	(-40.9 to -30.1)
Tuberculosis	32.4 (30.8 to 34.0)	76.4 (73.3 to 79.6)	136.3 (126.7 to 146.7)	17.2 (12.2 to 22.7)	8.7 (6.1 to 11.6)	22.2 (15.4 to 29.4)	25.4 (136.1 to 179.2)	31.8 (19.1 to 42.2)
HIV/AIDS	-	-	-	-	1.1 (0.1 to 4.7)	3.2 (0.5 to 34.0)	191.9	357.6 (22.0 to 1,312.7)
HIV/AIDS resulting in mycobacterial infection	0.3 (0.0 to 1.7)	0.8 (0.1 to 5.4)	257.1 (-6.7 to 1,152.0)	82.5 (-52.9 to 557.5)	0.1 (0.0 to 0.6)	0.3 (0.0 to 1.9)	278.5	101.2 (0.2 to 1,554.8)
HIV/AIDS resulting in other diseases	13.5 (0.8 to 63.8)	26.8 (5.0 to 111.2)	323.9 (-0.8 to 1,267.2)	148.0 (-43.3 to 690.8)	1.0 (0.0 to 4.5)	2.9 (0.4 to 13.6)	386.8	186.4 (-33.5 to 868.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	47.0 (32.9 to 63.7)	38.3 (27.2 to 51.6)	-18.5	-38.4 (-27.3 to -8.0)
Diarrheal diseases	194.2 (159.7 to 207.4)	122.4 (110.2 to 134.9)	-33.4 (-42.8 to -21.1)	-46.9 (-54.1 to -37.8)	29.4 (20.0 to 40.9)	19.8 (13.2 to 27.4)	-32.6	-45.3 (-52.9 to -36.1)
Intestinal infectious diseases	-	-	-	-	1.7 (1.0 to 2.6)	0.8 (0.4 to 1.2)	-53.7	-64.6 (-78.4 to -47.8)
Typhoid fever	8.6 (6.0 to 11.5)	4.2 (2.9 to 5.6)	-51.6 (-67.9 to -29.5)	-65.7 (-77.1 to -48.1)	1.1 (0.7 to 1.7)	0.6 (0.3 to 0.9)	-50.0	-63.4 (-76.7 to -42.7)
Paratyphoid fever	5.6 (3.8 to 7.3)	2.2 (1.5 to 2.9)	-61.2 (-74.2 to -41.6)	-72.2 (-81.3 to -57.0)	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-60.0	-71.3 (-80.6 to -53.9)
Other intestinal infectious diseases	-	-	-	-	0.3 (0.1 to 0.5)	0.1 (0.0 to 0.2)	-64.9	-74.4 (-86.8 to -54.4)
Lower respiratory infections	9.4 (7.9 to 11.0)	11.8 (9.6 to 14.5)	26.7 (-1.7 to 55.3)	10.9 (13.3 to 30.4)	1.0 (0.6 to 1.4)	1.2 (0.8 to 1.7)	23.2	12.6 (6.4 to 55.9)
Upper respiratory infections	386.2 (360.7 to 412.5)	588.0 (546.5 to 629.5)	52.8 (39.1 to 67.0)	-5.6 (-14.1 to 3.1)	4.4 (2.5 to 7.4)	6.9 (3.8 to 11.3)	56.3	2.1 (-11.3 to 7.4)
Otitis media	126.4 (117.8 to 135.9)	162.7 (152.4 to 173.1)	29.0 (19.9 to 39.1)	-14.8 (-21.2 to -8.1)	2.4 (1.4 to 3.9)	3.2 (1.9 to 5.2)	32.7	10.9 (-18.5 to -1.8)
Meningitis	-	-	-	-	5.8 (4.0 to 8.0)	5.1 (3.5 to 7.1)	-12.1	-47.3 (-57.5 to -37.1)
Pneumococcal meningitis	26.4 (16.1 to 39.5)	25.1 (14.9 to 39.6)	-3.8 (-29.3 to 31.1)	-47.5 (-60.8 to -29.1)	2.2 (1.5 to 3.1)	2.1 (1.4 to 3.1)	-2.1	-42.8 (-57.8 to -27.9)
H influenzae type B meningitis	15.4 (6.5 to 28.2)	11.3 (4.4 to 21.0)	-27.4 (-48.6 to -1.9)	-58.4 (-70.3 to -44.6)	1.6 (1.0 to 2.4)	1.3 (0.8 to 2.0)	-17.7	-49.4 (-66.2 to -27.8)
Meningococcal meningitis	2.6 (1.0 to 5.2)	1.9 (0.6 to 4.3)	-26.8 (-55.5 to 13.1)	-62.2 (-75.7 to -40.8)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.4)	-27.2	-60.6 (-74.5 to -39.4)
Other meningitis	15.6 (8.4 to 28.0)	12.0 (5.8 to 21.8)	-23.9 (-45.0 to 3.5)	-55.2 (-67.6 to -40.6)	1.7 (1.1 to 2.6)	1.4 (0.9 to 2.2)	-15.8	-47.9 (-63.7 to -26.9)
Encephalitis	3.3 (1.6 to 6.8)	4.4 (2.0 to 9.3)	30.7 (6.5 to 48.7)	-28.4 (-42.1 to -19.1)	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	59.7	19.9 (18.4 to 65.6)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-	-	0.0 (-98.5 to 116.8)	0.0 (0.0 to 0.0)	-	-
Whooping cough	15.2 (11.7 to 19.6)	3.2 (2.5 to 4.1)	-78.8 (-80.8 to -76.6)	-79.9 (-81.8 to -77.8)	0.7 (0.4 to 1.2)	0.2 (0.1 to 0.3)	-78.5	-79.8 (-81.8 to -74.9)
Tetanus	8.4 (5.2 to 15.0)	0.3 (0.1 to 0.6)	-97.0 (-98.6 to -91.8)	-98.2 (-99.2 to -95.2)	0.4 (0.2 to 0.6)	0.0 (0.0 to 0.0)	-95.1	-96.6 (-97.7 to -89.4)
Measles	5.4 (3.9 to 7.2)	0.5 (0.4 to 0.7)	-90.9 (-92.3 to -86.9)	-95.5 (-92.8 to -87.8)	0.5 (0.3 to 0.8)	0.0 (0.0 to 0.1)	-99.7	-90.3 (-93.9 to -85.1)
Varicella and herpes zoster	9.4 (8.6 to 10.3)	15.6 (14.2 to 17.1)	66.7 (46.8 to 87.9)	0.1 (-12.5 to 16.6)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.9)	100.3	6.1 (-14.1 to 33.9)
Neglected tropical diseases and malaria	-	-	-	-	34.7 (22.0 to 53.1)	18.1 (12.0 to 26.9)	-48.3	-69.9 (-78.9 to -54.2)
Malaria	91.3 (86.6 to 96.1)	140.5 (133.3 to 147.9)	54.2 (47.7 to 61.5)	-7.6 (-10.9 to -3.4)	1.0 (0.7 to 1.6)	1.1 (0.7 to 1.7)	8.8	27.0 (-43.7 to 1.9)
Chagas disease	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.5	-46.5 (-61.1 to -23.6)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.9 (-70.8 to 121.2)	-27.8 (-69.8 to 72.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.9	-27.8 (-69.9 to 72.6)
Cutaneous and mucocutaneous leishmaniasis	0.8 (0.6 to 1.0)	0.8 (0.6 to 1.0)	-1.0 (-19.7 to 28.2)	-49.5 (-58.6 to -35.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.5	-46.5 (-61.1 to -23.6)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	8.9 (3.3 to 20.4)	2.4 (0.0 to 5.1)	-99.5 (-99.7 to -21.2)	-99.7 (-99.8 to -58.6)	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-97.4	-98.4 (-99.2 to -79.9)
Cysticercosis	8.2 (4.4 to 11.7)	11.1 (6.3 to 17.4)	33.2 (-27.0 to 145.6)	-38.9 (-65.8 to 13.4)	1.9 (0.9 to 3.1)	3.1 (1.7 to 5.3)	64.2	-22.9 (-57.3 to 46.8)
Cystic echinococcosis	1.8 (1.6 to 2.1)	2.7 (2.0 to 3.3)	60.8 (1.8 to 78.5)	-21.2 (-47.1 to -7.5)	0.2 (0.1 to 0.2)	0.3 (0.1 to 0.4)	62.4	-15.5 (-46.3 to 8.1)
Lymphatic filariasis	8.8 (5.9 to 12.9)	5.0 (2.7 to 8.9)	-44.4 (-69.7 to -11.1)	-72.0 (-84.4 to -56.4)	0.3 (0.1 to 0.7)	0.4 (0.2 to 0.9)	32.6	-39.3 (-68.9 to 5.6)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	11.6 (7.5 to 17.0)	6.9 (4.6 to 10.0)	-40.6 (-60.8 to -4.2)	-77.2 (-85.2 to -63.1)	0.6 (0.3 to 0.9)	0.4 (0.2 to 0.6)	-33.8	-75.4 (-83.9 to -61.6)
Dengue	3.0 (1.1 to 6.8)	24.8 (9.1 to 55.8)	718.7 (717.0 to 720.5)	384.5 (383.5 to 385.6)	0.5 (0.2 to 1.2)	4.0 (1.3 to 9.9)	737.1	408.4 (346.2 to 489.9)
Yellow fever	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Intestinal nematode infections	-	-	-	-	20.8 (11.6 to 34.8)	0.7 (0.3 to 1.1)	-96.7	-98.2 (-99.0 to -97.4)
Ascariasis	2,587.6 (1,994.3 to 3,360.9)	117.3 (72.2 to 182.8)	-95.6 (-97.4 to -92.3)	-97.5 (-98.6 to -95.6)	6.8 (3.3 to 12.8)	0.0 (0.0 to 0.0)	-100.0	-100.0 (-100.0 to -100.0)
Trichuriasis	537.8 (359.7 to 793.7)	-	-99.8 (-99.9 to -99.5)	-99.9 (-99.9 to -99.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-100.0	-100.0 (-100.0 to -100.0)
Hookworm disease	2,217.9 (2,136.0 to 3,453.9)	275.6 (182.0 to 418.9)	-90.0 (-93.8 to -83.7)	-94.4 (-96.6 to -90.7)	14.0 (8.0 to 22.9)	0.7 (0.3 to 1.1)	-92.3	-97.3 (-98.6 to -96.0)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	229.7 (174.1 to 285.3)	224.6 (207.9 to 245.7)	-2.0 (-21.5 to 29.6)	-31.8 (-44.1 to -13.7)	9.3 (6.0 to 13.5)	8.0 (5.2 to 11.5)	-15.1	-38.5 (-47.4 to -15.9)
Maternal disorders	-	-	-	-	0.6 (0.3 to 0.8)	0.5 (0.3 to 0.8)	-9.4	-56.7 (-69.4 to -37.4)
Maternal hemorrhage	4.3 (2.8 to 6.2)	4.7 (3.0 to 6.5)	10.2 (-33.0 to 71.0)	-48.7 (-68.5 to -20.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-7.8	-96.5 (-78.6 to -24.1)
Maternal sepsis and other maternal infections	5.6 (3.4 to 8.0)	3.9 (2.5 to 5.9)	-29.5 (-49.5 to -14.0)	-66.2 (-75.7 to -59.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-31.4	-66.6 (-80.4 to -43.2)
Maternal hypertensive disorders	2.5 (1.3 to 4.2)	2.4 (1.2 to 4.1)	-1.3 (-15.9 to 25.2)	-51.9 (-58.8 to -39.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	0.1	-50.9 (-61.3 to -35.4)
Obstructed labor	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.2)	-24.9 (-64.8 to 39.4)	-64.8 (-83.8 to -38.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-16.0	-60.4 (-82.7 to -12.3)
Complications of abortion	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	42.7 (-36.1 to 200.6)	-34.1 (-68.5 to 34.0)	0.1 (0.0 to 0.0)	0.1 (0.0 to 0.0)	-	-
Other maternal disorders	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-9.2	-56.8 (-78.7 to 24.8)
Neonatal disorders	-	-	-	-	7.6 (4.0 to 12.7)	28.2 (17.6 to 45.2)	262.9	147.3 (52.1 to 414.5)
Preterm birth complications	32.6 (15.4 to 64.5)	147.7 (75.6 to 284.0)	355.1 (212.3 to 580.2)	175.4 (84.7 to 309.9)	2.6 (1.5 to 4.3)	15.8 (9.2 to 29.0)	496.3	295.5 (163.3 to 636.4)
Neonatal encephalopathy due to birth asphyxia and trauma	47.7 (10.9 to 115.0)	61.3 (20.2 to 138.7)	35.9 (-20.6 to 157.9)	-19.9 (-53.3 to 61.2)	1.9 (0.8 to 3.5)	4.9 (3.0 to 7.4)	175.4	88.7 (-3.1 to 316.3)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	177.9 (169.6 to 219.9)	0.0 (-165.8 to 215.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	186.6 (128.7 to 251.5)
Hemolytic disease and other neonatal jaundice	2.8 (1.2 to 6.5)	9.9 (3.7 to 19.7)	240.1 (23.8 to 916.6)	135.7 (-16.0 to 617.3)	1.0 (0.4 to 2.5)	3.5 (1.3 to 7.0)	224.6	122.5 (-18.8 to 611.9)
Other neonatal disorders	-	-	-	-	2.1 (0.4 to 5.9)	4.0 (1.7 to 8.0)	95.5	32.2 (-47.7 to 548.9)
Nutritional deficiencies	-	-	-	-	168.8 (114.3 to 238.7)	150.1 (102.4 to 214.8)	-10.8	-43.1 (-46.5 to -39.3)
Protein-energy malnutrition	106.7 (60.6 to 171.9)	71.0 (44.7 to 110.3)	-33.3 (-66.2 to 33.5)	-36.8 (-67.8 to 25.6)	3.8 (6.2 to 22.9)	8.9 (4.5 to 15.2)	-36.0	-26.9 (-67.8 to 26.9)
Iodine deficiency	114.3 (56.2 to 189.4)	82.2 (35.8 to 148.6)	-32.7 (-71.7 to 98.4)	-67.0 (-86.1 to -35.3)	2.0 (0.8 to 3.9)	1.5 (0.5 to 3.0)	-30.2	-65.2 (-70.7 to 106.3)
Vitamin A deficiency	8.0 (5.8 to 10.3)	6.2 (4.4 to 8.4)	-22.2 (-33.4 to -7.3)	-47.1 (-53.7 to -38.6)	0.4 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-21.1	-47.5 (-56.1 to -38.3)

Appendix Table G.4 - Cambodia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes								
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	65.2 (57.1 to 73.3)	118.8 (104.9 to 131.9)	82.6 (56.9 to 118.4)	-30.5 (-39.9 to -17.7)	1.6 (1.0 to 2.2)	3.1 (2.1 to 4.4)	95.9 (65.0 to 132.6)	-24.3 (-35.8 to -9.8)
Other oral disorders	131.4 (123.9 to 138.4)	254.2 (239.8 to 269.3)	94.0 (82.4 to 106.9)	-0.1 (-6.0 to 5.8)	3.7 (2.3 to 5.6)	7.4 (4.6 to 11.1)	100.6 (87.3 to 116.6)	5.0 (-2.0 to 13.6)
Injuries	-	-	-	-	802.3 (310.9 to 1,557.3)	399.9 (169.9 to 778.0)	399.9 (-54.9 to -42.5)	-50.2 (-75.7 to -68.3)
Transport injuries	-	-	-	-	6.2 (4.7 to 8.0)	12.0 (9.0 to 15.8)	93.2 (79.1 to 110.2)	-4.4 (-10.7 to 3.7)
Road injuries	-	-	-	-	4.9 (3.7 to 6.3)	9.8 (7.3 to 12.8)	99.8 (84.0 to 118.4)	4.0 (-7.1 to 8.9)
Pedestrian road injuries	-	-	-	-	0.7 (0.5 to 0.9)	1.4 (1.1 to 1.9)	103.7 (80.5 to 126.3)	4.2 (-6.4 to 14.4)
Cyclist road injuries	-	-	-	-	0.3 (0.3 to 0.4)	0.6 (0.5 to 0.8)	86.9 (72.2 to 105.4)	-6.6 (-14.2 to 2.8)
Motorcyclist road injuries	-	-	-	-	2.1 (1.6 to 2.8)	3.9 (2.8 to 5.1)	78.9 (61.7 to 97.6)	-9.8 (-18.2 to -0.9)
Motor vehicle road injuries	-	-	-	-	1.7 (1.3 to 2.2)	3.9 (2.9 to 5.0)	127.7 (105.8 to 155.5)	18.1 (2.8 to 26.5)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	74.6 (60.8 to 92.8)	-19.2 (-25.2 to -11.6)
Other transport injuries	-	-	-	-	1.3 (1.0 to 1.7)	2.2 (1.6 to 2.9)	68.8 (55.6 to 85.1)	-19.6 (-25.9 to -11.6)
Unintentional injuries	-	-	-	-	13.2 (10.1 to 16.9)	27.3 (20.7 to 35.6)	106.1 (94.5 to 122.2)	2.0 (-3.5 to 10.2)
Falls	-	-	-	-	2.4 (1.9 to 3.1)	6.3 (4.7 to 8.3)	161.4 (143.3 to 181.1)	17.2 (9.4 to 26.4)
Drowning	-	-	-	-	0.7 (0.5 to 0.9)	1.0 (0.7 to 1.3)	36.9 (21.5 to 57.4)	-26.9 (-33.9 to -17.7)
Fire, heat, and hot substances	-	-	-	-	1.3 (1.0 to 1.6)	1.2 (0.9 to 1.5)	-7.3 (-17.6 to 3.7)	-51.5 (-56.3 to -46.2)
Poisonings	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	19.1 (1.7 to 37.9)	-36.7 (-44.7 to -27.8)
Exposure to mechanical forces	-	-	-	-	4.9 (3.8 to 6.4)	10.2 (7.7 to 13.6)	107.4 (90.8 to 128.8)	5.9 (-1.7 to 17.0)
Unintentional firearm injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	69.5 (54.9 to 88.4)	-16.0 (-22.6 to -6.2)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	113.8 (93.6 to 134.3)	14.2 (3.9 to 24.8)
Other exposure to mechanical forces	-	-	-	-	4.5 (3.4 to 5.9)	9.5 (7.1 to 12.6)	109.9 (92.1 to 132.6)	7.3 (-0.7 to 18.9)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	107.6 (94.6 to 121.0)	2.3 (-3.9 to 8.8)
Animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	27.3 (15.7 to 41.4)	-32.5 (-37.7 to -25.9)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	31.2 (16.1 to 51.1)	-31.5 (-38.6 to -22.1)
Non-venomous animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	24.6 (10.3 to 38.8)	-33.3 (-39.2 to -27.0)
Foreign body	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	98.0 (84.9 to 113.6)	3.7 (-2.0 to 11.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	64.8 (44.4 to 85.2)	-7.3 (-16.4 to 1.7)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	86.7 (73.6 to 101.8)	0.8 (-5.4 to 7.0)
Foreign body in other body part	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	134.4 (116.0 to 157.7)	12.6 (4.0 to 23.4)
Other unintentional injuries	-	-	-	-	3.2 (2.4 to 4.2)	7.5 (5.6 to 9.9)	133.2 (114.0 to 156.6)	11.0 (2.3 to 21.8)
Self-harm and interpersonal violence	-	-	-	-	1.5 (1.1 to 1.9)	1.6 (1.2 to 2.1)	9.3 (0.0 to 20.1)	45.5 (-49.9 to -40.0)
Self-harm	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	22.0 (10.7 to 35.3)	-43.7 (-48.8 to -37.7)
Interpersonal violence	-	-	-	-	1.3 (1.0 to 1.6)	1.4 (1.0 to 1.8)	7.3 (-1.9 to 18.4)	-45.8 (-50.3 to -40.0)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	12.6 (1.7 to 25.7)	-41.7 (-47.2 to -35.0)
Assault by sharp object	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	20.5 (8.1 to 37.0)	-40.3 (-46.8 to -31.9)
Assault by other means	-	-	-	-	0.9 (0.7 to 1.1)	0.9 (0.7 to 1.2)	2.7 (-7.0 to 14.5)	-48.0 (-52.7 to -42.2)
Forces of nature, war, and legal intervention	-	-	-	-	781.5 (291.0 to 1,537.0)	359.1 (131.9 to 735.0)	-54.6 (-59.1 to -47.9)	-74.7 (-77.7 to -69.9)
Exposure to forces of nature	-	-	-	-	-	0.4 (0.2 to 0.9)	-	-
Collective violence and legal intervention	-	-	-	-	781.5 (291.0 to 1,537.0)	358.6 (131.8 to 734.3)	-54.7 (-59.1 to -48.0)	-74.7 (-77.8 to -69.9)

Appendix Table G.4 - Cameroon prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	73.1	-3.4
Silicosis	0.1	0.1	61.5	-8.1	0.0	0.0	61.4	-8.1
Asbestosis	-	-	0.0	0.0	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.1	0.1	88.4	1.2	0.0	0.0	84.4	1.9
Asthma	160.9	252.1	55.5	-9.9	7.0	10.9	55.3	-1.1
Interstitial lung disease and pulmonary sarcoidosis	0.3	0.5	90.9	-0.4	0.0	0.1	89.7	-0.4
Other chronic respiratory diseases	-	-	-	-	6.9	13.1	90.4	5.1
Cirrhosis	-	-	-	-	1.1	1.6	49.6	-16.6
Cirrhosis due to hepatitis B	2.3	2.8	22.6	-29.7	0.4	0.5	23.0	-29.5
Cirrhosis due to hepatitis C	1.3	2.2	60.7	-9.4	0.2	0.4	59.0	-9.6
Cirrhosis due to alcohol use	1.4	2.0	39.6	-21.2	0.2	0.3	41.8	-20.5
Cirrhosis due to other causes	1.4	2.7	87.6	13.9	0.1	0.4	89.2	15.3
Digestive diseases	-	-	-	-	15.3	29.6	93.3	7.9
Peptic ulcer disease	62.6	94.0	50.7	-15.0	2.3	3.6	59.6	-11.8
Gastritis and duodenitis	150.4	252.7	68.0	0.7	6.3	10.9	74.8	5.0
Appendicitis	1.3	3.4	150.9	22.7	0.4	1.0	154.9	24.1
Paralytic ileus and intestinal obstruction	0.2	0.3	48.1	0.1	0.1	0.1	49.1	4.0
Inguinal, femoral, and abdominal hernia	49.8	67.6	36.1	-16.4	0.5	0.7	36.6	-17.4
Inflammatory bowel disease	11.0	25.9	136.4	2.3	5.5	13.1	137.1	26.5
Vascular intestinal disorders	0.0	0.0	126.2	2.7	0.0	0.0	127.3	3.7
Gallbladder and biliary diseases	3.7	7.5	103.4	0.4	0.8	1.8	106.8	10.2
Pancreatitis	1.9	3.8	105.9	9.4	0.5	1.1	107.3	10.1
Other digestive diseases	-	-	-	-	2.6	5.8	128.5	27.5
Neurological disorders	-	-	-	-	50.2	103.5	106.3	8.5
Alzheimer disease and other dementias	18.6	32.6	75.3	1.2	2.5	4.6	79.0	2.6
Parkinson disease	0.8	1.4	68.4	0.2	0.1	0.2	71.8	2.4
Epilepsy	26.0	45.7	76.3	-5.3	7.6	14.0	84.9	0.1
Multiple sclerosis	0.7	1.4	116.0	13.4	0.2	0.5	115.3	12.7
Migraine	898.5	1,529.6	69.3	-2.1	27.4	52.3	91.0	-1.5
Tension-type headache	1,410.6	2,866.4	103.3	3.4	21.7	43.3	104.5	4.1
Medication overuse headache	52.6	151.7	187.3	50.7	8.2	23.8	190.6	51.8
Other neurological disorders	0.0	0.0	74.4	-4.1	2.1	3.7	77.8	0.8
Mental and substance use disorders	-	-	-	-	235.1	446.6	89.9	-1.3
Schizophrenia	23.6	45.7	93.8	-0.3	14.9	29.2	95.7	0.3
Alcohol use disorders	59.6	138.6	132.6	18.1	5.7	13.5	136.8	19.5
Drug use disorders	-	-	-	-	13.8	27.9	102.5	0.6
Opioid use disorders	18.2	35.4	93.8	-0.9	7.4	14.5	95.8	-0.1
Cocaine use disorders	5.5	11.4	110.3	0.7	3.6	7.6	111.4	3.3
Amphetamine use disorders	17.9	37.1	107.4	0.0	2.3	4.8	110.1	1.1
Cannabis use disorders	8.0	16.4	104.2	0.2	0.2	0.5	106.1	1.0
Other drug use disorders	-	-	-	-	3.1	6.5	110.0	2.1
Depressive disorders	-	-	-	-	100.4	184.2	82.8	3.7
Major depressive disorder	439.8	795.1	80.1	-4.7	89.7	163.5	81.6	-4.3
Dysthymia	112.9	216.0	91.5	-0.3	10.8	20.8	93.0	0.2
Bipolar disorder	63.3	124.7	97.2	-0.7	12.7	25.3	99.2	-0.2
Anxiety disorders	270.9	521.4	92.6	-2.2	24.9	48.2	94.2	0.2
Eating disorders	-	-	-	-	2.8	5.8	107.1	0.7
Anorexia nervosa	1.9	4.0	105.7	2.1	0.4	0.9	107.8	2.8
Bulimia nervosa	11.3	23.3	105.8	-0.4	2.4	4.9	107.3	0.3
Autistic spectrum disorders	-	-	-	-	14.3	26.8	86.0	1.1
Autism	36.8	68.6	86.9	0.4	9.0	17.0	88.3	1.2
Asperger syndrome	52.9	98.6	86.5	0.5	5.3	9.9	87.4	1.0
Attention-deficit/hyperactivity disorder	87.9	164.1	87.0	0.1	1.1	2.0	88.1	0.7
Conduct disorder	127.9	240.1	87.3	0.1	0.6	1.6	89.0	0.3
Idiopathic intellectual disability	387.4	689.4	78.2	-5.5	18.6	33.8	79.2	-5.0
Other mental and substance use disorders	142.3	281.5	98.0	0.3	10.5	21.0	99.7	0.9
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	70.5	142.1	102.0	14.0
Diabetes mellitus	152.3	465.5	207.3	68.9	10.9	32.9	201.8	68.3
Acute glomerulonephritis	0.1	0.1	27.0	-0.2	0.0	0.0	25.5	-27.2
Chronic kidney disease	111.0	200.7	80.1	3.9	1.8	3.2	76.4	1.2
Chronic kidney disease due to diabetes mellitus	529.5	976.5	81.9	0.7	6.3	11.6	84.5	-1.0
Chronic kidney disease due to hypertension	455.1	862.8	89.2	-0.2	6.9	12.5	89.5	-0.1
Chronic kidney disease due to glomerulonephritis	362.1	644.7	79.5	-1.5	4.5	7.8	74.4	-6.0
Chronic kidney disease due to other causes	-	-	-	-	19.5	35.0	79.4	-1.5
Urinary diseases and male infertility	-	-	-	-	4.5	7.9	76.2	1.2

Appendix Table G.4 - Cameroon prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	33.2 (30.1 to 36.1)	60.4 (56.1 to 64.8)	82.1 (61.9 to 105.4)	4.9 (-5.4 to 17.9)	0.9 (0.6 to 1.2)	1.6 (1.1 to 2.3)	82.8 (61.6 to 108.5)	5.8 (-5.8 to 19.2)
Other oral disorders	172.4 (163.1 to 182.0)	325.5 (305.0 to 345.9)	88.9 (79.9 to 105.1)	-0.9 (-8.2 to 6.9)	5.0 (3.1 to 7.4)	9.5 (5.9 to 14.2)	90.0 (74.0 to 107.0)	-0.6 (-8.1 to 7.8)
Injuries	-	-	-	-	46.9 (35.8 to 60.2)	74.2 (55.8 to 96.2)	58.2 (51.5 to 65.5)	-11.5 (-15.2 to -7.3)
Transport injuries	-	-	-	-	21.2 (15.9 to 27.3)	34.3 (25.8 to 44.6)	62.1 (53.6 to 72.0)	-8.7 (-13.2 to -3.5)
Road injuries	-	-	-	-	19.7 (14.8 to 25.4)	31.5 (23.7 to 41.1)	60.1 (51.2 to 70.1)	1.6 (-14.3 to -4.6)
Pedestrian road injuries	-	-	-	-	4.7 (3.5 to 6.0)	6.7 (4.9 to 8.7)	42.4 (30.6 to 54.7)	-18.3 (-23.8 to -12.9)
Cyclist road injuries	-	-	-	-	1.7 (1.2 to 2.2)	2.2 (1.6 to 2.9)	32.9 (24.0 to 43.0)	-22.0 (-27.8 to -15.9)
Motorcyclist road injuries	-	-	-	-	3.1 (2.3 to 4.0)	4.4 (3.2 to 5.8)	41.2 (29.5 to 51.9)	-21.3 (-27.3 to -15.2)
Motor vehicle road injuries	-	-	-	-	9.9 (7.5 to 12.7)	17.9 (13.5 to 23.1)	80.3 (66.6 to 95.0)	1.6 (-6.3 to 8.3)
Other road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	17.1 (9.0 to 26.5)	-38.0 (-41.9 to -33.6)
Other transport injuries	-	-	-	-	1.5 (1.1 to 1.9)	2.8 (2.1 to 3.6)	87.1 (73.7 to 101.3)	6.6 (-0.6 to 14.8)
Unintentional injuries	-	-	-	-	23.7 (18.0 to 30.4)	37.8 (28.5 to 49.3)	59.5 (53.8 to 65.2)	-11.7 (-15.2 to -8.2)
Falls	-	-	-	-	9.6 (7.2 to 12.3)	15.8 (11.8 to 20.8)	65.0 (56.2 to 73.7)	-10.7 (-15.9 to -5.5)
Drowning	-	-	-	-	0.6 (0.4 to 0.7)	0.7 (0.5 to 0.9)	24.1 (10.6 to 37.7)	-17.2 (-36.4 to -23.7)
Fire, heat, and hot substances	-	-	-	-	1.4 (1.1 to 1.8)	2.0 (1.5 to 2.6)	38.6 (26.5 to 51.2)	-20.4 (-26.3 to -14.5)
Poisonings	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	37.5 (15.2 to 66.6)	-26.2 (-36.3 to -14.6)
Exposure to mechanical forces	-	-	-	-	7.3 (5.2 to 9.5)	11.5 (8.6 to 15.3)	57.3 (50.7 to 65.3)	-13.2 (-16.6 to -9.1)
Unintentional firearm injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.6)	51.7 (40.1 to 64.3)	-17.2 (-23.3 to -10.2)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	101.1 (80.5 to 123.0)	11.0 (0.8 to 20.7)
Other exposure to mechanical forces	-	-	-	-	6.9 (5.3 to 9.1)	10.9 (8.2 to 14.6)	57.1 (50.4 to 65.2)	-13.2 (-16.8 to -8.9)
Adverse effects of medical treatment	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	99.5 (86.9 to 114.3)	15.8 (7.6 to 24.1)
Animal contact	-	-	-	-	0.5 (0.4 to 0.6)	0.7 (0.5 to 1.0)	57.5 (46.4 to 69.1)	-11.9 (-17.3 to -6.2)
Venomous animal contact	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	60.8 (42.6 to 81.6)	-11.9 (-20.5 to -2.1)
Non-venomous animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	54.5 (44.2 to 65.3)	-12.2 (-17.1 to -6.9)
Foreign body	-	-	-	-	0.5 (0.4 to 0.6)	0.8 (0.6 to 1.1)	66.7 (57.2 to 78.3)	-5.8 (-10.6 to -0.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	40.4 (19.5 to 59.4)	-15.7 (-26.0 to -7.3)
Foreign body in eyes	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	82.6 (65.0 to 103.6)	-2.7 (-10.7 to 6.8)
Foreign body in other body part	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.6)	73.5 (62.3 to 86.3)	-3.2 (-9.5 to 3.7)
Other unintentional injuries	-	-	-	-	3.6 (2.7 to 4.6)	5.8 (4.3 to 7.6)	60.7 (50.7 to 73.4)	-9.4 (-14.8 to -3.0)
Self-harm and interpersonal violence	-	-	-	-	1.0 (0.8 to 1.3)	1.6 (1.2 to 2.1)	60.3 (50.0 to 70.0)	-12.5 (-17.8 to -7.0)
Self-harm	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	82.9 (67.1 to 99.2)	-1.0 (-8.6 to 6.5)
Interpersonal violence	-	-	-	-	0.9 (0.7 to 1.1)	1.4 (1.0 to 1.8)	56.2 (45.9 to 66.1)	-15.2 (-20.7 to -9.8)
Assault by firearm	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	67.6 (54.4 to 80.1)	-8.5 (-15.5 to -2.1)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	89.2 (76.4 to 105.1)	1.1 (-5.9 to 10.0)
Assault by other means	-	-	-	-	0.6 (0.4 to 0.7)	0.8 (0.6 to 1.1)	45.7 (33.9 to 56.7)	-21.1 (-27.3 to -15.1)
Forces of nature, war, and legal intervention	-	-	-	-	1.0 (0.4 to 2.3)	0.5 (0.2 to 1.1)	-50.3 (-56.1 to -41.1)	-62.0 (-66.2 to -55.9)
Exposure to forces of nature	-	-	-	-	0.5 (0.2 to 0.9)	0.2 (0.1 to 0.5)	-50.3 (-54.2 to -46.0)	-62.1 (-65.8 to -58.3)
Collective violence and legal intervention	-	-	-	-	0.6 (0.1 to 1.5)	0.3 (0.1 to 0.7)	-50.0 (-57.9 to -18.6)	-61.6 (-67.3 to -40.3)

Appendix Table G.4 - Canada prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	3,248.1 (2,111.2 to 4,179.3)	4,644.7 (3,444.8 to 5,936.7)	43.0 (40.0 to 45.9)	43.0 (-2.7 to 1.3)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	124.8 (87.7 to 175.8)	165.1 (117.6 to 225.6)	32.1 (22.4 to 45.5)	14.1 (6.5 to 24.8)
HIV/AIDS and tuberculosis	-	-	-	-	3.8 (2.4 to 5.3)	3.1 (2.0 to 4.4)	-17.5 (-39.0 to 5.0)	-39.7 (-55.1 to -23.5)
Tuberculosis	4.5 (4.3 to 4.7)	3.8 (3.6 to 4.1)	-14.5 (-18.0 to -10.8)	-35.1 (-37.7 to -32.4)	1.4 (0.9 to 1.9)	1.2 (0.8 to 1.6)	-15.4 (-32.2 to 5.1)	-35.0 (-48.4 to -18.3)
HIV/AIDS	-	-	-	-	2.4 (1.4 to 3.6)	1.9 (1.1 to 3.1)	-42.7 (-50.4 to -35.1)	-42.7 (-64.7 to -15.8)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-78.2 (-87.9 to -67.2)	-83.9 (-91.2 to -75.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-78.2 (-88.1 to -67.1)	-83.9 (-91.4 to -75.6)
HIV/AIDS resulting in other diseases	18.4 (13.9 to 22.9)	25.2 (16.1 to 35.4)	37.5 (5.6 to 78.3)	-2.5 (-33.4 to 28.6)	2.4 (1.4 to 3.6)	1.9 (1.1 to 3.1)	-18.8 (-50.3 to 17.3)	-42.6 (-64.7 to -15.4)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	21.7 (13.4 to 34.1)	25.7 (15.9 to 40.4)	18.7 (13.0 to 24.2)	-5.2 (-9.8 to -1.1)
Diarrheal diseases	8.7 (7.6 to 9.6)	11.2 (9.9 to 12.4)	29.1 (9.1 to 52.8)	0.2 (-15.0 to 19.7)	1.4 (0.9 to 2.0)	1.8 (1.2 to 2.5)	28.0 (4.9 to 57.2)	1.0 (-17.4 to 25.6)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (44.1 to 65.1)	-7.3 (56.0 to 30.8)
Typhoid fever	0.2 (0.2 to 0.2)	0.2 (0.1 to 0.2)	-11.0 (-25.6 to 11.1)	-29.8 (-41.3 to -13.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.0 (-25.6 to 11.2)	-29.8 (-41.3 to -13.1)
Paratyphoid fever	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	27.5 (-3.7 to 69.1)	2.1 (-21.0 to 33.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.5 (-3.7 to 70.8)	2.1 (-21.0 to 33.9)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.8 (-88.8 to 529.1)	-34.8 (-91.0 to 398.9)
Lower respiratory infections	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-18.6 (-25.5 to -10.0)	-46.7 (-51.6 to -40.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.5 (-18.2 to 11.2)	-36.7 (-45.2 to -25.6)
Upper respiratory infections	1,012.1 (969.1 to 1,060.3)	1,246.8 (1,197.5 to 1,298.9)	23.4 (15.2 to 30.8)	0.8 (-6.1 to 6.6)	11.9 (6.7 to 19.7)	14.5 (8.1 to 24.1)	22.7 (14.1 to 31.0)	0.8 (-6.5 to 7.3)
Otitis media	322.3 (304.3 to 340.6)	344.5 (324.0 to 362.6)	6.9 (-0.7 to 15.2)	-15.4 (-20.7 to -9.4)	5.7 (3.3 to 9.1)	6.1 (3.6 to 9.9)	7.8 (0.5 to 16.4)	-15.1 (-21.2 to -8.6)
Meningitis	-	-	-	-	1.2 (0.8 to 1.7)	1.1 (0.7 to 1.6)	-4.1 (-31.0 to 17.8)	-23.5 (-45.2 to -4.1)
Pneumococcal meningitis	8.3 (5.3 to 13.9)	8.0 (4.9 to 13.5)	-3.5 (-15.8 to 11.1)	-29.0 (-38.2 to -17.3)	0.7 (0.5 to 1.0)	0.7 (0.5 to 1.0)	-3.2 (-20.8 to 20.2)	-25.1 (-39.3 to -5.3)
H influenzae type B meningitis	0.9 (0.3 to 2.1)	0.9 (0.3 to 2.1)	-0.8 (-42.0 to 115.9)	-19.0 (51.0 to 88.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	8.3 (-46.8 to 154.4)	-6.3 (-53.6 to 122.2)
Meningococcal meningitis	0.8 (0.2 to 2.0)	0.7 (0.2 to 1.9)	-13.7 (-53.5 to 69.6)	-32.9 (-63.0 to 41.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-10.8 (-55.7 to 86.5)	-27.5 (-65.3 to 57.9)
Other meningitis	1.9 (0.9 to 4.0)	1.6 (0.7 to 3.7)	-16.0 (-47.5 to 18.3)	-33.8 (-56.9 to -2.3)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-18.9 (-53.4 to 30.2)	-32.9 (-61.3 to 8.1)
Encephalitis	1.5 (0.6 to 4.1)	2.1 (0.9 to 6.0)	36.0 (8.6 to 67.3)	-9.9 (-21.5 to 22.1)	0.3 (0.1 to 0.3)	0.3 (0.2 to 0.4)	-34.0 (-68.5 to 74.6)	-3.4 (-23.1 to 25.8)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.6 (-90.5 to 408.6)	53.0 (-92.5 to 304.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.6 (-92.5 to 409.0)	-53.0 (-92.5 to 305.2)
Whooping cough	4.3 (3.4 to 5.5)	3.8 (2.9 to 4.8)	-12.3 (-13.0 to -11.5)	-13.8 (-14.5 to -13.0)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-12.2 (-24.0 to 2.5)	-13.7 (-25.5 to 1.0)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.2 (-44.6 to 46.7)	-10.5 (-55.3 to 20.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.8 (-41.0 to 37.1)	-13.3 (-52.1 to 14.1)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-92.0 (-93.8 to -90.2)	-92.0 (-93.8 to -90.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-92.0 (-93.8 to -90.2)	-92.0 (-93.8 to -90.3)
Varicella and herpes zoster	27.0 (24.5 to 29.9)	37.7 (33.5 to 42.9)	39.4 (18.0 to 63.9)	0.0 (-13.2 to 15.1)	1.1 (0.6 to 1.7)	1.6 (1.0 to 2.6)	51.6 (22.6 to 90.7)	0.7 (-18.9 to 25.3)
Neglected tropical diseases and malaria	-	-	-	-	0.9 (0.6 to 1.5)	0.5 (0.3 to 0.7)	-42.2 (-67.0 to -24.4)	-58.3 (-76.3 to -44.8)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.4 (-53.5 to 284.1)	-1.2 (-61.2 to 221.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.0 (-53.0 to 294.7)	-0.3 (-60.9 to 226.6)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.7 (0.2 to 2.3)	0.2 (0.1 to 0.4)	-65.5 (-89.1 to 26.6)	-74.3 (-91.8 to 3.6)	0.3 (0.1 to 0.9)	0.1 (0.0 to 0.2)	-62.6 (-87.8 to 43.8)	-72.4 (-91.1 to 18.6)
Cystic echinococcosis	6.8 (6.4 to 7.2)	4.3 (4.0 to 4.6)	-36.6 (-41.5 to -30.0)	-55.1 (-59.3 to -50.0)	0.6 (0.4 to 0.8)	0.4 (0.3 to 0.6)	-35.3 (-47.6 to -21.5)	-53.9 (-62.6 to -42.9)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.2 (-59.5 to 58.2)	-5.6 (-69.2 to 17.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.2 (-60.1 to 58.3)	-5.6 (-69.2 to 18.2)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	221.1 (2.4 to 320.2)	149.9 (-21.7 to 230.9)
Maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	16.1 (-21.6 to 59.0)	10.7 (-24.8 to 52.4)
Maternal hemorrhage	1.6 (1.2 to 2.1)	1.7 (1.4 to 2.1)	5.4 (-18.4 to 43.6)	0.7 (-22.1 to 36.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.0 (-47.4 to 94.5)	21.0 (-48.2 to 84.5)
Maternal sepsis and other maternal infections	0.4 (0.2 to 0.6)	0.3 (0.2 to 0.5)	-17.5 (-48.7 to 24.1)	-25.0 (-52.4 to 12.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.7 (-48.1 to 25.2)	-27.7 (-51.0 to 13.2)
Maternal hypertensive disorders	0.7 (0.4 to 1.0)	0.7 (0.5 to 1.0)	8.5 (-1.9 to 18.5)	3.0 (-7.0 to 12.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	7.6 (-38.6 to 87.2)	2.2 (-41.1 to 78.3)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.0 (-3.1 to 18.1)	0.8 (-7.8 to 12.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.0 (-3.1 to 18.2)	0.8 (-7.8 to 12.6)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.7 (-3.8 to 14.4)	0.2 (-7.8 to 9.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.7 (-3.8 to 14.5)	0.2 (-7.8 to 9.6)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.1 (-13.3 to 133.2)	39.9 (-17.1 to 122.7)
Neonatal disorders	-	-	-	-	29.1 (20.2 to 38.2)	56.0 (39.6 to 74.9)	92.7 (51.1 to 146.5)	56.7 (23.0 to 99.8)
Preterm birth complications	169.3 (120.0 to 237.1)	357.7 (252.6 to 508.6)	110.3 (81.1 to 150.6)	66.5 (43.6 to 97.6)	16.9 (11.5 to 23.2)	33.4 (23.7 to 45.9)	97.1 (53.0 to 164.5)	59.9 (23.9 to 115.1)
Neonatal encephalopathy due to birth asphyxia and trauma	32.4 (16.7 to 69.8)	33.5 (15.3 to 81.9)	0.8 (-29.2 to 34.1)	-18.5 (-42.4 to 8.2)	6.3 (4.2 to 9.3)	6.0 (3.9 to 8.7)	-3.3 (-43.1 to 46.5)	-19.7 (-53.5 to 20.8)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	157.6 (113.9 to 190.1)	152.0 (102.2 to 183.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	156.2 (82.8 to 249.6)	150.6 (78.4 to 242.0)
Hemolytic disease and other neonatal jaundice	5.6 (2.1 to 16.0)	8.0 (3.8 to 15.0)	57.8 (-39.5 to 225.7)	27.4 (-50.8 to 163.8)	2.3 (0.8 to 6.1)	3.3 (1.4 to 6.5)	57.6 (-38.8 to 234.1)	27.6 (-50.1 to 170.8)
Other neonatal disorders	-	-	-	-	3.6 (2.2 to 5.6)	13.3 (7.4 to 20.6)	275.6 (96.2 to 476.9)	205.5 (60.1 to 368.0)
Nutritional deficiencies	-	-	-	-	62.3 (41.0 to 90.9)	71.0 (46.9 to 103.7)	14.0 (6.9 to 22.5)	7.0 (1.4 to 14.6)
Protein-energy malnutrition	0.7 (0.4 to 1.1)	0.9 (0.4 to 1.5)	26.8 (-9.2 to 83.5)	-40.4 (-56.5 to -15.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	26.0 (-24.7 to 109.6)	-40.0 (-63.1 to -2.4)
Iodine deficiency	172.2 (87.5 to 300.7)	140.1 (82.0 to 264.2)	-13.3 (-64.0 to 131.6)	-32.4 (-71.5 to 80.4)	3.1 (1.3 to 6.0)	2.7 (1.2 to 5.2)	-13.6 (-64.2 to 132.7)	-32.4 (-72.0 to 79.7)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron deficiency anemia	2,126.6 (2,039.8 to 2,204.1)	2,660.8 (2,597.0 to 2,718.4)	25.0 (20.5 to 30.6)	8.8 (4.7 to 14.0)	59.2 (39.2 to 86.0)	68.3 (45.0 to 99.8)	15.1 (9.5 to 23.6)	8.5 (3.5 to 16.6)

Appendix Table G.4 - Canada prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Other oral disorders	518.7 (491.4 to 546.9)	697.0 (662.0 to 731.9)	34.4 (24.9 to 44.7)	0.2 (-7.3 to 7.8)	15.1 (9.4 to 22.4)	20.3 (12.9 to 30.5)	33.8 (23.8 to 44.7)	0.2 (-7.3 to 8.3)
Injuries	-	-	-	-	197.5 (150.4 to 252.7)	237.3 (171.4 to 318.9)	19.6 (8.0 to 33.2)	-25.2 (-32.4 to -16.9)
Transport injuries	-	-	-	-	46.8 (35.2 to 60.5)	52.5 (37.9 to 70.4)	11.9 (0.9 to 24.9)	-25.5 (-32.5 to -16.8)
Road injuries	-	-	-	-	41.5 (31.3 to 53.6)	46.1 (33.3 to 61.6)	10.8 (-0.2 to 24.3)	-26.3 (-33.4 to -17.5)
Pedestrian road injuries	-	-	-	-	5.2 (3.9 to 6.7)	7.7 (5.4 to 10.5)	47.6 (31.7 to 64.7)	-3.5 (-13.9 to 7.7)
Cyclist road injuries	-	-	-	-	4.6 (3.4 to 5.9)	6.6 (4.8 to 8.9)	45.3 (27.8 to 68.4)	0.5 (-11.5 to 16.2)
Motorcyclist road injuries	-	-	-	-	5.4 (4.0 to 7.0)	5.7 (4.0 to 7.8)	5.7 (-11.7 to 25.7)	-28.5 (-40.1 to -15.1)
Motor vehicle road injuries	-	-	-	-	25.8 (19.4 to 33.1)	25.3 (18.5 to 33.1)	-2.1 (-10.7 to 8.0)	-35.5 (-41.0 to -29.0)
Other road injuries	-	-	-	-	0.6 (0.4 to 0.8)	0.8 (0.6 to 1.1)	41.1 (22.9 to 61.5)	-7.6 (-19.4 to 5.8)
Other transport injuries	-	-	-	-	5.3 (4.0 to 6.8)	6.4 (4.6 to 8.8)	21.3 (9.5 to 33.1)	-18.2 (-25.9 to -10.7)
Unintentional injuries	-	-	-	-	142.1 (108.6 to 181.7)	175.8 (127.1 to 236.4)	23.2 (10.1 to 37.4)	-24.9 (-32.8 to -16.3)
Falls	-	-	-	-	96.5 (73.7 to 122.9)	128.4 (91.5 to 173.1)	32.2 (15.4 to 52.0)	-23.1 (-32.9 to -11.7)
Drowning	-	-	-	-	0.9 (0.7 to 1.2)	0.9 (0.7 to 1.2)	4.0 (4.5 to 18.5)	-30.1 (-38.7 to -20.8)
Fire, heat, and hot substances	-	-	-	-	4.0 (2.5 to 6.2)	4.3 (2.5 to 6.9)	6.9 (6.5 to 20.2)	-29.5 (-38.1 to -20.7)
Poisonings	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	0.4 (-13.5 to 14.8)	-29.5 (-39.2 to -18.0)
Exposure to mechanical forces	-	-	-	-	30.4 (22.8 to 40.0)	32.1 (22.8 to 43.6)	5.2 (-4.5 to 16.1)	-27.0 (-33.5 to -19.9)
Unintentional firearm injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.5)	-11.6 (-21.6 to 0.5)	-37.9 (-44.3 to -29.9)
Unintentional suffocation	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	70.7 (47.6 to 94.2)	16.5 (1.5 to 31.5)
Other exposure to mechanical forces	-	-	-	-	29.9 (22.4 to 39.3)	31.4 (22.4 to 42.8)	5.0 (-4.7 to 16.0)	-27.1 (-33.6 to -20.0)
Adverse effects of medical treatment	-	-	-	-	2.1 (1.3 to 3.1)	3.4 (2.1 to 5.0)	60.0 (50.0 to 69.2)	4.8 (-1.0 to 10.6)
Animal contact	-	-	-	-	1.1 (0.8 to 1.5)	1.8 (1.2 to 2.5)	53.8 (42.0 to 66.1)	3.4 (-3.9 to 11.5)
Venomous animal contact	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	41.4 (28.1 to 55.5)	-0.7 (-9.8 to 9.5)
Non-venomous animal contact	-	-	-	-	0.9 (0.7 to 1.3)	1.5 (1.0 to 2.1)	56.4 (44.5 to 70.1)	4.2 (-3.7 to 13.1)
Foreign body	-	-	-	-	1.7 (1.2 to 2.4)	1.8 (1.2 to 2.7)	6.3 (-3.5 to 14.5)	-22.4 (-31.1 to -15.5)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.3)	-13.8 (-23.3 to -3.4)	-40.2 (-47.3 to -32.1)
Foreign body in eyes	-	-	-	-	0.6 (0.4 to 0.9)	0.7 (0.4 to 1.0)	7.8 (-1.0 to 15.1)	-17.4 (-26.6 to -11.0)
Foreign body in other body part	-	-	-	-	0.8 (0.5 to 1.1)	0.9 (0.5 to 1.3)	13.0 (0.0 to 23.8)	-19.4 (-30.2 to -10.7)
Other unintentional injuries	-	-	-	-	5.0 (3.6 to 6.7)	2.8 (2.0 to 3.9)	-43.1 (-47.4 to -38.9)	-63.6 (-66.3 to -60.9)
Self-harm and interpersonal violence	-	-	-	-	8.6 (6.5 to 11.1)	9.0 (6.5 to 12.0)	3.5 (-5.6 to 13.3)	-28.9 (-35.0 to -22.3)
Self-harm	-	-	-	-	2.1 (1.5 to 2.8)	2.6 (1.8 to 3.5)	22.4 (10.3 to 37.2)	-17.3 (-25.9 to -7.4)
Interpersonal violence	-	-	-	-	6.5 (5.0 to 8.3)	6.3 (4.6 to 8.6)	-3.0 (-12.7 to 8.6)	-32.8 (-39.3 to -25.1)
Assault by firearm	-	-	-	-	1.5 (1.1 to 2.0)	1.3 (1.0 to 1.8)	-13.5 (-22.4 to -4.3)	-40.6 (-46.6 to -34.2)
Assault by sharp object	-	-	-	-	0.6 (0.4 to 0.8)	0.7 (0.5 to 0.9)	14.5 (4.0 to 26.8)	-21.0 (-28.1 to -12.9)
Assault by other means	-	-	-	-	4.4 (3.3 to 5.6)	4.4 (3.1 to 5.9)	-1.5 (-13.1 to 12.2)	-31.5 (-39.3 to -22.1)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.1 (-36.5 to 76.9)	-9.7 (-50.6 to 45.6)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.5 (-39.6 to 70.5)	-13.1 (-52.8 to 40.5)
Collective violence and legal intervention	-	-	-	-	-	(0.0 to 0.0)	-	-

Appendix Table G.4 - Cape Verde prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
All causes	-	-	-	-	31.9 (23.2 to 41.6)	48.7 (35.6 to 63.4)	52.8 (48.4 to 57.7)	53.8 (-6.4 to -0.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	7.8 (5.4 to 10.8)	8.4 (6.0 to 11.4)	8.5 (2.3 to 15.7)	-13.4 (-18.8 to -6.8)
HIV/AIDS and tuberculosis	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	59.4 (41.5 to 84.7)	-14.4 (-23.5 to -2.3)
Tuberculosis	0.7 (0.6 to 0.7)	1.1 (1.0 to 1.2)	63.1 (53.2 to 75.3)	-14.1 (-18.9 to -8.8)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	63.7 (50.7 to 78.1)	-13.7 (-20.1 to -6.9)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	37.5 (19.1 to 177.6)	38.2 (52.2 to 56.1)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.1 (-76.5 to 73.5)	-64.9 (-87.5 to -12.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.9 (-82.0 to 90.1)	63.7 (-90.3 to 2.0)
HIV/AIDS resulting in other diseases	0.5 (0.3 to 0.7)	0.8 (0.6 to 1.1)	60.2 (2.5 to 205.2)	-0.4 (-35.5 to 80.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	42.6 (-18.1 to 188.4)	-14.9 (51.6 to 65.7)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	1.5 (1.1 to 2.1)	1.4 (0.9 to 1.9)	-11.6 (-24.6 to 2.3)	-26.9 (-37.1 to -17.1)
Diarrheal diseases	4.1 (3.3 to 5.1)	3.5 (2.8 to 4.1)	-16.2 (-36.2 to 9.2)	-14.1 (-33.3 to 9.5)	0.7 (0.4 to 1.0)	0.6 (0.4 to 0.8)	-16.3 (-36.9 to 9.5)	-46.4 (-33.7 to 10.9)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.0 (-52.9 to -6.7)	45.4 (-61.4 to -26.1)
Typhoid fever	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-29.9 (-47.8 to -11.3)	-44.5 (-57.2 to -29.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.8 (-47.9 to -4.4)	-43.3 (-57.0 to -24.6)
Paratyphoid fever	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-13.8 (-34.9 to 13.6)	-29.8 (-46.3 to -8.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.7 (-38.7 to 15.8)	29.5 (-48.3 to -6.7)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-91.4 (-99.8 to 295.0)	92.9 (-99.8 to 204.3)
Lower respiratory infections	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-48.4 (-62.8 to -25.1)	-47.9 (-64.6 to -31.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.0 (-64.0 to -24.3)	-48.0 (-64.7 to -30.4)
Upper respiratory infections	20.7 (18.4 to 22.8)	27.3 (24.8 to 29.5)	31.2 (14.3 to 51.2)	-2.8 (-15.7 to 11.7)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	31.1 (13.7 to 51.0)	-2.8 (-15.7 to 11.7)
Otitis media	7.9 (7.1 to 8.9)	9.6 (8.8 to 10.5)	21.3 (7.9 to 35.7)	-9.7 (-20.0 to 2.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	19.5 (5.8 to 35.9)	-9.3 (-19.3 to 3.7)
Meningitis	-	-	-	-	0.4 (0.3 to 0.6)	0.2 (0.2 to 0.3)	-41.0 (-54.4 to -22.6)	-59.1 (-68.4 to -48.0)
Pneumococcal meningitis	1.7 (1.1 to 2.6)	1.1 (0.6 to 1.6)	-38.1 (-59.3 to -10.1)	-59.0 (-73.0 to -42.3)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-46.0 (-64.0 to -15.1)	-43.2 (-75.6 to -43.9)
H influenzae type B meningitis	0.5 (0.2 to 1.0)	0.3 (0.1 to 0.6)	-42.9 (-62.8 to -7.5)	-61.2 (-74.2 to -37.8)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-40.8 (-61.8 to 13.9)	-57.2 (-72.3 to -19.2)
Meningococcal meningitis	0.7 (0.2 to 1.4)	0.5 (0.2 to 1.0)	-36.4 (-57.2 to -7.8)	-58.9 (-71.4 to -39.4)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-34.8 (-57.9 to 2.1)	-56.3 (-70.5 to -34.1)
Other meningitis	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-36.1 (-54.7 to -13.8)	-54.3 (-67.0 to -38.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-34.1 (-50.2 to -9.9)	-51.4 (-64.0 to -33.6)
Encephalitis	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	25.3 (-1.8 to 45.5)	-82.2 (-35.6 to -5.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.6 (9.3 to 56.1)	-13.7 (-26.6 to 2.0)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.9 (-97.1 to 1,255.3)	-43.0 (-96.0 to 792.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.9 (-97.2 to 1,271.1)	-43.0 (-96.1 to 795.4)
Whooping cough	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-79.1 (-80.8 to -77.3)	-73.1 (-75.2 to -70.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-79.0 (-86.4 to -68.4)	-72.9 (-82.4 to -59.4)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-73.2 (-91.2 to -51.8)	-80.6 (-93.7 to -64.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-60.2 (-85.5 to -14.4)	-68.4 (-88.6 to -35.0)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-73.5 (-77.0 to -69.7)	-65.8 (-71.1 to -62.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-73.1 (-81.3 to -57.9)	-66.4 (-76.5 to -47.8)
Varicella and herpes zoster	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.4)	46.2 (29.2 to 67.7)	5.3 (-12.6 to 28.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.6 (30.6 to 150.4)	5.8 (-23.9 to 52.6)
Neglected tropical diseases and malaria	-	-	-	-	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.8)	6.0 (-26.4 to 64.6)	-15.3 (-46.3 to 33.9)
Malaria	0.4 (0.3 to 0.6)	0.2 (0.1 to 0.3)	-60.2 (-75.1 to -26.4)	-71.2 (-82.8 to -41.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.5 (-68.7 to 20.9)	-50.8 (-70.7 to -3.2)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.5 (-18.8 to 241.3)	26.5 (-42.6 to 145.9)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.3 (-20.4 to 77.8)	-2.1 (-28.5 to 44.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.3 (-20.4 to 77.9)	-2.1 (-28.6 to 44.6)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	79.1 (-10.4 to 221.6)	27.8 (-38.3 to 127.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.3 (-19.1 to 246.1)	26.6 (-42.8 to 147.0)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.6 (0.3 to 0.9)	0.8 (0.3 to 1.5)	34.5 (-49.6 to 211.4)	-26.8 (-72.6 to 68.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.5)	43.3 (-46.6 to 229.2)	-22.2 (-70.8 to 82.6)
Cystic echinococcosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-21.9 (-29.2 to -7.1)	-44.9 (-50.5 to -32.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.9 (-37.8 to 4.7)	-44.3 (-54.6 to -26.6)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.3)	585.5 (577.2 to 595.2)	386.1 (380.2 to 393.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	549.3 (446.1 to 671.4)	356.6 (285.4 to 435.5)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-89.3 to 133.1)	0.0 (0.0 to 0.0)	14.2 (-87.5 to 180.5)	5.3 (-89.3 to 133.5)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Ascariasis	0.2 (0.1 to 0.3)	-	88.6 (-5.3 to 327.4)	3.2 (-48.3 to 133.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Trichuriasis	4.3 (3.2 to 5.8)	5.8 (3.4 to 9.5)	31.8 (-26.6 to 145.4)	-11.8 (-54.3 to 72.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.5 (-83.7 to 880.3)	-13.9 (-90.3 to 627.2)
Hookworm disease	0.8 (0.6 to 1.1)	1.2 (0.7 to 2.0)	43.3 (-16.0 to 152.5)	5.5 (-45.8 to 75.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.9 (-32.4 to 85.7)	-21.9 (-56.4 to 40.0)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	7.2 (5.3 to 9.3)	6.5 (6.0 to 7.0)	-11.0 (-31.0 to 22.7)	-11.1 (-30.2 to 19.5)	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-17.5 (-28.1 to 25.2)	-12.2 (-23.3 to 33.6)
Maternal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	22.2 (2.9 to 41.7)	-36.1 (-46.1 to -26.1)
Maternal hemorrhage	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-2.1 (-28.7 to 35.0)	-50.4 (-63.0 to -32.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.5 (-54.2 to 65.3)	-97.4 (-76.6 to -17.9)
Maternal sepsis and other maternal infections	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-79.7 (-71.1 to -27.4)	-79.7 (-88.2 to -69.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.6 (-81.6 to -18.0)	-80.5 (-89.6 to -65.4)
Maternal hypertensive disorders	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-30.5 (-39.9 to -20.6)	-65.5 (-72.1 to -59.1)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.2)	-30.5 (-46.3 to -10.9)	-65.5 (-74.2 to -55.2)
Obstructed labor	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.4)	26.3 (11.8 to 42.5)	-33.6 (-41.7 to -25.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	26.5 (6.0 to 46.8)	-33.4 (-43.7 to -23.1)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.6 (-38.6 to 157.5)	-49.5 (-72.0 to 1.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.6 (-38.7 to 157.5)	-49.5 (-72.0 to 2.1)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.3)	27.5 (8.2 to 411.9)	-34.3 (-56.3 to 4.3)
Neonatal disorders	-	-	-	-	0.6 (0.4 to 0.8)	1.4 (0.9 to 1.9)	146.2 (84.4 to 219.7)	90.5 (43.0 to 146.9)
Preterm birth complications	2.6 (1.8 to 3.6)	7.4 (5.4 to 10.0)	185.1 (135.7 to 257.0)	109.3 (73.4 to 161.0)	0.3 (0.2 to 0.4)	0.9 (0.6 to 1.2)	194.6 (113.8 to 331.8)	124.3 (64.0 to 226.9)
Neonatal encephalopathy due to birth asphyxia and trauma	1.4 (0.3 to 3.9)	1.5 (0.6 to 4.0)	21.9 (-16.4 to 126.3)	-10.8 (-39.6 to 69.2)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	81.5 (13.3 to 214.0)	44.5 (-10.7 to 151.5)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.3 (26.5 to 32.5)	78.9 (73.7 to 82.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	30.3 (17.2 to 47.5)	79.0 (61.0 to 102.6)
Hemolytic disease and other neonatal jaundice	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	67.4 (-29.9 to 271.9)	29.6 (-47.1 to 178.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	66.9 (-30.5 to 272.3)	28.3 (-47.1 to 176.8)
Other neonatal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	137.2 (8.2 to 411.9)	81.7 (-17.5 to 295.0)
Nutritional deficiencies	-	-	-	-	4.5 (3.0 to 6.5)	5.0 (2.9 to 6.3)	-11.1 (-9.7 to 0.2)	-21.1 (-25.2 to -16.3)
Protein-energy malnutrition	1.2 (0.7 to 1.9)	1.1 (0.6 to 1.1)	-6.0 (-59.7 to 118.6)	11.6 (-48.0 to 143.6)	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.3)	5.6 (-59.7 to 121.5)	22.5 (-48.8 to 148.9)
Iodine deficiency	16.9 (10.4 to 22.8)	20.9 (15.3 to 26.4)	22.5 (-19.8 to 106.9)	-28.6 (-53.6 to 30.9)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	21.9 (-20.3 to 103.5)	-28.5 (-53.7 to 33.4)
Vitamin A deficiency	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-49.8 (-60.9 to -39.1)	-61.4 (-68.9 to -51.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.4 (-62.5 to -33.6)	-62.6 (-70.8 to -52.0)

Appendix Table G.4 - Cape Verde prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	108.8 (106.8 to 110.7)	113.2 (112.5 to 114.0)	4.1 (2.1 to 6.0)	-8.2 (-19.4 to -17.0)	4.1 (2.7 to 5.8)	3.8 (2.5 to 5.5)	-6.9 (-9.6 to -4.9)	-21.1 (-22.9 to -19.7)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-37.3 to 753.2)	0.0 (-21.7 to 879.3)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	0.3 (-3.6 to 29.6)	-16.4 (-24.2 to -5.2)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	0.1 (27.0 to 102.5)	-13.2 (-29.5 to 3.9)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.1 (-15.1 to 34.3)	-42.3 (-53.3 to -30.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-22.7 to 45.5)	0.0 (-57.4 to -25.4)
Chlamydial infection	5.0 (3.8 to 6.4)	8.1 (4.1 to 10.8)	67.6 (-27.3 to 140.6)	-9.6 (58.3 to 29.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (-11.3 to 192.4)	-1.7 (-5.1 to 60.0)
Gonococcal infection	1.5 (1.1 to 1.9)	2.7 (1.8 to 3.7)	80.5 (16.0 to 205.6)	-0.3 (-32.3 to 60.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (14.1 to 179.0)	-1.0 (-32.4 to 48.7)
Trichomoniasis	4.8 (2.6 to 7.1)	6.6 (3.6 to 12.3)	35.6 (-34.6 to 187.2)	-24.0 (59.4 to 40.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-45.2 to 185.6)	-28.6 (-65.4 to 39.9)
Genital herpes	54.4 (50.0 to 58.9)	94.5 (86.0 to 102.2)	73.5 (54.6 to 95.9)	-10.1 (-20.1 to 2.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (50.0 to 96.3)	-10.1 (-20.7 to 2.7)
Other sexually transmitted diseases	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	64.6 (39.7 to 99.5)	-29.3 (-40.5 to -15.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (6.2 to 132.2)	-25.3 (-47.0 to 6.2)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.1 (-6.1 to 38.0)	-34.0 (-48.0 to -17.3)
Hepatitis A	0.6 (0.6 to 0.6)	0.6 (0.6 to 0.6)	3.7 (1.6 to 5.9)	-6.3 (-6.5 to -6.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (22.4 to 55.1)	1.0 (-9.7 to 12.9)
Hepatitis B	67.1 (56.0 to 80.0)	62.8 (53.5 to 71.6)	-6.1 (-23.4 to 17.5)	-41.5 (-51.7 to -26.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-25.2 to 39.9)	-43.4 (-60.2 to -22.4)
Hepatitis C	22.5 (20.3 to 24.7)	29.4 (25.8 to 32.9)	30.2 (12.1 to 53.4)	-22.5 (-32.5 to -10.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-20.6 to 44.7)	-25.5 (-45.2 to 4.3)
Hepatitis E	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	29.5 (-21.3 to 128.8)	-22.5 (52.8 to 35.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-23.6 to 139.6)	-22.9 (-54.7 to 37.6)
Leprosy	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	25.7 (-44.0 to 555.6)	-27.6 (-66.7 to 294.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-45.5 to 728.8)	-26.6 (-65.5 to 391.5)
Other infectious diseases	5.1 (3.8 to 6.5)	4.7 (4.2 to 5.2)	-8.1 (-16.0 to 9.4)	-12.7 (-20.4 to -0.8)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	0.2 (-20.4 to 18.9)	-9.6 (-18.8 to 20.8)
Non-communicable diseases	-	-	-	-	22.9 (16.8 to 29.9)	38.5 (28.5 to 50.4)	69.6 (64.5 to 75.3)	0.2 (-3.2 to 3.0)
Neoplasms	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	0.3 (68.5 to 154.9)	106.6 (-3.3 to 47.9)
Esophageal cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	77.2 (16.4 to 162.2)	6.4 (-29.3 to 58.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (16.1 to 144.7)	0.9 (-30.7 to 46.0)
Stomach cancer	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	66.5 (14.9 to 139.7)	-3.1 (-33.5 to 39.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (8.7 to 121.0)	-9.5 (-37.5 to 28.7)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	82.1 (-16.7 to 267.4)	-2.2 (55.8 to 99.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-13.9 to 240.6)	-13.7 (-54.6 to 85.7)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	339.5 (123.7 to 1,213.7)	153.1 (28.5 to 670.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (108.4 to 1,078.8)	129.4 (22.4 to 569.3)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.1 (-43.1 to 87.0)	-44.4 (-67.9 to 4.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-4.1 to 66.9)	-44.9 (-67.1 to -5.7)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.1 (-51.4 to 68.7)	-50.2 (-73.6 to -3.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-48.3 to 45.1)	-52.1 (-71.6 to -15.5)
Larynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	47.4 (-13.1 to 140.8)	-9.9 (48.0 to 47.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-15.5 to 149.9)	-11.4 (-49.0 to 51.1)
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	69.4 (21.9 to 136.3)	3.2 (-26.1 to 44.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (12.3 to 128.6)	-2.6 (-32.4 to 38.8)
Breast cancer	0.7 (0.6 to 0.8)	1.4 (1.2 to 1.6)	96.2 (69.0 to 131.8)	9.7 (-4.9 to 30.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	0.1 (50.3 to 140.8)	1.3 (-17.0 to 30.9)
Cervical cancer	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	53.8 (-16.8 to 122.6)	30.8 (56.3 to 13.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-16.5 to 120.1)	-90.1 (-56.1 to 14.0)
Uterine cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	125.7 (21.6 to 322.8)	30.1 (-29.0 to 138.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (14.3 to 306.8)	26.6 (-33.9 to 129.4)
Prostate cancer	0.1 (0.1 to 0.2)	0.6 (0.3 to 1.0)	303.5 (122.5 to 679.6)	150.7 (40.0 to 385.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	0.1 (91.7 to 567.8)	108.6 (19.7 to 302.4)
Colon and rectum cancer	0.2 (0.2 to 0.2)	0.5 (0.4 to 0.6)	145.8 (100.7 to 202.4)	41.0 (15.3 to 73.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (90.6 to 189.7)	33.4 (8.9 to 64.6)
Lip and oral cavity cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.2 (16.2 to 187.7)	5.1 (-32.4 to 60.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (13.4 to 179.1)	1.1 (-37.3 to 54.4)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.3 (-13.5 to 143.6)	-22.0 (52.2 to 29.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-12.9 to 125.8)	-26.1 (-53.1 to 18.2)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.1 (-11.4 to 154.4)	-16.5 (51.8 to 39.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-8.8 to 136.8)	-19.0 (-50.6 to 30.2)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.7 (-11.9 to 207.8)	-5.7 (49.2 to 81.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-15.7 to 173.4)	-13.9 (-51.3 to 61.0)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	219.0 (115.7 to 371.7)	84.1 (25.3 to 172.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (103.9 to 318.9)	70.4 (15.3 to 142.7)
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.9 (40.0 to 211.0)	14.9 (-22.7 to 73.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (31.6 to 203.8)	30.3 (-28.3 to 70.0)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	126.5 (42.8 to 264.3)	25.6 (-21.6 to 103.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (93.9 to 381.9)	62.4 (3.4 to 159.3)
Ovarian cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	187.6 (66.7 to 372.5)	57.1 (-7.6 to 162.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (55.4 to 386.2)	50.3 (-16.9 to 173.1)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	211.0 (65.2 to 542.4)	59.9 (-13.4 to 229.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (45.1 to 502.5)	48.9 (-24.6 to 200.1)
Kidney cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.9 (2.2 to 200.4)	39.3 (-11.0 to 106.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (4.8 to 200.7)	23.2 (-18.2 to 89.8)
Bladder cancer	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	182.2 (120.5 to 261.3)	56.3 (21.8 to 101.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (122.2 to 276.5)	58.9 (23.7 to 109.9)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	130.4 (44.0 to 260.9)	66.8 (8.3 to 138.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (48.1 to 257.7)	57.1 (1.7 to 117.8)
Thyroid cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	116.5 (27.3 to 282.5)	18.0 (-32.7 to 111.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (17.5 to 264.3)	10.9 (-35.4 to 102.1)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.0 (-4.4 to 121.1)	16.3 (46.5 to 28.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (7.1 to 118.7)	23.2 (-49.0 to 25.7)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	95.4 (22.0 to 223.0)	46.3 (-7.8 to 135.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (23.2 to 210.2)	36.8 (-12.1 to 113.2)
Non-Hodgkin lymphoma	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	146.4 (57.3 to 319.9)	78.1 (19.4 to 189.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (55.7 to 299.5)	64.4 (10.2 to 163.7)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	139.6 (52.9 to 303.2)	48.4 (-9.2 to 146.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (36.8 to 267.2)	36.7 (-18.5 to 128.1)
Leukemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	99.5 (19.6 to 233.6)	63.3 (8.2 to 144.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (38.0 to 301.8)	40.8 (-2.5 to 105.3)
Other neoplasms	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	164.8 (64.2 to 314.5)	106.2 (34.3 to 191.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (69.7 to 285.4)	80.7 (20.4 to 155.7)
Cardiovascular diseases	-	-	-	-	0.8 (0.5 to 1.1)	1.4 (0.9 to 1.9)	1.4 (40.4 to 115.0)	3.7 (-17.6 to 26.8)
Rheumatic heart disease	4.1 (3.1 to 5.1)	6.0 (4.8 to 7.6)	45.5 (10.2 to 100.3)	-11.3 (-30.6 to 17.0)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	0.3 (13.8 to 109.7)	-7.5 (-29.0 to 24.0)
Ischemic heart disease	3.7 (3.0 to 4.8)	4.5 (3.9 to 5.1)	23.4 (-9.2 to 55.1)	-22.7 (-43.0 to -2.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	0.5 (-36.3 to 43.8)	44.9 (-58.4 to -5.5)
Cerebrovascular disease	-	-	-	-	0.1 (0.0 to 0.0)	0.1 (0.0 to 0.1)	0.1 (36.0 to 116.6)	0.1 (-23.3 to 23.9)
Ischemic stroke	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	74.8 (38.1 to 117.8)	0.9 (-20.8 to 26.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (36.4 to 120.2)	1.4 (-22.4 to 27.4)
Hemorrhagic stroke	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	70.3 (30.6 to 119.9)	-4.8 (-28.2 to 23.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (30.9 to 124.9)	-4.3 (-29.6 to 26.1)
Hypertensive heart disease	0.9 (0.6 to 1.1)	1.6 (1.0 to 2.1)	79.5 (13.7 to 300.9)	0.6 (-38.0 to 58.7)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	0.2 (14.2 to 189.7)	0.0 (-37.4 to 59.5)
Cardiomyopathy and myocarditis	0.5 (0.3 to 0.7)	0.9 (0.7 to 1.2)	100.2 (21.2 to 208.9)	16.1 (-33.2 to 84.2)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	0.1 (22.4 to 209.9)	16.8 (-32.2 to 86.6)
Atrial fibrillation and flutter	0.1 (0.1 to 0.1)	0.5 (0.3 to 0.7)	437.6 (253.7 to 800.9)	173.1 (75.2 to 367.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (255.4 to 797.9)	437.7 (78.0 to 367.8)
Peripheral vascular disease	7.5 (5.9 to 9.2)	11.5 (8.0 to 15.4)	52.2 (1.9 to 132.5)	-11.2 (-40.4 to 34.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-52.9 to 269.2)	-21.8 (-75.3 to 85.2)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	45.7 (-12.8 to 134.2)	-4.4 (-48.1 to 66.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-14.9 to 172.2)	-0.7 (-50.9 to 83.4)
Other cardiovascular and circulatory diseases	2.9 (1.9 to 4.2)	7.1 (3.7 to 10.3)	141.3 (27.2 to 318.1)	42.1 (-28.4 to 148.9)	0.2 (0.1 to 0.3)	0.5 (0.2 to 0.8)	0.2 (26.4 to 320.3)	40.4 (-29.0 to 151.0)
Chronic respiratory diseases	-	-	-	-	1.5 (1.0 to 2.1)	2.5 (1.6 to 3.4)	63.8 (42.9 to 88.1)	-6.3 (-19.2 to 6.9)
Chronic obstructive pulmonary disease	12.1 (11.5 to 12.7)	21.9 (20.8 to 23.0)	81.0 (75.7 to 86.2)	-0.2 (-3.1 to 2.9)	1.0 (0.6 to 1.4)	1.8 (1.1 to 2.5)	80.0 (55.6 to 111.5)	-0.6 (-14.3 to 16.4)

Appendix Table G.4 - Cape Verde prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.7 (69.0 to 83.3)	-3.2 (-6.9 to 0.5)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.5 (56.8 to 75.1)	-8.6 (-13.1 to -3.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.6 (56.5 to 75.3)	-8.6 (-13.3 to -3.5)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.4 (76.5 to 91.4)	1.6 (-2.6 to 5.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.7 (77.3 to 94.3)	2.3 (-2.2 to 7.2)
Asthma	6.7 (5.0 to 8.4)	9.5 (7.3 to 12.2)	39.9 (-5.7 to 114.4)	-9.9 (-32.2 to 32.6)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	38.4 (-6.7 to 116.4)	-7.7 (-33.1 to 31.8)
Interstitial lung disease and pulmonary sarcoidosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.1 (27.8 to 172.7)	7.0 (-23.7 to 52.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.2 (28.4 to 170.4)	7.0 (-23.3 to 50.6)
Other chronic respiratory diseases	-	-	-	-	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.5)	22.5 (-18.3 to 76.5)	-32.4 (-55.3 to -2.9)
Cirrhosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.0 (21.2 to 64.0)	-13.9 (-24.8 to -1.7)
Cirrhosis due to hepatitis B	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	5.6 (-36.9 to 55.1)	-34.3 (-62.0 to -2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.0 (-39.1 to 60.6)	-34.8 (-63.0 to -9.9)
Cirrhosis due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	96.9 (-10.3 to 263.4)	16.0 (-51.5 to 115.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.1 (-11.1 to 281.5)	15.2 (-51.6 to 119.5)
Cirrhosis due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	43.6 (2.2 to 102.4)	-20.3 (-43.1 to 12.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.4 (-4.1 to 119.5)	20.1 (-45.9 to 20.2)
Cirrhosis due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.5 (4.1 to 117.7)	18.5 (-20.1 to 81.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.9 (-9.0 to 152.8)	18.6 (-28.4 to 87.7)
Digestive diseases	-	-	-	-	0.5 (0.3 to 0.6)	0.7 (0.5 to 1.0)	53.9 (40.6 to 68.5)	5.1 (-12.8 to 3.4)
Peptic ulcer disease	2.2 (1.9 to 2.3)	2.3 (2.0 to 2.5)	5.1 (-5.1 to 16.4)	-41.6 (-46.9 to -34.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	20.4 (-0.2 to 43.0)	-33.0 (-44.1 to -22.0)
Gastritis and duodenitis	4.8 (4.5 to 5.1)	6.3 (5.8 to 6.8)	32.6 (20.5 to 44.9)	-8.8 (-18.1 to 1.1)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	31.8 (17.4 to 49.2)	-5.9 (-14.0 to 7.4)
Appendicitis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	94.5 (21.7 to 189.5)	14.2 (-26.1 to 67.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.9 (18.1 to 214.4)	13.9 (-28.2 to 80.9)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.3 (12.2 to 89.1)	0.9 (-11.0 to 16.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.9 (0.9 to 101.9)	2.2 (-24.1 to 31.4)
Inguinal, femoral, and abdominal hernia	1.1 (1.0 to 1.3)	1.4 (1.3 to 1.6)	28.0 (6.3 to 55.4)	-11.7 (-26.8 to 8.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.1 (4.7 to 54.7)	-11.6 (-26.6 to 8.7)
Inflammatory bowel disease	0.3 (0.3 to 0.3)	0.8 (0.7 to 0.8)	136.4 (123.1 to 150.5)	27.6 (20.9 to 34.8)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	137.3 (115.5 to 159.7)	28.0 (17.5 to 38.5)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.5 (50.0 to 255.0)	13.9 (-24.1 to 102.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.8 (28.8 to 294.5)	17.3 (-35.3 to 136.5)
Gallbladder and biliary diseases	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	89.2 (54.5 to 119.9)	9.4 (-12.7 to 28.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.7 (53.3 to 124.7)	10.3 (-14.0 to 31.4)
Pancreatitis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	110.9 (94.3 to 127.5)	12.5 (3.4 to 21.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	110.9 (77.4 to 151.6)	13.1 (-4.8 to 32.4)
Other digestive diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	47.2 (0.6 to 96.7)	-9.3 (-37.6 to 21.5)
Neurological disorders	-	-	-	-	1.6 (1.1 to 2.2)	2.9 (1.9 to 3.9)	76.8 (50.4 to 104.8)	2.0 (-12.0 to 16.6)
Alzheimer disease and other dementias	0.9 (0.7 to 1.0)	1.7 (1.4 to 1.9)	94.1 (60.6 to 136.0)	2.2 (-15.2 to 24.7)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	99.1 (64.7 to 143.0)	2.4 (-15.1 to 26.7)
Parkinson disease	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	68.4 (55.9 to 81.7)	0.1 (-6.1 to 5.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.7 (37.8 to 107.7)	0.6 (-16.9 to 21.8)
Epilepsy	0.8 (0.4 to 1.3)	1.1 (0.6 to 1.8)	35.6 (-36.8 to 183.8)	-5.6 (-56.1 to 101.9)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.6)	44.4 (-35.8 to 206.5)	-0.1 (-55.1 to 111.7)
Multiple sclerosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.2 (77.9 to 150.9)	6.7 (-9.1 to 26.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.9 (70.1 to 163.9)	6.2 (-14.1 to 32.5)
Migraine	23.9 (21.8 to 26.0)	38.6 (34.9 to 41.6)	61.2 (43.3 to 79.4)	1.3 (-14.9 to 6.1)	4.8 (0.5 to 1.1)	6.0 (0.8 to 2.0)	61.0 (42.5 to 82.3)	4.6 (-14.7 to 7.5)
Tension-type headache	41.9 (38.5 to 45.3)	75.6 (70.2 to 81.1)	80.9 (61.2 to 100.8)	1.8 (-7.6 to 12.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	80.6 (60.8 to 101.4)	1.9 (-8.1 to 12.7)
Medication overuse headache	1.5 (1.0 to 2.1)	4.3 (2.8 to 5.9)	179.7 (105.5 to 267.7)	51.8 (10.3 to 93.2)	0.2 (0.1 to 0.4)	0.7 (0.4 to 1.1)	181.5 (106.9 to 272.9)	52.0 (10.3 to 94.9)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.5 (4.4 to 97.4)	-6.7 (-29.8 to 27.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	6.8 (-33.4 to 76.9)	-44.8 (-65.9 to -8.0)
Mental and substance use disorders	-	-	-	-	7.2 (5.0 to 9.9)	12.1 (8.3 to 16.7)	67.3 (60.1 to 74.6)	-0.8 (-6.0 to 4.2)
Schizophrenia	0.7 (0.6 to 0.7)	1.3 (1.2 to 1.4)	98.1 (88.7 to 108.3)	-0.4 (-4.4 to 4.6)	0.4 (0.3 to 0.5)	0.8 (0.6 to 1.0)	99.3 (85.8 to 114.0)	0.2 (-5.9 to 7.0)
Alcohol use disorders	1.6 (1.5 to 1.7)	3.4 (3.1 to 3.6)	109.4 (100.5 to 121.7)	17.8 (13.1 to 24.0)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	113.1 (98.9 to 130.6)	18.7 (11.7 to 27.5)
Drug use disorders	-	-	-	-	0.4 (0.2 to 0.5)	0.7 (0.5 to 1.0)	104.3 (78.8 to 133.3)	4.7 (-6.0 to 17.3)
Opioid use disorders	0.5 (0.3 to 0.7)	1.1 (0.8 to 1.6)	147.6 (108.7 to 200.3)	13.6 (-0.9 to 31.0)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	148.4 (105.3 to 201.2)	13.8 (-1.6 to 33.8)
Cocaine use disorders	0.1 (0.1 to 0.1)	0.3 (0.3 to 0.4)	112.4 (66.4 to 187.1)	6.3 (-11.2 to 32.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	113.1 (55.0 to 193.3)	7.1 (-16.5 to 41.4)
Amphetamine use disorders	0.5 (0.4 to 0.5)	0.7 (0.6 to 0.7)	36.0 (20.7 to 52.0)	-19.0 (-27.3 to -10.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	36.1 (12.0 to 64.3)	-18.7 (-32.3 to -3.4)
Cannabis use disorders	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	73.1 (69.2 to 77.4)	1.7 (1.3 to 2.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.3 (37.3 to 119.6)	2.0 (-16.9 to 25.2)
Other drug use disorders	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	55.2 (12.5 to 113.5)	-10.5 (-34.9 to 22.6)
Depressive disorders	-	-	-	-	3.3 (2.0 to 5.2)	5.6 (3.3 to 8.9)	69.8 (56.1 to 83.7)	3.1 (-11.7 to 8.4)
Major depressive disorder	14.5 (9.6 to 19.7)	24.4 (15.2 to 33.4)	68.0 (52.5 to 83.6)	-2.2 (-13.1 to 9.6)	3.0 (1.7 to 4.8)	5.0 (2.8 to 8.2)	68.2 (52.7 to 83.9)	-2.0 (-13.0 to 9.9)
Dysthymia	3.4 (2.7 to 4.1)	6.2 (5.0 to 7.4)	85.0 (78.3 to 93.1)	-2.1 (-3.1 to -1.4)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	85.2 (77.2 to 94.6)	-2.0 (-4.6 to 0.6)
Bipolar disorder	1.9 (1.6 to 2.1)	3.4 (3.0 to 3.9)	84.1 (73.4 to 96.6)	-1.5 (-5.8 to 3.8)	0.4 (0.2 to 0.6)	0.7 (0.4 to 1.1)	84.1 (71.2 to 100.6)	-1.3 (-7.1 to 6.0)
Anxiety disorders	8.1 (6.7 to 9.6)	12.8 (10.6 to 15.2)	58.1 (51.8 to 67.0)	1.2 (-1.8 to -0.4)	3.3 (0.5 to 1.1)	5.6 (0.8 to 1.7)	69.8 (49.8 to 68.8)	2.1 (-3.9 to 2.3)
Eating disorders	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	60.0 (46.0 to 73.8)	4.4 (-11.9 to 3.9)
Anorexia nervosa	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	57.8 (39.6 to 75.3)	-1.7 (-12.3 to 9.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.4 (22.6 to 106.0)	-1.7 (-23.8 to 26.9)
Bulimia nervosa	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.8)	60.3 (55.4 to 64.1)	-5.0 (-6.7 to -3.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	60.1 (45.7 to 76.0)	-4.9 (-12.8 to 4.2)
Autistic spectrum disorders	-	-	-	-	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.8)	45.2 (38.7 to 50.7)	3.6 (0.4 to 7.2)
Autism	1.1 (1.0 to 1.1)	1.5 (1.5 to 1.6)	46.0 (44.8 to 47.2)	3.1 (3.0 to 3.3)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	45.5 (37.7 to 53.8)	3.3 (-1.6 to 8.1)
Asperger syndrome	1.5 (1.4 to 1.6)	2.2 (2.1 to 2.3)	45.4 (43.8 to 47.3)	4.1 (3.9 to 4.3)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	45.1 (38.6 to 52.6)	4.3 (0.3 to 7.9)
Attention-deficit/hyperactivity disorder	2.6 (2.4 to 2.8)	3.2 (3.0 to 3.5)	23.8 (22.9 to 24.2)	0.2 (0.1 to 0.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	23.6 (14.9 to 33.2)	0.3 (-7.1 to 7.9)
Conduct disorder	3.8 (3.6 to 4.0)	4.1 (4.5 to 5.1)	25.2 (24.4 to 27.4)	0.5 (-0.2 to 0.0)	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.8)	26.0 (28.9 to 32.3)	0.1 (-3.8 to 5.1)
Idiopathic intellectual disability	10.6 (7.9 to 13.3)	12.9 (10.1 to 16.4)	22.7 (4.0 to 44.7)	-12.0 (-25.2 to 4.5)	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.9)	22.8 (37.3 to 45.2)	-11.9 (-25.7 to 5.0)
Other mental and substance use disorders	4.1 (3.8 to 4.4)	8.1 (7.6 to 8.6)	98.7 (95.8 to 102.0)	2.9 (2.0 to 3.8)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	99.3 (90.5 to 108.4)	3.2 (-0.8 to 7.0)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	2.1 (1.5 to 2.8)	4.0 (2.8 to 5.4)	88.3 (73.1 to 105.5)	15.8 (5.9 to 27.0)
Diabetes mellitus	6.8 (5.6 to 8.2)	21.1 (17.9 to 24.1)	209.5 (148.4 to 293.6)	65.9 (32.5 to 114.6)	0.5 (0.3 to 0.6)	1.6 (1.0 to 2.2)	203.9 (146.0 to 281.2)	63.8 (-3.3 to 108.2)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.2 (-24.4 to -12.4)	-29.7 (-33.4 to -25.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.2 (-24.4 to -12.3)	-29.7 (-33.4 to -25.2)
Chronic kidney disease	-	-	-	-	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.3)	64.6 (47.9 to 82.8)	-0.2 (-8.5 to 10.2)
Chronic kidney disease due to diabetes mellitus	3.4 (2.3 to 5.2)	6.1 (4.3 to 9.3)	83.0 (15.5 to 164.3)	6.5 (-36.4 to 48.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	89.5 (19.2 to 157.3)	5.9 (-34.7 to 45.1)
Chronic kidney disease due to hypertension	15.9 (9.7 to 27.4)	23.0 (14.8 to 33.6)	46.5 (7.6 to 96.2)	0.7 (-25.4 to 38.2)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.5)	77.2 (42.8 to 129.7)	0.1 (-18.9 to 29.4)
Chronic kidney disease due to glomerulonephritis	14.0 (9.3 to 19.6)	23.8 (16.7 to 34.7)	71.1 (30.5 to 125.0)	5.0 (-19.5 to 35.9)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	58.3 (23.4 to 99.4)	3.5 (-19.6 to 30.9)
Chronic kidney disease due to other causes	10.9 (6.9 to 18.2)	14.7 (9.9 to 23.1)	37.0 (2.3 to 73.1)	-6.1 (-27.8 to 17.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	43.9 (16.1 to 78.3)	-7.7 (-29.0 to 17.3)
Urinary diseases and male infertility	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	64.1 (47.7 to 86.6)	-1.6 (-10.8 to 10.1)

Appendix Table G.4 - Cape Verde prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	63.8 (52.1 to 80.3)	-3.1 to 12.9	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.1 (31.2 to 106.6)	4.1 (-14.4 to 27.6)
Urolithiasis	0.9 (0.7 to 1.2)	1.5 (1.1 to 1.9)	63.8 (43.8 to 85.9)	-9.4	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.8 (70.6 to 119.0)	4.6 (-5.6 to 16.0)
Benign prostatic hyperplasia	3.0 (2.7 to 3.2)	4.4 (4.1 to 4.8)	48.7 (33.2 to 68.2)	-5.4	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	48.3 (32.6 to 68.6)	-5.1 (-15.5 to 7.8)
Male infertility due to other causes	2.8 (2.1 to 3.6)	6.9 (5.5 to 8.4)	147.7 (74.3 to 253.2)	24.2	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	141.2 (72.2 to 248.3)	23.5 (-11.9 to 77.9)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.4 (44.6 to 286.7)	27.3 (-19.3 to 114.0)
Gynecological diseases	-	-	-	-	0.4 (0.2 to 0.6)	0.7 (0.5 to 1.0)	90.5 (63.7 to 123.0)	-12.4 (-22.9 to 1.6)
Uterine fibroids	4.6 (4.1 to 5.0)	9.7 (8.8 to 10.5)	113.4 (109.6 to 117.1)	-16.9	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	77.4 (60.4 to 89.1)	-25.0 (-31.7 to -20.8)
Polycystic ovarian syndrome	4.5 (4.0 to 5.0)	8.6 (7.8 to 9.6)	92.8 (65.7 to 127.3)	-13.4	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	93.4 (63.8 to 128.0)	-12.4 (-23.8 to 1.1)
Female infertility due to other causes	2.9 (1.7 to 4.2)	5.7 (3.1 to 8.3)	102.5 (-11.0 to 269.8)	-17.2	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	101.4 (-10.7 to 277.5)	-16.1 (-63.8 to 51.4)
Endometriosis	0.4 (0.4 to 0.5)	0.8 (0.7 to 0.9)	78.2 (42.6 to 131.0)	-21.1	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	78.1 (40.1 to 143.3)	22.0 (-37.8 to 4.0)
Genital prolapse	12.1 (10.4 to 13.9)	21.8 (18.9 to 24.8)	78.3 (47.1 to 122.9)	-6.8	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	78.3 (45.9 to 124.5)	-6.8 (-22.1 to 13.4)
Premenstrual syndrome	12.4 (9.1 to 16.2)	28.3 (19.8 to 37.4)	128.3 (44.9 to 247.4)	13.0	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	129.1 (44.4 to 250.5)	13.5 (-26.4 to 75.8)
Other gynecological diseases	1.3 (1.1 to 1.6)	1.9 (1.7 to 2.2)	48.2 (13.3 to 92.8)	-26.1	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	39.8 (3.3 to 108.0)	-30.2 (-48.4 to 4.9)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-1.8 (-10.7 to 8.4)	-16.0 (-25.0 to -6.4)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.5 (-35.0 to 26.4)	-23.6	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.1 (-30.8 to 12.4)	-24.6 (-44.6 to -3.5)
Thalassemia trait	2.4 (1.6 to 3.2)	3.4 (2.3 to 4.4)	41.3 (19.7 to 67.2)	0.0	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	26.3 (8.5 to 50.4)	0.6 (-13.4 to 18.8)
Sickle cell disorders	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	9.3 (6.5 to 34.8)	-12.3	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.5 (0.9 to 46.8)	-10.5 (-25.0 to 3.8)
Sickle cell trait	13.7 (12.4 to 14.9)	16.0 (14.5 to 17.5)	165.5 (111.3 to 233.3)	-27.1	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-9.8 (-26.2 to 33.4)	22.3 (-37.0 to 24.5)
G6PD deficiency	11.1 (7.1 to 15.4)	14.1 (9.9 to 19.8)	30.2 (-33.2 to 108.3)	-8.3	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.5 (26.8 to 34.2)	-1.8 (-5.3 to 3.9)
G6PD trait	75.5 (65.5 to 82.9)	104.2 (90.8 to 115.2)	38.1 (17.4 to 64.3)	-4.5	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.0 (-80.8 to 261.7)	-1.1 (-11.1 to 208.3)
Other hemoglobinopathies and hemolytic anemias	4.3 (4.0 to 4.7)	4.5 (4.1 to 4.8)	3.6 (-5.8 to 13.6)	-18.0	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-12.1 (-24.0 to 2.0)	-21.1 (-33.9 to -9.4)
Endocrine, metabolic, blood, and immune disorders	5.6 (5.2 to 5.9)	4.2 (5.2 to 6.3)	-26.3 to -9.2	4.2	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-9.5 (-18.9 to 15.9)	-13.9 (-25.7 to 3.1)
Musculoskeletal disorders	-	-	-	-	4.3 (3.0 to 5.6)	7.8 (5.5 to 10.4)	82.7 (63.5 to 106.4)	-0.6 (-9.5 to 10.5)
Rheumatoid arthritis	0.5 (0.5 to 0.5)	0.6 (0.6 to 0.6)	17.8 (8.8 to 26.5)	-36.4	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	18.7 (7.3 to 30.7)	-36.0 (-41.9 to -29.8)
Osteoarthritis	8.2 (7.8 to 8.5)	14.9 (14.3 to 15.5)	81.8 (73.0 to 92.5)	1.7	0.5 (0.3 to 0.7)	0.9 (0.6 to 1.2)	82.2 (72.4 to 92.7)	1.9 (-3.5 to 7.9)
Low back and neck pain	-	-	-	-	3.0 (2.1 to 4.1)	5.6 (3.8 to 7.6)	81.1 (56.8 to 118.0)	-1.0 (-13.5 to 16.0)
Low back pain	17.4 (13.7 to 20.3)	32.3 (26.7 to 38.0)	85.7 (49.8 to 150.1)	1.4	1.9 (1.2 to 2.8)	3.6 (2.3 to 5.1)	86.4 (49.9 to 151.5)	1.7 (-16.4 to 36.1)
Neck pain	11.2 (9.4 to 13.3)	20.3 (17.6 to 22.9)	81.7 (43.7 to 122.1)	-5.1	1.1 (0.7 to 1.5)	2.0 (1.3 to 2.8)	82.0 (42.9 to 124.9)	-4.9 (-24.5 to 17.5)
Gout	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	89.6 (57.8 to 123.2)	2.5	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.1 (47.2 to 148.1)	2.7 (-20.9 to 34.1)
Other musculoskeletal disorders	6.6 (5.3 to 8.1)	12.6 (9.8 to 15.4)	89.5 (72.9 to 108.1)	4.2	0.6 (0.4 to 0.9)	1.1 (0.7 to 1.7)	86.3 (73.4 to 109.9)	1.1 (-4.3 to 11.7)
Other non-communicable diseases	-	-	-	-	4.8 (3.1 to 7.0)	7.2 (4.7 to 10.8)	51.9 (43.0 to 61.5)	-5.5 (-9.5 to -1.1)
Congenital anomalies	-	-	-	-	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.8)	67.6 (36.1 to 104.2)	27.6 (5.5 to 53.6)
Neural tube defects	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	99.9 (58.2 to 153.0)	59.1	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	107.0 (49.8 to 182.0)	67.2 (21.3 to 126.3)
Congenital heart anomalies	1.2 (0.9 to 1.5)	2.8 (2.4 to 3.5)	139.5 (76.9 to 245.3)	84.3	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	140.3 (78.9 to 244.4)	87.1 (38.4 to 166.5)
Orofacial clefts	0.2 (0.1 to 0.2)	0.5 (0.4 to 0.5)	154.7 (95.0 to 240.3)	116.0	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	141.1 (45.7 to 213.8)	74.1 (22.6 to 146.9)
Down syndrome	0.3 (0.3 to 0.4)	0.5 (0.4 to 0.6)	69.9 (34.3 to 109.8)	27.7	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	77.7 (37.6 to 121.8)	33.2 (2.1 to 68.4)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.3 (4.1 to 130.3)	8.5	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.7 (5.3 to 150.3)	8.3 (-29.9 to 65.7)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.3 (-12.7 to 118.7)	7.1	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.7 (33.9 to 198.7)	13.1 (-29.7 to 79.1)
Chromosomal unbalanced rearrangements	0.5 (0.4 to 0.7)	0.9 (0.8 to 1.0)	69.5 (27.7 to 126.2)	27.5	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	75.8 (130.9 to 134.2)	32.7 (0.1 to 74.1)
Other congenital anomalies	1.7 (1.2 to 2.2)	2.2 (1.7 to 2.8)	32.3 (7.3 to 64.5)	-10.4	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	36.5 (-4.5 to 88.3)	2.6 (-26.2 to 43.0)
Skin and subcutaneous diseases	-	-	-	-	1.6 (1.0 to 2.6)	2.5 (1.6 to 4.0)	56.7 (38.0 to 72.9)	2.0 (-7.4 to 10.1)
Dermatitis	14.5 (11.6 to 18.0)	23.8 (18.4 to 29.9)	63.3 (55.6 to 70.5)	-0.5	0.4 (0.3 to 0.6)	0.7 (0.4 to 1.0)	54.3 (45.0 to 62.3)	-0.3 (-3.0 to 2.5)
Psoriasis	2.3 (1.8 to 2.7)	4.0 (3.1 to 4.8)	72.3 (66.5 to 78.7)	0.1	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	72.3 (60.4 to 84.6)	0.3 (-4.7 to 5.7)
Cellulitis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	37.1 (16.9 to 65.6)	-1.0	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.4 (4.4 to 81.0)	-1.6 (-22.0 to 23.4)
Pyoderma	0.6 (0.5 to 0.8)	0.7 (0.5 to 0.8)	5.7 (-6.4 to 19.6)	-4.1	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.3 (-9.2 to 21.3)	-3.9 (-13.1 to 6.7)
Scabies	3.2 (2.8 to 3.5)	4.0 (3.4 to 4.6)	25.1 (2.8 to 53.6)	-12.2	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	24.7 (2.0 to 54.3)	-12.2 (-27.6 to 6.8)
Fungal skin diseases	41.6 (30.0 to 57.8)	64.5 (47.1 to 90.7)	54.2 (43.3 to 69.8)	4.1	0.2 (0.1 to 0.5)	0.4 (0.1 to 0.8)	54.1 (42.9 to 70.1)	1.2 (0.4 to 2.0)
Viral skin diseases	5.3 (4.1 to 6.6)	6.6 (5.0 to 8.5)	23.8 (9.6 to 37.7)	0.1	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	23.8 (9.6 to 38.4)	0.1 (-5.6 to 6.2)
Acne vulgaris	28.1 (19.7 to 38.4)	42.2 (27.8 to 58.4)	57.4 (-18.3 to 147.8)	4.8	0.3 (0.1 to 0.6)	0.5 (0.2 to 0.9)	57.9 (-18.5 to 149.1)	5.1 (-43.8 to 59.7)
Alopecia areata	0.3 (0.3 to 0.4)	0.5 (0.4 to 0.6)	60.8 (36.0 to 89.5)	1.9	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.3 (30.8 to 96.2)	2.2 (-14.6 to 23.0)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.3 (27.1 to 99.5)	-3.8	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.3 (27.1 to 100.0)	-0.8 (-2.1 to 32.6)
Urticaria	1.6 (0.9 to 2.0)	3.4 (2.4 to 4.6)	124.8 (52.6 to 218.2)	23.1	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	125.2 (51.5 to 217.1)	23.7 (-18.2 to 78.2)
Decubitus ulcer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	93.2 (43.1 to 158.4)	2.7	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.7 (42.8 to 159.6)	3.6 (-25.7 to 46.6)
Other skin and subcutaneous diseases	19.2 (12.7 to 29.0)	32.3 (21.4 to 47.3)	68.1 (53.5 to 89.0)	0.1	0.2 (-2.6 to 2.9)	0.2 (0.0 to 0.2)	68.3 (53.0 to 88.9)	0.2 (-2.5 to 3.1)
Sense organ diseases	-	-	-	-	2.3 (1.5 to 3.4)	3.4 (2.2 to 5.0)	64.8 (31.8 to 58.2)	-12.5 (-17.3 to -6.0)
Glaucoma	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	58.1 (23.0 to 100.2)	-10.5	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	73.8 (32.5 to 131.9)	-2.2 (-25.4 to 33.7)
Cataract	1.8 (1.2 to 2.3)	2.2 (1.5 to 2.8)	23.1 (4.6 to 48.1)	-29.2	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	30.4 (7.7 to 54.0)	-26.3 (-38.3 to -14.1)
Macular degeneration	0.3 (0.2 to 0.4)	0.9 (0.6 to 1.1)	161.1 (91.4 to 225.0)	51.0	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	130.3 (77.8 to 185.1)	28.9 (0.2 to 65.6)
Uncorrected refractive error	28.6 (21.3 to 35.9)	44.6 (35.2 to 56.1)	54.0 (8.8 to 205.5)	5.7	0.5 (0.3 to 0.8)	0.7 (0.4 to 1.1)	43.3 (15.4 to 85.1)	-12.0 (-26.7 to 11.1)
Age-related and other hearing loss	46.7 (40.9 to 51.6)	77.7 (67.3 to 87.5)	66.3 (57.7 to 75.1)	-5.6	1.3 (0.8 to 2.0)	2.0 (1.2 to 3.1)	51.7 (32.7 to 70.6)	-10.5 (-17.9 to -3.0)
Other vision loss	1.0 (0.8 to 1.2)	0.9 (0.7 to 1.2)	-42.9 (-17.8 to 8.1)	0.1	0.1 (-0.1 to 0.1)	0.1 (0.1 to 0.1)	2.0 (-13.4 to 19.9)	-38.4 (-49.1 to -29.2)
Other sense organ diseases	8.8 (8.3 to 9.2)	11.1 (10.5 to 11.7)	26.5 (17.5 to 37.1)	-0.9	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.4)	26.0 (15.6 to 37.9)	-0.8 (-7.7 to 6.8)
Oral disorders	-	-	-	-	0.4 (0.2 to 0.7)	0.7 (0.4 to 1.2)	66.3 (56.3 to 79.6)	-3.9 (-10.0 to 4.2)
Deciduous caries	35.8 (33.8 to 37.4)	31.4 (29.8 to 33.0)	-12.0 (-18.3 to -5.6)	0.4	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-19.9 to -4.1)	0.6 (-8.7 to 9.3)
Permanent caries	87.4 (79.2 to 96.6)	148.1 (132.9 to 165.1)	70.3 (46.4 to 93.2)	3.6	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	70.1 (46.1 to 93.4)	3.9 (-11.0 to 18.3)
Periodontal diseases	20.6 (18.4 to 22.8)	38.1 (33.3 to 43.1)	83.6 (62.0 to 115.0)	-0.8	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.5)	84.2 (62.5 to 115.4)	-0.6 (-13.0 to 17.6)

Appendix Table G.4 - Cape Verde prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Edentulism and severe tooth loss	1.4 (1.3 to 1.5)	1.9 (1.7 to 2.0)	32.1 (19.9 to 44.4)	-25.4 (-31.9 to -18.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	33.1 (18.6 to 46.6)	-25.3 (-32.7 to -17.4)
Other oral disorders	5.1 (4.8 to 5.4)	8.4 (7.9 to 8.9)	66.1 (52.3 to 81.3)	-2.2 (-10.1 to 5.8)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	66.1 (51.4 to 82.0)	-2.0 (-10.0 to 6.4)
Injuries	-	-	-	-	1.2 (0.9 to 1.5)	1.5 (1.1 to 2.0)	21.1 (9.6 to 34.2)	-30.1 (-36.8 to -22.7)
Transport injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	7.4 (5.4 to 22.7)	-38.0 (-45.0 to -29.7)
Road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	7.2 (6.0 to 22.7)	-38.1 (-45.4 to -29.7)
Pedestrian road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	5.1 (-19.0 to 9.6)	-43.9 (-50.9 to -35.3)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-10.8 to 12.6)	-39.7 (-45.9 to -32.7)
Motorcyclist road injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	1.6 (-13.5 to 18.4)	-43.7 (-51.7 to -35.0)
Motor vehicle road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	18.3 (14.1 to 37.7)	-32.7 (-41.8 to -22.1)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.4 (-30.2 to -8.3)	-55.8 (-61.1 to -49.5)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	9.0 (2.8 to 24.3)	-36.5 (-43.4 to -27.6)
Unintentional injuries	-	-	-	-	0.8 (0.6 to 1.0)	1.0 (0.7 to 1.3)	28.2 (17.2 to 40.2)	-25.9 (-32.6 to -19.0)
Falls	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.6)	30.7 (15.7 to 46.7)	-28.6 (-37.1 to -19.8)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.7 (-21.7 to 6.7)	-43.1 (-50.5 to -34.2)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-7.1 (-19.9 to 7.1)	-40.4 (-47.7 to -32.5)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.7 (7.9 to 32.9)	-31.5 (-40.8 to -20.2)
Exposure to mechanical forces	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	29.4 (19.3 to 40.5)	-20.0 (-25.6 to -14.4)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.8 (26.4 to 60.9)	-15.0 (-24.5 to -4.6)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.3 (79.4 to 127.2)	30.3 (16.0 to 45.3)
Other exposure to mechanical forces	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	27.6 (17.5 to 38.6)	-21.3 (-27.0 to -15.7)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.7 (70.8 to 94.4)	14.7 (6.8 to 22.7)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.8 (6.1 to 31.3)	-27.4 (-33.9 to -20.1)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.5 (7.4 to 40.3)	-26.2 (-34.8 to -17.3)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.1 (1.2 to 27.4)	-28.3 (-34.8 to -20.1)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.3 (16.0 to 40.4)	-21.4 (-28.2 to -14.5)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.1 (-36.0 to -3.6)	-44.2 (-53.4 to -33.1)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.4 (33.0 to 67.4)	-8.9 (-17.2 to 2.4)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.5 (30.1 to 58.7)	-17.1 (-24.4 to -9.0)
Other unintentional injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	38.1 (26.5 to 48.5)	-19.7 (-26.2 to -13.8)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	24.6 (9.6 to 43.5)	-28.5 (-37.1 to -17.9)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.1 (34.9 to 70.0)	-21.1 (-29.4 to -11.7)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.6 (4.1 to 39.1)	-30.1 (-39.1 to -19.2)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.1 (29.7 to 62.7)	-14.5 (-23.1 to -5.4)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.6 (40.8 to 86.6)	-8.8 (-20.1 to 4.9)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.4 (-11.1 to 21.4)	-39.5 (-48.1 to -29.1)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.7 (-23.6 to 21.4)	-25.9 (-37.3 to -11.5)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.7 (-23.6 to 21.4)	-25.9 (-37.3 to -11.5)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Central African Republic prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	333.8 (244.1 to 433.1)	487.2 (356.4 to 636.1)	46.1 (40.1 to 52.0)	46.1 (-11.9 to -4.8)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	135.4 (94.3 to 184.0)	163.8 (115.3 to 223.0)	21.2 (8.3 to 35.1)	21.2 (-34.4 to -16.1)
HIV/AIDS and tuberculosis	-	-	-	-	17.9 (10.0 to 28.6)	21.3 (14.3 to 30.5)	20.7 (-15.9 to 90.6)	-27.8 (-49.6 to 15.5)
Tuberculosis	14.0 (13.2 to 14.7)	21.7 (20.6 to 22.9)	55.3 (48.9 to 61.4)	-8.4 (-12.0 to -5.1)	4.2 (2.8 to 5.6)	6.6 (4.5 to 8.9)	57.5 (49.6 to 65.3)	-7.3 (-11.6 to -3.2)
HIV/AIDS	-	-	-	-	13.8 (6.5 to 24.4)	14.7 (9.4 to 23.0)	34.7 (-32.5 to 107.6)	-34.7 (-59.6 to 27.4)
HIV/AIDS resulting in mycobacterial infection	4.0 (2.5 to 5.4)	4.0 (2.6 to 5.4)	-1.4 (-28.2 to 46.2)	-40.3 (-56.8 to -11.1)	1.5 (0.8 to 2.2)	1.5 (0.8 to 2.2)	0.3 (-28.2 to 49.7)	-39.5 (-56.3 to -9.2)
HIV/AIDS resulting in other diseases	106.0 (61.4 to 149.3)	89.3 (79.4 to 100.2)	-13.6 (-43.9 to 53.6)	-47.4 (-65.8 to -6.3)	12.3 (5.4 to 22.5)	13.3 (8.2 to 21.2)	9.7 (-34.1 to 118.7)	-34.1 (-60.6 to 34.0)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	16.2 (11.7 to 21.8)	19.2 (13.8 to 25.8)	18.8 (12.5 to 25.7)	-19.8 (-24.1 to -15.0)
Diarrheal diseases	60.5 (57.5 to 63.7)	68.9 (66.1 to 71.9)	14.0 (7.9 to 20.5)	-20.5 (-24.5 to -16.3)	9.7 (6.7 to 13.6)	11.1 (7.6 to 15.4)	13.9 (7.4 to 21.2)	-20.5 (-24.8 to -15.4)
Intestinal infectious diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	0.1 (-43.0 to 10.0)	-19.4 (-62.1 to -28.4)
Typhoid fever	0.9 (0.7 to 1.0)	0.8 (0.7 to 1.0)	-6.5 (-26.1 to 15.0)	-38.7 (-52.5 to -24.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	6.0 (-29.8 to 26.1)	-38.0 (-53.4 to -18.8)
Paratyphoid fever	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.6)	12.0 (-12.8 to 61.0)	-26.4 (-42.9 to 4.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.4 (-16.3 to 68.0)	26.1 (-44.8 to 8.0)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-79.9 (-99.6 to -39.5)	-83.0 (-93.1 to -60.8)
Lower respiratory infections	4.5 (3.6 to 5.3)	6.4 (5.3 to 7.5)	43.3 (15.0 to 88.3)	-3.6 (-18.8 to 18.9)	0.5 (0.3 to 0.7)	0.7 (0.4 to 1.0)	44.1 (14.4 to 87.8)	-2.7 (-19.6 to 21.2)
Upper respiratory infections	81.0 (75.0 to 87.7)	115.2 (104.7 to 125.3)	42.6 (26.2 to 59.9)	-10.3 (-20.8 to 0.3)	0.9 (0.5 to 1.6)	1.3 (0.8 to 2.2)	43.0 (25.8 to 61.0)	-9.7 (-21.0 to 0.9)
Otitis media	49.4 (45.1 to 53.6)	71.5 (65.3 to 78.5)	44.9 (32.3 to 57.8)	-8.3 (-16.5 to 0.1)	1.0 (0.6 to 1.6)	1.4 (0.8 to 2.3)	44.1 (29.1 to 61.3)	-8.2 (-17.3 to 2.7)
Meningitis	-	-	-	-	3.4 (2.3 to 4.5)	3.9 (2.7 to 5.3)	14.1 (-1.1 to 41.1)	-27.2 (-36.5 to -11.2)
Pneumococcal meningitis	17.2 (10.6 to 24.8)	19.1 (12.2 to 27.4)	11.3 (-4.2 to 30.8)	-29.3 (-39.2 to -17.2)	1.4 (1.0 to 1.9)	1.7 (1.2 to 2.3)	17.9 (4.4 to 52.1)	25.3 (-39.5 to 4.6)
H influenzae type B meningitis	9.1 (3.7 to 16.3)	10.0 (4.8 to 17.3)	10.0 (-9.4 to 40.3)	-30.3 (-43.7 to -12.7)	0.9 (0.6 to 1.4)	1.1 (0.7 to 1.7)	23.8 (-9.5 to 67.0)	-22.5 (-42.0 to 3.8)
Meningococcal meningitis	1.5 (0.5 to 3.2)	1.8 (0.8 to 3.9)	29.4 (-0.2 to 62.9)	-17.1 (-35.7 to 4.3)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	37.0 (-3.9 to 76.6)	-12.8 (-36.1 to 10.1)
Other meningitis	7.1 (4.3 to 11.8)	7.0 (4.1 to 11.6)	-2.1 (-19.4 to 26.4)	-35.4 (-46.7 to -16.8)	0.9 (0.6 to 1.2)	0.8 (0.5 to 1.3)	0.8 (-28.6 to 40.1)	-2.6 (-5.2 to -9.5)
Encephalitis	0.6 (0.3 to 1.3)	1.0 (0.5 to 2.0)	60.0 (42.6 to 83.7)	-1.1 (-8.4 to 13.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	61.5 (33.0 to 100.4)	1.4 (-13.9 to 21.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.7 (-93.3 to 3,607.5)	25.6 (-93.2 to 1,370.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.7 (-93.3 to 3,659.4)	25.6 (-93.3 to 3,385.8)
Whooping cough	4.7 (3.6 to 6.0)	7.8 (6.0 to 10.1)	66.4 (64.3 to 68.6)	20.8 (19.3 to 22.4)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.6)	66.7 (54.7 to 78.3)	21.1 (12.3 to 29.7)
Tetanus	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.3)	-31.9 (-66.0 to 108.0)	-57.3 (-79.1 to -33.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.2 (-51.9 to 49.1)	-51.2 (-69.0 to 4.1)
Measles	1.1 (0.8 to 1.5)	0.4 (0.3 to 0.5)	-63.7 (-70.1 to -55.3)	-74.0 (-78.6 to -68.0)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	69.7 (-74.3 to -49.2)	-74.0 (-81.5 to -63.9)
Varicella and herpes zoster	1.8 (1.7 to 2.0)	3.1 (2.8 to 3.3)	66.1 (41.6 to 91.5)	3.8 (-16.8 to 26.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	64.8 (14.3 to 130.3)	4.7 (-29.9 to 50.2)
Neglected tropical diseases and malaria	-	-	-	-	72.5 (46.2 to 103.4)	66.0 (42.3 to 96.1)	-9.4 (-21.2 to 7.8)	-42.7 (-50.9 to -29.2)
Malaria	2,537.1 (2,345.4 to 2,713.8)	2,580.7 (2,229.8 to 2,992.0)	1.6 (-8.6 to 13.2)	-40.0 (-46.4 to -32.9)	21.2 (14.2 to 30.5)	20.5 (13.9 to 29.5)	-3.3 (-6.6 to 2.5)	-41.0 (-44.6 to -37.1)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.7 (54.4 to 208.7)	41.1 (3.6 to 100.5)
Visceral leishmaniasis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	68.4 (4.9 to 168.3)	6.1 (-29.1 to 59.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.4 (4.7 to 168.4)	6.1 (-29.2 to 59.9)
Cutaneous and mucocutaneous leishmaniasis	0.3 (0.2 to 0.4)	0.8 (0.5 to 1.3)	170.0 (77.7 to 309.6)	69.5 (7.7 to 156.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	170.0 (75.6 to 347.2)	70.5 (9.1 to 170.7)
African trypanosomiasis	2.0 (0.8 to 4.1)	1.1 (0.8 to 2.8)	-21.1 (-33.4 to -9.3)	-52.4 (-59.8 to -45.3)	0.5 (0.2 to 1.1)	0.4 (0.2 to 0.8)	-21.2 (-36.1 to 11.2)	-52.4 (-61.0 to -41.5)
Schistosomiasis	306.7 (125.5 to 614.1)	254.0 (98.9 to 553.7)	-19.6 (-30.9 to 10.4)	-51.1 (-58.0 to -33.0)	2.5 (1.0 to 5.6)	2.1 (0.8 to 4.9)	-7.4 (-31.3 to 8.8)	-49.7 (-58.2 to -34.1)
Cysticercosis	1.5 (0.6 to 2.5)	1.8 (1.0 to 3.2)	15.1 (-43.3 to 188.5)	-23.0 (-61.2 to 72.0)	0.4 (0.1 to 0.7)	0.5 (0.2 to 0.9)	18.5 (-43.0 to 210.2)	-21.3 (-61.3 to 74.7)
Cystic echinococcosis	0.8 (0.6 to 1.0)	0.7 (0.6 to 0.8)	-11.5 (-28.3 to 7.9)	-64.0 (-70.7 to -56.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	-8.2 (-32.3 to 21.4)	-62.8 (-71.8 to -51.0)
Lymphatic filariasis	191.0 (157.2 to 232.3)	277.2 (224.4 to 338.1)	46.1 (12.6 to 80.1)	-8.2 (-25.4 to 10.8)	5.0 (2.6 to 8.6)	7.3 (3.8 to 12.2)	43.9 (11.7 to 74.5)	-7.3 (-27.8 to 8.9)
Onchocerciasis	576.6 (377.7 to 863.3)	335.0 (228.0 to 489.6)	-43.1 (-54.5 to -18.5)	-62.4 (-69.9 to -47.0)	35.6 (18.5 to 57.2)	24.4 (10.7 to 44.2)	-24.1 (-53.7 to -0.1)	-56.2 (-69.3 to -34.5)
Trachoma	1.1 (0.4 to 1.9)	0.8 (0.4 to 1.4)	-26.2 (-66.1 to 80.3)	-52.5 (-79.0 to 7.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	12.7 (-37.2 to 108.8)	-30.2 (-62.5 to 19.5)
Dengue	0.2 (0.1 to 0.5)	1.5 (0.5 to 3.5)	671.7 (662.5 to 682.4)	383.1 (377.4 to 389.8)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.6)	649.0 (471.9 to 868.6)	361.7 (272.5 to 466.9)
Yellow fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.2 (-69.3 to -40.2)	-73.8 (-79.9 to -44.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.2 (-69.4 to -40.2)	-73.8 (-79.9 to -44.6)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.2 (-15.6 to 92.0)	-12.8 (-40.2 to 18.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.2 (-15.7 to 92.3)	-12.8 (-40.3 to 18.9)
Intestinal nematode infections	-	-	-	-	4.6 (2.8 to 7.3)	7.3 (4.4 to 11.5)	58.5 (40.7 to 78.2)	-1.1 (-13.9 to 13.7)
Ascariasis	344.1 (292.3 to 403.1)	537.9 (453.3 to 635.6)	56.6 (24.2 to 96.9)	-2.1 (-25.9 to 28.0)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	53.7 (15.5 to 97.7)	-1.7 (-28.6 to 33.2)
Trichuriasis	248.2 (202.8 to 300.4)	388.2 (317.0 to 475.9)	55.4 (19.1 to 109.0)	-2.7 (-28.5 to 38.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	55.4 (8.3 to 123.7)	-1.4 (-34.2 to 52.8)
Hookworm disease	879.0 (782.2 to 986.3)	1,399.3 (1,233.4 to 1,606.3)	59.2 (33.9 to 91.7)	-15.5 (-18.7 to 21.8)	4.4 (2.7 to 6.9)	7.9 (4.2 to 10.9)	88.5 (40.6 to 79.2)	-1.0 (-14.1 to 14.5)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	33.3 (26.9 to 40.8)	67.4 (63.2 to 73.3)	102.9 (63.2 to 153.7)	35.2 (10.2 to 62.8)	2.4 (1.1 to 5.3)	3.3 (1.9 to 5.5)	49.9 (-11.3 to 103.1)	-12.2 (-52.7 to 30.0)
Maternal disorders	-	-	-	-	0.7 (0.5 to 1.0)	0.8 (0.6 to 1.1)	14.0 (-2.3 to 32.8)	-34.3 (-43.0 to -24.4)
Maternal hemorrhage	0.9 (0.7 to 1.2)	1.2 (0.7 to 1.6)	26.1 (-25.0 to 92.6)	-29.6 (-55.8 to 3.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	25.1 (-42.2 to 115.3)	-32.0 (-65.4 to 17.2)
Maternal sepsis and other maternal infections	1.5 (1.0 to 1.9)	1.4 (1.0 to 1.8)	-9.2 (-21.5 to 11.4)	-48.0 (-54.9 to -36.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.2 (-45.8 to 46.9)	-48.3 (-66.4 to -20.6)
Maternal hypertensive disorders	0.8 (0.4 to 1.2)	1.0 (0.5 to 1.6)	25.9 (6.7 to 32.4)	-30.2 (-41.2 to -27.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	24.3 (0.9 to 51.1)	-31.3 (-43.8 to -17.0)
Obstructed labor	1.6 (1.4 to 1.7)	1.7 (1.5 to 1.9)	11.4 (3.4 to 19.7)	-34.9 (-39.3 to -30.1)	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.8)	12.5 (-3.4 to 30.6)	-34.3 (-43.1 to -24.5)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.4 (-15.7 to 136.0)	-27.7 (-51.3 to 23.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.4 (-15.9 to 138.2)	-22.7 (-51.6 to 24.0)
Other maternal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	15.2 (-27.7 to 108.1)	-34.6 (-58.5 to 20.2)
Neonatal disorders	-	-	-	-	1.7 (0.9 to 2.9)	4.3 (2.7 to 6.7)	159.2 (73.4 to 298.8)	73.1 (14.0 to 166.4)
Preterm birth complications	9.3 (4.5 to 16.8)	30.2 (16.1 to 55.0)	226.1 (173.1 to 312.9)	105.2 (75.6 to 153.0)	0.5 (0.3 to 0.9)	2.0 (1.2 to 3.3)	275.0 (113.6 to 590.1)	145.6 (44.7 to 343.4)
Neonatal encephalopathy due to birth asphyxia and trauma	18.9 (1.6 to 59.5)	26.2 (2.6 to 82.9)	39.8 (22.6 to 91.5)	-11.8 (-21.6 to 21.6)	0.6 (0.2 to 1.5)	1.0 (0.4 to 2.3)	57.4 (-14.8 to 213.4)	2.6 (-31.8 to 119.4)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	60.5 (97.1 to 121.1)	112.4 (48.9 to 67.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.8 (85.6 to 135.6)	58.5 (40.3 to 78.0)
Hemolytic disease and other neonatal jaundice	0.4 (0.2 to 0.8)	1.2 (0.5 to 2.2)	180.5 (9.2 to 683.9)	94.5 (-27.7 to 470.9)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.8)	180.0 (61.1 to 700.9)	96.4 (-29.9 to 494.8)
Other neonatal disorders	-	-	-	-	0.3 (0.1 to 0.7)	0.8 (0.3 to 1.7)	139.7 (0.1 to 408.1)	58.9 (-35.4 to 241.5)
Nutritional deficiencies	-	-	-	-	24.5 (16.4 to 35.0)	48.7 (32.9 to 69.5)	98.3 (74.3 to 132.6)	29.5 (17.1 to 47.0)
Protein-energy malnutrition	19.7 (8.4 to 40.8)	38.7 (14.0 to 85.0)	89.3 (-42.7 to 557.1)	30.4 (-53.4 to 281.8)	4.7 (0.9 to 5.3)	4.7 (1.6 to 11.3)	89.4 (-43.7 to 579.1)	31.5 (-5.8 to 299.1)
Iodine deficiency	194.6 (151.0 to 239.4)	187.7 (138.4 to 243.1)	-3.1 (-33.8 to 36.7)	-41.8 (-60.2 to -14.6)	3.5 (2.0 to 5.8)	3.4 (1.9 to 5.6)	-2.2 (-32.8 to 37.9)	-41.5 (-60.0 to -13.9)
Vitamin A deficiency	7.6 (6.3 to 9.1)	11.0 (9.1 to 13.2)	44.6 (29.9 to 60.1)	-3.9 (-13.5 to 6.5)	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	40.0 (22.8 to 59.0)	-5.5 (-16.0 to 7.0)

Appendix Table G.4 - Central African Republic prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	531.6 (520.6 to 542.4)	1,170.4 (1,158.6 to 1,181.9)	120.1 (115.1 to 125.3)	44.4 (41.2 to 49.4)	18.2 (12.3 to 26.3)	40.1 (26.9 to 57.3)	119.4 (112.5 to 126.9)	47.2 (42.7 to 60.2)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	47.6 (-62.1 to 500.7)	1.7 (-70.5 to 266.9)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.0 (1.3 to 2.9)	3.4 (2.2 to 5.2)	73.4 (57.1 to 93.6)	3.1 (-6.2 to 13.5)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.7 (0.4 to 1.2)	1.1 (0.6 to 2.0)	65.3 (31.6 to 98.7)	-5.0 (-22.5 to 11.6)
Syphilis	0.4 (0.3 to 0.4)	0.3 (0.3 to 0.4)	-9.4 (-23.5 to 7.0)	-42.2 (-50.2 to -32.8)	0.1 (0.0 to 0.1)	0.2 (0.0 to 0.1)	41.9 (-30.1 to 19.1)	-27.0 (-53.7 to -27.0)
Chlamydial infection	55.6 (44.8 to 67.3)	99.6 (82.8 to 116.1)	79.3 (37.7 to 139.9)	2.7 (-19.0 to 34.5)	0.3 (0.2 to 0.5)	0.6 (0.3 to 1.0)	79.6 (19.3 to 143.2)	2.1 (-30.4 to 36.6)
Gonococcal infection	13.6 (10.7 to 16.7)	22.2 (16.9 to 27.9)	64.1 (34.1 to 124.5)	-9.0 (-33.7 to 23.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	56.6 (-6.7 to 149.6)	-12.4 (-44.2 to 32.0)
Trichomoniasis	30.7 (21.3 to 42.1)	54.2 (38.3 to 74.3)	79.1 (7.9 to 189.0)	2.0 (-35.9 to 57.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	68.9 (-6.1 to 186.5)	-1.3 (-42.8 to 58.0)
Genital herpes	555.1 (478.4 to 597.5)	988.1 (872.9 to 1,033.8)	79.5 (55.6 to 104.4)	8.6 (-5.0 to 22.6)	0.0 (0.0 to 0.3)	0.0 (0.1 to 0.6)	83.2 (57.9 to 112.0)	9.3 (-4.8 to 24.9)
Other sexually transmitted diseases	1.5 (1.0 to 2.0)	2.0 (1.3 to 2.7)	35.3 (20.8 to 56.4)	-22.1 (-31.2 to -10.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.4 (1.9 to 97.6)	-20.6 (-40.1 to 6.6)
Hepatitis	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	28.1 (6.8 to 54.7)	-25.1 (-40.3 to -6.8)
Hepatitis A	5.2 (4.9 to 5.5)	7.8 (7.4 to 8.1)	49.6 (48.4 to 50.7)	-0.8 (-0.8 to -0.7)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	64.4 (46.1 to 87.2)	1.7 (-9.1 to 15.2)
Hepatitis B	366.0 (305.8 to 431.9)	335.1 (275.3 to 399.8)	-7.7 (-31.1 to 18.4)	-42.3 (-54.4 to -27.5)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-1.3 (-31.6 to 41.7)	-39.8 (-60.5 to -11.6)
Hepatitis C	108.5 (99.1 to 118.8)	127.8 (114.9 to 140.8)	17.5 (2.4 to 35.7)	-25.6 (-34.3 to -15.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.7 (-14.7 to 48.1)	-27.2 (-44.9 to 0.5)
Hepatitis E	1.0 (0.8 to 1.2)	1.8 (1.5 to 2.0)	73.6 (36.1 to 138.5)	0.1 (-20.7 to 42.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	75.9 (28.9 to 154.8)	1.7 (-24.9 to 50.1)
Leprosy	1.2 (0.8 to 1.5)	1.2 (1.1 to 1.4)	6.6 (-10.9 to 30.8)	-27.2 (-38.2 to -11.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	8.1 (-11.9 to 37.2)	-26.4 (-38.6 to -8.5)
Other infectious diseases	24.8 (20.9 to 28.9)	50.7 (47.1 to 54.9)	104.5 (77.6 to 140.9)	35.1 (21.9 to 52.5)	0.9 (0.6 to 1.3)	1.8 (1.2 to 2.7)	99.1 (74.0 to 158.4)	35.1 (15.3 to 67.5)
Non-communicable diseases	-	-	-	-	185.8 (136.9 to 238.3)	304.2 (224.1 to 394.3)	63.7 (59.5 to 68.0)	1.1 (-1.2 to 3.7)
Neoplasms	-	-	-	-	0.9 (0.6 to 1.3)	1.5 (1.0 to 2.1)	68.4 (30.5 to 115.0)	11.9 (-12.9 to 42.8)
Esophageal cancer	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	18.3 (-22.2 to 71.5)	-17.7 (-44.6 to 18.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.1 (-19.6 to 74.4)	-16.7 (-43.3 to 20.4)
Stomach cancer	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.6)	16.6 (-13.5 to 60.8)	-19.4 (-40.3 to 10.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	16.4 (-13.8 to 59.7)	-19.5 (-41.4 to 11.3)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.8 (1.5 to 153.5)	12.4 (-29.5 to 74.0)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	197.0 (24.8 to 595.8)	108.4 (-12.0 to 389.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	180.3 (34.4 to 537.4)	96.0 (-6.3 to 343.6)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	208.9 (20.4 to 731.7)	122.8 (-13.9 to 490.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	206.0 (26.2 to 620.4)	121.6 (-10.8 to 429.4)
Liver cancer due to alcohol use	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-4.8 (-51.4 to 76.7)	-33.8 (-65.4 to 21.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.3 (-47.6 to 61.8)	-33.9 (-63.4 to 14.3)
Liver cancer due to other causes	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	51.5 (-16.0 to 178.9)	-5.5 (-44.8 to 91.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.5 (-10.6 to 138.5)	0.9 (-39.9 to 63.9)
Larynx cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	5.0 (-30.8 to 62.0)	-26.4 (50.8 to 13.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.0 (-32.5 to 67.5)	-26.7 (-52.4 to 16.2)
Tracheal, bronchus and lung cancer	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	13.3 (-16.1 to 70.4)	-20.2 (-40.7 to 15.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	14.7 (-18.4 to 76.7)	-19.6 (-42.5 to 21.8)
Breast cancer	1.3 (1.0 to 1.7)	2.5 (1.7 to 3.7)	91.4 (31.1 to 175.0)	28.4 (-11.0 to 83.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	78.9 (22.8 to 155.5)	20.9 (-17.0 to 71.3)
Cervical cancer	2.0 (1.3 to 2.7)	2.2 (1.8 to 3.9)	16.0 (-14.6 to 115.9)	-5.6 (-45.2 to 32.5)	0.2 (0.1 to 0.2)	0.3 (0.1 to 0.3)	37.9 (-12.5 to 114.5)	-14.6 (-43.9 to 30.3)
Uterine cancer	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.7)	24.3 (-30.5 to 127.8)	-13.8 (50.4 to 55.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	25.7 (-28.5 to 134.2)	-13.3 (-49.9 to 63.4)
Prostate cancer	0.6 (0.4 to 1.0)	2.2 (1.2 to 3.4)	241.0 (91.3 to 470.5)	133.1 (32.6 to 280.3)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	186.3 (59.3 to 362.6)	93.9 (13.5 to 212.9)
Colon and rectum cancer	0.5 (0.4 to 0.6)	0.9 (0.7 to 1.1)	75.4 (36.2 to 124.5)	17.7 (-8.6 to 50.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	69.8 (28.3 to 120.2)	13.1 (-14.4 to 46.7)
Lip and oral cavity cancer	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.7)	37.7 (-8.8 to 112.4)	-5.9 (-36.8 to 42.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	34.9 (-10.1 to 110.1)	-8.9 (-39.0 to 44.1)
Nasopharynx cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	61.1 (1.5 to 153.5)	0.4 (-36.5 to 54.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.8 (0.3 to 128.4)	-4.6 (-37.1 to 43.4)
Other pharynx cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	28.5 (-32.3 to 123.4)	-11.3 (52.7 to 54.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.7 (-27.5 to 107.4)	-12.6 (-48.4 to 44.3)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	39.9 (-8.5 to 114.1)	-5.2 (-38.2 to 45.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.1 (-6.8 to 108.3)	-5.1 (-36.2 to 46.8)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	65.5 (20.2 to 127.2)	11.6 (-17.9 to 53.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.0 (27.2 to 116.1)	13.1 (-15.3 to 48.9)
Malignant skin melanoma	0.2 (0.1 to 0.4)	0.4 (0.3 to 0.7)	88.1 (34.9 to 196.1)	32.4 (-15.2 to 88.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.9 (72.6 to 184.8)	26.2 (-20.4 to 78.6)
Non-melanoma skin cancer	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	84.4 (43.5 to 138.7)	19.5 (-7.0 to 58.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.4 (33.6 to 174.5)	23.2 (-17.5 to 89.4)
Ovarian cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	60.1 (2.1 to 139.1)	6.1 (-32.3 to 59.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.0 (-4.0 to 155.4)	6.4 (-36.5 to 70.6)
Testicular cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	185.1 (50.4 to 407.6)	57.1 (-12.4 to 172.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	154.0 (30.0 to 374.0)	40.3 (-22.1 to 145.3)
Kidney cancer	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	58.1 (-6.2 to 156.9)	6.1 (-28.1 to 59.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.6 (-3.8 to 141.6)	4.0 (-28.9 to 55.6)
Bladder cancer	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	21.7 (-11.9 to 73.4)	-15.4 (-39.8 to 19.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.2 (-12.5 to 73.0)	-16.7 (-39.9 to 18.9)
Brain and nervous system cancer	0.1 (0.1 to 0.3)	0.3 (0.2 to 0.5)	104.5 (17.4 to 216.6)	31.5 (-17.3 to 82.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.2 (16.8 to 187.3)	21.7 (-18.3 to 67.0)
Thyroid cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	54.5 (-2.9 to 151.2)	-4.5 (-39.9 to 56.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.7 (-5.5 to 145.2)	-7.4 (-41.4 to 51.4)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.4 (-7.6 to 97.0)	37.0 (-36.8 to 31.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.5 (-7.4 to 96.2)	7.2 (-37.1 to 33.2)
Hodgkin lymphoma	0.2 (0.1 to 0.4)	0.5 (0.2 to 0.8)	129.4 (35.3 to 320.5)	41.0 (-14.4 to 150.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	110.1 (29.3 to 269.3)	27.1 (-20.4 to 115.7)
Non-Hodgkin lymphoma	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	79.5 (23.0 to 165.7)	16.9 (-17.5 to 71.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	76.0 (26.2 to 159.7)	13.9 (-18.1 to 66.7)
Multiple myeloma	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	72.5 (2.8 to 182.1)	17.7 (-29.2 to 88.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.2 (-0.7 to 170.8)	11.8 (-32.0 to 82.1)
Leukemia	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	93.1 (4.3 to 276.7)	24.8 (-21.1 to 99.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	79.6 (18.0 to 189.6)	11.9 (-18.8 to 65.7)
Other neoplasms	0.9 (0.5 to 2.1)	2.1 (1.1 to 5.2)	153.9 (46.6 to 306.3)	51.1 (3.8 to 116.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	134.7 (52.1 to 252.2)	37.0 (-5.4 to 91.8)
Cardiovascular diseases	-	-	-	-	4.2 (2.9 to 5.8)	7.6 (5.2 to 10.6)	79.5 (48.1 to 113.8)	13.5 (-6.1 to 38.3)
Rheumatic heart disease	24.1 (22.8 to 25.5)	47.0 (43.8 to 50.0)	94.6 (78.0 to 111.9)	21.5 (11.8 to 31.2)	1.2 (0.8 to 1.7)	2.3 (1.5 to 3.3)	91.8 (73.6 to 114.5)	19.2 (5.5 to 36.4)
Ischemic heart disease	18.1 (15.0 to 22.5)	24.1 (20.7 to 29.2)	31.9 (5.9 to 73.1)	-10.2 (-26.3 to 17.8)	0.7 (0.5 to 1.2)	1.0 (0.6 to 1.5)	22.8 (-11.9 to 80.7)	-15.2 (-39.0 to 23.3)
Cerebrovascular disease	-	-	-	-	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	51.4 (12.7 to 91.6)	-0.3 (-26.0 to 25.5)
Ischemic stroke	1.3 (1.1 to 1.5)	1.9 (1.5 to 2.3)	49.1 (12.5 to 89.9)	-0.1 (-25.6 to 25.3)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	51.4 (11.5 to 94.3)	0.4 (-26.2 to 29.0)
Hemorrhagic stroke	0.4 (0.3 to 0.4)	0.5 (0.4 to 0.6)	48.9 (11.4 to 101.3)	4.4 (-30.5 to 27.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	50.3 (11.8 to 107.4)	-3.9 (-30.5 to 32.4)
Hypertensive heart disease	4.4 (3.4 to 5.7)	7.6 (5.7 to 9.7)	68.3 (14.7 to 156.4)	10.9 (-23.2 to 65.7)	0.5 (0.3 to 0.7)	0.8 (0.5 to 1.2)	69.7 (14.7 to 160.5)	11.9 (-22.8 to 70.5)
Cardiomyopathy and myocarditis	2.0 (2.2 to 3.5)	4.1 (3.7 to 5.8)	102.7 (22.0 to 132.7)	30.7 (-18.0 to 66.1)	0.2 (0.2 to 0.4)	0.3 (0.3 to 0.7)	102.5 (21.8 to 137.2)	32.5 (-18.7 to 67.3)
Atrial fibrillation and flutter	35.5 (1.5 to 2.9)	49.0 (2.9 to 5.6)	39.4 (29.1 to 219.9)	-4.5 (-23.6 to 116.7)	0.0 (0.1 to 0.2)	0.0 (0.2 to 0.5)	67.1 (29.6 to 219.4)	-0.8 (-22.7 to 115.7)
Endocarditis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	34.8 (-10.4 to 111.5)	-13.4 (-44.4 to 49.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.5 (-16.0 to 146.0)	-11.8 (-47.8 to 81.9)
Other cardiovascular and circulatory diseases	14.9 (8.6 to 24.1)	32.3 (17.2 to 46.8)	120.8 (0.8 to 301.2)	28.4 (-39.6 to 175.3)	1.0 (0.5 to 1.8)	2.2 (1.1 to 3.7)	128.8 (0.5 to 310.9)	40.4 (-40.3 to 182.9)
Chronic respiratory diseases	-	-	-	-	12.3 (8.3 to 17.0)	18.6 (12.6 to 26.1)	51.2 (30.4 to 71.1)	-3.6 (-16.4 to 9.3)
Chronic obstructive pulmonary disease	106.5 (101.9 to 110.9)	165.2 (157.5 to 173.2)	55.2 (50.4 to 60.3)	-0.5 (-3.4 to 2.7)	8.5 (5.6 to 12.0)	13.0 (8.5 to 18.6)	52.9 (33.5 to 74.7)	-1.8 (-15.3 to 12.4)

Appendix Table G.4 - Central African Republic prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	47.0	-
Silicosis	0.0	0.0	36.7	-10.8	0.0	0.0	(41.7 to 52.5)	(-8.9 to -2.0)
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	36.5	-10.8
Coal workers pneumoconiosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Other pneumoconiosis	0.0	0.0	57.4	0.3	0.0	0.0	57.4	0.3
Asthma	54.3	85.9	58.4	0.7	2.3	3.7	59.0	1.0
Interstitial lung disease and pulmonary sarcoidosis	0.1	0.1	81.1	7.1	0.0	0.0	80.3	7.2
Other chronic respiratory diseases	-	-	-	-	1.4	1.8	25.7	-19.4
Cirrhosis	-	-	-	-	0.3	0.3	39.7	12.5
Cirrhosis due to hepatitis B	0.5	0.5	-6.6	-35.5	0.1	0.1	6.0	34.9
Cirrhosis due to hepatitis C	0.3	0.7	123.6	37.6	0.0	0.0	126.0	39.7
Cirrhosis due to alcohol use	0.4	0.4	-8.0	-39.0	0.1	0.1	6.4	-38.9
Cirrhosis due to other causes	0.3	0.5	60.3	12.3	0.1	0.1	59.4	11.1
Digestive diseases	-	-	-	-	4.4	6.4	46.5	-7.3
Peptic ulcer disease	34.1	36.7	7.2	-28.7	1.2	1.3	10.7	-25.7
Gastritis and duodenitis	33.4	51.4	53.6	-1.5	1.5	2.1	44.2	-5.5
Appendicitis	0.4	0.7	80.2	4.6	0.1	0.2	80.7	5.1
Paralytic ileus and intestinal obstruction	0.0	0.1	47.0	-2.0	0.0	0.0	49.1	2.0
Inguinal, femoral, and abdominal hernia	15.3	17.5	20.4	-18.0	0.2	0.2	20.6	-17.9
Inflammatory bowel disease	2.8	5.7	103.2	26.0	0.6	1.2	105.8	27.3
Vascular intestinal disorders	0.0	0.0	42.8	-10.6	0.0	0.0	44.2	-9.1
Gallbladder and biliary diseases	1.0	1.7	73.9	1.6	0.1	0.2	74.8	13.1
Pancreatitis	0.5	0.9	69.6	4.4	0.1	0.3	71.0	5.1
Other digestive diseases	-	-	-	-	0.6	0.9	58.0	-0.1
Neurological disorders	-	-	-	-	12.0	21.6	79.7	9.0
Alzheimer disease and other dementias	8.2	13.6	65.2	5.3	1.1	1.9	67.5	5.9
Parkinson disease	0.2	0.4	47.1	-1.2	0.0	0.0	47.7	-0.4
Epilepsy	3.6	6.0	64.4	3.4	1.0	1.7	69.4	7.1
Multiple sclerosis	0.1	0.3	84.6	13.9	0.0	0.0	84.8	13.6
Migraine	200.2	327.9	63.9	1.6	6.7	11.6	66.6	0.0
Tension-type headache	356.7	619.9	73.5	2.8	0.5	0.9	74.6	3.4
Medication overuse headache	13.1	32.2	144.5	47.7	2.0	5.0	147.8	48.8
Other neurological disorders	0.0	0.0	46.2	-7.1	0.5	0.8	50.4	-5.2
Mental and substance use disorders	-	-	-	-	62.0	103.9	67.6	0.7
Schizophrenia	6.0	10.1	68.0	0.7	3.8	6.4	70.6	2.0
Alcohol use disorders	33.7	52.2	55.2	-10.4	3.3	5.1	56.7	-9.7
Drug use disorders	-	-	-	-	3.4	6.0	76.4	2.5
Opioid use disorders	4.5	7.7	71.5	1.7	1.8	3.1	74.3	3.2
Cocaine use disorders	1.4	2.5	84.8	0.2	0.3	0.5	85.9	6.2
Amphetamine use disorders	4.5	7.9	74.3	-1.0	0.6	1.0	76.4	0.1
Cannabis use disorders	3.2	5.6	75.1	0.2	0.1	0.2	76.0	0.8
Other drug use disorders	-	-	-	-	0.8	1.4	78.1	1.4
Depressive disorders	-	-	-	-	26.3	44.4	69.3	1.9
Major depressive disorder	116.3	194.9	67.9	1.2	23.5	39.8	69.5	2.1
Dysthymia	29.6	48.7	64.9	-0.1	2.8	4.7	66.3	0.7
Bipolar disorder	16.0	27.5	71.5	0.3	3.2	5.5	73.9	1.5
Anxiety disorders	76.2	128.1	68.2	-0.1	6.8	11.7	69.7	0.8
Eating disorders	-	-	-	-	0.7	1.2	78.2	0.7
Anorexia nervosa	0.5	0.8	78.4	2.8	0.1	0.2	78.7	2.6
Bulimia nervosa	2.8	5.0	76.7	-0.5	0.6	1.0	78.0	0.2
Autistic spectrum disorders	-	-	-	-	3.4	5.5	61.8	1.0
Autism	8.8	14.2	60.7	0.1	2.1	3.5	62.1	1.1
Asperger syndrome	12.7	20.3	60.3	0.2	1.3	2.0	61.4	0.9
Attention-deficit/hyperactivity disorder	20.5	32.9	60.4	-0.0	0.4	0.6	60.8	0.4
Conduct disorder	30.0	48.5	61.5	0.0	3.6	5.8	62.6	0.1
Idiopathic intellectual disability	96.7	148.0	53.4	-3.4	4.7	7.2	53.9	-2.9
Other mental and substance use disorders	36.4	61.6	69.3	0.1	2.7	4.6	71.4	1.1
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	13.0	22.2	70.6	7.5
Diabetes mellitus	5.5	11.0	103.2	26.2	0.4	0.8	105.7	30.2
Acute glomerulonephritis	0.0	0.0	23.0	-18.2	0.0	0.0	23.0	-18.2
Chronic kidney disease	-	-	-	-	4.2	6.7	61.2	3.2
Chronic kidney disease due to diabetes mellitus	55.4	81.6	46.9	-2.1	0.8	1.3	53.2	0.2
Chronic kidney disease due to hypertension	93.8	152.0	59.8	5.3	1.2	1.9	59.9	0.7
Chronic kidney disease due to glomerulonephritis	80.9	122.6	52.2	6.5	1.3	2.2	62.5	7.5
Chronic kidney disease due to other causes	61.1	98.9	62.7	-0.3	0.8	1.4	64.8	2.6
Urinary diseases and male infertility	-	-	-	-	1.1	1.7	54.9	0.9

Appendix Table G.4 - Central African Republic prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.6 (0.5 to 0.6)	1.0 (0.9 to 1.0)	72.3 (57.8 to 89.1)	0.0 (-0.6 to 17.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.0 (37.1 to 123.0)	9.4 (-10.6 to 32.6)
Urolithiasis	6.7 (4.9 to 8.9)	8.7 (6.7 to 11.6)	31.4 (10.7 to 44.4)	-13.5 (-26.2 to -6.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	58.8 (38.6 to 82.3)	-0.6 (-12.0 to 11.6)
Benign prostatic hyperplasia	21.8 (20.1 to 23.7)	32.0 (29.3 to 34.9)	46.5 (29.0 to 66.7)	0.3 (-11.4 to 13.9)	0.8 (0.5 to 1.1)	1.1 (0.7 to 1.6)	47.7 (29.5 to 68.0)	1.4 (-10.7 to 15.1)
Male infertility due to other causes	38.0 (29.6 to 46.9)	65.9 (51.0 to 81.8)	72.5 (26.5 to 139.8)	-4.0 (-29.7 to 33.7)	0.2 (0.1 to 0.5)	0.4 (0.2 to 0.9)	75.0 (26.9 to 149.8)	-2.6 (-29.8 to 37.3)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	9.1 (5.7 to 119.8)	-
Gynecological diseases	-	-	-	-	3.0 (1.9 to 4.6)	5.5 (3.4 to 8.4)	83.9 (58.1 to 109.4)	6.7 (-6.8 to 20.0)
Uterine fibroids	45.5 (41.2 to 49.4)	72.7 (65.5 to 79.3)	60.0 (58.7 to 61.2)	-1.8 (-1.9 to -1.7)	0.7 (0.4 to 1.1)	1.4 (0.9 to 2.2)	110.6 (89.8 to 131.7)	27.6 (15.3 to 41.1)
Polycystic ovarian syndrome	40.9 (36.9 to 44.9)	73.6 (64.3 to 81.5)	80.9 (51.7 to 112.2)	2.6 (-12.6 to 19.6)	0.4 (0.2 to 0.8)	0.7 (0.3 to 1.4)	81.8 (51.8 to 113.0)	2.9 (-12.2 to 20.0)
Female infertility due to other causes	60.4 (50.7 to 71.3)	96.1 (74.6 to 122.5)	57.1 (20.2 to 111.9)	5.5 (-35.0 to 21.9)	0.5 (0.1 to 0.7)	0.5 (0.2 to 1.1)	99.6 (21.8 to 112.9)	-12.2 (-33.7 to 21.0)
Endometriosis	4.1 (3.5 to 4.7)	6.5 (5.5 to 7.5)	59.5 (27.5 to 97.3)	-9.8 (-27.7 to 11.3)	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.9)	61.5 (25.9 to 103.2)	8.8 (-28.1 to 15.1)
Genital prolapse	91.3 (79.0 to 103.0)	152.6 (127.9 to 176.4)	67.6 (34.7 to 104.2)	4.4 (-14.6 to 25.3)	0.3 (0.1 to 0.5)	0.5 (0.2 to 0.9)	68.5 (35.5 to 104.6)	4.8 (-14.2 to 25.7)
Premenstrual syndrome	90.7 (66.2 to 122.6)	147.7 (93.0 to 203.9)	63.9 (-7.3 to 164.8)	-9.7 (-49.8 to 44.4)	0.8 (0.4 to 1.2)	1.2 (0.6 to 2.0)	65.8 (8.3 to 166.0)	-9.0 (-49.6 to 46.4)
Other gynecological diseases	5.6 (3.7 to 7.6)	15.3 (11.1 to 19.4)	174.9 (93.6 to 320.3)	58.1 (13.6 to 134.8)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.8)	171.2 (63.1 to 424.9)	58.8 (-0.7 to 197.8)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	3.3 (2.2 to 4.7)	5.4 (3.6 to 7.8)	64.8 (39.4 to 79.2)	10.0 (-5.1 to 20.8)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.3 (-29.4 to 58.6)	0.5 (-53.6 to 5.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.4 (-31.5 to 45.6)	-7.4 (-53.7 to -2.5)
Thalassemia trait	14.5 (10.0 to 19.2)	21.8 (14.1 to 28.8)	58.2 (9.6 to 58.9)	-0.3 (-31.2 to 0.1)	0.2 (0.2 to 0.4)	0.3 (0.2 to 0.5)	40.6 (13.7 to 77.3)	-8.3 (-25.8 to 14.7)
Sickle cell disorders	4.2 (3.6 to 4.7)	6.9 (6.0 to 7.6)	62.7 (37.6 to 92.0)	5.3 (-10.8 to 25.1)	0.3 (0.3 to 0.6)	0.7 (0.5 to 1.0)	66.2 (34.8 to 102.6)	5.6 (-12.8 to 27.6)
Sickle cell trait	388.6 (375.8 to 420.8)	621.5 (583.2 to 654.7)	55.7 (51.9 to 61.5)	1.8 (-4.4 to 1.7)	2.7 (1.2 to 2.6)	2.7 (1.7 to 3.9)	479.9 (82.0 to 67.8)	2.8 (-30.0 to 11.0)
G6PD deficiency	324.6 (308.5 to 341.6)	514.3 (481.3 to 546.8)	58.3 (45.7 to 70.9)	-0.6 (-8.4 to 7.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	50.0 (8.5 to 102.8)	-3.2 (-24.8 to 22.1)
G6PD trait	716.7 (714.4 to 718.6)	1,143.5 (1,139.5 to 1,147.0)	59.5 (58.9 to 60.2)	0.5 (0.1 to 1.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	62.2 (-54.7 to 532.4)	4.4 (-67.2 to 254.0)
Other hemoglobinopathies and hemolytic anemias	27.0 (24.0 to 30.3)	57.5 (52.8 to 63.8)	112.8 (89.9 to 143.5)	40.5 (22.9 to 59.8)	0.8 (0.5 to 1.1)	1.6 (1.0 to 2.3)	111.0 (72.5 to 174.7)	46.5 (14.7 to 84.2)
Endocrine, metabolic, blood, and immune disorders	31.5 (27.2 to 35.5)	60.7 (50.8 to 69.0)	92.9 (55.3 to 136.3)	1.1 (-5.8 to 50.4)	2.1 (0.7 to 1.6)	2.1 (1.3 to 3.0)	94.7 (35.5 to 164.6)	29.9 (-4.0 to 66.5)
Musculoskeletal disorders	-	-	-	-	35.6 (25.5 to 47.0)	58.6 (41.3 to 77.3)	64.5 (51.9 to 76.2)	2.3 (-3.6 to 8.9)
Rheumatoid arthritis	7.4 (7.1 to 7.7)	11.0 (10.5 to 11.4)	49.0 (40.6 to 58.3)	-8.5 (-13.4 to -2.5)	1.7 (1.2 to 2.3)	2.6 (1.8 to 3.4)	51.0 (39.3 to 64.4)	-7.4 (-13.6 to 0.2)
Osteoarthritis	64.7 (62.0 to 67.2)	97.5 (93.3 to 101.4)	50.5 (42.4 to 59.2)	1.7 (-3.5 to 7.5)	3.9 (2.7 to 5.2)	5.9 (4.1 to 8.0)	66.7 (42.7 to 60.5)	8.2 (-3.0 to 2.6)
Low back and neck pain	-	-	-	-	25.9 (18.1 to 34.9)	43.6 (29.9 to 58.2)	67.7 (49.6 to 83.6)	1.3 (-7.5 to 11.0)
Low back pain	142.9 (135.8 to 150.3)	227.5 (215.1 to 239.4)	59.1 (48.2 to 71.1)	-1.0 (-7.9 to 5.7)	15.6 (10.6 to 21.5)	25.1 (17.1 to 34.7)	60.8 (48.7 to 73.3)	-1.1 (-7.2 to 7.0)
Neck pain	106.8 (89.9 to 125.1)	184.9 (147.7 to 223.6)	73.1 (39.5 to 113.6)	3.0 (-14.6 to 24.9)	10.3 (6.9 to 14.2)	18.0 (11.7 to 25.6)	75.7 (40.1 to 116.5)	4.1 (-14.0 to 26.1)
Gout	0.4 (0.4 to 0.5)	0.6 (0.5 to 0.7)	49.4 (24.8 to 81.5)	-2.1 (-16.9 to 17.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.0 (12.8 to 102.0)	-1.1 (-25.4 to 33.0)
Other musculoskeletal disorders	47.0 (36.4 to 57.9)	77.8 (60.9 to 94.5)	65.5 (52.8 to 78.8)	4.2 (0.8 to 18.0)	9.2 (2.7 to 6.1)	7.0 (4.6 to 10.1)	80.0 (53.6 to 82.2)	9.8 (-0.9 to 19.1)
Other non-communicable diseases	-	-	-	-	41.1 (26.1 to 61.2)	63.5 (40.4 to 96.8)	55.0 (47.3 to 60.8)	2.9 (-6.6 to 0.1)
Congenital anomalies	-	-	-	-	1.7 (1.1 to 2.5)	2.6 (1.7 to 3.9)	58.4 (33.6 to 89.2)	-0.9 (-16.8 to 19.3)
Neural tube defects	0.2 (0.1 to 0.2)	0.4 (0.4 to 0.6)	160.9 (83.8 to 280.3)	83.2 (27.2 to 175.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	172.2 (61.4 to 341.0)	96.3 (13.3 to 224.1)
Congenital heart anomalies	1.3 (0.9 to 1.8)	3.3 (2.2 to 4.7)	157.6 (41.8 to 307.7)	79.0 (-2.5 to 192.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	122.8 (30.8 to 263.8)	56.6 (-7.1 to 163.4)
Orofacial clefts	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.6)	160.4 (41.6 to 388.3)	91.6 (1.3 to 273.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	157.0 (30.6 to 425.5)	90.7 (-4.9 to 293.9)
Down syndrome	1.1 (0.8 to 1.4)	2.4 (1.8 to 3.2)	112.8 (50.9 to 214.0)	41.5 (0.5 to 109.9)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	117.4 (49.1 to 227.7)	47.3 (1.1 to 124.2)
Turner syndrome	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	81.6 (19.2 to 231.5)	16.9 (-24.0 to 113.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.6 (21.0 to 238.3)	17.3 (-23.9 to 114.6)
Klinefelter syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	50.0 (-1.1 to 124.6)	-4.9 (-37.6 to 42.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.5 (5.5 to 139.8)	-4.2 (-37.1 to 43.4)
Chromosomal unbalanced rearrangements	0.0 (1.3 to 2.1)	0.0 (2.8 to 4.6)	17.5 (53.0 to 197.6)	3.6 (1.1 to 99.4)	0.4 (0.1 to 0.3)	0.4 (0.3 to 0.6)	44.3 (51.8 to 205.5)	44.3 (3.3 to 106.5)
Other congenital anomalies	12.8 (8.9 to 17.6)	17.5 (12.0 to 24.5)	36.7 (15.1 to 61.0)	-14.7 (-27.2 to -0.2)	1.3 (0.7 to 2.0)	1.7 (1.0 to 2.9)	36.1 (11.3 to 70.9)	-14.5 (-30.1 to 7.2)
Skin and subcutaneous diseases	-	-	-	-	16.5 (10.3 to 25.4)	27.2 (17.1 to 41.8)	65.2 (53.7 to 75.5)	1.5 (-4.7 to 7.3)
Dermatitis	173.5 (146.0 to 200.4)	284.8 (237.5 to 330.6)	64.2 (62.1 to 65.9)	0.1 (0.0 to 0.1)	6.1 (3.9 to 8.7)	10.0 (6.3 to 14.4)	62.9 (58.0 to 67.6)	0.6 (-1.6 to 3.0)
Psoriasis	19.3 (16.5 to 22.0)	31.6 (26.9 to 36.3)	63.7 (61.5 to 65.8)	0.0 (-0.1 to 0.1)	1.5 (1.1 to 2.2)	2.6 (1.7 to 3.6)	65.2 (55.0 to 75.5)	0.9 (-4.1 to 6.1)
Cellulitis	0.6 (0.5 to 0.8)	1.0 (0.8 to 1.2)	56.6 (37.5 to 75.4)	-0.3 (-13.4 to 10.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	57.2 (22.5 to 99.5)	0.3 (-19.9 to 23.9)
Pyoderma	4.9 (3.6 to 6.3)	6.9 (5.2 to 8.8)	40.7 (31.4 to 52.3)	-4.3 (-10.6 to 3.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	40.9 (26.5 to 56.4)	-3.8 (-13.3 to 5.7)
Scabies	42.2 (33.2 to 51.4)	45.0 (39.4 to 50.5)	6.2 (-16.2 to 37.3)	-34.7 (-48.7 to -16.0)	1.1 (0.6 to 1.8)	1.2 (0.7 to 1.9)	6.8 (-16.4 to 38.5)	-34.3 (-48.7 to -14.8)
Fungal skin diseases	456.8 (368.7 to 575.8)	789.5 (588.8 to 919.2)	59.8 (56.9 to 63.3)	0.1 (0.0 to 0.1)	2.5 (1.0 to 5.6)	4.1 (1.6 to 9.1)	60.4 (57.1 to 64.4)	0.5 (-3.0 to 14.8)
Viral skin diseases	57.3 (44.2 to 69.8)	93.5 (71.4 to 113.9)	63.2 (57.8 to 67.9)	2.6 (0.9 to 4.7)	1.8 (1.0 to 2.8)	2.9 (1.7 to 4.5)	63.6 (55.9 to 70.6)	3.0 (-0.1 to 6.7)
Acne vulgaris	121.4 (84.9 to 169.7)	267.6 (196.7 to 339.8)	122.5 (31.5 to 261.5)	29.4 (-18.9 to 103.7)	1.3 (0.6 to 2.6)	2.9 (1.3 to 5.5)	122.8 (31.4 to 265.4)	30.1 (-19.1 to 106.2)
Alopecia areata	2.6 (2.3 to 2.9)	4.3 (3.8 to 4.8)	63.7 (41.0 to 94.7)	1.1 (-12.3 to 17.9)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	64.3 (36.3 to 102.5)	1.7 (-13.9 to 21.5)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.1 (30.8 to 95.7)	0.3 (-18.0 to 25.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.1 (30.6 to 95.9)	-0.3 (-18.0 to 25.8)
Urticaria	13.6 (8.4 to 20.3)	27.1 (15.7 to 37.8)	95.6 (7.5 to 221.4)	18.9 (-31.9 to 77.7)	0.8 (0.4 to 1.4)	1.6 (0.8 to 2.6)	102.3 (9.5 to 228.3)	20.5 (-32.4 to 82.5)
Decubitus ulcer	0.4 (0.3 to 0.4)	0.6 (0.5 to 0.7)	68.4 (26.3 to 109.1)	6.8 (-28.6 to 46.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	68.0 (24.1 to 112.6)	6.9 (-28.5 to 46.0)
Other skin and subcutaneous diseases	192.8 (134.1 to 273.1)	288.5 (198.5 to 404.1)	49.6 (42.3 to 57.8)	-5.4 (-8.7 to -2.3)	1.1 (0.5 to 2.3)	1.7 (0.8 to 3.4)	50.8 (43.4 to 58.8)	-4.8 (-8.0 to -1.7)
Sense organ diseases	-	-	-	-	18.0 (11.8 to 27.4)	26.1 (16.4 to 40.5)	46.6 (34.9 to 55.0)	-5.9 (-10.7 to -0.9)
Glaucoma	1.3 (0.9 to 1.7)	2.4 (1.7 to 3.2)	90.6 (58.2 to 131.1)	0.7 (-17.6 to 22.8)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	111.4 (67.8 to 159.0)	15.6 (-9.4 to 42.2)
Cataract	5.8 (3.9 to 7.9)	7.7 (5.3 to 10.9)	33.7 (4.2 to 73.6)	-13.9 (-31.8 to 15.3)	0.4 (0.2 to 0.5)	0.5 (0.3 to 0.8)	42.9 (19.7 to 73.1)	-10.3 (-24.1 to 8.2)
Macular degeneration	1.0 (0.7 to 1.5)	2.1 (1.3 to 3.3)	106.5 (54.7 to 163.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	99.7 (58.0 to 146.7)	24.3 (-0.4 to 54.1)
Uncorrected refractive error	476.8 (445.5 to 504.3)	731.7 (683.0 to 781.3)	53.4 (40.8 to 68.5)	-1.4 (-8.0 to 7.0)	6.4 (3.7 to 10.9)	9.4 (6.4 to 12.9)	46.2 (36.0 to 58.2)	-6.1 (-11.5 to 0.6)
Age-related and other hearing loss	376.5 (323.8 to 424.2)	533.7 (455.7 to 606.9)	41.7 (36.5 to 46.6)	-6.6 (-9.2 to -3.8)	9.1 (5.3 to 14.3)	12.7 (7.6 to 20.0)	39.8 (24.1 to 59.3)	-7.2 (-14.7 to 1.6)
Other vision loss	2.4 (1.9 to 3.1)	4.4 (3.5 to 5.6)	84.8 (68.2 to 106.7)	5.8 (-3.9 to 15.2)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	86.4 (61.5 to 115.9)	1.1 (-0.7 to 25.0)
Other sense organ diseases	69.5 (66.0 to 73.2)	106.5 (101.0 to 111.5)	53.3 (42.5 to 64.1)	-0.2 (-7.1 to 6.4)	1.8 (1.1 to 2.8)	2.8 (1.7 to 4.2)	53.4 (42.9 to 66.0)	0.2 (-6.7 to 7.7)
Oral disorders	-	-	-	-	4.9 (2.9 to 7.6)	7.6 (4.5 to 12.1)	56.0 (45.7 to 63.4)	-1.8 (-6.2 to 3.0)
Deciduous caries	261.5 (251.1 to 272.0)	380.2 (364.6 to 395.8)	45.4 (37.6 to 53.7)	0.5 (-4.9 to 6.2)	0.5 (0.0 to 0.2)	0.5 (0.1 to 0.3)	45.8 (34.5 to 56.5)	0.7 (-6.9 to 8.1)
Permanent caries	872.7 (829.0 to 919.0)	1,440.8 (1,372.8 to 1,513.6)	65.1 (54.5 to 77.0)	-0.4 (-5.8 to 5.9)	0.9 (0.4 to 1.6)	1.4 (0.6 to 2.7)	65.9 (54.5 to 78.3)	0.7 (-5.1 to 6.6)
Periodontal diseases	167.4 (157.6 to 175.8)	264.1 (248.8 to 278.3)	57.7					

Appendix Table G.4 - Central African Republic prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	59.7 (55.8 to 63.9)	84.7 (79.3 to 90.2)	42.0 (29.3 to 55.7)	-5.4 (-13.5 to 3.2)	1.6 (1.1 to 2.2)	2.3 (1.6 to 3.2)	43.0 (29.6 to 57.3)	4.7 (-13.1 to 4.6)
Other oral disorders	43.0 (40.5 to 45.5)	70.7 (66.6 to 74.8)	64.0 (52.4 to 79.2)	-0.1 (-6.9 to 7.6)	1.2 (0.8 to 1.8)	2.1 (1.3 to 3.1)	65.3 (52.0 to 80.6)	0.5 (-7.2 to 9.1)
Injuries	-	-	-	-	12.6 (9.7 to 16.2)	19.2 (14.6 to 24.7)	51.9 (47.3 to 61.6)	-3.8 (-6.6 to 2.2)
Transport injuries	-	-	-	-	5.1 (3.8 to 6.6)	7.1 (5.4 to 9.2)	40.0 (35.8 to 45.2)	-12.3 (-14.7 to -9.7)
Road injuries	-	-	-	-	4.1 (3.1 to 5.3)	5.8 (4.4 to 7.5)	41.4 (36.4 to 47.3)	-11.5 (-14.2 to -8.5)
Pedestrian road injuries	-	-	-	-	1.1 (0.8 to 1.4)	1.6 (1.2 to 2.0)	40.9 (31.6 to 50.7)	-11.4 (-15.9 to -6.6)
Cyclist road injuries	-	-	-	-	0.5 (0.4 to 0.6)	0.6 (0.4 to 0.7)	17.8 (9.4 to 26.0)	-23.4 (-28.7 to -18.2)
Motorcyclist road injuries	-	-	-	-	0.8 (0.6 to 1.1)	1.0 (0.7 to 1.3)	18.3 (11.7 to 27.0)	-26.0 (-30.3 to -21.3)
Motor vehicle road injuries	-	-	-	-	1.7 (1.2 to 2.1)	2.7 (2.0 to 3.4)	61.2 (52.0 to 72.8)	-4.9 (-5.1 to 6.1)
Other road injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.3 (-5.6 to 5.7)	-40.6 (-43.4 to -37.4)
Other transport injuries	-	-	-	-	0.9 (0.7 to 1.2)	1.3 (1.0 to 1.7)	34.7 (27.4 to 41.9)	-15.5 (-20.1 to -10.9)
Unintentional injuries	-	-	-	-	6.9 (5.2 to 8.9)	10.4 (7.9 to 13.5)	51.7 (48.1 to 55.4)	-3.3 (-5.8 to -0.8)
Falls	-	-	-	-	2.8 (2.1 to 3.7)	4.5 (3.4 to 5.8)	58.0 (53.3 to 65.2)	0.5 (-4.6 to 5.0)
Drowning	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	26.8 (14.9 to 39.2)	-19.1 (-25.8 to -12.0)
Fire, heat, and hot substances	-	-	-	-	0.8 (0.6 to 1.0)	1.0 (0.8 to 1.3)	25.3 (16.2 to 35.9)	-18.9 (-23.8 to -12.7)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.3 (7.9 to 44.1)	-21.5 (-31.3 to -12.0)
Exposure to mechanical forces	-	-	-	-	1.8 (1.4 to 2.4)	3.0 (2.3 to 3.9)	60.9 (54.4 to 67.9)	0.3 (-3.7 to 4.6)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	82.0 (68.5 to 95.0)	13.3 (5.3 to 20.8)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.6 (72.5 to 110.8)	21.8 (10.2 to 31.7)
Other exposure to mechanical forces	-	-	-	-	1.8 (1.3 to 2.3)	2.8 (2.1 to 3.7)	59.7 (53.0 to 66.9)	-0.4 (-4.6 to 4.1)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	73.1 (62.7 to 84.5)	12.3 (5.5 to 20.2)
Animal contact	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.3)	31.7 (24.2 to 39.3)	-17.1 (-21.1 to -12.8)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	34.8 (21.4 to 49.1)	-16.4 (-24.1 to -8.4)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	29.1 (22.0 to 36.8)	-17.6 (-21.3 to -13.3)
Foreign body	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	56.9 (49.5 to 64.6)	-0.6 (-5.3 to 4.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	41.9 (28.3 to 57.0)	-4.9 (-12.2 to 2.3)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	63.4 (47.4 to 80.0)	1.2 (-7.7 to 9.2)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	61.7 (51.1 to 73.2)	0.5 (-6.4 to 7.7)
Other unintentional injuries	-	-	-	-	0.9 (0.6 to 1.1)	1.2 (0.9 to 1.6)	44.1 (35.3 to 52.9)	-7.3 (-13.2 to -1.8)
Self-harm and interpersonal violence	-	-	-	-	0.7 (0.5 to 0.9)	1.0 (0.7 to 1.3)	47.3 (41.5 to 54.0)	-8.3 (-11.6 to -4.7)
Self-harm	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	65.9 (52.9 to 79.8)	3.1 (-4.2 to 10.6)
Interpersonal violence	-	-	-	-	0.6 (0.4 to 0.7)	0.8 (0.6 to 1.0)	43.6 (37.5 to 50.9)	-11.1 (-14.6 to -7.0)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	41.5 (33.4 to 50.4)	-13.0 (-18.3 to -7.6)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	60.2 (48.8 to 72.6)	-1.9 (-8.5 to 5.7)
Assault by other means	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.6)	40.0 (32.4 to 49.7)	-13.0 (-17.5 to -7.4)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.7 (0.3 to 1.7)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	0.7 (0.3 to 1.7)	-	-

Appendix Table G.4 - Chad prevalence and VIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VIDs 1990 (thousands)	VIDs 2013 (thousands)	% change VIDs, 1990 to 2013	% change age-standardized VIDs, 1990 to 2013
All causes	-	-	-	-	659.5 (477.1 to 870.7)	1,218.4 (890.6 to 1,607.4)	85.4 (73.6 to 92.1)	85.4 (15.0 to -6.2)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	236.5 (166.8 to 328.2)	413.1 (291.5 to 568.2)	74.4 (64.2 to 85.5)	-20.3 (-25.4 to -14.6)
HIV/AIDS and tuberculosis	-	-	-	-	9.7 (6.5 to 13.4)	34.0 (22.2 to 47.2)	247.5 (167.7 to 377.0)	70.4 (31.2 to 139.4)
Tuberculosis	15.5 (14.3 to 16.8)	30.5 (28.3 to 32.9)	96.9 (85.1 to 108.7)	-3.9 (-9.2 to 1.9)	4.6 (3.2 to 6.3)	9.3 (6.3 to 12.5)	99.6 (84.3 to 115.6)	-2.9 (-9.6 to 4.4)
HIV/AIDS	-	-	-	-	5.1 (2.8 to 7.5)	24.7 (15.2 to 36.2)	375.1 (222.4 to 780.1)	138.8 (60.1 to 350.5)
HIV/AIDS resulting in mycobacterial infection	1.3 (0.7 to 2.0)	3.9 (2.2 to 5.6)	200.8 (120.4 to 378.0)	55.9 (13.3 to 152.5)	0.5 (0.2 to 0.8)	1.4 (0.7 to 2.3)	204.1 (116.9 to 381.9)	58.1 (10.9 to 151.1)
HIV/AIDS resulting in other diseases	41.2 (24.9 to 52.8)	145.7 (124.4 to 172.8)	250.2 (145.1 to 509.5)	78.6 (24.3 to 210.2)	4.6 (2.4 to 6.9)	23.3 (14.1 to 34.3)	393.3 (223.5 to 891.0)	147.3 (60.3 to 409.6)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	40.4 (28.9 to 54.1)	65.4 (46.6 to 88.9)	61.5 (48.9 to 77.4)	-24.6 (-29.7 to -17.8)
Diarrheal diseases	126.1 (115.9 to 136.9)	209.4 (189.7 to 229.8)	65.5 (46.7 to 88.5)	-22.0 (-23.9 to -12.7)	20.2 (13.7 to 27.8)	33.6 (22.7 to 47.0)	66.4 (46.8 to 91.1)	-21.1 (-29.9 to -12.2)
Intestinal infectious diseases	-	-	-	-	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.7)	-18.0 (-70.8 to -51.0)
Typhoid fever	2.8 (2.4 to 3.3)	2.6 (2.1 to 3.0)	-10.3 (-28.8 to 15.7)	-57.9 (-67.3 to -47.1)	0.4 (0.2 to 0.5)	0.3 (0.2 to 0.5)	-7.4 (-31.9 to 26.1)	-56.8 (-67.8 to -42.7)
Paratyphoid fever	1.9 (1.6 to 2.2)	2.2 (1.8 to 2.5)	15.6 (-11.4 to 47.9)	-48.6 (-60.4 to -33.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	16.6 (-15.9 to 58.7)	47.9 (-6.1 to 29.1)
Other intestinal infectious diseases	-	-	-	-	0.1 (0.1 to 0.3)	0.0 (0.0 to 0.1)	-57.9 (-82.3 to -43.1)	85.1 (-91.8 to -74.0)
Lower respiratory infections	4.3 (3.7 to 5.1)	7.8 (6.7 to 9.3)	80.6 (50.6 to 123.4)	-5.1 (-18.5 to 9.9)	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.2)	82.2 (42.2 to 131.2)	9.0 (-20.9 to 13.6)
Upper respiratory infections	351.6 (315.9 to 385.5)	682.7 (614.7 to 748.1)	93.8 (67.7 to 125.7)	-11.0 (-22.5 to 2.4)	4.1 (2.3 to 6.8)	8.0 (4.5 to 13.2)	94.6 (68.7 to 128.2)	-10.6 (-21.6 to 3.0)
Otitis media	128.6 (116.6 to 140.6)	265.8 (239.6 to 291.9)	105.5 (84.8 to 134.3)	-6.9 (-17.4 to 6.1)	2.7 (1.6 to 4.2)	5.5 (3.3 to 8.8)	107.6 (84.9 to 135.1)	-6.1 (-17.3 to 6.6)
Meningitis	-	-	-	-	10.7 (7.3 to 15.0)	14.7 (10.0 to 20.4)	35.4 (17.6 to 72.6)	-35.4 (-43.9 to -18.8)
Pneumoococcal meningitis	49.7 (29.4 to 75.8)	59.4 (36.9 to 89.9)	18.4 (-9.5 to 66.4)	-41.7 (-55.2 to -17.5)	4.2 (2.9 to 5.9)	5.5 (3.7 to 7.6)	30.0 (4.7 to 73.5)	38.1 (-50.7 to -19.4)
H influenzae type B meningitis	19.0 (7.8 to 35.1)	23.5 (10.6 to 41.8)	24.9 (-11.9 to 81.8)	-42.0 (-59.1 to -16.3)	1.9 (1.2 to 2.8)	2.9 (1.8 to 4.5)	51.8 (4.7 to 132.3)	-30.4 (-51.4 to 6.4)
Meningococcal meningitis	24.2 (9.1 to 50.8)	30.9 (12.7 to 62.8)	29.0 (-11.9 to 101.5)	-37.9 (-56.8 to -9.6)	2.8 (1.6 to 4.3)	4.1 (2.2 to 6.6)	47.5 (-13.3 to 137.4)	-31.0 (-56.0 to 6.1)
Other meningitis	14.6 (9.5 to 22.2)	17.2 (11.6 to 25.4)	17.3 (-5.5 to 49.5)	-41.2 (-52.6 to -22.5)	1.8 (1.2 to 2.5)	2.2 (1.5 to 3.1)	22.4 (-1.9 to 53.0)	-38.8 (-51.4 to -24.5)
Encephalitis	1.2 (0.6 to 2.5)	2.2 (1.1 to 4.5)	83.6 (60.7 to 107.2)	-11.8 (-23.3 to 2.5)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	93.9 (64.5 to 129.6)	-9.4 (-21.3 to 4.0)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	92.6 (-93.4 to 5,872.9)	-6.6 (-95.3 to 1,783.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.6 (93.7 to 6,524.8)	-6.6 (-95.3 to 1,806.4)
Whooping cough	17.4 (13.3 to 22.7)	32.7 (25.0 to 42.6)	87.6 (86.3 to 88.9)	-9.8 (-10.4 to -9.2)	0.9 (0.5 to 1.4)	1.6 (0.9 to 2.6)	88.3 (77.7 to 99.6)	-9.4 (-14.7 to -3.6)
Tetanus	4.6 (1.3 to 11.0)	2.8 (1.1 to 7.3)	-38.3 (-86.9 to 173.6)	-72.5 (-94.5 to 26.1)	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.3)	-19.6 (-70.4 to 75.1)	-64.7 (-87.8 to -23.2)
Measles	5.0 (3.4 to 6.9)	1.2 (0.8 to 1.8)	-75.2 (-80.5 to -68.3)	-88.3 (-90.8 to -85.1)	0.4 (0.2 to 0.7)	0.1 (0.1 to 0.2)	-94.9 (-82.9 to -63.3)	-88.2 (-92.0 to -82.8)
Varicella and herpes zoster	3.8 (3.4 to 4.1)	8.4 (7.7 to 9.1)	122.6 (97.6 to 151.6)	2.9 (-15.9 to 26.6)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	103.7 (47.8 to 183.3)	3.1 (-27.7 to 49.0)
Neglected tropical diseases and malaria	-	-	-	-	80.4 (52.2 to 118.7)	114.4 (74.0 to 176.2)	41.7 (25.1 to 60.2)	-34.8 (-43.6 to -25.5)
Malaria	2,335.3 (2,084.2 to 2,623.5)	3,407.2 (2,994.7 to 3,876.1)	45.8 (29.4 to 63.2)	-33.8 (-41.8 to -24.7)	21.2 (13.8 to 30.1)	31.0 (20.8 to 44.4)	45.7 (35.2 to 73.2)	-35.3 (-39.5 to -22.0)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.1 to 0.2)	-	-
Leishmaniasis	-	-	-	-	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	119.1 (21.0 to 239.5)	5.6 (-38.8 to 60.1)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.3 (37.4 to 209.4)	-3.4 (-30.1 to 27.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.3 (37.3 to 210.4)	-3.4 (-30.2 to 27.7)
Cutaneous and mucocutaneous leishmaniasis	8.2 (4.9 to 13.2)	17.6 (9.3 to 29.1)	120.0 (21.1 to 238.0)	5.6 (-39.3 to 57.9)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	119.1 (21.0 to 239.5)	5.6 (-38.8 to 60.1)
African trypanosomiasis	2.5 (0.8 to 5.7)	0.8 (0.4 to 1.5)	-66.2 (-76.4 to -49.7)	-83.7 (-88.7 to -75.8)	0.7 (0.2 to 1.6)	0.2 (0.1 to 0.4)	-61.1 (-78.2 to -43.9)	-83.7 (-89.7 to -74.3)
Schistosomiasis	1,366.8 (619.5 to 2,483.1)	2,967.2 (1,371.9 to 5,327.9)	116.4 (110.5 to 122.2)	0.1 (-2.4 to 2.4)	12.2 (5.0 to 26.9)	26.4 (10.9 to 58.6)	117.6 (87.7 to 133.7)	0.6 (-12.8 to 7.2)
Cysticercosis	5.7 (2.4 to 10.5)	10.5 (3.7 to 22.4)	80.6 (-32.9 to 443.6)	-20.0 (-70.1 to 120.9)	1.4 (0.5 to 2.7)	2.6 (0.9 to 5.6)	87.0 (-31.1 to 462.7)	-17.8 (-69.7 to 135.0)
Cystic echinococcosis	1.5 (1.2 to 1.8)	2.1 (1.7 to 2.3)	31.5 (17.4 to 55.3)	-45.3 (-50.7 to -29.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	34.4 (2.2 to 76.2)	-43.6 (-54.3 to -24.9)
Lymphatic filariasis	224.2 (160.3 to 296.5)	412.8 (310.0 to 520.7)	84.1 (32.0 to 163.5)	-11.9 (-33.8 to 18.8)	6.7 (3.0 to 11.9)	11.6 (5.0 to 21.5)	78.2 (12.2 to 134.9)	-9.9 (-45.6 to 25.2)
Onchocerciasis	355.5 (218.7 to 573.7)	216.8 (137.2 to 312.3)	-37.2 (-63.4 to -7.1)	-63.2 (-77.9 to 47.2)	21.2 (11.1 to 33.6)	15.3 (7.0 to 27.1)	59.1 (53.9 to 64.4)	59.1 (-7.5 to -38.3)
Trachoma	25.1 (15.3 to 37.4)	12.7 (6.8 to 20.4)	-49.8 (-64.5 to -35.4)	-69.7 (-78.7 to -59.8)	1.8 (1.0 to 2.9)	1.0 (0.5 to 1.7)	45.8 (-58.8 to -31.8)	-67.9 (-76.3 to -58.8)
Dengue	0.3 (0.1 to 0.8)	3.1 (1.0 to 7.8)	951.3 (938.5 to 966.2)	382.5 (376.7 to 389.4)	0.1 (0.0 to 0.1)	0.5 (0.1 to 1.4)	896.7 (716.4 to 1,094.3)	348.4 (282.5 to 418.9)
Yellow fever	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-43.2 (-60.8 to -12.9)	-73.8 (-80.8 to -63.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.2 (-60.9 to -12.5)	-73.8 (-80.8 to -63.7)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (51.5 to 231.1)	0.0 (-23.6 to 50.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (50.8 to 231.4)	6.0 (-23.6 to 50.2)
Intestinal nematode infections	-	-	-	-	5.1 (3.2 to 7.9)	11.0 (6.9 to 17.1)	114.6 (92.6 to 137.1)	-2.1 (-12.1 to 8.5)
Ascariasis	93.0 (58.5 to 145.3)	200.5 (127.2 to 308.1)	115.0 (12.2 to 289.8)	-0.8 (-53.9 to 116.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.0 (67.6 to 184.4)	0.3 (-26.8 to 39.9)
Trichuriasis	89.0 (52.8 to 144.7)	192.8 (117.2 to 316.3)	118.5 (6.6 to 331.4)	0.1 (-61.9 to 138.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	116.4 (46.3 to 235.9)	-0.7 (-38.5 to 64.4)
Hookworm disease	1,124.6 (809.6 to 1,550.2)	2,440.2 (1,786.6 to 3,293.6)	115.6 (35.2 to 243.6)	115.6 (43.7 to 76.0)	5.1 (3.2 to 7.9)	11.0 (6.9 to 17.1)	114.6 (92.6 to 137.1)	5.1 (-12.1 to 8.5)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	132.3 (100.7 to 167.1)	269.3 (250.2 to 298.3)	103.2 (60.2 to 168.5)	-10.9 (-26.5 to 11.2)	9.9 (5.3 to 18.2)	14.6 (9.0 to 24.1)	51.2 (52.2 to 105.9)	-41.4 (-62.5 to -16.5)
Maternal disorders	-	-	-	-	1.9 (1.2 to 2.8)	2.9 (1.7 to 4.3)	50.2 (25.7 to 80.9)	-32.2 (-41.8 to -19.9)
Maternal hemorrhage	2.8 (2.3 to 3.4)	5.4 (3.9 to 7.1)	94.9 (30.9 to 169.1)	-12.8 (-39.0 to 17.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	79.1 (-12.7 to 202.5)	21.5 (-60.5 to 31.2)
Maternal sepsis and other maternal infections	3.2 (1.8 to 4.9)	5.1 (3.1 to 7.3)	58.3 (38.0 to 99.0)	-25.6 (-34.6 to -6.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	58.5 (-6.9 to 222.1)	-27.7 (-55.3 to 26.4)
Maternal hypertensive disorders	2.3 (0.9 to 4.3)	4.4 (1.6 to 8.1)	88.6 (73.6 to 103.1)	-17.3 (-22.9 to -11.8)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.5)	89.1 (60.3 to 127.5)	-17.2 (-29.1 to -1.7)
Obstructed labor	4.0 (2.6 to 5.4)	5.7 (3.8 to 7.7)	41.3 (28.3 to 61.2)	-34.8 (-41.2 to -26.2)	1.3 (0.7 to 2.0)	1.9 (1.1 to 2.9)	42.5 (22.7 to 69.0)	-34.6 (-43.2 to -23.5)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.6 (-7.9 to 326.4)	-27.6 (-57.5 to 75.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.6 (-8.1 to 328.1)	-27.6 (-57.5 to 75.5)
Other maternal disorders	-	-	-	-	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.9)	57.4 (4.0 to 141.4)	-29.7 (-56.9 to 7.6)
Neonatal disorders	-	-	-	-	3.3 (1.8 to 6.1)	12.1 (7.3 to 18.8)	267.2 (149.0 to 477.4)	76.6 (13.9 to 189.5)
Preterm birth complications	18.1 (8.8 to 35.0)	82.6 (43.9 to 150.8)	355.2 (287.0 to 478.2)	108.7 (79.6 to 160.4)	1.0 (0.6 to 1.7)	5.9 (3.2 to 9.8)	470.9 (220.0 to 897.2)	167.6 (54.2 to 369.6)
Neonatal encephalopathy due to birth asphyxia and trauma	42.2 (3.5 to 134.3)	75.5 (7.8 to 239.0)	81.6 (52.6 to 153.3)	-16.8 (-29.8 to 15.0)	1.4 (0.5 to 3.4)	3.0 (1.2 to 6.8)	117.4 (50.4 to 319.7)	0.5 (-26.5 to 111.2)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.7)	341.3 (321.7 to 394.8)	126.4 (116.4 to 153.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	135.0 (299.3 to 412.2)	131.2 (104.9 to 162.8)
Hemolytic disease and other neonatal jaundice	1.0 (0.4 to 2.3)	3.5 (1.7 to 6.6)	264.6 (39.6 to 998.0)	86.1 (-32.7 to 509.7)	0.4 (0.1 to 0.9)	1.3 (0.6 to 2.6)	272.4 (41.4 to 1,069.1)	91.7 (-32.7 to 545.9)
Other neonatal disorders	-	-	-	-	0.6 (0.2 to 1.4)	1.8 (0.8 to 3.7)	243.3 (52.0 to 666.5)	64.2 (-27.5 to 274.1)
Nutritional deficiencies	-	-	-	-	94.6 (64.0 to 132.0)	172.8 (116.7 to 245.2)	82.2 (64.0 to 102.9)	-21.0 (-26.7 to -14.8)
Protein-energy malnutrition	81.4 (40.7 to 140.0)	144.0 (67.8 to 272.5)	71.6 (-27.8 to 333.6)	-17.1 (-62.9 to 98.2)	10.0 (4.4 to 19.1)	17.7 (7.2 to 35.3)	72.2 (-28.0 to 335.9)	-36.8 (-63.5 to 100.1)
Iodine deficiency	167.7 (140.4 to 195.1)	195.8 (157.2 to 232.7)	15.7 (-59.8 to -25.2)	-46.2 (-18.8 to 48.8)	3.0 (1.8 to 4.8)	3.5 (2.1 to 5.9)	16.5 (-11.0 to 55.5)	-46.0 (-59.7 to -24.7)
Vitamin A deficiency	16.3 (11.6 to 21.1)	26.9 (19.4 to 36.4)	64.5 (36.1 to 101.5)	-20.4 (-32.5 to -5.3)	0.8 (0.4 to 1.2)	1.3 (0.7 to 2.0)	66.7 (37.7 to 103.2)	-18.3 (-30.8 to -2.8)

Appendix Table G.4 - Chad prevalence and VIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VIDs 1990 (thousands)	VIDs 2013 (thousands)	% change VIDs, 1990 to 2013	% change age-standardized VIDs, 1990 to 2013
Iron-deficiency anemia	2,025.5 (1,978.8 to 2,091.2)	3,924.6 (3,864.6 to 3,990.0)	93.2 (86.8 to 99.6)	-15.5 (-18.2 to -13.4)	80.9 (54.8 to 115.0)	150.2 (101.1 to 214.9)	85.8 (77.6 to 91.4)	85.8 (-23.8 to -17.0)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.3)	97.0 (-38.2 to 546.5)	97.0 (-69.4 to 202.3)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	6.0 (4.0 to 8.6)	11.5 (7.5 to 16.7)	89.1 (72.7 to 123.0)	16.5 (-26.0 to -6.2)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.1 (0.6 to 1.9)	2.2 (1.3 to 3.9)	101.8 (56.1 to 161.2)	9.0 (-27.6 to 10.5)
Syphilis	0.6 (0.6 to 0.7)	0.7 (0.6 to 0.8)	8.8 (-8.7 to 28.4)	-41.7 (-48.8 to -32.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	150.2 (-17.2 to 43.7)	41.0 (-53.0 to -25.6)
Chlamydial infection	80.4 (59.6 to 111.0)	158.6 (104.1 to 245.0)	105.3 (20.1 to 259.3)	-9.4 (-47.2 to 56.2)	0.4 (0.2 to 0.6)	0.9 (0.4 to 1.5)	122.7 (26.7 to 269.4)	-0.6 (-41.8 to 58.4)
Gonococcal infection	29.0 (22.2 to 36.6)	66.0 (44.6 to 93.3)	129.6 (31.2 to 238.4)	-1.7 (-43.1 to 40.4)	0.2 (0.1 to 0.3)	0.5 (0.2 to 0.8)	122.7 (24.5 to 251.1)	-3.8 (-43.6 to 48.7)
Trichomoniasis	71.0 (33.7 to 111.6)	155.5 (77.5 to 246.3)	123.4 (8.1 to 277.2)	2.4 (-44.0 to 63.0)	0.1 (0.0 to 0.1)	0.3 (0.1 to 0.7)	125.8 (-8.1 to 304.1)	3.3 (-50.2 to 74.2)
Genital herpes	888.8 (821.0 to 960.4)	1,732.2 (1,595.5 to 1,872.6)	94.5 (72.1 to 118.7)	3.8 (-14.9 to 7.7)	0.2 (0.1 to 0.6)	0.5 (0.2 to 1.1)	99.0 (72.8 to 126.3)	3.4 (-15.3 to 9.1)
Other sexually transmitted diseases	2.2 (1.5 to 3.0)	3.4 (2.3 to 4.6)	54.5 (30.4 to 82.5)	-26.1 (-37.8 to -13.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	70.7 (11.7 to 164.5)	-20.8 (-44.4 to 14.2)
Hepatitis	-	-	-	-	0.8 (0.5 to 1.2)	1.2 (0.8 to 1.8)	52.5 (16.8 to 86.2)	-30.3 (-50.9 to -10.2)
Hepatitis A	11.4 (10.7 to 12.1)	23.6 (22.3 to 25.0)	106.3 (105.7 to 107.1)	-2.7 (-2.9 to -2.4)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	125.7 (99.9 to 155.8)	3.9 (-7.5 to 16.5)
Hepatitis B	1,182.9 (963.4 to 1,366.8)	1,473.1 (1,278.7 to 1,661.2)	237.1 (3.5 to 55.9)	-43.5 (-51.2 to -31.5)	0.5 (0.3 to 0.9)	0.6 (0.3 to 0.9)	17.0 (-23.9 to 65.5)	-42.0 (-65.8 to -12.0)
Hepatitis C	408.6 (354.2 to 464.0)	608.7 (537.1 to 687.5)	48.2 (23.6 to 76.5)	-26.6 (-36.7 to -14.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	58.0 (-19.9 to 117.1)	-19.9 (-38.6 to 6.4)
Hepatitis E	3.0 (2.3 to 3.7)	5.7 (3.5 to 7.2)	95.6 (18.6 to 175.2)	-11.0 (-44.9 to 25.2)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	95.5 (12.7 to 187.0)	-10.8 (-46.8 to 29.2)
Leprosy	1.3 (0.9 to 1.7)	1.9 (1.7 to 2.2)	52.7 (24.4 to 95.5)	-11.8 (-26.7 to 9.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	54.4 (20.0 to 102.9)	-10.6 (-28.1 to 13.8)
Other infectious diseases	96.9 (75.8 to 119.5)	193.8 (180.7 to 206.9)	99.4 (77.2 to 145.4)	-12.9 (-20.8 to 0.9)	7.9 (2.6 to 5.8)	9.9 (5.1 to 11.4)	93.2 (75.8 to 152.4)	-15.8 (-24.2 to 6.3)
Non-communicable diseases	-	-	-	-	361.0 (265.4 to 460.0)	743.6 (539.6 to 964.0)	105.8 (100.3 to 111.0)	0.6 (-2.0 to 3.0)
Neoplasms	-	-	-	-	1.0 (0.7 to 1.3)	2.5 (1.7 to 3.4)	148.1 (101.0 to 216.8)	32.1 (5.9 to 69.4)
Esophageal cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	99.2 (34.9 to 191.3)	16.5 (-21.5 to 69.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.9 (37.0 to 174.5)	10.9 (-22.1 to 57.7)
Stomach cancer	0.5 (0.4 to 0.6)	0.7 (0.5 to 0.9)	50.2 (13.0 to 107.0)	-13.8 (-34.5 to 17.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	53.2 (14.0 to 111.9)	-11.9 (-34.9 to 20.0)
Liver cancer	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	60.0 (14.9 to 128.1)	9.6 (-35.2 to 27.0)
Liver cancer due to hepatitis B	0.3 (0.2 to 0.5)	0.6 (0.3 to 0.9)	68.5 (-12.6 to 196.4)	-13.1 (55.2 to 54.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	69.3 (-3.3 to 170.1)	-12.5 (-51.7 to 42.4)
Liver cancer due to hepatitis C	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.6)	323.2 (82.7 to 825.2)	150.6 (20.2 to 429.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	301.4 (86.0 to 705.9)	137.6 (17.4 to 356.3)
Liver cancer due to alcohol use	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	0.6 (-50.5 to 107.9)	-41.1 (-69.5 to 14.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	2.5 (-44.9 to 96.6)	-40.1 (-67.9 to 11.1)
Liver cancer due to other causes	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	3.4 (-48.0 to 95.9)	-88.7 (-72.3 to 11.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	5.0 (-45.5 to 80.6)	49.3 (-70.5 to -0.8)
Larynx cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	35.1 (-10.0 to 206.9)	-24.2 (-48.2 to 71.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-10.5 to 204.8)	-23.5 (-48.4 to 70.4)
Tracheal, bronchus and lung cancer	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	70.1 (24.9 to 129.7)	-1.0 (-27.3 to 32.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	68.5 (25.4 to 131.8)	-1.5 (-27.1 to 34.5)
Breast cancer	1.2 (0.9 to 1.5)	3.7 (2.7 to 5.0)	198.2 (112.4 to 326.6)	57.0 (14.5 to 127.6)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	165.5 (85.9 to 280.0)	40.5 (0.2 to 102.3)
Cervical cancer	2.4 (1.6 to 3.2)	4.6 (3.1 to 6.6)	87.6 (21.3 to 211.0)	0.2 (-35.0 to 57.0)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	86.3 (42.3 to 206.6)	-1.1 (-34.3 to 55.7)
Uterine cancer	0.4 (0.2 to 0.6)	1.0 (0.5 to 1.7)	156.9 (37.6 to 332.9)	40.2 (-22.3 to 133.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	151.5 (19.7 to 130.1)	37.6 (-19.7 to 130.1)
Prostate cancer	0.7 (0.5 to 1.3)	4.0 (2.4 to 6.6)	447.7 (180.8 to 849.5)	229.2 (66.3 to 445.1)	0.1 (0.0 to 0.1)	0.4 (0.2 to 0.6)	373.4 (136.8 to 682.0)	185.7 (44.8 to 359.2)
Colon and rectum cancer	0.4 (0.4 to 0.5)	1.3 (1.0 to 1.6)	179.4 (119.1 to 257.7)	51.5 (19.2 to 94.1)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.2)	160.4 (100.5 to 236.1)	42.2 (8.7 to 85.7)
Lip and oral cavity cancer	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	109.6 (43.6 to 195.5)	16.6 (-19.7 to 66.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	105.6 (45.3 to 190.5)	14.4 (-20.9 to 65.4)
Nasopharynx cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	101.7 (33.0 to 216.0)	-2.4 (-35.3 to 50.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (30.8 to 193.5)	-6.2 (-35.6 to 39.7)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	77.1 (7.4 to 190.3)	-0.4 (-41.0 to 66.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.2 (13.4 to 170.8)	-0.5 (-39.4 to 55.6)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	111.5 (46.6 to 216.9)	15.3 (-22.1 to 73.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	100.4 (45.2 to 180.6)	9.8 (-21.1 to 56.5)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	168.1 (97.2 to 286.3)	51.4 (9.9 to 113.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	160.0 (98.1 to 254.2)	43.1 (8.3 to 96.6)
Malignant skin melanoma	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.5)	124.3 (57.8 to 228.0)	15.0 (-18.2 to 68.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	118.0 (50.0 to 226.6)	13.6 (-22.1 to 67.5)
Non-melanoma skin cancer	0.2 (0.2 to 0.4)	0.6 (0.5 to 0.8)	156.8 (64.9 to 307.0)	41.2 (-11.2 to 120.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	201.7 (99.2 to 347.0)	55.8 (-5.9 to 137.0)
Ovarian cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	122.4 (46.5 to 241.7)	16.1 (-22.0 to 78.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	114.2 (36.2 to 235.9)	12.2 (-28.6 to 75.6)
Testicular cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	250.5 (90.6 to 522.9)	59.0 (-9.0 to 177.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	230.7 (73.6 to 499.7)	50.9 (-16.8 to 157.0)
Kidney cancer	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	124.0 (73.3 to 481.4)	35.8 (-6.5 to 102.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	185.9 (50.5 to 458.0)	27.3 (-13.8 to 86.5)
Bladder cancer	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.5)	82.4 (29.5 to 170.8)	-1.4 (-31.7 to 51.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	78.2 (28.2 to 173.7)	-2.8 (-31.3 to 57.0)
Brain and nervous system cancer	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	291.6 (157.5 to 488.1)	70.7 (26.1 to 129.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	269.4 (159.2 to 428.0)	57.2 (18.3 to 110.2)
Thyroid cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	131.5 (33.8 to 302.9)	16.5 (-33.4 to 96.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	120.8 (29.6 to 294.1)	11.6 (-36.1 to 90.9)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.4 (30.2 to 164.8)	0.0 (-32.9 to 45.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.5 (18.1 to 164.8)	0.1 (-34.4 to 44.5)
Hodgkin lymphoma	0.2 (0.1 to 0.3)	0.8 (0.5 to 1.1)	318.2 (166.4 to 576.9)	98.0 (32.7 to 198.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	280.6 (142.7 to 497.1)	80.7 (19.5 to 171.8)
Non-Hodgkin lymphoma	0.4 (0.3 to 0.6)	1.4 (1.0 to 2.0)	221.2 (121.5 to 361.9)	47.2 (8.3 to 104.2)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.2)	200.6 (110.5 to 335.1)	37.5 (2.4 to 95.7)
Multiple myeloma	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	140.3 (51.0 to 290.4)	34.2 (-17.2 to 122.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.0 (47.2 to 247.1)	28.2 (-19.9 to 107.4)
Leukemia	0.1 (0.1 to 0.2)	0.5 (0.3 to 0.8)	261.6 (112.2 to 544.3)	39.4 (-6.3 to 111.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	188.9 (94.2 to 352.9)	14.0 (-18.2 to 65.8)
Other neoplasms	1.4 (0.9 to 2.6)	5.6 (3.5 to 9.9)	314.3 (138.7 to 560.5)	58.1 (1.1 to 144.6)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.6)	270.8 (125.1 to 482.8)	40.5 (-9.5 to 123.2)
Cardiovascular diseases	-	-	-	-	9.8 (6.7 to 13.5)	18.1 (11.9 to 25.3)	85.2 (44.9 to 128.9)	-1.8 (-21.6 to 20.5)
Rheumatic heart disease	63.5 (47.0 to 81.7)	115.1 (90.8 to 141.6)	79.4 (28.7 to 177.5)	-18.5 (-37.2 to 17.2)	3.1 (1.8 to 4.7)	5.7 (3.5 to 8.5)	83.9 (33.0 to 174.6)	-13.6 (-34.8 to 18.7)
Ischemic heart disease	50.1 (40.3 to 61.1)	58.8 (50.6 to 69.4)	17.3 (9.6 to 50.5)	-26.7 (-42.1 to -8.4)	2.5 (1.5 to 3.7)	2.5 (1.6 to 3.7)	8.8 (-30.3 to 43.3)	-35.4 (-54.7 to -10.8)
Cerebrovascular disease	-	-	-	-	0.5 (0.3 to 0.6)	0.8 (0.6 to 1.1)	82.7 (51.0 to 125.1)	-1.6 (-19.0 to 24.3)
Ischemic stroke	2.3 (1.9 to 2.8)	4.2 (3.6 to 4.8)	78.2 (49.3 to 123.9)	-2.1 (-18.4 to 22.9)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	82.4 (49.0 to 128.8)	-0.5 (-18.8 to 26.2)
Hemorrhagic stroke	0.7 (0.5 to 0.8)	1.2 (1.0 to 1.4)	80.0 (42.0 to 133.3)	-6.7 (-27.7 to 21.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	82.4 (42.2 to 139.4)	-6.3 (-28.6 to 25.2)
Hypertensive heart disease	9.4 (7.0 to 12.4)	15.3 (11.0 to 19.8)	60.7 (7.3 to 145.2)	5.1 (-36.6 to 44.4)	1.0 (0.5 to 1.5)	1.6 (1.0 to 2.4)	62.1 (6.8 to 147.0)	-4.4 (-37.5 to 45.2)
Cardiomyopathy and myocarditis	5.6 (4.2 to 7.6)	10.2 (7.2 to 12.8)	87.4 (0.1 to 157.6)	10.6 (-46.4 to 63.9)	0.6 (0.4 to 0.9)	1.1 (0.7 to 1.6)	87.3 (1.6 to 159.3)	10.9 (-46.1 to 66.2)
Atrial fibrillation and flutter	0.7 (0.5 to 1.1)	3.1 (2.2 to 4.3)	179.3 (180.7 to 652.4)	0.1 (-50.1 to 463.6)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	331.6 (176.4 to 665.6)	181.6 (51.2 to 469.4)
Peripheral vascular disease	82.2 (60.6 to 105.5)	152.3 (106.9 to 210.4)	83.4 (25.8 to 189.0)	0.1 (-28.1 to 55.7)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	32.6 (-32.5 to 252.7)	-22.6 (-58.1 to 115.7)
Endocarditis	0.5 (0.3 to 0.9)	0.7 (0.5 to 1.0)	46.1 (-16.6 to 144.4)	-18.0 (-64.0 to 72.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	47.8 (-25.8 to 172.5)	0.0 (-65.8 to 96.9)
Other cardiovascular and circulatory diseases	29.1 (16.8 to 44.6)	85.6 (41.2 to 131.8)	192.6 (33.5 to 471.9)	29.4 (-33.8 to 218.5)	2.0 (1.1 to 3.3)	6.0 (2.4 to 10.2)	195.7 (37.7 to 481.5)	51.3 (-33.1 to 223.4)
Chronic respiratory diseases	-	-	-	-	22.4 (14.9 to 31.9)	43.6 (28.8 to 61.5)	94.8 (72.1 to 130.6)	0.6

Appendix Table G.4 - Chad prevalence and VIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VIDs 1990 (thousands)	VIDs 2013 (thousands)	% change VIDs, 1990 to 2013	% change age-standardized VIDs, 1990 to 2013	
Pneumoconiosis	-	-	-	-	0.0	0.0	81.5	-3.0	
Silicosis	0.0	0.0	67.1	-7.7	0.0	0.0	67.1	-7.7	
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-	
Coal workers pneumoconiosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-	
Other pneumoconiosis	0.0	0.1	94.2	1.4	0.0	0.0	94.7	1.8	
Asthma	81.5	144.9	77.7	-19.3	3.5	6.4	80.5	-18.7	
Interstitial lung disease and pulmonary sarcoidosis	0.1	0.3	121.4	5.9	0.0	0.0	118.9	5.4	
Other chronic respiratory diseases	-	-	-	-	4.2	8.3	97.3	3.3	
Cirrhosis	-	-	-	-	0.5	0.8	70.3	-14.3	
Cirrhosis due to hepatitis B	1.2	1.3	6.7	-41.9	0.2	0.2	6.1	-41.7	
Cirrhosis due to hepatitis C	0.5	1.1	126.6	14.7	0.1	0.2	129.9	16.0	
Cirrhosis due to alcohol use	0.6	0.9	62.4	-12.4	0.1	0.1	66.7	-12.4	
Cirrhosis due to other causes	0.7	1.7	139.3	24.3	0.1	0.3	141.5	24.1	
Digestive diseases	-	-	-	-	7.6	16.2	112.7	3.2	
Peptic ulcer disease	33.2	57.5	72.8	-3.2	1.3	2.2	66.0	-11.1	
Gastritis and duodenitis	68.4	146.4	113.0	3.6	3.1	6.3	106.9	-1.1	
Appendicitis	0.7	1.8	171.4	15.7	0.2	0.5	176.1	17.1	
Paralytic ileus and intestinal obstruction	0.1	0.2	84.9	-1.2	0.0	0.1	88.0	-0.9	
Inguinal, femoral, and abdominal hernia	31.7	62.0	92.3	-7.7	0.3	0.6	95.0	-6.8	
Inflammatory bowel disease	5.2	13.3	153.6	26.4	1.1	2.8	156.8	27.7	
Vascular intestinal disorders	0.0	0.0	168.3	12.2	0.0	0.0	172.3	17.8	
Gallbladder and biliary diseases	1.7	3.8	119.6	0.2	0.4	0.4	123.7	9.1	
Pancreatitis	0.9	3.0	119.2	10.2	0.3	0.6	122.6	11.8	
Other digestive diseases	-	-	-	-	1.2	2.6	131.7	12.6	
Neurological disorders	-	-	-	-	24.3	54.6	124.9	8.7	
Alzheimer disease and other dementias	8.3	13.9	67.6	-3.0	1.1	1.9	69.5	-1.5	
Parkinson disease	0.4	0.6	69.3	0.4	0.0	0.1	70.8	1.0	
Epilepsy	13.1	25.6	91.9	-10.7	3.5	7.1	99.4	-7.8	
Multiple sclerosis	0.3	0.7	126.4	12.6	0.1	0.3	126.1	12.2	
Migraine	396.0	831.1	109.7	13.4	28.8	28.5	111.1	-2.1	
Tension-type headache	683.6	1,526.9	122.1	2.8	1.0	2.3	124.0	3.4	
Medication overuse headache	25.8	78.5	205.7	48.4	4.0	12.3	209.9	49.1	
Other neurological disorders	0.0	0.0	98.8	-7.0	1.1	2.3	112.8	20.7	
Mental and substance use disorders	-	-	-	-	111.3	237.0	113.3	-0.6	
Schizophrenia	11.4	23.3	104.2	-0.1	7.1	14.8	107.7	1.2	
Alcohol use disorders	27.2	68.0	149.0	16.3	2.6	6.5	153.6	18.2	
Drug use disorders	-	-	-	-	6.7	14.5	116.8	1.6	
Opioid use disorders	8.9	18.1	103.9	0.5	3.6	7.4	106.3	1.3	
Cocaine use disorders	2.7	5.8	117.9	0.4	0.8	1.8	120.9	3.9	
Amphetamine use disorders	8.7	19.9	127.9	-0.7	1.1	2.6	130.1	0.2	
Cannabis use disorders	3.9	9.0	128.9	0.2	0.1	0.3	129.1	0.5	
Other drug use disorders	-	-	-	-	1.5	3.4	128.6	1.6	
Depressive disorders	-	-	-	-	47.7	86.5	103.6	3.2	
Major depressive disorder	208.9	419.7	101.5	-4.6	42.5	86.0	103.5	-3.8	
Dysthymia	54.2	110.9	103.8	-0.3	5.2	10.6	105.7	0.4	
Bipolar disorder	30.4	65.0	113.0	-0.1	6.1	13.2	115.9	1.0	
Anxiety disorders	131.9	290.0	119.2	11.2	12.1	26.7	121.4	0.5	
Eating disorders	-	-	-	-	1.4	3.2	131.4	0.2	
Anorexia nervosa	1.0	2.2	134.2	1.7	0.2	0.5	137.1	2.7	
Bulimia nervosa	5.6	12.8	129.6	-0.7	1.2	2.7	130.5	-0.2	
Autistic spectrum disorders	-	-	-	-	7.0	15.4	120.7	1.4	
Autism	18.0	39.6	118.8	0.5	4.4	9.7	121.0	1.4	
Asperger syndrome	26.0	57.1	118.8	0.6	2.6	5.7	119.9	1.2	
Attention-deficit/hyperactivity disorder	43.3	100.3	130.7	0.1	0.5	1.2	131.4	0.5	
Conduct disorder	61.1	146.9	132.0	0.1	0.7	1.7	133.3	0.1	
Idiopathic intellectual disability	15.5	339.9	115.6	-2.0	7.7	16.6	116.4	-1.5	
Other mental and substance use disorders	68.2	144.3	110.7	0.4	5.0	10.7	113.5	1.2	
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	34.4	72.0	108.8	5.0	
Diabetes mellitus	61.1	184.7	201.5	57.2	4.3	12.8	195.2	58.6	
Acute glomerulonephritis	0.1	0.1	50.2	-28.0	0.0	0.0	50.2	-28.0	
Chronic kidney disease	-	-	-	-	9.6	18.8	95.2	-3.6	
Chronic kidney disease due to diabetes mellitus	53.7	103.5	91.5	6.6	0.9	1.7	84.9	1.2	
Chronic kidney disease due to hypertension	26.2	53.9	104.2	-0.2	3.2	6.2	103.9	-0.2	
Chronic kidney disease due to glomerulonephritis	22.1	46.1	108.3	2.2	5.5	6.6	90.1	5.8	
Chronic kidney disease due to other causes	169.8	360.9	108.5	-0.5	2.1	4.3	103.7	-2.8	
Urinary diseases and male infertility	-	-	-	-	1.8	3.3	85.1	4.0	
	-	-	-	-	1.1	2.6	64.7	111.5	5.9

Appendix Table G.4 - Chad prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.1 (1.0 to 1.2)	2.6 (2.4 to 2.7)	130.2 (109.5 to 152.7)	-2.3 to 17.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	132.0 (80.4 to 199.2)	7.4 (-13.0 to 29.7)
Urolithiasis	12.9 (9.5 to 16.7)	19.9 (14.9 to 24.7)	56.5 (28.6 to 75.0)	-12.1 (-25.8 to -2.8)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	102.4 (75.2 to 134.4)	4.4 (-6.9 to 17.0)
Benign prostatic hyperplasia	36.4 (33.1 to 39.6)	62.4 (56.9 to 68.0)	70.4 (49.7 to 95.9)	3.2 (-9.0 to 17.8)	1.3 (0.8 to 1.8)	2.2 (1.4 to 3.1)	72.3 (51.0 to 98.5)	4.3 (-7.9 to 19.1)
Male infertility due to other causes	59.0 (42.8 to 73.5)	130.5 (102.2 to 159.3)	119.6 (57.8 to 222.5)	1.5 (-26.8 to 48.6)	0.3 (0.1 to 0.7)	0.8 (0.3 to 1.6)	121.6 (57.4 to 222.8)	1.6 (-26.4 to 47.1)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	107.6 (19.5 to 225.6)	0.0 (-39.5 to 62.8)
Gynecological diseases	-	-	-	-	6.3 (4.0 to 9.3)	13.0 (8.3 to 19.5)	106.5 (77.4 to 140.8)	-2.9 (-15.0 to 10.7)
Uterine fibroids	83.5 (75.4 to 90.9)	163.7 (147.3 to 178.8)	95.6 (94.3 to 96.7)	-1.3 (-1.4 to -1.3)	1.6 (1.0 to 2.5)	2.9 (1.7 to 4.5)	77.5 (62.6 to 90.2)	-13.4 (-21.1 to -7.3)
Polycystic ovarian syndrome	77.3 (67.9 to 86.0)	173.2 (152.6 to 193.9)	123.2 (91.5 to 165.7)	2.5 (-10.6 to 20.3)	0.7 (0.3 to 1.4)	1.7 (0.8 to 3.1)	124.9 (93.1 to 168.6)	3.1 (-10.1 to 20.2)
Female infertility due to other causes	61.0 (44.0 to 79.7)	125.4 (91.5 to 168.8)	104.9 (35.0 to 205.0)	0.1 (-35.0 to 52.0)	0.3 (0.1 to 0.7)	0.6 (0.2 to 1.3)	105.6 (36.5 to 204.1)	0.3 (-34.9 to 51.9)
Endometriosis	7.9 (6.7 to 9.0)	15.4 (13.2 to 17.9)	95.7 (57.0 to 142.2)	-8.5 (-26.4 to 12.6)	0.7 (0.5 to 1.0)	1.4 (0.9 to 2.0)	97.1 (56.5 to 150.6)	8.0 (-26.5 to 15.0)
Genital prolapse	187.7 (163.9 to 211.3)	379.6 (327.7 to 428.7)	102.0 (66.5 to 147.4)	1.8 (-13.3 to 18.7)	0.6 (0.3 to 1.1)	1.2 (0.6 to 2.2)	102.9 (67.7 to 149.1)	2.3 (-13.6 to 20.1)
Premenstrual syndrome	201.4 (127.0 to 264.2)	491.1 (345.6 to 642.8)	144.8 (46.9 to 316.8)	1.7 (-31.0 to 86.6)	4.1 (0.9 to 2.8)	7.4 (2.4 to 6.5)	145.8 (46.6 to 315.5)	15.2 (-31.6 to 87.1)
Other gynecological diseases	19.2 (13.1 to 24.8)	35.8 (27.1 to 45.1)	85.9 (37.0 to 170.0)	-15.6 (-38.7 to 20.2)	0.6 (0.3 to 0.9)	1.1 (0.6 to 1.7)	77.4 (31.1 to 225.0)	-20.2 (-54.6 to 42.1)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	8.4 (5.7 to 11.9)	16.5 (11.1 to 23.5)	96.5 (81.6 to 115.0)	-14.0 (-20.2 to -5.5)
Thalassemias	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.3)	122.8 (105.0 to 139.6)	-0.4 (-9.7 to 7.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	120.3 (90.8 to 171.2)	-1.0 (-13.1 to 19.7)
Thalassemia trait	82.6 (77.1 to 88.4)	179.5 (167.2 to 192.0)	116.7 (108.5 to 125.8)	1.6 (-3.6 to 4.5)	0.3 (1.1 to 2.3)	3.5 (2.4 to 5.1)	117.5 (94.0 to 141.7)	-0.8 (-12.5 to 13.3)
Sickle cell disorders	4.4 (3.6 to 5.1)	9.9 (8.0 to 11.5)	126.2 (75.3 to 180.5)	2.1 (-19.1 to 23.3)	0.5 (0.3 to 0.7)	1.1 (0.7 to 1.6)	129.4 (74.3 to 204.9)	4.4 (-16.3 to 33.3)
Sickle cell trait	571.8 (526.5 to 615.6)	1,226.9 (1,126.9 to 1,317.0)	113.9 (105.5 to 123.3)	-1.0 (-4.9 to 3.3)	2.8 (1.9 to 4.0)	5.8 (3.8 to 8.4)	107.8 (60.7 to 145.0)	4.2 (-27.1 to 14.9)
G6PD deficiency	498.0 (375.4 to 629.5)	1,059.2 (749.9 to 1,344.3)	109.6 (36.8 to 213.5)	0.1 (-36.6 to 45.0)	-2.8 (0.0 to 0.1)	0.1 (0.1 to 0.2)	113.9 (73.2 to 164.2)	-1.2 (-12.3 to 10.4)
G6PD trait	1,360.2 (1,246.3 to 1,433.0)	2,924.5 (2,654.2 to 3,102.1)	114.8 (91.8 to 138.3)	-0.8 (-11.4 to 10.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	130.3 (-13.7 to 437.8)	6.4 (-61.0 to 169.6)
Other hemoglobinopathies and hemolytic anemias	99.5 (85.7 to 113.4)	182.0 (169.4 to 197.2)	82.8 (59.1 to 112.0)	-3.4 (-27.8 to -7.8)	3.4 (2.2 to 4.9)	5.8 (3.9 to 8.4)	72.1 (53.4 to 116.4)	-28.0 (-37.4 to -11.6)
Endocrine, metabolic, blood, and immune disorders	105.0 (90.4 to 118.7)	202.8 (160.4 to 241.2)	92.7 (44.5 to 144.7)	-4.2 (-29.0 to 1.4)	7.7 (2.5 to 5.9)	7.7 (4.5 to 11.4)	82.2 (34.0 to 146.4)	-17.4 (-36.6 to 1.8)
Musculoskeletal disorders	-	-	-	-	75.6 (53.5 to 100.0)	152.6 (107.6 to 204.0)	101.5 (88.8 to 116.8)	1.7 (-4.6 to 8.2)
Rheumatoid arthritis	7.6 (7.2 to 7.9)	11.0 (10.5 to 11.6)	45.5 (36.6 to 56.1)	-32.7 (-37.0 to -27.7)	1.8 (1.3 to 2.4)	2.6 (1.8 to 3.5)	48.5 (33.9 to 65.4)	-31.8 (-37.4 to -25.5)
Osteoarthritis	109.0 (105.0 to 112.9)	193.1 (186.0 to 201.9)	76.7 (67.4 to 87.0)	1.5 (-3.6 to 6.9)	6.5 (4.6 to 8.9)	11.7 (8.1 to 15.8)	78.1 (68.4 to 89.2)	2.1 (-3.2 to 8.2)
Low back and neck pain	-	-	-	-	61.6 (43.5 to 83.5)	126.1 (86.7 to 170.5)	104.6 (89.6 to 122.1)	1.2 (-6.1 to 9.2)
Low back pain	406.3 (384.2 to 428.8)	820.8 (775.1 to 871.0)	101.4 (85.1 to 118.2)	0.9 (-6.5 to 8.8)	44.5 (30.5 to 62.1)	91.0 (61.5 to 124.3)	104.1 (86.9 to 121.9)	1.9 (-5.6 to 10.3)
Neck pain	176.1 (146.1 to 209.0)	359.0 (309.3 to 407.6)	103.9 (66.7 to 153.4)	-1.1 (-19.8 to 21.2)	17.0 (11.4 to 24.5)	35.1 (23.8 to 48.6)	106.3 (68.2 to 157.3)	-0.2 (-19.0 to 22.8)
Gout	0.5 (0.4 to 0.5)	0.8 (0.7 to 1.0)	80.1 (53.4 to 119.8)	-1.0 (-14.7 to 19.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.8 (45.6 to 132.0)	-0.5 (-21.8 to 27.5)
Other musculoskeletal disorders	64.3 (34.6 to 92.5)	135.3 (88.5 to 180.2)	106.9 (72.0 to 202.8)	10.6 (-6.0 to 54.0)	5.7 (2.7 to 9.2)	12.2 (7.0 to 18.7)	109.2 (74.2 to 210.4)	11.5 (-5.3 to 57.2)
Other non-communicable diseases	-	-	-	-	74.1 (48.1 to 108.7)	146.2 (93.8 to 217.5)	97.2 (88.8 to 107.0)	-4.5 (-8.1 to -1.2)
Congenital anomalies	-	-	-	-	3.3 (2.1 to 5.1)	7.4 (4.7 to 11.1)	125.4 (80.5 to 182.8)	4.8 (-16.2 to 35.4)
Neural tube defects	0.3 (0.3 to 0.4)	1.2 (1.0 to 1.4)	283.8 (183.8 to 418.3)	90.4 (36.6 to 160.5)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.4)	298.5 (170.3 to 474.9)	104.3 (40.7 to 194.4)
Congenital heart anomalies	2.4 (1.7 to 3.4)	9.3 (6.2 to 13.4)	271.0 (147.8 to 546.3)	85.8 (20.7 to 242.1)	0.1 (0.0 to 0.2)	0.3 (0.2 to 0.6)	217.1 (110.2 to 460.0)	57.9 (5.0 to 182.5)
Orofacial clefts	0.2 (0.2 to 0.4)	1.1 (0.7 to 1.7)	364.7 (148.4 to 724.8)	155.7 (28.1 to 382.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	366.3 (126.7 to 815.0)	156.0 (22.2 to 424.5)
Down syndrome	2.1 (1.6 to 2.8)	6.4 (5.0 to 8.1)	198.5 (112.3 to 340.9)	38.1 (-2.4 to 105.4)	0.2 (0.2 to 0.4)	0.7 (0.5 to 1.0)	196.4 (104.1 to 351.8)	37.6 (-4.3 to 109.1)
Turner syndrome	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	185.0 (85.9 to 361.4)	0.0 (-16.8 to 111.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	186.3 (86.2 to 366.8)	28.8 (-16.9 to 112.9)
Klinefelter syndrome	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.4)	107.9 (53.1 to 188.0)	-4.1 (-29.4 to 32.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.6 (54.1 to 190.6)	-3.6 (-29.1 to 33.8)
Chromosomal unbalanced rearrangements	5.3 (2.6 to 4.0)	10.3 (8.5 to 13.9)	307.1 (137.2 to 354.2)	0.4 (-8.5 to 112.8)	1.2 (0.2 to 0.5)	1.2 (0.8 to 1.7)	309.3 (126.3 to 350.0)	40.8 (4.5 to 110.4)
Other congenital anomalies	26.4 (19.2 to 35.3)	52.7 (38.0 to 69.8)	99.2 (64.4 to 147.1)	-5.8 (-22.0 to 17.1)	2.5 (1.4 to 4.2)	4.9 (2.7 to 8.1)	96.4 (48.3 to 160.4)	-8.3 (-31.0 to 28.1)
Skin and subcutaneous diseases	-	-	-	-	25.9 (16.3 to 41.1)	56.4 (35.0 to 89.0)	115.7 (103.0 to 142.4)	0.2 (-6.2 to 10.1)
Dermatitis	245.0 (193.8 to 305.9)	529.4 (416.1 to 663.3)	115.4 (113.2 to 117.9)	-0.1 (-4.2 to -0.0)	7.0 (4.4 to 10.1)	15.4 (9.6 to 22.5)	118.6 (110.8 to 126.5)	0.5 (-2.2 to 3.4)
Psoriasis	37.7 (29.8 to 45.1)	79.2 (63.1 to 95.0)	109.9 (104.8 to 113.1)	0.0 (-0.0 to 0.1)	6.4 (2.0 to 4.4)	6.4 (4.2 to 9.4)	112.1 (97.7 to 126.5)	0.9 (-4.1 to 5.9)
Cellulitis	1.1 (0.9 to 1.4)	2.3 (1.8 to 2.9)	102.6 (75.7 to 144.5)	-7.3 (-21.0 to 12.3)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	103.1 (52.9 to 177.7)	-5.9 (-26.5 to 20.6)
Pyoderma	10.6 (7.8 to 13.7)	21.3 (15.9 to 27.5)	100.7 (88.9 to 115.5)	-4.2 (-10.5 to 3.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.3)	101.7 (81.5 to 125.0)	-3.8 (-12.7 to 6.8)
Scabies	92.6 (72.4 to 122.0)	128.3 (101.2 to 160.1)	38.7 (-1.5 to 95.3)	-32.4 (-51.9 to -4.2)	2.4 (1.3 to 4.0)	3.3 (1.8 to 5.4)	39.4 (-2.3 to 96.3)	-32.2 (-51.8 to -3.5)
Fungal skin diseases	690.9 (498.7 to 964.8)	1,537.5 (1,083.9 to 2,146.1)	118.8 (114.1 to 122.6)	6.1 (0.1 to 12.6)	3.9 (1.5 to 8.7)	8.5 (3.3 to 19.1)	120.0 (115.0 to 124.0)	0.4 (-0.2 to 1.4)
Viral skin diseases	89.0 (69.9 to 109.2)	197.5 (151.8 to 244.7)	121.3 (108.2 to 135.0)	-0.7 (-5.3 to 4.7)	2.7 (1.6 to 4.3)	6.1 (3.5 to 9.6)	121.8 (105.2 to 138.5)	-0.4 (-6.5 to 6.1)
Acne vulgaris	300.3 (192.0 to 388.5)	793.7 (522.1 to 1,117.4)	157.1 (56.7 to 427.7)	11.4 (-29.2 to 113.0)	3.2 (1.4 to 6.5)	8.6 (3.5 to 17.8)	158.4 (56.5 to 431.5)	11.8 (-29.2 to 114.0)
Alopecia areata	5.2 (4.5 to 5.8)	11.0 (9.7 to 12.3)	111.4 (80.8 to 147.9)	-0.6 (-15.7 to 17.2)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	112.3 (73.2 to 160.3)	0.2 (-16.6 to 22.6)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.0 (62.4 to 156.6)	2.0 (-22.3 to 24.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.0 (62.4 to 156.7)	-2.0 (-22.4 to 20.6)
Urticaria	24.6 (16.7 to 36.0)	63.4 (29.4 to 102.6)	145.8 (20.2 to 425.9)	19.8 (-40.9 to 107.0)	1.4 (0.8 to 2.4)	3.8 (1.4 to 6.9)	148.4 (20.7 to 439.4)	20.6 (-40.0 to 111.1)
Decubitus ulcer	0.5 (0.4 to 0.6)	1.0 (0.9 to 1.2)	109.4 (76.7 to 154.5)	9.5 (-15.9 to 42.1)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	112.5 (74.1 to 165.0)	10.1 (-17.6 to 45.0)
Other skin and subcutaneous diseases	313.7 (212.8 to 452.2)	605.3 (409.5 to 863.3)	92.6 (78.5 to 106.5)	-4.4 (-9.7 to -0.4)	1.8 (0.8 to 3.7)	3.5 (1.6 to 7.3)	94.2 (80.0 to 108.2)	-3.8 (-9.2 to 0.2)
Sense organ diseases	-	-	-	-	38.1 (24.8 to 55.6)	66.6 (44.8 to 101.0)	80.2 (68.7 to 92.9)	-7.7 (-12.2 to -2.8)
Glaucoma	3.3 (2.5 to 4.3)	8.5 (5.9 to 11.3)	155.5 (91.3 to 222.3)	30.1 (-3.6 to 63.6)	0.3 (0.2 to 0.4)	0.7 (0.4 to 1.0)	159.1 (87.6 to 235.4)	32.8 (-3.8 to 76.3)
Cataract	19.5 (14.3 to 25.4)	33.3 (23.5 to 42.5)	70.2 (24.9 to 126.6)	2.0 (-24.7 to 33.9)	1.6 (1.0 to 2.3)	2.8 (1.7 to 4.1)	76.6 (36.6 to 122.9)	2.5 (-17.9 to 30.7)
Macular degeneration	2.8 (2.0 to 3.6)	10.9 (7.1 to 15.5)	278.8 (173.1 to 489.9)	122.1 (61.3 to 247.9)	0.2 (0.1 to 0.2)	0.6 (0.4 to 1.0)	261.1 (160.4 to 473.4)	105.4 (46.0 to 218.9)
Uncorrected refractive error	636.0 (581.1 to 681.6)	1,193.2 (1,110.4 to 1,274.5)	87.2 (70.0 to 106.7)	-5.3 (-19.2 to 2.1)	11.6 (7.3 to 17.9)	20.2 (12.5 to 31.3)	74.1 (62.2 to 88.7)	-12.2 (-17.2 to -6.1)
Age-related and other hearing loss	712.9 (604.8 to 805.7)	1,247.5 (1,058.2 to 1,422.0)	74.5 (64.2 to 84.5)	4.4 (-10.3 to -2.7)	19.8 (12.0 to 30.3)	34.2 (20.6 to 53.2)	111.0 (52.3 to 94.7)	73.0 (-18.3 to 9.1)
Other vision loss	9.9 (8.0 to 12.5)	20.3 (15.7 to 25.7)	104.9 (81.4 to 127.1)	4.9 (-7.9 to 20.6)	0.9 (0.6 to 1.3)	1.9 (1.2 to 2.9)	113.9 (79.8 to 145.8)	9.5 (-7.4 to 29.2)
Other sense organ diseases	142.9 (135.5 to 151.2)	306.5 (290.2 to 323.8)	114.1 (97.9 to 131.4)	-0.5 (-6.6 to 6.3)	3.8 (2.3 to 5.6)	8.1 (5.0 to 12.2)	115.6 (97.0 to 136.0)	0.1 (-6.8 to 7.5)
Oral disorders	-	-	-	-	6.7 (3.7 to 11.2)	13.7 (7.5 to 23.4)	103.3 (92.1 to 116.3)	-1.4 (-7.0 to 6.9)
Deciduous caries	612.8 (579.9 to 644.2)	1,363.5 (1,290.1 to 1,434.8)	121.6 (105.6 to 139.6)	0.2 (-6.9 to 8.4)	0.2 (0.1 to 0.5)			

Appendix Table G.4 - Chad prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	21.1 (19.4 to 22.8)	30.8 (28.3 to 33.2)	45.5 (31.3 to 63.4)	-16.9 (-24.0 to -7.6)	0.6 (0.4 to 0.8)	0.8 (0.6 to 1.2)	46.5 (31.3 to 66.6)	-16.5 (-24.0 to -6.5)
Other oral disorders	82.9 (78.1 to 88.2)	175.6 (164.0 to 187.1)	111.6 (92.0 to 130.8)	-0.2 (-8.8 to 8.1)	2.4 (1.5 to 3.6)	5.1 (3.2 to 7.6)	113.0 (93.2 to 133.4)	0.2 (-8.5 to 8.7)
Injuries	-	-	-	-	62.0 (33.6 to 124.1)	61.8 (42.4 to 95.9)	4.4 (-25.2 to 37.0)	-38.0 (-50.8 to -23.8)
Transport injuries	-	-	-	-	8.5 (6.5 to 10.9)	18.2 (13.6 to 23.2)	114.6 (105.6 to 125.2)	11.2 (7.5 to 15.7)
Road injuries	-	-	-	-	7.7 (5.9 to 9.9)	16.5 (12.4 to 21.1)	115.3 (105.3 to 126.2)	11.2 (7.1 to 16.0)
Pedestrian road injuries	-	-	-	-	2.0 (1.5 to 2.5)	4.0 (3.0 to 5.1)	102.3 (87.4 to 120.9)	5.1 (-1.1 to 12.6)
Cyclist road injuries	-	-	-	-	0.7 (0.5 to 0.8)	1.1 (0.9 to 1.5)	73.9 (62.9 to 86.0)	-4.4 (-10.7 to 1.9)
Motorcyclist road injuries	-	-	-	-	1.2 (0.9 to 1.5)	2.1 (1.6 to 2.7)	72.6 (60.1 to 83.3)	-10.5 (-16.5 to -5.2)
Motor vehicle road injuries	-	-	-	-	3.7 (2.8 to 4.8)	9.1 (6.9 to 11.7)	144.5 (128.0 to 164.7)	25.1 (18.2 to 33.0)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	70.9 (59.8 to 84.1)	-16.3 (-20.9 to -10.8)
Other transport injuries	-	-	-	-	0.8 (0.6 to 1.0)	1.7 (1.3 to 2.1)	108.4 (96.9 to 120.8)	12.3 (6.7 to 18.9)
Unintentional injuries	-	-	-	-	11.5 (8.8 to 14.8)	21.8 (16.7 to 27.9)	88.6 (83.5 to 93.2)	-3.8 (-6.4 to -1.3)
Falls	-	-	-	-	4.6 (3.5 to 5.9)	8.9 (6.8 to 11.5)	95.0 (85.4 to 102.8)	-0.5 (-5.3 to 3.9)
Drowning	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	59.0 (42.3 to 78.7)	-20.6 (-27.2 to -12.5)
Fire, heat, and hot substances	-	-	-	-	0.7 (0.6 to 0.9)	1.3 (1.0 to 1.7)	79.2 (63.1 to 94.6)	-9.8 (-15.8 to -3.9)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	55.2 (31.3 to 86.6)	-26.0 (-34.7 to -14.4)
Exposure to mechanical forces	-	-	-	-	3.6 (2.8 to 4.7)	6.8 (5.2 to 8.9)	87.2 (78.2 to 97.0)	-7.0 (-11.0 to -2.6)
Unintentional firearm injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	84.2 (70.2 to 98.3)	-6.7 (-13.2 to -0.1)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	139.8 (116.9 to 170.1)	18.2 (8.8 to 29.7)
Other exposure to mechanical forces	-	-	-	-	3.4 (2.6 to 4.5)	6.4 (4.9 to 8.4)	86.8 (77.3 to 96.9)	-7.4 (-11.7 to -2.6)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	115.0 (100.7 to 130.2)	14.4 (6.2 to 22.7)
Animal contact	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	87.0 (75.4 to 99.7)	-5.9 (-10.6 to -0.8)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	88.4 (68.2 to 110.8)	-6.4 (-14.5 to 2.7)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	86.2 (75.1 to 97.0)	-5.4 (-10.1 to -1.0)
Foreign body	-	-	-	-	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.6)	101.6 (92.1 to 113.4)	2.2 (-2.4 to 7.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	94.4 (69.1 to 122.4)	1.0 (-8.8 to 10.5)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	111.8 (90.1 to 139.0)	-0.3 (-9.2 to 9.4)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	101.6 (89.8 to 115.0)	3.1 (-2.9 to 10.3)
Other unintentional injuries	-	-	-	-	1.7 (1.3 to 2.2)	3.1 (2.4 to 4.0)	80.9 (71.2 to 91.0)	-6.1 (-11.4 to -1.3)
Self-harm and interpersonal violence	-	-	-	-	0.5 (0.4 to 0.6)	0.9 (0.7 to 1.2)	82.7 (84.9 to 101.4)	-3.4 (-7.1 to 0.6)
Self-harm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	102.8 (88.4 to 120.0)	5.6 (-0.7 to 13.1)
Interpersonal violence	-	-	-	-	0.4 (0.3 to 0.5)	0.8 (0.6 to 1.0)	90.8 (82.3 to 100.6)	-5.6 (-9.7 to -1.4)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	96.0 (82.7 to 109.1)	-2.2 (-8.2 to 3.7)
Assault by sharp object	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	121.3 (108.0 to 135.6)	8.8 (2.8 to 15.4)
Assault by other means	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.6)	82.6 (70.6 to 96.3)	-9.9 (-15.5 to -3.9)
Forces of nature, war, and legal intervention	-	-	-	-	41.5 (15.0 to 103.0)	20.9 (7.5 to 52.3)	-49.8 (-57.7 to -41.9)	-60.9 (-66.0 to -55.4)
Exposure to forces of nature	-	-	-	-	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.2)	-49.1 (-52.6 to -45.0)	-60.7 (-63.9 to -57.4)
Collective violence and legal intervention	-	-	-	-	41.3 (14.9 to 102.8)	20.8 (7.5 to 52.1)	-49.8 (-57.7 to -41.8)	-60.9 (-66.0 to -55.4)

Appendix Table G.4 - Chile prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,244.9 (934.4 to 1,608.4)	1,916.0 (1,439.6 to 2,462.0)	54.0 (50.2 to 57.7)	54.0 (-3.3 to 1.3)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	84.4 (59.0 to 117.9)	96.5 (68.5 to 134.4)	14.7 (6.4 to 22.8)	14.7 (-11.9 to 1.1)
HIV/AIDS and tuberculosis	-	-	-	-	2.0 (1.3 to 2.9)	3.2 (2.0 to 5.1)	3.9 (6.9 to 133.8)	3.9 (29.5 to 55.0)
Tuberculosis	5.4 (5.2 to 5.7)	5.6 (5.2 to 6.0)	2.7 (-2.6 to 8.9)	-32.2 (-35.5 to -28.3)	1.7 (1.1 to 2.3)	1.7 (1.2 to 2.4)	1.6 (-12.3 to 16.3)	-32.3 (-41.2 to -22.5)
HIV/AIDS	-	-	-	-	0.3 (0.1 to 0.1)	1.4 (0.6 to 3.1)	496.4 (19.3 to 1,774.0)	496.4 (-21.2 to 1,185.6)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.1 (-61.0 to 526.4)	40.5 (-75.2 to 316.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.1 (-61.0 to 530.0)	40.5 (-75.3 to 318.1)
HIV/AIDS resulting in other diseases	2.8 (0.6 to 7.7)	19.4 (9.2 to 39.3)	729.8 (99.5 to 2,100.0)	486.2 (38.9 to 1,468.1)	0.3 (0.1 to 1.0)	1.4 (0.6 to 3.1)	501.0 (19.3 to 1,845.9)	308.6 (-21.3 to 1,222.5)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	10.3 (7.0 to 14.8)	10.2 (6.6 to 15.1)	-1.1 (-8.1 to 6.2)	-23.1 (-28.2 to -17.4)
Diarrheal diseases	3.0 (2.7 to 3.3)	3.3 (2.9 to 3.6)	7.5 (-6.9 to 24.5)	-13.9 (-25.1 to -0.4)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.8)	1.8 (-13.1 to 33.2)	17.5 (-29.6 to 6.8)
Intestinal infectious diseases	-	-	-	-	0.3 (0.2 to 0.6)	0.2 (0.1 to 0.3)	0.2 (-59.3 to -11.2)	-47.2 (-66.4 to -27.2)
Typhoid fever	1.3 (1.2 to 1.5)	1.0 (0.9 to 1.2)	-24.3 (-38.4 to -6.4)	-37.9 (-49.6 to -24.7)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-23.2 (-38.7 to -4.2)	-37.0 (-49.4 to -22.2)
Paratyphoid fever	0.5 (0.4 to 0.6)	0.6 (0.5 to 0.7)	18.3 (-6.1 to 53.0)	-0.6 (-20.8 to 27.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.3 (-6.0 to 53.3)	-0.6 (-20.8 to 27.9)
Other intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.3)	0.0 (0.0 to 0.1)	-74.9 (-95.4 to -50.0)	-79.4 (-96.2 to -31.1)
Lower respiratory infections	18.3 (17.2 to 19.2)	14.6 (13.6 to 15.8)	-20.5 (-26.4 to -12.1)	-41.0 (-45.4 to -35.1)	1.9 (1.3 to 2.7)	1.5 (1.0 to 2.1)	-22.1 (-29.7 to -11.7)	-41.0 (-46.7 to -33.9)
Upper respiratory infections	216.8 (207.2 to 228.7)	271.8 (257.8 to 288.3)	25.5 (15.9 to 36.0)	-0.8 (-8.4 to 7.8)	2.6 (1.4 to 4.2)	3.2 (1.8 to 5.4)	24.8 (14.8 to 37.2)	-1.0 (-8.8 to 8.9)
Otitis media	160.0 (150.9 to 169.9)	173.8 (162.9 to 184.3)	8.7 (0.6 to 17.1)	-13.9 (-20.8 to -7.4)	2.9 (1.7 to 4.6)	3.1 (1.8 to 5.1)	8.7 (0.1 to 18.0)	-14.3 (-21.1 to -7.6)
Meningitis	-	-	-	-	1.6 (1.1 to 2.2)	0.9 (0.6 to 1.3)	-41.1 (-54.2 to -26.7)	-54.2 (-64.4 to -42.7)
Pneumococcal meningitis	5.8 (3.6 to 8.7)	3.7 (2.3 to 5.9)	-36.0 (-49.7 to -18.4)	-55.0 (-64.1 to -43.4)	0.4 (0.4 to 0.9)	0.4 (0.2 to 0.5)	-36.4 (-57.7 to -9.0)	-51.8 (-67.2 to -30.9)
H influenzae type B meningitis	2.3 (0.8 to 4.7)	1.2 (0.4 to 2.6)	-49.2 (-70.1 to -29.6)	-61.5 (-76.3 to -44.5)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-44.6 (-70.8 to -10.6)	-54.5 (-76.1 to -27.2)
Meningococcal meningitis	2.5 (0.9 to 5.6)	1.4 (0.5 to 3.7)	-43.4 (-65.8 to -21.3)	-59.4 (-74.0 to -42.2)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-44.8 (-64.3 to -11.9)	-58.1 (-72.1 to -33.2)
Other meningitis	2.9 (1.5 to 5.5)	1.7 (0.9 to 3.7)	-41.9 (-59.2 to -24.3)	-56.9 (-67.6 to -43.6)	0.4 (0.2 to 0.6)	0.2 (0.1 to 0.3)	-44.1 (-60.7 to -18.8)	-56.2 (-68.6 to -36.2)
Encephalitis	1.3 (0.6 to 3.0)	1.4 (0.7 to 3.6)	11.2 (-15.7 to 33.0)	-26.4 (-43.5 to -10.3)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	21.0 (0.2 to 46.7)	-17.3 (-30.8 to 0.3)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.2 (-93.4 to 411.7)	-54.3 (-94.6 to 274.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.2 (-93.4 to 415.1)	-54.3 (-94.6 to 277.2)
Whooping cough	2.1 (1.6 to 2.7)	1.6 (1.3 to 2.1)	-22.6 (-23.0 to -22.2)	-7.8 (-8.3 to -7.3)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-22.9 (-34.8 to -10.6)	-8.1 (-22.4 to 6.6)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.2 (-92.8 to -60.6)	-86.2 (-94.4 to -69.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-80.8 (-92.1 to -62.8)	-84.6 (-93.7 to -70.6)
Measles	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -98.6)	-100.0 (-100.0 to -98.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -98.6)	-100.0 (-100.0 to -98.4)
Varicella and herpes zoster	10.9 (10.1 to 12.0)	14.0 (12.5 to 15.5)	28.1 (10.6 to 46.7)	-0.6 (-13.5 to 14.1)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	58.2 (22.6 to 98.0)	-0.5 (-21.7 to 23.9)
Neglected tropical diseases and malaria	-	-	-	-	13.3 (8.6 to 19.8)	11.5 (7.7 to 16.8)	-13.1 (-34.1 to 16.9)	-40.1 (-53.0 to -21.1)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	146.5 (-54.3 to 767.7)	101.0 (-63.0 to 605.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	149.0 (-54.0 to 780.7)	102.5 (-62.7 to 618.8)
Chagas disease	511.8 (491.6 to 531.5)	362.3 (347.3 to 376.0)	-29.2 (-33.2 to -25.1)	-55.0 (-57.6 to -52.4)	5.2 (3.5 to 7.3)	5.0 (3.3 to 7.0)	-4.9 (-11.8 to 2.6)	-48.5 (-52.3 to -44.5)
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.7 (12.8 to 69.3)	-0.8 (-19.8 to 23.0)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.4 (-20.8 to 120.9)	11.7 (-36.4 to 79.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.4 (-20.9 to 121.0)	11.7 (-36.5 to 79.8)
Cutaneous and mucocutaneous leishmaniasis	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	0.0 (11.5 to 71.4)	-1.2 (-20.7 to 23.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.6 (11.5 to 71.6)	-1.2 (-20.8 to 23.4)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Cysticercosis	2.0 (0.8 to 4.1)	2.8 (1.2 to 5.3)	46.1 (-39.6 to 304.9)	-2.9 (-59.0 to 167.4)	0.7 (0.3 to 1.6)	1.1 (0.4 to 2.1)	48.8 (-42.4 to 314.0)	0.2 (-59.0 to 173.7)
Cystic echinococcosis	6.1 (5.4 to 7.0)	4.5 (4.3 to 5.0)	-25.1 (-30.1 to -18.5)	-53.7 (-57.5 to -49.5)	0.6 (0.4 to 0.8)	0.4 (0.3 to 0.6)	-25.3 (-35.8 to -12.5)	-53.6 (-60.4 to -45.8)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.1 (-49.3 to 35.5)	-16.3 (-62.0 to 3.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.1 (-49.4 to 35.6)	-16.3 (-62.0 to 3.1)
Intestinal nematode infections	-	-	-	-	4.1 (1.8 to 8.8)	2.4 (0.8 to 5.9)	-41.1 (-77.9 to 50.7)	-58.8 (-83.1 to 11.7)
Ascariasis	2,189.5 (1,570.8 to 3,049.5)	3,077.6 (2,086.7 to 4,436.3)	40.4 (-16.5 to 137.4)	0.9 (-39.7 to 70.3)	4.0 (1.7 to 8.5)	4.0 (0.8 to 7.0)	2.3 (-79.4 to 51.4)	60.7 (-84.3 to 11.2)
Trichuriasis	886.1 (593.0 to 1,307.7)	37.1 (75.4 to 1,884.9)	-96.6 (-32.3 to 138.0)	-1.4 (-50.4 to 72.3)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	21.0 (-72.0 to 439.7)	-12.0 (-79.5 to 287.1)
Hookworm disease	9.5 (6.0 to 14.6)	14.4 (9.0 to 21.2)	54.4 (-17.8 to 182.3)	2.9 (-45.2 to 88.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	38.9 (-43.6 to 297.9)	-0.8 (-59.8 to 163.2)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	79.1 (57.4 to 102.3)	79.4 (63.6 to 94.8)	0.2 (-23.4 to 38.8)	0.5 (-23.2 to 39.6)	2.6 (1.5 to 3.9)	2.6 (1.6 to 3.9)	-0.4 (-31.0 to 67.6)	1.9 (-29.7 to 72.0)
Maternal disorders	-	-	-	-	0.4 (0.2 to 0.7)	0.3 (0.2 to 0.5)	-20.0 (-45.4 to -0.5)	-32.7 (-54.2 to -15.8)
Maternal hemorrhage	7.2 (6.0 to 8.4)	5.0 (3.1 to 6.7)	-30.6 (-55.2 to -2.6)	-41.3 (-62.2 to -47.4)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-24.1 (-71.2 to 17.7)	-35.3 (-75.6 to 0.5)
Maternal sepsis and other maternal infections	1.7 (0.6 to 3.5)	1.1 (0.3 to 2.4)	-39.7 (-81.2 to 77.0)	-54.0 (-85.5 to 39.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-30.8 (-58.0 to 33.3)	-43.1 (-65.7 to 7.7)
Maternal hypertensive disorders	2.9 (1.3 to 5.1)	2.5 (1.1 to 4.3)	-15.4 (-22.0 to -4.4)	-29.4 (-34.9 to -21.2)	0.1 (0.1 to 0.3)	0.1 (0.0 to 0.2)	-14.6 (-32.7 to 9.5)	-28.7 (-43.8 to -9.0)
Obstructed labor	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-17.5 (-63.0 to 138.3)	-30.3 (-68.8 to 94.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.5 (-63.3 to 139.1)	-30.3 (-68.8 to 94.7)
Complications of abortion	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-14.2 (-39.1 to 19.5)	-27.7 (-48.2 to -0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.2 (-39.1 to 19.6)	-27.7 (-48.2 to 0.0)
Other maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-16.0 (-46.3 to 10.7)	-29.2 (-55.0 to 10.7)
Neonatal disorders	-	-	-	-	14.0 (9.6 to 19.7)	21.6 (15.4 to 29.1)	56.5 (9.8 to 99.8)	26.0 (-11.7 to 61.4)
Preterm birth complications	60.1 (44.9 to 79.8)	120.9 (90.6 to 164.3)	100.6 (59.7 to 151.7)	55.2 (23.6 to 95.4)	6.7 (4.8 to 9.2)	13.5 (9.4 to 17.7)	102.4 (49.3 to 156.5)	60.4 (18.2 to 102.0)
Neonatal encephalopathy due to birth asphyxia and trauma	20.7 (12.0 to 38.2)	15.4 (7.7 to 34.1)	-29.2 (-53.2 to -19.0)	-43.1 (-62.2 to -6.2)	4.2 (2.9 to 5.7)	4.2 (2.1 to 6.6)	-23.9 (-51.1 to 16.2)	-36.8 (-59.5 to -3.1)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.8 (0.9 to 47.2)	42.7 (25.4 to 83.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.8 (-14.1 to 56.9)	46.3 (6.7 to 95.0)
Hemolytic disease and other neonatal jaundice	5.7 (1.4 to 17.4)	3.6 (0.9 to 11.9)	-26.5 (-92.6 to 94.2)	-40.8 (-94.1 to 56.7)	2.3 (0.5 to 7.1)	1.5 (0.3 to 5.0)	-23.7 (-92.3 to 104.8)	-38.5 (-93.8 to 64.5)
Other neonatal disorders	-	-	-	-	0.8 (0.5 to 1.3)	3.4 (1.8 to 5.1)	335.2 (120.6 to 657.3)	249.7 (78.4 to 508.7)
Nutritional deficiencies	-	-	-	-	39.6 (26.0 to 57.7)	43.9 (29.3 to 64.4)	10.9 (6.0 to 15.8)	1.0 (-3.2 to 6.0)
Protein-energy malnutrition	0.6 (0.4 to 1.2)	1.5 (0.6 to 2.5)	166.1 (-21.4 to 251.3)	27.9 (-63.9 to 68.2)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	156.8 (-22.6 to 249.7)	24.5 (-64.0 to 71.8)
Iodine deficiency	38.7 (32.9 to 44.2)	31.1 (25.8 to 36.9)	-19.9 (-55.6 to -27.9)	-43.1 (-55.6 to -27.9)	0.7 (0.4 to 1.1)	0.6 (0.3 to 0.9)	-19.5 (-38.5 to 2.3)	-42.8 (-56.1 to -26.8)
Vitamin A deficiency	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-

Appendix Table G.4 - Chile prevalence and VIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VIDs 1990 (thousands)	VIDs 2013 (thousands)	% change VIDs, 1990 to 2013	% change age-standardized VIDs, 1990 to 2013
Iron-deficiency anemia	1,282.3 (1,254.4 to 1,309.2)	1,493.4 (1,460.3 to 1,520.9)	16.4 (12.8 to 20.4)	-1.7 (-1.6 to 5.2)	38.9 (25.6 to 56.6)	43.2 (28.8 to 63.5)	11.2 (6.2 to 16.2)	11.2 (-2.5 to 6.9)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.9 (-37.6 to 101.7)	-36.4 (-70.6 to -0.5)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	4.7 (3.0 to 7.2)	5.7 (3.4 to 9.3)	22.8 (-1.6 to 42.9)	2.1 (-18.1 to 18.6)
Sexually transmitted diseases excluding HIV	-	-	-	-	2.4 (1.4 to 4.0)	3.2 (1.8 to 5.7)	37.1 (-2.6 to 73.3)	1.4 (-26.7 to 26.6)
Syphilis	0.7 (0.6 to 0.9)	1.5 (1.3 to 1.8)	112.8 (73.3 to 172.1)	-1.7 (-4.9 to 41.6)	14.0 (1.1 to 4.2)	0.3 (0.2 to 0.4)	114.6 (53.8 to 202.5)	15.9 (-14.5 to 58.8)
Chlamydial infection	282.0 (222.5 to 348.0)	362.9 (298.3 to 431.6)	29.6 (-4.6 to 70.9)	1.8 (-24.3 to 33.9)	1.3 (0.7 to 2.3)	1.7 (0.8 to 3.0)	31.0 (-29.2 to 107.8)	4.8 (-43.3 to 65.2)
Gonococcal infection	39.3 (26.5 to 51.5)	36.8 (28.3 to 49.0)	-8.0 (-35.1 to 49.2)	-24.7 (-46.3 to 20.9)	0.3 (0.2 to 0.6)	0.3 (0.2 to 0.6)	3.2 (-30.1 to 74.9)	-16.0 (-43.1 to 40.7)
Trichomoniasis	75.8 (53.0 to 105.4)	96.9 (74.2 to 124.1)	29.4 (-14.1 to 94.0)	-2.9 (-34.4 to 42.5)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.4)	30.0 (-21.6 to 111.9)	-3.4 (-40.3 to 52.5)
Genital herpes	1,595.9 (1,499.4 to 1,683.7)	2,541.2 (2,420.3 to 2,669.9)	58.2 (48.7 to 72.6)	3.9 (-9.7 to 8.7)	11.5 (0.1 to 1.0)	0.7 (0.2 to 1.6)	54.7 (40.6 to 70.1)	3.8 (-11.4 to 5.1)
Other sexually transmitted diseases	3.0 (1.9 to 4.2)	2.5 (1.7 to 3.6)	-16.5 (-43.6 to 36.0)	-38.3 (-57.9 to 0.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	13.5 (-22.4 to 72.0)	15.1 (-41.1 to 27.0)
Hepatitis	-	-	-	-	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	16.0 (4.4 to 28.5)	-9.0 (-18.0 to 0.9)
Hepatitis A	15.8 (15.2 to 16.3)	16.1 (15.7 to 16.6)	2.4 (1.9 to 2.9)	-10.1 (-10.5 to -9.6)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	18.0 (6.1 to 31.7)	-5.3 (-14.8 to 5.5)
Hepatitis B	80.2 (74.8 to 85.2)	63.4 (58.9 to 67.9)	-20.9 (-29.0 to -12.7)	-44.6 (-50.3 to -39.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-3.9 (-36.2 to 45.1)	-37.5 (-58.1 to -5.6)
Hepatitis C	45.2 (41.3 to 49.8)	56.2 (51.0 to 61.2)	24.6 (10.5 to 40.9)	-24.7 (-33.2 to -15.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.2 (5.6 to 63.1)	27.7 (-44.6 to -1.5)
Hepatitis E	-	-	35.9 (18.6 to 61.9)	2.0 (-10.7 to 20.3)	-	-	-	-
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.5 (0.6 to 73.3)	-33.0 (-46.3 to -7.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.4 (3.0 to 81.4)	-30.8 (-44.6 to -3.7)
Other infectious diseases	54.5 (42.4 to 67.8)	55.7 (43.2 to 68.5)	2.2 (-23.4 to 34.4)	0.6 (-25.1 to 32.6)	1.9 (1.1 to 2.8)	2.0 (1.2 to 3.0)	7.4 (-29.5 to 53.8)	6.8 (-30.5 to 52.4)
Non-communicable diseases	-	-	-	-	60.8 (797.8 to 1,377.9)	1,721.0 (1,283.5 to 2,212.8)	2.5 (56.4 to 65.1)	2.5 (-0.1 to 5.3)
Neoplasms	-	-	-	-	9.8 (7.3 to 12.7)	22.6 (16.8 to 29.0)	129.9 (108.3 to 152.1)	15.8 (5.1 to 27.6)
Esophageal cancer	1.0 (0.7 to 1.3)	1.5 (1.1 to 2.1)	57.5 (10.7 to 125.9)	-27.5 (-49.0 to 3.7)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.4)	51.3 (14.2 to 101.2)	-30.3 (-47.5 to -7.1)
Stomach cancer	6.4 (5.7 to 7.3)	11.5 (9.8 to 13.3)	78.5 (44.5 to 117.5)	-16.2 (-32.4 to 2.0)	0.8 (0.6 to 1.1)	1.3 (0.9 to 1.7)	60.4 (31.2 to 92.1)	-25.1 (-38.6 to -9.6)
Liver cancer	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.2 to 0.3)	119.9 (246.6 to 475.7)	6.7 (6.2 to 174.0)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	448.4 (89.1 to 1,060.5)	175.9 (-3.7 to 488.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	412.4 (87.4 to 909.1)	156.5 (-5.8 to 412.1)
Liver cancer due to hepatitis C	0.1 (0.0 to 0.1)	0.8 (0.5 to 1.0)	1,361.3 (736.1 to 2,645.0)	585.2 (287.8 to 1,181.5)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	1,142.1 (702.6 to 1,997.3)	478.5 (271.7 to 877.1)
Liver cancer due to alcohol use	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.6)	186.9 (74.1 to 408.5)	34.5 (-17.7 to 139.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	156.1 (69.1 to 315.2)	20.1 (-21.0 to 92.9)
Liver cancer due to other causes	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	135.1 (13.9 to 306.1)	16.1 (-44.4 to 102.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.9 (18.9 to 237.5)	6.7 (-42.4 to 68.0)
Larynx cancer	0.5 (0.3 to 0.6)	1.1 (0.9 to 1.4)	141.7 (77.7 to 236.1)	15.5 (-15.7 to 60.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	73.7 (28.8 to 131.1)	-16.6 (-38.7 to 11.3)
Tracheal, bronchus and lung cancer	2.6 (2.2 to 2.9)	4.5 (3.9 to 5.2)	74.4 (43.9 to 112.0)	-16.2 (-31.3 to 1.6)	0.5 (0.3 to 0.6)	0.7 (0.5 to 1.0)	60.6 (31.4 to 95.1)	-23.0 (-36.6 to -6.1)
Breast cancer	14.3 (12.4 to 16.3)	51.3 (45.7 to 56.7)	261.6 (196.6 to 327.0)	86.1 (51.8 to 119.7)	1.3 (1.0 to 1.8)	3.0 (2.1 to 4.0)	121.6 (79.1 to 176.6)	11.7 (9.9 to 39.1)
Cervical cancer	15.3 (11.5 to 17.8)	11.9 (9.6 to 15.5)	-24.1 (-40.3 to 25.5)	-97.4 (-66.9 to -30.6)	0.4 (0.8 to 1.6)	0.9 (0.6 to 1.3)	47.4 (-2.5 to 25.0)	-97.8 (-68.1 to -30.7)
Uterine cancer	3.6 (2.6 to 5.8)	8.4 (4.8 to 11.5)	139.5 (32.0 to 249.8)	14.6 (-37.4 to 66.1)	0.6 (0.1 to 0.4)	0.6 (0.3 to 0.9)	131.2 (21.0 to 244.5)	9.8 (-40.5 to 62.7)
Prostate cancer	12.9 (9.9 to 16.3)	49.6 (36.9 to 66.5)	282.0 (198.5 to 390.0)	78.5 (39.0 to 127.9)	1.4 (0.9 to 2.0)	5.0 (3.3 to 7.3)	259.2 (179.8 to 356.9)	65.9 (29.0 to 111.0)
Colon and rectum cancer	7.3 (6.7 to 8.0)	22.4 (19.8 to 25.1)	208.7 (161.6 to 255.9)	46.1 (23.6 to 69.4)	0.7 (0.5 to 0.9)	1.9 (1.4 to 2.5)	177.6 (133.3 to 222.3)	30.6 (9.1 to 52.0)
Lip and oral cavity cancer	1.6 (1.2 to 2.0)	2.5 (1.9 to 3.3)	57.4 (18.6 to 117.5)	-23.0 (-42.1 to 38.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	51.2 (14.1 to 110.0)	-26.8 (-44.7 to 2.0)
Nasopharynx cancer	0.3 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-18.1 (-42.1 to 38.7)	-56.7 (-69.3 to -26.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.7 (-42.2 to 28.0)	58.8 (-69.9 to -33.0)
Other pharynx cancer	0.7 (0.5 to 0.9)	1.0 (0.7 to 1.3)	46.5 (-3.2 to 129.3)	-28.4 (-53.5 to 11.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	40.6 (-7.5 to 110.4)	-31.6 (-55.0 to 2.0)
Gallbladder and biliary tract cancer	1.6 (1.2 to 1.9)	2.5 (1.9 to 3.3)	62.3 (16.3 to 124.3)	-25.7 (-47.2 to 2.0)	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	47.7 (5.2 to 104.1)	-32.2 (-51.7 to -5.8)
Pancreatic cancer	0.2 (0.1 to 0.2)	1.1 (0.9 to 1.4)	634.2 (457.7 to 863.4)	241.5 (160.0 to 348.6)	0.0 (0.0 to 0.1)	0.2 (0.2 to 0.3)	545.4 (414.9 to 697.1)	198.4 (137.4 to 269.6)
Malignant skin melanoma	3.4 (2.8 to 4.2)	5.2 (4.0 to 7.1)	49.7 (16.4 to 102.7)	-18.0 (-36.4 to 11.2)	0.3 (0.1 to 0.3)	0.3 (0.2 to 0.5)	46.9 (17.0 to 103.0)	37.2 (-39.8 to 10.0)
Non-melanoma skin cancer	8.0 (5.9 to 10.3)	20.7 (17.5 to 24.6)	161.0 (94.5 to 256.3)	22.0 (-10.0 to 65.2)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	159.2 (86.6 to 265.0)	17.2 (-17.0 to 67.5)
Ovarian cancer	0.8 (0.7 to 0.9)	3.4 (2.8 to 4.1)	318.4 (230.6 to 435.6)	115.7 (71.4 to 174.0)	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.6)	293.2 (187.8 to 422.8)	101.6 (47.1 to 170.4)
Testicular cancer	0.7 (0.3 to 1.7)	5.1 (1.5 to 9.9)	1,305.1 (31.8 to 3,109.3)	986.5 (1.8 to 2,357.3)	0.0 (0.0 to 0.1)	0.3 (0.1 to 0.7)	1,217.0 (27.5 to 3,163.2)	916.8 (-2.8 to 3,006.6)
Kidney cancer	2.1 (2.9 to 3.8)	3.8 (8.3 to 11.7)	82.1 (138.2 to 265.3)	24.0 (20.8 to 85.8)	0.3 (0.2 to 0.4)	0.7 (0.5 to 1.0)	58.2 (117.3 to 241.1)	37.2 (10.1 to 73.1)
Bladder cancer	2.5 (2.0 to 2.9)	6.4 (5.0 to 7.7)	156.3 (102.8 to 228.4)	20.6 (-4.7 to 54.1)	0.2 (0.2 to 0.3)	0.2 (0.3 to 0.7)	131.5 (80.0 to 196.7)	8.3 (-15.6 to 38.9)
Brain and nervous system cancer	0.4 (0.3 to 0.8)	2.4 (1.2 to 3.0)	632.2 (75.0 to 814.9)	394.6 (19.0 to 519.7)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	650.7 (78.1 to 837.4)	383.5 (13.6 to 501.2)
Thyroid cancer	2.5 (2.0 to 3.4)	7.7 (5.1 to 10.0)	217.0 (99.9 to 338.2)	75.9 (12.1 to 141.6)	0.2 (0.1 to 0.2)	0.5 (0.3 to 0.7)	202.8 (88.4 to 318.1)	64.7 (2.8 to 125.8)
Mesothelioma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	56.8 (23.7 to 94.4)	-24.5 (-40.3 to -5.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.2 (27.0 to 96.5)	32.9 (-39.1 to -4.7)
Hodgkin lymphoma	0.2 (0.1 to 0.5)	1.5 (0.6 to 2.1)	839.9 (18.9 to 1,274.0)	578.9 (-15.9 to 866.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	806.9 (104.0 to 1,207.8)	529.0 (-25.0 to 786.2)
Non-Hodgkin lymphoma	4.2 (3.4 to 5.0)	10.7 (8.3 to 12.7)	152.6 (106.2 to 209.1)	39.9 (13.0 to 70.5)	0.3 (0.2 to 0.5)	0.8 (0.5 to 1.1)	136.3 (89.9 to 190.9)	29.4 (3.5 to 58.3)
Multiple myeloma	0.7 (0.5 to 0.9)	2.2 (1.5 to 2.9)	234.6 (104.1 to 417.2)	60.1 (-2.4 to 149.4)	0.1 (0.1 to 0.2)	0.5 (0.3 to 0.6)	205.9 (84.8 to 398.3)	46.6 (-10.9 to 138.6)
Leukemia	2.1 (1.7 to 2.6)	3.8 (3.1 to 4.6)	78.1 (31.0 to 132.5)	24.0 (-8.3 to 62.4)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	80.0 (39.2 to 132.9)	14.0 (-12.7 to 46.5)
Other neoplasms	11.5 (8.8 to 13.8)	34.1 (27.0 to 45.3)	179.7 (119.4 to 356.2)	66.5 (30.4 to 170.9)	0.8 (0.5 to 1.2)	2.3 (1.5 to 3.4)	158.8 (104.0 to 321.5)	50.7 (16.4 to 142.4)
Cardiovascular diseases	-	-	-	-	18.9 (12.8 to 26.6)	51.8 (34.9 to 71.7)	175.0 (108.1 to 246.8)	28.1 (-2.5 to 61.9)
Rheumatic heart disease	2.3 (1.9 to 2.7)	4.3 (3.5 to 5.2)	87.0 (38.0 to 150.2)	-2.1 (-28.1 to 32.9)	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.7)	92.4 (35.9 to 171.6)	-1.8 (-30.5 to 11.2)
Ischemic heart disease	116.2 (101.1 to 139.3)	282.6 (244.5 to 331.7)	142.7 (94.1 to 204.2)	12.8 (-10.4 to 41.2)	7.1 (4.7 to 9.9)	17.5 (11.5 to 24.6)	143.1 (89.6 to 212.6)	11.2 (-13.2 to 42.1)
Cerebrovascular disease	-	-	-	-	3.2 (2.2 to 4.2)	6.2 (4.2 to 8.2)	94.1 (60.5 to 128.7)	2.8 (-20.3 to 14.6)
Ischemic stroke	15.9 (14.1 to 18.0)	29.6 (25.4 to 33.6)	86.8 (55.4 to 120.0)	-8.9 (-24.8 to 7.2)	2.4 (1.6 to 3.2)	4.4 (2.9 to 5.9)	86.9 (53.8 to 123.5)	-8.3 (-25.2 to 9.5)
Hemorrhagic stroke	5.4 (4.6 to 6.2)	11.7 (9.6 to 13.6)	118.2 (72.3 to 169.1)	14.1 (-10.4 to 41.9)	0.8 (0.6 to 1.1)	1.8 (1.1 to 2.4)	115.7 (65.8 to 174.9)	14.6 (-12.4 to 44.7)
Hypertensive heart disease	17.3 (15.5 to 20.3)	45.4 (39.7 to 51.3)	163.3 (119.3 to 217.0)	15.9 (-1.1 to 39.5)	1.9 (1.3 to 2.6)	4.9 (3.4 to 6.8)	163.5 (121.6 to 219.0)	16.5 (-2.2 to 40.7)
Cardiomyopathy and myocarditis	10.3 (8.2 to 12.7)	26.7 (23.8 to 29.8)	159.7 (111.4 to 217.0)	23.2 (0.4 to 51.8)	1.1 (0.7 to 1.6)	2.9 (1.9 to 4.0)	160.5 (109.3 to 225.1)	23.8 (-0.5 to 53.5)
Atrial fibrillation and flutter	13.4 (11.2 to 16.2)	48.9 (39.0 to 61.3)	265.6 (179.3 to 384.8)	63.6 (24.0 to 116.9)	1.0 (0.7 to 1.5)	3.8 (2.5 to 5.4)	273.8 (179.3 to 389.4)	67.8 (25.0 to 120.7)
Peripheral vascular disease	200.1 (148.1 to 246.1)	423.7 (340.7 to 519.1)	109.3 (66.1 to 188.8)	-3.1 (-22.0 to 28.8)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.5)	108.5 (14.9 to 260.7)	-11.5 (-50.9 to 53.1)
Endocarditis	0.4 (0.2 to 0.5)	0.9 (0.6 to 1.1)	146.6 (74.8 to 254.3)	18.6 (-17.1 to 60.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	136.8 (55.8 to 248.9)	14.3 (-25.5 to 71.2)
Other cardiovascular and circulatory diseases	59.5 (24.2 to 117.2)	221.7 (90.8 to 342.4)	355.0 (29.5 to 899.6)	4.2 (-39.7 to 380.7)	4.2 (1.5 to 8.6)	15.9 (6.2 to 26.5)	288.4 (30.8 to 926.2)	81.7 (-38.4 to 388.3)
Chronic respiratory diseases	-	-	-	-	84.6 (58.0 to 116.3)	136.2 (93.4 to 184.4)	61.3 (35.9 to 89.0)	2.3 (-14.5 to 1

Appendix Table G.4 - Chile prevalence and VIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VIDs 1990 (thousands)	VIDs 2013 (thousands)	% change VIDs, 1990 to 2013	% change age-standardized VIDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.1	103.2	3.5
Silicosis	0.1	0.2	103.3	1.5	(0.0 to 0.0)	(0.0 to 0.1)	(94.1 to 111.6)	(-1.0 to 7.5)
Asbestosis	-	-	0.0	0.0	0.0	0.0	106.3	2.3
Coal workers pneumoconiosis	-	-	0.0	0.0	0.0	0.0	-	-
Other pneumoconiosis	0.1	0.1	95.2	3.8	(0.0 to 0.0)	(0.0 to 0.0)	99.1	4.9
Asthma	961.5	1,280.4	33.2	-0.5	(82.1 to 110.0)	(37.0 to 80.1)	21.8 to 44.1	(-8.2 to 7.8)
Interstitial lung disease and pulmonary sarcoidosis	0.9	1.7	99.4	6.6	(0.7 to 1.1)	(0.1 to 0.2)	(47.7 to 176.4)	(22.9 to 46.6)
Other chronic respiratory diseases	-	-	-	-	-	-	-	-
Cirrhosis	-	-	-	-	0.8	1.2	43.8	21.8
Cirrhosis due to hepatitis B	0.5	1.0	76.7	-4.3	(0.6 to 1.2)	(0.8 to 1.7)	(26.4 to 60.5)	(-30.5 to -12.7)
Cirrhosis due to hepatitis C	1.8	3.5	97.7	7.5	(0.0 to 0.2)	(0.1 to 0.3)	(-29.6 to 273.3)	(-62.6 to 106.9)
Cirrhosis due to alcohol use	2.3	2.2	-5.1	0.4	(0.2 to 0.4)	(0.3 to 0.9)	(29.5 to 197.0)	(-29.0 to 62.8)
Cirrhosis due to other causes	0.6	0.1	-81.0	0.6	(1.9 to 2.8)	(0.2 to 0.6)	(-46.4 to 38.7)	(-71.1 to -27.7)
Digestive diseases	62.5	64.9	3.8	-5.1	13.1	23.6	79.6	-0.2
Peptic ulcer disease	60.4 to 64.6	(62.4 to 67.6)	(-0.5 to 8.8)	(-53.5 to -49.1)	(1.2 to 2.6)	(1.3 to 2.7)	(-6.3 to 11.9)	(-55.7 to -47.2)
Gastritis and duodenitis	36.0	39.4	9.8	-38.8	(34.6 to 37.4)	(36.2 to 42.1)	(0.3 to 16.9)	(-44.4 to -34.9)
Appendicitis	0.9	0.9	0.0	-18.8	(0.7 to 1.0)	(0.7 to 1.0)	(-18.1 to 27.3)	(-34.6 to 1.7)
Paralytic ileus and intestinal obstruction	0.1	0.3	174.8	59.8	(0.1 to 0.1)	(0.1 to 0.3)	(0.1 to 0.3)	(-3.8 to 164.8)
Inguinal, femoral, and abdominal hernia	41.2	41.5	0.7	-54.3	(0.1 to 0.1)	(0.1 to 0.1)	(105.0 to 254.4)	(17.8 to 118.2)
Inflammatory bowel disease	26.2	52.4	99.1	16.7	(37.1 to 46.1)	(34.2 to 48.8)	(-21.3 to 22.0)	(-64.7 to -44.5)
Vascular intestinal disorders	0.1	0.1	98.2	-1.2	(23.8 to 28.4)	(48.3 to 56.6)	(80.0 to 123.8)	(5.6 to 30.2)
Gallbladder and biliary diseases	19.6	35.1	78.4	2.1	(0.1 to 0.1)	(0.1 to 0.2)	(-3.1 to 29.0)	(-31.4 to 29.0)
Pancreatitis	3.2	6.2	91.6	11.9	(17.5 to 21.8)	(31.1 to 39.2)	(52.4 to 113.7)	(-19.9 to 11.8)
Other digestive diseases	-	-	-	-	0.4	2.7	590.1	283.1
Neurological disorders	-	-	-	-	120.0	183.5	53.3	1.5
Alzheimer disease and other dementias	53.8	130.4	142.7	1.3	(48.2 to 59.9)	(112.0 to 149.6)	(98.0 to 188.2)	(-17.2 to 20.2)
Parkinson disease	3.4	7.5	118.4	1.1	(2.9 to 4.1)	(6.3 to 8.9)	(103.9 to 132.6)	(-6.0 to 7.5)
Epilepsy	130.0	157.4	21.7	-10.2	(101.8 to 156.1)	(118.5 to 191.7)	(-11.9 to 64.4)	(-35.3 to 21.1)
Multiple sclerosis	3.6	9.5	165.6	62.2	(3.2 to 3.9)	(8.8 to 10.1)	(135.3 to 195.0)	(43.4 to 79.8)
Migraine	1,261.1	1,875.6	49.5	43.2	(1,031.4 to 1,474.4)	(1,520.3 to 2,202.6)	(17.6 to 88.6)	(-21.2 to 24.8)
Tension-type headache	2,354.8	3,448.6	47.3	-0.2	(2,235.3 to 2,469.4)	(2,904.6 to 3,976.3)	(22.7 to 69.6)	(-17.2 to 15.2)
Medication overuse headache	61.8	148.5	144.6	51.9	(39.5 to 83.5)	(94.6 to 205.0)	(74.3 to 202.6)	(6.4 to 89.6)
Other neurological disorders	0.0	0.0	51.7	-0.1	(0.0 to 0.0)	(0.0 to 0.0)	(17.6 to 100.1)	(-23.0 to 30.7)
Mental and substance use disorders	-	-	-	-	331.6	466.5	40.7	-0.1
Schizophrenia	36.6	56.1	53.2	-2.3	(32.1 to 40.7)	(49.7 to 61.9)	(44.8 to 63.6)	(-7.1 to 3.2)
Alcohol use disorders	196.3	307.2	56.5	10.8	(176.8 to 218.3)	(280.4 to 338.2)	(46.3 to 66.8)	(3.7 to 18.1)
Drug use disorders	-	-	-	-	33.7	42.5	26.1	-2.8
Opioid use disorders	31.1	43.9	40.1	1.5	(23.2 to 40.0)	(34.6 to 53.2)	(27.5 to 63.4)	(-6.1 to 16.1)
Cocaine use disorders	17.0	21.0	23.8	2.3	(13.9 to 19.6)	(18.7 to 25.5)	(23.2 to 53.9)	(-19.8 to 18.2)
Amphetamine use disorders	57.0	65.3	14.0	-8.1	(53.4 to 60.4)	(61.5 to 69.2)	(6.0 to 26.5)	(-14.3 to 1.8)
Cannabis use disorders	32.7	39.0	19.5	-1.8	(27.5 to 37.5)	(33.3 to 44.7)	(10.6 to 28.5)	(-8.9 to 5.8)
Other drug use disorders	-	-	-	-	9.9	11.6	15.9	-7.2
Depressive disorders	-	-	-	-	61.1	71.1	16.4	0.6
Major depressive disorder	404.0	592.7	47.0	-0.9	(285.6 to 534.4)	(421.0 to 777.6)	(34.1 to 59.1)	(-7.9 to 6.2)
Dysthymia	193.3	296.5	53.4	-0.4	(161.9 to 224.9)	(251.2 to 341.1)	(47.7 to 60.0)	(-0.5 to -0.3)
Bipolar disorder	101.6	146.2	44.0	-0.1	(89.3 to 113.6)	(130.4 to 161.7)	(35.7 to 51.6)	(-5.1 to 4.5)
Anxiety disorders	786.0	1,101.6	40.2	2.8	(690.3 to 883.1)	(980.2 to 1,232.2)	(31.9 to 49.4)	(-5.8 to 4.9)
Eating disorders	-	-	-	-	8.4	10.3	23.1	4.6
Anorexia nervosa	5.9	9.3	56.5	32.9	(4.4 to 7.7)	(7.0 to 11.6)	(40.7 to 75.9)	(19.2 to 48.9)
Bulimia nervosa	33.7	39.5	17.1	-0.4	(21.7 to 49.4)	(25.5 to 57.9)	(15.4 to 19.3)	(-0.4 to -0.4)
Autistic spectrum disorders	-	-	-	-	15.9	20.7	30.4	0.3
Autism	41.2	54.2	31.3	0.6	(39.0 to 43.4)	(51.2 to 57.1)	(30.3 to 32.5)	(0.5 to 0.6)
Asperger syndrome	56.6	74.2	31.1	0.8	(53.1 to 60.5)	(69.5 to 79.5)	(29.7 to 32.5)	(0.7 to 0.8)
Attention-deficit/hyperactivity disorder	94.6	101.5	7.4	0.2	(87.1 to 101.7)	(93.6 to 109.3)	(7.1 to 10.2)	(0.2 to 0.2)
Conduct disorder	109.6	119.2	8.8	13.2	(100.0 to 119.7)	(108.5 to 130.3)	(8.1 to 9.4)	(0.1 to 0.2)
Idiopathic intellectual disability	70.8	72.1	2.0	-3.1	(53.2 to 90.0)	(47.7 to 95.7)	(-20.9 to 23.3)	(-40.1 to -7.4)
Other mental and substance use disorders	211.8	327.5	54.6	0.5	(198.2 to 224.5)	(308.4 to 346.3)	(52.1 to 57.1)	(0.4 to 0.7)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	79.8	140.6	76.2	7.7
Diabetes mellitus	297.7	695.3	132.8	30.2	(244.0 to 352.1)	(584.1 to 836.9)	(84.0 to 197.0)	(16.6 to 69.2)
Acute glomerulonephritis	0.0	0.0	24.7	-38.6	(0.0 to 0.0)	(0.0 to 0.0)	(-30.4 to -18.6)	(-42.7 to -34.4)
Chronic kidney disease	-	-	-	-	25.7	42.1	64.0	-1.9
Chronic kidney disease due to diabetes mellitus	54.7	170.8	217.7	71.3	(33.7 to 98.1)	(111.5 to 303.3)	(126.0 to 325.7)	(22.4 to 134.0)
Chronic kidney disease due to hypertension	111.0	134.1	20.7	-26.0	(70.0 to 167.3)	(90.3 to 199.8)	(-16.5 to 81.0)	(-48.9 to 8.1)
Chronic kidney disease due to glomerulonephritis	195.0	147.8	-35.9	15.4	(76.6 to 159.6)	(100.4 to 275.5)	(2.8 to 104.9)	(-37.2 to 20.4)
Chronic kidney disease due to other causes	239.0	287.1	19.7	-30.5	(166.5 to 387.9)	(215.2 to 453.1)	(43.9 to 13.9)	(-7.9 to 15.9)
Urinary diseases and male infertility	-	-	-	-	6.4	14.1	119.5	5.9
	-	-	-	-	(4.1 to 9.3)	(8.9 to 20.4)	(90.2 to 157.9)	(8.7 to 24.5)

Appendix Table G.4 - Chile prevalence and VIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VIDs 1990 (thousands)	VIDs 2013 (thousands)	% change VIDs, 1990 to 2013	% change age-standardized VIDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	2.9 (2.5 to 3.3)	5.5 (4.8 to 6.2)	91.0 (61.2 to 127.7)	91.0 (9.3 to 51.4)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	89.5 (49.2 to 142.1)	89.5 (2.9 to 62.2)
Urolithiasis	73.6 (43.3 to 125.5)	203.7 (102.0 to 353.4)	274.6 (119.4 to 237.9)	37.8 (7.4 to 70.3)	0.6 (0.3 to 1.0)	1.5 (0.7 to 2.9)	165.5 (108.1 to 215.2)	39.5 (8.9 to 64.9)
Benign prostatic hyperplasia	148.3 (129.6 to 170.8)	329.2 (287.9 to 373.8)	120.7 (85.8 to 166.9)	2.6 (-13.6 to 24.0)	5.3 (3.4 to 7.6)	11.8 (7.5 to 17.0)	121.4 (86.1 to 169.9)	3.0 (-13.4 to 25.1)
Male infertility due to other causes	40.2 (29.8 to 52.1)	49.3 (35.1 to 64.5)	23.4 (-23.1 to 81.2)	-1.8 (-39.0 to 43.3)	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.7)	23.5 (-27.3 to 85.7)	-1.8 (-42.2 to 45.7)
Other urinary diseases	-	-	-	-	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.3)	34.8 (-11.4 to 235.7)	-34.8 (53.0 to 80.4)
Gynecological diseases	-	-	-	-	15.6 (10.2 to 22.9)	21.5 (14.0 to 32.5)	37.1 (18.8 to 60.2)	4.1 (-16.1 to 11.8)
Uterine fibroids	325.7 (287.6 to 366.3)	536.8 (479.4 to 599.8)	64.9 (61.9 to 68.1)	-1.3 (-1.3 to -1.2)	3.3 (1.7 to 6.0)	5.2 (2.7 to 9.3)	59.5 (44.5 to 73.0)	0.4 (-8.8 to 8.4)
Polycystic ovarian syndrome	216.5 (190.3 to 244.4)	292.3 (263.6 to 323.1)	35.2 (13.2 to 58.4)	-1.2 (-16.4 to 15.0)	2.0 (1.0 to 3.8)	2.7 (1.3 to 5.1)	34.4 (12.7 to 56.7)	-1.4 (-16.7 to 14.4)
Female infertility due to other causes	3.0 (1.3 to 8.8)	3.0 (1.5 to 9.2)	4.4 (-77.4 to 363.8)	-21.0 (-83.8 to 256.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-74.0 to 340.0)	-18.1 (-81.7 to 246.9)
Endometriosis	39.4 (32.5 to 46.2)	50.6 (42.3 to 58.9)	27.6 (1.9 to 67.1)	-7.2 (26.5 to 20.0)	3.7 (2.4 to 5.1)	4.7 (3.1 to 6.7)	27.9 (0.8 to 66.3)	-7.1 (-27.5 to 20.7)
Genital prolapse	518.2 (445.7 to 587.5)	806.2 (698.3 to 930.0)	55.2 (28.4 to 93.6)	-6.9 (-22.7 to 15.2)	1.7 (0.8 to 3.1)	2.6 (1.2 to 4.9)	54.9 (26.2 to 92.9)	-6.8 (-23.5 to 16.0)
Premenstrual syndrome	487.3 (306.1 to 660.5)	605.4 (400.6 to 847.4)	23.8 (-26.7 to 113.3)	-3.8 (-42.4 to 70.1)	4.1 (2.1 to 6.8)	5.1 (2.7 to 8.5)	23.4 (-26.6 to 114.5)	-4.1 (-42.6 to 71.8)
Other gynecological diseases	35.4 (30.3 to 42.3)	46.9 (42.9 to 51.3)	33.5 (11.6 to 53.7)	-3.4 (-19.6 to 10.7)	0.9 (0.6 to 1.3)	1.1 (0.8 to 1.6)	32.7 (-5.6 to 81.6)	-3.8 (-29.8 to 29.1)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	8.0 (5.3 to 11.5)	9.2 (6.2 to 13.2)	14.9 (5.4 to 25.6)	-0.1 (-8.2 to 9.1)
Thalassemias	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	14.3 (2.5 to 27.2)	9.2 (-2.0 to 21.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.6 (-12.9 to 67.2)	12.0 (-18.2 to 55.2)
Thalassemia trait	147.0 (141.7 to 153.2)	191.0 (182.8 to 202.3)	29.9 (25.1 to 34.9)	-2.6 (-6.6 to 1.2)	5.8 (3.9 to 8.2)	6.5 (4.4 to 9.3)	13.1 (4.5 to 23.0)	-3.8 (-10.9 to 5.1)
Sickle cell disorders	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	11.6 (7.2 to 52.4)	-1.3 (-19.1 to 31.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.5 (2.1 to 43.8)	3.7 (-11.9 to 22.1)
Sickle cell trait	41.8 (36.9 to 46.0)	55.0 (50.1 to 60.2)	31.9 (18.7 to 47.0)	0.5 (-9.8 to 11.4)	0.8 (0.4 to 1.1)	0.8 (0.5 to 1.2)	5.4 (-20.4 to 60.4)	-2.5 (-26.9 to 46.5)
G6PD deficiency	234.5 (206.6 to 260.1)	327.1 (298.7 to 355.6)	39.1 (21.8 to 62.0)	4.8 (-8.3 to 22.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	19.4 (-42.8 to 180.6)	6.4 (-50.6 to 148.2)
G6PD trait	1,619.9 (1,573.7 to 1,663.5)	2,084.0 (2,019.7 to 2,157.0)	28.6 (22.8 to 34.7)	-4.8 (-9.1 to -0.3)	0.2 (0.0 to 0.2)	0.2 (0.1 to 0.3)	4.8 (-56.0 to 333.9)	-7.4 (-62.7 to 255.5)
Other hemoglobinopathies and hemolytic anemias	41.4 (32.7 to 50.3)	53.8 (46.2 to 64.2)	29.4 (1.9 to 56.7)	1.3 (-12.6 to 41.8)	1.7 (0.8 to 2.0)	1.7 (1.0 to 2.6)	25.0 (-5.0 to 104.6)	14.5 (-120.2 to 83.8)
Endocrine, metabolic, blood, and immune disorders	105.8 (97.4 to 118.1)	164.9 (154.2 to 174.0)	53.5 (37.6 to 73.4)	3.7 (4.5 to 30.4)	5.8 (2.5 to 5.2)	5.8 (4.0 to 8.1)	56.7 (40.7 to 83.7)	38.3 (5.6 to 37.4)
Musculoskeletal disorders	-	-	-	-	209.3 (147.7 to 279.3)	376.3 (269.9 to 493.9)	80.0 (64.6 to 94.8)	6.2 (-1.9 to 14.6)
Rheumatoid arthritis	43.9 (42.2 to 45.8)	75.6 (72.2 to 78.9)	72.6 (62.2 to 82.6)	-7.9 (-13.6 to -2.5)	10.4 (7.4 to 13.8)	17.8 (12.7 to 23.7)	71.1 (58.3 to 85.0)	-8.0 (-14.5 to -0.6)
Osteoarthritis	396.3 (379.9 to 413.6)	832.8 (797.8 to 869.0)	110.2 (97.4 to 122.4)	-1.0 (-6.8 to 4.8)	13.8 (9.2 to 20.0)	29.0 (19.1 to 41.5)	110.0 (96.6 to 122.4)	0.7 (-6.8 to 5.0)
Low back and neck pain	-	-	-	-	142.6 (98.8 to 197.6)	235.5 (164.8 to 316.2)	64.9 (46.2 to 88.2)	2.7 (-8.4 to 16.5)
Low back pain	689.3 (647.0 to 731.4)	1,098.8 (1,037.3 to 1,157.5)	59.6 (46.5 to 74.1)	-1.1 (-9.0 to 7.5)	77.5 (51.5 to 107.5)	123.0 (82.8 to 172.6)	58.4 (45.7 to 73.9)	-0.9 (-8.8 to 7.9)
Neck pain	657.3 (535.6 to 787.9)	1,140.9 (1,006.7 to 1,256.9)	73.3 (37.5 to 121.0)	6.6 (-14.4 to 35.6)	65.1 (42.2 to 94.2)	112.5 (78.2 to 157.1)	72.9 (38.2 to 120.2)	6.8 (-13.9 to 36.0)
Gout	18.4 (16.1 to 21.0)	38.1 (32.6 to 43.4)	108.2 (69.8 to 151.2)	4.8 (-14.0 to 26.8)	0.6 (0.4 to 0.8)	1.2 (0.8 to 1.7)	108.3 (63.2 to 160.5)	5.6 (-16.9 to 31.2)
Other musculoskeletal disorders	453.3 (401.0 to 509.8)	1,007.3 (891.6 to 1,123.5)	122.0 (109.4 to 137.8)	22.5 (16.1 to 30.5)	41.9 (28.3 to 59.2)	97.7 (63.1 to 129.7)	121.3 (108.0 to 138.0)	22.8 (15.9 to 31.3)
Other non-communicable diseases	-	-	-	-	202.8 (135.7 to 294.8)	318.8 (212.4 to 460.3)	57.2 (51.8 to 62.9)	-2.3 (-5.3 to 1.6)
Congenital anomalies	-	-	-	-	18.7 (13.4 to 24.5)	32.3 (23.0 to 43.0)	72.3 (51.5 to 95.9)	26.1 (10.3 to 44.4)
Neural tube defects	3.3 (2.8 to 4.0)	4.0 (3.4 to 4.9)	19.5 (6.6 to 58.9)	-1.5 (-22.9 to 31.1)	1.0 (0.7 to 1.4)	1.2 (0.8 to 1.8)	20.1 (-16.0 to 83.8)	-0.0 (-29.9 to 52.4)
Congenital heart anomalies	102.0 (90.9 to 113.0)	161.6 (132.8 to 196.7)	57.6 (25.0 to 95.7)	24.6 (-1.1 to 54.7)	3.6 (1.6 to 5.6)	5.9 (2.4 to 10.4)	62.3 (32.8 to 97.6)	30.7 (6.4 to 58.8)
Orofacial clefts	15.9 (12.7 to 20.1)	23.3 (17.8 to 29.4)	46.4 (1.5 to 109.0)	17.9 (-18.5 to 68.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	0.5 (-29.1 to 65.8)	-12.1 (-42.7 to 34.1)
Down syndrome	28.7 (24.4 to 32.7)	48.5 (40.6 to 58.9)	68.0 (34.3 to 116.3)	20.4 (-3.5 to 54.7)	3.7 (2.6 to 4.8)	7.1 (5.1 to 9.5)	89.4 (49.0 to 146.5)	25.8 (0.1 to 63.8)
Turner syndrome	0.6 (0.6 to 0.7)	0.9 (0.7 to 1.1)	38.8 (3.1 to 89.5)	9.7 (-18.4 to 49.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.2 (0.6 to 93.9)	9.9 (-20.7 to 51.8)
Klinefelter syndrome	0.6 (0.4 to 0.8)	0.7 (0.6 to 1.1)	35.1 (-16.5 to 99.0)	4.0 (-35.9 to 53.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.3 (-18.3 to 122.3)	2.9 (-37.9 to 67.9)
Chromosomal unbalanced rearrangements	30.2 (26.0 to 36.1)	50.3 (40.8 to 61.1)	65.9 (32.0 to 109.7)	3.9 (-5.2 to 50.8)	7.3 (2.8 to 5.2)	7.3 (5.2 to 9.8)	24.5 (15.1 to 59.2)	5.8 (-1.5 to 59.2)
Other congenital anomalies	29.8 (23.4 to 35.4)	35.0 (24.8 to 43.0)	19.0 (5.0 to 35.6)	-16.2 (-32.3 to -4.4)	6.3 (4.1 to 8.7)	10.6 (6.5 to 15.9)	67.2 (29.5 to 123.3)	29.0 (-6.6 to 73.0)
Skin and subcutaneous diseases	-	-	-	-	79.9 (51.8 to 121.5)	110.7 (72.6 to 162.5)	38.6 (29.0 to 49.8)	2.0 (-4.2 to 10.0)
Dermatitis	803.2 (667.3 to 942.5)	1,098.0 (912.7 to 1,277.4)	36.7 (32.9 to 40.4)	-0.0 (-0.1 to 0.0)	22.6 (14.5 to 32.8)	30.1 (19.3 to 43.9)	33.1 (28.0 to 38.2)	0.1 (-2.4 to 2.6)
Psoriasis	158.4 (138.7 to 177.3)	243.0 (213.1 to 272.1)	53.4 (48.6 to 58.7)	0.1 (0.0 to 0.2)	13.0 (8.8 to 18.0)	19.8 (13.5 to 27.8)	0.2 (44.2 to 61.2)	0.2 (-4.0 to 4.5)
Cellulitis	5.9 (4.8 to 7.3)	9.2 (7.5 to 11.5)	56.3 (43.9 to 73.0)	-0.7 (-9.8 to 7.9)	0.4 (0.3 to 0.6)	0.6 (0.4 to 1.0)	55.5 (32.1 to 85.6)	-0.5 (-15.3 to 18.1)
Pyoderma	15.1 (12.1 to 19.5)	16.4 (12.7 to 21.7)	9.1 (-3.3 to 20.2)	-14.1 (-20.3 to -7.6)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	8.0 (-6.3 to 22.9)	-14.3 (-22.7 to -4.5)
Scabies	8.1 (6.7 to 9.7)	8.5 (7.2 to 10.2)	4.0 (-18.3 to 38.5)	-21.2 (-37.3 to 3.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	4.7 (-21.5 to 41.2)	-20.6 (-39.4 to 14.8)
Fungal skin diseases	728.9 (581.7 to 883.7)	1,112.2 (907.3 to 1,318.5)	53.0 (46.2 to 60.5)	0.4 (0.2 to 0.5)	6.2 (1.7 to 8.6)	6.2 (2.6 to 13.2)	0.5 (45.6 to 59.9)	0.2 (-0.5 to 1.5)
Viral skin diseases	325.9 (253.1 to 396.4)	382.4 (304.4 to 465.3)	17.2 (12.9 to 23.5)	0.0 (-2.0 to 2.2)	10.1 (5.9 to 16.0)	11.8 (6.9 to 18.7)	16.8 (11.4 to 23.9)	0.0 (-3.1 to 3.5)
Acne vulgaris	1,719.1 (1,378.6 to 2,088.4)	2,174.4 (1,701.3 to 2,638.1)	25.0 (8.0 to 75.9)	7.4 (-21.1 to 49.0)	18.6 (8.6 to 36.1)	23.6 (10.6 to 44.5)	25.0 (8.1 to 75.7)	7.4 (-20.9 to 49.4)
Alopecia areata	19.1 (17.3 to 20.8)	28.6 (26.5 to 30.8)	49.9 (33.2 to 70.4)	-1.5 (-11.9 to 11.9)	0.6 (0.4 to 1.0)	1.0 (0.6 to 1.4)	49.1 (29.0 to 72.1)	-1.1 (-13.8 to 13.3)
Pruritus	4.1 (3.3 to 4.9)	7.4 (5.7 to 8.9)	82.8 (29.3 to 146.0)	5.3 (-24.7 to 42.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	80.0 (24.9 to 144.2)	5.8 (-27.2 to 44.1)
Urticaria	86.2 (58.0 to 111.8)	142.3 (111.0 to 178.7)	64.9 (13.1 to 159.4)	6.4 (-27.2 to 66.8)	5.1 (3.0 to 8.2)	8.4 (5.0 to 13.0)	64.2 (12.4 to 156.5)	6.6 (-27.5 to 66.6)
Decubitus ulcer	5.0 (4.1 to 5.9)	9.3 (7.4 to 11.5)	84.9 (38.5 to 164.3)	-9.5 (-32.9 to 30.4)	0.7 (0.5 to 1.0)	1.3 (0.9 to 2.0)	83.7 (34.6 to 163.6)	-9.1 (-34.3 to 31.8)
Other skin and subcutaneous diseases	704.5 (454.8 to 1,082.9)	1,251.7 (768.6 to 2,028.7)	77.1 (57.8 to 93.7)	1.1 (-1.3 to 4.0)	4.1 (1.8 to 8.6)	7.3 (3.1 to 16.0)	76.3 (57.8 to 93.6)	1.2 (-1.5 to 4.4)
Sense organ diseases	-	-	-	-	58.0 (38.3 to 83.3)	97.7 (63.9 to 140.1)	68.5 (59.5 to 76.9)	-10.7 (-15.2 to -6.5)
Glaucoma	14.2 (11.1 to 17.6)	19.8 (15.6 to 24.6)	40.2 (20.0 to 63.6)	-29.9 (-40.6 to -38.2)	1.0 (0.6 to 1.4)	1.4 (0.9 to 2.0)	44.9 (24.2 to 76.7)	-29.9 (-40.2 to -15.1)
Cataract	16.5 (11.1 to 22.5)	23.2 (14.1 to 31.0)	41.4 (3.5 to 98.3)	-38.7 (-56.1 to -13.8)	1.0 (0.7 to 1.6)	1.4 (0.8 to 2.1)	32.0 (-1.5 to 73.3)	-43.1 (-58.2 to -25.9)
Macular degeneration	18.0 (12.9 to 23.2)	47.5 (33.9 to 62.6)	164.2 (117.6 to 212.7)	18.4 (-4.1 to 40.3)	1.0 (0.6 to 1.5)	2.6 (1.6 to 3.9)	151.0 (106.3 to 196.2)	9.6 (-1.5 to 29.5)
Uncorrected refractive error	880.6 (820.6 to 941.5)	1,501.4 (1,405.5 to 1,597.7)	70.6 (54.7 to 88.1)	6.3 (-14.0 to 2.5)	12.6 (7.2 to 20.8)	20.0 (11.2 to 33.9)	58.8 (47.0 to 73.0)	-10.9 (-17.0 to -3.5)
Age-related and other hearing loss	1,244.2 (1,159.1 to 1,323.1)	2,298.1 (2,141.7 to 2,434.7)	84.3 (76.3 to 90.6)	-8.2 (-11.4 to -5.5)	32.1 (21.1 to 46.4)	32.1 (39.3 to 84.4)	88.0 (69.1 to 98.0)	-10.1 (-16.7 to -3.1)
Other vision loss	46.0 (37.3 to 54.9)	52.9 (40.8 to 65.1)	35.2 (3.3 to 26.5)	-2.3 (-40.8 to -28.8)	2.3 (1.5 to 3.3)	2.8 (1.8 to 4.0)	19.5 (6.5 to 33.3)	-35.2 (-41.7 to -27.5)
Other sense organ diseases	298.0 (284.9 to 313.8)	406.2 (387.2 to 425.9)	36.4 (27.3 to 45.3)	0.3 (-6.1 to 6.5)	8.0 (4.9 to 11.9)	10.7 (6.6 to 15.8)	34.5 (25.0 to 45.5)	0.3 (-6.7 to 7.9)
Oral disorders	-	-	-	-	46.2 (27.6 to 72.0)	78.1 (47.0 to 121.4)	69.1 (60.0 to 77.2)	69.1 (-10.5 to 11.2)
Deciduous caries	807.0 (775.5 to 839.8)	719.0 (694.4 to 745.4)	-10.8 (-15.2 to -6.4)	-3.1 (-7.8 to 1.7)	0.3 (0.1 to 0.5)	0.3 (0.1 to 0.5)	-11.0 (-17.6 to -3.6)	

Appendix Table G.4 - Chile prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	730.4 (684.5 to 775.3)	1,320.3 (1,216.0 to 1,420.0)	81.1 (64.0 to 98.7)	-12.7 (-20.9 to -4.6)	20.3 (13.5 to 27.9)	36.6 (24.8 to 51.1)	80.6 (63.6 to 98.3)	-22.7 (-20.8 to -4.4)
Other oral disorders	224.8 (211.8 to 237.8)	330.4 (312.1 to 349.6)	46.9 (35.5 to 60.6)	-0.3 (-7.7 to 8.5)	6.6 (4.1 to 10.0)	9.7 (6.1 to 14.5)	46.2 (34.3 to 60.6)	-0.4 (-8.0 to 9.6)
Injuries	-	-	-	-	89.6 (68.1 to 115.5)	98.5 (70.3 to 132.7)	9.4 (-0.7 to 20.6)	-36.6 (-42.4 to -30.1)
Transport injuries	-	-	-	-	23.9 (18.0 to 30.8)	17.6 (12.8 to 23.4)	-26.5 (-33.6 to -18.0)	-56.2 (-60.2 to -51.6)
Road injuries	-	-	-	-	21.5 (16.2 to 27.7)	14.2 (10.4 to 18.8)	-34.1 (-40.5 to -26.2)	-90.9 (-64.2 to -56.1)
Pedestrian road injuries	-	-	-	-	4.2 (3.1 to 5.5)	3.2 (2.3 to 4.4)	-22.7 (-30.8 to -13.9)	-54.2 (-58.6 to -49.5)
Cyclist road injuries	-	-	-	-	2.9 (2.1 to 3.7)	1.7 (1.3 to 2.3)	-40.0 (-47.6 to -30.8)	-63.9 (-68.2 to -58.8)
Motorcyclist road injuries	-	-	-	-	3.5 (2.6 to 4.6)	1.8 (1.3 to 2.4)	-49.6 (-56.9 to -40.4)	-69.5 (-73.6 to -64.3)
Motor vehicle road injuries	-	-	-	-	10.7 (8.1 to 13.7)	7.4 (5.4 to 9.6)	-31.2 (-37.9 to -24.0)	-98.9 (-62.6 to -54.8)
Other road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.1)	-53.1 (-59.0 to -46.4)	-71.8 (-75.2 to -68.1)
Other transport injuries	-	-	-	-	2.4 (1.8 to 3.2)	3.4 (2.4 to 4.6)	40.0 (27.7 to 55.2)	-20.3 (-27.1 to -11.9)
Unintentional injuries	-	-	-	-	61.0 (46.6 to 79.2)	76.6 (54.5 to 103.6)	25.1 (13.9 to 37.5)	-28.6 (-35.2 to -21.6)
Falls	-	-	-	-	31.6 (24.3 to 40.7)	42.5 (30.8 to 57.6)	35.5 (21.2 to 50.6)	-29.5 (-37.8 to -21.0)
Drowning	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	-2.2 (-14.2 to 11.2)	-40.8 (-47.9 to -33.1)
Fire, heat, and hot substances	-	-	-	-	2.6 (1.7 to 4.1)	3.2 (1.9 to 5.2)	20.4 (5.1 to 36.9)	-27.4 (-36.3 to -17.6)
Poisonings	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	5.2 (-11.4 to 23.3)	-31.6 (-41.8 to -20.6)
Exposure to mechanical forces	-	-	-	-	23.5 (17.7 to 30.7)	21.8 (15.4 to 29.7)	-7.5 (-16.8 to 2.2)	-40.0 (-45.6 to -34.5)
Unintentional firearm injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.7 (0.5 to 1.0)	77.7 (58.1 to 100.2)	13.3 (2.1 to 26.7)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	21.7 (5.7 to 37.4)	-24.0 (-32.7 to -15.3)
Other exposure to mechanical forces	-	-	-	-	22.9 (17.3 to 30.1)	20.9 (14.7 to 28.5)	-9.2 (-18.5 to 0.4)	-41.1 (-46.6 to -35.6)
Adverse effects of medical treatment	-	-	-	-	0.5 (0.3 to 0.7)	0.8 (0.5 to 1.2)	69.2 (56.7 to 82.2)	-0.2 (-7.7 to 8.1)
Animal contact	-	-	-	-	0.6 (0.4 to 0.8)	0.9 (0.6 to 1.2)	52.3 (40.4 to 66.4)	-2.6 (-9.2 to 5.5)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	44.7 (28.2 to 61.9)	-5.0 (-14.9 to 5.6)
Non-venomous animal contact	-	-	-	-	0.5 (0.3 to 0.6)	0.7 (0.5 to 1.0)	54.1 (41.7 to 68.7)	-2.0 (-9.2 to 6.7)
Foreign body	-	-	-	-	0.6 (0.4 to 0.8)	0.7 (0.4 to 1.0)	17.2 (6.6 to 26.5)	-19.8 (-28.1 to -12.6)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	7.5 (5.5 to 22.7)	-29.0 (-37.1 to -19.6)
Foreign body in eyes	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	25.2 (11.9 to 39.7)	-11.0 (-21.6 to 0.2)
Foreign body in other body part	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	15.8 (2.6 to 27.0)	-21.4 (-31.1 to -12.8)
Other unintentional injuries	-	-	-	-	1.2 (0.8 to 1.6)	5.8 (4.0 to 8.1)	400.2 (345.7 to 462.6)	155.9 (127.3 to 188.7)
Self-harm and interpersonal violence	-	-	-	-	4.5 (3.4 to 5.7)	4.1 (3.0 to 5.4)	-8.8 (-16.2 to 0.1)	-44.2 (-48.4 to -39.2)
Self-harm	-	-	-	-	0.8 (0.6 to 1.1)	1.1 (0.8 to 1.5)	27.3 (14.2 to 42.4)	-25.4 (-32.5 to -16.9)
Interpersonal violence	-	-	-	-	3.6 (2.7 to 4.6)	3.0 (2.2 to 4.0)	-17.1 (-24.9 to -8.1)	-48.7 (-53.3 to -43.6)
Assault by firearm	-	-	-	-	1.2 (0.9 to 1.5)	1.0 (0.7 to 1.4)	-12.6 (-20.9 to -4.2)	-46.4 (-51.1 to -41.5)
Assault by sharp object	-	-	-	-	0.6 (0.4 to 0.8)	0.7 (0.5 to 0.9)	13.1 (2.7 to 25.4)	-30.3 (-36.2 to -23.2)
Assault by other means	-	-	-	-	1.9 (1.4 to 2.4)	1.3 (1.0 to 1.8)	-29.2 (-37.5 to -19.0)	-55.9 (-61.0 to -49.6)
Forces of nature, war, and legal intervention	-	-	-	-	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.2)	-36.6 (-55.4 to -16.0)	-47.6 (-63.2 to -30.6)
Exposure to forces of nature	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-3.7 (-23.8 to 21.1)	-18.8 (-35.9 to 1.5)
Collective violence and legal intervention	-	-	-	-	0.1 (0.1 to 0.3)	0.1 (0.0 to 0.1)	-56.5 (-71.4 to -38.5)	-65.8 (-77.5 to -51.7)

Appendix Table G.4 - China prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Edentulism and severe tooth loss	25,515.7 (24,932.3 to 25,982.7)	26,596.3 (26,073.1 to 27,194.6)	4.0 (1.0 to 7.1)	-45.1 (-46.6 to -43.5)	712.9 (481.5 to 983.8)	741.4 (499.9 to 1,027.4)	4.0 (1.0 to 7.1)	4.0 (-6.5 to -43.4)
Other oral disorders	19,662.7 (19,406.6 to 19,900.6)	26,668.1 (26,361.8 to 26,984.3)	35.1 (33.0 to 37.5)	-0.5 (-2.0 to 1.2)	582.4 (367.5 to 868.8)	785.6 (495.7 to 1,170.8)	34.9 (32.5 to 37.2)	-0.2 (-1.8 to 1.5)
Injuries	-	-	-	-	3,555.0 (2,669.0 to 4,604.3)	3,969.6 (2,812.6 to 5,401.8)	11.0 (-1.0 to 25.1)	29.6 (-36.9 to -21.4)
Transport injuries	-	-	-	-	1,707.9 (1,278.7 to 2,218.9)	1,748.9 (1,235.0 to 2,379.9)	1.7 (-10.5 to 16.7)	-35.6 (-42.9 to -27.0)
Road injuries	-	-	-	-	405.3 (1,053.8 to 1,823.1)	1,467.4 (1,035.0 to 1,998.3)	1.7 (-9.3 to 19.8)	34.3 (-42.0 to -25.0)
Pedestrian road injuries	-	-	-	-	407.3 (303.7 to 524.4)	512.0 (360.5 to 698.6)	24.9 (8.6 to 45.5)	-20.5 (-30.2 to -8.5)
Cyclist road injuries	-	-	-	-	121.1 (89.9 to 159.1)	146.5 (104.0 to 197.7)	20.5 (9.8 to 31.8)	-26.6 (-32.6 to -20.0)
Motorcyclist road injuries	-	-	-	-	410.0 (308.0 to 536.0)	339.1 (237.7 to 469.1)	-17.9 (-28.4 to -5.1)	-48.5 (-54.7 to -41.0)
Motor vehicle road injuries	-	-	-	-	462.8 (347.1 to 596.6)	464.6 (330.1 to 631.6)	-3.2 (-13.7 to 16.3)	-36.3 (-44.4 to -26.6)
Other road injuries	-	-	-	-	4.1 (3.0 to 5.3)	5.3 (3.8 to 7.3)	30.4 (14.3 to 49.4)	-19.9 (-29.2 to -9.2)
Other transport injuries	-	-	-	-	302.6 (226.4 to 395.5)	281.5 (199.7 to 381.7)	-7.3 (-16.4 to 3.1)	-41.5 (-47.0 to -35.1)
Unintentional injuries	-	-	-	-	1,578.9 (1,186.3 to 2,049.0)	2,019.9 (1,451.8 to 2,747.5)	27.3 (15.8 to 40.4)	-19.9 (-27.0 to -11.8)
Falls	-	-	-	-	992.9 (741.3 to 1,295.9)	1,272.0 (898.2 to 1,740.3)	27.5 (14.6 to 42.1)	-22.9 (-30.7 to -14.3)
Drowning	-	-	-	-	84.4 (62.4 to 110.1)	41.3 (29.0 to 55.8)	-51.4 (-57.5 to -43.6)	64.5 (-68.6 to -59.4)
Fire, heat, and hot substances	-	-	-	-	66.7 (51.0 to 84.8)	39.9 (28.5 to 54.7)	-40.4 (-47.4 to -32.5)	-59.2 (-63.9 to -54.4)
Poisonings	-	-	-	-	22.4 (15.9 to 30.1)	21.5 (15.2 to 28.7)	-4.2 (-8.7 to 0.6)	-31.2 (-34.2 to -28.1)
Exposure to mechanical forces	-	-	-	-	200.8 (151.5 to 263.3)	385.1 (278.3 to 526.2)	91.2 (79.5 to 104.1)	28.3 (21.4 to 35.4)
Unintentional firearm injuries	-	-	-	-	10.5 (7.9 to 13.4)	6.2 (4.5 to 8.5)	-40.5 (-45.7 to -34.6)	59.4 (-62.6 to -55.9)
Unintentional suffocation	-	-	-	-	5.0 (3.8 to 6.6)	8.0 (5.8 to 10.7)	59.5 (49.6 to 69.8)	10.5 (4.5 to 16.7)
Other exposure to mechanical forces	-	-	-	-	185.3 (139.6 to 243.9)	370.9 (267.6 to 506.6)	99.6 (87.7 to 113.0)	33.7 (26.9 to 40.8)
Adverse effects of medical treatment	-	-	-	-	22.2 (14.1 to 32.7)	32.4 (20.6 to 47.5)	45.9 (43.5 to 48.5)	-0.3 (-2.1 to 1.5)
Animal contact	-	-	-	-	18.5 (13.9 to 24.2)	15.5 (11.3 to 20.7)	-16.5 (-23.0 to -9.0)	-42.6 (-46.7 to -38.2)
Venomous animal contact	-	-	-	-	7.0 (5.1 to 9.2)	5.6 (4.0 to 7.4)	-19.7 (-24.8 to -14.1)	-44.2 (-47.5 to -40.8)
Non-venomous animal contact	-	-	-	-	11.5 (8.6 to 15.3)	9.9 (7.2 to 13.6)	-14.4 (-22.4 to -5.7)	-41.7 (-46.3 to -36.7)
Foreign body	-	-	-	-	29.5 (22.3 to 37.4)	34.5 (25.4 to 45.1)	16.7 (7.0 to 28.4)	-22.3 (-28.3 to -15.3)
Pulmonary aspiration and foreign body in airway	-	-	-	-	8.9 (6.8 to 11.3)	7.4 (5.3 to 9.8)	-18.2 (-30.8 to -1.2)	-41.2 (-49.7 to -29.9)
Foreign body in eyes	-	-	-	-	6.8 (4.1 to 10.2)	8.8 (5.4 to 13.1)	29.5 (25.2 to 35.3)	-7.9 (-12.6 to -4.5)
Foreign body in other body part	-	-	-	-	13.7 (10.4 to 17.9)	18.4 (13.4 to 24.4)	33.4 (22.6 to 45.5)	-17.2 (-22.9 to -10.9)
Other unintentional injuries	-	-	-	-	141.5 (106.3 to 184.6)	177.5 (128.6 to 238.0)	25.2 (18.1 to 32.4)	-17.9 (-21.8 to -13.5)
Self-harm and interpersonal violence	-	-	-	-	215.7 (162.3 to 277.6)	146.2 (103.1 to 197.6)	-32.7 (-40.3 to -23.0)	-56.0 (-60.7 to -50.3)
Self-harm	-	-	-	-	71.3 (52.5 to 92.5)	48.6 (34.8 to 64.8)	-32.1 (-37.7 to -25.4)	-58.1 (-61.5 to -54.1)
Interpersonal violence	-	-	-	-	144.4 (109.6 to 184.7)	97.6 (68.9 to 133.0)	-32.9 (-41.6 to -21.9)	-54.9 (-60.4 to -48.1)
Assault by firearm	-	-	-	-	9.9 (7.4 to 12.8)	4.6 (3.3 to 6.3)	-53.4 (-57.3 to -49.2)	-67.3 (-69.8 to -64.8)
Assault by sharp object	-	-	-	-	27.9 (21.1 to 36.6)	24.7 (17.1 to 35.0)	-12.3 (-22.6 to 0.4)	-40.7 (-47.1 to -33.3)
Assault by other means	-	-	-	-	106.6 (80.8 to 136.3)	68.3 (48.7 to 92.4)	-36.4 (-44.8 to -25.5)	-57.3 (-62.6 to -50.6)
Forces of nature, war, and legal intervention	-	-	-	-	52.6 (21.3 to 114.6)	54.6 (29.3 to 109.0)	6.6 (-23.6 to 50.2)	-34.3 (-53.2 to -5.5)
Exposure to forces of nature	-	-	-	-	35.6 (14.4 to 79.8)	50.8 (27.3 to 100.2)	45.2 (12.5 to 109.4)	-10.6 (-31.2 to 33.2)
Collective violence and legal intervention	-	-	-	-	17.0 (6.0 to 40.7)	3.8 (1.6 to 8.2)	-76.9 (-85.2 to -65.7)	-85.9 (-91.1 to -78.9)

Appendix Table G.4 - Colombia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	3,193.2 (2,373.0 to 4,127.0)	5,117.5 (3,757.0 to 6,622.8)	60.2 (56.2 to 64.5)	-3.1 (-5.2 to -0.8)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	394.2 (272.8 to 555.4)	468.6 (330.0 to 656.0)	18.9 (12.1 to 26.8)	-7.6 (-13.1 to -1.2)
HIV/AIDS and tuberculosis	-	-	-	-	5.1 (3.4 to 7.2)	13.1 (8.8 to 18.5)	158.7 (96.7 to 235.3)	49.0 (16.3 to 89.7)
Tuberculosis	14.9 (14.1 to 15.7)	23.6 (22.7 to 24.5)	58.5 (51.5 to 66.0)	-8.0 (-12.0 to -3.4)	4.5 (3.0 to 6.1)	7.1 (4.8 to 9.7)	57.2 (39.3 to 81.4)	-7.7 (-17.5 to 4.7)
HIV/AIDS	-	-	-	-	0.5 (0.2 to 1.0)	6.0 (3.5 to 9.9)	783.1 (285.1 to 2,415.9)	131.1 (135.1 to 1,471.9)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	800.6 (114.8 to 1,538.9)	419.4 (25.1 to 830.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	800.6 (114.5 to 1,540.0)	419.4 (23.5 to 836.8)
HIV/AIDS resulting in other diseases	5.5 (2.3 to 12.8)	74.3 (54.8 to 95.3)	1,598.4 (440.3 to 2,624.3)	1,006.8 (250.5 to 1,682.2)	0.5 (0.2 to 1.5)	6.0 (3.4 to 9.8)	1,322.2 (286.3 to 2,473.6)	786.3 (134.3 to 1,516.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	93.5 (64.5 to 129.9)	102.1 (70.0 to 144.2)	9.0 (2.6 to 15.7)	-12.5 (-17.0 to -8.5)
Diarrheal diseases	283.7 (271.6 to 295.5)	283.0 (268.1 to 297.6)	0.0 (-6.5 to 7.2)	-11.3 (-17.1 to -5.3)	46.4 (31.3 to 64.5)	46.0 (31.2 to 63.3)	-0.9 (-8.0 to 6.8)	-11.7 (-17.9 to 5.2)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (-39.7 to -8.1)	-0.0 (-54.4 to -30.7)
Typhoid fever	0.2 (0.2 to 0.2)	0.2 (0.1 to 0.2)	-12.0 (-27.7 to 8.3)	-33.6 (-44.6 to -19.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.0 (-27.8 to 8.3)	-33.6 (-44.6 to -18.9)
Paratyphoid fever	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-14.5 (-34.5 to 7.7)	-34.2 (-49.1 to -17.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.5 (-34.6 to 7.8)	-34.2 (-49.1 to -17.2)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-81.8 (-91.6 to -63.1)	-86.3 (-93.6 to -71.9)
Lower respiratory infections	33.9 (28.7 to 39.5)	28.5 (24.7 to 32.5)	-15.6 (-34.0 to 4.8)	-30.3 (-44.2 to -15.4)	3.6 (2.3 to 5.2)	3.0 (2.0 to 4.3)	-16.2 (-35.3 to 5.3)	-30.6 (-47.1 to -13.8)
Upper respiratory infections	2,249.0 (2,154.6 to 2,360.5)	3,141.5 (2,990.9 to 3,276.6)	40.3 (31.1 to 47.9)	-0.3 (-6.2 to 5.2)	26.4 (14.6 to 44.1)	36.8 (20.7 to 60.9)	39.8 (30.3 to 48.1)	0.0 (-6.5 to 5.7)
Otitis media	437.0 (414.2 to 463.5)	519.2 (489.2 to 552.0)	19.1 (11.1 to 27.7)	-12.2 (-18.3 to -5.9)	8.3 (4.9 to 13.2)	9.6 (5.6 to 15.3)	16.6 (8.0 to 27.1)	-13.4 (-19.9 to -5.7)
Meningitis	-	-	-	-	7.3 (5.0 to 10.3)	4.9 (3.2 to 6.9)	-32.2 (-46.1 to -19.5)	-51.0 (-60.0 to -41.5)
Pneumococcal meningitis	37.5 (22.2 to 59.1)	25.3 (15.2 to 40.7)	-32.9 (-42.8 to -17.9)	-55.4 (-62.0 to -45.8)	5.4 (2.1 to 4.7)	2.3 (1.5 to 3.4)	-51.6 (-66.6 to -39.9)	-51.2 (-61.0 to -34.0)
H influenzae type B meningitis	16.4 (4.8 to 34.1)	8.7 (3.0 to 18.1)	-46.8 (-63.1 to -18.3)	-63.1 (-73.5 to -40.1)	1.8 (1.0 to 2.8)	1.1 (0.6 to 1.7)	-39.2 (-63.9 to 4.2)	-54.8 (-72.5 to -23.0)
Meningococcal meningitis	3.0 (1.1 to 6.7)	1.9 (0.6 to 4.6)	-39.1 (-60.3 to -14.1)	-58.7 (-71.2 to -42.5)	0.4 (0.2 to 0.7)	0.2 (0.1 to 0.4)	-43.1 (-62.3 to -11.4)	-59.2 (-71.8 to -39.1)
Other meningitis	13.9 (6.2 to 27.1)	9.5 (4.4 to 18.8)	-32.3 (-47.0 to -10.8)	-53.2 (-62.3 to -36.9)	1.7 (1.1 to 2.7)	1.2 (0.8 to 1.8)	-28.0 (-51.2 to -0.2)	-47.0 (-62.9 to -27.0)
Encephalitis	2.9 (1.3 to 6.9)	4.7 (2.1 to 11.4)	61.1 (34.5 to 93.9)	12.2 (14.5 to 24.6)	0.4 (0.3 to 0.5)	0.7 (0.4 to 0.9)	69.8 (38.7 to 116.0)	10.2 (9.9 to 37.5)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.2 (-95.2 to 505.9)	-56.9 (-95.8 to 275.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.2 (-95.8 to 528.5)	-56.9 (-95.8 to 307.7)
Whooping cough	13.2 (10.3 to 16.9)	6.0 (4.7 to 7.7)	-54.2 (-56.5 to -51.7)	-55.9 (-58.2 to -53.6)	0.7 (0.4 to 1.1)	0.3 (0.2 to 0.5)	-54.1 (-61.5 to -45.3)	-55.9 (-63.0 to -47.5)
Tetanus	0.2 (0.2 to 0.3)	0.1 (0.0 to 0.1)	-79.7 (-87.7 to -64.0)	-85.4 (-91.3 to -74.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-75.5 (-88.7 to -56.0)	-81.3 (-91.3 to -66.8)
Measles	0.3 (0.3 to 0.3)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	25.2 (23.1 to 27.7)	32.1 (28.3 to 36.5)	27.6 (8.4 to 48.7)	-3.3 (-23.0 to 13.9)	0.5 (0.3 to 0.8)	0.9 (0.5 to 1.4)	65.2 (10.3 to 136.2)	-9.2 (-40.2 to 29.6)
Neglected tropical diseases and malaria	-	-	-	-	90.7 (57.7 to 140.3)	105.4 (66.5 to 158.7)	16.1 (4.1 to 42.8)	-9.9 (-25.8 to 10.6)
Malaria	1,318.1 (781.5 to 2,085.9)	1,354.4 (650.3 to 2,163.2)	2.4 (-35.5 to 67.5)	-19.2 (-48.5 to 31.2)	19.0 (12.0 to 29.0)	28.6 (15.8 to 45.8)	52.2 (-2.7 to 89.6)	28.2 (-17.6 to 59.7)
Chagas disease	347.6 (327.9 to 367.9)	523.8 (495.4 to 552.7)	50.8 (39.5 to 64.5)	-5.0 (-11.9 to 3.3)	2.1 (1.9 to 3.9)	4.9 (3.2 to 6.9)	79.3 (59.3 to 102.0)	5.5 (-15.9 to 6.3)
Leishmaniasis	-	-	-	-	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.5)	133.7 (88.5 to 190.0)	66.1 (34.3 to 110.3)
Visceral leishmaniasis	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-8.3 (-36.2 to 22.6)	-25.6 (-48.0 to -3.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.3 (-36.3 to 22.9)	-25.6 (-48.1 to -3.0)
Cutaneous and mucocutaneous leishmaniasis	9.6 (7.1 to 12.7)	23.2 (18.4 to 29.7)	143.7 (105.4 to 188.8)	69.2 (43.7 to 110.1)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.5)	142.5 (95.6 to 203.1)	70.9 (36.7 to 118.9)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	21.9 (10.1 to 43.2)	10.2 (3.8 to 20.6)	-54.3 (-83.7 to 20.8)	-69.5 (-88.4 to -25.6)	6.5 (2.9 to 13.5)	3.3 (1.2 to 7.0)	-51.6 (-82.8 to 32.9)	67.6 (-88.0 to -16.4)
Cystic echinococcosis	1.4 (1.3 to 1.7)	1.2 (1.1 to 1.4)	-13.4 (-21.0 to -8.5)	-56.3 (-59.5 to -53.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-12.5 (-30.7 to 12.5)	-54.9 (-64.6 to -41.8)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	4.3 (1.7 to 9.6)	30.4 (12.3 to 67.0)	605.9 (599.1 to 613.8)	394.4 (389.6 to 399.9)	0.7 (0.2 to 1.7)	4.9 (1.7 to 11.9)	599.0 (467.3 to 794.0)	393.8 (307.5 to 511.4)
Yellow fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.3 (-44.3 to -17.7)	-51.4 (-60.2 to -41.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.3 (-44.3 to -17.6)	-51.4 (-60.2 to -41.8)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.9 (-49.4 to 23.3)	-52.2 (-65.1 to -14.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.9 (-49.4 to 23.3)	-52.2 (-65.2 to -14.3)
Intestinal nematode infections	-	-	-	-	52.1 (28.7 to 90.2)	54.1 (30.9 to 88.3)	4.0 (-22.7 to 41.6)	-18.8 (-40.6 to 11.8)
Ascariasis	9,105.6 (7,637.0 to 10,795.4)	12,670.3 (9,816.6 to 16,003.6)	39.3 (0.6 to 85.5)	-2.6 (-30.1 to 31.7)	27.0 (13.7 to 51.5)	15.3 (6.7 to 30.3)	-40.0 (-69.4 to 3.3)	-52.9 (-74.3 to -12.8)
Trichuriasis	6,599.5 (5,272.3 to 8,309.6)	9,359.1 (7,356.8 to 11,963.6)	41.6 (2.3 to 99.0)	-2.0 (-31.4 to 39.8)	4.2 (1.7 to 8.8)	5.4 (2.4 to 11.4)	28.0 (-43.2 to 207.1)	-7.3 (-61.5 to 135.1)
Hookworm disease	3,876.9 (3,102.2 to 4,775.7)	5,792.1 (4,644.3 to 7,112.5)	50.0 (11.4 to 101.2)	0.6 (-26.6 to 37.0)	21.0 (12.2 to 33.0)	34.4 (19.6 to 55.4)	69.7 (13.4 to 124.4)	15.3 (-22.0 to 69.6)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	268.1 (208.8 to 326.8)	270.8 (242.7 to 297.1)	1.1 (-18.4 to 29.0)	-15.0 (-30.4 to 6.5)	9.3 (5.6 to 13.9)	9.1 (6.0 to 13.4)	-3.3 (-19.0 to 42.5)	-15.2 (-28.9 to 24.0)
Maternal disorders	-	-	-	-	0.1 (0.2 to 0.8)	0.5 (0.2 to 0.8)	-1.1 (-26.3 to 19.8)	-3.8 (-46.4 to -13.0)
Maternal hemorrhage	1.3 (0.8 to 1.7)	1.8 (1.5 to 2.2)	39.5 (-1.3 to 143.7)	1.4 (-27.8 to 69.2)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-31.8 (-67.6 to 52.1)	-52.2 (-76.1 to 4.4)
Maternal sepsis and other maternal infections	2.0 (1.2 to 3.2)	2.3 (1.3 to 4.2)	17.7 (-12.9 to 49.9)	-28.0 (-46.4 to -8.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-36.3 to 64.1)	-28.0 (-55.6 to 8.9)
Maternal hypertensive disorders	4.8 (1.7 to 8.8)	4.9 (1.8 to 9.2)	4.2 (-3.6 to 9.7)	-24.1 (-29.4 to -20.8)	0.2 (0.1 to 0.5)	0.2 (0.1 to 0.5)	5.8 (-17.6 to 38.9)	-23.4 (-40.7 to 1.6)
Obstructed labor	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	23.1 (-54.2 to 187.4)	-8.2 (-65.7 to 110.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-54.3 to 187.8)	-8.2 (-65.7 to 110.2)
Complications of abortion	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.6)	1.7 (-35.1 to 65.8)	-25.7 (-51.7 to 16.6)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	1.3 (-52.4 to 110.3)	-26.1 (-64.1 to 45.9)
Other maternal disorders	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-25.5 (-48.4 to 4.1)	-46.2 (-62.5 to -24.4)
Neonatal disorders	-	-	-	-	35.8 (24.8 to 47.6)	79.7 (55.3 to 108.6)	119.0 (68.9 to 209.3)	62.9 (25.5 to 131.5)
Preterm birth complications	125.3 (91.3 to 173.4)	318.3 (238.7 to 434.6)	154.0 (112.1 to 213.4)	79.9 (49.9 to 121.8)	14.6 (9.8 to 20.1)	38.9 (26.9 to 52.6)	164.6 (98.1 to 260.2)	93.4 (46.1 to 162.6)
Neonatal encephalopathy due to birth asphyxia and trauma	89.4 (35.7 to 193.2)	94.2 (39.7 to 197.2)	6.3 (-20.3 to 43.3)	-24.3 (-42.4 to -14.1)	10.4 (6.4 to 15.4)	13.4 (8.3 to 19.6)	28.7 (-20.7 to 105.6)	-1.1 (-39.3 to 57.6)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	136.1 (121.7 to 147.8)	134.6 (121.6 to 147.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (96.6 to 172.2)	136.1 (96.5 to 172.0)
Hemolytic disease and other neonatal jaundice	19.3 (9.3 to 31.3)	39.2 (18.6 to 75.4)	98.2 (-25.3 to 551.0)	47.6 (-45.6 to 385.8)	7.5 (3.4 to 12.4)	15.5 (6.6 to 30.3)	99.8 (-27.4 to 557.1)	49.2 (-46.7 to 392.3)
Other neonatal disorders	-	-	-	-	3.4 (2.1 to 5.1)	12.0 (6.4 to 18.9)	264.8 (78.4 to 492.7)	172.5 (32.4 to 339.8)
Nutritional deficiencies	-	-	-	-	152.3 (102.3 to 219.7)	147.7 (98.8 to 213.7)	-3.0 (-7.9 to 2.0)	-23.9 (-27.6 to -19.8)
Protein-energy malnutrition	47.5 (30.2 to 70.9)	25.3 (14.5 to 41.5)	-47.8 (-72.9 to 3.4)	-50.8 (-72.6 to -8.8)	5.9 (3.0 to 10.2)	3.1 (1.5 to 5.7)	-48.9 (-73.8 to 4.4)	-51.4 (-78.2 to -8.0)
Iodine deficiency	338.0 (178.5 to 520.7)	319.5 (148.0 to 516.2)	-5.7 (-61.1 to 120.8)	-39.3 (-74.7 to 43.7)	6.0 (2.8 to 10.6)	5.7 (2.3 to 10.9)	-7.0 (-61.8 to 121.4)	-39.1 (-75.0 to 42.9)
Vitamin A deficiency	7.5 (5.3 to 9.7)	4.4 (3.2 to 5.7)	-40.9 (-60.5 to -27.2)	-53.7 (-61.4 to -43.2)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-39.6 (-52.5 to -23.1)	-44.1 (-63.5 to -42.6)

Appendix Table G.4 - Colombia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	4,452.0 (4,382.0 to 4,526.7)	4,653.2 (4,572.1 to 4,735.8)	4.7 (2.0 to 7.6)	-22.0 (-24.0 to -19.9)	139.8 (93.3 to 201.7)	138.6 (92.7 to 201.0)	-0.7 (-4.4 to 2.3)	-21.9 (-24.7 to -19.4)
Other nutritional deficiencies	-	-	-	-	0.3 (0.1 to 0.6)	0.1 (0.0 to 0.2)	-	-64.8 (-85.8 to -21.0)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	16.3 (10.2 to 24.9)	20.1 (12.6 to 32.0)	23.1 (11.0 to 36.8)	-10.7 (-18.9 to -2.8)
Sexually transmitted diseases excluding HIV	-	-	-	-	6.8 (3.8 to 11.8)	9.8 (5.5 to 17.2)	43.3 (23.5 to 63.9)	-6.3 (-17.5 to 6.1)
Syphilis	0.8 (0.7 to 0.9)	1.1 (1.0 to 1.3)	38.6 (10.5 to 70.1)	-30.5 (-43.1 to -16.3)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	29.8 (-2.8 to 97.7)	49.4 (-50.2 to -2.1)
Chlamydial infection	853.6 (568.9 to 1,112.4)	1,225.6 (867.4 to 1,639.6)	43.3 (-2.0 to 120.9)	-0.5 (-31.0 to 53.8)	3.6 (2.1 to 5.9)	5.2 (2.9 to 8.7)	42.3 (11.3 to 76.1)	-1.7 (-22.5 to 20.9)
Gonococcal infection	119.8 (80.0 to 168.5)	152.1 (109.3 to 194.9)	29.7 (-16.8 to 90.8)	-6.8 (-40.0 to 34.8)	0.8 (0.5 to 1.4)	1.0 (0.5 to 1.7)	18.3 (-17.5 to 72.3)	-15.9 (-41.1 to 19.4)
Trichomoniasis	260.8 (143.2 to 358.3)	311.1 (212.1 to 451.7)	15.9 (-30.1 to 145.6)	-21.8 (-50.3 to 56.3)	0.5 (0.2 to 1.0)	0.5 (0.2 to 1.2)	10.6 (-38.3 to 164.5)	-23.9 (-56.3 to 69.1)
Genital herpes	6,153.7 (5,916.4 to 6,412.4)	10,569.0 (10,064.3 to 11,034.1)	72.4 (61.1 to 82.4)	3.8 (-9.9 to 1.9)	1.7 (0.5 to 4.0)	2.8 (0.9 to 6.7)	67.9 (51.3 to 80.5)	-3.5 (-10.9 to 3.2)
Other sexually transmitted diseases	3.8 (2.8 to 5.1)	4.5 (3.4 to 6.0)	17.6 (-2.1 to 40.7)	-29.1 (-41.2 to -15.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	42.4 (5.6 to 112.7)	-9.8 (-38.7 to 26.5)
Hepatitis	-	-	-	-	2.2 (1.4 to 3.2)	2.9 (1.8 to 4.2)	28.9 (9.2 to 54.8)	-17.5 (-30.2 to 4.3)
Hepatitis A	43.5 (41.8 to 45.2)	52.1 (50.5 to 53.8)	20.1 (19.2 to 21.0)	-4.2 (-4.3 to -4.0)	1.0 (0.7 to 1.5)	1.4 (0.9 to 2.0)	31.9 (18.7 to 48.6)	-2.2 (-11.9 to 7.5)
Hepatitis B	2,458.0 (2,094.9 to 2,842.0)	2,591.7 (2,580.0 to 2,934.1)	5.3 (-11.7 to 27.4)	-31.1 (-41.6 to -15.7)	1.1 (0.7 to 1.7)	1.4 (0.8 to 2.1)	22.9 (4.8 to 80.0)	9.5 (-46.1 to 10.1)
Hepatitis C	985.2 (889.7 to 1,081.2)	1,266.8 (1,160.9 to 1,379.6)	28.6 (13.2 to 48.1)	-27.2 (-34.9 to -16.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	28.7 (2.2 to 71.4)	-25.6 (-45.2 to 9.6)
Hepatitis E	-	-	-	-	-	-	-	-
Leprosy	1.1 (0.8 to 1.5)	1.5 (1.2 to 1.9)	41.7 (21.2 to 72.3)	-30.2 (-40.2 to -15.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	45.4 (8.3 to 98.2)	-28.1 (-46.9 to -1.8)
Other infectious diseases	192.6 (160.8 to 232.4)	197.3 (176.5 to 217.6)	2.8 (-13.7 to 19.3)	-16.1 (-28.7 to -3.5)	7.2 (4.5 to 10.6)	7.4 (4.6 to 11.2)	2.3 (-15.2 to 29.6)	-13.1 (-27.5 to 8.0)
Non-communicable diseases	-	-	-	-	-	4,395.0 (3,230.5 to 5,676.7)	74.4 (69.4 to 79.4)	3.1 (0.6 to 5.9)
Neoplasms	-	-	-	-	16.4 (11.9 to 21.8)	41.8 (29.1 to 55.7)	154.8 (110.4 to 207.2)	26.7 (5.6 to 52.2)
Esophageal cancer	1.3 (1.1 to 1.7)	2.4 (1.8 to 3.2)	76.3 (30.3 to 141.8)	-18.5 (-40.4 to 12.1)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	75.3 (31.7 to 129.6)	-18.8 (-39.9 to 6.5)
Stomach cancer	13.7 (12.2 to 15.4)	23.2 (18.8 to 28.1)	69.3 (37.1 to 114.6)	-22.1 (-37.0 to -11.1)	1.5 (1.1 to 2.0)	2.5 (1.8 to 3.4)	62.1 (32.1 to 107.0)	-24.8 (-39.2 to -4.1)
Liver cancer	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	77.2 (37.9 to 134.5)	-47.2 (-35.9 to 9.3)
Liver cancer due to hepatitis B	0.5 (0.3 to 0.7)	1.0 (0.6 to 1.5)	107.1 (8.2 to 286.8)	-3.0 (-49.6 to 85.9)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	103.9 (16.5 to 247.8)	-4.7 (-46.0 to 64.1)
Liver cancer due to hepatitis C	0.2 (0.1 to 0.3)	1.1 (0.7 to 1.7)	477.2 (184.0 to 966.0)	162.7 (30.1 to 387.9)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	443.1 (190.0 to 756.1)	144.5 (32.6 to 286.5)
Liver cancer due to alcohol use	0.5 (0.3 to 0.6)	0.2 (0.2 to 0.6)	-26.9 (-62.0 to 34.3)	-66.0 (-82.2 to -36.9)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-24.4 (-55.0 to 19.6)	-64.3 (-79.4 to -42.9)
Liver cancer due to other causes	0.4 (0.2 to 0.5)	0.3 (0.2 to 0.5)	-19.4 (-56.6 to 58.7)	-41.9 (-80.0 to -24.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-22.6 (-52.0 to 33.8)	-43.1 (-78.1 to -34.9)
Larynx cancer	3.5 (2.7 to 4.6)	5.7 (4.2 to 8.1)	60.3 (21.4 to 113.4)	-25.9 (-44.0 to 0.4)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	23.7 (24.2 to 124.0)	-23.7 (-42.6 to 4.4)
Tracheal, bronchus and lung cancer	4.0 (3.5 to 4.5)	8.4 (6.9 to 10.3)	110.7 (69.2 to 170.4)	-1.1 (-20.6 to 27.0)	0.6 (0.5 to 0.8)	1.3 (0.9 to 1.7)	105.0 (62.0 to 156.7)	-4.0 (-23.5 to 20.7)
Breast cancer	20.5 (18.1 to 23.5)	61.8 (45.5 to 79.5)	201.0 (114.6 to 306.8)	1.7 (-1.8 to 8.8)	4.8 (1.2 to 2.2)	8.8 (3.1 to 6.8)	184.8 (102.3 to 278.6)	33.4 (-4.2 to 74.8)
Cervical cancer	23.2 (19.2 to 30.6)	35.0 (22.4 to 47.6)	52.7 (-15.6 to 120.2)	-25.4 (-57.5 to 5.9)	1.5 (1.1 to 2.5)	2.6 (1.5 to 3.9)	45.8 (-11.1 to 120.8)	-25.0 (-56.1 to 6.8)
Uterine cancer	6.4 (4.4 to 9.7)	12.1 (7.2 to 18.0)	90.8 (15.5 to 199.4)	-14.8 (-47.1 to 32.7)	0.4 (0.3 to 0.7)	0.8 (0.4 to 1.3)	89.5 (49.1 to 204.6)	-15.2 (-49.1 to 33.6)
Prostate cancer	21.3 (14.1 to 31.4)	99.0 (59.0 to 144.6)	364.2 (220.5 to 584.1)	109.9 (46.7 to 208.9)	2.1 (1.3 to 3.2)	8.3 (4.9 to 12.6)	299.7 (188.7 to 458.7)	82.6 (31.0 to 153.1)
Colon and rectum cancer	11.1 (10.2 to 12.2)	38.4 (31.9 to 45.6)	246.9 (183.4 to 327.4)	61.3 (32.6 to 98.3)	0.9 (0.7 to 1.2)	3.1 (2.1 to 4.2)	231.1 (163.2 to 307.3)	54.3 (23.4 to 89.4)
Lip and oral cavity cancer	3.7 (2.9 to 4.7)	7.3 (5.3 to 10.1)	98.4 (43.5 to 169.5)	-7.2 (-34.3 to 28.1)	0.3 (0.2 to 0.5)	0.6 (0.4 to 1.0)	95.3 (39.3 to 164.4)	-9.3 (-36.5 to 27.0)
Nasopharynx cancer	0.5 (0.4 to 0.6)	0.8 (0.6 to 1.2)	74.5 (17.6 to 154.6)	-14.4 (-42.3 to 25.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	0.1 (20.3 to 147.7)	-17.0 (-41.5 to 21.5)
Other pharynx cancer	0.9 (0.7 to 1.2)	1.7 (1.1 to 2.5)	75.8 (17.9 to 174.6)	-19.5 (-46.2 to 25.9)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	71.2 (17.8 to 159.9)	-21.5 (-45.4 to 19.3)
Gallbladder and biliary tract cancer	0.7 (0.6 to 0.9)	1.2 (0.8 to 1.6)	68.1 (15.4 to 137.9)	-22.6 (-47.4 to 10.3)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.4)	62.5 (10.0 to 129.2)	25.3 (-50.0 to 6.4)
Pancreatic cancer	0.9 (0.8 to 1.1)	2.1 (1.7 to 2.6)	127.7 (76.3 to 191.7)	4.8 (-18.0 to 33.7)	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	119.3 (73.1 to 181.3)	0.8 (-21.4 to 30.7)
Malignant skin melanoma	3.8 (3.0 to 5.1)	9.6 (7.1 to 13.1)	154.6 (90.9 to 228.7)	24.9 (6.4 to 60.1)	0.6 (0.2 to 0.4)	0.6 (0.4 to 0.9)	146.2 (84.1 to 224.7)	20.3 (-9.6 to 59.1)
Non-melanoma skin cancer	7.4 (5.8 to 8.9)	23.8 (17.2 to 32.4)	220.5 (133.6 to 349.9)	45.1 (3.0 to 110.5)	0.3 (0.2 to 0.4)	1.1 (0.6 to 1.8)	280.4 (165.8 to 460.1)	75.5 (18.0 to 166.5)
Ovarian cancer	2.6 (2.3 to 3.1)	6.3 (4.7 to 8.5)	137.9 (74.9 to 231.1)	21.5 (-9.7 to 67.9)	0.4 (0.2 to 0.5)	0.8 (0.5 to 1.2)	130.0 (60.1 to 238.8)	18.4 (-17.4 to 72.8)
Testicular cancer	2.1 (1.4 to 3.4)	4.8 (2.8 to 7.6)	126.0 (21.2 to 396.0)	45.9 (-20.1 to 144.4)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	122.8 (11.7 to 296.8)	39.1 (-25.6 to 138.5)
Kidney cancer	1.8 (2.2 to 2.9)	3.0 (5.6 to 8.5)	68.5 (120.2 to 253.7)	-21.6 (-13.1 to 79.9)	0.2 (0.1 to 0.3)	0.3 (0.3 to 0.7)	68.9 (110.4 to 242.5)	-21.3 (-5.5 to 70.4)
Bladder cancer	1.5 (1.5 to 2.3)	4.1 (2.3 to 4.1)	128.2 (28.5 to 188.2)	-6.5 (-40.8 to 5.8)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	68.9 (26.7 to 125.2)	-21.3 (-41.9 to 7.0)
Brain and nervous system cancer	3.3 (2.7 to 4.5)	8.5 (6.1 to 10.7)	162.0 (82.1 to 240.4)	66.5 (13.1 to 113.0)	0.3 (0.2 to 0.5)	0.8 (0.5 to 1.2)	162.4 (80.5 to 239.8)	56.0 (6.8 to 99.0)
Thyroid cancer	12.7 (9.6 to 16.1)	31.0 (19.9 to 43.2)	141.4 (70.8 to 240.4)	21.8 (-12.4 to 68.0)	0.7 (0.5 to 1.1)	1.8 (1.0 to 2.7)	134.1 (68.9 to 232.9)	17.7 (-15.5 to 66.5)
Mesothelioma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	23.3 (-4.2 to 64.3)	0.0 (-53.7 to -20.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.8 (0.9 to 70.8)	-38.0 (-51.8 to -17.0)
Hodgkin lymphoma	3.5 (2.8 to 4.5)	6.8 (4.9 to 10.7)	89.4 (33.6 to 167.4)	20.4 (-14.1 to 65.8)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.8)	80.1 (27.9 to 155.5)	11.3 (-19.7 to 55.2)
Non-Hodgkin lymphoma	7.1 (5.9 to 9.6)	19.5 (14.9 to 24.7)	177.3 (101.5 to 269.1)	54.7 (6.5 to 105.2)	0.5 (0.4 to 0.8)	1.4 (0.9 to 2.1)	169.3 (90.1 to 260.7)	46.0 (-2.3 to 96.9)
Multiple myeloma	1.1 (0.8 to 1.4)	3.1 (2.2 to 4.1)	189.9 (101.9 to 302.7)	29.8 (-9.6 to 79.6)	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.9)	181.9 (86.8 to 307.9)	26.8 (-15.1 to 82.6)
Leukemia	10.4 (8.5 to 12.9)	19.2 (15.1 to 24.6)	85.0 (35.5 to 147.9)	34.6 (3.1 to 77.3)	1.0 (0.7 to 1.4)	2.0 (1.3 to 2.7)	95.1 (48.4 to 148.3)	28.1 (-1.8 to 64.7)
Other neoplasms	19.3 (16.3 to 25.3)	71.0 (52.6 to 87.8)	277.3 (135.2 to 389.5)	149.4 (54.5 to 226.0)	1.2 (0.8 to 1.8)	4.5 (2.7 to 6.5)	269.8 (133.3 to 377.6)	135.3 (47.0 to 208.9)
Cardiovascular diseases	-	-	-	-	25.5 (17.8 to 35.4)	87.7 (59.5 to 121.8)	243.9 (161.0 to 347.9)	55.7 (21.8 to 100.0)
Rheumatic heart disease	0.6 (0.6 to 0.7)	1.3 (1.2 to 1.4)	103.4 (86.8 to 121.1)	-0.5 (-8.4 to 8.4)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	102.7 (64.1 to 145.6)	-0.5 (-21.7 to 23.9)
Ischemic heart disease	193.3 (158.0 to 243.7)	837.0 (667.3 to 1,057.1)	327.4 (213.0 to 503.7)	79.2 (33.2 to 151.9)	9.7 (6.4 to 14.7)	48.5 (30.7 to 72.2)	389.7 (238.3 to 634.8)	103.9 (43.7 to 206.5)
Cerebrovascular disease	-	-	-	-	3.9 (2.7 to 5.1)	5.2 (3.9 to 6.5)	119.8 (73.1 to 170.5)	2.8 (-18.1 to 26.6)
Ischemic stroke	6.6 (5.4 to 8.0)	15.2 (11.7 to 18.9)	132.5 (66.6 to 200.0)	5.2 (-25.1 to 36.0)	1.0 (0.6 to 1.4)	2.3 (1.5 to 3.3)	132.4 (65.4 to 211.1)	6.1 (-25.0 to 42.0)
Hemorrhagic stroke	19.4 (16.8 to 21.7)	41.3 (35.1 to 47.8)	113.7 (73.3 to 162.5)	0.2 (-18.2 to 24.4)	2.9 (2.0 to 3.8)	6.2 (4.2 to 8.5)	114.0 (69.4 to 169.0)	1.3 (-18.7 to 27.2)
Hypertensive heart disease	15.8 (14.1 to 17.5)	39.3 (35.9 to 42.6)	147.9 (119.6 to 181.4)	10.9 (-2.9 to 25.5)	1.7 (1.2 to 2.4)	4.3 (3.0 to 5.8)	148.7 (115.9 to 187.4)	11.4 (-3.5 to 29.2)
Cardiomyopathy and myocarditis	8.6 (7.5 to 9.8)	20.6 (18.6 to 22.5)	139.5 (108.1 to 180.9)	18.5 (1.1 to 42.1)	1.0 (0.6 to 1.3)	2.3 (1.5 to 3.2)	193.1 (101.5 to 188.1)	19.3 (-0.4 to 45.0)
Atrial fibrillation and flutter	21.6 (18.2 to 25.1)	58.8 (43.6 to 77.6)	164.5 (99.9 to 301.9)	16.2 (-14.4 to 85.1)	1.6 (1.1 to 2.2)	4.5 (2.7 to 6.7)	169.3 (100.6 to 309.3)	18.6 (-11.7 to 87.7)
Peripheral vascular disease	580.4 (391.1 to 799.3)	1,433.9 (1,158.2 to 1,715.0)	151.6 (64.3 to 274.0)	9.1 (-25.2 to 55.8)	0.3 (0.1 to 0.6)	0.6 (0.3 to 1.2)	118.7 (28.3 to 412.2)	-6.3 (-44.3 to 127.8)
Endocarditis	0.6 (0.5 to 0.8)	1.2 (0.9 to 1.5)	88.2 (55.6 to 138.1)	9.5 (-5.2 to 39.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	96.3 (61.2 to 155.1)	14.1 (-6.6 to 48.6)
Other cardiovascular and circulatory diseases	102.6 (64.1 to 173.5)	369.2 (163.4 to 370.4)	277.4 (32.1 to 354.2)	7.1 (-34.6 to 123.1)	2.1 (3.8 to 12.6)	7.2 (3.8 to 12.6)	18.2 (31.6 to 358.1)	34.2 (-32.8 to 126.4)
Chronic respiratory diseases	-	-	-	-	170.2 (116.5 to 231.6)	308.0 (210.7 to 418.4)	81.8 (61.6 to 100.4)	11.0 (0.1 to 21.1)
Chronic								

Appendix Table G.4 - Colombia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumococcosis	0.0	0.1	77.2	-13.5	0.0	0.0	80.4	-11.7
Silicosis	(0.0 to 0.0)	(0.0 to 0.1)	(70.1 to 83.6)	(-16.7 to -10.4)	(0.0 to 0.0)	(0.0 to 0.0)	(68.9 to 82.9)	(-17.0 to -10.7)
Asbestosis	0.0	0.1	93.8	-9.5	0.0	0.0	93.5	-9.6
Coal workers pneumococcosis	0.0	0.0	79.6	-11.3	0.0	0.0	79.1	-11.6
Other pneumococcosis	(0.0 to 0.0)	(0.0 to 0.0)	(72.1 to 86.2)	(-14.6 to -8.2)	(0.0 to 0.0)	(0.0 to 0.0)	(71.6 to 85.6)	(-14.9 to -8.5)
Asthma	(2,165.1 to 2,627.4)	(3,364.3 to 3,886.9)	(33.8 to 69.8)	(-7.2 to 14.5)	(69.1 to 151.1)	(103.9 to 225.4)	(33.0 to 68.6)	(-6.7 to 15.0)
Interstitial lung disease and pulmonary sarcoidosis	0.5	1.1	106.7	3.1	0.1	0.2	109.6	4.4
Other chronic respiratory diseases	-	-	-	-	6.5	5.7	-13.1	-55.9
Cirrhosis	-	-	-	-	(3.9 to 9.7)	(3.4 to 8.7)	(-32.4 to 14.3)	(-65.6 to -41.7)
Cirrhosis due to hepatitis B	0.2	0.5	115.1	15.6	0.0	0.1	115.1	15.6
Cirrhosis due to hepatitis C	3.0	5.2	78.9	-0.5	0.5	0.8	73.8	-1.5
Cirrhosis due to alcohol use	3.5	4.4	24.5	0.6	0.6	0.7	23.4	35.9
Cirrhosis due to other causes	(2.6 to 4.3)	(3.1 to 5.8)	(-16.3 to 81.3)	(-55.3 to -11.3)	(0.3 to 0.9)	(0.4 to 1.1)	(-20.4 to 89.7)	(-57.2 to -5.6)
Digestive diseases	-	-	-	-	22.5	40.1	78.5	-12.1
Peptic ulcer disease	205.4	218.4	6.4	-49.1	7.2	8.2	12.6	-45.8
Gastritis and duodenitis	38.7	69.2	79.2	-5.1	1.9	3.5	82.3	-3.6
Appendicitis	1.5	1.8	24.3	-9.2	0.5	0.6	26.1	-8.2
Paralytic ileus and intestinal obstruction	0.2	0.3	55.8	0.1	0.3	0.1	46.1	5.6
Inguinal, femoral, and abdominal hernia	82.4	124.8	51.3	-24.5	0.8	1.3	51.0	-23.8
Inflammatory bowel disease	34.8	80.4	131.3	24.8	7.4	17.0	130.7	25.4
Vascular intestinal disorders	0.0	0.1	110.7	3.1	0.0	0.0	100.3	-3.0
Gallbladder and biliary diseases	18.3	37.5	105.9	-7.9	3.9	5.9	105.9	6.9
Pancreatitis	1.7	4.6	165.5	47.2	0.5	1.4	167.6	49.1
Other digestive diseases	-	-	-	-	2.1	4.1	94.2	-4.5
Neurological disorders	-	-	-	-	212.9	367.1	71.4	2.3
Alzheimer disease and other dementias	136.3	307.6	128.2	0.6	18.9	43.5	132.1	1.5
Parkinson disease	2.3	5.2	130.3	3.8	0.3	0.6	132.0	4.6
Epilepsy	164.0	240.8	46.4	-1.2	53.2	84.1	58.0	8.0
Multiple sclerosis	0.8	2.8	243.3	88.9	0.3	1.0	241.5	37.3
Migraine	3,021.2	4,081.7	35.1	52.5	102.8	158.8	54.4	-3.6
Tension-type headache	(2,568.4 to 3,530.5)	(3,675.3 to 5,804.3)	(15.8 to 107.0)	(-25.9 to 26.8)	(59.9 to 154.7)	(88.9 to 243.6)	(16.8 to 106.9)	(-26.1 to 27.5)
Medication overuse headache	134.5	347.4	156.5	45.9	21.0	54.4	155.8	46.3
Other neurological disorders	0.1	0.1	45.7	-10.2	6.8	8.9	30.6	-42.6
Mental and substance use disorders	-	-	-	-	918.0	1,445.8	57.6	0.2
Schizophrenia	79.5	139.7	76.1	-0.7	(637.8 to 1,225.6)	(997.4 to 1,941.1)	(51.2 to 63.2)	(-2.3 to 3.1)
Alcohol use disorders	451.9	653.0	44.7	-9.9	50.6	89.3	76.1	-0.2
Drug use disorders	-	-	-	-	44.0	71.3	62.7	8.2
Opioid use disorders	20.1	39.6	98.5	9.1	8.2	16.2	99.2	10.3
Cocaine use disorders	(9.1 to 35.2)	(20.1 to 64.2)	(77.9 to 143.4)	(-0.9 to 27.8)	(3.4 to 15.2)	(7.5 to 28.0)	(70.5 to 149.8)	(-3.5 to 31.6)
Amphetamine use disorders	66.5	88.0	32.5	-2.4	8.7	11.5	32.4	-2.3
Cannabis use disorders	34.4	45.7	33.2	-3.1	1.0	1.3	33.6	-3.0
Other drug use disorders	28.5 to 40.1	(37.7 to 52.7)	(22.6 to 43.6)	(-9.9 to 4.4)	(0.6 to 1.5)	(0.8 to 1.9)	(6.3 to 65.2)	(-21.4 to 18.3)
Depressive disorders	-	-	-	-	17.5	27.0	53.7	7.3
Major depressive disorder	1,679.2	2,790.3	67.1	1.4	343.4	569.6	66.5	1.8
Dysthymia	345.7	613.7	77.7	33.2	203.1 to 536.2)	(338.2 to 899.5)	(50.0 to 80.9)	(-4.8 to 9.4)
Bipolar disorder	287.5	469.4	63.6	-0.1	58.3	95.1	63.4	0.5
Anxiety disorders	1,943.8	2,992.7	54.2	4.8	35.7 to 87.9)	(60.0 to 140.8)	(51.8 to 76.0)	(-5.2 to 6.7)
Eating disorders	(1,714.9 to 2,178.9)	(2,671.5 to 3,317.5)	(50.3 to 58.6)	(-0.0 to 0.0)	(118.1 to 250.0)	(185.6 to 384.5)	(49.3 to 58.9)	(-1.5 to 2.3)
Anorexia nervosa	8.1	11.2	38.7	5.7	1.7	2.4	38.1	5.2
Bulimia nervosa	43.4	57.3	32.3	-0.2	9.1	12.1	32.4	-0.1
Autistic spectrum disorders	-	-	-	-	39.3	55.9	42.3	0.5
Autism	100.1	142.9	43.0	0.0	24.6	35.1	42.7	0.7
Asperger syndrome	147.2	208.8	42.2	0.0	14.7	20.8	41.6	0.3
Attention-deficit/hyperactivity disorder	286.6	339.4	18.6	0.2	3.5	4.1	18.8	0.4
Conduct disorder	378.3	450.8	49.4	0.0	45.3	54.3	19.6	0.4
Idiopathic intellectual disability	632.4	690.6	9.2	-22.0	30.9	33.7	9.0	-21.8
Other mental and substance use disorders	478.0	805.3	68.8	-0.0	35.5	59.9	68.8	0.6
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	181.1	400.2	121.8	30.2
Diabetes mellitus	794.2	2,779.1	251.1	82.0	(123.9 to 249.9)	(276.0 to 547.6)	(98.6 to 144.2)	(15.5 to 45.0)
Acute glomerulonephritis	0.1	0.1	-1.9	-27.4	0.0	0.0	0.0	-27.4
Chronic kidney disease	-	-	-	-	41.2	71.1	72.5	4.6
Chronic kidney disease due to diabetes mellitus	533.3	1,121.4	110.3	3.9	(29.5 to 54.8)	(50.1 to 94.5)	(55.3 to 92.6)	(-5.9 to 16.9)
Chronic kidney disease due to hypertension	535.7	915.0	69.5	12.9	14.7	20.8	67.7	-3.1
Chronic kidney disease due to glomerulonephritis	719.8	1,168.6	64.1	2.1	14.2	15.5	74.3	19.9
Chronic kidney disease due to other causes	919.1	1,394.9	51.1	-5.5	14.0	21.5	52.3	-1.3
Urinary diseases and male infertility	-	-	-	-	7.4	17.1	130.5	10.4

Appendix Table G.4 - Colombia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	1,177.9 (1,144.3 to 1,213.5)	2,312.4 (2,251.1 to 2,375.3)	96.7 (88.2 to 105.5)	-10.1 (-13.8 to -6.3)	32.1 (21.9 to 45.2)	63.4 (42.7 to 87.4)	97.3 (88.8 to 106.7)	97.3 (-13.4 to -5.6)
Other oral disorders	533.0 (504.4 to 563.1)	845.3 (792.6 to 895.1)	58.9 (45.9 to 71.3)	-1.1 (-8.4 to 5.9)	15.6 (9.8 to 23.6)	24.7 (15.5 to 36.8)	58.6 (45.0 to 71.6)	-0.8 (-9.1 to 6.7)
Injuries	-	-	-	-	279.0 (212.1 to 359.3)	253.9 (180.7 to 341.0)	-9.4 (-19.1 to 2.5)	-49.6 (-54.9 to -43.7)
Transport injuries	-	-	-	-	152.3 (114.9 to 196.6)	130.1 (93.0 to 176.1)	-14.8 (-25.2 to -2.5)	-53.7 (-59.1 to -47.8)
Road injuries	-	-	-	-	147.1 (111.0 to 189.8)	125.2 (89.5 to 169.4)	-15.1 (-25.6 to -2.7)	-53.9 (-59.2 to -47.9)
Pedestrian road injuries	-	-	-	-	49.4 (37.3 to 63.7)	38.6 (27.4 to 52.1)	-22.0 (-32.5 to -9.5)	-57.3 (-62.5 to -51.2)
Cyclist road injuries	-	-	-	-	10.4 (7.8 to 13.6)	11.5 (8.2 to 15.5)	10.1 (-2.9 to 25.7)	-41.9 (-48.5 to -33.8)
Motorcyclist road injuries	-	-	-	-	24.1 (18.1 to 31.2)	18.1 (12.5 to 25.3)	-25.4 (-35.9 to -12.5)	-58.9 (-64.3 to -52.3)
Motor vehicle road injuries	-	-	-	-	61.3 (46.5 to 79.1)	55.4 (40.0 to 74.9)	-10.0 (-22.2 to 4.4)	-51.5 (-57.4 to -44.5)
Other road injuries	-	-	-	-	1.9 (1.4 to 2.5)	1.7 (1.2 to 2.3)	-12.1 (-23.9 to 1.1)	-53.2 (-58.9 to -47.0)
Other transport injuries	-	-	-	-	5.2 (3.9 to 6.7)	4.9 (3.5 to 6.7)	-5.9 (-17.2 to 7.8)	-49.1 (-54.9 to -42.1)
Unintentional injuries	-	-	-	-	82.4 (62.8 to 106.9)	83.5 (61.1 to 111.6)	1.0 (-6.9 to 10.1)	-41.9 (-46.7 to -36.8)
Falls	-	-	-	-	25.0 (19.0 to 32.2)	35.3 (25.2 to 47.7)	40.5 (24.5 to 59.2)	-31.5 (-39.8 to -21.8)
Drowning	-	-	-	-	1.6 (1.2 to 2.1)	1.2 (0.8 to 1.6)	-27.2 (-36.5 to -14.4)	-55.8 (-61.2 to -48.9)
Fire, heat, and hot substances	-	-	-	-	3.7 (2.9 to 4.7)	3.0 (2.1 to 4.0)	-20.8 (-31.8 to -7.5)	-51.7 (-57.6 to -44.3)
Poisonings	-	-	-	-	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-38.2 (-48.5 to -24.0)	-61.2 (-67.2 to -53.1)
Exposure to mechanical forces	-	-	-	-	42.3 (32.1 to 55.4)	33.3 (24.2 to 45.0)	-21.4 (-27.2 to -15.1)	-51.7 (-54.9 to -48.4)
Unintentional firearm injuries	-	-	-	-	3.0 (2.3 to 3.9)	1.8 (1.3 to 2.5)	-39.4 (-46.0 to -31.9)	-64.8 (-68.4 to -60.9)
Unintentional suffocation	-	-	-	-	1.2 (0.9 to 1.6)	0.7 (0.5 to 0.9)	-43.2 (-49.9 to -35.6)	-65.4 (-69.0 to -60.9)
Other exposure to mechanical forces	-	-	-	-	38.1 (28.8 to 50.2)	30.8 (22.3 to 41.6)	-19.3 (-25.2 to -12.9)	-50.2 (-53.3 to -46.7)
Adverse effects of medical treatment	-	-	-	-	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	60.2 (50.1 to 71.7)	-14.3 (-19.7 to -8.3)
Animal contact	-	-	-	-	1.5 (1.1 to 1.9)	1.4 (1.0 to 1.8)	-6.3 (-15.2 to 3.8)	-44.8 (-49.8 to -39.4)
Venomous animal contact	-	-	-	-	0.6 (0.4 to 0.8)	0.5 (0.4 to 0.7)	-12.1 (-23.2 to -0.7)	-47.4 (-53.1 to -41.1)
Non-venomous animal contact	-	-	-	-	0.9 (0.7 to 1.2)	0.9 (0.6 to 1.2)	-2.4 (-13.1 to 9.4)	-43.3 (-48.9 to -37.4)
Foreign body	-	-	-	-	1.5 (1.2 to 1.9)	1.7 (1.3 to 2.2)	11.5 (-1.8 to 26.8)	-33.9 (-41.3 to -25.5)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.8 (0.6 to 1.0)	0.6 (0.5 to 0.9)	-15.4 (-29.7 to 2.4)	-47.2 (-55.5 to -36.9)
Foreign body in eyes	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	49.1 (33.6 to 65.8)	-9.5 (-18.6 to 0.8)
Foreign body in other body part	-	-	-	-	0.6 (0.5 to 0.8)	0.8 (0.6 to 1.1)	35.8 (20.5 to 53.2)	-24.0 (-31.9 to -15.0)
Other unintentional injuries	-	-	-	-	6.1 (4.6 to 8.0)	7.1 (5.2 to 9.4)	16.8 (5.2 to 29.6)	-32.7 (-39.0 to -25.8)
Self-harm and interpersonal violence	-	-	-	-	42.9 (32.9 to 54.7)	36.0 (25.6 to 48.7)	-16.7 (-26.6 to -4.1)	-54.4 (-59.4 to -48.1)
Self-harm	-	-	-	-	0.9 (0.7 to 1.2)	1.4 (1.0 to 1.9)	54.1 (37.9 to 73.4)	-19.8 (-28.1 to -9.9)
Interpersonal violence	-	-	-	-	42.0 (32.2 to 53.5)	34.5 (24.6 to 46.8)	-18.2 (-28.1 to -5.8)	-55.2 (-60.2 to -49.0)
Assault by firearm	-	-	-	-	14.5 (11.1 to 18.7)	16.0 (11.4 to 21.7)	9.4 (-1.7 to 22.7)	-41.5 (-46.9 to -34.8)
Assault by sharp object	-	-	-	-	9.2 (6.8 to 11.7)	7.7 (5.4 to 10.6)	-17.1 (-28.3 to -2.9)	-54.5 (-60.5 to -46.9)
Assault by other means	-	-	-	-	18.3 (13.9 to 23.0)	10.9 (7.9 to 14.4)	-40.7 (-49.7 to -29.1)	-66.9 (-71.6 to -60.7)
Forces of nature, war, and legal intervention	-	-	-	-	1.4 (0.8 to 2.6)	4.3 (2.0 to 8.6)	198.0 (109.2 to 335.2)	129.6 (57.9 to 221.2)
Exposure to forces of nature	-	-	-	-	0.6 (0.3 to 0.9)	0.8 (0.4 to 1.5)	44.7 (15.2 to 91.1)	19.3 (-3.9 to 50.6)
Collective violence and legal intervention	-	-	-	-	0.9 (0.4 to 1.8)	3.5 (1.6 to 7.4)	314.2 (145.8 to 571.6)	196.7 (76.2 to 359.4)

Appendix Table G.4 - Comoros prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	37.8 (27.9 to 49.4)	67.5 (49.5 to 87.9)	78.3 (73.4 to 83.9)	78.3 (-6.6 to -1.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	9.0 (6.1 to 12.5)	14.8 (10.3 to 20.5)	65.2 (52.2 to 81.0)	-12.9 (-22.8 to -3.5)
HIV/AIDS and tuberculosis	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.7)	76.6 (45.3 to 338.3)	-7.4 (-22.3 to 122.3)
Tuberculosis	0.5 (0.4 to 0.5)	0.7 (0.6 to 0.8)	41.9 (32.0 to 53.1)	-24.0 (-29.0 to -18.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	42.3 (27.2 to 57.7)	-23.8 (-30.7 to -16.7)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.5)	23,957.9 (1,930.7 to 125,291.2)	0.1 (980.5 to 69,781.1)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18,951.5 (1,465.6 to 122,586.4)	10,183.7 (722.8 to 66,209.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18,951.5 (1,447.2 to 123,073.4)	10,183.7 (722.6 to 66,511.3)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.6 (0.1 to 2.7)	16,438.2 (1,445.3 to 119,666.2)	8,878.6 (728.1 to 64,073.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.5)	24,555.1 (1,928.3 to 165,484.7)	13,387.5 (984.9 to 92,073.5)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	1.5 (1.1 to 2.0)	2.3 (1.6 to 3.1)	51.3 (38.6 to 66.8)	-15.2 (-22.0 to -7.3)
Diarrheal diseases	4.2 (3.7 to 4.7)	7.8 (7.1 to 8.5)	85.7 (60.3 to 117.7)	9.3 (-4.0 to 24.8)	0.3 (0.5 to 1.0)	1.3 (0.9 to 1.8)	86.1 (59.9 to 119.4)	9.4 (-4.5 to 25.8)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.7 (20.5 to 103.5)	9.2 (-28.8 to 12.3)
Typhoid fever	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	52.4 (30.1 to 75.5)	-13.0 (-25.0 to 1.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.8 (19.3 to 95.6)	-12.4 (-28.0 to 7.0)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.5 (58.1 to 132.8)	12.7 (-11.0 to 35.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.5 (58.0 to 133.0)	12.7 (-11.1 to 36.1)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.3 (96.8 to 10,161.3)	16.1 (-98.1 to 5,690.7)
Lower respiratory infections	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	69.5 (19.0 to 123.4)	11.9 (-8.9 to 33.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	69.8 (13.0 to 128.7)	11.6 (-13.1 to 37.1)
Upper respiratory infections	14.5 (13.8 to 15.1)	25.5 (24.3 to 26.8)	75.4 (65.7 to 90.5)	-1.2 (-6.5 to 6.6)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	75.7 (64.5 to 91.3)	-1.0 (-6.7 to 6.9)
Otitis media	7.2 (6.5 to 8.0)	11.4 (10.5 to 12.3)	57.0 (41.2 to 73.1)	-11.6 (-20.7 to -2.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	55.9 (37.9 to 74.6)	-11.6 (-21.8 to -1.3)
Meningitis	-	-	-	-	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.5)	-16.0 (-28.4 to -1.0)	-51.2 (-57.7 to -43.4)
Pneumococcal meningitis	1.6 (1.0 to 2.3)	1.3 (0.8 to 1.9)	-17.0 (-33.2 to 10.0)	-5.3 (-60.9 to -37.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-18.3 (-37.7 to 18.6)	-52.6 (-63.0 to -33.7)
H influenzae type B meningitis	0.8 (0.3 to 1.5)	0.7 (0.3 to 1.2)	-16.8 (-36.6 to 12.3)	-52.5 (-64.0 to -36.0)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-10.2 (-38.9 to 24.9)	-48.9 (-63.8 to -30.2)
Meningococcal meningitis	0.2 (0.1 to 0.5)	0.2 (0.1 to 0.4)	-8.2 (-32.0 to 25.0)	-45.8 (-59.4 to -27.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-6.7 (-39.8 to 38.1)	-45.8 (-62.4 to -24.6)
Other meningitis	1.2 (0.5 to 2.1)	1.0 (0.5 to 1.7)	-17.9 (-33.6 to 16.5)	-51.9 (-60.2 to -31.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-18.8 (-41.3 to 13.3)	-52.3 (-64.3 to -34.7)
Encephalitis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	75.0 (54.0 to 98.3)	-2.4 (-12.5 to 8.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.4 (42.3 to 110.6)	-3.0 (-17.8 to 12.5)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.6 (-96.3 to 68.8)	-62.2 (-96.7 to 283.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.6 (-96.4 to 68.5)	-62.2 (-96.7 to 294.2)
Whooping cough	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.8)	67.2 (67.2 to 67.2)	-2.9 (-2.9 to 2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	67.4 (51.7 to 82.6)	-2.9 (-11.9 to 6.1)
Tetanus	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-82.0 (-94.2 to -48.0)	-89.5 (-96.8 to -68.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-73.5 (-86.0 to -50.2)	-83.1 (-91.1 to -69.4)
Measles	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-36.5 (-43.0 to -29.2)	-36.5 (-66.8 to -58.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.5 (-51.1 to -16.7)	-43.1 (-71.3 to -51.7)
Varicella and herpes zoster	0.3 (0.2 to 0.3)	0.5 (0.4 to 0.5)	89.6 (63.6 to 115.7)	2.4 (-19.6 to 26.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.2 (33.2 to 165.2)	3.0 (-31.1 to 45.7)
Neglected tropical diseases and malaria	-	-	-	-	3.8 (2.5 to 5.5)	4.9 (3.2 to 7.1)	29.1 (11.2 to 44.7)	-32.2 (-45.2 to -19.2)
Malaria	158.7 (144.7 to 171.8)	215.6 (195.7 to 236.6)	35.6 (24.6 to 49.8)	-25.1 (-31.3 to -16.6)	1.6 (1.1 to 2.3)	2.1 (1.4 to 3.0)	30.2 (24.9 to 36.3)	-25.0 (-28.2 to -21.2)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.2 (8.3 to 200.4)	5.0 (-34.9 to 50.9)
Visceral leishmaniasis	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	61.5 (-18.5 to 190.5)	-2.6 (-45.8 to 50.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.6 (-22.7 to 209.3)	-3.3 (-48.3 to 59.9)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	164.7 (68.8 to 335.8)	38.1 (-7.8 to 111.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	163.3 (62.4 to 357.4)	38.8 (-10.7 to 124.6)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	138.8 (13.7 to 516.1)	26.6 (-36.7 to 170.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	154.2 (20.5 to 579.0)	33.4 (-33.2 to 189.9)
Cystic echinococcosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	92.5 (49.2 to 112.7)	14.9 (-3.1 to 24.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.8 (39.8 to 138.1)	12.7 (-8.5 to 35.5)
Lymphatic filariasis	55.2 (44.7 to 67.5)	20.8 (15.5 to 27.8)	-62.4 (-72.2 to -49.9)	-76.2 (-81.8 to -67.8)	1.3 (0.7 to 2.3)	1.2 (0.7 to 2.1)	-7.1 (-33.2 to 24.8)	-46.8 (-61.4 to -26.2)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.5)	771.2 (760.8 to 783.4)	391.3 (385.4 to 398.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	746.8 (542.0 to 1,055.7)	368.1 (281.0 to 485.1)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.5 (-39.2 to 72.6)	-35.8 (-60.6 to 2.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.5 (-39.6 to 72.7)	-35.8 (-60.6 to 2.4)
Intestinal nematode infections	-	-	-	-	0.7 (0.4 to 1.1)	1.2 (0.6 to 1.9)	75.4 (33.2 to 132.3)	-0.9 (-29.9 to 42.6)
Ascariasis	90.6 (62.9 to 127.7)	161.9 (112.9 to 234.5)	78.3 (7.4 to 198.6)	-0.6 (-45.4 to 90.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	76.2 (0.5 to 217.5)	1.3 (-51.0 to 102.2)
Trichuriasis	137.0 (99.7 to 186.5)	246.0 (172.2 to 340.4)	78.3 (9.9 to 195.0)	-0.6 (-42.8 to 80.9)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.6)	77.0 (-1.5 to 221.5)	1.0 (-50.5 to 103.4)
Hookworm disease	81.2 (56.7 to 114.6)	148.9 (101.3 to 200.5)	76.5 (9.0 to 187.8)	2.2 (-44.2 to 70.0)	0.7 (0.2 to 0.6)	0.7 (0.4 to 1.1)	78.0 (26.6 to 139.8)	-2.0 (-35.5 to 47.1)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	4.6 (3.6 to 5.6)	8.6 (7.6 to 9.5)	88.1 (52.3 to 138.9)	10.6 (-9.5 to 37.7)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	85.9 (53.7 to 160.5)	10.4 (-9.8 to 53.2)
Maternal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	53.4 (31.5 to 80.3)	-18.7 (-30.2 to -5.3)
Maternal hemorrhage	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	81.5 (18.3 to 151.9)	-9.9 (-39.8 to 22.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.5 (-2.7 to 211.3)	-4.0 (-49.6 to 58.4)
Maternal sepsis and other maternal infections	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	27.2 (6.4 to 46.6)	-37.7 (-47.6 to -28.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.8 (-21.8 to 83.1)	-37.9 (-58.9 to -9.6)
Maternal hypertensive disorders	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	53.3 (34.2 to 74.2)	-20.5 (-31.5 to -11.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.1 (26.9 to 85.8)	-21.6 (-34.9 to -4.7)
Obstructed labor	0.3 (0.2 to 0.4)	0.4 (0.4 to 0.5)	49.9 (35.0 to 63.0)	-20.4 (-28.4 to -13.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	48.9 (29.2 to 71.6)	-20.5 (-30.7 to -9.3)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.2 (-11.0 to 301.4)	-21.0 (-56.0 to 86.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.2 (-12.0 to 301.7)	-21.0 (-56.0 to 87.4)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	63.2 (13.5 to 144.1)	-14.2 (-39.6 to 29.9)
Neonatal disorders	-	-	-	-	0.4 (0.3 to 0.7)	1.6 (1.1 to 2.5)	263.4 (134.5 to 572.2)	116.8 (34.2 to 293.5)
Preterm birth complications	1.6 (0.8 to 3.0)	6.1 (3.5 to 10.3)	294.1 (177.1 to 475.3)	117.6 (59.0 to 208.3)	0.1 (0.1 to 0.3)	0.8 (0.5 to 1.2)	425.6 (133.3 to 977.7)	202.2 (40.3 to 516.8)
Neonatal encephalopathy due to birth asphyxia and trauma	3.1 (0.4 to 10.2)	3.5 (0.9 to 10.0)	28.7 (-20.8 to 204.7)	-29.9 (-58.2 to 72.8)	0.2 (0.1 to 0.3)	0.6 (0.2 to 0.6)	160.9 (34.9 to 485.4)	53.5 (-23.6 to 275.2)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.2 (78.2 to 112.0)	21.1 (7.3 to 27.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.6 (78.7 to 125.5)	21.4 (7.5 to 35.7)
Hemolytic disease and other neonatal jaundice	0.2 (0.1 to 0.4)	0.6 (0.3 to 1.2)	270.7 (27.4 to 1,217.1)	130.3 (-23.1 to 703.4)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.5)	280.0 (29.1 to 1,225.0)	132.5 (-23.8 to 700.2)
Other neonatal disorders	-	-	-	-	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	197.8 (51.0 to 559.9)	76.2 (-13.2 to 295.3)
Nutritional deficiencies	-	-	-	-	2.6 (1.7 to 3.8)	5.0 (3.3 to 7.2)	88.3 (72.1 to 112.5)	7.4 (-1.1 to 17.8)
Protein-energy malnutrition	2.0 (1.2 to 3.0)	4.8 (2.4 to 8.4)	136.4 (105.5 to 410.4)	30.9 (-29.5 to 153.0)	0.2 (0.1 to 0.4)	0.6 (0.3 to 1.1)	136.5 (98.1 to 413.1)	32.0 (-30.1 to 164.0)
Iodine deficiency	7.4 (4.9 to 10.5)	7.9 (5.4 to 10.8)	9.2 (-37.8 to 73.3)	-40.1 (-67.2 to 3.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	8.1 (-38.2 to 72.0)	-40.1 (-67.5 to 2.4)
Vitamin A deficiency	0.9 (0.6 to 1.6)	1.1 (0.6 to 1.9)	10.9 (-18.5 to 60.3)	-37.7 (-53.2 to -11.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	4.0 (-23.4 to 40.4)	-40.0 (-55.0 to -19.1)

Appendix Table G.4 - Comorbid prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	63.1 (61.8 to 64.1)	121.9 (120.9 to 123.2)	93.4 (89.7 to 97.8)	-11.3 (9.3 to 13.2)	2.2 (1.5 to 3.2)	4.2 (2.8 to 6.1)	90.2 (83.1 to 95.2)	10.6 (6.6 to 13.7)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (29.4 to 1,189.2)	0.0 (-22.5 to 553.3)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	78.5 (58.9 to 102.1)	-5.3 (-15.4 to 6.5)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	81.5 (45.9 to 131.7)	-6.3 (-22.9 to 14.4)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	7.7 (-11.5 to 28.3)	-43.6 (52.2 to -34.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.5 (-18.6 to -41.0)	43.3 (-55.3 to -30.2)
Chlamydial infection	7.6 (5.5 to 10.0)	14.6 (9.4 to 19.8)	92.4 (18.3 to 200.0)	2.5 (36.6 to 55.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	89.9 (8.0 to 218.0)	-1.0 (-40.6 to 64.4)
Gonococcal infection	3.5 (1.6 to 5.0)	6.2 (3.6 to 8.6)	71.2 (-12.8 to 349.3)	-7.8 (-52.0 to 131.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	69.4 (-3.7 to 214.6)	-8.4 (-46.4 to 62.8)
Trichomoniasis	5.6 (3.5 to 9.5)	10.5 (6.4 to 17.4)	82.9 (-23.4 to 323.0)	-7.7 (55.7 to 95.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.9 (-33.3 to 447.5)	-6.1 (-60.4 to 134.6)
Genital herpes	88.1 (77.0 to 99.6)	183.1 (147.6 to 233.2)	107.1 (55.9 to 169.5)	-5.1 (-15.7 to 26.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	188.8 (54.8 to 372.9)	6.6 (-14.9 to 29.7)
Other sexually transmitted diseases	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	67.9 (50.4 to 95.5)	-18.3 (-27.4 to -4.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.4 (17.2 to 134.5)	-17.0 (-38.5 to 15.1)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	43.9 (15.2 to 85.7)	-25.7 (-42.7 to -1.5)
Hepatitis A	0.7 (0.6 to 0.7)	1.2 (1.1 to 1.3)	80.4 (80.1 to 80.5)	2.5 (2.3 to 2.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.0 (55.5 to 102.8)	-0.3 (-12.3 to 12.1)
Hepatitis B	60.0 (47.7 to 74.4)	72.4 (57.7 to 88.3)	22.3 (-12.1 to 52.9)	-33.9 (-51.8 to -12.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	26.0 (-16.8 to 94.9)	-34.8 (-56.9 to 1.1)
Hepatitis C	6.0 (5.3 to 6.8)	8.5 (7.5 to 9.5)	40.0 (18.1 to 65.1)	-23.6 (-34.5 to -12.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.8 (8.8 to 81.2)	-0.3 (-43.0 to 11.7)
Hepatitis E	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	58.0 (6.2 to 135.6)	-14.2 (-43.6 to 27.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.5 (-0.9 to 149.2)	-14.3 (-45.8 to 31.5)
Leprosy	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	164.6 (57.0 to 374.3)	32.0 (-18.2 to 139.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	137.4 (36.0 to 372.5)	21.2 (-26.9 to 134.2)
Other infectious diseases	3.1 (2.3 to 3.9)	5.9 (5.2 to 6.7)	89.1 (65.8 to 127.7)	10.9 (-2.4 to 29.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	84.5 (56.7 to 141.2)	8.2 (-10.4 to 37.0)
Non-communicable diseases	-	-	-	-	27.1 (19.9 to 35.0)	50.4 (37.3 to 65.2)	85.5 (80.6 to 91.2)	0.5 (-3.2 to 2.2)
Neoplasms	-	-	-	-	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	91.3 (42.4 to 159.5)	3.7 (-20.0 to 36.3)
Esophageal cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	81.4 (11.4 to 192.5)	-2.1 (-38.5 to 52.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.1 (13.6 to 186.9)	-0.9 (-36.2 to 50.3)
Stomach cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	76.1 (16.7 to 177.5)	0.7 (-32.0 to 53.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.6 (17.8 to 176.8)	3.4 (-31.9 to 55.8)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.6 (23.0 to 203.9)	5.1 (-32.7 to 59.2)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.9 (-11.7 to 375.0)	0.3 (-54.8 to 166.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.5 (-9.7 to 343.2)	-1.7 (-52.7 to 143.9)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	421.0 (110.2 to 1,235.7)	166.7 (11.4 to 564.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	390.8 (109.3 to 1,084.6)	146.5 (13.6 to 481.7)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.0 (-49.8 to 109.8)	-41.6 (-70.8 to 9.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.6 (-47.0 to 88.0)	-4.4 (-68.3 to 2.3)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.4 (-41.7 to 140.4)	-36.0 (-67.8 to 32.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.0 (-39.5 to 112.9)	-38.5 (-66.6 to 16.6)
Larynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.9 (-3.9 to 180.3)	-8.4 (-44.8 to 54.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.3 (-5.8 to 183.3)	-7.7 (-45.4 to 60.9)
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.7 (14.8 to 169.1)	-2.1 (-33.4 to 51.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.8 (11.8 to 181.5)	1.1 (-33.3 to 57.2)
Breast cancer	0.8 (0.7 to 1.0)	0.8 (0.4 to 1.3)	-8.2 (-47.7 to 50.3)	-63.3 (-77.7 to -41.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	51.9 (-11.4 to 149.8)	-32.8 (-59.4 to 7.1)
Cervical cancer	0.3 (0.2 to 0.6)	0.5 (0.2 to 0.9)	58.6 (-23.2 to 221.5)	-6.9 (-58.9 to 65.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	60.3 (-21.3 to 215.3)	-15.4 (-57.0 to 66.2)
Uterine cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	70.0 (-18.1 to 259.9)	-11.0 (-55.5 to 81.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.8 (-20.6 to 254.2)	-10.7 (-55.6 to 86.2)
Prostate cancer	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.9)	221.3 (99.2 to 389.0)	82.4 (19.3 to 171.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	221.5 (93.7 to 403.2)	88.4 (18.1 to 186.6)
Colon and rectum cancer	0.3 (0.3 to 0.3)	0.6 (0.6 to 0.7)	102.1 (77.8 to 132.9)	10.1 (-1.6 to 24.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	103.6 (77.4 to 135.5)	10.7 (-1.2 to 25.3)
Lip and oral cavity cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	91.3 (17.0 to 212.5)	3.5 (-31.1 to 65.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.7 (15.9 to 207.2)	4.6 (-34.3 to 64.8)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.0 (-14.9 to 168.6)	-21.9 (-53.8 to 38.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.4 (-15.1 to 159.8)	-22.5 (-53.8 to 35.4)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.6 (-10.7 to 219.6)	-11.7 (-50.6 to 74.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.9 (-6.2 to 204.7)	-9.2 (-48.5 to 68.7)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.9 (19.2 to 247.0)	10.5 (-35.4 to 84.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	100.9 (21.4 to 227.4)	7.7 (-34.1 to 74.7)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.5 (22.4 to 199.7)	2.5 (-32.7 to 56.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.8 (-6.2 to 185.8)	2.3 (-29.9 to 50.5)
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	157.7 (58.1 to 307.9)	62.1 (-17.2 to 111.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	147.6 (46.3 to 256.9)	29.2 (-19.4 to 104.8)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	138.0 (80.8 to 221.4)	30.1 (0.8 to 77.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	165.7 (80.8 to 319.9)	49.4 (-0.4 to 137.7)
Ovarian cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	65.3 (-9.1 to 204.5)	-12.4 (-52.4 to 56.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.0 (-14.5 to 200.7)	-11.6 (-53.7 to 56.8)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	187.9 (36.8 to 350.9)	44.8 (-30.6 to 188.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	178.1 (30.8 to 499.5)	39.5 (-31.5 to 177.8)
Kidney cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	44.5 (-19.6 to 180.3)	6.2 (-32.3 to 71.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.0 (-8.6 to 187.1)	11.6 (-25.6 to 75.7)
Bladder cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	61.3 (34.8 to 93.2)	-8.3 (-24.1 to 9.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.7 (34.8 to 97.5)	-7.1 (-24.0 to 11.9)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	164.3 (56.4 to 326.7)	43.3 (-6.4 to 115.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	158.4 (62.3 to 303.0)	37.3 (-9.4 to 107.7)
Thyroid cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	95.8 (-5.3 to 287.5)	-0.2 (-52.7 to 96.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.8 (-6.6 to 278.5)	-3.6 (-52.9 to 89.0)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.8 (6.1 to 202.6)	0.4 (-39.6 to 69.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.1 (6.2 to 215.6)	1.7 (-39.0 to 74.2)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	137.3 (38.0 to 307.4)	41.2 (-16.7 to 141.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	122.0 (38.7 to 262.7)	28.9 (-22.6 to 109.5)
Non-Hodgkin lymphoma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	60.6 (-5.4 to 176.1)	0.6 (-33.9 to 60.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.2 (6.7 to 175.1)	2.4 (-30.8 to 62.6)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	124.5 (33.6 to 289.0)	21.7 (-27.1 to 110.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	124.3 (29.4 to 280.3)	20.9 (-28.2 to 105.3)
Leukemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	86.2 (-1.4 to 234.5)	14.2 (-27.4 to 76.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.3 (23.1 to 198.3)	12.5 (-25.6 to 73.8)
Other neoplasms	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.6)	150.7 (27.5 to 343.7)	44.3 (-7.8 to 120.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	148.5 (39.0 to 301.4)	36.3 (-9.1 to 102.3)
Cardiovascular diseases	-	-	-	-	0.7 (0.5 to 0.9)	1.2 (0.8 to 1.6)	74.9 (39.6 to 111.6)	-0.6 (-18.9 to 20.9)
Rheumatic heart disease	4.5 (3.5 to 5.5)	7.5 (5.9 to 9.8)	67.6 (18.2 to 150.5)	-7.2 (-31.9 to 30.3)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	63.6 (16.5 to 142.4)	-11.6 (-35.5 to 24.8)
Ischemic heart disease	3.3 (2.7 to 4.2)	4.4 (3.6 to 5.3)	31.5 (-9.9 to 75.6)	-21.5 (-42.2 to 3.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	27.7 (-2.0 to 78.2)	-27.7 (-51.5 to 7.7)
Cerebrovascular disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	100.9 (-16.8 to 163.9)	7.6 (-16.8 to 41.0)
Ischemic stroke	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	100.0 (54.9 to 158.3)	7.3 (-14.2 to 38.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.8 (49.6 to 164.7)	8.1 (-17.1 to 41.3)
Hemorrhagic stroke	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	101.6 (45.0 to 174.0)	6.9 (-22.8 to 45.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.7 (44.0 to 172.6)	6.2 (-23.1 to 43.8)
Hypertensive heart disease	0.5 (0.4 to 0.7)	1.1 (0.7 to 1.5)	106.5 (23.8 to 202.7)	18.1 (-31.1 to 76.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	108.0 (24.1 to 200.8)	19.2 (-30.7 to 78.3)
Cardiomyopathy and myocarditis	0.4 (0.3 to 0.5)	0.9 (0.7 to 1.3)	143.9 (67.3 to 281.0)	34.8 (-15.0 to 139.4)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	148.8 (67.6 to 284.7)	36.5 (-14.0 to 142.9)
Atrial fibrillation and flutter	0.2 (0.2 to 0.3)	0.6 (0.5 to 0.8)	175.5 (85.7 to 302.9)	70.5 (-0.9 to 153.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	174.8 (85.5 to 303.4)	69.7 (1.8 to 158.2)
Peripheral vascular disease	5.9 (4.0 to 8.1)	10.2 (6.9 to 16.8)	70.9 (11.8 to 195.9)	-1.8 (-33.7 to 49.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.0 (-53.5 to 223.5)	8.3 (-73.0 to 99.3)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.8 (35.7 to 218.7)	18.0 (-31.4 to 130.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	119.2 (34.0 to 259.3)	24.6 (-33.3 to 152.5)
Other cardiovascular and circulatory diseases	2.0 (1.0 to 3.3)	4.0 (2.1 to 6.1)	110.6 (-15.1 to 354.7)	10.7 (-55.0 to 154.8)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.5)	112.6 (-12.9 to 356.3)	11.3 (-53.9 to 158.6)
Chronic respiratory diseases	-	-	-	-	1.8 (1.2 to 2.6)	3.0 (2.0 to 4.2)	63.4 (38.2 to 94.2)	-13.8 (-26.9 to 1.4)
Chronic obstructive pulmonary disease	13.4 (12.8 to 14.0)	25.3 (24.2 to 26.5)	89.1 (83.8 to 94.4)	-0.4 (-3.0 to 2.2)	1.1 (0.7 to 1.6)	2.2 (

Appendix Table G.4 - Comoros prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	80.6	-4.0
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.5 (64.7 to 80.2)	-8.2 (-12.1 to -3.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.3 (64.4 to 79.9)	-8.2 (-12.1 to -3.6)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.8 (81.7 to 98.2)	0.8 (-3.3 to 4.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.0 (81.4 to 97.2)	0.4 (-3.7 to 4.5)
Asthma	7.5 (5.6 to 9.5)	12.6 (9.2 to 16.3)	66.1 (17.0 to 151.7)	-9.5 (-29.4 to 22.7)	0.3 (0.2 to 0.5)	0.6 (0.3 to 0.9)	66.4 (16.8 to 156.4)	-9.0 (-29.8 to 24.5)
Interstitial lung disease and pulmonary sarcoidosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.5 (15.0 to 182.8)	1.4 (-35.5 to 40.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.1 (17.2 to 180.2)	1.2 (-34.6 to 38.9)
Other chronic respiratory diseases	-	-	-	-	0.4 (0.2 to 0.7)	0.3 (0.1 to 0.5)	-27.1 (-57.0 to 16.8)	-61.5 (-77.2 to -38.3)
Cirrhosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	48.1 (27.8 to 71.0)	45.7 (-24.5 to -4.2)
Cirrhosis due to hepatitis B	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	28.9 (-49.7 to 140.2)	-26.3 (74.4 to 27.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.0 (-49.7 to 149.3)	-26.6 (-74.5 to 31.4)
Cirrhosis due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	114.7 (20.2 to 405.9)	18.7 (-32.2 to 255.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.3 (13.2 to 396.7)	21.0 (-33.6 to 253.1)
Cirrhosis due to alcohol use	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	25.6 (-15.3 to 69.3)	-31.5 (-51.9 to -8.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.3 (-17.9 to 78.9)	-31.4 (-52.2 to -5.1)
Cirrhosis due to other causes	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	54.0 (14.7 to 122.3)	0.1 (-30.7 to 50.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.0 (-1.0 to 142.1)	0.2 (-35.3 to 60.0)
Digestive diseases	-	-	-	-	0.5 (0.4 to 0.7)	0.9 (0.7 to 1.3)	81.0 (67.7 to 96.4)	2.4 (-3.9 to 11.0)
Peptic ulcer disease	2.8 (2.6 to 3.1)	3.7 (3.5 to 4.0)	30.8 (19.2 to 47.3)	-24.3 (-30.4 to -16.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	41.2 (24.6 to 66.9)	-18.3 (-26.7 to -6.6)
Gastritis and duodenitis	5.0 (4.5 to 5.4)	8.5 (7.9 to 9.1)	70.4 (55.0 to 89.0)	-1.0 (-10.4 to 11.4)	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	66.8 (45.7 to 86.4)	-0.0 (-10.4 to 11.1)
Appendicitis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	86.3 (35.5 to 172.7)	-0.2 (-24.3 to 47.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.2 (24.9 to 195.1)	0.5 (-29.5 to 54.8)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.2 (26.8 to 161.9)	-2.2 (-16.2 to 17.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.9 (12.0 to 193.1)	-1.1 (-24.3 to 30.8)
Inguinal, femoral, and abdominal hernia	0.8 (0.7 to 0.9)	2.6 (2.2 to 3.1)	242.4 (169.7 to 336.9)	183.2 (125.4 to 273.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	236.0 (160.0 to 335.2)	181.3 (122.0 to 271.0)
Inflammatory bowel disease	0.4 (0.4 to 0.4)	0.9 (0.9 to 0.9)	140.6 (125.1 to 157.6)	25.8 (18.1 to 33.7)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	142.7 (119.8 to 166.3)	26.7 (16.3 to 37.5)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.7 (14.8 to 123.0)	-11.5 (-42.6 to 32.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.4 (15.6 to 127.4)	-4.9 (-40.9 to 45.3)
Gallbladder and biliary diseases	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.3)	106.1 (72.2 to 145.5)	0.0 (-4.5 to 38.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.9 (66.8 to 155.8)	16.4 (-4.0 to 41.8)
Pancreatitis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	106.8 (91.0 to 124.5)	4.6 (-3.2 to 12.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	107.5 (68.0 to 148.6)	5.1 (-10.2 to 22.7)
Other digestive diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	79.2 (39.6 to 141.0)	2.0 (-20.9 to 38.1)
Neurological disorders	-	-	-	-	1.6 (1.0 to 2.2)	3.3 (2.1 to 4.8)	110.7 (58.6 to 161.5)	10.9 (-11.8 to 33.0)
Alzheimer disease and other dementias	0.6 (0.5 to 0.7)	1.1 (1.0 to 1.2)	71.1 (43.2 to 105.3)	-0.5 (-16.5 to 19.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	75.9 (45.4 to 109.8)	0.7 (-15.9 to 21.8)
Parkinson disease	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	74.4 (59.0 to 91.8)	-0.4 (-9.7 to 6.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.5 (47.6 to 113.5)	0.2 (-15.2 to 18.6)
Epilepsy	0.8 (0.4 to 1.2)	1.6 (0.9 to 2.5)	98.0 (-5.2 to 347.2)	8.4 (-48.7 to 137.8)	0.2 (0.1 to 0.4)	0.5 (0.2 to 0.8)	110.3 (3.7 to 375.4)	14.6 (-44.4 to 154.3)
Multiple sclerosis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	130.4 (99.0 to 168.7)	14.8 (-0.7 to 32.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.5 (79.7 to 185.8)	14.7 (-9.9 to 43.3)
Migraine	24.1 (15.7 to 30.8)	45.8 (32.7 to 61.2)	95.7 (23.2 to 169.2)	5.8 (-33.3 to 33.4)	0.8 (0.5 to 1.3)	1.6 (0.8 to 2.6)	96.0 (23.5 to 167.5)	5.1 (-33.6 to 35.2)
Tension-type headache	46.9 (43.4 to 50.9)	95.5 (87.0 to 104.0)	103.5 (79.6 to 128.1)	4.7 (-5.0 to 15.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	104.0 (78.9 to 130.9)	5.4 (-4.9 to 16.5)
Medication overuse headache	1.9 (1.2 to 2.6)	5.2 (3.4 to 7.0)	180.4 (107.5 to 273.4)	47.8 (9.8 to 98.0)	0.3 (0.2 to 0.5)	0.8 (0.5 to 1.3)	182.0 (106.5 to 277.5)	48.5 (9.4 to 98.9)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.7 (25.9 to 130.0)	-7.4 (-31.9 to 27.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	59.9 (-6.2 to 160.1)	-9.0 (-46.4 to 49.8)
Mental and substance use disorders	-	-	-	-	9.4 (6.5 to 12.7)	17.7 (12.3 to 23.6)	87.8 (81.1 to 95.1)	1.3 (-1.8 to 4.7)
Schizophrenia	0.8 (0.8 to 0.9)	1.7 (1.5 to 1.8)	99.3 (90.9 to 108.5)	0.9 (-2.9 to 5.2)	0.5 (0.4 to 0.7)	1.1 (0.8 to 1.3)	100.5 (88.0 to 113.6)	1.5 (-4.2 to 7.4)
Alcohol use disorders	4.0 (3.7 to 4.3)	6.7 (6.1 to 7.2)	67.1 (57.8 to 75.9)	-11.4 (-16.0 to -6.8)	0.4 (0.3 to 0.5)	0.7 (0.4 to 0.9)	67.2 (56.4 to 78.3)	-11.3 (-16.6 to -5.6)
Drug use disorders	-	-	-	-	0.5 (0.3 to 0.7)	1.0 (0.6 to 1.4)	96.8 (75.2 to 122.2)	1.3 (-8.1 to 13.7)
Opioid use disorders	0.6 (0.4 to 0.9)	1.3 (0.9 to 1.9)	113.1 (92.6 to 146.7)	3.0 (-5.7 to 16.7)	0.3 (0.1 to 0.4)	0.6 (0.3 to 0.9)	113.9 (91.1 to 152.4)	3.8 (-7.0 to 19.3)
Cocaine use disorders	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.5)	99.4 (48.9 to 155.5)	0.3 (-19.8 to 24.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	99.4 (42.1 to 175.4)	1.8 (-23.4 to 34.6)
Amphetamine use disorders	0.6 (0.6 to 0.7)	1.1 (1.0 to 1.2)	69.2 (49.0 to 92.8)	-5.1 (-15.4 to 7.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	70.4 (42.2 to 105.7)	-4.1 (-19.3 to 14.5)
Cannabis use disorders	0.5 (0.4 to 0.6)	0.9 (0.7 to 1.1)	79.4 (77.0 to 82.6)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.3 (50.6 to 116.4)	0.5 (-15.0 to 18.9)
Other drug use disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	76.8 (30.2 to 148.0)	-2.8 (-28.0 to 34.7)
Depressive disorders	-	-	-	-	4.6 (2.9 to 6.6)	8.6 (5.5 to 12.6)	88.5 (76.2 to 101.7)	1.6 (-4.2 to 8.0)
Major depressive disorder	20.2 (15.4 to 24.9)	38.0 (29.0 to 47.1)	87.9 (75.2 to 101.6)	1.4 (-4.7 to 8.1)	4.2 (2.6 to 6.2)	7.9 (4.9 to 11.8)	88.3 (74.8 to 102.4)	1.8 (-4.7 to 9.0)
Dysthymia	4.0 (3.3 to 4.8)	7.7 (6.3 to 9.1)	92.1 (89.1 to 95.6)	-0.2 (-0.3 to -0.2)	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.1)	92.8 (86.7 to 99.3)	0.3 (-2.2 to 2.8)
Bipolar disorder	2.2 (1.9 to 2.6)	4.3 (3.7 to 4.8)	95.0 (79.2 to 101.2)	-0.5 (-5.2 to 4.5)	0.5 (0.3 to 0.7)	0.9 (0.5 to 1.3)	90.8 (76.7 to 106.4)	-0.0 (-6.4 to 6.8)
Anxiety disorders	12.2 (5.0 to 20.3)	22.8 (9.3 to 37.0)	86.8 (80.9 to 93.3)	0.3 (-0.6 to -0.2)	1.1 (0.4 to 2.1)	2.1 (0.8 to 3.7)	86.9 (78.8 to 95.2)	-0.1 (-2.4 to 2.6)
Eating disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	79.8 (64.7 to 97.5)	0.7 (-7.3 to 10.1)
Anorexia nervosa	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	85.8 (65.8 to 106.6)	5.0 (-6.1 to 16.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.2 (45.0 to 139.7)	5.7 (-17.7 to 34.3)
Bulimia nervosa	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.1)	78.4 (75.0 to 83.1)	-0.2 (-0.3 to -0.2)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	78.5 (63.0 to 96.6)	-0.2 (-8.5 to 9.3)
Autistic spectrum disorders	-	-	-	-	0.5 (0.3 to 0.7)	0.9 (0.6 to 1.2)	79.4 (72.5 to 86.6)	0.8 (-2.4 to 4.2)
Autism	1.3 (1.2 to 1.3)	2.3 (2.2 to 2.4)	79.1 (78.8 to 79.4)	0.4 (0.4 to 0.4)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	79.4 (70.4 to 89.7)	0.8 (-3.6 to 5.9)
Asperger syndrome	1.8 (1.7 to 1.9)	3.3 (3.1 to 3.5)	79.1 (78.8 to 79.5)	0.5 (0.5 to 0.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	79.4 (71.8 to 88.3)	0.8 (-3.1 to 4.9)
Attention-deficit/hyperactivity disorder	3.1 (2.9 to 3.4)	5.2 (4.8 to 5.6)	67.5 (67.3 to 67.6)	0.4 (0.3 to 0.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	67.6 (55.6 to 81.2)	0.5 (-6.8 to 8.3)
Conduct disorder	4.5 (4.3 to 4.8)	7.8 (7.1 to 8.0)	67.4 (67.2 to 67.6)	0.5 (0.3 to 0.4)	0.1 (0.0 to 0.1)	0.9 (0.6 to 1.3)	67.5 (60.4 to 76.0)	0.4 (-3.8 to 5.5)
Idiopathic intellectual disability	5.7 (1.7 to 8.6)	12.5 (7.0 to 16.8)	114.8 (69.6 to 368.6)	26.3 (-1.4 to 183.5)	0.3 (0.1 to 0.5)	0.6 (0.3 to 0.9)	114.9 (69.3 to 376.0)	25.9 (-1.1 to 189.4)
Other mental and substance use disorders	5.0 (4.7 to 5.3)	9.6 (8.9 to 10.2)	91.8 (90.5 to 93.1)	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	0.7 (0.5 to 1.0)	92.6 (84.6 to 101.5)	0.8 (-2.6 to 4.6)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	1.8 (1.3 to 2.4)	3.6 (2.5 to 4.8)	94.1 (79.0 to 107.5)	5.4 (-4.3 to 14.6)
Diabetes mellitus	4.6 (3.6 to 5.4)	10.8 (8.8 to 13.2)	133.8 (90.8 to 208.9)	19.9 (-5.9 to 59.7)	0.4 (0.2 to 0.5)	0.8 (0.5 to 1.2)	134.6 (77.7 to 214.6)	20.1 (-12.4 to 63.1)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.6 (32.3 to 51.3)	-16.0 (-20.3 to -10.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.6 (32.2 to 51.3)	-16.0 (-20.3 to -10.0)
Chronic kidney disease	-	-	-	-	0.7 (0.5 to 0.9)	1.2 (0.9 to 1.6)	82.2 (63.3 to 98.9)	-1.8 (-11.5 to 8.7)
Chronic kidney disease due to diabetes mellitus	5.3 (3.2 to 8.2)	9.6 (5.8 to 15.2)	81.6 (32.5 to 147.9)	-2.5 (-28.1 to 36.3)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	78.6 (36.3 to 144.4)	-2.5 (-27.9 to 34.4)
Chronic kidney disease due to hypertension	16.6 (10.6 to 25.5)	30.1 (19.5 to 44.4)	82.9 (46.6 to 114.6)	0.9 (-16.9 to 21.7)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.5)	89.7 (49.9 to 142.9)	1.3 (-18.0 to 22.3)
Chronic kidney disease due to glomerulonephritis	14.2 (9.8 to 21.1)	27.0 (18.8 to 40.5)	91.4 (52.7 to 143.1)	7.7 (-19.1 to 26.5)	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	91.4 (47.5 to 111.6)	1.4 (-1.8 to 20.9)
Chronic kidney disease due to other causes	11.0 (7.0 to 19.0)	19.7 (11.8 to 33.9)	79.9 (32.1 to 131.2)	-4.1 (-28.6 to 22.9)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	78.6 (39.1 to 127.1)	-5.2 (-26.8 to 23.4)
Urinary diseases and male infertility	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	78.7 (59.7 to 104.4)	3.5 (-6.8 to 17.2)

Appendix Table G.4 - Comorbid prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	94.1 (75.9 to 112.3)	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.3 (53.0 to 145.6)	7.2 (-11.6 to 28.7)
Urolithiasis	0.9 (0.7 to 1.2)	1.3 (1.0 to 1.7)	43.9 (22.8 to 58.6)	-20.7 (-28.9 to -13.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.5 (65.7 to 116.9)	-2.6 (-12.4 to 8.8)
Benign prostatic hyperplasia	2.4 (2.2 to 2.7)	4.3 (4.0 to 4.8)	78.3 (57.1 to 104.0)	5.0 (-7.2 to 19.8)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	80.0 (58.6 to 107.2)	6.1 (-6.1 to 21.2)
Male infertility due to other causes	3.4 (2.3 to 4.8)	5.4 (3.6 to 7.8)	57.9 (3.9 to 169.3)	-20.3 (49.2 to 35.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	62.6 (6.0 to 176.9)	-17.5 (-46.6 to 39.7)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.5 (32.2 to 164.5)	0.2 (-30.9 to 37.7)
Gynecological diseases	-	-	-	-	0.4 (0.2 to 0.6)	0.7 (0.5 to 1.1)	94.9 (62.4 to 127.1)	-0.7 (-15.6 to 15.2)
Uterine fibroids	5.8 (5.2 to 6.3)	12.1 (11.0 to 13.2)	110.5 (109.4 to 111.6)	-0.2 (-0.2 to -0.2)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	109.5 (84.8 to 128.9)	2.4 (-10.1 to 12.2)
Polycystic ovarian syndrome	5.5 (4.9 to 6.0)	11.5 (10.1 to 12.9)	110.3 (79.7 to 143.4)	4.9 (-8.7 to 19.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	110.4 (79.9 to 145.2)	5.2 (-8.6 to 21.2)
Female infertility due to other causes	3.6 (2.3 to 5.0)	8.3 (6.0 to 11.1)	130.9 (49.8 to 280.2)	12.9 (-28.7 to 93.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	130.8 (49.6 to 272.3)	0.0 (-27.9 to 89.1)
Endometriosis	0.6 (0.5 to 0.7)	1.0 (0.9 to 1.2)	77.8 (43.5 to 123.5)	-11.4 (27.6 to 10.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	78.6 (43.3 to 127.8)	-10.9 (-27.9 to 11.6)
Genital prolapse	10.1 (8.7 to 11.6)	20.9 (17.6 to 24.0)	107.0 (65.9 to 157.6)	2.9 (-15.0 to 27.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	107.0 (66.2 to 157.0)	3.2 (-14.5 to 27.3)
Premenstrual syndrome	15.6 (10.7 to 20.0)	27.2 (18.0 to 36.0)	75.2 (6.1 to 187.1)	-5.9 (-43.9 to 54.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.4)	74.9 (4.5 to 188.1)	-6.5 (-44.6 to 58.2)
Other gynecological diseases	0.7 (0.5 to 0.9)	1.5 (1.1 to 1.8)	109.7 (46.1 to 201.6)	8.9 (-22.6 to 50.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.3)	112.1 (12.9 to 355.1)	12.3 (-37.6 to 112.4)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	73.7 (54.2 to 109.8)	1.9 (-9.4 to 20.5)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.3 (-7.1 to 143.7)	-11.7 (-45.5 to 44.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.3 (-4.3 to 143.8)	-12.4 (-44.7 to 44.3)
Thalassemia trait	2.5 (1.9 to 3.0)	4.4 (3.4 to 5.3)	78.9 (61.8 to 94.7)	-0.0 (-9.5 to 10.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	71.1 (46.6 to 94.7)	-0.1 (-12.8 to 13.1)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.0 (42.4 to 75.0)	-7.6 (-14.6 to 1.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.4 (46.9 to 78.3)	-4.3 (-12.2 to 4.6)
Sickle cell trait	6.8 (5.8 to 7.8)	11.0 (9.4 to 12.6)	62.0 (54.8 to 70.1)	-9.5 (-13.5 to -4.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	48.1 (3.8 to 129.2)	-12.7 (-40.7 to 37.1)
G6PD deficiency	16.7 (13.7 to 19.3)	27.9 (21.3 to 35.7)	64.9 (20.2 to 134.9)	-7.6 (-32.5 to 31.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.3 (18.9 to 110.1)	-7.8 (-23.2 to 11.6)
G6PD trait	54.3 (51.4 to 57.1)	98.7 (92.4 to 104.3)	81.6 (67.6 to 96.5)	1.3 (-6.5 to 9.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.7 (-49.3 to 351.6)	-9.9 (-70.0 to 150.9)
Other hemoglobinopathies and hemolytic anemias	2.4 (1.9 to 2.8)	4.6 (4.1 to 5.1)	93.9 (67.6 to 141.8)	13.2 (-0.3 to 32.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	89.1 (48.5 to 174.0)	11.9 (-11.0 to 56.1)
Endocrine, metabolic, blood, and immune disorders	9.8 (3.3 to 4.3)	7.0 (5.7 to 8.1)	83.0 (44.0 to 133.9)	0.1 (-14.6 to 23.2)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.4)	81.1 (25.1 to 141.2)	3.7 (-22.7 to 29.4)
Musculoskeletal disorders	-	-	-	-	4.6 (3.3 to 6.1)	9.4 (6.6 to 12.4)	101.8 (84.9 to 121.3)	5.3 (-2.0 to 13.2)
Rheumatoid arthritis	0.9 (0.8 to 0.9)	1.4 (1.4 to 1.5)	60.9 (51.4 to 70.5)	-14.0 (-19.0 to -8.6)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	61.9 (48.8 to 76.2)	-13.5 (-19.6 to -6.5)
Osteoarthritis	7.5 (7.2 to 7.8)	14.2 (13.6 to 14.7)	88.1 (79.1 to 98.6)	0.9 (-3.7 to 6.3)	0.5 (0.3 to 0.6)	0.5 (0.6 to 1.2)	89.6 (80.2 to 100.5)	1.6 (-3.1 to 7.1)
Low back and neck pain	-	-	-	-	3.5 (2.4 to 4.7)	7.0 (4.8 to 9.4)	100.3 (78.4 to 126.7)	4.1 (-5.7 to 15.8)
Low back pain	19.2 (18.0 to 20.4)	37.9 (35.6 to 40.3)	96.8 (80.8 to 116.4)	4.0 (-4.7 to 13.3)	2.1 (1.4 to 2.9)	4.2 (2.9 to 5.8)	98.2 (81.6 to 118.6)	4.6 (-4.1 to 14.6)
Neck pain	13.8 (10.9 to 16.7)	27.9 (23.8 to 33.0)	101.9 (57.5 to 166.4)	3.0 (-17.2 to 31.5)	1.4 (0.9 to 1.9)	2.7 (1.8 to 3.9)	103.1 (58.4 to 169.2)	3.6 (-17.0 to 32.4)
Gout	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	91.3 (59.7 to 128.9)	-0.1 (-16.0 to 18.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.7 (50.1 to 156.3)	1.2 (-22.8 to 32.5)
Other musculoskeletal disorders	5.4 (4.1 to 6.9)	12.9 (9.7 to 16.2)	137.8 (119.5 to 160.2)	21.6 (11.9 to 30.4)	0.5 (0.3 to 0.7)	1.2 (0.7 to 1.7)	119.9 (119.5 to 154.7)	19.9 (12.0 to 29.4)
Other non-communicable diseases	-	-	-	-	6.4 (4.3 to 9.5)	11.0 (7.3 to 16.1)	70.7 (62.8 to 77.5)	-7.5 (-10.9 to -4.3)
Congenital anomalies	-	-	-	-	0.4 (0.3 to 0.5)	0.9 (0.6 to 1.2)	119.9 (92.1 to 156.7)	21.8 (6.9 to 41.4)
Neural tube defects	0.0 (0.0 to 0.1)	0.2 (0.2 to 0.3)	397.9 (297.6 to 514.1)	206.8 (144.3 to 279.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	477.6 (309.1 to 704.3)	261.7 (158.7 to 392.3)
Congenital heart anomalies	0.4 (0.3 to 0.5)	2.4 (1.9 to 3.0)	543.1 (338.0 to 842.1)	299.0 (167.8 to 489.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	476.9 (286.4 to 752.5)	264.7 (143.2 to 432.4)
Orofacial clefts	0.0 (0.0 to 0.1)	0.4 (0.3 to 0.5)	450.0 (400.9 to 1,392.8)	385.2 (221.2 to 892.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	635.2 (304.2 to 1,265.4)	89.9 (169.9 to 795.7)
Down syndrome	0.2 (0.2 to 0.3)	0.6 (0.5 to 0.7)	179.9 (125.1 to 247.4)	70.2 (37.1 to 111.7)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	185.9 (123.4 to 264.1)	75.5 (37.4 to 122.1)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	157.2 (81.6 to 316.5)	48.4 (4.5 to 138.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	162.3 (81.0 to 328.9)	49.3 (1.1 to 145.7)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.2 (26.5 to 159.8)	1.2 (-28.5 to 46.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.2 (32.7 to 170.5)	0.8 (-29.0 to 46.2)
Chromosomal unbalanced rearrangements	0.0 (0.3 to 0.4)	0.0 (0.8 to 1.3)	89.7 (126.6 to 293.4)	81.7 (37.7 to 141.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	89.0 (132.0 to 306.3)	89.0 (42.5 to 151.8)
Other congenital anomalies	3.0 (2.2 to 3.7)	4.8 (3.4 to 6.2)	57.6 (36.5 to 84.3)	-11.9 (-22.7 to 3.0)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.8)	70.1 (43.3 to 103.9)	-5.6 (-20.1 to 12.4)
Skin and subcutaneous diseases	-	-	-	-	2.0 (1.2 to 3.1)	3.5 (2.2 to 5.4)	77.3 (65.9 to 91.6)	-0.8 (-6.9 to 6.8)
Dermatitis	16.0 (12.4 to 20.7)	29.4 (23.5 to 37.9)	83.0 (80.5 to 85.7)	-0.1 (-0.1 to -0.0)	0.6 (0.4 to 0.9)	1.0 (0.6 to 1.5)	79.6 (71.1 to 87.0)	0.1 (-2.9 to 3.4)
Psoriasis	2.5 (2.1 to 2.8)	4.6 (4.0 to 5.3)	86.1 (84.1 to 88.3)	0.2 (-0.0 to 0.1)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.5)	86.7 (75.3 to 99.9)	0.6 (-4.5 to 6.3)
Cellulitis	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	84.8 (57.1 to 110.6)	1.9 (-14.3 to 13.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.1 (37.5 to 142.3)	2.0 (-20.1 to 27.2)
Pyoderma	0.7 (0.5 to 0.9)	1.1 (0.9 to 1.5)	61.9 (52.1 to 74.5)	-4.2 (-10.5 to 3.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.2 (45.5 to 82.7)	-3.8 (-13.2 to 7.2)
Scabies	5.8 (4.7 to 7.3)	9.3 (7.1 to 12.1)	60.5 (10.7 to 122.2)	-12.0 (-38.0 to 23.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	61.0 (11.1 to 124.1)	-11.7 (-37.7 to 25.2)
Fungal skin diseases	46.5 (33.4 to 66.0)	83.3 (59.7 to 118.8)	78.8 (75.0 to 84.4)	0.1 (0.1 to 0.6)	0.3 (0.1 to 0.6)	0.5 (0.2 to 1.1)	79.1 (75.1 to 84.7)	0.4 (-0.3 to 1.1)
Viral skin diseases	10.0 (7.4 to 12.7)	17.4 (12.7 to 22.0)	73.1 (65.7 to 80.6)	0.0 (-2.9 to 3.6)	0.3 (0.2 to 0.5)	0.3 (0.3 to 0.9)	73.3 (64.4 to 82.6)	0.3 (-3.8 to 4.9)
Acne vulgaris	19.7 (11.4 to 26.7)	30.5 (19.5 to 42.9)	58.1 (-17.8 to 184.6)	-8.5 (50.1 to 51.1)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.7)	58.0 (-17.6 to 185.4)	-8.6 (-49.9 to 52.7)
Alopecia areata	0.4 (0.3 to 0.4)	0.7 (0.6 to 0.7)	82.1 (55.1 to 110.9)	0.0 (-15.1 to 15.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.2 (50.7 to 122.7)	-0.6 (-16.5 to 19.2)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.4 (42.4 to 122.9)	-3.8 (-23.2 to 36.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.4 (42.4 to 122.9)	-1.8 (-23.3 to 27.1)
Urticaria	1.6 (0.8 to 2.2)	3.6 (2.3 to 5.1)	115.7 (24.1 to 400.3)	9.6 (-36.0 to 130.5)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	116.1 (23.8 to 403.5)	10.2 (-35.8 to 133.4)
Decubitus ulcer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	92.2 (55.7 to 140.4)	7.7 (-21.3 to 44.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.5 (54.1 to 146.8)	8.4 (-21.8 to 49.2)
Other skin and subcutaneous diseases	20.5 (13.9 to 29.2)	37.2 (25.2 to 52.8)	81.2 (71.5 to 90.3)	-2.2 (-5.7 to 0.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	81.6 (72.1 to 90.9)	-1.7 (-5.5 to 1.6)
Sense organ diseases	-	-	-	-	3.4 (1.2 to 5.6)	5.3 (3.4 to 7.9)	58.0 (45.4 to 70.2)	-12.9 (-47.7 to -8.2)
Glaucoma	0.7 (0.5 to 0.9)	1.1 (0.7 to 1.5)	55.3 (19.8 to 109.8)	-16.5 (32.9 to 17.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	57.7 (13.2 to 105.2)	-18.1 (-37.5 to 11.8)
Cataract	3.5 (2.2 to 4.8)	4.5 (2.7 to 6.2)	30.3 (5.8 to 54.7)	-26.8 (-37.9 to -13.0)	0.3 (0.1 to 0.4)	0.3 (0.2 to 0.5)	30.0 (11.4 to 56.1)	-25.7 (-36.8 to -12.8)
Macular degeneration	0.5 (0.3 to 0.7)	1.1 (0.7 to 1.8)	122.6 (65.2 to 263.2)	19.1 (-12.1 to 105.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	117.5 (57.4 to 240.8)	15.9 (-13.4 to 86.1)
Uncorrected refractive error	53.3 (40.2 to 57.1)	98.0 (90.6 to 104.9)	83.6 (67.5 to 103.7)	-0.1 (-7.9 to 8.6)	0.9 (0.5 to 1.4)	1.5 (0.9 to 2.4)	69.1 (55.9 to 84.6)	-8.2 (-14.7 to -0.9)
Age-related and other hearing loss	54.7 (46.6 to 61.5)	92.5 (76.4 to 106.1)	68.8 (58.9 to 82.7)	-7.6 (-10.9 to -3.6)	1.8 (1.1 to 2.7)	2.7 (1.6 to 4.2)	54.6 (34.5 to 75.7)	-24.9 (-19.7 to -5.8)
Other vision loss	1.2 (1.0 to 1.6)	1.6 (1.1 to 2.1)	28.4 (2.0 to 54.1)	-27.2 (-42.2 to -11.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	28.6 (2.1 to 57.5)	-25.4 (-39.9 to -9.2)
Other sense organ diseases	9.8 (9.2 to 10.3)	17.2 (16.3 to 18.2)	76.2 (63.5 to 91.5)	-0.1 (-6.6 to 7.1)	0.3 (0.2 to 0.4)	0.3 (0.3 to 0.7)	76.1 (62.3 to 94.1)	0.2 (-6.8 to 8.0)
Oral disorders	-	-	-	-	0.7 (0.4 to 1.2)	1.3 (0.8 to 2.2)	83.1 (74.4 to 92.0)	-2.1 (-6.6 to 2.0)
Deciduous caries	45.9 (43.6 to 48.2)	76.0 (72.3 to 80.1)	65.7 (53.2 to 78.8)	-0.3 (-7.6 to 7.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	65.2 (50.4 to 83.3)	-0.0 (-9.4 to 10.1)
Permanent caries	126.7 (114.6 to 140.5)	232.0 (212.2 to 257.2)	83.0 (59.3 to 112.7)	0.4 (-11.3 to 14.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.5)	82.7 (59.3 to 114.0)	0.7 (-11.6 to 15.5)
Periodontal diseases	34.5 (33.4 to 35.5)	67.5 (65.4 to 69.7)	95.8 (87.8 to 105.5)	1.3 (-2.8 to 5.9)	0.2 (0.1 to 0.5)	0.4 (0.2 to 0.9)	96.7 (88.5 to 106.5)	1.8 (-2.3 to 6.5)

Appendix Table G.4 - Comorbid prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	7.0 (6.5 to 7.5)	11.8 (11.0 to 12.5)	67.1 (53.0 to 86.5)	-7.8 (-15.5 to 1.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	68.8 (53.7 to 88.6)	-7.1 (-15.2 to -2.6)
Other oral disorders	6.0 (5.6 to 6.3)	11.0 (10.3 to 11.7)	83.2 (69.2 to 98.1)	-1.0 (-8.0 to 6.3)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	83.5 (69.2 to 99.5)	0.7 (-8.0 to 7.4)
Injuries	-	-	-	-	1.7 (1.3 to 2.2)	2.3 (1.8 to 3.0)	32.9 (27.0 to 39.1)	-24.0 (-27.2 to -20.4)
Transport injuries	-	-	-	-	0.9 (0.6 to 1.1)	0.9 (0.6 to 1.1)	-0.0 (-5.5 to 5.8)	-41.6 (-44.5 to -38.5)
Road injuries	-	-	-	-	0.8 (0.6 to 1.0)	0.8 (0.6 to 1.0)	-0.6 (-6.1 to 5.6)	-42.1 (-44.9 to -39.9)
Pedestrian road injuries	-	-	-	-	0.3 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-6.7 (-14.6 to 1.4)	-44.0 (-47.9 to -39.8)
Cyclist road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-3.6 (-11.0 to 3.9)	-41.5 (-45.9 to -36.8)
Motorcyclist road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-10.2 (-17.7 to -2.4)	-49.3 (-52.8 to -45.3)
Motor vehicle road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	7.9 (0.0 to 16.6)	-38.4 (-42.3 to -33.9)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.7 (-41.4 to -31.9)	-63.9 (-66.2 to -61.5)
Other transport injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	6.9 (-0.7 to 15.6)	-35.3 (-39.5 to -30.5)
Unintentional injuries	-	-	-	-	0.8 (0.6 to 1.0)	1.3 (1.0 to 1.7)	61.6 (55.1 to 67.8)	-9.1 (-12.6 to -5.7)
Falls	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.8)	80.1 (69.3 to 91.1)	-2.4 (-8.2 to 3.4)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.4 (7.6 to 32.4)	-30.9 (-36.7 to -24.2)
Fire, heat, and hot substances	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	35.1 (21.8 to 48.0)	-24.0 (-30.1 to -17.9)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.2 (8.6 to 52.2)	-29.3 (-37.6 to -18.7)
Exposure to mechanical forces	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	54.2 (46.1 to 63.3)	-13.4 (-17.7 to -8.8)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.4 (67.4 to 101.4)	-1.3 (-9.0 to 7.6)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.6 (85.3 to 124.1)	12.9 (4.4 to 22.1)
Other exposure to mechanical forces	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	52.4 (44.1 to 61.8)	-14.3 (-18.7 to -9.5)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.8 (83.7 to 106.8)	9.7 (2.9 to 16.4)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	17.2 (8.5 to 26.8)	-33.4 (-37.6 to -29.2)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.2 (5.0 to 33.9)	-34.8 (-41.0 to -27.1)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.9 (6.9 to 27.6)	-32.6 (-36.8 to -28.3)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.3 (55.1 to 76.1)	-8.4 (-12.7 to -3.0)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.8 (22.2 to 65.3)	-13.5 (-21.9 to -3.1)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.5 (62.2 to 99.8)	-3.0 (-11.0 to 6.3)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.9 (57.5 to 80.6)	-8.3 (-14.1 to -1.4)
Other unintentional injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	58.5 (45.4 to 76.8)	-7.6 (-14.5 to 1.7)
Self-harm and interpersonal violence	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	66.4 (55.5 to 76.4)	-6.8 (-12.2 to -1.5)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.7 (62.6 to 94.3)	-7.0 (-13.6 to 1.2)
Interpersonal violence	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	64.8 (53.6 to 75.4)	-6.8 (-12.6 to -1.1)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.8 (66.2 to 93.4)	1.3 (-5.7 to 8.7)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.7 (76.3 to 110.6)	5.9 (-2.3 to 15.8)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	54.4 (41.6 to 65.6)	-12.3 (-18.8 to -6.2)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	187.4 (74.1 to 466.6)	94.3 (14.4 to 289.0)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.8 (-43.6 to -31.3)	-55.9 (-60.5 to -51.1)
Collective violence and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.1)	-	-

Appendix Table G.4 - Congo prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
All causes	-	-	-	-	245.2 (178.5 to 321.7)	444.3 (323.6 to 584.8)	81.2 (77.3 to 85.0)	81.2 (-5.7 to -1.9)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	82.7 (58.2 to 114.8)	139.4 (98.0 to 193.3)	68.5 (59.9 to 77.2)	-13.2 (-17.9 to -8.6)
HIV/AIDS and tuberculosis	-	-	-	-	8.8 (6.1 to 11.8)	15.0 (10.2 to 21.5)	68.8 (47.9 to 97.7)	-15.2 (-25.4 to 0.4)
Tuberculosis	7.9 (7.4 to 8.4)	14.4 (13.4 to 15.3)	81.9 (73.0 to 92.9)	-7.7 (-11.9 to -2.4)	2.4 (1.6 to 3.2)	4.4 (3.0 to 5.9)	82.8 (71.6 to 96.3)	-7.4 (-12.7 to -1.0)
HIV/AIDS	-	-	-	-	6.4 (4.3 to 9.0)	10.6 (6.9 to 16.1)	63.6 (36.6 to 102.0)	-18.6 (-32.3 to 3.5)
HIV/AIDS resulting in mycobacterial infection	1.4 (0.9 to 1.8)	1.7 (1.0 to 2.4)	23.5 (1.9 to 46.4)	-37.0 (-48.1 to -24.3)	0.5 (0.3 to 0.8)	0.6 (0.3 to 1.0)	23.9 (0.2 to 53.5)	-36.8 (-49.3 to -21.5)
HIV/AIDS resulting in other diseases	54.3 (47.8 to 62.0)	72.9 (66.0 to 80.7)	34.4 (15.1 to 54.5)	-29.8 (-39.9 to -18.9)	5.9 (3.9 to 8.4)	10.0 (6.4 to 15.4)	67.1 (37.9 to 109.2)	-17.1 (-31.8 to 6.3)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	9.8 (6.9 to 13.2)	16.8 (11.8 to 22.5)	72.9 (57.7 to 84.5)	-7.8 (-16.2 to -2.3)
Diarrheal diseases	32.6 (30.5 to 34.5)	63.5 (60.2 to 66.8)	95.0 (79.5 to 110.9)	6.1 (-1.6 to 14.3)	6.1 (3.6 to 7.3)	95.2 (6.9 to 14.3)	95.2 (79.4 to 112.3)	-1.7 (-1.7 to 14.9)
Intestinal infectious diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	6.2 (-21.7 to 42.1)	6.2 (-57.3 to -23.9)
Typhoid fever	0.7 (0.6 to 0.9)	0.8 (0.6 to 0.9)	5.4 (-18.1 to 34.0)	-43.0 (-55.9 to -26.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	7.0 (-21.8 to 42.2)	42.0 (-57.2 to -23.6)
Paratyphoid fever	0.4 (0.3 to 0.4)	0.5 (0.4 to 0.6)	29.8 (-2.3 to 73.0)	-30.5 (-47.6 to -4.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.9 (-6.0 to 85.0)	29.5 (-48.7 to -0.6)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.7 (-8.9 to 130.5)	-4.4 (-89.5 to 27.8)
Lower respiratory infections	1.3 (1.1 to 1.6)	2.1 (1.7 to 2.5)	54.4 (24.0 to 107.2)	-17.6 (-31.2 to 0.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	56.4 (20.2 to 115.3)	-16.9 (-32.5 to 3.0)
Upper respiratory infections	73.0 (68.3 to 78.1)	145.5 (138.0 to 153.5)	99.2 (84.6 to 116.0)	7.4 (-0.5 to 16.4)	0.9 (0.5 to 1.5)	1.7 (1.0 to 2.9)	99.5 (84.4 to 117.3)	7.6 (-0.7 to 17.2)
Otitis media	40.9 (37.1 to 44.6)	70.5 (64.4 to 76.9)	72.6 (56.6 to 88.5)	-7.4 (-15.7 to 0.9)	0.8 (0.5 to 1.3)	1.4 (0.8 to 2.3)	71.2 (52.3 to 90.8)	-7.8 (-18.0 to 2.3)
Meningitis	-	-	-	-	2.3 (1.6 to 3.3)	2.9 (2.0 to 3.9)	25.4 (-10.4 to 48.5)	-31.8 (-49.9 to -21.2)
Pneumococcal meningitis	12.4 (7.6 to 18.9)	14.8 (9.1 to 22.2)	20.5 (-4.5 to 39.9)	-33.8 (-46.4 to -24.6)	1.1 (0.7 to 1.6)	1.3 (0.9 to 1.8)	26.2 (-20.8 to 71.9)	-30.7 (-55.5 to -10.3)
H influenzae type B meningitis	6.0 (2.1 to 11.9)	6.6 (2.5 to 12.9)	10.0 (-17.8 to 47.2)	-40.8 (-54.6 to -21.2)	0.6 (0.4 to 0.9)	0.8 (0.5 to 1.1)	18.2 (-29.1 to 77.1)	-36.5 (-60.4 to -5.7)
Meningococcal meningitis	1.0 (0.3 to 2.4)	1.4 (0.5 to 3.2)	39.3 (2.4 to 95.6)	-24.8 (-42.6 to 2.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	47.0 (8.4 to 126.5)	-22.1 (-46.9 to 13.0)
Other meningitis	4.3 (2.2 to 8.0)	5.0 (2.6 to 9.1)	17.3 (-4.0 to 41.5)	-35.8 (-46.7 to -22.6)	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.9)	22.0 (-7.8 to 62.6)	-33.9 (-48.3 to -13.0)
Encephalitis	0.4 (0.2 to 0.9)	0.7 (0.3 to 1.6)	75.4 (54.1 to 101.2)	-5.3 (-15.5 to 5.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	79.6 (46.0 to 120.2)	-4.5 (-20.7 to 14.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.6 (93.1 to 2,183.8)	-29.4 (-94.3 to 713.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.6 (93.4 to 2,199.7)	-29.4 (-94.4 to 736.1)
Whooping cough	1.3 (1.0 to 1.7)	1.0 (0.7 to 1.2)	-28.3 (-32.5 to -23.8)	-61.6 (-63.9 to -59.2)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-28.3 (-39.9 to -15.4)	-61.5 (-67.9 to -54.4)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.7 (-81.9 to 55.5)	-67.6 (-90.6 to -16.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.0 (-61.9 to 77.6)	-55.6 (-78.1 to -9.9)
Measles	0.7 (0.6 to 0.9)	0.3 (0.2 to 0.4)	-57.1 (-63.3 to -49.9)	-77.0 (-80.3 to -73.2)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	59.9 (-69.8 to -40.3)	-76.4 (-83.7 to -68.2)
Varicella and herpes zoster	1.5 (1.3 to 1.6)	2.9 (2.7 to 3.2)	96.6 (75.5 to 126.9)	2.6 (-13.9 to 27.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	87.6 (40.9 to 176.4)	2.4 (-26.3 to 52.8)
Neglected tropical diseases and malaria	-	-	-	-	34.8 (22.5 to 51.3)	49.6 (30.7 to 77.5)	42.1 (27.7 to 56.9)	-24.6 (-33.5 to -15.8)
Malaria	1,379.3 (1,254.1 to 1,507.6)	1,806.5 (1,591.9 to 2,042.3)	31.2 (17.2 to 44.5)	-31.1 (-39.3 to -23.6)	11.9 (8.0 to 17.1)	14.5 (9.9 to 20.9)	22.4 (14.8 to 31.6)	-34.8 (-38.7 to -30.4)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	137.6 (53.5 to 286.5)	27.3 (-14.6 to 95.0)
Visceral leishmaniasis	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	126.7 (42.0 to 283.8)	17.5 (-23.2 to 81.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	126.7 (41.6 to 284.4)	17.5 (-23.4 to 82.0)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	294.9 (139.3 to 467.0)	143.3 (51.8 to 271.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	294.9 (138.4 to 469.8)	143.3 (51.6 to 272.7)
African trypanosomiasis	3.3 (2.2 to 10.3)	0.1 (0.1 to 0.2)	-98.1 (-98.5 to -97.5)	-99.0 (-99.2 to -98.7)	1.5 (0.6 to 3.0)	0.0 (0.0 to 0.1)	-98.0 (-98.4 to -97.3)	-98.9 (-99.2 to -98.6)
Schistosomiasis	859.9 (422.3 to 1,442.3)	1,611.4 (789.0 to 2,712.8)	87.4 (83.5 to 91.4)	0.1 (-2.0 to 1.9)	0.1 (3.2 to 16.9)	0.1 (5.8 to 31.7)	86.3 (65.7 to 95.0)	0.6 (-11.0 to 3.7)
Cysticercosis	0.8 (0.3 to 1.8)	0.8 (0.2 to 1.8)	-4.3 (-67.4 to 155.0)	-40.0 (-78.9 to 38.3)	0.2 (0.1 to 0.5)	0.2 (0.1 to 0.5)	-1.0 (-67.5 to 156.8)	-37.4 (-79.4 to 42.8)
Cystic echinococcosis	0.9 (0.8 to 1.0)	0.7 (0.7 to 0.8)	-20.1 (-25.5 to -9.9)	-60.7 (-63.4 to -56.2)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-18.8 (-34.8 to 0.3)	-60.1 (-67.0 to -51.9)
Lymphatic filariasis	130.0 (109.3 to 152.3)	214.2 (179.7 to 251.0)	65.2 (38.2 to 94.9)	-12.9 (-25.8 to 1.5)	3.5 (1.9 to 5.8)	5.8 (3.0 to 10.0)	67.8 (35.0 to 98.4)	-14.9 (-30.9 to 4.6)
Onchocerciasis	62.8 (31.3 to 120.0)	28.6 (16.7 to 45.0)	-54.2 (-70.9 to -26.3)	-74.2 (-84.4 to -60.4)	2.2 (1.6 to 6.4)	2.2 (0.8 to 4.1)	67.7 (-60.6 to -16.3)	-67.7 (-77.8 to -53.0)
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	0.1 (0.0 to 0.3)	1.3 (0.4 to 3.1)	809.3 (798.3 to 822.0)	389.7 (383.8 to 396.5)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.6)	766.4 (587.8 to 1,003.7)	359.0 (282.4 to 451.5)
Yellow fever	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-50.2 (-66.2 to -25.7)	-73.1 (-80.7 to -62.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.2 (-66.2 to -25.5)	-73.1 (-80.7 to -62.0)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.3 (-29.3 to 88.5)	-21.1 (-42.6 to -3.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.3 (-29.5 to 89.0)	-21.1 (-42.7 to -2.9)
Intestinal nematode infections	-	-	-	-	4.1 (2.5 to 6.8)	7.6 (4.5 to 12.4)	84.6 (56.7 to 119.4)	-1.6 (-18.6 to 21.6)
Ascariasis	784.3 (624.9 to 995.2)	1,454.0 (1,124.0 to 1,844.4)	84.9 (29.2 to 158.3)	-0.8 (-35.9 to 49.8)	1.2 (0.6 to 2.2)	2.2 (1.2 to 3.8)	86.6 (32.4 to 157.4)	0.6 (-33.3 to 48.0)
Trichuriasis	683.9 (506.9 to 898.1)	1,275.6 (939.9 to 1,721.1)	86.1 (26.3 to 184.5)	-0.3 (-38.1 to 65.9)	0.8 (0.4 to 1.3)	1.4 (0.7 to 2.5)	87.1 (29.4 to 167.5)	1.4 (-36.2 to 57.4)
Hookworm disease	500.1 (378.6 to 666.9)	933.6 (696.7 to 1,242.4)	86.4 (26.0 to 174.2)	-0.2 (-37.4 to 54.4)	2.0 (1.3 to 3.4)	4.0 (2.4 to 6.4)	82.7 (47.8 to 129.8)	-2.4 (-24.5 to 27.3)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	29.1 (22.3 to 36.0)	59.0 (55.2 to 63.4)	103.5 (62.2 to 166.4)	9.6 (-11.1 to 39.3)	1.8 (0.9 to 3.3)	4.0 (2.1 to 7.6)	121.0 (75.0 to 201.1)	23.4 (-9.3 to 74.5)
Maternal disorders	-	-	-	-	0.6 (0.4 to 0.8)	0.7 (0.5 to 1.0)	27.0 (9.8 to 48.1)	-35.3 (-43.8 to -25.8)
Maternal hemorrhage	0.7 (0.5 to 0.8)	1.1 (0.6 to 1.6)	58.0 (-14.3 to 162.1)	22.9 (-56.4 to 28.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	48.6 (-37.5 to 197.2)	-25.8 (-68.3 to 45.1)
Maternal sepsis and other maternal infections	1.1 (0.7 to 1.5)	1.5 (1.0 to 2.1)	39.8 (23.8 to 61.2)	-32.8 (-40.1 to -22.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.0 (-16.0 to 101.2)	-32.4 (-55.2 to -1.7)
Maternal hypertensive disorders	0.6 (0.3 to 0.9)	1.0 (0.5 to 1.6)	76.4 (47.6 to 84.5)	-13.7 (-26.4 to -7.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	75.4 (42.6 to 113.0)	-13.4 (-29.1 to 5.6)
Obstructed labor	1.2 (1.1 to 1.4)	1.5 (1.3 to 1.7)	19.7 (11.0 to 28.6)	-38.6 (-42.7 to -34.1)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	19.8 (3.2 to 40.4)	-38.4 (-46.7 to -29.8)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.4 (-20.6 to 257.2)	-9.9 (-58.8 to 62.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.9 (-20.7 to 257.4)	-9.9 (-58.8 to 62.5)
Other maternal disorders	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	37.1 (-13.4 to 109.0)	-30.5 (-56.5 to 5.3)
Neonatal disorders	-	-	-	-	3.0 (2.0 to 4.2)	10.2 (7.0 to 13.8)	244.1 (165.3 to 373.7)	90.1 (46.1 to 160.9)
Preterm birth complications	14.9 (10.2 to 21.8)	57.0 (41.5 to 79.0)	282.7 (222.6 to 360.1)	103.0 (72.3 to 142.0)	1.3 (0.8 to 1.9)	5.9 (4.0 to 8.0)	353.8 (212.0 to 533.3)	146.1 (73.6 to 235.1)
Neonatal encephalopathy due to birth asphyxia and trauma	10.8 (1.7 to 33.3)	18.4 (4.2 to 53.2)	76.8 (44.1 to 207.4)	7.5 (-24.0 to 63.9)	0.6 (0.3 to 1.2)	1.7 (0.9 to 2.7)	163.3 (63.1 to 306.5)	43.8 (-9.5 to 235.7)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	226.8 (211.4 to 251.6)	78.5 (70.2 to 92.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	226.7 (199.1 to 266.1)	78.5 (63.4 to 100.0)
Hemolytic disease and other neonatal jaundice	1.2 (0.5 to 2.6)	2.6 (1.4 to 4.7)	117.4 (-14.0 to 524.5)	21.0 (-51.7 to 260.5)	0.5 (0.2 to 1.0)	1.0 (0.5 to 1.9)	117.3 (-13.6 to 504.3)	21.1 (-51.7 to 249.0)
Other neonatal disorders	-	-	-	-	0.5 (0.3 to 1.1)	1.6 (0.7 to 2.8)	195.5 (33.9 to 467.2)	62.4 (-25.8 to 212.1)
Nutritional deficiencies	-	-	-	-	24.2 (16.1 to 35.3)	43.9 (29.2 to 62.7)	81.2 (62.6 to 104.2)	-5.7 (-16.1 to 4.6)
Protein-energy malnutrition	9.6 (4.1 to 19.9)	24.0 (8.9 to 53.4)	135.3 (-28.2 to 737.9)	13.9 (-55.0 to 226.4)	1.3 (0.4 to 2.5)	3.0 (0.9 to 7.1)	156.2 (-28.7 to 751.9)	15.3 (-56.2 to 239.0)
Iodine deficiency	299.2 (233.5 to 377.6)	333.3 (253.1 to 414.4)	12.0 (-24.5 to 57.3)	-39.0 (-59.9 to -11.3)	5.4 (3.1 to 8.7)	6.0 (3.5 to 9.7)	11.9 (-24.2 to 57.1)	-38.9 (-59.9 to -11.3)
Vitamin A deficiency	11.0 (9.1 to 13.0)	12.6 (10.3 to 14.9)	15.4 (2.5 to 26.4)	-40.7 (-48.0 to -33.9)	0.4 (0.3 to 0.7)	0.5 (0.3 to 0.7)	4.2 (-9.2 to 18.2)	-45.8 (-52.7 to -38.2)

Appendix Table G.4 - Congo prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	474.3 (462.7 to 488.4)	962.4 (929.5 to 994.9)	103.0 (94.2 to 111.2)	2.0 (2.9 to 13.1)	17.2 (11.5 to 24.7)	34.5 (23.1 to 49.5)	100.3 (90.7 to 114.1)	7.1 (2.7 to 14.7)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	0.1 (-47.8 to 685.4)	-6.1 (-68.0 to 207.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.6 (1.1 to 2.5)	3.1 (2.0 to 4.8)	87.8 (66.5 to 113.6)	-3.8 (-14.5 to 7.6)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.6 (0.3 to 1.0)	1.1 (0.6 to 1.9)	87.3 (48.8 to 134.0)	-4.3 (-21.8 to 14.2)
Syphilis	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.3)	7.7 (-10.8 to 32.3)	-42.6 (-51.5 to -31.9)	0.1 (0.0 to 0.1)	0.4 (0.0 to 0.1)	4.4 (-18.3 to 42.5)	42.3 (-55.3 to -27.0)
Chlamydial infection	46.8 (38.5 to 57.8)	93.4 (78.4 to 107.7)	100.4 (51.5 to 162.1)	5.2 (-19.8 to 32.9)	0.3 (0.1 to 0.5)	0.5 (0.3 to 0.9)	96.3 (35.7 to 205.7)	3.1 (-26.8 to 52.8)
Gonococcal infection	12.8 (9.7 to 15.6)	21.7 (16.8 to 27.7)	67.1 (23.7 to 167.6)	-12.6 (-34.4 to 31.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	63.1 (6.8 to 154.4)	-14.6 (-42.1 to 27.7)
Trichomoniasis	26.6 (17.9 to 36.7)	58.5 (38.7 to 79.1)	125.9 (34.8 to 248.8)	9.3 (-32.8 to 63.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	126.0 (22.6 to 289.7)	9.4 (-38.3 to 77.1)
Genital herpes	441.4 (388.8 to 496.4)	920.4 (837.5 to 1,012.6)	107.8 (79.7 to 147.2)	6.5 (-6.7 to 23.6)	0.1 (0.0 to 0.3)	0.3 (0.1 to 0.6)	108.8 (79.5 to 151.4)	6.8 (-7.0 to 25.2)
Other sexually transmitted diseases	0.9 (0.6 to 1.2)	1.4 (1.0 to 1.9)	58.3 (36.7 to 82.4)	-23.3 (-34.0 to -12.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.4 (4.2 to 132.9)	-20.1 (-45.5 to 13.1)
Hepatitis	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	42.9 (22.8 to 67.5)	-27.6 (-39.3 to -13.1)
Hepatitis A	3.7 (3.5 to 3.9)	6.8 (6.5 to 7.1)	83.9 (83.7 to 84.1)	-0.2 (-0.2 to -0.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	84.1 (63.2 to 108.6)	-0.0 (-10.5 to 11.9)
Hepatitis B	307.2 (269.0 to 345.3)	297.0 (259.5 to 331.3)	-2.9 (-18.6 to 14.9)	-48.1 (-56.0 to -38.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	3.5 (-27.7 to 41.1)	-46.1 (-60.9 to 23.8)
Hepatitis C	194.1 (93.8 to 114.7)	138.4 (124.4 to 154.0)	33.1 (15.2 to 53.0)	-28.7 (-37.2 to -18.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.7 (11.1 to 83.0)	-25.9 (-44.6 to -9.9)
Hepatitis E	0.5 (0.5 to 0.6)	1.4 (1.2 to 1.5)	164.7 (123.1 to 214.5)	38.8 (15.0 to 63.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	166.2 (107.4 to 241.0)	39.7 (9.3 to 76.2)
Leprosy	0.7 (0.4 to 0.9)	0.8 (0.7 to 0.9)	18.7 (6.5 to 61.4)	-31.0 (-44.6 to -8.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	19.4 (6.6 to 71.2)	-30.4 (-45.3 to -4.9)
Other infectious diseases	20.8 (16.0 to 26.1)	42.1 (37.1 to 47.5)	102.0 (75.4 to 138.1)	8.3 (-5.3 to 26.5)	0.8 (0.5 to 1.2)	1.6 (1.0 to 2.4)	103.0 (71.8 to 161.9)	10.9 (-7.9 to 43.6)
Non-communicable diseases	-	-	-	-	152.7 (112.5 to 196.9)	289.9 (214.8 to 373.7)	89.9 (85.6 to 94.3)	0.7 (-1.5 to 3.0)
Neoplasms	-	-	-	-	1.0 (0.7 to 1.4)	2.1 (1.5 to 2.8)	104.6 (65.2 to 160.5)	14.8 (-7.7 to 46.5)
Esophageal cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	44.8 (-0.0 to 100.9)	-16.8 (-42.2 to 14.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.8 (-3.1 to 100.2)	-18.2 (-43.3 to 15.2)
Stomach cancer	0.4 (0.4 to 0.5)	0.5 (0.4 to 0.7)	24.3 (7.9 to 66.8)	-28.5 (-47.0 to -5.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	24.2 (8.7 to 69.3)	-28.4 (-48.0 to -3.5)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	79.9 (51.5 to 145.4)	-0.8 (-3.1 to 40.7)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	120.9 (8.7 to 343.4)	23.9 (-39.3 to 152.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	110.6 (15.2 to 301.6)	19.6 (-35.9 to 131.6)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	362.4 (96.4 to 1,254.7)	167.0 (16.4 to 681.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	332.1 (99.6 to 1,049.5)	143.7 (16.9 to 565.1)
Liver cancer due to alcohol use	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-11.5 (-56.8 to 56.0)	-48.3 (-74.9 to -8.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.9 (-53.4 to 42.9)	-48.0 (-72.8 to -15.1)
Liver cancer due to other causes	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	34.4 (-32.0 to 165.4)	-24.6 (-62.1 to 51.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.8 (-27.8 to 128.4)	0.6 (-60.8 to 27.6)
Larynx cancer	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	29.3 (-14.5 to 99.3)	-26.2 (50.6 to 13.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.4 (-19.9 to 96.4)	-25.7 (-54.0 to 12.5)
Tracheal, bronchus and lung cancer	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	34.9 (-3.4 to 87.2)	-21.5 (-43.6 to 7.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	35.2 (5.1 to 85.5)	-21.7 (-44.6 to 6.7)
Breast cancer	1.8 (1.4 to 2.4)	4.5 (3.3 to 6.0)	149.2 (63.1 to 246.6)	35.2 (-11.2 to 84.9)	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.5)	126.7 (51.2 to 220.2)	23.5 (-16.0 to 72.1)
Cervical cancer	2.0 (1.4 to 2.7)	2.5 (1.7 to 3.5)	24.4 (-14.9 to 96.9)	-84.4 (-54.1 to 14.4)	0.2 (0.1 to 0.3)	0.4 (0.1 to 0.3)	34.4 (-16.5 to 93.1)	-24.4 (-54.8 to -0.4)
Uterine cancer	0.5 (0.3 to 0.8)	0.7 (0.4 to 1.1)	37.7 (-17.6 to 140.7)	-21.5 (52.6 to 34.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	36.1 (-21.4 to 130.0)	-23.1 (-54.2 to 29.1)
Prostate cancer	0.9 (0.6 to 1.5)	4.0 (2.4 to 6.8)	331.5 (143.3 to 743.0)	149.6 (41.3 to 391.5)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.7)	258.6 (99.0 to 577.5)	109.3 (16.3 to 291.5)
Colon and rectum cancer	0.7 (0.6 to 0.8)	1.7 (1.4 to 2.1)	147.3 (94.9 to 215.7)	39.0 (10.5 to 73.7)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	132.1 (81.7 to 195.7)	30.2 (2.5 to 65.2)
Lip and oral cavity cancer	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.9)	67.7 (14.4 to 153.2)	-6.0 (-31.9 to 39.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	62.8 (12.9 to 146.0)	-8.8 (-36.8 to 35.3)
Nasopharynx cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	67.3 (4.4 to 168.9)	-12.6 (-45.8 to 39.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.6 (2.0 to 152.2)	-16.6 (-47.3 to 31.3)
Other pharynx cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	63.1 (-8.2 to 186.5)	-8.4 (-47.9 to 58.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.0 (-10.0 to 172.5)	-10.3 (-48.5 to 50.9)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	38.9 (-24.4 to 118.4)	-20.8 (-56.4 to 24.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.4 (-24.8 to 115.6)	23.0 (-58.0 to 25.0)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	84.1 (35.4 to 147.3)	4.6 (-22.8 to 39.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.6 (37.5 to 140.5)	2.4 (-22.8 to 37.9)
Malignant skin melanoma	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	136.4 (63.8 to 228.8)	25.7 (-13.8 to 74.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	124.4 (54.2 to 219.9)	18.6 (-17.8 to 67.0)
Non-melanoma skin cancer	0.2 (0.2 to 0.3)	0.6 (0.5 to 0.8)	182.4 (117.4 to 274.8)	53.4 (16.3 to 91.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	200.9 (111.8 to 332.3)	64.0 (9.1 to 145.9)
Ovarian cancer	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	61.7 (9.3 to 138.9)	-11.7 (-40.8 to 30.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	58.4 (2.6 to 147.4)	-13.5 (-44.5 to 34.8)
Testicular cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	242.6 (91.2 to 519.1)	66.4 (-18.8 to 188.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	216.5 (72.7 to 472.1)	53.1 (-16.4 to 162.7)
Kidney cancer	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.5)	73.6 (18.4 to 158.0)	31.8 (-33.8 to 40.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.8 (13.5 to 139.1)	7.5 (-35.4 to 32.7)
Bladder cancer	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	36.8 (-1.2 to 91.1)	-21.2 (-43.8 to 9.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	34.7 (-3.8 to 91.1)	-22.3 (-44.9 to 8.4)
Brain and nervous system cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	152.2 (67.9 to 257.5)	30.8 (-4.2 to 74.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	133.5 (67.8 to 219.3)	20.4 (-10.6 to 57.9)
Thyroid cancer	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	99.5 (30.8 to 195.2)	4.2 (-32.1 to 55.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.5 (22.6 to 185.6)	-2.5 (-35.7 to 49.5)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.2 (0.5 to 116.0)	-16.1 (-43.5 to 22.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.3 (9.9 to 117.7)	-14.8 (-42.6 to 24.3)
Hodgkin lymphoma	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	151.4 (61.7 to 312.8)	34.5 (-12.2 to 113.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	130.5 (48.8 to 271.3)	22.7 (-19.6 to 88.1)
Non-Hodgkin lymphoma	0.4 (0.3 to 0.6)	0.9 (0.7 to 1.2)	117.5 (64.6 to 206.2)	18.3 (-13.1 to 63.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	109.3 (55.2 to 188.2)	12.9 (-16.5 to 56.8)
Multiple myeloma	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	104.9 (36.2 to 216.0)	15.5 (-23.8 to 76.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.6 (24.2 to 213.8)	9.4 (-29.2 to 75.0)
Leukemia	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.6)	151.4 (47.0 to 306.0)	31.8 (-7.7 to 82.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	122.3 (55.6 to 222.3)	16.3 (-15.0 to 56.7)
Other neoplasms	0.9 (0.6 to 1.7)	3.4 (2.5 to 4.9)	280.9 (131.7 to 464.7)	97.4 (36.3 to 173.2)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	242.9 (122.1 to 383.8)	74.0 (22.7 to 135.5)
Cardiovascular diseases	-	-	-	-	3.5 (2.4 to 4.9)	7.1 (4.9 to 9.8)	104.9 (64.6 to 143.1)	10.8 (-11.2 to 33.7)
Rheumatic heart disease	19.5 (18.5 to 20.5)	44.1 (41.4 to 46.8)	125.6 (106.7 to 145.7)	21.3 (12.1 to 30.7)	1.0 (0.6 to 1.4)	2.2 (1.4 to 3.1)	121.6 (98.7 to 145.2)	18.1 (2.9 to 34.1)
Ischemic heart disease	15.6 (13.0 to 18.7)	24.4 (21.4 to 29.5)	57.2 (23.3 to 94.4)	37.2 (-27.7 to 12.4)	0.7 (0.5 to 1.1)	1.1 (0.7 to 1.6)	69.8 (6.4 to 100.5)	-13.3 (-37.3 to 17.1)
Cerebrovascular disease	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	76.9 (46.4 to 119.0)	-4.2 (-22.3 to 20.5)
Ischemic stroke	1.0 (0.9 to 1.1)	1.7 (1.5 to 2.0)	75.0 (42.0 to 115.2)	-4.6 (-23.0 to 18.1)	0.2 (0.0 to 0.2)	0.3 (0.2 to 0.4)	76.2 (42.9 to 122.4)	-3.7 (-23.0 to 22.5)
Hemorrhagic stroke	0.3 (0.2 to 0.3)	0.5 (0.4 to 0.6)	76.1 (37.3 to 127.2)	-7.3 (-28.1 to 19.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	78.8 (37.5 to 133.8)	-6.2 (-28.2 to 23.8)
Hypertensive heart disease	3.2 (2.4 to 4.0)	6.6 (5.1 to 8.3)	109.2 (42.4 to 206.7)	17.2 (-22.9 to 67.8)	0.3 (0.2 to 0.5)	0.7 (0.5 to 1.0)	109.6 (43.5 to 211.4)	18.0 (-21.1 to 70.5)
Cardiomyopathy and myocarditis	1.8 (1.8 to 3.0)	3.9 (3.6 to 5.5)	109.8 (40.0 to 168.5)	15.6 (-24.2 to 59.6)	0.1 (0.2 to 0.4)	0.3 (0.3 to 0.7)	114.0 (38.3 to 170.6)	17.4 (-24.6 to 63.6)
Atrial fibrillation and flutter	25.7 (18.9 to 33.0)	48.4 (37.4 to 57.6)	90.5 (37.3 to 145.6)	7.7 (-16.6 to 34.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.2 (-36.8 to 231.7)	-25.2 (-63.8 to 87.3)
Endocarditis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	89.6 (36.3 to 165.5)	11.0 (-29.5 to 72.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.1 (34.1 to 203.8)	17.3 (-32.6 to 101.5)
Other cardiovascular and circulatory diseases	11.9 (6.7 to 19.8)	38.5 (14.8 to 41.8)	145.9 (5.6 to 386.4)	34.5 (-45.3 to 183.7)	0.8 (0.4 to 1.4)	2.0 (1.0 to 3.2)	145.2 (5.2 to 391.0)	34.5 (-45.4 to 185.6)
Chronic respiratory diseases	-	-	-	-	9.9 (6.7 to 13.6)	19.6 (13.5 to 27.1)	96.1 (77.1 to 124.4)	4.0 (-7.1 to 15.5)
Chronic obstructive pulmonary disease	84.4 (80.8 to 87.9)	157.7 (150.8 to 164.2)	87.0 (81.1 to 93.0)	-0.2 (-3.1 to 2.7)	6.8 (4.4 to 9.6)	13.1 (8.5 to 18.6)	92.1 (71.3 to 116.0)	2.5 (-8.7 to 14.9)

Appendix Table G.4 - Congo prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	-	-
Silicosis	0.0	0.0	67.0	-9.1	(0.0 to 0.0)	(0.0 to 0.0)	(72.1 to 83.6)	(-7.1 to -1.1)
Asbestosis	(0.0 to 0.0)	(0.0 to 0.0)	(60.9 to 75.9)	(-12.5 to -4.0)	0.0	0.0	66.9	-9.1
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	88.1	0.7	0.0	0.0	88.1	0.8
Asthma	(41.8 to 65.2)	(106.2 to 137.1)	(79.2 to 204.9)	(-2.0 to 43.5)	(1.4 to 3.5)	(3.3 to 7.5)	(79.5 to 209.6)	(-2.0 to 45.1)
Interstitial lung disease and pulmonary sarcoidosis	0.1	0.1	104.5	6.1	0.0	0.0	104.2	6.0
Other chronic respiratory diseases	-	-	-	-	0.7	1.2	73.2	-7.8
Cirrhosis	-	-	-	-	(0.4 to 1.3)	(0.6 to 2.3)	(14.2 to 167.9)	(-39.0 to 40.9)
Cirrhosis due to hepatitis B	0.4	0.4	-7.3	-45.0	(0.1 to 0.3)	(0.2 to 0.4)	(38.2 to 76.7)	(-23.9 to -5.4)
Cirrhosis due to hepatitis C	0.2	0.7	182.2	42.1	0.0	0.1	183.8	43.2
Cirrhosis due to alcohol use	0.3	0.3	5.4	-39.2	0.0	0.1	6.8	-38.8
Cirrhosis due to other causes	0.3	0.5	96.2	16.0	(0.0 to 0.1)	(0.0 to 0.1)	(43.0 to 61.3)	(-66.4 to -9.0)
Digestive diseases	-	-	-	-	3.0	5.4	76.5	-7.7
Peptic ulcer disease	19.0	20.9	9.9	-36.9	(2.1 to 4.1)	(3.7 to 7.4)	(59.7 to 97.5)	(-16.1 to 2.5)
Gastritis and duodenitis	26.3	45.2	72.0	-4.6	0.7	0.8	17.0	-34.2
Appendicitis	0.3	0.6	106.0	3.5	0.1	0.2	110.3	5.3
Paralytic ileus and intestinal obstruction	0.0	0.1	91.3	-0.4	(0.0 to 0.1)	(0.1 to 0.3)	(26.9 to 233.8)	(-32.5 to 63.3)
Inguinal, femoral, and abdominal hernia	6.2	10.3	66.6	-12.9	0.1	0.1	68.3	-12.2
Inflammatory bowel disease	2.2	5.4	141.3	26.1	(0.0 to 0.1)	(0.1 to 0.2)	(32.4 to 109.2)	(-32.6 to 12.9)
Vascular intestinal disorders	0.0	0.0	84.1	1.7	(0.3 to 0.6)	(0.8 to 1.6)	(122.4 to 168.3)	(17.3 to 38.0)
Gallbladder and biliary diseases	0.8	1.5	97.8	0.1	0.0	0.0	97.4	7.3
Pancreatitis	0.4	0.8	103.8	4.4	(0.1 to 0.2)	(0.2 to 0.3)	(72.0 to 140.0)	(-11.5 to 32.5)
Other digestive diseases	-	-	-	-	0.4	0.7	102.3	5.9
Neurological disorders	-	-	-	-	9.6	20.1	110.2	11.7
Alzheimer disease and other dementias	5.5	10.1	84.7	6.3	(6.4 to 13.3)	(13.7 to 28.3)	(83.2 to 140.7)	(0.5 to 26.8)
Parkinson disease	0.2	0.3	72.4	-1.0	0.0	0.0	73.9	-0.0
Epilepsy	2.9	5.6	92.2	4.3	0.9	1.8	102.3	10.0
Multiple sclerosis	0.1	0.2	123.8	14.2	(0.4 to 1.5)	(0.8 to 3.0)	(4.4 to 312.6)	(-47.6 to 122.3)
Migraine	162.3	388.4	90.5	0.2	(0.0 to 0.1)	(0.1 to 0.1)	(81.7 to 170.7)	(6.9 to 37.6)
Tension-type headache	289.7	575.3	97.9	2.6	0.4	0.9	99.3	3.1
Medication overuse headache	10.2	30.5	195.6	52.5	(0.2 to 0.8)	(0.4 to 1.5)	(67.3 to 121.4)	(-12.2 to 15.0)
Other neurological disorders	0.0	0.0	77.3	-6.9	0.4	0.7	98.8	13.2
Mental and substance use disorders	-	-	-	-	51.9	98.8	90.4	0.5
Schizophrenia	4.8	9.6	99.2	0.7	(6.4 to 68.4)	(69.4 to 131.3)	(85.1 to 95.9)	(-1.9 to 3.3)
Alcohol use disorders	26.8	46.8	74.2	-10.3	2.6	4.6	74.5	-10.0
Drug use disorders	-	-	-	-	2.9	5.7	97.5	0.5
Opioid use disorders	3.6	7.5	107.2	0.8	1.5	3.1	109.2	1.7
Cocaine use disorders	(2.4 to 5.4)	(5.0 to 11.0)	(86.3 to 135.0)	(-9.0 to 13.7)	(0.8 to 2.3)	(1.8 to 4.8)	(84.8 to 137.3)	(-9.9 to 15.5)
Amphetamine use disorders	3.9	7.0	81.7	-2.2	0.5	0.9	82.6	-2.0
Cannabis use disorders	2.7	5.1	86.3	0.1	0.1	0.1	87.2	0.5
Other drug use disorders	-	-	-	-	0.7	1.2	86.0	-1.6
Depressive disorders	-	-	-	-	(0.4 to 1.0)	(0.8 to 1.9)	(35.4 to 159.0)	(-27.4 to 36.4)
Major depressive disorder	98.0	189.1	92.9	1.9	20.0	38.7	93.6	2.2
Dysthymia	23.5	45.3	92.6	-0.2	2.2	4.3	93.6	0.2
Bipolar disorder	13.1	25.5	94.3	-0.1	2.6	5.2	95.7	0.5
Anxiety disorders	(11.2 to 15.0)	(21.9 to 28.9)	(82.1 to 107.1)	(-5.3 to 5.2)	(1.6 to 4.0)	(3.2 to 7.8)	(79.8 to 112.2)	(-6.2 to 7.6)
Eating disorders	-	-	-	-	0.6	1.1	88.4	0.6
Anorexia nervosa	0.4	0.8	92.4	3.4	(0.3 to 0.9)	(0.6 to 1.7)	(72.4 to 105.4)	(-7.3 to 9.7)
Bulimia nervosa	2.4	4.4	87.0	-0.1	0.5	0.9	87.8	0.2
Autistic spectrum disorders	-	-	-	-	2.8	5.3	87.6	0.6
Autism	7.3	13.7	86.9	0.2	1.8	3.4	87.3	0.6
Asperger syndrome	10.5	19.7	87.0	0.3	1.0	2.0	87.4	0.6
Attention-deficit/hyperactivity disorder	17.6	31.3	77.7	-0.1	0.4	0.7	79.6 to 95.6	(-3.2 to 4.2)
Conduct disorder	25.9	45.6	76.0	0.1	1.1	2.1	84.5 to 92.1	(-7.0 to 8.1)
Idiopathic intellectual disability	(24.4 to 27.4)	(43.0 to 48.3)	(75.9 to 76.1)	(-0.1 to -0.1)	(0.0 to 0.5)	(3.4 to 8.0)	(62.2 to 84.1)	(-4.4 to 4.5)
Other mental and substance use disorders	29.5	57.2	93.8	0.2	2.2	4.3	95.1	0.8
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	11.2	21.2	89.2	0.3
Diabetes mellitus	6.8	11.0	63.9	-16.0	(7.8 to 15.2)	(14.9 to 28.7)	(77.0 to 100.5)	(-5.5 to 6.1)
Acute glomerulonephritis	0.0	0.0	50.4	-17.7	0.0	0.0	50.4	-
Chronic kidney disease	-	-	-	-	3.3	6.3	91.0	2.7
Chronic kidney disease due to diabetes mellitus	43.6	78.1	75.2	-4.5	0.6	1.2	84.6	0.4
Chronic kidney disease due to hypertension	75.8	135.5	81.1	0.3	0.9	1.8	97.9	4.1
Chronic kidney disease due to glomerulonephritis	64.0	124.1	91.2	0.8	1.1	2.0	94.6	3.4
Chronic kidney disease due to other causes	50.1	95.9	89.1	0.5	0.7	1.3	92.1	-0.3
Urinary diseases and male infertility	-	-	-	-	0.8	1.4	79.9	2.2

Appendix Table G.4 - Congo prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.5 (0.4 to 0.5)	0.9 (0.8 to 1.0)	101.6 (81.3 to 121.2)	0.0 (-2.0 to 16.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.9 (58.7 to 157.2)	1.0 (-11.9 to 30.0)
Urolithiasis	5.0 (3.8 to 6.4)	8.5 (6.4 to 10.9)	67.7 (51.5 to 91.9)	-7.4 (-15.1 to 4.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	99.8 (76.9 to 125.2)	6.1 (-3.7 to 17.2)
Benign prostatic hyperplasia	16.8 (15.4 to 18.2)	29.3 (27.0 to 32.0)	73.9 (54.8 to 94.2)	1.5 (-9.0 to 13.1)	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.5)	75.0 (55.2 to 96.3)	2.1 (-8.7 to 14.3)
Male infertility due to other causes	12.4 (8.6 to 17.1)	24.0 (17.8 to 32.0)	93.8 (71.5 to 206.7)	-5.9 (-41.5 to 49.8)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	93.9 (19.8 to 200.2)	-5.0 (-41.2 to 49.8)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	98.2 (31.4 to 171.3)	3.0 (-29.8 to 42.9)
Gynecological diseases	-	-	-	-	2.4 (1.5 to 3.6)	4.9 (3.2 to 7.3)	104.4 (76.2 to 137.2)	0.7 (-11.4 to 16.2)
Uterine fibroids	35.3 (32.0 to 38.4)	71.3 (64.3 to 77.7)	102.0 (101.2 to 102.7)	-1.7 (-1.7 to -1.6)	0.7 (0.4 to 1.0)	1.3 (0.8 to 2.1)	104.0 (86.4 to 131.3)	0.1 (-8.2 to 12.1)
Polycystic ovarian syndrome	32.8 (29.7 to 36.2)	69.7 (63.4 to 77.9)	111.7 (85.4 to 147.3)	3.2 (-8.6 to 20.3)	0.3 (0.1 to 0.6)	0.7 (0.3 to 1.2)	112.2 (85.2 to 147.9)	3.7 (-8.6 to 20.5)
Female infertility due to other causes	17.1 (12.1 to 22.9)	36.6 (27.5 to 47.8)	112.2 (47.0 to 225.7)	1.3 (-32.1 to 56.7)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	111.8 (47.6 to 227.7)	1.6 (-31.8 to 58.0)
Endometriosis	3.3 (2.8 to 3.8)	6.2 (5.3 to 7.2)	87.9 (51.5 to 133.7)	-8.9 (-25.5 to 12.3)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	87.5 (48.5 to 140.9)	9.1 (-26.0 to 15.4)
Genital prolapse	70.0 (60.4 to 80.5)	140.5 (114.8 to 164.9)	100.8 (55.7 to 149.7)	3.7 (-15.8 to 26.9)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.8)	101.0 (54.8 to 154.1)	4.0 (-16.8 to 28.3)
Premenstrual syndrome	72.6 (50.4 to 100.4)	149.9 (98.3 to 211.4)	106.3 (24.0 to 231.0)	2.5 (-37.5 to 69.4)	0.6 (0.3 to 1.0)	1.7 (0.7 to 2.1)	106.7 (19.9 to 233.7)	1.7 (-38.4 to 67.2)
Other gynecological diseases	6.9 (4.4 to 9.3)	14.7 (10.3 to 19.2)	111.1 (45.9 to 235.4)	6.7 (-26.4 to 69.9)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	105.7 (19.8 to 315.5)	3.9 (-39.0 to 106.7)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	3.3 (2.2 to 4.7)	6.0 (4.0 to 8.5)	81.5 (64.8 to 99.8)	-1.9 (-9.7 to 7.6)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.4 (13.0 to 92.2)	-3.5 (-38.3 to 5.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.3 (44.9 to 85.4)	-3.1 (-20.7 to 1.2)
Thalassemia trait	16.5 (12.5 to 20.0)	29.3 (21.8 to 36.0)	81.9 (47.4 to 88.3)	-2.6 (-21.0 to 0.8)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	68.2 (39.0 to 104.7)	-8.4 (-24.3 to 10.2)
Sickle cell disorders	5.4 (4.7 to 5.9)	10.5 (9.5 to 11.4)	95.1 (72.8 to 125.4)	7.2 (-6.0 to 23.1)	0.6 (0.4 to 0.8)	1.1 (0.8 to 1.5)	94.9 (59.5 to 129.4)	7.1 (-11.6 to 25.4)
Sickle cell trait	390.5 (368.7 to 410.1)	722.7 (681.5 to 755.8)	85.0 (79.2 to 92.2)	1.8 (-4.1 to 2.9)	3.1 (1.2 to 2.6)	3.1 (2.0 to 4.5)	75.1 (35.6 to 105.6)	-5.8 (-21.9 to 10.1)
G6PD deficiency	425.0 (401.8 to 446.7)	782.7 (736.9 to 820.0)	84.3 (71.1 to 98.1)	-1.4 (-8.4 to 5.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	76.6 (0.8 to 226.3)	-2.4 (-41.3 to 65.3)
G6PD trait	592.1 (590.4 to 593.7)	1,107.9 (1,105.7 to 1,109.7)	87.1 (86.5 to 87.8)	-0.1 (-0.4 to 0.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	90.6 (-32.8 to 435.3)	7.3 (-62.6 to 181.3)
Other hemoglobinopathies and hemolytic anemias	19.3 (15.9 to 22.4)	38.2 (33.1 to 43.0)	97.3 (66.1 to 144.4)	8.5 (-6.6 to 28.3)	0.6 (0.4 to 0.9)	1.2 (0.7 to 1.7)	91.4 (45.6 to 168.8)	4.2 (-18.3 to 39.2)
Endocrine, metabolic, blood, and immune disorders	26.1 (22.9 to 29.0)	50.8 (42.4 to 58.6)	94.6 (56.7 to 141.4)	0.9 (-12.7 to 22.9)	1.8 (0.6 to 1.3)	1.8 (1.1 to 2.7)	93.9 (70.3 to 149.5)	3.8 (-20.4 to 29.3)
Musculoskeletal disorders	-	-	-	-	28.4 (20.1 to 37.6)	53.7 (38.1 to 71.0)	89.2 (40.3 to 108.4)	-0.4 (-6.7 to 7.6)
Rheumatoid arthritis	5.6 (5.4 to 5.8)	9.6 (9.1 to 10.0)	70.5 (61.4 to 81.2)	-10.2 (-15.3 to -4.4)	1.3 (0.9 to 1.7)	2.3 (1.6 to 3.0)	71.9 (59.1 to 87.4)	-9.5 (-15.9 to -2.0)
Osteoarthritis	48.5 (46.4 to 50.3)	88.3 (84.9 to 92.0)	82.0 (72.2 to 93.0)	0.8 (-4.2 to 6.7)	2.9 (2.1 to 3.9)	5.4 (3.7 to 7.3)	83.1 (72.8 to 94.9)	1.3 (-3.8 to 7.5)
Low back and neck pain	-	-	-	-	20.9 (14.5 to 28.1)	39.5 (27.7 to 53.7)	90.5 (71.8 to 118.7)	-0.5 (-9.7 to 12.5)
Low back pain	113.0 (106.5 to 119.3)	211.0 (199.7 to 223.7)	86.8 (73.2 to 101.8)	-1.3 (-8.2 to 6.3)	12.4 (8.5 to 17.1)	23.4 (15.7 to 32.7)	87.7 (73.7 to 103.2)	-0.9 (-7.9 to 6.8)
Neck pain	86.9 (63.8 to 102.3)	169.1 (138.4 to 196.6)	93.1 (54.4 to 165.2)	0.2 (-20.1 to 32.3)	8.5 (5.5 to 12.0)	16.5 (10.9 to 23.3)	93.9 (55.7 to 169.3)	0.6 (-19.4 to 32.5)
Gout	0.3 (0.3 to 0.4)	0.6 (0.5 to 0.7)	90.7 (59.1 to 123.3)	2.5 (-14.0 to 19.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.4 (47.2 to 148.7)	2.8 (-21.2 to 34.0)
Other musculoskeletal disorders	35.9 (28.1 to 44.5)	68.2 (51.4 to 84.7)	91.6 (60.0 to 111.8)	1.9 (-14.5 to 12.2)	3.2 (2.1 to 4.7)	6.1 (3.9 to 9.0)	89.8 (59.7 to 115.4)	3.8 (-13.7 to 13.3)
Other non-communicable diseases	-	-	-	-	34.0 (22.0 to 50.3)	61.6 (40.0 to 92.3)	81.2 (74.6 to 87.8)	-3.6 (-6.7 to -0.5)
Congenital anomalies	-	-	-	-	1.9 (1.3 to 2.7)	4.0 (2.7 to 5.6)	111.8 (83.4 to 152.7)	13.5 (-0.9 to 34.8)
Neural tube defects	0.5 (0.4 to 0.6)	1.4 (1.2 to 1.7)	204.3 (143.8 to 285.1)	73.7 (38.5 to 121.2)	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.5)	220.4 (120.7 to 388.4)	83.6 (28.5 to 176.6)
Congenital heart anomalies	4.0 (3.2 to 5.3)	12.5 (10.2 to 15.7)	209.1 (121.0 to 320.2)	76.6 (25.2 to 141.2)	0.1 (0.1 to 0.1)	0.4 (0.2 to 0.7)	195.6 (113.0 to 305.7)	70.8 (23.7 to 134.1)
Orofacial clefts	0.6 (0.4 to 0.8)	2.0 (1.5 to 2.7)	234.6 (113.6 to 421.2)	93.3 (23.1 to 202.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	203.4 (83.9 to 400.2)	78.5 (6.8 to 192.6)
Down syndrome	1.7 (1.4 to 2.2)	3.9 (3.2 to 4.6)	127.9 (65.8 to 197.9)	29.9 (-6.0 to 69.0)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	131.1 (65.4 to 208.3)	33.9 (-4.5 to 79.3)
Turner syndrome	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	120.3 (41.1 to 255.0)	20.4 (-23.0 to 92.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.1 (41.8 to 252.1)	21.2 (-22.7 to 91.9)
Klinefelter syndrome	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	81.6 (47.8 to 166.3)	-1.7 (-20.1 to 44.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.9 (53.6 to 178.1)	-1.8 (-20.3 to 45.6)
Chromosomal unbalanced rearrangements	2.5 (2.0 to 3.3)	6.0 (4.8 to 8.0)	136.2 (71.3 to 223.5)	0.3 (-3.4 to 84.6)	0.7 (0.2 to 0.4)	0.7 (0.5 to 1.0)	139.2 (68.2 to 232.2)	39.4 (-2.5 to 91.5)
Other congenital anomalies	10.5 (7.4 to 14.1)	17.0 (11.6 to 24.3)	61.3 (37.6 to 93.3)	-13.8 (-26.3 to 2.4)	1.1 (0.6 to 1.8)	2.0 (1.1 to 3.3)	76.6 (46.2 to 129.3)	-7.2 (-22.0 to 20.1)
Skin and subcutaneous diseases	-	-	-	-	13.3 (8.5 to 20.6)	25.7 (16.4 to 39.3)	93.1 (84.9 to 102.1)	3.8 (-0.9 to 9.1)
Dermatitis	142.9 (120.0 to 165.3)	270.8 (226.5 to 314.2)	89.5 (87.6 to 91.3)	0.0 (-0.0 to 0.1)	5.1 (3.2 to 7.3)	9.6 (6.0 to 13.8)	87.6 (82.0 to 93.2)	0.3 (-1.9 to 2.8)
Psoriasis	15.6 (13.3 to 17.9)	29.5 (25.1 to 33.9)	89.5 (87.8 to 91.0)	0.0 (-0.0 to 0.1)	1.3 (0.9 to 1.8)	2.4 (1.6 to 3.4)	90.0 (78.9 to 103.8)	0.5 (-4.7 to 6.4)
Cellulitis	0.5 (0.4 to 0.6)	0.9 (0.7 to 1.2)	84.8 (57.6 to 108.6)	-2.6 (-16.9 to 9.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	84.5 (43.4 to 140.4)	-2.6 (-22.3 to 19.9)
Pyoderma	4.0 (3.0 to 5.2)	6.9 (5.2 to 8.9)	72.8 (62.2 to 85.8)	-4.2 (-10.6 to 3.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	73.3 (56.5 to 92.7)	-4.2 (-13.2 to 5.7)
Scabies	17.0 (15.3 to 18.9)	38.2 (34.0 to 42.2)	125.0 (90.0 to 158.1)	16.1 (-0.1 to 33.7)	0.4 (0.2 to 0.7)	1.0 (0.6 to 1.6)	125.3 (90.7 to 159.0)	16.6 (-0.8 to 34.1)
Fungal skin diseases	378.6 (304.7 to 479.9)	701.5 (564.3 to 886.5)	85.2 (83.3 to 87.5)	0.1 (0.0 to 0.1)	2.1 (0.8 to 4.6)	4.0 (2.6 to 8.6)	85.5 (83.8 to 88.2)	0.2 (-0.4 to 0.9)
Viral skin diseases	47.9 (37.0 to 58.2)	90.5 (69.3 to 109.6)	88.8 (84.8 to 92.6)	2.6 (0.8 to 4.6)	1.5 (0.9 to 2.3)	2.8 (1.6 to 4.3)	89.2 (82.3 to 96.8)	2.9 (-0.1 to 6.6)
Acne vulgaris	116.1 (90.9 to 139.8)	235.5 (190.6 to 286.4)	103.0 (48.1 to 178.5)	12.3 (-18.0 to 49.6)	1.2 (0.6 to 2.4)	2.5 (1.2 to 4.8)	103.0 (48.4 to 178.0)	12.3 (-17.8 to 50.1)
Alopecia areata	2.1 (1.9 to 2.4)	4.1 (3.7 to 4.6)	92.3 (64.7 to 124.2)	1.6 (-12.4 to 17.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	91.4 (59.0 to 134.3)	1.7 (-13.8 to 20.1)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.5 (47.7 to 140.1)	1.0 (-22.6 to 30.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.6 (47.7 to 140.1)	1.0 (-22.6 to 30.7)
Urticaria	10.9 (7.8 to 14.6)	25.2 (16.2 to 34.6)	147.3 (34.3 to 288.9)	25.8 (-22.6 to 100.6)	0.6 (0.4 to 1.0)	1.5 (0.8 to 2.4)	149.1 (36.5 to 292.1)	26.5 (-23.6 to 103.7)
Decubitus ulcer	0.3 (0.2 to 0.3)	0.6 (0.5 to 0.6)	93.0 (54.6 to 136.3)	7.1 (-21.7 to 36.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	94.4 (53.8 to 142.5)	7.6 (-21.2 to 40.2)
Other skin and subcutaneous diseases	144.7 (100.5 to 201.7)	271.2 (189.1 to 375.0)	87.4 (80.9 to 94.8)	0.8 (-1.3 to 3.1)	0.8 (0.4 to 1.7)	1.6 (0.7 to 3.2)	88.0 (81.6 to 95.7)	1.1 (-1.2 to 3.5)
Sense organ diseases	-	-	-	-	14.9 (9.7 to 22.3)	24.5 (16.0 to 37.8)	66.4 (55.7 to 76.6)	-9.2 (-13.5 to -4.6)
Glaucoma	3.7 (3.0 to 4.5)	5.0 (4.1 to 6.0)	35.1 (14.7 to 58.4)	-26.1 (-37.8 to -11.5)	0.2 (0.2 to 0.3)	0.4 (0.2 to 0.5)	45.4 (22.8 to 67.1)	-18.6 (-30.9 to -4.1)
Cataract	12.3 (9.8 to 14.9)	16.7 (13.5 to 20.3)	36.4 (18.6 to 50.3)	-22.1 (-30.6 to -14.6)	0.8 (0.5 to 1.1)	1.1 (0.7 to 1.5)	37.5 (23.7 to 49.6)	-21.7 (-28.7 to -15.4)
Macular degeneration	2.9 (2.1 to 3.7)	6.3 (4.9 to 7.9)	117.9 (74.8 to 189.6)	23.8 (-1.0 to 69.3)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	109.7 (72.4 to 172.8)	17.0 (-3.1 to 53.0)
Uncorrected refractive error	348.9 (321.1 to 371.3)	616.8 (565.3 to 673.9)	76.7 (59.9 to 95.2)	4.4 (-12.1 to 3.7)	4.8 (2.8 to 8.0)	8.2 (4.6 to 13.7)	68.6 (55.9 to 82.9)	-8.9 (-14.7 to -2.0)
Age-related and other hearing loss	292.3 (249.6 to 330.8)	496.5 (420.0 to 568.1)	70.0 (63.2 to 76.4)	-6.7 (-9.3 to -3.7)	7.1 (4.1 to 11.0)	11.7 (7.0 to 18.5)	65.9 (46.3 to 86.8)	-7.4 (-15.0 to 0.5)
Other vision loss	5.7 (4.7 to 6.7)	8.0 (6.7 to 9.2)	40.6 (28.5 to 54.8)	-25.2 (-32.4 to -16.9)	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.7)	32.3 (18.7 to 46.1)	-25.8 (-32.3 to -18.6)
Other sense organ diseases	56.6 (53.6 to 59.4)	104.8 (99.3 to 109.6)	85.1 (72.1 to 99.0)	-0.4 (-6.6 to 5.6)	1.5 (0.9 to 2.2)	2.8 (1.7 to 4.2)	85.4 (69.5 to 101.1)	-0.1 (-7.1 to 6.5)
Oral disorders	-	-	-	-	3.9 (2.3 to 6.1)	7.1 (4.2 to 11.2)	83.1 (74.8 to 91.5)	-2.4 (-7.3 to 2.0)
Deciduous caries	216.3 (208.8 to 224.1)	398.4 (382.1 to 415.0)	84.5 (73.8 to 94.5)	1.0 (-4.9 to 6.4)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	84.1 (70.8 to 100.4)	0.6 (-6.7 to 9.6)
Permanent caries	713.2 (679.5 to 751.0)	1,344.5 (1,276.6 to 1,407.3)	88.6 (75.7 to 101.7)	0.6 (-5.5 to 6.2)	0.7 (0.3 to 1.4)	1.3 (0.6 to 2.6)	88.9 (75.1 to 102.8)	0.8 (-5.5 to 6.9)
Periodontal diseases								

Appendix Table G.4 - Congo prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	44.9 (41.9 to 47.8)	75.8 (70.7 to 80.8)	68.8 (54.1 to 86.1)	-6.2 (-14.1 to 2.5)	1.2 (0.8 to 1.7)	2.1 (1.4 to 2.8)	69.8 (54.1 to 87.5)	-5.6 (-13.7 to 3.2)
Other oral disorders	34.8 (32.8 to 36.7)	65.9 (62.2 to 69.9)	89.8 (75.9 to 104.7)	0.2 (-6.9 to 7.4)	1.0 (0.6 to 1.5)	1.9 (1.2 to 2.8)	90.3 (74.9 to 106.3)	0.4 (-7.0 to 8.4)
Injuries	-	-	-	-	9.9 (7.5 to 12.7)	15.0 (10.9 to 20.2)	50.3 (34.7 to 80.0)	-16.6 (-24.9 to 0.5)
Transport injuries	-	-	-	-	3.8 (2.9 to 5.0)	4.4 (3.2 to 6.0)	15.1 (3.0 to 28.9)	-35.2 (-41.4 to -28.2)
Road injuries	-	-	-	-	3.3 (2.5 to 4.2)	3.7 (2.7 to 5.0)	14.6 (2.3 to 29.5)	-34.8 (-41.3 to -27.4)
Pedestrian road injuries	-	-	-	-	0.9 (0.7 to 1.1)	1.0 (0.7 to 1.3)	9.1 (5.0 to 25.0)	-36.6 (-43.7 to -28.8)
Cyclist road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	9.8 (0.8 to 21.0)	-37.2 (-42.9 to -31.5)
Motorcyclist road injuries	-	-	-	-	0.6 (0.5 to 0.8)	0.6 (0.5 to 0.9)	3.7 (0.3 to 17.8)	-42.5 (-48.8 to -35.2)
Motor vehicle road injuries	-	-	-	-	1.3 (1.0 to 1.7)	1.7 (1.2 to 2.2)	25.7 (10.8 to 44.0)	-28.5 (-36.8 to -19.4)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-18.5 (-28.0 to -8.1)	-56.8 (-61.4 to -51.8)
Other transport injuries	-	-	-	-	0.6 (0.4 to 0.8)	0.7 (0.5 to 0.9)	17.5 (5.0 to 32.1)	-36.8 (-43.5 to -29.2)
Unintentional injuries	-	-	-	-	5.5 (4.2 to 7.1)	8.0 (5.9 to 10.7)	45.2 (35.3 to 55.6)	-20.6 (-26.0 to -14.9)
Falls	-	-	-	-	2.3 (1.7 to 2.9)	3.3 (2.4 to 4.5)	45.4 (31.8 to 59.7)	-21.5 (-28.9 to -13.6)
Drowning	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	4.4 (-10.4 to 21.3)	-40.3 (-47.9 to -32.1)
Fire, heat, and hot substances	-	-	-	-	0.6 (0.5 to 0.8)	0.7 (0.5 to 0.9)	12.1 (-1.0 to 27.1)	-36.9 (-43.6 to -29.5)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.9 (19.3 to 63.7)	-25.3 (-35.3 to -14.9)
Exposure to mechanical forces	-	-	-	-	1.5 (1.1 to 2.0)	2.4 (1.8 to 3.2)	61.5 (52.0 to 72.1)	-12.2 (-17.3 to -6.7)
Unintentional firearm injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	61.9 (44.4 to 81.3)	-12.5 (-22.0 to -2.4)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.5 (68.2 to 107.8)	3.5 (-5.6 to 13.7)
Other exposure to mechanical forces	-	-	-	-	1.4 (1.1 to 1.9)	2.3 (1.7 to 3.1)	61.2 (51.9 to 72.0)	-12.4 (-17.4 to -6.9)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	103.9 (91.5 to 116.4)	12.2 (5.3 to 19.2)
Animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	25.6 (16.0 to 35.7)	-30.8 (-36.0 to -25.9)
Venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	31.5 (17.7 to 47.2)	-28.6 (-35.7 to -21.2)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	20.6 (10.1 to 32.7)	-32.6 (-38.1 to -26.8)
Foreign body	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	45.9 (33.1 to 59.1)	-18.7 (-25.1 to -11.8)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.4 (-16.4 to 17.5)	-40.3 (-48.4 to -30.4)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	76.2 (58.4 to 99.6)	-7.2 (-14.9 to 3.0)
Foreign body in other body part	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	57.4 (43.0 to 73.2)	-14.0 (-21.5 to -6.0)
Other unintentional injuries	-	-	-	-	0.7 (0.5 to 0.9)	1.0 (0.8 to 1.3)	48.9 (36.1 to 60.9)	-16.4 (-23.3 to -10.2)
Self-harm and interpersonal violence	-	-	-	-	0.5 (0.4 to 0.7)	0.7 (0.5 to 0.9)	23.6 (11.5 to 38.4)	-32.5 (-38.6 to -24.9)
Self-harm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	55.5 (39.5 to 72.3)	-18.2 (-25.9 to -9.5)
Interpersonal violence	-	-	-	-	0.4 (0.3 to 0.6)	0.5 (0.4 to 0.7)	16.9 (4.1 to 31.9)	-35.9 (-42.6 to -28.4)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	33.4 (20.9 to 46.3)	-28.4 (-34.3 to -22.0)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	36.5 (22.8 to 55.4)	-26.9 (-34.0 to -17.2)
Assault by other means	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	7.4 (5.4 to 23.0)	-40.6 (-47.4 to -32.5)
Forces of nature, war, and legal intervention	-	-	-	-	-	1.9 (0.7 to 4.3)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	1.9 (0.7 to 4.3)	-	-

Appendix Table G.4 - Costa Rica prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	277.7 (204.7 to 361.9)	512.5 (382.7 to 664.3)	84.8 (78.2 to 91.4)	84.8 (-3.6 to 3.6)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	31.6 (22.2 to 44.8)	41.1 (29.1 to 56.9)	30.2 (19.8 to 40.3)	-4.1 (-11.9 to 3.4)
HIV/AIDS and tuberculosis	-	-	-	-	0.5 (0.3 to 0.7)	0.9 (0.6 to 1.2)	75.5 (44.4 to 117.8)	-10.5 (-26.0 to 9.5)
Tuberculosis	1.2 (1.1 to 1.3)	1.5 (1.4 to 1.6)	25.2 (18.2 to 32.5)	-36.4 (-39.8 to -32.8)	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.6)	24.5 (8.3 to 42.5)	-36.4 (-43.8 to -28.1)
HIV/AIDS	-	-	-	-	0.1 (0.1 to 0.3)	0.4 (0.2 to 0.6)	260.1 (87.3 to 453.1)	36.2 (4.2 to 201.5)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.1 (37.4 to 79.6)	-38.9 (-69.6 to -10.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.1 (37.5 to 79.9)	-38.9 (-69.7 to -9.9)
HIV/AIDS resulting in other diseases	1.0 (0.6 to 1.6)	5.5 (3.4 to 7.6)	462.9 (308.4 to 650.7)	221.0 (127.3 to 326.4)	0.1 (0.1 to 0.3)	0.4 (0.2 to 0.6)	263.4 (87.9 to 458.6)	96.1 (-3.8 to 205.5)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	7.3 (5.1 to 10.0)	8.0 (5.4 to 11.1)	9.8 (0.5 to 21.0)	-12.4 (-18.6 to -5.7)
Diarrheal diseases	23.2 (21.7 to 24.8)	22.1 (20.5 to 23.7)	-4.7 (-14.2 to 5.3)	-11.5 (-19.7 to -2.9)	3.8 (2.5 to 5.3)	5.6 (2.5 to 5.0)	5.9 (-16.0 to 4.8)	-11.9 (-20.7 to -2.5)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.5 (45.6 to -3.1)	-44.8 (-61.4 to -31.6)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.6 (-24.8 to 10.3)	-34.5 (-46.2 to -22.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.6 (-24.8 to 10.4)	-34.5 (-46.2 to -22.1)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.2 (-25.7 to 12.3)	-34.4 (-45.8 to -17.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.2 (-25.8 to 12.5)	-34.4 (-45.8 to -17.6)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-98.2 (-99.9 to -58.1)	-98.7 (-99.9 to -58.1)
Lower respiratory infections	4.2 (3.1 to 5.4)	3.2 (2.7 to 3.9)	-24.9 (-40.7 to 10.6)	-41.0 (-52.4 to -17.0)	0.4 (0.3 to 0.7)	0.3 (0.2 to 0.5)	-25.2 (-42.9 to 8.9)	-40.7 (-53.6 to -15.9)
Upper respiratory infections	149.5 (134.8 to 164.2)	221.5 (200.6 to 242.2)	48.1 (28.2 to 70.1)	-0.4 (-13.8 to 14.2)	1.8 (1.0 to 3.0)	2.6 (1.5 to 4.3)	47.9 (27.4 to 70.0)	-0.3 (-14.0 to 14.7)
Otitis media	39.9 (37.4 to 42.3)	51.0 (48.1 to 54.0)	27.8 (18.4 to 38.0)	-12.3 (-18.7 to -5.6)	0.8 (0.5 to 1.2)	1.0 (0.5 to 1.5)	25.2 (14.7 to 37.8)	-13.3 (-20.2 to -5.3)
Meningitis	-	-	-	-	0.4 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-15.2 (-30.3 to 2.5)	-44.1 (-53.3 to -33.2)
Pneumococcal meningitis	1.8 (1.1 to 2.9)	1.6 (0.9 to 2.5)	-11.8 (-27.3 to 5.3)	-47.5 (-56.9 to -37.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-9.0 (-28.0 to 11.1)	-42.1 (-53.2 to -28.9)
H influenzae type B meningitis	0.8 (0.2 to 1.7)	0.5 (0.2 to 1.1)	-33.7 (-58.0 to 3.5)	-57.8 (-72.0 to -33.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-30.5 (-58.0 to 31.1)	-51.8 (-70.3 to -10.1)
Meningococcal meningitis	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.3)	-16.4 (-47.8 to 22.6)	-50.5 (-66.9 to -23.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.0 (-49.6 to 44.3)	-49.6 (-66.5 to -9.5)
Other meningitis	0.7 (0.3 to 1.4)	0.6 (0.3 to 1.2)	-17.3 (-37.0 to 7.7)	-47.5 (-58.8 to -29.3)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-14.4 (-40.9 to 26.7)	-42.5 (-59.3 to -15.0)
Encephalitis	0.3 (0.1 to 0.6)	0.4 (0.2 to 1.1)	72.1 (37.5 to 104.4)	31.1 (20.3 to 16.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	79.2 (46.7 to 119.9)	3.5 (-13.8 to 25.9)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.0 (-90.9 to 693.1)	-27.1 (-93.1 to 470.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.0 (-91.1 to 703.9)	-27.1 (-91.1 to 487.7)
Whooping cough	1.0 (0.8 to 1.3)	1.0 (0.8 to 1.3)	-0.6 (-1.2 to 0.1)	8.4 (7.7 to 9.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-0.5 (-12.8 to 14.5)	8.5 (-4.9 to 24.7)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.5 (-92.9 to -83.1)	-93.3 (-95.5 to -89.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-88.1 (-93.1 to -80.0)	-92.2 (-95.4 to -86.8)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	2.4 (2.2 to 2.6)	3.1 (2.6 to 3.5)	26.6 (8.3 to 51.7)	-4.2 (-20.0 to 15.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	81.4 (30.8 to 157.2)	-5.9 (-33.4 to 30.3)
Neglected tropical diseases and malaria	-	-	-	-	5.7 (3.6 to 8.7)	6.4 (4.2 to 9.6)	13.1 (-11.8 to 45.3)	-20.8 (-38.0 to 1.9)
Malaria	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	718.7 (320.5 to 1,120.7)	480.2 (196.0 to 765.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	272.3 (176.5 to 496.4)	194.8 (114.3 to 377.3)
Chagas disease	16.5 (15.6 to 17.4)	28.2 (26.6 to 29.9)	71.2 (57.4 to 84.8)	-3.2 (-11.2 to 4.4)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	403.1 (77.6 to 131.4)	-3.2 (-15.6 to 8.4)
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.6 (47.4 to 125.7)	13.2 (-9.4 to 45.1)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.4 (-25.4 to 166.5)	-3.1 (-42.1 to 89.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.4 (-25.5 to 168.2)	-3.1 (-42.2 to 90.9)
Cutaneous and mucocutaneous leishmaniasis	1.3 (1.0 to 1.8)	2.5 (1.9 to 3.2)	83.6 (55.8 to 125.1)	13.4 (-5.2 to 43.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.3 (47.7 to 128.5)	13.3 (-9.4 to 46.1)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	2.5 (0.7 to 5.6)	1.3 (0.3 to 4.1)	-51.0 (-89.9 to 115.4)	-72.5 (-94.3 to 15.4)	0.8 (0.2 to 1.8)	0.4 (0.1 to 1.3)	-50.8 (-89.4 to 129.9)	-72.1 (-94.0 to 22.3)
Cystic echinococcosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	81.3 (59.3 to 102.8)	-14.4 (-23.7 to -3.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.6 (44.8 to 129.0)	-12.2 (-31.7 to 12.4)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.4 (0.1 to 0.8)	2.8 (1.1 to 6.2)	672.4 (664.5 to 681.6)	392.6 (387.6 to 398.4)	0.1 (0.0 to 0.1)	0.4 (0.2 to 1.1)	665.5 (505.2 to 871.7)	390.7 (298.5 to 510.6)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.3 (4.5 to 64.9)	-22.6 (-32.6 to 4.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.3 (4.5 to 64.9)	22.6 (-32.6 to 4.9)
Intestinal nematode infections	-	-	-	-	3.9 (2.2 to 6.3)	4.3 (2.7 to 6.9)	11.7 (-12.7 to 46.4)	-20.4 (-38.5 to 3.7)
Ascariasis	627.8 (418.8 to 919.2)	953.8 (590.3 to 1,474.3)	50.5 (-17.1 to 170.6)	-5.3 (-49.0 to 69.8)	1.6 (0.7 to 3.0)	0.6 (0.3 to 1.3)	-62.5 (-80.0 to -21.6)	-71.9 (-84.8 to -42.7)
Trichuriasis	396.9 (239.0 to 649.0)	645.4 (383.2 to 1,027.2)	63.7 (-18.0 to 238.2)	-0.6 (-51.5 to 107.8)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.4)	68.5 (-50.5 to 477.3)	1.1 (-71.9 to 246.1)
Hookworm disease	262.7 (173.8 to 389.5)	437.4 (279.9 to 676.6)	65.8 (-10.4 to 212.0)	3.2 (-46.8 to 95.7)	1.2 (1.4 to 3.4)	3.5 (2.2 to 5.5)	61.7 (28.4 to 103.1)	14.1 (-12.7 to 44.9)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	22.1 (17.6 to 27.2)	25.8 (23.1 to 28.8)	16.8 (-4.2 to 46.3)	0.7 (-16.9 to 25.0)	0.8 (0.5 to 1.1)	0.9 (0.6 to 1.3)	13.5 (-6.6 to 56.9)	1.4 (-16.4 to 39.8)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-20.1 to 26.8)	-
Maternal hemorrhage	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	36.6 (-53.4 to -17.1)	-51.8 (-72.5 to -49.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.3 (-33.5 to 169.7)	-15.2 (-56.6 to 68.6)
Maternal sepsis and other maternal infections	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	15.2 (-14.9 to 55.7)	-37.0 (-52.9 to -15.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.7 (-40.8 to 60.2)	-36.5 (-64.1 to -3.2)
Maternal hypertensive disorders	0.4 (0.2 to 0.8)	0.4 (0.1 to 0.8)	-4.4 (-10.8 to 3.9)	-39.9 (-44.3 to -35.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.5 (-30.0 to 25.9)	-39.7 (-55.8 to -21.1)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.1 (-45.2 to 117.9)	-25.4 (-64.8 to 35.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.1 (-45.2 to 121.4)	-25.4 (-64.9 to 35.3)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.5 (-41.2 to 68.2)	-40.8 (-62.7 to 4.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.3 (-44.5 to 87.4)	-39.0 (-64.6 to 14.6)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.5 (-31.2 to 49.4)	-37.7 (-56.5 to -6.5)
Neonatal disorders	-	-	-	-	4.9 (3.4 to 6.8)	9.9 (6.8 to 13.3)	99.4 (52.6 to 164.8)	33.2 (2.1 to 76.7)
Preterm birth complications	18.6 (13.7 to 24.9)	43.8 (32.3 to 58.1)	137.1 (92.5 to 183.3)	53.4 (24.7 to 83.0)	2.4 (1.7 to 3.4)	5.8 (4.0 to 7.8)	142.8 (77.2 to 222.5)	60.3 (17.1 to 112.0)
Neonatal encephalopathy due to birth asphyxia and trauma	9.1 (4.1 to 18.3)	8.2 (3.8 to 16.4)	-9.4 (-37.2 to 29.3)	-40.8 (-58.8 to -14.4)	1.4 (0.9 to 2.0)	1.4 (0.9 to 2.1)	4.5 (-36.8 to 61.8)	-28.5 (-56.7 to 11.2)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.7 (2.1 to 57.1)	28.7 (14.6 to 76.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.7 (-50.5 to 477.3)	17.0 (-71.9 to 246.1)
Hemolytic disease and other neonatal jaundice	1.4 (0.6 to 2.9)	1.9 (0.7 to 4.5)	23.2 (-61.3 to 400.6)	-17.7 (-74.4 to 234.4)	0.6 (0.2 to 1.2)	0.8 (0.3 to 1.9)	25.0 (-61.8 to 393.6)	-16.6 (-74.7 to 223.0)
Other neonatal disorders	-	-	-	-	0.6 (0.3 to 0.9)	1.8 (1.1 to 2.7)	227.7 (91.9 to 444.6)	119.5 (27.8 to 262.6)
Nutritional deficiencies	-	-	-	-	11.9 (7.9 to 17.4)	14.0 (9.4 to 20.6)	18.4 (11.8 to 25.4)	-7.3 (-12.9 to -1.8)
Protein-energy malnutrition	3.1 (1.6 to 5.6)	1.5 (0.8 to 2.8)	-49.3 (-80.5 to 20.0)	-47.6 (-79.5 to 15.0)	0.4 (0.2 to 0.8)	0.2 (0.1 to 0.4)	-49.6 (-80.3 to 18.4)	-47.7 (-79.0 to 15.4)
Iodine deficiency	29.1 (11.6 to 50.3)	32.1 (14.2 to 54.0)	11.7 (-50.3 to 152.1)	-36.5 (-71.0 to 43.3)	0.5 (0.2 to 1.0)	0.6 (0.2 to 1.2)	12.1 (-50.1 to 155.1)	-36.0 (-71.5 to 41.5)
Vitamin A deficiency	0.6 (0.4 to 0.8)	0.4 (0.3 to 0.5)	-34.9 (-44.6 to -23.5)	-51.0 (-58.1 to -42.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.0 (-46.2 to -14.2)	-50.3 (-60.6 to -39.2)

Appendix Table G.4 - Costa Rica prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	344.5 (339.0 to 350.2)	454.8 (442.6 to 468.0)	31.9 (28.3 to 36.3)	-1.1 (-5.9 to 0.1)	10.9 (7.3 to 15.8)	13.2 (8.9 to 19.2)	21.2 (16.6 to 27.5)	4.3 (8.0 to 0.2)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-0.1 (-69.8 to 132.6)	-8.7 (-67.9 to 126.5)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.4 (0.9 to 2.1)	1.9 (1.2 to 3.1)	42.6 (26.3 to 61.9)	-4.6 (-13.7 to 6.0)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.6 (0.4 to 1.1)	1.0 (0.6 to 1.8)	61.0 (39.0 to 84.0)	-8.0 (-19.3 to 4.6)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	99.9 (59.4 to 144.4)	-9.7 (-25.9 to 7.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.1 (35.9 to 183.8)	-9.6 (-37.9 to 28.4)
Chlamydial infection	76.0 (58.7 to 94.7)	109.8 (79.1 to 151.4)	42.4 (-5.6 to 121.7)	-13.9 (-42.8 to 33.7)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.9)	57.5 (21.5 to 97.8)	-5.8 (-26.8 to 16.6)
Gonococcal infection	10.9 (8.3 to 14.7)	15.9 (12.0 to 20.1)	45.4 (1.6 to 109.0)	-8.7 (-36.9 to 30.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	35.6 (-5.3 to 96.3)	-16.1 (-41.0 to 21.0)
Trichomoniasis	23.8 (15.7 to 33.5)	31.6 (19.7 to 44.1)	32.5 (-21.5 to 118.2)	-21.2 (-52.2 to 27.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	30.1 (-30.1 to 122.3)	-22.2 (-57.0 to 29.5)
Genital herpes	590.0 (568.2 to 611.9)	1,125.2 (1,075.5 to 1,169.2)	90.4 (80.4 to 102.4)	-5.3 (-10.1 to 0.6)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.7)	85.7 (68.8 to 99.8)	-5.3 (-11.6 to 1.4)
Other sexually transmitted diseases	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.6)	59.2 (35.6 to 85.7)	-14.0 (-26.2 to 0.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.1 (33.7 to 182.8)	6.5 (-23.6 to 53.7)
Hepatitis	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	35.2 (8.2 to 59.3)	-20.2 (-38.0 to -4.9)
Hepatitis A	3.9 (3.7 to 4.0)	4.4 (4.2 to 4.6)	14.0 (14.0 to 14.1)	-14.8 (-15.8 to -13.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	38.1 (21.7 to 55.6)	-9.2 (-19.4 to 1.8)
Hepatitis B	96.1 (75.6 to 123.1)	114.1 (83.9 to 156.8)	18.2 (-21.1 to 75.3)	-33.7 (-56.2 to -2.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	29.6 (-29.4 to 96.2)	-34.0 (-64.3 to 0.8)
Hepatitis C	72.1 (64.5 to 79.6)	105.5 (94.5 to 117.7)	46.3 (25.1 to 71.5)	-25.5 (-35.9 to -13.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.6 (6.8 to 80.9)	-25.7 (-46.1 to 0.8)
Hepatitis E	-	-	-	-	-	-	-	-
Leprosy	0.0 (0.0 to 0.2)	0.1 (0.0 to 0.1)	69.0 (-28.5 to 731.4)	-22.4 (-66.9 to 298.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.2 (30.5 to 1,147.8)	-19.4 (-68.0 to 485.6)
Other infectious diseases	15.5 (12.4 to 18.9)	18.7 (16.2 to 20.3)	20.7 (1.1 to 46.5)	0.5 (-15.7 to 20.3)	0.6 (0.3 to 0.8)	0.7 (0.4 to 1.1)	24.8 (0.5 to 65.6)	6.8 (-14.2 to 39.8)
Non-communicable diseases	-	-	-	-	233.3 (172.1 to 303.5)	456.6 (340.2 to 593.5)	95.9 (87.6 to 104.6)	3.0 (-1.4 to 7.4)
Neoplasms	-	-	-	-	1.6 (1.2 to 2.1)	4.5 (3.3 to 5.9)	180.7 (146.8 to 210.1)	26.9 (10.5 to 40.3)
Esophageal cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	109.6 (51.3 to 190.3)	-11.1 (-36.1 to 22.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.9 (54.7 to 179.1)	-13.6 (-35.9 to 19.3)
Stomach cancer	1.9 (1.7 to 2.1)	3.0 (2.6 to 3.4)	57.8 (34.6 to 85.9)	-33.7 (-44.0 to -21.0)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	50.2 (28.4 to 75.5)	-36.9 (-46.9 to -25.6)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	196.6 (130.4 to 264.1)	27.8 (1.5 to 61.3)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	206.5 (49.5 to 1,048.8)	38.0 (-33.6 to 458.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	194.1 (56.0 to 1,000.4)	32.6 (-32.1 to 437.3)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.2)	788.4 (359.4 to 2,003.6)	284.3 (98.5 to 813.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	693.4 (361.5 to 1,691.2)	239.9 (96.6 to 669.1)
Liver cancer due to alcohol use	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	55.9 (-27.9 to 182.6)	-32.9 (-69.0 to 20.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.5 (-26.1 to 142.0)	-35.0 (-68.3 to 3.3)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.8 (-32.5 to 134.6)	-41.3 (-70.6 to 8.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.4 (-26.0 to 95.1)	43.6 (-67.5 to -10.3)
Larynx cancer	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	96.7 (54.5 to 153.3)	-18.1 (-35.9 to 7.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	102.1 (50.5 to 168.9)	-15.1 (-38.1 to 13.1)
Tracheal, bronchus and lung cancer	0.3 (0.3 to 0.3)	0.6 (0.5 to 0.7)	111.0 (77.8 to 154.7)	-9.2 (-23.8 to 8.9)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	96.8 (60.5 to 141.5)	-15.6 (-32.0 to 3.9)
Breast cancer	2.3 (2.1 to 2.5)	7.1 (6.1 to 8.2)	206.4 (158.1 to 267.8)	30.7 (10.5 to 56.5)	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.7)	187.1 (142.1 to 246.1)	22.9 (3.3 to 46.9)
Cervical cancer	2.3 (1.8 to 2.6)	2.6 (2.1 to 3.5)	13.4 (-10.4 to 58.6)	-49.4 (-59.8 to -29.4)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	49.4 (-12.3 to 58.5)	49.4 (-60.2 to -28.7)
Uterine cancer	0.5 (0.4 to 0.8)	1.4 (0.8 to 2.0)	189.9 (73.5 to 320.3)	17.2 (-30.3 to 69.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	151.4 (68.0 to 311.5)	13.9 (-31.3 to 67.7)
Prostate cancer	1.8 (1.2 to 2.7)	11.0 (6.8 to 15.3)	528.3 (256.1 to 815.8)	166.6 (47.5 to 290.2)	0.2 (0.1 to 0.3)	0.9 (0.6 to 1.4)	426.9 (201.1 to 669.6)	124.1 (26.6 to 224.4)
Colon and rectum cancer	1.3 (1.2 to 1.4)	5.4 (4.9 to 6.0)	308.2 (264.8 to 359.3)	75.5 (56.7 to 98.2)	0.1 (0.1 to 0.1)	0.6 (0.3 to 0.6)	282.9 (235.6 to 339.7)	64.1 (44.1 to 90.1)
Lip and oral cavity cancer	0.4 (0.3 to 0.5)	0.9 (0.6 to 1.1)	119.1 (70.2 to 183.3)	-5.5 (-21.2 to 24.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	116.1 (65.5 to 181.3)	-6.7 (-30.1 to 23.7)
Nasopharynx cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	53.7 (11.5 to 121.8)	-27.6 (-46.6 to 5.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.2 (11.6 to 109.4)	-30.1 (-46.8 to -2.0)
Other pharynx cancer	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	89.4 (30.0 to 183.6)	-22.5 (-47.4 to 16.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.9 (29.9 to 176.2)	-23.4 (-47.4 to 14.2)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-7.9 (-34.6 to 115.1)	-61.7 (-72.9 to -30.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.6 (-37.6 to 111.7)	-61.9 (-74.5 to -9.8)
Pancreatic cancer	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.3)	337.5 (259.9 to 435.3)	83.6 (50.0 to 124.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	315.2 (236.4 to 412.5)	73.5 (38.1 to 116.3)
Malignant skin melanoma	0.4 (0.3 to 0.5)	1.1 (0.8 to 1.4)	300.0 (139.3 to 274.2)	33.1 (6.1 to 67.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	38.6 (128.2 to 262.5)	27.4 (1.4 to 62.2)
Non-melanoma skin cancer	0.8 (0.6 to 1.0)	2.7 (2.0 to 3.6)	241.3 (137.3 to 402.0)	39.9 (-3.5 to 108.5)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	271.5 (143.7 to 467.3)	52.2 (-3.6 to 141.8)
Ovarian cancer	0.2 (0.1 to 0.2)	0.6 (0.5 to 0.7)	272.4 (196.4 to 368.1)	66.7 (31.7 to 108.1)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	259.3 (163.3 to 378.9)	60.2 (16.0 to 117.8)
Testicular cancer	0.1 (0.1 to 0.2)	0.6 (0.2 to 1.1)	514.5 (63.1 to 1,214.3)	269.8 (-2.8 to 633.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	469.0 (52.4 to 1,235.3)	233.4 (-9.2 to 626.1)
Kidney cancer	0.4 (0.3 to 0.4)	1.0 (0.9 to 1.2)	222.3 (162.7 to 296.5)	38.5 (12.2 to 70.3)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	206.7 (147.8 to 280.7)	30.9 (4.5 to 63.6)
Bladder cancer	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	55.8 (17.8 to 129.5)	-34.1 (-50.4 to -3.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	53.3 (17.4 to 126.8)	-35.4 (-50.9 to -5.2)
Brain and nervous system cancer	0.2 (0.1 to 0.2)	0.6 (0.4 to 0.8)	313.7 (124.0 to 417.8)	145.0 (34.8 to 207.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	318.2 (132.6 to 424.0)	129.4 (27.6 to 187.3)
Thyroid cancer	0.9 (0.7 to 1.2)	2.6 (2.0 to 3.5)	182.5 (122.6 to 272.0)	35.1 (6.8 to 76.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	178.5 (117.8 to 263.0)	32.3 (3.1 to 70.8)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	116.9 (77.7 to 172.1)	81.6 (-22.2 to 21.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	121.6 (90.9 to 176.7)	-2.9 (-21.9 to 23.1)
Hodgkin lymphoma	0.1 (0.1 to 0.1)	0.6 (0.2 to 0.8)	721.0 (107.1 to 1,084.0)	409.1 (24.5 to 620.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	710.3 (90.9 to 1,039.1)	385.4 (9.6 to 569.1)
Non-Hodgkin lymphoma	0.7 (0.6 to 0.9)	2.5 (1.9 to 3.0)	227.2 (151.8 to 315.8)	57.9 (20.7 to 99.0)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	213.1 (139.0 to 295.3)	48.9 (12.3 to 88.6)
Multiple myeloma	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	230.9 (116.8 to 410.2)	38.5 (-10.0 to 113.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	209.9 (104.0 to 373.5)	29.9 (-17.3 to 100.7)
Leukemia	0.9 (0.7 to 1.0)	1.4 (1.1 to 1.7)	61.7 (24.4 to 104.9)	5.9 (-16.5 to 33.1)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	79.9 (44.9 to 122.4)	4.7 (-16.4 to 30.0)
Other neoplasms	2.1 (1.8 to 2.6)	7.8 (6.5 to 9.3)	271.7 (190.0 to 352.4)	114.6 (65.7 to 160.3)	0.1 (0.1 to 0.2)	0.5 (0.3 to 0.7)	267.0 (186.5 to 345.6)	102.7 (55.5 to 146.8)
Cardiovascular diseases	-	-	-	-	2.6 (1.8 to 3.7)	10.0 (6.9 to 14.0)	279.7 (193.8 to 385.3)	60.2 (26.6 to 102.3)
Rheumatic heart disease	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	124.4 (106.5 to 143.1)	-0.3 (-8.5 to 8.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	124.6 (81.7 to 168.4)	-0.1 (-20.0 to 21.9)
Ischemic heart disease	21.6 (18.4 to 25.8)	96.2 (76.0 to 119.9)	94.1 (239.8 to 466.5)	76.0 (35.8 to 125.7)	1.1 (0.7 to 1.6)	5.6 (3.5 to 8.3)	401.0 (264.1 to 575.5)	97.1 (45.3 to 168.0)
Cerebrovascular disease	-	-	-	-	0.4 (0.3 to 0.5)	1.0 (0.7 to 1.3)	134.6 (92.1 to 194.1)	0.6 (-17.6 to 28.0)
Ischemic stroke	0.7 (0.6 to 0.9)	1.7 (1.4 to 2.1)	135.8 (75.2 to 206.1)	-1.4 (-26.6 to 30.0)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	135.2 (70.8 to 216.3)	-0.8 (-27.0 to 33.5)
Hemorrhagic stroke	2.0 (1.7 to 2.3)	4.7 (4.1 to 5.5)	135.5 (94.9 to 196.4)	1.3 (-16.9 to 31.4)	0.3 (0.2 to 0.4)	0.7 (0.5 to 0.9)	134.2 (91.9 to 199.3)	1.3 (-17.3 to 31.3)
Hypertensive heart disease	1.8 (1.7 to 2.0)	4.8 (4.4 to 5.2)	161.0 (133.4 to 198.2)	8.5 (-3.2 to 24.5)	0.2 (0.1 to 0.3)	0.5 (0.4 to 0.7)	160.8 (129.2 to 198.4)	8.7 (-4.7 to 24.5)
Cardiomyopathy and myocarditis	1.1 (1.0 to 1.2)	2.8 (2.5 to 3.0)	157.1 (128.0 to 193.5)	15.7 (1.4 to 34.2)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	154.0 (119.7 to 201.2)	15.2 (-2.0 to 37.3)
Atrial fibrillation and flutter	0.7 (0.4 to 1.2)	4.9 (3.6 to 6.7)	579.3 (312.7 to 1,308.6)	185.7 (70.3 to 490.6)	0.1 (0.0 to 0.1)	0.4 (0.2 to 0.6)	567.9 (301.5 to 1,308.5)	180.8 (66.9 to 490.3)
Peripheral vascular disease	54.3 (34.3 to 75.5)	152.0 (126.5 to 187.0)	178.8 (90.4 to 346.2)	10.2 (-23.2 to 74.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	130.0 (4.8 to 312.5)	-5.9 (-56.5 to 67.6)
Endocarditis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	109.8 (59.7 to 163.7)	-0.0 (-23.3 to 27.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.7 (59.3 to 168.0)	1.3 (-24.1 to 30.1)
Other cardiovascular and circulatory diseases	9.9 (5.5 to 18.0)	30.5 (18.2 to 42.2)	220.8 (46.1 to 500.4)	44.1 (-34.2 to 176.2)	0.7 (0.3 to 1.3)	2.2 (1.1 to 3.3)	211.6 (49.3 to 507.5)	44.7 (-35.4 to 177.5)
Chronic respiratory diseases	-	-	-	-	22.3 (15.6 to 30.5)	41.4 (28.6 to 56.3)	86.1 (66.3 to 108.1)	2.6 (-6.9 to 12.7)
Chronic obstructive pulmonary disease	97.6 (91.4 to 103.9)	214.1 (199.8 to 227.4)	119.3 (111.2 to 127.9)	0.4 (-3.1 to 4.3)	6.0 (3.9			

Appendix Table G.4 - Costa Rica prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	136.5 (129.1 to 143.6)	-
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	121.9 (112.8 to 131.7)	-2.1 (-5.9 to 2.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	122.0 (112.4 to 131.9)	-2.1 (-5.9 to 2.2)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	351.4 (141.7 to 160.2)	16.1 (12.3 to 20.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	151.2 (141.4 to 160.2)	16.0 (12.3 to 20.5)
Asthma	356.8 (327.9 to 390.6)	562.9 (520.9 to 604.3)	58.0 (40.8 to 76.3)	-6.3 (-15.8 to 3.5)	15.8 (10.2 to 22.7)	24.8 (16.3 to 35.7)	57.2 (39.8 to 75.8)	-6.3 (-15.7 to 3.9)
Interstitial lung disease and pulmonary sarcoidosis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	127.7 (63.7 to 210.8)	1.4 (-26.7 to 39.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	128.2 (63.8 to 210.6)	1.4 (-26.6 to 39.8)
Other chronic respiratory diseases	-	-	-	-	0.5 (0.3 to 0.8)	0.6 (0.4 to 1.0)	26.7 (-11.0 to 71.3)	-41.9 (-58.3 to -21.0)
Cirrhosis	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	98.8 (67.6 to 133.9)	-5.5 (-16.6 to 14.0)
Cirrhosis due to hepatitis B	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	193.9 (33.7 to 379.4)	38.5 (-37.0 to 129.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	193.9 (33.6 to 379.4)	38.5 (-37.2 to 129.3)
Cirrhosis due to hepatitis C	0.3 (0.2 to 0.4)	0.6 (0.5 to 0.8)	111.9 (54.7 to 196.2)	2.8 (-23.7 to 45.4)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	108.5 (44.9 to 212.3)	1.9 (-28.1 to 52.9)
Cirrhosis due to alcohol use	0.4 (0.3 to 0.4)	0.6 (0.5 to 0.8)	78.7 (35.2 to 131.0)	-20.1 (-39.4 to 1.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	76.7 (31.4 to 143.1)	-20.8 (-41.1 to 7.8)
Cirrhosis due to other causes	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	115.7 (36.6 to 204.5)	33.2 (-18.7 to 89.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	111.3 (27.1 to 242.3)	30.0 (-23.5 to 107.4)
Digestive diseases	-	-	-	-	1.8 (1.3 to 2.4)	4.2 (3.0 to 5.6)	129.5 (109.4 to 148.6)	4.0 (-5.2 to 13.1)
Peptic ulcer disease	16.2 (15.2 to 17.2)	19.1 (17.3 to 20.9)	17.8 (3.6 to 32.8)	-50.1 (-55.4 to -44.4)	0.5 (0.4 to 0.7)	0.7 (0.5 to 1.1)	42.5 (17.8 to 65.8)	-39.2 (-48.6 to -29.8)
Gastritis and duodenitis	3.0 (2.7 to 3.3)	4.2 (3.8 to 4.6)	40.2 (21.9 to 62.5)	-32.0 (-39.4 to -22.8)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	38.9 (8.7 to 77.3)	-31.3 (-42.8 to -15.2)
Appendicitis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	31.3 (6.3 to 55.9)	-13.9 (-29.4 to 1.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	33.3 (5.6 to 86.2)	-13.0 (-37.3 to 20.5)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	199.2 (77.4 to 441.0)	85.8 (31.0 to 229.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	195.0 (70.7 to 444.0)	84.9 (23.6 to 237.7)
Inguinal, femoral, and abdominal hernia	5.4 (4.9 to 5.9)	8.9 (7.8 to 10.0)	65.6 (42.6 to 91.2)	-29.2 (-40.1 to -16.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	66.3 (41.8 to 93.3)	-28.5 (-39.5 to -15.3)
Inflammatory bowel disease	3.4 (3.2 to 3.5)	8.7 (8.4 to 9.1)	157.9 (144.1 to 172.0)	24.3 (17.7 to 31.2)	0.7 (0.5 to 1.0)	1.9 (1.3 to 2.5)	157.5 (138.9 to 178.2)	24.8 (16.2 to 34.3)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	140.2 (89.8 to 198.9)	9.3 (-14.1 to 38.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	126.5 (67.5 to 212.7)	2.5 (-26.5 to 43.9)
Gallbladder and biliary diseases	1.9 (1.6 to 2.1)	3.8 (3.4 to 4.3)	106.5 (77.4 to 147.1)	-3.7 (-16.4 to 12.7)	0.4 (0.1 to 0.3)	0.4 (0.3 to 0.6)	106.1 (73.5 to 149.3)	-3.6 (-18.2 to 14.0)
Pancreatitis	0.2 (0.2 to 0.2)	0.5 (0.5 to 0.6)	178.2 (161.1 to 196.7)	39.1 (31.1 to 47.3)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	178.1 (117.8 to 252.1)	40.9 (10.7 to 75.5)
Other digestive diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.6 (0.4 to 0.9)	1,015.4 (488.9 to 1,211.7)	405.7 (176.5 to 498.1)
Neurological disorders	-	-	-	-	20.4 (14.1 to 27.7)	39.1 (26.3 to 53.5)	90.7 (53.4 to 145.4)	1.2 (-16.8 to 27.6)
Alzheimer disease and other dementias	15.5 (13.2 to 17.5)	37.3 (30.1 to 44.1)	140.6 (91.8 to 198.9)	-0.1 (-20.8 to 25.4)	2.2 (1.5 to 2.9)	5.4 (3.7 to 7.2)	143.1 (94.7 to 203.7)	0.3 (-19.8 to 25.1)
Parkinson disease	0.2 (0.2 to 0.3)	0.6 (0.5 to 0.7)	143.0 (128.2 to 160.6)	2.2 (-3.8 to 8.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	141.5 (102.3 to 191.7)	1.8 (-15.8 to 23.2)
Epilepsy	17.3 (11.4 to 23.6)	26.1 (17.0 to 36.8)	48.8 (-13.5 to 165.8)	-8.7 (-46.2 to 62.8)	6.0 (3.5 to 9.1)	9.2 (5.1 to 14.1)	51.8 (-13.1 to 171.5)	-5.7 (-45.9 to 70.0)
Multiple sclerosis	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.4)	286.3 (249.7 to 320.7)	89.0 (71.2 to 105.5)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	279.0 (229.7 to 334.1)	85.6 (61.0 to 113.2)
Migraine	241.1 (193.5 to 293.4)	446.8 (327.7 to 579.4)	84.5 (18.7 to 176.2)	0.5 (-34.3 to 47.4)	15.5 (4.8 to 12.9)	8.4 (8.5 to 25.1)	84.4 (56.8 to 176.3)	0.4 (-35.1 to 49.0)
Tension-type headache	581.1 (486.2 to 687.3)	1,007.0 (1,021.6 to 1,176.8)	88.3 (57.4 to 131.1)	3.4 (-11.8 to 22.6)	1.7 (0.4 to 1.6)	1.7 (0.8 to 2.9)	87.8 (56.3 to 131.3)	3.6 (-12.2 to 23.1)
Medication overuse headache	12.9 (8.3 to 18.4)	36.0 (23.3 to 48.9)	174.7 (108.9 to 308.2)	39.4 (5.2 to 99.2)	2.0 (1.1 to 3.3)	5.6 (3.2 to 8.7)	174.1 (107.3 to 306.8)	39.6 (4.7 to 99.8)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.7 (22.4 to 119.4)	-4.3 (-27.5 to 24.3)	0.8 (0.5 to 1.3)	1.7 (1.1 to 2.4)	103.6 (43.0 to 180.8)	-16.0 (-41.3 to 16.7)
Mental and substance use disorders	-	-	-	-	75.5 (52.9 to 102.4)	131.6 (91.4 to 180.0)	77.8 (67.3 to 82.6)	-1.2 (-4.3 to 2.1)
Schizophrenia	7.6 (6.9 to 8.2)	15.0 (13.8 to 16.2)	98.2 (89.3 to 108.2)	-0.5 (-4.8 to 3.9)	4.9 (3.6 to 5.9)	9.7 (7.1 to 11.8)	97.7 (84.5 to 111.0)	-0.3 (-6.4 to 5.6)
Alcohol use disorders	31.6 (27.7 to 35.9)	53.8 (48.1 to 60.0)	70.2 (56.9 to 85.7)	-8.9 (-14.9 to -1.4)	3.1 (2.1 to 4.5)	5.3 (3.5 to 7.7)	70.1 (56.0 to 87.5)	-8.6 (-15.5 to -0.5)
Drug use disorders	-	-	-	-	4.3 (2.9 to 6.0)	8.1 (5.4 to 11.1)	86.7 (55.0 to 130.8)	7.4 (-10.4 to 31.4)
Opioid use disorders	2.2 (1.1 to 3.5)	4.5 (2.4 to 7.3)	111.5 (88.3 to 139.1)	4.7 (-4.1 to 17.8)	0.9 (0.4 to 1.6)	1.9 (0.9 to 3.2)	112.4 (79.2 to 150.0)	5.4 (-8.9 to 23.1)
Cocaine use disorders	7.1 (5.3 to 8.8)	13.9 (11.8 to 16.2)	95.8 (49.4 to 183.1)	1.0 (-12.8 to 59.8)	1.0 (0.6 to 1.5)	1.9 (1.2 to 2.8)	95.7 (47.3 to 185.5)	13.8 (-14.3 to 61.6)
Amphetamine use disorders	5.4 (5.0 to 5.7)	8.5 (8.0 to 9.0)	59.9 (44.8 to 73.1)	-0.8 (-9.7 to 7.4)	0.7 (0.4 to 1.0)	1.1 (0.7 to 1.6)	59.4 (35.6 to 88.1)	-1.0 (-15.2 to 16.1)
Cannabis use disorders	2.6 (2.0 to 3.2)	4.2 (3.2 to 5.1)	60.9 (57.9 to 64.6)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	61.9 (32.0 to 102.4)	0.6 (-17.6 to 25.2)
Other drug use disorders	-	-	-	-	1.7 (1.1 to 2.5)	3.1 (2.0 to 4.4)	82.0 (27.8 to 159.3)	8.5 (-23.6 to 53.7)
Depressive disorders	-	-	-	-	31.7 (18.6 to 49.5)	56.2 (31.4 to 87.3)	76.7 (60.7 to 96.0)	-1.2 (-8.4 to 5.6)
Major depressive disorder	137.6 (86.9 to 187.0)	242.4 (141.0 to 333.7)	75.3 (55.5 to 95.9)	-1.4 (-9.6 to 6.1)	28.5 (16.1 to 45.5)	49.9 (28.8 to 79.5)	74.3 (54.6 to 95.4)	-1.4 (-9.8 to 6.3)
Dysthymia	32.7 (26.6 to 38.7)	65.3 (53.9 to 77.1)	99.5 (91.4 to 110.0)	-0.0 (-0.1 to 0.0)	3.2 (2.1 to 4.6)	6.3 (4.0 to 9.3)	98.9 (88.3 to 110.3)	0.0 (-2.5 to 2.5)
Bipolar disorder	23.7 (19.2 to 28.5)	43.9 (36.2 to 51.5)	84.9 (72.6 to 99.2)	-0.4 (-6.3 to 6.0)	4.9 (2.9 to 7.4)	8.9 (5.4 to 13.5)	84.0 (69.0 to 100.1)	-0.3 (-7.2 to 7.0)
Anxiety disorders	128.3 (83.9 to 168.9)	226.1 (150.1 to 293.4)	76.8 (64.8 to 89.0)	11.9 (-0.1 to 0.0)	31.7 (6.9 to 18.1)	56.2 (12.4 to 31.3)	76.7 (64.1 to 88.9)	-1.2 (-2.3 to 2.3)
Eating disorders	-	-	-	-	1.0 (0.6 to 1.5)	1.5 (0.9 to 2.4)	55.2 (42.5 to 68.5)	1.0 (-6.9 to 9.2)
Anorexia nervosa	0.7 (0.6 to 0.9)	1.2 (0.9 to 1.5)	58.3 (40.5 to 77.2)	5.1 (-6.7 to 17.0)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.4)	58.8 (28.1 to 96.7)	5.5 (-14.7 to 30.0)
Bulimia nervosa	3.8 (2.5 to 5.7)	5.9 (3.8 to 8.7)	54.0 (51.3 to 57.5)	-0.1 (-0.2 to 0.0)	0.8 (0.5 to 1.3)	1.3 (0.7 to 2.1)	54.4 (41.0 to 68.5)	0.0 (-8.1 to 8.8)
Autistic spectrum disorders	-	-	-	-	3.7 (2.6 to 5.0)	5.7 (4.0 to 7.8)	56.9 (51.1 to 62.5)	0.4 (-3.0 to 3.8)
Autism	9.3 (8.7 to 9.8)	14.6 (13.8 to 15.4)	57.9 (56.8 to 59.2)	0.1 (0.1 to 0.1)	2.3 (1.5 to 3.2)	3.6 (2.4 to 5.0)	57.2 (49.0 to 65.1)	0.5 (-4.4 to 5.4)
Asperger syndrome	13.7 (12.8 to 14.5)	21.4 (20.0 to 22.7)	56.8 (55.2 to 58.3)	0.1 (0.1 to 0.1)	1.4 (0.9 to 1.9)	2.1 (1.5 to 3.0)	56.1 (49.2 to 62.8)	0.3 (-3.9 to 4.3)
Attention-deficit/hyperactivity disorder	24.7 (22.6 to 26.3)	31.9 (29.1 to 34.0)	29.3 (28.8 to 29.6)	0.2 (0.2 to 0.2)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.5)	29.6 (21.5 to 38.2)	0.4 (-5.6 to 7.3)
Conduct disorder	32.0 (29.7 to 34.2)	42.3 (39.3 to 45.5)	32.5 (31.1 to 33.4)	3.8 (0.3 to 0.3)	3.9 (2.4 to 5.6)	5.1 (3.2 to 7.4)	32.8 (26.7 to 38.6)	0.0 (-3.7 to 5.0)
Idiopathic intellectual disability	53.6 (42.7 to 67.1)	66.5 (50.0 to 83.3)	24.0 (3.5 to 43.8)	-22.0 (-35.2 to -9.3)	2.6 (1.7 to 3.7)	3.2 (2.1 to 4.7)	23.4 (2.7 to 44.0)	-21.9 (-34.9 to -9.1)
Other mental and substance use disorders	45.8 (42.8 to 48.6)	88.3 (83.0 to 93.3)	92.9 (89.9 to 96.1)	0.0 (-0.0 to 0.1)	3.4 (2.3 to 4.6)	6.6 (4.5 to 9.0)	92.6 (84.4 to 100.4)	0.2 (-3.3 to 3.9)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	17.5 (12.0 to 24.4)	38.2 (26.5 to 52.6)	118.2 (97.4 to 140.1)	14.6 (2.7 to 27.5)
Diabetes mellitus	83.2 (68.7 to 97.3)	242.1 (198.2 to 286.1)	190.8 (132.5 to 260.4)	36.4 (6.3 to 74.9)	6.0 (4.0 to 8.5)	17.9 (11.8 to 25.1)	197.2 (138.2 to 266.2)	33.2 (4.8 to 67.5)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.9 (19.7 to 43.5)	-7.9 (-13.4 to 0.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.9 (19.7 to 43.6)	-7.9 (-13.4 to 0.9)
Chronic kidney disease	-	-	-	-	4.6 (3.3 to 6.2)	8.5 (5.9 to 11.4)	83.4 (57.9 to 105.1)	5.0 (-7.6 to 17.7)
Chronic kidney disease due to diabetes mellitus	54.1 (36.5 to 76.8)	125.6 (89.6 to 194.5)	133.1 (77.4 to 197.6)	6.1 (-16.8 to 33.1)	0.8 (0.6 to 1.2)	2.1 (1.4 to 2.9)	146.6 (98.1 to 207.3)	11.8 (-9.3 to 40.2)
Chronic kidney disease due to hypertension	48.8 (32.3 to 74.0)	94.9 (64.7 to 145.2)	96.4 (46.9 to 161.7)	11.8 (-11.1 to 53.6)	1.0 (0.6 to 1.4)	2.0 (1.3 to 2.6)	98.5 (57.0 to 149.7)	4.8 (-18.1 to 30.4)
Chronic kidney disease due to glomerulonephritis	62.0 (39.2 to 93.5)	113.2 (74.6 to 170.4)	84.2 (32.5 to 142.3)	11.9 (-30.1 to 32.1)	0.8 (0.8 to 1.5)	1.9 (1.3 to 2.6)	75.9 (34.9 to 112.2)	14.1 (-13.8 to 40.2)
Chronic kidney disease due to other causes	87.4 (54.5 to 129.0)	143.4 (86.7 to 210.1)	64.9 (23.6 to 127.2)	-4.5 (-28.7 to 23.8)	1.7 (1.2 to 2.3)	2.6 (1.7 to 3.5)	52.6 (10.2 to 86.8)	-3.6 (-28.9 to 20.0)
Urinary diseases and male infertility	-	-	-	-	0.9 (0.6 to 1.3)	2.0 (1.3 to 2.9)	133.5 (110.1 to 164.6)	2.6 (-7.9 to 17.4)

Appendix Table G.4 - Costa Rica prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	117.0 (114.1 to 120.1)	237.7 (231.4 to 243.8)	103.2 (96.1 to 110.4)	-14.1 (-17.1 to -10.9)	3.2 (2.2 to 4.4)	6.5 (4.4 to 9.1)	102.8 (95.1 to 110.8)	-14.1 (-17.3 to -10.8)
Other oral disorders	49.3 (46.5 to 52.2)	88.5 (83.4 to 93.4)	79.4 (65.2 to 93.7)	-0.9 (-8.3 to 6.6)	1.5 (0.9 to 2.2)	2.6 (1.6 to 3.9)	78.8 (63.1 to 94.2)	-0.8 (-8.7 to 7.4)
Injuries	-	-	-	-	12.8 (9.7 to 16.3)	14.8 (10.6 to 19.9)	15.4 (3.6 to 29.4)	43.3 (-49.1 to -36.6)
Transport injuries	-	-	-	-	4.8 (3.6 to 6.1)	5.0 (3.5 to 6.8)	4.5 (9.1 to 21.5)	-48.3 (-54.6 to -40.5)
Road injuries	-	-	-	-	4.2 (3.1 to 5.4)	4.4 (3.1 to 5.9)	2.7 (-11.0 to 20.2)	-49.1 (-55.5 to -41.1)
Pedestrian road injuries	-	-	-	-	1.4 (1.0 to 1.8)	1.4 (1.0 to 1.9)	0.5 (-15.3 to 18.6)	-49.7 (-57.2 to -41.4)
Cyclist road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	18.4 (4.0 to 34.1)	-43.5 (-50.2 to -36.0)
Motorcyclist road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	-6.4 (-20.3 to 9.3)	-54.1 (-60.5 to -47.0)
Motor vehicle road injuries	-	-	-	-	2.1 (1.5 to 2.7)	2.2 (1.5 to 3.0)	5.0 (-10.8 to 25.4)	-48.0 (-55.5 to -39.0)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-50.0 (-56.9 to -42.2)	-75.4 (-78.7 to -71.6)
Other transport injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.7 (0.5 to 0.9)	19.7 (4.5 to 37.1)	-41.3 (-48.8 to -33.3)
Unintentional injuries	-	-	-	-	7.1 (5.4 to 9.2)	8.5 (6.2 to 11.5)	18.5 (8.3 to 30.7)	-41.9 (-47.2 to -35.6)
Falls	-	-	-	-	2.1 (2.1 to 3.5)	3.8 (2.7 to 5.2)	39.3 (21.6 to 59.8)	-40.0 (-48.3 to -30.7)
Drowning	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-18.0 (-30.9 to -3.8)	-58.6 (-64.7 to -52.0)
Fire, heat, and hot substances	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-11.1 (-24.3 to 3.3)	-51.2 (-57.8 to -44.0)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.3 (-23.8 to 12.8)	-51.3 (-58.7 to -41.0)
Exposure to mechanical forces	-	-	-	-	3.5 (2.6 to 4.6)	3.2 (2.3 to 4.3)	-8.4 (-16.1 to 0.3)	-50.8 (-54.5 to -46.4)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.2)	220.1 (157.5 to 306.9)	68.6 (36.4 to 113.6)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	118.6 (85.9 to 157.6)	19.5 (2.8 to 39.2)
Other exposure to mechanical forces	-	-	-	-	3.4 (2.5 to 4.5)	3.0 (2.2 to 4.1)	-12.6 (-20.0 to -4.4)	-53.0 (-56.6 to -48.9)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	85.8 (75.0 to 98.2)	-9.5 (-14.8 to -3.4)
Animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	92.4 (70.0 to 115.0)	1.1 (-9.1 to 12.9)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	78.3 (54.0 to 107.1)	-4.9 (-16.7 to 9.7)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	101.7 (77.0 to 128.6)	4.9 (-6.4 to 17.9)
Foreign body	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	35.3 (20.8 to 52.9)	-32.4 (-39.2 to -24.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	5.7 (-22.6 to 14.4)	-53.0 (-61.1 to -43.5)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.7 (43.7 to 81.4)	-11.4 (-20.9 to -0.3)
Foreign body in other body part	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	60.1 (42.3 to 79.6)	-20.5 (-28.8 to -11.6)
Other unintentional injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.7 (0.5 to 1.0)	234.0 (204.4 to 270.8)	51.3 (38.4 to 67.3)
Self-harm and interpersonal violence	-	-	-	-	0.9 (0.7 to 1.1)	1.3 (0.9 to 1.7)	47.3 (28.7 to 71.5)	-28.3 (-37.1 to -17.4)
Self-harm	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	55.6 (38.5 to 75.6)	-28.0 (-35.6 to -18.7)
Interpersonal violence	-	-	-	-	0.8 (0.6 to 1.0)	1.1 (0.8 to 1.5)	46.3 (27.2 to 71.2)	-28.3 (-37.4 to -16.7)
Assault by firearm	-	-	-	-	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.7)	108.1 (87.5 to 134.8)	0.1 (-9.2 to 12.2)
Assault by sharp object	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	55.4 (33.9 to 85.0)	-24.7 (-34.9 to -10.9)
Assault by other means	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	4.1 (-11.8 to 24.8)	-48.1 (-55.8 to -38.1)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.1 (-18.5 to 76.4)	0.7 (-33.7 to 45.4)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.1 (-18.5 to 76.4)	0.7 (-33.7 to 45.4)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Cote d'Ivoire prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	2.2 (2.1 to 2.4)	4.2 (3.9 to 4.5)	87.7 (70.0 to 105.7)	0.1 (-1.6 to 15.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	87.9 (48.0 to 140.4)	7.7 (-10.8 to 31.3)
Urolithiasis	25.6 (18.7 to 32.5)	39.8 (31.4 to 52.3)	55.5 (28.8 to 83.0)	-0.4 (-25.1 to 4.8)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	80.2 (58.0 to 108.2)	4.8 (-6.9 to 18.3)
Benign prostatic hyperplasia	79.5 (71.9 to 86.6)	154.7 (140.4 to 168.5)	93.9 (71.0 to 122.2)	6.7 (-4.9 to 21.6)	2.8 (1.8 to 4.0)	5.5 (3.6 to 7.8)	95.9 (72.1 to 124.7)	8.1 (-3.8 to 23.4)
Male infertility due to other causes	164.1 (128.7 to 206.9)	236.7 (187.4 to 285.1)	43.3 (5.7 to 94.6)	-19.5 (-41.1 to 11.3)	1.0 (0.4 to 2.1)	1.4 (0.6 to 3.0)	44.9 (4.7 to 95.3)	-18.4 (-41.0 to 10.0)
Other urinary diseases	-	-	-	-	0.0	0.0	0.0	0.0
Gynecological diseases	-	-	-	-	11.6	24.0	107.7	18.7
Uterine fibroids	169.8 (153.8 to 184.5)	315.3 (284.8 to 343.8)	85.2 (84.5 to 85.8)	9.3 (9.2 to 9.5)	2.8 (1.6 to 4.4)	5.7 (3.4 to 8.8)	103.7 (87.6 to 166.4)	19.1 (9.2 to 55.6)
Polycystic ovarian syndrome	153.1 (138.0 to 168.4)	313.7 (279.2 to 350.2)	104.7 (76.9 to 134.2)	15.1 (0.3 to 30.5)	1.5 (0.7 to 2.8)	3.0 (1.4 to 5.8)	105.2 (76.8 to 134.7)	15.1 (0.4 to 30.4)
Female infertility due to other causes	132.8 (104.2 to 169.6)	221.2 (168.9 to 285.0)	66.1 (18.5 to 137.3)	-3.6 (-31.9 to 39.1)	0.7 (0.3 to 1.4)	1.1 (0.4 to 2.4)	64.7 (17.4 to 134.5)	-4.0 (-32.1 to 37.1)
Endometriosis	15.7 (13.3 to 18.4)	28.0 (23.8 to 32.5)	77.6 (39.6 to 127.8)	1.3 (-20.2 to 29.5)	1.4 (0.9 to 2.0)	2.6 (1.7 to 3.6)	78.2 (37.9 to 131.2)	1.6 (-21.0 to 31.8)
Genital prolapse	370.0 (319.2 to 423.0)	695.1 (604.2 to 790.3)	87.4 (55.8 to 127.5)	1.2 (-9.8 to 25.4)	2.2 (0.6 to 2.2)	2.2 (1.1 to 4.1)	88.0 (54.8 to 129.0)	7.2 (-9.7 to 27.1)
Premenstrual syndrome	388.9 (270.7 to 528.3)	892.3 (685.9 to 1,145.1)	130.9 (51.4 to 250.5)	33.1 (-13.2 to 102.6)	3.2 (1.8 to 5.4)	7.4 (4.4 to 11.6)	131.1 (50.8 to 252.9)	33.8 (-12.8 to 101.8)
Other gynecological diseases	25.1 (16.1 to 34.5)	60.2 (39.9 to 80.0)	139.8 (52.6 to 286.2)	36.2 (-12.7 to 117.2)	0.8 (0.4 to 1.3)	2.0 (0.9 to 2.9)	136.2 (11.7 to 397.0)	34.5 (-34.8 to 178.1)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	23.3	38.6	65.1	2.5
Thalassemias	2.5 (2.2 to 2.9)	4.1 (3.6 to 4.7)	60.2 (46.8 to 73.0)	-0.9 (-9.1 to 7.3)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	59.8 (-4.5 to 148.5)	-2.2 (-39.9 to 51.3)
Thalassemia trait	559.7 (517.9 to 598.2)	943.9 (876.8 to 1,011.3)	68.0 (61.6 to 74.6)	-0.0 (-3.8 to 3.9)	10.3 (6.8 to 14.9)	16.5 (11.0 to 23.9)	59.9 (41.5 to 78.0)	-0.9 (-15.6 to 11.5)
Sickle cell disorders	22.3 (20.2 to 24.2)	38.5 (35.4 to 41.4)	72.1 (55.3 to 91.9)	4.8 (-5.1 to 16.0)	2.3 (1.6 to 3.1)	3.9 (2.8 to 5.3)	71.8 (46.4 to 99.5)	3.8 (-10.4 to 18.2)
Sickle cell trait	1,530.9 (1,445.3 to 1,586.7)	2,569.6 (2,435.2 to 2,679.4)	68.3 (64.6 to 72.9)	0.1 (-2.1 to 2.9)	7.0 (4.5 to 10.1)	11.2 (7.1 to 16.2)	61.5 (6.5 to 87.2)	0.2 (-37.1 to 20.5)
G6PD deficiency	3,801.4 (3,426.4 to 4,164.4)	5,729.6 (5,167.3 to 6,264.4)	50.2 (31.0 to 72.5)	-10.7 (-22.0 to 2.6)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.5)	50.7 (-28.9 to 234.5)	-5.6 (-54.7 to 113.8)
G6PD trait	2,875.5 (2,837.6 to 2,899.6)	4,896.5 (4,762.5 to 4,984.1)	69.9 (64.9 to 73.7)	1.6 (-1.4 to 3.9)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	71.9 (-42.8 to 362.3)	8.3 (-62.8 to 187.3)
Other hemoglobinopathies and hemolytic anemias	108.0 (92.6 to 123.6)	215.7 (193.2 to 239.3)	98.6 (69.6 to 134.0)	3.3 (4.3 to 42.7)	6.3 (2.1 to 4.8)	6.3 (4.1 to 9.2)	91.0 (53.7 to 148.8)	22.1 (-10.1 to 53.6)
Endocrine, metabolic, blood, and immune disorders	135.5 (109.7 to 159.8)	248.8 (203.2 to 286.8)	83.3 (41.8 to 146.4)	4.7 (-7.8 to 37.4)	8.9 (2.9 to 6.9)	9.9 (5.5 to 12.7)	86.7 (36.5 to 198.3)	16.6 (-11.4 to 63.7)
Musculoskeletal disorders	-	-	-	-	140.6	247.5	76.1	0.7
Rheumatoid arthritis	14.6 (14.0 to 15.3)	19.6 (18.7 to 20.4)	33.6 (25.7 to 42.7)	-29.8 (-34.4 to -25.1)	3.4 (2.4 to 4.6)	4.6 (3.3 to 6.2)	35.8 (21.7 to 50.2)	-28.3 (-34.9 to -21.9)
Osteoarthritis	217.7 (208.4 to 227.2)	389.8 (373.1 to 405.3)	78.5 (68.1 to 89.2)	1.1 (-4.3 to 6.9)	13.2 (9.2 to 17.8)	23.7 (16.5 to 32.3)	80.3 (68.8 to 92.1)	2.6 (-3.3 to 9.0)
Low back and neck pain	-	-	-	-	109.4	190.3	74.1	-0.4
Low back pain	642.6 (604.6 to 680.1)	1,119.4 (1,049.7 to 1,184.3)	73.4 (58.5 to 90.1)	-1.0 (-9.2 to 8.0)	70.9 (47.7 to 98.7)	124.1 (83.7 to 171.9)	74.8 (59.4 to 92.1)	-0.0 (-8.6 to 9.3)
Neck pain	394.6 (324.7 to 464.9)	676.4 (568.7 to 795.9)	70.8 (41.2 to 110.2)	-3.2 (-17.4 to 17.3)	38.4 (25.5 to 54.3)	66.1 (43.1 to 93.1)	71.7 (41.8 to 111.4)	-2.1 (-16.7 to 18.9)
Gout	1.1 (0.9 to 1.2)	1.8 (1.6 to 2.0)	70.5 (40.3 to 108.1)	-1.1 (-17.7 to 15.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	68.9 (27.2 to 118.1)	-1.8 (-27.1 to 29.4)
Other musculoskeletal disorders	162.9 (122.0 to 210.1)	319.0 (245.1 to 399.2)	95.6 (78.0 to 112.5)	10.5 (0.7 to 18.3)	14.6 (9.3 to 21.5)	28.5 (18.4 to 42.5)	97.6 (79.2 to 116.4)	12.0 (1.8 to 20.5)
Other non-communicable diseases	-	-	-	-	153.3	262.4	71.1	3.4
Congenital anomalies	-	-	-	-	7.3	13.8	89.7	12.0
Neural tube defects	0.9 (0.7 to 1.1)	3.1 (2.6 to 3.6)	243.8 (159.3 to 351.5)	118.9 (65.4 to 189.2)	0.2 (0.1 to 0.3)	0.8 (0.5 to 1.1)	274.7 (134.2 to 491.9)	145.5 (54.8 to 287.4)
Congenital heart anomalies	7.9 (5.2 to 11.0)	29.1 (22.7 to 36.8)	265.2 (140.4 to 395.3)	132.4 (50.9 to 305.3)	0.3 (0.2 to 0.5)	1.0 (0.4 to 1.8)	215.9 (107.9 to 430.1)	100.6 (32.9 to 243.1)
Orofacial clefts	0.7 (0.4 to 1.0)	3.6 (2.4 to 5.1)	408.7 (187.1 to 897.3)	0.1 (-9.2 to 62.1)	0.1 (0.0 to 0.0)	0.1 (0.0 to 0.1)	393.9 (170.8 to 891.4)	238.5 (82.4 to 623.3)
Down syndrome	5.3 (3.8 to 7.1)	12.2 (10.4 to 14.5)	133.4 (65.6 to 254.5)	42.0 (-0.0 to 117.5)	0.6 (0.4 to 0.9)	1.4 (1.0 to 1.9)	133.6 (60.7 to 262.9)	41.1 (-2.4 to 119.5)
Turner syndrome	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.7)	117.7 (46.1 to 217.3)	31.3 (-11.9 to 91.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	120.4 (45.3 to 224.6)	31.7 (-11.9 to 93.3)
Klinefelter syndrome	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.8)	61.2 (0.9 to 180.9)	-4.6 (-40.3 to 65.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.4 (1.6 to 182.8)	-6.6 (-41.6 to 62.3)
Chromosomal unbalanced rearrangements	8.7 (7.3 to 10.4)	20.3 (16.7 to 24.0)	73.8 (78.5 to 199.8)	1.0 (-9.2 to 83.5)	1.0 (0.7 to 1.3)	2.3 (1.6 to 3.2)	42.2 (75.8 to 208.4)	42.2 (7.3 to 86.9)
Other congenital anomalies	54.3 (39.0 to 69.6)	86.0 (64.0 to 107.3)	57.7 (36.5 to 88.9)	-7.4 (-19.5 to 12.5)	5.2 (3.0 to 8.0)	8.1 (4.9 to 12.4)	59.0 (23.9 to 106.0)	-6.2 (-26.3 to 24.3)
Skin and subcutaneous diseases	-	-	-	-	55.4	94.8	71.6	1.2
Dermatitis	514.9 (405.3 to 646.8)	889.9 (694.4 to 1,118.2)	72.3 (71.0 to 73.5)	0.2 (-0.1 to 0.5)	14.7 (9.1 to 21.0)	25.2 (15.6 to 36.5)	71.7 (65.8 to 77.8)	0.7 (-1.7 to 3.7)
Psoriasis	80.4 (63.2 to 96.9)	140.2 (110.0 to 159.0)	73.8 (72.7 to 75.0)	0.0 (-0.3 to 0.2)	6.5 (4.2 to 9.5)	11.4 (7.4 to 16.6)	75.1 (65.2 to 87.1)	0.8 (-4.2 to 6.1)
Cellulitis	2.3 (1.8 to 2.9)	3.9 (3.0 to 4.8)	68.7 (44.1 to 101.7)	-1.7 (-15.1 to 17.8)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	68.8 (26.5 to 124.0)	0.0 (-21.2 to 26.9)
Pyoderma	20.5 (15.1 to 26.3)	31.0 (23.3 to 39.8)	50.9 (41.4 to 62.9)	-4.2 (-10.6 to 2.9)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.4)	50.9 (36.6 to 67.7)	-4.0 (-12.7 to 6.4)
Scabies	131.3 (111.7 to 149.6)	171.5 (145.2 to 205.4)	29.5 (5.9 to 65.7)	-21.4 (-37.3 to 3.3)	3.4 (1.9 to 5.4)	4.4 (2.4 to 7.3)	29.8 (5.6 to 66.0)	-21.0 (-36.9 to 0.1)
Fungal skin diseases	1,766.8 (1,337.0 to 2,292.9)	2,976.9 (2,252.2 to 3,889.2)	67.9 (66.1 to 70.0)	4.4 (-0.6 to 4.2)	16.0 (9.3 to 22.0)	16.8 (6.6 to 37.1)	68.4 (56.0 to 70.8)	-0.2 (-0.7 to 0.2)
Viral skin diseases	177.1 (137.5 to 219.1)	293.6 (229.9 to 366.0)	65.6 (54.9 to 75.2)	-0.5 (-6.2 to 4.8)	5.5 (3.2 to 8.6)	9.0 (5.3 to 14.3)	65.8 (53.2 to 77.5)	-0.0 (-6.7 to 6.5)
Acne vulgaris	738.4 (478.4 to 1,058.1)	1,251.2 (842.3 to 1,846.6)	67.6 (4.1 to 191.1)	-3.4 (-38.4 to 54.3)	8.0 (3.3 to 15.2)	13.4 (5.8 to 27.5)	68.3 (4.0 to 192.5)	-3.2 (-38.4 to 54.6)
Alopecia areata	10.9 (9.5 to 12.2)	18.5 (16.5 to 20.5)	70.0 (51.3 to 89.1)	-0.1 (-10.3 to 11.1)	0.4 (0.2 to 0.5)	0.6 (0.4 to 1.0)	70.5 (44.0 to 100.8)	0.8 (-12.7 to 16.5)
Pruritus	0.1 (0.0 to 0.0)	0.1 (0.0 to 0.1)	68.9 (33.9 to 123.7)	-2.6 (-25.4 to 28.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.9 (33.9 to 124.0)	-2.6 (-25.4 to 28.6)
Urticaria	45.8 (31.0 to 62.6)	109.8 (75.1 to 158.8)	135.7 (42.0 to 310.0)	32.5 (-20.3 to 112.4)	2.7 (1.5 to 4.3)	5.5 (3.7 to 10.8)	136.8 (41.5 to 321.0)	34.9 (-20.1 to 114.0)
Decubitus ulcer	0.9 (0.8 to 1.1)	1.7 (1.4 to 2.0)	81.3 (37.6 to 125.7)	2.5 (-31.3 to 40.8)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	83.6 (39.0 to 131.7)	5.3 (-28.7 to 45.7)
Other skin and subcutaneous diseases	688.3 (478.2 to 972.8)	1,162.4 (800.0 to 1,656.1)	68.2 (63.1 to 73.8)	-2.2 (-4.8 to 0.4)	4.0 (1.8 to 8.0)	6.8 (3.1 to 13.7)	68.9 (63.2 to 75.3)	-1.5 (-4.4 to 1.6)
Sense organ diseases	-	-	-	-	76.4	129.1	69.1	4.3
Glaucoma	3.4 (2.5 to 4.5)	27.0 (20.8 to 36.0)	685.1 (470.9 to 1,002.2)	310.8 (187.2 to 464.9)	0.3 (0.2 to 0.4)	1.9 (1.2 to 2.9)	573.8 (396.0 to 849.0)	241.2 (137.8 to 373.1)
Cataract	15.5 (10.8 to 22.0)	95.5 (66.6 to 125.0)	523.1 (338.1 to 748.0)	174.9 (97.0 to 270.5)	1.5 (0.9 to 2.4)	8.0 (5.0 to 11.8)	425.3 (276.2 to 604.2)	133.4 (74.5 to 208.0)
Macular degeneration	2.2 (1.4 to 3.3)	45.8 (31.3 to 62.9)	2,015.3 (1,325.8 to 3,190.2)	806.0 (494.1 to 1,321.7)	0.1 (0.1 to 0.2)	2.5 (1.5 to 3.8)	1,636.1 (1,061.3 to 2,616.9)	580.4 (331.6 to 967.9)
Uncorrected refractive error	1,158.3 (1,075.3 to 1,240.4)	1,970.7 (1,815.1 to 2,128.9)	69.8 (53.1 to 86.5)	-0.7 (-9.4 to 8.2)	22.1 (14.2 to 33.8)	34.4 (21.4 to 53.6)	54.9 (44.2 to 67.4)	-10.2 (-15.5 to -3.4)
Age-related and other hearing loss	1,554.8 (1,389.7 to 1,737.6)	2,485.0 (2,208.2 to 2,747.2)	59.7 (51.3 to 66.8)	4.6 (-10.0 to -3.5)	43.2 (27.9 to 63.3)	65.3 (42.3 to 95.2)	50.9 (33.9 to 66.9)	-10.1 (-17.3 to -3.9)
Other vision loss	18.5 (14.3 to 23.7)	53.5 (42.1 to 67.3)	127.9 (130.7 to 262.7)	1.5 (85.1 to 181.1)	1.5 (0.9 to 2.4)	4.7 (2.9 to 7.0)	206.1 (127.0 to 295.6)	120.2 (71.4 to 185.6)
Other sense organ diseases	284.9 (270.5 to 299.1)	469.5 (448.1 to 492.4)	64.0 (52.2 to 77.8)	-0.5 (-6.8 to 5.8)	7.6 (4.7 to 11.2)	12.4 (7.6 to 18.6)	64.7 (51.5 to 79.1)	0.1 (-6.3 to 7.1)
Oral disorders	-	-	-	-	14.1	24.7	75.0	1.3
Deciduous caries	1,167.7 (1,114.0 to 1,219.3)	1,811.4 (1,708.2 to 1,900.5)	54.6 (43.1 to 65.4)	0.2 (-7.1 to 7.2)	0.2 (0.2 to 0.9)	0.7 (0.3 to 1.4)	64.2 (60.4 to 70.2)	0.6 (-9.0 to 10.3)
Permanent caries	3,091.4 (2,786.8 to 3,435.9)	5,378.3 (4,891.4 to 5,979.0)	73.6 (51.6 to 98.7)	0.0 (-12.6 to 14.2)	3.0 (1.4 to 5.8)	5.3 (2.4 to 10.1)	74.3 (52.5 to 99.0)	0.5 (-12.5 to 15.2)
Periodontal diseases	720.2 (650.6 to 792.9)	1,254.4 (1,135.7 to 1,376.7)	73.6 (54.6 to 96.7)	-0.2 (-11.7 to 13.7)	4.7 (1.8 to 9.7)	8.1 (3.2 to 16		

Appendix Table G.4 - Cote d'Ivoire prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	32.4 (30.0 to 35.0)	62.4 (57.5 to 67.2)	91.8 (70.7 to 113.3)	6.4 (-3.8 to 16.3)	0.9 (0.6 to 1.2)	1.7 (1.2 to 2.4)	93.9 (70.6 to 117.5)	7.9 (-2.9 to 19.4)
Other oral disorders	175.4 (165.2 to 184.9)	303.8 (285.0 to 322.7)	72.7 (59.2 to 87.3)	-0.3 (-7.7 to 7.2)	5.1 (3.3 to 7.5)	8.9 (5.5 to 13.2)	73.7 (58.6 to 89.0)	0.2 (-7.9 to 8.5)
Injuries	-	-	-	-	48.5 (36.8 to 62.2)	72.7 (55.0 to 93.8)	49.7 (44.2 to 56.9)	-10.2 (-13.4 to -6.1)
Transport injuries	-	-	-	-	23.0 (17.3 to 29.6)	32.5 (24.6 to 42.3)	41.3 (33.8 to 48.7)	-14.2 (-18.1 to -10.3)
Road injuries	-	-	-	-	21.2 (15.9 to 27.3)	29.8 (22.5 to 38.7)	40.3 (31.6 to 47.9)	-15.9 (-19.0 to -11.0)
Pedestrian road injuries	-	-	-	-	5.3 (4.0 to 6.8)	6.7 (5.0 to 8.7)	26.8 (16.9 to 37.1)	-22.0 (-26.9 to -17.1)
Cyclist road injuries	-	-	-	-	1.8 (1.3 to 2.3)	2.1 (1.6 to 2.8)	19.7 (11.0 to 29.0)	-24.4 (-29.8 to -19.2)
Motorcyclist road injuries	-	-	-	-	3.3 (2.4 to 4.2)	4.1 (3.0 to 5.3)	24.2 (14.6 to 35.3)	-25.2 (-30.5 to -19.3)
Motor vehicle road injuries	-	-	-	-	10.6 (7.9 to 13.6)	6 (4.5 to 8.1)	56.7 (45.5 to 69.2)	-5.9 (-11.9 to 0.8)
Other road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	3.1 (4.4 to 9.5)	-41.3 (-45.2 to -37.5)
Other transport injuries	-	-	-	-	1.8 (1.3 to 2.3)	2.8 (2.0 to 3.6)	53.3 (43.4 to 64.4)	-4.7 (-10.5 to 1.6)
Unintentional injuries	-	-	-	-	24.5 (18.7 to 31.6)	36.9 (28.2 to 47.9)	50.6 (46.2 to 55.6)	-10.9 (-13.6 to -7.8)
Falls	-	-	-	-	9.6 (7.3 to 12.3)	15.5 (11.6 to 20.2)	61.5 (53.9 to 70.5)	-8.5 (-12.8 to -3.5)
Drowning	-	-	-	-	0.6 (0.4 to 0.8)	0.7 (0.5 to 0.9)	17.9 (4.8 to 32.3)	-28.2 (-35.0 to -21.0)
Fire, heat, and hot substances	-	-	-	-	1.5 (1.1 to 1.9)	2.0 (1.5 to 2.5)	33.3 (22.3 to 44.7)	-17.6 (-23.1 to -12.1)
Poisonings	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	22.4 (3.7 to 45.4)	-28.0 (-37.1 to -16.6)
Exposure to mechanical forces	-	-	-	-	8.0 (6.1 to 10.5)	11.4 (8.7 to 14.9)	42.6 (36.0 to 50.3)	-14.0 (-18.0 to -10.0)
Unintentional firearm injuries	-	-	-	-	0.3 (0.3 to 0.4)	0.5 (0.4 to 0.6)	39.0 (27.8 to 51.0)	-17.1 (-23.5 to -10.2)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	87.5 (66.4 to 107.3)	11.5 (0.4 to 21.8)
Other exposure to mechanical forces	-	-	-	-	7.6 (5.7 to 10.0)	10.8 (8.2 to 14.2)	42.4 (35.5 to 50.2)	-14.1 (-18.3 to -10.0)
Adverse effects of medical treatment	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	90.1 (77.4 to 104.6)	15.7 (7.5 to 25.3)
Animal contact	-	-	-	-	0.5 (0.3 to 0.6)	0.7 (0.5 to 0.9)	49.9 (40.5 to 61.3)	-8.8 (-13.8 to -3.8)
Venomous animal contact	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	51.6 (33.5 to 69.7)	-8.8 (-17.8 to 0.6)
Non-venomous animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	48.9 (39.9 to 59.2)	-8.8 (-13.3 to -4.0)
Foreign body	-	-	-	-	0.5 (0.4 to 0.6)	0.8 (0.6 to 1.0)	61.0 (51.7 to 69.9)	-3.4 (-8.7 to 1.8)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	39.9 (24.2 to 58.7)	-9.9 (-17.3 to -2.0)
Foreign body in eyes	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	69.3 (52.6 to 87.7)	-1.3 (-10.4 to 8.6)
Foreign body in other body part	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.6)	66.9 (55.1 to 78.4)	-2.1 (-8.9 to 4.9)
Other unintentional injuries	-	-	-	-	3.7 (2.8 to 4.8)	5.5 (4.1 to 7.2)	49.3 (39.4 to 57.8)	-10.9 (-16.6 to -5.8)
Self-harm and interpersonal violence	-	-	-	-	1.0 (0.7 to 1.2)	1.4 (1.0 to 1.8)	44.5 (36.9 to 50.8)	-12.3 (-16.7 to -8.5)
Self-harm	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	66.6 (54.2 to 81.9)	-2.2 (-8.5 to 5.7)
Interpersonal violence	-	-	-	-	0.8 (0.6 to 1.0)	1.1 (0.8 to 1.4)	39.3 (31.8 to 46.2)	-15.4 (-20.1 to -11.2)
Assault by firearm	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	43.0 (33.9 to 52.5)	-12.6 (-17.8 to -7.1)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	67.8 (55.5 to 80.8)	0.0 (-7.1 to 8.2)
Assault by other means	-	-	-	-	0.5 (0.4 to 0.7)	0.7 (0.5 to 0.9)	31.7 (22.2 to 40.2)	-20.1 (-25.5 to -15.1)
Forces of nature, war, and legal intervention	-	-	-	-	-	1.9 (0.7 to 4.2)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	1.8 (0.7 to 4.1)	-	-

Appendix Table G.4 - Croatia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	551.0 (411.3 to 709.6)	549.9 (409.6 to 711.9)	-0.1 (-2.9 to 2.3)	-2.0 (-4.5 to 0.3)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	30.9 (21.6 to 42.4)	24.1 (17.0 to 33.3)	-21.6 (-28.4 to -16.4)	-1.7 (-9.9 to 4.4)
HIV/AIDS and tuberculosis	-	-	-	-	0.8 (0.6 to 1.1)	0.7 (0.5 to 1.0)	-13.4 (-22.6 to -3.0)	-14.1 (-23.1 to -3.7)
Tuberculosis	2.7 (2.6 to 2.7)	2.2 (2.1 to 2.4)	-15.4 (-19.4 to -11.5)	-17.7 (-21.3 to -14.1)	0.8 (0.5 to 1.1)	0.7 (0.4 to 0.9)	-16.7 (-25.6 to -6.5)	-17.7 (-27.1 to -7.7)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	148.8 (44.5 to 276.2)	170.8 (58.0 to 312.1)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.6 (-26.9 to 105.0)	39.0 (-22.9 to 114.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.6 (-27.1 to 105.2)	39.0 (-23.4 to 114.3)
HIV/AIDS resulting in other diseases	0.1 (0.1 to 0.2)	0.5 (0.2 to 0.8)	292.1 (176.2 to 431.1)	311.8 (188.4 to 460.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	150.3 (44.7 to 284.9)	173.1 (58.4 to 317.7)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	3.9 (2.7 to 5.5)	2.9 (2.0 to 4.0)	-25.4 (-30.3 to -20.5)	-14.1 (-20.5 to -7.4)
Diarrheal diseases	12.3 (11.3 to 13.4)	8.9 (8.3 to 9.4)	-28.0 (-35.3 to -18.9)	-18.4 (-27.0 to -7.8)	2.0 (1.3 to 2.7)	1.4 (0.9 to 1.9)	-30.2 (-36.7 to -19.8)	-18.5 (-27.9 to -6.4)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.1 to 6.2)	60.6 to 20.0)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.7 (-42.8 to -18.6)	-24.1 (-35.5 to -9.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.7 (-42.9 to -18.6)	-24.1 (-35.5 to -9.6)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.5 (-46.6 to -11.0)	-22.0 (-37.5 to 1.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.5 (-46.6 to -10.8)	-22.0 (-37.5 to 1.2)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-79.9 (-99.2 to -1570.6)	-76.4 (-99.1 to -1,759.0)
Lower respiratory infections	0.4 (0.4 to 0.4)	0.2 (0.2 to 0.2)	-38.2 (-41.3 to -34.8)	-27.6 (-32.1 to -22.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-37.5 (-49.7 to -23.9)	-26.5 (-42.0 to -8.3)
Upper respiratory infections	46.4 (44.5 to 48.6)	39.5 (37.3 to 41.2)	-14.9 (-20.9 to -9.4)	-0.4 (-7.7 to 6.4)	0.5 (0.3 to 0.9)	0.5 (0.3 to 0.8)	-15.1 (-21.8 to -8.4)	-0.3 (-8.6 to 7.8)
Otitis media	49.2 (46.1 to 52.1)	39.3 (36.7 to 41.8)	-20.1 (-25.7 to -13.7)	-4.6 (-11.3 to 2.7)	1.0 (0.6 to 1.6)	0.8 (0.5 to 1.2)	-22.4 (-28.6 to -15.1)	-6.8 (-14.5 to 2.1)
Meningitis	-	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-33.8 (-48.2 to -19.9)	-27.2 (-43.2 to -0.5)
Pneumococcal meningitis	1.1 (0.6 to 1.8)	0.7 (0.4 to 1.2)	-31.2 (-45.4 to -17.6)	-30.0 (-44.9 to -16.6)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-36.5 (-52.1 to -17.9)	-31.5 (-49.5 to -10.9)
H influenzae type B meningitis	0.3 (0.1 to 0.6)	0.1 (0.0 to 0.3)	-44.4 (-69.8 to -6.9)	-37.8 (-64.9 to 13.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-43.2 (-72.1 to 14.4)	-32.4 (-67.7 to 38.0)
Meningococcal meningitis	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.2)	-33.1 (-61.8 to 4.4)	-29.5 (-60.5 to 21.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.7 (-68.6 to 21.8)	-25.0 (-66.8 to 45.7)
Other meningitis	0.3 (0.1 to 0.6)	0.2 (0.1 to 0.5)	-22.6 (-44.0 to 14.1)	-18.2 (-40.7 to 32.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-15.8 (-45.7 to 62.1)	-7.6 (-41.3 to 91.3)
Encephalitis	0.6 (0.2 to 1.4)	0.6 (0.2 to 1.5)	2.6 (-13.0 to 18.7)	5.8 (-7.7 to 27.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	3.8 (-13.6 to 27.9)	11.0 (-7.4 to 36.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-77.3 (-96.8 to 73.1)	-73.8 (-96.2 to 91.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-77.3 (-96.8 to 76.4)	-73.8 (-96.2 to 96.1)
Whooping cough	1.2 (0.9 to 1.5)	0.1 (0.1 to 0.2)	-88.4 (-89.7 to -87.1)	-83.0 (-84.8 to -81.1)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-88.4 (-90.7 to -85.6)	-83.0 (-86.3 to -78.8)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-74.0 (-82.6 to -49.2)	-75.1 (-82.4 to -59.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-74.0 (-82.7 to -48.3)	-75.1 (-82.5 to -59.1)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.2 (-100.0 to -97.5)	-98.8 (-100.0 to -96.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.2 (-100.0 to -97.5)	-98.8 (-100.0 to -96.2)
Varicella and herpes zoster	2.5 (2.3 to 2.8)	2.2 (1.9 to 2.4)	-14.3 (-25.7 to -1.7)	-3.3 (-11.6 to 7.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-0.2 (-23.8 to 30.0)	-2.2 (-23.2 to 25.3)
Neglected tropical diseases and malaria	-	-	-	-	0.1 (0.1 to 0.3)	0.0 (0.0 to 0.0)	-81.2 (-91.0 to -48.8)	-80.5 (-90.5 to -50.9)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.0 (-79.7 to 202.3)	-15.3 (-74.7 to 279.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.6 (-79.3 to 208.3)	-14.1 (-74.4 to 289.4)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.7 (-53.9 to 6.1)	-13.7 (-43.9 to 34.1)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.3 (-55.2 to 6.0)	-14.0 (-45.3 to 34.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.3 (-55.4 to 6.2)	-14.0 (-45.3 to 34.7)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.2 (-52.7 to 62.6)	4.8 (-35.4 to 60.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.2 (-52.7 to 62.8)	4.8 (-35.4 to 61.2)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.4 (0.1 to 0.8)	0.0 (0.0 to 0.1)	-94.6 (-98.4 to -51.4)	-95.0 (-98.5 to -58.3)	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-93.7 (-98.2 to -44.5)	-94.3 (-98.3 to -53.4)
Cystic echinococcosis	0.5 (0.4 to 0.5)	0.2 (0.2 to 0.2)	-58.2 (-61.3 to -54.7)	-56.2 (-59.8 to -51.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-57.1 (-66.4 to -45.1)	-54.4 (-63.3 to -42.7)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.6 (-65.5 to -15.3)	-19.2 (-43.2 to -3.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.6 (-65.6 to -15.3)	-19.2 (-63.2 to -3.4)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.1 (-59.4 to -5.7)	-27.8 (-49.9 to 16.6)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-27.6 (-41.9 to -9.3)	-10.2 (-28.2 to 12.7)
Maternal hemorrhage	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.2)	-24.5 (-42.7 to -0.4)	-5.4 (-29.3 to 27.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.2 (-61.1 to 14.8)	-27.4 (-53.8 to 43.7)
Maternal sepsis and other maternal infections	0.6 (0.3 to 0.9)	0.4 (0.2 to 0.5)	-36.3 (-58.0 to 19.0)	-24.1 (-49.0 to 36.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.9 (-55.5 to -21.5)	-29.3 (-44.3 to -6.1)
Maternal hypertensive disorders	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-21.8 (-28.5 to -14.6)	-2.3 (-10.2 to 6.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.9 (-43.2 to 8.1)	-2.9 (-29.4 to 34.0)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.7 (-31.7 to -10.0)	-1.9 (-14.6 to 13.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.7 (-31.9 to -9.7)	-1.9 (-14.6 to 13.3)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.4 (-26.5 to -0.4)	5.9 (-7.9 to 25.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.4 (-26.5 to -0.2)	5.9 (-7.9 to 25.2)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.7 (-53.8 to 33.5)	-1.7 (-43.1 to 66.1)
Neonatal disorders	-	-	-	-	5.9 (3.8 to 9.1)	4.7 (3.2 to 6.4)	-18.5 (-46.2 to 9.2)	-3.2 (-34.9 to 30.0)
Preterm birth complications	16.9 (13.0 to 21.8)	16.5 (12.7 to 21.2)	-2.4 (-16.3 to 13.6)	13.0 (-3.3 to 32.2)	2.0 (1.4 to 2.6)	2.1 (1.4 to 2.9)	7.6 (-17.3 to 41.6)	27.8 (-2.1 to 69.5)
Neonatal encephalopathy due to birth asphyxia and trauma	5.7 (3.0 to 11.6)	2.8 (1.4 to 6.1)	-52.7 (-72.0 to -12.9)	-43.2 (-66.4 to 5.4)	1.5 (0.8 to 2.4)	0.8 (0.4 to 1.3)	-51.1 (-73.2 to 5.5)	-40.6 (-67.4 to 30.4)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	533.9 (500.9 to 623.7)	702.2 (741.0 to 912.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	574.6 (276.0 to 1,305.2)	844.2 (426.3 to 1,866.7)
Hemolytic disease and other neonatal jaundice	1.8 (0.5 to 7.8)	2.0 (0.3 to 1.1)	-11.7 (-91.9 to 239.0)	3.8 (-90.3 to 296.5)	0.7 (0.2 to 3.2)	0.4 (0.1 to 0.9)	-8.8 (-91.7 to 254.6)	6.0 (-90.0 to 311.6)
Other neonatal disorders	-	-	-	-	1.7 (1.0 to 2.6)	1.4 (0.8 to 2.3)	-20.2 (-50.8 to 37.9)	-5.4 (-41.5 to 65.3)
Nutritional deficiencies	-	-	-	-	18.3 (12.1 to 26.9)	14.4 (9.5 to 21.2)	-21.4 (-25.6 to -17.0)	2.2 (-2.7 to 7.8)
Protein-energy malnutrition	1.1 (0.8 to 1.5)	0.6 (0.4 to 0.9)	-42.3 (-64.1 to -5.4)	-14.9 (-47.1 to 39.1)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-41.8 (-64.5 to -3.7)	-14.2 (-47.5 to 41.5)
Iodine deficiency	30.8 (10.0 to 74.1)	18.8 (7.1 to 30.9)	-32.3 (-78.0 to 157.0)	-21.7 (-74.3 to 190.4)	0.3 (0.1 to 1.4)	0.3 (0.1 to 0.6)	-32.0 (-78.5 to 171.1)	-21.8 (-74.5 to 200.8)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-

Appendix Table G.4 - Croatia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	676.9 (666.3 to 686.9)	581.2 (572.4 to 590.1)	-14.2 (-16.0 to -12.0)	-4.2 (0.0 to 4.7)	17.5 (11.5 to 25.6)	13.8 (9.1 to 20.3)	-21.2 (-24.0 to -17.2)	-11.6 (-0.5 to 7.3)
Other nutritional deficiencies	-	-	-	-	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	44.5 (-67.9 to 232.9)	114.6 (-52.4 to 393.2)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.7 (1.0 to 2.8)	1.4 (0.8 to 2.2)	-21.3 (-32.6 to -9.4)	0.0 (-18.4 to 19.0)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.8 (0.4 to 1.5)	0.7 (0.3 to 1.3)	-14.7 (-22.9 to 4.0)	-1.1 (-10.8 to 13.0)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	13.1 (-6.4 to 37.1)	-3.3 (-22.0 to 18.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.9 (-20.8 to 50.3)	-3.9 (-29.5 to 29.9)
Chlamydial infection	109.5 (98.0 to 120.8)	87.9 (78.9 to 97.5)	-19.7 (-30.6 to -7.2)	-1.0 (-14.5 to 14.9)	0.3 (0.2 to 0.5)	0.3 (0.1 to 0.4)	-19.3 (-31.6 to -3.3)	-0.4 (-16.3 to 20.4)
Gonococcal infection	25.4 (20.6 to 30.2)	17.8 (14.3 to 21.5)	-30.1 (-47.2 to -7.4)	-10.0 (-31.9 to 19.5)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-29.1 (-50.4 to -2.9)	-8.8 (-37.3 to 25.4)
Trichomoniasis	55.3 (42.1 to 69.6)	53.2 (40.2 to 66.4)	-4.7 (-34.2 to 40.8)	20.7 (-20.3 to 87.7)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-3.5 (-35.0 to 49.6)	22.4 (-20.9 to 98.5)
Genital herpes	904.0 (820.5 to 985.6)	898.7 (754.9 to 919.9)	-7.3 (-18.8 to 6.1)	-7.5 (-18.7 to 6.2)	0.2 (0.1 to 0.6)	0.2 (0.1 to 0.5)	0.2 (-21.0 to 5.2)	-7.4 (-19.2 to 7.3)
Other sexually transmitted diseases	0.5 (0.4 to 0.6)	0.3 (0.3 to 0.4)	-35.8 (-48.0 to -16.9)	-23.9 (-37.6 to -1.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-46.5 to 9.2)	-25.4 (-37.7 to 27.2)
Hepatitis	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-22.3 (-33.6 to -11.7)	-11.4 (-23.0 to 0.4)
Hepatitis A	4.2 (4.0 to 4.3)	3.1 (3.0 to 3.2)	-25.0 (-25.2 to -24.8)	-8.5 (-9.4 to -7.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-20.1 (-29.3 to -11.4)	-6.2 (-17.2 to 5.8)
Hepatitis B	107.2 (92.8 to 122.3)	80.2 (66.6 to 92.2)	-25.0 (-37.9 to -11.2)	-18.6 (-32.3 to -2.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-25.8 (-53.5 to -4.8)	-19.8 (-47.8 to 11.5)
Hepatitis C	87.6 (79.3 to 96.2)	67.1 (61.1 to 73.5)	-23.3 (-32.9 to -11.6)	-25.4 (-34.6 to -13.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.0 (-50.7 to 9.0)	-29.5 (-49.9 to -0.4)
Hepatitis E	-	-	-15.5 (-27.1 to -4.0)	-2.0 (-14.0 to 9.7)	-	-	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	27.0 (22.7 to 30.7)	21.2 (18.3 to 24.1)	-21.4 (-36.0 to -5.5)	1.6 (-20.1 to 25.6)	0.8 (0.5 to 1.1)	0.6 (0.3 to 0.8)	-27.6 (-50.4 to 0.3)	3.1 (-31.8 to 45.1)
Non-communicable diseases	-	-	-	-	467.0 (347.5 to 603.6)	483.0 (359.5 to 623.9)	3.5 (0.3 to 6.3)	1.1 (-1.8 to 3.8)
Neoplasms	-	-	-	-	6.9 (5.1 to 8.8)	10.0 (7.4 to 12.8)	46.0 (33.5 to 57.1)	18.7 (8.1 to 28.0)
Esophageal cancer	0.5 (0.4 to 0.5)	0.5 (0.4 to 0.6)	0.6 (-22.3 to 30.7)	-15.3 (-33.9 to 9.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.4 (-25.0 to 30.8)	-16.2 (-36.6 to 9.3)
Stomach cancer	3.9 (3.4 to 4.5)	2.8 (2.3 to 3.3)	-28.9 (-40.3 to -16.1)	-44.8 (-53.7 to -35.2)	0.5 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-31.6 (-43.9 to -19.0)	-6.9 (-56.4 to 37.3)
Liver cancer	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	33.7 (3.4 to 152.5)	33.7 (-19.2 to 95.2)
Liver cancer due to hepatitis B	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	16.5 (-45.1 to 170.9)	-3.6 (-53.8 to 119.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.1 (-45.4 to 125.4)	-8.8 (-55.3 to 82.4)
Liver cancer due to hepatitis C	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	277.3 (63.7 to 633.9)	191.9 (27.0 to 471.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	252.8 (63.9 to 508.0)	173.6 (29.3 to 367.7)
Liver cancer due to alcohol use	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	71.6 (-8.0 to 197.0)	29.6 (-30.9 to 125.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	60.3 (-8.5 to 154.1)	20.7 (-30.9 to 93.3)
Liver cancer due to other causes	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-12.8 (-56.8 to 61.6)	-12.8 (-65.3 to 25.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.0 (-55.0 to 37.1)	-34.5 (-64.4 to 7.7)
Larynx cancer	1.5 (1.1 to 2.0)	1.5 (1.2 to 1.9)	-1.3 (-28.0 to 40.3)	-14.0 (-37.2 to 20.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-17.5 (-36.7 to 9.6)	-28.7 (-44.9 to -5.7)
Tracheal, bronchus and lung cancer	4.2 (3.7 to 4.7)	4.9 (4.3 to 5.5)	16.4 (-0.3 to 36.3)	-2.6 (-16.5 to 14.0)	0.7 (0.5 to 0.8)	0.7 (0.5 to 0.9)	12.5 (-4.6 to 31.5)	-5.9 (-20.3 to 9.3)
Breast cancer	10.9 (8.9 to 13.3)	23.4 (19.6 to 26.3)	117.4 (63.3 to 178.9)	77.4 (35.1 to 125.2)	0.9 (0.6 to 1.2)	1.4 (1.0 to 1.9)	68.0 (20.9 to 100.0)	36.8 (0.2 to 62.0)
Cervical cancer	2.4 (3.1 to 4.5)	4.9 (1.9 to 2.8)	98.7 (-50.0 to -25.7)	42.8 (-53.5 to -30.5)	0.2 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-49.5 (-52.2 to -22.0)	-43.5 (-55.5 to -27.6)
Uterine cancer	5.4 (4.5 to 6.2)	5.4 (4.0 to 6.9)	-0.9 (-27.7 to 30.8)	-14.9 (-37.2 to 11.4)	0.4 (0.2 to 0.5)	0.4 (0.2 to 0.5)	-2.2 (-29.2 to 32.0)	-16.6 (-39.5 to 10.9)
Prostate cancer	5.9 (4.7 to 7.2)	13.9 (11.4 to 17.0)	136.2 (91.9 to 197.8)	76.5 (43.7 to 123.0)	0.6 (0.4 to 0.8)	1.4 (0.9 to 1.9)	122.4 (81.0 to 175.9)	63.2 (32.7 to 101.6)
Colon and rectum cancer	8.4 (7.9 to 8.9)	19.2 (17.5 to 20.9)	127.9 (106.2 to 152.1)	78.1 (61.5 to 96.1)	0.8 (0.5 to 1.0)	1.6 (1.2 to 2.0)	112.8 (90.0 to 139.1)	64.0 (46.4 to 84.0)
Lip and oral cavity cancer	2.2 (2.0 to 2.4)	2.0 (1.5 to 2.5)	-10.7 (-30.8 to 16.0)	-23.3 (-40.3 to -0.2)	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-14.6 (-32.1 to 4.4)	-27.1 (-43.3 to -4.4)
Nasopharynx cancer	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-48.5 (-65.7 to -19.8)	-52.1 (-67.7 to -25.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.2 (-64.3 to -25.6)	-53.3 (-66.8 to -32.9)
Other pharynx cancer	1.0 (0.7 to 1.5)	1.0 (0.6 to 1.5)	-2.4 (-45.1 to 63.8)	-14.4 (-49.3 to 47.6)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-6.3 (-42.4 to 52.8)	-16.0 (-48.2 to 37.7)
Gallbladder and biliary tract cancer	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	16.3 (-32.3 to 48.1)	-13.9 (-49.5 to 8.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	11.0 (-37.5 to 51.2)	-16.8 (-52.3 to 13.2)
Pancreatic cancer	0.5 (0.4 to 0.6)	0.7 (0.6 to 0.9)	49.1 (21.6 to 81.1)	15.1 (-6.5 to 39.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	43.2 (16.5 to 76.5)	11.9 (-8.0 to 37.4)
Malignant skin melanoma	1.9 (1.4 to 2.8)	3.8 (2.5 to 4.9)	99.2 (37.7 to 156.7)	89.2 (28.9 to 131.8)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.4)	90.9 (30.5 to 143.3)	70.9 (21.0 to 119.8)
Non-melanoma skin cancer	4.4 (2.8 to 5.8)	6.6 (4.5 to 8.9)	53.7 (-11.0 to 151.5)	10.2 (-34.9 to 78.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	94.5 (8.0 to 235.2)	30.0 (-28.3 to 119.2)
Ovarian cancer	1.7 (1.4 to 1.9)	1.9 (1.6 to 2.2)	14.4 (-8.9 to 38.1)	2.4 (-18.0 to 23.7)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	11.8 (-14.0 to 44.2)	-0.7 (-23.8 to 27.8)
Testicular cancer	1.0 (0.7 to 1.6)	1.1 (0.6 to 1.7)	15.7 (-49.8 to 112.9)	35.7 (-41.6 to 154.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	11.3 (-51.0 to 112.2)	28.7 (-45.2 to 150.1)
Kidney cancer	2.0 (1.3 to 1.8)	2.7 (3.6 to 5.0)	35.0 (123.4 to 250.7)	17.0 (89.7 to 196.2)	0.3 (0.1 to 0.2)	0.3 (0.2 to 0.4)	162.9 (106.9 to 239.1)	121.2 (75.3 to 181.3)
Bladder cancer	3.6 (3.1 to 4.2)	5.6 (4.4 to 6.6)	54.9 (26.5 to 87.3)	19.8 (-2.3 to 45.0)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	47.7 (18.5 to 79.8)	13.2 (-8.5 to 37.1)
Brain and nervous system cancer	1.5 (1.3 to 1.8)	2.1 (1.6 to 2.4)	42.9 (6.9 to 68.5)	31.9 (1.5 to 55.6)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	39.6 (0.7 to 71.5)	28.6 (-4.2 to 54.6)
Thyroid cancer	2.2 (1.5 to 2.7)	2.3 (1.8 to 3.4)	-0.1 (-26.0 to 94.5)	-4.8 (-28.7 to 86.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-1.0 (-28.4 to 87.0)	-7.8 (-33.6 to 75.5)
Mesothelioma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	26.0 (-42.7 to 40.7)	26.0 (-52.2 to 17.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.4 (-40.5 to 45.7)	33.7 (-49.1 to 22.3)
Hodgkin lymphoma	0.5 (0.4 to 0.6)	0.4 (0.3 to 0.6)	-21.0 (-41.1 to 8.0)	-15.6 (-39.0 to 17.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-27.1 (-44.7 to -1.3)	-23.9 (-43.9 to 5.3)
Non-Hodgkin lymphoma	1.8 (1.5 to 2.9)	2.8 (1.8 to 3.6)	68.9 (-27.8 to 111.7)	47.0 (-36.9 to 84.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	62.0 (-30.8 to 107.0)	40.6 (-41.1 to 77.2)
Multiple myeloma	0.4 (0.3 to 0.6)	0.7 (0.4 to 1.0)	58.1 (-2.5 to 132.6)	27.7 (-22.1 to 86.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	52.3 (-13.4 to 138.3)	21.5 (-29.6 to 88.6)
Leukemia	2.0 (1.7 to 2.2)	2.7 (2.3 to 3.1)	35.0 (13.5 to 62.8)	14.1 (-6.5 to 35.8)	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.5)	35.8 (9.9 to 66.0)	9.9 (-10.2 to 33.3)
Other neoplasms	3.7 (3.2 to 4.9)	8.8 (6.3 to 10.9)	155.5 (48.9 to 222.5)	111.6 (26.3 to 163.4)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	143.1 (40.2 to 215.9)	100.4 (17.8 to 154.5)
Cardiovascular diseases	-	-	-	-	9.0 (6.4 to 12.6)	12.1 (8.5 to 16.4)	34.8 (9.9 to 61.5)	5.0 (-14.9 to 25.3)
Rheumatic heart disease	0.3 (0.3 to 0.3)	0.3 (0.3 to 0.4)	5.6 (-4.8 to 16.2)	-9.6 (-18.2 to -1.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	4.6 (-22.3 to 37.0)	-10.1 (-31.2 to 16.4)
Ischemic heart disease	73.7 (64.3 to 84.5)	96.8 (86.8 to 108.4)	32.0 (10.3 to 55.4)	2.2 (-14.6 to 20.7)	3.1 (2.3 to 5.0)	4.1 (3.0 to 6.0)	26.4 (-1.3 to 65.0)	26.4 (-25.0 to 24.1)
Cerebrovascular disease	-	-	-	-	1.4 (0.9 to 1.9)	1.7 (1.1 to 2.3)	20.2 (-9.5 to 54.4)	2.7 (-2.2 to 31.8)
Ischemic stroke	7.7 (6.5 to 9.5)	9.2 (7.8 to 10.8)	20.3 (-8.2 to 55.0)	0.4 (-23.7 to 30.4)	1.1 (0.8 to 1.6)	1.4 (0.9 to 1.9)	19.9 (-10.5 to 56.8)	1.2 (-24.8 to 32.0)
Hemorrhagic stroke	1.6 (1.2 to 2.0)	1.9 (1.5 to 2.3)	11.2 (-11.6 to 66.7)	11.2 (-19.7 to 47.6)	0.2 (0.2 to 0.4)	0.3 (0.2 to 0.4)	20.8 (-13.7 to 70.4)	9.8 (-19.7 to 52.8)
Hypertensive heart disease	8.0 (7.2 to 8.8)	11.6 (10.6 to 12.7)	45.6 (27.4 to 66.0)	3.9 (-9.1 to 18.4)	0.9 (0.6 to 1.2)	1.2 (0.9 to 1.7)	44.9 (25.6 to 67.6)	4.1 (-9.7 to 20.0)
Cardiomyopathy and myocarditis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	26.0 (-42.7 to 40.7)	26.0 (-52.2 to 17.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.4 (-40.5 to 45.7)	33.7 (-49.1 to 22.3)
Atrial fibrillation and flutter	0.4 (0.3 to 0.5)	10.8 (7.9 to 15.2)	2541.8 (1,748.3 to 3,879.0)	1823.5 (1,270.1 to 2,802.1)	0.0 (0.0 to 0.0)	0.8 (0.5 to 1.3)	2,459.7 (1,548.3 to 4,070.8)	1,768.1 (1,137.2 to 2,900.8)
Peripheral vascular disease	168.1 (127.3 to 207.0)	219.0 (164.0 to 278.8)	29.2 (-3.1 to 80.3)	-1.2 (-28.4 to 37.0)	0.3 (0.1 to 0.5)	0.2 (0.1 to 0.5)	-14.6 (-55.7 to 124.3)	-46.8 (-72.1 to 40.2)
Endocarditis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	163.3 (86.9 to 277.0)	138.5 (72.8 to 240.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-38.5 to 213.8)	79.5 (-24.9 to 177.9)
Other cardiovascular and circulatory diseases	29.6 (19.5 to 50.0)	40.7 (23.9 to 57.4)	41.9 (-36.0 to 133.9)	12.3 (-47.8 to 94.1)	2.1 (1.2 to 3.6)	2.9 (1.5 to 4.6)	42.1 (-36.3 to 137.5)	17.3 (-48.1 to 97.0)
Chronic respiratory diseases	-	-	-	-	24.6 (16.8 to 33.5)	24.8 (16.8 to 34.3)	0.5 (-11.9 to 17.6)	-4.1 (-15.5 to 12.0)
Chronic obstructive pulmonary disease	273.7 (260.5 to 285.5)	303.9 (290.7 to 316.8)	11.0 (8.0 to 14.7)	-0.3 (-2.8 to 3.0)	15.4 (9.9 to 21.8)	16.8 (10.8 to 23.9)	8.7 (-6.6 to 34.8)	-1.8 (-16.4 to 21.1)

Appendix Table G.4 - Croatia prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.2 (-23.1 to -14.4)	-30.7 (-33.8 to -25.8)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.9 (15.4 to 28.3)	1.6 (-3.6 to 6.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.0 (16.3 to 29.5)	2.6 (-2.8 to 7.6)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	28.7 (-31.8 to -25.8)	-38.2 (-40.8 to -35.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.6 (-30.7 to -24.4)	-37.2 (-39.6 to -34.4)
Asthma	199.6 (177.8 to 219.1)	177.9 (159.3 to 194.5)	-10.5 (-22.8 to 3.4)	-5.3 (-20.6 to 13.2)	8.8 (5.7 to 12.4)	7.7 (5.0 to 11.0)	-11.5 (-24.2 to 2.7)	-5.4 (-21.2 to 12.5)
Interstitial lung disease and pulmonary sarcoidosis	0.6 (0.5 to 0.8)	0.6 (0.5 to 0.6)	-8.9 (-35.5 to 25.1)	-8.9 (-35.0 to 25.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-7.4 (-33.1 to 26.8)	-7.9 (-33.5 to 25.7)
Other chronic respiratory diseases	-	-	-	-	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.4)	-34.7 (-51.1 to -8.1)	-41.3 (-55.7 to -18.3)
Cirrhosis	-	-	-	-	0.5 (0.4 to 0.9)	0.5 (0.3 to 0.7)	-21.5 (-29.1 to -13.0)	-23.1 (-30.8 to -14.4)
Cirrhosis due to hepatitis B	0.9 (0.7 to 1.2)	0.9 (0.6 to 1.1)	-2.2 (-36.7 to 40.1)	-4.4 (-38.9 to 33.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-0.2 (-39.0 to 48.5)	-0.7 (-41.7 to 42.4)
Cirrhosis due to hepatitis C	1.1 (0.8 to 1.5)	0.9 (0.6 to 1.2)	-25.3 (-55.1 to 20.7)	-31.0 (-57.0 to 10.3)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-26.4 (-56.9 to 21.0)	-31.2 (-59.6 to 11.3)
Cirrhosis due to alcohol use	1.1 (0.7 to 1.4)	0.6 (0.4 to 0.9)	-46.9 (-67.8 to 5.0)	-42.6 (-70.3 to -0.2)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-43.0 (-68.6 to 5.6)	-46.8 (-71.1 to 0.6)
Cirrhosis due to other causes	0.7 (0.5 to 1.0)	0.7 (0.5 to 0.9)	-1.2 (-37.7 to 47.4)	4.9 (-32.1 to 48.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-2.0 (-31.6 to 51.3)	5.0 (-35.1 to 56.1)
Digestive diseases	-	-	-	-	5.8 (4.1 to 7.6)	6.0 (4.3 to 8.0)	4.5 (-3.8 to 12.5)	-4.3 (-12.8 to 3.0)
Peptic ulcer disease	35.8 (34.0 to 37.4)	16.5 (13.8 to 18.8)	-53.9 (-61.3 to -46.7)	-67.6 (-72.9 to -62.8)	1.3 (0.9 to 1.9)	0.7 (0.5 to 1.0)	-48.2 (-53.4 to -37.4)	-62.7 (-66.8 to -55.5)
Gastritis and duodenitis	1.5 (1.4 to 1.6)	3.7 (3.4 to 4.1)	146.5 (119.7 to 175.2)	103.5 (80.5 to 128.2)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	105.1 (63.9 to 153.5)	75.3 (38.8 to 119.6)
Appendicitis	0.3 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-39.1 (-47.4 to -29.1)	-22.5 (-33.8 to -8.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-38.7 (-54.7 to -10.7)	-22.4 (-45.7 to 17.5)
Paralytic ileus and intestinal obstruction	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	35.0 (-25.3 to 91.7)	15.6 (-47.4 to 111.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.8 (-29.0 to 105.5)	13.6 (-47.8 to 125.7)
Inguinal, femoral, and abdominal hernia	23.1 (19.9 to 26.6)	25.3 (22.5 to 28.3)	9.9 (-9.6 to 30.1)	-11.3 (-26.0 to 4.9)	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.5)	9.2 (-10.3 to 30.1)	-10.5 (-25.8 to 5.4)
Inflammatory bowel disease	7.9 (7.5 to 8.2)	11.2 (10.7 to 11.6)	41.9 (34.1 to 51.0)	37.7 (30.2 to 46.2)	1.7 (1.1 to 2.3)	2.3 (1.6 to 3.1)	40.9 (30.1 to 52.3)	37.9 (27.8 to 49.5)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Gallbladder and biliary diseases	15.9 (13.6 to 18.4)	14.0 (12.4 to 15.8)	-12.1 (-26.5 to 5.8)	-15.5 (-34.5 to -6.3)	1.7 (1.1 to 2.3)	1.5 (1.0 to 2.0)	-12.5 (-27.3 to 5.9)	-21.2 (-34.4 to -5.7)
Pancreatitis	1.7 (1.6 to 1.7)	2.0 (1.9 to 2.0)	18.5 (12.2 to 26.0)	11.0 (5.2 to 17.8)	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.8)	17.3 (12.2 to 24.2)	11.1 (2.6 to 27.2)
Other digestive diseases	-	-	-	-	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.6)	137.2 (58.4 to 182.9)	116.1 (44.1 to 157.5)
Neurological disorders	-	-	-	-	47.7 (32.4 to 65.1)	52.2 (36.4 to 71.0)	9.2 (-1.8 to 22.2)	7.5 (-3.3 to 19.4)
Alzheimer disease and other dementias	50.2 (44.7 to 56.2)	76.4 (67.3 to 87.0)	52.0 (28.0 to 82.0)	-3.1 (-17.1 to 16.8)	7.2 (5.1 to 9.5)	11.3 (8.0 to 14.8)	-5.4 (-29.8 to 86.2)	-1.6 (-17.7 to 17.3)
Parkinson disease	3.6 (2.3 to 4.7)	5.0 (3.4 to 6.5)	38.9 (28.5 to 52.9)	2.4 (-4.9 to 11.7)	0.4 (0.2 to 0.6)	0.6 (0.3 to 0.9)	37.9 (20.4 to 59.1)	2.5 (-9.7 to 16.8)
Epilepsy	14.4 (9.5 to 19.9)	12.7 (8.2 to 17.6)	-11.8 (-47.4 to 45.8)	-2.2 (-42.0 to 63.4)	4.3 (2.5 to 6.7)	4.0 (2.2 to 6.1)	-8.3 (-48.6 to 61.9)	3.1 (-42.3 to 80.5)
Multiple sclerosis	1.6 (1.6 to 1.7)	2.8 (2.7 to 3.0)	72.0 (58.1 to 85.6)	79.0 (64.5 to 93.3)	0.5 (0.4 to 0.7)	0.9 (0.7 to 1.2)	69.9 (45.8 to 99.9)	78.1 (51.8 to 108.1)
Migraine	72.3 (66.6 to 78.4)	64.3 (59.6 to 69.1)	-10.2 (-20.2 to -0.1)	0.5 (-11.7 to 11.4)	24.0 (17.7 to 36.3)	21.8 (13.0 to 32.1)	-10.7 (-20.2 to 0.3)	-1.6 (-11.8 to 11.4)
Tension-type headache	940.7 (866.3 to 1,036.3)	859.9 (794.3 to 926.5)	-9.2 (-19.8 to 2.3)	0.4 (-11.1 to 13.7)	1.7 (0.7 to 2.5)	1.3 (0.6 to 2.3)	-9.6 (-20.0 to 2.4)	0.5 (-11.4 to 14.0)
Medication overuse headache	53.1 (34.3 to 74.1)	73.1 (42.4 to 102.8)	41.3 (-11.3 to 88.9)	48.2 (-1.6 to 98.9)	8.3 (4.6 to 13.2)	11.4 (5.8 to 18.2)	40.9 (-11.7 to 89.8)	48.1 (-0.7 to 99.9)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.3 (-23.1 to 46.6)	5.7 (-21.4 to 43.7)	1.0 (0.7 to 1.4)	1.0 (0.7 to 1.4)	4.2 (-25.1 to 37.0)	-29.8 (-49.9 to -7.5)
Mental and substance use disorders	-	-	-	-	106.4 (77.5 to 138.1)	94.8 (69.1 to 122.1)	-11.0 (-13.1 to -8.5)	-1.9 (-4.1 to 0.5)
Schizophrenia	16.6 (15.3 to 18.0)	15.2 (14.0 to 16.4)	-8.8 (-12.2 to -5.4)	-1.6 (-5.2 to 2.4)	10.6 (7.8 to 12.9)	9.7 (7.1 to 11.8)	-8.9 (-14.1 to -3.4)	-1.2 (-6.9 to 4.8)
Alcohol use disorders	56.8 (51.7 to 62.3)	44.9 (41.0 to 48.8)	-21.0 (-25.9 to -15.2)	-14.0 (-19.4 to -7.3)	5.6 (3.7 to 8.1)	4.4 (2.9 to 6.3)	-4.4 (-26.9 to -14.9)	-21.4 (-19.9 to -6.3)
Drug use disorders	-	-	-	-	5.4 (3.5 to 7.7)	4.3 (2.7 to 6.1)	-21.3 (-32.8 to -6.9)	-6.8 (-21.0 to 10.5)
Opioid use disorders	5.2 (2.6 to 8.7)	4.4 (2.2 to 7.4)	-15.4 (-23.5 to -5.6)	-0.7 (-11.7 to 13.3)	2.2 (1.0 to 3.8)	1.8 (0.8 to 3.2)	-15.2 (-26.6 to -1.2)	-0.6 (-14.5 to 16.5)
Cocaine use disorders	2.1 (2.4 to 3.7)	2.6 (2.0 to 3.1)	28.3 (-38.4 to 13.9)	1.8 (-27.4 to 39.0)	0.4 (0.3 to 0.6)	0.4 (0.2 to 0.5)	17.1 (-41.1 to 18.1)	0.5 (-31.0 to 43.3)
Amphetamine use disorders	8.2 (6.6 to 9.8)	5.8 (4.6 to 8.8)	-28.4 (-45.6 to -6.8)	-15.9 (-36.2 to 10.8)	1.1 (0.6 to 1.6)	0.8 (0.5 to 1.1)	-29.0 (-47.0 to -3.0)	-15.6 (-38.5 to 14.8)
Cannabis use disorders	9.0 (7.8 to 10.1)	7.1 (6.2 to 8.0)	-20.2 (-25.6 to -15.3)	0.5 (-6.7 to 7.2)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-20.4 (-30.6 to -7.3)	0.5 (-13.3 to 17.8)
Other drug use disorders	-	-	-	-	1.5 (0.9 to 2.3)	1.1 (0.7 to 1.6)	-25.9 (-48.9 to 6.4)	-12.2 (-39.7 to 26.6)
Depressive disorders	-	-	-	-	40.3 (27.6 to 55.6)	37.6 (25.8 to 51.9)	-6.4 (-11.9 to -1.9)	0.4 (-5.2 to 3.9)
Major depressive disorder	162.2 (139.4 to 182.9)	151.4 (129.5 to 172.7)	-6.5 (-13.0 to -0.8)	-0.4 (-6.4 to 4.5)	33.0 (22.0 to 46.4)	30.6 (20.2 to 42.6)	-7.2 (-13.9 to -1.6)	-0.3 (-6.2 to 5.0)
Dysthymia	75.5 (62.6 to 88.1)	74.0 (61.7 to 85.9)	-1.9 (-4.7 to 1.1)	-0.4 (-0.6 to -0.3)	7.2 (4.7 to 10.6)	7.0 (4.6 to 10.4)	-2.7 (-6.0 to 1.3)	-0.4 (-2.9 to 2.1)
Bipolar disorder	36.5 (29.8 to 43.4)	33.8 (28.1 to 39.7)	-7.3 (-11.9 to -2.2)	-0.6 (-5.3 to 4.8)	7.4 (4.5 to 11.2)	6.8 (4.2 to 10.2)	-7.9 (-14.3 to -2.1)	-0.5 (-6.7 to 6.2)
Anxiety disorders	176.3 (147.8 to 203.3)	159.9 (135.6 to 183.1)	-9.3 (-11.4 to -6.8)	-9.5 (-0.7 to -0.3)	16.1 (10.9 to 23.1)	14.5 (9.7 to 20.6)	-9.9 (-13.2 to -6.5)	-0.2 (-3.0 to 2.2)
Eating disorders	-	-	-	-	1.1 (0.7 to 1.7)	0.9 (0.5 to 1.3)	-22.7 (-28.9 to -16.5)	0.9 (-7.4 to 9.4)
Anorexia nervosa	0.6 (0.4 to 0.7)	0.5 (0.4 to 0.6)	-16.4 (-23.5 to -6.6)	9.8 (0.4 to 22.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-16.5 (-34.8 to 7.9)	9.9 (-14.6 to 41.9)
Bulimia nervosa	4.7 (3.4 to 6.4)	3.6 (2.6 to 4.9)	-23.5 (-24.3 to -22.7)	-0.2 (-0.4 to -0.1)	1.0 (0.6 to 1.6)	0.8 (0.5 to 1.2)	-23.3 (-30.0 to -16.9)	0.0 (-8.8 to 8.2)
Autistic spectrum disorders	-	-	-	-	5.5 (3.8 to 7.5)	4.7 (3.3 to 6.4)	-13.6 (-16.6 to -10.9)	0.6 (-2.7 to 4.0)
Autism	14.3 (13.5 to 15.1)	12.4 (11.7 to 13.1)	-13.0 (-13.6 to -12.4)	0.5 (0.4 to 0.5)	3.5 (2.3 to 4.8)	3.0 (2.0 to 4.1)	-13.7 (-17.7 to -9.6)	0.5 (-4.1 to 5.4)
Asperger syndrome	20.2 (18.9 to 21.6)	17.6 (16.4 to 18.8)	-13.1 (-13.9 to -12.4)	0.6 (0.6 to 0.7)	2.0 (1.4 to 2.8)	1.7 (1.2 to 2.4)	-13.7 (-17.2 to -10.2)	0.7 (-3.4 to 5.0)
Attention-deficit/hyperactivity disorder	20.7 (19.1 to 22.4)	14.4 (13.2 to 15.5)	-30.6 (-30.8 to -30.5)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-30.5 (-35.6 to -24.9)	0.3 (-7.2 to 8.5)
Conduct disorder	30.4 (28.7 to 32.3)	20.9 (19.7 to 22.3)	-31.2 (-31.5 to -30.9)	3.1 (1.0 to 0.1)	3.7 (2.3 to 5.3)	2.5 (1.6 to 3.7)	-31.1 (-34.0 to -27.9)	4.9 (-4.0 to 4.9)
Idiopathic intellectual disability	79.2 (66.9 to 93.8)	58.4 (49.3 to 70.5)	-26.2 (-32.4 to -19.4)	-15.2 (-22.2 to -7.6)	3.8 (2.6 to 5.4)	2.8 (1.9 to 3.9)	-26.7 (-32.0 to -19.5)	-15.2 (-22.7 to -7.0)
Other mental and substance use disorders	89.1 (83.8 to 94.4)	85.9 (80.9 to 90.9)	-3.6 (-4.9 to -2.3)	0.4 (0.2 to 0.6)	6.6 (4.5 to 8.9)	6.3 (4.3 to 8.5)	-4.3 (-7.9 to 0.5)	0.6 (-3.1 to 4.5)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	52.3 (37.8 to 70.4)	57.8 (40.9 to 78.6)	10.3 (-0.9 to 23.9)	8.4 (-1.1 to 20.0)
Diabetes mellitus	280.8 (226.2 to 336.2)	343.3 (274.6 to 423.5)	21.6 (-4.4 to 55.5)	20.0 (-4.4 to 55.1)	21.4 (14.6 to 30.3)	26.4 (17.4 to 38.0)	23.0 (-2.8 to 61.5)	18.4 (-5.6 to 54.0)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.4 (-37.9 to -28.8)	-25.1 (-29.9 to -20.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.4 (-37.9 to -28.8)	-25.1 (-29.9 to -20.2)
Chronic kidney disease	-	-	-	-	15.7 (11.6 to 20.5)	16.9 (12.5 to 21.8)	7.6 (-0.1 to 16.5)	2.9 (-4.4 to 11.0)
Chronic kidney disease due to diabetes mellitus	100.0 (70.1 to 144.9)	134.8 (92.8 to 201.7)	31.7 (6.5 to 97.8)	18.1 (-3.9 to 63.4)	2.8 (1.9 to 3.8)	3.6 (2.6 to 4.8)	29.5 (1.9 to 78.7)	18.6 (-5.7 to 61.1)
Chronic kidney disease due to hypertension	130.2 (89.4 to 179.9)	109.4 (76.7 to 153.8)	-14.6 (-36.5 to 6.9)	-14.0 (-32.4 to 9.1)	4.2 (2.9 to 5.6)	2.4 (1.8 to 3.2)	-41.6 (-53.6 to -27.8)	-41.1 (-55.3 to -32.1)
Chronic kidney disease due to glomerulonephritis	149.7 (100.1 to 224.2)	93.2 (72.5 to 123.4)	-36.6 (-51.9 to -17.0)	-26.6 (-51.4 to -23.9)	3.4 (2.4 to 4.6)	3.0 (2.1 to 4.0)	-11.8 (-31.0 to 10.6)	-7.8 (-26.0 to 10.9)
Chronic kidney disease due to other causes	204.4 (141.6 to 300.1)	286.4 (204.7 to 391.8)	38.8 (16.3 to 80.9)	29.7 (10.1 to 59.7)	5.4 (3.7 to 7.3)	7.9 (5.8 to 10.4)	45.7 (23.4 to 80.5)	38.1 (17.1 to 67.8)
Urinary diseases and male infertility	-	-	-	-	3.1 (2.0 to 4.5)	4.0 (2.6 to 5.6)	29.7 (14.4 to 43.8)	3.5 (-8.1 to 14.9)

Appendix Table G.4 - Croatia prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.1 (1.0 to 1.2)	1.3 (1.3 to 1.4)	18.7 (11.6 to 27.2)	0.0 (17.8 to 35.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	16.7 (-2.3 to 40.4)	5.2 (3.8 to 5.2)
Urolithiasis	46.4 (30.1 to 78.4)	54.5 (38.7 to 78.5)	24.4 (-4.7 to 43.9)	0.3 (-20.0 to 16.6)	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.7)	24.3 (1.1 to 42.6)	5.2 (-11.8 to 21.1)
Benign prostatic hyperplasia	70.0 (64.0 to 76.0)	96.0 (91.6 to 100.4)	37.8 (24.0 to 51.1)	2.5 (-4.3 to 16.9)	3.4 (1.6 to 3.5)	3.6 (2.3 to 4.8)	6.6 (23.2 to 51.0)	6.6 (-4.6 to 17.1)
Male infertility due to other causes	17.8 (12.8 to 23.2)	15.3 (11.6 to 19.4)	-14.3 (-40.4 to 29.8)	9.3 (-23.6 to 66.5)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-12.7 (-40.5 to 32.0)	11.2 (-23.9 to 69.2)
Other urinary diseases	-	-	-	-	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.1)	8.1 (-87.1 to 63.5)	45.4 (-89.1 to 41.9)
Gynecological diseases	-	-	-	-	5.9 (3.8 to 8.9)	5.1 (3.2 to 7.9)	-12.9 (-25.0 to 0.2)	0.8 (-13.4 to 17.0)
Uterine fibroids	113.3 (103.4 to 122.6)	104.9 (96.3 to 113.2)	-7.5 (-8.3 to -6.6)	0.5 (0.4 to 0.5)	1.3 (0.7 to 2.2)	1.2 (0.7 to 2.0)	-8.5 (-14.6 to -4.4)	1.8 (-4.7 to 6.7)
Polycystic ovarian syndrome	84.9 (77.5 to 93.2)	71.7 (64.4 to 79.1)	-15.7 (-26.4 to -3.0)	0.6 (-12.8 to 15.9)	0.8 (0.4 to 1.5)	0.7 (0.3 to 1.3)	-15.5 (-25.9 to -3.1)	0.9 (-11.9 to 16.1)
Female infertility due to other causes	9.4 (2.1 to 19.9)	10.6 (4.4 to 19.3)	12.7 (-65.5 to 460.2)	0.0 (-55.7 to 556.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	25.4 (-66.0 to 432.0)	44.2 (-56.4 to 592.2)
Endometriosis	9.1 (7.7 to 10.6)	8.1 (7.0 to 9.3)	-11.5 (-28.5 to 9.6)	4.1 (-15.7 to 28.4)	0.8 (0.5 to 1.2)	0.7 (0.5 to 1.0)	0.8 (-29.9 to 11.6)	11.2 (-17.3 to 30.4)
Genital prolapse	287.5 (255.7 to 321.6)	268.6 (234.6 to 298.1)	-6.4 (-20.6 to 8.3)	-2.0 (-17.6 to 13.5)	0.9 (0.4 to 1.7)	0.9 (0.4 to 1.6)	-5.9 (-20.4 to 8.9)	-1.9 (-17.1 to 13.9)
Premenstrual syndrome	187.6 (118.2 to 258.3)	147.8 (102.8 to 203.0)	-20.1 (-54.4 to 34.0)	-1.5 (-43.4 to 66.5)	1.6 (0.8 to 2.6)	1.2 (0.7 to 2.1)	-20.2 (-54.7 to 36.0)	-1.9 (-4.1 to 65.4)
Other gynecological diseases	15.5 (14.0 to 16.9)	13.4 (12.7 to 14.3)	-13.3 (-20.1 to -5.0)	1.8 (-6.4 to 11.4)	0.4 (0.3 to 0.6)	0.4 (0.2 to 0.5)	-11.7 (-25.7 to 5.4)	4.0 (-12.4 to 23.9)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	4.4 (3.0 to 6.5)	3.7 (2.4 to 5.3)	-16.2 (-24.6 to -9.7)	3.7 (-12.0 to 3.6)
Thalassemias	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-28.2 (-34.1 to -22.0)	3.8 (-4.4 to 12.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.8 (-50.4 to -1.2)	0.9 (-30.8 to 45.5)
Thalassemia trait	119.1 (110.3 to 129.7)	105.1 (95.8 to 116.5)	-11.7 (-16.1 to -7.9)	-1.0 (-5.5 to 3.1)	3.5 (2.3 to 5.1)	2.9 (2.0 to 4.2)	-16.3 (-24.8 to -9.8)	-4.7 (-12.9 to 1.9)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.7 (-50.2 to -21.4)	-9.7 (-33.5 to 6.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.5 (-53.4 to -18.0)	-12.0 (-38.3 to 8.3)
Sickle cell trait	14.8 (9.3 to 22.3)	12.1 (7.4 to 18.6)	-18.2 (-40.9 to -8.0)	16.2 (-34.4 to 4.0)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-5.9 (-57.1 to -4.3)	20.7 (-51.8 to 22.8)
G6PD deficiency	42.3 (30.8 to 52.8)	57.3 (40.0 to 73.7)	36.0 (-7.4 to 98.0)	55.2 (5.5 to 126.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.5 (-8.1 to -3.8)	8.1 (4.6 to 10.6)
G6PD trait	374.5 (360.4 to 388.5)	338.8 (321.8 to 355.6)	-9.4 (-15.0 to -3.8)	-0.1 (-6.2 to 6.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.6 (-73.5 to 83.2)	-13.2 (-65.0 to 112.8)
Other hemoglobinopathies and hemolytic anemias	36.2 (33.0 to 38.9)	35.4 (31.9 to 38.5)	-2.0 (-13.3 to 9.9)	3.8 (-9.5 to 17.9)	0.8 (0.5 to 1.1)	0.7 (0.4 to 1.0)	-13.6 (-36.9 to 17.6)	3.0 (-21.3 to 39.6)
Endocrine, metabolic, blood, and immune disorders	56.4 (53.3 to 59.8)	54.7 (53.0 to 56.5)	-2.8 (-8.5 to 2.7)	2.8 (-2.0 to 16.6)	1.7 (1.2 to 2.4)	1.6 (1.1 to 2.2)	-6.1 (-12.9 to 0.7)	10.2 (1.3 to 21.8)
Musculoskeletal disorders	-	-	-	-	127.9 (90.9 to 170.7)	137.7 (98.4 to 180.1)	7.5 (0.2 to 15.9)	2.6 (-4.3 to 11.1)
Rheumatoid arthritis	9.4 (8.6 to 10.2)	16.1 (15.0 to 17.1)	70.7 (53.5 to 91.3)	43.7 (29.7 to 61.2)	2.2 (1.5 to 2.9)	3.7 (2.6 to 4.8)	68.3 (49.7 to 92.3)	44.2 (29.3 to 63.6)
Osteoarthritis	285.8 (273.6 to 298.4)	357.0 (344.4 to 370.7)	24.9 (17.7 to 32.6)	0.6 (-5.2 to 6.8)	17.4 (12.3 to 23.6)	21.6 (15.4 to 29.4)	24.0 (16.5 to 31.9)	0.7 (-5.5 to 7.1)
Low back and neck pain	-	-	-	-	95.8 (65.9 to 129.6)	98.6 (68.5 to 133.7)	2.8 (-5.5 to 13.3)	1.6 (-7.1 to 12.7)
Low back pain	654.9 (610.6 to 694.3)	677.6 (640.6 to 712.6)	3.4 (-4.6 to 13.5)	0.5 (-7.7 to 10.3)	72.4 (49.0 to 99.4)	74.3 (51.1 to 102.4)	2.5 (-5.5 to 12.9)	0.6 (-7.4 to 10.7)
Neck pain	239.5 (203.0 to 279.7)	250.7 (184.4 to 302.0)	4.5 (-23.5 to 39.7)	4.7 (-21.9 to 38.9)	23.4 (15.6 to 32.7)	24.3 (15.9 to 33.9)	4.0 (-24.5 to 38.8)	4.6 (-21.7 to 40.3)
Gout	2.7 (2.5 to 2.8)	3.2 (3.0 to 3.4)	18.8 (8.4 to 29.2)	4.5 (-4.7 to 13.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	18.0 (-7.0 to 48.9)	4.8 (-18.4 to 33.3)
Other musculoskeletal disorders	137.3 (104.9 to 169.7)	151.9 (119.4 to 184.7)	10.7 (1.8 to 20.2)	4.9 (-2.1 to 13.9)	12.5 (8.1 to 18.2)	13.7 (9.0 to 19.8)	10.5 (15.0 to 20.3)	5.4 (-2.0 to 14.9)
Other non-communicable diseases	-	-	-	-	85.8 (57.0 to 124.0)	87.2 (59.0 to 126.0)	1.6 (-2.3 to 5.4)	-5.6 (-9.1 to -2.2)
Congenital anomalies	-	-	-	-	6.1 (4.5 to 7.7)	6.3 (4.7 to 8.1)	4.2 (8.9 to 19.3)	14.2 (0.3 to 32.0)
Neural tube defects	1.3 (1.1 to 1.5)	1.0 (0.9 to 1.2)	-20.4 (-34.4 to -5.2)	-3.2 (-20.2 to 15.4)	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.5)	-20.7 (-40.3 to 4.5)	-3.2 (-27.4 to 29.1)
Congenital heart anomalies	24.4 (19.9 to 29.3)	21.3 (18.4 to 26.0)	-13.7 (-32.5 to 18.0)	-0.6 (-22.0 to 35.6)	0.8 (0.3 to 1.5)	0.8 (0.3 to 1.4)	-11.8 (-29.9 to 17.4)	2.7 (-18.1 to 36.6)
Orofacial clefts	5.4 (4.7 to 6.2)	4.9 (4.3 to 5.9)	-9.5 (-23.4 to 12.2)	1.7 (-14.1 to 26.4)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-0.0 (-42.0 to 3.3)	-13.6 (-35.3 to 18.1)
Down syndrome	6.4 (5.5 to 7.8)	6.4 (5.5 to 7.5)	1.6 (-21.8 to 22.5)	7.6 (-17.1 to 29.6)	0.9 (0.7 to 1.2)	1.0 (0.7 to 1.3)	10.2 (-15.7 to 35.6)	10.2 (-15.5 to 35.7)
Turner syndrome	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-6.3 (-37.1 to 47.6)	10.9 (-25.7 to 75.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.4 (-38.1 to 47.0)	10.9 (-26.8 to 74.1)
Klinefelter syndrome	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-4.7 (-27.7 to 46.8)	10.4 (-16.3 to 69.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.3 (-38.2 to 59.1)	11.9 (-26.3 to 86.1)
Chromosomal unbalanced rearrangements	10.2 (8.2 to 13.2)	10.5 (8.5 to 13.7)	1.9 (-23.8 to 43.3)	1.9 (-19.5 to 51.6)	1.5 (1.0 to 2.1)	1.6 (1.2 to 2.3)	11.0 (-17.4 to 58.2)	11.0 (-17.0 to 58.7)
Other congenital anomalies	16.6 (13.3 to 19.4)	14.0 (11.6 to 16.4)	-15.7 (-23.1 to -6.0)	-2.2 (-16.6 to 2.1)	2.3 (1.6 to 3.2)	2.5 (1.7 to 3.5)	8.1 (-10.9 to 35.2)	25.8 (2.8 to 57.5)
Skin and subcutaneous diseases	-	-	-	-	23.9 (15.5 to 35.1)	20.4 (13.5 to 30.5)	-14.3 (-22.6 to -6.8)	-5.1 (-12.7 to 1.5)
Dermatitis	229.2 (192.7 to 270.5)	203.9 (172.5 to 237.9)	-11.0 (-12.6 to -9.3)	-0.1 (-0.1 to -0.0)	5.9 (3.7 to 8.6)	5.2 (3.3 to 7.5)	-12.1 (-15.0 to -9.0)	0.0 (-2.0 to 2.7)
Psoriasis	43.4 (38.0 to 48.7)	41.5 (36.5 to 46.5)	-4.4 (-6.5 to -1.7)	4.4 (-0.1 to 0.2)	0.0 (2.4 to 5.0)	0.0 (2.3 to 4.7)	-4.4 (-9.9 to 0.4)	0.1 (-4.9 to 5.5)
Cellulitis	0.7 (0.6 to 0.8)	0.6 (0.5 to 0.8)	-8.8 (-13.5 to 3.6)	2.3 (-5.2 to 12.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-8.8 (-24.0 to 13.3)	0.0 (-14.9 to 27.1)
Pyoderma	3.3 (2.7 to 4.1)	3.3 (2.6 to 4.1)	-0.0 (-6.4 to 4.4)	-0.0 (-2.5 to 1.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.1 (-11.8 to 8.4)	0.1 (-8.7 to 9.5)
Scabies	8.7 (8.0 to 9.5)	6.6 (6.0 to 7.2)	-23.7 (-32.7 to -13.9)	-10.2 (-21.0 to 1.4)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-24.0 (-33.9 to -12.3)	-10.1 (-21.4 to 2.5)
Fungal skin diseases	402.2 (314.3 to 521.2)	377.2 (298.3 to 477.8)	-6.2 (-9.5 to -1.4)	5.7 (-0.0 to 0.4)	2.2 (0.9 to 2.9)	2.1 (0.8 to 4.6)	-2.1 (-10.0 to -1.9)	2.1 (-0.7 to 12.3)
Viral skin diseases	92.9 (70.8 to 115.5)	74.8 (57.8 to 94.2)	-19.5 (-22.5 to -16.0)	0.1 (-1.6 to 1.8)	2.9 (1.7 to 4.5)	2.3 (1.4 to 3.6)	-19.9 (-23.3 to -16.2)	38.9 (-2.8 to 3.3)
Acne vulgaris	128.6 (102.2 to 151.7)	91.0 (75.5 to 105.6)	-30.3 (-44.2 to -3.0)	-8.5 (-27.1 to 30.3)	1.4 (0.6 to 2.7)	1.0 (0.5 to 1.9)	-30.2 (-44.6 to -1.4)	-8.6 (-27.5 to 31.9)
Alopecia areata	6.0 (5.1 to 6.8)	6.2 (5.3 to 7.0)	2.2 (-17.2 to 28.0)	2.8 (-15.6 to 26.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	2.0 (-19.1 to 26.3)	3.7 (-18.8 to 26.9)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.0 (-24.6 to 35.5)	-1.9 (-24.2 to 29.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.0 (-24.6 to 35.8)	-1.9 (-24.2 to 30.0)
Urticaria	87.2 (66.1 to 109.3)	61.6 (46.1 to 76.9)	-28.5 (-54.0 to 1.3)	-22.5 (-48.7 to 8.2)	5.1 (3.1 to 7.6)	3.6 (2.2 to 5.4)	-29.0 (-54.3 to 0.6)	-30.3 (-48.1 to 8.3)
Decubitus ulcer	0.8 (0.7 to 1.1)	1.6 (1.3 to 2.0)	93.4 (39.4 to 167.2)	0.1 (-3.1 to 3.9)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	86.9 (29.6 to 168.7)	38.9 (-1.4 to 95.0)
Other skin and subcutaneous diseases	374.5 (220.2 to 628.1)	385.0 (211.0 to 677.9)	1.5 (-9.1 to 13.5)	-3.5 (-8.1 to 0.7)	2.2 (0.9 to 4.8)	2.2 (0.8 to 5.2)	1.1 (-9.5 to 12.9)	-3.3 (-8.1 to 1.0)
Sense organ diseases	-	-	-	-	42.5 (27.9 to 61.5)	46.2 (31.1 to 66.0)	8.8 (3.3 to 13.7)	-10.1 (-14.2 to -6.5)
Glaucoma	6.5 (5.3 to 8.5)	6.2 (5.0 to 7.6)	-4.8 (-25.5 to 19.7)	-15.8 (-33.4 to 2.2)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	0.4 (-20.3 to 21.4)	0.4 (-16.2 to -13.1)
Cataract	68.9 (51.0 to 85.7)	71.8 (57.6 to 87.9)	3.4 (-12.0 to 26.7)	-27.5 (-38.0 to -11.7)	2.4 (1.5 to 3.6)	2.5 (1.6 to 3.8)	5.3 (-9.7 to 27.6)	-26.3 (-36.2 to -12.5)
Macular degeneration	18.8 (14.5 to 25.2)	24.2 (18.2 to 30.4)	28.6 (2.3 to 69.5)	6.1 (-15.5 to 39.6)	0.6 (0.4 to 1.0)	0.8 (0.5 to 1.2)	29.8 (3.9 to 69.0)	5.2 (-15.0 to 36.6)
Uncorrected refractive error	419.1 (372.7 to 461.3)	433.3 (387.3 to 476.3)	3.5 (-10.4 to 18.9)	9.0 (-20.1 to 4.7)	6.8 (4.0 to 11.3)	6.6 (3.9 to 10.8)	-3.1 (-17.7 to 6.2)	-33.3 (-20.3 to -5.1)
Age-related and other hearing loss	1,037.5 (919.5 to 1,137.6)	1,119.0 (1,005.1 to 1,217.1)	7.8 (3.3 to 12.6)	-8.0 (-11.4 to -4.2)	28.0 (18.5 to 40.1)	32.0 (21.5 to 44.9)	8.7 (6.9 to 22.3)	-8.7 (-14.4 to -3.6)
Other vision loss	34.0 (29.1 to 40.8)	24.8 (21.0 to 29.7)	-26.6 (-38.4 to -17.4)	-30.4 (-38.8 to -22.9)	1.4 (0.9 to 2.1)	1.2 (0.8 to 1.7)	-1.2 (-30.7 to -9.6)	-19.0 (-34.9 to -19.3)
Other sense organ diseases	114.7 (108.8 to 120.7)	108.6 (103.4 to 114.0)	-5.2 (-11.6 to 1.9)	-0.3 (-6.9 to 6.5)	3.0 (1.9 to 4.4)	2.8 (1.7 to 4.1)	-6.3 (-13.2 to 1.6)	-0.3 (-7.6 to 7.7)
Oral disorders	-	-	-	-	13.4 (7.9 to 21.2)	14.3 (8.5 to 22.4)	6.5 (2.4 to 10.5)	-1.7 (-5.7 to 1.9)
Deciduous caries	270.6 (259.9 to 280.2)	176.6 (171.3 to 182.9)	-34.8 (-37.7 to -31.3)	0.3 (-4.3 to 5.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.1 (-40.1 to -28.9)	0.1 (-7.9 to 9.6)
Permanent caries	2,412.5 (2,278.2 to 2,577.2)	2,232.2 (2,127.4 to 2,348.1)	-7.3 (-14.1 to -0.5)	4.2 (-3.2 to 12.4)	1.4 (0.6 to 2.8)	1.3 (0.6 to 2.5)	-7.8 (-14.6 to -0.6)	4.3 (-3.3 to 12.8)
Periodontal diseases	652.9 (626.8 to 677.2)	699.1 (666.2 to 729.3)	7.0 (1.1 to					

Appendix Table G.4 - Croatia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	182.8 (175.0 to 190.6)	217.7 (209.2 to 225.2)	19.1 (12.3 to 26.6)	-7.8 (-13.0 to -2.1)	5.0 (3.4 to 6.9)	5.9 (4.0 to 8.1)	18.3 (11.2 to 26.0)	18.3 (-13.4 to -1.6)
Other oral disorders	92.5 (87.4 to 97.4)	85.5 (80.9 to 89.8)	-7.6 (-14.6 to -0.3)	-0.7 (-8.3 to 7.3)	2.7 (1.7 to 4.0)	2.5 (1.6 to 3.7)	-9.9 (-15.3 to -4.4)	-0.5 (-8.5 to 7.7)
Injuries	-	-	-	-	53.1 (39.8 to 68.7)	42.8 (30.7 to 58.2)	-19.7 (-27.9 to -10.6)	-30.2 (-37.3 to -21.8)
Transport injuries	-	-	-	-	18.0 (13.4 to 23.3)	11.1 (7.8 to 15.1)	-38.6 (-46.2 to -30.1)	-41.8 (-48.9 to -33.7)
Road injuries	-	-	-	-	16.0 (12.0 to 20.7)	10.4 (7.3 to 14.1)	-35.4 (-43.6 to -26.2)	-38.9 (-46.4 to -29.8)
Pedestrian road injuries	-	-	-	-	4.3 (3.2 to 5.5)	2.8 (2.0 to 3.8)	-35.3 (-43.7 to -25.5)	-40.9 (-49.3 to -31.7)
Cyclist road injuries	-	-	-	-	2.2 (1.6 to 2.9)	1.5 (1.0 to 2.0)	-33.8 (-41.1 to -26.7)	-37.5 (-44.5 to -30.8)
Motorcyclist road injuries	-	-	-	-	1.4 (1.0 to 1.9)	0.9 (0.7 to 1.3)	-33.5 (-42.0 to -23.1)	-33.9 (-42.3 to -23.1)
Motor vehicle road injuries	-	-	-	-	7.9 (5.9 to 10.2)	5.1 (3.6 to 7.0)	-35.5 (-44.4 to -24.9)	-37.9 (-46.4 to -27.7)
Other road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-72.3 (-75.7 to -68.3)	-73.6 (-76.9 to -69.7)
Other transport injuries	-	-	-	-	1.9 (1.4 to 2.6)	0.7 (0.5 to 0.9)	-65.2 (-68.8 to -60.7)	-68.6 (-71.8 to -64.6)
Unintentional injuries	-	-	-	-	34.5 (25.9 to 44.5)	31.3 (22.6 to 42.2)	-9.5 (-18.4 to -0.4)	-24.0 (-31.5 to -16.1)
Falls	-	-	-	-	26.6 (20.0 to 34.3)	24.8 (17.9 to 33.6)	-6.9 (-17.2 to 3.9)	-24.7 (-33.2 to -15.7)
Drowning	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-42.6 (-49.7 to -34.3)	-41.3 (-52.7 to -37.9)
Fire, heat, and hot substances	-	-	-	-	0.5 (0.4 to 0.6)	0.4 (0.3 to 0.5)	-28.0 (-37.5 to -18.7)	-31.3 (-40.1 to -22.4)
Poisonings	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-15.6 (-27.4 to -2.1)	-9.8 (-22.5 to 5.9)
Exposure to mechanical forces	-	-	-	-	5.0 (3.7 to 6.6)	4.4 (3.1 to 5.9)	-13.0 (-19.0 to -7.3)	-15.9 (-21.3 to -10.7)
Unintentional firearm injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-41.0 (-48.6 to -32.4)	-41.3 (-48.6 to -33.1)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-48.3 (-54.5 to -41.9)	-50.2 (-56.3 to -43.9)
Other exposure to mechanical forces	-	-	-	-	4.8 (3.5 to 6.3)	4.2 (3.1 to 5.8)	-11.6 (-17.7 to -5.8)	-14.5 (-20.0 to -9.3)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-7.9 (-9.3 to -6.2)	-1.8 (-9.0 to 5.0)
Animal contact	-	-	-	-	0.3 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-17.5 (-24.7 to -9.2)	-16.6 (-23.5 to -8.5)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-14.7 (-24.3 to -3.5)	-11.3 (-21.4 to 1.1)
Non-venomous animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-18.8 (-27.0 to -9.3)	-19.3 (-27.2 to -9.7)
Foreign body	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-27.1 (-34.3 to -18.4)	-28.7 (-36.1 to -20.5)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-43.4 (-53.1 to -31.7)	-45.5 (-54.8 to -34.2)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-14.0 (-19.1 to -8.5)	-9.7 (-16.2 to -3.1)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-14.9 (-22.9 to -5.6)	-18.8 (-26.0 to -10.1)
Other unintentional injuries	-	-	-	-	1.5 (1.1 to 2.0)	1.1 (0.8 to 1.5)	-27.7 (-32.8 to -22.0)	-34.9 (-39.2 to -29.7)
Self-harm and interpersonal violence	-	-	-	-	0.6 (0.5 to 0.8)	0.4 (0.3 to 0.6)	-36.9 (-43.7 to -28.9)	-39.7 (-46.1 to -32.3)
Self-harm	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-27.9 (-35.6 to -18.8)	-30.8 (-38.3 to -22.6)
Interpersonal violence	-	-	-	-	0.3 (0.3 to 0.4)	0.2 (0.1 to 0.3)	-44.8 (-51.4 to -36.3)	-47.4 (-53.6 to -39.6)
Assault by firearm	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-36.5 (-41.8 to -29.9)	-39.8 (-44.7 to -33.7)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-29.0 (-37.8 to -18.0)	-31.7 (-40.2 to -21.3)
Assault by other means	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-49.3 (-56.3 to -41.2)	-51.8 (-58.3 to -44.2)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-

Appendix Table G.4 - Cuba prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,091.6 (811.5 to 1,417.3)	1,382.5 (1,025.9 to 1,799.1)	26.7 (23.8 to 29.6)	26.7 (-1.1 to 3.3)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	108.9 (74.6 to 154.4)	101.5 (70.9 to 143.3)	-6.7 (-11.8 to -1.1)	-0.4 (-5.5 to 5.0)
HIV/AIDS and tuberculosis	-	-	-	-	1.5 (1.0 to 2.1)	1.5 (1.0 to 2.1)	-1.2 (-21.8 to 28.4)	-22.6 (-39.4 to 0.6)
Tuberculosis	4.2 (3.9 to 4.6)	2.6 (2.3 to 3.0)	-37.6 (-43.0 to -31.4)	-51.9 (-55.8 to -48.1)	1.3 (0.9 to 1.7)	0.8 (0.5 to 1.1)	-38.2 (-48.8 to -26.7)	-51.8 (-59.9 to -43.2)
HIV/AIDS	-	-	-	-	0.3 (0.1 to 0.5)	0.7 (0.5 to 1.1)	136.1 (29.1 to 445.0)	136.1 (1.7 to 340.6)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.3 (-72.4 to 20.3)	-50.2 (-79.2 to -9.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.3 (-72.4 to 20.4)	-50.2 (-79.3 to -9.4)
HIV/AIDS resulting in other diseases	1.8 (1.2 to 2.7)	9.8 (7.3 to 13.1)	469.0 (238.6 to 722.9)	376.0 (176.4 to 588.5)	0.3 (0.1 to 0.5)	0.7 (0.5 to 1.1)	195.4 (30.0 to 451.4)	138.2 (2.0 to 346.0)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	19.9 (13.6 to 27.7)	17.6 (12.2 to 24.7)	-11.5 (-17.6 to -4.7)	-5.2 (-11.6 to 1.7)
Diarrheal diseases	58.5 (54.4 to 62.2)	53.2 (49.1 to 57.3)	-9.1 (-17.6 to 0.3)	1.8 (-7.4 to 12.1)	9.4 (6.4 to 13.2)	8.4 (5.7 to 11.6)	-10.8 (-19.8 to -0.9)	1.6 (-8.7 to 12.3)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Typhoid fever	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-39.5 (-49.5 to -27.4)	-35.9 (-46.1 to -24.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.5 (-49.5 to -27.4)	-35.9 (-46.1 to -24.0)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.1 (-49.8 to -17.3)	-32.5 (-44.8 to -13.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.1 (-49.8 to -17.2)	-32.5 (-44.8 to -13.1)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Lower respiratory infections	11.0 (9.4 to 12.7)	7.0 (6.2 to 7.8)	-36.7 (-45.7 to -23.8)	-36.6 (-46.1 to -21.6)	1.1 (0.8 to 1.6)	0.7 (0.5 to 1.0)	-39.2 (-48.0 to -24.0)	-36.8 (-47.1 to -20.5)
Upper respiratory infections	530.1 (473.9 to 583.5)	504.2 (449.5 to 557.6)	-4.7 (-18.1 to 8.7)	-4.0 (-17.9 to 9.0)	6.2 (3.5 to 10.4)	5.9 (3.2 to 10.1)	-5.3 (-18.5 to 8.4)	-4.1 (-17.9 to 9.6)
Otitis media	114.2 (108.5 to 121.6)	96.2 (91.3 to 101.5)	-15.8 (-21.9 to -9.5)	-12.2 (-18.5 to -5.9)	2.2 (1.3 to 3.5)	1.8 (1.1 to 2.9)	-16.8 (-23.5 to -9.0)	-13.5 (-20.5 to -6.0)
Meningitis	-	-	-	-	0.5 (0.4 to 0.8)	0.3 (0.2 to 0.5)	-37.7 (-51.7 to -25.4)	-39.8 (-52.7 to -26.9)
Pneumococcal meningitis	1.9 (1.1 to 3.0)	1.3 (0.8 to 2.1)	-30.6 (-43.3 to -9.1)	-39.2 (-50.0 to -19.6)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-35.8 (-52.2 to -7.2)	-39.2 (-54.1 to -11.0)
H influenzae type B meningitis	0.8 (0.3 to 1.5)	0.4 (0.2 to 0.9)	-45.8 (-68.9 to -24.3)	-47.4 (-67.2 to -26.4)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-50.9 (-73.9 to -19.9)	-47.4 (-71.8 to -14.8)
Meningococcal meningitis	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.4)	-22.2 (-45.4 to 3.7)	-32.7 (-51.5 to -7.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.1 (-41.1 to 13.1)	-25.6 (-45.9 to 4.9)
Other meningitis	1.3 (0.6 to 2.4)	0.9 (0.4 to 1.7)	-34.7 (-53.0 to -21.3)	-40.8 (-56.3 to -28.0)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-33.4 (-57.8 to -11.1)	-37.0 (-59.9 to -15.0)
Encephalitis	1.3 (0.6 to 3.2)	1.2 (0.5 to 3.1)	-6.7 (-20.1 to 7.2)	-4.9 (-33.0 to -9.4)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-9.1 (-20.6 to 19.1)	-18.2 (-33.0 to 1.4)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Whooping cough	0.9 (0.7 to 1.2)	0.7 (0.5 to 0.8)	-29.6 (-30.0 to -29.1)	10.6 (9.9 to 11.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-29.2 (-42.5 to -12.2)	11.2 (-9.7 to 37.9)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Varicella and herpes zoster	7.1 (6.1 to 8.1)	7.8 (6.6 to 9.5)	11.0 (-11.9 to 42.5)	2.0 (-16.4 to 25.4)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	44.4 (-0.3 to 110.2)	2.9 (-28.7 to 47.0)
Neglected tropical diseases and malaria	-	-	-	-	13.6 (8.3 to 21.1)	14.9 (9.4 to 23.4)	9.4 (-15.6 to 42.9)	9.7 (-13.7 to 38.8)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.3 (-42.6 to 87.4)	10.8 (-40.7 to 92.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.1 (-42.8 to 88.8)	10.8 (-41.5 to 93.3)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.3 (-44.9 to 21.8)	-11.2 (-38.2 to 35.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cutaneous and mucocutaneous leishmaniasis	1.8 (1.1 to 2.6)	1.8 (1.0 to 3.0)	-5.5 (-48.2 to 105.7)	-14.5 (-50.5 to 71.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.6 (-50.0 to 117.8)	-13.1 (-52.9 to 82.4)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	1.2 (0.4 to 2.8)	0.5 (0.2 to 1.0)	-55.2 (-85.9 to 25.3)	-60.0 (-86.6 to 6.0)	0.4 (0.1 to 0.9)	0.2 (0.1 to 0.3)	-54.0 (-86.0 to 41.2)	-59.3 (-86.6 to 16.1)
Cystic echinococcosis	0.6 (0.6 to 0.7)	0.6 (0.5 to 0.7)	3.1 (-13.1 to 8.7)	-23.9 (-35.1 to -19.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	2.1 (-23.8 to 32.0)	-23.6 (-42.2 to -2.3)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	2.4 (1.0 to 5.4)	12.6 (5.0 to 28.1)	419.5 (416.8 to 422.5)	397.0 (394.5 to 399.9)	0.4 (0.1 to 1.0)	2.0 (0.7 to 4.9)	413.2 (335.2 to 513.9)	397.5 (322.4 to 490.2)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Intestinal nematode infections	-	-	-	-	9.6 (5.5 to 16.0)	10.1 (5.7 to 16.6)	5.8 (-24.0 to 48.3)	1.2 (-26.3 to 36.4)
Ascariasis	1,385.9 (1,202.0 to 1,605.4)	1,472.5 (1,207.3 to 1,800.3)	5.6 (-17.2 to 39.2)	-1.1 (-20.8 to 27.4)	2.1 (1.0 to 3.9)	2.2 (1.0 to 4.2)	3.4 (-46.9 to 91.9)	1.1 (-45.0 to 75.0)
Trichuriasis	610.6 (520.6 to 716.8)	646.4 (545.5 to 765.4)	5.7 (-15.5 to 33.0)	5.7 (-19.7 to 22.4)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	0.9 (-60.6 to 162.7)	-0.6 (-58.2 to 139.4)
Hookworm disease	1,374.5 (1,221.2 to 1,549.8)	1,590.6 (1,315.5 to 1,691.4)	9.6 (-9.2 to 29.0)	9.6 (-15.9 to 17.5)	7.8 (4.3 to 12.2)	7.8 (4.5 to 13.1)	0.5 (-28.0 to 55.8)	0.9 (-29.6 to 43.9)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	99.5 (81.0 to 119.5)	80.1 (76.1 to 85.0)	-19.5 (-32.9 to -1.4)	-4.2 (-21.0 to 18.7)	3.2 (1.9 to 4.7)	2.5 (1.6 to 3.6)	-23.1 (-32.3 to 9.3)	-3.5 (-15.2 to 38.2)
Maternal disorders	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-	-
Maternal hemorrhage	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-7.5 (-15.8 to -0.5)	16.5 (6.6 to 25.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Maternal sepsis and other maternal infections	0.5 (0.3 to 0.8)	0.4 (0.3 to 0.7)	-16.6 (-41.3 to 5.6)	-26.7 (-47.2 to -5.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Maternal hypertensive disorders	0.8 (0.5 to 1.2)	0.5 (0.3 to 0.8)	-32.9 (-39.4 to -24.3)	-11.1 (-18.0 to -2.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-	-
Obstructed labor	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Complications of abortion	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-39.2 (-68.4 to 66.2)	-19.9 (-58.2 to 111.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Neonatal disorders	-	-	-	-	10.8 (7.2 to 14.6)	14.4 (9.8 to 19.6)	33.5 (-3.6 to 82.4)	35.0 (-2.2 to 83.0)
Preterm birth complications	45.7 (32.5 to 64.9)	64.6 (43.4 to 96.6)	40.7 (9.9 to 77.9)	37.1 (7.2 to 72.6)	5.3 (3.7 to 7.2)	7.8 (5.3 to 11.0)	47.2 (4.3 to 97.7)	47.1 (3.8 to 98.0)
Neonatal encephalopathy due to birth asphyxia and trauma	24.6 (10.0 to 57.6)	14.1 (5.1 to 34.7)	-43.5 (-64.9 to -13.0)	-44.4 (-64.9 to -14.2)	3.4 (2.1 to 5.1)	2.1 (1.2 to 3.2)	-39.6 (-65.5 to -14.4)	-37.3 (-63.9 to 8.0)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hemolytic disease and other neonatal jaundice	2.7 (1.1 to 6.6)	2.3 (0.6 to 5.5)	-16.5 (-76.9 to 216.9)	-16.1 (-76.8 to 215.1)	1.1 (0.4 to 2.7)	0.9 (0.2 to 2.3)	-15.8 (-76.8 to 217.6)	-15.2 (-76.6 to 212.3)
Other neonatal disorders	-	-	-	-	0.9 (0.4 to 2.2)	3.5 (2.0 to 5.4)	374.6 (27.9 to 800.5)	378.0 (28.8 to 807.8)
Nutritional deficiencies	-	-	-	-	57.2 (38.0 to 83.4)	48.1 (31.6 to 70.1)	-15.9 (-18.3 to -14.2)	-6.1 (-8.7 to -3.8)
Protein-energy malnutrition	2.3 (1.3 to 3.8)	3.1 (1.8 to 5.3)	39.8 (-37.0 to 203.7)	120.3 (-3.8 to 380.0)	0.3 (0.1 to 0.5)	0.4 (0.2 to 0.7)	40.2 (-38.5 to 204.4)	120.7 (-4.9 to 379.7)
Iodine deficiency	18.7 (14.6 to 23.8)	9.2 (6.5 to 12.2)	-50.0 (-68.5 to -30.7)	-53.2 (-70.6 to -35.9)	0.3 (0.2 to 0.6)	0.2 (0.1 to 0.3)	-50.3 (-69.2 to -30.2)	-53.2 (-70.8 to -35.2)
Vitamin A deficiency	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-

Appendix Table G.4 - Cuba prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	808.5 (780.6 to 833.7)	1,220.9 (1,181.9 to 1,258.6)	51.0 (44.3 to 58.0)	-4.2 (-10.5 to -1.9)	22.1 (15.0 to 30.4)	33.3 (22.6 to 46.0)	50.6 (43.8 to 57.5)	-6.4 (-10.7 to -2.2)
Other oral disorders	191.3 (181.0 to 201.9)	221.3 (209.4 to 233.8)	15.6 (6.8 to 25.4)	-1.0 (-8.0 to 6.5)	5.6 (3.5 to 8.4)	6.4 (4.0 to 9.5)	14.9 (5.7 to 24.5)	-1.1 (-8.3 to 6.8)
Injuries	-	-	-	-	72.7 (55.3 to 93.6)	64.9 (46.4 to 87.8)	-11.3 (-20.3 to -0.8)	-36.3 (-42.5 to -28.8)
Transport injuries	-	-	-	-	27.6 (20.6 to 35.8)	21.0 (14.9 to 28.5)	-24.2 (-34.0 to -12.4)	-45.8 (-52.6 to -37.7)
Road injuries	-	-	-	-	24.4 (18.2 to 31.6)	18.5 (13.3 to 25.6)	-23.0 (-33.2 to -10.7)	-45.9 (-52.1 to -36.5)
Pedestrian road injuries	-	-	-	-	6.5 (4.9 to 8.4)	4.6 (3.2 to 6.2)	-30.3 (-39.4 to -18.4)	-50.3 (-56.5 to -42.1)
Cyclist road injuries	-	-	-	-	1.9 (1.4 to 2.5)	1.6 (1.2 to 2.2)	-13.2 (-22.8 to -2.8)	-39.3 (-45.9 to -32.0)
Motorcyclist road injuries	-	-	-	-	3.1 (2.3 to 4.1)	2.2 (1.6 to 3.1)	-29.4 (-39.4 to -18.4)	-49.1 (-56.0 to -41.2)
Motor vehicle road injuries	-	-	-	-	12.3 (9.1 to 15.9)	10.0 (7.1 to 13.5)	-19.0 (-30.7 to -5.3)	-41.9 (-50.0 to -31.9)
Other road injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.4 (0.3 to 0.6)	-23.7 (-33.2 to -11.8)	-46.8 (-53.1 to -38.6)
Other transport injuries	-	-	-	-	3.2 (2.4 to 4.2)	2.1 (1.5 to 2.9)	-33.2 (-40.9 to -24.3)	-52.4 (-57.9 to -46.3)
Unintentional injuries	-	-	-	-	41.7 (31.8 to 53.8)	40.7 (29.7 to 54.7)	-2.6 (-11.1 to 6.6)	-30.0 (-35.8 to -23.6)
Falls	-	-	-	-	18.9 (14.5 to 24.3)	19.5 (13.9 to 26.3)	3.0 (-9.1 to 15.6)	-31.1 (-39.2 to -22.1)
Drowning	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-22.8 (-34.7 to -9.4)	-43.1 (-51.4 to -33.5)
Fire, heat, and hot substances	-	-	-	-	1.5 (1.1 to 1.9)	1.0 (0.7 to 1.4)	-29.8 (-38.9 to -19.7)	-47.4 (-53.8 to -39.9)
Poisonings	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-25.4 (-36.1 to -11.0)	-36.3 (-45.7 to -24.2)
Exposure to mechanical forces	-	-	-	-	14.9 (11.2 to 19.5)	11.3 (8.1 to 15.3)	-24.7 (-30.9 to -18.4)	-39.0 (-43.3 to -34.4)
Unintentional firearm injuries	-	-	-	-	0.8 (0.6 to 1.0)	1.1 (0.8 to 1.5)	37.8 (20.3 to 59.4)	7.5 (-5.7 to 23.8)
Unintentional suffocation	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-16.6 (-27.3 to -5.6)	-35.1 (-42.9 to -27.0)
Other exposure to mechanical forces	-	-	-	-	13.9 (10.4 to 18.2)	10.0 (7.2 to 13.6)	-28.4 (-34.3 to -22.3)	-41.6 (-45.8 to -37.0)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	74.0 (62.7 to 86.3)	22.9 (15.6 to 31.5)
Animal contact	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	47.0 (32.8 to 62.8)	9.6 (0.4 to 20.3)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	46.3 (29.2 to 64.7)	12.8 (-0.3 to 26.5)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	47.0 (31.8 to 65.8)	7.3 (-3.2 to 19.6)
Foreign body	-	-	-	-	0.5 (0.4 to 0.6)	0.5 (0.4 to 0.6)	4.5 (-5.8 to 16.8)	-25.0 (-32.0 to -16.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-16.3 (-29.4 to 0.1)	-39.2 (-48.4 to -27.8)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	9.0 (-4.2 to 24.5)	-12.4 (-22.2 to 1.2)
Foreign body in other body part	-	-	-	-	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.4)	15.7 (3.6 to 29.1)	-19.2 (-26.5 to -10.3)
Other unintentional injuries	-	-	-	-	5.1 (3.8 to 6.7)	7.5 (5.5 to 10.1)	46.0 (34.0 to 59.9)	0.2 (-7.7 to 9.5)
Self-harm and interpersonal violence	-	-	-	-	3.5 (2.6 to 4.4)	3.1 (2.2 to 4.2)	-10.8 (-20.8 to 3.6)	-35.1 (-42.3 to -25.1)
Self-harm	-	-	-	-	0.7 (0.5 to 0.9)	0.6 (0.4 to 0.8)	-22.6 (-31.3 to -12.6)	-45.3 (-51.2 to -38.8)
Interpersonal violence	-	-	-	-	2.7 (2.1 to 3.5)	2.5 (1.8 to 3.5)	-7.6 (-19.0 to 7.9)	-32.3 (-40.2 to -21.2)
Assault by firearm	-	-	-	-	0.6 (0.5 to 0.8)	0.8 (0.6 to 1.1)	20.4 (8.2 to 35.1)	-12.4 (-20.9 to -2.1)
Assault by sharp object	-	-	-	-	0.7 (0.5 to 0.9)	0.7 (0.5 to 1.0)	-0.2 (-13.3 to 17.7)	-26.1 (-35.8 to -13.8)
Assault by other means	-	-	-	-	1.4 (1.0 to 1.8)	1.1 (0.8 to 1.4)	-24.1 (-34.8 to -9.5)	-44.6 (-52.3 to -34.7)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.8 (48.3 to 285.7)	89.1 (26.8 to 203.0)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.8 (48.3 to 285.7)	89.1 (26.8 to 203.0)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Cyprus prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	77.1 (57.7 to 100.2)	111.6 (83.6 to 144.0)	44.6 (37.5 to 51.6)	4.4 (-9.4 to 0.3)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	3.7 (2.6 to 5.0)	4.6 (3.4 to 6.2)	26.2 (6.8 to 52.5)	9.4 (-7.3 to 30.8)
HIV/AIDS and tuberculosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	67.6 (35.1 to 111.4)	18.2 (-3.6 to 47.8)
Tuberculosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	46.0 (38.6 to 53.4)	3.4 (-1.6 to 8.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	46.1 (20.2 to 80.3)	4.2 (-14.5 to 28.3)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3,617.3 (1,363.3 to 13,616.8)	2,288.1 (840.1 to 6,690.8)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,627.0 (980.4 to 10,127.2)	1,663.8 (596.4 to 6,468.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,627.0 (971.9 to 10,348.6)	1,663.8 (589.0 to 6,634.9)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	4,805.1 (1,829.2 to 14,680.3)	3,039.1 (1,147.6 to 9,438.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3,619.1 (1,362.4 to 13,662.5)	2,289.0 (839.5 to 8,720.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.0 (0.3 to 0.7)	0.4 (0.3 to 0.7)	-2.2 (-12.4 to 8.3)	-24.2 (-32.1 to -15.4)
Diarrheal diseases	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	4.8 (-10.2 to 21.3)	-15.9 (-29.1 to 0.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-14.6 to 25.9)	-16.1 (-32.1 to 4.7)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.4 (45.5 to 65.2)	-10.4 (-54.8 to 39.4)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.1 (-25.9 to 53.3)	-12.1 (-39.6 to 28.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.1 (-26.5 to 53.4)	-12.1 (-39.8 to 28.6)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.8 (-6.4 to 139.8)	28.9 (-14.5 to 104.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.8 (-6.7 to 140.0)	28.9 (-14.6 to 104.3)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.0 (-98.4 to 1,145.9)	-43.7 (-98.6 to 946.1)
Lower respiratory infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.0 (-14.1 to 3.8)	-25.8 (-33.2 to -18.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.3 (-23.8 to 17.7)	-23.6 (-40.2 to -4.7)
Upper respiratory infections	10.6 (10.1 to 11.1)	13.3 (12.7 to 13.8)	25.4 (18.3 to 34.2)	0.3 (-5.5 to 6.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	25.3 (16.4 to 35.5)	0.6 (-6.5 to 8.3)
Otitis media	8.9 (7.9 to 10.1)	9.9 (8.6 to 11.2)	11.7 (5.2 to 28.2)	-13.1 (-25.8 to -0.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	10.6 (5.6 to 27.9)	-13.7 (-25.1 to -1.0)
Meningitis	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-75.7 (-80.6 to -69.9)	-83.7 (-87.0 to -79.6)
Pneumococcal meningitis	0.3 (0.2 to 0.5)	0.1 (0.0 to 0.1)	-79.3 (-84.9 to -72.5)	86.8 (-90.3 to -42.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-74.9 (-81.3 to -66.1)	83.3 (-87.5 to -77.7)
H influenzae type B meningitis	0.1 (0.0 to 0.3)	0.0 (0.0 to 0.0)	82.2 (-90.3 to -62.5)	87.7 (-93.3 to -73.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-89.6 to -54.5)	-82.4 (-92.3 to -66.9)
Meningococcal meningitis	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.1)	-81.9 (-87.6 to -63.3)	88.4 (-92.0 to -76.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-85.7 to -54.4)	-85.6 (-90.5 to -69.9)
Other meningitis	0.2 (0.1 to 0.5)	0.0 (0.0 to 0.1)	-79.8 (-85.9 to -69.7)	86.8 (-90.8 to -79.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (-84.9 to -61.2)	-84.2 (-90.0 to -74.3)
Encephalitis	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	46.0 (12.3 to 87.1)	46.0 (-23.8 to 29.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.7 (17.0 to 101.6)	4.8 (-20.3 to 39.6)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.2 (-96.0 to 370.7)	-55.4 (-96.9 to 276.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.2 (-96.9 to 372.1)	-55.4 (-96.9 to 286.6)
Whooping cough	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	80.2 (-81.7 to -78.6)	-70.5 (-72.7 to -68.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-80.2 (-86.9 to -71.9)	-70.6 (-80.5 to -58.2)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-68.1 (-87.4 to -37.7)	-74.5 (-89.8 to -50.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-64.6 (-86.0 to -31.1)	-71.7 (-88.8 to -44.0)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to 0.0)	-100.0 (-100.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to nan)	-100.0 (-100.0 to nan)
Varicella and herpes zoster	0.6 (0.5 to 0.6)	0.7 (0.6 to 0.8)	20.4 (-0.7 to 49.5)	-1.5 (-15.4 to 19.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (11.0 to 106.8)	-0.6 (-24.9 to 37.7)
Neglected tropical diseases and malaria	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.2 (-60.3 to -32.5)	65.4 (-73.9 to -55.6)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.4 (-68.1 to 290.6)	30.2 (-74.5 to 217.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.3 (-67.7 to 305.0)	38.7 (-74.5 to 224.7)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.1 (-18.8 to 276.2)	41.0 (-33.6 to 192.7)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.1 (-22.4 to 292.0)	42.1 (-36.0 to 205.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.1 (-22.5 to 292.5)	42.1 (-36.0 to 205.9)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.1 (-3.1 to 209.3)	27.7 (-25.7 to 126.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.1 (-3.3 to 209.6)	27.7 (-25.7 to 127.0)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-68.6 (-85.3 to 11.9)	-80.0 (-90.6 to -29.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-66.5 (-84.9 to 19.3)	-78.8 (-90.3 to -23.8)
Cystic echinococcosis	0.2 (0.2 to 0.2)	0.1 (0.1 to 0.1)	-47.3 (-53.5 to -37.6)	-66.0 (-70.2 to -59.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.2 (-57.3 to -30.3)	-64.9 (-72.1 to -54.8)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.4 (-54.3 to 67.5)	-2.4 (-67.3 to 22.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.4 (-54.3 to 67.9)	2.4 (-67.4 to 22.7)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Ascariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trichuriasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hookworm disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.3 (-7.2 to 176.1)	12.8 (-27.0 to 118.4)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.0 (-36.9 to 14.1)	-43.7 (-58.0 to -24.2)
Maternal hemorrhage	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.4 (-48.1 to 49.1)	-39.5 (-66.0 to -2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.8 (-65.3 to 77.9)	-6.3 (-76.5 to 18.8)
Maternal sepsis and other maternal infections	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-11.5 (-72.9 to 198.7)	-40.1 (-81.4 to 104.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.1 (-44.6 to 45.4)	-43.1 (-62.6 to -1.7)
Maternal hypertensive disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.4 (-23.7 to -6.0)	-43.4 (-49.5 to -37.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.5 (-47.1 to 25.5)	-44.7 (-64.7 to -16.9)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.8 (-39.4 to 15.2)	-47.0 (-60.4 to -25.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.8 (-39.5 to 15.2)	-47.0 (-60.4 to -24.7)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.1 (-13.2 to 9.4)	-36.2 (-42.8 to -28.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.1 (-13.2 to 9.4)	-36.2 (-42.8 to -28.1)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.8 (-45.5 to 41.8)	-41.4 (-63.9 to -5.5)
Neonatal disorders	-	-	-	-	1.4 (0.9 to 2.0)	2.3 (1.6 to 3.2)	69.7 (19.4 to 140.1)	35.5 (-4.8 to 91.6)
Preterm birth complications	6.4 (4.6 to 9.2)	10.7 (7.4 to 15.6)	66.3 (28.1 to 112.8)	30.0 (0.7 to 66.9)	0.7 (0.5 to 1.0)	1.3 (0.9 to 1.7)	73.0 (29.2 to 132.3)	37.1 (2.0 to 83.1)
Neonatal encephalopathy due to birth asphyxia and trauma	0.9 (0.5 to 1.7)	0.6 (0.3 to 1.5)	-33.3 (-60.6 to 8.3)	-46.4 (-68.5 to -13.9)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-30.1 (-54.7 to 6.0)	-43.2 (-63.3 to -14.5)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.9 (-39.3 to -3.6)	19.8 (-3.2 to 53.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.0 (-54.9 to 35.1)	19.5 (-28.1 to 115.3)
Hemolytic disease and other neonatal jaundice	0.4 (0.1 to 1.0)	0.3 (0.1 to 0.8)	-21.9 (-88.1 to 227.5)	-37.0 (-90.5 to 166.9)	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.3)	-15.3 (-85.6 to 223.3)	-33.2 (-88.7 to 153.0)
Other neonatal disorders	-	-	-	-	0.3 (0.1 to 0.5)	0.8 (0.5 to 1.3)	185.6 (35.1 to 557.9)	127.1 (7.2 to 425.4)
Nutritional deficiencies	-	-	-	-	1.6 (1.0 to 2.4)	2.6 (1.0 to 2.4)	-1.4 (-24.6 to 22.5)	-0.2 (-24.6 to 20.5)
Protein-energy malnutrition	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	56.1 (-93.6 to 409.0)	-37.8 (-96.6 to 157.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.2 (-94.0 to 594.6)	21.6 (-96.8 to 254.7)
Iodine deficiency	10.5 (5.0 to 19.7)	11.3 (5.4 to 20.5)	7.8 (-55.2 to 179.8)	-26.0 (-69.7 to 90.5)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	8.2 (-56.3 to 175.8)	-25.7 (-69.7 to 88.6)
Vitamin A deficiency	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-

Appendix Table G.4 - Cyprus prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	58.7 (54.5 to 62.6)	66.2 (60.2 to 69.4)	12.6 (1.7 to 24.1)	-9.9 (-10.9 to 11.2)	1.4 (0.9 to 2.1)	1.4 (0.9 to 2.0)	-3.3 (-24.6 to 14.3)	2.9 (-22.1 to 19.8)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-95.4 to 226.4)	-50.0 (-97.5 to 69.6)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	18.2 (-4.4 to 77.8)	-0.9 (-21.5 to 71.9)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	48.3 (24.7 to 81.1)	0.5 (-15.6 to 23.8)
Syphilis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	157.0 (101.4 to 234.0)	55.2 (21.3 to 102.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	154.0 (76.7 to 280.7)	53.9 (7.7 to 132.1)
Chlamydial infection	13.3 (9.0 to 17.8)	17.6 (13.3 to 23.2)	28.9 (-10.5 to 115.5)	-8.7 (-36.7 to 52.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	36.6 (-0.4 to 108.1)	-3.6 (-29.3 to 47.5)
Gonococcal infection	2.0 (1.4 to 3.1)	2.8 (1.5 to 4.2)	38.0 (-45.6 to 172.8)	1.1 (-60.3 to 103.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.8 (-24.0 to 103.9)	-4.3 (-45.6 to 50.6)
Trichomoniasis	1.6 (1.1 to 2.2)	2.8 (1.7 to 4.3)	71.7 (13.1 to 178.3)	17.1 (-23.7 to 91.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.9 (2.7 to 221.8)	18.5 (-30.0 to 118.2)
Genital herpes	74.5 (63.0 to 84.4)	113.4 (97.8 to 129.3)	52.2 (26.6 to 84.0)	-9.9 (-21.0 to 15.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	50.3 (24.5 to 83.6)	4.5 (-21.5 to 16.5)
Other sexually transmitted diseases	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	11.6 (-22.3 to 70.3)	-24.4 (-47.6 to 15.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-11.0 to 86.2)	-10.6 (-39.3 to 27.4)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (9.3 to 45.6)	-7.9 (-20.4 to 5.0)
Hepatitis A	0.6 (0.6 to 0.6)	0.6 (0.6 to 0.7)	9.8 (9.4 to 9.9)	-8.0 (-9.2 to -6.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.9 (11.1 to 39.8)	-6.5 (-16.3 to 5.9)
Hepatitis B	11.1 (9.7 to 12.9)	13.8 (11.4 to 15.9)	25.0 (-2.8 to 53.9)	-11.7 (-31.5 to 10.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.4 (-18.3 to 113.0)	-7.1 (-45.5 to 40.8)
Hepatitis C	12.3 (10.9 to 13.8)	14.3 (12.7 to 15.9)	16.0 (-1.1 to 36.4)	-24.6 (-35.6 to -10.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.7 (-23.8 to 60.6)	-25.7 (-47.7 to 4.2)
Hepatitis E	-	-	62.1 (9.3 to 130.8)	14.1 (-23.0 to 63.3)	-	-	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	2.9 (2.4 to 3.6)	3.0 (2.5 to 4.8)	-0.8 (-26.0 to 69.7)	0.8 (-27.3 to 89.6)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.2)	-10.7 (-41.9 to 112.4)	-1.5 (-38.1 to 152.9)
Non-communicable diseases	-	-	-	-	64.6 (47.7 to 84.0)	100.2 (74.9 to 129.6)	54.8 (49.6 to 63.1)	1.5 (-2.0 to 7.0)
Neoplasms	-	-	-	-	0.9 (0.6 to 1.1)	1.9 (1.4 to 2.5)	126.9 (102.3 to 148.9)	27.6 (13.7 to 39.6)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	120.7 (36.8 to 253.3)	23.8 (-23.1 to 97.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.8 (45.2 to 205.1)	17.9 (-19.0 to 70.3)
Stomach cancer	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.4)	118.9 (75.1 to 244.1)	21.5 (-2.0 to 88.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	110.3 (66.3 to 233.4)	17.3 (-6.7 to 83.4)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-75.7 to 3.8)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.0 (-33.1 to 348.3)	3.7 (-62.6 to 149.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.6 (-35.9 to 290.3)	-2.5 (-64.2 to 117.7)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	274.3 (81.0 to 704.2)	106.9 (-1.6 to 341.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	228.5 (74.9 to 588.7)	81.4 (-2.8 to 276.8)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.1 (-54.7 to 99.4)	-50.5 (-75.4 to 8.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.7 (-52.8 to 79.0)	-51.5 (-74.3 to -4.5)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.1 (-70.9 to 93.3)	-9.2 (-83.7 to 5.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.0 (-69.5 to 66.7)	-66.1 (-83.0 to -10.8)
Larynx cancer	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	628.2 (222.6 to 1,143.8)	310.4 (79.6 to 602.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	370.4 (87.2 to 669.6)	155.1 (5.1 to 338.3)
Tracheal, bronchus and lung cancer	0.2 (0.2 to 0.3)	0.6 (0.5 to 0.7)	126.5 (83.2 to 180.0)	26.9 (2.6 to 57.7)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	115.8 (72.9 to 167.5)	21.3 (-3.1 to 50.3)
Breast cancer	4.2 (3.9 to 4.7)	10.6 (9.9 to 11.3)	151.1 (126.3 to 180.2)	42.0 (27.7 to 58.4)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	142.5 (92.6 to 175.7)	38.3 (10.0 to 56.9)
Cervical cancer	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	30.1 (-16.8 to 91.6)	-31.8 (-50.0 to 15.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.2 (-17.9 to 96.4)	-21.0 (-50.8 to 18.3)
Uterine cancer	0.2 (0.1 to 0.4)	0.7 (0.4 to 0.9)	317.4 (17.4 to 565.0)	138.7 (-32.2 to 281.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	309.2 (-34.8 to 559.6)	132.0 (-34.8 to 281.3)
Prostate cancer	2.4 (2.0 to 2.9)	6.6 (5.6 to 7.7)	174.3 (123.2 to 231.5)	48.8 (21.7 to 79.5)	0.2 (0.1 to 0.2)	0.5 (0.3 to 0.6)	191.5 (129.8 to 258.9)	56.8 (25.1 to 93.1)
Colon and rectum cancer	1.4 (1.2 to 1.6)	2.7 (2.4 to 3.0)	94.9 (64.5 to 133.8)	8.9 (-8.1 to 30.3)	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	88.6 (56.9 to 128.3)	4.9 (-12.7 to 27.5)
Ulip and oral cavity cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	67.0 (12.2 to 130.0)	4.6 (-3.4 to 35.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.5 (11.7 to 132.0)	-6.9 (-35.7 to 32.3)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.5 (-54.2 to 42.5)	-48.7 (-70.2 to -9.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.6 (-53.6 to 37.1)	50.7 (-70.2 to -14.3)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	57.2 (-1.9 to 147.9)	-7.4 (-41.9 to 47.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.1 (-1.5 to 139.1)	-9.2 (-42.1 to 40.2)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.0 (3.1 to 191.6)	2.9 (-44.1 to 52.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.5 (-2.4 to 182.7)	-3.7 (-46.8 to 49.1)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	170.1 (106.3 to 250.5)	49.3 (14.2 to 93.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	145.0 (90.3 to 216.2)	36.2 (6.2 to 75.5)
Malignant skin melanoma	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.1)	118.8 (51.8 to 195.1)	36.8 (-8.0 to 76.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	111.7 (50.8 to 187.4)	27.1 (-9.8 to 72.4)
Non-melanoma skin cancer	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.1)	144.0 (27.1 to 404.1)	35.4 (-28.5 to 173.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	201.3 (80.5 to 620.5)	65.1 (0.6 to 280.2)
Ovarian cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	103.8 (50.1 to 167.7)	17.8 (-12.7 to 55.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.5 (42.7 to 180.3)	14.9 (-17.8 to 63.0)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	60.9 (-9.7 to 178.3)	6.1 (-40.3 to 81.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.3 (-16.3 to 195.5)	3.6 (-45.1 to 94.6)
Kidney cancer	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	136.7 (87.2 to 217.4)	36.3 (8.0 to 81.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	136.4 (74.6 to 207.4)	30.7 (0.8 to 75.1)
Bladder cancer	0.9 (0.8 to 1.0)	1.6 (1.4 to 1.9)	85.3 (45.7 to 127.2)	0.4 (-20.7 to 23.6)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	59.2 (32.0 to 94.3)	-13.5 (-28.2 to 5.3)
Brain and nervous system cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	33.3 (-0.1 to 102.4)	-16.4 (-38.1 to 29.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.4 (0.6 to 104.3)	-17.9 (-39.1 to 26.5)
Thyroid cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	79.4 (21.1 to 164.7)	11.3 (-25.0 to 64.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.6 (17.3 to 158.6)	8.6 (-28.1 to 60.4)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.5 (12.4 to 144.4)	4.9 (-38.2 to 33.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.6 (6.5 to 163.3)	4.8 (-4.0 to 46.2)
Hodgkin lymphoma	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	66.4 (-11.4 to 168.3)	20.0 (-35.9 to 93.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.9 (-12.6 to 163.5)	17.5 (-38.6 to 87.9)
Non-Hodgkin lymphoma	0.3 (0.2 to 0.4)	0.7 (0.5 to 0.9)	152.0 (71.8 to 229.9)	43.1 (-1.5 to 86.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	139.6 (64.5 to 215.7)	36.6 (-5.5 to 78.7)
Multiple myeloma	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	159.6 (37.9 to 447.9)	46.3 (-23.1 to 206.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	149.1 (23.2 to 415.6)	40.9 (-29.7 to 188.1)
Leukemia	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.6)	101.0 (59.5 to 158.3)	16.5 (-6.8 to 48.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	94.4 (49.0 to 150.6)	10.7 (-14.4 to 42.5)
Other neoplasms	0.5 (0.4 to 0.7)	1.5 (1.2 to 1.8)	172.3 (106.1 to 287.6)	67.4 (28.6 to 138.4)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	153.8 (92.7 to 265.2)	55.2 (18.6 to 121.6)
Cardiovascular diseases	-	-	-	-	2.1 (1.5 to 2.8)	3.2 (2.2 to 4.3)	54.1 (23.9 to 81.4)	-13.5 (-30.6 to 1.6)
Rheumatic heart disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	72.8 (56.1 to 93.9)	2.0 (-7.9 to 14.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.7 (23.6 to 155.4)	-0.5 (-27.4 to 49.7)
Ischemic heart disease	13.3 (10.8 to 15.0)	20.4 (17.4 to 23.5)	56.3 (5.2 to 100.4)	-14.1 (-42.2 to 11.2)	0.7 (0.4 to 1.1)	0.9 (0.6 to 1.3)	35.9 (-17.5 to 89.1)	-25.6 (-55.0 to 4.7)
Cerebrovascular disease	-	-	-	-	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.4)	79.4 (48.2 to 114.8)	0.7 (-15.9 to 20.5)
Ischemic stroke	3.4 (2.9 to 3.9)	6.0 (4.9 to 6.9)	79.2 (37.5 to 120.6)	0.1 (-22.8 to 24.0)	0.5 (0.3 to 0.6)	0.9 (0.6 to 1.2)	81.5 (41.0 to 124.9)	1.9 (-20.7 to 26.5)
Hemorrhagic stroke	0.7 (0.5 to 0.9)	1.2 (0.9 to 1.8)	68.1 (11.8 to 157.9)	-3.2 (-35.8 to 46.6)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.3)	70.6 (12.9 to 158.1)	-1.3 (-34.2 to 46.4)
Hypertensive heart disease	0.6 (0.5 to 0.7)	0.9 (0.8 to 1.1)	53.3 (27.6 to 85.5)	-15.5 (-23.7 to 2.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	55.8 (27.1 to 89.4)	-13.9 (-29.7 to 5.0)
Cardiomyopathy and myocarditis	0.6 (0.5 to 0.7)	0.7 (0.6 to 0.7)	16.2 (8.9 to 48.4)	-32.8 (-47.6 to -14.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	17.6 (9.4 to 51.0)	31.8 (-47.5 to -12.2)
Atrial fibrillation and flutter	2.4 (1.9 to 3.1)	3.5 (2.8 to 4.6)	44.6 (7.2 to 95.6)	-22.2 (-41.9 to 6.4)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	45.9 (8.7 to 100.8)	-21.1 (-41.1 to 9.0)
Peripheral vascular disease	18.5 (14.5 to 23.5)	34.8 (25.1 to 42.2)	85.9 (27.3 to 168.1)	5.4 (-27.8 to 50.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-72.5 to 440.1)	-28.6 (-85.7 to 185.2)
Endocarditis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-13.2 (-51.8 to 63.1)	-45.1 (-70.1 to 2.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.4 (-45.8 to 64.6)	-41.0 (-65.6 to 5.3)
Other cardiovascular and circulatory diseases	6.9 (4.4 to 9.6)	11.0 (7.1 to 14.2)	57.9 (6.9 to 159.4)	-8.8 (-45.5 to 50.2)	0.5 (0.3 to 0.7)	0.8 (0.4 to 1.1)	59.6 (-6.2 to 162.5)	-7.9 (-45.3 to 51.2)
Chronic respiratory diseases	-	-	-	-	2.9 (2.0 to 4.1)	4.3 (2.9 to 5.9)	46.8 (22.7 to 79.3)	-3.9 (-19.1 to 17.3)
Chronic obstructive pulmonary disease	32.9 (28.0 to 38.5)	53.4 (44.8 to 63.5)	62.3 (48.6 to 80.4)	-2.2 (-10.5 to 9.4)	1.5 (1.0 to 2.2)	2.5 (1.5 to 3.7)	62.9 (25.6 to 118.4)	-1.6 (-24.2 to 33.1)

Appendix Table G.4 - Cyprus prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	35.2	21.5
Silicosis	0.0	0.0	10.8	-36.6	0.0	0.0	13.6 to 53.5	-34.4 to -10.0
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	10.4	-36.8
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	47.1	-14.2	0.0	0.0	46.6	-14.5
Asthma	28.8	38.5	33.1	-2.2	1.3	1.7	33.1	-1.9
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	110.7	24.3	0.0	0.0	111.3	24.7
Other chronic respiratory diseases	0.0	0.0	55.5 to 191.5	-8.0 to 72.0	0.0 to 0.0	0.0 to 0.0	56.7 to 193.0	8.0 to 73.4
Cirrhosis	-	-	-	-	0.1	0.1	-11.2	-46.4
Cirrhosis due to hepatitis B	0.0	0.0	46.0	-12.0	0.0	0.0	43.8 to 52.7	-65.9 to -7.6
Cirrhosis due to hepatitis C	0.0	0.0	76.4	6.9	0.0	0.0	39.9	-18.1
Cirrhosis due to alcohol use	0.0	0.0	-46.2	-9.4	0.0	0.0	14.2 to 58.7	-30.3 to -3.1
Cirrhosis due to other causes	0.0	0.0	46.7	-1.5	0.0	0.0	46.7	-1.5
Digestive diseases	-	-	-	-	0.7	1.2	68.4	4.3
Peptic ulcer disease	2.0	1.3	-35.9	-66.3	0.1	0.1	-21.2	-57.8
Gastritis and duodenitis	0.4	0.5	34.7	-13.3	0.0	0.0	50.3	-2.7
Appendicitis	0.0	0.0	5.4	-8.5	0.0	0.0	5.7	-8.4
Paralytic ileus and intestinal obstruction	0.0	0.0	88.8 to 21.0	-20.7 to 5.1	0.0 to 0.0	0.0 to 0.0	24.4 to 46.4	-37.0 to 30.0
Inguinal, femoral, and abdominal hernia	2.3	3.7	60.9	-8.1	0.0	0.0	62.9	-6.5
Inflammatory bowel disease	2.1	3.8	80.3	12.6	0.4	0.8	80.7	13.3
Vascular intestinal disorders	0.0	0.0	28.7	-26.1	0.0	0.0	33.5	-23.7
Gallbladder and biliary diseases	0.6	1.1	82.9	0.1	0.1	0.1	83.5	2.6
Pancreatitis	0.1	0.2	82.7	13.2	0.0	0.0	82.9	13.9
Other digestive diseases	-	-	-	-	0.1	0.1	73.1	7.1
Neurological disorders	-	-	-	-	6.6	10.8	62.3	5.7
Alzheimer disease and other dementias	7.4	14.0	89.2	0.3	1.1	2.1	94.3	8.3
Parkinson disease	0.6	1.1	80.9	-0.5	0.1	0.1	83.8	1.1
Epilepsy	2.4	2.9	24.1	-9.2	0.9	1.2	29.2	-4.6
Multiple sclerosis	0.3	0.6	135.1	0.1	0.2	0.2	134.6	49.7
Migraine	99.9	148.9	48.1	1.5	3.4	5.0	44.7	-1.1
Tension-type headache	142.2	250.2	77.9	22.2	0.2	0.4	77.9	22.7
Medication overuse headache	4.5	10.3	126.3	50.2	0.7	1.6	126.5	50.7
Other neurological disorders	0.0	0.0	50.8	2.6	0.2	0.2	61.4	-12.7
Mental and substance use disorders	-	-	-	-	15.2	21.5	40.9	-1.5
Schizophrenia	1.7	2.7	54.8	-0.3	1.1	1.7	55.4	0.4
Alcohol use disorders	6.0	8.1	36.2	-7.1	0.6	0.8	36.2	-6.7
Drug use disorders	0.8	1.2	42.0	0.8	0.2	0.3	42.0	-2.8
Opioid use disorders	0.7	1.1	52.2	-0.1	0.3	0.5	53.1	0.4
Cocaine use disorders	0.9	1.2	30.3	0.1	0.2	0.2	28.9	-9.1
Amphetamine use disorders	0.9	1.3	43.0	-0.7	0.1	0.2	42.3	-0.8
Cannabis use disorders	1.1	1.5	29.0	0.3	0.0	0.0	29.8	0.9
Other drug use disorders	-	-	-	-	0.3	0.3	37.6	-4.4
Depressive disorders	-	-	-	-	5.6	8.0	42.2	3.0
Major depressive disorder	22.7	32.0	39.8	-4.0	4.6	6.5	39.6	-3.8
Dysthymia	10.0	15.4	54.8	0.3	1.0	1.5	54.8	0.6
Bipolar disorder	4.7	7.0	50.3	-0.1	0.9	1.4	50.3	0.3
Anxiety disorders	33.2	48.3	45.8	0.3	3.0	4.4	45.6	0.6
Eating disorders	-	-	-	-	0.5	0.7	43.9	7.0
Anorexia nervosa	0.5	0.8	74.5	31.9	0.1	0.2	75.4	32.6
Bulimia nervosa	1.8	2.5	35.0	0.0	0.4	0.5	35.2	0.1
Autistic spectrum disorders	-	-	-	-	0.8	1.0	28.5	-6.1
Autism	2.0	2.5	28.8	-0.4	0.5	0.6	28.3	0.0
Asperger syndrome	2.8	3.6	29.3	-0.5	0.3	0.4	28.8	-0.3
Attention-deficit/hyperactivity disorder	4.4	4.3	-8.8	0.1	0.1	0.1	-3.9	0.1
Conduct disorder	6.5	6.1	-7.2	0.0	0.1	0.1	-9.9 to 2.9	-6.0 to 7.1
Idiopathic intellectual disability	3.0	2.9	-3.9	-2.4	0.2	0.2	-4.2	-27.6
Other mental and substance use disorders	11.3	17.7	57.0	-0.3	0.8	1.3	57.3	0.3
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	7.9	12.7	59.9	6.4
Diabetes mellitus	35.5	70.3	99.8	20.3	2.4	4.9	101.0	19.9
Acute glomerulonephritis	0.0	0.0	94.9	0.0	0.0	0.0	94.9	0.0
Chronic kidney disease	0.0	0.0	107.5 to 163.6	73.7 to 119.1	0.0 to 0.0	0.0 to 0.0	107.4 to 163.7	73.7 to 119.2
Chronic kidney disease due to diabetes mellitus	6.1	14.3	127.9	36.9	0.4	0.8	107.8	27.6
Chronic kidney disease due to hypertension	6.3	9.2	43.7	-0.3	0.6	0.4	40.2	-6.4
Chronic kidney disease due to glomerulonephritis	6.2 to 14.9	5.3 to 10.9	-45.1 to 24.5	-64.8 to -19.7	0.2 to 0.3	0.4 to 1.0	91.9 to 292.8	26.5 to 160.4
Chronic kidney disease due to other causes	21.0	35.7	71.5	13.1	1.0	1.8	79.6	13.9
Urinary diseases and male infertility	-	-	-	-	0.3	0.7	99.9	15.3

Appendix Table G.4 - Cyprus prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.7 (93.8 to 127.6)	44.2 (33.2 to 56.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.5 (75.8 to 143.4)	42.0 (22.8 to 67.3)
Urolithiasis	6.9 (4.4 to 11.3)	22.9 (15.3 to 37.0)	239.4 (157.9 to 301.7)	99.3 (52.1 to 138.8)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	210.7 (145.0 to 278.7)	84.2 (45.9 to 129.6)
Benign prostatic hyperplasia	5.3 (5.0 to 5.7)	9.5 (9.0 to 10.0)	77.5 (62.3 to 93.9)	-1.7 (-10.1 to 7.6)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	80.5 (63.7 to 98.7)	0.1 (-9.1 to 10.4)
Male infertility due to other causes	2.8 (2.0 to 3.6)	4.0 (2.8 to 5.4)	41.5 (-6.1 to 128.5)	-5.6 (-37.5 to 52.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	43.8 (-4.2 to 132.3)	-4.0 (-36.1 to 54.8)
Other urinary diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	89.6 (54.4 to 289.4)	8.5 (-37.6 to 130.1)
Gynecological diseases	-	-	-	-	0.8 (0.5 to 1.2)	1.2 (0.7 to 1.8)	50.3 (33.1 to 72.7)	1.1 (-10.6 to 16.4)
Uterine fibroids	25.2 (21.4 to 29.2)	38.8 (33.1 to 44.9)	54.2 (53.9 to 54.6)	3.9 (3.7 to 4.0)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.6)	53.5 (48.5 to 57.7)	3.4 (-0.0 to 6.2)
Polycystic ovarian syndrome	11.5 (9.9 to 13.2)	16.8 (14.5 to 19.2)	45.2 (17.2 to 76.7)	-0.8 (-20.0 to 20.6)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	46.3 (18.8 to 78.5)	0.0 (-18.7 to 21.8)
Female infertility due to other causes	0.9 (0.1 to 2.2)	1.5 (0.2 to 4.0)	66.1 (80.2 to 203.1)	12.0 (86.9 to 1,366.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.1 (-79.5 to 2,036.3)	15.1 (-86.1 to 1,339.9)
Endometriosis	2.0 (1.5 to 2.5)	2.7 (1.9 to 3.5)	36.8 (-6.3 to 106.1)	-7.8 (36.6 to 39.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	36.8 (-7.8 to 109.2)	7.6 (-37.9 to 40.8)
Genital prolapse	38.5 (34.9 to 42.7)	59.9 (54.2 to 66.2)	55.9 (37.0 to 76.9)	-0.5 (-12.8 to 13.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.4)	56.0 (35.8 to 76.5)	-0.4 (-13.3 to 13.0)
Premenstrual syndrome	16.1 (9.8 to 21.8)	26.2 (19.1 to 34.4)	62.2 (11.2 to 168.4)	11.8 (-23.4 to 85.6)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	62.3 (12.3 to 163.6)	11.8 (-22.6 to 82.7)
Other gynecological diseases	1.0 (0.9 to 1.2)	1.4 (1.2 to 1.6)	44.1 (17.4 to 62.8)	-0.9 (-19.3 to 12.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.5 (15.3 to 67.4)	0.3 (-21.9 to 27.7)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	2.0 (1.3 to 2.9)	2.2 (1.5 to 3.2)	9.5 (-1.0 to 16.2)	-3.3 (-12.3 to 3.3)
Thalassemias	0.6 (0.6 to 0.7)	0.6 (0.6 to 0.7)	-0.6 (-3.9 to 3.1)	-0.4 (-3.4 to 3.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-9.6 (-25.2 to 12.3)	-2.3 (-18.3 to 20.3)
Thalassemia trait	70.2 (69.1 to 71.7)	92.6 (90.9 to 94.8)	31.9 (29.7 to 34.3)	-0.0 (-1.7 to 2.0)	1.7 (1.1 to 2.4)	1.9 (1.3 to 2.7)	11.8 (0.4 to 17.2)	-2.6 (-13.1 to 1.9)
Sickle cell disorders	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	8.9 (9.1 to 51.5)	-6.6 (-21.3 to 30.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.3 (3.2 to 43.1)	-3.2 (-19.3 to 13.5)
Sickle cell trait	20.9 (19.3 to 22.3)	26.0 (24.2 to 27.7)	24.5 (19.6 to 30.9)	-5.5 (-9.2 to -0.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	24.5 (-31.0 to 14.1)	-0.9 (-34.1 to 7.7)
G6PD deficiency	31.5 (27.7 to 35.0)	40.7 (34.5 to 47.1)	29.2 (7.1 to 58.3)	-1.9 (-18.7 to 20.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.9 (-53.2 to 106.9)	-20.7 (-59.3 to 65.9)
G6PD trait	117.2 (113.9 to 120.4)	158.1 (152.6 to 162.6)	34.8 (29.2 to 40.5)	1.2 (-3.0 to 5.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.5 (-48.0 to 63.7)	-3.3 (-56.0 to 41.4)
Other hemoglobinopathies and hemolytic anemias	3.3 (2.9 to 3.8)	4.2 (3.8 to 5.1)	26.8 (0.9 to 63.1)	0.3 (-21.0 to 43.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	1.1 (-2.1 to 57.9)	-2.9 (-25.4 to 65.9)
Endocrine, metabolic, blood, and immune disorders	5.9 (5.4 to 6.5)	7.0 (6.6 to 8.3)	19.6 (1.9 to 42.2)	-6.3 (-18.4 to 22.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	16.7 (0.7 to 54.7)	5.2 (-22.3 to 41.8)
Musculoskeletal disorders	-	-	-	-	16.8 (11.9 to 22.9)	27.9 (19.7 to 37.1)	63.6 (47.6 to 95.3)	3.7 (-6.7 to 24.1)
Rheumatoid arthritis	2.5 (2.3 to 2.8)	4.7 (4.3 to 5.2)	86.3 (61.4 to 114.6)	13.7 (-1.5 to 30.4)	0.6 (0.4 to 0.8)	1.1 (0.8 to 1.5)	87.3 (60.6 to 118.0)	14.9 (-1.1 to 33.7)
Osteoarthritis	28.1 (23.4 to 31.8)	51.6 (44.9 to 60.5)	82.1 (48.1 to 133.9)	3.6 (-15.8 to 33.0)	1.0 (0.6 to 1.4)	1.8 (1.1 to 2.6)	83.2 (48.8 to 134.6)	4.6 (-15.2 to 33.6)
Low back and neck pain	-	-	-	-	13.6 (9.4 to 18.8)	21.3 (14.5 to 28.9)	44.1 (35.8 to 92.2)	-0.9 (-13.0 to 23.5)
Low back pain	80.4 (67.3 to 91.9)	130.7 (111.9 to 149.3)	61.5 (33.6 to 110.1)	3.0 (-15.0 to 34.4)	8.9 (5.8 to 12.7)	14.4 (9.6 to 20.2)	61.7 (33.0 to 112.0)	3.7 (-14.9 to 36.2)
Neck pain	48.1 (42.3 to 54.9)	69.7 (55.5 to 84.4)	44.7 (14.5 to 80.6)	-7.5 (-25.6 to 14.8)	4.7 (3.2 to 6.6)	6.8 (4.5 to 9.8)	44.5 (14.4 to 80.0)	-7.3 (-25.5 to 14.9)
Gout	1.2 (1.1 to 1.4)	2.0 (1.8 to 2.3)	62.2 (39.2 to 92.5)	-5.5 (-18.9 to 12.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	63.8 (34.4 to 101.4)	-4.1 (-21.7 to 18.5)
Other musculoskeletal disorders	18.3 (14.9 to 21.8)	40.3 (33.1 to 48.2)	120.1 (106.4 to 135.8)	36.6 (28.2 to 46.0)	1.7 (1.1 to 2.4)	3.7 (2.5 to 5.2)	120.5 (105.7 to 136.8)	37.1 (28.9 to 47.0)
Other non-communicable diseases	-	-	-	-	11.3 (7.5 to 16.3)	16.6 (11.2 to 23.9)	46.5 (40.2 to 53.9)	-3.0 (-7.3 to 2.2)
Congenital anomalies	-	-	-	-	0.9 (0.6 to 1.2)	1.4 (1.0 to 2.0)	59.8 (34.9 to 92.0)	18.3 (0.1 to 43.5)
Neural tube defects	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	24.5 (-10.3 to 66.5)	-0.5 (-28.2 to 33.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	25.4 (-16.9 to 87.0)	0.8 (-31.9 to 52.0)
Congenital heart anomalies	5.0 (4.2 to 6.0)	7.0 (5.7 to 8.2)	40.9 (10.3 to 79.4)	8.8 (-14.6 to 38.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	44.4 (14.7 to 79.7)	13.3 (-9.6 to 40.9)
Orofacial clefts	0.9 (0.7 to 1.1)	1.2 (0.9 to 1.6)	27.4 (-4.7 to 71.7)	-2.3 (-26.8 to 31.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.5 (-26.6 to 60.7)	15.1 (-43.5 to 24.2)
Down syndrome	0.8 (0.6 to 1.0)	1.1 (1.0 to 1.4)	46.6 (9.0 to 100.2)	4.9 (-22.2 to 42.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	56.5 (16.4 to 117.3)	6.1 (-21.2 to 46.6)
Turner syndrome	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	39.3 (-18.3 to 114.9)	7.2 (-37.1 to 65.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.4 (-19.0 to 123.2)	7.2 (-39.3 to 68.8)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	35.3 (-17.4 to 116.4)	4.2 (-36.4 to 66.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.4 (-15.1 to 147.7)	4.4 (-39.3 to 76.5)
Chromosomal unbalanced rearrangements	1.5 (1.2 to 1.9)	2.2 (1.8 to 2.7)	46.7 (9.5 to 101.7)	4.9 (-21.8 to 43.9)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	58.1 (17.5 to 120.6)	7.1 (-20.4 to 49.5)
Other congenital anomalies	2.0 (1.3 to 2.9)	2.3 (1.4 to 3.4)	17.7 (-11.7 to 49.5)	-15.5 (-36.3 to 8.1)	0.4 (0.2 to 0.6)	0.6 (0.4 to 0.9)	75.2 (32.9 to 151.3)	34.9 (2.0 to 94.7)
Skin and subcutaneous diseases	-	-	-	-	4.3 (2.8 to 6.6)	5.7 (3.7 to 8.9)	32.4 (20.4 to 46.8)	-1.3 (-9.7 to 10.2)
Dermatitis	40.4 (31.7 to 49.1)	56.0 (43.7 to 68.5)	38.8 (36.1 to 41.7)	-0.1 (-0.2 to 0.1)	1.1 (0.7 to 1.5)	1.4 (0.9 to 2.1)	34.4 (28.6 to 39.3)	0.3 (-2.3 to 2.8)
Psoriasis	0.1 (7.8 to 10.4)	13.6 (11.7 to 15.7)	49.4 (47.5 to 52.1)	0.1 (-0.2 to 0.0)	0.7 (0.5 to 1.0)	1.1 (0.7 to 1.5)	49.4 (42.6 to 55.9)	0.3 (-3.8 to 4.5)
Cellulitis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	42.2 (28.3 to 57.0)	-3.4 (-13.7 to 6.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.9 (21.0 to 65.9)	-3.5 (-17.1 to 11.9)
Pyoderma	0.5 (0.4 to 0.6)	0.6 (0.5 to 0.7)	30.3 (20.7 to 43.3)	-0.1 (-4.2 to 4.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.9 (14.5 to 48.0)	0.2 (-9.9 to 11.3)
Scabies	0.5 (0.4 to 0.5)	0.5 (0.4 to 0.5)	-20.4 (-18.3 to 26.2)	1.4 (-35.6 to 1.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.9 (-20.3 to 30.8)	-20.6 (-36.5 to 1.7)
Fungal skin diseases	45.8 (40.0 to 51.1)	66.5 (59.0 to 73.3)	45.3 (40.5 to 49.4)	4.3 (-0.4 to -0.2)	0.3 (0.1 to 0.5)	0.4 (0.2 to 0.8)	45.2 (40.0 to 48.7)	0.9 (-0.9 to 0.8)
Viral skin diseases	15.3 (12.3 to 18.4)	17.5 (13.5 to 21.9)	14.5 (6.1 to 22.3)	0.5 (-2.0 to 3.1)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.9)	14.1 (4.9 to 22.1)	0.8 (-2.7 to 4.2)
Acne vulgaris	109.5 (83.8 to 137.3)	122.6 (90.9 to 159.9)	11.1 (-20.6 to 66.9)	-5.6 (-31.9 to 41.7)	1.2 (0.6 to 2.3)	1.3 (0.6 to 2.6)	11.0 (-20.6 to 68.1)	-5.3 (-31.9 to 43.0)
Alopecia areata	1.1 (1.0 to 1.1)	1.6 (1.4 to 1.7)	46.0 (30.1 to 64.0)	-0.7 (-10.9 to 10.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	46.0 (26.6 to 66.6)	0.1 (-12.7 to 13.6)
Pruritus	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	37.9 (-26.9 to 112.6)	-14.2 (-53.4 to 30.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.2 (-27.8 to 134.5)	-13.6 (-53.7 to 39.3)
Urticaria	4.8 (3.3 to 6.3)	7.1 (5.3 to 9.0)	53.1 (-7.1 to 127.7)	-0.1 (-40.9 to 52.2)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	53.1 (-5.3 to 128.9)	0.5 (-39.6 to 55.3)
Decubitus ulcer	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.6)	71.3 (29.1 to 160.9)	-4.4 (-28.0 to 45.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	73.1 (26.5 to 160.7)	-2.8 (-29.4 to 44.3)
Other skin and subcutaneous diseases	45.7 (27.9 to 73.6)	73.0 (41.7 to 126.2)	59.3 (48.3 to 69.8)	-0.1 (-3.2 to 2.3)	0.3 (0.1 to 0.6)	0.4 (0.2 to 1.0)	59.1 (47.6 to 70.3)	0.3 (-3.1 to 3.2)
Sense organ diseases	-	-	-	-	4.2 (2.8 to 6.0)	6.5 (4.3 to 9.4)	55.4 (44.4 to 70.3)	7.2 (-13.8 to 0.3)
Glaucoma	0.6 (0.5 to 0.8)	0.8 (0.5 to 1.1)	29.3 (-3.5 to 66.9)	-26.9 (-44.5 to -6.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.1 (-1.2 to 80.9)	-28.3 (-43.2 to 0.6)
Cataract	1.7 (1.0 to 2.5)	2.3 (1.4 to 3.5)	32.7 (5.8 to 92.1)	-29.2 (-44.1 to 2.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	33.9 (6.0 to 68.6)	-28.4 (-43.3 to -9.8)
Macular degeneration	2.2 (1.5 to 3.0)	3.8 (2.8 to 5.0)	68.3 (40.5 to 114.6)	-6.3 (-20.7 to 20.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	72.6 (40.5 to 103.8)	-5.0 (-22.5 to 12.5)
Uncorrected refractive error	70.7 (57.1 to 83.2)	107.7 (84.3 to 127.1)	52.3 (10.7 to 103.8)	-6.5 (-32.4 to 36.8)	0.9 (0.5 to 1.6)	1.4 (0.7 to 2.4)	45.6 (14.2 to 94.0)	-9.3 (-29.2 to 14.6)
Age-related and other hearing loss	83.2 (71.4 to 94.8)	133.0 (113.2 to 153.2)	59.9 (52.3 to 67.0)	-8.8 (-13.5 to -4.5)	4.0 (1.6 to 3.6)	4.0 (2.6 to 5.9)	5.7 (53.1 to 86.5)	5.7 (-12.7 to 4.2)
Other vision loss	1.8 (1.4 to 2.4)	1.9 (1.4 to 2.5)	35.9 (-16.8 to 28.5)	0.1 (-49.5 to -24.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	19.4 (-3.9 to 42.8)	-28.9 (-42.5 to -14.6)
Other sense organ diseases	15.7 (15.0 to 16.4)	20.7 (19.7 to 21.6)	31.9 (24.3 to 40.4)	0.4 (-5.1 to 6.8)	0.5 (0.3 to 0.6)	0.5 (0.3 to 0.8)	30.9 (22.1 to 40.2)	0.8 (-6.1 to 8.0)
Oral disorders	-	-	-	-	1.9 (1.2 to 2.9)	2.9 (1.8 to 4.3)	51.9 (38.3 to 62.7)	-7.7 (-15.8 to -1.0)
Deciduous caries	33.3 (31.0 to 35.8)	25.1 (23.4 to 26.7)	-24.5 (-31.7 to -16.7)	-0.3 (-9.9 to 9.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.3 (-33.4 to -15.2)	0.0 (-11.8 to 11.7)
Permanent caries	251.2 (227.7 to 274.1)	353.7 (320.9 to 390.6)	40.4 (23.7 to 61.3)	1.8 (-10.0 to 16.5)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.4)	40.1 (23.4 to 60.9)	1.9 (-9.9 to 16.9)
Periodontal diseases	56.5 (49.8 to 64.9)	95.9 (83.4 to 111.9)	69.6 (46.4 to 100.4)	4.0 (-10.3 to 22.7)	0.4 (0.1 to 0.8)	0.6 (0.2 to 1.3)	69.6 (46.7 to 100.3)	4.4 (-9.6 to 22.9)

Appendix Table G.4 - Cyprus prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulous and severe tooth loss	38.4 (35.1 to 42.4)	56.6 (51.3 to 61.4)	48.1 (28.7 to 65.9)	-16.5 (-27.5 to -6.5)	1.0 (0.7 to 1.4)	1.5 (1.0 to 2.2)	48.8 (28.9 to 66.8)	-16.0 (-27.2 to -5.7)
Other oral disorders	11.9 (11.2 to 12.5)	17.5 (16.5 to 18.5)	47.7 (36.8 to 59.4)	0.7 (-6.5 to 8.7)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	47.6 (36.2 to 59.9)	0.9 (-6.5 to 9.5)
Injuries	-	-	-	-	8.9 (6.1 to 13.6)	6.8 (4.9 to 9.0)	-21.2 (-46.8 to -2.2)	-52.4 (-68.3 to -41.0)
Transport injuries	-	-	-	-	1.2 (0.9 to 1.5)	0.6 (0.5 to 0.9)	-44.1 (-49.9 to -37.5)	-65.3 (-68.9 to -61.4)
Road injuries	-	-	-	-	1.0 (0.8 to 1.3)	0.5 (0.4 to 0.7)	-52.2 (-57.3 to -46.5)	-70.3 (-73.8 to -66.8)
Pedestrian road injuries	-	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.1)	-58.3 (-62.8 to -53.2)	-74.6 (-77.4 to -71.5)
Cyclist road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-65.7 (-70.3 to -60.5)	-78.7 (-81.5 to -75.4)
Motorcyclist road injuries	-	-	-	-	0.2 (0.2 to 0.2)	0.1 (0.1 to 0.2)	-45.0 (-53.6 to -35.1)	-65.2 (-70.6 to -59.0)
Motor vehicle road injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.3 (0.2 to 0.3)	-50.7 (-55.3 to -45.5)	-69.4 (-72.3 to -66.3)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-81.0 (-83.5 to -77.8)	-87.9 (-89.5 to -85.8)
Other transport injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	19.5 (8.7 to 31.8)	-26.4 (-32.8 to -19.0)
Unintentional injuries	-	-	-	-	4.8 (3.7 to 6.1)	5.5 (4.0 to 7.5)	15.6 (2.2 to 30.3)	-30.1 (-37.9 to -21.2)
Falls	-	-	-	-	3.8 (2.9 to 4.9)	4.2 (3.0 to 5.7)	10.2 (-3.9 to 26.2)	-34.4 (-42.6 to -25.1)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.7 (-4.2 to 21.0)	-34.3 (-41.4 to -26.4)
Fire, heat, and hot substances	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-26.6 (-37.6 to -13.5)	-56.8 (-63.1 to -49.1)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.5 (10.1 to 80.7)	-7.8 (28.6 to 18.1)
Exposure to mechanical forces	-	-	-	-	0.7 (0.5 to 0.9)	0.9 (0.6 to 1.2)	31.6 (16.5 to 50.5)	-14.8 (-23.9 to -2.9)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.6 (-21.1 to 1.9)	-40.2 (-46.9 to -32.1)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.2 (13.4 to 51.8)	-14.0 (-25.6 to -1.5)
Other exposure to mechanical forces	-	-	-	-	0.6 (0.5 to 0.9)	0.9 (0.6 to 1.2)	31.9 (16.8 to 51.0)	-14.6 (-23.7 to -2.6)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	59.0 (44.6 to 73.9)	0.2 (-8.4 to 9.4)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	58.0 (43.1 to 73.7)	4.3 (-5.3 to 14.5)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.1 (23.1 to 76.3)	-0.5 (-17.1 to 18.9)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.0 (44.9 to 78.5)	5.0 (-4.6 to 16.7)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	10.9 (-2.8 to 27.0)	-23.6 (-34.2 to -12.0)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.0 (-22.6 to 4.5)	-41.9 (-50.5 to -32.1)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.9 (5.5 to 31.8)	-13.5 (-23.9 to -2.5)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.9 (-1.5 to 35.1)	-21.9 (-33.3 to -7.2)
Other unintentional injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	77.7 (48.1 to 117.3)	5.0 (-12.7 to 27.9)
Self-harm and interpersonal violence	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	3.0 (-7.0 to 15.5)	-34.9 (-41.2 to -27.2)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	170.4 (130.5 to 213.2)	65.6 (41.0 to 92.1)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-16.1 (-24.7 to -5.4)	-46.5 (-51.9 to -39.8)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.3 (-22.6 to -4.1)	-46.7 (-51.7 to -40.4)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.6 (-17.4 to 0.4)	-42.8 (-47.6 to -36.6)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.6 (-27.0 to -6.2)	-47.0 (-53.0 to -39.7)
Forces of nature, war, and legal intervention	-	-	-	-	2.9 (0.9 to 7.4)	0.5 (0.3 to 1.0)	-81.1 (-89.1 to -67.4)	-88.5 (-93.7 to -79.5)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	2.9 (0.9 to 7.4)	0.5 (0.3 to 1.0)	-81.1 (-89.1 to -67.4)	-88.5 (-93.7 to -79.5)

Appendix Table G.4 - Czech Republic prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,262.9 (949.4 to 1,626.3)	1,416.3 (1,062.0 to 1,833.2)	11.1 (9.4 to 15.0)	13.1 (5.6 to -0.8)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	65.6 (45.5 to 90.8)	60.6 (42.9 to 84.2)	-7.5 (-12.8 to -1.6)	3.0 (-2.3 to 8.9)
HIV/AIDS and tuberculosis	-	-	-	-	0.7 (0.5 to 1.0)	0.8 (0.5 to 1.1)	5.8 (-11.4 to 27.3)	-9.2 (-24.5 to 9.6)
Tuberculosis	2.5 (2.3 to 2.6)	2.5 (2.2 to 2.8)	-0.6 (-9.8 to 8.0)	-15.6 (-23.7 to -8.7)	0.0 (0.5 to 1.0)	0.0 (0.5 to 1.0)	-18.1 to 19.0 (-18.1 to 19.0)	-30.4 to 2.1 (-30.4 to 2.1)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	684.1 (216.3 to 1,199.3)	520.7 (174.7 to 1,019.8)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	240.0 (41.9 to 528.2)	192.2 (20.9 to 435.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	240.0 (41.6 to 529.3)	192.2 (20.7 to 436.1)
HIV/AIDS resulting in other diseases	0.1 (0.0 to 0.1)	0.8 (0.5 to 1.1)	1,272.9 (710.1 to 2,018.6)	1,039.4 (567.8 to 1,679.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	628.0 (216.7 to 1,206.0)	522.8 (175.0 to 1,024.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	8.5 (5.9 to 11.7)	7.7 (5.4 to 10.5)	-9.0 (-14.7 to -2.9)	-8.7 (-15.2 to -1.9)
Diarrheal diseases	27.2 (25.2 to 29.5)	24.7 (23.0 to 26.6)	-9.9 (-18.7 to 0.1)	-10.8 (-20.8 to -0.4)	4.4 (2.9 to 6.1)	3.9 (2.6 to 5.4)	-10.9 (-20.3 to -0.2)	-11.1 (-21.3 to 0.6)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.5 (-39.5 to -5.1)	-23.9 (-39.4 to -6.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.5 (-39.5 to -4.9)	-23.9 (-39.5 to -6.8)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.7 (-39.3 to -2.1)	-22.9 (-36.8 to -3.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.7 (-39.4 to -1.9)	-22.9 (-36.8 to -3.2)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Lower respiratory infections	0.5 (0.5 to 0.6)	0.6 (0.6 to 0.6)	13.2 (8.2 to 18.5)	11.8 (5.8 to 18.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	12.3 (8.2 to 36.5)	11.7 (-10.0 to 39.5)
Upper respiratory infections	99.3 (94.8 to 104.1)	97.5 (93.7 to 101.7)	-2.1 (-8.7 to 3.7)	-0.9 (-7.7 to 4.9)	1.2 (0.7 to 1.9)	1.1 (0.6 to 1.9)	-2.5 (-10.3 to 4.7)	-0.8 (-8.9 to 6.5)
Otitis media	106.2 (98.1 to 114.4)	97.9 (91.5 to 104.3)	-8.4 (-16.0 to 1.0)	-4.9 (-12.5 to 3.7)	2.1 (1.3 to 3.4)	1.9 (1.1 to 3.0)	-10.8 (-19.0 to -1.4)	-6.6 (-14.2 to 2.6)
Meningitis	-	-	-	-	0.2 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-30.0 (-46.7 to -10.6)	-32.2 (-48.3 to -11.8)
Pneumococcal meningitis	1.1 (0.6 to 1.8)	0.9 (0.5 to 1.5)	-18.1 (-39.2 to 7.7)	-26.8 (-46.1 to -4.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-19.3 (-44.5 to 13.2)	24.3 (-48.7 to 8.3)
H influenzae type B meningitis	0.4 (0.1 to 0.9)	0.2 (0.1 to 0.6)	-40.8 (-71.0 to 3.4)	-41.7 (-70.0 to 5.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-42.7 (-73.2 to 15.0)	-40.3 (-71.5 to 23.9)
Meningococcal meningitis	0.2 (0.1 to 0.6)	0.2 (0.1 to 0.4)	-34.3 (-58.4 to 0.6)	-37.8 (-59.2 to 3.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-32.2 (-57.7 to 11.5)	-32.6 (-59.6 to 15.6)
Other meningitis	0.5 (0.2 to 1.1)	0.4 (0.2 to 0.9)	-27.4 (-61.5 to 2.5)	-31.8 (-63.1 to 0.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-28.6 (-71.3 to 25.9)	-30.5 (-72.6 to 25.7)
Encephalitis	2.7 (1.1 to 7.2)	3.0 (1.2 to 8.3)	9.9 (-14.6 to 30.1)	9.5 (-23.2 to 17.2)	0.4 (0.2 to 0.5)	0.4 (0.3 to 0.6)	10.4 (-12.0 to 43.8)	6.5 (-20.8 to 30.8)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Whooping cough	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-39.6 (-41.0 to -38.2)	-32.0 (-33.6 to -30.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.7 (-63.7 to -3.9)	-33.3 (-59.3 to 8.3)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.1 (-58.1 to -20.9)	-32.2 (-59.1 to -14.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.0 (-57.6 to -20.5)	-32.1 (-58.9 to -14.0)
Measles	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-99.4 (-99.7 to -99.1)	-99.3 (-99.6 to -98.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.4 (-99.7 to -99.0)	-99.3 (-99.6 to -98.9)
Varicella and herpes zoster	5.5 (5.1 to 6.0)	5.3 (4.8 to 5.9)	-4.6 (-15.3 to 10.4)	-3.7 (-11.0 to 7.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	9.5 (-13.6 to 43.1)	-3.5 (-23.4 to 21.6)
Neglected tropical diseases and malaria	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-56.7 (-66.4 to -43.6)	-58.1 (-68.8 to -43.7)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.7 (-79.0 to 286.1)	-7.2 (-78.2 to 318.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.8 (-79.0 to 293.9)	-5.8 (-78.0 to 327.1)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-69.9 (-90.6 to -22.3)	-76.1 (-93.0 to -38.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-68.9 (-90.6 to -15.8)	-74.9 (-92.9 to -33.0)
Cystic echinococcosis	1.3 (1.1 to 1.5)	0.5 (0.5 to 0.5)	-57.8 (-63.9 to -53.2)	-58.7 (-66.9 to -52.9)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-57.0 (-67.4 to -42.8)	-58.5 (-69.8 to -43.1)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.1 (-46.8 to 19.5)	-10.5 (-50.8 to 15.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.1 (-46.9 to 19.7)	-10.5 (-50.9 to 15.7)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.1 (-31.2 to 128.8)	31.6 (-34.6 to 118.1)
Maternal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-18.7 (-35.9 to 3.8)	-27.6 (-43.3 to -8.4)
Maternal hemorrhage	0.9 (0.7 to 1.1)	0.8 (0.6 to 1.0)	-7.3 (-29.0 to 18.7)	-17.2 (-37.3 to 6.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.5 (-58.8 to 25.1)	-38.5 (-62.5 to 18.9)
Maternal sepsis and other maternal infections	1.2 (0.8 to 2.0)	0.6 (0.4 to 0.9)	-49.5 (-72.7 to -16.3)	-44.2 (-75.3 to -23.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.2 (-67.5 to -28.8)	-55.5 (-70.9 to -34.3)
Maternal hypertensive disorders	1.1 (0.7 to 1.5)	1.0 (0.6 to 1.4)	-8.4 (-20.5 to 9.0)	-20.5 (-30.0 to -6.1)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-8.2 (-32.8 to 26.1)	-20.3 (-40.9 to 7.9)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.8 (-25.4 to -0.5)	-22.9 (-33.2 to -11.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.8 (-25.4 to -0.5)	-22.9 (-33.3 to -11.1)
Complications of abortion	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-12.3 (-9.5 to 10.5)	-12.3 (-20.5 to -3.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.2 (-52.4 to 110.3)	-16.0 (-61.0 to 90.5)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Neonatal disorders	-	-	-	-	11.0 (7.9 to 14.8)	12.1 (8.4 to 16.4)	9.5 (-18.2 to 41.9)	11.4 (-16.7 to 45.2)
Preterm birth complications	52.5 (39.7 to 67.8)	48.0 (36.6 to 63.7)	-9.2 (-22.5 to 7.3)	-9.5 (-22.9 to 7.1)	6.1 (4.2 to 8.2)	6.2 (4.3 to 8.6)	3.1 (-20.6 to 34.6)	4.7 (-19.7 to 36.6)
Neonatal encephalopathy due to birth asphyxia and trauma	11.2 (6.2 to 21.7)	5.2 (2.3 to 12.0)	-53.7 (-79.1 to -20.4)	-52.1 (-78.3 to -18.7)	3.0 (1.8 to 5.1)	1.5 (0.8 to 2.6)	-49.3 (-79.1 to -7.4)	-47.2 (-78.2 to -2.7)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.2 (80.8 to 93.8)	95.6 (95.1 to 109.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.7 (21.8 to 165.7)	98.2 (31.5 to 186.8)
Hemolytic disease and other neonatal jaundice	2.1 (0.9 to 4.5)	2.1 (0.7 to 5.0)	3.9 (-68.6 to 151.8)	3.9 (-68.5 to 160.4)	0.8 (0.3 to 1.8)	0.8 (0.3 to 2.0)	8.8 (-67.9 to 159.0)	9.3 (-67.7 to 166.4)
Other neonatal disorders	-	-	-	-	1.1 (0.6 to 2.5)	3.5 (1.9 to 5.2)	260.7 (16.2 to 467.5)	268.8 (18.5 to 485.9)
Nutritional deficiencies	-	-	-	-	41.3 (27.3 to 59.9)	36.6 (24.2 to 52.9)	-11.4 (-15.6 to -7.1)	4.0 (-0.5 to 9.1)
Protein-energy malnutrition	6.7 (4.9 to 9.2)	7.2 (5.1 to 9.6)	6.7 (-32.1 to 68.4)	17.5 (-25.3 to 85.4)	0.8 (0.5 to 1.4)	0.9 (0.5 to 1.4)	6.8 (-32.3 to 68.5)	18.0 (-25.1 to 86.2)
Iodine deficiency	44.5 (29.5 to 61.2)	21.5 (12.2 to 35.1)	-51.5 (-75.1 to -19.5)	-52.5 (-75.5 to -23.0)	0.8 (0.4 to 1.4)	0.4 (0.2 to 0.7)	-51.5 (-76.0 to -18.9)	-53.3 (-76.3 to -22.9)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron deficiency anemia	1,465.1 (1,439.1 to 1,493.1)	1,491.0 (1,465.2 to 1,517.0)	1.3 (-1.0 to 3.7)	6.5 (4.1 to 9.0)	38.9 (25.7 to 57.1)	35.1 (23.3 to 50.9)	-9.6 (-13.4 to -6.0)	6.8 (2.7 to 10.4)

Appendix Table G.4 - Czech Republic prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	29.9 (24.4 to 35.1)	0.0 (-5.0 to 3.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.1 (25.5 to 36.7)	-
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	21.2 (15.0 to 26.4)	-5.8 (-10.7 to -1.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.2 (16.0 to 27.6)	-5.2 (-10.1 to -1.1)
Other pneumoconiosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-44.3 (-46.6 to -41.7)	0.0 (-57.6 to 53.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.4 (-45.9 to -40.8)	-55.2 (-57.1 to -53.3)
Asthma	171.5 (121.2 to 224.5)	162.3 (132.9 to 192.4)	-5.3 (-27.9 to 30.8)	-5.2 (-4.0 to -11.5)	7.4 (4.1 to 11.8)	6.9 (4.4 to 10.2)	-6.7 (-29.9 to 30.2)	-23.0 (-45.2 to 11.6)
Interstitial lung disease and pulmonary sarcoidosis	1.2 (1.0 to 1.5)	1.9 (1.7 to 2.0)	48.3 (18.1 to 93.3)	15.3 (-8.4 to 49.5)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.4)	47.2 (16.3 to 93.6)	15.0 (-9.0 to 49.8)
Other chronic respiratory diseases	-	-	-	-	0.4 (0.2 to 0.7)	0.7 (0.4 to 1.1)	65.6 (19.1 to 150.5)	31.7 (-5.4 to 99.5)
Cirrhosis	-	-	-	-	1.2 (0.9 to 1.7)	1.3 (0.9 to 1.8)	4.0 (-6.8 to 16.8)	-12.9 (-21.8 to -2.0)
Cirrhosis due to hepatitis B	1.8 (1.3 to 2.2)	2.3 (1.7 to 2.9)	28.3 (-6.5 to 92.0)	4.5 (-24.3 to 56.9)	0.4 (0.2 to 0.4)	0.6 (0.2 to 0.6)	27.9 (-12.3 to 102.6)	5.0 (-28.9 to 65.6)
Cirrhosis due to hepatitis C	2.1 (1.4 to 2.6)	2.1 (1.2 to 3.0)	1.8 (-45.7 to 67.6)	-18.0 (56.8 to 34.7)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.6)	1.6 (-48.7 to 70.6)	-18.2 (-59.1 to 37.2)
Cirrhosis due to alcohol use	2.4 (1.8 to 2.9)	1.8 (1.2 to 2.3)	-24.5 (-52.9 to 8.3)	-40.9 (-63.1 to -14.1)	0.4 (0.2 to 0.6)	0.3 (0.2 to 0.4)	-24.5 (-55.8 to 15.6)	-40.7 (-65.1 to -8.7)
Cirrhosis due to other causes	1.5 (1.2 to 1.8)	1.9 (1.4 to 2.4)	27.8 (-6.1 to 64.1)	15.2 (-12.7 to 45.9)	0.2 (0.2 to 0.4)	0.3 (0.2 to 0.5)	25.4 (-16.2 to 76.3)	14.3 (-21.5 to 58.8)
Digestive diseases	-	-	-	-	14.6 (10.4 to 19.2)	16.6 (12.0 to 22.1)	13.9 (3.3 to 22.3)	-6.0 (-14.5 to 1.3)
Peptic ulcer disease	95.3 (89.6 to 100.1)	51.4 (44.9 to 57.5)	-46.2 (-53.8 to -38.7)	-62.2 (-67.9 to -56.8)	3.4 (2.4 to 4.7)	2.1 (1.5 to 3.0)	-37.6 (-44.1 to -25.2)	-55.6 (-60.5 to -47.3)
Gastritis and duodenitis	10.1 (9.0 to 11.4)	10.9 (9.9 to 11.9)	7.2 (-9.5 to 25.4)	-2.4 (-17.5 to 14.7)	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.9)	8.7 (-22.6 to 39.0)	0.3 (-29.3 to 28.6)
Appendicitis	0.8 (0.7 to 0.9)	0.5 (0.5 to 0.5)	-32.7 (-41.4 to -20.9)	-18.7 (-29.4 to -4.2)	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-17.6 (-49.2 to -7.0)	-17.6 (-41.4 to 14.2)
Paralytic ileus and intestinal obstruction	0.2 (0.2 to 0.2)	0.3 (0.2 to 0.3)	32.2 (1.4 to 76.5)	14.5 (-24.6 to 80.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	30.7 (-8.2 to 83.5)	13.4 (-29.7 to 86.3)
Inguinal, femoral, and abdominal hernia	31.1 (27.8 to 35.2)	34.5 (30.8 to 39.3)	10.2 (-6.1 to 30.6)	-14.2 (-26.2 to 0.6)	0.3 (0.2 to 0.6)	0.3 (0.2 to 0.6)	10.6 (-5.6 to 32.1)	-13.3 (-35.6 to 1.9)
Inflammatory bowel disease	18.1 (17.3 to 19.0)	29.3 (28.1 to 30.6)	60.8 (51.4 to 71.1)	34.8 (27.2 to 43.3)	3.8 (2.6 to 5.2)	6.1 (4.2 to 8.4)	60.4 (48.1 to 73.1)	35.5 (25.1 to 46.6)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (-2.9 to 76.0)	-2.3 (-25.8 to 29.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.0 (-2.9 to 76.1)	-2.3 (-25.9 to 29.3)
Gallbladder and biliary diseases	38.9 (34.6 to 44.4)	34.0 (29.3 to 38.3)	-12.7 (-29.7 to 1.4)	-31.0 (-44.5 to -20.2)	4.0 (2.7 to 5.7)	3.5 (2.4 to 4.8)	-12.9 (-30.3 to 2.3)	-30.7 (-44.8 to -19.6)
Pancreatitis	4.7 (4.4 to 4.9)	6.1 (6.0 to 6.3)	21.0 (24.6 to 38.9)	1.3 (3.4 to 15.2)	1.8 (0.9 to 1.8)	1.8 (1.2 to 2.4)	8.5 (15.1 to 45.8)	8.5 (-3.9 to 23.4)
Other digestive diseases	-	-	-	-	0.8 (0.6 to 1.2)	1.9 (1.3 to 2.6)	132.3 (45.5 to 178.1)	91.7 (19.4 to 129.0)
Neurological disorders	-	-	-	-	109.4 (73.8 to 148.0)	129.2 (89.2 to 177.3)	18.3 (4.3 to 32.6)	4.0 (-8.5 to 16.7)
Alzheimer disease and other dementias	114.0 (99.2 to 127.4)	169.8 (148.4 to 191.0)	48.1 (24.9 to 75.2)	1.1 (-15.0 to 20.0)	16.0 (11.6 to 21.0)	24.1 (17.4 to 31.5)	50.8 (26.1 to 78.9)	1.8 (-14.8 to 21.2)
Parkinson disease	6.0 (5.4 to 10.8)	11.1 (7.5 to 14.5)	87.2 (25.9 to 52.7)	0.9 (-8.7 to 11.0)	3.2 (0.5 to 1.4)	1.3 (0.7 to 1.8)	37.5 (18.1 to 58.4)	0.6 (-13.6 to 15.4)
Epilepsy	47.4 (30.4 to 67.2)	41.0 (26.2 to 60.1)	-13.5 (-53.5 to 56.8)	-15.6 (-53.4 to 49.4)	15.1 (8.1 to 23.4)	13.5 (7.4 to 21.9)	-9.6 (-53.0 to 67.7)	-11.0 (-53.3 to 65.1)
Multiple sclerosis	10.3 (8.0 to 12.8)	13.0 (9.7 to 15.7)	25.4 (-15.4 to 77.4)	7.5 (-26.8 to 52.2)	3.4 (2.2 to 4.7)	4.2 (2.7 to 5.8)	24.8 (-17.0 to 78.6)	7.8 (-28.6 to 53.0)
Migraine	1,539.7 (1,418.3 to 1,661.7)	1,611.9 (1,478.4 to 1,737.4)	4.2 (-6.7 to 17.1)	-1.5 (-11.6 to 11.0)	52.0 (31.2 to 76.2)	53.9 (32.4 to 80.0)	3.5 (-7.5 to 17.1)	-1.2 (-11.6 to 11.8)
Tension-type headache	2,005.8 (1,854.6 to 2,186.6)	2,125.2 (1,945.4 to 2,300.5)	5.2 (-6.0 to 18.9)	0.5 (-11.4 to 13.3)	3.7 (1.5 to 5.2)	4.7 (1.5 to 6.2)	46.5 (7.0 to 19.4)	46.5 (-11.7 to 14.1)
Medication overuse headache	108.4 (67.7 to 151.6)	172.9 (103.3 to 251.0)	58.4 (9.7 to 127.6)	38.8 (-0.4 to 98.6)	38.8 (9.2 to 27.0)	26.7 (14.0 to 45.6)	58.1 (9.7 to 126.4)	38.9 (-0.1 to 99.9)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.9 (-18.1 to 69.8)	4.1 (-26.4 to 43.7)	2.1 (1.4 to 2.8)	2.3 (1.6 to 3.1)	11.1 (-22.1 to 47.7)	-21.5 (-44.8 to 4.8)
Mental and substance use disorders	-	-	-	-	221.3 (161.3 to 286.0)	231.5 (169.4 to 299.9)	4.6 (2.2 to 7.1)	-1.1 (-3.1 to 1.1)
Schizophrenia	34.4 (31.7 to 37.0)	38.7 (35.8 to 41.5)	12.3 (8.0 to 16.4)	-1.3 (-5.3 to 2.5)	21.8 (15.9 to 26.4)	24.4 (18.0 to 29.6)	12.0 (6.0 to 18.3)	-1.1 (-6.7 to 4.7)
Alcohol use disorders	86.3 (79.7 to 93.3)	88.9 (82.3 to 95.6)	2.5 (-2.6 to 7.7)	8.5 (-11.5 to -2.1)	6.9 (5.8 to 12.1)	8.7 (5.9 to 12.3)	2.3 (-4.5 to 8.8)	6.7 (-12.9 to 0.9)
Drug use disorders	-	-	-	-	11.4 (7.8 to 15.4)	11.6 (8.1 to 15.1)	1.8 (-10.3 to 16.2)	-2.1 (-14.1 to 12.8)
Opioid use disorders	11.2 (9.5 to 12.8)	12.5 (10.6 to 14.3)	11.3 (3.7 to 20.0)	1.5 (-5.7 to 9.1)	4.6 (3.2 to 6.1)	5.2 (3.5 to 6.8)	2.2 (-0.5 to 26.4)	2.2 (-9.3 to 14.9)
Cocaine use disorders	5.3 (4.4 to 6.1)	5.4 (4.5 to 6.1)	2.2 (-19.7 to 27.8)	0.7 (-22.4 to 25.9)	0.7 (0.5 to 1.1)	0.7 (0.4 to 1.1)	2.4 (-26.7 to 41.1)	0.1 (-29.3 to 37.6)
Amphetamine use disorders	17.4 (14.5 to 20.2)	16.5 (14.6 to 18.5)	-5.2 (-20.9 to 14.9)	-7.7 (-22.6 to 13.4)	2.3 (1.4 to 3.5)	2.1 (1.3 to 3.1)	6.3 (-23.1 to 11.3)	7.4 (-24.2 to 19.3)
Cannabis use disorders	27.8 (25.7 to 29.7)	25.3 (23.7 to 26.9)	-9.3 (-13.6 to -4.8)	1.8 (-2.7 to 7.0)	0.8 (0.5 to 1.2)	0.7 (0.5 to 1.1)	-9.6 (-20.5 to 3.6)	1.9 (-11.0 to 16.3)
Other drug use disorders	-	-	-	-	3.0 (1.8 to 4.7)	2.9 (1.7 to 4.3)	-4.0 (-32.1 to 38.6)	-5.4 (-33.0 to 38.2)
Depressive disorders	-	-	-	-	84.5 (57.5 to 117.1)	92.2 (62.4 to 127.0)	9.1 (4.0 to 14.5)	-0.3 (-4.3 to 4.8)
Major depressive disorder	343.6 (296.8 to 388.4)	374.4 (314.7 to 426.8)	8.4 (3.0 to 14.2)	-0.5 (-4.9 to 4.9)	69.5 (45.9 to 97.6)	75.0 (49.6 to 104.1)	7.8 (2.0 to 14.2)	-0.3 (-5.0 to 5.8)
Dysthymia	157.8 (131.9 to 183.5)	182.2 (151.2 to 211.9)	14.9 (12.4 to 17.6)	-0.8 (-0.9 to 0.6)	15.0 (9.9 to 22.0)	17.2 (11.3 to 25.1)	14.6 (10.8 to 18.2)	-0.5 (-2.8 to 1.8)
Bipolar disorder	76.2 (61.5 to 90.0)	85.5 (70.4 to 101.6)	11.9 (5.2 to 18.4)	-0.4 (-7.3 to 5.6)	15.3 (9.2 to 23.3)	17.0 (10.3 to 26.1)	11.5 (3.3 to 20.0)	-0.2 (-7.5 to 7.3)
Anxiety disorders	373.3 (318.5 to 435.3)	390.8 (327.2 to 450.0)	3.2 (-0.8 to 6.7)	-0.8 (-1.0 to 0.6)	34.3 (23.2 to 49.0)	35.1 (23.7 to 49.9)	2.4 (-2.0 to 6.9)	-0.5 (-3.1 to 1.9)
Eating disorders	-	-	-	-	2.4 (1.5 to 3.7)	2.2 (1.4 to 3.4)	-2.1 (-16.0 to 1.6)	2.1 (-6.6 to 10.7)
Anorexia nervosa	1.3 (1.0 to 1.7)	1.4 (1.1 to 1.8)	6.0 (-4.4 to 17.1)	20.9 (9.9 to 32.4)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	5.5 (-18.3 to 33.8)	21.1 (-6.2 to 52.4)
Bulimia nervosa	10.1 (7.4 to 13.5)	9.2 (6.6 to 12.7)	-8.9 (-13.9 to -4.8)	-0.6 (-0.7 to 0.4)	2.1 (1.3 to 3.4)	1.9 (1.2 to 3.1)	-9.1 (-18.2 to 0.1)	-0.4 (-8.9 to 8.3)
Autistic spectrum disorders	-	-	-	-	11.8 (8.2 to 16.0)	11.8 (8.2 to 15.9)	-0.2 (-3.4 to 3.3)	1.0 (-2.2 to 4.6)
Autism	30.7 (29.0 to 32.4)	31.0 (29.3 to 32.8)	0.6 (-0.1 to 1.3)	0.9 (0.8 to 0.9)	7.5 (5.1 to 10.2)	7.4 (5.0 to 10.2)	0.2 (-4.7 to 4.3)	1.0 (-3.4 to 6.0)
Asperger syndrome	43.5 (40.7 to 46.3)	44.0 (41.0 to 47.1)	0.7 (-0.2 to 1.6)	1.1 (1.1 to 1.2)	4.3 (3.0 to 6.0)	4.3 (3.0 to 6.0)	0.1 (-3.7 to 4.1)	1.3 (-2.3 to 5.4)
Attention-deficit/hyperactivity disorder	49.3 (45.5 to 53.2)	32.6 (29.9 to 35.2)	-34.2 (-34.9 to -33.9)	0.2 (0.2 to 0.2)	0.6 (0.4 to 0.9)	0.4 (0.2 to 0.6)	-34.3 (-39.3 to -29.1)	0.3 (-7.0 to 7.9)
Conduct disorder	75.2 (70.8 to 79.8)	45.1 (42.3 to 47.9)	-40.4 (-41.1 to -39.6)	0.2 (0.2 to 0.2)	9.1 (5.7 to 13.2)	5.4 (3.4 to 8.0)	-40.3 (-43.1 to -37.4)	0.3 (-4.2 to 4.8)
Idiopathic intellectual disability	166.7 (139.5 to 200.3)	143.9 (118.9 to 174.8)	-14.3 (-20.8 to -6.9)	-14.3 (-21.9 to -7.5)	8.1 (5.4 to 11.4)	6.9 (4.5 to 9.7)	-14.7 (-21.9 to -6.9)	-14.5 (-21.7 to -6.7)
Other mental and substance use disorders	183.7 (173.1 to 193.9)	215.2 (202.9 to 227.3)	16.7 (15.5 to 17.8)	0.8 (0.6 to 1.0)	13.5 (9.2 to 18.1)	15.7 (10.7 to 20.9)	1.6 (12.3 to 20.7)	1.0 (-2.6 to 4.5)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	112.2 (79.3 to 151.1)	144.1 (101.9 to 192.5)	28.3 (16.9 to 41.8)	9.2 (-0.0 to 19.9)
Diabetes mellitus	590.1 (490.5 to 702.7)	837.0 (700.2 to 981.0)	40.9 (14.5 to 75.4)	19.5 (-1.2 to 47.8)	45.6 (30.1 to 65.1)	65.5 (44.1 to 92.9)	43.1 (17.2 to 76.3)	19.2 (-1.4 to 46.3)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.2 (-46.3 to -38.0)	-39.2 (-43.4 to -35.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.2 (-46.3 to -37.9)	-39.2 (-43.4 to -35.1)
Chronic kidney disease	-	-	-	-	29.6 (22.0 to 38.7)	36.1 (26.3 to 46.9)	22.5 (10.6 to 31.7)	2.8 (-7.1 to 10.5)
Chronic kidney disease due to diabetes mellitus	197.4 (124.0 to 298.1)	281.2 (188.1 to 434.0)	39.6 (2.8 to 111.9)	12.3 (-17.2 to 66.9)	4.6 (3.1 to 6.4)	6.9 (4.8 to 9.6)	49.3 (9.7 to 119.4)	21.3 (-12.5 to 74.0)
Chronic kidney disease due to hypertension	278.9 (191.3 to 394.1)	257.8 (170.7 to 375.3)	-7.9 (-32.5 to 19.8)	-15.2 (-36.3 to 12.5)	8.4 (5.8 to 11.6)	6.4 (4.4 to 8.4)	-24.0 (-41.5 to -0.2)	-35.8 (-51.3 to -16.2)
Chronic kidney disease due to glomerulonephritis	326.4 (220.2 to 459.3)	257.5 (177.5 to 376.6)	-21.8 (-41.2 to 1.4)	-32.6 (-49.5 to -13.3)	6.5 (4.5 to 8.9)	6.3 (4.4 to 8.3)	-3.4 (-23.6 to 23.5)	-3.4 (-29.7 to 9.4)
Chronic kidney disease due to other causes	437.8 (309.8 to 610.2)	508.5 (480.4 to 912.1)	16.8 (18.0 to 104.1)	10.2 (1.3 to 64.6)	15.7 (7.6 to 13.6)	16.5 (11.4 to 22.2)	6.1 (31.8 to 104.1)	31.9 (10.9 to 68.5)
Urinary diseases and male infertility	-	-	-	-	9.7 (6.4 to 13.6)	14.9 (9.8 to 21.1)	54.2 (42.1 to 67.5)	13.4 (4.5 to 22.7)
Interstitial nephritis and urinary tract infections	2.9 (2.7 to 3.0)	3.2 (3.1 to 3.4)	12.2 (4.2 to 20.6)	11.2 (2.7 to 20.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	11.4 (-6.3 to 33.8)	11.5 (-7.3 to 34.6)

Appendix Table G.4 - Czech Republic prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	194.3 (184.4 to 204.6)	211.6 (201.0 to 222.8)	8.3 (1.0 to 17.2)	-0.4 (-7.3 to 7.6)	5.6 (3.5 to 8.3)	6.1 (3.8 to 9.1)	7.9 (0.0 to 17.0)	-0.3 (-7.7 to 8.3)
Injuries	-	-	-	-	216.9 (163.2 to 279.3)	206.4 (147.1 to 277.8)	-5.2 (-14.8 to 5.5)	-24.0 (-31.7 to -15.3)
Transport injuries	-	-	-	-	40.0 (30.2 to 51.8)	26.1 (18.4 to 35.6)	-35.0 (-42.7 to -25.1)	-47.0 (-53.4 to -39.1)
Road injuries	-	-	-	-	35.9 (27.1 to 46.6)	25.1 (17.6 to 34.2)	-30.6 (-39.0 to -19.9)	-43.5 (-50.5 to -34.8)
Pedestrian road injuries	-	-	-	-	9.9 (7.4 to 12.8)	7.1 (5.1 to 9.7)	-28.1 (-37.7 to -16.9)	-48.2 (-56.5 to -33.5)
Cyclist road injuries	-	-	-	-	6.3 (4.8 to 8.3)	5.2 (3.6 to 7.0)	-18.5 (-27.1 to -9.9)	-33.5 (-40.6 to -26.3)
Motorcyclist road injuries	-	-	-	-	2.2 (1.6 to 2.9)	1.9 (1.3 to 2.6)	-15.7 (-27.0 to -2.7)	-29.3 (-38.9 to -18.1)
Motor vehicle road injuries	-	-	-	-	17.1 (12.9 to 22.1)	10.7 (7.5 to 14.5)	-38.1 (-46.1 to -26.8)	-49.3 (-56.0 to -40.1)
Other road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.2 (0.2 to 0.3)	-38.2 (-46.5 to -29.4)	-48.2 (-55.1 to -40.6)
Other transport injuries	-	-	-	-	4.1 (3.0 to 5.3)	1.1 (0.8 to 1.5)	-73.5 (-76.1 to -70.3)	-78.4 (-80.5 to -75.8)
Unintentional injuries	-	-	-	-	175.2 (131.9 to 225.3)	179.0 (127.8 to 240.5)	1.8 (8.1 to 12.6)	-18.4 (-26.5 to -9.4)
Falls	-	-	-	-	135.5 (102.2 to 173.5)	135.7 (96.8 to 181.6)	-0.2 (-11.3 to 12.1)	-21.6 (-30.4 to -11.6)
Drowning	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-37.4 (-46.4 to -28.1)	-48.1 (-55.3 to -40.2)
Fire, heat, and hot substances	-	-	-	-	2.5 (1.9 to 3.2)	2.2 (1.6 to 3.0)	-11.7 (-22.7 to 1.8)	-23.0 (-32.6 to -10.7)
Poisonings	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-4.6 (-17.2 to 9.7)	-12.4 (-24.4 to 1.3)
Exposure to mechanical forces	-	-	-	-	20.7 (15.4 to 27.1)	23.3 (16.7 to 31.4)	12.2 (4.7 to 20.4)	-3.5 (-9.6 to 2.9)
Unintentional firearm injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-28.3 (-39.3 to -15.7)	-38.4 (-47.7 to -27.7)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-18.3 (-26.0 to -10.0)	-30.6 (-37.3 to -23.6)
Other exposure to mechanical forces	-	-	-	-	20.2 (15.0 to 26.4)	22.9 (16.4 to 30.9)	13.1 (5.8 to 21.3)	-2.7 (-8.6 to 3.8)
Adverse effects of medical treatment	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	24.7 (15.9 to 33.9)	2.3 (-4.3 to 9.2)
Animal contact	-	-	-	-	1.3 (1.0 to 1.7)	1.3 (0.9 to 1.8)	-1.8 (-10.5 to 7.1)	-11.8 (-19.2 to -3.9)
Venomous animal contact	-	-	-	-	0.5 (0.3 to 0.6)	0.5 (0.3 to 0.6)	1.0 (-10.1 to 13.8)	-8.2 (-18.8 to 4.2)
Non-venomous animal contact	-	-	-	-	0.8 (0.6 to 1.1)	0.8 (0.6 to 1.1)	-3.6 (-13.1 to 7.4)	-14.1 (-22.0 to -4.6)
Foreign body	-	-	-	-	0.9 (0.7 to 1.2)	0.8 (0.6 to 1.0)	-15.7 (-23.7 to -6.3)	-27.3 (-34.0 to -19.4)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-37.0 (-47.2 to -24.0)	-44.7 (-53.4 to -33.4)
Foreign body in eyes	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	1.8 (-4.5 to 8.3)	-6.4 (-14.6 to -1.9)
Foreign body in other body part	-	-	-	-	0.5 (0.4 to 0.6)	0.5 (0.3 to 0.6)	-5.7 (-14.3 to 4.0)	-20.5 (-27.6 to -12.0)
Other unintentional injuries	-	-	-	-	13.7 (10.2 to 18.0)	15.2 (11.1 to 20.5)	10.8 (3.4 to 19.2)	-10.3 (-16.1 to -3.5)
Self-harm and interpersonal violence	-	-	-	-	1.7 (1.2 to 2.1)	1.3 (0.9 to 1.7)	-23.7 (-31.6 to -14.8)	-37.0 (-43.4 to -29.8)
Self-harm	-	-	-	-	1.0 (0.7 to 1.3)	0.8 (0.6 to 1.1)	-16.3 (-24.4 to -6.7)	-30.6 (-37.8 to -23.1)
Interpersonal violence	-	-	-	-	0.7 (0.5 to 0.9)	0.4 (0.3 to 0.6)	-34.5 (-42.8 to -25.1)	-46.2 (-52.9 to -38.3)
Assault by firearm	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-12.7 (-20.7 to -4.5)	-28.9 (-35.4 to -22.4)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-17.1 (-26.7 to -5.6)	-31.5 (-39.3 to -22.1)
Assault by other means	-	-	-	-	0.5 (0.4 to 0.7)	0.3 (0.2 to 0.4)	-40.0 (-47.8 to -30.4)	-50.7 (-57.1 to -42.8)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Democratic Republic of the Congo prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	574.5 (527.9 to 616.9)	1,012.6 (943.5 to 1,080.7)	76.1 (59.8 to 94.6)	-5.4 (-13.5 to 3.4)	15.5 (10.6 to 21.3)	27.4 (18.3 to 37.8)	77.5 (60.0 to 96.5)	-4.7 (-13.1 to 4.5)
Other oral disorders	500.5 (470.0 to 532.9)	969.6 (910.6 to 1,031.7)	93.5 (78.0 to 111.1)	-0.7 (-8.0 to 7.7)	14.5 (9.0 to 21.5)	28.2 (17.6 to 42.1)	94.6 (78.0 to 112.8)	-0.3 (-8.0 to 8.9)
Injuries	-	-	-	-	143.9 (110.1 to 184.2)	306.5 (215.7 to 451.5)	106.1 (75.5 to 195.3)	14.7 (-4.2 to 71.2)
Transport injuries	-	-	-	-	55.5 (42.3 to 71.0)	80.6 (61.0 to 103.9)	45.4 (39.4 to 51.8)	-21.0 (-24.0 to -17.7)
Road injuries	-	-	-	-	47.5 (36.1 to 60.7)	68.4 (51.4 to 87.8)	43.9 (37.4 to 50.7)	-21.8 (-25.1 to -18.2)
Pedestrian road injuries	-	-	-	-	13.1 (9.8 to 16.8)	18.5 (13.9 to 24.1)	41.8 (30.2 to 54.2)	-22.5 (-28.0 to -16.9)
Cyclist road injuries	-	-	-	-	5.2 (3.9 to 6.9)	6.6 (5.0 to 8.7)	26.5 (18.8 to 34.8)	-29.2 (-33.5 to -24.8)
Motorcyclist road injuries	-	-	-	-	9.3 (7.0 to 12.0)	11.3 (8.5 to 14.9)	21.5 (12.7 to 30.6)	-33.7 (-38.1 to -29.1)
Motor vehicle road injuries	-	-	-	-	19.2 (14.6 to 24.5)	31.3 (23.7 to 40.0)	62.5 (51.7 to 74.2)	-12.5 (-18.2 to -6.8)
Other road injuries	-	-	-	-	0.6 (0.5 to 0.8)	0.6 (0.5 to 0.8)	0.3 (-6.6 to 6.7)	-49.6 (-52.6 to -46.3)
Other transport injuries	-	-	-	-	8.0 (6.0 to 10.3)	12.3 (9.2 to 16.0)	54.2 (44.9 to 64.0)	-16.2 (-21.5 to -11.1)
Unintentional injuries	-	-	-	-	79.1 (60.7 to 101.7)	130.3 (98.7 to 169.3)	64.7 (58.6 to 70.2)	-12.3 (-15.5 to -9.0)
Falls	-	-	-	-	32.1 (24.8 to 41.1)	53.9 (40.2 to 70.5)	67.9 (58.6 to 77.1)	-32.0 (-46.7 to -6.7)
Drowning	-	-	-	-	2.0 (1.5 to 2.6)	2.7 (2.0 to 3.5)	34.0 (19.5 to 47.4)	-27.6 (-34.2 to -21.1)
Fire, heat, and hot substances	-	-	-	-	9.6 (7.3 to 12.2)	12.6 (9.6 to 16.3)	31.0 (20.1 to 43.0)	-28.7 (-33.5 to -23.3)
Poisonings	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	48.0 (27.0 to 74.7)	-22.6 (-31.9 to -12.0)
Exposure to mechanical forces	-	-	-	-	21.2 (16.1 to 27.5)	38.1 (28.9 to 50.2)	79.8 (71.1 to 88.9)	-4.6 (-9.0 to 0.2)
Unintentional firearm injuries	-	-	-	-	0.8 (0.6 to 1.0)	1.5 (1.1 to 1.9)	92.0 (75.6 to 108.0)	2.6 (-5.4 to 11.0)
Unintentional suffocation	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	115.0 (91.8 to 140.0)	14.7 (4.2 to 26.4)
Other exposure to mechanical forces	-	-	-	-	20.2 (15.3 to 26.3)	36.2 (27.4 to 47.7)	78.9 (70.1 to 88.5)	-5.1 (-9.5 to -0.2)
Adverse effects of medical treatment	-	-	-	-	0.5 (0.3 to 0.7)	1.0 (0.6 to 1.5)	111.0 (98.0 to 122.9)	14.1 (7.2 to 21.5)
Animal contact	-	-	-	-	2.3 (1.7 to 3.0)	3.4 (2.5 to 4.4)	46.2 (37.3 to 55.5)	-22.2 (-26.2 to -18.0)
Venomous animal contact	-	-	-	-	1.0 (0.7 to 1.3)	1.5 (1.1 to 2.0)	50.2 (34.5 to 66.6)	-21.0 (-27.9 to -13.9)
Non-venomous animal contact	-	-	-	-	1.3 (0.9 to 1.7)	1.9 (1.3 to 2.5)	43.1 (35.0 to 52.6)	-23.1 (-27.1 to -18.9)
Foreign body	-	-	-	-	1.5 (1.1 to 1.9)	2.5 (1.9 to 3.2)	71.9 (62.6 to 83.0)	-7.7 (-12.3 to -2.7)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.7)	49.1 (31.5 to 66.3)	-16.6 (-24.2 to -9.7)
Foreign body in eyes	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.8)	87.5 (68.9 to 108.6)	-2.9 (-11.2 to 5.2)
Foreign body in other body part	-	-	-	-	0.8 (0.6 to 1.1)	1.5 (1.1 to 1.9)	77.5 (65.7 to 90.1)	-5.7 (-11.8 to 1.7)
Other unintentional injuries	-	-	-	-	9.8 (7.4 to 12.7)	15.8 (12.0 to 20.6)	61.9 (50.3 to 71.1)	-11.8 (-17.7 to -6.9)
Self-harm and interpersonal violence	-	-	-	-	8.0 (6.2 to 10.2)	12.0 (9.0 to 15.4)	49.4 (41.8 to 57.6)	-20.1 (-23.9 to -15.9)
Self-harm	-	-	-	-	1.3 (1.0 to 1.7)	2.3 (1.7 to 3.0)	78.8 (64.4 to 93.2)	-4.8 (-12.2 to 1.9)
Interpersonal violence	-	-	-	-	6.7 (5.2 to 8.6)	9.7 (7.4 to 12.5)	44.1 (36.3 to 52.4)	-23.5 (-27.5 to -19.2)
Assault by firearm	-	-	-	-	1.1 (0.9 to 1.5)	1.7 (1.3 to 2.2)	50.0 (41.0 to 60.8)	-21.4 (-26.2 to -15.9)
Assault by sharp object	-	-	-	-	1.1 (0.8 to 1.5)	1.8 (1.4 to 2.4)	64.8 (54.4 to 77.9)	-33.6 (-49.0 to -6.4)
Assault by other means	-	-	-	-	4.5 (3.5 to 5.7)	6.1 (4.7 to 7.9)	37.1 (27.5 to 47.3)	-26.9 (-31.5 to -21.7)
Forces of nature, war, and legal intervention	-	-	-	-	1.3 (0.5 to 2.9)	83.6 (28.4 to 214.3)	6,229.7 (3,250.9 to 10,084.0)	3,766.6 (2,016.0 to 6,026.6)
Exposure to forces of nature	-	-	-	-	-	-	-	-
Collective violence and legal intervention	-	-	-	-	1.3 (0.5 to 2.9)	83.6 (28.4 to 214.3)	6,229.7 (3,250.9 to 10,084.0)	3,766.6 (2,016.0 to 6,026.6)

Appendix Table G.4 - Denmark prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	676.1 (510.2 to 873.8)	744.8 (559.7 to 961.7)	10.2 (8.0 to 12.4)	-2.7 (-4.4 to -0.9)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	27.9 (19.1 to 40.0)	27.8 (19.3 to 39.2)	0.2 (-9.3 to 9.4)	-6.6 (-14.3 to 0.8)
HIV/AIDS and tuberculosis	-	-	-	-	0.6 (0.4 to 0.9)	0.6 (0.4 to 0.9)	0.0 (-29.3 to 56.0)	-3.2 (-35.5 to 40.1)
Tuberculosis	0.9 (0.9 to 0.9)	0.9 (0.8 to 0.9)	-4.4 (-8.0 to -0.3)	-11.2 (-14.6 to -7.7)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-4.3 (-21.7 to 16.0)	-10.8 (-27.4 to 9.2)
HIV/AIDS	-	-	-	-	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	6.7 (-43.6 to 120.6)	5.3 (-51.7 to 102.1)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.6 (-79.3 to -8.0)	-56.2 (-80.2 to -30.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.6 (-79.3 to -7.4)	-56.2 (-80.2 to -9.9)
HIV/AIDS resulting in other diseases	2.0 (1.5 to 2.7)	4.9 (3.0 to 7.3)	139.2 (49.9 to 278.0)	107.4 (25.9 to 240.1)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	19.3 (-43.6 to 121.7)	6.0 (-51.7 to 103.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	2.8 (1.8 to 4.1)	2.8 (1.8 to 4.2)	-0.3 (-8.6 to 6.6)	-10.1 (-17.1 to -4.0)
Diarrheal diseases	1.8 (1.6 to 2.1)	1.8 (1.6 to 2.0)	-2.4 (-18.2 to 16.6)	-12.9 (-30.9 to 8.8)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	0.0 (-21.4 to 21.2)	-12.6 (-32.5 to 11.7)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (66.0 to 34.5)	-19.7 (-68.6 to 23.9)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.7 (-24.2 to 1.6)	-19.7 (-29.8 to -7.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.7 (-24.3 to 1.7)	-19.7 (-29.8 to -7.4)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.6 (8.1 to 54.0)	11.3 (-14.4 to 39.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.6 (8.3 to 54.1)	11.3 (-14.4 to 39.8)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-77.6 (-99.4 to 1,527.2)	-79.2 (-99.4 to 1,410.9)
Lower respiratory infections	0.5 (0.4 to 0.5)	0.5 (0.4 to 0.5)	-4.5 (-11.3 to 2.3)	-13.5 (-19.9 to -7.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-2.7 (-18.5 to 15.7)	-12.2 (-27.6 to 5.4)
Upper respiratory infections	76.8 (72.7 to 80.5)	83.5 (80.1 to 87.6)	8.7 (1.5 to 17.5)	0.7 (-6.3 to 8.4)	0.9 (0.5 to 1.5)	1.0 (0.5 to 1.6)	8.9 (0.7 to 18.9)	1.0 (-6.8 to 9.5)
Otitis media	53.4 (47.6 to 59.8)	52.2 (47.1 to 58.0)	-2.2 (-15.0 to 12.8)	-12.9 (-24.0 to -0.3)	1.0 (0.6 to 1.6)	0.9 (0.6 to 1.5)	-1.3 (-14.9 to 13.1)	-12.3 (-23.9 to -0.2)
Meningitis	-	-	-	-	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-34.8 (-52.7 to -11.2)	-40.1 (-57.1 to -15.8)
Pneumococcal meningitis	0.8 (0.5 to 1.3)	0.6 (0.4 to 1.0)	-21.4 (-39.5 to 6.5)	-30.1 (-47.0 to -5.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-16.4 (-38.5 to 23.2)	-24.7 (-45.4 to 14.1)
H influenzae type B meningitis	0.5 (0.1 to 1.1)	0.3 (0.1 to 0.7)	-38.1 (-70.4 to 5.3)	-43.2 (-73.6 to 1.7)	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-36.9 (-75.0 to 22.7)	-40.5 (-76.8 to 19.6)
Meningococcal meningitis	0.4 (0.1 to 1.0)	0.2 (0.1 to 0.5)	-42.3 (-74.3 to -14.8)	-48.3 (-77.5 to -21.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-44.3 (-76.5 to -1.8)	-49.1 (-79.7 to -6.2)
Other meningitis	0.7 (0.4 to 1.5)	0.5 (0.2 to 1.0)	-36.3 (-54.4 to -17.3)	-41.8 (-57.6 to -23.3)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-36.0 (-57.9 to -4.8)	-40.2 (-61.4 to -8.3)
Encephalitis	0.4 (0.2 to 1.2)	0.5 (0.2 to 1.3)	22.9 (-6.9 to 46.0)	12.4 (-18.5 to 31.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	21.3 (-5.3 to 54.5)	7.9 (-16.7 to 39.4)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.2 (-92.7 to 601.9)	-45.4 (-94.5 to 490.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.2 (-92.9 to 616.0)	-45.4 (-94.6 to 496.0)
Whooping cough	0.8 (0.6 to 1.0)	0.6 (0.6 to 1.1)	-4.1 (-3.4 to 4.7)	-4.3 (-4.8 to 3.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	4.2 (8.6 to 19.4)	-4.1 (-16.1 to 10.2)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.1 (-53.0 to 26.8)	-18.8 (-57.9 to 15.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.3 (-51.3 to 24.8)	-15.9 (-56.1 to 17.9)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-90.5 (-95.0 to -85.7)	-91.5 (-95.5 to -87.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-90.5 (-95.0 to -85.7)	-91.5 (-95.5 to -87.1)
Varicella and herpes zoster	4.2 (3.7 to 4.9)	5.0 (4.2 to 5.7)	17.4 (-6.5 to 44.1)	0.8 (-15.6 to 18.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	19.2 (-12.3 to 59.3)	1.9 (-23.6 to 33.7)
Neglected tropical diseases and malaria	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-40.7 (-56.1 to -22.6)	-47.1 (-60.5 to -32.0)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.3 (-66.4 to 373.6)	15.2 (-68.4 to 345.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.9 (-65.9 to 381.6)	18.6 (-68.3 to 352.0)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-65.4 (-92.2 to 16.8)	-68.8 (-92.5 to 2.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.8 (-92.1 to 22.3)	-66.8 (-92.4 to 8.6)
Cystic echinococcosis	0.5 (0.5 to 0.5)	0.3 (0.3 to 0.3)	-39.4 (-43.2 to -34.3)	-47.2 (-50.1 to -41.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-38.1 (-51.5 to -20.7)	-45.5 (-56.3 to -31.6)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.9 (-39.4 to 29.5)	-6.9 (-48.1 to 15.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.9 (-39.5 to 29.5)	-6.9 (-48.1 to 15.9)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	337.8 (33.7 to 596.6)	290.7 (5.2 to 523.6)
Maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-1.3 (-36.6 to 46.2)	12.3 (-29.4 to 64.1)
Maternal hemorrhage	0.8 (0.4 to 1.1)	0.8 (0.3 to 1.2)	-3.2 (-55.8 to 77.3)	10.1 (-52.0 to 101.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.8 (-61.6 to 104.7)	11.9 (-55.6 to 131.0)
Maternal sepsis and other maternal infections	0.3 (0.1 to 0.5)	0.3 (0.1 to 0.7)	-8.6 (-67.3 to 169.9)	-2.2 (-63.4 to 171.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.6 (-54.1 to 80.0)	-9.9 (-49.2 to 99.1)
Maternal hypertensive disorders	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	10.5 (-17.5 to 14.5)	10.5 (-6.3 to 25.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.2 (-29.7 to 43.0)	10.7 (-22.5 to 57.7)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.9 (-14.8 to 4.6)	8.0 (-3.2 to 18.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.9 (-14.8 to 4.6)	8.0 (-3.3 to 18.8)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.1 (-11.0 to 12.9)	12.1 (-0.7 to 26.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.5 (-11.0 to 13.0)	12.1 (-0.7 to 26.2)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.8 (-44.7 to 110.0)	20.0 (-37.8 to 139.1)
Neonatal disorders	-	-	-	-	4.8 (3.4 to 6.5)	5.6 (3.9 to 7.6)	15.7 (-15.4 to 58.2)	5.8 (-23.2 to 44.9)
Preterm birth complications	25.0 (18.0 to 36.4)	33.6 (23.9 to 49.2)	34.4 (7.9 to 70.1)	22.8 (-1.4 to 54.8)	2.8 (1.9 to 3.7)	4.0 (2.7 to 5.4)	45.0 (5.5 to 98.4)	32.9 (-4.0 to 82.9)
Neonatal encephalopathy due to birth asphyxia and trauma	5.5 (2.9 to 11.4)	3.4 (1.7 to 8.5)	-41.5 (-59.0 to -11.2)	-46.0 (-62.5 to -19.1)	1.1 (0.8 to 1.6)	0.7 (0.5 to 1.1)	-33.9 (-55.3 to -6.7)	-39.1 (-58.7 to -12.6)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	435.5 (355.4 to 1,377.7)	424.2 (345.8 to 1,346.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	449.7 (81.7 to 1,732.5)	438.1 (77.9 to 1,693.8)
Hemolytic disease and other neonatal jaundice	1.1 (0.4 to 2.7)	0.8 (0.2 to 1.9)	-24.3 (-91.4 to 198.5)	-31.4 (-92.2 to 172.4)	0.5 (0.2 to 1.1)	0.4 (0.1 to 0.8)	-20.4 (-90.4 to 204.5)	-28.3 (-91.3 to 178.3)
Other neonatal disorders	-	-	-	-	0.5 (0.2 to 0.9)	0.5 (0.3 to 0.9)	-5.9 (-57.5 to 196.3)	-14.1 (-61.3 to 171.8)
Nutritional deficiencies	-	-	-	-	17.8 (11.5 to 26.8)	17.1 (11.0 to 25.5)	-3.3 (-22.1 to 5.9)	-8.8 (-25.6 to -1.6)
Protein-energy malnutrition	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	226.7 (-14.7 to 537.5)	160.9 (-32.3 to 391.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	218.4 (-28.9 to 637.7)	155.8 (-42.8 to 447.5)
Iodine deficiency	185.4 (136.6 to 237.7)	66.5 (36.4 to 105.7)	-65.5 (-82.1 to -33.3)	-65.8 (-83.0 to -35.6)	3.3 (1.8 to 5.5)	1.2 (0.5 to 2.2)	-65.4 (-82.4 to -32.8)	-66.6 (-83.3 to -34.2)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron-deficiency anemia	581.4 (557.9 to 592.0)	650.4 (594.1 to 670.2)	12.4 (0.9 to 16.3)	1.8 (-8.7 to 6.0)	14.5 (9.6 to 21.5)	15.9 (10.2 to 23.5)	10.9 (-12.4 to 18.1)	0.7 (-18.9 to 8.0)

Appendix Table G.4 - Denmark prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.0	0.0	141.2	91.9
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.8	1.7	-4.8	-8.9
Sexually transmitted diseases excluding HIV	-	-	-	-	0.9	0.9	-1.9	-3.9
Syphilis	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	50.6 (18.9 to 101.2)	24.6 (-1.9 to 72.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	51.1 (5.2 to 128.0)	26.1 (-14.3 to 91.6)
Chlamydial infection	178.3 (153.9 to 207.1)	146.5 (118.4 to 173.1)	-18.1 (-35.5 to 2.9)	-5.6 (-33.0 to 9.2)	0.5 (0.2 to 0.9)	0.4 (0.2 to 0.8)	-4.7 (-26.6 to 15.4)	-9.7 (-23.9 to 21.8)
Gonococcal infection	22.1 (16.3 to 29.6)	17.5 (11.0 to 24.8)	-18.9 (-56.5 to 26.9)	-2.4 (-53.9 to 40.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-2.7 (-49.0 to 9.3)	-16.2 (-45.6 to 20.3)
Trichomoniasis	15.7 (10.7 to 21.4)	12.2 (8.5 to 16.4)	-24.1 (-52.5 to 32.9)	-2.7 (-53.4 to 37.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.1 (-60.9 to 38.7)	-24.7 (-62.9 to 46.3)
Genital herpes	887.2 (819.2 to 956.8)	994.8 (918.2 to 1,066.8)	12.1 (0.7 to 25.8)	0.1 (-10.3 to 12.4)	0.2 (0.1 to 0.6)	0.3 (0.1 to 0.6)	10.9 (-1.5 to 24.8)	0.4 (-11.1 to 13.0)
Other sexually transmitted diseases	0.6 (0.4 to 0.8)	0.4 (0.3 to 0.6)	-31.0 (-54.2 to 4.0)	-27.1 (-51.4 to 9.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.2 (-32.6 to 38.4)	-2.8 (-32.7 to 44.7)
Hepatitis	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-17.1 (-28.1 to -5.8)	-21.0 (-31.7 to -11.0)
Hepatitis A	3.6 (3.4 to 3.8)	3.7 (3.5 to 3.9)	1.4 (0.6 to 2.2)	-5.8 (-6.8 to -4.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	1.2 (0.9 to 12.5)	-4.8 (-15.4 to 6.8)
Hepatitis B	71.8 (54.1 to 91.1)	24.4 (20.3 to 28.1)	-65.6 (-75.6 to -52.7)	-68.5 (-77.7 to -57.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-66.2 (-80.1 to -48.9)	69.0 (-81.8 to -52.9)
Hepatitis C	17.3 (15.5 to 19.2)	15.3 (13.7 to 16.9)	-11.5 (-23.6 to 1.2)	-23.7 (-34.2 to -12.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.6 (-40.7 to 18.8)	-28.6 (-47.9 to -7.1)
Hepatitis E	-	-	-	-	3.3 (43.1 to 85.5)	-	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	23.4 (20.1 to 26.4)	27.0 (22.8 to 46.5)	13.6 (-5.1 to 100.9)	2.0 (-16.9 to 92.7)	0.7 (0.4 to 1.4)	0.7 (0.4 to 1.7)	-6.4 (-33.5 to 148.6)	-11.5 (-38.8 to 141.1)
Non-communicable diseases	-	-	-	-	581.1 (434.2 to 753.3)	669.6 (496.9 to 864.9)	15.2 (15.5 to 17.9)	1.5 (-0.5 to 3.5)
Neoplasms	-	-	-	-	10.2 (7.6 to 12.9)	14.2 (10.5 to 18.3)	8.6 (30.5 to 51.6)	8.6 (-1.1 to 18.1)
Esophageal cancer	0.6 (0.5 to 0.7)	0.7 (0.6 to 0.9)	26.1 (-1.1 to 56.1)	-2.4 (-23.4 to 20.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	20.5 (-7.4 to 53.3)	-7.1 (-27.6 to 18.9)
Stomach cancer	2.0 (1.7 to 2.2)	1.7 (1.4 to 2.0)	-15.9 (-27.6 to -2.5)	-34.1 (-43.6 to -23.9)	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-18.8 (-32.6 to -1.0)	-36.5 (-47.2 to -23.0)
Liver cancer	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	39.0 (-1.6 to 85.5)	8.6 (-22.3 to 45.3)
Liver cancer due to hepatitis B	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	47.0 (-39.4 to 400.8)	13.0 (-52.7 to 271.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.4 (-2.2 to 479.2)	32.4 (-42.7 to 336.3)
Liver cancer due to hepatitis C	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	164.1 (38.2 to 377.1)	106.1 (9.1 to 265.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	204.9 (62.6 to 428.6)	139.6 (29.1 to 308.0)
Liver cancer due to alcohol use	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.2)	-42.7 (-69.3 to 8.1)	-55.3 (-76.3 to -16.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.1 (-63.2 to 22.7)	-46.9 (-71.4 to -5.5)
Liver cancer due to other causes	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-52.7 (-79.0 to 0.6)	-63.7 (-83.5 to -24.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.3 (-75.6 to 11.5)	-57.8 (-80.5 to -15.5)
Larynx cancer	1.1 (0.8 to 1.3)	1.0 (0.8 to 1.3)	-11.1 (-29.1 to 17.4)	-34.4 (-47.5 to -11.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-17.7 (-37.5 to 10.0)	-37.8 (-52.7 to -16.4)
Tracheal, bronchus and lung cancer	6.1 (5.6 to 6.5)	8.0 (6.9 to 8.9)	30.1 (11.7 to 47.1)	-1.9 (-15.3 to 11.0)	0.9 (0.6 to 1.1)	1.0 (0.7 to 1.3)	17.6 (-0.1 to 34.3)	-11.2 (-24.2 to 2.4)
Breast cancer	41.7 (38.5 to 45.3)	55.4 (51.5 to 59.8)	32.9 (20.1 to 49.3)	3.2 (-6.7 to 15.6)	2.3 (1.6 to 3.2)	2.6 (1.8 to 3.7)	14.0 (1.0 to 35.1)	-11.7 (-22.3 to 5.9)
Cervical cancer	3.7 (2.9 to 4.2)	1.8 (1.4 to 2.4)	-50.9 (-62.9 to -33.5)	-58.6 (-68.6 to -44.2)	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-50.5 (-62.7 to -30.7)	-8.1 (-68.2 to -42.6)
Uterine cancer	3.8 (3.2 to 4.5)	4.7 (3.6 to 5.9)	21.0 (-8.7 to 62.8)	-21.4 (-32.2 to -10.7)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	19.0 (-13.4 to 61.8)	-10.7 (-34.5 to 22.1)
Prostate cancer	9.0 (7.2 to 10.9)	27.0 (22.4 to 33.6)	200.8 (134.7 to 282.6)	140.9 (89.2 to 206.2)	1.0 (0.7 to 1.3)	2.3 (1.6 to 3.2)	128.6 (83.5 to 209.8)	84.0 (-15.0 to 151.0)
Colon and rectum cancer	17.1 (16.3 to 18.2)	27.2 (24.7 to 29.8)	59.2 (42.3 to 76.9)	24.0 (11.1 to 37.7)	1.5 (1.1 to 1.9)	2.2 (1.6 to 2.8)	48.2 (31.0 to 66.5)	16.1 (-2.8 to 30.6)
Lip and oral cavity cancer	2.3 (2.0 to 2.8)	5.1 (3.5 to 6.2)	125.5 (28.0 to 185.7)	69.8 (-4.8 to 113.7)	0.2 (0.1 to 0.3)	0.6 (0.3 to 0.6)	115.7 (25.0 to 181.9)	63.7 (-5.8 to 110.6)
Nasopharynx cancer	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-54.3 (-68.2 to -9.3)	-44.1 (-75.1 to -28.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.3 (-69.2 to -29.6)	-65.8 (-75.8 to -29.6)
Other pharynx cancer	0.9 (0.7 to 1.2)	2.0 (1.2 to 2.6)	130.9 (12.6 to 213.2)	77.8 (-12.4 to 143.8)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	115.4 (1.6 to 201.3)	67.2 (-20.2 to 133.4)
Gallbladder and biliary tract cancer	0.3 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-16.9 (-33.8 to 18.3)	-34.7 (-47.7 to -6.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-19.0 (-39.6 to 19.4)	-36.9 (-52.2 to -7.1)
Pancreatic cancer	0.7 (0.6 to 0.8)	1.1 (0.9 to 1.2)	61.1 (35.5 to 87.9)	25.9 (5.9 to 47.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	43.8 (17.1 to 77.0)	12.5 (-8.2 to 36.9)
Malignant skin melanoma	7.3 (5.0 to 9.6)	10.8 (7.9 to 16.2)	45.1 (16.4 to 92.2)	18.1 (-4.4 to 58.5)	0.4 (0.3 to 0.7)	0.6 (0.4 to 1.0)	40.4 (15.2 to 86.7)	14.6 (-9.1 to 55.0)
Non-melanoma skin cancer	5.1 (2.5 to 9.1)	6.9 (5.4 to 8.8)	34.3 (60.7 to 195.9)	7.3 (31.2 to 133.4)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	127.1 (49.1 to 240.4)	80.6 (24.4 to 169.5)
Ovarian cancer	1.6 (1.4 to 1.8)	2.3 (1.9 to 2.7)	46.2 (16.5 to 77.6)	10.8 (-11.2 to 34.2)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	42.3 (8.7 to 83.4)	8.0 (-17.5 to 39.7)
Testicular cancer	2.1 (1.4 to 2.8)	1.4 (1.0 to 2.2)	-33.1 (-57.4 to 14.3)	-35.4 (-59.6 to 12.9)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-33.7 (-58.7 to 19.1)	-36.4 (-60.7 to 13.5)
Kidney cancer	2.3 (2.1 to 2.7)	4.2 (3.6 to 4.9)	80.4 (52.8 to 115.0)	40.3 (17.6 to 65.2)	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.4)	72.3 (41.5 to 108.6)	34.2 (10.1 to 61.7)
Bladder cancer	0.7 (6.7 to 9.4)	9.4 (8.0 to 11.0)	134.0 (-3.7 to 36.8)	-13.5 (-26.0 to 5.8)	0.6 (0.4 to 0.8)	0.7 (0.5 to 0.9)	19.9 (4.5 to 33.0)	-16.2 (-29.4 to 2.9)
Brain and nervous system cancer	2.0 (1.6 to 2.2)	3.6 (3.0 to 4.2)	81.7 (58.3 to 112.7)	40.5 (21.8 to 64.4)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	69.8 (40.4 to 103.4)	32.8 (10.8 to 57.0)
Thyroid cancer	0.9 (0.7 to 1.1)	1.2 (1.0 to 1.6)	32.9 (3.7 to 89.2)	9.8 (-15.3 to 58.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	27.9 (-2.3 to 76.7)	6.2 (-20.1 to 50.7)
Mesothelioma	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	26.2 (-6.0 to 84.9)	-3.4 (-26.7 to 42.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	29.0 (-15.1 to 108.3)	-1.3 (-33.4 to 57.2)
Hodgkin lymphoma	0.7 (0.5 to 0.9)	0.7 (0.5 to 1.0)	-10.4 (-34.2 to 35.3)	-33.1 (-43.7 to 19.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-14.4 (-35.3 to 26.5)	-26.7 (-46.2 to 11.1)
Non-Hodgkin lymphoma	3.6 (2.5 to 5.1)	5.8 (4.0 to 7.8)	59.4 (-4.8 to 158.1)	23.1 (-26.4 to 101.4)	0.3 (0.2 to 0.6)	0.4 (0.2 to 0.6)	49.1 (-13.9 to 141.3)	15.6 (-32.5 to 89.2)
Multiple myeloma	0.9 (0.6 to 1.3)	1.4 (0.9 to 2.1)	61.0 (4.0 to 163.9)	26.6 (-18.3 to 111.0)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	51.3 (-0.9 to 150.3)	19.5 (-23.4 to 96.0)
Leukemia	2.7 (2.5 to 3.0)	3.5 (3.0 to 4.0)	28.9 (9.8 to 50.4)	-1.2 (-16.5 to 16.1)	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	19.6 (-1.2 to 43.1)	-5.7 (-21.1 to 11.7)
Other neoplasms	2.0 (1.6 to 2.5)	6.9 (5.1 to 8.8)	253.5 (137.7 to 367.4)	176.5 (89.5 to 252.9)	0.2 (0.1 to 0.2)	0.5 (0.3 to 0.7)	201.2 (96.9 to 295.2)	140.3 (61.7 to 205.0)
Cardiovascular diseases	-	-	-	-	18.6 (18.6 to 34.6)	22.5 (22.5 to 41.5)	43.3 (4.3 to 41.8)	-3.3 (-17.1 to 13.2)
Rheumatic heart disease	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.2)	21.0 (9.8 to 33.8)	-2.0 (-10.4 to 7.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.4 (8.9 to 67.6)	-3.2 (-24.5 to 29.3)
Ischemic heart disease	135.4 (110.5 to 173.9)	160.6 (136.5 to 184.5)	19.9 (-7.1 to 48.1)	-8.3 (-30.2 to 12.6)	7.9 (5.1 to 11.9)	8.4 (5.7 to 11.8)	7.5 (-17.4 to 36.3)	-17.9 (-38.2 to 5.5)
Cerebrovascular disease	-	-	-	-	9.1 (6.8 to 11.9)	9.1 (6.3 to 12.1)	25.5 (6.8 to 54.1)	1.1 (-12.9 to 23.4)
Ischemic stroke	47.9 (41.5 to 54.1)	58.9 (51.9 to 67.4)	22.4 (3.1 to 51.5)	-0.9 (-15.5 to 20.5)	5.0 (4.7 to 9.2)	5.8 (4.5 to 11.3)	23.5 (3.8 to 53.5)	-0.4 (-15.1 to 22.0)
Hemorrhagic stroke	2.8 (2.3 to 3.4)	4.5 (3.5 to 5.5)	58.5 (19.1 to 105.3)	28.5 (-2.4 to 64.5)	0.4 (0.3 to 0.6)	0.7 (0.4 to 0.9)	56.9 (14.9 to 106.9)	27.6 (-5.5 to 66.1)
Hypertensive heart disease	7.5 (6.4 to 8.6)	11.2 (9.0 to 11.5)	35.9 (13.5 to 64.1)	10.4 (-7.5 to 33.0)	0.8 (0.5 to 1.1)	1.1 (0.8 to 1.5)	37.3 (14.3 to 69.1)	11.4 (-6.9 to 35.5)
Cardiomyopathy and myocarditis	7.8 (6.3 to 9.9)	7.8 (7.0 to 8.7)	35.0 (-24.2 to 28.1)	-17.4 (-37.1 to 2.7)	0.8 (0.5 to 1.2)	0.8 (0.6 to 1.2)	2.4 (-2.0 to 29.2)	-17.2 (-37.3 to 3.9)
Atrial fibrillation and flutter	30.3 (24.6 to 37.2)	40.6 (34.2 to 47.9)	35.0 (-0.8 to 75.5)	31.5 (-22.9 to 37.7)	2.3 (1.5 to 3.4)	3.1 (2.1 to 4.5)	36.1 (-0.5 to 76.8)	7.3 (-22.7 to 39.7)
Peripheral vascular disease	313.7 (265.5 to 372.6)	393.2 (334.2 to 462.1)	25.4 (-2.3 to 61.5)	0.3 (-21.1 to 28.1)	0.8 (0.4 to 1.5)	1.0 (0.5 to 1.9)	14.3 (-20.9 to 89.6)	-7.1 (-36.8 to 53.8)
Endocarditis	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	85.3 (13.2 to 153.0)	48.3 (-9.3 to 103.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.1 (8.7 to 177.7)	52.7 (-10.7 to 112.8)
Other cardiovascular and circulatory diseases	87.5 (55.7 to 121.5)	114.1 (72.6 to 150.6)	29.0 (-21.5 to 114.4)	5.5 (-36.0 to 75.5)	6.1 (3.4 to 9.5)	8.0 (4.4 to 11.8)	29.9 (-22.1 to 116.9)	6.5 (-35.7 to 77.0)
Chronic respiratory diseases	-	-	-	-	38.6 (26.5 to 52.0)	44.5 (30.2 to 61.3)	15.2 (-5.2 to 35.0)	0.3 (-15.2 to 15.2)
Chronic obstructive pulmonary disease	553.8 (483.8 to 617.6)	651.5 (566.8 to 733.6)	17.4 (8.8 to 28.4)	-3.1 (-10.1 to 6.5)	24.8 (15.7 to 35.3)	29.0 (18.3 to 41.3)	16.7 (-11.1 to 48.7)	-3.5 (-26.0 to 22.5)
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.6 (-21.8 to -9.9)	-30.2 (-35.5 to -25.5)

Appendix Table G.4 - Denmark prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.0 (-24.0 to -13.4)	-39.9 (-38.5 to -30.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.2 (-24.2 to -13.5)	-34.1 (-38.7 to -30.3)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-14.4 (-24.5 to -6.4)	-28.7 (-36.5 to -21.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.8 (-24.4 to 5.8)	-28.0 (-36.2 to -21.1)
Asthma	307.4 (293.2 to 320.7)	344.2 (327.7 to 359.5)	12.1 (5.1 to 18.9)	12.1 (3.1 to 10.9)	13.4 (8.9 to 18.8)	15.6 (9.9 to 21.5)	13.4 (4.9 to 19.7)	13.4 (3.1 to 11.8)
Interstitial lung disease and pulmonary sarcoidosis	2.2 (1.7 to 2.7)	2.4 (1.8 to 3.0)	10.3 (-20.4 to 49.9)	-10.0 (33.8 to 23.1)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	11.7 (-20.4 to 57.3)	-8.1 (-33.1 to 28.6)
Other chronic respiratory diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	35.8 (5.0 to 88.7)	12.0 (-21.5 to 55.2)
Cirrhosis	-	-	-	-	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	13.8 (2.8 to 26.3)	-8.7 (-17.8 to 1.2)
Cirrhosis due to hepatitis B	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	28.9 (-33.7 to 125.3)	1.6 (-47.6 to 79.4)	1.6 (0.0 to 0.1)	0.1 (0.0 to 0.1)	26.3 (-38.0 to 141.1)	1.2 (-50.4 to 92.2)
Cirrhosis due to hepatitis C	1.0 (0.7 to 1.2)	1.4 (1.0 to 1.7)	40.7 (-8.2 to 127.3)	11.9 (-26.7 to 82.0)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	12.7 (-11.0 to 129.5)	41.0 (-29.2 to 83.4)
Cirrhosis due to alcohol use	1.1 (0.8 to 1.3)	0.8 (0.5 to 1.1)	-23.9 (-54.6 to 13.6)	-40.5 (-65.2 to -11.1)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-23.8 (-54.4 to 16.0)	-40.2 (-64.9 to 9.0)
Cirrhosis due to other causes	0.2 (0.2 to 0.3)	0.4 (0.2 to 0.6)	55.8 (-11.6 to 171.6)	27.3 (-25.4 to 111.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	55.8 (-17.2 to 193.0)	27.5 (-29.4 to 128.3)
Digestive diseases	-	-	-	-	7.8 (5.6 to 10.4)	8.6 (6.1 to 11.3)	9.3 (1.5 to 17.3)	-6.0 (-13.0 to 0.8)
Peptic ulcer disease	65.5 (63.8 to 67.2)	40.1 (37.1 to 42.4)	-38.7 (-42.9 to -35.4)	-50.8 (-54.4 to -47.8)	2.0 (1.4 to 2.8)	1.4 (1.0 to 2.0)	-31.6 (-36.1 to -25.8)	-45.7 (-49.5 to -40.5)
Gastritis and duodenitis	2.4 (2.0 to 2.8)	4.5 (3.9 to 5.0)	91.0 (57.7 to 126.8)	59.0 (30.0 to 90.1)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	82.3 (30.7 to 130.1)	48.4 (5.7 to 94.1)
Appendicitis	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.2)	-16.0 (-28.7 to -1.8)	-20.4 (-33.1 to -4.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-15.7 (-38.4 to 16.6)	-20.2 (-43.7 to 13.6)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	30.2 (17.8 to 42.4)	9.4 (-3.2 to 23.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	31.4 (-0.5 to 73.1)	9.8 (-13.9 to 39.4)
Inguinal, femoral, and abdominal hernia	14.4 (12.4 to 16.9)	15.8 (13.8 to 18.1)	9.6 (-10.5 to 33.5)	9.6 (-25.4 to 7.9)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.3)	11.3 (-9.7 to 34.0)	9.0 (-2.6 to 8.6)
Inflammatory bowel disease	16.1 (15.0 to 17.2)	19.4 (18.2 to 20.8)	20.6 (10.4 to 32.5)	2.7 (-5.9 to 13.0)	3.4 (2.3 to 4.6)	4.1 (2.8 to 5.5)	20.6 (9.4 to 33.3)	3.2 (-6.7 to 14.1)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	20.3 (-24.2 to 75.5)	-1.9 (-35.2 to 39.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.9 (-33.9 to 92.8)	-1.2 (-40.7 to 50.9)
Gallbladder and biliary diseases	6.9 (6.3 to 7.6)	8.1 (7.1 to 8.9)	17.9 (-0.8 to 34.3)	-2.5 (-18.1 to 11.8)	0.7 (0.5 to 1.0)	0.8 (0.6 to 1.2)	17.9 (-1.2 to 36.6)	-2.0 (-19.3 to 14.3)
Pancreatitis	1.7 (1.1 to 1.2)	2.2 (1.6 to 1.7)	40.3 (31.4 to 48.8)	1.3 (12.9 to 27.5)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.6)	41.2 (20.0 to 66.4)	21.5 (3.2 to 43.4)
Other digestive diseases	-	-	-	-	1.0 (0.7 to 1.4)	1.3 (0.8 to 1.8)	28.6 (7.4 to 53.7)	10.6 (-7.9 to 32.4)
Neurological disorders	-	-	-	-	59.7 (41.3 to 80.0)	71.7 (50.2 to 95.7)	19.9 (8.9 to 32.7)	6.0 (-4.0 to 17.8)
Alzheimer disease and other dementias	129.2 (109.5 to 145.6)	164.0 (142.9 to 185.9)	27.2 (6.6 to 52.6)	3.8 (-12.3 to 23.6)	18.8 (13.1 to 24.4)	24.2 (17.3 to 31.8)	29.0 (8.1 to 50.3)	5.6 (-10.8 to 26.4)
Parkinson disease	2.3 (2.0 to 2.5)	2.9 (2.6 to 3.2)	26.1 (20.3 to 31.7)	17.7 (-2.7 to 61.1)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	27.2 (9.2 to 47.1)	2.4 (-1.1 to 2.8)
Epilepsy	12.1 (8.6 to 15.5)	12.7 (8.7 to 16.8)	4.6 (-30.9 to 63.2)	-4.2 (-38.0 to 46.9)	4.8 (2.9 to 7.0)	5.2 (3.0 to 7.6)	8.6 (-29.7 to 70.4)	-2.5 (-36.9 to 53.8)
Multiple sclerosis	5.9 (5.4 to 6.5)	8.0 (7.0 to 9.0)	36.2 (14.0 to 59.6)	1.9 (0.5 to 41.2)	1.9 (1.4 to 2.5)	2.6 (1.9 to 3.4)	35.9 (12.6 to 62.0)	19.6 (-1.8 to 43.7)
Migraine	684.7 (599.9 to 768.6)	687.9 (600.1 to 786.6)	0.1 (-15.1 to 20.1)	-4.5 (-18.9 to 13.4)	23.1 (13.9 to 34.9)	23.2 (13.9 to 34.9)	0.2 (-15.2 to 20.7)	-4.0 (-19.4 to 14.6)
Tension-type headache	1,186.3 (892.5 to 1,523.9)	1,511.8 (1,283.7 to 1,726.1)	27.5 (-5.2 to 71.2)	19.2 (-11.8 to 60.7)	18.3 (0.8 to 32.0)	19.3 (1.1 to 41.1)	27.6 (-5.7 to 71.1)	19.3 (-12.0 to 61.4)
Medication overuse headache	38.0 (23.6 to 51.9)	64.6 (41.7 to 90.1)	71.3 (25.3 to 165.9)	48.5 (8.4 to 129.8)	5.9 (3.2 to 9.2)	10.0 (5.5 to 15.9)	67.5 (24.0 to 166.5)	49.1 (8.9 to 129.8)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.3 (-25.5 to 53.7)	-3.8 (-33.2 to 36.3)	3.2 (2.1 to 5.0)	3.8 (2.5 to 5.4)	19.3 (-15.7 to 62.6)	-1.3 (-30.4 to 33.8)
Mental and substance use disorders	-	-	-	-	123.8 (85.0 to 168.4)	134.5 (92.9 to 183.1)	8.8 (5.4 to 12.0)	2.3 (-0.1 to 5.1)
Schizophrenia	14.3 (11.1 to 16.8)	16.5 (14.2 to 19.0)	15.9 (8.2 to 24.3)	5.2 (-1.1 to 12.9)	9.1 (6.6 to 11.5)	10.5 (7.7 to 13.1)	16.0 (6.7 to 26.8)	5.7 (-2.1 to 15.4)
Alcohol use disorders	76.7 (69.4 to 84.5)	102.4 (94.9 to 110.4)	33.6 (24.8 to 42.3)	25.1 (17.2 to 33.2)	10.2 (5.1 to 10.8)	10.2 (6.8 to 14.4)	33.5 (24.5 to 42.6)	25.4 (17.2 to 34.0)
Drug use disorders	-	-	-	-	7.4 (5.2 to 9.8)	7.1 (4.9 to 9.3)	-4.9 (-16.4 to 10.2)	-2.1 (-14.2 to 13.1)
Opioid use disorders	6.2 (5.4 to 7.0)	6.0 (5.2 to 6.8)	-2.1 (-9.0 to 4.1)	0.2 (-7.3 to 6.7)	2.5 (1.8 to 3.4)	2.5 (1.7 to 3.3)	0.4 (-12.3 to 9.2)	0.4 (-10.3 to 12.4)
Cocaine use disorders	7.2 (6.2 to 8.3)	7.2 (6.4 to 8.2)	0.2 (-17.0 to 23.1)	3.4 (-14.7 to 28.1)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.4)	0.0 (-20.2 to 28.8)	3.4 (-17.2 to 34.5)
Amphetamine use disorders	10.1 (8.6 to 11.5)	9.0 (7.8 to 10.2)	-11.3 (-25.1 to 9.3)	9.3 (-23.5 to 11.4)	1.1 (0.8 to 2.0)	1.2 (0.7 to 1.7)	-10.8 (-27.5 to 10.7)	1.1 (-26.4 to 13.3)
Cannabis use disorders	9.0 (8.2 to 9.7)	8.7 (7.9 to 9.4)	-3.7 (-8.7 to 2.2)	-0.1 (-5.6 to 6.5)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-3.4 (-16.6 to 11.7)	0.0 (-14.3 to 16.6)
Other drug use disorders	-	-	-	-	2.3 (1.5 to 3.3)	2.2 (1.3 to 3.1)	-6.5 (-32.0 to 31.0)	-3.8 (-29.8 to 34.2)
Depressive disorders	-	-	-	-	44.0 (23.0 to 71.1)	47.9 (25.4 to 77.0)	8.9 (2.7 to 15.7)	0.5 (-5.2 to 8.2)
Major depressive disorder	176.2 (79.5 to 260.4)	191.5 (88.3 to 279.0)	9.0 (1.4 to 17.0)	0.4 (-6.4 to 9.8)	35.7 (15.7 to 60.1)	38.7 (16.9 to 64.4)	8.7 (1.3 to 17.4)	0.5 (-6.5 to 10.0)
Dysthymia	87.1 (73.7 to 100.9)	95.0 (80.1 to 110.4)	9.1 (6.0 to 12.2)	-0.1 (-0.2 to 0.0)	8.3 (5.4 to 12.3)	9.1 (5.9 to 13.4)	9.0 (5.1 to 13.3)	0.2 (-2.1 to 2.6)
Bipolar disorder	39.2 (32.9 to 45.4)	41.2 (35.0 to 47.1)	5.4 (-0.2 to 10.9)	-0.4 (-5.2 to 4.9)	7.9 (4.8 to 11.8)	8.3 (5.2 to 12.3)	5.4 (-1.5 to 12.6)	-0.1 (-6.1 to 6.8)
Anxiety disorders	271.2 (152.2 to 381.0)	287.9 (171.3 to 403.0)	6.6 (-0.1 to 14.5)	24.6 (-0.5 to 0.1)	24.6 (12.1 to 38.9)	26.1 (13.6 to 41.5)	6.4 (-0.6 to 14.8)	0.1 (-1.9 to 2.4)
Eating disorders	-	-	-	-	4.2 (2.5 to 6.7)	4.0 (2.5 to 6.4)	-4.5 (-9.9 to 1.6)	3.9 (-1.8 to 10.1)
Anorexia nervosa	5.1 (3.0 to 7.5)	5.4 (3.3 to 7.6)	6.2 (-8.2 to 17.4)	13.8 (-1.5 to 24.8)	1.1 (0.5 to 1.9)	1.1 (0.6 to 1.9)	5.7 (-8.9 to 21.0)	12.8 (-2.4 to 29.0)
Bulimia nervosa	14.9 (8.7 to 22.2)	13.7 (8.0 to 20.4)	-8.3 (-10.0 to -5.6)	0.7 (0.4 to 0.9)	3.1 (1.6 to 5.2)	2.9 (1.5 to 4.8)	-7.8 (-12.9 to -2.2)	0.9 (-4.2 to 6.2)
Autistic spectrum disorders	-	-	-	-	5.6 (3.9 to 7.7)	6.1 (4.3 to 8.3)	8.5 (5.1 to 11.7)	0.4 (-2.7 to 3.4)
Autism	14.6 (13.7 to 15.5)	15.8 (14.8 to 16.8)	8.4 (7.9 to 9.0)	0.1 (0.1 to 0.1)	0.1 (2.4 to 4.9)	0.1 (2.6 to 5.3)	3.8 (3.8 to 13.4)	3.8 (-0.1 to 4.8)
Asperger syndrome	20.9 (19.5 to 22.3)	22.6 (21.1 to 24.2)	8.5 (7.9 to 9.1)	0.1 (0.1 to 0.2)	2.1 (1.4 to 2.9)	2.2 (1.5 to 3.1)	8.5 (4.5 to 12.8)	0.3 (-3.5 to 4.2)
Attention-deficit/hyperactivity disorder	25.6 (21.2 to 30.1)	26.5 (21.9 to 31.1)	3.2 (3.0 to 3.7)	-0.0 (-0.0 to 0.0)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	3.3 (-3.6 to 10.3)	-0.1 (-6.8 to 6.9)
Conduct disorder	37.3 (31.3 to 43.5)	38.6 (32.5 to 44.9)	3.6 (2.5 to 4.7)	0.0 (0.0 to 0.0)	4.5 (2.7 to 6.8)	4.6 (2.8 to 6.9)	3.9 (-0.7 to 8.3)	0.3 (-3.8 to 4.3)
Idiopathic intellectual disability	19.6 (11.2 to 31.1)	22.8 (13.3 to 32.2)	18.3 (-31.8 to 101.8)	1.5 (-36.4 to 84.0)	1.3 (0.6 to 2.0)	1.3 (0.7 to 2.1)	18.1 (-31.4 to 102.3)	9.7 (-35.9 to 96.1)
Other mental and substance use disorders	100.2 (94.5 to 105.8)	108.7 (102.3 to 114.8)	8.5 (7.3 to 9.7)	8.5 (0.0 to 0.3)	7.4 (5.0 to 9.9)	8.0 (5.5 to 10.7)	8.5 (4.7 to 12.6)	0.6 (-2.9 to 4.4)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	49.0 (35.0 to 64.6)	61.6 (43.9 to 80.5)	25.5 (16.7 to 36.9)	6.2 (-0.4 to 15.5)
Diabetes mellitus	135.8 (98.9 to 171.5)	212.5 (168.7 to 274.8)	55.7 (17.5 to 125.4)	31.1 (0.4 to 87.6)	10.0 (6.2 to 15.0)	15.6 (10.2 to 23.1)	56.2 (20.9 to 115.4)	29.4 (1.4 to 78.9)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.0 (13.0 to 30.2)	4.3 (-1.8 to 10.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.0 (13.0 to 30.2)	4.3 (-1.8 to 10.7)
Chronic kidney disease	-	-	-	-	20.9 (14.0 to 28.6)	25.6 (16.9 to 34.6)	25.6 (15.7 to 32.7)	21.9 (-2.0 to 9.1)
Chronic kidney disease due to diabetes mellitus	64.3 (36.5 to 100.6)	87.4 (61.0 to 124.1)	36.2 (-2.6 to 98.2)	5.2 (-21.6 to 50.0)	3.8 (2.0 to 5.8)	4.7 (2.8 to 6.8)	23.6 (-5.3 to 86.3)	-1.7 (-25.5 to 46.0)
Chronic kidney disease due to hypertension	52.0 (39.8 to 69.8)	55.0 (37.2 to 76.9)	4.0 (-19.2 to 43.2)	-13.9 (-34.6 to 13.9)	5.7 (3.7 to 8.2)	2.4 (1.6 to 3.5)	-57.6 (-69.4 to -46.1)	-63.4 (-72.1 to -53.2)
Chronic kidney disease due to glomerulonephritis	94.4 (66.5 to 136.9)	51.8 (38.3 to 68.1)	-44.8 (-62.8 to -21.7)	-48.0 (-63.9 to -30.5)	1.9 (1.2 to 2.8)	3.8 (2.4 to 5.5)	103.1 (52.5 to 171.9)	69.4 (30.1 to 128.2)
Chronic kidney disease due to other causes	203.7 (135.2 to 284.4)	295.7 (206.1 to 412.3)	45.3 (26.6 to 76.6)	45.3 (6.4 to 84.1)	9.5 (6.4 to 13.2)	14.5 (8.9 to 19.9)	52.2 (33.4 to 97.3)	26.6 (12.2 to 59.8)
Urinary diseases and male infertility	-	-	-	-	5.2 (3.4 to 7.4)	7.2 (4.6 to 10.3)	38.8 (27.4 to 51.3)	8.5 (-0.3 to 18.9)
Interstitial nephritis and urinary tract infections	1.2 (1.2 to 1.3)	1.9 (1.7 to 2.0)	49.8 (37.0 to 62.5)	35.6 (22.9 to 48.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	49.2 (26.6 to 81.9)	35.6 (12.1 to 68.8)

Appendix Table G.4 - Denmark prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Urolithiasis	80.4 (55.8 to 105.3)	132.5 (70.8 to 228.6)	56.3 (22.7 to 135.8)	6.4 (-5.6 to 87.5)	0.6 (0.4 to 1.0)	1.0 (0.5 to 2.0)	48.7 (17.8 to 120.8)	38.7 (-7.7 to 76.9)
Benign prostatic hyperplasia	119.6 (109.0 to 130.5)	165.3 (159.4 to 171.8)	38.2 (25.7 to 52.6)	6.8 (-2.8 to 17.8)	4.2 (2.7 to 6.0)	5.9 (3.9 to 8.3)	39.3 (26.6 to 54.8)	7.5 (-2.6 to 18.9)
Male infertility due to other causes	21.6 (16.4 to 27.5)	18.6 (13.8 to 24.2)	-13.0 (-42.7 to 24.0)	-4.1 (-36.7 to 35.9)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.3)	-12.9 (-43.8 to 24.7)	-3.9 (-37.9 to 36.6)
Other urinary diseases	-	-	-	-	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.3)	-4.4 (-37.8 to 89.6)	-24.0 (-50.8 to 49.9)
Gynecological diseases	-	-	-	-	6.6 (4.1 to 10.2)	6.7 (4.2 to 10.4)	1.5 (-12.2 to 21.1)	-3.2 (-13.5 to 19.7)
Uterine fibroids	212.7 (181.4 to 246.5)	230.1 (197.5 to 266.2)	8.2 (7.3 to 9.0)	0.9 (0.9 to 1.0)	1.8 (0.9 to 3.3)	1.9 (0.9 to 3.5)	5.3 (-4.9 to 31.0)	-0.7 (-11.1 to 23.3)
Polycystic ovarian syndrome	88.3 (75.8 to 101.0)	90.0 (77.9 to 102.5)	1.4 (-16.6 to 25.5)	4.3 (-15.1 to 30.6)	0.8 (0.4 to 1.5)	0.8 (0.4 to 1.6)	1.5 (-16.2 to 25.3)	5.0 (-14.2 to 30.9)
Female infertility due to other causes	0.6 (0.3 to 1.0)	0.6 (0.3 to 1.2)	-4.3 (-51.3 to 126.3)	2.7 (-48.4 to 158.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.6 (-57.1 to 145.0)	2.7 (-54.8 to 180.2)
Endometriosis	15.6 (11.6 to 19.9)	14.6 (11.4 to 18.1)	-6.5 (-33.1 to 33.6)	3.8 (-31.0 to 38.5)	1.4 (0.9 to 2.1)	1.3 (0.9 to 2.0)	3.3 (-32.7 to 35.2)	-3.2 (-31.0 to 40.0)
Genital prolapse	332.1 (301.6 to 363.9)	365.0 (331.3 to 397.9)	9.8 (-4.3 to 25.2)	-2.1 (-15.0 to 11.5)	1.1 (0.5 to 2.0)	1.2 (0.5 to 2.2)	10.1 (-4.2 to 25.9)	-1.8 (-15.1 to 12.6)
Premenstrual syndrome	140.0 (90.1 to 198.7)	137.3 (100.4 to 180.3)	-3.4 (-35.6 to 60.3)	3.0 (-30.6 to 67.1)	1.2 (0.6 to 1.9)	1.2 (0.6 to 1.9)	-2.9 (-35.7 to 62.3)	3.5 (-30.3 to 68.8)
Other gynecological diseases	12.9 (10.4 to 21.9)	13.5 (9.4 to 26.4)	-2.4 (-47.1 to 120.3)	-1.1 (-42.5 to 90.0)	0.3 (0.2 to 0.8)	0.3 (0.1 to 1.1)	-9.8 (-71.1 to 312.6)	-10.5 (-69.1 to 219.2)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	3.7 (2.5 to 5.3)	4.2 (2.8 to 6.2)	12.3 (4.0 to 38.7)	2.0 (-4.7 to 23.3)
Thalassemias	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	13.6 (3.1 to 31.1)	11.9 (1.5 to 28.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.6 (3.5 to 38.9)	15.1 (-15.0 to 53.8)
Thalassemia trait	71.7 (63.3 to 82.6)	83.6 (74.2 to 95.6)	15.9 (9.5 to 29.2)	5.7 (-0.0 to 17.5)	2.1 (1.4 to 3.0)	2.5 (1.6 to 3.5)	14.3 (3.5 to 38.9)	4.1 (-4.8 to 24.2)
Sickle cell disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	2.9 (-14.3 to 18.0)	0.2 (-17.0 to 17.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.7 (-4.0 to 16.9)	2.8 (-6.3 to 16.7)
Sickle cell trait	75.4 (68.2 to 83.9)	78.5 (70.5 to 86.7)	4.0 (-1.7 to 11.5)	-5.1 (-10.6 to 2.6)	0.9 (0.5 to 1.3)	1.0 (0.6 to 1.5)	7.1 (-9.0 to 50.3)	-0.3 (-16.0 to 36.6)
G6PD deficiency	34.1 (22.9 to 46.5)	38.4 (23.6 to 52.5)	14.0 (-37.9 to 94.8)	1.6 (-43.5 to 77.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.2 (-70.6 to 10.5)	45.9 (-76.2 to -9.3)
G6PD trait	643.6 (576.4 to 700.9)	681.2 (607.7 to 745.9)	6.0 (-8.3 to 23.7)	-3.1 (-16.2 to 13.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	11.9 (-42.8 to 116.4)	6.3 (-46.9 to 111.6)
Other hemoglobinopathies and hemolytic anemias	30.4 (28.4 to 32.3)	37.1 (33.8 to 41.5)	22.3 (8.5 to 37.7)	4.8 (-9.2 to 18.4)	0.6 (0.4 to 0.9)	0.7 (0.4 to 1.1)	16.2 (-6.6 to 53.9)	-0.5 (-17.1 to 27.2)
Endocrine, metabolic, blood, and immune disorders	81.4 (77.8 to 86.6)	71.8 (67.7 to 79.3)	-11.9 (-18.9 to -2.1)	-22.3 (-30.4 to -11.9)	2.6 (1.8 to 3.6)	2.2 (1.5 to 3.1)	-14.8 (-24.9 to 1.3)	-25.1 (-35.3 to -8.1)
Musculoskeletal disorders	-	-	-	-	167.3 (119.8 to 220.4)	194.6 (139.5 to 255.7)	16.2 (11.4 to 21.4)	1.7 (-2.5 to 6.4)
Rheumatoid arthritis	23.4 (21.3 to 25.3)	33.3 (31.0 to 35.8)	42.6 (27.2 to 59.7)	18.8 (6.7 to 32.6)	5.3 (3.8 to 7.0)	7.6 (5.4 to 10.1)	44.1 (27.6 to 61.4)	20.0 (7.1 to 34.1)
Osteoarthritis	378.1 (352.8 to 401.6)	457.2 (428.0 to 483.7)	20.7 (10.4 to 33.2)	-3.8 (-12.2 to 5.8)	12.9 (8.4 to 18.7)	15.7 (10.2 to 22.5)	21.5 (10.7 to 34.3)	-3.4 (-12.0 to 6.8)
Low back and neck pain	-	-	-	-	130.1 (91.4 to 175.5)	144.7 (100.1 to 193.8)	11.0 (5.5 to 17.2)	0.7 (-5.7 to 5.1)
Low back pain	806.6 (774.5 to 839.5)	897.9 (854.4 to 937.4)	10.9 (5.7 to 19.1)	-0.9 (-6.0 to 5.5)	99.1 (60.5 to 123.0)	99.2 (67.2 to 135.3)	18.8 (5.6 to 18.9)	-0.6 (-5.7 to 5.9)
Neck pain	420.3 (381.9 to 457.5)	466.8 (420.7 to 512.4)	10.7 (-1.8 to 26.2)	-1.7 (-12.6 to 12.1)	40.9 (28.3 to 56.5)	45.5 (30.8 to 62.4)	10.7 (-1.8 to 26.4)	-1.4 (-12.3 to 12.7)
Gout	11.6 (10.4 to 12.9)	14.5 (12.9 to 16.2)	24.3 (5.2 to 46.0)	0.1 (-14.9 to 17.7)	0.4 (0.2 to 0.5)	0.4 (0.3 to 0.6)	25.0 (1.7 to 52.0)	0.7 (-18.4 to 23.6)
Other musculoskeletal disorders	206.0 (165.1 to 248.3)	287.7 (231.7 to 344.7)	39.4 (30.5 to 49.2)	16.9 (10.3 to 25.6)	18.7 (12.2 to 26.6)	17.6 (17.2 to 37.8)	40.1 (30.5 to 50.2)	17.6 (10.3 to 26.4)
Other non-communicable diseases	-	-	-	-	38.2 (66.2 to 140.3)	40.7 (72.7 to 152.9)	9.7 (4.7 to 14.5)	3.3 (-8.1 to 1.3)
Congenital anomalies	-	-	-	-	7.8 (5.6 to 10.3)	9.8 (6.9 to 13.3)	25.7 (7.0 to 48.6)	11.3 (-5.8 to 32.4)
Neural tube defects	2.1 (1.8 to 2.4)	1.7 (1.5 to 2.0)	-18.1 (-32.7 to 4.5)	-23.9 (-37.4 to -2.4)	0.7 (0.5 to 1.0)	0.6 (0.4 to 0.8)	-16.5 (-39.5 to 16.6)	-22.5 (-43.5 to 8.1)
Congenital heart anomalies	51.2 (43.5 to 63.5)	46.6 (37.9 to 56.7)	-9.3 (-31.7 to 16.5)	-17.0 (-37.4 to 6.2)	1.8 (0.7 to 3.2)	1.7 (0.7 to 3.0)	-8.4 (-28.6 to 15.1)	-15.9 (-34.3 to 5.3)
Crofacial clefts	9.7 (7.8 to 12.2)	9.7 (8.4 to 12.9)	-0.7 (-24.3 to 45.2)	-10.2 (-31.7 to 11.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-5.2 (-32.0 to 29.5)	-14.1 (-38.2 to 29.5)
Down syndrome	5.8 (4.9 to 7.3)	6.9 (6.0 to 8.4)	17.6 (-6.6 to 52.9)	0.6 (-19.5 to 31.9)	0.9 (0.6 to 1.2)	1.1 (0.8 to 1.4)	1.9 (-2.8 to 62.1)	2.1 (-19.8 to 33.7)
Turner syndrome	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	14.4 (-24.0 to 85.4)	6.5 (-28.8 to 71.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.7 (-28.2 to 81.2)	7.4 (-31.8 to 73.0)
Klinefelter syndrome	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.5)	34.2 (4.5 to 95.6)	22.2 (-5.2 to 78.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.2 (-15.1 to 87.1)	21.9 (-16.4 to 84.1)
Chromosomal unbalanced rearrangements	15.1 (12.4 to 17.9)	17.9 (14.6 to 21.4)	19.8 (7.5 to 54.5)	2.5 (-20.8 to 22.5)	2.2 (1.6 to 2.9)	2.8 (2.0 to 3.7)	26.5 (-2.0 to 63.5)	4.4 (-19.6 to 34.9)
Other congenital anomalies	6.2 (4.1 to 8.2)	5.7 (3.8 to 7.7)	-8.5 (-25.9 to 10.0)	-28.2 (-32.6 to -2.7)	2.1 (1.3 to 3.1)	3.6 (2.2 to 5.6)	7.0 (26.6 to 132.0)	60.8 (17.7 to 116.6)
Skin and subcutaneous diseases	-	-	-	-	37.8 (24.1 to 57.3)	40.3 (25.6 to 61.3)	6.6 (2.4 to 19.1)	-0.7 (-7.2 to 6.8)
Dermatitis	376.2 (279.0 to 465.4)	395.2 (297.3 to 483.6)	5.0 (3.2 to 7.3)	-0.1 (-0.1 to 0.0)	11.5 (6.7 to 17.3)	12.2 (7.1 to 18.4)	6.2 (2.6 to 10.0)	0.1 (-2.2 to 2.6)
Psoriasis	77.7 (66.9 to 89.7)	86.8 (74.6 to 99.9)	11.6 (9.3 to 34.4)	0.0 (-0.1 to 0.2)	6.2 (4.2 to 8.8)	7.0 (4.7 to 9.7)	12.0 (7.0 to 17.0)	0.5 (-3.3 to 4.7)
Cellulitis	0.8 (0.6 to 0.9)	0.8 (0.7 to 1.0)	0.8 (-3.7 to 18.6)	5.6 (-12.9 to 6.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	5.7 (-15.0 to 31.6)	4.4 (-21.8 to 15.9)
Pyoderma	7.0 (5.8 to 8.5)	10.7 (8.7 to 13.3)	52.0 (42.3 to 64.1)	27.5 (21.0 to 35.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	51.4 (39.2 to 67.0)	27.1 (17.6 to 38.7)
Scabies	3.6 (3.0 to 4.3)	2.9 (2.5 to 3.4)	-18.7 (-36.4 to 1.0)	-22.3 (-38.5 to -2.8)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-18.0 (-37.9 to 2.6)	-21.9 (-39.5 to 0.2)
Fungal skin diseases	387.8 (343.6 to 426.8)	441.3 (390.7 to 483.9)	13.7 (12.3 to 15.4)	0.1 (-0.0 to 0.2)	2.2 (0.9 to 4.5)	2.5 (1.0 to 5.1)	13.8 (12.1 to 15.8)	0.3 (-0.6 to 1.2)
Viral skin diseases	102.6 (81.4 to 126.1)	119.9 (89.1 to 133.1)	8.0 (3.5 to 12.9)	0.5 (-1.8 to 4.9)	3.1 (1.8 to 4.9)	3.4 (2.0 to 5.3)	9.2 (3.3 to 13.9)	0.7 (-2.9 to 4.2)
Acne vulgaris	802.2 (615.2 to 1,006.2)	739.6 (541.3 to 921.5)	-6.6 (-31.9 to 18.3)	-3.8 (-29.8 to 23.1)	8.7 (3.9 to 17.0)	8.0 (3.4 to 15.5)	-6.6 (-32.0 to 18.3)	-3.8 (-29.8 to 23.4)
Alopecia areata	9.1 (8.3 to 9.9)	10.4 (9.5 to 11.2)	13.6 (1.3 to 27.4)	-0.4 (-10.2 to 11.0)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	13.7 (-1.3 to 30.8)	0.2 (-12.4 to 14.7)
Pruritus	0.7 (0.4 to 1.0)	0.8 (0.6 to 1.1)	12.3 (-26.5 to 99.6)	-7.3 (-36.7 to 62.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.3 (-29.5 to 109.1)	-6.9 (-40.9 to 71.8)
Urticaria	44.3 (32.4 to 58.8)	52.7 (32.1 to 69.0)	20.7 (-32.7 to 88.6)	4.3 (-39.9 to 62.0)	1.5 (1.5 to 4.0)	3.1 (1.6 to 4.9)	7.1 (-31.1 to 89.6)	7.1 (-39.8 to 62.9)
Decubitus ulcer	3.3 (2.5 to 4.5)	3.8 (2.9 to 5.0)	14.6 (-31.5 to 65.0)	-5.3 (-40.6 to 33.4)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.8)	13.9 (-30.3 to 69.2)	-5.2 (-39.6 to 37.4)
Other skin and subcutaneous diseases	447.3 (256.2 to 774.9)	541.5 (296.3 to 967.8)	20.5 (12.2 to 27.9)	0.5 (-2.5 to 4.0)	2.6 (1.0 to 5.7)	3.1 (1.2 to 7.3)	20.7 (12.1 to 28.2)	0.8 (-2.4 to 4.4)
Sense organ diseases	-	-	-	-	35.0 (23.6 to 49.6)	38.6 (26.0 to 54.2)	10.2 (4.4 to 19.1)	-8.8 (-14.6 to -1.5)
Glaucoma	3.3 (2.4 to 4.6)	3.7 (2.8 to 5.0)	11.5 (-9.2 to 46.8)	-6.6 (-23.4 to 20.3)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	18.8 (-5.0 to 55.0)	-1.2 (-20.3 to 27.5)
Cataract	10.5 (7.2 to 13.9)	7.1 (3.6 to 10.9)	-32.7 (-60.1 to -0.1)	-44.4 (-66.2 to -38.2)	0.8 (0.5 to 1.2)	0.5 (0.2 to 0.8)	-35.5 (-60.6 to -6.5)	-47.0 (-66.5 to -23.2)
Macular degeneration	15.9 (11.6 to 21.3)	18.4 (13.2 to 25.1)	14.3 (-4.6 to 45.3)	-8.4 (-22.2 to 15.5)	1.2 (0.8 to 1.8)	1.4 (0.9 to 2.1)	17.3 (-0.4 to 42.5)	-5.3 (-19.4 to 14.5)
Uncorrected refractive error	641.8 (484.8 to 770.7)	719.1 (562.6 to 897.8)	12.1 (-17.5 to 54.2)	-6.7 (-31.9 to 28.2)	8.0 (4.3 to 13.6)	8.7 (4.8 to 15.7)	9.2 (-14.7 to 40.3)	-8.9 (-28.8 to 16.7)
Age-related and other hearing loss	608.4 (551.0 to 655.1)	685.6 (615.2 to 746.8)	12.7 (8.4 to 17.0)	-9.7 (-13.4 to -6.0)	20.7 (13.3 to 29.4)	23.2 (14.8 to 33.2)	12.2 (2.1 to 23.9)	-8.6 (-16.1 to 0.2)
Other vision loss	11.8 (9.3 to 14.8)	9.8 (7.3 to 12.9)	-16.6 (-32.5 to -1.1)	-30.0 (-42.2 to -20.1)	0.8 (0.6 to 1.3)	0.8 (0.5 to 1.1)	-0.8 (-26.6 to 3.9)	-25.7 (-37.7 to -14.8)
Other sense organ diseases	122.7 (117.3 to 128.4)	140.8 (134.3 to 147.6)	14.6 (7.8 to 22.8)	-0.2 (-6.1 to 6.7)	3.2 (2.0 to 4.7)	3.7 (2.2 to 5.4)	14.8 (6.6 to 24.0)	-0.1 (-6.9 to 7.6)
Oral disorders	-	-	-	-	17.5 (10.6 to 26.7)	18.9 (11.5 to 29.5)	7.8 (2.4 to 12.2)	-9.4 (-15.8 to -2.8)
Deciduous caries	136.2 (132.3 to 140.0)	155.5 (150.1 to 160.9)	14.1 (9.3 to 19.4)	-1.8 (-5.9 to 2.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	14.1 (3.1 to 25.5)	-1.7 (-11.2 to 7.9)
Permanent caries	1,838.4 (1,653.7 to 2,103.0)	2,000.9 (1,784.8 to 2,196.7)	9.4 (-8.7 to 25.9)	8.9 (-15.2 to 16.6)	1.1 (0.5 to 2.1)	1.2 (0.5 to 2.7)	9.4 (8.9 to 26.2)	1.2 (-15.6 to 16.8)
Periodontal diseases	784.3 (716.5 to 853.1)	878.5 (790.8 to 985.1)	11.8 (-2.7 to 30.4)	-7.5 (-19.3 to 7.7)	5.1 (2.0 to 10.5)	5.3 (2.3 to 11.9)	12.0 (2.7 to 30.8)	-7.2 (-2.7 to 7.8)
Edentulism and severe tooth loss	313.7 (280.7 to 344.5)	326.4 (299.5 to 352.8)	3.9 (-9.3 to 20.7)	-17.2 (-27.1 to -3.4)	8.5 (5.5 to 11.7)	8.9 (6.0 to 12.5)	4.4 (8.6 to 21.3)	-16.8 (-3.0 to 30.0)

Appendix Table G.4 - Denmark prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	99.3 (94.0 to 105.1)	108.6 (102.9 to 113.9)	9.5 (1.5 to 17.4)	-0.5 (-7.9 to 7.0)	2.9 (1.8 to 4.3)	3.2 (2.0 to 4.7)	9.4 (0.5 to 18.3)	-0.4 (-8.5 to 7.8)
Injuries	-	-	-	-	67.2 (51.3 to 86.2)	47.4 (33.7 to 63.8)	-29.6 (-37.3 to -21.0)	-41.1 (-47.0 to -34.3)
Transport injuries	-	-	-	-	11.3 (8.5 to 14.6)	5.4 (3.9 to 7.2)	-53.0 (-57.8 to -47.5)	-60.9 (-64.9 to -56.3)
Road injuries	-	-	-	-	10.4 (7.8 to 13.4)	4.2 (3.1 to 5.7)	-59.5 (-63.8 to -54.8)	-66.1 (-69.6 to -62.0)
Pedestrian road injuries	-	-	-	-	1.6 (1.2 to 2.1)	0.6 (0.4 to 0.8)	-62.7 (-66.8 to -58.0)	-49.3 (-72.7 to -64.9)
Cyclist road injuries	-	-	-	-	1.5 (1.1 to 1.9)	0.6 (0.4 to 0.8)	-61.2 (-66.2 to -55.1)	-67.2 (-71.3 to -61.8)
Motorcyclist road injuries	-	-	-	-	1.8 (1.3 to 2.4)	0.7 (0.5 to 1.0)	-59.5 (-65.8 to -51.8)	-65.7 (-71.3 to -59.2)
Motor vehicle road injuries	-	-	-	-	5.5 (4.1 to 7.0)	2.3 (1.7 to 3.0)	-58.1 (-62.0 to -53.7)	-64.9 (-68.2 to -61.0)
Other road injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-99.7 (-73.6 to -64.6)	-74.1 (-77.6 to -69.6)
Other transport injuries	-	-	-	-	0.9 (0.7 to 1.2)	1.1 (0.8 to 1.5)	21.4 (9.2 to 35.7)	0.2 (-9.3 to 11.9)
Unintentional injuries	-	-	-	-	54.9 (42.0 to 70.3)	41.4 (29.5 to 56.0)	-24.7 (-33.2 to -15.1)	-36.3 (-42.8 to -29.0)
Falls	-	-	-	-	41.6 (31.7 to 53.1)	33.3 (23.8 to 44.7)	-20.4 (-30.7 to -7.7)	-32.1 (-40.2 to -22.2)
Drowning	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-20.1 (-28.2 to -12.1)	-33.4 (-40.5 to -26.2)
Fire, heat, and hot substances	-	-	-	-	1.2 (0.7 to 1.8)	1.1 (0.6 to 1.8)	-8.4 (-20.2 to 3.3)	-21.9 (-32.0 to -11.1)
Poisonings	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-59.8 (-66.6 to -52.6)	-65.5 (-71.6 to -58.8)
Exposure to mechanical forces	-	-	-	-	6.7 (5.1 to 8.9)	4.4 (3.1 to 6.0)	-35.1 (-41.9 to -28.7)	-43.5 (-49.6 to -37.8)
Unintentional firearm injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-44.0 (-51.7 to -36.0)	-49.6 (-56.8 to -42.2)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	2.2 (-10.9 to 17.9)	-10.8 (-22.6 to 3.7)
Other exposure to mechanical forces	-	-	-	-	6.7 (5.0 to 8.8)	4.3 (3.1 to 5.9)	-35.2 (-42.1 to -28.8)	-43.6 (-49.8 to -37.9)
Adverse effects of medical treatment	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	21.7 (10.4 to 32.0)	2.7 (-5.9 to 11.1)
Animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-7.4 (-14.9 to 1.1)	-20.0 (-26.9 to -12.0)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-13.5 (-26.9 to 2.9)	-23.1 (-36.4 to -8.6)
Non-venomous animal contact	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-6.2 (-14.4 to 3.0)	-19.4 (-26.7 to -10.4)
Foreign body	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-14.8 (-23.6 to -5.6)	-23.2 (-32.4 to -13.7)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-23.5 (-34.7 to -11.6)	-34.6 (-45.2 to -22.0)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-4.3 (-15.2 to 7.2)	-12.3 (-23.1 to -0.4)
Foreign body in other body part	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-15.0 (-24.8 to -3.5)	-23.1 (-33.4 to -10.9)
Other unintentional injuries	-	-	-	-	4.4 (3.1 to 5.9)	1.7 (1.2 to 2.5)	-60.3 (-65.8 to -54.1)	-69.8 (-73.9 to -65.4)
Self-harm and interpersonal violence	-	-	-	-	0.9 (0.7 to 1.2)	0.6 (0.4 to 0.8)	-38.0 (-43.3 to -32.5)	-47.7 (-52.3 to -43.1)
Self-harm	-	-	-	-	0.5 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-38.4 (-45.7 to -30.9)	-48.3 (-54.4 to -41.8)
Interpersonal violence	-	-	-	-	0.5 (0.4 to 0.6)	0.3 (0.2 to 0.4)	-37.6 (-43.4 to -30.9)	-47.2 (-52.0 to -41.4)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-38.9 (-44.6 to -33.0)	-48.6 (-53.4 to -43.6)
Assault by sharp object	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-19.2 (-25.2 to -10.8)	-32.5 (-37.6 to -25.6)
Assault by other means	-	-	-	-	0.3 (0.3 to 0.4)	0.2 (0.1 to 0.3)	-40.3 (-46.6 to -32.8)	-49.2 (-54.5 to -42.6)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.8 (-23.0 to 160.9)	26.6 (-40.4 to 113.9)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.8 (-23.0 to 160.9)	26.6 (-40.4 to 113.9)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Djibouti prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	51.6 (37.3 to 68.3)	87.0 (63.8 to 114.6)	68.7 (63.5 to 74.4)	68.7 (3.1 to 2.3)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	11.1 (7.2 to 17.3)	17.9 (11.9 to 26.8)	61.7 (51.4 to 77.8)	13.6 (4.5 to 27.1)
HIV/AIDS and tuberculosis	-	-	-	-	0.5 (0.3 to 0.6)	2.4 (1.5 to 3.7)	405.7 (288.9 to 679.4)	163.1 (99.9 to 313.5)
Tuberculosis	1.4 (1.2 to 1.5)	2.9 (2.7 to 3.2)	112.2 (96.6 to 131.5)	9.7 (2.5 to 18.6)	0.4 (0.3 to 0.6)	0.9 (0.6 to 1.2)	112.3 (94.3 to 135.1)	10.1 (1.9 to 20.1)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.1)	1.5 (0.8 to 2.8)	15.7 (1,533.3 to 10,883.3)	352.1 (903.7 to 6,886.6)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	3,272.6 (1,428.6 to 7,334.8)	1,782.3 (756.1 to 4,166.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	2,994.8 (1,304.8 to 7,008.3)	1,607.5 (669.2 to 3,909.7)
HIV/AIDS resulting in other diseases	0.4 (0.2 to 0.9)	8.8 (6.7 to 11.1)	2,195.4 (821.8 to 4,616.4)	1,319.2 (480.8 to 2,879.5)	0.0 (0.0 to 0.1)	1.4 (0.8 to 2.7)	4,021.9 (1,509.5 to 11,568.9)	2,409.5 (879.3 to 7,475.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	1.6 (1.1 to 2.2)	1.7 (1.2 to 2.4)	9.9 (4.3 to 24.0)	-23.4 (-33.3 to -13.9)
Diarrheal diseases	1.6 (1.2 to 2.0)	1.8 (1.5 to 2.2)	15.8 (-15.5 to 62.0)	-8.3 (-30.7 to 22.1)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	15.7 (-17.0 to 63.3)	8.1 (-31.6 to 22.8)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-42.6 to 6.9)	-43.4 (-58.4 to -26.2)
Typhoid fever	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-15.7 (-30.6 to 0.2)	-40.9 (-50.4 to -30.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-33.3 to 9.8)	-40.2 (-51.9 to -26.2)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.6 (-19.0 to 31.0)	-28.2 (-41.7 to -8.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.5 (-21.0 to 34.4)	-27.8 (-43.3 to -6.6)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.0 (-99.7 to 133.1)	-93.0 (-99.8 to 60.5)
Lower respiratory infections	0.5 (0.4 to 0.7)	0.4 (0.3 to 0.4)	-28.1 (-56.3 to -2.2)	-44.2 (-62.5 to -28.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-5.7 to 0.6)	-44.4 (-62.7 to -25.1)
Upper respiratory infections	37.4 (33.1 to 41.2)	54.9 (50.2 to 59.9)	46.1 (28.7 to 70.7)	-1.2 (-13.2 to 15.2)	0.4 (0.2 to 0.7)	0.6 (0.4 to 1.1)	45.9 (28.0 to 70.2)	-1.0 (-13.4 to 15.4)
Otitis media	10.0 (9.1 to 11.0)	12.6 (11.6 to 13.7)	25.1 (13.0 to 40.2)	-13.0 (-21.2 to -2.7)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	23.2 (9.6 to 40.2)	-13.5 (-22.6 to -1.9)
Meningitis	-	-	-	-	0.5 (0.3 to 0.8)	0.4 (0.3 to 0.6)	-19.9 (-42.4 to -0.1)	-46.7 (-59.7 to -33.5)
Pneumococcal meningitis	1.9 (1.2 to 2.9)	1.6 (0.9 to 2.4)	-15.4 (-37.7 to 7.6)	-45.2 (-58.1 to -31.1)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-18.5 (-42.4 to 16.6)	-46.1 (-61.1 to -24.0)
H influenzae type B meningitis	1.0 (0.4 to 2.0)	0.8 (0.3 to 1.5)	-20.1 (-43.8 to 11.4)	-47.7 (-62.6 to -25.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-14.0 (-47.0 to 25.8)	-41.9 (-63.7 to -15.2)
Meningococcal meningitis	0.3 (0.1 to 0.6)	0.2 (0.1 to 0.5)	-6.0 (-31.5 to 29.9)	-41.0 (-56.4 to -16.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-4.7 (-30.9 to 36.4)	-39.8 (-56.5 to -12.6)
Other meningitis	1.6 (0.7 to 2.9)	1.2 (0.6 to 2.2)	-22.9 (-48.4 to -3.9)	-49.2 (-63.6 to -34.1)	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.2)	-23.8 (-60.9 to 7.0)	-49.2 (-71.9 to -27.8)
Encephalitis	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	54.9 (33.0 to 81.4)	51.5 (14.4 to 12.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.5 (24.2 to 91.3)	-2 (-19.6 to 15.4)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.0 (-97.0 to 1,059.0)	-55.2 (-96.8 to 621.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.0 (-97.0 to 1,066.9)	-55.2 (-96.8 to 627.6)
Whooping cough	0.3 (0.3 to 0.4)	0.3 (0.2 to 0.3)	-24.9 (-27.2 to -22.5)	-34.9 (-37.0 to -32.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.2 (-34.4 to -14.3)	-35.1 (-43.3 to -25.7)
Tetanus	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-66.3 (-85.7 to -32.4)	-77.1 (-90.4 to -54.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.2 (-77.8 to 1.2)	-65.0 (-84.1 to -31.5)
Measles	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.0)	87.4 (-91.1 to -81.9)	-89.4 (-92.5 to -84.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.5 (-93.8 to -78.2)	49.5 (-94.8 to -81.6)
Varicella and herpes zoster	0.4 (0.3 to 0.4)	0.6 (0.5 to 0.6)	59.5 (36.5 to 86.1)	-0.7 (-19.9 to 23.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.0 (23.2 to 155.8)	-3.4 (-33.4 to 39.7)
Neglected tropical diseases and malaria	-	-	-	-	2.4 (1.0 to 6.0)	3.5 (1.3 to 9.2)	46.5 (24.6 to 59.5)	-8.3 (-25.0 to 1.1)
Malaria	4.3 (3.3 to 5.6)	2.7 (2.0 to 3.6)	-36.3 (-50.0 to -23.7)	-58.7 (-68.6 to -48.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-9.9 (-31.2 to 15.2)	-35.6 (-51.9 to -16.4)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.6 (149.9 to 153.4)	10.1 (-19.1 to 70.7)
Visceral leishmaniasis	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	38.8 (1.9 to 138.3)	-4.1 (-30.4 to 60.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.8 (-3.2 to 138.8)	-2.8 (-32.4 to 63.9)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	186.9 (90.8 to 316.1)	59.9 (0.7 to 126.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	186.4 (74.5 to 341.1)	61.1 (-2.2 to 141.1)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	174.2 (24.8 to 403.3)	282.6 (39.0 to 656.0)	62.2 (54.0 to 67.8)	-0.2 (-4.2 to 3.1)	1.6 (0.4 to 5.0)	2.6 (0.6 to 8.0)	57.2 (26.6 to 77.1)	0.2 (-15.5 to 14.1)
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.1 (-42.8 to 695.8)	-4.7 (-69.9 to 240.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.1 (-40.4 to 731.9)	-0.9 (-69.3 to 257.7)
Cystic echinococcosis	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	20.2 (6.5 to 40.9)	-29.4 (-35.8 to -19.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.4 (8.0 to 54.7)	-29.3 (-42.7 to -12.8)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	1.2 (0.5 to 2.5)	1.2 (0.5 to 2.3)	-1.8 (-50.9 to 148.7)	-55.8 (-78.1 to -7.4)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-3.2 (-53.6 to 114.0)	-58.5 (-79.8 to -16.1)
Dengue	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.3)	647.3 (638.3 to 657.7)	395.8 (389.9 to 402.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	610.3 (424.8 to 817.3)	367.2 (261.2 to 487.1)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.7 (-76.0 to 128.8)	-61.9 (-84.0 to 62.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.7 (-76.0 to 129.6)	61.9 (84.0 to 63.0)
Intestinal nematode infections	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.5)	44.3 (-10.2 to 132.8)	0.5 (-44.3 to 69.1)
Ascariasis	25.7 (19.4 to 33.7)	39.0 (28.6 to 52.7)	51.5 (-0.3 to 135.0)	0.2 (-38.0 to 64.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.5 (-46.7 to 282.0)	2.1 (-67.9 to 205.0)
Trichuriasis	122.2 (94.1 to 158.0)	184.7 (140.5 to 241.5)	50.6 (3.8 to 119.7)	-0.5 (-3.4 to 52.6)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	46.2 (-41.6 to 250.6)	1.5 (-63.8 to 161.3)
Hookworm disease	25.3 (19.5 to 32.9)	39.8 (29.5 to 51.9)	55.4 (4.7 to 132.1)	0.1 (-36.6 to 56.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	41.1 (-11.7 to 116.1)	-1.7 (-41.5 to 58.6)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	8.9 (6.7 to 11.3)	12.0 (11.2 to 13.0)	35.3 (6.0 to 79.6)	11.5 (-11.5 to 44.4)	0.2 (0.2 to 0.6)	0.5 (0.3 to 0.7)	26.9 (8.1 to 80.6)	0.8 (-19.3 to 41.3)
Maternal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	29.9 (9.7 to 52.0)	-25.3 (-35.9 to -12.6)
Maternal hemorrhage	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	18.3 (-22.0 to 66.7)	38.4 (-58.2 to -13.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.0 (-31.1 to 97.6)	33.3 (63.4 to 3.7)
Maternal sepsis and other maternal infections	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-29.4 (-37.7 to -14.3)	-61.9 (-66.1 to -53.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.0 (56.0 to 9.2)	-61.5 (-74.7 to -41.3)
Maternal hypertensive disorders	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-4.8 (-15.7 to 10.3)	-47.0 (-54.5 to -40.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.4 (-22.1 to 21.3)	-47.5 (-57.5 to -34.3)
Obstructed labor	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.7)	32.5 (20.6 to 45.6)	-23.5 (-29.3 to -16.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	32.3 (15.4 to 53.3)	-23.4 (-32.3 to -12.3)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.3 (-52.1 to 67.8)	-50.0 (-72.8 to -9.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.3 (-52.2 to 68.1)	-90.0 (-72.9 to -9.1)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	35.4 (-13.2 to 110.9)	21.9 (-49.4 to 22.9)
Neonatal disorders	-	-	-	-	0.5 (0.3 to 0.7)	1.3 (0.8 to 1.8)	172.8 (84.8 to 327.3)	93.3 (29.6 to 207.6)
Preterm birth complications	2.0 (1.0 to 3.5)	6.1 (3.5 to 10.1)	210.3 (155.9 to 301.7)	105.9 (70.1 to 163.2)	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.9)	295.6 (160.3 to 553.9)	170.8 (80.9 to 339.9)
Neonatal encephalopathy due to birth asphyxia and trauma	3.0 (0.4 to 9.9)	3.5 (0.7 to 10.7)	25.1 (-6.1 to 128.5)	-16.9 (-39.0 to 56.5)	0.1 (0.0 to 0.3)	0.3 (0.1 to 0.5)	99.2 (-1.7 to 301.6)	44.8 (-27.8 to 205.3)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.8 (29.8 to 58.2)	39.9 (24.5 to 51.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.6 (28.2 to 60.2)	39.7 (23.0 to 53.7)
Hemolytic disease and other neonatal jaundice	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	91.8 (6.6 to 360.0)	39.2 (-32.9 to 236.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	91.9 (8.7 to 379.6)	37.8 (-33.2 to 241.3)
Other neonatal disorders	-	-	-	-	0.1 (0.0 to 0.2)	0.2 (0.0 to 0.4)	137.1 (4.2 to 524.9)	69.6 (-26.1 to 340.8)
Nutritional deficiencies	-	-	-	-	5.6 (3.7 to 7.9)	8.2 (5.4 to 11.7)	46.0 (32.2 to 65.0)	10.1 (0.9 to 23.9)
Protein-energy malnutrition	4.9 (3.2 to 7.2)	8.8 (4.7 to 15.0)	75.2 (-13.9 to 249.5)	44.0 (-25.3 to 175.9)	0.5 (0.3 to 1.0)	1.1 (0.5 to 2.2)	75.7 (-13.6 to 252.7)	45.1 (-24.8 to 176.5)
Iodine deficiency	26.2 (13.8 to 43.9)	30.5 (17.5 to 49.7)	12.1 (-35.7 to 167.2)	-31.9 (-60.7 to 66.8)	0.5 (0.2 to 0.9)	0.5 (0.3 to 1.0)	10.9 (-35.3 to 165.1)	-31.8 (-61.2 to 65.9)
Vitamin A deficiency	1.2 (0.8 to 2.1)	1.1 (0.6 to 1.7)	-15.7 (-36.1 to 26.3)	-43.5 (-56.3 to -15.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-16.2 (-34.1 to 11.5)	-43.8 (-55.6 to -26.5)

Appendix Table G.4 - Djibouti prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	124.4 (121.9 to 126.7)	191.0 (185.2 to 197.6)	53.5 (48.2 to 59.0)	5.1 (10.7 to 19.7)	4.4 (2.9 to 6.4)	6.5 (4.3 to 9.3)	46.2 (41.1 to 54.3)	62.2 (9.0 to 20.6)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (3.5 to 689.2)	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.5 (0.3 to 0.7)	0.6 (0.4 to 1.0)	-4.8 (19.2 to 66.2)	-4.8 (20.0 to 10.2)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	71.4 (17.2 to 126.4)	-4.4 (30.0 to 23.4)
Syphilis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	12.8 (-9.8 to 42.6)	-41.4 (-50.6 to -28.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.5 (-17.8 to 57.8)	41.6 (-54.7 to -22.9)
Chlamydial infection	9.0 (6.2 to 12.4)	18.1 (10.9 to 24.8)	107.5 (10.4 to 233.2)	22.0 (34.1 to 91.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	127.9 (-16.4 to 327.5)	36.0 (-48.6 to 143.4)
Gonococcal infection	5.3 (3.4 to 7.7)	7.8 (5.4 to 10.4)	47.2 (-14.8 to 166.2)	-12.9 (-48.2 to 52.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	34.5 (-23.4 to 165.2)	-19.9 (51.9 to 55.2)
Trichomoniasis	10.0 (6.7 to 15.3)	13.9 (8.6 to 19.9)	39.3 (-13.4 to 123.2)	-16.4 (-50.6 to 35.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	31.3 (-33.5 to 126.0)	-20.4 (-58.7 to 38.4)
Genital herpes	116.0 (94.2 to 139.4)	204.3 (174.1 to 240.3)	78.3 (36.7 to 117.6)	6.2 (-23.4 to 11.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	75.0 (31.6 to 116.5)	64.2 (-24.6 to 12.7)
Other sexually transmitted diseases	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	42.1 (21.6 to 74.0)	-24.4 (-35.8 to -7.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (3.8 to 118.9)	44.8 (41.0 to 13.2)
Hepatitis	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	36.2 (6.7 to 70.1)	-19.3 (-39.0 to 4.2)
Hepatitis A	0.9 (0.9 to 0.9)	1.2 (1.1 to 1.2)	31.4 (30.1 to 32.7)	-1.8 (-1.9 to -1.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.7 (28.8 to 62.8)	0.2 (-11.3 to 11.0)
Hepatitis B	81.4 (62.2 to 100.0)	85.2 (66.9 to 104.4)	3.9 (-21.9 to 51.8)	-34.3 (-49.2 to -9.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	28.2 (-1.7 to 84.0)	-27.1 (-51.0 to 5.1)
Hepatitis C	10.6 (9.5 to 11.7)	13.8 (12.0 to 15.4)	30.1 (8.5 to 52.8)	-25.0 (-35.6 to -13.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.3 (7.1 to 54.6)	-28.2 (-49.8 to -2.4)
Hepatitis E	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	87.5 (-4.8 to 210.9)	11.0 (-39.4 to 80.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.3 (-5.4 to 237.4)	11.3 (-39.5 to 91.5)
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.0 (-28.5 to 471.1)	-27.0 (-60.4 to 201.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.2 (-32.5 to 549.6)	-26.8 (-62.9 to 243.0)
Other infectious diseases	6.1 (4.6 to 7.7)	8.5 (7.7 to 9.3)	39.6 (23.1 to 58.6)	13.5 (0.4 to 27.3)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	30.5 (4.9 to 57.8)	4.9 (-23.1 to 28.5)
Non-communicable diseases	-	-	-	-	38.6 (28.3 to 49.9)	65.8 (48.8 to 84.7)	70.8 (64.9 to 75.6)	-2.8 (-5.7 to -0.3)
Neoplasms	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.8)	91.5 (35.1 to 175.3)	1.6 (-27.2 to 41.3)
Esophageal cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	88.7 (1.2 to 273.4)	-5.5 (-48.0 to 78.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.9 (4.4 to 276.3)	-2.3 (-45.6 to 82.3)
Stomach cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	72.4 (0.1 to 184.2)	-12.0 (-46.7 to 40.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.5 (7.0 to 197.2)	-7.2 (-43.2 to 47.6)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.6 (7.9 to 205.2)	3.7 (-42.1 to 57.3)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.5 (-38.2 to 710.9)	-10.1 (-68.7 to 432.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.1 (-34.9 to 694.9)	-8.8 (-67.3 to 390.5)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	333.5 (88.3 to 953.2)	111.3 (-4.7 to 413.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	332.2 (94.9 to 931.5)	104.0 (-4.6 to 398.2)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.1 (-55.6 to 114.9)	-49.7 (-75.7 to 10.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.1 (-50.7 to 119.4)	-46.5 (-72.6 to 11.8)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.6 (-48.3 to 151.1)	-8.8 (-72.7 to 40.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.9 (-43.5 to 136.6)	-41.6 (-70.4 to 30.0)
Larynx cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	279.4 (117.7 to 554.1)	97.1 (11.7 to 234.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	175.5 (61.4 to 396.3)	40.2 (-17.3 to 148.9)
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	88.2 (11.5 to 217.2)	-4.5 (-40.5 to 53.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.7 (18.1 to 238.7)	1.3 (-38.6 to 66.9)
Breast cancer	1.2 (0.9 to 1.5)	1.1 (0.7 to 1.8)	-10.9 (-41.3 to 46.4)	-63.8 (-76.0 to -40.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	38.1 (-15.1 to 133.3)	-37.5 (-61.4 to 4.0)
Cervical cancer	0.4 (0.2 to 0.7)	0.7 (0.3 to 1.2)	74.9 (-23.7 to 175.2)	52.1 (60.5 to 41.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-1.0 (-22.0 to 176.7)	-41.6 (-59.3 to 45.1)
Uterine cancer	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	45.4 (-32.4 to 225.6)	-25.4 (-63.9 to 63.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.5 (-31.3 to 234.1)	-23.9 (-63.5 to 65.1)
Prostate cancer	0.2 (0.2 to 0.4)	1.0 (0.6 to 1.6)	313.3 (159.8 to 561.6)	90.8 (23.9 to 192.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	303.3 (156.3 to 554.0)	87.1 (25.5 to 196.4)
Colon and rectum cancer	0.5 (0.4 to 0.5)	1.0 (0.9 to 1.2)	117.9 (76.9 to 164.5)	5.5 (-9.8 to 24.2)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	118.8 (76.0 to 168.6)	6.2 (-10.3 to 25.8)
Lip and oral cavity cancer	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	81.5 (5.2 to 231.5)	4.1 (-43.5 to 72.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.0 (9.0 to 229.5)	-2.9 (-42.7 to 71.9)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.0 (-35.6 to 133.2)	-36.1 (-64.5 to 24.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.9 (-33.6 to 130.6)	34.4 (-62.4 to 25.3)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.0 (-20.4 to 215.7)	-17.3 (-57.9 to 58.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.9 (-15.4 to 211.3)	-16.3 (-54.0 to 57.0)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.7 (10.8 to 233.2)	-1.7 (-42.1 to 69.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.4 (13.3 to 225.0)	-1.3 (-40.3 to 67.2)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	125.6 (32.6 to 279.4)	14.4 (-30.0 to 88.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	133.6 (39.4 to 273.4)	16.1 (-28.0 to 80.9)
Malignant skin melanoma	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	136.2 (35.3 to 306.3)	21.7 (-28.7 to 106.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	137.7 (32.2 to 258.6)	19.4 (-32.0 to 102.0)
Non-melanoma skin cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	163.2 (80.9 to 273.1)	28.1 (-11.6 to 82.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	195.2 (79.5 to 387.4)	41.8 (-16.4 to 141.9)
Ovarian cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	89.5 (-5.2 to 256.6)	0.3 (-48.7 to 88.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.2 (-4.1 to 282.8)	2.9 (-49.7 to 99.8)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	82.3 (-8.4 to 259.1)	-1.5 (-49.5 to 89.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.6 (-8.8 to 281.3)	0.2 (-50.0 to 93.9)
Kidney cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	61.7 (-10.9 to 185.1)	21.7 (-28.9 to 105.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.2 (0.4 to 213.5)	32.9 (-25.1 to 129.8)
Bladder cancer	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	83.1 (45.5 to 126.6)	-10.6 (-27.7 to 10.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.5 (55.3 to 133.3)	-7.7 (-24.9 to 13.7)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	98.7 (32.6 to 203.7)	22.6 (-16.4 to 81.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.7 (35.1 to 209.2)	18.3 (-19.1 to 80.5)
Thyroid cancer	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	42.0 (-35.5 to 175.1)	-25.0 (-66.6 to 48.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.5 (-35.1 to 187.8)	-23.8 (-66.2 to 50.8)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.7 (18.4 to 253.6)	0.7 (-36.9 to 80.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.5 (37.2 to 266.8)	11.1 (-35.8 to 90.0)
Hodgkin lymphoma	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	107.2 (23.2 to 255.7)	30.0 (-22.7 to 123.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.4 (26.2 to 248.6)	24.2 (-26.2 to 111.8)
Non-Hodgkin lymphoma	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	39.0 (-16.8 to 164.9)	-4.6 (-44.9 to 84.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.5 (-10.4 to 185.0)	0.7 (-43.3 to 90.2)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.9 (12.4 to 276.9)	8.2 (-40.0 to 92.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.6 (10.2 to 287.3)	7.6 (-42.4 to 94.2)
Leukemia	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	89.4 (-1.0 to 132.9)	0.7 (-32.1 to 56.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.1 (7.7 to 151.6)	2.2 (-33.5 to 62.6)
Other neoplasms	0.4 (0.2 to 0.5)	0.7 (0.5 to 1.0)	97.9 (16.6 to 203.0)	40.5 (-3.3 to 104.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	102.1 (25.2 to 198.8)	35.1 (-7.6 to 101.8)
Cardiovascular diseases	-	-	-	-	0.9 (0.6 to 1.3)	1.7 (1.2 to 2.4)	90.3 (46.5 to 128.2)	-2.0 (-22.3 to 17.7)
Rheumatic heart disease	6.0 (4.8 to 7.3)	10.1 (8.0 to 12.1)	69.4 (24.6 to 124.3)	-3.1 (-24.0 to 22.8)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	65.9 (22.1 to 120.5)	-8.6 (-28.3 to 18.5)
Ischemic heart disease	5.0 (4.0 to 6.1)	7.4 (6.0 to 9.3)	48.7 (10.0 to 110.5)	-27.6 (-45.4 to -0.5)	0.3 (0.2 to 0.4)	0.6 (0.2 to 0.6)	38.6 (5.9 to 119.8)	-31.2 (-53.9 to 5.2)
Cerebrovascular disease	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	104.1 (-11.0 to 172.3)	6.6 (-22.4 to 47.1)
Ischemic stroke	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	105.7 (53.7 to 180.1)	7.2 (-22.2 to 46.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	105.2 (55.8 to 178.5)	6.5 (-22.6 to 48.2)
Hemorrhagic stroke	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	99.4 (40.9 to 172.2)	7.4 (-26.0 to 45.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.9 (41.0 to 169.7)	6.7 (-26.2 to 46.2)
Hypertensive heart disease	0.7 (0.4 to 0.9)	1.7 (1.1 to 2.2)	158.1 (71.2 to 304.6)	20.9 (-21.9 to 87.4)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	156.0 (70.6 to 305.6)	21.4 (-24.2 to 87.6)
Cardiomyopathy and myocarditis	0.6 (0.5 to 0.7)	1.4 (1.0 to 2.2)	154.5 (67.6 to 286.9)	30.5 (-22.0 to 118.4)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	153.6 (64.7 to 286.2)	30.6 (-21.6 to 118.7)
Atrial fibrillation and flutter	0.2 (0.2 to 0.3)	1.3 (1.0 to 1.5)	419.0 (267.4 to 598.0)	143.2 (61.7 to 225.7)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	413.1 (254.6 to 596.5)	142.4 (60.8 to 228.3)
Peripheral vascular disease	7.8 (5.6 to 10.2)	15.4 (8.3 to 24.1)	93.2 (15.8 to 241.3)	-9.2 (-40.0 to 52.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.1 (-1.1 to 266.4)	-23.3 (-61.3 to 46.6)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	38.7 (-15.1 to 156.8)	-26.4 (-58.1 to 64.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.4 (-20.3 to 197.1)	-26.3 (-61.6 to 84.5)
Other cardiovascular and circulatory diseases	2.5 (1.2 to 4.6)	5.4 (2.6 to 8.1)	121.2 (-18.0 to 421.4)	2.7 (-62.9 to 158.7)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	121.4 (-19.6 to 415.1)	5.0 (-62.8 to 163.1)
Chronic respiratory diseases	-	-	-	-	2.7 (1.8 to 3.7)	4.5 (3.0 to 6.4)	66.0 (36.7 to 99.6)	-13.5 (-28.1 to 3.0)
Chronic obstructive pulmonary disease	18.6 (17.8 to 19.5)	35.1 (33.5 to 36.6)	88.6 (82.9 to 94.9)	-0.7 (-3.5 to 2.4)	1.5 (1.0 to 2.2)	3.0 (2.0 to		

Appendix Table G.4 - Djibouti prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	89.3	-3.7
Silicosis	0.0	0.0	86.1	-7.7	0.0	0.0	(83.1 to 95.3)	(-6.7 to -0.8)
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	86.0	-7.7
Coal workers pneumoconiosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Other pneumoconiosis	0.0	0.0	92.8	0.7	0.0	0.0	89.2	0.5
Asthma	9.1	22.2	(85.3 to 100.9)	(-2.7 to 4.7)	0.4	1.0	(84.7 to 100.8)	(-3.1 to 4.6)
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	94.4	8.7	0.0	0.0	94.8	8.6
Other chronic respiratory diseases	0.0	0.0	(29.2 to 154.1)	(-22.1 to 39.0)	0.8	0.6	(31.8 to 153.6)	(-22.3 to 38.8)
Cirrhosis	0.1	0.1	41.5	-14.3	0.0	0.1	50.5	-9.9
Cirrhosis due to hepatitis B	0.0	0.1	77.8	0.9	0.0	0.0	42.9	-14.2
Cirrhosis due to hepatitis C	0.1	0.1	40.4	-26.1	0.0	0.0	39.9	26.0
Cirrhosis due to alcohol use	0.1	0.1	50.2	10.9	0.0	0.0	49.3	11.1
Cirrhosis due to other causes	0.0	0.0	(11.0 to 99.6)	(-22.4 to 54.2)	0.7	1.2	67.8	1.1
Digestive diseases	3.4	5.3	58.2	-23.2	0.1	0.2	70.2	-12.9
Peptic ulcer disease	7.3	10.6	45.6	-6.7	0.3	0.4	34.8	-8.6
Gastritis and duodenitis	0.1	0.1	66.3	0.7	0.0	0.0	67.9	2.7
Appendicitis	0.0	0.0	(14.3 to 158.1)	(-25.6 to 46.2)	0.0	0.0	(3.6 to 172.2)	(-30.0 to 55.1)
Paralytic ileus and intestinal obstruction	1.3	3.6	177.2	0.0	0.0	0.0	43.7	-5.7
Inguinal, femoral, and abdominal hernia	0.5	1.2	131.4	25.3	0.1	0.3	131.0	25.7
Inflammatory bowel disease	0.0	0.0	(115.9 to 146.9)	(17.8 to 32.7)	0.0	0.0	(108.1 to 154.2)	(14.7 to 37.1)
Vascular intestinal disorders	0.0	0.0	74.6	-5.4	0.0	0.0	74.6	-5.4
Gallbladder and biliary diseases	0.1	0.2	(80.1 to 156.6)	(-7.4 to 31.7)	0.0	0.1	(72.9 to 161.8)	(-8.9 to 33.0)
Pancreatitis	0.1	0.2	99.8	4.3	0.0	0.1	99.3	5.1
Other digestive diseases	0.1	0.1	(84.6 to 120.8)	(-3.1 to 13.9)	0.0	0.0	(69.9 to 142.7)	(-9.4 to 23.3)
Neurological disorders	0.7	1.7	133.9	1.2	0.1	0.2	137.8	1.3
Alzheimer disease and other dementias	0.0	0.1	114.2	-1.1	0.0	0.0	113.3	-0.7
Parkinson disease	1.2	1.8	59.1	3.6	0.3	0.6	66.6	8.9
Epilepsy	0.0	0.0	(112.8 to 149.5)	(-0.1 to 31.8)	0.0	0.0	(66.3 to 171.1)	(-10.6 to 43.3)
Multiple sclerosis	0.0	0.0	112.8	12.9	0.0	0.0	112.2	12.9
Migraine	31.9	50.1	48.5	9.3	1.1	1.7	49.9	-9.5
Tension-type headache	67.5	125.3	85.7	4.6	0.5	0.2	85.9	4.8
Medication overuse headache	2.7	6.9	155.7	44.4	0.4	1.1	154.7	44.7
Other neurological disorders	0.0	0.0	49.3	-7.7	0.1	0.2	21.6	-46.8
Mental and substance use disorders	1.2	2.3	87.1	0.6	0.6	1.5	86.1	-1.1
Schizophrenia	5.7	8.9	55.7	-10.7	0.9	0.9	55.5	-10.9
Alcohol use disorders	0.9	1.8	89.6	0.6	0.4	0.7	89.5	0.6
Drug use disorders	0.6	1.3	113.3	0.7	0.3	0.7	113.3	0.6
Opioid use disorders	0.0	0.0	(71.4 to 111.7)	(-9.0 to 11.2)	0.0	0.0	(67.4 to 112.4)	(-10.9 to 11.5)
Cocaine use disorders	0.0	0.0	(51.9 to 143.1)	(-15.5 to 26.7)	0.0	0.0	(42.7 to 159.2)	(-20.2 to 35.3)
Amphetamine use disorders	0.9	1.5	66.7	-0.4	0.1	0.2	67.2	-0.1
Cannabis use disorders	0.8	1.3	63.4	-0.1	0.0	0.0	62.9	-0.4
Other drug use disorders	0.0	0.0	(60.5 to 67.3)	(-0.2 to 0.0)	0.0	0.0	(37.5 to 93.1)	(-14.9 to 16.3)
Depressive disorders	29.2	49.0	67.4	-1.2	6.0	10.1	66.7	-1.2
Major depressive disorder	5.7	10.4	83.4	-0.2	0.5	1.0	83.2	-0.3
Dysthymia	3.2	5.8	79.7	-0.0	0.7	1.2	79.2	0.1
Bipolar disorder	17.5	30.0	72.5	0.2	1.6	2.8	68.1	-1.1
Anxiety disorders	0.1	0.2	62.0	4.4	0.0	0.0	61.3	4.1
Eating disorders	0.0	0.0	(44.5 to 82.0)	(-6.0 to 16.1)	0.0	0.0	(27.4 to 104.2)	(-17.8 to 30.6)
Anorexia nervosa	0.6	1.0	63.2	0.6	0.1	0.2	62.7	0.5
Bulimia nervosa	0.0	0.0	(56.8 to 67.8)	(0.3 to 1.1)	0.0	0.0	(47.1 to 79.8)	(-8.3 to 10.8)
Autistic spectrum disorders	1.8	2.7	52.0	0.2	0.7	1.1	51.1	0.2
Autism	2.6	3.9	51.4	0.3	0.4	0.7	50.6	0.1
Asperger syndrome	4.3	5.7	31.6	0.0	0.1	0.1	31.9	0.5
Attention-deficit/hyperactivity disorder	6.4	8.2	29.2	0.1	0.3	0.5	29.5	0.4
Conduct disorder	7.2	13.6	85.2	26.2	0.4	0.7	85.5	26.0
Idiopathic intellectual disability	7.2	13.4	85.0	0.1	0.5	1.0	84.9	0.2
Other mental and substance use disorders	0.0	0.0	(83.8 to 86.2)	(-0.1 to 0.2)	0.0	0.0	(77.0 to 92.7)	(-3.3 to 3.9)
Diabetes, urogenital, blood, and endocrine diseases	6.6	14.8	125.2	20.3	0.5	1.2	131.2	21.4
Diabetes mellitus	0.0	0.0	(75.0 to 194.4)	(-11.3 to 64.0)	0.0	0.0	(69.2 to 221.3)	(-13.5 to 73.0)
Acute glomerulonephritis	0.0	0.0	12.2	-19.2	0.0	0.0	12.2	-19.2
Chronic kidney disease	7.2	13.1	78.4	-6.1	0.1	0.2	77.8	-6.8
Chronic kidney disease due to diabetes mellitus	22.1	37.4	68.4	3.9	0.3	0.5	64.8	9.2
Chronic kidney disease due to hypertension	12.1	35.6	88.4	6.5	0.3	0.5	63.7	0.9
Chronic kidney disease due to glomerulonephritis	16.0	23.1	44.4	-9.6	0.2	0.3	47.2	-8.9
Chronic kidney disease due to other causes	0.0	0.0	(12.2 to 91.9)	(-27.4 to 19.0)	0.0	0.0	(11.9 to 91.0)	(-29.6 to 18.6)
Urinary diseases and male infertility	0.0	0.0	-	-	0.2	0.3	110.5	4.5

Appendix Table G.4 - Djibouti prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	77.8 (62.8 to 93.5)	0.0 (-1.5 to 15.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.7 (38.5 to 127.2)	0.0 (-11.0 to 31.1)
Urolithiasis	1.2 (0.9 to 1.6)	2.0 (1.5 to 2.5)	57.8 (42.9 to 96.9)	-19.9 (-25.9 to -3.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.4 (72.4 to 128.1)	3.8 (-6.8 to 17.3)
Benign prostatic hyperplasia	3.1 (2.9 to 3.3)	6.9 (6.3 to 7.5)	122.9 (97.5 to 149.1)	4.6 (-6.3 to 16.8)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	122.9 (97.6 to 148.9)	5.0 (-6.5 to 17.2)
Male infertility due to other causes	5.5 (3.0 to 7.9)	10.3 (7.4 to 15.0)	87.1 (8.2 to 243.8)	2.7 (-39.7 to 88.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	85.9 (6.9 to 234.8)	2.1 (-39.4 to 84.7)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.0 (26.8 to 154.4)	0.7 (-30.8 to 36.5)
Gynecological diseases	-	-	-	-	0.6 (0.4 to 0.9)	1.1 (0.7 to 1.6)	82.2 (57.2 to 112.8)	0.5 (-12.1 to 15.2)
Uterine fibroids	8.6 (7.8 to 9.4)	16.3 (14.8 to 17.8)	89.3 (88.9 to 89.8)	-1.7 (-1.8 to -1.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	101.9 (82.6 to 122.0)	7.6 (-2.7 to 19.4)
Polycystic ovarian syndrome	8.2 (7.3 to 9.2)	15.6 (14.1 to 17.0)	91.2 (63.0 to 121.2)	3.5 (-10.4 to 18.3)	0.1 (0.0 to 0.1)	0.3 (0.1 to 0.3)	91.2 (61.8 to 120.1)	3.7 (-10.9 to 17.6)
Female infertility due to other causes	9.1 (6.2 to 12.1)	14.4 (10.4 to 19.5)	58.5 (1.0 to 158.7)	-35.0 (-46.6 to -41.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	59.4 (0.3 to 157.3)	-15.1 (-46.4 to 42.1)
Endometriosis	0.8 (0.7 to 1.0)	1.4 (1.2 to 1.6)	66.2 (33.8 to 107.9)	-9.7 (-27.3 to 12.3)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	66.2 (30.9 to 108.6)	-9.5 (-28.6 to 12.3)
Genital prolapse	14.6 (12.6 to 16.8)	28.2 (23.4 to 32.9)	93.4 (54.5 to 141.0)	0.5 (-17.6 to 21.9)	0.0 (0.0 to 0.1)	0.2 (0.0 to 0.2)	93.1 (54.5 to 143.1)	0.7 (-18.2 to 22.8)
Premenstrual syndrome	21.3 (14.5 to 27.7)	36.9 (24.5 to 49.1)	71.7 (8.5 to 171.6)	-1.8 (-38.0 to 55.1)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.5)	72.0 (6.5 to 170.4)	-1.9 (-39.9 to 54.5)
Other gynecological diseases	1.4 (1.1 to 1.8)	2.8 (2.4 to 3.5)	93.9 (45.2 to 164.8)	10.1 (-14.8 to 46.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	101.5 (28.2 to 278.8)	17.3 (-22.5 to 108.2)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.8)	337.7 (21.0 to 50.6)	1.4 (-8.0 to 13.6)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.9 (4.1 to 34.1)	-10.2 (-21.3 to 3.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.5 (-3.5 to 40.0)	-13.2 (-25.0 to 8.6)
Thalassemia trait	8.2 (6.6 to 10.1)	12.3 (9.7 to 15.2)	49.3 (43.2 to 57.9)	-1.5 (-5.4 to 3.8)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	23.9 (8.1 to 45.0)	-9.4 (-20.8 to 5.7)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.6 (41.2 to 137.6)	33.6 (3.4 to 67.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.4 (52.7 to 130.4)	30.6 (7.7 to 59.5)
Sickle cell trait	13.3 (11.1 to 15.8)	23.0 (19.8 to 26.3)	74.7 (61.2 to 88.9)	18.6 (5.8 to 23.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	35.3 (-3.8 to 116.8)	3.9 (-26.9 to 67.6)
G6PD deficiency	40.4 (28.3 to 52.6)	62.1 (36.3 to 82.8)	52.6 (-13.3 to 161.2)	0.6 (-43.1 to 71.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.8 (-15.3 to 79.4)	-5.3 (-35.7 to 29.5)
G6PD trait	121.5 (106.9 to 131.2)	186.6 (163.5 to 204.7)	53.0 (34.7 to 81.8)	-0.2 (-12.1 to 18.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.8 (-76.5 to 674.6)	-0.2 (-80.0 to 451.0)
Other hemoglobinopathies and hemolytic anemias	4.7 (3.8 to 5.4)	7.7 (7.0 to 8.3)	64.3 (41.5 to 103.5)	0.2 (-10.6 to 50.4)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	44.3 (18.3 to 104.6)	16.6 (-3.8 to 64.1)
Endocrine, metabolic, blood, and immune disorders	6.8 (6.2 to 7.4)	10.0 (8.8 to 11.0)	48.0 (25.6 to 68.7)	0.7 (-3.7 to 21.9)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.5)	40.8 (15.7 to 70.2)	6.4 (-9.8 to 24.5)
Musculoskeletal disorders	-	-	-	-	6.4 (4.5 to 8.5)	12.1 (8.5 to 15.9)	89.1 (71.7 to 109.8)	0.1 (-7.1 to 8.3)
Rheumatoid arthritis	1.2 (1.1 to 1.2)	2.0 (1.9 to 2.0)	66.2 (56.5 to 75.6)	-11.7 (-16.3 to -6.7)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.6)	65.3 (52.6 to 79.2)	-11.6 (-17.5 to -5.1)
Osteoarthritis	9.8 (9.4 to 10.2)	20.6 (19.7 to 21.4)	109.5 (97.8 to 120.8)	1.0 (-4.3 to 6.0)	0.6 (0.4 to 0.8)	1.7 (0.9 to 1.7)	108.9 (97.0 to 121.2)	1.2 (-4.4 to 6.5)
Low back and neck pain	-	-	-	-	4.7 (3.2 to 6.4)	8.7 (6.0 to 11.6)	85.5 (63.5 to 114.3)	0.2 (-10.2 to 12.8)
Low back pain	23.8 (21.7 to 26.0)	44.0 (40.0 to 47.6)	84.5 (62.7 to 110.1)	-0.6 (-12.1 to 11.2)	2.7 (1.8 to 3.8)	4.9 (3.3 to 6.8)	83.9 (61.7 to 109.2)	-0.4 (-12.7 to 11.3)
Neck pain	20.3 (16.2 to 24.5)	38.6 (32.7 to 44.4)	89.8 (45.7 to 146.5)	2.0 (-20.6 to 27.5)	2.0 (1.3 to 2.9)	3.8 (2.5 to 5.3)	89.5 (44.7 to 146.5)	1.9 (-20.6 to 28.5)
Gout	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	99.3 (66.6 to 140.1)	-0.6 (-15.9 to 18.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.5 (48.8 to 161.1)	-0.8 (-24.4 to 30.9)
Other musculoskeletal disorders	9.3 (6.9 to 11.7)	18.9 (14.2 to 23.8)	103.1 (85.3 to 121.2)	2.3 (-7.1 to 10.9)	1.7 (0.5 to 1.3)	1.7 (1.1 to 2.5)	102.3 (83.6 to 121.8)	3.8 (-7.2 to 11.1)
Other non-communicable diseases	-	-	-	-	8.9 (5.8 to 13.1)	13.9 (9.1 to 20.2)	55.0 (47.4 to 62.5)	-8.3 (-11.9 to -5.3)
Congenital anomalies	-	-	-	-	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.3)	65.6 (45.8 to 91.3)	9.4 (-3.5 to 25.9)
Neural tube defects	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	153.6 (102.0 to 218.4)	88.7 (49.1 to 138.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	173.9 (97.9 to 287.7)	107.2 (50.6 to 193.2)
Congenital heart anomalies	0.8 (0.6 to 1.1)	2.2 (1.8 to 2.7)	194.4 (97.4 to 315.1)	114.8 (43.9 to 205.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	17.9 (85.7 to 291.0)	100.1 (37.4 to 189.6)
Orofacial clefts	0.1 (0.1 to 0.1)	0.3 (0.3 to 0.4)	279.3 (156.5 to 504.2)	197.5 (98.1 to 381.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	256.6 (120.7 to 498.8)	0.0 (-74.5 to 375.5)
Down syndrome	0.4 (0.3 to 0.4)	0.7 (0.6 to 0.8)	89.9 (49.1 to 138.3)	30.6 (1.6 to 66.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	93.7 (47.3 to 151.4)	31.2 (-1.3 to 70.6)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.7 (22.0 to 161.2)	19.3 (-18.5 to 77.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.2 (19.9 to 175.2)	19.3 (-21.1 to 78.1)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.8 (13.0 to 107.2)	-0.9 (-24.9 to 37.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.6 (23.8 to 130.6)	-1.2 (-25.1 to 37.7)
Chromosomal unbalanced rearrangements	0.0 (0.5 to 0.7)	0.0 (0.9 to 1.4)	89.3 (49.8 to 152.4)	0.4 (-2.5 to 13.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	98.5 (50.5 to 160.0)	32.9 (1.3 to 76.9)
Other congenital anomalies	4.3 (3.1 to 5.3)	5.8 (4.1 to 7.4)	35.9 (14.7 to 59.5)	-12.1 (-25.3 to 2.3)	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.9)	44.2 (21.4 to 74.8)	-5.8 (-20.1 to 13.9)
Skin and subcutaneous diseases	-	-	-	-	3.1 (1.9 to 4.9)	4.6 (2.9 to 7.3)	46.5 (32.4 to 60.8)	-3.8 (-10.8 to 3.3)
Dermatitis	22.6 (17.4 to 29.2)	36.4 (27.8 to 46.9)	60.9 (57.0 to 64.9)	-0.0 (-0.1 to 0.0)	0.8 (0.5 to 1.2)	1.2 (0.8 to 1.8)	54.0 (46.2 to 61.5)	0.0 (-3.1 to 3.1)
Psoriasis	3.5 (3.0 to 4.0)	6.0 (5.2 to 6.9)	60.2 (69.2 to 74.4)	0.0 (-0.0 to 0.1)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	71.2 (59.6 to 82.2)	0.0 (-5.3 to 5.3)
Cellulitis	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	60.2 (44.0 to 83.8)	0.8 (-9.8 to 12.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.1 (20.4 to 103.8)	0.8 (-20.3 to 24.2)
Pyoderma	1.0 (0.7 to 1.2)	1.2 (0.9 to 1.6)	28.1 (17.9 to 40.6)	-4.2 (-10.6 to 3.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.9 (12.5 to 44.3)	-4.3 (-14.1 to 5.4)
Scabies	8.8 (6.8 to 11.7)	10.5 (8.7 to 13.1)	19.7 (-12.3 to 63.3)	-20.2 (-40.9 to 6.3)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.4)	19.8 (-1.9 to 63.5)	-20.0 (-41.4 to 6.7)
Fungal skin diseases	65.5 (46.9 to 93.2)	101.3 (73.7 to 144.4)	54.0 (46.7 to 64.7)	0.0 (-0.0 to 0.1)	0.6 (0.1 to 0.8)	0.6 (0.2 to 1.3)	54.0 (46.2 to 64.8)	0.1 (-0.7 to 0.8)
Viral skin diseases	13.8 (10.2 to 17.6)	19.5 (13.8 to 25.6)	41.2 (32.6 to 49.1)	-0.4 (-3.3 to 2.8)	0.4 (0.2 to 0.7)	0.6 (0.3 to 1.0)	41.0 (31.4 to 49.6)	-0.4 (-4.4 to 3.8)
Acne vulgaris	62.6 (45.0 to 84.8)	67.2 (38.2 to 102.3)	7.1 (-41.8 to 72.4)	-26.9 (58.7 to 13.5)	0.7 (0.3 to 1.3)	0.7 (0.3 to 1.5)	7.4 (-41.9 to 73.3)	-27.1 (59.0 to 13.8)
Alopecia areata	0.5 (0.5 to 0.6)	0.8 (0.7 to 0.9)	64.2 (41.1 to 88.4)	0.8 (-13.4 to 16.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.6 (35.9 to 97.2)	1.2 (-15.3 to 19.9)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.3 (35.1 to 109.7)	0.4 (-21.3 to 28.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.3 (35.0 to 109.8)	0.4 (-21.3 to 28.2)
Urticaria	2.0 (1.2 to 2.8)	5.1 (3.9 to 6.9)	150.1 (55.0 to 387.0)	35.9 (-12.7 to 167.8)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	149.2 (53.3 to 399.0)	36.2 (-12.9 to 170.4)
Decubitus ulcer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	96.4 (59.3 to 172.5)	-1.8 (-27.2 to 54.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.4 (52.6 to 170.9)	-1.8 (-28.4 to 56.8)
Other skin and subcutaneous diseases	28.9 (19.5 to 41.1)	49.6 (33.3 to 71.1)	71.5 (57.8 to 84.2)	-2.6 (-5.8 to 0.8)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.6)	71.1 (56.9 to 83.7)	-2.5 (-6.0 to 1.2)
Sense organ diseases	-	-	-	-	4.2 (2.7 to 6.2)	6.5 (4.2 to 9.6)	54.1 (39.5 to 67.0)	-12.7 (-18.3 to -8.1)
Glaucoma	1.0 (0.7 to 1.4)	1.5 (1.1 to 2.0)	49.7 (13.3 to 98.9)	-21.8 (-41.9 to 4.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	47.6 (4.9 to 94.4)	-25.0 (-45.0 to 5.8)
Cataract	3.0 (2.1 to 4.1)	6.0 (3.5 to 8.8)	96.8 (28.7 to 199.1)	-11.3 (-37.0 to 33.8)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.8)	98.0 (45.1 to 168.3)	-10.7 (-31.2 to 16.8)
Macular degeneration	0.7 (0.3 to 1.1)	1.6 (1.0 to 2.5)	130.3 (29.6 to 326.3)	20.2 (-30.5 to 116.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	122.8 (31.2 to 300.6)	15.9 (-29.0 to 92.4)
Uncorrected refractive error	42.2 (34.5 to 50.3)	73.1 (60.5 to 86.1)	72.5 (39.3 to 126.2)	3.1 (-19.5 to 26.2)	0.9 (0.6 to 1.4)	1.4 (0.9 to 2.1)	56.4 (37.7 to 83.2)	-12.8 (-21.4 to 2.3)
Age-related and other hearing loss	75.3 (63.7 to 85.4)	127.7 (106.6 to 145.9)	69.2 (59.2 to 83.0)	-7.6 (-10.9 to -3.5)	2.5 (1.5 to 3.8)	3.7 (2.2 to 5.6)	14.0 (30.2 to 74.1)	50.6 (-21.1 to -6.7)
Other vision loss	1.8 (1.3 to 2.3)	2.2 (1.5 to 2.9)	19.5 (-4.8 to 48.3)	-30.0 (-43.0 to -14.1)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	28.9 (1.4 to 59.7)	-26.7 (-39.8 to -5.9)
Other sense organ diseases	13.3 (12.5 to 14.0)	19.6 (18.7 to 20.5)	48.0 (38.5 to 59.6)	-0.2 (-5.9 to 7.7)	0.5 (0.2 to 0.5)	0.4 (0.3 to 0.8)	47.0 (35.6 to 59.9)	0.1 (-7.0 to 8.3)
Oral disorders	-	-	-	-	1.0 (0.6 to 1.7)	1.8 (1.0 to 3.0)	80.2 (72.2 to 88.5)	-2.4 (-6.4 to 1.4)
Deciduous caries	59.6 (57.0 to 62.3)	71.4 (68.2 to 75.8)	19.6 (12.2 to 28.0)	-0.4 (-6.6 to 6.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	20.0 (9.2 to 30.9)	0.0 (-0.1 to 9.1)
Permanent caries	180.8 (164.9 to 199.1)	293.7 (264.6 to 318.8)	62.1 (42.6 to 86.3)	-0.1 (-10.5 to 13.2)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.5)	61.8 (41.6 to 87.5)	-0.1 (-10.5 to 13.6)
Periodontal diseases	48.5 (47.1 to 50.0)	93.7 (80.9 to 96.7)	93.1 (85.5 to 101.9)	0.7 (-3.1 to 5.1)	0.3 (0.1 to 0.7)	0.6 (0.2 to 1.2)	92.7 (84.9 to 101.6)	0.8 (-3.1 to 5.1)

Appendix Table G.4 - Djibouti prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	8.9 (8.3 to 9.5)	17.4 (16.2 to 18.6)	94.8 (77.7 to 114.6)	-4.9 (-14.3 to 2.2)	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.7)	94.7 (76.2 to 115.4)	-6.9 (-14.5 to 2.5)
Other oral disorders	8.4 (7.9 to 8.9)	14.2 (13.3 to 15.1)	68.4 (53.4 to 82.6)	-0.6 (-8.5 to 7.8)	0.2 (0.2 to 0.4)	0.4 (0.3 to 0.6)	67.9 (52.5 to 82.9)	-0.7 (-9.3 to 7.9)
Injuries	-	-	-	-	1.9 (1.5 to 2.5)	3.3 (2.5 to 4.3)	68.9 (58.7 to 91.4)	-2.5 (-7.8 to 12.1)
Transport injuries	-	-	-	-	0.7 (0.5 to 0.9)	1.0 (0.8 to 1.3)	42.3 (34.9 to 49.6)	-17.6 (-20.9 to -14.1)
Road injuries	-	-	-	-	0.6 (0.5 to 0.8)	0.9 (0.7 to 1.2)	45.1 (36.8 to 53.1)	-16.2 (-20.0 to -12.5)
Pedestrian road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	34.7 (23.1 to 45.6)	-20.2 (-25.7 to -15.2)
Cyclist road injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	35.9 (26.2 to 46.4)	-20.1 (-25.6 to -14.1)
Motorcyclist road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	27.3 (17.8 to 37.1)	-28.0 (-32.6 to -23.4)
Motor vehicle road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.6)	60.9 (48.1 to 74.0)	-8.4 (-14.6 to -1.9)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.8 (-17.0 to -2.9)	-49.7 (-52.9 to -46.4)
Other transport injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	21.0 (13.6 to 29.7)	-27.6 (-32.1 to -22.6)
Unintentional injuries	-	-	-	-	1.1 (0.9 to 1.5)	1.9 (1.4 to 2.4)	64.7 (58.4 to 70.9)	-5.9 (-9.3 to -2.3)
Falls	-	-	-	-	0.5 (0.4 to 0.6)	1.0 (0.7 to 1.2)	94.4 (82.9 to 106.6)	1.7 (-4.1 to 8.6)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.8 (7.4 to 31.5)	-25.8 (-33.3 to -21.1)
Fire, heat, and hot substances	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	28.4 (16.7 to 41.0)	-21.0 (-26.4 to -15.3)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.4 (0.7 to 38.2)	-27.7 (-36.4 to -17.5)
Exposure to mechanical forces	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	45.9 (38.5 to 54.0)	-11.9 (-15.4 to -7.9)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.6 (65.4 to 100.1)	2.4 (-6.0 to 11.7)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.1 (76.7 to 112.3)	12.2 (4.2 to 22.5)
Other exposure to mechanical forces	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	43.9 (36.5 to 52.1)	-12.9 (-16.5 to -8.7)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.9 (83.4 to 108.1)	9.8 (2.9 to 17.9)
Animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	21.5 (12.1 to 32.5)	-28.2 (-32.7 to -23.0)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.4 (7.0 to 40.2)	-28.3 (-36.3 to -19.0)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.0 (11.5 to 31.9)	-28.0 (-32.1 to -22.8)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.6 (55.0 to 74.1)	-5.2 (-10.2 to 0.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.2 (23.6 to 60.9)	-7.2 (-15.9 to 1.8)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.0 (47.2 to 82.7)	-1.4 (-9.7 to 8.6)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.6 (61.7 to 87.2)	-5.7 (-12.0 to 1.5)
Other unintentional injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	56.9 (44.9 to 70.7)	-8.1 (-13.9 to -0.4)
Self-harm and interpersonal violence	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	91.8 (81.3 to 102.3)	11.9 (6.6 to 17.3)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.4 (71.6 to 99.2)	-1.3 (-7.9 to 4.9)
Interpersonal violence	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	92.8 (81.1 to 104.4)	14.5 (8.3 to 20.7)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.6 (88.3 to 120.7)	21.2 (12.5 to 30.0)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.1 (111.0 to 147.3)	31.8 (21.7 to 41.6)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	81.4 (68.1 to 96.2)	8.6 (1.1 to 16.3)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.3 (0.1 to 0.7)	1,429.6 (800.5 to 2,720.5)	869.9 (461.8 to 1,701.6)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	295.3 (249.4 to 347.3)	149.0 (116.6 to 181.8)
Collective violence and legal intervention	-	-	-	-	-	0.2 (0.1 to 0.6)	-	-

Appendix Table G.4 - Dominica prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	6.5 (4.8 to 8.4)	7.4 (5.5 to 9.6)	14.3 (10.0 to 17.9)	2.9 (-7.3 to 0.1)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.7 (0.5 to 1.0)	0.7 (0.5 to 0.9)	-0.2 (-15.9 to -0.4)	-3.0 (-10.9 to 6.2)
HIV/AIDS and tuberculosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.2 (-11.1 to 79.6)	2.5 (-23.7 to 54.6)
Tuberculosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.9 (10.3 to 19.6)	-2.6 (-6.4 to 1.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.7 (3.2 to 27.1)	-2.0 (-11.1 to 8.6)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-40.6 to 213.2)	25.1 (-47.7 to 176.4)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.3 (-49.3 to 185.7)	-12.1 (-57.7 to 141.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.3 (-49.4 to 186.3)	-12.1 (-57.9 to 141.4)
HIV/AIDS resulting in other diseases	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	27.6 (-39.4 to 242.1)	14.6 (-45.8 to 207.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.9 (-41.1 to 219.4)	9.3 (-48.3 to 181.9)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-18.8 (-25.1 to -12.3)	-10.3 (-16.9 to -3.4)
Diarrheal diseases	0.5 (0.4 to 0.5)	0.4 (0.4 to 0.4)	-16.3 (-24.1 to -7.0)	0.5 (-8.6 to 10.8)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-17.0 (-25.2 to -7.5)	0.5 (-9.4 to 11.4)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.8 (-76.5 to -8.3)	-31.3 (-75.1 to -4.2)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.3 (-44.1 to -18.2)	-28.9 (-40.8 to -14.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.3 (-44.1 to -18.1)	-28.9 (-40.8 to -13.9)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.7 (-46.7 to -12.8)	-26.9 (-43.3 to -6.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.7 (-46.8 to -12.8)	-26.9 (-43.3 to -6.0)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.1 (-98.3 to 170.7)	-49.6 (-98.2 to 163.3)
Lower respiratory infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.7 (-45.5 to -9.2)	-31.8 (-45.0 to -11.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.4 (-49.5 to -3.8)	-31.6 (-47.8 to -5.6)
Upper respiratory infections	3.5 (3.2 to 3.9)	3.3 (3.0 to 3.6)	-3.7 (-17.8 to 9.7)	-3.2 (-17.1 to 10.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-4.0 (-17.8 to 9.5)	-3.1 (-17.0 to 10.5)
Otitis media	0.8 (0.7 to 0.8)	0.7 (0.6 to 0.7)	-15.4 (-21.4 to -8.8)	-11.9 (-17.8 to -5.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.0 (-24.2 to -8.6)	-13.4 (-20.5 to -5.0)
Meningitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-69.4 (-75.3 to -60.7)	-69.6 (-75.4 to -61.7)
Pneumococcal meningitis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-69.8 (-74.8 to -62.6)	-72.2 (-76.7 to -65.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-68.8 (-77.0 to -54.8)	-67.9 (-77.2 to -56.4)
H influenzae type B meningitis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-72.8 (-81.8 to -58.6)	-73.7 (-81.8 to -58.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-68.5 (-80.8 to -46.3)	-68.1 (-80.0 to -45.6)
Meningococcal meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.1 (-78.2 to -53.3)	-70.1 (-79.4 to -56.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-65.4 (-77.7 to -45.7)	-67.3 (-78.2 to -49.1)
Other meningitis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-72.6 (-80.5 to -62.9)	-73.8 (-80.6 to -64.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-72.0 (-81.6 to -60.4)	-72.4 (-81.4 to -60.4)
Encephalitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.6 (-31.2 to -2.7)	-37.9 (-39.5 to -42.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.3 (-25.2 to 10.8)	-35.9 (-32.8 to -0.8)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.8 (-94.6 to 576.2)	-27.2 (-93.8 to 691.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.8 (-94.8 to 580.6)	-27.2 (-93.8 to 696.6)
Whooping cough	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.1 (-6.1 to -2.0)	36.5 (33.6 to 39.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.4 (-24.2 to 23.6)	36.0 (8.1 to 75.5)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-88.4 (-94.4 to -76.5)	-88.7 (-94.5 to -76.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-88.0 (-94.3 to -75.7)	-88.0 (-94.1 to -75.9)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-7.4 (-20.8 to 9.1)	-2.5 (-18.0 to 18.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.5 (-16.0 to 62.9)	-4.9 (-31.4 to 34.8)
Neglected tropical diseases and malaria	-	-	-	-	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-57.3 (-74.1 to -25.9)	-56.3 (-73.4 to -23.5)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.8 (-62.2 to 78.6)	-12.0 (-61.4 to 82.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.0 (-60.5 to 81.6)	-8.4 (-59.9 to 86.8)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.8 (-37.6 to 207.6)	1.7 (-38.5 to 195.1)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.6 (-55.6 to 128.0)	-7.0 (-49.2 to 138.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.6 (-55.7 to 129.7)	-7.0 (-49.3 to 139.4)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.6 (-33.1 to 253.0)	0.8 (-36.9 to 226.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.5 (-38.6 to 259.9)	2.3 (-41.5 to 231.3)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-63.6 (-79.9 to -12.5)	-65.9 (-81.1 to -18.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-62.7 (-80.3 to -9.2)	-64.8 (-81.8 to -15.9)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.9 (-17.8 to 4.6)	-26.8 (-32.1 to -17.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.8 (-29.9 to 16.8)	-27.1 (-43.0 to -5.0)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.3)	399.9 (399.1 to 400.9)	386.0 (385.1 to 386.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	398.4 (330.9 to 473.3)	388.5 (326.2 to 456.2)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.7 (-66.9 to -6.5)	-41.0 (-67.7 to -12.8)
Intestinal nematode infections	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-99.9 (-100.0 to -99.9)	-99.9 (-100.0 to -99.9)
Ascariasis	3.0 (1.8 to 4.7)	-	-99.7 (-99.9 to -99.5)	-99.7 (-99.9 to -99.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Trichuriasis	5.3 (3.2 to 8.7)	-	-99.8 (-99.9 to -99.7)	-99.9 (-99.9 to -99.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Hookworm disease	12.4 (8.9 to 17.3)	0.0 (0.0 to 0.0)	-99.9 (-100.0 to -99.9)	-99.9 (-100.0 to -99.9)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-99.9 (-100.0 to -99.9)	-99.9 (-100.0 to -99.9)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	0.7 (0.5 to 0.8)	0.6 (0.6 to 0.7)	-10.2 (-26.2 to 11.7)	5.5 (-12.8 to 30.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.8 (-21.8 to 25.7)	7.6 (-6.6 to 49.3)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.3 (-42.3 to -15.6)	-28.8 (-40.9 to -13.9)
Maternal hemorrhage	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.1 (-33.2 to 35.4)	16.1 (-35.4 to 33.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.2 (-13.7 to 115.5)	39.0 (-15.9 to 112.5)
Maternal sepsis and other maternal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.5 (-55.1 to -15.2)	-44.0 (-60.6 to -26.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.0 (-56.1 to -27.8)	-46.2 (-58.4 to -31.1)
Maternal hypertensive disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.8 (-42.2 to -29.6)	-34.1 (-40.7 to -28.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.7 (-50.7 to -14.7)	-34.1 (-49.7 to -13.4)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.7 (-61.2 to -4.8)	-38.7 (-58.9 to -1.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.7 (-61.2 to -4.4)	-38.7 (-58.9 to -1.6)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.5 (-59.9 to 23.7)	-32.3 (-58.8 to 25.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.9 (-60.0 to 24.5)	-32.3 (-58.8 to 25.7)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Neonatal disorders	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	48.0 (-1.9 to 115.0)	52.9 (1.0 to 122.5)
Preterm birth complications	0.3 (0.1 to 0.5)	0.6 (0.3 to 1.1)	126.8 (75.3 to 204.9)	126.5 (76.4 to 205.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	106.9 (40.8 to 274.3)	110.9 (43.8 to 281.8)
Neonatal encephalopathy due to birth asphyxia and trauma	0.3 (0.1 to 0.8)	0.3 (0.1 to 0.7)	-11.7 (-35.5 to 18.6)	-11.6 (-34.4 to 18.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.4 (-48.5 to 43.8)	-4.6 (-45.3 to 53.1)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.9 (15.9 to 93.2)	142.8 (119.7 to 179.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.6 (44.9 to 100.3)	143.8 (109.6 to 189.7)
Hemolytic disease and other neonatal jaundice	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	14.7 (-60.3 to 204.5)	17.7 (-59.5 to 212.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.9 (-56.8 to 210.9)	20.1 (-56.0 to 222.0)
Other neonatal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.1 (-15.1 to 307.6)	83.7 (-12.0 to 324.3)
Nutritional deficiencies	-	-	-	-	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	-4.8 (-7.8 to -2.3)	4.6 (1.4 to 7.4)
Protein-energy malnutrition	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	46.0 (-70.8 to -1.3)	37.3 (-63.9 to 12.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.6 (-71.3 to -21.1)	-36.4 (-64.3 to 15.4)
Iodine deficiency	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-34.3 (-57.4 to -7.4)	-40.0 (-61.3 to -14.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.2 (-57.8 to -5.8)	-39.5 (-61.6 to -13.6)
Vitamin A deficiency	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.1 (-65.0 to -48.8)	-53.2 (-61.2 to -43.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.8 (-67.0 to -49.0)	-56.0 (-64.2 to -45.1)

Appendix Table G.4 - Dominica prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	10.8 (10.6 to 11.0)	10.9 (10.8 to 11.0)	0.6 (-1.2 to 2.4)	-2.2 (5.3 to 9.2)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	-4.0 (-7.1 to -1.5)	-4.0 (2.3 to 8.4)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-73.0 to 143.4)	0.0 (-66.2 to 184.5)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-4.1 (-12.9 to 9.8)	-1.5 (-10.0 to 9.9)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-10.0 to 13.4)	0.0 (-16.3 to 3.8)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.0 (0.8 to 36.4)	-13.8 (26.1 to 0.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.5 (-15.9 to 61.3)	-12.0 (37.4 to 20.9)
Chlamydial infection	1.9 (1.6 to 2.2)	1.8 (1.5 to 2.1)	-7.8 (-27.8 to 17.6)	-9.8 (-29.1 to 13.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.2 (-20.7 to 18.6)	-7.1 (-22.5 to 14.0)
Gonococcal infection	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.2)	-6.8 (-29.7 to 28.1)	-7.3 (-29.7 to 25.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.8 (-43.3 to 30.8)	-19.4 (-43.5 to 27.7)
Trichomoniasis	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.7)	7.9 (-37.6 to 102.0)	-1.9 (-41.8 to 79.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.9 (-41.6 to 122.7)	-0.5 (-45.1 to 95.8)
Genital herpes	15.8 (14.9 to 16.7)	18.1 (17.3 to 19.0)	15.7 (7.0 to 23.7)	5.7 (-12.4 to 1.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.5 (23.5 to 23.2)	5.6 (-13.3 to 2.6)
Other sexually transmitted diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.0 (-23.4 to 5.3)	-23.5 (-34.6 to -9.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.0 (-20.4 to 59.0)	1.0 (-27.6 to 41.4)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-36.0 to -9.2)	-23.0 (-41.6 to -15.7)
Hepatitis A	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-16.1 (-16.5 to -15.8)	-8.0 (-8.3 to -7.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-15.7 to 5.6)	-3.9 (-14.0 to 6.6)
Hepatitis B	3.4 (2.6 to 4.1)	1.9 (1.4 to 2.3)	-45.5 (-61.9 to -19.6)	-50.6 (-65.5 to -28.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.3 (-62.6 to -16.0)	-52.8 (-68.5 to -27.4)
Hepatitis C	1.1 (1.0 to 1.3)	1.0 (0.9 to 1.1)	-13.6 (-25.6 to 1.8)	-29.3 (-38.6 to -17.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.3 (-37.1 to 16.2)	-27.6 (-49.5 to 0.7)
Hepatitis E	-	-	-14.2 (-27.1 to 1.4)	-16.7 (-29.1 to -2.0)	-	-	-	-
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.5 (-69.1 to 427.0)	-34.4 (-69.3 to 317.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.3 (-63.6 to 584.7)	-32.6 (-72.8 to 459.9)
Other infectious diseases	0.5 (0.4 to 0.6)	0.4 (0.4 to 0.5)	-7.9 (-24.1 to 13.5)	5.8 (-11.8 to 28.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.4 (-18.5 to 31.7)	12.6 (-4.2 to 52.8)
Non-communicable diseases	-	-	-	-	3.1 (3.8 to 6.6)	6.3 (4.7 to 8.2)	23.9 (20.1 to 27.3)	3.2 (0.9 to 6.7)
Neoplasms	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	74.2 (36.3 to 115.4)	25.9 (-2.3 to 56.3)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.9 (-12.9 to 73.6)	-12.9 (-39.1 to 22.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.0 (-13.5 to 70.2)	-14.2 (-39.4 to 19.8)
Stomach cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.6 (-38.3 to 10.0)	-42.6 (-56.6 to -22.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.3 (-40.9 to 9.5)	-44.5 (-58.4 to -22.9)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (128.4 to 352.3)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	378.9 (132.8 to 860.8)	249.3 (68.1 to 609.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	365.5 (156.4 to 744.6)	237.9 (53.5 to 518.5)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,348.0 (655.8 to 2,739.8)	914.4 (433.1 to 1,899.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,282.9 (700.4 to 2,414.0)	861.2 (455.5 to 1,669.6)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	146.1 (25.7 to 375.4)	72.9 (-11.9 to 233.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	138.6 (35.4 to 297.5)	67.4 (-4.9 to 179.0)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.2 (-2.4 to 267.9)	104.2 (-30.7 to 168.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.3 (3.8 to 215.3)	41.8 (-25.9 to 130.0)
Larynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.7 (-4.8 to 102.5)	-2.8 (-32.5 to 44.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.2 (-4.7 to 117.1)	1.3 (-32.3 to 55.0)
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.9 (-4.8 to 77.5)	-8.7 (-32.9 to 25.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.2 (-8.8 to 71.9)	-11.2 (-35.3 to 22.0)
Breast cancer	0.4 (0.3 to 0.5)	0.1 (0.1 to 0.2)	-67.8 (-77.6 to -51.2)	-78.1 (-84.8 to -66.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.7 (-60.8 to -13.2)	-59.5 (-72.8 to -39.0)
Cervical cancer	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-40.5 (-60.5 to -12.6)	45.9 (-70.5 to -34.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-63.3 to 10.7)	96.4 (-70.7 to -34.7)
Uterine cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	77.2 (-20.3 to 200.8)	24.5 (-43.6 to 113.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.1 (-24.1 to 197.9)	20.1 (-46.2 to 109.1)
Prostate cancer	0.1 (0.1 to 0.2)	0.5 (0.3 to 0.8)	327.1 (116.3 to 656.7)	200.1 (51.2 to 432.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	291.6 (101.5 to 540.0)	174.3 (40.4 to 348.1)
Colon and rectum cancer	0.2 (0.2 to 0.2)	0.4 (0.4 to 0.5)	102.4 (74.3 to 129.2)	39.5 (19.4 to 58.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.5 (73.6 to 127.8)	39.2 (19.4 to 58.2)
Lip and oral cavity cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.7 (-8.6 to 88.1)	-7.9 (-35.6 to 33.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.7 (-9.4 to 84.9)	-9.4 (-36.5 to 32.0)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.5 (-35.6 to 37.7)	-30.2 (-51.8 to 4.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.3 (-36.5 to 32.8)	-32.0 (-52.7 to -0.1)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.3 (-22.7 to 101.1)	-12.7 (-45.6 to 42.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.6 (-19.7 to 95.1)	-13.4 (-43.9 to 36.9)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.5 (-75.5 to 12.1)	-73.0 (-82.9 to -21.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-60.6 (-75.0 to 17.2)	-72.3 (-82.4 to -16.8)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	571.8 (395.4 to 811.2)	371.6 (247.9 to 540.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	490.2 (325.7 to 694.1)	311.5 (200.1 to 456.4)
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.6 (-36.2 to 43.4)	-21.7 (-52.0 to 7.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.8 (-37.0 to 47.8)	-33.2 (-52.5 to 10.5)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.8 (43.2 to 143.5)	27.7 (0.1 to 72.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.9 (39.7 to 211.2)	46.5 (-3.7 to 117.4)
Ovarian cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	257.1 (140.9 to 417.8)	170.4 (83.7 to 293.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	231.4 (122.9 to 397.7)	150.9 (67.8 to 280.7)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	406.0 (2.1 to 923.3)	332.3 (-11.7 to 772.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	364.9 (-8.1 to 941.8)	296.3 (-22.2 to 799.9)
Kidney cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.1 (-9.6 to 61.6)	9.5 (-32.7 to 22.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.2 (-13.2 to 59.1)	-13.0 (-35.4 to 19.0)
Bladder cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	64.0 (9.9 to 194.5)	12.3 (-25.0 to 103.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.3 (11.3 to 215.4)	17.7 (-24.0 to 118.0)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	309.1 (24.9 to 563.7)	295.7 (21.8 to 518.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	324.6 (25.6 to 542.6)	283.5 (11.1 to 450.2)
Thyroid cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	42.0 (-5.7 to 116.4)	13.9 (-24.7 to 73.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.2 (-8.5 to 113.9)	11.5 (-26.5 to 69.1)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	134.9 (74.2 to 204.0)	67.1 (23.5 to 116.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	146.4 (85.1 to 220.8)	74.9 (31.3 to 127.0)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	589.1 (-0.5 to 991.5)	574.7 (-2.9 to 960.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	609.0 (-2.5 to 992.1)	572.1 (-7.9 to 914.6)
Non-Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.3 (2.1 to 117.3)	21.5 (-18.8 to 69.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.4 (0.5 to 108.7)	15.5 (-22.9 to 62.0)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.5 (17.1 to 226.4)	40.6 (-16.8 to 132.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.8 (11.3 to 226.0)	36.6 (-21.9 to 130.1)
Leukemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.5 (-25.6 to 87.1)	12.5 (-23.3 to 74.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.2 (-14.8 to 76.2)	5.5 (-21.7 to 49.1)
Other neoplasms	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	106.5 (40.1 to 207.3)	80.9 (31.7 to 167.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.2 (40.8 to 192.9)	68.8 (25.4 to 144.0)
Cardiovascular diseases	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	87.2 (51.2 to 126.3)	33.8 (9.1 to 61.7)
Rheumatic heart disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.5 (7.2 to 43.8)	-6.3 (-17.9 to 9.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (7.2 to 45.5)	-6.0 (-17.9 to 10.9)
Ischemic heart disease	0.5 (0.4 to 0.5)	1.1 (0.9 to 1.5)	150.5 (86.6 to 223.3)	74.3 (29.7 to 129.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	150.9 (106.6 to 307.4)	102.3 (39.7 to 185.8)
Cerebrovascular disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (11.9 to 84.8)	-0.3 (-20.1 to 32.5)
Ischemic stroke	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	37.9 (8.3 to 86.3)	-3.0 (-23.4 to 32.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.6 (10.1 to 88.6)	-1.4 (-22.3 to 34.3)
Hemorrhagic stroke	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	48.4 (-3.7 to 104.1)	7.9 (-30.7 to 48.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.8 (-4.4 to 105.5)	8.0 (-30.7 to 50.5)
Hypertensive heart disease	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	23.8 (10.3 to 39.6)	-13.8 (-23.4 to -2.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.9 (9.3 to 44.0)	-12.7 (-23.5 to 0.7)
Cardiomyopathy and myocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.8 (27.1 to 77.9)	10.9 (-7.2 to 32.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.1 (24.6 to 87.6)	12.5 (-8.0 to 39.8)
Atrial fibrillation and flutter	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	117.8 (59.9 to 201.3)	47.8 (8.1 to 107.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	120.6 (62.4 to 203.4)	50.2 (9.9 to 109.3)
Peripheral vascular disease	1.8 (1.4 to 2.2)	2.6 (1.9 to 3.2)	43.9 (4.3 to 118.3)	-1.0 (-27.4 to 46.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.8 (-27.5 to 172.7)	-12.0 (-51.7 to 82.7)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.4 (-25.9 to 26.5)	-22.4 (-42.1 to -1.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.5 (-29.0 to 35.7)	-21.6 (-44.2 to 7.3)
Other cardiovascular and circulatory diseases	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.4)	29.3 (-31.6 to 156.8)	29.3 (-47.5 to 93.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.9 (-30.9 to 157.6)	-1.6 (-47.1 to 94.1)
Chronic respiratory diseases	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.6)	27.0 (7.4 to 48.6)	4.3 (-12.3 to 21.5)
Chronic obstructive pulmonary disease	2.8 (2.7 to 3.0)	3.7 (3.6 to 3.9)	32.0 (27.0 to 36.0)	-0.1 (-3.8 to 3.0)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.4)	44.7 (8.8 to 77.8)	10.3 (1.6 to 36.4)

Appendix Table G.4 - Dominica prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	29.4	-4.8
Silicosis	0.0	0.0	20.4	-11.5	0.0	0.0	19.7	-12.0
Asbestosis	-	-	0.0	0.0	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	37.7	1.4	0.0	0.0	36.7	0.6
Asthma	4.2	4.7	11.7	-1.1	0.2	0.2	11.0	-1.0
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	41.9	4.7	0.0	0.0	42.2	4.9
Other chronic respiratory diseases	-	-	-	-	0.0	0.0	16.9	-11.5
Cirrhosis	-	-	-	-	0.0	0.0	22.8	-1.2
Cirrhosis due to hepatitis B	0.0	0.0	-14.1	-33.0	0.0	0.0	-12.1	-31.0
Cirrhosis due to hepatitis C	0.0	0.0	69.7	33.9	0.0	0.0	67.1	33.4
Cirrhosis due to alcohol use	0.0	0.0	4.7	-22.7	0.0	0.0	-22.8	-
Cirrhosis due to other causes	0.0	0.0	21.6	13.8	0.0	0.0	18.7	12.3
Digestive diseases	-	-	-	-	0.1	0.1	38.2	8.6
Peptic ulcer disease	0.5	0.4	-28.5	-49.2	0.0	0.0	-19.7	-42.5
Gastritis and duodenitis	1.3	1.7	30.2	2.6	0.1	0.1	20.0	-0.6
Appendicitis	0.0	0.0	-0.4	-2.0	0.0	0.0	0.4	-1.5
Paralytic ileus and intestinal obstruction	0.0	0.0	13.8	18.0	0.0	0.0	11.2	15.9
Inguinal, femoral, and abdominal hernia	0.2	0.1	-29.9	-50.6	0.0	0.0	-28.6	-49.5
Inflammatory bowel disease	0.1	0.1	56.6	24.1	0.0	0.0	56.5	24.8
Vascular intestinal disorders	0.0	0.0	30.5	-5.3	0.0	0.0	30.5	-5.3
Gallbladder and biliary diseases	0.0	0.0	-7.1	-32.1	0.0	0.0	-2.3	-32.3
Pancreatitis	0.0	0.0	87.2	49.6	0.0	0.0	84.6	48.9
Other digestive diseases	-	-	-	-	0.0	0.0	596.1	449.1
Neurological disorders	-	-	-	-	0.4	0.5	24.9	5.3
Alzheimer disease and other dementias	0.4	0.7	47.8	0.6	0.3	0.4	60.0	22.4
Parkinson disease	0.0	0.0	39.7	-2.1	0.0	0.0	40.9	-1.2
Epilepsy	0.2	0.2	29.5	23.2	0.1	0.1	32.6	27.1
Multiple sclerosis	0.0	0.0	133.8	86.7	0.0	0.0	122.8	78.9
Migraine	7.3	7.7	7.7	4.0	0.2	0.2	87.8	3.2
Tension-type headache	13.2	15.5	17.2	3.1	0.0	0.0	17.5	3.7
Medication overuse headache	0.3	0.5	76.0	43.5	0.0	0.1	75.7	44.0
Other neurological disorders	0.0	0.0	13.8	3.4	0.0	0.0	-18.9	-44.9
Mental and substance use disorders	-	-	-	-	1.6	1.7	11.3	0.6
Schizophrenia	0.2	0.2	21.5	-0.5	0.1	0.1	21.4	-0.1
Alcohol use disorders	0.4	0.5	23.2	7.2	0.0	0.0	23.7	8.1
Drug use disorders	-	-	-	-	0.1	0.1	7.8	1.3
Opioid use disorders	0.0	0.1	27.8	3.3	0.0	0.0	27.8	3.5
Cocaine use disorders	0.1	0.1	12.7	0.0	0.0	0.0	10.4	4.9
Amphetamine use disorders	0.1	0.1	-7.0	-4.2	0.0	0.0	-7.1	-4.1
Cannabis use disorders	0.2	0.2	-2.6	0.2	0.0	0.0	-2.6	0.4
Other drug use disorders	-	-	-	-	0.0	0.0	2.6	0.6
Depressive disorders	-	-	-	-	0.6	0.7	14.4	1.0
Major depressive disorder	2.5	2.9	13.7	0.8	0.5	0.6	13.2	1.0
Dysthymia	0.8	1.0	22.4	0.1	0.1	0.1	22.2	0.3
Bipolar disorder	0.5	0.6	13.6	-0.3	0.1	0.1	13.3	0.2
Anxiety disorders	2.7	3.0	10.9	0.4	0.2	0.2	10.5	0.1
Eating disorders	-	-	-	-	0.0	0.0	-4.4	0.7
Anorexia nervosa	0.0	0.0	-0.5	5.1	0.0	0.0	-0.4	5.1
Bulimia nervosa	0.1	0.1	-5.5	-0.4	0.0	0.0	-5.2	-0.0
Autistic spectrum disorders	-	-	-	-	0.1	0.1	2.4	0.5
Autism	0.2	0.2	2.9	0.0	0.1	0.1	2.6	0.6
Asperger syndrome	0.3	0.3	2.3	0.1	0.0	0.0	2.1	0.5
Attention-deficit/hyperactivity disorder	0.5	0.5	-11.4	0.3	0.0	0.0	-11.4	0.3
Conduct disorder	0.7	0.7	-10.5	0.1	0.1	0.1	-10.3	0.1
Idiopathic intellectual disability	0.2	0.2	20.2	-21.8	0.0	0.0	-20.1	-21.4
Other mental and substance use disorders	1.0	1.2	17.7	-0.0	0.1	0.1	17.5	0.4
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	0.6	0.8	42.9	18.4
Diabetes mellitus	3.5	6.3	77.6	36.8	0.2	0.5	80.3	35.0
Acute glomerulonephritis	0.0	0.0	-7.7	-1.9	0.0	0.0	-7.7	-1.3
Chronic kidney disease	-	-	-	-	0.1	0.1	19.8	1.2
Chronic kidney disease due to diabetes mellitus	1.8	2.3	32.5	0.0	0.0	0.0	32.0	1.3
Chronic kidney disease due to hypertension	1.0	1.2	18.8	8.1	0.0	0.0	16.8	-1.8
Chronic kidney disease due to glomerulonephritis	2.3	2.8	20.9	0.0	0.0	0.0	31.6	20.1
Chronic kidney disease due to other causes	2.3	2.6	11.0	-5.0	0.0	0.0	10.3	-2.3
Urinary diseases and male infertility	-	-	-	-	0.0	0.0	34.3	0.0

Appendix Table G.4 - Dominica prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.1 (32.6 to 63.4)	31.7 (20.3 to 46.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.5 (18.8 to 80.6)	32.6 (8.3 to 60.4)
Urolithiasis	0.5 (0.3 to 0.6)	0.7 (0.4 to 1.1)	33.4 (-11.2 to 119.1)	-2.9 (-35.9 to 59.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.9 (4.4 to 124.0)	8.0 (-23.0 to 68.1)
Benign prostatic hyperplasia	0.4 (0.4 to 0.5)	0.6 (0.5 to 0.6)	35.7 (20.7 to 52.9)	-4.2 (-15.0 to 8.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.6 (22.9 to 56.8)	-2.0 (-13.4 to 10.8)
Male infertility due to other causes	0.5 (0.4 to 0.6)	0.5 (0.4 to 0.7)	6.4 (-20.8 to 40.3)	0.6 (-24.6 to 34.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.2 (-21.7 to 43.2)	1.2 (-25.3 to 36.6)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-32.7 to 64.3)	0.0 (-48.5 to 24.9)
Gynecological diseases	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	18.2 (3.6 to 33.0)	3.1 (-8.7 to 16.2)
Uterine fibroids	1.2 (1.1 to 1.3)	1.6 (1.5 to 1.8)	34.2 (32.6 to 36.1)	0.3 (0.3 to 0.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.4 (13.2 to 45.0)	5.0 (-8.4 to 17.2)
Polycystic ovarian syndrome	1.3 (1.1 to 1.4)	1.5 (1.3 to 1.6)	15.3 (-0.5 to 36.4)	0.9 (-13.0 to 18.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.2 (-0.5 to 36.4)	1.1 (-12.7 to 18.7)
Female infertility due to other causes	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.8)	16.7 (-47.0 to 165.4)	0.0 (-50.7 to 151.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.3 (-45.6 to 153.3)	9.0 (-49.5 to 138.6)
Endometriosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	20.1 (-4.7 to 50.9)	4.0 (-17.4 to 30.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.2 (5.1 to 53.2)	4.4 (-17.7 to 31.5)
Genital prolapse	3.4 (2.7 to 4.1)	4.4 (3.7 to 5.1)	31.5 (-0.6 to 74.8)	3.7 (-19.8 to 34.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.0 (-0.6 to 75.5)	3.5 (-20.5 to 36.5)
Premenstrual syndrome	3.3 (2.5 to 4.1)	3.5 (2.6 to 4.4)	7.0 (-25.1 to 51.6)	0.4 (-29.8 to 42.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.9 (-25.7 to 53.1)	0.6 (-30.0 to 45.5)
Other gynecological diseases	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.2)	17.5 (-5.2 to 52.1)	8.7 (-11.5 to 37.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.9 (-15.2 to 98.2)	12.1 (-19.8 to 79.7)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	6.8 (-13.4 to 0.8)	-0.9 (-7.8 to 6.7)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.2 (-25.1 to -12.6)	-0.0 (-11.1 to 5.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.1 (-26.3 to -9.0)	0.1 (-11.3 to 10.1)
Thalassemia trait	0.6 (0.4 to 1.1)	0.7 (0.4 to 1.2)	2.9 (-4.5 to 9.3)	-0.4 (-7.8 to 6.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.3 (-17.0 to 11.2)	-1.5 (-15.9 to 11.7)
Sickle cell disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-2.2 (-9.9 to 8.9)	3.9 (-4.1 to 14.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.5 (-11.1 to 14.7)	3.5 (-8.4 to 16.4)
Sickle cell trait	8.6 (8.0 to 9.1)	8.8 (8.2 to 9.4)	2.2 (-1.5 to 6.1)	-1.3 (-4.9 to 2.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-11.7 (-22.7 to 1.9)	-4.2 (-16.2 to 9.5)
G6PD deficiency	3.2 (2.6 to 3.9)	3.4 (2.5 to 4.3)	4.1 (-28.0 to 51.4)	0.6 (-30.4 to 46.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.7 (-14.4 to 62.2)	18.1 (-13.2 to 64.2)
G6PD trait	10.7 (9.9 to 11.4)	11.3 (10.5 to 12.0)	5.3 (-4.9 to 17.0)	1.3 (-8.5 to 12.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.5 (-73.9 to 518.5)	57.2 (-71.1 to 422.8)
Other hemoglobinopathies and hemolytic anemias	0.4 (0.4 to 0.5)	0.5 (0.4 to 0.5)	17.0 (-9.7 to 21.8)	4.1 (-5.2 to 23.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.2 (-25.0 to 23.0)	4.6 (-16.6 to 33.9)
Endocrine, metabolic, blood, and immune disorders	0.5 (0.4 to 0.6)	0.5 (0.5 to 0.6)	2.7 (-11.0 to 20.2)	2.7 (-5.7 to 24.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.6 (-19.5 to 28.9)	7.7 (-12.3 to 37.0)
Musculoskeletal disorders	-	-	-	-	0.8 (0.6 to 1.1)	1.1 (0.8 to 1.4)	33.4 (21.4 to 44.5)	3.6 (-4.7 to 11.6)
Rheumatoid arthritis	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	60.4 (48.6 to 70.8)	28.1 (18.5 to 36.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	58.9 (45.2 to 72.0)	27.9 (17.1 to 38.5)
Osteoarthritis	2.1 (2.0 to 2.2)	2.1 (3.0 to 3.2)	47.2 (40.2 to 55.2)	2.5 (-2.3 to 8.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	47.7 (40.3 to 56.3)	3.0 (-2.2 to 8.9)
Low back and neck pain	-	-	-	-	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.8)	22.0 (4.7 to 39.7)	4.9 (-14.5 to 12.5)
Low back pain	2.8 (2.4 to 3.1)	3.3 (2.8 to 3.7)	20.0 (-3.0 to 43.0)	-2.9 (-20.4 to 14.7)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	20.0 (-4.1 to 43.4)	-2.2 (-20.8 to 15.7)
Neck pain	2.0 (1.7 to 2.3)	2.5 (2.2 to 2.8)	25.9 (2.9 to 53.8)	1.0 (-17.4 to 21.5)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	25.9 (2.8 to 54.4)	1.2 (-16.8 to 22.6)
Gout	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.1 (18.3 to 47.9)	-5.0 (-15.1 to 6.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.7 (6.2 to 65.0)	-3.6 (-23.2 to 19.6)
Other musculoskeletal disorders	1.6 (1.3 to 1.9)	2.4 (2.0 to 2.9)	52.4 (42.1 to 65.9)	12.4 (5.9 to 21.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	54.7 (41.3 to 66.2)	12.9 (5.3 to 22.1)
Other non-communicable diseases	-	-	-	-	1.1 (0.8 to 1.6)	1.3 (0.9 to 1.8)	15.0 (11.4 to 18.8)	-4.8 (-7.4 to -1.9)
Congenital anomalies	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	22.2 (6.3 to 42.2)	18.4 (3.2 to 38.5)
Neural tube defects	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.4 (-20.4 to 16.0)	1.5 (-15.5 to 23.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.5 (-28.7 to 34.8)	5.4 (-23.4 to 44.2)
Congenital heart anomalies	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.4)	23.8 (-4.6 to 62.0)	27.0 (-1.9 to 66.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.6 (-4.4 to 60.0)	27.7 (-1.8 to 65.5)
Orofacial clefts	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	6.4 (-18.8 to 34.8)	13.8 (-13.6 to 43.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.8 (-30.3 to 38.6)	5.0 (-26.0 to 47.4)
Down syndrome	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	16.0 (-13.3 to 61.5)	11.8 (-16.3 to 55.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.4 (-8.7 to 74.7)	14.8 (-15.9 to 60.5)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.4 (-20.1 to 89.6)	11.1 (-19.7 to 91.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.6 (-21.8 to 97.6)	10.4 (-21.2 to 98.3)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.8 (-16.2 to 52.4)	4.6 (-17.9 to 49.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.8 (-13.5 to 58.4)	4.5 (-18.0 to 49.8)
Chromosomal unbalanced rearrangements	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	12.8 (-17.0 to 50.3)	9.2 (-19.9 to 44.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.3 (-12.7 to 63.0)	11.3 (-19.2 to 48.1)
Other congenital anomalies	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.3)	-6.8 (-14.3 to 1.5)	-12.4 (-19.3 to -4.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	26.2 (1.0 to 68.6)	22.1 (-2.3 to 63.2)
Skin and subcutaneous diseases	-	-	-	-	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.5)	6.5 (-1.9 to 15.7)	-0.2 (-7.6 to 8.4)
Dermatitis	3.2 (2.6 to 3.8)	3.5 (2.8 to 4.1)	9.9 (6.8 to 12.7)	0.0 (-0.0 to 0.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	6.9 (3.1 to 10.9)	0.2 (-2.5 to 3.0)
Psoriasis	0.5 (0.5 to 0.6)	0.6 (0.5 to 0.7)	16.3 (14.0 to 19.2)	0.0 (-0.0 to 0.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	16.3 (9.6 to 23.2)	0.5 (-4.4 to 5.9)
Cellulitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.5 (-16.0 to 7.8)	-13.6 (-24.2 to -3.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.4 (-23.8 to 16.2)	-4.4 (-28.1 to 5.6)
Pyoderma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.4 (19.5 to 36.8)	0.0 (17.0 to 28.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.2 (10.3 to 47.7)	23.1 (8.1 to 39.4)
Scabies	0.9 (0.7 to 1.0)	0.9 (0.7 to 1.0)	0.7 (-19.2 to 21.8)	1.5 (-18.3 to 23.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.1 (-19.9 to 22.1)	1.5 (-18.6 to 23.9)
Fungal skin diseases	4.9 (3.8 to 6.5)	5.6 (4.3 to 7.3)	12.6 (7.7 to 18.1)	0.0 (-0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	12.5 (7.3 to 18.2)	0.3 (-0.6 to 1.3)
Viral skin diseases	1.4 (1.1 to 1.8)	1.3 (1.0 to 1.7)	-6.9 (-10.5 to -1.9)	0.2 (-1.9 to 2.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-7.1 (-11.5 to -1.5)	0.2 (-3.0 to 4.0)
Acne vulgaris	5.0 (3.6 to 6.7)	4.5 (3.4 to 5.7)	-8.8 (-38.3 to 45.3)	-2.6 (-34.1 to 50.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-8.7 (-38.4 to 45.8)	-2.7 (-34.1 to 50.1)
Alopecia areata	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	12.8 (-0.3 to 27.3)	-2.3 (-13.8 to 10.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-5.0 to 31.8)	-2.0 (-16.8 to 15.1)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.2 (5.1 to 56.2)	1.7 (-21.8 to 31.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.2 (5.3 to 56.3)	1.7 (-21.9 to 31.0)
Urticaria	0.7 (0.4 to 1.0)	0.8 (0.6 to 1.0)	19.8 (-31.9 to 101.5)	1.9 (-42.3 to 69.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	19.3 (-32.7 to 103.1)	2.5 (-42.5 to 72.3)
Decubitus ulcer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.6 (-12.4 to 48.6)	-17.1 (-37.2 to 12.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.9 (-17.3 to 49.1)	-17.7 (-39.9 to 13.5)
Other skin and subcutaneous diseases	4.0 (2.6 to 6.1)	5.0 (3.1 to 8.0)	25.8 (14.2 to 35.9)	-0.7 (-5.2 to 3.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	25.9 (14.3 to 36.4)	-0.2 (-4.7 to 4.3)
Sense organ diseases	-	-	-	-	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.8)	15.8 (9.8 to 21.5)	-10.4 (-14.2 to -6.5)
Glaucoma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	8.2 (-7.9 to 22.7)	-19.2 (-30.5 to -9.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.8 (-3.8 to 32.1)	-17.4 (-29.9 to -4.4)
Cataract	0.5 (0.4 to 0.6)	0.5 (0.4 to 0.6)	2.1 (-6.8 to 14.9)	-29.5 (-35.4 to -20.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.8 (-4.9 to 14.7)	-28.0 (-34.8 to -21.3)
Macular degeneration	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	61.3 (30.2 to 100.1)	11.3 (-10.4 to 39.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.5 (30.0 to 97.5)	10.5 (-10.9 to 36.7)
Uncorrected refractive error	6.4 (6.0 to 6.8)	7.8 (7.3 to 8.3)	21.8 (11.8 to 32.0)	-5.4 (-13.0 to 2.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	13.7 (6.5 to 21.8)	-10.3 (-15.8 to -4.0)
Age-related and other hearing loss	9.6 (9.0 to 10.2)	11.6 (11.0 to 12.4)	21.6 (17.6 to 26.9)	-9.4 (-12.1 to -5.7)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	20.1 (11.4 to 28.5)	-8.7 (-14.5 to -3.3)
Other vision loss	0.2 (0.2 to 0.2)	0.2 (0.1 to 0.2)	-19.0 (-27.1 to -10.8)	-32.9 (-38.7 to -26.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-21.9 to -2.8)	-31.2 (-38.0 to -24.7)
Other sense organ diseases	1.6 (1.5 to 1.6)	1.6 (1.5 to 1.7)	2.6 (-4.2 to 9.4)	-0.6 (-7.1 to 5.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	2.2 (-5.0 to 9.5)	-0.1 (-7.3 to 6.8)
Oral disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	24.5 (20.5 to 28.5)	-3.5 (-6.5 to -0.7)
Deciduous caries	5.0 (4.8 to 5.2)	4.0 (3.8 to 4.1)	-20.3 (-25.0 to -15.3)	0.8 (-5.2 to 7.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-20.4 to 18.4)	0.7 (-7.8 to 9.8)
Permanent caries	29.8 (28.5 to 30.9)	31.5 (30.2 to 33.0)	5.7 (-0.0 to 12.6)	-0.6 (-5.8 to 5.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	5.5 (-0.4 to 12.5)	-0.5 (-6.0 to 5.6)
Periodontal diseases	7.0 (6.7 to 7.3)	8.8 (8.4 to 9.2)	26.1 (18.6 to 34.5)	-2.4 (-8.4 to 4.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	26.1 (18.5 to 34.7)	-2.1 (-7.9 to 5.1)

Appendix Table G.4 - Dominica prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	4.0 (3.9 to 4.1)	5.3 (5.1 to 5.5)	32.5 (26.6 to 38.5)	-4.0 (-10.1 to -1.9)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	33.1 (27.1 to 39.5)	-5.5 (-9.7 to -0.9)
Other oral disorders	1.1 (1.1 to 1.2)	1.3 (1.2 to 1.3)	12.4 (4.2 to 21.2)	-0.8 (-8.0 to 6.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	12.3 (3.3 to 21.5)	-0.3 (-8.1 to 7.8)
Injuries	-	-	-	-	0.6 (0.4 to 0.9)	0.4 (0.3 to 0.5)	-36.3 (-50.4 to -23.9)	-52.1 (-63.5 to -41.6)
Transport injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-9.3 (-21.1 to 4.5)	-27.3 (-36.3 to -16.7)
Road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-13.4 (-24.7 to 0.2)	-30.4 (-39.1 to -20.2)
Pedestrian road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.4 (-34.7 to -11.9)	-39.0 (-46.9 to -29.1)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.7 (-14.3 to 9.4)	-24.0 (-32.2 to -13.7)
Motorcyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.0 (-29.3 to -5.3)	-34.2 (-43.0 to -24.3)
Motor vehicle road injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-7.1 (-20.0 to 8.2)	-25.5 (-35.3 to -13.9)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.4 (-32.3 to -10.7)	-39.2 (-46.6 to -30.5)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.0 (33.9 to 72.6)	19.4 (5.3 to 35.5)
Unintentional injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-6.7 (-14.0 to 2.0)	-25.9 (-31.8 to -19.3)
Falls	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-5.2 (-15.7 to 7.5)	-29.4 (-37.3 to -19.8)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.4 (-35.7 to -13.5)	-38.5 (-46.6 to -29.3)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.2 (-40.4 to -23.0)	-43.0 (-49.4 to -35.7)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.5 (-37.0 to -12.1)	-33.6 (-43.6 to -22.2)
Exposure to mechanical forces	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-20.1 (-26.2 to -13.8)	-30.9 (-35.3 to -25.6)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.8 (17.8 to 53.5)	12.4 (-1.5 to 27.2)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.9 (9.3 to 42.0)	5.0 (-7.5 to 18.7)
Other exposure to mechanical forces	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-24.4 (-30.0 to -18.4)	-34.4 (-38.7 to -29.5)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.9 (48.4 to 65.7)	23.1 (16.1 to 30.4)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.2 (31.3 to 59.5)	18.3 (8.2 to 29.4)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.8 (30.7 to 65.1)	23.4 (10.2 to 37.3)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.4 (27.4 to 58.2)	14.9 (3.6 to 27.1)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.6 (-13.3 to 6.9)	-21.9 (-29.1 to -13.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.3 (-36.4 to -10.4)	-37.0 (-46.5 to -25.1)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.7 (-8.6 to 17.5)	-9.5 (-19.6 to 2.8)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.8 (-2.8 to 20.1)	-15.1 (-22.8 to -6.2)
Other unintentional injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.2 (28.8 to 52.7)	3.2 (-5.1 to 11.9)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.5 (-41.3 to -19.1)	-28.3 (-36.7 to -17.7)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.0 (-31.0 to -12.1)	-39.1 (-45.9 to -31.3)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.6 (-19.5 to 7.1)	-25.5 (-34.8 to -14.1)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.2 (11.3 to 40.4)	-0.1 (-10.3 to 11.2)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.6 (-15.9 to 14.0)	-22.1 (-32.5 to -8.5)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.8 (-37.8 to -13.1)	-40.6 (-49.3 to -29.9)
Forces of nature, war, and legal intervention	-	-	-	-	0.2 (0.1 to 0.5)	0.0 (0.0 to 0.1)	-81.3 (-86.8 to -74.6)	-86.4 (-90.5 to -81.0)
Exposure to forces of nature	-	-	-	-	0.2 (0.1 to 0.5)	0.0 (0.0 to 0.1)	-81.3 (-86.8 to -74.6)	-86.4 (-90.5 to -81.0)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Dominican Republic prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	613.4 (456.6 to 800.5)	988.8 (736.9 to 1,281.4)	61.3 (57.8 to 64.8)	-11 (-2.9 to 0.9)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	101.0 (70.0 to 140.5)	124.0 (86.4 to 170.6)	23.0 (15.7 to 30.0)	-5.5 (-11.3 to 0.2)
HIV/AIDS and tuberculosis	-	-	-	-	2.1 (1.4 to 3.0)	4.1 (2.8 to 5.8)	101.3 (53.9 to 153.1)	22.7 (5.2 to 53.2)
Tuberculosis	5.3 (5.1 to 5.5)	7.5 (7.2 to 7.7)	41.8 (37.1 to 46.7)	-14.8 (-17.5 to -11.9)	1.6 (1.1 to 2.2)	2.3 (1.6 to 3.1)	41.0 (27.8 to 55.4)	-14.5 (-21.8 to -6.8)
HIV/AIDS	-	-	-	-	0.4 (0.2 to 1.0)	1.9 (1.0 to 3.1)	391.1 (82.4 to 618.3)	28.1 (16.4 to 356.0)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	114.5 (-21.7 to 259.5)	27.7 (-54.0 to 112.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	114.5 (-22.0 to 260.2)	27.7 (-54.2 to 113.3)
HIV/AIDS resulting in other diseases	4.8 (3.2 to 10.0)	24.7 (14.8 to 35.8)	453.4 (142.1 to 723.0)	265.3 (63.0 to 442.8)	0.4 (0.2 to 1.0)	1.8 (1.0 to 3.1)	362.4 (82.4 to 631.9)	195.2 (16.5 to 365.5)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	21.9 (15.6 to 29.4)	22.4 (15.6 to 30.9)	2.5 (-5.6 to 10.2)	-18.7 (-24.9 to -13.4)
Diarrheal diseases	65.6 (62.2 to 68.9)	76.4 (72.2 to 80.4)	16.4 (8.2 to 26.3)	0.4 (-6.2 to 8.0)	10.7 (7.2 to 14.7)	12.4 (8.4 to 17.3)	15.5 (6.7 to 25.8)	0.2 (-7.2 to 8.3)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.8 (-48.8 to -2.4)	-25.9 (-60.7 to -25.9)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.9 (-20.0 to 16.9)	-26.1 (-39.4 to -11.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.9 (-20.1 to 16.9)	-26.1 (-39.5 to -10.9)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.4 (-24.2 to 21.0)	-26.2 (-41.8 to -7.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.4 (-24.2 to 21.1)	-26.2 (-41.9 to -7.8)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-79.9 (-93.9 to -30.0)	-48.8 (-95.4 to -49.1)
Lower respiratory infections	6.2 (5.6 to 6.9)	4.8 (4.2 to 5.4)	-22.3 (-33.4 to -10.0)	-35.6 (-44.1 to -27.0)	0.7 (0.4 to 0.9)	0.5 (0.3 to 0.7)	-22.9 (-35.7 to -7.9)	-35.9 (-45.6 to -24.7)
Upper respiratory infections	356.3 (338.1 to 372.9)	478.6 (454.0 to 505.5)	34.4 (25.4 to 45.0)	-3.6 (-10.2 to 3.9)	4.2 (2.4 to 7.0)	5.6 (3.1 to 9.2)	33.8 (24.8 to 44.9)	-3.7 (-10.1 to 4.2)
Otitis media	87.9 (82.6 to 93.4)	103.4 (96.8 to 110.0)	17.8 (8.1 to 27.8)	-11.3 (-18.4 to -4.0)	1.7 (1.0 to 2.7)	2.0 (1.1 to 3.1)	15.7 (5.1 to 27.9)	-12.6 (-20.3 to -4.3)
Meningitis	-	-	-	-	4.0 (2.8 to 5.7)	1.5 (1.0 to 2.1)	-63.3 (-73.3 to -50.9)	-70.5 (-80.2 to -64.7)
Pneumococcal meningitis	19.8 (11.7 to 30.1)	6.6 (4.0 to 10.5)	-66.7 (-75.0 to -58.9)	-77.6 (-82.5 to -72.7)	1.9 (1.2 to 3.0)	0.6 (0.4 to 0.9)	-65.8 (-78.9 to -53.1)	-75.6 (-84.3 to -67.2)
H influenzae type B meningitis	9.7 (3.8 to 19.3)	3.1 (1.1 to 6.2)	-69.3 (-81.6 to -45.4)	-78.6 (-86.6 to -61.9)	1.2 (0.7 to 1.8)	0.4 (0.2 to 0.8)	-65.6 (-80.4 to -18.0)	-74.7 (-85.3 to -40.0)
Meningococcal meningitis	1.1 (0.4 to 2.4)	0.4 (0.2 to 0.9)	-62.9 (-77.4 to -42.9)	-75.0 (-84.3 to -61.5)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-61.6 (-77.5 to -27.6)	-73.2 (-83.3 to -50.9)
Other meningitis	6.8 (3.4 to 13.0)	2.6 (1.2 to 4.9)	-62.3 (-73.7 to -46.8)	-74.0 (-81.3 to -61.5)	0.8 (0.5 to 1.2)	0.4 (0.2 to 0.6)	-54.9 (-72.8 to -29.4)	-67.2 (-79.6 to -48.9)
Encephalitis	0.9 (0.4 to 2.0)	1.0 (0.4 to 2.3)	8.5 (-12.5 to 26.3)	-11.7 (-44.5 to -49.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	16.4 (-3.2 to 43.8)	-24.7 (-37.5 to -8.4)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.3 (-96.9 to 751.2)	-57.7 (-96.8 to 483.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.3 (-97.0 to 753.2)	-57.7 (-96.9 to 493.5)
Whooping cough	6.8 (5.3 to 8.7)	3.2 (2.5 to 4.1)	-53.5 (-55.9 to -51.1)	-55.9 (-58.1 to -53.5)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-53.5 (-58.8 to -47.7)	-55.9 (-60.9 to -50.3)
Tetanus	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-41.9 (-70.8 to 41.3)	-58.9 (-79.5 to -40.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.0 (-61.3 to 20.1)	-47.9 (-71.6 to -13.4)
Measles	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	5.6 (5.0 to 6.2)	7.2 (6.4 to 8.1)	27.5 (9.6 to 53.5)	-1.8 (-21.8 to 28.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	60.6 (13.1 to 159.2)	-3.8 (-35.2 to 62.4)
Neglected tropical diseases and malaria	-	-	-	-	7.8 (4.8 to 12.7)	10.4 (6.3 to 16.8)	31.0 (8.0 to 81.8)	-2.8 (-21.0 to 33.7)
Malaria	59.1 (46.6 to 74.3)	66.9 (54.0 to 81.5)	13.7 (9.1 to 42.0)	-14.9 (-32.2 to 7.5)	0.5 (0.3 to 0.8)	0.6 (0.4 to 0.9)	12.8 (-22.6 to 59.3)	-11.0 (-38.8 to 24.4)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.5 (-44.8 to 111.6)	-12.5 (-53.3 to 64.6)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.1 (-45.5 to 111.0)	-12.6 (-53.5 to 64.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.1 (-45.5 to 111.9)	-12.6 (-53.7 to 65.2)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.5 (6.2 to 143.4)	17.9 (-27.0 to 74.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.5 (5.9 to 143.5)	17.9 (-27.4 to 74.2)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	220.4 (86.9 to 471.1)	337.7 (135.0 to 713.0)	53.4 (48.7 to 59.0)	0.6 (-1.9 to 3.9)	1.6 (0.6 to 3.7)	2.5 (0.9 to 5.7)	52.9 (26.4 to 89.8)	2.4 (-13.4 to 23.1)
Cysticercosis	1.9 (1.1 to 3.3)	1.2 (0.5 to 2.0)	-34.7 (-79.8 to 40.4)	-57.4 (-86.3 to -10.1)	0.6 (0.3 to 1.1)	0.4 (0.1 to 0.7)	-30.8 (-80.6 to 51.5)	-54.9 (-86.2 to -20.0)
Cystic echinococcosis	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.4)	-9.0 (-16.1 to 16.5)	-50.9 (-54.4 to -38.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-3.0 (-23.2 to 27.9)	-47.5 (-58.7 to -30.5)
Lymphatic filariasis	9.1 (7.1 to 11.4)	4.7 (3.3 to 6.7)	-49.0 (-61.8 to -32.5)	-68.7 (-76.5 to -60.1)	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.6)	4.2 (-27.0 to 46.9)	-43.4 (-60.7 to -21.2)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	2.3 (0.9 to 5.3)	16.3 (6.1 to 36.6)	598.3 (596.7 to 600.2)	392.2 (391.1 to 393.5)	0.4 (0.1 to 0.9)	2.7 (0.9 to 6.5)	596.7 (500.2 to 712.0)	392.3 (334.0 to 465.3)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-66.0 (-73.3 to -52.1)	-52.1 (-66.0 to -34.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.8 (-66.0 to -34.9)	64.5 (-73.3 to -52.1)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.7 (13.4 to 109.8)	6.8 (-32.0 to 29.3)
Ascariasis	-	-	66.7 (-13.2 to 246.9)	2.5 (-46.7 to 113.4)	-	-	-	-
Trichuriasis	-	-	69.5 (-17.4 to 254.3)	4.2 (-49.2 to 118.3)	-	-	-	-
Hookworm disease	4.5 (3.5 to 5.8)	7.6 (4.3 to 12.4)	63.2 (-9.3 to 195.1)	0.3 (-44.2 to 81.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.7 (13.4 to 109.8)	6.8 (-32.0 to 29.3)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	101.7 (79.3 to 124.9)	109.4 (102.9 to 117.2)	7.7 (-13.2 to 38.5)	-11.1 (-27.0 to 11.6)	4.3 (2.5 to 6.9)	3.8 (2.5 to 5.6)	-10.3 (-28.9 to 28.4)	-28.3 (-47.0 to 10.0)
Maternal disorders	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	8.5 (-10.4 to 29.6)	-23.2 (-36.0 to -9.1)
Maternal hemorrhage	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	24.4 (2.0 to 51.9)	-15.9 (-30.4 to 2.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.8 (-11.2 to 46.3)	-21.0 (-39.9 to -1.4)
Maternal sepsis and other maternal infections	0.6 (0.3 to 0.9)	0.6 (0.4 to 0.9)	0.0 (-13.9 to 27.9)	-36.0 (-47.7 to -22.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.3 (-25.5 to 17.1)	-37.8 (-49.8 to -21.8)
Maternal hypertensive disorders	1.0 (0.7 to 1.5)	1.1 (0.7 to 1.5)	2.2 (-4.6 to 11.7)	-26.9 (-32.0 to -20.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	2.3 (-21.8 to 33.5)	2.3 (-44.0 to -4.7)
Obstructed labor	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	6.0 (-34.6 to 67.1)	-23.1 (-51.0 to 17.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.0 (-34.6 to 67.1)	23.1 (-51.1 to 17.3)
Complications of abortion	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	29.9 (-41.5 to 176.9)	-11.0 (-56.2 to 80.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.9 (-41.7 to 177.8)	-11.0 (-56.6 to 81.3)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.3 (-12.7 to 89.6)	9.1 (-38.2 to 33.5)
Neonatal disorders	-	-	-	-	9.7 (6.2 to 14.6)	22.0 (15.2 to 29.5)	134.1 (49.8 to 211.0)	74.1 (11.7 to 133.0)
Preterm birth complications	33.2 (17.9 to 60.7)	102.7 (59.0 to 180.9)	211.8 (148.9 to 297.5)	122.7 (76.9 to 185.3)	3.4 (2.0 to 5.1)	11.4 (7.3 to 16.1)	241.8 (127.4 to 390.9)	150.8 (67.0 to 257.9)
Neonatal encephalopathy due to birth asphyxia and trauma	57.0 (15.1 to 148.2)	59.2 (19.8 to 142.0)	6.9 (-24.3 to 63.1)	-24.5 (-46.8 to 18.1)	3.7 (2.1 to 5.8)	5.6 (3.5 to 9.2)	52.0 (-9.5 to 162.5)	14.6 (-30.7 to 96.5)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	0.0 (114.6 to 151.1)	127.9 (113.9 to 150.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	21.1 (106.4 to 151.9)	41.7 (105.8 to 151.1)
Hemolytic disease and other neonatal jaundice	4.8 (2.0 to 12.6)	8.3 (4.4 to 14.6)	94.6 (-50.7 to 374.7)	44.5 (-62.9 to 252.3)	1.7 (0.7 to 4.3)	3.1 (1.6 to 5.6)	98.5 (-45.2 to 385.6)	46.2 (-59.9 to 257.8)
Other neonatal disorders	-	-	-	-	0.8 (0.5 to 1.4)	1.9 (1.0 to 3.5)	117.5 (15.2 to 368.3)	62.4 (-13.4 to 248.0)
Nutritional deficiencies	-	-	-	-	54.8 (36.3 to 79.3)	59.5 (39.7 to 85.8)	8.6 (-5.3 to 11.2)	-15.9 (-18.1 to -14.0)
Protein-energy malnutrition	10.8 (7.6 to 15.1)	8.1 (4.5 to 14.0)	-27.5 (-61.6 to 40.8)	-43.1 (-68.3 to 9.2)	1.3 (0.7 to 2.3)	1.0 (0.5 to 1.9)	-21.1 (-61.9 to 45.1)	-41.7 (-67.6 to 13.3)
Iodine deficiency	10.7 (8.6 to 13.1)	11.1 (8.5 to 14.1)	2.9 (-25.6 to 49.2)	-33.0 (-52.0 to -3.8)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	3.6 (-28.1 to 49.0)	-32.5 (-52.7 to -1.7)
Vitamin A deficiency	4.2 (3.2 to 5.2)	2.5 (1.9 to 3.2)	-40.3 (-47.3 to -33.3)	-53.1 (-58.5 to -47.8)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.1)	-41.8 (-51.3 to -31.8)	-55.3 (-62.5 to -48.2)

Appendix Table G.4 - Dominican Republic prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	1,636.2 (1,614.2 to 1,657.9)	1,887.8 (1,868.4 to 1,904.4)	15.4 (13.5 to 17.4)	-14.2 (-15.4 to -12.9)	53.1 (35.2 to 75.9)	58.2 (38.7 to 84.1)	9.6 (6.7 to 11.8)	-15.1 (-17.3 to -13.4)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	94.7 (-34.8 to 428.7)	54.5 (-43.3 to 298.8)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	4.7 (3.0 to 7.2)	5.4 (3.4 to 8.5)	15.4 (4.3 to 34.3)	-14.4 (-22.0 to -3.8)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.6 (0.8 to 2.7)	2.2 (1.2 to 4.0)	44.2 (26.7 to 63.0)	-7.1 (-16.3 to 3.2)
Syphilis	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.4)	50.3 (24.4 to 80.7)	23.3 (-35.4 to -8.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	69.2 (6.9 to 108.1)	-22.6 (-44.3 to 5.9)
Chlamydial infection	199.3 (163.4 to 235.1)	277.9 (233.4 to 320.8)	39.3 (11.6 to 86.7)	-5.3 (-23.4 to 23.4)	0.8 (0.4 to 1.3)	1.2 (0.6 to 1.8)	41.2 (17.8 to 72.7)	-5.0 (-19.6 to 14.5)
Gonococcal infection	22.6 (17.5 to 28.8)	29.9 (23.4 to 35.7)	33.1 (-5.9 to 78.5)	-6.7 (-33.8 to 23.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	14.4 (-26.9 to 68.8)	-21.1 (-49.1 to 14.0)
Trichomoniasis	44.0 (30.0 to 66.0)	69.8 (47.2 to 96.3)	60.7 (-14.7 to 174.1)	0.8 (-43.8 to 64.5)	0.1 (0.0 to 0.2)	0.3 (0.0 to 0.3)	58.9 (-24.2 to 196.2)	0.5 (-49.2 to 77.9)
Genital herpes	1,491.4 (1,410.7 to 1,564.8)	2,444.5 (2,303.6 to 2,575.0)	64.6 (52.6 to 75.7)	-5.4 (-11.8 to 0.9)	5.4 (0.1 to 1.0)	7.9 (0.2 to 1.5)	39.4 (44.6 to 72.9)	-5.7 (-12.8 to 1.5)
Other sexually transmitted diseases	1.5 (1.1 to 2.0)	2.0 (1.5 to 2.6)	32.3 (12.6 to 51.2)	-20.3 (-32.8 to -9.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	60.2 (17.0 to 127.2)	2.1 (-26.0 to 40.9)
Hepatitis	-	-	-	-	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	11.7 (5.6 to 41.7)	-26.2 (-38.7 to -4.8)
Hepatitis A	10.0 (9.6 to 10.4)	11.8 (11.4 to 12.2)	17.9 (17.0 to 18.9)	-5.2 (-5.3 to -5.0)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	31.7 (17.3 to 48.4)	-1.9 (-12.1 to 10.3)
Hepatitis B	324.3 (244.4 to 415.9)	277.0 (211.8 to 351.6)	-15.4 (-40.4 to 96.8)	-46.1 (-61.5 to -42.1)	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.2)	-15.2 (-45.8 to 55.0)	-49.3 (-68.2 to -10.4)
Hepatitis C	99.1 (89.6 to 108.5)	124.4 (112.4 to 136.6)	25.6 (9.8 to 45.1)	-27.0 (-35.7 to -36.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.9 (5.2 to 60.7)	-25.3 (-46.1 to 3.3)
Hepatitis E	-	-	-	-	39.7 (23.5 to 55.7)	-0.1 (-11.2 to 11.5)	-	-
Leprosy	0.4 (0.2 to 0.6)	0.5 (0.4 to 0.6)	35.3 (5.9 to 88.2)	-30.7 (-45.8 to -4.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.1 (-3.2 to 110.3)	-29.5 (-50.1 to 6.5)
Other infectious diseases	73.0 (57.6 to 89.8)	79.7 (73.0 to 86.8)	9.1 (-3.0 to 26.4)	-12.5 (-21.0 to -1.4)	2.7 (1.6 to 4.1)	2.7 (1.7 to 4.0)	-1.4 (-14.5 to 26.2)	-18.7 (-30.1 to 3.6)
Non-communicable diseases	-	-	-	-	478.5 (354.6 to 622.1)	821.1 (611.1 to 1,059.1)	71.6 (67.7 to 76.1)	1.9 (-0.3 to 4.3)
Neoplasms	-	-	-	-	2.6 (1.9 to 3.5)	10.2 (6.8 to 14.6)	293.8 (184.8 to 416.1)	93.9 (33.8 to 155.9)
Esophageal cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	146.9 (78.2 to 254.6)	8.7 (-21.6 to 58.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	136.9 (78.1 to 237.1)	4.4 (-23.6 to 51.3)
Stomach cancer	0.8 (0.7 to 0.9)	2.1 (1.7 to 2.7)	175.2 (114.8 to 257.1)	21.8 (-4.8 to 57.9)	0.1 (0.0 to 0.1)	0.2 (0.2 to 0.3)	154.0 (96.7 to 233.2)	12.1 (-12.8 to 49.0)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	485.3 (341.5 to 716.2)	156.8 (92.6 to 261.9)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	548.5 (247.2 to 1,164.0)	212.7 (64.7 to 523.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	524.2 (267.9 to 1,031.8)	198.1 (171.2 to 457.1)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.4 (0.2 to 0.6)	2,004.2 (987.8 to 4,224.6)	791.4 (347.6 to 1,787.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	1,820.6 (986.8 to 3,502.6)	700.4 (336.4 to 1,442.2)
Liver cancer due to alcohol use	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	194.4 (56.8 to 442.6)	26.2 (-32.0 to 127.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	182.8 (74.4 to 344.3)	20.3 (-26.4 to 89.1)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	144.8 (47.3 to 411.6)	154.8 (-34.2 to 133.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	157.5 (56.8 to 334.6)	24.1 (-30.4 to 95.2)
Larynx cancer	0.6 (0.4 to 0.7)	1.0 (0.7 to 1.5)	78.8 (27.7 to 166.0)	-15.3 (-39.9 to 27.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	84.2 (29.0 to 177.6)	-13.2 (-39.7 to 30.7)
Tracheal, bronchus and lung cancer	0.7 (0.6 to 0.8)	1.9 (1.5 to 2.3)	176.5 (112.0 to 262.5)	27.1 (-2.1 to 69.5)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	162.1 (99.6 to 248.0)	20.9 (-7.8 to 58.5)
Breast cancer	4.1 (3.5 to 4.7)	14.5 (10.7 to 19.7)	249.1 (155.1 to 398.6)	69.0 (24.9 to 140.9)	0.3 (0.2 to 0.5)	1.2 (0.8 to 1.7)	239.4 (145.5 to 382.5)	63.1 (19.0 to 130.9)
Cervical cancer	4.0 (2.3 to 3.7)	6.6 (3.2 to 6.8)	62.1 (3.8 to 152.8)	-73.1 (-46.7 to 29.5)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	-22.2 (0.8 to 15.8)	-23.3 (-48.1 to 30.4)
Uterine cancer	1.2 (0.9 to 1.9)	3.6 (2.3 to 5.8)	200.2 (85.8 to 384.4)	43.3 (-9.1 to 133.4)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	196.9 (86.1 to 374.8)	40.0 (-10.5 to 124.0)
Prostate cancer	4.7 (3.0 to 7.9)	39.8 (20.5 to 59.9)	874.6 (219.4 to 1,570.7)	306.9 (33.8 to 605.3)	0.5 (0.3 to 0.8)	3.8 (1.7 to 6.1)	813.1 (200.6 to 1,368.7)	272.8 (21.9 to 504.0)
Colon and rectum cancer	2.0 (1.8 to 2.2)	7.4 (6.0 to 9.4)	266.1 (192.3 to 381.1)	57.8 (26.5 to 107.6)	0.2 (0.1 to 0.2)	0.6 (0.4 to 0.9)	238.4 (173.0 to 349.4)	45.0 (16.9 to 92.3)
Lip and oral cavity cancer	1.2 (0.9 to 1.5)	3.2 (2.3 to 4.4)	176.2 (92.0 to 287.7)	20.7 (-15.9 to 72.7)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	174.3 (92.0 to 289.9)	18.4 (-17.4 to 70.3)
Nasopharynx cancer	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	130.1 (53.9 to 257.5)	11.4 (-25.4 to 75.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	122.8 (54.7 to 241.3)	6.5 (-26.9 to 65.8)
Other pharynx cancer	0.3 (0.2 to 0.4)	0.9 (0.6 to 1.2)	208.8 (102.0 to 396.4)	38.7 (-9.5 to 121.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	202.5 (101.2 to 364.8)	35.0 (-11.7 to 107.6)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-39.0 (-60.7 to 143.2)	-74.7 (-83.6 to 3.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.7 (-60.6 to 141.2)	-74.3 (-83.3 to 6.2)
Pancreatic cancer	0.1 (0.0 to 0.1)	0.4 (0.3 to 0.5)	633.7 (466.6 to 889.3)	216.1 (142.9 to 333.0)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	563.7 (424.3 to 780.6)	182.8 (121.6 to 278.7)
Malignant skin melanoma	0.4 (0.4 to 0.6)	0.9 (0.6 to 1.3)	94.4 (45.7 to 182.4)	84.4 (26.5 to 44.5)	0.1 (0.0 to 0.0)	0.1 (0.0 to 0.0)	94.1 (37.8 to 195.5)	-3.0 (-32.1 to 45.5)
Non-melanoma skin cancer	1.2 (1.0 to 1.7)	6.1 (4.5 to 8.0)	399.6 (229.5 to 601.2)	119.7 (43.6 to 214.2)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.5)	562.0 (282.9 to 961.0)	177.6 (32.1 to 354.7)
Ovarian cancer	0.1 (0.1 to 0.2)	0.5 (0.4 to 0.7)	246.5 (151.1 to 406.7)	78.2 (30.9 to 162.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	232.6 (133.6 to 397.7)	71.6 (16.5 to 161.1)
Testicular cancer	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	662.3 (59.5 to 1,400.8)	334.4 (-9.5 to 743.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	624.8 (50.6 to 1,371.6)	304.1 (-10.1 to 717.0)
Kidney cancer	0.4 (0.4 to 0.6)	1.0 (0.8 to 1.3)	90.1 (50.0 to 164.0)	1.9 (-20.2 to 43.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	87.7 (45.9 to 166.0)	2.8 (-24.5 to 37.9)
Bladder cancer	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	60.0 (8.7 to 187.8)	-37.3 (-58.5 to 14.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.9 (8.1 to 184.1)	-37.4 (-57.9 to 12.1)
Brain and nervous system cancer	0.2 (0.2 to 0.3)	1.1 (0.6 to 1.4)	525.9 (126.8 to 727.0)	325.9 (45.8 to 450.7)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	548.0 (123.4 to 791.1)	308.3 (34.2 to 441.3)
Thyroid cancer	1.4 (1.1 to 1.9)	4.2 (3.0 to 6.1)	205.6 (115.9 to 336.6)	73.7 (19.1 to 146.9)	0.2 (0.0 to 0.1)	0.2 (0.1 to 0.4)	208.1 (111.8 to 341.5)	73.3 (16.4 to 147.7)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	178.4 (120.2 to 266.0)	21.9 (-4.2 to 61.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	291.5 (137.5 to 392.1)	29.8 (-2.3 to 70.8)
Hodgkin lymphoma	0.1 (0.1 to 0.2)	0.5 (0.2 to 0.7)	519.3 (56.6 to 792.4)	373.3 (15.9 to 577.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	557.0 (58.7 to 845.1)	376.2 (12.3 to 570.8)
Non-Hodgkin lymphoma	0.7 (0.5 to 0.9)	2.0 (1.4 to 2.6)	198.2 (112.3 to 299.7)	69.0 (16.6 to 132.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	185.4 (103.1 to 293.5)	55.5 (6.8 to 118.0)
Multiple myeloma	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.5)	233.6 (104.3 to 430.5)	54.2 (-5.7 to 145.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	216.7 (96.6 to 389.1)	46.5 (-10.9 to 128.1)
Leukemia	1.3 (1.0 to 1.7)	2.6 (2.1 to 3.1)	95.0 (46.8 to 156.2)	42.8 (10.6 to 83.2)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	112.3 (64.1 to 175.2)	38.9 (6.3 to 80.6)
Other neoplasms	4.9 (4.1 to 6.0)	18.4 (13.6 to 22.8)	276.4 (169.4 to 391.1)	150.0 (81.1 to 224.2)	0.3 (0.2 to 0.4)	1.2 (0.8 to 1.7)	273.4 (168.8 to 382.4)	136.0 (68.8 to 209.4)
Cardiovascular diseases	-	-	-	-	6.1 (4.2 to 8.3)	16.2 (11.4 to 22.2)	168.9 (112.8 to 239.7)	25.4 (1.1 to 57.6)
Rheumatic heart disease	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	76.8 (53.6 to 102.6)	-5.1 (-18.5 to 9.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.7 (53.0 to 108.0)	-4.7 (-18.6 to 11.4)
Ischemic heart disease	33.9 (29.3 to 39.2)	131.2 (106.7 to 168.2)	283.7 (198.8 to 411.8)	67.3 (31.3 to 123.1)	1.6 (1.0 to 2.3)	6.9 (4.4 to 10.5)	339.2 (216.1 to 531.9)	92.9 (39.8 to 171.6)
Cerebrovascular disease	-	-	-	-	1.8 (1.3 to 2.5)	4.0 (2.7 to 5.4)	113.6 (72.4 to 180.0)	3.8 (-23.2 to 27.8)
Ischemic stroke	9.1 (8.0 to 10.4)	20.2 (17.0 to 24.2)	119.4 (79.4 to 180.0)	-4.5 (-23.5 to 22.2)	1.3 (0.9 to 1.8)	2.9 (2.0 to 4.1)	116.2 (76.1 to 178.7)	-4.8 (-23.9 to 22.8)
Hemorrhagic stroke	3.3 (2.6 to 4.4)	6.9 (5.6 to 9.3)	108.6 (33.8 to 221.5)	-1.9 (-36.9 to 57.8)	0.5 (0.3 to 0.8)	1.5 (0.7 to 1.5)	106.0 (33.9 to 216.8)	-1.5 (-37.2 to 56.3)
Hypertensive heart disease	3.6 (3.3 to 4.0)	7.2 (6.5 to 7.8)	98.5 (73.3 to 128.0)	-14.6 (-25.7 to -1.4)	0.4 (0.3 to 0.5)	0.8 (0.5 to 1.0)	96.8 (67.5 to 129.1)	-14.1 (-27.1 to 0.1)
Cardiomyopathy and myocarditis	1.6 (1.3 to 1.9)	3.6 (3.3 to 3.9)	129.7 (88.8 to 178.1)	15.6 (-9.5 to 44.8)	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	128.0 (81.2 to 190.6)	16.0 (-11.5 to 51.6)
Atrial fibrillation and flutter	3.3 (2.3 to 4.3)	14.6 (10.5 to 19.5)	330.1 (192.2 to 617.1)	68.2 (5.8 to 192.1)	0.3 (0.1 to 0.4)	1.1 (0.7 to 1.7)	326.5 (185.9 to 607.3)	68.9 (7.6 to 188.1)
Peripheral vascular disease	146.5 (110.7 to 189.0)	306.9 (237.4 to 373.4)	112.7 (45.4 to 200.2)	-4.0 (-31.4 to 28.7)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	151.7 (32.9 to 408.2)	-13.3 (-55.4 to 78.1)
Endocarditis	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	83.7 (11.7 to 131.0)	17.2 (-27.4 to 46.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.1 (18.5 to 156.9)	0.7 (-26.3 to 61.6)
Other cardiovascular and circulatory diseases	24.8 (13.9 to 41.2)	40.7 (33.9 to 51.1)	70.4 (-4.2 to 204.2)	-12.5 (-50.5 to 57.5)	1.7 (0.9 to 3.1)	2.9 (1.9 to 4.2)	70.7 (-4.2 to 205.7)	-12.3 (-50.4 to 57.6)
Chronic respiratory diseases	-	-	-	-	31.2 (21.1 to 43.1)	44.8 (30.6 to 61.7)	43.0 (23.7 to 68.3)	-17.0 (-30.1 to -1.8)

Appendix Table G.4 - Dominican Republic prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	90.7	-6.0
Silicosis	0.0	0.0	78.1	-12.4	0.0	0.0	77.0	-13.1
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Coal workers pneumoconiosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Other pneumoconiosis	0.0	0.0	102.7	0.4	0.0	0.0	100.8	-0.7
Asthma	237.7	244.5	3.7	-28.6	10.6	10.8	2.7	-28.8
Interstitial lung disease and pulmonary sarcoidosis	0.1	0.3	124.2	11.7	0.0	0.0	127.3	12.8
Other chronic respiratory diseases	-	-	-	-	5.9	3.7	-37.5	-67.0
Cirrhosis	-	-	-	-	0.3	0.5	34.4	-24.1
Cirrhosis due to hepatitis B	0.2	0.2	13.7	-38.6	0.0	0.0	13.6	-38.7
Cirrhosis due to hepatitis C	0.5	1.0	91.7	2.7	0.1	0.2	90.7	4.1
Cirrhosis due to alcohol use	0.7	0.8	44.6	9.9	0.1	0.1	24.9	44.9
Cirrhosis due to other causes	0.6	0.7	23.7	-13.1	0.1	0.1	22.5	-13.0
Digestive diseases	-	-	-	-	7.9	14.3	79.8	-4.7
Peptic ulcer disease	36.2	43.7	20.9	-47.7	1.3	1.8	34.3	-40.6
Gastritis and duodenitis	106.2	195.8	84.3	-1.2	3.9	6.5	68.3	-3.4
Appendicitis	0.2	0.3	38.8	-1.7	0.1	0.1	40.3	-1.5
Paralytic ileus and intestinal obstruction	0.1	0.2	68.6	0.0	0.1	0.1	66.7	25.7
Inguinal, femoral, and abdominal hernia	19.1	25.7	35.3	-40.3	0.2	0.3	35.2	-39.7
Inflammatory bowel disease	7.3	16.1	122.3	23.7	1.6	3.4	121.2	23.7
Vascular intestinal disorders	0.0	0.0	106.4	-5.7	0.0	0.0	106.4	-5.7
Gallbladder and biliary diseases	3.6	4.7	32.5	0.4	0.5	0.6	30.4	-33.7
Pancreatitis	0.4	1.0	164.7	47.9	0.1	0.3	162.6	48.2
Other digestive diseases	-	-	-	-	0.4	1.4	242.6	81.2
Neurological disorders	-	-	-	-	40.9	72.9	78.1	3.3
Alzheimer disease and other dementias	29.8	80.1	168.5	0.2	4.2	11.6	176.0	0.2
Parkinson disease	0.5	1.1	126.3	-2.5	0.1	0.1	123.8	-2.3
Epilepsy	17.2	29.9	74.2	19.4	5.8	10.4	81.4	26.4
Multiple sclerosis	0.4	1.3	231.2	87.0	0.1	0.4	219.6	81.2
Migraine	676.2	1,039.0	52.1	1.4	23.2	35.6	52.1	-1.4
Tension-type headache	1,342.2	2,200.8	64.1	2.1	13.0	33.3	63.9	2.5
Medication overuse headache	28.3	66.7	134.7	37.5	4.5	10.5	133.7	37.5
Other neurological disorders	0.0	0.0	60.2	4.1	0.9	0.9	-2.4	-64.2
Mental and substance use disorders	-	-	-	-	159.3	248.3	56.0	0.7
Schizophrenia	16.5	28.3	71.8	-0.5	10.7	17.6	71.0	-0.5
Alcohol use disorders	33.7	63.6	88.8	17.4	3.3	6.3	89.5	17.8
Drug use disorders	-	-	-	-	8.7	13.5	55.6	1.6
Opioid use disorders	4.4	7.8	76.4	-0.2	1.8	3.2	75.6	-0.4
Cocaine use disorders	10.9	18.1	66.9	1.5	2.5	4.5	66.2	5.6
Amphetamine use disorders	13.4	18.4	38.2	-1.2	1.8	2.4	37.8	-1.1
Cannabis use disorders	10.2	14.2	38.5	0.0	0.3	0.4	38.8	-0.2
Other drug use disorders	-	-	-	-	3.3	5.0	51.0	2.6
Depressive disorders	-	-	-	-	59.7	95.0	58.9	0.3
Major depressive disorder	252.9	399.1	58.1	0.3	52.5	82.4	57.0	0.2
Dysthymia	74.8	130.5	74.5	7.3	12.6	17.6	73.6	0.5
Bipolar disorder	48.4	78.2	61.6	0.1	9.9	16.0	60.8	0.1
Anxiety disorders	395.3	614.2	56.7	0.6	36.7	56.7	54.9	0.6
Eating disorders	-	-	-	-	2.3	3.2	37.2	0.7
Anorexia nervosa	1.7	2.4	41.0	5.2	0.4	0.5	42.2	5.8
Bulimia nervosa	9.1	12.4	36.1	-0.3	1.9	2.6	36.3	-0.2
Autistic spectrum disorders	-	-	-	-	8.7	12.3	41.2	-0.3
Autism	21.9	31.1	42.0	-0.6	5.4	7.7	41.6	-0.3
Asperger syndrome	32.2	45.4	41.1	-0.7	3.2	4.6	40.6	-0.6
Attention-deficit/hyperactivity disorder	63.7	77.4	21.6	0.3	0.8	0.9	21.5	0.4
Conduct disorder	84.8	103.3	21.1	0.4	1.2	1.5	22.2	0.2
Idiopathic intellectual disability	14.6	22.3	49.1	5.5	0.7	1.1	48.2	5.3
Other mental and substance use disorders	100.0	167.8	68.0	-0.6	7.5	12.6	67.1	-0.4
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	47.4	93.5	96.8	17.8
Diabetes mellitus	255.8	656.5	156.2	40.7	17.9	46.9	160.5	37.3
Acute glomerulonephritis	0.0	0.0	16.9	0.0	0.0	0.0	16.9	9.0
Chronic kidney disease	0.0	0.0	72.2	-15.4	0.0	0.0	72.2	-15.5
Chronic kidney disease due to diabetes mellitus	153.6	283.7	82.9	-4.7	2.0	3.6	80.7	-3.7
Chronic kidney disease due to hypertension	104.3	167.2	60.0	6.5	2.7	4.5	66.3	-1.7
Chronic kidney disease due to glomerulonephritis	225.3	375.6	67.1	1.4	2.3	3.4	64.9	8.2
Chronic kidney disease due to other causes	216.1	360.0	68.6	6.0	2.6	4.5	71.9	8.6
Urinary diseases and male infertility	-	-	-	-	1.8	3.9	111.2	2.3

Appendix Table G.4 - Dominican Republic prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.5 (1.4 to 1.6)	3.2 (2.9 to 3.4)	109.4 (90.8 to 134.5)	33.7 (23.6 to 47.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	107.4 (69.2 to 157.0)	33.7 (11.8 to 62.5)
Urolithiasis	30.4 (21.7 to 47.5)	69.0 (39.3 to 135.8)	119.1 (74.4 to 211.4)	3.2 (20.5 to 50.1)	0.2 (0.1 to 0.4)	0.5 (0.3 to 1.1)	118.0 (75.6 to 206.6)	12.4 (-9.5 to 59.3)
Benign prostatic hyperplasia	32.6 (29.3 to 35.1)	68.1 (62.6 to 73.9)	108.2 (89.7 to 134.4)	-6.7 (-15.6 to 5.7)	1.2 (0.8 to 1.7)	2.4 (1.6 to 3.4)	106.9 (88.3 to 134.0)	-6.7 (-15.5 to 6.1)
Male infertility due to other causes	39.9 (32.4 to 48.4)	60.3 (48.2 to 74.7)	51.4 (12.0 to 103.6)	-1.6 (-26.9 to 33.0)	0.3 (0.1 to 0.5)	0.4 (0.2 to 0.8)	51.6 (8.1 to 105.7)	-0.5 (-28.4 to 34.0)
Other urinary diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.5 (0.2 to 1.1)	34.1 (130.5 to 420.7)	86.3 (22.8 to 177.5)
Gynecological diseases	-	-	-	-	8.1 (5.3 to 12.3)	13.5 (8.6 to 20.8)	66.8 (46.1 to 91.8)	0.9 (-10.4 to 15.8)
Uterine fibroids	111.3 (99.9 to 121.3)	217.1 (196.6 to 235.3)	95.1 (92.6 to 98.0)	3.0 (2.9 to 3.1)	1.7 (1.0 to 2.9)	2.8 (1.6 to 4.9)	60.8 (45.9 to 77.4)	-8.8 (-17.4 to 0.1)
Polycystic ovarian syndrome	125.4 (108.3 to 140.8)	209.7 (188.1 to 231.1)	67.4 (41.3 to 99.2)	3.2 (-11.7 to 21.1)	1.2 (0.6 to 2.3)	2.1 (1.0 to 3.9)	66.4 (40.0 to 98.7)	3.0 (-12.2 to 19.7)
Female infertility due to other causes	27.9 (20.1 to 36.2)	47.6 (33.2 to 63.5)	68.8 (15.6 to 155.3)	3.9 (-28.1 to 56.5)	0.1 (0.1 to 0.3)	0.3 (0.1 to 0.6)	66.6 (14.4 to 152.1)	3.4 (-28.7 to 56.5)
Endometriosis	11.6 (9.7 to 13.8)	20.5 (17.8 to 23.6)	76.3 (39.1 to 122.1)	7.0 (-15.0 to 33.9)	1.1 (0.7 to 1.5)	1.9 (1.2 to 2.7)	76.6 (36.6 to 128.7)	7.2 (-16.4 to 37.3)
Genital prolapse	314.7 (255.5 to 371.7)	583.9 (480.0 to 675.2)	85.8 (44.1 to 142.4)	4.4 (-17.5 to 33.0)	1.0 (0.5 to 1.9)	1.9 (0.9 to 3.5)	85.6 (43.3 to 142.9)	4.4 (-18.0 to 34.1)
Premenstrual syndrome	267.2 (202.9 to 325.8)	453.6 (293.7 to 570.8)	68.8 (7.3 to 163.1)	7.4 (-31.6 to 67.7)	2.3 (1.4 to 3.5)	3.8 (2.1 to 6.1)	68.3 (7.4 to 162.1)	7.4 (-32.0 to 68.7)
Other gynecological diseases	22.9 (18.5 to 27.4)	30.6 (26.8 to 35.6)	33.7 (6.6 to 68.0)	-13.2 (-30.0 to 7.4)	0.6 (0.4 to 1.0)	0.8 (0.5 to 1.2)	26.5 (15.6 to 85.3)	-16.7 (-43.0 to 17.4)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	8.5 (5.7 to 12.2)	11.7 (7.9 to 16.5)	36.7 (28.8 to 48.5)	3.6 (-1.8 to 11.5)
Thalassemias	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	18.2 (8.5 to 32.5)	1.2 (-7.3 to 13.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.2 (4.9 to 41.6)	0.7 (-9.0 to 21.7)
Thalassemia trait	70.2 (62.8 to 76.9)	100.7 (93.2 to 109.5)	43.8 (37.1 to 51.9)	0.5 (-4.3 to 6.3)	1.5 (1.0 to 2.2)	2.1 (1.3 to 3.1)	43.9 (22.3 to 60.8)	7.2 (-8.1 to 19.6)
Sickle cell disorders	13.0 (11.8 to 13.9)	18.7 (17.5 to 19.9)	44.2 (34.5 to 59.3)	7.7 (0.7 to 17.4)	1.5 (1.0 to 2.0)	2.2 (1.6 to 2.9)	51.4 (35.0 to 70.7)	8.1 (-2.5 to 20.6)
Sickle cell trait	740.0 (693.3 to 781.5)	1,121.5 (1,055.2 to 1,182.4)	51.6 (46.0 to 57.0)	4.7 (1.8 to 9.5)	3.6 (2.3 to 5.2)	5.2 (3.4 to 7.4)	41.1 (30.2 to 69.7)	11.5 (1.6 to 30.8)
G6PD deficiency	264.0 (211.4 to 319.8)	381.7 (289.5 to 473.7)	45.6 (2.2 to 95.7)	1.3 (-28.9 to 36.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (8.2 to 75.6)	0.0 (-15.5 to 23.9)
G6PD trait	1,092.9 (1,019.1 to 1,163.6)	1,603.3 (1,468.8 to 1,711.5)	46.6 (32.9 to 61.7)	2.8 (-6.8 to 13.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	25.5 (-78.2 to 707.9)	4.7 (-78.8 to 379.8)
Other hemoglobinopathies and hemolytic anemias	69.4 (63.0 to 76.3)	80.1 (73.2 to 86.8)	15.6 (2.4 to 31.4)	-17.7 (-25.5 to -9.0)	1.9 (1.2 to 2.8)	2.0 (1.3 to 3.0)	5.9 (-1.8 to 28.4)	-18.3 (-32.1 to -4.0)
Endocrine, metabolic, blood, and immune disorders	72.9 (63.8 to 80.8)	87.1 (78.6 to 95.0)	19.4 (4.1 to 39.4)	-11.1 (-21.2 to 1.7)	2.3 (1.5 to 3.4)	2.6 (1.7 to 3.8)	14.1 (-0.4 to 46.5)	-10.3 (-26.3 to 10.9)
Musculoskeletal disorders	-	-	-	-	78.0 (55.4 to 103.4)	147.3 (105.6 to 195.8)	89.0 (77.1 to 103.2)	3.9 (-1.7 to 10.0)
Rheumatoid arthritis	12.8 (12.2 to 13.5)	26.3 (25.0 to 27.7)	105.3 (90.6 to 119.1)	16.2 (7.5 to 25.1)	3.1 (2.2 to 4.1)	6.2 (4.4 to 8.3)	101.2 (83.6 to 118.8)	15.6 (5.8 to 25.1)
Osteoarthritis	157.7 (151.4 to 164.0)	358.0 (344.5 to 372.3)	127.2 (115.7 to 138.9)	3.0 (-1.8 to 8.1)	9.7 (6.8 to 13.2)	21.8 (15.2 to 29.4)	125.6 (113.7 to 138.3)	2.8 (-2.1 to 8.3)
Low back and neck pain	-	-	-	-	53.9 (37.3 to 73.5)	93.8 (64.9 to 127.2)	44.2 (59.5 to 94.2)	0.3 (-7.6 to 10.5)
Low back pain	316.2 (297.4 to 335.1)	542.2 (510.6 to 570.0)	71.9 (58.5 to 86.0)	-0.4 (-7.5 to 6.8)	35.7 (24.1 to 49.9)	60.8 (41.4 to 84.3)	70.6 (56.8 to 84.6)	-0.5 (-8.0 to 7.2)
Neck pain	183.5 (146.7 to 218.2)	333.6 (285.4 to 379.7)	80.8 (47.0 to 136.6)	1.9 (-16.7 to 27.0)	18.2 (12.0 to 25.7)	32.9 (22.1 to 46.6)	80.0 (45.8 to 134.6)	1.9 (-16.7 to 27.3)
Gout	1.8 (1.6 to 2.0)	3.4 (3.1 to 3.8)	91.6 (69.8 to 116.8)	-7.2 (-18.0 to 4.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	91.0 (50.5 to 142.8)	-6.5 (-26.2 to 18.8)
Other musculoskeletal disorders	123.1 (101.1 to 147.0)	277.6 (229.9 to 328.1)	125.4 (111.8 to 144.4)	15.7 (9.4 to 25.0)	11.3 (7.4 to 16.2)	25.4 (16.6 to 35.9)	15.6 (109.3 to 143.6)	15.6 (9.0 to 25.3)
Other non-communicable diseases	-	-	-	-	104.7 (70.6 to 151.2)	173.2 (117.2 to 249.0)	65.6 (59.7 to 71.6)	-4.7 (-7.7 to -1.8)
Congenital anomalies	-	-	-	-	6.8 (5.0 to 9.1)	12.0 (8.7 to 15.6)	76.2 (52.4 to 106.0)	23.4 (6.4 to 44.0)
Neural tube defects	1.4 (1.2 to 1.7)	2.4 (2.0 to 2.8)	75.2 (39.7 to 125.6)	35.2 (7.8 to 74.5)	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.1)	82.4 (23.2 to 169.2)	42.0 (-3.9 to 109.0)
Congenital heart anomalies	18.7 (14.6 to 22.8)	45.9 (39.1 to 55.8)	145.0 (86.2 to 231.6)	83.4 (39.2 to 148.9)	0.6 (0.3 to 1.1)	1.6 (0.7 to 2.7)	143.3 (86.1 to 223.0)	83.9 (39.1 to 145.1)
Orofacial clefts	3.3 (2.3 to 4.4)	7.4 (5.7 to 9.4)	128.0 (46.4 to 256.6)	0.1 (-14.2 to 181.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	93.5 (18.5 to 231.1)	51.3 (-7.6 to 158.6)
Down syndrome	6.1 (5.0 to 7.3)	10.1 (8.4 to 12.7)	65.3 (27.8 to 124.8)	16.6 (-9.2 to 58.6)	0.7 (0.5 to 1.0)	1.3 (0.9 to 1.8)	75.3 (33.5 to 144.2)	18.9 (-9.0 to 63.2)
Turner syndrome	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	61.2 (15.1 to 145.9)	16.9 (-16.5 to 78.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.4 (12.2 to 161.1)	17.7 (-19.8 to 87.2)
Klinefelter syndrome	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	41.4 (-0.9 to 109.5)	-0.8 (-30.6 to 47.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.3 (5.1 to 121.4)	-0.6 (-30.7 to 47.6)
Chromosomal unbalanced rearrangements	18.7 (8.8 to 13.7)	37.9 (14.6 to 22.6)	62.7 (22.0 to 139.3)	7.3 (-14.3 to 68.5)	1.3 (0.9 to 1.8)	2.3 (1.6 to 3.2)	66.3 (47.8 to 153.2)	19.0 (-14.1 to 70.9)
Other congenital anomalies	29.5 (24.6 to 34.1)	38.2 (32.3 to 44.6)	29.2 (18.6 to 41.5)	-12.4 (-19.5 to -3.7)	3.6 (2.4 to 5.2)	5.9 (4.0 to 8.1)	63.1 (37.6 to 99.7)	13.3 (-3.2 to 37.2)
Skin and subcutaneous diseases	-	-	-	-	35.5 (22.6 to 54.2)	54.0 (34.6 to 81.3)	51.9 (40.5 to 66.1)	1.7 (-5.3 to 10.0)
Dermatitis	327.2 (266.4 to 391.4)	501.5 (408.9 to 600.4)	53.4 (49.4 to 57.5)	0.1 (-0.0 to 0.2)	9.0 (5.6 to 13.1)	13.3 (8.4 to 19.4)	48.4 (42.4 to 54.5)	0.2 (-2.5 to 3.0)
Psoriasis	53.0 (46.6 to 59.9)	86.3 (75.4 to 97.4)	62.7 (59.7 to 66.5)	4.4 (-0.2 to 0.1)	6.2 (2.9 to 6.1)	7.1 (4.8 to 9.9)	61.9 (52.7 to 72.5)	0.1 (-4.8 to 5.5)
Cellulitis	0.5 (0.4 to 0.6)	0.6 (0.5 to 0.8)	33.2 (14.2 to 51.4)	-11.7 (-21.2 to -1.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	32.7 (3.5 to 63.2)	-11.5 (-27.2 to 5.7)
Pyoderma	2.5 (2.1 to 3.0)	4.5 (3.7 to 5.5)	77.1 (63.7 to 88.0)	0.0 (16.5 to 27.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	74.9 (50.9 to 103.9)	21.5 (7.6 to 37.9)
Scabies	94.2 (80.8 to 108.9)	128.5 (108.7 to 150.7)	36.7 (8.0 to 69.5)	0.3 (-20.4 to 24.3)	2.4 (1.4 to 4.1)	3.3 (1.8 to 5.4)	36.2 (7.8 to 69.1)	0.3 (-20.4 to 24.8)
Fungal skin diseases	504.0 (379.6 to 666.6)	782.6 (600.6 to 1,029.7)	55.6 (47.9 to 63.8)	4.4 (-0.5 to 40.0)	2.8 (1.1 to 6.3)	4.4 (1.8 to 9.8)	65.2 (47.0 to 63.5)	-0.2 (-1.1 to 0.7)
Viral skin diseases	162.4 (123.4 to 201.7)	209.5 (155.6 to 262.6)	29.0 (23.8 to 34.7)	0.1 (-1.9 to 2.2)	5.0 (2.9 to 8.1)	6.8 (3.7 to 10.3)	28.8 (27.8 to 35.0)	0.2 (-3.2 to 3.4)
Acne vulgaris	525.5 (392.7 to 658.8)	762.7 (607.4 to 939.9)	43.0 (2.1 to 130.0)	7.4 (-22.7 to 70.3)	11.0 (2.6 to 11.0)	5.7 (3.8 to 15.5)	43.4 (2.1 to 129.0)	7.4 (-22.7 to 70.8)
Alopecia areata	6.1 (5.5 to 6.8)	9.6 (8.8 to 10.5)	57.8 (40.7 to 77.2)	-2.0 (-12.2 to 10.1)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	57.3 (33.9 to 84.0)	-1.7 (-15.0 to 13.9)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.8 (35.9 to 118.1)	0.5 (-21.5 to 31.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.8 (35.8 to 118.2)	0.5 (-21.5 to 31.4)
Urticaria	61.3 (36.0 to 84.4)	113.3 (84.7 to 147.2)	90.6 (23.4 to 207.9)	7.7 (-28.9 to 62.6)	3.6 (1.9 to 6.0)	6.7 (4.0 to 10.2)	89.1 (21.5 to 210.6)	8.1 (-28.6 to 64.1)
Decubitus ulcer	0.7 (0.6 to 0.8)	1.3 (1.0 to 1.5)	78.4 (47.6 to 121.8)	-20.8 (-36.2 to 2.4)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	73.9 (35.7 to 128.2)	-20.7 (-39.6 to 6.3)
Other skin and subcutaneous diseases	359.7 (243.9 to 525.6)	639.8 (414.0 to 986.3)	77.3 (61.4 to 95.0)	-1.4 (-6.1 to 3.9)	2.1 (0.9 to 4.4)	3.8 (1.6 to 7.9)	76.4 (59.9 to 94.5)	-1.2 (-6.3 to 4.1)
Sense organ diseases	-	-	-	-	43.1 (29.1 to 60.7)	72.8 (49.8 to 102.1)	69.0 (60.4 to 77.5)	-10.8 (-14.8 to -7.4)
Glaucoma	8.7 (7.5 to 9.9)	14.7 (12.9 to 16.8)	69.5 (53.0 to 94.0)	-16.5 (-25.3 to -4.6)	0.7 (0.5 to 1.0)	1.7 (0.9 to 1.8)	83.9 (60.4 to 118.4)	1.3 (-26.8 to 1.0)
Cataract	38.4 (33.3 to 44.0)	70.0 (62.4 to 77.5)	82.8 (65.4 to 101.0)	-25.6 (-31.7 to -18.6)	2.1 (1.4 to 2.9)	3.9 (2.7 to 5.4)	91.0 (71.7 to 114.9)	-24.5 (-30.6 to -15.7)
Macular degeneration	9.2 (7.3 to 11.1)	22.3 (18.6 to 26.0)	140.0 (96.6 to 206.0)	11.6 (-8.7 to 44.4)	0.4 (0.3 to 0.6)	1.4 (0.6 to 1.4)	140.3 (95.3 to 208.8)	10.5 (-10.4 to 45.1)
Uncorrected refractive error	594.5 (556.9 to 633.9)	1,012.7 (951.2 to 1,074.2)	70.7 (55.0 to 86.9)	-7.6 (-15.0 to 0.2)	9.2 (5.6 to 15.0)	14.9 (8.8 to 23.7)	61.1 (50.8 to 73.0)	-11.8 (-16.8 to -6.1)
Age-related and other hearing loss	800.9 (742.2 to 860.6)	1,415.3 (1,326.1 to 1,517.8)	76.8 (69.9 to 84.8)	-9.4 (-12.2 to -5.9)	4.6 (1.6 to 34.9)	4.4 (2.9 to 60.6)	9.2 (62.5 to 90.6)	-9.2 (-14.6 to -3.6)
Other vision loss	21.0 (18.6 to 23.8)	24.6 (21.7 to 27.5)	16.9 (8.9 to 26.6)	-31.2 (-35.8 to -26.1)	1.5 (1.0 to 2.1)	1.9 (1.3 to 2.6)	26.3 (14.4 to 41.6)	-30.6 (-36.6 to -23.3)
Other sense organ diseases	166.2 (157.1 to 175.1)	236.2 (224.3 to 247.9)	42.0 (32.2 to 53.1)	-0.1 (-6.7 to 6.7)	4.4 (2.7 to 6.6)	6.3 (3.9 to 9.3)	41.4 (30.3 to 53.9)	-0.1 (-7.2 to 8.0)
Oral disorders	-	-	-	-	19.3 (11.6 to 30.1)	34.4 (21.0 to 52.7)	78.5 (73.2 to 85.8)	-4.3 (-7.0 to -1.2)
Deciduous caries	624.3 (596.1 to 651.4)	701.4 (667.7 to 734.5)	12.3 (5.5 to 19.4)	0.8 (-5.3 to 7.1)	0.8 (-1.0 to 1.1)	0.3 (0.1 to 0.5)	12.5 (7.4 to 22.8)	0.9 (-7.1 to 10.1)
Permanent caries	3,191.4 (3,042.2 to 3,344.8)	4,658.3 (4,461.1 to 4,870.1)	45.9 (39.2 to 53.7)					

Appendix Table G.4 - Dominican Republic prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	299.8 (289.9 to 310.3)	609.7 (589.8 to 630.4)	103.6 (94.3 to 113.5)	-4.0 (-10.1 to -1.8)	8.3 (5.6 to 11.4)	16.8 (11.3 to 23.6)	101.9 (92.8 to 112.4)	101.9 (-10.2 to -1.6)
Other oral disorders	112.6 (105.9 to 118.9)	177.2 (167.0 to 187.1)	57.5 (45.4 to 70.8)	-0.3 (-7.2 to 7.5)	3.3 (2.1 to 5.0)	5.2 (3.3 to 7.9)	56.9 (43.9 to 70.9)	-0.3 (-7.8 to 8.4)
Injuries	-	-	-	-	33.9 (25.7 to 43.8)	43.6 (31.7 to 58.5)	28.4 (15.3 to 43.3)	-29.2 (-36.2 to -21.2)
Transport injuries	-	-	-	-	12.4 (9.3 to 15.9)	14.9 (10.5 to 20.2)	20.0 (3.9 to 40.2)	-32.3 (-40.7 to -21.8)
Road injuries	-	-	-	-	12.1 (9.1 to 15.6)	14.4 (10.2 to 19.5)	18.1 (2.3 to 38.0)	-33.2 (-41.6 to -22.8)
Pedestrian road injuries	-	-	-	-	2.9 (2.2 to 3.8)	2.7 (1.9 to 3.7)	-7.5 (-20.5 to 8.0)	-47.0 (-53.8 to -38.8)
Cyclist road injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.8 (0.5 to 1.0)	9.7 (2.5 to 23.5)	-39.8 (-46.2 to -32.3)
Motorcyclist road injuries	-	-	-	-	1.6 (1.2 to 2.1)	1.5 (1.1 to 2.1)	-7.3 (-20.4 to 8.1)	-47.2 (-54.2 to -38.9)
Motor vehicle road injuries	-	-	-	-	6.6 (4.9 to 8.6)	9.2 (6.6 to 12.5)	38.8 (18.2 to 64.1)	-21.8 (-32.4 to -8.7)
Other road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-30.5 (-39.7 to -19.2)	61.9 (-66.6 to -56.3)
Other transport injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	100.8 (76.3 to 133.1)	6.0 (-7.0 to 22.6)
Unintentional injuries	-	-	-	-	19.6 (15.0 to 25.4)	26.3 (19.3 to 35.3)	33.7 (22.8 to 45.6)	-27.5 (-33.6 to -20.9)
Falls	-	-	-	-	7.6 (5.7 to 9.8)	10.5 (7.5 to 14.2)	37.7 (22.2 to 54.8)	-33.2 (-41.1 to -24.4)
Drowning	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-2.8 (-16.5 to 13.6)	-42.1 (-49.7 to -33.4)
Fire, heat, and hot substances	-	-	-	-	0.8 (0.6 to 1.0)	0.7 (0.5 to 0.9)	-7.6 (-20.1 to 5.4)	-44.6 (-51.8 to -37.4)
Poisonings	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	2.1 (-16.2 to 25.0)	-34.9 (-45.2 to -21.1)
Exposure to mechanical forces	-	-	-	-	8.4 (6.4 to 11.1)	9.3 (6.7 to 12.5)	10.2 (1.7 to 19.8)	-31.8 (-36.6 to -26.5)
Unintentional firearm injuries	-	-	-	-	0.4 (0.3 to 0.6)	1.0 (0.7 to 1.4)	126.9 (98.4 to 162.7)	34.5 (18.4 to 53.8)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	36.9 (19.1 to 58.5)	-16.5 (-26.4 to -5.1)
Other exposure to mechanical forces	-	-	-	-	7.8 (5.9 to 10.3)	8.1 (5.9 to 10.9)	3.1 (-4.9 to 11.8)	-36.1 (-40.6 to -31.4)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	137.9 (124.9 to 151.5)	28.0 (20.6 to 35.7)
Animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	100.5 (81.4 to 123.4)	17.8 (7.7 to 29.8)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	96.1 (72.7 to 125.1)	19.6 (6.9 to 34.6)
Non-venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	102.9 (81.8 to 128.8)	16.5 (5.1 to 30.2)
Foreign body	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	33.5 (20.1 to 49.7)	-24.3 (-31.3 to -16.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	3.5 (-12.9 to 25.4)	-39.2 (-48.1 to -27.9)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	42.4 (26.1 to 65.4)	-11.6 (-21.2 to 2.1)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	50.8 (35.2 to 68.5)	-17.9 (-25.6 to -9.2)
Other unintentional injuries	-	-	-	-	2.2 (1.6 to 2.8)	4.8 (3.5 to 6.4)	122.2 (104.3 to 142.2)	7.6 (-0.9 to 16.8)
Self-harm and interpersonal violence	-	-	-	-	1.7 (1.3 to 2.2)	2.2 (1.5 to 2.9)	24.3 (9.8 to 43.6)	-30.2 (-38.2 to -20.0)
Self-harm	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	14.9 (1.9 to 30.5)	-38.7 (-45.2 to -30.7)
Interpersonal violence	-	-	-	-	1.5 (1.1 to 1.9)	1.8 (1.3 to 2.5)	26.3 (10.3 to 46.8)	-28.4 (-37.0 to -17.4)
Assault by firearm	-	-	-	-	0.4 (0.3 to 0.5)	0.7 (0.5 to 0.9)	76.7 (56.9 to 97.9)	-0.6 (-11.1 to 10.1)
Assault by sharp object	-	-	-	-	0.3 (0.3 to 0.4)	0.5 (0.3 to 0.6)	36.0 (16.8 to 61.7)	-23.3 (-33.6 to -9.7)
Assault by other means	-	-	-	-	0.7 (0.6 to 0.9)	0.7 (0.5 to 0.9)	4.3 (-17.7 to 14.2)	-45.1 (-52.6 to -35.0)
Forces of nature, war, and legal intervention	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.5)	78.4 (24.7 to 224.1)	-0.8 (-30.3 to 81.2)
Exposure to forces of nature	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.5)	78.4 (24.7 to 224.1)	-0.8 (-30.3 to 81.2)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Ecuador prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.								
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	908.0 (666.7 to 1,182.1)	1,531.8 (1,134.0 to 1,987.5)	68.7 (65.3 to 72.5)	26 (-4.3 to 0.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	157.7 (113.6 to 231.8)	210.4 (146.4 to 292.7)	27.0 (19.0 to 36.3)	-10.7 (-16.6 to -4.2)
HIV/AIDS and tuberculosis	-	-	-	-	4.8 (3.2 to 6.4)	9.6 (6.4 to 13.5)	97.5 (73.4 to 153.0)	12.2 (0.6 to 43.6)
Tuberculosis	14.4 (13.6 to 15.2)	21.3 (20.1 to 22.6)	47.6 (40.5 to 55.9)	-15.9 (-19.8 to -11.9)	4.5 (3.0 to 6.0)	6.5 (4.5 to 8.0)	46.8 (35.8 to 59.5)	-15.8 (-21.6 to -9.3)
HIV/AIDS	-	-	-	-	0.3 (0.1 to 0.6)	9.3 (7.7 to 5.8)	270.5 (418.3 to 2,691.2)	40.9 (193.0 to 1,427.7)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.4)	595.4 (247.7 to 1,844.1)	290.4 (89.7 to 949.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	594.1 (228.2 to 1,960.7)	275.2 (83.4 to 1,007.3)
HIV/AIDS resulting in other diseases	2.4 (0.9 to 4.9)	26.3 (19.6 to 42.1)	1,032.0 (402.8 to 2,914.3)	568.3 (202.4 to 1,652.8)	0.3 (0.1 to 0.6)	2.9 (1.6 to 5.7)	935.6 (412.3 to 2,920.4)	475.3 (186.2 to 1,562.3)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	31.9 (22.2 to 43.6)	37.9 (26.2 to 52.5)	18.7 (9.9 to 28.7)	-10.0 (-15.7 to -3.3)
Diarrheal diseases	124.6 (117.9 to 132.2)	133.7 (125.5 to 142.6)	7.2 (-1.5 to 16.5)	-13.4 (-20.0 to -6.2)	20.3 (13.8 to 28.0)	21.7 (14.5 to 29.7)	6.7 (-3.0 to 16.5)	-13.4 (-20.7 to -6.2)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-61.2 to -24.2)	-
Typhoid fever	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-10.5 (-25.1 to 7.6)	-37.7 (-48.4 to -26.1)	0.0 (0.0 to 0.0)	-0.5 (0.0 to 0.0)	-10.5 (-25.2 to 7.6)	-37.7 (-48.4 to -26.1)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.0 (-29.5 to 6.0)	-39.4 (-50.3 to -25.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.0 (-29.5 to 6.2)	-39.4 (-50.3 to -25.5)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-90.4 (-96.2 to -77.7)	-93.3 (-97.9 to -84.3)
Lower respiratory infections	4.6 (4.2 to 4.9)	4.6 (4.4 to 4.9)	1.0 (-6.2 to 12.3)	-25.4 (-30.2 to -18.7)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.7)	0.9 (-13.3 to 19.6)	24.7 (-34.3 to -12.4)
Upper respiratory infections	669.8 (605.2 to 739.4)	1,013.1 (925.1 to 1,108.1)	50.6 (32.1 to 74.4)	0.3 (-12.4 to 15.5)	7.9 (4.5 to 13.5)	11.9 (6.7 to 19.8)	50.6 (31.9 to 74.5)	0.6 (-12.0 to 16.3)
Otitis media	122.2 (114.6 to 130.0)	158.6 (149.8 to 168.2)	29.5 (21.0 to 38.8)	-9.8 (-15.7 to -3.8)	2.4 (1.4 to 3.8)	3.0 (1.8 to 4.9)	27.4 (17.6 to 38.2)	-11.0 (-17.6 to -4.2)
Meningitis	-	-	-	-	0.4 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-14.4 (-31.1 to 7.8)	-42.2 (-52.9 to -27.5)
Pneumococcal meningitis	1.3 (0.8 to 2.1)	1.2 (0.7 to 1.9)	-9.5 (-25.7 to 8.9)	-43.6 (-53.3 to -33.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-10.3 (-35.9 to 15.9)	-40.9 (-56.7 to -24.7)
H influenzae type B meningitis	0.8 (0.3 to 1.7)	0.6 (0.2 to 1.3)	-18.9 (-51.2 to 23.8)	-47.3 (-66.8 to -16.8)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-12.8 (-57.0 to 55.2)	-39.9 (-70.3 to 6.1)
Meningococcal meningitis	0.2 (0.1 to 0.5)	0.2 (0.1 to 0.5)	-8.6 (-40.2 to 37.4)	-42.9 (-59.5 to -6.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-44.3 to 83.1)	-33.4 (-61.3 to 16.3)
Other meningitis	0.9 (0.4 to 1.7)	0.7 (0.3 to 1.3)	-23.3 (-37.6 to -4.3)	-49.4 (-58.0 to -35.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-19.2 (-39.6 to 14.0)	-44.4 (-58.2 to -22.0)
Encephalitis	0.7 (0.3 to 1.7)	1.0 (0.4 to 2.4)	32.5 (13.1 to 53.3)	-21.2 (-31.5 to -8.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	37.2 (13.5 to 47.6)	-16.3 (-29.1 to 0.8)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.9 (-96.8 to 972.9)	-54.1 (-97.2 to 520.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.9 (-96.8 to 1,001.6)	-54.1 (-97.2 to 522.8)
Whooping cough	2.4 (1.8 to 3.0)	0.1 (0.1 to 0.1)	-95.8 (-96.6 to -94.9)	-96.3 (-97.0 to -95.4)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.0)	-95.8 (-97.1 to -94.2)	-96.3 (-97.4 to -94.8)
Tetanus	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	59.6 (-78.6 to -19.7)	-74.4 (-86.5 to -48.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.9 (-74.3 to -15.9)	-69.8 (-82.9 to -47.9)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	7.6 (7.0 to 8.3)	10.7 (9.2 to 12.3)	40.3 (15.0 to 65.4)	-2.6 (-25.2 to 20.0)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	76.4 (11.8 to 160.1)	-4.1 (-41.2 to 42.7)
Neglected tropical diseases and malaria	-	-	-	-	37.2 (23.6 to 55.0)	45.5 (27.1 to 71.6)	21.7 (-5.3 to 55.9)	-22.8 (-40.3 to -2.4)
Malaria	66.1 (47.2 to 87.4)	108.2 (76.0 to 145.9)	61.1 (26.6 to 125.7)	9.2 (-13.3 to 55.2)	0.7 (0.4 to 1.0)	1.4 (0.9 to 2.1)	101.3 (65.6 to 156.6)	46.5 (20.8 to 85.1)
Chagas disease	157.5 (148.9 to 166.1)	257.2 (242.7 to 270.8)	63.3 (49.8 to 75.7)	2.9 (-10.7 to 4.4)	1.3 (0.8 to 1.8)	2.4 (1.6 to 3.4)	5.4 (72.8 to 112.0)	-3.4 (-13.3 to 7.2)
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.3)	512.8 (397.9 to 656.8)	295.1 (225.2 to 377.9)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.9 (-36.2 to 130.9)	-19.1 (-49.6 to 63.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.9 (-36.2 to 131.6)	-19.1 (-49.6 to 63.0)
Cutaneous and mucocutaneous leishmaniasis	2.1 (1.5 to 2.7)	12.8 (10.1 to 16.2)	517.9 (438.3 to 631.3)	296.5 (237.8 to 359.9)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.3)	514.9 (399.5 to 660.6)	296.1 (225.8 to 380.0)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	16.7 (8.3 to 26.2)	5.6 (2.6 to 12.0)	-68.1 (-85.8 to -16.6)	-80.7 (-91.2 to -53.0)	4.7 (2.1 to 8.2)	1.7 (0.7 to 3.8)	-64.5 (-84.4 to -4.7)	-78.3 (-90.4 to -44.6)
Cystic echinococcosis	0.3 (0.3 to 0.4)	0.4 (0.3 to 0.4)	9.0 (-2.4 to 16.0)	-44.5 (-49.8 to -41.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	12.3 (-7.1 to 35.3)	-42.1 (-53.1 to -28.2)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	1.3 (0.5 to 2.9)	9.7 (3.9 to 21.5)	655.9 (648.5 to 664.4)	391.2 (386.4 to 396.7)	0.2 (0.1 to 0.5)	1.6 (0.6 to 3.8)	653.9 (508.4 to 857.5)	389.8 (310.2 to 504.4)
Yellow fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-59.0 (-66.5 to -48.5)	-73.2 (-77.7 to -66.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-59.0 (-66.5 to -48.5)	-73.2 (-77.7 to -66.9)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-87.3 (-90.2 to -34.3)	-82.4 (-93.8 to -58.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.8 (-90.2 to -34.2)	92.4 (-93.8 to -58.6)
Intestinal nematode infections	-	-	-	-	18.3 (9.4 to 30.8)	19.1 (8.8 to 34.5)	3.7 (-29.0 to 52.4)	-32.0 (-55.1 to 2.4)
Ascariasis	4,015.1 (3,293.7 to 4,888.2)	5,278.1 (3,668.4 to 7,485.2)	30.0 (-13.4 to 95.0)	-16.8 (-45.4 to 27.3)	8.9 (4.2 to 15.4)	9.6 (4.6 to 18.1)	6.5 (-36.4 to 77.7)	-30.3 (-60.9 to 23.6)
Trichuriasis	3,360.4 (2,651.5 to 4,232.4)	4,671.9 (3,371.1 to 6,403.2)	37.7 (-7.0 to 105.4)	-12.6 (-42.8 to 33.3)	6.5 (3.0 to 12.6)	7.8 (3.5 to 16.2)	18.1 (-39.7 to 133.4)	-22.5 (-62.8 to 58.3)
Hookworm disease	689.7 (515.5 to 919.6)	529.7 (332.9 to 830.9)	-27.0 (-57.0 to 29.1)	-45.9 (-73.7 to -15.6)	2.9 (1.6 to 4.8)	2.8 (1.0 to 3.0)	1.8 (-59.7 to -7.8)	-58.8 (-75.0 to -36.7)
Food-borne trematodiasis	93.2 (59.9 to 128.9)	186.0 (117.2 to 267.2)	99.3 (58.0 to 158.5)	2.7 (-17.5 to 33.1)	6.8 (1.6 to 15.4)	13.5 (1.1 to 31.1)	97.9 (51.8 to 156.4)	4.6 (-18.0 to 36.8)
Other neglected tropical diseases	137.3 (100.9 to 174.3)	152.5 (146.0 to 159.7)	10.3 (-12.7 to 49.6)	-12.5 (-30.1 to 16.9)	5.2 (3.0 to 7.6)	5.6 (3.7 to 8.2)	6.1 (-4.9 to 63.6)	-13.8 (-22.6 to 32.7)
Maternal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	16.1 (-1.1 to 38.0)	-26.8 (-37.7 to -12.9)
Maternal hemorrhage	0.6 (0.5 to 0.8)	0.6 (0.4 to 0.7)	-5.9 (-36.6 to 20.6)	-41.6 (-61.0 to -25.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.9 (-18.0 to 119.3)	-20.3 (-48.1 to 42.6)
Maternal sepsis and other maternal infections	0.9 (0.6 to 1.3)	0.9 (0.6 to 1.3)	0.0 (-17.6 to 22.4)	-43.8 (-55.4 to -32.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.9 (-22.7 to 11.4)	-45.4 (-54.5 to -33.3)
Maternal hypertensive disorders	1.6 (1.1 to 2.3)	1.9 (1.3 to 2.7)	17.2 (8.2 to 26.0)	-26.1 (-32.1 to -20.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	16.0 (8.3 to 48.7)	-26.9 (-41.5 to 6.4)
Obstructed labor	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	23.4 (12.5 to 35.1)	-20.2 (-27.0 to -13.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.5 (-19.1 to 98.4)	-17.3 (-45.9 to 21.4)
Complications of abortion	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	18.3 (9.2 to 29.6)	-25.3 (-30.8 to -18.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.9 (-28.7 to 124.1)	-23.2 (-54.0 to 38.3)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.0 (-27.4 to 58.2)	-34.8 (-54.2 to -9.9)
Neonatal disorders	-	-	-	-	8.2 (5.4 to 11.4)	21.3 (14.9 to 28.7)	158.3 (90.7 to 292.9)	77.8 (31.6 to 170.9)
Preterm birth complications	28.8 (20.4 to 40.6)	88.9 (64.5 to 123.0)	208.1 (158.1 to 275.2)	102.7 (69.7 to 146.3)	2.9 (1.9 to 4.1)	10.4 (7.1 to 14.5)	263.7 (163.1 to 406.8)	144.9 (102.9 to 239.2)
Neonatal encephalopathy due to birth asphyxia and trauma	25.8 (8.4 to 60.3)	33.3 (13.3 to 73.5)	30.3 (3.4 to 76.8)	-14.3 (-37.1 to 18.0)	2.1 (1.2 to 3.3)	3.9 (2.4 to 6.0)	99.7 (17.4 to 228.7)	35.1 (-17.2 to 131.7)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	101.2 (77.0 to 119.4)	86.2 (63.8 to 103.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	100.5 (67.8 to 130.2)	85.6 (55.3 to 113.1)
Hemolytic disease and other neonatal jaundice	5.5 (2.6 to 9.9)	11.9 (4.9 to 21.2)	102.1 (-11.1 to 574.6)	38.5 (-38.8 to 366.3)	2.1 (0.9 to 3.8)	4.6 (1.8 to 8.9)	109.2 (-7.5 to 636.2)	43.7 (-36.7 to 408.1)
Other neonatal disorders	-	-	-	-	1.1 (0.6 to 1.8)	2.3 (1.4 to 3.4)	105.9 (25.4 to 223.2)	41.6 (-13.4 to 122.5)
Nutritional deficiencies	-	-	-	-	78.1 (52.0 to 111.8)	89.1 (59.3 to 128.6)	14.1 (10.6 to 16.6)	-16.4 (-18.6 to -14.7)
Protein-energy malnutrition	14.8 (10.1 to 22.1)	14.9 (9.7 to 22.4)	0.5 (-43.4 to 81.2)	-24.5 (-53.8 to 25.8)	1.8 (1.0 to 3.0)	1.8 (1.0 to 3.0)	0.9 (-4.1 to 82.8)	22.7 (-5.4 to 31.5)
Iodine deficiency	2.3 (1.7 to 3.0)	2.3 (1.7 to 3.1)	-3.7 (-34.3 to 46.5)	-42.3 (-60.9 to -12.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-3.6 (-34.7 to 47.1)	-42.3 (-61.0 to -10.8)
Vitamin A deficiency	4.0 (2.9 to 5.0)	2.6 (1.9 to 3.3)	-33.0 (-41.0 to -26.6)	-51.4 (-57.3 to -46.7)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-34.0 (-45.0 to -21.9)	-53.3 (-60.8 to -45.4)

Appendix Table G.4 - Ecuador prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.4 (91.2 to 102.4)	96.4 (-7.0 to -1.7)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.7 (84.5 to 97.8)	-9.9 (-12.6 to -6.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.6 (84.5 to 97.7)	-10.0 (-12.7 to -6.6)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	99.1 (92.3 to 107.3)	-1.7 (-5.0 to 2.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.8 (91.9 to 106.7)	-1.8 (-5.2 to 2.0)
Asthma	460.7 (406.1 to 546.1)	774.4 (698.8 to 852.7)	69.3 (41.8 to 97.3)	3.1 (-11.0 to 18.2)	20.5 (13.3 to 30.4)	34.4 (22.2 to 49.9)	69.4 (40.8 to 98.2)	3.8 (-10.7 to 19.2)
Interstitial lung disease and pulmonary sarcoidosis	0.3 (0.2 to 0.3)	0.9 (0.9 to 1.0)	238.7 (168.9 to 348.8)	55.0 (21.1 to 116.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	227.7 (152.8 to 333.8)	50.1 (13.0 to 110.6)
Other chronic respiratory diseases	-	-	-	-	2.9 (1.7 to 4.6)	2.3 (1.3 to 3.9)	-26.5 (-50.2 to 66.7)	-63.8 (-75.7 to -16.1)
Cirrhosis	-	-	-	-	0.4 (0.2 to 0.5)	0.7 (0.5 to 1.0)	183.2 (78.0 to 330.0)	8.6 (-3.7 to 21.8)
Cirrhosis due to hepatitis B	0.4 (0.2 to 0.5)	0.7 (0.4 to 0.9)	95.6 (27.9 to 206.7)	0.7 (-34.8 to 58.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	92.4 (19.2 to 211.1)	0.2 (-40.6 to 64.7)
Cirrhosis due to hepatitis C	0.4 (0.2 to 0.5)	1.4 (1.0 to 1.8)	280.9 (120.7 to 560.1)	98.3 (12.1 to 251.3)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	274.2 (114.5 to 577.8)	95.9 (11.7 to 264.9)
Cirrhosis due to alcohol use	0.8 (0.6 to 0.9)	1.1 (0.8 to 1.3)	38.8 (5.9 to 87.1)	-32.5 (-48.3 to -9.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	38.1 (-2.2 to 95.2)	-32.6 (-52.4 to -5.7)
Cirrhosis due to other causes	0.6 (0.5 to 0.7)	1.2 (1.0 to 1.4)	90.3 (33.9 to 149.6)	20.3 (-20.3 to 65.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	84.2 (21.0 to 184.7)	17.5 (-25.9 to 83.2)
Digestive diseases	-	-	-	-	6.8 (4.8 to 9.2)	13.4 (9.5 to 17.7)	96.3 (80.7 to 112.8)	-10.2 (-17.3 to -2.7)
Peptic ulcer disease	56.2 (52.9 to 59.8)	37.2 (35.8 to 38.6)	-33.7 (-38.7 to -28.9)	-71.6 (-73.7 to -49.6)	2.1 (1.4 to 3.0)	1.5 (1.0 to 2.1)	-30.3 (-36.2 to -23.1)	-69.8 (-71.9 to -66.8)
Gastritis and duodenitis	15.5 (14.2 to 16.9)	35.2 (33.0 to 37.3)	127.6 (105.5 to 151.2)	17.3 (7.3 to 29.8)	0.8 (0.5 to 1.1)	1.6 (1.1 to 2.3)	110.1 (71.6 to 148.0)	6.1 (-9.2 to 21.7)
Appendicitis	0.4 (0.4 to 0.5)	1.0 (1.0 to 1.1)	158.6 (127.5 to 189.8)	64.9 (46.3 to 83.8)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	150.0 (77.3 to 283.4)	60.1 (17.6 to 123.1)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	104.5 (19.8 to 168.9)	24.4 (-9.3 to 51.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	106.6 (13.8 to 191.7)	22.6 (-14.6 to 62.3)
Inguinal, femoral, and abdominal hernia	44.6 (39.7 to 50.8)	80.6 (73.6 to 88.3)	81.2 (53.4 to 112.7)	-16.5 (-28.6 to -3.5)	0.5 (0.2 to 0.9)	0.8 (0.4 to 1.5)	81.1 (51.9 to 113.2)	-15.5 (-27.5 to -2.1)
Inflammatory bowel disease	8.6 (8.3 to 9.0)	21.4 (20.5 to 22.2)	147.1 (134.4 to 161.4)	28.3 (21.5 to 35.3)	1.8 (1.3 to 2.5)	4.6 (3.1 to 6.2)	147.0 (126.2 to 169.9)	28.8 (18.8 to 39.5)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.8 (52.7 to 190.7)	-6.1 (-32.2 to 36.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.8 (52.4 to 190.7)	-6.1 (-32.2 to 36.5)
Gallbladder and biliary diseases	10.1 (8.4 to 11.6)	24.1 (22.4 to 25.9)	136.4 (103.1 to 191.9)	1.1 (-3.8 to 32.4)	1.1 (0.7 to 1.5)	2.6 (1.8 to 3.5)	137.8 (101.0 to 195.3)	11.5 (3.8 to 34.3)
Pancreatitis	0.6 (0.6 to 0.6)	2.1 (2.0 to 2.1)	230.6 (215.3 to 247.8)	74.2 (66.2 to 83.1)	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.8)	226.7 (162.6 to 308.8)	73.7 (42.0 to 114.1)
Other digestive diseases	-	-	-	-	0.2 (0.1 to 0.3)	1.3 (0.9 to 1.8)	610.7 (271.2 to 808.7)	224.8 (74.2 to 317.0)
Neurological disorders	-	-	-	-	63.3 (42.2 to 86.3)	116.5 (79.4 to 160.9)	84.3 (57.0 to 115.4)	4.3 (-9.0 to 21.6)
Alzheimer disease and other dementias	31.6 (28.2 to 35.0)	80.4 (70.3 to 91.3)	154.4 (115.5 to 199.5)	-0.3 (-15.7 to 17.9)	4.5 (3.3 to 5.8)	11.7 (8.5 to 15.3)	159.5 (118.9 to 205.0)	0.2 (-15.4 to 18.5)
Parkinson disease	1.9 (1.6 to 2.2)	4.5 (3.8 to 5.1)	136.4 (125.1 to 147.6)	0.3 (-4.1 to 4.9)	0.2 (0.1 to 0.3)	0.5 (0.4 to 0.7)	136.2 (108.5 to 169.3)	0.9 (-10.8 to 14.4)
Epilepsy	51.8 (35.3 to 70.5)	75.6 (51.0 to 102.6)	45.0 (-11.9 to 136.8)	-8.7 (-44.0 to 49.0)	16.0 (9.4 to 24.1)	26.0 (14.9 to 39.7)	62.1 (-3.3 to 168.2)	2.5 (-38.5 to 69.5)
Multiple sclerosis	0.5 (0.4 to 0.5)	1.6 (1.5 to 1.8)	252.9 (219.0 to 295.3)	85.9 (67.9 to 108.1)	0.2 (0.1 to 0.2)	0.6 (0.4 to 0.7)	239.6 (186.8 to 303.5)	78.5 (50.4 to 113.5)
Migraine	938.6 (824.1 to 1,040.0)	1,584.5 (1,354.4 to 1,861.5)	68.4 (38.2 to 106.3)	0.2 (-17.6 to 22.9)	32.4 (19.2 to 48.3)	4.4 (3.9 to 83.2)	68.0 (37.5 to 107.6)	-0.1 (-17.5 to 23.2)
Tension-type headache	1,511.5 (1,337.3 to 1,688.0)	2,766.2 (2,542.0 to 3,003.1)	83.0 (58.0 to 110.9)	7.2 (-5.8 to 24.4)	2.3 (1.1 to 4.0)	4.2 (2.0 to 7.5)	82.9 (58.5 to 113.2)	7.4 (-6.0 to 25.9)
Medication overuse headache	40.1 (26.4 to 54.5)	104.7 (66.7 to 145.3)	160.7 (94.6 to 250.1)	41.0 (4.9 to 93.2)	6.3 (3.5 to 10.1)	16.5 (8.9 to 26.0)	159.4 (93.4 to 251.4)	41.2 (5.9 to 94.2)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.8 (21.3 to 131.1)	0.7 (-25.9 to 41.7)	1.4 (0.9 to 1.9)	2.5 (1.7 to 3.4)	81.1 (32.8 to 146.1)	-29.3 (-48.0 to -3.4)
Mental and substance use disorders	-	-	-	-	235.4 (167.3 to 311.9)	396.1 (282.3 to 523.5)	68.3 (63.6 to 72.9)	0.6 (-1.5 to 2.9)
Schizophrenia	23.2 (21.2 to 25.0)	43.0 (39.5 to 46.4)	84.8 (76.9 to 93.6)	-0.7 (-4.6 to 3.4)	15.0 (11.1 to 18.3)	27.9 (20.5 to 33.6)	85.2 (73.6 to 97.3)	-0.3 (-6.1 to 6.1)
Alcohol use disorders	108.2 (99.0 to 117.3)	234.5 (216.9 to 253.0)	116.5 (105.2 to 127.7)	27.4 (21.4 to 33.4)	10.8 (7.2 to 15.3)	23.5 (15.7 to 33.5)	117.5 (104.3 to 130.9)	28.3 (21.0 to 35.6)
Drug use disorders	-	-	-	-	10.9 (7.2 to 15.0)	18.8 (12.3 to 26.2)	71.9 (45.9 to 100.4)	4.7 (-9.1 to 21.1)
Opioid use disorders	6.1 (3.0 to 9.9)	12.1 (5.8 to 20.2)	98.1 (74.3 to 117.5)	4.8 (-7.5 to 14.9)	2.5 (1.2 to 4.5)	5.0 (2.3 to 8.8)	99.4 (67.1 to 127.5)	5.5 (-10.7 to 20.4)
Cocaine use disorders	7.9 (7.9 to 13.3)	20.5 (16.7 to 25.3)	93.2 (45.7 to 164.9)	1.5 (-10.4 to 54.2)	2.8 (0.9 to 2.3)	5.8 (1.7 to 4.3)	94.3 (44.3 to 173.7)	15.5 (-12.2 to 59.2)
Amphetamine use disorders	18.9 (17.5 to 20.4)	27.9 (26.1 to 30.0)	47.2 (32.5 to 64.5)	-3.1 (-12.5 to 7.7)	2.5 (1.5 to 3.7)	3.7 (2.3 to 5.4)	47.4 (25.3 to 71.0)	-2.7 (-17.3 to 12.2)
Cannabis use disorders	14.9 (11.7 to 17.7)	22.8 (18.2 to 26.9)	53.1 (50.2 to 56.4)	-0.0 (-0.1 to 0.0)	0.4 (0.3 to 0.7)	0.7 (0.4 to 1.0)	53.7 (30.7 to 82.7)	0.3 (-13.3 to 18.0)
Other drug use disorders	-	-	-	-	4.0 (2.5 to 5.9)	6.6 (4.1 to 9.7)	65.2 (19.0 to 124.7)	5.1 (-23.3 to 42.2)
Depressive disorders	-	-	-	-	82.6 (54.0 to 116.4)	141.7 (91.6 to 200.1)	71.7 (61.0 to 82.4)	0.4 (-5.3 to 5.2)
Major depressive disorder	348.6 (277.8 to 411.8)	593.4 (462.3 to 706.2)	70.0 (58.5 to 80.4)	-0.9 (-6.1 to 5.0)	72.3 (46.3 to 103.2)	122.5 (77.7 to 175.5)	69.4 (57.4 to 81.6)	-0.6 (-6.5 to 5.8)
Dysthymia	105.8 (87.3 to 124.3)	198.5 (165.9 to 231.7)	87.2 (81.8 to 94.5)	0.1 (0.0 to 0.1)	10.3 (6.7 to 14.8)	19.2 (12.4 to 28.0)	87.0 (78.8 to 95.9)	0.4 (-2.1 to 2.8)
Bipolar disorder	67.6 (56.4 to 78.2)	116.7 (98.7 to 133.2)	72.7 (63.5 to 82.7)	-1.4 (-5.5 to 3.6)	13.9 (8.6 to 21.2)	23.9 (14.7 to 36.1)	72.1 (60.8 to 84.9)	-1.2 (-6.7 to 5.4)
Anxiety disorders	551.6 (369.0 to 719.1)	930.6 (635.0 to 1,188.8)	68.5 (60.6 to 78.3)	0.1 (0.1 to 0.2)	51.1 (30.0 to 77.4)	85.9 (51.9 to 128.2)	68.2 (59.2 to 79.4)	0.4 (-1.5 to 2.4)
Eating disorders	-	-	-	-	3.2 (1.9 to 5.2)	4.9 (2.8 to 7.8)	51.1 (38.7 to 64.1)	1.3 (-6.5 to 9.1)
Anorexia nervosa	2.3 (1.8 to 3.0)	3.6 (2.7 to 4.7)	53.6 (36.3 to 74.8)	4.9 (-6.6 to 18.4)	0.5 (0.3 to 0.8)	0.8 (0.5 to 1.2)	54.7 (22.4 to 93.0)	5.5 (-16.4 to 31.4)
Bulimia nervosa	12.9 (8.4 to 18.7)	19.4 (12.5 to 28.2)	49.7 (46.3 to 53.9)	0.1 (0.0 to 0.2)	2.7 (1.5 to 4.6)	4.1 (2.3 to 6.8)	50.6 (37.6 to 63.5)	0.6 (-7.9 to 8.9)
Autistic spectrum disorders	-	-	-	-	12.1 (8.3 to 16.4)	18.5 (12.9 to 25.0)	53.9 (48.2 to 59.1)	0.2 (-2.9 to 3.6)
Autism	30.4 (28.8 to 32.0)	47.0 (44.6 to 49.4)	54.1 (53.3 to 55.0)	-0.1 (-0.1 to -0.1)	7.6 (5.0 to 10.4)	11.6 (7.8 to 15.9)	53.6 (45.9 to 61.7)	0.2 (-4.5 to 5.0)
Asperger syndrome	44.7 (41.9 to 47.3)	68.6 (64.2 to 72.8)	53.2 (52.1 to 54.3)	-0.1 (-0.1 to -0.1)	4.5 (3.1 to 6.3)	6.9 (4.7 to 9.6)	53.2 (46.6 to 60.1)	0.2 (-3.5 to 4.4)
Attention-deficit/hyperactivity disorder	87.7 (80.4 to 93.5)	115.8 (106.0 to 123.5)	31.8 (31.5 to 32.0)	0.2 (0.2 to 0.2)	1.1 (0.6 to 1.6)	1.4 (0.8 to 2.1)	32.1 (23.0 to 41.1)	0.4 (-6.4 to 7.4)
Conduct disorder	117.1 (109.3 to 124.8)	154.3 (144.0 to 164.8)	31.6 (31.3 to 32.0)	0.2 (0.2 to 0.2)	14.1 (8.8 to 20.4)	18.7 (11.7 to 27.2)	31.1 (26.7 to 37.6)	0.7 (-3.6 to 4.7)
Idiopathic intellectual disability	202.3 (163.0 to 246.9)	241.2 (192.8 to 300.8)	18.9 (3.4 to 36.4)	-22.5 (-32.4 to -11.0)	11.8 (6.6 to 14.4)	11.8 (7.6 to 17.1)	18.5 (3.4 to 35.9)	-22.4 (-32.2 to -11.0)
Other mental and substance use disorders	140.1 (130.9 to 148.9)	254.3 (238.9 to 269.1)	81.2 (79.1 to 83.3)	-0.1 (-0.1 to -0.0)	10.5 (7.1 to 14.2)	19.1 (13.1 to 25.8)	80.9 (73.7 to 88.8)	0.3 (-3.4 to 4.0)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	44.6 (30.7 to 60.7)	86.3 (59.6 to 119.2)	92.9 (80.6 to 109.9)	9.9 (2.4 to 19.9)
Diabetes mellitus	92.6 (73.7 to 113.2)	248.7 (194.9 to 321.5)	266.8 (105.0 to 258.2)	38.7 (5.1 to 95.2)	7.0 (4.5 to 10.2)	19.1 (12.4 to 29.0)	170.1 (106.5 to 267.7)	33.2 (0.6 to 85.3)
Acute glomerulonephritis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-33.0 (-12.7 to -1.9)	-0.0 (-36.6 to -29.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-12.8 to -1.8)	0.0 (-36.6 to -29.9)
Chronic kidney disease	-	-	-	-	12.6 (8.9 to 17.0)	23.5 (16.5 to 31.2)	86.3 (66.1 to 119.1)	4.1 (-6.6 to 22.3)
Chronic kidney disease due to diabetes mellitus	222.1 (159.3 to 329.6)	452.3 (303.1 to 682.3)	103.3 (61.4 to 144.3)	0.1 (-20.4 to 19.7)	2.7 (1.9 to 3.8)	5.5 (3.7 to 7.3)	105.3 (56.7 to 148.0)	3.0 (-21.7 to 23.5)
Chronic kidney disease due to hypertension	165.4 (105.2 to 255.9)	308.7 (207.0 to 447.9)	86.6 (40.1 to 153.3)	13.8 (-8.0 to 51.9)	3.5 (2.5 to 4.8)	6.6 (4.6 to 9.0)	87.4 (47.4 to 124.4)	4.1 (-18.0 to 26.3)
Chronic kidney disease due to glomerulonephritis	285.5 (179.3 to 411.8)	489.1 (316.4 to 739.5)	74.2 (19.6 to 124.8)	4.0 (-33.0 to 25.1)	2.3 (1.5 to 3.2)	4.0 (2.6 to 5.6)	76.5 (30.7 to 133.9)	8.5 (-22.6 to 42.2)
Chronic kidney disease due to other causes	320.1 (216.0 to 470.4)	546.0 (391.5 to 777.4)	71.9 (33.9 to 119.3)	0.4 (-26.3 to 28.6)	0.4 (2.8 to 5.6)	7.4 (5.1 to 10.1)	82.3 (43.8 to 137.4)	6.2 (-18.0 to 38.6)
Urinary diseases and male infertility	-	-	-	-	3.2 (2.1 to 4.6)	8.7 (5.7 to 12.3)	168.7 (147.5 to 186.8)	18.4 (9.3 to 25.8)

Appendix Table G.4 - Ecuador prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Renal diseases								
Interstitial nephritis and urinary tract infections	2.3 (2.1 to 2.4)	5.8 (5.5 to 5.9)	153.5 (133.2 to 175.9)	1.0 (-0.5 to 2.5)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	152.3 (105.8 to 209.5)	17.2 (24.0 to 80.1)
Urolithiasis	41.5 (29.1 to 57.1)	103.8 (59.5 to 169.3)	133.2 (76.8 to 220.7)	8.3 (-20.0 to 44.6)	0.2 (0.1 to 0.3)	0.7 (0.3 to 1.2)	170.0 (108.8 to 260.6)	31.0 (0.2 to 72.2)
Benign prostatic hyperplasia	73.4 (69.1 to 79.0)	199.6 (190.7 to 206.1)	173.2 (151.6 to 188.2)	2.6 (-6.9 to 22.1)	1.7 (1.7 to 3.8)	7.2 (4.7 to 10.2)	173.8 (151.8 to 190.0)	16.2 (7.1 to 23.5)
Male infertility due to other causes	28.3 (21.2 to 36.2)	44.7 (30.5 to 57.7)	57.9 (4.8 to 134.1)	-6.5 (-36.8 to 38.7)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.6)	55.6 (0.5 to 140.9)	-6.3 (-40.0 to 43.0)
Other urinary diseases	-	-	-	-	-	-	-	-
Gynecological diseases								
Uterine fibroids	163.4 (147.0 to 177.9)	329.3 (298.2 to 357.2)	101.2 (99.3 to 103.4)	1.0 (-1.0 to 1.0)	2.8 (1.7 to 4.5)	4.9 (2.8 to 8.1)	75.7 (62.0 to 87.6)	-7.5 (-14.3 to -2.2)
Polycystic ovarian syndrome	177.9 (154.8 to 201.6)	320.9 (282.9 to 359.6)	80.5 (51.3 to 115.9)	2.4 (-12.9 to 21.2)	1.7 (0.8 to 3.2)	3.1 (1.5 to 5.7)	80.0 (51.9 to 114.0)	2.2 (-12.6 to 20.8)
Female infertility due to other causes	17.2 (9.8 to 26.0)	28.2 (15.1 to 43.6)	62.3 (-14.2 to 219.2)	-1.3 (-5.9 to 73.5)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	62.0 (-14.5 to 227.4)	-11.6 (53.3 to 74.7)
Endometriosis	16.8 (13.9 to 19.6)	31.6 (27.1 to 36.3)	88.4 (49.3 to 135.7)	5.8 (-15.2 to 31.6)	1.6 (1.0 to 2.2)	2.9 (1.9 to 4.2)	89.5 (45.6 to 140.3)	6.4 (-17.4 to 34.1)
Genital prolapse	460.7 (387.9 to 529.8)	895.1 (766.1 to 1,029.2)	93.3 (56.6 to 149.2)	1.2 (-16.8 to 27.8)	1.5 (0.7 to 2.8)	2.9 (1.3 to 5.4)	93.3 (55.9 to 149.0)	1.5 (-16.9 to 27.3)
Premenstrual syndrome	437.9 (327.1 to 549.8)	790.5 (620.4 to 1,013.8)	79.8 (32.0 to 152.8)	6.9 (-22.3 to 50.8)	3.7 (2.2 to 5.8)	6.7 (3.9 to 10.4)	80.1 (31.2 to 155.5)	7.1 (-23.2 to 52.6)
Other gynecological diseases	36.8 (31.7 to 42.2)	53.6 (48.4 to 59.3)	45.3 (26.4 to 69.3)	-13.3 (-24.5 to -0.2)	1.1 (0.7 to 1.6)	1.6 (1.0 to 2.3)	40.3 (21.0 to 82.5)	-16.1 (-27.7 to 8.7)
Hemoglobinopathies and hemolytic anemias								
Thalassemias	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.4)	24.1 (4.3 to 39.7)	-4.5 (-19.8 to 7.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	24.8 (4.6 to 44.3)	-3.4 (-19.1 to 11.1)
Thalassemia trait	129.5 (120.9 to 138.8)	201.9 (191.2 to 215.1)	55.5 (49.9 to 62.2)	3.2 (-3.5 to 4.7)	3.2 (2.1 to 4.6)	5.2 (3.4 to 7.5)	64.6 (48.4 to 83.5)	13.4 (3.0 to 26.3)
Sickle cell disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	39.7 (31.0 to 49.5)	-1.9 (-8.0 to 4.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.0 (30.3 to 54.5)	-1.9 (-9.7 to 7.3)
Sickle cell trait	84.7 (75.2 to 94.5)	117.9 (105.4 to 128.5)	38.3 (28.3 to 47.6)	0.4 (-12.3 to -4.8)	0.7 (0.2 to 0.6)	0.7 (0.4 to 1.0)	65.7 (15.5 to 158.8)	18.9 (-15.2 to 76.6)
G6PD deficiency	130.1 (118.9 to 141.3)	180.8 (164.0 to 196.6)	39.0 (22.4 to 57.1)	-10.3 (-21.0 to 1.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.1 (-1.3 to 91.7)	-10.7 (-30.0 to 33.1)
G6PD trait	1,048.4 (1,011.5 to 1,086.5)	1,641.6 (1,580.0 to 1,701.7)	56.4 (48.1 to 64.3)	0.3 (-5.0 to 5.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-55.4 (-82.4 to 23.9)	-68.7 (-87.2 to -8.1)
Other hemoglobinopathies and hemolytic anemias	76.4 (68.1 to 84.4)	89.2 (82.1 to 96.9)	16.3 (4.2 to 30.7)	-19.7 (-27.6 to -10.6)	2.5 (1.5 to 3.6)	2.8 (1.8 to 4.0)	12.7 (8.1 to 36.9)	-14.5 (-29.7 to 3.7)
Endocrine, metabolic, blood, and immune disorders								
Rheumatoid arthritis	28.5 (27.3 to 29.8)	51.7 (49.7 to 53.6)	81.5 (71.2 to 92.0)	-10.8 (-16.4 to -5.4)	6.7 (4.9 to 8.9)	12.1 (8.7 to 16.0)	80.2 (67.1 to 93.5)	-10.6 (-17.1 to -4.4)
Osteoarthritis	234.3 (225.4 to 243.0)	545.2 (523.4 to 567.2)	132.2 (119.9 to 146.2)	1.4 (-3.8 to 7.3)	14.4 (10.0 to 19.4)	33.4 (23.4 to 45.5)	131.8 (119.5 to 146.2)	1.7 (-3.7 to 7.8)
Low back and neck pain	-	-	-	-	-	-	-	-
Low back pain	520.0 (490.7 to 553.0)	962.3 (908.0 to 1,017.1)	84.6 (70.6 to 101.2)	-0.8 (-8.0 to 7.8)	58.7 (40.1 to 81.1)	108.2 (72.7 to 150.6)	84.2 (69.5 to 101.2)	-0.3 (-8.1 to 8.4)
Neck pain	265.0 (217.1 to 311.3)	517.1 (449.8 to 584.2)	93.6 (58.9 to 145.4)	2.3 (-16.0 to 25.9)	26.3 (17.6 to 37.8)	51.1 (34.9 to 71.2)	93.4 (57.2 to 145.5)	2.6 (-15.7 to 26.5)
Gout	3.0 (2.7 to 3.3)	6.6 (6.0 to 7.2)	119.1 (92.8 to 147.8)	0.7 (-11.4 to 13.9)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	0.7 (71.3 to 381.2)	0.7 (-20.7 to 29.6)
Other musculoskeletal disorders	208.4 (171.6 to 249.8)	517.5 (411.7 to 638.4)	147.6 (125.0 to 169.3)	-18.2 (8.3 to 27.3)	19.1 (12.5 to 27.7)	47.4 (30.9 to 69.1)	147.3 (124.4 to 170.8)	18.8 (8.1 to 28.5)
Other non-communicable diseases								
Congenital anomalies	-	-	-	-	-	-	-	-
Neural tube defects	2.6 (2.3 to 2.9)	4.0 (3.5 to 4.8)	55.3 (31.8 to 94.9)	9.8 (-6.9 to 37.5)	0.8 (0.5 to 1.1)	1.3 (0.9 to 1.8)	62.9 (21.0 to 124.6)	16.0 (-11.8 to 60.4)
Congenital heart anomalies	39.1 (33.6 to 48.4)	89.2 (76.2 to 104.1)	129.3 (78.4 to 182.6)	57.7 (22.5 to 94.7)	1.4 (0.1 to 2.4)	3.1 (1.4 to 5.3)	132.0 (81.6 to 182.6)	61.9 (26.7 to 99.2)
Orofacial clefts	8.6 (6.9 to 10.5)	17.7 (15.2 to 20.5)	106.6 (59.7 to 162.0)	48.0 (14.4 to 89.0)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	75.1 (23.4 to 151.3)	24.8 (-11.0 to 76.6)
Down syndrome	13.3 (11.4 to 15.7)	24.9 (20.0 to 31.4)	85.9 (40.9 to 141.8)	20.7 (-8.7 to 57.4)	1.7 (1.2 to 2.2)	3.3 (2.3 to 4.6)	99.3 (49.3 to 159.9)	24.3 (-7.1 to 63.3)
Turner syndrome	0.3 (0.3 to 0.5)	0.6 (0.4 to 0.8)	68.8 (18.6 to 167.5)	13.1 (-20.5 to 79.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.9 (16.8 to 179.9)	13.5 (-23.3 to 83.5)
Klinefelter syndrome	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	49.7 (-3.5 to 88.3)	-2.2 (-37.0 to 29.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.2 (2.0 to 111.8)	-2.6 (-37.2 to 29.3)
Chromosomal unbalanced rearrangements	15.9 (13.7 to 20.0)	28.9 (25.0 to 34.2)	82.9 (33.6 to 122.4)	2.0 (-13.7 to 45.1)	3.8 (1.4 to 7.2)	3.8 (2.8 to 5.1)	22.3 (15.5 to 142.8)	0.2 (-10.2 to 51.2)
Other congenital anomalies	39.0 (32.4 to 45.3)	56.0 (47.1 to 63.2)	43.5 (29.4 to 59.8)	-9.6 (-18.3 to 0.7)	5.8 (3.9 to 7.9)	8.7 (5.9 to 11.9)	48.7 (26.4 to 81.5)	-2.1 (-16.6 to 19.2)
Skin and subcutaneous diseases								
Dermatitis	551.1 (462.9 to 639.8)	901.3 (751.4 to 1,044.5)	63.2 (59.1 to 68.3)	-0.0 (-0.0 to 0.0)	17.4 (11.2 to 25.3)	27.3 (17.6 to 40.0)	56.8 (50.4 to 64.2)	0.2 (-2.3 to 2.8)
Psoriasis	74.1 (64.8 to 83.4)	130.4 (113.8 to 147.3)	75.8 (72.5 to 79.7)	-0.0 (-0.0 to 0.0)	6.1 (4.1 to 8.5)	10.7 (7.3 to 14.9)	75.4 (64.1 to 86.1)	0.3 (-4.9 to 9.2)
Cellulitis	1.0 (0.8 to 1.1)	1.7 (1.4 to 2.0)	74.7 (56.0 to 93.2)	9.9 (-1.2 to 19.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	73.4 (40.2 to 109.6)	5.2 (-8.7 to 30.1)
Pyoderma	3.1 (2.6 to 3.7)	4.9 (4.1 to 6.0)	59.4 (51.8 to 68.6)	0.9 (-1.7 to 3.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	59.4 (35.0 to 83.0)	1.4 (-11.5 to 14.9)
Scabies	132.6 (111.3 to 157.6)	190.2 (163.1 to 219.6)	43.0 (12.1 to 84.9)	-3.8 (-24.6 to 24.0)	3.5 (1.9 to 5.7)	4.9 (2.8 to 8.2)	43.1 (11.7 to 85.3)	-3.5 (-24.4 to 24.0)
Fungal skin diseases	702.9 (530.8 to 928.0)	1,183.8 (910.1 to 1,558.9)	68.4 (60.2 to 77.0)	4.0 (-0.1 to 0.0)	6.7 (1.6 to 8.8)	6.7 (2.7 to 14.8)	68.2 (59.7 to 77.1)	0.2 (-0.2 to 1.1)
Viral skin diseases	261.4 (197.9 to 320.2)	367.4 (279.1 to 457.1)	40.4 (34.9 to 45.5)	0.1 (-1.8 to 1.8)	8.1 (4.7 to 12.9)	11.4 (6.4 to 18.2)	40.2 (33.4 to 46.6)	0.2 (-2.7 to 3.3)
Acne vulgaris	483.5 (401.6 to 560.7)	611.2 (511.8 to 730.2)	25.1 (-3.2 to 67.8)	-13.9 (-32.9 to 15.2)	5.3 (2.4 to 10.1)	6.6 (3.1 to 13.0)	25.0 (-3.2 to 68.5)	-14.0 (-33.0 to 15.8)
Alopecia areata	8.4 (7.6 to 9.3)	14.6 (13.4 to 15.9)	73.4 (51.9 to 94.9)	-0.1 (-12.3 to 12.6)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	72.5 (44.4 to 104.6)	0.5 (-15.8 to 17.2)
Pruritus	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	87.8 (42.3 to 141.2)	2.6 (-2.4 to 34.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.8 (42.0 to 141.3)	2.6 (-22.4 to 34.4)
Urticaria	98.0 (70.9 to 132.9)	151.2 (100.1 to 213.7)	53.3 (0.1 to 132.9)	-10.2 (-40.5 to 38.5)	5.9 (3.4 to 9.3)	9.0 (4.8 to 14.9)	50.9 (-0.7 to 134.1)	-10.1 (-40.5 to 39.3)
Decubitus ulcer	0.7 (0.6 to 1.0)	1.4 (1.1 to 1.6)	84.0 (32.1 to 149.8)	-17.0 (-44.9 to 26.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	84.3 (29.6 to 147.7)	-15.0 (-44.6 to 27.5)
Other skin and subcutaneous diseases	529.5 (357.2 to 773.8)	991.0 (640.0 to 1,533.5)	86.2 (69.5 to 103.9)	-2.7 (-6.8 to 2.6)	3.1 (1.4 to 6.5)	5.8 (2.5 to 12.4)	85.5 (68.8 to 103.4)	-2.5 (-6.5 to 3.1)
Sense organ diseases								
Glaucoma	11.0 (9.7 to 12.4)	18.2 (16.1 to 20.3)	65.4 (45.3 to 86.4)	-21.0 (-31.1 to -10.3)	0.8 (0.6 to 1.1)	1.4 (1.0 to 2.0)	75.4 (47.5 to 105.4)	0.3 (-33.9 to -6.0)
Cataract	61.0 (53.7 to 68.3)	110.2 (98.3 to 121.8)	80.3 (66.8 to 94.7)	-26.0 (-31.1 to -20.5)	3.8 (2.6 to 5.1)	7.0 (4.9 to 9.5)	86.2 (72.5 to 102.5)	-24.5 (-29.8 to -18.3)
Macular degeneration	12.0 (9.5 to 14.5)	31.9 (26.8 to 38.1)	164.6 (119.5 to 224.7)	17.1 (-3.8 to 46.5)	0.6 (0.4 to 0.9)	1.6 (1.1 to 2.3)	162.9 (116.9 to 223.1)	15.2 (-6.2 to 43.9)
Uncorrected refractive error	1,034.6 (950.4 to 1,079.8)	1,904.9 (1,782.0 to 2,019.6)	87.7 (72.5 to 102.8)	4.6 (-12.0 to 2.2)	15.3 (9.1 to 24.5)	26.5 (15.7 to 44.0)	79.4 (65.1 to 97.9)	-10.0 (-15.3 to -4.3)
Age-related and other hearing loss	1,136.2 (1,077.9 to 1,212.7)	2,122.2 (2,014.5 to 2,246.8)	86.4 (79.5 to 95.1)	-9.8 (-12.6 to -6.4)	35.2 (23.7 to 49.3)	67.9 (43.0 to 88.1)	79.7 (66.5 to 94.4)	-10.6 (-15.5 to -4.4)
Other vision loss	28.3 (25.5 to 31.5)	34.1 (30.5 to 37.8)	20.2 (11.4 to 28.5)	-33.6 (-38.2 to -29.4)	2.1 (1.5 to 2.9)	2.7 (1.9 to 3.7)	26.4 (14.1 to 39.1)	-3.9 (-39.8 to -27.7)
Other sense organ diseases	232.7 (220.4 to 244.9)	356.9 (340.4 to 373.6)	53.3 (42.6 to 64.4)	-0.4 (-6.7 to 6.3)	6.2 (3.8 to 9.2)	9.5 (5.8 to 14.1)	52.9 (41.1 to 65.2)	-0.1 (-6.8 to 7.4)
Oral disorders								
Deciduous caries	810.9 (784.0 to 837.1)	989.1 (960.0 to 1,019.3)	21.8 (16.7 to 27.2)	0.5 (-3.7 to 4.8)	0.5 (0.1 to 0.6)	0.4 (0.2 to 0.7)	22.1 (8.5 to 31.2)	0.7 (-6.9 to 8.3)
Permanent caries	3,948.7 (3,760.9 to 4,117.7)	6,383.8 (6,112.9 to 6,669.6)	61.1 (52.4 to 72.0)	1.8 (-3.8 to 8.2)	3.9 (1.8 to 7.7)	6.3 (2.9 to 12.2)	61.0 (51.7 to 72.0)	2.0 (-3.8 to 8.5)
Periodontal diseases	904.3 (860.8 to 948.7)	1,798.0 (1,703.3 to 1,893.6)	98.6 (84.6 to 111.8)	0.5 (-6.6 to 7.3)	6.0 (2.4 to 12.4)	11.8 (4.7 to 24.5)	98.5 (84.7 to 111.7)	0.6 (-6.5 to 7.5)

Appendix Table G.4 - Ecuador prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.								
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	438.8 (423.7 to 453.6)	901.3 (872.4 to 928.8)	105.1 (95.7 to 114.6)	-9.1 (-13.1 to -5.1)	12.2 (8.2 to 16.9)	24.9 (16.8 to 34.5)	104.6 (95.1 to 114.4)	-9.0 (-13.2 to -4.9)
Other oral disorders	156.9 (148.3 to 165.7)	267.4 (252.5 to 281.6)	70.2 (56.3 to 83.6)	-0.5 (-8.1 to 6.7)	4.6 (2.9 to 6.9)	7.9 (4.9 to 11.8)	69.7 (55.6 to 84.6)	-0.4 (-8.3 to 7.1)
Injuries	-	-	-	-	50.6 (38.6 to 65.3)	60.0 (44.1 to 80.2)	18.2 (8.6 to 28.1)	-37.1 (-41.9 to -31.7)
Transport injuries	-	-	-	-	16.4 (12.3 to 21.2)	18.3 (13.2 to 24.4)	11.4 (0.8 to 25.2)	-41.0 (-46.9 to -34.3)
Road injuries	-	-	-	-	15.6 (11.7 to 20.2)	16.6 (11.9 to 22.3)	6.0 (-6.0 to 19.1)	-34.8 (-49.5 to -37.4)
Pedestrian road injuries	-	-	-	-	6.9 (5.1 to 9.0)	6.2 (4.4 to 8.4)	-10.2 (-21.2 to 2.3)	-51.7 (-57.0 to -45.5)
Cyclist road injuries	-	-	-	-	1.1 (0.8 to 1.4)	1.3 (1.0 to 1.8)	25.0 (12.9 to 37.9)	-34.8 (-40.9 to -28.2)
Motorcyclist road injuries	-	-	-	-	1.7 (1.2 to 2.2)	1.6 (1.2 to 2.2)	-2.5 (-14.5 to 11.0)	-48.2 (-54.4 to -41.4)
Motor vehicle road injuries	-	-	-	-	4.3 (4.3 to 7.4)	7.1 (5.2 to 9.6)	24.9 (9.9 to 41.7)	-33.6 (-41.9 to -25.3)
Other road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-4.9 (-15.5 to 6.4)	-50.7 (-55.6 to -45.2)
Other transport injuries	-	-	-	-	0.7 (0.6 to 1.0)	1.7 (1.2 to 2.3)	126.2 (101.7 to 152.6)	16.1 (4.1 to 29.3)
Unintentional injuries	-	-	-	-	31.4 (23.8 to 40.5)	38.1 (28.1 to 51.0)	21.0 (12.3 to 29.1)	-35.6 (-39.9 to -31.4)
Falls	-	-	-	-	11.3 (8.5 to 14.5)	17.8 (13.0 to 23.8)	57.6 (42.0 to 73.9)	-26.2 (-33.5 to -18.1)
Drowning	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-7.2 (-18.6 to 7.1)	-47.8 (-53.8 to -40.6)
Fire, heat, and hot substances	-	-	-	-	1.3 (1.0 to 1.6)	1.0 (0.7 to 1.4)	-18.1 (-27.4 to -7.6)	-52.8 (-57.7 to -47.3)
Poisonings	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	10.0 (7.2 to 29.7)	-35.4 (-44.7 to -25.1)
Exposure to mechanical forces	-	-	-	-	14.7 (11.2 to 19.1)	10.6 (7.7 to 14.1)	-28.2 (-33.1 to -22.9)	-58.1 (-60.0 to -55.4)
Unintentional firearm injuries	-	-	-	-	0.8 (0.6 to 1.0)	0.9 (0.7 to 1.2)	17.8 (4.1 to 35.8)	33.6 (-41.1 to -24.1)
Unintentional suffocation	-	-	-	-	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.5)	38.6 (20.4 to 58.4)	-16.1 (-26.6 to -4.6)
Other exposure to mechanical forces	-	-	-	-	13.7 (10.3 to 17.8)	9.3 (6.8 to 12.6)	-32.1 (-36.7 to -27.0)	-60.3 (-62.7 to -57.7)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	119.9 (107.4 to 135.6)	16.4 (9.7 to 25.3)
Animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	97.2 (80.6 to 115.9)	7.3 (-1.1 to 16.0)
Venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	94.9 (72.6 to 119.7)	8.2 (-2.9 to 20.0)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	98.9 (81.2 to 119.6)	6.6 (-2.1 to 16.5)
Foreign body	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	26.1 (14.4 to 40.5)	-31.2 (-37.1 to -24.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	7.8 (5.9 to 25.1)	-40.3 (-47.4 to -31.5)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	56.2 (37.2 to 83.2)	-9.4 (-19.7 to 5.5)
Foreign body in other body part	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	46.8 (32.5 to 61.7)	-23.0 (-29.6 to -15.8)
Other unintentional injuries	-	-	-	-	3.2 (2.3 to 4.1)	7.3 (5.4 to 9.7)	131.1 (113.2 to 150.4)	8.6 (0.2 to 17.1)
Self-harm and interpersonal violence	-	-	-	-	2.3 (1.7 to 2.9)	2.8 (2.1 to 3.8)	24.3 (12.2 to 40.1)	-35.3 (-41.8 to -27.4)
Self-harm	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	39.3 (25.5 to 55.7)	-29.4 (-36.3 to -21.2)
Interpersonal violence	-	-	-	-	1.9 (1.4 to 2.4)	2.3 (1.6 to 3.0)	21.2 (8.5 to 37.2)	-36.6 (-42.9 to -28.6)
Assault by firearm	-	-	-	-	0.5 (0.3 to 0.6)	0.7 (0.5 to 1.0)	57.6 (43.1 to 72.9)	-19.1 (-26.1 to -11.4)
Assault by sharp object	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	31.6 (17.1 to 52.9)	-32.0 (-39.2 to -21.8)
Assault by other means	-	-	-	-	1.0 (0.7 to 1.2)	1.0 (0.7 to 1.3)	-0.6 (-12.6 to 13.5)	-47.4 (-53.6 to -40.0)
Forces of nature, war, and legal intervention	-	-	-	-	0.5 (0.2 to 1.1)	0.8 (0.4 to 1.3)	36.9 (-0.1 to 263.9)	33.4 (7.3 to 300.4)
Exposure to forces of nature	-	-	-	-	0.5 (0.2 to 1.1)	0.7 (0.4 to 1.3)	32.7 (-2.5 to 247.7)	28.9 (-9.6 to 282.0)
Collective violence and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.1)	-	-

Appendix Table G.4 – Egypt prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	63.6 (57.4 to 67.8)	-5.5 (-8.6 to -2.4)
Silicosis	0.3 (0.3 to 0.4)	0.5 (0.5 to 0.5)	48.8 (41.9 to 58.0)	-14.1 (-18.1 to -8.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	48.6 (41.4 to 58.2)	-14.2 (-18.5 to -8.6)
Asbestosis	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.3)	64.3 (57.4 to 70.7)	-5.0 (-8.8 to -1.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	65.0 (57.9 to 71.5)	-4.5 (-8.6 to -0.7)
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	-	-	-	-	-
Other pneumoconiosis	0.6 (0.5 to 0.6)	0.9 (0.9 to 1.0)	48.5 (62.3 to 75.3)	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	70.2 (63.7 to 77.0)	-0.3 (-4.4 to 3.7)
Asthma	811.6 (400.2 to 1,140.0)	1,275.2 (1,078.7 to 1,514.4)	51.9 (7.5 to 213.7)	-14.6 (-36.7 to 63.2)	35.1 (15.6 to 58.3)	55.7 (35.7 to 80.7)	53.3 (64 to 221.4)	-14.3 (-36.6 to 67.4)
Interstitial lung disease and pulmonary sarcoidosis	4.1 (3.1 to 5.0)	7.5 (6.1 to 9.0)	86.6 (35.1 to 154.6)	11.1 (-19.0 to 51.2)	0.5 (0.3 to 0.8)	1.0 (0.6 to 1.5)	86.0 (31.5 to 155.9)	9.6 (22.4 to 51.3)
Other chronic respiratory diseases	-	-	-	-	31.3 (17.0 to 51.3)	16.4 (10.1 to 25.5)	-48.7 (-63.2 to -15.2)	-69.6 (-78.3 to -48.7)
Cirrhosis	-	-	-	-	6.0 (4.1 to 8.1)	8.7 (6.1 to 12.0)	46.0 (33.6 to 59.7)	-3.5 (-11.0 to 4.0)
Cirrhosis due to hepatitis B	6.6 (4.3 to 9.2)	14.1 (8.7 to 18.8)	118.1 (12.9 to 251.9)	38.3 (-29.4 to 111.9)	1.1 (0.6 to 1.7)	2.3 (1.3 to 3.6)	115.1 (10.7 to 259.1)	36.2 (-31.2 to 119.4)
Cirrhosis due to hepatitis C	17.9 (14.2 to 21.2)	26.1 (20.0 to 32.0)	44.9 (6.0 to 96.8)	-6.5 (-30.2 to 26.4)	2.9 (1.9 to 4.4)	4.2 (2.7 to 6.1)	43.7 (34 to 97.7)	-7.2 (-32.2 to 27.0)
Cirrhosis due to alcohol use	4.4 (3.1 to 6.0)	4.5 (2.8 to 6.8)	0.0 (-36.9 to 63.8)	-41.0 (-63.2 to -4.4)	0.7 (0.4 to 1.1)	0.7 (0.4 to 1.2)	-0.7 (-39.5 to 71.2)	-11.1 (-63.6 to 41.1)
Cirrhosis due to other causes	7.2 (5.7 to 8.9)	8.8 (6.3 to 11.2)	22.9 (-16.0 to 64.6)	-1.9 (-33.8 to 35.2)	1.2 (0.7 to 1.9)	1.5 (0.9 to 2.3)	21.5 (-19.9 to 78.4)	-0.9 (-37.5 to 44.1)
Digestive diseases	-	-	-	-	39.3 (27.6 to 52.7)	56.0 (39.6 to 75.1)	43.0 (24.7 to 62.2)	-14.5 (-25.5 to -3.4)
Peptic ulcer disease	225.0 (160.3 to 287.8)	173.0 (135.5 to 210.6)	-23.1 (-38.3 to -4.3)	-53.6 (-62.9 to -42.1)	8.3 (5.4 to 12.3)	7.7 (5.0 to 11.5)	-6.9 (-28.1 to 13.4)	-43.3 (-55.3 to -31.8)
Gastritis and duodenitis	180.5 (149.4 to 209.5)	152.8 (131.2 to 173.9)	-15.7 (-28.7 to 3.1)	-44.5 (-52.5 to -32.1)	8.2 (5.3 to 11.6)	7.1 (4.5 to 10.9)	-14.3 (-30.7 to 14.1)	-40.1 (-49.1 to -23.4)
Appendicitis	4.1 (3.2 to 5.1)	4.7 (3.6 to 5.9)	16.0 (-23.5 to 63.2)	-25.5 (-49.2 to 1.5)	1.2 (0.7 to 1.9)	1.4 (0.8 to 2.2)	14.8 (-28.8 to 85.8)	-25.0 (-51.6 to 15.7)
Paralytic ileus and intestinal obstruction	0.7 (0.6 to 0.8)	1.5 (0.8 to 3.1)	100.8 (18.0 to 373.7)	23.2 (-15.8 to 147.0)	0.2 (0.1 to 0.3)	0.5 (0.2 to 1.1)	101.7 (7.7 to 388.5)	24.5 (-19.7 to 162.2)
Inguinal, femoral, and abdominal hernia	230.1 (191.2 to 288.3)	325.3 (281.7 to 377.4)	42.3 (7.9 to 82.0)	-11.5 (-28.8 to 10.8)	2.4 (1.1 to 4.4)	3.4 (1.7 to 6.2)	41.6 (5.9 to 82.0)	-11.5 (-28.9 to 11.7)
Inflammatory bowel disease	42.6 (38.8 to 46.1)	107.9 (98.9 to 116.7)	152.3 (123.1 to 184.7)	49.4 (32.5 to 68.1)	9.0 (6.1 to 12.4)	22.9 (15.3 to 31.4)	153.3 (119.5 to 192.8)	50.1 (31.3 to 72.2)
Vascular digestive disorders	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	61.1 (20.5 to 137.1)	-4.5 (-32.1 to 51.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	60.6 (15.8 to 147.5)	-4.1 (-37.3 to 71.4)
Gallbladder and biliary diseases	21.5 (18.6 to 25.1)	34.8 (28.5 to 41.6)	61.7 (33.7 to 96.3)	3.3 (-20.4 to 31.4)	2.2 (1.5 to 3.1)	3.6 (2.3 to 5.2)	69.0 (28.8 to 99.9)	-3.9 (-21.5 to 22.0)
Pancreatitis	10.6 (10.0 to 11.2)	16.0 (15.0 to 17.1)	50.3 (38.2 to 64.6)	-9.5 (-16.6 to -1.3)	3.1 (2.1 to 4.3)	4.7 (3.1 to 6.4)	49.9 (25.8 to 78.8)	-9.5 (-22.4 to 6.5)
Other digestive diseases	-	-	-	-	4.4 (2.3 to 8.2)	4.6 (2.7 to 6.8)	43.5 (-52.9 to 91.7)	-14.3 (-72.0 to 15.3)
Neurological disorders	-	-	-	-	409.4 (275.6 to 566.6)	736.4 (486.3 to 1,011.0)	79.5 (45.2 to 122.4)	11.5 (-9.5 to 35.8)
Alzheimer disease and other dementias	245.1 (209.7 to 280.8)	441.3 (385.2 to 511.0)	79.2 (48.2 to 121.9)	-0.1 (-18.3 to 23.8)	33.7 (24.3 to 44.3)	61.4 (43.4 to 81.8)	80.9 (49.7 to 124.6)	0.6 (-18.4 to 24.9)
Parkinson disease	58.8 (50.6 to 67.5)	107.5 (93.4 to 121.6)	82.9 (71.2 to 94.4)	4.5 (-2.0 to 11.3)	6.9 (4.7 to 9.5)	12.5 (8.7 to 17.2)	82.2 (66.8 to 99.8)	4.5 (-4.1 to 14.1)
Epilepsy	269.2 (223.6 to 310.5)	408.4 (343.8 to 464.2)	51.7 (20.2 to 88.8)	3.8 (-17.3 to 28.6)	78.0 (52.5 to 108.6)	134.1 (89.6 to 180.4)	72.4 (33.5 to 120.0)	18.6 (-8.0 to 51.0)
Multiple sclerosis	7.1 (4.7 to 9.4)	21.7 (15.0 to 29.4)	206.3 (89.8 to 417.5)	76.7 (11.7 to 195.6)	2.4 (1.4 to 3.6)	7.2 (4.2 to 10.6)	199.1 (82.9 to 411.4)	73.4 (7.2 to 190.5)
Migraine	5,727.1 (4,151.1 to 7,191.3)	9,249.8 (6,568.5 to 11,638.8)	61.7 (4.4 to 158.1)	63.0 (-35.8 to 64.8)	337.6 (107.3 to 302.8)	514.5 (176.1 to 490.6)	69.0 (37.7 to 154.7)	-3.9 (-35.9 to 65.3)
Tension-type headache	9,216.1 (8,471.7 to 9,864.7)	14,920.0 (11,074.2 to 18,729.9)	61.1 (20.2 to 109.7)	0.6 (-24.1 to 27.7)	14.0 (6.7 to 24.9)	22.6 (10.5 to 42.5)	60.7 (19.8 to 110.0)	0.7 (-23.9 to 27.9)
Medication overuse headache	439.6 (296.3 to 589.9)	1,104.6 (741.2 to 1,469.2)	151.6 (100.7 to 215.3)	52.1 (21.3 to 94.0)	69.0 (39.5 to 106.7)	172.8 (97.7 to 265.7)	151.0 (98.4 to 217.5)	52.1 (20.9 to 94.9)
Other neurological disorders	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	48.1 (-0.0 to 117.2)	-1.9 (-32.5 to 45.9)	9.5 (6.0 to 14.5)	11.2 (7.7 to 15.3)	19.1 (-18.2 to 71.8)	-34.9 (-55.0 to -3.8)
Mental and substance use disorders	-	-	-	-	1,089.3 (759.3 to 1,408.8)	1,677.2 (1,193.7 to 2,197.6)	56.8 (52.6 to 61.3)	-0.7 (-1.3 to 1.9)
Schizophrenia	134.6 (122.9 to 145.9)	229.5 (210.8 to 246.8)	70.4 (63.7 to 77.5)	0.1 (-4.0 to 4.1)	0.1 (63.7 to 104.2)	0.1 (106.9 to 178.0)	0.1 (60.2 to 82.0)	-1.1 (-5.6 to 6.4)
Alcohol use disorders	205.8 (181.2 to 232.3)	386.9 (351.5 to 420.9)	88.3 (74.2 to 101.5)	13.8 (6.0 to 21.1)	20.3 (13.4 to 29.3)	38.4 (25.8 to 54.5)	89.4 (72.1 to 106.6)	14.4 (4.5 to 24.4)
Drug use disorders	-	-	-	-	151.5 (84.5 to 248.0)	248.2 (138.1 to 401.9)	63.8 (41.0 to 87.0)	-2.9 (-16.3 to 11.0)
Opioid use disorders	281.4 (154.1 to 479.6)	471.6 (252.4 to 774.2)	68.2 (35.7 to 98.9)	-1.9 (-20.1 to 15.8)	117.2 (58.2 to 207.7)	196.1 (97.8 to 341.4)	67.5 (36.6 to 99.7)	-2.2 (-19.5 to 16.7)
Cocaine use disorders	44.8 (35.7 to 54.9)	73.3 (59.2 to 88.2)	63.2 (24.5 to 122.2)	6.2 (-22.3 to 33.8)	6.2 (3.8 to 9.2)	6.2 (6.3 to 15.2)	63.6 (19.4 to 131.6)	-0.4 (-25.7 to 39.0)
Amphetamine use disorders	74.4 (57.4 to 90.6)	107.0 (82.3 to 131.4)	43.4 (4.8 to 103.3)	-10.5 (-33.4 to 23.6)	9.8 (5.6 to 15.1)	14.0 (8.3 to 21.1)	43.3 (3.2 to 108.8)	-10.2 (-34.3 to 27.5)
Cannabis use disorders	81.2 (62.7 to 98.0)	127.3 (99.6 to 153.2)	56.6 (53.7 to 60.4)	-0.1 (-0.2 to -0.1)	2.4 (1.4 to 3.6)	3.7 (2.2 to 5.6)	56.8 (31.8 to 83.8)	-0.2 (-15.8 to 16.8)
Other drug use disorders	-	-	-	-	16.1 (9.8 to 23.9)	24.4 (15.0 to 36.0)	51.2 (6.7 to 117.5)	-6.1 (-34.0 to 33.7)
Depressive disorders	-	-	-	-	184.0 (184.0 to 389.7)	303.1 (303.1 to 631.4)	64.0 (55.5 to 73.0)	0.7 (-3.8 to 6.1)
Major depressive disorder	1,065.9 (835.5 to 1,311.7)	1,741.6 (1,378.3 to 2,121.4)	63.4 (53.6 to 73.2)	0.9 (-4.6 to 6.8)	218.2 (139.4 to 316.7)	355.9 (229.3 to 521.2)	63.0 (52.5 to 74.3)	0.9 (-4.7 to 7.8)
Dysthymia	570.0 (462.9 to 690.8)	959.5 (780.0 to 1,164.8)	68.2 (67.0 to 69.4)	-0.3 (-0.4 to -0.2)	54.7 (34.9 to 80.1)	92.0 (59.2 to 136.0)	68.3 (63.5 to 72.6)	-0.2 (-2.6 to 2.2)
Bipolar disorder	365.0 (317.3 to 410.8)	603.5 (525.1 to 680.8)	65.2 (57.4 to 74.1)	-1.1 (-5.4 to 3.4)	74.2 (45.3 to 111.9)	122.3 (76.6 to 183.3)	64.8 (54.4 to 76.2)	-1.3 (-6.8 to 4.8)
Anxiety disorders	1,701.4 (1,092.0 to 2,340.7)	2,641.6 (1,715.1 to 3,645.4)	55.2 (46.7 to 63.3)	28.4 (-0.3 to 0.2)	156.9 (85.0 to 246.4)	243.1 (134.5 to 383.3)	65.1 (46.3 to 64.1)	0.1 (-2.6 to 2.7)
Eating disorders	-	-	-	-	7.3 (4.3 to 11.3)	12.1 (7.2 to 18.6)	66.1 (47.7 to 87.3)	6.3 (-5.1 to 20.0)
Anorexia nervosa	7.0 (4.5 to 10.0)	13.5 (8.9 to 19.4)	94.1 (71.0 to 122.3)	28.3 (13.3 to 47.0)	1.5 (0.8 to 2.5)	2.9 (1.6 to 4.7)	93.9 (46.7 to 160.4)	28.5 (-2.1 to 72.8)
Bulimia nervosa	27.3 (18.6 to 38.5)	43.5 (29.5 to 62.4)	59.1 (54.7 to 62.9)	0.7 (0.6 to 0.9)	5.8 (3.3 to 9.3)	9.2 (5.3 to 14.8)	59.0 (39.7 to 80.7)	0.9 (-11.6 to 14.2)
Autistic spectrum disorders	-	-	-	-	65.8 (45.9 to 89.4)	95.6 (66.6 to 129.3)	45.2 (40.5 to 50.5)	0.4 (-2.5 to 3.6)
Autism	165.3 (156.5 to 174.6)	241.3 (228.8 to 254.9)	45.9 (45.3 to 46.6)	0.2 (0.2 to 0.2)	40.9 (27.4 to 56.1)	59.6 (39.7 to 81.8)	45.6 (38.5 to 53.5)	0.4 (-4.0 to 5.1)
Asperger syndrome	247.9 (232.4 to 262.6)	360.3 (337.6 to 382.2)	45.2 (44.4 to 46.1)	0.3 (0.3 to 0.3)	24.9 (17.3 to 35.0)	36.1 (24.9 to 50.3)	44.7 (38.9 to 51.5)	0.2 (-3.3 to 4.4)
Attention-deficit/hyperactivity disorder	380.2 (313.6 to 448.2)	485.8 (401.1 to 572.5)	27.7 (27.1 to 28.1)	-0.2 (-0.2 to -0.2)	4.6 (2.6 to 7.2)	5.9 (3.3 to 9.3)	27.8 (18.2 to 37.3)	-0.1 (-7.4 to 7.3)
Conduct disorder	69.6 (50.3 to 81.2)	88.4 (73.4 to 1,032.6)	26.8 (25.4 to 28.6)	8.4 (-0.2 to 8.1)	8.4 (51.5 to 127.7)	107.2 (66.0 to 164.4)	27.0 (21.9 to 32.7)	-0.1 (-4.0 to 4.1)
Idiopathic intellectual disability	1,795.7 (1,524.6 to 2,128.7)	2,294.8 (1,964.9 to 2,736.8)	27.7 (16.8 to 38.8)	-10.8 (-18.7 to -3.1)	27.7 (58.0 to 123.9)	112.1 (74.7 to 157.8)	27.6 (16.9 to 37.7)	-10.7 (-18.5 to -3.0)
Other mental and substance use disorders	764.5 (716.4 to 810.4)	1,306.9 (1,224.5 to 1,385.5)	70.8 (70.0 to 71.6)	0.2 (0.1 to 0.4)	57.1 (39.2 to 77.1)	97.5 (66.7 to 131.3)	70.6 (64.2 to 77.8)	0.2 (-3.2 to 4.3)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	438.5 (308.0 to 591.7)	820.8 (578.5 to 1,125.0)	86.8 (65.1 to 115.9)	16.1 (1.5 to 35.2)
Diabetes mellitus	1,819.7 (1,483.0 to 2,183.1)	4,283.3 (3,437.4 to 5,170.2)	137.9 (81.5 to 207.2)	37.4 (4.9 to 81.1)	187.1 (124.6 to 265.6)	442.0 (295.6 to 640.9)	135.6 (83.1 to 214.4)	35.2 (5.1 to 79.2)
Acute glomerulonephritis	0.4 (0.4 to 0.4)	0.4 (0.3 to 0.4)	-	-29.1 (-33.5 to -25.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-29.1 (-33.6 to -25.3)
Chronic kidney disease	-	-	-	-	55.2 (39.5 to 74.7)	87.5 (62.7 to 118.2)	58.9 (46.0 to 72.1)	-0.3 (-7.1 to 7.2)
Chronic kidney disease due to diabetes mellitus	687.7 (404.2 to 1,142.2)	1,161.5 (720.4 to 2,059.8)	69.4 (20.9 to 135.2)	0.8 (-27.1 to 39.9)	11.5 (7.9 to 15.6)	21.8 (15.1 to 30.5)	89.5 (46.9 to 138.0)	15.1 (-10.1 to 46.7)
Chronic kidney disease due to hypertension	433.3 (280.7 to 720.6)	482.1 (310.3 to 900.3)	11.4 (-24.1 to 49.3)	-28.4 (-49.8 to -8.7)	16.5 (11.2 to 23.5)	21.4 (15.0 to 30.2)	31.3 (-0.2 to 61.7)	-21.3 (-40.4 to -2.7)
Chronic kidney disease due to glomerulonephritis	957.7 (538.1 to 1,583.4)	1,091.7 (600.9 to 1,769.2)	14.5 (-16.6 to 47.2)	-32.2 (-53.4 to -12.8)	8.1 (5.3 to 12.6)	9.9 (5.9 to 14.6)	12.2 (-21.1 to 67.9)	-18.9 (-45.5 to 15.7)
Chronic kidney disease due to other causes	1,036.3 (636.3 to 1,613.0)	1,698.4 (1,123.8 to 2,581.0)	65.0 (20.9 to 117.5)	-1.8 (-28.0 to 36.0)	18.8 (13.1 to 25.6)	34.5 (23.9 to 47.8)	84.0 (43.8 to 133.	

Appendix Table G.4 - Egypt prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	11.5 (10.8 to 12.3)	18.9 (17.9 to 20.0)	63.6 (50.2 to 79.6)		0.4 (0.2 to 0.6)	0.6 (0.4 to 1.0)	63.3 (31.0 to 103.2)	4.1 (-13.9 to 27.0)
Urolithiasis	505.8 (344.1 to 793.5)	875.1 (466.3 to 1,710.5)	78.0 (7.2 to 140.4)		2.8 (1.7 to 4.4)	6.3 (3.4 to 11.9)	120.5 (62.4 to 195.5)	33.2 (-2.6 to 78.8)
Benign prostatic hyperplasia	459.0 (416.9 to 498.5)	845.3 (773.8 to 910.1)	84.6 (60.7 to 110.0)		5.9 (-7.6 to 20.1)	16.5 (10.8 to 23.8)	30.3 (60.4 to 110.9)	6.3 (-7.5 to 20.5)
Male infertility due to other causes	321.5 (237.7 to 423.6)	518.9 (357.8 to 694.7)	60.8 (4.9 to 150.8)		-3.7 (0.9 to 4.6)	2.3 (1.4 to 7.5)	3.7 (4.1 to 160.8)	-3.3 (-36.3 to 54.3)
Other urinary diseases	-	-	-		-	-	-	-
Gynecological diseases	-	-	-		-	-	-	-
Uterine fibroids	949.0 (861.0 to 1,030.8)	1,609.9 (1,460.5 to 1,747.4)	69.5 (68.9 to 70.0)		-1.7 (-1.8 to -1.5)	16.6 (10.0 to 26.5)	26.7 (46.2 to 69.9)	-6.8 (-15.3 to -1.7)
Polycystic ovarian syndrome	1,066.2 (972.9 to 1,173.3)	1,745.3 (1,573.2 to 1,925.8)	63.7 (42.3 to 87.5)		-1.9 (-1.4 to 11.5)	10.5 (5.0 to 19.9)	17.2 (42.5 to 87.4)	-1.5 (-13.9 to 11.6)
Female infertility due to other causes	156.5 (106.0 to 220.5)	294.1 (196.9 to 403.5)	88.6 (14.7 to 216.3)		1.0 (-30.3 to 93.9)	1.9 (0.8 to 2.2)	1.9 (17.5 to 214.9)	0.6 (-25.6 to 96.7)
Endometriosis	89.0 (74.5 to 102.8)	157.7 (135.1 to 181.5)	78.1 (44.6 to 121.0)		4.8 (-15.0 to 29.8)	8.2 (5.4 to 11.6)	14.6 (41.2 to 122.9)	9.1 (-17.0 to 31.7)
Genital prolapse	3,300.3 (2,886.1 to 3,729.3)	5,445.2 (4,738.1 to 6,176.1)	64.4 (38.3 to 97.2)		-4.2 (-18.5 to 14.2)	10.5 (5.1 to 19.6)	17.2 (37.1 to 98.5)	-3.9 (-19.4 to 14.9)
Premenstrual syndrome	2,997.3 (2,013.0 to 4,146.7)	5,139.4 (3,154.2 to 7,220.6)	70.8 (-4.3 to 186.7)		2.5 (-41.7 to 70.4)	25.2 (13.2 to 41.2)	43.2 (21.5 to 75.1)	2.2 (-4.6 to 187.8)
Other gynecological diseases	189.4 (144.5 to 233.3)	291.8 (271.0 to 315.6)	53.9 (25.0 to 100.8)		-6.7 (-24.3 to 21.3)	5.7 (3.4 to 8.6)	8.8 (28.2 to 141.1)	-8.7 (-22.5 to 45.9)
Hemoglobinopathies and hemolytic anemias	-	-	-		-	-	-	-
Thalassemias	9.1 (7.5 to 10.6)	10.8 (9.1 to 12.7)	17.0 (6.1 to 35.2)		-7.8 (-16.5 to 5.6)	0.7 (0.4 to 1.1)	0.8 (0.5 to 1.3)	11.5 (-18.4 to 64.1)
Thalassemia trait	2,042.1 (1,849.1 to 2,235.3)	2,971.5 (2,739.6 to 3,223.5)	45.3 (39.9 to 51.9)		-0.3 (-4.0 to 4.3)	39.8 (26.3 to 58.5)	54.9 (19.1 to 56.2)	3.3 (-13.0 to 16.2)
Sickle cell disorders	3.0 (2.3 to 3.6)	5.2 (4.3 to 5.8)	69.9 (40.7 to 119.5)		0.4 (0.3 to 0.6)	0.7 (0.5 to 0.9)	29.2 (27.1 to 100.9)	14.1 (-5.5 to 41.0)
Sickle cell trait	1,539.4 (1,408.7 to 1,664.9)	2,239.2 (2,067.4 to 2,378.7)	45.1 (40.2 to 52.9)		0.9 (-3.8 to 5.1)	9.5 (4.3 to 10.5)	24.3 (6.2 to 75.3)	1.7 (-16.6 to 35.2)
G6PD deficiency	3,355.3 (2,723.0 to 3,956.8)	4,323.7 (3,555.2 to 5,039.5)	29.0 (0.9 to 66.6)		-11.4 (-30.7 to 15.0)	0.4 (0.3 to 0.6)	0.5 (0.8 to 52.6)	-9.7 (-22.4 to 6.4)
G6PD trait	11,789.1 (10,764.3 to 12,634.2)	17,350.6 (16,029.9 to 18,460.5)	47.3 (32.5 to 63.9)		0.4 (-9.7 to 11.7)	0.4 (0.0 to 0.7)	0.4 (94.1 to 1,738.8)	19.1 (-94.1 to 1,072.5)
Other hemoglobinopathies and hemolytic anemias	594.4 (471.7 to 675.4)	752.6 (643.1 to 844.3)	25.9 (5.7 to 61.3)		-12.0 (-24.4 to 8.8)	16.6 (9.4 to 24.9)	19.2 (11.6 to 28.7)	-16.7 (-20.7 to 92.9)
Endocrine, metabolic, blood, and immune disorders	773.8 (656.1 to 866.1)	977.7 (898.3 to 1,040.2)	25.9 (11.6 to 51.6)		-0.6 (-18.8 to 3.7)	25.9 (16.9 to 37.4)	31.5 (21.1 to 45.2)	26.7 (4.7 to 56.8)
Musculoskeletal disorders	-	-	-		-	-	-	-
Rheumatoid arthritis	45.9 (41.7 to 49.9)	75.7 (69.5 to 82.3)	65.2 (46.2 to 86.7)		-0.4 (-12.4 to 12.8)	10.7 (7.5 to 14.3)	17.5 (40.9 to 89.2)	-0.5 (-13.6 to 14.8)
Osteoarthritis	1,378.0 (1,297.2 to 1,453.9)	2,395.8 (2,254.0 to 2,531.2)	73.8 (60.9 to 87.9)		-1.2 (-7.9 to 6.6)	83.5 (88.8 to 114.6)	145.0 (102.0 to 198.4)	-1.1 (-60.2 to 6.9)
Low back and neck pain	-	-	-		-	-	-	-
Low back pain	6,563.1 (5,962.3 to 7,169.8)	11,164.8 (9,856.1 to 12,515.5)	70.6 (42.1 to 96.6)		1.9 (-13.6 to 16.3)	1,241.4 (491.9 to 1,025.5)	1,241.4 (826.0 to 1,769.5)	2.1 (-41.6 to 96.0)
Neck pain	1,923.7 (1,512.0 to 2,263.1)	3,407.6 (2,859.1 to 3,994.4)	76.0 (43.8 to 125.3)		3.7 (-16.6 to 33.9)	187.6 (123.3 to 266.8)	331.6 (43.4 to 124.4)	3.7 (-16.2 to 33.7)
Gout	22.8 (19.6 to 26.0)	39.2 (32.7 to 45.2)	72.9 (35.5 to 110.1)		-0.3 (-21.2 to 20.5)	0.7 (0.5 to 1.0)	1.3 (26.5 to 128.6)	-1.3 (-26.1 to 30.6)
Other musculoskeletal disorders	1,230.6 (959.0 to 1,508.3)	2,232.8 (1,740.6 to 2,724.3)	81.2 (67.7 to 96.9)		4.2 (-3.2 to 13.2)	1.0 (72.2 to 160.3)	1.1 (130.4 to 291.5)	8.9 (-66.8 to 97.1)
Other non-communicable diseases	-	-	-		-	-	-	-
Congenital anomalies	-	-	-		-	-	-	-
Neural tube defects	7.4 (5.7 to 9.8)	22.3 (18.9 to 25.8)	205.1 (120.5 to 315.3)		1.9 (1.2 to 3.3)	731.7 (2.0 to 3.0)	1,241.4 (102.4 to 422.1)	2.1 (-1.0 to 15.3)
Congenital heart anomalies	124.6 (92.5 to 168.2)	495.0 (410.9 to 589.2)	299.6 (191.3 to 459.8)		4.5 (1.9 to 7.9)	174.0 (7.4 to 30.5)	289.3 (187.2 to 440.0)	195.6 (-117.4 to 311.4)
Orofacial clefts	16.8 (10.3 to 26.0)	85.3 (64.0 to 110.7)	417.3 (197.8 to 719.7)		0.3 (0.2 to 0.5)	0.3 (0.7 to 1.8)	1.1 (108.9 to 524.5)	1.7 (63.1 to 388.9)
Down syndrome	66.8 (50.2 to 88.5)	140.9 (108.5 to 192.5)	112.3 (54.0 to 184.3)		8.2 (9.8 to 104.6)	18.1 (5.4 to 11.9)	18.1 (60.6 to 207.6)	122.2 (-14.3 to 110.7)
Turner syndrome	1.5 (1.2 to 1.9)	3.0 (1.8 to 4.0)	99.5 (18.7 to 183.0)		0.0 (-16.9 to 98.0)	0.0 (0.0 to 0.0)	0.1 (18.6 to 194.4)	39.5 (-18.5 to 100.9)
Klinefelter syndrome	1.7 (1.4 to 2.2)	2.4 (1.8 to 3.1)	46.0 (-4.6 to 102.7)		1.6 (-33.7 to 40.7)	0.0 (0.0 to 0.0)	0.0 (2.7 to 120.5)	1.2 (-34.0 to 40.5)
Chromosomal unbalanced rearrangements	60.7 (48.3 to 76.7)	125.2 (99.6 to 159.9)	106.1 (48.2 to 183.9)		7.4 (6.3 to 104.6)	16.0 (4.8 to 10.6)	16.0 (11.3 to 21.9)	55.0 (55.6 to 110.6)
Other congenital anomalies	158.0 (131.0 to 185.8)	205.9 (173.6 to 239.1)	30.6 (13.4 to 49.6)		-14.1 (-26.3 to -1.5)	17.9 (11.8 to 26.6)	27.1 (18.1 to 39.8)	4.0 (-16.9 to 124.2)
Skin and subcutaneous diseases	-	-	-		-	-	-	-
Dermatitis	2,589.4 (2,198.5 to 2,981.3)	4,019.6 (3,367.4 to 4,631.6)	55.1 (52.2 to 58.1)		-0.1 (-0.1 to 0.0)	71.2 (45.4 to 105.3)	107.9 (68.6 to 160.1)	-0.0 (-2.9 to 2.8)
Psoriasis	189.1 (169.1 to 211.5)	304.9 (271.6 to 342.3)	61.2 (59.4 to 62.8)		0.1 (-0.0 to 0.1)	15.4 (10.4 to 21.9)	24.8 (16.7 to 35.1)	0.2 (47.4 to 74.4)
Cellulitis	12.0 (9.9 to 14.7)	15.2 (12.2 to 18.8)	25.7 (10.2 to 43.0)		-13.9 (-22.9 to -1.0)	0.9 (0.5 to 1.3)	1.1 (1.1 to 57.8)	26.2 (-28.9 to 6.7)
Pyoderma	45.0 (35.7 to 57.3)	54.4 (44.0 to 70.7)	20.7 (11.4 to 31.0)		-7.5 (-13.0 to -1.0)	0.3 (0.1 to 0.6)	0.3 (5.1 to 37.1)	-7.6 (-17.9 to 3.8)
Scabies	289.6 (234.2 to 358.8)	427.9 (313.7 to 551.0)	48.6 (3.5 to 100.6)		0.5 (-32.1 to 37.1)	7.5 (4.1 to 12.4)	11.0 (2.7 to 101.5)	0.9 (-32.7 to 38.7)
Fungal skin diseases	3,360.1 (2,697.4 to 3,968.3)	5,349.1 (4,257.2 to 6,344.3)	58.2 (55.4 to 62.4)		18.9 (-0.1 to 0.2)	18.9 (7.5 to 40.6)	29.6 (11.9 to 64.9)	69.5 (55.1 to 62.6)
Viral skin diseases	1,170.4 (979.4 to 1,361.1)	1,582.7 (1,299.5 to 1,868.0)	34.8 (28.9 to 41.7)		0.1 (-1.7 to 2.3)	36.3 (22.9 to 53.8)	48.9 (30.6 to 72.7)	34.9 (-3.1 to 40.3)
Acne vulgaris	5,908.4 (4,492.4 to 7,580.4)	7,518.0 (5,995.6 to 9,119.7)	27.5 (-14.1 to 91.5)		-10.1 (-38.9 to 35.6)	64.0 (29.8 to 123.7)	81.8 (36.9 to 159.5)	-10.0 (-14.4 to 92.4)
Alopecia areata	75.2 (66.0 to 85.7)	116.6 (101.1 to 132.4)	55.3 (26.7 to 86.6)		0.7 (-18.2 to 21.8)	2.5 (1.6 to 3.9)	3.9 (24.9 to 89.8)	1.1 (-17.7 to 24.2)
Pruritus	12.6 (9.1 to 17.0)	21.8 (14.4 to 31.1)	75.1 (9.1 to 174.3)		0.1 (-33.0 to 87.7)	0.1 (0.1 to 0.2)	0.2 (8.2 to 169.8)	11.2 (-32.5 to 81.9)
Urticaria	549.6 (368.4 to 694.5)	692.4 (471.9 to 975.0)	25.9 (-13.6 to 82.9)		-18.3 (-42.9 to 17.3)	32.7 (18.0 to 49.7)	40.9 (22.7 to 68.5)	24.7 (-15.0 to 82.7)
Decubitus ulcer	8.2 (6.5 to 9.9)	12.5 (10.3 to 14.9)	51.8 (14.0 to 98.9)		-1.6 (-35.5 to 22.0)	1.2 (0.8 to 1.7)	1.8 (11.7 to 103.4)	-11.3 (-35.8 to 25.5)
Other skin and subcutaneous diseases	2,685.5 (1,763.0 to 4,003.0)	4,396.4 (2,834.4 to 6,704.3)	63.4 (55.4 to 70.5)		-1.1 (-4.1 to 2.6)	15.7 (7.0 to 31.4)	25.7 (55.4 to 70.8)	-1.1 (-4.3 to 2.8)
Sense organ diseases	-	-	-		-	-	-	-
Glaucoma	182.5 (147.6 to 218.6)	297.2 (234.0 to 358.0)	63.8 (21.7 to 109.0)		-5.5 (-28.9 to 19.8)	18.4 (12.4 to 26.0)	88.7 (42.4 to 53.3)	9.8 (-13.4 to 6.5)
Cataract	698.7 (589.0 to 815.1)	1,203.6 (1,024.5 to 1,366.4)	72.5 (43.9 to 115.1)		-2.2 (-16.6 to 20.8)	67.8 (45.8 to 95.1)	116.1 (80.5 to 158.8)	-0.9 (-36.1 to 110.8)
Macular degeneration	114.6 (84.0 to 143.4)	189.8 (143.9 to 231.2)	66.6 (18.4 to 150.6)		-5.9 (-35.7 to 38.1)	8.8 (5.8 to 12.7)	14.4 (19.1 to 138.4)	-7.8 (-35.8 to 29.2)
Uncorrected refractive error	6,150.4 (5,823.5 to 6,491.9)	9,496.3 (8,983.5 to 10,010.3)	54.1 (43.9 to 65.3)		6.6 (-12.4 to 0.0)	151.4 (110.8 to 226.0)	228.0 (155.9 to 326.1)	-13.4 (-17.6 to 9.3)
Age-related and other hearing loss	4,847.6 (4,532.2 to 5,181.6)	5,342.1 (7,033.0 to 8,106.5)	55.5 (49.6 to 62.3)		-9.0 (-11.9 to -5.6)	126.9 (84.5 to 181.1)	192.6 (127.4 to 274.5)	10.9 (43.2 to 60.8)
Other vision loss	461.6 (397.0 to 517.4)	602.4 (522.7 to 676.3)	29.9 (16.3 to 46.3)		-16.7 (-26.7 to -4.3)	46.7 (31.1 to 65.8)	59.3 (39.2 to 84.3)	-25.9 (-29.9 to 4.8)
Other sense organ diseases	1,332.7 (1,270.2 to 1,397.5)	1,870.8 (1,767.0 to 1,954.3)	40.3 (30.6 to 49.7)		-0.2 (-6.3 to 5.9)	35.5 (22.0 to 52.9)	49.6 (30.4 to 74.1)	0.1 (29.8 to 50.3)
Oral disorders	-	-	-		-	-	-	-
Deciduous caries	5,822.0 (5,553.7 to 6,105.2)	6,678.2 (6,384.7 to 6,996.7)	14.8 (8.7 to 20.8)		0.7 (-4.7 to 5.4)	18.0 (1.0 to 4.3)	203.8 (50.6 to 71.1)	1.5 (-11.5 to 2.1)
Permanent caries	18,150.8 (16,500.7 to 19,709.5)	30,047.5 (26,508.5 to 32,830.6)	65.6 (45.8 to 83.7)		6.8 (-6.3 to 18.7)	34.0 (8.0 to 18.9)	29.7 (13.3 to 56.3)	6.9 (-6.1 to 18.9)
Periodontal diseases	2,514.3 (2,291.2 to 2,739.3)	4,516.8 (4,051.0 to 4,944.7)	79.9 (54.1 to 104.2)		4.5 (-11.1 to 19.2)	16.4 (6.5 to 34.0)	29.5 (54.2 to 104.4)	4.6 (-11.1 to 19.4)

Appendix Table G.4 - Egypt prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	2,345.3 (2,174.2 to 2,533.7)	3,724.7 (3,449.1 to 3,992.0)	59.2 (40.8 to 75.7)	-4.4 (-18.6 to 0.9)	64.2 (43.0 to 89.4)	101.6 (68.5 to 140.3)	59.0 (40.6 to 75.1)	-8.5 (-18.6 to 0.6)
Other oral disorders	871.6 (821.7 to 919.9)	1,380.8 (1,299.6 to 1,465.9)	58.1 (45.1 to 73.1)	-0.6 (-8.4 to 8.4)	25.5 (16.1 to 38.2)	40.4 (25.2 to 60.0)	58.0 (44.4 to 72.5)	-0.5 (-8.9 to 8.0)
Injuries	-	-	-	-	156.1 (114.6 to 213.8)	203.6 (149.6 to 267.7)	32.9 (0.9 to 52.7)	-19.7 (-42.2 to -5.7)
Transport injuries	-	-	-	-	55.0 (41.3 to 71.4)	80.2 (58.5 to 106.4)	45.0 (31.4 to 63.8)	-7.8 (-15.9 to 3.4)
Road injuries	-	-	-	-	45.8 (34.3 to 59.4)	67.6 (49.4 to 89.9)	47.2 (32.3 to 65.8)	-3.3 (-14.6 to 6.1)
Pedestrian road injuries	-	-	-	-	11.9 (8.8 to 15.3)	14.6 (10.5 to 19.5)	23.0 (6.0 to 42.4)	-17.4 (-27.9 to -5.9)
Cyclist road injuries	-	-	-	-	4.2 (3.2 to 5.5)	7.4 (5.3 to 9.9)	74.0 (57.6 to 93.1)	11.2 (1.0 to 23.4)
Motorcyclist road injuries	-	-	-	-	5.4 (4.0 to 7.1)	6.9 (4.9 to 9.4)	27.3 (12.2 to 44.8)	-20.8 (-29.6 to -10.9)
Motor vehicle road injuries	-	-	-	-	23.8 (17.8 to 30.9)	30.7 (28.2 to 50.7)	60.2 (41.9 to 83.3)	-1.3 (-9.8 to 15.1)
Other road injuries	-	-	-	-	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.5)	-21.6 (-30.8 to -11.3)	51.1 (-56.5 to -45.0)
Other transport injuries	-	-	-	-	9.2 (6.8 to 12.0)	12.5 (9.0 to 16.8)	35.4 (22.3 to 50.7)	-17.2 (-25.0 to -8.3)
Unintentional injuries	-	-	-	-	71.9 (55.1 to 92.6)	113.9 (84.4 to 150.7)	58.1 (47.5 to 70.3)	-3.5 (-9.8 to 3.7)
Falls	-	-	-	-	32.8 (24.5 to 42.3)	45.6 (33.0 to 61.2)	38.6 (27.0 to 52.5)	-14.9 (-21.8 to -6.8)
Drowning	-	-	-	-	2.1 (1.6 to 2.8)	1.6 (1.2 to 2.2)	-24.1 (-32.9 to -13.1)	51.6 (-56.8 to -45.0)
Fire, heat, and hot substances	-	-	-	-	5.4 (4.2 to 7.0)	3.3 (2.4 to 4.3)	-40.1 (-48.3 to -30.8)	-58.5 (-63.6 to -52.9)
Poisonings	-	-	-	-	0.6 (0.4 to 0.9)	0.7 (0.5 to 0.9)	9.7 (-13.6 to 37.8)	-27.0 (-40.9 to -11.3)
Exposure to mechanical forces	-	-	-	-	14.4 (10.8 to 18.9)	35.0 (25.5 to 46.3)	142.0 (124.1 to 162.2)	51.7 (42.1 to 63.3)
Unintentional firearm injuries	-	-	-	-	0.6 (0.5 to 0.8)	1.3 (1.0 to 1.8)	106.0 (81.5 to 130.2)	24.9 (11.0 to 38.6)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.5)	205.3 (170.6 to 244.5)	94.0 (73.1 to 116.9)
Other exposure to mechanical forces	-	-	-	-	13.7 (10.2 to 17.9)	33.3 (24.2 to 44.1)	143.1 (124.7 to 164.3)	52.6 (42.7 to 64.5)
Adverse effects of medical treatment	-	-	-	-	0.8 (0.5 to 1.2)	1.6 (1.0 to 2.4)	95.9 (83.3 to 108.9)	23.4 (15.6 to 32.3)
Animal contact	-	-	-	-	1.1 (0.8 to 1.4)	1.4 (1.0 to 1.9)	35.3 (20.5 to 51.7)	-11.0 (-19.5 to -1.2)
Venomous animal contact	-	-	-	-	0.5 (0.4 to 0.7)	0.7 (0.5 to 0.9)	35.6 (15.6 to 57.5)	-12.3 (-24.2 to 0.8)
Non-venomous animal contact	-	-	-	-	0.6 (0.4 to 0.8)	0.8 (0.6 to 1.1)	35.4 (18.1 to 53.1)	-9.5 (-19.4 to 0.9)
Foreign body	-	-	-	-	1.9 (1.5 to 2.5)	2.4 (1.7 to 3.1)	24.7 (13.8 to 34.4)	-21.0 (-27.0 to -15.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.3 to 0.4)	-19.9 (-32.7 to -5.6)	44.1 (-52.1 to -35.8)
Foreign body in eyes	-	-	-	-	0.5 (0.3 to 0.7)	0.7 (0.4 to 1.1)	45.8 (31.6 to 62.7)	-6.9 (-15.2 to 3.5)
Foreign body in other body part	-	-	-	-	1.0 (0.8 to 1.3)	1.4 (1.0 to 1.8)	32.5 (20.2 to 45.5)	-18.6 (-25.6 to -11.2)
Other unintentional injuries	-	-	-	-	12.6 (9.4 to 16.4)	22.3 (16.3 to 29.5)	76.8 (61.8 to 92.5)	3.7 (-4.6 to 12.2)
Self-harm and interpersonal violence	-	-	-	-	2.4 (1.8 to 3.1)	4.4 (3.2 to 5.8)	82.8 (64.8 to 104.5)	21.4 (9.9 to 34.7)
Self-harm	-	-	-	-	0.2 (0.1 to 0.2)	1.1 (0.8 to 1.5)	588.1 (504.7 to 674.2)	292.4 (247.1 to 338.9)
Interpersonal violence	-	-	-	-	2.2 (1.7 to 2.9)	3.3 (2.4 to 4.3)	45.6 (30.5 to 63.6)	-3.8 (-13.1 to 7.5)
Assault by firearm	-	-	-	-	0.5 (0.3 to 0.6)	0.7 (0.5 to 1.0)	58.4 (41.7 to 75.1)	5.9 (-4.4 to 16.8)
Assault by sharp object	-	-	-	-	0.4 (0.3 to 0.5)	0.7 (0.5 to 1.0)	76.1 (56.2 to 100.7)	13.1 (0.8 to 28.2)
Assault by other means	-	-	-	-	1.4 (1.0 to 1.8)	1.8 (1.3 to 2.4)	32.8 (17.5 to 51.3)	-12.0 (-21.7 to -0.6)
Forces of nature, war, and legal intervention	-	-	-	-	26.8 (8.0 to 71.7)	5.2 (2.1 to 11.7)	-79.4 (-87.5 to -66.7)	-88.6 (-93.3 to -81.2)
Exposure to forces of nature	-	-	-	-	0.9 (0.4 to 1.7)	0.8 (0.3 to 1.5)	-12.1 (-26.2 to 1.9)	-19.1 (-31.7 to -7.1)
Collective violence and legal intervention	-	-	-	-	25.9 (7.3 to 71.1)	4.4 (1.6 to 10.3)	-82.0 (-88.8 to -73.2)	-89.8 (-93.7 to -84.3)

Appendix Table G.4 - El Salvador prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	493.0 (361.0 to 644.2)	653.6 (478.5 to 844.7)	33.9 (26.5 to 38.3)	33.9 (7.9 to 2.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	82.7 (56.7 to 114.9)	82.7 (57.5 to 115.6)	0.0 (-5.5 to 6.1)	-7.7 (-13.6 to -1.8)
HIV/AIDS and tuberculosis	-	-	-	-	1.0 (0.6 to 1.5)	1.7 (1.1 to 2.5)	1.7 (20.0 to 137.6)	19.2 (14.9 to 70.4)
Tuberculosis	2.2 (2.0 to 2.3)	2.6 (2.5 to 2.7)	19.8 (13.4 to 26.3)	-17.6 (-21.6 to -13.6)	0.7 (0.4 to 0.9)	0.8 (0.5 to 1.1)	19.1 (54.4 to 36.7)	-17.3 (-25.9 to -7.0)
HIV/AIDS	-	-	-	-	0.3 (0.1 to 0.7)	0.9 (0.4 to 1.5)	102.7 (23.8 to 696.3)	302.7 (11.0 to 490.4)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.3 (-34.1 to 343.9)	7.3 (-55.4 to 202.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.3 (-34.2 to 344.6)	7.3 (-55.5 to 203.7)
HIV/AIDS resulting in other diseases	2.9 (1.0 to 5.1)	11.0 (6.9 to 16.0)	293.0 (111.2 to 846.3)	202.9 (62.7 to 633.0)	0.3 (0.1 to 0.7)	0.9 (0.4 to 1.5)	178.0 (23.7 to 732.1)	105.3 (11.0 to 516.3)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	14.4 (10.1 to 19.5)	11.5 (7.8 to 16.0)	-2.1 (-26.1 to -13.1)	-17.0 (-22.3 to -11.0)
Diarrheal diseases	49.3 (46.3 to 52.1)	35.5 (33.1 to 37.9)	-28.1 (-34.2 to -21.4)	-15.9 (-22.9 to -8.7)	8.1 (5.4 to 11.2)	5.8 (3.9 to 8.1)	-28.8 (-35.1 to -21.5)	-16.3 (-23.6 to -8.0)
Intestinal infectious diseases	0.0	0.0	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-64.3 to -35.2)	-29.6 (-66.5 to -40.5)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.6 (-41.2 to -16.8)	-35.0 (-45.2 to -23.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-41.3 to -16.8)	-29.6 (-45.2 to -23.2)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.6 (-42.4 to -15.1)	-34.6 (-46.3 to -20.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-42.5 to -15.1)	-34.6 (-46.4 to -20.9)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-95.5 (-99.5 to -91.5)	-95.8 (-99.6 to -94.5)
Lower respiratory infections	3.6 (2.8 to 4.8)	2.1 (1.6 to 3.0)	-40.8 (-64.2 to -11.5)	-43.8 (-63.5 to -23.8)	0.4 (0.2 to 0.6)	0.2 (0.1 to 0.3)	-43.2 (-67.2 to -19.4)	-45.1 (-71.2 to -23.6)
Upper respiratory infections	264.0 (237.6 to 292.6)	298.9 (268.6 to 330.6)	13.4 (-1.5 to 31.2)	0.7 (-13.0 to 16.4)	3.1 (1.8 to 5.2)	3.5 (2.0 to 6.0)	13.1 (2.5 to 30.9)	0.9 (-13.2 to 16.7)
Otitis media	72.3 (67.9 to 76.8)	69.5 (65.1 to 73.6)	-3.9 (-10.9 to 4.0)	-12.2 (-18.6 to -5.2)	1.4 (0.8 to 2.2)	1.3 (0.8 to 2.1)	-6.1 (-13.9 to 2.6)	-13.3 (-20.2 to -5.6)
Meningitis	-	-	-	-	1.1 (0.7 to 1.5)	0.5 (0.3 to 0.7)	-53.5 (-61.7 to -44.3)	-58.1 (-65.1 to -50.2)
Pneumococcal meningitis	5.1 (3.0 to 7.8)	2.7 (1.6 to 4.3)	-47.0 (-56.8 to -35.3)	-56.2 (-63.8 to -47.2)	0.5 (0.3 to 0.7)	0.3 (0.2 to 0.4)	-45.8 (-58.4 to -29.6)	-52.1 (-62.3 to -38.9)
H influenzae type B meningitis	2.4 (0.9 to 4.7)	0.8 (0.3 to 1.7)	-66.9 (-78.6 to -56.5)	-71.7 (-80.9 to -63.0)	0.3 (0.2 to 0.5)	0.1 (0.1 to 0.1)	-67.0 (-79.8 to -50.8)	-70.1 (-81.4 to -55.6)
Meningococcal meningitis	0.4 (0.1 to 0.9)	0.2 (0.1 to 0.5)	-45.7 (-61.7 to -24.5)	-55.4 (-67.4 to -36.8)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-42.8 (-61.8 to -16.8)	-51.6 (-65.4 to -29.2)
Other meningitis	2.2 (1.0 to 4.2)	1.0 (0.5 to 2.1)	-53.4 (-63.0 to -38.1)	-59.4 (-67.0 to -45.4)	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-54.1 (-64.8 to -35.8)	-57.7 (-66.8 to -41.6)
Encephalitis	0.5 (0.2 to 1.1)	0.6 (0.3 to 1.4)	21.5 (1.1 to 43.4)	-5.0 (-19.3 to 8.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	26.2 (8.5 to 57.4)	2.1 (-11.4 to 25.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-79.0 (-97.8 to 125.2)	-76.5 (-97.1 to 110.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-79.0 (-97.8 to 125.6)	-76.5 (-97.1 to 111.1)
Whooping cough	3.5 (2.7 to 4.4)	0.9 (0.7 to 1.1)	-75.0 (-76.7 to -73.2)	-68.0 (-70.2 to -65.6)	0.2 (0.1 to 0.3)	0.0 (0.0 to 0.1)	-75.0 (-78.8 to -70.8)	-68.0 (-72.8 to -62.6)
Tetanus	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-94.1 (-97.2 to -88.9)	-94.9 (-97.6 to -90.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-91.0 (-95.2 to -81.7)	-92.3 (-95.5 to -84.7)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to 0.0)	-99.9 (-100.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.7 (-100.0 to nan)	-99.6 (-100.0 to nan)
Varicella and herpes zoster	4.4 (4.1 to 4.9)	4.4 (3.7 to 4.9)	-1.5 (-16.4 to 13.4)	-0.8 (-20.2 to 20.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	36.4 (5.1 to 90.8)	-0.5 (-33.9 to 42.9)
Neglected tropical diseases and malaria	-	-	-	-	12.2 (7.9 to 18.5)	10.6 (6.7 to 16.2)	-13.7 (-36.0 to 21.3)	-23.5 (-45.1 to 7.9)
Malaria	1.2 (0.7 to 2.2)	1.4 (0.4 to 3.3)	4.3 (-62.0 to 175.8)	-7.0 (-64.3 to 171.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.8 (-7.2 to 52.2)	19.2 (-12.2 to 41.4)
Chagas disease	148.0 (140.4 to 156.1)	189.8 (179.7 to 200.2)	28.2 (18.1 to 38.8)	-1.3 (-9.0 to 7.5)	1.7 (0.8 to 1.6)	1.7 (1.2 to 2.5)	8.9 (37.1 to 67.5)	-2.1 (-11.0 to 9.4)
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.0 (-44.2 to 46.9)	-8.9 (-43.8 to 33.8)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.6 (-60.1 to 95.7)	-2.5 (-58.9 to 93.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.6 (-60.1 to 95.9)	-2.5 (-59.0 to 93.1)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.4 (-21.5 to 19.7)	-16.4 (-31.8 to 8.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.4 (-21.5 to 19.7)	-16.4 (-31.8 to 8.8)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Cysticercosis	4.7 (1.5 to 9.1)	1.6 (0.3 to 4.7)	-70.6 (-95.4 to 56.3)	-77.6 (-96.2 to 5.7)	1.3 (0.4 to 2.7)	0.5 (0.1 to 1.6)	-67.9 (-95.3 to 87.4)	-75.3 (-96.0 to 21.1)
Cystic echinococcosis	0.2 (0.2 to 0.2)	0.2 (0.1 to 0.2)	-16.8 (-28.5 to -7.1)	-47.6 (-55.2 to -42.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.6 (-34.3 to 13.2)	-44.8 (-58.6 to -29.1)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Dengue	1.5 (0.6 to 3.3)	8.4 (3.2 to 19.0)	475.9 (473.8 to 478.3)	388.4 (386.7 to 390.4)	0.2 (0.1 to 0.6)	1.4 (0.5 to 3.3)	472.6 (388.6 to 583.5)	388.5 (319.9 to 468.6)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-88.2 (-88.2 to -44.9)	-85.9 (-88.8 to -51.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-85.0 (-88.2 to -44.7)	-85.9 (-88.8 to -51.5)
Intestinal nematode infections	-	-	-	-	6.8 (3.7 to 11.8)	4.7 (2.4 to 8.9)	-34.6 (-58.6 to 22.2)	-39.1 (-63.4 to 15.2)
Ascariasis	379.6 (286.3 to 509.9)	210.7 (119.8 to 353.9)	-46.1 (-70.3 to 1.2)	-53.7 (-74.4 to -10.5)	0.9 (0.2 to 2.5)	0.0 (0.0 to 1.1)	-96.9 (-99.4 to -83.9)	-96.1 (-99.2 to -79.2)
Trichuriasis	882.3 (687.6 to 1,126.5)	561.0 (330.1 to 890.9)	-37.7 (-64.3 to 4.6)	-48.0 (-71.2 to -8.9)	0.5 (0.1 to 1.3)	0.2 (0.0 to 0.8)	-55.0 (-90.5 to 118.3)	-62.5 (-92.7 to 104.7)
Hookworm disease	1,069.0 (869.3 to 1,301.8)	1,085.6 (663.6 to 1,503.9)	-7.6 (-39.5 to 43.6)	-44.4 (-50.6 to 22.9)	5.5 (3.0 to 9.5)	4.4 (2.3 to 8.4)	-22.5 (-54.0 to 46.8)	-39.6 (-61.6 to 36.6)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	69.4 (48.4 to 90.6)	61.2 (58.7 to 64.3)	-11.8 (-32.7 to 24.6)	-7.4 (-28.2 to 29.3)	2.6 (1.5 to 3.8)	2.3 (1.5 to 3.3)	-15.0 (-23.3 to 37.5)	-7.6 (-16.5 to 52.3)
Maternal disorders	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-27.5 (-41.4 to -6.7)	-46.4 (-57.1 to -32.5)
Maternal hemorrhage	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-15.6 (-25.4 to 4.0)	-38.5 (-45.1 to -30.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.2 (-33.3 to 6.8)	-38.9 (-53.2 to -23.8)
Maternal sepsis and other maternal infections	0.4 (0.2 to 0.6)	0.3 (0.1 to 0.5)	-23.7 (-49.1 to 4.9)	-46.8 (-64.3 to -26.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.0 (-70.7 to 55.9)	-53.9 (-75.1 to 1.3)
Maternal hypertensive disorders	0.9 (0.3 to 1.6)	0.7 (0.2 to 1.3)	-22.0 (-31.8 to -8.9)	-43.0 (-48.9 to -34.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-21.2 (-41.9 to 5.5)	-42.5 (-57.0 to -23.9)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.8 (-88.5 to 7.0)	-60.4 (-90.3 to -28.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.8 (-88.5 to 7.2)	-60.4 (-90.4 to -28.1)
Complications of abortion	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-22.2 (-56.0 to 35.5)	-42.8 (-66.4 to -6.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.2 (-66.5 to 70.9)	-43.4 (-73.2 to 13.3)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.6 (-63.4 to 21.3)	-54.0 (-73.1 to -25.7)
Neonatal disorders	-	-	-	-	4.9 (3.3 to 7.1)	8.6 (6.0 to 11.4)	73.9 (19.0 to 157.0)	58.3 (7.4 to 136.0)
Preterm birth complications	14.2 (10.1 to 20.0)	33.2 (24.7 to 43.7)	135.3 (87.4 to 190.6)	105.2 (62.9 to 153.4)	1.6 (1.1 to 2.3)	4.1 (2.8 to 5.7)	153.3 (78.6 to 248.3)	128.3 (60.9 to 212.5)
Neonatal encephalopathy due to birth asphyxia and trauma	19.6 (6.7 to 43.7)	11.6 (5.0 to 24.0)	-40.3 (-64.6 to 9.0)	-48.5 (-70.2 to -5.8)	1.1 (0.9 to 2.8)	1.8 (1.1 to 2.6)	4.2 (-31.6 to 97.8)	-3.9 (-38.3 to 94.4)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-26.2 (-39.6 to -8.0)	-26.2 (-19.7 to 22.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.2 (-42.7 to -5.5)	-26.2 (-23.8 to 25.6)
Hemolytic disease and other neonatal jaundice	2.8 (1.2 to 6.3)	4.9 (2.7 to 8.5)	81.1 (-32.0 to 358.5)	62.1 (-38.5 to 315.3)	1.1 (0.4 to 2.5)	1.9 (1.0 to 3.5)	85.2 (-30.9 to 395.1)	67.9 (-38.3 to 339.9)
Other neonatal disorders	-	-	-	-	0.5 (0.3 to 0.9)	0.7 (0.4 to 1.3)	22.9 (-28.0 to 156.0)	22.9 (-35.6 to 131.0)
Nutritional deficiencies	-	-	-	-	47.0 (31.6 to 67.9)	47.3 (31.7 to 68.1)	0.6 (-2.4 to 2.9)	-8.4 (-10.7 to -6.1)
Protein-energy malnutrition	7.1 (4.5 to 10.6)	4.5 (2.5 to 7.5)	-38.3 (-67.0 to 27.5)	-30.5 (-59.7 to 33.9)	0.9 (0.5 to 1.5)	0.5 (0.3 to 1.0)	-39.2 (-69.0 to 27.5)	-30.8 (-61.3 to 36.6)
Iodine deficiency	53.3 (29.2 to 79.7)	44.6 (19.7 to 73.8)	-17.6 (-60.8 to 77.1)	-38.4 (-70.2 to 30.5)	1.0 (0.4 to 1.7)	0.8 (0.3 to 1.5)	-18.1 (-60.7 to 75.9)	-38.5 (-70.0 to 30.8)
Vitamin A deficiency	2.1 (1.5 to 2.6)	0.9 (0.6 to 1.1)	-58.2 (-63.9 to -52.7)	-59.2 (-64.4 to -53.8)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-60.0 (-68.0 to -50.1)	-61.6 (-68.5 to -53.0)

Appendix Table G-4 - El Salvador prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	1,267.4 (1,244.1 to 1,287.6)	1,353.0 (1,344.9 to 1,361.8)	6.7 (4.9 to 8.8)	6.3 (-7.7 to -4.8)	45.1 (30.3 to 65.1)	45.9 (30.7 to 66.2)	1.9 (-0.7 to 3.3)	-7.1 (-9.2 to -5.7)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.8 (-74.6 to 40.2)	-35.7 (-69.3 to 47.2)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	3.1 (2.0 to 4.7)	3.1 (1.9 to 4.8)	-0.1 (-8.6 to 10.5)	-9.5 (-17.3 to -1.6)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.9 (0.5 to 1.6)	1.2 (0.7 to 2.0)	24.0 (8.8 to 43.4)	-9.8 (-19.2 to 1.9)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	11.6 (-10.5 to 37.1)	-28.5 (-41.5 to -13.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.2 (-1.5 to 4.9)	-26.0 (-43.3 to -2.1)
Chlamydial infection	125.2 (94.7 to 180.2)	131.3 (97.0 to 181.2)	7.5 (-35.7 to 58.1)	-20.1 (51.5 to 15.0)	0.5 (0.3 to 0.8)	0.6 (0.4 to 1.0)	23.8 (-0.3 to 55.0)	-9.3 (-26.4 to 11.2)
Gonococcal infection	17.0 (12.0 to 21.5)	17.9 (10.4 to 24.8)	4.3 (-38.5 to 74.3)	-21.6 (52.8 to 30.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	4.5 (-29.9 to 58.9)	-23.1 (-46.9 to 15.1)
Trichomoniasis	36.3 (19.7 to 53.9)	40.3 (28.5 to 54.9)	9.1 (-37.7 to 129.4)	-16.1 (-49.9 to 67.0)	0.1 (0.0 to 0.1)	0.2 (0.0 to 0.2)	6.0 (-43.7 to 143.7)	-16.7 (-52.9 to 77.1)
Genital herpes	832.5 (788.3 to 877.4)	1,188.2 (1,110.4 to 1,255.8)	42.7 (31.6 to 55.0)	-3.0 (-10.2 to 5.4)	30.7 (1.1 to 0.5)	30.7 (1.1 to 0.8)	45.8 (27.6 to 53.8)	25.8 (-10.8 to 5.9)
Other sexually transmitted diseases	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.5)	-1.1 (-20.3 to 11.2)	-34.3 (-44.4 to -22.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-21.5 to 69.0)	14.4 (-41.7 to 18.5)
Hepatitis	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	5.9 (-7.7 to 24.3)	-14.8 (-26.4 to 1.7)
Hepatitis A	8.0 (7.6 to 8.4)	7.4 (7.1 to 7.6)	-7.8 (-8.9 to -6.8)	-7.5 (-7.6 to -7.3)	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.3)	0.2 (-1.3 to 25.0)	-1.6 (-12.1 to 10.4)
Hepatitis B	178.8 (140.0 to 226.9)	141.6 (107.0 to 190.4)	-21.1 (-43.2 to 15.6)	-37.6 (-54.4 to -20.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-4.0 (-33.3 to 53.2)	-32.0 (-51.8 to 9.6)
Hepatitis C	111.1 (98.9 to 123.4)	109.6 (97.4 to 120.9)	-1.2 (-15.1 to 14.2)	-29.2 (-39.3 to -18.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.4 (-24.1 to 25.2)	-23.9 (-45.0 to 2.6)
Hepatitis E	-	-	-	-	-	-	-	-
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	120.2 (9.5 to 968.7)	39.9 (-42.5 to 632.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	120.3 (-10.8 to 1,158.5)	39.8 (-42.9 to 720.2)
Other infectious diseases	49.4 (41.5 to 58.0)	44.8 (41.6 to 48.0)	-9.4 (-25.1 to 1.3)	-8.4 (-25.5 to 3.9)	1.9 (-2.1 to 2.7)	2.4 (1.0 to 2.4)	-12.7 (-25.0 to -1.5)	-8.5 (-21.3 to 2.3)
Non-communicable diseases	-	-	-	-	360.7 (265.2 to 466.5)	360.7 (392.2 to 683.7)	46.5 (41.6 to 52.7)	4.4 (1.2 to 8.6)
Neoplasms	-	-	-	-	1.9 (1.4 to 2.5)	4.1 (2.9 to 5.6)	116.6 (86.4 to 154.8)	40.2 (19.5 to 64.2)
Esophageal cancer	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	185.6 (61.7 to 326.5)	61.0 (9.9 to 141.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	173.7 (54.1 to 309.9)	54.8 (-13.8 to 133.5)
Stomach cancer	1.3 (1.1 to 1.5)	2.9 (2.5 to 3.4)	123.5 (88.8 to 173.6)	28.4 (7.0 to 57.7)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	109.6 (73.3 to 156.5)	21.0 (-0.8 to 48.3)
Liver cancer	0.0	0.0	-	-	0.0	0.0	0.0	0.0
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	4,183.3 (1,696.0 to 7,572.7)	2,744.4 (1,081.6 to 5,276.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	4,251.2 (3,345.9 to 5,629.3)	2,639.9 (2,014.4 to 3,433.6)
Liver cancer due to hepatitis C	0.0	0.2	10,703.8	6,014.6	0.0	0.0	4,128.4	2,691.8
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	2,179.3 (858.5 to 4,371.2)	1,177.4 (436.2 to 2,412.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9,608.3 (881.8 to 3,942.2)	5,397.2 (450.7 to 2,146.7)
Liver cancer due to other causes	0.0	0.0	1,967.9	1,260.0	0.0	0.0	1,272.7	1,272.7
Larynx cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	80.6 (27.3 to 150.9)	11.5 (-22.5 to 56.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.9 (24.2 to 160.7)	11.7 (-24.8 to 62.3)
Tracheal, bronchus and lung cancer	0.3 (0.3 to 0.4)	0.7 (0.5 to 0.8)	97.4 (61.9 to 141.1)	16.4 (-4.6 to 42.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	86.8 (47.2 to 131.9)	11.0 (-13.3 to 38.4)
Breast cancer	2.7 (2.2 to 3.1)	5.1 (3.9 to 6.7)	81.8 (38.0 to 185.8)	18.9 (-9.3 to 86.3)	0.4 (0.1 to 0.3)	0.4 (0.3 to 0.6)	74.8 (33.5 to 177.7)	14.0 (-13.0 to 78.6)
Cervical cancer	3.7 (3.1 to 5.2)	7.4 (5.1 to 9.7)	99.4 (25.2 to 175.2)	30.2 (-18.0 to 79.2)	0.3 (0.2 to 0.4)	0.6 (0.3 to 0.8)	102.6 (270.9 to 176.4)	32.2 (-17.4 to 80.1)
Uterine cancer	1.0 (0.6 to 1.3)	1.7 (1.1 to 2.5)	79.3 (20.9 to 179.9)	15.2 (-21.1 to 77.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	79.2 (22.4 to 186.0)	14.7 (-27.4 to 80.8)
Prostate cancer	1.6 (1.1 to 2.5)	8.2 (4.8 to 11.4)	410.8 (234.5 to 623.7)	182.1 (85.1 to 305.4)	0.2 (0.1 to 0.3)	0.7 (0.4 to 1.0)	310.7 (168.5 to 466.4)	123.4 (44.9 to 211.4)
Colon and rectum cancer	1.3 (1.2 to 1.4)	3.2 (2.8 to 3.8)	153.9 (114.2 to 204.7)	49.6 (25.1 to 80.0)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	136.9 (97.0 to 187.2)	39.4 (14.9 to 69.5)
Lip and oral cavity cancer	0.5 (0.4 to 0.7)	0.9 (0.6 to 1.1)	88.9 (26.6 to 124.7)	0.0 (-25.3 to 35.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	65.7 (24.5 to 118.2)	-2.3 (-26.9 to 30.4)
Nasopharynx cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	20.8 (-43.5 to 29.2)	-48.6 (-63.4 to -36.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.7 (-42.9 to 26.5)	-49.5 (-62.9 to -18.3)
Other pharynx cancer	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	46.8 (-0.3 to 112.7)	-10.9 (-39.8 to 29.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.5 (3.0 to 100.6)	-14.3 (-39.1 to 22.3)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	-9.4 (-43.0 to 76.1)	-49.1 (-68.0 to -1.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.0 (-44.1 to 62.7)	-49.7 (-68.3 to -6.5)
Pancreatic cancer	0.1 (0.0 to 0.1)	0.2 (0.2 to 0.3)	317.7 (229.6 to 426.6)	143.4 (91.4 to 210.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	280.2 (205.6 to 379.1)	120.8 (78.2 to 179.4)
Malignant skin melanoma	0.8 (0.6 to 0.9)	0.4 (0.3 to 0.6)	-46.8 (-60.5 to -44.6)	-64.7 (-73.7 to -44.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	45.8 (-74.4 to -43.2)	64.3 (-74.4 to -43.2)
Non-melanoma skin cancer	0.9 (0.6 to 1.1)	2.1 (1.6 to 2.6)	144.2 (57.8 to 227.2)	33.7 (-11.0 to 80.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	238.2 (136.9 to 402.6)	80.7 (24.6 to 169.3)
Ovarian cancer	0.3 (0.2 to 0.3)	0.8 (0.6 to 1.0)	197.5 (116.8 to 296.1)	98.1 (43.1 to 164.2)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	186.6 (107.7 to 299.8)	89.1 (36.7 to 171.1)
Testicular cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	369.5 (21.7 to 855.7)	235.7 (-14.7 to 538.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	342.8 (9.6 to 823.6)	217.2 (-23.2 to 513.8)
Kidney cancer	0.4 (0.3 to 0.5)	0.7 (0.6 to 0.9)	78.8 (42.4 to 127.4)	21.7 (-3.1 to 56.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	77.6 (37.7 to 131.6)	16.7 (-8.5 to 53.6)
Bladder cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	30.6 (0.1 to 96.7)	-29.9 (-46.9 to 4.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.0 (0.0 to 96.8)	-28.9 (-47.0 to 5.4)
Brain and nervous system cancer	0.3 (0.2 to 0.4)	0.8 (0.5 to 1.0)	275.8 (56.0 to 381.7)	217.9 (31.2 to 302.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	298.9 (66.8 to 411.8)	213.0 (24.4 to 298.8)
Thyroid cancer	3.5 (2.0 to 4.5)	4.7 (3.2 to 8.1)	12.8 (-21.2 to 186.4)	-23.6 (-47.2 to 91.0)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.5)	13.7 (-21.2 to 178.2)	-23.6 (-47.5 to 87.4)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hodgkin lymphoma	0.1 (0.0 to 0.2)	0.5 (0.2 to 0.7)	972.9 (16.9 to 1,445.2)	938.9 (3.7 to 1,350.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	1,109.5 (52.1 to 1,564.9)	980.7 (-2.7 to 1,347.1)
Non-Hodgkin lymphoma	0.4 (0.2 to 0.7)	2.2 (1.0 to 3.2)	744.9 (71.2 to 1,099.1)	516.8 (15.5 to 786.7)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	688.8 (60.3 to 1,026.4)	455.5 (5.8 to 691.5)
Multiple myeloma	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	116.9 (53.2 to 199.0)	33.6 (-6.0 to 83.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.8 (54.7 to 174.9)	27.5 (-7.1 to 68.9)
Leukemia	1.4 (1.1 to 1.7)	1.8 (1.5 to 2.1)	30.5 (1.0 to 71.2)	25.6 (1.0 to 58.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	49.8 (18.7 to 89.1)	26.8 (1.9 to 50.1)
Other neoplasms	2.3 (1.6 to 2.8)	5.0 (4.0 to 6.6)	114.2 (59.7 to 238.4)	81.2 (36.8 to 168.0)	0.3 (0.1 to 0.2)	0.3 (0.2 to 0.5)	113.7 (61.2 to 233.1)	71.4 (29.9 to 148.4)
Cardiovascular diseases	-	-	-	-	3.4 (2.3 to 4.7)	9.4 (6.3 to 13.1)	174.2 (123.7 to 236.0)	65.0 (35.1 to 101.8)
Rheumatic heart disease	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	51.9 (40.3 to 64.7)	1.7 (-6.6 to 11.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.3 (21.7 to 88.1)	1.4 (-20.7 to 30.0)
Ischemic heart disease	32.6 (28.0 to 39.6)	102.5 (84.4 to 124.0)	211.1 (148.3 to 304.4)	79.0 (41.9 to 133.4)	1.5 (1.0 to 2.2)	5.7 (3.7 to 8.3)	264.3 (173.4 to 394.9)	18.1 (56.5 to 186.2)
Cerebrovascular disease	-	-	-	-	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.4)	62.1 (28.3 to 101.0)	0.5 (-22.1 to 23.8)
Ischemic stroke	1.1 (1.0 to 1.4)	1.9 (1.6 to 2.4)	72.2 (25.9 to 123.3)	-0.3 (-27.6 to 30.6)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	71.9 (24.3 to 126.4)	0.6 (-27.4 to 33.6)
Hemorrhagic stroke	3.2 (2.8 to 3.7)	5.1 (4.3 to 6.0)	61.1 (28.2 to 101.3)	-0.7 (-21.6 to 25.3)	0.5 (0.3 to 0.6)	0.7 (0.5 to 1.0)	59.5 (24.1 to 99.4)	-0.8 (-23.2 to 24.8)
Hypertensive heart disease	2.2 (1.9 to 2.6)	4.5 (3.9 to 5.1)	99.7 (72.4 to 127.9)	11.0 (-4.6 to 26.3)	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.7)	98.5 (68.5 to 132.9)	11.3 (-5.9 to 30.7)
Cardiomyopathy and myocarditis	0.9 (0.7 to 1.1)	1.8 (1.5 to 2.2)	100.6 (69.3 to 137.3)	25.8 (3.2 to 51.9)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	99.7 (64.0 to 140.0)	26.7 (2.3 to 55.5)
Atrial fibrillation and flutter	0.7 (0.4 to 1.2)	3.5 (2.3 to 5.0)	356.5 (185.3 to 776.3)	140.9 (48.2 to 373.4)	0.1 (0.0 to 0.1)	0.3 (0.1 to 0.4)	353.3 (178.5 to 758.2)	142.2 (44.8 to 371.4)
Peripheral vascular disease	98.2 (74.6 to 126.1)	172.1 (138.5 to 203.0)	76.4 (25.2 to 149.7)	4.7 (-23.7 to 45.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	136.0 (29.9 to 349.9)	12.7 (-37.6 to 110.4)
Endocarditis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	44.4 (-6.6 to 74.8)	17.6 (-25.9 to 42.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.5 (-1.1 to 93.6)	25.2 (-24.2 to 55.8)
Other cardiovascular and circulatory diseases	11.1 (6.3 to 19.0)	22.7 (12.7 to 34.1)	101.8 (-13.3 to 263.2)	36.5 (-36.7 to 146.8)	1.6 (0.4 to 1.4)	1.6 (0.8 to 2.6)	109.9 (-2.2 to 274.0)	36.9 (-3.6 to 147.6)
Chronic respiratory diseases	-	-	-	-	26.3 (18.1 to 36.5)	42.7 (29.8 to 58.0)	63.5 (38.3 to 90.4)	9.1 (-3.7 to 25.1)
Chronic obstructive pulmonary disease	147.9 (139.2 to 157.0)	225.8 (211.8 to 240.3)	52.7 (47.3 to 58.1)	0.1 (-3.3 to 4.0)	8.8 (5.8 to 12.3)	16.4 (10.8 to 23.2)	87.6 (59.4 to 118.2)	24.3 (6.4 to 45.7)

Appendix Table G.4 - El Salvador prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.9 (47.8 to 56.1)	4.7 (-7.2 to 2.1)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.7 (42.3 to 54.5)	-9.2 (-12.4 to -5.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.6 (42.9 to 55.3)	-8.8 (-12.1 to -4.7)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	53.3 (0.0 to 0.0)	-1.2 (48.1 to 58.7)	-1.2 (-4.4 to 1.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.6 (49.1 to 59.8)	-0.7 (-4.1 to 2.2)
Asthma	353.2 (291.8 to 421.0)	574.3 (515.0 to 639.5)	64.0 (32.1 to 103.4)	10.3 (-7.2 to 31.3)	15.4 (9.7 to 23.1)	25.3 (16.3 to 36.5)	65.0 (31.4 to 105.6)	11.6 (-6.5 to 33.1)
Interstitial lung disease and pulmonary sarcoidosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	69.1 (22.2 to 119.8)	7.1 (-24.5 to 39.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.8 (22.4 to 120.5)	7.2 (-24.1 to 40.2)
Other chronic respiratory diseases	-	-	-	-	2.1 (1.2 to 3.5)	1.0 (0.6 to 1.6)	-50.0 (-67.0 to -22.9)	-66.8 (-78.0 to -48.3)
Cirrhosis	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.2 to 0.5)	44.2 (26.2 to 64.5)	3.6 (-10.1 to 18.5)
Cirrhosis due to hepatitis B	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	114.3 (11.8 to 530.6)	48.5 (-21.4 to 356.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.4 (9.7 to 528.5)	44.3 (-24.9 to 349.6)
Cirrhosis due to hepatitis C	0.5 (0.4 to 0.6)	0.8 (0.6 to 1.0)	69.3 (10.5 to 129.3)	19.6 (-22.3 to 63.3)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	64.3 (4.2 to 139.3)	17.2 (-26.7 to 71.5)
Cirrhosis due to alcohol use	0.6 (0.5 to 0.7)	0.7 (0.6 to 0.9)	23.6 (-10.3 to 63.4)	-18.0 (-40.8 to 10.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	22.9 (-16.0 to 72.8)	-17.7 (-44.2 to 15.6)
Cirrhosis due to other causes	0.3 (0.3 to 0.4)	0.5 (0.4 to 0.6)	47.3 (9.0 to 99.0)	25.4 (-12.7 to 71.3)	0.0 (0.0 to 0.1)	0.2 (0.0 to 0.4)	46.3 (-9.9 to 115.7)	23.7 (-19.8 to 81.9)
Digestive diseases	-	-	-	-	4.0 (2.8 to 5.4)	5.4 (3.8 to 7.2)	34.4 (22.9 to 45.4)	-20.0 (-27.4 to -13.1)
Peptic ulcer disease	49.2 (43.8 to 54.2)	45.2 (39.3 to 50.9)	-7.9 (-18.7 to 3.2)	-50.4 (-56.6 to -44.2)	1.7 (1.1 to 2.4)	1.7 (1.2 to 2.4)	1.8 (-12.3 to 13.4)	-44.4 (-52.4 to -38.3)
Gastritis and duodenitis	6.7 (5.8 to 7.6)	4.3 (3.8 to 4.8)	-35.4 (-42.7 to -27.3)	-56.7 (-61.4 to -51.2)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-28.3 (-44.5 to -16.0)	-52.9 (-61.4 to -45.0)
Appendicitis	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.3)	3.0 (-17.9 to 26.6)	-13.0 (-30.4 to 4.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	4.6 (-35.5 to 61.9)	-12.1 (-41.7 to 26.7)
Paralytic ileus and intestinal obstruction	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-2.1 (-48.3 to 31.7)	-8.7 (-40.6 to 20.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.1 (-51.4 to 49.6)	-10.2 (-43.9 to 31.4)
Inguinal, femoral, and abdominal hernia	14.8 (13.4 to 16.3)	16.3 (14.6 to 18.3)	9.7 (-4.5 to 27.7)	-35.1 (-43.9 to -24.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	8.9 (-7.0 to 27.0)	-34.7 (-44.2 to -23.5)
Inflammatory bowel disease	5.2 (5.0 to 5.5)	9.6 (9.2 to 9.9)	82.8 (73.3 to 92.7)	23.6 (17.2 to 30.2)	1.1 (0.8 to 1.5)	2.0 (1.4 to 2.7)	82.2 (68.1 to 99.1)	24.1 (15.0 to 34.8)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.1 (30.8 to 188.8)	4.5 (-24.5 to 59.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.4 (1.1 to 194.0)	1.8 (-42.1 to 76.7)
Gallbladder and biliary diseases	3.1 (2.8 to 3.5)	4.4 (3.8 to 5.0)	40.9 (17.6 to 65.4)	0.3 (-24.5 to 5.6)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.6)	49.3 (15.4 to 71.4)	9.9 (-25.5 to 8.5)
Pancreatitis	0.3 (0.3 to 0.3)	0.6 (0.6 to 0.6)	118.6 (106.5 to 131.3)	48.0 (40.2 to 56.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	117.9 (73.6 to 182.2)	48.5 (19.1 to 91.1)
Other digestive diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	124.9 (38.4 to 187.2)	33.8 (-17.5 to 72.8)
Neurological disorders	-	-	-	-	30.1 (20.5 to 41.3)	44.0 (29.7 to 60.2)	46.7 (16.8 to 82.6)	3.9 (-14.3 to 25.4)
Alzheimer disease and other dementias	24.7 (21.4 to 28.2)	49.8 (42.2 to 58.0)	99.9 (61.8 to 153.5)	0.4 (-18.6 to 27.4)	3.4 (2.5 to 4.5)	7.1 (4.9 to 9.5)	104.0 (65.1 to 159.7)	1.3 (-18.1 to 29.2)
Parkinson disease	0.4 (0.3 to 0.4)	0.7 (0.6 to 0.8)	82.5 (71.6 to 95.4)	1.9 (-3.8 to 8.4)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	81.3 (49.4 to 118.7)	2.1 (-15.6 to 23.2)
Epilepsy	28.0 (19.0 to 38.0)	33.2 (22.0 to 46.6)	18.5 (-30.3 to 104.7)	-3.0 (-42.8 to 65.6)	8.9 (5.1 to 13.5)	11.4 (6.7 to 17.5)	29.1 (-25.1 to 125.2)	6.4 (-36.6 to 86.1)
Multiple sclerosis	0.2 (0.2 to 0.2)	0.5 (0.4 to 0.5)	181.6 (157.9 to 210.2)	0.1 (77.5 to 113.0)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	174.4 (132.0 to 223.3)	88.8 (59.4 to 122.5)
Migraine	378.7 (272.1 to 474.4)	486.5 (361.9 to 643.5)	24.2 (-12.7 to 97.9)	9.3 (-36.1 to 36.9)	12.8 (7.1 to 19.5)	16.3 (9.2 to 26.5)	48.3 (-13.2 to 99.5)	-8.9 (-35.3 to 38.8)
Tension-type headache	973.2 (807.8 to 1,162.3)	1,353.0 (1,254.4 to 1,445.8)	39.9 (16.4 to 70.1)	0.4 (-15.0 to 19.9)	1.5 (0.7 to 2.6)	2.0 (1.0 to 3.6)	40.3 (15.6 to 71.6)	0.8 (-14.8 to 21.7)
Medication overuse headache	19.8 (12.9 to 27.6)	41.8 (27.0 to 56.6)	113.1 (55.2 to 191.5)	44.8 (8.3 to 100.7)	3.1 (1.7 to 4.9)	6.5 (3.7 to 10.0)	113.6 (52.1 to 190.9)	45.9 (8.2 to 104.4)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.2 (-18.7 to 53.7)	-12.9 (-36.5 to 22.4)	0.2 (0.2 to 0.4)	0.4 (0.2 to 0.6)	53.6 (0.7 to 131.8)	-23.2 (-49.2 to 15.7)
Mental and substance use disorders	-	-	-	-	116.7 (81.1 to 159.9)	156.1 (107.4 to 212.8)	33.4 (28.7 to 40.0)	0.1 (-3.1 to 2.9)
Schizophrenia	11.2 (10.3 to 12.1)	16.2 (14.9 to 17.5)	44.0 (37.5 to 50.1)	-0.7 (-5.0 to 3.1)	7.2 (5.2 to 8.7)	10.3 (7.6 to 12.6)	44.4 (34.9 to 54.4)	-0.3 (-6.3 to 6.0)
Alcohol use disorders	87.3 (79.1 to 96.5)	135.1 (124.3 to 148.4)	54.9 (44.2 to 65.6)	9.3 (1.9 to 16.4)	8.7 (5.7 to 12.2)	13.5 (9.1 to 19.4)	55.8 (44.8 to 66.8)	9.8 (2.4 to 17.4)
Drug use disorders	-	-	-	-	5.8 (3.7 to 8.1)	7.6 (4.8 to 10.5)	31.0 (8.2 to 56.6)	-4.1 (-20.0 to 13.6)
Opioid use disorders	2.8 (1.4 to 4.7)	4.2 (2.0 to 7.0)	49.9 (35.0 to 62.5)	2.3 (-7.1 to 10.9)	1.1 (0.5 to 2.1)	1.7 (0.8 to 3.0)	50.0 (29.9 to 72.7)	2.4 (-11.2 to 18.4)
Cocaine use disorders	5.9 (5.9 to 8.7)	7.2 (6.1 to 11.3)	22.3 (-20.6 to 64.2)	10.9 (40.5 to 16.4)	1.0 (0.6 to 1.5)	1.2 (0.7 to 1.8)	11.2 (-22.5 to 67.7)	-11.3 (-41.0 to 18.9)
Amphetamine use disorders	9.7 (9.0 to 10.4)	12.6 (11.7 to 13.5)	30.2 (17.5 to 44.9)	-1.8 (-10.7 to 8.6)	1.3 (0.8 to 1.8)	1.7 (1.0 to 2.5)	30.5 (13.9 to 52.1)	-1.4 (-14.2 to 14.0)
Cannabis use disorders	3.9 (3.0 to 4.7)	5.1 (4.0 to 6.2)	31.3 (29.8 to 33.1)	-0.0 (-0.2 to 0.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	31.7 (4.1 to 69.7)	0.5 (-19.7 to 25.6)
Other drug use disorders	-	-	-	-	2.3 (1.4 to 3.3)	2.9 (1.7 to 4.3)	25.7 (-11.1 to 75.5)	-6.8 (-33.8 to 28.9)
Depressive disorders	-	-	-	-	42.3 (23.0 to 69.0)	58.0 (30.5 to 94.1)	36.3 (24.9 to 50.4)	0.4 (-8.2 to 6.4)
Major depressive disorder	182.7 (99.0 to 268.6)	248.5 (127.2 to 356.2)	35.2 (21.3 to 50.2)	-1.3 (-10.1 to 6.4)	37.4 (18.5 to 62.7)	50.8 (24.3 to 85.3)	34.8 (21.2 to 50.8)	-0.7 (-10.0 to 7.2)
Dysthymia	51.2 (41.6 to 60.4)	75.4 (62.2 to 88.6)	47.3 (45.2 to 50.1)	1.0 (0.7 to 1.3)	4.9 (3.2 to 7.1)	7.2 (4.7 to 10.5)	47.3 (42.6 to 52.1)	1.3 (-1.2 to 3.9)
Bipolar disorder	35.6 (28.6 to 42.2)	50.4 (40.5 to 59.9)	41.5 (33.3 to 49.0)	-0.1 (-5.1 to 4.8)	7.2 (4.4 to 11.1)	10.2 (6.1 to 15.6)	41.5 (32.1 to 51.6)	0.3 (-5.8 to 7.0)
Anxiety disorders	211.2 (138.7 to 278.9)	262.9 (188.2 to 366.4)	33.9 (27.7 to 40.5)	0.7 (0.3 to 1.2)	19.4 (11.3 to 29.6)	25.9 (15.6 to 39.5)	33.7 (26.6 to 41.5)	1.0 (-1.4 to 3.3)
Eating disorders	-	-	-	-	1.6 (1.0 to 2.5)	2.1 (1.3 to 3.3)	31.8 (20.0 to 43.4)	1.5 (-7.0 to 10.2)
Anorexia nervosa	1.2 (0.9 to 1.6)	1.7 (1.2 to 2.1)	33.8 (19.3 to 47.9)	7.6 (-4.6 to 19.1)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	31.8 (6.5 to 70.3)	6.2 (-14.3 to 33.9)
Bulimia nervosa	6.4 (4.3 to 9.4)	8.4 (5.5 to 12.3)	31.0 (27.7 to 34.0)	-0.1 (-0.9 to 0.8)	1.4 (0.8 to 2.2)	1.8 (1.0 to 2.9)	31.7 (19.4 to 43.6)	0.5 (-8.0 to 9.3)
Autistic spectrum disorders	-	-	-	-	6.2 (4.3 to 8.5)	7.3 (5.1 to 9.9)	16.7 (12.1 to 21.3)	-6.7 (-4.0 to 2.6)
Autism	15.8 (15.0 to 16.7)	18.6 (17.6 to 19.6)	17.5 (16.8 to 18.2)	-0.9 (-1.0 to -0.9)	3.9 (2.6 to 5.4)	4.6 (3.1 to 6.3)	17.3 (10.8 to 23.4)	-0.6 (-5.5 to 4.2)
Asperger syndrome	23.3 (21.8 to 24.6)	27.1 (25.4 to 28.7)	16.3 (15.5 to 17.2)	-1.2 (-1.3 to -1.2)	2.3 (1.6 to 3.3)	2.7 (1.9 to 3.8)	16.1 (11.1 to 21.4)	-0.8 (-4.6 to 3.1)
Attention-deficit/hyperactivity disorder	49.3 (45.1 to 52.5)	51.5 (47.2 to 55.0)	4.7 (4.1 to 5.0)	0.6 (0.6 to 0.7)	0.6 (0.4 to 0.9)	0.6 (0.4 to 1.0)	5.0 (-2.5 to 12.1)	1.0 (-6.1 to 7.7)
Conduct disorder	65.8 (61.2 to 70.5)	70.0 (65.1 to 75.1)	6.4 (5.3 to 7.5)	0.7 (0.7 to 0.8)	7.9 (4.9 to 11.5)	8.4 (5.2 to 12.3)	6.7 (2.1 to 11.6)	1.1 (-3.1 to 5.4)
Idiopathic intellectual disability	99.0 (74.6 to 123.9)	99.4 (80.5 to 120.9)	0.1 (-13.2 to 21.2)	-14.0 (-25.1 to 5.3)	4.8 (3.2 to 6.9)	4.9 (3.2 to 6.8)	0.1 (-13.7 to 21.2)	-13.5 (-25.6 to 5.8)
Other mental and substance use disorders	67.4 (63.0 to 71.5)	97.8 (91.8 to 103.6)	45.1 (44.3 to 45.9)	-0.9 (-1.2 to -0.6)	5.0 (3.4 to 6.7)	7.3 (5.0 to 9.7)	45.0 (39.5 to 51.4)	-0.6 (-4.1 to 3.2)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	29.4 (20.3 to 39.9)	50.1 (34.9 to 68.6)	70.2 (55.1 to 89.6)	25.5 (12.8 to 41.7)
Diabetes mellitus	151.1 (124.7 to 179.1)	350.3 (295.4 to 409.9)	130.3 (88.8 to 190.7)	60.5 (27.7 to 110.9)	10.6 (7.9 to 15.0)	24.9 (16.8 to 35.5)	132.9 (91.4 to 194.9)	56.6 (24.9 to 102.0)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.9 (-22.9 to -13.1)	-20.7 (-24.5 to -17.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.9 (-22.9 to -13.1)	-20.7 (-24.5 to -17.0)
Chronic kidney disease	-	-	-	-	6.1 (4.3 to 8.2)	8.5 (6.2 to 11.3)	40.2 (21.0 to 59.1)	7.1 (-7.6 to 22.1)
Chronic kidney disease due to diabetes mellitus	83.3 (57.0 to 134.0)	130.3 (90.5 to 201.5)	57.3 (23.4 to 96.3)	3.7 (-15.3 to 29.6)	1.2 (0.8 to 1.6)	1.9 (1.3 to 2.6)	68.8 (31.4 to 105.7)	11.8 (-13.8 to 35.7)
Chronic kidney disease due to hypertension	87.8 (52.5 to 147.8)	117.4 (73.8 to 177.1)	35.6 (3.5 to 73.0)	9.5 (-13.2 to 44.6)	1.5 (1.1 to 2.1)	2.3 (1.6 to 3.0)	47.5 (25.4 to 78.8)	6.3 (-9.8 to 27.1)
Chronic kidney disease due to glomerulonephritis	112.7 (76.8 to 166.7)	157.2 (104.5 to 225.4)	39.8 (15.0 to 69.3)	1.4 (-16.8 to 24.9)	1.4 (0.9 to 1.9)	1.7 (1.2 to 2.4)	27.1 (-1.6 to 69.7)	10.2 (-17.0 to 47.1)
Chronic kidney disease due to other causes	148.8 (90.3 to 225.5)	180.2 (128.4 to 253.5)	21.6 (2.6 to 57.5)	-2.2 (-22.6 to 26.3)	2.1 (1.4 to 2.9)	2.6 (1.8 to 3.5)	28.0 (2.6 to 62.0)	2.2 (-21.9 to 36.3)
Urinary diseases and male infertility	-	-	-	-	1.2 (0.8 to 1.7)	2.0 (1.3 to 2.8)	64.3 (37.8 to 95.4)	-3.8 (-19.5 to 15.9)

Appendix Table G.4 - El Salvador prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.2 (1.1 to 1.3)	1.6 (1.3 to 1.9)	35.8 (11.1 to 61.4)	0.0 (-8.1 to 23.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	34.0 (2.4 to 74.6)	34.0 (-14.4 to 32.8)
Urolithiasis	30.9 (22.5 to 48.0)	65.9 (41.9 to 99.4)	113.7 (74.1 to 160.3)	0.2 (3.9 to 53.4)	0.4 (0.1 to 0.3)	0.4 (0.2 to 0.6)	128.8 (84.9 to 169.9)	40.9 (15.9 to 66.6)
Benign prostatic hyperplasia	24.9 (20.7 to 28.3)	39.3 (32.9 to 46.9)	57.4 (31.7 to 98.0)	-1.2 (-25.8 to 11.9)	0.9 (0.6 to 1.2)	1.4 (0.9 to 2.0)	53.7 (28.4 to 93.7)	-12.5 (-27.6 to 11.0)
Male infertility due to other causes	12.4 (8.4 to 16.6)	14.4 (11.0 to 18.2)	16.4 (-22.2 to 80.5)	-18.5 (-45.2 to 21.6)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	16.6 (-25.5 to 89.7)	-17.6 (-46.9 to 26.9)
Other urinary diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	17.4 (79.9 to 190.5)	46.8 (14.7 to 85.2)
Gynecological diseases	-	-	-	-	6.9 (4.5 to 10.2)	10.0 (6.5 to 15.0)	46.1 (32.1 to 61.8)	2.1 (-7.3 to 12.2)
Uterine fibroids	84.3 (76.1 to 91.7)	132.1 (119.5 to 143.5)	56.8 (56.1 to 57.5)	6.8 (6.6 to 7.0)	1.8 (1.1 to 2.8)	2.6 (1.6 to 4.1)	44.6 (37.2 to 50.3)	-0.8 (-5.8 to 3.2)
Polycystic ovarian syndrome	77.4 (68.3 to 86.5)	114.8 (101.5 to 127.5)	48.0 (26.0 to 77.3)	4.5 (-9.9 to 23.9)	0.7 (0.3 to 1.4)	1.1 (0.5 to 2.1)	47.6 (25.1 to 75.7)	4.3 (-9.9 to 22.8)
Female infertility due to other causes	7.6 (4.5 to 11.4)	8.8 (4.7 to 14.3)	14.2 (-42.3 to 58.6)	-22.1 (-60.4 to 54.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	13.5 (-59.5 to 56.1)	-22.2 (-59.5 to 56.1)
Endometriosis	8.2 (6.9 to 9.6)	13.1 (11.2 to 15.1)	58.6 (28.8 to 98.9)	11.1 (-10.1 to 38.0)	0.8 (0.5 to 1.1)	1.2 (0.8 to 1.7)	58.8 (26.0 to 101.4)	11.1 (-11.9 to 40.6)
Genital prolapse	286.7 (251.0 to 323.7)	439.8 (381.0 to 500.7)	54.2 (26.1 to 82.1)	4.0 (-13.5 to 21.6)	0.9 (0.4 to 1.7)	1.4 (0.7 to 2.6)	54.4 (26.5 to 84.4)	4.3 (-13.6 to 22.8)
Premenstrual syndrome	216.9 (170.8 to 272.3)	320.8 (244.8 to 418.0)	48.3 (5.8 to 107.7)	5.1 (-25.5 to 50.5)	1.8 (1.0 to 2.9)	2.7 (1.6 to 4.2)	48.5 (6.0 to 111.2)	5.3 (-25.5 to 50.9)
Other gynecological diseases	24.3 (22.3 to 26.5)	32.0 (27.1 to 34.6)	31.8 (5.4 to 53.1)	-4.0 (-23.2 to 11.0)	0.8 (0.5 to 1.2)	1.0 (0.7 to 1.5)	22.0 (-5.3 to 44.3)	-10.6 (-29.9 to 5.1)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	2.7 (1.7 to 3.9)	2.7 (1.8 to 3.9)	1.2 (-6.5 to 12.3)	-3.5 (-11.8 to 6.6)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.0 (-16.0 to 3.8)	-2.7 (-11.2 to 9.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.4 (-16.8 to -6.8)	-4.1 (-10.0 to 0.6)
Thalassemia trait	36.5 (30.9 to 42.4)	43.5 (36.5 to 50.3)	18.6 (13.3 to 25.5)	0.3 (-4.3 to 6.1)	0.8 (0.5 to 1.2)	0.9 (0.6 to 1.2)	4.5 (8.5 to 23.5)	1.1 (-12.0 to 19.8)
Sickle cell disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	8.6 (-0.0 to 21.5)	0.4 (-7.4 to 9.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.7 (8.1 to 29.2)	4.2 (-2.4 to 13.3)
Sickle cell trait	72.2 (64.4 to 80.8)	84.7 (74.7 to 95.8)	17.2 (12.3 to 23.1)	0.4 (-5.0 to 4.0)	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.6)	17.2 (-25.8 to 33.5)	0.2 (-22.6 to 29.0)
G6PD deficiency	102.9 (84.9 to 121.4)	122.9 (94.6 to 152.0)	18.8 (-14.0 to 64.2)	0.6 (-27.0 to 38.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.9 (9.7 to 19.5)	5.1 (1.6 to 9.9)
G6PD trait	664.1 (611.7 to 713.3)	805.3 (730.8 to 882.1)	21.1 (7.5 to 36.9)	2.2 (-9.3 to 15.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	22.4 (-18.0 to 82.2)	3.8 (-20.0 to 46.1)
Other hemoglobinopathies and hemolytic anemias	45.8 (43.0 to 54.5)	48.7 (45.5 to 51.9)	6.5 (-13.3 to 15.0)	1.4 (-25.8 to -0.2)	1.4 (0.9 to 2.1)	1.4 (0.9 to 2.0)	-0.8 (-12.1 to 13.8)	-7.3 (-18.9 to 3.8)
Endocrine, metabolic, blood, and immune disorders	53.3 (47.7 to 57.7)	58.7 (54.0 to 62.9)	9.9 (-0.6 to 23.4)	1.9 (-10.9 to 14.9)	2.0 (1.2 to 2.7)	2.0 (1.3 to 2.8)	4.3 (-5.7 to 62.5)	1.5 (-10.8 to 52.2)
Musculoskeletal disorders	-	-	-	-	68.7 (47.2 to 92.0)	109.5 (77.5 to 146.2)	59.8 (36.8 to 84.4)	8.1 (-5.2 to 20.1)
Rheumatoid arthritis	10.6 (9.6 to 11.7)	14.3 (12.1 to 16.5)	34.7 (10.0 to 66.4)	-12.5 (-29.8 to 11.8)	2.5 (1.7 to 3.3)	3.3 (2.2 to 4.5)	33.2 (7.9 to 66.8)	-12.4 (-30.0 to 12.3)
Osteoarthritis	127.0 (121.8 to 131.9)	219.2 (211.8 to 227.1)	72.7 (64.2 to 81.6)	2.5 (-2.6 to 7.7)	7.6 (5.4 to 10.3)	13.1 (9.2 to 17.7)	72.2 (63.2 to 82.1)	2.9 (-2.6 to 8.7)
Low back and neck pain	-	-	-	-	50.7 (33.0 to 69.8)	74.2 (49.8 to 103.3)	46.5 (17.5 to 80.7)	1.0 (-18.3 to 18.7)
Low back pain	345.5 (268.4 to 412.5)	504.0 (416.5 to 593.5)	45.7 (9.0 to 91.6)	-0.1 (-23.7 to 25.6)	38.2 (23.8 to 55.8)	55.5 (36.9 to 78.4)	44.9 (8.2 to 90.8)	0.2 (-24.0 to 25.7)
Neck pain	128.4 (99.1 to 155.5)	192.1 (141.9 to 248.0)	49.1 (3.6 to 117.5)	0.7 (-29.8 to 47.5)	12.5 (8.0 to 18.1)	18.7 (11.8 to 28.4)	48.4 (2.4 to 119.7)	1.3 (-29.5 to 48.8)
Gout	1.7 (1.5 to 2.0)	2.8 (2.4 to 3.2)	62.6 (29.0 to 93.2)	0.2 (-21.4 to 19.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	0.6 (-17.0 to 108.5)	-0.6 (-27.5 to 30.8)
Other musculoskeletal disorders	87.3 (51.5 to 117.2)	209.8 (169.1 to 248.3)	136.4 (104.2 to 240.1)	54.5 (32.2 to 125.7)	7.9 (4.3 to 12.2)	18.5 (12.4 to 26.9)	151.1 (103.0 to 242.7)	94.6 (31.5 to 139.5)
Other non-communicable diseases	-	-	-	-	79.9 (54.7 to 112.7)	107.0 (73.3 to 152.9)	34.0 (7.6 to -2.0)	-4.7 (-29.1 to 38.8)
Congenital anomalies	-	-	-	-	5.7 (4.2 to 7.5)	9.1 (6.5 to 11.8)	60.2 (37.6 to 90.5)	39.5 (19.8 to 65.2)
Neural tube defects	1.6 (1.3 to 2.0)	2.3 (1.9 to 2.8)	39.1 (6.6 to 84.4)	32.0 (1.2 to 73.8)	0.5 (0.3 to 0.7)	0.7 (0.5 to 1.0)	47.8 (-0.1 to 121.9)	42.0 (-3.7 to 111.9)
Congenital heart anomalies	16.7 (12.1 to 21.5)	42.3 (35.6 to 48.6)	154.0 (79.6 to 264.6)	137.8 (67.7 to 244.6)	0.6 (0.2 to 1.0)	1.5 (0.6 to 2.6)	163.9 (88.6 to 282.8)	152.3 (77.7 to 266.4)
Orofacial clefts	3.0 (2.3 to 4.2)	6.6 (5.6 to 7.5)	122.6 (54.1 to 196.3)	0.0 (-58.5 to 204.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	44.2 (-7.7 to 115.8)	47.4 (-4.7 to 118.0)
Down syndrome	6.1 (4.9 to 7.4)	9.3 (8.0 to 10.8)	53.6 (19.9 to 100.1)	37.6 (8.0 to 78.9)	0.7 (0.5 to 1.0)	1.2 (0.9 to 1.6)	65.4 (27.6 to 115.6)	45.3 (12.6 to 88.0)
Turner syndrome	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.3)	34.9 (-6.6 to 102.6)	17.3 (-18.7 to 78.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.0 (-5.0 to 113.0)	18.0 (-19.6 to 82.4)
Klinefelter syndrome	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.2)	15.7 (-17.5 to 55.4)	-0.8 (-29.2 to 32.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.0 (-9.2 to 72.0)	-1.4 (-29.7 to 32.4)
Chromosomal unbalanced rearrangements	47.8 (6.5 to 9.4)	12.5 (10.5 to 15.2)	48.8 (25.9 to 112.6)	61.6 (-0.7 to 31.6)	0.9 (0.6 to 1.3)	1.6 (1.2 to 2.2)	76.6 (23.0 to 129.4)	52.7 (18.8 to 103.3)
Other congenital anomalies	24.2 (20.6 to 27.9)	26.2 (22.1 to 30.6)	8.2 (-2.1 to 19.5)	-12.9 (-21.1 to -4.1)	2.9 (1.9 to 4.1)	3.9 (2.7 to 5.5)	36.3 (13.2 to 75.0)	13.5 (-5.0 to 46.2)
Skin and subcutaneous diseases	-	-	-	-	26.2 (16.7 to 38.9)	32.4 (20.7 to 49.7)	24.2 (12.8 to 34.4)	0.8 (-7.0 to 7.2)
Dermatitis	262.3 (211.7 to 320.1)	333.4 (267.4 to 405.7)	27.2 (24.1 to 29.7)	0.1 (-0.1 to 0.2)	8.3 (5.1 to 12.2)	10.0 (6.1 to 14.8)	21.0 (14.6 to 26.8)	0.4 (-2.4 to 3.2)
Psoriasis	37.8 (33.4 to 42.5)	51.8 (45.6 to 58.4)	37.0 (35.3 to 39.1)	0.0 (-0.2 to 0.2)	4.2 (2.1 to 4.3)	4.2 (2.9 to 5.9)	36.8 (29.4 to 45.3)	0.4 (-4.3 to 5.6)
Cellulitis	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.4)	25.6 (14.4 to 37.9)	-1.1 (-9.5 to 7.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (11.7 to 39.8)	-1.7 (-12.3 to 10.4)
Pyoderma	2.2 (1.7 to 2.9)	2.7 (2.1 to 3.8)	24.1 (1.7 to 49.6)	12.0 (-6.1 to 31.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.6 (-3.5 to 56.1)	12.2 (-10.2 to 37.1)
Scabies	67.5 (58.8 to 77.6)	66.4 (59.4 to 74.3)	-1.7 (-19.1 to 18.7)	-14.0 (-29.6 to 3.6)	1.7 (1.0 to 2.8)	1.7 (1.0 to 2.8)	-1.9 (-19.5 to 18.2)	-13.9 (-30.0 to 3.8)
Fungal skin diseases	364.4 (275.8 to 478.2)	472.5 (360.7 to 622.2)	29.8 (24.0 to 35.6)	29.4 (-0.7 to 31.6)	2.6 (0.8 to 4.5)	2.6 (1.1 to 5.9)	29.4 (23.7 to 35.5)	-0.2 (-1.2 to 0.8)
Viral skin diseases	105.0 (82.7 to 125.2)	111.6 (86.6 to 137.6)	6.1 (-0.1 to 12.5)	-0.0 (-2.4 to 2.5)	3.3 (1.9 to 5.0)	3.5 (2.0 to 5.5)	6.2 (-1.5 to 13.3)	0.2 (-3.6 to 3.9)
Acne vulgaris	298.1 (209.6 to 393.1)	400.7 (294.3 to 532.1)	33.0 (-15.2 to 105.9)	11.7 (-27.3 to 65.3)	3.2 (1.4 to 6.2)	4.4 (1.9 to 8.7)	33.0 (-15.3 to 105.9)	11.9 (-27.4 to 66.6)
Alopecia areata	4.4 (4.0 to 4.9)	5.7 (5.2 to 6.3)	30.5 (12.6 to 47.1)	-0.9 (-13.8 to 12.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	29.5 (7.8 to 54.5)	-0.6 (-17.7 to 17.1)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.5 (2.0 to 75.7)	4.3 (-27.2 to 28.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.3 (1.8 to 75.9)	4.3 (-7.3 to 28.1)
Urticaria	47.4 (28.3 to 65.6)	60.3 (42.6 to 84.3)	24.7 (-12.7 to 117.5)	-3.4 (-31.0 to 54.4)	2.8 (1.4 to 4.6)	3.5 (2.1 to 5.9)	23.4 (-13.5 to 117.1)	-3.3 (-31.4 to 55.4)
Decubitus ulcer	0.5 (0.4 to 0.7)	1.2 (0.9 to 1.5)	123.5 (61.4 to 219.1)	27.8 (-11.7 to 88.4)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	26.9 (54.2 to 215.0)	26.9 (-14.1 to 93.3)
Other skin and subcutaneous diseases	258.2 (174.1 to 385.2)	371.5 (240.7 to 580.6)	43.3 (32.4 to 54.0)	-1.1 (-4.1 to 2.7)	1.5 (0.7 to 3.1)	2.2 (0.9 to 4.5)	42.6 (32.0 to 53.5)	-0.9 (-4.1 to 3.1)
Sense organ diseases	-	-	-	-	35.0 (24.0 to 48.5)	46.5 (32.2 to 64.0)	31.1 (27.0 to 39.4)	-12.1 (-15.2 to -8.4)
Glaucoma	8.5 (7.3 to 9.8)	11.5 (9.9 to 13.2)	35.7 (18.6 to 53.3)	-18.2 (-29.4 to -6.8)	0.6 (0.4 to 0.8)	0.8 (0.6 to 1.1)	41.4 (18.0 to 68.5)	16.8 (-31.4 to -0.5)
Cataract	33.6 (28.1 to 39.8)	46.2 (38.5 to 53.1)	37.6 (22.6 to 54.0)	-27.4 (-35.3 to -19.2)	2.1 (1.4 to 2.9)	3.0 (2.1 to 4.0)	42.7 (25.6 to 59.4)	-25.8 (-34.9 to -17.0)
Macular degeneration	11.7 (9.2 to 14.4)	21.3 (17.3 to 25.9)	83.9 (48.3 to 124.3)	9.3 (-12.1 to 34.6)	0.5 (0.3 to 0.7)	0.9 (0.6 to 1.3)	82.2 (47.2 to 121.7)	7.4 (-13.8 to 32.0)
Uncorrected refractive error	470.5 (410.0 to 537.6)	644.4 (554.9 to 723.6)	37.5 (13.6 to 62.2)	-5.5 (-21.7 to 12.5)	7.7 (4.7 to 12.1)	9.9 (5.9 to 15.9)	28.8 (14.7 to 44.6)	-11.4 (-21.3 to 0.4)
Age-related and other hearing loss	589.7 (550.8 to 631.5)	831.0 (782.0 to 886.0)	40.8 (35.8 to 47.0)	-9.8 (-12.6 to -6.2)	19.2 (13.1 to 26.4)	26.6 (18.3 to 36.2)	26.9 (29.9 to 48.6)	-10.5 (-14.2 to -6.0)
Other vision loss	21.5 (19.0 to 24.4)	20.5 (18.2 to 23.0)	-4.3 (-10.9 to 2.2)	-32.5 (-37.2 to -27.7)	1.6 (1.1 to 2.1)	1.5 (1.1 to 2.1)	-0.3 (-8.6 to 9.5)	-31.8 (-38.1 to -25.4)
Other sense organ diseases	127.0 (120.4 to 133.0)	144.5 (137.6 to 151.5)	13.7 (6.0 to 22.2)	-0.2 (-6.1 to 6.6)	3.4 (2.1 to 5.0)	3.8 (2.3 to 5.7)	12.9 (4.5 to 22.4)	0.1 (-6.4 to 7.6)
Oral disorders	-	-	-	-	13.1 (7.9 to 20.3)	18.9 (11.5 to 29.2)	44.4 (35.3 to 49.4)	-4.3 (-7.7 to -0.8)
Deciduous caries	472.1 (449.1 to 496.4)	392.2 (372.5 to 410.2)	-16.9 (-22.9 to -10.6)	1.1 (-6.3 to 8.8)	1.1 (0.1 to 0.3)	1.1 (0.1 to 0.3)	-1.2 (-1.8 to -0.6)	1.2 (-8.9 to 11.2)
Permanent caries	2,095.1 (1,979.3 to 2,221.7)	2,680.5 (2,531.6 to 2,824.4)	28.3 (18.1 to 38.2)	1.3 (-6.0 to 8.3)	2.1 (0.9 to 3.9)	2.6 (1.2 to 5.2)	28.2 (17.5 to 38.1)	1.7 (-6.3 to 8.7)
Periodontal diseases	448.3 (427.8 to 470.0)	685.9 (650.5 to 720.4)	53.0 (42.8 to 63.9)	2.4 (-4.8 to 10.0)	2.9 (1.1 to 5.9)	4.5 (1.8 to 9.0)	52.9 (42.4 to 64.1)	2.5 (-4.8 to 10.3)

Appendix Table G.4 - El Salvador prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.								
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	205.7 (197.9 to 213.2)	316.2 (305.9 to 327.1)	53.6 (46.7 to 61.6)	-9.2 (-13.3 to -4.4)	5.6 (3.8 to 7.7)	8.5 (5.8 to 11.8)	52.8 (45.6 to 61.3)	52.8 (-13.5 to -4.0)
Other oral disorders	80.8 (75.8 to 85.5)	107.5 (101.6 to 113.8)	32.7 (23.5 to 44.4)	-0.6 (-7.5 to 7.5)	2.4 (1.5 to 3.6)	3.1 (2.0 to 4.7)	32.6 (22.6 to 45.0)	-0.4 (-7.7 to 8.3)
Injuries	-	-	-	-	49.6 (31.5 to 80.7)	42.2 (28.0 to 65.1)	-13.4 (-41.9 to 15.7)	-36.3 (-59.9 to -11.1)
Transport injuries	-	-	-	-	9.9 (7.4 to 12.8)	8.6 (6.3 to 11.7)	-12.8 (-21.1 to -5.0)	-41.2 (-46.6 to -36.1)
Road injuries	-	-	-	-	9.3 (7.1 to 12.2)	7.9 (5.7 to 10.7)	-16.9 (-25.1 to -9.2)	-42.2 (-49.2 to -39.0)
Pedestrian road injuries	-	-	-	-	2.2 (1.6 to 2.8)	1.7 (1.2 to 2.3)	-21.0 (-31.5 to -9.4)	-46.3 (-52.6 to -39.2)
Cyclist road injuries	-	-	-	-	0.8 (0.6 to 1.1)	0.7 (0.5 to 0.9)	-17.6 (-26.0 to -9.3)	-46.8 (-52.3 to -41.3)
Motorcyclist road injuries	-	-	-	-	0.7 (0.5 to 1.0)	0.6 (0.4 to 0.8)	-21.0 (-29.5 to -11.6)	-46.9 (-52.4 to -40.8)
Motor vehicle road injuries	-	-	-	-	5.7 (4.3 to 7.4)	4.9 (3.6 to 6.6)	-14.5 (-24.4 to -5.5)	-42.2 (-48.3 to -36.4)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-59.7 (-65.1 to -53.2)	-71.1 (-74.6 to -67.0)
Other transport injuries	-	-	-	-	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.0)	80.4 (63.3 to 101.1)	27.3 (17.0 to 39.8)
Unintentional injuries	-	-	-	-	17.6 (12.7 to 24.4)	8.7 (6.4 to 11.6)	-50.2 (-54.7 to -46.9)	-64.8 (-67.4 to -62.8)
Falls	-	-	-	-	4.7 (3.6 to 6.1)	4.0 (2.9 to 5.4)	-14.6 (-23.0 to -6.3)	-49.0 (-54.5 to -43.0)
Drowning	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-1.9 (-18.3 to 10.8)	-31.8 (-40.9 to -20.7)
Fire, heat, and hot substances	-	-	-	-	0.6 (0.5 to 0.8)	0.3 (0.2 to 0.5)	-46.4 (-53.7 to -37.7)	-60.4 (-65.6 to -54.2)
Poisonings	-	-	-	-	0.3 (0.2 to 0.4)	0.0 (0.0 to 0.0)	-92.2 (-93.8 to -90.5)	-94.0 (-95.1 to -92.8)
Exposure to mechanical forces	-	-	-	-	10.5 (7.2 to 15.5)	3.2 (2.3 to 4.4)	-68.6 (-73.8 to -64.2)	-76.9 (-80.6 to -73.6)
Unintentional firearm injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-64.2 (-59.1 to -48.5)	-68.5 (-71.5 to -65.0)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-28.8 (-39.4 to -17.6)	-46.6 (-53.8 to -39.1)
Other exposure to mechanical forces	-	-	-	-	10.1 (6.9 to 15.0)	3.1 (2.2 to 4.1)	-69.3 (-74.5 to -64.7)	-77.3 (-81.1 to -73.9)
Adverse effects of medical treatment	-	-	-	-	0.6 (0.4 to 0.8)	0.0 (0.0 to 0.1)	-91.7 (-95.1 to -85.7)	-94.4 (-96.7 to -90.3)
Animal contact	-	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-42.6 (-57.1 to -28.7)	-52.3 (-63.2 to -42.4)
Venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-36.1 (-46.4 to -23.9)	-49.8 (-58.2 to -40.9)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-45.9 (-64.5 to -23.1)	-53.5 (-68.3 to -35.8)
Foreign body	-	-	-	-	0.3 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-41.4 (-47.9 to -34.9)	-56.5 (-60.7 to -51.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-36.3 (-47.0 to -22.8)	-50.6 (-58.0 to -41.4)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.3 (-25.3 to 5.1)	-33.1 (-46.0 to -20.8)
Foreign body in other body part	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-49.6 (-57.2 to -40.9)	-63.3 (-68.0 to -57.7)
Other unintentional injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.8)	78.6 (56.3 to 98.9)	9.2 (5.0 to 21.9)
Self-harm and interpersonal violence	-	-	-	-	4.9 (3.7 to 6.4)	5.0 (3.6 to 6.7)	2.0 (-5.7 to 8.9)	-31.9 (-36.9 to -27.2)
Self-harm	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-16.0 (-25.1 to -7.7)	-44.9 (-50.5 to -39.3)
Interpersonal violence	-	-	-	-	4.7 (3.5 to 6.2)	4.8 (3.5 to 6.5)	2.8 (-4.8 to 9.8)	-31.3 (-36.4 to -26.6)
Assault by firearm	-	-	-	-	1.5 (1.1 to 2.0)	2.2 (1.6 to 3.1)	42.7 (31.3 to 55.0)	-6.2 (-13.7 to 1.5)
Assault by sharp object	-	-	-	-	1.0 (0.7 to 1.4)	1.0 (0.7 to 1.4)	0.8 (-7.6 to 12.8)	-32.4 (-38.0 to -24.8)
Assault by other means	-	-	-	-	2.2 (1.6 to 2.7)	1.6 (1.2 to 2.1)	-25.2 (-32.1 to -19.0)	-49.8 (-54.4 to -45.5)
Forces of nature, war, and legal intervention	-	-	-	-	17.1 (3.4 to 46.1)	19.8 (9.1 to 38.6)	29.1 (-50.8 to 359.3)	2.0 (-65.6 to 330.7)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4,821,018.1 (694,255.5 to 39,410,867.0)	2,464,944.1 (378,927.2 to 24,840,404.7)
Collective violence and legal intervention	-	-	-	-	17.1 (3.4 to 46.1)	19.8 (9.0 to 38.6)	28.9 (-50.9 to 358.9)	1.9 (-65.7 to 330.5)

Appendix Table G.4 - Equatorial Guinea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	39.4 (29.0 to 51.3)	74.3 (54.2 to 96.9)	88.3 (82.2 to 95.6)	88.3 (-9.2 to 2.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	11.9 (8.3 to 16.4)	18.7 (13.1 to 25.8)	56.3 (43.0 to 77.0)	56.3 (-29.7 to -10.3)
HIV/AIDS and tuberculosis	-	-	-	-	0.5 (0.3 to 0.8)	3.5 (1.9 to 6.1)	526.1 (296.9 to 918.3)	202.7 (91.9 to 393.4)
Tuberculosis	1.1 (1.0 to 1.2)	2.1 (1.9 to 2.3)	93.5 (79.5 to 108.3)	-2.5 (-8.5 to 3.2)	0.2 (0.2 to 0.5)	0.9 (0.4 to 2.9)	22.1 (78.6 to 112.6)	-1.9 (-8.7 to 5.3)
HIV/AIDS	-	-	-	-	0.2 (0.1 to 0.4)	2.9 (1.3 to 5.5)	548.2 (650.9 to 3,703.1)	346.2 (261.0 to 1,982.6)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.1)	0.3 (0.1 to 0.5)	691.7 (277.0 to 2,782.9)	297.0 (85.3 to 1,477.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	697.6 (275.8 to 2,678.7)	305.2 (87.3 to 1,472.4)
HIV/AIDS resulting in other diseases	1.8 (0.6 to 3.2)	24.9 (13.6 to 35.8)	1,268.1 (778.8 to 3,489.5)	648.7 (375.9 to 2,003.6)	0.2 (0.1 to 0.4)	2.8 (1.2 to 5.5)	1,252.6 (652.7 to 4,660.0)	571.7 (261.2 to 2,638.7)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	1.9 (1.4 to 2.6)	2.5 (1.8 to 3.4)	29.2 (19.2 to 38.6)	-30.5 (-35.9 to -25.5)
Diarrheal diseases	7.2 (6.7 to 7.6)	8.7 (8.2 to 9.2)	21.5 (12.0 to 32.7)	-30.9 (-36.0 to -25.4)	1.2 (0.8 to 1.6)	1.4 (1.0 to 2.0)	22.1 (11.1 to 33.7)	-94.6 (-35.8 to -24.6)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-11.0 (54.6 to 39.8)	-54.3 (-77.0 to -29.0)
Typhoid fever	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	16.6 (-6.7 to 45.4)	-40.2 (-53.1 to -25.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.1 (-12.8 to 58.7)	-39.2 (-55.1 to -20.6)
Paratyphoid fever	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	43.2 (10.9 to 77.1)	-27.3 (-44.4 to -7.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.4 (5.7 to 90.7)	43.4 (-46.0 to -2.7)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-89.5 (-99.7 to 68.2)	-94.6 (-99.9 to -14.1)
Lower respiratory infections	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	-8.0 (-42.2 to 36.0)	-46.3 (-65.3 to -28.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	8.2 (-42.4 to 37.3)	-45.9 (-65.3 to -26.1)
Upper respiratory infections	9.4 (8.5 to 10.4)	18.1 (16.4 to 20.1)	92.9 (69.5 to 118.5)	-4.0 (-15.1 to 8.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	93.2 (69.1 to 121.4)	-4.0 (-15.1 to 9.2)
Otitis media	6.2 (5.6 to 6.8)	11.8 (10.8 to 12.8)	91.5 (74.1 to 109.4)	-6.3 (-14.5 to 2.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	91.3 (70.6 to 112.0)	-6.5 (-16.0 to 3.4)
Meningitis	-	-	-	-	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	14.5 (7.4 to 41.5)	-43.2 (-53.5 to -29.7)
Pneumococcal meningitis	2.1 (1.3 to 3.2)	2.3 (1.4 to 3.6)	5.7 (-16.8 to 32.7)	-47.7 (-58.9 to -34.1)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	23.9 (9.0 to 63.3)	39.7 (-54.5 to -22.6)
H influenzae type B meningitis	1.1 (0.5 to 2.0)	0.9 (0.3 to 1.9)	-22.2 (-59.0 to 13.7)	-62.6 (-82.1 to -44.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	0.1 (-35.2 to 60.8)	-50.6 (-67.8 to -21.2)
Meningococcal meningitis	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.5)	-10.2 (-56.5 to 42.1)	-56.1 (-80.9 to -29.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.2 (-28.9 to 61.0)	47.0 (-65.1 to -23.1)
Other meningitis	0.9 (0.5 to 1.5)	0.8 (0.4 to 1.5)	-10.6 (-44.4 to 30.5)	-55.4 (-73.6 to -33.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	10.4 (-35.7 to 77.6)	43.4 (-66.9 to -9.4)
Encephalitis	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	15.4 (-39.3 to 56.4)	-44.3 (-72.4 to -16.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-4.9 to 73.0)	-36.0 (-49.7 to -20.5)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	176.2 (88.4 to 5,711.0)	51.2 (-90.6 to 1,836.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.2 (-88.5 to 5,714.3)	51.2 (-90.6 to 1,859.0)
Whooping cough	0.5 (0.4 to 0.7)	1.1 (0.8 to 1.4)	110.8 (107.8 to 113.9)	28.1 (26.3 to 30.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	111.6 (95.3 to 128.2)	28.6 (18.0 to 39.1)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-76.5 (-89.3 to -44.5)	-87.6 (-94.4 to -70.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-76.3 (-93.0 to -48.7)	-86.8 (-94.3 to -71.5)
Measles	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	28.4 (7.0 to 52.4)	-24.5 (-37.3 to -10.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.8 (-2.2 to 81.7)	-24.0 (-46.4 to 5.5)
Varicella and herpes zoster	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.6)	108.4 (75.6 to 143.9)	4.5 (-17.9 to 29.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.7 (42.1 to 209.0)	5.1 (-32.4 to 54.0)
Neglected tropical diseases and malaria	-	-	-	-	5.7 (3.8 to 8.1)	7.4 (4.8 to 10.6)	28.1 (18.4 to 40.5)	-39.1 (-45.0 to -32.3)
Malaria	294.7 (273.2 to 316.2)	312.8 (284.8 to 343.0)	6.3 (-1.0 to 14.1)	-50.4 (-53.9 to -46.3)	2.3 (1.5 to 3.4)	2.7 (1.8 to 3.9)	18.1 (8.2 to 26.4)	46.2 (-50.8 to -42.3)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.0	-	-
Leishmaniasis	-	-	-	-	0.0	0.0	73.3	-21.3
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	130.0 (15.0 to 262.8)	13.7 (-39.0 to 74.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.6 (13.7 to 264.4)	13.4 (-39.3 to 74.4)
Cutaneous and mucocutaneous leishmaniasis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	32.2 (-19.5 to 103.9)	-36.9 (-60.3 to -1.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.0 (-22.7 to 111.8)	-36.9 (-62.4 to 1.6)
African trypanosomiasis	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.0)	94.4 (-95.1 to -93.8)	-97.2 (-97.5 to -96.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-97.7 (-94.9 to -92.3)	-96.8 (-97.3 to -96.2)
Schistosomiasis	8.0 (3.0 to 17.7)	16.7 (6.4 to 36.7)	108.3 (101.1 to 116.8)	0.4 (-2.6 to 3.8)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	110.3 (67.1 to 159.6)	1.4 (-17.2 to 22.3)
Cysticercosis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-62.4 (-86.9 to 101.1)	-79.5 (-93.6 to -17.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.5 (-85.8 to 142.2)	-77.1 (-92.5 to 3.5)
Cystic echinococcosis	0.2 (0.2 to 0.2)	0.1 (0.1 to 0.1)	-38.3 (-45.6 to -29.1)	-67.8 (-71.5 to -61.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.1 (-50.1 to -24.2)	67.8 (-73.4 to -59.9)
Lymphatic filariasis	20.5 (17.2 to 24.3)	36.3 (30.5 to 42.7)	77.0 (43.9 to 114.2)	-14.0 (-28.4 to 0.1)	0.5 (0.3 to 0.9)	1.0 (0.5 to 1.7)	86.0 (42.5 to 115.6)	-13.0 (-36.1 to 4.6)
Onchocerciasis	29.3 (18.8 to 48.2)	28.4 (17.1 to 52.2)	-4.4 (-21.2 to 17.2)	53.6 (-61.6 to -42.9)	1.9 (1.0 to 3.0)	1.7 (0.8 to 3.0)	84.4 (24.6 to 84.4)	55.4 (-62.7 to -46.6)
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.0	-	-
Dengue	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.3)	475.8 (422.5 to 543.6)	181.5 (155.4 to 214.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	439.8 (322.7 to 627.0)	161.7 (111.8 to 242.8)
Yellow fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.3 (-65.8 to -8.6)	-74.1 (-83.0 to -57.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.3 (-65.9 to -8.5)	-74.1 (-83.0 to -57.2)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-81.4 (-41.5 to 45.6)	-54.4 (-71.2 to -32.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.1 (-41.6 to 45.6)	54.4 (-71.2 to -32.5)
Intestinal nematode infections	-	-	-	-	0.7 (0.4 to 1.1)	1.4 (0.8 to 2.4)	107.2 (70.5 to 150.6)	-0.8 (-20.1 to 23.8)
Ascariasis	145.2 (118.1 to 178.9)	296.4 (240.1 to 363.4)	104.7 (52.6 to 173.1)	-0.6 (-28.7 to 38.5)	0.3 (0.2 to 0.5)	0.6 (0.3 to 1.0)	106.5 (45.0 to 193.0)	-0.3 (-32.6 to 51.7)
Trichuriasis	106.2 (82.6 to 135.7)	219.3 (174.0 to 278.2)	106.0 (46.2 to 190.4)	0.4 (-3.4 to 48.0)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.5)	108.8 (37.8 to 241.9)	0.1 (-37.5 to 73.4)
Hookworm disease	67.5 (52.4 to 86.2)	137.7 (106.8 to 177.0)	104.9 (44.7 to 189.4)	0.2 (-32.2 to 47.4)	0.6 (0.2 to 0.5)	0.6 (0.3 to 0.9)	106.1 (62.0 to 163.3)	1.2 (-25.3 to 29.2)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.0	-	-
Other neglected tropical diseases	4.3 (3.5 to 5.2)	6.6 (5.9 to 7.3)	54.2 (26.5 to 92.5)	-29.5 (-41.0 to -14.2)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	61.8 (30.9 to 144.8)	-21.8 (-39.3 to 21.7)
Maternal disorders	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	11.5 (6.7 to 34.2)	43.8 (-53.2 to -33.3)
Maternal hemorrhage	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	51.9 (6.6 to 129.2)	-31.4 (-43.9 to 18.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.5 (-36.9 to 119.5)	-36.6 (-66.3 to 12.9)
Maternal sepsis and other maternal infections	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	32.9 (19.1 to 51.1)	-32.4 (-40.1 to -19.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.5 (-26.5 to 83.5)	-36.2 (-59.5 to -6.3)
Maternal hypertensive disorders	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	38.7 (16.5 to 46.1)	-25.8 (-36.3 to -19.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	38.7 (9.5 to 28.5)	-25.9 (-55.2 to -37.4)
Obstructed labor	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.3)	8.0 (-4.0 to 19.3)	-46.9 (-52.4 to -41.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	7.9 (-9.5 to 28.5)	46.8 (-52.3 to 37.4)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.8 (-19.1 to 170.9)	-24.3 (-55.1 to 30.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.3 (-35.8 to 105.2)	-41.9 (-67.5 to 5.0)
Neonatal disorders	-	-	-	-	0.3 (0.1 to 0.5)	0.9 (0.5 to 1.3)	238.8 (97.8 to 520.0)	84.4 (5.2 to 236.8)
Preterm birth complications	1.3 (0.6 to 2.4)	5.3 (2.8 to 9.4)	326.2 (255.6 to 442.0)	111.7 (79.2 to 164.0)	0.1 (0.0 to 0.1)	0.4 (0.3 to 0.7)	469.3 (232.2 to 853.4)	195.8 (78.4 to 399.8)
Neonatal encephalopathy due to birth asphyxia and trauma	2.3 (0.2 to 7.1)	3.6 (0.4 to 11.2)	61.2 (29.1 to 144.8)	-19.7 (-35.0 to -25.2)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	99.4 (13.9 to 341.5)	5.6 (-34.2 to 151.7)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	980.8 (696.4 to 1,266.6)	680.0 (421.7 to 795.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,007.0 (686.8 to 1,324.0)	625.1 (415.4 to 832.8)
Hemolytic disease and other neonatal jaundice	0.1 (0.0 to 0.1)	0.3 (0.1 to 0.7)	264.4 (42.5 to 1,017.8)	109.0 (-19.8 to 550.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.3)	272.4 (47.4 to 1,076.4)	113.1 (-18.1 to 569.5)
Other neonatal disorders	-	-	-	-	0.1 (0.0 to 0.2)	0.2 (0.0 to 0.4)	111.8 (-37.6 to 793.7)	16.0 (-66.1 to 388.0)
Nutritional deficiencies	-	-	-	-	3.1 (2.1 to 4.5)	4.0 (2.6 to 5.9)	28.1 (13.2 to 42.4)	-39.9 (-47.2 to -32.5)
Protein-energy malnutrition	1.7 (0.7 to 3.9)	1.1 (0.5 to 2.5)	-34.5 (-77.9 to 104.2)	58.1 (-82.3 to -2.8)	0.1 (0.1 to 0.5)	0.1 (0.1 to 0.3)	58.0 (-78.5 to 112.9)	58.0 (-82.8 to 2.0)
Iodine deficiency	22.5 (12.3 to 35.2)	27.5 (16.7 to 41.4)	24.7 (-41.3 to 138.5)	-38.8 (-72.1 to 22.8)	0.4 (0.2 to 0.7)	0.5 (0.2 to 0.9)	24.4 (-40.8 to 140.8)	-38.1 (-72.0 to 23.4)
Vitamin A deficiency	1.6 (1.3 to 1.8)	1.8 (1.5 to 2.1)	15.8 (3.8 to 28.5)	-44.7 (-50.6 to -37.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	8.3 (5.4 to 23.7)	47.4 (-40.4 to -39.6)

Appendix Table G.4 - Equatorial Guinea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	73.8 (72.5 to 75.2)	106.6 (105.1 to 108.0)	44.5 (40.2 to 47.9)	-32.9 (-34.7 to -31.2)	2.4 (1.6 to 3.5)	3.3 (2.2 to 4.7)	34.9 (28.8 to 47.5)	34.9 (-11.9 to 33.2)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.9 (-87.3 to 337.4)	-64.3 (-89.6 to 150.6)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.7)	60.9 (41.2 to 85.8)	-19.3 (-29.2 to -8.1)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	83.1 (50.4 to 121.6)	-5.5 (-20.3 to 11.0)
Syphilis	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	6.2 (-10.2 to 27.3)	-46.6 (-53.9 to -37.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.5 (-19.8 to 43.7)	-41.3 (-58.1 to -31.5)
Chlamydial infection	8.4 (6.8 to 10.1)	16.1 (13.3 to 18.6)	91.0 (52.5 to 148.6)	1.2 (-17.8 to 31.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	90.7 (39.7 to 174.1)	0.5 (-23.8 to 42.6)
Gonococcal infection	2.1 (1.7 to 2.7)	5.0 (3.4 to 7.0)	132.5 (55.2 to 240.6)	25.5 (-16.5 to 83.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.0 (0.9 to 199.0)	-5.1 (-43.8 to 62.0)
Trichomoniasis	4.8 (3.0 to 6.8)	8.8 (5.2 to 12.9)	88.0 (-17.5 to 230.7)	5.5 (-50.2 to 75.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.0 (-26.3 to 280.1)	8.1 (-54.8 to 98.2)
Genital herpes	78.9 (70.3 to 87.0)	165.0 (148.2 to 180.1)	109.3 (81.4 to 140.2)	1.8 (-10.4 to 15.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	156.8 (75.8 to 239.5)	2.5 (-11.0 to 16.7)
Other sexually transmitted diseases	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	89.7 (45.3 to 144.4)	-6.5 (-28.3 to 26.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.4 (15.5 to 167.3)	6.0 (-36.4 to 32.8)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	49.4 (19.4 to 87.3)	-26.2 (-44.0 to -5.3)
Hepatitis A	0.6 (0.6 to 0.7)	0.9 (0.9 to 1.0)	44.9 (43.9 to 46.4)	-17.4 (-17.9 to -16.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.8 (66.5 to 114.7)	-0.9 (-11.5 to 12.0)
Hepatitis B	50.5 (43.0 to 58.4)	53.4 (45.7 to 62.1)	5.8 (-15.0 to 28.9)	-47.6 (-57.7 to -36.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.2 (-23.7 to 71.0)	-41.3 (-63.4 to -12.5)
Hepatitis C	16.7 (14.9 to 18.6)	25.4 (24.0 to 28.8)	59.1 (37.1 to 82.4)	-23.0 (-33.3 to -12.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.8 (13.2 to 98.5)	-24.1 (-43.3 to 1.2)
Hepatitis E	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	185.7 (134.1 to 260.8)	44.6 (20.5 to 82.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	182.0 (110.8 to 301.3)	44.5 (11.9 to 106.4)
Leprosy	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	91.5 (11.8 to 321.9)	-3.0 (-40.7 to 105.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.7 (9.8 to 361.6)	-1.2 (-42.7 to 128.5)
Other infectious diseases	3.3 (2.7 to 3.9)	4.8 (4.0 to 5.6)	46.9 (22.0 to 76.9)	-33.1 (-43.2 to -21.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	42.8 (10.8 to 89.1)	-33.7 (-48.8 to -16.0)
Non-communicable diseases	-	-	-	-	25.2 (18.6 to 32.4)	52.2 (38.5 to 67.6)	107.5 (102.0 to 112.4)	1.7 (-1.0 to 4.4)
Neoplasms	0.0	0.0	-	-	0.2 (0.2 to 0.3)	0.7 (0.4 to 1.1)	192.3 (111.0 to 332.5)	42.6 (3.7 to 111.7)
Esophageal cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	102.5 (14.1 to 265.9)	4.4 (-40.2 to 84.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.0 (2.9 to 226.6)	-8.2 (-47.1 to 64.2)
Stomach cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	160.3 (50.7 to 395.0)	34.7 (-19.9 to 150.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.6 (17.3 to 283.8)	3.2 (-39.3 to 96.9)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	188.8 (53.4 to 418.0)	47.3 (-22.1 to 162.8)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	453.5 (164.3 to 1,195.2)	168.2 (28.3 to 527.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	286.8 (91.7 to 743.3)	87.9 (-7.6 to 315.4)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	786.9 (271.1 to 2,241.0)	350.5 (84.1 to 1,082.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	501.7 (174.4 to 1,434.7)	204.7 (34.5 to 662.2)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.3 (1.4 to 388.6)	18.0 (-43.5 to 154.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.9 (-25.7 to 220.7)	-14.5 (-58.2 to 71.1)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.2 (0.0 to 0.2)	272.2 (27.2 to 505.7)	39.2 (-35.7 to 194.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.9 (-0.9 to 288.7)	2.9 (-50.8 to 92.7)
Larynx cancer	0.0 (0.0 to 0.1)	0.2 (0.2 to 0.4)	566.7 (61.7 to 1,425.1)	286.8 (-19.3 to 807.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	355.7 (66.5 to 781.6)	152.1 (-16.8 to 397.8)
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	138.2 (41.6 to 341.8)	25.6 (-25.0 to 135.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.3 (13.1 to 248.3)	-1.1 (-40.0 to 87.9)
Breast cancer	1.0 (0.8 to 1.1)	1.4 (0.8 to 2.4)	30.0 (-16.6 to 133.5)	-51.1 (-68.4 to -23.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	109.2 (30.0 to 283.1)	-15.8 (-47.5 to 55.3)
Cervical cancer	0.3 (0.2 to 0.4)	0.6 (0.4 to 1.1)	144.3 (33.4 to 351.5)	3.3 (-42.0 to 98.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	128.1 (45.1 to 313.4)	-2.8 (-45.1 to 72.0)
Uterine cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.5)	271.2 (74.4 to 884.1)	61.4 (-22.8 to 316.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	246.1 (56.9 to 824.4)	51.3 (-28.8 to 301.4)
Prostate cancer	0.2 (0.1 to 0.2)	1.2 (0.6 to 2.7)	648.7 (308.9 to 1,848.7)	372.0 (163.1 to 1,061.6)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	502.3 (229.1 to 1,553.4)	297.3 (120.7 to 928.7)
Colon and rectum cancer	0.5 (0.5 to 0.6)	1.2 (1.0 to 1.6)	124.0 (83.1 to 199.1)	17.0 (-1.7 to 49.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	113.4 (74.3 to 184.1)	13.1 (-5.2 to 44.1)
Lip and oral cavity cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	149.6 (39.2 to 375.9)	20.5 (-31.7 to 129.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	127.5 (29.4 to 339.9)	11.2 (-36.6 to 114.8)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	128.0 (15.8 to 338.6)	0.6 (-49.1 to 89.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.3 (6.2 to 284.6)	8.3 (-51.8 to 73.4)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	296.7 (79.7 to 700.3)	79.4 (-19.0 to 264.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	230.6 (53.6 to 552.3)	50.7 (-29.8 to 199.6)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	169.1 (55.7 to 403.2)	52.7 (-9.7 to 187.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.3 (24.5 to 318.1)	21.4 (-29.0 to 128.8)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	216.9 (92.5 to 476.5)	72.9 (10.5 to 201.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	156.3 (61.7 to 360.3)	38.9 (-12.6 to 143.3)
Malignant skin melanoma	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	176.9 (52.6 to 413.0)	34.9 (-25.0 to 141.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	159.2 (42.9 to 361.3)	25.8 (-28.3 to 124.6)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	246.7 (107.2 to 510.9)	69.0 (5.7 to 185.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	275.4 (73.6 to 657.4)	87.2 (-13.8 to 274.3)
Ovarian cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	358.2 (148.2 to 720.1)	94.2 (5.9 to 257.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	284.3 (108.0 to 618.4)	64.6 (9.9 to 219.1)
Testicular cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	545.0 (213.9 to 1,136.1)	252.8 (80.5 to 548.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	485.4 (187.6 to 1,085.5)	212.0 (63.4 to 493.6)
Kidney cancer	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.4)	315.0 (291.9 to 1,09.9)	37.8 (110.4 to 515.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	468.1 (236.3 to 876.2)	181.9 (69.5 to 371.7)
Bladder cancer	0.2 (0.2 to 0.2)	0.5 (0.4 to 0.6)	115.0 (66.1 to 213.9)	9.1 (-15.0 to 51.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	73.4 (33.8 to 141.0)	-8.9 (-28.2 to 24.2)
Brain and nervous system cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	198.8 (38.9 to 393.3)	45.7 (-15.4 to 136.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	179.4 (48.5 to 367.6)	31.9 (-20.4 to 123.4)
Thyroid cancer	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	683.4 (292.5 to 1,339.0)	245.0 (76.2 to 552.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	571.1 (234.7 to 1,166.1)	195.0 (54.5 to 451.8)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.5 (-20.6 to 176.3)	-20.7 (-58.1 to 43.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.9 (61.9 to 173.6)	-20.0 (-58.6 to 46.1)
Hodgkin lymphoma	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	210.9 (84.8 to 481.4)	60.9 (-1.4 to 185.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	176.0 (22.9 to 398.6)	39.2 (-15.9 to 194.5)
Non-Hodgkin lymphoma	0.1 (0.0 to 0.1)	0.4 (0.2 to 0.6)	619.7 (313.0 to 1,123.8)	262.8 (107.2 to 521.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	482.1 (246.2 to 903.8)	184.2 (66.7 to 383.8)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	250.9 (94.2 to 577.1)	82.5 (1.6 to 247.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	215.9 (66.9 to 524.6)	63.0 (-13.3 to 215.5)
Leukemia	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	315.0 (126.8 to 663.3)	128.0 (43.0 to 264.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	288.2 (122.3 to 453.4)	73.4 (15.9 to 171.5)
Other neoplasms	0.2 (0.1 to 0.4)	1.3 (0.7 to 2.8)	806.5 (378.2 to 1,295.9)	350.0 (176.6 to 610.3)	0.0 (0.0 to 0.2)	0.1 (0.0 to 0.2)	671.3 (353.1 to 1,092.8)	260.4 (133.8 to 483.4)
Cardiovascular diseases	-	-	-	-	0.6 (0.4 to 0.8)	1.3 (0.9 to 1.8)	128.1 (89.7 to 174.1)	18.2 (-3.3 to 41.8)
Rheumatic heart disease	3.1 (2.9 to 3.3)	7.7 (7.2 to 8.1)	145.6 (127.0 to 166.4)	20.6 (12.3 to 29.9)	0.4 (0.1 to 0.2)	0.4 (0.2 to 0.5)	141.7 (119.6 to 165.8)	18.9 (-3.6 to 36.6)
Ischemic heart disease	2.5 (2.1 to 3.2)	4.1 (3.5 to 5.0)	63.3 (24.7 to 108.9)	-8.8 (-27.2 to 19.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	65.0 (33.6 to 111.5)	-13.2 (-40.2 to 24.5)
Cerebrovascular disease	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	107.8 (63.6 to 175.2)	3.7 (-18.1 to 41.8)
Ischemic stroke	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.4)	106.5 (63.3 to 178.3)	3.3 (-17.7 to 41.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	109.0 (62.3 to 187.7)	4.4 (-18.2 to 46.2)
Hemorrhagic stroke	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	102.2 (54.4 to 176.0)	-0.8 (-24.1 to 37.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.0 (55.0 to 179.2)	-0.6 (-24.5 to 36.9)
Hypertensive heart disease	0.6 (0.4 to 0.7)	1.2 (1.0 to 1.5)	118.6 (57.9 to 207.1)	19.7 (-13.6 to 67.4)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	127.3 (60.4 to 213.9)	21.3 (-12.6 to 71.4)
Cardiomyopathy and myocarditis	0.4 (0.3 to 0.5)	0.9 (0.7 to 1.1)	128.4 (61.6 to 223.3)	20.1 (-18.5 to 80.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	130.5 (62.2 to 228.8)	20.5 (-17.9 to 83.8)
Atrial fibrillation and flutter	0.3 (0.2 to 0.4)	0.8 (0.6 to 0.9)	132.9 (53.4 to 241.7)	44.9 (8.0 to 127.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	136.3 (53.2 to 248.4)	48.3 (-8.8 to 129.5)
Peripheral vascular disease	4.4 (3.4 to 5.2)	7.5 (5.8 to 9.7)	72.3 (22.1 to 147.9)	-7.4 (-29.9 to 30.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.0 (-39.7 to 173.6)	-2.0 (-58.5 to 86.5)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.9 (-14.2 to 179.2)	-14.8 (-58.6 to 66.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.8 (-12.2 to 233.5)	-9.3 (-58.4 to 103.6)
Other cardiovascular and circulatory diseases	1.9 (1.0 to 3.2)	5.7 (3.0 to 8.1)	196.5 (42.9 to 467.3)	47.9 (-32.6 to 194.3)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	202.4 (44.7 to 481.5)	48.4 (-32.2 to 195.4)
Chronic respiratory diseases	-	-	-	-	1.7 (1.1 to 2.3)	3.7 (2.4 to 5.1)	117.9 (87.0 to 150.9)	3

Appendix Table G.4 - Equatorial Guinea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	98.7	-0.4
Silicosis	0.0	0.0	89.2	-3.1	(0.0 to 0.0)	(0.0 to 0.0)	(91.1 to 105.9)	(-3.8 to 2.8)
Asbestosis	-	-	0.0	0.0	-	-	89.3	-3.0
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	107.5	2.1	0.0	0.0	107.9	2.4
Asthma	8.0	17.4	(98.4 to 117.3)	(-2.1 to 6.2)	0.3	0.8	118.5	7.2
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	114.7	6.4	0.0	0.0	115.3	6.7
Other chronic respiratory diseases	-	-	-	-	0.2	0.4	115.3	2.9
Cirrhosis	-	-	-	-	(0.1 to 0.4)	(0.2 to 0.8)	(6.9 to 304.8)	(-49.4 to 90.8)
Cirrhosis due to hepatitis B	0.1	0.1	11.4	-42.5	0.0	0.0	11.8	-42.5
Cirrhosis due to hepatitis C	0.0	0.1	206.9	42.2	0.0	0.0	209.5	44.2
Cirrhosis due to alcohol use	0.0	0.1	30.4	-35.5	0.0	0.0	33.8	-35.2
Cirrhosis due to other causes	0.0	0.0	108.7	8.9	0.0	0.0	111.7	96.5
Digestive diseases	-	-	-	-	(0.0 to 0.0)	(0.0 to 0.0)	(49.6 to 202.3)	(-21.3 to 58.2)
Peptic ulcer disease	3.5	3.6	2.5	-44.0	0.1	0.1	11.3	-41.6
Gastritis and duodenitis	4.1	7.9	92.7	-6.4	0.2	0.3	104.1	-4.5
Appendicitis	0.1	0.1	98.2	-2.1	0.0	0.0	99.3	-1.2
Paralytic ileus and intestinal obstruction	0.0	0.0	66.2	-2.5	0.0	0.0	67.9	-1.8
Inguinal, femoral, and abdominal hernia	2.1	3.2	58.6	-12.9	0.0	0.0	60.7	-12.8
Inflammatory bowel disease	0.4	1.0	164.4	26.5	0.1	0.2	165.8	27.2
Vascular intestinal disorders	0.0	0.0	93.5	-3.9	0.0	0.0	97.6	0.3
Gallbladder and biliary diseases	0.1	0.3	114.9	11.3	0.0	0.0	117.9	12.1
Pancreatitis	0.1	0.2	117.5	4.8	0.0	0.0	119.6	5.7
Other digestive diseases	-	-	-	-	0.1	0.2	134.4	9.5
Neurological disorders	-	-	-	-	(0.0 to 0.1)	(0.1 to 0.3)	(47.6 to 236.5)	(33.2 to 58.2)
Alzheimer disease and other dementias	1.1	1.6	53.2	1.4	0.1	0.2	55.0	2.7
Parkinson disease	0.0	0.1	69.0	-0.1	0.0	0.0	72.3	0.2
Epilepsy	0.5	0.6	35.1	-32.9	0.1	0.2	54.2	-23.4
Multiple sclerosis	0.0	0.0	147.1	13.5	0.0	0.0	143.9	12.7
Migraine	25.8	53.5	107.0	0.5	0.8	1.8	108.6	0.8
Tension-type headache	47.7	101.1	111.4	2.1	0.1	0.2	111.8	2.6
Medication overuse headache	1.8	5.3	201.6	44.3	0.3	0.8	202.7	45.2
Other neurological disorders	0.0	0.0	94.3	-4.0	0.1	0.2	114.0	37.4
Mental and substance use disorders	-	-	-	-	8.5	17.5	105.1	0.1
Schizophrenia	0.9	1.8	106.2	0.3	0.5	1.1	106.6	0.9
Alcohol use disorders	5.0	8.4	69.4	-12.0	0.5	0.8	69.3	-11.6
Drug use disorders	-	-	-	-	1.0	1.0	98.1	-0.3
Opioid use disorders	0.7	1.4	115.8	-0.7	0.3	0.6	114.8	-0.2
Cocaine use disorders	0.2	0.4	89.9	0.0	0.1	0.1	91.9	0.0
Amphetamine use disorders	0.7	1.2	78.4	-1.9	0.1	0.2	79.0	-1.6
Cannabis use disorders	0.5	0.9	92.7	-0.3	0.0	0.0	93.8	0.2
Other drug use disorders	-	-	-	-	0.1	0.2	82.2	-1.6
Depressive disorders	-	-	-	-	(0.1 to 0.2)	(0.1 to 0.3)	(36.0 to 144.2)	(-26.1 to 31.9)
Major depressive disorder	15.7	33.0	110.2	1.9	3.2	6.8	111.7	2.6
Dysthymia	4.1	8.2	103.0	-0.4	0.4	0.8	104.3	0.1
Bipolar disorder	2.4	4.5	91.4	-0.4	0.5	0.9	92.0	0.3
Anxiety disorders	10.3	20.6	98.4	0.9	1.9	3.9	99.8	0.3
Eating disorders	-	-	-	-	0.1	0.2	88.9	2.1
Anorexia nervosa	0.1	0.1	103.5	4.1	0.0	0.0	104.7	4.8
Bulimia nervosa	0.4	0.7	85.1	1.1	0.1	0.2	86.1	1.7
Autistic spectrum disorders	-	-	-	-	0.4	0.9	104.7	1.0
Autism	1.2	2.3	104.0	0.3	0.3	0.6	105.2	1.0
Asperger syndrome	1.7	3.4	103.2	0.5	0.2	0.3	103.8	0.8
Attention-deficit/hyperactivity disorder	2.2	5.1	130.9	0.1	0.0	0.1	132.2	0.6
Conduct disorder	3.0	7.1	148.8	0.1	0.4	0.9	156.6	0.3
Idiopathic intellectual disability	12.4	25.4	104.9	1.0	0.6	1.2	105.6	1.3
Other mental and substance use disorders	5.5	10.8	96.2	0.2	0.4	0.8	96.9	0.9
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	2.0	4.0	101.7	1.6
Diabetes mellitus	2.9	7.8	169.4	22.6	(1.4 to 2.7)	(2.8 to 5.4)	(88.2 to 115.0)	(-5.8 to 9.2)
Acute glomerulonephritis	0.0	0.0	40.3	-28.8	0.0	0.0	40.3	-28.8
Chronic kidney disease	-	-	-	-	0.6	1.2	106.1	1.3
Chronic kidney disease due to diabetes mellitus	7.0	14.8	111.0	0.3	0.1	0.2	118.2	5.2
Chronic kidney disease due to hypertension	12.4	24.2	94.2	-1.1	0.2	0.3	119.3	5.8
Chronic kidney disease due to glomerulonephritis	10.4	22.6	117.7	0.2	0.4	0.4	97.7	0.5
Chronic kidney disease due to other causes	8.2	15.4	90.2	-8.4	0.1	0.2	89.8	-8.0
Urinary diseases and male infertility	-	-	-	-	0.1	0.3	88.6	13.5

Appendix Table G.4 - Equatorial Guinea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	105.4 (89.3 to 123.2)	0.0 (-1.5 to 12.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.7 (63.3 to 160.0)	14.4 (-12.1 to 28.5)
Urolithiasis	0.9 (0.7 to 1.2)	1.5 (1.2 to 2.0)	70.5 (52.6 to 114.0)	-9.7 (-17.2 to 2.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	132.5 (99.0 to 169.5)	14.4 (2.6 to 28.6)
Benign prostatic hyperplasia	3.0 (2.7 to 3.3)	5.5 (5.0 to 6.0)	83.3 (62.9 to 106.5)	13.6 (1.2 to 27.0)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	86.0 (64.3 to 109.9)	14.8 (1.6 to 28.7)
Male infertility due to other causes	3.6 (2.6 to 4.7)	5.8 (4.3 to 7.5)	60.8 (9.6 to 144.7)	-10.0 (-39.9 to 38.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	61.9 (11.6 to 141.5)	-8.2 (-37.1 to 38.2)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.0 (77.8 to 366.2)	41.0 (-11.0 to 130.3)
Gynecological diseases	-	-	-	-	0.4 (0.2 to 0.6)	0.7 (0.5 to 1.1)	94.0 (62.2 to 128.9)	-3.9 (-16.0 to 11.9)
Uterine fibroids	5.0 (4.5 to 5.5)	13.6 (12.4 to 14.7)	170.4 (161.4 to 180.2)	3.1 (2.9 to 3.3)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	86.1 (59.2 to 121.9)	-19.0 (-29.2 to -7.9)
Polycystic ovarian syndrome	5.4 (4.8 to 6.1)	11.4 (10.1 to 12.7)	111.7 (78.3 to 146.7)	6.1 (-9.7 to 21.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	109.9 (77.8 to 144.8)	6.5 (-8.3 to 22.1)
Female infertility due to other causes	3.7 (1.9 to 5.7)	8.4 (5.0 to 13.0)	127.2 (13.2 to 398.5)	28.4 (-41.0 to 166.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	125.8 (10.3 to 385.7)	27.3 (-40.8 to 164.9)
Endometriosis	0.6 (0.5 to 0.6)	1.0 (0.9 to 1.2)	88.9 (51.2 to 140.2)	-5.9 (24.2 to 16.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	89.2 (49.4 to 143.7)	5.6 (-24.7 to 19.8)
Genital prolapse	11.8 (9.9 to 13.6)	26.6 (21.5 to 31.1)	126.2 (71.4 to 192.8)	1.9 (-19.7 to 29.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	126.8 (70.2 to 195.2)	2.2 (-19.1 to 30.5)
Premenstrual syndrome	12.1 (7.3 to 17.2)	23.1 (14.0 to 31.3)	89.2 (6.1 to 265.0)	9.7 (-33.6 to 94.2)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	89.5 (6.5 to 275.3)	10.0 (-33.1 to 100.8)
Other gynecological diseases	0.9 (0.6 to 1.2)	1.5 (1.0 to 1.9)	67.5 (10.0 to 161.5)	-19.4 (46.3 to 26.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	43.1 (-33.8 to 180.7)	-30.0 (-66.6 to 34.5)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.6 (0.4 to 0.8)	1.1 (0.7 to 1.5)	88.1 (65.8 to 104.6)	-11.2 (-21.0 to -2.0)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.1 (-5.4 to 103.0)	-0.8 (-51.5 to 4.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.9 (9.4 to 108.7)	-8.0 (-42.2 to 9.5)
Thalassemia trait	1.9 (1.6 to 2.3)	3.7 (3.0 to 4.4)	101.5 (42.8 to 103.4)	-0.1 (-29.7 to 0.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	117.7 (77.4 to 159.1)	6.9 (-11.5 to 25.9)
Sickle cell disorders	1.1 (1.0 to 1.2)	2.2 (2.0 to 2.4)	101.4 (83.1 to 128.6)	3.4 (-6.7 to 16.9)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	110.7 (74.9 to 142.2)	8.6 (-9.0 to 25.2)
Sickle cell trait	71.6 (67.2 to 75.2)	142.8 (134.7 to 150.1)	99.4 (92.2 to 105.3)	-1.3 (-4.8 to 1.7)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	109.3 (64.7 to 133.3)	4.0 (-20.6 to 10.8)
G6PD deficiency	62.1 (58.8 to 65.1)	123.4 (117.4 to 130.2)	98.5 (84.9 to 114.0)	-1.7 (-8.5 to 6.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.0 (-53.4 to 104.9)	57.8 (-81.4 to -22.9)
G6PD trait	90.6 (90.3 to 90.9)	183.5 (182.9 to 183.9)	102.6 (101.6 to 103.3)	-0.6 (-1.1 to -0.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	86.5 (-93.2 to 451.0)	-6.0 (-94.1 to 172.9)
Other hemoglobinopathies and hemolytic anemias	3.8 (3.3 to 4.3)	4.6 (4.0 to 5.2)	21.5 (3.4 to 42.6)	-42.7 (-49.3 to -34.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	11.3 (-21.6 to 49.9)	-51.2 (-63.1 to -37.5)
Endocrine, metabolic, blood, and immune disorders	4.2 (3.7 to 4.8)	6.5 (5.5 to 7.3)	52.5 (24.4 to 82.5)	0.1 (-36.6 to -15.5)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	52.2 (9.4 to 101.7)	25.2 (-41.3 to -6.0)
Musculoskeletal disorders	-	-	-	-	4.7 (3.3 to 6.2)	10.0 (7.0 to 13.2)	114.6 (96.6 to 131.9)	1.8 (-5.6 to 9.8)
Rheumatoid arthritis	0.9 (0.9 to 1.0)	1.7 (1.7 to 1.8)	87.4 (77.1 to 98.8)	-11.7 (-16.4 to -6.0)	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	90.0 (75.2 to 105.6)	-10.8 (-16.9 to -4.4)
Osteoarthritis	8.1 (7.8 to 8.4)	16.8 (16.1 to 17.5)	107.4 (95.3 to 119.1)	-0.5 (-5.8 to 5.0)	0.5 (0.3 to 0.7)	0.5 (0.7 to 1.4)	110.4 (97.7 to 123.0)	0.3 (-5.1 to 5.9)
Low back and neck pain	-	-	-	-	3.5 (2.4 to 4.6)	7.4 (5.0 to 9.9)	112.5 (92.1 to 135.1)	1.5 (-8.0 to 12.9)
Low back pain	19.0 (17.9 to 20.2)	39.2 (37.0 to 41.5)	106.2 (89.0 to 124.6)	-1.0 (-8.4 to 6.9)	2.1 (1.4 to 2.9)	4.4 (2.9 to 6.0)	108.0 (90.3 to 126.7)	-0.3 (-8.1 to 7.8)
Neck pain	14.2 (11.7 to 17.0)	31.0 (26.2 to 36.0)	118.3 (70.7 to 179.2)	3.9 (-17.9 to 32.2)	1.4 (0.9 to 2.0)	3.0 (2.0 to 4.2)	119.5 (71.0 to 181.0)	4.5 (-17.1 to 34.0)
Gout	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	115.0 (79.7 to 153.5)	4.0 (-12.5 to 20.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.5 (64.0 to 183.4)	4.4 (-21.3 to 35.0)
Other musculoskeletal disorders	5.4 (3.9 to 6.9)	12.8 (9.8 to 16.2)	128.8 (108.6 to 181.2)	8.1 (-1.3 to 28.4)	0.5 (0.3 to 0.7)	1.2 (0.7 to 1.7)	128.6 (110.3 to 185.3)	28.6 (-1.1 to 30.1)
Other non-communicable diseases	-	-	-	-	5.4 (3.4 to 8.1)	10.6 (6.8 to 15.9)	96.3 (89.9 to 104.2)	-4.6 (-8.4 to -0.9)
Congenital anomalies	-	-	-	-	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	126.4 (94.5 to 167.1)	10.7 (-5.4 to 31.1)
Neural tube defects	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	269.3 (193.6 to 378.5)	109.4 (64.2 to 176.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	288.1 (164.4 to 437.7)	126.1 (52.9 to 212.6)
Congenital heart anomalies	0.2 (0.2 to 0.3)	0.3 (0.6 to 1.3)	306.1 (139.6 to 565.2)	131.0 (32.9 to 291.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	270.1 (125.8 to 506.4)	111.5 (27.3 to 252.6)
Orofacial clefts	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	354.1 (102.8 to 782.0)	190.3 (18.0 to 501.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	327.6 (86.0 to 853.2)	172.6 (10.1 to 535.9)
Down syndrome	0.2 (0.1 to 0.2)	0.5 (0.4 to 0.6)	195.0 (97.1 to 295.5)	56.8 (4.6 to 110.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	207.5 (105.3 to 324.0)	63.7 (8.1 to 129.2)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	148.3 (51.4 to 278.6)	28.9 (-21.9 to 96.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	148.7 (50.6 to 279.5)	29.4 (-22.1 to 98.7)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.1 (33.2 to 174.7)	-2.9 (-32.9 to 38.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.6 (25.2 to 159.1)	-5.4 (-34.8 to 34.4)
Chromosomal unbalanced rearrangements	0.2 (0.2 to 0.3)	0.7 (0.6 to 0.9)	189.3 (122.8 to 285.7)	6.1 (18.3 to -10.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	205.8 (125.3 to 309.5)	62.7 (21.0 to 120.3)
Other congenital anomalies	1.7 (1.2 to 2.3)	3.0 (2.0 to 4.2)	78.5 (54.4 to 111.4)	-12.2 (-25.4 to 2.9)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	88.0 (57.4 to 141.8)	-8.8 (-24.6 to 16.0)
Skin and subcutaneous diseases	-	-	-	-	2.1 (1.3 to 3.2)	4.5 (2.9 to 6.9)	113.2 (100.7 to 123.5)	3.3 (-3.1 to 8.3)
Dermatitis	22.7 (19.0 to 26.4)	46.6 (39.2 to 54.2)	105.0 (99.9 to 111.7)	-0.2 (-0.3 to -0.1)	0.8 (0.5 to 1.1)	1.6 (1.0 to 2.4)	106.8 (98.8 to 116.6)	0.4 (-2.1 to 3.1)
Psoriasis	2.6 (2.2 to 3.0)	5.3 (4.5 to 6.1)	105.1 (98.0 to 113.0)	0.0 (-0.2 to 0.3)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	106.6 (92.5 to 122.4)	0.7 (-4.5 to 6.2)
Cellulitis	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	100.3 (69.1 to 141.2)	0.9 (-14.7 to 21.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.2 (53.3 to 171.4)	1.3 (-20.8 to 31.5)
Pyoderma	0.6 (0.5 to 0.8)	1.1 (0.9 to 1.5)	81.0 (66.9 to 95.0)	-4.1 (-10.5 to 3.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.0 (61.1 to 102.0)	-3.9 (-13.5 to 5.9)
Scabies	4.3 (3.7 to 5.0)	6.1 (5.6 to 6.8)	42.2 (20.3 to 69.2)	-31.4 (-41.5 to -18.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	42.2 (21.3 to 70.8)	-1.3 (-41.9 to 17.8)
Fungal skin diseases	56.8 (45.3 to 72.8)	119.1 (96.1 to 150.0)	109.9 (104.3 to 116.0)	0.0 (-0.2 to 1.1)	0.3 (0.2 to 0.4)	0.7 (0.3 to 1.5)	110.5 (104.7 to 116.8)	0.2 (-0.3 to 1.0)
Viral skin diseases	7.2 (5.2 to 9.2)	14.9 (11.4 to 18.1)	105.1 (94.0 to 123.3)	2.5 (0.7 to 4.7)	0.2 (0.1 to 0.4)	0.5 (0.3 to 0.7)	106.0 (94.3 to 125.7)	2.9 (-0.5 to 6.8)
Acne vulgaris	16.1 (12.3 to 20.1)	41.4 (31.1 to 52.0)	156.9 (83.1 to 245.7)	21.9 (-12.7 to 62.4)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.9)	158.5 (84.1 to 247.0)	22.5 (-12.8 to 62.8)
Alopecia areata	0.3 (0.3 to 0.4)	0.7 (0.6 to 0.8)	106.5 (70.8 to 143.7)	0.5 (-15.3 to 18.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.2 (69.3 to 156.7)	1.2 (-15.9 to 22.1)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.9 (68.4 to 156.6)	2.4 (-20.5 to 28.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.9 (68.2 to 157.6)	2.4 (-20.6 to 28.5)
Urticaria	1.8 (1.3 to 2.5)	5.4 (3.7 to 7.3)	296.9 (70.4 to 371.7)	38.0 (-21.0 to 117.3)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	210.0 (71.1 to 380.3)	39.5 (-20.0 to 121.3)
Decubitus ulcer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	81.8 (53.7 to 129.0)	-3.9 (-23.6 to 38.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.3 (46.2 to 139.0)	-2.0 (-25.2 to 41.8)
Other skin and subcutaneous diseases	24.4 (16.8 to 35.1)	49.5 (34.4 to 69.8)	104.4 (77.2 to 130.0)	-2.9 (-6.2 to -0.2)	0.1 (0.1 to 0.3)	0.3 (0.1 to 0.6)	105.9 (78.8 to 131.6)	-2.4 (-5.0 to 0.5)
Sense organ diseases	-	-	-	-	2.4 (1.5 to 3.6)	4.4 (2.8 to 6.6)	79.3 (67.2 to 92.2)	-10.1 (-15.3 to -4.9)
Glaucoma	0.5 (0.4 to 0.6)	0.8 (0.7 to 0.9)	69.9 (39.6 to 100.7)	-12.0 (-28.5 to 3.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	86.1 (57.8 to 121.2)	-1.3 (-17.2 to 18.1)
Cataract	1.6 (1.3 to 2.0)	2.3 (1.7 to 2.8)	39.4 (16.6 to 75.2)	-18.9 (-29.5 to -1.6)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	46.3 (27.0 to 68.3)	-15.8 (-24.4 to -4.9)
Macular degeneration	0.3 (0.2 to 0.4)	1.0 (0.7 to 1.3)	47.2 (131.2 to 296.1)	0.0 (9.6 to 82.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	191.5 (122.4 to 273.8)	36.2 (7.6 to 67.6)
Uncorrected refractive error	60.1 (56.3 to 64.3)	100.2 (89.9 to 110.8)	66.7 (46.2 to 88.3)	-13.3 (-27.9 to -10.8)	0.8 (0.5 to 1.4)	1.4 (0.8 to 2.2)	64.4 (49.4 to 81.3)	-19.4 (-25.8 to -12.8)
Age-related and other hearing loss	49.5 (42.5 to 55.9)	95.0 (79.4 to 108.2)	91.7 (79.9 to 104.8)	4.4 (-9.1 to -3.5)	1.2 (0.7 to 1.8)	2.2 (1.3 to 3.5)	86.2 (63.5 to 109.0)	-6.3 (-14.5 to 3.2)
Other vision loss	0.7 (0.6 to 0.9)	1.4 (1.2 to 1.6)	91.4 (72.1 to 111.7)	-6.2 (-15.2 to 2.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	85.7 (66.5 to 108.7)	-5.3 (-13.2 to 4.3)
Other sense organ diseases	8.8 (8.3 to 9.2)	17.5 (16.4 to 18.4)	99.0 (85.8 to 114.5)	-0.				

Appendix Table G.4 - Equatorial Guinea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	7.8 (7.3 to 8.4)	13.7 (12.8 to 14.7)	74.6 (58.4 to 91.1)	-6.6 (-14.7 to 1.5)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.5)	77.1 (60.2 to 93.6)	-5.3 (-14.2 to 2.3)
Other oral disorders	5.7 (5.3 to 6.0)	11.7 (11.0 to 12.3)	106.2 (88.0 to 122.8)	-0.1 (-8.1 to 7.0)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	106.7 (88.3 to 125.6)	0.3 (-8.0 to 8.2)
Injuries	-	-	-	-	2.3 (1.6 to 3.5)	3.3 (2.5 to 4.3)	46.5 (10.6 to 68.6)	-25.1 (-42.6 to -14.0)
Transport injuries	-	-	-	-	0.7 (0.5 to 0.9)	1.2 (0.9 to 1.6)	70.7 (62.8 to 79.3)	-13.2 (-16.9 to -9.3)
Road injuries	-	-	-	-	0.6 (0.5 to 0.8)	1.0 (0.8 to 1.3)	69.1 (66.3 to 78.2)	-13.5 (-17.4 to -9.6)
Pedestrian road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	64.0 (52.1 to 77.2)	-15.4 (-20.6 to -9.5)
Cyclist road injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	51.3 (40.3 to 62.3)	-20.9 (-26.5 to -15.3)
Motorcyclist road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	46.7 (33.4 to 59.5)	-25.8 (-31.9 to -19.7)
Motor vehicle road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.6)	90.1 (75.3 to 104.2)	-3.2 (-9.4 to 3.0)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.5 (8.9 to 25.1)	-44.4 (-47.7 to -40.6)
Other transport injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	80.3 (67.9 to 93.1)	-11.4 (-16.8 to -5.2)
Unintentional injuries	-	-	-	-	1.0 (0.7 to 1.2)	1.7 (1.3 to 2.2)	78.4 (71.8 to 85.0)	-9.2 (-12.4 to -6.2)
Falls	-	-	-	-	0.4 (0.3 to 0.5)	0.7 (0.5 to 1.0)	84.7 (75.6 to 95.1)	-5.7 (-10.7 to -0.6)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.6 (27.1 to 56.3)	-27.8 (-34.9 to -21.8)
Fire, heat, and hot substances	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	41.3 (29.6 to 53.0)	-28.1 (-33.1 to -22.7)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.8 (32.9 to 80.6)	-23.4 (-33.0 to -12.8)
Exposure to mechanical forces	-	-	-	-	0.3 (0.2 to 0.3)	0.5 (0.4 to 0.6)	91.1 (82.2 to 101.2)	-5.2 (-9.5 to -0.5)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.2 (85.0 to 118.1)	0.8 (-7.4 to 8.4)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	133.3 (112.0 to 151.2)	16.5 (7.0 to 24.4)
Other exposure to mechanical forces	-	-	-	-	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.6)	90.4 (81.1 to 100.5)	-5.6 (-10.2 to -0.8)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	114.1 (100.8 to 129.2)	12.2 (5.0 to 19.9)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	53.4 (45.2 to 63.5)	-23.3 (-27.0 to -18.8)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.8 (42.3 to 73.9)	-22.8 (-29.3 to -14.9)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.4 (42.3 to 60.5)	-23.8 (-27.3 to -19.5)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.5 (69.8 to 92.9)	-6.3 (-11.7 to -1.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.5 (45.0 to 81.4)	-11.5 (-19.8 to -3.6)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.7 (76.7 to 118.7)	-1.1 (-8.7 to 8.7)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.1 (70.3 to 100.0)	-5.8 (-12.8 to 1.3)
Other unintentional injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	73.8 (63.4 to 88.9)	-11.3 (-17.0 to -4.0)
Self-harm and interpersonal violence	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	63.8 (54.3 to 72.7)	-18.5 (-22.8 to -14.6)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.8 (82.3 to 115.4)	-3.2 (-10.4 to 4.5)
Interpersonal violence	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	56.9 (47.3 to 66.7)	-22.2 (-26.4 to -17.8)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.3 (51.6 to 72.8)	-21.8 (-26.3 to -16.7)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.1 (61.6 to 89.3)	-14.6 (-20.6 to -7.1)
Assault by other means	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	51.1 (40.1 to 62.6)	-24.5 (-29.5 to -19.2)
Forces of nature, war, and legal intervention	-	-	-	-	0.6 (0.1 to 1.6)	0.3 (0.1 to 0.7)	-55.3 (-60.9 to -45.3)	-72.8 (-76.4 to -67.5)
Exposure to forces of nature	-	-	-	-	-	-	-	-
Collective violence and legal intervention	-	-	-	-	0.6 (0.1 to 1.6)	0.3 (0.1 to 0.7)	-55.3 (-60.9 to -45.3)	-72.8 (-76.4 to -67.5)

Appendix Table G.4 - Eritrea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	317.3 (229.5 to 417.7)	628.3 (455.2 to 819.5)	97.2 (89.5 to 112.6)	0.7 (-3.7 to 10.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	107.3 (71.9 to 153.0)	174.5 (117.8 to 252.3)	62.3 (51.5 to 73.5)	-14.7 (-21.9 to -7.5)
HIV/AIDS and tuberculosis	-	-	-	-	4.0 (2.0 to 6.9)	7.2 (4.7 to 10.9)	72.9 (12.4 to 247.9)	-9.4 (-40.1 to 80.0)
Tuberculosis	6.3 (5.7 to 6.9)	8.5 (7.8 to 9.3)	35.5 (27.5 to 43.1)	-28.1 (-31.6 to -24.2)	1.9 (1.3 to 2.6)	2.6 (1.7 to 3.5)	34.6 (23.8 to 46.9)	-28.9 (-33.8 to -23.4)
HIV/AIDS	-	-	-	-	2.1 (0.3 to 4.7)	4.7 (2.7 to 7.9)	107.2 (18.1 to 1,295.2)	-
HIV/AIDS resulting in mycobacterial infection	0.3 (0.0 to 0.6)	0.3 (0.1 to 0.6)	-2.4 (-48.8 to 597.2)	-43.1 (-70.7 to 297.0)	0.1 (0.0 to 0.3)	0.1 (0.1 to 0.2)	-4.7 (-50.8 to 667.1)	-44.0 (-72.1 to 343.9)
HIV/AIDS resulting in other diseases	20.1 (2.9 to 39.5)	29.3 (23.5 to 38.0)	40.2 (-28.5 to 859.2)	-21.5 (-60.1 to 406.7)	2.0 (0.2 to 4.6)	4.5 (2.6 to 7.8)	114.2 (2.2 to 1,807.0)	14.0 (-46.3 to 1,016.0)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	17.2 (12.1 to 23.2)	23.3 (16.6 to 31.9)	35.2 (19.8 to 50.6)	-25.8 (-33.2 to -18.6)
Diarrheal diseases	47.3 (40.0 to 53.9)	65.4 (57.4 to 73.9)	38.4 (12.1 to 71.7)	-22.2 (-35.3 to -7.0)	7.6 (4.9 to 10.6)	10.5 (7.1 to 15.1)	38.8 (12.6 to 72.1)	-22.3 (-35.0 to -6.3)
Intestinal infectious diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-27.7 (-48.4 to -4.4)	61.5 (-71.9 to -50.0)
Typhoid fever	1.4 (1.2 to 1.5)	1.1 (1.0 to 1.3)	-16.1 (-29.5 to 1.2)	-55.9 (-62.4 to -46.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-13.7 (-34.0 to 12.1)	-54.6 (-64.0 to -41.5)
Paratyphoid fever	0.5 (0.4 to 0.6)	0.5 (0.4 to 0.6)	4.1 (-20.5 to 29.4)	-44.6 (-57.3 to -29.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.8 (-24.5 to 40.3)	43.9 (-59.3 to -26.4)
Other intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-74.4 (-97.2 to -42.1)	85.9 (-93.2 to -70.8)
Lower respiratory infections	12.5 (10.3 to 14.7)	20.7 (16.4 to 24.3)	65.1 (24.1 to 122.5)	-3.8 (-22.7 to 22.1)	1.3 (0.8 to 2.0)	2.2 (1.4 to 3.1)	65.4 (23.6 to 120.8)	3.9 (-23.8 to 22.2)
Upper respiratory infections	216.6 (199.5 to 234.2)	414.3 (377.5 to 452.5)	91.2 (68.4 to 115.1)	-0.2 (-12.0 to 13.1)	2.5 (1.4 to 4.3)	4.9 (2.7 to 8.3)	91.2 (67.3 to 115.3)	-0.3 (-12.3 to 12.8)
Otitis media	57.1 (52.3 to 62.4)	97.9 (90.0 to 106.6)	71.6 (54.2 to 90.9)	-10.6 (-19.7 to -0.3)	1.2 (0.7 to 1.9)	2.0 (1.2 to 3.2)	69.6 (50.4 to 92.3)	-11.2 (-20.7 to 0.3)
Meningitis	-	-	-	-	3.6 (2.4 to 4.9)	3.2 (2.2 to 4.3)	-9.7 (-26.2 to 5.6)	-51.2 (-59.2 to -41.1)
Pneumococcal meningitis	12.0 (7.7 to 17.5)	11.6 (7.4 to 17.0)	-4.0 (-25.4 to 25.2)	-48.2 (-58.9 to -34.5)	1.1 (0.7 to 1.7)	1.1 (0.7 to 1.6)	1.9 (-32.1 to 40.0)	45.7 (-62.0 to -27.3)
H influenzae type B meningitis	7.8 (3.8 to 12.9)	5.9 (2.9 to 10.4)	-24.5 (-47.8 to 4.7)	-59.8 (-71.4 to -45.9)	1.0 (0.5 to 1.6)	0.7 (0.4 to 1.2)	-29.6 (-56.5 to 30.7)	-62.7 (-76.7 to -33.7)
Meningococcal meningitis	1.9 (0.8 to 3.9)	1.7 (0.8 to 3.4)	-10.1 (-32.2 to 26.0)	-51.2 (-62.2 to -30.7)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	-4.8 (-28.6 to 33.6)	-48.7 (-60.2 to -29.9)
Other meningitis	10.2 (5.4 to 17.5)	9.1 (5.0 to 14.9)	-10.0 (-25.3 to 7.9)	-50.7 (-59.7 to -41.4)	1.2 (0.8 to 1.7)	1.1 (0.7 to 1.7)	-6.5 (-26.9 to 22.6)	-49.4 (-59.1 to -34.2)
Encephalitis	0.6 (0.3 to 1.2)	1.0 (0.5 to 2.1)	70.5 (55.3 to 89.1)	-14.4 (-18.3 to -3.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	75.0 (53.5 to 108.1)	-10.1 (-19.4 to 3.2)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.1 (99.5 to 93.7)	-94.2 (-99.6 to -32.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-90.1 (-99.6 to 94.7)	-94.2 (-99.6 to -32.2)
Whooping cough	8.1 (6.2 to 10.6)	1.0 (0.8 to 1.3)	-87.9 (-89.8 to -85.7)	-93.0 (-94.1 to -91.7)	0.4 (0.2 to 0.6)	0.0 (0.0 to 0.1)	-87.9 (-90.5 to -84.8)	93.0 (-94.5 to -91.1)
Tetanus	0.5 (0.2 to 1.0)	0.1 (0.0 to 0.2)	-82.2 (-92.1 to -34.6)	-90.6 (-95.8 to -84.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-75.0 (-89.1 to -48.2)	87.1 (-93.8 to -76.2)
Measles	2.6 (1.8 to 3.5)	0.5 (0.4 to 0.7)	-78.7 (-83.6 to -72.0)	-91.8 (-90.6 to -84.0)	0.2 (0.1 to 0.4)	0.2 (0.0 to 0.1)	-29.0 (-85.4 to -69.3)	-88.0 (-91.6 to -82.4)
Varicella and herpes zoster	2.0 (1.8 to 2.2)	4.1 (3.8 to 4.6)	105.2 (83.7 to 136.9)	6.3 (-17.9 to 28.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	117.6 (42.3 to 199.2)	6.7 (-31.8 to 49.1)
Neglected tropical diseases and malaria	-	-	-	-	26.7 (14.9 to 47.5)	46.6 (24.5 to 87.3)	74.1 (46.7 to 93.9)	-9.8 (-27.2 to 4.3)
Malaria	277.5 (215.2 to 339.9)	140.4 (103.5 to 182.1)	-49.6 (-62.1 to -26.2)	-74.1 (-80.5 to -62.3)	2.6 (1.7 to 3.7)	1.4 (0.9 to 2.0)	-47.4 (-53.2 to -39.6)	-74.2 (-77.1 to -70.5)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	80.9 (-0.9 to 200.8)	-9.5 (-42.5 to 30.7)
Visceral leishmaniasis	0.3 (0.2 to 0.5)	0.6 (0.3 to 0.9)	83.1 (-6.4 to 212.4)	-6.3 (-45.9 to 49.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	82.3 (-9.9 to 223.6)	-5.5 (-50.0 to 52.6)
Cutaneous and mucocutaneous leishmaniasis	0.5 (0.3 to 0.8)	0.9 (0.5 to 1.5)	72.5 (2.0 to 172.3)	-19.1 (-50.6 to 25.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.4 (-0.6 to 185.1)	-18.1 (-51.9 to 31.1)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	1,468.6 (516.5 to 2,504.0)	2,927.9 (1,030.2 to 4,983.8)	99.4 (94.5 to 103.5)	0.1 (-1.9 to 1.8)	14.0 (4.8 to 33.0)	27.8 (9.1 to 66.1)	98.5 (69.6 to 114.4)	0.9 (-12.6 to 6.8)
Cysticercosis	0.7 (0.3 to 1.2)	1.9 (0.8 to 3.4)	181.3 (-7.1 to 645.9)	14.3 (-50.5 to 150.0)	0.2 (0.1 to 0.4)	0.5 (0.2 to 1.0)	204.3 (-2.8 to 774.8)	25.6 (-49.4 to 185.7)
Cystic echinococcosis	0.8 (0.8 to 0.9)	1.6 (1.4 to 1.9)	99.6 (54.8 to 138.5)	7.2 (-17.2 to 22.1)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	95.4 (45.2 to 163.4)	5.1 (-21.5 to 34.2)
Lymphatic filariasis	231.0 (176.3 to 305.9)	400.0 (298.5 to 495.0)	74.3 (17.3 to 153.1)	-10.2 (-33.8 to 21.0)	5.9 (3.0 to 10.2)	11.0 (6.1 to 19.0)	90.3 (15.4 to 161.1)	-0.6 (-40.1 to 38.8)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	4.8 (2.8 to 6.8)	3.3 (2.2 to 4.4)	-31.8 (-49.0 to -4.4)	-69.4 (-77.9 to -54.5)	0.4 (0.2 to 0.6)	0.3 (0.2 to 0.4)	-25.4 (-44.4 to 6.4)	-67.6 (-77.0 to -51.2)
Dengue	0.1 (0.0 to 0.2)	0.6 (0.1 to 2.0)	847.2 (835.9 to 860.3)	389.8 (384.0 to 396.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.3)	793.7 (557.7 to 1,087.0)	355.5 (258.6 to 487.3)
Yellow fever	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-48.1 (-62.4 to -25.5)	-73.1 (-79.2 to -44.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.1 (-62.3 to -25.4)	-73.1 (-79.2 to -44.3)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Intestinal nematode infections	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.8)	85.6 (30.7 to 147.9)	-1.5 (-27.1 to 28.7)
Ascariasis	152.8 (94.4 to 240.6)	295.7 (176.8 to 469.9)	94.4 (-2.2 to 279.5)	-8.8 (-56.4 to 125.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.5 (32.1 to 169.2)	-1.6 (-30.3 to 40.6)
Trichuriasis	359.1 (231.1 to 575.2)	686.2 (436.2 to 1,058.0)	92.9 (3.0 to 251.7)	-0.4 (-54.0 to 109.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	90.0 (45.2 to 148.5)	0.1 (-27.4 to 38.9)
Hookworm disease	77.1 (51.3 to 113.5)	149.4 (98.9 to 217.8)	93.3 (11.8 to 234.7)	0.2 (-49.3 to 90.8)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	85.5 (16.4 to 165.1)	-1.8 (-34.4 to 36.1)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	74.4 (55.4 to 94.2)	121.1 (112.8 to 134.3)	61.9 (27.4 to 118.8)	-14.5 (-29.9 to 8.9)	3.3 (2.0 to 4.9)	4.9 (3.2 to 7.0)	47.0 (24.6 to 107.5)	-24.5 (-38.2 to 1.5)
Maternal disorders	-	-	-	-	1.3 (0.9 to 1.8)	2.0 (1.3 to 2.9)	54.0 (31.1 to 78.4)	-24.0 (-34.7 to -11.8)
Maternal hemorrhage	0.9 (0.7 to 1.1)	1.3 (0.8 to 1.9)	50.4 (-11.3 to 132.1)	-29.6 (-57.2 to 6.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	39.4 (-32.0 to 145.4)	-34.2 (-67.5 to 13.3)
Maternal sepsis and other maternal infections	1.8 (1.2 to 2.4)	1.9 (1.4 to 2.6)	4.4 (-9.1 to 25.0)	-48.7 (-55.3 to -39.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.9 (-32.3 to 52.0)	-50.5 (-65.9 to -29.0)
Maternal hypertensive disorders	1.5 (0.7 to 2.5)	2.1 (1.1 to 3.4)	40.2 (23.6 to 58.8)	-34.7 (-42.1 to -27.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	39.5 (16.6 to 67.5)	-35.1 (-45.2 to -23.2)
Obstructed labor	2.6 (2.1 to 3.2)	4.0 (3.2 to 5.0)	52.8 (36.2 to 72.5)	-23.9 (-32.1 to -14.4)	0.9 (0.6 to 1.2)	1.3 (0.8 to 1.9)	52.7 (30.9 to 78.5)	-24.0 (-33.9 to -11.9)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.8 (-17.6 to 232.8)	-26.0 (-59.8 to 40.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.8 (-17.9 to 235.1)	-26.0 (-59.9 to 40.8)
Other maternal disorders	-	-	-	-	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	66.4 (17.8 to 131.3)	-17.9 (-41.2 to 12.5)
Neonatal disorders	-	-	-	-	2.4 (1.3 to 4.3)	10.9 (6.8 to 16.3)	370.2 (171.6 to 615.6)	161.2 (42.8 to 316.4)
Preterm birth complications	10.6 (5.3 to 20.6)	46.5 (26.5 to 80.9)	346.2 (243.2 to 534.0)	125.0 (76.9 to 215.6)	0.7 (0.4 to 1.2)	5.3 (2.8 to 8.2)	653.7 (307.0 to 1,188.0)	307.3 (128.8 to 604.7)
Neonatal encephalopathy due to birth asphyxia and trauma	16.9 (1.8 to 54.8)	23.2 (4.7 to 68.8)	50.1 (-0.7 to 260.1)	-24.2 (-50.0 to 82.3)	0.6 (0.3 to 1.4)	2.0 (1.0 to 3.6)	234.4 (71.2 to 686.8)	87.2 (-13.3 to 391.2)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	187.0 (159.6 to 209.9)	0.0 (-59.0 to 89.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.8 (141.9 to 236.1)	153.7 (48.1 to 105.8)
Hemolytic disease and other neonatal jaundice	0.7 (0.2 to 1.5)	3.0 (1.4 to 6.4)	336.1 (25.6 to 1,340.2)	164.5 (-25.4 to 807.2)	0.3 (0.1 to 0.6)	1.1 (0.5 to 2.6)	341.0 (21.3 to 1,422.2)	161.6 (-29.7 to 815.7)
Other neonatal disorders	-	-	-	-	0.8 (0.2 to 2.0)	2.4 (0.8 to 5.9)	216.0 (19.4 to 610.8)	73.0 (-36.6 to 298.6)
Nutritional deficiencies	-	-	-	-	52.0 (34.9 to 74.1)	78.4 (52.1 to 112.1)	50.4 (37.9 to 67.4)	-23.5 (-28.7 to -16.1)
Protein-energy malnutrition	39.3 (21.6 to 63.4)	67.7 (33.2 to 124.2)	69.0 (-27.8 to 300.9)	-0.1 (-53.2 to 115.3)	4.9 (2.3 to 8.8)	8.4 (3.5 to 16.6)	70.7 (-28.6 to 309.1)	0.3 (-5.4 to 120.4)
Iodine deficiency	184.1 (125.8 to 249.5)	169.6 (88.0 to 252.2)	-11.0 (-44.7 to 60.4)	-55.1 (-73.1 to -15.2)	3.3 (1.7 to 5.6)	3.1 (1.4 to 5.7)	-11.2 (-44.4 to 59.4)	-55.1 (-73.0 to -15.6)
Vitamin A deficiency	6.2 (4.7 to 7.9)	6.8 (5.1 to 9.1)	10.2 (-11.3 to 29.8)	-41.8 (-52.6 to -31.4)	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.6)	5.8 (-17.5 to 31.7)	-42.3 (-54.5 to -27.6)

Appendix Table G.4 - Eritrea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	1,137.5 (1,116.5 to 1,157.9)	1,833.4 (1,778.8 to 1,892.1)	61.1 (55.7 to 67.0)	-18.5 (-21.7 to -14.9)	43.4 (29.1 to 61.8)	66.5 (44.4 to 95.9)	52.8 (48.5 to 60.5)	21.9 (-24.3 to 15.8)
Other nutritional deficiencies	-	-	-	-	0.0	0.0	102.3 (44.0 to 634.9)	19.6 (-66.3 to 301.2)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	3.7 (2.3 to 5.6)	6.1 (3.8 to 9.3)	65.0 (46.0 to 90.6)	-15.0 (-25.8 to -3.7)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.0 (0.6 to 1.9)	2.0 (1.1 to 3.7)	95.7 (50.0 to 149.3)	-8.0 (-26.8 to 12.8)
Syphilis	0.4 (0.4 to 0.5)	0.4 (0.4 to 0.5)	0.8 (-17.3 to 26.2)	-48.0 (-5.7 to 48.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	48.1 (-24.6 to 37.9)	-59.1 (-59.1 to -34.5)
Chlamydial infection	59.3 (45.3 to 80.3)	127.3 (88.9 to 174.7)	112.3 (33.7 to 239.0)	0.3 (-0.3 to 0.9)	0.3 (0.1 to 0.6)	0.7 (0.3 to 1.3)	116.9 (15.3 to 295.3)	1.7 (-43.8 to 83.8)
Gonococcal infection	25.7 (17.8 to 33.8)	52.8 (34.3 to 69.5)	103.5 (25.0 to 241.7)	-2.4 (-39.0 to 56.0)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	93.3 (23.2 to 231.9)	-6.6 (-39.2 to 55.1)
Trichomoniasis	48.4 (27.7 to 76.2)	94.0 (55.0 to 149.1)	91.7 (4.7 to 290.2)	-6.9 (-44.1 to 68.7)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	87.6 (-6.2 to 350.0)	-9.1 (-50.2 to 91.3)
Genital herpes	1,266.2 (1,194.3 to 1,334.8)	2,591.5 (2,430.0 to 2,738.3)	102.4 (89.4 to 144.2)	1.2 (-6.3 to 4.4)	0.8 (0.1 to 0.9)	1.2 (0.3 to 1.8)	102.7 (84.5 to 126.1)	-1.5 (-8.6 to 6.3)
Other sexually transmitted diseases	1.5 (1.0 to 2.1)	2.7 (1.8 to 3.7)	77.2 (52.3 to 99.1)	-13.9 (-26.7 to -2.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	92.4 (36.3 to 194.8)	8.2 (-34.1 to 31.6)
Hepatitis	-	-	-	-	0.4 (0.2 to 0.5)	0.5 (0.3 to 0.8)	45.8 (7.5 to 82.4)	-28.8 (-50.4 to -7.1)
Hepatitis A	6.5 (6.1 to 6.9)	11.5 (10.9 to 12.0)	76.6 (75.5 to 77.7)	-1.4 (-1.6 to -1.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	91.8 (69.3 to 117.8)	2.9 (-8.6 to 16.1)
Hepatitis B	441.8 (336.3 to 549.8)	579.2 (448.1 to 699.3)	32.2 (-6.8 to 78.9)	-34.5 (-51.8 to -11.1)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	25.3 (-21.7 to 89.2)	37.1 (-63.0 to -4.5)
Hepatitis C	52.0 (45.3 to 58.3)	74.4 (66.3 to 82.8)	42.8 (20.8 to 71.3)	-28.9 (-39.2 to -17.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.6 (27.0 to 86.7)	-23.0 (-47.2 to 3.8)
Hepatitis E	0.9 (0.7 to 1.3)	1.2 (0.7 to 1.7)	23.6 (-35.1 to 118.4)	-40.8 (-67.6 to 5.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	24.7 (-39.3 to 131.4)	-39.9 (-69.4 to 9.9)
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	274.8 (42.4 to 1,206.9)	70.4 (-31.9 to 541.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	288.7 (36.8 to 1,459.1)	72.6 (-35.9 to 635.6)
Other infectious diseases	53.7 (41.5 to 66.1)	85.9 (78.9 to 94.5)	60.1 (36.3 to 80.5)	-16.8 (-26.6 to -7.6)	2.3 (1.4 to 3.3)	3.5 (2.3 to 5.2)	54.9 (32.4 to 88.1)	-16.9 (-32.7 to 0.5)
Non-communicable diseases	-	-	-	-	199.0 (146.5 to 258.1)	398.4 (294.0 to 516.1)	100.2 (94.1 to 106.5)	-3.2 (-6.9 to 0.1)
Neoplasms	-	-	-	-	0.6 (0.4 to 0.9)	1.8 (1.2 to 2.5)	184.3 (118.1 to 257.5)	35.8 (7.1 to 67.4)
Esophageal cancer	0.3 (0.1 to 0.6)	0.7 (0.3 to 1.2)	116.0 (33.8 to 254.1)	-2.0 (-39.3 to 60.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	111.2 (37.8 to 225.6)	-5.2 (-37.7 to 47.1)
Stomach cancer	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	117.9 (60.6 to 191.2)	5.0 (-22.0 to 41.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	116.1 (57.1 to 191.1)	3.4 (-24.9 to 42.2)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	156.4 (69.1 to 259.5)	20.9 (-19.2 to 65.9)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	207.9 (41.0 to 718.9)	52.3 (-38.0 to 369.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	201.6 (49.4 to 657.1)	47.6 (-39.3 to 318.4)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	463.8 (181.6 to 1,193.5)	151.8 (18.9 to 453.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	421.4 (183.0 to 1,103.7)	132.0 (17.6 to 390.5)
Liver cancer due to alcohol use	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	29.1 (-34.5 to 158.9)	-34.2 (-65.3 to 26.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.3 (-30.6 to 132.8)	-36.4 (-64.6 to 9.4)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	60.8 (-18.0 to 187.2)	-32.5 (-62.7 to 41.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.4 (-16.2 to 150.6)	27.1 (-61.5 to 23.8)
Larynx cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	111.6 (40.0 to 227.5)	0.9 (-32.0 to 53.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.3 (34.4 to 223.2)	-1.3 (-36.8 to 48.0)
Tracheal, bronchus and lung cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	135.6 (70.9 to 230.8)	12.3 (-17.5 to 54.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	127.8 (59.9 to 226.7)	8.0 (-23.0 to 55.2)
Breast cancer	0.9 (0.6 to 1.2)	3.5 (2.3 to 5.0)	305.7 (176.2 to 473.4)	97.7 (40.0 to 165.7)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.5)	257.5 (145.4 to 421.2)	74.0 (22.7 to 141.4)
Cervical cancer	1.6 (0.8 to 2.3)	3.2 (1.4 to 4.8)	96.4 (17.8 to 215.7)	1.8 (-39.7 to 55.2)	0.3 (0.1 to 0.2)	0.3 (0.1 to 0.5)	81.2 (19.3 to 204.8)	-4.4 (-39.5 to 50.7)
Uterine cancer	0.2 (0.1 to 0.3)	0.5 (0.2 to 0.8)	144.9 (34.4 to 357.0)	19.2 (-33.2 to 108.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	136.3 (30.1 to 324.5)	14.0 (-35.7 to 94.7)
Prostate cancer	0.3 (0.2 to 0.5)	2.4 (1.4 to 3.7)	611.9 (298.7 to 1,160.2)	202.6 (73.9 to 423.5)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.4)	482.7 (227.5 to 896.8)	147.8 (46.7 to 313.1)
Colon and rectum cancer	0.3 (0.3 to 0.4)	1.1 (0.9 to 1.4)	272.9 (189.4 to 373.4)	67.1 (27.5 to 112.9)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	241.5 (160.6 to 345.7)	54.2 (16.9 to 99.9)
Lip and oral cavity cancer	0.2 (0.1 to 0.3)	0.5 (0.4 to 0.7)	154.3 (70.9 to 287.2)	22.4 (-17.4 to 69.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	147.6 (65.0 to 289.7)	17.4 (-20.4 to 80.9)
Nasopharynx cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	72.1 (6.1 to 200.4)	-12.7 (-45.6 to 47.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.7 (5.9 to 182.6)	-15.2 (-45.2 to 37.2)
Other pharynx cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	129.1 (28.0 to 321.5)	11.1 (-39.8 to 96.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	125.0 (35.7 to 287.8)	6.9 (-35.8 to 78.8)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	222.2 (128.2 to 369.9)	43.8 (1.2 to 108.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	210.1 (130.2 to 332.1)	39.2 (3.0 to 93.0)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	205.4 (117.7 to 316.1)	36.7 (-4.3 to 85.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	196.9 (128.6 to 281.5)	32.2 (1.5 to 68.1)
Malignant skin melanoma	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.6)	357.9 (134.2 to 396.8)	65.6 (9.6 to 131.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	340.8 (121.2 to 381.3)	54.4 (2.2 to 121.8)
Non-melanoma skin cancer	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.5)	192.5 (118.4 to 283.1)	32.4 (-3.1 to 84.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	238.0 (141.8 to 394.5)	46.5 (7.2 to 131.9)
Ovarian cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	162.5 (72.4 to 294.5)	24.4 (-15.9 to 81.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	155.8 (59.2 to 313.2)	21.0 (-23.9 to 98.0)
Testicular cancer	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	350.5 (153.4 to 687.3)	105.2 (20.7 to 240.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	308.5 (122.6 to 620.8)	81.4 (7.0 to 206.0)
Kidney cancer	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	233.5 (5.9 to 464.4)	48.7 (-8.7 to 138.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	142.2 (11.6 to 443.2)	49.0 (-1.8 to 121.5)
Bladder cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	26.1 (-15.7 to 84.8)	-35.2 (-55.6 to -9.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.3 (-25.3 to 64.5)	-41.0 (-59.3 to -16.4)
Brain and nervous system cancer	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	270.1 (108.5 to 512.8)	82.1 (19.5 to 150.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	258.1 (116.2 to 452.2)	68.8 (11.0 to 126.7)
Thyroid cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	195.3 (51.1 to 401.2)	38.2 (-26.7 to 126.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	175.0 (41.0 to 370.6)	26.0 (-31.0 to 111.1)
Mesothelioma	0.0 (0.0 to 0.0)	0.2 (0.0 to 0.0)	111.6 (36.3 to 233.3)	0.5 (-33.6 to 62.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	118.0 (181.8 to 251.1)	5.0 (-33.0 to 68.3)
Hodgkin lymphoma	0.2 (0.1 to 0.2)	0.5 (0.3 to 0.8)	205.8 (82.1 to 430.1)	67.2 (2.3 to 157.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	179.1 (78.1 to 336.8)	40.5 (-9.9 to 111.2)
Non-Hodgkin lymphoma	0.3 (0.2 to 0.5)	0.9 (0.6 to 1.3)	171.6 (44.2 to 377.7)	54.2 (5.5 to 129.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	171.3 (57.9 to 352.3)	47.0 (3.5 to 110.1)
Multiple myeloma	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	244.4 (106.9 to 435.7)	58.5 (-3.8 to 149.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	219.9 (93.1 to 397.4)	43.7 (-14.5 to 130.3)
Leukemia	0.1 (0.0 to 0.1)	0.2 (0.2 to 0.4)	186.4 (54.4 to 488.0)	50.4 (-0.7 to 131.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	174.2 (77.7 to 324.2)	34.9 (-4.6 to 91.7)
Other neoplasms	0.8 (0.4 to 1.4)	2.8 (1.7 to 4.1)	295.1 (58.4 to 670.9)	77.5 (2.2 to 164.9)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	281.5 (72.6 to 542.8)	58.1 (0.2 to 131.1)
Cardiovascular diseases	-	-	-	-	4.3 (2.9 to 5.9)	8.6 (5.8 to 12.1)	101.4 (59.1 to 148.4)	-3.4 (-22.7 to 16.9)
Rheumatic heart disease	33.7 (28.0 to 39.9)	60.0 (44.8 to 75.5)	78.8 (24.2 to 133.6)	-9.3 (-33.1 to 17.2)	1.6 (1.0 to 2.5)	2.9 (1.7 to 4.6)	76.6 (23.2 to 130.8)	-12.7 (-34.2 to 12.1)
Ischemic heart disease	19.8 (15.0 to 25.6)	32.2 (26.8 to 39.0)	64.2 (17.1 to 127.9)	-25.2 (-44.5 to 1.2)	1.5 (0.6 to 1.6)	1.5 (1.0 to 2.3)	48.9 (40.1 to 124.8)	-92.2 (-53.3 to -0.0)
Cerebrovascular disease	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	120.8 (63.0 to 193.8)	5.5 (-19.8 to 36.9)
Ischemic stroke	0.7 (0.5 to 0.8)	1.5 (1.2 to 1.8)	125.2 (65.7 to 203.1)	6.8 (-18.6 to 37.8)	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	123.1 (65.3 to 195.4)	5.8 (-18.6 to 39.5)
Hemorrhagic stroke	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.6)	113.6 (48.8 to 202.2)	3.9 (-25.7 to 40.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	112.3 (44.9 to 200.9)	2.7 (-26.8 to 39.1)
Hypertensive heart disease	2.5 (1.8 to 3.3)	7.1 (4.8 to 9.3)	188.1 (74.6 to 326.3)	20.8 (-21.0 to 81.2)	0.3 (0.1 to 0.6)	0.8 (0.5 to 1.1)	183.7 (75.4 to 323.2)	19.8 (-24.1 to 81.4)
Cardiomyopathy and myocarditis	2.2 (1.8 to 2.7)	6.2 (4.5 to 8.4)	172.1 (103.8 to 287.6)	30.4 (-11.4 to 104.0)	0.2 (0.2 to 0.3)	0.7 (0.4 to 1.0)	173.3 (98.4 to 283.0)	30.1 (-11.8 to 103.4)
Atrial fibrillation and flutter	0.7 (0.6 to 0.9)	3.0 (2.3 to 4.0)	307.4 (196.0 to 490.5)	67.2 (11.7 to 162.2)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	298.0 (189.9 to 486.2)	67.5 (11.9 to 128.1)
Peripheral vascular disease	33.1 (23.9 to 47.3)	65.0 (41.0 to 92.0)	94.8 (3.4 to 233.1)	-12.9 (-42.3 to 29.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	180.8 (16.0 to 758.6)	-3.7 (-64.6 to 227.2)
Endocarditis	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	92.9 (22.6 to 218.0)	-2.4 (-50.4 to 97.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.8 (18.8 to 269.5)	3.7 (-52.7 to 128.5)
Other cardiovascular and circulatory diseases	12.3 (6.2 to 21.7)	31.3 (16.0 to 47.5)	161.1 (11.7 to 452.4)	19.9 (-50.9 to 175.2)	0.9 (0.4 to 1.6)	2.2 (1.0 to 3.6)	165.3 (9.1 to 453.1)	19.6 (-51.1 to 176.8)
Chronic respiratory diseases	-	-	-	-	13.9 (9.1 to 20.6)	24.0 (16.0 to 33.8)	73.7 (35.4 to 120.4)	-17.3 (-35.4 to 1

Appendix Table G.4 - Eritrea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumococcal	-	-	-	-	0.0	0.0	104.5	-3.3
Silicosis	0.0	0.0	97.7	-7.2	(0.0 to 0.0)	(0.0 to 0.0)	(98.4 to 111.9)	(-6.2 to -0.2)
Asbestosis	-	-	0.0	0.0	-	-	97.2	-7.3
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	111.5	0.0	0.0	0.0	110.5	0.5
Asthma	37.9	86.0	(103.3 to 121.0)	(-2.3 to 4.7)	1.6	3.7	123.6	3.7
Interstitial lung disease and pulmonary sarcoidosis	0.1	0.1	(41.1 to 275.0)	(-29.1 to 56.8)	1.0	2.5	(41.3 to 277.3)	(-29.2 to 57.1)
Other chronic respiratory diseases	-	-	130.0	8.6	0.0	0.0	130.7	8.6
Cirrhosis	-	-	(65.3 to 229.6)	(-19.7 to 48.0)	(0.0 to 0.0)	(0.0 to 0.0)	(66.6 to 229.2)	(-19.4 to 48.4)
Cirrhosis due to hepatitis B	0.3	0.6	100.0	-4.3	(2.0 to 8.3)	(2.1 to 6.9)	(-49.2 to 66.3)	(-7.3 to -20.3)
Cirrhosis due to hepatitis C	0.2	0.4	91.0	-7.4	(0.2 to 0.3)	(0.3 to 0.5)	(41.5 to 83.1)	(-25.1 to -8.0)
Cirrhosis due to alcohol use	0.4	0.5	19.4	0.1	0.0	0.1	99.7	-3.3
Cirrhosis due to other causes	0.5	0.6	(-27.4 to 71.2)	(-61.7 to -14.3)	(0.0 to 0.1)	(0.0 to 0.1)	(-30.1 to 80.6)	(-62.0 to -11.4)
Digestive diseases	-	-	55.4	-5.4	(0.1 to 0.1)	(0.1 to 0.1)	(0.6 to 142.7)	(-43.8 to 42.1)
Peptic ulcer disease	21.1	30.4	43.4	-33.7	3.9	7.3	89.3	-11.5
Gastritis and duodenitis	35.0	64.3	83.7	-4.1	(2.7 to 5.3)	(5.2 to 10.1)	(70.0 to 109.1)	(-18.5 to -4.5)
Appendicitis	0.4	0.9	110.6	3.6	0.8	1.2	45.9	-33.5
Paralytic ileus and intestinal obstruction	0.0	0.1	(51.9 to 196.3)	(-24.7 to 40.0)	(0.5 to 1.1)	(0.8 to 1.7)	(14.6 to 79.9)	(-42.8 to -22.6)
Inguinal, femoral, and abdominal hernia	9.4	24.0	175.9	138.6	1.6	2.9	82.2	-9.4
Inflammatory bowel disease	2.8	7.2	159.1	25.9	(1.1 to 2.2)	(1.9 to 4.1)	(56.0 to 112.5)	(-17.0 to 2.3)
Vascular intestinal disorders	0.0	0.0	108.5	-2.8	0.0	0.0	107.3	-5.7
Gallbladder and biliary diseases	0.8	1.9	134.9	1.9	(0.0 to 0.0)	(0.0 to 0.0)	(43.7 to 206.2)	(-40.5 to 73.7)
Pancreatitis	0.5	1.1	124.4	4.5	(0.1 to 0.1)	(0.1 to 0.3)	(89.7 to 187.6)	(-7.0 to 34.4)
Other digestive diseases	-	-	108.5 to 146.5	(-2.5 to 14.5)	0.4	0.7	58.2	-25.6
Neurological disorders	-	-	-	-	(0.2 to 0.7)	(0.4 to 1.1)	(11.4 to 143.6)	(-45.5 to 13.1)
Alzheimer disease and other dementias	2.6	7.0	166.7	1.0	11.4	27.1	139.9	5.7
Parkinson disease	0.2	0.4	136.7	0.1	(7.4 to 16.4)	(17.8 to 39.1)	(82.4 to 199.9)	(-13.5 to 26.4)
Epilepsy	6.4	13.5	110.7	6.3	0.3	0.9	169.8	0.5
Multiple sclerosis	0.2	0.5	136.3	15.8	(0.2 to 0.5)	(0.7 to 1.2)	(127.1 to 218.3)	(-16.5 to 21.9)
Migraine	173.1	377.8	126.5	5.9	(0.0 to 0.0)	(0.0 to 0.1)	(88.1 to 188.7)	(-17.4 to 19.1)
Tension-type headache	371.3	820.3	120.5	4.6	(0.9 to 3.1)	(2.1 to 7.0)	(12.6 to 365.9)	(-42.3 to 137.5)
Medication overuse headache	14.1	43.8	207.8	51.8	0.1	0.2	(83.1 to 195.5)	(9.7 to 43.2)
Other neurological disorders	0.0	0.0	85.8	-6.5	0.2	0.6	128.6	15.9
Mental and substance use disorders	-	-	-	-	(0.1 to 0.7)	(0.3 to 1.0)	(92.5 to 216.3)	(-27.8 to 51.2)
Schizophrenia	6.6	13.8	107.5	0.8	(3.0 to 4.7)	(4.0 to 8.4)	(68.8 to 93.1)	(-18.1 to -7.2)
Alcohol use disorders	34.2	61.7	80.6	-12.4	4.0	8.2	103.3	-0.9
Drug use disorders	-	-	-	-	(2.6 to 5.6)	(5.4 to 11.5)	(80.0 to 130.8)	(-11.1 to 11.6)
Opioid use disorders	5.0	10.5	108.7	1.5	2.1	4.3	108.6	1.1
Cocaine use disorders	1.5	3.4	114.1	0.2	(1.2 to 3.3)	(2.3 to 6.7)	(81.1 to 140.2)	(-11.4 to 15.3)
Amphetamine use disorders	5.4	10.3	92.6	-5.9	(0.1 to 0.3)	(0.3 to 0.7)	(69.1 to 195.5)	(-24.6 to 34.0)
Cannabis use disorders	4.2	8.5	102.2	0.2	0.7	1.3	92.3	-6.2
Other drug use disorders	-	-	-	-	(0.4 to 1.0)	(0.8 to 2.0)	(62.3 to 132.7)	(-20.1 to 11.5)
Depressive disorders	-	-	-	-	(0.1 to 0.2)	(0.1 to 0.4)	(71.9 to 146.7)	(-14.1 to 20.6)
Major depressive disorder	152.5	314.1	105.5	1.5	(0.6 to 1.4)	(1.1 to 2.7)	(45.6 to 176.6)	(-28.8 to 34.2)
Dysthymia	30.5	63.3	107.3	2.9	0.9	1.7	94.2	0.3
Bipolar disorder	17.4	36.7	110.3	0.3	(2.1 to 5.0)	(4.5 to 11.2)	(94.1 to 126.7)	(-6.3 to 6.7)
Anxiety disorders	96.3	198.4	104.7	8.8	0.2	0.6	104.2	-0.3
Eating disorders	-	-	-	-	(3.1 to 16.2)	(6.4 to 32.8)	(91.1 to 113.5)	(-2.9 to 2.2)
Anorexia nervosa	0.6	1.2	108.1	3.9	0.8	1.7	103.9	-0.1
Bulimia nervosa	3.3	6.8	103.6	-0.7	(0.5 to 1.3)	(1.0 to 2.6)	(87.0 to 123.6)	(-7.8 to 8.4)
Autistic spectrum disorders	-	-	-	-	(0.4 to 1.1)	(0.8 to 2.3)	(84.4 to 124.1)	(-9.5 to 8.4)
Autism	10.0	19.5	94.3	0.4	3.9	7.6	94.2	0.3
Asperger syndrome	14.4	28.0	94.0	0.5	(2.7 to 5.3)	(5.3 to 10.3)	(86.1 to 101.6)	(-2.9 to 3.5)
Attention-deficit/hyperactivity disorder	24.6	45.7	86.2	0.7	2.5	4.8	94.4	0.3
Conduct disorder	35.9	65.8	83.5	4.3	(1.7 to 3.4)	(3.2 to 6.6)	(83.7 to 105.7)	(-4.4 to 5.3)
Idiopathic intellectual disability	61.2	128.7	107.4	11.3	1.4	2.8	93.8	0.3
Other mental and substance use disorders	38.4	80.8	110.5	0.2	(0.4 to 0.8)	(0.7 to 1.5)	(73.4 to 101.3)	(-6.2 to 8.9)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	(0.2 to 5.0)	(0.3 to 0.8)	(74.4 to 101.3)	(-6.2 to 8.9)
Diabetes mellitus	20.5	55.0	170.1	36.3	(0.7 to 6.2)	(4.9 to 11.4)	(75.3 to 92.1)	(-3.5 to 5.5)
Acute glomerulonephritis	0.0	0.1	29.2	-28.2	3.0	6.3	108.0	11.7
Chronic kidney disease	-	-	-	-	(1.4 to 4.6)	(3.7 to 9.2)	(75.3 to 200.4)	(-6.6 to 68.9)
Chronic kidney disease due to diabetes mellitus	38.1	72.8	92.8	-6.6	2.9	6.0	110.2	-0.1
Chronic kidney disease due to hypertension	125.3	256.9	104.6	5.0	(1.9 to 3.8)	(4.1 to 8.1)	(101.0 to 119.5)	(-3.8 to 3.6)
Chronic kidney disease due to glomerulonephritis	82.2	169.1	109.2	-0.9	15.1	29.4	94.8	0.8
Chronic kidney disease due to other causes	-	-	-	-	(10.6 to 20.5)	(20.7 to 40.2)	(83.0 to 108.8)	(-5.5 to 7.8)
Urinary diseases and male infertility	-	-	-	-	1.5	4.0	173.9	35.5
	-	-	-	-	(0.2 to 2.1)	(2.6 to 5.7)	(96.3 to 258.8)	(-0.2 to 84.3)
	-	-	-	-	29.2	0.0	28.2	-28.2
	-	-	-	-	(0.0 to 0.0)	(0.0 to 0.0)	(15.6 to 42.4)	(-34.2 to -22.4)
	-	-	-	-	4.8	9.6	100.9	1.0
	-	-	-	-	(3.4 to 6.3)	(6.9 to 12.8)	(81.5 to 124.6)	(-8.0 to 13.6)
	-	-	-	-	0.6	1.1	97.8	-3.9
	-	-	-	-	(0.4 to 0.8)	(0.8 to 1.6)	(38.6 to 158.3)	(-33.0 to 28.1)
	-	-	-	-	5.0	2.9	94.9	0.6
	-	-	-	-	(1.0 to 2.0)	(2.0 to 3.9)	(54.4 to 140.3)	(-17.3 to 20.6)
	-	-	-	-	1.7	3.4	106.0	6.3
	-	-	-	-	(2.0 to 2.7)	(4.2 to 4.6)	(74.5 to 141.7)	(-10.9 to 26.8)
	-	-	-	-	1.1	2.2	109.5	0.6
	-	-	-	-	(24.1 to 34.6)	(1.5 to 3.1)	(55.3 to 179.7)	(-24.2 to 38.6)
	-	-	-	-	0.7	1.5	134.7	5.7
	-	-	-	-	(0.4 to 1.0)	(1.0 to 2.2)	(103.9 to 173.2)	(5.1 to 18.5)

Appendix Table G.4 - Eritrea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.6 (0.6 to 0.6)	1.3 (1.2 to 1.3)	113.5 (94.5 to 133.3)	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	113.8 (64.6 to 174.9)	6.1 (-12.2 to 28.6)
Urolithiasis	5.7 (4.1 to 7.4)	9.2 (6.4 to 12.2)	60.3 (36.2 to 103.1)	-23.2 (-32.2 to -8.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	123.9 (91.0 to 163.7)	10.4 (-2.4 to 23.9)
Benign prostatic hyperplasia	10.6 (9.8 to 11.6)	26.8 (24.5 to 29.1)	150.9 (121.5 to 185.5)	7.0 (5.3 to 20.9)	0.4 (0.2 to 0.5)	0.9 (0.6 to 1.3)	148.9 (118.8 to 182.5)	6.4 (-6.0 to 20.0)
Male infertility due to other causes	29.2 (19.1 to 43.5)	60.7 (41.8 to 87.6)	110.2 (28.9 to 246.2)	-1.9 (-40.4 to 63.3)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.8)	114.3 (33.2 to 249.4)	0.0 (-37.4 to 61.0)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	125.5 (60.1 to 233.6)	16.4 (-19.9 to 65.5)
Gynecological diseases	-	-	-	-	3.8 (2.5 to 5.7)	7.3 (4.7 to 11.1)	91.3 (66.6 to 121.5)	-7.0 (-17.7 to 5.2)
Uterine fibroids	49.1 (44.3 to 53.5)	96.3 (86.4 to 105.3)	96.2 (94.7 to 97.8)	1.5 (1.5 to 1.6)	1.0 (0.6 to 1.6)	1.7 (1.1 to 2.7)	73.7 (55.0 to 85.1)	-14.5 (-23.8 to -7.7)
Polycystic ovarian syndrome	46.4 (41.5 to 51.1)	101.1 (89.4 to 112.5)	118.8 (84.3 to 155.3)	5.5 (-8.9 to 20.9)	0.5 (0.2 to 0.9)	0.5 (0.5 to 1.9)	119.7 (84.3 to 156.8)	5.6 (-8.0 to 22.0)
Female infertility due to other causes	43.8 (30.8 to 56.3)	88.0 (65.8 to 114.2)	97.5 (34.8 to 217.0)	-4.7 (-36.6 to 56.8)	0.2 (0.1 to 0.5)	0.5 (0.2 to 1.0)	98.8 (37.5 to 209.6)	4.6 (-35.8 to 53.1)
Endometriosis	4.8 (4.1 to 5.6)	8.9 (7.4 to 10.2)	88.2 (48.9 to 131.3)	-3.4 (-26.4 to 11.7)	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.2)	87.2 (46.7 to 134.5)	8.7 (-27.6 to 12.7)
Genital prolapse	77.9 (66.5 to 90.0)	172.7 (146.6 to 201.4)	122.1 (75.8 to 177.2)	5.1 (-13.4 to 26.7)	0.2 (0.1 to 0.5)	0.5 (0.3 to 1.0)	121.5 (74.5 to 177.1)	5.1 (-12.9 to 26.6)
Premenstrual syndrome	118.4 (81.8 to 151.3)	248.4 (181.7 to 332.3)	108.2 (39.9 to 232.7)	1.0 (-32.2 to 60.3)	1.0 (0.6 to 1.6)	2.1 (1.2 to 3.4)	109.0 (39.4 to 229.8)	1.0 (-32.0 to 60.6)
Other gynecological diseases	13.2 (10.7 to 16.0)	22.8 (19.5 to 28.0)	72.8 (29.6 to 119.9)	-14.8 (-36.5 to 10.8)	0.5 (0.3 to 0.7)	0.7 (0.4 to 1.0)	52.7 (-0.5 to 130.9)	-25.4 (-53.0 to 17.8)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	2.3 (1.5 to 3.3)	3.6 (2.4 to 5.3)	59.4 (38.7 to 91.7)	-20.0 (-30.0 to -7.3)
Thalassemias	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	65.6 (4.4 to 152.1)	-9.9 (-43.0 to 36.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.3 (6.3 to 155.3)	-8.9 (-41.7 to 37.8)
Thalassemia trait	24.8 (21.3 to 28.6)	49.3 (41.0 to 57.3)	98.7 (89.3 to 108.0)	2.9 (-2.0 to 7.7)	0.5 (0.3 to 0.7)	0.9 (0.6 to 1.3)	94.3 (59.9 to 133.4)	2.6 (-14.4 to 22.8)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	57.0 (43.4 to 70.4)	-14.4 (-22.3 to -7.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.1 (51.3 to 92.9)	-6.1 (-18.3 to 4.8)
Sickle cell trait	33.7 (26.0 to 42.1)	57.4 (44.8 to 72.2)	70.2 (55.4 to 87.9)	-11.9 (-19.8 to -2.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	68.2 (3.3 to 208.4)	3.2 (-39.5 to 79.9)
G6PD deficiency	180.9 (124.4 to 238.8)	340.7 (206.2 to 480.1)	86.5 (14.6 to 221.3)	-3.3 (-40.4 to 67.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	85.4 (53.5 to 123.6)	-2.3 (-12.7 to 9.8)
G6PD trait	688.4 (609.3 to 744.9)	1,307.3 (1,042.4 to 1,433.8)	90.2 (54.0 to 124.1)	-1.7 (-20.5 to 15.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	68.7 (-47.2 to 404.4)	-12.1 (-73.3 to 168.7)
Other hemoglobinopathies and hemolytic anemias	49.4 (41.6 to 55.4)	75.7 (68.8 to 83.9)	53.0 (36.7 to 78.9)	-24.2 (-31.8 to -16.0)	1.6 (1.0 to 2.4)	2.4 (1.5 to 3.6)	48.7 (28.6 to 96.6)	-7.8 (-39.9 to -9.6)
Endocrine, metabolic, blood, and immune disorders	56.1 (52.2 to 60.5)	91.1 (76.2 to 103.2)	62.5 (36.2 to 92.1)	-6.9 (-27.1 to -4.9)	2.1 (1.4 to 3.0)	3.3 (2.2 to 4.7)	52.2 (19.2 to 99.5)	-9.7 (-33.5 to 1.0)
Musculoskeletal disorders	-	-	-	-	31.7 (22.2 to 42.5)	66.2 (46.8 to 89.6)	108.8 (84.5 to 136.6)	-1.8 (-11.5 to 6.7)
Rheumatoid arthritis	6.6 (6.3 to 6.9)	11.9 (11.3 to 12.5)	79.5 (68.5 to 91.4)	-15.0 (-20.2 to -9.6)	1.6 (1.1 to 2.1)	2.8 (2.0 to 3.8)	78.7 (63.3 to 96.2)	-15.1 (-21.1 to -8.5)
Osteoarthritis	45.5 (43.5 to 47.5)	100.2 (96.1 to 104.4)	120.2 (107.8 to 134.6)	1.1 (-4.0 to 7.1)	1.8 (1.9 to 3.8)	6.1 (4.2 to 8.2)	118.9 (105.9 to 134.4)	0.8 (-4.5 to 6.8)
Low back and neck pain	-	-	-	-	23.4 (16.0 to 31.9)	51.0 (35.7 to 69.6)	180.0 (89.8 to 148.4)	3.2 (-7.7 to 15.9)
Low back pain	120.7 (109.2 to 132.0)	253.1 (229.2 to 276.4)	109.6 (86.6 to 135.1)	1.2 (-8.5 to 12.0)	13.4 (9.1 to 18.8)	28.0 (18.7 to 39.7)	108.3 (84.9 to 135.4)	0.7 (-9.1 to 12.2)
Neck pain	101.9 (78.1 to 123.1)	234.5 (195.3 to 275.2)	131.2 (76.1 to 198.3)	6.1 (-15.3 to 37.0)	10.0 (6.4 to 14.6)	23.0 (15.0 to 33.2)	131.3 (74.2 to 198.5)	6.4 (-15.3 to 37.5)
Gout	0.3 (0.3 to 0.4)	0.7 (0.6 to 0.8)	119.0 (84.2 to 169.7)	2.3 (-11.6 to 22.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	119.2 (66.2 to 198.0)	3.5 (-20.4 to 40.2)
Other musculoskeletal disorders	43.8 (32.2 to 56.4)	69.4 (36.5 to 101.6)	64.5 (-11.5 to 113.1)	-20.4 (-56.9 to 1.7)	4.0 (2.5 to 5.9)	6.2 (3.0 to 10.3)	64.0 (13.4 to 114.7)	-20.5 (-57.7 to 1.6)
Other non-communicable diseases	-	-	-	-	44.5 (29.5 to 64.7)	84.8 (56.6 to 122.9)	90.7 (80.2 to 100.3)	-6.3 (-10.4 to -3.0)
Congenital anomalies	-	-	-	-	3.0 (2.0 to 4.3)	7.2 (5.0 to 10.0)	141.3 (108.0 to 183.8)	23.7 (6.6 to 45.3)
Neural tube defects	0.3 (0.3 to 0.4)	2.0 (1.7 to 2.3)	491.9 (365.4 to 645.7)	256.5 (179.0 to 352.8)	0.1 (0.1 to 0.1)	0.5 (0.4 to 0.8)	592.3 (387.7 to 837.7)	330.9 (202.8 to 476.4)
Congenital heart anomalies	3.1 (2.3 to 4.1)	21.0 (16.5 to 28.6)	572.3 (348.9 to 941.1)	304.1 (163.3 to 531.9)	0.1 (0.0 to 0.2)	0.7 (0.3 to 1.3)	523.6 (310.5 to 852.8)	276.7 (148.2 to 414.6)
Orofacial clefts	0.3 (0.2 to 0.5)	3.0 (2.3 to 3.8)	712.9 (450.7 to 1,390.7)	469.7 (250.5 to 921.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	697.0 (358.8 to 1,361.2)	412.1 (198.4 to 864.5)
Down syndrome	1.7 (1.3 to 2.1)	5.2 (4.3 to 6.6)	207.5 (128.4 to 317.7)	77.7 (32.9 to 140.9)	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.8)	214.6 (126.6 to 339.3)	85.2 (36.0 to 156.9)
Turner syndrome	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	175.7 (86.5 to 322.5)	51.2 (1.9 to 133.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	181.2 (83.6 to 332.1)	52.0 (-1.2 to 135.3)
Klinefelter syndrome	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	90.0 (29.2 to 200.3)	-0.1 (-3.2 to 58.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.8 (34.0 to 218.6)	-0.5 (-32.6 to 57.7)
Chromosomal unbalanced rearrangements	2.7 (2.1 to 3.2)	8.6 (7.1 to 10.5)	215.5 (144.5 to 338.0)	61.1 (41.9 to 154.5)	0.1 (0.2 to 0.4)	0.2 (0.7 to 1.4)	222.8 (139.3 to 359.2)	91.9 (43.0 to 167.6)
Other congenital anomalies	23.4 (16.8 to 28.8)	40.7 (28.9 to 51.6)	73.9 (48.6 to 104.6)	-9.7 (-22.3 to 4.7)	2.3 (1.4 to 3.4)	4.3 (2.6 to 6.6)	85.6 (55.8 to 127.7)	-5.4 (-20.0 to 14.6)
Skin and subcutaneous diseases	-	-	-	-	14.8 (9.5 to 22.6)	29.2 (18.5 to 45.3)	98.5 (82.3 to 110.9)	0.6 (-6.4 to 6.8)
Dermatitis	126.8 (97.1 to 164.1)	250.2 (191.1 to 323.9)	97.3 (95.2 to 99.5)	-0.0 (-0.1 to -0.0)	4.6 (2.8 to 6.8)	8.9 (5.4 to 13.1)	94.9 (87.1 to 102.8)	-0.0 (-3.1 to 3.1)
Psoriasis	18.9 (16.3 to 21.8)	38.4 (33.0 to 44.3)	102.7 (101.1 to 104.5)	1.5 (-0.1 to 0.1)	0.0 (1.1 to 2.2)	3.1 (2.1 to 4.4)	102.6 (87.2 to 117.7)	-0.3 (-5.9 to 5.7)
Cellulitis	0.7 (0.6 to 0.8)	1.2 (1.0 to 1.6)	79.1 (50.7 to 120.4)	-14.5 (-28.3 to 8.3)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	79.3 (31.4 to 144.3)	-13.3 (-33.9 to 14.0)
Pyoderma	5.7 (4.2 to 7.3)	9.8 (7.3 to 12.5)	72.3 (61.2 to 86.4)	-4.2 (-10.5 to 3.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	72.5 (54.7 to 93.2)	-4.1 (-13.4 to 6.0)
Scabies	55.3 (40.9 to 79.2)	90.8 (67.4 to 118.6)	66.3 (2.6 to 145.2)	-13.1 (-45.0 to 27.1)	1.4 (0.7 to 2.6)	2.3 (1.2 to 4.0)	66.0 (1.3 to 145.4)	-12.9 (-44.4 to 27.3)
Fungal skin diseases	363.0 (258.7 to 518.6)	710.7 (505.4 to 1,018.2)	95.5 (91.9 to 100.8)	6.1 (0.1 to 12.8)	0.1 (0.8 to 4.6)	0.0 (1.5 to 3.1)	95.5 (91.8 to 101.1)	0.1 (-0.2 to 0.8)
Viral skin diseases	79.7 (58.7 to 101.0)	151.2 (110.7 to 194.8)	89.6 (81.9 to 97.5)	-0.3 (-3.1 to 2.8)	2.5 (1.4 to 4.0)	4.7 (2.7 to 7.6)	89.8 (80.4 to 99.2)	-0.2 (-3.7 to 3.8)
Acne vulgaris	83.5 (53.9 to 117.2)	213.0 (137.6 to 285.3)	159.4 (38.8 to 310.8)	33.9 (-25.2 to 103.3)	0.9 (0.4 to 1.9)	2.3 (1.0 to 4.5)	159.6 (84.4 to 313.5)	34.6 (-25.2 to 105.1)
Alopecia areata	2.8 (2.5 to 3.1)	5.6 (5.0 to 6.4)	102.6 (72.1 to 137.7)	0.8 (-14.7 to 19.0)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	103.1 (65.7 to 151.0)	0.8 (-17.7 to 21.6)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.7 (56.1 to 159.1)	3.1 (-19.7 to 31.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.7 (55.9 to 159.5)	3.1 (-19.8 to 31.0)
Urticaria	12.2 (7.7 to 17.2)	29.3 (16.1 to 44.4)	137.8 (50.1 to 276.3)	11.1 (-35.7 to 96.2)	0.7 (0.4 to 1.2)	1.7 (0.8 to 3.0)	138.3 (46.9 to 280.6)	10.3 (-35.4 to 97.0)
Decubitus ulcer	0.3 (0.2 to 0.3)	0.6 (0.6 to 0.7)	128.4 (91.3 to 175.9)	-0.9 (-22.8 to 29.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	125.8 (80.5 to 178.6)	-1.1 (-26.0 to 32.7)
Other skin and subcutaneous diseases	152.8 (104.2 to 218.0)	297.8 (202.1 to 425.2)	95.0 (81.1 to 108.1)	-4.6 (-14.6 to 0.4)	0.9 (0.4 to 1.8)	1.7 (0.8 to 3.5)	94.4 (81.2 to 107.7)	-4.8 (-14.7 to 0.3)
Sense organ diseases	-	-	-	-	21.6 (14.2 to 31.5)	37.7 (24.2 to 55.4)	74.5 (59.2 to 90.3)	-11.7 (-17.1 to -7.4)
Glaucoma	3.3 (2.6 to 4.1)	5.9 (4.8 to 7.3)	81.0 (47.3 to 125.0)	-13.5 (-31.6 to 12.5)	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.9)	68.9 (28.9 to 119.8)	-20.1 (-41.0 to 15.2)
Cataract	15.2 (12.2 to 18							

Appendix Table G.4 - Eritrea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	39.5 (35.6 to 42.7)	84.5 (78.7 to 90.1)	114.1 (91.7 to 140.2)	-5.1 (-13.7 to 3.9)	1.1 (0.7 to 1.5)	2.3 (1.6 to 3.2)	112.6 (90.2 to 139.4)	-5.5 (-13.9 to 3.8)
Other oral disorders	46.3 (43.2 to 48.8)	93.1 (87.8 to 98.9)	100.7 (84.8 to 120.1)	-0.4 (-7.6 to 8.0)	1.4 (0.8 to 2.0)	2.7 (1.7 to 4.1)	100.7 (83.8 to 120.9)	-0.4 (-7.9 to 8.6)
Injuries	-	-	-	-	11.0 (8.4 to 14.1)	55.3 (29.1 to 108.4)	365.7 (190.7 to 880.8)	141.9 (48.7 to 401.9)
Transport injuries	-	-	-	-	4.3 (3.2 to 5.5)	5.7 (4.3 to 7.4)	33.4 (26.9 to 39.7)	-31.0 (-33.4 to -28.5)
Road injuries	-	-	-	-	3.9 (2.8 to 4.9)	5.0 (3.9 to 6.5)	34.5 (27.1 to 41.4)	-30.7 (-33.5 to -27.9)
Pedestrian road injuries	-	-	-	-	1.3 (1.0 to 1.7)	1.6 (1.2 to 2.1)	26.0 (15.4 to 34.8)	-33.5 (-37.7 to -29.8)
Cyclist road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	22.2 (12.9 to 33.2)	-36.5 (-40.7 to -32.2)
Motorcyclist road injuries	-	-	-	-	0.4 (0.3 to 0.6)	0.5 (0.4 to 0.7)	14.6 (4.7 to 24.5)	-41.7 (-45.8 to -36.9)
Motor vehicle road injuries	-	-	-	-	1.7 (1.3 to 2.2)	2.5 (1.9 to 3.2)	50.9 (36.1 to 62.5)	-23.3 (-28.5 to -18.5)
Other road injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-16.7 (-21.3 to -11.3)	-59.0 (-60.9 to -56.8)
Other transport injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.6 (0.5 to 0.8)	25.7 (18.6 to 33.6)	-32.7 (-36.7 to -28.3)
Unintentional injuries	-	-	-	-	6.2 (4.7 to 8.0)	10.9 (8.3 to 14.1)	76.1 (69.8 to 81.8)	-10.7 (-13.6 to -7.2)
Falls	-	-	-	-	2.4 (1.8 to 3.1)	5.1 (3.7 to 6.5)	112.2 (98.7 to 124.1)	0.0 (-6.0 to 6.2)
Drowning	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	41.7 (29.0 to 56.0)	-24.8 (-30.3 to -18.6)
Fire, heat, and hot substances	-	-	-	-	0.8 (0.6 to 1.0)	1.2 (0.9 to 1.5)	52.4 (38.2 to 69.9)	-21.4 (-26.8 to -15.0)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.5 (21.8 to 65.5)	-27.6 (-35.5 to -17.5)
Exposure to mechanical forces	-	-	-	-	1.5 (1.2 to 2.0)	2.6 (2.0 to 3.4)	67.1 (59.0 to 74.6)	-13.4 (-17.2 to -9.8)
Unintentional firearm injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	104.3 (89.8 to 122.9)	2.6 (-3.4 to 10.3)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	125.6 (106.4 to 144.4)	16.2 (8.0 to 23.9)
Other exposure to mechanical forces	-	-	-	-	1.5 (1.1 to 1.9)	2.4 (1.8 to 3.2)	65.0 (56.6 to 72.7)	-14.4 (-18.5 to -10.8)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	119.1 (104.5 to 133.4)	10.0 (3.1 to 17.4)
Animal contact	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.6)	32.9 (23.6 to 42.2)	-31.4 (-35.2 to -27.5)
Venomous animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	33.4 (19.8 to 47.8)	-32.2 (-38.3 to -26.1)
Non-venomous animal contact	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	32.5 (22.5 to 42.9)	-30.9 (-34.7 to -26.7)
Foreign body	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	91.2 (79.9 to 101.7)	-3.4 (-8.0 to 1.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	69.9 (45.1 to 94.5)	-5.3 (-15.2 to 3.6)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	95.8 (74.6 to 124.1)	-1.6 (-10.4 to 8.3)
Foreign body in other body part	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	98.6 (85.7 to 110.6)	-3.3 (-9.3 to 2.5)
Other unintentional injuries	-	-	-	-	0.8 (0.6 to 1.0)	1.1 (0.8 to 1.4)	31.9 (22.3 to 42.1)	-32.6 (-37.2 to -27.5)
Self-harm and interpersonal violence	-	-	-	-	0.5 (0.4 to 0.6)	1.0 (0.7 to 1.2)	89.5 (79.9 to 98.3)	-0.6 (-4.8 to 3.4)
Self-harm	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	97.6 (82.4 to 114.1)	-3.0 (-9.2 to 3.6)
Interpersonal violence	-	-	-	-	0.4 (0.3 to 0.6)	0.8 (0.7 to 1.1)	88.6 (77.8 to 98.3)	-0.2 (-5.0 to 4.5)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	97.2 (84.4 to 110.2)	4.1 (-2.1 to 10.3)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	118.2 (102.3 to 138.0)	12.3 (4.6 to 21.8)
Assault by other means	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	79.5 (67.0 to 91.6)	-4.6 (-10.5 to 1.0)
Forces of nature, war, and legal intervention	-	-	-	-	-	37.8 (13.7 to 90.2)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	37.8 (13.7 to 90.2)	-	-

Appendix Table G.4 - Estonia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	100.8 (135.0 to 233.7)	171.5 (128.3 to 221.1)	-5.2 (-7.1 to -3.2)	-1.7 (-3.6 to 0.6)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	11.7 (7.9 to 16.6)	7.3 (5.1 to 10.3)	-37.6 (-46.8 to -26.0)	-17.4 (-29.3 to -3.0)
HIV/AIDS and tuberculosis	-	-	-	-	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.5)	-7.3 (-19.6 to 9.8)	0.1 (-18.0 to 20.0)
Tuberculosis	1.3 (1.3 to 1.4)	0.9 (0.8 to 1.0)	-32.1 (-36.0 to -27.9)	-28.2 (-32.3 to -23.7)	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-32.3 (-39.5 to -25.0)	-28.0 (-35.9 to -20.0)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	44,332.8 (8,718.5 to 1,599,111.4)	48,417.1 (9,522.0 to 1,642,369.3)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17,204.0 (3,233.8 to 0.0)	19,047.3 (3,547.3 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17,204.0 (3,162.8 to nan)	19,047.3 (5,514.4 to nan)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	1.4 (0.9 to 2.0)	58,879.6 (13,232.2 to 0.0)	63,299.4 (13,232.2 to 0.0)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	46,107.0 (8,713.7 to nan)	50,187.6 (9,440.8 to nan)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	1.7 (1.1 to 2.4)	1.2 (0.8 to 1.8)	-26.1 (-31.1 to -21.1)	-9.0 (-15.3 to -2.4)
Diarrheal diseases	2.4 (2.2 to 2.6)	1.9 (1.7 to 2.1)	-20.7 (-29.4 to -10.1)	-3.0 (-15.2 to 11.3)	0.3 (0.3 to 0.5)	0.2 (0.2 to 0.4)	-21.6 (-31.3 to -10.0)	-18.8 (-16.6 to 12.3)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.3 (-70.2 to 21.5)	-18.8 (-63.4 to 50.0)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.9 (-51.9 to -7.4)	-15.1 (-39.9 to 13.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.9 (-52.0 to -7.4)	-15.1 (-40.0 to 13.1)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.4 (-52.2 to -10.5)	-15.5 (-39.7 to 13.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.4 (-52.2 to -10.5)	-15.5 (-39.8 to 13.8)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.2 (-98.7 to 2,799.4)	-48.5 (-98.5 to 3,338.5)
Lower respiratory infections	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-18.7 (-37.2 to 13.5)	12.4 (-15.2 to 63.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.9 (-40.2 to 16.9)	12.6 (-18.5 to 65.5)
Upper respiratory infections	51.9 (47.2 to 56.8)	41.3 (37.1 to 45.4)	-20.4 (-30.2 to -8.8)	-2.0 (-13.5 to 12.7)	0.6 (0.3 to 1.0)	0.5 (0.3 to 0.8)	-20.8 (-30.8 to -9.0)	-1.9 (-13.7 to 12.8)
Otitis media	20.9 (19.4 to 22.5)	15.2 (14.1 to 16.2)	-27.6 (-33.8 to -20.9)	-10.8 (-18.0 to -3.3)	0.4 (0.3 to 0.7)	0.3 (0.2 to 0.5)	-29.5 (-36.1 to -22.1)	-11.7 (-19.8 to -3.1)
Meningitis	-	-	-	-	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-64.4 (-71.8 to -57.0)	-58.3 (-66.8 to -48.4)
Pneumococcal meningitis	0.5 (0.3 to 0.8)	0.2 (0.1 to 0.3)	-59.6 (-66.1 to -49.7)	-56.8 (-63.6 to -46.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-62.2 (-70.3 to -50.0)	-56.6 (-66.5 to -42.3)
H influenzae type B meningitis	0.3 (0.1 to 0.6)	0.1 (0.0 to 0.2)	-71.6 (-84.9 to -59.7)	-66.6 (-80.9 to -51.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-71.4 (-85.9 to -55.2)	-63.7 (-82.0 to -42.1)
Meningococcal meningitis	0.1 (0.0 to 0.3)	0.0 (0.0 to 0.1)	-65.3 (-79.2 to -44.7)	-61.1 (-75.4 to -32.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-64.1 (-77.6 to -35.5)	-58.1 (-74.6 to -18.1)
Other meningitis	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.2)	-59.9 (-72.5 to -46.1)	-55.6 (-69.7 to -38.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-57.4 (-72.0 to -36.8)	-51.5 (-69.3 to -23.3)
Encephalitis	0.6 (0.2 to 1.5)	0.5 (0.2 to 1.4)	-16.2 (-38.6 to 1.0)	-11.0 (-33.0 to 6.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-13.4 (-31.3 to 5.9)	-4.8 (-23.5 to 16.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-75.8 (-96.5 to 101.1)	-71.1 (-95.7 to 105.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-75.8 (-96.5 to 102.5)	-71.1 (-95.7 to 107.0)
Whooping cough	0.4 (0.3 to 0.5)	0.1 (0.0 to 0.1)	-83.5 (-84.8 to -82.0)	-74.2 (-76.3 to -72.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-83.4 (-86.5 to -79.9)	-74.1 (-79.0 to -68.8)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-76.7 (-88.2 to -65.5)	-69.9 (-87.0 to -58.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-74.0 (-86.3 to -65.3)	-66.2 (-85.5 to -54.3)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-93.6 (-100.0 to -83.9)	-89.8 (-100.0 to -74.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-93.6 (-100.0 to -83.9)	-89.8 (-100.0 to -74.4)
Varicella and herpes zoster	0.9 (0.8 to 1.0)	0.7 (0.7 to 0.8)	-18.6 (-28.5 to -7.5)	-1.1 (-9.4 to 10.8)	0.1 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.2 (-24.8 to 23.7)	1.0 (-19.1 to 27.8)
Neglected tropical diseases and malaria	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-63.4 (-74.2 to -51.5)	-60.2 (-71.3 to -47.9)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.0 (-78.9 to 117.0)	-1.4 (-73.2 to 188.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.1 (-78.4 to 126.5)	1.8 (-72.7 to 197.3)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-90.8 (-96.1 to -74.1)	-90.4 (-95.7 to -74.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-89.5 (-95.9 to -69.0)	-89.1 (-95.3 to -69.4)
Cystic echinococcosis	0.3 (0.3 to 0.3)	0.1 (0.1 to 0.2)	-54.5 (-59.8 to -49.6)	-50.9 (-56.6 to -45.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.5 (-64.9 to -41.8)	-50.5 (-61.5 to -37.0)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.0 (-72.9 to -20.9)	-26.0 (-70.6 to -8.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.0 (-72.9 to -20.9)	-26.0 (-70.7 to -8.5)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.6 (-74.6 to -24.1)	-38.8 (-72.1 to -12.2)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-33.9 (-52.1 to -13.5)	-27.1 (-47.7 to -4.9)
Maternal hemorrhage	0.6 (0.5 to 0.7)	0.5 (0.4 to 0.6)	-19.3 (-44.4 to 10.7)	-10.6 (-38.4 to 22.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.3 (-64.4 to 21.6)	-20.5 (-60.4 to 32.0)
Maternal sepsis and other maternal infections	0.8 (0.5 to 1.2)	0.3 (0.2 to 0.5)	-55.2 (-68.1 to -40.6)	-48.5 (-63.5 to -31.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.0 (-75.3 to -42.8)	-57.4 (-71.9 to -35.6)
Maternal hypertensive disorders	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-22.4 (-35.3 to -6.2)	-14.9 (-29.5 to 3.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.3 (-41.8 to 2.9)	-15.2 (-36.4 to 12.5)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.9 (-58.2 to 6.9)	-27.3 (-54.4 to 18.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.9 (-58.3 to 7.0)	-27.3 (-54.4 to 18.7)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.6 (-32.1 to 26.3)	0.7 (-25.3 to 40.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.9 (-46.0 to 66.6)	5.0 (-41.7 to 91.5)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.3 (-61.1 to -21.6)	-27.6 (-59.2 to 33.2)
Neonatal disorders	-	-	-	-	3.0 (1.6 to 5.0)	1.2 (0.8 to 1.8)	-61.6 (-75.5 to -11.8)	52.4 (-70.0 to 9.3)
Preterm birth complications	6.7 (5.2 to 8.7)	5.6 (4.3 to 7.3)	-16.3 (-30.0 to -0.4)	0.5 (-16.1 to 19.6)	0.7 (0.5 to 1.0)	0.7 (0.5 to 1.0)	-6.4 (-30.3 to 25.8)	15.3 (-14.8 to 55.1)
Neonatal encephalopathy due to birth asphyxia and trauma	2.1 (1.2 to 4.3)	0.7 (0.4 to 1.5)	-67.4 (-84.6 to -42.0)	-59.5 (-81.0 to -28.1)	0.5 (0.3 to 0.9)	0.2 (0.1 to 0.3)	-64.1 (-82.9 to -36.2)	-54.7 (-78.3 to -19.8)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.9 (63.3 to 161.7)	208.6 (141.2 to 288.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.4 (42.5 to 242.7)	209.2 (111.4 to 408.6)
Hemolytic disease and other neonatal jaundice	0.7 (0.2 to 2.1)	0.2 (0.0 to 0.4)	-75.0 (-89.4 to -25.7)	-68.9 (-87.1 to -8.1)	0.3 (0.1 to 0.8)	0.1 (0.0 to 0.2)	-72.8 (-88.1 to -15.6)	66.1 (-85.6 to 3.7)
Other neonatal disorders	-	-	-	-	1.5 (0.3 to 2.9)	0.3 (0.1 to 0.6)	-88.7 (-94.2 to 65.4)	-85.8 (-92.8 to 106.1)
Nutritional deficiencies	-	-	-	-	5.9 (3.9 to 8.7)	4.0 (2.7 to 5.8)	-32.1 (-37.4 to -27.3)	-5.0 (-12.5 to 2.1)
Protein-energy malnutrition	1.6 (0.6 to 3.4)	0.7 (0.3 to 1.4)	-57.2 (-87.7 to 25.6)	-32.9 (-80.8 to 97.3)	0.2 (0.1 to 0.5)	0.1 (0.0 to 0.2)	-57.6 (-87.6 to 26.1)	-33.6 (-80.7 to 98.3)
Iodine deficiency	19.0 (9.7 to 30.1)	12.1 (6.8 to 19.2)	-36.0 (-72.2 to 58.2)	-36.0 (-68.0 to 80.4)	0.3 (0.1 to 0.6)	0.2 (0.1 to 0.4)	-36.7 (-72.3 to 58.8)	-27.2 (-68.2 to 80.5)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron-deficiency anemia	182.1 (180.1 to 184.2)	134.8 (132.5 to 137.3)	-25.9 (-27.4 to -24.4)	-2.7 (-4.8 to 0.6)	5.4 (3.5 to 7.8)	3.7 (2.5 to 5.4)	-31.2 (-33.5 to -29.1)	-3.4 (-6.0 to 0.1)

Appendix Table G.4 - Estonia prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.0	0.0	17.3	94.5
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.6	0.4	-28.2	-7.0
Sexually transmitted diseases excluding HIV	-	-	-	-	0.3	0.2	-16.3	-4.2
Syphilis	0.0	0.0	-18.7	-27.7	0.0	0.0	-25.8 to -6.4	-15.5 to 8.0
	(0.0 to 0.1)	(0.0 to 0.0)	(-29.7 to -5.8)	(-38.0 to -15.7)	(0.0 to 0.0)	(0.0 to 0.0)	(-41.1 to -11.7)	(-45.6 to -1.4)
Chlamydial infection	37.9	32.0	-15.9	-1.1	0.1	0.1	-17.4	-1.1
	(32.6 to 42.8)	(27.6 to 36.1)	(-31.3 to 3.9)	(-18.9 to 34.8)	(0.1 to 0.2)	(0.0 to 0.2)	(-33.9 to -0.4)	(-22.1 to 19.6)
Gonococcal infection	8.4	6.2	-26.9	-10.1	0.0	0.0	-29.8	-13.9
	(6.8 to 10.1)	(5.1 to 7.2)	(-42.2 to -5.6)	(-30.2 to 16.1)	(0.0 to 0.1)	(0.0 to 0.0)	(-49.5 to -1.3)	(-38.9 to 22.2)
Trichomoniasis	19.2	17.6	-6.6	12.7	0.0	0.0	-6.7	13.3
	(13.2 to 26.2)	(12.8 to 23.0)	(-41.8 to 39.8)	(-32.9 to 74.6)	(0.0 to 0.1)	(0.0 to 0.1)	(-44.8 to 48.0)	(-35.7 to 84.1)
Genital herpes	282.1	263.1	-6.7	-3.9	0.1	0.1	-7.8	-3.7
	(275.4 to 288.9)	(256.1 to 270.7)	(-10.2 to -3.3)	(-7.7 to -0.4)	(0.0 to 0.2)	(0.0 to 0.2)	(-13.1 to -3.3)	(-9.2 to 1.4)
Other sexually transmitted diseases	0.5	0.3	-38.5	-28.6	0.0	0.0	-21.1	-21.2
	(0.4 to 0.7)	(0.2 to 0.4)	(-46.7 to -25.5)	(-38.4 to -13.3)	(0.0 to 0.0)	(0.0 to 0.0)	(-50.8 to -6.5)	(-43.4 to 9.0)
Hepatitis	-	-	-	-	0.1	0.1	-32.3	-21.4
	(0.0 to 0.1)	(0.0 to 0.1)	(0.0 to 0.1)	(0.0 to 0.1)	(0.0 to 0.1)	(0.0 to 0.1)	(-40.4 to -23.4)	(-30.4 to -10.9)
Hepatitis A	1.4	1.0	-31.1	-13.1	0.0	0.0	-25.0	-10.0
	(1.4 to 1.5)	(0.9 to 1.0)	(-31.7 to -30.5)	(-14.5 to -11.7)	(0.0 to 0.1)	(0.0 to 0.0)	(-33.1 to -15.7)	(-20.6 to 1.2)
Hepatitis B	60.6	32.8	-45.8	-38.5	0.0	0.0	-42.0	-36.2
	(56.6 to 64.3)	(30.9 to 34.9)	(-50.5 to -41.2)	(-43.7 to -33.1)	(0.0 to 0.0)	(0.0 to 0.0)	(-55.5 to -24.7)	(-50.7 to -17.2)
Hepatitis C	39.3	28.0	-28.9	-26.6	0.0	0.0	-29.6	-26.8
	(35.4 to 43.5)	(25.5 to 30.7)	(-37.6 to -18.9)	(-35.6 to -16.3)	(0.0 to 0.0)	(0.0 to 0.0)	(-51.4 to -0.4)	(-46.9 to -1.3)
Hepatitis E	-	-	-	-	5.6	23.5	-	-
	(0.0 to 0.0)	(0.0 to 0.0)	(0.0 to 0.0)	(0.0 to 0.0)	(0.0 to 0.0)	(0.0 to 0.0)	(0.0 to 0.0)	(0.0 to 0.0)
Leprosy	-	-	-	-	0.0	0.0	-	-
	(0.0 to 0.0)	(0.0 to 0.0)	(0.0 to 0.0)	(0.0 to 0.0)	(0.0 to 0.0)	(0.0 to 0.0)	(0.0 to 0.0)	(0.0 to 0.0)
Other infectious diseases	6.7	4.4	-34.0	-1.2	0.2	0.1	-39.1	-5.4
	(5.1 to 7.7)	(3.3 to 5.4)	(-47.8 to -13.1)	(-25.6 to 30.0)	(0.1 to 0.4)	(0.1 to 0.2)	(-61.0 to -12.1)	(-40.5 to 35.7)
Non-communicable diseases	-	-	-	-	156.5	156.7	0.2	3.1
	(116.4 to 201.2)	(116.8 to 202.2)	(-2.0 to 2.8)	(-2.0 to 2.8)	(116.4 to 201.2)	(116.8 to 202.2)	(-2.0 to 2.5)	(0.3 to 5.7)
Neoplasms	-	-	-	-	2.0	2.8	37.1	20.1
	(1.5 to 2.6)	(2.0 to 3.6)	(17.9 to 49.2)	(3.8 to 30.8)	(1.5 to 2.6)	(2.0 to 3.6)	(17.9 to 49.2)	(3.8 to 30.8)
Esophageal cancer	0.1	0.1	11.0	2.4	0.0	0.0	7.9	-0.9
	(0.1 to 0.1)	(0.1 to 0.2)	(-17.6 to 48.8)	(-23.0 to 38.5)	(0.0 to 0.0)	(0.0 to 0.0)	(-23.2 to 50.5)	(-29.0 to 38.0)
Stomach cancer	1.2	0.9	-23.4	-33.1	0.1	0.1	-29.2	-38.2
	(1.0 to 1.4)	(0.8 to 1.1)	(-34.7 to -9.3)	(-43.4 to -21.1)	(0.1 to 0.2)	(0.1 to 0.1)	(-40.0 to -14.2)	(-47.5 to -25.9)
Liver cancer	-	-	-	-	0.0	0.0	23.0	4.4
	(0.0 to 0.0)	(0.0 to 0.0)	(0.0 to 0.0)	(0.0 to 0.0)	(0.0 to 0.0)	(0.0 to 0.0)	(9.3 to 60.2)	(-21.7 to 36.7)
Liver cancer due to hepatitis B	0.0	0.0	35.7	23.2	0.0	0.0	24.7	12.3
	(0.0 to 0.0)	(0.0 to 0.0)	(-31.9 to 197.2)	(-38.2 to 166.1)	(0.0 to 0.0)	(0.0 to 0.0)	(-40.0 to 139.0)	(-37.5 to 113.0)
Liver cancer due to hepatitis C	0.0	0.0	197.2	154.6	0.0	0.0	169.4	129.4
	(0.0 to 0.0)	(0.0 to 0.1)	(67.8 to 411.1)	(44.3 to 341.6)	(0.0 to 0.0)	(0.0 to 0.0)	(64.9 to 334.8)	(40.2 to 268.4)
Liver cancer due to alcohol use	0.0	0.0	9.3	-8.2	0.0	0.0	-0.1	-16.2
	(0.0 to 0.1)	(0.0 to 0.1)	(-32.9 to 77.2)	(-43.7 to 47.5)	(0.0 to 0.0)	(0.0 to 0.0)	(-31.3 to 42.7)	(-41.9 to 17.7)
Liver cancer due to other causes	0.0	0.0	-48.3	-55.0	0.0	0.0	-51.4	-57.9
	(0.0 to 0.0)	(0.0 to 0.0)	(-73.0 to -8.6)	(-76.1 to -21.6)	(0.0 to 0.0)	(0.0 to 0.0)	(-72.9 to -26.0)	(-76.2 to -36.5)
Larynx cancer	0.3	0.2	-33.8	-33.8	0.0	0.0	-30.1	-32.4
	(0.3 to 0.5)	(0.2 to 0.3)	(-53.8 to 6.7)	(-55.2 to 2.6)	(0.0 to 0.1)	(0.0 to 0.0)	(-50.2 to -1.5)	(-51.7 to -5.5)
Tracheal, bronchus and lung cancer	1.2	1.0	-10.0	0.2	0.2	0.2	-4.8	-15.1
	(1.0 to 1.3)	(1.0 to 1.3)	(-13.7 to 19.0)	(-22.9 to 5.8)	(0.1 to 0.2)	(0.1 to 0.2)	(-18.0 to 10.7)	(-26.8 to -1.2)
Breast cancer	3.8	5.6	50.4	33.8	0.3	0.3	23.9	10.4
	(3.2 to 4.4)	(4.6 to 6.4)	(18.0 to 81.2)	(6.0 to 59.4)	(0.2 to 0.4)	(0.2 to 0.5)	(-11.8 to 45.7)	(-20.3 to 29.5)
Cervical cancer	1.4	0.8	-43.2	-43.2	0.1	0.1	-42.5	-43.6
	(1.1 to 1.6)	(0.5 to 1.1)	(-57.9 to -22.9)	(-59.4 to -23.9)	(0.1 to 0.1)	(0.0 to 0.1)	(-59.2 to -20.4)	(-60.6 to -22.0)
Uterine cancer	1.1	0.9	-16.5	-5.0	0.1	0.1	-29.7	-18.9
	(0.9 to 1.4)	(0.7 to 1.3)	(-42.7 to 18.2)	(-46.9 to 8.9)	(0.1 to 0.1)	(0.0 to 0.1)	(-44.2 to 15.6)	(-44.2 to 15.6)
Prostate cancer	2.4	5.2	117.9	85.4	0.2	0.5	138.4	98.1
	(2.0 to 2.9)	(4.0 to 6.3)	(60.3 to 194.4)	(36.7 to 152.8)	(0.1 to 0.3)	(0.3 to 0.7)	(64.8 to 220.4)	(37.0 to 171.3)
Colon and rectum cancer	3.0	4.9	64.9	39.3	0.3	0.4	56.7	31.3
	(2.7 to 3.3)	(4.4 to 5.5)	(44.7 to 89.0)	(22.6 to 58.7)	(0.2 to 0.4)	(0.3 to 0.5)	(37.0 to 80.3)	(15.2 to 50.7)
Lip and oral cavity cancer	0.5	0.6	30.6	20.5	0.0	0.1	26.6	16.4
	(0.4 to 0.5)	(0.4 to 0.8)	(-12.3 to 75.8)	(-18.8 to 62.2)	(0.0 to 0.1)	(0.0 to 0.1)	(-15.2 to 71.8)	(-23.5 to 58.1)
Nasopharynx cancer	0.1	0.1	-68.8	-68.8	0.0	0.0	-69.6	-69.8
	(0.1 to 0.1)	(0.0 to 0.0)	(-81.0 to -29.7)	(-80.7 to -31.4)	(0.0 to 0.0)	(0.0 to 0.0)	(-80.2 to -32.1)	(-80.3 to -32.9)
Other pharynx cancer	0.2	0.2	3.7	1.7	0.0	0.0	1.8	-0.4
	(0.1 to 0.3)	(0.1 to 0.3)	(-43.1 to 80.5)	(-43.4 to 80.3)	(0.0 to 0.0)	(0.0 to 0.0)	(-43.5 to 66.6)	(-44.6 to 63.3)
Gallbladder and biliary tract cancer	0.1	0.1	-13.6	-29.1	0.0	0.0	-17.9	-31.8
	(0.0 to 0.1)	(0.0 to 0.1)	(-41.8 to 16.9)	(-51.6 to -5.5)	(0.0 to 0.0)	(0.0 to 0.0)	(-43.9 to 14.1)	(-52.3 to -6.6)
Pancreatic cancer	0.2	0.2	35.7	13.9	0.0	0.0	26.5	7.6
	(0.2 to 0.2)	(0.2 to 0.3)	(9.6 to 69.2)	(-7.7 to 41.3)	(0.0 to 0.1)	(0.0 to 0.1)	(1.4 to 58.9)	(-13.3 to 35.0)
Malignant skin melanoma	0.6	1.1	65.6	57.2	0.0	0.1	55.4	47.3
	(0.5 to 0.9)	(0.7 to 1.4)	(12.1 to 110.1)	(6.5 to 101.2)	(0.0 to 0.1)	(0.0 to 0.1)	(6.7 to 100.9)	(0.6 to 89.7)
Non-melanoma skin cancer	1.7	2.5	49.8	21.6	0.0	0.1	32.2	40.9
	(1.3 to 2.0)	(2.2 to 3.0)	(18.3 to 97.4)	(-4.5 to 61.3)	(0.0 to 0.1)	(0.0 to 0.1)	(27.9 to 153.7)	(3.1 to 94.3)
Ovarian cancer	0.5	0.6	19.2	9.4	0.1	0.1	15.7	5.3
	(0.4 to 0.6)	(0.5 to 0.7)	(9.4 to 50.5)	(-16.6 to 38.0)	(0.0 to 0.1)	(0.1 to 0.1)	(-15.7 to 51.6)	(-23.5 to 37.1)
Testicular cancer	0.2	0.1	-17.8	-8.5	0.0	0.0	-20.8	-13.1
	(0.1 to 0.2)	(0.1 to 0.2)	(-48.2 to 38.9)	(-43.2 to 57.1)	(0.0 to 0.0)	(0.0 to 0.0)	(-50.2 to 34.2)	(-47.6 to 53.0)
Kidney cancer	0.5	1.4	170.5	144.6	0.0	0.1	149.4	124.4
	(0.4 to 0.6)	(1.1 to 1.7)	(107.9 to 241.7)	(91.7 to 203.4)	(0.0 to 0.1)	(0.1 to 0.1)	(88.6 to 221.4)	(70.8 to 185.1)
Bladder cancer	0.7	1.5	110.1	71.1	0.1	0.1	99.4	68.4
	(0.6 to 0.9)	(1.3 to 1.8)	(66.9 to 155.2)	(42.4 to 114.4)	(0.0 to 0.1)	(0.1 to 0.2)	(57.2 to 147.8)	(34.4 to 107.4)
Brain and nervous system cancer	0.3	0.3	6.7	9.7	0.0	0.0	8.4	9.9
	(0.3 to 0.4)	(0.3 to 0.4)	(-17.6 to 31.9)	(-15.1 to 37.3)	(0.0 to 0.0)	(0.0 to 0.1)	(-16.1 to 35.0)	(-13.7 to 34.4)
Thyroid cancer	0.4	0.7	70.2	67.7	0.0	0.0	63.3	57.2
	(0.3 to 0.5)	(0.4 to 0.9)	(8.7 to 138.9)	(4.2 to 137.1)	(0.0 to 0.0)	(0.0 to 0.1)	(4.9 to 126.4)	(0.2 to 120.4)
Mesothelioma	0.0	0.0	-8.5	-20.9	0.0	0.0	-4.5	-17.8
	(0.0 to 0.0)	(0.0 to 0.0)	(-32.8 to 23.9)	(-41.2 to 6.2)	(0.0 to 0.0)	(0.0 to 0.0)	(-30.7 to 29.0)	(-39.3 to 9.9)
Hodgkin lymphoma	0.2	0.1	-48.4	-43.8	0.0	0.0	-51.8	-48.5
	(0.2 to 0.3)	(0.1 to 0.2)	(-64.1 to -13.4)	(-61.6 to -3.5)	(0.0 to 0.0)	(0.0 to 0.0)	(-65.6 to -15.9)	(-63.9 to -9.5)
Non-Hodgkin lymphoma	0.5	0.7	51.4	35.8	0.0	0.1	42.1	27.0
	(0.4 to 0.7)	(0.4 to 0.9)	(-29.3 to 101.7)	(-33.0 to 80.9)	(0.0 to 0.1)	(0.1 to 0.1)	(-31.3 to 90.3)	(-36.6 to 66.6)
Multiple myeloma	0.1	0.2	55.7	39.2	0.0	0.0	49.5	32.6
	(0.1 to 0.2)	(0.1 to 0.3)	(-5.3 to 142.4)	(-15.5 to 114.3)	(0.0 to 0.0)	(0.0 to 0.1)	(-16.5 to 142.9)	(-24.2 to 114.0)
Leukemia	0.7	0.9	27.8	13.6	0.1	0.1	30.5	13.9
	(0.6 to 0.9)	(0.7 to 1.1)	(8.6 to 52.3)	(-20.9 to 36.1)	(0.1 to 0.1)	(0.1 to 0.2)	(5.0 to 59.0)	(-18.8 to 38.3)
Other neoplasms	0.9	2.3	177.5	151.5	0.1	0.2	151.3	127.4
	(0.7 to 1.2)	(1.7 to 2.9)	(63.2 to 275.5)	(51.3 to 237.6)	(0.0 to 0.1)	(0.1 to 0.2)	(47.2 to 246.2)	(35.5 to 207.2)
Cardiovascular diseases	-	-	-	-	2.9	3.4	20.0	4.0
	(2.0 to 4.0)	(2.4 to 4.7)	(5.6 to 46.4)	(-18.3 to 29.1)	(2.0 to 4.0)	(2.4 to 4.7)	(5.6 to 46.4)	(-18.3 to 29.1)
Rheumatic heart disease	0.5	0.5	0.6	-3.3	0.0	0.0	5.7	1.4
	(0.4 to 0.5)	(0.4 to 0.5)	(-13.4 to 16.7)	(-16.5 to 11.2)	(0.0 to 0.1)	(0.0 to 0.1)	(-18.3 to 44.3)	(-23.0 to 39.5)
Ischemic heart disease	24.3	26.1	9.2	-8.2	1.2	1.2	3.5	-15.2
	(20.3 to 31.3)	(23.0 to 29.9)	(-15.9 to 31.7)	(-29.2 to 10.6)	(0.8 to 1.8)	(0.8 to 1.7)	(-25.8 to 34.6)	(-38.9 to 10.2)
Cerebrovascular disease	-	-	-	-	0.7	0.8	4.5	-2.4
	(0.5 to 1.0)	(0.5 to 1.0)	(-0.5 to 10.0)	(-0.5 to 10.0)	(0.5 to 1.0)	(0.5 to 1.0)	(-1.2 to 21.9)	(-20.6 to 30.0)
Ischemic stroke	4.5	4.8	4.8	-3.5	0.7	0.7	4.6	2.7
	(3.8 to 5.2)	(4.0 to 5.6)						

Appendix Table G.4 - Estonia prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.5 (1.9 to 14.1)	-6.4 to 4.4	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.9 (1.3 to 13.3)	-6.8 to 3.8
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.8 (-24.0 to -15.1)	-28.2 to -20.5	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.7 (-23.9 to -15.0)	-24.2 (-27.7 to -20.1)
Asthma	61.4 (57.1 to 65.7)	52.8 (49.2 to 56.2)	-14.2 (-15.5 to -5.6)	-6.7 to 12.3	2.7 (1.7 to 3.8)	2.3 (1.5 to 3.2)	-14.9 (-21.4 to -6.6)	-12.0 (-7.2 to 12.2)
Interstitial lung disease and pulmonary sarcoidosis	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-3.5 (-41.1 to 47.4)	1.5 (-39.4 to 55.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.3 (-40.2 to 47.3)	2.7 (-37.6 to 56.0)
Other chronic respiratory diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	16.2 (-16.6 to 68.4)	11.6 (-20.5 to 58.5)
Cirrhosis	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	55.0 (34.2 to 79.9)	64.3 (41.8 to 90.5)
Cirrhosis due to hepatitis B	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	27.6 (-15.9 to 86.3)	34.7 (-11.2 to 97.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.2 (-24.0 to 102.3)	34.7 (-18.7 to 112.9)
Cirrhosis due to hepatitis C	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.5)	195.9 (89.3 to 385.9)	209.3 (102.2 to 398.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	196.4 (85.0 to 399.1)	211.4 (99.0 to 417.0)
Cirrhosis due to alcohol use	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.4)	20.5 (-13.0 to 64.4)	22.8 (-12.0 to 69.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	18.5 (-16.1 to 72.2)	21.8 (-14.1 to 76.0)
Cirrhosis due to other causes	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	17.3 (-12.0 to 60.6)	37.4 (6.9 to 84.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.4 (-17.7 to 78.5)	35.5 (-2.3 to 109.3)
Digestive diseases	-	-	-	-	1.9 (1.4 to 2.5)	2.0 (1.5 to 2.7)	5.7 (-0.5 to 11.8)	5.0 (-1.6 to 11.4)
Peptic ulcer disease	12.7 (12.4 to 13.1)	9.7 (9.6 to 9.9)	-23.5 (-26.0 to -20.9)	-35.5 (-37.9 to -33.2)	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-20.1 (-27.4 to -13.4)	-35.1 (-41.3 to -29.8)
Gastritis and duodenitis	1.9 (1.7 to 2.2)	1.9 (1.6 to 2.2)	-5.2 (-19.4 to 14.6)	2.8 (-12.4 to 21.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-16.0 (-30.3 to 1.7)	0.7 (-16.4 to 21.6)
Appendicitis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-32.6 (-42.1 to -20.3)	-12.2 (-24.8 to 4.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-31.8 (-49.4 to -9.4)	-11.6 (-36.5 to 22.8)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.8 (15.1 to 69.3)	33.9 (10.8 to 62.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.5 (5.0 to 77.9)	33.8 (5.4 to 68.1)
Inguinal, femoral, and abdominal hernia	4.8 (4.0 to 5.6)	4.6 (3.9 to 5.4)	-4.6 (-22.0 to 21.7)	-3.4 (-29.6 to 6.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-3.9 (-22.8 to 22.3)	-3.8 (-30.3 to 7.9)
Inflammatory bowel disease	3.3 (3.1 to 3.4)	3.9 (3.8 to 4.0)	19.3 (13.2 to 26.6)	22.0 (15.8 to 29.6)	0.7 (0.5 to 0.9)	0.8 (0.6 to 1.1)	19.0 (10.8 to 28.0)	22.7 (14.0 to 32.0)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.8 (-29.5 to 64.6)	-10.6 (-39.6 to 32.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.4 (-38.8 to 83.5)	-9.9 (-45.7 to 46.5)
Gallbladder and biliary diseases	2.8 (2.5 to 3.1)	2.3 (2.0 to 2.6)	-19.3 (-31.8 to -2.6)	-24.0 (-35.1 to -9.2)	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-19.9 (-33.1 to -31.0)	-24.1 (-36.1 to -8.4)
Pancreatitis	0.8 (0.8 to 0.8)	1.1 (1.0 to 1.1)	34.3 (25.0 to 44.3)	35.4 (26.3 to 45.5)	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.4)	33.3 (17.5 to 54.4)	35.3 (19.4 to 54.4)
Other digestive diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	102.4 (14.5 to 161.6)	101.7 (13.3 to 161.3)
Neurological disorders	-	-	-	-	17.8 (12.1 to 24.6)	19.1 (13.0 to 26.2)	7.2 (-3.4 to 18.7)	10.0 (-0.9 to 21.7)
Alzheimer disease and other dementias	17.1 (14.6 to 19.5)	23.8 (20.5 to 27.3)	38.9 (14.8 to 71.7)	-1.0 (-17.5 to 22.1)	2.5 (1.8 to 3.4)	3.6 (2.6 to 4.8)	41.9 (16.3 to 76.0)	-0.7 (-18.0 to 22.8)
Parkinson disease	1.0 (0.9 to 1.1)	1.2 (1.0 to 1.3)	20.2 (13.9 to 27.4)	-1.3 (-6.4 to 3.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	20.5 (6.0 to 36.6)	0.8 (-12.3 to 12.3)
Epilepsy	3.2 (2.1 to 4.3)	2.4 (1.6 to 3.5)	-25.4 (-53.9 to 34.2)	-13.2 (-46.3 to 55.0)	0.9 (0.5 to 1.5)	0.8 (0.4 to 1.2)	-17.9 (-53.2 to 47.7)	-3.6 (-45.7 to 73.4)
Multiple sclerosis	1.0 (0.9 to 1.2)	1.3 (1.1 to 1.4)	21.5 (4.2 to 38.9)	29.9 (11.0 to 48.4)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	20.8 (1.2 to 42.9)	29.8 (8.1 to 54.0)
Migraine	267.4 (245.2 to 291.2)	235.4 (215.8 to 258.3)	-11.9 (-22.1 to -0.8)	-9.3 (-12.0 to 12.3)	9.0 (5.4 to 13.3)	7.9 (4.7 to 11.6)	-12.2 (-23.3 to -1.0)	-0.3 (-12.0 to 12.7)
Tension-type headache	464.5 (432.6 to 494.4)	498.6 (359.6 to 458.0)	12.2 (-24.7 to 0.5)	-12.2 (-14.9 to 13.9)	0.6 (0.3 to 1.2)	0.6 (0.3 to 1.2)	-12.3 (-24.9 to 0.5)	-0.1 (-15.1 to 14.8)
Medication overuse headache	23.7 (15.4 to 32.1)	33.7 (22.2 to 46.1)	42.2 (3.6 to 84.7)	53.1 (12.7 to 98.0)	3.7 (2.1 to 5.7)	5.2 (3.0 to 8.4)	42.3 (3.7 to 83.4)	53.2 (12.8 to 98.6)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.9 (-20.7 to 30.5)	8.5 (-14.6 to 35.9)	0.4 (0.3 to 0.6)	0.4 (0.2 to 0.5)	-19.9 (-41.9 to 6.6)	-39.5 (-56.1 to -20.3)
Mental and substance use disorders	-	-	-	-	46.0 (32.8 to 60.0)	41.8 (29.7 to 54.7)	-9.2 (-11.4 to -6.5)	1.6 (-0.8 to 4.5)
Schizophrenia	5.2 (4.7 to 5.6)	4.7 (4.3 to 5.0)	-9.6 (-13.0 to -5.8)	-0.6 (-4.4 to 3.6)	3.3 (2.5 to 4.0)	3.0 (2.2 to 3.6)	-9.6 (-15.5 to -4.2)	-0.3 (-6.6 to 5.8)
Alcohol use disorders	39.9 (36.4 to 43.7)	39.6 (36.6 to 42.8)	-0.9 (-6.6 to 5.3)	10.7 (4.2 to 17.5)	4.0 (2.7 to 5.7)	4.0 (2.7 to 5.6)	0.7 (-6.6 to 5.9)	11.1 (4.3 to 18.3)
Drug use disorders	-	-	-	-	2.4 (1.6 to 3.1)	2.1 (1.4 to 2.7)	-12.3 (-21.5 to -2.2)	2.6 (-8.5 to 15.2)
Opioid use disorders	2.7 (2.4 to 3.2)	2.4 (2.1 to 2.7)	-12.2 (-18.1 to -5.6)	1.6 (-5.2 to 9.8)	1.1 (0.8 to 1.5)	1.0 (0.7 to 1.3)	-12.0 (-20.1 to -2.7)	1.9 (-7.5 to 13.2)
Cocaine use disorders	1.7 (1.5 to 2.0)	1.6 (1.4 to 1.8)	-7.2 (-21.7 to 15.7)	10.1 (-7.5 to 38.9)	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	10.6 (-24.8 to 18.4)	10.6 (-10.5 to 41.9)
Amphetamine use disorders	2.1 (2.1 to 2.9)	2.4 (1.8 to 2.4)	16.1 (-31.9 to 4.9)	-16.1 (-21.4 to 23.1)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-16.1 (-34.9 to 7.5)	-16.1 (-24.7 to 26.6)
Cannabis use disorders	3.1 (2.7 to 3.5)	2.5 (2.2 to 2.7)	-20.8 (-26.0 to -15.5)	0.4 (-6.6 to 6.9)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-20.8 (-31.5 to -9.1)	0.1 (-13.5 to 15.4)
Other drug use disorders	-	-	-	-	0.6 (0.4 to 0.8)	0.5 (0.3 to 0.7)	-11.4 (-36.6 to 21.9)	3.9 (-25.9 to 42.3)
Depressive disorders	-	-	-	-	23.5 (16.0 to 32.5)	22.0 (14.9 to 30.3)	-6.7 (-10.8 to -1.3)	1.4 (-2.8 to 7.5)
Major depressive disorder	103.5 (88.1 to 121.0)	97.1 (82.1 to 112.5)	-6.3 (-10.9 to -0.4)	1.6 (-3.1 to 7.8)	1.6 (1.2 to 2.9)	1.6 (1.0 to 2.2)	-6.7 (-11.6 to -0.8)	1.4 (-3.0 to 8.3)
Dysthymia	26.3 (21.8 to 30.7)	25.1 (20.9 to 29.2)	-4.6 (-6.2 to -2.7)	-0.4 (-0.5 to -0.3)	2.5 (1.6 to 3.7)	2.4 (1.6 to 3.5)	-5.0 (-7.8 to -2.6)	-0.3 (-2.7 to 1.7)
Bipolar disorder	11.6 (10.3 to 13.0)	10.7 (9.5 to 11.9)	-8.2 (-12.9 to -3.5)	-0.2 (-6.0 to 4.8)	2.3 (1.4 to 3.5)	2.1 (1.3 to 3.1)	-8.5 (-14.1 to -2.6)	0.1 (-6.5 to 6.8)
Anxiety disorders	41.8 (36.8 to 46.3)	36.5 (32.1 to 40.3)	-12.7 (-14.3 to -11.2)	-4.4 (-0.5 to -0.4)	3.8 (2.6 to 5.3)	3.3 (2.3 to 4.6)	-13.3 (-16.2 to -10.3)	-0.3 (-3.2 to 2.6)
Eating disorders	-	-	-	-	0.4 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-9.8 (-27.3 to -12.4)	0.5 (-7.6 to 8.7)
Anorexia nervosa	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-16.7 (-24.0 to -7.9)	7.9 (-1.0 to 19.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-16.8 (-36.5 to 7.3)	7.8 (-17.8 to 38.6)
Bulimia nervosa	1.5 (1.1 to 2.0)	1.2 (0.8 to 1.6)	-20.1 (-23.4 to -16.5)	-0.1 (-0.4 to 0.1)	0.3 (0.2 to 0.5)	0.3 (0.1 to 0.4)	-20.0 (-28.3 to -12.4)	-0.3 (-8.7 to 8.7)
Autistic spectrum disorders	-	-	-	-	1.8 (1.2 to 2.4)	1.5 (1.0 to 2.0)	-16.9 (-19.6 to -14.3)	0.9 (-2.3 to 4.1)
Autism	4.6 (4.3 to 4.8)	3.8 (3.6 to 4.0)	-16.5 (-17.0 to -16.0)	0.6 (0.5 to 0.6)	0.6 (0.7 to 1.5)	0.9 (0.6 to 1.3)	-16.8 (-20.7 to -13.1)	0.9 (-3.8 to 5.9)
Asperger syndrome	6.5 (6.1 to 6.9)	5.4 (5.0 to 5.7)	-16.8 (-17.4 to -16.1)	0.7 (0.7 to 0.8)	0.5 (0.4 to 0.9)	0.5 (0.4 to 0.7)	-17.1 (-20.2 to -13.9)	0.9 (-3.0 to 5.0)
Attention-deficit/hyperactivity disorder	7.0 (6.4 to 7.6)	4.4 (4.0 to 4.7)	-37.1 (-37.7 to -36.8)	0.3 (0.3 to 0.3)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-37.1 (-42.0 to -32.0)	0.6 (-7.2 to 8.2)
Conduct disorder	10.2 (9.6 to 10.8)	6.0 (5.6 to 6.4)	-41.2 (-41.8 to -40.4)	0.3 (0.2 to 0.3)	1.2 (0.8 to 1.8)	0.7 (0.5 to 1.1)	-41.1 (-43.7 to -38.3)	0.4 (-3.9 to 4.9)
Idiopathic intellectual disability	24.0 (20.1 to 28.8)	17.7 (14.6 to 21.2)	-26.3 (-32.8 to -19.1)	-11.4 (-19.2 to -2.9)	1.2 (0.8 to 1.7)	0.9 (0.6 to 1.2)	-26.6 (-33.5 to -19.3)	-11.5 (-19.6 to -2.4)
Other mental and substance use disorders	28.0 (26.4 to 29.6)	26.9 (25.4 to 28.5)	-3.8 (-4.7 to -2.8)	0.3 (0.1 to 0.5)	2.1 (1.4 to 2.8)	2.0 (1.4 to 2.7)	-4.0 (-7.6 to 0.4)	0.5 (-3.1 to 4.3)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	14.4 (10.2 to 19.0)	15.7 (10.9 to 21.2)	8.8 (-1.2 to 20.8)	11.4 (2.0 to 23.4)
Diabetes mellitus	63.1 (50.7 to 74.7)	82.4 (66.7 to 100.5)	30.2 (3.4 to 65.4)	33.0 (7.5 to 68.3)	5.2 (3.4 to 7.2)	6.8 (4.4 to 9.5)	31.9 (6.5 to 67.4)	31.6 (7.0 to 66.5)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.4 (-66.9 to -59.6)	-48.1 (-53.2 to -43.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.4 (-66.9 to -59.6)	-48.1 (-53.3 to -43.0)
Chronic kidney disease	-	-	-	-	4.1 (3.0 to 5.5)	4.0 (2.8 to 5.3)	-1.3 (-12.8 to 10.2)	-1.3 (-10.2 to 11.3)
Chronic kidney disease due to diabetes mellitus	26.4 (18.6 to 37.8)	27.2 (19.0 to 36.1)	2.9 (-21.8 to 39.4)	-4.1 (-27.1 to 26.4)	0.8 (0.6 to 1.2)	0.8 (0.6 to 1.2)	-1.5 (-24.8 to 31.7)	-4.4 (-28.0 to 26.9)
Chronic kidney disease due to hypertension	26.7 (18.2 to 37.0)	26.1 (19.3 to 35.1)	-2.4 (-23.6 to 30.3)	0.4 (-17.7 to 29.6)	1.2 (0.8 to 1.7)	1.2 (0.5 to 1.1)	-37.6 (-50.3 to -23.5)	-38.6 (-50.5 to -25.9)
Chronic kidney disease due to glomerulonephritis	33.8 (23.8 to 47.9)	24.9 (18.4 to 33.1)	-25.5 (-42.4 to -2.8)	-25.8 (-39.9 to -8.3)	0.8 (0.6 to 1.1)	0.9 (0.6 to 1.1)	4.8 (-14.9 to 33.6)	16.1 (-3.8 to 45.6)
Chronic kidney disease due to other causes	38.3 (29.1 to 51.1)	48.7 (34.0 to 64.6)	25.8 (1.9 to 66.3)	1.2 (3.3 to 56.3)	1.5 (0.9 to 1.7)	1.5 (1.1 to 2.0)	25.2 (14.1 to 57.1)	25.5 (4.8 to 57.1)
Urinary diseases and male infertility	-	-	-	-	1.4 (0.9 to 2.0)	1.8 (1.2 to 2.6)	25.4 (13.7 to 37.8)	8.5 (-1.0 to 18.8)
Interstitial nephritis and urinary tract infections	0.6 (0.6 to 0.7)	0.6 (0.6 to 0.6)	-3.3 (-11.0 to 5.3)	11.4 (1.8 to 22.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.9 (-18.2 to 12.7)	11.3 (5.8 to 31.5)

Appendix Table G.4 - Estonia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Urolithiasis	10.9 (7.8 to 15.8)	13.3 (9.8 to 18.4)	24.3 (2.9 to 42.2)	0.1 (-11.3 to 18.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	18.1 (3.8 to 32.0)	7.3 (-4.8 to 19.0)
Benign prostatic hyperplasia	34.4 (31.9 to 36.5)	44.2 (40.5 to 47.6)	28.2 (14.9 to 42.6)	8.1 (-2.6 to 20.2)	1.2 (0.8 to 1.8)	1.6 (1.0 to 2.3)	28.4 (14.7 to 42.6)	8.7 (-2.7 to 20.7)
Male infertility due to other causes	10.3 (8.1 to 13.0)	8.9 (7.0 to 10.9)	-12.8 (-40.3 to 20.1)	1.6 (-30.4 to 39.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	1.6 (-41.4 to 20.3)	1.6 (-32.1 to 39.9)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	316.0 (-11.3 to 464.6)	291.7 (-16.4 to 437.5)
Gynecological diseases	-	-	-	-	2.0 (1.2 to 2.9)	1.8 (1.1 to 2.7)	-10.2 (-21.4 to 1.9)	7.9 (-10.4 to 19.9)
Uterine fibroids	37.5 (34.3 to 40.6)	33.3 (30.5 to 36.0)	-11.3 (-11.7 to -10.9)	-1.0 (-1.0 to -0.9)	0.5 (0.3 to 0.8)	0.4 (0.2 to 0.7)	-12.7 (-16.8 to -8.6)	-1.6 (-6.0 to 2.9)
Polycystic ovarian syndrome	27.8 (24.9 to 30.6)	23.8 (21.6 to 26.4)	-14.3 (-26.6 to -1.4)	-0.4 (-14.4 to 14.8)	0.3 (0.1 to 0.5)	0.2 (0.1 to 0.4)	-13.9 (-26.5 to -0.3)	0.1 (-14.7 to 15.7)
Female infertility due to other causes	6.6 (3.5 to 9.9)	6.1 (3.7 to 8.8)	-7.0 (-49.7 to 89.2)	9.8 (-40.7 to 122.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-6.9 (-49.5 to 81.9)	9.8 (-40.4 to 113.1)
Endometriosis	3.0 (2.5 to 3.5)	2.7 (2.3 to 3.1)	-8.1 (-26.4 to 13.1)	5.6 (-15.2 to 29.3)	0.2 (0.2 to 0.4)	0.2 (0.2 to 0.4)	3.3 (-28.4 to 16.1)	5.3 (-17.7 to 32.8)
Genital prolapse	92.7 (82.8 to 102.8)	87.0 (77.1 to 97.2)	-6.0 (-20.8 to 10.0)	0.8 (-15.7 to 18.6)	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.5)	-6.2 (-21.6 to 10.4)	0.8 (-15.6 to 18.9)
Premenstrual syndrome	59.8 (31.6 to 84.2)	56.0 (38.4 to 72.3)	-7.4 (-40.9 to 83.3)	8.3 (-31.0 to 112.2)	0.5 (0.2 to 0.8)	0.5 (0.3 to 0.7)	-7.7 (-41.2 to 86.0)	8.2 (-31.2 to 110.8)
Other gynecological diseases	4.9 (4.3 to 5.4)	3.9 (3.6 to 4.3)	-18.8 (-29.1 to -8.2)	-5.0 (-17.0 to 8.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-19.9 (-34.8 to 2.1)	-5.9 (-24.0 to 20.5)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	1.1 (0.7 to 1.5)	0.8 (0.6 to 1.2)	-24.2 (-30.1 to -13.7)	-2.3 (-9.9 to 10.2)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.8 (-36.2 to -19.3)	7.8 (-2.1 to 24.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.0 (-48.5 to -5.8)	6.2 (-23.0 to 43.5)
Thalassemia trait	26.5 (25.1 to 28.2)	23.3 (22.0 to 24.7)	-12.1 (-15.6 to -8.1)	2.9 (-1.1 to 7.2)	0.9 (0.6 to 1.3)	0.7 (0.5 to 1.0)	-22.8 (-28.8 to -15.6)	-1.4 (-9.8 to 7.3)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.9 (-22.4 to 38.2)	21.7 (2.8 to 81.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.5 (-23.0 to 44.9)	20.2 (3.2 to 90.7)
Sickle cell trait	0.7 (0.7 to 0.8)	0.6 (0.6 to 0.7)	-14.7 (-19.0 to -13.2)	-0.2 (-5.7 to 2.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.6 (-71.1 to -24.3)	-37.1 (-62.4 to 12.5)
G6PD deficiency	2.6 (2.3 to 2.9)	2.3 (2.1 to 2.5)	-13.2 (-25.2 to -0.2)	12.2 (-12.1 to 17.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.7 (-38.4 to 40.1)	21.3 (-20.2 to 67.0)
G6PD trait	167.1 (165.0 to 169.2)	144.0 (142.1 to 145.8)	-13.8 (-14.9 to -12.1)	-1.5 (-2.9 to 0.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.2 (-71.4 to 25.5)	-8.5 (-69.8 to 62.8)
Other hemoglobinopathies and hemolytic anemias	6.8 (5.3 to 7.8)	5.5 (4.6 to 6.1)	-18.9 (-36.7 to 6.5)	-3.5 (-28.1 to 28.5)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-27.8 (-61.2 to 33.8)	-3.3 (-48.2 to 75.8)
Endocrine, metabolic, blood, and immune disorders	18.7 (17.6 to 19.9)	14.9 (14.2 to 15.5)	-20.6 (-26.2 to -14.3)	-4.8 (-11.8 to 3.5)	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.7)	-22.5 (-28.7 to -12.0)	-5.2 (-13.3 to 7.8)
Musculoskeletal disorders	-	-	-	-	37.5 (29.9 to 49.7)	42.2 (27.9 to 51.4)	11.9 (-1.2 to 10.2)	1.9 (-2.5 to 8.9)
Rheumatoid arthritis	8.3 (8.0 to 8.7)	8.4 (8.1 to 8.8)	1.3 (-4.8 to 7.7)	-6.5 (-12.1 to -1.1)	1.9 (1.4 to 2.5)	1.9 (1.4 to 2.5)	0.2 (-6.3 to 7.8)	-6.7 (-12.1 to 0.2)
Osteoarthritis	94.1 (90.4 to 97.6)	108.7 (105.1 to 112.5)	15.5 (9.4 to 22.4)	0.6 (-4.9 to 6.6)	5.7 (4.1 to 7.9)	6.6 (4.6 to 9.0)	14.8 (8.7 to 21.6)	0.6 (-4.9 to 6.7)
Low back and neck pain	-	-	-	-	24.9 (17.3 to 33.9)	24.9 (17.4 to 33.6)	0.1 (-7.2 to 8.5)	0.1 (-2.3 to 10.9)
Low back pain	158.4 (149.5 to 167.8)	160.4 (151.1 to 169.5)	1.4 (-6.7 to 9.5)	1.7 (-5.7 to 9.7)	1.7 (1.8 to 2.4)	1.7 (1.9 to 2.4)	0.7 (-7.0 to 8.8)	1.9 (-5.5 to 9.9)
Neck pain	75.4 (63.2 to 88.1)	74.7 (61.5 to 86.8)	-0.9 (-19.5 to 22.1)	2.9 (-17.4 to 25.9)	7.4 (5.0 to 10.4)	7.3 (4.9 to 10.3)	-1.2 (-20.1 to 21.8)	3.1 (-17.5 to 26.1)
Gout	1.1 (1.0 to 1.2)	1.2 (1.1 to 1.3)	11.4 (0.5 to 22.4)	4.8 (-5.5 to 15.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	10.4 (-11.0 to 35.0)	4.8 (-14.9 to 27.8)
Other musculoskeletal disorders	54.6 (43.6 to 65.7)	62.7 (50.2 to 76.2)	15.0 (6.5 to 23.0)	12.3 (5.0 to 20.0)	4.9 (3.3 to 7.1)	5.7 (3.7 to 8.3)	14.4 (5.8 to 22.8)	12.2 (4.3 to 20.7)
Other non-communicable diseases	-	-	-	-	27.4 (18.7 to 38.9)	26.4 (18.1 to 37.2)	-4.8 (-7.0 to 0.7)	-4.8 (-8.2 to -0.4)
Congenital anomalies	-	-	-	-	2.0 (1.4 to 2.6)	1.9 (1.3 to 2.5)	-3.8 (-15.9 to 14.7)	12.1 (-3.1 to 33.7)
Neural tube defects	0.3 (0.3 to 0.4)	0.2 (0.2 to 0.2)	-43.2 (-56.3 to -26.2)	-28.5 (-45.2 to -7.6)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-41.8 (-60.0 to -15.8)	-26.2 (-49.9 to 5.5)
Congenital heart anomalies	8.9 (7.3 to 10.8)	8.2 (6.7 to 9.9)	-8.5 (-30.6 to 19.3)	9.5 (-16.7 to 41.6)	0.3 (0.1 to 0.5)	0.3 (0.1 to 0.5)	-5.5 (-26.3 to 19.2)	14.8 (-9.6 to 44.9)
Crofacial clefts	1.3 (1.0 to 1.6)	1.3 (1.1 to 1.6)	-0.0 (-26.9 to 38.3)	15.2 (-15.8 to 59.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.1 (-49.2 to 9.9)	-13.7 (-41.2 to 26.1)
Down syndrome	1.7 (1.4 to 2.1)	1.7 (1.4 to 2.2)	5.7 (-20.6 to 45.1)	17.8 (-11.6 to 59.3)	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.4)	22.7 (-14.5 to 61.1)	15.8 (-9.1 to 70.3)
Turner syndrome	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-14.9 (-43.6 to 27.5)	3.9 (-31.1 to 55.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.8 (-45.2 to 31.3)	3.7 (-32.8 to 60.2)
Klinefelter syndrome	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-1.5 (-32.6 to 45.5)	19.8 (-18.0 to 76.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.9 (-37.7 to 57.8)	18.1 (-26.8 to 84.0)
Chromosomal unbalanced rearrangements	2.3 (1.9 to 2.8)	2.5 (2.0 to 3.1)	7.6 (-17.6 to 36.8)	19.3 (-8.5 to 52.3)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	18.4 (-10.6 to 52.4)	25.1 (5.9 to 61.1)
Other congenital anomalies	7.4 (6.1 to 8.6)	5.5 (4.6 to 6.4)	-25.3 (-33.6 to -18.1)	45.5 (-24.4 to -7.4)	0.9 (0.6 to 1.3)	0.9 (0.6 to 1.2)	-9.9 (-26.5 to 18.7)	8.3 (-11.9 to 44.2)
Skin and subcutaneous diseases	-	-	-	-	8.1 (5.3 to 11.8)	6.8 (4.5 to 10.0)	-16.3 (-21.8 to -8.0)	-3.1 (-9.9 to 6.5)
Dermatitis	77.4 (64.3 to 90.4)	66.9 (55.5 to 78.0)	-13.7 (-15.1 to -11.9)	-0.1 (-0.1 to 0.0)	2.3 (1.5 to 3.3)	1.9 (1.2 to 2.8)	-15.6 (-18.7 to -12.5)	0.0 (-2.9 to 2.9)
Psoriasis	13.9 (12.3 to 15.4)	12.8 (11.3 to 14.3)	-7.8 (-9.2 to -5.8)	0.0 (-0.1 to 0.1)	1.1 (0.8 to 1.6)	1.0 (0.7 to 1.4)	-8.0 (-13.0 to -3.0)	3.3 (-4.9 to 5.6)
Cellulitis	0.9 (0.7 to 1.0)	0.7 (0.6 to 0.9)	-16.1 (-23.2 to -6.3)	-0.6 (-7.8 to 8.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-0.6 (-29.2 to 1.0)	-0.6 (-15.6 to 19.2)
Pyoderma	1.3 (1.1 to 1.6)	2.1 (1.7 to 2.6)	54.7 (42.3 to 68.0)	67.0 (56.0 to 79.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.8 (36.2 to 71.9)	67.2 (49.9 to 85.4)
Scabies	4.6 (4.0 to 5.4)	3.8 (3.1 to 4.6)	-17.3 (-34.5 to 5.4)	2.8 (-17.9 to 31.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-17.7 (-34.8 to 6.0)	2.7 (-18.1 to 32.3)
Fungal skin diseases	127.4 (108.1 to 165.8)	114.7 (90.4 to 146.7)	-10.0 (-13.3 to -6.4)	0.2 (0.1 to 0.4)	0.7 (0.3 to 1.5)	0.6 (0.3 to 1.4)	-10.3 (-13.7 to -6.7)	0.3 (-0.5 to 1.3)
Viral skin diseases	31.0 (23.7 to 38.3)	23.8 (17.7 to 30.3)	-23.3 (-26.6 to -20.0)	2.3 (-1.9 to 1.9)	1.0 (0.5 to 1.5)	0.7 (0.4 to 1.1)	-23.5 (-27.3 to -19.8)	0.1 (-3.0 to 3.3)
Acne vulgaris	44.5 (36.9 to 52.2)	37.8 (27.2 to 38.4)	-16.1 (-43.2 to -5.2)	-0.6 (-22.7 to 31.8)	0.1 (0.2 to 0.9)	0.1 (0.2 to 0.7)	-0.6 (-42.9 to -4.8)	-0.6 (-22.8 to 32.2)
Alopecia areata	2.0 (1.7 to 2.2)	1.9 (1.6 to 2.2)	-5.0 (-22.9 to 19.3)	-0.1 (-16.4 to 24.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-5.0 (-24.4 to 19.2)	2.7 (-18.7 to 26.3)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-24.0 to 29.2)	0.0 (0.0 to 0.0)	-	-
Urticaria	26.1 (17.7 to 32.9)	19.6 (13.9 to 25.7)	-26.9 (-50.3 to 27.8)	-8.5 (-45.5 to 45.4)	1.5 (0.9 to 2.3)	1.2 (0.6 to 1.8)	-27.1 (-50.6 to 27.9)	-18.1 (-45.9 to 48.6)
Decubitus ulcer	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	70.6 (18.8 to 130.9)	42.4 (1.2 to 83.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	65.1 (14.8 to 128.0)	39.7 (0.1 to 85.4)
Other skin and subcutaneous diseases	120.4 (71.4 to 201.1)	117.5 (65.5 to 207.6)	-3.2 (-11.4 to 6.2)	-2.6 (-6.6 to 2.1)	0.7 (0.3 to 1.6)	0.7 (0.3 to 1.6)	-3.6 (-12.0 to 6.0)	-2.5 (-6.7 to 2.5)
Sense organ diseases	-	-	-	-	13.6 (9.1 to 19.3)	13.9 (9.4 to 19.5)	1.9 (-2.6 to 8.2)	-9.8 (-14.1 to -5.0)
Glaucoma	1.4 (1.1 to 1.7)	1.5 (1.2 to 1.9)	7.1 (-15.0 to 31.6)	-9.2 (-23.6 to 11.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	17.3 (-6.8 to 52.5)	-3.1 (-21.4 to 22.2)
Cataract	14.5 (11.5 to 17.7)	12.8 (9.5 to 16.3)	-11.7 (-29.5 to 5.5)	-31.3 (-45.3 to -17.6)	0.5 (0.3 to 0.8)	0.5 (0.3 to 0.7)	-9.7 (-27.5 to 6.8)	-30.6 (-44.4 to -17.0)
Macular degeneration	3.5 (2.5 to 4.6)	4.8 (3.5 to 6.5)	34.1 (0.5 to 88.2)	18.1 (-10.7 to 60.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	36.1 (1.0 to 89.0)	17.5 (-12.1 to 57.7)
Uncorrected refractive error	138.0 (122.9 to 153.7)	135.1 (122.5 to 149.2)	-2.2 (-14.9 to 14.9)	-0.0 (-20.6 to 7.0)	2.0 (1.0 to 3.2)	1.8 (1.0 to 3.1)	-6.9 (-16.4 to 5.0)	-12.1 (-20.8 to -0.9)
Age-related and other hearing loss	32.9 (28.7 to 35.4)	328.0 (295.5 to 356.1)	1.5 (-2.5 to 5.7)	-7.5 (-11.1 to -3.4)	9.7 (6.4 to 13.5)	10.2 (7.0 to 14.4)	5.7 (-0.6 to 15.2)	-9.5 (-15.1 to -2.7)
Other vision loss	6.4 (5.3 to 7.6)	4.8 (3.9 to 5.8)	-27.2 (-35.9 to -11.2)	-2.7 (-35.2 to 15.8)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-20.9 (-30.7 to -6.2)	-24.4 (-32.1 to -12.5)
Other sense organ diseases	38.1 (36.4 to 40.0)	33.8 (32.3 to 35.5)	-11.2 (-16.9 to -5.2)	-0.4 (-6.7 to 6.1)	1.0 (0.6 to 1.5)	0.9 (0.5 to 1.3)	-11.9 (-18.0 to -5.2)	-0.1 (-7.2 to 7.4)
Oral disorders	-	-	-	-	3.7 (2.3 to 5.7)	3.8 (2.4 to 5.7)	1.7 (-2.5 to 6.0)	-1.7 (-5.4 to 2.0)
Deciduous caries	69.6 (67.6 to 71.4)	42.2 (41.1 to 43.2)	-39.4 (-41.5 to -36.8)	0.4 (-3.0 to 4.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.6 (-45.1 to -33.8)	0.1 (-8.9 to 9.6)
Permanent caries	738.6 (708.7 to 772.6)	662.4 (638.4 to 691.8)	-9.3 (-15.7 to -4.7)	-10.3 (-1.4 to 11.4)	0.8 (0.2 to 0.8)	0.4 (0.2 to 0.8)	-5.5 (-16.2 to 4.8)	5.0 (-1.4 to 11.7)
Periodontal diseases	109.5 (103.8 to 114.8)	109.4 (104.3 to 114.3)	-0.1 (-6.1 to 6.7)	0.6 (-5.9 to 7.6)	0.7 (0.3 to 1.5)	0.7 (0.3 to 1.5)	-0.3 (-6.5 to 7.0)	0.8 (-5.8 to 8.0)
Edentulism and severe tooth loss	62.8 (60.2 to 65.3)	70.6 (68.0 to 73.2)	12.4 (7.0 to 18.7)	-5.4 (-10.1 to 0.0)	1.7 (1.2 to 2.4)	1.9 (1.3 to 2.6)	11.9 (6.3 to 18.4)	-5.2 (-9.9 to 0.3)

Appendix Table G.4 - Estonia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	29.5 (28.0 to 31.1)	26.5 (25.0 to 27.9)	-10.4 (-16.8 to -3.5)	-4.6 (-7.9 to 7.1)	0.9 (0.5 to 1.3)	0.8 (0.5 to 1.1)	-10.6 (-17.5 to -3.2)	-0.1 (-8.4 to 7.5)
Injuries	-	-	-	-	12.6 (9.5 to 16.5)	7.4 (5.3 to 10.0)	-41.8 (-46.8 to -35.9)	-44.5 (-49.2 to -38.7)
Transport injuries	-	-	-	-	3.8 (2.8 to 4.9)	1.1 (0.8 to 1.5)	-71.1 (-74.5 to -67.2)	-71.4 (-74.9 to -67.5)
Road injuries	-	-	-	-	3.1 (2.3 to 4.0)	0.8 (0.5 to 1.1)	-75.0 (-78.0 to -71.4)	-75.3 (-78.3 to -71.7)
Pedestrian road injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.2 (0.1 to 0.2)	-71.1 (-76.5 to -69.1)	-74.5 (-77.8 to -70.6)
Cyclist road injuries	-	-	-	-	0.5 (0.3 to 0.6)	0.1 (0.1 to 0.2)	-73.8 (-76.6 to -70.6)	-73.8 (-76.7 to -70.7)
Motorcyclist road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.1 (0.0 to 0.1)	-79.8 (-82.4 to -77.0)	-79.4 (-82.1 to -76.5)
Motor vehicle road injuries	-	-	-	-	1.6 (1.2 to 2.1)	0.4 (0.3 to 0.6)	-75.0 (-78.4 to -70.9)	-75.1 (-78.6 to -70.8)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other transport injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.3 (0.2 to 0.4)	-53.7 (-58.9 to -47.9)	-54.0 (-59.2 to -48.2)
Unintentional injuries	-	-	-	-	8.5 (6.4 to 11.0)	6.1 (4.4 to 8.2)	-28.1 (-33.8 to -22.0)	-31.9 (-37.2 to -26.0)
Falls	-	-	-	-	3.7 (2.8 to 4.8)	2.8 (2.0 to 3.8)	-23.0 (-31.1 to -13.7)	-30.5 (-37.9 to -22.1)
Drowning	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-58.2 (-63.9 to -51.8)	-58.3 (-63.8 to -51.6)
Fire, heat, and hot substances	-	-	-	-	0.4 (0.3 to 0.5)	0.2 (0.2 to 0.3)	-38.8 (-46.1 to -30.9)	-37.8 (-45.4 to -29.9)
Poisonings	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-50.3 (-56.5 to -42.9)	-45.2 (-52.4 to -36.5)
Exposure to mechanical forces	-	-	-	-	2.2 (1.6 to 2.9)	1.3 (1.0 to 1.8)	-39.1 (-43.3 to -34.3)	-37.2 (-41.4 to -32.4)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.9 (-66.6 to -57.2)	-60.5 (-66.5 to -53.2)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other exposure to mechanical forces	-	-	-	-	2.1 (1.6 to 2.8)	1.3 (0.9 to 1.8)	-38.7 (-42.9 to -33.9)	-36.8 (-41.0 to -32.1)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.1 (-3.1 to 12.6)	1.5 (-5.1 to 9.5)
Animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-21.0 (-27.3 to -13.2)	-17.6 (-23.7 to -9.9)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.5 (-27.0 to -8.3)	-13.0 (-22.2 to -1.6)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-22.2 (-29.7 to -13.4)	-19.8 (-26.9 to -11.1)
Foreign body	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-29.7 (-36.2 to -21.6)	-28.3 (-34.8 to -20.6)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-43.0 (-51.4 to -31.7)	-43.1 (-51.4 to -32.1)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.4 (-21.5 to -10.8)	-6.8 (-15.8 to -2.7)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-21.4 (-28.5 to -12.4)	-21.4 (-28.4 to -12.9)
Other unintentional injuries	-	-	-	-	1.8 (1.3 to 2.3)	1.4 (1.0 to 1.9)	-20.7 (-26.8 to -13.7)	-25.6 (-31.3 to -19.3)
Self-harm and interpersonal violence	-	-	-	-	0.4 (0.3 to 0.5)	0.2 (0.1 to 0.3)	-47.8 (-53.0 to -41.1)	-47.6 (-52.8 to -40.9)
Self-harm	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-42.0 (-47.5 to -35.2)	-41.3 (-46.7 to -34.5)
Interpersonal violence	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.1)	-52.8 (-58.4 to -45.9)	-53.0 (-58.6 to -46.2)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.0 (-58.2 to -49.1)	-53.8 (-57.8 to -48.9)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.6 (-53.6 to -40.6)	-47.8 (-53.8 to -41.2)
Assault by other means	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-53.8 (-59.6 to -46.4)	-54.1 (-59.8 to -46.8)
Forces of nature, war, and legal intervention	-	-	-	-	-	-	-	-
Exposure to forces of nature	-	-	-	-	-	-	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Ethiopia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	4,954.8 (3,631.0 to 6,480.5)	8,766.6 (6,526.0 to 11,469.9)	77.9 (65.3 to 84.9)	9.7 (-16.1 to -6.3)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1,317.7 (915.2 to 1,851.9)	1,988.2 (1,375.5 to 2,778.3)	50.9 (43.5 to 58.9)	-21.6 (-25.8 to -16.9)
HIV/AIDS and tuberculosis	-	-	-	-	62.8 (42.1 to 88.1)	159.9 (106.1 to 232.3)	152.5 (102.8 to 232.2)	24.8 (-1.1 to 73.2)
Tuberculosis	98.2 (93.5 to 102.8)	174.8 (166.3 to 183.0)	78.0 (71.6 to 85.1)	-14.0 (-16.9 to -10.9)	29.7 (20.1 to 39.8)	53.4 (36.4 to 72.0)	79.9 (68.9 to 90.7)	-13.2 (-18.0 to -8.2)
HIV/AIDS	-	-	-	-	33.1 (20.3 to 50.4)	106.4 (68.0 to 166.0)	223.5 (121.0 to 385.1)	64.4 (8.7 to 160.4)
HIV/AIDS resulting in mycobacterial infection	5.1 (2.8 to 8.1)	10.2 (5.6 to 15.3)	100.7 (38.9 to 185.0)	4.8 (-28.2 to 53.4)	1.9 (0.9 to 3.2)	3.8 (1.8 to 6.4)	10.0 (3.2 to 20.4)	5.8 (-3.1 to 60.1)
HIV/AIDS resulting in other diseases	324.0 (242.7 to 426.0)	783.4 (706.8 to 877.4)	150.5 (84.1 to 219.4)	34.9 (-1.8 to 73.3)	31.2 (18.8 to 48.3)	102.6 (65.5 to 161.9)	230.2 (123.8 to 404.1)	68.9 (9.7 to 170.9)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	243.5 (173.6 to 325.7)	293.7 (208.3 to 401.0)	20.7 (9.7 to 31.3)	-32.3 (-38.3 to -26.9)
Diarrheal diseases	768.7 (707.0 to 829.6)	909.9 (847.6 to 969.9)	18.4 (7.0 to 31.1)	-29.1 (-35.4 to -21.9)	128.0 (84.1 to 173.3)	147.5 (99.8 to 208.2)	18.8 (6.8 to 32.9)	-28.2 (-35.3 to -21.1)
Intestinal infectious diseases	-	-	-	-	3.6 (2.3 to 5.5)	2.7 (1.7 to 3.8)	2.7 (1.7 to 3.8)	-26.0 (-44.1 to -2.7)
Typhoid fever	18.0 (15.9 to 20.3)	15.1 (13.3 to 17.1)	-15.8 (-30.9 to 1.1)	-56.1 (-64.3 to -47.8)	2.4 (1.5 to 3.5)	2.0 (1.3 to 3.0)	-13.2 (-33.8 to 13.3)	-54.7 (-65.0 to -42.4)
Paratyphoid fever	6.7 (5.8 to 7.7)	6.9 (5.8 to 8.3)	3.2 (-18.3 to 36.6)	-45.6 (-56.9 to -30.7)	0.4 (0.2 to 0.5)	0.4 (0.2 to 0.6)	3.6 (-23.9 to 43.9)	45.9 (-58.6 to -27.6)
Other intestinal infectious diseases	-	-	-	-	0.9 (0.4 to 2.0)	0.2 (0.1 to 0.5)	-73.2 (-83.7 to -55.7)	-86.1 (-91.6 to -77.0)
Lower respiratory infections	27.8 (23.9 to 31.9)	36.4 (30.7 to 42.5)	30.6 (6.0 to 58.0)	-23.8 (-33.8 to -13.5)	2.9 (1.9 to 4.1)	3.8 (2.4 to 5.5)	31.4 (28.8 to 68.6)	-23.0 (-35.1 to -8.3)
Upper respiratory infections	1,701.2 (1,604.2 to 1,776.0)	3,246.0 (3,108.4 to 3,410.2)	91.3 (78.2 to 103.5)	-1.6 (-7.9 to 4.4)	19.9 (11.1 to 33.6)	38.1 (21.5 to 64.1)	91.8 (77.8 to 105.7)	-1.3 (-7.9 to 5.6)
Otitis media	835.2 (760.1 to 924.8)	1,442.5 (1,331.1 to 1,568.0)	72.6 (56.1 to 91.2)	-11.8 (-21.1 to -2.4)	17.1 (10.2 to 27.8)	29.5 (17.7 to 47.1)	72.2 (52.8 to 95.0)	-12.1 (-21.8 to -0.7)
Meningitis	-	-	-	-	64.0 (42.2 to 92.3)	60.2 (39.7 to 86.3)	-3.7 (-26.5 to 15.6)	-49.3 (-60.3 to -40.4)
Pneumococcal meningitis	158.4 (101.6 to 227.1)	146.2 (91.7 to 212.7)	-7.6 (-30.9 to 19.2)	-50.4 (-62.0 to -36.8)	16.3 (10.8 to 23.4)	15.2 (9.9 to 23.6)	6.7 (-38.0 to 32.3)	-50.2 (-66.0 to -32.0)
H influenzae type B meningitis	182.2 (86.9 to 306.4)	149.4 (72.4 to 255.9)	-17.5 (-45.1 to 16.7)	-58.8 (-71.6 to -42.7)	21.3 (12.4 to 34.4)	20.3 (11.3 to 34.5)	-4.0 (-48.8 to 53.9)	-51.6 (-73.9 to -22.9)
Meningococcal meningitis	60.4 (23.8 to 110.1)	49.3 (16.8 to 93.5)	-17.5 (-42.1 to 3.0)	-54.8 (-67.9 to -43.8)	8.1 (4.1 to 13.2)	7.0 (3.7 to 11.2)	-12.9 (-36.3 to 18.5)	-52.6 (-64.8 to -38.4)
Other meningitis	139.8 (79.5 to 231.3)	140.9 (71.1 to 239.5)	-0.5 (-21.6 to 31.5)	-45.8 (-58.6 to -28.5)	18.2 (11.2 to 26.8)	17.7 (10.9 to 26.2)	-2.8 (-28.5 to 33.4)	-47.5 (-60.4 to -28.2)
Encephalitis	9.6 (4.6 to 19.2)	16.3 (7.5 to 33.3)	69.3 (50.4 to 87.7)	-2.1 (-22.5 to 5.1)	2.1 (0.8 to 1.6)	2.1 (1.4 to 2.8)	2.1 (5.2 to 100.6)	-41.7 (-21.5 to -0.8)
Diphtheria	0.1 (0.0 to 0.6)	0.1 (0.0 to 0.2)	-39.9 (-97.0 to 1,196.9)	-63.8 (-97.4 to 386.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.9 (97.0 to 1,221.0)	-63.8 (-97.4 to 387.8)
Whooping cough	136.0 (103.7 to 177.8)	152.3 (116.9 to 197.5)	12.1 (9.9 to 14.3)	-27.4 (-28.8 to -26.0)	6.7 (3.9 to 10.8)	7.5 (4.4 to 12.0)	12.4 (5.7 to 19.9)	-27.3 (-31.8 to -22.5)
Tetanus	3.7 (2.1 to 6.9)	1.2 (1.2 to 2.5)	-67.6 (-76.4 to -13.5)	-75.4 (-87.6 to -55.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-37.9 (-63.9 to 3.5)	-66.2 (-81.2 to -44.3)
Measles	34.7 (24.3 to 47.5)	8.5 (6.0 to 11.9)	-75.4 (-79.4 to -70.4)	-44.7 (-47.2 to -41.6)	3.1 (1.8 to 5.1)	0.8 (0.4 to 1.3)	-51.2 (-82.2 to -46.9)	-44.5 (-89.0 to -79.4)
Varicella and herpes zoster	30.0 (27.4 to 33.0)	61.5 (56.0 to 68.0)	105.3 (78.2 to 130.6)	3.8 (-15.6 to 24.6)	0.7 (0.4 to 1.1)	1.4 (0.8 to 2.2)	107.2 (44.2 to 176.4)	2.8 (-28.9 to 44.3)
Neglected tropical diseases and malaria	-	-	-	-	396.1 (251.3 to 606.2)	690.0 (428.2 to 1,097.6)	74.2 (57.6 to 87.1)	-19.8 (-28.0 to -12.3)
Malaria	2,658.3 (2,523.3 to 2,794.8)	2,874.0 (2,720.3 to 3,049.9)	8.2 (2.9 to 13.4)	-43.9 (-46.6 to -41.4)	33.5 (22.1 to 49.5)	41.7 (28.0 to 60.8)	24.9 (10.1 to 40.4)	-36.1 (-43.9 to -28.2)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	90.5 (37.1 to 159.5)	-5.0 (-31.5 to 34.4)
Visceral leishmaniasis	1.0 (0.6 to 1.5)	1.6 (1.1 to 2.5)	71.2 (20.1 to 128.0)	-9.7 (-30.8 to 21.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	71.2 (19.6 to 128.1)	-9.8 (-30.9 to 21.5)
Cutaneous and mucocutaneous leishmaniasis	8.7 (5.3 to 13.5)	17.7 (10.6 to 26.7)	104.7 (31.8 to 226.7)	-2.8 (-35.9 to 55.1)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	106.5 (28.0 to 249.3)	-2.7 (-37.9 to 61.2)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	16,871.3 (11,927.4 to 22,834.6)	35,775.1 (25,534.7 to 47,991.7)	112.1 (109.5 to 115.3)	1.9 (0.9 to 3.0)	157.1 (74.8 to 299.9)	359.2 (180.6 to 680.5)	129.4 (119.7 to 145.6)	6.8 (3.7 to 13.4)
Cysticercosis	11.6 (4.4 to 18.5)	23.8 (12.8 to 37.0)	97.2 (33.0 to 148.3)	-7.8 (-47.5 to 137.5)	2.9 (1.0 to 5.0)	6.1 (3.0 to 10.3)	101.3 (14.0 to 478.3)	-5.2 (-48.1 to 143.4)
Cystic echinococcosis	15.6 (14.1 to 17.1)	20.6 (19.0 to 23.1)	33.3 (18.5 to 45.4)	-29.4 (-39.5 to -22.3)	1.4 (0.9 to 2.1)	1.9 (1.3 to 2.7)	33.2 (8.5 to 61.7)	-29.0 (-41.0 to -16.5)
Lymphatic filariasis	1,958.9 (1,496.6 to 2,633.1)	3,552.5 (2,786.9 to 4,349.8)	85.8 (23.0 to 155.4)	-6.4 (-34.6 to 21.6)	49.2 (24.8 to 83.5)	85.1 (41.4 to 144.6)	77.5 (1.6 to 142.7)	-9.6 (-43.3 to 22.6)
Onchocerciasis	738.3 (893.7 to 1,419.1)	449.0 (293.3 to 656.9)	-39.2 (-57.1 to -4.7)	-48.0 (-78.3 to -52.0)	16.3 (20.9 to 77.5)	15.2 (15.1 to 60.6)	15.2 (42.4 to 4.3)	-61.3 (-70.7 to -47.1)
Trachoma	419.4 (312.1 to 520.9)	416.6 (294.4 to 560.2)	-0.7 (-15.7 to 14.9)	-51.8 (-59.0 to -43.6)	32.3 (20.6 to 46.3)	33.4 (20.3 to 50.9)	2.7 (-13.2 to 22.9)	-50.5 (-58.1 to -39.8)
Dengue	1.4 (0.3 to 4.0)	13.2 (3.3 to 38.1)	855.1 (843.5 to 868.5)	380.1 (374.3 to 386.8)	0.2 (0.1 to 0.2)	2.2 (0.5 to 6.6)	802.8 (599.9 to 1,066.0)	348.3 (266.2 to 458.1)
Yellow fever	0.3 (0.1 to 0.8)	0.2 (0.1 to 0.4)	-47.7 (-62.2 to -27.8)	-73.7 (-80.0 to -65.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.7 (-62.2 to -27.8)	-73.7 (-80.3 to -65.9)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	62.2 (51.3 to 56.5)	0.0 (0.0 to 0.0)	62.2 (51.4 to 56.6)	-47.6 (-68.9 to -22.0)
Intestinal nematode infections	-	-	-	-	32.6 (19.6 to 51.1)	72.1 (43.9 to 111.8)	122.6 (78.6 to 153.4)	7.5 (-11.3 to 23.2)
Ascariasis	7,405.5 (5,580.4 to 9,987.5)	14,712.3 (10,903.3 to 20,071.8)	96.4 (32.4 to 202.9)	-0.5 (-38.5 to 69.1)	5.0 (2.8 to 8.4)	9.6 (5.1 to 16.1)	93.5 (59.9 to 134.9)	0.4 (-20.2 to 26.4)
Trichuriasis	7,959.2 (5,966.7 to 10,843.3)	15,846.8 (11,761.1 to 21,047.6)	98.5 (33.4 to 209.9)	0.5 (-39.6 to 70.3)	4.5 (2.5 to 7.6)	9.0 (4.8 to 15.2)	98.3 (62.1 to 144.9)	0.5 (-20.7 to 30.0)
Hookworm disease	5,330.3 (3,813.3 to 7,237.5)	10,694.6 (7,627.2 to 14,410.4)	100.8 (24.1 to 213.3)	1.0 (-43.5 to 68.3)	23.1 (14.2 to 35.5)	45.0 (33.0 to 81.9)	133.5 (72.6 to 177.0)	10.1 (-15.6 to 30.8)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	875.4 (652.4 to 1,061.4)	1,183.5 (1,072.4 to 1,325.5)	35.1 (8.0 to 80.1)	-28.6 (-41.5 to -9.4)	41.8 (25.5 to 64.3)	53.4 (32.8 to 85.4)	26.3 (3.4 to 72.3)	-32.7 (-48.5 to -12.0)
Maternal disorders	-	-	-	-	16.2 (11.1 to 22.0)	22.6 (15.7 to 30.7)	39.0 (21.1 to 64.4)	-33.8 (-42.2 to -22.7)
Maternal hemorrhage	18.0 (15.4 to 20.9)	31.0 (24.2 to 37.5)	72.3 (27.2 to 123.8)	-22.5 (-42.0 to 15.5)	0.7 (0.4 to 1.0)	0.8 (0.4 to 1.3)	24.3 (-29.2 to 104.0)	-45.1 (-68.5 to -10.7)
Maternal sepsis and other maternal infections	28.1 (19.0 to 37.5)	23.9 (15.7 to 35.2)	-14.7 (-31.2 to -1.9)	-58.0 (-66.1 to -52.0)	0.3 (0.2 to 0.6)	0.3 (0.1 to 0.5)	-13.6 (-44.1 to 30.6)	-58.8 (-72.6 to -40.2)
Maternal hypertensive disorders	24.6 (14.3 to 37.9)	30.4 (18.2 to 46.6)	23.8 (11.8 to 39.9)	-43.0 (-48.4 to -35.9)	1.2 (0.6 to 2.1)	1.5 (0.8 to 2.6)	23.9 (5.5 to 47.4)	-43.2 (-51.3 to -32.9)
Obstructed labor	30.8 (27.2 to 34.2)	43.7 (39.0 to 48.4)	42.3 (31.9 to 53.8)	-31.6 (-36.4 to -25.6)	10.1 (6.8 to 13.9)	14.5 (9.9 to 20.2)	43.3 (23.5 to 67.1)	-31.2 (-39.7 to -20.7)
Complications of abortion	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	39.7 (-11.8 to 115.2)	-36.1 (-59.3 to -2.4)	0.1 (0.0 to 0.0)	0.0 (0.0 to 0.1)	39.7 (-12.1 to 115.4)	-36.1 (-59.4 to -2.3)
Other maternal disorders	-	-	-	-	3.8 (2.4 to 5.4)	5.5 (3.5 to 7.9)	40.6 (42.2 to 112.5)	33.4 (-50.9 to -1.1)
Neonatal disorders	-	-	-	-	24.0 (12.1 to 47.3)	104.9 (68.9 to 149.5)	361.3 (158.1 to 694.9)	168.1 (30.6 to 390.2)
Preterm birth complications	75.9 (48.5 to 116.5)	340.5 (241.1 to 469.9)	352.4 (276.4 to 454.0)	128.0 (89.2 to 177.6)	3.9 (2.4 to 5.9)	33.1 (21.9 to 47.7)	749.1 (505.1 to 1,143.2)	351.3 (221.4 to 567.7)
Neonatal encephalopathy due to birth asphyxia and trauma	406.0 (30.8 to 1,380.1)	471.3 (92.0 to 1,420.1)	31.9 (-17.4 to 137.1)	-34.1 (-59.3 to 82.2)	12.9 (4.3 to 30.8)	38.0 (18.5 to 65.7)	227.5 (59.9 to 679.9)	83.5 (-20.6 to 142.7)
Neonatal sepsis and other neonatal infections	0.9 (0.3 to 1.7)	1.5 (0.5 to 3.2)	73.2 (55.5 to 91.0)	26.5 (13.6 to 39.5)	0.1 (0.0 to 0.3)	0.1 (0.1 to 0.4)	26.5 (51.0 to 93.9)	72.9 (10.3 to 41.6)
Hemolytic disease and other neonatal jaundice	8.4 (3.4 to 18.8)	43.3 (13.5 to 91.7)	438.5 (92.6 to 1,283.3)	247.7 (22.2 to 807.0)	3.2 (1.2 to 7.4)	3.2 (4.9 to 36.9)	16.9 (98.3 to 1,328.3)	247.9 (22.2 to 810.5)
Other neonatal disorders	-	-	-	-	4.0 (1.5 to 9.6)	16.7 (7.9 to 31.1)	362.3 (74.9 to 1,018.0)	166.4 (8.3 to 588.7)
Nutritional deficiencies	-	-	-	-	530.4 (355.0 to 755.2)	647.1 (423.8 to 911.5)	21.9 (10.9 to 34.7)	-37.6 (-42.6 to -32.1)
Protein-energy malnutrition	415.9 (225.6 to 730.3)	600.7 (346.4 to 1,012.5)	43.8 (-33.4 to 216.6)	-1.8 (-55.0 to 82.9)	50.9 (23.8 to 93.1)	74.5 (36.6 to 139.6)	-10.6 (-33.1 to 22.5)	-10.6 (-55.6 to 87.2)
Iodine deficiency	2,872.5 (2,491.4 to 3,321.7)	4,033.4 (3,268.1 to 4,689.3)	40.6 (9.6 to 76.3)	-31.6 (-48.6 to -12.0)	51.8 (31.0 to 83.8)	72.8 (43.4 to 115.1)	40.7 (8.9 to 78.4)	-31.5 (-48.8 to -11.8)
Vitamin A deficiency	115.9 (91.4 to 139.5)	131.1 (100.1 to 164.1)	12.9 (-3.3 to 31.2)	-41.4 (-51.2 to -32.6)	7.1 (4.6 to 10.6)	7.9 (4.9 to 11.8)	10.7 (

Appendix Table G.4 - Ethiopia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	11,744.2 (11,536.4 to 11,976.3)	14,382.6 (14,107.6 to 14,631.7)	22.6 (19.3 to 25.7)	-40.2 (-41.9 to -38.5)	420.5 (282.4 to 602.3)	491.5 (328.5 to 710.9)	17.0 (12.7 to 20.1)	41.2 (-44.0 to -39.4)
Other nutritional deficiencies	-	-	-	-	0.2 (0.1 to 0.5)	0.4 (0.1 to 1.0)	123.3 (-30.1 to 563.7)	35.3 (-54.6 to 283.8)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	44.7 (29.1 to 65.3)	70.0 (44.5 to 107.1)	56.7 (36.7 to 82.1)	-18.7 (-28.4 to -8.4)
Sexually transmitted diseases excluding HIV	-	-	-	-	16.0 (9.2 to 27.2)	32.0 (18.5 to 54.4)	99.4 (58.4 to 151.4)	-7.0 (-23.8 to 13.0)
Syphilis	6.9 (6.1 to 7.6)	7.7 (7.0 to 8.6)	12.5 (-1.4 to 30.2)	-42.4 (-43.2 to -41.3)	1.4 (0.8 to 1.7)	3.4 (0.9 to 2.1)	13.7 (-11.3 to 40.5)	42.1 (-53.1 to -29.8)
Chlamydial infection	1,176.4 (936.3 to 1,431.4)	2,461.3 (1,962.3 to 3,070.3)	109.2 (50.3 to 186.6)	-2.1 (-28.6 to 31.1)	8.3 (4.4 to 14.5)	17.8 (9.8 to 30.2)	117.9 (48.3 to 203.4)	1.5 (-29.8 to 37.8)
Gonococcal infection	323.7 (211.0 to 446.6)	705.9 (540.1 to 898.0)	120.1 (38.1 to 250.5)	-1.0 (-37.0 to 55.1)	1.8 (0.9 to 3.2)	4.1 (2.2 to 6.8)	127.6 (39.0 to 284.6)	4.8 (-34.1 to 71.6)
Trichomoniasis	750.1 (380.4 to 1,198.3)	1,318.5 (456.3 to 2,488.6)	81.9 (-51.1 to 251.4)	-10.8 (-71.4 to 52.1)	1.3 (0.4 to 3.0)	2.2 (0.5 to 5.9)	69.9 (-54.9 to 263.9)	-15.7 (-75.0 to 54.0)
Genital herpes	11,204.8 (10,503.8 to 11,852.0)	21,810.6 (20,491.6 to 23,135.5)	94.2 (77.6 to 113.3)	-3.7 (-10.9 to 4.3)	3.1 (1.0 to 7.3)	6.1 (2.0 to 14.6)	86.1 (77.6 to 118.1)	-3.3 (-11.4 to 5.2)
Other sexually transmitted diseases	20.5 (13.8 to 27.7)	32.1 (23.5 to 42.0)	57.0 (32.3 to 88.3)	-23.0 (-35.3 to -7.0)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.7)	68.3 (12.4 to 146.1)	19.0 (-43.1 to 14.1)
Hepatitis	-	-	-	-	4.7 (3.0 to 7.0)	6.6 (4.2 to 9.7)	39.8 (17.2 to 64.4)	-36.9 (-49.9 to -23.0)
Hepatitis A	92.9 (87.5 to 98.4)	163.0 (155.0 to 170.9)	75.6 (73.8 to 77.4)	-2.1 (-2.4 to -1.8)	1.5 (1.0 to 2.3)	3.2 (2.0 to 4.7)	107.9 (83.4 to 134.8)	4.6 (-6.7 to 17.6)
Hepatitis B	6,492.4 (5,602.7 to 7,414.7)	5,914.6 (4,874.8 to 7,033.3)	-8.4 (-30.5 to 14.2)	-54.2 (-63.2 to -42.9)	2.8 (1.7 to 4.2)	2.6 (1.5 to 4.0)	-8.0 (-36.2 to 29.6)	-54.7 (-70.3 to -36.0)
Hepatitis C	666.5 (603.0 to 731.5)	964.5 (872.1 to 1,054.5)	44.6 (27.4 to 64.5)	-38.5 (-35.6 to -39.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	46.7 (33.2 to 89.6)	-26.1 (-40.5 to 7.1)
Hepatitis E	11.6 (7.8 to 15.8)	25.6 (18.9 to 31.6)	121.4 (35.2 to 237.8)	6.4 (-36.9 to 61.7)	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.2)	121.8 (30.7 to 271.5)	6.3 (-38.0 to 73.3)
Leprosy	7.6 (5.4 to 9.7)	12.1 (9.9 to 14.0)	60.2 (37.1 to 92.9)	-16.1 (-26.9 to -1.5)	0.5 (0.3 to 0.7)	0.7 (0.5 to 1.1)	60.8 (30.4 to 109.6)	-15.6 (-29.1 to 5.6)
Other infectious diseases	618.5 (513.4 to 734.9)	822.7 (747.0 to 911.1)	32.6 (10.3 to 63.3)	-31.6 (-41.0 to -18.9)	23.4 (14.7 to 34.0)	30.6 (19.9 to 45.6)	30.1 (8.2 to 69.2)	-28.7 (-40.7 to -8.8)
Non-communicable diseases	-	-	-	-	108.9 (2,277.6 to 3,964.5)	104.6 (4,664.3 to 8,090.2)	104.6 (98.7 to 110.7)	0.2 (-2.4 to 3.0)
Neoplasms	-	-	-	-	16.1 (11.2 to 21.7)	30.5 (21.6 to 40.9)	89.5 (50.2 to 141.4)	-0.7 (-18.1 to 24.9)
Esophageal cancer	5.9 (3.4 to 8.8)	8.6 (5.5 to 12.6)	49.3 (-6.9 to 125.5)	-22.6 (-51.5 to 14.4)	0.9 (0.5 to 1.5)	1.4 (0.8 to 2.1)	46.2 (0.3 to 106.6)	-24.7 (-48.2 to 5.8)
Stomach cancer	4.2 (3.5 to 5.0)	5.8 (4.7 to 7.1)	36.1 (3.9 to 79.0)	-27.8 (-44.5 to -3.5)	0.6 (0.4 to 0.8)	0.8 (0.5 to 1.1)	32.6 (11.1 to 75.9)	-29.6 (-46.6 to -5.8)
Liver cancer	-	-	-	-	0.5 (0.3 to 0.7)	0.8 (0.5 to 1.2)	74.5 (8.4 to 145.5)	-9.1 (-42.7 to 25.1)
Liver cancer due to hepatitis B	0.3 (0.2 to 0.5)	0.8 (0.4 to 1.5)	139.4 (-4.1 to 403.9)	28.5 (-48.7 to 192.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	125.0 (0.7 to 344.4)	19.5 (-47.6 to 154.8)
Liver cancer due to hepatitis C	0.8 (0.5 to 1.2)	2.3 (1.2 to 3.6)	177.0 (26.3 to 436.0)	43.4 (-35.7 to 174.4)	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.6)	160.6 (22.1 to 377.3)	32.6 (-37.0 to 141.8)
Liver cancer due to alcohol use	0.8 (0.5 to 1.1)	0.8 (0.4 to 1.4)	1.2 (-50.0 to 94.5)	-47.0 (-72.0 to 1.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-3.2 (-46.3 to 71.4)	-49.1 (-71.0 to -12.0)
Liver cancer due to other causes	0.7 (0.5 to 1.0)	0.9 (0.4 to 1.4)	22.4 (-45.7 to 128.3)	-33.9 (-70.9 to 28.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	16.8 (-42.4 to 94.6)	38.1 (-69.2 to 7.9)
Larynx cancer	0.9 (0.6 to 1.2)	1.3 (0.9 to 1.7)	46.8 (2.2 to 108.3)	-24.7 (-46.8 to 6.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	39.2 (-1.9 to 95.4)	-28.9 (-51.0 to 3.6)
Tracheal, bronchus and lung cancer	2.0 (1.4 to 2.4)	3.0 (2.5 to 3.6)	48.4 (12.4 to 132.1)	-23.6 (-41.8 to 17.0)	0.4 (0.2 to 0.5)	0.5 (0.4 to 0.7)	45.4 (5.8 to 128.6)	-25.1 (-45.4 to 16.3)
Breast cancer	24.2 (19.1 to 29.4)	61.8 (48.0 to 77.6)	155.7 (88.2 to 247.8)	38.6 (3.7 to 85.5)	2.3 (1.6 to 3.2)	5.3 (3.5 to 7.3)	125.5 (64.2 to 203.0)	21.2 (-10.5 to 62.2)
Cervical cancer	41.3 (23.0 to 56.8)	48.7 (25.6 to 61.3)	8.1 (-30.6 to 66.4)	-99.6 (-61.0 to -7.2)	0.1 (1.8 to 5.4)	0.8 (2.2 to 5.9)	74.5 (-28.1 to 61.2)	-40.3 (-59.8 to -10.5)
Uterine cancer	4.4 (2.3 to 7.0)	6.6 (3.3 to 10.9)	47.1 (-16.3 to 169.3)	-19.4 (-53.5 to 42.7)	0.3 (0.2 to 0.6)	0.5 (0.2 to 0.9)	44.3 (-17.5 to 177.5)	-20.6 (-45.4 to 5.9)
Prostate cancer	14.9 (8.4 to 23.2)	60.4 (38.0 to 92.8)	303.3 (141.1 to 635.8)	103.0 (23.0 to 256.9)	1.8 (0.9 to 2.8)	5.5 (3.2 to 8.6)	209.7 (98.1 to 459.0)	54.8 (-6.0 to 179.2)
Colon and rectum cancer	9.0 (7.8 to 10.3)	22.8 (19.5 to 26.4)	152.1 (108.0 to 211.7)	26.5 (4.1 to 57.8)	1.0 (0.7 to 1.3)	2.2 (1.6 to 3.0)	128.6 (85.7 to 183.0)	13.0 (-9.1 to 42.3)
Lip and oral cavity cancer	5.0 (3.6 to 6.6)	8.3 (6.1 to 11.4)	62.0 (7.9 to 147.0)	-15.3 (-42.8 to 32.2)	0.5 (0.3 to 0.7)	0.8 (0.5 to 1.1)	55.8 (7.5 to 130.8)	-19.6 (-45.3 to 21.8)
Nasopharynx cancer	0.6 (0.4 to 0.9)	0.8 (0.6 to 1.1)	38.5 (-17.4 to 131.8)	-27.3 (-54.9 to 19.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	34.9 (-16.9 to 119.4)	-29.3 (-54.9 to 13.6)
Other pharynx cancer	0.9 (0.6 to 1.3)	1.5 (0.9 to 2.2)	61.4 (-10.3 to 187.9)	-14.8 (-52.8 to 50.1)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	57.8 (-3.2 to 161.4)	-18.2 (-50.9 to 36.7)
Gallbladder and biliary tract cancer	0.3 (0.2 to 0.4)	0.6 (0.5 to 0.8)	98.4 (40.5 to 176.9)	1.0 (-29.4 to 40.5)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	91.9 (43.2 to 153.5)	-2.9 (-28.5 to 30.0)
Pancreatic cancer	0.4 (0.3 to 0.5)	0.8 (0.7 to 1.0)	106.5 (55.2 to 179.1)	5.4 (-18.8 to 41.4)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	102.7 (63.9 to 156.2)	2.7 (-16.4 to 30.5)
Malignant skin melanoma	1.6 (2.3 to 4.3)	3.0 (5.6 to 9.5)	85.9 (50.2 to 228.5)	10.2 (-20.1 to 17.1)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.7)	89.5 (42.9 to 214.9)	1.0 (-26.7 to 60.1)
Non-melanoma skin cancer	3.4 (2.7 to 4.2)	6.9 (5.4 to 8.8)	101.6 (50.5 to 172.7)	2.6 (-23.9 to 38.7)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.4)	104.3 (44.7 to 201.4)	2.7 (-33.1 to 58.4)
Ovarian cancer	1.0 (0.8 to 1.3)	2.2 (1.7 to 2.9)	116.1 (43.8 to 222.4)	15.7 (-24.0 to 71.0)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	108.8 (34.6 to 234.5)	11.5 (-31.4 to 85.4)
Testicular cancer	1.1 (0.6 to 1.6)	2.9 (1.8 to 4.5)	170.0 (48.1 to 374.2)	33.9 (-24.5 to 131.7)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	136.5 (34.8 to 323.3)	16.0 (-32.9 to 97.5)
Kidney cancer	1.6 (1.7 to 5.4)	2.2 (3.7 to 7.9)	40.7 (-14.3 to 239.1)	-26.4 (-28.3 to 65.9)	0.2 (0.1 to 0.4)	0.2 (0.3 to 0.6)	33.3 (-14.4 to 201.8)	-30.7 (-27.5 to 49.2)
Bladder cancer	1.6 (1.2 to 2.0)	2.2 (1.7 to 2.9)	40.7 (3.1 to 93.9)	-26.4 (-46.7 to 3.6)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	33.3 (4.6 to 90.9)	-30.7 (-51.4 to 1.6)
Brain and nervous system cancer	3.4 (1.9 to 5.0)	7.1 (4.8 to 10.1)	109.1 (22.1 to 274.6)	9.0 (-27.4 to 60.6)	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.0)	105.1 (26.5 to 226.4)	3.5 (-28.4 to 44.8)
Thyroid cancer	1.4 (0.8 to 2.5)	3.3 (2.0 to 6.2)	140.1 (18.9 to 349.4)	27.2 (-36.3 to 139.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.4)	119.0 (13.8 to 303.5)	11.8 (-40.8 to 109.6)
Mesothelioma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	59.3 (-0.8 to 147.8)	-16.1 (-46.1 to 32.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.9 (-1.5 to 150.8)	-27.8 (-48.0 to 31.6)
Hodgkin lymphoma	3.0 (1.8 to 4.3)	5.6 (3.4 to 9.5)	82.8 (4.3 to 275.1)	7.8 (-33.3 to 90.3)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.9)	72.7 (6.4 to 204.9)	-4.2 (-38.7 to 56.7)
Non-Hodgkin lymphoma	4.7 (2.8 to 6.9)	9.8 (7.1 to 13.3)	112.8 (24.9 to 275.3)	22.7 (-19.0 to 90.1)	0.4 (0.2 to 0.6)	0.9 (0.6 to 1.2)	112.0 (36.4 to 237.8)	15.4 (-20.0 to 74.6)
Multiple myeloma	0.6 (0.4 to 0.9)	1.4 (1.0 to 1.9)	135.9 (44.9 to 282.5)	19.4 (-26.8 to 95.9)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	123.7 (42.8 to 246.0)	12.5 (-29.9 to 81.3)
Leukemia	18.8 (0.8 to 2.7)	48.3 (2.0 to 4.3)	185.5 (-3.1 to 270.2)	41.3 (-29.7 to 73.9)	1.3 (0.1 to 3.3)	3.2 (0.3 to 6.6)	167.2 (22.7 to 192.5)	24.6 (-28.9 to 47.1)
Other neoplasms	10.1 (10.1 to 35.8)	68.1 (30.0 to 68.1)	442.5 (3.9 to 442.5)	-113.5 (-26.0 to 113.5)	2.5 (0.7 to 2.5)	5.0 (1.9 to 5.0)	353.0 (9.6 to 353.0)	80.5 (-31.0 to 80.5)
Cardiovascular diseases	-	-	-	-	80.1 (56.6 to 111.8)	155.6 (105.9 to 214.7)	95.1 (58.8 to 131.9)	-4.4 (-21.7 to 14.0)
Rheumatic heart disease	295.0 (269.4 to 323.8)	545.1 (486.1 to 605.1)	84.8 (59.2 to 113.6)	-9.1 (-22.6 to 5.4)	14.6 (9.3 to 21.1)	27.6 (17.7 to 40.0)	89.0 (60.6 to 119.4)	-5.2 (-21.1 to 12.2)
Ischemic heart disease	684.2 (556.1 to 853.7)	959.9 (807.4 to 1,123.8)	40.5 (8.0 to 81.8)	-28.3 (-44.1 to -8.4)	37.1 (24.3 to 55.9)	49.6 (32.4 to 73.6)	32.2 (-6.6 to 78.2)	-32.1 (-49.7 to -7.5)
Cerebrovascular disease	-	-	-	-	1.5 (1.0 to 2.0)	3.1 (2.1 to 4.2)	110.3 (76.5 to 155.3)	5.5 (-12.0 to 30.2)
Ischemic stroke	6.8 (6.0 to 7.7)	14.4 (12.9 to 16.2)	110.8 (80.6 to 152.0)	4.9 (-10.8 to 27.7)	1.1 (0.8 to 1.5)	2.3 (1.6 to 3.2)	109.6 (74.1 to 155.5)	5.5 (-12.7 to 31.8)
Hemorrhagic stroke	1.9 (1.6 to 2.2)	4.2 (3.6 to 4.9)	117.7 (73.2 to 170.2)	8.1 (-11.8 to 33.9)	0.3 (0.2 to 0.5)	0.7 (0.5 to 1.0)	116.0 (73.2 to 167.7)	6.7 (-12.9 to 31.5)
Hypertensive heart disease	58.7 (45.6 to 73.0)	118.8 (79.5 to 159.2)	103.2 (24.0 to 196.1)	-7.9 (-42.1 to 34.6)	6.2 (4.2 to 9.1)	12.7 (7.5 to 19.1)	103.3 (23.5 to 195.1)	-7.1 (-42.6 to 31.3)
Cardiomyopathy and myocarditis	69.1 (57.8 to 82.3)	169.6 (135.6 to 231.2)	138.6 (88.0 to 264.7)	16.5 (-12.3 to 92.1)	7.4 (4.9 to 10.6)	18.4 (11.9 to 27.7)	141.7 (87.3 to 264.8)	18.1 (-12.1 to 94.0)
Atrial fibrillation and flutter	21.3 (17.0 to 26.6)	85.4 (62.1 to 108.4)	306.6 (169.8 to 477.5)	86.6 (16.7 to 173.0)	1.6 (1.0 to 2.3)	6.3 (4.0 to 9.2)	305.2 (161.9 to 475.5)	89.4 (16.4 to 175.6)
Peripheral vascular disease	738.7 (520.2 to 936.4)	1,250.9 (869.8 to 1,632.8)	64.9 (7.5 to 176.9)	-16.0 (-46.7 to 32.5)	0.4 (0.2 to 0.8)	0.7 (0.3 to 1.4)	69.9 (-20.8 to 277.4)	-20.5 (-61.6 to 86.5)
Endocarditis	1.3 (0.9 to 1.9)	2.6 (1.4 to 4.0)	99.4 (-6.5 to 214.2)	3.5 (-61.9 to 88.8)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.5)	113.2 (-10.5 to 284.1)	8.5 (-65.9 to 122.1)
Other cardiovascular and circulatory diseases	153.0 (88.0 to 248.9)	528.1 (238.5 to 811.6)	254.1 (40.8 to 599.8)	73.7 (-33.1 to 256.3)	25.1 (5.3 to 18.5)			

Appendix Table G.4 - Ethiopia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	90.4 (83.8 to 97.0)	-6.3 (-9.6 to -3.4)
Silicosis	0.2 (0.2 to 0.2)	0.4 (0.4 to 0.4)	79.3 (71.2 to 88.6)	-11.1 (-15.4 to -6.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	78.8 (70.7 to 88.1)	-11.3 (-15.4 to -6.4)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.2 (0.2 to 0.2)	0.5 (0.4 to 0.5)	102.5 (94.8 to 110.7)	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	101.0 (93.6 to 109.2)	-0.9 (-4.4 to 2.8)
Asthma	1,185.5 (1,026.3 to 1,346.6)	2,807.2 (2,398.7 to 3,233.7)	138.5 (90.8 to 194.6)	8.0 (-8.2 to 25.4)	52.1 (33.7 to 75.1)	124.3 (79.1 to 178.5)	139.8 (91.3 to 196.7)	8.8 (-8.4 to 26.6)
Interstitial lung disease and pulmonary sarcoidosis	0.9 (0.7 to 1.2)	2.1 (1.6 to 2.6)	122.7 (56.8 to 248.2)	9.0 (-19.9 to 60.9)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	123.1 (58.9 to 242.4)	9.2 (-19.4 to 59.7)
Other chronic respiratory diseases	-	-	-	-	46.0 (18.8 to 86.6)	55.0 (27.4 to 95.3)	20.6 (-24.4 to 117.5)	-39.8 (-61.9 to 9.1)
Cirrhosis	-	-	-	-	4.1 (2.8 to 5.6)	6.3 (4.3 to 8.7)	54.4 (34.4 to 75.7)	49.2 (-27.6 to -9.9)
Cirrhosis due to hepatitis B	7.2 (4.6 to 9.5)	10.1 (6.4 to 13.3)	37.8 (-14.9 to 156.2)	-27.6 (53.9 to 38.7)	1.2 (0.6 to 1.9)	1.7 (0.9 to 2.6)	38.3 (-18.6 to 170.1)	27.5 (-56.4 to 43.6)
Cirrhosis due to hepatitis C	3.8 (2.4 to 6.1)	7.1 (3.6 to 10.1)	104.1 (-20.6 to 220.1)	6.4 (-61.6 to 73.8)	0.6 (0.3 to 1.1)	1.2 (0.6 to 1.9)	102.4 (-19.2 to 235.3)	7.3 (-59.8 to 79.0)
Cirrhosis due to alcohol use	6.6 (5.3 to 7.9)	8.2 (6.0 to 10.6)	26.0 (-13.0 to 67.4)	-34.7 (-55.2 to -13.2)	1.1 (0.7 to 1.5)	1.3 (0.8 to 2.0)	26.7 (-15.6 to 80.3)	34.9 (-55.8 to -8.3)
Cirrhosis due to other causes	7.1 (6.0 to 8.0)	12.4 (10.5 to 14.7)	74.1 (45.7 to 125.6)	0.2 (-20.3 to 37.9)	1.2 (0.8 to 1.8)	2.1 (1.3 to 3.1)	75.2 (25.2 to 151.6)	-0.1 (-28.7 to 49.5)
Digestive diseases	-	-	-	-	66.8 (46.7 to 92.3)	124.8 (88.4 to 171.2)	87.4 (72.6 to 99.4)	-12.4 (-18.3 to -6.9)
Peptic ulcer disease	428.4 (400.3 to 451.6)	535.4 (493.8 to 582.5)	25.1 (13.1 to 37.8)	-39.0 (-43.8 to -34.1)	14.8 (10.2 to 20.7)	18.5 (12.5 to 26.8)	25.6 (7.1 to 47.7)	-40.7 (-47.9 to -32.3)
Gastritis and duodenitis	601.4 (549.6 to 652.4)	1,065.2 (996.5 to 1,123.4)	76.5 (62.4 to 95.4)	-13.9 (-21.0 to -5.2)	27.1 (18.2 to 38.7)	52.3 (35.9 to 73.8)	93.8 (76.5 to 111.0)	-9.3 (-17.8 to -2.2)
Appendicitis	6.0 (4.5 to 7.6)	12.6 (9.6 to 15.6)	105.5 (57.3 to 230.7)	-3.3 (-23.5 to 44.8)	1.8 (1.1 to 2.7)	3.8 (2.3 to 5.9)	108.5 (42.7 to 237.0)	-1.4 (-29.7 to 51.3)
Paralytic ileus and intestinal obstruction	0.9 (0.7 to 1.2)	1.5 (1.2 to 2.1)	70.2 (17.2 to 162.6)	-4.0 (-19.0 to 14.7)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	70.1 (7.8 to 179.2)	4.7 (-27.4 to 27.0)
Inguinal, femoral, and abdominal hernia	172.6 (145.0 to 230.8)	561.8 (474.4 to 669.2)	234.5 (122.3 to 317.2)	148.8 (101.8 to 198.5)	1.8 (0.8 to 3.7)	5.8 (2.8 to 11.0)	225.8 (114.7 to 315.9)	145.9 (97.7 to 195.6)
Inflammatory bowel disease	43.5 (41.5 to 45.5)	110.1 (105.1 to 114.9)	25.6 (137.8 to 170.1)	25.6 (18.5 to 32.9)	9.1 (6.3 to 12.4)	23.4 (16.1 to 32.3)	155.4 (132.8 to 181.5)	26.8 (16.9 to 36.9)
Vascular disorders	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	103.7 (45.2 to 170.7)	-6.2 (-37.4 to 55.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	107.8 (49.1 to 179.0)	1.9 (-34.7 to 72.1)
Galbladder and biliary diseases	15.0 (13.4 to 16.6)	33.5 (29.7 to 37.8)	123.1 (89.9 to 161.5)	13.7 (-2.7 to 33.2)	1.6 (1.0 to 2.2)	3.5 (2.3 to 4.9)	122.9 (84.0 to 171.9)	4.4 (-3.7 to 36.2)
Pancreatitis	7.7 (7.3 to 8.2)	16.0 (15.9 to 17.7)	117.3 (101.5 to 134.6)	5.5 (-2.0 to 13.8)	2.3 (1.5 to 3.1)	5.0 (3.4 to 6.8)	120.4 (83.0 to 161.2)	6.9 (-8.5 to 24.9)
Other digestive diseases	-	-	-	-	8.1 (4.5 to 13.3)	11.9 (7.4 to 18.9)	50.1 (3.3 to 124.5)	-30.1 (-52.1 to 6.0)
Neurological disorders	-	-	-	-	130.4 (88.4 to 180.1)	314.5 (213.5 to 444.1)	142.0 (104.8 to 179.1)	12.3 (-4.2 to 28.6)
Alzheimer disease and other dementias	69.8 (62.5 to 78.0)	163.7 (142.0 to 184.0)	134.5 (96.8 to 174.3)	3.8 (-12.8 to 22.4)	9.4 (6.8 to 12.2)	22.5 (15.8 to 29.6)	128.9 (102.3 to 181.2)	4.4 (-12.7 to 23.4)
Parkinson disease	1.9 (1.4 to 2.5)	4.2 (3.1 to 5.5)	115.6 (93.8 to 136.5)	6.1 (-3.2 to 15.4)	0.2 (0.1 to 0.4)	0.5 (0.3 to 0.8)	113.3 (70.0 to 164.6)	5.6 (-16.4 to 31.2)
Epilepsy	59.0 (33.4 to 93.1)	121.3 (66.8 to 194.1)	102.7 (-4.8 to 346.8)	1.4 (-52.6 to 125.6)	15.9 (8.0 to 27.5)	33.9 (16.3 to 57.3)	111.4 (0.4 to 362.1)	5.4 (-50.6 to 130.8)
Multiple sclerosis	2.5 (2.2 to 2.8)	5.8 (5.2 to 6.5)	129.9 (97.9 to 173.9)	15.4 (0.4 to 36.0)	0.9 (0.6 to 1.2)	2.0 (1.4 to 2.7)	128.0 (80.6 to 191.1)	14.3 (-10.7 to 45.3)
Migraine	1,619.7 (1,450.2 to 1,786.5)	3,880.9 (3,175.4 to 3,964.5)	241.7 (89.0 to 153.8)	6.9 (-6.3 to 22.5)	95.7 (32.5 to 121.5)	122.7 (72.4 to 184.6)	183.1 (84.0 to 159.6)	9.9 (-6.9 to 24.6)
Tension-type headache	5,433.5 (5,025.0 to 5,857.1)	12,122.7 (11,082.1 to 13,282.1)	122.9 (98.5 to 150.1)	4.3 (-5.2 to 15.4)	8.2 (4.0 to 14.4)	8.2 (4.0 to 32.3)	124.6 (98.4 to 153.8)	5.2 (-4.8 to 16.7)
Medication overuse headache	206.5 (132.5 to 286.2)	636.4 (393.8 to 873.8)	209.5 (109.9 to 333.1)	53.9 (9.8 to 117.6)	32.2 (17.5 to 51.0)	100.0 (54.4 to 158.6)	211.8 (107.0 to 334.9)	55.6 (9.1 to 118.9)
Other neurological disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	89.3 (43.2 to 164.1)	-4.2 (-27.2 to 32.1)	8.4 (4.3 to 14.1)	14.4 (8.9 to 21.3)	73.9 (-0.2 to 216.3)	-23.1 (-56.7 to 38.6)
Mental and substance use disorders	-	-	-	-	1,052.8 (756.0 to 1,405.1)	2,229.7 (1,602.5 to 2,983.5)	111.7 (104.6 to 119.1)	2.5 (-0.8 to 5.8)
Schizophrenia	97.6 (89.4 to 105.1)	198.4 (180.7 to 213.1)	103.4 (95.1 to 111.3)	1.2 (-2.6 to 5.0)	1.2 (44.4 to 75.0)	1.2 (91.8 to 154.7)	106.1 (92.2 to 119.6)	2.3 (-4.0 to 8.5)
Alcohol use disorders	493.9 (459.4 to 533.8)	894.6 (834.4 to 963.1)	81.3 (71.9 to 90.4)	-13.3 (-17.9 to -9.2)	48.3 (32.4 to 67.8)	88.0 (58.0 to 124.6)	82.3 (71.4 to 94.1)	-12.9 (-18.1 to -7.6)
Drug use disorders	-	-	-	-	56.0 (37.7 to 78.2)	118.8 (77.8 to 163.5)	111.8 (87.3 to 139.7)	2.4 (-8.5 to 15.3)
Opioid use disorders	71.3 (47.7 to 100.5)	149.6 (97.7 to 219.1)	108.6 (84.8 to 141.1)	3.6 (-6.5 to 18.3)	29.0 (16.7 to 44.8)	61.6 (35.9 to 96.3)	111.4 (84.6 to 145.9)	5.1 (-7.1 to 20.8)
Cocaine use disorders	18.9 (18.9 to 26.1)	48.1 (40.2 to 55.8)	254.5 (65.1 to 166.9)	11.1 (-1.7 to 26.3)	6.6 (1.9 to 6.4)	11.6 (4.1 to 9.6)	106.1 (54.5 to 195.6)	3.0 (-22.5 to 38.1)
Amphetamine use disorders	73.4 (67.8 to 78.7)	151.7 (139.0 to 163.1)	106.6 (84.4 to 131.5)	-5.3 (-14.6 to 5.0)	9.6 (5.9 to 14.2)	20.0 (12.3 to 29.5)	108.8 (75.5 to 145.1)	-4.5 (-18.5 to 12.4)
Cannabis use disorders	58.2 (43.2 to 70.9)	127.0 (93.8 to 155.3)	118.4 (116.9 to 119.5)	0.2 (0.1 to 0.2)	1.7 (1.0 to 2.6)	3.7 (2.1 to 5.8)	120.6 (82.5 to 166.9)	1.2 (-15.0 to 20.5)
Other drug use disorders	-	-	-	-	12.7 (8.0 to 18.1)	26.9 (16.3 to 40.3)	111.9 (55.3 to 188.2)	-1.7 (-26.0 to 32.2)
Depressive disorders	-	-	-	-	966.0 (292.2 to 636.2)	966.0 (635.2 to 1,393.8)	118.0 (106.4 to 133.1)	5.5 (-0.3 to 11.9)
Major depressive disorder	1,939.8 (1,502.6 to 2,362.1)	4,231.6 (3,318.0 to 5,165.9)	117.9 (105.3 to 134.8)	5.4 (-1.0 to 12.5)	396.9 (257.1 to 573.0)	872.7 (568.3 to 1,264.5)	119.5 (106.8 to 136.0)	6.2 (-0.4 to 13.6)
Dysthymia	475.7 (382.7 to 575.3)	968.4 (777.6 to 1,172.4)	103.8 (88.9 to 115.5)	-0.3 (-6.6 to 5.4)	45.5 (29.1 to 67.2)	93.3 (59.6 to 137.0)	104.6 (90.6 to 118.2)	0.2 (-6.1 to 6.4)
Bipolar disorder	252.8 (217.2 to 287.2)	528.2 (452.6 to 604.6)	108.2 (96.8 to 122.3)	-0.2 (-4.8 to 5.3)	51.0 (31.2 to 77.0)	107.8 (66.8 to 162.8)	110.8 (95.4 to 129.0)	0.8 (-5.5 to 8.1)
Anxiety disorders	1,960.6 (1,214.1 to 2,741.7)	3,999.9 (2,327.5 to 5,801.2)	102.8 (79.9 to 124.8)	2.5 (-12.9 to 7.6)	192.7 (97.1 to 292.1)	396.1 (189.4 to 610.8)	184.0 (79.7 to 129.3)	-1.9 (-13.2 to 8.1)
Eating disorders	-	-	-	-	11.1 (6.7 to 17.6)	24.6 (14.7 to 38.4)	121.3 (103.0 to 141.9)	0.8 (-7.3 to 10.1)
Anorexia nervosa	7.6 (5.6 to 9.8)	17.5 (13.2 to 23.2)	129.2 (101.0 to 159.8)	5.1 (-7.6 to 18.9)	1.6 (1.0 to 2.5)	3.7 (2.2 to 5.8)	130.3 (78.1 to 200.3)	6.2 (-17.3 to 36.2)
Bulimia nervosa	45.3 (31.0 to 66.0)	98.8 (67.6 to 144.0)	118.3 (115.9 to 119.7)	-0.6 (-0.8 to -0.4)	9.5 (5.5 to 15.5)	20.9 (12.0 to 33.8)	119.8 (99.5 to 142.1)	0.0 (-9.0 to 10.0)
Autistic spectrum disorders	-	-	-	-	96.7 (39.5 to 77.1)	113.5 (78.8 to 154.0)	100.3 (92.1 to 107.9)	0.8 (-2.8 to 4.0)
Autism	145.7 (138.3 to 153.4)	290.6 (275.6 to 305.9)	99.4 (99.0 to 99.9)	0.1 (0.1 to 0.1)	0.1 (23.8 to 49.4)	0.1 (47.9 to 98.3)	100.7 (89.7 to 111.9)	0.9 (-4.1 to 5.4)
Asperger syndrome	209.9 (196.8 to 222.2)	416.9 (390.7 to 441.6)	98.6 (98.0 to 99.3)	0.1 (0.1 to 0.1)	20.9 (14.5 to 29.2)	41.7 (28.9 to 57.8)	99.5 (91.1 to 109.2)	0.6 (-3.1 to 4.6)
Attention-deficit/hyperactivity disorder	347.7 (321.1 to 376.0)	723.5 (667.8 to 781.8)	108.2 (107.8 to 108.2)	0.2 (0.2 to 0.2)	4.2 (2.5 to 6.4)	8.8 (5.2 to 13.3)	108.4 (92.8 to 124.9)	0.4 (-6.8 to 8.3)
Conduct disorder	50.6 (47.8 to 53.8)	1,079.7 (1,017.9 to 1,143.7)	12.6 (111.9 to 113.3)	6.7 (0.1 to 0.1)	60.7 (81.3 to 88.0)	129.7 (81.3 to 187.9)	118.8 (104.3 to 123.6)	0.7 (-3.8 to 5.3)
Idiopathic intellectual disability	797.1 (255.9 to 1,165.1)	1,814.2 (1,074.8 to 2,400.0)	121.4 (82.5 to 355.6)	16.8 (-5.1 to 141.2)	38.8 (11.2 to 63.3)	88.6 (48.6 to 135.0)	121.9 (83.8 to 356.0)	15.9 (-4.6 to 145.2)
Other mental and substance use disorders	566.1 (528.5 to 600.5)	1,173.0 (1,093.4 to 1,247.6)	107.1 (106.0 to 108.2)	-0.1 (-0.3 to 0.0)	41.9 (28.6 to 56.0)	87.4 (59.7 to 117.6)	108.8 (100.7 to 117.3)	0.7 (-2.9 to 4.3)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	222.3 (157.3 to 299.8)	439.5 (305.5 to 588.7)	97.9 (83.8 to 112.2)	1.9 (-5.2 to 9.1)
Diabetes mellitus	289.7 (227.5 to 369.3)	811.4 (651.5 to 1,002.8)	177.4 (110.3 to 276.8)	40.4 (4.8 to 89.5)	23.0 (15.1 to 33.1)	63.2 (41.2 to 93.0)	173.8 (103.8 to 264.2)	38.8 (2.0 to 83.5)
Acute glomerulonephritis	0.6 (0.5 to 0.6)	0.8 (0.7 to 0.9)	36.0 (25.6 to 45.6)	0.0 (-27.6 to -19.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.3 (25.5 to 45.6)	36.0 (-27.7 to 15.1)
Chronic kidney disease	-	-	-	-	76.6 (54.4 to 99.9)	159.6 (113.4 to 212.6)	108.2 (86.8 to 130.6)	2.3 (-8.1 to 12.9)
Chronic kidney disease due to diabetes mellitus	669.0 (408.4 to 1,110.2)	1,227.1 (770.1 to 1,817.4)	84.4 (29.0 to 165.8)	-5.3 (-31.5 to 42.6)	10.0 (6.5 to 14.8)	18.5 (12.3 to 26.1)	86.6 (32.5 to 157.1)	-4.4 (-30.5 to 36.4)
Chronic kidney disease due to hypertension	1,827.2 (1,158.7 to 2,823.4)	3,837.8 (2,379.2 to 6,144.4)	105.8 (68.5 to 177.2)	6.5 (-11.5 to 44.8)	23.5 (16.7 to 31.3)	48.8 (33.2 to 66.1)	106.3 (74.0 to 147.8)	0.0 (-15.4 to 20.3)
Chronic kidney disease due to glomerulonephritis	1,975.9 (1,200.3 to 2,412.7)	1,386.0 (2,282.9 to 4,769.7)	100.7 (68.5 to 153.0)	25.6 (-18.5 to 26.2)	100.7 (17.7 to 34.5)	25.6 (40.2 to 76.6)	116.3 (82.9 to 175.1)	11.5 (-8.8 to 39.9)
Chronic kidney disease due to other causes	1,339.1 (837.6 to 2,381.6)	2,468.5 (1,598.2 to 4,031.5)	90.2 (38.1 to 148.1)	-6.8 (-24.8 to 17.8)	17.3 (12.1 to 23.6)	34.7 (20.4 to 47.1)	99.9 (57.5 to 155.8)	-4.0 (-24.2 to 24.2)
Urinary diseases and male infertility	-	-	-	-	14.0 (9.0 to 20.2)	28.0 (17.9 to 40.0)	100.2 (78.5 to 124.5)	-2.8 (-12.6 to 8.4)

Appendix Table G.4 - Ethiopia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	9.0 (8.5 to 9.5)	19.2 (18.0 to 20.4)	113.1 (94.6 to 132.2)	0.3 (-1.2 to 15.2)	0.3 (0.2 to 0.5)	0.6 (0.4 to 1.0)	114.6 (69.7 to 173.8)	7.1 (-11.6 to 29.0)
Urolithiasis	114.3 (84.6 to 144.8)	173.8 (126.4 to 223.7)	50.6 (26.1 to 91.2)	-24.5 (-35.8 to -5.8)	0.8 (0.5 to 1.2)	1.8 (1.1 to 2.5)	109.8 (78.6 to 145.4)	5.3 (-8.0 to 20.1)
Benign prostatic hyperplasia	313.3 (285.0 to 342.0)	619.4 (562.2 to 674.9)	97.3 (73.9 to 124.0)	-4.3 (-15.3 to 7.7)	11.0 (7.0 to 15.4)	21.8 (14.0 to 30.9)	98.5 (74.8 to 125.5)	-3.2 (-14.2 to 9.2)
Male infertility due to other causes	253.6 (163.1 to 371.4)	531.8 (353.2 to 769.2)	113.6 (81.1 to 146.1)	3.0 (-3.5 to 9.5)	1.6 (0.6 to 3.5)	3.3 (1.3 to 7.2)	108.6 (22.1 to 264.0)	1.1 (-41.9 to 75.7)
Other urinary diseases	-	-	-	-	0.3 (0.2 to 0.5)	0.5 (0.2 to 0.9)	52.1 (11.9 to 149.3)	-2.7 (-55.3 to 24.4)
Gynecological diseases	-	-	-	-	41.1 (26.4 to 60.8)	79.4 (49.9 to 121.6)	91.1 (62.0 to 139.7)	-7.4 (-20.3 to 13.9)
Uterine fibroids	721.6 (653.2 to 784.2)	1,380.1 (1,245.3 to 1,505.0)	91.2 (90.1 to 92.3)	-0.8 (-0.9 to -0.7)	8.6 (4.8 to 14.5)	11.6 (5.7 to 20.8)	32.1 (9.0 to 56.5)	-29.6 (-41.4 to -16.0)
Polycystic ovarian syndrome	655.3 (591.7 to 725.0)	1,412.2 (1,239.7 to 1,564.0)	116.3 (82.6 to 147.3)	3.0 (-11.2 to 16.8)	6.4 (3.1 to 12.2)	13.8 (6.4 to 26.3)	118.4 (84.1 to 150.0)	3.6 (-10.4 to 17.6)
Female infertility due to other causes	252.8 (152.2 to 352.0)	542.3 (369.4 to 726.1)	114.6 (82.5 to 146.7)	5.1 (-3.7 to 85.8)	1.3 (0.5 to 2.9)	2.8 (1.1 to 6.2)	115.8 (32.0 to 276.3)	5.1 (-36.8 to 84.2)
Endometriosis	67.7 (57.2 to 78.4)	122.2 (102.6 to 141.5)	80.4 (41.9 to 126.9)	-11.2 (-30.8 to 10.1)	6.2 (4.0 to 9.1)	11.3 (7.4 to 15.9)	81.5 (40.4 to 132.7)	-10.9 (-30.6 to 12.5)
Genital prolapse	1,194.9 (1,019.0 to 1,347.7)	2,503.5 (2,146.3 to 2,856.8)	109.7 (71.4 to 158.5)	5.2 (-11.8 to 27.1)	3.8 (1.8 to 7.0)	7.9 (3.8 to 15.4)	109.6 (71.1 to 162.6)	5.5 (-12.0 to 28.6)
Premenstrual syndrome	1,521.8 (1,031.3 to 1,938.2)	3,658.0 (2,501.5 to 4,850.3)	133.4 (56.4 to 327.5)	9.0 (-28.8 to 99.3)	12.7 (7.1 to 20.3)	30.8 (16.5 to 50.4)	134.2 (55.6 to 329.5)	9.9 (-28.3 to 101.1)
Other gynecological diseases	80.5 (60.1 to 103.2)	59.8 (49.9 to 72.8)	26.1 (-46.1 to 6.9)	-42.3 (-71.6 to -47.7)	2.1 (1.0 to 3.1)	1.1 (0.7 to 1.7)	47.2 (-65.8 to 16.8)	-69.8 (-80.5 to -41.2)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	44.2 (29.2 to 63.1)	77.6 (51.3 to 112.4)	75.6 (58.3 to 99.3)	-12.5 (-21.7 to -2.5)
Thalassemias	3.1 (2.5 to 3.7)	5.6 (4.7 to 6.5)	80.3 (57.4 to 105.1)	-5.2 (-17.5 to 9.3)	0.3 (0.2 to 0.5)	0.6 (0.3 to 0.9)	65.2 (10.5 to 145.8)	-13.2 (-39.6 to 24.9)
Thalassemia trait	1,072.4 (990.1 to 1,169.8)	2,176.2 (2,035.4 to 2,330.8)	103.0 (93.0 to 112.7)	3.8 (-1.5 to 9.1)	24.8 (16.7 to 35.7)	52.4 (35.2 to 75.4)	112.2 (87.7 to 133.0)	4.1 (-12.3 to 17.3)
Sickle cell disorders	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	70.9 (61.1 to 84.7)	-8.7 (-14.2 to -1.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.0 (70.6 to 105.0)	-1.2 (-9.4 to 9.9)
Sickle cell trait	287.1 (274.9 to 301.1)	501.3 (471.7 to 527.4)	74.5 (64.5 to 87.5)	-11.2 (-16.0 to -4.5)	1.2 (0.5 to 2.0)	3.2 (1.4 to 5.0)	160.8 (24.8 to 471.8)	26.7 (-31.3 to 167.3)
G6PD deficiency	2,205.8 (1,273.6 to 3,066.6)	5,892.5 (4,014.6 to 7,914.9)	170.5 (52.1 to 380.3)	37.3 (-22.9 to 145.3)	0.3 (0.2 to 0.5)	0.6 (0.3 to 1.1)	64.9 (10.3 to 261.4)	-21.4 (-43.4 to 69.7)
G6PD trait	9,741.6 (8,014.1 to 10,954.0)	18,893.0 (16,195.6 to 20,887.5)	94.0 (59.3 to 147.8)	-0.7 (-18.4 to 26.9)	1.0 (0.1 to 0.6)	1.0 (0.2 to 1.6)	152.7 (52.9 to 1,002.8)	34.5 (-7.1 to 500.7)
Other hemoglobinopathies and hemolytic anemias	542.9 (450.6 to 612.4)	664.5 (575.1 to 755.1)	22.5 (4.2 to 46.2)	-41.7 (-49.1 to -33.3)	17.1 (10.2 to 25.2)	19.9 (12.3 to 30.5)	16.6 (-9.8 to 50.6)	-42.6 (-55.6 to -27.9)
Endocrine, metabolic, blood, and immune disorders	657.1 (611.2 to 704.9)	900.6 (721.0 to 1,065.9)	37.1 (10.9 to 66.6)	29.1 (-38.5 to -18.1)	23.4 (15.6 to 33.7)	31.6 (20.1 to 46.0)	26.4 (-2.8 to 68.2)	-24.4 (-42.4 to -12.5)
Musculoskeletal disorders	-	-	-	-	484.8 (343.3 to 651.3)	1,026.7 (723.4 to 1,364.9)	112.5 (90.9 to 134.9)	4.5 (-3.8 to 13.6)
Rheumatoid arthritis	108.5 (104.2 to 112.9)	187.9 (180.0 to 195.3)	73.0 (63.1 to 83.4)	-15.6 (-20.7 to -10.8)	25.6 (18.0 to 33.8)	44.5 (31.4 to 58.4)	74.1 (59.6 to 88.6)	-15.0 (-21.1 to -8.8)
Osteoarthritis	884.9 (851.6 to 923.2)	1,797.8 (1,732.2 to 1,858.0)	103.3 (92.2 to 113.9)	2.5 (-3.1 to 7.6)	53.4 (37.2 to 72.0)	108.9 (76.2 to 147.8)	104.4 (92.1 to 115.0)	3.3 (-2.6 to 8.3)
Low back and neck pain	-	-	-	-	359.2 (250.6 to 491.1)	752.3 (521.7 to 1,013.2)	110.4 (83.4 to 139.7)	2.5 (-9.0 to 15.4)
Low back pain	1,816.6 (1,711.7 to 1,931.1)	3,608.3 (3,384.2 to 3,845.7)	98.5 (81.2 to 116.1)	-2.0 (-9.8 to 6.5)	199.9 (134.8 to 275.9)	400.2 (269.3 to 553.6)	100.2 (81.9 to 117.9)	-1.2 (-9.1 to 7.4)
Neck pain	1,634.1 (1,345.6 to 1,951.4)	3,586.3 (2,953.2 to 4,183.4)	119.5 (65.0 to 192.3)	5.6 (-16.1 to 35.0)	159.4 (106.6 to 231.3)	352.1 (233.2 to 500.0)	121.4 (66.7 to 197.3)	6.6 (-15.8 to 37.1)
Gout	6.3 (5.5 to 7.0)	12.7 (11.2 to 14.1)	103.7 (71.4 to 139.3)	1.9 (-14.8 to 18.6)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	105.6 (58.1 to 164.7)	3.1 (-21.1 to 31.9)
Other musculoskeletal disorders	517.7 (293.2 to 765.8)	1,330.0 (866.5 to 1,791.0)	154.0 (116.1 to 252.1)	25.8 (8.3 to 66.1)	46.4 (22.9 to 77.1)	120.6 (71.0 to 187.9)	27.6 (117.5 to 259.6)	27.6 (9.3 to 70.3)
Other non-communicable diseases	-	-	-	-	765.8 (502.8 to 1,118.4)	1,463.1 (966.2 to 2,131.5)	91.1 (82.4 to 98.9)	-4.5 (-8.6 to -1.4)
Congenital anomalies	-	-	-	-	39.6 (25.4 to 58.4)	95.0 (63.5 to 133.0)	140.6 (105.0 to 183.3)	21.4 (4.9 to 42.0)
Neural tube defects	2.3 (1.9 to 2.9)	20.2 (17.7 to 23.2)	785.0 (594.3 to 1,022.3)	462.8 (332.2 to 621.1)	0.5 (0.3 to 0.7)	5.5 (3.7 to 7.7)	981.8 (690.5 to 1,446.8)	617.8 (431.9 to 920.7)
Congenital heart anomalies	17.0 (10.9 to 25.9)	187.9 (137.6 to 245.9)	1,008.7 (565.7 to 1,792.1)	623.4 (316.9 to 1,491.1)	0.7 (0.3 to 1.3)	6.3 (2.5 to 11.6)	796.3 (399.9 to 1,496.5)	473.6 (217.2 to 965.6)
Orofacial clefts	2.0 (1.3 to 3.1)	28.8 (20.0 to 39.1)	925.0 (770.8 to 2,225.8)	0.0 (-504.5 to 1,701.9)	0.5 (0.0 to 0.1)	0.5 (0.3 to 0.8)	1,299.0 (663.9 to 2,398.4)	925.5 (453.3 to 1,816.0)
Down syndrome	15.4 (11.2 to 19.4)	68.8 (55.0 to 83.4)	348.8 (220.0 to 536.9)	167.0 (89.1 to 281.4)	1.7 (1.1 to 2.5)	8.0 (5.4 to 11.2)	363.7 (222.0 to 575.3)	183.6 (94.6 to 322.7)
Turner syndrome	0.8 (0.5 to 1.1)	2.9 (2.2 to 4.0)	250.9 (143.4 to 513.7)	91.7 (32.3 to 241.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	260.2 (146.2 to 539.1)	93.7 (31.8 to 246.4)
Klinefelter syndrome	1.3 (1.0 to 1.7)	2.7 (2.0 to 3.7)	105.4 (35.1 to 179.7)	6.7 (-23.8 to 45.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	114.6 (40.5 to 192.2)	7.0 (-29.7 to 45.9)
Chromosomal unbalanced rearrangements	25.9 (19.5 to 33.8)	113.9 (93.2 to 138.6)	336.7 (231.5 to 531.9)	192.3 (97.1 to 279.5)	13.2 (1.9 to 4.3)	13.2 (0.1 to 18.3)	340.9 (234.5 to 559.1)	375.0 (103.8 to 305.4)
Other congenital anomalies	345.4 (251.9 to 425.2)	613.5 (428.4 to 783.5)	77.8 (50.2 to 105.5)	-10.3 (-24.2 to 3.5)	33.7 (20.5 to 51.7)	61.3 (35.7 to 92.8)	81.1 (51.7 to 115.2)	-8.8 (-23.6 to 8.8)
Skin and subcutaneous diseases	-	-	-	-	276.5 (174.0 to 431.2)	545.7 (346.1 to 849.3)	97.3 (89.0 to 107.2)	-1.6 (-6.2 to 3.8)
Dermatitis	1,921.8 (1,569.2 to 2,338.0)	3,879.7 (3,148.1 to 4,731.1)	101.8 (99.5 to 104.2)	0.0 (-0.0 to 0.1)	70.8 (45.3 to 102.9)	142.8 (91.4 to 209.7)	101.6 (93.8 to 109.5)	0.5 (-2.3 to 3.7)
Psoriasis	282.6 (245.4 to 323.1)	578.6 (500.5 to 662.5)	104.7 (102.8 to 106.3)	0.0 (-0.1 to 0.1)	0.0 (15.6 to 32.1)	0.2 (32.2 to 66.4)	106.2 (92.7 to 121.4)	0.7 (-4.9 to 6.7)
Cellulitis	10.6 (8.5 to 12.7)	19.3 (15.0 to 24.3)	82.5 (51.2 to 119.3)	-8.4 (-26.7 to 12.5)	0.8 (0.5 to 1.1)	1.4 (0.8 to 2.1)	82.3 (33.7 to 142.1)	-7.8 (-29.7 to 19.2)
Pyoderma	83.4 (61.5 to 107.5)	142.4 (106.9 to 182.0)	71.0 (58.7 to 85.4)	-4.1 (-10.5 to 3.1)	0.5 (0.2 to 1.1)	0.8 (0.3 to 1.8)	71.0 (53.5 to 91.2)	-4.1 (-13.0 to 6.1)
Scabies	958.6 (690.0 to 1,332.5)	1,308.3 (1,076.8 to 1,576.9)	38.3 (-7.7 to 102.2)	-33.1 (-55.4 to 0.5)	24.7 (12.7 to 42.1)	38.8 (18.4 to 55.6)	38.8 (-7.8 to 103.6)	-32.8 (-55.4 to 1.5)
Fungal skin diseases	11,483.4 (10,017.6 to 13,098.3)	22,980.9 (19,589.9 to 25,649.2)	96.7 (94.1 to 99.6)	96.7 (81.0 to 124.2)	62.2 (26.6 to 135.8)	62.2 (52.5 to 267.9)	92.2 (94.2 to 100.3)	0.2 (-0.4 to 1.1)
Viral skin diseases	1,651.9 (1,371.0 to 1,922.7)	3,297.3 (2,717.1 to 3,882.1)	99.6 (92.7 to 106.3)	-0.0 (-2.1 to 2.4)	50.9 (31.5 to 76.7)	101.9 (63.1 to 153.7)	100.4 (91.5 to 108.8)	0.4 (-2.9 to 3.5)
Acne vulgaris	528.8 (375.4 to 696.0)	1,230.7 (940.1 to 1,577.3)	130.7 (51.5 to 264.4)	6.1 (-28.4 to 62.9)	5.7 (2.5 to 11.0)	13.3 (5.9 to 25.5)	132.0 (50.9 to 267.0)	6.9 (-28.3 to 64.5)
Alopecia areata	42.8 (37.8 to 47.9)	85.7 (76.4 to 95.7)	100.4 (72.0 to 136.0)	0.2 (-15.4 to 17.1)	1.4 (0.9 to 2.2)	2.9 (1.8 to 4.3)	100.8 (66.3 to 145.5)	0.7 (-1.6 to 20.3)
Pruritus	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	95.4 (59.6 to 146.8)	0.6 (-21.8 to 26.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.4 (57.9 to 147.5)	-0.6 (-21.9 to 26.6)
Urticaria	211.7 (132.9 to 314.0)	534.1 (377.0 to 696.6)	151.1 (68.4 to 324.8)	14.5 (-26.0 to 100.8)	12.5 (6.9 to 21.4)	12.5 (18.8 to 49.5)	31.7 (67.6 to 326.1)	15.8 (-25.8 to 104.2)
Decubitus ulcer	5.4 (4.6 to 6.4)	11.5 (9.9 to 13.1)	112.4 (68.3 to 165.6)	-1.5 (-27.9 to 31.9)	0.8 (0.5 to 1.1)	1.7 (1.1 to 2.4)	111.9 (65.2 to 167.8)	-0.4 (-29.6 to 32.6)
Other skin and subcutaneous diseases	3,505.9 (2,382.0 to 4,792.4)	6,716.5 (4,525.8 to 9,213.7)	91.3 (84.0 to 98.9)	-4.4 (-4.6 to -1.2)	20.6 (9.2 to 42.8)	39.7 (17.8 to 81.4)	92.3 (84.5 to 100.2)	-3.8 (-8.1 to -0.5)
Sense organ diseases	-	-	-	-	364.8 (244.3 to 530.7)	653.1 (429.6 to 947.2)	79.0 (63.2 to 91.5)	-7.9 (-13.9 to -3.1)
Glaucoma	85.3 (73.1 to 101.7)	216.7 (185.6 to 255.2)	154.2 (120.2 to 197.0)	22.7 (5.8 to 48.1)	10.5 (7.1 to 15.0)	24.3 (16.4 to 34.7)	131.0 (95.5 to 174.7)	10.2 (-9.9 to 39.2)
Cataract	199.9 (168.2 to 232.9)	482.0 (403.7 to 550.3)	141.7 (96.4 to 183.8)	18.5 (-1.9 to 38.6)	21.3 (14.7 to 29.7)	49.2 (33.3 to 68.7)	132.6 (86.7 to 173.4)	14.8 (-6.8 to 32.7)
Macular degeneration	26.8 (20.3 to 34.7)	96.0 (73.5 to 118.2)	257.4 (155.3 to 400.8)	85.0 (30.1 to 158.6)	1.5 (1.0 to 2.2)	5.4 (3.5 to 7.7)	259.9 (158.1 to 399.6)	81.1 (30.8 to 149.4)
Uncorrected refractive error	3,566.5 (3,338.4 to 3,810.2)	6,679.8 (6,252.2 to 7,099.1)	87.3 (71.8 to 103.5)	6.0 (-13.2 to 0.9)	86.6 (59.1 to 124.2)	153.1 (103.2 to 223.8)	76.5 (68.2 to 86.0)	-12.1 (-15.4 to -7.7)
Age-related and other hearing loss	6,378.3 (5,426.9 to 7,203.5)	11,565.9 (9,635.1 to 13,179.9)	81.0 (72.2 to 91.8)	-7.6 (-10.8 to -3.8)	206.9 (127.8 to 310.9)	206.9 (210.5 to 531.4)	134.4 (46.8 to 89.9)	68.9 (-22.0 to -6.4)
Other vision loss	118.4 (101.1 to 136.5)	219.2 (188.5 to 250.1)	94.3 (66.0 to 113.2)	-1.9 (-12.0 to 13.1)	7.5 (5.1 to 10.4)	14.0 (9.6 to 19.8)	85.9 (6	

Appendix Table G.4 - Ethiopia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	823.3 (768.3 to 881.2)	1,547.5 (1,456.5 to 1,646.5)	87.7 (70.7 to 106.5)	-7.2 (-15.0 to 1.2)	22.3 (15.2 to 31.3)	42.2 (28.5 to 58.2)	88.5 (71.0 to 107.1)	-6.6 (-14.4 to 2.2)
Other oral disorders	682.1 (644.2 to 721.6)	1,390.8 (1,312.0 to 1,470.4)	103.6 (89.5 to 121.6)	-0.7 (-7.4 to 7.3)	19.9 (12.6 to 29.6)	40.8 (25.5 to 61.0)	104.5 (88.8 to 123.6)	-0.3 (-7.6 to 7.9)
Injuries	-	-	-	-	588.8 (329.0 to 1,108.3)	539.5 (363.2 to 833.8)	-4.6 (-28.0 to 19.6)	-43.8 (-55.5 to -31.8)
Transport injuries	-	-	-	-	37.9 (28.6 to 49.1)	67.7 (51.2 to 87.3)	78.4 (72.9 to 85.3)	-8.0 (-10.4 to -5.0)
Road injuries	-	-	-	-	29.8 (22.5 to 38.5)	57.7 (43.5 to 74.3)	-1.1 (86.5 to 101.7)	-1.1 (-4.5 to 2.3)
Pedestrian road injuries	-	-	-	-	10.4 (7.9 to 13.3)	19.5 (14.7 to 25.1)	87.9 (75.0 to 102.0)	-3.4 (-8.6 to 1.8)
Cyclist road injuries	-	-	-	-	2.6 (2.0 to 3.4)	4.5 (3.4 to 5.9)	71.5 (59.9 to 82.6)	-10.5 (-17.3 to -5.2)
Motorcyclist road injuries	-	-	-	-	3.3 (2.5 to 4.2)	4.7 (3.6 to 6.1)	44.9 (37.3 to 53.8)	-24.8 (-28.5 to -21.0)
Motor vehicle road injuries	-	-	-	-	13.1 (9.8 to 16.8)	28.4 (21.5 to 36.4)	116.9 (106.1 to 129.7)	9.6 (4.5 to 15.6)
Other road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.6)	18.4 (11.6 to 23.8)	-40.3 (-43.3 to -37.6)
Other transport injuries	-	-	-	-	8.1 (6.1 to 10.4)	10.0 (7.5 to 12.9)	23.2 (16.9 to 30.3)	-32.9 (-36.7 to -28.3)
Unintentional injuries	-	-	-	-	119.5 (91.2 to 153.8)	235.3 (180.4 to 302.3)	96.9 (89.9 to 104.8)	-0.2 (-3.3 to 3.5)
Falls	-	-	-	-	50.3 (38.1 to 64.9)	115.6 (87.7 to 149.1)	130.0 (117.4 to 142.1)	10.3 (5.1 to 16.1)
Drowning	-	-	-	-	2.3 (1.7 to 3.0)	3.4 (2.5 to 4.4)	47.8 (34.4 to 62.0)	-22.7 (-28.5 to -16.7)
Fire, heat, and hot substances	-	-	-	-	11.7 (9.0 to 14.9)	18.9 (14.4 to 24.1)	61.4 (48.3 to 77.7)	-15.5 (-21.0 to -9.0)
Poisonings	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	43.7 (24.6 to 69.5)	-27.0 (-34.8 to -16.9)
Exposure to mechanical forces	-	-	-	-	24.1 (18.3 to 31.4)	43.5 (33.1 to 56.7)	81.0 (73.1 to 89.0)	-7.8 (-11.4 to -3.8)
Unintentional firearm injuries	-	-	-	-	0.8 (0.6 to 1.1)	1.9 (1.4 to 2.4)	124.6 (109.0 to 141.3)	13.9 (6.4 to 21.4)
Unintentional suffocation	-	-	-	-	0.3 (0.2 to 0.4)	0.7 (0.6 to 1.0)	149.5 (126.8 to 172.6)	25.9 (15.9 to 35.5)
Other exposure to mechanical forces	-	-	-	-	22.9 (17.3 to 30.0)	40.9 (31.0 to 53.5)	78.5 (70.4 to 86.4)	-9.2 (-12.9 to -5.0)
Adverse effects of medical treatment	-	-	-	-	0.7 (0.4 to 1.1)	1.5 (0.9 to 2.2)	108.8 (96.2 to 123.1)	7.6 (0.5 to 15.2)
Animal contact	-	-	-	-	6.5 (4.9 to 8.5)	9.6 (7.2 to 12.5)	48.0 (39.1 to 57.2)	-23.8 (-27.6 to -20.0)
Venomous animal contact	-	-	-	-	2.9 (2.1 to 3.8)	4.3 (3.1 to 5.6)	47.0 (33.9 to 62.9)	-25.5 (-31.3 to -19.1)
Non-venomous animal contact	-	-	-	-	3.6 (2.6 to 4.9)	5.3 (3.9 to 7.2)	49.1 (39.0 to 59.5)	-22.3 (-26.5 to -18.2)
Foreign body	-	-	-	-	1.8 (1.4 to 2.3)	3.7 (2.8 to 4.7)	103.5 (92.8 to 114.5)	3.2 (-2.3 to 8.5)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.4 (0.3 to 0.5)	0.8 (0.6 to 1.0)	100.2 (76.2 to 127.9)	7.8 (-1.2 to 18.3)
Foreign body in eyes	-	-	-	-	0.4 (0.2 to 0.6)	0.8 (0.4 to 1.2)	101.9 (81.0 to 126.5)	1.8 (-6.6 to 11.7)
Foreign body in other body part	-	-	-	-	1.0 (0.8 to 1.4)	2.1 (1.6 to 2.7)	105.8 (90.7 to 119.1)	2.4 (-5.5 to 9.2)
Other unintentional injuries	-	-	-	-	21.9 (16.5 to 28.5)	38.8 (29.5 to 50.8)	76.5 (65.2 to 91.3)	-8.9 (-14.2 to -1.5)
Self-harm and interpersonal violence	-	-	-	-	9.0 (6.9 to 11.5)	18.9 (14.4 to 24.0)	109.9 (99.7 to 120.2)	8.9 (3.8 to 13.5)
Self-harm	-	-	-	-	0.9 (0.7 to 1.2)	2.0 (1.4 to 2.5)	111.6 (97.2 to 129.3)	7.1 (0.7 to 14.5)
Interpersonal violence	-	-	-	-	8.1 (6.2 to 10.2)	16.9 (13.0 to 21.4)	109.8 (98.5 to 120.9)	8.9 (3.6 to 14.3)
Assault by firearm	-	-	-	-	1.5 (1.1 to 1.9)	3.1 (2.3 to 3.9)	109.4 (95.6 to 125.0)	8.0 (1.6 to 15.8)
Assault by sharp object	-	-	-	-	1.2 (0.9 to 1.6)	2.8 (2.1 to 3.7)	127.0 (110.0 to 146.6)	16.0 (7.8 to 25.7)
Assault by other means	-	-	-	-	5.4 (4.1 to 6.8)	11.0 (8.4 to 14.1)	105.7 (90.6 to 119.8)	7.4 (0.5 to 14.5)
Forces of nature, war, and legal intervention	-	-	-	-	422.5 (172.1 to 922.8)	217.7 (81.1 to 509.5)	-48.8 (-61.3 to -36.8)	-64.5 (-71.9 to -57.5)
Exposure to forces of nature	-	-	-	-	48.9 (22.0 to 100.2)	26.9 (12.0 to 57.5)	-49.9 (-47.9 to -42.1)	-60.9 (-63.4 to -58.4)
Collective violence and legal intervention	-	-	-	-	373.6 (142.7 to 854.5)	190.8 (65.1 to 462.9)	-49.3 (-62.9 to -35.8)	-65.0 (-73.4 to -57.2)

Appendix Table G.4 - Federated States of Micronesia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	7.1 (5.2 to 9.3)	8.2 (6.1 to 10.6)	15.0 (11.3 to 18.8)	15.0 (4.3 to 1.1)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.4 (1.0 to 2.0)	1.3 (0.9 to 1.7)	-12.2 (-20.9 to -0.7)	-11.0 (-20.3 to 0.3)
HIV/AIDS and tuberculosis	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (5.9 to 30.4)	-5.8 (-13.5 to 4.3)
Tuberculosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	9.9 (4.6 to 15.3)	-12.5 (-16.2 to -8.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	9.8 (0.3 to 19.4)	-12.5 (-18.7 to -6.1)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	301.5 (61.3 to 685.3)	247.6 (40.6 to 577.6)
HIV/AIDS resulting in mycobacterial infection	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	422.8 (155.0 to 819.3)	380.7 (136.3 to 731.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	301.5 (61.3 to 685.3)	247.6 (40.6 to 577.6)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-23.3 (-29.8 to -16.8)	-22.2 (-27.9 to -16.2)
Diarrheal diseases	0.5 (0.4 to 0.5)	0.4 (0.4 to 0.4)	-19.5 (-30.9 to -7.3)	-7.2 (-18.7 to 4.6)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-39.5 (-31.6 to -6.7)	-7.0 (-19.4 to 4.9)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.4 (-44.1 to -5.4)	-29.8 (-42.7 to -6.1)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.5 (-41.2 to -16.0)	-29.1 (-40.3 to -15.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.2 (-43.9 to -8.5)	-28.7 (-42.0 to -10.1)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.0 (-52.6 to -27.0)	-42.1 (-52.6 to -26.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.6 (-55.1 to -22.6)	-42.0 (-54.7 to -24.4)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.2 (89.8 to 14,545.9)	44.7 (89.9 to 14,803.2)
Lower respiratory infections	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-30.2 (-44.1 to 0.3)	-24.1 (-36.9 to 6.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.8 (-45.5 to -1.7)	-24.4 (-38.2 to 7.2)
Upper respiratory infections	3.0 (2.8 to 3.1)	3.1 (2.9 to 3.2)	4.1 (-3.0 to 11.2)	-1.1 (-6.4 to 5.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	4.1 (-3.9 to 11.8)	-0.9 (-7.3 to 5.5)
Otitis media	1.4 (1.3 to 1.5)	1.3 (1.2 to 1.4)	-9.0 (-14.6 to -2.0)	-12.0 (-17.7 to -5.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.2 (-16.2 to -1.0)	-11.7 (-18.2 to -3.9)
Meningitis	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-40.9 (-50.6 to -32.6)	-42.8 (-50.9 to -34.9)
Pneumococcal meningitis	0.5 (0.3 to 0.8)	0.3 (0.2 to 0.5)	-39.3 (-49.3 to -30.2)	-4.4 (-52.5 to -34.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-43.2 (-56.3 to -29.3)	-45.0 (-57.3 to -33.0)
H influenzae type B meningitis	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	47.4 (-62.2 to -22.0)	-51.6 (-63.5 to -29.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.3 (-69.0 to -0.5)	-48.0 (-68.7 to -7.2)
Meningococcal meningitis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-34.4 (-52.5 to -9.6)	-41.1 (-55.2 to -20.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.9 (-54.5 to 8.7)	-37.1 (-55.8 to -8.0)
Other meningitis	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.2)	-34.9 (-53.5 to -21.6)	-37.4 (-53.8 to -23.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.5 (-59.7 to -18.3)	-35.5 (-58.5 to -18.8)
Encephalitis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-11.6 to 16.7)	1.4 (-21.7 to 1.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-12.5 to 28.2)	4.9 (-2.0 to 11.3)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.3 (-94.1 to 361.3)	-44.1 (-91.7 to 317.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.3 (-94.3 to 369.8)	-44.1 (-91.8 to 319.5)
Whooping cough	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-25.4 (-25.7 to -25.2)	-4.4 (-4.6 to -4.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.0 (-33.9 to -14.9)	-3.9 (-15.1 to 9.1)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.7 (-95.3 to -76.2)	-91.2 (-95.4 to -77.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-84.1 (-92.7 to -62.0)	-83.7 (-92.2 to -64.3)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.7 (-85.1 to -80.0)	-82.2 (-81.3 to -74.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.5 (-89.3 to -73.7)	78.0 (-86.5 to -66.9)
Varicella and herpes zoster	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-1.1 (-11.5 to 11.6)	-1.0 (-14.0 to 15.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.1 (-7.5 to 47.5)	-1.8 (-20.8 to 24.3)
Neglected tropical diseases and malaria	-	-	-	-	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-14.8 (-41.6 to 32.9)	-11.6 (-41.4 to 36.1)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.1 (-39.3 to 125.6)	15.9 (-40.8 to 124.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.1 (-39.3 to 117.9)	14.1 (-40.5 to 118.3)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.4 (-19.3 to 26.8)	0.8 (-19.7 to 30.7)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.4 (-58.4 to 121.7)	-2.0 (-45.0 to 112.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.4 (-58.5 to 121.8)	-2.0 (-45.1 to 114.9)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.5 (-18.8 to 28.3)	0.7 (-20.2 to 30.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.5 (-18.8 to 28.7)	0.7 (-20.2 to 30.9)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.2 (-87.3 to 75.9)	-66.6 (-89.9 to -4.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.4 (-88.2 to 82.3)	-65.9 (-90.0 to 4.4)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.0 (17.4 to 54.8)	15.5 (-0.7 to 31.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.3 (6.5 to 77.8)	16.1 (-8.7 to 45.0)
Lymphatic filariasis	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	23.3 (6.1 to 47.2)	-0.6 (-13.6 to 16.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.2 (3.9 to 53.5)	-4.4 (-21.0 to 20.5)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	0.1 (0.0 to 0.1)	0.3 (0.1 to 0.7)	424.1 (423.3 to 424.8)	385.2 (384.5 to 385.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	423.5 (360.4 to 490.5)	385.5 (337.4 to 437.8)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.0 (-67.6 to -2.5)	-50.7 (-70.2 to -12.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.0 (-67.6 to -2.3)	-50.7 (-70.3 to -12.7)
Intestinal nematode infections	-	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-38.9 (-62.5 to 10.4)	-34.3 (-63.5 to 25.9)
Ascariasis	34.7 (25.9 to 45.5)	36.3 (24.5 to 52.5)	4.3 (-35.8 to 69.5)	-3.5 (-44.5 to 63.1)	0.1 (0.1 to 0.3)	0.1 (0.0 to 0.1)	-56.1 (-77.7 to 3.8)	-50.3 (-77.4 to 28.1)
Trichuriasis	8.4 (5.8 to 12.8)	9.3 (6.0 to 14.3)	9.0 (-38.7 to 96.1)	-0.3 (-50.0 to 95.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.4 (-77.8 to 461.3)	8.6 (-83.0 to 480.6)
Hookworm disease	2.4 (6.1 to 11.3)	9.7 (6.6 to 13.9)	14.1 (-28.8 to 86.1)	2.3 (-39.1 to 81.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	14.8 (-28.8 to 86.5)	6.4 (-39.8 to 87.8)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	1.2 (0.8 to 1.5)	0.9 (0.7 to 1.1)	-22.8 (-42.1 to 6.9)	-14.0 (-34.9 to 18.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-24.8 (-50.9 to 19.8)	-15.5 (-45.0 to 37.2)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-31.5 (-51.9 to -15.2)	-39.0 (-56.5 to -25.3)
Maternal hemorrhage	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-18.2 (-45.3 to 8.9)	-36.7 (-51.0 to -3.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.8 (-54.9 to 3.1)	-31.5 (-60.8 to -9.9)
Maternal sepsis and other maternal infections	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-58.8 (-65.5 to -52.0)	-61.1 (-67.3 to -54.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-60.1 (-80.8 to -24.7)	-63.8 (-80.5 to -33.8)
Maternal hypertensive disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.0 (-37.5 to -15.9)	-36.2 (-41.8 to -24.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.5 (-44.5 to -10.8)	-35.9 (-48.4 to -18.9)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.1 (-72.5 to -7.1)	-59.7 (-75.8 to -25.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.8 (-77.4 to 27.0)	-58.6 (-80.9 to 5.6)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.5 (-67.4 to -8.2)	-51.3 (-68.8 to -16.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.2 (-69.5 to 13.8)	-46.2 (-71.5 to 4.9)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-30.6 (-58.3 to 267.9)	-38.6 (-58.3 to 270.2)
Neonatal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	36.6 (-22.0 to 185.5)	38.8 (-20.1 to 187.4)
Preterm birth complications	0.5 (0.3 to 0.9)	1.0 (0.5 to 1.8)	98.9 (50.4 to 191.1)	90.7 (46.1 to 177.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	102.8 (36.8 to 292.2)	103.2 (40.6 to 281.4)
Neonatal encephalopathy due to birth asphyxia and trauma	0.4 (0.1 to 0.8)	0.2 (0.1 to 0.4)	-45.0 (-68.4 to -1.6)	-48.6 (-71.5 to -1.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.7 (-41.1 to 38.5)	-13.8 (-46.2 to 39.2)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.8 (-21.9 to -9.9)	4.9 (4.6 to 20.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.9 (-29.7 to -4.4)	11.8 (-5.7 to 28.2)
Hemolytic disease and other neonatal jaundice	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	36.8 (-54.4 to 257.9)	37.5 (-53.5 to 249.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.8 (-55.5 to 213.1)	33.6 (-55.6 to 208.0)
Other neonatal disorders	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	8.4 (-58.3 to 267.9)	9.7 (-58.3 to 270.2)
Nutritional deficiencies	-	-	-	-	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.7)	-22.3 (-26.6 to -18.2)	-19.7 (-24.6 to -15.7)
Protein-energy malnutrition	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-40.8 (-68.0 to 7.4)	-29.6 (-59.1 to 17.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-40.2 (-68.6 to 11.5)	-29.4 (-59.6 to 20.4)
Iodine deficiency	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-26.2 (-41.1 to -6.8)	-39.7 (-52.7 to -20.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.5 (-43.1 to -4.4)	-38.4 (-52.4 to -18.6)
Vitamin A deficiency	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-45.5 (-56.9 to -33.8)	-45.9 (-56.8 to -36.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.1 (-59.9 to -37.7)	-50.0 (-59.3 to -40.4)

Appendix Table G.4 - Federated States of Micronesia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	17.6 (17.2 to 17.9)	14.7 (14.3 to 15.1)	-16.6 (-19.8 to -13.4)	-16.5 (-19.9 to -12.7)	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.7)	-20.9 (-25.4 to -17.5)	-20.9 (-24.2 to -14.2)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-51.2 to 134.7)	29.7 (-39.3 to 178.4)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.8 (-11.7 to 17.1)	-7.2 (-18.0 to 6.4)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	18.7 (5.9 to 34.2)	-1.9 (-11.3 to 9.1)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.7 (-34.8 to -7.5)	-38.1 (-46.3 to -26.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.3 (-45.9 to 5.5)	37.8 (-55.0 to -15.8)
Chlamydial infection	5.6 (3.9 to 8.3)	6.5 (5.1 to 8.5)	19.9 (-22.2 to 62.1)	-0.1 (-32.9 to 36.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.0 (2.6 to 37.7)	-0.7 (-13.7 to 13.6)
Gonococcal infection	0.7 (0.5 to 1.0)	0.8 (0.6 to 1.2)	14.7 (-28.8 to 88.3)	-5.9 (-38.9 to 49.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.4 (8.7 to 77.4)	4.4 (-23.0 to 42.9)
Trichomoniasis	0.9 (0.5 to 1.3)	1.0 (0.6 to 1.5)	11.9 (-42.0 to 93.9)	3.3 (-42.4 to 68.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.8 (-46.6 to 115.0)	7.6 (-48.6 to 85.5)
Genital herpes	11.7 (11.5 to 12.0)	14.2 (13.9 to 14.6)	-	21.5 (-4.4 to -40.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.9 (11.4 to 28.8)	-3.3 (-8.5 to 1.3)
Other sexually transmitted diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.3 (-32.3 to -11.3)	-28.2 (-37.3 to -18.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.8 (-34.6 to 11.2)	-25.5 (-40.5 to -5.7)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-44.5 to -10.5)	-42.5 (-55.4 to -23.0)
Hepatitis A	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-7.6 (-8.3 to -6.7)	-3.6 (-3.6 to -3.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.5 (5.7 to 20.4)	-0.7 (-11.0 to 11.1)
Hepatitis B	17.1 (10.9 to 24.1)	7.9 (6.0 to 10.0)	-53.8 (-71.9 to -24.5)	-40.0 (-73.7 to -36.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.7 (-68.1 to -25.7)	-8.1 (-71.5 to -33.7)
Hepatitis C	2.6 (2.3 to 2.9)	2.4 (2.1 to 2.6)	-8.9 (-22.5 to 6.5)	-26.4 (-35.4 to -16.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.1 (-34.4 to 12.2)	-25.6 (-45.5 to 1.5)
Hepatitis E	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.7 (14.9 to 66.9)	15.2 (-3.2 to 37.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.1 (7.1 to 82.9)	15.2 (-9.6 to 47.4)
Leprosy	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	80.1 (-17.5 to 246.2)	33.3 (-39.6 to 176.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.9 (-24.4 to 594.3)	44.5 (-43.4 to 417.0)
Other infectious diseases	0.8 (0.6 to 1.0)	0.6 (0.5 to 0.8)	-22.4 (-44.1 to 4.1)	-15.3 (-37.4 to 12.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.3 (-35.6 to 31.7)	4.5 (-25.3 to 51.9)
Non-communicable diseases	-	-	-	-	5.5 (4.0 to 7.1)	6.7 (5.0 to 8.7)	22.4 (18.7 to 26.3)	0.3 (-2.7 to 3.3)
Neoplasms	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	61.1 (13.9 to 144.9)	10.8 (-19.2 to 61.4)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.9 (-20.3 to 268.5)	32.0 (-41.2 to 176.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-18.6 to 250.4)	33.3 (-39.8 to 163.9)
Stomach cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.4 (1.5 to 153.1)	18.1 (-21.8 to 84.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.3 (-6.6 to 150.9)	16.6 (-25.2 to 81.4)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (7.5 to 54.0)	210.1 (27.0 to 368.9)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	270.6 (59.9 to 817.4)	175.1 (18.1 to 548.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	251.3 (71.1 to 701.4)	157.0 (24.6 to 464.5)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	641.9 (214.6 to 1,872.4)	431.5 (133.2 to 1,360.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	601.2 (241.1 to 1,628.9)	409.3 (142.3 to 1,168.3)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.4 (-36.4 to 230.8)	-2.2 (-54.7 to 140.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.7 (-34.8 to 186.2)	-6.1 (-53.3 to 113.2)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.5 (-18.0 to 371.4)	37.1 (-40.9 to 243.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.5 (-14.3 to 302.9)	0.3 (-38.3 to 194.6)
Larynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.7 (-19.8 to 372.9)	26.4 (-42.2 to 302.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.6 (-19.9 to 287.1)	30.3 (-41.8 to 221.6)
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.6 (-11.0 to 122.8)	0.9 (-33.1 to 55.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.3 (-9.3 to 117.9)	-0.7 (-33.2 to 55.6)
Breast cancer	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.8)	201.3 (83.3 to 436.7)	136.3 (49.8 to 307.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	160.6 (61.3 to 366.2)	102.9 (30.2 to 250.4)
Cervical cancer	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-3.7 (-48.2 to 83.7)	33.4 (-57.3 to 38.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.4 (-46.4 to 81.6)	-23.8 (-55.5 to 36.7)
Uterine cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	52.7 (-20.0 to 197.0)	4.5 (-43.7 to 101.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.1 (-21.8 to 191.6)	3.2 (-43.7 to 96.4)
Prostate cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	171.0 (65.0 to 368.5)	93.0 (20.2 to 221.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	147.9 (56.5 to 328.0)	80.4 (17.2 to 199.0)
Colon and rectum cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	162.3 (77.8 to 313.0)	87.6 (28.3 to 186.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	148.4 (68.2 to 296.7)	76.4 (22.3 to 171.5)
Lip and oral cavity cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.0)	27.2 (-27.0 to 130.2)	-9.4 (-47.3 to 67.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.4 (-23.8 to 128.2)	-10.8 (-47.7 to 66.6)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.9 (-29.8 to 145.1)	-1.8 (-44.9 to 87.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.1 (-29.5 to 132.6)	5.3 (-45.2 to 76.2)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.1 (-37.1 to 108.9)	-18.0 (-54.3 to 44.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.5 (-35.1 to 99.6)	-19.3 (-53.6 to 39.6)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.3 (-37.6 to 154.9)	-10.2 (-56.6 to 80.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.4 (-38.2 to 134.5)	-14.3 (-56.3 to 65.3)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.7 (30.5 to 243.2)	47.9 (-2.4 to 138.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.8 (37.6 to 220.7)	48.1 (2.1 to 121.6)
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.9 (12.0 to 296.3)	52.8 (-16.6 to 189.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.8 (2.9 to 282.9)	43.1 (-21.5 to 166.2)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.1 (33.0 to 207.5)	47.8 (1.2 to 121.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.1 (16.4 to 246.4)	52.2 (-13.3 to 165.1)
Ovarian cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.4 (-23.6 to 190.3)	18.1 (-36.4 to 135.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.8 (-23.9 to 173.6)	18.7 (-36.5 to 119.3)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.2 (-25.9 to 205.0)	21.9 (-35.3 to 133.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.3 (-28.4 to 209.2)	19.5 (-37.6 to 134.1)
Kidney cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.7 (-20.3 to 134.4)	0.0 (-32.5 to 90.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.9 (-19.7 to 129.9)	6.9 (-35.2 to 83.3)
Bladder cancer	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-44.8 (-65.8 to -1.2)	-62.3 (-77.7 to -30.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.4 (-66.7 to -2.1)	-62.3 (-78.4 to -29.8)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.3 (-27.3 to 103.2)	21.4 (-24.9 to 96.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.9 (-21.0 to 120.6)	19.2 (-26.8 to 94.6)
Thyroid cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.1 (-15.6 to 178.2)	15.8 (-33.8 to 116.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.3 (-18.0 to 178.1)	12.9 (-35.5 to 112.2)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.3 (-4.9 to 162.3)	0.0 (-24.8 to 98.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.7 (-4.0 to 164.8)	20.8 (-24.1 to 97.0)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.6 (-12.4 to 255.0)	47.8 (-20.1 to 172.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.6 (-11.1 to 220.8)	35.9 (-22.4 to 140.5)
Non-Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	155.6 (-6.2 to 386.7)	119.8 (-22.2 to 321.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	153.5 (-8.5 to 398.6)	114.2 (-26.3 to 316.0)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.8 (-4.8 to 295.6)	41.6 (-30.0 to 209.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.6 (-6.7 to 292.9)	36.0 (-32.2 to 208.1)
Leukemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	157.4 (37.0 to 334.2)	142.8 (47.7 to 285.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	186.4 (57.1 to 322.9)	117.9 (33.3 to 247.0)
Other neoplasms	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	197.8 (27.5 to 446.8)	195.3 (23.4 to 417.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	195.5 (30.3 to 432.0)	158.6 (13.5 to 385.4)
Cardiovascular diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	50.5 (21.5 to 81.8)	17.3 (-1.1 to 38.8)
Rheumatic heart disease	2.6 (2.0 to 3.2)	3.2 (2.5 to 4.1)	23.8 (-13.8 to 73.1)	2.3 (-23.9 to 41.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	23.2 (-14.0 to 69.6)	1.7 (-24.7 to 39.1)
Ischemic heart disease	0.3 (0.3 to 0.4)	0.5 (0.4 to 0.6)	47.7 (12.4 to 88.9)	1.8 (-21.6 to 29.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	54.3 (28.9 to 94.4)	6.0 (-16.7 to 31.9)
Cerebrovascular disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.1 (20.4 to 78.4)	6.4 (-13.6 to 29.3)
Ischemic stroke	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	48.4 (19.0 to 82.3)	7.1 (-15.8 to 31.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.6 (16.6 to 83.1)	6.2 (-16.2 to 31.7)
Hemorrhagic stroke	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	47.3 (20.7 to 77.4)	6.6 (-13.3 to 30.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.9 (18.6 to 80.7)	6.2 (-13.3 to 32.2)
Hypertensive heart disease	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	88.6 (38.5 to 109.6)	15.9 (-6.6 to 44.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.9 (37.4 to 113.4)	15.9 (-5.9 to 45.9)
Cardiomyopathy and myocarditis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	72.5 (48.9 to 104.1)	31.2 (10.6 to 56.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.2 (45.6 to 109.0)	32.2 (9.5 to 59.3)
Atrial fibrillation and flutter	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	196.8 (114.3 to 320.5)	90.4 (31.9 to 179.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	199.7 (120.6 to 334.1)	92.5 (34.1 to 186.1)
Peripheral vascular disease	0.8 (0.6 to 1.1)	1.1 (0.9 to 1.5)	49.6 (-13.1 to 128.8)	2.6 (-37.6 to 51.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.6 (-49.0 to 132.7)	-24.1 (-63.0 to 57.5)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.8 (7.4 to 69.2)	11.1 (-16.9 to 42.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.2 (5.0 to 83.5)	12.6 (-21.1 to 56.0)
Other cardiovascular and circulatory diseases	0.5 (0.3 to 0.6)	1.1 (0.5 to 1.6)	126.7 (10.7 to 310.4)	64.8 (-22.5 to 206.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	135.2 (10.7 to 309.7)	64.7 (-21.2 to 208.7)
Chronic respiratory diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	18.3 (-6.5 to 42.2)	-8.5 (-23.8 to 8.3)
Chronic obstructive pulmonary disease	2.0 (1.9 to 2.1)	2.6 (2.5 to 2.8)	31.3 (27.1 to 35.3)	-0.1 (-3.0 to 2.9)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	35	

Appendix Table G.4 - Federated States of Micronesia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumococcal	-	-	-	-	0.0	0.0	118.1	56.9
Silicosis	0.0	0.0	16.4	-17.6	0.0	0.0	(102.6 to 132.1)	(44.7 to 68.6)
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	(10.7 to 21.2)	(-21.4 to -13.9)
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	163.9	97.6	0.0	0.0	158.7	93.6
Asthma	1.4	1.6	14.6	-8.5	0.1	0.1	(146.4 to 173.4)	(83.5 to 106.0)
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	32.1	0.8	0.0	0.0	(-39.6 to 99.2)	(-38.5 to 42.9)
Other chronic respiratory diseases	0.0	0.0	32.1	0.8	0.0	0.0	(-6.2 to 79.8)	(-29.1 to 37.6)
Cirrhosis	-	-	-	-	0.1	0.0	-28.4	-44.5
Cirrhosis due to hepatitis B	0.0	0.0	-15.3	-26.0	0.0	0.0	(-45.3 to -5.4)	(-57.8 to -26.7)
Cirrhosis due to hepatitis C	0.0	0.0	-9.9	-20.6	0.0	0.0	(-33.5 to -11.6)	(-40.6 to -25.0)
Cirrhosis due to alcohol use	0.0	0.0	-48.4	-59.5	0.0	0.0	-15.2	-26.3
Cirrhosis due to other causes	0.0	0.0	-33.9	-31.5	0.0	0.0	(-68.6 to -22.6)	(-74.5 to -39.2)
Digestive diseases	-	-	-	-	0.1	0.1	(-59.3 to 10.5)	(-56.2 to 11.6)
Peptic ulcer disease	0.7	0.5	-20.2	-41.5	0.0	0.0	1.7	-15.3
Gastritis and duodenitis	0.7	0.6	-11.5	-27.1	0.0	0.0	(-10.1 to 21.3)	(-26.8 to -3.0)
Appendicitis	0.0	0.0	-16.1	-29.6	0.0	0.0	-13.3	-34.8
Paralytic ileus and intestinal obstruction	0.0	0.0	9.9	-9.2	0.0	0.0	(-27.5 to -0.3)	(-44.1 to -26.4)
Inguinal, femoral, and abdominal hernia	0.2	0.2	10.2	-13.0	0.0	0.0	(-23.3 to 21.2)	(-27.8 to 3.0)
Inflammatory bowel disease	0.0	0.0	16.5	-8.7	0.0	0.0	(-2.7 to 38.7)	(-22.5 to 7.7)
Vascular intestinal disorders	0.0	0.0	84.9	135.6	0.0	0.0	80.9	124.3
Gallbladder and biliary diseases	0.0	0.0	22.0	22.0	0.0	0.0	(11.7 to 176.5)	(41.5 to 261.2)
Pancreatitis	0.0	0.0	28.4	5.0	0.0	0.0	(3.2 to 44.4)	(-21.3 to 5.9)
Other digestive diseases	0.0	0.0	17.8	-3.5	0.0	0.0	27.1	4.9
Neurological disorders	-	-	-	-	0.0	0.0	(6.2 to 51.6)	(-9.5 to 21.8)
Alzheimer disease and other dementias	0.2	0.3	48.1	2.4	0.4	0.5	39.6	14.7
Parkinson disease	0.0	0.1	39.6	-0.4	0.0	0.0	(-12.8 to 84.2)	(-29.0 to 49.9)
Epilepsy	0.3	0.3	7.8	-0.5	0.1	0.1	25.0	-0.1
Multiple sclerosis	0.0	0.0	126.0	78.7	0.0	0.0	(5.5 to 47.0)	(-13.7 to 14.8)
Migraine	7.1	7.1	19.8	0.2	0.2	0.2	49.7	2.7
Tension-type headache	11.7	13.7	17.0	-1.6	0.0	0.0	(26.5 to 74.2)	(-13.7 to 19.9)
Medication overuse headache	0.3	0.5	88.2	52.3	0.0	0.1	39.8	-0.2
Other neurological disorders	0.0	0.0	11.5	1.3	0.0	0.0	(25.8 to 57.1)	(-9.3 to 11.0)
Mental and substance use disorders	-	-	-	-	1.4	1.7	(-25.4 to 64.2)	(-29.8 to 53.1)
Schizophrenia	0.2	0.3	21.3	-0.7	0.2	0.2	(100.4 to 154.8)	(60.1 to 100.3)
Alcohol use disorders	0.6	0.9	66.1	32.5	0.1	0.1	(16.5 to 22.7)	(-1.6 to 2.9)
Drug use disorders	-	-	-	-	0.2	0.2	21.1	-0.7
Opioid use disorders	0.1	0.1	16.0	1.7	0.0	0.0	(18.8 to 29.0)	(-19.7 to 7.5)
Cocaine use disorders	0.1	0.1	23.3	48.8	0.0	0.0	15.4	1.3
Amphetamine use disorders	0.3	0.3	3.6	-13.2	0.0	0.0	(-0.3 to 33.2)	(-11.9 to 15.3)
Cannabis use disorders	0.3	0.4	21.7	0.3	0.0	0.0	12.2	0.6
Other drug use disorders	-	-	-	-	0.1	0.1	(1.2 to 48.5)	(-15.8 to 20.4)
Depressive disorders	-	-	-	-	0.1	0.1	4.0	-12.8
Major depressive disorder	1.6	1.9	20.9	-0.2	0.3	0.4	(-18.5 to 31.2)	(-30.2 to 7.4)
Dysthymia	0.9	1.1	26.7	0.4	0.1	0.1	22.1	0.7
Bipolar disorder	0.4	0.5	22.4	-0.0	0.0	0.0	(8.5 to 36.5)	(-10.3 to 11.6)
Anxiety disorders	2.2	2.6	17.8	0.2	0.4	0.5	6.9	-10.7
Eating disorders	-	-	-	-	0.0	0.0	(-24.3 to 48.1)	(-36.0 to 22.1)
Anorexia nervosa	0.0	0.0	3.9	-12.1	0.0	0.0	8.3	-0.0
Bulimia nervosa	0.0	0.0	18.5	-1.7	0.0	0.0	(15.8 to 27.8)	(-4.0 to 4.3)
Autistic spectrum disorders	-	-	-	-	0.1	0.1	20.5	-0.2
Autism	0.3	0.3	8.6	-0.2	0.1	0.1	(13.1 to 28.0)	(-5.4 to 5.5)
Asperger syndrome	0.4	0.5	8.1	-0.2	0.0	0.0	26.5	0.5
Attention-deficit/hyperactivity disorder	0.8	0.8	4.4	0.2	0.0	0.0	(22.0 to 30.7)	(-1.8 to 2.7)
Conduct disorder	0.8	0.8	6.9	0.1	0.0	0.0	22.2	-0.1
Idiopathic intellectual disability	0.3	0.4	18.6	14.1	0.0	0.0	(11.6 to 33.2)	(-7.4 to 7.1)
Other mental and substance use disorders	1.2	1.5	27.1	-0.2	0.1	0.1	(13.1 to 22.3)	(-2.7 to 3.1)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	0.7	0.9	10.7	-6.9
Diabetes mellitus	4.1	6.2	51.6	16.6	0.3	0.6	(4.8 to 29.5)	(-19.4 to 7.7)
Acute glomerulonephritis	0.0	0.0	7.4	4.7	0.0	0.0	4.1	-11.7
Chronic kidney disease	0.3	0.6	77.1	36.8	0.0	0.0	(-16.8 to 31.6)	(-29.2 to 11.6)
Chronic kidney disease due to diabetes mellitus	0.6	0.3	-49.5	-7.1	0.0	0.0	18.8	-1.0
Chronic kidney disease due to hypertension	0.7	0.8	5.1	0.0	0.0	0.0	(-2.1 to 43.9)	(-17.5 to 18.3)
Chronic kidney disease due to glomerulonephritis	1.6	2.0	28.1	8.4	0.0	0.0	8.3	-0.0
Chronic kidney disease due to other causes	1.1	1.4	28.1	10.3	0.0	0.0	(4.4 to 12.6)	(-3.1 to 3.2)
Urinary diseases and male infertility	-	-	-	-	0.0	0.0	8.3	0.0

Appendix Table G.4 - Federated States of Micronesia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.7 (33.2 to 56.3)	26.5 (16.8 to 37.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.7 (13.6 to 85.4)	26.3 (3.5 to 56.9)
Urolithiasis	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	21.7 (4.1 to 37.9)	-11.0 (-23.6 to -1.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.1 (3.7 to 31.4)	-8.1 (-16.6 to 0.5)
Benign prostatic hyperplasia	0.5 (0.5 to 0.6)	0.7 (0.6 to 0.8)	38.0 (20.7 to 56.7)	-5.4 (-17.6 to 7.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.7 (21.1 to 57.7)	-5.0 (-17.2 to 8.2)
Male infertility due to other causes	0.7 (0.6 to 0.8)	0.8 (0.6 to 1.0)	12.8 (-1.6 to 50.0)	-1.5 (-26.0 to 30.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.4 (-17.3 to 53.9)	-1.3 (-26.5 to 32.6)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-12.3 to 68.8)	-3.8 (-29.6 to 32.6)
Gynecological diseases	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	12.8 (2.9 to 30.2)	-3.3 (-14.6 to 9.6)
Uterine fibroids	1.3 (1.2 to 1.5)	1.6 (1.5 to 1.7)	21.4 (19.6 to 23.1)	4.6 (4.3 to 5.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.8 (2.4 to 14.2)	-9.0 (-16.2 to -2.2)
Polycystic ovarian syndrome	1.1 (1.0 to 1.2)	1.3 (1.1 to 1.4)	13.1 (4.6 to 34.3)	0.0 (-14.2 to 16.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.2 (5.1 to 34.4)	0.2 (-14.5 to 17.7)
Female infertility due to other causes	0.7 (0.6 to 0.9)	0.8 (0.6 to 1.0)	13.0 (-16.5 to 52.9)	6.2 (-23.4 to 46.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.9 (-14.0 to 54.7)	0.3 (-23.1 to 44.8)
Endometriosis	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	12.7 (-10.7 to 45.1)	2.5 (-19.1 to 29.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.1 (-12.2 to 47.5)	2.6 (-19.8 to 30.6)
Genital prolapse	3.2 (2.8 to 3.7)	3.9 (3.3 to 4.5)	21.7 (-1.8 to 49.9)	-2.7 (-18.8 to 16.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.4 (-1.8 to 50.0)	-3.0 (-18.6 to 16.1)
Premenstrual syndrome	2.4 (1.2 to 3.3)	2.9 (1.9 to 3.8)	21.2 (-34.3 to 119.8)	2.2 (-38.8 to 76.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.7 (-33.5 to 122.4)	2.2 (-39.4 to 74.6)
Other gynecological diseases	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.3)	0.1 (-21.2 to 34.4)	-14.3 (-33.4 to 15.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.4 (-19.9 to 71.0)	-16.9 (-30.6 to 45.4)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	4.9 (3.8 to 21.3)	10.9 (5.0 to 26.6)
Thalassemias	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-5.4 (-13.3 to 4.3)	1.6 (-6.8 to 11.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.5 (-31.8 to 40.2)	7.6 (-24.4 to 50.8)
Thalassemia trait	6.7 (5.7 to 7.8)	7.4 (6.5 to 8.5)	10.4 (6.0 to 16.0)	2.4 (-1.6 to 8.1)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	13.8 (1.7 to 26.6)	15.5 (-3.8 to 31.7)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.0 (-45.6 to -45.4)	-57.7 (-64.6 to -44.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-55.5 (-66.3 to -35.2)	-54.4 (-66.6 to -33.5)
Sickle cell trait	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	37.2 (-51.2 to -22.3)	-42.1 (-55.1 to -28.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.0 (-60.3 to 1.8)	37.2 (-57.3 to -7.6)
G6PD deficiency	6.7 (4.5 to 8.6)	7.2 (5.0 to 9.3)	7.0 (-30.1 to 79.5)	-0.7 (-35.2 to 66.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.3 (-59.8 to 70.0)	-9.0 (-55.8 to 46.9)
G6PD trait	20.1 (18.6 to 21.2)	21.8 (20.4 to 23.0)	8.7 (-6.6 to 19.0)	1.6 (-7.1 to 11.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.6 (-92.7 to 2,605.3)	5.1 (-90.9 to 1,633.6)
Other hemoglobinopathies and hemolytic anemias	0.6 (0.5 to 0.7)	0.5 (0.4 to 0.6)	-19.3 (-36.7 to 9.3)	-18.7 (-35.8 to 7.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.8 (-48.4 to 29.1)	-19.6 (-46.4 to 39.2)
Endocrine, metabolic, blood, and immune disorders	1.1 (0.9 to 1.1)	1.0 (0.9 to 1.1)	-7.7 (-17.0 to 12.1)	-7.7 (-14.1 to 9.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.3)	4.3 (-22.5 to 20.3)	4.3 (-17.8 to 18.0)
Musculoskeletal disorders	-	-	-	-	1.0 (0.7 to 1.3)	1.3 (0.9 to 1.7)	29.1 (16.9 to 48.4)	1.0 (-7.0 to 12.9)
Rheumatoid arthritis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	133.0 (118.8 to 147.8)	80.3 (69.4 to 92.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	131.7 (106.1 to 157.7)	80.0 (63.9 to 97.2)
Osteoarthritis	1.1 (1.0 to 1.1)	1.6 (1.5 to 1.6)	44.2 (35.9 to 53.6)	1.5 (-4.4 to 7.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	44.1 (35.1 to 53.7)	1.5 (-4.5 to 7.6)
Low back and neck pain	-	-	-	-	0.7 (0.5 to 1.0)	0.9 (0.6 to 1.3)	25.4 (10.0 to 51.4)	0.3 (-11.1 to 17.6)
Low back pain	4.0 (3.7 to 4.3)	5.1 (4.8 to 5.5)	26.1 (15.1 to 39.9)	-0.1 (-7.5 to 9.2)	0.5 (0.3 to 0.6)	0.5 (0.4 to 0.8)	25.8 (14.5 to 40.5)	-0.0 (-7.6 to 9.7)
Neck pain	2.7 (1.9 to 3.4)	3.4 (2.6 to 4.5)	26.3 (-10.9 to 94.8)	1.1 (-25.3 to 48.7)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	25.8 (-12.2 to 95.6)	1.0 (-25.3 to 48.9)
Gout	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	44.8 (30.8 to 58.2)	4.3 (-5.3 to 14.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.6 (18.8 to 73.1)	4.6 (-13.0 to 23.2)
Other musculoskeletal disorders	1.7 (1.3 to 2.0)	2.2 (1.7 to 2.7)	30.3 (17.6 to 41.9)	3.4 (-9.9 to 5.1)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	31.8 (16.4 to 42.8)	-4.4 (-10.2 to 5.5)
Other non-communicable diseases	-	-	-	-	1.4 (0.9 to 2.0)	1.6 (1.1 to 2.2)	13.0 (7.3 to 20.5)	-5.9 (-9.4 to -1.4)
Congenital anomalies	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	40.4 (-1.8 to 110.8)	43.7 (3.5 to 112.0)
Neural tube defects	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.3 (28.8 to 99.7)	63.8 (34.6 to 108.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.1 (13.1 to 137.9)	71.8 (20.1 to 148.3)
Congenital heart anomalies	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.6)	119.5 (73.4 to 216.6)	129.7 (81.7 to 229.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	130.4 (78.9 to 227.0)	143.1 (89.2 to 244.0)
Orofacial clefts	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	110.8 (44.8 to 211.2)	138.5 (64.3 to 251.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.8 (-7.4 to 132.1)	63.3 (7.3 to 158.3)
Down syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	36.3 (0.7 to 76.5)	38.8 (2.2 to 79.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.0 (5.3 to 98.2)	49.2 (6.9 to 99.8)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.5 (-11.1 to 58.1)	16.6 (-13.8 to 54.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.7 (-15.3 to 70.8)	16.2 (-18.2 to 63.4)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.4 (-15.1 to 93.1)	11.6 (-20.8 to 80.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.1 (-23.0 to 118.0)	12.8 (-31.3 to 92.2)
Chromosomal unbalanced rearrangements	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	37.2 (7.2 to 88.1)	39.9 (9.6 to 92.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.1 (14.2 to 106.7)	50.0 (15.6 to 109.3)
Other congenital anomalies	0.3 (0.3 to 0.4)	0.3 (0.3 to 0.4)	-7.1 (-15.4 to 4.5)	-13.7 (-21.3 to -3.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	29.0 (-18.9 to 134.5)	32.1 (-15.4 to 135.7)
Skin and subcutaneous diseases	-	-	-	-	0.6 (0.4 to 0.9)	0.7 (0.4 to 1.0)	10.9 (2.9 to 20.8)	0.9 (-7.5 to 6.9)
Dermatitis	5.2 (4.2 to 6.4)	5.8 (4.7 to 7.1)	11.0 (8.5 to 12.7)	0.0 (-0.1 to 0.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	7.7 (2.5 to 12.5)	0.2 (-2.6 to 2.7)
Psoriasis	0.0 (0.5 to 0.6)	0.7 (0.6 to 0.8)	20.3 (19.1 to 22.1)	0.0 (-0.1 to 0.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	20.1 (11.7 to 28.9)	-0.1 (-5.5 to 5.8)
Cellulitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.8 (-24.5 to 0.8)	-13.8 (-22.2 to -3.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.5 (-34.0 to 14.1)	-13.5 (-29.9 to 5.2)
Pyoderma	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-57.0 (-64.3 to -48.1)	-51.9 (-59.0 to -42.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.2 (-65.1 to -47.0)	-52.1 (-60.2 to -42.4)
Scabies	2.3 (1.6 to 3.2)	1.8 (1.4 to 2.5)	-18.3 (-47.7 to 24.4)	-24.5 (-51.7 to 11.6)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-18.1 (-48.2 to 25.3)	-24.4 (-51.3 to 12.3)
Fungal skin diseases	9.6 (7.9 to 11.3)	11.2 (9.4 to 13.0)	16.6 (14.0 to 19.1)	0.0 (-0.0 to 0.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	16.5 (13.8 to 19.3)	0.1 (-0.6 to 0.8)
Viral skin diseases	2.3 (1.8 to 2.7)	2.3 (1.8 to 2.9)	2.3 (-2.5 to 7.3)	0.1 (-1.9 to 2.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	2.3 (-3.4 to 8.2)	0.2 (-3.3 to 3.8)
Acne vulgaris	7.6 (5.2 to 10.5)	9.4 (6.9 to 12.2)	22.0 (-16.9 to 112.0)	4.6 (-25.4 to 73.4)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	22.1 (-17.0 to 112.7)	4.6 (-25.4 to 73.6)
Alopecia areata	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	17.3 (-3.6 to 45.4)	2.4 (-17.4 to 28.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.7 (-7.2 to 50.8)	2.5 (-17.7 to 30.9)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.1 (-7.4 to 39.0)	3.6 (-23.7 to 14.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.8 (-16.3 to 53.0)	4.2 (-29.1 to 23.7)
Urticaria	0.7 (0.5 to 1.0)	1.0 (0.8 to 1.2)	30.2 (-6.9 to 86.1)	7.3 (-23.3 to 51.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	30.9 (-6.6 to 87.1)	7.7 (-23.2 to 51.2)
Decubitus ulcer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.6 (-4.5 to 48.6)	0.5 (-23.3 to 25.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.9 (-11.0 to 56.2)	-0.5 (-27.0 to 31.6)
Other skin and subcutaneous diseases	5.3 (3.6 to 7.5)	6.5 (4.4 to 9.4)	24.0 (13.9 to 34.5)	-1.7 (-5.1 to 2.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	23.9 (13.3 to 34.8)	-1.6 (-5.1 to 2.2)
Sense organ diseases	-	-	-	-	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.9)	9.5 (3.5 to 14.6)	-12.7 (-15.4 to -9.8)
Glaucoma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	13.4 (-8.9 to 40.0)	-14.6 (-34.1 to 12.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.8 (-18.9 to 30.8)	-22.2 (-41.3 to 3.4)
Cataract	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	-3.8 (-24.8 to 16.4)	-30.6 (-43.6 to -17.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.0 (-22.4 to 11.2)	-30.8 (-42.8 to -21.6)
Macular degeneration	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	32.1 (5.5 to 77.7)	-10.3 (-28.1 to 29.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.2 (5.9 to 69.4)	-12.0 (-27.6 to 18.2)
Uncorrected refractive error	5.4 (5.0 to 5.9)	6.1 (5.9 to 6.9)	17.9 (6.5 to 30.4)	-7.2 (-14.5 to 1.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	7.2 (-0.4 to 16.7)	-14.2 (-19.3 to -7.5)
Age-related and other hearing loss	10.0 (9.2 to 10.7)	12.0 (11.3 to 12.8)	20.6 (15.4 to 25.1)	-9.1 (-12.3 to -6.5)	0.3 (0.2 to 0.5)	0.2 (0.2 to 0.5)	13.3 (4.4 to 22.2)	-9.9 (-13.7 to -5.9)
Other vision loss	0.5 (0.4 to 0.6)	0.4 (0.3 to 0.6)	-8.8 (-20.0 to 8.5)	-21.6 (-37.6 to -7.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.6 (-19.1 to 10.1)	-22.6 (-34.9 to -10.7)
Other sense organ diseases	2.3 (2.2 to 2.4)	2.3 (2.2 to 2.5)	0.2 (-3.8 to 10.8)	0.2 (-5.8 to 6.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	3.1 (-4.7 to 11.6)	0.3 (-6.2 to 7.8)
Oral disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	11.3 (5.7 to 17.0)	-13.4 (-18.2 to -8.8)
Deciduous caries	12.7 (12.4 to 12.9)	10.5 (10.3 to 10.7)	-17.1 (-19.5 to -15.0)	0.2 (-2.7 to 2.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-15.0 to 15.0)	0.2 (-5.6 to 5.9)
Permanent caries	29.3 (27.9 to 30.7)	34.8 (33.0 to 36.7)	19.2 (10.5 to 27.9)	2.6 (-3.3 to 8.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	19.1 (10.2 to 28.5)	2.6 (-3.7 to 9.0)
Periodontal diseases	0.6 (0.6 to 0.7)	0.9 (0.8 to 0.9)	37.3 (25.4 to 49.2)	1.7 (-6.5 to 10.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.9 (24.5 to 49.9)	1.7 (-6.7 to 10.2)

Appendix Table G.4 - Federated States of Micronesia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	0.9 (0.9 to 1.0)	0.9 (0.8 to 0.9)	-7.2 (-14.4 to 1.1)	-33.9 (-38.8 to -28.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.2 (-14.7 to 1.5)	-33.8 (-38.9 to -28.3)
Other oral disorders	1.4 (1.3 to 1.5)	1.7 (1.6 to 1.8)	18.4 (9.4 to 29.4)	0.3 (-6.7 to 8.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	18.4 (8.3 to 29.9)	0.4 (-7.4 to 8.7)
Injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	4.7 (5.2 to 16.2)	-13.7 (-21.2 to -5.1)
Transport injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-1.3 (-13.4 to 12.1)	-17.4 (-26.3 to -7.6)
Road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-1.3 (-14.1 to 12.2)	-17.4 (-26.1 to -6.6)
Pedestrian road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.9 (-14.1 to 16.5)	-13.6 (-23.8 to -1.5)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.7 (7.1 to 15.1)	-13.1 (-22.3 to -4.1)
Motorcyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.7 (-15.9 to 9.2)	-20.2 (-29.1 to -10.2)
Motor vehicle road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.7 (-13.7 to 15.9)	-15.6 (-25.7 to -3.6)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.1 (-12.5 to 16.0)	-19.0 (-27.7 to -7.8)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.8 (-11.0 to 14.4)	-20.3 (-29.0 to -10.1)
Unintentional injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	11.4 (3.1 to 20.3)	-9.6 (-15.6 to -2.6)
Falls	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	2.9 (-7.1 to 14.9)	-17.8 (-25.5 to -8.8)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.3 (-30.5 to -8.3)	-31.1 (-39.0 to -21.8)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.3 (-39.3 to -19.3)	-39.4 (-46.3 to -30.9)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.9 (-42.6 to -14.0)	-37.9 (-47.4 to -26.4)
Exposure to mechanical forces	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.6 (15.9 to 38.6)	6.5 (0.0 to 13.5)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.1 (-30.6 to -12.0)	-35.4 (-42.1 to -27.7)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.2 (-0.8 to 22.8)	-5.3 (-13.7 to 4.6)
Other exposure to mechanical forces	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.1 (24.0 to 43.8)	10.1 (3.4 to 17.4)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.0 (20.1 to 34.8)	4.6 (-1.7 to 10.1)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.4 (-3.3 to 11.2)	-16.0 (-23.1 to -9.2)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.6 (-6.2 to 22.6)	-10.7 (-20.5 to -0.2)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.2 (-13.6 to 6.0)	-20.6 (-27.6 to -13.2)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.6 (-12.9 to 4.5)	-18.4 (-24.8 to -11.4)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.0 (-42.1 to -14.1)	-32.5 (-43.1 to -20.7)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.6 (-2.0 to 13.0)	-8.8 (-15.5 to -2.3)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.0 (-5.1 to 17.2)	-16.2 (-23.8 to -7.1)
Other unintentional injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.4 (21.8 to 46.6)	8.2 (0.8 to 18.3)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.3 (-28.3 to -8.9)	-33.9 (-40.6 to -26.0)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.3 (-21.6 to 0.9)	-30.2 (-38.1 to -21.3)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.5 (-32.0 to -11.2)	-35.6 (-42.7 to -27.2)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.3 (-23.2 to -5.1)	-27.4 (-34.3 to -20.6)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.3 (-25.2 to -1.9)	-29.8 (-38.0 to -20.5)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.5 (-36.1 to -15.1)	-38.6 (-46.0 to -29.8)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	128.5 (74.4 to 214.6)	105.3 (59.4 to 180.9)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	128.5 (74.4 to 214.6)	105.3 (59.4 to 180.9)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Fjji prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	58.2 (42.5 to 75.4)	77.9 (57.6 to 101.1)	34.0 (28.8 to 39.0)	-3.6 (-7.0 to 0.1)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	13.4 (9.1 to 18.9)	13.1 (8.9 to 18.6)	-2.6 (-14.8 to 11.3)	-18.5 (-30.6 to -4.2)
HIV/AIDS and tuberculosis	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	9.1 (5.7 to 30.8)	-23.1 (-33.2 to -8.4)
Tuberculosis	0.7 (0.6 to 0.7)	0.6 (0.6 to 0.7)	-6.9 (-12.6 to 0.5)	-34.2 (-37.9 to -29.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-7.3 (-16.9 to 4.1)	-34.0 (-40.3 to -26.9)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (98.4 to 818.6)	0.0 (42.8 to 562.9)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	140.7 (-25.4 to 385.2)	66.2 (-48.7 to 239.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	140.7 (-26.2 to 388.8)	66.2 (-49.6 to 239.6)
HIV/AIDS resulting in other diseases	0.1 (0.0 to 0.1)	0.4 (0.2 to 0.7)	521.2 (207.0 to 981.9)	380.0 (136.7 to 731.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	380.4 (98.6 to 831.6)	246.2 (43.8 to 571.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	1.8 (1.3 to 2.4)	1.6 (1.1 to 2.2)	-10.1 (-16.6 to -3.2)	-18.9 (-24.5 to -13.1)
Diarrheal diseases	3.7 (3.3 to 4.1)	3.0 (2.7 to 3.3)	-19.6 (-30.6 to -7.5)	-18.1 (-28.6 to -7.0)	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.7)	-27.9 (-31.9 to -7.0)	-27.9 (-29.2 to -5.9)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-43.8 to -5.1)	0.0 (-46.9 to -13.8)
Typhoid fever	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-28.3 (-39.6 to -14.7)	-34.0 (-43.5 to -22.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.5 (-43.1 to -9.5)	-33.4 (-46.3 to -18.2)
Paratyphoid fever	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-41.5 (-54.9 to -26.6)	-45.3 (-57.3 to -31.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.9 (-56.2 to -21.3)	-45.4 (-58.4 to -28.8)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.1 (-97.7 to 1566.3)	-61.9 (-97.9 to 1473.2)
Lower respiratory infections	0.8 (0.7 to 1.0)	0.7 (0.6 to 0.8)	-18.5 (-36.0 to 3.5)	-30.5 (-44.0 to -16.8)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	0.1 (-38.3 to 5.2)	0.1 (-45.0 to -16.0)
Upper respiratory infections	22.2 (20.9 to 23.4)	25.3 (24.1 to 26.4)	14.0 (5.5 to 23.1)	-0.8 (-7.7 to 6.7)	0.3 (0.1 to 0.4)	0.3 (0.2 to 0.5)	13.6 (4.2 to 23.0)	-0.7 (-8.4 to 7.3)
Otitis media	10.3 (9.7 to 11.0)	10.3 (9.7 to 10.9)	-0.6 (-7.8 to 6.8)	-11.0 (-17.1 to -4.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-1.4 (-9.9 to 6.5)	-10.8 (-18.1 to -3.8)
Meningitis	-	-	-	-	0.6 (0.4 to 0.8)	0.5 (0.3 to 0.7)	-16.1 (-28.5 to -12)	-29.7 (-38.8 to -17.0)
Pneumococcal meningitis	3.3 (1.9 to 5.0)	2.9 (1.7 to 4.5)	-13.3 (-27.7 to 4.1)	-32.0 (-42.7 to -19.3)	0.2 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-14.9 (-32.9 to 8.3)	-29.0 (-43.0 to -11.4)
H influenzae type B meningitis	0.7 (0.3 to 1.4)	0.5 (0.1 to 0.9)	-34.1 (-62.6 to -8.0)	-45.9 (-68.0 to -25.5)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-38.9 (-70.3 to 0.2)	-46.1 (-73.3 to -12.8)
Meningococcal meningitis	0.4 (0.1 to 0.9)	0.3 (0.1 to 0.8)	-14.5 (-36.3 to 15.3)	-36.3 (-49.4 to -12.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-16.1 (-40.6 to 16.2)	-35.1 (-51.1 to -9.3)
Other meningitis	1.2 (0.5 to 2.3)	1.1 (0.5 to 2.1)	-8.4 (-25.5 to 14.3)	-25.4 (-38.7 to -3.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-2.7 (-32.2 to 37.3)	-17.1 (-40.2 to 15.0)
Encephalitis	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.5)	15.9 (0.3 to 32.4)	-13.9 (-23.8 to -1.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.7 (0.6 to 44.2)	9.7 (-22.6 to 7.5)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.3 (-88.1 to 1,048.3)	-0.6 (-88.2 to 862.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.3 (-88.3 to 871.0)	-0.6 (-88.3 to 871.0)
Whooping cough	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	175.5 (156.0 to 197.0)	219.7 (197.1 to 244.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	177.9 (102.0 to 295.0)	222.8 (135.2 to 354.6)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.3 (-75.2 to 191.2)	-44.9 (-78.7 to 148.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.9 (-74.8 to 55.3)	-47.2 (-76.4 to 33.7)
Measles	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	36.7 (25.2 to 48.4)	36.7 (44.4 to 71.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.8 (-5.3 to 95.8)	39.8 (8.6 to 124.4)
Varicella and herpes zoster	0.8 (0.7 to 0.9)	0.9 (0.8 to 1.0)	14.8 (1.8 to 32.6)	-1.6 (-13.9 to 16.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	37.9 (11.5 to 74.3)	-1.6 (-18.9 to 23.5)
Neglected tropical diseases and malaria	-	-	-	-	5.9 (3.7 to 9.1)	5.5 (3.3 to 8.6)	-7.6 (-30.8 to 26.0)	-31.0 (-49.5 to -3.4)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.9 (-55.9 to 134.3)	8.7 (-59.7 to 117.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.2 (-56.2 to 124.8)	4.7 (-59.7 to 108.6)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.6 (-11.0 to 33.5)	-3.5 (-22.1 to 19.8)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.2 (-49.6 to 128.5)	3.2 (-43.6 to 119.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.2 (-49.6 to 130.1)	3.2 (-43.6 to 119.7)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.5 (-11.2 to 34.2)	-3.8 (-23.1 to 18.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.5 (-11.2 to 34.3)	-3.8 (-23.1 to 18.8)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.2 (0.1 to 0.3)	0.0 (0.0 to 0.1)	-79.2 (-90.7 to -49.2)	-85.7 (-93.9 to -47.1)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-78.3 (-91.3 to -43.1)	-85.2 (-94.2 to -63.6)
Cystic echinococcosis	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-28.8 (-36.4 to -17.8)	-49.0 (-53.6 to -39.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.8 (-43.9 to -6.7)	-48.0 (-58.4 to -32.8)
Lymphatic filariasis	39.4 (33.0 to 46.9)	5.7 (3.5 to 8.5)	-85.6 (-90.7 to -80.5)	-89.6 (-93.3 to -86.0)	1.3 (0.6 to 2.3)	0.5 (0.2 to 0.9)	-60.3 (-79.4 to -44.1)	-75.5 (-87.6 to -64.5)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	1.0 (0.5 to 1.7)	0.7 (0.4 to 1.2)	-25.6 (-60.8 to 40.0)	-67.8 (-84.1 to -42.5)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-26.2 (-60.8 to 33.8)	-67.8 (-84.0 to -44.5)
Dengue	0.3 (0.1 to 0.7)	1.7 (0.6 to 3.8)	483.7 (483.2 to 484.4)	391.6 (391.1 to 392.1)	0.0 (0.0 to 0.1)	0.3 (0.1 to 0.7)	479.4 (407.3 to 577.3)	391.3 (333.3 to 463.2)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.1 (-51.5 to 46.7)	-37.0 (-60.1 to 13.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.0 (-51.5 to 46.9)	37.0 (-60.1 to 13.5)
Intestinal nematode infections	-	-	-	-	4.2 (2.4 to 6.9)	4.5 (2.5 to 7.4)	5.0 (-25.7 to 49.1)	-12.2 (-40.1 to 28.8)
Ascariasis	148.3 (105.9 to 206.6)	255.4 (179.2 to 362.2)	72.0 (10.0 to 180.2)	41.4 (-13.0 to 141.8)	0.5 (0.2 to 0.9)	0.4 (0.2 to 0.8)	-20.4 (-51.1 to 28.4)	-24.6 (-54.7 to 21.9)
Trichuriasis	213.7 (156.3 to 285.0)	339.4 (255.1 to 444.9)	58.7 (5.2 to 138.6)	27.9 (-18.3 to 98.1)	1.7 (0.8 to 3.3)	2.2 (1.0 to 4.0)	30.7 (-34.5 to 160.5)	2.4 (-50.5 to 106.8)
Hookworm disease	281.9 (226.4 to 343.9)	264.8 (189.5 to 345.0)	-6.1 (-36.9 to 29.3)	37.6 (-50.6 to 5.5)	1.8 (1.2 to 3.1)	1.8 (1.1 to 2.9)	2.2 (-30.9 to 22.6)	-22.3 (-43.1 to 7.2)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	6.6 (4.8 to 8.7)	5.7 (5.0 to 6.3)	-14.5 (-35.5 to 18.6)	-7.4 (-29.9 to 29.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-14.1 (-27.7 to 43.2)	-5.6 (-20.8 to 60.2)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-11.4 (-39.3 to 7.4)	-23.7 (-47.5 to -7.5)
Maternal hemorrhage	0.5 (0.5 to 0.5)	0.5 (0.4 to 0.7)	5.0 (-27.4 to 39.8)	-9.0 (-37.4 to 21.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.1 (-47.0 to 27.0)	-15.9 (-54.2 to 10.1)
Maternal sepsis and other maternal infections	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-42.3 (-36.8 to -12.3)	-42.3 (-51.9 to -34.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.2 (-60.9 to 21.6)	-44.1 (-66.8 to -3.4)
Maternal hypertensive disorders	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-15.1 (-25.7 to 5.2)	-26.9 (-35.5 to -10.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.9 (-32.9 to 15.3)	-26.8 (-41.9 to -11.8)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.0 (-71.1 to 1.7)	-50.7 (-74.8 to -13.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.0 (-73.1 to 61.7)	-46.7 (-76.2 to 32.0)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.4 (-47.2 to 71.1)	-13.8 (-53.0 to 45.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-47.8 to 71.2)	-13.8 (-53.3 to 45.4)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.0 (-52.3 to 41.1)	-26.0 (-58.7 to 21.8)
Neonatal disorders	-	-	-	-	0.9 (0.6 to 1.3)	1.4 (0.9 to 2.1)	63.3 (15.2 to 160.4)	48.3 (6.1 to 134.3)
Preterm birth complications	3.7 (2.0 to 6.9)	8.7 (4.4 to 17.1)	135.0 (72.6 to 215.6)	101.6 (54.4 to 168.5)	0.4 (0.3 to 0.7)	0.9 (0.5 to 1.4)	95.5 (25.0 to 229.5)	74.5 (14.3 to 190.9)
Neonatal encephalopathy due to birth asphyxia and trauma	2.2 (0.8 to 4.8)	2.8 (1.0 to 6.3)	30.4 (4.5 to 64.0)	12.2 (-6.9 to 40.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	20.0 (-29.2 to 108.4)	13.1 (-32.8 to 99.2)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.7 (93.3 to 115.8)	138.8 (128.8 to 155.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.8 (77.7 to 137.3)	102.8 (110.3 to 180.8)
Hemolytic disease and other neonatal jaundice	0.3 (0.1 to 0.6)	0.5 (0.2 to 1.1)	67.8 (-57.2 to 487.6)	54.7 (-60.8 to 435.2)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	59.4 (-57.5 to 403.1)	45.1 (-61.7 to 354.0)
Other neonatal disorders	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	24.0 (-50.8 to 240.6)	12.6 (-55.2 to 206.1)
Nutritional deficiencies	-	-	-	-	3.9 (2.6 to 5.6)	3.4 (2.3 to 5.0)	-11.5 (-18.3 to -4.8)	-11.8 (-17.8 to -5.8)
Protein-energy malnutrition	3.8 (2.3 to 5.5)	2.5 (1.6 to 3.8)	-34.0 (-62.6 to 23.9)	-24.7 (-56.8 to 38.9)	0.5 (0.2 to 0.9)	0.3 (0.2 to 0.5)	-34.1 (-63.1 to 25.4)	-24.6 (-56.9 to 41.3)
Iodine deficiency	0.5 (0.4 to 0.6)	0.4 (0.3 to 0.5)	-14.5 (-32.5 to 6.5)	-35.2 (-48.7 to -18.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.5 (-35.1 to 10.9)	-34.9 (-50.3 to -15.1)
Vitamin A deficiency	0.8 (0.7 to 1.0)	0.5 (0.4 to 0.6)	-36.6 (-45.8 to -26.7)	-41.8 (-49.6 to -33.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-36.7 (-46.9 to -24.7)	-43.5 (-52.1 to -33.2)

Appendix Table G.4 - FJI prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	103.2 (101.4 to 104.9)	100.7 (99.1 to 102.6)	-2.4 (-5.0 to 0.2)	-2.2 (-9.6 to -4.7)	3.4 (2.2 to 4.9)	3.1 (2.0 to 4.5)	-0.0 (-11.8 to -5.2)	-0.0 (-13.7 to -7.2)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.7 (-68.2 to 79.3)	-12.3 (-63.4 to 102.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.7 (0.4 to 1.1)	0.9 (0.5 to 1.3)	20.2 (9.8 to 33.2)	2.8 (-5.6 to 12.8)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.5 (0.3 to 0.7)	0.6 (0.3 to 0.9)	22.7 (14.5 to 32.7)	-1.6 (-7.7 to 5.7)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.7 (-20.0 to 11.8)	-40.0 (-47.7 to -30.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-32.8 to 31.3)	-99.9 (-55.4 to -18.7)
Chlamydial infection	85.7 (71.4 to 100.0)	105.4 (91.6 to 118.9)	23.5 (1.5 to 49.0)	0.3 (-16.6 to 21.3)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.7)	23.7 (14.9 to 34.5)	0.9 (-6.1 to 9.2)
Gonococcal infection	6.2 (4.8 to 8.0)	6.2 (4.5 to 8.1)	-2.1 (-30.5 to 41.6)	-17.5 (-40.4 to 18.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	16.0 (-18.4 to 58.9)	-3.2 (-30.6 to 32.7)
Trichomoniasis	8.4 (5.5 to 12.2)	8.9 (5.7 to 11.8)	11.7 (-40.1 to 71.8)	-10.4 (-49.9 to 32.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.5 (-45.5 to 73.9)	-12.5 (-54.4 to 38.3)
Genital herpes	100.6 (97.9 to 103.4)	145.0 (139.6 to 146.2)	43.5 (37.2 to 48.4)	4.0 (-7.1 to -0.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	38.6 (25.3 to 47.4)	-3.2 (-8.5 to 1.6)
Other sexually transmitted diseases	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-3.8 (-15.3 to 8.8)	-29.4 (-37.9 to -20.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-33.2 to 29.3)	-3.8 (-47.9 to -4.8)
Hepatitis	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	18.9 (0.2 to 44.9)	-5.9 (-21.5 to 17.1)
Hepatitis A	1.1 (1.0 to 1.1)	1.0 (1.0 to 1.1)	-3.5 (-4.5 to -2.5)	-4.8 (-4.9 to -4.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.9 (-2.1 to 23.6)	-0.9 (-11.3 to 10.7)
Hepatitis B	46.2 (38.1 to 54.7)	51.3 (44.6 to 58.2)	11.6 (-12.8 to 39.2)	-13.1 (-31.6 to 8.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.6 (-17.5 to 95.5)	-13.4 (-40.9 to 42.6)
Hepatitis C	20.9 (18.6 to 23.5)	22.1 (19.8 to 24.2)	6.2 (-9.4 to 22.8)	-27.0 (-36.8 to -36.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.8 (-14.8 to 47.5)	-17.7 (-39.6 to 11.7)
Hepatitis E	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.4)	41.4 (15.9 to 66.3)	10.8 (-7.9 to 29.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.9 (8.3 to 81.3)	10.8 (-14.8 to 39.7)
Leprosy	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	23.9 (-30.9 to 444.8)	-23.9 (-56.0 to 267.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.1 (-37.5 to 518.6)	-22.7 (-60.0 to 302.3)
Other infectious diseases	4.5 (3.6 to 5.6)	3.9 (3.2 to 4.7)	-13.4 (-31.1 to 8.5)	-7.7 (-26.3 to 15.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	14.5 (-13.1 to 56.1)	18.7 (-10.8 to 61.4)
Non-communicable diseases	-	-	-	-	43.2 (31.7 to 55.9)	62.8 (46.3 to 81.4)	45.7 (40.2 to 50.9)	127.1 (-3.2 to 3.2)
Neoplasms	-	-	-	-	0.4 (0.3 to 0.6)	1.0 (0.7 to 1.4)	129.8 (60.6 to 225.1)	40.8 (1.0 to 92.0)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.6 (18.2 to 198.2)	1.5 (-37.0 to 58.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.4 (17.3 to 180.1)	-1.0 (-38.8 to 49.1)
Stomach cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	24.7 (-11.1 to 73.4)	-36.1 (-54.0 to -13.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.9 (-13.2 to 68.7)	-38.3 (-55.4 to -15.5)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	153.2 (64.4 to 332.6)	34.7 (-13.1 to 115.6)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	227.6 (78.8 to 526.8)	73.2 (-3.6 to 217.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	192.8 (73.1 to 417.5)	55.0 (-6.7 to 161.3)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	593.3 (195.3 to 1,334.4)	250.2 (59.6 to 594.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	512.2 (182.4 to 1,126.6)	209.9 (47.5 to 478.3)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.1 (-48.8 to 213.6)	-43.3 (-74.5 to 43.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.3 (-50.5 to 160.1)	-49.0 (-74.8 to 18.0)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.5 (-29.8 to 209.9)	-25.6 (-62.8 to 65.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.3 (-31.7 to 160.2)	-31.3 (-63.9 to 35.0)
Larynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	91.0 (18.2 to 195.4)	5.8 (-35.2 to 60.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.1 (18.9 to 227.3)	9.6 (-35.8 to 85.0)
Tracheal, bronchus and lung cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	38.6 (-2.6 to 93.1)	-21.9 (-42.5 to 3.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.0 (-4.0 to 94.3)	-23.0 (-44.8 to 6.0)
Breast cancer	2.5 (1.6 to 3.5)	7.2 (5.8 to 9.0)	193.5 (94.8 to 353.6)	85.6 (26.2 to 147.8)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	148.6 (64.3 to 292.8)	54.5 (4.0 to 133.2)
Cervical cancer	0.7 (0.4 to 1.0)	1.1 (0.5 to 1.4)	46.0 (-14.5 to 147.2)	9.9 (-45.6 to 48.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	49.5 (-15.6 to 147.5)	-9.6 (-45.4 to 47.3)
Uterine cancer	0.5 (0.2 to 0.8)	1.0 (0.4 to 1.6)	99.4 (10.8 to 264.2)	5.4 (-40.8 to 87.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	100.1 (8.7 to 266.1)	4.3 (-41.4 to 86.6)
Prostate cancer	0.1 (0.0 to 0.1)	0.7 (0.2 to 1.4)	2,063.2 (144.7 to 3,875.9)	741.9 (11.6 to 1,568.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	4,149.8 (154.7 to 8,230.5)	1,760.3 (22.6 to 3,670.5)
Colon and rectum cancer	0.4 (0.3 to 0.5)	0.7 (0.6 to 0.8)	83.4 (36.9 to 140.4)	8.1 (-17.5 to 37.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	78.2 (34.8 to 136.5)	5.4 (-19.8 to 36.2)
Lip and oral cavity cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	64.4 (-4.4 to 131.0)	-3.0 (-4.0 to 64.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.6 (-1.0 to 191.6)	-4.0 (-40.4 to 58.7)
Nasopharynx cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	27.5 (-25.7 to 146.0)	-18.5 (-50.5 to 54.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.9 (-25.5 to 143.4)	-20.7 (-52.7 to 44.8)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.7 (-1.9 to 222.3)	-11.7 (-50.1 to 57.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.5 (-0.4 to 199.1)	-15.1 (-50.2 to 44.0)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.1 (-33.0 to 107.0)	-36.9 (-66.6 to 2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.2 (-34.3 to 95.9)	-38.1 (-66.7 to 0.8)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,705.2 (1,819.9 to 3,957.1)	2,175.8 (1,521.0 to 3,049.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3,111.3 (2,216.8 to 4,395.6)	2,388.4 (1,699.9 to 3,551.0)
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	231.1 (90.2 to 442.1)	142.4 (47.7 to 275.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	142.4 (81.6 to 421.9)	127.0 (38.4 to 249.7)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	199.3 (130.6 to 307.5)	53.4 (17.1 to 113.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	300.8 (157.9 to 520.8)	108.0 (13.1 to 230.2)
Ovarian cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.4 (-5.1 to 201.3)	8.9 (-35.5 to 89.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.7 (-1.6 to 196.6)	9.3 (-33.0 to 85.7)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	225.8 (24.0 to 797.4)	180.9 (-10.4 to 669.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	247.9 (20.7 to 964.3)	209.9 (-19.2 to 824.9)
Kidney cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	437.2 (221.3 to 757.9)	290.0 (148.6 to 499.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	428.8 (222.4 to 727.6)	272.5 (133.0 to 471.2)
Bladder cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	227.1 (62.7 to 862.5)	11.1 (-40.2 to 311.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	164.3 (43.8 to 737.9)	-5.8 (-53.5 to 257.3)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	606.6 (78.9 to 1,142.4)	491.6 (35.9 to 881.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	633.5 (78.4 to 1,102.9)	482.7 (25.8 to 808.7)
Thyroid cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	95.3 (11.5 to 229.5)	33.7 (-20.6 to 120.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.8 (9.4 to 236.0)	32.6 (-23.8 to 115.0)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.1 (-45.5 to 30.9)	-55.6 (-70.0 to -31.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.0 (-42.3 to 31.1)	-56.0 (-69.9 to -30.9)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	310.7 (42.4 to 763.7)	264.4 (19.6 to 624.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	307.8 (44.3 to 738.1)	246.6 (12.6 to 546.3)
Non-Hodgkin lymphoma	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	355.2 (64.8 to 621.7)	219.6 (12.4 to 385.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	337.9 (61.4 to 604.1)	191.6 (4.7 to 350.1)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	101.4 (14.0 to 233.0)	6.4 (-37.4 to 72.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.4 (9.0 to 242.9)	3.5 (-39.5 to 74.4)
Leukemia	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	31.1 (-37.6 to 80.2)	11.8 (-43.9 to 37.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	31.0 (-30.8 to 62.6)	0.0 (-45.1 to 17.3)
Other neoplasms	0.1 (0.0 to 0.3)	1.1 (0.6 to 1.7)	1,830.3 (129.4 to 3,196.5)	1,332.9 (79.4 to 2,194.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	1,650.6 (118.6 to 2,968.9)	1,137.2 (56.7 to 1,921.1)
Cardiovascular diseases	-	-	-	-	0.8 (0.5 to 1.1)	2.0 (1.4 to 2.8)	157.8 (100.6 to 219.3)	31.1 (5.6 to 58.4)
Rheumatic heart disease	1.1 (1.1 to 1.2)	1.5 (1.4 to 1.6)	35.7 (25.8 to 47.1)	2.3 (-4.6 to 10.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	39.5 (7.6 to 64.3)	-2.7 (-26.8 to 12.8)
Ischemic heart disease	2.6 (2.1 to 3.1)	5.7 (4.6 to 7.0)	123.1 (65.6 to 195.4)	2.0 (-22.5 to 33.8)	0.2 (0.1 to 0.3)	0.6 (0.3 to 0.6)	128.1 (76.4 to 192.1)	5.1 (-16.5 to 35.9)
Cerebrovascular disease	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	95.6 (49.2 to 140.5)	-1.5 (-25.0 to 21.6)
Ischemic stroke	0.4 (0.4 to 0.5)	0.8 (0.7 to 1.0)	102.6 (52.2 to 156.8)	-2.7 (-26.7 to 24.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	102.6 (51.1 to 159.7)	-1.8 (-27.9 to 26.0)
Hemorrhagic stroke	0.5 (0.5 to 0.6)	1.0 (0.9 to 1.2)	91.6 (49.1 to 136.4)	-1.2 (-24.1 to 21.3)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	90.9 (47.0 to 135.8)	-0.6 (-26.1 to 22.1)
Hypertensive heart disease	0.6 (0.5 to 0.7)	1.4 (1.3 to 1.6)	143.2 (101.6 to 190.3)	17.8 (-1.1 to 38.6)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	143.7 (99.3 to 194.1)	18.0 (-2.6 to 40.7)
Cardiomyopathy and myocarditis	0.4 (0.4 to 0.5)	0.9 (0.8 to 1.0)	108.1 (78.7 to 142.2)	19.0 (1.8 to 39.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	197.8 (75.4 to 151.7)	19.1 (1.0 to 42.4)
Atrial fibrillation and flutter	0.5 (0.4 to 0.6)	1.7 (1.4 to 2.0)	259.6 (160.9 to 372.5)	63.5 (12.8 to 122.2)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	262.0 (162.7 to 381.3)	64.4 (14.2 to 124.7)
Peripheral vascular disease	6.0 (4.4 to 8.0)	14.8 (10.6 to 19.8)	140.9 (62.1 to 314.1)	12.8 (-18.8 to 64.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.9 (-17.8 to 284.8)	-14.8 (-59.3 to 86.8)
Endocarditis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-3.5 (-28.4 to 48.9)	-38.0 (-55.8 to -1.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.0 (-35.2 to 56.4)	-38.4 (-60.2 to 0.4)
Other cardiovascular and circulatory diseases	2.9 (1.6 to 4.5)	10.9 (5.6 to 16.2)	382.8 (75.9 to 654.6)	112.3 (-1.5 to 330.2)	0.2 (0.1 to 0.3)	0.8 (0.4 to 1.3)	280.5 (75.2 to 651.8)	112.1 (-3.1 to 331.4)
Chronic respiratory diseases	-	-	-	-	2.3 (1.6 to 3.2)	3.3 (2.3 to 4.5)	44.9 (25.8 to 65.2)	-8.0 (-17.5 to 3.9)
Chronic obstructive pulmonary disease	16.7 (15.7 to 17.6)	27.9 (26.4 to						

Appendix Table G.4 - Fiji prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	185.9	56.0
Silicosis	0.0	0.0	61.3	-17.5	(0.0 to 0.0)	(0.0 to 0.0)	(166.7 to 201.5)	(43.4 to 67.2)
Asbestosis	-	-	0.0	0.0	-	-	60.9	-17.7
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	238.5	97.5	0.0	0.0	234.7	93.2
Asthma	16.3	18.2	(225.0 to 256.5)	(90.1 to 107.6)	0.7	0.8	(221.4 to 252.6)	(82.8 to 105.0)
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.1	(-18.0 to 46.0)	(-37.1 to -0.1)	(0.4 to 1.1)	(0.5 to 1.2)	(-19.1 to 45.8)	(-37.9 to 1.2)
Other chronic respiratory diseases	0.0	0.1	70.0	3.4	0.0	0.0	69.9	2.0
Cirrhosis	-	-	-	-	0.1	0.1	(-4.7 to -8.1)	(-44.7 to -8.1)
Cirrhosis due to hepatitis B	0.2	0.2	-3.8	-31.3	(0.0 to 0.1)	(0.0 to 0.1)	(-24.2 to -1.7)	(-44.5 to -29.8)
Cirrhosis due to hepatitis C	0.0	0.1	22.3	-15.5	0.0	0.0	23.8	-13.5
Cirrhosis due to alcohol use	0.1	0.0	-44.7	-65.6	(0.0 to 0.0)	(0.0 to 0.0)	(-38.0 to 139.9)	(54.8 to 53.7)
Cirrhosis due to other causes	0.1	0.0	-32.1	-35.8	(0.0 to 0.0)	(0.0 to 0.0)	(-67.7 to -10.5)	(-78.6 to -46.3)
Digestive diseases	-	-	-	-	0.6	0.7	(58.3 to 2.2)	(-60.2 to -5.0)
Peptic ulcer disease	4.9	4.8	-0.8	-46.4	0.2	0.2	4.7	-40.6
Gastritis and duodenitis	5.2	6.0	15.8	-22.8	(0.1 to 0.2)	(0.1 to 0.2)	(-10.1 to 22.7)	(-47.8 to -31.0)
Appendicitis	0.1	0.0	-9.9	-29.4	0.0	0.0	-9.8	-28.2
Paralytic ileus and intestinal obstruction	0.0	0.0	17.5	-12.1	(0.0 to 0.0)	(0.0 to 0.0)	(4.2 to 44.4)	(54.5 to 7.5)
Inguinal, femoral, and abdominal hernia	0.9	1.5	62.1	-13.6	0.0	0.0	61.4	-13.5
Inflammatory bowel disease	0.1	0.2	40.7	-8.9	(0.0 to 0.0)	(0.0 to 0.0)	(28.4 to 95.7)	(-33.0 to 8.8)
Vascular intestinal disorders	0.0	0.0	86.3	70.8	(0.0 to 0.0)	(0.0 to 0.0)	(16.7 to 69.4)	(-22.3 to 7.6)
Gallbladder and biliary diseases	0.2	0.4	73.8	13.5	0.0	0.0	73.8	4.7
Pancreatitis	0.1	0.2	65.9	5.5	(0.0 to 0.0)	(0.0 to 0.1)	63.9	5.1
Other digestive diseases	-	-	-	-	0.1	0.1	(58.8 to 264.4)	(1.7 to 135.0)
Neurological disorders	-	-	-	-	3.2	4.7	46.8	3.1
Alzheimer disease and other dementias	1.5	3.3	120.6	3.8	(2.1 to 4.5)	(3.2 to 6.5)	(21.8 to 75.9)	(-11.6 to 20.0)
Parkinson disease	0.3	0.6	109.7	-0.5	(0.1 to 0.3)	(0.3 to 0.6)	(81.7 to 159.2)	(-14.3 to 22.7)
Epilepsy	2.1	2.5	18.3	-1.1	0.7	0.9	20.1	1.5
Multiple sclerosis	0.0	0.0	172.5	79.7	(0.0 to 0.0)	(0.0 to 0.0)	(140.6 to 203.4)	(60.0 to 100.5)
Migraine	49.5	45.6	-7.8	0.8	2.2	2.2	1.5	0.5
Tension-type headache	90.6	126.9	40.8	2.7	(0.1 to 2.6)	(1.3 to 3.5)	(4.3 to 79.2)	(-28.7 to 29.0)
Medication overuse headache	2.3	5.1	125.2	53.3	0.4	0.8	124.3	53.6
Other neurological disorders	0.0	0.0	34.6	3.7	(0.0 to 0.1)	(0.1 to 0.1)	25.6	-41.1
Mental and substance use disorders	-	-	-	-	11.6	15.4	32.6	0.4
Schizophrenia	2.1	3.0	44.0	-0.1	(8.3 to 15.1)	(11.2 to 19.9)	(28.9 to 36.4)	(-1.7 to 2.7)
Alcohol use disorders	5.5	8.8	62.0	25.6	1.4	1.9	43.6	0.2
Drug use disorders	-	-	-	-	1.2	1.4	15.8	-5.5
Opioid use disorders	0.7	1.0	35.5	1.1	(0.8 to 1.7)	(1.0 to 1.9)	(0.6 to 34.9)	(-18.2 to 9.0)
Cocaine use disorders	0.5	0.7	23.4	0.1	(0.2 to 0.5)	(0.3 to 0.6)	(16.4 to 56.3)	(-12.1 to 15.8)
Amphetamine use disorders	2.5	2.6	4.0	-11.8	(0.1 to 1.0)	(0.1 to 0.1)	(0.8 to 48.7)	(-18.1 to 18.9)
Cannabis use disorders	2.6	3.1	18.1	0.3	0.3	0.3	4.0	-11.7
Other drug use disorders	-	-	-	-	0.1	0.1	18.6	0.8
Depressive disorders	-	-	-	-	0.4	0.5	9.0	-8.4
Major depressive disorder	13.1	18.3	39.3	-0.0	(0.3 to 0.7)	(0.3 to 0.7)	(20.8 to 50.9)	(-33.4 to 26.8)
Dysthymia	7.7	11.7	52.1	0.2	0.4	0.5	41.4	0.1
Bipolar disorder	3.7	5.0	37.4	-0.7	0.8	1.0	37.0	-0.4
Anxiety disorders	17.7	23.0	29.4	0.1	1.6	2.1	29.0	0.1
Eating disorders	-	-	-	-	0.1	0.1	5.9	-6.7
Anorexia nervosa	0.2	0.2	-1.3	-12.2	(0.1 to 0.1)	(0.1 to 0.1)	(-1.2 to 21.1)	(-27.2 to 8.0)
Bulimia nervosa	0.2	0.2	13.4	-1.1	0.0	0.0	14.3	-0.4
Autistic spectrum disorders	-	-	-	-	0.9	1.1	18.9	0.4
Autism	2.3	2.7	19.3	0.1	(0.6 to 1.2)	(0.7 to 1.4)	(14.7 to 22.9)	(-2.7 to 3.7)
Asperger syndrome	3.3	3.9	19.0	0.2	0.4	0.4	18.7	0.4
Attention-deficit/hyperactivity disorder	5.3	5.3	0.2	0.4	(0.2 to 0.5)	(0.3 to 0.5)	(13.9 to 23.9)	(-3.3 to 4.5)
Conduct disorder	5.3	4.8	-9.5	0.0	(0.0 to 0.1)	(0.0 to 0.1)	(-7.1 to 7.2)	(-6.2 to 7.7)
Idiopathic intellectual disability	3.2	2.5	-21.3	-29.7	(0.4 to 0.9)	(0.4 to 0.9)	(-4.7 to 5.9)	(-4.7 to 5.9)
Other mental and substance use disorders	10.2	14.6	43.6	0.0	0.8	1.1	43.3	0.3
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	5.0	8.3	65.4	10.3
Diabetes mellitus	40.3	77.1	90.8	16.6	(3.4 to 6.9)	(5.6 to 11.5)	(47.1 to 86.5)	(-1.9 to 25.0)
Acute glomerulonephritis	0.0	0.0	31.0	14.3	(0.0 to 0.0)	(0.0 to 0.0)	(22.0 to 39.5)	(7.5 to 20.8)
Chronic kidney disease	-	-	-	-	0.6	0.8	43.6	6.7
Chronic kidney disease due to diabetes mellitus	2.3	6.1	161.3	56.5	(0.4 to 0.8)	(0.6 to 1.1)	(30.6 to 61.9)	(-1.6 to 17.0)
Chronic kidney disease due to hypertension	4.6	4.7	39.4	-50.5	0.1	0.2	(82.2 to 252.1)	(19.7 to 121.6)
Chronic kidney disease due to glomerulonephritis	5.5	6.9	26.1	8.4	(0.1 to 0.2)	(0.1 to 0.3)	(6.5 to 85.8)	(-19.7 to 33.8)
Chronic kidney disease due to other causes	12.1	17.8	47.8	5.0	0.3	0.4	(36.4 to 96.8)	(-2.2 to 40.5)
Urinary diseases and male infertility	-	-	-	-	0.2	0.4	83.5	-2.6
	-	-	-	-	(0.2 to 0.3)	(0.3 to 0.6)	(66.2 to 104.7)	(-11.3 to 9.4)

Appendix Table G.4 - FJII prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	67.7 (54.3 to 84.0)	27.5 (17.7 to 38.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.3 (33.9 to 111.0)	27.2 (5.5 to 54.7)
Urolithiasis	1.5 (1.1 to 2.0)	2.6 (1.9 to 3.7)	77.0 (39.1 to 100.7)	-0.8 (-21.6 to 14.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	49.3 (32.1 to 69.0)	-6.0 (-16.0 to 3.9)
Benign prostatic hyperplasia	3.7 (3.3 to 4.0)	7.7 (6.9 to 8.5)	108.4 (84.0 to 142.4)	-5.0 (-16.8 to 10.0)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	109.0 (84.2 to 143.4)	-4.6 (-16.0 to 10.2)
Male infertility due to other causes	6.0 (4.8 to 7.3)	7.5 (6.1 to 9.0)	25.8 (3.4 to 69.6)	1.5 (-21.7 to 35.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	25.6 (5.6 to 73.4)	1.9 (-23.3 to 39.8)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (21.5 to 158.3)	0.0 (-19.9 to 65.4)
Gynecological diseases	-	-	-	-	0.8 (0.5 to 1.2)	1.0 (0.6 to 1.5)	29.5 (12.3 to 48.4)	-4.5 (-15.5 to 7.9)
Uterine fibroids	12.9 (11.7 to 14.2)	19.4 (17.7 to 21.1)	50.1 (48.5 to 52.0)	-1.3 (-1.3 to -1.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	36.2 (23.4 to 48.7)	-6.4 (-14.8 to 2.2)
Polycystic ovarian syndrome	10.1 (9.0 to 11.2)	12.6 (11.3 to 13.9)	24.6 (7.3 to 48.0)	-5.0 (-17.5 to 10.8)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	24.5 (6.8 to 48.7)	-4.9 (-17.5 to 11.2)
Female infertility due to other causes	6.6 (5.2 to 8.0)	8.4 (6.7 to 10.4)	27.3 (3.4 to 74.8)	-0.9 (-25.7 to 37.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	26.1 (5.0 to 72.3)	-0.9 (-25.6 to 35.8)
Endometriosis	1.2 (1.1 to 1.5)	1.7 (1.4 to 1.9)	31.7 (7.2 to 67.2)	-0.4 (-19.0 to 25.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	32.4 (5.3 to 68.4)	0.1 (-20.1 to 27.3)
Genital prolapse	29.4 (25.0 to 33.7)	42.8 (37.6 to 49.2)	45.9 (18.4 to 80.9)	-3.6 (-19.5 to 17.2)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	45.6 (18.8 to 81.4)	-3.4 (-19.8 to 17.2)
Premenstrual syndrome	21.3 (14.2 to 29.3)	25.7 (18.1 to 34.1)	18.9 (-28.0 to 94.7)	-5.9 (-39.6 to 51.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	17.9 (-28.6 to 100.4)	-6.3 (-40.6 to 55.0)
Other gynecological diseases	1.8 (1.4 to 2.3)	2.2 (1.9 to 2.5)	21.1 (-7.5 to 64.3)	-6.8 (-29.1 to 27.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	16.1 (-17.3 to 104.7)	-10.4 (-36.1 to 60.8)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.6 (0.4 to 0.9)	0.7 (0.5 to 1.0)	10.2 (0.5 to 23.5)	6.3 (-3.8 to 19.8)
Thalassemias	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-11.9 (-24.3 to 10.6)	-9.0 (-22.3 to 14.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.5 (-34.3 to 23.5)	-12.1 (-33.6 to 25.2)
Thalassemia trait	18.9 (15.8 to 23.5)	22.9 (19.3 to 28.4)	20.9 (15.3 to 27.6)	0.7 (-4.0 to 6.9)	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.9)	15.9 (4.6 to 29.8)	10.7 (-1.5 to 24.4)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.8 (-72.2 to -39.3)	-48.7 (-72.3 to -40.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.6 (-71.2 to -26.1)	-38.7 (-72.2 to -28.4)
Sickle cell trait	0.4 (0.3 to 0.5)	0.3 (0.3 to 0.4)	-28.2 (-45.8 to -10.7)	-21.1 (-55.0 to -26.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.5 (-65.5 to -18.2)	-52.8 (-66.3 to -28.6)
G6PD deficiency	8.3 (4.7 to 12.7)	7.4 (4.5 to 13.5)	-13.6 (-59.9 to 78.6)	-28.1 (-66.8 to 49.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.6 (0.4 to 21.6)	-5.0 (-8.7 to 12.1)
G6PD trait	79.4 (52.1 to 100.9)	83.6 (30.7 to 123.5)	5.3 (-61.3 to 77.0)	-12.1 (-67.8 to 47.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.5 (-40.9 to 292.8)	23.2 (-43.3 to 269.0)
Other hemoglobinopathies and hemolytic anemias	3.2 (2.6 to 3.9)	3.1 (2.6 to 3.7)	-3.7 (-29.9 to 24.0)	-5.0 (-28.6 to 18.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-13.0 (-37.9 to 27.3)	-13.0 (-36.3 to 29.9)
Endocrine, metabolic, blood, and immune disorders	6.7 (5.7 to 7.7)	7.6 (7.1 to 8.2)	12.4 (-1.4 to 32.5)	0.3 (-10.4 to 14.4)	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.4)	40.7 (-2.2 to 41.4)	-0.1 (-10.8 to 20.4)
Musculoskeletal disorders	-	-	-	-	8.3 (5.8 to 11.0)	13.2 (9.4 to 17.6)	59.0 (40.4 to 77.9)	0.3 (-10.3 to 9.3)
Rheumatoid arthritis	0.6 (0.6 to 0.7)	1.7 (1.7 to 1.8)	168.4 (153.7 to 182.2)	68.4 (60.0 to 77.0)	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	166.9 (142.3 to 192.4)	68.9 (55.4 to 83.1)
Osteoarthritis	8.7 (8.3 to 9.0)	17.4 (16.6 to 18.1)	99.9 (87.6 to 111.7)	1.7 (-4.1 to 7.4)	0.5 (0.4 to 0.7)	0.7 (0.7 to 1.5)	99.6 (86.9 to 112.3)	1.7 (-4.1 to 7.8)
Low back and neck pain	-	-	-	-	6.2 (4.3 to 8.3)	9.4 (6.4 to 12.9)	51.3 (28.3 to 75.0)	0.4 (-14.9 to 13.8)
Low back pain	34.0 (31.7 to 36.3)	51.8 (48.8 to 55.2)	52.5 (38.8 to 69.0)	0.0 (-7.8 to 9.1)	3.8 (2.6 to 5.4)	5.8 (4.0 to 8.2)	51.9 (37.8 to 67.3)	0.4 (-7.9 to 10.0)
Neck pain	23.8 (18.4 to 29.6)	35.9 (27.5 to 44.1)	52.5 (0.6 to 117.1)	-1.0 (-32.6 to 37.3)	2.4 (1.5 to 3.4)	3.5 (2.3 to 5.3)	51.8 (0.6 to 115.4)	-0.9 (-33.3 to 38.8)
Gout	0.4 (0.4 to 0.4)	0.8 (0.7 to 0.9)	92.9 (74.8 to 113.2)	4.2 (-5.2 to 14.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.2 (57.4 to 136.6)	4.8 (-12.7 to 25.9)
Other musculoskeletal disorders	14.9 (11.7 to 18.2)	24.9 (19.4 to 30.5)	67.1 (15.1 to 82.5)	6.5 (-12.4 to 1.6)	1.4 (0.9 to 2.0)	2.3 (1.5 to 3.3)	66.7 (56.7 to 82.3)	-6.5 (-12.2 to 1.8)
Other non-communicable diseases	-	-	-	-	10.9 (7.4 to 15.6)	14.1 (9.4 to 20.4)	28.8 (23.0 to 34.8)	-8.7 (-12.0 to -5.6)
Congenital anomalies	-	-	-	-	0.7 (0.5 to 1.0)	0.7 (0.5 to 0.9)	-3.5 (-17.4 to 12.8)	-13.4 (-25.3 to 0.6)
Neural tube defects	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	3.1 (-15.0 to 28.2)	-1.2 (-18.8 to 22.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	4.5 (-23.2 to 42.9)	1.1 (-25.4 to 36.6)
Congenital heart anomalies	2.1 (1.8 to 2.5)	2.4 (2.0 to 2.9)	16.3 (-7.1 to 44.7)	6.5 (-14.3 to 32.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	16.8 (-6.9 to 43.2)	8.8 (-12.9 to 33.1)
Orofacial clefts	0.5 (0.4 to 0.6)	0.5 (0.4 to 0.6)	4.5 (-27.2 to 38.4)	0.4 (-30.0 to 33.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.2 (-33.6 to 55.0)	-0.8 (-35.8 to 46.5)
Down syndrome	0.6 (0.5 to 0.8)	0.8 (0.7 to 1.0)	24.6 (-7.4 to 61.9)	0.1 (-21.4 to 39.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	33.1 (-0.5 to 76.5)	8.2 (-19.6 to 41.3)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.9 (-13.3 to 49.4)	1.9 (-22.6 to 34.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.1 (-15.3 to 59.6)	1.5 (-25.6 to 39.1)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.6 (-16.2 to 87.6)	7.2 (-28.9 to 59.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.2 (-21.5 to 125.5)	7.2 (-35.8 to 81.2)
Chromosomal unbalanced rearrangements	0.9 (0.7 to 1.1)	1.1 (0.9 to 1.3)	23.5 (-7.8 to 60.9)	0.1 (-21.1 to 37.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	31.6 (-1.9 to 74.7)	7.1 (-20.2 to 42.3)
Other congenital anomalies	2.7 (2.3 to 3.1)	2.8 (2.4 to 3.2)	4.2 (-6.5 to 13.7)	-12.8 (-21.0 to -4.7)	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.5)	-23.1 (-40.4 to -1.8)	-28.8 (-44.6 to -10.1)
Skin and subcutaneous diseases	-	-	-	-	4.6 (2.9 to 7.0)	5.5 (3.4 to 8.3)	19.1 (8.3 to 31.1)	-2.5 (-10.7 to 5.7)
Dermatitis	39.7 (32.6 to 46.1)	48.9 (41.0 to 56.5)	23.4 (19.7 to 27.8)	0.0 (-0.1 to 0.1)	1.4 (0.9 to 2.0)	1.6 (1.0 to 2.4)	17.6 (11.1 to 23.8)	0.2 (-2.4 to 2.8)
Psoriasis	4.5 (3.9 to 5.2)	6.2 (5.4 to 7.1)	38.9 (35.3 to 43.6)	0.0 (-0.1 to 0.1)	0.4 (0.2 to 0.5)	0.5 (0.3 to 0.7)	38.0 (28.7 to 47.9)	0.1 (-5.4 to 6.1)
Cellulitis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	6.8 (-10.3 to 27.6)	-8.8 (-20.4 to 5.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.6 (-19.3 to 42.8)	-8.8 (-26.2 to 14.5)
Pyoderma	1.1 (0.8 to 1.5)	0.6 (0.4 to 0.7)	-51.0 (-59.5 to -40.5)	-51.8 (-59.0 to -42.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.1 (-60.7 to -39.6)	-52.0 (-60.2 to -42.8)
Scabies	25.6 (16.3 to 36.0)	24.5 (16.0 to 37.6)	-4.6 (-47.8 to 77.6)	-20.4 (-54.9 to 38.7)	0.7 (0.3 to 1.2)	0.6 (0.3 to 1.1)	-4.6 (-48.0 to 78.1)	-20.1 (-55.2 to 39.9)
Fungal skin diseases	75.7 (62.9 to 88.0)	98.3 (82.8 to 112.3)	29.9 (26.1 to 34.7)	0.4 (0.1 to 0.2)	0.6 (0.2 to 0.9)	0.6 (0.2 to 0.9)	29.6 (25.6 to 34.4)	0.6 (-0.5 to 1.0)
Viral skin diseases	16.2 (12.4 to 20.0)	17.2 (13.2 to 21.5)	6.5 (1.6 to 11.7)	-0.0 (-2.1 to 2.1)	0.5 (0.3 to 0.8)	0.5 (0.3 to 0.9)	6.2 (0.4 to 12.5)	0.1 (-3.3 to 3.6)
Acne vulgaris	53.8 (37.9 to 67.7)	59.2 (41.6 to 75.2)	9.7 (-29.8 to 82.1)	-0.1 (-35.9 to 65.1)	0.6 (0.3 to 1.1)	0.6 (0.3 to 1.3)	9.9 (-30.1 to 83.5)	0.1 (-36.0 to 66.8)
Alopecia areata	0.7 (0.6 to 0.8)	1.0 (0.9 to 1.2)	38.1 (13.7 to 66.7)	3.3 (-14.8 to 23.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	37.5 (10.8 to 71.5)	3.5 (-15.8 to 26.6)
Pruritus	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	41.1 (10.7 to 80.6)	0.0 (-25.3 to 23.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.7 (21.1 to 98.1)	-2.8 (-29.6 to 32.5)
Urticaria	6.0 (4.2 to 7.7)	8.8 (6.1 to 11.5)	48.8 (1.6 to 122.9)	2.4 (-28.2 to 52.4)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.8)	47.8 (1.3 to 118.5)	3.1 (-29.0 to 52.9)
Decubitus ulcer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	57.2 (3.8 to 122.4)	-0.8 (-36.9 to 43.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.8 (1.3 to 117.0)	-1.4 (-38.8 to 41.7)
Other skin and subcutaneous diseases	45.6 (32.2 to 62.6)	67.5 (45.5 to 99.2)	47.5 (30.7 to 67.8)	-3.5 (-8.8 to 7.7)	0.3 (0.1 to 0.5)	0.4 (0.2 to 0.8)	46.8 (29.5 to 67.5)	-3.4 (-8.7 to 2.8)
Sense organ diseases	-	-	-	-	4.8 (3.3 to 6.7)	6.8 (4.6 to 9.5)	42.5 (35.3 to 48.8)	-11.1 (-13.8 to -8.2)
Glaucoma	0.9 (0.7 to 1.0)	1.4 (1.2 to 1.7)	67.6 (39.6 to 102.3)	-5.0 (-21.0 to 16.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	70.3 (36.8 to 109.5)	-7.7 (-28.5 to 18.3)
Cataract	3.4 (2.5 to 4.5)	6.0 (4.7 to 7.4)	73.3 (26.8 to 142.2)	-14.7 (-36.2 to 13.8)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	64.6 (29.5 to 123.0)	-19.8 (-35.7 to 6.1)
Macular degeneration	1.8 (1.3 to 2.4)	3.6 (2.9 to 4.4)	101.0 (51.3 to 165.3)	-2.7 (-26.6 to 36.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	99.7 (51.1 to 167.2)	-3.5 (-25.4 to 35.2)
Uncorrected refractive error	45.3 (41.4 to 49.0)	67.7 (62.9 to 72.0)	49.4 (34.4 to 66.5)	7.1 (-14.7 to 16.6)	1.0 (0.7 to 1.5)	1.4 (0.9 to 2.1)	38.7 (30.4 to 47.4)	-13.2 (-17.4 to -7.4)
Age-related and other hearing loss	82.4 (75.9 to 88.6)	129.4 (121.2 to 138.8)	57.3 (50.5 to 63.4)	-9.2 (-12.3 to -6.5)	2.6 (1.7 to 3.7)	3.7 (2.4 to 5.2)	43.4 (32.5 to 55.0)	-10.1 (-13.7 to -6.0)
Other vision loss	4.2 (3.6 to 4.9)	5.4 (4.6 to 6.2)	27.9 (13.1 to 45.7)	-15.4 (-28.6 to -2.3)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	35.6 (20.3 to 55.2)	-1.0 (-27.4 to -1.8)
Other sense organ diseases	16.7 (15.8 to 17.6)	19.9 (19.0 to 20.8)	19.3 (10.3 to 27.8)	0.2 (-6.7 to 7.3)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.8)	18.3 (8.5 to 28.7)	0.5 (-7.1 to 8.8)
Oral disorders	-	-	-	-	0.8 (0.5 to 1.3)	1.1 (0.7 to 1.7)	32.7 (26.3 to 39.9)	-13.9 (-18.8 to -8.7)
Deciduous caries	84.0 (82.4 to 85.5)	74.5 (72.9 to 75.9)	-11.4 (-13.8 to -8.9)	-0.1 (-2.8 to 2.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-11.3 (-16.4 to -6.0)	0.0 (-5.7 to 5.9)
Permanent caries	232.3 (220.6 to 243.8)	301.5 (290.1 to 314.8)	29.7 (22.1 to 38.3)	1.8 (-3.8 to 7.7)	0.2 (0.1 to 0.2)	0.3 (0.1 to 0.6)	29.4 (21.8 to 38.4)	1.8 (-4.0 to 8.3)
Periodontal diseases	5.5 (5.2 to 5.8)	9.7 (9.1 to 10.3)	77.0 (61.5 to 92.6)	2.0 (-1.0 to 5.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	76.5 (60.7 to 93.5)	2.2 (-6.4 to 11.1)

Appendix Table G.4 - Fiji prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	7.0 (6.5 to 7.4)	9.3 (8.8 to 9.8)	32.8 (21.9 to 45.4)	-34.6 (-39.5 to -29.2)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	33.7 (21.2 to 45.6)	-34.4 (-39.7 to -28.8)
Other oral disorders	11.4 (10.7 to 12.1)	15.4 (14.5 to 16.3)	34.7 (24.1 to 46.9)	0.1 (-7.6 to 8.4)	1.5 (0.2 to 0.5)	2.0 (0.3 to 0.7)	31.0 (23.0 to 46.9)	-12.5 (-8.0 to 9.0)
Injuries	-	-	-	-	1.5 (1.2 to 2.0)	2.0 (1.5 to 2.7)	31.0 (18.6 to 44.4)	-12.5 (-19.8 to -4.5)
Transport injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.9 (0.6 to 1.2)	30.5 (14.7 to 47.8)	-12.9 (-22.3 to -3.1)
Road injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.7 (0.5 to 1.0)	41.0 (22.7 to 60.8)	-4.4 (-14.9 to 6.8)
Pedestrian road injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	45.7 (25.3 to 69.0)	1.1 (-10.8 to 14.8)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	57.6 (40.0 to 79.5)	3.2 (-8.5 to 16.8)
Motorcyclist road injuries	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	37.2 (19.3 to 58.4)	-9.1 (-19.5 to 2.7)
Motor vehicle road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.0 (0.2 to 0.4)	40.5 (20.3 to 64.8)	-3.1 (-15.5 to 11.0)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.1 (30.4 to 72.5)	-2.5 (-13.2 to 10.1)
Other transport injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-7.3 (-17.5 to 4.0)	-41.6 (-47.9 to -34.9)
Unintentional injuries	-	-	-	-	0.8 (0.6 to 1.0)	1.0 (0.8 to 1.4)	37.4 (26.9 to 48.9)	-8.2 (-14.6 to -1.4)
Falls	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	27.4 (14.3 to 42.1)	-17.9 (-26.0 to -8.9)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.9 (6.9 to 27.2)	-22.6 (-32.1 to -11.7)
Fire, heat, and hot substances	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-15.5 (-26.0 to -2.6)	-40.0 (-46.5 to -32.3)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.9 (-34.6 to -4.5)	-42.5 (-50.8 to -31.5)
Exposure to mechanical forces	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	63.3 (51.8 to 75.2)	13.8 (7.5 to 21.2)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.9 (-16.1 to 6.2)	-33.9 (-40.3 to -26.1)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.4 (28.1 to 57.7)	1.1 (-8.5 to 10.8)
Other exposure to mechanical forces	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	69.1 (57.1 to 81.6)	17.8 (11.2 to 25.6)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.4 (48.8 to 69.8)	6.2 (-1.0 to 12.7)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.8 (10.8 to 36.3)	-15.2 (-22.6 to -7.8)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.0 (13.5 to 46.3)	-9.8 (-19.7 to 0.6)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.7 (4.2 to 30.6)	-19.7 (-27.4 to -12.0)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.1 (4.5 to 27.0)	-19.8 (-26.5 to -12.8)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.2 (-32.9 to -2.6)	-36.6 (-45.7 to -25.9)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.7 (15.8 to 33.6)	-8.6 (-15.9 to -1.6)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.3 (18.9 to 47.6)	-16.4 (-24.3 to -7.8)
Other unintentional injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	57.5 (44.4 to 72.6)	5.6 (-1.9 to 14.8)
Self-harm and interpersonal violence	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	4.8 (-12.6 to 12.1)	-32.7 (-40.1 to -24.8)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.1 (4.2 to 34.5)	-22.9 (-31.7 to -13.5)
Interpersonal violence	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-7.5 (-19.9 to 6.2)	-36.3 (-43.9 to -28.0)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.4 (5.1 to 18.1)	-26.9 (-33.6 to -20.1)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.6 (9.1 to 19.6)	-29.7 (-37.3 to -20.0)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-13.4 (-25.7 to 0.6)	-40.0 (-47.8 to -31.2)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-16.0 (-26.4 to -3.2)	-43.7 (-50.9 to -35.3)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-16.0 (-26.4 to -3.2)	-43.7 (-50.9 to -35.3)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Finland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	671.5 (503.6 to 861.9)	802.2 (602.8 to 1,028.0)	19.4 (16.4 to 22.6)	19.4 (-5.1 to 0.4)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	23.4 (16.3 to 32.6)	23.6 (16.3 to 32.9)	1.1 (-6.4 to 9.7)	1.6 (-4.8 to 8.9)
HIV/AIDS and tuberculosis	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	0.2 (-16.8 to 22.4)	-12.2 (-28.0 to 8.1)
Tuberculosis	0.8 (0.8 to 0.8)	0.8 (0.7 to 0.8)	-6.8 (-11.2 to -2.2)	-19.5 (-23.6 to -15.4)	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-8.6 (-25.1 to 14.4)	-19.9 (-35.1 to 0.5)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	115.0 (15.3 to 237.8)	94.1 (2.4 to 205.0)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.3 (-48.2 to 59.4)	-3.2 (50.6 to 51.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.3 (-48.3 to 60.4)	-3.2 (51.1 to 52.1)
HIV/AIDS resulting in other diseases	0.2 (0.1 to 0.3)	0.5 (0.3 to 1.0)	258.9 (145.4 to 402.4)	214.6 (115.9 to 341.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	115.6 (15.4 to 239.3)	94.5 (2.5 to 206.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	2.8 (1.8 to 4.2)	2.8 (1.8 to 4.2)	-0.6 (-6.4 to 4.7)	-10.4 (-15.0 to -5.4)
Diarrheal diseases	1.7 (1.5 to 1.9)	1.6 (1.5 to 1.8)	-2.5 (-16.9 to 15.3)	-15.7 (-30.0 to 2.2)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.3)	0.0 (-21.1 to 14.7)	-19.1 (-33.8 to 4.6)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (64.4 to 42.5)	0.0 (66.1 to 33.8)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.1 (-28.7 to -0.2)	-20.4 (-33.1 to -7.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-28.7 to -0.2)	-15.1 (-33.1 to -7.0)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.9 (-14.8 to 45.5)	7.3 (-15.6 to 38.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.9 (-14.9 to 45.8)	7.3 (-15.9 to 38.3)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-71.6 (-99.3 to 1,994.2)	-73.1 (-99.3 to 1,911.5)
Lower respiratory infections	0.7 (0.7 to 0.8)	0.7 (0.7 to 0.8)	-1.9 (-8.2 to 3.5)	-22.4 (-26.9 to -17.6)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	0.1 (-16.9 to 13.3)	0.1 (-32.6 to -6.7)
Upper respiratory infections	75.2 (72.3 to 78.2)	80.2 (76.7 to 83.9)	6.5 (1.1 to 13.3)	1.0 (-3.8 to 7.1)	0.9 (0.5 to 1.4)	0.9 (0.5 to 1.5)	6.2 (-0.2 to 13.9)	1.0 (-4.8 to 8.1)
Otitis media	64.1 (59.2 to 69.1)	59.7 (54.6 to 64.6)	-6.9 (-16.6 to 3.5)	-16.3 (-24.1 to -7.7)	1.1 (0.7 to 1.8)	1.0 (0.6 to 1.7)	-6.8 (-16.8 to 4.0)	-16.3 (-24.3 to -7.5)
Meningitis	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-19.6 (-35.4 to 0.5)	-25.5 (-40.9 to -4.3)
Pneumococcal meningitis	0.5 (0.3 to 0.8)	0.4 (0.2 to 0.7)	-17.7 (-37.7 to 3.4)	-23.3 (-47.2 to -11.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-33.4 to 15.0)	0.0 (-41.4 to 6.7)
H influenzae type B meningitis	0.2 (0.1 to 0.6)	0.2 (0.1 to 0.4)	-30.8 (-56.6 to 8.1)	-35.8 (-60.6 to 5.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (-61.0 to 24.9)	-28.3 (-63.0 to 19.0)
Meningococcal meningitis	0.2 (0.1 to 0.6)	0.2 (0.1 to 0.5)	-19.1 (-50.8 to 46.2)	-30.1 (-55.5 to 32.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-51.0 to 60.7)	-13.9 (-56.7 to 53.9)
Other meningitis	0.5 (0.2 to 0.9)	0.3 (0.2 to 0.7)	-29.4 (-47.9 to -4.9)	-34.7 (-52.3 to -8.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.0 (-51.5 to 8.6)	-28.0 (-57.2 to 7.6)
Encephalitis	0.8 (0.3 to 2.2)	0.9 (0.4 to 2.4)	13.3 (-9.9 to 38.3)	10.3 (-24.8 to 20.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	0.1 (-8.9 to 49.7)	0.1 (-23.7 to 30.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.7 (-93.7 to 414.9)	-46.7 (-94.0 to 316.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.7 (-93.7 to 417.8)	-46.7 (-94.0 to 317.6)
Whooping cough	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-38.5 (-40.2 to -36.7)	-35.7 (-37.5 to -33.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.6 (-55.9 to -17.4)	-35.8 (-54.0 to -13.5)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.8 (-59.9 to 6.9)	-24.9 (-63.6 to 3.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.8 (-58.4 to 1.7)	-24.0 (-62.2 to -1.0)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.7 (-100.0 to 0.0)	-31.3 (-100.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-100.0 to nan)	0.0 (-100.0 to nan)
Varicella and herpes zoster	4.2 (3.7 to 4.9)	4.9 (4.3 to 5.7)	16.8 (-4.8 to 42.5)	-1.4 (-16.5 to 15.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	23.8 (7.1 to 62.2)	-2.7 (-26.4 to 25.2)
Neglected tropical diseases and malaria	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-4.2 (-35.9 to 43.8)	-20.8 (-47.4 to 24.6)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.6 (-76.0 to 507.9)	3.9 (-75.7 to 498.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-75.8 to 519.9)	4.7 (-75.9 to 508.0)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-90.1 (-96.6 to -59.8)	-91.8 (-97.6 to -69.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-89.6 (-96.5 to -57.5)	-91.4 (-97.5 to -68.0)
Cystic echinococcosis	0.4 (0.4 to 0.5)	0.6 (0.6 to 0.7)	55.9 (37.4 to 68.6)	25.8 (6.5 to 37.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	51.6 (19.1 to 97.4)	24.4 (-4.5 to 60.7)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.7 (-53.8 to 16.1)	-9.7 (-58.1 to 5.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.7 (-53.9 to 16.2)	-9.7 (-58.2 to 5.8)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	178.1 (-17.4 to 263.2)	153.0 (-25.0 to 229.5)
Maternal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-11.2 (-30.4 to 14.9)	-3.0 (-23.4 to 25.4)
Maternal hemorrhage	1.2 (0.9 to 1.5)	1.1 (0.8 to 1.3)	-13.5 (-37.1 to 18.7)	-6.6 (-32.1 to 29.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.5 (-62.1 to 56.6)	-22.6 (-59.2 to 68.2)
Maternal sepsis and other maternal infections	0.9 (0.5 to 1.5)	0.8 (0.3 to 1.3)	-14.4 (-55.6 to 51.6)	-0.7 (-49.3 to 77.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.8 (-50.7 to 51.1)	-5.1 (-45.3 to 70.9)
Maternal hypertensive disorders	0.9 (0.6 to 1.3)	0.8 (0.6 to 1.2)	-8.0 (-15.3 to 1.2)	1.8 (-6.2 to 12.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-7.8 (-25.6 to 14.3)	2.3 (-17.7 to 27.2)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.4 (-13.2 to 2.5)	2.0 (-6.5 to 10.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.4 (-13.3 to 2.6)	2.0 (-6.5 to 10.8)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.6 (-11.3 to 4.6)	5.3 (-3.0 to 14.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.6 (-11.3 to 4.6)	5.3 (-3.1 to 14.3)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-37.9 to 75.2)	6.1 (-32.3 to 92.5)
Neonatal disorders	-	-	-	-	4.5 (3.2 to 5.9)	5.6 (3.9 to 7.5)	23.6 (5.9 to 61.5)	16.9 (-10.9 to 53.5)
Preterm birth complications	15.8 (12.1 to 20.6)	22.5 (17.4 to 29.6)	42.9 (23.1 to 65.0)	33.1 (14.7 to 54.2)	2.2 (1.5 to 2.9)	3.1 (2.2 to 4.1)	41.7 (10.2 to 83.4)	34.4 (4.0 to 75.5)
Neonatal encephalopathy due to birth asphyxia and trauma	3.7 (2.1 to 7.0)	2.3 (1.1 to 5.2)	-40.3 (-61.2 to -10.9)	-42.5 (-62.7 to -15.1)	0.9 (0.6 to 1.3)	0.6 (0.3 to 0.9)	-37.5 (-62.7 to 0.2)	-39.3 (-64.1 to -9.9)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	242.3 (228.1 to 309.1)	258.3 (243.5 to 328.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	263.6 (105.5 to 694.1)	280.6 (115.1 to 710.3)
Hemolytic disease and other neonatal jaundice	1.0 (0.4 to 1.8)	0.8 (0.2 to 2.0)	-37.7 (-80.5 to 161.2)	-41.2 (-81.4 to 146.6)	0.4 (0.2 to 0.9)	0.4 (0.1 to 0.9)	-36.1 (-79.7 to 163.6)	-39.3 (-80.6 to 149.1)
Other neonatal disorders	-	-	-	-	1.0 (0.6 to 1.6)	1.6 (0.9 to 2.7)	62.7 (8.2 to 182.3)	54.5 (-13.1 to 167.0)
Nutritional deficiencies	-	-	-	-	14.2 (9.3 to 20.9)	13.4 (8.7 to 19.7)	-5.9 (-14.4 to 2.3)	-0.7 (-7.8 to 5.8)
Protein-energy malnutrition	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.6 (-61.5 to 49.3)	-44.0 (-74.0 to -14.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.5 (-61.7 to 49.5)	-44.0 (-74.0 to -14.3)
Iodine deficiency	83.2 (44.6 to 158.9)	54.3 (21.2 to 100.6)	-33.8 (-76.5 to 50.9)	-40.7 (-78.4 to 37.4)	1.5 (0.6 to 3.0)	1.0 (0.3 to 2.1)	-36.4 (-77.0 to 50.0)	-40.6 (-78.7 to 37.4)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron-deficiency anemia	487.3 (474.2 to 497.3)	517.3 (505.6 to 529.5)	6.1 (4.0 to 8.8)	3.2 (1.1 to 6.4)	12.7 (8.4 to 18.7)	12.4 (8.2 to 18.1)	-2.7 (-5.9 to 0.7)	2.7 (-0.6 to 6.2)

Appendix Table G.4 - Finland prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.5 (-53.5 to 10.6)	-52.6 (-68.8 to -35.8)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.4 (0.9 to 2.2)	1.5 (0.9 to 2.4)	4.4 (-10.0 to 20.7)	4.7 (-10.8 to 23.1)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.6 (0.3 to 1.1)	0.6 (0.4 to 1.1)	4.0 (-13.2 to 23.2)	-1.6 (-18.6 to 16.2)
Syphilis	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.8)	83.6 (14.6 to 198.1)	31.9 (-20.9 to 129.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	79.3 (3.8 to 210.0)	29.9 (-26.7 to 138.1)
Chlamydial infection	110.1 (87.9 to 136.8)	93.6 (61.3 to 117.7)	-13.3 (-47.6 to 18.5)	-8.7 (-45.9 to 27.9)	0.3 (0.2 to 0.6)	0.3 (0.1 to 0.5)	-5.3 (-35.9 to 24.9)	-7.2 (-33.1 to 32.4)
Gonococcal infection	16.9 (9.1 to 23.8)	14.7 (9.1 to 20.0)	-15.0 (-51.7 to 87.0)	-8.9 (-49.7 to 103.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-19.8 (-47.2 to 32.7)	-13.7 (-43.7 to 45.7)
Trichomoniasis	14.8 (9.5 to 20.7)	12.9 (6.3 to 18.9)	-10.4 (-60.3 to 40.5)	-1.6 (-58.1 to 60.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.1 (-63.5 to 61.9)	-0.5 (-62.8 to 84.7)
Genital herpes	583.8 (527.9 to 638.7)	684.0 (610.8 to 757.3)	17.3 (1.0 to 37.3)	-0.7 (-14.6 to 17.3)	0.1 (0.0 to 0.4)	0.2 (0.1 to 0.4)	14.7 (-1.3 to 35.2)	-0.6 (-15.1 to 17.4)
Other sexually transmitted diseases	1.6 (1.1 to 2.1)	1.0 (0.7 to 1.3)	-39.6 (-55.1 to -18.4)	-31.3 (-48.3 to -7.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.2 (-36.2 to 20.7)	-30.0 (-32.6 to 30.0)
Hepatitis	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-10.0 (-21.2 to 5.2)	-16.1 (-27.1 to -3.4)
Hepatitis A	3.8 (3.6 to 3.9)	3.5 (3.3 to 3.7)	-7.2 (-8.6 to -6.0)	-11.4 (-13.3 to -9.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-4.4 (-14.4 to 7.6)	-10.0 (-19.9 to 1.9)
Hepatitis B	75.3 (59.1 to 92.1)	56.0 (44.4 to 69.9)	-26.6 (-46.8 to 4.1)	-36.7 (-56.1 to -8.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-24.1 (-47.7 to 24.9)	-30.9 (-52.4 to 11.9)
Hepatitis C	101.8 (90.5 to 113.1)	94.4 (84.7 to 104.9)	-7.1 (-19.9 to 8.0)	-25.2 (-35.8 to -13.1)	0.1 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.7 (-35.6 to 40.7)	-26.3 (-47.0 to 3.6)
Hepatitis E	-	-	-	-	37.0 (-9.3 to 131.6)	37.0 (-12.0 to 117.1)	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	21.7 (18.6 to 25.6)	21.5 (19.2 to 23.8)	-0.4 (-16.5 to 17.2)	1.7 (-16.4 to 21.7)	0.6 (0.4 to 0.9)	0.7 (0.4 to 1.0)	9.3 (-16.2 to 41.8)	13.7 (-11.9 to 49.6)
Non-communicable diseases	-	-	-	-	537.3 (399.3 to 690.2)	655.8 (487.6 to 841.3)	22.1 (18.7 to 25.5)	0.6 (-2.1 to 3.4)
Neoplasms	-	-	-	-	73.9 (5.9 to 102.2)	140.0 (105.5 to 181.0)	77.6 (65.0 to 91.2)	18.1 (9.5 to 26.6)
Esophageal cancer	0.4 (0.3 to 0.4)	0.5 (0.4 to 0.6)	37.5 (6.0 to 77.1)	-11.2 (-31.2 to 14.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	31.4 (-1.4 to 71.1)	-14.4 (-34.7 to 10.3)
Stomach cancer	2.9 (2.5 to 3.3)	2.6 (2.1 to 3.1)	-10.7 (-24.2 to 4.5)	-42.5 (-50.7 to -33.8)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.3)	-15.4 (-30.0 to 2.6)	-44.8 (-54.0 to -34.5)
Liver cancer	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	101.6 (36.3 to 172.0)	30.5 (-10.7 to 74.6)
Liver cancer due to hepatitis B	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	116.5 (9.2 to 354.2)	43.9 (-26.3 to 197.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.4 (2.6 to 305.0)	31.0 (-31.7 to 162.8)
Liver cancer due to hepatitis C	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.6)	328.2 (112.2 to 702.4)	176.8 (38.6 to 411.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	258.5 (83.7 to 552.7)	132.5 (22.6 to 318.4)
Liver cancer due to alcohol use	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	33.6 (-21.2 to 152.8)	-15.5 (-51.0 to 60.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.7 (-27.8 to 126.2)	-23.9 (-54.4 to 43.7)
Liver cancer due to other causes	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-9.9 (-59.7 to 105.9)	-38.4 (-72.2 to 32.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.0 (-60.4 to 89.1)	-42.2 (-73.9 to 19.0)
Larynx cancer	0.5 (0.4 to 0.6)	0.6 (0.4 to 0.7)	15.2 (-9.0 to 52.3)	-23.6 (-39.3 to -1.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	9.0 (-18.5 to 47.9)	-27.8 (-44.9 to -3.5)
Tracheal, bronchus and lung cancer	4.0 (3.8 to 4.3)	5.4 (4.6 to 6.1)	34.5 (11.3 to 53.2)	-12.5 (-27.4 to -1.0)	0.6 (0.4 to 0.7)	0.7 (0.5 to 0.9)	25.9 (4.4 to 46.7)	-17.8 (-31.5 to -4.5)
Breast cancer	37.9 (35.2 to 40.8)	69.0 (64.4 to 73.4)	82.7 (64.0 to 101.4)	19.2 (7.0 to 31.5)	1.9 (1.3 to 2.6)	3.0 (2.0 to 4.2)	60.8 (36.3 to 79.5)	7.3 (-8.7 to 19.6)
Cervical cancer	1.5 (1.0 to 1.7)	0.9 (0.7 to 1.1)	-40.1 (-55.6 to -10.0)	-52.8 (-64.9 to -32.8)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-41.1 (-57.3 to -8.2)	-53.4 (-66.3 to -31.0)
Uterine cancer	3.3 (2.3 to 3.9)	6.6 (4.2 to 8.4)	97.0 (48.3 to 156.5)	30.3 (-1.2 to 68.6)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	88.7 (40.7 to 146.2)	25.0 (-5.7 to 64.0)
Prostate cancer	16.4 (14.1 to 18.6)	50.5 (44.3 to 61.0)	207.1 (159.7 to 281.2)	98.1 (67.0 to 145.4)	1.3 (0.9 to 1.6)	3.5 (2.5 to 4.8)	177.5 (136.4 to 242.5)	79.7 (53.0 to 123.4)
Colon and rectum cancer	9.5 (9.1 to 10.2)	20.8 (18.7 to 22.8)	118.4 (91.8 to 142.6)	42.3 (24.6 to 57.8)	0.8 (0.6 to 1.0)	1.6 (1.2 to 2.1)	102.3 (76.1 to 129.4)	31.8 (-15.7 to 49.6)
Lip and oral cavity cancer	1.8 (1.5 to 2.0)	3.4 (2.5 to 4.1)	96.0 (30.8 to 147.0)	28.3 (-14.9 to 60.0)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	83.0 (20.0 to 136.7)	20.9 (-21.1 to 54.2)
Nasopharynx cancer	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-60.2 (-72.7 to -21.0)	-49.9 (-73.3 to -42.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-60.5 (-72.0 to -43.8)	-70.4 (-79.0 to -43.8)
Other pharynx cancer	0.5 (0.4 to 0.7)	0.7 (0.5 to 0.9)	26.9 (-18.6 to 81.5)	-13.0 (-43.9 to 22.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	13.0 (-19.0 to 77.2)	25.1 (-44.9 to 22.0)
Gallbladder and biliary tract cancer	0.3 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-8.2 (-31.0 to 24.1)	-42.6 (-56.8 to -23.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-7.0 (-33.6 to 31.7)	-41.2 (-57.4 to -18.9)
Pancreatic cancer	0.8 (0.7 to 0.8)	1.2 (1.0 to 1.4)	58.0 (30.6 to 88.9)	1.8 (-16.1 to 21.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	53.3 (21.8 to 89.2)	-0.3 (-20.1 to 22.7)
Malignant skin melanoma	4.1 (3.0 to 5.8)	7.8 (5.4 to 11.4)	89.1 (52.7 to 132.0)	35.7 (10.3 to 66.3)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.7)	79.5 (45.1 to 116.9)	29.4 (5.3 to 56.0)
Non-melanoma skin cancer	2.3 (1.8 to 2.9)	4.2 (3.2 to 5.4)	78.9 (22.5 to 157.0)	15.0 (-21.1 to 63.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	94.9 (30.0 to 198.7)	24.1 (-13.4 to 85.0)
Ovarian cancer	1.9 (1.6 to 2.1)	2.5 (2.0 to 2.9)	31.9 (5.9 to 57.9)	-9.4 (-26.2 to 8.1)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	26.1 (-2.9 to 61.0)	-12.7 (-33.1 to 11.1)
Testicular cancer	0.5 (0.4 to 0.7)	0.5 (0.3 to 0.7)	-7.7 (-37.2 to 48.9)	-2.2 (-36.1 to 56.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-9.1 (-41.0 to 46.5)	-6.2 (-41.3 to 54.1)
Kidney cancer	2.8 (2.5 to 3.3)	5.5 (4.7 to 6.4)	96.6 (63.2 to 138.2)	29.4 (7.7 to 54.5)	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.5)	86.7 (50.1 to 128.2)	23.6 (-0.1 to 50.0)
Bladder cancer	4.2 (3.4 to 4.7)	5.4 (4.4 to 6.4)	30.8 (10.5 to 56.3)	-15.7 (-28.7 to 10.0)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	23.6 (1.4 to 49.0)	-30.7 (-34.5 to -3.6)
Brain and nervous system cancer	1.1 (0.9 to 1.3)	2.5 (2.0 to 2.9)	119.4 (84.4 to 154.1)	59.7 (36.6 to 84.7)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	96.1 (58.5 to 135.6)	44.7 (20.7 to 72.7)
Thyroid cancer	1.6 (1.4 to 2.0)	2.4 (1.8 to 3.1)	52.7 (14.9 to 101.3)	16.3 (-11.4 to 52.6)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	45.8 (9.0 to 95.2)	10.6 (-15.7 to 49.4)
Mesothelioma	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	181.4 (39.1 to 262.4)	84.5 (-7.3 to 139.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	165.6 (23.6 to 269.8)	73.6 (-16.7 to 144.1)
Hodgkin lymphoma	0.7 (0.4 to 0.8)	0.6 (0.5 to 0.9)	-14.3 (-29.2 to 48.2)	-15.8 (-38.6 to 29.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-14.3 (-35.1 to 33.0)	-25.7 (-43.9 to 13.1)
Non-Hodgkin lymphoma	4.1 (3.0 to 6.4)	7.3 (4.9 to 9.4)	86.4 (-13.9 to 141.9)	26.6 (-40.8 to 64.5)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.7)	70.4 (-20.7 to 122.8)	16.7 (-44.6 to 52.9)
Multiple myeloma	0.7 (0.5 to 1.1)	1.2 (0.8 to 1.8)	69.0 (18.5 to 140.6)	9.7 (-22.7 to 56.0)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.4)	61.0 (6.6 to 126.9)	4.7 (-29.6 to 48.6)
Leukemia	2.1 (1.9 to 2.4)	3.5 (2.9 to 4.0)	65.2 (29.9 to 95.7)	10.6 (-15.4 to 30.7)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	57.4 (21.0 to 90.0)	5.9 (-17.9 to 26.2)
Other neoplasms	1.5 (1.3 to 1.9)	6.2 (4.4 to 7.8)	308.3 (170.9 to 431.8)	190.4 (92.2 to 271.2)	0.1 (0.1 to 0.2)	0.1 (0.3 to 0.6)	235.7 (115.4 to 341.6)	140.4 (58.3 to 210.9)
Cardiovascular diseases	-	-	-	-	22.1 (15.4 to 29.5)	30.1 (21.1 to 40.3)	36.6 (15.7 to 59.3)	-10.7 (-24.5 to 4.4)
Rheumatic heart disease	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	34.1 (22.0 to 46.3)	-5.2 (-13.3 to 2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.9 (0.6 to 84.9)	-6.5 (-26.9 to 26.0)
Ischemic heart disease	156.2 (133.3 to 189.5)	204.1 (180.9 to 230.1)	30.8 (6.7 to 59.9)	-16.8 (-31.9 to 2.8)	8.6 (5.5 to 12.6)	10.9 (7.3 to 15.2)	26.5 (0.5 to 62.1)	20.4 (-7.0 to 2.8)
Cerebrovascular disease	-	-	-	-	6.6 (4.6 to 8.7)	7.6 (5.3 to 10.2)	15.3 (-2.4 to 40.0)	-31.5 (-33.6 to -5.2)
Ischemic stroke	36.6 (31.7 to 41.4)	43.3 (37.8 to 49.2)	17.9 (-1.7 to 44.6)	-21.8 (-34.4 to -5.1)	5.2 (3.5 to 7.0)	6.0 (4.1 to 8.2)	16.0 (-1.1 to 41.7)	-22.3 (-35.2 to -5.8)
Hemorrhagic stroke	10.0 (8.5 to 11.6)	11.6 (9.9 to 13.6)	14.9 (-4.5 to 44.3)	-19.0 (-32.4 to 1.3)	1.4 (1.0 to 2.0)	1.6 (1.1 to 2.3)	13.6 (-7.7 to 43.8)	-18.6 (-33.5 to 2.1)
Hypertensive heart disease	5.5 (4.7 to 6.2)	11.3 (10.1 to 12.5)	105.6 (75.7 to 139.1)	30.2 (11.8 to 52.3)	0.6 (0.4 to 0.8)	1.2 (0.8 to 1.6)	104.3 (72.3 to 142.8)	30.5 (10.6 to 54.7)
Cardiomyopathy and myocarditis	5.9 (5.0 to 6.8)	8.8 (8.0 to 9.5)	48.3 (25.1 to 80.6)	0.9 (-14.3 to 21.8)	0.6 (0.4 to 0.9)	0.9 (0.6 to 1.2)	48.8 (22.8 to 83.4)	1.4 (-15.0 to 24.3)
Atrial fibrillation and flutter	21.8 (16.9 to 27.5)	16.8 (11.0 to 26.2)	-26.6 (-56.3 to 41.6)	-53.2 (-72.2 to -11.3)	1.6 (1.1 to 2.4)	1.2 (0.7 to 2.1)	-26.7 (-56.4 to 40.3)	-53.1 (-72.1 to -10.1)
Peripheral vascular disease	184.4 (136.0 to 237.0)	291.2 (225.3 to 357.7)	59.5 (6.1 to 128.0)	6.6 (-31.4 to 52.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	72.5 (-24.6 to 188.5)	4.6 (-56.8 to 81.0)
Endocarditis	0.2 (0.1 to 0.3)	0.6 (0.5 to 0.7)	214.1 (59.8 to 476.8)	146.3 (27.8 to 370.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	146.3 (37.5 to 330.2)	92.9 (9.6 to 238.2)
Other cardiovascular and circulatory diseases	57.6 (32.1 to 84.8)	116.6 (73.6 to 155.5)	101.9 (15.9 to 283.4)	33.2 (-23.8 to 151.4)	4.0 (2.0 to 6.5)	8.0 (4.4 to 11.8)	101.1 (14.4 to 280.8)	33.0 (-23.7 to 151.2)
Chronic respiratory diseases	-	-	-	-	23.9 (16.6 to 32.0)	36.5 (18.2 to 35.2)	26.5 (-3.1 to 26.5)	-10.5 (-20.6 to 2.6)
Chronic obstructive pulmonary disease	182.9 (165.0 to 202.7)	245.7 (217.9 to 272.2)	34.5 (25.9 to 41.7)	0.0 (-5.9 to 4.8)	8.4 (5.4 to 11.9)	11.1 (7.3 to 15.5)	33.1 (2.7 to 66.7)	-0.8 (-22.0 to 23.2)
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.5 (7.3 to 15.4)	-18.3 (-21.3 to -15.7)

Appendix Table G.4 - Finland prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.7 (7.0 to 20.2)	-21.9 (-26.3 to -17.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.7 (6.7 to 20.5)	-22.0 (-26.6 to -17.6)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	9.9 (5.0 to 14.4)	-18.0 (-21.6 to -14.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.9 (5.9 to 15.5)	-17.4 (-21.2 to -14.1)
Asthma	349.9 (327.8 to 369.9)	445.6 (316.2 to 373.1)	-1.7 (-11.5 to 9.5)	-44.4 (-47.7 to -42.7)	15.2 (9.9 to 22.0)	15.2 (9.7 to 21.1)	2.5 (-12.6 to 8.6)	2.5 (-25.0 to 32.2)
Interstitial lung disease and pulmonary sarcoidosis	0.7 (0.6 to 0.9)	1.2 (1.1 to 1.4)	66.5 (27.9 to 127.1)	13.1 (-13.4 to 54.3)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	58.8 (12.6 to 124.9)	9.4 (-18.5 to 53.6)
Other chronic respiratory diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	10.6 (-21.6 to 49.8)	-17.8 (-41.1 to 10.5)
Cirrhosis	-	-	-	-	0.3 (0.3 to 0.5)	0.4 (0.4 to 0.8)	45.9 (28.9 to 63.8)	13.7 (0.2 to 27.1)
Cirrhosis due to hepatitis B	0.2 (0.2 to 0.4)	0.3 (0.2 to 0.5)	39.6 (-16.4 to 120.1)	5.3 (-38.5 to 65.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	37.5 (-25.4 to 146.8)	5.7 (-42.7 to 93.4)
Cirrhosis due to hepatitis C	0.8 (0.5 to 1.2)	1.8 (1.3 to 2.2)	115.1 (40.4 to 225.2)	66.1 (8.5 to 152.2)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	115.4 (33.9 to 245.6)	66.2 (3.3 to 167.1)
Cirrhosis due to alcohol use	1.1 (0.8 to 1.4)	1.0 (0.7 to 1.4)	-10.0 (-41.2 to 41.4)	-33.8 (-56.8 to 5.7)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-10.4 (-44.5 to 44.5)	-33.4 (-59.1 to 7.8)
Cirrhosis due to other causes	0.2 (0.1 to 0.4)	0.4 (0.3 to 0.7)	82.4 (7.9 to 216.7)	54.1 (-8.2 to 158.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	81.2 (-3.3 to 244.9)	53.8 (-14.1 to 178.1)
Digestive diseases	-	-	-	-	7.3 (5.2 to 9.5)	7.9 (5.7 to 10.5)	8.3 (-0.2 to 16.8)	-16.3 (-23.1 to -9.4)
Peptic ulcer disease	40.9 (36.3 to 45.6)	21.7 (18.1 to 25.4)	-47.1 (-55.0 to -38.5)	-68.2 (-72.7 to -63.4)	1.2 (0.8 to 1.7)	0.8 (0.6 to 1.2)	-30.5 (-40.1 to -17.7)	-57.3 (-63.0 to -48.8)
Gastritis and duodenitis	1.3 (1.1 to 1.5)	1.5 (1.3 to 1.7)	13.7 (-1.8 to 33.5)	-18.6 (-29.1 to -5.3)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	21.7 (-4.8 to 67.0)	-12.9 (-31.2 to 17.1)
Appendicitis	0.3 (0.3 to 0.3)	0.2 (0.2 to 0.2)	-27.7 (-37.7 to -15.1)	-32.1 (-42.0 to -18.9)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-26.7 (-46.0 to -1.4)	-31.4 (-51.5 to -4.6)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	89.4 (73.0 to 105.0)	32.4 (21.6 to 42.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	81.9 (37.8 to 139.3)	30.1 (4.3 to 61.8)
Inguinal, femoral, and abdominal hernia	8.7 (8.4 to 11.3)	14.2 (12.3 to 15.5)	65.9 (19.5 to 77.3)	14.5 (-21.2 to 14.1)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	44.9 (18.2 to 76.9)	4.4 (-21.5 to 15.1)
Inflammatory bowel disease	18.9 (17.8 to 19.9)	19.2 (18.0 to 20.5)	1.7 (-6.4 to 9.9)	-19.4 (-26.0 to -13.0)	3.9 (2.7 to 5.3)	3.9 (2.7 to 5.3)	0.5 (-8.7 to 9.2)	-19.2 (-26.8 to -12.1)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (2.8 to 93.8)	-9.3 (-31.7 to 23.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.6 (-15.7 to 107.0)	-9.3 (-38.9 to 32.0)
Gallbladder and biliary diseases	8.4 (7.3 to 9.8)	10.5 (9.1 to 12.1)	23.7 (2.4 to 52.5)	-9.3 (-24.5 to 11.4)	0.9 (0.6 to 1.2)	1.1 (0.7 to 1.4)	22.5 (0.8 to 52.1)	-8.7 (-25.5 to 12.9)
Pancreatitis	1.4 (1.3 to 1.5)	2.2 (2.1 to 2.3)	62.9 (46.8 to 66.2)	21.4 (19.4 to 35.3)	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	54.4 (33.6 to 80.3)	27.5 (10.9 to 48.6)
Other digestive diseases	-	-	-	-	0.7 (0.5 to 0.9)	1.1 (0.8 to 1.6)	78.3 (15.4 to 115.6)	38.2 (-12.1 to 67.0)
Neurological disorders	-	-	-	-	53.6 (36.8 to 72.8)	68.1 (46.7 to 90.8)	28.2 (2.0 to 49.7)	5.0 (-15.3 to 25.3)
Alzheimer disease and other dementias	79.2 (67.2 to 91.1)	121.3 (89.6 to 148.7)	53.5 (12.9 to 95.0)	-12.1 (-34.1 to 10.4)	11.2 (8.0 to 14.6)	17.3 (11.3 to 23.6)	54.9 (13.0 to 96.1)	-12.2 (-34.4 to 10.2)
Parkinson disease	2.9 (2.3 to 3.5)	4.6 (3.7 to 5.9)	60.3 (46.1 to 80.1)	0.3 (-5.1 to 15.5)	0.5 (0.2 to 0.5)	0.5 (0.3 to 0.8)	59.2 (35.1 to 86.8)	4.1 (-11.4 to 22.7)
Epilepsy	16.1 (11.8 to 20.0)	15.4 (10.7 to 20.4)	-3.4 (-36.3 to 41.7)	-13.1 (-42.4 to 27.7)	6.4 (4.1 to 9.1)	6.3 (3.7 to 9.3)	-0.9 (-36.0 to 49.0)	-9.8 (-41.9 to 35.6)
Multiple sclerosis	4.8 (4.5 to 5.0)	9.8 (9.1 to 10.5)	104.7 (87.9 to 126.6)	79.5 (64.8 to 98.7)	1.5 (1.1 to 2.0)	3.2 (2.3 to 4.0)	103.5 (81.5 to 130.9)	79.7 (60.0 to 104.1)
Migraine	741.5 (539.9 to 908.8)	795.1 (634.4 to 952.6)	6.1 (-23.1 to 48.8)	0.5 (-28.1 to 42.5)	24.9 (13.9 to 38.2)	26.6 (15.7 to 40.6)	5.3 (-22.9 to 48.3)	0.5 (-28.1 to 43.2)
Tension-type headache	1,047.7 (745.3 to 1,533.5)	1,403.7 (1,221.7 to 1,670.3)	40.3 (-5.6 to 101.6)	29.4 (-12.5 to 67.7)	1.1 (0.7 to 1.6)	0.1 (0.0 to 0.3)	28.9 (-6.8 to 101.2)	2.3 (-12.4 to 88.8)
Medication overuse headache	37.8 (24.4 to 52.2)	63.1 (41.2 to 88.5)	66.6 (21.8 to 129.9)	45.6 (4.5 to 101.4)	5.8 (3.9 to 9.2)	9.7 (5.3 to 15.5)	65.5 (18.3 to 129.3)	45.5 (2.4 to 104.0)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.8 (-17.3 to 55.3)	-5.4 (-31.8 to 29.0)	1.8 (1.2 to 2.5)	2.4 (1.6 to 3.3)	31.3 (8.6 to 84.6)	-17.9 (-42.0 to 15.6)
Mental and substance use disorders	-	-	-	-	121.1 (88.2 to 158.9)	130.8 (95.4 to 171.8)	8.0 (5.1 to 11.1)	0.3 (-2.1 to 2.7)
Schizophrenia	14.3 (11.5 to 17.7)	15.5 (12.6 to 18.8)	8.3 (2.4 to 16.5)	-0.7 (-6.4 to 7.4)	9.0 (6.3 to 11.7)	9.7 (7.0 to 12.5)	7.8 (0.7 to 18.1)	-0.4 (-7.0 to 9.3)
Alcohol use disorders	108.9 (101.0 to 117.4)	127.2 (119.3 to 135.8)	16.8 (10.4 to 23.4)	14.1 (7.4 to 20.6)	10.8 (7.3 to 15.3)	12.6 (8.5 to 17.8)	14.6 (9.8 to 23.9)	16.6 (7.5 to 21.9)
Drug use disorders	-	-	-	-	6.2 (4.3 to 8.3)	6.0 (4.1 to 8.0)	-3.2 (-14.9 to 9.5)	-2.5 (-14.6 to 10.7)
Opioid use disorders	5.2 (4.7 to 5.7)	5.0 (4.6 to 5.5)	-2.7 (-8.2 to 2.8)	1.0 (-5.0 to 7.3)	2.1 (1.5 to 2.8)	2.1 (1.5 to 2.7)	1.7 (-13.0 to 9.4)	1.7 (-9.5 to 13.6)
Cocaine use disorders	6.2 (5.7 to 6.8)	6.0 (5.4 to 6.7)	-3.3 (-15.6 to 10.0)	-2.7 (-15.7 to 11.1)	0.8 (0.6 to 1.2)	0.8 (0.5 to 1.2)	-0.3 (-19.2 to 16.4)	-2.3 (-19.6 to 17.6)
Amphetamine use disorders	7.4 (7.4 to 9.2)	9.0 (6.9 to 9.0)	21.9 (-19.9 to 11.5)	-2.4 (-22.8 to 9.4)	1.1 (0.7 to 1.6)	0.1 (0.0 to 1.5)	29.9 (-22.8 to 15.6)	2.3 (-25.9 to 14.1)
Cannabis use disorders	7.7 (7.1 to 8.2)	7.8 (7.2 to 8.3)	1.1 (-4.7 to 7.1)	1.2 (-5.1 to 7.8)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	1.9 (-14.1 to 18.5)	2.0 (-14.2 to 19.7)
Other drug use disorders	-	-	-	-	1.9 (1.2 to 2.8)	1.9 (1.2 to 2.8)	-3.4 (-29.3 to 29.9)	-4.4 (-30.3 to 29.0)
Depressive disorders	-	-	-	-	53.3 (36.5 to 72.9)	58.7 (39.9 to 80.4)	10.0 (5.0 to 16.0)	-1.6 (-6.2 to 3.7)
Major depressive disorder	224.9 (182.1 to 267.6)	249.6 (204.1 to 298.9)	10.9 (4.8 to 17.3)	-1.9 (-6.9 to 4.2)	45.2 (30.4 to 62.8)	49.7 (33.3 to 69.4)	9.9 (3.9 to 16.6)	-1.7 (-6.9 to 4.6)
Dysthymia	85.4 (71.4 to 99.5)	95.3 (78.1 to 112.6)	11.6 (3.1 to 20.7)	-1.2 (-7.3 to 5.0)	8.1 (5.3 to 11.7)	9.0 (6.0 to 13.1)	10.8 (1.8 to 20.1)	-1.0 (-7.5 to 5.9)
Bipolar disorder	41.1 (35.0 to 47.7)	43.8 (37.8 to 49.9)	6.7 (1.1 to 12.4)	-0.5 (-5.1 to 4.5)	8.2 (5.1 to 12.3)	8.7 (5.4 to 12.8)	6.0 (-0.2 to 13.5)	-0.4 (-6.0 to 6.4)
Anxiety disorders	117.3 (97.2 to 137.3)	125.6 (103.0 to 149.1)	7.5 (-1.2 to 15.1)	-2.0 (-10.0 to 5.7)	10.6 (7.0 to 15.2)	11.3 (7.4 to 16.2)	6.6 (-2.8 to 15.2)	-1.9 (-10.5 to 6.0)
Eating disorders	-	-	-	-	4.0 (2.5 to 5.9)	3.9 (2.4 to 5.6)	-0.3 (-7.1 to 4.7)	5.5 (-0.3 to 11.6)
Anorexia nervosa	6.7 (5.1 to 8.5)	7.3 (5.6 to 9.1)	8.3 (-2.1 to 19.6)	14.8 (4.7 to 27.4)	1.4 (0.9 to 2.2)	1.5 (1.0 to 2.3)	8.4 (-4.6 to 22.1)	14.9 (1.8 to 29.1)
Bulimia nervosa	12.2 (7.9 to 16.9)	11.3 (7.3 to 15.6)	-7.0 (-9.0 to -4.8)	-0.2 (-0.4 to -0.1)	2.6 (1.4 to 4.0)	2.4 (1.3 to 3.7)	-6.7 (-12.1 to -1.0)	-0.0 (-5.7 to 5.2)
Autistic spectrum disorders	-	-	-	-	5.4 (3.8 to 7.4)	5.8 (4.1 to 7.8)	6.9 (3.2 to 10.6)	1.0 (-2.6 to 4.7)
Autism	14.2 (13.3 to 15.1)	15.2 (14.3 to 16.3)	7.5 (6.6 to 8.4)	0.8 (0.7 to 0.8)	3.4 (2.4 to 4.7)	3.7 (2.5 to 5.0)	8.8 (1.9 to 11.8)	1.0 (-3.8 to 5.9)
Asperger syndrome	20.2 (18.8 to 21.6)	21.8 (20.2 to 23.3)	7.8 (6.9 to 8.8)	1.0 (0.9 to 1.1)	2.0 (1.4 to 2.8)	2.1 (1.5 to 3.0)	7.2 (3.1 to 11.5)	1.2 (-2.8 to 5.1)
Attention-deficit/hyperactivity disorder	27.2 (23.7 to 31.3)	25.9 (22.6 to 29.8)	-4.9 (-5.0 to -4.9)	0.3 (-0.0 to 0.0)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	-4.7 (-11.2 to 1.0)	0.3 (-6.6 to 6.5)
Conduct disorder	30.8 (25.9 to 36.0)	29.7 (24.9 to 34.9)	-3.6 (-4.8 to -2.5)	3.7 (-0.1 to 4.0)	3.7 (2.2 to 5.4)	3.6 (2.1 to 5.3)	-3.5 (-8.0 to 3.1)	0.1 (-4.3 to 5.0)
Idiopathic intellectual disability	45.4 (37.5 to 55.7)	42.1 (33.3 to 52.6)	-7.1 (-19.4 to 4.4)	-4.1 (-24.9 to -3.3)	2.2 (1.8 to 3.8)	2.5 (1.6 to 3.4)	-7.6 (-19.9 to 5.3)	-13.8 (-25.0 to -2.1)
Other mental and substance use disorders	94.5 (89.1 to 99.8)	107.2 (100.7 to 113.7)	13.4 (11.3 to 15.6)	0.8 (0.6 to 1.2)	6.9 (4.7 to 9.3)	7.8 (5.3 to 10.4)	12.4 (8.2 to 17.2)	1.1 (-2.5 to 4.9)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	53.8 (38.5 to 71.6)	82.8 (57.8 to 109.8)	53.8 (33.6 to 75.7)	17.8 (3.8 to 32.9)
Diabetes mellitus	277.1 (232.8 to 323.1)	584.1 (459.3 to 734.6)	112.9 (51.9 to 177.9)	55.1 (11.6 to 104.6)	19.5 (13.1 to 27.4)	40.5 (25.5 to 59.1)	109.1 (51.0 to 170.1)	52.1 (10.4 to 96.3)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.7 (-17.8 to -5.0)	-19.4 (-24.7 to -13.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.7 (-17.8 to -4.9)	-19.4 (-24.8 to -13.8)
Chronic kidney disease	-	-	-	-	19.1 (12.6 to 26.0)	25.0 (16.6 to 33.9)	30.9 (20.8 to 40.8)	2.4 (-1.8 to 7.4)
Chronic kidney disease due to diabetes mellitus	99.6 (65.3 to 169.7)	164.3 (109.3 to 270.6)	61.0 (25.1 to 145.7)	13.2 (-9.5 to 64.2)	4.6 (2.8 to 6.7)	6.6 (4.1 to 9.3)	43.5 (16.3 to 92.7)	9.3 (-12.1 to 42.2)
Chronic kidney disease due to hypertension	55.6 (38.8 to 77.8)	73.7 (42.5 to 116.6)	29.8 (-10.4 to 89.1)	-2.1 (-29.4 to 32.4)	3.9 (2.4 to 6.0)	0.9 (0.5 to 1.2)	-77.3 (-85.1 to -67.5)	-81.6 (-87.6 to -74.2)
Chronic kidney disease due to glomerulonephritis	86.0 (53.4 to 168.4)	38.0 (30.7 to 48.4)	-55.5 (-73.6 to -31.6)	-10.0 (-7.6 to -43.5)	1.9 (1.3 to 2.9)	3.9 (2.6 to 5.5)	67.3 (55.5 to 161.2)	7.3 (-29.3 to 109.3)
Chronic kidney disease due to other causes	234.9 (177.4 to 331.2)	378.7 (273.7 to 558.1)	62.3 (21.2 to 125.7)	58.7 (-7.9 to 51.8)	58.7 (5.6 to 12.3)	88.7 (9.1 to 18.5)	56.1 (30.8 to 84.4)	20.1 (3.8 to 41.3)
Urinary diseases and male infertility	-	-	-	-	4.2 (2.8 to 6.0)	6.8 (4.4 to 9.6)	61.0 (43.1 to 77.0)	5.5 (-6.1 to 16.1)
Interstitial nephritis and urinary tract infections	1.6 (1.5 to 1.7)	2.4 (2.3 to 2.5)	48.4 (38.3 to 59.9)	20.8 (11.7 to 30.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	47.0 (26.1 to 74.8)	21.4 (2.3 to 45.7)

Appendix Table G.4 - Finland prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Urolithiasis	89.6 (58.3 to 115.4)	86.8 (31.3 to 137.7)	0.9 (-64.1 to 39.1)	-0.7 (-78.4 to -9.3)	0.7 (0.4 to 1.2)	0.7 (0.2 to 1.3)	-4.5 (-63.7 to 31.6)	-38.2 (-76.9 to -12.8)
Benign prostatic hyperplasia	92.1 (83.9 to 100.6)	168.0 (159.6 to 176.3)	82.8 (64.5 to 103.0)	18.1 (6.6 to 31.1)	3.2 (2.1 to 4.5)	5.8 (3.8 to 8.1)	81.6 (62.1 to 101.1)	17.7 (5.5 to 30.1)
Male infertility due to other causes	15.9 (12.3 to 20.2)	13.0 (10.1 to 16.6)	-17.2 (-43.7 to 18.0)	-0.7 (-31.9 to 41.0)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-0.7 (-43.4 to 20.3)	-0.7 (-32.4 to 42.9)
Other urinary diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-2.9 (-74.1 to 51.2)	-36.3 (-82.6 to -0.1)
Gynecological diseases	-	-	-	-	6.4 (4.0 to 10.1)	6.0 (3.8 to 9.7)	-6.9 (-18.8 to 5.0)	-2.1 (-15.7 to 10.0)
Uterine fibroids	210.2 (178.7 to 243.9)	206.4 (177.3 to 238.7)	-1.8 (-3.0 to -0.6)	-0.1 (-0.2 to -0.1)	1.8 (0.9 to 3.3)	1.8 (0.9 to 3.2)	-1.3 (-4.8 to 2.8)	1.1 (-2.2 to 5.6)
Polycystic ovarian syndrome	88.4 (74.4 to 100.8)	82.1 (69.1 to 94.0)	-6.9 (-24.4 to 13.2)	2.1 (-17.7 to 24.9)	0.8 (0.4 to 1.5)	0.8 (0.4 to 1.5)	-7.2 (-24.7 to 12.3)	1.9 (-17.2 to 23.7)
Female infertility due to other causes	2.3 (0.7 to 5.8)	2.5 (0.5 to 7.8)	0.7 (-83.7 to 380.0)	0.0 (-78.8 to 465.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-1.6 (-81.8 to 347.8)	19.6 (-76.6 to 414.5)
Endometriosis	15.8 (11.3 to 20.6)	12.8 (8.8 to 16.5)	-18.6 (-47.5 to 23.6)	0.0 (-41.6 to 38.3)	1.2 (0.9 to 2.2)	1.2 (0.7 to 1.8)	-1.2 (-47.9 to 24.3)	9.1 (-42.2 to 38.9)
Genital prolapse	331.6 (299.5 to 365.9)	360.4 (325.6 to 398.9)	8.7 (5.6 to 26.0)	-4.3 (-17.8 to 11.9)	1.0 (0.5 to 1.9)	1.1 (0.5 to 2.2)	1.1 (6.5 to 26.5)	-4.2 (-17.8 to 12.7)
Premenstrual syndrome	129.6 (89.2 to 175.5)	117.6 (87.9 to 155.0)	-10.5 (-43.6 to 50.5)	-3.2 (-39.3 to 64.0)	1.1 (0.6 to 1.8)	1.0 (0.5 to 1.6)	-10.8 (-43.6 to 52.2)	-2.7 (-39.0 to 66.8)
Other gynecological diseases	9.3 (8.3 to 13.4)	8.6 (7.8 to 9.8)	-6.5 (-23.6 to 3.6)	-0.2 (-21.5 to 8.1)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-6.0 (-35.9 to 19.2)	-2.9 (-36.0 to 24.7)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	3.0 (2.0 to 4.5)	2.9 (2.0 to 4.3)	-3.5 (-10.5 to 5.0)	-7.5 (-14.3 to -0.5)
Thalassemias	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-13.9 (-25.3 to -3.3)	-7.5 (-19.7 to 4.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.0 (-28.5 to 3.6)	-6.8 (-23.6 to 13.1)
Thalassemia trait	74.4 (66.5 to 85.8)	78.8 (68.3 to 92.3)	5.6 (0.2 to 12.8)	-3.8 (-8.2 to 2.1)	2.0 (1.3 to 2.9)	2.0 (1.3 to 2.9)	-2.4 (-12.0 to 8.6)	-7.5 (-16.3 to 1.1)
Sickle cell disorders	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-13.2 (-27.8 to -2.8)	-9.2 (-25.5 to 2.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.0 (-24.3 to -1.9)	-8.2 (-20.7 to 3.2)
Sickle cell trait	53.3 (46.8 to 59.7)	51.2 (45.8 to 56.4)	-3.5 (-11.2 to 2.3)	-11.8 (-18.7 to -6.1)	0.5 (0.3 to 0.7)	0.5 (0.2 to 0.5)	-23.3 (-40.4 to -7.8)	-21.6 (-42.7 to -5.3)
G6PD deficiency	16.8 (9.5 to 24.4)	20.8 (14.4 to 27.6)	24.8 (-30.3 to 132.8)	19.9 (-36.3 to 113.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.2 (4.2 to 16.1)	9.2 (-0.6 to 13.1)
G6PD trait	574.3 (515.9 to 636.8)	604.0 (531.9 to 660.6)	5.5 (-11.3 to 21.4)	4.4 (-19.7 to 10.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.1 (-45.0 to 60.1)	-6.1 (-49.3 to 50.3)
Other hemoglobinopathies and hemolytic anemias	24.5 (22.5 to 26.7)	29.9 (27.8 to 32.1)	22.7 (9.8 to 35.0)	6.2 (6.9 to 18.7)	0.5 (0.3 to 0.8)	0.5 (0.3 to 0.8)	10.8 (-12.0 to 31.2)	6.5 (-15.4 to 29.0)
Endocrine, metabolic, blood, and immune disorders	50.1 (47.5 to 54.0)	54.4 (52.2 to 57.0)	8.8 (1.3 to 16.0)	-6.7 (-15.2 to 1.0)	1.6 (1.1 to 2.2)	1.7 (1.1 to 2.3)	4.7 (-4.8 to 15.4)	-8.4 (-18.8 to 1.9)
Musculoskeletal disorders	-	-	-	-	92.8 (113.7 to 210.3)	92.8 (134.1 to 246.1)	-0.7 (-18.6 to 15.6)	-0.7 (-13.6 to 23.0)
Rheumatoid arthritis	34.7 (32.5 to 36.8)	46.4 (43.6 to 49.2)	33.5 (22.3 to 46.7)	-4.0 (-11.8 to 5.0)	7.8 (5.5 to 10.3)	10.4 (7.5 to 13.5)	32.6 (20.8 to 45.4)	-3.2 (-11.5 to 6.2)
Osteoarthritis	204.4 (178.9 to 229.7)	366.4 (306.0 to 438.2)	78.3 (47.6 to 117.4)	17.7 (-3.4 to 44.0)	6.9 (4.5 to 10.1)	12.2 (7.9 to 18.1)	76.0 (43.8 to 115.4)	17.1 (-4.4 to 44.2)
Low back and neck pain	-	-	-	-	133.8 (94.2 to 177.7)	150.8 (105.5 to 200.4)	12.7 (7.7 to 18.3)	-2.5 (-6.7 to 2.2)
Low back pain	754.5 (728.4 to 784.0)	850.3 (811.2 to 891.5)	12.6 (6.1 to 19.6)	-3.8 (-9.3 to 2.3)	92.8 (56.6 to 113.7)	92.8 (63.2 to 128.1)	3.5 (5.0 to 18.4)	-3.5 (-9.2 to 2.4)
Neck pain	527.0 (502.5 to 554.5)	608.1 (578.8 to 636.8)	15.5 (7.4 to 23.4)	-0.9 (-7.7 to 5.9)	51.0 (36.0 to 71.2)	58.5 (40.8 to 80.1)	14.6 (6.7 to 23.2)	0.7 (-7.6 to 6.1)
Gout	10.2 (9.3 to 11.2)	14.8 (13.2 to 16.6)	44.7 (26.2 to 70.2)	2.3 (-10.5 to 20.3)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	43.0 (16.3 to 76.7)	2.5 (-16.0 to 26.6)
Other musculoskeletal disorders	118.2 (88.2 to 147.0)	161.3 (121.1 to 198.7)	36.7 (24.5 to 48.9)	11.5 (3.5 to 19.6)	10.6 (6.8 to 15.5)	14.4 (9.2 to 20.9)	35.9 (24.2 to 49.3)	12.2 (3.9 to 21.4)
Other non-communicable diseases	-	-	-	-	97.7 (58.9 to 126.1)	106.8 (74.1 to 149.2)	9.9 (16.7 to 28.6)	9.6 (8.0 to 2.7)
Congenital anomalies	-	-	-	-	6.4 (4.7 to 8.3)	9.2 (6.5 to 12.3)	43.8 (23.9 to 67.0)	26.7 (9.0 to 50.8)
Neural tube defects	1.0 (0.9 to 1.2)	0.9 (0.8 to 1.1)	-6.5 (-23.6 to 13.6)	-8.7 (-25.7 to 10.9)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-6.8 (-31.6 to 24.7)	-8.6 (-33.0 to 22.9)
Congenital heart anomalies	53.3 (45.0 to 64.0)	47.0 (39.1 to 61.1)	-12.3 (-33.3 to 18.1)	-17.9 (-37.4 to 10.5)	1.9 (0.8 to 3.3)	1.7 (0.7 to 2.9)	-12.2 (-31.9 to 15.8)	-16.8 (-35.3 to 8.9)
Crofacial clefts	9.6 (7.9 to 11.3)	9.1 (7.4 to 11.0)	-5.1 (-27.6 to 22.8)	-12.2 (-33.0 to 13.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	-5.6 (-31.4 to 22.6)	-12.5 (-37.4 to 12.6)
Down syndrome	6.3 (5.5 to 7.3)	8.4 (6.9 to 10.9)	31.7 (4.6 to 75.2)	10.5 (-12.1 to 47.1)	0.9 (0.7 to 1.2)	1.3 (1.0 to 1.9)	42.8 (12.8 to 91.9)	12.1 (-11.3 to 50.3)
Turner syndrome	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	9.6 (-27.5 to 107.8)	5.4 (-30.5 to 100.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.2 (-30.6 to 103.6)	4.9 (-32.3 to 98.9)
Klinefelter syndrome	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.3)	13.3 (-22.2 to 62.9)	5.1 (-27.8 to 51.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.4 (-38.4 to 62.2)	5.8 (-37.2 to 63.9)
Chromosomal unbalanced rearrangements	13.0 (11.1 to 16.4)	15.9 (12.8 to 19.5)	23.6 (7.6 to 53.4)	4.0 (-22.5 to 29.0)	1.9 (1.4 to 2.6)	2.5 (1.8 to 3.3)	33.5 (0.9 to 66.5)	5.3 (-21.4 to 31.4)
Other congenital anomalies	10.2 (7.5 to 12.4)	9.0 (6.0 to 11.7)	-10.3 (-32.6 to 8.5)	-14.4 (-39.9 to -5.3)	1.3 (0.9 to 1.7)	3.3 (2.1 to 5.0)	154.1 (74.5 to 279.7)	144.1 (64.8 to 265.8)
Skin and subcutaneous diseases	-	-	-	-	32.9 (20.9 to 50.4)	35.0 (23.1 to 52.2)	6.5 (-3.1 to 18.5)	-1.9 (-11.5 to 11.9)
Dermatitis	322.2 (253.6 to 394.0)	329.6 (263.8 to 395.9)	2.3 (-0.2 to 5.5)	-0.1 (-0.2 to -0.0)	8.4 (5.4 to 12.0)	8.7 (5.6 to 12.5)	3.5 (0.4 to 7.7)	0.0 (-2.5 to 2.5)
Psoriasis	74.4 (64.1 to 86.1)	85.3 (73.4 to 97.9)	14.6 (11.2 to 19.0)	0.1 (-0.1 to 0.4)	5.9 (4.0 to 8.2)	6.7 (4.6 to 9.4)	13.8 (8.0 to 19.9)	0.3 (-3.7 to 4.5)
Cellulitis	0.7 (0.6 to 0.9)	0.8 (0.7 to 1.0)	11.9 (2.1 to 24.4)	15.5 (-12.2 to 4.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	2.6 (9.8 to 40.8)	0.7 (-19.8 to 19.6)
Pyoderma	6.7 (5.5 to 8.4)	8.9 (7.0 to 11.6)	31.8 (22.5 to 44.0)	4.8 (0.5 to 9.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	30.1 (18.1 to 44.0)	4.5 (-3.4 to 13.2)
Scabies	3.4 (2.9 to 4.0)	2.8 (2.3 to 3.3)	-18.3 (-37.1 to 2.2)	-21.4 (-39.0 to -1.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-19.0 (-37.6 to 3.0)	-21.3 (-39.2 to -0.7)
Fungal skin diseases	368.3 (325.7 to 406.4)	435.2 (384.7 to 476.1)	18.1 (15.8 to 20.7)	0.6 (0.4 to 0.8)	2.0 (0.8 to 4.3)	2.4 (1.0 to 5.0)	17.3 (14.7 to 19.9)	0.7 (-0.3 to 1.6)
Viral skin diseases	101.5 (80.3 to 124.0)	108.3 (84.2 to 126.8)	6.3 (-0.0 to 8.5)	3.9 (-1.7 to 3.0)	3.1 (1.8 to 4.7)	3.2 (1.9 to 5.0)	0.7 (-1.0 to 8.4)	0.7 (-2.4 to 4.0)
Acne vulgaris	738.8 (530.6 to 910.7)	623.5 (496.6 to 818.9)	-17.5 (-41.8 to 49.5)	-12.7 (-39.2 to 60.6)	8.0 (3.5 to 15.8)	6.7 (3.5 to 12.5)	-17.5 (-41.9 to 49.9)	-12.5 (-39.3 to 62.5)
Alopecia areata	8.6 (7.9 to 9.2)	10.3 (9.4 to 11.2)	20.2 (6.0 to 34.5)	-0.2 (-10.6 to 11.8)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	18.3 (3.0 to 36.1)	0.3 (-13.2 to 14.9)
Pruritus	0.6 (0.3 to 0.9)	0.8 (0.5 to 1.1)	28.0 (-31.9 to 147.7)	-1.9 (-44.3 to 80.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.3 (-34.4 to 153.0)	-1.0 (-47.4 to 90.0)
Urticaria	41.9 (31.3 to 56.2)	54.8 (43.0 to 71.1)	31.7 (-13.3 to 91.0)	12.7 (-21.8 to 52.2)	2.4 (1.5 to 3.8)	3.1 (1.9 to 4.9)	31.5 (-14.3 to 89.7)	13.7 (-21.5 to 54.6)
Decubitus ulcer	2.3 (1.7 to 2.9)	4.3 (3.5 to 5.2)	93.5 (24.8 to 176.1)	25.4 (-14.7 to 76.1)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.8)	88.5 (20.7 to 178.6)	24.3 (-16.2 to 81.1)
Other skin and subcutaneous diseases	402.6 (230.5 to 681.9)	533.5 (282.0 to 985.6)	31.3 (14.3 to 45.6)	0.7 (-2.6 to 4.3)	2.3 (0.9 to 5.1)	3.0 (1.1 to 7.1)	30.3 (13.8 to 44.9)	0.7 (-2.7 to 4.7)
Sense organ diseases	-	-	-	-	32.7 (22.0 to 46.9)	43.9 (30.0 to 61.6)	34.0 (25.2 to 48.5)	-9.2 (-15.1 to -0.8)
Glaucoma	5.9 (4.5 to 7.6)	6.2 (4.7 to 8.3)	3.4 (-21.7 to 39.8)	-30.5 (-46.9 to -10.5)	0.5 (0.3 to 0.7)	0.5 (0.4 to 0.8)	6.1 (-18.3 to 33.9)	-30.1 (-43.6 to -12.2)
Cataract	15.7 (9.7 to 23.5)	18.2 (12.2 to 24.9)	19.5 (-24.0 to 66.3)	-29.3 (-54.8 to -0.4)	0.9 (0.6 to 1.3)	1.1 (0.7 to 1.5)	19.3 (-16.1 to 64.2)	-29.6 (-50.1 to -2.5)
Macular degeneration	21.2 (14.0 to 28.0)	32.3 (23.6 to 41.8)	47.7 (22.2 to 135.6)	8.7 (-24.2 to 40.9)	1.2 (0.8 to 1.7)	1.8 (1.2 to 2.5)	48.7 (27.1 to 112.0)	-11.0 (-24.0 to 25.2)
Uncorrected refractive error	578.3 (456.1 to 681.1)	746.5 (598.1 to 909.9)	27.8 (-1.6 to 91.7)	-7.3 (-29.0 to 38.4)	7.5 (4.2 to 12.7)	9.2 (5.1 to 15.5)	21.9 (0.0 to 67.3)	-10.2 (-26.8 to 11.0)
Age-related and other hearing loss	720.1 (695.8 to 747.4)	969.4 (940.1 to 1,003.9)	10.1 (30.2 to 38.7)	-10.1 (-13.5 to -7.3)	18.5 (12.5 to 26.3)	26.7 (18.3 to 37.0)	44.1 (32.9 to 59.4)	-8.1 (-14.8 to 0.3)
Other vision loss	15.8 (11.4 to 20.2)	13.9 (10.5 to 17.9)	-12.1 (-30.3 to 9.0)	-36.2 (-48.4 to -25.5)	1.0 (0.7 to 1.4)	1.0 (0.6 to 1.4)	0.7 (-19.3 to 16.1)	0.7 (-40.9 to 17.5)
Other sense organ diseases	119.0 (113.6 to 124.8)	139.2 (132.7 to 145.7)	16.9 (8.8 to 25.4)	-0.5 (-7.0 to 6.1)	3.1 (1.9 to 4.5)	3.6 (2.2 to 5.3)	3.6 (7.5 to 24.3)	-0.5 (-7.3 to 7.3)
Oral disorders	-	-	-	-	15.7 (10.3 to 22.3)	18.7 (12.3 to 27.0)	19.6 (9.8 to 29.6)	-11.1 (-18.1 to -4.0)
Deciduous caries	195.8 (187.6 to 203.7)	167.6 (160.9 to 174.4)	-34.5 (-19.3 to -9.0)	-5.3 (-10.7 to 0.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-14.4 (-23.0 to -5.0)	-5.1 (-13.9 to 2.2)
Permanent caries	1,349.9 (1,317.7 to 1,383.9)	1,434.5 (1,397.5 to 1,473.9)	6.2 (2.6 to 10.8)	6.2 (-5.9 to 2.0)	0.8 (0.4 to 1.5)	0.8 (0.4 to 1.6)	5.5 (1.2 to 10.6)	0.7 (-6.9 to 5.4)
Periodontal diseases	261.1 (238.7 to 283.6)	371.8 (340.1 to 404.0)	42.3 (26.7 to 61.6)	11.9 (0.1 to 26.6)	1.7 (0.7 to 3.4)	2.4 (1.0 to 4.8)	41.4 (25.5 to 60.8)	11.8 (-0.1 to 26.5)
Edentulism and severe tooth loss	388.4 (354.4 to 417.3)	467.4 (429.0 to 507.0)	20.2 (6.4 to 36.0)	-19.5 (-28.8 to -9.3)	10.4 (7.0 to 14.3)	12.4 (8.4 to 17.2)	19.2 (5.4 to 34.5)	-19.7 (-29.0 to -9.4)

Appendix Table G.4 - Finland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	95.4 (89.8 to 100.4)	106.6 (100.7 to 112.5)	11.9 (3.7 to 21.6)	-0.1 (-7.4 to 8.0)	2.8 (1.7 to 4.1)	3.1 (1.9 to 4.6)	11.3 (3.0 to 21.0)	0.1 (-7.3 to 8.7)
Injuries	-	-	-	-	110.8 (84.5 to 142.4)	122.7 (88.6 to 164.4)	10.3 (-0.0 to 21.6)	-22.3 (-29.6 to -14.5)
Transport injuries	-	-	-	-	18.8 (14.3 to 24.1)	14.3 (10.4 to 18.9)	-24.4 (-31.6 to -15.9)	-41.5 (-47.0 to -34.7)
Road injuries	-	-	-	-	17.3 (13.1 to 21.9)	13.2 (9.6 to 17.4)	-24.2 (-31.7 to -15.3)	-41.3 (-47.1 to -34.3)
Pedestrian road injuries	-	-	-	-	1.6 (1.2 to 2.1)	1.5 (1.0 to 2.0)	-11.4 (-19.6 to -2.6)	-36.6 (-42.6 to -30.1)
Cyclist road injuries	-	-	-	-	4.0 (3.0 to 5.1)	2.6 (1.9 to 3.4)	-35.9 (-43.6 to -26.6)	-50.0 (-55.7 to -42.7)
Motorcyclist road injuries	-	-	-	-	3.2 (2.3 to 4.1)	2.4 (1.7 to 3.2)	-26.0 (-36.6 to -13.4)	-38.8 (-47.5 to -27.9)
Motor vehicle road injuries	-	-	-	-	8.4 (6.4 to 10.6)	6.7 (5.0 to 8.7)	-20.1 (-26.9 to -12.1)	-38.8 (-44.0 to -32.6)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-38.5 (-45.5 to -29.8)	-90.7 (-56.5 to -43.5)
Other transport injuries	-	-	-	-	1.6 (1.2 to 2.1)	1.2 (0.8 to 1.6)	-25.9 (-31.9 to -19.7)	-42.7 (-47.2 to -37.8)
Unintentional injuries	-	-	-	-	90.9 (69.2 to 116.8)	107.5 (77.6 to 144.2)	17.8 (6.5 to 29.4)	-18.1 (-25.7 to -10.1)
Falls	-	-	-	-	61.7 (47.6 to 78.6)	71.9 (52.3 to 95.6)	16.2 (3.2 to 30.8)	-23.4 (-31.8 to -14.0)
Drowning	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-5.3 (-15.9 to 5.8)	-25.2 (-33.2 to -17.0)
Fire, heat, and hot substances	-	-	-	-	1.9 (1.2 to 3.0)	2.0 (1.2 to 3.3)	2.3 (-10.2 to 16.5)	-19.5 (-29.7 to -8.1)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.1 (-38.4 to -18.9)	-40.2 (-48.7 to -30.4)
Exposure to mechanical forces	-	-	-	-	11.9 (8.9 to 15.6)	11.0 (7.7 to 15.0)	-7.9 (-16.5 to 1.1)	-24.3 (-31.2 to -16.9)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-18.5 (-27.9 to -8.2)	-29.0 (-37.1 to -20.0)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	6.6 (5.5 to 23.3)	-14.8 (-25.6 to -3.0)
Other exposure to mechanical forces	-	-	-	-	11.7 (8.8 to 15.4)	10.8 (7.6 to 14.8)	-7.9 (-16.6 to 1.1)	-24.3 (-31.3 to -17.0)
Adverse effects of medical treatment	-	-	-	-	0.2 (0.2 to 0.4)	0.3 (0.2 to 0.5)	34.4 (26.2 to 43.6)	3.5 (-2.4 to 10.1)
Animal contact	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	17.0 (8.0 to 27.0)	-6.7 (-13.8 to 1.3)
Venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	6.9 (-4.4 to 18.1)	-8.4 (-18.8 to 2.1)
Non-venomous animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	18.8 (8.9 to 29.4)	-6.3 (-13.9 to 2.2)
Foreign body	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.2 to 0.5)	-7.0 (-15.2 to 0.4)	-18.8 (-27.3 to -11.6)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-12.3 (-22.1 to -1.0)	-27.2 (-35.9 to -16.4)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-2.5 (-12.4 to 9.0)	-10.3 (-21.1 to 1.1)
Foreign body in other body part	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-5.1 (-16.0 to 2.3)	-17.8 (-27.9 to -9.6)
Other unintentional injuries	-	-	-	-	14.2 (10.2 to 19.0)	21.3 (15.0 to 29.5)	50.4 (38.8 to 62.3)	10.5 (2.0 to 19.4)
Self-harm and interpersonal violence	-	-	-	-	1.0 (0.8 to 1.4)	0.9 (0.7 to 1.2)	-12.1 (-18.8 to -5.1)	-29.2 (-34.6 to -23.8)
Self-harm	-	-	-	-	0.6 (0.4 to 0.7)	0.6 (0.4 to 0.8)	11.1 (1.4 to 23.3)	-10.0 (-18.1 to -0.2)
Interpersonal violence	-	-	-	-	0.5 (0.4 to 0.6)	0.3 (0.2 to 0.4)	-38.0 (-43.8 to -31.3)	-49.7 (-54.5 to -44.4)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-31.7 (-37.9 to -24.5)	-45.7 (-50.6 to -40.3)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-23.3 (-29.1 to -16.7)	-38.2 (-42.7 to -32.9)
Assault by other means	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.2)	-44.0 (-50.1 to -36.7)	-54.2 (-59.3 to -48.2)
Forces of nature, war, and legal intervention	-	-	-	-	-	-	-	-
Exposure to forces of nature	-	-	-	-	-	-	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - France prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	7,036.3 (5,281.1 to 9,011.7)	8,478.0 (6,373.5 to 10,835.3)	20.5 (17.4 to 23.5)	1.7 (-4.1 to 0.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	300.2 (208.9 to 416.7)	329.9 (231.3 to 465.8)	10.0 (0.1 to 20.5)	2.4 (-6.5 to 11.6)
HIV/AIDS and tuberculosis	-	-	-	-	17.9 (10.4 to 27.2)	9.6 (6.1 to 15.1)	-46.5 (-63.4 to -17.9)	-54.8 (-69.3 to -30.2)
Tuberculosis	13.1 (12.6 to 13.6)	12.3 (11.8 to 12.8)	-6.3 (-9.6 to -3.3)	-17.8 (-20.9 to -15.0)	4.0 (2.6 to 5.5)	3.7 (2.5 to 5.1)	-6.9 (-21.9 to 10.6)	-17.9 (-31.5 to -1.3)
HIV/AIDS	-	-	-	-	14.0 (7.1 to 23.2)	5.9 (3.2 to 10.6)	-58.0 (-75.5 to -42.9)	-45.9 (-80.5 to -36.5)
HIV/AIDS resulting in mycobacterial infection	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-76.5 (-87.5 to -53.9)	-79.1 (-89.0 to -58.6)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-76.5 (-87.6 to -53.8)	-79.1 (-89.1 to -58.5)
HIV/AIDS resulting in other diseases	60.1 (43.8 to 84.4)	69.6 (43.2 to 113.4)	11.9 (-20.4 to 80.1)	-11.1 (-38.2 to 49.3)	13.9 (7.0 to 23.1)	5.9 (3.2 to 10.6)	-58.0 (-75.5 to -22.6)	-65.9 (-80.5 to -36.3)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	35.6 (23.2 to 53.2)	34.4 (21.8 to 51.4)	-3.5 (-10.5 to 4.7)	-16.1 (-22.3 to -9.0)
Diarrheal diseases	20.8 (18.3 to 23.4)	20.0 (17.8 to 22.8)	-3.6 (-19.5 to 14.8)	-30.0 (-35.3 to -0.2)	3.3 (2.2 to 4.6)	3.2 (2.1 to 4.4)	-4.3 (-24.2 to 17.6)	-19.6 (-38.4 to 3.5)
Intestinal infectious diseases	0	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-30.5 (58.4 to 11.6)	-34.3 (-61.8 to 5.6)
Typhoid fever	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-25.3 (-53.8 to 21.6)	-30.4 (-57.9 to 11.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-25.3 (-53.8 to 21.8)	-30.4 (-57.9 to 11.5)
Paratyphoid fever	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	-1.3 (-31.5 to 64.9)	-3.2 (-32.2 to 57.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.3 (-31.5 to 64.9)	-3.2 (-32.2 to 57.9)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-71.0 (-93.7 to -18.4)	-73.4 (-94.1 to 9.9)
Lower respiratory infections	10.2 (8.0 to 13.2)	12.5 (9.1 to 17.4)	23.6 (-18.0 to 84.2)	-13.9 (-41.8 to 19.6)	1.0 (0.6 to 1.5)	1.2 (0.7 to 1.8)	21.4 (-21.6 to 83.4)	-13.0 (-42.3 to 21.4)
Upper respiratory infections	868.6 (825.4 to 903.2)	952.9 (912.6 to 992.3)	9.7 (3.3 to 17.2)	0.1 (-5.6 to 6.9)	10.2 (5.6 to 16.9)	11.1 (6.3 to 18.5)	9.4 (2.2 to 17.9)	0.2 (-6.4 to 8.0)
Otitis media	734.6 (642.2 to 842.7)	722.3 (634.8 to 826.4)	-1.0 (-15.9 to 13.2)	-12.8 (-24.2 to -1.6)	13.5 (7.8 to 22.1)	13.1 (7.5 to 20.8)	-1.9 (-16.0 to 13.5)	-13.9 (-24.6 to -1.7)
Meningitis	-	-	-	-	4.3 (2.7 to 6.1)	2.3 (1.5 to 3.3)	-45.8 (-59.0 to -28.3)	-52.6 (-64.9 to -36.3)
Pneumococcal meningitis	9.1 (5.5 to 15.5)	5.0 (3.1 to 8.6)	-43.1 (-61.3 to -24.8)	-53.6 (-68.2 to -39.1)	0.9 (0.6 to 1.3)	0.5 (0.3 to 0.8)	-38.8 (-53.8 to -16.8)	-48.3 (-61.5 to -29.0)
H influenzae type B meningitis	6.9 (2.1 to 17.5)	3.3 (1.1 to 7.8)	-51.7 (-71.5 to -2.3)	-56.1 (-75.4 to -8.8)	0.8 (0.5 to 1.3)	0.5 (0.3 to 0.8)	-42.6 (-68.7 to 9.9)	-47.4 (-72.1 to 3.7)
Meningococcal meningitis	4.4 (1.4 to 10.7)	2.3 (0.9 to 5.5)	-46.5 (-72.9 to -3.5)	-56.4 (-78.1 to -36.3)	0.7 (0.3 to 1.3)	0.4 (0.2 to 0.6)	-38.1 (-74.7 to 7.8)	-50.4 (-79.6 to -5.8)
Other meningitis	14.4 (5.6 to 34.1)	6.7 (2.6 to 16.2)	-53.5 (-67.5 to -36.5)	-60.3 (-72.0 to -41.5)	1.9 (1.1 to 2.9)	0.9 (0.5 to 1.4)	-52.7 (-68.9 to -26.8)	-57.7 (-73.1 to -31.9)
Encephalitis	2.1 (0.9 to 5.8)	2.5 (1.1 to 6.8)	19.8 (-0.0 to 49.3)	2.1 (-18.0 to 25.6)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	27.4 (-21.1 to 58.0)	5.9 (-15.3 to 32.5)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-92.5 to 411.8)	0.0 (0.0 to 0.0)	-	-
Whooping cough	5.1 (4.0 to 6.6)	1.1 (0.8 to 1.4)	-78.8 (-80.8 to -76.6)	-79.5 (-81.4 to -77.3)	0.3 (0.1 to 0.4)	0.1 (0.0 to 0.1)	-78.8 (-85.6 to -71.6)	-79.5 (-86.1 to -72.5)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-43.9 to -55.1)	0.0 (-84.9 to -47.1)	-	-
Measles	4.3 (4.3 to 4.4)	0.0 (0.0 to 0.0)	-99.8 (-99.8 to -99.8)	-99.8 (-99.9 to -99.8)	0.4 (0.3 to 0.6)	0.0 (0.0 to 0.0)	-99.8 (-99.9 to -99.8)	-99.8 (-99.9 to -99.8)
Varicella and herpes zoster	57.9 (51.9 to 64.6)	69.9 (62.4 to 79.2)	21.0 (1.1 to 42.3)	0.8 (-13.2 to 15.5)	2.4 (1.4 to 3.7)	3.0 (1.8 to 4.7)	25.5 (-1.4 to 56.7)	0.6 (-20.4 to 25.4)
Neglected tropical diseases and malaria	-	-	-	-	2.7 (1.8 to 3.8)	1.4 (0.9 to 2.1)	-45.6 (-63.4 to -23.4)	-58.5 (-72.2 to -42.2)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.8 (-67.3 to 442.7)	-7.7 (-69.2 to 413.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.0 (-66.8 to 446.9)	-5.7 (-69.1 to 416.7)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.6 (-32.1 to 16.5)	-16.9 (-36.9 to 3.8)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.1 (-33.2 to 17.0)	-17.3 (-37.9 to 4.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.1 (-33.3 to 17.0)	-17.3 (-38.1 to 4.4)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.4 (-22.8 to 30.2)	-8.7 (-29.1 to 14.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.4 (-22.8 to 30.3)	-8.7 (-29.3 to 14.6)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	2.1 (1.0 to 3.4)	0.5 (0.2 to 1.1)	-76.6 (-91.7 to -31.3)	-80.4 (-93.7 to -45.3)	0.8 (0.3 to 1.4)	0.2 (0.1 to 0.5)	-73.6 (-90.7 to -21.0)	-78.2 (-93.0 to -36.9)
Cystic echinococcosis	20.0 (18.6 to 21.1)	13.3 (11.3 to 16.0)	-36.2 (-44.3 to -18.9)	-52.4 (-58.9 to -41.6)	1.9 (1.3 to 2.6)	1.2 (0.8 to 1.7)	-35.9 (-49.3 to -15.6)	-51.6 (-62.3 to -37.5)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	2.0 (-4.9 to 8.2)	0.0 (0.0 to 0.0)	2.0 (-57.8 to 23.9)	-10.5 (-64.9 to 8.2)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Ascariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trichuriasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hookworm disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	207.4 (19.2 to 452.9)	177.5 (9.2 to 398.6)
Maternal disorders	-	-	-	-	1.1 (0.6 to 2.0)	1.3 (0.7 to 2.2)	15.1 (-12.8 to 48.4)	22.2 (-7.6 to 57.3)
Maternal hemorrhage	5.7 (3.4 to 8.0)	11.3 (8.1 to 14.5)	98.2 (26.4 to 249.9)	112.3 (33.4 to 274.8)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.5)	33.5 (-40.8 to 194.9)	44.2 (-36.5 to 213.9)
Maternal sepsis and other maternal infections	6.8 (3.9 to 11.4)	7.0 (3.9 to 11.5)	5.3 (-25.8 to 32.0)	5.3 (-27.1 to 27.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-1.7 (-41.0 to 76.9)	0.5 (-40.5 to 88.3)
Maternal hypertensive disorders	10.0 (3.1 to 19.3)	10.9 (3.7 to 20.6)	9.8 (-10.2 to 29.5)	16.2 (-5.4 to 37.6)	0.5 (0.1 to 1.0)	0.5 (0.2 to 1.1)	9.0 (-16.6 to 43.5)	15.5 (-10.7 to 52.3)
Obstructed labor	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	1.1 (-62.9 to 90.8)	7.8 (-60.5 to 101.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	1.1 (-63.0 to 90.8)	7.8 (-60.7 to 102.3)
Complications of abortion	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	18.6 (-28.2 to 105.8)	26.8 (-24.2 to 120.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.6 (-28.3 to 105.9)	26.8 (-24.4 to 120.3)
Other maternal disorders	-	-	-	-	0.3 (0.1 to 0.5)	0.3 (0.1 to 0.5)	19.3 (-19.3 to 76.2)	26.7 (-14.0 to 87.1)
Neonatal disorders	-	-	-	-	50.1 (35.3 to 67.1)	84.3 (56.7 to 116.7)	68.6 (19.6 to 132.3)	53.9 (9.3 to 111.8)
Preterm birth complications	225.4 (164.9 to 316.1)	365.9 (265.5 to 528.3)	61.2 (29.9 to 106.1)	44.5 (17.0 to 84.7)	29.5 (20.1 to 41.7)	47.9 (33.1 to 66.0)	62.3 (21.0 to 116.1)	48.1 (10.5 to 98.3)
Neonatal encephalopathy due to birth asphyxia and trauma	43.6 (24.2 to 87.5)	32.1 (15.8 to 78.4)	-28.2 (-52.6 to 7.4)	-34.2 (-56.4 to -1.6)	1.2 (6.9 to 14.1)	0.1 (4.9 to 11.9)	-1.7 (-50.9 to 21.8)	0.5 (-54.6 to 13.5)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	36.1 (5.0 to 114.0)	29.8 (0.2 to 104.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.6 (-60.7 to 120.9)	34.1 (-11.0 to 110.7)
Hemolytic disease and other neonatal jaundice	13.1 (3.1 to 29.1)	12.1 (5.8 to 22.6)	-3.6 (-68.3 to 382.1)	-12.5 (-71.0 to 344.0)	5.6 (1.2 to 13.0)	5.3 (2.4 to 10.2)	-1.2 (-67.3 to 380.2)	-10.6 (-69.9 to 340.3)
Other neonatal disorders	-	-	-	-	4.8 (2.8 to 8.9)	23.2 (9.1 to 37.8)	468.9 (42.2 to 896.1)	420.8 (30.2 to 806.0)
Nutritional deficiencies	-	-	-	-	177.6 (117.5 to 262.4)	182.4 (121.1 to 265.3)	2.9 (-5.8 to 11.8)	-2.2 (-9.0 to 5.1)
Protein-energy malnutrition	8.0 (4.6 to 12.7)	8.9 (4.8 to 14.7)	11.5 (-21.5 to 50.7)	35.9 (-54.3 to -14.7)	0.9 (0.4 to 1.5)	1.0 (0.4 to 1.7)	11.4 (-25.4 to 57.8)	-35.4 (-55.9 to -10.8)
Iodine deficiency	1,003.7 (461.0 to 1,784.5)	582.2 (217.3 to 1,027.9)	-43.0 (-75.6 to 68.9)	-48.6 (-78.3 to 55.5)	17.9 (7.0 to 37.1)	10.4 (3.3 to 21.3)	-43.4 (-76.2 to 69.0)	-48.5 (-78.7 to 56.9)
Vitamin A deficiency	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-

Appendix Table G.4 - France prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	6,084.0 (5,912.0 to 6,204.1)	6,745.3 (6,625.5 to 6,880.0)	10.9 (8.8 to 13.6)	1.4 (-0.6 to 4.3)	158.8 (105.5 to 232.8)	171.0 (112.5 to 251.7)	7.6 (4.5 to 12.2)	7.6 (-0.9 to 6.3)
Other nutritional deficiencies	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-0.1 (-4.1 to 3.7)	-0.1 (-6.8 to -2.6)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	15.1 (9.2 to 23.7)	16.4 (10.2 to 26.1)	8.7 (-3.7 to 27.4)	1.7 (-11.4 to 21.8)
Sexually transmitted diseases excluding HIV	-	-	-	-	5.0 (2.6 to 9.8)	6.0 (3.2 to 11.2)	18.5 (-1.2 to 47.1)	8.5 (-10.5 to 37.6)
Syphilis	2.5 (2.0 to 2.8)	4.6 (3.6 to 5.5)	83.8 (39.2 to 154.3)	4.4 (1.5 to 10.1)	0.5 (0.3 to 0.7)	0.8 (0.5 to 1.2)	62.3 (24.3 to 185.1)	40.3 (8.9 to 123.2)
Chlamydial infection	561.8 (412.3 to 712.5)	612.8 (497.0 to 747.8)	6.2 (-20.3 to 63.0)	8.1 (-20.6 to 64.6)	1.5 (0.6 to 2.8)	1.8 (0.9 to 3.4)	16.7 (-25.3 to 148.8)	20.4 (-25.4 to 155.4)
Gonococcal infection	173.2 (113.7 to 261.3)	173.5 (123.2 to 247.2)	2.2 (-44.7 to 80.9)	9.6 (-42.4 to 97.6)	0.7 (0.3 to 1.3)	0.6 (0.3 to 1.1)	-6.9 (-38.5 to 40.1)	-1.7 (-36.3 to 52.4)
Trichomoniasis	261.0 (187.7 to 337.4)	199.2 (142.1 to 266.4)	-23.1 (-52.0 to 12.6)	-24.5 (-54.5 to 15.2)	0.4 (0.2 to 1.0)	0.3 (0.1 to 0.7)	-26.0 (-56.4 to 22.8)	-27.0 (-58.6 to 25.4)
Genital herpes	6,891.8 (6,281.8 to 7,549.7)	8,632.3 (7,868.5 to 9,392.5)	25.4 (9.2 to 42.7)	2.8 (-10.8 to 17.8)	2.8 (0.5 to 4.5)	2.2 (0.7 to 5.3)	23.4 (7.3 to 41.7)	3.0 (-10.9 to 18.3)
Other sexually transmitted diseases	8.9 (6.4 to 12.3)	7.8 (5.7 to 10.3)	-11.0 (-29.5 to 6.0)	-13.6 (-30.9 to 2.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	1.8 (-37.9 to 86.0)	-0.3 (-40.4 to 89.8)
Hepatitis	-	-	-	-	2.0 (1.2 to 3.0)	1.8 (1.1 to 2.6)	-11.3 (-24.4 to 7.8)	-11.3 (-30.9 to -2.6)
Hepatitis A	43.8 (41.7 to 45.9)	44.0 (41.6 to 46.4)	0.5 (-0.2 to 1.0)	-6.7 (-7.8 to -5.6)	1.3 (0.8 to 1.9)	1.3 (0.8 to 2.0)	2.1 (-8.3 to 14.9)	-5.8 (-15.6 to 6.7)
Hepatitis B	1,083.6 (880.4 to 1,343.7)	632.8 (478.2 to 772.4)	-41.0 (-57.4 to -22.9)	-49.1 (-63.2 to -34.5)	0.6 (0.3 to 1.0)	0.4 (0.2 to 0.6)	-40.9 (-63.9 to -15.3)	-48.8 (-68.7 to -21.1)
Hepatitis C	464.7 (428.6 to 503.0)	429.9 (395.1 to 467.2)	-7.3 (-17.6 to 3.5)	-26.0 (-34.2 to -17.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	2.2 (-28.0 to 29.7)	-24.0 (-42.6 to -1.8)
Hepatitis E	-	-	-	-	16.3 (-6.4 to 44.8)	-	-	-
Leprosy	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Other infectious diseases	262.8 (224.1 to 305.9)	282.5 (254.7 to 309.9)	7.6 (-8.9 to 29.2)	1.0 (-15.8 to 23.4)	8.0 (5.0 to 12.1)	8.7 (5.5 to 13.0)	7.9 (-13.2 to 42.8)	2.9 (-17.6 to 38.9)
Non-communicable diseases	-	-	-	-	4,485.5 (7,705.1)	5,603.5 (9,581.4)	24.9 (21.4 to 28.2)	24.9 (-0.9 to 4.5)
Neoplasms	-	-	-	-	120.9 (90.5 to 155.0)	185.9 (138.1 to 240.9)	53.8 (43.7 to 64.7)	4.0 (-2.9 to 11.5)
Esophageal cancer	10.9 (8.3 to 13.5)	11.0 (8.3 to 16.6)	-2.7 (-29.0 to 66.8)	-35.1 (-52.5 to 17.3)	1.5 (1.0 to 2.1)	1.5 (1.0 to 2.4)	-6.8 (-29.3 to 57.9)	-37.2 (-52.8 to 10.0)
Stomach cancer	29.0 (25.2 to 33.9)	30.6 (25.7 to 37.0)	5.1 (-11.5 to 26.2)	-31.3 (-41.4 to -19.3)	3.1 (2.2 to 4.1)	3.2 (2.2 to 4.2)	-0.2 (-19.6 to 23.8)	-34.1 (-45.7 to -20.4)
Liver cancer	-	-	-	-	1.1 (0.8 to 1.6)	1.9 (1.2 to 2.8)	68.7 (22.9 to 137.7)	14.1 (-16.5 to 58.5)
Liver cancer due to hepatitis B	1.3 (0.5 to 2.4)	2.6 (1.4 to 4.5)	102.4 (-16.0 to 408.6)	42.0 (-39.7 to 265.0)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.7)	96.4 (-11.9 to 382.8)	37.8 (-38.0 to 239.0)
Liver cancer due to hepatitis C	1.4 (0.6 to 2.4)	5.6 (2.9 to 8.5)	298.3 (102.2 to 865.1)	165.4 (31.7 to 568.0)	0.2 (0.1 to 0.4)	0.9 (0.4 to 1.3)	265.3 (99.2 to 724.6)	146.4 (31.7 to 480.9)
Liver cancer due to alcohol use	3.8 (2.4 to 5.8)	3.5 (1.8 to 5.9)	-7.4 (-56.0 to 90.0)	-39.0 (-71.2 to 27.3)	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.9)	-9.7 (-52.2 to 56.8)	-40.1 (-69.6 to 8.1)
Liver cancer due to other causes	0.5 (0.3 to 0.8)	0.6 (0.2 to 1.2)	9.5 (-58.1 to 161.6)	-27.4 (-70.8 to 60.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	0.5 (-55.5 to 137.2)	-30.7 (-69.4 to 49.4)
Larynx cancer	20.3 (13.5 to 25.3)	16.4 (12.3 to 26.4)	-24.4 (-44.3 to 35.4)	-47.3 (-61.3 to -3.6)	2.2 (1.3 to 3.1)	1.6 (1.0 to 2.6)	-32.5 (-52.3 to 21.9)	-52.9 (-66.6 to -12.8)
Tracheal, bronchus and lung cancer	44.8 (40.3 to 49.9)	68.5 (56.4 to 78.7)	54.2 (20.9 to 83.2)	6.9 (-15.5 to 27.1)	6.7 (4.9 to 8.7)	9.9 (7.0 to 13.0)	48.8 (18.3 to 75.6)	3.7 (-17.3 to 22.8)
Breast cancer	422.3 (384.1 to 458.8)	764.5 (709.9 to 813.0)	81.4 (63.4 to 102.8)	22.0 (9.8 to 36.7)	22.0 (15.3 to 29.8)	35.8 (24.2 to 50.3)	62.6 (42.0 to 83.7)	10.1 (-3.0 to 24.1)
Cervical cancer	34.7 (27.1 to 40.7)	30.6 (24.2 to 37.7)	-12.1 (-31.2 to 11.1)	-2.5 (-47.3 to -14.8)	2.2 (1.7 to 3.5)	2.2 (1.5 to 3.2)	-12.2 (-49.1 to -12.7)	-32.2 (-49.1 to -12.7)
Uterine cancer	78.8 (57.6 to 97.1)	99.7 (73.8 to 130.0)	26.2 (-8.8 to 74.1)	-13.7 (-37.8 to 39.3)	5.1 (3.3 to 7.3)	6.3 (4.0 to 9.4)	24.2 (-11.1 to 72.6)	-15.3 (-39.3 to 17.8)
Prostate cancer	228.4 (199.4 to 264.3)	502.9 (432.8 to 619.2)	120.7 (80.0 to 170.2)	47.2 (21.0 to 79.9)	18.1 (13.0 to 24.0)	37.8 (26.4 to 54.3)	106.8 (64.3 to 172.1)	36.2 (11.0 to 77.4)
Colon and rectum cancer	186.0 (174.2 to 198.5)	279.8 (248.2 to 313.1)	50.7 (31.3 to 70.8)	-0.9 (-12.3 to 11.0)	15.4 (11.4 to 20.1)	22.2 (16.0 to 28.9)	44.3 (24.5 to 65.9)	-5.0 (-17.6 to 7.0)
Lip and oral cavity cancer	61.6 (50.6 to 74.0)	59.2 (47.3 to 73.7)	-3.5 (-28.4 to 27.4)	-33.5 (-50.7 to -13.1)	3.0 (3.4 to 6.3)	4.7 (3.3 to 6.5)	-6.0 (-30.2 to 26.0)	-35.1 (-52.0 to -13.6)
Nasopharynx cancer	6.7 (4.6 to 9.1)	3.3 (2.1 to 6.5)	-54.4 (-71.3 to 1.7)	-67.0 (-79.6 to -24.4)	0.6 (0.4 to 0.9)	0.3 (0.2 to 0.6)	-54.7 (-70.3 to 0.3)	-67.5 (-78.5 to -26.7)
Other pharynx cancer	39.4 (27.2 to 53.8)	37.9 (26.6 to 58.9)	-6.0 (-40.7 to 63.1)	-33.8 (-58.2 to 16.4)	3.1 (1.9 to 4.6)	3.0 (1.8 to 4.7)	-7.5 (-38.7 to 57.4)	-35.0 (-58.0 to 13.8)
Gallbladder and biliary tract cancer	2.4 (1.7 to 3.0)	2.2 (1.5 to 3.4)	-11.0 (-38.2 to 46.3)	-44.1 (-60.3 to -6.4)	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.9)	-14.5 (-44.2 to 51.3)	-45.9 (-62.0 to -5.0)
Pancreatic cancer	5.1 (4.1 to 6.1)	9.2 (7.3 to 11.3)	79.8 (36.7 to 142.5)	18.6 (-9.3 to 58.8)	1.1 (0.8 to 1.5)	1.9 (1.3 to 2.6)	74.8 (31.0 to 123.4)	16.4 (-6.3 to 45.1)
Malignant skin melanoma	54.4 (39.9 to 77.4)	99.4 (63.9 to 129.6)	82.0 (26.6 to 144.1)	36.2 (-1.5 to 78.8)	3.2 (2.1 to 5.0)	5.7 (3.1 to 8.6)	77.6 (28.0 to 140.0)	31.9 (-8.8 to 76.2)
Non-melanoma skin cancer	51.4 (28.7 to 77.9)	81.9 (57.1 to 121.5)	56.6 (-8.1 to 258.3)	8.2 (-37.1 to 162.7)	1.0 (0.6 to 1.6)	2.1 (1.3 to 3.3)	113.1 (39.1 to 234.9)	39.1 (-6.7 to 117.2)
Ovarian cancer	18.0 (15.5 to 20.7)	25.1 (20.0 to 31.1)	38.7 (10.8 to 79.3)	-5.4 (-23.2 to 20.1)	2.3 (1.6 to 3.1)	3.1 (2.1 to 4.4)	36.8 (3.1 to 81.7)	-6.7 (-28.0 to 24.2)
Testicular cancer	15.8 (10.7 to 22.2)	16.3 (10.0 to 23.9)	3.6 (-33.0 to 60.7)	-2.0 (-38.1 to 52.6)	0.9 (0.5 to 1.5)	1.0 (0.5 to 1.6)	2.6 (-36.4 to 59.5)	-4.1 (-40.7 to 51.3)
Kidney cancer	38.2 (32.9 to 43.4)	72.2 (59.9 to 85.8)	88.8 (51.5 to 130.0)	88.8 (3.8 to 57.6)	2.2 (2.0 to 3.8)	4.9 (3.3 to 6.8)	80.9 (43.9 to 122.3)	22.9 (-0.5 to 51.7)
Bladder cancer	72.0 (61.6 to 82.5)	95.5 (70.9 to 115.8)	33.2 (3.4 to 64.3)	-12.4 (-31.1 to 7.0)	5.4 (3.9 to 7.3)	6.9 (4.6 to 9.6)	29.2 (0.0 to 61.0)	-14.5 (-33.2 to 4.6)
Brain and nervous system cancer	12.6 (10.4 to 15.1)	21.9 (17.0 to 25.9)	74.2 (39.5 to 111.5)	33.7 (8.9 to 61.2)	1.3 (0.9 to 1.8)	2.3 (1.4 to 3.0)	60.1 (27.9 to 100.7)	23.4 (-1.4 to 52.2)
Thyroid cancer	27.1 (19.5 to 32.4)	30.7 (23.6 to 45.7)	6.2 (-19.8 to 87.9)	-18.0 (-37.6 to 46.6)	1.6 (1.0 to 2.4)	1.8 (1.1 to 2.9)	4.1 (-2.4 to 83.6)	-19.5 (-40.2 to 21.1)
Mesothelioma	1.4 (1.4 to 2.3)	2.1 (1.6 to 3.1)	61.1 (-18.2 to 65.6)	-27.5 (-43.8 to 11.1)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.7)	12.1 (-20.4 to 88.7)	-23.8 (-44.8 to 42.1)
Hodgkin lymphoma	13.6 (9.7 to 17.8)	14.1 (9.8 to 18.4)	4.1 (-28.9 to 48.5)	-10.6 (-39.8 to 32.1)	1.1 (0.7 to 1.6)	1.1 (0.7 to 1.5)	2.2 (-33.5 to 44.6)	-13.4 (-43.5 to 28.0)
Non-Hodgkin lymphoma	52.6 (38.6 to 77.7)	99.3 (57.4 to 127.2)	99.0 (-1.9 to 155.5)	34.8 (-31.9 to 68.6)	3.8 (2.4 to 5.8)	6.9 (3.6 to 10.0)	92.0 (-8.9 to 151.1)	30.6 (-36.7 to 66.8)
Multiple myeloma	7.6 (5.0 to 11.7)	13.8 (8.5 to 20.9)	79.8 (8.6 to 189.6)	21.3 (-25.0 to 92.6)	1.6 (1.0 to 2.7)	2.8 (1.6 to 4.5)	73.9 (4.4 to 164.9)	17.3 (-28.3 to 79.6)
Leukemia	22.9 (20.6 to 27.6)	36.9 (30.0 to 44.3)	63.8 (24.3 to 93.4)	1.3 (-17.0 to 26.4)	1.3 (2.3 to 4.3)	4.9 (3.4 to 6.5)	48.9 (17.1 to 91.2)	-1.6 (-20.5 to 23.3)
Other neoplasms	53.3 (43.1 to 63.9)	139.9 (111.7 to 182.2)	161.2 (100.5 to 260.6)	77.6 (39.9 to 138.4)	4.0 (2.7 to 5.4)	9.3 (6.4 to 13.1)	77.6 (79.2 to 223.5)	59.2 (24.7 to 114.4)
Cardiovascular diseases	-	-	-	-	260.6 (180.6 to 356.3)	370.4 (254.1 to 500.5)	42.2 (16.3 to 73.1)	-4.4 (-21.6 to 16.5)
Rheumatic heart disease	5.0 (3.7 to 6.6)	7.0 (5.1 to 9.2)	40.2 (-7.1 to 119.9)	1.2 (-32.3 to 55.6)	0.5 (0.3 to 0.9)	0.8 (0.4 to 1.1)	36.3 (-39.6 to 62.7)	-2.6 (-9.9 to 6.2)
Ischemic heart disease	1,309.0 (1,110.2 to 1,570.7)	1,910.8 (1,622.3 to 2,256.4)	46.0 (12.5 to 86.2)	-3.3 (-26.3 to 23.7)	81.4 (54.4 to 114.4)	110.3 (72.3 to 155.9)	35.5 (2.5 to 74.8)	-12.1 (-34.7 to 14.9)
Cerebrovascular disease	-	-	-	-	54.7 (38.3 to 74.4)	79.2 (53.7 to 106.0)	44.0 (15.4 to 82.4)	0.5 (-17.5 to 25.4)
Ischemic stroke	349.6 (296.3 to 404.3)	519.9 (434.4 to 608.6)	48.2 (17.3 to 90.8)	2.3 (-15.1 to 30.0)	49.9 (34.7 to 68.9)	74.3 (49.6 to 100.0)	48.2 (18.6 to 89.8)	3.4 (-15.1 to 30.2)
Hemorrhagic stroke	32.9 (23.4 to 47.0)	33.4 (25.6 to 44.0)	2.3 (-37.1 to 65.6)	-28.0 (-54.4 to 13.9)	4.8 (2.9 to 7.4)	4.9 (3.1 to 7.3)	2.6 (-36.3 to 66.6)	-26.8 (-54.0 to 14.2)
Hypertensive heart disease	137.9 (109.9 to 167.8)	223.3 (183.1 to 261.4)	62.1 (23.9 to 111.9)	6.0 (-18.7 to 37.1)	14.8 (9.7 to 21.1)	23.8 (15.6 to 33.8)	61.9 (22.4 to 110.5)	6.5 (-19.3 to 38.3)
Cardiomyopathy and myocarditis	104.5 (82.4 to 129.0)	123.7 (104.3 to 144.3)	18.9 (-11.3 to 56.2)	-18.5 (-38.6 to 6.4)	18.9 (7.2 to 16.4)	18.2 (8.9 to 18.5)	13.2 (-11.7 to 56.5)	-18.3 (-39.0 to 7.5)
Atrial fibrillation and flutter	216.4 (161.4 to 289.9)	252.0 (155.2 to 339.6)	17.8 (-28.6 to 71.1)	-20.7 (-53.6 to 14.4)	16.6 (10.4 to 24.9)	19.3 (11.0 to 29.8)	18.4 (-29.7 to 72.6)	-20.7 (-54.1 to 12.6)
Peripheral vascular disease	2,311.1 (1,798.9 to 2,881.8)	3,178.9 (2,496.7 to 3,986.7)	36.8 (1.3 to 93.6)	-7.7 (-33.1 to 35.2)	3.0 (1.4 to 5.6)	3.7 (1.2 to 8.0)	18.9 (-53.9 to 156.0)	-23.5 (-69.5 to 70.2)
Endocarditis	3.2 (2.2 to 4.1)	3.3 (2.4 to 5.2)	4.1 (-32.4 to 76.6)	-25.8 (-52.0 to 27.8)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	6.8 (-37.0 to 96.6)	-24.1 (-53.5 to 39.5)
Other cardiovascular and circulatory diseases	1,108.6 (669.9 to 1,624.3)	1,690.4 (1,083.6 to 2,306.2)	53.2 (-13.5 to 162.7)	53.2 (-39.4 to 79.7)	51.6 (41.5 to 125.8)	78.0 (64.2 to 178.8)	51.6 (-13.7 to 166.3)	5.3 (-40.3 to 82.4)
Chronic respiratory diseases	-	-	-	-	251.3 (171.5 to 344.9)	302.7 (209.1 to 408.2)	20.6 (9.7 to 32.1)	1

Appendix Table G.4 - France prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-3.6 (-18.8 to 8.9)	-
Silicosis	0.3 (0.3 to 0.3)	0.3 (0.3 to 0.3)	-7.1 (-13.1 to -1.0)	-34.1 (-38.3 to -30.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-5.6 (-12.8 to -0.3)	-33.8 (-38.1 to -29.6)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.8 (0.5 to 1.1)	0.8 (0.5 to 1.0)	-3.7 (-25.1 to 14.7)	-3.0 (-8.4 to -30.3)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-2.2 (-24.2 to 16.2)	-32.1 (-47.8 to -18.7)
Asthma	3,832.4 (3,651.5 to 4,010.9)	4,384.9 (4,184.9 to 4,581.8)	14.6 (6.8 to 22.8)	2.3 (-5.0 to 9.8)	167.8 (110.0 to 238.5)	191.4 (124.5 to 270.3)	14.2 (5.9 to 22.3)	2.6 (-5.3 to 10.3)
Interstitial lung disease and pulmonary sarcoidosis	6.7 (5.1 to 8.3)	9.1 (6.8 to 11.2)	34.7 (-3.9 to 95.7)	-0.9 (-29.0 to 41.0)	0.9 (0.5 to 1.4)	1.2 (0.7 to 1.9)	34.8 (-5.7 to 95.0)	-0.7 (-30.2 to 41.3)
Other chronic respiratory diseases	-	-	-	-	2.1 (1.2 to 3.3)	2.8 (1.7 to 4.2)	33.2 (-3.5 to 74.6)	-1.0 (-27.1 to 31.9)
Cirrhosis	-	-	-	-	6.6 (4.6 to 9.2)	5.5 (3.7 to 7.7)	-17.3 (-27.7 to -4.5)	-38.4 (-46.8 to -28.8)
Cirrhosis due to hepatitis B	3.7 (2.4 to 5.0)	3.3 (1.8 to 5.2)	-11.6 (-54.3 to 63.5)	-35.0 (-66.1 to 22.1)	0.6 (0.3 to 1.0)	0.5 (0.3 to 0.9)	-12.8 (-56.7 to 74.8)	-35.5 (-68.2 to 30.6)
Cirrhosis due to hepatitis C	14.6 (9.4 to 22.0)	15.9 (10.5 to 20.6)	12.3 (-36.2 to 82.0)	-16.9 (-53.1 to 35.7)	2.4 (1.3 to 3.9)	2.6 (1.5 to 4.0)	12.4 (-38.5 to 83.7)	-16.4 (-53.9 to 39.4)
Cirrhosis due to alcohol use	18.4 (11.4 to 22.8)	10.2 (7.0 to 13.7)	-46.0 (-64.9 to -4.3)	-40.5 (-74.9 to -30.4)	3.0 (1.7 to 4.4)	1.6 (1.0 to 2.6)	-45.4 (-66.1 to -4.0)	60.5 (-76.0 to -4.0)
Cirrhosis due to other causes	3.9 (2.5 to 6.0)	4.4 (2.4 to 6.3)	14.0 (-47.4 to 101.7)	-12.2 (-57.3 to 48.5)	0.7 (0.4 to 1.2)	0.7 (0.4 to 1.2)	12.1 (-50.7 to 107.2)	-13.5 (-59.9 to 55.0)
Digestive diseases	-	-	-	-	75.6 (53.5 to 100.8)	95.0 (67.5 to 125.5)	25.5 (17.1 to 35.1)	2.4 (-9.6 to 5.8)
Peptic ulcer disease	383.1 (354.7 to 411.6)	313.4 (274.9 to 348.2)	-18.2 (-26.6 to -10.5)	-50.3 (-55.9 to -45.4)	12.6 (8.4 to 17.8)	11.2 (7.5 to 15.6)	-11.2 (-20.7 to 0.7)	-43.9 (-49.9 to -36.0)
Gastritis and duodenitis	197.2 (172.9 to 220.7)	125.2 (105.3 to 145.5)	-36.5 (-45.8 to -25.3)	-54.3 (-61.5 to -46.5)	6.7 (4.4 to 9.7)	5.3 (3.5 to 7.7)	-17.3 (-32.4 to -2.1)	-43.4 (-52.3 to -27.2)
Appendicitis	2.2 (1.7 to 2.7)	1.8 (1.3 to 2.4)	-19.8 (-43.4 to 37.3)	-21.7 (-46.7 to 32.9)	0.7 (0.4 to 1.0)	0.6 (0.3 to 0.9)	-19.8 (-48.5 to 46.8)	-22.5 (-52.6 to 45.2)
Paralytic ileus and intestinal obstruction	0.9 (0.7 to 1.2)	1.4 (1.2 to 1.7)	57.1 (14.3 to 121.3)	16.8 (-22.6 to 75.4)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	99.8 (0.1 to 158.5)	19.3 (-29.0 to 95.9)
Inguinal, femoral, and abdominal hernia	283.5 (198.2 to 384.6)	390.1 (275.5 to 547.9)	38.1 (-16.2 to 148.2)	-3.5 (-40.1 to 62.6)	2.8 (1.2 to 5.8)	3.9 (1.7 to 7.8)	38.3 (-15.7 to 146.3)	-2.6 (-39.3 to 62.4)
Inflammatory bowel disease	146.8 (139.1 to 154.0)	219.4 (207.3 to 231.4)	49.4 (39.6 to 60.8)	19.6 (11.5 to 28.8)	30.8 (20.7 to 41.7)	45.9 (31.1 to 62.4)	48.6 (36.8 to 63.0)	19.8 (9.9 to 31.2)
Vascular intestinal disorders	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.0)	59.3 (-7.0 to 153.9)	4.7 (-40.8 to 64.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	68.8 (-30.6 to 205.0)	4.7 (-51.2 to 89.4)
Gallbladder and biliary diseases	185.5 (89.4 to 120.8)	106.5 (90.2 to 121.6)	-42.1 (-22.5 to 27.9)	-57.5 (-45.1 to -8.8)	2.2 (7.3 to 15.3)	2.2 (7.2 to 15.3)	2.1 (-22.5 to 29.6)	-26.8 (-45.0 to 6.3)
Pancreatitis	13.1 (12.3 to 13.8)	20.2 (19.1 to 21.2)	54.1 (42.1 to 68.2)	21.2 (11.7 to 32.0)	3.8 (2.5 to 5.2)	5.8 (3.9 to 8.0)	54.0 (31.2 to 82.4)	22.2 (3.6 to 45.9)
Other digestive diseases	-	-	-	-	6.9 (4.7 to 9.5)	10.8 (6.5 to 15.4)	59.9 (15.6 to 94.7)	24.3 (-10.1 to 52.2)
Neurological disorders	-	-	-	-	615.6 (428.8 to 824.9)	878.8 (606.1 to 1,165.4)	42.2 (28.8 to 59.3)	13.7 (4.0 to 23.9)
Alzheimer disease and other dementias	807.0 (693.9 to 905.5)	1,467.4 (1,167.0 to 1,808.0)	80.3 (36.2 to 136.2)	9.7 (-13.9 to 40.4)	159.5 (83.5 to 157.4)	222.1 (150.8 to 305.4)	41.3 (38.8 to 142.0)	10.9 (-14.3 to 43.3)
Parkinson disease	89.4 (73.3 to 107.1)	128.1 (99.3 to 158.0)	44.3 (25.9 to 55.4)	-2.1 (-13.5 to 4.8)	10.3 (6.8 to 14.4)	13.1 (9.7 to 21.2)	44.0 (23.6 to 60.0)	-1.6 (-15.5 to 8.9)
Epilepsy	189.5 (140.2 to 236.2)	197.2 (133.2 to 256.8)	4.5 (-34.5 to 51.0)	-8.8 (-43.1 to 31.1)	75.1 (47.0 to 107.5)	81.5 (48.9 to 117.8)	9.7 (-30.4 to 60.6)	-3.6 (-38.5 to 41.2)
Multiple sclerosis	28.5 (22.6 to 36.2)	59.5 (51.3 to 67.6)	113.8 (58.0 to 167.2)	74.1 (27.6 to 117.1)	9.3 (6.1 to 13.2)	19.4 (13.5 to 25.3)	110.4 (55.5 to 179.2)	72.7 (26.0 to 129.8)
Migraine	7,656.2 (7,134.2 to 8,172.4)	7,084.6 (6,359.3 to 9,806.3)	-7.4 (-6.6 to -8.1)	18.5 (-4.6 to 18.9)	259.4 (157.2 to 379.5)	407.1 (186.4 to 457.0)	18.4 (4.5 to 32.0)	7.5 (-4.6 to 20.1)
Tension-type headache	14,207.4 (10,622.0 to 17,686.9)	17,246.5 (16,190.1 to 18,411.0)	21.3 (-3.1 to 63.6)	8.8 (-12.9 to 46.1)	21.4 (9.4 to 40.5)	25.9 (12.1 to 45.3)	20.9 (-4.1 to 63.1)	9.1 (-13.1 to 46.4)
Medication overuse headache	537.4 (365.3 to 713.4)	1,023.0 (684.2 to 1,354.4)	90.0 (57.6 to 127.4)	59.4 (33.1 to 91.0)	83.6 (47.5 to 127.3)	159.1 (90.1 to 243.9)	89.6 (56.7 to 127.9)	60.1 (33.6 to 92.6)
Other neurological disorders	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	20.6 (-19.5 to 98.8)	-0.1 (-32.5 to 63.7)	37.0 (24.5 to 52.6)	48.8 (31.5 to 70.1)	32.1 (-10.1 to 98.9)	-16.4 (-41.8 to 22.0)
Mental and substance use disorders	-	-	-	-	1,593.5 (1,143.8 to 2,073.5)	1,738.3 (1,253.7 to 2,271.0)	9.1 (4.9 to 12.9)	-1.4 (-4.3 to 1.4)
Schizophrenia	161.3 (127.3 to 201.3)	184.1 (147.7 to 225.6)	14.1 (8.1 to 22.6)	-1.8 (-6.8 to 4.9)	102.8 (73.4 to 136.4)	117.4 (83.4 to 154.9)	14.1 (6.2 to 23.4)	-1.4 (-8.2 to 6.7)
Alcohol use disorders	1,175.1 (1,090.7 to 1,268.1)	1,178.5 (1,082.0 to 1,279.7)	0.6 (-5.2 to 6.6)	-0.6 (-10.8 to 1.0)	117.8 (78.8 to 167.9)	118.1 (79.1 to 165.8)	0.4 (-5.9 to 7.5)	-4.8 (-10.9 to 1.8)
Drug use disorders	-	-	-	-	113.0 (74.5 to 155.4)	111.5 (72.9 to 151.4)	-0.8 (-13.6 to 10.8)	-3.8 (-16.6 to 6.7)
Opioid use disorders	166.8 (109.2 to 243.3)	165.3 (98.1 to 238.9)	0.0 (-17.7 to 14.2)	-5.9 (-25.3 to 10.2)	68.8 (39.6 to 103.0)	68.3 (37.3 to 101.3)	-0.0 (-18.7 to 16.3)	-5.5 (-25.5 to 7.4)
Cocaine use disorders	70.4 (65.1 to 75.2)	69.6 (65.0 to 74.5)	-0.9 (-10.2 to 5.8)	-0.9 (-10.2 to 5.8)	9.5 (6.3 to 13.7)	9.5 (6.2 to 13.7)	0.7 (-15.4 to 16.3)	-0.2 (-15.0 to 17.1)
Amphetamine use disorders	78.6 (72.2 to 84.4)	76.5 (70.9 to 81.5)	-2.6 (-12.2 to 8.2)	-1.6 (-12.0 to 9.5)	10.2 (6.4 to 15.0)	9.9 (6.3 to 14.6)	-3.0 (-17.6 to 15.3)	-1.6 (-16.6 to 17.4)
Cannabis use disorders	146.2 (129.9 to 162.2)	139.9 (124.8 to 153.5)	-4.2 (-10.2 to 1.9)	0.8 (-5.9 to 7.4)	4.2 (2.8 to 6.0)	4.0 (2.7 to 5.9)	-3.8 (-16.0 to 9.1)	1.2 (-12.5 to 15.4)
Other drug use disorders	-	-	-	-	20.1 (12.7 to 29.7)	19.7 (12.5 to 28.4)	-0.4 (-27.8 to 30.9)	-1.1 (-27.0 to 32.8)
Depressive disorders	-	-	-	-	542.5 (369.4 to 756.1)	542.5 (410.3 to 855.8)	0.0 (-2.0 to 2.0)	-1.4 (-10.3 to 5.6)
Major depressive disorder	2,238.4 (1,815.4 to 2,636.6)	2,518.6 (2,020.4 to 3,048.5)	13.2 (-0.6 to 23.5)	-1.9 (-12.4 to 6.0)	452.6 (300.7 to 645.3)	507.9 (333.4 to 733.7)	12.6 (-1.2 to 23.3)	-1.7 (-12.5 to 6.7)
Dysthymia	939.5 (793.0 to 1,101.7)	1,089.8 (924.0 to 1,276.4)	16.2 (9.1 to 23.8)	-0.3 (-5.6 to 5.8)	89.9 (59.1 to 127.6)	104.0 (69.1 to 148.7)	15.6 (8.1 to 24.1)	0.0 (-5.9 to 6.7)
Bipolar disorder	423.2 (354.3 to 495.4)	465.9 (391.1 to 540.8)	10.3 (3.8 to 16.9)	-0.6 (-6.7 to 5.4)	85.2 (52.2 to 128.7)	93.7 (57.9 to 142.2)	9.9 (2.1 to 18.3)	-0.6 (-8.0 to 7.5)
Anxiety disorders	3,935.1 (3,314.9 to 4,569.1)	4,385.2 (3,710.0 to 5,039.4)	11.5 (8.5 to 14.9)	-0.1 (-0.2 to 0.0)	542.5 (241.1 to 510.3)	542.5 (269.2 to 559.2)	0.0 (-1.5 to 1.5)	-1.4 (-7.4 to 5.2)
Eating disorders	-	-	-	-	57.8 (34.2 to 89.7)	55.6 (33.3 to 85.3)	-4.0 (-9.1 to 1.4)	2.5 (-2.5 to 8.5)
Anorexia nervosa	55.3 (29.0 to 82.2)	58.3 (31.0 to 85.7)	5.7 (-6.9 to 21.5)	12.1 (-1.7 to 28.7)	11.7 (5.6 to 20.1)	12.3 (5.7 to 20.6)	5.2 (-9.6 to 26.0)	11.3 (-4.1 to 33.4)
Bulimia nervosa	219.7 (137.1 to 307.7)	205.4 (127.8 to 288.1)	-6.5 (-7.6 to -5.0)	0.1 (-0.0 to 0.2)	46.1 (24.8 to 73.0)	43.2 (23.3 to 68.5)	-6.3 (-10.8 to -2.0)	0.2 (-4.2 to 4.8)
Autistic spectrum disorders	-	-	-	-	61.4 (43.1 to 83.0)	67.8 (47.8 to 92.1)	10.3 (6.2 to 14.5)	0.4 (-3.4 to 4.4)
Autism	157.3 (148.2 to 167.4)	173.8 (163.0 to 185.2)	10.6 (7.1 to 14.4)	0.3 (-2.9 to 3.5)	38.3 (26.0 to 52.6)	42.3 (28.8 to 57.9)	10.3 (4.3 to 17.2)	0.5 (-5.2 to 7.0)
Asperger syndrome	233.4 (218.0 to 249.0)	257.7 (240.1 to 275.7)	10.5 (9.7 to 11.3)	0.1 (0.1 to 0.2)	23.1 (16.0 to 31.8)	25.5 (17.5 to 35.3)	10.3 (6.1 to 14.6)	0.4 (-3.2 to 4.4)
Attention-deficit/hyperactivity disorder	307.9 (255.3 to 362.1)	295.9 (245.2 to 348.0)	-3.8 (-3.9 to -3.7)	0.0 (0.0 to 0.1)	3.7 (2.1 to 5.9)	3.6 (2.0 to 5.6)	-0.2 (-9.7 to 3.5)	0.2 (-6.0 to 7.7)
Conduct disorder	465.2 (375.1 to 518.4)	426.2 (359.1 to 494.0)	-13.1 (-15.1 to -11.1)	-11.5 (-10.0 to 0.1)	53.3 (32.7 to 80.4)	51.2 (31.8 to 77.1)	-3.8 (-13.8 to 4.6)	0.1 (-3.8 to 4.6)
Idiopathic intellectual disability	1,481.5 (1,193.3 to 1,879.9)	1,279.3 (985.9 to 1,572.7)	-13.8 (-15.5 to -12.1)	-18.4 (-19.8 to -16.9)	20.5 (11.5 to 31.9)	18.1 (8.5 to 29.8)	9.9 (-5.7 to 45.8)	-18.2 (-61.4 to 31.7)
Other mental and substance use disorders	1,050.0 (889.2 to 1,110.1)	1,242.4 (1,167.8 to 1,313.5)	18.5 (16.8 to 20.1)	0.1 (-0.0 to 0.3)	77.4 (52.6 to 103.7)	91.3 (62.5 to 121.9)	17.9 (13.9 to 22.4)	0.4 (-3.1 to 3.9)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	545.5 (390.1 to 721.6)	787.8 (562.2 to 1,030.9)	44.1 (33.3 to 58.0)	11.6 (4.2 to 21.0)
Diabetes mellitus	1,928.2 (1,336.2 to 2,388.3)	3,729.4 (2,735.5 to 4,639.9)	94.5 (48.7 to 150.3)	45.0 (11.0 to 94.2)	134.4 (84.4 to 194.3)	264.7 (171.2 to 366.7)	98.1 (54.4 to 156.8)	46.5 (14.3 to 92.1)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-30.5 to -21.8)	26.0 (-36.0 to -28.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-30.5 to -21.8)	-32.1 (-36.0 to -28.8)
Chronic kidney disease	-	-	-	-	213.8 (143.5 to 290.1)	284.5 (190.1 to 385.5)	33.3 (22.7 to 41.6)	2.5 (-2.7 to 8.5)
Chronic kidney disease due to diabetes mellitus	602.3 (371.0 to 1,086.5)	1,210.9 (802.7 to 2,018.3)	99.8 (55.4 to 178.2)	40.1 (8.9 to 92.5)	31.0 (19.0 to 47.6)	53.2 (34.9 to 77.5)	70.8 (34.4 to 136.6)	24.4 (-5.8 to 72.5)
Chronic kidney disease due to hypertension	869.8 (635.7 to 1,180.9)	1,553.5 (1,039.9 to 2,662.3)	77.6 (37.3 to 144.5)	27.1 (-0.9 to 71.6)	75.1 (49.7 to 105.2)	46.6 (29.8 to 67.4)	-39.0 (-53.1 to -18.4)	-31.8 (-63.6 to -36.0)
Chronic kidney disease due to glomerulonephritis	1,481.5 (838.5 to 2,469.2)	1,279.3 (875.4 to 2,030.1)	-13.8 (-35.4 to 28.1)	-18.4 (-48.9 to -3.0)	29.4 (19.4 to 42.3)	29.4 (52.0 to 118.0)	0.0 (-10.1 to 10.1)	11.2 (-63.3 to 191.1)
Chronic kidney disease due to other causes	1,943.5 (1,299.8 to 3,020.8)	2,618.1 (1,738.9 to 3,857.3)	38.1 (6.1 to 73.5)	0.6 (-27.5 to 26.5)	78.3 (47.0 to 116.6)	103.1 (62.4 to 145.4)	34.3 (-4.2 to 7	

Appendix Table G.4 - France prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	6.4 (5.1 to 7.7)	9.9 (7.4 to 14.0)	52.1 (8.7 to 115.3)	11.7 (-21.9 to 63.4)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	51.1 (-1.0 to 126.6)	11.7 (-28.2 to 72.3)
Urolithiasis	733.7 (67.6 to 1,242.9)	1,736.1 (1,072.5 to 2,784.4)	130.1 (87.7 to 223.4)	67.3 (38.1 to 130.7)	5.5 (2.6 to 10.2)	13.0 (6.6 to 24.1)	135.8 (90.4 to 203.6)	71.4 (41.3 to 116.3)
Benign prostatic hyperplasia	1,266.0 (1,079.9 to 1,498.0)	1,924.9 (1,605.1 to 2,236.9)	50.1 (21.4 to 99.3)	4.1 (-16.1 to 35.0)	45.0 (28.8 to 65.8)	68.6 (43.0 to 100.2)	50.6 (21.8 to 99.3)	4.6 (-15.3 to 35.5)
Male infertility due to other causes	417.2 (326.9 to 506.2)	371.6 (281.3 to 470.4)	-10.8 (-38.2 to 25.5)	-6.0 (-34.7 to 31.2)	2.9 (1.2 to 5.9)	2.6 (1.1 to 5.3)	-10.0 (-38.4 to 28.2)	-5.5 (-34.8 to 34.7)
Other urinary diseases	-	-	-	-	-	-	-	-
Gynecological diseases	-	-	-	-	70.8 (44.6 to 110.8)	71.1 (46.6 to 115.7)	4.7 (-6.4 to 16.2)	-3.0 (-13.5 to 7.8)
Uterine fibroids	1,882.9 (1,667.8 to 2,111.0)	2,248.8 (1,999.4 to 2,505.9)	19.5 (18.2 to 21.1)	1.7 (1.6 to 1.7)	16.7 (8.7 to 31.5)	19.7 (10.2 to 36.9)	18.1 (10.3 to 23.9)	2.8 (-3.8 to 8.1)
Polycystic ovarian syndrome	961.7 (815.6 to 1,113.2)	1,048.7 (901.5 to 1,198.2)	9.5 (-10.7 to 30.7)	6.7 (-13.2 to 27.6)	9.5 (4.5 to 17.7)	10.2 (4.8 to 19.3)	8.6 (-11.0 to 29.9)	6.2 (-12.7 to 27.0)
Female infertility due to other causes	233.3 (128.9 to 357.6)	144.9 (36.8 to 294.7)	-38.6 (-83.9 to 51.3)	-38.9 (-83.6 to 44.4)	1.4 (0.5 to 3.3)	0.8 (0.2 to 2.1)	-45.3 (-84.8 to 35.1)	-46.0 (-84.7 to 30.8)
Endometriosis	163.2 (113.5 to 213.8)	152.4 (109.1 to 198.8)	-6.5 (-37.4 to 44.8)	-8.8 (-38.9 to 40.0)	15.1 (9.0 to 23.1)	14.1 (8.3 to 21.1)	4.7 (-37.8 to 43.4)	-9.3 (-39.2 to 38.8)
Genital prolapse	3,566.5 (3,199.1 to 3,928.3)	4,140.6 (3,727.3 to 4,522.1)	16.3 (0.9 to 33.6)	-2.7 (-15.7 to 12.0)	11.3 (5.5 to 21.1)	13.1 (6.3 to 24.4)	16.0 (0.9 to 33.9)	-2.6 (-15.8 to 12.8)
Premenstrual syndrome	1,634.9 (1,438.9 to 1,844.3)	1,608.2 (1,346.7 to 1,851.9)	-1.3 (-19.5 to 19.3)	-0.9 (-18.8 to 18.1)	13.7 (8.3 to 20.9)	13.5 (8.2 to 20.7)	-1.7 (-19.6 to 20.7)	-1.7 (-11.0 to 20.0)
Other gynecological diseases	122.3 (92.6 to 207.5)	118.0 (96.3 to 138.9)	0.8 (-43.9 to 31.2)	-0.3 (-49.3 to 20.9)	3.1 (1.6 to 7.5)	2.8 (1.7 to 4.3)	-3.6 (-63.6 to 49.9)	-11.0 (-68.4 to 35.4)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	49.2 (33.0 to 72.0)	51.2 (34.2 to 73.9)	4.0 (-3.1 to 11.1)	-4.7 (-10.7 to 1.3)
Thalassemias	0.5 (0.5 to 0.5)	0.5 (0.4 to 0.5)	-4.4 (-10.5 to 3.2)	-2.0 (-8.2 to 5.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	10.9 (-6.7 to 42.4)	14.2 (-3.7 to 46.9)
Thalassemia trait	727.3 (700.9 to 759.0)	827.4 (792.0 to 868.6)	13.6 (9.3 to 20.0)	0.6 (-3.3 to 4.9)	19.0 (12.7 to 27.7)	20.5 (13.6 to 29.8)	8.1 (5.0 to 19.5)	-2.7 (-12.5 to 6.1)
Sickle cell disorders	6.9 (5.6 to 7.5)	6.9 (6.0 to 7.6)	-0.0 (-15.3 to 28.2)	-1.3 (-16.2 to 24.9)	0.9 (0.7 to 1.3)	1.0 (0.7 to 1.4)	7.8 (8.5 to 24.3)	4.9 (-11.3 to 22.0)
Sickle cell trait	1,949.1 (1,879.0 to 2,016.4)	2,158.7 (2,078.4 to 2,238.3)	10.9 (7.7 to 13.6)	-4.8 (-4.6 to 0.7)	20.4 (13.1 to 30.1)	20.7 (13.2 to 29.3)	-1.7 (-10.2 to 8.7)	-7.7 (-15.9 to 1.6)
G6PD deficiency	540.0 (433.5 to 632.8)	463.5 (381.2 to 539.3)	-14.5 (-33.3 to 10.5)	-24.5 (-41.1 to -2.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	2.9 (-11.6 to 10.6)	-4.2 (-20.5 to 2.1)
G6PD trait	4,821.3 (4,560.4 to 5,081.2)	5,595.0 (5,240.6 to 5,938.5)	16.2 (6.7 to 25.8)	2.1 (-6.3 to 10.5)	0.3 (0.1 to 0.5)	0.2 (0.1 to 0.5)	0.2 (-58.8 to 204.1)	-27.3 (-63.0 to 169.7)
Other hemoglobinopathies and hemolytic anemias	318.1 (290.0 to 356.3)	384.0 (348.0 to 420.7)	21.2 (4.3 to 39.2)	2.9 (-13.5 to 19.6)	8.4 (5.5 to 12.2)	9.2 (6.0 to 13.4)	9.9 (-16.6 to 36.2)	-0.7 (-23.3 to 23.3)
Endocrine, metabolic, blood, and immune disorders	663.5 (613.7 to 717.6)	789.5 (727.0 to 861.2)	18.9 (6.9 to 32.7)	0.2 (-9.7 to 11.2)	21.8 (14.7 to 30.4)	26.1 (17.8 to 36.6)	19.9 (4.8 to 36.2)	0.4 (-10.8 to 14.7)
Musculoskeletal disorders	-	-	-	-	1,428.5 (1,014.6 to 1,890.0)	1,808.7 (1,292.5 to 2,360.5)	27.0 (16.5 to 37.9)	3.2 (-5.0 to 13.0)
Rheumatoid arthritis	127.2 (118.5 to 136.2)	172.0 (157.7 to 187.5)	35.6 (19.9 to 51.2)	-0.8 (-11.4 to 9.8)	28.9 (20.3 to 38.5)	39.2 (27.8 to 51.2)	35.7 (18.5 to 53.4)	0.1 (-11.8 to 12.0)
Osteoarthritis	2,835.0 (2,649.7 to 3,039.7)	4,022.0 (3,794.5 to 4,240.8)	42.4 (30.2 to 54.4)	-1.5 (-10.1 to 7.2)	97.1 (63.8 to 140.7)	137.7 (90.0 to 198.7)	42.1 (29.6 to 55.2)	-1.2 (-10.1 to 7.9)
Low back and neck pain	-	-	-	-	1,112.3 (772.8 to 1,507.6)	1,346.0 (939.7 to 1,803.0)	21.1 (9.3 to 35.2)	0.9 (-9.1 to 13.3)
Low back pain	6,462.5 (5,808.0 to 6,919.5)	7,844.9 (7,343.4 to 8,645.8)	20.9 (9.5 to 39.0)	0.1 (-9.4 to 15.4)	714.4 (479.1 to 987.9)	864.3 (591.2 to 1,193.5)	20.2 (9.2 to 38.1)	0.4 (-9.1 to 15.8)
Neck pain	4,076.0 (3,537.4 to 4,631.2)	4,946.5 (4,325.8 to 5,548.1)	21.3 (-1.4 to 48.4)	0.6 (-18.3 to 23.0)	397.9 (268.2 to 552.1)	481.7 (324.6 to 665.2)	21.2 (-2.3 to 47.6)	0.9 (-18.4 to 23.1)
Gout	121.4 (109.6 to 134.8)	169.0 (151.9 to 187.4)	39.1 (20.7 to 61.3)	-0.6 (-14.0 to 15.5)	3.8 (2.5 to 5.2)	5.2 (3.5 to 7.1)	39.4 (17.7 to 70.1)	0.9 (-18.8 to 23.0)
Other musculoskeletal disorders	2,048.3 (1,671.2 to 2,442.6)	3,080.4 (2,461.8 to 3,704.6)	50.3 (40.5 to 60.9)	19.6 (11.8 to 27.0)	186.4 (123.7 to 264.9)	280.6 (185.2 to 404.6)	50.4 (40.2 to 61.0)	0.4 (-11.5 to 28.1)
Other non-communicable diseases	-	-	-	-	1,110.0 (752.5 to 1,609.9)	1,329.0 (906.2 to 1,894.0)	19.8 (13.8 to 25.6)	-4.5 (-9.5 to -0.4)
Congenital anomalies	-	-	-	-	83.0 (57.3 to 113.7)	97.1 (68.6 to 129.3)	0.9 (2.6 to 34.3)	0.9 (-11.8 to 16.8)
Neural tube defects	9.8 (8.7 to 11.3)	9.3 (7.8 to 11.2)	-5.5 (-24.7 to 18.0)	-11.8 (-29.5 to 10.0)	3.3 (2.2 to 4.5)	3.2 (2.1 to 4.5)	-4.5 (-31.1 to 31.9)	-10.6 (-35.2 to 23.8)
Congenital heart anomalies	515.8 (424.4 to 647.5)	505.7 (423.3 to 624.1)	-1.5 (-26.2 to 34.6)	-11.2 (-33.3 to 20.8)	17.7 (7.1 to 31.6)	17.6 (7.0 to 30.4)	-0.5 (-24.1 to 33.3)	-9.6 (-30.5 to 21.0)
Orofacial clefts	63.2 (52.5 to 76.1)	62.8 (50.7 to 78.6)	-1.5 (-23.9 to 35.8)	-1.8 (-31.9 to 21.7)	0.6 (0.4 to 0.9)	0.6 (0.4 to 0.9)	1.2 (-27.6 to 48.1)	9.6 (-36.8 to 34.2)
Down syndrome	67.4 (55.6 to 83.1)	78.1 (65.3 to 93.1)	16.6 (-13.3 to 52.9)	-2.2 (-27.7 to 21.7)	9.9 (7.1 to 13.3)	12.3 (8.9 to 16.4)	23.6 (9.1 to 66.6)	-1.5 (-27.1 to 31.9)
Turner syndrome	2.9 (2.4 to 3.7)	3.2 (2.7 to 3.9)	13.8 (-21.0 to 52.5)	5.1 (-26.9 to 41.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-24.3 to 54.0)	4.7 (-28.4 to 43.8)
Klinefelter syndrome	2.7 (1.8 to 3.9)	3.3 (2.6 to 4.3)	25.9 (-19.2 to 94.0)	13.2 (-27.3 to 74.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-23.3 to 99.5)	18.9 (-31.6 to 88.3)
Chromosomal unbalanced rearrangements	114.2 (97.8 to 132.7)	139.2 (120.4 to 153.7)	18.6 (-0.9 to 44.7)	0.8 (-16.9 to 20.5)	16.8 (12.1 to 22.0)	21.5 (15.8 to 27.4)	0.5 (-17.6 to 21.8)	0.6 (-17.6 to 23.9)
Other congenital anomalies	180.1 (114.8 to 254.7)	175.1 (107.6 to 245.6)	-2.7 (-25.5 to 21.2)	-16.6 (-35.9 to 3.3)	34.6 (21.6 to 51.0)	42.2 (26.1 to 61.6)	21.6 (-1.3 to 52.7)	8.8 (-12.2 to 37.5)
Skin and subcutaneous diseases	-	-	-	-	453.0 (297.9 to 679.1)	483.9 (322.7 to 717.5)	7.3 (-1.8 to 15.1)	-3.0 (-10.9 to 3.7)
Dermatitis	4,702.1 (3,833.5 to 5,553.7)	5,090.6 (4,171.3 to 5,939.8)	8.3 (6.2 to 11.3)	-0.0 (-0.1 to 0.0)	163.6 (106.6 to 234.6)	176.5 (115.2 to 253.2)	7.9 (4.9 to 11.2)	0.1 (-2.1 to 2.4)
Psoriasis	827.3 (714.6 to 952.2)	971.6 (835.9 to 1,117.6)	17.5 (14.8 to 20.7)	0.0 (-0.1 to 0.1)	66.6 (45.6 to 92.0)	78.0 (53.3 to 109.0)	17.2 (12.1 to 22.6)	0.4 (-3.7 to 4.3)
Cellulitis	23.3 (14.4 to 33.8)	28.8 (17.3 to 47.5)	26.3 (-21.5 to 62.7)	-1.0 (-28.0 to 23.1)	1.6 (0.8 to 2.6)	2.0 (1.0 to 3.5)	23.5 (-23.6 to 66.3)	-1.4 (-29.9 to 27.9)
Pyoderma	52.8 (38.3 to 78.6)	63.7 (45.0 to 96.4)	20.7 (5.8 to 35.6)	0.4 (-8.7 to 7.8)	0.3 (0.1 to 0.7)	0.4 (0.1 to 0.8)	20.3 (2.3 to 39.0)	0.3 (-11.7 to 12.1)
Scabies	27.1 (23.1 to 30.5)	27.6 (23.5 to 32.0)	1.7 (-15.6 to 27.2)	-4.5 (-20.6 to 21.1)	0.7 (0.4 to 1.1)	0.7 (0.4 to 1.2)	1.9 (-19.0 to 28.8)	-4.0 (-24.4 to 22.7)
Fungal skin diseases	4,148.5 (3,673.8 to 4,580.4)	4,967.9 (4,404.5 to 5,444.6)	19.7 (17.8 to 22.0)	19.7 (0.0 to 42.2)	23.1 (9.4 to 48.5)	27.6 (11.2 to 57.9)	19.5 (-17.2 to 21.8)	0.2 (-0.6 to 1.1)
Viral skin diseases	1,190.9 (943.8 to 1,455.4)	1,265.6 (1,017.9 to 1,518.6)	6.4 (2.7 to 10.6)	0.6 (-1.7 to 3.1)	36.6 (21.4 to 57.3)	38.8 (22.6 to 60.5)	6.2 (1.9 to 10.9)	0.7 (-2.6 to 4.7)
Acne vulgaris	9,116.3 (7,348.8 to 10,970.1)	6,993.1 (5,162.4 to 8,829.3)	-23.8 (-43.9 to 2.1)	-20.7 (-42.3 to 8.2)	98.4 (46.4 to 182.6)	75.3 (35.5 to 139.5)	-23.7 (-44.2 to 2.3)	-20.6 (-42.8 to 8.5)
Alopecia areata	97.4 (89.6 to 105.1)	119.6 (109.4 to 130.4)	22.8 (9.9 to 38.7)	0.1 (-9.9 to 11.6)	3.2 (2.0 to 4.9)	3.9 (2.5 to 5.9)	22.3 (6.7 to 40.6)	0.2 (-13.1 to 15.4)
Pruritus	0.4 (0.3 to 0.4)	0.5 (0.4 to 0.5)	25.2 (7.9 to 65.2)	2.3 (-17.1 to 36.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.2 (7.8 to 65.2)	2.3 (-17.1 to 26.6)
Urticaria	430.4 (241.3 to 611.4)	633.4 (368.6 to 843.2)	52.3 (-35.6 to 205.1)	24.9 (-43.4 to 153.9)	25.2 (11.8 to 41.2)	36.9 (18.1 to 59.4)	52.1 (-35.2 to 205.6)	24.8 (-43.8 to 155.0)
Decubitus ulcer	38.4 (31.6 to 45.7)	49.0 (38.7 to 60.5)	28.2 (5.5 to 71.2)	-14.1 (-35.4 to 11.8)	5.4 (3.7 to 7.5)	6.9 (4.5 to 9.8)	26.5 (8.0 to 73.0)	-14.2 (-36.7 to 14.1)
Other skin and subcutaneous diseases	4,876.3 (2,791.8 to 8,244.7)	6,372.3 (5,420.0 to 11,445.8)	32.1 (18.5 to 40.9)	1.4 (-2.9 to 5.0)	28.3 (11.7 to 63.5)	37.0 (14.1 to 85.9)	29.6 (18.3 to 40.6)	1.5 (-3.0 to 4.5)
Sense organ diseases	-	-	-	-	415.5 (272.0 to 604.9)	555.7 (371.1 to 805.2)	7.1 (4.6 to 9.6)	-7.1 (-14.1 to 0.6)
Glaucoma	46.2 (34.4 to 66.2)	47.6 (33.8 to 71.7)	2.2 (-19.1 to 28.5)	-31.3 (-44.5 to -13.0)	3.9 (2.4 to 6.1)	4.1 (2.4 to 6.5)	4.6 (-16.2 to 35.9)	-29.4 (-44.1 to -8.7)
Cataract	129.6 (83.5 to 188.1)	134.6 (77.2 to 209.9)	2.8 (-33.1 to 61.1)	-34.5 (-57.2 to -0.6)	8.0 (4.6 to 12.2)	8.6 (4.6 to 14.4)	9.3 (-29.6 to 52.9)	-31.6 (-54.6 to -5.0)
Macular degeneration	171.1 (114.7 to 266.5)	261.6 (179.4 to 378.8)	52.6 (15.4 to 103.8)	-2.6 (-23.4 to 27.9)	10.7 (6.3 to 17.8)	15.9 (9.4 to 25.2)	48.4 (17.3 to 92.0)	-6.8 (-24.5 to 20.4)
Uncorrected refractive error	6,677.9 (5,221.0 to 8,308.7)	8,424.2 (6,623.5 to 9,766.5)	28.0 (-10.2 to 70.8)	-5.9 (-34.5 to 25.1)	81.6 (43.1 to 148.1)	100.0 (52.5 to 177.2)	23.5 (-7.4 to 57.2)	-8.3 (-31.6 to 16.3)
Age-related and other hearing loss	9,063.8 (7,880.0 to 10,214.4)	11,975.8 (10,363.5 to 13,523.9)	32.5 (26.7 to 37.3)	-8.5 (-13.6 to -4.7)	268.0 (176.2 to 395.1)	277.7 (248.9 to 545.1)	40.2 (29.2 to 59.6)	-6.1 (-13.9 to 3.3)
Other vision loss	118.8 (85.0 to 161.1)	100.4 (71.1 to 142.1)	-15.4 (-29.3 to -0.7)	-40.4 (-49.1 to -27.9)	7.5 (4.7 to 11.3)	6.9 (4.2 to 10.5)	-8.5 (-23.1 to 5.4)	-3.0 (-44.7 to -24.6)
Other sense organ diseases	1,370.3 (1,309.7 to 1,434.3)	1,631.2 (1,548.4 to 1,704.3)	19.3 (10.9 to 27.5)	-0.1 (-6.7 to 6.1)	35.8 (22.1 to 53.2)	42.4 (26.3 to 62.5)	18.7 (

Appendix Table G.4 - France prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	2,668.0 (2,358.0 to 2,990.8)	3,090.4 (2,707.0 to 3,453.4)	16.4 (2.7 to 38.1)	-19.1 (-32.4 to -4.3)	72.3 (47.7 to 100.1)	83.7 (55.6 to 119.8)	16.3 (-3.1 to 37.6)	16.3 (-32.3 to -4.1)
Other oral disorders	1,063.4 (1,010.9 to 1,121.8)	1,228.9 (1,168.9 to 1,291.0)	15.6 (7.9 to 24.8)	0.5 (-6.3 to 8.1)	30.9 (19.3 to 45.4)	35.7 (22.2 to 53.0)	15.4 (7.0 to 24.7)	0.7 (-6.3 to 8.7)
Injuries	-	-	-	-	728.1 (551.2 to 927.0)	645.9 (464.8 to 865.2)	-11.7 (-21.6 to -0.5)	-36.4 (-43.1 to -28.9)
Transport injuries	-	-	-	-	153.9 (115.7 to 196.9)	78.7 (56.8 to 105.6)	-49.0 (-54.4 to -43.2)	-60.8 (-64.9 to -56.1)
Road injuries	-	-	-	-	142.8 (107.4 to 182.4)	64.7 (47.1 to 86.7)	-54.8 (-59.5 to -49.5)	-64.9 (-68.6 to -60.8)
Pedestrian road injuries	-	-	-	-	12.4 (9.1 to 16.2)	8.4 (5.9 to 11.4)	-32.1 (-39.8 to -24.1)	-49.0 (-54.9 to -42.4)
Cyclist road injuries	-	-	-	-	8.8 (6.5 to 11.2)	6.3 (4.6 to 8.4)	-28.6 (-38.3 to -17.5)	-44.4 (-52.2 to -35.9)
Motorcyclist road injuries	-	-	-	-	41.5 (30.7 to 53.6)	13.7 (9.7 to 18.6)	-67.2 (-72.1 to -61.2)	-73.8 (-77.7 to -68.9)
Motor vehicle road injuries	-	-	-	-	79.5 (60.0 to 102.0)	36.1 (26.5 to 47.5)	-54.7 (-58.8 to -50.0)	-64.9 (-68.1 to -61.2)
Other road injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.2 (0.2 to 0.3)	-68.3 (-72.2 to -63.1)	-75.7 (-78.8 to -71.6)
Other transport injuries	-	-	-	-	11.1 (8.3 to 14.5)	14.0 (9.9 to 19.2)	25.7 (12.3 to 38.3)	-4.5 (-14.4 to 4.7)
Unintentional injuries	-	-	-	-	564.5 (427.3 to 718.8)	559.5 (403.0 to 749.0)	-1.3 (-13.1 to 11.9)	-28.7 (-36.3 to -20.2)
Falls	-	-	-	-	434.8 (330.1 to 553.1)	450.2 (323.7 to 597.4)	3.2 (-10.7 to 19.5)	-25.5 (-34.8 to -15.0)
Drowning	-	-	-	-	0.9 (0.7 to 1.2)	0.8 (0.6 to 1.1)	-12.9 (-22.2 to -0.5)	-34.6 (-41.4 to -25.5)
Fire, heat, and hot substances	-	-	-	-	11.3 (7.2 to 17.3)	11.8 (6.9 to 19.6)	3.1 (-9.3 to 18.8)	-19.5 (-30.2 to -7.0)
Poisonings	-	-	-	-	0.6 (0.4 to 0.8)	0.4 (0.3 to 0.5)	-39.7 (-50.5 to -27.4)	-51.4 (-60.9 to -41.2)
Exposure to mechanical forces	-	-	-	-	68.9 (51.0 to 91.0)	42.0 (30.0 to 58.5)	-39.3 (-45.3 to -32.2)	-51.2 (-56.1 to -45.5)
Unintentional firearm injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.4 (0.3 to 0.6)	-37.9 (-45.7 to -30.8)	-48.2 (-54.6 to -41.9)
Unintentional suffocation	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	21.1 (3.6 to 37.8)	-8.8 (-21.8 to 4.5)
Other exposure to mechanical forces	-	-	-	-	67.9 (50.3 to 89.7)	41.2 (29.4 to 57.5)	-39.6 (-45.6 to -32.5)	-51.4 (-56.3 to -45.7)
Adverse effects of medical treatment	-	-	-	-	3.2 (2.0 to 4.7)	4.2 (2.6 to 6.2)	29.8 (19.3 to 41.8)	0.5 (-7.0 to 8.7)
Animal contact	-	-	-	-	2.9 (2.1 to 3.9)	3.6 (2.5 to 5.0)	22.0 (12.7 to 33.3)	-2.8 (-11.1 to 5.9)
Venomous animal contact	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.6)	18.8 (2.4 to 35.3)	-0.9 (-15.3 to 14.0)
Non-venomous animal contact	-	-	-	-	2.5 (1.8 to 3.4)	3.1 (2.2 to 4.4)	22.5 (12.3 to 34.9)	-3.2 (-11.8 to 7.0)
Foreign body	-	-	-	-	3.4 (2.4 to 4.6)	3.1 (2.1 to 4.4)	-7.2 (-17.2 to 4.6)	-22.4 (-32.2 to -11.8)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.8 (0.6 to 1.0)	0.7 (0.5 to 0.9)	-10.9 (-21.1 to 0.6)	-32.4 (-41.1 to -20.9)
Foreign body in eyes	-	-	-	-	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.7)	-9.9 (-11.4 to 10.2)	-12.3 (-23.4 to -1.0)
Foreign body in other body part	-	-	-	-	2.1 (1.4 to 3.0)	2.0 (1.2 to 3.0)	-7.4 (-20.6 to 9.5)	-21.3 (-34.0 to -5.5)
Other unintentional injuries	-	-	-	-	38.4 (27.3 to 52.2)	43.5 (29.8 to 60.8)	13.0 (-0.1 to 26.7)	-22.4 (-31.2 to -13.9)
Self-harm and interpersonal violence	-	-	-	-	9.7 (7.2 to 12.6)	7.7 (5.5 to 10.3)	-21.1 (-27.5 to -13.8)	-38.8 (-43.7 to -33.3)
Self-harm	-	-	-	-	4.7 (3.4 to 6.2)	4.4 (3.1 to 6.0)	-6.4 (-16.0 to 2.8)	-27.8 (-35.6 to -20.2)
Interpersonal violence	-	-	-	-	5.0 (3.8 to 6.4)	3.3 (2.4 to 4.4)	-34.5 (-40.9 to -27.3)	-48.6 (-53.6 to -42.9)
Assault by firearm	-	-	-	-	1.0 (0.8 to 1.3)	0.7 (0.5 to 1.0)	-29.2 (-35.3 to -22.7)	-45.7 (-50.3 to -40.6)
Assault by sharp object	-	-	-	-	0.5 (0.4 to 0.7)	0.4 (0.3 to 0.6)	-14.9 (-22.3 to -6.7)	-33.4 (-39.2 to -26.8)
Assault by other means	-	-	-	-	3.5 (2.7 to 4.5)	2.2 (1.6 to 2.9)	-38.9 (-45.6 to -30.9)	-51.5 (-56.9 to -45.0)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.2 (-50.2 to 47.1)	-21.4 (-57.9 to 32.8)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.2 (-50.2 to 47.1)	-21.4 (-57.9 to 32.8)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Gabon prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
All causes	-	-	-	-	102.2 (74.8 to 134.2)	181.9 (133.3 to 237.9)	78.0 (74.2 to 82.6)	78.0 (-0.2 to 4.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	30.6 (20.9 to 43.5)	56.9 (39.5 to 78.6)	85.9 (77.1 to 98.2)	9.9 (3.7 to 19.5)
HIV/AIDS and tuberculosis	-	-	-	-	1.8 (1.3 to 2.5)	9.7 (6.3 to 13.6)	417.1 (329.2 to 554.3)	189.1 (137.0 to 269.0)
Tuberculosis	4.3 (4.0 to 4.5)	8.8 (8.4 to 9.2)	106.4 (96.6 to 116.7)	11.3 (6.1 to 16.6)	1.3 (0.9 to 1.7)	2.6 (1.8 to 3.5)	107.0 (95.6 to 119.6)	11.0 (5.1 to 17.4)
HIV/AIDS	-	-	-	-	0.6 (0.4 to 0.8)	7.1 (4.3 to 10.5)	1,186.3 (838.4 to 1,617.9)	595.4 (436.7 to 859.9)
HIV/AIDS resulting in mycobacterial infection	0.2 (0.1 to 0.3)	1.4 (1.0 to 1.9)	680.9 (502.8 to 1,023.7)	330.7 (232.4 to 515.2)	0.1 (0.0 to 0.1)	0.5 (0.3 to 0.8)	683.6 (495.0 to 1,032.3)	329.7 (224.7 to 514.2)
HIV/AIDS resulting in other diseases	4.9 (3.8 to 6.1)	41.8 (34.9 to 50.1)	744.9 (584.2 to 1,050.8)	381.2 (289.4 to 553.5)	0.5 (0.3 to 0.8)	6.5 (3.9 to 9.9)	1,166.8 (852.1 to 1,785.2)	631.2 (444.9 to 990.3)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	4.3 (3.0 to 5.7)	6.3 (4.4 to 8.5)	46.3 (37.1 to 56.3)	-12.6 (-17.9 to -6.9)
Diarrheal diseases	15.9 (14.9 to 16.8)	23.3 (22.0 to 24.6)	46.8 (35.3 to 58.1)	-9.0 (-15.4 to -1.5)	2.6 (1.7 to 3.5)	46.2 (2.5 to 5.2)	58.7 (34.7 to 58.7)	-16.0 (-16.0 to -1.1)
Intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	4.9 (37.1 to 23.0)	48.0 (-63.7 to -29.7)
Typhoid fever	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.3)	-0.7 (-21.3 to 23.4)	-42.6 (-54.2 to -28.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.7 (-25.3 to 36.1)	-41.7 (-55.9 to -22.5)
Paratyphoid fever	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	20.1 (-5.6 to 54.4)	-30.5 (-45.9 to -9.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.9 (9.0 to 60.6)	-29.8 (-47.0 to -7.9)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-93.9 (-93.9 to -41.0)	-96.4 (-99.9 to -41.0)
Lower respiratory infections	2.0 (1.7 to 2.3)	3.0 (2.5 to 3.4)	48.0 (18.6 to 82.1)	-9.7 (-26.0 to 11.0)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	48.4 (16.1 to 85.6)	-2.3 (-27.1 to 13.0)
Upper respiratory infections	18.5 (16.8 to 20.2)	32.5 (29.9 to 35.1)	75.7 (56.3 to 98.5)	-1.3 (-11.1 to 11.4)	0.2 (0.1 to 0.4)	0.6 (0.2 to 0.6)	75.9 (55.6 to 98.5)	-1.1 (-11.5 to 12.7)
Otitis media	15.9 (14.7 to 17.2)	25.6 (23.5 to 27.9)	60.9 (48.2 to 76.2)	-8.2 (-15.7 to 0.6)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	59.8 (43.5 to 79.3)	-8.2 (-17.6 to 1.7)
Meningitis	-	-	-	-	0.8 (0.6 to 1.2)	1.1 (0.8 to 1.6)	35.3 (9.8 to 67.7)	-23.8 (-37.1 to -7.5)
Pneumococcal meningitis	4.5 (2.7 to 7.5)	5.4 (3.4 to 8.5)	19.5 (0.3 to 49.9)	-32.1 (-42.4 to -16.0)	0.5 (0.3 to 0.5)	0.5 (0.3 to 0.8)	31.2 (-3.5 to 80.8)	25.6 (-44.5 to -0.4)
H influenzae type B meningitis	1.8 (0.6 to 4.4)	2.3 (0.9 to 4.8)	29.1 (-12.6 to 110.8)	-27.7 (50.6 to 18.2)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	56.3 (-15.0 to 146.0)	-12.3 (52.7 to 35.3)
Meningococcal meningitis	0.3 (0.1 to 0.9)	0.4 (0.1 to 1.0)	26.7 (-11.2 to 77.7)	-26.3 (-46.3 to 1.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	25.9 (-19.0 to 93.8)	-27.4 (-50.6 to 7.8)
Other meningitis	1.5 (0.8 to 3.1)	1.7 (0.9 to 3.3)	14.6 (-14.9 to 64.2)	-32.5 (-50.0 to -2.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	22.0 (-20.0 to 93.8)	-29.2 (54.1 to 11.4)
Encephalitis	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.5)	67.9 (41.6 to 99.2)	-9.8 (-16.5 to 12.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.7 (30.7 to 108.2)	-3.8 (-2.6 to 16.8)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	181.2 (-84.4 to 4,777.9)	79.4 (-86.4 to 1,903.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	151.2 (-84.6 to 4,829.4)	79.4 (-86.6 to 1,946.9)
Whooping cough	0.6 (0.5 to 0.8)	1.1 (0.9 to 1.5)	87.5 (85.3 to 89.7)	19.9 (18.5 to 21.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	86.8 (69.2 to 109.5)	19.5 (8.2 to 34.1)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.3 (-72.1 to 44.8)	-61.0 (-84.5 to -34.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.6 (-54.8 to 80.1)	-45.2 (-73.4 to -0.2)
Measles	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-9.8 (-18.8 to 0.3)	-42.8 (-48.6 to -36.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.1 (-33.5 to 19.8)	-42.4 (-57.8 to -24.6)
Varicella and herpes zoster	0.6 (0.5 to 0.7)	1.1 (1.0 to 1.2)	79.1 (56.0 to 110.1)	3.0 (-15.3 to 28.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.2 (23.6 to 141.7)	1.3 (-27.8 to 47.9)
Neglected tropical diseases and malaria	-	-	-	-	14.9 (9.4 to 23.3)	22.4 (13.5 to 36.0)	49.2 (37.7 to 60.9)	-13.7 (-20.9 to -7.2)
Malaria	729.0 (660.7 to 788.0)	823.8 (738.1 to 916.2)	13.0 (4.3 to 22.4)	-38.6 (-43.8 to -33.2)	5.9 (3.9 to 8.5)	6.3 (4.2 to 9.0)	6.6 (-0.1 to 14.3)	40.7 (-44.7 to -36.0)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	130.4 (38.9 to 300.3)	41.1 (8.2 to 128.8)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	88.9 (5.7 to 254.7)	7.0 (-33.6 to 83.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.9 (5.6 to 256.1)	7.0 (-33.8 to 83.5)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	732.7 (404.6 to 1,251.5)	483.8 (251.6 to 818.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	699.3 (367.5 to 1,244.5)	453.0 (229.9 to 825.7)
African trypanosomiasis	0.5 (0.2 to 1.1)	0.1 (0.0 to 0.2)	-81.3 (-82.9 to -77.1)	-89.8 (-90.6 to -87.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-71.2 (-82.2 to -73.3)	-88.5 (-90.3 to -85.2)
Schistosomiasis	452.7 (258.3 to 669.5)	820.3 (468.2 to 1,212.2)	81.1 (76.9 to 85.5)	0.2 (-2.5 to 2.2)	4.5 (2.0 to 9.0)	8.1 (3.5 to 16.4)	1.2 (63.0 to 92.7)	-1.2 (-10.9 to 4.3)
Cysticercosis	0.3 (0.1 to 0.6)	0.4 (0.2 to 0.8)	44.1 (-33.7 to 236.4)	-18.6 (-63.2 to 87.5)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	48.2 (-33.3 to 263.2)	-17.2 (-63.2 to 96.5)
Cystic echinococcosis	0.3 (0.3 to 0.3)	0.2 (0.2 to 0.2)	-33.6 (-37.3 to -28.5)	-52.0 (-55.6 to -47.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-44.3 to -20.4)	-52.7 (-59.9 to -42.8)
Lymphatic filariasis	70.8 (60.4 to 82.4)	116.9 (100.7 to 136.8)	64.5 (41.0 to 95.6)	-5.2 (-18.4 to 11.1)	1.9 (1.0 to 3.0)	2.9 (1.5 to 5.0)	59.0 (29.4 to 89.1)	-3.3 (-22.8 to 14.9)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	0.1 (0.0 to 0.2)	0.9 (0.3 to 2.0)	758.7 (749.6 to 769.2)	384.8 (379.7 to 390.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.4)	760.6 (574.7 to 1,029.5)	382.9 (287.9 to 514.1)
Yellow fever	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-53.0 (-66.6 to -32.2)	-73.5 (-80.5 to -63.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.0 (-66.6 to -32.1)	-73.5 (-80.5 to -63.3)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.5 (19.0 to 115.5)	79.3 (-28.7 to 21.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.5 (19.0 to 115.6)	-7.9 (-28.8 to 22.2)
Intestinal nematode infections	-	-	-	-	1.7 (1.0 to 2.7)	2.9 (1.6 to 4.8)	74.2 (44.3 to 106.6)	-1.5 (-19.2 to 20.0)
Ascariasis	323.8 (277.3 to 385.9)	574.1 (486.3 to 685.0)	77.6 (41.3 to 125.3)	0.4 (-23.2 to 32.9)	0.5 (0.3 to 0.9)	0.9 (0.5 to 1.7)	73.6 (20.0 to 146.6)	-0.1 (-35.8 to 50.5)
Trichuriasis	292.2 (246.4 to 347.9)	512.1 (429.0 to 603.6)	76.2 (37.6 to 121.4)	-0.5 (-25.6 to 29.9)	0.4 (0.2 to 0.7)	0.7 (0.4 to 1.2)	75.3 (18.0 to 160.2)	0.6 (-36.1 to 55.9)
Hookworm disease	171.0 (142.1 to 207.1)	305.8 (251.8 to 367.9)	79.3 (37.0 to 136.2)	0.3 (-26.3 to 37.2)	1.3 (0.5 to 1.2)	1.3 (0.8 to 2.1)	75.4 (34.9 to 119.8)	-3.1 (-27.6 to 27.4)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	10.3 (7.8 to 12.9)	20.4 (19.1 to 21.9)	97.5 (54.8 to 162.2)	14.2 (-8.3 to 45.9)	0.8 (0.4 to 1.6)	1.8 (0.8 to 3.6)	137.4 (69.0 to 239.1)	45.5 (-4.2 to 111.1)
Maternal disorders	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	31.2 (9.7 to 55.6)	-33.4 (-43.1 to -21.6)
Maternal hemorrhage	0.2 (0.2 to 0.3)	0.3 (0.1 to 0.5)	30.4 (-39.0 to 112.9)	-37.6 (-69.5 to 11.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.9 (-46.0 to 131.6)	-37.5 (-73.3 to 7.8)
Maternal sepsis and other maternal infections	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	-45.6 (-7.0 to 52.9)	-45.6 (-54.4 to -25.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.5 (-31.6 to 67.9)	-46.8 (-64.1 to -21.1)
Maternal hypertensive disorders	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	44.7 (21.4 to 52.7)	-30.5 (-41.1 to -26.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.1 (15.3 to 71.2)	-31.4 (-43.7 to -18.0)
Obstructed labor	0.5 (0.4 to 0.6)	0.6 (0.6 to 0.7)	27.1 (17.6 to 36.6)	-34.7 (-39.2 to -30.1)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	26.8 (9.9 to 46.9)	-34.8 (-43.1 to -24.9)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.0 (-13.8 to 235.5)	-28.5 (57.0 to 47.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.0 (-13.9 to 236.7)	-28.5 (-57.0 to 48.0)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	54.6 (-25.3 to 189.2)	24.0 (-63.3 to 42.5)
Neonatal disorders	-	-	-	-	1.1 (0.7 to 1.6)	3.1 (2.1 to 4.5)	192.5 (114.2 to 320.9)	65.5 (23.1 to 138.3)
Preterm birth complications	4.3 (3.0 to 6.0)	15.4 (11.3 to 20.9)	259.6 (203.6 to 340.7)	101.4 (70.4 to 143.1)	0.4 (0.3 to 0.6)	1.6 (1.1 to 2.3)	301.3 (188.4 to 484.0)	123.8 (62.9 to 223.5)
Neonatal encephalopathy due to birth asphyxia and trauma	4.3 (0.7 to 13.0)	6.9 (1.6 to 19.8)	62.8 (32.9 to 179.7)	8.6 (-23.9 to 53.1)	0.3 (0.1 to 0.5)	0.6 (0.3 to 1.0)	113.0 (15.6 to 332.3)	20.5 (-32.9 to 154.7)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	167.5 (146.9 to 196.4)	75.8 (62.3 to 94.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	163.5 (140.1 to 195.4)	73.2 (57.8 to 94.1)
Hemolytic disease and other neonatal jaundice	0.4 (0.2 to 0.8)	1.0 (0.5 to 1.8)	149.4 (-2.4 to 417.9)	39.5 (-45.4 to 192.3)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	139.7 (5.4 to 425.4)	33.7 (-47.2 to 195.9)
Other neonatal disorders	-	-	-	-	0.2 (0.1 to 0.5)	0.5 (0.2 to 1.2)	167.3 (13.8 to 492.3)	51.3 (-35.2 to 233.9)
Nutritional deficiencies	-	-	-	-	7.6 (5.2 to 11.0)	14.0 (9.4 to 19.9)	84.6 (67.1 to 98.4)	4.0 (-3.7 to 11.3)
Protein-energy malnutrition	3.3 (1.2 to 7.9)	6.0 (2.3 to 6.7)	31.9 (-56.8 to 251.3)	-14.5 (-67.2 to 86.4)	0.5 (0.1 to 1.1)	0.5 (0.2 to 0.9)	30.8 (-57.6 to 257.9)	15.2 (-68.1 to 91.3)
Iodine deficiency	15.7 (11.8 to 20.3)	15.0 (8.4 to 23.5)	-4.6 (-49.2 to 60.6)	-48.8 (-73.4 to -11.3)	0.3 (0.2 to 0.5)	0.3 (0.1 to 0.5)	-4.7 (-48.8 to 60.1)	-48.8 (-73.2 to -11.4)
Vitamin A deficiency	3.9 (3.2 to 4.6)	4.2 (3.5 to 5.1)	8.9 (-2.3 to 21.1)	-40.7 (-47.4 to -33.2)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-0.0 (-12.1 to 15.1)	-44.6 (-51.6 to -35.9)

Appendix Table G.4 - Gabon prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	189.1 (183.2 to 196.6)	376.9 (363.9 to 392.0)	99.4 (89.5 to 109.4)	11.4 (5.5 to 17.2)	6.8 (4.6 to 9.7)	13.1 (8.8 to 18.6)	93.3 (83.2 to 108.0)	8.7 (3.3 to 16.3)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	11.3 (-69.6 to 248.4)	-28.4 (-77.2 to 86.9)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.6 (0.4 to 0.9)	1.2 (0.7 to 1.8)	87.6 (64.7 to 115.8)	1.4 (-10.4 to 14.7)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.8)	95.4 (56.3 to 135.0)	-0.6 (-18.6 to 17.1)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-1.6 (-18.6 to 19.0)	-41.9 (-51.5 to -30.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.2 (-24.4 to 28.0)	0.0 (-55.0 to -25.3)
Chlamydial infection	16.2 (12.1 to 20.5)	35.8 (30.2 to 41.4)	123.3 (58.8 to 205.3)	11.3 (-19.1 to 48.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	123.3 (44.8 to 210.2)	10.1 (-28.1 to 51.0)
Gonococcal infection	5.7 (4.3 to 7.5)	10.0 (7.0 to 13.5)	75.7 (8.8 to 156.3)	-13.2 (-44.2 to 23.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	70.2 (-10.7 to 165.4)	-14.7 (-54.3 to 28.3)
Trichomoniasis	9.6 (5.5 to 15.6)	21.2 (14.0 to 31.5)	129.3 (7.8 to 328.2)	10.5 (-43.7 to 90.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	126.6 (-6.8 to 407.3)	9.8 (-50.1 to 118.8)
Genital herpes	198.2 (179.9 to 215.7)	393.3 (363.0 to 427.8)	99.5 (73.1 to 125.2)	10.4 (-2.9 to 23.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.3)	183.3 (76.2 to 332.9)	10.8 (-3.3 to 25.4)
Other sexually transmitted diseases	0.4 (0.3 to 0.6)	0.7 (0.5 to 0.9)	61.5 (38.7 to 85.3)	-20.8 (-32.5 to -9.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.0 (15.7 to 137.1)	-17.3 (-39.6 to 13.6)
Hepatitis	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	46.3 (25.0 to 70.4)	-22.1 (-33.5 to -6.0)
Hepatitis A	1.2 (1.2 to 1.3)	2.0 (1.9 to 2.1)	60.6 (60.5 to 60.7)	-5.9 (-6.1 to -5.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	75.8 (54.7 to 96.6)	-3.0 (-13.3 to 7.5)
Hepatitis B	102.4 (89.1 to 116.0)	114.6 (97.7 to 131.0)	11.3 (-6.4 to 38.1)	-38.8 (-46.7 to -30.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	15.8 (-13.9 to 57.5)	-37.5 (-52.8 to -11.8)
Hepatitis C	46.4 (43.0 to 50.0)	56.4 (52.3 to 61.0)	21.7 (9.4 to 35.5)	27.5 (-34.4 to -39.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.1 (5.2 to 60.6)	-22.3 (-40.5 to 2.0)
Hepatitis E	0.2 (0.2 to 0.2)	0.5 (0.5 to 0.6)	151.2 (113.2 to 194.8)	28.8 (10.2 to 51.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	150.8 (94.0 to 231.1)	28.7 (0.7 to 66.1)
Leprosy	0.3 (0.1 to 0.5)	0.3 (0.2 to 0.4)	9.5 (-22.5 to 88.3)	-30.2 (-49.1 to 17.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.1 (-23.1 to 100.7)	-29.6 (-49.9 to 26.5)
Other infectious diseases	7.7 (6.2 to 9.4)	15.2 (13.5 to 17.0)	96.5 (66.5 to 138.1)	12.3 (-2.9 to 33.3)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	97.2 (66.8 to 161.8)	17.2 (-2.0 to 56.9)
Non-communicable diseases	-	-	-	-	0.0 (50.1 to 86.5)	0.0 (88.4 to 153.5)	77.4 (73.2 to 81.7)	0.8 (-1.7 to 3.2)
Neoplasms	-	-	-	-	0.7 (0.5 to 0.9)	1.4 (1.0 to 2.0)	107.7 (68.6 to 160.1)	32.7 (7.3 to 66.6)
Esophageal cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	61.6 (17.3 to 121.1)	8.0 (-21.5 to 46.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.3 (18.9 to 132.0)	8.4 (-21.4 to 53.2)
Stomach cancer	0.3 (0.3 to 0.4)	0.4 (0.3 to 0.6)	41.5 (9.0 to 81.2)	-7.0 (-28.9 to 19.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	43.3 (61.5 to 86.6)	-6.1 (-30.9 to 22.1)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.9 (21.3 to 129.2)	9.6 (-20.6 to 51.8)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	106.4 (4.2 to 311.0)	35.6 (-32.7 to 173.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.1 (1.7 to 277.6)	29.7 (-14.7 to 146.7)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	277.1 (105.4 to 633.7)	151.9 (41.0 to 378.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	240.2 (95.7 to 550.3)	125.7 (30.3 to 325.5)
Liver cancer due to alcohol use	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-19.1 (-52.6 to 49.1)	-45.5 (-68.5 to -0.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.7 (-52.2 to 39.5)	-46.8 (-68.2 to -5.7)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.6 (-32.6 to 115.8)	22.6 (-57.4 to 42.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.8 (-34.3 to 96.9)	25.5 (-58.1 to 29.4)
Larynx cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	46.9 (-0.3 to 116.9)	-0.9 (-33.1 to 46.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.6 (-1.9 to 132.9)	0.3 (-33.4 to 56.3)
Tracheal, bronchus and lung cancer	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	43.4 (14.1 to 82.0)	-2.3 (-22.3 to 22.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	46.6 (12.4 to 91.5)	-1.0 (-24.0 to 29.1)
Breast cancer	1.4 (1.0 to 1.7)	3.2 (2.1 to 4.3)	125.8 (42.0 to 265.8)	44.7 (-7.7 to 131.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	116.6 (38.6 to 246.4)	39.0 (-10.3 to 121.3)
Cervical cancer	0.8 (0.6 to 1.1)	1.2 (0.8 to 1.7)	46.5 (9.9 to 130.7)	6.1 (-46.4 to 36.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	46.7 (-6.7 to 128.0)	-12.5 (-44.9 to 35.8)
Uterine cancer	0.3 (0.2 to 0.6)	0.5 (0.3 to 0.9)	41.8 (-19.4 to 153.0)	-3.8 (-44.5 to 43.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	43.4 (-18.6 to 154.4)	-3.0 (-44.7 to 72.8)
Prostate cancer	0.8 (0.4 to 1.5)	2.8 (1.5 to 6.1)	239.9 (118.4 to 421.3)	130.4 (48.5 to 255.4)	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.6)	224.1 (113.7 to 375.9)	115.6 (42.4 to 215.1)
Colon and rectum cancer	0.7 (0.6 to 0.8)	1.2 (1.0 to 1.5)	77.8 (41.5 to 119.3)	17.4 (-7.0 to 45.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	79.0 (40.1 to 122.3)	17.8 (-7.9 to 46.9)
Lip and oral cavity cancer	0.2 (0.2 to 0.3)	0.4 (0.2 to 0.5)	63.5 (15.9 to 309.9)	6.7 (-24.4 to 50.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.0 (14.8 to 136.3)	7.4 (-24.9 to 56.5)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.2 (-2.8 to 122.3)	-11.7 (-42.6 to 33.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.7 (-1.8 to 111.2)	-12.0 (-41.2 to 27.8)
Other pharynx cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	38.1 (-14.6 to 126.9)	-6.8 (-42.2 to 51.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.3 (-12.2 to 128.1)	-4.6 (-40.7 to 52.3)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.9 (-28.3 to 101.0)	-17.9 (-52.0 to 34.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.5 (-30.8 to 98.8)	-19.1 (-54.0 to 31.9)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	65.3 (27.5 to 120.0)	8.9 (-16.9 to 43.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.6 (22.6 to 119.8)	9.8 (-19.8 to 45.9)
Malignant skin melanoma	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	104.7 (49.6 to 206.6)	24.1 (-9.2 to 82.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.6 (43.5 to 201.6)	22.2 (-13.4 to 78.1)
Non-melanoma skin cancer	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.4)	207.6 (130.6 to 305.5)	82.7 (35.3 to 144.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	274.3 (145.0 to 457.9)	115.6 (33.1 to 236.4)
Ovarian cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	112.4 (21.7 to 255.9)	33.2 (-23.1 to 116.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	114.3 (19.1 to 270.7)	33.6 (-25.4 to 129.6)
Testicular cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	141.3 (46.5 to 309.9)	16.6 (-27.3 to 94.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	143.1 (46.6 to 305.6)	20.4 (-24.3 to 95.6)
Kidney cancer	0.1 (0.2 to 0.3)	0.2 (0.3 to 0.7)	105.9 (39.2 to 193.8)	27.2 (-8.5 to 93.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	105.7 (37.1 to 197.0)	36.1 (-10.3 to 93.6)
Bladder cancer	0.4 (0.3 to 0.6)	0.6 (0.5 to 0.8)	38.3 (3.2 to 90.1)	-8.3 (-32.1 to 24.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	41.0 (4.8 to 93.6)	-7.1 (-31.7 to 26.9)
Brain and nervous system cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	119.4 (56.1 to 204.7)	26.9 (-4.3 to 68.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.9 (58.3 to 184.4)	20.3 (-7.3 to 58.1)
Thyroid cancer	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	77.9 (18.0 to 170.3)	4.8 (-28.9 to 57.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.3 (16.9 to 161.6)	4.2 (-29.8 to 57.1)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.5 (-7.5 to 93.9)	-10.2 (-39.5 to 28.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.3 (6.0 to 102.1)	9.2 (-38.2 to 33.3)
Hodgkin lymphoma	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	208.2 (102.1 to 397.7)	72.1 (13.5 to 174.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	195.7 (90.1 to 375.0)	64.1 (8.4 to 164.1)
Non-Hodgkin lymphoma	0.4 (0.3 to 0.5)	0.9 (0.6 to 1.4)	107.8 (51.8 to 266.9)	28.2 (-7.2 to 123.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	106.5 (52.6 to 267.3)	27.6 (8.1 to 126.7)
Multiple myeloma	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	78.6 (18.4 to 166.8)	20.4 (-20.0 to 77.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.2 (12.9 to 175.9)	18.1 (-24.7 to 83.5)
Leukemia	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	120.3 (43.9 to 235.1)	28.0 (-6.7 to 76.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.0 (50.2 to 191.0)	20.1 (-9.7 to 67.2)
Other neoplasms	0.7 (0.4 to 1.1)	2.2 (1.3 to 3.4)	226.7 (118.4 to 356.9)	95.4 (42.8 to 160.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	208.8 (124.0 to 317.5)	84.5 (38.7 to 146.0)
Cardiovascular diseases	-	-	-	-	1.7 (1.2 to 2.4)	3.3 (2.2 to 4.4)	88.0 (52.0 to 124.6)	13.4 (-8.3 to 35.7)
Rheumatic heart disease	8.2 (7.7 to 8.6)	17.4 (16.4 to 18.5)	113.0 (97.3 to 132.8)	20.3 (11.8 to 30.4)	0.4 (0.3 to 0.6)	0.9 (0.6 to 1.2)	107.5 (86.0 to 130.9)	16.4 (3.3 to 32.1)
Ischemic heart disease	7.9 (6.5 to 9.3)	11.0 (9.5 to 12.8)	38.3 (12.4 to 76.2)	-7.5 (-25.3 to 16.2)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.7)	33.9 (-3.6 to 101.2)	-10.4 (-34.6 to 31.7)
Cerebrovascular disease	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	54.5 (22.6 to 92.1)	3.1 (-23.4 to 20.7)
Ischemic stroke	0.5 (0.5 to 0.6)	0.8 (0.7 to 0.9)	52.0 (21.8 to 86.8)	-3.4 (-22.7 to 18.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	52.7 (19.8 to 92.6)	-3.3 (-24.3 to 21.8)
Hemorrhagic stroke	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	62.2 (22.2 to 107.8)	-3.0 (-27.1 to 24.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.3 (21.8 to 113.0)	-2.6 (-28.2 to 28.1)
Hypertensive heart disease	2.2 (1.6 to 2.8)	3.7 (3.0 to 4.6)	70.8 (21.7 to 160.3)	4.8 (-24.1 to 61.1)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	70.8 (21.3 to 162.0)	5.4 (-24.6 to 60.5)
Cardiomyopathy and myocarditis	1.3 (1.0 to 1.6)	2.2 (1.7 to 2.7)	62.8 (15.6 to 126.8)	3.5 (-27.3 to 44.8)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	62.0 (14.8 to 124.5)	2.9 (-27.8 to 45.0)
Atrial fibrillation and flutter	1.4 (1.1 to 1.7)	3.5 (2.8 to 4.4)	158.6 (83.6 to 272.8)	45.2 (-1.1 to 119.4)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	160.0 (84.4 to 270.6)	47.8 (0.8 to 119.6)
Peripheral vascular disease	13.9 (10.7 to 17.2)	21.9 (16.9 to 27.9)	56.9 (19.7 to 115.6)	3.5 (-20.8 to 39.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.3 (-12.0 to 235.6)	1.5 (-49.3 to 92.8)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	24.7 (-16.7 to 76.3)	-21.1 (-48.9 to 15.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.5 (-20.3 to 95.1)	-21.1 (-51.3 to 30.8)
Other cardiovascular and circulatory diseases	5.8 (3.3 to 9.5)	12.7 (6.6 to 18.6)	126.5 (-9.7 to 333.9)	34.5 (-45.9 to 167.2)	0.4 (0.2 to 0.7)	0.9 (0.4 to 1.4)	126.3 (57.6 to 336.4)	35.1 (-47.5 to 170.2)
Chronic respiratory diseases	-	-	-	-	4.7 (3.2 to 6.5)	8.3 (5.7 to 11.3)	76.6 (50.7 to 102.7)	4.2 (-7.2 to 18.3)
Chronic obstructive pulmonary disease	41.5 (39.8 to 43.3)	69.0 (65.9 to 72.1)	66.1 (61.0 to 71.6)	0.1 (-2.8 to 3.2)	3.3 (2.2 to 4.6)			

Appendix Table G.4 - Gabon prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	0.0	0.0	0.0	0.0	0.0	0.0	59.9	-2.6
Silicosis	0.0	0.0	50.5	-6.6	0.0	0.0	50.3	-6.5
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Coal workers pneumoconiosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Other pneumoconiosis	0.0	0.0	49.9	1.4	0.0	0.0	69.7	1.7
Asthma	24.2	47.9	98.1	8.4	1.1	2.1	98.1	8.1
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	89.1	5.9	0.0	0.0	87.4	5.4
Other chronic respiratory diseases	0.0	0.0	89.1	5.9	0.0	0.0	87.4	5.4
Cirrhosis	0.2	0.2	-1.9	-36.7	0.0	0.0	-2.0	-36.8
Cirrhosis due to hepatitis B	0.1	0.1	0.3	-29.3	0.0	0.0	-32.5	-56.0
Cirrhosis due to hepatitis C	0.1	0.1	164.4	55.9	0.0	0.0	166.1	56.3
Cirrhosis due to alcohol use	0.1	0.1	11.3	-28.7	0.0	0.0	12.6	-28.5
Cirrhosis due to other causes	0.1	0.1	98.8	28.5	0.0	0.0	97.2	26.7
Digestive diseases	8.2	10.8	31.8	-16.5	0.3	0.4	28.8	-18.9
Peptic ulcer disease	7.5	9.0	12.6	-30.1	0.2	0.3	54.4	-33.3
Gastritis and duodenitis	11.5	18.9	64.2	-0.2	0.5	0.8	57.7	-3.9
Appendicitis	0.1	0.2	84.1	-1.9	0.0	0.1	86.4	-0.7
Paralytic ileus and intestinal obstruction	0.0	0.0	42.7	-3.3	0.0	0.0	42.2	-7.2
Inguinal, femoral, and abdominal hernia	3.4	4.9	43.5	-10.5	0.0	0.1	44.1	-10.3
Inflammatory bowel disease	1.0	2.2	120.5	26.6	0.2	0.5	121.2	26.5
Vascular intestinal disorders	0.0	0.0	40.7	-15.6	0.0	0.0	44.2	-12.6
Gallbladder and biliary diseases	0.4	0.7	80.4	1.8	0.1	0.1	81.0	12.2
Pancreatitis	0.2	0.3	83.8	5.2	0.1	0.1	83.0	4.6
Other digestive diseases	0.2	0.2	70.0	-2.7	0.1	0.1	50.8	-9.0
Neurological disorders	3.8	6.4	70.8	2.0	0.5	0.9	74.1	2.3
Alzheimer disease and other dementias	0.1	0.2	53.7	-0.1	0.0	0.0	53.9	0.6
Parkinson disease	0.9	1.7	86.7	6.0	0.3	0.6	90.7	7.8
Epilepsy	0.0	0.1	101.6	12.2	0.0	0.0	101.0	11.5
Multiple sclerosis	0.0	0.1	70.3	-4.8	0.0	0.0	64.3	-9.6
Migraine	65.1	119.4	82.5	1.6	2.2	4.0	83.5	-1.1
Tension-type headache	118.8	227.0	91.1	2.7	0.2	0.3	91.4	2.6
Medication overuse headache	4.7	11.7	150.7	42.3	0.7	1.8	152.8	42.5
Other neurological disorders	0.0	0.0	68.9	-1.8	0.1	0.3	85.5	8.9
Mental and substance use disorders	2.0	3.8	86.4	0.6	1.3	2.4	87.0	0.4
Schizophrenia	10.1	18.8	86.6	-3.6	1.0	1.8	87.1	-3.9
Alcohol use disorders	0.9	1.7	86.7	6.0	0.3	0.6	90.7	7.8
Drug use disorders	1.5	2.9	94.2	0.4	0.6	1.2	94.2	0.2
Opioid use disorders	0.0	0.1	75.1	-8.2	0.0	0.0	71.4	-11.1
Cocaine use disorders	0.0	0.0	108.0	0.1	0.0	0.0	107.2	4.8
Amphetamine use disorders	1.4	2.8	101.3	0.2	0.2	0.4	100.5	-0.2
Cannabis use disorders	1.0	2.0	98.6	0.7	0.0	0.1	98.2	0.6
Other drug use disorders	0.0	0.0	96.9	0.6	0.0	0.0	66.6	-15.4
Depressive disorders	41.5	74.1	78.7	-2.6	8.4	15.1	79.1	-2.7
Major depressive disorder	10.3	18.4	78.9	-1.0	1.0	1.7	79.2	-1.1
Dysthymia	5.4	10.2	89.4	-0.6	1.1	2.0	89.8	-0.8
Bipolar disorder	25.0	46.2	84.8	-4.2	9.4	16.8	79.1	-2.5
Anxiety disorders	13.8	24.4	74.7	-1.5	0.9	1.6	77.8	-1.2
Eating disorders	0.1	0.3	99.0	1.3	0.0	0.1	97.7	0.9
Anorexia nervosa	0.0	0.0	82.2	-7.2	0.0	0.0	54.6	-20.2
Bulimia nervosa	0.9	1.7	99.0	-1.5	0.2	0.4	98.9	-1.4
Autistic spectrum disorders	2.8	5.1	80.3	1.3	0.7	1.3	80.3	1.2
Autism	4.1	7.4	80.5	1.8	0.4	0.7	80.3	1.7
Asperger syndrome	6.4	11.4	78.2	0.3	0.1	0.1	78.6	0.5
Attention-deficit/hyperactivity disorder	9.3	16.6	78.1	0.3	0.1	0.2	64.4	-6.9
Conduct disorder	25.0	46.2	84.8	-4.2	9.4	16.8	79.1	-2.5
Idiopathic intellectual disability	12.3	23.3	89.9	1.1	0.9	1.7	90.2	1.0
Other mental and substance use disorders	0.0	0.0	88.0	0.9	0.6	1.2	83.5	-4.4
Diabetes, urogenital, blood, and endocrine diseases	3.5	8.5	143.7	39.1	0.3	0.7	135.0	40.0
Diabetes mellitus	2.8	6.3	122.2	31.9	0.2	0.4	119.2	38.4
Acute glomerulonephritis	0.0	0.0	40.1	-14.0	0.0	0.0	40.1	-14.0
Chronic kidney disease	22.7	34.7	54.2	-2.2	0.3	0.5	63.5	2.5
Chronic kidney disease due to diabetes mellitus	30.6	54.4	77.5	4.1	0.4	0.7	64.8	-4.7
Chronic kidney disease due to hypertension	21.5	37.7	75.4	-1.9	0.3	0.5	68.7	-1.3
Chronic kidney disease due to glomerulonephritis	21.9	34.7	79.7	6.3	0.3	0.5	76.5	5.0
Chronic kidney disease due to other causes	14.3	27.1	129.7	30.9	0.4	0.7	139.5	38.8
Urinary diseases and male infertility	0.0	0.0	0.0	0.0	0.0	0.0	62.9	4.0

Appendix Table G.4 - Gabon prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.4)	84.3 (69.7 to 100.3)	0.0 (-2.8 to 13.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.9 (45.3 to 125.8)	5.3 (-14.5 to 25.3)
Urolithiasis	2.8 (2.0 to 3.5)	4.1 (3.1 to 5.2)	47.5 (37.1 to 58.9)	0.0 (-13.6 to -1.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	69.8 (52.2 to 92.3)	0.6 (-8.3 to 11.1)
Benign prostatic hyperplasia	9.9 (8.9 to 10.8)	15.3 (14.0 to 16.6)	56.2 (36.2 to 77.0)	0.5 (-8.7 to 18.0)	0.3 (0.2 to 0.5)	0.5 (0.4 to 0.8)	56.0 (35.7 to 77.2)	4.8 (-8.5 to 18.3)
Male infertility due to other causes	7.7 (5.7 to 9.9)	15.4 (11.3 to 19.4)	101.6 (30.7 to 197.0)	-3.5 (-38.5 to 41.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	102.0 (32.7 to 202.1)	-3.2 (-36.8 to 43.9)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	99.6 (38.5 to 205.3)	16.8 (-17.7 to 77.8)
Gynecological diseases	-	-	-	-	1.0 (0.7 to 1.5)	2.1 (1.4 to 3.1)	104.8 (76.4 to 155.8)	2.5 (-10.5 to 25.0)
Uterine fibroids	15.2 (13.9 to 16.5)	27.1 (24.5 to 29.5)	78.0 (76.1 to 79.6)	-5.0 (-5.1 to -4.9)	0.3 (0.2 to 0.5)	0.6 (0.3 to 0.8)	86.3 (72.6 to 143.5)	-2.3 (-9.5 to 28.4)
Polycystic ovarian syndrome	12.6 (11.5 to 13.9)	26.3 (23.2 to 29.0)	109.1 (77.9 to 140.8)	1.5 (-12.8 to 15.6)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.5)	109.9 (76.9 to 143.8)	1.8 (-13.0 to 16.3)
Female infertility due to other causes	12.8 (9.6 to 16.3)	26.9 (20.2 to 31.0)	94.4 (44.3 to 169.1)	-5.3 (-30.5 to 33.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.3)	94.8 (43.8 to 168.9)	-5.6 (-30.5 to 32.5)
Endometriosis	1.3 (1.1 to 1.5)	2.3 (2.0 to 2.7)	79.9 (45.5 to 125.2)	-12.2 (-28.7 to 9.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	80.4 (41.7 to 128.6)	-11.9 (-30.6 to 10.7)
Genital prolapse	32.7 (28.5 to 37.1)	57.6 (49.2 to 66.7)	76.6 (41.8 to 112.5)	0.5 (-17.7 to 19.5)	0.2 (0.0 to 0.2)	0.2 (0.1 to 0.3)	77.2 (41.2 to 113.9)	0.4 (-17.7 to 20.3)
Premenstrual syndrome	26.5 (11.6 to 39.5)	66.8 (45.9 to 88.9)	147.5 (40.3 to 599.2)	17.6 (-30.2 to 204.6)	0.2 (0.1 to 0.4)	0.6 (0.3 to 0.9)	146.7 (42.2 to 597.2)	17.8 (-30.4 to 208.6)
Other gynecological diseases	2.7 (1.5 to 3.9)	6.0 (3.4 to 8.7)	118.6 (22.2 to 298.8)	9.6 (-37.6 to 99.1)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	119.0 (4.8 to 436.9)	9.5 (-51.3 to 160.9)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	1.3 (0.9 to 1.9)	2.3 (1.6 to 3.3)	75.0 (50.7 to 91.1)	0.2 (-14.4 to 10.0)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.9 (16.0 to 80.0)	-3.9 (-31.6 to 6.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.1 (38.6 to 91.5)	-1.5 (-17.7 to 10.5)
Thalassemia trait	6.5 (5.0 to 8.0)	11.0 (8.5 to 13.3)	70.3 (46.6 to 77.2)	-3.4 (-16.8 to 0.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	62.8 (37.2 to 101.3)	-4.0 (-20.9 to 16.8)
Sickle cell disorders	2.2 (2.0 to 2.5)	4.3 (3.9 to 4.7)	93.8 (71.5 to 121.6)	0.2 (-4.6 to 25.5)	0.2 (0.2 to 0.3)	0.6 (0.3 to 0.6)	97.0 (63.0 to 131.6)	8.5 (-8.7 to 27.3)
Sickle cell trait	158.4 (148.9 to 166.7)	287.0 (271.1 to 300.3)	81.1 (74.8 to 87.6)	2.8 (-0.8 to 6.5)	0.7 (0.5 to 1.0)	1.2 (0.8 to 1.7)	69.0 (29.4 to 95.4)	-2.9 (-27.5 to 13.4)
G6PD deficiency	184.9 (178.1 to 190.2)	326.2 (315.7 to 338.6)	75.9 (68.2 to 86.6)	-0.2 (-4.6 to 5.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.9 (-8.2 to 139.0)	-10.6 (-46.2 to 32.2)
G6PD trait	238.8 (238.3 to 239.4)	412.5 (411.8 to 413.2)	72.7 (72.2 to 73.2)	-2.5 (-2.8 to -2.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.2 (-51.1 to 346.8)	12.3 (-69.4 to 175.5)
Other hemoglobinopathies and hemolytic anemias	9.0 (7.6 to 10.3)	17.3 (15.4 to 19.1)	91.1 (63.6 to 131.5)	10.0 (-4.7 to 29.2)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	79.8 (44.8 to 150.4)	3.7 (-16.6 to 40.2)
Endocrine, metabolic, blood, and immune disorders	10.9 (9.4 to 12.2)	20.0 (16.4 to 23.2)	84.2 (47.3 to 124.4)	6.3 (-11.0 to 25.2)	0.4 (0.2 to 0.5)	0.7 (0.4 to 1.0)	63.3 (32.0 to 134.5)	6.1 (-19.5 to 31.0)
Musculoskeletal disorders	-	-	-	-	13.2 (9.5 to 17.3)	22.9 (16.4 to 30.2)	73.5 (60.3 to 87.9)	1.2 (-6.5 to 9.5)
Rheumatoid arthritis	2.6 (2.5 to 2.7)	4.1 (3.9 to 4.3)	58.2 (47.6 to 68.7)	-7.5 (-13.9 to -1.5)	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.3)	58.6 (46.2 to 72.0)	-7.4 (-14.3 to -0.3)
Osteoarthritis	27.7 (26.5 to 28.7)	42.7 (41.3 to 44.2)	54.3 (46.5 to 63.3)	0.2 (-4.7 to 5.7)	1.7 (1.2 to 2.3)	2.6 (1.8 to 3.5)	54.0 (46.6 to 63.2)	0.1 (-4.5 to 5.9)
Low back and neck pain	-	-	-	-	9.2 (6.4 to 12.4)	16.6 (11.6 to 22.2)	79.5 (60.6 to 101.3)	1.3 (-9.6 to 13.9)
Low back pain	51.7 (49.1 to 54.5)	88.3 (83.0 to 92.8)	70.8 (57.3 to 82.7)	-1.2 (-8.5 to 5.8)	5.7 (3.8 to 7.8)	9.7 (6.6 to 13.3)	71.4 (57.4 to 83.6)	-1.2 (-9.1 to 5.9)
Neck pain	37.2 (29.9 to 45.4)	71.0 (60.5 to 80.6)	90.5 (48.2 to 147.7)	5.3 (-18.9 to 36.4)	3.6 (2.3 to 5.1)	6.9 (4.6 to 9.7)	91.7 (48.7 to 150.3)	5.4 (-18.5 to 37.6)
Gout	0.2 (0.2 to 0.2)	0.3 (0.2 to 0.3)	59.8 (36.8 to 88.2)	-0.1 (-14.3 to 17.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.8 (22.6 to 109.8)	-0.4 (-23.4 to 31.8)
Other musculoskeletal disorders	19.0 (14.9 to 23.8)	31.5 (25.0 to 38.1)	66.1 (51.8 to 79.7)	4.4 (-4.4 to 11.5)	1.7 (1.1 to 2.5)	2.8 (1.9 to 4.0)	65.5 (51.8 to 80.4)	6.5 (-4.8 to 11.9)
Other non-communicable diseases	-	-	-	-	15.2 (10.0 to 22.0)	25.2 (16.4 to 37.0)	66.1 (59.3 to 72.0)	4.3 (-7.8 to -1.2)
Congenital anomalies	-	-	-	-	0.8 (0.5 to 1.1)	1.4 (1.0 to 2.0)	81.2 (57.1 to 114.2)	0.7 (-12.1 to 18.6)
Neural tube defects	0.2 (0.2 to 0.2)	0.5 (0.4 to 0.6)	139.7 (83.5 to 210.2)	35.0 (2.8 to 74.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	147.2 (65.5 to 262.7)	40.7 (-5.2 to 104.5)
Congenital heart anomalies	1.7 (1.4 to 2.2)	4.4 (3.6 to 5.5)	154.1 (83.8 to 264.0)	42.6 (3.1 to 107.0)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	144.0 (77.2 to 262.5)	39.0 (-0.7 to 98.9)
Orofacial clefts	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	146.7 (37.6 to 330.6)	41.5 (-22.1 to 152.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	124.4 (27.6 to 336.4)	32.1 (-27.7 to 147.9)
Down syndrome	0.7 (0.6 to 0.9)	1.3 (1.1 to 1.7)	91.8 (49.5 to 135.2)	6.8 (-17.2 to 29.6)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	86.6 (42.8 to 138.5)	5.0 (-20.0 to 32.6)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	82.8 (22.7 to 198.0)	-1.4 (-33.9 to 61.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.4 (21.0 to 202.6)	-1.3 (-36.7 to 59.8)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	69.2 (15.0 to 137.7)	-4.4 (-35.3 to 34.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.3 (23.8 to 167.3)	-3.4 (-34.9 to 38.2)
Chromosomal unbalanced rearrangements	1.1 (0.9 to 1.4)	2.0 (1.7 to 2.3)	81.8 (37.1 to 134.2)	1.4 (-24.2 to 30.8)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	79.6 (32.0 to 131.5)	-0.4 (-26.6 to 31.8)
Other congenital anomalies	4.2 (3.0 to 5.8)	6.5 (4.5 to 9.2)	51.9 (26.2 to 83.1)	-14.2 (-27.5 to 1.5)	0.5 (0.3 to 0.7)	0.8 (0.4 to 1.2)	65.4 (34.9 to 113.5)	-7.8 (-23.4 to 17.5)
Skin and subcutaneous diseases	-	-	-	-	5.4 (3.5 to 8.1)	10.0 (6.5 to 15.0)	85.6 (77.8 to 96.8)	3.5 (-1.8 to 9.6)
Dermatitis	58.1 (49.7 to 65.6)	106.5 (90.5 to 120.7)	83.3 (80.6 to 85.8)	0.0 (-0.1 to 0.2)	2.0 (1.4 to 2.9)	3.7 (2.5 to 5.2)	80.6 (74.4 to 86.5)	-0.0 (-2.5 to 2.5)
Psoriasis	6.6 (5.7 to 7.6)	11.8 (10.2 to 13.7)	79.4 (75.8 to 83.3)	0.1 (-0.2 to 0.3)	0.5 (0.4 to 0.7)	0.9 (0.6 to 1.3)	79.6 (68.9 to 91.6)	-0.0 (-5.0 to 5.6)
Cellulitis	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.4)	69.6 (52.1 to 91.3)	-1.0 (-11.1 to 10.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.8 (36.1 to 114.8)	-0.6 (-19.4 to 22.5)
Pyoderma	1.6 (1.2 to 2.0)	2.5 (1.9 to 3.2)	57.6 (47.3 to 71.0)	-4.1 (-10.5 to 3.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.6 (41.6 to 76.0)	-3.8 (-13.0 to 6.1)
Scabies	6.6 (6.0 to 7.3)	12.7 (11.5 to 14.1)	91.0 (69.1 to 116.9)	4.1 (-7.5 to 17.9)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	91.7 (68.4 to 117.7)	4.3 (-7.9 to 18.1)
Fungal skin diseases	153.8 (124.5 to 186.5)	272.4 (220.9 to 333.1)	75.8 (73.9 to 80.9)	0.4 (0.2 to 0.5)	0.9 (0.4 to 1.9)	1.5 (0.6 to 3.3)	79.0 (73.9 to 81.3)	0.0 (-0.3 to 1.0)
Viral skin diseases	18.7 (15.2 to 22.2)	34.3 (27.2 to 40.8)	83.1 (76.6 to 89.7)	2.5 (0.6 to 4.4)	0.6 (0.4 to 0.9)	1.1 (0.6 to 1.6)	83.4 (74.3 to 91.6)	2.6 (-0.8 to 6.3)
Acne vulgaris	41.0 (29.3 to 50.7)	95.0 (76.6 to 124.3)	124.9 (73.4 to 246.6)	18.3 (-9.1 to 77.6)	0.4 (0.2 to 0.8)	1.0 (0.5 to 1.9)	125.0 (72.6 to 246.5)	18.4 (-9.4 to 78.1)
Alopecia areata	0.9 (0.8 to 1.0)	1.6 (1.4 to 1.8)	77.4 (55.3 to 108.4)	2.1 (-11.1 to 20.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	77.2 (48.5 to 114.7)	2.0 (-13.6 to 23.1)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.2 (35.4 to 119.6)	2.5 (-21.3 to 30.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.8 (35.4 to 120.0)	2.5 (-21.3 to 30.1)
Urticaria	5.2 (3.7 to 7.1)	11.2 (7.4 to 15.0)	118.4 (19.0 to 256.8)	21.8 (-35.1 to 104.6)	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.0)	119.2 (19.0 to 257.2)	22.1 (-34.8 to 104.8)
Decubitus ulcer	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	77.6 (37.3 to 120.6)	2.5 (-23.3 to 32.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	77.4 (35.8 to 125.9)	2.9 (-24.9 to 35.2)
Other skin and subcutaneous diseases	66.8 (45.8 to 99.1)	112.7 (77.7 to 163.3)	69.0 (57.7 to 81.1)	0.3 (-2.8 to 3.1)	0.4 (0.2 to 0.8)	0.7 (0.3 to 1.3)	69.4 (58.1 to 81.6)	0.2 (-9.4 to 3.3)
Sense organ diseases	-	-	-	-	7.2 (4.7 to 10.5)	10.7 (6.9 to 16.1)	89.8 (40.0 to 58.4)	-9.4 (-14.3 to -4.8)
Glaucoma	2.2 (1.8 to 2.5)	2.5 (2.0 to 2.9)	14.2 (-3.6 to 33.8)	-3.1 (-43.4 to -39.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	22.5 (31.1 to 42.2)	-24.4 (-37.3 to -12.8)
Cataract	8.1 (6.5 to 9.9)	9.7 (7.8 to 11.7)	19.8 (1.6 to 42.0)	-22.8 (-33.9 to -9.6)	0.5 (0.4 to 0.7)	0.6 (0.4 to 0.9)	20.5 (7.8 to 36.3)	-23.2 (-31.2 to -13.9)
Macular degeneration	1.7 (1.3 to 2.3)	3.1 (2.4 to 3.9)	78.1 (26.1 to 147.4)	18.9 (-14.8 to 62.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	73.5 (29.9 to 128.7)	12.1 (-14.6 to 44.2)
Uncorrected refractive error	150.6 (138.5 to 163.1)	240.4 (217.4 to 263.6)	59.6 (40.5 to 78.0)	4.1 (-15.1 to 7.6)	2.1 (1.3 to 3.5)	3.2 (1.8 to 5.3)	51.2 (36.9 to 66.4)	-9.3 (-16.8 to -0.5)
Age-related and other hearing loss	145.5 (128.1 to 161.5)	219.9 (189.8 to 246.8)	51.0 (45.9 to 56.2)	-4.4 (-9.1 to -3.5)	3.5 (2.1 to 5.4)	5.3 (3.3 to 8.2)	52.0 (37.2 to 69.0)	-7.0 (-14.6 to 1.7)
Other vision loss	3.1 (2.5 to 3.6)	3.8 (3.2 to 4.4)	23.5 (10.8 to 40.6)	-26.9 (-35.2 to -15.1)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	18.5 (5.9 to 33.2)	-26.9 (-35.1 to -17.6)
Other sense organ diseases	23.1 (22.0 to 24.3)	39.0 (37.3 to 40.7)	68.5 (58.4 to 81.1)	-0.8 (-6.4 to 5.7)	0.6 (0.4 to 0.9)	1.0 (0.6 to 1.5)	68.8 (57.0 to 82.4)	-0.6 (-6.9 to 6.2)
Oral disorders	-	-	-	-	1.8 (1.1 to 2.9)	3.0 (1.8 to 4.7)	64.4 (51.1 to 77.2)	-2.8 (-7.0 to 1.5)
Deciduous caries	81.7 (78.4 to 84.7)	139.9 (129.2 to 138.9)	63.8 (55.5 to 72.8)	0.8 (-4.2 to 6.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	63.6 (51.7 to 77.4)	0.7 (-6.7 to 9.4)
Permanent caries	282.8 (269.6 to 296.5)	523.4 (494.5 to 550.0)	85.4 (71.9 to 98.0)	0.8 (-5.6 to 6.9)	0.3 (0.1 to 0.5)	0.5 (0.2 to 1.0)	85.6 (71.8 to 98.4)	0.7 (-5.9 to 6.8)
Periodontal diseases	62.4 (58.8 to 65.8)	103.5 (98.2 to 109.1)	66.0 (53.5 to 79.0)	-0.8 (-8.6 to 7.0)	0.4 (0.2 to 0.8)	0.7 (0.3 to 1.4)	66.3 (53.8 to 79.3)	-0.9 (-8.6 to 6.9)

Appendix Table G.4 - Gabon prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	25.8 (24.2 to 27.7)	37.9 (35.7 to 40.3)	46.7 (34.5 to 60.7)	-5.5 (-12.9 to 3.5)	0.7 (0.5 to 1.0)	1.0 (0.7 to 1.4)	46.6 (34.4 to 60.8)	-5.4 (-13.0 to 3.8)
Other oral disorders	14.4 (13.6 to 15.3)	25.8 (24.4 to 27.4)	80.2 (65.2 to 94.8)	-0.9 (-8.7 to 7.0)	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.1)	80.7 (64.7 to 95.1)	-0.9 (-8.9 to 7.0)
Injuries	-	-	-	-	4.5 (3.4 to 5.8)	5.9 (4.4 to 7.8)	31.2 (22.0 to 41.9)	-22.8 (-28.4 to -16.5)
Transport injuries	-	-	-	-	1.8 (1.3 to 2.3)	2.1 (1.6 to 2.8)	20.6 (9.7 to 33.3)	-28.5 (-34.8 to -21.2)
Road injuries	-	-	-	-	1.5 (1.1 to 2.0)	1.8 (1.3 to 2.3)	16.3 (5.4 to 29.0)	-31.7 (-37.5 to -23.8)
Pedestrian road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.6)	11.9 (0.1 to 27.2)	-32.9 (-39.8 to -24.4)
Cyclist road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	11.8 (1.4 to 23.2)	-31.6 (-38.0 to -24.8)
Motorcyclist road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	5.4 (5.4 to 18.3)	-38.4 (-44.5 to -30.6)
Motor vehicle road injuries	-	-	-	-	0.6 (0.5 to 0.8)	0.8 (0.6 to 1.1)	26.1 (12.6 to 41.9)	-25.7 (-33.6 to -16.6)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.5 (-28.9 to -12.2)	-55.1 (-59.3 to -49.7)
Other transport injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	48.2 (35.2 to 63.4)	-12.7 (-20.5 to -3.2)
Unintentional injuries	-	-	-	-	2.5 (1.9 to 3.2)	3.5 (2.6 to 4.6)	39.5 (30.9 to 48.4)	-18.4 (-23.9 to -13.0)
Falls	-	-	-	-	1.1 (0.9 to 1.5)	1.5 (1.1 to 2.0)	36.7 (24.7 to 48.0)	-19.6 (-27.0 to -12.3)
Drowning	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	2.2 (-10.3 to 15.7)	-39.7 (-47.0 to -32.2)
Fire, heat, and hot substances	-	-	-	-	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.4)	9.3 (2.2 to 21.7)	-35.1 (-41.4 to -28.1)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.5 (15.9 to 55.7)	-24.4 (-33.5 to -13.7)
Exposure to mechanical forces	-	-	-	-	0.6 (0.5 to 0.8)	1.0 (0.7 to 1.3)	61.9 (52.8 to 71.3)	-7.5 (-12.6 to -1.8)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.4 (43.4 to 79.0)	8.7 (-18.3 to 2.2)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.5 (58.0 to 92.3)	0.9 (-7.8 to 11.2)
Other exposure to mechanical forces	-	-	-	-	0.6 (0.4 to 0.8)	0.9 (0.7 to 1.2)	61.7 (52.7 to 71.4)	-7.5 (-12.7 to -1.8)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.9 (77.0 to 101.4)	13.9 (5.9 to 21.7)
Animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	22.2 (13.5 to 31.6)	-29.5 (-34.6 to -24.2)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.5 (15.6 to 43.7)	-27.1 (-33.9 to -18.9)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	17.4 (8.7 to 27.4)	-31.3 (-36.5 to -25.4)
Foreign body	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	37.6 (27.2 to 48.5)	-18.6 (-24.6 to -12.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.1 (-10.4 to 20.0)	-35.9 (-44.1 to -25.5)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.6 (45.4 to 84.9)	-8.2 (-18.0 to 2.1)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	44.9 (32.7 to 58.9)	-14.6 (-22.1 to -6.8)
Other unintentional injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	41.3 (31.0 to 52.0)	-15.5 (-21.4 to -9.4)
Self-harm and interpersonal violence	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	25.6 (14.8 to 38.9)	-27.6 (-34.0 to -19.7)
Self-harm	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	50.8 (37.4 to 66.2)	-13.4 (-21.3 to -4.7)
Interpersonal violence	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	20.0 (9.4 to 33.9)	-31.0 (-37.4 to -22.9)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	35.4 (24.7 to 47.6)	-22.3 (-28.7 to -15.3)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	42.2 (27.7 to 61.0)	-19.0 (-27.7 to -7.4)
Assault by other means	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	10.3 (0.3 to 24.1)	-36.5 (-43.0 to -28.6)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-

Appendix Table G.4 - Georgia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	558.3 (417.2 to 725.1)	502.5 (376.8 to 650.7)	-10.0 (-12.0 to -8.1)	-10.0 (-1.8 to 2.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	41.2 (28.8 to 57.0)	31.0 (21.9 to 42.1)	-24.5 (-32.7 to -15.4)	5.0 (-6.1 to 17.5)
HIV/AIDS and tuberculosis	-	-	-	-	2.9 (2.0 to 3.9)	2.5 (1.7 to 3.4)	-13.1 (-19.2 to -6.1)	4.7 (-2.9 to 13.0)
Tuberculosis	9.4 (8.9 to 9.9)	8.0 (7.7 to 8.4)	-14.2 (-18.1 to -10.2)	2.7 (-1.8 to 7.3)	2.9 (2.0 to 3.9)	2.5 (1.7 to 3.4)	-14.6 (-20.4 to -7.8)	2.9 (-4.4 to 10.9)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-2,939.3 to 44,507.4)	14,795.2 (3,542.7 to 53,216.7)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6,894.9 (1,607.9 to 27,418.9)	8,521.7 (1,988.4 to 33,780.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6,894.9 (1,606.8 to 27,485.2)	8,521.7 (1,982.9 to 33,791.9)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.6 (0.3 to 0.9)	17,397.6 (5,737.0 to 58,187.3)	20,972.4 (6,841.3 to 69,993.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	12,697.7 (2,935.6 to 54,050.7)	15,336.0 (3,508.5 to 65,136.0)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	6.9 (4.8 to 9.5)	4.7 (3.3 to 6.3)	-32.4 (-36.4 to -27.9)	-9.5 (-15.0 to -3.4)
Diarrheal diseases	16.7 (15.7 to 17.7)	12.0 (11.2 to 12.7)	-28.2 (-33.8 to -21.6)	-2.4 (-10.1 to 6.4)	2.7 (1.8 to 3.8)	1.9 (1.3 to 2.7)	-28.8 (-35.2 to -21.5)	-2.4 (-11.2 to 7.8)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-64.5 to -2.1)	0.0 (53.9 to 26.4)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.1 (-51.6 to -30.8)	-25.1 (-37.4 to -9.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.1 (-51.7 to -30.8)	-25.1 (-37.5 to -9.7)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.9 (-53.1 to -26.8)	-21.5 (-37.0 to -4.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.9 (-53.1 to -26.8)	-21.5 (-37.2 to -4.0)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.1 (-99.2 to 860.2)	-61.2 (-98.9 to 1,149.7)
Lower respiratory infections	0.6 (0.5 to 0.6)	0.3 (0.3 to 0.4)	-39.6 (-53.9 to -23.3)	-23.8 (-45.4 to -0.4)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-40.5 (-57.3 to -18.7)	-23.9 (-47.6 to 6.8)
Upper respiratory infections	90.6 (80.4 to 100.0)	67.5 (59.4 to 76.7)	-25.7 (-36.1 to -9.9)	-1.7 (-15.2 to 18.4)	1.1 (0.6 to 1.8)	0.8 (0.4 to 1.4)	-26.1 (-36.4 to -10.8)	-1.6 (-15.4 to 18.7)
Otitis media	66.0 (60.8 to 71.1)	45.0 (41.7 to 48.4)	-31.7 (-37.2 to -26.3)	-9.6 (-16.4 to -2.5)	1.3 (0.8 to 2.1)	0.9 (0.5 to 1.4)	-32.8 (-38.6 to -26.3)	-9.8 (-17.5 to -1.3)
Meningitis	-	-	-	-	1.1 (0.7 to 1.6)	0.6 (0.4 to 0.9)	-44.5 (-53.6 to -33.4)	-28.6 (-40.5 to -12.8)
Pneumococcal meningitis	5.3 (3.1 to 8.6)	2.8 (1.6 to 4.4)	-47.0 (-55.9 to -36.0)	-37.2 (-47.8 to -24.3)	0.2 (0.3 to 0.6)	0.2 (0.2 to 0.3)	-46.3 (-60.8 to -31.0)	-32.7 (-51.0 to -12.3)
H influenzae type B meningitis	3.1 (0.9 to 6.4)	1.7 (0.6 to 3.3)	-44.5 (-56.2 to -19.0)	-29.7 (-45.4 to 9.9)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-37.9 (-59.9 to -4.2)	-16.4 (-46.1 to 29.0)
Meningococcal meningitis	1.1 (0.3 to 2.7)	0.6 (0.2 to 1.4)	-47.0 (-59.8 to -29.8)	-36.7 (-51.2 to -10.2)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-48.9 (-65.0 to -23.6)	-36.3 (-56.5 to -1.9)
Other meningitis	1.5 (0.7 to 3.0)	0.9 (0.4 to 1.7)	-44.5 (-58.5 to -25.6)	-31.9 (-48.9 to -9.7)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-45.1 (-66.4 to -25.4)	-31.0 (-58.1 to -5.2)
Encephalitis	2.1 (0.9 to 5.0)	1.7 (0.7 to 4.1)	-17.7 (-28.0 to -5.1)	-47.0 (-16.6 to 12.4)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-20.0 (-33.6 to -3.4)	-4.7 (-20.7 to 15.6)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-78.3 (-97.5 to 79.4)	-71.6 (-96.9 to 156.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-78.3 (-97.5 to 81.0)	-71.6 (-96.9 to 157.2)
Whooping cough	5.4 (4.2 to 7.1)	1.9 (1.5 to 2.4)	-65.4 (-66.7 to -64.1)	-45.8 (-47.9 to -43.7)	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-65.5 (-68.3 to -62.6)	-45.9 (-50.2 to -41.4)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-77.6 (-82.5 to -64.5)	-71.3 (-77.7 to -59.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-77.7 (-82.6 to -64.4)	-71.4 (-77.7 to -59.1)
Measles	0.0 (0.0 to 0.0)	0.2 (0.2 to 0.2)	2,098.9 (1,887.2 to 2,350.0)	3,377.2 (3,042.5 to 3,774.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3,659.0 (1,616.3 to 2,612.1)	5,329.9 (2,619.4 to 4,181.2)
Varicella and herpes zoster	3.2 (3.0 to 3.5)	2.4 (2.2 to 2.6)	-25.1 (-33.9 to -16.1)	-8.8 (-10.3 to 8.5)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-12.8 (-32.1 to 10.6)	-0.8 (-22.3 to 24.5)
Neglected tropical diseases and malaria	-	-	-	-	1.5 (0.9 to 2.5)	0.8 (0.5 to 1.2)	-46.8 (-65.5 to -15.9)	-15.1 (-46.4 to 37.7)
Malaria	0.5 (0.4 to 0.6)	0.4 (0.3 to 0.5)	-21.3 (-36.0 to -2.6)	7.5 (-13.0 to 31.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.4 (-38.3 to -3.9)	7.1 (-17.5 to 38.5)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.7 (-27.9 to 41.0)	30.7 (-2.6 to 93.8)
Visceral leishmaniasis	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-10.8 (-33.1 to 29.6)	23.2 (-7.2 to 80.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.3 (-34.0 to 30.6)	22.7 (-9.5 to 81.5)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	672.7 (509.9 to 942.1)	753.8 (574.3 to 1,050.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	672.7 (509.8 to 943.8)	753.8 (574.3 to 1,050.3)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.4 (0.1 to 1.1)	0.2 (0.0 to 0.7)	-59.7 (-86.8 to 76.3)	-54.7 (-85.2 to 98.9)	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.2)	-57.2 (-86.4 to 82.3)	-52.6 (-85.2 to 100.8)
Cystic echinococcosis	2.2 (2.0 to 2.4)	0.9 (0.8 to 0.9)	-60.7 (-65.3 to -54.9)	-55.4 (-61.6 to -49.2)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.1)	-60.9 (-68.1 to -52.8)	-55.3 (-64.2 to -45.7)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.7 (-54.9 to -16.8)	-13.3 (-43.6 to 6.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.7 (-55.0 to -16.6)	-13.3 (-43.6 to 7.2)
Intestinal nematode infections	-	-	-	-	0.1 (0.0 to 0.4)	0.1 (0.0 to 0.0)	-85.2 (-98.0 to -32.8)	-82.8 (-97.7 to -20.9)
Ascariasis	29.6 (16.9 to 54.8)	20.0 (11.2 to 33.4)	-31.4 (-68.9 to 47.2)	-12.3 (-60.1 to 83.2)	0.1 (0.0 to 0.4)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -99.8)	-100.0 (-100.0 to -99.7)
Trichuriasis	-	-	-22.1 (-63.7 to 67.0)	-9.9 (-51.7 to 102.9)	-	-	-	-
Hookworm disease	4.4 (2.6 to 7.4)	3.8 (2.2 to 6.1)	-12.9 (-60.5 to 75.4)	0.7 (-54.3 to 102.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.4 (-80.4 to 115.8)	-14.5 (-74.9 to 157.2)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	34.6 (23.7 to 49.9)	20.9 (16.9 to 24.7)	-38.2 (-59.6 to -5.4)	-0.7 (-35.6 to 52.0)	1.1 (0.5 to 1.9)	0.6 (0.3 to 1.0)	-41.0 (-66.6 to 31.9)	-0.1 (-43.1 to 122.4)
Maternal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-42.1 (-58.3 to -21.3)	-24.9 (-46.2 to 2.0)
Maternal hemorrhage	1.0 (0.9 to 1.2)	0.7 (0.5 to 0.9)	-28.7 (-51.6 to -3.9)	-5.6 (-36.0 to 26.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-32.0 (-66.5 to 0.8)	-10.1 (-55.3 to 33.9)
Maternal sepsis and other maternal infections	3.8 (2.1 to 6.4)	2.3 (1.4 to 3.2)	-40.2 (-58.4 to 12.0)	-24.9 (-48.0 to 38.9)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-53.6 (-71.1 to -19.5)	-40.5 (-62.5 to 3.2)
Maternal hypertensive disorders	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-31.2 (-45.9 to -20.7)	-12.2 (-30.7 to 0.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.9 (-56.4 to 0.8)	-14.2 (-44.4 to 28.4)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.6 (-54.4 to -0.7)	-15.0 (-40.7 to 30.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.6 (-54.5 to -0.5)	-15.0 (-40.9 to 30.9)
Complications of abortion	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-32.8 (-44.8 to -17.2)	-13.0 (-28.6 to 7.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.9 (-66.4 to 33.0)	-13.6 (-55.6 to 71.1)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.6 (-62.9 to 14.8)	-17.7 (-52.1 to 48.5)
Neonatal disorders	-	-	-	-	4.3 (3.0 to 6.1)	6.4 (4.2 to 9.1)	52.2 (-10.8 to 109.3)	104.8 (20.0 to 182.8)
Preterm birth complications	10.3 (7.5 to 14.2)	17.6 (13.2 to 23.7)	72.0 (39.8 to 109.6)	121.6 (80.6 to 169.9)	1.2 (0.8 to 1.7)	2.1 (1.4 to 2.9)	71.5 (21.6 to 134.4)	127.4 (60.8 to 212.3)
Neonatal encephalopathy due to birth asphyxia and trauma	8.7 (4.1 to 21.4)	6.2 (3.3 to 12.6)	-28.5 (-52.2 to 25.6)	-3.8 (-35.7 to 71.9)	1.8 (1.1 to 2.8)	1.6 (0.9 to 2.7)	-13.2 (-49.7 to 71.5)	19.7 (-29.7 to 135.9)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.7 (44.9 to 69.9)	143.8 (126.8 to 166.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.7 (29.0 to 92.6)	145.3 (101.9 to 201.5)
Hemolytic disease and other neonatal jaundice	2.9 (1.5 to 4.9)	3.0 (1.5 to 5.2)	0.8 (-59.5 to 158.2)	35.2 (-46.2 to 242.2)	1.1 (0.5 to 2.0)	1.2 (0.5 to 2.0)	0.9 (-59.5 to 157.7)	35.2 (-45.6 to 243.8)
Other neonatal disorders	-	-	-	-	0.2 (0.1 to 0.6)	1.6 (0.4 to 2.9)	863.3 (-5.9 to 2,151.7)	1,206.0 (27.9 to 2,936.0)
Nutritional deficiencies	-	-	-	-	22.8 (14.7 to 33.4)	14.7 (9.5 to 21.5)	-35.8 (-44.5 to -23.4)	-6.4 (-19.0 to 10.9)
Protein-energy malnutrition	3.6 (1.4 to 7.9)	2.1 (0.9 to 4.3)	-40.7 (-82.6 to 89.2)	-7.2 (-72.8 to 195.1)	0.5 (0.2 to 1.0)	0.3 (0.1 to 0.6)	-41.5 (-83.1 to 93.3)	8.5 (-73.5 to 201.7)
Iodine deficiency	141.4 (66.9 to 239.7)	66.1 (27.5 to 150.1)	-61.2 (-83.6 to 33.2)	-52.5 (-79.6 to 60.8)	2.5 (1.0 to 5.1)	1.2 (0.4 to 2.9)	-61.8 (-83.6 to 31.7)	-52.6 (-79.8 to 58.5)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-

Appendix Table G.4 - Georgia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	630.0 (592.1 to 647.6)	459.6 (442.8 to 477.0)	-27.3 (-30.5 to -22.8)	-0.2 (-4.0 to 6.6)	18.5 (12.2 to 27.1)	12.6 (8.3 to 18.6)	-32.0 (-36.8 to -24.2)	-32.0 (-6.2 to 11.6)
Other nutritional deficiencies	-	-	-	-	1.3 (0.4 to 3.4)	0.7 (0.2 to 1.7)	-47.8 (-86.7 to 98.9)	-18.3 (-79.2 to 210.9)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.6 (1.6 to 4.3)	1.9 (1.2 to 3.0)	-28.2 (-39.7 to -16.2)	-3.7 (-21.3 to 14.0)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.4 (0.8 to 2.4)	1.1 (0.6 to 1.9)	-23.3 (-31.4 to -14.2)	-4.0 (-14.1 to 8.2)
Syphilis	0.2 (0.2 to 0.2)	0.1 (0.1 to 0.1)	-27.0 (-38.7 to -13.0)	-26.6 (-38.8 to -12.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.1 (-46.7 to 21.0)	-24.7 (-45.3 to 2.1)
Chlamydial infection	167.5 (148.4 to 186.7)	132.4 (115.6 to 147.5)	-20.9 (-33.5 to -6.4)	1.6 (-14.7 to 20.6)	0.7 (0.4 to 1.2)	0.6 (0.3 to 0.9)	-22.9 (-35.1 to -7.8)	-0.7 (-16.6 to 19.5)
Gonococcal infection	31.9 (26.0 to 37.9)	20.5 (16.7 to 24.4)	-35.3 (-49.7 to -17.9)	-13.6 (-33.4 to 10.0)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-35.4 (-56.5 to -8.3)	-13.8 (-42.2 to 22.3)
Trichomoniasis	77.7 (54.9 to 106.7)	57.1 (38.4 to 77.8)	-27.0 (-52.7 to 17.4)	-6.1 (-40.7 to 51.6)	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.2)	-27.9 (-55.5 to 23.0)	-7.5 (-44.0 to 62.0)
Genital herpes	991.7 (960.7 to 1,022.8)	883.0 (856.9 to 909.1)	-11.1 (-14.7 to -7.1)	1.6 (-5.8 to 2.7)	0.2 (0.1 to 0.6)	0.2 (0.1 to 0.5)	-22.2 (-17.5 to -7.5)	-1.1 (-7.1 to 4.2)
Other sexually transmitted diseases	1.7 (1.2 to 2.2)	1.2 (0.9 to 1.6)	-29.8 (-40.7 to -17.1)	-13.9 (-27.4 to 1.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-23.7 (-41.6 to 1.8)	-5.2 (-28.0 to 27.6)
Hepatitis	-	-	-	-	0.5 (0.3 to 0.8)	0.3 (0.2 to 0.5)	-36.0 (-48.0 to -20.5)	-21.5 (-35.8 to -3.4)
Hepatitis A	5.4 (5.3 to 5.6)	3.8 (3.7 to 3.9)	-29.3 (-29.9 to -28.8)	-0.1 (-0.1 to 0.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-26.0 (-33.8 to -17.8)	-0.1 (-10.7 to 11.2)
Hepatitis B	595.8 (524.1 to 665.8)	329.3 (274.3 to 384.9)	-44.7 (-54.7 to -33.6)	-33.0 (-44.6 to -20.2)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-42.4 (-61.8 to -18.0)	-32.9 (-54.5 to -3.7)
Hepatitis C	495.5 (448.8 to 541.0)	331.8 (300.3 to 361.9)	-33.1 (-41.3 to -23.7)	-26.1 (-35.7 to -15.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-27.5 (-48.4 to 10.0)	-19.3 (-41.8 to 12.7)
Hepatitis E	0.6 (0.5 to 0.6)	0.5 (0.4 to 0.5)	-22.1 (-31.5 to -8.9)	-2.2 (-13.9 to 13.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.4 (-42.9 to 7.3)	-2.6 (-29.6 to 33.6)
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	23.8 (17.2 to 31.6)	15.0 (10.7 to 19.5)	-36.3 (-58.4 to -3.2)	-6.6 (-35.9 to 51.5)	0.7 (0.3 to 1.2)	0.5 (0.3 to 0.8)	-31.8 (-64.9 to 40.9)	9.3 (-43.9 to 124.9)
Non-communicable diseases	-	-	-	-	339.2 (344.7 to 601.7)	430.0 (319.4 to 557.7)	25.9 (-8.4 to 4.5)	21.6 (0.3 to 5.4)
Neoplasms	-	-	-	-	3.9 (2.8 to 5.1)	4.3 (3.1 to 5.7)	12.7 (-6.7 to 29.6)	14.2 (-4.9 to 30.4)
Esophageal cancer	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-11.6 (-41.5 to 39.0)	-13.1 (-41.6 to 38.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.4 (-36.3 to 37.3)	-12.3 (-37.5 to 35.4)
Stomach cancer	1.9 (1.6 to 2.2)	1.2 (1.0 to 1.5)	-33.4 (-46.8 to -17.8)	-37.5 (-49.9 to -22.8)	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-30.7 (-44.6 to -13.4)	-35.1 (-47.7 to -18.6)
Liver cancer	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	48.6 (15.1 to 86.4)	40.4 (9.1 to 76.9)
Liver cancer due to hepatitis B	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	26.9 (-20.7 to 100.0)	24.6 (-22.3 to 97.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.6 (-8.8 to 67.9)	21.2 (-10.0 to 64.2)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	273.6 (122.9 to 521.1)	251.9 (110.9 to 485.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	265.5 (149.5 to 434.3)	241.1 (133.7 to 399.7)
Liver cancer due to alcohol use	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.3)	-40.0 (-12.5 to 125.8)	29.4 (-19.6 to 110.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.3 (-4.4 to 94.5)	23.8 (-11.5 to 80.9)
Liver cancer due to other causes	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-33.4 (-62.8 to 19.4)	-33.4 (-63.4 to 14.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.8 (-58.2 to 4.2)	-27.3 (-59.4 to -1.4)
Larynx cancer	0.7 (0.5 to 1.0)	0.6 (0.5 to 0.9)	-13.5 (-41.9 to 37.4)	-11.3 (-40.0 to 40.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-15.1 (-40.4 to 25.6)	-13.3 (-37.8 to 27.1)
Tracheal, bronchus and lung cancer	1.8 (1.6 to 2.1)	1.6 (1.3 to 1.8)	-14.7 (-31.4 to 4.0)	-13.8 (-30.5 to 4.7)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-12.3 (-29.0 to 9.1)	-11.8 (-28.0 to 9.7)
Breast cancer	9.0 (7.6 to 10.6)	14.1 (12.6 to 15.7)	58.0 (29.8 to 91.9)	54.8 (26.6 to 87.7)	0.8 (0.6 to 1.0)	0.8 (0.6 to 1.1)	7.8 (-13.4 to 35.1)	7.0 (-14.0 to 33.5)
Cervical cancer	4.8 (3.6 to 5.7)	2.4 (1.9 to 3.1)	-48.4 (-61.2 to -31.8)	-43.2 (-57.3 to -34.5)	0.4 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-43.9 (-61.1 to -30.8)	-43.9 (-58.4 to -24.6)
Uterine cancer	3.2 (2.2 to 5.7)	3.6 (1.8 to 5.2)	26.0 (-50.2 to 102.9)	32.0 (-47.0 to 108.6)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	23.5 (-49.5 to 100.3)	28.9 (-47.2 to 108.1)
Prostate cancer	2.8 (2.2 to 3.8)	5.9 (3.6 to 8.1)	118.2 (25.6 to 220.3)	106.6 (18.9 to 205.0)	0.2 (0.1 to 0.3)	0.6 (0.3 to 1.0)	204.9 (48.8 to 345.8)	187.1 (40.1 to 315.5)
Colon and rectum cancer	3.5 (3.2 to 3.8)	3.2 (2.8 to 3.6)	-9.5 (-21.4 to 5.9)	-9.8 (-21.6 to 5.5)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-8.7 (-23.0 to 9.7)	-9.8 (-24.5 to 7.4)
Lip and oral cavity cancer	1.0 (0.8 to 1.3)	1.0 (0.7 to 1.3)	-3.2 (-31.0 to 33.7)	-1.6 (-29.6 to 34.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-0.6 (-21.8 to 35.2)	-0.2 (-26.7 to 34.8)
Nasopharynx cancer	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-6.0 (-37.9 to 35.5)	2.5 (-33.6 to 47.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.6 (-34.6 to 31.1)	1.0 (-29.7 to 40.6)
Other pharynx cancer	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	20.5 (-35.2 to 109.4)	23.7 (-32.6 to 112.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.9 (-22.6 to 94.7)	27.8 (-21.7 to 96.8)
Gallbladder and biliary tract cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	140.8 (-33.5 to 253.0)	128.4 (-37.0 to 232.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	137.4 (-35.5 to 232.7)	125.2 (-38.8 to 212.2)
Pancreatic cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	91.8 (51.1 to 139.4)	82.9 (43.5 to 129.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	87.0 (51.2 to 130.8)	79.0 (44.3 to 118.3)
Malignant skin melanoma	1.3 (1.0 to 1.9)	2.0 (1.4 to 2.7)	49.5 (8.3 to 98.9)	49.4 (9.6 to 98.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	46.7 (4.5 to 93.2)	44.6 (4.5 to 91.9)
Non-melanoma skin cancer	3.3 (2.6 to 4.2)	5.8 (4.6 to 7.2)	76.0 (24.5 to 141.7)	57.1 (12.6 to 116.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	129.9 (50.1 to 278.4)	102.2 (32.9 to 234.6)
Ovarian cancer	0.5 (0.4 to 0.7)	0.6 (0.5 to 0.8)	20.1 (-15.2 to 71.5)	25.2 (-11.5 to 78.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	20.1 (-22.2 to 86.6)	25.2 (-19.7 to 92.3)
Testicular cancer	0.8 (0.5 to 1.3)	0.8 (0.5 to 1.2)	-3.2 (-39.5 to 53.8)	16.4 (-27.0 to 86.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-4.3 (-39.5 to 54.5)	34.1 (-28.9 to 90.2)
Kidney cancer	1.2 (0.7 to 1.0)	1.0 (1.2 to 1.7)	-18.0 (-34.2 to 127.8)	-20.5 (-43.3 to 140.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	75.0 (30.7 to 127.8)	83.4 (39.9 to 137.6)
Bladder cancer	1.2 (1.0 to 1.5)	1.0 (0.8 to 1.3)	-18.0 (-36.8 to 7.9)	-20.5 (-38.6 to 4.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-13.0 (-34.6 to 16.1)	-17.1 (-37.3 to 9.3)
Brain and nervous system cancer	0.7 (0.5 to 1.2)	1.3 (0.9 to 1.5)	100.8 (-0.7 to 157.9)	127.0 (15.5 to 190.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	96.5 (-3.1 to 157.6)	117.7 (10.1 to 186.2)
Thyroid cancer	1.2 (0.9 to 1.9)	1.2 (0.9 to 1.5)	0.2 (-34.5 to 45.9)	19.5 (-22.0 to 71.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.7 (-34.1 to 49.3)	18.3 (-22.3 to 74.0)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.2 (48.5 to 147.0)	92.1 (44.5 to 139.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.9 (57.4 to 160.0)	102.9 (52.6 to 152.6)
Hodgkin lymphoma	1.1 (0.7 to 1.4)	0.7 (0.6 to 1.0)	-36.5 (-55.3 to 25.9)	-22.9 (-45.6 to 53.7)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-37.1 (-54.5 to 29.6)	-25.8 (-45.9 to 49.7)
Non-Hodgkin lymphoma	0.6 (0.4 to 1.0)	0.6 (0.6 to 1.2)	78.4 (-27.6 to 142.6)	96.1 (-19.5 to 167.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	84.5 (-25.5 to 149.7)	98.5 (-17.4 to 169.2)
Multiple myeloma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	53.1 (9.0 to 117.9)	53.1 (-6.1 to 125.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.4 (-10.5 to 111.2)	46.3 (-6.3 to 116.6)
Leukemia	2.0 (1.6 to 2.5)	1.3 (1.1 to 1.6)	-35.7 (-48.1 to -19.3)	-38.4 (-35.1 to 41.1)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-30.9 (-44.0 to -12.7)	-17.3 (-33.5 to 3.2)
Other neoplasms	1.7 (1.2 to 2.6)	2.7 (2.2 to 3.3)	65.5 (-0.2 to 129.8)	93.5 (18.4 to 170.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	59.6 (0.8 to 122.4)	80.7 (14.9 to 151.9)
Cardiovascular diseases	-	-	-	-	7.8 (5.3 to 10.7)	8.8 (6.1 to 12.1)	13.9 (-10.3 to 43.5)	4.0 (-18.3 to 30.1)
Rheumatic heart disease	1.0 (0.9 to 1.1)	0.9 (0.8 to 1.1)	-5.0 (-22.1 to 14.2)	-4.5 (-21.7 to 14.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-3.3 (-26.4 to 30.6)	-2.7 (-25.6 to 29.8)
Ischemic heart disease	69.8 (61.1 to 81.1)	74.0 (66.2 to 83.9)	6.8 (-14.3 to 27.3)	-2.8 (-21.6 to 14.9)	3.5 (2.3 to 5.0)	3.6 (2.5 to 5.0)	-1.7 (-20.6 to 30.4)	-7.8 (-27.9 to 16.6)
Cerebrovascular disease	-	-	-	-	0.8 (0.6 to 1.1)	0.8 (0.6 to 1.1)	0.5 (-19.4 to 25.8)	0.2 (-19.7 to 24.9)
Ischemic stroke	3.1 (2.6 to 3.7)	3.2 (2.6 to 3.8)	2.5 (-19.3 to 29.4)	-2.3 (-22.1 to 24.4)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.7)	1.6 (-21.3 to 33.8)	-2.1 (-23.8 to 28.8)
Hemorrhagic stroke	2.3 (1.9 to 2.7)	2.3 (1.9 to 2.7)	-0.6 (-20.8 to 29.7)	1.3 (-19.1 to 32.0)	0.4 (0.2 to 0.5)	0.4 (0.2 to 0.5)	0.7 (-23.8 to 30.1)	2.0 (-2.4 to 3.0)
Hypertensive heart disease	8.8 (7.8 to 9.9)	10.7 (9.6 to 11.9)	22.2 (4.4 to 42.4)	2.4 (-11.6 to 19.1)	1.0 (0.6 to 1.3)	1.2 (0.8 to 1.6)	21.1 (3.2 to 41.8)	2.2 (-12.7 to 19.9)
Cardiomyopathy and myocarditis	4.6 (3.9 to 5.4)	5.5 (5.0 to 6.0)	19.2 (0.5 to 43.5)	6.3 (-10.4 to 28.2)	0.6 (0.3 to 0.7)	0.6 (0.4 to 0.8)	19.6 (1.0 to 47.5)	6.5 (-11.9 to 30.9)
Atrial fibrillation and flutter	0.3 (0.2 to 0.4)	0.9 (0.7 to 1.1)	198.3 (85.8 to 345.5)	203.3 (92.0 to 347.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	194.7 (70.3 to 367.2)	202.4 (79.7 to 368.6)
Peripheral vascular disease	152.7 (117.9 to 191.8)	185.4 (143.6 to 228.2)	20.8 (-13.2 to 228.2)	6.9 (-23.9 to 51.4)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	-8.1 (-69.9 to 121.8)	-34.3 (-79.0 to 59.6)
Endocarditis	0.6 (0.4 to 0.8)	0.2 (0.2 to 0.5)	-65.8 (-78.2 to 1.1)	-62.3 (-81.4 to -22.9)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-58.5 (-81.3 to 1.5)	-64.6 (-83.8 to -11.0)
Other cardiovascular and circulatory diseases	22.8 (9.5 to 42.3)	32.8 (16.8 to 49.3)	46.0 (-44.7 to 285.3)	46.0 (-45.4 to 285.8)	2.3 (0.6 to 3.2)	2.3 (1.1 to 3.9)	46.5 (-45.4 to 285.0)	42.4 (-46.3 to 286.6)
Chronic respiratory diseases	-	-	-	-	23.7 (16.3 to 32.8)	21.5 (14.9 to 29.4)	-9.1 (-21.7 to 7.3)	0.1 (-14.1 to 18.6)
Chronic obstructive pulmonary disease	233.7 (222.8 to 245.4)	225.7 (215.5 to 236.1)	-3.4 (-6.3 to 0.7)	-0.5 (-3.3 to 2.4)	14.8 (9.5 to 21.5)	13.9 (9.3 to 19.8)	-6.1 (-23.0 to 19.4)	-2.5 (-20.9 to 24.

Appendix Table G.4 - Georgia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.5 (-15.8 to -9.3)	-12.5 (-15.6 to -9.8)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.6 (-7.0 to 2.3)	-2.6 (-7.0 to 1.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.9 (-7.3 to 2.1)	-2.9 (-7.3 to 1.6)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-17.7 (-21.3 to -13.8)	-17.7 (-20.8 to -14.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.8 (-21.5 to -13.7)	-17.8 (-20.9 to -14.2)
Asthma	181.1 (152.7 to 202.0)	147.3 (133.0 to 162.3)	-18.8 (-29.0 to -5.6)	2.0 (-11.0 to 19.9)	8.0 (5.3 to 11.4)	6.4 (4.2 to 9.4)	-19.3 (-29.7 to -6.4)	2.0 (-10.9 to 19.7)
Interstitial lung disease and pulmonary sarcoidosis	0.6 (0.5 to 0.8)	0.5 (0.4 to 0.7)	-12.1 (-41.6 to 24.3)	-3.3 (-34.8 to 36.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-11.3 (-40.3 to 24.8)	-3.3 (-34.2 to 36.6)
Other chronic respiratory diseases	-	-	-	-	0.9 (0.5 to 1.4)	1.1 (0.7 to 1.8)	17.7 (-19.3 to 132.2)	20.6 (-16.2 to 139.6)
Cirrhosis	-	-	-	-	0.7 (0.5 to 1.0)	0.6 (0.4 to 0.8)	-11.4 (-22.0 to 0.3)	0.1 (-11.3 to 12.7)
Cirrhosis due to hepatitis B	1.8 (1.4 to 2.2)	1.5 (1.1 to 1.9)	-15.8 (-38.0 to 12.3)	-6.3 (-31.2 to 24.8)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.4)	-16.0 (-40.5 to 18.7)	-5.9 (-35.1 to 30.7)
Cirrhosis due to hepatitis C	1.0 (0.5 to 1.3)	0.8 (0.5 to 1.2)	-18.6 (-50.1 to 75.1)	-8.2 (-42.1 to 93.5)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-18.7 (-52.8 to 76.2)	-7.8 (-44.7 to 94.8)
Cirrhosis due to alcohol use	0.9 (0.7 to 1.2)	0.9 (0.5 to 1.3)	0.8 (-41.0 to 50.8)	5.9 (-39.1 to 58.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	1.5 (-42.8 to 58.3)	6.9 (-40.1 to 69.0)
Cirrhosis due to other causes	0.5 (0.4 to 0.6)	0.5 (0.4 to 0.6)	-7.0 (-35.9 to 39.5)	-20.2 (-16.3 to 77.9)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-9.1 (-41.1 to 49.9)	17.7 (-22.9 to 90.1)
Digestive diseases	-	-	-	-	5.4 (3.9 to 7.3)	5.5 (3.9 to 7.2)	1.0 (-5.9 to 8.3)	5.7 (-1.8 to 13.8)
Peptic ulcer disease	48.3 (45.0 to 51.2)	31.2 (30.3 to 32.2)	-35.6 (-39.5 to -30.0)	-39.1 (-42.7 to -34.2)	1.5 (1.0 to 2.1)	1.0 (0.7 to 1.4)	-33.9 (-42.2 to -26.2)	-39.1 (-46.3 to -32.4)
Gastritis and duodenitis	9.1 (8.2 to 9.9)	8.4 (7.4 to 9.4)	-6.6 (-20.5 to 6.3)	3.3 (-11.9 to 18.5)	0.5 (0.4 to 0.8)	0.4 (0.3 to 0.6)	-19.4 (-31.0 to -4.0)	-3.6 (-17.7 to 17.9)
Appendicitis	0.5 (0.4 to 0.6)	0.3 (0.3 to 0.4)	-27.2 (-41.1 to -9.0)	0.6 (-21.0 to 26.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-26.9 (-49.3 to 3.2)	0.8 (-30.3 to 45.8)
Paralytic ileus and intestinal obstruction	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	1.5 (-13.7 to 21.6)	4.0 (-11.9 to 27.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.2 (-23.9 to 33.1)	4.0 (-21.3 to 41.3)
Inguinal, femoral, and abdominal hernia	31.3 (26.5 to 36.7)	28.1 (23.8 to 33.0)	-10.7 (-27.7 to 14.4)	-12.8 (-28.8 to 9.6)	0.3 (0.2 to 0.6)	0.3 (0.1 to 0.5)	-10.9 (-28.6 to 14.5)	-12.4 (-29.0 to 11.7)
Inflammatory bowel disease	7.6 (7.3 to 7.9)	9.5 (9.1 to 9.8)	24.0 (17.7 to 30.7)	34.9 (28.1 to 42.2)	1.6 (1.1 to 2.2)	2.0 (1.4 to 2.7)	23.4 (14.6 to 33.4)	35.3 (25.6 to 45.8)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	10.8 (-21.7 to 80.2)	-3.9 (-30.7 to 53.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.4 (-38.1 to 96.3)	-3.2 (-43.0 to 73.2)
Gallbladder and biliary diseases	7.4 (6.3 to 8.5)	6.2 (5.4 to 7.1)	-16.0 (-29.5 to 3.4)	-18.7 (-31.2 to -0.7)	0.6 (0.5 to 1.1)	0.6 (0.4 to 0.9)	-16.5 (-31.1 to 3.0)	-18.6 (-32.3 to -0.1)
Pancreatitis	1.5 (1.5 to 1.6)	2.1 (2.0 to 2.2)	38.0 (29.5 to 46.5)	46.5 (37.4 to 55.5)	0.5 (0.3 to 0.6)	0.6 (0.4 to 0.8)	37.1 (29.1 to 45.2)	46.5 (29.1 to 70.2)
Other digestive diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.5)	420.0 (109.4 to 543.6)	445.7 (119.8 to 579.4)
Neurological disorders	-	-	-	-	51.5 (34.3 to 71.1)	48.7 (33.1 to 66.3)	-5.4 (-16.1 to 5.2)	5.8 (-6.3 to 18.1)
Alzheimer disease and other dementias	45.6 (39.8 to 51.1)	60.5 (52.4 to 68.1)	32.8 (11.1 to 60.4)	-9.2 (-16.5 to 20.6)	9.0 (4.8 to 8.6)	9.0 (6.3 to 11.8)	34.9 (12.4 to 64.4)	-9.2 (-17.1 to 21.4)
Parkinson disease	2.9 (2.4 to 3.3)	3.3 (2.8 to 3.8)	16.6 (9.5 to 23.0)	0.4 (-4.7 to 5.7)	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.5)	15.9 (1.4 to 30.3)	0.5 (-11.2 to 12.9)
Epilepsy	22.7 (15.3 to 30.2)	19.4 (13.4 to 25.8)	-15.4 (-46.3 to 41.2)	6.1 (-33.1 to 77.7)	7.0 (4.2 to 10.8)	6.2 (3.6 to 9.2)	-11.8 (-45.6 to 50.3)	11.7 (-31.4 to 89.7)
Multiple sclerosis	1.3 (1.2 to 1.4)	1.4 (1.3 to 1.6)	10.6 (-3.0 to 26.7)	24.9 (9.8 to 43.3)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.6)	8.9 (-10.2 to 35.9)	23.7 (2.2 to 54.2)
Migraine	855.1 (779.9 to 934.6)	699.3 (616.5 to 765.7)	-18.5 (-30.6 to -7.7)	1.4 (-15.9 to 12.4)	23.6 (17.3 to 43.7)	23.6 (14.0 to 34.2)	-1.1 (-31.3 to -8.6)	-1.1 (-16.4 to 12.1)
Tension-type headache	1,276.4 (1,194.7 to 1,371.7)	1,065.5 (937.0 to 1,181.4)	-16.1 (-27.9 to -6.2)	0.5 (-14.1 to 12.9)	1.9 (0.9 to 3.4)	1.6 (0.8 to 2.9)	-16.4 (-28.3 to -6.1)	0.7 (-14.4 to 13.7)
Medication overuse headache	37.0 (24.3 to 49.5)	47.1 (31.0 to 62.2)	26.9 (-2.2 to 64.6)	46.3 (11.7 to 89.0)	5.8 (3.2 to 9.0)	7.4 (4.2 to 11.2)	26.9 (-3.7 to 64.5)	46.4 (11.3 to 88.5)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.2 (-35.6 to 24.8)	5.4 (-25.7 to 41.6)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	11.6 (-26.9 to 57.2)	-13.5 (-42.9 to 22.5)
Mental and substance use disorders	-	-	-	-	119.8 (86.6 to 157.1)	100.5 (72.4 to 131.4)	-16.1 (-48.4 to -13.8)	1.9 (-0.8 to 4.7)
Schizophrenia	17.3 (15.9 to 18.6)	14.7 (13.5 to 15.9)	-14.8 (-18.3 to -11.1)	-0.8 (-4.5 to 3.6)	11.1 (8.2 to 13.4)	9.5 (7.0 to 11.5)	-15.2 (-19.8 to -9.4)	0.6 (-6.1 to 5.8)
Alcohol use disorders	53.8 (47.1 to 60.5)	68.7 (62.7 to 76.1)	27.6 (17.7 to 40.3)	57.5 (44.8 to 73.1)	5.4 (3.6 to 7.9)	6.9 (4.6 to 9.9)	27.8 (16.7 to 41.2)	58.0 (44.0 to 75.1)
Drug use disorders	-	-	-	-	6.8 (4.6 to 9.2)	5.3 (3.7 to 7.1)	-21.4 (-30.9 to -11.8)	0.1 (-11.8 to 12.3)
Opioid use disorders	6.7 (5.0 to 8.4)	5.4 (4.3 to 6.6)	-18.8 (-26.7 to -6.8)	1.6 (-7.4 to 15.7)	2.8 (1.8 to 3.9)	2.3 (1.5 to 3.1)	-18.6 (-28.9 to -4.5)	2.3 (-10.4 to 18.9)
Cocaine use disorders	4.1 (3.6 to 4.6)	3.2 (2.8 to 3.6)	-22.3 (-33.9 to -6.4)	0.6 (-17.3 to 17.9)	0.4 (0.4 to 0.8)	0.4 (0.3 to 0.6)	-22.3 (-38.9 to 2.5)	2.0 (-23.8 to 22.5)
Amphetamine use disorders	9.8 (9.2 to 10.5)	7.5 (7.0 to 8.0)	-23.5 (-31.2 to -15.3)	-0.9 (-11.0 to 9.7)	1.3 (0.8 to 1.9)	1.0 (0.6 to 1.5)	-23.6 (-34.6 to -10.7)	-0.8 (-15.2 to 15.7)
Cannabis use disorders	9.2 (8.5 to 9.9)	6.9 (6.4 to 7.4)	-25.3 (-25.8 to -24.7)	0.0 (-0.0 to 0.0)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-25.0 (-35.7 to -13.9)	0.4 (-13.7 to 15.6)
Other drug use disorders	-	-	-	-	1.9 (1.2 to 2.8)	1.4 (0.9 to 2.1)	-24.0 (-43.5 to 2.0)	-2.4 (-27.1 to 32.0)
Depressive disorders	-	-	-	-	40.3 (33.0 to 69.0)	41.8 (27.8 to 58.5)	-15.2 (-20.0 to -10.3)	0.2 (-5.9 to 5.1)
Major depressive disorder	200.7 (160.6 to 237.9)	170.2 (132.9 to 202.7)	-15.3 (-21.5 to -9.5)	-0.3 (-7.1 to 5.7)	41.2 (26.8 to 58.8)	34.7 (22.5 to 49.6)	-15.9 (-21.8 to -10.1)	-0.3 (-7.1 to 6.3)
Dysthymia	83.7 (68.9 to 97.2)	74.6 (61.7 to 86.1)	-9.9 (-12.6 to -8.9)	8.1 (-0.4 to -0.1)	7.1 (5.2 to 11.8)	7.1 (4.7 to 10.4)	-11.3 (-14.1 to -8.6)	-0.2 (-2.5 to 2.1)
Bipolar disorder	39.3 (34.3 to 44.3)	33.5 (29.6 to 37.5)	-14.7 (-18.6 to -10.5)	0.2 (-4.3 to 5.0)	8.0 (5.0 to 12.0)	6.8 (4.2 to 10.1)	-15.3 (-20.2 to -9.3)	0.1 (-5.8 to 6.9)
Anxiety disorders	189.0 (138.7 to 200.5)	137.6 (111.8 to 161.7)	-28.5 (-40.4 to -16.3)	0.3 (-0.5 to -0.2)	15.5 (10.5 to 22.4)	12.6 (8.4 to 17.9)	-18.1 (-21.9 to -15.9)	-0.4 (-3.1 to 2.4)
Eating disorders	-	-	-	-	1.3 (0.8 to 2.0)	1.0 (0.6 to 1.5)	-26.8 (-33.5 to -20.6)	0.3 (-7.9 to 8.4)
Anorexia nervosa	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-22.6 (-29.0 to -12.4)	8.3 (-0.4 to 22.4)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-22.3 (-44.6 to 6.8)	8.9 (-22.4 to 50.9)
Bulimia nervosa	5.7 (4.0 to 7.6)	4.1 (2.9 to 5.6)	-27.2 (-29.1 to -25.3)	-0.3 (-0.6 to -0.0)	1.2 (0.7 to 1.9)	0.9 (0.5 to 1.4)	-27.3 (-33.7 to -20.6)	-0.3 (-8.5 to 8.2)
Autistic spectrum disorders	-	-	-	-	6.3 (4.4 to 8.5)	4.8 (3.3 to 6.6)	-27.7 (-25.3 to -20.1)	0.7 (-2.6 to 4.1)
Autism	16.2 (15.3 to 17.0)	12.6 (11.9 to 13.3)	-22.1 (-22.6 to -21.7)	0.6 (0.6 to 0.7)	4.0 (2.7 to 5.5)	3.1 (2.1 to 4.2)	-22.8 (-26.2 to -19.2)	0.5 (-3.9 to 5.3)
Asperger syndrome	22.9 (21.5 to 24.3)	17.8 (16.6 to 19.0)	-22.3 (-22.9 to -21.7)	0.8 (0.8 to 0.8)	2.3 (1.6 to 3.2)	1.8 (1.2 to 2.5)	-22.7 (-25.5 to -19.7)	0.9 (-2.9 to 4.8)
Attention-deficit/hyperactivity disorder	26.8 (24.7 to 28.9)	16.7 (15.3 to 18.0)	-37.9 (-38.3 to -37.7)	1.1 (1.0 to 1.1)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-37.9 (-42.2 to -33.3)	1.2 (-6.0 to 8.4)
Conduct disorder	39.0 (35.8 to 41.4)	23.3 (21.7 to 24.6)	-40.7 (-41.2 to -40.0)	1.0 (0.9 to 1.1)	4.7 (2.9 to 6.8)	1.6 (1.8 to 4.1)	-40.6 (-43.3 to -37.6)	3.1 (-3.4 to 5.9)
Idiopathic intellectual disability	83.0 (67.9 to 99.8)	52.8 (43.1 to 64.3)	-36.5 (-42.9 to -29.5)	-17.3 (-25.7 to -8.1)	2.6 (2.6 to 5.8)	2.6 (1.7 to 3.6)	-36.5 (-43.0 to -29.5)	-0.4 (-2.7 to 7.7)
Other mental and substance use disorders	94.0 (88.3 to 99.6)	84.4 (79.5 to 89.4)	-10.2 (-11.2 to -9.1)	0.4 (0.1 to 0.6)	7.0 (4.7 to 9.4)	6.3 (4.3 to 8.4)	-10.6 (-13.8 to -7.1)	0.5 (-3.1 to 4.3)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	59.1 (41.4 to 79.5)	65.3 (46.3 to 88.7)	10.5 (-1.2 to 22.8)	21.1 (9.0 to 33.7)
Diabetes mellitus	343.0 (284.9 to 403.1)	467.1 (393.3 to 545.2)	36.3 (9.4 to 66.9)	48.3 (19.7 to 79.4)	27.4 (18.1 to 38.6)	37.2 (25.2 to 51.7)	36.4 (8.3 to 65.1)	45.9 (16.4 to 75.3)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Chronic kidney disease	-	-	-	-	13.0 (9.3 to 17.0)	12.0 (8.8 to 15.3)	-8.3 (-18.1 to 3.3)	0.4 (-10.5 to 12.7)
Chronic kidney disease due to diabetes mellitus	41.4 (26.6 to 64.3)	40.9 (30.3 to 62.7)	-1.3 (-24.3 to 40.3)	-0.8 (-21.5 to 39.8)	2.3 (1.5 to 3.4)	2.6 (1.7 to 3.7)	-11.9 (-18.4 to 66.3)	11.9 (-15.0 to 65.9)
Chronic kidney disease due to hypertension	63.3 (43.1 to 88.5)	45.6 (29.3 to 71.9)	-28.5 (-47.5 to -6.2)	-15.6 (-38.1 to 7.7)	3.6 (2.5 to 5.1)	1.5 (1.0 to 2.0)	-59.6 (-67.7 to -46.4)	57.0 (-67.5 to -43.1)
Chronic kidney disease due to glomerulonephritis	67.3 (45.1 to 103.5)	33.5 (25.3 to 45.5)	-50.2 (-62.1 to -34.6)	-41.2 (-55.0 to -22.5)	2.8 (1.9 to 3.8)	2.8 (1.9 to 3.8)	-11.1 (-26.6 to 34.8)	17.9 (-10.5 to 61.0)
Chronic kidney disease due to other causes	83.9 (55.6 to 131.8)	91.0 (65.4 to 130.2)	8.5 (-16.1 to 47.5)	20.9 (-5.4 to 57.7)	4.2 (2.7 to 5.7)	5.1 (3.7 to 6.8)	20.2 (-4.5 to 61.1)	29.9 (5.6 to 75.2)
Urinary diseases and male infertility	-	-	-	-	4.1 (2.7 to 5.9)	5.0 (3.3 to 7.1)	20.7 (7.9 to 33.3)	13.6 (1.8 to 24.6)

Appendix Table G.4 - Georgia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.5 (1.4 to 1.6)	1.5 (1.4 to 1.7)	4.4 (5.8 to 16.7)	0.0 (14.3 to 43.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	3.6 (-14.9 to 26.3)	0.0 (4.8 to 55.3)
Urolithiasis	40.3 (29.7 to 53.1)	46.7 (32.6 to 65.7)	13.8 (-1.3 to 36.7)	6.6 (-7.5 to 32.4)	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	-2.2 (-12.7 to 14.2)	-1.2 (-10.4 to 16.2)
Benign prostatic hyperplasia	95.3 (89.1 to 101.8)	117.5 (108.4 to 127.3)	23.3 (11.9 to 36.5)	3.4 (1.8 to 23.9)	4.2 (2.2 to 4.9)	4.2 (2.7 to 6.1)	0.0 (11.4 to 36.3)	0.0 (2.1 to 24.0)
Male infertility due to other causes	27.8 (21.3 to 34.5)	21.5 (16.1 to 27.5)	-23.2 (-46.1 to 13.6)	0.3 (-29.8 to 48.1)	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.3)	-23.0 (-46.8 to 13.0)	0.3 (-30.8 to 46.6)
Other urinary diseases	-	-	-	-	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	391.9 (-15.2 to 471.6)	313.9 (-11.9 to 489.7)
Gynecological diseases	-	-	-	-	6.9 (4.4 to 10.5)	5.8 (3.8 to 8.9)	-15.0 (-26.5 to -3.6)	2.2 (-11.6 to 15.6)
Uterine fibroids	120.3 (109.4 to 130.2)	111.3 (102.2 to 120.2)	-7.5 (-8.5 to -6.3)	1.6 (1.6 to 1.7)	1.5 (0.9 to 2.6)	1.4 (0.8 to 2.3)	-12.0 (-17.4 to -7.8)	0.3 (-5.0 to 5.2)
Polycystic ovarian syndrome	95.7 (84.9 to 107.4)	80.2 (72.1 to 88.7)	-16.0 (-27.9 to -3.3)	2.3 (-11.9 to 17.4)	0.9 (0.4 to 1.7)	0.8 (0.4 to 1.5)	-16.3 (-28.3 to -3.4)	2.3 (-12.0 to 17.7)
Female infertility due to other causes	20.7 (8.2 to 37.9)	14.4 (4.9 to 26.6)	-30.4 (-80.9 to 107.1)	-4.4 (-75.0 to 171.7)	0.1 (0.0 to 0.3)	0.2 (0.0 to 0.2)	-31.3 (-79.6 to 96.0)	8.9 (-73.5 to 156.9)
Endometriosis	10.0 (8.5 to 11.5)	8.8 (7.6 to 10.2)	-11.7 (-27.9 to 8.2)	6.3 (-13.4 to 30.2)	0.9 (0.6 to 1.3)	0.8 (0.5 to 1.2)	-11.9 (-29.7 to 10.3)	6.2 (-15.3 to 32.4)
Genital prolapse	307.7 (274.0 to 343.7)	273.1 (242.4 to 302.5)	-10.9 (-25.9 to 5.2)	0.8 (-17.5 to 19.7)	1.0 (0.5 to 1.8)	0.9 (0.4 to 1.6)	-10.9 (-26.5 to 5.7)	0.9 (-18.1 to 20.4)
Premenstrual syndrome	229.0 (163.7 to 303.9)	182.7 (129.6 to 238.2)	-21.1 (-48.4 to 22.6)	2.0 (-35.7 to 57.3)	1.9 (1.1 to 3.1)	1.5 (0.8 to 2.4)	-29.2 (-49.0 to 23.1)	2.2 (-36.1 to 57.6)
Other gynecological diseases	16.8 (14.5 to 19.2)	14.2 (12.9 to 15.7)	-15.1 (-27.5 to 0.3)	3.2 (-11.9 to 22.3)	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.6)	-15.0 (-30.2 to 15.9)	3.1 (-15.9 to 39.6)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	5.5 (3.6 to 8.1)	3.9 (2.6 to 5.7)	-29.8 (-40.5 to -16.9)	2.7 (-17.2 to 11.8)
Thalassemias	0.3 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-42.1 (-48.2 to -34.9)	-8.4 (-17.7 to 2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.6 (-65.7 to -13.1)	-15.0 (-46.0 to 40.2)
Thalassemia trait	154.5 (146.0 to 172.1)	121.2 (114.5 to 132.4)	-21.5 (-30.1 to -13.9)	-1.3 (-12.6 to 6.8)	4.8 (3.2 to 7.0)	3.4 (2.3 to 5.0)	-29.3 (-41.0 to -16.3)	-2.2 (-18.3 to 11.9)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-44.9 to -28.7)	-8.8 (-19.8 to 3.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.2 (-48.8 to -28.8)	-13.3 (-25.8 to 2.8)
Sickle cell trait	4.4 (4.0 to 4.7)	3.1 (2.8 to 3.2)	-31.0 (-37.3 to -21.1)	-11.8 (-20.0 to 8.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-43.3 (-66.2 to 18.3)	8.7 (-17.0 to 86.0)
G6PD deficiency	10.2 (9.5 to 10.9)	9.4 (8.9 to 9.8)	-8.0 (-15.1 to -0.0)	16.5 (7.6 to 26.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.2 (-36.6 to -0.0)	0.0 (-8.2 to 37.7)
G6PD trait	639.1 (631.5 to 645.5)	516.5 (510.5 to 521.7)	-19.2 (-20.7 to -17.7)	-0.5 (-2.4 to 1.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-23.1 (-88.4 to 545.4)	4.1 (-85.3 to 752.9)
Other hemoglobinopathies and hemolytic anemias	22.4 (17.7 to 27.4)	17.3 (15.6 to 19.3)	-23.0 (-39.8 to 2.5)	0.6 (-24.8 to 30.3)	0.4 (0.3 to 0.9)	0.4 (0.2 to 0.6)	-32.2 (-54.4 to 31.7)	-4.1 (-36.4 to 82.2)
Endocrine, metabolic, blood, and immune disorders	65.1 (59.2 to 70.9)	46.5 (44.6 to 48.3)	-28.6 (-34.5 to -21.6)	9.1 (-16.8 to -0.1)	2.2 (1.5 to 3.0)	1.5 (1.0 to 2.1)	-31.0 (-36.5 to -20.2)	-10.8 (-18.1 to 2.9)
Musculoskeletal disorders	-	-	-	-	93.2 (66.5 to 124.7)	87.9 (63.8 to 116.5)	-5.8 (-12.6 to 2.6)	-0.5 (-8.0 to 8.7)
Rheumatoid arthritis	9.7 (9.2 to 10.1)	10.5 (9.8 to 11.0)	8.0 (0.7 to 16.8)	14.3 (6.8 to 23.4)	2.3 (1.6 to 3.1)	2.4 (1.7 to 3.3)	6.1 (-3.4 to 18.2)	13.9 (3.6 to 26.2)
Osteoarthritis	281.5 (269.6 to 293.0)	304.1 (291.7 to 316.2)	8.0 (2.0 to 14.4)	0.3 (-5.2 to 6.1)	17.2 (12.1 to 23.9)	7.2 (3.1 to 25.4)	7.2 (11.1 to 13.8)	0.2 (-5.4 to 6.3)
Low back and neck pain	-	-	-	-	60.1 (41.6 to 81.1)	53.8 (37.7 to 72.1)	-10.3 (-20.6 to 1.9)	-1.9 (-13.0 to 12.4)
Low back pain	307.3 (289.3 to 326.2)	285.1 (266.9 to 303.7)	-7.3 (-14.7 to 1.7)	-0.2 (-8.1 to 9.5)	34.1 (22.9 to 47.3)	31.4 (21.3 to 43.4)	-8.0 (-15.8 to 1.1)	-0.1 (-8.6 to 9.9)
Neck pain	264.7 (206.9 to 311.3)	229.6 (192.5 to 265.8)	-13.6 (-31.6 to 14.2)	-5.1 (-24.7 to 28.4)	26.0 (17.1 to 37.4)	22.4 (15.0 to 31.8)	-14.2 (-32.0 to 13.7)	-5.2 (-24.6 to 29.2)
Gout	4.3 (4.1 to 4.6)	4.5 (4.2 to 4.7)	2.9 (-4.7 to 11.4)	2.9 (-4.8 to 11.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	2.5 (-16.2 to 25.8)	3.0 (-15.2 to 26.3)
Other musculoskeletal disorders	146.4 (112.8 to 180.7)	142.2 (110.8 to 174.4)	-2.7 (-11.8 to 7.1)	2.6 (-6.4 to 11.5)	6.8 (8.7 to 19.6)	6.8 (8.3 to 18.8)	-1.0 (-12.5 to 6.9)	-0.2 (-6.7 to 12.4)
Other non-communicable diseases	-	-	-	-	97.0 (64.9 to 139.4)	86.8 (59.0 to 124.1)	-10.7 (-13.2 to -7.0)	-5.8 (-8.6 to -2.3)
Congenital anomalies	-	-	-	-	5.2 (3.7 to 6.7)	4.9 (3.6 to 6.5)	-4.2 (-19.2 to 13.5)	23.6 (3.9 to 46.6)
Neural tube defects	1.2 (1.0 to 1.4)	1.1 (1.0 to 1.3)	-7.7 (-25.9 to 14.9)	27.2 (2.1 to 58.1)	0.4 (0.3 to 0.6)	0.4 (0.2 to 0.5)	-6.1 (-34.3 to 28.5)	30.1 (-7.6 to 77.5)
Congenital heart anomalies	20.0 (16.0 to 27.2)	23.0 (19.3 to 28.9)	17.1 (-22.1 to 55.3)	55.3 (3.2 to 105.9)	0.7 (0.3 to 1.2)	0.8 (0.3 to 1.4)	16.8 (-20.4 to 54.1)	55.3 (6.0 to 106.0)
Orofacial clefts	3.0 (2.3 to 3.8)	3.2 (2.6 to 3.9)	6.0 (-23.8 to 51.8)	6.0 (3.8 to 106.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-38.3 to 42.0)	25.0 (-16.9 to 93.7)
Down syndrome	5.1 (4.2 to 5.9)	4.8 (3.9 to 6.0)	-6.3 (-28.8 to 26.0)	17.8 (-10.2 to 57.7)	0.7 (0.5 to 0.9)	0.7 (0.5 to 1.0)	0.1 (-24.9 to 39.6)	20.6 (-8.7 to 67.8)
Turner syndrome	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-19.4 (-47.1 to 14.9)	6.3 (-30.2 to 51.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.7 (-48.0 to 21.5)	5.5 (-32.4 to 58.9)
Klinefelter syndrome	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-19.7 (-42.0 to 13.0)	4.9 (-24.4 to 47.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.9 (-40.7 to 16.2)	4.0 (-25.1 to 46.0)
Chromosomal unbalanced rearrangements	17.8 (6.5 to 9.7)	18.2 (6.0 to 8.5)	2.2 (-28.6 to 19.4)	-7.1 (-10.5 to 49.6)	1.0 (0.7 to 1.5)	1.0 (0.7 to 1.4)	-16.7 (-24.6 to 26.7)	20.1 (-9.5 to 53.1)
Other congenital anomalies	19.0 (15.9 to 21.9)	13.2 (11.3 to 15.2)	-30.8 (-38.9 to -21.6)	-14.7 (-24.3 to -3.9)	2.3 (1.5 to 3.2)	2.0 (1.3 to 2.8)	-12.5 (-32.9 to 16.9)	14.9 (-11.5 to 53.5)
Skin and subcutaneous diseases	-	-	-	-	25.0 (16.2 to 37.2)	19.5 (12.9 to 28.8)	-22.2 (-28.3 to -15.8)	-5.6 (-12.6 to 2.4)
Dermatitis	225.1 (183.0 to 268.9)	184.3 (150.0 to 218.7)	-18.2 (-19.6 to -16.4)	-0.1 (-0.1 to -0.0)	5.4 (3.3 to 7.9)	4.4 (2.7 to 6.4)	-18.9 (-21.5 to -16.2)	-0.0 (-2.8 to 2.9)
Psoriasis	46.7 (41.4 to 52.0)	40.1 (35.3 to 44.8)	-14.1 (-15.5 to -12.4)	0.0 (-0.1 to 0.2)	3.9 (2.6 to 5.3)	3.2 (2.2 to 4.6)	-18.6 (-19.2 to -9.5)	0.2 (-5.2 to 5.6)
Cellulitis	2.0 (1.6 to 2.5)	1.6 (1.2 to 2.0)	-20.2 (-28.1 to -10.9)	-5.2 (-15.2 to 5.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-20.9 (-35.6 to -4.3)	-5.8 (-23.0 to 16.4)
Pyoderma	5.3 (4.4 to 6.4)	4.8 (4.0 to 6.0)	-9.1 (-15.0 to -2.8)	9.0 (4.6 to 13.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-10.2 (-18.8 to -0.2)	8.8 (0.3 to 19.1)
Scabies	15.1 (11.7 to 18.0)	10.8 (9.3 to 12.5)	-28.3 (-42.9 to -8.6)	-5.5 (-25.7 to 19.8)	0.4 (0.2 to 0.6)	0.3 (0.2 to 0.5)	-28.8 (-43.9 to -13.1)	-5.6 (-26.1 to 22.0)
Fungal skin diseases	43.4 (38.7 to 567.6)	36.6 (28.7 to 467.2)	-16.3 (-19.3 to -12.8)	0.2 (0.1 to 0.3)	2.4 (1.0 to 5.3)	2.0 (0.8 to 4.4)	-16.7 (-19.8 to -13.2)	0.2 (-0.6 to 1.2)
Viral skin diseases	113.5 (87.0 to 140.5)	81.6 (61.2 to 102.8)	-28.2 (-30.9 to -25.5)	0.1 (-1.9 to 2.1)	3.5 (2.0 to 5.5)	2.5 (1.4 to 3.9)	-28.5 (-31.8 to -25.2)	0.0 (-2.9 to 3.6)
Acne vulgaris	123.1 (92.4 to 152.4)	85.6 (64.4 to 101.5)	-29.5 (-52.7 to -0.8)	0.9 (-33.7 to 42.0)	1.3 (0.6 to 2.6)	0.9 (0.4 to 1.7)	-29.6 (-52.5 to -0.7)	0.9 (-33.9 to 43.1)
Alopecia areata	6.5 (5.6 to 7.3)	5.9 (5.2 to 6.6)	-8.8 (-23.8 to 8.4)	3.4 (-13.5 to 22.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-8.8 (-26.3 to 10.3)	3.2 (-14.8 to 26.6)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.1 (-30.2 to 11.9)	-1.1 (-21.3 to 24.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.1 (-30.2 to 11.9)	-1.1 (-21.3 to 24.2)
Urticaria	93.2 (71.8 to 117.7)	63.7 (49.2 to 79.4)	-31.6 (-52.7 to -2.7)	-23.3 (-47.0 to 10.6)	3.7 (3.3 to 8.4)	3.7 (2.3 to 5.6)	-32.2 (-53.5 to -3.5)	-23.6 (-47.7 to 10.6)
Decubitus ulcer	0.3 (0.3 to 0.4)	0.3 (0.2 to 0.4)	-12.8 (-36.9 to 30.4)	-4.3 (-31.2 to 32.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-12.8 (-39.6 to 32.2)	-3.6 (-31.8 to 38.4)
Other skin and subcutaneous diseases	377.0 (227.9 to 624.4)	343.9 (197.7 to 589.9)	-9.4 (-16.6 to -2.0)	-2.7 (-6.5 to 1.8)	2.2 (0.9 to 4.9)	2.0 (0.8 to 4.5)	-9.7 (-16.8 to -2.6)	-2.7 (-6.8 to 2.0)
Sense organ diseases	-	-	-	-	51.3 (34.5 to 73.2)	47.9 (32.7 to 67.2)	-7.7 (-9.8 to -2.8)	-9.8 (-13.1 to -6.6)
Glaucoma	9.7 (8.0 to 11.6)	8.5 (6.8 to 10.0)	-12.8 (-25.7 to 0.8)	-17.4 (-28.7 to -4.6)	0.7 (0.5 to 1.0)	0.7 (0.4 to 1.0)	-3.7 (-17.2 to 12.9)	-13.2 (-24.8 to -0.3)
Cataract	69.7 (55.4 to 83.7)	59.0 (47.1 to 73.4)	-15.6 (-28.6 to 4.2)	-30.2 (-39.9 to -13.6)	2.4 (1.5 to 3.6)	2.0 (1.2 to 3.1)	-14.3 (-26.9 to 2.1)	-29.6 (-38.6 to -15.7)
Macular degeneration	19.5 (14.6 to 25.4)	21.3 (15.6 to 27.5)	10.6 (-20.3 to 36.0)	5.0 (-23.5 to 29.2)	0.6 (0.4 to 1.0)	0.7 (0.4 to 1.1)	9.6 (-18.6 to 34.0)	2.9 (-22.9 to 25.2)
Uncorrected refractive error	666.6 (620.6 to 706.5)	651.1 (608.8 to 694.0)	-2.4 (-10.6 to 6.6)	-2.4 (-10.5 to 5.5)	9.8 (5.6 to 16.2)	8.8 (5.0 to 14.9)	-10.1 (-16.1 to -3.1)	-8.1 (-13.9 to -1.4)
Age-related and other hearing loss	1,020.8 (901.2 to 1,127.1)	961.2 (860.5 to 1,049.5)	-5.9 (-9.9 to -1.2)	-7.7 (-11.2 to -3.8)	32.5 (21.9 to 45.5)	31.7 (21.7 to 43.7)	-2.7 (-7.7 to 3.8)	-2.7 (-13.7 to -3.6)
Other vision loss	39.6 (34.4 to 46.7)	24.4 (20.6 to 28.4)	-38.5 (-45.9 to -30.3)	-33.2 (-40.6 to -25.6)	1.9 (1.3 to 2.7)	1.2 (0.8 to 1.8)	-34.4 (-42.2 to -25.5)	-3.1 (-38.1 to -23.7)
Other sense organ diseases	130.2 (124.0 to 136.0)	107.0 (102.2 to 111.6)	-18.0 (-22.7 to -12.4)	-5.5 (-6.3 to 6.1)	2.8 (2.1 to 5.2)	2.8 (1.7 to 4.2)	-18.7 (-24.1 to -12.3)	-0.6 (-7.0 to 7.0)
Oral disorders	-	-	-	-	15.5 (9.4 to 24.1)	14.4 (8.9 to 22.2)	-6.8 (-10.1 to -3.5)	-2.3 (-5.8 to 1.0)
Deciduous caries	399.4 (381.0 to 396.6)	233.5 (228.3 to 238.1)	-40.0 (-41.8 to -38.4)	1.0 (-2.0 to 3.7)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.2)	-39.9 (-43.5 to -36.5)	1.1 (-5.0 to 6.8)
Permanent caries	2,991.7 (2,878.3 to 3,072.7)	2,409.2 (2,356.2 to 2,457.3)	-19.6 (-21.8 to -16.4)	0.6 (-2.6 to 4.7)	3.0 (1.3 to 5.7)	2.4 (1.1 to 4.6)	-19.9 (-22.3 to -16.6)	0.6 (-2.8 to 4.8)
Periodontal diseases	448.8 (427.4 to 471.8)	427.8 (407.6 to 447.8)	-4.6 (-11.1 to 2.2)	1.8 (-4.9 to 8.9)	2.9 (1.2 to 6.0)	2.8 (1.1 to 5.7)	-5.0 (-11.4 to 1.9)	1.9 (-5.2 to 8.9)

Appendix Table G.4 - Georgia prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Edentulism and severe tooth loss	238.0 (227.5 to 248.1)	247.1 (237.2 to 256.9)	3.8 (-2.1 to 10.1)	-6.1 (-11.4 to -0.8)	6.5 (4.4 to 9.1)	6.8 (4.6 to 9.4)	3.2 (-3.0 to 9.2)	-6.1 (-11.4 to -0.8)
Other oral disorders	100.1 (94.3 to 106.0)	83.7 (78.8 to 88.7)	-16.5 (-23.3 to -8.7)	-0.7 (-8.6 to 8.4)	2.9 (1.8 to 4.4)	2.4 (1.5 to 3.7)	-16.8 (-23.6 to -8.7)	-0.5 (-9.1 to 9.0)
Injuries	-	-	-	-	55.0 (41.4 to 71.6)	41.5 (30.2 to 54.9)	-24.8 (-30.0 to -18.4)	-23.0 (-28.2 to -16.9)
Transport injuries	-	-	-	-	9.1 (6.8 to 11.8)	3.8 (2.7 to 5.0)	-58.7 (-62.2 to -54.8)	-55.5 (-59.2 to -51.4)
Road injuries	-	-	-	-	7.3 (5.9 to 10.2)	2.7 (1.9 to 3.6)	-65.8 (-68.8 to -62.4)	-49.3 (-66.4 to -59.8)
Pedestrian road injuries	-	-	-	-	1.5 (1.1 to 2.0)	0.6 (0.4 to 0.8)	-60.7 (-64.3 to -56.4)	-58.9 (-62.6 to -54.4)
Cyclist road injuries	-	-	-	-	0.9 (0.7 to 1.2)	0.3 (0.2 to 0.4)	-65.3 (-68.0 to -62.2)	-62.9 (-65.7 to -59.7)
Motorcyclist road injuries	-	-	-	-	0.8 (0.6 to 1.0)	0.2 (0.2 to 0.3)	-70.4 (-73.5 to -66.8)	-67.7 (-71.0 to -63.9)
Motor vehicle road injuries	-	-	-	-	4.6 (3.4 to 5.9)	1.5 (1.1 to 2.0)	-66.8 (-70.3 to -63.0)	-64.1 (-67.8 to -60.1)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-68.8 (-71.8 to -66.0)	-66.6 (-69.7 to -63.6)
Other transport injuries	-	-	-	-	1.3 (0.9 to 1.7)	1.1 (0.8 to 1.5)	-14.7 (-22.1 to -6.9)	-7.8 (-15.7 to 0.7)
Unintentional injuries	-	-	-	-	45.1 (33.9 to 58.7)	35.4 (25.8 to 47.3)	-21.7 (-26.7 to -16.7)	-20.2 (-25.3 to -15.0)
Falls	-	-	-	-	32.0 (24.1 to 41.4)	26.1 (18.9 to 35.0)	-18.5 (-24.7 to -12.2)	-19.4 (-25.8 to -12.8)
Drowning	-	-	-	-	0.4 (0.3 to 0.6)	0.2 (0.1 to 0.2)	-57.3 (-61.6 to -52.3)	-52.3 (-56.9 to -46.9)
Fire, heat, and hot substances	-	-	-	-	1.3 (1.0 to 1.7)	0.8 (0.5 to 1.0)	-42.9 (-48.2 to -37.1)	-36.8 (-42.5 to -30.5)
Poisonings	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-48.6 (-55.4 to -40.7)	-38.8 (-47.3 to -29.2)
Exposure to mechanical forces	-	-	-	-	6.8 (5.1 to 9.0)	4.7 (3.5 to 6.4)	-30.9 (-34.7 to -26.5)	-21.9 (-26.2 to -17.3)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-97.0 (-44.2 to -29.2)	-30.5 (-38.0 to -22.5)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-14.5 (-22.6 to -5.8)	-4.9 (-13.8 to 4.5)
Other exposure to mechanical forces	-	-	-	-	6.6 (4.9 to 8.7)	4.6 (3.3 to 6.2)	-31.0 (-34.8 to -26.6)	-21.9 (-26.2 to -17.3)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-0.7 (-6.4 to 6.8)	4.4 (-2.1 to 12.1)
Animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-19.0 (-25.2 to -12.3)	-7.5 (-14.6 to -0.1)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-19.2 (-28.4 to -9.4)	-6.8 (-17.6 to 4.9)
Non-venomous animal contact	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-18.8 (-24.9 to -11.2)	-7.9 (-14.5 to -0.1)
Foreign body	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.3)	-28.3 (-33.4 to -22.6)	-19.9 (-25.6 to -13.8)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-38.7 (-45.9 to -30.3)	-31.1 (-39.0 to -22.1)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-20.3 (-24.5 to -15.5)	-6.6 (-12.0 to -0.4)
Foreign body in other body part	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-23.5 (-29.8 to -17.1)	-16.5 (-23.0 to -9.9)
Other unintentional injuries	-	-	-	-	3.6 (2.7 to 4.8)	2.9 (2.1 to 3.9)	-19.2 (-24.7 to -13.3)	-15.7 (-21.4 to -10.1)
Self-harm and interpersonal violence	-	-	-	-	0.8 (0.6 to 1.0)	0.5 (0.4 to 0.7)	-35.9 (-40.8 to -30.1)	-30.3 (-35.5 to -24.3)
Self-harm	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-24.2 (-30.5 to -16.1)	-18.1 (-24.9 to -9.5)
Interpersonal violence	-	-	-	-	0.5 (0.4 to 0.6)	0.3 (0.2 to 0.4)	-43.4 (-48.2 to -37.9)	-38.2 (-43.1 to -32.2)
Assault by firearm	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-36.1 (-41.3 to -29.7)	-30.7 (-36.1 to -24.1)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-36.7 (-42.2 to -30.2)	-30.7 (-36.6 to -23.7)
Assault by other means	-	-	-	-	0.3 (0.3 to 0.4)	0.2 (0.1 to 0.2)	-46.1 (-51.3 to -40.0)	-41.0 (-46.5 to -34.6)
Forces of nature, war, and legal intervention	-	-	-	-	-	1.9 (0.6 to 4.3)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	1.8 (0.6 to 4.3)	-	-

Appendix Table G.4 - Germany prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	11,258.9 (8,412.6 to 14,521.0)	12,566.2 (9,364.6 to 16,114.4)	11.7 (9.1 to 13.9)	11.7 (5.0 to -0.8)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	412.3 (287.3 to 578.8)	410.5 (292.1 to 573.5)	-0.2 (-9.3 to 9.3)	3.3 (-4.1 to 12.0)
HIV/AIDS and tuberculosis	-	-	-	-	11.6 (7.5 to 16.3)	7.2 (4.8 to 10.1)	-4.4 (-51.9 to -22.4)	-43.6 (-56.3 to -30.0)
Tuberculosis	17.5 (16.9 to 18.2)	13.3 (12.6 to 14.0)	-24.0 (-27.3 to -20.8)	-30.9 (-33.9 to -27.8)	5.3 (3.5 to 7.3)	4.0 (2.6 to 5.2)	-1.3 (-38.1 to -10.7)	-30.6 (-43.2 to -16.8)
HIV/AIDS	-	-	-	-	6.3 (3.8 to 9.9)	3.2 (1.8 to 5.2)	-3.1 (-68.8 to -21.4)	-55.7 (-73.4 to -30.7)
HIV/AIDS resulting in mycobacterial infection	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-80.3 (-89.2 to -68.7)	-81.7 (-89.9 to -70.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.1 (-89.3 to -68.7)	-81.7 (-90.4 to -70.9)
HIV/AIDS resulting in other diseases	32.5 (25.6 to 43.8)	41.2 (26.7 to 61.9)	24.9 (8.9 to 75.6)	6.2 (-23.8 to 52.6)	6.2 (3.8 to 9.8)	3.2 (1.8 to 5.2)	-48.9 (-68.8 to -21.2)	-55.6 (-73.4 to -30.4)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	51.6 (33.5 to 74.8)	48.8 (31.8 to 72.2)	-2.8 (-12.3 to 1.2)	-10.1 (-16.3 to -4.4)
Diarrheal diseases	26.0 (23.7 to 28.2)	25.6 (23.4 to 27.6)	-1.6 (-12.5 to 10.6)	-9.1 (-19.5 to 4.2)	4.1 (2.8 to 5.7)	4.0 (2.7 to 5.6)	-0.1 (-17.7 to 16.0)	-49.9 (-23.2 to 11.0)
Intestinal infectious diseases	0.0	0.0	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.4 (-48.6 to -28.4)	-37.4 (-46.4 to -27.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.7 (-36.3 to 15.2)	-6.7 (-30.1 to 20.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Lower respiratory infections	58.7 (44.9 to 76.8)	74.0 (57.1 to 97.5)	26.1 (-6.3 to 64.6)	16.5 (-16.9 to 45.7)	5.6 (3.6 to 8.5)	7.1 (4.5 to 10.8)	25.9 (8.6 to 65.4)	18.7 (-15.3 to 53.8)
Upper respiratory infections	1,180.6 (1,128.5 to 1,230.2)	1,182.5 (1,128.9 to 1,233.4)	-0.0 (-6.3 to 7.8)	0.7 (-5.7 to 7.9)	13.7 (7.8 to 22.9)	13.7 (7.7 to 22.7)	-0.2 (-7.2 to 8.6)	1.0 (-6.5 to 9.1)
Otitis media	977.4 (876.1 to 1,077.4)	879.7 (788.6 to 968.3)	-10.4 (-21.6 to 4.6)	-12.2 (-21.7 to -0.8)	19.1 (11.3 to 30.5)	16.9 (10.0 to 27.1)	-12.2 (-23.6 to 3.0)	-13.8 (-23.7 to -1.1)
Meningitis	-	-	-	-	4.1 (2.9 to 7.2)	2.5 (1.7 to 3.7)	-1.6 (-59.6 to -29.3)	-48.8 (-60.9 to -29.5)
Pneumococcal meningitis	12.6 (7.6 to 21.7)	7.2 (4.1 to 13.1)	-42.2 (-58.4 to -23.1)	-47.6 (-62.0 to -31.4)	1.2 (0.8 to 1.7)	0.7 (0.5 to 1.0)	-0.5 (-57.7 to -22.1)	-43.0 (-61.5 to -24.3)
H influenzae type B meningitis	7.0 (2.0 to 17.0)	3.5 (1.1 to 8.7)	-50.1 (-71.5 to -7.8)	-51.0 (-72.5 to -4.1)	0.9 (0.5 to 1.6)	0.5 (0.3 to 0.8)	-0.4 (-72.7 to 3.6)	-45.2 (-73.1 to 10.7)
Meningococcal meningitis	6.5 (2.1 to 17.0)	3.7 (1.1 to 9.5)	-43.2 (-66.7 to 1.5)	-48.2 (-69.4 to -4.1)	1.0 (0.5 to 1.8)	0.6 (0.3 to 1.2)	-0.4 (-68.6 to 12.4)	-39.4 (-71.6 to 5.7)
Other meningitis	10.7 (4.3 to 24.3)	5.1 (2.1 to 12.3)	-52.3 (-69.7 to -33.4)	-55.5 (-69.7 to -37.8)	1.5 (0.9 to 2.5)	0.7 (0.4 to 1.1)	-0.8 (-70.8 to -32.7)	-56.4 (-71.6 to -33.4)
Encephalitis	4.2 (1.8 to 11.6)	4.6 (2.1 to 13.3)	10.2 (-11.4 to 44.4)	4.9 (-23.3 to 30.7)	0.6 (0.4 to 0.8)	0.7 (0.5 to 1.0)	0.1 (-18.0 to 36.4)	6.8 (-18.0 to 36.4)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Whooping cough	11.8 (9.2 to 15.1)	0.1 (0.1 to 0.2)	-98.8 (-99.1 to -98.4)	-98.5 (-98.9 to -98.1)	0.6 (0.3 to 1.0)	0.0 (0.0 to 0.0)	-0.6 (-99.2 to -98.2)	-98.5 (-99.1 to -97.8)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	37.0 (-75.1 to -12.9)	0.0 (0.0 to 0.0)	-37.0 (-76.6 to -8.0)	-36.7 (-79.5 to -6.9)
Measles	0.0 (0.0 to 0.0)	3,088.0 (0.0 to 0.1)	3,088.0 (3,014.9 to 5,431.8)	4,568.3 (3,702.4 to 6,652.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (3,014.2 to 5,438.8)	4,765.3 (3,701.6 to 6,661.4)
Varicella and herpes zoster	73.5 (65.8 to 82.7)	85.3 (74.2 to 96.9)	16.1 (-3.9 to 37.2)	4.2 (-9.7 to 18.7)	3.1 (1.9 to 4.7)	3.9 (2.4 to 5.9)	24.2 (-1.7 to 55.6)	5.9 (-15.6 to 30.4)
Neglected tropical diseases and malaria	-	-	-	-	1.9 (1.3 to 2.7)	0.7 (0.5 to 1.0)	-1.2 (-73.8 to -48.2)	-68.8 (-77.9 to -57.5)
Malaria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	1.1 (-74.2 to 164.0)	6.1 (-73.3 to 175.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-73.7 to 168.3)	8.3 (-72.8 to 179.9)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Visceral leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Cysticercosis	1.2 (0.3 to 2.3)	0.3 (0.1 to 0.7)	-72.6 (-90.9 to 33.6)	-76.5 (-92.7 to 0.0)	0.5 (0.1 to 1.0)	0.1 (0.1 to 0.3)	-0.4 (-90.3 to 49.0)	-73.9 (-92.2 to 10.7)
Cystic echinococcosis	16.0 (14.9 to 17.6)	6.1 (5.7 to 6.4)	-61.8 (-65.3 to -58.2)	-69.0 (-71.0 to -66.0)	1.5 (1.0 to 2.1)	0.6 (0.4 to 0.8)	-10.4 (-69.9 to -49.7)	-68.3 (-74.8 to -59.3)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.4 (-66.3 to 8.1)	-13.3 (-69.8 to 3.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.4 (-66.4 to 8.2)	-13.3 (-69.9 to 3.6)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Ascariasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trichuriasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Hookworm disease	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	171.3 (-52.7 to 259.3)	160.8 (-57.2 to 241.7)
Maternal disorders	-	-	-	-	1.7 (0.9 to 2.9)	1.2 (0.6 to 2.1)	-0.5 (-56.1 to 4.7)	-15.2 (-44.8 to 28.3)
Maternal hemorrhage	43.3 (32.1 to 54.4)	22.8 (11.7 to 33.0)	-47.0 (-68.3 to -25.1)	-34.7 (-61.7 to -7.8)	0.7 (0.3 to 1.3)	0.3 (0.1 to 0.8)	-0.4 (-81.5 to 17.3)	-42.8 (-76.9 to 45.3)
Maternal sepsis and other maternal infections	5.3 (2.1 to 9.4)	2.3 (0.5 to 5.7)	-56.2 (-92.2 to -42.4)	-57.5 (-90.8 to 41.4)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-0.1 (-76.4 to 18.9)	-45.4 (-71.5 to 41.0)
Maternal hypertensive disorders	10.7 (5.5 to 17.2)	9.2 (4.2 to 15.2)	-13.1 (-38.7 to 6.6)	-12.5 (-22.7 to 30.2)	0.4 (0.2 to 1.0)	0.4 (0.2 to 0.8)	-0.1 (-42.9 to 18.7)	5.7 (-28.7 to 45.4)
Obstructed labor	0.2 (0.0 to 0.3)	0.1 (0.1 to 0.3)	-35.2 (-54.7 to 24.6)	-35.2 (-43.5 to 321.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-0.1 (-54.8 to 247.1)	35.2 (-43.5 to 323.9)
Complications of abortion	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-4.8 (-38.6 to 82.2)	-4.8 (-24.6 to 123.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.8 (-38.8 to 82.5)	16.9 (-24.8 to 124.4)
Other maternal disorders	-	-	-	-	0.3 (0.2 to 0.6)	0.3 (0.1 to 0.5)	-0.1 (-56.7 to 31.9)	-6.3 (-45.3 to 59.7)
Neonatal disorders	-	-	-	-	84.2 (61.5 to 109.3)	112.3 (80.4 to 148.1)	33.1 (6.7 to 71.0)	32.5 (6.4 to 71.2)
Preterm birth complications	482.9 (348.2 to 689.7)	730.5 (513.3 to 1,082.7)	50.9 (24.5 to 83.6)	47.9 (22.8 to 79.2)	55.4 (40.0 to 74.1)	79.5 (56.2 to 106.8)	43.0 (16.1 to 83.1)	43.5 (16.2 to 84.3)
Neonatal encephalopathy due to birth asphyxia and trauma	73.4 (39.5 to 151.4)	48.8 (20.9 to 125.5)	-33.7 (-59.2 to -0.4)	-37.7 (-59.1 to -0.9)	16.0 (10.5 to 22.0)	10.2 (6.4 to 15.5)	-37.1 (-60.9 to 9.1)	-36.1 (-60.4 to 10.6)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	167.7 (4.1 to 32.0)	40.0 (24.8 to 58.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.6 (-17.5 to 63.6)	41.0 (-1.1 to 96.2)
Hemolytic disease and other neonatal jaundice	15.1 (6.2 to 24.9)	19.8 (4.2 to 44.0)	31.0 (-79.5 to 446.5)	13.4 (-79.5 to 438.1)	6.4 (2.7 to 11.4)	8.3 (1.7 to 19.2)	28.5 (-80.4 to 442.0)	11.5 (-80.3 to 433.6)
Other neonatal disorders	-	-	-	-	6.4 (3.6 to 10.5)	14.2 (8.2 to 20.1)	123.3 (27.2 to 305.8)	123.7 (27.5 to 305.0)
Nutritional deficiencies	-	-	-	-	240.1 (156.9 to 360.4)	220.7 (141.6 to 331.4)	-19.4 (-21.5 to 3.9)	-0.4 (-10.9 to 8.1)
Protein-energy malnutrition	0.7 (0.3 to 1.4)	1.1 (0.3 to 2.0)	63.6 (-32.9 to 142.7)	3.2 (-55.7 to 49.4)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	51.5 (-49.1 to 215.5)	-4.0 (-65.1 to 88.1)
Iodine deficiency	1,255.8 (460.7 to 2,403.3)	1,060.7 (423.8 to 1,742.2)	-15.1 (-68.7 to 112.5)	-20.5 (-69.7 to 106.7)	22.4 (7.7 to 48.5)	38.4 (6.9 to 36.7)	-16.2 (-68.7 to 113.1)	-30.5 (-69.6 to 106.4)
Vitamin A deficiency	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Iron deficiency anemia	8,738.0 (8,358.1 to 9,064.6)	8,920.1 (8,374.8 to 9,313.1)	2.1 (-4.8 to 6.9)	2.1 (-3.9 to 6.1)	217.6 (143.2 to 321.9)	202.1 (131.1 to 301.8)	-6.0 (-21.5 to 1.1)	1.3 (-9.6 to 7.3)

Appendix Table G.4 - Germany prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-24.1 (-63.8 to 43.1)	-24.1 (-75.5 to -15.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	21.1 (12.3 to 35.2)	19.8 (11.9 to 33.2)	-6.2 (-27.9 to 17.3)	-0.5 (-31.8 to 35.3)
Sexually transmitted diseases excluding HIV	-	-	-	-	9.5 (4.9 to 17.3)	9.4 (5.1 to 17.3)	-1.2 (-14.4 to 14.5)	0.5 (-13.2 to 20.6)
Syphilis	3.7 (2.8 to 4.5)	6.0 (4.9 to 7.1)	63.9 (26.5 to 119.3)	33.8 (-0.6 to 81.5)	0.7 (0.4 to 1.1)	1.1 (0.7 to 1.7)	-0.4 (-9.7 to 143.6)	4.2 (-13.5 to 104.7)
Chlamydial infection	1,511.6 (1,272.3 to 1,811.4)	1,446.1 (1,209.8 to 1,713.3)	-3.9 (-24.8 to 20.7)	3.9 (-15.9 to 37.9)	3.9 (2.3 to 7.7)	4.2 (2.2 to 7.5)	-0.3 (-25.8 to 25.2)	-0.5 (-11.9 to 42.8)
Gonococcal infection	287.1 (192.8 to 385.4)	208.4 (145.9 to 284.4)	-28.0 (-56.4 to 29.5)	-13.4 (-49.0 to 59.1)	1.0 (0.5 to 1.9)	0.8 (0.4 to 1.4)	-26.0 (-50.8 to 12.6)	-11.9 (-42.4 to 37.3)
Trichomoniasis	262.2 (187.1 to 357.7)	213.0 (142.8 to 290.1)	-18.1 (-49.5 to 26.3)	-13.9 (-48.4 to 41.8)	0.3 (0.1 to 1.0)	0.3 (0.1 to 0.8)	-21.0 (-55.1 to 38.0)	-17.3 (-54.7 to 57.8)
Genital herpes	10,539.2 (9,983.8 to 11,134.5)	11,195.3 (10,453.0 to 11,923.3)	6.4 (-3.3 to 16.2)	-5.7 (-14.5 to 3.2)	2.7 (0.8 to 6.5)	2.8 (0.8 to 6.8)	4.7 (-5.9 to 14.7)	-5.4 (-14.7 to 4.7)
Other sexually transmitted diseases	11.8 (8.2 to 16.5)	6.3 (3.7 to 9.7)	-46.5 (-70.9 to -16.9)	-43.7 (-68.6 to -13.3)	0.2 (0.2 to 0.5)	0.2 (0.1 to 0.4)	-26.0 (-54.5 to 21.9)	-20.5 (-52.5 to 36.0)
Hepatitis	-	-	-	-	2.1 (1.3 to 3.1)	1.9 (1.2 to 2.8)	-7.9 (-17.2 to 4.4)	-8.7 (-18.6 to 2.4)
Hepatitis A	56.9 (54.1 to 59.6)	51.6 (48.8 to 54.3)	-9.3 (-10.0 to -8.9)	-7.7 (-9.0 to -6.4)	1.7 (1.1 to 2.6)	1.6 (1.0 to 2.4)	-6.3 (-16.9 to 5.7)	-6.0 (-16.9 to 5.6)
Hepatitis B	508.8 (444.2 to 582.3)	403.1 (357.8 to 453.7)	-20.7 (-33.6 to -5.3)	-27.5 (-39.5 to -11.6)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.4)	-15.3 (-44.6 to 34.6)	-23.4 (-49.2 to 23.9)
Hepatitis C	298.9 (270.4 to 327.6)	253.9 (232.1 to 276.3)	-14.9 (-25.4 to -3.6)	-26.7 (-35.8 to -16.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-12.3 (-36.8 to 27.1)	-27.1 (-44.9 to -1.0)
Hepatitis E	-	-	-	-	4.5 (3.0 to 8.0)	5.7 (2.8 to 8.0)	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	346.4 (294.0 to 452.0)	331.7 (289.6 to 404.3)	-4.4 (-30.7 to 27.0)	1.7 (-32.1 to 42.4)	9.6 (5.6 to 16.7)	8.5 (5.1 to 14.0)	-10.6 (-48.1 to 43.5)	-0.3 (-47.6 to 73.5)
Non-communicable diseases	-	-	-	-	9,887.5 (7,349.9 to 12,750.0)	11,366.7 (8,406.6 to 14,555.3)	15.0 (12.2 to 17.6)	0.3 (-2.6 to 2.1)
Neoplasms	-	-	-	-	155.8 (116.4 to 197.4)	218.9 (163.1 to 279.6)	40.4 (32.5 to 48.0)	0.6 (-4.9 to 7.3)
Esophageal cancer	6.8 (5.3 to 8.6)	11.2 (8.8 to 14.2)	64.9 (21.3 to 125.9)	21.7 (-11.2 to 69.2)	1.1 (0.7 to 1.5)	1.6 (1.1 to 2.2)	5.2 (18.1 to 104.3)	13.0 (-13.2 to 50.3)
Stomach cancer	56.7 (48.2 to 67.0)	48.7 (41.5 to 57.8)	-14.1 (-27.1 to 0.4)	-40.2 (-48.7 to -30.6)	6.3 (4.5 to 8.3)	5.1 (3.6 to 6.7)	-18.5 (-32.6 to -2.4)	-42.9 (-52.2 to -32.0)
Liver cancer	-	-	-	-	0.8 (0.5 to 1.2)	1.7 (1.0 to 2.5)	134.8 (27.9 to 245.8)	63.9 (-7.1 to 138.2)
Liver cancer due to hepatitis B	0.4 (0.4 to 1.2)	1.5 (0.8 to 2.2)	106.8 (-2.4 to 309.7)	52.7 (-26.3 to 202.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	105.7 (6.5 to 278.4)	50.6 (-20.1 to 171.4)
Liver cancer due to hepatitis C	0.9 (0.6 to 1.4)	4.6 (2.8 to 6.9)	436.6 (139.3 to 880.2)	272.0 (72.8 to 575.5)	0.1 (0.1 to 0.2)	0.7 (0.4 to 1.1)	418.3 (152.6 to 753.8)	264.9 (81.1 to 491.5)
Liver cancer due to alcohol use	2.3 (1.5 to 3.5)	3.6 (2.1 to 5.5)	62.2 (-21.5 to 203.2)	12.2 (-44.6 to 105.8)	0.4 (0.2 to 0.6)	0.6 (0.3 to 0.9)	58.7 (-13.2 to 167.9)	9.2 (-39.0 to 80.9)
Liver cancer due to other causes	0.7 (0.4 to 1.2)	0.9 (0.5 to 1.5)	32.9 (-45.2 to 154.4)	-6.4 (-59.5 to 74.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	30.5 (-39.3 to 114.2)	-8.5 (-56.0 to 47.9)
Larynx cancer	16.2 (11.5 to 21.0)	16.7 (12.3 to 21.0)	2.6 (-18.3 to 33.2)	-23.5 (-39.4 to -6.6)	1.7 (1.1 to 2.5)	1.6 (1.0 to 2.2)	8.5 (-30.3 to 22.1)	-31.2 (-48.0 to -6.6)
Tracheal, bronchus and lung cancer	80.7 (73.4 to 89.8)	95.1 (80.2 to 108.0)	20.4 (-4.9 to 38.7)	-12.9 (-31.3 to 0.2)	11.4 (8.4 to 14.5)	13.1 (9.5 to 17.0)	16.5 (5.2 to 34.9)	-15.6 (-31.7 to -1.9)
Breast cancer	570.0 (520.0 to 623.9)	819.8 (764.9 to 870.6)	44.1 (28.2 to 60.7)	3.3 (-7.9 to 14.8)	31.6 (22.4 to 43.2)	39.8 (27.3 to 55.1)	25.9 (10.4 to 41.1)	-8.9 (-20.0 to 1.6)
Cervical cancer	54.3 (41.3 to 64.1)	28.2 (22.9 to 37.7)	-48.8 (-60.9 to -25.2)	-58.6 (-68.3 to -39.6)	4.1 (2.7 to 5.8)	2.2 (1.4 to 3.2)	2.2 (-61.4 to -21.2)	-48.5 (-68.3 to -36.1)
Uterine cancer	55.8 (44.2 to 79.5)	78.7 (61.7 to 105.3)	41.0 (3.4 to 89.4)	2.5 (-24.5 to 38.2)	3.8 (2.5 to 5.6)	5.1 (3.2 to 7.5)	32.9 (-2.3 to 85.5)	67.8 (28.6 to 132.5)
Prostate cancer	237.4 (199.6 to 284.2)	635.7 (539.6 to 756.5)	168.9 (121.0 to 220.7)	84.6 (14.0 to 25.8)	25.5 (14.0 to 25.8)	46.4 (32.8 to 63.6)	135.9 (94.3 to 201.9)	61.8 (34.0 to 105.3)
Colon and rectum cancer	254.9 (238.0 to 273.9)	332.0 (303.1 to 360.5)	30.3 (16.5 to 43.9)	-8.0 (-17.2 to 0.8)	22.2 (16.4 to 28.9)	26.8 (19.7 to 34.2)	21.2 (7.2 to 35.3)	-14.4 (-23.7 to -5.2)
Lip and oral cavity cancer	34.5 (27.9 to 42.2)	44.1 (35.4 to 53.8)	26.8 (-3.5 to 69.0)	-2.8 (-26.7 to 28.7)	3.0 (2.1 to 4.1)	3.7 (2.5 to 5.1)	22.0 (8.2 to 62.0)	-6.8 (-29.4 to 22.8)
Nasopharynx cancer	7.9 (3.5 to 11.1)	2.1 (1.4 to 3.9)	-76.1 (-84.3 to -63.3)	-81.5 (-97.9 to -34.8)	0.7 (0.3 to 1.1)	0.2 (0.1 to 0.4)	-75.9 (-84.2 to -37.9)	-81.4 (-87.9 to -34.8)
Other pharynx cancer	19.0 (13.4 to 28.9)	30.7 (20.7 to 41.3)	67.5 (-13.1 to 160.4)	30.2 (-32.0 to 103.3)	1.6 (1.0 to 2.6)	2.5 (1.5 to 3.7)	27.3 (-15.7 to 143.6)	27.3 (-33.4 to 90.4)
Gallbladder and biliary tract cancer	6.2 (4.5 to 7.9)	4.6 (3.5 to 7.0)	-29.3 (-47.3 to 15.6)	-51.3 (-63.0 to -19.7)	1.5 (1.0 to 2.2)	1.1 (0.7 to 1.8)	-28.6 (-49.5 to 20.0)	-50.4 (-64.0 to -17.6)
Pancreatic cancer	12.0 (10.3 to 13.9)	17.5 (14.5 to 20.9)	45.4 (16.7 to 82.3)	1.9 (-17.8 to 27.9)	2.2 (1.6 to 3.0)	3.3 (2.3 to 4.5)	3.3 (18.0 to 82.6)	4.9 (-15.3 to 28.1)
Malignant skin melanoma	70.3 (51.2 to 97.9)	117.3 (81.4 to 170.4)	67.3 (35.1 to 104.0)	28.4 (3.0 to 58.8)	4.3 (2.7 to 6.5)	6.9 (4.3 to 10.7)	60.1 (25.9 to 97.7)	23.3 (-1.7 to 53.3)
Non-melanoma skin cancer	94.8 (81.2 to 113.2)	209.3 (159.9 to 246.9)	111.2 (54.1 to 178.2)	45.1 (7.4 to 91.1)	1.1 (0.8 to 2.3)	2.4 (2.0 to 5.6)	144.0 (93.3 to 218.1)	67.8 (28.6 to 115.7)
Ovarian cancer	40.3 (33.7 to 46.5)	38.7 (32.3 to 45.8)	-4.5 (-23.6 to 22.1)	-30.0 (-43.6 to -9.5)	5.2 (3.6 to 6.9)	4.8 (3.3 to 6.5)	-5.5 (-28.3 to 20.3)	-31.4 (-47.4 to -11.7)
Testicular cancer	23.7 (17.0 to 36.4)	19.5 (13.6 to 29.9)	-18.2 (-47.1 to 25.5)	-16.7 (-46.6 to 30.4)	1.5 (0.9 to 2.3)	1.2 (0.7 to 1.9)	-21.3 (-48.0 to 23.3)	-19.8 (-48.1 to 26.8)
Kidney cancer	58.3 (51.2 to 67.5)	113.8 (97.6 to 133.1)	95.6 (61.9 to 130.4)	40.4 (17.0 to 68.1)	4.2 (2.9 to 5.6)	7.8 (5.4 to 10.5)	86.2 (53.6 to 125.7)	33.7 (11.0 to 60.1)
Bladder cancer	94.1 (76.2 to 109.5)	113.7 (95.4 to 139.1)	19.8 (-3.2 to 56.7)	19.2 (-34.4 to 7.3)	7.2 (5.0 to 9.6)	8.2 (5.8 to 11.3)	12.8 (-8.1 to 46.9)	22.8 (-36.1 to 1.8)
Brain and nervous system cancer	20.5 (16.6 to 24.2)	29.3 (23.7 to 35.7)	43.1 (19.8 to 73.4)	12.5 (-2.9 to 33.6)	2.2 (1.5 to 3.0)	3.0 (2.0 to 4.1)	38.3 (11.7 to 69.4)	9.2 (-8.5 to 30.8)
Thyroid cancer	28.7 (23.4 to 35.7)	35.3 (28.0 to 50.6)	19.8 (-7.0 to 73.4)	-2.9 (-24.9 to 44.0)	1.8 (1.2 to 2.6)	2.1 (1.4 to 3.3)	17.6 (-9.9 to 74.4)	-6.3 (-27.7 to 40.8)
Mesothelioma	0.9 (0.8 to 1.5)	2.1 (1.4 to 2.7)	151.8 (22.1 to 215.9)	73.5 (-9.7 to 112.9)	0.2 (0.1 to 0.4)	0.5 (0.3 to 0.7)	137.6 (16.8 to 233.3)	66.4 (-13.6 to 123.9)
Hodgkin lymphoma	15.3 (10.4 to 20.2)	9.2 (6.9 to 16.1)	-42.9 (-57.8 to 0.5)	-50.6 (-64.0 to -10.9)	1.3 (0.8 to 1.9)	0.8 (0.5 to 1.3)	-43.5 (-58.8 to -2.7)	-23.5 (-65.6 to -15.9)
Non-Hodgkin lymphoma	58.5 (43.6 to 85.5)	94.0 (62.0 to 120.2)	67.1 (-8.1 to 107.9)	20.0 (-34.8 to 53.5)	4.3 (2.8 to 6.7)	6.6 (3.9 to 9.5)	59.4 (-12.7 to 99.6)	14.9 (-37.8 to 45.6)
Multiple myeloma	7.0 (4.3 to 11.5)	15.5 (10.1 to 23.3)	124.1 (38.9 to 270.4)	60.5 (0.4 to 159.9)	1.6 (0.9 to 2.8)	3.2 (1.8 to 5.0)	101.9 (26.8 to 225.2)	45.5 (-7.6 to 130.3)
Leukemia	29.4 (25.3 to 33.9)	45.6 (37.4 to 53.6)	55.3 (23.6 to 90.9)	5.9 (-15.3 to 27.7)	4.2 (3.0 to 5.5)	6.0 (4.3 to 8.0)	44.8 (14.7 to 77.9)	-0.1 (-19.2 to 19.9)
Other neoplasms	68.5 (57.6 to 83.1)	150.9 (121.4 to 181.7)	120.9 (71.4 to 175.9)	66.1 (32.2 to 102.1)	6.1 (3.5 to 6.8)	10.6 (6.9 to 13.4)	103.6 (53.5 to 157.1)	53.8 (21.6 to 89.0)
Cardiovascular diseases	-	-	-	-	388.3 (274.0 to 526.3)	500.3 (408.1 to 791.6)	30.0 (22.4 to 85.4)	8.1 (-13.2 to 31.8)
Rheumatic heart disease	7.9 (5.5 to 10.4)	9.5 (6.6 to 12.5)	17.6 (-20.7 to 103.1)	-9.9 (-38.9 to 52.3)	0.9 (0.5 to 1.3)	1.0 (0.6 to 1.6)	17.3 (-27.4 to 120.2)	-12.8 (-45.6 to 64.2)
Ischemic heart disease	2,128.9 (1,784.3 to 2,582.7)	2,858.4 (2,471.6 to 3,396.8)	35.6 (2.5 to 72.7)	-4.4 (-29.7 to 21.5)	121.6 (80.2 to 177.5)	151.7 (99.4 to 214.6)	15.7 (-11.6 to 67.0)	-13.9 (-40.2 to 17.0)
Cerebrovascular disease	-	-	-	-	108.2 (76.5 to 143.2)	190.7 (136.1 to 249.6)	76.2 (52.9 to 107.3)	25.8 (9.8 to 47.4)
Ischemic stroke	638.6 (566.0 to 727.6)	1,113.3 (985.1 to 1,226.3)	74.5 (49.5 to 103.8)	22.8 (5.8 to 42.5)	87.7 (62.3 to 120.7)	155.9 (109.6 to 207.4)	74.0 (48.7 to 104.0)	23.3 (6.0 to 43.5)
Hemorrhagic stroke	128.9 (105.6 to 152.6)	246.0 (207.2 to 292.9)	89.3 (52.2 to 141.7)	38.3 (12.5 to 73.3)	18.5 (12.0 to 25.6)	34.8 (23.7 to 47.3)	87.6 (48.5 to 142.7)	37.8 (10.3 to 75.4)
Hypertensive heart disease	124.7 (94.6 to 156.6)	207.8 (156.7 to 265.1)	66.3 (14.9 to 136.0)	16.9 (-19.2 to 63.5)	13.2 (8.4 to 19.2)	22.0 (13.6 to 32.7)	68.5 (13.6 to 135.3)	17.9 (-19.5 to 65.3)
Cardiomyopathy and myocarditis	119.6 (94.7 to 151.7)	153.0 (120.4 to 184.7)	29.5 (-9.2 to 75.1)	-5.9 (-32.7 to 25.5)	12.6 (8.1 to 18.3)	16.1 (10.3 to 22.9)	29.6 (-10.4 to 78.9)	-5.0 (-32.9 to 29.6)
Atrial fibrillation and flutter	452.0 (360.6 to 601.6)	579.9 (484.3 to 683.1)	29.4 (-4.5 to 72.5)	-9.3 (-31.8 to 19.2)	34.5 (22.3 to 51.1)	44.1 (29.5 to 62.0)	28.9 (5.0 to 71.6)	9.5 (-32.5 to 19.8)
Peripheral vascular disease	2,545.3 (1,997.0 to 3,023.9)	3,719.9 (2,916.4 to 4,379.2)	46.7 (13.0 to 87.4)	5.0 (-19.8 to 35.9)	3.1 (1.3 to 5.9)	3.5 (1.2 to 7.7)	12.2 (-53.4 to 152.5)	-26.8 (-70.1 to 72.3)
Endocarditis	3.5 (2.2 to 4.8)	4.1 (3.0 to 5.5)	18.2 (-22.2 to 102.8)	-13.3 (-42.8 to 50.0)	0.3 (0.2 to 0.6)	0.4 (0.2 to 0.7)	23.9 (-26.0 to 126.0)	-6.9 (-42.0 to 65.2)
Other cardiovascular and circulatory diseases	1,354.4 (800.4 to 2,031.0)	2,301.7 (1,362.8 to 3,155.5)	68.8 (-7.9 to 210.5)	23.8 (-31.3 to 124.2)	94.0 (49.7 to 151.5)	160.7 (86.7 to 249.7)	70.2 (-8.1 to 212.6)	25.0 (-31.1 to 126.3)
Chronic respiratory diseases	-	-	-	-	444.4 (305.3 to 593.7)	507.0 (349.9 to 686.3)	14.3 (8.7 to 32.6)	-1.8 (-14.4 to 11.7)
Chronic obstructive pulmonary disease	4,606.5 (4,192.6 to 5,055.8)	5,755.7 (5,182.						

Appendix Table G.4 - Germany prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.5 (0.4 to 0.5)	0.4 (0.4 to 0.5)	-5.0 (-10.9 to 1.6)	-29.7 (-34.1 to -25.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-4.3 (-10.4 to 2.6)	-29.4 (-33.8 to -24.5)
Asbestosis	-	-	-	-	-	-	-	-
Coal workers pneumoconiosis	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	28.6 (14.3 to 51.0)	-1.2 (-12.1 to 12.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	31.7 (16.1 to 55.6)	0.9 (-10.8 to 15.3)
Other pneumoconiosis	1.6 (1.1 to 2.3)	1.1 (0.7 to 1.5)	-30.6 (-43.2 to -17.2)	0.3 (-57.6 to -39.1)	0.2 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-28.8 (-42.2 to -15.3)	-46.3 (-56.6 to -38.2)
Asthma	4,256.3 (4,071.8 to 4,453.6)	4,381.6 (4,197.1 to 4,576.8)	2.9 (-3.2 to 9.3)	185.1 (7.6 to 5.5)	2.9 (121.3 to 261.6)	2.9 (125.2 to 267.5)	-1.2 (-3.8 to 1.1)	189.6 (-7.7 to 6.1)
Interstitial lung disease and pulmonary sarcoidosis	10.0 (7.4 to 12.5)	13.2 (9.5 to 17.1)	33.6 (-15.2 to 90.5)	3.3 (-33.2 to 46.0)	1.4 (0.8 to 2.1)	1.8 (1.0 to 2.8)	32.7 (-16.5 to 93.6)	3.6 (-33.6 to 49.4)
Other chronic respiratory diseases	-	-	-	-	3.2 (2.0 to 4.9)	2.7 (1.7 to 4.1)	-13.2 (-36.0 to 13.7)	-31.3 (-48.4 to -10.0)
Cirrhosis	-	-	-	-	10.2 (7.1 to 14.0)	9.0 (6.1 to 12.4)	-11.8 (-23.9 to 1.0)	-30.2 (-39.6 to -20.3)
Cirrhosis due to hepatitis B	5.8 (3.1 to 8.3)	6.3 (4.3 to 8.8)	5.7 (-38.0 to 122.0)	-18.0 (-52.3 to 72.8)	0.5 (0.4 to 1.6)	1.0 (0.5 to 1.6)	5.5 (-44.5 to 122.5)	1.6 (-17.2 to 76.3)
Cirrhosis due to hepatitis C	22.0 (14.8 to 31.7)	26.3 (17.6 to 33.9)	25.8 (-38.5 to 98.8)	-2.1 (-51.9 to 56.7)	3.6 (1.9 to 5.9)	4.2 (2.4 to 6.5)	4.2 (-42.0 to 104.0)	3.0 (-55.2 to 62.4)
Cirrhosis due to alcohol use	29.5 (21.4 to 37.0)	16.6 (10.9 to 24.1)	-45.7 (-64.4 to -4.7)	4.7 (-72.4 to -26.1)	2.7 (3.0 to 6.9)	2.7 (1.5 to 4.3)	-45.8 (-66.4 to -3.4)	-8.2 (-74.6 to -24.5)
Cirrhosis due to other causes	5.8 (3.6 to 9.2)	6.6 (3.6 to 10.5)	19.5 (-55.6 to 144.1)	-2.9 (-61.7 to 92.0)	0.9 (0.5 to 1.8)	1.1 (0.5 to 1.9)	16.9 (-59.5 to 152.1)	-4.4 (-64.3 to 97.7)
Digestive diseases	-	-	-	-	125.5 (89.1 to 166.4)	165.0 (117.2 to 219.5)	31.7 (-20.0 to 43.2)	5.3 (-4.8 to 16.1)
Peptic ulcer disease	871.8 (795.5 to 939.8)	543.0 (497.4 to 583.5)	-37.8 (-43.9 to -30.3)	57.9 (-62.2 to 52.5)	26.4 (18.2 to 36.5)	20.2 (13.8 to 28.1)	-31.1 (-31.9 to -15.1)	47.1 (-53.3 to -41.2)
Gastritis and duodenitis	477.1 (395.6 to 542.7)	609.2 (526.9 to 693.8)	27.2 (14.0 to 47.2)	-12.9 (-21.6 to 0.2)	17.3 (11.6 to 24.4)	23.7 (16.2 to 33.1)	37.0 (20.7 to 55.5)	-7.9 (-18.4 to 6.4)
Appendicitis	2.9 (1.9 to 3.7)	1.9 (1.3 to 2.5)	-34.5 (-58.9 to 20.0)	0.9 (-63.0 to 19.1)	0.9 (0.5 to 1.4)	0.6 (0.4 to 1.0)	-31.9 (-58.6 to 32.9)	-30.6 (-62.9 to 38.6)
Paralytic ileus and intestinal obstruction	1.3 (1.1 to 1.5)	1.7 (1.4 to 2.1)	32.9 (4.7 to 75.8)	-6.9 (-29.2 to 19.6)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.7)	30.9 (-10.8 to 92.1)	-8.2 (-35.4 to 30.7)
Inguinal, femoral, and abdominal hernia	421.8 (219.1 to 602.1)	506.1 (306.6 to 709.0)	22.7 (-34.1 to 200.5)	12.7 (-51.1 to 99.2)	4.2 (1.6 to 8.4)	5.0 (2.1 to 9.9)	19.2 (-34.0 to 196.1)	9.2 (-50.8 to 96.9)
Inflammatory bowel disease	182.7 (163.0 to 203.9)	280.8 (257.7 to 302.5)	55.3 (34.0 to 77.1)	31.4 (14.7 to 52.8)	37.9 (25.3 to 52.2)	58.0 (39.6 to 78.4)	53.1 (33.2 to 77.9)	32.1 (14.2 to 54.6)
Vascular intestinal disorders	0.7 (0.6 to 1.0)	1.1 (0.8 to 1.8)	54.0 (-5.5 to 129.6)	8.4 (-32.2 to 53.6)	0.3 (0.1 to 0.3)	0.3 (0.2 to 0.6)	53.9 (-25.3 to 184.1)	9.2 (-41.2 to 82.4)
Gallbladder and biliary diseases	240.6 (208.8 to 273.7)	263.2 (230.1 to 302.8)	9.2 (-8.3 to 30.9)	-15.7 (-31.2 to 1.3)	24.7 (17.0 to 34.3)	26.9 (17.9 to 37.3)	8.8 (-9.8 to 31.0)	-15.5 (-32.2 to 2.2)
Pancreatitis	19.3 (18.2 to 20.5)	29.0 (27.3 to 31.0)	50.5 (37.1 to 63.9)	5.5 (14.6 to 37.2)	8.3 (3.7 to 7.6)	8.3 (5.5 to 11.4)	36.6 (27.5 to 75.5)	26.6 (7.0 to 49.0)
Other digestive diseases	-	-	-	-	7.9 (5.4 to 11.2)	21.5 (13.5 to 30.3)	179.3 (74.4 to 226.8)	123.2 (37.9 to 162.7)
Neurological disorders	-	-	-	-	923.9 (644.3 to 1,228.2)	1,117.4 (795.5 to 1,462.7)	21.2 (8.3 to 34.6)	3.7 (-6.2 to 14.8)
Alzheimer disease and other dementias	1,543.1 (1,343.8 to 1,772.4)	2,283.8 (1,882.8 to 2,688.2)	48.3 (15.1 to 82.3)	-1.8 (-23.5 to 20.2)	224.5 (160.6 to 298.0)	337.2 (236.9 to 450.1)	50.7 (16.6 to 87.4)	-0.7 (-22.7 to 22.6)
Parkinson disease	128.4 (110.0 to 146.0)	179.1 (151.5 to 209.1)	39.2 (29.7 to 49.1)	-3.2 (-9.8 to 2.9)	14.6 (10.0 to 20.0)	20.5 (14.1 to 28.6)	39.5 (25.9 to 54.4)	14.5 (-12.5 to 7.7)
Epilepsy	312.4 (223.2 to 399.2)	288.7 (200.3 to 385.3)	-7.8 (-42.1 to 41.5)	-13.0 (-44.9 to 33.9)	120.2 (75.4 to 170.7)	119.0 (72.3 to 173.9)	-0.7 (-38.5 to 54.6)	-4.9 (-41.0 to 47.5)
Multiple sclerosis	42.7 (33.3 to 51.9)	122.0 (96.3 to 150.0)	185.6 (103.8 to 283.3)	13.9 (80.0 to 240.6)	13.9 (9.5 to 19.0)	39.2 (26.7 to 53.6)	39.2 (101.5 to 292.2)	150.7 (77.9 to 249.2)
Migraine	11,478.7 (10,461.6 to 12,433.1)	11,156.8 (10,365.5 to 12,002.1)	-2.9 (-12.3 to 9.0)	-4.6 (-13.6 to 7.6)	385.1 (233.9 to 564.0)	373.1 (224.6 to 544.1)	-3.2 (-13.1 to 9.7)	-4.2 (-14.1 to 8.5)
Tension-type headache	21,012.4 (15,480.3 to 27,648.2)	23,953.3 (21,883.8 to 24,390.2)	13.3 (-1.6 to 52.0)	6.7 (-17.8 to 66.7)	34.8 (14.2 to 58.9)	35.7 (16.7 to 60.4)	9.8 (-17.1 to 51.5)	5.7 (-18.4 to 47.6)
Medication overuse headache	698.1 (408.2 to 817.0)	992.4 (669.5 to 1,337.3)	42.1 (34.6 to 105.3)	62.1 (21.8 to 86.6)	93.8 (52.4 to 144.7)	152.4 (87.9 to 231.0)	61.9 (37.1 to 106.3)	47.3 (21.6 to 89.6)
Other neurological disorders	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	14.1 (-28.2 to 62.5)	1.6 (-35.3 to 43.2)	40.3 (26.6 to 58.4)	41.6 (27.8 to 58.9)	4.1 (-28.6 to 45.7)	-26.7 (-49.7 to 1.6)
Mental and substance use disorders	-	-	-	-	1,889.5 (1,357.5 to 2,464.5)	1,930.3 (1,388.8 to 2,532.3)	2.2 (-1.5 to 5.5)	0.6 (-2.4 to 3.4)
Schizophrenia	233.6 (183.0 to 285.2)	247.3 (194.0 to 298.7)	5.9 (0.1 to 13.3)	-1.3 (-7.8 to 4.7)	146.9 (101.5 to 191.7)	155.5 (109.1 to 200.7)	5.8 (-1.7 to 15.0)	-0.8 (-8.4 to 8.1)
Alcohol use disorders	1,635.4 (1,511.8 to 1,750.4)	1,490.8 (1,371.3 to 1,588.6)	-9.5 (-14.3 to -4.5)	-7.3 (-12.2 to -1.9)	162.4 (110.8 to 228.4)	146.8 (100.4 to 210.0)	-9.6 (-15.2 to -3.8)	-7.0 (-12.7 to -1.0)
Drug use disorders	-	-	-	-	132.2 (95.5 to 172.1)	125.5 (89.1 to 161.1)	-5.0 (-14.2 to 5.4)	6.4 (-4.4 to 18.1)
Opioid use disorders	168.3 (150.5 to 188.0)	161.9 (147.2 to 177.1)	-4.0 (-11.1 to 3.9)	5.9 (-1.5 to 14.4)	69.2 (49.0 to 91.6)	66.8 (47.9 to 85.4)	-3.6 (-12.7 to 7.3)	6.9 (-3.6 to 19.0)
Cocaine use disorders	106.0 (96.3 to 115.0)	96.3 (88.5 to 104.2)	-9.1 (-20.4 to 2.9)	2.3 (-10.4 to 16.5)	14.3 (9.3 to 20.6)	13.1 (8.5 to 18.5)	-3.2 (-23.4 to 9.0)	3.2 (-13.1 to 23.9)
Amphetamine use disorders	115.5 (105.3 to 127.9)	110.9 (100.0 to 120.8)	-4.0 (-16.7 to 9.0)	-4.0 (-7.5 to 23.4)	14.9 (9.2 to 21.8)	14.5 (9.1 to 21.1)	-0.7 (-19.9 to 15.9)	9.7 (-10.2 to 31.2)
Cannabis use disorders	142.1 (127.2 to 157.8)	122.8 (110.8 to 135.5)	-13.6 (-18.4 to -8.3)	-0.0 (-6.5 to 6.5)	4.1 (2.7 to 6.0)	3.6 (2.2 to 5.2)	-13.5 (-25.0 to 1.0)	-0.0 (-14.1 to 17.5)
Other drug use disorders	-	-	-	-	29.6 (18.6 to 42.5)	27.7 (17.4 to 40.2)	-6.6 (-31.3 to 30.7)	5.4 (-22.1 to 48.2)
Depressive disorders	-	-	-	-	589.3 (401.7 to 832.8)	640.1 (424.9 to 907.0)	8.6 (-1.8 to 16.7)	3.3 (-6.3 to 11.4)
Major depressive disorder	2,280.0 (1,803.3 to 2,809.5)	2,495.1 (1,924.4 to 3,155.0)	9.5 (-3.0 to 19.1)	3.6 (-6.9 to 13.7)	455.0 (296.9 to 666.0)	497.5 (316.9 to 738.7)	9.4 (-3.7 to 19.5)	4.4 (-6.7 to 14.6)
Dysthymia	1,413.5 (1,189.9 to 1,663.6)	1,506.3 (1,272.8 to 1,759.4)	6.6 (2.9 to 10.6)	-0.6 (-0.8 to -0.4)	134.2 (89.5 to 192.3)	142.5 (95.3 to 205.6)	6.1 (1.7 to 10.9)	-0.1 (-2.5 to 2.1)
Bipolar disorder	595.5 (514.8 to 680.8)	605.5 (524.8 to 686.9)	1.7 (-3.5 to 6.7)	-0.3 (-5.0 to 4.6)	118.9 (73.4 to 177.3)	120.6 (74.9 to 178.9)	1.5 (-5.2 to 8.2)	0.3 (-5.9 to 7.1)
Anxiety disorders	4,641.0 (4,095.6 to 5,223.7)	4,795.7 (4,273.8 to 5,350.2)	3.4 (-2.9 to 9.7)	0.1 (-5.7 to 5.4)	418.1 (290.9 to 588.1)	430.5 (297.6 to 599.4)	3.0 (-3.3 to 9.6)	0.5 (-5.6 to 6.1)
Eating disorders	-	-	-	-	35.1 (19.5 to 55.9)	30.3 (16.9 to 48.2)	-13.4 (-19.5 to -6.5)	4.0 (-2.7 to 11.8)
Anorexia nervosa	39.9 (24.4 to 62.5)	38.5 (23.3 to 60.9)	-3.5 (-17.0 to 8.6)	14.8 (0.2 to 27.8)	8.4 (4.6 to 14.6)	8.1 (4.5 to 14.5)	-3.4 (-19.1 to 13.3)	15.2 (-3.2 to 34.5)
Bulimia nervosa	127.5 (66.9 to 189.3)	106.0 (55.6 to 157.3)	-17.0 (-19.2 to -13.9)	0.2 (0.1 to 0.3)	26.6 (12.9 to 44.8)	22.2 (10.7 to 37.6)	-16.7 (-22.8 to -10.2)	0.4 (-6.4 to 7.9)
Autistic spectrum disorders	-	-	-	-	86.1 (60.1 to 116.3)	87.6 (61.2 to 118.5)	1.7 (-1.6 to 5.1)	1.2 (-2.3 to 4.4)
Autism	225.4 (212.1 to 238.3)	230.2 (216.0 to 245.1)	2.1 (1.1 to 3.2)	0.7 (0.7 to 0.8)	54.4 (36.3 to 74.1)	55.3 (37.4 to 75.6)	1.6 (-3.2 to 6.4)	1.1 (-3.7 to 5.7)
Asperger syndrome	322.5 (300.7 to 344.6)	330.4 (306.8 to 355.0)	2.4 (1.4 to 3.4)	2.0 (0.9 to 1.1)	31.7 (22.1 to 43.8)	32.3 (22.5 to 44.7)	2.0 (-1.9 to 6.0)	1.3 (-2.6 to 5.1)
Attention-deficit/hyperactivity disorder	357.1 (296.2 to 420.9)	304.4 (252.3 to 358.3)	-14.8 (-14.9 to -14.5)	-0.0 (-0.0 to 0.0)	4.3 (2.4 to 6.9)	3.7 (2.1 to 5.8)	0.2 (-20.4 to -8.3)	0.2 (-6.9 to 7.3)
Conduct disorder	494.5 (414.7 to 579.5)	433.6 (364.7 to 506.5)	-12.3 (-13.2 to -11.6)	0.0 (-0.0 to 0.0)	59.3 (36.5 to 89.6)	52.1 (32.0 to 78.5)	-12.2 (-15.8 to -8.2)	0.2 (-3.8 to 4.5)
Idiopathic intellectual disability	342.2 (199.9 to 497.5)	202.0 (109.6 to 320.1)	-40.6 (-63.9 to -9.0)	-42.3 (-64.9 to -12.2)	20.2 (10.3 to 32.6)	11.0 (5.8 to 20.4)	-45.0 (-63.8 to -10.1)	-42.6 (-64.4 to -12.2)
Other mental and substance use disorders	1,595.8 (1,500.6 to 1,688.3)	1,729.3 (1,627.4 to 1,828.7)	8.3 (6.4 to 10.4)	0.8 (0.5 to 1.2)	116.7 (79.5 to 156.3)	125.8 (85.6 to 169.0)	7.7 (3.8 to 12.0)	1.2 (-2.6 to 4.7)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	956.3 (693.9 to 1,267.0)	1,273.5 (916.4 to 1,680.4)	33.0 (21.2 to 48.1)	9.3 (1.1 to 20.3)
Diabetes mellitus	5,312.2 (4,458.2 to 6,363.3)	8,117.0 (6,783.9 to 9,747.0)	53.1 (20.7 to 92.6)	22.2 (-2.4 to 53.0)	354.0 (237.8 to 503.3)	539.6 (349.6 to 773.7)	52.3 (20.6 to 92.8)	21.5 (-2.1 to 55.2)
Acute glomerulonephritis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	25.1 (-32.6 to -17.4)	-28.1 (-35.6 to -20.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.1 (-32.7 to -17.3)	-28.1 (-35.7 to -20.4)
Chronic kidney disease	-	-	-	-	353.5 (241.1 to 472.4)	428.3 (292.6 to 574.3)	21.3 (14.4 to 27.8)	0.8 (-3.2 to 4.7)
Chronic kidney disease due to diabetes mellitus	1,644.0 (987.4 to 2,814.4)	2,387.4 (1,685.4 to 3,757.8)	47.5 (0.3 to 115.5)	11.1 (-22.8 to 58.8)	70.3 (43.3 to 102.6)	102.2 (65.5 to 150.1)	44.8 (7.5 to 98.8)	14.7 (-3.3 to 55.2)
Chronic kidney disease due to hypertension	1,237.8 (922.7 to 1,716.7)	1,475.1 (1,026.2 to 2,423.8)	17.9 (-19.3 to 65.5)	-2.4 (-31.8 to 30.5)	94.0 (62.9 to 137.5)	39.0 (24.1 to 58.7)	-58.9 (-70.8 to -40.8)	-64.8 (-74.1 to -50.4)
Chronic kidney disease due to glomerulonephritis	2,121.7 (1,453.5 to 3,741.5)	1,172.6 (843.8 to 1,859.3)	-46.0 (-63.5 to -24.6)	-50.8 (-66.1 to -33.9)	36.5 (23.6 to 54.0)	78.5 (50.8 to 109.4)	117.4 (50.6 to 191.2)	78.2 (-28.7 to 136.3)
Chronic kidney disease due to other causes	4,354.1 (2,933.3 to 6,119.3)	5,407.7 (4,151.9 to 8,213.2)	25.9 (-6.6 to 65.8)	25.9 (-21.8 to 29.2)	152.7 (101.7			

Appendix Table G.4 - Germany prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Urolithiasis	688.9 (312.7 to 1,070.3)	1,740.4 (726.9 to 2,990.1)	147.7 (87.9 to 211.4)	5.6 (34.9 to 124.5)	5.6 (2.4 to 10.1)	14.7 (5.6 to 29.2)	156.8 (96.7 to 219.9)	58.1 (42.3 to 135.7)
Benign prostatic hyperplasia	1,812.2 (1,560.0 to 2,083.6)	2,879.4 (2,343.6 to 3,381.8)	58.1 (21.5 to 97.9)	12.3 (-11.8 to 39.2)	63.6 (40.9 to 91.4)	101.0 (63.7 to 147.4)	58.4 (21.6 to 97.4)	12.9 (-11.8 to 40.0)
Male infertility due to other causes	283.1 (210.5 to 357.9)	249.8 (178.8 to 333.0)	-13.2 (-39.7 to 35.3)	0.2 (-30.3 to 57.4)	2.0 (0.8 to 4.1)	1.8 (0.7 to 3.7)	1.2 (-40.2 to 38.2)	1.2 (-30.5 to 60.0)
Other urinary diseases	-	-	-	-	1.2 (0.5 to 2.0)	3.6 (1.2 to 6.9)	195.3 (84.1 to 336.5)	115.7 (30.3 to 218.1)
Gynecological diseases	-	-	-	-	101.1 (64.7 to 153.5)	104.2 (65.5 to 161.8)	0.7 (-11.9 to 23.0)	0.7 (-13.0 to 18.9)
Uterine fibroids	3,440.8 (3,015.3 to 3,836.5)	3,853.2 (3,374.8 to 4,284.7)	12.0 (10.6 to 13.3)	0.1 (0.1 to 0.2)	28.0 (14.3 to 52.9)	31.7 (15.7 to 59.5)	12.1 (-14.6 to 55.0)	1.9 (-22.7 to 39.1)
Polycystic ovarian syndrome	1,303.4 (1,137.0 to 1,476.3)	1,330.0 (1,152.5 to 1,523.4)	1.9 (-14.9 to 23.5)	5.2 (-12.3 to 28.4)	12.1 (5.5 to 23.3)	12.2 (5.7 to 22.9)	1.1 (-14.8 to 22.1)	5.0 (-12.4 to 27.2)
Female infertility due to other causes	17.2 (7.0 to 55.6)	16.4 (4.4 to 68.4)	-23.1 (-87.3 to 473.5)	-15.8 (-86.2 to 469.6)	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.4)	-17.5 (-85.8 to 444.3)	-10.4 (-431.7 to 431.7)
Endometriosis	278.8 (220.9 to 330.6)	287.1 (235.3 to 337.4)	4.8 (-19.4 to 33.8)	7.4 (-17.4 to 36.3)	25.2 (16.5 to 35.7)	26.4 (17.0 to 37.8)	5.2 (-19.5 to 34.4)	0.7 (-17.5 to 37.2)
Genital prolapse	5,448.2 (4,924.5 to 5,978.7)	5,678.7 (5,142.7 to 6,196.4)	4.5 (-10.3 to 18.9)	-1.1 (-18.7 to 10.1)	17.2 (8.4 to 32.2)	17.9 (8.6 to 32.8)	4.6 (-10.6 to 19.5)	-3.9 (-18.5 to 11.3)
Premenstrual syndrome	1,723.7 (1,276.1 to 2,133.1)	1,381.9 (1,022.1 to 1,820.4)	-20.6 (-44.4 to 11.5)	-14.9 (-39.0 to 23.3)	14.4 (8.5 to 22.6)	11.5 (6.9 to 18.3)	-20.3 (-44.5 to 13.6)	-14.5 (-39.8 to 23.5)
Other gynecological diseases	181.7 (129.2 to 431.2)	181.2 (127.9 to 545.9)	1.8 (-60.8 to 232.8)	5.4 (-56.7 to 220.9)	4.1 (1.7 to 15.6)	4.4 (1.8 to 17.3)	14.9 (-79.8 to 610.0)	14.7 (-78.5 to 598.0)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	-	46.1 (30.0 to 67.8)	-2.1 (-18.8 to 30.6)	-1.7 (-15.5 to 26.4)
Thalassemias	0.5 (0.4 to 0.5)	0.4 (0.4 to 0.5)	-8.5 (-17.3 to 0.9)	11.0 (0.5 to 22.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.5 (-2.0 to 4.3)	9.4 (-3.2 to 28.0)
Thalassemia trait	854.8 (783.2 to 942.7)	910.0 (825.8 to 1,075.9)	6.1 (-5.6 to 30.9)	2.1 (-8.1 to 25.9)	25.5 (16.5 to 37.0)	24.6 (15.7 to 36.7)	-4.4 (-22.0 to 40.0)	-3.1 (-17.5 to 32.5)
Sickle cell disorders	1.1 (1.0 to 1.1)	1.0 (0.9 to 1.0)	-9.8 (-16.3 to -2.2)	-0.4 (-8.6 to 9.1)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-6.8 (-12.6 to -1.0)	1.9 (-5.4 to 8.7)
Sickle cell trait	941.2 (878.4 to 1,021.2)	964.7 (900.0 to 1,052.8)	2.3 (-5.7 to 11.8)	-1.1 (-9.1 to 9.7)	11.6 (6.7 to 18.4)	10.4 (6.0 to 16.4)	-11.7 (-36.6 to 33.8)	-6.8 (-32.4 to 36.7)
G6PD deficiency	763.7 (742.0 to 1,056.7)	845.7 (498.2 to 1,168.2)	10.4 (-34.2 to 105.6)	6.5 (-37.1 to 98.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	7.6 (-28.6 to 40.5)	7.2 (-37.1 to 35.0)
G6PD trait	10,759.2 (9,672.9 to 11,701.2)	10,675.5 (9,554.0 to 11,557.4)	-0.9 (-13.2 to 12.9)	-4.6 (-16.5 to 8.6)	0.6 (0.3 to 1.0)	0.5 (0.2 to 0.9)	0.5 (-59.6 to 64.4)	-5.4 (-59.2 to 101.3)
Other hemoglobinopathies and hemolytic anemias	441.8 (410.3 to 478.8)	537.3 (485.3 to 623.7)	21.5 (6.7 to 40.4)	6.5 (-6.2 to 25.7)	8.1 (5.2 to 12.5)	9.4 (5.6 to 15.6)	7.6 (-19.8 to 67.7)	7.6 (-15.9 to 67.3)
Endocrine, metabolic, blood, and immune disorders	929.4 (831.3 to 1,013.7)	1,091.3 (981.6 to 1,201.8)	16.3 (4.1 to 36.4)	5.6 (-7.3 to 24.4)	28.9 (19.6 to 40.4)	34.6 (23.1 to 48.2)	18.6 (15.0 to 44.9)	8.8 (-8.2 to 34.0)
Musculoskeletal disorders	-	-	-	-	-	2,218.7 (2,280.6 to 4,278.7)	3,504.6 (2,490.3 to 4,645.4)	58.3 (3.7 to 14.7)
Rheumatoid arthritis	362.9 (330.0 to 396.4)	315.3 (280.3 to 355.5)	-13.5 (-24.6 to 1.7)	-32.7 (-40.6 to -21.9)	81.6 (57.4 to 108.2)	70.7 (49.1 to 93.8)	-13.7 (-25.4 to 1.8)	-32.1 (-40.7 to -21.2)
Osteoarthritis	4,884.7 (4,177.9 to 5,796.6)	6,563.2 (5,555.0 to 7,683.8)	36.5 (2.9 to 63.8)	-1.0 (-24.8 to 19.5)	165.6 (104.6 to 247.1)	222.2 (142.1 to 328.4)	36.2 (2.8 to 64.1)	-0.4 (-24.7 to 20.3)
Low back and neck pain	-	-	-	-	2,693.4 (1,878.5 to 3,636.4)	2,818.6 (1,952.0 to 3,805.7)	4.5 (-1.7 to 11.5)	5.7 (-11.5 to 5.7)
Low back pain	18,381.4 (17,437.7 to 19,426.9)	19,612.0 (18,825.7 to 20,484.7)	6.5 (-1.0 to 14.2)	-4.7 (-11.7 to 2.9)	2,018.0 (1,370.2 to 2,795.5)	2,141.1 (1,462.3 to 2,957.1)	6.0 (-1.7 to 13.9)	-4.2 (-11.6 to 3.3)
Neck pain	6,981.1 (6,291.8 to 7,644.3)	7,027.5 (6,229.1 to 7,774.8)	0.8 (-11.3 to 12.6)	-9.8 (-19.6 to 1.1)	675.3 (466.8 to 926.0)	677.5 (469.5 to 937.6)	0.6 (-11.3 to 12.7)	-9.4 (-19.2 to 1.5)
Gout	179.1 (161.0 to 195.4)	242.0 (216.4 to 271.6)	34.7 (17.3 to 56.7)	2.6 (-10.9 to 19.6)	5.5 (3.7 to 7.4)	7.4 (5.0 to 10.2)	34.1 (9.6 to 64.2)	3.0 (-16.0 to 26.4)
Other musculoskeletal disorders	3,036.8 (2,471.8 to 3,662.3)	4,285.4 (3,384.8 to 5,176.9)	41.0 (28.4 to 53.8)	20.1 (10.8 to 30.8)	272.6 (180.5 to 388.9)	385.8 (234.4 to 550.8)	41.5 (28.6 to 54.7)	21.0 (11.4 to 31.8)
Other non-communicable diseases	-	-	-	-	-	1,779.8 (1,217.0 to 2,478.1)	2,050.7 (1,415.2 to 2,850.3)	15.6 (7.0 to 20.8)
Congenital anomalies	-	-	-	-	-	134.3 (95.9 to 176.1)	174.5 (122.1 to 231.7)	29.8 (10.6 to 53.4)
Neural tube defects	28.5 (24.4 to 33.5)	24.8 (21.9 to 28.8)	-12.9 (-28.8 to 5.0)	-11.0 (-26.9 to 7.7)	9.3 (6.3 to 13.0)	8.1 (5.6 to 11.2)	-12.6 (-34.9 to 17.6)	-10.4 (-33.5 to 21.0)
Congenital heart anomalies	847.2 (698.8 to 1,047.7)	738.2 (633.9 to 877.4)	-12.0 (-34.6 to 12.4)	-13.6 (-35.6 to 10.7)	29.4 (11.7 to 52.4)	25.8 (10.3 to 46.5)	-11.9 (-32.9 to 11.4)	-12.5 (-33.0 to 10.5)
Crofacial clefts	147.8 (124.1 to 176.1)	121.2 (100.2 to 148.2)	-18.5 (-36.3 to 6.7)	-21.1 (-38.2 to 3.3)	1.4 (0.9 to 2.0)	1.1 (0.7 to 1.7)	-21.9 (-43.3 to 7.9)	-24.0 (-45.1 to 4.2)
Down syndrome	83.9 (71.2 to 98.7)	98.2 (80.1 to 126.4)	17.5 (-9.2 to 52.9)	15.5 (-18.4 to 38.4)	12.5 (9.1 to 16.3)	15.7 (11.0 to 21.7)	7.6 (-3.0 to 64.9)	25.2 (-17.0 to 41.0)
Turner syndrome	4.5 (3.2 to 6.2)	4.6 (3.2 to 6.1)	-0.6 (-37.1 to 57.3)	0.7 (-36.9 to 59.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-2.6 (-39.2 to 56.9)	0.1 (-38.2 to 61.4)
Klinefelter syndrome	3.4 (2.6 to 4.6)	4.3 (3.9 to 4.9)	26.8 (-5.9 to 69.1)	23.4 (-8.6 to 64.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	17.2 (-18.9 to 74.8)	20.3 (-17.1 to 78.3)
Chromosomal unbalanced rearrangements	170.5 (139.4 to 211.2)	191.3 (152.1 to 251.2)	11.4 (-17.6 to 55.6)	0.8 (-24.9 to 41.7)	25.4 (17.5 to 34.9)	30.4 (20.9 to 43.0)	30.4 (-13.3 to 70.6)	2.7 (-25.3 to 46.7)
Other congenital anomalies	392.0 (288.1 to 505.3)	395.5 (290.9 to 483.8)	0.3 (-28.4 to 29.6)	0.3 (-32.1 to 20.7)	56.3 (35.9 to 81.8)	62.3 (60.9 to 130.6)	56.9 (18.2 to 131.2)	56.9 (18.8 to 131.3)
Skin and subcutaneous diseases	-	-	-	-	-	484.6 (314.3 to 726.5)	497.2 (330.9 to 740.4)	2.7 (-2.9 to 8.5)
Dermatitis	4,752.7 (3,806.0 to 5,636.3)	4,744.2 (3,862.9 to 5,607.1)	-0.2 (-3.0 to 2.7)	-0.1 (-0.2 to -0.1)	121.1 (79.6 to 173.6)	120.5 (78.8 to 173.1)	-0.5 (-3.6 to 2.9)	0.1 (-2.5 to 2.8)
Psoriasis	1,278.1 (1,171.1 to 1,378.8)	1,421.6 (1,297.8 to 1,537.4)	11.2 (9.1 to 12.8)	10.8 (0.0 to 0.5)	101.8 (70.8 to 141.6)	112.8 (78.2 to 155.7)	10.8 (6.3 to 15.5)	4.5 (-3.0 to 4.5)
Cellulitis	93.2 (20.3 to 46.5)	99.6 (24.3 to 57.9)	7.0 (5.7 to 34.6)	2.7 (-11.7 to 10.5)	2.7 (1.2 to 3.6)	2.7 (1.4 to 4.4)	0.4 (-3.3 to 43.9)	0.4 (-13.3 to 20.4)
Pyoderma	61.4 (43.6 to 91.6)	80.5 (53.9 to 126.2)	30.4 (9.4 to 52.0)	12.8 (1.6 to 25.1)	0.3 (0.1 to 0.8)	0.4 (0.2 to 1.0)	29.4 (8.7 to 54.0)	19.0 (-1.4 to 28.4)
Scabies	63.6 (54.9 to 73.6)	44.5 (38.3 to 51.8)	-29.7 (-43.0 to -15.1)	-27.8 (-41.1 to -13.4)	1.6 (0.9 to 2.6)	1.1 (0.6 to 1.8)	-29.7 (-43.8 to -13.6)	-27.7 (-42.7 to -11.6)
Fungal skin diseases	6,059.5 (5,529.3 to 6,598.5)	6,810.4 (6,218.5 to 7,385.0)	12.4 (10.5 to 14.1)	0.6 (0.4 to 0.9)	33.5 (13.9 to 69.5)	37.5 (15.4 to 77.0)	11.9 (9.9 to 13.9)	0.9 (-0.1 to 1.9)
Viral skin diseases	1,551.0 (1,200.7 to 1,941.4)	1,484.0 (1,174.6 to 1,812.3)	-4.4 (-9.1 to 2.2)	-4.4 (-2.0 to 2.6)	47.4 (27.2 to 75.5)	45.2 (26.0 to 70.7)	0.5 (-10.0 to 2.0)	0.5 (-2.6 to 4.0)
Acne vulgaris	8,161.4 (7,018.1 to 9,384.5)	6,626.3 (5,670.8 to 7,547.3)	-19.7 (-33.9 to 1.3)	-19.7 (-23.6 to 22.4)	88.2 (40.7 to 166.0)	71.7 (33.0 to 138.0)	-19.7 (-33.7 to 1.6)	-4.3 (-23.4 to 22.8)
Alopecia areata	140.2 (129.2 to 151.4)	163.4 (150.0 to 177.5)	16.8 (4.3 to 31.1)	1.2 (-9.7 to 13.4)	4.6 (2.9 to 6.8)	5.3 (3.4 to 7.9)	15.5 (11.1 to 31.9)	1.4 (-11.6 to 15.4)
Pruritus	29.8 (26.7 to 32.9)	36.9 (33.0 to 40.9)	23.6 (6.3 to 44.3)	0.5 (-13.2 to 17.4)	0.3 (0.1 to 0.6)	0.4 (0.2 to 0.7)	23.6 (20.0 to 48.0)	0.9 (-16.8 to 21.1)
Urticaria	652.0 (447.0 to 839.4)	738.9 (513.7 to 980.1)	16.7 (-32.3 to 68.1)	-0.6 (-39.3 to 53.0)	38.0 (21.5 to 58.3)	42.7 (24.2 to 66.5)	15.8 (-3.8 to 68.9)	-0.8 (-39.1 to 53.1)
Decubitus ulcer	47.6 (35.7 to 60.1)	68.4 (44.4 to 89.6)	43.8 (-4.8 to 117.8)	0.0 (-30.8 to 44.3)	6.6 (4.2 to 9.6)	9.5 (5.4 to 14.5)	43.2 (-7.8 to 114.5)	0.3 (-31.0 to 45.2)
Other skin and subcutaneous diseases	6,748.0 (3,899.8 to 11,511.6)	8,275.0 (4,464.7 to 14,833.9)	21.9 (10.2 to 31.4)	0.9 (-2.5 to 3.5)	38.9 (15.8 to 86.9)	47.5 (18.0 to 110.9)	21.5 (10.0 to 31.0)	1.1 (-2.7 to 4.0)
Sense organ diseases	-	-	-	-	-	837.3 (575.9 to 1,159.8)	1,013.5 (697.6 to 1,403.8)	21.1 (11.3 to 31.4)
Glaucoma	116.0 (83.1 to 153.0)	117.4 (78.6 to 158.2)	0.7 (-23.0 to 32.9)	37.2 (-42.4 to -4.4)	10.6 (6.0 to 15.5)	10.6 (6.2 to 16.3)	0.1 (-26.6 to 36.9)	-28.2 (-44.2 to -3.6)
Cataract	309.9 (169.3 to 471.9)	320.8 (174.8 to 441.0)	3.6 (-24.8 to 50.3)	-30.7 (-49.4 to -1.7)	19.6 (10.5 to 31.5)	20.5 (11.3 to 31.5)	5.2 (-21.6 to 39.6)	-29.3 (-40.8 to -7.6)
Macular degeneration	411.1 (294.5 to 555.6)	539.0 (391.5 to 783.7)	32.1 (-3.6 to 74.4)	-7.9 (-29.6 to 18.8)	26.1 (15.8 to 39.0)	33.2 (20.1 to 50.6)	28.1 (0.2 to 56.8)	-11.2 (-28.3 to 7.4)
Uncorrected refractive error	10,481.6 (8,421.3 to 12,725.7)	11,979.1 (9,559.0 to 13,954.0)	15.7 (-19.2 to 50.4)	-9.2 (-35.0 to 19.7)	138.1 (78.1 to 228.9)	152.5 (83.8 to 256.8)	11.2 (-15.0 to 37.0)	0.9 (-12.0 to 9.6)
Age-related and other hearing loss	15,847.2 (14,624.6 to 17,144.4)	19,661.5 (18,017.7 to 21,496.5)	24.1 (19.1 to 29.1)	-8.9 (-13.2 to -3.6)	574.3 (398.8 to 796.8)	724.7 (493.3 to 1,010.3)	25.8 (14.2 to 41.3)	-9.2 (-17.0 to 2.6)
Other vision loss	289.3 (218.7 to 376.4)	242.4 (163.4 to 345.7)	-20.4 (-30.8 to 1.0)	-36.4 (-46.1 to -24.0)	19.3 (11.9 to 27.7)	17.6 (10.2 to 27.1)	3.3 (-22.0 to 6.7)	-30.1 (-38.9 to -19.2)
Other sense organ diseases	1,915.1 (1,830.6 to 1,999.6)	2,113.4 (2,010.4 to 2,217.1)	10.2 (3.4 to 17.6)	-0.5 (-6.3 to 5.9)	49.4 (30.8 to 73.1)	54.2 (33.7 to 79.0)	9.7 (2.0 to 17.0)	-0.3 (-6.8 to 6.6)
Oral disorders	-	-	-	-	-	3		

Appendix Table G.4 - Germany prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	1,544.3 (1,467.4 to 1,627.8)	1,644.8 (1,565.0 to 1,735.2)	6.5 (-1.2 to 15.1)	0.3 (-7.6 to 8.2)	44.6 (28.1 to 66.4)	47.4 (29.7 to 70.4)	5.3 (-2.2 to 15.4)	0.5 (-7.9 to 9.2)
Injuries	-	-	-	-	959.1 (731.8 to 1,220.6)	788.9 (566.4 to 1,059.7)	-17.8 (-27.3 to -7.3)	-36.8 (-43.6 to -29.1)
Transport injuries	-	-	-	-	183.5 (137.8 to 235.1)	69.8 (50.3 to 93.1)	-62.2 (-66.1 to -57.7)	-69.1 (-72.3 to -65.3)
Road injuries	-	-	-	-	166.9 (125.8 to 213.0)	53.7 (38.8 to 71.4)	-67.9 (-71.3 to -63.9)	-73.5 (-76.3 to -70.1)
Pedestrian road injuries	-	-	-	-	25.1 (18.6 to 32.6)	7.4 (5.2 to 10.1)	-70.6 (-73.8 to -66.6)	-76.2 (-78.8 to -72.7)
Cyclist road injuries	-	-	-	-	18.1 (13.6 to 23.2)	5.9 (4.2 to 7.8)	-67.6 (-72.0 to -62.4)	-73.3 (-77.0 to -68.9)
Motorcyclist road injuries	-	-	-	-	28.7 (21.3 to 36.9)	9.5 (6.7 to 12.8)	-67.1 (-72.4 to -60.4)	-72.4 (-77.0 to -66.7)
Motor vehicle road injuries	-	-	-	-	94.1 (71.1 to 119.9)	30.8 (22.7 to 40.3)	-67.4 (-70.7 to -63.7)	-73.0 (-75.7 to -69.8)
Other road injuries	-	-	-	-	0.2 (0.6 to 1.1)	0.2 (0.2 to 0.3)	-74.3 (-77.6 to -70.2)	-78.2 (-81.3 to -74.6)
Other transport injuries	-	-	-	-	16.6 (12.2 to 21.9)	16.0 (11.4 to 21.9)	-3.7 (-13.8 to 6.3)	-23.7 (-31.7 to -16.2)
Unintentional injuries	-	-	-	-	762.9 (581.2 to 972.8)	709.9 (510.2 to 956.2)	-7.2 (-17.7 to 4.9)	-28.0 (-35.6 to -19.7)
Falls	-	-	-	-	599.6 (454.5 to 761.4)	590.6 (425.6 to 793.0)	-1.8 (-15.0 to 13.4)	-23.8 (-33.1 to -13.3)
Drowning	-	-	-	-	1.1 (0.8 to 1.4)	0.7 (0.5 to 0.9)	-34.0 (-46.5 to -25.4)	-46.3 (-52.0 to -39.6)
Fire, heat, and hot substances	-	-	-	-	17.9 (11.2 to 27.9)	11.8 (6.8 to 19.4)	-34.4 (-43.8 to -23.6)	-47.6 (-56.1 to -38.7)
Poisonings	-	-	-	-	0.7 (0.5 to 1.0)	0.3 (0.2 to 0.4)	-62.6 (-68.3 to -54.4)	-68.3 (-73.4 to -61.3)
Exposure to mechanical forces	-	-	-	-	123.7 (92.7 to 162.3)	59.7 (42.0 to 81.5)	-51.9 (-56.9 to -46.6)	-57.5 (-61.9 to -52.7)
Unintentional firearm injuries	-	-	-	-	0.8 (0.6 to 1.0)	0.4 (0.3 to 0.6)	-45.4 (-52.7 to -38.0)	-48.9 (-56.2 to -42.0)
Unintentional suffocation	-	-	-	-	0.5 (0.3 to 0.6)	0.5 (0.4 to 0.7)	12.9 (-3.6 to 31.0)	6.1 (-21.0 to 9.9)
Other exposure to mechanical forces	-	-	-	-	122.4 (91.7 to 160.8)	58.7 (41.3 to 80.2)	-52.2 (-57.2 to -46.9)	-57.7 (-62.2 to -52.9)
Adverse effects of medical treatment	-	-	-	-	4.6 (3.0 to 6.9)	5.8 (3.7 to 8.6)	25.0 (13.7 to 38.6)	0.9 (-7.1 to 10.0)
Animal contact	-	-	-	-	3.1 (2.3 to 4.2)	4.0 (2.8 to 5.6)	28.5 (18.1 to 41.0)	7.6 (-1.8 to 18.9)
Venomous animal contact	-	-	-	-	0.5 (0.3 to 0.6)	0.5 (0.4 to 0.7)	18.3 (-0.6 to 41.9)	5.1 (-12.5 to 27.1)
Non-venomous animal contact	-	-	-	-	2.7 (1.9 to 3.6)	3.5 (2.4 to 4.9)	30.3 (18.9 to 43.1)	7.9 (-1.8 to 19.6)
Foreign body	-	-	-	-	4.6 (3.2 to 6.2)	3.9 (2.6 to 5.5)	-14.7 (-24.5 to -5.7)	-23.1 (-33.8 to -14.0)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.9 (0.7 to 1.1)	0.7 (0.5 to 0.9)	-19.2 (-28.7 to -7.8)	-39.0 (-46.9 to -29.2)
Foreign body in eyes	-	-	-	-	0.6 (0.4 to 1.0)	0.6 (0.3 to 0.9)	-9.9 (-17.7 to 2.7)	-11.3 (-21.9 to 0.7)
Foreign body in other body part	-	-	-	-	3.0 (2.0 to 4.4)	2.6 (1.6 to 3.8)	-14.8 (-27.5 to -3.3)	-21.8 (-34.0 to -9.9)
Other unintentional injuries	-	-	-	-	7.7 (5.4 to 10.6)	33.1 (23.0 to 46.6)	330.5 (251.0 to 420.5)	245.9 (182.9 to 315.1)
Self-harm and interpersonal violence	-	-	-	-	12.7 (9.6 to 16.5)	9.2 (6.6 to 12.4)	-27.7 (-33.8 to -21.0)	-40.1 (-44.8 to -34.5)
Self-harm	-	-	-	-	5.4 (3.9 to 7.2)	4.9 (3.5 to 6.6)	-20.1 (-19.4 to -0.1)	-25.9 (-33.6 to -16.7)
Interpersonal violence	-	-	-	-	7.3 (5.5 to 9.3)	4.4 (3.1 to 5.8)	-40.5 (-46.3 to -34.1)	-49.9 (-54.7 to -44.5)
Assault by firearm	-	-	-	-	1.1 (0.8 to 1.4)	0.6 (0.5 to 0.8)	-42.2 (-47.5 to -36.5)	-52.9 (-57.2 to -48.3)
Assault by sharp object	-	-	-	-	0.9 (0.7 to 1.2)	0.7 (0.5 to 0.9)	-26.0 (-32.1 to -18.6)	-38.0 (-43.0 to -31.8)
Assault by other means	-	-	-	-	5.3 (4.0 to 6.8)	3.1 (2.2 to 4.1)	-42.6 (-49.5 to -35.5)	-51.2 (-56.6 to -45.0)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-84.6 (-93.9 to -57.8)	-85.4 (-94.4 to -59.6)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-84.6 (-93.9 to -57.8)	-85.4 (-94.4 to -59.6)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Ghana prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.								
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
All causes	-	-	-	-	1,427.6 (1,032.4 to 1,893.1)	2,380.9 (1,730.7 to 3,117.2)	66.9 (60.9 to 72.7)	9.1 (-11.9 to -6.3)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	527.3 (357.9 to 739.5)	620.6 (429.8 to 861.2)	17.7 (9.8 to 28.0)	37.4 (-42.2 to -31.4)
HIV/AIDS and tuberculosis	-	-	-	-	13.7 (9.1 to 19.1)	42.0 (27.9 to 60.9)	201.2 (135.2 to 314.1)	51.0 (19.1 to 111.7)
Tuberculosis	24.7 (22.7 to 26.9)	34.2 (32.1 to 36.4)	38.4 (29.4 to 47.8)	-27.1 (-31.7 to -22.2)	7.5 (5.1 to 10.2)	10.5 (7.1 to 14.2)	39.5 (27.9 to 52.0)	-26.6 (-32.2 to -20.5)
HIV/AIDS	-	-	-	-	6.2 (3.3 to 10.1)	31.5 (20.4 to 48.6)	499.9 (227.5 to 764.9)	165.5 (69.1 to 359.7)
HIV/AIDS resulting in mycobacterial infection	0.8 (0.4 to 1.3)	1.9 (1.0 to 3.1)	150.3 (62.8 to 334.3)	31.2 (-15.2 to 128.4)	0.3 (0.1 to 0.5)	0.7 (0.3 to 1.3)	149.5 (50.9 to 353.4)	30.8 (-21.1 to 141.8)
HIV/AIDS resulting in other diseases	60.4 (38.1 to 86.6)	243.2 (208.4 to 283.5)	306.3 (180.4 to 532.7)	122.3 (51.8 to 248.0)	5.9 (3.1 to 9.8)	30.8 (19.7 to 47.6)	422.5 (232.1 to 818.3)	173.6 (71.8 to 392.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	77.1 (55.0 to 103.6)	84.5 (60.3 to 114.9)	9.2 (0.5 to 20.1)	31.3 (-36.7 to -25.2)
Diarrheal diseases	194.9 (181.4 to 208.0)	163.5 (152.5 to 174.5)	-16.4 (-23.4 to -7.7)	-44.2 (-48.6 to -38.8)	31.6 (21.1 to 44.7)	26.5 (17.7 to 36.6)	-18.1 (-24.0 to -6.8)	44.0 (-49.1 to -38.4)
Intestinal infectious diseases	-	-	-	-	0.8 (0.5 to 1.2)	0.5 (0.3 to 0.7)	0.5 (-5.1 to -21.1)	0.5 (-7.3 to -54.7)
Typhoid fever	4.3 (3.6 to 5.0)	2.7 (2.1 to 3.2)	-37.9 (-52.7 to -15.3)	-63.2 (-71.5 to -50.9)	0.6 (0.4 to 0.8)	0.4 (0.2 to 0.5)	0.4 (-54.7 to -10.8)	61.6 (-72.0 to -48.4)
Paratyphoid fever	2.8 (2.3 to 3.3)	2.1 (1.6 to 2.6)	-24.5 (-43.9 to -1.5)	-55.3 (-66.6 to -41.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	0.1 (-45.8 to 4.9)	23.8 (-67.3 to -39.7)
Other intestinal infectious diseases	-	-	-	-	0.1 (0.1 to 0.3)	0.0 (0.0 to 0.0)	-8.4 (-92.5 to -71.6)	91.3 (-95.6 to -43.6)
Lower respiratory infections	6.7 (5.4 to 8.1)	8.9 (7.4 to 10.5)	34.0 (-0.5 to 75.3)	-8.6 (25.5 to 11.1)	0.7 (0.4 to 1.0)	0.9 (0.6 to 1.4)	0.9 (-4.1 to 84.2)	8.7 (-28.4 to 16.7)
Upper respiratory infections	910.6 (850.2 to 975.1)	1,534.3 (1,422.0 to 1,645.7)	68.5 (52.3 to 85.5)	-3.7 (-12.9 to 6.1)	10.7 (5.9 to 17.4)	18.0 (10.0 to 29.7)	69.0 (52.4 to 86.4)	-3.2 (-12.5 to 7.0)
Otitis media	318.4 (287.2 to 350.2)	512.8 (466.7 to 570.4)	61.0 (45.5 to 75.9)	-7.2 (-16.3 to 1.6)	6.6 (4.0 to 10.8)	10.7 (6.2 to 16.9)	60.7 (44.2 to 78.5)	-6.9 (-16.8 to 3.5)
Meningitis	-	-	-	-	24.5 (16.9 to 33.4)	26.4 (17.8 to 36.2)	7.5 (-1.5 to 32.3)	36.1 (-46.6 to -23.5)
Pneumococcal meningitis	118.8 (72.4 to 176.1)	122.0 (74.1 to 185.1)	1.5 (-18.0 to 32.2)	-4.4 (-53.6 to -26.6)	10.1 (6.6 to 14.3)	11.4 (7.6 to 16.8)	12.4 (-13.5 to 61.7)	35.3 (-48.5 to -10.4)
H influenzae type B meningitis	48.7 (19.3 to 95.7)	44.8 (17.2 to 88.7)	-9.5 (-37.7 to 31.3)	-48.9 (-64.9 to -25.6)	5.2 (3.3 to 7.9)	5.0 (3.2 to 7.3)	-4.1 (-36.8 to 39.1)	44.3 (-62.9 to -19.6)
Meningococcal meningitis	50.6 (18.7 to 112.1)	49.3 (17.8 to 110.0)	-2.8 (-25.5 to 26.0)	-42.5 (-56.2 to -26.1)	5.5 (3.5 to 8.1)	5.9 (3.6 to 8.9)	6.6 (-18.9 to 43.4)	34.2 (-49.9 to -14.9)
Other meningitis	30.2 (19.7 to 48.6)	31.7 (20.9 to 51.4)	4.3 (-19.5 to 39.1)	-36.8 (-53.0 to -14.8)	3.7 (2.4 to 5.2)	4.0 (2.7 to 5.5)	7.1 (-15.0 to 44.9)	-34.0 (-47.2 to -11.7)
Encephalitis	2.9 (1.4 to 6.2)	4.6 (2.1 to 9.9)	56.9 (32.0 to 79.3)	-5.1 (-7.3 to -4.4)	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	64.3 (38.3 to 96.5)	11.2 (-24.2 to 3.7)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-	-	-
Whooping cough	19.4 (14.9 to 24.9)	7.2 (5.6 to 9.1)	-63.1 (-66.2 to -59.8)	-75.0 (-77.1 to -72.7)	1.0 (0.6 to 1.6)	0.4 (0.2 to 0.6)	-63.0 (-68.6 to -56.2)	75.0 (-78.8 to -70.3)
Tetanus	0.4 (0.2 to 0.7)	0.2 (0.1 to 0.4)	-51.3 (-76.1 to 47.3)	-73.1 (-86.9 to -36.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.3 (-73.9 to 44.6)	-71.3 (-85.7 to -22.4)
Measles	6.7 (4.9 to 9.0)	0.6 (0.5 to 0.8)	-90.4 (-92.8 to -86.9)	-93.6 (-95.2 to -91.3)	0.6 (0.3 to 1.0)	0.1 (0.0 to 0.1)	90.5 (-94.6 to -84.5)	29.7 (-96.4 to -89.7)
Varicella and herpes zoster	8.8 (7.9 to 9.8)	17.1 (15.5 to 19.0)	92.4 (69.7 to 126.4)	5.3 (-12.9 to 34.4)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	112.0 (51.2 to 209.9)	7.1 (-24.3 to 63.0)
Neglected tropical diseases and malaria	-	-	-	-	240.6 (153.3 to 365.4)	196.0 (124.8 to 312.6)	19.0 (-30.5 to -0.7)	-19.4 (-67.5 to -52.1)
Malaria	7,029.1 (6,476.7 to 7,586.5)	9,965.0 (9,232.8 to 10,757.7)	41.3 (32.7 to 51.2)	-20.0 (-25.2 to -13.2)	60.2 (40.1 to 86.9)	81.9 (55.4 to 117.0)	36.3 (26.5 to 47.2)	-19.7 (-26.1 to -13.2)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-1.0 (-82.0 to -22.4)	-74.9 (-88.8 to -48.9)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.4 (21.4 to 170.4)	12.3 (-22.4 to 52.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.4 (21.3 to 170.5)	12.3 (-22.5 to 53.0)
Cutaneous and mucocutaneous leishmaniasis	2.9 (1.9 to 4.4)	1.2 (0.6 to 2.2)	-60.8 (-81.3 to -27.2)	-75.0 (-88.1 to -51.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-61.2 (-82.3 to -22.8)	-75.0 (-88.9 to -48.9)
African trypanosomiasis	0.1 (0.0 to 0.2)	-	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	-	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Schistosomiasis	7,912.6 (4,637.0 to 11,331.2)	6,482.9 (3,588.2 to 10,919.4)	-21.7 (-34.8 to 17.1)	-57.8 (-64.9 to -37.6)	57.8 (36.4 to 166.8)	83.5 (28.9 to 156.5)	59.5 (-32.6 to 24.4)	56.9 (-63.2 to -33.3)
Cysticercosis	18.7 (7.4 to 35.3)	20.5 (7.1 to 42.4)	9.8 (-73.1 to 340.7)	-44.0 (81.7 to 83.5)	5.0 (1.8 to 9.6)	5.9 (2.0 to 12.2)	5.9 (-72.1 to 394.2)	40.0 (80.1 to 105.6)
Cystic echinococcosis	5.6 (5.0 to 6.0)	3.1 (2.9 to 3.2)	-45.5 (-49.0 to -40.4)	-75.3 (-80.4 to -73.2)	0.5 (0.3 to 0.7)	0.5 (0.2 to 0.4)	-44.5 (-55.6 to -30.8)	-75.1 (-80.7 to -69.9)
Lymphatic filariasis	832.5 (722.3 to 960.1)	212.5 (143.2 to 292.8)	-74.4 (-82.7 to -65.5)	-84.9 (-89.6 to -80.1)	21.5 (11.6 to 35.3)	16.9 (8.7 to 27.7)	-19.5 (-53.7 to 10.9)	-16.9 (-75.3 to -40.8)
Onchocerciasis	1,095.4 (877.1 to 1,338.9)	0.0	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	56.1 (32.7 to 86.4)	0.0	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Trachoma	20.7 (11.1 to 32.3)	33.9 (19.9 to 52.2)	63.7 (0.5 to 162.3)	-32.2 (-57.8 to 7.2)	0.8 (0.4 to 1.4)	1.4 (0.7 to 2.4)	83.6 (13.1 to 187.3)	-26.0 (53.9 to 16.1)
Dengue	2.4 (1.0 to 5.2)	20.4 (8.4 to 44.8)	761.4 (754.4 to 769.4)	388.1 (384.2 to 392.6)	0.4 (0.1 to 0.9)	3.3 (1.2 to 8.0)	764.5 (598.3 to 1,015.8)	390.1 (311.2 to 504.8)
Yellow fever	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-52.8 (-62.7 to -39.3)	-73.4 (-78.4 to -66.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.8 (-62.7 to -39.2)	-73.4 (-78.5 to -66.9)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-37.1 to 65.9)	0.0 (0.0 to 0.0)	-	-
Intestinal nematode infections	-	-	-	-	2.3 (1.3 to 3.6)	3.9 (2.2 to 6.3)	71.9 (26.7 to 134.3)	4.1 (-29.7 to 28.8)
Ascariasis	567.0 (373.0 to 857.5)	993.5 (635.2 to 1,499.1)	76.1 (-6.0 to 216.6)	-0.8 (-52.2 to 98.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	66.0 (18.5 to 137.2)	-1.8 (-31.3 to 39.8)
Trichuriasis	373.9 (235.0 to 575.0)	677.2 (423.7 to 1,075.3)	78.4 (-4.7 to 249.0)	2.3 (-52.6 to 119.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.7 (9.2 to 158.6)	-2.9 (-39.9 to 60.3)
Hookworm disease	741.9 (489.1 to 1,104.3)	1,385.6 (869.9 to 1,992.0)	74.9 (1.2 to 216.1)	74.9 (-47.0 to 93.2)	2.3 (1.3 to 3.5)	3.8 (2.2 to 6.2)	72.1 (25.4 to 136.9)	4.1 (-29.9 to 29.4)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	-	-
Other neglected tropical diseases	232.2 (173.3 to 292.8)	326.5 (301.7 to 358.3)	40.4 (10.7 to 88.2)	-15.8 (-32.0 to 9.1)	10.3 (6.1 to 15.2)	12.8 (8.2 to 18.7)	22.6 (1.0 to 70.6)	-30.0 (-43.7 to -5.0)
Maternal disorders	-	-	-	-	3.4 (3.4 to 8.7)	9.7 (5.6 to 14.7)	79.2 (43.1 to 93.7)	-11.4 (-24.1 to 0.1)
Maternal hemorrhage	4.8 (3.3 to 6.2)	9.4 (5.6 to 13.3)	95.2 (14.6 to 207.2)	-1.6 (-41.9 to 53.7)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.6)	79.2 (-15.9 to 233.2)	-11.4 (-58.2 to 64.3)
Maternal sepsis and other maternal infections	3.1 (1.8 to 4.9)	4.5 (3.0 to 6.5)	45.9 (9.0 to 106.2)	-31.0 (-47.6 to -1.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	35.5 (-31.4 to 226.6)	-34.1 (-63.4 to 61.3)
Maternal hypertensive disorders	7.3 (4.0 to 11.5)	10.2 (5.6 to 16.3)	40.9 (21.9 to 57.0)	-28.7 (-38.4 to -19.4)	0.4 (0.2 to 0.6)	0.5 (0.2 to 0.9)	40.1 (16.7 to 67.3)	-28.7 (-40.5 to -14.5)
Obstructed labor	12.3 (8.1 to 16.4)	20.7 (13.1 to 27.5)	68.1 (45.8 to 87.2)	-12.5 (-23.3 to -2.8)	4.0 (2.3 to 6.3)	6.8 (3.7 to 10.7)	68.4 (41.8 to 94.7)	-11.7 (-24.6 to 1.8)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	40.3 (-23.0 to 169.2)	-31.1 (-62.3 to 27.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-23.2 to 169.9)	0.0 (-62.3 to 28.0)
Other maternal disorders	-	-	-	-	1.1 (0.6 to 1.8)	1.9 (1.0 to 3.1)	68.7 (17.5 to 139.7)	-11.8 (-38.3 to 25.3)
Neonatal disorders	-	-	-	-	11.7 (7.4 to 17.7)	42.7 (27.9 to 60.9)	260.1 (148.3 to 513.5)	120.9 (49.4 to 280.0)
Preterm birth complications	50.8 (25.9 to 93.7)	201.5 (118.1 to 349.1)	297.2 (219.9 to 446.0)	127.4 (83.6 to 207.7)	4.3 (2.5 to 7.3)	22.3 (13.8 to 34.4)	407.7 (215.7 to 810.1)	205.3 (91.0 to 439.9)
Neonatal encephalopathy due to birth asphyxia and trauma	81.1 (9.8 to 251.4)	121.2 (24.2 to 360.5)	56.5 (21.5 to 191.2)	-12.6 (-31.2 to 68.4)	4.0 (1.6 to 8.0)	10.1 (5.4 to 17.5)	159.0 (47.4 to 460.1)	58.1 (-11.8 to 272.9)
Neonatal sepsis and other neonatal infections	6.3 (0.1 to 0.5)	0.8 (0.3 to 1.6)	139.8 (217.8 to 237.6)	23.9 (126.5 to 140.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	139.8 (206.7 to 247.4)	131.6 (118.5 to 147.5)
Hemolytic disease and other neonatal jaundice	6.1 (2.8 to 10.4)	17.8 (8.9 to 38.0)	173.5 (35.0 to 637.1)	66.7 (-19.3 to 356.7)	2.3 (1.0 to 4.1)	6.8 (3.2 to 15.4)	177.2 (34.1 to 672.4)	68.9 (-18.9 to 373.0)
Other neonatal disorders	-	-	-	-	1.0 (0.5 to 2.0)	3.4 (1.4 to 6.3)	225.4 (47.5 to 730.0)	99.1 (-10.7 to 407.5)
Nutritional deficiencies	-	-	-	-	166.4 (111.0 to 237.8)	229.2 (154.2 to 325.7)	37.3 (26.9 to 51.0)	-19.4 (-25.3 to -11.6)
Protein-energy malnutrition	111.3 (72.2 to 164.5)	115.8 (57.8 to 213.4)	0.0 (-53.2 to 118.6)	-29.4 (-64.3 to 45.9)	13.7 (7.5 to 23.2)	14.3 (6.1 to 30.6)	0.1 (-53.2 to 120.7)	29.3 (-64.8 to 49.1)
Iodine deficiency	415.6 (194.5 to 681.1)	760.3 (462.0 to 1,204.0)	78.1 (-13.5 to 386.0)	-1.5 (-53.4 to 190.0)	7.5 (3.0 to 14.1)	13.7 (6.9 to 26.4)	77.7 (-13.3 to 401.2)	-1.4 (-52.9 to 192.5)
Vitamin A deficiency	38.3 (29.2 to 48.6)	42.9 (32.4 to 54.1)	12.1 (8.1 to 31.6)	-23.6 (-37.6 to -8.3)	1.3 (0.8 to 2.1)	1.5 (0.9 to 2.4)	13.3 (7.0 to 34.3)	21.7 (-5.9 to 59.9)

Appendix Table G.4 - Ghana prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	3,798.9 (3,694.9 to 3,937.4)	5,602.2 (5,491.5 to 5,724.6)	47.2 (41.4 to 51.6)	-37.0 (-19.9 to -14.3)	143.9 (97.0 to 206.2)	199.6 (133.7 to 286.7)	38.7 (31.5 to 44.8)	26.1 (-23.4 to -15.0)
Other nutritional deficiencies	-	-	-	-	0.0	0.0	82.6 (44.0 to 144.6)	31.9 (-56.7 to 271.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	12.0 (7.6 to 17.6)	16.5 (10.5 to 25.2)	37.2 (21.4 to 56.5)	-24.3 (-32.3 to -13.7)
Sexually transmitted diseases excluding HIV	-	-	-	-	3.0 (1.7 to 5.0)	5.0 (2.6 to 9.3)	68.7 (23.7 to 118.1)	-13.3 (-33.1 to 8.0)
Syphilis	1.5 (1.3 to 1.7)	1.7 (1.5 to 1.9)	9.2 (-7.0 to 24.2)	-45.3 (-52.1 to -38.8)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	9.0 (-16.0 to 41.2)	45.3 (-55.7 to -31.3)
Chlamydial infection	240.4 (169.3 to 323.5)	575.6 (447.1 to 713.9)	141.7 (61.0 to 263.4)	28.8 (-11.7 to 95.9)	1.1 (0.6 to 1.9)	2.1 (1.0 to 3.6)	81.7 (12.1 to 196.2)	-4.0 (-45.8 to 52.4)
Gonococcal infection	64.0 (42.5 to 91.1)	117.4 (83.3 to 149.9)	81.8 (16.7 to 202.9)	-4.5 (-35.8 to 52.0)	0.5 (0.3 to 0.9)	0.8 (0.4 to 1.4)	61.5 (-17.4 to 175.3)	-15.4 (-54.7 to 37.7)
Trichomoniasis	202.7 (120.8 to 293.1)	326.3 (155.7 to 561.4)	62.1 (-33.8 to 224.2)	-9.5 (-59.0 to 62.5)	0.4 (0.1 to 0.8)	0.6 (0.1 to 1.4)	58.0 (-45.5 to 245.4)	-10.7 (-65.3 to 74.8)
Genital herpes	2,242.6 (2,056.5 to 2,446.5)	4,386.1 (4,024.3 to 4,732.9)	94.3 (72.3 to 118.9)	-2.5 (-13.6 to 9.0)	1.2 (0.2 to 1.5)	1.2 (0.4 to 2.8)	93.8 (70.8 to 119.8)	-2.0 (-13.4 to 10.7)
Other sexually transmitted diseases	5.4 (3.6 to 7.4)	9.1 (6.3 to 12.4)	70.2 (44.5 to 94.8)	-16.4 (-29.4 to -4.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	68.9 (11.7 to 150.5)	-15.0 (-41.7 to 18.8)
Hepatitis	-	-	-	-	2.5 (1.5 to 3.6)	2.8 (1.7 to 4.0)	12.4 (6.6 to 36.5)	-43.0 (-53.0 to -27.9)
Hepatitis A	25.5 (24.2 to 26.8)	37.6 (36.0 to 39.2)	46.9 (45.7 to 48.4)	-5.8 (-6.0 to -5.5)	0.5 (0.3 to 0.7)	0.8 (0.5 to 1.2)	70.0 (51.6 to 93.1)	3.1 (-7.9 to 16.4)
Hepatitis B	3,496.0 (2,991.1 to 4,044.5)	3,382.9 (2,976.3 to 3,740.6)	-4.0 (-20.6 to 16.6)	-48.6 (-57.1 to -39.0)	1.6 (1.0 to 2.4)	1.5 (0.9 to 2.2)	-7.1 (-31.5 to 26.4)	-53.1 (-65.7 to -35.4)
Hepatitis C	820.5 (757.0 to 885.4)	1,131.5 (1,031.4 to 1,234.6)	37.4 (22.5 to 55.6)	-27.6 (-35.0 to -18.9)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	39.3 (23.9 to 86.1)	-23.7 (-44.0 to 5.0)
Hepatitis E	8.7 (7.0 to 10.6)	10.4 (8.1 to 12.5)	19.5 (-1.5 to 44.7)	-34.6 (-47.1 to -22.3)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.4)	19.8 (-7.8 to 55.0)	-35.0 (-49.7 to -18.0)
Leprosy	0.8 (0.5 to 1.1)	0.8 (0.7 to 1.0)	4.7 (-16.3 to 34.4)	-44.1 (-54.8 to -29.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	13.6 (-18.5 to 72.8)	-39.8 (-55.7 to -13.3)
Other infectious diseases	168.8 (130.4 to 214.5)	236.4 (207.0 to 263.5)	39.6 (22.7 to 59.3)	-18.1 (-27.8 to -6.1)	6.5 (4.0 to 9.5)	8.6 (5.6 to 12.5)	32.6 (13.4 to 58.0)	-9.7 (-31.5 to 11.1)
Non-communicable diseases	-	-	-	-	857.1 (636.7 to 1,118.1)	1,693.2 (1,235.6 to 2,216.7)	97.4 (92.0 to 103.1)	3.5 (0.7 to 6.2)
Neoplasms	-	-	-	-	4.5 (2.9 to 6.3)	8.0 (5.4 to 11.3)	69.9 (24.8 to 177.3)	-17.6 (-39.1 to 42.0)
Esophageal cancer	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	89.9 (23.1 to 201.3)	-9.2 (-41.4 to 42.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	89.8 (25.9 to 181.9)	-9.3 (-41.4 to 36.1)
Stomach cancer	1.6 (1.2 to 2.0)	1.7 (1.4 to 2.2)	6.8 (-22.0 to 57.6)	-48.3 (-62.6 to -21.5)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	9.8 (-21.3 to 61.7)	-47.3 (-62.6 to -19.6)
Liver cancer	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	29.0 (-6.2 to 87.9)	37.7 (-54.8 to -9.1)
Liver cancer due to hepatitis B	0.7 (0.4 to 1.0)	0.8 (0.3 to 1.5)	1.2 (-60.6 to 164.9)	-53.6 (83.2 to 28.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	0.7 (-60.7 to 152.5)	53.8 (82.5 to 23.9)
Liver cancer due to hepatitis C	0.2 (0.1 to 0.4)	0.8 (0.4 to 1.2)	238.5 (59.1 to 694.8)	62.0 (-19.6 to 282.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	223.8 (62.4 to 639.1)	53.3 (-21.4 to 253.9)
Liver cancer due to alcohol use	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.7)	1.5 (-49.1 to 98.2)	-52.7 (-74.4 to -9.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	1.7 (-44.1 to 89.1)	-51.7 (-72.8 to -16.1)
Liver cancer due to other causes	0.4 (0.3 to 0.7)	0.4 (0.2 to 0.6)	20.7 (-55.2 to 48.5)	-43.5 (-79.7 to -33.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	20.7 (-51.0 to 40.3)	-43.5 (-77.3 to -37.8)
Larynx cancer	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.2)	-37.9 (-57.5 to 149.6)	-77.1 (-85.1 to 8.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-58.2 to 153.4)	-38.5 (-85.5 to 19.2)
Tracheal, bronchus and lung cancer	0.5 (0.4 to 0.7)	0.5 (0.4 to 0.7)	-13.1 (-35.8 to 42.5)	-60.5 (-71.1 to -32.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-11.1 (-35.9 to 42.9)	-59.2 (-71.0 to -32.1)
Breast cancer	7.8 (5.2 to 10.5)	14.4 (10.2 to 19.5)	82.9 (17.8 to 224.1)	-15.6 (-44.8 to 55.8)	0.7 (0.4 to 1.0)	1.1 (0.7 to 1.7)	59.5 (3.9 to 190.0)	-27.0 (-51.9 to 42.1)
Cervical cancer	9.5 (6.0 to 13.3)	12.1 (7.7 to 17.6)	24.7 (-24.9 to 128.3)	48.1 (-62.6 to 13.1)	0.1 (0.4 to 1.2)	1.0 (0.6 to 1.6)	-99.3 (-24.2 to 135.4)	-9.3 (-62.1 to 18.2)
Uterine cancer	3.3 (1.7 to 5.2)	5.0 (3.1 to 8.4)	51.8 (-17.7 to 201.8)	-27.8 (-60.4 to 48.3)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.6)	50.8 (-18.4 to 207.9)	-30.1 (-62.1 to 51.8)
Prostate cancer	7.4 (3.4 to 11.8)	27.9 (17.7 to 49.7)	266.8 (81.7 to 760.9)	64.5 (-13.6 to 289.2)	0.8 (0.3 to 1.3)	2.5 (1.5 to 4.3)	208.3 (64.7 to 631.1)	38.2 (-23.5 to 231.8)
Colon and rectum cancer	1.9 (1.5 to 2.3)	4.3 (3.5 to 5.1)	123.5 (73.5 to 199.6)	-3.7 (-26.1 to 32.2)	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	110.7 (62.4 to 189.2)	-10.0 (-33.1 to 28.2)
Lip and oral cavity cancer	0.7 (0.4 to 0.9)	0.7 (0.5 to 1.3)	-3.0 (-38.5 to 159.1)	-56.8 (-73.7 to 24.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	1.1 (-39.3 to 156.6)	-57.3 (-74.1 to 25.6)
Nasopharynx cancer	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-17.1 (-48.9 to 42.6)	-62.0 (-75.8 to -29.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-48.3 to 40.8)	-20.5 (-76.3 to -31.7)
Other pharynx cancer	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-13.2 (-49.3 to 113.8)	-64.6 (-80.0 to 5.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-46.0 to 116.2)	-15.7 (-79.1 to 3.4)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-19.8 (-56.0 to 92.5)	-63.4 (-80.0 to -6.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-55.6 to 81.6)	-63.8 (-79.7 to -8.2)
Pancreatic cancer	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	146.1 (74.2 to 269.9)	13.4 (-20.5 to 75.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	140.2 (76.9 to 248.4)	10.9 (-20.8 to 71.1)
Malignant skin melanoma	0.5 (0.4 to 0.6)	1.0 (0.7 to 1.5)	99.9 (38.8 to 197.4)	65.9 (-37.4 to 43.3)	0.1 (0.0 to 0.0)	0.1 (0.0 to 0.0)	94.0 (17.6 to 192.5)	-11.2 (-40.6 to 40.1)
Non-melanoma skin cancer	0.8 (0.5 to 1.1)	1.6 (1.0 to 2.3)	101.6 (2.1 to 221.1)	-11.6 (-51.2 to 41.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	142.4 (57.1 to 325.2)	-4.8 (-46.2 to 100.8)
Ovarian cancer	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.5)	75.7 (6.9 to 203.9)	-17.0 (-50.5 to 53.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	73.1 (2.3 to 212.8)	-17.8 (-54.4 to 60.7)
Testicular cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	99.3 (-14.1 to 354.0)	-4.3 (-56.0 to 111.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.6 (-22.6 to 333.6)	-11.6 (-62.4 to 99.4)
Kidney cancer	0.5 (0.3 to 0.8)	0.6 (0.4 to 1.0)	20.0 (-33.7 to 130.7)	-45.1 (-64.6 to -7.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-38.6 to 119.0)	-50.9 (-68.1 to -20.2)
Bladder cancer	0.5 (0.4 to 0.7)	0.9 (0.7 to 1.3)	68.1 (17.2 to 154.4)	-29.4 (-50.6 to 13.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	68.6 (16.4 to 159.1)	-29.7 (-50.7 to 17.8)
Brain and nervous system cancer	1.0 (0.5 to 1.2)	1.1 (0.9 to 1.6)	15.2 (-21.7 to 176.2)	-43.3 (-59.5 to 40.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	11.1 (-22.3 to 161.0)	-46.7 (-61.6 to 35.7)
Thyroid cancer	0.3 (0.2 to 0.5)	0.7 (0.5 to 1.2)	159.4 (44.8 to 361.7)	28.0 (-31.5 to 131.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (38.4 to 335.9)	18.5 (-35.3 to 119.5)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.5 (-40.7 to 25.7)	-63.9 (-76.1 to -44.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-42.6 to 22.7)	45.2 (-77.0 to -47.6)
Hodgkin lymphoma	0.6 (0.4 to 0.8)	1.2 (0.9 to 1.8)	120.1 (38.4 to 256.0)	17.3 (-23.7 to 79.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	105.2 (29.4 to 222.2)	2.0 (-34.3 to 63.6)
Non-Hodgkin lymphoma	3.1 (1.4 to 4.7)	3.3 (2.2 to 5.5)	-12.5 (-42.6 to 224.3)	-56.0 (-70.9 to 67.4)	0.3 (0.1 to 0.4)	0.3 (0.1 to 0.5)	-18.9 (-47.7 to 205.0)	-59.2 (-73.5 to 56.5)
Multiple myeloma	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	48.9 (-47.8 to 296.2)	-28.9 (-77.5 to 100.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	44.9 (-53.7 to 320.1)	-30.9 (-80.6 to 115.5)
Leukemia	0.8 (0.5 to 1.2)	1.4 (0.9 to 2.4)	78.8 (0.2 to 248.1)	-18.1 (-49.5 to 45.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	45.3 (-1.1 to 141.6)	-39.9 (-56.2 to 2.5)
Other neoplasms	3.3 (2.2 to 4.6)	7.5 (4.8 to 11.4)	115.4 (29.8 to 351.6)	-14.2 (-45.7 to 103.3)	0.2 (0.1 to 0.4)	0.5 (0.3 to 0.8)	93.4 (20.6 to 318.9)	-25.6 (-52.9 to 82.5)
Cardiovascular diseases	-	-	-	-	25.5 (17.2 to 35.4)	51.6 (33.9 to 72.1)	103.7 (56.7 to 157.3)	1.4 (-19.3 to 26.5)
Rheumatic heart disease	166.0 (121.6 to 198.9)	264.2 (180.2 to 334.3)	63.4 (-1.8 to 121.9)	-14.6 (-43.9 to 13.2)	8.1 (5.0 to 12.4)	13.3 (7.9 to 20.9)	66.7 (5.6 to 127.1)	-12.7 (-13.9 to 15.8)
Ischemic heart disease	124.4 (98.0 to 160.2)	191.7 (161.6 to 227.6)	52.7 (16.2 to 112.8)	-22.3 (-39.5 to 5.4)	6.5 (3.9 to 9.9)	8.9 (5.6 to 13.1)	39.1 (-6.7 to 109.7)	-29.1 (-49.8 to 6.6)
Cerebrovascular disease	-	-	-	-	1.3 (0.7 to 1.6)	2.3 (1.5 to 3.1)	106.5 (63.1 to 155.7)	1.3 (-20.1 to 25.7)
Ischemic stroke	5.6 (4.6 to 6.7)	11.7 (9.9 to 13.5)	108.6 (65.0 to 158.2)	1.1 (-21.2 to 27.0)	0.9 (0.6 to 1.2)	1.8 (1.2 to 2.5)	110.9 (64.3 to 166.0)	2.7 (-19.4 to 31.0)
Hemorrhagic stroke	1.7 (1.3 to 2.0)	3.2 (2.7 to 3.7)	89.7 (48.8 to 147.8)	-7.2 (-27.7 to 20.9)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	91.6 (46.5 to 155.2)	-6.1 (-28.1 to 25.0)
Hypertensive heart disease	13.3 (9.8 to 18.7)	26.3 (18.0 to 37.8)	92.7 (26.9 to 202.8)	-16.5 (-45.7 to 32.1)	1.5 (0.9 to 2.1)	2.9 (1.7 to 4.7)	94.2 (25.9 to 206.4)	-15.6 (-45.7 to 35.1)
Cardiomyopathy and myocarditis	12.3 (10.0 to 15.6)	32.1 (23.2 to 43.5)	164.1 (64.4 to 265.6)	30.0 (-16.9 to 89.9)	1.3 (0.9 to 2.0)	3.5 (2.1 to 5.3)	164.5 (64.3 to 269.2)	30.8 (-16.3 to 93.6)
Atrial fibrillation and flutter	1.7 (1.3 to 2.1)	10.1 (6.5 to 15.1)	498.1 (271.6 to 862.5)	134.1 (29.2 to 346.2)	0.1 (0.1 to 0.2)	0.1 (0.4 to 1.3)	488.8 (258.3 to 876.2)	140.5 (30.3 to 360.6)
Peripheral vascular disease	188.3 (144.3 to 258.9)	434.0 (264.4 to 580.3)	134.0 (41.0 to 229.6)	-2.3 (-37.4 to 39.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.7)	108.7 (13.2 to 325.7)	-17.6 (-56.2 to 46.9)
Endocarditis	1.4 (1.0 to 2.1)	2.2 (1.5 to 3.2)	56.2 (1.3 to 161.2)	-19.6 (-55.3 to 37.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	64.5 (0.7 to 176.7)	-16.9 (-55.7 to 53.4)
Other cardiovascular and circulatory diseases	92.0 (59.6 to 139.6)	375.3 (160.8 to 393.1)	306.4 (62.1 to 476.5)	45.6 (-22.8 to 189.7)	6.4 (3.4 to 10.7)	19.2 (10.5 to 31.2)	199.2 (63.0 to 487.2)	43.5 (-22.0 to 193.8)
Chronic respiratory diseases	-	-	-	-	52.9 (35.4 to 73.1)			

Appendix Table G.4 - Ghana prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	93.4 (85.8 to 99.1)	-7.5 (-10.7 to -4.5)
Silicosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	81.9 (72.5 to 90.7)	-14.2 (-18.3 to -9.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.5 (72.3 to 90.4)	-14.2 (-18.4 to -9.8)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	101.6 (93.2 to 110.0)	-4.8 (-4.5 to 2.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.8 (94.0 to 112.0)	-0.1 (-3.9 to 4.2)
Asthma	216.2 (170.4 to 277.7)	317.2 (238.4 to 399.4)	49.9 (-11.8 to 101.7)	-19.1 (-43.0 to 0.6)	9.5 (5.9 to 14.4)	14.0 (8.6 to 21.2)	50.8 (-11.8 to 104.6)	-18.5 (-43.0 to 2.0)
Interstitial lung disease and pulmonary sarcoidosis	0.3 (0.2 to 0.4)	0.6 (0.5 to 0.8)	104.2 (52.7 to 201.0)	4.8 (-21.0 to 50.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	104.4 (53.1 to 201.4)	4.7 (-21.1 to 49.7)
Other chronic respiratory diseases	-	-	-	-	5.3 (3.2 to 8.6)	11.9 (7.5 to 18.2)	122.3 (67.5 to 205.1)	9.8 (-18.3 to 50.3)
Cirrhosis	-	-	-	-	1.3 (0.9 to 1.7)	1.9 (1.3 to 2.7)	59.2 (35.7 to 72.6)	47.1 (-25.9 to -7.2)
Cirrhosis due to hepatitis B	3.1 (2.3 to 3.7)	3.5 (2.0 to 5.0)	12.9 (-35.1 to 75.9)	-8.0 (-67.0 to -3.5)	0.5 (0.3 to 0.7)	0.6 (0.3 to 1.0)	13.5 (-36.3 to 90.1)	-38.0 (-66.4 to -0.5)
Cirrhosis due to hepatitis C	1.2 (0.5 to 2.0)	2.6 (1.6 to 3.9)	119.0 (7.7 to 330.8)	22.6 (-37.0 to 124.1)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.7)	118.4 (2.6 to 351.3)	22.9 (-40.1 to 143.8)
Cirrhosis due to alcohol use	1.6 (1.2 to 2.0)	2.2 (1.5 to 3.0)	35.0 (-12.6 to 133.4)	-31.5 (-55.4 to 13.7)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	37.8 (-13.3 to 144.4)	-30.2 (-54.8 to 20.8)
Cirrhosis due to other causes	1.7 (1.4 to 2.3)	3.3 (2.6 to 4.0)	89.0 (38.9 to 147.5)	16.3 (-19.6 to 55.4)	0.3 (0.2 to 0.5)	0.6 (0.3 to 0.9)	89.0 (27.1 to 174.7)	17.2 (-23.9 to 69.5)
Digestive diseases	-	-	-	-	15.6 (11.6 to 22.7)	32.7 (23.2 to 44.8)	97.2 (77.3 to 118.3)	-1.2 (-9.3 to 7.5)
Peptic ulcer disease	73.5 (58.8 to 83.2)	110.1 (95.1 to 125.3)	49.4 (27.1 to 77.4)	-30.6 (-39.5 to -19.9)	2.8 (1.8 to 4.2)	4.0 (2.7 to 5.8)	43.2 (6.3 to 76.1)	-31.9 (-44.5 to -20.0)
Gastritis and duodenitis	166.6 (143.7 to 184.7)	311.6 (274.8 to 341.2)	86.1 (57.4 to 121.9)	1.6 (-12.0 to 19.5)	7.0 (4.7 to 9.9)	12.6 (8.4 to 18.1)	80.6 (49.2 to 116.6)	-0.8 (-15.6 to 15.1)
Appendicitis	1.7 (1.3 to 2.1)	3.4 (2.7 to 4.6)	102.7 (36.3 to 199.8)	4.9 (-23.8 to 47.0)	0.5 (0.3 to 0.8)	1.0 (0.6 to 1.6)	106.4 (29.0 to 233.0)	7.3 (-26.8 to 63.4)
Paralytic ileus and intestinal obstruction	0.2 (0.1 to 0.3)	0.3 (0.3 to 0.4)	89.1 (31.2 to 144.4)	-2.6 (-14.5 to 9.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	89.0 (21.7 to 167.8)	-1.6 (-23.5 to 26.9)
Inguinal, femoral, and abdominal hernia	43.5 (37.3 to 53.1)	75.4 (65.6 to 90.4)	74.9 (36.8 to 117.5)	-14.3 (-31.9 to 6.7)	0.5 (0.2 to 0.9)	0.8 (0.4 to 1.5)	74.9 (35.7 to 116.5)	-13.4 (-31.8 to 8.1)
Inflammatory bowel disease	13.4 (12.8 to 14.0)	33.7 (32.2 to 35.2)	150.2 (135.7 to 166.8)	26.0 (19.0 to 33.5)	2.9 (2.0 to 3.9)	7.2 (4.9 to 9.9)	151.7 (129.3 to 176.9)	27.0 (17.3 to 38.1)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	225.9 (137.8 to 322.8)	19.2 (-19.4 to 78.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	221.4 (132.8 to 332.7)	16.2 (-28.9 to 92.2)
Gallbladder and biliary diseases	4.1 (3.7 to 4.6)	9.6 (8.4 to 10.7)	134.4 (99.0 to 173.5)	-6.9 (-9.7 to 25.2)	1.0 (0.7 to 1.4)	1.0 (0.7 to 1.4)	135.1 (93.5 to 187.4)	8.4 (-10.5 to 29.7)
Pancreatitis	2.3 (2.1 to 2.4)	5.0 (4.7 to 5.2)	119.9 (101.3 to 139.0)	8.3 (0.1 to 17.9)	0.7 (0.4 to 0.9)	1.5 (1.0 to 2.0)	120.3 (84.1 to 160.5)	9.5 (-7.0 to 27.6)
Other digestive diseases	-	-	-	-	1.8 (1.2 to 2.7)	4.5 (3.0 to 6.4)	152.8 (87.2 to 214.4)	26.4 (-4.5 to 56.4)
Neurological disorders	-	-	-	-	60.2 (39.7 to 84.4)	124.3 (83.5 to 171.9)	106.1 (82.4 to 137.7)	6.1 (-4.7 to 20.9)
Alzheimer disease and other dementias	16.4 (14.4 to 18.4)	42.5 (37.8 to 47.8)	157.7 (118.0 to 211.5)	1.7 (-14.4 to 23.9)	2.2 (1.6 to 2.9)	6.0 (4.3 to 7.8)	168.1 (126.0 to 226.1)	3.3 (-13.6 to 26.5)
Parkinson disease	0.8 (0.7 to 1.0)	1.8 (1.5 to 2.1)	119.3 (104.1 to 132.3)	0.3 (-5.4 to 4.9)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	120.1 (79.6 to 168.4)	1.3 (-17.1 to 22.6)
Epilepsy	28.4 (15.8 to 44.9)	47.0 (25.9 to 72.5)	67.1 (-21.3 to 229.6)	-7.7 (-57.0 to 84.1)	8.4 (4.1 to 14.8)	15.0 (7.2 to 24.5)	82.5 (-14.2 to 267.1)	1.5 (-52.6 to 105.2)
Multiple sclerosis	0.8 (0.7 to 0.9)	1.9 (1.7 to 2.1)	129.1 (97.0 to 173.0)	14.2 (-0.5 to 34.7)	0.3 (0.2 to 0.4)	0.7 (0.5 to 0.9)	126.8 (83.4 to 186.7)	13.8 (-8.0 to 43.4)
Migraine	1,015.5 (932.6 to 1,089.7)	1,870.5 (1,720.0 to 2,026.2)	83.4 (65.0 to 109.0)	1.6 (-11.0 to 11.4)	38.7 (20.5 to 51.1)	64.1 (37.9 to 94.3)	88.5 (64.3 to 111.9)	-0.6 (-10.9 to 10.9)
Tension-type headache	1,772.8 (1,610.4 to 1,930.4)	3,541.6 (3,202.7 to 3,876.1)	99.5 (75.1 to 126.7)	3.3 (-7.4 to 14.7)	2.7 (1.3 to 4.7)	5.4 (2.6 to 9.5)	100.9 (84.6 to 130.1)	4.2 (-6.9 to 16.2)
Medication overuse headache	62.7 (38.7 to 89.7)	185.1 (119.7 to 259.6)	193.3 (114.4 to 331.9)	52.0 (12.6 to 123.4)	9.8 (5.3 to 16.0)	29.1 (16.2 to 46.8)	194.0 (115.6 to 326.9)	52.6 (13.4 to 124.4)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.3 (23.3 to 136.4)	-7.3 (-32.9 to 28.2)	2.0 (1.3 to 3.2)	3.8 (2.0 to 5.9)	91.4 (14.2 to 194.2)	-24.7 (-55.5 to 13.7)
Mental and substance use disorders	-	-	-	-	296.1 (205.7 to 405.0)	571.2 (394.8 to 775.3)	93.0 (85.5 to 100.0)	3.1 (-0.6 to 6.8)
Schizophrenia	29.9 (27.3 to 32.4)	59.9 (54.7 to 65.2)	100.4 (91.9 to 109.0)	-0.1 (-3.9 to 3.9)	19.1 (14.0 to 23.3)	19.1 (28.0 to 47.0)	102.5 (89.0 to 116.0)	1.0 (-5.2 to 7.2)
Alcohol use disorders	80.7 (75.9 to 86.2)	172.7 (162.6 to 183.1)	113.7 (104.0 to 124.1)	11.6 (6.9 to 17.1)	7.8 (5.2 to 11.1)	16.9 (11.3 to 24.3)	116.9 (102.4 to 131.0)	13.1 (5.8 to 20.1)
Drug use disorders	-	-	-	-	18.4 (11.9 to 25.5)	35.5 (23.2 to 49.5)	93.3 (72.0 to 116.6)	-1.8 (-11.5 to 8.7)
Opioid use disorders	24.0 (15.7 to 35.1)	48.3 (31.8 to 70.1)	100.7 (80.8 to 120.7)	-2.0 (-11.6 to 7.2)	9.9 (5.7 to 15.4)	20.0 (11.9 to 30.2)	103.2 (78.7 to 126.9)	-0.8 (-12.1 to 10.9)
Cocaine use disorders	6.0 (6.0 to 8.9)	8.9 (9.9 to 16.7)	49.7 (26.3 to 151.9)	1.0 (-30.4 to 22.2)	1.0 (0.6 to 1.5)	1.9 (1.1 to 2.8)	92.3 (23.4 to 172.9)	2.2 (-31.9 to 32.8)
Amphetamine use disorders	23.4 (21.8 to 25.1)	42.1 (38.9 to 45.6)	78.6 (62.5 to 99.4)	-3.5 (-11.9 to 7.2)	3.1 (1.9 to 4.5)	5.5 (3.5 to 8.3)	81.0 (53.9 to 116.0)	-2.1 (-16.9 to 15.5)
Cannabis use disorders	10.5 (8.3 to 12.8)	19.4 (15.2 to 23.4)	83.3 (81.0 to 85.9)	-0.6 (-0.8 to -0.5)	0.3 (0.2 to 0.5)	0.6 (0.3 to 0.9)	85.2 (44.2 to 132.9)	0.1 (-20.6 to 23.5)
Other drug use disorders	-	-	-	-	4.1 (2.5 to 6.1)	7.5 (4.6 to 11.0)	82.4 (30.6 to 149.9)	-3.1 (-30.6 to 32.5)
Depressive disorders	-	-	-	-	127.4 (76.3 to 199.0)	257.9 (151.5 to 396.4)	102.6 (87.0 to 119.1)	6.1 (-0.8 to 15.6)
Major depressive disorder	554.6 (356.4 to 752.1)	1,118.5 (713.8 to 1,510.3)	101.3 (84.8 to 120.4)	5.7 (-2.0 to 16.8)	114.0 (65.4 to 181.2)	230.8 (129.1 to 360.4)	102.7 (85.2 to 121.9)	6.6 (-1.2 to 17.7)
Dysthymia	139.4 (112.3 to 167.9)	280.0 (226.5 to 338.4)	100.5 (98.3 to 102.8)	1.1 (0.9 to 1.4)	13.4 (8.6 to 19.5)	27.0 (17.4 to 39.6)	101.8 (95.8 to 107.9)	1.9 (-0.5 to 4.5)
Bipolar disorder	80.1 (69.0 to 91.0)	158.4 (135.8 to 179.0)	97.3 (86.2 to 110.1)	0.5 (-4.2 to 6.2)	16.3 (10.1 to 24.6)	32.4 (20.0 to 49.3)	98.8 (83.5 to 115.1)	1.4 (-4.9 to 8.6)
Anxiety disorders	338.8 (280.4 to 403.5)	623.2 (515.6 to 741.8)	83.3 (79.9 to 88.4)	0.6 (0.4 to 0.9)	31.2 (20.5 to 44.7)	57.7 (38.0 to 82.6)	85.0 (71.4 to 92.9)	1.5 (-1.7 to 4.6)
Eating disorders	-	-	-	-	3.6 (2.2 to 5.6)	6.8 (4.0 to 10.7)	89.1 (77.9 to 106.8)	3.5 (-5.1 to 12.6)
Anorexia nervosa	2.5 (1.9 to 3.2)	4.8 (3.6 to 6.1)	90.1 (74.0 to 115.4)	6.2 (-3.1 to 19.4)	0.5 (0.3 to 0.8)	1.0 (0.6 to 1.6)	92.9 (49.7 to 146.1)	7.1 (-15.4 to 36.7)
Bulimia nervosa	14.6 (10.0 to 21.4)	27.5 (18.7 to 40.0)	87.5 (82.2 to 93.0)	2.0 (1.5 to 2.6)	3.1 (1.8 to 4.9)	5.8 (3.3 to 9.5)	88.6 (70.3 to 108.3)	2.9 (-6.1 to 12.8)
Autistic spectrum disorders	-	-	-	-	17.7 (12.1 to 23.9)	31.2 (21.7 to 42.4)	76.9 (69.9 to 83.2)	-0.6 (-3.7 to 2.7)
Autism	45.2 (42.9 to 47.6)	79.5 (75.4 to 83.7)	75.5 (75.1 to 76.0)	-1.4 (-1.4 to -1.3)	11.1 (7.4 to 15.3)	19.7 (13.2 to 27.1)	77.1 (67.8 to 86.7)	-0.3 (-5.0 to 4.6)
Asperger syndrome	65.1 (61.0 to 69.0)	113.9 (106.7 to 120.6)	74.5 (73.9 to 75.1)	-1.8 (-1.9 to -1.7)	6.5 (4.5 to 9.0)	11.4 (7.9 to 15.9)	75.2 (67.2 to 83.6)	-1.2 (-4.9 to 2.8)
Attention-deficit/hyperactivity disorder	108.9 (100.5 to 117.7)	179.9 (165.8 to 194.2)	64.8 (64.5 to 65.0)	-0.0 (-0.1 to -0.0)	1.3 (0.8 to 2.0)	2.2 (1.3 to 3.3)	65.8 (54.2 to 78.7)	0.6 (-6.5 to 8.4)
Conduct disorder	159.9 (150.8 to 169.4)	261.1 (248.4 to 279.2)	64.0 (64.1 to 64.8)	0.1 (0.1 to 0.1)	19.1 (12.1 to 27.7)	31.7 (20.0 to 46.1)	68.8 (58.1 to 78.8)	1.1 (-3.8 to 5.7)
Idiopathic intellectual disability	420.7 (260.4 to 565.3)	680.6 (462.4 to 885.8)	61.6 (36.9 to 96.5)	6.7 (-11.2 to 16.8)	20.6 (11.5 to 31.0)	33.4 (19.9 to 49.5)	62.5 (36.7 to 102.9)	6.0 (-21.5 to 18.7)
Other mental and substance use disorders	181.8 (169.3 to 193.5)	357.1 (333.0 to 379.4)	95.9 (94.9 to 97.0)	-1.4 (-1.8 to -1.1)	13.6 (9.3 to 18.4)	26.8 (18.1 to 36.0)	97.4 (89.5 to 105.4)	-0.5 (-3.8 to 2.9)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	89.2 (62.9 to 120.2)	192.3 (136.0 to 260.4)	116.3 (98.9 to 131.4)	20.3 (9.6 to 30.2)
Diabetes mellitus	194.8 (156.1 to 239.3)	782.5 (669.9 to 937.4)	305.7 (205.9 to 418.9)	111.3 (57.6 to 177.3)	13.8 (8.9 to 19.7)	56.1 (37.1 to 80.6)	312.9 (210.8 to 418.2)	111.8 (58.4 to 172.3)
Acute glomerulonephritis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-46.2 (-13.8 to 1.5)	-46.2 (-49.9 to -42.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.3 (-13.8 to 1.7)	-46.2 (-50.0 to -42.0)
Chronic kidney disease	-	-	-	-	21.5 (14.9 to 28.7)	39.8 (27.6 to 53.7)	84.8 (68.1 to 103.0)	-5.0 (-12.6 to 2.6)
Chronic kidney disease due to diabetes mellitus	83.5 (53.4 to 124.9)	145.2 (92.9 to 231.8)	70.7 (5.5 to 166.5)	-14.1 (-43.5 to 35.4)	2.1 (1.2 to 3.4)	3.8 (2.4 to 5.4)	83.3 (16.9 to 193.3)	-8.7 (-36.2 to 4.7)
Chronic kidney disease due to hypertension	399.3 (227.7 to 609.0)	691.6 (447.0 to 1,034.5)	73.7 (38.5 to 122.4)	-6.5 (-27.7 to 17.2)	7.3 (4.9 to 9.9)	13.6 (9.2 to 19.2)	88.1 (54.8 to 128.8)	-7.7 (-21.8 to 10.4)
Chronic kidney disease due to glomerulonephritis	303.8 (228.8 to 584.1)	541.7 (419.6 to 1,012.4)	76.3 (46.4 to 128.2)	0.6 (-29.1 to 7.8)	7.4 (4.9 to 10.5)	14.0 (9.5 to 10.5)	97.3 (54.2 to 133.2)	0.9 (-17.0 to 24.2)
Chronic kidney disease due to other causes	260.8 (162.1 to 391.2)	444.3 (271.1 to 653.0)	68.8 (29.7 to 135.7)	-12.4 (-35.1 to 20.3)	4.7 (3.1 to 6.5)	8.4 (5.1 to 12.0)	76.4 (38.4 to 137.9)	-8.3 (-30.6 to 25.7)
Urinary diseases and male infertility	-	-	-	-	4.4 (2.8 to 6.6)	8.9 (5.6 to 13.0)	102.2 (78.1 to 125.0)	-3.7 (-14.8 to 6.9)

Appendix Table G.4 - Ghana prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	2.7 (2.6 to 2.9)	5.6 (5.2 to 6.0)	102.6 (85.4 to 122.1)	0.1 (1.0 to 17.8)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	102.2 (56.1 to 159.8)	9.1 (-9.9 to 33.7)
Urolithiasis	32.0 (26.0 to 40.7)	55.2 (43.5 to 71.3)	72.5 (51.5 to 90.9)	-17.0 (-26.2 to -9.6)	0.3 (0.2 to 0.4)	0.7 (0.4 to 0.9)	110.0 (84.2 to 138.1)	3.8 (-6.0 to 15.4)
Benign prostatic hyperplasia	82.9 (75.5 to 90.4)	172.0 (154.3 to 187.9)	107.2 (80.8 to 133.5)	-4.9 (-16.5 to 6.3)	3.0 (1.9 to 4.3)	6.2 (3.9 to 8.8)	108.3 (80.9 to 136.7)	-3.8 (-16.2 to 8.5)
Male infertility due to other causes	164.7 (129.9 to 204.2)	280.3 (228.9 to 340.7)	69.5 (27.9 to 123.7)	-16.1 (-37.5 to 11.6)	1.0 (0.4 to 2.1)	1.7 (0.7 to 3.6)	70.6 (27.1 to 127.0)	-15.3 (-37.4 to 11.8)
Other urinary diseases	-	-	-	-	0.1	0.1	100.0	210.1
Gynecological diseases	-	-	-	-	16.1	34.4	113.9	7.1
Uterine fibroids	214.7 (194.2 to 233.4)	465.1 (420.2 to 506.7)	116.2 (115.5 to 116.9)	5.8 (5.8 to 5.9)	4.3 (2.7 to 6.6)	8.4 (5.1 to 13.3)	93.0 (76.2 to 115.2)	-5.6 (-13.8 to 6.5)
Polycystic ovarian syndrome	203.2 (181.0 to 224.6)	437.2 (388.4 to 493.5)	114.3 (82.5 to 153.8)	8.1 (-7.1 to 26.2)	1.9 (0.9 to 3.6)	4.2 (2.0 to 7.9)	113.8 (82.4 to 153.4)	8.2 (-7.1 to 27.2)
Female infertility due to other causes	91.7 (70.2 to 116.5)	205.5 (142.2 to 281.6)	124.3 (42.5 to 237.0)	9.5 (-31.3 to 66.7)	0.5 (0.2 to 1.0)	1.0 (0.4 to 2.3)	124.6 (42.2 to 235.9)	9.3 (-30.7 to 65.4)
Endometriosis	20.2 (17.1 to 23.1)	40.2 (34.1 to 46.4)	99.2 (57.6 to 145.9)	-1.7 (-21.5 to 21.1)	1.8 (1.2 to 2.7)	3.7 (2.4 to 5.1)	100.3 (55.5 to 154.7)	-1.2 (-23.0 to 26.0)
Genital prolapse	468.7 (408.6 to 528.9)	998.2 (869.5 to 1,124.2)	113.6 (74.1 to 154.9)	6.1 (-10.4 to 23.9)	1.5 (0.7 to 2.8)	3.2 (1.5 to 5.9)	114.2 (74.9 to 155.7)	6.7 (-9.8 to 24.3)
Premenstrual syndrome	508.3 (320.0 to 668.9)	1,308.2 (945.0 to 1,701.0)	158.5 (64.5 to 299.4)	36.2 (-14.2 to 102.9)	4.2 (2.2 to 7.0)	10.9 (6.3 to 16.6)	160.0 (65.1 to 310.9)	37.1 (-13.7 to 106.6)
Other gynecological diseases	50.5 (30.3 to 71.1)	90.2 (60.6 to 122.0)	79.6 (16.5 to 192.5)	-7.0 (-39.5 to 49.4)	1.8 (0.8 to 2.7)	3.0 (1.5 to 4.4)	65.5 (20.4 to 232.1)	-14.5 (-58.1 to 66.3)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	25.9	42.3	63.1	-6.5
Thalassemias	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	57.5 (29.9 to 67.1)	-3.4 (-20.2 to 3.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.7 (41.2 to 72.7)	-3.7 (-14.9 to 7.0)
Thalassemia trait	94.2 (87.2 to 100.2)	165.3 (153.9 to 175.2)	77.0 (59.6 to 79.9)	0.0 (-9.8 to 1.6)	1.6 (1.0 to 2.4)	2.8 (1.8 to 4.2)	74.7 (45.7 to 111.7)	2.7 (-15.0 to 24.8)
Sickle cell disorders	75.4 (69.9 to 80.8)	130.6 (122.2 to 138.4)	72.5 (59.9 to 89.0)	3.1 (-5.0 to 13.6)	7.5 (5.4 to 10.1)	13.5 (9.8 to 18.0)	79.8 (60.7 to 101.1)	5.5 (-5.5 to 17.7)
Sickle cell trait	2,432.5 (2,307.5 to 2,538.9)	4,279.8 (4,077.3 to 4,466.8)	75.4 (71.0 to 80.9)	-0.7 (-3.4 to 2.1)	11.2 (7.4 to 16.0)	18.6 (12.2 to 26.6)	66.6 (37.2 to 90.2)	-3.9 (-16.8 to 13.5)
G6PD deficiency	1,892.4 (1,773.5 to 2,009.2)	3,532.1 (3,307.6 to 3,734.9)	86.4 (71.5 to 102.5)	5.2 (-3.3 to 14.4)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	53.7 (0.6 to 125.3)	-16.5 (-40.7 to 16.2)
G6PD trait	3,440.0 (3,388.2 to 3,487.3)	6,224.7 (6,146.8 to 6,290.7)	80.6 (77.4 to 84.1)	2.9 (1.0 to 4.8)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	60.8 (-46.1 to 488.8)	-10.1 (-68.9 to 221.4)
Other hemoglobinopathies and hemolytic anemias	168.0 (141.7 to 193.5)	228.0 (201.0 to 256.8)	35.2 (14.4 to 63.7)	-25.5 (-36.7 to -11.4)	5.2 (3.3 to 7.6)	6.9 (4.4 to 10.1)	30.4 (5.2 to 77.7)	-27.6 (-41.9 to 0.3)
Endocrine, metabolic, blood, and immune disorders	195.5 (170.9 to 224.4)	296.6 (238.7 to 338.5)	48.2 (15.2 to 84.3)	-34.9 (-30.6 to 1.5)	7.5 (4.5 to 10.8)	10.8 (6.7 to 15.5)	44.7 (88.4 to 93.0)	-14.4 (-34.3 to 6.9)
Musculoskeletal disorders	-	-	-	-	146.8	298.2	102.6	0.6
Rheumatoid arthritis	15.5 (14.5 to 16.4)	24.5 (23.3 to 25.8)	57.8 (46.0 to 72.4)	-25.7 (-31.7 to -18.9)	3.7 (2.6 to 4.9)	5.9 (4.1 to 7.8)	59.6 (41.9 to 79.0)	-24.6 (-31.9 to -16.2)
Osteoarthritis	255.7 (245.2 to 265.8)	554.6 (534.5 to 575.0)	116.3 (105.3 to 129.2)	2.8 (-1.9 to 8.5)	15.7 (10.9 to 21.1)	34.1 (23.7 to 46.4)	117.3 (106.2 to 130.8)	3.8 (-1.3 to 9.6)
Low back and neck pain	-	-	-	-	108.6	209.0	88.5	-0.6
Low back pain	531.4 (501.2 to 559.4)	1,046.0 (990.6 to 1,101.2)	96.8 (82.3 to 113.0)	-1.1 (-7.4 to 7.2)	59.3 (39.9 to 81.8)	117.2 (78.6 to 162.0)	98.0 (82.6 to 115.1)	-0.2 (-6.6 to 8.5)
Neck pain	461.6 (349.5 to 549.4)	929.4 (775.6 to 1,058.5)	99.1 (58.5 to 182.2)	-2.1 (-21.3 to 32.5)	45.3 (28.7 to 65.6)	91.8 (61.5 to 129.4)	100.5 (58.8 to 184.7)	-1.4 (-20.6 to 33.7)
Gout	1.2 (1.0 to 1.3)	2.3 (2.1 to 2.6)	97.5 (68.3 to 137.7)	-4.5 (-17.9 to 14.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	99.2 (54.9 to 154.4)	-3.3 (-25.8 to 25.5)
Other musculoskeletal disorders	251.8 (189.9 to 316.9)	599.0 (408.4 to 668.3)	113.9 (97.8 to 129.7)	4.4 (-3.8 to 11.6)	22.8 (14.4 to 33.8)	49.2 (31.2 to 72.7)	115.4 (99.0 to 134.4)	5.9 (-3.0 to 13.9)
Other non-communicable diseases	-	-	-	-	164.1	307.2	87.3	0.4
Congenital anomalies	-	-	-	-	(105.6 to 242.2)	(198.5 to 456.6)	(80.3 to 107.8)	(-3.4 to 4.1)
Neural tube defects	1.9 (1.7 to 2.2)	5.9 (5.1 to 7.1)	209.7 (155.5 to 289.1)	93.9 (59.4 to 145.4)	0.5 (0.3 to 0.7)	1.6 (1.1 to 2.3)	237.3 (143.8 to 372.4)	114.0 (57.3 to 196.4)
Congenital heart anomalies	17.6 (13.1 to 23.2)	58.7 (47.7 to 72.3)	232.8 (135.2 to 378.1)	100.8 (42.7 to 192.8)	0.7 (0.3 to 1.2)	2.0 (0.8 to 5.3)	203.2 (111.7 to 338.9)	78.5 (25.2 to 160.2)
Orofacial clefts	1.9 (1.4 to 2.6)	8.5 (6.5 to 11.1)	363.1 (190.8 to 578.9)	205.0 (88.0 to 354.4)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	30.2 (173.6 to 604.6)	399.0 (78.5 to 356.2)
Down syndrome	8.3 (7.0 to 9.7)	19.8 (16.1 to 24.2)	138.0 (86.6 to 205.5)	42.3 (11.9 to 83.1)	1.0 (0.7 to 1.3)	2.4 (1.6 to 3.2)	144.6 (85.9 to 219.0)	46.4 (12.5 to 92.3)
Turner syndrome	0.4 (0.3 to 0.5)	0.8 (0.6 to 1.1)	114.9 (41.5 to 240.8)	25.5 (-17.2 to 99.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	118.4 (39.6 to 248.9)	25.8 (-19.7 to 100.9)
Klinefelter syndrome	0.4 (0.3 to 0.6)	0.7 (0.6 to 0.9)	64.7 (6.8 to 154.4)	-6.9 (-39.8 to 44.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.3 (12.1 to 167.2)	-8.1 (-40.5 to 42.8)
Chromosomal unbalanced rearrangements	14.0 (11.2 to 16.8)	32.0 (27.1 to 37.9)	127.7 (77.5 to 198.8)	1.6 (-5.9 to 7.8)	3.8 (1.1 to 2.3)	3.8 (2.7 to 5.1)	44.0 (78.9 to 208.1)	41.0 (6.4 to 85.6)
Other congenital anomalies	68.6 (50.8 to 87.2)	117.6 (86.7 to 151.2)	70.1 (46.2 to 103.6)	-6.7 (-20.7 to 13.1)	6.1 (3.6 to 9.4)	11.6 (7.0 to 18.8)	87.4 (48.9 to 146.6)	4.3 (-18.8 to 44.2)
Skin and subcutaneous diseases	-	-	-	-	57.6	110.3	90.5	4.1
Dermatitis	591.7 (477.6 to 699.5)	1,107.0 (885.5 to 1,308.5)	86.7 (84.3 to 88.8)	0.3 (0.1 to 0.5)	17.2 (11.3 to 24.6)	31.7 (20.8 to 45.0)	84.0 (77.0 to 90.6)	1.0 (-1.7 to 4.1)
Psoriasis	97.1 (78.8 to 121.1)	185.8 (150.1 to 232.8)	90.9 (86.6 to 93.2)	0.1 (-0.3 to 0.2)	7.9 (5.2 to 11.7)	15.2 (9.8 to 22.4)	92.3 (80.5 to 104.7)	0.9 (-4.2 to 6.5)
Cellulitis	2.7 (2.0 to 3.3)	4.7 (3.7 to 6.0)	75.3 (54.2 to 100.8)	-3.2 (-16.8 to 9.2)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	75.8 (30.7 to 136.1)	-2.8 (-24.0 to 23.1)
Pyoderma	24.5 (18.1 to 31.3)	37.8 (28.6 to 48.7)	54.3 (43.0 to 67.0)	-4.4 (-10.7 to 2.8)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.5)	54.9 (38.5 to 73.7)	-4.0 (-13.3 to 6.5)
Scabies	125.4 (111.7 to 141.0)	160.0 (145.9 to 175.0)	28.1 (9.1 to 47.6)	-26.2 (-36.7 to -16.5)	3.2 (1.8 to 5.3)	4.1 (2.4 to 6.7)	28.4 (9.0 to 48.0)	-26.0 (-36.6 to -16.0)
Fungal skin diseases	1,779.3 (1,253.8 to 2,436.7)	2,210.2 (2,285.4 to 4,417.8)	80.0 (75.1 to 86.5)	80.0 (-0.5 to 4.2)	80.0 (3.9 to 22.4)	80.0 (7.1 to 40.8)	80.0 (75.5 to 87.5)	0.1 (-0.7 to 10.9)
Viral skin diseases	178.0 (135.9 to 220.5)	306.1 (231.8 to 377.6)	71.5 (63.5 to 79.8)	0.9 (-2.4 to 4.4)	5.5 (3.3 to 8.6)	9.5 (5.6 to 14.7)	72.1 (62.0 to 82.8)	1.6 (-3.3 to 6.8)
Acne vulgaris	456.9 (336.1 to 612.2)	1,267.9 (879.7 to 1,614.7)	177.7 (70.1 to 335.5)	59.4 (2.3 to 145.6)	4.9 (2.1 to 9.5)	13.7 (6.0 to 26.6)	177.9 (71.6 to 338.4)	59.8 (2.4 to 147.3)
Alopecia areata	12.8 (11.3 to 14.5)	23.9 (21.1 to 26.5)	86.3 (55.2 to 120.1)	0.0 (-16.2 to 17.5)	0.4 (0.3 to 0.7)	0.8 (0.5 to 1.2)	85.9 (48.6 to 129.7)	0.7 (-18.0 to 21.8)
Pruritus	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	85.6 (44.3 to 133.8)	-2.5 (-25.4 to 27.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.6 (44.3 to 133.8)	-2.5 (-25.4 to 27.3)
Urticaria	59.4 (36.8 to 84.5)	132.7 (74.1 to 192.9)	118.6 (22.3 to 307.8)	14.4 (-41.1 to 106.0)	3.5 (1.8 to 6.0)	7.9 (3.8 to 13.2)	119.0 (21.3 to 310.1)	14.8 (-40.0 to 107.9)
Decubitus ulcer	1.1 (0.9 to 1.3)	2.5 (2.0 to 3.0)	133.2 (64.4 to 201.5)	5.5 (-30.5 to 51.8)	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.5)	130.8 (62.0 to 205.2)	7.6 (-30.4 to 56.5)
Other skin and subcutaneous diseases	727.5 (494.4 to 1,052.7)	1,413.3 (955.9 to 2,047.9)	93.7 (84.9 to 103.9)	0.8 (-2.5 to 4.8)	4.3 (1.9 to 7.7)	8.3 (3.7 to 17.2)	94.3 (85.4 to 104.7)	1.5 (-2.0 to 5.4)
Sense organ diseases	-	-	-	-	80.5	144.8	80.5	-2.6
Glaucoma	7.7 (5.6 to 10.1)	40.0 (30.8 to 50.6)	415.3 (265.5 to 675.4)	125.6 (63.9 to 230.6)	0.4 (0.2 to 0.6)	2.1 (1.3 to 3.0)	442.0 (306.2 to 636.3)	127.8 (69.7 to 209.6)
Cataract	35.3 (22.7 to 49.7)	144.1 (99.2 to 185.3)	303.0 (172.4 to 559.1)	60.4 (15.0 to 143.7)	1.6 (1.0 to 2.5)	6.7 (4.0 to 10.0)	325.7 (210.9 to 533.1)	64.2 (23.1 to 136.2)
Macular degeneration	8.0 (5.5 to 11.1)	78.5 (58.8 to 103.8)	896.6 (531.9 to 1,397.8)	325.1 (181.8 to 532.7)	0.3 (0.2 to 0.5)	3.4 (2.1 to 5.1)	879.0 (568.5 to 1,322.5)	264.9 (162.6 to 412.5)
Uncorrected refractive error	1,068.8 (1,009.8 to 1,131.0)	1,885.3 (1,777.3 to 1,993.0)	75.8 (62.8 to 89.4)	-8.0 (-13.5 to -2.0)	20.9 (13.1 to 32.3)	34.4 (21.3 to 53.3)	64.1 (55.6 to 73.7)	-14.1 (-18.6 to -9.7)
Age-related and other hearing loss	1,774.7 (1,492.6 to 2,010.4)	3,243.6 (2,771.2 to 3,663.9)	82.8 (72.6 to 92.9)	6.8 (-10.6 to -3.2)	46.7 (27.1 to 72.3)	77.6 (47.5 to 121.7)	67.3 (46.2 to 85.7)	-12.4 (-20.4 to -5.9)
Other vision loss	25.7 (20.6 to 31.3)	72.4 (59.4 to 87.2)	92.3 (130.0 to 247.5)	1.5 (-40.9 to 116.5)	4.8 (1.0 to 2.2)	4.8 (3.2 to 6.9)	214.3 (158.4 to 285.7)	79.5 (45.9 to 124.6)
Other sense organ diseases	340.2 (322.8 to 357.3)	592.3 (559.9 to 622.1)	73.7 (60.7 to 86.7)	0.2 (-6.7 to 6.4)	9.1 (5.6 to 13.6)	9.1 (9.8 to 23.7)	15.8 (59.5 to 89.0)	1.1 (-6.2 to 7.7)
Oral disorders	-	-	-	-	16.2	30.7	89.2	-3.1
Deciduous caries	1,385.4 (1,320.4 to 1,456.3)	2,152.7 (2,035.2 to 2,261.7)	55.4 (43.8 to 66.1)	0.0 (-7.5 to 6.8)	0.0 (0.2 to 1.0)	0.8 (0.4 to 1.6)	55.7 (78.1 to 102.1)	0.2 (-9.1 to 4.6)
Permanent caries	2,840.4 (2,704.8 to 2,981.8)	5,244.9 (4,981.9 to 5,528.2)	84.4 (71.3 to 98.6)	-0.3 (-6.7 to 6.5)	2.8 (1.3 to 5.3)	5.2 (2.4 to 10.0)	85.3 (71.6 to 100.2)	0.2 (-6.2 to 7.6)
Periodontal diseases	825.0 (732.4 to 907.3)	1,638.9 (1,464.9 to 1,795.8)	97.9 (71.4					

Appendix Table G.4 - Ghana prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	44.4 (40.9 to 47.8)	78.6 (72.6 to 84.9)	76.8 (57.9 to 97.1)	-18.1 (-25.9 to -8.9)	1.2 (0.8 to 1.7)	2.2 (1.4 to 3.0)	78.0 (56.6 to 99.7)	-27.1 (-25.8 to -8.0)
Other oral disorders	212.9 (200.4 to 225.5)	401.2 (377.4 to 425.9)	88.3 (71.2 to 104.7)	-0.1 (-8.4 to 7.3)	6.2 (3.9 to 9.3)	11.8 (7.4 to 17.3)	88.9 (70.0 to 106.3)	0.4 (-8.2 to 8.7)
Injuries	-	-	-	-	43.1 (32.9 to 55.4)	67.1 (49.9 to 88.3)	55.1 (45.8 to 66.7)	-18.4 (-23.2 to -12.7)
Transport injuries	-	-	-	-	13.6 (10.2 to 17.5)	20.7 (15.2 to 27.2)	51.6 (39.3 to 66.4)	-17.8 (-23.7 to -10.9)
Road injuries	-	-	-	-	11.8 (8.9 to 15.3)	18.3 (13.3 to 23.8)	52.3 (39.5 to 67.9)	-27.8 (-23.8 to -10.7)
Pedestrian road injuries	-	-	-	-	3.1 (2.3 to 4.0)	4.3 (3.1 to 5.6)	37.9 (22.8 to 54.9)	-23.4 (-30.5 to -15.3)
Cyclist road injuries	-	-	-	-	1.0 (0.8 to 1.4)	1.4 (1.1 to 1.9)	37.6 (27.1 to 50.5)	-24.5 (-30.2 to -17.2)
Motorcyclist road injuries	-	-	-	-	1.6 (1.2 to 2.1)	2.2 (1.6 to 3.0)	38.3 (24.6 to 54.1)	-27.3 (-33.8 to -19.7)
Motor vehicle road injuries	-	-	-	-	5.9 (4.5 to 7.6)	9.9 (7.3 to 13.1)	67.6 (51.4 to 86.6)	-10.1 (-17.7 to -1.1)
Other road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	14.1 (3.3 to 25.8)	-42.6 (-47.2 to -37.5)
Other transport injuries	-	-	-	-	1.7 (1.3 to 2.3)	2.6 (1.9 to 3.4)	47.2 (34.6 to 62.5)	-17.9 (-25.0 to -9.9)
Unintentional injuries	-	-	-	-	28.1 (21.3 to 36.2)	43.7 (32.5 to 57.5)	55.1 (47.3 to 64.8)	-19.8 (-24.1 to -14.7)
Falls	-	-	-	-	10.8 (8.1 to 14.0)	18.3 (13.4 to 24.4)	69.0 (56.9 to 84.8)	-19.6 (-25.8 to -12.4)
Drowning	-	-	-	-	0.7 (0.5 to 0.9)	0.7 (0.5 to 1.0)	6.1 (4.5 to 20.0)	-39.9 (-46.0 to -32.9)
Fire, heat, and hot substances	-	-	-	-	1.7 (1.3 to 2.2)	2.1 (1.6 to 2.8)	24.2 (11.1 to 38.7)	-30.8 (-37.1 to -23.8)
Poisonings	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	28.9 (8.3 to 57.4)	-30.4 (-40.1 to -16.9)
Exposure to mechanical forces	-	-	-	-	9.2 (7.9 to 12.0)	13.3 (9.9 to 17.9)	44.4 (36.0 to 54.0)	-21.2 (-25.3 to -16.5)
Unintentional firearm injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	35.3 (22.2 to 50.7)	-28.4 (-35.1 to -20.8)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	87.8 (67.3 to 108.1)	1.7 (-8.3 to 11.0)
Other exposure to mechanical forces	-	-	-	-	8.7 (6.6 to 11.4)	12.7 (9.4 to 16.9)	44.3 (36.0 to 54.0)	-21.0 (-25.3 to -16.2)
Adverse effects of medical treatment	-	-	-	-	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	113.3 (99.7 to 125.3)	14.1 (7.1 to 21.7)
Animal contact	-	-	-	-	0.6 (0.4 to 0.7)	0.8 (0.6 to 1.1)	45.3 (32.6 to 58.4)	-20.2 (-25.8 to -13.9)
Venomous animal contact	-	-	-	-	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	48.4 (30.2 to 69.7)	-18.9 (-27.3 to -8.9)
Non-venomous animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	42.5 (30.4 to 56.2)	-21.1 (-27.0 to -14.6)
Foreign body	-	-	-	-	0.6 (0.4 to 0.7)	0.9 (0.7 to 1.2)	59.3 (47.8 to 72.1)	-14.2 (-19.6 to -7.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	17.2 (0.1 to 37.8)	-27.6 (-36.4 to -16.8)
Foreign body in eyes	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	77.2 (57.9 to 97.6)	-5.7 (-15.0 to 4.0)
Foreign body in other body part	-	-	-	-	0.3 (0.3 to 0.4)	0.6 (0.4 to 0.8)	71.3 (57.0 to 87.0)	-12.4 (-19.2 to -4.7)
Other unintentional injuries	-	-	-	-	4.2 (3.1 to 5.5)	6.9 (5.1 to 9.0)	62.9 (52.8 to 75.1)	-14.2 (-19.0 to -8.5)
Self-harm and interpersonal violence	-	-	-	-	1.3 (1.0 to 1.7)	1.8 (1.3 to 2.3)	34.6 (23.4 to 47.6)	-28.4 (-34.1 to -21.8)
Self-harm	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	57.1 (43.1 to 72.7)	-22.3 (-28.8 to -15.2)
Interpersonal violence	-	-	-	-	1.1 (0.9 to 1.4)	1.5 (1.1 to 1.9)	30.3 (18.9 to 43.7)	-30.0 (-35.7 to -23.0)
Assault by firearm	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	55.3 (43.0 to 67.9)	-16.2 (-22.3 to -9.8)
Assault by sharp object	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	66.7 (51.5 to 85.5)	-32.0 (-20.0 to -2.3)
Assault by other means	-	-	-	-	0.7 (0.6 to 0.9)	0.8 (0.6 to 1.1)	14.3 (2.2 to 27.2)	-38.9 (-44.9 to -32.3)
Forces of nature, war, and legal intervention	-	-	-	-	0.2 (0.1 to 0.3)	1.0 (0.4 to 2.3)	548.3 (317.1 to 880.3)	276.7 (140.0 to 475.6)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	56,581,683.2 (271,479.1 to nan)	80,996,068.8 (379,358.1 to nan)
Collective violence and legal intervention	-	-	-	-	0.2 (0.1 to 0.3)	1.0 (0.3 to 2.2)	521.9 (304.1 to 839.8)	264.7 (133.6 to 456.4)

Appendix Table G.4 - Greece prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,501.0 (941.5 to 1,628.5)	1,257.2 (1,128.2 to 1,931.6)	19.4 (16.2 to 22.4)	-2.9 (-5.4 to -0.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	46.1 (32.0 to 65.4)	42.5 (29.6 to 59.9)	-7.8 (-16.1 to 1.4)	-5.1 (-13.5 to 2.8)
HIV/AIDS and tuberculosis	-	-	-	-	0.7 (0.4 to 0.9)	0.6 (0.4 to 0.8)	-11.3 (-28.6 to -10.7)	-23.8 (-39.5 to -3.7)
Tuberculosis	1.8 (1.7 to 1.9)	1.6 (1.5 to 1.7)	-6.8 (-11.0 to -2.2)	-19.5 (-23.0 to -15.6)	0.5 (0.4 to 0.8)	0.5 (0.3 to 0.7)	-7.8 (-25.1 to 13.0)	-19.5 (-35.3 to -1.2)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.3)	0.1 (0.1 to 0.1)	-14.3 (-60.4 to 111.1)	-42.4 (-69.5 to 69.1)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-73.6 (-87.0 to -30.8)	-78.7 (-89.3 to -43.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-73.6 (-87.0 to -30.5)	-78.7 (-89.4 to -43.0)
HIV/AIDS resulting in other diseases	0.8 (0.4 to 1.2)	1.3 (1.0 to 1.7)	65.1 (26.0 to 237.2)	26.1 (-5.3 to 162.5)	0.1 (0.0 to 0.3)	0.1 (0.1 to 0.1)	-26.6 (-60.3 to 111.8)	-42.2 (-69.4 to 69.5)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	6.1 (4.0 to 9.1)	5.9 (3.8 to 8.8)	-2.9 (-11.6 to 5.5)	-13.0 (-20.4 to -5.9)
Diarrheal diseases	3.5 (3.1 to 3.9)	3.5 (3.1 to 4.0)	1.2 (-14.3 to 19.8)	-15.1 (-32.6 to 7.5)	0.5 (0.4 to 0.8)	0.5 (0.4 to 0.8)	-14.3 (-18.6 to 25.4)	-14.3 (-34.6 to 13.1)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.3 (59.9 to 18.2)	-30.9 (-60.5 to 12.0)
Typhoid fever	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-24.9 (-48.1 to 11.7)	-27.0 (-50.8 to 4.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.9 (-48.2 to 11.7)	-27.0 (-51.0 to 4.2)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.0 (-35.1 to 59.9)	1.3 (-32.1 to 55.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.0 (-35.1 to 60.4)	1.3 (-32.2 to 55.1)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-77.8 (-99.4 to 509.9)	-78.6 (-99.4 to 503.9)
Lower respiratory infections	2.0 (1.3 to 2.9)	2.5 (2.0 to 3.1)	26.2 (-11.9 to 135.9)	-19.5 (-40.0 to 43.0)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	25.2 (-14.7 to 133.0)	18.5 (-41.6 to 41.7)
Upper respiratory infections	154.2 (147.3 to 160.3)	161.4 (153.5 to 169.4)	5.4 (-1.7 to 12.2)	0.4 (-6.2 to 7.4)	1.8 (1.0 to 3.0)	1.9 (1.1 to 3.2)	5.2 (-2.8 to 12.8)	0.7 (-6.8 to 8.2)
Otitis media	128.2 (112.4 to 144.5)	124.5 (104.9 to 141.7)	-2.2 (-18.1 to 14.4)	-9.6 (-22.9 to 3.6)	2.4 (1.4 to 3.8)	2.3 (1.3 to 3.7)	-4.2 (-19.8 to 12.5)	-11.0 (-23.8 to 2.4)
Meningitis	-	-	-	-	0.7 (0.4 to 1.0)	0.5 (0.3 to 0.7)	-27.0 (-42.7 to -10.2)	-33.5 (-49.9 to -16.8)
Pneumococcal meningitis	2.0 (1.2 to 3.2)	1.5 (0.9 to 2.5)	-22.5 (-40.7 to 3.3)	-33.3 (-50.5 to -12.5)	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-26.1 (-46.9 to 5.3)	-35.7 (-54.4 to -5.5)
H influenzae type B meningitis	0.8 (0.3 to 1.9)	0.7 (0.2 to 1.5)	-20.6 (-52.6 to 35.1)	-26.9 (-57.4 to 33.3)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.2)	-10.8 (-55.0 to 64.0)	-14.3 (-59.4 to 60.3)
Meningococcal meningitis	1.2 (0.3 to 3.0)	0.8 (0.2 to 2.0)	-34.3 (-69.3 to -1.1)	-43.1 (-72.4 to -8.6)	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.2)	-34.4 (-71.7 to 8.7)	-41.6 (-74.9 to -0.1)
Other meningitis	1.6 (0.8 to 3.3)	1.2 (0.6 to 2.5)	-27.9 (-46.9 to -3.3)	-35.1 (-52.0 to -9.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-26.4 (-51.0 to 13.5)	-33.1 (-55.3 to 4.7)
Encephalitis	0.8 (0.4 to 2.1)	1.3 (0.5 to 3.6)	58.4 (26.6 to 99.1)	34.9 (7.6 to 67.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	59.2 (27.5 to 104.4)	38.0 (7.1 to 77.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.7 (-96.7 to 239.0)	-68.8 (-97.0 to 152.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-65.7 (-96.7 to 241.8)	-68.8 (-97.1 to 155.1)
Whooping cough	2.9 (2.3 to 3.7)	0.1 (0.1 to 0.1)	-97.1 (-97.7 to -96.4)	-97.2 (-97.7 to -96.4)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.0)	-97.1 (-98.3 to -95.6)	-97.2 (-98.3 to -95.6)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.8 (-77.9 to 75.1)	-48.4 (-80.5 to 62.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.1 (-80.9 to 64.8)	-49.9 (-82.3 to 62.2)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.2 (-100.0 to -98.0)	99.2 (-100.0 to -97.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.2 (-100.0 to -98.0)	99.2 (-100.0 to -97.9)
Varicella and herpes zoster	6.6 (6.0 to 7.3)	7.1 (6.1 to 8.1)	8.1 (-10.1 to 26.8)	-4.6 (-15.7 to 8.9)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	17.4 (9.7 to 53.1)	-2.7 (-23.9 to 23.4)
Neglected tropical diseases and malaria	-	-	-	-	0.5 (0.4 to 0.8)	0.5 (0.3 to 0.7)	-10.9 (-34.3 to 5.7)	-23.1 (-44.1 to -6.9)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.5 (-70.8 to 574.7)	30.0 (-71.7 to 573.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.9 (-69.8 to 594.0)	33.7 (-70.3 to 597.5)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.3 (-13.6 to 39.3)	-3.8 (-24.5 to 23.1)
Visceral leishmaniasis	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	9.4 (-13.7 to 39.5)	-3.8 (-24.6 to 23.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.4 (-13.8 to 40.2)	-3.8 (-24.7 to 23.9)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.9 (-28.8 to 43.0)	-7.7 (-31.0 to 28.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.9 (-28.9 to 43.2)	-7.7 (-31.0 to 29.3)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.2 (0.0 to 0.7)	0.1 (0.0 to 0.2)	-46.0 (-87.7 to 111.1)	-52.9 (-88.3 to 86.6)	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-39.4 (-86.5 to 148.2)	-47.4 (-87.6 to 113.9)
Cystic echinococcosis	5.3 (4.9 to 5.8)	4.8 (4.5 to 5.1)	-8.7 (-16.3 to 2.1)	-21.9 (-30.3 to -11.4)	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.6)	-8.8 (-21.7 to 8.6)	-21.6 (-34.6 to -5.0)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.0 (-69.4 to 6.6)	-14.4 (-72.1 to -2.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.0 (-69.4 to 6.6)	-14.4 (-72.1 to -2.6)
Intestinal nematode infections	-	-	-	-	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.8 (21.7 to 107.3)	40.3 (6.3 to 84.6)
Maternal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	13.5 (-23.1 to 55.8)	8.1 (-24.0 to 47.2)
Maternal hemorrhage	2.2 (1.7 to 2.6)	2.2 (1.5 to 2.8)	-0.6 (-32.4 to 39.3)	-8.1 (-38.4 to 29.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	5.5 (-4.4 to 87.2)	2.0 (-48.2 to 77.5)
Maternal sepsis and other maternal infections	0.6 (0.1 to 1.1)	0.9 (0.2 to 1.6)	56.5 (-54.3 to 771.9)	25.5 (-60.4 to 587.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.5 (-49.2 to 162.1)	22.6 (-53.8 to 134.5)
Maternal hypertensive disorders	1.4 (0.4 to 2.6)	1.6 (0.5 to 3.2)	13.5 (-22.1 to 72.2)	7.7 (-16.9 to 49.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	13.1 (-28.5 to 84.0)	7.9 (-25.2 to 64.2)
Obstructed labor	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	32.2 (-63.9 to 259.0)	24.1 (-68.6 to 248.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.2 (-64.2 to 259.2)	24.1 (-68.8 to 248.9)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.8 (-26.9 to 76.3)	6.9 (-32.1 to 68.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.8 (-27.0 to 77.4)	6.9 (-32.1 to 68.3)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	15.3 (-31.7 to 109.6)	11.1 (-34.5 to 96.6)
Neonatal disorders	-	-	-	-	9.6 (6.7 to 13.6)	9.7 (6.7 to 13.7)	1.5 (-28.4 to 34.8)	-2.8 (-31.7 to 28.7)
Preterm birth complications	44.3 (32.4 to 60.9)	55.8 (39.4 to 80.5)	25.7 (2.8 to 58.3)	17.3 (-3.3 to 48.2)	5.6 (3.8 to 7.6)	7.1 (4.9 to 9.9)	26.3 (-4.7 to 73.4)	20.7 (-9.5 to 67.1)
Neonatal encephalopathy due to birth asphyxia and trauma	10.8 (6.2 to 20.2)	6.6 (3.3 to 15.9)	-38.9 (-62.1 to -2.8)	-45.8 (-63.4 to -10.5)	2.5 (1.7 to 3.6)	1.5 (1.0 to 2.3)	-39.3 (-63.3 to -14.7)	-61.6 (-61.1 to -6.8)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.0 (-58.2 to -31.2)	-45.8 (-59.5 to -33.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.6 (-67.9 to -19.3)	-47.3 (-68.9 to -21.8)
Hemolytic disease and other neonatal jaundice	3.7 (0.8 to 9.9)	2.3 (0.7 to 10.0)	-37.7 (-89.3 to 203.6)	-50.8 (-90.2 to 184.6)	1.5 (0.3 to 3.9)	0.9 (0.3 to 3.9)	-45.7 (-88.3 to 214.5)	-49.5 (-88.9 to 198.0)
Other neonatal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	187.0 (16.3 to 390.2)	176.7 (11.1 to 371.0)
Nutritional deficiencies	-	-	-	-	26.3 (17.4 to 39.3)	22.9 (14.6 to 34.7)	-12.9 (-27.7 to -4.2)	-4.1 (-22.8 to 4.1)
Protein-energy malnutrition	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	81.1 (-91.6 to -18.0)	82.2 (-91.7 to -61.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-79.4 (-91.0 to -7.1)	-81.9 (-91.0 to -48.1)
Iodine deficiency	207.0 (154.4 to 258.8)	136.4 (99.9 to 185.2)	-33.9 (-56.0 to 2.4)	-40.3 (-59.9 to -8.2)	3.7 (2.1 to 6.0)	2.4 (1.3 to 4.1)	-34.2 (-56.5 to 2.3)	-40.3 (-60.3 to -8.6)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-

Appendix Table G.4 - Greece prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	1,004.8 (963.2 to 1,049.4)	1,001.3 (924.2 to 1,042.8)	0.6 (-7.6 to 5.3)	0.5 (-11.1 to 4.3)	22.7 (15.0 to 33.5)	20.4 (13.1 to 30.4)	-9.3 (-26.7 to 0.1)	0.9 (-21.2 to 10.8)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-7.1 (-86.9 to -46.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.6 (1.6 to 4.2)	2.7 (1.6 to 4.8)	1.2 (-27.6 to 77.0)	3.8 (-31.6 to 119.5)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.1 (0.5 to 1.9)	1.2 (0.6 to 2.2)	12.6 (4.2 to 36.2)	3.0 (-13.7 to 24.9)
Syphilis	0.5 (0.4 to 0.6)	0.8 (0.6 to 1.0)	65.9 (28.3 to 129.3)	24.7 (6.0 to 76.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	63.2 (10.6 to 143.1)	24.2 (-18.0 to 91.0)
Chlamydial infection	143.2 (87.3 to 187.8)	153.6 (114.6 to 193.8)	5.8 (-23.2 to 84.2)	6.1 (-24.7 to 82.7)	0.4 (0.2 to 0.7)	0.5 (0.2 to 0.8)	9.8 (-19.7 to 61.6)	11.7 (-21.0 to 61.9)
Gonococcal infection	30.9 (23.2 to 42.8)	25.5 (17.6 to 34.1)	-17.3 (-45.3 to 28.8)	-8.7 (-41.7 to 50.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-11.6 (-40.5 to 29.6)	-4.7 (-35.7 to 41.5)
Trichomoniasis	40.6 (25.8 to 52.7)	38.2 (28.4 to 49.4)	-6.5 (-39.8 to 68.4)	-12.7 (-46.2 to 63.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-8.9 (-45.3 to 82.6)	-14.8 (-51.1 to 77.8)
Genital herpes	1,286.8 (1,098.3 to 1,469.1)	1,529.0 (1,321.9 to 1,723.4)	19.2 (-1.9 to 43.7)	3.6 (-21.4 to 16.8)	0.3 (0.1 to 0.8)	0.4 (0.1 to 0.9)	17.5 (-3.8 to 42.8)	3.2 (-22.1 to 19.2)
Other sexually transmitted diseases	1.3 (0.8 to 1.8)	1.0 (0.6 to 1.5)	-19.5 (-49.6 to 40.8)	-31.6 (-55.9 to 20.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-21.2 (-54.7 to 32.6)	27.1 (-59.4 to 24.7)
Hepatitis	-	-	-	-	0.4 (0.3 to 0.6)	0.4 (0.2 to 0.6)	0.4 (-22.4 to 11.0)	-13.4 (-27.5 to 0.7)
Hepatitis A	8.1 (7.0 to 8.4)	7.7 (7.4 to 8.0)	-3.9 (-4.0 to -3.9)	-5.3 (-6.1 to -4.5)	0.2 (0.2 to 0.4)	0.1 (0.2 to 0.4)	-1.0 (-12.2 to 10.8)	-4.2 (-15.1 to 7.1)
Hepatitis B	316.6 (285.5 to 344.6)	252.9 (229.3 to 277.3)	-19.8 (-28.8 to -8.1)	-24.4 (-37.6 to -18.5)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-17.7 (-45.3 to 27.8)	27.1 (-52.8 to 4.5)
Hepatitis C	99.9 (92.2 to 107.3)	88.6 (80.7 to 97.0)	-10.5 (-20.6 to 0.7)	-17.5 (-35.9 to -18.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.9 (-32.2 to 32.2)	25.8 (-43.1 to 1.5)
Hepatitis E	-	-	-	-	3.6 (-21.1 to 31.2)	-	-	-
Leprosy	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-
Other infectious diseases	45.5 (37.6 to 63.4)	44.3 (36.2 to 84.5)	-6.2 (-33.9 to 87.4)	-0.8 (-32.6 to 124.5)	1.1 (0.7 to 2.0)	1.1 (0.6 to 2.8)	-7.3 (-49.9 to 203.0)	8.7 (-44.3 to 280.2)
Non-communicable diseases	-	-	-	-	1,106.4 (826.0 to 1,433.4)	1,367.7 (1,021.5 to 1,760.3)	23.7 (20.0 to 27.0)	0.2 (-2.6 to 2.7)
Neoplasms	-	-	-	-	15.9 (11.8 to 20.3)	30.3 (22.4 to 39.2)	92.0 (75.4 to 105.5)	28.1 (17.5 to 36.9)
Esophageal cancer	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.6)	34.5 (3.2 to 93.6)	-8.9 (-34.2 to 30.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	30.4 (-2.4 to 71.1)	-11.6 (-31.5 to 13.8)
Stomach cancer	5.4 (4.7 to 6.3)	7.1 (5.9 to 8.6)	32.4 (10.0 to 61.0)	-15.4 (-28.5 to 1.6)	0.6 (0.4 to 0.8)	0.8 (0.5 to 1.0)	24.9 (3.8 to 55.0)	-19.9 (-32.7 to -3.1)
Liver cancer	-	-	-	-	0.3 (0.1 to 0.5)	0.2 (0.1 to 0.5)	35.8 (-68.8 to 91.9)	56.2 (-78.4 to 23.8)
Liver cancer due to hepatitis B	0.8 (0.3 to 1.3)	0.5 (0.2 to 0.9)	-34.5 (-77.5 to 107.2)	-51.8 (-83.4 to 46.7)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-34.5 (-77.9 to 93.3)	-52.8 (-83.6 to 36.9)
Liver cancer due to hepatitis C	0.3 (0.2 to 0.6)	0.5 (0.3 to 1.1)	45.1 (-41.1 to 436.5)	-4.4 (-61.0 to 239.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	36.4 (-41.4 to 392.1)	-10.0 (-61.2 to 211.1)
Liver cancer due to alcohol use	0.6 (0.3 to 1.1)	0.1 (0.1 to 0.5)	-63.6 (-88.1 to 34.6)	-76.3 (-92.2 to -13.5)	0.0 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-63.5 (-87.0 to 26.1)	-76.5 (-91.5 to -21.0)
Liver cancer due to other causes	0.3 (0.1 to 0.5)	0.1 (0.0 to 0.1)	-80.8 (-92.9 to 34.9)	-46.7 (-95.0 to -12.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-61.5 (-92.7 to 30.9)	47.4 (-94.8 to -17.4)
Larynx cancer	3.3 (2.5 to 4.3)	4.3 (3.1 to 5.5)	28.7 (-1.2 to 66.1)	-7.0 (-28.1 to 20.1)	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	20.3 (-6.6 to 59.7)	-13.5 (-34.5 to 13.4)
Tracheal, bronchus and lung cancer	10.2 (9.1 to 11.3)	15.9 (14.0 to 17.9)	57.2 (33.5 to 84.6)	10.7 (-6.0 to 29.5)	1.5 (1.1 to 1.9)	2.2 (1.6 to 2.9)	49.0 (27.6 to 72.0)	5.0 (-9.7 to 21.3)
Breast cancer	53.6 (48.8 to 58.8)	113.3 (103.4 to 123.3)	113.1 (83.4 to 138.9)	44.1 (25.5 to 62.0)	2.9 (2.0 to 4.1)	5.8 (3.9 to 8.0)	102.2 (58.5 to 126.9)	35.1 (9.5 to 51.9)
Cervical cancer	4.7 (3.7 to 5.6)	5.2 (3.9 to 6.6)	10.8 (-13.5 to 42.8)	-19.9 (-37.2 to 21.0)	0.4 (0.2 to 0.5)	0.4 (0.3 to 0.6)	11.7 (-16.1 to 47.3)	-19.5 (-39.1 to 5.7)
Uterine cancer	6.8 (5.2 to 8.8)	8.4 (6.5 to 11.0)	23.6 (-10.8 to 74.3)	-8.7 (-35.0 to 29.3)	0.7 (0.3 to 0.7)	0.6 (0.3 to 0.8)	23.3 (-13.5 to 78.3)	-10.0 (-36.3 to 30.7)
Prostate cancer	32.5 (25.9 to 37.5)	74.5 (63.9 to 89.6)	128.1 (88.5 to 198.1)	44.0 (19.6 to 88.0)	2.4 (1.7 to 3.2)	6.0 (4.2 to 8.5)	150.6 (103.4 to 219.5)	56.3 (28.6 to 93.3)
Colon and rectum cancer	18.2 (17.0 to 19.7)	42.1 (37.5 to 47.1)	131.8 (104.1 to 165.4)	50.8 (33.9 to 70.8)	1.5 (1.1 to 2.0)	3.5 (2.5 to 4.5)	125.0 (95.5 to 160.7)	44.7 (26.8 to 64.9)
Lip and oral cavity cancer	2.9 (2.4 to 3.5)	4.6 (3.6 to 5.7)	57.8 (18.7 to 114.1)	8.8 (-17.8 to 43.6)	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	54.5 (14.9 to 107.8)	5.8 (-20.8 to 40.1)
Nasopharynx cancer	0.5 (0.4 to 0.8)	0.7 (0.5 to 0.9)	31.0 (-15.1 to 94.5)	0.6 (-35.8 to 48.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	26.6 (-15.9 to 85.6)	4.4 (-37.3 to 37.1)
Other pharynx cancer	0.8 (0.6 to 1.1)	1.4 (1.0 to 1.9)	83.1 (11.0 to 166.6)	38.0 (-15.4 to 101.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	77.9 (7.8 to 159.8)	32.9 (-18.5 to 91.6)
Gallbladder and biliary tract cancer	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	118.8 (10.8 to 225.6)	34.5 (-30.6 to 94.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	100.3 (-0.6 to 203.7)	24.7 (-36.5 to 84.0)
Pancreatic cancer	0.9 (0.8 to 1.1)	2.1 (1.8 to 2.6)	130.3 (81.4 to 199.8)	50.8 (19.0 to 93.7)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.5)	112.8 (69.2 to 167.8)	40.6 (12.8 to 75.0)
Malignant skin melanoma	5.7 (4.4 to 8.5)	12.3 (7.7 to 15.9)	121.0 (43.1 to 191.7)	62.5 (6.7 to 111.4)	0.7 (0.2 to 0.5)	0.7 (0.4 to 1.1)	115.8 (55.9 to 188.4)	57.8 (9.9 to 107.1)
Non-melanoma skin cancer	7.6 (6.6 to 8.8)	15.0 (12.1 to 18.2)	100.2 (54.9 to 153.4)	27.0 (-0.8 to 57.9)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	161.3 (83.1 to 293.9)	57.6 (14.4 to 130.1)
Ovarian cancer	2.4 (2.1 to 3.0)	4.6 (3.6 to 5.6)	92.6 (39.8 to 141.2)	38.6 (2.3 to 72.3)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	88.2 (30.4 to 151.8)	34.4 (-4.8 to 78.1)
Testicular cancer	1.4 (1.0 to 2.0)	2.2 (1.3 to 3.1)	54.9 (1.0 to 145.8)	38.2 (-12.1 to 124.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	52.4 (-2.9 to 144.8)	35.4 (-16.1 to 120.2)
Kidney cancer	14.3 (3.9 to 5.2)	26.2 (7.7 to 10.8)	84.5 (67.0 to 148.6)	20.8 (21.0 to 77.2)	1.1 (0.2 to 0.5)	1.9 (0.4 to 0.9)	78.9 (58.5 to 144.6)	16.2 (13.9 to 72.9)
Bladder cancer	14.3 (11.8 to 16.6)	26.2 (20.4 to 31.7)	84.5 (45.8 to 129.4)	20.8 (-3.8 to 49.9)	1.1 (0.8 to 1.5)	1.9 (1.3 to 2.6)	78.9 (41.2 to 123.6)	16.2 (-6.1 to 44.2)
Brain and nervous system cancer	3.8 (3.2 to 4.7)	6.6 (5.2 to 7.9)	78.5 (37.6 to 120.8)	32.3 (6.2 to 59.4)	0.4 (0.3 to 0.5)	0.7 (0.5 to 0.9)	72.4 (28.9 to 120.0)	28.7 (0.5 to 60.4)
Thyroid cancer	3.6 (2.9 to 4.6)	6.3 (4.7 to 8.1)	74.5 (33.0 to 130.1)	32.9 (18.8 to 74.8)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	70.6 (26.9 to 130.4)	27.2 (-4.5 to 69.9)
Mesothelioma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	0.1 (2.9 to 93.5)	0.1 (-28.7 to 28.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.2 (3.8 to 100.7)	9.4 (-27.9 to 32.4)
Hodgkin lymphoma	2.5 (1.9 to 3.9)	5.2 (2.8 to 6.8)	115.8 (9.9 to 198.3)	69.7 (-11.6 to 133.0)	0.2 (0.1 to 0.4)	0.4 (0.1 to 0.6)	104.0 (17.5 to 112.8)	57.8 (-1.5 to 112.8)
Non-Hodgkin lymphoma	3.2 (2.3 to 4.6)	5.9 (3.8 to 7.5)	93.6 (16.2 to 150.3)	35.8 (-16.5 to 74.3)	0.2 (0.2 to 0.4)	0.6 (0.3 to 0.6)	85.0 (6.6 to 144.3)	29.6 (-23.7 to 69.7)
Multiple myeloma	1.0 (0.6 to 1.5)	1.7 (1.1 to 2.5)	71.9 (10.3 to 160.4)	17.5 (-24.0 to 80.5)	0.2 (0.1 to 0.3)	0.5 (0.2 to 0.5)	66.6 (3.4 to 164.0)	12.8 (-28.3 to 81.5)
Leukemia	5.0 (4.2 to 5.8)	9.9 (8.0 to 11.8)	101.1 (54.0 to 151.9)	28.1 (-0.1 to 56.6)	0.7 (0.5 to 0.9)	1.3 (0.9 to 1.7)	99.8 (54.5 to 154.1)	27.3 (0.2 to 55.3)
Other neoplasms	7.5 (6.2 to 9.1)	19.6 (15.7 to 25.7)	156.7 (100.1 to 262.2)	78.3 (41.2 to 141.6)	0.5 (0.4 to 0.8)	1.3 (0.9 to 1.9)	138.5 (86.3 to 236.6)	64.7 (31.6 to 123.2)
Cardiovascular diseases	-	-	-	-	48.8 (33.7 to 65.6)	67.1 (47.2 to 88.6)	-7.7 (-12.6 to 68.9)	-7.7 (-24.1 to 12.9)
Rheumatic heart disease	0.9 (0.6 to 1.2)	1.3 (0.9 to 1.7)	41.5 (-13.5 to 134.1)	2.8 (-37.0 to 70.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	39.4 (-24.4 to 155.4)	0.0 (-43.9 to 80.6)
Ischemic heart disease	272.2 (231.6 to 324.3)	341.4 (292.9 to 406.9)	26.0 (1.3 to 57.5)	26.0 (-31.8 to 5.7)	16.2 (10.6 to 22.9)	28.2 (12.5 to 26.6)	15.5 (-10.3 to 49.5)	-24.4 (-40.6 to -2.0)
Cerebrovascular disease	-	-	-	-	11.8 (8.2 to 15.6)	17.6 (12.0 to 24.7)	49.1 (23.8 to 75.8)	0.7 (-16.4 to 17.0)
Ischemic stroke	72.3 (64.0 to 82.1)	108.7 (84.7 to 130.2)	50.3 (24.4 to 82.5)	-1.5 (-17.5 to 18.0)	10.2 (6.9 to 13.8)	15.4 (10.3 to 21.8)	49.3 (23.4 to 78.4)	-0.8 (-17.1 to 17.5)
Hemorrhagic stroke	10.9 (9.1 to 13.0)	15.8 (12.5 to 20.1)	44.0 (7.0 to 103.1)	-2.4 (-27.2 to 35.1)	1.6 (1.1 to 2.2)	2.3 (1.5 to 3.2)	43.0 (4.3 to 101.7)	-1.3 (-27.6 to 36.8)
Hypertensive heart disease	16.3 (13.0 to 19.6)	26.2 (20.0 to 33.3)	60.6 (18.3 to 133.2)	1.6 (-22.5 to 42.6)	1.1 (1.0 to 2.5)	2.8 (1.8 to 4.0)	60.7 (16.3 to 124.1)	4.8 (-23.5 to 43.6)
Cardiomyopathy and myocarditis	17.9 (13.7 to 23.3)	19.5 (14.8 to 24.4)	11.9 (-22.4 to 54.6)	-23.0 (-45.0 to 5.7)	2.1 (1.2 to 2.9)	2.1 (1.4 to 2.9)	11.0 (-24.3 to 56.2)	-23.5 (-46.3 to 7.1)
Atrial fibrillation and flutter	54.2 (45.9 to 62.9)	69.4 (54.2 to 91.5)	26.3 (-1.3 to 76.1)	-16.0 (-34.1 to 14.2)	4.2 (2.8 to 5.9)	5.4 (3.4 to 8.0)	25.5 (-3.2 to 72.5)	5.5 (-35.3 to 13.4)
Peripheral vascular disease	385.4 (292.6 to 491.7)	585.2 (466.2 to 719.5)	54.1 (10.0 to 125.2)	4.2 (-26.4 to 58.4)	0.5 (0.2 to 1.0)	0.8 (0.3 to 1.5)	49.6 (-30.6 to 204.2)	-11.4 (-59.7 to 81.3)
Endocarditis	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.2)	119.3 (18.6 to 255.0)	54.1 (-12.6 to 147.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	114.5 (9.4 to 284.3)	55.5 (-18.3 to 170.7)
Other cardiovascular and circulatory diseases	175.6 (103.7 to 256.4)	279.4 (166.0 to 387.0)	58.6 (-11.4 to 199.9)	28.6 (-38.3 to 102.8)	9.9 (6.5 to 20.3)	12.3 (10.6 to 29.9)	19.7 (-11.5 to 199.5)	9.0 (-38.5 to 100.9)
Chronic respiratory diseases	-	-	-	-	54.4 (37.4 to 75.3)	65.6 (44.9 to 90.5)	20.3 (3.8 to 44.1)	-3.5 (-14.8 to 14.6)
Chronic obstructive pulmonary disease	750.6 (609.5 to 890.8)	1,026.7 (846.1 to 1,221.7)	37.6 (22.9 to 57.2)	2.1 (-8.6 to 17.7)	34.7 (21.7 to 49.9)	46.0 (29.5 to 66.6)	32.2 (7.9 to 71.4)	-2

Appendix Table G.4 - Greece prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.1	2.6	-27.0
Silicosis	0.1	0.1	-9.2	-36.0	(0.0 to 0.1)	(0.0 to 0.1)	(5.7 to 13.8)	(-33.5 to -20.6)
Asbestosis	(0.1 to 0.1)	(0.1 to 0.1)	(-14.8 to -4.0)	(-39.5 to -32.4)	0.0	0.0	-10.2	(-40.0 to -32.8)
Coal workers pneumoconiosis	0.0	0.0	0.0	0.0	0.0	0.0	41.7	2.4
Other pneumoconiosis	(0.0 to 0.0)	(0.0 to 0.1)	(17.6 to 63.7)	(-16.4 to 17.3)	0.0	0.0	(17.7 to 63.5)	(-16.6 to 17.1)
Asthma	436.3	442.0	2.0	-3.4	19.0	19.3	1.2	-3.3
Interstitial lung disease and pulmonary sarcoidosis	(410.7 to 465.0)	(416.3 to 467.6)	(-6.4 to 10.7)	(-11.8 to 5.1)	(12.5 to 26.9)	(12.5 to 27.1)	(-7.1 to 10.6)	(-12.2 to 5.8)
Other chronic respiratory diseases	0.2	0.2	40.9	2.2	0.0	0.0	41.1	2.5
Cirrhosis	(0.1 to 0.2)	(0.2 to 0.3)	(-7.2 to 108.0)	(-30.8 to 50.6)	(0.0 to 0.0)	(0.0 to 0.1)	(-7.5 to 108.2)	(-31.0 to 50.8)
Cirrhosis due to hepatitis B	-	-	-	-	0.6	0.2	-65.0	-73.8
Cirrhosis due to hepatitis C	0.4	0.4	2.1	-20.3	(0.4 to 1.0)	(0.1 to 0.3)	(-74.9 to -50.6)	(-81.1 to -63.0)
Cirrhosis due to alcohol use	1.6	1.1	-27.1	-43.9	0.7	0.5	-24.2	-39.9
Cirrhosis due to other causes	1.7	1.1	-38.0	-52.2	(0.5 to 0.9)	(0.3 to 0.7)	(-32.2 to -11.6)	(-48.5 to -29.8)
Digestive diseases	67.3	61.4	-7.9	-47.1	2.3	2.1	-6.3	-44.7
Peptic ulcer disease	(64.1 to 69.9)	(51.1 to 68.4)	(-26.1 to 3.1)	(-56.0 to -40.5)	(1.5 to 3.2)	(1.5 to 3.0)	(-16.0 to 10.4)	(-50.7 to -32.9)
Gastritis and duodenitis	6.9	7.5	9.8	-17.2	0.3	0.4	24.1	-5.9
Appendicitis	0.4	0.3	-26.7	-25.3	0.1	0.1	-25.9	-25.1
Paralytic ileus and intestinal obstruction	0.1	0.2	(0.2 to 0.3)	(47.4 to 1.9)	(0.0 to 0.2)	(0.0 to 0.1)	(-49.6 to 11.7)	(-51.9 to 17.5)
Inguinal, femoral, and abdominal hernia	46.9	72.1	54.9	2.0	0.5	0.7	54.4	2.6
Inflammatory bowel disease	(31.9 to 64.4)	(51.2 to 104.4)	(2.4 to 143.1)	(-32.9 to 54.4)	(0.2 to 0.9)	(0.3 to 1.4)	(2.0 to 143.1)	(-32.6 to 57.2)
Vascular intestinal disorders	0.1	0.1	14.0	-25.9	0.0	0.0	11.1	-25.3
Gallbladder and biliary diseases	11.5	16.8	48.2	2.6	1.2	1.7	46.3	4.2
Pancreatitis	(8.5 to 14.9)	(13.0 to 20.1)	(8.6 to 105.9)	(-26.9 to 48.4)	(0.7 to 1.8)	(1.1 to 2.4)	(6.3 to 107.4)	(-26.4 to 51.0)
Other digestive diseases	2.3	3.8	64.2	27.1	0.7	1.1	64.1	28.1
Neurological disorders	149.7	274.9	84.6	3.2	92.3	127.4	38.2	5.4
Alzheimer disease and other dementias	(116.4 to 181.3)	(218.4 to 329.4)	(33.3 to 149.4)	(-26.1 to 36.9)	(62.9 to 126.3)	(89.4 to 167.8)	(16.1 to 60.9)	(-11.6 to 23.0)
Parkinson disease	12.8	19.7	57.2	0.9	1.5	2.3	56.2	1.3
Epilepsy	36.4	37.4	2.8	-8.4	13.7	15.2	10.4	-0.8
Multiple sclerosis	3.3	4.8	49.1	20.5	1.1	1.6	48.2	20.5
Migraine	1,088.2	1,134.4	5.9	4.6	36.8	38.4	4.2	1.9
Tension-type headache	(904.2 to 1,284.3)	(932.2 to 1,353.3)	(-20.2 to 37.4)	(-28.3 to 25.5)	(21.3 to 56.6)	(21.9 to 59.0)	(-10.5 to 37.7)	(-28.7 to 25.0)
Medication overuse headache	73.9	129.1	76.4	48.3	11.5	20.1	75.2	48.4
Other neurological disorders	0.0	0.0	19.8	1.0	3.1	4.1	33.0	-24.5
Mental and substance use disorders	29.3	34.3	17.6	-0.9	243.6	258.2	5.8	-3.3
Schizophrenia	(23.0 to 35.4)	(26.7 to 41.6)	(10.5 to 25.0)	(-7.2 to 5.1)	(168.5 to 330.1)	(179.8 to 350.9)	(1.9 to 10.0)	(-7.0 to 0.0)
Alcohol use disorders	69.9	68.8	-1.0	-9.5	7.0	6.9	-1.3	-9.7
Drug use disorders	19.3	21.2	10.7	0.6	15.6	16.4	5.0	1.6
Opioid use disorders	(17.5 to 20.9)	(19.3 to 23.1)	(4.4 to 17.8)	(-5.2 to 6.9)	(11.0 to 20.1)	(11.5 to 21.2)	(-4.9 to 16.2)	(-8.5 to 13.9)
Cocaine use disorders	13.1	12.9	-1.2	0.6	8.0	8.9	11.0	1.3
Amphetamine use disorders	(11.9 to 14.2)	(11.6 to 14.4)	(-14.3 to 14.7)	(-14.1 to 16.4)	(5.7 to 10.3)	(6.3 to 11.4)	(11.9 to 21.0)	(-7.1 to 10.3)
Cannabis use disorders	13.6	13.5	-0.3	4.5	1.8	1.8	0.5	4.6
Other drug use disorders	(11.8 to 15.0)	(12.0 to 15.0)	(-14.3 to 18.5)	(-10.7 to 24.6)	(1.1 to 2.6)	(1.1 to 2.6)	(-19.0 to 25.4)	(-14.8 to 32.7)
Depressive disorders	15.9	14.1	-10.7	1.8	0.5	0.4	-10.2	2.2
Major depressive disorder	(14.6 to 17.2)	(13.2 to 15.1)	(-15.7 to -6.1)	(-3.9 to 7.6)	(0.3 to 0.7)	(0.3 to 0.6)	(-24.8 to 4.2)	(-14.2 to 19.9)
Dysthymia	69.9	68.8	-1.0	-9.5	3.6	3.6	-0.9	2.5
Bipolar disorder	76.3	84.4	11.2	-1.3	2.2	2.3	4.5	1.8
Anxiety disorders	(53.0 to 89.7)	(71.3 to 97.7)	(5.4 to 18.3)	(-6.2 to 5.4)	(2.2 to 5.1)	(2.3 to 5.2)	(-27.2 to 33.2)	(-25.2 to 38.3)
Eating disorders	530.2	578.5	10.3	0.5	87.9	89.7	6.3	8.2
Anorexia nervosa	(294.6 to 750.1)	(348.4 to 809.2)	(0.5 to 22.6)	(-0.7 to -0.3)	11.2	10.3	-7.8	1.9
Bulimia nervosa	12.5	12.8	2.5	11.5	(6.7 to 16.8)	(6.1 to 15.5)	(-15.4 to -0.9)	(-3.9 to 7.6)
Autistic spectrum disorders	(8.0 to 16.8)	(8.4 to 17.3)	(-14.1 to 19.1)	(-4.9 to 25.5)	2.7	2.7	2.1	11.4
Autism	40.5	35.9	-11.0	-1.2	8.5	7.6	-11.3	-1.1
Asperger syndrome	(25.6 to 56.7)	(22.4 to 51.7)	(-17.6 to -4.6)	(-1.6 to -0.8)	11.3	12.0	6.3	0.8
Attention-deficit/hyperactivity disorder	29.4	31.3	6.8	0.6	(7.9 to 15.4)	(8.4 to 16.3)	(3.1 to 10.2)	(-2.8 to 4.3)
Conduct disorder	42.2	44.8	7.0	0.8	7.2	7.5	6.3	0.8
Idiopathic intellectual disability	(39.4 to 45.1)	(41.7 to 48.1)	(6.0 to 7.9)	(0.8 to 0.8)	(4.8 to 9.7)	(5.1 to 10.4)	(1.6 to 11.5)	(-4.1 to 5.8)
Other mental and substance use disorders	56.4	41.9	-25.2	0.2	4.2	4.4	6.6	1.0
Diabetes, urogenital, blood, and endocrine diseases	42.2	44.8	7.0	0.8	(2.9 to 5.8)	(3.1 to 6.1)	(2.1 to 10.7)	(-3.0 to 4.9)
Diabetes mellitus	61.1	59.3	-2.7	-1.1	0.7	0.5	-25.1	0.2
Acute glomerulonephritis	(69.4 to 96.2)	(50.0 to 68.9)	(-28.6 to -37.4)	(0.1 to 0.1)	(0.4 to 1.1)	(0.3 to 0.8)	(-30.1 to -20.1)	(-6.4 to 7.0)
Chronic kidney disease	66.6	52.9	-20.0	-35.1	0.9	0.7	-27.8	0.2
Chronic kidney disease due to diabetes mellitus	(43.2 to 95.2)	(30.4 to 76.7)	(-52.0 to 28.0)	(-54.3 to 20.5)	(6.0 to 15.0)	(4.4 to 10.8)	(-30.8 to -34.8)	(-3.7 to 4.2)
Chronic kidney disease due to hypertension	192.2	227.1	18.9	0.5	3.9	3.1	-20.2	-24.8
Chronic kidney disease due to glomerulonephritis	(181.0 to 203.4)	(213.8 to 240.0)	(17.2 to 20.7)	(0.4 to 0.7)	(1.7 to 4.9)	(1.7 to 4.9)	(50.2 to 27.1)	(54.2 to 21.3)
Chronic kidney disease due to other causes	530.2	578.5	10.3	0.5	48.1	52.6	9.8	40.3
Urinary diseases and male infertility	125.1	204.0	66.8	18.5	(23.6 to 76.5)	(28.1 to 83.7)	(-0.2 to 21.6)	(-2.5 to 21.1)
Diabetes mellitus	(78.0 to 194.6)	(135.4 to 288.4)	(10.8 to 133.3)	(-14.6 to 57.1)	127.8	173.8	34.8	6.3
Acute glomerulonephritis	98.6	106.6	7.2	-16.8	(89.9 to 172.0)	(124.1 to 235.4)	(23.7 to 57.8)	(-2.1 to 20.1)
Chronic kidney disease	(68.7 to 130.6)	(77.0 to 142.7)	(-19.4 to 59.5)	(-38.2 to 11.5)	37.1	62.1	63.7	22.8
Chronic kidney disease due to diabetes mellitus	185.2	275.6	48.9	17.6	33.1	62.1	63.7	22.8
Chronic kidney disease due to hypertension	379.2	645.7	69.0	21.4	0.0	0.0	-22.1	-22.8
Chronic kidney disease due to glomerulonephritis	(262.8 to 524.7)	(452.8 to 888.6)	(42.4 to 135.4)	(4.5 to 61.8)	(0.0 to 0.0)	(0.0 to 0.0)	(-27.8 to -15.9)	(-28.0 to -16.8)
Chronic kidney disease due to other causes	-	-	-	-	39.2	53.8	37.8	6.8
Urinary diseases and male infertility	-	-	-	-	(25.7 to 53.8)	(35.7 to 73.2)	(29.2 to 46.0)	(1.3 to 12.0)
Chronic kidney disease due to diabetes mellitus	125.1	204.0	66.8	18.5	7.3	10.8	51.0	15.5
Chronic kidney disease due to hypertension	(88.7 to 130.6)	(77.0 to 142.7)	(-19.4 to 59.5)	(-38.2 to 11.5)	(4.4 to 11.0)	(7.1 to 15.1)	(9.2 to 98.6)	(-13.8 to 48.4)
Chronic kidney disease due to glomerulonephritis	185.2	275.6	48.9	17.6	11.4	4.8	-58.1	-67.4
Chronic kidney disease due to other causes	379.2	645.7	69.0	21.4	(38.2 to 115.0)	(7.1 to 18.0)	(-73.7 to -44.4)	(-73.9 to -58.6)
Urinary diseases and male infertility	(262.8 to 524.7)	(452.8 to 888.6)	(42.4 to 135.4)	(4.5 to 61.8)	17.1	31.1	77.8	37.2
Chronic kidney disease due to diabetes mellitus	-	-	-	-	11.4	17.1	49.7	6.1
Chronic kidney disease due to hypertension	-	-	-	-	(11.3 to 24.4)	(20.5 to 43.1)	(51.2 to 131.8)	(17.3 to 73.2)
Chronic kidney disease due to glomerulonephritis	-	-	-	-	7.4	17.1	49.7	6.1
Chronic kidney disease due to other causes	-	-	-	-	(7.4 to 16.2)	(10.8 to 25.0)	(22.4 to 76.1)	(12.4 to 25.3)

Appendix Table G.4 - Greece prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.1 (0.8 to 1.3)	1.4 (1.2 to 1.7)	27.1 (1.0 to 88.9)	0.0 (-20.2 to 52.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	27.9 (-9.0 to 100.9)	27.9 (-26.8 to 65.7)
Urolithiasis	153.3 (103.5 to 217.7)	331.0 (184.4 to 496.6)	117.4 (47.2 to 195.8)	1.2 (7.2 to 120.5)	1.2 (0.7 to 1.9)	2.8 (1.4 to 4.8)	133.1 (63.9 to 202.3)	71.4 (20.7 to 126.5)
Benign prostatic hyperplasia	276.5 (248.6 to 309.2)	378.5 (303.4 to 437.7)	37.1 (14.0 to 64.4)	-5.9 (-20.4 to 11.2)	9.8 (6.4 to 13.9)	9.8 (8.6 to 19.9)	13.5 (14.1 to 63.9)	-5.4 (-19.9 to 11.7)
Male infertility due to other causes	42.9 (29.7 to 59.7)	47.8 (34.2 to 63.6)	12.6 (-25.0 to 74.5)	1.1 (-32.5 to 57.2)	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.7)	10.8 (-26.5 to 74.8)	-0.8 (-33.8 to 59.2)
Other urinary diseases	-	-	-	-	0.1 (0.0 to 0.2)	0.5 (0.1 to 1.0)	410.9 (52.2 to 1,192.1)	410.9 (8.3 to 868.2)
Gynecological diseases	-	-	-	-	12.6 (8.0 to 19.5)	14.4 (9.3 to 22.3)	14.3 (28.2 to 28.6)	-2.8 (-12.6 to 10.3)
Uterine fibroids	384.7 (329.0 to 444.4)	481.9 (412.7 to 558.9)	26.0 (25.0 to 27.0)	-1.8 (-1.9 to -1.7)	3.0 (1.4 to 5.6)	3.8 (1.8 to 7.1)	24.4 (19.4 to 27.9)	-2.1 (-6.0 to 0.7)
Polycystic ovarian syndrome	168.6 (143.8 to 191.6)	180.4 (159.1 to 202.1)	7.4 (-10.3 to 30.9)	-7.4 (-23.2 to 13.6)	1.6 (0.7 to 3.0)	1.7 (0.8 to 3.2)	7.2 (-10.0 to 31.0)	-7.6 (-22.7 to 13.2)
Female infertility due to other causes	10.6 (1.0 to 28.9)	12.5 (1.1 to 38.9)	4.9 (-89.7 to 1,676.1)	-18.8 (-90.6 to 1,282.6)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	67.3 (-90.8 to 1,380.5)	-20.3 (-91.4 to 1,124.5)
Endometriosis	27.3 (19.7 to 33.9)	32.0 (23.8 to 42.6)	14.9 (-16.3 to 79.4)	-3.3 (-29.1 to 51.0)	2.5 (1.5 to 3.7)	3.0 (1.8 to 4.5)	16.0 (-16.4 to 79.7)	2.6 (-29.1 to 51.9)
Genital prolapse	656.9 (595.5 to 718.5)	750.1 (683.0 to 817.3)	14.7 (1.6 to 31.2)	-4.3 (-15.6 to 10.0)	2.1 (1.0 to 3.9)	2.4 (1.1 to 4.6)	14.3 (1.0 to 31.7)	-4.2 (-16.0 to 10.9)
Premenstrual syndrome	356.5 (280.6 to 433.3)	374.8 (287.1 to 458.2)	6.1 (-25.0 to 44.7)	-0.3 (-29.4 to 36.5)	3.0 (1.8 to 4.6)	3.1 (1.8 to 5.0)	6.0 (-25.9 to 46.1)	-0.2 (-29.9 to 38.8)
Other gynecological diseases	20.0 (16.0 to 24.0)	21.0 (17.0 to 24.9)	4.8 (-16.5 to 37.2)	-9.5 (-28.0 to 19.6)	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.6)	5.7 (-31.5 to 84.4)	-11.5 (-42.8 to 52.3)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	22.7 (15.0 to 33.1)	21.6 (14.4 to 30.8)	4.9 (-13.5 to 3.5)	-7.0 (-14.1 to 2.4)
Thalassemias	3.3 (3.0 to 3.6)	2.7 (2.4 to 2.9)	-18.7 (-24.2 to -12.0)	-5.9 (-12.6 to 1.8)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-22.4 (-42.5 to 4.9)	-10.0 (-33.0 to 20.9)
Thalassemia trait	718.8 (695.8 to 746.8)	760.3 (732.5 to 788.7)	6.4 (3.0 to 10.1)	-2.8 (-6.0 to 0.7)	18.5 (11.7 to 26.8)	17.6 (11.7 to 25.2)	-4.7 (-15.3 to 1.0)	-8.0 (-17.1 to -2.5)
Sickle cell disorders	1.0 (0.8 to 1.1)	1.0 (0.8 to 1.1)	2.9 (-16.7 to 31.2)	6.7 (-11.9 to 37.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	7.7 (-9.0 to 26.5)	8.0 (-10.4 to 27.3)
Sickle cell trait	343.3 (321.7 to 363.9)	378.2 (353.5 to 400.0)	11.1 (6.0 to 14.2)	1.6 (-3.0 to 4.8)	2.6 (1.6 to 3.8)	2.3 (1.4 to 3.4)	9.0 (-19.7 to 7.1)	6.3 (-18.0 to 10.2)
G6PD deficiency	364.4 (328.4 to 403.4)	388.2 (320.8 to 446.0)	7.4 (-13.3 to 28.0)	-1.8 (-20.5 to 17.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-53.3 to 64.9)	-22.4 (-58.3 to 54.2)
G6PD trait	1,711.7 (1,674.1 to 1,748.2)	1,865.1 (1,816.7 to 1,912.8)	9.7 (6.1 to 13.1)	-1.0 (-4.3 to 2.1)	0.1 (0.0 to 0.2)	0.1 (0.0 to 1.1)	1.7 (-39.3 to 52.1)	4.7 (-61.9 to 60.8)
Other hemoglobinopathies and hemolytic anemias	59.5 (55.4 to 64.5)	65.5 (59.4 to 81.9)	9.9 (-2.6 to 41.3)	-0.9 (-15.0 to 42.9)	1.2 (0.7 to 1.8)	1.2 (0.7 to 2.1)	3.6 (-18.5 to 80.0)	6.3 (-19.2 to 111.6)
Endocrine, metabolic, blood, and immune disorders	147.9 (134.9 to 162.8)	149.0 (133.3 to 166.3)	0.8 (-11.7 to 16.3)	-0.8 (-22.3 to 5.0)	4.7 (3.2 to 6.6)	4.8 (3.2 to 6.8)	4.5 (-13.2 to 22.0)	4.2 (-23.0 to 17.9)
Musculoskeletal disorders	-	-	-	-	305.8 (216.8 to 407.8)	384.3 (275.4 to 504.2)	25.6 (19.4 to 34.1)	2.7 (-2.5 to 10.2)
Rheumatoid arthritis	8.7 (7.9 to 9.9)	24.6 (21.6 to 28.2)	185.3 (133.5 to 234.6)	105.7 (73.8 to 137.9)	2.0 (1.4 to 2.7)	5.6 (3.9 to 7.6)	182.6 (128.0 to 235.3)	106.7 (71.7 to 143.3)
Osteoarthritis	538.6 (496.6 to 581.5)	760.8 (704.2 to 815.6)	42.0 (27.0 to 59.4)	-1.9 (-11.9 to 10.0)	18.5 (12.0 to 26.6)	26.1 (17.2 to 38.1)	41.2 (26.6 to 58.8)	-1.6 (-11.8 to 10.4)
Low back and neck pain	-	-	-	-	247.8 (172.6 to 336.8)	298.8 (208.5 to 399.4)	20.5 (12.6 to 30.4)	0.2 (-6.0 to 9.2)
Low back pain	1,517.4 (1,418.3 to 1,600.5)	1,826.4 (1,711.9 to 1,935.0)	20.5 (11.7 to 34.3)	-0.0 (-7.5 to 11.1)	167.5 (113.0 to 232.2)	201.6 (138.0 to 282.7)	19.9 (11.2 to 33.8)	0.2 (-7.3 to 11.6)
Neck pain	825.9 (714.4 to 932.5)	997.2 (903.4 to 1,090.8)	21.3 (7.0 to 40.4)	0.0 (-11.7 to 14.7)	80.3 (55.0 to 113.7)	97.2 (66.8 to 134.2)	20.8 (6.5 to 39.8)	0.2 (-11.7 to 14.7)
Gout	24.0 (21.4 to 26.5)	33.2 (29.8 to 36.6)	39.5 (20.2 to 62.5)	1.2 (-12.8 to 17.3)	0.7 (0.5 to 1.0)	1.0 (0.7 to 1.4)	38.3 (13.9 to 68.7)	1.5 (-16.8 to 23.4)
Other musculoskeletal disorders	405.5 (320.7 to 489.0)	578.4 (467.4 to 692.2)	44.0 (33.7 to 54.9)	17.0 (9.5 to 24.7)	36.7 (24.2 to 52.7)	47.8 (34.8 to 75.7)	17.1 (33.6 to 54.6)	39.9 (9.2 to 25.5)
Other non-communicable diseases	-	-	-	-	203.4 (136.4 to 290.9)	243.2 (164.2 to 349.2)	19.6 (14.4 to 25.2)	-4.9 (-9.7 to 0.3)
Congenital anomalies	-	-	-	-	16.3 (11.4 to 21.8)	17.0 (12.2 to 22.2)	4.6 (-9.6 to 19.4)	-6.4 (-18.8 to 7.2)
Neural tube defects	3.4 (2.7 to 4.2)	2.7 (2.4 to 3.1)	-18.2 (-37.1 to 2.6)	-20.3 (-38.5 to -0.2)	1.1 (0.7 to 1.6)	0.9 (0.6 to 1.2)	-17.3 (-43.1 to 15.2)	-18.9 (-44.5 to 12.0)
Congenital heart anomalies	107.9 (86.8 to 135.0)	105.7 (86.2 to 131.5)	-1.5 (-28.1 to 35.2)	-7.9 (-32.9 to 26.2)	3.7 (1.5 to 6.7)	3.7 (1.5 to 6.5)	0.2 (-26.3 to 25.5)	-5.4 (-30.3 to 34.4)
Orofacial clefts	14.8 (12.1 to 17.8)	16.6 (13.8 to 20.6)	12.8 (-8.4 to 39.3)	5.2 (-16.0 to 27.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	6.3 (-24.0 to 38.0)	6.3 (-30.6 to 28.0)
Down syndrome	12.4 (8.9 to 17.3)	14.5 (11.9 to 18.9)	18.8 (-20.2 to 72.6)	5.1 (-29.8 to 52.5)	1.9 (1.2 to 2.7)	2.3 (1.6 to 3.1)	24.8 (-17.0 to 83.0)	6.4 (-29.5 to 56.0)
Turner syndrome	0.6 (0.5 to 0.7)	0.6 (0.4 to 0.9)	6.8 (-23.9 to 56.7)	2.0 (-27.5 to 50.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.7 (-25.3 to 62.3)	1.7 (-29.4 to 53.4)
Klinefelter syndrome	0.4 (0.3 to 0.6)	0.5 (0.4 to 0.8)	30.1 (-16.0 to 106.7)	21.6 (-21.6 to 92.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-20.1 to 124.5)	22.8 (-27.7 to 106.3)
Chromosomal unbalanced rearrangements	24.5 (19.2 to 30.6)	27.7 (22.6 to 33.5)	14.2 (-13.3 to 52.2)	4.4 (-23.1 to 34.9)	2.7 (2.5 to 5.1)	4.4 (3.2 to 5.8)	19.6 (9.9 to 60.5)	2.3 (-22.9 to 38.1)
Other congenital anomalies	31.8 (20.7 to 45.2)	31.0 (18.7 to 44.8)	-1.6 (-22.0 to 20.6)	-14.1 (-30.1 to 6.1)	5.7 (3.6 to 8.7)	5.5 (3.3 to 8.3)	-3.9 (-20.4 to 15.7)	-12.0 (-27.0 to 6.9)
Skin and subcutaneous diseases	-	-	-	-	68.4 (44.1 to 103.2)	72.6 (47.1 to 110.8)	6.5 (-4.5 to 19.0)	-0.1 (-10.3 to 13.7)
Dermatitis	629.6 (496.4 to 765.9)	690.7 (539.2 to 842.2)	10.3 (6.6 to 14.0)	0.0 (-0.1 to 0.2)	16.5 (10.6 to 24.1)	17.7 (11.2 to 26.2)	7.7 (38.0 to 11.8)	0.2 (-2.2 to 2.6)
Psoriasis	152.2 (131.4 to 175.0)	176.1 (150.8 to 202.9)	16.3 (14.6 to 18.7)	0.1 (-0.0 to 0.2)	12.2 (8.3 to 17.0)	14.2 (9.6 to 19.8)	16.0 (10.9 to 21.0)	0.4 (-3.8 to 4.7)
Cellulitis	4.1 (2.5 to 5.8)	5.1 (3.3 to 7.6)	25.5 (-3.8 to 43.5)	-1.1 (-18.4 to 11.0)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.6)	24.2 (9.3 to 52.5)	2.3 (-23.0 to 21.5)
Pyoderma	9.0 (6.4 to 13.2)	10.1 (7.2 to 14.9)	13.9 (-4.1 to 30.6)	-4.3 (-15.0 to 4.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	12.5 (-7.5 to 31.8)	-4.5 (-17.6 to 8.2)
Scabies	7.0 (5.8 to 8.6)	5.4 (4.6 to 6.3)	-21.5 (-38.2 to -3.0)	-23.0 (-38.1 to -4.2)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-22.3 (-39.6 to 13.7)	-23.4 (-40.0 to -1.2)
Fungal skin diseases	765.6 (679.4 to 844.7)	891.9 (792.0 to 975.0)	16.3 (14.5 to 20.0)	6.4 (0.3 to 5.0)	5.0 (1.7 to 8.9)	5.0 (2.0 to 10.3)	16.8 (13.9 to 19.3)	0.2 (-0.3 to 1.5)
Viral skin diseases	211.8 (168.4 to 257.5)	204.7 (163.7 to 250.1)	-2.6 (-7.1 to 1.6)	-0.5 (-1.8 to 3.1)	6.5 (3.8 to 10.1)	6.3 (3.7 to 9.8)	-3.1 (-8.1 to 2.2)	-0.6 (-3.0 to 4.2)
Acne vulgaris	1,482.8 (944.1 to 2,027.8)	1,209.4 (954.8 to 1,542.5)	-18.6 (-45.6 to 56.4)	-2.7 (-35.2 to 81.7)	16.0 (7.0 to 32.7)	13.1 (6.0 to 25.1)	-18.6 (-45.7 to 55.7)	-2.6 (-35.7 to 82.2)
Alopecia areata	17.7 (16.5 to 19.0)	21.9 (20.0 to 23.8)	24.2 (10.7 to 38.4)	0.7 (-9.3 to 12.1)	0.6 (0.4 to 0.9)	0.7 (0.5 to 1.1)	23.3 (7.3 to 40.9)	1.2 (-11.8 to 15.8)
Pruritus	1.5 (1.1 to 2.0)	1.8 (1.2 to 2.4)	16.3 (-23.9 to 76.9)	0.1 (-36.9 to 34.8)	0.1 (0.0 to 0.0)	0.1 (0.0 to 0.0)	14.2 (-28.0 to 33.5)	0.4 (-41.1 to 42.3)
Urticaria	105.5 (85.5 to 129.5)	131.0 (104.3 to 163.8)	25.6 (-8.1 to 65.7)	4.8 (-20.5 to 36.9)	6.2 (3.8 to 9.0)	7.6 (4.7 to 11.4)	24.6 (9.3 to 63.4)	4.6 (-20.4 to 38.1)
Decubitus ulcer	5.3 (4.1 to 6.6)	8.3 (6.3 to 10.4)	57.3 (5.6 to 127.3)	-3.5 (-32.1 to 36.7)	0.8 (0.5 to 1.1)	1.2 (0.7 to 1.7)	54.4 (5.1 to 131.3)	-3.4 (-32.3 to 39.7)
Other skin and subcutaneous diseases	857.8 (483.6 to 1,483.6)	1,085.9 (883.6 to 1,962.6)	26.8 (17.3 to 35.6)	0.9 (-1.9 to 4.1)	5.0 (2.0 to 11.3)	6.3 (2.4 to 14.6)	26.3 (16.8 to 35.3)	1.1 (-2.1 to 4.5)
Sense organ diseases	-	-	-	-	79.8 (51.5 to 116.0)	106.9 (72.4 to 153.0)	34.3 (22.4 to 46.5)	-8.2 (-15.6 to -0.2)
Glaucoma	12.8 (8.9 to 17.5)	13.7 (9.8 to 18.8)	6.9 (-12.8 to 35.3)	-29.3 (-41.5 to -5.6)	1.0 (0.6 to 1.5)	1.1 (0.7 to 1.7)	13.1 (-15.1 to 38.5)	-24.9 (-42.6 to -8.1)
Cataract	38.1 (24.0 to 61.0)	41.6 (25.2 to 66.0)	7.5 (-26.2 to 56.0)	-38.4 (-57.7 to -11.6)	2.1 (1.2 to 3.4)	2.4 (1.4 to 4.1)	16.0 (-16.4 to 58.3)	-33.2 (-52.2 to -9.8)
Macular degeneration	50.3 (33.7 to 69.2)	74.8 (48.9 to 114.0)	48.5 (9.6 to 99.2)	-4.0 (-27.6 to 24.1)	2.7 (1.6 to 4.1)	4.2 (2.5 to 6.6)	55.3 (19.8 to 99.0)	-3.5 (-23.9 to 19.2)
Uncorrected refractive error	1,287.5 (934.9 to 1,634.3)	1,650.0 (1,367.8 to 1,921.1)	29.7 (-9.9 to 86.9)	4.1 (-31.0 to 41.8)	16.9 (9.1 to 28.8)	20.8 (11.1 to 34.3)	23.5 (-4.8 to 64.3)	-8.2 (-30.7 to 24.1)
Age-related and other hearing loss	1,687.5 (1,439.7 to 1,918.8)	2,207.7 (1,922.3 to 2,486.8)	31.8 (25.8 to 38.5)	31.8 (-14.1 to -4.7)	48.7 (31.9 to 72.5)	48.7 (45.3 to 100.1)	69.0 (27.6 to 60.9)	-7.6 (-14.5 to 1.2)
Other vision loss	37.4 (26.7 to 53.7)	30.5 (21.0 to 44.6)	-18.1 (-31.8 to 2.6)	-41.0 (-50.1 to -27.2)	2.1 (1.3 to 3.3)	2.0 (1.2 to 3.1)	-5.3 (-19.7 to 16.0)	-3.1 (-40.8 to -17.6)
Other sense organ diseases	245.4 (235.3 to 255.6)	281.5 (266.8 to 295.6)	15.5 (8.3 to 23.1)	-0.7 (-6.1 to 5.9)	6.4 (3.9 to 9.5)	7.3 (4.5 to 10.7)	14.7 (7.1 to 22.3)	-0.4 (-6.7 to 6.8)
Oral disorders	-	-	-	-	39.0 (24.1 to 58.7)	46.7 (29.1 to 71.2)	19.6 (11.4 to 30.0)	-8.9 (-15.0 to -1.9)
Deciduous caries	466.7 (455.6 to 478.3)	394.3 (384.4 to 405.8)	-15.0 (-17.9 to -11.9)	-0.5 (-4.1 to 3.1)	2.3 (0.0 to 0.2)	2.5 (0.0 to 0.2)	7.1 (-21.5 to 7.3)	-8.0 (-31.0 to 8

Appendix Table G.4 - Greece prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	775.7 (697.2 to 853.0)	927.4 (853.4 to 1,010.5)	19.8 (6.7 to 39.8)	-17.7 (-26.3 to -3.5)	21.1 (13.8 to 29.6)	25.2 (16.8 to 35.2)	19.1 (5.9 to 39.2)	-27.6 (-26.4 to -3.6)
Other oral disorders	195.1 (184.7 to 205.1)	219.4 (207.1 to 230.9)	13.2 (6.5 to 20.3)	-0.3 (-6.3 to 5.6)	5.7 (3.6 to 8.4)	6.4 (4.0 to 9.5)	12.8 (5.3 to 20.1)	-0.3 (-7.0 to 6.3)
Injuries	-	-	-	-	104.8 (80.0 to 133.9)	90.9 (64.9 to 122.7)	-13.6 (-23.5 to -3.7)	-38.3 (-45.0 to -31.5)
Transport injuries	-	-	-	-	18.3 (13.8 to 23.5)	7.8 (5.6 to 10.4)	-57.8 (-62.4 to -52.8)	-67.2 (-70.8 to -63.2)
Road injuries	-	-	-	-	17.0 (12.8 to 21.7)	5.5 (4.0 to 7.3)	-67.7 (-71.1 to -63.9)	-74.8 (-77.4 to -71.8)
Pedestrian road injuries	-	-	-	-	2.6 (2.0 to 3.4)	0.9 (0.7 to 1.3)	-64.6 (-68.5 to -60.8)	-73.3 (-76.3 to -70.1)
Cyclist road injuries	-	-	-	-	0.9 (0.7 to 1.1)	0.6 (0.4 to 0.7)	-36.6 (-45.1 to -25.2)	-49.9 (-56.7 to -40.6)
Motorcyclist road injuries	-	-	-	-	4.0 (3.0 to 5.1)	1.4 (1.0 to 1.8)	-66.0 (-71.2 to -60.6)	-73.2 (-77.3 to -68.8)
Motor vehicle road injuries	-	-	-	-	9.4 (7.1 to 11.9)	2.6 (1.9 to 3.4)	-72.1 (-74.7 to -69.2)	-78.2 (-80.2 to -76.0)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-73.9 (-76.9 to -70.0)	-79.8 (-82.2 to -76.8)
Other transport injuries	-	-	-	-	1.3 (1.0 to 1.7)	2.3 (1.6 to 3.1)	68.5 (50.6 to 88.4)	32.7 (19.3 to 48.0)
Unintentional injuries	-	-	-	-	85.3 (64.7 to 109.2)	82.3 (58.7 to 110.9)	-3.9 (-15.1 to 7.3)	-31.6 (-38.8 to -24.1)
Falls	-	-	-	-	68.7 (52.1 to 87.2)	73.6 (52.5 to 99.5)	6.5 (-7.8 to 21.6)	-25.1 (-34.6 to -15.0)
Drowning	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-5.9 (-16.7 to 7.6)	-29.7 (-37.6 to -19.6)
Fire, heat, and hot substances	-	-	-	-	3.5 (2.2 to 5.5)	1.4 (0.8 to 2.3)	-59.3 (-64.6 to -54.2)	-69.8 (-73.8 to -65.8)
Poisonings	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-26.5 (-39.2 to -10.6)	-41.5 (-52.1 to -27.9)
Exposure to mechanical forces	-	-	-	-	5.4 (4.0 to 7.0)	4.4 (3.1 to 6.0)	-18.9 (-26.3 to -9.7)	-33.1 (-39.3 to -25.7)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-49.3 (-47.8 to -31.7)	-49.5 (-56.0 to -42.1)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.4 (-10.7 to 16.0)	-19.5 (-29.3 to -8.0)
Other exposure to mechanical forces	-	-	-	-	5.3 (3.9 to 6.9)	4.3 (3.1 to 6.0)	-18.7 (-26.1 to -9.3)	-32.9 (-39.1 to -25.5)
Adverse effects of medical treatment	-	-	-	-	0.6 (0.4 to 0.9)	0.7 (0.5 to 1.1)	29.3 (17.4 to 44.5)	-0.8 (-9.1 to 10.3)
Animal contact	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	32.2 (19.9 to 45.6)	8.4 (-1.9 to 19.4)
Venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	25.2 (4.0 to 49.3)	5.3 (-13.2 to 26.0)
Non-venomous animal contact	-	-	-	-	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	33.7 (19.9 to 48.9)	9.2 (-2.4 to 21.5)
Foreign body	-	-	-	-	0.6 (0.4 to 0.8)	0.5 (0.3 to 0.7)	-10.8 (-21.2 to 3.1)	-24.2 (-34.4 to -12.3)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-16.0 (-26.1 to -2.6)	-35.8 (-44.6 to -23.6)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-3.2 (-11.8 to 11.1)	-11.5 (-22.5 to 1.4)
Foreign body in other body part	-	-	-	-	0.4 (0.2 to 0.5)	0.3 (0.2 to 0.5)	-11.3 (-25.6 to 7.6)	-23.5 (-35.7 to -9.0)
Other unintentional injuries	-	-	-	-	5.9 (4.2 to 7.9)	0.8 (0.6 to 1.2)	-86.0 (-88.0 to -83.9)	-89.3 (-90.7 to -87.6)
Self-harm and interpersonal violence	-	-	-	-	1.1 (0.8 to 1.4)	0.9 (0.6 to 1.1)	-23.5 (-30.3 to -15.1)	-40.0 (-45.3 to -33.7)
Self-harm	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	11.7 (-1.4 to 25.8)	-14.6 (-24.9 to -3.0)
Interpersonal violence	-	-	-	-	0.9 (0.7 to 1.1)	0.6 (0.4 to 0.8)	-31.6 (-38.3 to -23.8)	-45.7 (-50.9 to -39.5)
Assault by firearm	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-24.5 (-31.7 to -16.1)	-41.6 (-47.1 to -35.0)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-10.1 (-18.6 to -0.6)	-30.4 (-37.2 to -22.9)
Assault by other means	-	-	-	-	0.6 (0.5 to 0.8)	0.4 (0.3 to 0.5)	-36.4 (-43.5 to -28.0)	-48.9 (-54.4 to -42.0)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.1 (-3.8 to 92.8)	21.6 (-18.4 to 71.6)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.1 (-3.8 to 92.8)	21.6 (-18.4 to 71.6)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Grenada prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
All causes	-	-	-	-	9.1 (6.7 to 11.9)	10.5 (7.8 to 13.6)	15.3 (10.1 to 19.6)	3.2 (-7.0 to 0.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.8 (1.2 to 2.6)	1.3 (0.9 to 1.8)	-26.4 (-38.3 to -15.8)	-28.8 (-42.5 to -16.8)
HIV/AIDS and tuberculosis	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	78.0 (30.0 to 147.8)	38.8 (1.4 to 93.3)
Tuberculosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	24.9 (20.2 to 31.1)	-2.2 (-5.7 to 2.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.5 (13.5 to 41.5)	-1.7 (-10.3 to 9.0)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	126.2 (33.1 to 340.2)	75.6 (1.9 to 244.9)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.2 (9.9 to 278.8)	39.2 (-16.7 to 183.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.2 (9.8 to 280.4)	39.2 (-17.0 to 183.8)
HIV/AIDS resulting in other diseases	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	128.0 (32.8 to 389.0)	81.4 (7.4 to 282.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	126.8 (32.2 to 355.6)	76.2 (1.6 to 254.9)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-17.3 (-23.2 to -9.7)	-10.6 (-16.6 to -3.9)
Diarrheal diseases	0.8 (0.7 to 0.8)	0.6 (0.6 to 0.7)	-17.4 (-25.2 to -8.3)	1.2 (-7.6 to 11.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-18.0 (-26.3 to -8.6)	1.0 (-8.7 to 11.8)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.5 (-76.5 to -14.1)	-32.0 (-76.8 to -12.7)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.0 (-41.2 to -14.3)	-29.8 (-40.0 to -14.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.0 (-41.2 to -14.0)	-29.8 (-40.0 to -14.2)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.7 (-44.4 to -10.6)	-28.0 (-41.7 to -8.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.7 (-44.4 to -10.5)	-28.0 (-41.7 to -8.2)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.4 (-98.8 to -91.9)	-54.2 (-98.8 to -98.9)
Lower respiratory infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.1 (-51.5 to -1.8)	-34.5 (-52.5 to -9.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.2 (-53.9 to -0.8)	-34.3 (-52.5 to -7.1)
Upper respiratory infections	5.0 (4.6 to 5.4)	5.1 (4.6 to 5.7)	2.5 (-9.2 to 17.3)	-3.5 (-14.6 to 10.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	2.6 (-9.7 to 17.3)	-3.2 (-14.8 to 10.7)
Otitis media	1.2 (1.1 to 1.2)	1.0 (1.0 to 1.1)	-10.5 (-16.4 to -3.5)	-11.4 (-17.2 to -4.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.8 (-19.2 to -3.6)	-12.2 (-19.6 to -4.7)
Meningitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.0 (-73.8 to -56.6)	-70.1 (-76.2 to -61.0)
Pneumococcal meningitis	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-69.2 (-75.3 to -58.0)	-73.3 (-78.7 to -64.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-69.9 (-72.1 to -52.9)	-68.6 (-74.9 to -58.3)
H influenzae type B meningitis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-75.1 (-84.7 to -61.0)	-78.1 (-86.0 to -64.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-71.2 (-83.8 to -49.5)	-73.6 (-85.0 to -53.6)
Meningococcal meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-66.5 (-79.1 to -32.2)	-71.2 (-81.3 to -42.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-60.8 (-78.7 to -12.4)	-65.5 (-80.9 to -23.8)
Other meningitis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-70.9 (-77.0 to -58.7)	-73.9 (-79.9 to -61.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.4 (-76.7 to -45.5)	-69.8 (-78.4 to -49.9)
Encephalitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.3 (-34.6 to -3.1)	-11.2 (-4.9 to 18.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.7 (-26.2 to 9.5)	-24.4 (-37.2 to -7.6)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.1 (-96.7 to 303.4)	-56.9 (-95.2 to 266.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.1 (-96.7 to 309.4)	-56.9 (-95.2 to 272.4)
Whooping cough	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-87.4 (-88.7 to -86.0)	-82.2 (-84.0 to -80.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-87.3 (-90.5 to -83.5)	-82.1 (-86.5 to -76.7)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-91.3 (-94.7 to -84.0)	-91.7 (-95.0 to -84.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-88.8 (-94.1 to -75.1)	-89.1 (-94.0 to -76.2)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-13.2 (-26.4 to 4.1)	-1.1 (-19.7 to 24.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.5 (-19.7 to 60.2)	-1.2 (-32.1 to 44.8)
Neglected tropical diseases and malaria	-	-	-	-	0.6 (0.3 to 1.0)	0.2 (0.1 to 0.3)	-69.1 (-81.1 to -49.7)	-72.9 (-84.3 to -54.4)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.1 (-52.2 to 136.9)	1.5 (-55.8 to 117.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.0 (-48.6 to 160.3)	7.1 (-53.2 to 139.6)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.0 (-37.8 to 87.1)	-3.9 (-41.6 to 77.2)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.7 (-60.1 to 105.2)	-3.8 (-52.9 to 114.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.7 (-60.3 to 105.9)	-3.8 (-53.1 to 115.8)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.3 (-36.0 to 88.0)	-4.3 (-40.9 to 74.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.3 (-38.6 to 98.0)	-3.9 (-42.8 to 83.7)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-22.8 (-62.1 to 72.7)	-40.4 (-70.3 to 28.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.8 (-60.8 to 93.2)	-36.4 (-69.1 to 40.3)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.8 (-42.4 to -23.2)	-45.9 (-56.2 to -42.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.2 (-47.4 to -7.8)	-47.6 (-59.6 to -30.1)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.4)	431.1 (432.5 to 433.8)	385.6 (385.1 to 386.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	430.2 (364.1 to 506.2)	384.7 (331.7 to 450.9)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.0 (-49.7 to 58.8)	-1.5 (-52.8 to 35.5)
Intestinal nematode infections	-	-	-	-	0.5 (0.2 to 0.9)	0.1 (0.0 to 0.1)	-83.1 (-90.5 to -70.9)	-85.5 (-92.2 to -74.1)
Ascariasis	65.3 (58.1 to 73.3)	12.3 (7.5 to 19.3)	-81.9 (-88.6 to -69.6)	-84.3 (-90.2 to -73.7)	0.5 (0.2 to 0.9)	0.0 (0.0 to 0.0)	-99.2 (-99.7 to -97.8)	-99.3 (-99.8 to -98.0)
Trichuriasis	24.9 (17.1 to 34.9)	4.9 (3.0 to 7.9)	-80.6 (-89.4 to -65.0)	-83.1 (-91.1 to -68.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-99.6 (-99.9 to -97.4)	-99.7 (-99.8 to -97.6)
Hookworm disease	0.1 (0.1 to 0.2)	0.1 (1.6 to 25.2)	12,835.4 (7,700.6 to 22,665.0)	11,189.9 (6,368.8 to 20,813.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	11,121.7 (7,737.8 to 22,536.8)	11,121.7 (6,912.3 to 21,377.0)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	1.4 (1.1 to 1.7)	1.1 (1.0 to 1.2)	-21.1 (-34.5 to -0.1)	-10.4 (-24.5 to 10.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-24.4 (-34.3 to 7.4)	-9.0 (-20.5 to 25.7)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.2 (-33.3 to -1.2)	-42.5 (-52.3 to -30.9)
Maternal hemorrhage	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.7 (-28.3 to -3.8)	-41.6 (-50.0 to -33.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.9 (-32.8 to 3.3)	-16.9 (-52.5 to -25.4)
Maternal sepsis and other maternal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.9 (-49.3 to -4.1)	-59.9 (-65.5 to -33.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.5 (-50.3 to -16.1)	-52.8 (-63.9 to -39.0)
Maternal hypertensive disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.7 (-27.4 to -13.7)	-43.3 (-48.2 to -38.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.5 (-40.5 to 4.7)	-43.0 (-56.9 to -25.4)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.1 (-44.6 to 52.0)	-39.8 (-60.2 to 1.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.1 (-45.0 to 52.3)	-39.8 (-60.3 to 3.0)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.3 (-46.5 to 53.8)	-37.5 (-61.4 to 4.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.3 (-46.5 to 53.9)	-37.5 (-61.4 to 4.7)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.6 (-48.1 to 35.7)	-40.9 (-63.0 to -3.6)
Neonatal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	42.0 (-4.5 to 103.4)	34.7 (-9.8 to 93.6)
Preterm birth complications	0.4 (0.3 to 0.8)	0.9 (0.5 to 1.7)	110.9 (57.8 to 172.6)	96.5 (47.9 to 152.9)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	122.0 (43.7 to 241.4)	107.3 (34.6 to 217.7)
Neonatal encephalopathy due to birth asphyxia and trauma	0.4 (0.2 to 1.1)	0.3 (0.1 to 0.7)	-33.9 (-56.3 to -2.6)	-37.7 (-59.3 to -2.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-21.0 (-49.3 to 19.9)	-24.2 (-50.9 to 14.9)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.0 (39.1 to 64.3)	102.6 (89.2 to 123.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.0 (28.3 to 72.9)	103.9 (74.4 to 135.1)
Hemolytic disease and other neonatal jaundice	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-19.1 (-74.6 to 140.6)	-24.2 (-76.4 to 124.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-17.5 (-71.0 to 156.6)	-22.4 (-72.7 to 141.2)
Other neonatal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.5 (-21.4 to 260.1)	63.6 (-25.6 to 240.8)
Nutritional deficiencies	-	-	-	-	0.7 (0.5 to 1.1)	0.6 (0.4 to 0.9)	-17.7 (-20.8 to -15.4)	-14.8 (-17.8 to -12.6)
Protein-energy malnutrition	0.1 (0.1 to 0.3)	0.1 (0.0 to 0.1)	-51.1 (-78.3 to 13.0)	-34.4 (-69.2 to 43.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.1 (-78.4 to 14.0)	-34.0 (-69.2 to 44.7)
Iodine deficiency	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-21.6 (-44.6 to 14.1)	-40.5 (-58.5 to -13.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.4 (-46.2 to 14.9)	-40.2 (-58.9 to -11.8)
Vitamin A deficiency	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-54.7 (-62.3 to -44.9)	-53.4 (-60.6 to -43.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-55.4 (-64.0 to -44.6)	-55.0 (-62.9 to -44.3)

Appendix Table G.4 - Grenada prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	22.5 (22.2 to 22.8)	20.2 (20.0 to 20.4)	-10.1 (-11.8 to -8.3)	-13.5 (-15.1 to -11.8)	0.7 (0.5 to 1.0)	0.6 (0.4 to 0.9)	-16.8 (-19.5 to -14.9)	-14.3 (-17.0 to -12.3)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-73.3 to 202.1)	0.0 (-61.5 to 287.4)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-0.9 (-11.1 to 13.2)	-5.2 (-14.3 to 4.7)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (11.7 to 49.4)	0.0 (-16.8 to 8.7)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.1 (9.7 to 31.4)	-16.1 (-29.7 to 0.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-21.5 to 11.1)	0.0 (-39.7 to 17.1)
Chlamydial infection	2.3 (2.0 to 2.7)	3.0 (2.5 to 3.5)	25.9 (0.6 to 63.6)	-8.5 (-25.3 to 18.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.7 (7.1 to 70.2)	-3.2 (-21.2 to 22.2)
Gonococcal infection	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.4)	35.9 (0.9 to 89.7)	-0.2 (-24.8 to 36.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.3 (-22.1 to 57.9)	-15.2 (-40.0 to 14.9)
Trichomoniasis	0.5 (0.3 to 0.8)	0.7 (0.4 to 1.0)	32.5 (-24.6 to 144.6)	-6.1 (-43.3 to 69.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.3 (-31.3 to 173.7)	-6.6 (-47.6 to 86.9)
Genital herpes	20.3 (19.2 to 21.4)	25.6 (24.3 to 27.0)	26.1 (17.6 to 35.6)	-5.9 (-12.0 to 1.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.1 (15.8 to 37.3)	5.7 (-12.9 to 2.1)
Other sexually transmitted diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.7 (2.6 to 35.8)	-20.8 (-30.6 to -6.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (2.0 to 91.0)	0.0 (-25.5 to 33.6)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-25.4 to 10.9)	-8.3 (-40.5 to -7.6)
Hepatitis A	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-12.0 (-12.4 to -11.7)	-9.3 (-9.8 to -8.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-4.7 to 21.3)	7.2 (-15.2 to 6.4)
Hepatitis B	4.5 (3.6 to 5.5)	2.7 (2.0 to 3.3)	-39.3 (-59.7 to -16.8)	-48.7 (-65.7 to -28.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.8 (-56.6 to 17.6)	-43.9 (-67.7 to -10.5)
Hepatitis C	1.6 (1.4 to 1.7)	1.5 (1.3 to 1.6)	-7.0 (-20.3 to 6.9)	-24.7 (-34.4 to -13.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.4 (-41.5 to 17.6)	-28.3 (-49.7 to 9.9)
Hepatitis E	-	-	7.4 (-10.6 to 27.0)	-14.3 (-28.0 to 0.3)	-	-	-	-
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.9 (9.1 to 60.0)	-5.1 (-25.2 to 28.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.0 (-12.9 to 69.8)	-5.8 (-28.9 to 35.3)
Other infectious diseases	1.0 (0.8 to 1.3)	0.8 (0.8 to 0.9)	-17.7 (-27.3 to -6.0)	-11.2 (-21.3 to 0.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-15.5 (-26.6 to 7.2)	-1.0 (-14.2 to 23.8)
Non-communicable diseases	-	-	-	-	6.9 (5.1 to 9.0)	8.8 (6.5 to 11.4)	27.3 (23.5 to 30.8)	3.3 (0.5 to 6.2)
Neoplasms	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	110.9 (74.1 to 142.3)	81.6 (48.2 to 109.3)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.6 (-12.8 to 53.8)	1.5 (-22.5 to 36.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-15.8 to 48.0)	-1.4 (-25.8 to 30.7)
Stomach cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.3 (-26.6 to 11.7)	-20.6 (-35.4 to -2.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-3.3 to 6.6)	-14.2 (-39.9 to -6.7)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-1.3 to 1.3)	0.0 (-26.6 to 26.6)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	418.0 (159.1 to 918.7)	343.9 (116.6 to 793.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	399.9 (162.9 to 828.2)	206.6 (119.3 to 707.3)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,387.1 (727.1 to 2,675.5)	1,189.3 (610.5 to 2,309.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,287.2 (718.0 to 2,308.2)	1,100.0 (613.5 to 1,980.4)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	131.3 (34.0 to 290.5)	101.9 (16.2 to 238.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	121.4 (40.9 to 232.3)	91.9 (20.8 to 185.4)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	122.2 (23.2 to 286.0)	88.4 (2.7 to 233.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.1 (32.4 to 236.7)	78.9 (10.5 to 187.1)
Larynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.8 (-64.0 to -15.2)	-47.7 (-68.1 to -25.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-44.7 to 17.4)	-16.5 (-51.7 to 3.5)
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.5 (6.8 to 64.7)	16.9 (-6.2 to 44.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.1 (-0.6 to 59.7)	9.9 (-13.9 to 38.0)
Breast cancer	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	62.5 (25.0 to 116.2)	29.2 (-0.7 to 72.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.4 (27.1 to 116.1)	30.9 (1.4 to 73.5)
Cervical cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-5.3 (-31.1 to 35.3)	46.1 (-45.5 to 5.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-30.8 to 34.1)	-25.9 (-45.3 to 4.4)
Uterine cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	130.4 (-8.3 to 247.3)	100.2 (-20.2 to 202.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	127.3 (8.6 to 238.8)	98.7 (-20.6 to 194.4)
Prostate cancer	0.2 (0.1 to 0.3)	0.7 (0.4 to 0.9)	252.5 (108.9 to 412.3)	233.6 (96.6 to 382.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	229.1 (90.8 to 354.4)	205.7 (78.5 to 322.4)
Colon and rectum cancer	0.2 (0.2 to 0.2)	0.5 (0.4 to 0.6)	154.6 (96.4 to 230.1)	111.5 (64.1 to 172.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	146.5 (90.3 to 224.1)	106.0 (59.8 to 166.9)
Lip and oral cavity cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.5 (0.8 to 81.3)	12.9 (-14.8 to 52.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.2 (-2.6 to 76.0)	10.8 (-16.9 to 50.3)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.1 (-20.6 to 55.2)	-12.8 (-37.9 to 23.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.6 (-21.8 to 47.0)	-14.7 (-39.6 to 18.6)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.8 (-13.2 to 92.1)	7.1 (-28.3 to 57.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.7 (-12.3 to 82.2)	4.4 (-27.7 to 49.6)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.3 (-75.1 to 12.0)	-67.8 (-78.3 to -1.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-64.0 (-76.2 to 10.5)	-68.7 (-78.9 to -3.1)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	560.6 (417.5 to 731.9)	470.2 (345.9 to 618.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	473.7 (350.6 to 619.9)	393.5 (286.2 to 517.3)
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.2 (-24.7 to 43.3)	-21.5 (-39.8 to 15.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-25.5 to 43.3)	0.0 (-40.7 to 15.5)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.3 (34.8 to 154.9)	46.9 (9.1 to 105.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.9 (32.8 to 232.1)	68.6 (3.9 to 159.2)
Ovarian cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	379.6 (258.4 to 549.4)	299.0 (199.7 to 437.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	359.1 (233.5 to 531.7)	279.5 (174.9 to 425.5)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	673.3 (36.0 to 1,363.4)	470.9 (-1.4 to 961.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	602.6 (23.2 to 1,378.4)	403.2 (-9.1 to 995.3)
Kidney cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.0 (4.6 to 62.7)	15.1 (-7.7 to 45.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.9 (-1.3 to 50.1)	9.4 (-13.7 to 41.5)
Bladder cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	123.3 (27.0 to 249.1)	91.7 (9.0 to 196.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	136.3 (30.0 to 287.7)	104.8 (12.3 to 233.9)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	364.3 (33.2 to 602.2)	376.5 (32.8 to 566.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	398.4 (36.7 to 608.6)	378.2 (25.8 to 529.7)
Thyroid cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	131.4 (58.2 to 213.5)	72.5 (17.8 to 137.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	124.1 (51.6 to 200.5)	68.8 (13.4 to 127.9)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	144.1 (90.8 to 204.2)	105.5 (68.8 to 160.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	152.6 (101.8 to 210.8)	116.6 (72.8 to 165.4)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	898.7 (43.3 to 1,499.7)	788.2 (22.5 to 1,289.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	913.2 (34.1 to 1,495.8)	782.2 (14.8 to 1,218.2)
Non-Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	112.2 (37.3 to 191.7)	75.0 (11.6 to 141.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.7 (32.4 to 174.8)	63.7 (7.3 to 125.1)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.1 (6.8 to 215.2)	61.6 (-6.4 to 178.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.4 (2.1 to 213.6)	54.3 (-10.2 to 171.0)
Leukemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.0 (-10.7 to 90.2)	35.7 (0.7 to 135.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.2 (5.4 to 90.1)	30.9 (3.3 to 72.7)
Other neoplasms	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	140.1 (76.5 to 217.4)	124.0 (69.8 to 183.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	133.4 (74.4 to 203.6)	105.5 (61.9 to 166.4)
Cardiovascular diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	50.6 (26.2 to 80.3)	29.2 (8.4 to 54.8)
Rheumatic heart disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.6 (-1.6 to 30.3)	-5.1 (-18.8 to 8.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-1.4 to 34.2)	-4.8 (-18.6 to 11.6)
Ischemic heart disease	0.7 (0.6 to 0.8)	1.4 (1.1 to 1.7)	99.9 (61.4 to 157.1)	80.6 (45.1 to 135.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	126.3 (71.2 to 215.1)	106.4 (57.4 to 187.4)
Cerebrovascular disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	17.3 (8.3 to 45.3)	0.3 (-22.5 to 25.2)
Ischemic stroke	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	15.0 (-12.0 to 43.2)	-0.9 (-24.6 to 23.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.5 (-11.9 to 42.8)	-1.0 (-24.6 to 24.0)
Hemorrhagic stroke	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	24.5 (-13.3 to 83.1)	3.2 (-29.9 to 51.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.7 (-12.5 to 82.9)	3.6 (-28.0 to 52.7)
Hypertensive heart disease	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	0.0 (-11.7 to 14.1)	-14.2 (-24.1 to -1.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.3 (-13.5 to 15.3)	-14.2 (-25.8 to -0.8)
Cardiomyopathy and myocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.4 (4.0 to 45.7)	5.4 (-11.7 to 25.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (1.7 to 52.7)	0.0 (-13.7 to 30.8)
Atrial fibrillation and flutter	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	43.8 (6.8 to 105.2)	16.7 (-13.1 to 63.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.2 (6.5 to 102.1)	17.3 (-12.6 to 64.1)
Peripheral vascular disease	2.9 (2.3 to 3.4)	3.1 (2.5 to 4.0)	8.3 (-18.5 to 49.1)	-11.1 (-32.3 to 22.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-39.3 to 126.1)	-8.6 (-52.2 to 75.9)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.3 (-21.9 to 24.4)	-20.8 (-36.6 to 3.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.4 (-26.1 to 21.1)	-22.6 (-39.9 to 0.4)
Other cardiovascular and circulatory diseases	0.3 (0.1 to 0.5)	0.4 (0.3 to 0.5)	30.2 (-31.9 to 164.7)	30.2 (-47.3 to 103.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-31.7 to 167.1)	0.0 (-47.8 to 104.9)
Chronic respiratory diseases	-	-	-	-	0.5 (0.3 to 0.6)	0.6 (0.4 to 0.8)	25.9 (8.1 to 51.6)	3.9 (-12.0 to 25.6)
Chronic obstructive pulmonary disease	3.9 (3.7 to 4.1)	4.9 (4.6 to 5.1)	24.5 (20.9 to 28.1)	0.0 (-2.8 to 3.1)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.5)	42.5 (9.7 to 69.8)	14.2 (13.6 to 36.6)

Appendix Table G.4 - Grenada prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	18.7	-3.3
Silicosis	0.0	0.0	10.4	-9.3	(0.0 to 0.0)	(0.0 to 0.0)	(13.9 to 23.8)	(-7.0 to 0.3)
Asbestosis	-	-	0.0	0.0	0.0	0.0	9.6	-9.9
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	26.7	-	0.0	0.0	25.4	1.7
Asthma	(0.0 to 0.0)	(0.0 to 0.0)	(18.3 to 35.0)	(-3.3 to 8.5)	(0.0 to 0.0)	(0.0 to 0.0)	(17.3 to 33.7)	(-4.3 to 7.5)
Interstitial lung disease and pulmonary sarcoidosis	5.0	5.7	14.3	-3.2	0.2	0.2	14.2	-3.2
Other chronic respiratory diseases	(4.2 to 5.8)	(4.6 to 6.7)	(-11.2 to 46.1)	(-25.6 to 23.2)	(0.1 to 0.3)	(0.2 to 0.4)	(-11.6 to 47.0)	(-25.6 to 23.4)
Cirrhosis	0.0	0.0	26.0	5.8	0.0	0.0	26.3	5.9
Cirrhosis due to hepatitis B	(0.0 to 0.0)	(0.0 to 0.0)	(-10.1 to 80.0)	(-23.6 to 54.1)	(0.0 to 0.0)	(0.0 to 0.0)	(-10.5 to 80.3)	(-23.9 to 54.4)
Cirrhosis due to hepatitis C	-	-	-	-	0.0	0.0	0.8	-19.3
Cirrhosis due to alcohol use	0.0	0.0	16.0	-4.6	(0.0 to 0.0)	(0.0 to 0.0)	(-40.7 to 58.4)	(-52.5 to 26.5)
Cirrhosis due to other causes	(0.0 to 0.0)	(0.0 to 0.0)	(-28.3 to 126.3)	(-42.1 to 85.7)	(0.0 to 0.0)	(0.0 to 0.0)	(-35.5 to 142.5)	(-49.1 to 101.6)
Digestive diseases	0.0	0.0	38.6	15.6	0.0	0.0	38.5	16.1
Peptic ulcer disease	0.0	0.0	0.0	0.0	(0.0 to 0.0)	(0.0 to 0.0)	(-5.6 to 119.8)	(-21.8 to 88.4)
Gastritis and duodenitis	2.1	2.4	14.2	2.2	0.1	0.1	6.6	-3.0
Appendicitis	(2.0 to 2.2)	(2.2 to 2.5)	(5.7 to 23.5)	(-4.5 to 9.8)	(0.0 to 0.1)	(0.1 to 0.1)	(2.5 to 21.6)	(-11.0 to 9.6)
Paralytic ileus and intestinal obstruction	0.0	0.0	10.2	-6.1	0.0	0.0	11.6	-5.3
Inguinal, femoral, and abdominal hernia	(0.0 to 0.0)	(0.0 to 0.0)	(-16.0 to 49.4)	(-27.5 to 22.9)	(0.0 to 0.0)	(0.0 to 0.0)	(-20.8 to 59.6)	(-31.4 to 30.5)
Inflammatory bowel disease	0.3	0.2	-35.4	-46.8	0.0	0.0	-35.1	-46.3
Vascular intestinal disorders	(0.3 to 0.4)	(0.2 to 0.2)	(-47.3 to -22.7)	(-57.1 to -36.0)	(0.0 to 0.0)	(0.0 to 0.0)	(-47.0 to -22.3)	(-56.7 to -35.3)
Gallbladder and biliary diseases	0.1	0.1	64.7	26.7	0.0	0.0	65.2	26.9
Pancreatitis	(0.1 to 0.1)	(0.2 to 0.2)	(56.2 to 73.7)	(20.0 to 33.7)	(0.0 to 0.0)	(0.0 to 0.0)	(51.8 to 79.7)	(16.8 to 37.6)
Other digestive diseases	0.0	0.0	5.7	-12.9	0.0	0.0	5.7	-12.9
Neurological disorders	(0.0 to 0.0)	(0.0 to 0.0)	(-46.3 to 94.7)	(-55.5 to 65.1)	(0.0 to 0.0)	(0.0 to 0.0)	(-46.2 to 94.8)	(-55.5 to 65.3)
Alzheimer disease and other dementias	0.1	0.1	384.0	-34.0	0.0	0.0	34.3	-34.3
Parkinson disease	(0.1 to 0.1)	(0.0 to 0.1)	(-30.3 to -3.7)	(-43.4 to -21.7)	(0.0 to 0.0)	(0.0 to 0.0)	(-31.8 to -3.1)	(-44.6 to -21.4)
Epilepsy	0.0	0.0	95.3	52.5	0.0	0.0	93.8	51.1
Multiple sclerosis	(0.0 to 0.0)	(0.0 to 0.0)	(83.4 to 108.8)	(43.9 to 62.5)	(0.0 to 0.0)	(0.0 to 0.0)	(50.3 to 152.5)	(19.0 to 93.9)
Migraine	-	-	-	-	0.0	0.0	425.6	347.7
Tension-type headache	-	-	-	-	(0.0 to 0.0)	(0.0 to 0.0)	(280.5 to 544.0)	(225.1 to 444.5)
Medication overuse headache	0.7	0.9	20.3	-0.6	(0.4 to 0.8)	(0.5 to 1.0)	30.3	3.0
Other neurological disorders	(0.6 to 0.8)	(0.8 to 1.0)	(2.6 to 41.7)	(-15.6 to 17.2)	0.1	0.1	(9.8 to 50.8)	(-11.2 to 17.7)
Mental and substance use disorders	0.0	0.0	9.6	-1.2	0.0	0.0	8.6	-1.8
Schizophrenia	(0.0 to 0.0)	(0.0 to 0.0)	(0.8 to 17.7)	(-7.7 to 4.6)	(0.0 to 0.0)	(0.0 to 0.0)	(9.1 to 30.5)	(-18.1 to 16.6)
Alcohol use disorders	0.2	0.3	30.3	16.6	0.1	0.1	38.1	24.1
Drug use disorders	(0.1 to 0.3)	(0.2 to 0.4)	(-24.0 to 123.6)	(-31.5 to 100.2)	(0.0 to 0.1)	(0.1 to 0.2)	(-21.6 to 143.5)	(-30.1 to 118.9)
Opioid use disorders	0.0	0.0	155.3	83.8	0.0	0.0	147.6	78.5
Cocaine use disorders	(0.0 to 0.0)	(0.0 to 0.0)	(129.3 to 185.7)	(65.2 to 106.9)	(0.0 to 0.0)	(0.0 to 0.0)	(106.3 to 197.0)	(47.4 to 116.5)
Amphetamine use disorders	8.6	10.5	22.4	4.3	0.4	0.4	23.3	4.6
Cannabis use disorders	(7.1 to 10.0)	(8.6 to 12.4)	(-6.7 to 51.3)	(-26.6 to 16.1)	(0.2 to 0.4)	(0.2 to 0.6)	(7.1 to 52.2)	(-26.9 to 17.0)
Other drug use disorders	17.5	23.0	31.3	1.3	0.0	0.0	32.0	1.7
Depressive disorders	(14.9 to 20.7)	(21.5 to 24.6)	(9.9 to 55.5)	(-13.8 to 18.5)	(0.0 to 0.0)	(0.0 to 0.1)	(9.9 to 57.8)	(-14.1 to 19.1)
Major depressive disorder	0.4	0.7	76.1	33.2	0.1	0.1	77.5	33.9
Dysthymia	(0.3 to 0.5)	(0.5 to 0.9)	(42.5 to 151.9)	(7.4 to 91.9)	(0.0 to 0.1)	(0.1 to 0.2)	(42.6 to 153.3)	(7.6 to 90.9)
Bipolar disorder	0.0	0.0	15.8	4.4	0.0	0.0	-17.9	-33.7
Anxiety disorders	(0.0 to 0.0)	(0.0 to 0.0)	(-17.5 to 61.7)	(-27.8 to 48.2)	(0.0 to 0.0)	(0.0 to 0.0)	(-44.4 to 14.1)	(-55.0 to -7.4)
Eating disorders	-	-	-	-	2.0	2.6	28.2	0.3
Anorexia nervosa	0.2	0.3	37.0	-0.6	(1.5 to 2.7)	(1.9 to 3.5)	(24.3 to 32.0)	(-1.9 to 2.8)
Bulimia nervosa	(0.2 to 0.2)	(0.3 to 0.3)	(31.2 to 43.6)	(-4.8 to 4.0)	0.1	0.2	37.9	-0.3
Autistic spectrum disorders	0.5	0.8	50.0	12.7	0.0	0.1	51.9	13.6
Autism	(0.5 to 0.7)	(0.7 to 1.0)	(27.6 to 42.6)	(-4.8 to 4.6)	(0.0 to 0.1)	(0.0 to 0.1)	(26.3 to 46.2)	(-5.9 to 6.6)
Asperger syndrome	(3.5 to 6.5)	(4.4 to 8.3)	(20.4 to 33.0)	(-1.1 to -0.7)	0.3	0.5	27.8	-0.5
Attention-deficit/hyperactivity disorder	-	-	-	-	0.0	0.0	32.9	1.2
Conduct disorder	-	-	-	-	(0.0 to 0.0)	(0.0 to 0.1)	(19.8 to 45.8)	(-6.6 to 9.1)
Idiopathic intellectual disability	0.0	0.0	29.8	4.5	0.0	0.0	30.6	5.4
Other mental and substance use disorders	(0.0 to 0.0)	(0.0 to 0.0)	(16.5 to 47.5)	(-5.5 to 17.5)	(0.0 to 0.0)	(0.0 to 0.0)	(3.8 to 63.6)	(-15.7 to 31.0)
Diabetes, urogenital, blood, and endocrine diseases	0.1	0.1	32.3	-0.6	0.0	0.0	33.4	0.2
Diabetes mellitus	(0.1 to 0.2)	(0.1 to 0.2)	(24.8 to 39.8)	(-0.9 to -0.4)	(0.0 to 0.0)	(0.0 to 0.0)	(18.7 to 48.5)	(-7.7 to 9.1)
Acute glomerulonephritis	-	-	-	-	0.1	0.1	12.3	1.5
Chronic kidney disease	-	-	-	-	(0.1 to 0.2)	(0.1 to 0.2)	(6.6 to 35.8)	(-7.9 to 16.8)
Chronic kidney disease due to diabetes mellitus	0.3	0.3	12.4	0.9	0.1	0.1	12.5	1.4
Chronic kidney disease due to hypertension	(0.3 to 0.3)	(0.3 to 0.3)	(11.7 to 13.1)	(0.9 to 1.0)	(0.0 to 0.1)	(0.1 to 0.1)	(6.9 to 18.6)	(-3.1 to 6.3)
Chronic kidney disease due to glomerulonephritis	0.4	0.5	11.7	1.2	0.0	0.0	11.9	1.7
Chronic kidney disease due to other causes	(0.4 to 0.4)	(0.4 to 0.5)	(10.8 to 12.7)	(1.1 to 1.3)	(0.0 to 0.1)	(0.0 to 0.1)	(7.1 to 16.7)	(-2.2 to 5.6)
Urinary diseases and male infertility	0.8	0.8	-3.6	0.3	0.0	0.0	-3.7	0.5
Urinary tract infections	(0.7 to 0.8)	(0.7 to 0.8)	(-4.5 to -3.2)	(0.3 to 0.3)	(0.0 to 0.0)	(0.0 to 0.0)	(-9.6 to 3.3)	(-5.8 to 7.4)
Diabetes insipidus	1.0	1.1	9.9	0.3	0.1	0.1	9.3	0.5
Diabetes mellitus (type 1)	(1.0 to 1.1)	(0.9 to 1.1)	(-5.1 to -2.6)	(0.2 to 0.3)	(0.0 to 0.2)	(0.1 to 0.2)	(-3.3 to 5.5)	(-3.3 to 5.5)
Diabetes mellitus (type 2)	0.3	0.4	6.3	4.9	0.0	0.0	7.2	-4.4
Other diabetes mellitus	(0.2 to 0.5)	(0.2 to 0.5)	(-30.3 to 62.4)	(-37.7 to 44.9)	(0.0 to 0.0)	(0.0 to 0.0)	(-31.1 to 62.4)	(-39.1 to 44.5)
Other endocrine diseases	1.3	1.8	43.1	0.8	0.1	0.1	44.0	1.2
Diabetes, urogenital, blood, and endocrine diseases	(1.2 to 1.3)	(1.7 to 1.9)	(41.6 to 44.4)	(0.5 to 1.0)	(0.1 to 0.1)	(0.1 to 0.2)	(38.0 to 49.8)	(-2.5 to 4.9)
Diabetes mellitus	4.3	6.9	60.3	26.4	0.3	0.5	56.2	24.0
Acute glomerulonephritis	(3.6 to 5.1)	(5.7 to 8.2)	(30.3 to 99.3)	(0.8 to 58.2)	(0.2 to 0.4)	(0.3 to 0.7)	(25.4 to 95.6)	(-1.7 to 56.1)
Chronic kidney disease	0.0	0.0	-13.9	-6.4	0.0	0.0	-13.9	-6.4
Chronic kidney disease due to diabetes mellitus	(0.0 to 0.0)	(0.0 to 0.0)	(-19.7 to -8.5)	(-12.0 to -2.0)	(0.0 to 0.0)	(0.0 to 0.0)	(-19.7 to -8.5)	(-12.0 to -2.0)
Chronic kidney disease due to hypertension	-	-	-	-	0.1	0.2	20.3	3.0
Chronic kidney disease due to glomerulonephritis	2.5	2.9	16.5	-5.6	(0.1 to 0.2)	(0.1 to 0.2)	(6.6 to 35.8)	(-7.9 to 16.8)
Chronic kidney disease due to other causes	(1.6 to 3.6)	(1.9 to 4.1)	(-12.6 to 47.2)	(-27.9 to 38.8)	(0.0 to 0.0)	(0.0 to 0.1)	(-11.4 to 52.5)	(-26.2 to 24.4)
Urinary diseases and male infertility	1.5	1.8	18.5	8.2	0.0	0.0	18.6	-1.0
Urinary tract infections	(1.0 to 2.2)	(1.1 to 2.8)	(9.4 to 53.5)	(-20.1 to 39.7)	(0.0 to 0.1)	(0.0 to 0.1)	(-10.9 to 44.0)	(-23.1 to 17.5)
Diabetes insipidus	2.4	3.9	61.7	3.9	0.0	0.0	26.3	14.5
Diabetes mellitus (type 1)	(2.4 to 4.6)	(2.5 to 5.8)	(-22.0 to 44.8)	(-35.6 to 20.7)	(0.0 to 0.0)	(0.0 to 0.0)	(-15.8 to 72.6)	(-26.9 to 56.1)
Diabetes mellitus (type 2)	3.2	3.8	16.1	4.4	0.0	0.0	22.5	9.0
Other diabetes mellitus	(2.1 to 4.9)	(2.5 to 5.7)	(-15.5 to 47.3)	(-21.6 to 32.1)	(0.0 to 0.0)	(0.0 to 0.1)	(9.1 to 52.0)	(-18.9 to 38.9)
Urinary diseases and male infertility	-	-	-	-	0.0	0.0	18.6	4.9
Urinary tract infections	-	-	-	-	(0.0 to 0.0)	(0.0 to 0.1)	(7.9 to 35.0)	(-4.9 to 18.8)

Appendix Table G.4 - Grenada prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.8 (48.4 to 78.7)	30.7 (20.0 to 42.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.3 (31.4 to 102.5)	30.8 (8.5 to 60.2)
Urolithiasis	0.7 (0.4 to 0.9)	0.9 (0.5 to 1.5)	31.3 (-13.5 to 98.1)	9.3 (-28.9 to 65.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.4 (-1.3 to 100.0)	14.5 (-20.7 to 64.1)
Benign prostatic hyperplasia	0.6 (0.6 to 0.7)	0.7 (0.6 to 0.7)	9.2 (-2.2 to 24.8)	4.3 (-6.5 to 18.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.9 (-2.2 to 24.2)	4.4 (-6.4 to 18.9)
Male infertility due to other causes	0.6 (0.5 to 0.7)	0.9 (0.7 to 1.1)	48.7 (8.2 to 101.9)	3.9 (-24.2 to 40.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.4 (6.8 to 103.6)	4.0 (-25.2 to 40.2)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-36.8 to 123.7)	-20.6 (-48.0 to 81.1)
Gynecological diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	40.2 (22.8 to 59.3)	-3.1 (-14.6 to 9.4)
Uterine fibroids	1.4 (1.2 to 1.5)	2.0 (1.8 to 2.2)	47.0 (46.1 to 47.9)	-4.2 (-4.3 to -4.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.7 (18.6 to 42.4)	-12.6 (-20.6 to -4.6)
Polycystic ovarian syndrome	1.4 (1.2 to 1.6)	2.1 (1.8 to 2.4)	44.8 (24.4 to 78.7)	-0.9 (-13.1 to 18.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.1 (24.6 to 77.8)	-0.3 (-13.2 to 18.7)
Female infertility due to other causes	0.5 (0.3 to 0.8)	0.8 (0.4 to 1.1)	47.2 (-26.5 to 211.5)	2.3 (-51.1 to 124.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.9 (-24.8 to 199.5)	2.2 (-50.0 to 122.4)
Endometriosis	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.2)	51.3 (21.3 to 91.2)	2.1 (-17.3 to 27.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.2 (19.5 to 97.5)	2.4 (-18.5 to 29.7)
Genital prolapse	4.4 (3.8 to 5.1)	5.9 (4.7 to 7.0)	33.4 (5.5 to 69.4)	-4.3 (-23.6 to 18.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.8 (5.3 to 70.3)	-4.2 (-23.3 to 19.2)
Premenstrual syndrome	3.6 (2.7 to 4.3)	5.2 (3.9 to 6.5)	47.1 (1.7 to 113.0)	3.1 (-29.4 to 46.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	47.3 (0.4 to 114.8)	3.5 (-29.7 to 49.3)
Other gynecological diseases	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.3)	15.8 (-8.5 to 48.1)	-17.2 (-34.2 to 4.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.8 (-10.7 to 81.6)	-17.8 (-36.5 to 27.5)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	1.7 (-2.8 to 12.3)	3.2 (-3.1 to 11.1)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.6 (-24.9 to -8.9)	-4.7 (-13.6 to 3.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.6 (-22.9 to -9.9)	-4.3 (-9.7 to 4.8)
Thalassemia trait	1.2 (0.8 to 1.8)	1.3 (0.9 to 1.8)	6.5 (2.1 to 12.1)	-3.4 (-7.5 to 1.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.5 (-17.6 to 15.1)	-1.3 (-16.6 to 14.6)
Sickle cell disorders	0.2 (0.2 to 0.2)	0.3 (0.2 to 0.3)	21.5 (11.5 to 42.2)	14.8 (5.5 to 33.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.2 (15.9 to 64.6)	18.8 (2.1 to 44.9)
Sickle cell trait	13.1 (11.3 to 14.7)	15.6 (14.0 to 17.1)	17.9 (12.3 to 29.5)	0.1 (-1.9 to 1.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	4.0 (-6.9 to 20.1)	8.0 (-4.1 to 23.2)
G6PD deficiency	6.0 (4.6 to 7.2)	6.8 (5.0 to 8.4)	13.1 (-21.0 to 59.3)	3.0 (-28.0 to 44.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.5 (-20.4 to 40.7)	3.1 (-19.3 to 26.9)
G6PD trait	16.0 (14.8 to 17.1)	17.5 (16.3 to 18.7)	9.5 (-0.6 to 21.0)	-1.4 (-10.5 to 9.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.6 (-72.2 to 438.5)	-2.0 (-69.1 to 318.1)
Other hemoglobinopathies and hemolytic anemias	1.1 (1.0 to 1.2)	1.0 (0.9 to 1.1)	-9.1 (-16.2 to 3.9)	-13.3 (-20.8 to -4.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.0 (-32.0 to 1.8)	-15.6 (-30.1 to -0.5)
Endocrine, metabolic, blood, and immune disorders	1.1 (0.9 to 1.2)	0.9 (0.8 to 1.0)	-10.9 (-22.1 to 3.9)	0.0 (-21.3 to 2.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.5 (-35.1 to 5.5)	-10.4 (-28.8 to 11.8)
Musculoskeletal disorders	-	-	-	-	1.1 (0.8 to 1.5)	1.5 (1.0 to 1.9)	29.6 (20.2 to 47.2)	2.0 (-5.1 to 10.1)
Rheumatoid arthritis	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.4)	65.7 (54.5 to 76.1)	35.9 (26.4 to 45.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	65.2 (50.8 to 78.1)	35.4 (24.4 to 45.7)
Osteoarthritis	3.2 (3.0 to 3.3)	3.9 (3.7 to 4.0)	21.7 (15.0 to 28.3)	1.4 (-4.2 to 6.9)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	21.6 (14.4 to 28.3)	1.5 (-4.6 to 7.0)
Low back and neck pain	-	-	-	-	0.7 (0.5 to 0.9)	0.8 (0.6 to 1.1)	12.2 (12.4 to 47.2)	8.7 (-14.4 to 11.4)
Low back pain	3.7 (3.3 to 4.1)	4.6 (4.2 to 5.1)	22.9 (6.9 to 41.0)	-4.4 (-16.3 to 8.8)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	23.3 (6.9 to 41.2)	-4.3 (-16.3 to 9.2)
Neck pain	2.6 (2.2 to 2.9)	3.4 (2.9 to 4.0)	33.4 (5.8 to 71.3)	-0.3 (-20.4 to 26.5)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	34.1 (6.7 to 72.9)	-0.2 (-20.1 to 27.3)
Gout	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.0 (6.0 to 32.8)	-3.7 (-13.7 to 8.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.8 (-7.5 to 49.0)	-2.8 (-24.9 to 22.6)
Other musculoskeletal disorders	2.3 (1.9 to 2.7)	3.2 (2.7 to 3.7)	35.1 (25.3 to 44.9)	9.3 (-2.9 to 15.8)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	35.8 (26.0 to 46.3)	8.0 (2.6 to 16.1)
Other non-communicable diseases	-	-	-	-	1.6 (1.1 to 2.3)	1.8 (1.2 to 2.6)	14.2 (9.2 to 18.2)	-3.7 (-7.1 to -0.6)
Congenital anomalies	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	42.1 (21.2 to 67.5)	30.7 (11.3 to 54.2)
Neural tube defects	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.6 (-11.4 to 39.0)	6.2 (-15.1 to 33.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.9 (-19.8 to 64.7)	8.9 (-22.9 to 59.3)
Congenital heart anomalies	0.4 (0.3 to 0.5)	0.7 (0.6 to 0.8)	61.4 (25.1 to 117.8)	52.8 (18.0 to 107.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.4 (29.8 to 121.2)	58.9 (23.7 to 113.3)
Orofacial clefts	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	47.7 (10.7 to 93.6)	46.3 (9.4 to 91.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-24.1 to 65.6)	0.0 (-24.4 to 61.4)
Down syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	28.9 (-2.6 to 65.6)	20.0 (-9.6 to 54.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.1 (2.0 to 79.0)	25.7 (-5.6 to 65.9)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.8 (-15.0 to 55.2)	4.5 (-24.2 to 39.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.2 (-14.0 to 71.5)	4.0 (-26.4 to 43.5)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.5 (-15.6 to 61.0)	4.9 (-22.5 to 47.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.8 (-2.3 to 88.0)	5.2 (-22.5 to 49.2)
Chromosomal unbalanced rearrangements	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.2)	28.3 (1.7 to 68.7)	9.5 (-5.4 to 56.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.7 (5.8 to 82.4)	8.7 (-2.5 to 68.7)
Other congenital anomalies	0.4 (0.3 to 0.4)	0.4 (0.3 to 0.5)	1.5 (-7.2 to 10.6)	-11.2 (-18.2 to -3.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	44.1 (14.0 to 92.8)	29.0 (3.0 to 72.6)
Skin and subcutaneous diseases	-	-	-	-	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.9)	19.7 (8.8 to 28.7)	2.2 (-5.9 to 8.9)
Dermatitis	4.2 (3.5 to 5.0)	5.2 (4.2 to 6.2)	23.3 (20.0 to 26.1)	-0.1 (-0.2 to 0.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	18.3 (12.9 to 23.1)	0.3 (-2.5 to 3.2)
Psoriasis	0.7 (0.6 to 0.8)	0.9 (0.8 to 1.0)	25.4 (22.7 to 27.9)	0.1 (-0.1 to 0.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	26.1 (18.1 to 33.8)	0.4 (-4.5 to 5.7)
Cellulitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.9 (-24.5 to 0.2)	-14.7 (-25.1 to -4.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.4 (-30.2 to 8.5)	-14.4 (-29.1 to 2.7)
Pyoderma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	28.4 (17.5 to 38.1)	23.1 (17.5 to 28.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.1 (8.5 to 49.1)	23.4 (8.2 to 40.1)
Scabies	1.2 (1.0 to 1.4)	1.3 (1.1 to 1.5)	6.8 (-13.0 to 31.9)	-1.7 (-20.0 to 20.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	6.8 (-13.4 to 31.5)	-1.8 (-20.4 to 19.9)
Fungal skin diseases	6.7 (5.1 to 8.8)	8.1 (6.2 to 10.7)	20.3 (14.9 to 26.4)	0.4 (-0.1 to 0.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	20.6 (15.1 to 26.7)	0.6 (-0.3 to 1.6)
Viral skin diseases	2.1 (1.6 to 2.6)	2.1 (1.5 to 2.7)	-0.6 (-9.7 to 7.7)	0.1 (-2.2 to 2.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.4 (-10.2 to 8.3)	0.5 (-3.0 to 4.2)
Acne vulgaris	6.3 (4.7 to 7.8)	8.1 (5.9 to 10.4)	26.6 (-11.4 to 89.2)	5.0 (-25.8 to 56.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	26.7 (-11.3 to 91.2)	5.3 (-25.5 to 56.6)
Alopecia areata	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	18.4 (2.5 to 34.9)	0.3 (-12.7 to 14.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.7 (-1.2 to 40.4)	0.3 (-15.8 to 18.6)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.7 (-8.5 to 52.6)	5.3 (-21.5 to 34.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.7 (-8.8 to 52.8)	5.3 (-21.6 to 34.8)
Urticaria	0.9 (0.7 to 1.2)	1.2 (0.9 to 1.6)	36.9 (-6.4 to 97.7)	9.4 (-22.5 to 54.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	37.8 (-6.9 to 97.9)	9.3 (-22.6 to 56.5)
Decubitus ulcer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.6 (-32.1 to 32.3)	-26.9 (-47.9 to 6.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.6 (-33.4 to 36.6)	-25.9 (-48.3 to 9.5)
Other skin and subcutaneous diseases	5.5 (3.4 to 9.0)	6.6 (4.3 to 10.3)	20.4 (8.4 to 33.8)	-0.4 (-4.3 to 3.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	20.6 (8.4 to 34.0)	-0.3 (-4.3 to 3.5)
Sense organ diseases	-	-	-	-	0.7 (0.5 to 1.0)	0.7 (0.5 to 1.0)	5.8 (0.6 to 11.3)	-10.4 (-14.0 to -6.3)
Glaucoma	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	1.8 (-12.5 to 16.1)	-20.1 (-31.4 to -9.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-11.7 to 20.8)	0.0 (-28.8 to -5.1)
Cataract	0.8 (0.6 to 1.0)	0.7 (0.5 to 0.8)	-16.5 (-25.3 to -6.2)	-28.6 (-35.2 to -19.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-14.0 (-23.4 to -4.8)	-27.8 (-35.2 to -21.9)
Macular degeneration	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	32.9 (7.2 to 64.2)	11.8 (-7.8 to 36.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.7 (6.7 to 62.9)	10.5 (-8.4 to 35.5)
Uncorrected refractive error	9.0 (8.4 to 9.5)	10.2 (9.5 to 10.9)	14.3 (4.5 to 23.9)	-5.3 (-13.0 to 2.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	6.1 (-1.1 to 14.0)	-10.6 (-15.8 to -4.8)
Age-related and other hearing loss	13.7 (13.0 to 14.5)	14.9 (14.1 to 15.9)	8.4 (5.0 to 12.9)	-9.1 (-11.9 to -5.4)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.6)	9.3 (1.8 to 18.4)	8.7 (-13.9 to -2.2)
Other vision loss	0.3 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-21.4 (-28.5 to -12.2)	-33.1 (-39.7 to -26.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.7 (-27.3 to -9.0)	-30.9 (-38.1 to -23.7)
Other sense organ diseases	2.4 (2.3 to 2.5)	2.4 (2.3 to 2.5)	-0.2 (-6.1 to 6.9)	-0.8 (-6.7 to 5.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-0.2 (-7.3 to 7.5)	-0.5 (-7.0 to 6.7)
Oral disorders	-	-	-	-	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	15.3 (11.1 to 19.6)	-4.2 (-7.2 to -1.1)
Deciduous caries	8.6 (8.3 to 9.1)	6.3 (6.0 to 6.6)	-27.4 (-32.1 to -21.7)	0.3 (-6.0 to 8.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-33.4 to -19.8)	0.0 (-8.0 to 10.8)
Permanent caries	39.4 (37.6 to 41.0)	48.3 (46.3 to 50.4)	22.4 (15.8 to 29.7)	0.5 (-4.4 to 6.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	22.6 (15.9 to 30.2)	0.8 (-4.2 to 6.6)
Periodontal diseases	9.1 (8.6 to 9.5)	11.9 (11.4 to 12.4)	31.1 (22.6 to 39.7)	-2.1 (-8.6 to 4.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	31.6 (23.1 to 40.3)	4.0 (-8.5 to 4.9)

Appendix Table G.4 - Grenada prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	6.2 (6.0 to 6.4)	6.6 (6.4 to 6.8)	6.7 (2.1 to 11.5)	-6.6 (-10.5 to -2.3)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	6.6 (1.9 to 11.7)	-6.7 (-10.8 to -2.1)
Other oral disorders	1.5 (1.4 to 1.6)	1.8 (1.7 to 1.9)	23.7 (14.2 to 34.8)	-1.1 (-8.5 to 7.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	24.0 (14.1 to 36.0)	-0.8 (-8.5 to 8.2)
Injuries	-	-	-	-	0.5 (0.4 to 0.6)	0.5 (0.3 to 0.6)	-5.2 (-14.0 to 4.7)	-24.5 (-31.5 to -16.7)
Transport injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-2.1 (-13.3 to 12.1)	-22.6 (-31.6 to -11.6)
Road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	5.7 (-16.8 to 8.0)	25.8 (-34.8 to -14.8)
Pedestrian road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-19.8 (-29.8 to -6.7)	-34.8 (-42.7 to -24.7)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.2 (-9.3 to 12.7)	-17.8 (-26.4 to -8.4)
Motorcyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.2 (-23.5 to 3.1)	-31.7 (-41.1 to -20.8)
Motor vehicle road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	7.7 (-10.3 to 18.6)	19.8 (-30.0 to -7.5)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.4 (-29.2 to -7.6)	-36.0 (-43.9 to -26.9)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.6 (28.6 to 64.3)	13.3 (0.8 to 29.5)
Unintentional injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-6.9 (-14.7 to 1.2)	-25.4 (-31.6 to -19.0)
Falls	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-12.1 (-22.2 to -0.7)	-29.9 (-38.0 to -20.5)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.7 (-33.0 to -10.3)	-36.8 (-45.0 to -26.9)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.9 (-39.2 to -22.0)	-42.6 (-49.4 to -35.1)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.7 (-31.7 to -1.3)	-31.7 (-42.1 to -19.8)
Exposure to mechanical forces	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-11.2 (-17.9 to -4.6)	-28.1 (-33.7 to -23.2)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.1 (34.2 to 70.5)	16.9 (3.5 to 31.8)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.1 (14.6 to 47.4)	4.7 (-7.6 to 17.4)
Other exposure to mechanical forces	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-15.7 (-22.2 to -9.4)	-31.7 (-37.0 to -27.2)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.3 (47.7 to 65.2)	26.5 (19.1 to 33.4)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.4 (33.9 to 61.0)	20.6 (10.9 to 33.0)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.3 (35.8 to 71.4)	24.4 (12.1 to 38.1)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.2 (29.2 to 59.3)	18.4 (7.6 to 32.1)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.3 (-14.0 to 5.1)	-20.7 (-28.0 to -12.5)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.8 (-35.8 to -9.9)	-35.4 (-44.5 to -23.6)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.9 (-8.4 to 21.0)	-9.4 (-19.7 to 4.7)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.3 (-4.7 to 16.5)	-14.2 (-22.2 to -5.3)
Other unintentional injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	30.4 (20.4 to 41.7)	0.8 (-7.2 to 9.4)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.5 (-16.5 to 6.9)	-26.8 (-35.3 to -16.9)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.1 (-27.2 to -7.8)	-37.7 (-44.7 to -29.9)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.4 (-14.2 to 11.5)	-23.7 (-33.0 to -12.8)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.3 (18.5 to 45.1)	2.4 (-7.7 to 13.1)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.3 (-6.5 to 22.1)	-20.0 (-29.9 to -9.9)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.4 (-33.9 to -10.4)	-39.5 (-47.9 to -29.1)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Guatemala prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	978.0 (699.3 to 1,316.4)	1,431.9 (1,053.9 to 1,852.4)	47.8 (27.2 to 62.7)	-22.1 (-34.4 to -12.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	200.2 (136.3 to 285.8)	260.4 (177.6 to 362.6)	30.4 (18.1 to 43.0)	-22.5 (-31.5 to -13.1)
HIV/AIDS and tuberculosis	-	-	-	-	1.5 (1.0 to 2.1)	4.3 (2.6 to 6.4)	172.2 (105.9 to 287.4)	48.2 (12.0 to 115.3)
Tuberculosis	4.9 (4.7 to 5.1)	7.2 (6.9 to 7.5)	46.4 (42.3 to 51.9)	-22.4 (-24.8 to -19.2)	1.5 (1.0 to 2.0)	2.2 (1.5 to 3.0)	49.6 (33.6 to 69.8)	-19.9 (-27.4 to -10.8)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.2)	2.1 (0.9 to 3.9)	2,997.5 (987.5 to 9,988.9)	639.9 (164.0 to 5,555.8)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	1,221.7 (352.3 to 4,690.8)	622.2 (147.5 to 2,620.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,221.7 (348.3 to 4,833.3)	622.2 (143.0 to 1,648.1)
HIV/AIDS resulting in other diseases	0.8 (0.2 to 1.8)	25.4 (13.3 to 37.2)	3,696.3 (1,424.1 to 11,674.2)	2,152.2 (817.2 to 6,891.2)	0.1 (0.0 to 0.2)	2.1 (0.9 to 3.9)	3,019.1 (992.1 to 10,248.5)	1,652.4 (517.3 to 5,796.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	27.2 (19.2 to 37.1)	33.7 (23.7 to 46.0)	23.9 (16.3 to 32.7)	-17.6 (-22.2 to -12.7)
Diarrheal diseases	106.9 (101.9 to 111.6)	122.1 (115.9 to 128.5)	14.1 (7.0 to 22.6)	-19.9 (-25.0 to -13.9)	17.5 (11.7 to 24.3)	19.9 (13.5 to 27.4)	13.9 (6.1 to 23.2)	-20.1 (-25.5 to -13.7)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (35.4 to 5.7)	-49.8 (-61.5 to -37.5)
Typhoid fever	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	9.3 (8.5 to 29.3)	-35.3 (-45.1 to -23.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.3 (8.5 to 29.3)	-35.3 (-45.2 to -23.0)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.8 (-12.4 to 32.4)	-33.0 (-46.7 to -19.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.8 (-12.5 to 32.6)	-33.0 (-46.7 to -19.1)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-90.2 (-96.9 to -73.1)	-94.2 (-98.2 to -83.9)
Lower respiratory infections	8.3 (7.1 to 9.5)	9.1 (7.4 to 10.6)	10.0 (14.3 to 35.9)	-29.9 (-42.0 to -17.6)	0.9 (0.6 to 1.2)	0.8 (0.6 to 1.4)	9.9 (16.0 to 41.1)	-29.0 (-42.5 to -13.9)
Upper respiratory infections	331.2 (303.9 to 356.6)	599.7 (554.3 to 652.0)	80.7 (61.6 to 102.4)	5.6 (-4.5 to 17.7)	3.9 (2.2 to 6.6)	7.0 (4.0 to 11.8)	81.9 (61.9 to 105.1)	6.7 (-3.6 to 19.4)
Otitis media	123.5 (116.0 to 131.4)	181.9 (171.5 to 193.3)	47.2 (37.5 to 58.7)	-12.5 (-18.0 to -5.6)	2.3 (1.4 to 3.8)	3.4 (2.0 to 5.5)	44.9 (32.9 to 59.6)	-13.1 (-19.9 to -5.0)
Meningitis	-	-	-	-	2.0 (1.3 to 2.8)	1.8 (1.2 to 2.6)	-8.7 (-22.8 to 16.5)	-44.7 (-52.6 to -29.9)
Pneumococcal meningitis	10.3 (6.1 to 15.8)	9.0 (5.5 to 14.1)	-12.6 (-24.4 to 2.5)	-49.5 (-55.8 to -41.0)	0.9 (0.6 to 1.3)	0.8 (0.6 to 1.2)	-7.3 (-27.8 to 20.8)	-44.7 (-55.6 to -29.4)
H influenzae type B meningitis	4.0 (1.3 to 8.1)	2.8 (1.0 to 5.7)	-29.2 (-45.0 to 17.4)	-58.9 (-67.6 to -34.0)	0.4 (0.3 to 0.7)	0.4 (0.2 to 0.6)	-19.4 (-47.2 to 45.6)	-52.1 (-68.1 to -14.6)
Meningococcal meningitis	0.8 (0.2 to 1.9)	0.7 (0.2 to 1.7)	-11.9 (-33.2 to 23.3)	-48.9 (-60.0 to -29.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-8.5 (-37.7 to 46.0)	-46.0 (-60.4 to -19.5)
Other meningitis	4.4 (2.1 to 8.4)	3.9 (2.0 to 7.3)	-12.6 (-30.3 to 26.6)	-47.8 (-57.2 to -26.6)	0.5 (0.3 to 0.8)	0.5 (0.3 to 0.9)	-4.0 (-33.3 to 69.2)	-39.9 (-55.9 to 0.5)
Encephalitis	0.8 (0.4 to 1.8)	1.4 (0.7 to 3.2)	80.1 (51.7 to 111.4)	0.1 (-11.1 to 19.3)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	90.5 (51.0 to 135.5)	9.1 (-10.7 to 31.5)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-74.9 (-97.6 to 55.3)	0.0 (0.0 to 0.0)	-	-
Whooping cough	9.1 (7.1 to 11.6)	3.6 (2.8 to 4.5)	-60.8 (-63.9 to -57.5)	-72.8 (-75.0 to -70.5)	0.5 (0.3 to 0.7)	0.2 (0.1 to 0.3)	-60.5 (-66.6 to -54.1)	-72.6 (-76.4 to -68.2)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-78.3 (-89.1 to -60.9)	-88.9 (-94.1 to -80.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-72.5 (-85.9 to -53.9)	-87.5 (-93.8 to -79.7)
Measles	0.2 (0.2 to 0.2)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	7.9 (7.4 to 8.5)	12.4 (11.3 to 13.5)	55.1 (39.9 to 75.4)	-3.3 (-19.5 to 22.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	77.3 (31.0 to 152.1)	-1.5 (-32.3 to 48.9)
Neglected tropical diseases and malaria	-	-	-	-	64.2 (39.5 to 103.7)	57.7 (35.9 to 88.6)	-10.3 (-33.6 to 23.2)	-44.9 (-61.4 to -21.4)
Malaria	181.4 (86.3 to 351.5)	374.7 (151.3 to 799.1)	89.8 (-19.0 to 429.3)	18.0 (-48.6 to 230.4)	1.5 (1.0 to 2.1)	4.2 (2.7 to 6.2)	180.1 (135.9 to 235.6)	82.4 (46.4 to 125.9)
Chagas disease	135.0 (127.7 to 141.9)	243.3 (229.9 to 257.3)	80.2 (66.5 to 94.6)	-0.7 (-8.4 to 6.8)	1.9 (0.6 to 1.3)	1.9 (1.2 to 2.7)	97.2 (76.8 to 119.2)	9.1 (-5.5 to 11.7)
Leishmaniasis	-	-	-	-	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-11.1 (-26.6 to 10.9)	-44.9 (-61.4 to -44.5)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	187.7 (92.1 to 448.2)	77.2 (26.8 to 185.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	187.7 (91.8 to 451.2)	77.2 (26.8 to 186.8)
Cutaneous and mucocutaneous leishmaniasis	13.3 (9.9 to 17.9)	11.7 (9.1 to 15.1)	-12.8 (-26.3 to 7.6)	-56.2 (-61.6 to -47.1)	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-11.2 (-26.7 to 10.8)	-55.0 (-61.5 to -44.6)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	16.0 (8.5 to 24.6)	11.5 (3.3 to 25.0)	-28.9 (-82.0 to 88.4)	-62.4 (-89.0 to -6.8)	4.1 (1.9 to 7.1)	3.4 (0.9 to 7.5)	-19.5 (-79.9 to 118.1)	-57.3 (-87.6 to 8.9)
Cystic echinococcosis	0.4 (0.3 to 0.4)	0.5 (0.4 to 0.6)	23.9 (15.9 to 36.7)	-31.4 (-35.4 to -23.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	27.9 (-3.6 to 67.0)	-27.8 (-47.5 to -3.6)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	1.3 (0.8 to 1.9)	0.7 (0.4 to 1.1)	-47.1 (-70.5 to -10.6)	-79.8 (-89.2 to -63.9)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-41.4 (-67.6 to -4.5)	-77.9 (-88.3 to -62.2)
Dengue	1.3 (0.5 to 2.9)	11.2 (4.6 to 24.6)	743.5 (736.2 to 752.0)	385.9 (381.6 to 390.8)	0.2 (0.1 to 0.5)	1.8 (0.6 to 4.4)	745.3 (567.0 to 980.7)	392.3 (303.6 to 496.5)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-76.4 (-82.0 to -19.8)	-87.4 (-89.8 to -55.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-76.4 (-82.0 to -19.8)	87.4 (-89.8 to -55.3)
Intestinal nematode infections	-	-	-	-	50.7 (29.1 to 87.7)	37.9 (20.1 to 64.1)	-26.9 (-50.0 to 16.3)	-52.2 (-69.6 to -22.1)
Ascariasis	4,039.0 (3,419.5 to 4,787.7)	2,986.7 (1,933.0 to 4,363.1)	-27.2 (-53.6 to 12.5)	-54.7 (-72.6 to -25.4)	17.7 (8.8 to 31.8)	3.6 (1.3 to 8.1)	-81.3 (-91.4 to -54.5)	-85.8 (-94.0 to -62.0)
Trichuriasis	4,178.1 (3,558.0 to 4,948.7)	4,342.4 (3,163.3 to 5,788.8)	2.4 (-26.1 to 43.0)	-39.0 (-57.5 to -11.2)	13.3 (6.1 to 27.1)	8.3 (2.8 to 19.1)	-42.6 (-76.2 to 65.0)	-63.6 (-86.6 to 14.4)
Hookworm disease	3,499.6 (2,967.7 to 4,082.0)	442.1 (3,881.3 to 6,586.1)	-87.4 (-3.7 to 95.2)	-87.4 (-41.2 to 20.3)	19.7 (11.4 to 34.3)	26.1 (14.4 to 44.7)	-40.2 (-19.5 to 117.5)	-30.9 (-56.2 to 42.3)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	163.6 (128.0 to 199.3)	227.2 (215.5 to 244.2)	39.0 (14.5 to 76.5)	-16.2 (-28.9 to 2.3)	6.4 (4.0 to 9.3)	8.4 (5.5 to 12.2)	29.3 (13.5 to 78.9)	-22.8 (-33.1 to 3.2)
Maternal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	27.3 (4.1 to 53.4)	-34.3 (-45.8 to -21.3)
Maternal hemorrhage	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.4)	67.7 (48.1 to 92.0)	-12.9 (-22.4 to -1.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.1 (32.9 to 112.8)	-13.9 (-30.4 to 7.1)
Maternal sepsis and other maternal infections	0.8 (0.5 to 1.2)	1.2 (0.7 to 2.0)	49.6 (24.5 to 73.9)	-21.8 (-35.0 to -9.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.1 (-13.1 to 149.1)	-27.1 (-52.7 to 19.6)
Maternal hypertensive disorders	1.9 (0.7 to 3.5)	2.5 (0.9 to 4.8)	33.2 (16.8 to 51.6)	-31.4 (-38.9 to 23.8)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	33.3 (3.0 to 72.7)	-31.5 (-46.9 to -12.6)
Obstructed labor	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	10.5 (-63.9 to 145.2)	-42.1 (-74.3 to 18.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.5 (-54.2 to 145.9)	-42.1 (-74.3 to 18.7)
Complications of abortion	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	38.8 (-14.6 to 156.9)	-28.6 (-53.4 to 21.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.7 (-40.0 to 226.7)	-27.5 (-67.3 to 64.7)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-1.9 (-30.0 to 42.4)	-49.3 (-63.4 to -27.2)
Neonatal disorders	-	-	-	-	6.5 (4.1 to 9.5)	25.0 (16.9 to 35.2)	283.5 (149.5 to 508.7)	135.5 (52.7 to 274.2)
Preterm birth complications	26.6 (14.6 to 47.5)	105.1 (64.8 to 172.1)	300.5 (221.9 to 418.1)	132.7 (85.7 to 198.2)	2.5 (1.5 to 3.9)	13.2 (8.4 to 20.0)	434.3 (258.6 to 693.3)	221.0 (118.7 to 370.1)
Neonatal encephalopathy due to birth asphyxia and trauma	25.4 (7.2 to 59.9)	33.9 (13.5 to 74.1)	36.2 (-1.5 to 132.7)	-22.1 (-43.8 to 32.1)	1.5 (0.8 to 2.5)	4.0 (2.4 to 6.1)	173.8 (57.8 to 476.9)	68.5 (-3.1 to 268.5)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	109.1 (102.0 to 134.9)	51.8 (46.6 to 70.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (86.2 to 146.3)	112.3 (35.2 to 78.8)
Hemolytic disease and other neonatal jaundice	4.0 (1.7 to 7.1)	12.7 (6.1 to 20.3)	221.9 (-15.7 to 749.0)	102.0 (-47.2 to 438.6)	1.5 (0.6 to 2.8)	4.9 (2.3 to 8.2)	236.5 (-14.2 to 801.0)	111.6 (-47.6 to 465.5)
Other neonatal disorders	-	-	-	-	1.0 (0.6 to 1.7)	2.9 (1.8 to 4.5)	191.5 (64.9 to 422.6)	79.2 (1.2 to 227.8)
Nutritional deficiencies	-	-	-	-	94.6 (63.6 to 136.4)	130.8 (87.6 to 188.4)	38.3 (34.1 to 42.4)	-20.2 (-22.8 to -17.7)
Protein-energy malnutrition	29.0 (19.9 to 41.6)	28.6 (17.8 to 45.7)	-3.7 (-44.4 to 80.6)	56.5 (-68.3 to 25.4)	3.4 (1.9 to 5.7)	3.4 (1.8 to 6.0)	55.0 (-45.1 to 85.4)	-55.0 (-67.6 to -23.0)
Iodine deficiency	82.4 (33.0 to 144.8)	105.6 (48.7 to 170.1)	31.4 (-54.0 to 207.9)	-27.3 (-77.5 to 75.2)	1.5 (0.8 to 3.0)	1.9 (0.8 to 3.6)	31.7 (-54.2 to 200.4)	-27.0 (-77.4 to 74.8)
Vitamin A deficiency	3.2 (2.4 to 4.1)	2.4 (1.7 to 3.1)	-26.1 (-35.4 to -16.4)	-54.9 (-60.3 to -49.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-29.5 (-42.7 to -14.1)	-47.0 (-64.3 to -48.6)

Appendix Table G.4 - Guatemala prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	2,647.6 (2,612.3 to 2,683.4)	3,836.0 (3,809.9 to 3,857.9)	44.7 (42.8 to 46.6)	56.4 (-17.4 to -15.6)	89.4 (59.9 to 129.4)	125.3 (83.5 to 181.0)	40.2 (37.1 to 42.5)	48.2 (-19.6 to -15.4)
Other nutritional deficiencies	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-15.0 (-60.7 to 91.6)	-59.9 (-77.1 to -28.2)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	6.0 (3.8 to 8.9)	8.6 (5.4 to 12.8)	43.4 (31.5 to 64.2)	-15.8 (-22.2 to -4.4)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.3 (0.7 to 2.3)	2.2 (1.3 to 3.9)	68.4 (42.0 to 102.5)	-10.8 (-22.6 to 3.5)
Syphilis	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-34.8 (-30.9 to -0.6)	-56.0 (-63.6 to -49.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.4 (-31.3 to 16.6)	92.2 (-63.9 to -39.9)
Chlamydial infection	166.1 (128.1 to 221.0)	247.6 (181.1 to 342.6)	45.9 (3.8 to 123.2)	-21.5 (-42.4 to 14.1)	0.6 (0.4 to 1.1)	1.1 (0.6 to 1.8)	68.6 (26.2 to 135.4)	-10.9 (-30.7 to 20.6)
Gonococcal infection	27.4 (21.7 to 32.8)	44.5 (32.5 to 56.8)	62.8 (15.0 to 119.9)	-14.0 (-38.2 to 12.3)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	53.4 (5.3 to 125.5)	-20.6 (-43.3 to 11.5)
Trichomoniasis	55.8 (34.7 to 80.2)	80.3 (54.0 to 112.7)	48.3 (-23.9 to 147.6)	-17.5 (-52.5 to 30.8)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	47.1 (-30.9 to 161.0)	-17.5 (-56.7 to 37.6)
Genital herpes	1,271.8 (1,214.2 to 1,343.9)	2,406.9 (2,276.1 to 2,557.2)	89.4 (75.3 to 104.7)	1.3 (-8.4 to 6.8)	0.0 (0.1 to 0.8)	0.6 (0.2 to 1.6)	92.2 (73.2 to 108.9)	4.1 (-7.9 to 9.1)
Other sexually transmitted diseases	0.8 (0.6 to 1.1)	1.2 (0.9 to 1.6)	48.4 (27.8 to 68.9)	-22.9 (-33.3 to -12.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (33.5 to 192.6)	0.5 (-28.5 to 45.6)
Hepatitis	-	-	-	-	0.4 (0.3 to 0.6)	0.7 (0.4 to 1.0)	53.4 (29.2 to 81.2)	-13.8 (-33.0 to 5.7)
Hepatitis A	13.6 (13.0 to 14.3)	20.6 (19.7 to 21.5)	51.2 (50.3 to 52.1)	-5.0 (-5.1 to -4.9)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	69.0 (49.6 to 92.7)	-0.5 (-11.3 to 11.4)
Hepatitis B	298.7 (220.2 to 372.5)	317.3 (236.8 to 407.9)	6.0 (-25.4 to 58.8)	-39.4 (-55.9 to -15.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	25.7 (-27.6 to 104.4)	-29.6 (-63.9 to 18.5)
Hepatitis C	194.6 (172.9 to 217.6)	249.8 (222.0 to 279.3)	28.6 (8.8 to 51.1)	31.2 (-41.0 to -20.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.7 (4.3 to 66.4)	-25.6 (-44.8 to 1.8)
Hepatitis E	-	-	-41.0 (-62.8 to -5.8)	-68.3 (-79.7 to -50.5)	-	-	-	-
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.7 (-27.2 to 1,618.5)	11.2 (-60.0 to 843.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	121.5 (-27.6 to 2,190.0)	12.7 (-60.0 to 1,137.7)
Other infectious diseases	119.9 (95.8 to 145.8)	166.7 (159.0 to 177.6)	38.9 (26.6 to 51.0)	-17.9 (-24.0 to -11.2)	4.2 (2.6 to 6.0)	5.7 (3.7 to 8.2)	34.4 (21.4 to 63.7)	-19.0 (-26.7 to -5.4)
Non-communicable diseases	-	-	-	-	528.2 (388.4 to 682.8)	1,026.5 (759.1 to 1,324.6)	94.2 (87.6 to 102.6)	4.1 (0.5 to 8.3)
Neoplasms	-	-	-	-	2.3 (1.7 to 3.1)	7.4 (5.4 to 9.9)	222.7 (158.4 to 265.6)	61.8 (27.7 to 85.6)
Esophageal cancer	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	228.2 (81.9 to 383.0)	53.9 (-16.4 to 125.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	225.6 (77.5 to 340.8)	48.5 (-18.1 to 109.5)
Stomach cancer	2.2 (1.9 to 2.4)	5.7 (5.0 to 6.6)	166.8 (118.5 to 217.8)	24.5 (1.6 to 49.2)	0.2 (0.2 to 0.3)	0.6 (0.5 to 0.8)	164.8 (119.7 to 215.0)	23.0 (1.0 to 48.1)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.2 (0.0 to 0.3)	115.2 (36,563.2 to 56,138.5)	35.411.7 (28,186.5 to 43,204.7)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.4)	39,262.3 (19,476.1 to 76,189.3)	33,121.4 (16,039.2 to 66,580.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	40,512.7 (21,326.8 to 74,178.0)	34,129.6 (18,093.6 to 65,299.9)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.5 (0.3 to 0.7)	174,733.0 (101,261.0 to 318,215.6)	102,641.6 (59,672.9 to 190,250.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	163,199.7 (106,380.0 to 277,046.3)	94,085.1 (59,605.4 to 160,427.0)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	36,750.5 (19,308.0 to 65,834.5)	20,958.8 (10,709.2 to 37,136.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37,128.4 (21,488.3 to 61,942.5)	20,872.9 (11,863.3 to 34,354.6)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	12,279.6 (6,922.5 to 20,803.7)	11,096.3 (5,838.2 to 20,213.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13,009.2 (7,918.3 to 19,222.4)	4.1 (-6.7 to 17.8)
Larynx cancer	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.6)	66.6 (24.8 to 118.9)	-16.7 (-38.8 to 11.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	73.6 (26.2 to 128.1)	-13.8 (-38.9 to 16.1)
Tracheal, bronchus and lung cancer	0.4 (0.4 to 0.5)	1.0 (0.8 to 1.1)	138.0 (102.1 to 184.1)	16.3 (-2.2 to 39.6)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	133.7 (94.4 to 179.8)	14.0 (-6.7 to 39.2)
Breast cancer	2.9 (2.6 to 3.3)	7.9 (6.6 to 9.5)	168.0 (119.8 to 240.9)	42.9 (16.6 to 82.4)	0.2 (0.2 to 0.3)	0.6 (0.4 to 0.8)	145.3 (94.0 to 214.9)	29.5 (3.6 to 67.6)
Cervical cancer	4.6 (3.7 to 7.2)	12.0 (6.8 to 14.8)	181.4 (22.6 to 259.1)	5.2 (-33.5 to 94.0)	0.3 (0.2 to 0.6)	0.9 (0.5 to 1.3)	181.1 (23.5 to 269.4)	53.9 (-33.9 to 99.8)
Uterine cancer	2.0 (1.4 to 3.0)	3.6 (2.5 to 5.4)	79.2 (27.3 to 155.6)	-3.3 (-31.1 to 37.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	79.4 (23.7 to 155.4)	-3.3 (-32.8 to 36.0)
Prostate cancer	2.2 (1.5 to 3.9)	16.7 (8.6 to 23.4)	767.8 (212.7 to 1,250.1)	291.4 (39.6 to 514.1)	0.2 (0.1 to 0.4)	1.3 (0.7 to 2.0)	635.4 (160.5 to 996.6)	216.3 (8.8 to 376.0)
Colon and rectum cancer	1.3 (1.2 to 1.4)	4.6 (4.2 to 5.1)	269.4 (224.5 to 319.6)	74.4 (52.7 to 98.8)	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.5)	244.9 (192.9 to 301.1)	61.1 (34.8 to 87.7)
Lip and oral cavity cancer	0.5 (0.4 to 0.8)	1.3 (0.9 to 1.7)	169.9 (53.9 to 282.5)	29.3 (-27.6 to 68.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	164.8 (53.1 to 275.3)	25.3 (-30.0 to 82.2)
Nasopharynx cancer	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	81.0 (37.5 to 141.2)	0.0 (-29.6 to 23.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.8 (37.1 to 125.7)	-10.8 (-30.9 to 16.8)
Other pharynx cancer	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	151.8 (43.0 to 281.7)	25.4 (-29.7 to 91.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	148.5 (43.3 to 263.5)	21.3 (-31.5 to 81.6)
Gallbladder and biliary tract cancer	0.3 (0.2 to 0.3)	0.2 (0.1 to 0.4)	-69.4 (-49.8 to 118.3)	-1.7 (-77.8 to -1.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-29.4 (-46.9 to 120.7)	67.4 (-76.1 to 3.2)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.3 (0.3 to 0.4)	681.3 (538.3 to 852.3)	267.0 (198.5 to 350.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	621.6 (510.3 to 754.8)	231.9 (176.9 to 297.7)
Malignant skin melanoma	0.7 (0.6 to 0.8)	1.1 (0.9 to 1.3)	59.2 (22.1 to 115.5)	16.0 (-37.3 to 12.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	59.2 (16.1 to 120.7)	-8.1 (-40.2 to 12.8)
Non-melanoma skin cancer	1.4 (1.1 to 1.8)	4.1 (3.2 to 5.4)	190.3 (92.6 to 317.7)	27.4 (-16.8 to 84.5)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	220.5 (122.3 to 347.6)	35.2 (-8.5 to 96.8)
Ovarian cancer	0.2 (0.2 to 0.2)	0.6 (0.5 to 0.7)	210.3 (143.2 to 294.3)	67.3 (31.3 to 112.3)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	200.4 (132.7 to 286.5)	58.9 (19.8 to 104.8)
Testicular cancer	0.1 (0.0 to 0.2)	0.6 (0.2 to 1.2)	1,650.8 (60.8 to 3,459.7)	782.9 (-13.1 to 1,596.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	1,555.3 (43.9 to 3,262.9)	716.3 (-24.7 to 1,448.6)
Kidney cancer	0.0 (0.4 to 0.5)	0.5 (1.0 to 1.3)	144.9 (104.5 to 194.0)	95.6 (40.0 to 58.8)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	140.0 (100.9 to 189.0)	25.2 (4.3 to 49.8)
Bladder cancer	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	37.1 (8.5 to 94.3)	-42.0 (-54.5 to -15.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.3 (6.6 to 97.7)	-42.3 (-56.7 to -14.6)
Brain and nervous system cancer	0.2 (0.2 to 0.4)	1.9 (0.9 to 2.4)	995.9 (153.0 to 1,295.2)	565.0 (40.9 to 709.8)	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	986.6 (134.5 to 1,292.2)	521.5 (26.2 to 647.8)
Thyroid cancer	3.0 (2.4 to 4.1)	7.7 (5.7 to 10.9)	158.9 (90.2 to 243.3)	38.9 (2.0 to 83.9)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.7)	153.3 (84.4 to 240.1)	35.0 (-0.8 to 81.3)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	264.9 (6.0 to 51.8)	16.0 (-46.8 to -23.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.7 (9.7 to 51.3)	35.9 (-4.7 to -23.7)
Hodgkin lymphoma	0.1 (0.0 to 0.2)	0.8 (0.2 to 1.2)	1,911.1 (54.5 to 2,933.4)	1,246.5 (-2.8 to 1,798.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	1,978.5 (45.5 to 2,887.2)	1,228.8 (-13.1 to 1,713.5)
Non-Hodgkin lymphoma	0.4 (0.4 to 0.6)	2.0 (1.0 to 2.6)	381.6 (107.7 to 529.7)	187.4 (12.8 to 264.7)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	367.5 (97.8 to 511.8)	167.2 (3.8 to 243.8)
Multiple myeloma	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	160.3 (89.0 to 269.5)	29.2 (-6.9 to 82.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	150.7 (91.1 to 233.4)	22.0 (-7.8 to 65.1)
Leukemia	1.4 (1.1 to 1.7)	5.6 (4.4 to 7.1)	900.4 (181.0 to 426.8)	147.5 (86.8 to 208.3)	0.1 (0.1 to 0.2)	0.5 (0.4 to 0.7)	293.6 (194.9 to 401.5)	127.3 (76.4 to 176.0)
Other neoplasms	3.9 (3.1 to 4.8)	13.0 (9.4 to 16.8)	227.8 (123.8 to 385.7)	88.6 (42.4 to 175.6)	0.3 (0.2 to 0.4)	0.8 (0.5 to 1.2)	215.8 (124.2 to 358.6)	74.2 (34.3 to 149.7)
Cardiovascular diseases	-	-	-	-	4.5 (3.1 to 6.3)	16.9 (11.0 to 24.0)	273.3 (183.5 to 395.5)	79.2 (40.2 to 139.3)
Rheumatic heart disease	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.3)	91.2 (76.3 to 105.5)	2.3 (-6.2 to 11.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.6 (55.9 to 131.6)	3.0 (-18.6 to 28.6)
Ischemic heart disease	44.6 (37.6 to 54.7)	176.0 (133.3 to 229.8)	288.9 (185.7 to 456.4)	78.1 (32.4 to 152.7)	2.1 (1.3 to 3.1)	9.8 (5.9 to 15.2)	372.8 (221.6 to 631.4)	116.1 (51.4 to 230.7)
Cerebrovascular disease	-	-	-	-	0.8 (0.6 to 1.1)	1.8 (1.2 to 2.4)	115.2 (72.4 to 169.2)	8.2 (-14.5 to 36.5)
Ischemic stroke	1.5 (1.2 to 1.7)	3.3 (2.7 to 4.2)	123.5 (71.5 to 199.2)	6.1 (-19.6 to 45.5)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	131.2 (71.1 to 208.1)	11.2 (-18.1 to 54.5)
Hemorrhagic stroke	4.4 (3.8 to 5.0)	8.9 (7.6 to 10.5)	102.9 (64.9 to 151.9)	2.2 (-17.7 to 28.9)	0.6 (0.4 to 0.8)	1.3 (0.9 to 1.8)	110.1 (67.5 to 166.1)	6.6 (-15.8 to 36.1)
Hypertensive heart disease	3.2 (2.8 to 3.6)	7.7 (6.9 to 8.5)	144.6 (113.7 to 179.5)	11.0 (-8.9 to 27.3)	0.3 (0.2 to 0.5)	0.8 (0.6 to 1.1)	150.5 (116.2 to 194.6)	14.8 (-0.7 to 34.5)
Cardiomyopathy and myocarditis	1.6 (1.3 to 1.9)	3.8 (3.3 to 4.2)	140.4 (106.3 to 179.9)	21.4 (0.5 to 44.9)	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.6)	146.4 (105.0 to 201.0)	26.4 (1.8 to 56.4)
Atrial fibrillation and flutter	0.5 (0.3 to 0.9)	6.8 (3.6 to 10.0)	1,163.8 (599.2 to 2,168.9)	500.1 (240.9 to 1,186.7)	0.0 (0.0 to 0.1)	0.5 (0.2 to 0.8)	1,141.7 (588.0 to 2,186.2)	500.5 (240.3 to 1,204.6)
Peripheral vascular disease	129.5 (81.4 to 189.9)	278.8 (217.3 to 342.8)	116.1 (39.4 to 259.7)	3.8 (-28.5 to 69.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.3)	92.8 (-12.5 to 326.3)	-31.6 (-69.1 to 49.8)
Endocarditis	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	205.0 (83.7 to 293.2)	83.2 (10.6 to 126.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	267.4 (101.7 to 398.2)	113.5 (14.9 to 173.3)
Other cardiovascular and circulatory diseases	14.3 (6.9 to 27.7)	47.4 (25.9 to 68.8)	344.7 (42.9 to 631.4)	65.1 (-30.6 to 260.0)	1.0 (0			

Appendix Table G.4 - Guatemala prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumococcal	-	-	-	-	0.0	0.0	83.3	-4.0
Silicosis	0.0	0.0	81.6	-9.6	0.0	0.0	81.4	-9.6
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Coal workers pneumoconiosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Other pneumoconiosis	0.0	0.0	85.4	-6.6	0.0	0.0	84.7	-6.7
Asthma	55.0	105.0	90.3	-0.0	2.4	4.5	91.8	1.3
Interstitial lung disease and pulmonary sarcoidosis	0.1	0.2	105.2	3.9	0.0	0.0	107.2	4.2
Other chronic respiratory diseases	-	-	-	-	1.8	2.4	32.4	-28.8
Cirrhosis	0.1	0.2	123.2	24.0	0.0	0.0	117.9	20.9
Cirrhosis due to hepatitis B	0.1	0.1	33.9	27.3	0.0	0.0	21.1	35.0
Cirrhosis due to hepatitis C	1.0	1.8	74.9	0.3	0.2	0.3	79.4	3.2
Cirrhosis due to alcohol use	1.3	1.6	18.5	-34.9	0.2	0.3	21.8	-32.1
Cirrhosis due to other causes	0.8	1.4	78.2	11.8	0.1	0.2	81.4	12.9
Digestive diseases	-	-	-	-	6.7	12.1	81.6	-15.3
Peptic ulcer disease	84.1	99.8	18.7	-46.3	2.9	3.9	34.7	-39.5
Gastritis and duodenitis	23.0	30.4	32.2	-29.9	0.9	1.4	49.1	-18.7
Appendicitis	0.5	0.8	67.7	-5.2	0.1	0.2	69.7	-4.5
Paralytic ileus and intestinal obstruction	0.1	0.1	150.3	37.7	0.0	0.0	140.7	33.8
Inguinal, femoral, and abdominal hernia	31.0	52.5	69.3	-19.3	0.3	0.5	71.5	-17.1
Inflammatory bowel disease	8.1	19.1	135.9	23.6	1.7	4.0	141.4	27.5
Vascular intestinal disorders	0.0	0.0	148.9	11.5	0.0	0.0	132.0	5.9
Gallbladder and biliary diseases	4.1	8.4	105.5	0.4	0.4	0.9	109.4	4.8
Pancreatitis	0.3	1.0	229.9	70.9	0.1	0.3	235.8	76.7
Other digestive diseases	-	-	-	-	0.2	0.8	299.5	88.0
Neurological disorders	-	-	-	-	49.4	95.5	93.4	-7.3
Alzheimer disease and other dementias	27.6	72.5	162.1	1.8	3.6	10.1	179.0	4.8
Parkinson disease	0.5	1.1	126.2	2.0	0.1	0.1	131.5	6.4
Epilepsy	48.6	81.1	66.3	-4.7	13.8	26.3	90.0	10.1
Multiple sclerosis	0.3	1.0	266.0	96.2	0.1	0.3	254.0	87.9
Migraine	60.5	1,112.5	82.9	2.8	20.5	37.9	86.3	-4.4
Tension-type headache	1,494.4	3,001.0	101.8	5.6	2.2	4.5	103.7	6.9
Medication overuse headache	31.8	86.1	168.8	43.9	4.9	13.4	172.2	46.5
Other neurological disorders	0.0	0.0	65.5	-6.4	4.3	2.8	34.9	-75.5
Mental and substance use disorders	-	-	-	-	178.8	333.6	86.5	1.5
Schizophrenia	17.8	33.3	87.3	-1.0	11.0	21.2	92.5	-1.9
Alcohol use disorders	171.3	303.8	76.9	-8.5	16.7	30.2	80.4	-6.3
Drug use disorders	-	-	-	-	9.2	16.7	82.9	-3.1
Opioid use disorders	4.5	8.5	86.6	-0.7	1.8	3.5	93.6	2.7
Cocaine use disorders	11.7	20.6	75.3	1.6	2.8	5.7	77.7	6.9
Amphetamine use disorders	15.4	27.8	79.1	-4.1	2.0	3.6	81.1	-2.9
Cannabis use disorders	5.8	10.7	84.8	-0.9	0.2	0.3	86.3	0.3
Other drug use disorders	-	-	-	-	3.6	6.5	81.0	-4.7
Depressive disorders	-	-	-	-	10.4	18.0	72.8	-0.1
Major depressive disorder	248.8	487.5	94.7	3.4	50.2	99.7	97.2	5.5
Dysthymia	78.1	151.0	93.2	1.5	7.4	14.4	95.8	3.4
Bipolar disorder	54.6	104.7	91.7	0.9	10.9	21.2	94.9	3.2
Anxiety disorders	333.1	621.8	86.4	1.3	30.3	57.1	88.8	3.9
Eating disorders	-	-	-	-	2.5	4.9	95.4	4.3
Anorexia nervosa	1.9	3.9	99.4	9.6	0.4	0.8	102.3	10.8
Bulimia nervosa	9.9	19.2	92.6	2.4	2.1	4.0	94.2	3.1
Autistic spectrum disorders	-	-	-	-	10.4	18.0	72.8	-0.1
Autism	26.7	45.9	71.6	-1.9	6.5	11.3	73.6	0.2
Asperger syndrome	39.6	67.5	70.3	-2.5	3.9	6.7	72.1	-0.6
Attention-deficit/hyperactivity disorder	83.8	139.8	66.7	-0.4	1.0	1.7	67.6	0.3
Conduct disorder	111.0	185.0	67.3	-0.4	13.2	22.4	69.0	-6.0
Idiopathic intellectual disability	170.7	228.2	33.9	-2.0	8.3	11.1	35.0	-2.0
Other mental and substance use disorders	106.0	201.6	89.9	-1.7	7.7	14.9	93.2	0.6
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	44.5	95.9	115.4	22.7
Diabetes mellitus	223.8	638.2	186.8	58.3	15.2	43.1	185.4	56.0
Acute glomerulonephritis	0.0	0.0	22.1	0.0	0.0	0.0	22.1	0.0
Chronic kidney disease	0.0	0.0	19.6	-28.3	0.0	0.0	95.5	-28.4
Chronic kidney disease due to diabetes mellitus	126.2	257.0	102.8	6.9	1.7	3.6	111.1	12.0
Chronic kidney disease due to hypertension	150.5	292.1	96.9	2.4	10.9	4.3	81.2	-0.3
Chronic kidney disease due to glomerulonephritis	173.8	308.4	77.5	2.1	7.4	4.0	91.8	10.9
Chronic kidney disease due to other causes	239.7	402.8	67.1	-5.9	3.1	5.3	72.2	-4.1
Urinary diseases and male infertility	-	-	-	-	1.6	3.6	127.4	8.2

Appendix Table G.4 - Guatemala prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.8 (1.6 to 2.0)	3.2 (2.7 to 3.8)	75.5 (40.9 to 111.0)	5.3 (-9.8 to 22.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	74.6 (27.9 to 130.1)	5.9 (-17.6 to 32.3)
Urolithiasis	45.1 (29.3 to 71.4)	108.4 (67.8 to 188.6)	139.5 (101.8 to 181.6)	12.9 (-6.6 to 34.7)	0.2 (0.1 to 0.3)	0.5 (0.3 to 1.0)	174.9 (133.5 to 233.4)	38.2 (16.8 to 67.7)
Benign prostatic hyperplasia	34.2 (30.9 to 38.2)	71.3 (62.3 to 79.7)	108.1 (79.1 to 141.4)	-4.2 (-18.0 to 11.9)	1.1 (0.7 to 1.5)	2.4 (1.6 to 3.5)	120.5 (88.4 to 159.5)	1.9 (-13.1 to 20.6)
Male infertility due to other causes	28.7 (21.2 to 38.6)	50.5 (37.5 to 64.0)	77.9 (15.9 to 146.3)	-9.8 (-40.0 to 25.3)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.7)	85.2 (16.4 to 159.6)	-6.3 (-39.4 to 29.8)
Other urinary diseases	-	-	-	-	-	-	-	-
Gynecological diseases	-	-	-	-	-	-	-	-
Uterine fibroids	125.2 (112.8 to 136.3)	253.2 (227.7 to 275.6)	102.1 (101.5 to 102.6)	9.7 (9.5 to 9.8)	2.4 (1.5 to 3.8)	4.3 (2.7 to 6.9)	80.9 (70.3 to 90.6)	-4.1 (-9.7 to 1.3)
Polycystic ovarian syndrome	118.4 (104.1 to 135.7)	242.4 (215.6 to 270.0)	103.7 (74.8 to 143.0)	7.4 (-6.2 to 25.9)	1.1 (0.5 to 2.1)	2.3 (1.1 to 4.5)	104.1 (75.6 to 144.9)	7.5 (-5.5 to 26.0)
Female infertility due to other causes	37.4 (28.9 to 47.3)	65.6 (44.2 to 88.6)	75.4 (10.0 to 161.1)	11.0 (-3.7 to 35.5)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.7)	79.1 (12.1 to 162.5)	-10.3 (-43.2 to 35.0)
Endometriosis	12.3 (10.7 to 14.3)	25.9 (22.9 to 31.6)	119.0 (74.2 to 166.4)	14.0 (-8.5 to 39.0)	1.1 (0.7 to 1.6)	2.5 (1.6 to 3.5)	119.1 (70.7 to 174.4)	14.4 (-9.2 to 42.4)
Genital prolapse	410.4 (352.4 to 471.9)	863.6 (736.6 to 1,001.4)	110.7 (69.0 to 157.3)	8.9 (-10.0 to 29.8)	1.3 (0.6 to 2.5)	2.7 (1.3 to 5.2)	112.1 (69.1 to 160.3)	9.6 (-9.7 to 31.3)
Premenstrual syndrome	291.4 (215.9 to 368.1)	643.1 (478.6 to 822.2)	120.4 (53.5 to 224.7)	13.6 (-18.8 to 59.5)	2.4 (1.4 to 3.9)	5.4 (3.1 to 9.0)	121.1 (53.2 to 224.2)	13.6 (-19.2 to 60.6)
Other gynecological diseases	31.8 (28.8 to 35.0)	53.3 (49.0 to 57.9)	67.3 (32.6 to 104.0)	-10.0 (-28.5 to 9.7)	1.0 (0.6 to 1.4)	1.6 (1.0 to 2.3)	61.7 (37.3 to 92.5)	-13.6 (-26.3 to 2.0)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	-	-	-	-
Thalassemias	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	77.0 (63.9 to 139.6)	11.3 (1.5 to 49.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.3 (66.3 to 129.3)	13.6 (5.2 to 43.4)
Thalassemia trait	51.7 (41.4 to 60.8)	90.6 (73.9 to 106.2)	72.9 (68.9 to 101.5)	-0.1 (-1.7 to 17.0)	1.0 (0.6 to 1.5)	1.8 (1.2 to 2.6)	80.0 (52.8 to 110.5)	10.0 (-7.2 to 27.2)
Sickle cell disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	66.8 (57.6 to 82.2)	-0.6 (-6.2 to 8.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.5 (60.4 to 96.4)	3.2 (-5.3 to 16.1)
Sickle cell trait	85.8 (71.7 to 102.4)	148.5 (121.5 to 182.4)	71.0 (60.0 to 93.3)	4.3 (-7.6 to 11.5)	0.3 (0.2 to 0.5)	0.6 (0.3 to 0.9)	69.6 (0.1 to 172.0)	1.9 (-31.8 to 64.8)
G6PD deficiency	151.6 (124.9 to 179.3)	273.6 (205.3 to 344.5)	80.6 (25.1 to 144.3)	4.0 (-27.9 to 40.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	82.5 (62.6 to 104.6)	12.1 (4.3 to 21.6)
G6PD trait	1,049.5 (956.0 to 1,131.3)	1,863.1 (1,686.4 to 1,993.6)	77.1 (58.6 to 102.0)	3.4 (-7.4 to 17.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	60.0 (-35.6 to 189.5)	-12.4 (-65.4 to 50.5)
Other hemoglobinopathies and hemolytic anemias	125.0 (112.7 to 135.1)	175.6 (161.0 to 189.0)	40.3 (26.1 to 53.5)	-20.8 (-28.5 to -12.5)	3.5 (2.3 to 5.1)	4.7 (3.0 to 6.8)	33.6 (15.0 to 54.1)	-25.4 (-35.8 to -9.5)
Endocrine, metabolic, blood, and immune disorders	118.2 (108.4 to 127.9)	175.9 (157.1 to 194.4)	48.5 (30.6 to 67.5)	-2.7 (-21.3 to -3.3)	3.9 (2.6 to 5.7)	5.5 (3.6 to 8.2)	39.9 (13.5 to 72.0)	29.8 (-29.6 to 0.1)
Musculoskeletal disorders	-	-	-	-	-	-	-	-
Rheumatoid arthritis	15.8 (14.1 to 17.6)	39.3 (36.6 to 42.1)	148.7 (117.7 to 185.4)	27.2 (10.5 to 45.0)	3.6 (2.5 to 4.8)	9.1 (6.4 to 12.1)	151.0 (116.1 to 195.6)	31.0 (12.2 to 52.3)
Osteoarthritis	173.0 (165.8 to 180.4)	363.7 (349.8 to 378.1)	110.2 (97.4 to 122.0)	2.8 (-3.2 to 8.5)	10.1 (7.1 to 13.7)	21.7 (15.2 to 29.2)	114.2 (100.9 to 129.6)	5.8 (-0.7 to 13.3)
Low back and neck pain	-	-	-	-	-	-	-	-
Low back pain	547.2 (516.9 to 578.0)	1,031.3 (965.2 to 1,085.4)	88.4 (73.3 to 103.4)	-0.9 (-8.5 to 6.1)	59.6 (40.3 to 81.9)	114.4 (77.0 to 156.9)	92.1 (76.1 to 108.0)	2.0 (-6.1 to 9.4)
Neck pain	205.6 (163.3 to 245.8)	367.5 (274.7 to 488.7)	76.8 (24.4 to 156.6)	-4.0 (-28.9 to 37.9)	19.7 (12.9 to 28.5)	35.7 (21.4 to 52.8)	79.6 (25.2 to 161.4)	-1.9 (-28.1 to 41.9)
Gout	2.6 (2.2 to 3.0)	5.2 (4.5 to 5.9)	98.4 (65.1 to 143.9)	0.7 (-16.4 to 24.3)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	105.2 (59.1 to 169.7)	5.5 (-17.3 to 38.4)
Other musculoskeletal disorders	103.8 (60.3 to 159.1)	255.6 (171.4 to 328.1)	151.5 (91.4 to 248.8)	36.9 (2.4 to 80.6)	8.2 (4.5 to 15.7)	23.0 (13.6 to 34.5)	157.7 (92.9 to 264.1)	40.7 (3.8 to 92.5)
Other non-communicable diseases	-	-	-	-	-	-	-	-
Congenital anomalies	-	-	-	-	-	-	-	-
Neural tube defects	1.8 (1.4 to 2.3)	4.9 (4.0 to 6.0)	162.1 (100.7 to 280.6)	67.1 (27.8 to 143.2)	0.6 (0.3 to 0.8)	1.6 (1.0 to 2.4)	179.4 (79.1 to 362.3)	79.3 (17.0 to 195.6)
Congenital heart anomalies	25.9 (20.1 to 32.2)	87.7 (73.9 to 108.3)	239.8 (150.7 to 358.7)	115.4 (58.2 to 191.5)	0.9 (0.6 to 1.6)	3.0 (1.2 to 5.0)	247.7 (161.5 to 366.7)	122.2 (64.3 to 200.2)
Orofacial clefts	4.9 (3.2 to 7.9)	17.2 (13.6 to 21.5)	255.0 (98.1 to 489.0)	140.6 (35.3 to 310.7)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	183.6 (58.2 to 415.3)	91.7 (8.4 to 250.3)
Down syndrome	8.8 (7.7 to 10.5)	20.2 (15.9 to 25.0)	126.7 (72.3 to 200.1)	42.6 (8.4 to 88.7)	1.0 (0.7 to 1.4)	2.5 (1.7 to 3.4)	135.6 (77.0 to 220.6)	51.9 (13.0 to 102.9)
Turner syndrome	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	115.2 (42.5 to 218.1)	30.2 (-13.3 to 93.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	118.5 (42.9 to 234.8)	29.6 (-15.1 to 95.0)
Klinefelter syndrome	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	70.2 (20.3 to 140.8)	-1.8 (-30.7 to 38.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.8 (25.9 to 151.9)	-3.3 (-31.6 to 37.0)
Chromosomal unbalanced rearrangements	12.0 (10.6 to 14.0)	26.5 (22.4 to 30.7)	49.3 (88.5 to 166.6)	122.0 (6.8 to 67.4)	0.3 (1.0 to 1.9)	0.6 (2.3 to 4.4)	150.2 (74.0 to 181.9)	49.0 (12.8 to 80.6)
Other congenital anomalies	39.6 (33.6 to 45.7)	61.4 (52.1 to 71.3)	54.6 (40.1 to 72.5)	-13.2 (-21.0 to -3.0)	4.4 (2.9 to 6.4)	9.9 (6.8 to 13.6)	122.5 (80.6 to 187.7)	23.2 (1.4 to 55.5)
Skin and subcutaneous diseases	-	-	-	-	-	-	-	-
Dermatitis	427.0 (344.8 to 522.6)	768.2 (617.0 to 940.3)	79.8 (77.3 to 81.8)	0.1 (-0.2 to 0.3)	13.5 (8.3 to 20.1)	24.0 (14.9 to 35.4)	77.5 (69.7 to 84.4)	1.6 (-1.4 to 4.9)
Psoriasis	59.7 (52.7 to 67.2)	110.7 (97.7 to 124.7)	85.1 (83.5 to 86.6)	0.1 (-0.3 to 0.2)	4.8 (3.2 to 6.6)	9.0 (6.1 to 12.5)	88.4 (76.0 to 101.1)	2.6 (-3.0 to 9.0)
Cellulitis	0.4 (0.3 to 0.5)	0.7 (0.6 to 0.8)	77.7 (60.3 to 98.1)	1.0 (-9.6 to 11.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	77.3 (59.1 to 98.9)	1.3 (-10.6 to 14.5)
Pyoderma	3.3 (2.4 to 4.4)	6.8 (5.2 to 9.0)	108.5 (71.8 to 149.5)	29.6 (8.4 to 58.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	107.3 (61.6 to 168.9)	30.7 (4.6 to 67.8)
Scabies	102.6 (90.9 to 115.7)	163.0 (145.6 to 182.3)	58.9 (35.9 to 86.8)	-5.6 (-20.0 to 10.4)	2.6 (1.5 to 4.3)	4.2 (2.4 to 6.9)	59.5 (35.7 to 88.3)	-4.9 (-19.6 to 11.4)
Fungal skin diseases	597.2 (439.6 to 774.7)	1,057.4 (798.5 to 1,394.4)	79.8 (76.8 to 83.0)	49.8 (-1.2 to 40.4)	3.3 (1.3 to 7.1)	3.3 (2.3 to 13.0)	81.4 (74.4 to 85.8)	0.7 (-0.7 to 2.9)
Viral skin diseases	179.2 (140.0 to 213.8)	300.4 (234.1 to 360.5)	67.3 (61.4 to 73.4)	0.2 (-2.1 to 2.5)	5.5 (3.3 to 8.5)	9.3 (5.4 to 14.6)	68.2 (59.4 to 76.4)	1.1 (-2.8 to 5.3)
Acne vulgaris	443.0 (297.8 to 589.4)	794.2 (514.5 to 1,228.3)	66.6 (13.7 to 264.2)	-9.2 (-36.8 to 99.7)	4.8 (2.0 to 9.4)	8.6 (3.7 to 17.2)	67.8 (13.6 to 267.6)	-8.6 (-36.9 to 101.8)
Alopecia areata	7.2 (6.6 to 8.0)	12.7 (11.6 to 13.8)	75.6 (51.9 to 98.5)	-3.3 (-15.1 to 8.7)	0.4 (0.2 to 0.4)	0.4 (0.3 to 0.6)	77.2 (48.1 to 109.3)	-1.5 (-16.6 to 15.1)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	75.2 (35.8 to 128.9)	-5.2 (-29.0 to 25.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.2 (35.5 to 129.0)	-5.2 (-29.2 to 25.6)
Urticaria	78.7 (49.0 to 112.1)	124.0 (89.1 to 158.2)	57.3 (0.5 to 181.0)	-14.1 (-44.0 to 33.3)	4.6 (2.5 to 7.4)	7.3 (4.4 to 11.1)	58.5 (1.0 to 188.7)	-12.7 (-44.4 to 37.7)
Decubitus ulcer	0.8 (0.7 to 1.0)	1.9 (1.3 to 2.4)	132.4 (62.8 to 217.3)	-0.6 (-34.1 to 48.0)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	135.1 (66.4 to 228.3)	3.0 (-30.5 to 57.4)
Other skin and subcutaneous diseases	397.1 (273.5 to 585.2)	734.9 (493.3 to 1,106.6)	84.2 (75.5 to 94.8)	-1.8 (-5.4 to 1.8)	2.3 (1.0 to 4.7)	4.3 (1.9 to 8.9)	86.8 (77.2 to 99.3)	0.4 (-3.8 to 5.0)
Sense organ diseases	-	-	-	-	-	-	-	-
Glaucoma	12.7 (11.3 to 14.4)	21.5 (19.2 to 24.1)	68.3 (49.5 to 91.0)	-17.9 (-28.1 to -6.0)	0.9 (0.6 to 1.2)	1.6 (1.1 to 2.1)	77.1 (52.3 to 104.5)	-14.8 (-27.2 to -1.6)
Cataract	48.1 (42.6 to 53.3)	84.8 (74.7 to 96.4)	75.9 (60.3 to 98.2)	-26.8 (-32.8 to -18.6)	3.3 (2.4 to 4.4)	6.3 (4.5 to 8.4)	89.5 (73.7 to 108.7)	-22.9 (-29.1 to -16.0)
Macular degeneration	17.4 (14.8 to 20.1)	38.2 (31.8 to 44.6)	121.3 (79.2 to 159.2)	10.0 (-14.7 to 29.4)	0.8 (0.5 to 1.1)	1.8 (1.2 to 2.5)	129.6 (84.2 to 170.7)	12.6 (-12.8 to 33.4)
Uncorrected refractive error	713.9 (642.2 to 809.1)	1,298.3 (1,138.9 to 1,491.2)	80.8 (51.0 to 122.4)	4.6 (-19.4 to 14.5)	12.4 (7.8 to 19.1)	21.0 (13.1 to 33.5)	70.9 (53.7 to 98.4)	-9.8 (-18.4 to 3.2)
Age-related and other hearing loss	868.7 (807.1 to 936.1)	1,508.5 (1,412.4 to 1,623.3)	73.2 (66.7 to 81.9)	-9.9 (-12.6 to -6.3)	27.1 (18.6 to 37.9)	48.0 (32.7 to 66.5)	76.8 (64.4 to 92.1)	-8.1 (-12.7 to -2.9)
Other vision loss	36.5 (33.0 to 40.4)	44.1 (39.4 to 49.0)	20.6 (12.7 to 28.2)	-33.3 (-38.1 to -28.7)	2.7 (1.9 to 3.7)	3.3 (2.3 to 4.5)	21.5 (11.1 to 33.2)	-31.3 (-37.1 to -25.6)
Other sense organ diseases	213.0 (200.7 to 224.0)	361.6 (344.5 to 379.4)	69.4 (58.5 to 82.6)	0.0 (-5.7 to 7.2)	5.6 (3.5 to 8.4)	9.6 (6.0 to 14.3)	70.5 (58.4 to 86.3)	1.6 (-5.0 to 9.4)
Oral disorders	-	-	-	-	-	-	-	-
Deciduous caries	866.1 (819.5 to 912.2)	1,323.5 (1,256.6 to 1,393.3)	52.6 (42.1 to 64.1)	0.1 (-6.8 to 7.7)	0.1 (0.1 to 0.7)	0.1 (0.2 to 1.0)	73.9 (83.1 to 68.4)	-10.3 (-8.7 to 10.9)
Permanent caries	3,382.4 (3,198.6 to 3,565.7)	6,094.6 (5,832.3 to 6,389.2)	79.9 (67.6 to 93.9)	-0.0 (-5.6 to 6.8)	0.3 (1.5 to 6.5)	6.0 (2.7 to 11.8)	80.9 (68.7 to 95.9)	1.0 (-4.8 to 8.1)
Periodontal diseases	688.4 (653.8 to 721.8)	1,321.9 (1,259.2 to 1,388.3)	91.7 (79.3 to 105.4)	1.5 (-5.6 to 8.9)	4.4 (1.8 to 9.2)	8.6 (3.5 to 17.3)	94.4 (82.0 to 109.0)	3.5 (-3.7 to 11.3)

Appendix Table G.4 - Guatemala prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	283.0 (271.0 to 295.3)	542.6 (519.1 to 563.6)	91.6 (79.7 to 102.7)	-7.3 (-12.8 to -2.1)	7.4 (5.1 to 10.2)	14.6 (9.9 to 20.2)	96.5 (83.1 to 109.5)	-4.2 (-10.3 to 2.1)
Other oral disorders	128.0 (120.5 to 135.9)	233.6 (220.0 to 247.2)	82.5 (66.3 to 99.4)	-0.5 (-8.5 to 7.7)	3.7 (2.3 to 5.6)	6.8 (4.3 to 10.2)	83.8 (67.0 to 101.4)	1.0 (-7.4 to 9.9)
Injuries	-	-	-	-	249.6 (123.2 to 476.6)	145.0 (95.8 to 224.6)	-40.5 (-54.8 to -13.1)	-68.5 (-75.4 to -55.1)
Transport injuries	-	-	-	-	12.4 (9.4 to 15.9)	44.2 (33.3 to 57.4)	256.0 (236.4 to 275.8)	90.3 (80.2 to 100.4)
Road injuries	-	-	-	-	11.6 (8.8 to 14.8)	48.1 (32.5 to 55.9)	271.5 (249.7 to 293.4)	98.3 (87.5 to 109.4)
Pedestrian road injuries	-	-	-	-	5.6 (4.2 to 7.1)	22.3 (16.8 to 28.8)	302.2 (270.0 to 333.6)	116.0 (99.9 to 131.2)
Cyclist road injuries	-	-	-	-	0.9 (0.7 to 1.2)	3.6 (2.7 to 4.7)	302.9 (267.0 to 339.9)	110.5 (91.9 to 130.3)
Motorcyclist road injuries	-	-	-	-	1.4 (1.0 to 1.7)	3.7 (2.8 to 4.8)	172.3 (147.9 to 198.4)	48.4 (35.9 to 62.4)
Motor vehicle road injuries	-	-	-	-	2.9 (2.2 to 3.7)	12.3 (9.3 to 16.1)	328.6 (292.7 to 365.6)	128.1 (109.7 to 148.7)
Other road injuries	-	-	-	-	0.9 (0.7 to 1.2)	1.2 (0.9 to 1.6)	29.1 (19.5 to 39.1)	-33.0 (-37.6 to -27.6)
Other transport injuries	-	-	-	-	0.8 (0.6 to 1.1)	1.1 (0.8 to 1.4)	35.2 (23.8 to 46.8)	-25.3 (-31.1 to -18.8)
Unintentional injuries	-	-	-	-	19.2 (14.8 to 24.8)	25.9 (19.7 to 33.4)	35.2 (29.0 to 41.4)	-25.0 (-28.0 to -21.6)
Falls	-	-	-	-	5.3 (4.0 to 6.8)	10.2 (7.8 to 13.1)	93.6 (83.5 to 106.7)	-5.0 (-11.2 to 1.9)
Drowning	-	-	-	-	0.3 (0.3 to 0.4)	0.4 (0.3 to 0.5)	6.1 (3.6 to 16.7)	-43.4 (-48.4 to -38.1)
Fire, heat, and hot substances	-	-	-	-	0.9 (0.7 to 1.1)	1.0 (0.8 to 1.3)	15.2 (4.1 to 26.4)	-37.1 (-42.0 to -31.9)
Poisonings	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	29.4 (8.9 to 53.6)	-29.1 (-38.7 to -17.3)
Exposure to mechanical forces	-	-	-	-	11.5 (8.8 to 15.0)	11.2 (8.4 to 14.6)	-2.7 (-7.8 to 2.9)	-46.3 (-49.0 to -43.3)
Unintentional firearm injuries	-	-	-	-	0.5 (0.4 to 0.6)	0.9 (0.7 to 1.2)	93.6 (75.9 to 112.3)	3.5 (-5.9 to 13.1)
Unintentional suffocation	-	-	-	-	0.2 (0.2 to 0.3)	0.6 (0.5 to 0.8)	152.8 (128.7 to 180.7)	35.4 (23.7 to 49.2)
Other exposure to mechanical forces	-	-	-	-	10.8 (8.2 to 14.1)	9.6 (7.2 to 12.6)	-10.7 (-15.6 to -5.4)	-51.0 (-53.6 to -48.0)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	89.0 (78.2 to 103.4)	-0.1 (-6.0 to 6.7)
Animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	161.5 (137.6 to 187.8)	71.3 (57.8 to 86.1)
Venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	123.4 (91.7 to 155.2)	38.1 (19.8 to 56.4)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	192.9 (160.5 to 227.3)	99.1 (83.2 to 116.3)
Foreign body	-	-	-	-	0.5 (0.4 to 0.6)	0.7 (0.6 to 0.9)	40.8 (29.7 to 51.9)	-20.3 (-25.5 to -15.0)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	20.2 (7.8 to 31.7)	-30.9 (-36.7 to -25.7)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	70.4 (52.0 to 90.7)	-3.3 (-12.3 to 6.2)
Foreign body in other body part	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	77.1 (61.8 to 96.8)	-4.4 (-12.1 to 5.3)
Other unintentional injuries	-	-	-	-	0.4 (0.3 to 0.5)	1.9 (1.4 to 2.4)	374.9 (338.5 to 418.6)	113.8 (98.0 to 131.1)
Self-harm and interpersonal violence	-	-	-	-	6.8 (5.3 to 8.7)	10.9 (8.2 to 14.1)	60.1 (49.5 to 70.3)	-15.4 (-20.6 to -10.1)
Self-harm	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	40.2 (29.1 to 52.4)	-28.1 (-33.4 to -22.3)
Interpersonal violence	-	-	-	-	6.5 (5.1 to 8.3)	10.5 (7.9 to 13.6)	61.0 (50.1 to 71.5)	-14.7 (-20.2 to -9.3)
Assault by firearm	-	-	-	-	1.8 (1.4 to 2.3)	4.0 (3.0 to 5.3)	123.9 (107.9 to 140.1)	17.9 (9.5 to 26.8)
Assault by sharp object	-	-	-	-	1.4 (1.0 to 1.8)	2.3 (1.8 to 3.0)	70.2 (55.3 to 84.7)	-11.7 (-18.7 to -4.4)
Assault by other means	-	-	-	-	3.4 (2.6 to 4.3)	4.1 (3.1 to 5.3)	23.6 (11.1 to 34.1)	-34.4 (-40.6 to -29.0)
Forces of nature, war, and legal intervention	-	-	-	-	211.2 (85.1 to 436.3)	63.9 (26.4 to 137.3)	-69.7 (-75.5 to -64.6)	-82.2 (-86.7 to -78.3)
Exposure to forces of nature	-	-	-	-	2.6 (1.0 to 5.1)	2.0 (0.8 to 4.0)	-23.6 (-28.9 to -1.3)	-18.5 (-24.3 to 1.5)
Collective violence and legal intervention	-	-	-	-	208.6 (83.2 to 432.4)	61.9 (24.8 to 135.5)	-70.3 (-76.0 to -65.5)	-82.6 (-87.1 to -78.6)

Appendix Table G.4 - Guinea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	622.2 (453.6 to 821.5)	1,119.2 (813.1 to 1,468.9)	80.0 (73.9 to 85.2)	-
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	226.8 (155.6 to 316.9)	332.6 (229.9 to 466.4)	46.6 (37.9 to 56.4)	-27.9 (-33.2 to -22.1)
HIV/AIDS and tuberculosis	-	-	-	-	5.3 (3.6 to 7.1)	23.4 (15.8 to 32.8)	117.4 (80.6 to 166.3)	117.4 (79.4 to 181.5)
Tuberculosis	15.4 (14.3 to 16.6)	27.5 (25.7 to 29.6)	79.4 (70.2 to 91.0)	-7.7 (-12.3 to -2.0)	4.7 (3.2 to 6.3)	8.4 (5.7 to 11.5)	80.6 (67.7 to 95.2)	-7.0 (-13.3 to 0.3)
HIV/AIDS	-	-	-	-	0.6 (0.3 to 1.0)	15.2 (9.3 to 22.8)	2,351.5 (1,525.7 to 3,843.6)	43.4 (741.3 to 1,933.1)
HIV/AIDS resulting in mycobacterial infection	0.1 (0.1 to 0.2)	2.0 (1.0 to 3.0)	1,490.6 (974.2 to 2,391.5)	724.8 (456.8 to 1,198.3)	0.0 (0.0 to 0.1)	0.7 (0.4 to 1.3)	1,460.8 (825.5 to 2,887.2)	706.6 (382.6 to 1,406.7)
HIV/AIDS resulting in other diseases	5.7 (3.6 to 8.6)	122.2 (97.5 to 149.2)	2,121.6 (1,342.1 to 3,183.3)	1,065.9 (667.6 to 1,674.3)	0.6 (0.3 to 1.0)	14.3 (8.9 to 21.8)	2,439.1 (1,539.3 to 4,180.6)	1,206.7 (740.4 to 2,113.7)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	38.6 (27.4 to 52.1)	46.3 (33.0 to 63.3)	20.1 (7.9 to 33.6)	-34.4 (-40.3 to -28.5)
Diarrheal diseases	114.0 (100.2 to 128.1)	120.7 (105.8 to 134.8)	6.3 (-11.0 to 26.0)	-40.7 (-49.5 to -31.2)	18.3 (12.1 to 25.5)	19.5 (13.1 to 27.4)	5.9 (-10.2 to 26.3)	40.6 (-49.8 to -30.7)
Intestinal infectious diseases	-	-	-	-	0.7 (0.4 to 1.0)	0.3 (0.2 to 0.5)	0.7 (-64.5 to -38.5)	-53.0 (-81.5 to -68.3)
Typhoid fever	3.0 (2.5 to 3.4)	1.6 (1.4 to 1.9)	-46.0 (-55.7 to -32.7)	-72.4 (-78.0 to -65.1)	0.4 (0.3 to 0.6)	0.2 (0.1 to 0.3)	-43.9 (-57.3 to -27.1)	-70.9 (-78.2 to -62.2)
Paratyphoid fever	2.0 (1.7 to 2.3)	1.3 (1.1 to 1.6)	-33.9 (-48.1 to -11.7)	-65.1 (-72.4 to -54.3)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-32.5 (-49.6 to -4.6)	-64.4 (-72.7 to -51.5)
Other intestinal infectious diseases	-	-	-	-	0.2 (0.1 to 0.4)	0.0 (0.0 to 0.0)	-88.5 (-94.1 to -76.4)	-94.0 (-97.0 to -47.9)
Lower respiratory infections	5.9 (4.8 to 7.5)	8.4 (6.6 to 10.5)	43.9 (3.9 to 87.2)	-10.3 (-29.7 to 15.2)	0.6 (0.4 to 0.9)	0.9 (0.6 to 1.3)	44.1 (43.0 to 94.2)	-10.1 (-30.5 to 16.7)
Upper respiratory infections	294.6 (269.5 to 318.9)	607.6 (545.0 to 662.5)	107.2 (80.4 to 134.5)	6.1 (-8.3 to 20.1)	3.4 (1.9 to 5.8)	7.2 (4.0 to 12.2)	108.0 (80.4 to 136.3)	6.4 (-7.9 to 20.7)
Otitis media	128.7 (117.1 to 142.3)	234.7 (212.3 to 255.1)	83.5 (63.7 to 103.3)	-7.0 (-18.4 to 3.7)	2.6 (1.6 to 4.2)	4.9 (2.9 to 7.8)	84.5 (64.3 to 106.0)	-6.7 (-18.1 to 5.1)
Meningitis	-	-	-	-	11.7 (8.1 to 16.1)	12.4 (8.5 to 17.2)	6.3 (-7.2 to 22.8)	-43.7 (-50.7 to -36.0)
Pneumococcal meningitis	54.1 (33.6 to 81.7)	54.9 (33.8 to 81.5)	1.5 (-23.7 to 41.5)	-46.4 (-59.2 to -24.7)	4.5 (3.0 to 6.2)	4.9 (3.3 to 6.7)	4.9 (-16.4 to 47.7)	43.4 (-55.7 to -23.6)
H influenzae type B meningitis	21.9 (8.9 to 41.4)	21.8 (9.7 to 40.6)	-1.9 (-24.3 to 53.2)	-49.6 (-60.8 to -24.1)	2.2 (1.4 to 3.3)	2.5 (1.5 to 4.1)	8.9 (-28.6 to 107.8)	-44.3 (-62.9 to 3.7)
Meningococcal meningitis	28.2 (11.5 to 57.8)	27.4 (10.1 to 56.3)	-2.5 (-27.2 to 26.7)	-47.1 (-61.0 to -23.9)	3.2 (1.9 to 4.9)	3.3 (1.9 to 5.0)	0.5 (-28.3 to 49.9)	-45.2 (-62.3 to -23.1)
Other meningitis	14.8 (9.6 to 22.3)	14.5 (9.2 to 22.3)	-2.2 (-23.6 to 29.2)	-45.8 (-58.2 to -25.7)	1.8 (1.2 to 2.5)	1.8 (1.2 to 2.4)	-1.0 (-24.1 to 25.2)	-44.6 (-58.9 to -30.0)
Encephalitis	1.3 (0.6 to 2.6)	2.3 (1.1 to 4.8)	85.1 (67.4 to 104.8)	-4.1 (-13.0 to 4.3)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.4)	94.5 (66.5 to 123.2)	-4.2 (-13.3 to 12.1)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-	-	0.0 (-98.3 to 389.8)	0.0 (0.0 to 0.0)	-	-
Whooping cough	13.4 (10.3 to 17.5)	11.5 (8.9 to 14.7)	-13.8 (-17.5 to -10.0)	-49.5 (-51.7 to -47.3)	0.7 (0.4 to 1.1)	0.6 (0.3 to 0.9)	-13.4 (-20.8 to -5.5)	-49.3 (-53.7 to -44.5)
Tetanus	1.6 (0.5 to 2.7)	0.5 (0.2 to 1.3)	-71.1 (-89.1 to 47.0)	-85.3 (-94.7 to -20.6)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-58.8 (-77.3 to 11.2)	-78.0 (-88.8 to -35.2)
Measles	3.4 (2.5 to 4.6)	0.9 (0.6 to 1.2)	-75.2 (-80.5 to -68.4)	-96.0 (-99.0 to -82.2)	0.3 (0.2 to 0.5)	0.1 (0.0 to 0.1)	95.1 (-83.1 to -64.1)	-96.0 (-90.5 to -79.7)
Varicella and herpes zoster	3.8 (3.4 to 4.2)	7.7 (7.0 to 8.5)	104.8 (77.4 to 136.0)	4.9 (-14.7 to 28.0)	0.2 (0.0 to 0.1)	0.2 (0.1 to 0.3)	103.0 (41.7 to 186.6)	6.2 (-25.6 to 47.9)
Neglected tropical diseases and malaria	-	-	-	-	95.4 (60.9 to 143.3)	106.0 (66.0 to 164.4)	11.1 (-3.7 to 27.2)	-49.1 (-57.2 to -40.6)
Malaria	2,339.2 (2,184.2 to 2,497.3)	4,021.6 (3,744.4 to 4,328.1)	72.5 (63.4 to 81.9)	-15.0 (-20.1 to -9.4)	21.7 (14.4 to 31.6)	36.2 (24.3 to 51.9)	66.9 (52.2 to 82.3)	-15.2 (-22.1 to -9.0)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	105.2 (-6.7 to 309.2)	0.2 (-55.1 to 95.1)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.0 (14.6 to 177.6)	-5.7 (-31.1 to 39.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.0 (14.1 to 178.1)	-5.7 (-31.1 to 39.6)
Cutaneous and mucocutaneous leishmaniasis	7.7 (4.2 to 12.4)	15.8 (7.7 to 27.4)	103.3 (-7.6 to 299.2)	-0.2 (-54.8 to 91.4)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	105.2 (-6.7 to 309.3)	0.2 (-55.1 to 95.1)
African trypanosomiasis	0.5 (0.2 to 1.0)	0.7 (0.3 to 1.5)	56.2 (38.2 to 71.5)	-20.7 (-29.9 to -13.0)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.5)	67.2 (36.3 to 125.8)	-13.3 (-29.8 to 18.5)
Schistosomiasis	2,857.8 (1,710.7 to 4,228.2)	3,381.5 (1,970.3 to 5,178.3)	16.7 (3.8 to 44.7)	-41.5 (-48.0 to -27.7)	28.7 (12.4 to 56.7)	34.7 (15.0 to 74.7)	18.3 (6.0 to 52.7)	-40.8 (-46.9 to -24.2)
Cysticercosis	2.3 (0.6 to 4.9)	2.8 (0.3 to 5.6)	27.6 (-80.7 to 397.3)	-43.2 (-86.7 to 111.3)	0.6 (0.1 to 1.3)	0.6 (0.1 to 1.6)	39.4 (-79.7 to 463.7)	-38.4 (-86.2 to 142.9)
Cystic echinococcosis	1.9 (1.8 to 2.1)	1.3 (1.2 to 1.4)	-33.2 (-40.4 to -21.5)	-68.4 (-73.4 to -64.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-31.7 (-45.9 to -13.5)	-68.0 (-74.2 to -61.1)
Lymphatic filariasis	244.6 (190.8 to 299.0)	380.0 (282.7 to 480.6)	55.7 (15.2 to 111.3)	-19.9 (-38.3 to 3.4)	6.9 (3.5 to 11.7)	11.3 (5.4 to 19.8)	67.0 (20.6 to 111.0)	-12.1 (-37.0 to 14.9)
Onchocerciasis	361.1 (285.4 to 467.8)	-	-	-	100.0 (-100.0 to -100.0)	22.5 (12.6 to 36.5)	-	-
Trachoma	7.9 (2.9 to 18.5)	10.5 (5.5 to 17.4)	43.0 (-24.5 to 191.8)	-39.8 (-62.7 to 15.4)	0.5 (0.2 to 1.3)	0.6 (0.3 to 1.1)	19.6 (-34.2 to 121.2)	-48.5 (-67.6 to -14.0)
Dengue	0.5 (0.2 to 1.1)	4.7 (1.7 to 10.5)	843.7 (832.7 to 856.4)	379.5 (373.9 to 385.9)	0.1 (0.0 to 0.2)	0.8 (0.2 to 1.9)	842.5 (627.4 to 1,187.8)	376.0 (281.3 to 527.3)
Yellow fever	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-48.0 (-58.7 to -30.2)	-73.4 (-78.6 to -65.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.0 (-58.9 to -30.1)	-73.4 (-78.7 to -65.9)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	24.2 (-31.9 to 97.1)	0.0 (0.0 to 0.0)	24.2 (-31.9 to 97.5)	23.0 (-54.0 to 7.7)
Intestinal nematode infections	-	-	-	-	6.5 (4.0 to 10.1)	12.6 (7.6 to 19.4)	93.1 (72.7 to 115.4)	-2.1 (-13.8 to 11.0)
Ascariasis	491.3 (312.5 to 732.5)	955.5 (605.2 to 1,492.5)	93.9 (7.0 to 252.8)	-0.5 (-52.0 to 104.7)	0.1 (0.1 to 0.3)	0.3 (0.1 to 0.5)	91.9 (44.1 to 152.2)	-0.5 (-30.3 to 36.6)
Trichuriasis	567.6 (378.5 to 837.7)	1,102.3 (725.0 to 1,634.7)	96.1 (10.2 to 241.1)	-0.9 (-50.3 to 91.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	95.5 (30.2 to 183.3)	0.6 (-37.0 to 56.3)
Hookworm disease	1,381.5 (1,040.1 to 1,854.4)	2,703.7 (1,993.6 to 3,675.0)	98.4 (28.3 to 199.9)	-0.5 (-40.2 to 62.4)	6.3 (3.9 to 9.7)	12.1 (7.4 to 18.6)	93.2 (72.3 to 116.1)	2.1 (-14.3 to 11.0)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	98.9 (73.2 to 125.4)	180.6 (167.0 to 199.2)	84.0 (44.0 to 148.7)	-2.0 (-20.9 to 26.4)	7.4 (4.0 to 13.7)	8.6 (5.6 to 12.8)	20.6 (-20.7 to 66.2)	-49.5 (-70.3 to -25.1)
Maternal disorders	-	-	-	-	2.6 (1.7 to 3.7)	4.4 (2.9 to 6.1)	67.9 (44.3 to 98.9)	-16.9 (-28.4 to -2.9)
Maternal hemorrhage	1.8 (1.4 to 2.2)	3.4 (2.1 to 4.6)	91.2 (16.6 to 204.5)	-9.1 (-43.2 to 44.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	80.8 (-17.0 to 286.1)	-13.7 (-60.3 to 80.2)
Maternal sepsis and other maternal infections	3.9 (2.3 to 5.7)	3.3 (2.1 to 5.3)	-16.9 (-31.8 to 7.8)	-57.6 (-65.3 to -45.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-15.5 (-51.7 to 58.7)	-58.1 (-73.9 to -25.9)
Maternal hypertensive disorders	2.2 (0.8 to 4.0)	3.2 (1.2 to 5.9)	47.4 (35.9 to 71.8)	-28.8 (-34.0 to -19.9)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	47.5 (23.2 to 78.2)	-28.8 (-40.3 to -15.2)
Obstructed labor	5.9 (4.8 to 7.1)	9.9 (8.4 to 11.5)	66.9 (49.8 to 91.8)	-17.4 (-25.8 to -4.7)	1.9 (1.2 to 2.8)	3.3 (2.1 to 4.5)	67.5 (44.9 to 97.8)	-16.9 (-28.0 to -2.5)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other maternal disorders	-	-	-	-	0.4 (0.2 to 0.7)	0.8 (0.5 to 1.2)	82.9 (17.3 to 193.2)	-10.1 (-42.9 to 43.5)
Neonatal disorders	-	-	-	-	3.0 (1.5 to 5.6)	13.8 (8.2 to 22.4)	379.2 (164.1 to 735.5)	172.5 (34.3 to 408.0)
Preterm birth complications	17.8 (8.3 to 35.0)	81.4 (44.3 to 140.7)	361.8 (276.5 to 541.7)	136.1 (94.6 to 215.6)	0.9 (0.5 to 1.6)	7.3 (4.2 to 12.9)	662.8 (336.3 to 1,328.7)	317.6 (146.1 to 703.9)
Neonatal encephalopathy due to birth asphyxia and trauma	47.3 (3.4 to 151.0)	60.9 (8.4 to 186.2)	37.3 (-3.7 to 177.6)	-31.0 (-51.1 to -44.4)	1.5 (0.5 to 3.7)	3.3 (1.4 to 6.5)	138.1 (42.6 to 488.0)	28.8 (-27.8 to 270.4)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.6)	151.9 (130.9 to 205.7)	65.7 (51.8 to 101.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	67.3 (125.2 to 208.1)	154.4 (48.1 to 102.6)
Hemolytic disease and other neonatal jaundice	0.7 (0.3 to 1.5)	5.1 (1.9 to 9.0)	379.2 (200.8 to 1,581.2)	0.3 (-92.8 to 1,042.6)	0.3 (0.1 to 0.6)	1.9 (0.7 to 3.6)	647.7 (211.8 to 1,707.3)	384.1 (92.7 to 1,105.3)
Other neonatal disorders	-	-	-	-	0.3 (0.1 to 0.7)	1.2 (0.5 to 2.5)	312.1 (70.4 to 996.4)	129.6 (-13.0 to 543.2)
Nutritional deficiencies	-	-	-	-	76.7 (52.0 to 109.6)	129.9 (86.9 to 185.4)	69.4 (54.8 to 84.2)	-11.7 (-17.8 to -5.3)
Protein-energy malnutrition	60.2 (32.5 to 101.1)	78.3 (36.3 to 145.0)	28.7 (-47.1 to 212.6)	-23.2 (-64.8 to 75.4)	2.3 (3.3 to 13.8)	9.7 (3.9 to 19.0)	23.8 (-47.6 to 219.2)	21.8 (-65.6 to 79.8)
Iodine deficiency	536.9 (464.9 to 615.1)	673.8 (561.9 to 799.4)	26.3 (1.9 to 55.1)	-36.8 (-50.3 to -21.2)	9.6 (5.9 to 16.0)	12.1 (7.2 to 19.7)	26.7 (1.5 to 55.9)	-36.7 (-50.3 to -21.0)
Vitamin A deficiency	11.3 (7.5 to 15.9)	14.4 (9.3 to 19.3)	26.4 (-2.3 to 75.2)	-27.1 (-43.4 to 7.4)	0.5 (0.3 to 0.8)	0.7 (0.4 to 1.0)	27.8 (2.0 to 72.4)	-25.4 (-41.8 to 2.3)

Appendix Table G.4 - Guinea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	1,503.7 (1,470.5 to 1,556.6)	2,795.3 (2,732.0 to 2,864.1)	86.8 (80.2 to 92.7)	-2.8 (-6.3 to 0.8)	59.2 (40.1 to 83.8)	107.4 (72.1 to 152.9)	81.3 (73.3 to 89.0)	4.7 (-8.2 to 0.2)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	67.4 (57.4 to 457.1)	-1.0 (-72.7 to 213.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	5.2 (3.4 to 7.6)	8.7 (5.7 to 13.0)	66.7 (53.1 to 94.0)	-17.7 (-24.7 to -8.2)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.1 (0.6 to 1.9)	2.1 (1.2 to 3.6)	82.1 (50.8 to 128.9)	-11.1 (-24.9 to 8.1)
Syphilis	0.7 (0.6 to 0.8)	0.8 (0.7 to 0.9)	8.4 (-11.0 to 28.2)	-42.0 (-50.3 to -32.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	8.8 (-18.5 to 41.1)	41.9 (-54.8 to -25.9)
Chlamydial infection	83.1 (53.1 to 109.6)	169.4 (124.6 to 220.7)	100.4 (44.7 to 242.8)	-2.7 (-29.1 to 60.7)	0.4 (0.2 to 0.7)	0.7 (0.4 to 1.4)	88.0 (24.4 to 193.6)	-8.4 (-39.6 to 39.8)
Gonococcal infection	27.1 (18.6 to 36.2)	59.0 (44.7 to 78.4)	118.1 (40.3 to 244.0)	4.4 (-30.1 to 61.4)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	111.5 (28.0 to 297.2)	1.8 (-36.6 to 86.5)
Trichomoniasis	72.2 (39.7 to 112.1)	135.9 (78.4 to 251.0)	90.0 (6.6 to 253.7)	-5.8 (-43.4 to 80.5)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.6)	89.4 (0.7 to 288.8)	-5.6 (-45.7 to 104.8)
Genital herpes	902.1 (912.2 to 1,061.0)	1,872.3 (1,734.1 to 2,028.0)	89.2 (70.1 to 113.8)	-2.9 (-12.9 to 9.8)	0.3 (0.1 to 0.7)	0.5 (0.2 to 1.2)	81.1 (69.8 to 117.5)	-2.5 (-13.4 to 10.7)
Other sexually transmitted diseases	2.6 (1.7 to 3.5)	4.0 (2.9 to 5.2)	54.6 (35.4 to 101.1)	-11.2 (-31.6 to 1.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	65.1 (19.7 to 128.8)	-17.5 (-39.1 to 12.4)
Hepatitis	-	-	-	-	0.9 (0.6 to 1.3)	1.2 (0.7 to 1.7)	36.6 (10.5 to 69.2)	-33.8 (-47.1 to -15.7)
Hepatitis A	10.9 (10.3 to 11.5)	19.6 (18.6 to 20.6)	80.5 (79.5 to 81.6)	-2.6 (-2.8 to -2.4)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	103.5 (80.3 to 129.7)	4.1 (-8.0 to 16.0)
Hepatitis B	1,226.7 (1,023.4 to 1,442.0)	1,384.0 (1,176.0 to 1,589.0)	13.3 (-8.1 to 35.5)	-43.2 (-54.5 to -30.6)	0.6 (0.3 to 0.9)	0.6 (0.4 to 0.9)	6.7 (-21.5 to 47.4)	-45.9 (-62.1 to -23.1)
Hepatitis C	446.3 (393.0 to 495.0)	597.8 (518.9 to 671.5)	34.4 (12.8 to 61.5)	-30.6 (-40.4 to -18.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	54.5 (16.3 to 107.6)	-15.7 (-37.7 to 13.4)
Hepatitis E	2.3 (1.7 to 2.9)	4.3 (2.7 to 6.2)	89.6 (0.7 to 204.5)	-3.9 (-49.6 to 42.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	90.8 (-1.5 to 218.5)	-3.8 (51.0 to 48.7)
Leprosy	5.3 (4.0 to 6.7)	4.5 (3.8 to 5.4)	-13.4 (-23.2 to -1.2)	-48.7 (-54.0 to -42.3)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-10.1 (-21.6 to 5.1)	-47.2 (-34.4 to -39.2)
Other infectious diseases	70.5 (53.6 to 89.6)	129.2 (117.1 to 140.8)	84.0 (63.2 to 111.4)	-2.5 (-13.5 to 11.6)	1.9 (1.8 to 4.1)	2.5 (3.5 to 7.5)	77.1 (59.3 to 133.7)	-4.9 (-15.1 to 23.1)
Non-communicable diseases	-	-	-	-	375.4 (275.4 to 485.5)	746.3 (548.7 to 967.9)	100.2 (93.0 to 106.0)	2.1 (-1.4 to 5.0)
Neoplasms	-	-	-	-	1.5 (1.1 to 2.0)	3.7 (2.5 to 5.2)	150.5 (105.4 to 208.7)	38.7 (14.4 to 70.3)
Esophageal cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	145.4 (62.3 to 265.8)	29.6 (-16.4 to 93.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	145.3 (76.6 to 230.8)	30.4 (-10.8 to 78.6)
Stomach cancer	0.6 (0.5 to 0.8)	1.4 (1.1 to 1.7)	115.6 (66.1 to 190.4)	16.6 (-9.7 to 54.3)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.3)	116.9 (63.8 to 186.2)	17.5 (-11.6 to 54.5)
Liver cancer	-	-	-	-	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.7)	104.7 (43.8 to 196.4)	10.2 (-21.6 to 54.8)
Liver cancer due to hepatitis B	0.6 (0.3 to 0.9)	1.4 (0.8 to 2.1)	133.9 (17.0 to 344.2)	23.1 (-37.5 to 135.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.4)	131.4 (29.9 to 300.2)	22.1 (-32.0 to 116.6)
Liver cancer due to hepatitis C	0.2 (0.1 to 0.3)	0.8 (0.4 to 1.4)	446.5 (106.2 to 1,308.8)	176.4 (17.1 to 523.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	411.9 (94.8 to 1,165.7)	167.7 (17.1 to 480.7)
Liver cancer due to alcohol use	0.3 (0.1 to 0.4)	0.1 (0.1 to 0.5)	-21.2 (-64.6 to 139.3)	-56.3 (-79.4 to 17.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-20.7 (-60.6 to 132.6)	-55.3 (-76.2 to 11.1)
Liver cancer due to other causes	0.4 (0.2 to 0.5)	0.5 (0.3 to 0.7)	22.8 (-30.6 to 136.6)	36.4 (-64.3 to 28.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	21.5 (-27.4 to 116.0)	37.4 (-62.1 to 15.4)
Larynx cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	117.3 (41.3 to 237.7)	15.2 (-24.5 to 79.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	121.2 (45.9 to 232.4)	17.8 (-21.4 to 80.4)
Tracheal, bronchus and lung cancer	0.2 (0.2 to 0.3)	0.6 (0.4 to 0.7)	138.6 (73.4 to 224.2)	26.7 (-6.1 to 68.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	135.6 (67.4 to 234.4)	25.5 (-10.0 to 76.3)
Breast cancer	1.8 (1.4 to 2.3)	5.7 (4.1 to 8.6)	208.1 (111.1 to 390.2)	62.1 (12.4 to 159.3)	0.2 (0.1 to 0.2)	0.5 (0.3 to 0.8)	179.1 (91.8 to 357.5)	50.2 (-2.3 to 137.3)
Cervical cancer	3.7 (2.7 to 4.9)	6.5 (4.4 to 9.4)	74.5 (11.3 to 167.4)	4.2 (-37.9 to 45.6)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.9)	79.8 (17.2 to 169.7)	-1.9 (-33.8 to 48.9)
Uterine cancer	0.5 (0.3 to 0.9)	1.2 (0.7 to 2.0)	113.9 (30.8 to 269.5)	15.5 (-29.0 to 89.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	117.0 (31.6 to 277.1)	18.2 (-29.3 to 103.5)
Prostate cancer	0.9 (0.5 to 1.3)	5.0 (3.0 to 8.3)	468.6 (265.7 to 843.5)	195.9 (87.7 to 373.0)	0.1 (0.1 to 0.2)	0.5 (0.3 to 0.8)	384.4 (222.7 to 629.7)	157.6 (66.6 to 299.8)
Colon and rectum cancer	0.4 (0.4 to 0.5)	1.2 (0.9 to 1.4)	169.8 (106.6 to 239.9)	38.1 (8.1 to 72.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	158.5 (102.7 to 225.3)	35.1 (3.1 to 67.8)
Lip and oral cavity cancer	0.6 (0.3 to 0.8)	1.4 (0.8 to 2.0)	133.7 (61.4 to 251.0)	22.5 (-13.6 to 61.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	133.2 (60.3 to 248.0)	22.5 (-13.0 to 81.5)
Nasopharynx cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	135.0 (38.9 to 325.7)	24.0 (-28.2 to 122.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	134.4 (41.1 to 256.2)	22.4 (-24.9 to 111.8)
Other pharynx cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	118.2 (14.4 to 334.6)	19.9 (-37.7 to 131.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	120.3 (30.3 to 315.2)	21.0 (-28.9 to 117.6)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	156.3 (61.4 to 321.9)	35.5 (-17.6 to 128.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	146.2 (57.8 to 287.2)	27.1 (-20.8 to 106.9)
Pancreatic cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	159.9 (91.3 to 264.1)	40.2 (3.6 to 99.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	162.6 (104.2 to 243.8)	41.3 (5.5 to 88.1)
Malignant skin melanoma	0.4 (0.3 to 0.5)	1.1 (0.8 to 1.5)	176.6 (105.9 to 279.2)	49.1 (6.8 to 106.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	174.4 (91.0 to 281.5)	45.7 (-2.5 to 107.1)
Non-melanoma skin cancer	0.3 (0.2 to 0.4)	0.8 (0.4 to 1.1)	149.6 (-0.6 to 323.4)	36.1 (-38.5 to 127.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	200.8 (101.3 to 353.1)	55.9 (-6.4 to 148.8)
Ovarian cancer	0.3 (0.2 to 0.4)	0.8 (0.5 to 1.2)	171.0 (61.1 to 348.0)	44.8 (-14.8 to 138.9)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	170.1 (57.1 to 379.2)	45.5 (-18.3 to 155.2)
Testicular cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	202.4 (60.2 to 471.4)	50.4 (-16.6 to 176.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	194.4 (53.3 to 467.9)	46.8 (-18.8 to 177.0)
Kidney cancer	0.2 (0.2 to 0.3)	0.6 (0.4 to 0.8)	181.2 (86.2 to 343.8)	49.1 (0.2 to 135.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	174.4 (82.7 to 333.9)	49.2 (-2.3 to 129.5)
Bladder cancer	0.5 (0.3 to 0.6)	1.1 (0.8 to 1.4)	142.8 (73.6 to 230.0)	28.1 (-9.9 to 80.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	147.5 (78.4 to 240.8)	32.2 (-8.1 to 82.5)
Brain and nervous system cancer	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.5)	164.1 (84.4 to 266.6)	40.5 (-5.8 to 108.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	156.2 (79.7 to 261.4)	37.0 (-12.9 to 110.4)
Thyroid cancer	0.4 (0.1 to 0.5)	0.9 (0.4 to 1.4)	161.4 (75.4 to 304.0)	33.6 (-12.4 to 112.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	156.4 (71.1 to 306.7)	30.1 (-14.1 to 105.5)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.6 (39.6 to 193.7)	4.3 (-26.9 to 56.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	99.8 (40.7 to 191.4)	5.1 (-25.5 to 55.6)
Hodgkin lymphoma	0.2 (0.2 to 0.4)	0.8 (0.5 to 1.1)	206.2 (90.2 to 418.7)	75.8 (11.5 to 175.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	201.3 (86.6 to 373.2)	67.4 (5.2 to 152.0)
Non-Hodgkin lymphoma	0.4 (0.3 to 0.6)	1.2 (0.9 to 1.7)	182.3 (95.3 to 333.6)	45.5 (-1.8 to 133.9)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	178.7 (101.2 to 326.4)	44.4 (-2.0 to 130.9)
Multiple myeloma	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	150.1 (59.7 to 290.7)	34.1 (-16.4 to 115.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	139.8 (57.3 to 275.7)	28.4 (-20.6 to 107.4)
Leukemia	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.6)	166.6 (59.9 to 402.2)	38.3 (-6.1 to 115.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	151.1 (77.6 to 272.4)	26.8 (-10.7 to 81.5)
Other neoplasms	1.7 (0.9 to 3.6)	4.5 (3.0 to 6.8)	197.0 (44.7 to 404.8)	37.9 (-13.3 to 116.6)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	182.1 (57.3 to 349.0)	27.8 (-15.2 to 105.0)
Cardiovascular diseases	-	-	-	-	8.2 (5.5 to 11.4)	16.0 (10.4 to 23.0)	94.0 (49.3 to 143.9)	2.3 (-19.0 to 27.2)
Rheumatic heart disease	18.5 (16.4 to 20.9)	33.1 (27.7 to 39.2)	80.0 (44.2 to 114.1)	-9.2 (-24.1 to 8.3)	1.0 (0.6 to 1.4)	1.8 (1.2 to 2.7)	89.1 (51.6 to 129.3)	-0.8 (-20.7 to 21.9)
Ischemic heart disease	50.9 (40.9 to 64.7)	69.2 (54.3 to 88.6)	36.3 (-2.0 to 87.5)	-22.2 (-40.1 to 2.7)	2.5 (1.5 to 3.9)	3.1 (1.8 to 4.7)	22.0 (-23.7 to 66.7)	-28.9 (50.9 to 4.5)
Cerebrovascular disease	-	-	-	-	0.5 (0.3 to 0.7)	1.0 (0.7 to 1.3)	88.3 (52.2 to 135.2)	1.1 (-18.2 to 27.1)
Ischemic stroke	2.6 (2.2 to 3.1)	4.9 (4.2 to 5.7)	88.5 (52.1 to 135.6)	1.8 (-17.4 to 28.4)	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.0)	89.6 (52.0 to 139.0)	2.6 (-18.0 to 29.1)
Hemorrhagic stroke	0.7 (0.6 to 0.9)	1.3 (1.1 to 1.6)	79.7 (39.2 to 134.6)	-5.8 (-25.3 to 22.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	81.0 (39.1 to 142.0)	-4.7 (-26.7 to 25.9)
Hypertensive heart disease	12.0 (9.7 to 14.4)	19.8 (14.6 to 25.0)	65.1 (17.0 to 129.9)	-11.5 (-37.7 to 22.3)	1.3 (0.9 to 1.9)	2.2 (1.4 to 3.2)	66.3 (17.8 to 129.9)	-10.1 (-37.3 to 23.1)
Cardiomyopathy and myocarditis	0.8 (0.6 to 1.1)	3.3 (2.3 to 4.6)	290.0 (144.9 to 521.8)	95.5 (8.3 to 267.7)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.4)	292.3 (145.3 to 526.5)	98.2 (-6.0 to 266.6)
Peripheral vascular disease	89.4 (66.4 to 117.1)	182.7 (110.0 to 255.9)	98.9 (3.5 to 252.7)	-0.1 (-43.4 to 57.0)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	61.8 (-42.6 to 253.5)	-7.2 (-68.5 to 92.8)
Endocarditis	0.7 (0.4 to 1.0)	0.7 (0.3 to 1.1)	-0.9 (-49.2 to 91.3)	-50.8 (-77.8 to 14.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-6.0 (-54.6 to 99.7)	-52.7 (-80.0 to 23.1)
Other cardiovascular and circulatory diseases	32.0 (20.7 to 47.1)	91.1 (42.9 to 138.9)	189.5 (34.6 to 408.0)	52.4 (-29.9 to 183.2)	2.2 (1.3 to 3.5)	6.4 (2.8 to 10.9)	151.0 (33.8 to 414.7)	54.0 (-29.7 to 187.0)
Chronic respiratory diseases	-	-	-	-	26.5 (17.9 to 36.6)	55.0 (36.8 to 75.8)	107.9 (78.7 to 141.4)	3.8 (-8.2 to 18.3)
Chronic obstructive pulmonary disease	203.2 (192.7 to 213.7)	382.6 (360.3 to 402.7)	89.1 (82.1 to 95.4)	-0.9 (-4.6 to 2.2)	16.4 (10.8 to 23.2)			

Appendix Table G.4 - Guinea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	-	84.4
Silicosis	0.0	0.0	74.8	-7.2	(0.0 to 0.0)	(0.0 to 0.0)	(78.0 to 91.3)	(6.5 to 0.3)
Asbestosis	-	-	0.0	0.0	0.0	0.0	-	-7.3
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.1	94.5	1.5	0.0	0.0	93.7	1.1
Asthma	142.7	399.5	(87.1 to 102.8)	(-2.2 to 5.5)	29.8	17.5	153.7	31.4
Interstitial lung disease and pulmonary sarcoidosis	0.1	0.3	(88.0 to 304.0)	(-2.3 to 72.2)	(3.8 to 9.1)	(10.9 to 26.6)	(89.4 to 312.2)	(-2.1 to 74.6)
Other chronic respiratory diseases	-	-	-	-	0.0	0.0	114.3	8.0
Cirrhosis	-	-	-	-	3.9	5.1	33.8	-29.5
Cirrhosis due to hepatitis B	1.2	1.4	11.5	-39.9	(1.9 to 6.6)	(3.0 to 8.2)	(8.9 to 97.7)	(52.3 to 3.1)
Cirrhosis due to hepatitis C	0.6	1.1	104.9	14.3	(0.4 to 0.7)	(0.6 to 1.2)	(42.2 to 82.6)	(-23.2 to -3.8)
Cirrhosis due to alcohol use	0.6	1.0	54.0	-17.9	0.2	0.2	12.6	-39.3
Cirrhosis due to other causes	0.7	1.5	115.4	21.6	(0.1 to 0.2)	(0.1 to 0.3)	(-11.3 to 153.1)	(-50.8 to 29.9)
Digestive diseases	-	-	-	-	7.5	14.5	93.0	-0.2
Peptic ulcer disease	36.3	57.2	58.3	-14.1	(5.1 to 10.5)	(10.1 to 19.9)	(70.1 to 117.4)	(-11.4 to 9.9)
Gastritis and duodenitis	72.8	132.5	82.9	-4.2	1.3	2.0	59.7	-13.9
Appendicitis	0.7	1.5	134.9	11.3	(0.9 to 1.9)	(1.3 to 3.0)	(19.0 to 96.7)	(-32.2 to 1.6)
Paralytic ileus and intestinal obstruction	0.1	0.1	70.0	0.0	0.0	0.0	71.6	-0.9
Inguinal, femoral, and abdominal hernia	32.5	44.4	37.7	-18.1	(2.0 to 4.3)	(3.7 to 8.0)	(54.8 to 123.2)	(-17.8 to 16.1)
Inflammatory bowel disease	5.8	14.1	145.9	26.4	(0.1 to 0.1)	(0.1 to 0.1)	(14.3 to 165.3)	(-25.5 to 28.3)
Vascular (intestinal) disorders	0.0	0.0	165.1	17.8	(0.2 to 0.7)	(0.2 to 0.9)	(40.0 to 93.7)	(-33.0 to 6.8)
Gallbladder and biliary diseases	1.9	4.1	123.9	0.2	(0.8 to 1.7)	(2.1 to 4.1)	(125.7 to 171.2)	(17.3 to 37.6)
Pancreatitis	1.0	2.1	114.6	10.3	0.0	0.0	165.8	17.1
Other digestive diseases	-	-	-	-	(0.0 to 0.0)	(0.0 to 0.0)	(90.9 to 263.6)	(-32.6 to 103.4)
Neurological disorders	-	-	-	-	1.1	2.1	125.2	9.6
Alzheimer disease and other dementias	8.3	15.5	88.0	-0.5	(0.0 to 0.0)	(0.0 to 0.0)	(90.9 to 263.6)	(-32.6 to 103.4)
Parkinson disease	0.4	0.8	84.4	0.4	(0.1 to 0.3)	(0.1 to 0.3)	(8.4 to 280.0)	(-41.1 to 98.8)
Epilepsy	12.8	24.9	95.4	-3.1	(0.0 to 0.1)	(0.1 to 0.1)	(52.2 to 126.2)	(-15.8 to 21.8)
Multiple sclerosis	0.4	0.8	118.3	12.4	0.0	0.0	84.1	0.7
Migraine	420.5	811.4	93.1	8.6	(1.7 to 6.3)	(3.6 to 13.1)	(-1.8 to 375.3)	(-50.9 to 132.3)
Tension-type headache	732.3	1,516.8	107.9	2.8	(0.1 to 0.2)	(0.1 to 0.2)	(74.5 to 175.0)	(-10.1 to 39.8)
Medication overuse headache	27.7	79.8	187.4	45.2	(0.3 to 0.6)	(0.3 to 0.6)	(83.3 to 180.0)	(-7.2 to 32.7)
Other neurological disorders	0.0	0.0	82.3	-6.8	(0.2 to 0.4)	(0.4 to 0.9)	(81.9 to 157.9)	(-4.5 to 30.2)
Mental and substance use disorders	-	-	-	-	0.9	1.8	87.7	-3.2
Schizophrenia	12.7	24.8	96.1	0.3	(0.5 to 1.7)	(1.1 to 2.7)	(25.6 to 209.2)	(-34.4 to 56.9)
Alcohol use disorders	28.8	66.9	133.6	17.1	25.6	54.4	112.3	6.0
Drug use disorders	-	-	-	-	(17.4 to 35.2)	(36.2 to 74.6)	(84.9 to 143.7)	(6.5 to 19.5)
Opioid use disorders	10.2	19.7	92.6	-0.6	1.1	2.1	92.5	0.8
Cocaine use disorders	8.0	6.0	102.7	0.4	(0.8 to 1.5)	(1.5 to 2.9)	(63.8 to 127.4)	(-15.8 to 20.3)
Amphetamine use disorders	8.9	18.6	108.8	-0.7	0.0	0.1	84.1	0.7
Cannabis use disorders	4.0	8.5	109.9	0.3	(0.0 to 0.1)	(0.1 to 0.1)	(52.2 to 126.2)	(-15.8 to 21.8)
Other drug use disorders	-	-	-	-	3.5	7.4	109.3	4.3
Depressive disorders	-	-	-	-	1.1	1.9	78.4	-7.3
Major depressive disorder	216.1	441.7	105.9	2.7	(0.6 to 2.2)	(1.1 to 2.9)	(12.0 to 183.5)	(-40.8 to 49.3)
Dysthymia	59.8	116.5	95.6	-0.4	116.5	238.4	104.6	2.4
Bipolar disorder	33.3	66.1	98.8	-0.5	(80.3 to 158.7)	(166.1 to 326.9)	(96.4 to 113.1)	(-2.0 to 6.6)
Anxiety disorders	138.9	274.2	101.1	0.3	8.1	16.0	97.5	1.1
Eating disorders	-	-	-	-	0.3	0.3	136.6	18.2
Anorexia nervosa	1.0	2.1	115.4	3.6	(1.8 to 3.8)	(4.4 to 9.3)	(119.0 to 154.0)	(10.2 to 26.6)
Bulimia nervosa	5.7	11.9	108.0	-0.8	7.4	14.9	101.2	0.5
Autistic spectrum disorders	-	-	-	-	4.9	10.3	79.3	123.8
Autism	18.2	36.0	98.1	0.6	(4.9 to 10.3)	(10.0 to 20.8)	(79.3 to 123.8)	(9.7 to 10.7)
Asperger syndrome	26.2	51.7	97.9	0.8	4.2	8.1	93.8	0.0
Attention-deficit/hyperactivity disorder	41.6	85.0	105.4	0.5	(2.6 to 6.3)	(4.9 to 12.8)	(68.2 to 119.0)	(-12.5 to 11.8)
Conduct disorder	60.5	125.4	107.4	0.5	0.2	0.4	106.6	3.2
Idiopathic intellectual disability	152.7	311.7	103.8	4.4	(0.2 to 0.6)	(0.5 to 1.2)	(59.0 to 175.3)	(-19.3 to 34.7)
Other mental and substance use disorders	75.1	150.0	100.7	0.5	(0.7 to 1.7)	(1.5 to 3.6)	(77.7 to 147.3)	(-14.7 to 16.4)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	0.1	0.2	111.5	1.4
Diabetes mellitus	66.2	210.1	213.9	67.2	(0.1 to 0.2)	(0.1 to 0.4)	(70.9 to 162.9)	(-17.6 to 23.5)
Acute glomerulonephritis	0.1	0.1	21.3	0.0	1.6	3.3	111.4	2.2
Chronic kidney disease	-	-	-	-	(1.0 to 2.3)	(2.1 to 4.9)	(52.8 to 185.9)	(-26.5 to 36.6)
Chronic kidney disease due to diabetes mellitus	62.7	110.7	77.3	-8.4	49.8	102.4	105.8	2.8
Chronic kidney disease due to hypertension	262.5	529.9	101.7	7.0	(28.9 to 77.5)	(58.6 to 160.3)	(88.8 to 125.0)	(-5.9 to 11.9)
Chronic kidney disease due to glomerulonephritis	175.2	322.5	85.9	-8.0	44.1	91.2	107.0	3.2
Chronic kidney disease due to other causes	104.6	303.2	196.2	32.5	(24.0 to 71.3)	(49.9 to 148.2)	(87.8 to 129.8)	(-6.9 to 13.9)
Urinary diseases and male infertility	-	-	-	-	5.7	11.3	96.9	0.2
	-	-	-	-	(3.7 to 8.4)	(7.3 to 16.4)	(90.4 to 102.4)	(-2.2 to 2.5)
	-	-	-	-	6.7	13.5	100.7	0.2
	-	-	-	-	(4.1 to 10.1)	(8.3 to 20.4)	(87.0 to 116.6)	(-5.8 to 7.1)
	-	-	-	-	0.3	0.3	102.2	0.1
	-	-	-	-	(8.2 to 17.9)	(16.9 to 35.9)	(94.8 to 109.2)	(-2.7 to 3.2)
	-	-	-	-	1.4	2.9	109.9	-0.1
	-	-	-	-	(0.8 to 2.2)	(1.8 to 4.7)	(91.6 to 128.7)	(-8.5 to 8.8)
	-	-	-	-	0.2	0.4	116.2	3.6
	-	-	-	-	(0.7 to 2.0)	(1.4 to 4.1)	(89.7 to 129.8)	(-9.4 to 9.2)
	-	-	-	-	7.1	14.3	99.3	1.4
	-	-	-	-	(4.8 to 9.6)	(9.9 to 19.2)	(92.2 to 107.4)	(-1.9 to 4.8)
	-	-	-	-	4.5	8.9	99.8	1.4
	-	-	-	-	(3.0 to 6.2)	(6.0 to 12.3)	(89.1 to 109.7)	(-3.4 to 5.9)
	-	-	-	-	2.6	5.2	99.0	1.3
	-	-	-	-	(1.8 to 3.6)	(3.6 to 7.3)	(90.3 to 107.8)	(-2.4 to 5.5)
	-	-	-	-	0.5	1.0	106.5	1.1
	-	-	-	-	(0.3 to 0.8)	(0.6 to 1.6)	(91.2 to 122.8)	(-6.3 to 8.7)
	-	-	-	-	7.2	15.0	108.1	0.5
	-	-	-	-	(4.6 to 10.5)	(9.5 to 21.9)	(98.6 to 117.6)	(-3.7 to 5.4)
	-	-	-	-	4.4	15.3	104.5	4.8
	-	-	-	-	(15.5 to 62.3)	(3.2 to 11.9)	(67.0 to 207.7)	(-15.0 to 64.6)
	-	-	-	-	5.6	11.3	102.2	1.2
	-	-	-	-	(3.8 to 7.5)	(7.7 to 15.1)	(94.3 to 111.2)	(-2.4 to 5.0)
	-	-	-	-	35.8	75.3	109.8	12.1
	-	-	-	-	(25.1 to 48.5)	(53.1 to 102.8)	(96.2 to 126.9)	(3.2 to 24.7)
	-	-	-	-	4.9	15.3	215.2	66.3
	-	-	-	-	(20.9 to 126.5)	(9.9 to 22.4)	(125.6 to 330.1)	(-19.3 to 133.8)
	-	-	-	-	0.0	0.0	21.3	-35.7
	-	-	-	-	(0.0 to 0.0)	(0.0 to 0.0)	(8.5 to 34.6)	(-4.1 to -29.7)
	-	-	-	-	10.0	19.3	94.0	0.9
	-	-	-	-	(7.0 to 13.2)	(13.5 to 26.1)	(77.1 to 109.8)	(-7.1 to 9.6)
	-	-	-	-	1.0	1.8	81.0	-5.2
	-	-	-	-	(0.6 to 1.4)	(1.1 to 2.6)	(34.7 to 175.5)	(-29.8 to 37.5)
	-	-	-	-	3.3	6.4	93.0	0.3
	-	-	-	-	(17.8 to 34.1)	(4.8 to 8.7)	(56.8 to 132.2)	(-16.6 to 19.8)
	-	-	-	-	2.4	7.0	106.0	11.3
	-	-	-	-	(17.1 to 22.4)	(8.8 to 9.5)	(53.2 to 160.4)	(-14.3 to 42.4)
	-	-	-	-	2.3	4.1	80.7	-9.6
	-	-	-	-	(32.1 to 25.2)	(2.7 to 5.9)	(35.2 to 153.6)	(-30.7 to 23.2)
	-	-	-	-	2.1	3.9	90.7	3.5
	-	-	-	-	(1.3 to 3.1)	(2.5 to 5.9)	(70.3 to 114.3)	(-7.2 to 15.9)

Appendix Table G.4 - Guinea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.2 (1.1 to 1.2)	2.4 (2.2 to 2.6)	109.8 (90.6 to 132.2)	0.0 (-2.3 to 14.7)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	109.9 (66.5 to 163.9)	109.9 (11.7 to 27.3)
Urolithiasis	13.5 (10.0 to 17.0)	21.9 (16.6 to 29.1)	64.1 (42.5 to 89.5)	-11.4 (-22.7 to -0.3)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	104.5 (78.8 to 133.9)	8.2 (-3.5 to 20.0)
Benign prostatic hyperplasia	39.9 (36.1 to 43.7)	74.3 (66.8 to 80.8)	87.3 (63.1 to 114.1)	3.1 (-9.3 to 17.2)	1.4 (0.9 to 2.0)	2.7 (1.7 to 3.8)	88.8 (64.8 to 116.7)	4.2 (-8.0 to 18.7)
Male infertility due to other causes	77.3 (58.9 to 97.2)	148.0 (119.5 to 181.6)	92.2 (39.6 to 163.0)	-3.5 (-29.4 to 33.3)	0.5 (0.2 to 0.9)	0.9 (0.4 to 1.8)	94.9 (42.8 to 173.2)	-3.3 (-27.9 to 35.1)
Other urinary diseases	-	-	-	-	0.0	0.0	0.0	-
Gynecological diseases	-	-	-	-	6.6	13.6	106.2	2.8
Uterine fibroids	94.9 (85.8 to 103.2)	180.1 (163.0 to 196.1)	90.6 (90.2 to 91.1)	-1.4 (-1.4 to -1.4)	1.7 (1.0 to 2.6)	3.1 (1.9 to 4.9)	86.2 (68.6 to 101.5)	-4.6 (-13.8 to 3.9)
Polycystic ovarian syndrome	85.7 (76.0 to 94.7)	171.6 (154.2 to 190.7)	100.8 (71.7 to 137.9)	-0.3 (-14.2 to 16.8)	0.8 (0.4 to 1.6)	1.7 (0.8 to 3.1)	101.5 (73.0 to 137.1)	0.3 (-14.0 to 17.1)
Female infertility due to other causes	83.9 (61.7 to 112.4)	151.6 (120.3 to 188.6)	82.3 (23.0 to 162.0)	-9.9 (-37.7 to 34.4)	0.4 (0.2 to 0.9)	0.8 (0.3 to 1.8)	82.8 (21.7 to 161.1)	-7.5 (-38.1 to 35.3)
Endometriosis	8.6 (7.3 to 9.9)	16.0 (13.5 to 18.3)	88.0 (48.5 to 131.8)	-5.6 (-25.4 to 14.6)	0.8 (0.5 to 1.1)	1.5 (1.0 to 2.1)	88.7 (46.6 to 134.3)	-5.5 (-26.2 to 16.9)
Genital prolapse	215.1 (189.7 to 243.8)	404.6 (353.5 to 460.4)	89.2 (58.1 to 126.2)	-1.8 (-17.4 to 14.7)	0.7 (0.3 to 1.3)	1.3 (0.6 to 2.4)	89.4 (57.8 to 128.2)	-1.5 (-17.5 to 15.3)
Premenstrual syndrome	193.0 (139.7 to 254.4)	491.4 (354.6 to 630.5)	151.1 (72.6 to 297.9)	24.7 (-12.9 to 96.2)	1.6 (0.9 to 2.6)	4.1 (2.4 to 6.8)	152.4 (74.4 to 302.7)	24.7 (-12.5 to 99.3)
Other gynecological diseases	17.5 (11.4 to 23.6)	35.0 (24.1 to 46.4)	99.4 (36.7 to 203.5)	-2.2 (-32.3 to 47.9)	0.6 (0.3 to 0.9)	1.1 (0.6 to 1.7)	95.2 (19.9 to 277.6)	-4.6 (-49.8 to 92.5)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	9.3	17.8	91.4	-0.8
Thalassemias	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	73.1 (-15.8 to 97.0)	-11.7 (-56.7 to 0.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.0 (34.1 to 85.4)	-13.8 (-31.1 to -5.3)
Thalassemia trait	48.8 (37.3 to 61.0)	93.2 (66.3 to 121.9)	95.3 (39.1 to 107.5)	-0.0 (-28.8 to 6.2)	0.9 (0.6 to 1.3)	1.6 (1.0 to 2.3)	83.2 (54.8 to 121.1)	-4.6 (-18.4 to 13.5)
Sickle cell disorders	14.7 (12.6 to 16.8)	30.9 (26.7 to 34.8)	110.7 (83.1 to 139.5)	8.9 (-5.4 to 23.6)	1.6 (1.1 to 2.2)	3.4 (2.3 to 4.7)	116.1 (81.0 to 156.6)	11.0 (-6.0 to 30.7)
Sickle cell trait	990.8 (881.7 to 1,087.6)	1,953.3 (1,739.0 to 2,132.7)	974.4 (89.4 to 107.2)	11.1 (-3.0 to 6.1)	4.7 (3.1 to 6.7)	8.8 (5.7 to 12.8)	89.8 (56.0 to 122.2)	21.5 (-13.2 to 14.3)
G6PD deficiency	272.1 (207.1 to 329.8)	602.3 (502.9 to 708.7)	123.0 (66.8 to 202.5)	14.3 (-14.5 to 54.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	107.9 (60.1 to 170.5)	7.1 (-8.9 to 26.8)
G6PD trait	860.0 (754.5 to 948.8)	1,503.3 (1,342.5 to 1,645.0)	75.0 (52.8 to 105.6)	-10.5 (-21.9 to 5.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	85.7 (23.3 to 175.1)	-4.6 (-32.6 to 40.9)
Other hemoglobinopathies and hemolytic anemias	64.1 (53.0 to 74.5)	117.9 (105.0 to 130.7)	84.4 (57.3 to 123.0)	-3.5 (-15.3 to 12.2)	2.1 (1.3 to 3.1)	3.8 (2.5 to 5.5)	78.2 (51.0 to 143.1)	-6.4 (-24.2 to 24.6)
Endocrine, metabolic, blood, and immune disorders	80.7 (70.8 to 89.9)	146.2 (114.8 to 168.3)	82.3 (33.3 to 133.2)	3.1 (-24.2 to 16.7)	5.4 (2.0 to 4.4)	5.4 (3.2 to 8.1)	77.4 (18.8 to 139.8)	5.5 (-31.9 to 19.8)
Musculoskeletal disorders	-	-	-	-	74.0	139.6	88.1	-2.6
Rheumatoid arthritis	8.3 (7.9 to 8.7)	11.2 (10.7 to 11.8)	36.0 (27.3 to 46.9)	-34.2 (-38.4 to -28.9)	1.9 (1.4 to 2.6)	2.7 (1.9 to 3.6)	38.5 (24.8 to 54.0)	-33.1 (-39.1 to -26.5)
Osteoarthritis	122.4 (117.2 to 127.5)	229.0 (219.1 to 238.7)	87.7 (77.1 to 99.2)	1.1 (-4.2 to 7.0)	7.4 (5.2 to 10.1)	14.1 (9.8 to 19.2)	89.0 (78.1 to 100.5)	1.9 (-3.7 to 7.7)
Low back and neck pain	-	-	-	-	55.1	104.5	89.0	-2.8
Low back pain	325.5 (273.5 to 383.1)	602.0 (489.0 to 731.0)	84.7 (39.5 to 145.4)	-4.1 (-25.6 to 23.6)	35.9 (23.6 to 53.1)	67.2 (43.6 to 95.9)	86.3 (40.6 to 148.3)	-3.5 (-25.8 to 24.4)
Neck pain	196.0 (161.5 to 235.4)	378.6 (320.2 to 434.8)	93.5 (62.3 to 136.2)	-2.4 (-18.9 to 18.9)	19.1 (12.5 to 27.8)	37.3 (25.2 to 52.5)	94.7 (63.0 to 137.9)	-2.0 (-18.2 to 20.2)
Gout	0.5 (0.5 to 0.6)	1.0 (0.9 to 1.1)	87.6 (58.7 to 120.0)	-0.0 (-14.1 to 16.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.8 (49.8 to 144.4)	0.6 (-20.5 to 30.8)
Other musculoskeletal disorders	106.6 (81.2 to 133.3)	201.2 (152.5 to 252.2)	89.7 (75.1 to 103.7)	1.0 (-7.4 to 8.1)	9.6 (6.1 to 14.0)	9.6 (11.7 to 27.2)	91.1 (75.3 to 106.1)	1.7 (-6.9 to 9.4)
Other non-communicable diseases	-	-	-	-	77.2	148.6	92.4	-0.8
Congenital anomalies	-	-	-	-	50.4 to 113.6	97.2 to 218.3	144.9	26.5
Neural tube defects	0.2 (0.2 to 0.3)	1.6 (1.3 to 1.9)	615.2 (421.2 to 812.3)	342.5 (217.1 to 473.1)	0.0 (0.0 to 0.1)	0.4 (0.3 to 0.6)	729.5 (450.5 to 1,115.6)	446.0 (265.5 to 684.2)
Congenital heart anomalies	2.0 (1.4 to 2.7)	15.2 (11.5 to 19.3)	695.8 (387.1 to 1,108.6)	388.7 (185.1 to 669.2)	0.1 (0.0 to 0.1)	0.5 (0.2 to 1.0)	480.0 (215.9 to 873.6)	245.9 (93.2 to 467.8)
Orofacial clefts	0.2 (0.1 to 0.3)	1.8 (1.2 to 2.6)	808.3 (458.0 to 1,432.3)	560.2 (288.6 to 1,056.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	480.0 (392.1 to 1,632.0)	548.2 (252.1 to 1,166.7)
Down syndrome	1.8 (1.4 to 2.2)	7.2 (6.2 to 8.4)	305.1 (215.0 to 459.5)	120.3 (69.0 to 206.6)	0.2 (0.1 to 0.3)	0.8 (0.6 to 1.1)	303.2 (203.3 to 475.2)	118.1 (63.9 to 210.0)
Turner syndrome	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	220.5 (113.0 to 407.4)	68.3 (10.3 to 164.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	226.1 (112.7 to 420.3)	68.7 (9.9 to 165.9)
Klinefelter syndrome	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.3)	106.1 (49.5 to 203.1)	6.0 (-23.6 to 56.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	110.5 (52.7 to 209.7)	6.4 (-23.2 to 56.4)
Chromosomal unbalanced rearrangements	12.9 (2.2 to 32.8)	11.7 (9.8 to 14.3)	908.1 (192.4 to 487.7)	12.7 (57.7 to 221.6)	0.3 (0.2 to 0.5)	1.4 (1.0 to 1.9)	309.5 (187.5 to 496.6)	21.5 (55.9 to 225.2)
Other congenital anomalies	27.3 (19.7 to 36.7)	49.0 (38.0 to 63.2)	79.9 (52.0 to 129.0)	-7.4 (-22.2 to 16.3)	2.5 (1.4 to 4.2)	4.6 (2.6 to 7.6)	83.2 (36.3 to 143.1)	-5.8 (-28.7 to 28.8)
Skin and subcutaneous diseases	-	-	-	-	27.2	55.4	103.6	1.8
Dermatitis	256.6 (201.9 to 221.7)	506.5 (395.9 to 634.6)	98.2 (97.0 to 99.6)	-0.1 (-0.2 to -0.0)	7.3 (4.5 to 10.6)	14.5 (8.9 to 20.9)	99.1 (92.1 to 107.2)	0.3 (-2.5 to 3.2)
Psoriasis	40.4 (31.8 to 48.7)	79.5 (62.4 to 95.6)	97.5 (95.4 to 98.9)	0.0 (-0.0 to 0.1)	3.3 (2.1 to 4.7)	6.5 (4.2 to 9.4)	98.5 (86.4 to 111.5)	0.6 (-4.3 to 5.8)
Cellulitis	1.1 (0.9 to 1.4)	2.1 (1.6 to 2.7)	94.4 (53.5 to 133.6)	-1.8 (-24.4 to 20.2)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	93.7 (38.6 to 166.5)	-1.4 (-28.2 to 30.7)
Pyoderma	10.2 (7.5 to 13.1)	17.9 (13.4 to 23.0)	76.9 (65.7 to 91.0)	-4.1 (-10.5 to 3.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	77.4 (59.8 to 97.5)	-4.0 (-12.7 to 5.9)
Scabies	100.0 (75.3 to 130.8)	102.5 (87.1 to 126.2)	4.2 (-27.6 to 46.2)	-45.2 (-61.6 to -23.1)	2.6 (1.4 to 4.3)	2.7 (1.5 to 4.4)	4.2 (-27.6 to 46.5)	-4.1 (-61.4 to -22.6)
Fungal skin diseases	710.5 (518.5 to 992.8)	1,419.0 (1,031.9 to 1,979.7)	100.5 (97.9 to 102.7)	0.2 (0.1 to 0.2)	4.0 (1.5 to 9.0)	8.0 (5.0 to 12.2)	101.2 (92.6 to 103.7)	0.5 (-0.2 to 1.3)
Viral skin diseases	86.9 (68.3 to 108.8)	169.5 (131.5 to 209.8)	95.7 (85.3 to 108.1)	-0.9 (-5.0 to 4.0)	2.7 (1.6 to 4.3)	5.3 (3.1 to 8.3)	96.2 (83.1 to 110.9)	-0.5 (-6.1 to 5.6)
Acne vulgaris	344.6 (260.3 to 475.5)	946.4 (646.1 to 1,288.0)	177.5 (60.9 to 313.4)	32.6 (-22.6 to 96.7)	3.7 (1.7 to 7.4)	10.2 (4.7 to 20.0)	177.3 (60.8 to 314.6)	32.7 (-22.5 to 97.5)
Alopecia areata	5.3 (4.8 to 6.0)	10.5 (9.3 to 11.9)	98.5 (70.1 to 135.4)	0.8 (-13.8 to 21.4)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	99.6 (62.0 to 146.4)	2.0 (-16.8 to 25.5)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.9 (49.8 to 140.6)	0.6 (-21.8 to 26.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.9 (49.6 to 140.7)	-0.6 (-21.8 to 26.9)
Urticaria	22.9 (14.0 to 34.0)	63.1 (41.2 to 86.4)	173.5 (58.3 to 380.4)	32.1 (-21.4 to 122.9)	1.3 (0.7 to 2.3)	3.8 (2.1 to 5.9)	176.0 (56.9 to 391.2)	33.1 (-20.1 to 127.4)
Decubitus ulcer	0.5 (0.4 to 0.6)	1.0 (0.9 to 1.2)	113.9 (67.2 to 166.1)	10.1 (-19.3 to 50.4)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	115.0 (62.2 to 172.6)	11.1 (-18.8 to 54.5)
Other skin and subcutaneous diseases	342.1 (231.7 to 493.1)	627.9 (426.5 to 910.7)	84.8 (72.6 to 93.8)	-5.3 (-12.6 to -1.3)	2.0 (0.9 to 3.1)	3.7 (1.6 to 7.7)	85.7 (73.6 to 95.1)	-4.7 (-11.9 to -0.6)
Sense organ diseases	-	-	-	-	39.5	71.2	80.1	-3.4
Glaucoma	4.1 (2.9 to 5.3)	14.7 (11.2 to 19.0)	271.3 (161.9 to 387.3)	86.5 (33.5 to 137.1)	0.3 (0.2 to 0.5)	1.1 (0.7 to 1.6)	253.2 (153.6 to 361.4)	74.2 (27.0 to 122.2)
Cataract	18.8 (12.4 to 28.1)	56.7 (43.1 to 72.9)	206.8 (111.7 to 344.8)	44.6 (6.2 to 97.5)	1.7 (1.1 to 2.7)	4.7 (2.9 to 7.0)	169.0 (96.3 to 276.4)	29.3 (1.3 to 74.0)
Macular degeneration	3.6 (2.4 to 5.4)	27.0 (18.8 to 38.6)	650.5 (420.5 to 1,009.0)	264.2 (161.4 to 419.2)	0.2 (0.1 to 0.3)	1.5 (0.9 to 2.3)	578.5 (381.2 to 884.8)	208.7 (124.9 to 326.8)
Uncorrected refractive error	547.9 (437.3 to 673.8)	947.7 (737.4 to 1,152.5)	72.1 (30.9 to 135.7)	-10.1 (-28.4 to 15.5)	11.1 (7.1 to 16.9)	18.1 (11.3 to 28.2)	62.3 (39.7 to 92.4)	-15.4 (-24.4 to -2.0)
Age-related and other hearing loss	787.0 (663.9 to 890.6)	1,377.3 (1,174.2 to 1,556.7)	75.7 (66.2 to 85.2)	-6.2 (-10.0 to -2.2)	21.2 (12.7 to 32.3)	46.2 (21.5 to 56.4)	69.2 (50.2 to 90.4)	-10.5 (-18.2 to -2.9)
Other vision loss	12.9 (10.1 to 16.4)	29.8 (23.3 to 37.2)	133.2 (91.6 to 175.2)	34.8 (9.3 to 60.8)	1.1 (0.7 to 1.8)	2.7 (1.7 to 4.0)	135.6 (89.4 to 185.5)	31.0 (5.1 to 59.1)
Other sense organ diseases	142.3 (134.8 to 149.5)	271.5 (256.2 to 288.6)	91.6 (76.5 to 107.9)	-0.5 (-7.2 to 6.3)	3.8 (2.3 to 5.5)	7.2 (4.5 to 10.7)	92.7 (76.6 to 111.0)	0.1 (-7.1 to 7.7)
Oral disorders	-	-	-	-	7.3	14.2	95.2	-0.3
Deciduous caries	566.2 (537.3 to 600.6)	1,065.5 (1,006.4 to 1,121.2)	89.0 (75.3 to 104.4)	-0.1 (-7.5 to 7.5)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.8)	83.8 (72.8 to 109.7)	0.0 (-8.9 to 10.9)
Permanent caries	1,488.6 (1,340.9 to 1,631.9)	3,035.3 (2,805.6 to 3,342.7)	104.1 (80.3 to 135.1)	1.6 (-10.2 to 17.5)	1.5 (0.7 to 2.8)	3.0 (1.3 to 5.8)	104.9 (80.5 to 136.6)	2.0 (-9.9 to 18.3)
Periodontal diseases	364.5 (333.9 to 400.5)	698.7 (628.9 to 779.8)	93.2 (65.3 to 122.1)	1.3 (-14.9 to 17.8)	2.4 (0.9 to 4.8)	4.6 (1.8 to 9.4)	94.2 (66.0 to 123.0)	1.8 (-14.4 to 18.6)

Appendix Table G.4 - Guinea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	23.7 (21.8 to 25.6)	40.7 (37.5 to 44.0)	72.3 (53.5 to 94.3)	-7.6 (-16.6 to 3.2)	0.6 (0.4 to 0.9)	1.1 (0.7 to 1.6)	73.4 (54.2 to 98.3)	-6.7 (-16.0 to 5.1)
Other oral disorders	88.6 (83.4 to 93.6)	173.0 (163.6 to 182.7)	96.1 (82.3 to 113.3)	-1.3 (-8.3 to 6.5)	2.6 (1.6 to 3.9)	5.1 (3.2 to 7.6)	97.0 (81.4 to 115.4)	-0.9 (-8.5 to 7.5)
Injuries	-	-	-	-	22.0 (16.7 to 28.2)	40.3 (30.7 to 51.5)	83.4 (77.5 to 90.7)	-2.1 (-5.1 to 2.2)
Transport injuries	-	-	-	-	9.0 (6.8 to 11.6)	16.4 (12.4 to 21.2)	81.7 (73.3 to 90.2)	-1.0 (-4.9 to 3.0)
Road injuries	-	-	-	-	8.3 (6.2 to 10.7)	14.9 (11.3 to 19.2)	79.8 (70.7 to 89.0)	-2.3 (-6.5 to 2.2)
Pedestrian road injuries	-	-	-	-	2.1 (1.6 to 2.8)	3.5 (2.6 to 4.6)	64.6 (50.7 to 79.8)	-8.7 (-14.6 to -2.0)
Cyclist road injuries	-	-	-	-	0.7 (0.5 to 0.9)	1.1 (0.8 to 1.4)	47.8 (38.7 to 58.9)	-15.0 (-20.0 to -9.2)
Motorcyclist road injuries	-	-	-	-	1.2 (0.9 to 1.6)	1.9 (1.4 to 2.5)	52.0 (40.2 to 63.6)	-18.1 (-24.0 to -12.3)
Motor vehicle road injuries	-	-	-	-	4.1 (3.0 to 5.2)	8.2 (6.2 to 10.6)	102.7 (86.2 to 121.0)	8.9 (1.0 to 17.8)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	40.3 (31.8 to 49.7)	-28.2 (-31.9 to -24.0)
Other transport injuries	-	-	-	-	0.7 (0.6 to 1.0)	1.5 (1.1 to 2.0)	103.6 (92.3 to 116.4)	12.8 (6.6 to 19.8)
Unintentional injuries	-	-	-	-	12.3 (9.4 to 15.8)	21.8 (16.6 to 28.2)	77.6 (73.1 to 82.3)	-6.7 (-9.4 to -4.1)
Falls	-	-	-	-	4.9 (3.7 to 6.3)	9.3 (6.9 to 12.0)	90.2 (81.3 to 98.6)	-3.1 (-7.8 to 1.4)
Drowning	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	43.5 (29.8 to 57.5)	-24.0 (-29.7 to -17.9)
Fire, heat, and hot substances	-	-	-	-	0.8 (0.6 to 1.0)	1.2 (0.9 to 1.5)	54.4 (40.1 to 67.8)	-17.5 (-23.6 to -12.0)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	46.5 (23.0 to 72.6)	-25.2 (-35.6 to -14.2)
Exposure to mechanical forces	-	-	-	-	3.9 (3.0 to 5.0)	6.6 (5.0 to 8.7)	70.8 (63.7 to 78.6)	-10.1 (-13.7 to -6.3)
Unintentional firearm injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	70.6 (58.9 to 82.7)	-10.2 (-15.9 to -4.3)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	123.6 (101.3 to 146.2)	16.3 (6.2 to 26.6)
Other exposure to mechanical forces	-	-	-	-	3.7 (2.8 to 4.8)	6.2 (4.7 to 8.3)	70.2 (62.9 to 78.3)	-10.3 (-14.2 to -6.5)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	110.3 (95.7 to 123.0)	15.1 (7.2 to 22.7)
Animal contact	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	73.1 (61.0 to 84.4)	-8.4 (-13.8 to -3.4)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	74.6 (54.1 to 98.3)	-8.6 (-18.1 to 1.7)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	71.2 (62.7 to 81.4)	-8.5 (-12.4 to -4.2)
Foreign body	-	-	-	-	0.3 (0.2 to 0.3)	0.5 (0.4 to 0.6)	88.9 (79.4 to 99.2)	-0.4 (-5.0 to 4.5)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	76.3 (51.7 to 98.2)	-3.2 (-13.2 to 5.1)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	94.3 (75.8 to 115.6)	-0.6 (-9.3 to 8.0)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	92.5 (80.7 to 105.6)	0.7 (-5.2 to 7.5)
Other unintentional injuries	-	-	-	-	1.9 (1.4 to 2.4)	3.2 (2.4 to 4.2)	71.9 (61.6 to 83.3)	-8.4 (-13.6 to -2.3)
Self-harm and interpersonal violence	-	-	-	-	0.5 (0.4 to 0.7)	0.9 (0.7 to 1.2)	76.2 (67.1 to 85.1)	-7.5 (-11.8 to -3.0)
Self-harm	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	93.8 (79.9 to 109.4)	2.1 (-4.0 to 9.5)
Interpersonal violence	-	-	-	-	0.5 (0.3 to 0.6)	0.8 (0.6 to 1.0)	73.2 (63.0 to 82.8)	-9.7 (-14.7 to -4.8)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	78.8 (68.6 to 89.6)	-6.5 (-11.4 to -1.2)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	103.0 (90.2 to 117.3)	4.6 (-1.7 to 12.0)
Assault by other means	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.6)	64.4 (51.0 to 77.3)	-14.2 (-20.8 to -8.0)
Forces of nature, war, and legal intervention	-	-	-	-	0.1 (0.0 to 0.2)	1.1 (0.4 to 2.7)	1,036.7 (482.6 to 2,231.9)	557.0 (234.9 to 1,279.5)
Exposure to forces of nature	-	-	-	-	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-50.5 (-54.8 to -45.9)	65.6 (-69.0 to -62.1)
Collective violence and legal intervention	-	-	-	-	-	1.0 (0.4 to 2.7)	-	-

Appendix Table G.4 - Guinea-Bissau prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	104.4 (76.3 to 137.6)	165.2 (119.2 to 217.8)	58.6 (49.3 to 65.5)	58.6 (-13.1 to -1.8)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	34.5 (24.0 to 48.2)	52.4 (36.2 to 73.4)	51.6 (41.9 to 64.4)	-7.6 (-15.2 to 3.5)
HIV/AIDS and tuberculosis	-	-	-	-	1.0 (0.7 to 1.3)	8.7 (5.5 to 13.0)	772.1 (549.3 to 1,130.9)	361.9 (236.5 to 567.5)
Tuberculosis	2.9 (2.7 to 3.2)	5.7 (5.3 to 6.1)	94.2 (81.6 to 107.1)	8.3 (1.8 to 15.3)	0.9 (0.6 to 1.2)	1.7 (1.2 to 2.3)	95.9 (81.3 to 111.9)	9.3 (1.8 to 17.5)
HIV/AIDS	-	-	-	-	0.1 (0.1 to 0.1)	6.9 (4.1 to 11.0)	7,203.2 (4,419.8 to 11,915.4)	4,070.0 (2,442.6 to 6,936.3)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.9 (0.5 to 1.3)	4,762.1 (3,058.6 to 7,369.7)	2,729.0 (1,735.8 to 4,322.2)	0.0 (0.0 to 0.0)	0.3 (0.2 to 0.6)	4,655.1 (2,646.5 to 8,240.9)	2,634.8 (1,525.1 to 4,686.1)
HIV/AIDS resulting in other diseases	0.9 (0.6 to 1.3)	44.2 (32.4 to 57.6)	4,820.2 (3,097.8 to 7,644.6)	2,659.9 (1,683.8 to 4,244.7)	0.1 (0.0 to 0.1)	6.6 (3.8 to 10.5)	7,439.3 (4,434.7 to 12,772.4)	4,198.4 (2,461.9 to 7,411.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	2.8 (4.4 to 8.3)	23.5 (5.6 to 10.5)	25.9 (12.8 to 40.9)	-20.9 (-28.6 to -12.5)
Diarrheal diseases	17.3 (15.1 to 19.4)	22.3 (19.6 to 25.1)	28.5 (8.1 to 53.8)	-15.8 (-27.4 to -1.7)	2.8 (1.9 to 3.9)	3.6 (2.4 to 5.1)	22.8 (8.4 to 54.4)	-15.5 (-27.4 to -6.6)
Intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-0.1 (-42.1 to 7.9)	-49.9 (-63.8 to -34.1)
Typhoid fever	0.3 (0.3 to 0.4)	0.3 (0.2 to 0.4)	-15.5 (-33.6 to 5.6)	-46.9 (-59.1 to -34.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-14.0 (-37.0 to 16.5)	-46.0 (-59.9 to -28.6)
Paratyphoid fever	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	5.7 (-22.1 to 37.4)	-35.8 (-52.5 to -15.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.5 (-25.8 to 47.4)	35.3 (-54.1 to -11.4)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-66.9 (-92.5 to -22.4)	-79.6 (-95.4 to -22.4)
Lower respiratory infections	1.0 (0.8 to 1.2)	1.1 (0.8 to 1.3)	14.7 (-22.4 to 48.3)	-17.8 (-37.2 to 1.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	14.7 (-23.7 to 52.1)	-17.5 (-38.4 to 4.4)
Upper respiratory infections	58.8 (53.4 to 64.1)	96.0 (87.1 to 104.8)	62.7 (44.3 to 85.9)	-1.7 (-12.8 to 12.5)	0.7 (0.4 to 1.2)	1.1 (0.6 to 1.9)	63.2 (44.2 to 86.5)	-1.4 (-12.5 to 13.1)
Otitis media	22.1 (19.9 to 24.3)	34.2 (31.5 to 37.5)	54.4 (40.7 to 72.5)	-7.4 (-16.5 to 4.7)	0.5 (0.3 to 0.7)	0.7 (0.4 to 1.1)	54.8 (39.5 to 72.9)	-6.9 (-16.6 to 4.9)
Meningitis	-	-	-	-	2.0 (1.4 to 2.7)	2.1 (1.4 to 2.9)	6.5 (-15.6 to 33.8)	-33.9 (-47.5 to -19.9)
Pneumococcal meningitis	9.4 (5.6 to 13.9)	8.9 (5.5 to 12.7)	-3.6 (-28.5 to 19.5)	-40.9 (-55.8 to -26.8)	0.8 (0.5 to 1.1)	0.8 (0.6 to 1.1)	2.2 (-22.8 to 32.9)	-37.3 (-52.6 to -20.3)
H influenzae type B meningitis	3.6 (1.4 to 6.7)	3.5 (1.4 to 6.6)	-4.8 (-40.4 to 81.9)	-43.0 (-63.5 to 3.5)	0.4 (0.2 to 0.6)	0.5 (0.2 to 0.8)	14.4 (-39.5 to 168.9)	-31.2 (-63.8 to 59.7)
Meningococcal meningitis	4.2 (1.4 to 8.8)	4.4 (1.8 to 9.1)	4.1 (-16.3 to 44.9)	-36.3 (-48.1 to -11.9)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.8)	7.5 (-17.1 to 61.0)	-33.7 (-46.9 to -3.1)
Other meningitis	2.6 (1.6 to 4.0)	2.4 (1.6 to 3.6)	-5.5 (-28.0 to 17.3)	-39.0 (-54.4 to -23.0)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-5.5 (-26.2 to 24.6)	-38.2 (-52.4 to -17.0)
Encephalitis	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.7)	69.0 (53.8 to 88.8)	-6.5 (-6.5 to 9.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	73.2 (48.2 to 101.3)	2.0 (-9.9 to 15.9)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.9 (-95.2 to 2,182.4)	-38.8 (-95.4 to 901.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.9 (95.3 to 2,185.3)	-38.8 (-95.4 to 904.3)
Whooping cough	1.0 (0.8 to 1.3)	0.7 (0.5 to 0.8)	-35.0 (-38.3 to -31.7)	-55.8 (-58.0 to -53.5)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-35.0 (-43.4 to -25.2)	-55.7 (-61.6 to -48.8)
Tetanus	0.4 (0.2 to 0.6)	0.1 (0.0 to 0.2)	-72.9 (-93.4 to -34.5)	-84.1 (-96.3 to -48.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-65.1 (-87.0 to -24.7)	-79.4 (-92.3 to -55.1)
Measles	0.3 (0.3 to 0.4)	0.1 (0.1 to 0.1)	-76.8 (-80.9 to -72.1)	-84.4 (-87.2 to -81.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-84.4 (-84.5 to -85.2)	-84.4 (-89.6 to -75.6)
Varicella and herpes zoster	0.6 (0.6 to 0.7)	1.1 (1.0 to 1.2)	73.7 (47.8 to 98.2)	2.3 (-19.7 to 24.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.2 (22.1 to 135.4)	1.7 (-31.5 to 41.1)
Neglected tropical diseases and malaria	-	-	-	-	11.6 (7.3 to 18.0)	12.8 (7.5 to 21.5)	9.6 (8.9 to 30.2)	-37.3 (-50.1 to -24.1)
Malaria	201.3 (185.9 to 217.9)	222.1 (201.8 to 249.1)	10.1 (1.7 to 20.5)	-36.0 (-41.5 to -29.8)	2.1 (1.3 to 3.0)	2.3 (1.5 to 3.4)	9.9 (-0.4 to 22.1)	-34.0 (-39.5 to -27.0)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.3 (6.5 to 557.2)	-3.8 (-46.5 to 270.8)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.2 (9.1 to 126.8)	-3.2 (-29.1 to 37.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.2 (9.0 to 127.5)	-3.2 (-29.3 to 37.7)
Cutaneous and mucocutaneous leishmaniasis	1.1 (0.4 to 2.0)	2.0 (1.2 to 3.4)	66.5 (-5.5 to 542.4)	-4.5 (-46.8 to 262.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.3 (-6.5 to 557.9)	-3.8 (-46.5 to 270.9)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	271.6 (73.5 to 578.3)	468.7 (126.9 to 997.8)	72.5 (67.6 to 77.4)	0.0 (-2.6 to 2.7)	2.7 (0.8 to 7.0)	4.6 (1.4 to 12.2)	72.6 (47.5 to 81.7)	0.1 (-12.9 to 6.1)
Cysticercosis	0.9 (0.4 to 1.8)	0.8 (0.3 to 1.7)	-9.1 (-79.3 to 156.6)	-47.7 (83.0 to 38.5)	0.2 (0.1 to 0.5)	0.2 (0.1 to 0.5)	-4.6 (-79.5 to 171.9)	-45.4 (82.8 to 46.2)
Cystic echinococcosis	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	3.8 (-7.0 to 23.0)	-32.0 (-36.9 to -21.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.0 (-20.3 to 41.5)	-31.2 (-43.5 to -14.2)
Lymphatic filariasis	58.5 (44.7 to 72.4)	99.2 (74.6 to 123.6)	67.1 (29.1 to 153.2)	-0.1 (-22.7 to 32.9)	1.7 (0.9 to 2.9)	3.0 (1.4 to 5.3)	77.5 (22.2 to 126.3)	3.8 (-33.2 to 50.1)
Onchocerciasis	49.1 (37.0 to 64.9)	-	100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	2.4 (1.4 to 3.8)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Trachoma	2.3 (1.0 to 4.2)	2.2 (1.2 to 4.1)	-0.3 (-53.2 to 67.2)	-45.1 (-72.4 to -11.9)	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-3.1 (-50.4 to 55.4)	-46.1 (-69.1 to -17.5)
Dengue	0.1 (0.1 to 0.3)	1.0 (0.4 to 2.3)	714.0 (706.0 to 723.3)	386.0 (381.2 to 391.5)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.4)	722.8 (547.6 to 984.0)	392.7 (298.3 to 517.4)
Yellow fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.5 (-77.9 to -10.1)	-74.0 (-83.3 to -50.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.5 (-78.2 to -30.0)	-74.0 (-85.4 to -50.6)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.3 (-33.1 to 58.1)	-40.7 (-61.9 to 12.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.3 (-33.1 to 58.7)	-30.7 (-62.0 to 12.1)
Intestinal nematode infections	-	-	-	-	1.2 (0.7 to 1.8)	1.0 (0.6 to 1.6)	-14.5 (-29.1 to -0.1)	-49.5 (-59.2 to -40.3)
Ascariasis	58.3 (46.6 to 71.2)	36.4 (29.3 to 44.9)	-37.3 (-54.0 to -16.9)	-62.9 (-74.1 to -47.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.0 (-58.8 to -6.7)	-62.5 (-75.5 to -38.4)
Trichuriasis	90.4 (71.4 to 114.7)	56.3 (44.3 to 71.3)	-38.0 (-55.8 to -11.6)	-62.9 (-75.2 to -43.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.2 (-62.1 to 0.9)	-62.2 (-77.4 to -37.4)
Hookworm disease	278.5 (233.9 to 340.0)	246.0 (203.5 to 293.4)	-12.0 (-31.7 to 14.1)	-48.2 (-61.7 to -30.0)	2.3 (0.7 to 1.8)	2.3 (0.6 to 1.6)	-14.3 (-29.1 to 0.2)	-49.3 (-59.2 to -40.2)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	20.5 (15.2 to 26.0)	31.3 (29.0 to 34.3)	53.0 (20.0 to 106.5)	-5.0 (-23.5 to 22.8)	1.1 (0.6 to 1.7)	1.4 (0.9 to 2.2)	30.8 (4.9 to 78.7)	-25.4 (-44.9 to -10.0)
Maternal disorders	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	30.7 (13.7 to 54.4)	-26.9 (-36.3 to -14.3)
Maternal hemorrhage	0.3 (0.2 to 0.4)	0.7 (0.4 to 0.9)	141.1 (93.3 to 270.7)	25.7 (-27.2 to 96.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	78.7 (-10.5 to 202.3)	-5.1 (-52.9 to 60.1)
Maternal sepsis and other maternal infections	0.5 (0.3 to 0.7)	0.5 (0.4 to 0.8)	14.7 (-14.5 to 46.2)	-35.3 (-50.5 to -38.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.1 (-44.6 to 213.3)	-39.4 (-67.7 to 52.8)
Maternal hypertensive disorders	0.4 (0.1 to 0.7)	0.5 (0.2 to 0.9)	37.7 (24.5 to 48.4)	-26.9 (-31.8 to -22.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	35.7 (15.8 to 62.3)	-27.5 (-37.8 to -14.5)
Obstructed labor	0.6 (0.4 to 0.8)	0.8 (0.5 to 1.0)	26.0 (14.4 to 42.1)	-28.6 (-35.7 to -19.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	26.8 (8.7 to 50.4)	-28.2 (-38.1 to -15.2)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.8 (8.0 to 172.3)	-12.5 (-49.5 to 33.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.8 (8.0 to 173.1)	-12.5 (-49.7 to 34.4)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	31.0 (-12.7 to 110.1)	-26.7 (-51.2 to 17.7)
Neonatal disorders	-	-	-	-	0.5 (0.3 to 0.9)	1.3 (0.8 to 2.0)	171.4 (79.6 to 339.4)	75.8 (8.3 to 193.5)
Preterm birth complications	2.9 (1.3 to 6.0)	10.5 (5.2 to 19.6)	258.2 (206.0 to 347.7)	113.3 (82.9 to 161.4)	0.1 (0.1 to 0.2)	0.7 (0.4 to 1.1)	380.9 (196.8 to 854.3)	194.5 (91.4 to 468.1)
Neonatal encephalopathy due to birth asphyxia and trauma	7.6 (0.6 to 24.2)	9.9 (0.9 to 31.4)	32.1 (6.5 to 76.7)	-20.8 (-35.4 to -9.4)	0.2 (0.1 to 0.5)	0.8 (0.1 to 0.8)	46.2 (-9.2 to 163.8)	-8.8 (-38.8 to 83.4)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	143.4 (124.7 to 156.7)	73.7 (60.4 to 83.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	143.4 (117.6 to 169.1)	75.0 (55.3 to 92.1)
Hemolytic disease and other neonatal jaundice	0.1 (0.1 to 0.3)	0.4 (0.2 to 0.8)	152.9 (-4.2 to 518.9)	74.2 (-39.7 to 340.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	168.4 (-13.3 to 575.8)	81.0 (-38.7 to 389.7)
Other neonatal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	118.6 (8.8 to 383.8)	42.5 (-37.3 to 211.8)
Nutritional deficiencies	-	-	-	-	14.1 (9.5 to 20.2)	42.0 (13.5 to 28.5)	42.0 (31.3 to 52.9)	-13.7 (-18.4 to -8.1)
Protein-energy malnutrition	9.1 (4.3 to 16.4)	8.8 (4.5 to 16.2)	-4.8 (-63.5 to 160.0)	-30.5 (-70.4 to 67.8)	1.1 (0.4 to 2.2)	1.1 (0.5 to 2.2)	4.6 (-63.3 to 161.4)	-30.9 (-70.7 to 71.5)
Iodine deficiency	40.7 (31.1 to 51.1)	33.3 (19.8 to 52.3)	-18.9 (-53.2 to 35.1)	-53.2 (-74.3 to -21.9)	0.7 (0.4 to 1.1)	0.6 (0.3 to 1.1)	-18.6 (-52.9 to 37.7)	53.0 (-74.2 to -21.4)
Vitamin A deficiency	2.6 (1.8 to 3.6)	2.6 (1.6 to 3.6)	-2.3 (-24.2 to 21.4)	-35.7 (-49.8 to -22.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-2.0 (-22.2 to 19.7)	-35.8 (-49.5 to -20.1)

Appendix Table G.4 - Guinea-Bissau prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	318.7 (312.8 to 324.3)	494.6 (483.6 to 505.4)	55.3 (51.2 to 59.1)	-7.2 (-10.0 to -4.5)	12.2 (8.2 to 17.5)	18.3 (12.2 to 26.0)	50.1 (46.1 to 54.7)	18.3 (11.3 to -5.2)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.5 (64.3 to 318.8)	-12.0 (-72.9 to 177.8)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.9 (0.6 to 1.3)	1.4 (0.9 to 2.0)	48.1 (36.9 to 71.7)	-13.2 (-20.5 to -2.6)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.6)	68.6 (34.3 to 128.0)	-8.5 (-25.2 to 15.4)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-6.0 (-20.9 to 15.0)	-43.5 (-51.7 to -33.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.0)	43.3 (-27.6 to 26.8)	43.3 (-54.2 to -27.3)
Chlamydial infection	14.0 (9.9 to 18.2)	23.3 (13.6 to 32.7)	68.7 (-9.2 to 187.6)	-7.2 (-49.2 to 55.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	67.6 (-3.6 to 209.3)	-6.7 (-45.5 to 60.4)
Gonococcal infection	5.3 (3.3 to 6.8)	8.5 (6.3 to 11.0)	57.2 (14.3 to 174.2)	-14.3 (-37.2 to 45.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	57.1 (5.9 to 158.7)	-13.9 (-40.3 to 35.2)
Trichomoniasis	9.0 (5.4 to 13.4)	25.9 (17.6 to 35.2)	192.3 (65.3 to 406.0)	46.3 (-13.7 to 156.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	210.3 (65.6 to 507.6)	54.0 (-15.4 to 205.6)
Genital herpes	159.8 (146.8 to 172.9)	279.9 (256.0 to 302.6)	75.1 (56.5 to 95.6)	-7.2 (-11.0 to 10.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	76.5 (56.0 to 100.3)	43.2 (-11.7 to 12.3)
Other sexually transmitted diseases	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.8)	40.2 (12.2 to 76.8)	-19.9 (-36.2 to 1.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.9 (-0.1 to 124.8)	18.6 (-42.6 to 20.5)
Hepatitis	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	18.4 (2.6 to 53.9)	-33.1 (-47.2 to -5.4)
Hepatitis A	1.8 (1.7 to 1.9)	2.9 (2.7 to 3.0)	58.5 (57.5 to 59.4)	-0.3 (-0.3 to -0.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	68.7 (49.0 to 89.1)	0.4 (-10.3 to 11.3)
Hepatitis B	205.3 (173.8 to 238.4)	194.5 (169.2 to 219.2)	-5.2 (-22.5 to 17.6)	-44.6 (-54.2 to -32.1)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-3.8 (-25.5 to 52.6)	-43.0 (-59.5 to -2.0)
Hepatitis C	85.6 (75.7 to 96.8)	99.1 (89.2 to 109.9)	15.8 (-2.7 to 36.4)	-32.4 (-41.5 to -22.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.8 (5.7 to 69.1)	-22.9 (-42.6 to 1.6)
Hepatitis E	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.6)	33.3 (-0.7 to 77.4)	-23.8 (-41.7 to 1.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.6 (-4.8 to 92.6)	-23.5 (-44.3 to 6.0)
Leprosy	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-1.4 (-33.2 to 69.1)	-36.8 (-55.5 to 6.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.2 (-35.8 to 85.7)	-36.7 (56.5 to 17.8)
Other infectious diseases	14.8 (11.4 to 18.4)	22.5 (20.3 to 25.3)	52.6 (37.9 to 70.6)	-6.3 (-15.1 to 3.6)	0.6 (0.4 to 0.9)	0.9 (0.6 to 1.3)	48.7 (35.4 to 77.5)	-6.7 (-16.2 to 8.2)
Non-communicable diseases	-	-	-	-	61.3 (44.6 to 79.8)	105.3 (77.1 to 135.3)	72.0 (64.8 to 78.4)	9.7 (-2.7 to 4.5)
Neoplasms	0.0	0.0	86.0	10.2	0.0	0.6	106.8	24.6
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	86.0 (4.7 to 246.7)	10.2 (-37.0 to 96.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.9 (3.8 to 236.2)	10.2 (-37.0 to 95.7)
Stomach cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	51.2 (-9.8 to 159.1)	-11.2 (-46.4 to 47.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.0 (-8.9 to 170.2)	-9.3 (-43.5 to 54.4)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	44.1 (-19.5 to 148.5)	-42.4 (-50.7 to 45.2)
Liver cancer due to hepatitis B	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	58.7 (-29.5 to 234.8)	-7.1 (-60.6 to 92.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.6 (-28.1 to 221.9)	-4.3 (-58.3 to 85.9)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	298.3 (71.0 to 1,039.6)	151.2 (9.5 to 589.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	273.5 (66.8 to 935.4)	130.8 (8.6 to 542.1)
Liver cancer due to alcohol use	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-27.9 (-68.9 to 55.5)	-55.6 (-79.9 to -6.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.6 (-64.6 to 54.8)	-53.7 (-77.6 to -5.8)
Liver cancer due to other causes	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-11.4 (-59.4 to 100.8)	-93.1 (-76.0 to 12.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.5 (-55.0 to 86.4)	-48.1 (-73.4 to 4.5)
Larynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	17.6 (-34.1 to 195.0)	-31.8 (-61.2 to 64.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.8 (-31.4 to 209.4)	-29.6 (-59.2 to 73.7)
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	58.1 (-5.9 to 165.4)	-7.7 (-43.9 to 50.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.1 (-3.0 to 170.1)	-4.2 (-42.4 to 56.9)
Breast cancer	0.4 (0.2 to 0.6)	0.9 (0.5 to 1.6)	144.6 (38.2 to 385.9)	37.7 (-21.5 to 166.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	126.2 (29.6 to 358.4)	28.8 (-25.2 to 149.4)
Cervical cancer	0.8 (0.4 to 1.2)	1.4 (0.8 to 2.2)	81.4 (1.4 to 239.8)	6.1 (-41.8 to 88.0)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	86.9 (4.2 to 237.5)	6.9 (-38.8 to 88.9)
Uterine cancer	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.5)	127.3 (3.5 to 390.2)	24.1 (-40.3 to 164.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.6 (4.4 to 399.9)	26.8 (-39.8 to 166.2)
Prostate cancer	0.2 (0.1 to 0.4)	0.8 (0.4 to 1.5)	352.2 (125.7 to 725.0)	175.0 (44.5 to 375.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	302.3 (108.2 to 617.8)	148.9 (35.1 to 325.5)
Colon and rectum cancer	0.5 (0.4 to 0.6)	0.8 (0.7 to 0.9)	63.4 (37.2 to 96.3)	-1.6 (-16.1 to 15.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	65.9 (36.6 to 101.0)	0.1 (-15.9 to 18.5)
Lip and oral cavity cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	82.3 (1.9 to 220.6)	6.5 (-38.8 to 80.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.2 (5.4 to 222.9)	9.2 (-37.6 to 82.5)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.2 (-6.5 to 194.5)	8.8 (-47.2 to 66.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.3 (-5.0 to 182.6)	9.6 (-46.5 to 60.2)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.3 (-29.7 to 197.0)	-12.4 (-57.2 to 72.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.1 (-21.6 to 191.1)	-9.1 (-52.0 to 67.5)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.8 (-11.8 to 178.5)	-7.8 (-49.0 to 55.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.3 (-8.7 to 167.8)	-9.0 (-46.6 to 53.8)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.3 (27.8 to 274.8)	29.4 (-22.5 to 116.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	122.0 (35.1 to 271.6)	30.5 (-19.9 to 118.6)
Malignant skin melanoma	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	100.9 (13.4 to 254.7)	11.0 (-37.8 to 93.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.8 (11.5 to 246.6)	9.7 (-37.5 to 93.7)
Non-melanoma skin cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	127.0 (11.4 to 283.4)	30.5 (-30.9 to 106.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	169.8 (60.3 to 347.1)	52.3 (-11.4 to 167.9)
Ovarian cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	112.1 (5.4 to 314.4)	20.0 (-40.3 to 132.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	118.1 (0.8 to 338.9)	24.3 (-43.8 to 150.8)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.2 (-4.8 to 284.7)	6.8 (-43.3 to 112.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.9 (-9.8 to 309.1)	7.4 (-43.7 to 122.4)
Kidney cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	92.8 (12.4 to 229.4)	12.5 (-31.9 to 83.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.8 (13.2 to 240.4)	12.7 (-32.7 to 90.1)
Bladder cancer	0.1 (0.0 to 0.1)	0.2 (0.2 to 0.3)	296.6 (137.4 to 514.6)	178.6 (70.7 to 325.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	364.0 (176.1 to 622.7)	223.3 (98.5 to 387.3)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	168.6 (82.4 to 302.8)	51.8 (4.6 to 127.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	165.6 (83.0 to 303.0)	44.9 (-2.4 to 119.2)
Thyroid cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	66.0 (-14.2 to 254.3)	-9.1 (-54.3 to 93.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.4 (-13.0 to 261.3)	-8.6 (-52.1 to 93.0)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.9 (4.2 to 204.0)	15.2 (-41.0 to 64.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.2 (4.5 to 204.4)	-1.1 (-41.6 to 65.9)
Hodgkin lymphoma	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	188.5 (73.5 to 362.7)	80.7 (6.4 to 199.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	179.2 (68.1 to 358.1)	70.8 (-0.7 to 189.6)
Non-Hodgkin lymphoma	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	106.8 (31.6 to 239.8)	25.3 (-24.7 to 121.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	110.2 (30.7 to 257.3)	24.9 (-26.4 to 122.5)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.6 (10.1 to 325.0)	21.2 (-36.9 to 143.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.1 (1.6 to 303.7)	15.2 (-42.3 to 140.4)
Leukemia	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	119.0 (34.2 to 355.9)	15.2 (-25.9 to 84.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	180.3 (28.6 to 308.2)	4.8 (-34.3 to 69.8)
Other neoplasms	0.3 (0.2 to 0.6)	0.7 (0.4 to 1.3)	142.3 (44.7 to 253.9)	28.5 (-20.4 to 97.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	129.8 (48.9 to 240.6)	20.9 (-27.2 to 97.7)
Cardiovascular diseases	-	-	-	-	1.8 (1.2 to 2.4)	2.8 (1.9 to 4.0)	60.0 (23.8 to 104.6)	-2.1 (-22.1 to 23.6)
Rheumatic heart disease	12.2 (9.7 to 15.2)	16.1 (12.1 to 20.7)	33.9 (-5.5 to 77.1)	-19.8 (-40.5 to 9.1)	0.6 (0.4 to 0.9)	0.8 (0.5 to 1.2)	37.7 (-1.6 to 82.2)	-15.5 (-36.2 to 16.2)
Ischemic heart disease	7.5 (6.1 to 9.6)	9.3 (7.7 to 11.3)	25.9 (-6.4 to 56.0)	-20.9 (-38.8 to -2.3)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	15.7 (-24.9 to 57.5)	-26.4 (-48.7 to -1.4)
Cerebrovascular disease	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	70.6 (37.6 to 110.2)	-0.5 (-18.7 to 23.8)
Ischemic stroke	0.4 (0.4 to 0.5)	0.7 (0.6 to 0.8)	69.4 (38.2 to 109.9)	-0.8 (-18.0 to 25.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	72.7 (36.1 to 113.5)	0.7 (-19.8 to 25.3)
Hemorrhagic stroke	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	63.6 (31.0 to 114.9)	-5.4 (-24.6 to 23.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.3 (29.8 to 119.8)	-4.2 (-24.8 to 24.9)
Hypertensive heart disease	1.5 (1.0 to 2.0)	2.3 (1.8 to 3.1)	56.4 (5.3 to 119.6)	-5.7 (-37.9 to 31.2)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.2)	58.0 (6.8 to 119.8)	-4.7 (-36.2 to 33.8)
Cardiomyopathy and myocarditis	1.0 (0.7 to 1.3)	1.6 (1.1 to 2.2)	63.3 (4.9 to 179.6)	4.4 (-42.4 to 99.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	64.2 (4.9 to 178.3)	4.4 (-41.5 to 102.0)
Atrial fibrillation and flutter	0.1 (0.1 to 0.2)	0.6 (0.5 to 0.9)	379.9 (231.1 to 629.9)	165.9 (56.4 to 406.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	384.0 (234.0 to 649.2)	170.2 (61.7 to 411.7)
Peripheral vascular disease	15.4 (11.4 to 19.5)	26.6 (18.3 to 36.2)	69.0 (12.5 to 189.0)	-3.6 (-34.8 to 55.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.6 (-42.3 to 258.1)	1.8 (-55.7 to 136.2)
Endocarditis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	2.1 (-31.7 to 66.3)	-41.6 (-68.3 to 23.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.8 (-39.9 to 82.6)	-43.4 (-71.6 to 29.4)
Other cardiovascular and circulatory diseases	6.3 (3.7 to 9.6)	13.9 (7.0 to 21.2)	119.6 (12.6 to 307.8)	21.7 (-39.4 to 149.8)	0.4 (0.2 to 0.7)	1.0 (0.4 to 1.6)	122.5 (11.5 to 315.3)	28.8 (-38.6 to 151.0)
Chronic respiratory diseases	-	-	-	-	3.9 (2.6 to 5.4)	6.3 (4.2 to 8.9)	63.6 (40.1 to 89.6)	-3.6 (-17.2 to 10.1)
Chronic obstructive pulmonary disease	33.2 (31.4 to 35.0)	56.2 (53.0 to 59.7)	69.0 (62.3 to 75.5)	-1.1 (-4.9 to 2.4)	2.7 (1.8 to 3.8)	4.6 (3.0 to		

Appendix Table G.4 - Guinea-Bissau prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	65.0	-3.4
Silicosis	0.0	0.0	56.6	-7.4	0.0	0.0	(59.3 to 71.0)	(-6.6 to -0.1)
Asbestosis	-	-	0.0	0.0	-	-	56.3	-7.5
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	79.3	1.3	0.0	0.0	73.3	1.3
Asthma	11.5	17.8	54.9	-6.8	0.5	0.8	55.5	-6.4
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	85.4	5.7	0.0	0.0	83.9	5.3
Other chronic respiratory diseases	-	-	-	-	0.7	0.9	44.8	-14.7
Cirrhosis	-	-	-	-	0.1	0.1	48.6	11.4
Cirrhosis due to hepatitis B	0.2	0.2	-9.0	-40.4	0.0	0.0	91.1	-40.3
Cirrhosis due to hepatitis C	0.1	0.1	131.1	31.4	0.0	0.0	131.0	33.1
Cirrhosis due to alcohol use	0.1	0.2	35.3	-21.8	0.0	0.0	38.1	20.4
Cirrhosis due to other causes	0.1	0.2	93.1	27.5	0.0	0.0	93.1	27.6
Digestive diseases	0.0	0.0	65.6	0.9	0.0	0.0	67.9	1.3
Peptic ulcer disease	6.0	9.0	50.9	-9.4	0.2	0.3	53.6	-9.7
Gastritis and duodenitis	12.7	20.8	64.0	5.0	0.5	0.8	60.8	-1.1
Appendicitis	0.1	0.2	88.0	5.2	0.0	0.1	90.0	6.3
Paralytic ileus and intestinal obstruction	0.0	0.0	14.8 to 178.2	-31.1 to 51.7	0.0 to 0.1	0.0 to 0.1	8.3 to 207.0	(-34.6 to 64.9)
Inguinal, femoral, and abdominal hernia	4.1	6.8	70.1	-2.8	0.0	0.1	72.2	-1.9
Inflammatory bowel disease	0.9	2.1	119.5	26.0	0.2	0.4	121.1	27.1
Vascular intestinal disorders	0.0	0.0	116.3	10.8	0.0	0.0	117.8	12.0
Gallbladder and biliary diseases	0.3	0.6	97.1	7.2	0.0	0.1	100.3	1.5
Pancreatitis	0.2	0.3	91.8	9.9	0.0	0.1	92.9	10.8
Other digestive diseases	-	-	-	-	0.2	0.4	91.1	12.3
Neurological disorders	-	-	-	-	4.4	8.0	83.7	6.7
Alzheimer disease and other dementias	1.4	2.2	60.7	0.4	0.2	0.3	62.6	1.5
Parkinson disease	0.1	0.1	63.5	0.8	0.0	0.0	65.6	1.9
Epilepsy	2.1	3.3	57.7	-7.4	0.6	1.0	65.9	-1.8
Multiple sclerosis	0.1	0.1	99.5	13.6	0.0	0.0	97.4	11.9
Migraine	70.9	118.9	67.8	-9.4	2.4	4.1	68.9	-2.1
Tension-type headache	122.4	225.6	84.7	3.3	0.2	0.3	85.8	4.0
Medication overuse headache	4.8	12.3	153.3	43.8	0.7	1.9	155.7	45.1
Other neurological disorders	0.0	0.0	60.3	-6.3	0.2	0.3	61.0	-1.2
Mental and substance use disorders	-	-	-	-	19.5	32.9	69.7	-1.9
Schizophrenia	2.1	3.7	76.4	-0.5	1.3	2.4	78.1	0.3
Alcohol use disorders	4.9	10.2	107.2	17.1	0.5	1.0	109.7	18.3
Drug use disorders	-	-	-	-	1.2	2.2	81.3	1.2
Opioid use disorders	1.6	2.9	73.7	-0.1	0.7	1.2	75.1	0.8
Cocaine use disorders	0.4	0.9	87.4	0.1	0.1	0.1	87.4	0.0
Amphetamine use disorders	1.5	2.8	87.7	0.5	0.2	0.4	89.6	2.1
Cannabis use disorders	0.7	1.2	78.1	0.1	0.0	0.0	78.8	0.8
Other drug use disorders	-	-	-	-	0.3	0.5	88.8	2.1
Depressive disorders	-	-	-	-	0.2 to 0.4	0.3 to 0.7	38.5 to 165.0	(-24.6 to 41.5)
Major depressive disorder	35.3	55.6	58.2	-7.3	7.2	11.4	58.7	-7.0
Dysthymia	9.8	17.3	76.4	-0.2	0.9	1.7	77.2	0.3
Bipolar disorder	5.4	9.8	79.7	-1.0	1.1	2.0	81.2	-0.3
Anxiety disorders	23.3	40.2	72.5	-0.2	2.1	3.7	72.4	0.3
Eating disorders	-	-	-	-	0.2	0.4	82.7	0.5
Anorexia nervosa	0.2	0.3	80.8	2.3	0.0	0.1	80.3	2.0
Bulimia nervosa	1.0	1.8	82.5	-0.1	0.2	0.4	83.4	0.4
Autistic spectrum disorders	-	-	-	-	1.2	2.0	68.9	0.8
Autism	3.1	5.2	68.4	0.3	0.8	1.3	69.4	1.0
Asperger syndrome	4.5	7.5	68.1	0.3	0.4	0.7	68.6	0.9
Attention-deficit/hyperactivity disorder	7.5	12.1	62.8	0.2	0.1	0.1	62.6	0.3
Conduct disorder	11.1	17.8	59.7	0.2	1.3	2.1	60.4	0.5
Idiopathic intellectual disability	27.5	44.7	62.2	-2.9	1.3	2.2	63.2	-2.4
Other mental and substance use disorders	11.7	22.2	90.3	0.2	0.9	1.7	91.7	0.8
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	5.8	10.9	89.4	16.6
Diabetes mellitus	13.4	42.3	213.6	85.2	1.0	3.0	205.2	80.5
Acute glomerulonephritis	0.0	0.0	13.6	-28.3	0.0	0.0	13.6	-28.3
Chronic kidney disease	-	-	-	-	1.7	2.8	65.6	-2.6
Chronic kidney disease due to diabetes mellitus	10.0	15.7	58.7	-3.3	0.2	0.3	59.3	-4.7
Chronic kidney disease due to hypertension	44.3	75.5	74.3	3.9	0.5	0.9	74.3	0.6
Chronic kidney disease due to glomerulonephritis	37.5	67.2	78.2	0.6	0.4	0.7	78.2	0.0
Chronic kidney disease due to other causes	30.8	47.3	53.1	-5.6	0.4	0.6	50.6	-8.7
Urinary diseases and male infertility	-	-	-	-	0.3	0.6	78.3	6.1

Appendix Table G.4 - Guinea-Bissau prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.4)	83.7 (69.1 to 100.7)	0.0 (-1.7 to 14.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.9 (45.8 to 135.7)	0.0 (-10.6 to 30.8)
Urolithiasis	2.2 (1.7 to 2.9)	3.1 (2.2 to 4.1)	42.9 (13.7 to 59.9)	-12.7 (-28.4 to -3.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	81.6 (59.5 to 108.3)	7.0 (-4.0 to 20.2)
Benign prostatic hyperplasia	6.4 (5.7 to 7.0)	11.0 (10.1 to 12.0)	72.7 (51.4 to 96.4)	5.8 (-6.4 to 19.7)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.5)	74.9 (53.4 to 100.8)	6.8 (-5.3 to 21.7)
Male infertility due to other causes	10.6 (7.9 to 13.7)	19.4 (15.1 to 24.2)	83.6 (30.4 to 154.3)	-3.3 (-31.2 to 34.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	86.6 (33.7 to 155.0)	-3.4 (-30.1 to 32.7)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	110.1 (43.1 to 238.7)	24.2 (-15.6 to 97.9)
Gynecological diseases	-	-	-	-	1.1 (0.7 to 1.7)	2.1 (1.3 to 3.1)	82.5 (62.0 to 108.1)	2.3 (-8.3 to 15.4)
Uterine fibroids	15.7 (14.2 to 17.1)	26.3 (23.7 to 28.7)	67.3 (66.2 to 68.4)	-0.2 (-0.2 to -0.2)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	63.8 (45.2 to 76.2)	-4.9 (-15.4 to 2.0)
Polycystic ovarian syndrome	14.2 (12.9 to 15.5)	26.3 (23.6 to 29.3)	85.2 (61.2 to 113.1)	3.3 (-9.2 to 18.0)	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.5)	86.7 (61.8 to 116.7)	3.8 (-9.3 to 19.0)
Female infertility due to other causes	9.1 (5.7 to 13.3)	16.8 (8.7 to 24.4)	83.7 (-12.0 to 239.2)	7.2 (-49.1 to 102.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	84.0 (-9.5 to 243.0)	7.5 (-48.8 to 102.2)
Endometriosis	1.4 (1.2 to 1.6)	2.4 (2.0 to 2.7)	67.8 (35.3 to 108.7)	-6.1 (-23.4 to 16.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	69.3 (33.2 to 113.3)	5.8 (-25.5 to 18.2)
Genital prolapse	33.9 (29.2 to 38.5)	60.6 (53.4 to 67.6)	79.0 (51.1 to 113.5)	0.3 (-15.3 to 17.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	79.6 (50.2 to 115.6)	0.7 (-15.2 to 18.2)
Premenstrual syndrome	33.7 (23.0 to 44.6)	74.3 (51.3 to 98.2)	117.2 (43.5 to 247.6)	21.0 (-23.6 to 88.9)	0.3 (0.2 to 0.5)	0.6 (0.3 to 1.0)	119.5 (44.3 to 246.2)	21.4 (-23.4 to 86.8)
Other gynecological diseases	3.8 (2.7 to 4.9)	6.3 (5.1 to 7.7)	67.9 (25.0 to 132.2)	-5.1 (-28.8 to 29.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	56.6 (37.8 to 159.1)	-11.0 (-43.0 to 46.7)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	1.0 (0.7 to 1.5)	1.6 (1.0 to 2.2)	50.6 (39.8 to 73.5)	8.7 (-17.0 to 6.3)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.7 (23.8 to 53.8)	-15.2 (-25.9 to -5.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.7 (15.9 to 48.3)	-20.1 (-32.0 to -9.4)
Thalassemia trait	10.3 (5.8 to 14.2)	16.8 (9.4 to 22.3)	62.0 (56.0 to 70.1)	-3.0 (-6.6 to 1.9)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	56.4 (31.2 to 85.1)	-3.4 (-20.7 to 14.4)
Sickle cell disorders	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.7)	57.7 (12.4 to 108.4)	-2.4 (-28.0 to 27.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	63.9 (23.0 to 112.3)	-0.4 (-21.2 to 24.2)
Sickle cell trait	71.6 (65.6 to 76.9)	115.8 (105.8 to 125.0)	61.7 (55.1 to 67.3)	-2.2 (-7.1 to 0.2)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.7)	54.5 (27.0 to 95.6)	45.1 (-23.6 to 26.3)
G6PD deficiency	107.7 (81.9 to 136.8)	175.2 (140.4 to 213.7)	62.0 (15.9 to 134.9)	-3.0 (-30.6 to 40.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.5 (17.2 to 109.9)	-4.0 (-23.6 to 21.7)
G6PD trait	237.3 (219.6 to 250.9)	395.4 (360.7 to 419.5)	66.6 (50.4 to 84.8)	-0.5 (-10.2 to 10.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.0 (-39.3 to 336.1)	12.1 (-62.5 to 181.6)
Other hemoglobinopathies and hemolytic anemias	14.1 (11.9 to 16.1)	21.3 (19.3 to 23.5)	50.9 (34.4 to 78.2)	-11.0 (-22.6 to 4.6)	0.5 (0.3 to 0.6)	0.7 (0.4 to 1.0)	44.0 (27.5 to 95.4)	-14.0 (-26.5 to 17.1)
Endocrine, metabolic, blood, and immune disorders	16.3 (14.6 to 18.1)	25.0 (20.4 to 28.7)	53.2 (19.3 to 97.9)	-2.2 (-24.6 to 12.8)	0.6 (0.4 to 0.9)	0.9 (0.6 to 1.3)	50.0 (7.6 to 102.4)	-7.7 (-29.4 to 17.1)
Musculoskeletal disorders	-	-	-	-	11.6 (8.2 to 15.7)	20.1 (14.1 to 26.7)	72.2 (48.5 to 100.0)	-0.3 (-12.2 to 12.5)
Rheumatoid arthritis	1.4 (1.3 to 1.4)	1.7 (1.6 to 1.8)	24.1 (17.0 to 33.0)	-32.8 (-36.6 to -28.2)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	25.9 (13.8 to 39.4)	-31.9 (-37.3 to -26.0)
Osteoarthritis	19.7 (19.0 to 20.6)	33.3 (31.8 to 34.7)	68.6 (58.7 to 78.8)	0.9 (-4.6 to 6.3)	1.2 (0.8 to 1.6)	1.7 (1.4 to 2.7)	69.9 (59.6 to 81.9)	1.0 (-4.2 to 7.6)
Low back and neck pain	-	-	-	-	9.1 (6.1 to 12.6)	15.4 (10.5 to 20.9)	69.8 (41.3 to 105.1)	9.7 (-17.8 to 14.4)
Low back pain	53.5 (45.7 to 63.1)	87.5 (73.2 to 101.4)	63.9 (26.0 to 111.5)	-5.6 (-24.9 to 20.4)	5.9 (3.9 to 8.3)	9.7 (6.5 to 14.0)	64.9 (26.6 to 114.8)	-4.8 (-24.3 to 21.9)
Neck pain	32.7 (26.8 to 39.6)	58.1 (50.1 to 65.6)	76.3 (41.7 to 128.1)	-1.0 (-19.6 to 25.2)	3.2 (2.1 to 4.5)	5.7 (3.8 to 8.0)	78.1 (42.7 to 128.4)	-0.1 (-19.2 to 26.4)
Gout	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	65.3 (37.7 to 98.5)	-2.3 (-17.0 to 16.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.2 (24.6 to 117.4)	-2.6 (-27.1 to 29.1)
Other musculoskeletal disorders	11.9 (6.3 to 16.4)	24.6 (18.1 to 31.3)	101.9 (70.1 to 202.0)	17.6 (-0.4 to 72.8)	1.1 (0.5 to 1.7)	2.2 (1.4 to 3.3)	84.1 (70.5 to 208.9)	18.1 (-0.1 to 77.7)
Other non-communicable diseases	-	-	-	-	12.7 (8.4 to 18.8)	21.2 (13.9 to 31.5)	66.8 (57.6 to 75.4)	-1.6 (-5.5 to 2.4)
Congenital anomalies	-	-	-	-	0.6 (0.3 to 0.9)	0.9 (0.6 to 1.4)	69.7 (36.9 to 109.3)	2.1 (-18.6 to 29.0)
Neural tube defects	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	188.6 (127.3 to 263.9)	94.0 (50.1 to 148.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	207.8 (122.2 to 325.1)	115.8 (54.5 to 191.9)
Congenital heart anomalies	0.3 (0.2 to 0.5)	1.1 (0.7 to 1.4)	212.5 (77.3 to 392.9)	109.3 (15.0 to 244.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	154.7 (45.1 to 318.7)	68.2 (-5.6 to 174.8)
Orofacial clefts	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.2)	224.5 (67.4 to 472.6)	144.5 (15.1 to 355.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	143.9 (59.9 to 551.2)	143.9 (15.1 to 405.4)
Down syndrome	0.3 (0.2 to 0.4)	0.7 (0.6 to 0.9)	130.3 (69.9 to 213.8)	37.9 (0.4 to 89.3)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	128.5 (64.9 to 228.7)	34.4 (-3.1 to 91.7)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.6 (19.1 to 220.6)	25.6 (-29.5 to 92.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	114.0 (20.7 to 224.4)	25.9 (-29.0 to 93.2)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	62.3 (9.5 to 137.1)	-3.2 (-34.5 to 40.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.2 (15.7 to 153.5)	-3.2 (-34.8 to 42.5)
Chromosomal unbalanced rearrangements	0.0 (0.4 to 0.6)	0.0 (1.0 to 1.6)	142.0 (79.2 to 252.0)	48.9 (7.6 to 112.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	141.7 (71.7 to 262.4)	42.0 (1.0 to 112.2)
Other congenital anomalies	4.7 (3.4 to 6.2)	9.3 (5.5 to 7.7)	55.5 (32.3 to 86.4)	-7.0 (-20.2 to 11.6)	0.4 (0.2 to 0.7)	0.6 (0.4 to 1.1)	48.5 (16.2 to 93.3)	-9.3 (-30.4 to 22.0)
Skin and subcutaneous diseases	-	-	-	-	4.4 (2.7 to 6.8)	8.0 (4.9 to 12.6)	81.8 (69.8 to 99.5)	6.3 (-0.5 to 15.6)
Dermatitis	43.3 (34.1 to 54.4)	74.5 (58.1 to 93.7)	72.0 (70.5 to 73.1)	-0.0 (-0.1 to -0.0)	1.2 (0.8 to 1.8)	2.1 (1.3 to 3.1)	71.2 (64.7 to 77.3)	0.4 (-2.3 to 3.2)
Psoriasis	6.7 (5.3 to 8.1)	11.7 (9.2 to 14.1)	74.2 (72.6 to 75.7)	0.5 (-0.0 to 0.1)	0.5 (0.4 to 0.8)	1.0 (0.6 to 1.4)	75.5 (64.3 to 87.7)	0.7 (-4.6 to 6.2)
Cellulitis	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	63.7 (38.8 to 95.3)	-3.8 (-20.0 to 18.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.6 (23.2 to 125.6)	-3.2 (-24.8 to 27.9)
Pyoderma	1.7 (1.3 to 2.2)	2.6 (1.9 to 3.3)	48.3 (38.6 to 60.2)	-4.2 (-10.5 to 3.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.1 (33.6 to 65.6)	-4.2 (-12.8 to 6.1)
Scabies	12.3 (10.6 to 14.3)	16.4 (13.4 to 20.1)	33.4 (3.4 to 74.0)	-18.8 (-37.4 to 6.3)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.7)	33.5 (29.9 to 76.1)	-18.5 (-37.5 to 8.0)
Fungal skin diseases	120.9 (88.0 to 168.4)	206.8 (150.3 to 289.7)	70.7 (68.0 to 74.5)	0.0 (0.0 to 0.1)	0.7 (0.3 to 1.5)	1.2 (0.4 to 2.6)	71.1 (67.9 to 75.2)	0.4 (-0.4 to 1.1)
Viral skin diseases	15.0 (11.9 to 18.3)	24.5 (18.9 to 30.5)	63.3 (51.6 to 73.9)	-0.9 (-5.3 to 4.2)	0.5 (0.3 to 0.7)	0.8 (0.4 to 1.2)	63.7 (50.2 to 76.6)	-0.4 (-6.1 to 6.3)
Acne vulgaris	46.7 (30.7 to 62.4)	128.6 (100.2 to 165.0)	169.5 (90.4 to 368.2)	59.6 (12.9 to 171.6)	0.5 (0.2 to 1.0)	1.4 (0.6 to 2.7)	171.1 (90.9 to 368.4)	59.8 (12.6 to 171.9)
Alopecia areata	0.9 (0.8 to 1.0)	1.5 (1.4 to 1.7)	68.7 (49.6 to 89.4)	-0.1 (-11.3 to 12.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	68.1 (42.8 to 100.8)	0.0 (-13.2 to 17.0)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.7 (31.3 to 108.3)	0.1 (-22.1 to 36.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.7 (31.1 to 108.4)	-0.1 (-22.2 to 26.5)
Urticaria	4.0 (1.3 to 6.0)	8.3 (5.9 to 11.6)	103.6 (21.6 to 423.1)	17.5 (-26.2 to 163.6)	0.2 (0.1 to 0.4)	0.5 (0.3 to 0.8)	104.7 (20.7 to 441.7)	18.7 (-26.4 to 175.7)
Decubitus ulcer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	82.2 (42.4 to 132.0)	11.9 (-16.8 to 50.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.4 (40.7 to 137.2)	12.2 (-16.7 to 55.4)
Other skin and subcutaneous diseases	54.2 (36.5 to 77.9)	92.2 (62.3 to 132.8)	69.6 (62.1 to 79.5)	-1.2 (-4.4 to 1.6)	0.3 (0.1 to 0.7)	0.5 (0.2 to 1.1)	70.5 (62.3 to 81.0)	-0.8 (-3.9 to 2.5)
Sense organ diseases	-	-	-	-	6.6 (4.3 to 9.6)	10.3 (6.7 to 15.1)	59.0 (44.2 to 67.1)	-5.4 (-10.3 to 0.4)
Glaucoma	0.8 (0.6 to 1.1)	2.1 (1.6 to 2.8)	155.2 (98.8 to 234.2)	43.6 (10.6 to 85.2)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	149.4 (100.8 to 216.2)	43.2 (9.7 to 77.5)
Cataract	3.9 (2.2 to 5.7)	7.9 (5.7 to 9.9)	98.4 (37.5 to 237.1)	14.2 (-16.2 to 66.7)	0.3 (0.2 to 0.6)	0.6 (0.4 to 1.0)	83.0 (35.3 to 194.8)	5.1 (-18.9 to 45.6)
Macular degeneration	0.8 (0.5 to 1.1)	3.5 (2.0 to 5.0)	369.0 (138.3 to 648.8)	174.6 (56.0 to 314.5)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	334.5 (124.4 to 551.1)	146.4 (42.7 to 248.4)
Uncorrected refractive error	86.7 (68.1 to 105.0)	142.1 (113.5 to 173.2)	62.9 (23.7 to 125.9)	-1.7 (-20.1 to 28.6)	1.8 (1.1 to 2.7)	2.6 (1.7 to 4.1)	47.4 (27.3 to 76.6)	-11.9 (-20.5 to 2.9)
Age-related and other hearing loss	128.3 (107.3 to 145.2)	201.1 (171.4 to 227.7)	56.9 (48.5 to 65.1)	-6.5 (-10.1 to -2.7)	3.5 (2.1 to 5.3)	5.2 (3.1 to 8.1)	47.5 (30.3 to 63.8)	-10.7 (-17.7 to -4.1)
Other vision loss	2.4 (1.9 to 3.0)	4.4 (3.5 to 5.5)	80.5 (50.4 to 111.2)	12.5 (-8.5 to 33.8)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	80.7 (49.0 to 116.9)	9.7 (-10.3 to 33.3)
Other sense organ diseases	24.3 (23.1 to 25.5)	39.4 (37.2 to 41.6)	62.2 (50.3 to 75.0)	-0.6 (-6.9 to 6.1)	0.6 (0.4 to 0.9)	1.0 (0.6 to 1.5)	62.7 (50.0 to 78.0)	-0.1 (-7.2 to 7.7)
Oral disorders	-	-	-	-	1.2 (0.7 to 2.0)	2.1 (1.1 to 3.5)	72.3 (60.8 to 85.6)	2.1 (-7.0 to 8.5)
Deciduous caries	98.6 (93.9 to 103.5)	152.3 (144.3 to 160.4)	54.7 (43.3 to 65.2)	0.6 (-6.9 to 7.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	54.9 (42.0 to 68.2)	0.6 (-8.3 to 9.6)
Permanent caries	258.6 (237.7 to 284.3)	450.6 (400.7 to 505.5)	73.6 (50.7 to 103.7)	-0.5 (-13.3 to 16.3)	0.3 (0.1 to 0.5)	0.4 (0.2 to 0.9)	74.1 (50.8 to 105.1)	0.0 (-13.1 to 17.3)
Periodontal diseases	59.8 (53.3 to 66.8)	102.4 (92.6 to 115.1)	71.2 (47.4 to 102.1)	-1.5				

Appendix Table G.4 - Guinea-Bissau prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	3.5 (3.2 to 3.7)	5.9 (5.5 to 6.4)	70.5 (54.7 to 91.8)	1.8 (-7.5 to 12.6)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	71.7 (54.1 to 94.2)	2.8 (-7.4 to 14.2)
Other oral disorders	14.7 (14.0 to 15.5)	25.5 (24.2 to 27.0)	73.0 (60.3 to 87.8)	-0.8 (-7.4 to 6.8)	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.1)	73.4 (60.8 to 88.7)	-0.2 (-7.2 to 7.8)
Injuries	-	-	-	-	8.6 (4.9 to 17.0)	7.5 (5.4 to 10.5)	-8.7 (-38.6 to 18.8)	-44.7 (-60.4 to -29.4)
Transport injuries	-	-	-	-	1.7 (1.3 to 2.2)	2.7 (2.1 to 3.5)	59.3 (50.2 to 68.5)	-3.8 (-8.7 to 1.7)
Road injuries	-	-	-	-	1.6 (1.2 to 2.0)	2.5 (1.9 to 3.2)	58.1 (48.6 to 67.4)	-4.9 (-9.9 to 0.6)
Pedestrian road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.7)	41.9 (29.4 to 54.6)	-12.4 (-18.8 to -5.7)
Cyclist road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	30.6 (21.6 to 39.2)	-17.6 (-23.4 to -11.9)
Motorcyclist road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	37.4 (26.1 to 48.1)	-17.7 (-24.3 to -11.4)
Motor vehicle road injuries	-	-	-	-	0.8 (0.6 to 1.0)	1.4 (1.0 to 1.8)	78.6 (65.5 to 92.7)	5.2 (-0.6 to 14.0)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.3 (7.3 to 23.0)	-34.3 (-38.3 to -30.3)
Other transport injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	71.8 (61.1 to 85.5)	7.2 (0.5 to 15.3)
Unintentional injuries	-	-	-	-	2.0 (1.5 to 2.6)	3.0 (2.3 to 3.9)	49.2 (44.5 to 54.6)	-11.1 (-14.2 to -8.0)
Falls	-	-	-	-	0.8 (0.6 to 1.0)	1.2 (0.9 to 1.6)	56.4 (48.1 to 64.8)	-9.7 (-14.9 to -5.3)
Drowning	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	16.5 (5.5 to 31.5)	-28.5 (-34.7 to -21.2)
Fire, heat, and hot substances	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	32.6 (21.9 to 45.1)	-18.5 (-24.1 to -12.1)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.7 (3.6 to 46.4)	-27.0 (-36.8 to -16.1)
Exposure to mechanical forces	-	-	-	-	0.6 (0.5 to 0.8)	0.9 (0.7 to 1.2)	45.5 (38.6 to 52.6)	-12.2 (-16.3 to -7.8)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.2 (29.7 to 53.2)	-16.1 (-22.4 to -8.8)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.9 (64.4 to 106.8)	11.0 (0.5 to 22.2)
Other exposure to mechanical forces	-	-	-	-	0.6 (0.5 to 0.8)	0.9 (0.7 to 1.2)	45.2 (38.0 to 52.9)	-12.2 (-16.4 to -7.8)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.5 (79.5 to 97.9)	15.8 (10.4 to 21.8)
Animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	45.9 (35.5 to 57.7)	-11.4 (-17.1 to -5.6)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.0 (30.4 to 68.3)	-10.9 (-20.8 to -1.0)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.6 (34.9 to 52.5)	-11.8 (-16.3 to -7.0)
Foreign body	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	57.4 (47.9 to 67.6)	-4.3 (-9.5 to 1.0)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.2 (13.8 to 51.1)	-12.2 (-22.3 to -3.5)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.7 (49.1 to 87.3)	-3.1 (-11.5 to 7.0)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	64.5 (54.6 to 76.0)	-2.1 (-8.3 to 4.3)
Other unintentional injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.6)	48.1 (39.5 to 58.8)	-10.8 (-16.1 to -4.6)
Self-harm and interpersonal violence	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	47.9 (40.3 to 55.8)	-12.2 (-16.7 to -7.5)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.9 (56.5 to 83.4)	-1.3 (-8.2 to 6.2)
Interpersonal violence	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	44.1 (36.3 to 52.9)	-14.8 (-19.5 to -9.7)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.1 (43.6 to 64.4)	-8.9 (-14.2 to -2.4)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.7 (63.1 to 86.8)	0.8 (-5.2 to 6.5)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	35.1 (26.0 to 45.0)	-20.3 (-25.4 to -14.3)
Forces of nature, war, and legal intervention	-	-	-	-	4.8 (1.5 to 12.8)	1.6 (0.6 to 4.1)	-65.5 (-69.2 to -60.3)	-73.0 (-75.7 to -69.4)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.8 (0.5 to 87.4)	-9.5 (-28.2 to 22.7)
Collective violence and legal intervention	-	-	-	-	4.8 (1.5 to 12.8)	1.6 (0.6 to 4.1)	-65.6 (-69.2 to -60.4)	-73.0 (-75.7 to -69.4)

Appendix Table G.4 - Guyana prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	67.4 (49.1 to 88.3)	71.5 (53.0 to 93.4)	6.2 (3.5 to 9.0)	-2.0 (-4.5 to 0.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	13.1 (9.1 to 18.2)	12.5 (8.7 to 17.2)	-4.9 (-10.9 to 2.7)	-15.9 (-21.6 to -8.9)
HIV/AIDS and tuberculosis	-	-	-	-	0.3 (0.2 to 0.5)	1.1 (0.6 to 1.8)	0.8 (-0.1 to 1.7)	259.7 (126.7 to 409.4)
Tuberculosis	0.5 (0.5 to 0.5)	0.7 (0.7 to 0.7)	43.6 (38.1 to 49.4)	28.1 (23.6 to 33.1)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	0.0 (-0.1 to 0.1)	28.9 (18.3 to 40.7)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.4)	0.9 (0.5 to 1.6)	708.8 (219.2 to 1,645.8)	637.2 (189.3 to 1,544.5)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	748.3 (228.0 to 1,693.1)	624.6 (176.1 to 1,463.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	686.9 (197.9 to 1,602.1)	558.8 (154.2 to 1,349.8)
HIV/AIDS resulting in other diseases	1.4 (0.4 to 3.4)	8.6 (6.4 to 11.5)	667.7 (190.1 to 1,599.3)	634.5 (175.6 to 1,545.2)	0.1 (0.0 to 0.4)	0.9 (0.5 to 1.5)	703.4 (215.2 to 1,717.3)	642.2 (187.0 to 1,585.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	1.6 (1.1 to 2.1)	1.3 (0.9 to 1.8)	-16.9 (-22.0 to -11.7)	-21.2 (-25.5 to -16.8)
Diarrheal diseases	4.9 (4.7 to 5.2)	4.3 (4.1 to 4.6)	-11.4 (-18.0 to -4.5)	-12.9 (-19.1 to -6.5)	0.8 (0.5 to 1.1)	0.7 (0.5 to 1.0)	-11.3 (-18.6 to -3.4)	-13.1 (-19.7 to -5.5)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-77.9 to -35.3)	0.0 (-79.9 to -41.1)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.6 (-48.9 to -26.7)	-44.4 (-53.0 to -33.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.6 (-49.0 to -26.6)	-44.4 (-53.0 to -33.0)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.0 (-50.8 to -22.2)	-43.9 (-54.7 to -29.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.0 (-50.8 to -22.1)	-43.9 (-54.7 to -28.9)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.4 (-99.9 to -57.5)	-99.4 (-99.9 to -57.5)
Lower respiratory infections	0.5 (0.4 to 0.7)	0.4 (0.3 to 0.5)	-22.8 (-44.1 to -2.2)	-22.9 (-42.8 to -6.2)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-22.6 (-44.6 to 1.1)	-23.0 (-43.8 to -4.0)
Upper respiratory infections	20.6 (19.6 to 21.6)	21.7 (20.9 to 22.6)	5.0 (-0.8 to 12.1)	-4.6 (-9.7 to 1.9)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.4)	5.3 (-1.5 to 12.9)	-4.3 (-10.2 to 2.9)
Otitis media	8.4 (8.0 to 9.0)	8.3 (7.8 to 8.8)	-1.5 (-8.7 to 5.5)	-11.5 (-17.7 to -5.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-3.1 (-11.0 to 7.2)	-12.8 (-19.6 to -4.7)
Meningitis	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.1)	-62.0 (-68.3 to -54.2)	-65.0 (-70.2 to -58.3)
Pneumococcal meningitis	1.3 (0.7 to 2.0)	0.4 (0.2 to 0.6)	-68.0 (-74.5 to -59.9)	-70.5 (-76.7 to -63.2)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-65.4 (-73.4 to -53.2)	-68.2 (-75.0 to -58.1)
H influenzae type B meningitis	0.5 (0.2 to 1.1)	0.2 (0.1 to 0.3)	-68.4 (-76.6 to -53.7)	-71.6 (-78.9 to -58.7)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-60.2 (-73.7 to -35.0)	-64.1 (-75.7 to -42.0)
Meningococcal meningitis	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-64.3 (-76.2 to -45.8)	-67.5 (-77.2 to -52.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.0 (-76.9 to -35.1)	-64.3 (-77.2 to -43.7)
Other meningitis	0.6 (0.3 to 1.1)	0.2 (0.1 to 0.4)	-63.4 (-70.4 to -52.1)	-66.1 (-72.6 to -56.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-59.4 (-68.2 to -41.5)	-61.4 (-69.3 to -45.7)
Encephalitis	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-39.0 (-31.5 to -4.4)	-39.3 (-40.2 to -16.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.9 (-25.6 to 9.3)	-22.9 (-34.0 to -5.8)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.0 (-95.7 to 487.0)	-48.0 (-95.7 to 355.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.0 (-95.8 to 357.0)	-48.0 (-95.8 to 357.0)
Whooping cough	0.5 (0.4 to 0.6)	0.2 (0.2 to 0.3)	-58.4 (-60.7 to -55.9)	-59.3 (-61.6 to -56.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.3 (-63.4 to -52.0)	-59.2 (-64.2 to -53.3)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.9 (-91.0 to -69.7)	-85.1 (-91.5 to -72.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-84.1 (-91.6 to -72.6)	-84.8 (-91.7 to -75.1)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to 0.0)	-100.0 (-100.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.9 (-100.0 to nan)	-99.9 (-100.0 to nan)
Varicella and herpes zoster	0.5 (0.5 to 0.5)	0.5 (0.5 to 0.6)	9.4 (-2.9 to 25.7)	0.3 (-17.1 to 21.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.9 (-19.3 to 57.2)	-0.9 (-30.3 to 41.4)
Neglected tropical diseases and malaria	-	-	-	-	2.4 (1.5 to 3.6)	1.8 (1.2 to 2.7)	-24.5 (-38.4 to -11.6)	-34.0 (-46.3 to -23.0)
Malaria	42.1 (34.2 to 52.6)	35.2 (27.8 to 46.5)	-16.9 (-33.9 to 4.6)	-23.0 (-38.7 to -4.0)	0.4 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-15.7 (-23.7 to -7.0)	-25.6 (-32.3 to -17.7)
Chagas disease	6.1 (5.6 to 6.6)	6.8 (6.2 to 7.4)	12.8 (0.4 to 26.5)	1.4 (-8.9 to 13.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	1.3 (-6.9 to 25.0)	-1.1 (-14.2 to 13.8)
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.8 (-51.3 to 63.8)	-16.3 (-56.2 to 40.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.8 (-51.3 to 64.0)	-16.3 (-56.2 to 41.3)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.9 (22.1 to 69.2)	28.5 (8.0 to 55.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.7 (11.0 to 86.1)	29.1 (-1.6 to 71.0)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.3 (0.2 to 0.6)	0.1 (0.0 to 0.1)	-85.5 (-95.3 to -58.7)	-85.3 (-94.5 to -60.7)	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-84.3 (-94.8 to -53.1)	-84.0 (-94.3 to -56.5)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	33.9 (24.2 to 49.9)	16.2 (5.5 to 26.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.5 (24.4 to 74.6)	17.0 (-10.7 to 48.8)
Lymphatic filariasis	35.4 (29.1 to 42.2)	15.1 (11.3 to 20.1)	-57.4 (-66.2 to -47.0)	-60.6 (-68.2 to -52.2)	1.1 (0.5 to 2.0)	0.8 (0.4 to 1.5)	-22.7 (-44.0 to -2.7)	-35.2 (-52.4 to -18.5)
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.1 (0.0 to 0.3)	0.6 (0.3 to 1.4)	437.0 (432.7 to 441.9)	389.4 (385.5 to 393.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	436.7 (339.1 to 565.6)	391.0 (308.8 to 488.4)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.3 (-54.9 to 7.7)	-25.6 (-58.2 to -9.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.3 (-54.9 to 7.9)	35.6 (-58.3 to -9.1)
Intestinal nematode infections	-	-	-	-	0.4 (0.2 to 0.9)	0.1 (0.1 to 0.2)	-71.4 (-86.4 to -44.6)	-69.8 (-85.2 to -40.1)
Ascariasis	93.7 (60.4 to 147.5)	101.8 (66.4 to 153.5)	8.9 (-40.7 to 110.4)	3.4 (-48.6 to 108.7)	0.3 (0.1 to 0.7)	0.0 (0.0 to 0.1)	0.0 (-95.2 to -56.9)	83.1 (-94.6 to -48.3)
Trichuriasis	120.9 (78.4 to 186.0)	70.0 (47.0 to 103.9)	-41.9 (-67.8 to 3.5)	-47.3 (-71.6 to 1.9)	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-86.8 (-96.4 to -45.4)	87.9 (-97.0 to -43.5)
Hookworm disease	20.5 (13.7 to 30.9)	22.6 (15.9 to 32.3)	10.1 (-35.1 to 86.5)	9.9 (-45.5 to 86.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	11.6 (-33.3 to 92.1)	0.1 (-42.2 to 82.6)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	11.0 (8.6 to 13.4)	10.7 (10.2 to 11.4)	-2.3 (-19.7 to 24.2)	-16.6 (-30.1 to 4.0)	0.4 (0.2 to 0.6)	0.4 (0.3 to 0.6)	-1.1 (-13.2 to 40.7)	-17.4 (-27.2 to 16.1)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Maternal hemorrhage	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.5 (-3.3 to 20.0)	3.2 (-5.0 to 17.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.7 (-11.1 to 32.8)	2.0 (-12.4 to 29.9)
Maternal sepsis and other maternal infections	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-14.2 (-13.9 to 29.7)	-14.2 (-26.0 to 10.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.3 (-29.1 to 12.6)	-16.6 (-34.2 to 6.8)
Maternal hypertensive disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-3.4 (-10.6 to 6.6)	-0.8 (-7.9 to 8.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.2 (-28.0 to 30.4)	-0.9 (-26.0 to 33.5)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.7 (-41.8 to 45.9)	3.2 (-37.4 to 52.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.7 (-41.8 to 46.3)	3.2 (-37.5 to 52.8)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.3 (-26.8 to 188.1)	41.2 (-21.7 to 173.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.3 (-39.5 to 205.1)	38.7 (-35.6 to 189.1)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Neonatal disorders	-	-	-	-	0.9 (0.5 to 1.3)	1.2 (0.8 to 1.6)	35.0 (-8.9 to 111.6)	22.1 (-17.3 to 91.6)
Preterm birth complications	3.0 (1.7 to 5.3)	6.2 (3.4 to 11.5)	113.2 (34.9 to 189.8)	94.5 (27.2 to 161.2)	0.6 (0.2 to 0.6)	0.6 (0.4 to 1.0)	87.8 (-11.1 to 232.2)	69.3 (-19.1 to 196.9)
Neonatal encephalopathy due to birth asphyxia and trauma	3.3 (1.0 to 8.7)	3.1 (0.9 to 8.1)	-8.0 (-34.4 to 19.9)	-16.6 (-38.1 to 6.8)	0.3 (0.1 to 0.4)	0.2 (0.1 to 0.4)	-13.6 (-64.2 to 65.0)	-21.4 (-66.0 to 47.2)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	144.2 (125.8 to 235.6)	151.2 (132.4 to 245.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (112.9 to 242.0)	0.0 (119.1 to 251.9)
Hemolytic disease and other neonatal jaundice	0.5 (0.2 to 1.0)	0.4 (0.3 to 0.8)	-13.1 (-66.9 to 108.8)	-20.9 (-70.4 to 87.9)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-8.2 (-64.8 to 108.9)	-17.1 (-68.2 to 89.7)
Other neonatal disorders	-	-	-	-	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.2)	96.2 (-5.6 to 278.6)	78.4 (-13.6 to 240.6)
Nutritional deficiencies	-	-	-	-	7.5 (5.0 to 10.7)	6.6 (4.4 to 9.4)	-11.8 (-16.9 to -7.6)	-24.2 (-28.1 to -20.6)
Protein-energy malnutrition	4.2 (2.3 to 6.9)	2.1 (1.2 to 3.6)	-49.0 (-75.8 to 8.5)	-48.6 (-75.2 to 6.4)	0.5 (0.2 to 0.9)	0.3 (0.1 to 0.5)	-48.9 (-76.0 to 10.7)	-48.8 (-75.5 to 7.9)
Iodine deficiency	1.2 (0.9 to 1.6)	0.8 (0.6 to 1.1)	-31.0 (-52.9 to 2.4)	-35.0 (-55.8 to -2.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.5 (-52.9 to 5.1)	-34.7 (-55.8 to -1.0)
Vitamin A deficiency	0.4 (0.3 to 0.5)	0.2 (0.1 to 0.3)	-50.2 (-58.2 to -39.1)	-54.7 (-61.4 to -45.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.5 (-61.0 to -38.9)	-55.8 (-63.6 to -45.1)

Appendix Table G.4 - Guyana prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	206.9 (204.5 to 209.1)	189.6 (188.5 to 191.0)	-8.3 (-9.4 to -7.2)	-20.0 (-21.0 to -19.0)	6.9 (4.6 to 10.0)	6.3 (4.2 to 9.1)	-8.7 (-10.5 to -7.5)	-22.4 (-23.8 to -21.0)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-47.2 (-82.0 to 38.9)	-46.6 (-81.7 to 36.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.5 (0.3 to 0.8)	0.5 (0.3 to 0.7)	-1.7 (-9.3 to 9.3)	-12.9 (-19.9 to -3.7)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-4.0 (-13.4 to 15.4)	-5.9 (-16.5 to 6.9)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.1 (-19.9 to 19.1)	-14.0 (-27.4 to 0.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.7 (-30.5 to 42.1)	-13.5 (-37.6 to 20.4)
Chlamydial infection	21.1 (17.1 to 25.3)	20.2 (16.8 to 23.8)	-4.2 (-25.4 to 25.4)	-6.1 (-26.5 to 20.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.1 (-18.2 to 24.4)	-3.6 (-19.3 to 17.2)
Gonococcal infection	2.3 (1.9 to 2.8)	2.3 (1.6 to 2.8)	-0.1 (-25.9 to 32.9)	-1.3 (-26.2 to 29.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.8 (-43.6 to 28.5)	-16.8 (-44.3 to 21.9)
Trichomoniasis	4.6 (3.2 to 6.9)	4.9 (2.1 to 7.4)	9.0 (-57.2 to 103.3)	-3.3 (-61.2 to 71.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.8 (-63.9 to 118.9)	-4.3 (-66.3 to 84.5)
Genital herpes	160.8 (152.7 to 167.9)	170.7 (161.9 to 179.7)	6.1 (-1.0 to 14.7)	-5.6 (-11.8 to 21.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-5.0 to 13.5)	0.0 (-13.1 to 12.2)
Other sexually transmitted diseases	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-5.0 (-15.9 to 14.2)	-19.8 (-29.4 to -4.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.9 (-22.0 to 56.9)	0.7 (-26.4 to 40.4)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-16.7 (-28.3 to -2.7)	-26.5 (-38.2 to -10.5)
Hepatitis A	1.0 (1.0 to 1.0)	1.0 (0.9 to 1.0)	-3.6 (-3.6 to -3.5)	-8.8 (-9.0 to -8.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.4 (-9.4 to 13.7)	-1.9 (-12.0 to 8.8)
Hepatitis B	33.3 (22.8 to 42.7)	18.4 (13.6 to 23.4)	-45.9 (-64.3 to -7.6)	-51.0 (-67.3 to -22.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.5 (-57.6 to -9.8)	-49.9 (-64.3 to -19.0)
Hepatitis C	11.5 (10.1 to 12.8)	9.6 (8.5 to 10.7)	-16.5 (-27.6 to -8.8)	-25.8 (-34.9 to -13.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.1 (-35.3 to 5.7)	-27.6 (-47.4 to -1.8)
Hepatitis E	-	-	-17.9 (-27.9 to -6.3)	-18.3 (-28.9 to -6.4)	-	-	-	-
Leprosy	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.1)	-15.8 (-51.0 to 98.5)	-23.1 (-52.9 to 78.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.2 (-51.8 to 116.2)	-20.8 (-54.0 to 88.4)
Other infectious diseases	8.2 (6.8 to 9.8)	7.8 (6.6 to 8.4)	-5.0 (-11.9 to 4.1)	-18.5 (-24.5 to -10.9)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	0.1 (-9.1 to 15.5)	-14.7 (-23.8 to -1.7)
Non-communicable diseases	-	-	-	-	50.8 (37.7 to 66.0)	56.2 (41.9 to 72.9)	10.6 (7.5 to 14.4)	2.6 (-0.5 to 5.6)
Neoplasms	-	-	-	-	0.5 (0.3 to 0.6)	0.8 (0.6 to 1.1)	79.1 (36.5 to 126.8)	68.3 (25.0 to 111.5)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.6 (-24.1 to 52.6)	2.1 (-28.3 to 43.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.6 (-25.9 to 47.1)	-0.8 (-31.0 to 37.5)
Stomach cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-12.8 (-33.5 to 19.0)	-15.7 (-35.7 to 13.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.5 (-37.6 to 12.5)	-19.7 (-39.2 to 9.8)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-0.4 to 0.0)	0.0 (-1.9 to 1.5)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	403.0 (160.1 to 801.9)	346.7 (123.2 to 733.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	376.3 (173.4 to 701.6)	329.2 (132.6 to 642.4)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,367.4 (689.0 to 3,272.4)	1,316.2 (682.6 to 3,066.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,249.1 (707.7 to 2,829.7)	1,206.3 (699.9 to 2,806.1)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.7 (7.6 to 234.0)	88.6 (7.2 to 228.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.7 (9.8 to 185.6)	82.1 (11.5 to 188.0)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.3 (32.1 to 310.7)	109.4 (10.3 to 287.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	120.9 (37.0 to 260.5)	98.1 (16.4 to 247.0)
Larynx cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	32.9 (-10.7 to 88.3)	8.1 (-25.9 to 54.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.1 (-8.8 to 97.2)	12.4 (-24.0 to 61.6)
Tracheal, bronchus and lung cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	19.3 (-9.2 to 56.8)	9.7 (-16.5 to 42.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.4 (-12.8 to 55.0)	5.7 (-19.7 to 40.9)
Breast cancer	0.7 (0.6 to 0.8)	1.5 (1.0 to 2.1)	107.8 (40.9 to 204.5)	76.5 (23.4 to 151.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	102.5 (38.6 to 193.1)	80.6 (27.6 to 155.1)
Cervical cancer	0.6 (0.4 to 0.8)	0.8 (0.5 to 1.2)	23.3 (-21.9 to 97.4)	8.1 (-3.5 to 59.1)	0.1 (0.0 to 0.1)	0.2 (0.0 to 0.1)	21.3 (-19.7 to 94.1)	3.1 (-31.4 to 58.9)
Uterine cancer	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	145.7 (13.3 to 316.5)	113.9 (3.8 to 248.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	139.1 (15.5 to 293.3)	117.1 (5.6 to 246.9)
Prostate cancer	0.8 (0.5 to 1.3)	1.7 (1.0 to 2.6)	122.6 (-0.4 to 306.8)	128.2 (2.6 to 303.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	80.3 (-19.9 to 225.0)	98.6 (-11.0 to 248.0)
Colon and rectum cancer	0.3 (0.3 to 0.4)	0.6 (0.5 to 0.8)	101.4 (54.9 to 157.6)	94.2 (51.4 to 145.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	82.1 (42.9 to 135.6)	80.7 (42.4 to 130.7)
Lip and oral cavity cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	19.1 (-17.4 to 69.7)	3.4 (-21.2 to 48.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.8 (-19.8 to 65.9)	1.5 (-27.8 to 47.5)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-10.6 (-25.5 to 63.8)	-10.6 (-40.3 to 30.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.1 (-27.2 to 53.4)	-12.9 (-40.6 to 24.5)
Other pharynx cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	23.6 (-23.8 to 113.0)	-3.1 (-39.8 to 55.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.7 (-24.5 to 96.4)	-4.9 (-39.0 to 51.9)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-59.1 (-75.2 to -8.1)	-57.9 (-74.1 to -7.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-74.3 to -8.2)	-57.3 (-74.3 to -7.7)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	395.4 (270.0 to 560.7)	393.0 (266.3 to 551.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	341.7 (233.7 to 469.5)	331.2 (222.3 to 465.8)
Malignant skin melanoma	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	7.3 (-22.0 to 63.0)	7.6 (-32.2 to 37.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.6 (-23.7 to 59.9)	8.6 (-32.2 to 34.7)
Non-melanoma skin cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	158.0 (59.8 to 258.7)	138.9 (49.4 to 236.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	320.4 (65.7 to 569.7)	318.8 (65.9 to 597.6)
Ovarian cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	391.2 (230.9 to 637.8)	349.8 (208.5 to 568.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	359.0 (193.7 to 613.6)	335.1 (179.1 to 570.2)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	512.4 (-20.2 to 1,204.6)	429.8 (-29.7 to 1,008.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	442.3 (-25.3 to 1,303.9)	379.8 (-36.1 to 1,052.7)
Kidney cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	43.5 (9.6 to 92.4)	26.1 (-4.3 to 72.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.2 (1.2 to 84.3)	10.9 (-11.3 to 62.8)
Bladder cancer	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-32.8 (-52.0 to 5.2)	-29.4 (-49.6 to 9.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.9 (-52.6 to 4.7)	-28.1 (-49.3 to 10.8)
Brain and nervous system cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	426.4 (59.6 to 776.3)	393.9 (40.5 to 646.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	433.5 (53.0 to 696.4)	394.2 (37.4 to 581.3)
Thyroid cancer	0.3 (0.2 to 0.4)	0.7 (0.4 to 1.0)	136.0 (12.5 to 264.1)	103.2 (-1.7 to 202.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	133.5 (11.9 to 256.4)	101.3 (-2.4 to 201.1)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.0 (48.7 to 150.9)	99.6 (48.6 to 147.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.3 (47.4 to 144.7)	97.9 (39.2 to 145.7)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.2)	1,178.7 (57.6 to 1,900.0)	1,130.5 (42.6 to 1,737.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,118.3 (39.9 to 1,739.9)	1,064.1 (40.2 to 1,589.4)
Non-Hodgkin lymphoma	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	93.5 (26.2 to 170.1)	69.8 (9.9 to 136.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.7 (19.0 to 149.2)	57.8 (4.0 to 119.5)
Multiple myeloma	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	80.0 (-0.7 to 215.7)	58.1 (-11.6 to 177.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.2 (-5.4 to 215.0)	52.8 (-15.6 to 180.8)
Leukemia	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	62.3 (13.3 to 180.9)	62.3 (13.9 to 141.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.7 (17.6 to 134.7)	55.9 (14.9 to 109.6)
Other neoplasms	0.5 (0.5 to 0.7)	1.5 (1.1 to 2.1)	165.7 (91.2 to 279.8)	147.5 (84.7 to 235.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	148.8 (79.6 to 241.8)	130.7 (72.1 to 205.6)
Cardiovascular diseases	-	-	-	-	0.6 (0.4 to 0.8)	0.8 (0.6 to 1.1)	35.1 (10.6 to 69.0)	40.9 (15.5 to 74.3)
Rheumatic heart disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.1 (-3.5 to 25.5)	-6.9 (-18.9 to 7.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.4 (-4.1 to 28.9)	-6.7 (-19.0 to 9.7)
Ischemic heart disease	3.6 (3.1 to 4.2)	6.2 (4.5 to 8.2)	70.7 (25.0 to 124.8)	74.2 (27.7 to 127.9)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	105.0 (38.1 to 189.8)	108.1 (39.4 to 191.8)
Cerebrovascular disease	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-7.0 (-24.3 to 16.8)	3.8 (-20.9 to 22.5)
Ischemic stroke	1.0 (0.9 to 1.2)	0.9 (0.8 to 1.1)	-11.0 (-29.1 to 21.1)	-3.3 (-21.7 to 30.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-9.5 (-28.3 to 22.5)	-3.1 (-21.6 to 29.7)
Hemorrhagic stroke	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.4)	-0.6 (-25.3 to 33.6)	-6.2 (-31.5 to 33.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	2.0 (-25.0 to 38.8)	-5.2 (-31.9 to 33.0)
Hypertensive heart disease	0.3 (0.3 to 0.4)	0.3 (0.2 to 0.3)	-27.2 (-36.6 to -15.2)	-27.7 (-33.1 to -9.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-2.8 (-37.3 to -11.8)	-22.4 (-33.8 to -8.0)
Cardiomyopathy and myocarditis	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	0.0 (-16.2 to 19.9)	0.0 (-24.0 to 12.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-19.6 to 27.4)	0.0 (-26.8 to 15.1)
Atrial fibrillation and flutter	0.8 (0.7 to 1.0)	1.7 (1.4 to 2.1)	117.0 (63.4 to 179.0)	155.5 (90.7 to 246.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	122.2 (63.8 to 190.8)	158.3 (92.6 to 250.8)
Peripheral vascular disease	15.3 (12.4 to 18.1)	16.8 (12.9 to 20.6)	10.0 (-16.9 to 48.8)	-0.7 (-21.7 to 29.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.9 (-76.9 to -4.7)	-27.4 (-63.7 to 46.3)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.7 (-48.4 to -23.7)	-37.2 (-49.7 to -23.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-51.3 to -19.4)	-39.3 (-53.2 to -22.1)
Other cardiovascular and circulatory diseases	1.7 (0.8 to 3.0)	9.4 (1.3 to 2.2)	44.7 (-43.3 to 127.7)	41.6 (-53.3 to 78.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	9.3 (-43.3 to 129.8)	12.2 (-53.9 to 81.6)
Chronic respiratory diseases	-	-	-	-	3.6 (2.4 to 4.9)	3.4 (2.2 to 4.8)	-5.9 (-27.3 to 17.6)	-9.4 (-27.9 to 12.3)
Chronic obstructive pulmonary disease	25.5 (24.3 to 26.6)	29.0 (27.6 to 30.4)	14.1 (10.2 to 17.9)	-0.3 (-3.6 to 2.7)	1.5 (1.0 to 2.2)	2.0 (1.3 to 2.8)	32.4 (4.0 to 60.2)	16.7 (8.4 to 40.1)

Appendix Table G.4 - Guyana prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.1 (-2.5 to 7.4)	7.2 (-10.7 to -3.3)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.3 (-11.5 to -4.8)	-16.7 (-19.5 to -14.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-11.7 to -5.1)	-15.9 (-19.8 to -14.1)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.9 (3.0 to 17.3)	-4.1 (-4.8 to 5.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.6 (2.7 to 17.0)	-0.3 (-5.1 to 5.0)
Asthma	34.5 (28.8 to 41.3)	23.0 (14.6 to 32.7)	-35.2 (-56.8 to 2.7)	-29.5 (-47.7 to 8.9)	1.5 (1.0 to 2.2)	1.0 (0.5 to 1.6)	-35.9 (-57.9 to 2.5)	-30.0 (-48.5 to 7.8)
Interstitial lung disease and pulmonary sarcoidosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.4 (-17.9 to 52.7)	9.0 (-22.2 to 48.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.8 (-18.1 to 52.9)	8.7 (-21.8 to 49.1)
Other chronic respiratory diseases	-	-	-	-	0.5 (0.3 to 0.8)	0.3 (0.2 to 0.6)	-36.9 (-59.7 to 10.2)	-44.1 (-64.4 to -1.8)
Cirrhosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	26.6 (9.8 to 44.6)	7.5 (-5.1 to 21.1)
Cirrhosis due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.7 (-54.0 to 98.7)	-19.3 (-54.6 to 71.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.2 (-57.3 to 112.1)	-19.4 (-59.7 to 81.4)
Cirrhosis due to hepatitis C	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	67.3 (-17.5 to 207.4)	46.6 (-31.8 to 162.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.7 (-22.8 to 225.1)	46.9 (-34.3 to 175.6)
Cirrhosis due to alcohol use	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-0.4 (-30.7 to 44.7)	-18.3 (-42.0 to 19.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.6 (-35.4 to 55.2)	-18.1 (-45.1 to 24.2)
Cirrhosis due to other causes	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	48.1 (16.8 to 89.1)	36.3 (5.6 to 85.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.2 (-1.1 to 127.2)	36.2 (-6.2 to 108.2)
Digestive diseases	-	-	-	-	0.9 (0.7 to 1.3)	1.1 (0.8 to 1.5)	12.9 (5.1 to 21.5)	6.4 (-0.5 to 12.8)
Peptic ulcer disease	6.0 (5.3 to 6.6)	3.4 (2.9 to 3.9)	-42.9 (-48.9 to -35.7)	-41.2 (-47.0 to -34.0)	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-36.9 (-46.4 to -27.4)	-36.6 (-45.3 to -28.9)
Gastritis and duodenitis	12.6 (11.6 to 13.4)	13.1 (12.2 to 13.9)	3.6 (-5.0 to 13.4)	7.6 (0.9 to 14.9)	0.5 (0.3 to 0.6)	0.5 (0.3 to 0.7)	4.4 (-1.7 to 17.6)	5.6 (-1.7 to 14.7)
Appendicitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.3 (-24.9 to 32.1)	-7.2 (-27.3 to 17.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.9 (-28.9 to 46.5)	-5.1 (-29.7 to 25.5)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.8 (-14.3 to 102.2)	35.4 (-1.7 to 83.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.7 (-19.8 to 118.9)	33.0 (-8.9 to 96.6)
Inguinal, femoral, and abdominal hernia	2.8 (2.5 to 3.1)	1.6 (1.4 to 1.8)	-41.7 (-50.9 to -31.9)	-42.9 (-52.2 to -31.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-40.7 (-50.1 to -30.5)	-42.4 (-52.1 to -30.9)
Inflammatory bowel disease	0.7 (0.6 to 0.7)	1.0 (0.9 to 1.0)	48.0 (37.8 to 59.8)	26.5 (17.8 to 36.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	48.9 (34.0 to 63.6)	27.1 (16.0 to 39.3)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.3 (-46.0 to 23.4)	-6.8 (-45.8 to 45.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.3 (-46.0 to 23.4)	-6.8 (-45.8 to 46.2)
Gallbladder and biliary diseases	0.4 (0.3 to 0.4)	0.3 (0.2 to 0.3)	-29.2 (-39.7 to -13.6)	-32.0 (-42.3 to -17.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-29.1 (-40.9 to -11.4)	-32.6 (-43.4 to -15.7)
Pancreatitis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	67.4 (56.3 to 79.1)	50.7 (41.3 to 61.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.8 (25.3 to 119.2)	48.7 (17.5 to 89.7)
Other digestive diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	335.0 (228.9 to 446.4)	316.6 (213.8 to 425.0)
Neurological disorders	-	-	-	-	4.5 (3.0 to 6.1)	5.1 (3.4 to 7.1)	15.5 (-3.3 to 34.1)	13.0 (-1.3 to 29.4)
Alzheimer disease and other dementias	3.7 (3.3 to 4.2)	2.7 (2.4 to 3.0)	-27.3 (-39.1 to -13.4)	-1.7 (-15.5 to 21.2)	0.5 (0.4 to 0.7)	0.4 (0.3 to 0.5)	-28.4 (-40.3 to -14.6)	2.1 (-15.6 to 22.0)
Parkinson disease	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-15.5 (-23.6 to -9.6)	-3.6 (-9.8 to 2.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.9 (-27.9 to 1.4)	-4.0 (-19.5 to 14.1)
Epilepsy	1.8 (1.2 to 2.3)	2.4 (1.6 to 3.2)	36.3 (-18.2 to 121.7)	24.1 (-25.5 to 101.5)	0.6 (0.3 to 0.9)	0.8 (0.5 to 1.3)	46.7 (-13.4 to 144.0)	33.6 (-21.4 to 122.8)
Multiple sclerosis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	124.0 (101.5 to 149.1)	85.6 (66.9 to 107.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.2 (78.7 to 162.3)	79.3 (49.1 to 115.9)
Migraine	7.7 (60.9 to 84.4)	76.3 (64.8 to 87.1)	878.5 (81.1 to 29.0)	878.5 (23.2 to 16.2)	2.5 (1.5 to 3.8)	2.6 (1.6 to 3.9)	3.7 (-18.5 to 30.4)	-3.8 (-23.7 to 16.3)
Tension-type headache	132.1 (99.7 to 173.4)	164.4 (152.4 to 175.7)	25.7 (-4.5 to 67.6)	7.5 (-15.2 to 46.0)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.4)	26.1 (-4.5 to 69.6)	7.8 (-15.0 to 48.3)
Medication overuse headache	3.1 (2.0 to 4.3)	5.1 (3.3 to 7.0)	64.4 (23.3 to 121.2)	40.1 (8.0 to 88.5)	0.5 (0.3 to 0.8)	0.8 (0.4 to 1.2)	64.7 (22.7 to 123.2)	40.6 (7.2 to 88.9)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.6 (-14.2 to 42.9)	1.3 (-21.7 to 32.8)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.4)	43.2 (0.5 to 109.0)	90.9 (34.3 to 182.8)
Mental and substance use disorders	-	-	-	-	16.7 (12.0 to 22.1)	18.2 (13.0 to 24.2)	8.9 (-5.7 to 22.2)	0.0 (-2.1 to 2.5)
Schizophrenia	1.7 (1.6 to 1.9)	2.0 (1.8 to 2.2)	17.4 (11.8 to 23.2)	-0.8 (-5.1 to 3.2)	1.1 (0.8 to 1.4)	1.3 (1.0 to 1.6)	17.4 (9.2 to 26.2)	-0.6 (-6.6 to 5.6)
Alcohol use disorders	4.4 (4.1 to 4.8)	5.5 (5.2 to 5.9)	24.5 (18.2 to 30.6)	11.6 (6.3 to 16.5)	0.4 (0.3 to 0.6)	0.5 (0.4 to 0.8)	24.8 (16.3 to 33.8)	12.1 (5.0 to 19.3)
Drug use disorders	-	-	-	-	0.9 (0.6 to 1.3)	1.0 (0.7 to 1.4)	5.3 (-12.7 to 27.3)	1.2 (-15.0 to 20.1)
Opioid use disorders	0.4 (0.2 to 0.8)	0.6 (0.3 to 1.0)	30.8 (15.2 to 46.8)	4.1 (-7.1 to 14.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	30.8 (9.6 to 54.7)	4.5 (-10.0 to 21.0)
Cocaine use disorders	1.2 (0.8 to 1.5)	1.3 (1.0 to 1.5)	7.8 (-23.5 to 66.4)	7.8 (-26.4 to 48.7)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	9.5 (-25.4 to 68.7)	2.3 (-27.9 to 52.2)
Amphetamine use disorders	1.5 (1.4 to 1.6)	1.4 (1.3 to 1.5)	-7.7 (-17.2 to 1.0)	-2.3 (-11.9 to 6.7)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-8.0 (-20.9 to 8.0)	-2.7 (-15.8 to 13.7)
Cannabis use disorders	1.2 (1.0 to 1.3)	1.1 (1.0 to 1.3)	-1.0 (-2.2 to 0.2)	1.1 (0.8 to 1.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.6 (-15.3 to 16.3)	1.5 (-12.8 to 18.0)
Other drug use disorders	-	-	-	-	0.4 (0.2 to 0.5)	0.4 (0.2 to 0.5)	-1.1 (-28.0 to 41.0)	-0.3 (-27.8 to 41.3)
Depressive disorders	-	-	-	-	6.2 (4.0 to 8.9)	6.6 (4.3 to 9.4)	7.4 (1.2 to 14.4)	0.9 (-5.6 to 4.4)
Major depressive disorder	26.2 (20.4 to 31.1)	27.9 (21.6 to 33.6)	6.5 (-0.4 to 13.5)	-1.0 (-6.5 to 5.2)	5.4 (3.5 to 7.8)	5.8 (3.7 to 8.3)	6.6 (-0.7 to 14.3)	-1.1 (-6.6 to 5.1)
Dysthymia	8.0 (6.6 to 9.4)	9.0 (7.5 to 10.6)	13.1 (9.0 to 18.2)	0.6 (0.3 to 1.0)	0.8 (0.5 to 1.1)	0.9 (0.6 to 1.3)	13.3 (7.8 to 19.2)	0.6 (-1.8 to 3.1)
Bipolar disorder	5.1 (4.3 to 6.0)	5.5 (4.7 to 6.3)	6.7 (0.3 to 14.2)	-0.9 (-6.0 to 4.1)	1.1 (0.6 to 1.6)	1.1 (0.7 to 1.7)	6.8 (-0.9 to 15.9)	-0.8 (-6.8 to 5.8)
Anxiety disorders	41.9 (27.9 to 54.8)	45.4 (30.5 to 58.4)	8.4 (3.6 to 13.1)	8.4 (-0.5 to 0.6)	3.9 (2.3 to 5.8)	4.2 (2.5 to 6.3)	8.4 (3.2 to 14.0)	0.1 (-1.7 to 2.2)
Eating disorders	-	-	-	-	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	-5.4 (-13.1 to 3.9)	-1.1 (-8.6 to 7.0)
Anorexia nervosa	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-0.2 (-8.6 to 10.7)	1.1 (-7.4 to 11.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.1 (-19.9 to 24.6)	1.2 (-19.0 to 25.5)
Bulimia nervosa	1.0 (0.7 to 1.5)	0.9 (0.6 to 1.4)	-8.7 (-10.0 to -1.9)	-1.8 (-2.4 to -1.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-6.6 (-14.9 to 3.4)	-1.5 (-10.1 to 7.5)
Autistic spectrum disorders	-	-	-	-	0.9 (0.6 to 1.2)	1.0 (0.7 to 1.3)	12.4 (8.2 to 16.9)	0.8 (-2.7 to 4.3)
Autism	2.2 (2.1 to 2.3)	2.4 (2.3 to 2.6)	11.9 (11.7 to 12.1)	0.4 (0.3 to 0.4)	0.5 (0.4 to 0.7)	0.6 (0.4 to 0.8)	12.3 (6.3 to 18.4)	0.9 (-4.2 to 5.6)
Asperger syndrome	3.2 (3.0 to 3.4)	3.6 (3.3 to 3.8)	12.3 (12.0 to 12.5)	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	12.7 (7.9 to 17.6)	0.8 (-2.8 to 4.8)
Attention-deficit/hyperactivity disorder	6.3 (5.8 to 6.7)	7.0 (6.4 to 7.4)	11.2 (11.0 to 11.7)	3.0 (2.9 to 3.2)	0.1 (0.0 to 1.1)	0.1 (0.0 to 1.1)	11.5 (3.6 to 19.2)	3.1 (-3.9 to 10.4)
Conduct disorder	8.5 (8.0 to 9.1)	9.5 (8.8 to 10.1)	10.9 (9.9 to 11.9)	1.3 (1.1 to 1.5)	1.1 (0.6 to 1.5)	1.1 (0.7 to 1.7)	11.3 (6.6 to 16.3)	3.7 (-0.6 to 8.3)
Idiopathic intellectual disability	3.0 (1.3 to 4.7)	2.9 (1.3 to 4.7)	-2.0 (-33.9 to 35.5)	-10.1 (-38.6 to 25.3)	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-2.2 (-34.8 to 39.8)	-10.7 (-40.0 to 26.3)
Other mental and substance use disorders	10.6 (9.9 to 11.3)	11.5 (10.8 to 12.2)	8.7 (6.9 to 10.6)	-0.8 (-1.4 to -0.2)	0.8 (0.5 to 1.1)	0.9 (0.6 to 1.2)	8.9 (4.3 to 14.3)	-0.5 (-3.9 to 3.4)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	5.2 (3.6 to 7.2)	6.4 (4.3 to 8.9)	22.8 (9.5 to 36.4)	7.7 (-6.3 to 21.1)
Diabetes mellitus	29.5 (24.8 to 34.4)	45.6 (37.4 to 54.5)	55.3 (25.1 to 91.7)	28.5 (-1.1 to 61.4)	2.0 (1.4 to 2.9)	3.1 (2.0 to 4.4)	51.5 (21.2 to 88.3)	25.6 (-2.6 to 56.7)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.7 (16.1 to 39.1)	19.4 (9.2 to 29.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.7 (16.1 to 39.1)	19.4 (9.2 to 29.0)
Chronic kidney disease	-	-	-	-	0.9 (0.6 to 1.2)	1.0 (0.7 to 1.3)	9.6 (-4.8 to 29.2)	-0.7 (-13.1 to 17.3)
Chronic kidney disease due to diabetes mellitus	15.4 (11.2 to 20.4)	18.3 (12.5 to 26.7)	17.5 (-8.9 to 59.7)	5.2 (-19.6 to 44.9)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	16.4 (-13.4 to 58.0)	2.8 (-23.1 to 52.7)
Chronic kidney disease due to hypertension	10.4 (6.9 to 16.4)	12.4 (6.7 to 20.6)	17.8 (-14.4 to 67.2)	6.5 (-19.4 to 43.5)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	6.6 (-12.4 to 29.2)	-2.3 (-17.3 to 15.0)
Chronic kidney disease due to glomerulonephritis	23.6 (16.1 to 35.1)	25.3 (17.1 to 39.1)	6.6 (-15.5 to 32.0)	0.7 (-18.0 to 26.3)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	17.8 (-20.4 to 62.0)	7.3 (-26.9 to 55.6)
Chronic kidney disease due to other causes	22.8 (14.2 to 35.3)	23.9 (16.2 to 37.2)	5.6 (-16.2 to 29.7)	-3.9 (-21.7 to 18.9)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	5.3 (-20.0 to 39.0)	-4.5 (-27.4 to 24.9)
Urinary diseases and male infertility	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-12.5 (-22.1 to 1.8)	-15.6 (-24.8 to -4.1)

Appendix Table G.4 - Guyana prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.2)	37.6 (23.2 to 55.0)	30.0 (18.2 to 43.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.4 (8.5 to 73.9)	30.6 (4.5 to 59.2)
Urolithiasis	3.9 (2.8 to 5.1)	4.4 (2.9 to 7.5)	1.2 (-17.3 to 77.5)	1.2 (-21.8 to 56.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	18.4 (-2.0 to 79.6)	11.9 (-9.0 to 62.9)
Benign prostatic hyperplasia	3.4 (3.0 to 3.8)	2.6 (2.4 to 2.7)	-22.1 (-33.9 to -15.5)	-22.1 (-31.5 to -12.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-24.2 (-33.1 to -14.0)	-21.6 (-31.0 to -11.0)
Male infertility due to other causes	7.3 (6.0 to 8.6)	6.9 (5.6 to 8.2)	-6.9 (-27.7 to 22.3)	-10.1 (-31.1 to 15.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-5.7 (-28.8 to 23.1)	-9.7 (-31.4 to 18.0)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.9 (-56.6 to 123.8)	-37.0 (-61.4 to 101.0)
Gynecological diseases	-	-	-	-	1.1 (0.7 to 1.6)	1.1 (0.7 to 1.7)	7.2 (5.9 to 21.5)	-7.4 (-18.1 to 4.4)
Uterine fibroids	12.1 (10.8 to 13.2)	16.2 (14.7 to 17.6)	34.1 (32.3 to 36.1)	-2.3 (-2.4 to -2.2)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	8.6 (0.0 to 15.7)	-16.9 (-23.4 to -11.9)
Polycystic ovarian syndrome	13.7 (12.1 to 15.6)	16.1 (14.4 to 17.8)	17.5 (6.6 to 37.3)	1.8 (-12.2 to 17.5)	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.3)	17.5 (0.6 to 37.1)	1.9 (-11.6 to 17.9)
Female infertility due to other causes	7.2 (5.6 to 9.1)	7.1 (5.1 to 9.2)	-2.4 (-33.0 to 39.0)	-14.1 (-41.3 to 22.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-14.7 (-33.8 to 36.6)	-14.7 (-41.5 to 22.4)
Endometriosis	1.3 (1.1 to 1.5)	1.6 (1.3 to 1.8)	19.5 (-4.4 to 50.8)	2.6 (-17.3 to 29.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	19.3 (6.1 to 53.4)	2.7 (-18.0 to 31.9)
Genital prolapse	33.5 (27.3 to 39.5)	42.1 (35.5 to 48.8)	25.2 (-3.0 to 63.2)	3.9 (-16.8 to 32.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	24.9 (-3.9 to 64.8)	3.9 (-17.5 to 32.9)
Premenstrual syndrome	34.9 (25.7 to 42.8)	36.0 (24.4 to 47.4)	3.4 (-30.8 to 52.1)	-2.6 (-33.9 to 43.3)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	2.9 (-31.3 to 51.7)	-2.6 (-35.0 to 44.2)
Other gynecological diseases	3.5 (2.8 to 4.5)	3.2 (2.7 to 3.7)	-9.9 (-32.0 to 17.5)	-17.5 (-37.5 to 5.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-20.1 (-41.4 to 30.3)	-26.5 (-46.5 to 17.1)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.7 (0.5 to 1.0)	0.7 (0.5 to 1.0)	0.4 (6.2 to 11.6)	-13.0 (-18.8 to -3.2)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.5 (0.2 to 14.6)	0.7 (-6.9 to 6.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.7 (-9.6 to 28.9)	0.7 (-18.5 to 18.5)
Thalassemia trait	12.8 (9.8 to 15.8)	14.0 (10.8 to 17.3)	9.7 (5.3 to 12.2)	-0.7 (-4.4 to 1.6)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	10.1 (6.0 to 24.2)	-2.8 (-16.9 to 9.4)
Sickle cell disorders	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.3)	7.7 (8.4 to 31.8)	-0.2 (-13.7 to 19.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	10.2 (-5.5 to 28.0)	2.3 (-10.7 to 17.0)
Sickle cell trait	40.2 (36.2 to 44.3)	44.1 (39.2 to 48.5)	9.4 (5.7 to 14.0)	-1.2 (-4.5 to 3.0)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	9.9 (-2.2 to 37.5)	-3.9 (-20.0 to 20.9)
G6PD deficiency	78.2 (58.4 to 96.2)	90.6 (62.6 to 114.5)	16.4 (-23.4 to 65.7)	3.8 (-31.3 to 47.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.1 (-52.1 to 69.7)	-16.9 (-55.2 to 41.3)
G6PD trait	129.3 (121.0 to 136.0)	139.3 (130.5 to 148.4)	7.7 (-1.6 to 18.4)	0.5 (-8.2 to 10.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.8 (-89.3 to 147.7)	-27.8 (-86.2 to 121.8)
Other hemoglobinopathies and hemolytic anemias	9.3 (8.6 to 10.2)	8.0 (7.4 to 8.8)	-14.2 (-22.7 to -4.0)	-25.1 (-31.5 to -17.7)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-15.8 (-26.9 to 4.0)	-30.1 (-39.8 to -15.0)
Endocrine, metabolic, blood, and immune disorders	49.8 (8.0 to 9.8)	8.3 (7.0 to 9.2)	-83.2 (-20.6 to 6.7)	-17.7 (-28.0 to -8.4)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-45.8 (-26.2 to 15.4)	-49.6 (-34.2 to -8.8)
Musculoskeletal disorders	-	-	-	-	7.8 (5.5 to 10.2)	9.2 (6.5 to 12.2)	17.9 (7.7 to 28.8)	4.6 (-2.7 to 12.0)
Rheumatoid arthritis	1.4 (1.4 to 1.5)	2.2 (2.1 to 2.3)	52.1 (42.9 to 63.1)	52.2 (41.9 to 63.4)	0.3 (0.2 to 0.5)	0.5 (0.4 to 0.7)	52.3 (39.8 to 65.8)	50.9 (39.1 to 64.3)
Osteoarthritis	17.6 (16.9 to 18.2)	19.6 (18.8 to 20.4)	11.5 (5.6 to 17.8)	5.5 (0.3 to 11.0)	1.1 (0.8 to 1.5)	1.2 (0.8 to 1.7)	12.8 (6.6 to 19.1)	5.4 (0.4 to 11.1)
Low back and neck pain	-	-	-	-	5.0 (3.5 to 6.9)	5.7 (3.9 to 7.8)	13.7 (-1.3 to 30.2)	-9.1 (-12.1 to 12.0)
Low back pain	28.0 (25.3 to 30.9)	30.4 (26.5 to 33.8)	8.3 (-8.9 to 28.3)	-2.9 (-14.9 to 11.7)	3.1 (2.1 to 4.4)	3.4 (2.3 to 4.8)	8.9 (-9.1 to 29.4)	-2.6 (-15.4 to 12.9)
Neck pain	19.4 (15.7 to 22.9)	23.4 (19.9 to 26.6)	20.5 (-3.1 to 51.8)	3.0 (-17.2 to 27.2)	1.9 (1.2 to 2.7)	2.3 (1.6 to 3.3)	3.2 (-2.2 to 52.4)	3.2 (-17.1 to 28.2)
Gout	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	5.8 (-6.6 to 20.9)	-9.7 (-19.4 to 3.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.4 (-17.0 to 37.3)	-8.8 (-29.3 to 15.9)
Other musculoskeletal disorders	14.7 (12.2 to 17.4)	19.0 (15.6 to 22.7)	29.1 (19.1 to 39.2)	8.5 (0.9 to 17.1)	1.3 (0.9 to 1.9)	1.7 (1.1 to 2.5)	8.3 (15.2 to 40.1)	8.3 (0.7 to 17.4)
Other non-communicable diseases	-	-	-	-	11.0 (7.3 to 15.9)	11.2 (7.4 to 16.5)	1.6 (-1.8 to 5.7)	-5.8 (-8.6 to -3.1)
Congenital anomalies	-	-	-	-	0.6 (0.5 to 0.9)	0.8 (0.6 to 1.1)	22.1 (7.5 to 43.0)	7.1 (-5.6 to 24.8)
Neural tube defects	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	5.9 (-13.4 to 32.3)	-2.5 (-20.1 to 22.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	7.8 (-24.1 to 53.8)	-0.3 (-29.4 to 40.7)
Congenital heart anomalies	2.3 (1.9 to 3.1)	3.1 (2.4 to 3.7)	32.2 (-4.3 to 78.6)	20.0 (-13.2 to 62.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	31.6 (-6.1 to 75.0)	19.7 (-14.3 to 59.0)
Orofacial clefts	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.6)	27.1 (-12.4 to 80.3)	17.0 (-19.2 to 66.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.5 (-24.6 to 88.0)	10.9 (-29.3 to 70.6)
Down syndrome	0.5 (0.4 to 0.6)	0.6 (0.5 to 0.8)	16.6 (-7.8 to 66.8)	3.1 (-18.1 to 47.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	17.3 (-8.6 to 69.3)	1.6 (-21.2 to 47.1)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.5 (-30.8 to 63.0)	-2.1 (-36.9 to 49.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.0 (-33.9 to 73.2)	-1.2 (-38.9 to 59.2)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.1 (-30.1 to 73.1)	-4.1 (-38.6 to 52.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.9 (-11.5 to 70.5)	-3.7 (-38.5 to 53.1)
Chromosomal unbalanced rearrangements	1.0 (0.8 to 1.3)	1.2 (1.0 to 1.4)	13.1 (-12.0 to 47.9)	0.2 (-22.0 to 31.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	18.4 (-11.5 to 50.6)	-1.2 (-23.2 to 31.1)
Other congenital anomalies	3.0 (2.5 to 3.4)	2.9 (2.5 to 3.4)	-1.5 (-10.6 to 6.8)	-11.7 (-19.3 to -4.1)	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	25.7 (5.9 to 55.4)	9.4 (-7.2 to 33.5)
Skin and subcutaneous diseases	-	-	-	-	3.7 (2.4 to 5.7)	4.0 (2.6 to 6.2)	8.4 (1.7 to 15.9)	-0.4 (-6.3 to 5.4)
Dermatitis	33.8 (27.4 to 40.6)	37.9 (30.9 to 45.6)	12.2 (9.1 to 14.7)	0.1 (-0.0 to 0.3)	0.9 (0.6 to 1.3)	1.0 (0.6 to 1.5)	11.6 (7.5 to 15.6)	0.3 (-2.7 to 3.1)
Psoriasis	5.5 (4.9 to 6.3)	6.2 (5.4 to 7.0)	11.5 (9.2 to 14.6)	0.1 (-0.4 to 0.3)	0.5 (0.3 to 0.6)	0.5 (0.3 to 0.7)	11.9 (4.9 to 18.8)	0.1 (-5.3 to 5.4)
Cellulitis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-7.1 (-18.6 to 6.0)	-12.7 (-23.2 to -3.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.3 (-22.7 to 15.6)	-11.7 (-27.6 to 4.5)
Pyoderma	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.4)	32.2 (24.5 to 39.8)	21.7 (16.1 to 27.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.0 (13.9 to 54.1)	21.8 (7.2 to 39.0)
Scabies	9.5 (7.9 to 10.9)	10.1 (8.5 to 11.7)	6.0 (-15.8 to 34.2)	-1.6 (-21.1 to 24.4)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.6)	6.2 (-15.8 to 34.1)	-1.4 (-21.4 to 25.1)
Fungal skin diseases	51.9 (39.2 to 68.8)	58.3 (44.1 to 77.0)	12.4 (10.4 to 14.9)	0.2 (-0.2 to 0.5)	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.6)	12.7 (10.3 to 15.6)	0.3 (-0.2 to 1.3)
Viral skin diseases	15.7 (11.7 to 19.9)	17.0 (12.9 to 21.1)	8.1 (4.3 to 13.8)	-0.0 (-2.2 to 2.2)	0.5 (0.3 to 0.8)	0.5 (0.3 to 0.8)	8.4 (3.6 to 14.8)	0.2 (-3.3 to 3.9)
Acne vulgaris	58.8 (45.2 to 75.8)	60.7 (45.0 to 77.7)	2.8 (-24.4 to 41.5)	2.7 (-24.3 to 39.7)	0.6 (0.3 to 1.2)	0.7 (0.3 to 1.3)	3.1 (-24.6 to 41.5)	3.0 (-24.7 to 40.1)
Alopecia areata	0.6 (0.6 to 0.7)	0.7 (0.6 to 0.8)	10.5 (-1.7 to 26.2)	-1.6 (-13.8 to 13.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.0 (-6.4 to 32.9)	-1.5 (-16.5 to 16.0)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.4 (-12.4 to 44.2)	2.0 (-23.2 to 25.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.4 (-12.5 to 44.2)	-2.0 (-23.3 to 25.5)
Urticaria	7.3 (4.9 to 9.5)	7.5 (5.1 to 9.9)	4.1 (-32.9 to 46.3)	-3.4 (-36.8 to 32.5)	0.4 (0.3 to 0.7)	0.4 (0.2 to 0.7)	3.9 (-32.7 to 47.6)	-3.7 (-36.7 to 32.8)
Decubitus ulcer	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-27.5 (-46.2 to -0.6)	-19.9 (-46.9 to 18.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.7 (-45.6 to 6.8)	-20.4 (-47.9 to 21.8)
Other skin and subcutaneous diseases	37.6 (25.1 to 56.2)	41.3 (28.7 to 59.0)	10.3 (-0.9 to 22.6)	-2.0 (-5.8 to 1.7)	0.2 (0.1 to 0.5)	0.2 (0.1 to 0.5)	11.0 (-0.4 to 22.6)	-1.9 (-5.8 to 1.7)
Sense organ diseases	-	-	-	-	4.5 (3.1 to 6.4)	4.2 (2.8 to 6.0)	8.2 (-13.9 to -2.7)	-10.9 (-15.0 to -7.1)
Glaucoma	0.9 (0.8 to 1.1)	0.6 (0.6 to 0.9)	-19.5 (-31.1 to -8.0)	-16.5 (-27.7 to -3.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-21.0 (-35.0 to -7.9)	-13.8 (-28.3 to 2.9)
Cataract	4.2 (3.2 to 5.2)	2.5 (2.0 to 3.1)	-41.2 (-47.8 to -32.5)	-27.6 (-34.0 to -19.3)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-42.4 (-49.5 to -35.3)	-27.7 (-34.6 to -20.9)
Macular degeneration	0.8 (0.6 to 1.1)	1.0 (0.8 to 1.3)	19.1 (-0.6 to 47.6)	8.2 (-11.7 to 35.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	15.5 (-4.0 to 41.1)	6.3 (-12.6 to 30.8)
Uncorrected refractive error	62.2 (58.2 to 66.3)	65.5 (60.5 to 70.0)	5.4 (-5.0 to 15.2)	6.6 (-13.7 to 1.2)	0.9 (0.5 to 1.5)	0.9 (0.5 to 1.5)	-2.3 (-10.0 to 6.1)	-11.5 (-16.8 to -5.4)
Age-related and other hearing loss	85.5 (79.4 to 91.6)	82.9 (76.4 to 90.4)	-3.2 (-7.0 to 2.2)	-9.5 (-12.3 to -6.0)	2.7 (1.8 to 3.8)	2.5 (1.6 to 3.5)	9.4 (-17.3 to -1.4)	-9.4 (-15.1 to -3.4)
Other vision loss	2.0 (1.7 to 2.4)	1.4 (1.2 to 1.7)	-29.3 (-36.5 to -20.8)	-31.7 (-38.5 to -24.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	0.1 (-38.3 to -18.4)	-29.9 (-38.2 to -22.2)
Other sense organ diseases	16.1 (15.3 to 16.9)	17.8 (16.8 to 18.6)	10.1 (3.0 to 18.8)	0.3 (-5.9 to 7.0)	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.7)	10.5 (2.5 to 20.1)	0.2 (-6.5 to 7.6)
Oral disorders	-	-	-	-	2.1 (1.2 to 3.2)	2.2 (1.3 to 3.4)	5.1 (1.3 to 9.1)	-3.6 (-6.4 to -0.8)
Deciduous caries	52.6 (50.2 to 54.9)	64.1 (61.0 to 66.9)	21.8 (14.2 to 30.1)	1.1 (-5.2 to 8.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.7 (11.6 to 33.3)	0.9 (-7.4 to 10.3)
Permanent caries	329.3 (312.8 to 345.2)	360.3 (346.0 to 374.7)	9.3 (3.7 to 15.9)	-0.2 (-5.0 to 5.4)	0.3 (0.1 to 0.6)	0.4 (0.2 to 0.7)	9.5 (3.5 to 16.6)	-0.1 (-5.2 to 6.0)
Periodontal diseases	66.8 (64.0 to 69.6)	77.9 (73.6 to 82.0)	16.7 (8.6 to 24.4)	-2.9 (-9.5 to 3.8)	0.4 (0.2 to 0.9)	0.5 (0.2 to 1.1)	16.9 (8.8 to 24.6)	-2.9 (-9.4 to 4.3)

Appendix Table G.4 - Guyana prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Edentulism and severe tooth loss	33.7 (32.6 to 34.8)	32.1 (30.9 to 33.3)	-4.8 (-9.2 to -0.3)	-5.2 (-9.1 to -0.8)	0.9 (0.6 to 1.3)	0.9 (0.6 to 1.2)	-4.0 (-8.5 to 0.9)	-5.3 (-9.3 to -0.5)
Other oral disorders	11.7 (11.0 to 12.4)	12.9 (12.2 to 13.6)	10.6 (0.7 to 20.3)	-0.6 (-8.5 to 7.0)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	10.7 (0.3 to 20.5)	-0.6 (-8.4 to 7.4)
Injuries	-	-	-	-	3.5 (2.7 to 4.5)	2.9 (2.1 to 3.8)	-18.8 (-26.3 to -10.4)	-25.4 (-32.2 to -18.1)
Transport injuries	-	-	-	-	1.2 (0.9 to 1.6)	1.0 (0.7 to 1.4)	-16.6 (-26.2 to -4.4)	-24.1 (-32.1 to -14.4)
Road injuries	-	-	-	-	1.1 (0.9 to 1.5)	0.9 (0.6 to 1.2)	-22.7 (-32.0 to -11.5)	-29.3 (-37.1 to -20.3)
Pedestrian road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-33.3 (-42.6 to -22.8)	-36.5 (-44.4 to -28.0)
Cyclist road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-18.7 (-27.1 to -8.2)	-25.6 (-33.0 to -16.1)
Motorcyclist road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-28.8 (-37.5 to -18.7)	-37.6 (-44.6 to -29.2)
Motor vehicle road injuries	-	-	-	-	0.6 (0.5 to 0.8)	0.5 (0.4 to 0.7)	-15.9 (-27.2 to -2.2)	-23.5 (-33.0 to -12.2)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.6 (-47.9 to -32.2)	-46.6 (-52.7 to -39.5)
Other transport injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	48.7 (34.1 to 67.8)	30.7 (18.0 to 46.1)
Unintentional injuries	-	-	-	-	2.1 (1.6 to 2.7)	1.6 (1.2 to 2.2)	-20.9 (-27.1 to -14.6)	-26.6 (-32.3 to -20.9)
Falls	-	-	-	-	0.8 (0.6 to 1.0)	0.6 (0.4 to 0.8)	-27.0 (-35.1 to -17.8)	-28.6 (-36.8 to -19.9)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.9 (-43.0 to -23.2)	-38.6 (-46.3 to -29.4)
Fire, heat, and hot substances	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-37.3 (-44.9 to -28.2)	-41.4 (-47.8 to -33.2)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.3 (-37.9 to -7.8)	-33.0 (-42.7 to -19.8)
Exposure to mechanical forces	-	-	-	-	0.9 (0.7 to 1.2)	0.7 (0.5 to 0.9)	-25.9 (-31.0 to -20.5)	-33.7 (-38.2 to -29.1)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	22.4 (6.7 to 39.9)	8.7 (-4.4 to 23.5)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.0 (-14.8 to 11.7)	-11.3 (-21.9 to -0.1)
Other exposure to mechanical forces	-	-	-	-	0.8 (0.6 to 1.1)	0.6 (0.4 to 0.8)	-29.2 (-34.0 to -24.0)	-36.8 (-41.0 to -32.3)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.2 (26.5 to 40.9)	26.4 (20.1 to 33.7)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.8 (25.3 to 52.5)	25.8 (14.9 to 37.3)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.7 (27.2 to 68.1)	31.3 (16.2 to 47.8)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.7 (20.9 to 47.2)	21.8 (10.8 to 33.9)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.7 (-22.8 to -5.1)	-19.0 (-26.0 to -11.0)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.9 (-43.3 to -21.6)	-32.7 (-41.8 to -21.4)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.1 (-13.0 to 20.6)	-10.7 (-21.7 to 3.3)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.4 (-14.5 to 4.6)	-12.3 (-19.8 to -3.9)
Other unintentional injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	22.1 (11.6 to 32.4)	2.3 (6.7 to 10.9)
Self-harm and interpersonal violence	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-16.9 (-26.1 to -5.4)	-27.8 (-35.4 to -18.4)
Self-harm	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-24.8 (-33.6 to -15.2)	-36.0 (-43.2 to -28.1)
Interpersonal violence	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-14.6 (-24.7 to -1.5)	-25.4 (-33.8 to -14.4)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	23.1 (10.1 to 35.9)	5.3 (-5.0 to 16.0)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.7 (-18.8 to 7.5)	-19.9 (-29.7 to -8.0)
Assault by other means	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-35.4 (-44.1 to -24.0)	-42.5 (-49.9 to -32.7)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-

Appendix Table G.4 - Haalt prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	661.9 (482.6 to 862.4)	1,018.8 (751.2 to 1,339.2)	53.4 (47.7 to 65.1)	53.4 (-3.3 to 6.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	196.6 (135.5 to 273.5)	209.2 (146.3 to 285.6)	6.5 (0.1 to 13.3)	-25.6 (-31.0 to -20.3)
HIV/AIDS and tuberculosis	-	-	-	-	16.2 (10.9 to 22.3)	18.7 (12.5 to 27.7)	14.5 (6.6 to 49.2)	-28.2 (-41.5 to -5.3)
Tuberculosis	5.9 (5.7 to 6.1)	11.3 (11.1 to 11.6)	92.7 (86.7 to 99.1)	15.4 (12.1 to 19.0)	1.8 (1.2 to 2.4)	3.5 (2.3 to 4.6)	92.9 (75.4 to 111.3)	15.9 (7.1 to 25.0)
HIV/AIDS	-	-	-	-	14.4 (9.6 to 20.2)	15.2 (9.9 to 23.5)	14.7 (-18.7 to 42.9)	-38.7 (-48.7 to -7.8)
HIV/AIDS resulting in mycobacterial infection	0.7 (0.4 to 0.9)	0.7 (0.4 to 1.1)	8.3 (-15.2 to 40.6)	-34.6 (-49.0 to -14.2)	0.3 (0.1 to 0.4)	0.3 (0.1 to 0.5)	8.7 (-24.4 to 56.0)	-33.8 (-53.6 to -5.4)
HIV/AIDS resulting in other diseases	127.4 (103.6 to 150.3)	121.2 (108.6 to 135.4)	-5.1 (-21.4 to 18.9)	-37.9 (-48.3 to -21.9)	14.2 (9.4 to 19.9)	15.0 (9.6 to 23.1)	4.4 (-19.1 to 43.1)	-33.7 (-48.9 to -7.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	25.9 (18.4 to 35.2)	26.1 (18.3 to 36.1)	0.4 (-6.5 to 7.6)	-21.9 (-27.1 to -16.6)
Diarrheal diseases	73.2 (69.6 to 76.9)	83.2 (78.6 to 87.9)	13.7 (5.3 to 22.0)	0.7 (-6.5 to 7.9)	11.9 (8.0 to 16.5)	13.4 (9.2 to 18.6)	13.5 (4.5 to 22.6)	0.4 (-7.0 to 8.6)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-53.3 to -12.8)	-36.0 (-65.2 to -36.1)
Typhoid fever	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-5.3 (-21.1 to 13.1)	-30.1 (-41.6 to -16.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-21.1 to 13.1)	-5.3 (-41.6 to -16.1)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.2 (-22.9 to 14.5)	-29.9 (-42.3 to -14.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-22.9 to 14.6)	-29.9 (-42.3 to -14.8)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.7 (-85.5 to -42.7)	-78.5 (-88.9 to -57.5)
Lower respiratory infections	5.9 (4.9 to 6.8)	5.6 (4.8 to 6.4)	-5.7 (-22.9 to 19.5)	-16.9 (-29.4 to -1.4)	0.6 (0.4 to 0.9)	0.6 (0.4 to 0.8)	6.3 (-25.5 to 22.4)	-16.9 (-31.6 to 3.0)
Upper respiratory infections	454.9 (434.0 to 475.0)	643.0 (613.1 to 677.2)	41.2 (34.2 to 50.2)	-0.7 (-5.6 to 5.6)	5.3 (3.0 to 8.8)	7.5 (4.2 to 12.5)	41.0 (33.0 to 50.5)	-0.8 (-5.9 to 5.8)
Otitis media	87.7 (82.8 to 93.3)	106.9 (100.3 to 113.3)	22.0 (13.5 to 31.1)	-10.8 (-16.7 to -4.0)	1.7 (1.0 to 2.7)	2.0 (1.2 to 3.2)	19.7 (9.4 to 31.1)	-12.1 (-18.9 to -4.2)
Meningitis	-	-	-	-	5.5 (3.7 to 7.5)	1.8 (1.3 to 2.4)	-67.2 (-71.9 to -60.0)	-77.1 (-80.1 to -72.3)
Pneumococcal meningitis	25.8 (16.5 to 38.2)	8.2 (5.0 to 12.0)	-68.0 (-74.2 to -62.3)	-78.5 (-82.7 to -74.7)	2.4 (1.6 to 3.3)	0.8 (0.5 to 1.0)	0.8 (-75.5 to -59.5)	0.8 (-82.9 to -72.6)
H influenzae type B meningitis	11.6 (4.3 to 21.4)	3.7 (1.6 to 6.7)	-68.4 (-77.0 to -51.0)	-78.6 (-83.8 to -67.1)	1.3 (0.7 to 2.1)	0.4 (0.3 to 0.7)	0.4 (-79.5 to -36.0)	-64.9 (-85.5 to -56.5)
Meningococcal meningitis	2.1 (0.8 to 4.5)	0.7 (0.3 to 1.5)	-66.1 (-73.8 to -54.2)	-77.0 (-82.2 to -69.2)	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.1)	0.1 (-75.4 to -50.6)	-67.0 (-82.6 to -66.1)
Other meningitis	13.7 (7.5 to 23.4)	4.5 (2.5 to 7.6)	-67.5 (-73.0 to -57.3)	-77.4 (-81.3 to -70.5)	1.6 (1.1 to 2.2)	0.6 (0.4 to 0.8)	0.6 (-73.8 to -51.7)	-65.7 (-80.7 to -66.4)
Encephalitis	0.0 (0.5 to 2.2)	1.3 (0.6 to 2.7)	28.3 (17.3 to 45.4)	-16.4 (-23.0 to -5.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	37.4 (18.1 to 61.8)	-9.4 (-21.3 to 5.7)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	80.1 (-98.8 to 445.2)	-82.6 (-98.7 to 222.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-80.1 (-98.8 to 446.6)	-82.6 (-98.7 to 224.3)
Whooping cough	11.4 (8.7 to 14.7)	5.7 (4.4 to 7.2)	-50.1 (-52.3 to -47.8)	-53.0 (-55.1 to -50.8)	0.6 (0.3 to 0.9)	0.3 (0.2 to 0.5)	-50.0 (-54.7 to -44.7)	-52.9 (-57.5 to -47.9)
Tetanus	2.6 (1.3 to 4.5)	0.3 (0.2 to 0.6)	-87.3 (-93.7 to -64.4)	-91.2 (-95.7 to -74.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.0)	0.1 (-86.6 to -58.9)	-87.7 (-89.9 to -70.7)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	5.9 (5.5 to 6.6)	7.4 (6.8 to 8.1)	24.4 (9.8 to 38.6)	2.3 (16.0 to 23.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	55.1 (9.6 to 110.5)	3.7 (-29.2 to 46.8)
Neglected tropical diseases and malaria	-	-	-	-	44.1 (28.0 to 67.8)	29.3 (18.9 to 43.7)	-33.0 (-51.2 to -12.6)	-51.5 (-65.0 to -37.4)
Malaria	264.9 (209.3 to 329.5)	297.3 (242.7 to 359.8)	11.8 (9.8 to 40.4)	-21.1 (-36.7 to -0.9)	2.4 (1.6 to 3.5)	2.4 (1.6 to 3.5)	0.7 (-13.0 to 13.5)	-28.5 (-37.3 to -17.9)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.7)	67.1 (7.6 to 198.2)	3.7 (-42.3 to 78.6)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.0 (-57.8 to 110.5)	-13.0 (-60.2 to 64.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.0 (-58.0 to 111.7)	-13.0 (-60.3 to 64.3)
Cutaneous and mucocutaneous leishmaniasis	18.8 (11.7 to 27.5)	32.0 (17.6 to 50.5)	68.6 (-6.4 to 199.5)	3.8 (-41.1 to 76.8)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.7)	67.9 (-7.7 to 200.9)	3.7 (-42.4 to 78.9)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	4.8 (2.5 to 7.5)	3.8 (1.3 to 9.2)	-29.3 (-76.1 to 156.6)	-46.9 (-81.4 to 65.6)	1.2 (0.6 to 2.2)	1.0 (0.3 to 2.5)	-27.0 (-75.5 to 172.7)	-45.0 (-80.9 to 75.7)
Cystic echinococcosis	0.4 (0.3 to 0.6)	0.7 (0.5 to 0.8)	70.2 (46.5 to 92.9)	8.7 (-5.4 to 24.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	69.3 (28.1 to 125.1)	8.8 (-16.9 to 43.1)
Lymphatic filariasis	666.5 (573.1 to 765.6)	248.1 (179.8 to 335.3)	-62.9 (-72.8 to -51.8)	-74.1 (-80.9 to -66.5)	17.3 (9.7 to 29.0)	17.1 (9.6 to 28.9)	0.1 (-36.1 to 34.0)	-36.7 (-59.3 to -14.9)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	0.9 (0.3 to 2.0)	6.2 (2.5 to 13.7)	606.0 (599.0 to 614.2)	386.2 (381.4 to 391.8)	0.1 (0.0 to 0.4)	1.0 (0.4 to 2.4)	601.2 (451.8 to 824.4)	383.9 (288.9 to 510.6)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.2 (-71.6 to -22.1)	-66.4 (-77.4 to -44.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-71.6 to -22.0)	0.0 (-77.4 to -44.2)
Intestinal nematode infections	-	-	-	-	16.8 (8.3 to 29.9)	0.7 (0.4 to 1.2)	0.7 (-97.3 to -93.4)	0.7 (-98.2 to -94.9)
Ascariasis	1,998.3 (1,651.9 to 2,431.8)	521.8 (332.1 to 792.1)	-74.4 (-84.1 to -58.2)	-81.9 (-89.4 to -68.8)	6.4 (2.7 to 13.1)	0.1 (0.1 to 0.2)	0.1 (-99.0 to -96.6)	0.1 (-99.2 to -96.9)
Trichuriasis	2,964.6 (2,539.1 to 3,466.0)	283.3 (171.5 to 453.1)	-90.7 (-94.4 to -84.5)	-93.6 (-96.3 to -88.7)	7.9 (3.3 to 16.9)	0.0 (0.0 to 0.1)	0.0 (-99.8 to -98.8)	0.0 (-99.9 to -99.1)
Hookworm disease	624.9 (508.0 to 761.6)	233.6 (152.3 to 347.3)	-63.2 (-76.3 to -43.5)	-65.4 (-85.2 to -40.6)	2.5 (1.4 to 4.5)	0.6 (0.3 to 1.0)	0.6 (-86.8 to -64.5)	0.6 (-91.7 to -75.1)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	153.7 (116.3 to 191.1)	171.0 (161.8 to 183.1)	11.3 (-11.4 to 46.9)	-13.7 (-29.7 to 10.8)	5.9 (3.6 to 8.6)	6.6 (4.4 to 9.7)	10.1 (2.7 to 60.9)	-11.4 (-21.9 to 27.7)
Maternal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	2.3 (-13.9 to 19.7)	-40.6 (-49.6 to -30.9)
Maternal hemorrhage	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	6.1 (-12.5 to 27.9)	-42.1 (-52.7 to -30.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-18.3 to 68.8)	0.0 (-55.4 to -75.6)
Maternal sepsis and other maternal infections	0.6 (0.5 to 0.9)	0.5 (0.4 to 0.8)	-14.0 (-30.6 to 1.5)	-49.3 (-59.0 to -40.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-32.2 to 1.4)	-17.4 (-60.2 to -39.9)
Maternal hypertensive disorders	1.3 (0.9 to 1.9)	1.3 (0.9 to 1.9)	-0.8 (-9.4 to 7.7)	-41.6 (-46.8 to -36.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.1 (-21.2 to 25.4)	-0.6 (-53.8 to -26.7)
Obstructed labor	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	5.2 (-27.8 to 63.7)	-38.9 (-56.7 to -11.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-27.8 to 63.7)	0.0 (-56.7 to -11.0)
Complications of abortion	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-3.1 (-34.7 to 55.3)	-43.7 (-61.4 to -9.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-43.5 to 115.4)	0.0 (-67.8 to 25.6)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-38.2 to 112.0)	0.0 (-63.9 to 23.1)
Neonatal disorders	-	-	-	-	4.0 (2.3 to 6.7)	14.9 (9.5 to 23.3)	275.1 (123.5 to 563.6)	178.8 (63.3 to 412.3)
Preterm birth complications	22.8 (10.4 to 46.9)	75.9 (41.5 to 142.3)	238.0 (158.3 to 366.5)	130.1 (73.4 to 219.6)	1.2 (0.7 to 2.0)	7.6 (4.8 to 12.3)	525.8 (293.5 to 930.7)	362.7 (196.0 to 673.2)
Neonatal encephalopathy due to birth asphyxia and trauma	65.0 (9.2 to 184.8)	56.2 (13.3 to 151.1)	-8.9 (-38.2 to 69.3)	-38.5 (-58.4 to 17.0)	1.5 (0.5 to 3.3)	3.0 (1.5 to 5.3)	105.1 (9.8 to 391.2)	46.5 (-21.9 to 295.4)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	10.2 (43.7 to 67.0)	54.1 (43.3 to 66.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	53.7 (38.6 to 71.8)	54.9 (38.2 to 71.3)
Hemolytic disease and other neonatal jaundice	2.0 (0.8 to 4.6)	7.4 (3.1 to 18.0)	250.9 (-2.6 to 1,603.8)	180.5 (-22.0 to 1,253.6)	0.7 (0.3 to 1.6)	2.7 (1.1 to 6.8)	259.4 (2.8 to 1,581.7)	183.3 (-18.2 to 1,231.4)
Other neonatal disorders	-	-	-	-	0.5 (0.2 to 1.1)	1.6 (0.7 to 3.2)	200.8 (38.6 to 601.0)	125.1 (-0.5 to 448.8)
Nutritional deficiencies	-	-	-	-	100.2 (67.0 to 143.2)	112.7 (76.2 to 161.5)	12.5 (9.0 to 15.5)	-19.3 (-21.3 to -17.5)
Protein-energy malnutrition	32.5 (22.6 to 46.6)	32.6 (21.5 to 47.6)	-0.5 (-41.7 to 66.9)	-1.7 (-46.3 to 35.3)	4.0 (2.2 to 6.3)	4.0 (2.2 to 6.5)	0.4 (-42.0 to 71.6)	-22.3 (-45.8 to 41.4)
Iodine deficiency	12.3 (9.7 to 15.3)	11.8 (9.0 to 14.9)	-3.6 (-31.6 to 32.2)	-40.2 (-57.7 to -16.9)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-3.0 (-31.1 to 34.8)	-40.0 (-57.5 to -15.3)
Vitamin A deficiency	4.8 (3.4 to 6.5)	3.0 (2.2 to 4.0)	-37.6 (-47.8 to -23.8)	-53.9 (-61.3 to -43.8)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-39.5 (-50.1 to -26.5)	-55.3 (-62.6 to -46.3)

Appendix Table G.4 - Haiti prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	2,596.9 (2,556.1 to 2,636.5)	3,155.7 (3,135.3 to 3,181.0)	21.5 (19.6 to 23.4)	-15.5 (-16.7 to -14.5)	95.8 (64.2 to 137.8)	108.3 (72.3 to 156.8)	13.1 (10.5 to 15.1)	13.1 (-21.0 to -18.0)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	6.1 (3.9 to 9.0)	7.4 (4.8 to 11.4)	11.8 (11.8 to 39.2)	-11.6 (-19.0 to -1.8)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.4 (0.8 to 2.5)	2.2 (1.2 to 3.7)	54.1 (33.6 to 75.3)	-7.4 (-18.3 to 3.3)
Syphilis	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.4)	31.4 (14.0 to 48.1)	-31.1 (-30.9 to -11.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	31.0 (5.9 to 82.9)	21.0 (-41.6 to 6.2)
Chlamydial infection	182.0 (152.0 to 213.0)	273.6 (227.1 to 314.4)	50.6 (16.2 to 91.6)	-8.6 (-28.8 to 14.5)	0.7 (0.4 to 1.2)	1.1 (0.6 to 1.8)	57.4 (27.5 to 96.1)	-5.2 (-22.6 to 17.1)
Gonococcal infection	21.0 (16.7 to 25.8)	29.4 (22.0 to 36.1)	40.7 (-0.9 to 83.9)	-15.5 (-38.6 to 9.8)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	28.2 (-11.9 to 87.0)	-23.3 (-46.0 to 9.9)
Trichomoniasis	40.8 (27.9 to 59.5)	66.8 (35.9 to 108.2)	56.3 (-29.2 to 222.8)	-7.8 (-55.7 to 77.6)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	54.8 (-44.8 to 250.5)	-9.0 (-64.6 to 87.5)
Genital herpes	1,429.7 (1,363.7 to 1,494.9)	2,255.2 (2,123.3 to 2,361.0)	57.5 (47.2 to 68.8)	-4.9 (-11.3 to 1.4)	0.4 (0.1 to 0.9)	0.6 (0.2 to 1.5)	57.5 (44.0 to 70.8)	-4.9 (-12.5 to 2.4)
Other sexually transmitted diseases	1.4 (1.0 to 1.9)	2.0 (1.5 to 2.7)	36.6 (23.3 to 55.3)	-18.9 (-27.3 to -7.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	70.3 (26.1 to 134.8)	1.4 (-22.8 to 36.1)
Hepatitis	-	-	-	-	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	15.9 (-1.0 to 37.3)	-28.5 (-42.7 to -11.8)
Hepatitis A	12.0 (11.4 to 12.6)	15.5 (14.9 to 16.1)	29.0 (27.2 to 30.7)	0.3 (0.3 to 0.4)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	45.6 (28.6 to 63.4)	0.1 (-11.3 to 11.7)
Hepatitis B	310.2 (244.7 to 379.1)	260.0 (195.7 to 321.9)	-15.5 (-39.7 to 13.2)	-47.0 (-60.7 to -30.5)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-23.3 (-52.5 to 20.7)	-53.2 (-73.6 to -24.1)
Hepatitis C	128.0 (114.9 to 141.6)	149.1 (133.6 to 164.9)	16.5 (0.2 to 34.8)	-27.2 (-35.3 to -17.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.6 (-14.9 to 40.9)	-28.0 (-46.8 to 1.6)
Hepatitis E	-	-	47.5 (21.5 to 80.3)	-6.4 (-23.6 to 14.8)	-	-	-	-
Leprosy	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-1.7 (-53.4 to 121.1)	-35.9 (-68.3 to 46.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.9 (-53.6 to 525.2)	-20.3 (-67.6 to 317.3)
Other infectious diseases	112.5 (89.4 to 137.5)	126.9 (104.9 to 134.4)	12.8 (5.9 to 20.0)	-15.4 (-21.5 to -9.6)	4.2 (2.7 to 6.2)	4.8 (3.1 to 7.1)	12.2 (15.0 to 34.0)	-11.7 (-21.1 to 3.9)
Non-communicable diseases	-	-	-	-	435.0 (324.6 to 562.3)	705.8 (525.5 to 915.5)	62.2 (58.3 to 66.9)	1.5 (-0.9 to 4.0)
Neoplasms	-	-	-	-	2.9 (2.1 to 3.9)	5.9 (4.2 to 8.0)	100.9 (66.0 to 141.6)	25.2 (4.5 to 49.8)
Esophageal cancer	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	33.8 (7.6 to 90.7)	-16.1 (-41.7 to 20.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	36.1 (4.0 to 84.9)	-15.1 (-41.1 to 17.6)
Stomach cancer	1.0 (0.8 to 1.2)	1.1 (0.9 to 1.3)	9.6 (-14.1 to 42.2)	-31.1 (-46.8 to -9.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	10.7 (-14.9 to 41.9)	-30.9 (-47.0 to -10.8)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	294.1 (173.1 to 431.2)	148.1 (72.9 to 237.4)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	290.6 (76.8 to 690.1)	145.3 (12.1 to 418.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	267.8 (91.5 to 621.9)	132.4 (19.3 to 373.6)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.3 (0.2 to 0.4)	1,414.5 (536.9 to 2,919.4)	831.8 (304.7 to 1,773.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	1,254.0 (508.2 to 2,435.8)	712.2 (298.2 to 1,477.1)
Liver cancer due to alcohol use	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	83.4 (2.7 to 247.3)	16.3 (-36.2 to 113.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.0 (9.6 to 183.7)	14.2 (-32.8 to 81.3)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	132.3 (15.0 to 380.5)	0.0 (-24.3 to 220.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	122.6 (22.8 to 327.0)	44.1 (-22.3 to 176.3)
Larynx cancer	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	0.3 (-33.4 to 40.0)	-36.1 (-58.3 to -10.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.5 (-29.7 to 50.3)	-32.3 (-57.2 to -2.5)
Tracheal, bronchus and lung cancer	0.5 (0.4 to 0.6)	0.6 (0.5 to 0.7)	27.6 (-2.8 to 72.9)	-20.3 (-39.1 to 7.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	29.0 (-2.1 to 77.4)	-19.5 (-38.9 to 8.2)
Breast cancer	5.0 (3.9 to 6.0)	8.5 (6.3 to 11.0)	70.1 (21.3 to 138.3)	4.0 (-25.3 to 43.0)	0.5 (0.3 to 0.7)	0.8 (0.6 to 1.2)	68.9 (20.5 to 133.1)	3.9 (-26.2 to 43.4)
Cervical cancer	2.7 (1.9 to 3.5)	2.7 (1.9 to 3.7)	0.5 (-36.7 to 55.7)	-46.8 (-59.6 to -3.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	1.6 (-36.5 to 57.4)	-36.0 (-60.0 to -3.6)
Uterine cancer	1.3 (0.9 to 2.2)	2.3 (1.2 to 3.6)	78.3 (-19.8 to 230.7)	13.5 (-47.8 to 104.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	77.8 (-22.8 to 229.8)	11.6 (-49.7 to 101.2)
Prostate cancer	6.0 (3.7 to 9.2)	17.8 (11.5 to 26.0)	198.0 (98.1 to 353.4)	73.2 (17.5 to 160.4)	0.7 (0.4 to 1.1)	1.8 (1.1 to 2.8)	155.0 (80.0 to 260.6)	49.8 (6.2 to 111.2)
Colon and rectum cancer	1.6 (1.4 to 1.8)	3.9 (3.2 to 4.5)	145.1 (98.2 to 206.0)	45.2 (16.8 to 81.2)	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	134.9 (88.1 to 197.9)	39.0 (10.0 to 73.4)
Lip and oral cavity cancer	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.3)	84.3 (14.9 to 175.2)	14.8 (-30.3 to 70.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	83.3 (14.1 to 169.8)	13.0 (-32.1 to 66.0)
Nasopharynx cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	80.2 (14.5 to 174.9)	9.3 (-28.7 to 64.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.4 (15.2 to 153.9)	4.7 (-29.9 to 52.8)
Other pharynx cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	57.5 (-3.5 to 166.9)	-2.7 (-41.1 to 60.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.8 (-2.9 to 154.5)	-2.9 (-39.5 to 52.3)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-31.2 (-53.4 to 72.6)	-58.1 (-72.2 to 4.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.8 (-49.9 to 75.1)	-56.1 (-70.6 to 6.8)
Pancreatic cancer	0.1 (0.0 to 0.1)	0.2 (0.2 to 0.2)	261.3 (17.4 to 382.1)	119.7 (66.8 to 190.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	250.4 (170.8 to 345.4)	111.5 (57.0 to 175.2)
Malignant skin melanoma	0.6 (0.5 to 0.8)	1.7 (1.2 to 2.2)	65.1 (89.9 to 292.5)	170.2 (18.6 to 139.6)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	156.6 (79.7 to 289.1)	58.7 (12.8 to 134.5)
Non-melanoma skin cancer	0.9 (0.7 to 1.2)	1.7 (1.3 to 2.2)	94.4 (38.7 to 168.3)	16.6 (-16.7 to 56.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	117.0 (42.4 to 232.2)	31.2 (-15.4 to 109.3)
Ovarian cancer	0.3 (0.2 to 0.4)	0.9 (0.6 to 1.2)	200.8 (102.4 to 355.4)	86.4 (30.6 to 172.4)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.2)	193.9 (95.7 to 355.7)	81.9 (17.1 to 178.5)
Testicular cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	178.6 (20.6 to 626.5)	67.8 (-28.1 to 311.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	170.5 (8.5 to 343.7)	64.7 (-33.4 to 281.8)
Kidney cancer	0.8 (0.4 to 0.9)	1.1 (0.8 to 1.5)	79.1 (5.0 to 199.8)	46.7 (-0.3 to 109.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	93.3 (18.8 to 201.1)	48.5 (4.2 to 102.4)
Bladder cancer	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	48.9 (5.1 to 106.0)	-10.9 (-39.4 to 29.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.8 (4.5 to 110.6)	-10.9 (-39.0 to 32.8)
Brain and nervous system cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	50.8 (-6.5 to 131.2)	8.3 (-23.9 to 50.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.7 (2.6 to 123.7)	3.7 (-25.8 to 37.5)
Thyroid cancer	1.0 (0.6 to 1.3)	1.2 (0.7 to 1.9)	17.7 (-32.6 to 125.4)	-29.4 (-59.2 to 36.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	12.2 (-36.4 to 118.1)	-32.6 (-61.2 to 29.4)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.8 (5.1 to 108.4)	30.8 (-36.5 to 28.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.7 (5.7 to 110.9)	-10.0 (-36.6 to 32.0)
Hodgkin lymphoma	0.3 (0.2 to 0.5)	1.3 (0.5 to 2.0)	331.4 (21.0 to 659.2)	234.7 (-11.6 to 447.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	350.6 (18.2 to 676.4)	236.1 (-18.2 to 434.3)
Non-Hodgkin lymphoma	1.1 (0.8 to 1.8)	2.8 (1.6 to 3.8)	175.4 (14.6 to 312.2)	93.1 (-17.7 to 185.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	187.3 (18.2 to 319.4)	93.3 (-19.8 to 180.6)
Multiple myeloma	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	112.1 (20.3 to 236.7)	28.0 (-26.6 to 103.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	99.7 (11.2 to 220.4)	19.1 (-31.5 to 90.1)
Leukemia	0.8 (0.5 to 1.2)	1.3 (1.0 to 2.0)	71.3 (-0.7 to 180.0)	30.8 (-10.6 to 96.5)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	79.7 (21.0 to 159.8)	23.1 (-10.3 to 70.4)
Other neoplasms	5.5 (4.0 to 8.7)	12.5 (9.2 to 16.8)	139.0 (13.7 to 261.9)	82.3 (4.9 to 150.0)	0.4 (0.2 to 0.6)	0.8 (0.5 to 1.2)	135.5 (22.5 to 232.1)	68.3 (3.4 to 128.9)
Cardiovascular diseases	-	-	-	-	5.1 (3.5 to 7.1)	10.9 (7.7 to 14.9)	116.5 (71.2 to 162.7)	29.7 (5.4 to 54.6)
Rheumatic heart disease	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	50.9 (31.0 to 73.0)	-6.2 (-20.0 to 8.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.6 (29.4 to 78.7)	-6.0 (-20.8 to 10.6)
Ischemic heart disease	29.3 (25.5 to 34.7)	91.2 (73.0 to 111.5)	214.4 (137.6 to 304.3)	82.7 (39.5 to 130.6)	1.3 (0.9 to 1.9)	4.8 (3.0 to 7.1)	265.3 (153.1 to 402.3)	111.1 (46.5 to 190.1)
Cerebrovascular disease	-	-	-	-	1.6 (1.2 to 2.2)	2.7 (1.9 to 3.7)	64.1 (36.1 to 104.9)	2.2 (-19.3 to 25.6)
Ischemic stroke	8.3 (6.9 to 9.8)	13.8 (11.9 to 16.4)	65.1 (36.6 to 108.9)	-1.7 (-19.2 to 27.9)	1.2 (0.8 to 1.7)	2.0 (1.4 to 2.8)	65.5 (33.7 to 110.7)	-1.5 (-19.5 to 27.7)
Hemorrhagic stroke	2.9 (2.3 to 3.6)	4.8 (3.8 to 6.1)	63.6 (22.6 to 132.0)	-1.9 (-28.8 to 44.3)	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.0)	64.4 (22.3 to 134.6)	-1.6 (-29.2 to 45.6)
Hypertensive heart disease	3.0 (2.7 to 3.3)	4.3 (3.9 to 4.7)	46.2 (27.1 to 67.3)	-13.3 (-24.2 to -0.8)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.7)	45.9 (23.5 to 71.0)	-13.3 (-26.0 to 1.0)
Cardiomyopathy and myocarditis	1.2 (1.1 to 1.5)	2.3 (2.1 to 2.5)	83.6 (54.6 to 118.1)	15.9 (-5.1 to 41.7)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	15.9 (49.5 to 127.7)	83.1 (-6.7 to 47.2)
Atrial fibrillation and flutter	2.9 (2.0 to 4.2)	6.7 (4.8 to 9.0)	137.8 (59.0 to 225.0)	40.5 (-15.9 to 99.9)	0.2 (0.1 to 0.4)	0.5 (0.3 to 0.8)	135.3 (59.5 to 229.4)	39.2 (-14.5 to 102.6)
Peripheral vascular disease	140.7 (106.1 to 178.1)	231.7 (181.1 to 275.6)	64.6 (25.7 to 116.3)	-0.7 (-24.0 to 25.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	35.1 (-33.7 to 175.5)	-26.4 (-59.9 to 52.8)
Endocarditis	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	31.6 (0.6 to 71.4)	-0.4 (-22.4 to 31.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.6 (6.6 to 107.5)	12.2 (-17.7 to 48.3)
Other cardiovascular and circulatory diseases	18.9 (10.5 to 31.9)	38.7 (23.8 to 35.5)	59.0 (-13.1 to 185.9)	9.3 (-49.3 to 64.9)	1.3 (0.7 to 2.4)	2.0 (1.3 to 2.9)	98.3 (-13.6 to 190.6)	9.6 (-49.4 to 65.9)
Chronic respiratory diseases	-	-	-	-	21.3 (14.3 to 29.4)	38.7 (25.8 to 54.6)	81.2 (46.9 to 118.1)	8.2 (-11.9 to 29.7)
Chronic obstructive pulmonary disease	220.8 (210.9 to 230.9)	364.6 (346.4 to 382.5)	65.1 (60.5 to 69.8)	0.4 (-2.5 to 3.1)	13.2 (8.6 to 18.7)	23.6		

Appendix Table G.4 - Halit prevalence and VIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VIDs 1990 (thousands)	VIDs 2013 (thousands)	% change VIDs, 1990 to 2013	% change age-standardized VIDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.1 (52.8 to 64.5)	-4.2 (-7.6 to -0.8)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.3 (41.2 to 51.0)	-11.9 (-15.0 to -8.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.3 (41.0 to 50.9)	-11.9 (-15.0 to -9.0)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.8 (58.2 to 75.7)	1.2 (-3.7 to 5.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.6 (58.1 to 75.5)	1.2 (-3.8 to 5.8)
Asthma	105.1 (76.0 to 147.7)	243.8 (155.7 to 339.9)	126.0 (50.2 to 277.5)	29.2 (-11.7 to 94.4)	4.5 (2.7 to 7.2)	10.5 (5.6 to 17.0)	126.7 (50.0 to 287.2)	29.4 (-11.1 to 96.8)
Interstitial lung disease and pulmonary sarcoidosis	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	67.1 (18.8 to 124.1)	0.9 (-30.3 to 37.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.5 (19.2 to 125.0)	1.3 (-30.3 to 37.4)
Other chronic respiratory diseases	-	-	-	-	3.6 (2.1 to 5.6)	4.6 (2.8 to 7.2)	28.1 (-10.9 to 84.8)	-22.0 (-45.7 to 12.6)
Cirrhosis	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	39.4 (19.7 to 63.6)	-10.9 (-21.5 to 2.8)
Cirrhosis due to hepatitis B	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	10.6 (-39.4 to 113.1)	-27.1 (60.6 to 50.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	11.6 (-44.7 to 113.5)	-26.6 (-63.7 to 48.3)
Cirrhosis due to hepatitis C	0.4 (0.3 to 0.6)	0.8 (0.6 to 1.1)	88.7 (29.8 to 234.7)	20.0 (-18.3 to 106.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	88.6 (19.6 to 245.3)	18.9 (-24.2 to 110.7)
Cirrhosis due to alcohol use	0.6 (0.5 to 0.7)	0.6 (0.4 to 0.8)	8.7 (-25.8 to 39.7)	0.1 (-53.6 to -16.3)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	7.8 (-30.2 to 50.5)	-34.4 (-56.9 to -9.6)
Cirrhosis due to other causes	0.5 (0.4 to 0.6)	0.7 (0.6 to 0.9)	44.2 (13.0 to 88.1)	3.9 (-22.4 to 43.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	45.1 (-6.8 to 131.9)	4.4 (-31.0 to 63.7)
Digestive diseases	-	-	-	-	10.2 (7.1 to 14.3)	14.6 (10.3 to 20.1)	43.3 (30.4 to 55.7)	-12.2 (-19.4 to -5.3)
Peptic ulcer disease	60.7 (52.2 to 67.6)	58.8 (50.1 to 67.6)	-3.1 (-18.6 to 12.3)	-39.4 (-48.2 to -30.0)	2.4 (1.6 to 3.3)	2.3 (1.6 to 3.3)	-1.6 (-19.1 to 14.7)	-40.2 (-49.3 to -31.2)
Gastritis and duodenitis	109.9 (100.3 to 116.8)	170.5 (156.5 to 186.4)	55.3 (41.4 to 70.5)	1.7 (-5.6 to 9.1)	4.2 (2.8 to 5.9)	5.9 (3.9 to 8.2)	40.2 (24.1 to 59.3)	-7.5 (-15.5 to 1.2)
Appendicitis	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.4)	48.3 (14.3 to 94.2)	-2.9 (-23.2 to 25.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	48.9 (11.9 to 98.1)	-2.2 (-23.8 to 27.8)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	57.7 (6.9 to 158.8)	30.4 (-4.6 to 71.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	57.7 (-9.5 to 182.8)	30.6 (-10.0 to 84.1)
Inguinal, femoral, and abdominal hernia	43.9 (37.7 to 53.0)	52.5 (45.4 to 63.2)	21.0 (-10.3 to 53.9)	-27.9 (-41.0 to -13.5)	0.5 (0.2 to 0.9)	0.5 (0.3 to 1.0)	21.1 (-11.6 to 55.4)	-27.6 (-41.3 to -12.7)
Inflammatory bowel disease	7.2 (6.9 to 7.5)	14.5 (13.9 to 15.0)	101.1 (90.4 to 111.9)	21.6 (15.5 to 28.3)	1.5 (1.0 to 2.1)	3.1 (2.1 to 4.2)	100.8 (85.3 to 118.3)	21.6 (12.5 to 31.4)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.6 (11.5 to 124.2)	-3.9 (-31.4 to 49.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.6 (11.5 to 124.2)	-3.9 (-32.0 to 49.1)
Gallbladder and biliary diseases	3.7 (3.3 to 4.1)	3.2 (3.3 to 4.3)	3.2 (-11.9 to 22.1)	-35.2 (-44.1 to -23.8)	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	3.2 (-15.1 to 24.4)	35.6 (-45.8 to -22.4)
Pancreatitis	0.3 (0.3 to 0.3)	0.8 (0.8 to 0.8)	145.7 (126.4 to 165.9)	52.3 (41.8 to 63.8)	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	142.1 (84.8 to 219.2)	50.4 (16.7 to 95.3)
Other digestive diseases	-	-	-	-	1.1 (0.7 to 1.7)	2.1 (1.4 to 3.0)	82.5 (35.4 to 158.7)	12.4 (-16.0 to 60.7)
Neurological disorders	-	-	-	-	36.8 (24.5 to 51.5)	63.8 (43.4 to 88.5)	72.7 (47.4 to 106.9)	7.3 (-5.7 to 24.1)
Alzheimer disease and other dementias	25.3 (22.2 to 28.8)	44.9 (39.4 to 49.8)	77.8 (47.5 to 107.1)	2.4 (-14.0 to 19.3)	3.5 (2.5 to 4.6)	6.3 (4.6 to 8.3)	79.0 (48.9 to 110.3)	2.3 (-14.0 to 20.8)
Parkinson disease	0.5 (0.4 to 0.6)	0.8 (0.7 to 1.0)	66.2 (55.5 to 75.1)	-0.7 (-6.7 to 4.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	63.7 (37.0 to 97.2)	-1.9 (-17.6 to 17.7)
Epilepsy	17.3 (11.4 to 23.1)	32.2 (21.4 to 43.0)	85.4 (13.6 to 199.2)	26.5 (-22.6 to 107.4)	4.9 (3.0 to 7.5)	9.8 (5.9 to 14.6)	96.9 (20.9 to 225.7)	34.7 (-15.7 to 123.6)
Multiple sclerosis	0.4 (0.3 to 0.4)	1.1 (1.0 to 1.2)	208.0 (181.6 to 242.9)	86.2 (69.8 to 108.2)	0.1 (0.0 to 0.2)	0.4 (0.3 to 0.5)	195.9 (144.2 to 259.7)	78.7 (47.4 to 118.6)
Migraine	629.3 (524.6 to 716.1)	975.1 (824.1 to 1,126.0)	53.8 (23.8 to 99.0)	3.7 (-20.7 to 22.6)	21.1 (12.3 to 32.1)	33.1 (19.5 to 49.1)	54.0 (24.2 to 98.7)	-4.1 (-20.5 to 22.2)
Tension-type headache	1,262.4 (1,053.8 to 1,476.0)	2,106.3 (1,971.0 to 2,258.7)	67.6 (41.1 to 104.4)	-0.0 (-15.6 to 19.5)	1.9 (0.9 to 3.5)	3.2 (1.5 to 5.6)	67.8 (39.9 to 104.8)	0.4 (-15.6 to 19.9)
Medication overuse headache	26.0 (17.3 to 35.4)	62.3 (40.3 to 86.1)	138.2 (90.0 to 217.7)	44.0 (12.5 to 87.7)	4.1 (2.3 to 6.5)	9.8 (5.3 to 15.5)	138.0 (89.4 to 219.6)	43.9 (12.7 to 88.6)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.2 (9.9 to 114.4)	4.8 (-24.1 to 48.8)	0.7 (0.4 to 1.0)	1.3 (0.8 to 1.8)	87.5 (28.5 to 149.9)	5.9 (-26.3 to 42.5)
Mental and substance use disorders	-	-	-	-	147.5 (105.6 to 196.3)	237.9 (169.5 to 316.6)	61.2 (57.4 to 65.3)	0.6 (-1.5 to 2.9)
Schizophrenia	15.1 (13.8 to 16.4)	25.1 (22.6 to 27.3)	65.7 (58.9 to 73.0)	-0.6 (-4.3 to 3.5)	9.7 (7.1 to 11.8)	16.0 (11.7 to 19.5)	65.8 (55.6 to 76.7)	-0.8 (-6.3 to 5.5)
Alcohol use disorders	41.4 (38.7 to 44.5)	69.6 (64.8 to 74.8)	68.0 (61.0 to 75.4)	3.6 (-0.3 to 8.0)	4.0 (2.7 to 5.7)	6.8 (4.5 to 9.6)	68.3 (58.2 to 78.7)	3.4 (-2.2 to 9.3)
Drug use disorders	-	-	-	-	10.4 (7.0 to 14.4)	17.3 (11.4 to 23.4)	66.2 (43.0 to 94.8)	0.6 (-12.6 to 17.5)
Opioid use disorders	3.8 (1.8 to 6.4)	6.6 (3.1 to 11.4)	73.7 (57.0 to 90.8)	3.6 (-6.3 to 14.4)	1.6 (0.7 to 2.9)	2.7 (1.2 to 5.0)	73.7 (49.7 to 100.3)	3.4 (-9.9 to 19.2)
Cocaine use disorders	19.2 (17.1 to 21.2)	32.4 (28.4 to 36.2)	68.0 (45.0 to 96.6)	3.2 (-12.0 to 17.9)	2.6 (1.7 to 3.8)	4.4 (2.9 to 6.5)	68.8 (39.8 to 98.2)	1.5 (-14.3 to 19.8)
Amphetamine use disorders	12.3 (11.4 to 13.2)	19.7 (18.1 to 21.3)	59.7 (44.5 to 79.3)	-2.8 (-11.7 to 8.3)	1.6 (1.0 to 2.4)	2.6 (1.6 to 3.8)	59.7 (37.2 to 86.0)	-2.8 (-16.1 to 12.5)
Cannabis use disorders	9.8 (8.2 to 11.5)	16.1 (13.4 to 18.8)	63.7 (62.9 to 64.8)	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	63.4 (38.4 to 91.6)	-0.1 (-14.9 to 16.0)
Other drug use disorders	-	-	-	-	4.3 (2.7 to 6.4)	7.1 (4.4 to 10.3)	64.4 (21.2 to 129.8)	-0.5 (-26.3 to 39.4)
Depressive disorders	-	-	-	-	33.4 (33.4 to 74.6)	54.5 (54.5 to 121.2)	55.7 (55.7 to 71.8)	0.7 (-3.4 to 5.8)
Major depressive disorder	222.1 (171.9 to 265.6)	362.3 (275.3 to 434.0)	63.1 (55.2 to 72.2)	0.8 (-4.0 to 6.5)	45.6 (28.9 to 65.8)	74.3 (46.3 to 106.6)	62.6 (54.2 to 72.8)	0.7 (-4.1 to 6.9)
Dysthymia	69.7 (57.7 to 81.9)	115.6 (95.6 to 135.7)	65.8 (65.0 to 66.5)	-0.1 (-0.1 to -0.0)	6.7 (4.4 to 9.7)	11.1 (7.3 to 16.1)	65.5 (60.9 to 70.4)	-0.2 (-2.7 to 2.3)
Bipolar disorder	43.0 (35.8 to 49.8)	71.4 (59.9 to 82.7)	66.3 (56.8 to 76.5)	0.2 (-5.2 to 5.4)	8.7 (5.3 to 13.3)	14.5 (8.9 to 22.0)	65.7 (53.9 to 78.8)	-0.2 (-6.8 to 6.6)
Anxiety disorders	388.6 (245.2 to 481.1)	591.9 (397.9 to 770.0)	60.3 (55.7 to 64.9)	0.2 (-0.3 to -0.1)	33.9 (19.7 to 51.0)	54.3 (32.4 to 82.0)	60.5 (54.1 to 66.3)	-0.3 (-2.2 to 1.5)
Eating disorders	-	-	-	-	2.0 (1.2 to 3.2)	3.2 (2.0 to 5.3)	64.3 (51.0 to 78.4)	0.3 (-7.2 to 8.7)
Anorexia nervosa	1.5 (1.2 to 2.0)	2.5 (1.9 to 3.3)	67.5 (48.8 to 86.1)	6.0 (-5.5 to 18.3)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	67.6 (35.2 to 113.3)	5.9 (-15.1 to 33.1)
Bulimia nervosa	8.1 (5.4 to 11.9)	13.3 (8.7 to 19.5)	63.5 (61.2 to 65.4)	-0.5 (-0.6 to -0.4)	1.7 (1.0 to 2.7)	2.8 (1.6 to 4.6)	63.6 (49.1 to 79.1)	-0.3 (-9.0 to 8.5)
Autistic spectrum disorders	-	-	-	-	8.3 (5.8 to 11.3)	12.1 (8.4 to 16.4)	45.9 (40.4 to 51.5)	0.3 (-3.1 to 3.6)
Autism	21.1 (20.0 to 22.2)	30.9 (29.3 to 32.4)	46.5 (45.9 to 47.1)	0.2 (0.2 to 0.2)	5.2 (3.5 to 7.1)	7.6 (5.1 to 10.5)	46.2 (38.4 to 54.0)	0.3 (-4.4 to 5.1)
Asperger syndrome	31.0 (29.1 to 32.8)	45.2 (42.3 to 47.9)	45.7 (44.9 to 46.5)	0.3 (0.3 to 0.3)	3.1 (2.1 to 4.3)	4.5 (3.1 to 6.2)	45.7 (38.6 to 51.9)	0.5 (-3.8 to 4.2)
Attention-deficit/hyperactivity disorder	62.5 (57.2 to 66.6)	86.8 (79.5 to 92.5)	38.8 (38.3 to 39.1)	0.4 (0.4 to 0.4)	0.8 (0.5 to 1.2)	1.1 (0.6 to 1.6)	39.0 (30.7 to 47.7)	0.6 (-5.6 to 8.0)
Conduct disorder	81.9 (76.4 to 87.3)	116.1 (108.2 to 124.1)	41.3 (40.6 to 42.8)	0.5 (0.4 to 0.5)	9.8 (6.1 to 14.2)	13.6 (8.7 to 20.4)	41.3 (35.4 to 48.7)	0.7 (-3.5 to 5.5)
Idiopathic intellectual disability	19.0 (9.1 to 35.5)	40.6 (16.5 to 68.8)	113.5 (35.9 to 228.0)	52.3 (-1.9 to 134.1)	0.9 (0.4 to 1.9)	2.0 (0.7 to 3.6)	113.7 (54.1 to 228.9)	51.8 (-3.4 to 135.6)
Other mental and substance use disorders	89.9 (84.0 to 95.4)	150.5 (140.6 to 159.7)	67.4 (67.0 to 67.8)	0.1 (-0.0 to 0.2)	6.7 (4.6 to 9.0)	11.2 (7.6 to 15.1)	67.4 (60.8 to 74.4)	0.1 (-3.4 to 3.5)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	44.1 (30.4 to 60.5)	74.0 (51.3 to 101.1)	68.0 (53.3 to 82.6)	11.4 (-0.5 to 23.4)
Diabetes mellitus	163.2 (127.5 to 200.5)	388.1 (320.0 to 460.1)	137.7 (87.5 to 206.6)	47.5 (13.2 to 97.3)	11.6 (7.5 to 16.4)	26.8 (18.0 to 38.4)	130.9 (81.7 to 199.7)	42.6 (8.1 to 89.5)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	18.3 (13.2 to 23.4)	-5.5 (-8.7 to -2.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.3 (13.2 to 23.4)	5.5 (-8.7 to -1.9)
Chronic kidney disease	-	-	-	-	8.3 (5.9 to 11.0)	12.7 (9.1 to 17.0)	53.5 (33.9 to 74.1)	0.9 (-11.2 to 14.9)
Chronic kidney disease due to diabetes mellitus	146.5 (99.4 to 209.7)	236.6 (161.3 to 347.5)	60.9 (29.5 to 112.0)	2.3 (-18.8 to 38.1)	1.8 (1.2 to 2.6)	3.0 (2.1 to 4.1)	61.0 (31.3 to 120.1)	3.9 (-17.4 to 42.6)
Chronic kidney disease due to hypertension	99.9 (66.8 to 160.1)	168.3 (107.1 to 264.6)	66.8 (26.8 to 122.1)	12.6 (-14.5 to 48.0)	2.7 (1.9 to 3.7)	4.0 (2.8 to 5.3)	45.8 (29.9 to 75.5)	-7.8 (-22.0 to 8.6)
Chronic kidney disease due to glomerulonephritis	221.1 (149.2 to 319.3)	327.8 (211.3 to 496.7)	48.5 (15.8 to 80.0)	3.9 (-28.0 to 19.3)	1.9 (0.8 to 1.8)	2.1 (1.4 to 3.1)	69.4 (18.1 to 125.6)	15.1 (-19.9 to 60.7)
Chronic kidney disease due to other causes	216.7 (125.4 to 350.8)	309.2 (207.4 to 456.2)	44.4 (0.1 to 100.3)	1.1 (-29.6 to 33.3)	2.5 (1.7 to 3.4)	3.7 (2.4 to 5.1)	49.1 (30.8 to 105.2)	4.5 (-30.8 to 41.4)
Urinary diseases and male infertility	-	-	-	-	1.6 (1.0 to 2.4)	2.7 (1.7 to 3.9)	66.5 (50.3 to 83.7)	0.3 (-8.9 to 9.9)

Appendix Table G.4 - Haiti prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.4 (1.3 to 1.5)	3.0 (2.8 to 3.2)	106.4 (87.2 to 129.7)	0.0 (19.6 to 42.7)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	107.1 (66.6 to 155.3)	107.1 (8.5 to 57.4)
Urolithiasis	35.4 (26.3 to 50.0)	62.7 (43.8 to 99.8)	75.8 (30.4 to 117.7)	7.4 (-19.7 to 33.2)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	52.4 (49.5 to 122.7)	15.2 (-7.1 to 41.8)
Benign prostatic hyperplasia	28.2 (26.0 to 30.5)	46.0 (42.5 to 49.8)	62.5 (47.9 to 81.4)	-2.5 (-12.1 to 9.3)	1.0 (0.7 to 1.4)	1.6 (1.1 to 2.3)	63.0 (47.0 to 82.7)	-2.2 (-12.4 to 9.8)
Male infertility due to other causes	48.8 (39.5 to 58.5)	77.2 (61.9 to 93.5)	58.9 (18.5 to 106.4)	-6.6 (-30.6 to 21.7)	0.3 (0.1 to 0.6)	0.5 (0.2 to 1.1)	59.7 (17.7 to 113.4)	-5.6 (-30.6 to 26.2)
Other urinary diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	0.1 (-35.4 to 74.2)
Gynecological diseases	-	-	-	-	9.1 (5.9 to 13.5)	15.4 (10.0 to 23.1)	68.9 (52.0 to 88.3)	-0.8 (-10.3 to 9.5)
Uterine fibroids	111.5 (100.6 to 121.3)	185.3 (167.0 to 201.5)	66.2 (66.0 to 66.4)	-0.7 (-0.7 to -0.7)	2.6 (1.7 to 4.0)	3.9 (2.4 to 6.0)	48.5 (37.2 to 56.7)	-11.9 (-18.8 to -6.8)
Polycystic ovarian syndrome	115.5 (100.2 to 130.0)	199.7 (176.0 to 223.4)	73.0 (45.7 to 105.0)	1.9 (-12.5 to 19.1)	1.1 (0.5 to 2.2)	2.0 (0.9 to 3.7)	72.8 (46.2 to 106.2)	2.1 (-12.4 to 20.0)
Female infertility due to other causes	52.3 (41.9 to 64.4)	82.0 (63.5 to 102.8)	56.5 (12.1 to 115.5)	-7.1 (-34.2 to 30.4)	0.3 (0.1 to 0.6)	0.4 (0.2 to 0.9)	35.1 (12.6 to 115.0)	6.9 (-34.2 to 28.8)
Endometriosis	10.8 (9.1 to 12.6)	19.3 (16.4 to 22.4)	78.5 (44.2 to 122.1)	5.2 (-14.9 to 30.9)	1.0 (0.6 to 1.4)	1.8 (1.2 to 2.5)	78.5 (41.0 to 124.9)	5.3 (-16.9 to 32.1)
Genital prolapse	294.4 (233.7 to 359.1)	517.0 (424.7 to 605.3)	75.2 (28.1 to 132.6)	3.4 (-19.9 to 31.8)	0.9 (0.4 to 1.9)	1.6 (0.8 to 3.1)	75.4 (28.5 to 131.9)	3.2 (-20.6 to 32.3)
Premenstrual syndrome	215.1 (159.6 to 277.4)	455.7 (338.9 to 575.6)	111.0 (46.7 to 210.4)	22.5 (-14.1 to 81.8)	1.8 (1.0 to 2.8)	3.8 (2.2 to 6.2)	112.6 (44.2 to 210.4)	23.3 (-14.3 to 82.7)
Other gynecological diseases	36.1 (32.3 to 39.9)	53.3 (47.7 to 58.2)	47.6 (23.6 to 76.8)	-11.4 (-25.8 to 6.1)	1.3 (0.8 to 1.9)	1.8 (1.2 to 2.7)	40.1 (13.1 to 80.3)	-16.2 (-32.4 to 7.6)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	9.6 (6.5 to 13.6)	11.9 (8.1 to 16.9)	24.5 (16.9 to 36.4)	-12.3 (-18.3 to -2.2)
Thalassemias	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	27.3 (13.5 to 41.0)	1.1 (-9.9 to 11.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.0 (15.9 to 47.3)	2.9 (-5.9 to 17.5)
Thalassemia trait	65.2 (57.7 to 71.6)	97.0 (89.0 to 105.0)	48.7 (40.4 to 56.6)	2.7 (-3.1 to 8.2)	1.2 (0.8 to 1.8)	1.7 (1.1 to 2.4)	35.5 (14.4 to 58.3)	-1.7 (-16.6 to 13.7)
Sickle cell disorders	11.2 (10.0 to 12.3)	16.4 (14.7 to 17.9)	46.1 (30.8 to 64.9)	3.2 (-6.9 to 14.8)	1.3 (0.9 to 1.7)	2.0 (1.4 to 2.6)	55.6 (33.1 to 79.1)	4.9 (-8.3 to 19.4)
Sickle cell trait	722.2 (662.5 to 786.7)	1,065.8 (971.7 to 1,154.7)	46.1 (41.3 to 52.4)	0.8 (-2.5 to 5.2)	4.4 (2.2 to 4.8)	4.4 (2.9 to 6.3)	32.1 (17.2 to 56.5)	-3.7 (-13.3 to 17.4)
G6PD deficiency	249.0 (191.8 to 304.3)	376.3 (290.8 to 468.4)	50.2 (7.9 to 108.0)	3.8 (-25.2 to 43.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (6.1 to 71.9)	-0.0 (-16.1 to 16.6)
G6PD trait	1,095.0 (1,024.2 to 1,163.6)	1,605.1 (1,482.8 to 1,721.8)	46.7 (32.2 to 60.6)	1.0 (-8.9 to 10.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	0.1 (2.7 to 116.6)	3.5 (-26.1 to 43.6)
Other hemoglobinopathies and hemolytic anemias	115.7 (100.0 to 123.5)	136.4 (126.4 to 147.7)	17.7 (7.6 to 37.4)	-21.0 (-29.0 to -8.6)	3.7 (2.4 to 5.3)	3.8 (2.5 to 5.5)	2.7 (-9.7 to 34.7)	-29.4 (-39.9 to -6.4)
Endocrine, metabolic, blood, and immune disorders	112.5 (104.6 to 122.9)	135.2 (121.6 to 149.2)	20.2 (6.4 to 33.7)	4.0 (-23.3 to -5.5)	4.5 (2.6 to 5.7)	4.5 (3.0 to 6.5)	13.4 (-6.4 to 34.9)	16.7 (-27.5 to -0.6)
Musculoskeletal disorders	-	-	-	-	70.3 (49.9 to 92.7)	114.1 (80.7 to 150.8)	62.2 (49.1 to 77.1)	-1.6 (-8.4 to 5.7)
Rheumatoid arthritis	17.1 (16.5 to 17.6)	31.8 (30.8 to 33.0)	86.1 (77.4 to 95.4)	4.1 (14.4 to 26.7)	4.1 (2.9 to 5.4)	7.5 (5.4 to 9.9)	84.5 (72.3 to 98.5)	19.1 (11.5 to 27.6)
Osteoarthritis	155.0 (148.4 to 161.4)	262.4 (251.7 to 273.7)	69.3 (59.7 to 79.3)	2.0 (-3.4 to 7.5)	9.2 (6.7 to 12.8)	15.9 (11.2 to 21.8)	68.5 (59.1 to 78.8)	1.8 (-3.6 to 7.2)
Low back and neck pain	-	-	-	-	44.6 (30.7 to 60.5)	72.6 (50.2 to 99.0)	62.4 (43.8 to 85.0)	-1.9 (-12.8 to 9.6)
Low back pain	243.9 (218.4 to 272.3)	393.4 (359.3 to 431.7)	61.5 (38.9 to 86.2)	-2.1 (-15.3 to 10.4)	27.2 (18.3 to 38.3)	43.8 (29.1 to 60.9)	61.1 (38.2 to 87.3)	-2.0 (-15.4 to 10.7)
Neck pain	177.8 (151.8 to 204.4)	293.8 (249.1 to 334.6)	65.1 (34.6 to 103.0)	-1.1 (-18.4 to 21.0)	17.4 (11.6 to 24.3)	28.8 (19.2 to 40.6)	65.3 (34.2 to 104.2)	-1.2 (-19.1 to 20.8)
Gout	1.6 (1.5 to 1.7)	2.5 (2.3 to 2.7)	58.3 (40.3 to 78.3)	-4.9 (-15.4 to 6.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	0.1 (24.8 to 97.6)	-5.1 (-24.5 to 18.9)
Other musculoskeletal disorders	132.8 (108.9 to 159.6)	197.8 (154.8 to 239.7)	50.0 (28.5 to 64.3)	8.5 (-20.8 to -0.4)	12.1 (7.9 to 17.3)	17.5 (11.5 to 25.7)	9.5 (27.1 to 64.1)	-8.9 (-21.5 to -0.3)
Other non-communicable diseases	-	-	-	-	96.4 (64.0 to 141.0)	145.4 (97.4 to 211.1)	50.8 (44.8 to 56.8)	-4.4 (-7.5 to -1.2)
Congenital anomalies	-	-	-	-	4.7 (3.3 to 6.4)	9.4 (6.9 to 12.3)	101.3 (70.3 to 145.1)	40.3 (19.2 to 70.1)
Neural tube defects	0.3 (0.3 to 0.4)	1.3 (1.1 to 1.5)	279.6 (203.5 to 377.3)	209.0 (146.4 to 288.5)	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.5)	339.1 (225.1 to 505.5)	265.7 (172.5 to 399.8)
Congenital heart anomalies	4.1 (2.8 to 5.6)	23.3 (18.6 to 28.8)	474.7 (286.4 to 766.9)	367.1 (208.3 to 614.0)	0.2 (0.1 to 0.3)	0.8 (0.3 to 1.4)	417.4 (251.1 to 670.0)	327.1 (184.6 to 548.8)
Orofacial clefts	0.6 (0.4 to 0.9)	3.5 (2.4 to 5.1)	489.5 (229.6 to 924.8)	0.0 (-185.2 to 816.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	0.1 (182.6 to 933.7)	0.1 (145.1 to 812.4)
Down syndrome	3.0 (2.5 to 3.8)	7.5 (6.4 to 8.8)	151.2 (87.3 to 214.1)	95.1 (46.2 to 144.5)	0.3 (0.2 to 0.5)	0.9 (0.7 to 1.2)	159.8 (89.7 to 241.9)	103.0 (47.9 to 167.0)
Turner syndrome	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	112.4 (21.2 to 238.4)	54.3 (-11.2 to 146.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (23.3 to 258.5)	0.0 (-14.0 to 149.6)
Klinefelter syndrome	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	47.4 (-2.0 to 116.2)	3.7 (-31.0 to 52.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.3 (5.7 to 137.6)	3.6 (-31.4 to 52.2)
Chromosomal unbalanced rearrangements	42.2 (4.2 to 6.2)	13.3 (11.4 to 15.6)	154.9 (106.1 to 227.2)	0.6 (-60.1 to 156.4)	1.6 (0.4 to 0.8)	1.6 (1.2 to 2.1)	108.3 (111.1 to 251.7)	108.3 (65.6 to 174.1)
Other congenital anomalies	28.1 (23.5 to 32.7)	37.3 (31.6 to 43.5)	33.0 (20.9 to 44.7)	-10.8 (-18.9 to -3.9)	3.5 (2.3 to 4.9)	5.7 (3.8 to 7.9)	63.3 (34.4 to 108.5)	10.1 (-8.2 to 38.1)
Skin and subcutaneous diseases	-	-	-	-	33.5 (20.8 to 52.0)	51.2 (33.2 to 77.5)	53.1 (40.8 to 68.5)	0.2 (-7.5 to 9.6)
Dermatitis	308.2 (253.0 to 367.4)	480.3 (390.2 to 574.6)	55.8 (53.5 to 57.8)	0.0 (-0.0 to 0.0)	8.5 (5.3 to 12.3)	12.9 (8.1 to 18.8)	51.4 (45.3 to 57.0)	-0.1 (-2.9 to 2.9)
Psoriasis	49.5 (43.6 to 55.9)	79.3 (69.6 to 89.6)	60.1 (58.9 to 61.1)	-0.0 (-0.0 to 0.0)	6.4 (2.7 to 5.6)	6.4 (4.3 to 9.0)	59.8 (49.9 to 69.5)	0.1 (-5.4 to 5.3)
Cellulitis	0.5 (0.4 to 0.6)	0.6 (0.4 to 0.7)	14.8 (7.0 to 38.6)	-12.6 (-27.5 to 4.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-13.4 to 48.9)	0.0 (-30.9 to 9.4)
Pyoderma	2.5 (2.1 to 3.0)	4.3 (3.5 to 5.2)	69.4 (57.1 to 80.0)	22.5 (17.0 to 28.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (43.0 to 95.9)	0.0 (7.4 to 38.7)
Scabies	92.8 (80.5 to 107.1)	129.3 (110.9 to 151.2)	38.8 (14.2 to 74.0)	-1.4 (-19.3 to 23.4)	2.4 (1.3 to 3.9)	3.3 (1.9 to 5.5)	38.5 (14.1 to 73.8)	-1.4 (-19.4 to 24.0)
Fungal skin diseases	474.3 (358.9 to 624.9)	737.9 (559.0 to 975.6)	55.4 (51.8 to 59.5)	2.1 (-0.1 to 1.1)	4.1 (1.1 to 5.8)	4.1 (1.6 to 9.2)	54.4 (51.4 to 59.9)	0.1 (-0.9 to 1.0)
Viral skin diseases	161.9 (122.8 to 198.6)	222.6 (165.4 to 279.3)	37.6 (30.4 to 44.3)	0.0 (-2.0 to 2.0)	5.0 (2.8 to 7.9)	6.9 (4.0 to 10.8)	37.5 (29.5 to 45.3)	0.1 (-3.3 to 3.2)
Acne vulgaris	497.3 (331.3 to 654.1)	765.9 (590.9 to 978.1)	54.2 (5.1 to 136.2)	-3.1 (-32.9 to 44.6)	5.4 (2.2 to 10.7)	8.3 (3.7 to 15.5)	54.5 (4.7 to 137.5)	-3.0 (-33.0 to 44.5)
Alopecia areata	5.8 (5.3 to 6.4)	8.9 (8.2 to 9.7)	53.5 (34.7 to 73.4)	0.5 (-11.7 to 13.2)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	53.3 (27.1 to 83.8)	0.3 (-15.1 to 17.9)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.5 (26.0 to 95.3)	2.1 (-18.9 to 28.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (25.8 to 95.3)	0.0 (-19.0 to 28.2)
Urticaria	52.4 (37.4 to 68.4)	94.2 (63.8 to 128.7)	80.8 (4.4 to 177.9)	8.8 (-35.7 to 63.7)	3.1 (1.8 to 4.8)	5.6 (3.1 to 9.0)	81.6 (3.5 to 176.8)	9.2 (-35.7 to 64.2)
Decubitus ulcer	0.6 (0.5 to 0.7)	0.8 (0.7 to 1.0)	34.0 (4.2 to 67.7)	-21.4 (-44.5 to 5.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	33.9 (-0.7 to 74.7)	-21.5 (-46.4 to 8.6)
Other skin and subcutaneous diseases	340.3 (230.6 to 502.9)	539.1 (363.6 to 805.3)	58.5 (50.9 to 65.3)	-1.0 (-5.8 to 2.8)	2.0 (0.9 to 4.2)	3.2 (1.4 to 6.6)	58.1 (50.3 to 65.4)	-1.1 (-6.0 to 2.9)
Sense organ diseases	-	-	-	-	40.3 (27.5 to 57.4)	56.6 (38.0 to 80.7)	60.6 (32.8 to 47.3)	-9.8 (-13.5 to -6.4)
Glaucoma	7.5 (6.1 to 8.9)	10.0 (8.1 to 11.9)	33.1 (17.2 to 53.6)	-18.7 (-29.3 to -8.8)	0.6 (0.4 to 0.8)	0.7 (0.5 to 1.2)	36.7 (17.3 to 58.0)	-17.2 (-29.6 to -1.5)
Cataract	31.8 (24.6 to 39.5)	38.5 (29.9 to 46.8)	20.7 (9.3 to 36.1)	-28.4 (-34.2 to -20.1)	1.6 (1.1 to 2.4)	2.0 (1.3 to 2.9)	23.4 (10.9 to 35.2)	-27.4 (-34.1 to -20.7)
Macular degeneration	8.1 (6.0 to 10.4)	14.3 (10.7 to 18.5)	76.8 (42.2 to 120.8)	9.5 (-13.4 to 36.8)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	74.9 (41.4 to 118.7)	7.7 (-13.6 to 34.9)
Uncorrected refractive error	586.4 (540.6 to 632.7)	921.9 (843.2 to 1,006.4)	57.5 (39.7 to 76.2)	-0.4 (-9.9 to 8.9)	8.6 (5.2 to 14.2)	12.7 (7.2 to 21.1)	46.1 (32.2 to 61.0)	-7.3 (-14.0 to 1.1)
Age-related and other hearing loss	755.7 (703.1 to 812.6)	1,107.8 (1,033.9 to 1,195.7)	46.3 (40.6 to 53.9)	-9.0 (-11.7 to -5.1)	23.2 (15.8 to 32.7)	29.0 (22.1 to 46.0)	32.9 (31.7 to 52.5)	-9.0 (-14.1 to -3.6)
Other vision loss	18.5 (15.7 to 21.4)	19.0 (16.2 to 22.3)	2.9 (-6.8 to 12.4)	-31.9 (-37.7 to -26.1)	1.3 (0.9 to 1.9)	1.4 (0.9 to 1.9)	2.8 (-9.2 to 15.0)	-31.0 (-38.0 to -24.1)
Other sense organ diseases	169.0 (160.3 to 176.8)	232.7 (221.4 to 244.3)	37.6 (29.4 to 47.3)	-0.4 (-6.4 to 6.0)	4.5 (2.8 to 6.7)	6.2 (3.8 to 9.2)	37.2 (27.2 to 48.6)	-0.3 (-7.0 to 7.1)
Oral disorders	-	-	-	-	18.0 (10.9 to 27.8)	28.2 (17.1 to 43.7)	56.3 (51.7 to 61.1)	-4.2 (-7.0 to -1.2)
Deciduous caries	698.5 (665.3 to 736.1)	797.2 (765.4 to 831.8)	14.3 (6.8 to 21.9)	0.5 (-5.9 to 7.2)	0.5 (0.1 to 0.5)	0.3 (0.1 to 0.6)	0.3 (1.4 to 25.2)	0.5 (-8.3 to 10.2)
Permanent caries	2,748.5 (2,636.8 to 2,861.6)	4,280.7 (4,113.1 to 4,472.5)	55.8 (48.9 to 62.3)	0.0 (-3.6 to				

Appendix Table G.4 - Halit prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	290.9 (279.9 to 301.3)	452.1 (437.2 to 466.5)	55.4 (48.0 to 63.7)	-6.2 (-10.4 to -1.7)	8.0 (5.4 to 11.0)	12.4 (8.5 to 17.1)	54.9 (47.0 to 62.8)	-6.4 (-10.8 to -2.1)
Other oral disorders	105.6 (99.9 to 111.2)	166.6 (156.7 to 176.6)	57.7 (46.4 to 70.8)	-0.5 (-7.1 to 7.5)	3.1 (1.9 to 4.6)	4.9 (3.1 to 7.2)	57.3 (45.1 to 72.2)	-0.6 (-7.5 to 8.3)
Injuries	-	-	-	-	30.4 (23.1 to 39.1)	103.9 (64.5 to 179.9)	224.7 (134.2 to 487.8)	81.3 (38.1 to 200.1)
Transport injuries	-	-	-	-	11.4 (8.7 to 14.8)	18.5 (13.8 to 24.0)	61.7 (54.7 to 67.9)	1.1 (-2.5 to 4.6)
Road injuries	-	-	-	-	5.3 (7.7 to 13.1)	16.6 (11.9 to 20.7)	58.2 (51.0 to 65.2)	-1.3 (-5.2 to 2.5)
Pedestrian road injuries	-	-	-	-	2.7 (2.1 to 3.5)	3.7 (2.8 to 4.8)	37.1 (28.7 to 45.5)	-13.3 (-17.8 to -8.7)
Cyclist road injuries	-	-	-	-	0.7 (0.5 to 0.9)	1.0 (0.7 to 1.3)	52.7 (42.2 to 64.7)	-3.3 (-10.0 to 5.6)
Motorcyclist road injuries	-	-	-	-	1.2 (0.9 to 1.6)	1.7 (1.3 to 2.3)	40.7 (30.1 to 50.8)	-13.1 (-19.5 to -7.4)
Motor vehicle road injuries	-	-	-	-	5.3 (4.0 to 6.8)	9.2 (6.9 to 11.9)	74.7 (62.6 to 86.8)	8.4 (2.1 to 15.3)
Other road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	38.0 (30.6 to 47.4)	-15.1 (-19.2 to -10.0)
Other transport injuries	-	-	-	-	1.3 (1.0 to 1.7)	2.5 (1.9 to 3.3)	87.6 (77.8 to 98.5)	18.4 (12.2 to 24.9)
Unintentional injuries	-	-	-	-	17.4 (13.2 to 22.3)	25.6 (19.3 to 33.2)	47.6 (42.4 to 51.9)	-7.1 (-10.3 to -4.8)
Falls	-	-	-	-	6.5 (4.9 to 8.4)	10.5 (7.9 to 13.6)	62.0 (52.2 to 69.7)	-1.8 (-6.7 to 2.6)
Drowning	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	32.1 (20.9 to 45.1)	-14.3 (-20.8 to -6.8)
Fire, heat, and hot substances	-	-	-	-	0.8 (0.6 to 1.0)	0.9 (0.7 to 1.1)	13.4 (6.0 to 21.4)	-25.4 (-29.6 to -20.6)
Poisonings	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	12.1 (6.1 to 36.3)	-27.6 (-37.8 to -14.3)
Exposure to mechanical forces	-	-	-	-	7.3 (5.9 to 9.5)	9.1 (6.8 to 11.9)	25.0 (18.0 to 30.9)	-19.7 (-23.8 to -16.3)
Unintentional firearm injuries	-	-	-	-	0.4 (0.3 to 0.6)	0.9 (0.7 to 1.2)	110.4 (94.8 to 127.8)	31.6 (22.3 to 42.1)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	87.9 (70.1 to 107.6)	19.1 (8.5 to 30.3)
Other exposure to mechanical forces	-	-	-	-	6.7 (5.0 to 8.8)	7.9 (5.9 to 10.4)	18.4 (11.1 to 24.2)	-24.0 (-28.4 to -20.4)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	92.8 (83.8 to 103.2)	23.2 (17.1 to 30.0)
Animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	89.7 (78.9 to 100.3)	20.7 (15.2 to 26.3)
Venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	86.0 (66.8 to 107.2)	18.6 (8.1 to 29.9)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	92.0 (82.9 to 102.1)	21.9 (17.5 to 27.0)
Foreign body	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.4)	61.1 (53.4 to 69.3)	3.6 (-1.0 to 8.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	51.9 (39.3 to 63.6)	0.6 (-5.6 to 6.7)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	50.3 (30.9 to 71.8)	-0.6 (-11.1 to 11.2)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	69.2 (59.4 to 80.6)	5.7 (-0.5 to 12.8)
Other unintentional injuries	-	-	-	-	2.2 (1.6 to 2.8)	4.2 (3.1 to 5.4)	89.3 (77.6 to 102.3)	8.7 (1.9 to 16.1)
Self-harm and interpersonal violence	-	-	-	-	1.4 (1.1 to 1.9)	2.4 (1.8 to 3.0)	63.5 (57.7 to 69.3)	0.0 (-3.5 to 3.3)
Self-harm	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.4)	43.2 (32.5 to 54.3)	-14.1 (-19.9 to -8.2)
Interpersonal violence	-	-	-	-	1.2 (0.9 to 1.6)	2.0 (1.5 to 2.6)	67.6 (61.0 to 73.9)	3.1 (-0.6 to 6.8)
Assault by firearm	-	-	-	-	0.3 (0.3 to 0.4)	0.7 (0.5 to 0.9)	99.5 (86.1 to 113.3)	21.9 (13.9 to 29.5)
Assault by sharp object	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.6)	74.0 (62.5 to 85.2)	5.5 (-1.3 to 12.6)
Assault by other means	-	-	-	-	0.6 (0.4 to 0.8)	0.9 (0.7 to 1.1)	46.1 (36.7 to 56.1)	-9.2 (-14.6 to -3.8)
Forces of nature, war, and legal intervention	-	-	-	-	0.1 (0.0 to 0.2)	57.4 (23.7 to 132.2)	56,937.6 (47,927.2 to 68,091.1)	29,081.4 (25,308.3 to 33,679.4)
Exposure to forces of nature	-	-	-	-	0.1 (0.0 to 0.2)	57.4 (23.7 to 132.1)	56,909.7 (47,887.3 to 68,071.6)	29,057.8 (25,288.5 to 33,656.1)
Collective violence and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.1)	-	-

Appendix Table G.4 - Honduras prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	430.4 (317.3 to 564.0)	755.8 (555.9 to 985.8)	75.7 (68.6 to 83.2)	75.7 (-7.9 to -0.8)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	89.8 (62.3 to 127.1)	110.1 (76.8 to 155.5)	22.8 (13.3 to 33.3)	-19.3 (-26.1 to -12.0)
HIV/AIDS and tuberculosis	-	-	-	-	2.5 (0.7 to 9.3)	3.1 (1.3 to 10.3)	55.0 (-24.7 to 126.0)	-16.8 (58.4 to 21.0)
Tuberculosis	2.4 (2.3 to 2.5)	4.0 (3.9 to 4.2)	67.8 (62.6 to 73.7)	-13.6 (-16.3 to -10.5)	0.7 (0.5 to 1.0)	1.2 (0.8 to 1.7)	68.9 (49.2 to 87.3)	-12.8 (-21.1 to -4.5)
HIV/AIDS	-	-	-	-	1.9 (0.1 to 8.6)	1.9 (0.2 to 8.8)	37.7 (-57.6 to 268.1)	-21.8 (-76.1 to 112.0)
HIV/AIDS resulting in mycobacterial infection	0.1 (0.0 to 0.4)	0.0 (0.0 to 0.3)	-35.8 (-82.9 to 99.5)	-65.7 (-91.0 to 5.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-34.5 (-83.3 to 102.1)	-65.7 (-91.1 to 8.8)
HIV/AIDS resulting in other diseases	16.8 (1.1 to 83.3)	13.3 (3.2 to 48.1)	49.7 (-56.9 to 330.4)	-10.6 (-74.3 to 150.3)	1.7 (0.1 to 8.5)	1.8 (0.2 to 8.8)	42.1 (-57.6 to 300.1)	-20.0 (-76.2 to 135.5)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	16.8 (11.7 to 23.1)	17.8 (12.4 to 24.6)	5.8 (-1.8 to 14.9)	-21.0 (-25.5 to -15.9)
Diarrheal diseases	63.9 (60.1 to 67.6)	58.3 (55.2 to 61.4)	-8.8 (-15.5 to -1.3)	-34.9 (-30.4 to -38.9)	10.5 (7.1 to 14.7)	9.5 (6.4 to 13.2)	-9.1 (-16.2 to -0.7)	-25.2 (-30.9 to -18.9)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-48.8 to -6.7)	0.0 (-66.2 to -38.2)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.3 (-16.0 to 22.1)	-33.7 (-45.1 to -20.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.3 (-16.1 to 22.1)	-33.7 (-45.1 to -20.1)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.9 (-21.1 to 22.9)	-33.0 (-46.0 to -16.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.9 (-21.1 to 22.9)	-33.0 (-46.0 to -16.7)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-89.4 (-97.2 to -89.7)	-93.0 (-98.1 to -90.1)
Lower respiratory infections	5.9 (5.0 to 6.9)	5.9 (5.3 to 6.7)	1.9 (-17.5 to 19.5)	-25.2 (-35.5 to -13.3)	0.6 (0.4 to 0.9)	0.6 (0.4 to 0.9)	1.4 (-19.2 to 22.5)	-24.8 (-37.6 to -10.9)
Upper respiratory infections	281.2 (256.7 to 299.7)	418.0 (386.3 to 446.0)	48.4 (35.0 to 65.1)	-7.3 (-15.6 to 2.6)	3.3 (1.8 to 5.5)	4.9 (2.8 to 8.1)	48.1 (34.3 to 65.7)	-7.0 (-15.7 to 3.2)
Otitis media	68.2 (63.6 to 72.8)	92.9 (87.3 to 98.8)	36.3 (27.2 to 45.6)	-12.4 (-17.8 to -6.4)	1.3 (0.8 to 2.1)	1.7 (1.0 to 2.8)	33.6 (22.7 to 44.1)	-13.1 (-19.7 to -6.9)
Meningitis	-	-	-	-	0.9 (0.6 to 1.3)	0.7 (0.5 to 1.0)	-20.6 (-34.1 to 7.5)	-49.7 (-57.3 to -33.9)
Pneumococcal meningitis	4.3 (2.6 to 6.6)	3.4 (2.0 to 5.4)	-21.6 (-34.9 to -4.7)	-5.6 (-61.4 to -44.0)	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-16.4 (-34.0 to 7.7)	-48.5 (-58.0 to -35.0)
H influenzae type B meningitis	1.9 (0.7 to 3.8)	1.3 (0.5 to 2.7)	-32.9 (-52.6 to 8.0)	-59.8 (-70.8 to -36.8)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-26.8 (-59.0 to 57.2)	-53.4 (-73.3 to -2.2)
Meningococcal meningitis	0.3 (0.1 to 0.7)	0.3 (0.1 to 0.6)	-14.0 (-34.6 to 17.8)	-49.7 (-61.9 to -31.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-11.6 (-38.3 to 28.4)	-46.8 (-61.0 to -23.4)
Other meningitis	1.9 (0.9 to 3.5)	1.4 (0.7 to 2.6)	-25.4 (-40.1 to -6.3)	-52.8 (-62.0 to -39.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-23.5 (-43.0 to 14.4)	-49.7 (-60.8 to -26.7)
Encephalitis	0.4 (0.2 to 1.0)	0.8 (0.4 to 1.7)	74.0 (49.5 to 101.6)	0.1 (-12.1 to 15.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	65.7 (45.2 to 121.4)	8.2 (-12.3 to 27.9)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.6 (-96.0 to 929.8)	-45.1 (-95.9 to 458.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.6 (-96.1 to 933.8)	-45.1 (-95.9 to 464.4)
Whooping cough	0.8 (0.6 to 1.0)	0.9 (0.7 to 1.1)	15.2 (15.1 to 15.3)	-1.4 (-1.5 to -1.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	15.5 (-6.5 to 44.7)	-1.0 (-20.1 to 23.9)
Tetanus	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-81.2 (-89.4 to -66.2)	-88.2 (-93.2 to -78.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-64.8 (-87.3 to -24.7)	-76.9 (-90.6 to -52.9)
Measles	0.2 (0.2 to 0.2)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	4.4 (4.1 to 4.7)	5.9 (5.4 to 6.6)	35.7 (21.6 to 53.8)	-2.0 (-19.0 to 21.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	77.1 (29.2 to 141.9)	-3.5 (-32.5 to 41.5)
Neglected tropical diseases and malaria	-	-	-	-	19.7 (12.7 to 29.8)	21.8 (14.2 to 32.6)	9.8 (-9.3 to 34.9)	-31.5 (-45.5 to -13.9)
Malaria	68.4 (40.0 to 100.1)	121.1 (70.6 to 191.3)	81.1 (-3.0 to 181.3)	16.4 (-36.1 to 84.4)	0.5 (0.5 to 1.2)	1.8 (1.5 to 4.1)	234.4 (134.0 to 311.5)	125.4 (60.7 to 174.9)
Chagas disease	126.9 (118.8 to 134.1)	226.1 (213.0 to 238.0)	78.1 (64.6 to 93.0)	-1.4 (-9.1 to 7.1)	0.1 (0.6 to 1.3)	0.1 (1.2 to 2.6)	85.7 (83.9 to 124.9)	8.2 (-10.4 to 8.5)
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	359.6 (273.5 to 477.8)	206.6 (154.2 to 293.5)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.9 (-18.4 to 64.0)	-19.7 (-40.0 to 14.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.9 (-18.4 to 64.2)	-19.7 (-40.0 to 14.4)
Cutaneous and mucocutaneous leishmaniasis	1.4 (1.0 to 1.8)	6.4 (4.9 to 8.2)	365.7 (301.4 to 457.0)	210.8 (160.3 to 285.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	364.4 (277.6 to 489.1)	209.8 (155.2 to 297.9)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	13.7 (8.1 to 19.5)	6.1 (2.0 to 13.7)	-58.0 (-87.2 to 12.8)	-71.5 (-91.6 to -35.0)	3.9 (2.0 to 6.2)	1.8 (0.6 to 4.3)	-55.2 (-86.4 to 23.9)	-70.1 (-91.1 to -27.6)
Cystic echinococcosis	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.4)	47.4 (21.2 to 66.4)	-20.5 (-29.6 to -12.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	46.7 (8.5 to 95.2)	20.2 (-41.0 to 4.9)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	1.3 (0.5 to 2.9)	10.2 (4.0 to 23.0)	703.1 (699.8 to 706.8)	388.7 (386.7 to 390.9)	0.2 (0.1 to 0.5)	1.7 (0.6 to 4.0)	701.1 (571.5 to 868.5)	389.6 (319.7 to 471.7)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.3 (-62.4 to -11.4)	-58.1 (-71.6 to -38.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.3 (-62.4 to -11.3)	-58.1 (-71.7 to -38.6)
Intestinal nematode infections	-	-	-	-	11.0 (6.0 to 19.1)	10.4 (5.6 to 17.7)	10.4 (-24.9 to 21.2)	-38.2 (-52.1 to -19.6)
Ascariasis	1,638.8 (1,209.0 to 2,202.2)	2,052.7 (1,449.0 to 2,924.1)	24.3 (-21.4 to 94.6)	-24.3 (-55.7 to 27.2)	5.8 (3.0 to 10.6)	3.0 (1.5 to 5.4)	-49.9 (-64.3 to -23.5)	-62.0 (-73.5 to -39.7)
Trichuriasis	1,711.7 (1,249.0 to 2,351.5)	2,466.8 (1,786.0 to 3,335.9)	44.6 (-6.4 to 127.6)	-16.0 (-47.8 to 41.5)	4.2 (2.2 to 7.4)	5.5 (2.9 to 10.2)	31.3 (-14.9 to 92.8)	-25.6 (-53.1 to 14.0)
Hookworm disease	225.5 (151.8 to 345.0)	400.4 (275.7 to 575.6)	77.4 (3.8 to 222.0)	0.9 (-43.4 to 107.0)	1.8 (0.5 to 1.3)	1.8 (1.1 to 2.9)	168.1 (68.1 to 163.8)	28.9 (-1.3 to 68.8)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	80.2 (63.6 to 97.2)	88.7 (83.3 to 96.7)	10.4 (-9.4 to 38.6)	-22.7 (-34.7 to -6.6)	2.9 (1.8 to 4.3)	3.3 (2.2 to 4.9)	11.0 (-1.4 to 55.4)	-18.7 (-27.6 to 11.0)
Maternal disorders	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	16.0 (-7.9 to 46.3)	-39.7 (-51.7 to -23.8)
Maternal hemorrhage	0.1 (0.1 to 0.2)	0.3 (0.3 to 0.4)	186.4 (97.8 to 385.4)	40.4 (-4.2 to 147.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.4 (-33.9 to 174.5)	-36.1 (-68.3 to 40.6)
Maternal sepsis and other maternal infections	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.9)	-	-46.7 (-62.5 to -34.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.3 (-43.4 to 63.1)	-46.4 (-68.8 to -19.2)
Maternal hypertensive disorders	1.0 (0.3 to 1.8)	1.1 (0.4 to 2.1)	16.5 (14.2 to 31.8)	-38.6 (-41.4 to -32.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	17.6 (-7.4 to 51.0)	-38.5 (-51.1 to -21.5)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.0 (-62.5 to 146.0)	-53.4 (-79.5 to 26.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.0 (-62.5 to 147.0)	-53.4 (-79.5 to 27.7)
Complications of abortion	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	20.4 (-22.4 to 94.2)	-37.2 (-58.2 to -4.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.2 (-42.4 to 171.0)	-36.0 (-68.2 to 31.7)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.7 (-27.2 to 90.5)	-36.3 (-61.7 to -1.2)
Neonatal disorders	-	-	-	-	5.6 (3.7 to 8.2)	17.3 (11.0 to 26.6)	209.4 (95.0 to 377.3)	104.9 (27.0 to 214.0)
Preterm birth complications	17.6 (10.7 to 29.9)	67.0 (39.7 to 113.5)	275.3 (179.5 to 460.9)	136.5 (80.0 to 248.6)	2.2 (1.3 to 3.4)	9.4 (5.3 to 16.3)	306.1 (133.0 to 692.8)	164.2 (52.7 to 410.1)
Neonatal encephalopathy due to birth asphyxia and trauma	19.2 (6.2 to 42.8)	23.3 (10.3 to 48.3)	22.8 (-11.3 to 95.1)	-24.3 (-45.5 to 23.1)	1.6 (0.9 to 2.7)	3.2 (2.0 to 4.6)	99.6 (14.1 to 231.8)	33.3 (-22.6 to 128.9)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (73.6 to 101.3)	0.0 (56.1 to 81.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (62.7 to 122.0)	0.0 (46.4 to 99.7)
Hemolytic disease and other neonatal jaundice	3.1 (1.8 to 5.5)	7.7 (3.3 to 16.9)	129.4 (-2.6 to 502.2)	48.6 (-38.0 to 286.6)	1.1 (0.6 to 2.1)	3.0 (1.2 to 6.6)	143.2 (3.7 to 518.7)	57.9 (-32.4 to 304.3)
Other neonatal disorders	-	-	-	-	0.7 (0.3 to 1.3)	1.8 (0.8 to 3.4)	179.1 (16.9 to 525.2)	84.1 (-22.6 to 311.2)
Nutritional deficiencies	-	-	-	-	41.5 (27.7 to 59.9)	45.1 (30.0 to 65.6)	8.5 (5.6 to 11.6)	-29.3 (-31.3 to -27.2)
Protein-energy malnutrition	7.4 (5.1 to 11.0)	6.1 (3.7 to 9.7)	-18.9 (-54.0 to 45.6)	-26.9 (-56.1 to 19.3)	0.9 (0.5 to 1.5)	0.7 (0.4 to 1.3)	-19.9 (-55.4 to 47.1)	27.4 (-56.4 to 22.2)
Iodine deficiency	47.2 (26.8 to 67.6)	52.3 (27.9 to 80.4)	5.6 (-45.6 to 148.7)	-43.0 (-71.0 to 40.3)	0.9 (0.4 to 1.5)	0.9 (0.4 to 1.8)	4.5 (-44.9 to 148.4)	-43.2 (-71.4 to 39.3)
Vitamin A deficiency	1.3 (0.9 to 1.7)	0.8 (0.6 to 1.1)	-35.6 (-47.0 to -21.3)	-56.5 (-63.4 to -47.4)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-38.9 (-53.2 to -21.9)	-59.2 (-67.1 to -48.6)

Appendix Table G.4 - Honduras prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990	YLDs 2013	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	1,210.7 (1,193.9 to 1,227.6)	1,411.7 (1,402.7 to 1,420.3)	16.6 (15.0 to 18.2)	-27.3 (-28.1 to -26.5)	39.4 (26.3 to 57.0)	43.1 (28.6 to 62.6)	9.4 (7.0 to 11.3)	9.4 (-30.5 to -27.7)
Other nutritional deficiencies	-	-	-	-	0.3 (0.1 to 0.5)	0.2 (0.1 to 0.5)	-11.2 (-57.3 to 88.8)	-19.4 (-59.2 to 55.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	3.6 (2.2 to 5.4)	5.0 (3.1 to 7.8)	38.8 (27.3 to 59.4)	-11.4 (-18.1 to -2.0)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.1 (0.6 to 1.8)	2.0 (1.2 to 3.5)	86.4 (66.7 to 110.5)	-3.5 (-12.2 to 7.2)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	25.1 (-1.6 to 55.5)	-48.8 (-51.3 to -46.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.4 (-6.3 to 81.4)	38.3 (-54.7 to -14.3)
Chlamydial infection	147.0 (101.8 to 193.0)	319.7 (237.4 to 400.1)	118.3 (56.7 to 229.1)	15.8 (-15.3 to 71.2)	0.7 (0.4 to 1.1)	1.3 (0.8 to 2.1)	90.4 (63.4 to 127.7)	-0.0 (-13.4 to 17.6)
Gonococcal infection	17.4 (11.1 to 22.7)	28.2 (20.6 to 35.4)	62.9 (12.2 to 140.0)	-12.2 (-37.9 to 24.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	51.8 (5.2 to 105.8)	-20.0 (-42.4 to 7.2)
Trichomoniasis	27.4 (17.9 to 38.6)	52.6 (32.6 to 69.6)	92.5 (9.3 to 273.0)	-2.9 (-39.0 to 61.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	93.8 (4.4 to 301.2)	-1.5 (-39.7 to 72.8)
Genital herpes	699.0 (656.1 to 735.2)	1,402.0 (1,323.9 to 1,480.9)	100.2 (86.1 to 117.8)	2.0 (-9.1 to 6.5)	0.0 (0.1 to 0.5)	0.0 (0.1 to 0.9)	97.7 (79.3 to 117.2)	-1.6 (-9.8 to 7.9)
Other sexually transmitted diseases	0.5 (0.4 to 0.7)	0.8 (0.6 to 1.1)	58.2 (35.4 to 82.5)	-23.6 (-33.4 to -12.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.3 (37.5 to 184.8)	-2.9 (-27.4 to 36.3)
Hepatitis	-	-	-	-	0.2 (0.2 to 0.4)	0.4 (0.2 to 0.5)	52.2 (29.8 to 80.6)	-13.5 (-28.1 to 5.3)
Hepatitis A	7.9 (7.6 to 8.4)	10.7 (10.3 to 11.1)	34.8 (33.3 to 36.5)	-4.6 (-4.7 to -4.5)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	58.4 (40.8 to 78.4)	-0.4 (-11.0 to 11.1)
Hepatitis B	147.3 (106.9 to 185.1)	175.6 (126.1 to 239.1)	17.0 (-13.5 to 75.7)	-32.4 (-51.5 to -3.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	44.4 (-9.1 to 131.9)	-28.5 (-54.6 to 18.7)
Hepatitis C	106.9 (94.0 to 119.3)	145.1 (129.6 to 161.0)	35.5 (15.6 to 62.7)	-28.9 (-38.7 to -16.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.3 (1.6 to 65.4)	-24.2 (-45.0 to 1.0)
Hepatitis E	-	-	-48.4 (-66.6 to -26.5)	-72.7 (-81.0 to -61.4)	-	-	-	-
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	169.2 (-11.5 to 1,627.3)	31.5 (-54.5 to 820.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	172.5 (-11.8 to 2,045.5)	32.6 (-54.7 to 978.9)
Other infectious diseases	57.9 (46.1 to 71.2)	64.5 (62.1 to 71.7)	11.6 (0.4 to 25.2)	-24.7 (-30.5 to -17.9)	2.2 (1.4 to 3.3)	2.6 (1.6 to 3.9)	14.7 (13.0 to 43.8)	-17.5 (-27.3 to 0.2)
Non-communicable diseases	-	-	-	-	311.9 (295.5 to 400.7)	613.0 (450.2 to 795.8)	96.4 (87.9 to 107.0)	2.1 (-0.8 to 8.0)
Neoplasms	-	-	-	-	1.4 (1.0 to 1.9)	3.9 (2.4 to 5.6)	173.6 (106.6 to 267.3)	37.6 (3.1 to 79.7)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	119.2 (45.0 to 234.4)	7.9 (-29.6 to 65.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	119.7 (50.9 to 226.3)	6.9 (-26.0 to 59.1)
Stomach cancer	0.9 (0.7 to 1.1)	1.9 (1.3 to 2.6)	106.8 (44.1 to 187.1)	-3.9 (-33.7 to 34.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	105.2 (44.5 to 187.3)	-4.7 (-33.8 to 36.4)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	156.7 (106.6 to 243.8)	14.0 (-20.6 to 65.6)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	174.5 (30.7 to 576.2)	38.8 (-33.5 to 239.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	167.8 (47.4 to 494.4)	34.4 (-26.1 to 196.0)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	438.9 (121.9 to 1,166.4)	142.7 (-21.0 to 485.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	426.1 (135.1 to 1,041.5)	135.2 (3.5 to 408.2)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.1 (-51.8 to 162.2)	-47.1 (-77.3 to 27.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.7 (-46.6 to 150.4)	-47.5 (-75.6 to 18.9)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.7 (-53.6 to 83.8)	-55.3 (-78.8 to -5.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.3 (-49.2 to 59.4)	57.1 (-76.1 to -19.5)
Larynx cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	100.5 (28.7 to 215.1)	-2.2 (-37.0 to 55.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.1 (33.1 to 228.0)	-0.2 (-36.5 to 57.6)
Tracheal, bronchus and lung cancer	0.3 (0.3 to 0.4)	0.7 (0.5 to 1.0)	112.9 (55.0 to 197.4)	1.8 (-25.7 to 40.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	112.0 (49.6 to 202.4)	1.9 (-28.4 to 45.3)
Breast cancer	2.3 (1.8 to 2.9)	7.8 (4.5 to 12.3)	231.7 (103.2 to 447.5)	55.5 (-3.8 to 155.7)	0.2 (0.1 to 0.3)	0.6 (0.3 to 1.1)	215.9 (93.2 to 409.4)	49.5 (8.5 to 135.7)
Cervical cancer	1.2 (0.8 to 1.7)	1.9 (1.0 to 3.1)	50.0 (-13.7 to 150.8)	-25.1 (-56.2 to 21.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.3)	51.8 (-10.5 to 155.3)	-23.0 (-55.2 to 22.1)
Uterine cancer	0.6 (0.4 to 0.9)	1.3 (0.6 to 2.4)	113.4 (6.0 to 300.0)	1.3 (-48.6 to 87.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	112.6 (10.0 to 301.9)	0.3 (-48.2 to 89.1)
Prostate cancer	0.5 (0.3 to 0.7)	2.7 (1.7 to 4.7)	466.3 (233.9 to 926.7)	158.4 (54.3 to 373.8)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.4)	381.0 (181.1 to 774.1)	116.7 (26.1 to 299.0)
Colon and rectum cancer	0.9 (0.8 to 1.1)	2.9 (2.1 to 4.0)	212.7 (132.7 to 331.6)	45.6 (8.2 to 97.3)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	199.8 (117.5 to 308.1)	38.9 (1.3 to 87.5)
Lip and oral cavity cancer	0.3 (0.2 to 0.4)	0.7 (0.4 to 1.0)	124.4 (48.7 to 249.2)	7.5 (-30.3 to 67.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	128.4 (52.0 to 248.9)	9.2 (-28.7 to 67.5)
Nasopharynx cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	102.4 (23.8 to 228.7)	-0.4 (-37.4 to 61.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.1 (27.4 to 224.3)	-1.3 (-37.1 to 59.2)
Other pharynx cancer	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.4)	126.8 (31.4 to 291.7)	9.6 (-36.2 to 87.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	125.6 (36.2 to 274.5)	8.5 (-34.7 to 79.6)
Gallbladder and biliary tract cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	112.0 (10.3 to 249.6)	-6.7 (-52.1 to 53.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	101.4 (6.1 to 226.6)	-10.7 (-54.5 to 46.7)
Pancreatic cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	200.9 (110.5 to 314.8)	36.3 (-13.9 to 86.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	192.7 (108.1 to 303.1)	33.9 (-6.4 to 85.0)
Malignant skin melanoma	1.1 (0.8 to 1.5)	2.9 (1.5 to 4.8)	153.3 (56.9 to 327.0)	25.8 (-19.9 to 106.1)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	148.8 (55.9 to 323.2)	24.1 (-21.2 to 103.7)
Non-melanoma skin cancer	1.0 (0.7 to 1.3)	3.9 (2.6 to 5.9)	293.3 (169.9 to 481.7)	73.2 (18.2 to 162.0)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.4)	367.8 (209.0 to 618.1)	106.8 (31.0 to 232.8)
Ovarian cancer	0.3 (0.2 to 0.4)	1.0 (0.5 to 1.6)	204.3 (72.1 to 448.1)	50.9 (-14.9 to 156.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	206.2 (66.7 to 442.5)	51.6 (-18.8 to 160.7)
Testicular cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	156.3 (32.6 to 358.3)	29.6 (-29.8 to 123.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	147.8 (27.4 to 360.1)	25.0 (-33.9 to 121.9)
Kidney cancer	0.9 (0.4 to 0.7)	2.2 (0.9 to 1.9)	168.2 (75.2 to 291.8)	1.3 (-8.7 to 132.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	167.3 (76.7 to 302.2)	50.5 (1.0 to 126.1)
Bladder cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	129.7 (60.4 to 235.7)	3.8 (-28.0 to 52.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	132.3 (62.2 to 236.3)	4.7 (-28.2 to 55.1)
Brain and nervous system cancer	0.4 (0.3 to 0.6)	1.1 (0.6 to 1.6)	157.8 (75.1 to 277.3)	47.0 (1.0 to 110.3)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.2)	155.6 (74.7 to 274.4)	38.6 (-3.3 to 97.7)
Thyroid cancer	1.6 (1.0 to 2.5)	4.3 (2.5 to 7.0)	163.7 (74.4 to 323.2)	30.0 (-12.9 to 102.5)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.4)	162.5 (79.9 to 319.7)	29.0 (-12.8 to 101.2)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.1 (23.8 to 180.1)	0.0 (-41.0 to 33.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	96.6 (26.9 to 180.7)	6.2 (-38.7 to 33.8)
Hodgkin lymphoma	0.5 (0.3 to 0.9)	1.1 (0.6 to 1.8)	106.7 (21.3 to 246.8)	43.8 (-9.2 to 126.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	118.2 (32.2 to 254.6)	43.4 (8.6 to 121.7)
Non-Hodgkin lymphoma	0.5 (0.3 to 0.8)	1.0 (0.5 to 2.3)	80.0 (18.2 to 244.9)	5.3 (-30.6 to 102.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	83.4 (17.0 to 243.3)	4.0 (-32.9 to 102.4)
Multiple myeloma	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	203.2 (80.6 to 399.6)	42.6 (-15.1 to 132.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	188.2 (67.3 to 365.9)	36.0 (-22.5 to 121.6)
Leukemia	0.9 (0.6 to 1.2)	2.2 (1.4 to 3.3)	151.2 (75.6 to 272.6)	82.5 (19.4 to 126.4)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.4)	153.6 (84.1 to 251.2)	50.3 (8.7 to 107.3)
Other neoplasms	2.2 (1.6 to 3.1)	7.4 (4.4 to 11.2)	238.3 (125.8 to 393.1)	112.7 (49.4 to 204.1)	0.1 (0.1 to 0.2)	0.5 (0.3 to 0.8)	236.0 (132.6 to 388.0)	100.4 (38.8 to 183.9)
Cardiovascular diseases	-	-	-	-	2.5 (1.7 to 3.5)	8.9 (6.0 to 12.6)	250.0 (168.3 to 358.5)	61.1 (25.0 to 114.2)
Rheumatic heart disease	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	104.8 (88.9 to 121.2)	0.5 (-7.6 to 9.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.4 (64.2 to 145.0)	0.1 (-20.5 to 24.4)
Ischemic heart disease	23.3 (19.6 to 28.4)	92.6 (74.0 to 117.8)	294.2 (182.1 to 440.5)	74.8 (25.4 to 139.5)	1.1 (0.7 to 1.6)	5.2 (3.2 to 7.8)	397.4 (206.0 to 593.1)	105.8 (35.3 to 206.3)
Cerebrovascular disease	-	-	-	-	0.5 (0.3 to 0.6)	1.1 (0.8 to 1.4)	123.2 (80.3 to 181.6)	4.6 (-1.6 to 35.4)
Ischemic stroke	0.9 (0.7 to 1.0)	2.1 (1.7 to 2.5)	142.7 (84.5 to 225.3)	10.8 (-16.2 to 53.7)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	141.8 (81.7 to 226.4)	11.0 (-17.7 to 53.4)
Hemorrhagic stroke	2.3 (2.0 to 2.7)	5.1 (4.3 to 5.9)	117.9 (73.1 to 172.6)	2.1 (-20.1 to 30.7)	0.4 (0.2 to 0.5)	0.8 (0.5 to 1.0)	117.7 (70.7 to 176.4)	2.4 (-20.1 to 32.0)
Hypertensive heart disease	1.5 (1.2 to 1.7)	3.7 (3.0 to 4.4)	154.8 (108.1 to 220.7)	14.1 (-7.4 to 42.4)	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.6)	153.4 (103.5 to 221.6)	14.3 (8.2 to 44.3)
Cardiomyopathy and myocarditis	0.7 (0.5 to 0.9)	1.7 (1.3 to 2.1)	136.9 (92.1 to 196.7)	17.4 (-6.9 to 54.6)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	136.5 (83.2 to 208.9)	18.2 (-8.9 to 61.1)
Atrial fibrillation and flutter	1.5 (1.1 to 2.0)	5.6 (3.9 to 8.1)	265.6 (149.5 to 454.9)	52.0 (1.2 to 129.7)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	265.4 (146.1 to 454.1)	54.2 (1.1 to 131.5)
Peripheral vascular disease	66.4 (44.7 to 84.3)	166.0 (123.7 to 203.8)	151.5 (69.4 to 262.2)	12.1 (-21.2 to 55.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	129.8 (34.5 to 256.7)	-10.3 (-48.6 to 38.9)
Endocarditis	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	35.7 (-2.3 to 76.9)	-9.2 (-36.7 to 17.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.3 (5.1 to 100.0)	-2.9 (-35.0 to 29.5)
Other cardiovascular and circulatory diseases	8.0 (4.3 to 14.1)	22.3 (12.2 to 34.9)	190.5 (28.7 to 415.4)	36.2 (-41.3 to 153.4)	0.6 (0.3 to 1.0)	1.6 (0.9 to 2.6)	190.1 (51.1 to 425.2)	36.0 (-40.9 to 158.9)
Chronic respiratory diseases	-	-	-	-	18.1 (12.3 to 24.7)	45.6 (31.9 to 61.9)	150.2 (124.5 to 189.8)	20.3 (7.1 to 36.7)
Chronic obstructive pulmonary disease	116.4 (108.9 to 123.8)	241.0 (226.1 to 256.9)	107.2 (9					

Appendix Table G.4 - Honduras prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.1 (90.7 to 101.6)	-6.7 (-9.2 to -4.2)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.8 (81.1 to 94.3)	-11.2 (-14.3 to -8.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.4 (81.5 to 95.1)	-11.1 (-14.3 to -8.1)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.7 (95.5 to 112.1)	-1.6 (-5.1 to 1.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.8 (96.0 to 112.3)	-1.6 (-5.1 to 2.0)
Asthma	202.7 (166.8 to 236.7)	544.9 (475.2 to 619.8)	166.8 (119.3 to 240.6)	25.7 (7.7 to 56.5)	8.9 (5.7 to 12.9)	24.0 (15.5 to 35.2)	169.2 (120.4 to 246.7)	27.0 (8.4 to 59.2)
Interstitial lung disease and pulmonary sarcoidosis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	121.5 (67.0 to 200.2)	8.7 (-19.2 to 49.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.8 (69.1 to 203.4)	9.3 (-19.6 to 50.1)
Other chronic respiratory diseases	-	-	-	-	2.3 (1.4 to 3.7)	3.3 (1.8 to 5.3)	43.8 (-3.3 to 115.6)	-28.9 (-52.9 to 5.9)
Cirrhosis	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	78.8 (51.3 to 101.6)	-9.8 (-20.6 to 3.3)
Cirrhosis due to hepatitis B	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	144.8 (29.2 to 355.8)	20.6 (-33.9 to 124.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	142.9 (25.8 to 355.3)	18.7 (-37.0 to 127.1)
Cirrhosis due to hepatitis C	0.4 (0.2 to 0.5)	0.8 (0.6 to 0.9)	78.8 (34.9 to 230.3)	-6.8 (-28.8 to 66.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	78.3 (24.9 to 255.5)	-6.2 (-33.1 to 73.9)
Cirrhosis due to alcohol use	0.5 (0.4 to 0.6)	0.7 (0.6 to 0.9)	54.6 (9.3 to 113.0)	-24.8 (-45.8 to 4.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	54.5 (6.1 to 123.4)	-24.3 (-46.1 to 6.7)
Cirrhosis due to other causes	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.6)	86.8 (18.7 to 192.5)	14.8 (-32.2 to 93.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	83.6 (11.3 to 195.8)	13.5 (-36.8 to 98.3)
Digestive diseases	-	-	-	-	3.3 (2.3 to 4.4)	6.6 (4.6 to 8.8)	101.5 (87.6 to 119.8)	5.9 (-12.0 to 1.6)
Peptic ulcer disease	20.3 (19.1 to 21.6)	24.8 (22.2 to 27.7)	22.3 (9.9 to 36.3)	-47.7 (-53.2 to -41.6)	0.7 (0.5 to 1.0)	0.9 (0.6 to 1.3)	33.6 (17.8 to 52.5)	-41.8 (-47.8 to -33.4)
Gastritis and duodenitis	16.6 (14.6 to 18.6)	27.8 (24.9 to 30.9)	67.0 (49.0 to 90.0)	-11.6 (-21.2 to 2.0)	0.7 (0.5 to 1.1)	1.3 (0.9 to 1.9)	77.8 (53.0 to 105.3)	-3.9 (-13.6 to 9.7)
Appendicitis	0.3 (0.3 to 0.3)	0.5 (0.4 to 0.5)	60.8 (31.5 to 97.6)	-2.3 (-17.0 to 17.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	60.8 (3.0 to 136.4)	-2.2 (-33.4 to 35.7)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	22.1 (-32.4 to 136.5)	7.7 (-32.5 to 65.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	22.1 (-36.6 to 159.3)	8.9 (-38.5 to 77.9)
Inguinal, femoral, and abdominal hernia	12.0 (10.9 to 13.4)	20.4 (18.3 to 22.8)	70.3 (46.6 to 97.8)	-18.5 (-30.1 to -4.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	70.3 (44.9 to 99.9)	-17.5 (-29.3 to -2.5)
Inflammatory bowel disease	4.3 (4.2 to 4.5)	11.0 (10.6 to 11.4)	153.9 (141.5 to 167.2)	24.6 (18.3 to 31.1)	0.9 (0.6 to 1.3)	2.3 (1.6 to 3.2)	153.1 (134.0 to 178.4)	24.9 (16.1 to 35.0)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.0 (78.9 to 200.3)	4.2 (-19.7 to 57.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	114.4 (55.8 to 205.3)	-0.5 (-31.1 to 53.3)
Gallbladder and biliary diseases	2.3 (2.0 to 2.7)	5.0 (4.4 to 5.7)	117.0 (81.6 to 163.3)	0.2 (-12.6 to 20.5)	0.5 (0.2 to 0.3)	0.5 (0.3 to 0.8)	117.2 (77.6 to 168.8)	3.1 (-13.9 to 21.1)
Pancreatitis	0.2 (0.2 to 0.2)	0.6 (0.6 to 0.7)	200.6 (181.6 to 219.8)	48.4 (38.9 to 57.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	200.2 (130.6 to 291.6)	48.8 (15.8 to 89.2)
Other digestive diseases	-	-	-	-	0.4 (0.2 to 0.5)	0.9 (0.6 to 1.4)	147.2 (97.7 to 214.6)	15.2 (-8.0 to 46.0)
Neurological disorders	-	-	-	-	29.3 (19.0 to 40.1)	54.3 (35.7 to 75.6)	84.3 (48.3 to 141.2)	-2.7 (-18.2 to 21.4)
Alzheimer disease and other dementias	15.9 (13.3 to 18.4)	39.0 (33.2 to 45.7)	145.2 (94.9 to 209.4)	1.6 (-19.4 to 28.3)	2.2 (1.5 to 2.9)	5.6 (4.0 to 7.5)	152.8 (100.8 to 218.9)	3.1 (-1.8 to 30.7)
Parkinson disease	0.3 (0.2 to 0.3)	0.6 (0.5 to 0.7)	126.0 (111.4 to 141.3)	1.7 (-4.4 to 7.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	126.4 (87.8 to 172.8)	2.6 (-14.8 to 24.1)
Epilepsy	31.7 (21.3 to 41.8)	50.8 (33.3 to 67.2)	60.4 (-0.9 to 164.1)	-5.4 (-41.5 to 54.2)	9.9 (5.9 to 15.1)	17.2 (9.6 to 25.9)	72.8 (24.4 to 189.7)	3.0 (-38.8 to 72.5)
Multiple sclerosis	0.1 (0.1 to 0.1)	0.6 (0.5 to 0.6)	290.1 (258.3 to 328.2)	90.6 (75.0 to 108.8)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	277.9 (218.1 to 348.2)	84.6 (54.3 to 119.6)
Migraine	358.0 (267.5 to 442.9)	580.7 (396.0 to 817.0)	64.2 (0.5 to 173.3)	-54.3 (-41.2 to 39.6)	12.3 (6.7 to 18.8)	19.8 (10.7 to 33.1)	117.2 (71.6 to 168.8)	-13.8 (-42.0 to 40.7)
Tension-type headache	828.9 (671.7 to 997.1)	1,652.1 (1,528.5 to 1,781.8)	100.3 (64.6 to 151.4)	1.9 (-14.6 to 23.9)	1.3 (0.6 to 2.3)	2.5 (1.2 to 4.4)	100.4 (44.6 to 152.9)	2.5 (-12.4 to 25.5)
Medication overuse headache	16.4 (10.1 to 23.2)	48.9 (31.8 to 66.8)	199.7 (123.7 to 296.4)	49.0 (13.7 to 95.7)	2.6 (1.4 to 4.2)	7.7 (4.2 to 11.9)	200.2 (122.9 to 301.4)	49.3 (13.2 to 99.2)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.9 (13.9 to 145.7)	-3.4 (-35.7 to 37.4)	1.0 (0.6 to 1.4)	1.3 (0.8 to 2.0)	31.5 (-14.0 to 103.9)	-46.4 (-65.1 to -15.9)
Mental and substance use disorders	-	-	-	-	111.7 (77.4 to 149.4)	208.8 (144.7 to 278.7)	86.7 (80.9 to 94.6)	0.2 (-2.3 to 3.9)
Schizophrenia	9.6 (8.8 to 10.4)	19.6 (17.9 to 21.1)	103.2 (95.0 to 112.9)	-0.6 (-4.3 to 3.8)	6.2 (4.5 to 7.5)	12.6 (9.2 to 15.2)	103.9 (90.5 to 119.6)	103.9 (-6.0 to 6.9)
Alcohol use disorders	53.4 (47.1 to 60.5)	91.5 (81.1 to 102.7)	70.9 (60.9 to 82.6)	-12.9 (-17.9 to -6.9)	5.3 (3.5 to 7.5)	9.1 (6.0 to 12.9)	72.4 (59.4 to 85.8)	-12.2 (-18.3 to -5.7)
Drug use disorders	-	-	-	-	5.5 (3.6 to 7.6)	10.9 (7.1 to 15.1)	99.0 (63.6 to 149.0)	2.9 (-14.5 to 26.0)
Opioid use disorders	2.4 (1.2 to 4.1)	5.2 (2.4 to 9.2)	113.1 (78.1 to 156.1)	1.8 (-12.8 to 12.9)	1.0 (0.4 to 1.8)	2.2 (0.9 to 4.0)	114.9 (72.9 to 150.5)	2.6 (-15.0 to 19.1)
Cocaine use disorders	5.3 (5.3 to 9.6)	16.2 (12.5 to 20.2)	117.6 (56.7 to 246.2)	7.9 (-20.2 to 63.0)	1.0 (0.6 to 1.6)	2.2 (1.3 to 3.0)	118.3 (51.9 to 243.4)	8.7 (-21.9 to 64.0)
Amphetamine use disorders	8.9 (8.3 to 9.6)	15.4 (14.4 to 16.6)	74.2 (57.1 to 92.0)	-4.4 (-13.1 to 5.0)	1.2 (0.7 to 1.7)	2.0 (1.2 to 3.0)	74.5 (48.2 to 102.9)	-4.0 (-18.2 to 10.7)
Cannabis use disorders	3.7 (2.8 to 4.5)	6.7 (5.2 to 8.1)	81.7 (79.1 to 84.8)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	81.0 (44.6 to 127.9)	0.3 (-19.6 to 22.6)
Other drug use disorders	-	-	-	-	2.2 (1.4 to 3.3)	4.3 (2.6 to 6.2)	95.4 (38.7 to 185.2)	2.5 (-26.6 to 49.0)
Depressive disorders	-	-	-	-	47.6 (29.5 to 71.7)	89.6 (57.8 to 139.5)	96.5 (83.1 to 114.3)	2.7 (-2.7 to 9.6)
Major depressive disorder	211.4 (152.3 to 276.4)	414.1 (303.8 to 539.1)	95.7 (81.7 to 113.8)	2.3 (-3.2 to 9.5)	43.5 (25.9 to 66.8)	85.4 (51.2 to 128.4)	96.0 (81.4 to 115.7)	2.8 (-3.0 to 10.7)
Dysthymia	42.4 (34.2 to 50.5)	85.7 (69.4 to 101.5)	102.2 (98.7 to 106.7)	0.2 (0.1 to 0.3)	4.1 (2.6 to 5.9)	8.3 (5.4 to 12.1)	102.5 (95.8 to 109.9)	0.6 (-1.8 to 3.0)
Bipolar disorder	30.7 (24.3 to 36.8)	60.4 (48.3 to 71.9)	96.9 (83.8 to 110.2)	0.0 (-6.0 to 6.4)	6.3 (3.8 to 9.7)	12.3 (7.5 to 19.0)	97.2 (80.9 to 115.8)	0.5 (-7.0 to 8.1)
Anxiety disorders	184.6 (119.6 to 247.1)	342.3 (224.1 to 447.3)	85.2 (77.4 to 94.6)	0.1 (-0.1 to 0.3)	17.0 (10.0 to 26.3)	31.6 (18.5 to 48.5)	85.5 (76.6 to 96.1)	0.4 (-1.6 to 2.6)
Eating disorders	-	-	-	-	1.5 (0.9 to 2.3)	2.7 (1.6 to 4.1)	82.4 (66.8 to 97.2)	1.3 (-6.6 to 8.9)
Anorexia nervosa	1.1 (0.9 to 1.4)	2.1 (1.6 to 2.7)	86.3 (67.7 to 105.4)	7.1 (-3.4 to 18.5)	0.2 (0.1 to 0.4)	0.4 (0.3 to 0.7)	87.4 (51.1 to 135.2)	7.8 (-12.0 to 33.8)
Bulimia nervosa	5.8 (3.8 to 8.5)	10.4 (6.9 to 15.3)	80.6 (76.2 to 84.9)	-0.3 (-0.5 to -0.0)	1.2 (0.7 to 2.0)	2.2 (1.2 to 3.6)	81.3 (65.8 to 96.6)	0.1 (-7.9 to 7.8)
Autistic spectrum disorders	-	-	-	-	5.8 (4.1 to 7.9)	9.6 (6.7 to 13.1)	65.3 (59.0 to 71.3)	0.3 (-2.7 to 3.8)
Autism	14.7 (13.9 to 15.5)	24.4 (23.0 to 25.7)	65.8 (65.0 to 66.7)	-0.1 (-0.1 to -0.1)	3.6 (2.5 to 5.0)	6.0 (4.1 to 8.3)	65.8 (56.8 to 74.4)	0.4 (-4.1 to 5.0)
Asperger syndrome	21.8 (20.4 to 23.1)	35.8 (33.6 to 38.0)	64.6 (63.5 to 65.8)	-0.1 (-0.1 to -0.1)	2.2 (1.5 to 3.0)	3.6 (2.5 to 5.0)	64.6 (57.4 to 72.5)	0.4 (-3.5 to 4.6)
Attention-deficit/hyperactivity disorder	46.3 (42.4 to 49.4)	69.3 (63.5 to 73.9)	49.6 (49.0 to 49.9)	0.4 (0.4 to 0.5)	0.6 (0.3 to 0.9)	0.8 (0.5 to 1.3)	50.0 (40.6 to 59.9)	0.8 (-5.5 to 7.5)
Conduct disorder	60.9 (56.7 to 65.2)	92 (85.8 to 99.2)	51.5 (50.4 to 52.6)	0.1 (0.5 to 0.5)	7.3 (4.6 to 10.6)	11.1 (7.0 to 16.1)	51.1 (45.7 to 58.6)	0.9 (-3.3 to 5.2)
Idiopathic intellectual disability	88.5 (65.9 to 111.1)	113.4 (77.5 to 145.3)	28.5 (3.9 to 50.9)	-11.5 (-37.0 to -7.4)	4.3 (2.8 to 6.3)	5.6 (3.4 to 8.1)	28.4 (3.0 to 51.6)	-21.4 (-37.0 to -6.7)
Other mental and substance use disorders	58.8 (54.8 to 62.6)	118.4 (110.6 to 125.8)	101.4 (100.2 to 102.6)	-0.2 (-0.3 to -0.1)	4.4 (3.0 to 5.9)	8.9 (6.0 to 11.9)	102.1 (93.6 to 109.9)	0.4 (-3.1 to 4.0)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	21.8 (15.1 to 29.8)	50.9 (35.4 to 69.8)	133.8 (109.6 to 158.3)	28.7 (12.6 to 44.0)
Diabetes mellitus	97.8 (79.8 to 115.7)	351.8 (298.6 to 404.6)	260.1 (189.0 to 361.0)	83.0 (41.5 to 138.0)	6.8 (4.4 to 9.7)	24.3 (16.4 to 34.6)	256.7 (181.0 to 352.4)	75.1 (34.7 to 123.1)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-4.6 to 13.6)	-26.2 (-31.3 to -21.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-4.6 to 13.7)	0.0 (-31.3 to -21.5)
Chronic kidney disease	-	-	-	-	5.2 (3.7 to 6.9)	10.0 (7.1 to 13.3)	91.2 (70.5 to 118.6)	4.2 (-8.8 to 20.9)
Chronic kidney disease due to diabetes mellitus	67.3 (42.8 to 98.9)	139.4 (99.2 to 206.9)	107.0 (59.1 to 178.7)	5.3 (-21.4 to 43.2)	1.0 (0.6 to 1.4)	2.0 (1.4 to 2.7)	107.2 (51.8 to 174.3)	6.8 (-24.0 to 49.1)
Chronic kidney disease due to hypertension	81.7 (48.4 to 136.3)	150.9 (98.7 to 225.3)	85.2 (30.7 to 180.9)	1.3 (-12.2 to 53.0)	1.3 (0.9 to 1.8)	2.7 (1.8 to 3.6)	101.0 (60.7 to 157.2)	4.9 (-15.4 to 38.8)
Chronic kidney disease due to glomerulonephritis	94.4 (64.0 to 143.1)	174.6 (117.5 to 257.9)	82.2 (47.3 to 157.6)	1.3 (-20.4 to 39.2)	1.3 (0.8 to 1.6)	2.4 (1.6 to 2.9)	98.4 (59.1 to 146.5)	17.4 (-8.9 to 51.5)
Chronic kidney disease due to other causes	126.1 (77.3 to 199.6)	196.0 (126.0 to 319.6)	55.6 (25.3 to 92.4)	-11.2 (-33.5 to 12.5)	1.7 (1.2 to 2.3)	2.9 (2.0 to 4.0)	74.1 (36.4 to 118.1)	-5.7 (-24.4 to 15.9)
Urinary diseases and male infertility	-	-	-	-	0.9 (0.6 to 1.4)	2.0 (1.3 to 3.0)	119.0 (77.6 to 159.9)	5.1 (-17.3 to 27.6)

Appendix Table G.4 - Honduras prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.0 (0.9 to 1.1)	1.8 (1.5 to 2.2)	82.5 (49.4 to 117.1)	0.0 (-8.5 to 23.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	82.7 (36.2 to 139.1)	82.7 (15.6 to 32.9)
Urolithiasis	28.0 (17.6 to 37.2)	51.1 (24.1 to 86.6)	76.1 (26.0 to 171.9)	-17.1 (-38.3 to 23.2)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.6)	112.2 (62.9 to 211.2)	2.5 (-20.4 to 46.4)
Benign prostatic hyperplasia	17.9 (15.2 to 20.4)	40.3 (33.9 to 45.3)	128.3 (76.0 to 180.2)	5.4 (-20.1 to 31.4)	0.6 (0.4 to 0.9)	1.4 (0.9 to 2.0)	130.3 (78.7 to 180.8)	7.1 (-18.3 to 32.6)
Male infertility due to other causes	15.9 (12.1 to 20.8)	28.3 (21.5 to 34.9)	77.1 (23.5 to 165.8)	-11.5 (-38.4 to 30.4)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	76.0 (16.8 to 175.9)	-12.3 (-41.1 to 34.7)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	88.3 (40.8 to 171.6)	0.0 (-30.2 to 35.8)
Gynecological diseases	-	-	-	-	4.8 (3.1 to 7.2)	9.5 (6.2 to 14.4)	96.8 (73.8 to 122.3)	-3.6 (-13.7 to 8.0)
Uterine fibroids	64.4 (57.7 to 70.3)	143.0 (128.6 to 155.6)	122.0 (120.5 to 123.7)	2.6 (2.5 to 2.8)	1.0 (0.6 to 1.6)	1.8 (1.0 to 3.1)	78.3 (60.9 to 92.3)	-14.8 (-22.8 to -8.6)
Polycystic ovarian syndrome	64.8 (57.3 to 72.5)	130.6 (116.7 to 144.7)	102.2 (72.2 to 135.2)	1.3 (-12.9 to 16.0)	0.6 (0.3 to 1.2)	1.3 (0.6 to 2.4)	102.6 (72.2 to 135.0)	1.8 (-12.4 to 15.9)
Female infertility due to other causes	14.0 (9.4 to 19.5)	29.8 (21.3 to 39.8)	112.2 (35.6 to 228.2)	1.2 (-37.1 to 63.5)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	113.0 (34.9 to 237.5)	1.9 (-36.6 to 64.2)
Endometriosis	6.9 (5.8 to 8.0)	15.1 (12.9 to 17.4)	118.8 (71.9 to 175.4)	6.9 (-15.0 to 33.4)	0.6 (0.4 to 0.9)	1.4 (0.9 to 2.0)	119.5 (72.0 to 181.7)	7.3 (-15.8 to 36.1)
Genital prolapse	221.7 (191.7 to 260.1)	470.9 (407.2 to 545.2)	111.7 (74.4 to 164.9)	0.6 (-14.4 to 20.4)	0.7 (0.3 to 1.3)	1.5 (0.7 to 2.9)	111.8 (73.3 to 164.9)	0.8 (-15.1 to 21.2)
Premenstrual syndrome	173.7 (135.8 to 210.5)	356.6 (266.1 to 455.0)	105.9 (44.4 to 193.0)	3.4 (-27.3 to 47.5)	1.5 (0.9 to 2.3)	3.0 (1.7 to 4.8)	105.4 (43.8 to 191.7)	3.3 (-28.0 to 48.1)
Other gynecological diseases	12.9 (11.5 to 14.2)	17.8 (15.8 to 19.4)	38.3 (15.5 to 61.5)	-28.7 (-39.9 to -15.8)	0.4 (0.2 to 0.5)	0.4 (0.3 to 0.6)	22.5 (8.7 to 65.0)	-37.0 (-53.2 to -16.0)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	2.3 (1.4 to 3.3)	3.1 (2.1 to 4.5)	38.2 (25.7 to 65.2)	-10.7 (-18.4 to 2.3)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.7 (7.2 to 85.0)	-1.6 (-19.9 to 37.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.4 (5.7 to 81.0)	-5.3 (-20.4 to 36.4)
Thalassemia trait	20.2 (16.2 to 24.1)	34.4 (28.2 to 41.7)	65.2 (60.0 to 115.6)	0.2 (-2.8 to 30.8)	0.5 (0.3 to 0.7)	0.9 (0.6 to 1.3)	91.4 (64.0 to 119.4)	26.4 (9.6 to 43.0)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	46.2 (34.8 to 59.6)	-4.7 (-12.2 to 3.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.7 (43.2 to 77.6)	2.7 (-8.4 to 13.7)
Sickle cell trait	43.8 (35.3 to 53.4)	72.0 (57.5 to 88.2)	63.6 (51.0 to 82.9)	0.2 (-8.5 to 10.9)	0.5 (0.1 to 0.3)	0.5 (0.3 to 0.8)	171.9 (41.8 to 253.8)	57.9 (1.5 to 123.3)
G6PD deficiency	86.9 (71.2 to 100.5)	144.7 (110.5 to 182.4)	65.7 (19.2 to 124.6)	0.6 (-27.7 to 36.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.3 (67.6 to 105.5)	28.0 (18.4 to 37.4)
G6PD trait	582.2 (531.9 to 628.0)	961.8 (876.3 to 1,050.7)	64.3 (47.0 to 88.1)	-0.4 (-10.9 to 14.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	127.0 (63.5 to 2,503.1)	72.4 (-67.4 to 1,108.1)
Other hemoglobinopathies and hemolytic anemias	55.1 (50.3 to 59.5)	65.2 (62.1 to 68.8)	18.3 (9.5 to 29.4)	-29.7 (-34.8 to -24.3)	1.5 (0.9 to 2.2)	1.6 (1.0 to 2.4)	6.3 (-4.0 to 32.3)	-32.6 (-40.8 to -20.4)
Endocrine, metabolic, blood, and immune disorders	55.9 (52.8 to 58.8)	66.8 (57.8 to 73.8)	19.4 (1.8 to 40.9)	-24.2 (-33.7 to -14.2)	1.9 (1.1 to 2.5)	2.0 (1.3 to 2.8)	13.2 (-12.0 to 43.4)	22.0 (-37.1 to 3.0)
Musculoskeletal disorders	-	-	-	-	56.3 (39.6 to 76.1)	110.6 (76.9 to 150.7)	95.4 (73.9 to 138.9)	-3.5 (-13.7 to 14.1)
Rheumatoid arthritis	12.2 (11.4 to 12.9)	26.9 (25.4 to 28.3)	121.1 (102.6 to 140.3)	11.2 (2.2 to 20.6)	2.9 (2.0 to 3.8)	6.3 (4.5 to 8.3)	119.3 (100.8 to 141.5)	11.2 (1.7 to 21.7)
Osteoarthritis	89.7 (86.3 to 93.1)	201.5 (193.6 to 209.2)	124.5 (113.2 to 137.8)	1.4 (-3.6 to 7.0)	5.4 (3.8 to 7.5)	12.2 (8.6 to 16.4)	124.8 (112.6 to 138.1)	1.9 (-3.5 to 7.6)
Low back and neck pain	-	-	-	-	41.9 (28.2 to 58.5)	77.9 (52.4 to 111.0)	84.4 (52.5 to 141.8)	-7.1 (-22.1 to 17.1)
Low back pain	279.3 (222.4 to 334.6)	521.5 (427.3 to 633.8)	86.8 (43.1 to 152.2)	-6.6 (-25.1 to 21.7)	31.1 (20.3 to 45.4)	58.2 (37.8 to 85.7)	87.0 (43.1 to 153.7)	-6.1 (-25.4 to 22.5)
Neck pain	109.5 (83.5 to 133.4)	200.6 (142.0 to 260.4)	86.1 (12.6 to 142.6)	-7.9 (-40.1 to 20.8)	10.8 (6.9 to 15.8)	19.7 (11.7 to 29.8)	86.4 (11.2 to 144.7)	-7.6 (-41.0 to 21.2)
Gout	1.3 (1.1 to 1.6)	3.0 (2.5 to 3.4)	121.9 (79.6 to 177.6)	2.2 (-16.6 to 28.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	123.0 (65.1 to 196.6)	3.2 (-22.5 to 37.7)
Other musculoskeletal disorders	66.8 (51.6 to 79.8)	155.0 (121.4 to 189.7)	131.2 (110.9 to 156.6)	8.3 (-1.0 to 20.1)	8.3 (3.9 to 8.8)	14.5 (9.2 to 20.4)	181.6 (111.0 to 258.7)	8.9 (-0.7 to 21.0)
Other non-communicable diseases	-	-	-	-	67.3 (45.9 to 95.6)	123.0 (84.7 to 173.5)	82.5 (73.9 to 94.1)	-3.4 (-7.0 to 1.1)
Congenital anomalies	-	-	-	-	5.9 (4.3 to 8.0)	15.3 (10.1 to 22.0)	153.1 (95.8 to 257.1)	54.8 (21.9 to 113.2)
Neural tube defects	1.5 (1.3 to 1.8)	3.2 (2.6 to 4.0)	103.9 (57.7 to 195.5)	38.6 (6.8 to 99.8)	0.5 (0.3 to 0.7)	1.0 (0.6 to 1.6)	114.2 (43.5 to 256.2)	47.2 (-0.0 to 145.7)
Congenital heart anomalies	16.0 (12.3 to 20.8)	42.9 (38.7 to 47.0)	170.2 (103.3 to 257.3)	78.3 (34.1 to 135.9)	0.5 (0.2 to 1.0)	1.5 (0.6 to 2.6)	174.1 (109.9 to 259.9)	83.0 (38.2 to 141.4)
Orofacial clefts	2.8 (2.2 to 3.7)	7.3 (6.0 to 8.9)	162.9 (85.6 to 253.7)	85.0 (29.7 to 149.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	113.3 (40.0 to 221.5)	53.3 (-0.1 to 119.9)
Down syndrome	5.3 (4.3 to 6.3)	10.8 (9.1 to 13.2)	100.1 (62.5 to 164.3)	27.8 (3.7 to 68.9)	0.6 (0.4 to 0.9)	1.3 (1.0 to 1.8)	109.5 (65.3 to 180.6)	32.4 (5.8 to 75.9)
Turner syndrome	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	82.0 (20.1 to 172.1)	13.7 (-25.2 to 70.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.1 (20.6 to 193.0)	14.1 (-26.2 to 73.5)
Klinefelter syndrome	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	69.3 (13.3 to 147.0)	3.7 (-30.6 to 51.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.0 (24.3 to 174.7)	3.3 (-31.1 to 51.2)
Chromosomal unbalanced rearrangements	0.0 (6.2 to 8.8)	0.0 (12.1 to 17.2)	79.8 (53.4 to 148.4)	-2.1 (-6.5 to 1.2)	0.0 (0.6 to 1.2)	0.0 (1.2 to 2.4)	79.8 (59.8 to 161.9)	-2.1 (0.1 to 65.7)
Other congenital anomalies	21.9 (18.5 to 25.2)	33.0 (28.0 to 38.4)	51.1 (36.8 to 64.1)	-12.9 (-20.7 to -6.0)	3.4 (2.3 to 4.9)	9.6 (5.5 to 15.6)	175.4 (86.8 to 361.1)	62.0 (12.9 to 168.0)
Skin and subcutaneous diseases	-	-	-	-	23.4 (14.9 to 34.8)	39.8 (25.5 to 60.6)	69.8 (53.0 to 91.6)	-0.6 (-9.6 to 10.7)
Dermatitis	235.3 (189.4 to 289.1)	418.1 (333.1 to 512.8)	77.7 (73.6 to 81.6)	-0.0 (-0.1 to 0.1)	7.5 (4.6 to 11.2)	12.8 (7.9 to 38.8)	69.5 (60.4 to 76.8)	0.3 (-2.4 to 2.9)
Psoriasis	32.6 (28.7 to 36.7)	61.6 (54.2 to 69.7)	89.3 (86.8 to 91.4)	0.0 (-0.1 to 0.1)	0.0 (1.8 to 3.7)	0.0 (3.4 to 7.1)	89.3 (77.4 to 102.3)	0.5 (-4.6 to 6.1)
Cellulitis	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.4)	73.0 (54.3 to 100.7)	0.7 (-10.9 to 19.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.6 (53.2 to 100.9)	0.0 (-12.4 to 21.3)
Pyoderma	1.9 (1.3 to 2.7)	3.0 (2.2 to 4.1)	58.9 (36.2 to 93.2)	4.3 (-8.2 to 20.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.8 (26.1 to 99.0)	5.3 (-13.9 to 28.6)
Scabies	62.5 (54.5 to 71.1)	87.5 (77.1 to 98.9)	40.4 (23.1 to 59.1)	-12.2 (-22.0 to -0.4)	1.6 (0.9 to 2.6)	2.3 (1.3 to 3.7)	40.5 (22.8 to 59.5)	-12.0 (-22.1 to -0.1)
Fungal skin diseases	320.4 (238.8 to 424.4)	577.4 (437.6 to 753.3)	80.3 (72.6 to 88.0)	0.0 (-0.1 to 0.0)	1.8 (0.7 to 4.0)	3.3 (1.3 to 7.2)	80.3 (72.5 to 88.3)	0.0 (-0.6 to 1.1)
Viral skin diseases	99.5 (77.3 to 119.1)	150.1 (115.5 to 183.0)	50.7 (42.2 to 58.4)	0.1 (-2.4 to 2.5)	3.1 (1.8 to 4.8)	4.7 (2.7 to 7.4)	50.6 (41.0 to 59.7)	0.3 (-3.2 to 4.2)
Acne vulgaris	264.1 (193.0 to 378.1)	476.2 (296.7 to 741.0)	82.0 (1.3 to 190.9)	8.0 (-37.3 to 71.6)	2.9 (1.2 to 5.5)	5.2 (2.1 to 11.0)	81.8 (1.5 to 194.8)	8.4 (-37.1 to 72.5)
Alopecia areata	3.9 (3.5 to 4.3)	7.0 (6.4 to 7.6)	78.0 (57.0 to 101.3)	-1.4 (-11.9 to 11.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	77.2 (51.8 to 113.0)	-0.9 (-13.5 to 16.6)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.8 (45.1 to 125.3)	-2.1 (-22.9 to 30.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.8 (44.8 to 125.5)	-2.1 (-22.9 to 30.4)
Urticaria	38.9 (24.7 to 58.8)	64.9 (37.3 to 103.1)	67.0 (-18.8 to 213.1)	-5.6 (46.2 to 74.4)	2.3 (1.2 to 4.1)	3.8 (1.8 to 6.9)	65.6 (-21.1 to 215.3)	-5.3 (-47.0 to 75.5)
Decubitus ulcer	0.4 (0.4 to 0.6)	1.1 (0.9 to 1.3)	147.8 (69.6 to 221.5)	12.7 (-29.0 to 55.3)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	141.4 (66.9 to 220.0)	11.8 (-29.1 to 56.2)
Other skin and subcutaneous diseases	212.5 (145.7 to 311.8)	412.0 (276.8 to 609.1)	93.5 (80.4 to 106.9)	-1.2 (-5.0 to 3.9)	1.2 (0.5 to 2.6)	2.4 (1.1 to 5.0)	93.4 (79.7 to 107.8)	-0.8 (-4.8 to 4.5)
Sense organ diseases	-	-	-	-	27.4 (18.9 to 38.4)	47.2 (32.4 to 66.1)	71.9 (60.1 to 82.4)	-11.9 (-14.8 to -7.6)
Glaucoma	5.8 (4.9 to 6.9)	9.5 (7.9 to 11.3)	63.7 (40.0 to 88.9)	-23.1 (-33.9 to -9.6)	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.0)	65.5 (40.0 to 90.7)	-22.6 (-34.6 to -8.4)
Cataract	19.8 (15.6 to 24.1)	33.0 (26.5 to 39.9)	66.8 (48.7 to 87.9)	-28.4 (-36.3 to -20.4)	1.3 (0.9 to 1.8)	2.3 (1.5 to 3.2)	73.3 (51.8 to 95.9)	-26.5 (-36.0 to -17.3)
Macular degeneration	7.1 (5.4 to 9.1)	16.1 (12.6 to 20.1)	128.8 (83.5 to 174.7)	5.3 (-16.5 to 28.5)	0.3 (0.2 to 0.5)	0.7 (0.5 to 1.1)	127.7 (81.2 to 170.8)	4.8 (-17.9 to 26.8)
Uncorrected refractive error	371.1 (321.4 to 424.9)	685.0 (598.4 to 772.5)	85.4 (54.3 to 121.7)	4.7 (-19.6 to 11.5)	4.7 (3.0 to 9.8)	10.4 (6.1 to 16.7)	71.2 (51.9 to 94.5)	-10.9 (-20.1 to -0.2)
Age-related and other hearing loss	456.4 (424.1 to 491.4)	844.8 (787.4 to 910.8)	84.9 (77.5 to 94.2)	-9.4 (-12.1 to -5.8)	15.0 (10.3 to 20.9)	26.8 (18.1 to 37.0)	78.4 (65.3 to 94.3)	-9.4 (-13.6 to -4.9)
Other vision loss	16.1 (14.0 to 18.3)	19.0 (16.4 to 22.0)	18.0 (8.1 to 30.4)	-35.1 (-41.3 to -28.5)	1.2 (0.8 to 1.6)	1.4 (1.0 to 2.0)	20.1 (5.4 to 36.6)	-34.5 (-41.9 to -25.6)
Other sense organ diseases	116.6 (110.1 to 123.3)	183.4 (173.8 to 192.4)	57.5 (46.3 to 68.3)	-0.1 (-6.1 to 6.1)	3.1 (1.9 to 4.6)	4.9 (3.0 to 7.2)	56.8 (44.1 to 69.6)	0.4 (-6.7 to 7.2)
Oral disorders	-	-	-	-	10.6 (6.3 to 16.6)	20.2 (12.2 to 32.4)	94.5 (87.0 to 102.0)	-3.6 (-7.6 to 0.3)
Deciduous caries	479.2 (455.8 to 503.9)	599.8 (570.3 to 628.7)	25.2 (16.9 to 33.9)	-0.1 (-6.6 to 6.8)	0.1 (0.1 to 0.4)	0.2 (0.1 to 0.5)	25.2 (14.2 to 38.6)	-0.2 (-8.9 to 10.6)
Permanent caries	1,874.0 (1,775.6 to 1,968.8)	3,325.0 (3,162.1 to 3,479.1)	77.4 (65.4 to 90.2)	0.8 (-4				

Appendix Table G.4 - Honduras prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	149.5 (142.9 to 155.7)	297.6 (283.8 to 310.3)	99.2 (86.9 to 111.1)	-4.4 (-14.0 to -2.8)	4.1 (2.7 to 5.6)	8.2 (5.5 to 11.2)	99.5 (86.8 to 111.4)	-7.9 (-13.6 to -2.4)
Other oral disorders	70.3 (66.1 to 74.5)	129.2 (121.5 to 137.0)	83.8 (68.4 to 101.5)	-0.7 (-7.8 to 8.0)	2.1 (1.3 to 3.1)	3.8 (2.4 to 5.6)	83.5 (67.3 to 102.5)	-0.5 (-8.1 to 8.6)
Injuries	-	-	-	-	28.7 (19.9 to 42.6)	32.7 (21.9 to 48.3)	14.0 (-3.2 to 32.6)	-42.4 (-53.5 to -31.8)
Transport injuries	-	-	-	-	4.6 (3.5 to 5.9)	6.3 (4.5 to 8.4)	34.7 (19.6 to 53.8)	-29.9 (-37.1 to -20.9)
Road injuries	-	-	-	-	3.9 (3.0 to 5.1)	5.3 (3.8 to 7.3)	35.4 (19.4 to 55.5)	-29.2 (-37.0 to -19.8)
Pedestrian road injuries	-	-	-	-	1.3 (1.0 to 1.7)	1.8 (1.3 to 2.4)	33.2 (16.5 to 54.0)	-28.9 (-37.0 to -19.3)
Cyclist road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	53.3 (35.8 to 70.4)	-20.8 (-29.3 to -11.5)
Motorcyclist road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	21.0 (3.5 to 40.9)	-37.0 (-45.5 to -27.3)
Motor vehicle road injuries	-	-	-	-	1.9 (1.4 to 2.4)	2.7 (1.9 to 3.6)	48.9 (23.4 to 66.9)	-25.1 (-34.9 to -13.9)
Other road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-26.5 (-35.5 to -16.1)	-63.1 (-67.4 to -58.3)
Other transport injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.9 (0.7 to 1.2)	30.1 (15.2 to 46.9)	-33.6 (-40.9 to -25.3)
Unintentional injuries	-	-	-	-	10.0 (7.6 to 12.9)	11.2 (8.3 to 14.8)	12.2 (3.9 to 21.2)	40.4 (-4.0 to -35.8)
Falls	-	-	-	-	3.0 (2.2 to 3.8)	4.3 (3.1 to 5.7)	44.3 (28.3 to 61.5)	-31.2 (-39.0 to -22.5)
Drowning	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-1.4 (-14.5 to 14.7)	-47.5 (-54.0 to -39.9)
Fire, heat, and hot substances	-	-	-	-	0.5 (0.3 to 0.6)	0.4 (0.3 to 0.6)	-4.8 (-17.4 to 8.6)	-48.1 (-53.9 to -41.6)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.1 (-30.5 to -0.1)	-54.1 (-60.7 to -46.7)
Exposure to mechanical forces	-	-	-	-	5.8 (4.4 to 7.6)	5.5 (4.0 to 7.4)	-5.1 (-11.9 to 2.0)	-48.8 (-52.1 to -45.2)
Unintentional firearm injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-5.6 (-16.1 to 10.9)	-50.2 (-56.3 to -43.3)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	72.8 (51.0 to 99.0)	-3.1 (-14.1 to 10.1)
Other exposure to mechanical forces	-	-	-	-	5.5 (4.2 to 7.2)	5.2 (3.8 to 6.9)	-6.2 (-12.8 to 1.0)	-49.4 (-52.6 to -45.7)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	79.9 (65.1 to 95.3)	-6.5 (-13.2 to 0.3)
Animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	42.4 (25.7 to 59.7)	-21.6 (-29.6 to -13.8)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	36.4 (11.0 to 63.3)	-24.7 (-36.3 to -12.4)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	46.9 (28.1 to 65.4)	-19.7 (-28.5 to -11.8)
Foreign body	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.3)	19.8 (6.4 to 34.8)	-33.1 (-39.7 to -26.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-14.3 (-27.5 to 2.4)	-50.8 (-57.9 to -42.6)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	60.4 (42.8 to 78.3)	-8.4 (-17.4 to 1.1)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	61.0 (42.9 to 82.1)	-13.9 (-21.9 to -4.1)
Other unintentional injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	55.1 (39.3 to 78.4)	-22.9 (-30.9 to -12.5)
Self-harm and interpersonal violence	-	-	-	-	2.9 (2.1 to 3.6)	4.0 (2.9 to 5.4)	41.3 (25.2 to 59.7)	-32.0 (-39.5 to -23.7)
Self-harm	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	63.3 (46.3 to 82.3)	-23.3 (-31.1 to -14.9)
Interpersonal violence	-	-	-	-	2.7 (2.1 to 3.4)	3.8 (2.7 to 5.1)	40.5 (24.1 to 59.1)	-32.4 (-39.9 to -24.0)
Assault by firearm	-	-	-	-	0.8 (0.6 to 1.1)	1.6 (1.2 to 2.2)	91.6 (74.5 to 113.4)	-8.7 (-16.6 to 0.9)
Assault by sharp object	-	-	-	-	0.6 (0.4 to 0.7)	0.8 (0.6 to 1.1)	48.2 (29.4 to 72.2)	-30.3 (-38.8 to -19.1)
Assault by other means	-	-	-	-	1.3 (1.0 to 1.7)	1.4 (1.0 to 1.8)	4.1 (9.9 to 20.6)	-49.4 (-55.7 to -41.6)
Forces of nature, war, and legal intervention	-	-	-	-	11.3 (5.0 to 23.7)	11.3 (4.5 to 24.2)	0.5 (-32.9 to 36.6)	-51.1 (-68.7 to -30.9)
Exposure to forces of nature	-	-	-	-	11.3 (5.0 to 23.7)	11.2 (4.5 to 24.1)	-0.3 (-33.3 to 35.9)	-51.5 (-68.8 to -31.3)
Collective violence and legal intervention	-	-	-	-	-	0.1 (0.0 to 0.1)	-	-

Appendix Table G.4 - Hungary prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,283.8 (963.1 to 1,653.6)	1,314.9 (983.3 to 1,697.9)	2.4 (-0.2 to 4.9)	2.4 (-6.4 to 1.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	-	-	-	-
HIV/AIDS and tuberculosis	-	-	-	-	73.5 (51.4 to 101.4)	62.3 (43.6 to 87.0)	-15.2 (-22.5 to -7.1)	-2.0 (-10.2 to 6.7)
Tuberculosis	4.4 (4.2 to 4.6)	4.3 (4.0 to 4.5)	-2.2 (-6.9 to 2.4)	-11.8 (-15.7 to -7.7)	1.3 (0.9 to 1.8)	1.3 (0.9 to 1.7)	-2.7 (-14.3 to 10.5)	-11.6 (-22.9 to 0.9)
HIV/AIDS	-	-	-	-	0.5 (0.3 to 0.8)	0.2 (0.1 to 0.3)	-68.5 (-79.3 to -50.0)	-70.4 (-80.8 to -52.7)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-79.6 (-87.1 to -69.2)	-80.8 (-87.8 to -70.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-79.6 (-87.1 to -69.1)	-80.8 (-87.8 to -70.8)
HIV/AIDS resulting in other diseases	2.4 (1.7 to 3.2)	1.4 (1.0 to 2.0)	-38.6 (-57.6 to -16.7)	-44.2 (-61.9 to -23.4)	0.5 (0.3 to 0.8)	0.2 (0.1 to 0.3)	-68.4 (-79.2 to -49.5)	-70.3 (-80.6 to -52.4)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	-	-	-	-
Diarrheal diseases	23.1 (21.3 to 24.9)	18.1 (16.8 to 19.3)	-21.6 (-29.5 to -13.0)	-17.0 (-25.7 to -7.5)	8.1 (5.6 to 11.1)	6.4 (4.4 to 8.9)	-20.7 (-25.7 to -15.2)	-14.9 (-20.8 to -8.6)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Typhoid fever	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-26.2 (-55.1 to 14.0)	-20.2 (-47.7 to 16.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.2 (-55.2 to 14.3)	-20.2 (-47.7 to 16.5)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Lower respiratory infections	2.0 (1.7 to 2.4)	1.6 (1.3 to 1.9)	-20.9 (-35.8 to 4.4)	-16.0 (-34.7 to 18.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-21.6 (-39.4 to 9.2)	-15.6 (-36.9 to 25.7)
Upper respiratory infections	100.7 (95.9 to 106.3)	92.3 (87.8 to 96.0)	-7.8 (-16.4 to -1.6)	-1.5 (-10.2 to 4.7)	1.2 (0.7 to 2.0)	1.1 (0.6 to 1.8)	-8.0 (-17.0 to -0.3)	-1.4 (-10.9 to 6.3)
Otitis media	108.0 (101.4 to 115.9)	91.5 (85.8 to 96.8)	-15.1 (-21.2 to -8.3)	-6.7 (-13.6 to -0.0)	2.2 (1.3 to 3.4)	1.8 (1.1 to 2.9)	-17.1 (-23.7 to -9.4)	-8.4 (-15.6 to 0.2)
Meningitis	-	-	-	-	0.5 (0.3 to 0.7)	0.2 (0.1 to 0.3)	-57.5 (-66.8 to -47.3)	-57.3 (-67.2 to -45.6)
Pneumococcal meningitis	2.2 (1.3 to 3.6)	1.0 (0.6 to 1.7)	-54.8 (-65.6 to -40.5)	-57.2 (-67.7 to -43.8)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.1)	-53.6 (-65.7 to -39.6)	-54.0 (-67.0 to -39.5)
H influenzae type B meningitis	0.9 (0.3 to 2.0)	0.3 (0.1 to 0.7)	-66.5 (-81.5 to -48.0)	-65.5 (-80.4 to -42.6)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-67.3 (-83.8 to -35.6)	-64.7 (-82.8 to -27.4)
Meningococcal meningitis	0.6 (0.2 to 1.5)	0.2 (0.1 to 0.5)	-64.6 (-77.8 to -43.0)	-65.2 (-78.1 to -41.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-64.2 (-79.7 to -39.7)	-63.8 (-80.2 to -34.7)
Other meningitis	1.0 (0.4 to 2.3)	0.5 (0.2 to 1.1)	-53.4 (-66.4 to -36.2)	-55.1 (-68.0 to -34.9)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-49.3 (-68.9 to -21.4)	-50.6 (-70.1 to -18.2)
Encephalitis	1.1 (0.5 to 2.8)	0.8 (0.4 to 1.9)	-27.3 (-42.9 to -14.3)	-31.6 (-44.9 to -15.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-23.4 (-37.0 to -6.8)	-24.5 (-37.8 to -8.8)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Whooping cough	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-20.6 (-20.7 to -20.4)	2.1 (1.9 to 2.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.6 (-49.7 to 23.9)	3.3 (-35.9 to 59.9)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Varicella and herpes zoster	5.5 (5.0 to 6.0)	5.0 (4.5 to 5.6)	-9.3 (-21.0 to 5.2)	-2.0 (-11.3 to 8.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	3.0 (-20.9 to 38.4)	-2.2 (-23.0 to 26.5)
Neglected tropical diseases and malaria	-	-	-	-	-	-	-	-
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.7 (-75.3 to 86.5)	-12.5 (-72.9 to 106.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.9 (-75.4 to 86.1)	-11.9 (-72.7 to 107.6)
Chagas disease	-	-	-	-	-	-	-	-
Leishmaniasis	-	-	-	-	-	-	-	-
Visceral leishmaniasis	-	-	-	-	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	-	-	-	-	-	-
African trypanosomiasis	-	-	-	-	-	-	-	-
Schistosomiasis	-	-	-	-	-	-	-	-
Cysticercosis	0.5 (0.2 to 0.8)	0.2 (0.1 to 0.4)	-61.5 (-85.4 to 37.7)	-66.3 (-88.0 to 20.8)	0.1 (0.1 to 0.3)	0.1 (0.0 to 0.1)	-58.6 (-85.9 to 47.0)	-63.9 (-87.5 to 24.0)
Cystic echinococcosis	2.4 (2.2 to 2.7)	2.1 (2.0 to 2.2)	-13.2 (-22.3 to -0.3)	-21.3 (-31.4 to -8.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-13.6 (-30.4 to 9.3)	-21.2 (-37.8 to 0.6)
Lymphatic filariasis	-	-	-	-	-	-	-	-
Onchocerciasis	-	-	-	-	-	-	-	-
Trachoma	-	-	-	-	-	-	-	-
Dengue	-	-	-	-	-	-	-	-
Yellow fever	-	-	-	-	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.2 (-57.2 to -8.3)	-34.3 (-59.0 to -4.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.2 (-57.3 to -8.3)	-14.3 (-59.0 to -4.1)
Intestinal nematode infections	-	-	-	-	-	-	-	-
Ascariasis	-	-	-	-	-	-	-	-
Trichuriasis	-	-	-	-	-	-	-	-
Hookworm disease	-	-	-	-	-	-	-	-
Food-borne trematodiasis	-	-	-	-	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.8 (-39.4 to 64.2)	12.6 (-39.9 to 63.0)
Maternal disorders	-	-	-	-	-	-	-	-
Maternal hemorrhage	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	57.6 (16.5 to 135.4)	42.4 (1.3 to 125.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.9 (-38.6 to 208.5)	79.0 (-37.4 to 247.2)
Maternal sepsis and other maternal infections	1.6 (0.9 to 2.7)	0.7 (0.4 to 1.2)	-57.2 (-76.1 to -34.8)	-58.4 (-76.6 to -36.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.1 (-72.8 to -32.7)	-58.4 (-74.1 to -33.1)
Maternal hypertensive disorders	1.4 (0.8 to 2.2)	1.2 (0.7 to 1.8)	-15.9 (-39.6 to 17.3)	-22.9 (-42.7 to 6.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-15.7 (-43.4 to 25.6)	-22.5 (-46.8 to 13.0)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	53.7 (-13.2 to 201.1)	40.8 (-22.3 to 184.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.7 (-13.6 to 204.5)	40.8 (-22.7 to 184.8)
Other maternal disorders	-	-	-	-	-	-	-	-
Neonatal disorders	-	-	-	-	-	-	-	-
Preterm birth complications	63.4 (49.6 to 79.8)	63.4 (49.7 to 80.1)	0.3 (-13.9 to 17.9)	6.2 (-9.4 to 25.5)	7.3 (5.0 to 9.9)	8.0 (5.5 to 10.7)	9.2 (-15.0 to 38.4)	17.9 (-9.2 to 50.1)
Neonatal encephalopathy due to birth asphyxia and trauma	16.3 (8.8 to 30.2)	7.0 (3.6 to 14.8)	-58.3 (-76.7 to -21.9)	-54.9 (-75.1 to -34.1)	4.3 (2.4 to 6.7)	1.9 (1.1 to 3.2)	-55.9 (-76.5 to -2.3)	-51.6 (-74.1 to 6.3)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hemolytic disease and other neonatal jaundice	3.0 (1.0 to 9.8)	1.0 (0.4 to 2.8)	-61.3 (-92.7 to 37.7)	-61.3 (-92.3 to 47.5)	1.2 (0.4 to 3.4)	0.4 (0.2 to 1.1)	-59.7 (-92.2 to 40.5)	-56.8 (-91.8 to 49.3)
Other neonatal disorders	-	-	-	-	0.8 (0.3 to 2.0)	4.2 (1.4 to 6.8)	755.3 (-2.8 to 1,298.6)	819.3 (4.2 to 1,386.3)
Nutritional deficiencies	-	-	-	-	-	-	-	-
Protein-energy malnutrition	8.5 (6.0 to 11.7)	5.4 (3.8 to 7.6)	-35.1 (-59.5 to -0.3)	-17.0 (-48.4 to 26.9)	1.1 (0.6 to 1.7)	0.7 (0.4 to 1.1)	-35.1 (-60.0 to 2.1)	-16.7 (-48.7 to 30.8)
Iodine deficiency	136.6 (67.7 to 228.6)	117.2 (76.6 to 169.4)	-12.6 (-53.4 to 75.8)	-11.6 (-52.2 to 75.9)	2.4 (1.0 to 4.7)	2.1 (1.1 to 3.6)	-11.9 (-53.2 to 73.7)	-10.5 (-52.0 to 78.0)
Vitamin A deficiency	-	-	-	-	-	-	-	-
Iron deficiency anemia	1,517.5 (1,494.2 to 1,537.9)	1,367.8 (1,344.5 to 1,389.6)	-9.6 (-11.6 to -7.4)	0.9 (-1.2 to 3.3)	40.2 (26.5 to 58.3)	32.7 (21.6 to 47.3)	-18.6 (-21.8 to -15.6)	0.6 (-2.6 to 4.1)

Appendix Table G.4 - Hungary prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	2.1 (0.9 to 3.9)	0.8 (0.4 to 2.1)	-64.4 (-83.5 to 26.4)	-57.0 (-79.0 to 62.3)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	4.0 (2.4 to 6.4)	3.3 (2.0 to 5.5)	-16.3 (-26.2 to -3.9)	-2.8 (-18.3 to 14.1)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.7 (0.8 to 3.2)	1.6 (0.8 to 3.1)	-3.7 (-14.8 to 8.6)	-3.4 (-15.3 to 11.0)
Syphilis	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.3)	10.5 (6.7 to 31.9)	-7.6 (-22.8 to 12.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-8.9 (-22.1 to 52.6)	-7.6 (-32.9 to 27.6)
Chlamydial infection	222.6 (205.9 to 257.9)	220.4 (193.5 to 242.9)	-4.8 (-19.7 to 11.0)	0.3 (-15.8 to 16.9)	4.8 (0.4 to 1.1)	0.6 (0.3 to 1.1)	-2.2 (-19.7 to 17.6)	0.3 (-16.5 to 23.5)
Gonococcal infection	54.0 (42.9 to 65.1)	44.7 (36.1 to 54.3)	-17.8 (-35.4 to 11.5)	-1.1 (-30.7 to 21.7)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-16.2 (-40.9 to 29.4)	-9.5 (-36.3 to 39.3)
Trichomoniasis	123.7 (90.0 to 179.1)	120.8 (90.1 to 165.6)	-4.6 (-35.3 to 55.7)	-5.7 (-38.5 to 70.4)	0.2 (0.1 to 0.5)	0.2 (0.1 to 0.5)	-7.0 (-40.6 to 67.6)	-8.7 (-44.9 to 84.0)
Genital herpes	1,952.1 (1,775.6 to 2,137.4)	1,952.5 (1,772.2 to 2,123.9)	0.4 (-11.7 to 14.0)	-7.2 (-18.6 to 5.9)	0.5 (0.2 to 1.2)	0.5 (0.2 to 1.3)	-0.5 (-13.1 to 13.6)	-7.0 (-19.0 to 7.0)
Other sexually transmitted diseases	1.6 (1.2 to 2.1)	1.4 (1.0 to 1.8)	-12.7 (-33.4 to 8.6)	-12.5 (-33.2 to 9.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-39.1 to 57.9)	0.0 (-39.2 to 59.8)
Hepatitis	-	-	-	-	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.5)	-19.1 (-33.8 to -8.1)	-11.1 (-31.2 to -6.9)
Hepatitis A	9.2 (9.0 to 9.4)	6.9 (6.6 to 7.2)	-24.5 (-26.0 to -23.2)	-18.8 (-20.8 to -16.7)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-17.9 (-26.5 to -8.5)	-14.0 (-23.6 to -4.2)
Hepatitis B	273.3 (229.1 to 318.0)	185.2 (150.7 to 218.7)	-32.1 (-50.0 to -10.5)	-32.0 (-50.3 to -11.0)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-25.9 (-55.5 to 9.4)	-27.6 (-55.5 to 6.5)
Hepatitis C	205.6 (187.0 to 225.4)	152.9 (137.7 to 168.6)	-25.2 (-35.8 to -15.1)	-30.7 (-40.2 to -21.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.9 (-51.6 to 12.7)	-28.0 (-51.3 to -0.1)
Hepatitis E	-	-	-	-	0.6 (-12.2 to 13.3)	-	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	60.4 (50.7 to 69.1)	49.6 (43.5 to 55.5)	-17.5 (-29.8 to -1.9)	1.0 (-17.8 to 22.9)	1.8 (1.1 to 2.7)	1.4 (0.8 to 2.0)	-26.2 (-44.9 to -0.4)	0.9 (-28.7 to 38.1)
Non-communicable diseases	-	-	-	-	1,049.7 (781.3 to 1,355.6)	1,130.5 (839.7 to 1,455.7)	7.7 (-19.8 to 10.6)	0.6 (-2.4 to 3.2)
Neoplasms	-	-	-	-	20.7 (15.2 to 26.5)	24.8 (18.5 to 31.8)	18.8 (13.0 to 28.1)	0.4 (-5.6 to 7.4)
Esophageal cancer	1.2 (1.0 to 1.5)	1.5 (1.2 to 1.9)	18.0 (-11.5 to 54.0)	0.5 (-24.7 to 31.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	15.5 (-14.8 to 51.6)	-2.2 (-27.8 to 28.5)
Stomach cancer	7.8 (6.7 to 9.2)	5.7 (4.8 to 6.6)	-27.7 (-38.5 to -13.8)	-27.7 (-49.6 to -29.4)	0.9 (0.7 to 1.2)	0.6 (0.5 to 0.9)	-32.0 (-43.8 to -18.0)	-44.3 (-54.0 to -33.0)
Liver cancer	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	9.9 (-19.6 to 37.5)	-8.1 (-33.2 to 13.5)
Liver cancer due to hepatitis B	0.3 (0.2 to 0.4)	0.3 (0.1 to 0.4)	-8.7 (-63.4 to 78.0)	-20.3 (-67.7 to 54.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-16.9 (-65.3 to 46.4)	-26.4 (-70.1 to 25.3)
Liver cancer due to hepatitis C	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	129.0 (29.1 to 304.5)	90.7 (8.1 to 242.9)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	98.2 (26.8 to 220.0)	65.4 (5.9 to 168.7)
Liver cancer due to alcohol use	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.7)	5.8 (-40.5 to 64.9)	-12.9 (-50.9 to 36.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-2.7 (-43.4 to 38.0)	-20.0 (-53.5 to 12.8)
Liver cancer due to other causes	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-40.8 (-69.7 to 8.5)	-48.8 (-73.8 to -7.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-45.9 (-69.0 to -6.8)	-53.6 (-73.1 to -22.6)
Larynx cancer	4.0 (2.7 to 5.2)	3.7 (2.3 to 6.0)	-7.3 (-44.5 to 59.0)	-17.8 (-50.9 to 37.2)	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.6)	-16.9 (-39.6 to 22.3)	26.4 (-46.3 to 7.4)
Tracheal, bronchus and lung cancer	12.1 (10.8 to 13.8)	15.2 (13.5 to 18.3)	37.1 (3.2 to 58.8)	16.0 (-12.6 to 34.3)	1.9 (1.4 to 2.5)	2.3 (1.7 to 3.0)	26.4 (-1.6 to 45.9)	7.0 (-16.8 to 23.3)
Breast cancer	35.2 (29.7 to 41.5)	60.2 (54.5 to 66.1)	72.6 (43.9 to 105.3)	42.3 (19.2 to 69.0)	2.7 (1.9 to 3.7)	3.5 (2.4 to 4.7)	27.3 (6.2 to 51.7)	6.3 (-11.1 to 26.5)
Cervical cancer	9.6 (7.0 to 11.4)	5.3 (4.0 to 6.4)	-44.3 (-55.3 to -31.8)	-49.1 (-59.2 to -37.5)	0.7 (0.5 to 1.0)	0.4 (0.3 to 0.6)	-44.5 (-56.7 to -29.0)	-49.3 (-60.9 to -32.2)
Uterine cancer	9.9 (6.7 to 12.2)	5.6 (4.3 to 7.4)	-44.1 (-59.1 to -7.7)	-52.4 (-65.0 to -39.0)	0.7 (0.4 to 1.0)	0.4 (0.2 to 0.6)	-45.9 (-60.5 to -9.9)	-53.5 (-66.1 to -22.4)
Prostate cancer	17.0 (12.4 to 21.8)	28.9 (23.9 to 36.8)	67.8 (22.3 to 144.2)	36.1 (-0.2 to 96.4)	1.8 (1.0 to 2.6)	2.6 (1.8 to 3.7)	38.7 (-0.2 to 124.6)	11.2 (-19.1 to 80.4)
Colon and rectum cancer	40.8 (38.0 to 43.7)	56.4 (51.7 to 61.0)	38.7 (24.5 to 53.5)	14.8 (3.3 to 26.4)	3.6 (2.6 to 4.7)	4.6 (3.4 to 6.0)	28.7 (14.5 to 43.2)	5.9 (-5.7 to 17.7)
Lip and oral cavity cancer	7.3 (5.8 to 9.3)	8.3 (6.2 to 10.6)	14.6 (-22.8 to 60.3)	-0.2 (-32.4 to 40.9)	0.7 (0.5 to 1.0)	0.8 (0.5 to 1.1)	9.4 (-23.5 to 48.7)	-4.2 (-34.4 to 30.1)
Nasopharynx cancer	0.5 (0.3 to 0.9)	0.6 (0.3 to 0.8)	24.1 (-51.5 to 95.6)	12.0 (-56.9 to 76.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	22.6 (-51.5 to 79.3)	9.3 (-55.8 to 62.4)
Other pharynx cancer	2.7 (1.8 to 4.0)	3.7 (2.2 to 5.3)	37.9 (-31.8 to 141.9)	37.9 (-37.5 to 116.0)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	25.9 (-32.2 to 111.0)	21.3 (-37.6 to 92.9)
Gallbladder and biliary tract cancer	1.2 (0.9 to 1.5)	0.9 (0.7 to 1.2)	-21.2 (-39.9 to 8.0)	-37.6 (-52.2 to -14.9)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-23.6 (-44.1 to 5.1)	-38.8 (-54.9 to -16.5)
Pancreatic cancer	1.5 (1.3 to 1.8)	2.1 (1.8 to 2.4)	36.6 (13.9 to 64.3)	11.4 (-7.2 to 33.7)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	30.2 (7.0 to 59.7)	7.4 (-11.2 to 30.9)
Malignant skin melanoma	6.4 (4.7 to 9.6)	10.5 (6.9 to 14.2)	68.2 (22.2 to 113.0)	47.7 (-6.2 to 87.1)	0.4 (0.3 to 0.7)	0.7 (0.4 to 1.0)	59.6 (16.3 to 104.8)	39.3 (0.4 to 78.5)
Non-melanoma skin cancer	25.4 (22.8 to 30.3)	30.2 (27.2 to 33.7)	14.9 (-3.9 to 37.4)	-8.0 (-22.3 to 9.2)	0.5 (0.3 to 0.7)	0.7 (0.5 to 1.1)	52.0 (15.0 to 113.9)	37.9 (-9.5 to 61.1)
Ovarian cancer	3.8 (3.1 to 4.4)	3.5 (3.0 to 4.1)	-7.8 (-24.3 to 15.9)	-19.5 (-33.3 to 1.3)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.6)	-10.8 (-30.6 to 20.2)	-22.1 (-39.1 to 3.9)
Testicular cancer	2.7 (1.9 to 4.1)	2.2 (1.2 to 3.3)	-19.3 (-57.6 to 38.3)	-24.2 (-60.0 to 31.8)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-21.3 (-58.4 to 31.9)	-26.0 (-60.6 to 27.1)
Kidney cancer	8.1 (7.0 to 9.4)	12.2 (10.4 to 14.2)	52.6 (24.5 to 81.4)	30.2 (-5.7 to 54.8)	0.6 (0.4 to 0.8)	0.9 (0.6 to 1.2)	43.7 (15.8 to 73.5)	23.0 (-0.4 to 47.5)
Bladder cancer	1.9 (8.2 to 11.7)	1.2 (10.0 to 15.6)	-39.2 (-1.7 to 77.1)	39.2 (-19.4 to 45.1)	0.8 (0.5 to 1.1)	1.0 (0.7 to 1.4)	30.5 (-7.7 to 67.3)	7.1 (-24.9 to 37.4)
Brain and nervous system cancer	3.3 (2.8 to 3.9)	3.8 (3.2 to 4.6)	12.9 (-5.1 to 35.1)	2.1 (-15.6 to 25.5)	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.5)	11.2 (-7.9 to 36.1)	1.5 (-16.0 to 22.5)
Thyroid cancer	3.2 (2.5 to 4.0)	3.7 (2.9 to 4.6)	13.5 (-12.0 to 48.0)	3.0 (-20.3 to 33.6)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	7.6 (-17.9 to 44.4)	-3.3 (-27.1 to 29.7)
Mesothelioma	0.3 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-65.8 (-72.2 to 22.8)	-70.8 (-76.2 to 3.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-65.0 (-71.4 to 23.1)	-70.2 (-75.6 to 4.0)
Hodgkin lymphoma	1.9 (1.1 to 2.4)	1.2 (0.9 to 1.8)	-39.7 (-56.7 to 14.0)	-49.9 (-58.0 to 4.8)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-45.5 (-60.1 to 4.0)	-47.2 (-61.9 to -1.7)
Non-Hodgkin lymphoma	5.5 (4.2 to 8.7)	8.4 (5.6 to 10.7)	60.2 (-22.6 to 110.6)	38.2 (-32.4 to 79.7)	0.4 (0.3 to 0.7)	0.6 (0.4 to 0.9)	49.5 (-27.4 to 100.5)	28.8 (-36.5 to 70.3)
Multiple myeloma	0.9 (0.6 to 1.4)	1.3 (0.9 to 2.0)	52.8 (-14.4 to 153.9)	30.1 (-26.8 to 117.3)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	44.4 (-16.3 to 148.6)	22.4 (-28.6 to 104.6)
Leukemia	5.4 (4.7 to 6.2)	6.6 (5.7 to 7.5)	23.8 (-1.0 to 49.7)	2.4 (-19.1 to 23.5)	0.7 (0.5 to 1.0)	0.9 (0.6 to 1.2)	17.9 (-6.0 to 46.1)	-1.8 (-22.6 to 19.6)
Other neoplasms	9.5 (8.0 to 11.1)	19.7 (16.2 to 24.3)	106.6 (69.7 to 163.9)	76.1 (46.7 to 125.1)	0.7 (0.5 to 1.0)	1.3 (0.9 to 1.9)	89.3 (53.8 to 139.8)	61.4 (31.9 to 109.9)
Cardiovascular diseases	-	-	-	-	24.2 (17.3 to 33.4)	33.7 (24.0 to 45.4)	40.0 (11.8 to 65.8)	13.6 (-10.4 to 34.8)
Rheumatic heart disease	1.7 (1.4 to 2.0)	2.0 (1.6 to 2.4)	17.7 (-11.0 to 50.5)	1.6 (-21.8 to 28.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	16.7 (-15.7 to 60.5)	0.7 (-26.6 to 38.9)
Ischemic heart disease	145.1 (124.0 to 178.9)	176.9 (152.0 to 199.5)	23.2 (-1.4 to 49.5)	-0.8 (-20.2 to 20.4)	9.1 (6.1 to 13.5)	11.0 (7.6 to 15.3)	22.9 (-4.6 to 51.1)	-3.1 (-24.5 to 18.7)
Cerebrovascular disease	-	-	-	-	3.4 (2.3 to 4.5)	4.0 (2.7 to 5.4)	17.2 (-7.7 to 47.0)	1.1 (-20.8 to 25.4)
Ischemic stroke	18.8 (15.8 to 21.7)	21.9 (18.3 to 25.9)	16.1 (-7.2 to 46.9)	-1.2 (-20.9 to 24.3)	2.8 (1.8 to 3.8)	3.2 (2.2 to 4.5)	15.9 (-9.5 to 49.0)	-0.8 (-23.3 to 26.2)
Hemorrhagic stroke	3.9 (3.2 to 4.6)	4.7 (3.7 to 5.8)	22.9 (-9.2 to 60.1)	7.6 (-19.4 to 39.9)	0.6 (0.4 to 0.8)	0.7 (0.5 to 1.0)	21.6 (-14.4 to 65.1)	8.0 (-22.3 to 44.3)
Hypertensive heart disease	25.3 (22.4 to 28.1)	37.1 (33.3 to 41.1)	46.7 (25.5 to 75.2)	14.7 (-1.5 to 36.9)	2.7 (1.9 to 3.7)	4.0 (2.8 to 5.4)	47.4 (25.7 to 76.1)	16.1 (-0.5 to 38.5)
Cardiomyopathy and myocarditis	28.1 (24.5 to 32.1)	25.3 (22.6 to 28.0)	-9.7 (-32.2 to 6.1)	-26.8 (-37.4 to -14.5)	3.0 (2.1 to 4.1)	2.7 (1.9 to 3.6)	-9.7 (-31.1 to 6.6)	-26.3 (-37.2 to -13.5)
Atrial fibrillation and flutter	6.0 (5.2 to 6.9)	37.1 (28.5 to 48.3)	526.2 (362.9 to 713.1)	389.2 (266.4 to 528.8)	0.5 (0.3 to 0.6)	2.9 (1.8 to 4.3)	537.3 (363.9 to 736.2)	400.4 (268.8 to 554.1)
Peripheral vascular disease	395.2 (301.9 to 511.9)	514.9 (414.1 to 638.2)	30.5 (-9.5 to 77.5)	7.4 (-23.9 to 47.0)	0.7 (0.3 to 1.5)	0.4 (0.2 to 0.9)	-38.8 (-77.8 to 12.6)	-56.6 (-83.5 to -20.6)
Endocarditis	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	12.7 (-28.5 to 67.2)	-3.0 (-38.8 to 42.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.7 (-28.8 to 87.9)	1.0 (-39.1 to 62.8)
Other cardiovascular and circulatory diseases	67.9 (39.6 to 125.3)	121.5 (66.9 to 175.1)	90.9 (-23.6 to 257.6)	59.7 (-36.6 to 198.8)	4.7 (2.4 to 8.7)	8.5 (4.2 to 13.6)	92.7 (-24.5 to 257.2)	62.3 (-36.2 to 200.6)
Chronic respiratory diseases	-	-	-	-	51.1 (35.0 to 70.3)	54.5 (47.8 to 74.4)	6.3 (-4.3 to 27.6)	2.2 (-11.7 to 18.9)
Chronic obstructive pulmonary disease	608.6 (580.9 to 634.9)	683.1 (651.0 to 713.7)	12.5 (9.6 to 15.9)	-0.4 (-3.2 to 2.6)	37.5 (24.6 to 53.8)	38.8 (25.8 to 54.8)	3.2 (-16.8 to 29.8)	-8.0 (-24.8 to 14.4)
Pneumoconiosis	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-18.5 (-25.5 to -11.7)	-30.3 (-36.3 to -24.4)

Appendix Table G.4 - Hungarian prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	11.1 (5.3 to 16.6)	-3.3 (-10.0 to -0.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.1 (6.1 to 17.7)	-4.6 (-9.5 to 0.1)
Asbestosis	-	-	-	-	-	-	-	-
Coal workers pneumoconiosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	10.2 (4.2 to 15.3)	-4.4 (-9.4 to 0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.5 (5.1 to 16.8)	-3.4 (-8.6 to 1.1)
Other pneumoconiosis	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-44.4 (-52.8 to -38.3)	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.5 (-52.0 to -37.0)	-51.4 (-58.8 to -46.2)
Asthma	299.8 (264.5 to 339.6)	345.4 (304.6 to 378.9)	14.8 (4.0 to 26.2)	25.9 (5.3 to 46.3)	13.0 (8.4 to 18.7)	15.0 (9.7 to 21.6)	14.9 (4.3 to 25.1)	11.1 (5.9 to 50.4)
Interstitial lung disease and pulmonary sarcoidosis	1.4 (1.0 to 1.8)	1.6 (1.1 to 2.0)	11.6 (23.4 to 68.4)	1.6 (30.9 to 54.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	12.5 (22.8 to 67.4)	2.5 (-29.7 to 5.0)
Other chronic respiratory diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	36.5 (1.8 to 90.7)	21.2 (-12.1 to 68.8)
Cirrhosis	-	-	-	-	2.4 (1.7 to 3.3)	1.9 (1.3 to 2.6)	-21.5 (-28.7 to -14.6)	-27.8 (-33.9 to -21.2)
Cirrhosis due to hepatitis B	3.1 (1.9 to 4.2)	3.6 (2.7 to 4.5)	14.7 (-21.9 to 92.7)	3.3 (30.6 to 76.7)	0.6 (0.3 to 0.8)	0.6 (0.4 to 0.9)	15.3 (-23.1 to 95.4)	3.8 (-34.0 to 81.4)
Cirrhosis due to hepatitis C	4.0 (2.8 to 5.3)	2.8 (1.9 to 4.0)	-27.3 (-59.6 to 14.5)	-34.2 (-62.3 to 6.0)	0.6 (0.4 to 1.0)	0.5 (0.3 to 0.8)	-28.2 (-60.2 to 17.6)	-34.2 (-62.6 to 8.2)
Cirrhosis due to alcohol use	4.7 (3.3 to 6.5)	2.4 (1.5 to 3.2)	-50.2 (-69.2 to -17.6)	-56.3 (-72.8 to -28.3)	0.8 (0.5 to 1.2)	0.4 (0.2 to 0.6)	-50.1 (-70.7 to -15.5)	-56.0 (-74.0 to -26.0)
Cirrhosis due to other causes	2.8 (2.0 to 3.5)	2.7 (1.9 to 3.6)	-0.4 (-33.9 to 44.4)	-0.5 (-34.9 to 31.4)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.7)	-5.0 (-37.3 to 43.8)	-8.7 (-38.2 to 32.4)
Digestive diseases	-	-	-	-	16.5 (11.9 to 21.7)	17.3 (12.5 to 23.0)	4.7 (-1.5 to 12.2)	-7.1 (-13.9 to -0.1)
Peptic ulcer disease	142.1 (133.7 to 150.2)	86.7 (76.1 to 95.5)	-38.7 (-46.7 to -31.5)	-53.3 (-59.3 to -47.5)	4.7 (3.2 to 6.6)	3.3 (2.3 to 4.6)	-30.0 (-36.5 to -21.0)	-45.8 (-50.8 to -38.3)
Gastritis and duodenitis	14.8 (13.4 to 16.2)	22.1 (20.1 to 24.1)	50.0 (30.8 to 70.7)	26.3 (8.5 to 43.6)	0.8 (0.5 to 1.1)	1.1 (0.7 to 1.5)	43.1 (12.4 to 64.6)	22.7 (5.8 to 45.6)
Appendicitis	0.5 (0.4 to 0.7)	0.3 (0.2 to 0.3)	-45.0 (-58.5 to -24.7)	-35.4 (-53.9 to -10.3)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.1)	-43.7 (-62.0 to -14.3)	-35.5 (-59.2 to 3.9)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	43.7 (8.9 to 81.8)	43.6 (0.4 to 101.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	43.2 (-3.3 to 100.8)	45.3 (-7.4 to 117.2)
Inguinal, femoral, and abdominal hernia	28.4 (24.0 to 33.1)	28.5 (23.9 to 34.1)	0.6 (-21.1 to 27.5)	0.6 (-32.6 to 5.0)	0.3 (0.1 to 0.5)	0.3 (0.1 to 0.6)	0.0 (-20.2 to 29.4)	0.0 (-31.4 to 7.9)
Inflammatory bowel disease	18.8 (17.9 to 19.6)	27.5 (26.4 to 28.6)	47.1 (38.2 to 55.8)	35.1 (27.4 to 42.8)	3.9 (2.7 to 5.3)	5.7 (3.9 to 7.8)	46.9 (36.0 to 58.6)	35.6 (25.3 to 46.6)
Vascular intestinal disorders	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	13.7 (-13.2 to 51.6)	-9.1 (-29.7 to 18.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.3 (-14.0 to 69.7)	-4.8 (-31.3 to 34.1)
Gallbladder and biliary diseases	42.3 (37.4 to 47.4)	33.2 (29.0 to 37.8)	-21.4 (-33.1 to -6.6)	-31.6 (-41.4 to -18.9)	4.4 (3.0 to 6.1)	3.5 (2.3 to 4.7)	-21.3 (-33.5 to -6.1)	-31.1 (-41.4 to -17.8)
Pancreatitis	4.6 (4.3 to 4.8)	5.2 (5.0 to 5.5)	15.6 (6.5 to 24.8)	5.3 (-2.5 to 13.9)	1.3 (0.9 to 1.8)	1.5 (1.0 to 2.1)	6.5 (1.0 to 12.1)	6.5 (1.4 to 21.7)
Other digestive diseases	-	-	-	-	0.9 (0.7 to 1.3)	1.7 (1.1 to 2.4)	87.2 (29.1 to 115.8)	65.5 (12.5 to 91.4)
Neurological disorders	-	-	-	-	112.3 (76.9 to 150.2)	126.3 (86.0 to 171.5)	12.4 (-2.1 to 28.5)	6.1 (-8.1 to 21.7)
Alzheimer disease and other dementias	122.8 (106.4 to 138.3)	166.3 (145.6 to 187.5)	35.6 (13.3 to 62.7)	-2.4 (-18.4 to 17.6)	17.4 (12.7 to 22.7)	24.3 (17.4 to 32.2)	39.9 (17.2 to 69.4)	-1.1 (-17.0 to 19.8)
Parkinson disease	8.7 (6.0 to 11.5)	10.7 (7.3 to 14.1)	23.5 (14.4 to 31.9)	23.5 (-9.2 to 48.8)	1.0 (0.6 to 1.5)	1.2 (0.7 to 1.8)	28.4 (8.4 to 40.5)	40.7 (-13.7 to 12.6)
Epilepsy	46.9 (30.3 to 64.7)	41.7 (27.2 to 59.7)	-10.6 (-49.3 to 64.0)	-9.9 (-47.8 to 71.0)	14.8 (8.1 to 23.3)	-9.9 (7.3 to 22.4)	13.5 (-52.3 to 68.1)	4.7 (-49.5 to 78.1)
Multiple sclerosis	7.0 (6.6 to 7.4)	13.5 (12.6 to 14.4)	95.1 (77.1 to 112.8)	85.4 (67.8 to 102.4)	2.3 (1.6 to 2.9)	4.4 (3.2 to 5.7)	95.6 (69.4 to 122.2)	85.9 (61.9 to 111.3)
Migraine	1,567.7 (1,434.8 to 1,708.8)	1,533.3 (1,411.5 to 1,647.7)	-2.0 (-13.0 to 10.2)	-0.7 (-11.3 to 11.3)	52.9 (32.1 to 77.8)	51.8 (31.0 to 75.8)	-2.1 (-13.6 to 10.3)	-0.3 (-11.6 to 11.5)
Tension-type headache	2,049.9 (1,878.3 to 2,247.1)	2,037.8 (1,884.9 to 2,205.8)	-0.5 (-11.4 to 11.9)	-0.5 (-10.5 to 13.4)	3.1 (1.5 to 5.4)	3.1 (1.5 to 5.4)	0.0 (-11.7 to 12.1)	0.0 (-10.8 to 14.4)
Medication overuse headache	112.6 (76.2 to 156.1)	164.6 (102.1 to 242.0)	45.3 (3.4 to 112.1)	39.1 (1.1 to 98.9)	17.5 (9.8 to 27.8)	25.6 (13.5 to 41.3)	45.0 (3.4 to 110.5)	40.2 (1.1 to 99.5)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.7 (-17.5 to 50.1)	6.2 (-21.1 to 38.2)	3.4 (2.3 to 4.9)	2.3 (1.6 to 3.1)	-32.4 (-54.4 to -6.5)	-48.7 (-65.4 to -29.1)
Mental and substance use disorders	-	-	-	-	229.2 (166.5 to 300.0)	222.9 (161.4 to 291.5)	-2.7 (-5.3 to -0.4)	-2.2 (-5.0 to -0.1)
Schizophrenia	35.3 (31.3 to 37.9)	36.1 (33.3 to 38.7)	2.5 (-1.2 to 6.4)	-1.1 (-4.9 to 2.7)	22.4 (16.5 to 27.1)	23.1 (17.1 to 28.0)	2.9 (-4.4 to 9.1)	-0.6 (-5.9 to 5.9)
Alcohol use disorders	139.2 (127.8 to 151.9)	94.9 (85.0 to 105.2)	-31.6 (-36.6 to -26.0)	-34.1 (-39.2 to -28.7)	13.8 (9.2 to 19.5)	9.4 (6.3 to 13.5)	-31.6 (-37.4 to -25.6)	-34.0 (-40.0 to -28.3)
Drug use disorders	-	-	-	-	10.6 (6.7 to 15.2)	10.2 (6.5 to 14.9)	-3.5 (-19.7 to 11.8)	-2.7 (-19.7 to 13.2)
Opioid use disorders	10.4 (4.8 to 17.8)	10.7 (5.3 to 18.6)	3.2 (-11.7 to 22.8)	1.6 (-13.1 to 19.3)	4.3 (1.8 to 7.7)	4.5 (2.1 to 8.3)	3.9 (-13.8 to 26.9)	2.3 (-15.3 to 24.5)
Cocaine use disorders	6.4 (4.9 to 7.5)	6.0 (5.0 to 7.0)	-5.5 (-28.6 to 30.4)	-2.2 (-28.4 to 38.3)	0.9 (0.5 to 1.3)	0.8 (0.5 to 1.2)	-0.8 (-31.0 to 34.7)	-2.0 (-30.6 to 42.5)
Amphetamine use disorders	15.9 (13.1 to 18.9)	14.2 (12.3 to 16.0)	-10.3 (-28.7 to 14.5)	-9.3 (-28.3 to 16.4)	1.9 (1.3 to 3.1)	1.9 (1.2 to 2.8)	0.0 (-30.5 to 35.6)	0.0 (-30.0 to 18.9)
Cannabis use disorders	13.9 (12.1 to 15.5)	12.6 (11.1 to 14.1)	-8.6 (-15.3 to -1.7)	1.1 (-6.0 to 9.0)	0.4 (0.3 to 0.6)	0.4 (0.2 to 0.5)	-9.0 (-24.3 to 7.7)	0.9 (-16.3 to 19.8)
Other drug use disorders	-	-	-	-	3.0 (1.8 to 4.5)	2.7 (1.7 to 4.0)	-9.3 (-36.3 to 28.5)	-7.2 (-35.7 to 30.5)
Depressive disorders	-	-	-	-	87.0 (59.3 to 119.5)	89.5 (61.1 to 122.6)	3.0 (-2.8 to 8.3)	0.7 (-4.9 to 5.5)
Major depressive disorder	353.5 (313.3 to 397.9)	360.8 (312.8 to 412.4)	2.5 (-4.3 to 9.1)	0.5 (-6.1 to 6.2)	71.4 (47.9 to 98.5)	74.0 (48.9 to 100.8)	2.2 (-4.7 to 8.8)	0.9 (-6.1 to 6.8)
Dysthymia	163.6 (136.4 to 190.5)	173.3 (144.3 to 201.0)	6.2 (4.8 to 8.0)	-0.2 (-0.3 to -0.1)	15.6 (10.2 to 22.8)	16.5 (10.8 to 24.1)	6.2 (3.2 to 9.1)	6.2 (-2.4 to 2.5)
Bipolar disorder	76.9 (62.6 to 91.3)	80.2 (66.1 to 95.1)	4.6 (-1.8 to 11.1)	0.8 (-5.8 to 7.4)	15.4 (9.2 to 23.6)	16.1 (9.8 to 24.4)	4.5 (-2.9 to 12.8)	1.2 (-5.9 to 9.2)
Anxiety disorders	384.4 (324.8 to 442.4)	375.5 (315.5 to 431.1)	-2.0 (-4.7 to 0.4)	-0.3 (-0.3 to -0.2)	34.9 (23.5 to 49.8)	34.1 (23.0 to 48.3)	-2.3 (-5.9 to 1.0)	0.0 (-2.6 to 2.6)
Eating disorders	-	-	-	-	2.5 (1.5 to 3.6)	2.3 (1.4 to 3.4)	-0.9 (-15.6 to 11.0)	1.2 (-6.5 to 10.0)
Anorexia nervosa	1.3 (1.0 to 1.6)	1.3 (1.0 to 1.6)	1.0 (-8.4 to 11.7)	14.9 (4.8 to 26.6)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	0.0 (-21.9 to 31.9)	0.0 (-11.2 to 49.4)
Bulimia nervosa	10.4 (7.5 to 12.9)	9.4 (6.7 to 11.9)	-9.0 (-12.5 to -6.0)	-0.5 (-0.7 to -0.4)	2.2 (1.3 to 3.2)	2.0 (1.2 to 3.0)	-8.9 (-17.2 to -0.3)	-0.4 (-8.4 to 8.6)
Autistic spectrum disorders	-	-	-	-	11.8 (8.1 to 15.9)	11.1 (7.7 to 14.9)	-5.8 (-8.9 to -2.5)	0.7 (-2.6 to 4.2)
Autism	30.7 (29.1 to 32.4)	28.9 (27.3 to 30.6)	-5.5 (-6.0 to -5.0)	0.3 (0.3 to 0.3)	7.5 (5.0 to 10.3)	7.0 (4.7 to 9.6)	-5.7 (-10.1 to -1.3)	0.7 (-3.9 to 5.6)
Asperger syndrome	43.5 (40.7 to 46.3)	40.9 (38.1 to 43.8)	-5.7 (-6.3 to -5.0)	0.4 (0.4 to 0.4)	4.3 (3.0 to 6.0)	4.0 (2.8 to 5.6)	0.8 (-9.4 to -2.1)	0.8 (-3.4 to 4.5)
Attention-deficit/hyperactivity disorder	47.2 (43.4 to 50.9)	32.9 (30.2 to 35.5)	-30.1 (-30.6 to -29.8)	0.1 (0.1 to 0.1)	0.6 (0.3 to 0.9)	0.4 (0.2 to 0.6)	-29.9 (-35.3 to -24.5)	0.4 (-7.1 to 7.8)
Conduct disorder	71.8 (67.6 to 76.2)	46.9 (44.0 to 49.9)	-34.5 (-35.2 to -33.7)	0.0 (0.0 to 0.0)	8.7 (5.4 to 12.6)	5.7 (3.6 to 8.3)	-34.5 (-37.5 to -31.3)	0.1 (-4.5 to 4.6)
Idiopathic intellectual disability	158.0 (130.3 to 189.8)	125 (105.9 to 157.7)	-21.5 (-26.7 to -9.4)	-18.1 (-23.3 to -4.5)	7.7 (5.1 to 10.7)	6.3 (4.1 to 8.9)	-18.2 (-21.9 to -9.4)	-13.1 (-22.7 to 3.8)
Other mental and substance use disorders	189.6 (178.8 to 200.2)	200.5 (189.0 to 211.7)	6.1 (5.2 to 7.1)	0.2 (0.1 to 0.3)	13.9 (9.5 to 18.8)	14.8 (10.2 to 19.8)	6.2 (2.6 to 10.1)	0.7 (-2.8 to 4.4)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	118.2 (84.0 to 155.5)	134.4 (96.0 to 178.2)	13.5 (3.4 to 24.5)	6.3 (-2.1 to 15.5)
Diabetes mellitus	596.2 (491.9 to 703.5)	740.1 (596.7 to 871.3)	23.9 (0.3 to 57.1)	16.4 (-4.8 to 44.4)	45.3 (29.8 to 63.9)	57.2 (37.5 to 81.7)	25.8 (3.0 to 56.2)	15.8 (-3.7 to 43.3)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.7 (-54.3 to -44.6)	-49.5 (-53.9 to -44.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.7 (-54.3 to -44.6)	-49.5 (-54.0 to -44.9)
Chronic kidney disease	-	-	-	-	39.0 (28.1 to 50.1)	43.2 (31.0 to 55.5)	10.9 (2.7 to 21.9)	2.1 (-5.1 to 11.2)
Chronic kidney disease due to diabetes mellitus	221.4 (153.3 to 347.7)	263.7 (169.3 to 400.1)	19.6 (-15.5 to 74.4)	7.2 (-23.4 to 54.2)	6.7 (4.5 to 9.3)	8.1 (5.4 to 11.4)	9.0 (-14.0 to 69.9)	9.0 (-20.4 to 55.1)
Chronic kidney disease due to hypertension	286.2 (197.6 to 437.6)	248.5 (174.1 to 362.8)	-13.1 (-39.7 to 22.2)	-14.6 (-39.0 to 15.8)	10.9 (7.8 to 14.8)	8.4 (6.0 to 11.5)	-22.1 (-40.4 to -3.3)	-29.4 (-45.1 to -11.6)
Chronic kidney disease due to glomerulonephritis	339.7 (237.2 to 481.9)	267.8 (186.0 to 384.0)	-21.0 (-39.6 to 1.1)	-27.6 (-47.7 to -10.0)	8.0 (5.3 to 10.8)	7.3 (5.0 to 10.3)	-12.4 (-31.0 to 37.1)	-10.8 (-31.4 to 30.6)
Chronic kidney disease due to other causes	465.5 (329.0 to 635.5)	565.0 (480.6 to 902.4)	21.2 (13.2 to 83.7)	13.4 (3.1 to 66.5)	41.3 (31.2 to 78.8)	44.9 (31.7 to 25.5)	32.2 (16.1 to 85.9)	32.2 (6.0 to 69.5)
Urinary diseases and male infertility	-	-	-	-	8.1 (5.3 to 11.5)	9.6 (6.2 to 13.6)	18.0 (2.2 to 38.1)	-1.9 (-15.0 to 13.9)
Interstitial nephritis and urinary tract infections	2.2 (1.9 to 2.5)	2.3 (2.1 to 2.6)	5.7 (9.9 to 33.1)	8.6 (-9.3 to 40.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	5.7 (-18.7 to 35.8)	9.0 (-17.4 to 46.5)

Appendix Table G.4 - Hungary prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Urolithiasis	106.3 (60.3 to 177.6)	116.3 (81.6 to 164.2)	8.0 (-15.9 to 68.9)	-10.1 (-30.8 to 37.1)	1.0 (0.5 to 1.7)	1.1 (0.7 to 1.7)	10.1 (-9.2 to 50.6)	-4.6 (-21.8 to 28.2)
Benign prostatic hyperplasia	189.4 (166.0 to 210.6)	221.3 (193.2 to 256.7)	17.1 (-1.9 to 42.8)	-4.7 (-20.1 to 15.3)	6.7 (4.4 to 9.6)	7.9 (5.0 to 11.3)	17.7 (-1.2 to 42.9)	-3.9 (-19.3 to 16.2)
Male infertility due to other causes	37.5 (27.3 to 50.6)	41.1 (29.7 to 52.3)	12.7 (-27.1 to 61.9)	9.6 (-28.7 to 56.9)	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.5)	12.8 (-26.6 to 60.8)	10.5 (-28.9 to 56.9)
Other urinary diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.5)	156.0 (-10.0 to 228.5)	124.1 (-22.1 to 189.3)
Gynecological diseases	-	-	-	-	12.8 (8.2 to 19.5)	12.5 (7.8 to 19.3)	-0.2 (-14.9 to 9.9)	-4.0 (-14.3 to 11.6)
Uterine fibroids	256.1 (234.3 to 276.9)	242.6 (221.6 to 262.7)	-5.0 (-5.3 to -4.7)	-2.0 (-2.0 to -2.0)	2.9 (1.6 to 5.0)	2.9 (1.6 to 4.9)	1.5 (-5.5 to 9.4)	2.6 (-4.2 to 10.1)
Polycystic ovarian syndrome	189.4 (171.3 to 208.5)	181.0 (161.4 to 198.9)	-3.9 (-17.0 to 10.0)	-0.4 (-14.1 to 14.2)	1.8 (0.8 to 3.4)	1.7 (0.8 to 3.3)	-0.2 (-17.0 to 9.9)	-0.7 (-14.1 to 14.1)
Female infertility due to other causes	25.2 (9.1 to 48.0)	24.3 (6.1 to 51.4)	-3.6 (-78.8 to 207.0)	-6.4 (-78.2 to 195.3)	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.3)	-6.6 (-78.7 to 205.4)	-7.0 (-77.4 to 192.8)
Endometriosis	20.0 (17.0 to 23.3)	20.1 (17.2 to 23.1)	1.0 (-17.1 to 25.9)	3.5 (-15.3 to 27.9)	1.9 (1.2 to 2.7)	1.9 (1.2 to 2.6)	1.1 (-19.1 to 26.9)	3.7 (-17.2 to 30.1)
Genital prolapse	625.0 (559.3 to 695.5)	638.4 (558.0 to 706.7)	2.9 (-14.5 to 19.7)	-2.3 (-19.7 to 14.0)	2.0 (0.9 to 3.7)	2.0 (1.0 to 3.8)	3.0 (-14.9 to 20.6)	2.3 (-19.8 to 15.0)
Premenstrual syndrome	390.7 (263.2 to 545.7)	369.3 (230.1 to 512.7)	-4.0 (-44.8 to 50.2)	-1.6 (-42.9 to 50.9)	3.3 (1.8 to 5.5)	3.1 (1.5 to 5.4)	-0.2 (-4.7 to 50.9)	-1.3 (-42.8 to 53.9)
Other gynecological diseases	34.4 (29.6 to 39.3)	30.3 (25.3 to 34.8)	-11.4 (-27.7 to 9.9)	-7.5 (-23.9 to 14.3)	0.9 (0.6 to 1.3)	0.8 (0.5 to 1.2)	0.8 (-39.9 to 21.4)	-12.0 (-36.3 to 26.2)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	9.2 (6.1 to 13.3)	8.3 (5.5 to 12.1)	-9.9 (-20.3 to 4.8)	-1.8 (-10.4 to 12.1)
Thalassemias	0.4 (0.1 to 0.6)	0.3 (0.1 to 0.5)	-27.1 (-42.3 to -19.2)	-3.5 (-23.9 to 7.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.8 (-51.8 to 12.8)	-3.1 (-39.1 to 55.6)
Thalassemia trait	285.0 (219.1 to 362.8)	267.0 (197.4 to 345.8)	-5.4 (-16.6 to 0.2)	-2.0 (-13.4 to 3.7)	7.2 (4.8 to 10.5)	6.5 (4.3 to 9.3)	-9.6 (-23.6 to 2.4)	-2.9 (-14.5 to 9.6)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.6 (-44.3 to -16.6)	-5.6 (-32.9 to 1.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.9 (-47.6 to -13.5)	-8.4 (-39.7 to -0.3)
Sickle cell trait	31.2 (19.8 to 46.5)	27.9 (16.2 to 44.0)	-8.3 (-35.7 to 0.9)	-4.9 (-33.0 to 4.8)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-26.1 (-55.1 to 12.4)	-15.3 (-52.9 to 30.1)
G6PD deficiency	80.0 (54.6 to 101.2)	71.4 (39.9 to 95.9)	-11.5 (-43.6 to 41.6)	-7.6 (-41.5 to 49.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.1 (-19.9 to 6.8)	17.2 (-14.1 to 29.3)
G6PD trait	1,377.7 (1,256.7 to 1,486.6)	1,330.8 (1,217.4 to 1,431.3)	-3.0 (-13.7 to 8.6)	-1.1 (-11.9 to 10.9)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-22.5 (-60.8 to 123.1)	-11.4 (-57.2 to 186.0)
Other hemoglobinopathies and hemolytic anemias	79.8 (71.6 to 87.5)	81.4 (74.4 to 89.6)	1.6 (-9.6 to 17.6)	4.5 (-9.3 to 20.1)	1.7 (1.1 to 2.5)	1.6 (1.0 to 2.4)	-5.2 (-29.3 to 27.7)	7.5 (-19.5 to 47.0)
Endocrine, metabolic, blood, and immune disorders	124.2 (116.6 to 131.0)	119.2 (113.3 to 125.1)	-3.9 (-10.0 to 3.7)	1.4 (-5.1 to 9.5)	3.8 (2.5 to 5.4)	3.5 (2.4 to 4.9)	-7.7 (-16.3 to 3.8)	1.6 (-6.4 to 14.8)
Musculoskeletal disorders	-	-	-	-	207.5 (204.5 to 379.1)	223.2 (229.1 to 429.1)	2.6 (-5.5 to 20.1)	2.5 (-3.8 to 10.0)
Rheumatoid arthritis	36.9 (34.9 to 39.1)	34.4 (32.2 to 36.6)	-6.5 (-14.0 to 1.7)	-20.8 (-27.0 to -13.9)	8.4 (6.0 to 11.0)	7.8 (5.6 to 10.3)	-6.9 (-15.1 to 2.3)	-20.3 (-27.4 to -12.7)
Osteoarthritis	648.6 (621.1 to 673.4)	796.9 (767.0 to 825.6)	23.2 (16.8 to 30.9)	1.9 (-3.4 to 8.4)	39.0 (27.6 to 53.1)	48.1 (33.8 to 65.5)	23.1 (16.9 to 31.3)	2.5 (-2.8 to 9.3)
Low back and neck pain	-	-	-	-	217.6 (149.5 to 293.7)	238.0 (165.0 to 321.2)	9.5 (-9.2 to 16.5)	1.8 (-6.4 to 11.6)
Low back pain	1,531.6 (1,438.1 to 1,628.9)	1,671.1 (1,578.1 to 1,773.9)	9.3 (-0.3 to 20.5)	1.1 (-7.1 to 10.6)	11.1 (114.7 to 233.5)	11.1 (123.7 to 252.6)	0.2 (-0.4 to 20.2)	1.2 (-6.6 to 11.0)
Neck pain	512.2 (404.5 to 611.3)	560.1 (460.4 to 667.4)	8.3 (-15.3 to 48.3)	0.6 (-21.0 to 39.2)	49.7 (32.5 to 72.6)	54.5 (36.5 to 77.5)	8.5 (-15.2 to 48.6)	1.9 (-20.6 to 39.9)
Gout	5.9 (5.5 to 6.2)	6.8 (6.4 to 7.2)	16.2 (7.0 to 27.8)	1.5 (-6.4 to 11.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	0.2 (-8.2 to 45.2)	1.2 (-19.2 to 27.7)
Other musculoskeletal disorders	248.6 (178.7 to 316.9)	321.3 (246.8 to 394.1)	30.0 (17.1 to 46.1)	18.0 (6.7 to 32.6)	22.4 (14.1 to 33.2)	29.1 (18.8 to 42.0)	30.2 (16.1 to 48.3)	18.6 (6.5 to 34.2)
Other non-communicable diseases	-	-	-	-	187.6 (125.5 to 269.2)	191.6 (129.7 to 274.5)	1.1 (-1.6 to 6.1)	-6.3 (-10.6 to -3.0)
Congenital anomalies	-	-	-	-	12.7 (8.7 to 17.2)	14.0 (9.5 to 18.9)	9.5 (5.5 to 26.9)	9.7 (5.7 to 28.2)
Neural tube defects	2.3 (2.1 to 2.6)	1.7 (1.5 to 1.9)	-23.9 (-37.5 to -9.6)	-17.1 (-32.0 to -1.4)	0.8 (0.5 to 1.0)	0.6 (0.4 to 0.8)	-22.1 (-41.4 to 1.9)	-14.7 (-36.6 to 10.9)
Congenital heart anomalies	79.2 (63.2 to 99.9)	88.8 (73.0 to 106.3)	13.2 (-17.3 to 49.7)	16.6 (-14.7 to 54.3)	2.7 (1.1 to 4.8)	3.1 (1.3 to 5.3)	16.5 (-13.3 to 54.3)	21.0 (-10.0 to 60.4)
Crofacial clefts	8.4 (7.2 to 10.6)	11.2 (9.4 to 14.3)	31.8 (3.6 to 73.8)	29.8 (2.4 to 71.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-6.9 (-34.0 to 35.6)	-7.9 (-35.7 to 34.1)
Down syndrome	8.8 (7.4 to 10.4)	11.3 (9.2 to 13.8)	29.4 (-1.5 to 71.7)	24.7 (-4.5 to 64.8)	1.2 (0.9 to 1.6)	1.7 (1.2 to 2.4)	1.7 (-7.7 to 92.4)	31.5 (-1.2 to 77.5)
Turner syndrome	0.3 (0.3 to 0.4)	0.4 (0.3 to 0.5)	5.7 (-29.0 to 54.6)	13.1 (-24.0 to 65.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.6 (-30.6 to 57.5)	13.8 (-25.7 to 66.4)
Klinefelter syndrome	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	0.0 (-22.5 to 52.7)	20.2 (-17.7 to 61.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.0 (-27.1 to 68.3)	18.5 (-24.6 to 73.2)
Chromosomal unbalanced rearrangements	13.2 (11.1 to 16.3)	16.7 (13.6 to 20.0)	28.6 (2.6 to 60.5)	23.8 (-6.2 to 54.3)	1.8 (1.3 to 2.5)	2.6 (1.9 to 3.4)	43.1 (54.0 to 83.4)	31.4 (-2.7 to 67.3)
Other congenital anomalies	35.4 (29.8 to 42.9)	32.1 (26.2 to 37.9)	-9.3 (-19.5 to -1.0)	-11.7 (-18.5 to -0.7)	5.9 (4.0 to 8.5)	5.9 (3.8 to 8.4)	-9.7 (-22.1 to 18.6)	-1.9 (-18.8 to 24.9)
Skin and subcutaneous diseases	-	-	-	-	52.3 (34.4 to 77.2)	47.1 (30.9 to 70.2)	-9.9 (-18.9 to -1.5)	-7.4 (-16.8 to 1.2)
Dermatitis	494.0 (415.9 to 582.7)	483.2 (407.4 to 566.6)	-1.9 (-3.3 to -0.5)	0.0 (-0.1 to 0.1)	12.7 (8.0 to 18.5)	12.3 (7.8 to 17.9)	-3.4 (-6.6 to -0.2)	0.2 (-2.5 to 3.0)
Psoriasis	94.1 (82.8 to 105.3)	96.7 (84.8 to 108.4)	3.0 (1.7 to 4.6)	0.0 (-0.1 to 0.1)	7.6 (5.1 to 10.6)	7.8 (5.3 to 11.0)	3.0 (-2.4 to 7.9)	0.6 (-4.7 to 5.9)
Cellulitis	1.7 (1.3 to 2.2)	1.7 (1.2 to 2.2)	-2.3 (-15.6 to 16.9)	-2.3 (-12.2 to 9.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-0.1 (-22.9 to 22.9)	-1.9 (-20.9 to 21.6)
Pyoderma	10.8 (8.6 to 13.7)	12.2 (9.4 to 16.2)	13.3 (3.8 to 25.7)	8.8 (2.7 to 16.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	12.2 (-0.2 to 27.5)	8.9 (-1.9 to 21.0)
Scabies	19.4 (17.7 to 21.1)	15.5 (14.2 to 17.0)	-19.7 (-28.7 to -8.8)	-13.2 (-23.4 to -1.5)	0.5 (0.3 to 0.8)	0.4 (0.2 to 0.6)	-19.7 (-30.4 to -7.6)	-13.1 (-25.4 to -0.1)
Fungal skin diseases	872.9 (688.6 to 1,127.7)	871.1 (685.6 to 1,115.9)	0.2 (-4.0 to 3.7)	0.2 (-0.1 to 0.2)	4.9 (1.9 to 10.5)	4.9 (1.9 to 10.5)	-0.0 (-4.4 to 3.9)	0.4 (-0.5 to 1.2)
Viral skin diseases	200.8 (156.4 to 247.8)	175.0 (131.4 to 222.1)	-12.3 (-16.5 to -9.5)	-12.3 (-1.6 to 9.5)	6.2 (3.6 to 9.5)	5.4 (3.2 to 8.4)	-12.9 (-17.4 to -8.1)	-0.9 (-2.7 to 3.5)
Acne vulgaris	309.0 (240.5 to 377.5)	242.1 (187.6 to 295.0)	-21.5 (-42.8 to 7.2)	-21.5 (-31.4 to 29.6)	3.3 (1.5 to 6.4)	2.6 (1.2 to 5.1)	-21.4 (-42.7 to 7.5)	-5.7 (-31.4 to 30.1)
Alopecia areata	13.7 (11.6 to 15.4)	14.2 (12.0 to 16.1)	3.8 (-12.8 to 21.6)	-0.5 (-15.7 to 14.9)	0.4 (0.3 to 0.7)	0.5 (0.3 to 0.7)	3.5 (-14.9 to 23.7)	-0.4 (-16.7 to 18.1)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-23.1 to 39.8)	-1.9 (-24.9 to 29.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.9 (-23.2 to 40.2)	-1.9 (-25.0 to 29.8)
Urticaria	195.2 (151.4 to 244.3)	127.5 (76.9 to 181.3)	-33.7 (-65.0 to 1.5)	-33.8 (-66.0 to 21.6)	11.4 (6.9 to 17.2)	11.4 (3.8 to 22.4)	-34.2 (-65.1 to 11.8)	-31.1 (-65.6 to 4.5)
Decubitus ulcer	1.9 (1.5 to 2.3)	3.7 (2.7 to 4.7)	96.6 (47.9 to 160.3)	50.1 (16.8 to 95.1)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.8)	92.5 (39.5 to 163.2)	48.8 (10.6 to 97.3)
Other skin and subcutaneous diseases	832.1 (475.1 to 1,434.5)	869.7 (482.9 to 1,532.3)	4.4 (-3.5 to 12.6)	-4.0 (-10.5 to 0.4)	4.8 (1.9 to 10.8)	5.0 (1.9 to 11.6)	-3.7 (-4.0 to 12.9)	-4.4 (-10.1 to 0.9)
Sense organ diseases	-	-	-	-	95.0 (63.1 to 137.5)	100.9 (67.9 to 144.6)	6.2 (-1.9 to 11.3)	-10.4 (-13.9 to -6.8)
Glaucoma	14.9 (11.8 to 17.8)	13.8 (11.1 to 17.0)	-7.7 (-24.5 to 13.9)	-20.7 (-33.8 to -4.4)	0.6 (0.4 to 0.9)	0.6 (0.4 to 0.9)	1.8 (-19.6 to 16.7)	-19.1 (-32.1 to -4.5)
Cataract	161.3 (127.9 to 194.9)	159.4 (128.3 to 191.8)	-0.5 (-15.7 to 16.0)	-23.8 (-35.6 to -11.0)	5.4 (3.4 to 8.0)	5.5 (3.4 to 8.3)	2.5 (-11.8 to 18.1)	-21.9 (-32.8 to -9.4)
Macular degeneration	42.9 (31.5 to 56.2)	52.7 (39.7 to 70.4)	22.2 (-5.4 to 67.2)	3.5 (-19.3 to 38.6)	1.4 (0.8 to 2.2)	1.8 (1.1 to 2.8)	24.0 (-2.9 to 67.4)	3.2 (-19.0 to 37.3)
Uncorrected refractive error	872.4 (789.2 to 961.3)	830.8 (739.5 to 917.8)	-4.6 (-16.4 to 10.4)	-16.0 (-26.9 to -2.6)	14.5 (8.5 to 23.4)	13.5 (8.0 to 22.1)	-7.2 (-14.6 to 2.5)	-17.2 (-24.2 to -8.8)
Age-related and other hearing loss	2,124.9 (2,083.2 to 2,542.0)	2,494.7 (2,236.1 to 2,711.7)	2,494.7 (3.7 to 41.4)	7.6 (-11.3 to -4.1)	8.1 (6.3 to 9.5)	7.5 (4.7 to 99.5)	11.2 (5.2 to 18.6)	-8.5 (-13.8 to -2.7)
Other vision loss	74.8 (63.5 to 87.5)	55.0 (46.6 to 65.3)	-26.7 (-34.9 to -14.2)	-26.7 (-39.3 to -24.2)	3.1 (2.0 to 4.5)	3.1 (1.7 to 3.6)	-21.8 (-27.8 to -9.7)	-2.7 (-34.5 to -21.4)
Other sense organ diseases	250.8 (239.4 to 262.4)	249.1 (236.7 to 260.6)	-0.3 (-7.3 to 6.6)	0.0 (-6.3 to 6.3)	6.5 (4.1 to 9.8)	6.5 (4.0 to 9.5)	-0.2 (-8.2 to 6.6)	0.2 (-7.1 to 7.8)
Oral disorders	-	-	-	-	27.5 (16.4 to 42.6)	29.7 (17.9 to 46.2)	7.9 (-2.4 to 13.9)	-3.0 (-8.0 to 2.6)
Deciduous caries	608.1 (590.9 to 626.4)	432.3 (417.9 to 447.3)	-28.7 (-32.0 to -25.2)	-1.3 (-5.9 to 3.6)	0.1 (0.1 to 0.3)	0.1 (0.0 to 0.2)	-1.2 (-34.7 to -22.9)	-1.2 (-9.6 to 6.8)
Permanent caries	3,034.3 (2,909.2 to 3,164.4)	3,039.0 (2,852.1 to 3,167.2)	0.1 (-7.6 to 6.1)	0.1 (-3.7 to 10.4)	1.8 (0.8 to 3.4)	1.8 (0.8 to 3.4)	0.1 (-8.2 to 6.3)	4.3 (-4.1 to 11.0)
Periodontal diseases	1,277.2 (1,153.2 to 1,393.6)	1,436.0 (1,297.4 to 1,562.6)	12.9					

Appendix Table G.4 - Hungary prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	198.6 (188.5 to 208.6)	201.1 (190.0 to 212.3)	1.7 (-5.5 to 8.9)	0.5 (-6.8 to 7.7)	5.8 (3.6 to 8.6)	5.8 (3.6 to 8.7)	1.7 (-6.4 to 9.2)	0.3 (-7.5 to 8.3)
Injuries	-	-	-	-	160.5 (121.6 to 207.4)	122.1 (88.0 to 164.5)	-24.2 (-32.3 to -15.6)	-35.7 (-42.4 to -28.4)
Transport injuries	-	-	-	-	26.1 (19.5 to 34.0)	10.8 (7.7 to 14.7)	-58.8 (-63.6 to -53.6)	-63.6 (-67.9 to -58.9)
Road injuries	-	-	-	-	21.2 (15.9 to 27.5)	8.8 (6.2 to 11.9)	-58.8 (-63.9 to -53.5)	-63.7 (-68.3 to -58.8)
Pedestrian road injuries	-	-	-	-	5.1 (3.8 to 6.6)	2.1 (1.5 to 2.8)	-59.9 (-64.9 to -54.2)	-65.6 (-70.0 to -60.6)
Cyclist road injuries	-	-	-	-	4.4 (3.3 to 5.7)	1.7 (1.2 to 2.3)	-61.4 (-65.1 to -57.3)	-66.1 (-69.5 to -62.5)
Motorcyclist road injuries	-	-	-	-	1.5 (1.1 to 2.0)	0.6 (0.4 to 0.9)	-58.7 (-64.2 to -52.2)	-62.5 (-67.7 to -56.4)
Motor vehicle road injuries	-	-	-	-	10.1 (7.5 to 13.0)	4.4 (3.1 to 5.9)	-56.8 (-63.0 to -50.1)	-61.6 (-67.2 to -55.3)
Other road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-74.1 (-77.2 to -70.5)	-77.2 (-80.0 to -73.9)
Other transport injuries	-	-	-	-	4.9 (3.6 to 6.5)	2.0 (1.4 to 2.8)	-58.7 (-63.3 to -53.9)	-63.2 (-67.3 to -58.9)
Unintentional injuries	-	-	-	-	131.9 (100.3 to 170.1)	110.1 (79.2 to 148.0)	-16.9 (-25.5 to -7.5)	-29.5 (-36.8 to -21.5)
Falls	-	-	-	-	111.5 (85.3 to 143.3)	96.6 (69.4 to 130.3)	-13.6 (-23.3 to -3.0)	-27.5 (-35.8 to -18.3)
Drowning	-	-	-	-	0.4 (0.3 to 0.5)	0.2 (0.1 to 0.2)	-50.5 (-57.2 to -43.0)	-56.2 (-62.2 to -49.5)
Fire, heat, and hot substances	-	-	-	-	1.6 (1.2 to 2.0)	1.1 (0.8 to 1.5)	-28.6 (-37.4 to -18.2)	-34.8 (-43.3 to -24.8)
Poisonings	-	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.1)	-52.3 (-58.4 to -45.1)	-54.0 (-60.2 to -46.4)
Exposure to mechanical forces	-	-	-	-	11.8 (8.7 to 15.5)	7.1 (5.1 to 9.7)	-40.0 (-45.0 to -34.2)	-42.7 (-47.6 to -36.6)
Unintentional firearm injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.1)	-65.4 (-70.6 to -58.8)	-66.0 (-71.2 to -59.4)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-65.3 (-61.6 to -49.9)	-57.8 (-63.1 to -51.2)
Other exposure to mechanical forces	-	-	-	-	11.5 (8.5 to 15.1)	7.0 (5.0 to 9.5)	-39.4 (-44.4 to -33.6)	-42.2 (-47.0 to -36.0)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	16.3 (5.4 to 28.2)	3.0 (-5.9 to 12.3)
Animal contact	-	-	-	-	0.7 (0.5 to 0.9)	0.6 (0.4 to 0.8)	-12.1 (-20.1 to -3.2)	-15.6 (-23.8 to -6.7)
Venomous animal contact	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-11.7 (-24.6 to 2.8)	-14.2 (-27.2 to 0.7)
Non-venomous animal contact	-	-	-	-	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.5)	-12.6 (-21.2 to -2.0)	-16.7 (-25.2 to -6.0)
Foreign body	-	-	-	-	0.9 (0.7 to 1.1)	0.7 (0.5 to 0.9)	-22.7 (-29.7 to -15.3)	-28.6 (-35.3 to -21.3)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.2)	-40.8 (-50.8 to -29.0)	-45.5 (-54.8 to -35.0)
Foreign body in eyes	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-5.5 (-11.8 to 1.0)	-6.1 (-15.2 to -1.5)
Foreign body in other body part	-	-	-	-	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.5)	-15.8 (-24.3 to -6.6)	-23.1 (-30.8 to -15.0)
Other unintentional injuries	-	-	-	-	4.9 (3.6 to 6.4)	3.5 (2.6 to 4.7)	-27.7 (-34.6 to -20.1)	-38.7 (-44.4 to -32.2)
Self-harm and interpersonal violence	-	-	-	-	2.6 (1.9 to 3.3)	1.2 (0.9 to 1.7)	-51.6 (-56.6 to -45.6)	-56.6 (-61.0 to -51.3)
Self-harm	-	-	-	-	1.8 (1.4 to 2.4)	0.8 (0.6 to 1.1)	-55.5 (-60.0 to -49.5)	-60.3 (-64.2 to -55.1)
Interpersonal violence	-	-	-	-	0.7 (0.6 to 0.9)	0.4 (0.3 to 0.6)	-41.9 (-48.8 to -34.1)	-47.6 (-53.7 to -40.6)
Assault by firearm	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-32.3 (-37.9 to -25.7)	-39.1 (-44.3 to -33.0)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-29.5 (-37.5 to -19.6)	-35.9 (-43.1 to -27.0)
Assault by other means	-	-	-	-	0.6 (0.4 to 0.7)	0.3 (0.2 to 0.4)	-45.4 (-52.1 to -37.4)	-50.9 (-56.9 to -43.5)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.2 (-15.9 to 40.9)	1.8 (-23.9 to 43.1)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.2 (-15.9 to 40.9)	1.8 (-23.9 to 43.1)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Iceland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	29.5 (22.0 to 38.0)	39.8 (29.6 to 51.1)	34.9 (30.7 to 38.7)	34.9 (4.2 to 1.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.5 (1.0 to 2.1)	1.7 (1.2 to 2.4)	16.8 (7.4 to 34.6)	2.2 (-6.1 to 17.1)
HIV/AIDS and tuberculosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.4 (4.7 to 50.5)	-0.0 (-16.9 to 20.2)
Tuberculosis	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	23.6 (18.9 to 29.6)	-2.0 (-5.7 to 2.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.9 (3.3 to 51.0)	-0.4 (-17.7 to 21.4)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-18.0 to 158.1)	0.0 (-39.5 to 98.7)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.3 (-55.1 to 69.1)	-29.0 (-65.3 to 31.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.3 (-55.1 to 69.3)	-29.0 (-65.3 to 31.7)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	185.3 (92.7 to 363.2)	116.9 (44.3 to 259.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.0 (-17.9 to 158.7)	12.8 (-39.5 to 99.0)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	6.9 (-2.6 to 17.4)	-14.0 (-21.9 to -5.3)
Diarrheal diseases	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	3.1 (-11.8 to 21.3)	-17.2 (-29.5 to -1.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.5 (-15.3 to 26.9)	0.0 (-31.8 to 3.7)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-55.9 to -5.1)	0.0 (-62.3 to -18.9)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.6 (-47.5 to -11.0)	-43.2 (-54.8 to -24.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.6 (-47.5 to -11.0)	-43.2 (-55.0 to -24.1)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.2 (-27.9 to 33.5)	-14.8 (-37.0 to 15.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.2 (-28.0 to 33.5)	-14.8 (-37.1 to 15.5)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.1 (-97.1 to 294.5)	-64.3 (-97.5 to 238.5)
Lower respiratory infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.4 (-20.3 to -1.2)	-35.0 (-41.6 to -27.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.9 (-26.3 to 13.6)	-32.9 (-45.3 to -15.3)
Upper respiratory infections	4.0 (3.9 to 4.2)	4.8 (4.6 to 5.1)	20.6 (13.6 to 28.2)	0.2 (-5.7 to 6.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	20.4 (12.6 to 28.8)	0.3 (-6.1 to 7.3)
Otitis media	3.2 (2.8 to 3.7)	3.6 (3.2 to 4.0)	15.0 (1.1 to 34.1)	-9.3 (-21.4 to 6.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	12.3 (-1.8 to 31.4)	-11.2 (-21.7 to 3.9)
Meningitis	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-14.8 (-32.3 to 8.4)	-31.6 (-45.6 to -10.9)
Pneumococcal meningitis	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-19.2 (-36.9 to 6.5)	-39.7 (-52.9 to -21.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.9 (-38.2 to 14.6)	-36.4 (-52.5 to -9.6)
H influenzae type B meningitis	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-32.5 (-59.8 to 16.2)	-45.3 (-67.8 to -1.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.0 (-63.2 to 38.9)	-42.6 (-69.0 to 19.7)
Meningococcal meningitis	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-20.2 (-48.7 to 43.1)	-39.5 (-61.0 to 15.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.1 (-53.0 to 61.0)	-34.9 (-62.8 to 29.8)
Other meningitis	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.3)	-13.7 (-35.8 to 34.6)	-30.6 (-49.2 to 11.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.1 (-37.8 to 61.0)	-21.7 (-50.2 to 34.4)
Encephalitis	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	40.4 (14.7 to 82.9)	-3.3 (-14.3 to 39.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.7 (11.4 to 96.6)	8.5 (-16.4 to 50.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.2 (-93.2 to 579.3)	-50.7 (-95.0 to 423.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.2 (-93.3 to 584.6)	-50.7 (-95.1 to 429.4)
Whooping cough	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	596.9 (520.5 to 684.6)	537.7 (467.8 to 617.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	598.1 (384.3 to 990.9)	538.9 (341.6 to 901.5)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.5 (-68.7 to -5.9)	-45.8 (-74.2 to -20.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.5 (-63.6 to 20.7)	-41.1 (-69.8 to 1.9)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -94.0)	-100.0 (-100.0 to -94.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -94.0)	-100.0 (-100.0 to -94.5)
Varicella and herpes zoster	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.3)	23.5 (9.2 to 38.8)	-1.4 (-11.6 to 10.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.6 (5.4 to 66.9)	-1.5 (-22.0 to 20.9)
Neglected tropical diseases and malaria	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-67.3 to -47.1)	0.0 (-76.4 to -60.8)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.3 (-65.9 to 445.1)	16.2 (-71.3 to 362.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.9 (-66.2 to 454.9)	17.0 (-71.6 to 370.3)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-82.2 (-94.7 to -32.6)	-87.9 (-96.4 to -55.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-81.9 (-94.8 to -28.8)	-87.7 (-96.4 to -52.7)
Cystic echinococcosis	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-56.6 (-65.8 to -51.8)	-68.1 (-75.5 to -65.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.7 (-66.5 to -46.3)	-68.2 (-75.8 to -60.1)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.8 (-57.5 to 33.7)	-17.2 (-68.3 to 3.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.8 (-57.8 to 33.8)	-17.2 (-68.4 to 4.0)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.0 (-33.4 to 54.9)	-13.8 (-49.8 to 18.3)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.1 (-37.7 to 22.6)	-13.4 (-41.5 to 15.3)
Maternal hemorrhage	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	5.6 (-46.5 to 106.4)	-0.3 (-49.6 to 92.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.1 (-63.3 to 104.5)	-8.2 (-64.9 to 95.7)
Maternal sepsis and other maternal infections	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	1.1 (-76.5 to 235.3)	-11.2 (-79.4 to 197.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.3 (-56.4 to 51.6)	-24.1 (-60.4 to 36.9)
Maternal hypertensive disorders	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-3.4 (-14.3 to 6.6)	-10.0 (-19.9 to -0.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.3 (-23.7 to 20.2)	-10.9 (-28.8 to 11.6)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.2 (-21.9 to 9.8)	-12.1 (-26.0 to 4.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.2 (-22.0 to 9.8)	-12.1 (-26.0 to 4.0)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.8 (-1.8 to 13.9)	-0.7 (-7.8 to 6.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.8 (-1.8 to 14.1)	-0.7 (-7.9 to 7.1)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.5 (-51.3 to 54.3)	-18.3 (-53.9 to 45.7)
Neonatal disorders	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.2 to 0.6)	55.8 (11.2 to 147.4)	28.9 (-7.7 to 106.9)
Preterm birth complications	1.2 (0.7 to 2.2)	1.8 (1.0 to 3.5)	55.5 (13.3 to 98.9)	27.0 (-7.4 to 62.5)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	52.9 (-0.3 to 123.8)	26.4 (-17.7 to 86.5)
Neonatal encephalopathy due to birth asphyxia and trauma	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.4)	-37.0 (-58.5 to 3.0)	-47.6 (-65.2 to -34.8)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-32.8 (-56.0 to 4.5)	-43.6 (-63.3 to -12.4)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	340.6 (116.0 to 187.8)	121.9 (92.1 to 165.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	152.6 (29.4 to 418.8)	133.0 (19.4 to 378.5)
Hemolytic disease and other neonatal jaundice	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.4)	95.8 (44.1 to 1,502.6)	62.4 (-54.0 to 1,264.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	91.9 (-45.8 to 1,301.1)	58.3 (-55.3 to 1,072.3)
Other neonatal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	4,916.0 (69.7 to 15,020.7)	4,062.6 (40.8 to 12,587.0)
Nutritional deficiencies	-	-	-	-	0.9 (0.6 to 1.3)	1.0 (0.7 to 1.5)	10.4 (-10.4 to 14.8)	0.3 (-19.3 to 4.0)
Protein-energy malnutrition	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	864.1 (-36.5 to 1,32.2)	409.8 (-61.6 to 1,027.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	726.5 (-62.0 to 1,933.0)	344.1 (-72.8 to 931.3)
Iodine deficiency	1.0 (0.5 to 1.6)	0.8 (0.5 to 1.4)	-20.2 (-58.8 to 100.2)	-35.9 (-66.9 to 59.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.0 (-58.5 to 102.0)	-35.5 (-66.5 to 61.6)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron-deficiency anemia	32.8 (32.3 to 33.2)	38.3 (34.7 to 39.5)	17.3 (5.8 to 21.5)	-0.0 (-10.9 to 3.7)	0.9 (0.6 to 1.3)	1.0 (0.6 to 1.5)	11.0 (-10.8 to 15.0)	0.9 (-19.3 to 4.8)

Appendix Table G.4 - Iceland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.0	0.0	303.8	116.4
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.1	0.1	(71.0 to 878.5)	(79.4 to 394.3)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.0	0.0	(17.5 to 117.2)	(-28.8 to 106.7)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	124.9 (54.9 to 211.7)	48.5 (0.0 to 106.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	(3.6 to 42.4)	(-19.8 to 18.6)
Chlamydial infection	5.2 (4.2 to 6.9)	5.7 (4.1 to 7.3)	10.3 (-29.7 to 52.7)	2.1 (-37.7 to 36.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.1 (-26.1 to 51.4)	-5.4 (-35.1 to 33.3)
Gonococcal infection	1.1 (0.8 to 1.5)	1.0 (0.6 to 1.4)	-7.0 (-48.8 to 38.1)	-14.3 (-53.2 to 29.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.8 (-39.8 to 32.5)	-12.3 (-45.0 to 22.1)
Trichomoniasis	0.9 (0.6 to 1.2)	1.2 (0.7 to 1.6)	27.6 (-30.6 to 117.7)	11.3 (-40.4 to 89.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.1 (-35.5 to 131.4)	12.8 (-4.5 to 102.3)
Genital herpes	27.4 (23.6 to 31.5)	36.7 (32.1 to 41.9)	34.4 (9.0 to 63.5)	-4.0 (-22.6 to 16.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.8 (5.7 to 60.2)	-4.1 (-23.4 to 16.5)
Other sexually transmitted diseases	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-14.0 (-38.4 to 37.9)	-25.1 (-47.1 to 21.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.4 (-18.3 to 56.6)	-3.4 (-29.2 to 35.4)
Hepatitis	-	-	-	-	0.0	0.0	3.1	-17.0
Hepatitis A	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	11.2 (10.7 to 11.6)	-5.5 (-6.5 to -4.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.8 (1.7 to 29.9)	-4.9 (-15.7 to 8.1)
Hepatitis B	3.6 (2.8 to 4.6)	3.0 (2.2 to 3.6)	-15.1 (-45.6 to 13.2)	-35.3 (-58.3 to -13.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.0 (-55.2 to 29.1)	-44.1 (-66.3 to -0.4)
Hepatitis C	4.7 (4.3 to 5.2)	5.0 (4.5 to 5.5)	5.6 (-8.6 to 21.4)	-24.5 (-34.3 to -13.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.6 (-25.4 to 58.2)	-24.8 (-46.9 to 10.4)
Hepatitis E	-	-	-	-	0.0	0.0	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	1.5 (1.3 to 2.0)	1.7 (1.4 to 2.1)	11.8 (-18.6 to 119.0)	0.4 (-27.1 to 107.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	11.6 (-37.6 to 235.0)	4.5 (-41.6 to 229.9)
Non-communicable diseases	-	-	-	-	25.5 (18.9 to 32.8)	35.8 (26.5 to 45.8)	40.2 (34.8 to 45.1)	2.2 (-1.5 to 5.8)
Neoplasms	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.8)	48.5 (33.4 to 64.7)	-7.8 (-17.2 to 2.1)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.4 (7.3 to 134.5)	-4.7 (-35.0 to 41.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.4 (7.7 to 105.1)	-10.0 (-34.6 to 23.6)
Stomach cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-11.8 (-30.7 to 12.9)	-46.6 (-58.0 to -32.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.7 (-34.2 to 9.4)	-49.0 (-59.9 to -34.4)
Liver cancer	-	-	-	-	0.0	0.0	54.8	-4.5
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.8 (-49.9 to 200.7)	-16.4 (-68.4 to 88.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.4 (-49.7 to 175.7)	-19.1 (-68.0 to 73.4)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	219.7 (53.9 to 628.4)	96.7 (5.1 to 343.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	202.9 (61.8 to 546.1)	86.5 (0.8 to 294.5)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.1 (-62.8 to 74.4)	-52.1 (-77.5 to 8.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.5 (-61.4 to 56.3)	-53.7 (-76.6 to -5.0)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.9 (-82.1 to 11.9)	-71.2 (-88.5 to -32.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-55.1 (-80.6 to -2.5)	-72.1 (-87.5 to -39.6)
Larynx cancer	0.0 (0.0 to 0.0)	0.3 (0.2 to 0.3)	157.7 (70.3 to 3,682.2)	694.5 (394.6 to 2,128.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	811.8 (474.9 to 1,635.8)	442.4 (246.5 to 937.3)
Tracheal, bronchus and lung cancer	0.2 (0.2 to 0.2)	0.3 (0.2 to 0.3)	54.5 (25.6 to 86.4)	-5.8 (-23.2 to 14.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.7 (18.7 to 79.6)	-9.8 (-27.2 to 9.7)
Breast cancer	1.3 (1.1 to 1.4)	2.1 (1.9 to 2.3)	62.2 (41.4 to 88.9)	-2.5 (-15.0 to 13.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	44.8 (24.1 to 67.5)	-12.5 (-25.5 to 1.3)
Cervical cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-33.6 (-53.8 to -4.1)	-52.8 (-67.1 to -30.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.5 (-53.5 to -2.5)	-52.5 (-66.9 to -30.2)
Uterine cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	53.4 (1.4 to 121.7)	25.0 (-38.7 to 34.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.3 (-2.3 to 118.3)	-10.7 (-41.0 to 33.0)
Prostate cancer	0.8 (0.7 to 1.0)	2.1 (1.7 to 2.5)	150.7 (103.8 to 223.2)	56.8 (27.5 to 101.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	124.0 (81.5 to 195.1)	40.7 (13.6 to 87.3)
Colon and rectum cancer	0.8 (0.7 to 0.9)	1.3 (1.2 to 1.5)	73.5 (39.8 to 109.2)	5.5 (-14.6 to 27.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	68.7 (36.0 to 103.7)	2.7 (-17.0 to 23.5)
Lip and oral cavity cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	37.5 (-2.0 to 86.0)	-15.6 (-40.2 to 12.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.1 (5.1 to 80.8)	-19.0 (-41.7 to 8.9)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.0)	-40.5 (-61.5 to -3.8)	-60.0 (-73.9 to -35.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.8 (-61.1 to -7.1)	-61.0 (-73.7 to -38.7)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.2 (-34.0 to 85.9)	-91.4 (-60.3 to 12.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.7 (-30.4 to 73.8)	33.3 (-58.1 to 5.4)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.5 (-21.9 to 70.9)	-28.9 (-52.2 to 1.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.6 (-25.2 to 58.5)	11.6 (-54.9 to -6.3)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.8 (-1.7 to 70.6)	-21.5 (-40.2 to 3.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.8 (-4.2 to 63.4)	24.8 (-41.4 to -1.3)
Malignant skin melanoma	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	131.4 (55.7 to 205.2)	49.8 (0.4 to 98.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.1 (65.1 to 187.8)	40.6 (-6.6 to 87.5)
Non-melanoma skin cancer	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	104.4 (53.3 to 169.2)	25.0 (-5.2 to 63.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.1 (49.9 to 215.3)	36.6 (4.8 to 88.7)
Ovarian cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	1.4 (-25.9 to 38.1)	-37.9 (-54.1 to -15.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.8 (-29.3 to 40.6)	-39.3 (-56.1 to -14.5)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.4 (-53.4 to 186.5)	21.1 (-60.7 to 143.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.0 (-58.9 to 198.0)	13.2 (-65.0 to 154.3)
Kidney cancer	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	71.8 (29.9 to 120.6)	5.9 (-19.2 to 36.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.9 (22.7 to 110.2)	1.6 (-23.7 to 29.7)
Bladder cancer	0.1 (0.7 to 0.9)	0.6 (0.5 to 0.6)	50.7 (-45.6 to -14.5)	-56.7 (-65.9 to -46.9)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	38.6 (-51.9 to -24.3)	-61.7 (-69.9 to -52.7)
Brain and nervous system cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	47.5 (16.9 to 84.9)	0.7 (-19.8 to 27.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.8 (8.2 to 82.2)	-4.2 (-25.5 to 22.9)
Thyroid cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	59.4 (0.8 to 124.0)	3.8 (-34.5 to 48.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.6 (-2.3 to 118.3)	0.7 (-36.5 to 42.4)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	219.2 (1.6 to 345.0)	92.5 (-37.5 to 167.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	207.2 (-11.7 to 358.4)	87.4 (-44.5 to 173.7)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.7 (-25.6 to 85.4)	0.4 (-41.4 to 52.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.5 (-26.7 to 82.1)	-3.7 (-42.4 to 46.5)
Non-Hodgkin lymphoma	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	64.1 (1.4 to 121.3)	3.3 (-36.2 to 40.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.3 (-4.4 to 110.7)	-2.1 (-39.3 to 31.4)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	59.4 (-5.1 to 152.3)	-3.1 (-42.4 to 53.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.3 (-4.8 to 145.9)	-5.2 (-42.6 to 48.4)
Leukemia	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	40.7 (7.5 to 84.7)	-8.4 (-29.7 to 20.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.6 (5.1 to 76.0)	-11.8 (-31.7 to 13.0)
Other neoplasms	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.6)	384.5 (209.8 to 601.6)	201.4 (97.8 to 324.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	322.7 (173.1 to 497.7)	162.9 (74.2 to 262.5)
Cardiovascular diseases	-	-	-	-	0.8 (0.5 to 1.0)	1.2 (0.8 to 1.6)	52.8 (26.1 to 84.9)	-5.6 (-22.1 to 14.8)
Rheumatic heart disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.0 (29.4 to 94.2)	3.4 (-15.6 to 26.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.1 (6.1 to 157.9)	-1.9 (-32.4 to 67.1)
Ischemic heart disease	5.2 (4.1 to 6.2)	7.4 (6.5 to 8.5)	41.8 (11.5 to 86.2)	-14.7 (-33.5 to 12.8)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	30.1 (-3.3 to 85.1)	-22.3 (-43.1 to 13.0)
Cerebrovascular disease	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.2 to 0.3)	57.5 (21.1 to 96.8)	-0.6 (-22.9 to 23.5)
Ischemic stroke	1.4 (1.2 to 1.6)	2.1 (1.8 to 2.5)	54.4 (20.0 to 94.7)	-3.3 (-24.5 to 21.3)	0.1 (0.1 to 0.3)	0.2 (0.2 to 0.4)	55.2 (20.2 to 94.3)	-2.1 (-24.3 to 21.3)
Hemorrhagic stroke	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	72.9 (22.4 to 142.2)	10.3 (-21.1 to 55.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	71.2 (21.7 to 141.9)	10.4 (-20.5 to 55.3)
Hypertensive heart disease	0.2 (0.2 to 0.3)	0.4 (0.4 to 0.4)	81.9 (49.2 to 115.4)	10.8 (-8.9 to 30.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	82.5 (49.0 to 118.8)	11.4 (-9.0 to 33.0)
Cardiomyopathy and myocarditis	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.3)	33.7 (4.7 to 62.1)	-15.1 (-32.2 to 2.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.1 (2.6 to 63.5)	-15.3 (-33.7 to 4.2)
Atrial fibrillation and flutter	0.4 (0.3 to 0.5)	0.7 (0.5 to 0.8)	72.3 (21.9 to 192.3)	5.5 (-25.0 to 77.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	71.7 (18.7 to 191.5)	5.1 (-27.0 to 78.4)
Peripheral vascular disease	7.5 (5.8 to 9.1)	11.8 (8.6 to 14.4)	54.9 (8.8 to 128.2)	-7.9 (-36.2 to 39.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.8 (-23.1 to 305.2)	-2.2 (-57.5 to 138.1)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	56.9 (7.7 to 100.9)	8.0 (-28.3 to 36.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.6 (7.6 to 102.5)	7.5 (-28.1 to 38.2)
Other cardiovascular and circulatory diseases	2.6 (1.6 to 3.7)	4.6 (2.9 to 6.0)	72.6 (2.4 to 191.5)	9.3 (-35.7 to 86.6)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	72.9 (1.9 to 194.9)	9.7 (-35.8 to 87.1)
Chronic respiratory diseases	-	-	-	-	1.5 (1.0 to 2.0)	2.1 (1.4 to 2.8)	49.8 (17.8 to 71.9)	1.7 (-19.1 to 17.0)
Chronic obstructive pulmonary disease	17.8 (16.2 to 19.4)	27.2 (24.9 to 29.4)	53.0 (45.8 to 61.6)	0.6 (-4.3 to 6.4)	1.0 (0.6 to 1.4)	1.5 (1.0 to 2.1)	54.0 (18.6 to 98.5)	1.8 (-21.6 to 31.3)
Pneumoconiosis	-	-	-	-	0.0	0.0	26.9	-19.8
	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	143.3 (14.3 to 44.9)	-7.5 (-27.6 to 7.5)

Appendix Table G.4 - Iceland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.5 (-6.3 to 5.8)	-67.7 (-40.4 to -32.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.1 (-6.8 to 5.6)	-37.0 (-40.6 to -32.8)
Asbestosis	-	-	-	-	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.2 (27.9 to 75.0)	-5.5 (-18.8 to 12.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.5 (28.9 to 75.5)	-5.0 (-18.5 to 12.7)
Asthma	10.9 (9.1 to 12.6)	13.7 (11.6 to 15.8)	25.8 (1.0 to 51.9)	24.7 (26.1 to 12.9)	0.6 (0.3 to 0.7)	0.6 (0.4 to 0.9)	7.8 (0.8 to 51.7)	7.0 (-26.4 to 12.6)
Interstitial lung disease and pulmonary sarcoidosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.3 (25.2 to 117.5)	10.2 (-16.0 to 46.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.9 (24.9 to 120.8)	10.7 (-16.0 to 48.9)
Other chronic respiratory diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.6 (-44.0 to 7.1)	-48.1 (-62.7 to -29.7)
Cirrhosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.0 (41.7 to 107.8)	7.5 (-11.7 to 30.8)
Cirrhosis due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.9 (24.3 to 351.3)	24.1 (-22.8 to 126.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.9 (24.1 to 361.6)	24.1 (-23.0 to 126.3)
Cirrhosis due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.2 (22.8 to 164.1)	12.3 (-23.9 to 63.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.2 (11.7 to 189.0)	12.8 (-30.9 to 82.0)
Cirrhosis due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.3 (-23.6 to 100.6)	-25.8 (-53.3 to 24.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.7 (-30.0 to 127.5)	-24.8 (-57.0 to 41.9)
Cirrhosis due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.3 (49.9 to 325.3)	7.3 (1.5 to 180.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	163.6 (49.4 to 325.5)	77.3 (1.4 to 180.9)
Digestive diseases	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.9)	62.6 (36.3 to 105.3)	12.9 (-5.5 to 42.4)
Peptic ulcer disease	1.6 (1.5 to 1.6)	0.6 (0.5 to 0.7)	-62.8 (-68.4 to -56.0)	-78.2 (-81.6 to -74.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-53.0 (-53.2 to -41.5)	-72.0 (-75.9 to -65.1)
Gastritis and duodenitis	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.2)	13.2 (-5.8 to 36.7)	-23.6 (-36.0 to -8.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.2 (-8.8 to 53.2)	-18.8 (-36.7 to 5.6)
Appendicitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.7 (-25.3 to 3.2)	-23.0 (-34.1 to -8.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.3 (-35.9 to 22.0)	-21.7 (-44.3 to 8.2)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.6 (61.4 to 92.5)	17.9 (8.0 to 29.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.6 (36.2 to 121.4)	18.2 (-5.9 to 46.3)
Inguinal, femoral, and abdominal hernia	0.4 (0.4 to 0.5)	0.6 (0.5 to 0.7)	46.7 (20.0 to 81.3)	29.8 (-23.5 to 12.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.3 (20.1 to 83.1)	6.8 (-23.5 to 15.0)
Inflammatory bowel disease	0.9 (0.7 to 1.1)	1.6 (1.3 to 1.8)	81.6 (40.8 to 136.7)	26.0 (-1.8 to 64.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	81.6 (38.4 to 136.8)	26.5 (-3.2 to 65.2)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.9 (18.1 to 164.7)	14.5 (-24.9 to 67.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.5 (6.6 to 183.7)	14.4 (-31.2 to 78.4)
Gallbladder and biliary diseases	0.4 (0.4 to 0.5)	0.6 (0.6 to 0.7)	51.9 (22.6 to 85.3)	1.4 (-17.6 to 23.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	53.0 (22.9 to 88.2)	2.8 (-17.6 to 26.3)
Pancreatitis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	54.2 (45.7 to 65.0)	7.9 (1.1 to 14.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.6 (32.2 to 80.8)	7.1 (-7.7 to 25.8)
Other digestive diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	118.6 (57.0 to 225.1)	51.6 (8.5 to 125.8)
Neurological disorders	-	-	-	-	2.5 (1.7 to 3.4)	3.7 (2.6 to 5.1)	50.9 (29.3 to 73.1)	10.8 (-5.7 to 26.7)
Alzheimer disease and other dementias	3.0 (2.2 to 3.6)	5.2 (4.1 to 6.1)	74.0 (24.2 to 166.6)	0.7 (-26.6 to 53.4)	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.0)	75.9 (24.3 to 176.1)	1.2 (-27.2 to 57.8)
Parkinson disease	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	61.4 (44.2 to 74.4)	27.0 (-10.9 to 80.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	61.7 (40.6 to 82.2)	0.2 (-13.6 to 12.2)
Epilepsy	0.7 (0.5 to 0.9)	0.8 (0.5 to 1.1)	16.5 (-24.7 to 87.8)	-7.9 (-40.7 to 49.3)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	17.1 (-25.1 to 91.4)	-6.7 (-40.3 to 53.4)
Multiple sclerosis	0.2 (0.2 to 0.3)	0.6 (0.6 to 0.7)	146.8 (116.5 to 181.6)	73.9 (52.9 to 98.5)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	145.9 (111.5 to 184.6)	74.1 (50.4 to 101.9)
Migraine	36.0 (30.1 to 42.9)	47.3 (38.4 to 57.1)	32.1 (-2.3 to 71.8)	5.5 (-23.5 to 38.3)	1.2 (0.7 to 1.9)	1.6 (0.9 to 2.4)	31.8 (-2.9 to 71.8)	5.8 (-22.9 to 39.0)
Tension-type headache	45.9 (32.6 to 65.2)	82.7 (71.6 to 96.3)	82.7 (27.1 to 162.5)	79.3 (-0.3 to 105.8)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	80.4 (47.8 to 162.1)	40.4 (0.1 to 106.2)
Medication overuse headache	1.6 (1.1 to 2.2)	3.3 (2.1 to 4.5)	104.6 (49.0 to 175.4)	48.9 (8.8 to 98.1)	0.3 (0.1 to 0.4)	0.5 (0.3 to 0.8)	103.8 (26.8 to 175.0)	49.5 (8.9 to 99.8)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.5 (-8.8 to 122.0)	-0.3 (-33.6 to 58.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	42.0 (0.2 to 106.5)	-13.4 (-38.9 to 24.8)
Mental and substance use disorders	-	-	-	-	5.5 (3.9 to 7.4)	7.1 (5.1 to 9.5)	28.4 (22.2 to 34.1)	3.3 (-0.5 to 7.0)
Schizophrenia	0.7 (0.5 to 0.8)	0.9 (0.7 to 1.1)	33.4 (23.7 to 44.9)	-1.4 (-6.9 to 6.2)	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.7)	33.3 (21.3 to 46.6)	-0.9 (-8.7 to 8.3)
Alcohol use disorders	3.5 (3.3 to 3.9)	3.8 (3.5 to 4.2)	7.9 (1.0 to 14.9)	-12.2 (-17.6 to -6.3)	0.4 (0.2 to 0.5)	0.4 (0.3 to 0.5)	7.5 (-0.3 to 14.7)	-12.0 (-18.1 to -6.2)
Drug use disorders	-	-	-	-	0.5 (0.3 to 0.7)	0.7 (0.4 to 0.9)	11.5 (10.5 to 53.8)	11.5 (-5.0 to 31.1)
Opioid use disorders	0.7 (0.4 to 1.1)	0.8 (0.5 to 1.2)	28.8 (10.4 to 57.8)	6.6 (-6.8 to 30.6)	0.3 (0.1 to 0.5)	0.4 (0.2 to 0.6)	29.1 (9.7 to 60.2)	6.9 (-7.5 to 32.6)
Cocaine use disorders	0.4 (0.3 to 0.4)	0.5 (0.4 to 0.6)	32.3 (7.4 to 91.2)	14.5 (-20.0 to 64.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	32.5 (-10.0 to 98.1)	14.8 (-22.3 to 70.4)
Amphetamine use disorders	0.4 (0.4 to 0.5)	0.5 (0.5 to 0.7)	36.1 (6.4 to 76.9)	18.7 (-8.0 to 53.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	36.0 (-8.6 to 55.4)	19.2 (-8.6 to 55.4)
Cannabis use disorders	0.5 (0.4 to 0.6)	0.5 (0.5 to 0.6)	10.2 (9.1 to 11.4)	-0.3 (-0.4 to -0.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.4 (-3.4 to 27.7)	-0.3 (-12.6 to 15.0)
Other drug use disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	35.0 (8.6 to 90.4)	17.6 (-20.5 to 66.1)
Depressive disorders	-	-	-	-	1.5 (0.9 to 2.3)	2.2 (1.3 to 3.2)	42.9 (24.5 to 62.0)	10.4 (-1.0 to 23.6)
Major depressive disorder	5.6 (4.0 to 7.5)	8.3 (5.7 to 11.5)	46.4 (21.5 to 74.7)	13.1 (-1.9 to 31.4)	1.1 (0.7 to 1.8)	1.7 (1.0 to 2.6)	46.1 (21.8 to 74.3)	13.5 (-1.6 to 32.0)
Dysthymia	3.9 (3.2 to 4.5)	5.1 (4.3 to 5.9)	32.8 (28.5 to 37.2)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.5)	0.5 (0.3 to 0.7)	32.4 (27.3 to 38.1)	0.6 (-1.8 to 3.1)
Bipolar disorder	1.8 (1.5 to 2.1)	2.2 (1.9 to 2.6)	25.9 (17.5 to 35.1)	0.6 (-5.6 to 7.7)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.7)	25.4 (16.6 to 37.1)	1.0 (-6.4 to 9.6)
Anxiety disorders	12.8 (6.5 to 18.2)	16.1 (8.9 to 22.7)	26.4 (16.3 to 40.4)	0.4 (0.1 to 0.6)	1.2 (0.5 to 1.9)	1.5 (0.7 to 2.3)	26.0 (15.7 to 40.0)	0.7 (-1.6 to 2.9)
Eating disorders	-	-	-	-	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	18.9 (3.3 to 19.3)	4.1 (-2.8 to 11.8)
Anorexia nervosa	0.3 (0.1 to 0.4)	0.3 (0.1 to 0.5)	19.9 (-1.5 to 45.9)	11.8 (-8.0 to 35.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	21.0 (-3.7 to 49.5)	12.8 (-9.8 to 38.8)
Bulimia nervosa	0.7 (0.4 to 1.3)	0.8 (0.4 to 1.4)	7.4 (6.3 to 9.2)	1.0 (0.6 to 1.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	7.5 (1.4 to 13.7)	1.1 (-4.6 to 6.7)
Autistic spectrum disorders	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	20.9 (16.9 to 24.8)	-0.2 (-3.7 to 3.0)
Autism	0.7 (0.7 to 0.8)	0.9 (0.8 to 0.9)	21.2 (20.3 to 22.1)	-4.4 (-0.5 to -0.4)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	20.8 (15.2 to 26.3)	-0.1 (-5.0 to 4.6)
Asperger syndrome	1.1 (1.0 to 1.1)	1.3 (1.2 to 1.4)	21.3 (20.4 to 22.2)	-0.6 (-0.6 to -0.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	21.0 (16.3 to 26.3)	-0.3 (-4.1 to 3.8)
Attention-deficit/hyperactivity disorder	1.6 (1.3 to 1.9)	1.7 (1.4 to 2.0)	3.7 (3.7 to 3.8)	-0.1 (-0.1 to -0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.7 (-2.9 to 10.6)	-0.1 (-6.4 to 6.7)
Conduct disorder	2.3 (2.0 to 2.7)	2.4 (2.0 to 2.8)	3.8 (3.3 to 4.4)	-0.0 (-0.1 to 0.0)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	4.1 (-0.2 to 8.4)	0.3 (-3.7 to 4.5)
Idiopathic intellectual disability	1.3 (0.7 to 1.9)	1.1 (0.6 to 2.1)	3.3 (-42.0 to 74.3)	-15.7 (-52.6 to 41.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	7.3 (-45.4 to 74.9)	-15.8 (-54.4 to 44.2)
Other mental and substance use disorders	4.4 (4.2 to 4.7)	5.9 (5.6 to 6.3)	33.7 (31.7 to 35.6)	0.4 (-0.6 to -0.2)	0.0 (0.2 to 0.4)	0.4 (0.3 to 0.6)	33.3 (28.2 to 38.5)	-0.2 (-3.9 to 3.4)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	2.6 (1.8 to 3.4)	4.2 (3.0 to 5.7)	65.4 (47.5 to 86.1)	13.9 (2.1 to 28.6)
Diabetes mellitus	12.7 (9.3 to 15.3)	27.3 (21.4 to 34.5)	112.9 (64.0 to 192.8)	38.8 (6.3 to 91.9)	0.9 (0.6 to 1.3)	1.9 (1.2 to 2.8)	112.5 (60.2 to 187.7)	38.0 (4.3 to 86.1)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.0 (-8.1 to 12.1)	-21.6 (-27.8 to -14.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.0 (-8.2 to 12.1)	-21.6 (-27.8 to -14.1)
Chronic kidney disease	-	-	-	-	0.9 (0.6 to 1.2)	1.3 (0.9 to 1.7)	45.5 (36.2 to 53.7)	1.1 (-3.6 to 5.5)
Chronic kidney disease due to diabetes mellitus	2.0 (1.4 to 2.6)	4.8 (3.1 to 7.5)	129.1 (60.9 to 312.1)	48.0 (4.0 to 159.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	75.0 (23.9 to 163.7)	11.6 (-19.2 to 69.0)
Chronic kidney disease due to hypertension	3.2 (2.5 to 4.1)	4.9 (3.5 to 7.2)	52.5 (9.3 to 144.6)	8.4 (-18.9 to 67.0)	0.3 (0.2 to 0.4)	0.3 (0.1 to 0.3)	-39.6 (-52.0 to -20.9)	-57.5 (-66.4 to -44.5)
Chronic kidney disease due to glomerulonephritis	4.7 (3.5 to 6.3)	4.7 (3.3 to 6.8)	-3.5 (-29.2 to 62.9)	-32.0 (-49.3 to 13.0)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	158.9 (101.1 to 233.4)	88.6 (46.5 to 140.7)
Chronic kidney disease due to other causes	7.4 (5.7 to 9.4)	15.5 (10.7 to 23.2)	101.3 (49.9 to 234.2)	15.5 (5.3 to 119.7)	0.6 (0.2 to 0.5)	0.6 (0.4 to 0.8)	78.3 (48.0 to 108.9)	24.5 (3.1 to 45.8)
Urinary diseases and male infertility	-	-	-	-	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	66.2 (53.0 to 79.5)	5.3 (-3.2 to 13.6)
Interstitial nephritis and urinary tract infections	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	65.4 (51.4 to 79.9)	27.4 (16.2 to 38.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.8 (35.3 to 98.2)	27.9 (4.3 to 53.6)

Appendix Table G.4 - Iceland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Urolithiasis	3.0 (1.5 to 5.1)	6.3 (3.4 to 10.0)	112.1 (58.3 to 153.7)	0.0 (-0.7 to 56.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	100.7 (53.1 to 139.2)	26.8 (-2.8 to 48.8)
Benign prostatic hyperplasia	5.2 (4.9 to 5.6)	8.6 (8.1 to 9.1)	64.5 (49.7 to 79.2)	2.5 (-6.8 to 11.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	65.0 (49.7 to 80.0)	2.9 (-6.7 to 12.3)
Male infertility due to other causes	1.2 (0.9 to 1.6)	1.3 (0.9 to 1.8)	5.1 (-34.5 to 63.4)	-2.7 (-39.5 to 52.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.5 (-34.3 to 65.4)	-3.0 (-39.1 to 53.8)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.3 (28.1 to 187.0)	21.2 (-18.5 to 81.1)
Gynecological diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	7.1 (12.6 to 48.8)	2.2 (-9.4 to 19.8)
Uterine fibroids	8.9 (7.5 to 10.3)	12.6 (10.8 to 14.6)	42.1 (40.0 to 44.2)	4.1 (4.0 to 4.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	36.6 (23.0 to 102.6)	1.8 (-7.8 to 52.1)
Polycystic ovarian syndrome	4.4 (3.8 to 5.0)	5.4 (4.5 to 6.2)	23.2 (-0.1 to 45.4)	6.9 (-13.8 to 25.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	22.1 (-1.3 to 46.0)	6.1 (-14.4 to 26.8)
Female infertility due to other causes	0.2 (0.0 to 0.6)	0.3 (0.0 to 1.0)	34.0 (-88.6 to 1,768.6)	23.2 (-89.9 to 1,592.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.1 (-89.4 to 1,941.4)	13.2 (-90.4 to 1,740.0)
Endometriosis	0.5 (0.4 to 0.6)	0.6 (0.4 to 0.7)	20.4 (-26.5 to 67.1)	3.8 (-36.6 to 44.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	19.3 (-26.6 to 69.3)	3.2 (-36.3 to 45.8)
Genital prolapse	14.1 (12.7 to 15.6)	20.1 (18.1 to 22.1)	42.8 (23.1 to 63.4)	1.8 (-12.5 to 16.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	42.6 (23.2 to 64.4)	1.9 (-12.3 to 17.2)
Premenstrual syndrome	6.6 (4.6 to 8.8)	7.6 (5.7 to 10.0)	14.7 (-23.2 to 72.3)	1.5 (-32.0 to 52.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	14.8 (-23.5 to 73.0)	1.6 (-32.8 to 54.9)
Other gynecological diseases	0.6 (0.5 to 0.7)	0.7 (0.6 to 1.0)	17.3 (-14.3 to 59.7)	-2.0 (-28.2 to 25.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.6 (-27.6 to 130.9)	-2.8 (-44.2 to 72.3)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	15.7 (7.3 to 30.0)	-1.3 (-8.4 to 12.4)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	9.5 (-4.3 to 32.9)	3.7 (-9.0 to 25.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.9 (-13.1 to 80.1)	11.1 (-23.3 to 70.6)
Thalassemia trait	5.8 (3.7 to 13.0)	7.2 (4.7 to 16.1)	26.8 (19.2 to 36.2)	2.1 (-4.0 to 10.1)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	19.5 (8.5 to 32.2)	1.6 (-7.5 to 11.8)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.0 (-29.4 to 5.3)	0.0 (-36.2 to -4.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.6 (-26.9 to 11.6)	-19.5 (-34.8 to -0.8)
Sickle cell trait	1.9 (1.4 to 2.4)	2.0 (1.4 to 2.6)	5.6 (-14.9 to 26.8)	-14.7 (-30.7 to 3.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.4 (-31.1 to 35.7)	-20.4 (-38.9 to 31.6)
G6PD deficiency	0.7 (0.4 to 1.1)	1.1 (0.7 to 1.5)	58.7 (-11.7 to 189.3)	27.6 (-29.0 to 132.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.6 (31.4 to 65.1)	17.4 (15.3 to 47.1)
G6PD trait	27.8 (24.3 to 30.5)	34.4 (29.9 to 38.7)	23.9 (5.4 to 45.4)	-0.8 (-15.7 to 16.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.5 (-55.0 to 72.0)	-24.6 (-61.7 to 49.7)
Other hemoglobinopathies and hemolytic anemias	1.6 (1.5 to 1.7)	2.1 (1.8 to 2.3)	28.6 (12.5 to 50.9)	1.7 (-11.9 to 19.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	21.7 (-15.6 to 81.3)	1.8 (-30.7 to 52.1)
Endocrine, metabolic, blood, and immune disorders	2.9 (2.8 to 3.0)	3.7 (3.5 to 3.9)	28.5 (17.2 to 37.7)	0.4 (-10.5 to 7.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	30.0 (16.6 to 41.6)	1.4 (-9.6 to 10.9)
Musculoskeletal disorders	-	-	-	-	6.8 (4.9 to 9.0)	9.5 (6.8 to 12.5)	38.9 (26.1 to 51.4)	-0.1 (-9.2 to 8.9)
Rheumatoid arthritis	0.3 (0.3 to 0.4)	0.6 (0.5 to 0.7)	81.1 (44.5 to 116.7)	23.0 (-0.4 to 46.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	82.4 (43.1 to 121.2)	25.5 (-0.8 to 51.6)
Osteoarthritis	13.2 (11.7 to 14.8)	21.1 (18.8 to 23.6)	58.2 (37.5 to 90.5)	-3.5 (-16.6 to 16.8)	0.5 (0.3 to 0.7)	0.7 (0.5 to 1.0)	58.7 (37.4 to 90.8)	-3.0 (-16.3 to 17.3)
Low back and neck pain	-	-	-	-	5.6 (3.9 to 7.5)	7.3 (5.1 to 9.9)	31.3 (16.8 to 44.9)	-3.1 (-13.7 to 7.1)
Low back pain	33.8 (31.5 to 35.7)	45.1 (42.7 to 48.4)	33.2 (23.8 to 46.8)	-1.8 (-8.9 to 7.9)	3.8 (2.6 to 5.2)	5.0 (3.4 to 6.9)	32.5 (23.2 to 46.2)	-1.6 (-8.8 to 8.4)
Neck pain	18.6 (16.2 to 21.0)	23.9 (18.6 to 28.5)	29.5 (-5.0 to 63.7)	-6.2 (-30.2 to 18.9)	1.8 (1.2 to 2.5)	2.3 (1.5 to 3.4)	28.8 (-4.9 to 63.0)	5.1 (-30.2 to 19.0)
Gout	0.5 (0.4 to 0.5)	0.7 (0.7 to 0.8)	61.2 (38.0 to 87.4)	0.0 (-13.5 to 17.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.5 (30.1 to 100.6)	2.1 (-18.0 to 27.3)
Other musculoskeletal disorders	7.8 (6.4 to 9.1)	13.9 (11.2 to 16.5)	78.3 (63.6 to 91.9)	20.5 (12.1 to 28.9)	0.7 (0.5 to 1.0)	1.3 (0.8 to 1.8)	78.5 (62.6 to 92.0)	21.1 (12.5 to 29.5)
Other non-communicable diseases	-	-	-	-	5.1 (3.5 to 7.2)	6.7 (4.6 to 9.4)	30.9 (24.8 to 38.1)	-4.3 (-16.4 to 1.3)
Congenital anomalies	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	49.2 (27.3 to 77.8)	6.4 (-0.8 to 39.7)
Neural tube defects	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	16.5 (-10.9 to 49.4)	-2.0 (-25.2 to 25.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.0 (-20.5 to 62.3)	-1.7 (-33.1 to 37.2)
Congenital heart anomalies	2.6 (2.1 to 3.2)	2.5 (2.2 to 3.0)	-1.7 (-24.2 to 25.6)	-19.9 (-38.1 to 2.3)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	0.7 (-21.3 to 24.2)	-18.5 (-35.3 to 1.8)
Crofacial clefts	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	16.3 (-25.6 to 64.5)	-5.7 (-39.8 to 33.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.5 (-21.5 to 72.5)	-5.6 (-42.4 to 41.3)
Down syndrome	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	35.9 (-3.4 to 77.4)	1.7 (-28.0 to 32.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	2.7 (1.9 to 95.0)	45.8 (-27.2 to 36.1)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.3 (-22.2 to 92.9)	4.2 (-35.3 to 60.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.8 (-25.3 to 96.7)	3.9 (-37.1 to 65.0)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.2 (-15.4 to 118.1)	5.6 (-31.3 to 77.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.8 (-25.7 to 113.5)	4.7 (-36.7 to 79.9)
Chromosomal unbalanced rearrangements	0.6 (0.5 to 0.7)	0.8 (0.6 to 1.1)	42.2 (8.0 to 101.2)	6.4 (-19.1 to 50.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	53.5 (15.7 to 116.4)	8.1 (-18.7 to 52.4)
Other congenital anomalies	0.8 (0.5 to 1.1)	0.8 (0.5 to 1.2)	12.1 (-10.2 to 35.8)	12.1 (-30.4 to 4.3)	0.0 (0.1 to 0.2)	0.0 (0.2 to 0.4)	46.9 (24.8 to 38.1)	46.9 (9.5 to 100.6)
Skin and subcutaneous diseases	-	-	-	-	2.2 (1.4 to 3.3)	2.6 (1.7 to 3.8)	17.8 (6.0 to 28.9)	-2.5 (-12.1 to 6.8)
Dermatitis	23.3 (18.4 to 27.6)	28.0 (22.3 to 32.9)	19.8 (17.5 to 23.0)	-0.0 (-0.2 to 0.1)	0.9 (0.6 to 1.3)	1.0 (0.7 to 1.5)	17.7 (14.3 to 21.9)	0.1 (-2.0 to 2.4)
Psoriasis	3.5 (3.0 to 4.0)	4.6 (4.0 to 5.3)	32.9 (29.5 to 37.1)	-0.1 (-0.2 to 0.1)	0.2 (0.2 to 0.4)	0.3 (0.3 to 0.5)	32.5 (26.3 to 39.4)	0.2 (-3.6 to 4.4)
Cellulitis	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	42.0 (26.6 to 57.0)	0.6 (-8.5 to 9.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.5 (21.4 to 65.1)	0.7 (-13.4 to 17.5)
Pyoderma	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.5)	11.8 (6.4 to 17.1)	-7.1 (-10.6 to -3.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.1 (2.5 to 20.0)	-7.1 (-14.1 to -0.1)
Scabies	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	0.2 (-23.2 to 22.9)	-5.6 (-35.8 to 2.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.3 (-25.1 to 26.0)	-20.8 (-37.6 to 5.9)
Fungal skin diseases	17.6 (15.4 to 19.5)	23.4 (20.8 to 25.9)	33.5 (30.4 to 36.6)	-0.3 (-0.4 to -0.2)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	33.0 (29.6 to 36.4)	-0.2 (-1.1 to 0.8)
Viral skin diseases	5.8 (4.5 to 7.0)	6.6 (5.3 to 8.0)	14.8 (11.3 to 19.3)	0.4 (-2.1 to 0.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	14.6 (10.0 to 20.2)	0.4 (-3.0 to 4.0)
Acne vulgaris	44.8 (29.8 to 59.3)	43.1 (32.0 to 54.4)	-4.2 (-38.2 to 59.4)	-11.1 (-43.5 to 48.0)	0.5 (0.2 to 1.0)	0.5 (0.2 to 0.9)	-4.3 (-38.3 to 59.5)	-10.9 (-43.6 to 48.5)
Alopecia areata	0.4 (0.4 to 0.4)	0.6 (0.5 to 0.6)	36.1 (22.4 to 51.6)	0.3 (-9.1 to 11.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.3 (18.8 to 54.5)	0.3 (-11.6 to 14.9)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	43.4 (-18.6 to 131.9)	-1.9 (-44.7 to 56.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.8 (-23.8 to 142.9)	-2.1 (-47.7 to 65.2)
Urticaria	2.0 (1.5 to 2.7)	2.6 (1.8 to 3.5)	24.2 (-13.0 to 94.1)	8.9 (-36.4 to 39.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	23.2 (-13.7 to 92.3)	2.2 (-8.8 to 41.0)
Decubitus ulcer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	70.2 (31.2 to 133.9)	6.6 (-17.1 to 46.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.3 (25.6 to 132.7)	7.0 (-19.5 to 48.3)
Other skin and subcutaneous diseases	19.7 (12.0 to 32.2)	28.7 (16.8 to 48.0)	44.9 (32.0 to 55.5)	-0.7 (-3.5 to 2.3)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	44.6 (31.1 to 55.7)	-0.6 (-3.6 to 2.5)
Sense organ diseases	-	-	-	-	1.7 (1.2 to 2.5)	2.5 (1.7 to 3.5)	42.1 (31.8 to 53.9)	-9.2 (-15.3 to -2.3)
Glaucoma	0.7 (0.5 to 0.9)	0.6 (0.4 to 0.8)	-13.4 (-31.3 to 7.4)	-4.5 (-54.8 to 32.5)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-17.8 (-37.2 to 4.4)	-47.2 (-58.1 to -34.9)
Cataract	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.9)	23.0 (-9.3 to 64.3)	-27.7 (-47.3 to -4.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	63.3 (18.9 to 114.3)	-4.7 (-29.6 to 24.7)
Macular degeneration	0.7 (0.5 to 1.0)	1.3 (0.9 to 1.8)	91.1 (63.3 to 119.4)	10.4 (-5.5 to 26.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	71.9 (46.5 to 102.2)	-1.0 (-15.9 to 15.7)
Uncorrected refractive error	25.9 (20.4 to 32.9)	35.9 (29.0 to 43.5)	37.5 (6.5 to 84.1)	-9.6 (-29.9 to 22.4)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.8)	30.8 (9.6 to 63.1)	-11.9 (-26.4 to 10.3)
Age-related and other hearing loss	32.3 (28.0 to 36.5)	47.2 (40.1 to 54.4)	46.1 (37.0 to 53.3)	-9.2 (-14.2 to -4.8)	0.9 (0.6 to 1.4)	1.4 (0.9 to 2.1)	52.9 (38.6 to 67.8)	-5.8 (-13.9 to 2.2)
Other vision loss	0.6 (0.5 to 0.8)	0.6 (0.4 to 0.7)	3.2 (-15.8 to 10.9)	-3.9 (-42.2 to -23.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	11.2 (-6.7 to 31.2)	-23.5 (-35.6 to -0.4)
Other sense organ diseases	5.9 (5.7 to 6.2)	7.7 (7.3 to 8.1)	29.1 (21.6 to 37.8)	-0.1 (-5.7 to 6.6)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	28.3 (20.0 to 37.5)	0.1 (-6.2 to 7.6)
Oral disorders	-	-	-	-	0.7 (0.5 to 1.1)	1.0 (0.6 to 1.5)	35.1 (25.1 to 46.2)	-8.6 (-15.7 to -1.6)
Deciduous caries	9.5 (9.1 to 9.9)	10.0 (9.5 to 10.5)	5.7 (-1.2 to 12.8)	3.1 (-3.6 to 10.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.5 (-5.5 to 19.1)	2.9 (-7.9 to 16.1)
Permanent caries	120.1 (113.1 to 127.5)	144.4 (135.0 to 153.3)	20.2 (11.1 to 30.5)	20.2 (-10.0 to 5.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	19.7 (10.8 to 30.7)	2.9 (-9.8 to 5.9)
Periodontal diseases	21.4 (18.7 to 24.3)	33.4 (30.0 to 37.0)	55.7 (32.9 to 85.7)	3.8 (-11.3 to 23.9)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.4)	55.7 (32.7 to 85.8)	3.8 (-11.5 to 23.9)
Edentulism and severe tooth loss	14.9 (13.5 to 16.2)	19.7 (17.8 to 21.6)	32.8 (15.0 to 53.1)	-17.3 (-28.5 to -4.7)	0.4 (0.3 to 0.6)	0.5 (0.4 to 0.7)	32.8 (14.7 to 53.2)	-17.2 (-28.4 to -4.6)

Appendix Table G.4 - Iceland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	4.6 (4.3 to 4.8)	5.9 (5.6 to 6.3)	30.5 (21.5 to 40.4)	0.5 (-6.5 to 8.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	30.2 (21.4 to 41.3)	0.5 (-6.7 to 9.0)
Injuries	-	-	-	-	2.5 (1.9 to 3.2)	2.3 (1.7 to 3.1)	-8.6 (-18.6 to 2.6)	-39.5 (-46.0 to -32.4)
Transport injuries	-	-	-	-	0.5 (0.4 to 0.6)	0.2 (0.2 to 0.3)	-64.4 (-51.8 to -39.5)	-62.5 (-66.2 to -57.5)
Road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.2 (0.1 to 0.2)	-53.4 (-58.4 to -47.2)	-67.2 (-70.8 to -62.9)
Pedestrian road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-74.0 (-77.3 to -49.8)	-42.0 (-84.3 to -79.1)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.9 (-58.2 to -41.3)	-64.0 (-69.4 to -57.0)
Motorcyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.6 (-56.1 to -31.4)	-61.6 (-68.8 to -51.5)
Motor vehicle road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.2)	-51.4 (-56.7 to -45.1)	-65.9 (-69.6 to -61.3)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.6 (-61.0 to -46.5)	-48.7 (-73.2 to -43.1)
Other transport injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	5.5 (-14.3 to 4.9)	-34.7 (-40.6 to -27.4)
Unintentional injuries	-	-	-	-	2.0 (1.6 to 2.6)	2.0 (1.5 to 2.7)	-0.1 (-11.5 to 12.0)	-34.3 (-41.5 to -26.8)
Falls	-	-	-	-	1.5 (1.2 to 1.9)	1.6 (1.1 to 2.1)	3.5 (-10.2 to 18.4)	-33.2 (-41.6 to -24.1)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.8 (-41.6 to -23.2)	-53.6 (-59.6 to -47.0)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.3 (-37.9 to -13.6)	-50.5 (-58.3 to -42.1)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.5 (-49.2 to -27.5)	-58.0 (-64.2 to -48.8)
Exposure to mechanical forces	-	-	-	-	0.4 (0.3 to 0.5)	0.2 (0.2 to 0.3)	-37.2 (-44.7 to -29.6)	-53.6 (-58.8 to -48.1)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.6 (-43.0 to -20.0)	-47.8 (-56.6 to -39.0)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.1 (-13.0 to 23.0)	-24.5 (-37.4 to -11.1)
Other exposure to mechanical forces	-	-	-	-	0.4 (0.3 to 0.5)	0.2 (0.2 to 0.3)	-37.4 (-44.8 to -29.8)	-53.7 (-58.9 to -48.2)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.8 (31.4 to 58.4)	1.4 (-7.9 to 10.7)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.6 (8.0 to 34.9)	-10.2 (-19.9 to 0.0)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.2 (-0.0 to 38.3)	-10.7 (-24.2 to 4.9)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.3 (7.7 to 37.4)	-9.9 (-20.5 to 1.3)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.5 (-9.8 to 12.6)	-23.4 (-32.2 to -13.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.7 (-13.4 to 19.9)	-25.4 (-37.2 to -12.2)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.8 (-1.3 to 23.3)	-13.1 (-23.1 to -1.6)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.9 (-14.3 to 13.1)	-25.4 (-36.0 to -12.6)
Other unintentional injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	205.2 (167.9 to 255.0)	93.7 (69.9 to 124.5)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.9 (-14.6 to 4.4)	-35.0 (-40.9 to -28.0)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.1 (0.3 to 28.7)	-22.8 (-31.3 to -11.9)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.0 (-30.0 to -13.4)	-45.3 (-50.8 to -39.2)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.8 (-27.9 to -9.0)	-42.5 (-48.9 to -35.7)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.4 (-50.8 to -38.8)	-61.3 (-65.1 to -56.5)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.9 (-28.5 to -10.3)	-43.9 (-50.0 to -37.2)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	154.9 (79.4 to 288.3)	124.4 (56.5 to 244.4)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	154.9 (79.4 to 288.3)	124.4 (56.5 to 244.4)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - India prevalence and VIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VIDs 1990 (thousands)	VIDs 2013 (thousands)	% change VIDs, 1990 to 2013	% change age-standardized VIDs, 1990 to 2013
All causes	-	-	-	-	91,854.8 (67,342.3 to 119,110.5)	133,118.3 (98,239.5 to 172,767.7)	45.0 (41.3 to 49.0)	45.0 (-9.3 to 5.2)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	24,124.6 (16,864.9 to 33,372.6)	23,434.9 (16,512.1 to 32,003.1)	-2.9 (-7.4 to 2.4)	-2.9 (-32.6 to -26.1)
HIV/AIDS and tuberculosis	-	-	-	-	920.3 (637.0 to 1,230.7)	1,041.8 (714.5 to 1,382.4)	12.9 (4.7 to 25.4)	33.5 (-38.1 to -26.8)
Tuberculosis	2,462.4 (2,359.9 to 2,563.8)	2,949.6 (2,844.6 to 3,062.3)	20.1 (15.9 to 24.3)	-31.2 (-33.4 to -28.9)	737.3 (507.9 to 937.7)	888.2 (605.1 to 1,187.0)	20.5 (13.6 to 27.4)	-30.6 (-34.3 to -26.8)
HIV/AIDS	-	-	-	-	183.1 (104.5 to 275.9)	153.6 (93.5 to 252.2)	-16.3 (-41.1 to -43.8)	-48.3 (-62.7 to -7.7)
HIV/AIDS resulting in mycobacterial infection	48.4 (21.8 to 86.0)	18.7 (9.2 to 32.1)	-61.6 (-77.0 to -28.3)	-78.4 (-87.1 to -59.5)	18.0 (7.1 to 34.1)	7.3 (2.9 to 13.9)	-60.0 (-78.4 to -18.6)	-77.2 (-87.0 to -52.4)
HIV/AIDS resulting in other diseases	1,698.8 (1,331.1 to 2,009.3)	1,338.7 (1,229.5 to 1,450.2)	-22.3 (-35.3 to 0.4)	-48.7 (-57.7 to -33.6)	165.1 (88.6 to 255.8)	146.3 (87.3 to 242.8)	-14.2 (-38.6 to 56.7)	-45.1 (-60.9 to 3.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	3,932.6 (2,780.1 to 5,311.6)	4,270.3 (3,005.5 to 5,803.9)	8.4 (3.3 to 15.3)	-14.1 (-17.7 to -9.8)
Diarrheal diseases	14,168.0 (13,537.4 to 14,789.5)	14,332.6 (13,707.3 to 15,017.5)	1.2 (-4.7 to 8.1)	-14.5 (-19.3 to -8.9)	156.3 (1,551.9 to 3,113.7)	2,314.3 (1,583.5 to 3,153.1)	1.5 (-5.1 to 38.8)	-13.9 (-19.2 to -7.9)
Intestinal infectious diseases	-	-	-	-	106.2 to 219.6	76.4 to 157.5	-41.3 to -11.6	-53.9 to -32.2
Typhoid fever	897.9 (732.5 to 1,056.2)	671.4 (582.7 to 771.9)	-24.9 (-40.9 to -3.4)	-42.3 (-53.8 to -26.9)	116.9 (76.7 to 170.7)	88.4 (59.0 to 126.5)	8.4 (-4.1 to -0.4)	-41.4 (-54.0 to -23.7)
Paratyphoid fever	655.9 (530.3 to 808.7)	438.1 (350.1 to 532.3)	-32.9 (-51.6 to -10.5)	-47.5 (-61.6 to -30.9)	33.6 (20.9 to 50.7)	22.8 (13.8 to 35.7)	22.8 (-5.1 to -6.0)	-46.7 (-61.3 to -26.6)
Other intestinal infectious diseases	-	-	-	-	20.5 to 7.7	1.1	-81.0	-85.2
Lower respiratory infections	560.8 (518.2 to 605.7)	504.7 (464.6 to 554.7)	-9.8 (-19.6 to 0.8)	-25.9 (-33.7 to -18.1)	58.2 (39.5 to 82.2)	52.4 (35.1 to 75.0)	-10.1 (-24.2 to 5.1)	-25.6 (-35.9 to -14.5)
Upper respiratory infections	52,646.7 (50,024.4 to 55,329.2)	74,408.4 (71,168.6 to 77,673.5)	41.4 (33.3 to 51.1)	-0.4 (-5.9 to 6.1)	615.2 (341.9 to 1,007.6)	872.4 (483.8 to 1,456.3)	41.7 (33.0 to 51.9)	6.2 (-5.8 to 19.2)
Otitis media	14,261.3 (13,177.4 to 15,337.6)	17,260.6 (15,886.1 to 18,739.8)	21.2 (12.2 to 32.3)	-11.8 (-18.4 to -3.8)	309.5 (183.3 to 490.0)	369.2 (219.5 to 587.3)	19.2 (8.4 to 31.9)	-11.6 (-19.3 to -1.6)
Meningitis	-	-	-	-	343.7 (232.6 to 474.6)	401.0 (275.2 to 557.3)	16.9 (-1.1 to 36.4)	-19.3 (-31.1 to -7.2)
Pneumococcal meningitis	1,494.4 (964.2 to 2,207.8)	1,954.7 (1,195.1 to 3,012.3)	29.6 (3.1 to 65.1)	-15.7 (-32.4 to 6.5)	147.0 (95.6 to 210.9)	175.0 (121.1 to 240.4)	20.3 (-12.0 to 61.2)	-18.6 (-39.0 to 6.7)
H influenzae type B meningitis	675.8 (278.5 to 1,212.0)	755.2 (276.9 to 1,464.1)	10.3 (-17.5 to 38.4)	-24.8 (-43.7 to -6.2)	75.1 (48.8 to 110.0)	85.4 (50.5 to 128.9)	13.3 (-16.3 to 60.1)	-18.1 (-39.1 to 13.1)
Meningococcal meningitis	136.2 (42.2 to 272.3)	182.8 (57.9 to 384.1)	33.3 (7.8 to 76.1)	-17.4 (-42.8 to 10.8)	17.8 (9.6 to 29.0)	24.2 (13.0 to 40.0)	35.7 (2.0 to 81.0)	-14.6 (-30.7 to 13.0)
Other meningitis	816.2 (436.8 to 1,391.6)	954.6 (487.9 to 1,712.1)	15.2 (-10.2 to 47.0)	-22.0 (-39.0 to -1.2)	103.8 (65.5 to 161.7)	116.3 (76.1 to 167.0)	14.6 (-18.5 to 41.9)	-20.7 (-42.7 to -3.3)
Encephalitis	484.9 (210.1 to 1,017.6)	515.8 (218.4 to 1,164.8)	6.2 (-17.4 to 21.7)	-32.5 (-46.9 to -23.2)	59.0 (40.3 to 80.4)	66.4 (45.1 to 90.8)	11.5 (-6.5 to 36.0)	-26.6 (-39.1 to -12.1)
Diphtheria	0.8 (0.1 to 3.1)	0.4 (0.1 to 1.2)	-47.5 (-94.8 to 55.0)	-37.7 (-46.6 to 0.1)	0.2 (0.0 to 0.2)	0.0	-37.7 (-94.9 to 560.1)	-46.5 (-94.9 to 374.8)
Whooping cough	1,062.7 (817.9 to 1,369.3)	889.4 (687.7 to 1,142.4)	-16.1 (-17.1 to -15.1)	-18.6 (-19.6 to -17.6)	52.4 (30.4 to 84.0)	44.2 (25.6 to 72.0)	-15.6 (-21.6 to -8.4)	-18.1 (-23.9 to -11.1)
Tetanus	709.7 (360.7 to 1,308.2)	127.0 (69.1 to 216.1)	-82.3 (-92.4 to -53.9)	-87.6 (-94.7 to -67.2)	27.1 (14.6 to 47.1)	9.6 (5.5 to 17.4)	-64.8 (-83.3 to -21.7)	-73.0 (-81.0 to -41.8)
Measles	224.1 (170.3 to 289.3)	76.1 (60.3 to 93.4)	-65.9 (-69.1 to -62.0)	-65.9 (-70.6 to -63.8)	20.0 (12.0 to 31.4)	5.8 (3.8 to 11.0)	-66.0 (-74.3 to -54.6)	-47.7 (-75.5 to -56.7)
Varicella and herpes zoster	638.9 (574.7 to 703.3)	825.8 (722.8 to 932.0)	28.8 (12.4 to 49.1)	-3.3 (-18.3 to 18.1)	13.8 (7.8 to 21.3)	21.6 (12.2 to 33.8)	55.0 (12.1 to 118.4)	-5.8 (-32.2 to 35.5)
Neglected tropical diseases and malaria	-	-	-	-	2,748.1 (1,793.4 to 3,950.5)	2,668.3 (1,773.4 to 3,823.8)	-2.6 (-15.7 to 11.4)	-34.3 (-43.9 to -24.9)
Malaria	54,834.3 (52,069.5 to 57,928.4)	70,654.4 (66,828.3 to 74,324.3)	29.1 (23.2 to 34.7)	-11.9 (-16.0 to -8.2)	464.3 (303.8 to 682.2)	564.2 (372.9 to 831.2)	21.1 (9.7 to 36.9)	-15.3 (-22.9 to -4.6)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.0	-	-
Leishmaniasis	-	-	-	-	3.7 (2.1 to 6.1)	4.4 (2.5 to 7.2)	20.5 (6.8 to 61.8)	-4.8 (-25.0 to 24.7)
Visceral leishmaniasis	52.0 (35.6 to 74.3)	62.0 (43.5 to 87.7)	19.2 (-3.7 to 51.4)	-5.1 (-23.0 to 18.3)	3.7 (2.1 to 6.1)	4.4 (2.5 to 7.2)	20.4 (7.0 to 61.8)	-4.8 (-25.1 to 25.0)
Cutaneous and mucocutaneous leishmaniasis	1.3 (1.0 to 1.7)	1.8 (1.4 to 2.4)	39.5 (12.1 to 76.6)	-13.0 (-29.7 to 10.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.5 (12.1 to 76.6)	-13.0 (-29.8 to 10.1)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.0	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.0	-	-
Cysticercosis	220.0 (134.3 to 322.1)	198.9 (110.5 to 347.6)	-10.8 (-56.9 to 68.7)	-42.1 (-72.0 to 4.7)	65.3 (34.5 to 106.5)	65.4 (31.8 to 120.7)	-0.1 (-55.4 to 92.7)	-36.3 (-70.4 to 18.8)
Cystic echinococcosis	176.0 (155.4 to 201.6)	126.5 (110.9 to 152.5)	-28.4 (-34.2 to -19.2)	-55.8 (-58.5 to -52.0)	16.2 (10.3 to 23.8)	11.8 (7.4 to 17.8)	11.8 (-4.1 to -8.7)	-27.6 (-62.8 to -44.7)
Lymphatic filariasis	22,083.3 (19,084.4 to 25,938.8)	7,162.9 (4,645.3 to 10,364.6)	-67.6 (-78.3 to -56.5)	-78.8 (-85.9 to -72.0)	700.5 (334.7 to 1,236.0)	596.6 (293.6 to 1,069.3)	-12.0 (-54.5 to 20.3)	-46.5 (-72.0 to -26.9)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.0	-	-
Trachoma	1,535.7 (1,059.3 to 2,097.3)	758.4 (554.5 to 996.7)	-50.5 (-65.2 to -25.8)	-75.3 (-82.3 to -63.4)	99.9 (63.4 to 146.8)	51.6 (34.0 to 75.7)	-48.5 (-60.6 to -29.9)	-74.1 (-80.1 to -65.1)
Dengue	158.1 (64.0 to 347.4)	1,108.0 (453.4 to 2,427.2)	602.8 (597.8 to 608.6)	390.4 (386.9 to 394.5)	25.6 (9.2 to 60.7)	179.7 (63.7 to 437.5)	601.1 (479.7 to 757.3)	392.5 (314.4 to 484.0)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.0	-	-
Rabies	0.8 (0.6 to 0.9)	0.5 (0.3 to 0.6)	-38.0 (-54.0 to -22.5)	-57.7 (-67.7 to -47.3)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-38.0 (-54.0 to -22.5)	57.6 (-67.7 to -47.2)
Intestinal nematode infections	-	-	-	-	670.0 (378.7 to 1,122.1)	637.9 (372.8 to 1,034.8)	-4.2 (-21.7 to 16.0)	-28.5 (-41.0 to -13.3)
Ascariasis	149,718.6 (118,302.3 to 190,175.6)	212,634.5 (158,616.0 to 284,283.2)	42.2 (-3.7 to 106.8)	-2.6 (-35.7 to 45.6)	392.7 (202.9 to 714.9)	234.4 (123.6 to 408.2)	40.1 (-55.0 to -20.2)	51.4 (-63.3 to -34.4)
Trichuriasis	43,761.5 (32,016.2 to 57,903.7)	63,747.8 (46,233.1 to 87,266.3)	43.9 (-3.5 to 131.3)	-2.8 (-36.6 to 62.4)	19.4 (9.9 to 34.2)	27.5 (13.5 to 48.7)	40.5 (-12.5 to 144.1)	-2.0 (-41.0 to 72.3)
Hookworm disease	65,983.9 (51,811.5 to 84,131.9)	98,581.3 (73,280.6 to 130,786.9)	49.0 (5.9 to 119.6)	49.0 (-31.8 to 47.5)	49.0 (155.7 to 403.1)	49.0 (219.5 to 595.1)	49.0 (11.7 to 87.3)	49.0 (25.4 to 25.0)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.0	-	-
Other neglected tropical diseases	18,796.0 (14,856.6 to 22,851.0)	16,088.3 (15,221.5 to 17,309.2)	-14.3 (-30.2 to 9.1)	-33.0 (-44.5 to -16.7)	702.4 (436.8 to 1,036.1)	556.5 (362.1 to 807.6)	-22.1 (-31.0 to 8.7)	-37.2 (-44.3 to -13.9)
Maternal disorders	-	-	-	-	631.3 (414.2 to 871.3)	684.6 (456.4 to 957.0)	9.1 (-8.0 to 24.9)	-30.6 (-41.0 to -20.9)
Maternal hemorrhage	223.2 (166.7 to 288.6)	218.8 (149.4 to 298.9)	-2.7 (-38.1 to 58.3)	34.5 (-58.5 to 6.3)	11.5 (6.7 to 17.5)	10.2 (5.8 to 15.7)	-10.4 (-47.9 to 50.9)	39.8 (-64.8 to 0.9)
Maternal sepsis and other maternal infections	727.0 (467.5 to 1,055.8)	575.4 (374.6 to 842.1)	-21.0 (-37.5 to -2.1)	-19.9 (-61.7 to -39.0)	10.0 (5.5 to 16.9)	7.2 (3.6 to 12.7)	-28.0 (-53.4 to 8.6)	-28.0 (-69.0 to -29.9)
Maternal hypertensive disorders	282.1 (170.7 to 425.6)	264.4 (160.8 to 401.8)	-6.8 (-16.0 to 9.0)	-36.7 (-42.2 to -26.3)	15.1 (7.7 to 25.3)	13.9 (7.1 to 23.6)	-8.8 (-26.4 to 12.2)	-37.9 (-49.6 to -23.5)
Obstructed labor	1,512.4 (1,261.8 to 1,787.6)	1,650.9 (1,412.7 to 1,898.3)	9.7 (-0.9 to 20.0)	-31.0 (-37.3 to -24.6)	494.2 (325.9 to 682.8)	542.5 (358.4 to 746.0)	10.0 (-2.3 to 22.5)	-30.7 (-38.2 to -22.9)
Complications of abortion	2.2 (1.1 to 3.5)	2.8 (1.6 to 4.5)	27.3 (-28.4 to 168.9)	-18.4 (-53.7 to 72.3)	0.3 (0.1 to 0.4)	0.3 (0.2 to 0.6)	0.3 (-28.9 to 173.6)	-18.3 (-53.7 to 76.0)
Other maternal disorders	-	-	-	-	100.2 (52.9 to 167.8)	110.5 (59.6 to 187.9)	15.8 (-44.1 to 100.3)	-24.9 (-63.7 to 29.0)
Neonatal disorders	-	-	-	-	859.6 (532.5 to 1,291.0)	2,797.4 (1,914.1 to 3,856.6)	225.2 (122.1 to 400.4)	147.5 (68.3 to 279.0)
Preterm birth complications	2,645.2 (1,786.1 to 3,919.5)	9,874.7 (7,294.1 to 13,183.8)	275.7 (201.8 to 381.3)	165.2 (113.8 to 238.2)	230.3 (139.6 to 348.8)	1,189.7 (801.5 to 1,663.1)	416.1 (247.3 to 707.3)	285.5 (162.1 to 493.8)
Neonatal encephalopathy due to birth asphyxia and trauma	7,318.9 (1,820.6 to 13,662.2)	7,862.6 (3,287.8 to 13,171.3)	7.0 (-13.4 to 100.1)	-2.4 (-39.7 to 41.7)	308.2 (147.0 to 543.5)	694.2 (443.9 to 1,003.8)	128.0 (42.7 to 300.0)	74.8 (-7.4 to 246.6)
Neonatal sepsis and other neonatal infections	7.7 (2.6 to 14.7)	15.0 (4.9 to 31.7)	90.7 (72.7 to 129.6)	97.3 (78.6 to 137.4)	1.0 (0.3 to 2.2)	2.0 (0.6 to 4.5)	2.0 (-64.7 to 173.6)	92.7 (70.3 to 140.8)
Hemolytic disease and other neonatal jaundice	409.0 (162.5 to 858.2)	1,648.5 (698.4 to 3,392.6)	307.2 (27.7 to 1,370.3)	220.8 (3.2 to 1,059.6)	144.6 (55.6 to 295.6)	492.9 (229.5 to 928.3)	243.3 (21.4 to 1,052.3)	164.1 (-4.9 to 783.7)
Other neonatal disorders	-	-	-	-	175.5 (94.9 to 346.2)	418.7 (225.2 to 698.4)	85.0 (9.3 to 424.8)	85.0 (-16.9 to 297.2)
Nutritional deficiencies	-	-	-	-	14,274.6 (9,540.8 to 20,250.2)	11,203.2 (7,432.8 to 16,136.4)	-21.5 (-27.3 to -15.8)	-42.6 (-46.1 to -38.7)
Protein-energy malnutrition	10,959.8 (7,030.4 to 16,520.3)	7,838.0 (4,446.0 to 12,439.8)	-30.1 (-63.0 to 41.2)	31.0 (-62.5 to 37.5)	31.0 (698.0 to 2,346.8)	235.9 (466.6 to 1,798.5)	97.2 (-62.6 to 41.9)	-31.1 (-62.6 to 37.4)
Iodine deficiency	34,357.9 (30,621.3 to 38,233.5)	31,376.3 (26,896.6 to 35,927.1)	-8.5 (-50.6 to -28.0)	-40.2 (-50.6				

Appendix Table G.4 - India prevalence and VIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VIDs 1990 (thousands)	VIDs 2013 (thousands)	% change VIDs, 1990 to 2013	% change age-standardized VIDs, 1990 to 2013
Iron-deficiency anemia	136,327.2 (332,529.1 to 340,006.9)	303,138.3 (301,291.2 to 304,846.5)	-9.7 (-10.8 to -8.6)	-66.9 (-37.6 to -36.3)	12,093.9 (8,100.2 to 17,384.0)	9,505.5 (6,347.9 to 13,712.9)	-21.5 (-23.5 to -19.2)	-43.8 (-45.4 to -42.2)
Other nutritional deficiencies	-	-	-	-	103.3 (42.9 to 214.6)	85.0 (34.3 to 198.0)	-20.8 (-66.6 to 104.8)	-22.1 (-66.9 to 97.0)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	758.0 (495.2 to 1,097.2)	769.3 (499.7 to 1,178.0)	0.5 (-10.0 to 18.7)	-26.0 (-33.2 to -14.6)
Sexually transmitted diseases excluding HIV	-	-	-	-	155.6 (93.5 to 264.5)	220.3 (128.3 to 389.8)	41.5 (18.6 to 66.3)	-13.3 (-26.1 to 0.1)
Syphilis	86.5 (76.9 to 97.2)	58.1 (51.1 to 64.4)	-32.9 (-41.3 to -21.5)	-60.9 (-65.4 to -45.3)	15.9 (10.4 to 22.6)	10.7 (6.7 to 15.5)	-31.4 (-49.6 to -11.5)	-40.9 (-50.1 to -49.9)
Chlamydial infection	9,134.2 (8,042.6 to 10,370.6)	13,674.7 (12,382.8 to 15,133.2)	50.3 (27.2 to 76.3)	-3.3 (-17.4 to 12.2)	36.1 (19.7 to 61.6)	51.0 (28.5 to 86.0)	41.8 (21.0 to 94.5)	-8.8 (-35.2 to 22.6)
Gonococcal infection	4,916.1 (4,011.8 to 5,885.1)	7,711.7 (6,342.5 to 9,904.7)	58.2 (20.0 to 106.2)	4.9 (-19.4 to 35.0)	43.7 (24.8 to 72.6)	71.8 (40.9 to 113.5)	64.5 (16.0 to 130.1)	9.5 (-21.3 to 50.8)
Trichomoniasis	8,976.3 (6,556.6 to 11,866.3)	13,406.6 (9,880.6 to 17,789.6)	48.5 (-0.2 to 132.0)	-3.8 (-33.4 to 51.1)	15.2 (5.9 to 33.2)	22.8 (8.2 to 47.4)	48.3 (-4.2 to 140.4)	-3.6 (-36.6 to 54.6)
Genital herpes	147,999.1 (138,428.1 to 158,180.8)	220,539.9 (204,260.1 to 236,975.6)	49.5 (35.3 to 65.4)	-22.8 (-20.5 to -4.4)	39.9 (28.8 to 95.8)	58.7 (18.2 to 139.7)	46.8 (30.3 to 65.0)	-32.9 (-21.3 to -3.2)
Other sexually transmitted diseases	214.1 (154.8 to 281.5)	181.9 (142.9 to 234.3)	-15.4 (-27.8 to 2.1)	-48.7 (-56.4 to -38.6)	4.8 (2.9 to 7.3)	5.4 (3.3 to 8.3)	13.4 (-24.1 to 67.8)	29.5 (-50.7 to 2.1)
Hepatitis	-	-	-	-	60.4 (38.8 to 88.4)	76.2 (49.3 to 110.7)	26.1 (14.3 to 38.7)	-14.4 (-22.4 to -5.8)
Hepatitis A	1,320.2 (1,263.9 to 1,375.9)	1,500.5 (1,453.1 to 1,547.5)	13.8 (12.6 to 15.1)	-7.2 (-7.4 to -6.9)	27.6 (17.7 to 40.8)	37.4 (24.2 to 54.5)	36.1 (20.3 to 52.7)	1.4 (-10.3 to 13.4)
Hepatitis B	32,396.0 (30,501.1 to 34,252.8)	32,931.7 (30,551.6 to 35,252.9)	1.8 (-7.6 to 11.1)	-32.1 (-38.1 to -26.0)	13.8 (8.4 to 20.3)	15.8 (9.8 to 24.3)	13.6 (-1.0 to 43.5)	-31.1 (-46.5 to -12.3)
Hepatitis C	16,048.9 (14,707.4 to 17,440.6)	18,226.0 (16,916.6 to 20,137.7)	15.6 (1.8 to 31.3)	-29.9 (-37.6 to -21.3)	1.9 (1.2 to 2.8)	2.1 (1.3 to 3.2)	12.0 (-14.0 to 48.9)	-2.7 (-4.8 to -2.7)
Hepatitis E	663.4 (587.3 to 743.4)	780.9 (701.1 to 872.4)	18.2 (0.0 to 38.1)	-17.3 (-30.8 to -3.3)	17.2 (11.0 to 25.5)	20.8 (13.2 to 31.1)	22.1 (-2.9 to 50.7)	-17.3 (-34.9 to 3.2)
Leprosy	177.8 (148.2 to 208.3)	333.3 (289.8 to 381.6)	88.0 (71.6 to 108.7)	7.2 (-2.2 to 17.9)	9.0 (5.8 to 13.2)	19.9 (12.8 to 28.5)	120.6 (90.2 to 159.2)	23.4 (7.7 to 42.2)
Other infectious diseases	14,300.7 (11,930.7 to 17,066.3)	12,142.8 (11,253.3 to 13,338.6)	-15.0 (-24.4 to -4.1)	-36.0 (-42.9 to -28.1)	532.9 (335.4 to 768.1)	452.9 (294.8 to 582.2)	-15.9 (-28.3 to 4.8)	-33.9 (-44.5 to -18.1)
Non-communicable diseases	-	-	-	-	62,453.9 (46,088.1 to 80,295.7)	102,119.9 (75,051.1 to 131,366.9)	63.5 (59.6 to 67.9)	-0.6 (-2.7 to 1.8)
Neoplasms	-	-	-	-	276.1 (198.8 to 371.0)	536.3 (370.0 to 728.1)	93.5 (57.6 to 141.1)	9.9 (-9.5 to 35.3)
Esophageal cancer	65.5 (49.9 to 85.2)	123.2 (92.1 to 158.0)	88.6 (34.6 to 162.8)	-1.0 (-28.8 to 37.6)	10.4 (6.9 to 14.6)	18.6 (12.3 to 26.1)	77.7 (33.3 to 145.9)	-7.0 (-30.3 to 29.3)
Stomach cancer	109.3 (90.9 to 130.3)	160.3 (131.1 to 196.2)	47.0 (15.0 to 91.6)	-22.2 (-39.2 to 1.4)	14.8 (10.4 to 20.1)	20.5 (13.7 to 28.6)	38.7 (15.2 to 81.9)	-26.7 (-44.7 to -3.9)
Liver cancer	-	-	-	-	7.4 (4.9 to 10.4)	14.5 (9.4 to 20.9)	96.4 (51.7 to 163.3)	2.5 (-25.1 to 38.0)
Liver cancer due to hepatitis B	14.0 (9.1 to 19.7)	34.1 (21.8 to 48.8)	144.1 (38.9 to 326.4)	28.5 (-27.1 to 127.6)	2.6 (1.6 to 3.8)	5.9 (3.6 to 8.8)	131.8 (46.4 to 256.0)	21.6 (-24.2 to 87.9)
Liver cancer due to hepatitis C	4.4 (2.7 to 6.7)	19.9 (12.1 to 31.1)	343.8 (150.5 to 761.1)	135.3 (31.5 to 345.4)	0.8 (0.5 to 1.3)	3.5 (2.1 to 5.5)	322.0 (152.0 to 601.9)	121.5 (33.5 to 269.3)
Liver cancer due to alcohol use	12.1 (7.8 to 17.5)	9.3 (5.0 to 22.4)	-23.3 (-30.7 to 122.9)	-36.6 (-64.5 to 13.2)	2.2 (1.4 to 3.2)	2.7 (1.6 to 4.1)	22.0 (-23.5 to 99.3)	-60.7 (-67.9 to -0.1)
Liver cancer due to other causes	9.7 (6.1 to 13.9)	13.8 (8.1 to 21.5)	43.4 (-24.9 to 168.1)	-24.3 (-60.2 to 42.1)	1.8 (1.1 to 2.7)	2.4 (1.4 to 3.8)	32.6 (-18.9 to 126.5)	-30.0 (-56.2 to 20.8)
Larynx cancer	69.1 (51.8 to 92.9)	135.0 (98.5 to 190.1)	93.7 (38.5 to 173.1)	4.3 (-23.9 to 45.7)	7.1 (4.4 to 10.5)	13.1 (8.2 to 20.2)	83.0 (29.8 to 164.0)	-2.6 (-30.4 to 39.9)
Tracheal, bronchus and lung cancer	53.1 (43.8 to 63.2)	107.8 (87.2 to 134.0)	101.6 (53.5 to 177.0)	5.2 (-19.4 to 42.3)	9.2 (6.3 to 12.7)	17.5 (11.6 to 24.5)	87.7 (39.4 to 162.6)	-2.1 (-26.0 to 34.8)
Breast cancer	370.3 (289.9 to 457.1)	1,078.7 (818.7 to 1,381.9)	193.3 (102.0 to 311.7)	33.2 (15.0 to 124.0)	33.2 (22.5 to 47.2)	85.7 (56.0 to 120.6)	158.3 (78.0 to 261.8)	42.2 (-0.3 to 95.0)
Cervical cancer	582.5 (389.1 to 744.4)	570.3 (406.2 to 763.2)	-2.4 (-33.4 to 52.1)	-43.7 (-61.0 to -45.6)	4.2 (2.3 to 6.3)	48.3 (27.2 to 65.6)	1.3 (-33.3 to 52.7)	49.3 (-61.0 to -15.1)
Uterine cancer	31.3 (20.6 to 49.9)	76.4 (46.4 to 113.0)	145.7 (38.7 to 305.3)	35.9 (-20.2 to 119.9)	2.3 (1.3 to 3.8)	5.5 (2.8 to 8.9)	141.1 (35.0 to 302.8)	32.0 (-23.4 to 113.2)
Prostate cancer	51.4 (25.2 to 73.0)	182.7 (120.6 to 288.4)	249.5 (111.7 to 550.5)	84.2 (16.2 to 231.1)	5.6 (2.6 to 8.8)	17.5 (10.4 to 29.0)	204.4 (82.9 to 467.2)	60.8 (-1.5 to 189.9)
Colon and rectum cancer	132.2 (115.1 to 150.8)	385.0 (328.1 to 466.5)	190.0 (138.0 to 266.5)	50.1 (24.0 to 87.5)	12.9 (9.1 to 17.2)	33.1 (22.8 to 44.9)	155.3 (102.4 to 228.9)	30.6 (5.3 to 68.1)
Lip and oral cavity cancer	366.2 (230.1 to 441.9)	750.1 (557.0 to 997.3)	146.4 (75.5 to 262.0)	24.0 (-10.3 to 62.7)	27.3 (17.9 to 41.6)	64.0 (40.6 to 94.6)	135.2 (67.1 to 266.4)	17.7 (-16.2 to 73.4)
Nasopharynx cancer	38.5 (28.5 to 50.1)	62.1 (44.0 to 90.2)	60.0 (11.0 to 149.4)	-13.6 (-39.9 to 36.2)	4.0 (2.6 to 5.9)	6.1 (3.8 to 9.7)	18.6 (9.7 to 130.6)	-18.6 (-41.9 to 23.9)
Other pharynx cancer	77.1 (50.5 to 109.5)	215.3 (132.3 to 304.1)	179.4 (65.1 to 369.6)	49.0 (-11.4 to 148.9)	7.4 (4.4 to 11.2)	19.6 (11.2 to 29.2)	166.0 (56.0 to 317.8)	41.4 (-15.3 to 117.8)
Gallbladder and biliary tract cancer	4.0 (3.1 to 5.0)	10.8 (7.7 to 14.0)	169.9 (91.3 to 288.1)	42.8 (1.4 to 98.5)	1.2 (0.8 to 1.7)	3.0 (1.8 to 4.2)	147.4 (78.4 to 229.2)	31.2 (-5.1 to 73.0)
Pancreatic cancer	5.4 (4.4 to 6.6)	12.4 (10.0 to 15.3)	126.7 (73.2 to 198.4)	19.8 (-6.4 to 56.5)	1.2 (0.9 to 1.7)	2.7 (1.8 to 3.7)	112.0 (71.1 to 164.9)	11.6 (-8.8 to 38.9)
Malignant skin melanoma	159.4 (115.6 to 210.1)	202.0 (128.7 to 356.3)	24.7 (-27.5 to 115.0)	24.7 (-64.1 to 116.3)	10.0 (6.1 to 15.7)	12.2 (6.5 to 23.4)	12.2 (-31.2 to 116.8)	45.0 (-66.8 to 13.3)
Non-melanoma skin cancer	30.4 (23.5 to 46.7)	148.1 (114.7 to 210.4)	389.8 (261.5 to 550.5)	161.5 (105.5 to 239.3)	1.5 (0.9 to 2.7)	5.8 (3.3 to 10.5)	283.2 (148.2 to 505.1)	99.9 (35.6 to 210.7)
Ovarian cancer	41.6 (32.1 to 52.2)	113.2 (83.1 to 149.9)	173.1 (80.5 to 311.3)	49.8 (1.4 to 120.9)	5.9 (3.8 to 8.4)	15.2 (9.4 to 22.5)	158.3 (62.7 to 306.1)	41.7 (9.9 to 117.5)
Testicular cancer	20.7 (11.2 to 31.1)	56.2 (33.9 to 85.2)	175.6 (55.7 to 387.6)	62.4 (-8.2 to 182.9)	1.4 (0.7 to 2.5)	3.7 (1.9 to 6.4)	157.8 (39.4 to 373.8)	48.3 (-15.5 to 165.5)
Kidney cancer	24.3 (25.6 to 48.5)	73.2 (55.1 to 87.9)	202.9 (33.4 to 202.9)	50.7 (1.4 to 92.6)	2.4 (1.7 to 4.0)	6.4 (3.6 to 7.9)	170.7 (38.4 to 201.2)	34.1 (-2.7 to 81.6)
Bladder cancer	19.0 (19.0 to 30.2)	55.4 (55.4 to 94.4)	120.9 (120.9 to 322.0)	30.0 (11.4 to 105.1)	5.7 (1.6 to 3.4)	11.6 (4.2 to 9.4)	101.2 (96.6 to 273.9)	27.0 (-1.7 to 84.4)
Brain and nervous system cancer	55.1 (42.7 to 75.2)	108.3 (81.3 to 164.5)	95.1 (44.0 to 177.2)	30.0 (-0.3 to 79.6)	5.7 (3.7 to 8.5)	11.6 (7.1 to 18.2)	101.2 (50.5 to 178.8)	27.0 (-2.9 to 75.0)
Thyroid cancer	90.2 (56.5 to 134.4)	180.2 (128.1 to 273.8)	97.5 (12.6 to 281.3)	32.1 (-16.4 to 118.6)	5.5 (3.1 to 8.9)	11.0 (6.5 to 17.9)	94.4 (15.8 to 264.6)	27.7 (-15.8 to 106.0)
Mesothelioma	0.4 (0.4 to 0.6)	0.8 (0.7 to 1.1)	89.3 (36.3 to 155.0)	89.3 (-20.4 to 43.5)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	90.9 (38.9 to 162.4)	8.3 (-2.0 to 45.0)
Hodgkin lymphoma	204.4 (127.4 to 335.8)	143.1 (88.0 to 259.8)	-33.1 (-67.6 to 68.6)	-44.8 (-70.6 to 41.3)	13.3 (7.4 to 22.6)	10.2 (5.5 to 18.4)	-26.5 (-61.3 to 79.6)	-42.9 (-66.3 to 40.9)
Non-Hodgkin lymphoma	70.0 (45.9 to 89.7)	159.4 (122.1 to 225.3)	116.7 (51.1 to 288.4)	34.3 (-6.0 to 131.3)	6.3 (3.8 to 9.1)	13.3 (8.3 to 20.2)	101.8 (42.8 to 252.6)	20.3 (-12.8 to 97.6)
Multiple myeloma	9.4 (6.6 to 12.7)	27.0 (18.3 to 36.8)	188.4 (82.9 to 353.3)	53.1 (-2.6 to 136.5)	2.2 (1.4 to 3.3)	5.9 (3.4 to 8.9)	163.0 (67.3 to 298.8)	38.7 (-12.7 to 111.4)
Leukemia	88.9 (69.2 to 118.6)	160.3 (128.6 to 198.4)	81.3 (29.4 to 150.2)	37.9 (1.5 to 85.6)	10.7 (7.2 to 15.0)	20.5 (13.4 to 28.1)	89.2 (42.5 to 147.5)	28.4 (-2.5 to 66.3)
Other neoplasms	313.9 (207.5 to 501.7)	778.4 (540.5 to 1,061.0)	164.3 (28.1 to 316.2)	101.4 (11.5 to 203.9)	20.1 (11.7 to 34.6)	49.8 (30.2 to 74.1)	160.2 (38.3 to 296.5)	80.5 (7.7 to 168.3)
Cardiovascular diseases	-	-	-	-	1,342.0 (889.9 to 1,894.2)	2,903.5 (1,757.6 to 4,360.4)	2,903.5 (41.7 to 206.2)	16.7 (-23.7 to 65.5)
Rheumatic heart disease	4,880.7 (4,543.2 to 5,221.1)	8,099.2 (7,482.0 to 8,723.3)	66.0 (51.8 to 83.3)	4.7 (-4.6 to 15.4)	47.3 (196.7 to 404.8)	47.3 (311.9 to 661.4)	63.3 (36.1 to 91.1)	-0.3 (-19.2 to 17.3)
Ischemic heart disease	7,124.5 (6,056.7 to 8,413.5)	10,121.8 (8,902.2 to 11,713.7)	42.1 (15.9 to 78.0)	-21.1 (-35.2 to -2.5)	370.7 (239.6 to 531.5)	449.0 (359.3 to 773.2)	19.9 (9.3 to 30.5)	-15.8 (-38.5 to 16.3)
Cerebrovascular disease	-	-	-	-	197.0 (136.3 to 261.4)	365.2 (250.0 to 490.6)	84.2 (53.3 to 130.2)	1.7 (-15.0 to 29.0)
Ischemic stroke	864.7 (772.1 to 964.2)	1,595.1 (1,349.5 to 1,897.4)	83.0 (54.7 to 130.6)	-0.1 (-16.3 to 27.4)	128.0 (88.1 to 173.9)	237.7 (158.1 to 323.4)	84.9 (53.9 to 133.2)	0.9 (-15.9 to 28.7)
Hemorrhagic stroke	458.6 (402.9 to 515.8)	846.5 (712.7 to 1,006.2)	84.2 (50.5 to 130.2)	3.4 (-15.7 to 31.2)	68.9 (46.3 to 94.5)	127.4 (83.8 to 178.0)	84.1 (45.9 to 139.3)	4.0 (-18.0 to 37.2)
Hypertensive heart disease	419.4 (281.5 to 604.5)	787.6 (561.0 to 1,069.5)	89.3 (11.9 to 229.7)	-7.6 (-4.7 to 57.8)	45.2 (26.2 to 73.2)	85.7 (52.6 to 129.6)	89.4 (11.7 to 233.8)	-6.6 (-47.3 to 61.9)
Cardiomyopathy and myocarditis	369.2 (298.6 to 461.8)	636.0 (510.5 to 780.3)	72.4 (30.2 to 130.1)	-10.1 (-34.4 to 23.3)	38.4 (24.4 to 57.6)	74.7 (43.1 to 98.1)	67.1 (27.5 to 136.1)	74.3 (-35.8 to 27.9)
Atrial fibrillation and flutter	99.5 (79.1 to 124.7)	90.2 (66.8 to 119.1)	-7.7 (-37.3 to 27.4)	-49.2				

Appendix Table G.4 - India prevalence and VIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VIDs 1990 (thousands)	VIDs 2013 (thousands)	% change VIDs, 1990 to 2013	% change age-standardized VIDs, 1990 to 2013
Pneumococcal	-	-	-	-	4.9	8.5	73.3	-5.7
					(3.5 to 6.7)	(6.1 to 11.5)	(67.6 to 78.5)	(-8.9 to -2.7)
Silicosis	8.6	12.7	48.0	-20.4	1.7	2.4	47.5	-20.6
	(7.7 to 9.4)	(11.5 to 13.8)	(39.1 to 56.8)	(-25.3 to -15.6)	(1.1 to 2.4)	(1.6 to 3.5)	(38.8 to 56.5)	(-25.5 to -16.0)
Asbestosis	3.8	6.7	77.4	-4.9	0.7	1.3	76.6	-5.2
	(3.5 to 4.0)	(6.1 to 7.1)	(70.1 to 86.0)	(-9.3 to 0.1)	(0.5 to 1.0)	(0.8 to 1.8)	(69.2 to 85.5)	(-9.7 to -0.2)
Coal workers pneumoconiosis	4.6	8.2	78.8	-0.9	0.9	1.6	78.1	-1.4
	(4.3 to 4.9)	(7.7 to 8.7)	(72.0 to 86.0)	(-4.3 to 2.7)	(0.6 to 1.3)	(1.0 to 2.2)	(71.2 to 85.1)	(-4.8 to 2.3)
Other pneumoconiosis	8.7	17.1	95.7	1.7	3.3	8.9	83.3	8.3
	(8.1 to 9.3)	(15.9 to 18.2)	(87.5 to 103.1)	(4.2 to 13.0)	(1.1 to 2.4)	(2.1 to 4.7)	(86.5 to 102.9)	(3.9 to 12.8)
Asthma	24,543.0	33,666.2	37.6	-4.9	1,081.0	1,485.7	37.5	4.6
	(23,075.3 to 26,115.8)	(31,794.7 to 35,809.8)	(26.9 to 49.5)	(-11.9 to 1.9)	(705.1 to 1,540.3)	(965.2 to 2,142.2)	(26.0 to 50.8)	(-11.8 to 3.2)
Interstitial lung disease and pulmonary sarcoidosis	51.1	99.1	95.2	14.0	6.9	13.6	96.7	13.3
	(39.9 to 62.6)	(77.8 to 120.0)	(37.7 to 163.4)	(-19.1 to 54.9)	(4.2 to 10.4)	(7.7 to 20.7)	(38.2 to 165.7)	(-20.9 to 55.4)
Other chronic respiratory diseases	-	-	-	-	185.0	264.0	42.1	-19.5
					(109.0 to 291.7)	(157.4 to 413.8)	(12.2 to 85.1)	(-36.3 to 4.7)
Cirrhosis	-	-	-	-	83.5	128.2	53.8	-1.8
					(56.1 to 115.8)	(87.2 to 176.5)	(36.6 to 72.6)	(-11.8 to 9.3)
Cirrhosis due to hepatitis B	124.9	193.7	56.6	-7.8	20.4	31.8	56.6	-7.6
	(93.6 to 159.9)	(144.0 to 248.7)	(6.5 to 117.8)	(-34.1 to 28.1)	(12.4 to 31.9)	(19.4 to 48.3)	(2.9 to 129.4)	(-35.8 to 33.5)
Cirrhosis due to hepatitis C	60.1	115.0	91.5	19.8	10.0	18.9	89.4	19.3
	(44.2 to 80.4)	(77.0 to 159.3)	(23.1 to 206.7)	(-22.6 to 88.0)	(5.7 to 15.7)	(10.5 to 29.8)	(11.9 to 227.8)	(-25.5 to 103.3)
Cirrhosis due to alcohol use	127.3	203.1	59.0	-10.9	20.7	33.3	60.7	-9.7
	(80.0 to 164.0)	(160.0 to 253.5)	(10.3 to 155.6)	(-36.1 to 34.5)	(11.0 to 32.7)	(20.6 to 50.8)	(5.5 to 172.0)	(-37.9 to 46.6)
Cirrhosis due to other causes	191.9	262.6	36.4	1.3	32.4	44.3	35.5	2.7
	(161.7 to 221.1)	(217.4 to 306.1)	(14.7 to 70.5)	(-15.1 to 28.9)	(20.8 to 47.1)	(28.3 to 54.1)	(4.8 to 85.4)	(-21.0 to 37.8)
Digestive diseases	-	-	-	-	1,340.5	1,580.3	18.1	-30.2
					(948.3 to 1,819.1)	(1,142.5 to 2,149.6)	(8.8 to 27.9)	(-34.9 to -25.2)
Peptic ulcer disease	5,898.0	7,049.3	19.5	-34.8	217.4	237.6	9.3	-40.3
	(4,626.6 to 6,884.8)	(5,526.5 to 8,300.7)	(5.0 to 45.3)	(-41.5 to -21.0)	(148.1 to 316.0)	(160.3 to 343.1)	(-14.4 to 34.3)	(-51.6 to -26.4)
Gastritis and duodenitis	16,607.4	14,872.9	-10.3	-44.1	666.9	525.0	-21.2	-49.9
	(15,095.9 to 18,062.7)	(13,489.1 to 16,162.7)	(-21.6 to -0.3)	(-49.7 to -38.9)	(457.6 to 933.0)	(355.6 to 752.3)	(-30.5 to -9.5)	(-54.9 to -43.9)
Appendicitis	191.2	203.8	8.1	-29.3	57.6	61.8	8.6	-28.3
	(149.8 to 248.5)	(135.6 to 275.5)	(-32.3 to 65.4)	(-53.1 to 4.4)	(33.5 to 85.5)	(33.3 to 97.5)	(-37.5 to 71.0)	(-56.4 to 8.0)
Paralytic ileus and intestinal obstruction	9.0	13.0	45.3	-11.7	2.8	4.0	44.9	-11.2
	(8.2 to 10.0)	(11.9 to 14.3)	(27.6 to 64.3)	(-20.3 to -2.5)	(1.8 to 3.8)	(2.6 to 5.6)	(19.2 to 75.4)	(-29.6 to 12.0)
Inguinal, femoral, and abdominal hernia	3,575.0	5,733.7	58.8	-10.2	36.9	59.3	58.5	-9.5
	(2,994.9 to 4,141.7)	(4,608.6 to 6,776.5)	(26.6 to 108.3)	(-28.3 to 17.4)	(18.2 to 68.2)	(28.6 to 113.2)	(26.5 to 109.3)	(-28.1 to 19.0)
Inflammatory bowel disease	1,040.5	2,087.6	100.9	17.7	219.3	441.8	101.7	18.6
	(994.5 to 1,088.0)	(1,985.5 to 2,177.8)	(88.8 to 113.3)	(10.7 to 24.4)	(150.7 to 300.0)	(304.7 to 610.0)	(83.9 to 120.6)	(8.8 to 28.4)
Vascular intestinal disorders	1.8	3.7	102.8	10.8	0.6	1.2	99.6	9.3
	(1.4 to 2.3)	(2.5 to 4.8)	(32.2 to 198.0)	(-33.9 to 79.0)	(0.4 to 0.9)	(0.7 to 1.8)	(27.9 to 199.5)	(-39.9 to 82.7)
Gallbladder and biliary diseases	524.4	847.2	60.8	-5.8	55.8	59.8	59.8	4.2
	(460.7 to 616.0)	(707.5 to 1,004.1)	(27.9 to 100.7)	(-27.0 to 14.6)	(36.9 to 77.8)	(59.2 to 125.7)	(24.9 to 101.0)	(-27.7 to 15.5)
Pancreatitis	179.3	298.3	66.4	-4.3	52.7	88.1	67.2	-3.3
	(169.3 to 189.5)	(279.4 to 318.9)	(55.0 to 80.9)	(-10.6 to 3.7)	(34.9 to 70.7)	(58.4 to 121.7)	(40.9 to 96.7)	(-17.3 to 13.1)
Other digestive diseases	-	-	-	-	30.7	72.7	141.4	42.8
					(20.5 to 43.8)	(45.8 to 105.5)	(71.7 to 190.7)	(2.8 to 71.6)
Neurological disorders	-	-	-	-	7,548.2	12,723.4	68.6	4.9
					(5,081.5 to 10,452.5)	(8,596.4 to 17,742.9)	(55.8 to 82.2)	(-19.1 to 13.0)
Alzheimer disease and other dementias	1,770.7	4,031.2	128.0	9.8	243.2	563.9	132.1	10.5
	(1,602.7 to 1,956.9)	(3,591.8 to 4,480.7)	(94.7 to 165.3)	(-6.4 to 29.4)	(175.2 to 311.3)	(408.3 to 740.3)	(98.8 to 171.2)	(-6.2 to 30.8)
Parkinson disease	192.9	375.8	95.2	-0.5	22.7	44.5	96.3	0.2
	(173.5 to 211.6)	(341.0 to 411.9)	(86.3 to 104.3)	(-4.9 to 3.7)	(15.4 to 31.4)	(30.4 to 60.7)	(71.2 to 125.9)	(-11.5 to 13.5)
Epilepsy	2,979.3	4,193.6	40.0	-2.9	977.5	1,521.5	55.3	8.7
	(2,316.6 to 3,601.6)	(3,227.1 to 5,080.0)	(2.7 to 96.7)	(-28.8 to 36.4)	(611.3 to 1,395.1)	(972.3 to 2,149.9)	(10.8 to 126.8)	(-22.2 to 58.4)
Multiple sclerosis	156.2	305.6	95.9	14.9	51.9	101.8	96.4	15.6
	(145.9 to 165.2)	(284.7 to 328.1)	(77.0 to 115.3)	(3.9 to 26.1)	(36.7 to 68.3)	(70.7 to 132.7)	(62.3 to 139.8)	(-4.4 to 41.2)
Migraine	149,823.3	239,454.8	60.1	0.6	5,087.4	8,175.6	60.5	1.5
	(140,901.9 to 158,621.8)	(228,699.5 to 249,838.2)	(48.9 to 72.2)	(-6.3 to 8.1)	(3,049.7 to 7,482.5)	(4,977.6 to 11,925.7)	(48.4 to 73.8)	(-5.9 to 9.5)
Tension-type headache	207,276.9	338,131.0	63.6	2.5	313.0	512.8	63.9	2.9
	(192,328.0 to 225,228.7)	(324,270.2 to 351,980.3)	(49.5 to 79.8)	(-5.7 to 11.3)	(148.0 to 550.5)	(250.5 to 894.9)	(48.9 to 81.2)	(-5.7 to 12.6)
Medication overuse headache	4,521.6	10,301.8	127.3	38.6	705.4	1,612.7	128.2	39.4
	(2,778.2 to 6,313.4)	(6,546.9 to 14,333.1)	(71.6 to 223.7)	(4.1 to 102.8)	(372.6 to 1,103.6)	(905.1 to 2,541.2)	(70.4 to 226.1)	(4.2 to 102.5)
Other neurological disorders	1.3	2.1	57.9	1.4	14.7	19.0	32.0	-34.9
	(1.0 to 1.6)	(1.6 to 2.7)	(15.6 to 127.8)	(-26.1 to 43.9)	(9.7 to 236.7)	(122.0 to 273.2)	(8.7 to 79.1)	(-56.2 to -11.7)
Mental and substance use disorders	-	-	-	-	16,740.9	26,672.7	59.0	1.7
					(11,756.2 to 22,054.9)	(18,452.2 to 35,453.5)	(53.4 to 65.8)	(-12.2 to 5.4)
Schizophrenia	1,530.1	2,571.1	68.4	-1.6	970.3	1,643.6	69.5	0.6
	(1,413.9 to 1,650.2)	(2,376.7 to 2,786.8)	(61.0 to 75.9)	(-5.7 to 2.6)	(716.0 to 1,174.5)	(1,223.8 to 1,988.6)	(57.9 to 82.2)	(-7.2 to 6.5)
Alcohol use disorders	8,392.7	13,677.9	63.3	0.5	829.3	1,360.5	64.1	1.0
	(7,720.0 to 9,103.3)	(12,621.3 to 14,839.2)	(54.5 to 72.9)	(-4.9 to 5.7)	(550.2 to 1,187.5)	(925.2 to 1,934.2)	(53.8 to 75.8)	(-4.9 to 7.4)
Drug use disorders	-	-	-	-	843.4	1,386.5	64.5	2.2
					(549.8 to 1,174.2)	(905.3 to 1,915.4)	(42.1 to 89.3)	(-10.8 to 16.2)
Opioid use disorders	745.7	1,284.5	73.4	0.2	304.9	530.2	74.3	1.3
	(410.8 to 1,146.1)	(649.9 to 1,981.2)	(48.6 to 94.0)	(-12.4 to 10.9)	(153.5 to 510.3)	(251.4 to 875.2)	(47.2 to 103.7)	(-13.3 to 16.0)
Cocaine use disorders	495.6	814.0	63.6	1.4	66.8	110.8	66.0	0.9
	(419.2 to 579.5)	(690.9 to 946.2)	(34.2 to 104.7)	(-17.8 to 21.3)	(41.8 to 98.6)	(71.0 to 161.2)	(26.1 to 122.3)	(-22.9 to 31.3)
Amphetamine use disorders	1,402.3	2,194.0	56.7	3.3	182.2	287.0	57.9	4.0
	(1,198.9 to 1,605.4)	(1,920.9 to 2,457.1)	(28.6 to 87.5)	(-14.3 to 22.0)	(109.9 to 272.5)	(175.2 to 424.3)	(25.1 to 98.2)	(-16.6 to 29.2)
Cannabis use disorders	1,357.9	1,965.6	45.3	-2.2	39.1	56.9	45.8	-1.7
	(1,209.6 to 1,501.5)	(1,745.6 to 2,164.7)	(35.5 to 53.7)	(-8.4 to 3.2)	(25.1 to 57.9)	(36.9 to 83.4)	(21.0 to 71.3)	(-17.6 to 14.9)
Other drug use disorders	-	-	-	-	250.3	401.6	60.8	3.9
					(152.5 to 379.5)	(245.6 to 504.7)	(17.0 to 118.6)	(-24.7 to 39.6)
Depressive disorders	-	-	-	-	6,889.9	11,529.6	66.8	3.8
					(4,226.3 to 10,268.4)	(7,124.0 to 16,998.4)	(53.3 to 83.2)	(-2.3 to 12.4)
Major depressive disorder	29,092.0	48,372.4	65.9	3.7	5,925.3	9,896.2	66.2	4.3
	(20,440.7 to 39,254.0)	(33,437.6 to 64,320.3)	(52.5 to 84.9)	(-3.7 to 13.7)	(3,505.2 to 9,121.1)	(5,920.6 to 15,098.8)	(51.0 to 85.5)	(-3.0 to 14.7)
Dysthymia	10,015.0	16,973.9	69.8	0.4	958.6	1,633.4	70.4	1.0
	(8,343.5 to 11,598.4)	(14,142.7 to 19,621.9)	(66.9 to 73.4)	(0.3 to 0.4)	(626.1 to 1,406.5)	(1,057.9 to 2,406.7)	(65.0 to 75.9)	(-1.6 to 3.4)
Bipolar disorder	5,327.9	8,730.7	64.0	0.5	1,076.3	1,774.8	64.8	1.3
	(4,631.8 to 6,038.5)	(7,609.0 to 9,772.5)	(55.2 to 74.9)	(-4.3 to 5.8)	(654.7 to 1,617.7)	(1,049.4 to 2,664.4)	(54.0 to 77.2)	(-4.8 to 7.9)
Anxiety disorders	23,824.5	36,711.6	54.2	0.2	2,178.0	3,368.7	64.8	0.9
	(18,011.0 to 29,440.4)	(28,093.0 to 45,210.1)	(50.0 to 61.0)	(0.2 to 0.4)	(1,384.8 to 3,197.1)	(2,147.6 to 4,901.3)	(47.9 to 61.9)	(-1.9 to 3.8)
Eating disorders	-	-	-	-	214.5	320.3	49.3	3.3
					(127.2 to 341.2)	(193.7 to 509.9)	(36.2 to 62.4)	(-5.5 to 12.5)
Anorexia nervosa	145.3	241.1	67.0	17.3	30.8	51.4	66.5	17.1
	(107.3 to 189.1)	(180.5 to 311.1)	(47.5 to 85.7)	(4.6 to 30.1)	(18.4 to 47.6)	(31.2 to 77.5)	(33.1 to 116.3)	(5.7 to 52.0)
Bulimia nervosa	874.0	1,271.1	45.7	0.2	183.7	268.8	46.4	0.9
	(594.7 to 1,273.2)	(856.1 to 1,856.0)	(42.0 to 49.0)	(-0.0 to 0.4)	(103.9 to 298.7)	(153.7 to 442.7)	(32.3 to 60.4)	(-8.2 to 10.2)
Autistic spectrum disorders	-	-	-	-	1,054.3	1,517.9	44.0	0.5
					(732.5 to 1,431.0)	(1,046.5 to 2,050.0)	(38.1 to 49.4)	(-2.7 to 3.9)

Appendix Table G.4 - India prevalence and VIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VIDs 1990 (thousands)	VIDs 2013 (thousands)	% change VIDs, 1990 to 2013	% change age-standardized VIDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	163.0 (152.1 to 174.0)	258.5 (241.1 to 277.0)	58.4 (45.8 to 75.0)	-	5.4 (3.3 to 8.1)	8.6 (5.3 to 13.2)	58.7 (25.5 to 100.8)	58.7 (15.8 to 27.2)
Urolithiasis	2,641.7 (2,039.0 to 3,335.4)	4,873.4 (3,388.7 to 6,264.1)	84.4 (54.5 to 128.2)	1.5 (-12.6 to 20.4)	28.7 (18.6 to 41.0)	57.5 (37.2 to 82.1)	100.8 (75.8 to 127.8)	15.1 (2.7 to 28.8)
Benign prostatic hyperplasia	7,333.5 (6,654.6 to 7,911.9)	13,620.6 (12,439.9 to 14,747.6)	85.8 (65.8 to 109.3)	-5.9 (-16.4 to 5.1)	258.6 (169.3 to 367.7)	485.0 (316.9 to 686.8)	87.2 (66.4 to 111.5)	-5.2 (-16.1 to 6.4)
Male infertility due to other causes	4,998.4 (3,922.8 to 6,230.0)	7,442.5 (5,624.7 to 9,290.3)	48.8 (7.7 to 102.2)	-4.2 (-29.9 to 29.5)	34.2 (15.0 to 68.3)	51.2 (20.4 to 109.5)	48.2 (4.7 to 108.2)	-4.3 (-32.9 to 33.7)
Other urinary diseases	-	-	-	-	6.3 (3.1 to 11.8)	23.3 (10.2 to 41.6)	494.7 (69.4 to 580.6)	396.5 (0.4 to 295.5)
Gynecological diseases	-	-	-	-	1,056.5 (682.8 to 1,549.5)	1,654.3 (1,074.9 to 2,445.3)	55.4 (36.6 to 85.5)	-6.8 (-17.2 to 11.7)
Uterine fibroids	14,634.9 (13,249.9 to 15,913.3)	26,187.0 (23,795.7 to 28,414.5)	79.3 (78.1 to 80.5)	0.3 (0.2 to 0.4)	346.6 (221.6 to 524.5)	454.5 (269.8 to 730.3)	30.6 (18.3 to 42.1)	-25.5 (-32.9 to -19.2)
Polycystic ovarian syndrome	13,484.8 (12,211.3 to 14,731.9)	22,241.2 (19,945.1 to 24,440.8)	65.4 (42.9 to 89.6)	0.1 (-12.8 to 14.5)	131.6 (61.8 to 247.5)	219.1 (104.7 to 418.7)	66.4 (43.6 to 91.9)	1.0 (-12.3 to 16.2)
Female infertility due to other causes	4,683.9 (3,053.7 to 5,186.2)	6,782.1 (4,836.1 to 8,686.8)	65.4 (15.4 to 141.7)	13.0 (-21.8 to 67.8)	26.3 (10.9 to 52.9)	42.4 (15.8 to 89.2)	59.9 (111.0 to 132.5)	9.9 (-24.1 to 60.1)
Endometriosis	1,415.7 (1,186.5 to 1,660.2)	2,445.9 (2,072.6 to 2,818.6)	73.6 (40.6 to 112.9)	4.7 (-14.7 to 27.4)	130.2 (84.1 to 185.3)	226.3 (152.4 to 316.8)	74.6 (38.6 to 116.1)	5.4 (-15.7 to 30.2)
Genital prolapse	22,912.4 (20,432.9 to 25,515.9)	40,363.6 (35,513.8 to 44,785.9)	76.7 (48.5 to 107.0)	4.4 (-12.1 to 21.3)	72.6 (35.1 to 136.9)	128.5 (60.7 to 242.7)	77.3 (47.7 to 109.0)	4.8 (-12.2 to 22.2)
Premenstrual syndrome	22,688.5 (10,930.2 to 33,028.3)	51,211.0 (34,826.1 to 70,186.0)	118.0 (28.5 to 417.9)	40.1 (-17.1 to 263.0)	189.3 (77.0 to 333.2)	431.0 (231.1 to 714.0)	120.7 (29.0 to 421.3)	41.0 (-17.0 to 267.0)
Other gynecological diseases	4,420.8 (3,344.0 to 5,566.9)	4,945.5 (3,913.9 to 6,017.8)	11.5 (-15.7 to 61.3)	-30.0 (-47.3 to 3.8)	159.8 (88.8 to 228.4)	152.4 (95.5 to 224.8)	-6.0 (-36.4 to 62.9)	-40.8 (-60.4 to 5.8)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	1,261.2 (848.2 to 1,811.0)	1,347.5 (893.7 to 1,927.6)	6.4 (0.8 to 19.1)	-25.5 (-30.9 to -16.3)
Thalassemias	74.9 (67.3 to 83.0)	91.5 (81.9 to 101.4)	21.6 (13.4 to 33.5)	1.2 (-5.6 to 10.7)	8.4 (5.7 to 11.9)	10.2 (6.7 to 14.5)	21.5 (-7.2 to 54.6)	1.9 (-21.5 to 28.1)
Thalassemia trait	28,552.1 (26,977.8 to 30,146.7)	41,246.8 (39,052.0 to 43,365.7)	44.7 (40.0 to 49.0)	0.3 (-3.0 to 3.2)	410.8 (279.1 to 590.6)	540.3 (356.3 to 774.4)	31.1 (14.5 to 51.5)	-5.0 (-18.0 to 10.4)
Sickle cell disorders	315.7 (257.9 to 359.5)	470.8 (401.2 to 532.9)	49.1 (23.6 to 84.2)	17.8 (-2.3 to 45.5)	34.2 (22.3 to 48.8)	54.1 (35.7 to 75.5)	58.5 (21.6 to 106.0)	20.1 (-7.0 to 54.2)
Sickle cell trait	61,710.9 (57,285.4 to 66,262.1)	88,616.5 (82,783.6 to 94,332.8)	43.8 (17.6 to 50.0)	43.8 (-4.6 to 3.9)	263.9 (165.5 to 383.8)	432.6 (234.6 to 513.1)	32.6 (10.1 to 82.0)	-3.6 (-20.5 to 39.2)
G6PD deficiency	56,019.2 (50,939.3 to 61,373.6)	79,092.4 (72,268.4 to 86,266.8)	41.7 (24.7 to 61.1)	-1.8 (-13.6 to 11.6)	6.3 (4.3 to 9.0)	9.0 (6.1 to 12.6)	42.4 (24.5 to 62.2)	1.9 (-8.2 to 12.7)
G6PD trait	186,310.2 (184,009.4 to 188,587.5)	266,632.2 (263,296.8 to 270,284.3)	43.3 (40.7 to 46.3)	-0.4 (-2.2 to 1.7)	7.8 (2.4 to 12.4)	8.9 (1.5 to 15.0)	16.2 (-81.2 to 298.5)	-17.4 (-86.2 to 177.2)
Other hemoglobinopathies and hemolytic anemias	16,971.8 (14,907.4 to 18,690.2)	14,114.2 (12,785.4 to 15,383.9)	-44.3 (-25.3 to -4.8)	529.7 (-50.0 to -36.9)	529.7 (344.8 to 762.7)	372.2 (236.7 to 555.7)	-29.6 (-41.2 to -12.6)	-29.6 (-60.1 to -11.2)
Endocrine, metabolic, blood, and immune disorders	15,902.0 (15,404.5 to 18,598.9)	16,406.9 (14,233.4 to 18,209.7)	2.4 (-11.5 to 11.0)	-2.4 (-39.6 to -22.3)	598.3 (399.0 to 837.5)	2.4 (354.4 to 776.5)	35.1 (-26.8 to 9.8)	35.1 (-45.8 to 2.7)
Musculoskeletal disorders	-	-	-	-	9,971.0 (7,051.9 to 13,353.4)	17,528.6 (12,344.8 to 23,219.3)	75.7 (66.0 to 86.8)	7.4 (3.4 to 14.1)
Rheumatoid arthritis	1,394.6 (1,311.2 to 1,489.9)	1,970.4 (1,857.2 to 2,090.1)	41.6 (29.9 to 54.6)	-20.1 (-26.8 to -12.7)	324.2 (227.1 to 430.1)	458.8 (325.3 to 610.3)	41.3 (27.5 to 57.9)	-19.9 (-27.7 to -10.6)
Osteoarthritis	13,590.4 (12,986.1 to 14,230.4)	26,056.0 (24,741.4 to 27,215.1)	92.4 (79.5 to 104.8)	0.3 (-5.9 to 6.5)	820.7 (576.9 to 1,118.2)	1,584.5 (1,111.1 to 2,119.3)	93.4 (80.1 to 105.4)	0.8 (-5.4 to 6.9)
Low back and neck pain	-	-	-	-	7,224.9 (5,405.7 to 10,512.2)	13,271.5 (9,121.4 to 17,836.0)	71.9 (58.7 to 86.0)	1.4 (-5.7 to 8.8)
Low back pain	49,255.0 (46,387.5 to 52,170.7)	84,357.8 (79,154.6 to 90,553.8)	71.6 (56.7 to 87.9)	0.9 (-6.7 to 9.6)	5,461.7 (3,692.0 to 7,570.8)	9,396.9 (6,292.5 to 12,977.7)	72.0 (56.5 to 88.6)	1.8 (-6.5 to 10.5)
Neck pain	23,175.5 (20,413.5 to 26,031.9)	39,436.4 (33,384.2 to 45,201.1)	71.4 (39.4 to 104.5)	0.4 (-18.0 to 19.4)	2,263.2 (1,540.6 to 3,147.5)	3,874.6 (2,580.7 to 5,501.5)	71.7 (39.6 to 106.3)	1.1 (-17.6 to 21.2)
Gout	75.9 (66.7 to 85.3)	146.3 (130.0 to 163.7)	93.2 (62.4 to 128.2)	3.4 (-11.4 to 22.1)	2.6 (1.7 to 3.6)	4.9 (3.2 to 7.1)	93.7 (47.3 to 155.5)	3.9 (-21.2 to 39.6)
Other musculoskeletal disorders	12,533.3 (9,671.4 to 14,966.6)	24,181.1 (19,386.2 to 30,294.3)	99.7 (79.1 to 121.7)	8.6 (-3.5 to 19.7)	7,228.9 (4,929.6 to 9,628.3)	2,208.8 (1,433.3 to 3,201.3)	8.8 (78.1 to 124.1)	9.8 (-3.0 to 21.1)
Other non-communicable diseases	-	-	-	-	14,103.7 (9,209.4 to 20,385.0)	21,882.8 (14,317.1 to 31,705.6)	55.3 (48.9 to 61.1)	-6.4 (-9.5 to -3.7)
Congenital anomalies	-	-	-	-	624.8 (418.0 to 861.3)	1,113.9 (795.0 to 1,463.4)	78.3 (53.2 to 114.1)	25.1 (7.2 to 49.6)
Neural tube defects	60.5 (51.3 to 72.1)	190.1 (166.8 to 215.8)	216.2 (154.5 to 286.3)	155.1 (104.6 to 212.7)	16.2 (10.6 to 22.6)	57.4 (38.9 to 80.5)	253.0 (162.7 to 390.7)	190.2 (116.3 to 302.7)
Congenital heart anomalies	789.4 (552.6 to 1,091.0)	3,786.7 (2,991.3 to 4,921.7)	389.9 (217.0 to 640.0)	276.8 (144.2 to 462.8)	30.3 (14.8 to 53.2)	130.9 (56.6 to 230.9)	328.8 (189.9 to 545.3)	215.6 (118.4 to 385.8)
Orofacial clefts	90.2 (61.3 to 133.4)	515.8 (384.9 to 630.8)	481.8 (244.2 to 795.6)	392.4 (186.5 to 665.7)	1.7 (1.0 to 2.9)	9.1 (5.4 to 13.9)	435.4 (195.7 to 772.8)	352.5 (148.1 to 638.8)
Down syndrome	591.3 (468.6 to 742.2)	1,353.4 (1,107.8 to 1,624.9)	130.9 (75.0 to 202.1)	73.4 (31.2 to 127.5)	68.7 (47.7 to 96.1)	167.8 (118.8 to 226.9)	144.8 (82.7 to 224.8)	81.8 (35.9 to 142.0)
Turner syndrome	21.5 (15.5 to 27.9)	41.0 (33.1 to 53.9)	89.7 (36.6 to 181.5)	39.3 (0.7 to 106.4)	0.4 (0.2 to 0.6)	0.7 (0.3 to 1.2)	94.2 (33.5 to 197.4)	39.4 (-4.0 to 113.1)
Klinefelter syndrome	22.5 (17.2 to 28.8)	31.3 (24.2 to 40.4)	39.7 (-7.2 to 107.7)	-1.8 (-34.8 to 45.9)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.4)	48.2 (-0.4 to 122.0)	-2.3 (-35.1 to 45.5)
Chromosomal unbalanced rearrangements	662.2 (560.4 to 758.1)	1,610.2 (1,226.5 to 2,074.7)	60.7 (80.1 to 146.9)	41.7 (35.0 to 45.7)	76.7 (54.6 to 102.3)	141.1 (134.1 to 158.3)	158.3 (90.9 to 253.1)	92.6 (42.6 to 164.6)
Other congenital anomalies	5,000.2 (3,906.6 to 6,013.0)	6,264.3 (4,780.0 to 7,477.0)	25.3 (8.9 to 44.3)	-16.5 (-27.1 to -4.1)	430.8 (255.7 to 629.9)	548.4 (339.7 to 804.6)	26.9 (5.8 to 56.8)	-12.6 (-28.9 to 7.2)
Skin and subcutaneous diseases	-	-	-	-	4,355.4 (2,656.8 to 6,880.7)	6,736.5 (4,082.5 to 10,625.3)	55.1 (38.3 to 71.4)	4.3 (-5.7 to 13.9)
Dermatitis	24,093.1 (18,991.8 to 29,385.0)	36,983.9 (29,435.3 to 44,833.9)	53.9 (50.9 to 57.0)	0.0 (-0.0 to 0.1)	638.4 (417.8 to 920.6)	976.4 (630.1 to 1,401.1)	53.1 (46.5 to 59.0)	0.7 (-2.9 to 4.0)
Psoriasis	5,569.7 (4,570.0 to 6,803.6)	9,842.2 (7,313.7 to 11,020.4)	60.7 (57.6 to 64.3)	60.7 (-0.1 to 0.1)	63.4 (301.0 to 662.4)	67.3 (482.6 to 1,082.5)	61.1 (50.7 to 72.0)	0.6 (-4.9 to 6.5)
Cellulitis	215.5 (177.4 to 265.4)	275.9 (211.1 to 358.7)	27.6 (6.8 to 57.3)	-19.6 (-32.0 to -2.9)	15.2 (9.1 to 23.1)	28.4 (12.0 to 30.4)	28.4 (-4.1 to 70.5)	-18.5 (-37.3 to 6.6)
Pyoderma	1,268.4 (931.6 to 1,637.9)	1,124.7 (875.3 to 1,460.2)	-10.7 (-22.7 to 2.7)	-8.7 (-36.5 to -20.5)	7.2 (2.7 to 16.1)	6.4 (2.4 to 14.3)	-11.1 (-34.3 to 5.5)	-8.9 (-37.9 to -17.7)
Scabies	14,973.6 (11,398.8 to 18,508.1)	18,994.1 (15,675.3 to 23,281.2)	25.1 (-5.8 to 90.8)	-11.5 (-32.5 to 33.7)	384.7 (209.1 to 637.5)	490.6 (268.3 to 804.0)	25.3 (-5.1 to 92.9)	-11.0 (-32.9 to 14.4)
Fungal skin diseases	71,803.5 (58,247.8 to 84,033.0)	106,275.6 (88,239.4 to 123,038.1)	48.3 (43.0 to 54.2)	48.3 (-0.3 to 0.1)	40.7 (159.9 to 864.1)	40.7 (234.7 to 1,259.3)	48.4 (42.0 to 54.6)	0.3 (-0.6 to 1.0)
Viral skin diseases	13,683.3 (11,664.3 to 16,138.2)	17,785.2 (15,192.9 to 20,793.4)	30.4 (21.9 to 38.6)	2.2 (-2.3 to 6.7)	422.0 (263.3 to 636.9)	550.4 (342.7 to 832.8)	30.7 (21.0 to 40.7)	2.7 (-3.2 to 7.7)
Acne vulgaris	109,253.8 (89,183.5 to 130,644.5)	156,172.8 (122,432.2 to 189,027.5)	43.9 (4.3 to 84.6)	3.7 (-23.7 to 32.5)	1,179.6 (556.3 to 2,246.4)	1,697.9 (777.3 to 3,206.6)	44.4 (4.6 to 84.8)	4.0 (-23.7 to 32.9)
Alopecia areata	731.9 (674.4 to 792.6)	1,136.4 (1,043.3 to 1,222.9)	55.7 (38.4 to 74.0)	-1.6 (-12.6 to 10.6)	24.5 (15.7 to 37.0)	38.0 (24.0 to 57.1)	55.9 (32.0 to 83.0)	0.7 (-15.4 to 14.6)
Pruritus	58.0 (45.7 to 73.9)	86.2 (59.4 to 108.1)	49.8 (-5.2 to 120.1)	0.6 (-4.9 to 35.2)	0.6 (0.3 to 1.2)	0.9 (0.4 to 1.8)	46.7 (-11.8 to 135.0)	9.7 (-5.3 to 42.5)
Urticaria	9,614.0 (7,278.5 to 12,253.5)	19,860.4 (14,692.5 to 25,965.6)	111.3 (36.1 to 203.7)	24.7 (-15.2 to 74.2)	567.1 (335.2 to 854.7)	1,181.9 (679.7 to 1,868.1)	111.7 (36.3 to 208.3)	25.7 (-15.6 to 75.7)
Decubitus ulcer	102.1 (88.3 to 117.8)	206.7 (172.7 to 240.2)	102.3 (74.7 to 139.9)	14.4 (-6.5 to 42.0)	15.3 (10.3 to 21.9)	30.5 (20.6 to 43.0)	98.3 (64.1 to 146.3)	14.0 (-9.6 to 47.9)
Other skin and subcutaneous diseases	42,088.7 (28,625.8 to 60,650.5)	71,197.8 (46,798.2 to 105,328.7)	69.1 (57.0 to 81.2)	-0.3 (-4.9 to 5.2)	245.9 (109.4 to 502.5)	417.3 (187.2 to 841.7)	69.6 (57.0 to 81.5)	0.3 (-4.6 to 5.7)
Sense organ diseases	-	-	-	-	7,230.0 (4,888.8 to 10,105.8)	10,898.8 (7,335.9 to 15,211.3)	50.6 (44.1 to 57.9)	-12.4 (-15.4 to -9.3)
Glaucoma	1,685.1 (1,379.6 to 2,065.0)	3,396.6 (2,832.2 to 4,045.2)	103.5 (53.4 to 145.7)	12.6 (-16.6 to 34.7)	107.7 (72.4 to 151.4)	208.3 (140.6 to 291.5)	93.4 (59.7 to 129.1)	7.5 (-13.9 to 27.4)
Cataract	8,455.0 (7,069.4 to 9,716.3)	13,216.7 (11,417.6 to 14,963.3)	56.2 (37.6 to 81.4)	-19.0 (-27.3 to -5.6)	550.9 (379.0 to 764.3)	895.2 (622.9 to 1,219.1)	62.4 (46.7 to 81.7)	-16.1 (-22.8 to -9.9)
Macular degeneration	483.0 (369.0 to 652.9)	888.0 (680.2 to 1,100.0)	87.2 (25.8 to 162.0)	-7.0 (-34.6 to 21.5)	32.0 (21.7 to 45.5)	57.6 (39.0 to 81.4)	82.1 (34.1 to 137.9)	-12.0 (-30.2 to 7.5)
Uncorrected refractive error	80,745.9 (76,580.9 to 85,138.6)	125,049.6 (118,852.5 to 131,784.1)	55.7 (44.8 to 65.7)	-11.2 (-16.5 to -5.7)	2,044.9 (1,388.9 to 2,944.0)	2,936.1 (1,998.8 to 4,274.6)	43.3 (38.5 to 49.9)	-16.9 (-19.7 to -13.5)
Age-related and other hearing loss	108,146.7 (96,971.3 to 118,809.4)	176,616.5 (158,444.1 to 194,013.9)	63.4 (56.5 to 71.8)	4.3 (-1.1 to 4.8)	634.9 (2,321.8 to 5,148.9)	5,624.0 (3,578.7 to 8,066.5)	54.8 (42.4 to 68.3)	-10.2 (-15.6 to -4.7)
Other vision loss								

Appendix Table G.4 - India prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	30,032.6 (28,604.9 to 31,500.5)	51,734.3 (49,209.9 to 54,155.9)	72.5 (61.4 to 84.4)	-9.8 (-14.8 to -4.4)	817.5 (552.9 to 1,118.2)	1,417.2 (968.8 to 1,937.7)	73.2 (61.8 to 85.7)	-9.4 (-14.4 to -3.6)
Other oral disorders	13,643.2 (12,908.9 to 14,442.7)	21,606.9 (20,382.8 to 22,887.4)	58.6 (46.6 to 71.8)	0.2 (-7.1 to 8.1)	398.1 (251.2 to 591.9)	632.6 (395.5 to 955.4)	59.2 (45.9 to 72.9)	0.7 (-7.2 to 8.7)
Injuries	-	-	-	-	5,276.3 (4,025.2 to 6,782.9)	7,569.5 (5,698.2 to 9,833.3)	43.4 (38.8 to 47.7)	-13.5 (-15.9 to -11.1)
Transport injuries	-	-	-	-	1,945.0 (1,464.3 to 2,515.1)	2,799.7 (2,092.1 to 3,642.0)	43.9 (37.9 to 49.8)	-12.5 (-15.7 to -9.5)
Road injuries	-	-	-	-	462.8 (1,113.2 to 1,889.9)	2,296.2 (1,710.8 to 2,992.4)	57.2 (49.4 to 64.3)	7.2 (-7.3 to 0.5)
Pedestrian road injuries	-	-	-	-	444.2 (337.1 to 573.6)	690.0 (510.7 to 902.9)	55.3 (44.1 to 66.7)	-1.5 (-7.5 to 4.3)
Cyclist road injuries	-	-	-	-	152.3 (114.7 to 199.1)	223.8 (166.2 to 293.9)	46.9 (38.0 to 56.8)	-6.7 (-12.5 to -0.3)
Motorcyclist road injuries	-	-	-	-	322.3 (241.6 to 419.8)	432.2 (316.7 to 561.1)	33.9 (24.0 to 44.6)	-19.7 (-25.0 to -14.0)
Motor vehicle road injuries	-	-	-	-	519.9 (394.5 to 665.1)	920.7 (685.3 to 1,193.3)	76.9 (63.6 to 90.4)	7.2 (0.2 to 14.5)
Other road injuries	-	-	-	-	24.3 (18.3 to 31.2)	29.6 (22.2 to 38.7)	22.0 (14.3 to 29.3)	-27.7 (-31.7 to -23.7)
Other transport injuries	-	-	-	-	482.1 (363.1 to 628.8)	503.5 (371.1 to 649.5)	4.5 (-1.6 to 10.9)	-39.5 (-42.7 to -35.8)
Unintentional injuries	-	-	-	-	3,161.3 (2,415.8 to 4,051.9)	4,541.3 (3,403.9 to 5,895.6)	43.5 (38.9 to 48.3)	-13.7 (-16.3 to -11.2)
Falls	-	-	-	-	1,400.5 (1,064.9 to 1,802.4)	2,437.2 (1,814.0 to 3,171.2)	74.1 (65.8 to 82.2)	-0.9 (-5.7 to 3.6)
Drowning	-	-	-	-	138.1 (101.4 to 180.2)	163.1 (118.1 to 212.0)	18.3 (8.5 to 27.8)	-26.5 (-31.8 to -21.7)
Fire, heat, and hot substances	-	-	-	-	601.7 (465.1 to 761.0)	556.8 (422.7 to 712.0)	-7.5 (-13.9 to -0.4)	-43.6 (-47.1 to -39.6)
Poisonings	-	-	-	-	7.7 (5.5 to 10.4)	12.0 (8.5 to 16.2)	55.7 (31.8 to 83.3)	-0.3 (-14.7 to 15.9)
Exposure to mechanical forces	-	-	-	-	388.8 (293.3 to 505.0)	626.4 (462.7 to 824.9)	61.1 (53.3 to 69.0)	-2.4 (-6.5 to 1.9)
Unintentional firearm injuries	-	-	-	-	16.2 (12.3 to 20.7)	27.2 (20.6 to 35.1)	68.0 (56.1 to 80.7)	-1.5 (-8.0 to 5.4)
Unintentional suffocation	-	-	-	-	3.8 (2.8 to 4.9)	6.8 (5.1 to 8.8)	78.9 (58.4 to 98.4)	10.0 (-0.7 to 20.0)
Other exposure to mechanical forces	-	-	-	-	368.8 (277.7 to 479.1)	592.4 (434.9 to 783.3)	60.6 (52.7 to 68.7)	-2.6 (-6.9 to 1.9)
Adverse effects of medical treatment	-	-	-	-	14.7 (9.3 to 21.7)	23.3 (14.5 to 34.4)	59.1 (47.7 to 69.1)	-4.3 (-11.3 to 1.9)
Animal contact	-	-	-	-	238.6 (178.7 to 312.4)	179.1 (132.1 to 234.3)	-25.0 (-29.0 to -20.5)	-53.2 (-55.4 to -50.9)
Venomous animal contact	-	-	-	-	100.1 (72.0 to 134.4)	76.7 (55.1 to 102.3)	-23.4 (-30.3 to -16.0)	-52.8 (-56.7 to -48.7)
Non-venomous animal contact	-	-	-	-	138.5 (102.7 to 183.1)	102.4 (75.3 to 136.2)	-26.1 (-30.6 to -21.4)	-53.4 (-55.7 to -51.2)
Foreign body	-	-	-	-	38.8 (29.4 to 49.2)	57.4 (43.0 to 73.4)	47.8 (39.7 to 56.2)	-12.1 (-16.5 to -7.3)
Pulmonary aspiration and foreign body in airway	-	-	-	-	6.0 (4.5 to 7.7)	7.8 (6.0 to 9.9)	30.1 (16.0 to 45.5)	-15.9 (-22.9 to -7.5)
Foreign body in eyes	-	-	-	-	7.3 (4.4 to 11.2)	11.4 (6.8 to 17.1)	55.2 (38.7 to 70.8)	-0.7 (-9.7 to 8.4)
Foreign body in other body part	-	-	-	-	25.5 (19.4 to 32.8)	38.3 (28.7 to 49.5)	49.9 (39.5 to 62.1)	-13.9 (-19.6 to -7.4)
Other unintentional injuries	-	-	-	-	332.5 (251.6 to 428.9)	486.0 (363.4 to 633.5)	45.8 (37.1 to 55.6)	-12.7 (-17.8 to -7.2)
Self-harm and interpersonal violence	-	-	-	-	139.1 (105.8 to 176.5)	188.4 (142.3 to 242.9)	35.3 (29.0 to 42.3)	-19.2 (-22.4 to -15.5)
Self-harm	-	-	-	-	15.6 (11.4 to 20.4)	15.5 (11.1 to 20.3)	-0.4 (-9.0 to 8.2)	-41.3 (-46.2 to -36.5)
Interpersonal violence	-	-	-	-	123.5 (94.2 to 156.3)	172.9 (130.8 to 222.3)	39.9 (32.9 to 47.4)	-16.3 (-20.0 to -12.4)
Assault by firearm	-	-	-	-	18.9 (14.4 to 24.7)	26.2 (19.5 to 34.4)	38.6 (29.5 to 47.2)	-18.6 (-23.3 to -14.1)
Assault by sharp object	-	-	-	-	28.0 (21.2 to 36.4)	40.5 (30.5 to 53.5)	46.2 (35.1 to 57.7)	-14.7 (-20.7 to -8.5)
Assault by other means	-	-	-	-	76.6 (57.8 to 97.6)	105.7 (80.5 to 134.6)	38.1 (28.7 to 47.5)	-16.3 (-21.3 to -11.3)
Forces of nature, war, and legal intervention	-	-	-	-	31.0 (14.7 to 70.5)	40.1 (20.6 to 79.2)	34.5 (-3.5 to 76.0)	-15.2 (-37.3 to 8.9)
Exposure to forces of nature	-	-	-	-	8.3 (3.7 to 17.0)	26.7 (14.4 to 51.1)	223.2 (144.5 to 406.4)	89.3 (47.8 to 183.5)
Collective violence and legal intervention	-	-	-	-	22.7 (9.6 to 55.1)	13.5 (5.2 to 32.3)	-40.1 (-59.1 to -20.9)	-59.6 (-70.8 to -48.9)

Appendix Table G.4 - Indonesia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	15,024.0 (10,982.3 to 19,583.7)	21,593.4 (15,859.9 to 27,914.9)	43.4 (38.3 to 50.0)	43.4 (-9.9 to -3.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	3,633.7 (2,491.3 to 5,094.9)	3,439.2 (2,412.9 to 4,745.3)	-5.7 (-11.3 to 4.3)	-30.5 (-35.0 to -23.1)
HIV/AIDS and tuberculosis	-	-	-	-	47.9 (32.3 to 64.5)	165.8 (99.5 to 382.8)	69.5 (162.4 to 603.1)	69.5 (49.1 to 263.6)
Tuberculosis	156.1 (150.1 to 162.2)	407.0 (395.3 to 418.6)	160.2 (151.8 to 170.3)	47.7 (42.9 to 53.0)	47.9 (32.3 to 64.5)	125.0 (85.9 to 168.3)	161.2 (141.1 to 181.8)	49.1 (38.8 to 58.9)
HIV/AIDS	-	-	-	-	-	40.5 (4.6 to 242.4)	-	-
HIV/AIDS resulting in mycobacterial infection	-	3.1 (0.2 to 18.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	1.2 (0.1 to 7.2)	-	-
HIV/AIDS resulting in other diseases	-	328.3 (51.7 to 1,539.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	39.5 (3.6 to 241.7)	-	-
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	581.4 (411.2 to 793.5)	554.1 (384.4 to 762.7)	-4.5 (-14.3 to 4.2)	-24.3 (-31.6 to -17.7)
Diarrheal diseases	1,489.2 (1,380.2 to 1,597.8)	1,382.7 (1,265.5 to 1,498.9)	-7.4 (-17.8 to 4.4)	-21.6 (-30.0 to -12.2)	242.7 (161.5 to 342.3)	225.2 (152.7 to 313.8)	-7.2 (-17.6 to 4.4)	-21.3 (-29.8 to -11.8)
Intestinal infectious diseases	-	-	-	-	24.5 (16.4 to 34.2)	20.5 (13.4 to 29.0)	-16.2 (-32.9 to 2.8)	-32.1 (-45.3 to -17.1)
Typhoid fever	139.8 (124.5 to 156.4)	116.0 (99.6 to 131.9)	-17.3 (-30.5 to -1.7)	-33.6 (-43.9 to -21.2)	18.4 (12.2 to 26.1)	15.4 (10.0 to 21.9)	-16.0 (-33.8 to 4.0)	-32.2 (-46.0 to -16.0)
Paratyphoid fever	87.7 (75.2 to 100.1)	59.3 (49.3 to 68.1)	-32.0 (-46.4 to -18.5)	-44.9 (-56.6 to -34.0)	4.6 (2.8 to 6.9)	3.1 (1.9 to 4.7)	-32.5 (-47.6 to -12.9)	-45.2 (-57.3 to -30.1)
Other intestinal infectious diseases	-	-	-	-	1.5 (0.6 to 2.9)	2.0 (0.9 to 4.1)	32.8 (-21.7 to 122.5)	7.3 (-35.6 to 79.9)
Lower respiratory infections	76.9 (56.6 to 87.4)	105.3 (93.2 to 115.9)	37.2 (13.9 to 62.9)	21.6 (1.4 to 43.0)	8.1 (5.4 to 11.7)	10.9 (7.2 to 15.5)	34.7 (8.5 to 68.3)	20.0 (-2.2 to 47.6)
Upper respiratory infections	9,488.2 (9,071.8 to 9,970.0)	12,772.2 (12,270.6 to 13,278.8)	34.4 (26.2 to 43.6)	-1.2 (-6.9 to 5.2)	112.0 (62.0 to 188.2)	150.6 (84.4 to 251.5)	34.4 (25.6 to 44.0)	-0.9 (-7.1 to 5.6)
Otitis media	2,335.1 (2,182.7 to 2,492.2)	2,576.3 (2,435.8 to 2,745.8)	10.1 (1.9 to 18.7)	-15.2 (-21.3 to -8.2)	46.0 (26.8 to 73.4)	51.3 (30.0 to 83.1)	11.2 (1.7 to 22.2)	-13.7 (-20.6 to -5.2)
Meningitis	-	-	-	-	118.7 (77.9 to 178.9)	67.4 (46.2 to 94.7)	-42.1 (-58.3 to -26.5)	-57.2 (-68.5 to -46.1)
Pneumococcal meningitis	573.8 (303.6 to 900.4)	338.8 (192.2 to 530.0)	-40.2 (-60.9 to -19.1)	-58.2 (-72.1 to -44.2)	52.5 (29.8 to 99.0)	29.5 (19.6 to 43.0)	-39.0 (-48.9 to -9.6)	-55.7 (-76.5 to -35.7)
H influenzae type B meningitis	293.6 (103.8 to 569.2)	144.3 (46.7 to 294.6)	-50.7 (-65.0 to -36.2)	-65.7 (-74.6 to -54.3)	30.4 (18.8 to 46.0)	15.5 (9.6 to 22.9)	-49.0 (-63.1 to -27.1)	-61.2 (-71.6 to -44.6)
Meningococcal meningitis	43.4 (12.3 to 96.1)	26.1 (7.4 to 61.9)	-41.4 (-59.3 to -18.3)	-61.0 (-71.7 to -43.6)	5.4 (2.8 to 8.9)	3.2 (1.7 to 5.4)	-40.6 (-59.8 to -13.4)	-59.1 (-70.5 to -39.7)
Other meningitis	260.7 (119.1 to 488.7)	153.0 (66.3 to 284.7)	-42.5 (-55.0 to -22.9)	-58.6 (-67.4 to -45.0)	30.3 (18.8 to 44.9)	18.7 (11.6 to 28.1)	-38.4 (-55.3 to -17.5)	-53.9 (-65.9 to -39.5)
Encephalitis	61.2 (26.7 to 131.4)	68.7 (31.6 to 152.3)	11.2 (-8.5 to 29.2)	-25.4 (-38.7 to -13.7)	7.7 (5.3 to 10.5)	9.3 (6.3 to 12.7)	20.7 (8.0 to 44.3)	-17.6 (-30.9 to -3.5)
Diphtheria	0.2 (0.0 to 1.0)	0.1 (0.0 to 0.4)	-33.6 (-94.6 to 88.7)	-44.1 (-95.3 to 65.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-33.6 (-94.7 to 903.1)	-44.1 (-95.3 to 663.9)
Whooping cough	133.8 (103.8 to 171.3)	128.4 (99.8 to 164.3)	-4.1 (-4.7 to -3.6)	-10.3 (-10.8 to -9.8)	6.7 (3.9 to 11.0)	6.4 (3.7 to 10.5)	-3.7 (-12.4 to 5.8)	-9.9 (-17.9 to -1.0)
Tetanus	95.1 (41.8 to 223.0)	5.4 (2.8 to 11.3)	-94.2 (-98.2 to -82.3)	-95.7 (-98.7 to -86.9)	4.6 (2.2 to 8.4)	0.5 (0.2 to 1.2)	-98.1 (-98.1 to -68.6)	-91.4 (-91.4 to -76.9)
Measles	47.6 (35.6 to 62.3)	29.2 (21.4 to 38.5)	-38.8 (-42.8 to -34.2)	-43.2 (-47.0 to -39.0)	4.3 (2.5 to 6.9)	2.6 (1.5 to 4.3)	-42.8 (-51.2 to -22.4)	-42.8 (-54.8 to -28.1)
Varicella and herpes zoster	167.8 (152.8 to 183.6)	236.3 (213.2 to 260.2)	40.9 (22.6 to 60.7)	-2.4 (-15.8 to 13.7)	6.1 (3.6 to 9.6)	9.4 (5.7 to 14.7)	-1.8 (24.3 to 91.9)	-1.8 (-20.3 to 23.5)
Neglected tropical diseases and malaria	-	-	-	-	763.2 (496.1 to 1,122.6)	639.7 (413.5 to 961.6)	-16.9 (-31.5 to 8.9)	-45.7 (-55.1 to -29.7)
Malaria	4,026.7 (3,834.9 to 4,238.0)	4,887.2 (4,621.6 to 5,159.5)	21.1 (16.0 to 26.2)	-13.6 (-17.2 to -9.9)	35.6 (23.0 to 54.0)	46.2 (29.9 to 68.7)	-29.8 (-15.9 to 50.4)	-5.2 (-15.7 to 11.4)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	21.5 (-11.9 to 72.3)	-19.4 (-41.1 to 11.6)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.4 (-57.2 to 137.1)	-15.7 (-60.6 to 86.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.3 (-57.3 to 137.8)	-15.6 (-60.7 to 87.4)
Cutaneous and mucocutaneous leishmaniasis	8.3 (6.0 to 11.0)	10.0 (7.4 to 13.6)	20.3 (-4.3 to 55.1)	-20.4 (-36.7 to 1.3)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	21.5 (-11.8 to 72.5)	-19.4 (-41.1 to 11.8)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	143.0 (54.7 to 348.0)	66.4 (14.4 to 223.8)	-53.5 (-85.9 to -27.0)	-73.4 (-90.4 to -13.7)	1.4 (0.7 to 3.0)	0.8 (0.4 to 1.7)	-48.3 (-69.0 to -4.3)	-64.9 (-78.7 to -35.1)
Cysticercosis	35.0 (13.2 to 91.9)	12.6 (3.7 to 26.7)	-64.2 (-89.5 to 35.0)	-77.4 (-93.3 to -16.7)	9.3 (3.3 to 24.5)	3.7 (1.0 to 8.3)	-60.8 (-88.8 to 58.6)	-75.2 (-92.7 to -5.9)
Cystic echinococcosis	30.1 (26.1 to 34.4)	29.8 (26.9 to 33.1)	-1.1 (-11.9 to 9.7)	-34.6 (-40.7 to -29.8)	2.8 (1.8 to 4.2)	2.8 (1.8 to 4.2)	-0.9 (-21.2 to 30.4)	-34.3 (-46.3 to -17.1)
Lymphatic filariasis	11,420.3 (10,084.7 to 12,986.6)	6,819.9 (5,596.9 to 8,361.9)	-40.5 (-49.9 to -30.3)	-62.5 (-68.6 to -36.8)	310.9 (170.3 to 514.5)	310.9 (151.6 to 474.3)	-284.1 (-31.1 to 11.1)	-49.4 (-62.5 to -38.8)
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	96.9 (32.3 to 238.8)	660.7 (220.1 to 1,628.6)	580.1 (579.3 to 580.7)	395.5 (394.9 to 396.0)	15.9 (4.6 to 43.0)	108.3 (31.2 to 293.8)	580.6 (506.0 to 667.2)	398.3 (348.2 to 455.1)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Intestinal nematode infections	-	-	-	-	280.0 (157.2 to 483.6)	109.0 (64.5 to 174.7)	-60.7 (-69.2 to -51.8)	-70.4 (-77.1 to -63.5)
Ascariasis	45,038.4 (36,970.8 to 55,200.8)	33,409.7 (24,285.7 to 45,170.7)	-25.9 (-49.2 to 5.4)	-47.3 (-64.6 to -23.7)	132.4 (67.3 to 250.4)	35.2 (17.8 to 61.0)	-73.5 (-81.7 to -60.5)	-77.8 (-85.2 to -66.7)
Trichuriasis	41,590.6 (33,323.2 to 52,239.1)	22,198.3 (16,596.1 to 29,639.1)	-47.1 (-63.6 to -22.3)	-62.7 (-75.0 to -44.0)	51.4 (25.4 to 97.5)	9.3 (4.7 to 16.4)	-81.5 (-89.0 to -71.1)	-81.5 (-92.9 to -79.4)
Hookworm disease	22,859.5 (18,068.2 to 28,670.4)	16,011.0 (12,429.9 to 20,705.6)	-30.3 (-50.4 to 1.7)	-51.2 (-66.2 to -27.6)	96.1 (56.6 to 154.6)	51.7 (38.5 to 100.4)	-52.2 (-53.5 to -15.0)	-52.2 (-67.5 to -39.2)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	3,022.5 (2,408.0 to 3,667.9)	2,536.7 (2,242.7 to 2,893.8)	-16.7 (-31.6 to 4.9)	-32.8 (-44.0 to -17.3)	107.3 (66.1 to 158.6)	84.8 (54.0 to 123.5)	-22.2 (-36.4 to 9.6)	-34.8 (-46.7 to -9.8)
Maternal disorders	-	-	-	-	7.4 (4.4 to 11.2)	7.9 (4.6 to 12.2)	8.2 (-27.0 to 49.5)	-24.6 (-48.9 to 3.1)
Maternal hemorrhage	68.7 (60.3 to 80.7)	111.9 (73.2 to 149.1)	60.4 (1.9 to 122.4)	13.5 (-27.1 to 57.9)	3.1 (1.9 to 4.7)	3.7 (1.6 to 5.8)	20.0 (-46.1 to 84.4)	20.0 (-61.5 to 30.4)
Maternal sepsis and other maternal infections	68.9 (41.4 to 107.1)	70.7 (45.3 to 102.3)	2.2 (-17.6 to 43.9)	-41.4 (-51.1 to -16.1)	0.8 (0.4 to 1.5)	0.7 (0.4 to 1.3)	-13.8 (-48.4 to 46.2)	-43.0 (-64.2 to -5.2)
Maternal hypertensive disorders	28.4 (14.0 to 48.5)	30.7 (16.4 to 50.7)	7.5 (-2.3 to 29.0)	-23.3 (-29.2 to -11.2)	1.5 (0.6 to 2.7)	1.6 (0.7 to 2.9)	8.5 (-14.8 to 46.0)	-22.8 (-38.9 to 0.8)
Obstructed labor	1.6 (0.8 to 2.7)	1.2 (0.6 to 2.1)	-19.3 (-60.3 to 58.4)	-44.3 (-72.9 to 8.6)	0.5 (0.2 to 1.0)	0.4 (0.2 to 0.8)	-15.9 (-65.2 to 111.7)	-42.0 (-76.1 to 41.7)
Complications of abortion	0.5 (0.3 to 0.9)	0.8 (0.5 to 1.3)	60.0 (-18.9 to 203.0)	-2.6 (-44.3 to 84.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	69.5 (-19.2 to 203.5)	-2.7 (-44.3 to 84.9)
Other maternal disorders	-	-	-	-	1.4 (0.7 to 2.6)	1.5 (0.7 to 2.5)	8.1 (-47.1 to 135.0)	-24.6 (-63.3 to 62.2)
Neonatal disorders	-	-	-	-	167.7 (109.4 to 242.5)	469.1 (332.5 to 625.7)	179.0 (110.8 to 298.2)	112.8 (61.1 to 202.0)
Preterm birth complications	817.7 (541.8 to 1,257.2)	2,823.7 (1,887.0 to 4,299.9)	245.4 (162.2 to 358.4)	150.7 (88.1 to 233.3)	70.4 (46.5 to 103.1)	287.4 (202.0 to 400.5)	311.1 (206.3 to 449.3)	210.0 (133.7 to 311.7)
Neonatal encephalopathy due to birth asphyxia and trauma	720.1 (192.8 to 1,702.5)	797.8 (302.2 to 1,769.7)	15.8 (-29.8 to 97.4)	-17.3 (-51.2 to 43.8)	33.6 (17.5 to 56.4)	76.9 (47.2 to 108.7)	134.3 (87.7 to 223.5)	77.7 (3.6 to 230.5)
Neonatal sepsis and other neonatal infections	6.9 (0.3 to 2.0)	1.2 (0.4 to 2.7)	-82.2 (-123.2 to 54.2)	-40.2 (-20.9 to 51.3)	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.4)	-82.2 (-18.5 to 69.0)	38.2 (16.3 to 65.9)
Hemolytic disease and other neonatal jaundice	56.9 (24.6 to 103.8)	111.8 (53.2 to 176.3)	96.6 (6.6 to 515.5)	48.5 (-27.3 to 375.2)	21.6 (8.8 to 39.6)	42.3 (18.9 to 70.4)	92.6 (-9.1 to 496.0)	47.0 (-29.2 to 356.3)
Other neonatal disorders	-	-	-	-	42.0 (20.7 to 72.5)	62.4 (29.6 to 128.0)	45.7 (-35.0 to 256.8)	11.0 (-50.5 to 167.9)
Nutritional deficiencies	-	-	-	-	1,936.0 (1,291.1 to 2,779.6)	1,472.5 (986.8 to 2,129.7)	-24.0 (-28.7 to -19.0)	-42.1 (-45.6 to -38.2)
Protein-energy malnutrition	1,167.2 (751.6 to 1,752.2)	881.7 (489.0 to 1,362.8)	-25.3 (-62.5 to 43.7)	-29.5 (-62.9 to 31.9)	96.1 (75.9 to 250.2)	146.4 (51.8 to 202.2)	25.1 (-62.5 to 43.4)	29.4 (-63.3 to 33.8)
Iodine deficiency	1,780.5 (823.4 to 3,208.1)	1,760.4 (902.6 to 3,010.4)	-1.4 (-60.3 to 143.4)	-35.7 (-73.9 to 53.5)	32.3 (12.9 to 66.9)	31.6 (13.6 to 60.2)	-1.7 (-60.5 to 147.0)	-36.1 (-74.1 to 56.5)
Vitamin A deficiency	95.9 (70.5 to 123.7)	47.3 (33.8 to 61.3)	-50.3 (-57.9 to -40.9)	-62.7 (-67.5 to -55.8)	5.3 (3.2 to 8.2)	2.6 (1.5 to 4.0)	-51.7 (-60.2 to -40.2)	-64.1 (-70.1 to -56.6)

Appendix Table G.4 - Indonesia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	53,185.9 (52,573.7 to 53,797.6)	44,562.6 (43,813.3 to 45,207.3)	-16.4 (-18.2 to -14.9)	-9.3 (-10.8 to -7.8)	1,743.4 (1,167.2 to 2,521.9)	1,319.9 (875.1 to 1,930.3)	-24.2 (-27.3 to -22.4)	-42.1 (-45.4 to -41.7)
Other nutritional deficiencies	-	-	-	-	8.6 (2.4 to 21.9)	7.7 (2.8 to 19.5)	-5.6 (-66.2 to 164.0)	-12.1 (-67.5 to 143.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	130.2 (82.9 to 192.5)	130.1 (83.2 to 194.9)	-0.2 (-14.6 to 13.4)	-24.1 (-34.1 to -15.1)
Sexually transmitted diseases excluding HIV	-	-	-	-	38.9 (22.1 to 63.8)	52.7 (29.3 to 84.1)	35.4 (15.6 to 57.9)	-7.7 (-19.9 to 6.2)
Syphilis	6.5 (5.7 to 7.3)	6.2 (5.3 to 7.0)	-5.7 (-21.5 to 13.3)	-44.5 (-52.3 to -35.3)	1.2 (0.7 to 1.9)	1.2 (0.7 to 1.8)	0.9 (-30.0 to 37.7)	43.9 (-58.1 to -21.8)
Chlamydial infection	5,795.8 (4,110.0 to 8,004.4)	5,107.3 (3,969.6 to 7,546.8)	-12.7 (-45.0 to 49.9)	-38.2 (-60.7 to 6.4)	26.6 (14.5 to 44.1)	35.2 (19.1 to 57.9)	32.3 (6.9 to 64.3)	-6.5 (-23.5 to 14.8)
Gonococcal infection	748.6 (490.9 to 1,096.6)	1,042.3 (666.5 to 1,437.1)	46.4 (-32.7 to 131.6)	6.0 (-50.3 to 66.8)	4.8 (2.6 to 8.4)	6.7 (3.6 to 11.3)	41.0 (-11.1 to 119.1)	0.9 (-34.5 to 54.6)
Trichomoniasis	593.9 (348.3 to 829.1)	971.9 (585.4 to 1,327.8)	65.0 (-8.3 to 194.4)	1.8 (-4.6 to 84.2)	0.9 (0.3 to 2.1)	1.5 (0.5 to 3.6)	70.1 (-22.5 to 255.1)	4.7 (-54.6 to 120.1)
Genital herpes	17,603.2 (16,790.4 to 18,434.4)	27,234.8 (25,940.8 to 28,711.8)	54.6 (44.3 to 64.9)	8.4 (-14.3 to -2.1)	4.8 (1.5 to 11.4)	7.2 (2.3 to 17.5)	50.4 (34.9 to 63.5)	8.3 (-15.3 to -0.8)
Other sexually transmitted diseases	32.1 (24.0 to 42.4)	37.9 (28.9 to 48.4)	18.1 (2.6 to 34.8)	32.2 (-41.4 to 23.3)	0.6 (0.4 to 1.0)	0.8 (0.5 to 1.3)	32.7 (-11.6 to 105.1)	15.7 (-42.8 to 28.6)
Hepatitis	-	-	-	-	11.5 (7.2 to 17.0)	13.9 (8.9 to 20.6)	20.8 (5.5 to 43.8)	-16.0 (-27.1 to 4.4)
Hepatitis A	264.8 (254.1 to 275.2)	302.3 (293.3 to 311.1)	13.9 (12.8 to 15.2)	-4.1 (-4.2 to -3.9)	5.8 (3.7 to 8.6)	7.5 (4.8 to 11.0)	27.4 (13.1 to 42.9)	1.8 (-9.7 to 13.8)
Hepatitis B	9,733.2 (8,321.7 to 11,285.3)	9,760.8 (8,827.4 to 10,871.3)	-0.2 (-17.4 to 21.6)	-31.8 (-43.4 to -17.9)	4.2 (2.4 to 6.5)	4.8 (2.9 to 7.6)	13.7 (-5.4 to 36.9)	-31.8 (-50.4 to 16.4)
Hepatitis C	1,796.3 (1,656.0 to 1,942.6)	2,084.9 (1,895.2 to 2,275.5)	15.9 (2.6 to 30.7)	-27.4 (-35.3 to -18.4)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	7.3 (-15.4 to 63.9)	-32.0 (-50.4 to -8.3)
Hepatitis E	42.5 (37.7 to 47.7)	48.4 (40.2 to 57.4)	14.1 (-10.5 to 40.2)	-17.3 (-34.5 to 1.4)	1.2 (0.8 to 1.8)	1.4 (0.8 to 2.2)	14.5 (-18.1 to 57.8)	-18.1 (-40.9 to 12.8)
Leprosy	25.3 (20.6 to 30.2)	42.7 (36.8 to 49.0)	68.8 (55.6 to 85.1)	-7.1 (-13.8 to 1.2)	1.5 (1.0 to 2.3)	2.6 (1.7 to 3.9)	70.8 (41.5 to 105.9)	-6.2 (-20.3 to 9.4)
Other infectious diseases	2,281.8 (1,873.8 to 2,670.0)	1,877.9 (1,576.4 to 2,184.8)	-17.7 (-35.3 to 0.9)	-35.8 (-48.5 to -22.7)	78.2 (49.5 to 112.9)	60.8 (37.6 to 89.1)	-21.9 (-46.3 to -3.7)	-36.3 (-55.2 to -22.9)
Non-communicable diseases	-	-	-	-	17,293.3 (7,796.3 to 13,694.5)	22,258.5 (12,827.7 to 22,258.5)	29.2 (55.8 to 71.6)	0.5 (-3.0 to 5.2)
Neoplasms	-	-	-	-	53.6 (37.6 to 72.0)	134.3 (94.5 to 177.9)	150.2 (110.3 to 194.7)	40.9 (20.8 to 64.1)
Esophageal cancer	2.6 (2.0 to 3.3)	6.1 (4.3 to 8.1)	133.0 (68.1 to 217.3)	22.6 (-11.8 to 64.7)	0.4 (0.3 to 0.6)	1.0 (0.6 to 1.4)	125.0 (71.1 to 191.4)	17.9 (-11.9 to 58.2)
Stomach cancer	15.0 (12.4 to 17.8)	31.7 (26.4 to 38.1)	113.3 (66.8 to 170.8)	12.8 (-12.0 to 44.8)	2.0 (1.4 to 2.7)	4.0 (2.7 to 5.4)	97.4 (53.1 to 154.7)	5.2 (-19.5 to 39.4)
Liver cancer	-	-	-	-	0.6 (0.4 to 0.8)	2.4 (1.5 to 3.3)	318.3 (216.4 to 446.1)	328.5 (171.5 to 196.9)
Liver cancer due to hepatitis B	0.7 (0.4 to 1.1)	3.3 (1.8 to 6.1)	375.2 (134.0 to 816.1)	161.0 (27.3 to 406.7)	0.1 (0.1 to 0.2)	0.6 (0.3 to 1.0)	339.1 (148.6 to 677.7)	138.8 (32.9 to 329.3)
Liver cancer due to hepatitis C	1.1 (0.7 to 1.6)	8.1 (4.7 to 12.0)	612.7 (307.1 to 1,133.8)	283.2 (122.5 to 552.7)	0.2 (0.1 to 0.3)	1.3 (0.7 to 2.0)	559.1 (317.6 to 921.8)	249.4 (125.3 to 425.9)
Liver cancer due to alcohol use	0.5 (0.3 to 0.7)	0.9 (0.5 to 1.6)	81.8 (-7.9 to 288.5)	-2.2 (-49.5 to 98.8)	0.1 (0.1 to 0.1)	0.3 (0.1 to 0.3)	69.8 (-5.0 to 230.1)	-7.9 (-48.1 to 71.2)
Liver cancer due to other causes	0.8 (0.6 to 1.2)	1.8 (1.1 to 2.8)	112.1 (20.1 to 291.4)	0.1 (-29.7 to 134.3)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	101.8 (25.3 to 248.2)	38.4 (-26.7 to 104.9)
Larynx cancer	8.5 (5.7 to 11.2)	17.5 (11.7 to 23.3)	108.5 (46.4 to 177.1)	12.8 (-20.6 to 50.0)	0.8 (0.5 to 1.2)	1.7 (1.0 to 2.6)	108.2 (44.4 to 187.6)	12.4 (-20.9 to 58.4)
Tracheal, bronchus and lung cancer	22.8 (19.1 to 27.2)	57.4 (45.7 to 70.6)	151.0 (102.9 to 213.3)	37.1 (10.0 to 70.6)	3.7 (2.6 to 5.1)	9.0 (6.1 to 12.2)	139.5 (88.2 to 201.7)	30.1 (1.5 to 65.0)
Breast cancer	112.0 (87.0 to 151.4)	452.6 (366.2 to 574.3)	306.9 (213.9 to 421.9)	123.1 (74.3 to 184.3)	8.8 (5.6 to 13.3)	29.8 (19.1 to 44.3)	240.8 (159.0 to 344.3)	84.0 (44.4 to 138.0)
Cervical cancer	140.0 (90.9 to 176.2)	202.5 (133.6 to 264.9)	43.9 (2.9 to 105.5)	49.8 (-4.2 to 111.4)	4.4 (6.2 to 15.2)	15.2 (8.9 to 22.0)	46.0 (3.2 to 113.3)	-18.8 (-41.8 to 14.7)
Uterine cancer	27.6 (16.5 to 41.8)	60.2 (37.8 to 96.9)	119.1 (19.5 to 261.2)	17.8 (-32.9 to 93.3)	1.9 (1.0 to 3.1)	4.0 (2.1 to 7.1)	115.7 (34.6 to 261.1)	15.5 (-34.6 to 91.2)
Prostate cancer	15.8 (10.1 to 22.6)	75.1 (49.2 to 112.8)	370.2 (223.5 to 635.4)	148.4 (69.5 to 286.6)	1.5 (0.9 to 2.4)	7.0 (4.2 to 11.1)	351.8 (209.2 to 623.3)	138.6 (61.7 to 275.7)
Colon and rectum cancer	39.7 (34.7 to 45.0)	129.1 (109.6 to 150.3)	225.6 (163.0 to 289.3)	73.4 (40.8 to 108.2)	3.7 (2.6 to 4.9)	11.2 (7.8 to 15.0)	201.7 (141.7 to 270.5)	60.8 (30.3 to 99.0)
Lip and oral cavity cancer	31.4 (21.1 to 40.8)	69.5 (49.6 to 92.6)	121.4 (62.6 to 198.3)	20.0 (-14.0 to 62.9)	2.8 (1.2 to 4.2)	6.2 (3.9 to 9.1)	117.1 (59.4 to 195.5)	17.6 (-15.2 to 53.7)
Nasopharynx cancer	12.4 (9.0 to 16.7)	24.5 (17.2 to 34.6)	96.5 (30.3 to 201.8)	8.9 (-27.8 to 61.8)	1.2 (0.8 to 1.8)	2.4 (1.5 to 3.6)	91.0 (29.1 to 183.4)	5.9 (-27.3 to 54.7)
Other pharynx cancer	9.0 (6.1 to 12.8)	16.3 (10.8 to 24.0)	79.3 (10.4 to 200.1)	-4.1 (-40.8 to 56.0)	0.9 (0.5 to 1.3)	1.5 (0.9 to 2.4)	75.9 (11.4 to 180.1)	-6.5 (-40.5 to 47.2)
Gallbladder and biliary tract cancer	2.2 (1.2 to 2.9)	3.6 (2.2 to 4.8)	65.5 (15.2 to 140.5)	-12.3 (-39.4 to 30.7)	0.6 (0.3 to 0.9)	1.0 (0.5 to 1.4)	54.6 (7.7 to 116.1)	-17.8 (-44.3 to 18.4)
Pancreatic cancer	2.2 (1.8 to 2.7)	5.5 (4.4 to 6.8)	147.4 (89.8 to 222.0)	30.9 (-1.6 to 71.3)	0.5 (0.3 to 0.7)	1.2 (0.8 to 1.6)	132.8 (85.5 to 191.9)	22.2 (-4.3 to 54.6)
Malignant skin melanoma	4.4 (4.4 to 8.3)	8.3 (11.6 to 22.8)	15.9 (76.4 to 300.9)	42.4 (0.4 to 118.4)	0.4 (0.2 to 0.6)	1.0 (0.6 to 1.7)	147.8 (61.2 to 287.5)	38.2 (-5.7 to 111.2)
Non-melanoma skin cancer	10.0 (6.1 to 13.8)	31.5 (22.6 to 43.0)	210.6 (118.6 to 470.1)	63.0 (14.9 to 196.1)	0.3 (0.2 to 0.5)	1.4 (0.8 to 2.1)	296.6 (169.6 to 488.7)	104.9 (27.3 to 223.7)
Ovarian cancer	10.9 (7.9 to 14.9)	28.9 (20.3 to 38.8)	166.6 (85.1 to 269.8)	49.3 (5.7 to 105.2)	1.5 (0.9 to 2.3)	3.8 (2.2 to 5.7)	158.2 (70.3 to 304.9)	45.6 (-3.7 to 121.4)
Testicular cancer	1.7 (0.9 to 3.2)	5.5 (2.9 to 10.0)	212.7 (68.5 to 455.6)	82.8 (-0.4 to 221.4)	0.1 (0.0 to 0.2)	0.3 (0.2 to 0.7)	205.2 (44.7 to 481.5)	77.4 (-16.0 to 237.7)
Kidney cancer	6.2 (6.4 to 10.9)	23.5 (18.8 to 28.9)	182.0 (102.0 to 280.3)	67.4 (24.6 to 117.8)	0.7 (0.4 to 1.0)	1.8 (1.2 to 2.6)	175.2 (99.0 to 271.0)	58.3 (18.8 to 108.8)
Bladder cancer	7.1 (5.1 to 8.8)	19.5 (14.6 to 25.0)	175.3 (99.5 to 282.3)	37.2 (-1.0 to 89.5)	0.7 (0.4 to 0.9)	1.7 (1.1 to 2.4)	161.8 (86.1 to 256.2)	28.8 (-9.5 to 76.6)
Brain and nervous system cancer	15.4 (9.6 to 26.3)	32.9 (23.4 to 40.9)	125.5 (24.4 to 211.8)	47.2 (-6.6 to 93.0)	1.5 (0.9 to 2.5)	3.4 (2.1 to 4.7)	124.6 (35.4 to 200.6)	41.5 (-2.3 to 83.7)
Thyroid cancer	33.1 (21.6 to 47.7)	97.5 (65.1 to 135.9)	196.4 (90.8 to 362.6)	59.6 (5.2 to 139.1)	2.0 (1.1 to 3.2)	5.7 (3.2 to 9.1)	187.6 (84.4 to 354.6)	56.2 (3.3 to 134.5)
Mesothelioma	0.4 (0.3 to 0.6)	0.7 (0.5 to 0.9)	67.5 (14.0 to 147.7)	67.5 (-37.3 to 35.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	79.5 (18.1 to 147.0)	6.8 (-35.6 to 33.6)
Hodgkin lymphoma	5.9 (3.6 to 8.8)	11.1 (8.1 to 14.9)	86.8 (9.4 to 239.8)	41.2 (8.4 to 130.1)	0.5 (0.3 to 0.7)	0.9 (0.6 to 1.4)	93.7 (21.3 to 214.4)	40.4 (-4.3 to 111.0)
Non-Hodgkin lymphoma	21.4 (16.0 to 30.2)	65.8 (50.4 to 85.3)	210.2 (121.5 to 314.4)	91.1 (39.5 to 153.0)	1.7 (1.1 to 2.6)	4.9 (3.1 to 7.3)	199.3 (114.9 to 308.1)	78.8 (29.0 to 147.6)
Multiple myeloma	1.0 (0.6 to 1.5)	2.7 (1.8 to 3.6)	170.6 (69.0 to 327.6)	43.3 (-10.7 to 126.1)	0.2 (0.1 to 0.4)	0.6 (0.4 to 0.9)	162.3 (72.3 to 290.4)	37.9 (-9.1 to 107.7)
Leukemia	22.7 (13.6 to 37.1)	50.0 (37.8 to 65.3)	124.1 (34.6 to 274.7)	66.9 (10.0 to 147.5)	2.5 (1.6 to 3.9)	5.8 (3.9 to 8.0)	131.4 (56.8 to 214.1)	58.1 (15.9 to 105.6)
Other neoplasms	19.5 (13.6 to 32.3)	74.8 (57.9 to 99.5)	300.6 (123.5 to 462.3)	138.5 (62.1 to 221.8)	1.5 (0.9 to 2.4)	5.3 (3.3 to 7.6)	271.2 (131.2 to 409.4)	112.1 (54.7 to 182.4)
Cardiovascular diseases	-	-	-	-	330.2 (225.9 to 454.5)	728.2 (496.9 to 1,013.2)	121.3 (76.9 to 176.8)	22.5 (0.8 to 47.5)
Rheumatic heart disease	2,182.3 (1,440.9 to 2,849.9)	3,453.1 (2,659.0 to 4,225.9)	58.9 (1.6 to 146.3)	2.9 (-32.4 to 47.2)	110.9 (62.6 to 171.9)	177.7 (110.1 to 265.5)	60.7 (6.2 to 143.0)	2.7 (-29.8 to 46.2)
Ischemic heart disease	846.0 (702.3 to 1,063.4)	1,666.3 (1,380.0 to 2,069.8)	96.5 (44.3 to 163.3)	0.3 (-24.5 to 32.0)	59.1 (39.4 to 84.8)	117.7 (76.9 to 169.4)	97.9 (49.0 to 160.4)	1.3 (-22.9 to 31.1)
Cerebrovascular disease	-	-	-	-	44.5 (30.8 to 58.8)	85.4 (59.0 to 116.1)	91.0 (56.8 to 133.1)	2.7 (-17.3 to 29.0)
Ischemic stroke	137.2 (117.8 to 158.4)	270.1 (227.6 to 316.8)	96.0 (56.7 to 148.8)	3.6 (-17.4 to 33.4)	20.5 (13.7 to 28.2)	40.4 (27.0 to 55.7)	96.2 (55.5 to 148.4)	4.1 (-18.4 to 33.8)
Hemorrhagic stroke	159.0 (141.0 to 180.9)	297.9 (252.2 to 345.3)	87.6 (47.6 to 126.1)	1.2 (-21.9 to 25.2)	24.0 (16.3 to 32.4)	44.9 (29.8 to 62.0)	87.8 (47.0 to 128.8)	1.8 (-21.8 to 26.8)
Hypertensive heart disease	208.2 (179.9 to 234.4)	398.6 (340.6 to 456.8)	90.3 (57.8 to 133.8)	1.6 (-18.8 to 20.2)	23.4 (16.0 to 32.8)	44.8 (29.6 to 63.4)	90.5 (56.2 to 136.3)	-1.3 (-19.2 to 23.1)
Cardiomyopathy and myocarditis	99.1 (84.4 to 113.7)	197.2 (173.7 to 221.1)	99.2 (65.1 to 141.2)	11.9 (-9.0 to 39.0)	10.9 (7.3 to 15.3)	21.7 (14.5 to 30.1)	99.4 (62.3 to 147.6)	12.1 (-9.6 to 41.9)
Atrial fibrillation and flutter	65.2 (50.1 to 79.6)	172.5 (133.0 to 219.6)	162.8 (94.1 to 263.4)	34.7 (-2.3 to 94.7)	5.2 (3.3 to 7.6)	13.7 (8.6 to 20.3)	163.4 (89.6 to 273.8)	35.6 (-2.4 to 99.0)
Peripheral vascular disease	4,195.6 (3,430.6 to 4,932.4)	7,584.2 (6,082.8 to 9,128.3)	80.7 (37.1 to 129.8)	-6.5 (-27.7 to 16.5)	2.0 (0.8 to 4.3)	3.1 (1.3 to 6.3)	57.1 (-29.3 to 265.5)	-21.1 (-63.7 to 88.8)
Endocarditis	6.7 (4.8 to 8.9)</							

Appendix Table G.4 - Indonesia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumococcosis	-	-	-	-	1.0 (0.7 to 1.4)	2.7 (1.9 to 3.8)	161.7 (143.6 to 178.4)	56.1 (29.7 to 50.5)
Silicosis	1.2 (1.1 to 1.2)	1.9 (1.8 to 2.1)	65.4 (57.9 to 73.6)	-13.0 (-16.9 to -8.5)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	64.7 (57.2 to 73.0)	-13.3 (-17.3 to -8.6)
Asbestosis	-	-	0.0 (0.0 to 0.0)	-	-	-	-	-
Coal workers pneumococcosis	1.4 (1.3 to 1.5)	2.2 (2.1 to 2.3)	56.5 (51.0 to 62.1)	-15.6 (-18.3 to -12.6)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	56.1 (50.2 to 61.6)	-15.6 (-18.4 to -12.6)
Other pneumococcosis	0.0 (2.8 to 3.2)	10.7 (9.8 to 11.4)	258.1 (240.8 to 275.2)	2.0 (89.9 to 107.1)	0.5 (0.4 to 0.8)	2.0 (1.3 to 2.9)	251.0 (231.8 to 270.6)	39.4 (18.4 to 108.7)
Asthma	3,824.4 (2,873.3 to 4,634.1)	2,889.7 (2,476.4 to 3,360.3)	-25.8 (-40.1 to -6.7)	-44.8 (-54.0 to -25.5)	170.2 (105.1 to 253.3)	127.2 (81.1 to 186.2)	-26.6 (-40.9 to 7.0)	-45.3 (-54.5 to -25.6)
Interstitial lung disease and pulmonary sarcoidosis	11.5 (9.1 to 13.9)	21.4 (17.0 to 25.9)	86.7 (34.6 to 146.7)	8.5 (-21.0 to 42.9)	1.6 (1.0 to 2.4)	2.9 (1.7 to 4.5)	86.7 (32.5 to 147.2)	6.8 (-24.1 to 44.8)
Other chronic respiratory diseases	-	-	-	-	192.7 (99.4 to 329.8)	122.8 (74.1 to 198.8)	-35.3 (-59.0 to 1.9)	-63.6 (-77.4 to -42.7)
Cirrhosis	-	-	-	-	12.6 (8.8 to 17.8)	16.1 (11.2 to 22.3)	28.1 (12.7 to 45.7)	-22.5 (-30.5 to -12.7)
Cirrhosis due to hepatitis B	23.8 (19.8 to 28.7)	30.6 (22.4 to 38.4)	27.2 (-13.1 to 81.6)	-24.1 (-48.2 to 8.0)	4.0 (2.5 to 5.9)	5.1 (3.1 to 7.9)	27.7 (-16.6 to 89.3)	23.8 (-49.3 to 11.9)
Cirrhosis due to hepatitis C	14.2 (9.6 to 20.1)	22.1 (11.8 to 33.8)	55.8 (-23.9 to 221.7)	-4.8 (-49.8 to 123.6)	2.4 (1.3 to 3.8)	3.7 (1.8 to 6.2)	54.1 (-27.1 to 219.5)	-4.8 (-53.0 to 115.0)
Cirrhosis due to alcohol use	23.8 (18.7 to 29.5)	25.5 (17.7 to 35.0)	6.8 (-30.5 to 64.5)	-40.5 (-60.2 to -11.1)	4.0 (2.4 to 6.0)	4.2 (2.5 to 6.8)	6.3 (-33.9 to 68.3)	40.5 (-1.3 to -9.4)
Cirrhosis due to other causes	12.9 (10.7 to 15.4)	18.0 (13.7 to 24.8)	38.1 (-1.8 to 97.2)	1.3 (-29.1 to 48.7)	2.2 (1.4 to 3.4)	3.1 (1.8 to 4.9)	38.4 (-11.9 to 119.7)	61.9 (-35.6 to 64.2)
Digestive diseases	-	-	-	-	140.9 (97.4 to 195.6)	174.3 (121.0 to 235.9)	23.6 (-33.7 to -21.5)	27.7 (-11.4 to 65.7)
Peptic ulcer disease	874.6 (691.6 to 993.6)	876.5 (742.7 to 978.9)	0.1 (-13.5 to 20.1)	-44.1 (-50.2 to -34.5)	32.0 (21.6 to 46.6)	32.6 (22.1 to 45.5)	2.8 (-22.9 to 24.4)	45.4 (-55.8 to -36.4)
Gastritis and duodenitis	1,610.2 (1,452.6 to 1,737.7)	1,729.3 (1,575.8 to 1,870.3)	6.9 (-4.4 to 20.2)	-33.8 (-39.7 to -27.1)	60.9 (40.6 to 86.6)	70.0 (46.8 to 98.4)	15.0 (-0.2 to 37.0)	27.0 (-34.4 to -16.8)
Appendicitis	13.6 (10.8 to 16.7)	15.1 (11 to 18.5)	10.3 (-20.6 to 55.4)	-24.4 (-45.4 to 4.1)	4.2 (2.5 to 6.4)	4.7 (2.8 to 7.0)	11.3 (-30.1 to 76.4)	-23.2 (-49.9 to 18.5)
Paralytic ileus and intestinal obstruction	1.1 (0.9 to 1.2)	1.9 (1.6 to 2.1)	77.0 (42.3 to 107.8)	1.7 (-14.7 to 22.8)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.8)	75.6 (35.6 to 112.0)	4.6 (-13.9 to 37.5)
Inguinal, femoral, and abdominal hernia	802.4 (654.1 to 1,009.0)	1,014.6 (848.3 to 1,170.8)	27.8 (-4.3 to 57.9)	-18.3 (-36.1 to 0.5)	8.5 (4.1 to 16.7)	10.7 (5.3 to 20.7)	26.8 (-5.4 to 58.2)	-28.1 (-36.2 to 1.5)
Inflammatory bowel disease	21.6 (20.5 to 22.6)	37.4 (35.6 to 39.0)	72.9 (62.6 to 84.3)	1.3 (-4.5 to 8.0)	4.7 (3.1 to 6.5)	8.0 (5.4 to 11.1)	71.2 (43.0 to 106.3)	0.8 (-14.6 to 20.0)
Vascular intestinal disorders	0.5 (0.4 to 0.6)	0.8 (0.6 to 1.0)	66.6 (29.2 to 121.7)	-7.3 (-31.8 to 32.9)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	65.7 (23.3 to 126.8)	-6.7 (-39.9 to 46.7)
Gallbladder and biliary diseases	44.5 (39.6 to 49.1)	56.2 (50.3 to 61.9)	26.2 (8.2 to 46.3)	-22.3 (-32.3 to -10.5)	4.8 (3.1 to 6.7)	6.0 (4.0 to 8.3)	25.0 (3.5 to 51.0)	42.5 (-34.4 to -8.2)
Pancreatitis	35.5 (33.4 to 38.0)	72.3 (68.7 to 75.6)	103.0 (88.4 to 120.3)	14.2 (5.8 to 23.8)	14.2 (7.2 to 14.5)	21.7 (14.7 to 29.6)	14.9 (7.6 to 138.0)	19.9 (-0.8 to 32.7)
Other digestive diseases	-	-	-	-	14.8 (9.5 to 22.9)	19.9 (12.8 to 29.1)	35.4 (0.5 to 77.3)	-20.8 (-41.0 to 2.7)
Neurological disorders	-	-	-	-	1,203.3 (779.6 to 1,735.1)	2,077.7 (1,371.8 to 2,912.7)	71.4 (31.9 to 135.8)	7.6 (-13.4 to 42.2)
Alzheimer disease and other dementias	567.0 (482.2 to 651.7)	1,116.2 (936.4 to 1,298.3)	97.6 (57.5 to 142.0)	-1.5 (-21.7 to 22.3)	79.8 (55.4 to 107.5)	160.0 (112.2 to 217.8)	101.8 (60.9 to 147.3)	-0.7 (-21.3 to 24.5)
Parkinson disease	55.5 (48.1 to 62.7)	108.2 (94.2 to 122.0)	94.4 (86.7 to 102.7)	1.2 (-3.0 to 5.7)	6.7 (4.6 to 9.2)	13.1 (8.9 to 18.0)	95.8 (74.0 to 118.1)	2.0 (-8.4 to 13.0)
Epilepsy	1,119.2 (830.1 to 1,408.9)	1,451.1 (1,041.1 to 1,842.1)	29.4 (-11.9 to 91.7)	-7.2 (-36.1 to 36.7)	326.8 (205.9 to 483.5)	459.0 (285.0 to 671.8)	39.9 (-5.3 to 111.4)	0.8 (-30.8 to 52.2)
Multiple sclerosis	1.1 (1.0 to 1.2)	3.4 (3.2 to 3.7)	216.4 (187.1 to 255.6)	0.4 (-64.1 to 101.1)	0.4 (0.3 to 0.5)	1.2 (0.9 to 1.6)	216.2 (186.7 to 255.4)	80.7 (64.1 to 101.2)
Migraine	17,813.9 (11,391.5 to 23,597.9)	31,766.7 (23,630.6 to 40,788.6)	77.0 (9.3 to 217.2)	11.2 (-29.0 to 97.3)	61.3 (327.8 to 999.5)	1,099.8 (605.1 to 1,702.5)	9.3 (8.4 to 211.1)	11.9 (-28.7 to 99.0)
Tension-type headache	37,510.9 (33,723.5 to 41,594.8)	57,747.1 (53,614.7 to 61,806.2)	53.5 (33.9 to 74.3)	1.0 (-10.4 to 14.1)	57.3 (27.6 to 99.4)	88.1 (42.3 to 154.1)	53.4 (34.1 to 76.4)	1.5 (-10.5 to 15.2)
Medication overuse headache	575.8 (381.5 to 762.3)	1,435.1 (986.1 to 1,880.1)	148.2 (108.7 to 193.7)	48.0 (27.0 to 76.8)	91.7 (51.4 to 140.4)	228.1 (129.8 to 353.5)	147.9 (108.0 to 195.2)	48.8 (25.4 to 78.0)
Other neurological disorders	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	52.6 (13.7 to 103.1)	5.3 (-22.9 to 39.5)	22.3 (13.1 to 35.3)	28.3 (18.3 to 42.6)	28.2 (-12.4 to 86.3)	36.7 (-57.4 to -6.8)
Mental and substance use disorders	-	-	-	-	2,970.7 (2,114.0 to 3,960.6)	4,533.0 (3,213.8 to 6,017.0)	52.6 (46.6 to 59.2)	0.2 (-3.6 to 2.8)
Schizophrenia	548.2 (472.2 to 632.1)	933.4 (808.9 to 1,068.2)	69.9 (61.7 to 78.7)	0.4 (-4.5 to 4.8)	0.4 (261.8 to 452.8)	0.4 (448.7 to 769.9)	0.4 (58.9 to 81.1)	0.4 (-5.2 to 7.0)
Alcohol use disorders	759.3 (679.5 to 838.2)	1,129.0 (1,017.7 to 1,232.1)	48.3 (39.9 to 57.7)	-4.9 (-10.0 to 0.1)	75.7 (50.7 to 107.3)	112.6 (76.0 to 161.2)	48.8 (37.6 to 61.1)	-4.5 (-11.2 to 2.6)
Drug use disorders	-	-	-	-	396.1 (261.2 to 557.0)	549.5 (375.6 to 779.0)	0.4 (13.8 to 71.8)	0.4 (-16.8 to 22.5)
Opioid use disorders	192.2 (151.1 to 237.5)	316.9 (254.3 to 383.8)	64.6 (50.7 to 81.9)	-0.0 (-8.0 to 8.8)	81.2 (53.8 to 114.6)	134.1 (88.5 to 184.4)	65.4 (45.3 to 88.6)	0.7 (-10.0 to 12.9)
Cocaine use disorders	144.6 (133.4 to 155.1)	209.2 (195.1 to 225.0)	44.9 (29.8 to 61.5)	0.9 (-8.6 to 12.0)	20.1 (13.1 to 28.9)	29.9 (18.7 to 41.7)	45.6 (21.0 to 69.3)	1.6 (-14.8 to 23.6)
Amphetamine use disorders	982.5 (778.7 to 1,182.9)	1,278.9 (1,037.9 to 1,541.6)	29.3 (2.2 to 69.9)	-0.6 (-21.4 to 29.2)	130.5 (79.0 to 198.3)	169.5 (104.9 to 259.8)	29.6 (-1.3 to 72.7)	-0.1 (-23.5 to 30.7)
Cannabis use disorders	417.7 (279.8 to 540.0)	555.9 (394.1 to 699.6)	32.4 (27.9 to 43.1)	0.1 (-0.0 to 0.2)	12.2 (6.6 to 19.5)	16.3 (9.0 to 25.4)	33.4 (16.3 to 55.5)	0.4 (-12.0 to 14.0)
Other drug use disorders	-	-	-	-	152.0 (90.3 to 233.8)	200.5 (111.1 to 310.0)	32.1 (-7.3 to 88.1)	0.7 (-29.0 to 42.2)
Depressive disorders	-	-	-	-	863.7 (534.5 to 1,256.3)	1,407.7 (878.2 to 2,073.1)	63.1 (51.1 to 73.7)	0.0 (-7.2 to 5.9)
Major depressive disorder	3,241.2 (2,141.7 to 4,257.4)	5,228.1 (3,403.6 to 7,025.5)	61.3 (45.9 to 73.4)	-0.7 (-9.9 to 7.3)	672.9 (387.5 to 1,012.8)	1,082.6 (603.9 to 1,674.2)	61.1 (45.9 to 74.1)	-0.1 (-9.7 to 7.9)
Dysthymia	1,959.8 (1,672.7 to 2,236.4)	3,341.4 (2,881.3 to 3,789.7)	70.2 (65.4 to 75.8)	-0.3 (-0.4 to -0.2)	190.8 (124.5 to 276.3)	325.1 (211.8 to 470.4)	70.4 (63.8 to 77.5)	0.2 (-2.1 to 2.7)
Bipolar disorder	996.6 (805.3 to 1,166.4)	1,592.4 (1,329.0 to 1,853.4)	59.6 (48.3 to 71.6)	-0.1 (-5.3 to 5.8)	206.0 (124.2 to 315.7)	327.9 (199.5 to 493.8)	59.2 (46.4 to 73.3)	0.4 (-6.3 to 7.7)
Anxiety disorders	4,476.5 (1,835.6 to 7,119.1)	6,920.3 (3,037.6 to 10,658.5)	55.0 (39.1 to 71.8)	0.4 (-0.7 to -0.2)	417.2 (156.0 to 737.5)	524.8 (256.0 to 1,131.2)	56.0 (38.8 to 72.6)	-0.1 (-2.9 to 3.0)
Eating disorders	-	-	-	-	20.4 (12.9 to 30.0)	26.0 (16.5 to 39.3)	27.9 (11.0 to 47.0)	0.6 (-12.6 to 15.8)
Anorexia nervosa	49.5 (38.6 to 63.2)	62.7 (48.9 to 79.9)	26.3 (12.9 to 40.6)	-0.4 (-10.5 to 10.7)	10.7 (6.6 to 15.9)	13.6 (8.4 to 20.5)	27.0 (3.3 to 55.0)	0.9 (-18.2 to 22.5)
Bulimia nervosa	45.2 (29.4 to 65.5)	58.3 (38.6 to 84.4)	28.2 (22.9 to 37.7)	0.1 (-0.1 to 0.3)	9.7 (5.2 to 16.0)	12.5 (7.1 to 21.1)	29.0 (5.3 to 59.3)	0.2 (-16.7 to 23.4)
Autistic spectrum disorders	-	-	-	-	215.7 (150.1 to 295.7)	300.6 (207.1 to 408.7)	1.1 (33.9 to 43.8)	1.1 (-2.0 to 4.5)
Autism	551.1 (522.2 to 579.4)	765.2 (725.0 to 805.6)	38.5 (37.8 to 39.4)	0.4 (0.4 to 0.4)	137.3 (91.8 to 188.5)	190.5 (127.6 to 261.4)	38.8 (31.9 to 45.7)	1.0 (-3.6 to 5.8)
Asperger syndrome	788.2 (739.3 to 834.6)	1,092.2 (1,023.1 to 1,159.3)	38.3 (37.2 to 39.3)	0.5 (0.5 to 0.5)	79.4 (54.7 to 111.1)	110.1 (76.4 to 152.9)	38.7 (33.0 to 44.9)	1.2 (-2.7 to 5.1)
Attention-deficit/hyperactivity disorder	1,310.0 (1,207.3 to 1,396.6)	1,478.4 (1,362.2 to 1,577.4)	12.5 (12.3 to 12.7)	0.3 (0.3 to 0.4)	16.0 (9.4 to 24.5)	18.1 (10.6 to 27.9)	13.2 (5.1 to 22.3)	0.9 (-6.2 to 8.9)
Conduct disorder	1,340.8 (1,262.8 to 1,418.8)	1,499.5 (1,412.2 to 1,586.6)	11.1 (11.4 to 11.5)	0.2 (0.2 to 0.3)	162.1 (102.8 to 236.2)	182.1 (114.6 to 266.0)	12.5 (65.1 to 18.7)	1.1 (-4.3 to 6.7)
Idiopathic intellectual disability	923.1 (43.4 to 1,659.5)	872.0 (365.6 to 1,768.0)	-8.3 (-62.8 to 126.5)	-29.9 (-71.7 to 74.4)	45.6 (15.8 to 90.6)	42.9 (11.6 to 92.7)	-2.7 (-6.0 to 2.7)	-29.2 (-71.4 to 73.6)
Other mental and substance use disorders	2,543.1 (2,372.9 to 2,703.3)	4,124.9 (3,878.6 to 4,365.4)	62.0 (59.2 to 64.7)	0.2 (0.0 to 0.3)	192.6 (129.9 to 261.0)	311.9 (212.2 to 420.4)	62.0 (54.9 to 69.0)	0.7 (-2.8 to 4.3)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	1,003.6 (695.2 to 1,386.8)	1,927.0 (1,349.4 to 2,695.2)	92.0 (76.9 to 111.1)	22.5 (12.4 to 34.8)
Diabetes mellitus	3,340.0 (2,734.0 to 3,892.6)	12,538.4 (10,537.7 to 14,613.0)	274.2 (207.0 to 367.4)	111.3 (71.1 to 164.4)	220.3 (139.7 to 319.9)	809.3 (532.2 to 1,177.4)	263.3 (195.3 to 369.4)	100.2 (58.5 to 155.6)
Acute glomerulonephritis	1.0 (0.9 to 1.1)	0.8 (0.8 to 0.9)	-34.6 (-20.7 to -102)	1.0 (-38.4 to -31.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-15.8 (-20.7 to -10.1)	-34.6 (-38.4 to -30.9)
Chronic kidney disease	-	-	-	-	169.5 (116.7 to 235.4)	269.9 (182.9 to 378.4)	58.9 (45.6 to 73.7)	-0.6 (-7.1 to 6.8)
Chronic kidney disease due to diabetes mellitus	568.5 (367.9 to 837.0)	1,654.7 (1,143.6 to 2,412.7)	191.8 (101.8 to 302.3)	76.5 (21.2 to 139.1)	16.6 (10.6 to 24.5)	46.8 (28.9 to 68.9)	182.9 (102.9 to 293.8)	64.8 (-18.8 to 128.5)
Chronic kidney disease due to hypertension	1,329.3 (781.7 to 2,388.3)	679.1 (486.9 to 1,012.5)	47.8 (-65.5 to -21.8)	-59.9 (-71.9 to -43.4)	37.8 (24.8 to 57.1)	58.4 (34.8 to 89.3)	54.5 (8.8 to 106.4)	-5.2 (-30.6 to 24.0)
Chronic kidney disease due to glomerulonephritis	1,421.8 (915.4 to 2,							

Appendix Table G.4 - Indonesia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	29.4 (27.6 to 31.4)	55.6 (52.4 to 58.6)	88.5 (73.5 to 106.6)	88.5 (16.7 to 37.1)	1.0 (0.6 to 1.5)	1.9 (1.1 to 2.8)	88.5 (50.3 to 140.7)	88.5 (3.5 to 56.0)
Urolithiasis	761.9 (575.4 to 1,019.7)	1,407.8 (1,044.4 to 1,863.3)	84.2 (59.0 to 113.3)	0.1 (-11.9 to 14.3)	9.9 (6.7 to 13.5)	17.0 (11.3 to 23.6)	72.5 (53.9 to 91.3)	1.0 (-8.7 to 11.0)
Benign prostatic hyperplasia	1,238.4 (1,128.0 to 1,346.2)	2,456.2 (2,256.9 to 2,656.1)	98.0 (77.5 to 124.3)	4.3 (-6.3 to 17.9)	44.8 (28.8 to 63.8)	89.2 (57.8 to 127.3)	98.9 (78.2 to 126.4)	5.0 (-5.6 to 18.8)
Male infertility due to other causes	1,244.9 (962.4 to 1,563.7)	1,925.0 (1,392.6 to 2,480.1)	51.8 (9.8 to 133.5)	-2.2 (-29.2 to 51.3)	8.4 (3.4 to 17.4)	12.9 (5.2 to 26.9)	52.3 (5.7 to 135.7)	-0.2 (-29.9 to 55.7)
Other urinary diseases	-	-	-	-	-	-	-	-
Gynaecological diseases	-	-	-	-	218.3 (139.6 to 327.4)	319.5 (205.4 to 489.0)	46.5 (28.5 to 65.6)	-12.8 (-22.7 to -1.9)
Uterine fibroids	3,123.8 (2,840.9 to 3,422.9)	5,942.8 (5,427.7 to 6,504.7)	89.7 (87.9 to 91.7)	-2.8 (-2.9 to -2.6)	58.2 (35.4 to 91.9)	78.0 (44.0 to 128.4)	32.9 (19.0 to 46.8)	-2.8 (-35.3 to -21.6)
Polycystic ovarian syndrome	2,584.4 (2,172.9 to 2,968.5)	3,888.9 (3,312.5 to 4,590.9)	49.7 (19.1 to 94.4)	-9.5 (-27.5 to 15.1)	25.8 (12.1 to 47.9)	38.8 (17.6 to 73.1)	50.0 (19.2 to 95.0)	-9.4 (-27.4 to 15.2)
Female infertility due to other causes	1,091.2 (802.0 to 1,395.4)	1,990.0 (1,516.4 to 2,512.7)	81.1 (25.5 to 166.6)	6.9 (-27.0 to 57.4)	6.0 (2.3 to 12.8)	9.7 (4.2 to 23.6)	116.3 (24.9 to 164.3)	8.4 (-25.7 to 59.7)
Endometriosis	295.1 (251.3 to 343.8)	504.5 (437.2 to 577.4)	70.3 (39.5 to 114.8)	-0.5 (-18.6 to 24.2)	27.6 (17.9 to 39.3)	47.2 (31.1 to 66.5)	70.6 (35.3 to 117.9)	0.5 (-20.5 to 27.8)
Genital prolapse	7,336.4 (6,269.7 to 8,374.4)	12,419.6 (10,634.1 to 14,289.4)	68.9 (39.6 to 108.4)	-3.7 (-18.8 to 16.4)	23.6 (10.9 to 45.0)	39.8 (18.6 to 75.0)	68.6 (39.8 to 109.6)	-3.8 (-18.9 to 16.8)
Premenstrual syndrome	6,482.2 (4,556.7 to 8,786.8)	10,097.7 (7,266.1 to 13,416.8)	54.7 (1.7 to 140.4)	2.0 (-32.8 to 57.4)	55.0 (30.9 to 90.3)	85.6 (47.5 to 138.6)	54.9 (2.0 to 140.2)	2.2 (-33.4 to 59.3)
Other gynaecological diseases	711.0 (546.6 to 883.8)	683.8 (604.6 to 762.0)	-4.3 (-22.9 to 24.9)	-37.8 (-49.9 to -19.3)	21.9 (12.6 to 32.3)	19.3 (12.1 to 28.4)	-13.2 (-36.0 to 36.5)	-43.5 (-58.3 to -11.9)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	224.0 (148.8 to 320.2)	294.5 (194.6 to 432.9)	31.1 (19.2 to 50.8)	-4.2 (-13.7 to 10.0)
Thalassemias	55.1 (5.1 to 58.7)	68.1 (64.2 to 72.3)	23.2 (17.6 to 30.0)	5.5 (0.7 to 11.3)	4.5 (2.9 to 6.5)	5.0 (3.1 to 7.3)	11.2 (-13.2 to 40.1)	-6.3 (-26.4 to 16.8)
Thalassemia trait	10,277.5 (9,939.5 to 10,640.7)	14,796.1 (14,391.3 to 15,282.7)	43.5 (40.1 to 48.0)	2.7 (0.3 to 5.7)	142.1 (94.1 to 202.1)	234.0 (155.1 to 347.7)	65.0 (46.2 to 89.0)	22.6 (7.2 to 41.1)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.2 (13.0 to 32.2)	1.0 (-8.0 to 7.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.8 (24.4 to 60.2)	16.3 (-0.7 to 27.6)
Sickle cell trait	237.9 (215.4 to 257.1)	307.1 (279.2 to 338.8)	28.4 (11.9 to 39.6)	2.0 (-19.9 to 0.1)	1.5 (1.1 to 3.0)	1.5 (0.8 to 2.3)	25.3 (-61.2 to 28.8)	45.9 (-71.1 to 8.2)
G6PD deficiency	10,676.7 (9,992.1 to 11,342.4)	13,961.0 (13,064.3 to 14,890.0)	30.4 (18.3 to 43.5)	-6.6 (-15.2 to 2.8)	1.3 (0.9 to 1.8)	1.8 (1.2 to 2.6)	39.3 (13.8 to 66.3)	2.2 (-14.7 to 20.1)
G6PD trait	32,197.4 (31,647.4 to 32,700.8)	44,191.9 (43,400.7 to 45,033.8)	36.9 (33.6 to 40.5)	-2.4 (-4.8 to 0.1)	1.4 (0.5 to 2.4)	1.5 (0.1 to 2.6)	6.1 (-93.6 to 186.5)	19.4 (-94.6 to 121.8)
Other hemoglobinopathies and hemolytic anemias	2,615.6 (2,166.4 to 2,897.1)	2,092.8 (1,822.4 to 2,312.1)	-20.3 (-31.7 to -2.3)	-44.6 (-51.9 to -35.2)	72.7 (44.2 to 107.6)	50.7 (30.6 to 76.6)	-30.3 (-52.4 to 6.9)	-30.3 (-65.5 to -30.7)
Endocrine, metabolic, blood, and immune disorders	2,868.4 (2,549.1 to 3,116.6)	2,860.4 (2,615.5 to 3,076.0)	-0.5 (-11.1 to 14.1)	-0.5 (-35.2 to -18.2)	97.6 (63.5 to 138.5)	91.5 (63.1 to 129.9)	6.3 (-20.0 to 13.7)	-30.1 (-39.3 to 3.6)
Musculoskeletal disorders	-	-	-	-	1,696.0 (1,192.7 to 2,266.0)	3,063.2 (2,165.1 to 4,059.0)	80.3 (62.9 to 99.5)	3.6 (-6.5 to 13.8)
Rheumatoid arthritis	136.3 (126.8 to 145.5)	317.2 (298.7 to 335.3)	132.1 (112.4 to 153.7)	38.6 (25.6 to 50.8)	32.9 (22.7 to 44.1)	76.1 (54.1 to 101.4)	131.6 (106.0 to 163.1)	38.7 (23.3 to 56.4)
Osteoarthritis	2,011.5 (1,894.4 to 2,132.5)	4,046.0 (3,808.9 to 4,289.2)	100.4 (84.9 to 119.9)	2.9 (-4.4 to 12.1)	125.1 (86.6 to 171.1)	251.9 (175.5 to 340.2)	101.0 (85.4 to 120.7)	3.5 (-4.2 to 13.3)
Low back and neck pain	-	-	-	-	2,269.9 (860.7 to 3,743.3)	2,799.0 (1,475.9 to 3,966.3)	71.2 (48.3 to 97.8)	1.1 (-13.7 to 15.6)
Low back pain	7,383.3 (6,643.5 to 8,119.2)	12,819.4 (11,781.0 to 13,811.3)	74.1 (48.1 to 98.1)	2.0 (-11.1 to 14.9)	2.0 (563.3 to 1,164.8)	1,448.4 (964.9 to 2,049.1)	78.8 (47.9 to 99.2)	2.6 (-11.0 to 15.7)
Neck pain	4,368.4 (3,526.1 to 5,113.4)	7,338.9 (5,711.8 to 8,799.1)	68.9 (23.9 to 120.2)	-0.5 (-28.0 to 27.9)	435.0 (285.5 to 620.1)	730.6 (468.0 to 1,042.7)	69.3 (25.3 to 121.0)	0.1 (-27.9 to 29.6)
Gout	84.3 (73.4 to 95.3)	171.2 (149.0 to 191.1)	102.6 (69.4 to 142.0)	6.4 (-11.0 to 25.8)	2.7 (1.8 to 3.8)	5.6 (3.7 to 7.9)	104.7 (56.0 to 170.7)	7.4 (-16.7 to 38.6)
Other musculoskeletal disorders	2,870.4 (2,089.2 to 3,606.3)	5,950.5 (4,273.7 to 7,656.8)	106.9 (87.1 to 127.8)	8.6 (-1.9 to 18.9)	265 (170.1 to 389.6)	859 (344.3 to 1,814.5)	107.1 (85.5 to 129.6)	9.9 (-2.2 to 19.9)
Other non-communicable diseases	-	-	-	-	2,417.2 (1,613.9 to 3,503.4)	3,553.3 (2,363.4 to 5,152.2)	47.0 (41.6 to 52.1)	-7.9 (-10.6 to -5.1)
Congenital anomalies	-	-	-	-	125.2 (88.7 to 165.4)	206.2 (149.9 to 270.3)	65.0 (41.9 to 93.6)	25.4 (8.3 to 46.7)
Neural tube defects	17.1 (14.6 to 20.4)	44.9 (38.7 to 51.7)	162.0 (101.1 to 228.3)	111.5 (62.5 to 165.3)	5.0 (3.3 to 7.2)	14.6 (9.6 to 20.4)	188.2 (109.2 to 298.9)	135.1 (71.1 to 226.5)
Congenital heart anomalies	227.3 (177.6 to 296.4)	773.6 (628.8 to 959.0)	243.7 (147.2 to 361.6)	168.0 (92.8 to 259.3)	8.7 (4.2 to 14.8)	27.1 (11.8 to 47.3)	209.3 (127.8 to 327.1)	143.0 (79.4 to 222.9)
Orofacial clefts	42.1 (31.2 to 54.4)	164.3 (139.8 to 191.4)	294.1 (169.2 to 446.0)	2.4 (-121.6 to 349.6)	2.4 (0.4 to 1.2)	2.4 (1.5 to 3.6)	169.1 (115.0 to 375.0)	169.1 (77.3 to 292.0)
Down syndrome	125.2 (98.3 to 151.6)	236.2 (202.2 to 280.9)	87.9 (47.7 to 144.9)	39.4 (9.7 to 81.2)	15.3 (10.4 to 20.9)	30.6 (21.8 to 41.7)	100.7 (54.8 to 167.4)	45.0 (11.8 to 93.9)
Turner syndrome	4.6 (3.5 to 6.2)	7.8 (7.2 to 8.3)	73.2 (27.8 to 121.0)	29.0 (-5.0 to 65.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	75.5 (26.1 to 130.5)	28.8 (-7.7 to 68.5)
Klinefelter syndrome	5.5 (4.2 to 6.8)	8.1 (6.2 to 10.1)	46.2 (8.1 to 103.3)	6.1 (-21.6 to 47.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	54.2 (5.3 to 135.6)	4.5 (-28.7 to 58.1)
Chromosomal unbalanced rearrangements	173.5 (145.7 to 208.6)	324.7 (272.4 to 422.2)	89.3 (51.7 to 144.4)	42.4 (12.2 to 166.2)	21.1 (14.7 to 29.1)	82.3 (30.1 to 59.9)	47.3 (13.8 to 92.7)	47.3 (13.8 to 92.7)
Other congenital anomalies	634.1 (510.0 to 756.8)	743.5 (612.2 to 872.2)	17.5 (-23.5 to -7.0)	-14.8 (-23.5 to -7.0)	74.2 (47.2 to 106.9)	88.0 (57.6 to 124.5)	18.4 (-2.5 to 48.1)	-8.3 (-23.9 to 14.9)
Skin and subcutaneous diseases	-	-	-	-	812.6 (513.1 to 1,254.2)	1,179.1 (748.9 to 1,797.8)	45.1 (35.3 to 55.0)	0.8 (-5.8 to 7.8)
Dermatitis	7,227.5 (6,094.5 to 8,392.3)	10,913.3 (9,229.5 to 12,703.0)	50.7 (45.9 to 56.4)	-0.1 (-0.2 to 0.0)	180.3 (112.3 to 263.6)	266.7 (164.8 to 391.7)	47.8 (41.4 to 54.7)	0.3 (-2.3 to 3.1)
Psoriasis	1,394.1 (1,048.2 to 1,639.0)	2,060.0 (1,632.9 to 2,641.9)	57.7 (52.0 to 63.0)	57.7 (-0.1 to 0.1)	57.7 (71.3 to 159.8)	57.7 (111.9 to 251.9)	0.5 (47.1 to 68.3)	0.5 (-4.6 to 6.0)
Cellulitis	38.5 (30.9 to 48.0)	58.8 (46.9 to 73.8)	52.4 (30.6 to 80.4)	3.1 (-12.0 to 18.7)	2.8 (1.7 to 4.2)	4.2 (2.6 to 6.2)	52.3 (16.3 to 101.1)	3.2 (-19.0 to 32.4)
Pyoderma	264.8 (194.8 to 341.9)	155.8 (123.7 to 199.6)	-41.3 (-51.0 to -29.4)	-51.8 (-59.0 to -42.9)	1.5 (0.6 to 3.4)	0.9 (0.3 to 2.0)	-41.3 (-52.6 to -28.0)	-51.7 (-59.9 to -42.2)
Scabies	2,283.5 (2,006.4 to 2,625.1)	3,166.4 (2,481.4 to 3,955.8)	38.0 (6.3 to 74.9)	-1.5 (-23.4 to 23.4)	59.3 (33.1 to 97.3)	81.8 (44.3 to 136.8)	38.3 (5.8 to 75.2)	-1.1 (-23.2 to 24.0)
Fungal skin diseases	19,614.9 (16,404.7 to 22,699.6)	28,572.6 (23,715.7 to 32,780.0)	45.4 (41.1 to 50.1)	45.4 (0.0 to 1.2)	111 (44.8 to 228.1)	162.1 (65.7 to 332.5)	45.4 (41.1 to 50.4)	45.4 (0.3 to 1.4)
Viral skin diseases	3,622.8 (2,942.3 to 4,404.6)	4,448.1 (3,525.0 to 5,465.4)	22.3 (17.6 to 27.4)	0.0 (-2.1 to 1.8)	112.5 (70.3 to 170.0)	138.3 (85.5 to 210.9)	22.8 (16.6 to 29.1)	0.0 (-3.0 to 4.2)
Acne vulgaris	6,724.4 (4,639.1 to 8,848.2)	8,427.1 (6,390.1 to 10,638.9)	25.0 (-12.1 to 89.7)	3.6 (-26.8 to 58.2)	73.2 (31.6 to 146.7)	91.6 (41.8 to 181.6)	24.9 (-12.4 to 90.8)	3.8 (-26.8 to 57.4)
Alopecia areata	213.5 (187.0 to 241.9)	335.0 (285.0 to 382.8)	56.5 (30.2 to 87.3)	0.5 (-16.2 to 19.7)	7.2 (4.5 to 11.0)	11.3 (6.9 to 17.9)	56.3 (27.7 to 90.7)	1.0 (-18.0 to 21.9)
Pruritus	29.2 (24.1 to 34.6)	47.5 (38.3 to 56.0)	62.1 (25.0 to 109.3)	0.3 (-24.9 to 29.6)	0.3 (0.1 to 0.6)	0.5 (0.2 to 0.9)	62.8 (15.3 to 124.7)	-0.8 (-27.8 to 35.7)
Urticaria	1,538.8 (1,099.1 to 1,997.5)	2,435.2 (1,738.6 to 3,190.2)	60.0 (-11.0 to 149.0)	4.3 (-38.4 to 66.6)	92.9 (54.0 to 143.1)	146.3 (84.2 to 224.6)	50.2 (9.4 to 151.5)	4.9 (-38.7 to 67.0)
Decubitus ulcer	22.0 (19.0 to 25.4)	37.1 (31.1 to 44.0)	69.3 (37.1 to 105.1)	0.9 (-21.6 to 30.3)	3.4 (2.3 to 4.7)	5.5 (3.7 to 7.9)	-0.3 (30.2 to 111.1)	-0.3 (-24.5 to 32.2)
Other skin and subcutaneous diseases	10,118.7 (6,862.9 to 14,357.1)	16,903.8 (11,233.8 to 24,510.9)	66.7 (52.5 to 78.8)	-0.1 (-2.8 to 3.3)	60.1 (26.6 to 122.4)	100.2 (43.1 to 206.4)	66.7 (52.7 to 79.2)	0.2 (-2.8 to 3.6)
Sense organ diseases	-	-	-	-	1,249.2 (848.2 to 1,740.9)	1,820.8 (1,218.1 to 2,572.7)	46.7 (39.1 to 52.4)	-13.2 (-16.1 to -10.3)
Glaucoma	235.3 (161.5 to 321.3)	337.3 (257.6 to 450.0)	41.6 (-1.8 to 104.0)	-22.4 (-48.4 to 15.0)	0.5 (1.4 to 27.0)	0.5 (17.8 to 44.2)	55.9 (15.1 to 114.0)	-15.0 (-40.1 to 17.3)
Cataract	682.0 (512.2 to 905.6)	1,078.1 (756.3 to 1,410.7)	57.9 (20.0 to 129.2)	-20.8 (-39.2 to 10.8)	59.9 (37.8 to 89.7)	94.3 (58.4 to 139.3)	58.7 (26.6 to 95.0)	-20.8 (-35.9 to -2.7)
Macular degeneration	123.3 (84.0 to 164.6)	361.2 (243.1 to 475.7)	196.3 (104.8 to 310.3)	53.6 (2.3 to 104.8)	8.0 (4.8 to 11.7)	21.4 (12.9 to 32.6)	168.8 (91.4 to 248.0)	31.3 (-4.5 to 66.9)
Uncorrected refractive error	16,280.9 (15,152.1 to 17,450.6)	26,303.9 (24,556.7 to 28,164.6)	60.9 (45.5 to 79.1)	-5.7 (-13.3 to 8.8)	274.6 (173.2 to 428.6)	412.3 (248.6 to 563.8)	49.5 (39.1 to 62.4)	-11.6 (-17.0 to -4.6)
Age-related and other hearing loss	22,116.3 (20,920.6 to 23,424.6)	35,622.5 (33,891.5 to 37,954.2)	60.9 (54.2 to 67.0)	60.9 (-12.4 to 6.7)	60.9 (462.5 to 940.8)	97.1 (671.4 to 1,408.2)	97.1 (36.8 to 56.	

Appendix Table G.4 - Indonesia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	1,431.3 (1,257.4 to 1,612.8)	1,983.8 (1,772.8 to 2,204.8)	38.0 (17.6 to 65.6)	-28.3 (-38.9 to -14.5)	39.8 (26.2 to 56.5)	55.2 (36.3 to 78.5)	38.5 (16.7 to 65.6)	-27.8 (-39.0 to -13.9)
Other oral disorders	2,836.3 (2,689.0 to 2,982.5)	4,359.2 (4,107.4 to 4,572.2)	53.3 (42.1 to 65.9)	-0.1 (-7.1 to 7.6)	83.9 (52.3 to 124.7)	128.7 (80.8 to 193.0)	53.3 (41.3 to 65.9)	0.3 (-7.1 to 8.1)
Injuries	-	-	-	-	746.7 (552.0 to 978.4)	850.9 (624.0 to 1,122.9)	14.5 (0.4 to 25.6)	-29.1 (-38.5 to -22.2)
Transport injuries	-	-	-	-	334.9 (251.5 to 435.8)	360.2 (266.5 to 478.6)	7.5 (-1.3 to 17.0)	-32.5 (-37.5 to -27.0)
Road injuries	-	-	-	-	282.7 (212.5 to 367.8)	292.1 (216.1 to 387.9)	9.2 (5.4 to 12.9)	-34.1 (-39.3 to -28.4)
Pedestrian road injuries	-	-	-	-	41.3 (30.6 to 54.5)	43.9 (32.3 to 57.9)	6.1 (5.1 to 19.6)	-28.9 (-35.7 to -21.4)
Cyclist road injuries	-	-	-	-	18.9 (14.0 to 24.6)	18.8 (13.7 to 24.9)	-0.7 (-8.8 to 8.8)	-35.5 (-40.4 to -29.9)
Motorcyclist road injuries	-	-	-	-	130.9 (96.8 to 169.4)	122.9 (90.2 to 164.5)	-6.2 (-16.0 to 5.1)	-41.2 (-46.7 to -34.4)
Motor vehicle road injuries	-	-	-	-	98.1 (66.7 to 116.5)	105.0 (77.1 to 138.8)	16.7 (4.0 to 30.5)	-25.8 (-33.2 to -17.1)
Other road injuries	-	-	-	-	1.6 (1.2 to 2.0)	1.5 (1.1 to 2.0)	-0.1 (-13.7 to 6.8)	-41.4 (-46.6 to -35.8)
Other transport injuries	-	-	-	-	52.2 (39.2 to 67.8)	68.2 (49.5 to 90.3)	30.2 (19.9 to 41.4)	-24.0 (-29.8 to -17.7)
Unintentional injuries	-	-	-	-	298.1 (226.2 to 384.6)	397.5 (294.2 to 526.8)	33.2 (25.4 to 40.8)	-17.9 (-21.8 to -13.5)
Falls	-	-	-	-	83.2 (62.1 to 107.4)	136.3 (100.0 to 181.2)	63.6 (51.2 to 77.1)	-7.3 (-14.2 to -0.1)
Drowning	-	-	-	-	20.9 (15.1 to 27.5)	16.3 (11.8 to 21.7)	-22.1 (-31.1 to -11.2)	-44.4 (-53.9 to -42.0)
Fire, heat, and hot substances	-	-	-	-	20.3 (15.3 to 26.2)	17.6 (12.8 to 23.6)	-13.6 (-23.8 to -2.6)	-44.4 (-50.1 to -38.1)
Poisonings	-	-	-	-	0.8 (0.5 to 1.1)	0.5 (0.4 to 0.7)	-32.7 (-44.2 to -18.9)	-56.1 (-63.0 to -47.7)
Exposure to mechanical forces	-	-	-	-	106.3 (80.4 to 139.5)	119.6 (86.7 to 159.5)	12.5 (3.8 to 20.5)	-28.7 (-33.4 to -24.2)
Unintentional firearm injuries	-	-	-	-	6.9 (5.2 to 8.8)	6.1 (4.5 to 8.1)	-10.2 (-18.6 to -1.6)	-44.4 (-49.1 to -39.4)
Unintentional suffocation	-	-	-	-	2.6 (1.9 to 3.4)	3.0 (2.2 to 3.9)	14.4 (2.7 to 26.4)	-24.2 (-30.7 to -17.0)
Other exposure to mechanical forces	-	-	-	-	96.8 (72.8 to 127.6)	110.5 (79.7 to 147.5)	14.1 (5.2 to 22.7)	-27.7 (-32.6 to -22.9)
Adverse effects of medical treatment	-	-	-	-	3.0 (2.0 to 4.5)	5.0 (3.2 to 7.4)	63.7 (53.4 to 73.3)	1.5 (-4.3 to 7.6)
Animal contact	-	-	-	-	7.7 (5.8 to 10.0)	9.1 (6.6 to 12.1)	18.0 (8.0 to 28.6)	-24.4 (-29.8 to -18.4)
Venomous animal contact	-	-	-	-	3.7 (2.7 to 5.0)	4.5 (3.2 to 5.9)	21.0 (7.0 to 36.2)	-22.6 (-30.4 to -13.8)
Non-venomous animal contact	-	-	-	-	4.0 (3.0 to 5.4)	4.7 (3.4 to 6.3)	15.3 (4.7 to 26.9)	-25.9 (-31.6 to -19.7)
Foreign body	-	-	-	-	3.4 (2.5 to 4.3)	5.0 (3.7 to 6.4)	48.4 (39.9 to 59.2)	-7.5 (-12.4 to -1.8)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.9 (0.7 to 1.2)	1.1 (0.9 to 1.5)	20.6 (6.6 to 34.9)	-18.3 (-26.5 to -10.3)
Foreign body in eyes	-	-	-	-	1.0 (0.6 to 1.5)	1.5 (0.9 to 2.2)	48.9 (39.1 to 59.0)	-4.6 (-10.9 to 1.5)
Foreign body in other body part	-	-	-	-	1.4 (1.1 to 1.9)	2.4 (1.8 to 3.2)	66.7 (54.1 to 82.9)	-3.3 (-10.2 to 5.4)
Other unintentional injuries	-	-	-	-	52.5 (39.2 to 68.7)	88.1 (64.8 to 117.1)	68.0 (50.6 to 83.0)	0.3 (-9.6 to 9.3)
Self-harm and interpersonal violence	-	-	-	-	12.4 (9.4 to 15.9)	12.4 (9.2 to 16.2)	4.2 (-7.6 to 8.3)	-38.5 (-43.0 to -33.6)
Self-harm	-	-	-	-	4.0 (2.9 to 5.2)	3.6 (2.6 to 4.7)	-11.1 (-18.9 to -2.9)	-50.1 (-54.4 to -45.8)
Interpersonal violence	-	-	-	-	8.4 (6.4 to 10.7)	8.8 (6.6 to 11.6)	5.0 (-4.5 to 14.8)	-31.7 (-37.5 to -25.8)
Assault by firearm	-	-	-	-	1.0 (0.7 to 1.2)	1.0 (0.7 to 1.3)	4.4 (-5.2 to 15.5)	-29.9 (-35.9 to -23.1)
Assault by sharp object	-	-	-	-	1.8 (1.4 to 2.4)	2.2 (1.6 to 3.1)	22.5 (9.8 to 39.0)	-22.2 (-30.0 to -12.5)
Assault by other means	-	-	-	-	5.6 (4.3 to 7.2)	5.6 (4.2 to 7.3)	-0.9 (-10.4 to 9.6)	-35.3 (-41.2 to -28.9)
Forces of nature, war, and legal intervention	-	-	-	-	101.3 (84.3 to 241.8)	80.8 (34.2 to 173.5)	-16.9 (-46.9 to 35.2)	-51.0 (-68.6 to -19.6)
Exposure to forces of nature	-	-	-	-	2.1 (0.8 to 3.8)	44.9 (18.5 to 99.6)	2,558.3 (953.8 to 5,249.2)	1,644.1 (607.3 to 3,287.5)
Collective violence and legal intervention	-	-	-	-	99.3 (33.0 to 239.4)	35.8 (13.9 to 82.2)	-63.1 (-69.4 to -54.5)	-77.2 (-81.8 to -71.0)

Appendix Table G.4 - Iran prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
All causes	-	-	-	-	5,131.1 (3,764.8 to 6,702.9)	8,206.1 (6,037.1 to 10,560.1)	60.3 (51.1 to 67.1)	60.3 (-11.4 to -2.2)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	808.5 (554.3 to 1,129.9)	705.5 (498.5 to 966.6)	-12.5 (-20.6 to -3.6)	-21.1 (-27.3 to -12.8)
HIV/AIDS and tuberculosis	-	-	-	-	6.1 (4.1 to 8.4)	9.5 (6.5 to 13.1)	55.9 (32.9 to 84.6)	-12.6 (-23.2 to 0.5)
Tuberculosis	20.0 (18.8 to 21.1)	27.9 (26.3 to 29.6)	39.9 (33.4 to 47.0)	-20.6 (-24.0 to -17.3)	6.1 (4.1 to 8.4)	8.5 (5.8 to 11.5)	39.0 (19.4 to 60.8)	-20.5 (-30.0 to -10.7)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.0)	1.1 (0.4 to 2.1)	29,077.2 (2,161.4 to 349,567.4)	14,433.5 (975.7 to 183,202.4)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18,941.0 (1,190.7 to 322,220.6)	9,377.4 (515.3 to 175,230.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18,941.0 (1,185.5 to 329,579.6)	9,377.4 (511.0 to 180,034.8)
HIV/AIDS resulting in other diseases	0.1 (0.0 to 0.4)	9.6 (5.8 to 15.4)	27,837.6 (2,195.1 to 331,074.0)	14,012.6 (1,076.5 to 165,580.0)	0.0 (0.0 to 0.0)	1.1 (0.4 to 2.1)	29,751.4 (2,136.9 to 432,795.5)	14,711.9 (966.5 to 233,199.7)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	168.4 (118.3 to 227.1)	148.0 (104.7 to 201.3)	-12.1 (-18.6 to -5.2)	-16.0 (-21.9 to -9.8)
Diarrheal diseases	711.2 (666.9 to 755.5)	633.4 (591.6 to 675.5)	-10.9 (-18.8 to -2.8)	-7.9 (-15.4 to -0.2)	115.9 (78.8 to 161.5)	102.7 (68.7 to 144.3)	-7.5 (-19.5 to -2.8)	0.9 (-15.5 to 0.9)
Intestinal infectious diseases	-	-	-	-	0.9 (0.6 to 1.4)	0.7 (0.4 to 0.9)	-30.2 (-46.6 to -8.2)	37.9 (-51.2 to -18.1)
Typhoid fever	5.0 (4.2 to 5.8)	3.9 (3.2 to 4.5)	-22.4 (-38.8 to -1.1)	-31.0 (-44.8 to -9.8)	0.7 (0.4 to 1.0)	0.5 (0.4 to 0.8)	-21.5 (-41.0 to 5.4)	-30.6 (-46.1 to -7.4)
Paratyphoid fever	2.6 (2.2 to 3.1)	2.0 (1.7 to 2.4)	-23.8 (-40.0 to -3.3)	-29.7 (-44.7 to -9.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-23.6 (-41.4 to -0.3)	29.5 (-47.4 to -7.4)
Other intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-87.3 (-93.1 to -77.7)	-88.8 (-93.8 to -79.8)
Lower respiratory infections	23.1 (16.5 to 34.5)	20.8 (15.0 to 27.7)	-9.0 (-53.1 to 56.7)	3.5 (-41.8 to 49.3)	2.4 (1.4 to 4.0)	2.2 (1.3 to 3.4)	-10.8 (-54.3 to 57.2)	0.2 (-44.2 to 52.3)
Upper respiratory infections	1,166.3 (1,048.0 to 1,296.7)	1,453.2 (1,288.0 to 1,605.7)	24.5 (7.6 to 45.0)	-1.0 (-13.9 to 14.2)	13.8 (7.7 to 23.8)	17.1 (9.7 to 29.1)	23.9 (7.0 to 45.3)	-0.9 (-14.1 to 15.4)
Otitis media	725.8 (674.6 to 778.2)	764.0 (700.9 to 844.3)	5.0 (-9.0 to 18.4)	-9.1 (-22.6 to 2.4)	13.4 (7.9 to 21.7)	14.0 (8.1 to 23.1)	4.1 (-7.9 to 18.3)	-9.6 (-22.0 to 2.1)
Meningitis	-	-	-	-	17.8 (11.5 to 26.2)	7.6 (5.2 to 11.0)	-57.2 (-65.5 to -47.0)	-68.4 (-73.9 to -61.0)
Pneumococcal meningitis	70.1 (41.1 to 115.4)	32.4 (18.9 to 53.1)	-53.9 (-63.4 to -42.5)	-69.6 (-75.8 to -62.5)	6.5 (4.1 to 9.7)	2.9 (2.0 to 4.1)	-53.7 (-68.3 to -38.4)	67.2 (-76.9 to -57.5)
H influenzae type B meningitis	41.3 (12.1 to 87.7)	14.7 (4.8 to 33.0)	-64.7 (-78.6 to -39.2)	-75.0 (-84.1 to -53.2)	4.7 (2.4 to 8.1)	1.8 (1.0 to 2.7)	-63.4 (-78.8 to -27.2)	-71.6 (-82.8 to -43.2)
Meningococcal meningitis	22.8 (7.0 to 54.4)	9.3 (2.4 to 22.6)	-59.9 (-75.5 to -43.0)	-72.9 (-81.5 to -60.1)	3.0 (1.5 to 5.3)	1.2 (0.6 to 2.1)	-60.3 (-75.8 to -37.7)	-71.4 (-81.1 to -54.9)
Other meningitis	27.8 (15.4 to 51.2)	13.6 (6.5 to 27.3)	-52.2 (-64.5 to -36.5)	-66.3 (-72.9 to -55.6)	3.6 (2.3 to 5.3)	1.7 (1.1 to 2.7)	-52.3 (-65.3 to -32.3)	-64.6 (-73.6 to -50.3)
Encephalitis	13.6 (5.9 to 32.4)	14.5 (6.3 to 36.2)	6.8 (-14.7 to 23.6)	-39.9 (-43.0 to -17.1)	6.8 (1.2 to 2.5)	5.9 (1.4 to 2.8)	11.1 (-10.0 to 36.8)	25.1 (-38.0 to -8.4)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-78.1 (-98.9 to 270.5)	-77.3 (-98.6 to 182.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-78.1 (-98.9 to 277.6)	-77.3 (-98.6 to 185.8)
Whooping cough	15.4 (12.0 to 19.6)	2.0 (1.5 to 2.6)	-87.0 (-88.4 to -85.5)	-83.3 (-85.1 to -81.4)	0.8 (0.4 to 1.3)	0.1 (0.1 to 0.2)	-87.0 (-91.0 to -82.6)	-83.3 (-88.4 to -77.7)
Tetanus	0.5 (0.3 to 0.7)	0.0 (0.0 to 0.0)	-94.7 (-97.4 to -90.0)	-95.9 (-98.0 to -92.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-89.5 (-94.7 to -77.7)	-90.7 (-95.3 to -81.1)
Measles	7.7 (6.2 to 9.5)	1.0 (0.7 to 1.4)	-87.5 (-90.6 to -83.3)	-83.7 (-87.7 to -78.2)	0.7 (0.4 to 1.1)	0.1 (0.0 to 0.2)	-97.4 (-93.7 to -77.8)	43.6 (-91.7 to 71.2)
Varicella and herpes zoster	45.4 (42.3 to 49.2)	52.3 (45.4 to 59.4)	15.5 (-2.6 to 36.4)	9.9 (-11.2 to 35.2)	0.8 (0.4 to 1.3)	1.6 (0.9 to 2.6)	106.2 (39.5 to 203.6)	18.9 (-19.9 to 74.6)
Neglected tropical diseases and malaria	-	-	-	-	44.7 (28.6 to 65.1)	27.3 (18.0 to 39.3)	-39.7 (-50.3 to -21.3)	-54.5 (-62.7 to -45.3)
Malaria	4.4 (3.1 to 5.7)	3.2 (2.1 to 4.9)	-27.4 (-55.2 to 19.7)	-41.4 (-63.6 to -1.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-18.3 (-46.1 to 11.5)	-33.8 (-56.1 to -8.8)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Leishmaniasis	-	-	-	-	0.3 (0.2 to 0.7)	0.4 (0.2 to 0.8)	28.5 (8.3 to 55.8)	10.9 (-6.2 to 32.6)
Visceral leishmaniasis	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-4.9 (-26.7 to 31.5)	-5.2 (-25.5 to 28.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.9 (-26.8 to 31.8)	-5.2 (-25.5 to 28.8)
Cutaneous and mucocutaneous leishmaniasis	28.8 (22.2 to 37.5)	38.1 (29.7 to 48.9)	31.7 (16.2 to 52.4)	11.6 (-1.4 to 26.9)	0.3 (0.1 to 0.6)	0.4 (0.2 to 0.8)	30.9 (9.1 to 60.8)	12.0 (6.3 to 34.5)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Cysticercosis	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.3)	-40.6 (-79.4 to 75.4)	-67.8 (-89.5 to -8.8)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-34.0 (-77.6 to 99.5)	-64.1 (-88.5 to 2.4)
Cystic echinococcosis	2.0 (1.4 to 2.5)	4.4 (3.5 to 5.3)	127.2 (110.1 to 146.5)	25.9 (17.1 to 35.6)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	125.0 (79.7 to 179.4)	26.3 (-1.8 to 59.9)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	210.6 (152.8 to 272.5)	112.8 (78.7 to 167.1)	-47.2 (-61.0 to -21.2)	-75.9 (-82.2 to -64.2)	11.4 (7.3 to 16.5)	6.3 (3.8 to 9.9)	-45.2 (-57.4 to -20.5)	-75.6 (-80.8 to -64.8)
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-82.1 (-82.1 to -38.1)	-73.4 (-85.1 to -60.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-62.8 (-82.2 to -38.1)	-73.4 (-85.1 to -60.6)
Intestinal nematode infections	-	-	-	-	1.8 (0.7 to 4.1)	1.1 (0.6 to 2.0)	-33.4 (-68.5 to 27.4)	-39.6 (-69.5 to 9.8)
Ascariasis	963.4 (819.4 to 1,147.0)	1,554.9 (1,137.6 to 2,116.8)	58.3 (14.4 to 130.7)	1.7 (-26.3 to 48.1)	1.6 (0.6 to 3.9)	0.3 (0.1 to 0.9)	-81.0 (-92.7 to -40.9)	-81.4 (-92.7 to -42.8)
Trichuriasis	241.2 (206.8 to 281.4)	192.4 (137.1 to 270.3)	-21.3 (-45.7 to 14.8)	-49.3 (-65.0 to -25.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -99.7)	-100.0 (-100.0 to -99.8)
Hookworm disease	29.3 (25.2 to 33.9)	237.8 (179.2 to 313.1)	700.9 (485.9 to 1,012.2)	327.5 (213.9 to 490.0)	0.1 (0.1 to 0.2)	0.8 (0.4 to 1.2)	492.2 (226.1 to 735.3)	212.7 (75.0 to 338.7)
Food-borne trematodiasis	13.4 (5.5 to 22.1)	18.9 (9.0 to 34.7)	33.1 (-34.9 to 271.4)	-30.6 (-66.0 to 94.0)	0.3 (0.0 to 0.8)	0.4 (0.1 to 1.2)	36.3 (-39.9 to 287.0)	-28.6 (-68.0 to 114.7)
Other neglected tropical diseases	881.6 (695.4 to 1,090.8)	611.9 (510.9 to 715.2)	-30.7 (-45.2 to -10.4)	-24.3 (-39.1 to -6.8)	30.5 (17.8 to 45.0)	18.4 (11.4 to 27.3)	-40.6 (-56.1 to -12.4)	-25.5 (-45.5 to 6.1)
Maternal disorders	-	-	-	-	3.0 (1.7 to 5.0)	2.4 (1.2 to 4.1)	-19.5 (-41.8 to 3.4)	-58.3 (-69.3 to -47.0)
Maternal hemorrhage	12.3 (9.7 to 14.8)	23.2 (14.8 to 31.6)	88.2 (20.0 to 183.6)	-7.3 (-39.0 to 36.2)	0.5 (0.3 to 0.8)	0.5 (0.2 to 1.0)	12.0 (-60.2 to 126.8)	-45.6 (-78.0 to 11.1)
Maternal sepsis and other maternal infections	19.6 (9.3 to 30.9)	14.2 (5.9 to 23.2)	-26.4 (-74.1 to 63.0)	-67.4 (-88.9 to -22.3)	0.4 (0.2 to 0.7)	0.2 (0.1 to 0.4)	-43.0 (-72.6 to 7.1)	-70.2 (-84.7 to -43.8)
Maternal hypertensive disorders	28.5 (10.3 to 52.4)	23.2 (7.5 to 42.6)	-19.9 (-27.2 to -5.2)	-57.1 (-63.2 to -51.8)	1.4 (0.5 to 3.0)	1.1 (0.3 to 2.3)	-19.3 (-34.8 to 0.2)	-57.3 (-66.1 to -48.7)
Obstructed labor	1.2 (0.6 to 1.9)	0.8 (0.4 to 1.4)	-29.2 (-58.1 to 12.4)	-63.6 (-78.4 to -43.9)	0.4 (0.1 to 0.7)	0.3 (0.1 to 0.5)	-26.6 (-70.0 to 68.5)	-62.2 (-83.5 to -16.8)
Complications of abortion	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	11.7 (-36.1 to 90.5)	-47.4 (-70.0 to -12.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.7 (-36.3 to 90.8)	47.4 (-70.0 to -12.0)
Other maternal disorders	-	-	-	-	0.3 (0.1 to 0.6)	0.2 (0.1 to 0.3)	-40.6 (-72.1 to 27.9)	-69.0 (-85.4 to -34.9)
Neonatal disorders	-	-	-	-	54.4 (35.3 to 81.2)	161.5 (110.0 to 227.2)	195.3 (108.5 to 331.0)	145.1 (75.8 to 256.1)
Preterm birth complications	229.9 (163.1 to 327.2)	722.0 (545.8 to 960.7)	213.7 (147.6 to 315.8)	137.3 (85.8 to 213.4)	23.0 (15.4 to 32.3)	89.2 (59.1 to 124.7)	285.9 (177.8 to 460.4)	207.4 (123.4 to 341.1)
Neonatal encephalopathy due to birth asphyxia and trauma	70.5 (28.0 to 168.9)	113.7 (62.7 to 217.2)	69.9 (-36.8 to 300.1)	37.2 (-43.5 to 241.4)	14.3 (6.8 to 25.0)	52.9 (18.8 to 53.4)	133.0 (9.3 to 396.1)	105.7 (-3.3 to 337.4)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.3)	2,058.0 (1,794.1 to 2,735.4)	2,615.8 (2,283.6 to 3,468.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,134.3 (990.9 to 5,875.8)	2,711.8 (1,272.9 to 7,420.3)
Hemolytic disease and other neonatal jaundice	9.9 (3.0 to 18.0)	31.8 (7.2 to 123.8)	165.8 (13.3 to 1,032.3)	115.9 (8.1 to 812.5)	4.0 (1.2 to 7.7)	10.6 (2.7 to 34.6)	136.5 (5.5 to 749.9)	89.9 (-14.8 to 575.0)
Other neonatal disorders	-	-	-	-	13.2 (4.8 to 28.0)	28.9 (15.2 to 51.8)	120.8 (-15.0 to 570.4)	83.4 (-29.7 to 453.7)
Nutritional deficiencies	-	-	-	-	491.3 (319.0 to 701.5)	313.6 (201.0 to 462.3)	-35.9 (-44.6 to -29.1)	-38.3 (-45.8 to -32.4)
Protein-energy malnutrition	323.4 (120.1 to 675.6)	112.0 (38.8 to 249.4)	65.7 (-90.4 to 21.8)	55.8 (-87.6 to 55.5)	5.8 (13.5 to 90.5)	14.1 (4.4 to 35.1)	55.9 (-90.3 to 22.0)	55.9 (-87.4 to 56.3)
Iodine deficiency	1,710.0 (1,180.6 to 2,294.8)	1,914.4 (1,200.5 to 2,666.7)	12.3 (-35.4 to 87.1)	-33.7 (-61.4 to 11.4)	30.7 (16.9 to 53.4)	34.3 (17.6 to 58.8)	11.8 (-34.2 to 86.9)	-33.9 (-61.3 to 12.2)
Vitamin A deficiency	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-

Appendix Table G.4 - Iran prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	12,939.1 (12,718.7 to 13,134.1)	10,569.1 (10,077.5 to 10,902.2)	-18.3 (-22.5 to -15.4)	-31.9 (-35.3 to -29.6)	417.3 (278.2 to 606.2)	263.9 (173.5 to 385.2)	-36.6 (-43.3 to -33.6)	-37.5 (-43.5 to -35.2)
Other nutritional deficiencies	-	-	-	-	2.9 (0.6 to 9.4)	1.4 (0.4 to 3.9)	-52.2 (-89.1 to 132.1)	-38.0 (-85.7 to 199.2)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	40.6 (25.8 to 62.5)	43.2 (26.3 to 71.2)	5.5 (-11.4 to 29.2)	-17.6 (-29.6 to -2.4)
Sexually transmitted diseases excluding HIV	-	-	-	-	15.2 (8.4 to 26.3)	26.5 (14.5 to 46.8)	71.0 (31.3 to 141.0)	-6.6 (-26.5 to 29.1)
Syphilis	1.2 (1.1 to 1.4)	1.7 (1.4 to 1.9)	32.3 (12.2 to 67.6)	-41.4 (-48.8 to -29.1)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.5)	36.9 (20.8 to 89.6)	-39.0 (-54.8 to -17.3)
Chlamydial infection	2,229.1 (1,893.1 to 2,582.0)	3,930.9 (3,416.3 to 4,548.4)	75.6 (41.0 to 124.8)	-1.4 (-20.1 to 24.8)	10.6 (5.6 to 18.2)	18.3 (9.7 to 33.0)	70.0 (14.7 to 175.6)	-5.1 (-35.5 to 51.7)
Gonococcal infection	252.4 (185.0 to 324.9)	378.8 (305.3 to 451.5)	49.8 (9.2 to 126.8)	-12.6 (-35.4 to 26.9)	1.6 (0.8 to 2.9)	2.5 (1.3 to 4.0)	53.2 (1.3 to 136.5)	-11.7 (-39.1 to 33.8)
Trichomoniasis	369.7 (247.9 to 487.4)	686.1 (479.4 to 861.5)	85.5 (20.0 to 191.8)	1.3 (-32.9 to 51.3)	0.6 (0.2 to 1.4)	1.2 (0.4 to 2.7)	84.7 (12.9 to 205.3)	2.5 (-36.5 to 61.0)
Genital herpes	7,200.1 (6,899.8 to 7,492.7)	14,514.3 (13,882.5 to 15,190.3)	101.8 (88.1 to 114.7)	3.0 (-9.4 to 3.4)	2.0 (0.6 to 4.7)	3.9 (1.2 to 9.3)	96.2 (76.1 to 113.3)	2.9 (-10.6 to 14.7)
Other sexually transmitted diseases	8.5 (6.5 to 11.3)	14.4 (10.5 to 19.5)	69.2 (36.6 to 105.7)	-22.8 (-37.7 to -3.6)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	104.8 (39.6 to 229.5)	1.5 (-28.9 to 54.9)
Hepatitis	-	-	-	-	2.5 (1.6 to 3.7)	3.2 (2.0 to 4.6)	26.6 (14.1 to 41.3)	-12.8 (-21.0 to -3.4)
Hepatitis A	80.5 (76.9 to 84.2)	81.3 (78.8 to 83.8)	1.0 (-0.6 to 2.6)	-6.3 (-6.5 to -6.1)	1.7 (1.1 to 2.6)	2.2 (1.4 to 3.2)	27.9 (13.1 to 44.4)	-2.4 (-12.7 to 8.8)
Hepatitis B	1,405.8 (1,283.7 to 1,534.3)	1,315.9 (1,222.6 to 1,425.0)	-6.4 (-16.6 to 6.2)	-37.5 (-44.2 to -29.9)	0.5 (0.3 to 0.9)	0.6 (0.4 to 1.0)	26.3 (5.1 to 65.9)	-34.5 (-50.3 to -10.5)
Hepatitis C	315.0 (288.6 to 341.3)	414.2 (378.9 to 449.4)	31.4 (17.5 to 48.4)	-27.7 (-35.4 to -19.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	20.4 (7.0 to 54.2)	-26.0 (-46.0 to 2.4)
Hepatitis E	8.7 (7.9 to 9.7)	9.5 (8.5 to 10.5)	9.6 (-6.3 to 25.7)	-14.4 (-25.3 to -1.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	22.7 (-13.5 to 75.7)	-15.7 (-39.7 to 19.2)
Leprosy	0.7 (0.5 to 1.1)	0.8 (0.7 to 1.0)	13.4 (5.3 to 43.3)	-44.0 (-52.6 to -30.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	15.8 (-13.0 to 73.4)	-43.0 (-58.4 to -12.5)
Other infectious diseases	628.3 (505.7 to 768.2)	457.7 (394.6 to 523.6)	-27.5 (-40.5 to -10.5)	-27.1 (-39.2 to -11.9)	22.9 (14.3 to 33.6)	13.5 (8.3 to 20.4)	-41.8 (-58.1 to -21.5)	-33.0 (-51.7 to -11.1)
Non-communicable diseases	-	-	-	-	3,890.2 (2,849.0 to 5,057.6)	7,221.7 (5,322.9 to 9,363.7)	86.1 (80.5 to 91.8)	3.9 (0.3 to 6.7)
Neoplasms	-	-	-	-	16.6 (11.5 to 22.5)	25.8 (18.0 to 34.8)	54.5 (26.1 to 103.1)	-22.5 (-36.1 to -0.2)
Esophageal cancer	4.5 (3.2 to 6.0)	8.6 (5.2 to 12.2)	90.9 (10.9 to 216.9)	-13.0 (-48.2 to 41.6)	0.7 (0.5 to 1.1)	1.4 (0.8 to 2.1)	87.1 (15.7 to 185.6)	-15.2 (-46.8 to 26.2)
Stomach cancer	13.5 (11.2 to 16.1)	23.0 (19.0 to 27.7)	71.0 (31.0 to 120.1)	-21.7 (-40.0 to 1.2)	1.6 (1.1 to 2.2)	2.6 (1.8 to 3.5)	76.5 (22.3 to 110.9)	-27.5 (-44.6 to -5.1)
Liver cancer	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	96.5 (38.9 to 169.2)	-3.9 (-30.1 to 32.9)
Liver cancer due to hepatitis B	0.7 (0.4 to 1.0)	1.5 (1.0 to 2.2)	111.2 (24.7 to 260.0)	4.4 (-39.1 to 78.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	95.7 (23.6 to 210.9)	-4.0 (-40.5 to 52.7)
Liver cancer due to hepatitis C	0.2 (0.1 to 0.4)	0.8 (0.5 to 1.3)	292.3 (68.3 to 725.1)	84.5 (-17.0 to 295.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	258.5 (58.1 to 599.0)	66.7 (-21.1 to 225.5)
Liver cancer due to alcohol use	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	82.6 (-24.7 to 447.8)	-16.7 (-63.9 to 129.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	75.2 (-24.7 to 390.3)	-21.6 (-65.9 to 111.3)
Liver cancer due to other causes	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-19.3 (-55.6 to 45.3)	-57.0 (-77.5 to -19.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	25.4 (56.5 to 28.4)	-49.7 (-78.1 to -29.5)
Larynx cancer	5.8 (4.1 to 7.8)	7.2 (4.8 to 9.5)	23.6 (-12.6 to 73.6)	-42.1 (-58.4 to -18.5)	0.6 (0.4 to 0.8)	0.7 (0.4 to 1.0)	20.0 (-16.4 to 68.2)	-44.3 (-60.8 to -21.3)
Tracheal, bronchus and lung cancer	5.3 (4.4 to 6.4)	6.9 (5.5 to 8.6)	29.1 (-2.6 to 76.4)	-41.6 (-55.2 to -20.6)	0.9 (0.6 to 1.2)	1.1 (0.8 to 1.5)	25.4 (-6.5 to 71.3)	-43.4 (-57.7 to -23.3)
Breast cancer	16.9 (13.0 to 21.6)	38.9 (28.6 to 51.6)	131.3 (53.5 to 235.9)	2.1 (-30.5 to 45.0)	1.5 (1.0 to 2.1)	3.1 (1.9 to 4.4)	106.1 (37.8 to 211.0)	-9.7 (-37.6 to 34.0)
Cervical cancer	4.7 (3.5 to 6.6)	6.3 (3.3 to 8.7)	36.7 (-35.4 to 113.4)	-85.4 (-67.1 to -4.0)	0.4 (0.2 to 0.6)	0.5 (0.2 to 0.8)	96.1 (-33.1 to 106.6)	-36.1 (-66.6 to -6.3)
Uterine cancer	3.0 (1.7 to 4.5)	3.1 (2.0 to 5.2)	-0.4 (-43.0 to 100.6)	-52.7 (-72.6 to -5.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	-3.1 (-45.5 to 105.0)	44.3 (-7.1 to -54.9)
Prostate cancer	8.3 (4.7 to 12.2)	36.2 (21.3 to 53.7)	338.7 (167.0 to 620.1)	81.7 (14.1 to 197.2)	1.0 (0.5 to 1.5)	3.3 (1.8 to 5.2)	230.5 (113.4 to 414.3)	33.8 (-12.0 to 108.1)
Colon and rectum cancer	9.3 (7.8 to 11.0)	21.2 (17.7 to 25.5)	126.9 (78.0 to 191.3)	6.4 (-15.3 to 34.6)	0.8 (0.6 to 1.2)	1.8 (1.2 to 2.4)	108.7 (60.2 to 173.1)	-4.0 (-25.3 to 24.1)
Lip and oral cavity cancer	4.5 (3.2 to 6.0)	5.9 (4.2 to 8.1)	27.7 (-15.6 to 108.0)	-36.9 (-58.1 to -0.5)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.8)	25.8 (-15.9 to 103.0)	-38.8 (-58.7 to -22.2)
Nasopharynx cancer	1.8 (1.3 to 2.5)	2.1 (1.5 to 2.9)	14.7 (-22.5 to 79.1)	-40.0 (-60.1 to -8.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	11.6 (-22.1 to 73.1)	-42.6 (-60.7 to -12.1)
Other pharynx cancer	1.0 (0.7 to 1.4)	0.9 (0.6 to 1.2)	-14.7 (-45.4 to 44.7)	-56.3 (-71.9 to -30.2)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-15.9 (-45.3 to 39.0)	-57.6 (-72.1 to -33.5)
Gallbladder and biliary tract cancer	0.5 (0.4 to 0.6)	0.8 (0.6 to 1.0)	68.2 (14.8 to 148.9)	-18.7 (-45.7 to 19.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	57.0 (9.6 to 131.8)	-23.7 (-49.1 to 13.2)
Pancreatic cancer	0.7 (0.5 to 0.8)	0.9 (0.8 to 1.2)	41.3 (7.2 to 89.8)	-30.1 (-47.3 to -5.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	44.9 (15.3 to 86.0)	-28.2 (-43.6 to -6.7)
Malignant skin melanoma	1.8 (1.3 to 2.5)	4.2 (2.9 to 5.6)	132.1 (51.2 to 219.7)	13.5 (-25.3 to 55.2)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	187.7 (40.8 to 210.2)	3.7 (-33.9 to 52.5)
Non-melanoma skin cancer	4.4 (2.9 to 6.3)	10.9 (7.9 to 14.5)	146.2 (53.8 to 294.8)	7.9 (-33.2 to 61.8)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	183.3 (102.8 to 314.1)	19.3 (-21.7 to 77.6)
Ovarian cancer	2.3 (1.7 to 3.2)	3.0 (2.2 to 4.1)	37.9 (-17.9 to 93.0)	-37.9 (-59.3 to -10.5)	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	31.2 (-15.4 to 102.0)	-37.4 (-59.7 to -3.6)
Testicular cancer	3.1 (1.4 to 5.2)	4.7 (2.9 to 7.8)	51.8 (-31.9 to 227.9)	-22.3 (-63.0 to 58.6)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	46.7 (-36.2 to 228.0)	-24.9 (-64.9 to 51.9)
Kidney cancer	4.8 (3.3 to 5.6)	4.3 (3.8 to 6.1)	-13.4 (-21.4 to 60.9)	-29.2 (-48.3 to -4.1)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.5)	11.6 (-20.5 to 61.8)	-33.7 (-51.5 to -8.3)
Bladder cancer	7.2 (4.5 to 9.4)	6.6 (5.0 to 9.2)	-8.9 (-38.9 to 82.4)	-58.9 (-71.5 to -18.3)	0.6 (0.4 to 0.9)	0.6 (0.4 to 0.8)	-13.9 (-41.0 to 76.9)	-60.8 (-73.2 to -23.0)
Brain and nervous system cancer	10.2 (6.4 to 13.7)	12.0 (9.3 to 15.5)	18.3 (-21.0 to 92.6)	-19.8 (-42.0 to 26.4)	1.0 (0.6 to 1.5)	1.2 (0.8 to 1.6)	21.7 (-16.0 to 104.2)	-23.5 (-43.8 to 23.0)
Thyroid cancer	6.8 (4.3 to 9.3)	10.9 (7.7 to 14.7)	59.4 (1.2 to 180.7)	-23.0 (-49.3 to 33.5)	0.4 (0.2 to 0.7)	0.6 (0.4 to 1.0)	49.6 (-6.5 to 169.5)	-29.0 (-53.3 to 22.1)
Mesothelioma	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	97.5 (7.6 to 131.7)	-22.0 (-46.3 to 13.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.6 (10.4 to 131.2)	-22.3 (-46.4 to 13.2)
Hodgkin lymphoma	5.9 (2.9 to 8.7)	4.6 (3.3 to 4.6)	-24.6 (-53.7 to 86.5)	-46.1 (-65.5 to 24.9)	0.5 (0.2 to 0.8)	0.4 (0.2 to 0.6)	-23.0 (-52.7 to 87.7)	-48.2 (-66.5 to 17.0)
Non-Hodgkin lymphoma	6.8 (3.6 to 9.7)	9.7 (7.2 to 14.4)	30.4 (-12.7 to 228.1)	-30.2 (-52.2 to 75.0)	0.5 (0.2 to 0.8)	0.7 (0.4 to 1.2)	25.7 (-18.1 to 217.1)	-33.5 (-56.4 to 67.9)
Multiple myeloma	1.0 (0.5 to 1.7)	1.5 (1.0 to 2.1)	43.9 (-16.8 to 219.4)	-26.5 (-56.5 to 47.4)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	42.2 (-20.2 to 203.8)	-27.9 (-59.8 to 42.7)
Leukemia	71.2 (14.7 to 28.8)	20.5 (16.3 to 25.3)	-71.2 (-33.4 to 40.5)	-24.2 (-43.3 to 5.8)	2.2 (1.3 to 3.1)	2.3 (1.5 to 3.2)	6.1 (-22.2 to 52.1)	-90.4 (-47.8 to -3.3)
Other neoplasms	15.1 (10.2 to 19.5)	24.0 (15.2 to 43.2)	26.8 (-10.6 to 278.2)	-27.5 (-49.6 to 112.5)	1.3 (0.7 to 1.6)	1.7 (0.9 to 3.3)	22.5 (-12.9 to 257.2)	-36.3 (-55.1 to 86.3)
Cardiovascular diseases	-	-	-	-	96.3 (66.2 to 133.6)	200.4 (137.8 to 276.3)	109.5 (69.3 to 153.7)	13.3 (-7.6 to 36.6)
Rheumatic heart disease	142.6 (111.0 to 179.5)	257.3 (200.4 to 332.9)	82.0 (14.4 to 157.4)	5.0 (-28.3 to 45.5)	7.5 (4.6 to 11.4)	15.0 (9.4 to 21.4)	100.3 (39.2 to 185.1)	17.3 (-12.9 to 66.1)
Ischemic heart disease	368.0 (311.0 to 446.8)	859.3 (738.1 to 1,027.9)	134.7 (79.1 to 207.5)	12.1 (-11.9 to 45.1)	11.1 (13.6 to 30.9)	50.2 (33.7 to 71.2)	141.9 (79.8 to 232.6)	21.2 (-8.1 to 64.5)
Cerebrovascular disease	-	-	-	-	2.8 (1.9 to 3.8)	3.8 (5.4 to 10.6)	38.7 (127.5 to 260.5)	42.3 (12.6 to 83.0)
Ischemic stroke	14.1 (11.8 to 17.0)	41.0 (36.0 to 46.4)	189.1 (131.5 to 269.2)	43.2 (12.4 to 84.7)	2.2 (1.4 to 3.1)	6.3 (4.3 to 8.6)	189.6 (127.7 to 280.2)	44.2 (12.8 to 90.7)
Hemorrhagic stroke	3.5 (2.9 to 4.2)	8.9 (7.7 to 10.4)	154.9 (104.8 to 222.6)	35.2 (7.7 to 72.1)	0.6 (0.4 to 0.8)	1.5 (1.0 to 2.1)	149.9 (100.3 to 221.2)	32.2 (4.4 to 71.3)
Hypertensive heart disease	40.0 (28.0 to 55.9)	124.1 (92.3 to 158.2)	211.5 (109.9 to 356.5)	52.9 (13.3 to 126.6)	4.4 (2.7 to 6.8)	13.7 (8.7 to 19.9)	208.7 (107.9 to 352.6)	51.9 (1.5 to 125.9)
Cardiomyopathy and myocarditis	30.7 (25.4 to 36.2)	98.3 (76.1 to 127.6)	212.6 (133.1 to 351.3)	61.9 (15.7 to 144.7)	3.4 (2.2 to 4.8)	10.9 (7.0 to 16.2)	110.9 (127.9 to 375.8)	65.2 (15.5 to 155.1)
Atrial fibrillation and flutter	45.8 (31.3 to 68.7)	111.9 (80.8 to 153.8)	145.5 (45.9 to 314.2)	-9.4 (-42.8 to 58.5)	3.5 (2.1 to 5.8)	8.6 (5.2 to 13.2)	147.4 (43.9 to 320.1)	-8.3 (-43.5 to 62.0)
Peripheral vascular disease	598.9 (462.9 to 783.0)	1,394.1 (1,020.0 to 1,706.7)	134.3 (53.3 to 244.0)	6.1 (-27.3 to 54.4)	0.3 (0.1 to 0.5)	0.8 (0.3 to 1.5)	202.3 (60.9 to 421.4)	7.3 (-39.1 to 78.8)
Endocarditis	0.6 (0.5 to 0.9)	2.3 (1.6 to 3.1)	298.5 (121.4 to 472.7)	113.4 (11.3 to 228.0)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.4)	332.6 (125.6 to 527.8)	140.0 (25.1 to 272.3)
Other cardiovascular and circulatory diseases	72.8 (60.6 to 97.5)	1,323.5 (920.8 to 1,693.7)	71.2 (17.9 to 139.3)	77.2 (-34.4 to 38.7)	0.5 (34.1 to 78.2)			

Appendix Table G.4 - Iran prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumococcosis	-	-	-	-	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.5)	95.1 (89.2 to 101.0)	40.2 (-13.1 to -7.6)
Silicosis	0.3 (0.3 to 0.3)	0.5 (0.5 to 0.6)	80.2 (70.4 to 90.3)	-19.4 (-23.7 to -14.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	77.1 (66.6 to 88.1)	-20.6 (-25.4 to -15.7)
Asbestosis	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.3)	101.8 (95.0 to 110.0)	-9.6 (-12.9 to -5.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	98.8 (91.1 to 107.9)	-10.8 (-14.7 to -6.7)
Coal workers pneumococcosis	0.2 (0.2 to 0.2)	0.4 (0.4 to 0.4)	107.9 (100.6 to 116.6)	-5.3 (-8.5 to -1.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	104.8 (96.5 to 114.3)	-6.5 (-10.0 to -2.7)
Other pneumococcosis	0.5 (0.4 to 0.5)	1.0 (0.9 to 1.0)	104.2 (95.8 to 112.6)	9.9 (-6.9 to 0.7)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	101.2 (92.7 to 109.7)	40.2 (-8.5 to -0.1)
Asthma	3,132.0 (2,854.1 to 3,406.9)	4,369.2 (4,035.1 to 4,789.1)	38.9 (22.7 to 60.7)	3.1 (-7.8 to 16.7)	139.2 (90.6 to 199.6)	193.0 (124.4 to 274.1)	38.4 (21.3 to 60.0)	3.7 (-8.1 to 17.4)
Interstitial lung disease and pulmonary sarcoidosis	3.4 (2.6 to 4.2)	7.5 (5.9 to 9.2)	120.5 (60.1 to 192.0)	7.6 (-20.4 to 42.5)	0.4 (0.3 to 0.7)	1.0 (0.6 to 1.5)	122.7 (59.3 to 199.3)	9.4 (-21.5 to 46.8)
Other chronic respiratory diseases	-	-	-	-	26.9 (16.5 to 43.9)	24.7 (14.8 to 38.7)	-8.6 (-37.6 to 39.9)	-55.0 (-69.2 to -30.4)
Cirrhosis	-	-	-	-	3.3 (2.2 to 4.6)	3.3 (2.2 to 4.7)	0.2 (-14.2 to 17.4)	-35.5 (-43.9 to -24.8)
Cirrhosis due to hepatitis B	5.9 (3.7 to 7.9)	6.7 (3.9 to 10.5)	14.4 (-42.0 to 97.3)	-32.7 (-64.9 to 13.2)	1.0 (0.5 to 1.6)	1.1 (0.5 to 1.9)	14.0 (-45.3 to 108.8)	32.6 (-66.8 to 18.8)
Cirrhosis due to hepatitis C	6.2 (4.2 to 8.4)	7.3 (3.8 to 10.7)	15.9 (-42.3 to 111.4)	-31.1 (-69.2 to 21.8)	1.0 (0.6 to 1.6)	1.2 (0.6 to 2.0)	15.3 (-44.4 to 123.1)	-31.3 (-69.5 to 29.6)
Cirrhosis due to alcohol use	2.0 (1.4 to 3.3)	1.8 (0.9 to 2.7)	-10.4 (-53.8 to 56.9)	0.3 (-7.7 to 22.4)	0.3 (0.2 to 0.6)	0.3 (0.1 to 0.5)	-11.1 (-56.7 to 68.0)	-56.3 (-78.6 to -21.6)
Cirrhosis due to other causes	5.7 (4.6 to 6.9)	4.2 (3.2 to 5.4)	-25.7 (-47.1 to -5.3)	-29.6 (-45.7 to -7.5)	1.0 (0.6 to 1.5)	0.7 (0.4 to 1.1)	-25.5 (-53.1 to 9.3)	-29.2 (-53.6 to 3.7)
Digestive diseases	-	-	-	-	33.8 (24.2 to 45.5)	53.5 (38.2 to 71.7)	59.0 (41.4 to 77.6)	-14.9 (-24.1 to -5.9)
Peptic ulcer disease	107.1 (81.4 to 131.3)	160.6 (133.7 to 184.2)	49.3 (16.4 to 97.3)	-27.7 (-42.5 to -7.3)	4.3 (2.9 to 6.2)	6.1 (4.2 to 8.7)	43.1 (6.6 to 81.6)	-34.2 (-49.5 to -18.1)
Gastritis and duodenitis	210.0 (186.6 to 231.7)	143.7 (128.9 to 158.5)	-31.8 (-41.2 to -19.5)	-54.8 (-61.3 to -46.4)	9.9 (6.6 to 14.1)	7.2 (4.7 to 10.2)	-27.2 (-42.5 to -9.6)	-46.5 (-55.3 to -35.5)
Appendicitis	3.9 (2.8 to 5.1)	4.4 (3.4 to 5.6)	14.2 (-19.2 to 62.8)	-30.3 (-49.1 to -3.2)	1.2 (0.6 to 1.9)	1.3 (0.8 to 2.1)	13.6 (-29.9 to 86.9)	-28.7 (-53.1 to 11.4)
Paralytic ileus and intestinal obstruction	0.9 (0.5 to 1.9)	1.1 (0.7 to 2.0)	17.5 (-18.8 to 268.8)	-4.6 (-48.5 to 117.4)	0.3 (0.1 to 0.6)	0.3 (0.2 to 0.7)	17.5 (-53.9 to 296.6)	3.6 (-50.6 to 131.0)
Inguinal, femoral, and abdominal hernia	136.4 (117.0 to 162.0)	242.7 (196.4 to 288.2)	77.7 (42.2 to 120.1)	-7.5 (-29.5 to 16.5)	1.4 (0.7 to 2.6)	2.5 (1.2 to 4.9)	77.0 (39.4 to 119.7)	-7.1 (-29.2 to 16.7)
Inflammatory bowel disease	37.7 (34.5 to 41.0)	108.2 (99.5 to 116.8)	187.2 (158.0 to 219.3)	42.7 (29.1 to 57.8)	8.0 (5.4 to 11.1)	23.0 (15.8 to 31.8)	186.5 (152.8 to 227.9)	43.3 (27.2 to 61.7)
Vascular disorders	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	115.0 (60.4 to 199.5)	3.3 (-28.3 to 70.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	111.7 (52.2 to 190.0)	4.0 (-33.6 to 70.4)
Gallbladder and biliary diseases	16.0 (13.9 to 18.4)	30.9 (26.4 to 36.2)	93.0 (56.8 to 129.7)	1.7 (-20.9 to 15.0)	1.9 (1.1 to 2.3)	3.2 (2.1 to 4.5)	92.1 (50.6 to 139.4)	3.6 (-23.2 to 18.6)
Pancreatitis	9.1 (8.6 to 9.6)	16.6 (15.5 to 17.9)	82.9 (68.0 to 101.2)	-8.2 (-14.8 to 2.2)	2.7 (1.8 to 3.6)	4.9 (3.3 to 6.7)	82.2 (65.2 to 117.7)	-7.6 (-21.5 to 8.2)
Other digestive diseases	-	-	-	-	4.3 (2.5 to 6.4)	4.8 (3.1 to 6.9)	11.1 (-19.9 to 75.7)	-40.7 (-57.1 to -6.9)
Neurological disorders	-	-	-	-	405.5 (273.5 to 547.9)	830.9 (567.0 to 1,128.0)	105.3 (83.4 to 128.3)	9.8 (-1.3 to 22.7)
Alzheimer disease and other dementias	185.1 (155.5 to 211.9)	503.4 (434.2 to 573.1)	172.0 (122.5 to 236.1)	1.4 (-17.8 to 25.1)	25.3 (17.8 to 33.2)	71.6 (51.1 to 93.0)	182.4 (130.2 to 251.5)	2.4 (-17.0 to 27.3)
Parkinson disease	36.7 (31.0 to 42.7)	86.5 (74.6 to 98.9)	136.0 (122.3 to 149.3)	2.1 (-2.8 to 7.4)	4.3 (3.0 to 6.0)	10.2 (7.1 to 14.1)	135.9 (115.2 to 158.8)	3.1 (-4.9 to 11.5)
Epilepsy	314.6 (262.3 to 363.7)	450.9 (372.0 to 529.2)	43.4 (12.5 to 83.5)	5.2 (-15.7 to 34.3)	101.6 (65.4 to 140.5)	158.9 (101.9 to 218.3)	56.7 (19.4 to 104.8)	16.8 (-10.6 to 52.9)
Multiple sclerosis	7.7 (7.1 to 8.3)	29.5 (27.1 to 31.4)	282.6 (240.7 to 327.6)	82.2 (63.5 to 102.8)	2.6 (1.8 to 3.4)	9.7 (6.7 to 12.6)	275.9 (207.3 to 354.5)	79.8 (50.2 to 117.7)
Migraine	4,651.0 (4,010.6 to 5,265.0)	9,012.3 (8,050.7 to 10,027.0)	94.3 (62.1 to 129.9)	6.7 (-9.9 to 25.2)	158.9 (94.5 to 236.4)	307.8 (183.6 to 455.2)	97.8 (61.6 to 129.8)	7.5 (-11.1 to 27.0)
Tension-type headache	17,327.9 (16,654.0 to 18,072.8)	30,611.1 (29,175.5 to 32,049.2)	76.5 (66.2 to 88.3)	1.7 (-3.8 to 8.0)	26.3 (12.7 to 46.2)	46.5 (28.8 to 81.7)	76.5 (65.6 to 88.4)	2.0 (-0.4 to 8.4)
Medication overuse headache	478.6 (322.7 to 630.1)	1,428.5 (969.4 to 1,843.9)	199.8 (151.7 to 246.7)	55.2 (32.0 to 81.2)	75.3 (43.8 to 115.8)	224.7 (127.2 to 338.2)	199.9 (152.5 to 249.3)	55.7 (31.5 to 82.3)
Other neurological disorders	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	44.9 (5.0 to 108.7)	-1.0 (-28.9 to 39.0)	11.1 (5.1 to 18.7)	1.6 (1.1 to 2.3)	-85.5 (-91.8 to -67.3)	-97.7 (-97.8 to -87.8)
Mental and substance use disorders	-	-	-	-	1,204.0 (836.9 to 1,668.7)	2,151.9 (1,517.5 to 2,916.3)	79.1 (67.9 to 90.3)	4.1 (-0.5 to 96.8)
Schizophrenia	117.6 (106.7 to 128.0)	246.1 (224.7 to 267.1)	109.3 (98.2 to 120.9)	-0.8 (-5.5 to 4.1)	75.3 (54.9 to 91.6)	158.1 (116.3 to 191.7)	109.8 (94.8 to 127.2)	0.2 (-6.6 to 6.6)
Alcohol use disorders	165.8 (141.6 to 194.1)	230.8 (186.5 to 271.9)	39.3 (25.8 to 52.3)	-31.0 (-38.8 to -24.9)	16.2 (10.5 to 23.3)	22.8 (14.5 to 32.7)	40.6 (23.1 to 59.5)	-30.9 (-40.2 to -22.2)
Drug use disorders	-	-	-	-	126.4 (80.1 to 182.6)	302.2 (200.4 to 424.2)	139.0 (102.8 to 190.5)	16.1 (-0.7 to 40.9)
Opioid use disorders	227.4 (145.0 to 313.9)	609.8 (432.1 to 785.6)	169.1 (123.8 to 246.3)	23.5 (4.2 to 56.4)	94.8 (55.1 to 145.8)	255.6 (162.5 to 368.9)	170.6 (122.1 to 248.6)	24.6 (3.8 to 58.3)
Cocaine use disorders	34.2 (28.1 to 40.7)	61.4 (53.3 to 69.7)	79.2 (43.1 to 133.2)	4.9 (-21.8 to 23.1)	4.7 (3.0 to 6.9)	8.5 (5.3 to 12.3)	79.8 (34.1 to 145.5)	4.1 (-26.3 to 31.6)
Amphetamine use disorders	75.7 (59.4 to 92.8)	98.2 (76.7 to 120.4)	29.8 (-3.2 to 74.8)	-23.1 (-42.1 to 2.1)	9.9 (5.9 to 15.0)	12.8 (7.7 to 19.3)	29.8 (8.3 to 79.5)	-23.0 (-44.9 to 4.5)
Cannabis use disorders	80.1 (61.2 to 97.6)	129.7 (103.0 to 155.2)	61.9 (52.9 to 73.7)	-0.3 (-0.3 to -0.2)	2.3 (1.4 to 3.6)	3.8 (2.3 to 5.8)	61.1 (36.1 to 95.6)	-0.5 (-15.4 to 17.4)
Other drug use disorders	-	-	-	-	14.7 (8.9 to 22.1)	21.5 (13.2 to 30.9)	45.6 (23.9 to 110.4)	-16.2 (-40.6 to 20.0)
Depressive disorders	-	-	-	-	419.7 (238.4 to 663.7)	823.7 (464.4 to 1,309.1)	97.8 (69.6 to 119.6)	8.8 (-0.7 to 26.6)
Major depressive disorder	1,811.8 (1,091.4 to 2,597.9)	3,549.9 (2,088.7 to 5,033.0)	97.6 (66.8 to 121.9)	9.3 (-1.2 to 31.8)	373.3 (201.1 to 607.6)	729.6 (382.2 to 1,183.5)	97.0 (65.4 to 121.5)	10.1 (-0.8 to 32.0)
Dysthymia	481.5 (391.1 to 571.2)	976.4 (786.1 to 1,164.7)	102.7 (97.1 to 108.7)	0.6 (0.4 to 0.8)	46.4 (29.7 to 67.9)	94.1 (59.8 to 137.0)	102.6 (94.3 to 110.9)	0.9 (-1.4 to 3.5)
Bipolar disorder	332.8 (287.3 to 375.4)	654.6 (570.6 to 737.2)	97.1 (85.0 to 108.4)	-0.3 (-5.2 to 4.4)	67.7 (41.5 to 102.3)	133.3 (81.5 to 200.5)	97.0 (82.1 to 112.9)	0.2 (-6.1 to 6.8)
Anxiety disorders	7,126.7 (5,950.8 to 8,303.3)	13,549.9 (11,835.7 to 15,264.1)	68.5 (43.4 to 93.3)	196.5 (104.0 to 288.9)	419.7 (308.7 to 530.7)	826.5 (502.2 to 1,150.8)	68.7 (42.2 to 94.4)	0.9 (-1.3 to 3.2)
Eating disorders	-	-	-	-	7.6 (4.6 to 11.6)	13.0 (7.8 to 20.1)	70.6 (50.5 to 93.2)	6.6 (-4.6 to 19.9)
Anorexia nervosa	8.4 (5.5 to 12.1)	15.5 (10.6 to 22.2)	85.3 (58.7 to 121.2)	25.5 (7.4 to 51.6)	3.0 (1.8 to 3.0)	3.3 (1.8 to 5.4)	83.6 (40.1 to 142.9)	25.5 (-3.1 to 65.0)
Bulimia nervosa	27.5 (18.7 to 38.7)	45.7 (30.7 to 66.0)	66.2 (53.7 to 77.1)	0.6 (0.5 to 0.7)	5.8 (3.3 to 9.3)	9.7 (5.5 to 15.8)	66.3 (43.0 to 91.2)	1.0 (-10.9 to 14.8)
Autistic spectrum disorders	-	-	-	-	66.2 (46.1 to 90.8)	89.8 (62.2 to 123.0)	89.8 (30.5 to 41.1)	-0.3 (-3.3 to 3.0)
Autism	165.7 (156.8 to 176.7)	226.6 (214.3 to 241.5)	36.8 (35.3 to 38.3)	-0.7 (-0.8 to -0.7)	41.0 (27.6 to 56.9)	55.6 (37.7 to 77.5)	36.1 (28.6 to 44.1)	-3.0 (-4.9 to 4.8)
Asperger syndrome	251.3 (235.5 to 265.9)	339.7 (318.3 to 360.6)	35.2 (33.4 to 37.1)	-0.9 (-1.0 to -0.9)	25.2 (17.4 to 35.4)	34.0 (23.6 to 47.5)	34.9 (28.5 to 41.2)	-0.5 (-4.4 to 3.6)
Attention-deficit/hyperactivity disorder	420.8 (346.9 to 496.2)	382.2 (314.7 to 451.4)	-9.0 (-10.5 to -8.3)	-0.4 (-0.4 to -0.4)	5.1 (2.9 to 8.1)	4.7 (2.7 to 7.3)	-9.1 (-16.1 to -1.6)	-0.1 (-7.4 to 8.0)
Conduct disorder	772.4 (643.9 to 894.1)	675.0 (560.9 to 791.3)	-12.8 (-15.3 to -9.2)	0.4 (-0.5 to 0.4)	92.8 (57.3 to 140.3)	81.4 (49.9 to 123.8)	-12.4 (-17.0 to -7.7)	-0.1 (-3.9 to 4.0)
Idiopathic intellectual disability	1,621.4 (1,359.8 to 1,941.8)	1,856.1 (1,558.5 to 2,139.3)	14.3 (4.9 to 25.3)	-14.2 (-21.2 to -5.8)	79.6 (52.3 to 112.3)	90.6 (59.8 to 129.2)	13.7 (4.1 to 24.9)	-14.0 (-21.4 to -5.4)
Other mental and substance use disorders	679.3 (634.8 to 722.3)	1,412.0 (1,320.6 to 1,497.3)	107.9 (105.8 to 110.0)	-0.5 (-0.7 to -0.4)	50.7 (34.5 to 68.2)	105.8 (72.0 to 142.6)	108.5 (100.3 to 117.6)	0.0 (-3.5 to 3.8)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	396.0 (281.8 to 541.7)	764.9 (541.7 to 1,058.0)	92.7 (73.7 to 116.5)	11.1 (-2.8 to 26.5)
Diabetes mellitus	1,675.2 (1,441.6 to 1,951.6)	4,789.0 (3,885.2 to 5,674.7)	184.5 (131.0 to 257.9)	43.4 (11.6 to 82.5)	137.7 (92.8 to 193.4)	336.9 (219.4 to 477.1)	143.8 (86.6 to 219.3)	16.1 (-12.5 to 53.7)
Acute glomerulonephritis	0.5 (0.4 to 0.5)	0.3 (0.3 to 0.4)	-27.5 (-32.9 to -21.3)	0.0 (-0.3 to -0.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.5 (-32.9 to -21.3)	35.6 (-39.7 to -30.9)
Chronic kidney disease	-	-	-	-	56.1 (39.1 to 72.8)	95.9 (67.8 to 126.7)	70.7 (53.5 to 91.5)	-2.4 (-10.9 to 6.9)
Chronic kidney disease due to diabetes mellitus	379.8 (221.6 to 629.1)	622.9 (479.3 to 773.8)	64.0 (10.9 to 179.2)	-15.8 (-45.4 to 42.4)	10.9 (7.3 to 14.7)	22.5 (14.8 to 31.0)	107.4 (51.2 to 175.7)	5.0 (-20.6 to 38.7)
Chronic kidney disease due to hypertension	234.3 (178.8 to 289.5)	261.5 (214.1 to 311.2)	14.6 (-18.0 to 48.4)	-30.9 (-51.9 to -22.2)	17.9 (12.0 to 24.7)	26.4 (17.4 to 37.4)	46.6 (11.3 to 112.9)	-22.4 (-42.5 to 13.4)
Chronic kidney disease due to glomerulonephritis	544.5 (295.1 to 1,005.5)	542.2 (388.4 to 753.3)	-0.5 (-41.2 to 78.8)	4.3 (-49.5 to 2.2)	6.2 (4.0 to 9.3)	7.0 (4.5 to 10.3)	6.7	

Appendix Table G.4 - Iran prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	10.7 (9.9 to 11.6)	18.3 (17.2 to 19.4)	70.9 (55.1 to 88.0)	0.4 (-3.1 to 14.4)	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.9)	69.6 (35.4 to 110.5)	69.6 (13.1 to 25.3)
Urolithiasis	362.9 (160.8 to 614.0)	1,398.4 (825.3 to 2,094.7)	263.9 (201.4 to 621.6)	2.1 (32.6 to 184.6)	2.1 (1.0 to 3.8)	9.2 (4.8 to 15.9)	323.9 (259.8 to 614.2)	95.0 (66.0 to 210.6)
Benign prostatic hyperplasia	390.1 (355.4 to 423.3)	859.3 (792.1 to 918.2)	119.9 (96.8 to 146.7)	-1.1 (-11.5 to 11.4)	14.0 (9.1 to 19.8)	30.9 (20.2 to 44.1)	121.1 (95.9 to 148.5)	-0.1 (-10.9 to 12.5)
Male infertility due to other causes	365.8 (227.2 to 523.1)	741.7 (486.8 to 1,081.1)	104.4 (14.6 to 258.4)	1.9 (-4.2 to 77.4)	2.6 (1.0 to 5.7)	5.3 (2.1 to 11.1)	104.2 (10.8 to 264.0)	2.4 (-4.3 to 81.3)
Other urinary diseases	-	-	-	-	0.2 (0.1 to 0.6)	3.3 (0.6 to 7.6)	3,099.2 (140.6 to 4,499.5)	1,392.6 (15.7 to 2,080.4)
Gynecological diseases	-	-	-	-	55.8 (35.6 to 83.9)	111.2 (71.1 to 172.3)	98.4 (67.2 to 142.3)	-4.3 (-18.2 to 14.3)
Uterine fibroids	771.8 (694.4 to 841.9)	1,798.7 (1,628.1 to 1,955.0)	133.0 (131.4 to 134.9)	1.5 (1.4 to 1.5)	11.4 (6.6 to 18.8)	18.4 (9.1 to 32.8)	56.9 (33.6 to 116.6)	-28.7 (-38.9 to -0.1)
Polycystic ovarian syndrome	989.9 (896.4 to 1,081.9)	1,973.8 (1,780.1 to 2,151.8)	99.2 (75.1 to 128.3)	-2.4 (-14.0 to 11.3)	9.6 (4.5 to 18.3)	19.1 (8.9 to 35.4)	99.5 (74.6 to 128.1)	-2.0 (-13.7 to 11.0)
Female infertility due to other causes	90.4 (42.4 to 158.8)	157.9 (83.3 to 258.7)	77.5 (37.0 to 130.7)	-2.4 (-60.2 to 130.9)	0.5 (0.2 to 1.5)	1.1 (0.4 to 2.7)	39.5 (-29.8 to 328.3)	-1.5 (-61.0 to 131.8)
Endometriosis	80.0 (66.0 to 94.1)	179.1 (154.3 to 206.4)	123.8 (76.4 to 185.6)	4.4 (-17.5 to 31.1)	7.4 (4.8 to 10.4)	16.5 (10.9 to 23.3)	123.1 (76.0 to 187.1)	4.2 (-17.6 to 33.7)
Genital prolapse	2,204.6 (1,686.3 to 2,665.5)	5,046.5 (4,077.0 to 6,050.4)	128.5 (71.8 to 219.6)	5.1 (-18.5 to 39.9)	7.0 (3.2 to 13.6)	16.0 (7.4 to 30.7)	128.6 (72.3 to 219.7)	5.3 (-18.7 to 40.9)
Premenstrual syndrome	1,928.8 (1,364.2 to 2,493.2)	4,433.7 (3,046.7 to 6,408.1)	126.1 (41.1 to 283.3)	15.0 (-26.3 to 89.5)	16.2 (8.9 to 25.3)	37.2 (20.8 to 62.5)	126.3 (38.5 to 279.7)	15.2 (-26.0 to 90.2)
Other gynecological diseases	126.3 (98.8 to 155.4)	172.4 (138.4 to 215.3)	36.4 (4.2 to 84.0)	-28.0 (-45.5 to -1.4)	3.6 (2.1 to 5.3)	2.8 (1.6 to 4.9)	-25.6 (-47.3 to -4.1)	-60.8 (-72.0 to -48.3)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	102.0 (68.2 to 145.6)	150.8 (100.8 to 216.4)	48.0 (16.7 to 40.6)	30.0 (-1.6 to 41.5)
Thalassemias	20.1 (16.0 to 24.0)	20.7 (17.1 to 24.0)	2.3 (-8.4 to 18.2)	6.7 (-3.4 to 22.3)	1.4 (0.8 to 2.2)	1.6 (1.1 to 2.3)	17.5 (-20.2 to 70.1)	23.0 (-14.6 to 73.7)
Thalassemia trait	3,080.6 (2,783.7 to 3,394.7)	4,347.8 (4,072.7 to 4,674.3)	41.1 (33.7 to 49.5)	2.6 (-2.9 to 9.1)	72.6 (48.2 to 104.2)	119.4 (80.3 to 171.4)	65.5 (46.2 to 76.5)	44.5 (23.2 to 54.1)
Sickle cell disorders	4.5 (3.8 to 5.1)	3.3 (3.1 to 3.4)	-17.3 (-26.8 to 0.4)	-23.4 (-32.1 to -9.2)	0.6 (0.4 to 0.9)	0.6 (0.4 to 0.8)	-3.9 (-17.4 to 10.7)	-19.6 (-29.2 to -9.9)
Sickle cell trait	1,941.2 (1,702.0 to 1,993.5)	2,143.8 (1,991.2 to 2,302.0)	16.4 (11.4 to 21.4)	-15.5 (-19.1 to -11.8)	10.7 (6.2 to 15.6)	17.0 (9.5 to 25.2)	15.7 (26.5 to 119.1)	45.8 (16.8 to 104.3)
G6PD deficiency	2,209.0 (2,018.2 to 2,426.5)	2,955.3 (2,745.1 to 3,163.1)	34.1 (18.6 to 50.0)	-2.7 (-13.9 to 8.8)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	22.4 (-16.6 to 67.0)	2.1 (-26.8 to 39.8)
G6PD trait	7,969.6 (7,782.5 to 8,183.9)	11,181.2 (10,908.6 to 11,471.6)	40.4 (34.6 to 45.3)	2.1 (-2.1 to 5.7)	0.4 (0.1 to 0.6)	0.7 (0.2 to 1.2)	99.2 (-48.8 to 1,132.2)	118.0 (-45.2 to 1,164.7)
Other hemoglobinopathies and hemolytic anemias	596.7 (527.7 to 679.7)	520.7 (470.7 to 576.1)	-12.9 (-26.0 to 7.0)	-35.8 (-43.4 to -23.4)	16.0 (10.1 to 23.4)	11.1 (6.8 to 16.6)	-31.5 (-46.9 to -4.5)	-37.4 (-51.5 to -10.2)
Endocrine, metabolic, blood, and immune disorders	753.8 (654.6 to 847.4)	709.6 (646.9 to 759.4)	-6.6 (-17.3 to 6.3)	-23.7 (-31.1 to -15.2)	25.2 (16.5 to 36.0)	20.8 (13.9 to 29.4)	-17.7 (-29.8 to 2.2)	23.1 (-34.3 to -8.6)
Musculoskeletal disorders	-	-	-	-	770.1 (544.5 to 1,027.6)	1,598.2 (1,131.8 to 2,121.8)	107.7 (93.9 to 122.5)	3.0 (-3.0 to 9.4)
Rheumatoid arthritis	62.7 (59.3 to 66.1)	115.0 (107.9 to 122.9)	83.6 (68.6 to 99.1)	-5.8 (-13.0 to 2.3)	14.9 (10.5 to 19.7)	27.2 (19.3 to 36.0)	82.6 (62.7 to 104.8)	-5.2 (-14.1 to 5.0)
Osteoarthritis	978.4 (921.1 to 1,037.6)	2,290.7 (2,153.3 to 2,417.9)	134.2 (116.3 to 151.8)	3.1 (-4.1 to 10.7)	59.7 (41.7 to 81.8)	139.9 (95.5 to 193.9)	134.2 (116.2 to 152.4)	3.6 (-4.1 to 11.5)
Low back and neck pain	-	-	-	-	1,242.0 (435.6 to 843.1)	2,424.0 (868.7 to 1,680.2)	93.3 (83.4 to 116.8)	0.4 (-7.1 to 8.3)
Low back pain	3,943.6 (3,669.7 to 4,209.2)	7,756.1 (7,248.3 to 8,368.4)	95.9 (78.4 to 117.3)	-0.4 (-8.7 to 9.5)	441.0 (298.2 to 607.1)	865.4 (583.7 to 1,195.2)	95.6 (77.9 to 117.4)	1.1 (-8.7 to 10.1)
Neck pain	1,853.4 (1,678.9 to 2,002.1)	3,847.6 (3,543.3 to 4,173.7)	107.4 (84.7 to 136.0)	0.6 (-9.7 to 12.7)	181.4 (125.1 to 251.3)	376.6 (259.2 to 522.9)	107.5 (84.4 to 137.5)	0.8 (-9.4 to 13.3)
Gout	26.4 (23.5 to 29.1)	59.5 (53.6 to 65.8)	124.5 (96.4 to 165.3)	1.0 (-11.0 to 19.6)	0.8 (0.6 to 1.2)	1.9 (1.2 to 2.7)	127.0 (77.8 to 195.4)	2.6 (-18.3 to 32.2)
Other musculoskeletal disorders	793.1 (516.5 to 1,025.6)	2,057.8 (1,618.8 to 2,524.4)	156.3 (128.8 to 255.8)	19.1 (6.9 to 65.2)	19.1 (41.3 to 109.0)	1.1 (119.4 to 268.9)	16.2 (127.4 to 256.9)	19.7 (7.1 to 67.2)
Other non-communicable diseases	-	-	-	-	674.8 (443.5 to 998.0)	1,128.2 (762.3 to 1,615.3)	67.5 (30.8 to 77.4)	-3.9 (-7.6 to -0.1)
Congenital anomalies	-	-	-	-	37.1 (26.6 to 49.4)	105.3 (72.6 to 143.5)	183.0 (120.7 to 268.1)	114.5 (68.9 to 177.6)
Neural tube defects	11.8 (9.1 to 14.8)	27.9 (22.9 to 33.1)	137.6 (73.8 to 221.3)	104.9 (50.2 to 176.6)	3.2 (1.9 to 5.0)	8.3 (5.2 to 11.9)	159.5 (58.6 to 324.5)	127.7 (41.3 to 267.4)
Congenital heart anomalies	135.1 (96.4 to 175.3)	492.9 (420.6 to 586.6)	263.1 (175.0 to 421.9)	202.6 (128.0 to 335.2)	4.9 (2.3 to 8.7)	17.1 (6.9 to 29.6)	243.0 (156.2 to 384.6)	198.4 (122.5 to 319.8)
Orofacial clefts	26.5 (18.3 to 37.4)	99.4 (84.9 to 117.7)	279.9 (162.8 to 442.1)	24.4 (138.0 to 396.1)	0.5 (0.3 to 0.8)	1.3 (0.8 to 1.9)	171.5 (70.2 to 330.8)	143.8 (57.1 to 283.4)
Down syndrome	46.6 (38.6 to 55.8)	91.9 (76.3 to 113.4)	95.2 (53.9 to 163.5)	5.6 (-19.2 to 104.1)	5.6 (4.0 to 7.7)	12.1 (8.5 to 16.6)	115.5 (65.5 to 198.4)	62.7 (24.7 to 121.4)
Turner syndrome	1.7 (1.2 to 2.2)	3.1 (2.5 to 4.1)	79.7 (26.7 to 166.7)	35.6 (-4.5 to 101.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	89.3 (27.0 to 193.8)	35.1 (-7.7 to 104.7)
Klinefelter syndrome	1.9 (1.3 to 2.8)	2.3 (1.7 to 3.3)	29.9 (-19.6 to 105.4)	-4.3 (-40.6 to 51.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.5 (-4.4 to 172.7)	-5.4 (-42.3 to 64.1)
Chromosomal unbalanced rearrangements	65.2 (51.1 to 83.8)	128.1 (102.5 to 157.0)	95.5 (38.5 to 169.7)	8.0 (7.5 to 109.5)	16.5 (5.4 to 11.4)	16.5 (11.9 to 23.0)	114.2 (48.7 to 197.3)	60.8 (12.8 to 124.1)
Other congenital anomalies	141.8 (119.0 to 164.6)	198.9 (161.5 to 241.7)	40.1 (13.4 to 74.5)	-8.7 (-26.8 to 11.9)	14.8 (9.6 to 22.7)	49.5 (31.2 to 74.4)	232.6 (112.5 to 436.3)	141.0 (57.1 to 283.9)
Skin and subcutaneous diseases	-	-	-	-	256.5 (159.5 to 404.9)	377.3 (234.8 to 593.4)	47.9 (30.8 to 64.9)	47.9 (-8.3 to 9.8)
Dermatitis	2,286.9 (1,939.9 to 2,609.6)	3,800.1 (3,144.1 to 4,410.5)	66.1 (59.0 to 73.1)	0.0 (-0.1 to 0.1)	57.3 (36.7 to 84.1)	91.0 (56.4 to 132.6)	58.6 (50.2 to 67.1)	0.4 (-2.3 to 3.0)
Psoriasis	285.9 (227.1 to 354.2)	516.5 (400.9 to 646.1)	80.5 (72.8 to 87.6)	0.0 (-0.2 to 0.2)	42.0 (15.3 to 34.1)	62.1 (27.0 to 62.9)	89.0 (66.1 to 94.4)	0.6 (-5.1 to 6.4)
Cellulitis	11.5 (9.1 to 14.3)	14.1 (11.2 to 17.8)	23.1 (5.0 to 43.7)	-15.8 (-25.1 to -3.9)	0.8 (0.5 to 1.3)	1.0 (0.6 to 1.5)	22.8 (-4.8 to 59.0)	-14.5 (-30.7 to 5.9)
Pyoderma	47.3 (37.3 to 60.3)	47.6 (38.0 to 62.0)	0.6 (-11.5 to 13.9)	-7.8 (-13.2 to -1.3)	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.6)	0.2 (-16.4 to 19.9)	-7.5 (-17.8 to 3.5)
Scabies	212.5 (175.9 to 261.6)	277.8 (223.4 to 356.0)	29.1 (-0.9 to 78.1)	-3.6 (-28.6 to 28.5)	5.5 (2.9 to 9.4)	7.1 (3.9 to 11.6)	28.9 (-2.4 to 78.9)	-3.4 (-28.2 to 30.1)
Fungal skin diseases	3,096.1 (2,335.9 to 3,894.7)	5,212.6 (4,030.9 to 6,477.5)	68.5 (55.2 to 84.1)	17.4 (-0.5 to 28.1)	17.4 (9.9 to 36.9)	29.2 (11.9 to 62.9)	69.8 (55.1 to 83.6)	-0.0 (-0.9 to 0.8)
Viral skin diseases	1,339.8 (1,040.4 to 1,609.0)	1,460.4 (1,050.3 to 1,889.3)	8.4 (-4.3 to 21.6)	-0.0 (-1.8 to 2.0)	41.6 (24.3 to 64.5)	45.2 (25.0 to 72.0)	8.0 (-8.0 to 21.0)	3.2 (-3.0 to 3.7)
Acne vulgaris	6,484.8 (4,946.1 to 8,173.1)	8,223.2 (6,361.5 to 10,287.2)	26.0 (8.6 to 78.9)	4.8 (-25.9 to 43.4)	70.5 (31.6 to 139.1)	90.3 (41.4 to 167.9)	29.1 (-8.7 to 79.8)	4.8 (-25.9 to 43.6)
Alopecia areata	71.9 (61.0 to 83.3)	112.7 (95.2 to 130.3)	56.2 (27.6 to 93.7)	-2.2 (-18.6 to 20.2)	2.4 (1.5 to 3.7)	3.8 (2.3 to 5.9)	55.5 (25.3 to 97.3)	-1.8 (-20.1 to 23.2)
Pruritus	11.6 (8.2 to 15.6)	22.4 (13.9 to 34.3)	92.3 (4.7 to 233.0)	5.2 (-46.2 to 92.2)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.5)	90.5 (41.1 to 247.3)	-3.9 (-46.0 to 96.1)
Urticaria	385.1 (272.6 to 532.2)	681.5 (504.6 to 928.7)	80.4 (8.7 to 189.7)	0.5 (-35.9 to 50.3)	23.0 (12.9 to 37.6)	40.4 (23.9 to 62.5)	79.6 (61.1 to 187.2)	0.5 (-36.1 to 52.0)
Decubitus ulcer	6.4 (4.9 to 7.7)	11.2 (9.0 to 15.1)	71.5 (29.4 to 192.2)	-23.0 (-46.2 to 50.2)	1.0 (0.6 to 1.3)	1.7 (1.1 to 2.5)	68.7 (26.3 to 186.1)	-22.5 (-45.4 to 53.9)
Other skin and subcutaneous diseases	2,254.8 (1,529.5 to 3,270.3)	4,265.5 (2,830.1 to 6,445.5)	89.6 (70.3 to 104.8)	-0.3 (-4.1 to 3.0)	13.3 (5.8 to 27.8)	25.0 (10.9 to 52.2)	89.3 (69.7 to 105.3)	0.0 (-3.9 to 3.7)
Sense organ diseases	-	-	-	-	283.5 (193.0 to 396.9)	460.9 (315.4 to 639.8)	62.8 (55.6 to 68.7)	-44.2 (-17.0 to -11.5)
Glaucoma	137.3 (111.0 to 177.6)	306.2 (253.5 to 375.9)	121.1 (76.1 to 203.8)	4.5 (-17.1 to 13.9)	9.3 (6.1 to 13.9)	20.1 (13.3 to 28.2)	116.1 (77.3 to 170.1)	0.4 (-11.2 to 24.4)
Cataract	276.7 (214.1 to 341.8)	485.4 (377.0 to 602.6)	75.0 (34.0 to 149.7)	-25.4 (-40.8 to 1.3)	16.1 (10.9 to 22.4)	28.9 (19.3 to 41.2)	77.8 (42.6 to 136.3)	-25.4 (-37.9 to -3.7)
Macular degeneration	92.3 (66.4 to 115.2)	158.6 (122.5 to 202.1)	70.0 (31.4 to 141.9)	-18.2 (-37.9 to 13.7)	4.7 (2.9 to 6.8)	8.6 (5.8 to 12.3)	83.5 (38.8 to 151.2)	-15.0 (-34.8 to 13.5)
Uncorrected refractive error	3,678.1 (3,477.0 to 3,871.4)	6,220.3 (5,905.6 to 6,536.5)	69.7 (58.0 to 82.0)	9.7 (-14.9 to -3.3)	85.7 (65.6 to 122.1)	126.7 (81.8 to 187.3)	47.5 (40.0 to 56.6)	-19.4 (-23.1 to -15.0)
Age-related and other hearing loss	3,877.4 (3,588.6 to 4,192.6)	7,398.6 (6,900.9 to 7,967.3)	91.0 (81.5 to 99.8)	-10.0 (-13.3 to -7.2)	105.5 (70.7 to 149.6)	196.6 (130.6 to 277.3)	108.8 (73.8 to 99.5)	88.8 (-15.6 to 65.5)
Other vision loss	417.5 (372.6 to 462.1)	548.1 (476.8 to 623.4)	30.8 (16.4 to 47.5)	-20.1 (-29.0 to -10.0)	26.4 (18.4 to 36.2)	35.4 (23.8 to 48.7)		

Appendix Table G.4 - Iran prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	1,525.2 (1,398.5 to 1,652.3)	3,189.6 (2,889.5 to 3,451.0)	109.2 (85.1 to 132.6)	-6.7 (-16.6 to 3.0)	41.9 (28.2 to 58.7)	87.6 (58.6 to 121.4)	109.2 (84.5 to 134.0)	-6.1 (-16.4 to 3.7)
Other oral disorders	817.2 (768.4 to 864.8)	1,319.9 to 1,483.5)	70.9 (57.5 to 86.1)	-0.1 (-7.4 to 7.6)	24.0 (15.1 to 36.3)	41.0 (25.6 to 61.7)	70.5 (56.9 to 86.7)	0.1 (-7.5 to 8.6)
Injuries	-	-	-	-	442.4 (270.4 to 791.2)	278.9 (193.6 to 388.4)	-34.5 (-58.4 to -11.8)	-63.6 (-76.7 to -51.6)
Transport injuries	-	-	-	-	77.6 (58.4 to 100.0)	96.1 (68.0 to 130.0)	23.4 (7.1 to 42.4)	-34.5 (-42.4 to -25.5)
Road injuries	-	-	-	-	66.9 (50.2 to 86.3)	83.7 (59.3 to 113.3)	24.1 (7.4 to 44.2)	-33.3 (-41.6 to -24.0)
Pedestrian road injuries	-	-	-	-	16.3 (12.2 to 21.1)	17.7 (12.4 to 24.4)	8.1 (-8.6 to 28.2)	-38.4 (-47.0 to -28.4)
Cyclist road injuries	-	-	-	-	6.2 (4.6 to 8.1)	10.2 (7.3 to 13.9)	65.2 (46.4 to 85.0)	-14.9 (-24.0 to -5.6)
Motorcyclist road injuries	-	-	-	-	8.6 (6.5 to 11.2)	9.5 (6.7 to 13.1)	9.7 (-6.1 to 26.1)	-43.5 (-50.7 to -35.7)
Motor vehicle road injuries	-	-	-	-	35.3 (26.3 to 45.4)	45.3 (33.0 to 62.0)	28.6 (10.5 to 52.7)	-31.7 (-40.8 to -20.9)
Other road injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.4 (0.3 to 0.6)	-24.8 (-34.9 to -13.0)	-60.0 (-65.0 to -54.6)
Other transport injuries	-	-	-	-	10.7 (8.0 to 14.0)	12.5 (8.9 to 16.8)	16.9 (3.9 to 31.5)	-41.1 (-47.6 to -33.9)
Unintentional injuries	-	-	-	-	99.2 (75.4 to 127.8)	115.3 (84.6 to 154.0)	15.9 (6.7 to 25.7)	-37.3 (-42.0 to -32.6)
Falls	-	-	-	-	17.3 (13.1 to 22.3)	25.7 (18.2 to 34.9)	47.8 (30.4 to 65.7)	-28.4 (-36.7 to -19.4)
Drowning	-	-	-	-	2.2 (1.6 to 2.9)	1.5 (1.0 to 2.0)	-33.9 (-42.6 to -21.7)	61.5 (-66.2 to -55.3)
Fire, heat, and hot substances	-	-	-	-	8.8 (6.8 to 11.2)	7.1 (5.1 to 9.6)	-19.6 (-30.8 to -7.0)	-54.8 (-60.7 to -48.5)
Poisonings	-	-	-	-	1.2 (0.8 to 1.6)	0.9 (0.6 to 1.3)	-19.5 (-33.6 to -3.3)	-51.2 (-58.8 to -42.8)
Exposure to mechanical forces	-	-	-	-	42.5 (32.1 to 55.7)	47.2 (34.5 to 63.6)	11.0 (1.8 to 20.5)	-37.5 (-41.3 to -33.0)
Unintentional firearm injuries	-	-	-	-	2.4 (1.8 to 3.0)	1.9 (1.4 to 2.6)	-20.9 (-29.7 to -10.0)	59.7 (-63.7 to -54.6)
Unintentional suffocation	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	49.0 (28.4 to 66.6)	-15.5 (-24.8 to -6.4)
Other exposure to mechanical forces	-	-	-	-	39.8 (29.9 to 52.4)	44.8 (32.6 to 60.4)	12.5 (3.2 to 22.3)	-36.2 (-40.0 to -31.7)
Adverse effects of medical treatment	-	-	-	-	0.7 (0.4 to 1.1)	1.4 (0.9 to 2.1)	103.2 (89.2 to 118.2)	15.7 (6.3 to 24.9)
Animal contact	-	-	-	-	2.1 (1.6 to 2.7)	2.4 (1.7 to 3.2)	13.6 (1.2 to 27.7)	-33.3 (-39.3 to -26.7)
Venomous animal contact	-	-	-	-	0.9 (0.7 to 1.2)	1.1 (0.8 to 1.5)	19.9 (3.0 to 36.9)	-31.0 (-40.0 to -22.0)
Non-venomous animal contact	-	-	-	-	1.2 (0.9 to 1.5)	1.3 (0.9 to 1.8)	8.6 (-5.6 to 24.8)	-35.3 (-41.4 to -27.5)
Foreign body	-	-	-	-	1.8 (1.4 to 2.3)	2.3 (1.7 to 3.0)	28.6 (15.8 to 42.7)	-25.8 (-32.2 to -19.0)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.5 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-31.9 (-45.3 to -16.3)	-52.9 (-61.0 to -43.2)
Foreign body in eyes	-	-	-	-	0.5 (0.3 to 0.7)	0.7 (0.4 to 1.0)	50.0 (34.2 to 69.1)	-9.6 (-17.8 to 0.3)
Foreign body in other body part	-	-	-	-	0.9 (0.7 to 1.1)	1.3 (1.0 to 1.8)	49.0 (33.6 to 66.6)	-21.5 (-28.8 to -13.2)
Other unintentional injuries	-	-	-	-	22.6 (17.0 to 29.4)	26.7 (19.4 to 35.7)	17.8 (7.0 to 29.4)	-39.9 (-44.4 to -34.7)
Self-harm and interpersonal violence	-	-	-	-	10.5 (7.9 to 13.4)	10.8 (7.7 to 14.5)	1.9 (-10.0 to 17.4)	-46.4 (-52.0 to -39.0)
Self-harm	-	-	-	-	2.1 (1.5 to 2.7)	3.9 (2.8 to 5.3)	89.5 (67.2 to 114.9)	-10.1 (-20.4 to 1.4)
Interpersonal violence	-	-	-	-	8.5 (6.4 to 10.7)	6.8 (4.9 to 9.3)	-19.4 (-30.3 to -6.1)	-56.3 (-61.7 to -49.9)
Assault by firearm	-	-	-	-	1.8 (1.3 to 2.3)	1.7 (1.2 to 2.3)	-4.4 (-14.3 to 8.6)	-48.3 (-53.0 to -42.1)
Assault by sharp object	-	-	-	-	1.1 (1.3 to 2.2)	1.6 (1.1 to 2.3)	5.6 (-10.6 to 11.4)	-50.7 (-57.2 to -42.5)
Assault by other means	-	-	-	-	5.0 (3.8 to 6.3)	3.5 (2.5 to 4.7)	-29.6 (-39.8 to -16.5)	-61.4 (-66.5 to -54.8)
Forces of nature, war, and legal intervention	-	-	-	-	255.1 (100.0 to 601.4)	56.7 (22.3 to 130.5)	-77.6 (-84.7 to -68.2)	-86.6 (-91.2 to -80.6)
Exposure to forces of nature	-	-	-	-	48.1 (21.4 to 102.6)	5.6 (2.3 to 13.0)	-88.6 (-94.8 to -77.5)	-92.1 (-96.4 to -84.8)
Collective violence and legal intervention	-	-	-	-	207.0 (69.6 to 516.4)	51.1 (19.9 to 118.4)	-74.4 (-83.3 to -62.9)	-85.3 (-90.6 to -78.1)

Appendix Table G.4 - Iraq prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
All causes	-	-	-	-	1,615.4 (1,191.8 to 2,104.6)	3,140.7 (2,320.9 to 4,047.2)	94.7 (83.5 to 105.3)	94.7 (7.9 to 3.2)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	277.7 (195.6 to 388.0)	504.3 (351.1 to 700.7)	81.8 (61.0 to 103.3)	-2.7 (-14.0 to 8.3)
HIV/AIDS and tuberculosis	-	-	-	-	2.4 (1.6 to 3.2)	5.4 (3.6 to 7.4)	125.3 (95.6 to 163.1)	10.2 (-1.8 to 26.2)
Tuberculosis	7.6 (7.2 to 8.0)	15.6 (15.0 to 16.2)	104.3 (94.9 to 114.9)	1.1 (-3.0 to 6.3)	2.3 (1.6 to 3.2)	4.8 (3.2 to 6.5)	105.0 (79.8 to 134.6)	1.1 (-8.3 to 11.9)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.1)	0.6 (0.2 to 1.3)	3,233.5 (489.6 to 15,253.4)	539.0 (165.0 to 6,770.1)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,256.8 (475.6 to 14,530.8)	509.8 (161.2 to 6,795.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,256.8 (474.5 to 15,442.2)	509.8 (160.2 to 8,009.8)
HIV/AIDS resulting in other diseases	0.4 (0.0 to 0.8)	4.3 (2.1 to 8.3)	1,106.4 (409.0 to 11,311.9)	451.0 (135.6 to 5,160.6)	0.0 (0.0 to 0.1)	0.6 (0.2 to 1.3)	1,328.5 (485.1 to 16,777.6)	540.3 (164.4 to 7,777.9)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	58.4 (40.9 to 79.2)	82.5 (57.8 to 112.5)	41.2 (32.2 to 51.2)	-19.9 (-24.6 to -14.7)
Diarrheal diseases	239.7 (225.5 to 253.0)	329.5 (309.2 to 349.9)	37.2 (27.1 to 49.1)	-30.3 (-26.2 to -14.3)	99.0 (26.2 to 54.0)	55.6 (35.9 to 74.4)	37.3 (25.8 to 50.0)	-20.2 (-26.5 to -13.6)
Intestinal infectious diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	7.5 (-15.6 to 35.9)	-40.6 (-52.8 to -26.1)
Typhoid fever	1.6 (1.3 to 1.8)	1.9 (1.6 to 2.1)	17.8 (-3.0 to 44.0)	-34.7 (-47.4 to -20.3)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	19.0 (8.1 to 53.3)	-34.4 (-48.6 to -17.8)
Paratyphoid fever	0.8 (0.7 to 0.9)	1.0 (0.9 to 1.2)	23.3 (0.8 to 53.6)	-32.0 (-45.0 to -15.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	23.4 (-2.7 to 58.7)	-32.1 (-45.9 to -14.8)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-85.5 (-95.9 to -72.8)	-93.7 (-97.7 to -85.2)
Lower respiratory infections	34.6 (29.9 to 39.3)	55.6 (49.3 to 61.6)	61.1 (34.3 to 91.3)	4.4 (-11.7 to 19.1)	3.6 (2.4 to 5.3)	5.8 (3.9 to 8.5)	60.5 (32.4 to 92.7)	2.7 (-14.7 to 19.9)
Upper respiratory infections	361.6 (321.8 to 402.7)	683.6 (612.7 to 758.7)	89.3 (60.7 to 119.5)	-0.7 (-15.3 to 15.6)	4.3 (2.4 to 7.2)	8.1 (4.6 to 13.6)	89.1 (61.2 to 121.2)	-0.5 (-15.1 to 16.5)
Otitis media	225.2 (209.2 to 239.9)	374.9 (351.3 to 400.9)	66.5 (53.3 to 80.1)	-9.8 (-16.9 to -2.2)	4.1 (2.5 to 6.8)	6.8 (4.0 to 11.2)	64.7 (50.0 to 80.2)	-10.6 (-18.4 to -2.4)
Meningitis	-	-	-	-	5.7 (3.8 to 8.3)	5.2 (3.4 to 7.2)	-9.9 (-29.3 to 14.1)	-51.7 (-61.1 to -39.5)
Pneumococcal meningitis	21.9 (13.2 to 34.5)	18.4 (11.0 to 28.4)	-15.2 (-36.1 to 6.1)	-55.2 (-66.1 to -44.2)	1.9 (1.3 to 2.7)	1.7 (1.1 to 2.4)	-12.1 (-35.3 to 20.0)	-52.8 (-64.5 to -37.8)
H influenzae type B meningitis	13.9 (4.9 to 28.9)	11.2 (4.2 to 21.3)	-19.8 (-43.0 to 24.9)	-58.5 (-69.8 to -35.4)	1.6 (0.9 to 2.5)	1.4 (0.8 to 2.3)	-13.0 (-48.0 to 51.5)	-54.2 (-71.7 to -21.8)
Meningococcal meningitis	8.0 (2.4 to 18.7)	6.4 (2.1 to 14.1)	-18.8 (-39.8 to 12.4)	-56.8 (-67.5 to -40.0)	1.1 (0.5 to 1.8)	1.1 (0.4 to 1.4)	-21.4 (-44.4 to 16.1)	-57.9 (-68.4 to -40.1)
Other meningitis	9.3 (5.1 to 16.7)	9.2 (5.1 to 16.1)	1.1 (-26.4 to 33.9)	-43.8 (-59.3 to -23.3)	1.2 (0.7 to 1.9)	1.2 (0.8 to 1.9)	5.8 (-31.2 to 59.4)	-41.0 (-61.5 to -12.6)
Encephalitis	4.4 (1.9 to 10.2)	6.9 (3.0 to 15.7)	55.9 (37.1 to 85.1)	-48.3 (-73.3 to -4.2)	0.6 (0.4 to 0.8)	0.9 (0.6 to 1.3)	56.8 (28.5 to 98.5)	-18.2 (-31.1 to 0.6)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.0 (85.3 to 2,958.4)	22.4 (87.7 to 1,149.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.0 (85.4 to 2,966.2)	22.4 (-87.8 to 1,150.9)
Whooping cough	4.9 (3.8 to 6.3)	25.3 (19.7 to 32.3)	413.6 (377.8 to 452.8)	213.4 (191.6 to 237.3)	0.2 (0.1 to 0.4)	1.3 (0.7 to 2.0)	416.0 (343.8 to 506.2)	215.3 (170.4 to 270.0)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.0 (-44.8 to -30.8)	-81.9 (-92.2 to -62.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.9 (-78.9 to 10.3)	-71.2 (-88.3 to -40.9)
Measles	3.0 (2.4 to 3.7)	0.2 (0.1 to 0.3)	-93.0 (-95.4 to -89.4)	-95.8 (-97.2 to -93.6)	0.3 (0.2 to 0.4)	0.0 (0.0 to 0.0)	29.9 (-95.5 to -88.6)	95.7 (-97.3 to -93.1)
Varicella and herpes zoster	14.6 (13.7 to 15.6)	26.8 (24.7 to 29.2)	82.9 (63.9 to 104.0)	9.0 (-9.7 to 31.3)	0.2 (0.1 to 0.4)	0.5 (0.3 to 0.9)	121.4 (62.4 to 204.6)	16.6 (-17.6 to 66.4)
Neglected tropical diseases and malaria	-	-	-	-	14.4 (9.2 to 20.6)	21.2 (13.9 to 30.7)	46.8 (24.2 to 94.9)	-36.2 (-50.8 to -17.5)
Malaria	3.6 (2.0 to 5.6)	5.8 (2.8 to 12.7)	60.7 (-28.4 to 178.1)	-16.5 (-63.5 to 58.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	74.5 (21.0 to 135.8)	-4.6 (-29.1 to 21.8)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.2 (0.1 to 0.3)	1.8 (0.8 to 3.3)	712.7 (424.1 to 1,099.9)	564.1 (328.1 to 841.3)
Visceral leishmaniasis	1.8 (1.2 to 2.7)	2.9 (2.0 to 4.3)	60.6 (26.1 to 117.9)	-7.9 (-26.0 to 18.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	62.3 (14.8 to 143.9)	-7.0 (-31.1 to 28.8)
Cutaneous and mucocutaneous leishmaniasis	8.1 (5.7 to 11.3)	147.0 (100.5 to 207.8)	1,713.4 (1,418.0 to 2,038.6)	1,293.4 (1,075.3 to 1,524.6)	0.1 (0.0 to 0.2)	1.6 (0.7 to 3.0)	1,690.7 (1,353.7 to 2,099.9)	1,269.9 (1,034.4 to 1,552.1)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	18.5 (6.8 to 40.6)	37.4 (13.7 to 82.0)	102.0 (99.2 to 105.3)	0.2 (-0.9 to 1.6)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.8)	99.4 (74.5 to 114.5)	0.2 (-11.3 to 7.4)
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-90.7 (-95.0 to -23.7)	-90.7 (-97.6 to -65.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cystic echinococcosis	0.7 (0.6 to 0.8)	1.8 (1.6 to 2.1)	171.6 (143.2 to 188.7)	36.5 (24.0 to 43.9)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	166.0 (111.8 to 238.6)	34.1 (4.8 to 71.6)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	55.2 (28.6 to 87.9)	34.0 (16.0 to 58.7)	-39.1 (-64.1 to -8.8)	-67.4 (-80.5 to -47.8)	4.0 (1.8 to 6.9)	2.3 (1.0 to 4.2)	-41.9 (-64.2 to -9.0)	-68.4 (-80.2 to -51.7)
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.1 (-22.1 to 55.2)	-30.8 (-51.2 to -8.8)
Intestinal nematode infections	-	-	-	-	0.1 (0.0 to 0.3)	0.0 (0.0 to 0.0)	-	-
Ascariasis	50.9 (27.9 to 88.8)	59.6 (32.1 to 99.4)	14.0 (-46.1 to 164.9)	-42.9 (-74.6 to 37.8)	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-	-
Trichuriasis	-	37.9 (19.8 to 67.4)	477.0 (136.7 to 1,249.3)	180.1 (79.9 to 598.1)	-	-	-	-
Hookworm disease	2.3 (1.4 to 3.6)	4.8 (3.0 to 7.3)	110.3 (5.6 to 314.9)	10.7 (-49.6 to 116.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.6 (76.0 to 131.1)	4.4 (-11.2 to 19.0)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	276.2 (210.5 to 341.0)	466.2 (429.7 to 507.5)	68.9 (36.5 to 120.8)	-4.8 (-21.1 to 20.4)	9.8 (6.1 to 14.4)	16.4 (10.7 to 23.9)	65.5 (41.7 to 145.1)	-5.1 (-18.8 to 39.1)
Maternal disorders	-	-	-	-	1.3 (0.7 to 2.2)	2.0 (1.1 to 3.4)	50.8 (21.1 to 83.3)	-36.6 (-50.3 to -23.5)
Maternal hemorrhage	4.0 (3.2 to 4.9)	6.9 (4.3 to 9.4)	72.0 (7.8 to 146.4)	31.4 (-56.4 to -2.5)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.5)	66.4 (-16.7 to 182.5)	-31.3 (-66.0 to 12.4)
Maternal sepsis and other maternal infections	10.7 (6.2 to 16.7)	14.1 (8.1 to 20.3)	29.8 (-20.6 to 129.2)	-48.6 (-70.7 to -1.7)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.3)	25.5 (-24.8 to 123.1)	-46.6 (-67.7 to -9.3)
Maternal hypertensive disorders	12.6 (4.8 to 22.8)	19.0 (6.7 to 35.1)	53.1 (30.4 to 66.1)	-35.0 (-47.5 to -24.1)	0.6 (0.2 to 1.3)	0.9 (0.3 to 1.9)	52.3 (24.8 to 79.2)	-35.0 (-48.9 to -21.6)
Obstructed labor	0.6 (0.3 to 0.9)	0.8 (0.5 to 1.3)	43.7 (-11.3 to 128.5)	-41.6 (-62.1 to -9.6)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.5)	45.6 (-27.3 to 180.3)	-39.6 (-68.1 to 8.6)
Complications of abortion	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.2)	35.3 (-38.8 to 126.8)	-45.8 (-74.5 to -10.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.3 (-39.3 to 127.0)	65.3 (-74.6 to -10.4)
Other maternal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.6)	65.1 (-13.7 to 219.4)	-30.7 (-64.7 to 33.0)
Neonatal disorders	-	-	-	-	27.6 (17.0 to 44.2)	97.2 (59.6 to 144.3)	253.9 (95.5 to 493.4)	92.6 (8.0 to 220.5)
Preterm birth complications	81.5 (47.2 to 133.0)	370.6 (220.6 to 569.1)	355.8 (196.1 to 601.4)	139.5 (60.5 to 265.5)	10.8 (6.1 to 17.3)	49.8 (27.4 to 77.9)	365.8 (146.5 to 665.8)	149.0 (35.2 to 305.7)
Neonatal encephalopathy due to birth asphyxia and trauma	32.3 (15.6 to 61.2)	88.3 (44.3 to 137.2)	183.8 (193.3 to 516.5)	53.9 (-33.5 to 238.0)	7.2 (3.2 to 13.1)	19.7 (10.1 to 39.2)	186.0 (18.5 to 499.4)	58.1 (-33.5 to 235.5)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.3)	0.3 (0.1 to 0.7)	124.8 (115.7 to 159.4)	41.8 (36.1 to 63.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	127.5 (99.4 to 165.3)	43.6 (25.9 to 67.4)
Hemolytic disease and other neonatal jaundice	21.9 (8.1 to 44.7)	65.4 (30.1 to 126.4)	214.3 (-5.3 to 890.6)	73.0 (-48.3 to 433.7)	6.4 (2.6 to 12.5)	16.7 (7.7 to 31.9)	170.9 (-5.9 to 603.6)	45.7 (-49.2 to 278.6)
Other neonatal disorders	-	-	-	-	3.2 (1.3 to 6.4)	10.8 (4.7 to 20.7)	244.9 (27.9 to 792.5)	89.1 (-29.8 to 380.3)
Nutritional deficiencies	-	-	-	-	162.6 (108.0 to 236.6)	276.6 (184.2 to 408.0)	69.7 (54.7 to 88.3)	-9.1 (-17.3 to 0.4)
Protein-energy malnutrition	65.2 (24.1 to 137.0)	125.9 (44.8 to 282.3)	89.8 (-46.2 to 594.4)	15.9 (-66.9 to 317.7)	15.9 (2.7 to 19.0)	15.9 (5.0 to 38.7)	91.3 (-47.0 to 599.8)	16.9 (-67.2 to 322.0)
Iodine deficiency	672.5 (45.2 to 1,100.5)	837.8 (462.2 to 1,443.9)	24.6 (-39.9 to 203.3)	-39.1 (-71.8 to 57.9)	12.1 (5.2 to 23.3)	15.1 (6.7 to 30.3)	23.8 (-40.5 to 202.8)	-39.2 (-71.9 to 57.8)
Vitamin A deficiency	18.7 (10.4 to 29.6)	18.8 (9.7 to 28.9)	-0.1 (-24.2 to 37.7)	-45.1 (-57.8 to -24.9)	1.0 (0.5 to 1.8)	1.0 (0.5 to 1.7)	-5.5 (-29.5 to 27.4)	-48.1 (-93.9 to -30.5)

Appendix Table G.4 - Iraq prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	4,242.8 (4,179.9 to 4,305.5)	7,549.7 (7,481.2 to 7,607.6)	77.9 (75.1 to 80.6)	5.9 (-7.5 to -4.4)	140.4 (93.3 to 203.9)	242.6 (161.3 to 352.0)	73.9 (68.6 to 76.0)	73.9 (-8.6 to 4.5)
Other nutritional deficiencies	-	-	-	-	0.9 (0.2 to 2.8)	2.1 (0.5 to 6.4)	142.8 (-46.5 to 892.2)	47.8 (-66.7 to 496.5)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	11.0 (6.9 to 16.6)	19.5 (12.2 to 29.4)	78.0 (49.6 to 107.5)	-6.5 (-21.0 to 9.5)
Sexually transmitted diseases excluding HIV	-	-	-	-	2.7 (1.4 to 4.6)	5.6 (3.0 to 9.9)	111.2 (33.8 to 213.4)	-1.5 (-33.7 to 38.5)
Syphilis	0.4 (0.3 to 0.4)	0.5 (0.4 to 0.6)	27.2 (6.5 to 59.6)	-39.4 (-48.1 to -26.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	33.5 (15.1 to 79.3)	47.3 (-53.4 to -16.3)
Chlamydial infection	294.7 (161.5 to 445.9)	602.8 (396.2 to 888.8)	97.3 (15.2 to 427.4)	-6.3 (-44.2 to 132.6)	1.3 (0.6 to 2.8)	2.9 (1.2 to 5.4)	118.3 (-21.2 to 397.8)	4.5 (-60.0 to 137.8)
Gonococcal infection	88.1 (68.3 to 118.5)	178.1 (133.0 to 222.2)	104.6 (38.9 to 183.7)	-4.3 (-32.5 to 29.9)	0.6 (0.3 to 1.0)	1.2 (0.6 to 2.0)	103.5 (26.4 to 187.2)	-5.4 (-39.3 to 30.8)
Trichomoniasis	69.9 (43.2 to 118.6)	134.7 (74.1 to 218.4)	90.8 (-5.3 to 272.7)	-14.3 (-50.8 to 60.6)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.6)	93.5 (-14.0 to 299.6)	-13.8 (-55.8 to 75.5)
Genital herpes	1,958.8 (1,846.1 to 2,059.0)	4,182.0 (3,967.0 to 4,411.3)	113.1 (97.2 to 131.0)	3.5 (-10.4 to 4.8)	1.1 (0.2 to 1.2)	1.7 (0.3 to 2.7)	51.1 (90.7 to 133.1)	-3.5 (-11.4 to 6.1)
Other sexually transmitted diseases	2.8 (2.0 to 4.0)	5.2 (3.9 to 6.9)	85.0 (46.0 to 142.6)	-26.1 (-43.2 to -3.7)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	138.8 (58.8 to 266.2)	1.4 (-30.0 to 51.2)
Hepatitis	-	-	-	-	1.3 (0.8 to 1.9)	2.2 (1.4 to 3.2)	67.8 (41.4 to 108.6)	-20.8 (-35.5 to 2.1)
Hepatitis A	26.1 (24.9 to 27.4)	44.7 (42.8 to 46.6)	71.1 (70.2 to 72.1)	-4.0 (-4.1 to -3.8)	0.6 (0.3 to 0.8)	1.0 (0.6 to 1.5)	86.7 (65.7 to 109.3)	-1.2 (-11.3 to 10.5)
Hepatitis B	1,433.6 (1,141.6 to 1,703.9)	1,576.5 (1,180.2 to 2,003.4)	8.8 (-22.3 to 49.1)	-43.1 (-57.5 to -21.5)	0.6 (0.4 to 1.0)	0.9 (0.6 to 1.4)	44.1 (14.4 to 119.5)	-34.9 (-56.7 to 2.2)
Hepatitis C	466.1 (421.6 to 512.0)	669.4 (597.8 to 739.1)	44.3 (23.7 to 65.0)	-30.0 (-39.0 to -20.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	41.7 (12.0 to 82.7)	25.6 (-44.4 to -1.5)
Hepatitis E	2.1 (1.3 to 3.0)	5.7 (3.8 to 8.3)	173.3 (68.4 to 317.7)	31.7 (-19.2 to 95.9)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	183.2 (57.0 to 368.6)	33.3 (-23.6 to 115.6)
Leprosy	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-9.7 (-46.6 to 394.8)	-49.0 (-68.2 to 177.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.0 (-46.6 to 437.9)	-48.4 (-68.1 to 197.9)
Other infectious diseases	197.5 (153.4 to 242.4)	336.1 (281.2 to 407.0)	70.8 (38.7 to 305.9)	-5.4 (-20.7 to 11.0)	7.0 (4.3 to 10.5)	11.7 (7.3 to 17.1)	67.7 (34.2 to 99.4)	-4.5 (-23.8 to 13.7)
Non-communicable diseases	-	-	-	-	1,199.9 (893.2 to 1,544.1)	2,404.2 (1,796.8 to 3,090.8)	102.2 (92.2 to 111.4)	-1.4 (-5.2 to 4.2)
Neoplasms	-	-	-	-	5.2 (3.5 to 7.4)	10.9 (7.0 to 15.1)	107.5 (52.4 to 187.3)	4.8 (-23.2 to 44.4)
Esophageal cancer	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	79.2 (12.7 to 182.2)	-5.4 (-39.9 to 45.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	80.9 (22.0 to 165.6)	-3.7 (-36.1 to 40.3)
Stomach cancer	1.8 (1.4 to 2.4)	2.5 (1.8 to 3.3)	36.5 (-6.8 to 100.2)	-28.7 (-50.7 to 2.8)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	47.9 (9.9 to 115.4)	-23.1 (-47.1 to 11.2)
Liver cancer	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	95.1 (32.9 to 193.2)	3.7 (-29.2 to 55.7)
Liver cancer due to hepatitis B	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.6)	49.8 (-36.1 to 317.0)	-23.8 (-68.3 to 109.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	49.8 (-28.0 to 278.4)	-23.5 (-84.6 to 86.6)
Liver cancer due to hepatitis C	0.2 (0.1 to 0.3)	0.1 (0.4 to 1.1)	358.3 (136.3 to 802.4)	146.8 (25.1 to 380.6)	0.0 (0.0 to 0.0)	0.0 (0.1 to 0.2)	333.6 (145.2 to 725.4)	131.9 (27.5 to 329.0)
Liver cancer due to alcohol use	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.2)	-31.3 (-72.9 to 49.5)	-61.2 (-83.6 to -18.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.6 (-70.5 to 43.5)	-60.3 (-82.6 to -20.3)
Liver cancer due to other causes	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	31.5 (-42.5 to 252.3)	-32.2 (-71.3 to 85.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	26.7 (-37.5 to 220.1)	-34.9 (-68.9 to 71.6)
Larynx cancer	0.9 (0.6 to 1.3)	1.2 (0.8 to 1.9)	31.5 (-18.5 to 111.6)	-32.2 (-57.8 to 10.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	37.1 (-14.4 to 122.3)	-29.3 (-56.2 to 15.7)
Tracheal, bronchus and lung cancer	1.6 (1.2 to 2.0)	2.7 (2.0 to 3.4)	69.5 (21.3 to 147.8)	-8.7 (-33.7 to 31.5)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	73.5 (22.5 to 158.9)	-6.9 (-33.6 to 39.0)
Breast cancer	13.4 (8.6 to 19.0)	34.4 (22.1 to 50.6)	153.4 (52.7 to 349.9)	16.2 (-29.1 to 103.3)	1.2 (0.7 to 1.7)	2.9 (1.7 to 4.5)	152.8 (50.3 to 336.1)	18.1 (-28.6 to 98.9)
Cervical cancer	2.5 (1.7 to 3.7)	4.9 (3.0 to 7.6)	4.9 (12.8 to 242.8)	-11.3 (-47.4 to 54.1)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	91.3 (13.0 to 252.3)	0.2 (-47.9 to 56.1)
Uterine cancer	4.2 (1.9 to 7.2)	7.2 (3.0 to 12.2)	71.5 (-9.8 to 218.2)	-16.0 (-56.4 to 53.4)	0.3 (0.1 to 0.5)	0.5 (0.2 to 0.8)	74.4 (9.5 to 225.2)	-14.9 (-56.5 to 57.9)
Prostate cancer	1.8 (1.1 to 3.1)	6.1 (3.4 to 10.7)	223.6 (83.0 to 501.1)	80.8 (6.5 to 229.1)	0.2 (0.1 to 0.4)	0.6 (0.3 to 1.1)	175.4 (62.5 to 375.6)	54.3 (-8.4 to 163.3)
Colon and rectum cancer	3.1 (2.5 to 4.0)	5.8 (4.3 to 7.6)	87.3 (30.2 to 165.3)	-5.4 (-33.2 to 31.0)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	87.9 (31.4 to 170.5)	-3.4 (-32.9 to 37.1)
Lip and oral cavity cancer	1.4 (1.0 to 1.9)	2.6 (1.8 to 3.7)	82.5 (17.8 to 173.9)	6.0 (-38.3 to 39.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	83.6 (21.0 to 170.0)	-5.3 (-38.0 to 41.4)
Nasopharynx cancer	0.5 (0.3 to 0.7)	0.7 (0.5 to 1.2)	47.6 (-13.4 to 154.4)	-31.0 (-59.0 to 17.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	45.5 (-13.4 to 144.5)	11.5 (-57.8 to 11.6)
Other pharynx cancer	0.4 (0.3 to 0.6)	0.6 (0.4 to 1.0)	52.1 (-13.2 to 172.4)	-25.4 (-56.4 to 31.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	56.4 (-9.4 to 165.8)	-22.8 (-55.3 to 29.6)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	50.5 (-1.6 to 132.8)	-19.6 (-46.9 to 21.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	51.7 (2.6 to 130.4)	-19.3 (-44.7 to 18.7)
Pancreatic cancer	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	96.4 (33.1 to 199.5)	4.9 (-27.9 to 56.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	102.4 (42.3 to 191.8)	7.5 (-25.1 to 54.5)
Malignant skin melanoma	0.3 (0.2 to 0.5)	0.9 (0.6 to 1.5)	146.0 (61.5 to 283.1)	25.8 (-18.5 to 97.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	132.8 (15.0 to 276.3)	19.3 (-23.8 to 91.0)
Non-melanoma skin cancer	1.8 (1.2 to 2.4)	4.1 (2.9 to 5.4)	131.6 (49.5 to 261.4)	21.1 (-24.9 to 94.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	188.9 (88.9 to 320.8)	52.3 (0.5 to 126.6)
Ovarian cancer	0.6 (0.4 to 1.0)	1.5 (0.9 to 2.2)	121.3 (33.1 to 313.8)	11.1 (-33.4 to 101.1)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	133.5 (24.2 to 337.7)	17.0 (-38.9 to 121.5)
Testicular cancer	0.7 (0.4 to 1.1)	1.5 (0.8 to 2.6)	127.5 (16.6 to 367.5)	-5.2 (-51.9 to 91.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	130.7 (9.6 to 375.7)	-5.3 (-63.7 to 96.0)
Kidney cancer	1.2 (0.8 to 1.6)	2.0 (1.5 to 2.9)	78.2 (13.0 to 181.1)	4.5 (-29.6 to 55.2)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	86.6 (20.2 to 193.8)	7.9 (-28.6 to 67.0)
Bladder cancer	1.5 (1.1 to 2.0)	2.4 (1.7 to 3.4)	57.0 (4.5 to 143.0)	-11.7 (-40.6 to 35.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	57.9 (5.7 to 142.3)	-11.3 (-40.7 to 35.0)
Brain and nervous system cancer	2.8 (1.7 to 4.4)	5.5 (3.7 to 7.6)	102.9 (28.6 to 196.0)	10.1 (-22.1 to 54.4)	0.3 (0.1 to 0.4)	0.5 (0.3 to 0.8)	107.2 (40.5 to 191.5)	7.4 (-22.8 to 52.4)
Thyroid cancer	2.7 (1.8 to 4.3)	5.1 (3.3 to 8.1)	85.1 (17.3 to 222.5)	-13.7 (-43.8 to 42.6)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	85.3 (15.5 to 217.4)	-12.5 (-43.6 to 41.4)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.5 (19.2 to 173.0)	0.1 (-41.0 to 39.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.1 (18.9 to 170.0)	9.2 (-40.5 to 38.3)
Hodgkin lymphoma	0.9 (0.5 to 1.3)	1.6 (1.0 to 2.9)	86.5 (-2.9 to 242.2)	11.1 (-36.9 to 91.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	92.9 (26.9 to 259.2)	12.6 (-35.7 to 89.8)
Non-Hodgkin lymphoma	2.2 (1.5 to 3.3)	4.3 (3.0 to 6.2)	91.7 (27.7 to 195.1)	-4.0 (-37.0 to 54.3)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	95.9 (29.6 to 210.3)	-1.1 (-35.7 to 57.8)
Multiple myeloma	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.8)	115.5 (28.6 to 271.4)	11.0 (-34.0 to 89.3)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	109.3 (27.4 to 252.0)	7.7 (-33.7 to 84.3)
Leukemia	5.1 (3.6 to 7.2)	9.1 (6.4 to 12.9)	78.0 (13.7 to 180.1)	0.0 (-31.7 to 46.1)	0.5 (0.3 to 0.8)	0.5 (0.6 to 1.5)	83.3 (30.1 to 169.6)	0.1 (-32.0 to 43.6)
Other neoplasms	6.5 (4.4 to 9.4)	14.9 (10.0 to 20.5)	134.5 (39.7 to 243.2)	26.6 (-13.5 to 77.2)	1.0 (0.3 to 0.7)	1.0 (0.6 to 1.5)	150.1 (45.8 to 233.5)	19.7 (-16.5 to 69.6)
Cardiovascular diseases	-	-	-	-	27.1 (18.6 to 37.5)	51.5 (34.6 to 70.5)	90.5 (51.0 to 133.6)	-1.7 (-19.2 to 17.6)
Rheumatic heart disease	45.1 (34.2 to 56.6)	88.7 (66.9 to 113.7)	96.7 (37.3 to 180.2)	-1.0 (-30.0 to 28.7)	2.4 (1.4 to 3.6)	5.0 (3.1 to 7.5)	110.7 (51.5 to 192.3)	10.3 (-18.9 to 51.1)
Ischemic heart disease	124.5 (100.3 to 158.6)	173.3 (149.0 to 206.4)	39.1 (2.2 to 90.0)	-19.0 (-39.9 to 9.9)	6.7 (4.4 to 10.3)	9.9 (6.5 to 13.8)	48.9 (0.9 to 108.5)	-17.2 (-42.7 to 17.9)
Cerebrovascular disease	-	-	-	-	0.8 (0.5 to 1.1)	1.5 (1.1 to 2.1)	97.3 (61.7 to 158.6)	-1.4 (-20.0 to 30.1)
Ischemic stroke	4.4 (3.7 to 5.3)	8.6 (7.3 to 10.2)	93.6 (58.1 to 154.4)	-1.9 (-19.6 to 29.0)	0.7 (0.4 to 0.9)	1.3 (0.9 to 1.8)	96.1 (58.3 to 159.4)	-1.6 (-20.7 to 31.0)
Hemorrhagic stroke	0.6 (0.5 to 0.8)	1.3 (1.0 to 1.7)	108.8 (42.4 to 201.6)	2.1 (-28.3 to 50.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	108.3 (42.4 to 201.1)	2.3 (-27.8 to 50.1)
Hypertensive heart disease	13.0 (10.6 to 15.5)	32.2 (27.2 to 38.1)	146.6 (95.5 to 222.8)	40.1 (9.6 to 86.0)	1.4 (0.9 to 2.1)	3.5 (2.4 to 5.1)	146.0 (94.7 to 221.5)	38.9 (7.7 to 83.1)
Cardiomyopathy and myocarditis	10.9 (9.4 to 12.7)	24.2 (21.3 to 27.0)	121.7 (84.9 to 163.5)	18.7 (-3.9 to 47.2)	1.2 (0.8 to 1.7)	2.7 (1.8 to 3.7)	122.3 (79.4 to 173.2)	18.8 (-6.2 to 49.5)
Atrial fibrillation and flutter	41.7 (34.4 to 49.5)	59.0 (48.6 to 71.2)	41.4 (10.5 to 84.7)	-19.4 (-37.5 to 7.4)	3.1 (2.1 to 4.4)	4.5 (3.0 to 6.5)	42.8 (11.6 to 87.7)	-18.9 (-37.7 to 8.2)
Peripheral vascular disease	179.6 (135.8 to 236.4)	428.0 (314.7 to 590.3)	139.9 (51.5 to 270.6)	27.3 (-16.7 to 82.9)	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.4)	57.4 (-30.3 to 159.1)	-5.3 (-58.2 to 59.7)
Endocarditis	0.8 (0.6 to 1.0)	1.4 (1.1 to 1.7)	77.9 (32.2 to 125.1)	-5.2 (-27.8 to 22.3)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	83.3 (28.4 to 140.9)	-3.9 (-32.1 to 31.3)
Other cardiovascular and circulatory diseases	157.8 (117.0 to 221.2)	345.0 (216.9 to 452.4)	120.9 (32.7 to 232.9)	10.9 (-32.1 to 61.2)	11.0 (6.7 to 17.1)	11.1 (6.7 to 17.1)	113.3 (32.2 to 232.5)	10.3 (-31.9 to 60.2)
Chronic respiratory diseases	-	-	-	-	69.3 (47.0 to 97.2)</			

Appendix Table G.4 - Iraq prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumococcosis	-	-	-	-	0.0	0.1	86.9	-
Silicosis	0.1	0.1	62.3	-19.7	0.0	0.0	(79.5 to 93.8)	(-12.6 to -6.0)
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Coal workers pneumococcosis	-	-	0.0	0.0	-	-	-	-
Other pneumococcosis	0.1	0.3	100.4	-2.8	0.0	0.1	101.5	-2.2
Asthma	491.0	518.8	5.0	-34.0	21.5	22.4	3.4	-35.0
Interstitial lung disease and pulmonary sarcoidosis	1.1	2.2	106.1	2.1	0.1	0.3	106.9	2.6
Other chronic respiratory diseases	-	-	-	-	12.6	16.6	32.4	-36.8
Cirrhosis	-	-	-	-	1.2	1.4	14.4	-39.4
Cirrhosis due to hepatitis B	1.6	2.3	46.1	-12.8	0.7	0.9	119.9	(-29.8 to -7.2)
Cirrhosis due to hepatitis C	2.1	3.4	62.4	-11.4	0.3	0.6	59.6	(-13.3 to 49.8)
Cirrhosis due to alcohol use	0.5	0.4	-11.7	-50.9	0.1	0.1	-12.1	(-41.3 to 34.2)
Cirrhosis due to other causes	1.7	2.0	19.4	-24.4	0.3	0.3	19.4	(-74.3 to 1.7)
Digestive diseases	-	-	-	-	10.1	18.6	83.8	(54.8 to 35.8)
Peptic ulcer disease	31.8	39.0	22.1	-29.4	1.3	1.8	39.6	-21.9
Gastritis and duodenitis	52.5	46.7	-11.4	-49.0	2.4	2.3	-6.6	-41.6
Appendicitis	1.3	1.8	46.2	-26.6	0.4	0.6	45.5	-26.3
Paralytic ileus and intestinal obstruction	0.3	0.9	183.9	33.6	0.1	0.3	189.9	36.8
Inguinal, femoral, and abdominal hernia	56.0	94.4	68.7	-12.6	0.6	1.0	69.9	-12.5
Inflammatory bowel disease	10.5	33.0	213.4	44.4	2.2	7.0	214.5	44.8
Vascular intestinal disorders	0.0	0.1	91.0	6.7	0.0	0.0	91.2	7.9
Gallbladder and biliary diseases	5.1	9.3	83.3	-4.2	0.5	1.0	89.8	-4.3
Pancreatitis	2.7	5.4	97.9	-8.7	0.8	1.6	98.9	-8.5
Other digestive diseases	-	-	-	-	1.8	3.1	76.3	-9.7
Neurological disorders	-	-	-	-	119.2	261.7	119.1	6.4
Alzheimer disease and other dementias	74.5	125.8	69.4	0.9	10.3	17.4	69.2	0.6
Parkinson disease	6.5	11.3	74.4	-1.4	0.7	1.3	75.8	-1.3
Epilepsy	83.0	154.6	86.4	-3.5	25.5	47.4	85.2	-3.6
Multiple sclerosis	2.2	9.0	297.9	72.9	0.8	3.0	296.3	71.1
Migraine	1,655.0	3,497.4	112.7	3.5	56.6	119.7	113.6	-2.1
Tension-type headache	2,667.1	5,288.1	95.4	-3.3	4.0	8.0	94.9	-2.4
Medication overuse headache	119.2	382.8	218.0	47.9	18.7	60.3	218.6	48.0
Other neurological disorders	0.0	0.1	93.3	1.3	2.5	4.6	85.6	4.0
Mental and substance use disorders	-	-	-	-	403.8	776.8	92.5	-7.8
Schizophrenia	34.2	78.6	130.0	-0.2	21.8	50.4	131.1	-0.1
Alcohol use disorders	72.4	166.8	130.4	6.7	7.1	16.5	131.3	7.1
Drug use disorders	-	-	-	-	46.4	82.3	80.8	-23.9
Opioid use disorders	87.0	148.0	74.5	-28.2	36.0	61.3	73.9	-28.4
Cocaine use disorders	12.5	26.1	107.9	4.1	2.7	3.6	108.6	-3.4
Amphetamine use disorders	23.5	46.6	102.0	-2.1	3.1	6.1	101.4	-1.8
Cannabis use disorders	25.6	52.2	103.8	0.5	0.7	1.5	103.7	0.7
Other drug use disorders	-	-	-	-	4.9	9.8	100.0	-4.3
Depressive disorders	-	-	-	-	107.2	207.2	93.6	-7.9
Major depressive disorder	452.4	860.0	90.5	-8.9	92.9	176.8	90.8	-8.8
Dysthymia	149.0	315.2	111.6	-2.1	14.3	30.4	112.0	-2.1
Bipolar disorder	99.4	213.8	115.6	-1.7	20.2	43.5	116.0	-1.7
Anxiety disorders	1,086.1	2,096.8	84.6	4.8	100.5	186.1	98.9	0.1
Eating disorders	-	-	-	-	2.4	4.9	103.0	-0.5
Anorexia nervosa	2.6	5.2	104.7	2.6	0.5	1.1	104.5	2.8
Bulimia nervosa	8.8	17.9	101.5	-1.9	1.9	3.8	103.1	-1.4
Autistic spectrum disorders	-	-	-	-	20.5	39.8	93.8	0.1
Autism	51.3	99.7	94.4	-0.0	12.7	24.7	94.1	-0.1
Asperger syndrome	77.7	150.6	93.8	-0.0	7.8	15.1	94.0	0.2
Attention-deficit/hyperactivity disorder	146.7	258.8	76.4	0.3	1.8	3.1	76.6	0.4
Conduct disorder	291.0	509.2	74.5	0.2	35.0	61.4	75.1	0.3
Idiopathic intellectual disability	520.3	976.5	87.3	-2.2	25.5	47.8	87.6	-2.1
Other mental and substance use disorders	205.6	453.0	120.2	-0.1	15.3	33.9	121.0	0.1
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	138.3	310.3	125.3	14.3
Diabetes mellitus	716.4	1,921.5	170.4	28.4	58.8	154.7	165.6	27.1
Acute glomerulonephritis	0.1	0.1	38.4	-19.2	0.0	0.0	-	-
Chronic kidney disease	-	-	-	-	15.4	31.1	101.9	0.7
Chronic kidney disease due to diabetes mellitus	115.5	256.3	120.1	14.2	2.9	6.6	126.0	13.5
Chronic kidney disease due to hypertension	96.0	148.6	56.3	-20.8	4.5	7.9	79.5	-19.1
Chronic kidney disease due to glomerulonephritis	164.8	372.6	68.0	4.1	8.0	16.6	85.7	-16.7
Chronic kidney disease due to other causes	207.2	462.8	125.1	17.0	5.4	12.4	129.0	19.5
Urinary diseases and male infertility	-	-	-	-	7.6	13.7	95.2	1.4

Appendix Table G.4 - Iraq prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	3.4 (3.1 to 3.7)	7.0 (6.5 to 7.4)	107.6 (87.2 to 132.3)	0.1 (-3.2 to 14.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	108.7 (66.5 to 165.9)	5.1 (-12.7 to 27.5)
Urolithiasis	183.9 (130.6 to 241.5)	473.9 (326.8 to 626.9)	157.4 (127.9 to 212.6)	2.6 (11.3 to 57.4)	1.2 (0.8 to 1.8)	3.2 (2.0 to 4.7)	157.1 (132.4 to 192.8)	24.7 (13.9 to 46.6)
Benign prostatic hyperplasia	122.0 (111.5 to 132.6)	204.8 (187.7 to 221.3)	67.8 (49.1 to 90.2)	-4.1 (-14.6 to 7.9)	4.3 (2.8 to 6.0)	7.2 (4.7 to 10.3)	67.7 (49.1 to 91.2)	-4.2 (-14.9 to 8.2)
Male infertility due to other causes	107.2 (73.7 to 151.1)	263.2 (177.3 to 374.1)	149.6 (36.5 to 291.4)	6.3 (-4.1 to 68.6)	0.7 (0.3 to 1.6)	1.8 (0.7 to 3.9)	149.1 (30.5 to 297.4)	7.0 (-42.0 to 72.3)
Other urinary diseases	-	-	-	-	-	-	-	-
Gynecological diseases	-	-	-	-	20.2 (12.8 to 30.1)	45.6 (28.7 to 68.4)	124.3 (90.3 to 178.9)	-2.0 (-16.3 to 18.0)
Uterine fibroids	229.2 (206.9 to 249.6)	572.3 (516.9 to 623.8)	149.6 (148.0 to 151.4)	1.6 (1.3 to 1.9)	3.9 (2.3 to 6.3)	9.2 (5.4 to 14.9)	136.4 (123.7 to 147.9)	-2.7 (-7.5 to 1.5)
Polycystic ovarian syndrome	296.8 (267.7 to 326.2)	670.6 (601.1 to 740.2)	125.6 (93.5 to 162.7)	-4.1 (-17.1 to 11.3)	2.9 (1.4 to 5.5)	6.5 (3.1 to 12.4)	125.6 (92.7 to 163.6)	-4.1 (-17.2 to 11.1)
Female infertility due to other causes	41.3 (15.3 to 86.3)	97.1 (29.4 to 217.0)	131.0 (-41.3 to 759.8)	0.4 (-79.3 to 319.4)	0.2 (0.1 to 0.7)	0.6 (0.1 to 1.5)	124.5 (-31.9 to 675.7)	-0.6 (-74.4 to 290.6)
Endometriosis	23.6 (20.1 to 27.2)	59.7 (51.2 to 68.8)	151.9 (103.4 to 210.2)	3.9 (-16.3 to 26.7)	2.2 (1.5 to 3.1)	5.5 (3.6 to 7.6)	152.8 (98.8 to 222.0)	4.1 (-17.8 to 30.4)
Genital prolapse	691.4 (577.9 to 825.8)	1,516.7 (1,212.2 to 1,846.7)	119.3 (67.8 to 185.5)	-2.9 (-24.1 to 26.7)	2.2 (1.1 to 4.2)	4.8 (2.3 to 9.3)	119.3 (68.4 to 189.3)	-2.7 (-24.1 to 27.0)
Premenstrual syndrome	866.3 (552.0 to 1,166.6)	1,878.3 (1,054.5 to 2,591.0)	112.2 (32.4 to 305.5)	-2.6 (-38.8 to 83.6)	7.3 (3.9 to 11.9)	15.8 (7.2 to 26.2)	111.9 (30.7 to 309.6)	-2.5 (-39.4 to 87.5)
Other gynecological diseases	50.3 (37.0 to 63.9)	103.8 (97.2 to 112.0)	105.8 (63.4 to 175.6)	-6.3 (-24.7 to 22.9)	1.5 (0.8 to 2.2)	3.1 (2.0 to 4.4)	102.2 (73.9 to 255.0)	-7.9 (-20.7 to 49.7)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	28.8 (19.1 to 41.5)	51.5 (34.6 to 74.5)	78.6 (67.5 to 93.8)	-1.3 (-8.8 to 7.0)
Thalassemias	4.3 (3.5 to 5.0)	7.9 (6.8 to 9.0)	83.3 (65.9 to 103.7)	2.6 (-7.5 to 13.6)	0.3 (0.2 to 0.5)	0.6 (0.3 to 0.9)	86.3 (25.3 to 177.7)	2.1 (-29.5 to 46.1)
Thalassemia trait	770.1 (693.1 to 839.5)	1,490.3 (1,380.7 to 1,609.7)	93.5 (84.0 to 104.2)	0.2 (-4.8 to 6.0)	16.4 (10.9 to 24.2)	29.7 (19.8 to 43.4)	81.1 (61.0 to 103.5)	1.2 (-13.2 to 13.7)
Sickle cell disorders	6.1 (4.4 to 7.2)	13.3 (11.0 to 15.0)	115.9 (75.1 to 209.1)	19.0 (-1.1 to 64.2)	0.7 (0.4 to 1.0)	1.5 (1.0 to 2.1)	122.0 (70.2 to 184.3)	17.7 (6.9 to 46.8)
Sickle cell trait	1,106.4 (1,002.3 to 1,207.0)	2,127.7 (1,945.0 to 2,319.1)	93.0 (83.2 to 101.8)	-0.1 (-5.2 to 4.5)	5.9 (3.7 to 8.6)	10.5 (6.8 to 15.3)	77.1 (43.0 to 112.3)	-1.5 (-15.4 to 16.4)
G6PD deficiency	938.5 (840.6 to 1,040.3)	2,004.1 (1,751.3 to 2,279.6)	114.1 (79.6 to 148.0)	11.0 (-7.0 to 28.7)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	93.7 (45.9 to 160.1)	8.6 (-9.9 to 31.6)
G6PD trait	3,338.0 (3,233.3 to 3,439.7)	6,336.6 (6,051.3 to 6,586.8)	89.9 (80.1 to 98.4)	-1.0 (-6.1 to 3.4)	0.1 (0.0 to 0.2)	0.2 (0.0 to 0.4)	85.9 (88.9 to 3,443.1)	5.3 (-90.4 to 1,142.8)
Other hemoglobinopathies and hemolytic anemias	184.5 (153.4 to 211.5)	324.2 (277.1 to 360.2)	76.1 (46.6 to 115.4)	-7.1 (-19.6 to 8.3)	5.2 (3.2 to 7.9)	8.8 (5.5 to 13.2)	67.6 (23.3 to 139.9)	-9.8 (-32.0 to 26.3)
Endocrine, metabolic, blood, and immune disorders	241.6 (206.1 to 272.8)	416.9 (371.4 to 457.7)	72.5 (51.3 to 100.3)	-7.1 (-15.8 to 2.7)	7.1 (5.3 to 11.7)	13.7 (9.1 to 19.9)	62.1 (36.3 to 110.7)	8.2 (-21.4 to 10.5)
Musculoskeletal disorders	-	-	-	-	189.2 (131.3 to 256.6)	425.5 (287.2 to 579.8)	124.7 (84.5 to 182.2)	4.8 (-9.5 to 25.5)
Rheumatoid arthritis	9.6 (8.7 to 10.6)	22.5 (20.1 to 25.2)	133.6 (101.3 to 173.6)	17.3 (2.2 to 37.6)	2.3 (1.6 to 3.1)	5.4 (3.7 to 7.3)	135.0 (91.6 to 182.0)	17.3 (-1.3 to 39.4)
Osteoarthritis	323.0 (304.1 to 342.4)	633.4 (593.1 to 671.8)	95.9 (79.8 to 114.1)	0.8 (-7.1 to 9.7)	19.5 (13.7 to 26.7)	38.4 (26.3 to 52.5)	97.0 (80.3 to 116.4)	0.8 (-7.1 to 9.7)
Low back and neck pain	-	-	-	-	147.9 (101.0 to 207.0)	334.9 (218.6 to 467.9)	125.4 (74.5 to 198.1)	4.4 (-14.8 to 31.3)
Low back pain	905.6 (679.2 to 1,143.1)	2,052.6 (1,595.5 to 2,635.5)	128.1 (58.1 to 220.6)	5.5 (-21.9 to 37.4)	100.1 (63.9 to 151.5)	228.4 (141.3 to 335.8)	129.7 (57.1 to 220.9)	6.0 (-22.4 to 38.0)
Neck pain	489.8 (407.3 to 565.7)	1,086.5 (918.2 to 1,259.5)	122.1 (77.0 to 172.3)	3.0 (-15.8 to 25.7)	47.8 (31.9 to 68.0)	106.3 (70.7 to 148.7)	123.4 (76.6 to 176.0)	3.1 (-15.8 to 26.1)
Gout	5.8 (5.0 to 6.5)	11.1 (9.5 to 12.8)	92.7 (59.6 to 129.0)	-7.0 (-23.1 to 8.4)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	95.0 (49.0 to 151.5)	-7.2 (-28.6 to 19.0)
Other musculoskeletal disorders	214.1 (115.4 to 287.1)	512.8 (330.5 to 654.0)	136.7 (101.2 to 172.1)	10.3 (-6.6 to 50.9)	19.3 (9.6 to 30.5)	46.6 (27.6 to 69.4)	188.8 (102.2 to 331.8)	4.4 (-6.6 to 51.8)
Other non-communicable diseases	-	-	-	-	236.7 (160.4 to 341.4)	435.9 (297.4 to 628.3)	84.4 (77.2 to 90.3)	-3.1 (-9.2 to -3.1)
Congenital anomalies	-	-	-	-	16.1 (11.3 to 21.2)	35.7 (25.6 to 47.2)	121.1 (85.2 to 171.7)	16.3 (-1.8 to 41.4)
Neural tube defects	3.9 (3.2 to 4.7)	9.3 (7.6 to 11.4)	138.6 (81.4 to 219.9)	29.3 (-1.7 to 72.5)	1.1 (0.7 to 1.6)	2.8 (1.8 to 4.1)	145.6 (64.4 to 286.2)	34.5 (-10.0 to 105.1)
Congenital heart anomalies	66.0 (53.4 to 79.6)	177.1 (145.1 to 213.1)	167.4 (105.3 to 259.6)	43.5 (9.7 to 93.3)	2.4 (1.1 to 4.1)	6.2 (2.8 to 10.8)	162.8 (105.6 to 253.3)	42.2 (11.5 to 90.8)
Orofacial clefts	11.7 (9.1 to 14.7)	34.1 (26.1 to 44.1)	192.8 (104.0 to 330.9)	61.9 (12.2 to 139.1)	0.5 (0.1 to 0.3)	1.5 (0.3 to 0.8)	157.1 (61.8 to 304.9)	43.1 (-8.9 to 123.9)
Down syndrome	23.6 (19.1 to 30.1)	50.7 (41.0 to 62.2)	115.2 (59.6 to 204.0)	13.9 (-15.9 to 62.0)	2.8 (1.9 to 4.0)	6.1 (4.3 to 8.3)	115.3 (61.1 to 206.0)	14.6 (-14.4 to 61.8)
Turner syndrome	0.6 (0.5 to 0.8)	1.2 (0.8 to 1.6)	112.8 (36.6 to 189.6)	9.8 (-29.3 to 50.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.4 (35.5 to 208.8)	9.4 (-30.7 to 57.1)
Klinefelter syndrome	0.5 (0.4 to 0.6)	1.0 (0.8 to 1.3)	92.5 (44.6 to 151.1)	-0.6 (-25.5 to 29.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	114.9 (61.8 to 182.9)	0.5 (-24.5 to 31.2)
Chromosomal unbalanced rearrangements	22.4 (17.3 to 29.1)	46.0 (39.4 to 56.1)	107.3 (50.7 to 186.1)	2.7 (-20.4 to 53.1)	5.5 (1.8 to 3.8)	10.9 (4.0 to 7.7)	197.6 (49.4 to 153.4)	10.5 (-20.4 to 57.7)
Other congenital anomalies	43.7 (36.1 to 50.4)	78.6 (65.7 to 92.2)	78.7 (57.4 to 106.3)	-10.6 (-20.9 to 2.6)	6.9 (4.6 to 10.1)	14.6 (9.6 to 20.9)	112.0 (51.5 to 201.0)	9.3 (-19.1 to 51.3)
Skin and subcutaneous diseases	-	-	-	-	89.4 (56.3 to 135.3)	171.1 (109.2 to 261.8)	91.7 (77.5 to 104.6)	-1.2 (-8.3 to 4.8)
Dermatitis	927.3 (732.6 to 1,133.1)	1,886.5 (1,479.7 to 2,300.4)	103.2 (99.2 to 107.8)	0.1 (0.0 to 0.2)	31.9 (18.9 to 47.6)	62.8 (37.0 to 93.6)	96.9 (87.8 to 104.9)	0.2 (-2.4 to 2.7)
Psoriasis	85.9 (71.0 to 102.2)	179.9 (148.1 to 215.9)	109.2 (105.1 to 113.6)	-0.1 (-0.2 to 0.1)	7.0 (4.7 to 10.1)	14.7 (9.9 to 21.2)	109.6 (93.4 to 125.7)	0.0 (-5.8 to 6.2)
Cellulitis	3.7 (3.0 to 4.4)	5.8 (4.7 to 7.2)	57.7 (43.8 to 77.2)	-15.2 (-22.5 to -9.9)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	59.4 (24.8 to 104.1)	-14.7 (-30.0 to 5.4)
Pyoderma	14.9 (11.8 to 19.0)	24.1 (19.3 to 30.6)	61.1 (51.1 to 73.1)	-7.7 (-13.1 to -1.2)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	61.3 (41.4 to 84.4)	-8.0 (-17.9 to 3.8)
Scabies	56.9 (48.1 to 68.5)	102.8 (91.6 to 115.6)	81.7 (43.2 to 123.4)	-3.8 (-23.7 to 15.9)	1.5 (0.8 to 2.4)	2.7 (1.5 to 4.4)	81.3 (41.6 to 126.2)	-3.8 (-24.3 to 17.1)
Fungal skin diseases	947.6 (709.2 to 1,197.1)	1,935.7 (1,460.4 to 2,435.3)	104.0 (98.1 to 111.7)	0.0 (-0.2 to 0.2)	5.3 (3.1 to 11.3)	10.9 (4.3 to 23.1)	104.2 (97.4 to 111.9)	0.1 (-0.9 to 1.0)
Viral skin diseases	423.1 (329.7 to 507.5)	770.5 (589.1 to 936.8)	81.8 (75.6 to 88.7)	-0.0 (-1.9 to 2.0)	1.1 (0.7 to 2.0)	23.9 (13.9 to 37.6)	81.9 (73.7 to 91.0)	0.1 (-3.1 to 3.7)
Acne vulgaris	1,593.3 (1,229.8 to 1,984.2)	2,713.6 (2,151.7 to 3,213.2)	70.3 (28.4 to 134.3)	-8.2 (-30.4 to 22.2)	17.3 (7.8 to 33.7)	29.4 (13.4 to 56.6)	70.3 (28.4 to 135.1)	-8.2 (-30.3 to 22.4)
Alopecia areata	18.3 (16.2 to 20.6)	36.6 (31.8 to 41.4)	98.8 (66.8 to 141.5)	-1.7 (-16.0 to 18.0)	0.6 (0.4 to 1.0)	1.2 (0.8 to 1.9)	99.8 (60.1 to 149.7)	-1.1 (-17.9 to 20.1)
Pruritus	1.1 (1.0 to 1.3)	2.2 (1.9 to 2.6)	90.4 (53.5 to 139.3)	-3.2 (-23.9 to 21.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.6 (43.5 to 152.0)	-2.6 (-28.8 to 29.9)
Urticaria	129.8 (79.5 to 186.3)	264.8 (197.7 to 349.9)	110.7 (27.0 to 215.7)	0.5 (-36.1 to 53.7)	7.7 (4.1 to 13.2)	15.8 (9.5 to 24.3)	111.0 (28.0 to 215.8)	0.4 (-36.2 to 56.0)
Decubitus ulcer	2.0 (1.6 to 2.6)	3.2 (2.6 to 3.9)	59.0 (18.0 to 133.7)	-15.0 (-41.6 to 35.5)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	60.3 (16.9 to 140.2)	-15.0 (-42.7 to 39.0)
Other skin and subcutaneous diseases	732.7 (499.8 to 1,072.3)	1,475.8 (1,023.3 to 2,098.4)	101.3 (87.3 to 116.1)	-0.4 (-4.2 to 3.8)	4.3 (1.9 to 9.0)	8.7 (3.8 to 17.7)	102.1 (87.6 to 116.7)	-0.5 (-4.2 to 4.2)
Sense organ diseases	-	-	-	-	98.8 (67.6 to 138.6)	165.0 (113.0 to 231.8)	67.0 (57.5 to 76.2)	-11.8 (-16.5 to -7.2)
Glaucoma	36.2 (26.2 to 46.7)	72.8 (55.1 to 93.3)	101.1 (56.6 to 162.5)	2.1 (-16.9 to 35.4)	2.8 (1.7 to 4.2)	5.5 (3.4 to 8.2)	93.3 (60.2 to 140.1)	0.3 (-18.8 to 30.0)
Cataract	132.0 (89.2 to 180.9)	183.3 (120.1 to 253.7)	37.1 (8.0 to 76.4)	-19.9 (-36.1 to 0.9)	10.2 (6.1 to 15.5)	14.7 (8.2 to 22.3)	45.8 (10.8 to 77.2)	-15.8 (-34.2 to 2.6)
Macular degeneration	19.1 (12.6 to 27.6)	38.9 (27.1 to 55.3)	101.0 (35.8 to 222.7)	9.3 (-24.7 to 69.7)	1.2 (0.7 to 2.0)	2.5 (1.5 to 3.9)	95.9 (39.7 to 207.5)	7.6 (-22.0 to 63.3)
Uncorrected refractive error	1,385.2 (1,215.6 to 1,592.8)	2,576.9 (2,249.7 to 2,916.5)	86.7 (52.8 to 117.8)	4.0 (-19.1 to 11.1)	4.0 (2.1 to 48.3)	54.5 (35.2 to 82.4)	67.7 (49.6 to 85.0)	-13.3 (-21.8 to -5.3)
Age-related and other hearing loss	1,214.3 (1,134.0 to 1,300.6)	2,142.5 (1,986.4 to 2,323.1)	76.4 (68.8 to 83.9)	-9.9 (-13.1 to -7.0)	33.0 (22.3 to 46.6)	33.0 (86.2 to 78.6)	54.7 (53.9 to 76.5)	-11.7 (-16.1 to -7.3)
Other vision loss	100.5 (79.8 to 129.5)	168.5 (129.4 to 211.4)	67.5 (45.2 to 98.6)	-11.9 (-21.1 to 0.8)	7.9 (5.0 to 11.7)	12.4 (7.8 to 18.5)	55.6 (35.2 to 86.1)	-17.4 (-26.6 to -5.1)
Other sense organ diseases	418.2 (397.4 to 439.6)	774.0 (732.5 to 816.7)	85.0 (72.3 to 99.6)	0.0 (-6.4 to 6.9)	11.2 (6.8 to 16.6)	20.7 (12.8 to 30.9)	85.1 (70.6 to 102.1)	0.1 (-7.1 to 7.8)
Oral disorders	-	-	-	-	32.5 (19.9 to 49.7)	64.1 (39.3 to 98.6)	97.0 (86.9 to 110.4)	-1.5 (-7

Appendix Table G.4 - Iraq prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Edentulism and severe tooth loss	535.9 (495.6 to 575.5)	983.6 (903.7 to 1,059.4)	83.5 (64.9 to 105.3)	-2.5 (-12.1 to 9.1)	14.6 (9.8 to 20.3)	26.9 (18.0 to 37.5)	84.4 (65.2 to 107.0)	-2.6 (-12.5 to 9.4)
Other oral disorders	249.5 (234.8 to 264.9)	515.3 (485.3 to 545.1)	106.4 (88.9 to 124.3)	0.0 (-7.6 to 8.0)	7.3 (4.5 to 11.0)	15.1 (9.5 to 22.7)	106.7 (89.0 to 125.6)	-0.0 (-8.0 to 8.3)
Injuries	-	-	-	-	137.8 (73.4 to 283.8)	232.1 (134.4 to 404.2)	73.5 (14.0 to 148.6)	-8.0 (-36.4 to 31.9)
Transport injuries	-	-	-	-	17.8 (13.4 to 23.0)	27.3 (20.3 to 35.2)	53.4 (43.5 to 61.8)	-22.6 (-26.4 to -18.8)
Road injuries	-	-	-	-	16.1 (12.1 to 20.8)	24.0 (17.9 to 31.0)	49.8 (39.7 to 58.8)	-24.0 (-28.4 to -20.1)
Pedestrian road injuries	-	-	-	-	4.3 (3.2 to 5.7)	5.6 (4.2 to 7.2)	30.3 (15.5 to 42.4)	-30.4 (-36.5 to -25.4)
Cyclist road injuries	-	-	-	-	1.6 (1.2 to 2.1)	2.7 (2.0 to 3.5)	65.1 (54.5 to 79.0)	-14.1 (-19.4 to -7.1)
Motorcyclist road injuries	-	-	-	-	1.9 (1.4 to 2.4)	2.3 (1.7 to 3.1)	23.6 (14.8 to 35.1)	-38.3 (-42.4 to -32.8)
Motor vehicle road injuries	-	-	-	-	8.1 (6.1 to 10.4)	13.3 (9.9 to 17.1)	64.4 (48.9 to 78.6)	-19.0 (-25.6 to -13.1)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-9.0 (-16.6 to -0.5)	-55.7 (-58.9 to -52.3)
Other transport injuries	-	-	-	-	1.7 (1.3 to 2.2)	3.2 (2.4 to 4.2)	86.1 (75.0 to 100.0)	-9.7 (-14.8 to -4.1)
Unintentional injuries	-	-	-	-	30.8 (23.7 to 39.7)	54.9 (41.9 to 71.1)	78.3 (72.2 to 85.3)	-12.3 (-15.3 to -9.2)
Falls	-	-	-	-	9.0 (6.8 to 11.8)	16.5 (12.6 to 21.9)	86.4 (76.0 to 96.0)	-6.7 (-11.7 to -1.7)
Drowning	-	-	-	-	0.6 (0.4 to 0.7)	0.7 (0.5 to 0.9)	25.2 (13.4 to 35.7)	-38.0 (-43.1 to -33.2)
Fire, heat, and hot substances	-	-	-	-	2.7 (2.1 to 3.5)	4.1 (3.1 to 5.2)	48.2 (34.6 to 62.9)	-26.6 (-32.3 to -20.3)
Poisonings	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	20.2 (-3.3 to 50.3)	-39.4 (-49.0 to -26.8)
Exposure to mechanical forces	-	-	-	-	10.4 (8.0 to 13.5)	19.1 (14.5 to 25.0)	83.6 (74.0 to 94.2)	-12.4 (-16.3 to -7.7)
Unintentional firearm injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.7 (0.5 to 0.9)	64.4 (52.5 to 77.2)	25.1 (-30.3 to -19.4)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	142.5 (114.4 to 170.0)	17.8 (5.7 to 29.9)
Other exposure to mechanical forces	-	-	-	-	9.9 (7.5 to 12.9)	18.3 (13.8 to 23.8)	83.9 (74.1 to 94.9)	-12.1 (-16.2 to -7.1)
Adverse effects of medical treatment	-	-	-	-	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	113.6 (99.6 to 129.9)	12.3 (4.4 to 21.3)
Animal contact	-	-	-	-	0.5 (0.4 to 0.6)	0.9 (0.6 to 1.1)	75.5 (63.6 to 89.5)	-14.7 (-19.4 to -9.3)
Venomous animal contact	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	73.2 (53.7 to 97.0)	-16.7 (-24.8 to -6.8)
Non-venomous animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.6)	77.5 (64.7 to 91.7)	-13.0 (-17.9 to -7.8)
Foreign body	-	-	-	-	0.5 (0.4 to 0.7)	1.0 (0.7 to 1.2)	85.8 (74.7 to 96.3)	-8.2 (-13.6 to -3.7)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	43.0 (22.9 to 65.1)	-23.2 (-31.7 to -14.8)
Foreign body in eyes	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	100.8 (78.7 to 122.4)	-1.5 (-10.4 to 7.7)
Foreign body in other body part	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	96.3 (82.5 to 109.6)	-6.0 (-12.7 to 0.8)
Other unintentional injuries	-	-	-	-	6.6 (5.0 to 8.5)	11.6 (8.7 to 15.3)	77.2 (62.8 to 91.8)	-14.0 (-20.6 to -7.2)
Self-harm and interpersonal violence	-	-	-	-	3.0 (2.3 to 3.8)	6.6 (5.0 to 8.5)	117.8 (106.2 to 128.4)	4.0 (-0.9 to 8.8)
Self-harm	-	-	-	-	0.3 (0.2 to 0.4)	0.7 (0.5 to 0.9)	115.3 (93.8 to 137.3)	0.5 (-8.8 to 9.5)
Interpersonal violence	-	-	-	-	2.7 (2.1 to 3.4)	5.9 (4.5 to 7.6)	117.8 (105.6 to 130.2)	4.5 (-0.7 to 9.8)
Assault by firearm	-	-	-	-	0.5 (0.4 to 0.7)	1.2 (0.9 to 1.5)	121.6 (104.8 to 137.4)	10.0 (1.9 to 17.5)
Assault by sharp object	-	-	-	-	0.5 (0.4 to 0.6)	1.1 (0.8 to 1.4)	133.8 (115.9 to 155.7)	11.2 (2.9 to 21.0)
Assault by other means	-	-	-	-	1.7 (1.3 to 2.2)	3.6 (2.7 to 4.7)	112.5 (96.1 to 127.6)	1.0 (-6.4 to 7.8)
Forces of nature, war, and legal intervention	-	-	-	-	86.2 (26.3 to 231.1)	143.3 (53.4 to 303.0)	75.0 (-5.5 to 263.7)	-3.3 (-44.4 to 101.0)
Exposure to forces of nature	-	-	-	-	-	-	-	-
Collective violence and legal intervention	-	-	-	-	86.2 (26.3 to 231.1)	143.3 (53.4 to 303.0)	75.0 (-5.5 to 263.7)	-3.3 (-44.4 to 101.0)

Appendix Table G.4 - Ireland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	402.5 (300.3 to 517.9)	548.8 (409.2 to 706.6)	36.2 (32.5 to 40.8)	36.2 (5.3 to 0.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	21.0 (14.1 to 30.0)	25.2 (17.4 to 35.5)	20.3 (10.3 to 30.4)	2.5 (-5.7 to 10.7)
HIV/AIDS and tuberculosis	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	63.4 (31.2 to 104.3)	15.9 (-7.1 to 43.0)
Tuberculosis	0.6 (0.6 to 0.7)	0.8 (0.8 to 0.8)	27.7 (22.2 to 33.2)	-6.4 (-10.3 to -2.4)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	28.8 (6.0 to 53.9)	-5.5 (-22.0 to 13.7)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	263.0 (79.3 to 551.0)	133.2 (14.6 to 319.6)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.8 (-13.2 to 228.7)	20.6 (-43.8 to 113.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.8 (-13.4 to 229.3)	20.6 (-43.8 to 114.1)
HIV/AIDS resulting in other diseases	0.3 (0.1 to 0.5)	1.6 (0.8 to 2.7)	506.1 (292.0 to 805.1)	289.9 (151.4 to 485.4)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	263.5 (79.3 to 552.4)	133.5 (14.6 to 320.3)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	2.4 (1.6 to 3.5)	2.7 (1.7 to 3.9)	12.3 (2.6 to 21.2)	-14.1 (-21.9 to -7.6)
Diarrheal diseases	1.2 (1.1 to 1.4)	1.5 (1.3 to 1.7)	17.0 (4.0 to 42.0)	-10.1 (-27.7 to 11.0)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	17.1 (7.5 to 48.4)	-8.9 (-30.0 to 16.3)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-67.3 to 49.5)	0.0 (-72.7 to 22.9)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.9 (-53.5 to 30.7)	-33.2 (-62.5 to 8.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.9 (-53.6 to 31.9)	-33.2 (-62.5 to 8.6)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.1 (-35.6 to 96.2)	0.3 (-46.7 to 62.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.1 (-35.7 to 96.8)	0.3 (-46.8 to 62.7)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-66.3 (-99.6 to 2428.0)	-72.2 (-99.6 to 1,956.9)
Lower respiratory infections	0.8 (0.7 to 1.0)	0.8 (0.6 to 1.0)	-0.1 (-23.9 to 28.2)	-33.7 (-49.5 to -14.8)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	0.3 (-25.5 to 33.4)	-33.0 (-50.1 to -10.8)
Upper respiratory infections	55.5 (52.9 to 57.8)	70.4 (67.5 to 73.2)	26.8 (20.3 to 35.5)	0.2 (-5.0 to 7.4)	0.7 (0.4 to 1.1)	0.8 (0.5 to 1.4)	26.7 (18.8 to 36.1)	0.4 (-5.9 to 7.9)
Otitis media	45.2 (40.0 to 50.9)	50.4 (44.1 to 56.8)	11.8 (-3.8 to 28.5)	-15.1 (-27.4 to -3.6)	0.8 (0.5 to 1.3)	0.9 (0.5 to 1.5)	11.1 (4.4 to 27.8)	-15.1 (-27.3 to -3.8)
Meningitis	-	-	-	-	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	4.6 (-28.0 to 59.5)	-18.2 (-43.7 to 27.3)
Pneumococcal meningitis	1.0 (0.6 to 1.6)	0.9 (0.5 to 1.5)	-7.7 (-32.6 to 27.2)	-32.8 (-51.2 to -7.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	4.2 (-40.8 to 34.3)	-27.6 (-55.5 to 2.3)
H influenzae type B meningitis	0.6 (0.2 to 1.4)	0.6 (0.2 to 1.3)	-2.3 (-69.6 to 100.7)	-24.3 (-76.8 to 62.6)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	14.3 (-75.7 to 129.4)	-7.8 (-80.5 to 88.7)
Meningococcal meningitis	0.5 (0.1 to 1.2)	0.5 (0.2 to 1.2)	3.7 (-34.6 to 113.2)	-22.3 (-51.6 to 66.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	23.0 (-30.6 to 128.4)	-5.9 (-46.9 to 79.0)
Other meningitis	0.9 (0.4 to 1.8)	0.8 (0.4 to 1.6)	-6.4 (-44.5 to 49.9)	-28.1 (-56.8 to 19.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	7.2 (-51.2 to 98.2)	-16.0 (-62.0 to 58.1)
Encephalitis	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.5)	40.3 (4.6 to 79.2)	0.1 (-25.7 to 29.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.9 (20.4 to 90.5)	33.5 (-13.8 to 38.5)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.9 (-96.3 to 245.0)	-71.5 (-97.2 to 165.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.9 (-96.4 to 248.6)	-71.5 (-97.2 to 168.3)
Whooping cough	2.0 (1.6 to 2.6)	0.3 (0.3 to 0.4)	-83.7 (-85.9 to -81.5)	-87.4 (-88.9 to -85.7)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.0)	-83.7 (-86.8 to -79.8)	-87.4 (-89.8 to -84.4)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.5 (-59.4 to 24.7)	-23.3 (-67.3 to 24.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.5 (-65.7 to 30.3)	-18.8 (-72.0 to 9.3)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-90.5 (-93.0 to -87.8)	-92.3 (-94.3 to -90.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-90.5 (-93.0 to -87.8)	-92.3 (-94.3 to -90.1)
Varicella and herpes zoster	3.0 (2.7 to 3.4)	4.0 (3.5 to 4.5)	30.7 (10.6 to 53.0)	-2.2 (-16.1 to 13.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	37.7 (51.1 to 77.2)	-3.0 (-25.1 to 25.9)
Neglected tropical diseases and malaria	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-13.6 (-44.8 to 15.1)	-37.6 (-60.5 to -16.1)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.8 (-54.9 to 480.2)	-4.1 (-63.9 to 369.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.3 (-53.0 to 500.9)	-0.3 (-62.3 to 382.0)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-73.9 (-91.0 to -24.6)	-82.3 (-94.0 to -48.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.2 (-89.8 to -13.0)	-79.8 (-93.2 to -40.1)
Cystic echinococcosis	0.7 (0.6 to 0.7)	0.7 (0.6 to 0.8)	1.1 (-14.6 to 21.4)	-26.8 (-37.5 to -11.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.4 (-23.3 to 31.6)	-26.5 (-43.9 to -4.0)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.8 (-57.2 to 39.4)	-11.0 (-67.4 to 7.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.8 (-57.2 to 39.5)	-11.0 (-67.4 to 7.2)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.4 (-56.1 to 89.7)	13.9 (-66.4 to 46.1)
Maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	67.3 (11.5 to 134.3)	16.7 (-21.5 to 63.5)
Maternal hemorrhage	0.9 (0.5 to 1.3)	2.0 (0.8 to 3.1)	115.2 (19.3 to 224.9)	52.4 (-13.9 to 133.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	98.0 (-14.3 to 263.2)	37.5 (-38.5 to 154.6)
Maternal sepsis and other maternal infections	0.5 (0.1 to 0.9)	0.4 (0.1 to 1.1)	-12.7 (-85.7 to 247.7)	-42.7 (-90.3 to 130.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.1 (-45.6 to 111.4)	-23.2 (-60.3 to 46.7)
Maternal hypertensive disorders	0.4 (0.2 to 0.6)	0.6 (0.4 to 1.0)	52.8 (32.3 to 80.8)	8.6 (-3.3 to 27.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	52.6 (15.1 to 100.0)	8.5 (-15.2 to 40.9)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.3 (-26.5 to 201.5)	3.5 (-49.8 to 106.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.3 (-26.7 to 201.6)	3.5 (-50.1 to 106.7)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.9 (-1.8 to 168.0)	10.9 (-30.6 to 88.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.9 (-2.0 to 170.0)	10.9 (-30.6 to 88.8)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.0 (-6.3 to 238.4)	24.7 (-33.9 to 135.9)
Neonatal disorders	-	-	-	-	3.0 (2.1 to 4.0)	5.0 (3.5 to 6.5)	67.1 (30.9 to 118.9)	31.0 (2.7 to 71.8)
Preterm birth complications	15.5 (11.2 to 22.0)	29.2 (21.3 to 41.1)	87.2 (59.9 to 125.4)	44.5 (23.6 to 74.0)	1.7 (1.2 to 2.3)	3.3 (2.3 to 4.5)	98.2 (49.2 to 161.0)	55.4 (16.4 to 104.8)
Neonatal encephalopathy due to birth asphyxia and trauma	3.8 (2.0 to 7.8)	3.4 (1.7 to 8.0)	-14.2 (-39.6 to 24.2)	-32.8 (-52.9 to -3.1)	0.8 (0.5 to 1.1)	0.7 (0.5 to 1.0)	-5.7 (-41.1 to 44.8)	-24.7 (-53.1 to 14.8)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	514.6 (425.3 to 650.7)	339.5 (275.7 to 436.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	553.5 (207.6 to 1,955.3)	367.3 (119.6 to 1,369.7)
Hemolytic disease and other neonatal jaundice	0.8 (0.3 to 1.6)	0.6 (0.2 to 1.2)	-20.3 (-80.0 to 162.1)	-37.6 (-84.3 to 105.7)	0.3 (0.1 to 0.7)	0.3 (0.1 to 0.5)	-16.3 (-79.4 to 172.5)	-34.5 (-83.9 to 111.9)
Other neonatal disorders	-	-	-	-	0.2 (0.1 to 0.2)	0.6 (0.3 to 1.0)	292.9 (96.4 to 545.5)	209.0 (54.2 to 405.1)
Nutritional deficiencies	-	-	-	-	14.2 (9.3 to 21.0)	15.8 (10.4 to 23.6)	11.5 (-0.5 to 22.2)	-0.3 (-11.0 to 9.1)
Protein-energy malnutrition	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.1 (-46.0 to 81.3)	-25.3 (-64.8 to 12.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.3 (-54.4 to 119.5)	-24.6 (-70.1 to 38.8)
Iodine deficiency	64.7 (32.4 to 121.5)	56.6 (20.0 to 97.6)	-12.7 (-71.5 to 118.0)	-33.2 (-79.0 to 61.8)	1.2 (0.5 to 2.4)	1.0 (0.3 to 2.1)	-13.1 (-71.7 to 121.8)	-35.2 (-78.8 to 64.1)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron-deficiency anemia	446.5 (428.6 to 457.8)	552.5 (524.7 to 570.1)	23.9 (17.0 to 29.1)	3.2 (-2.2 to 7.5)	13.0 (8.7 to 19.1)	14.8 (9.6 to 21.7)	13.6 (1.9 to 21.4)	2.5 (-7.1 to 9.4)

Appendix Table G.4 - Ireland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.8 (-67.6 to 19.6)	-58.2 (-78.3 to -24.9)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.1 (0.6 to 1.7)	1.2 (0.8 to 2.0)	16.0 (1.3 to 32.9)	-3.1 (-15.8 to 11.4)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.4 (0.2 to 0.8)	0.5 (0.3 to 1.0)	27.5 (11.7 to 54.6)	-4.6 (-16.4 to 15.5)
Syphilis	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	104.9 (43.8 to 182.9)	31.8 (-8.6 to 82.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	104.3 (33.6 to 213.7)	31.3 (-15.4 to 102.6)
Chlamydial infection	80.9 (58.2 to 98.6)	77.3 (63.5 to 95.1)	-4.8 (-28.7 to 31.5)	24.3 (-43.5 to 5.7)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	-8.7 (-10.7 to 68.8)	-4.7 (-29.4 to 33.7)
Gonococcal infection	10.4 (6.3 to 15.1)	13.0 (8.1 to 18.1)	26.3 (-34.2 to 136.1)	12.5 (-42.9 to 117.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	14.7 (-28.4 to 81.6)	-1.4 (-40.0 to 61.3)
Trichomoniasis	9.5 (6.6 to 13.0)	13.5 (8.8 to 18.6)	42.0 (-12.5 to 104.0)	1.4 (-39.4 to 48.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	45.0 (-14.5 to 121.3)	2.2 (-40.3 to 68.4)
Genital herpes	378.6 (325.1 to 434.9)	540.4 (469.5 to 613.1)	42.7 (19.5 to 70.3)	-6.3 (-21.4 to 12.4)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	41.1 (16.2 to 68.5)	-6.0 (-22.3 to 12.5)
Other sexually transmitted diseases	0.6 (0.4 to 0.8)	0.5 (0.3 to 0.7)	-7.1 (-40.1 to 40.1)	-36.4 (-59.0 to -4.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.8 (-31.5 to 72.8)	-20.6 (-50.0 to 26.8)
Hepatitis	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	5.7 (-7.7 to 27.6)	-19.5 (-29.6 to -3.4)
Hepatitis A	3.0 (2.8 to 3.1)	3.1 (2.9 to 3.4)	5.4 (3.2 to 7.3)	-14.4 (-16.6 to -12.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	10.3 (-2.1 to 25.3)	-12.0 (-22.5 to 0.4)
Hepatitis B	50.6 (39.2 to 60.6)	44.6 (36.1 to 55.2)	-11.7 (-34.8 to 20.0)	-36.1 (-52.8 to -34.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-39.5 to 100.0)	-11.8 (-59.1 to 31.8)
Hepatitis C	67.4 (60.5 to 74.4)	71.2 (63.7 to 78.6)	5.6 (-7.9 to 22.6)	-26.5 (-36.1 to -15.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.0 (-24.4 to 55.1)	-25.1 (-46.0 to 6.2)
Hepatitis E	-	-	-	-	0.0 (-10.2 to 254.1)	0.0 (-10.2 to 254.1)	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	20.1 (17.4 to 24.5)	22.6 (20.1 to 25.0)	13.0 (-6.3 to 31.6)	-0.3 (-18.0 to 16.0)	0.5 (0.3 to 0.8)	0.6 (0.4 to 0.9)	9.4 (-14.7 to 38.2)	1.9 (-21.2 to 29.7)
Non-communicable diseases	-	-	-	-	345.9 (257.9 to 443.1)	489.9 (363.5 to 629.7)	41.5 (37.0 to 46.9)	0.6 (-2.4 to 4.5)
Neoplasms	-	-	-	-	5.0 (3.8 to 6.5)	9.0 (6.5 to 11.8)	79.2 (60.3 to 99.8)	18.4 (6.1 to 32.0)
Esophageal cancer	0.4 (0.3 to 0.5)	0.7 (0.5 to 0.9)	52.0 (7.8 to 115.6)	0.4 (-28.9 to 42.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	42.9 (3.5 to 90.1)	-5.7 (-31.7 to 25.0)
Stomach cancer	1.4 (1.2 to 1.6)	1.7 (1.4 to 2.0)	22.2 (-1.1 to 50.0)	-18.4 (-34.0 to -0.3)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	8.4 (-13.9 to 35.0)	-27.7 (-42.6 to -10.4)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (-13.1 to 123.2)	9.2 (-24.3 to 49.4)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	80.8 (-22.3 to 311.8)	19.7 (-48.2 to 173.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.1 (-19.8 to 273.7)	18.4 (-46.5 to 146.6)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.2)	162.3 (19.3 to 418.8)	74.1 (-20.6 to 244.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	154.2 (22.5 to 356.4)	69.4 (-17.8 to 203.5)
Liver cancer due to alcohol use	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	14.0 (-44.4 to 153.7)	-23.7 (-62.8 to 70.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.5 (-37.6 to 115.3)	-23.8 (-58.3 to 44.6)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.5 (-80.5 to 97.3)	-51.7 (-86.7 to 30.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.7 (-78.9 to 70.3)	-52.5 (-85.5 to 14.5)
Larynx cancer	0.5 (0.4 to 0.6)	0.6 (0.4 to 0.8)	15.0 (-0.5 to 84.0)	35.3 (-37.0 to 16.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	23.1 (-14.6 to 72.1)	-21.4 (-44.7 to 9.5)
Tracheal, bronchus and lung cancer	2.5 (2.2 to 2.7)	4.2 (3.5 to 4.8)	68.3 (38.4 to 101.7)	12.0 (-7.6 to 34.2)	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.7)	46.3 (19.7 to 75.7)	-2.6 (-20.1 to 17.1)
Breast cancer	13.8 (12.3 to 15.4)	31.8 (29.7 to 33.9)	131.0 (101.8 to 162.7)	47.6 (29.0 to 67.6)	0.9 (0.6 to 1.2)	1.6 (1.1 to 2.2)	84.9 (55.5 to 116.0)	17.3 (-1.1 to 37.7)
Cervical cancer	1.3 (1.0 to 1.6)	1.6 (1.0 to 2.2)	26.3 (-21.9 to 83.3)	-19.7 (-50.3 to 17.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	24.0 (-23.3 to 79.3)	-20.9 (-51.5 to 15.0)
Uterine cancer	1.8 (1.4 to 2.3)	2.8 (1.9 to 3.9)	54.2 (-0.9 to 129.0)	2.8 (-36.7 to 44.6)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	45.5 (-4.4 to 126.0)	-6.5 (-39.9 to 42.0)
Prostate cancer	9.7 (8.0 to 11.0)	23.7 (18.8 to 29.6)	142.6 (91.7 to 222.3)	67.6 (33.1 to 120.8)	0.8 (0.5 to 1.0)	1.8 (1.2 to 2.5)	128.4 (83.8 to 195.8)	57.9 (27.7 to 103.8)
Colon and rectum cancer	8.3 (7.8 to 9.0)	14.4 (12.6 to 16.3)	73.1 (48.3 to 99.0)	13.8 (-2.7 to 30.9)	0.7 (0.5 to 0.9)	1.2 (0.8 to 1.5)	56.8 (32.9 to 81.4)	3.4 (-12.0 to 20.1)
Lip and oral cavity cancer	1.2 (1.0 to 1.5)	1.4 (1.1 to 1.8)	19.9 (-14.5 to 66.4)	-22.3 (-44.2 to 8.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	11.4 (-19.5 to 54.0)	-27.0 (-46.8 to 0.4)
Nasopharynx cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-7.5 (-38.0 to 40.6)	-38.6 (-58.8 to -7.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.7 (-40.4 to 30.0)	-42.2 (-60.2 to -14.3)
Other pharynx cancer	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.9)	58.2 (1.4 to 140.7)	0.6 (-35.6 to 52.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	51.7 (-3.3 to 124.9)	-3.6 (-37.7 to 43.2)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	2.2 (-25.7 to 48.7)	-31.6 (-50.3 to 0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.9 (-31.8 to 40.9)	-0.9 (-53.9 to -6.5)
Pancreatic cancer	0.3 (0.3 to 0.4)	0.6 (0.5 to 0.7)	76.2 (36.5 to 123.9)	17.3 (-9.3 to 48.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	53.2 (19.5 to 94.6)	1.6 (-20.5 to 28.2)
Malignant skin melanoma	3.4 (2.5 to 4.8)	6.1 (4.2 to 8.2)	81.8 (38.0 to 128.7)	18.4 (-9.9 to 48.9)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	75.9 (34.4 to 122.1)	14.8 (-12.7 to 45.0)
Non-melanoma skin cancer	5.0 (5.2 to 6.9)	12.0 (10.8 to 13.3)	100.1 (71.7 to 140.9)	32.8 (14.0 to 59.5)	0.2 (0.1 to 0.1)	0.2 (0.1 to 0.3)	71.7 (81.2 to 183.9)	47.0 (20.0 to 87.2)
Ovarian cancer	1.1 (0.9 to 1.3)	1.9 (1.5 to 2.4)	78.3 (33.2 to 135.6)	13.6 (-15.3 to 50.0)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	68.2 (23.3 to 122.4)	7.5 (-21.1 to 42.7)
Testicular cancer	0.7 (0.4 to 1.0)	1.0 (0.6 to 1.5)	41.4 (-23.2 to 152.3)	-1.1 (-45.1 to 72.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	36.4 (-25.1 to 153.1)	-4.4 (-47.2 to 74.7)
Kidney cancer	1.4 (1.3 to 1.7)	3.6 (2.9 to 4.3)	145.3 (91.2 to 190.2)	59.7 (24.4 to 100.2)	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	127.1 (74.5 to 189.7)	47.9 (13.2 to 88.3)
Bladder cancer	0.4 (1.8 to 2.6)	2.2 (3.2 to 5.0)	461.1 (47.5 to 135.1)	22.4 (-1.0 to 56.9)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	70.7 (34.2 to 120.4)	14.4 (-10.1 to 46.7)
Brain and nervous system cancer	1.5 (0.7 to 1.0)	71.0 (1.2 to 1.9)	15.9 (38.1 to 117.7)	0.1 (-6.7 to 47.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	62.2 (28.5 to 108.2)	9.7 (-12.9 to 41.2)
Thyroid cancer	0.7 (0.5 to 0.8)	1.2 (0.9 to 1.6)	70.7 (23.5 to 151.0)	12.7 (-18.6 to 65.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	57.5 (13.2 to 136.3)	5.0 (-25.7 to 57.9)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (-13.9 to 100.7)	-1.8 (-42.9 to 32.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-14.5 to 107.9)	2.4 (-43.9 to 36.1)
Hodgkin lymphoma	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	37.1 (-3.2 to 100.7)	2.7 (-28.4 to 49.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	19.3 (-12.5 to 71.4)	-11.3 (-35.6 to 25.7)
Non-Hodgkin lymphoma	1.8 (1.4 to 2.8)	4.1 (2.5 to 4.2)	134.0 (11.9 to 214.0)	53.3 (-26.8 to 105.3)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	115.2 (3.1 to 188.6)	41.3 (-3.2 to 90.5)
Multiple myeloma	0.4 (0.2 to 0.6)	0.7 (0.4 to 1.1)	92.1 (7.2 to 253.2)	27.3 (-28.6 to 136.5)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	74.8 (1.1 to 218.2)	15.5 (-32.5 to 112.1)
Leukemia	1.3 (1.2 to 1.6)	2.4 (2.0 to 2.9)	79.7 (41.0 to 123.1)	23.8 (-2.8 to 54.0)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	63.3 (28.9 to 103.4)	12.3 (-11.0 to 39.3)
Other neoplasms	2.1 (1.8 to 2.5)	7.9 (5.8 to 9.9)	279.6 (163.5 to 401.8)	155.9 (80.3 to 236.7)	0.2 (0.1 to 0.2)	0.5 (0.3 to 0.8)	243.8 (129.5 to 358.6)	132.4 (58.4 to 207.3)
Cardiovascular diseases	-	-	-	-	12.9 (9.0 to 17.7)	18.6 (12.7 to 25.0)	44.3 (13.8 to 78.8)	-3.6 (-24.0 to 19.2)
Rheumatic heart disease	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	47.1 (-2.5 to 132.8)	-0.2 (-33.0 to 55.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	45.6 (-14.2 to 158.1)	-2.6 (-42.5 to 70.0)
Ischemic heart disease	64.1 (52.1 to 79.6)	88.7 (78.5 to 101.4)	37.1 (7.6 to 78.9)	-10.5 (-30.1 to 17.3)	3.6 (2.3 to 5.4)	4.8 (3.1 to 6.6)	32.1 (-6.6 to 81.6)	-13.7 (-39.2 to 18.8)
Cerebrovascular disease	-	-	-	-	3.4 (2.3 to 4.5)	4.9 (3.3 to 6.7)	48.8 (14.8 to 73.3)	-1.6 (-22.2 to 16.9)
Ischemic stroke	19.8 (16.6 to 22.6)	28.3 (22.8 to 33.4)	44.6 (4.9 to 79.9)	-2.3 (-28.5 to 21.3)	2.8 (1.9 to 3.8)	4.1 (2.7 to 5.6)	45.2 (6.8 to 81.5)	-1.9 (-28.2 to 22.1)
Hemorrhagic stroke	3.9 (2.8 to 5.2)	5.7 (4.2 to 7.7)	47.4 (-2.9 to 142.2)	-1.3 (-33.9 to 58.4)	0.6 (0.3 to 0.8)	0.8 (0.5 to 1.2)	48.2 (-2.1 to 138.0)	-0.6 (-33.7 to 57.1)
Hypertensive heart disease	4.0 (2.7 to 5.2)	7.2 (5.6 to 8.8)	74.3 (27.8 to 184.9)	15.7 (-14.8 to 86.7)	0.4 (0.3 to 0.7)	0.8 (0.5 to 1.1)	76.7 (28.9 to 186.4)	17.3 (-13.9 to 86.7)
Cardiomyopathy and myocarditis	4.7 (3.2 to 6.4)	5.8 (4.6 to 6.9)	23.5 (-13.7 to 81.0)	-17.4 (-41.2 to 19.8)	0.5 (0.3 to 0.8)	0.6 (0.4 to 0.9)	23.7 (-14.9 to 82.7)	-17.3 (-42.7 to 20.8)
Atrial fibrillation and flutter	23.7 (20.4 to 27.2)	20.7 (17.0 to 25.1)	-12.8 (-32.1 to 11.8)	-41.0 (-53.9 to -24.4)	1.8 (1.2 to 2.6)	1.6 (1.1 to 2.3)	-12.5 (-31.4 to 12.3)	-40.7 (-53.5 to -23.6)
Peripheral vascular disease	103.6 (68.5 to 138.5)	175.9 (129.7 to 213.8)	72.3 (6.5 to 171.3)	11.3 (-32.7 to 73.3)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	77.9 (-9.5 to 228.8)	21.2 (-37.5 to 124.0)
Endocarditis	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	54.9 (10.9 to 164.1)	3.2 (-26.1 to 74.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.0 (2.5 to 178.7)	6.1 (-30.9 to 83.0)
Other cardiovascular and circulatory diseases	43.2 (23.4 to 65.4)	80.6 (49.4 to 107.4)	87.9 (1.0 to 257.4)	24.7 (-32.4 to 136.8)	3.0 (1.5 to 5.1)	5.7 (3.0 to 8.4)	89.3 (1.0 to 263.1)	25.3 (-32.9 to 140.2)
Chronic respiratory diseases	-	-	-	-	31.7 (21.8 to 43.0)	39.5 (27.4 to 53.7)	25.8 (12.8 to 40.6)	-7.1 (-19.0 to 3.2)
Chronic obstructive pulmonary disease	262.3 (223.5 to 301.7)	379.6 (317.2 to 444.3)	44.0 (28.3 to 64.2)	-5.5 (-16.2 to 7.3)	12.2 (7.9 to 17.3)	16.9 (10.5 to 24.8)	39.4 (11.6 to 71.8)	-8.4 (-27.7 to 12.8)
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.9 (8.6 to 32.8)	-22.1 (-28.9 to -12.8)

Appendix Table G.4 - Ireland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.7 (-7.8 to 6.0)	-34.2 (-38.9 to -29.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.9 (-8.3 to 5.9)	-34.4 (-39.1 to -29.9)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	30.9 (13.7 to 47.4)	-14.6 (-26.4 to -3.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.5 (15.3 to 50.5)	-13.5 (-25.4 to -1.6)
Asthma	49.1 (38.3 to 451.8)	511.8 (482.3 to 542.7)	21.9 (10.2 to 35.2)	2.3 (-11.2 to 8.4)	18.4 (12.1 to 26.0)	22.5 (14.4 to 31.7)	22.4 (10.3 to 35.7)	2.4 (-11.2 to 8.6)
Interstitial lung disease and pulmonary sarcoidosis	0.3 (0.3 to 0.4)	0.5 (0.4 to 0.7)	50.7 (0.4 to 114.0)	-0.2 (-32.3 to 41.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	51.6 (0.8 to 118.6)	0.4 (-33.1 to 43.7)
Other chronic respiratory diseases	-	-	-	-	1.1 (0.6 to 1.7)	0.4 (0.3 to 0.7)	-58.3 (-71.1 to -42.0)	-72.6 (-80.9 to -62.2)
Cirrhosis	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	108.6 (78.8 to 146.2)	38.1 (18.9 to 63.4)
Cirrhosis due to hepatitis B	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	147.5 (35.5 to 371.6)	62.5 (-10.7 to 212.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	139.7 (20.4 to 376.1)	57.4 (-20.0 to 212.8)
Cirrhosis due to hepatitis C	0.3 (0.2 to 0.3)	0.6 (0.4 to 0.8)	121.6 (22.5 to 267.9)	45.9 (-20.1 to 140.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	125.7 (14.1 to 290.3)	49.5 (-24.8 to 156.0)
Cirrhosis due to alcohol use	0.3 (0.2 to 0.3)	0.4 (0.2 to 0.6)	59.8 (-15.5 to 169.2)	2.8 (-45.5 to 73.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	59.2 (-18.0 to 176.5)	2.9 (-47.3 to 77.5)
Cirrhosis due to other causes	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.4)	200.1 (73.2 to 426.5)	113.5 (24.8 to 269.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	179.9 (55.5 to 403.5)	99.1 (14.2 to 254.4)
Digestive diseases	-	-	-	-	7.0 (4.9 to 9.5)	11.6 (8.0 to 15.5)	63.8 (40.0 to 91.1)	9.6 (-4.6 to 28.3)
Peptic ulcer disease	32.1 (30.5 to 33.7)	18.4 (16.6 to 20.2)	-42.7 (-48.4 to -37.3)	-62.7 (-66.5 to -59.1)	0.9 (0.6 to 1.3)	0.7 (0.5 to 0.9)	-27.9 (-35.1 to -18.4)	-53.1 (-58.0 to -46.9)
Gastritis and duodenitis	14.7 (11.8 to 17.5)	20.9 (18.2 to 23.8)	42.1 (21.9 to 69.8)	-3.4 (-17.7 to 15.9)	0.6 (0.4 to 0.9)	0.8 (0.6 to 1.2)	34.7 (14.8 to 57.7)	-4.1 (-18.6 to 12.3)
Appendicitis	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-6.4 (-53.0 to 70.4)	-20.4 (-59.8 to 40.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-4.5 (-51.9 to 81.1)	-18.8 (-59.1 to 48.6)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	109.5 (61.6 to 180.4)	42.6 (10.6 to 89.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.8 (49.1 to 205.8)	43.3 (3.3 to 107.0)
Inguinal, femoral, and abdominal hernia	17.0 (11.4 to 23.9)	24.5 (17.6 to 31.2)	43.5 (-9.2 to 124.2)	0.2 (-38.0 to 49.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.5)	50.1 (-8.1 to 123.3)	0.7 (-37.4 to 48.6)
Inflammatory bowel disease	16.8 (14.6 to 19.5)	30.7 (27.1 to 34.7)	81.9 (48.6 to 125.4)	19.9 (-2.6 to 48.7)	3.5 (2.4 to 5.1)	6.4 (4.4 to 8.9)	82.5 (47.2 to 127.6)	20.5 (-3.0 to 50.0)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.6 (-28.6 to 101.6)	-11.1 (-51.1 to 36.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.9 (-34.1 to 123.4)	-9.6 (-53.3 to 50.2)
Gallbladder and biliary diseases	4.0 (3.1 to 4.9)	4.7 (3.5 to 6.2)	16.5 (-22.4 to 79.3)	-23.7 (-48.7 to 16.8)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	16.8 (-2.8 to 79.6)	-23.6 (-49.4 to 17.9)
Pancreatitis	1.3 (0.6 to 0.7)	1.3 (1.2 to 1.3)	90.4 (76.3 to 103.4)	24.9 (16.1 to 33.7)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	90.4 (63.4 to 122.9)	25.5 (7.5 to 46.7)
Other digestive diseases	-	-	-	-	1.1 (0.8 to 1.6)	2.5 (1.6 to 3.5)	115.4 (73.6 to 174.0)	44.1 (16.4 to 83.1)
Neurological disorders	-	-	-	-	37.0 (24.9 to 51.6)	54.3 (36.9 to 74.6)	46.6 (26.9 to 72.1)	2.7 (-11.2 to 20.3)
Alzheimer disease and other dementias	41.2 (33.5 to 49.3)	62.2 (49.7 to 77.4)	49.3 (11.7 to 112.6)	-3.8 (-27.4 to 37.1)	6.0 (4.2 to 8.1)	9.2 (6.3 to 12.9)	51.7 (12.4 to 116.3)	-2.7 (-27.4 to 38.9)
Parkinson disease	3.4 (2.0 to 4.7)	5.0 (3.1 to 6.9)	49.5 (31.8 to 62.2)	0.4 (-10.4 to 8.6)	0.6 (0.2 to 0.6)	0.6 (0.3 to 0.9)	49.7 (30.2 to 71.8)	1.1 (-11.9 to 14.6)
Epilepsy	12.4 (9.4 to 15.6)	12.5 (8.5 to 17.0)	1.2 (-35.6 to 51.0)	-23.6 (-51.1 to 14.5)	4.7 (3.0 to 6.7)	5.3 (3.1 to 8.0)	11.5 (-29.4 to 69.3)	-15.2 (-46.7 to 29.2)
Multiple sclerosis	4.6 (4.1 to 5.2)	11.5 (10.0 to 12.9)	148.2 (108.0 to 191.0)	59.3 (33.4 to 87.3)	1.5 (1.1 to 2.0)	3.8 (2.7 to 5.0)	147.5 (105.1 to 197.5)	58.9 (32.2 to 91.1)
Migraine	519.6 (429.3 to 636.5)	687.1 (536.8 to 830.1)	31.2 (1.0 to 76.0)	-8.7 (-27.1 to 27.0)	17.7 (10.1 to 27.2)	3.8 (1.3 to 36.3)	86.2 (0.7 to 74.7)	36.2 (-27.3 to 271.1)
Tension-type headache	643.4 (392.9 to 846.0)	1,208.9 (975.5 to 1,426.9)	86.0 (31.2 to 214.1)	3.8 (-5.1 to 135.0)	3.8 (0.4 to 1.8)	3.8 (0.9 to 3.3)	86.2 (29.5 to 212.8)	36.2 (-5.4 to 135.9)
Medication overuse headache	23.4 (15.0 to 32.2)	50.9 (32.4 to 70.9)	116.9 (62.6 to 191.1)	49.5 (12.4 to 100.4)	3.7 (2.0 to 5.7)	5.7 (4.4 to 12.6)	116.8 (63.2 to 192.5)	48.9 (12.3 to 102.1)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.2 (-10.1 to 107.7)	-0.8 (-35.0 to 48.7)	2.1 (1.4 to 3.0)	2.4 (1.6 to 3.3)	16.5 (-20.0 to 60.1)	-24.1 (-47.8 to 3.6)
Mental and substance use disorders	-	-	-	-	89.2 (63.9 to 116.5)	121.2 (87.3 to 158.2)	35.8 (30.3 to 41.5)	2.4 (-1.1 to 6.4)
Schizophrenia	9.6 (7.9 to 11.6)	14.0 (11.5 to 17.1)	46.1 (37.5 to 55.5)	-4.8 (-10.3 to 11.2)	6.1 (4.3 to 7.8)	9.0 (6.3 to 11.6)	46.7 (35.8 to 57.3)	-4.2 (-11.2 to 2.2)
Alcohol use disorders	42.7 (38.5 to 47.5)	65.6 (59.9 to 72.2)	53.5 (43.1 to 63.9)	15.1 (7.7 to 22.6)	4.3 (2.8 to 6.1)	6.6 (4.3 to 9.4)	53.8 (42.1 to 65.2)	15.6 (7.6 to 23.9)
Drug use disorders	-	-	-	-	7.7 (5.5 to 10.0)	10.5 (7.4 to 13.6)	37.2 (25.1 to 51.1)	3.0 (-6.3 to 13.2)
Opioid use disorders	11.8 (10.4 to 13.4)	16.3 (14.3 to 18.3)	38.2 (28.9 to 49.8)	-1.8 (-8.9 to 6.0)	4.9 (3.5 to 6.4)	6.8 (4.8 to 9.0)	38.5 (27.0 to 51.9)	-1.5 (-9.8 to 7.8)
Cocaine use disorders	4.4 (3.6 to 5.4)	7.1 (6.1 to 8.1)	61.6 (26.2 to 106.8)	25.8 (-2.0 to 60.8)	0.6 (0.4 to 0.9)	1.0 (0.6 to 1.4)	61.3 (23.0 to 116.2)	26.0 (-4.0 to 68.2)
Amphetamine use disorders	4.2 (4.2 to 5.5)	5.0 (5.0 to 6.2)	17.7 (-3.4 to 39.2)	0.5 (-18.5 to 17.6)	0.7 (0.4 to 1.0)	0.7 (0.4 to 1.1)	17.3 (-7.8 to 44.7)	0.9 (-21.6 to 23.2)
Cannabis use disorders	9.4 (8.6 to 10.2)	9.9 (9.1 to 10.9)	4.7 (-6.3 to 10.9)	-0.8 (-6.3 to 4.7)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	5.0 (-8.6 to 19.8)	-0.7 (-13.2 to 13.3)
Other drug use disorders	-	-	-	-	1.2 (0.8 to 1.8)	1.7 (1.1 to 2.5)	39.0 (-1.8 to 94.1)	12.8 (-20.5 to 56.8)
Depressive disorders	-	-	-	-	32.0 (21.7 to 44.9)	45.0 (30.6 to 61.6)	40.9 (28.0 to 55.8)	2.3 (-6.4 to 12.3)
Major depressive disorder	131.9 (109.0 to 157.2)	184.6 (154.4 to 212.4)	40.0 (25.5 to 57.1)	2.0 (-7.6 to 13.5)	2.0 (1.7 to 3.8)	2.0 (2.0 to 53.0)	39.9 (25.4 to 57.4)	2.4 (-7.4 to 14.1)
Dysthymia	53.3 (45.3 to 62.5)	78.0 (65.9 to 91.5)	46.4 (37.7 to 56.1)	0.9 (-4.8 to 7.9)	5.1 (3.4 to 7.3)	7.5 (5.0 to 10.8)	46.4 (36.5 to 57.0)	1.2 (-5.0 to 8.5)
Bipolar disorder	24.1 (20.4 to 28.2)	33.5 (28.4 to 38.5)	39.1 (30.7 to 48.2)	-0.7 (-6.4 to 4.9)	4.9 (3.0 to 7.2)	6.8 (4.1 to 10.1)	39.0 (29.0 to 49.7)	-0.5 (-7.0 to 7.0)
Anxiety disorders	190.3 (148.2 to 234.8)	256.2 (205.5 to 312.3)	34.1 (22.7 to 50.3)	4.3 (-3.0 to 13.0)	17.4 (11.2 to 25.4)	23.4 (15.2 to 33.8)	34.0 (22.9 to 49.8)	4.5 (-3.4 to 13.6)
Eating disorders	-	-	-	-	2.6 (1.3 to 4.4)	3.3 (1.6 to 5.6)	24.5 (11.5 to 39.3)	10.4 (2.8 to 21.6)
Anorexia nervosa	2.7 (1.4 to 4.5)	4.3 (2.1 to 7.6)	58.7 (28.6 to 96.5)	37.3 (14.9 to 67.0)	0.6 (0.3 to 1.1)	0.9 (0.4 to 1.7)	58.7 (26.4 to 98.9)	37.8 (12.0 to 68.8)
Bulimia nervosa	9.7 (5.3 to 17.6)	11.1 (5.9 to 20.0)	14.1 (3.9 to 27.6)	2.6 (-1.6 to 3.6)	2.0 (1.0 to 3.6)	2.3 (1.1 to 4.4)	14.2 (1.6 to 28.5)	2.7 (-3.1 to 8.7)
Autistic spectrum disorders	-	-	-	-	4.0 (2.8 to 5.5)	5.1 (3.5 to 6.9)	26.5 (22.3 to 30.9)	-0.4 (-3.8 to 3.0)
Autism	10.4 (9.8 to 11.0)	13.2 (12.4 to 13.9)	26.8 (25.8 to 27.9)	-9.6 (-0.6 to 0.5)	2.6 (1.7 to 3.5)	3.2 (2.1 to 4.5)	26.5 (20.6 to 33.0)	-0.4 (-5.0 to 4.7)
Asperger syndrome	14.9 (13.9 to 15.8)	18.8 (17.6 to 20.1)	26.7 (25.7 to 27.6)	-0.8 (-0.8 to -0.7)	1.5 (1.0 to 2.0)	1.9 (1.3 to 2.6)	26.6 (21.4 to 31.6)	-0.5 (-4.7 to 3.3)
Attention-deficit/hyperactivity disorder	23.3 (19.5 to 26.4)	20.9 (17.5 to 23.7)	-10.2 (-10.5 to -10.0)	-0.3 (-0.9 to -0.7)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-10.0 (-16.1 to -3.5)	-0.5 (-7.0 to 6.2)
Conduct disorder	36.9 (31.2 to 42.7)	31.8 (26.8 to 36.7)	-13.8 (-15.0 to -12.7)	-0.5 (-0.7 to -0.4)	4.4 (2.7 to 6.7)	3.8 (2.4 to 5.8)	-13.7 (-17.3 to -10.1)	-0.5 (-4.6 to 3.6)
Idiopathic intellectual disability	20.1 (15.1 to 25.5)	21.9 (15.6 to 28.6)	9.2 (-10.0 to 27.2)	-14.8 (-29.8 to -0.7)	1.2 (0.7 to 1.7)	1.3 (0.8 to 1.9)	8.7 (-1.4 to 27.8)	-14.9 (-30.8 to 0.3)
Other mental and substance use disorders	58.2 (54.8 to 61.5)	83.6 (78.8 to 88.5)	43.9 (41.7 to 46.1)	0.7 (-0.9 to 0.3)	4.3 (2.9 to 5.8)	6.2 (4.2 to 8.3)	43.9 (38.4 to 49.5)	-0.4 (-4.2 to 3.4)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	32.6 (23.1 to 43.3)	55.5 (39.2 to 74.4)	69.8 (50.2 to 91.8)	14.8 (2.1 to 29.3)
Diabetes mellitus	135.2 (103.7 to 170.6)	310.1 (236.7 to 408.0)	128.5 (64.8 to 223.2)	49.2 (8.2 to 112.7)	9.4 (5.9 to 13.4)	21.3 (13.6 to 31.6)	126.2 (58.7 to 217.6)	47.1 (2.8 to 106.8)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.5 (-5.8 to 9.0)	-15.6 (-21.2 to -9.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.5 (-5.8 to 9.0)	-15.6 (-21.2 to -9.5)
Chronic kidney disease	-	-	-	-	12.9 (8.9 to 17.3)	18.9 (12.9 to 25.7)	47.0 (38.5 to 53.6)	-0.2 (-4.8 to 3.2)
Chronic kidney disease due to diabetes mellitus	55.5 (35.0 to 88.6)	91.9 (61.5 to 164.6)	65.6 (13.3 to 139.5)	11.1 (-24.7 to 57.5)	2.1 (1.2 to 3.1)	3.8 (2.3 to 5.7)	84.7 (31.0 to 155.9)	16.6 (-16.3 to 60.3)
Chronic kidney disease due to hypertension	57.1 (41.4 to 78.9)	70.2 (44.2 to 108.6)	22.0 (-13.5 to 79.8)	-9.8 (-35.3 to 34.2)	3.3 (2.3 to 4.6)	2.0 (1.2 to 2.9)	-40.7 (-58.2 to -19.4)	-60.1 (-71.3 to -46.3)
Chronic kidney disease due to glomerulonephritis	90.0 (54.5 to 135.1)	58.0 (41.6 to 80.9)	-34.8 (-52.1 to -9.6)	-51.7 (-64.5 to -34.0)	1.5 (0.9 to 2.2)	3.6 (2.4 to 5.1)	141.6 (79.1 to 227.7)	69.2 (25.0 to 125.0)
Chronic kidney disease due to other causes	193.8 (142.4 to 271.8)	258.4 (189.0 to 354.4)	33.9 (13.9 to 53.8)	6.0 (-14.6 to 13.5)	6.0 (4.1 to 8.2)	9.5 (6.3 to 13.2)	58.7 (32.7 to 88.6)	10.0 (-7.2 to 30.2)
Urinary diseases and male infertility	-	-	-	-	2.9 (1.8 to 4.2)	5.0 (3.2 to 7.3)	70.1 (44.9 to 105.8)	14.8 (-2.0 to 37.6)
Interstitial nephritis and urinary tract infections	0.3 (0.2 to 0.5)	0.7 (0.5 to 0.9)	28.5 (44.6 to 248.1)	58.9 (0.1 to 137.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	128.4 (40.2 to 266.7)	59.8 (2.5 to 153.8)

Appendix Table G.4 - Ireland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Urolithiasis	40.9 (24.6 to 66.6)	101.1 (58.0 to 165.7)	143.6 (112.9 to 224.0)	0.3 (36.9 to 113.2)	0.3 (0.2 to 0.6)	0.8 (0.4 to 1.6)	159.7 (124.2 to 243.8)	58.4 (44.2 to 125.4)
Benign prostatic hyperplasia	69.2 (56.2 to 79.6)	108.7 (92.8 to 123.0)	55.4 (29.8 to 99.1)	4.8 (-12.3 to 33.3)	2.5 (1.5 to 3.6)	3.9 (2.4 to 5.5)	56.5 (30.3 to 99.2)	5.7 (-11.8 to 33.6)
Male infertility due to other causes	14.7 (10.9 to 19.0)	20.0 (13.1 to 27.5)	35.7 (-18.2 to 111.3)	-6.0 (-43.3 to 46.7)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	36.2 (-18.5 to 114.2)	-5.8 (-44.3 to 48.8)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.3)	238.7 (92.7 to 401.6)	121.0 (24.1 to 228.8)
Gynecological diseases	-	-	-	-	3.9 (2.4 to 6.0)	5.8 (3.7 to 9.0)	90.5 (27.8 to 76.5)	4.2 (-14.4 to 19.3)
Uterine fibroids	120.2 (102.4 to 139.5)	195.9 (167.1 to 226.7)	62.9 (62.0 to 64.0)	1.8 (1.7 to 1.9)	1.0 (0.5 to 1.9)	1.6 (0.8 to 3.2)	63.5 (20.9 to 121.8)	2.7 (-24.1 to 38.7)
Polycystic ovarian syndrome	55.4 (48.0 to 63.5)	83.5 (71.3 to 95.1)	50.8 (21.1 to 90.2)	5.0 (-15.8 to 32.6)	0.5 (0.2 to 1.0)	0.8 (0.4 to 1.5)	48.6 (20.0 to 86.7)	3.7 (-16.9 to 30.6)
Female infertility due to other causes	3.9 (0.4 to 9.8)	4.2 (0.4 to 11.8)	-0.4 (-90.5 to 822.5)	-27.7 (-93.3 to 539.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	8.3 (-90.3 to 816.7)	-23.3 (-93.4 to 536.7)
Endometriosis	9.6 (7.1 to 12.3)	13.5 (10.5 to 16.5)	41.5 (-3.0 to 109.9)	-4.3 (-34.9 to 40.9)	0.9 (0.5 to 1.3)	1.3 (0.8 to 1.8)	41.6 (-4.4 to 109.2)	-4.2 (-34.8 to 39.4)
Genital prolapse	191.0 (168.8 to 209.9)	292.2 (261.7 to 322.3)	52.9 (32.5 to 77.5)	-1.7 (-14.7 to 14.2)	0.6 (0.3 to 1.1)	0.9 (0.4 to 1.7)	52.9 (31.7 to 78.0)	-1.6 (-15.4 to 14.6)
Premenstrual syndrome	79.1 (53.8 to 106.1)	115.7 (85.9 to 145.1)	49.3 (-0.8 to 126.7)	10.5 (-27.2 to 64.7)	0.7 (0.4 to 1.1)	1.0 (0.6 to 1.5)	48.5 (-2.6 to 126.4)	10.2 (-28.1 to 67.0)
Other gynecological diseases	7.3 (5.3 to 19.0)	10.1 (7.9 to 19.1)	45.4 (-34.2 to 201.4)	1.4 (-57.0 to 143.1)	0.2 (0.1 to 0.6)	0.2 (0.1 to 0.6)	45.9 (-62.1 to 462.1)	-5.2 (-77.2 to 329.3)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	2.2 (1.5 to 3.2)	2.5 (1.7 to 3.6)	14.0 (-3.1 to 36.4)	-3.9 (-17.6 to 12.4)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.5 (-10.9 to 13.5)	-10.1 (-20.0 to 2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.5 (-16.9 to 14.9)	-9.0 (-18.5 to 4.4)
Thalassemia trait	34.4 (27.3 to 41.6)	44.8 (35.8 to 54.9)	30.0 (19.8 to 43.4)	0.1 (-8.3 to 10.0)	1.0 (0.6 to 1.4)	1.2 (0.8 to 1.7)	21.6 (2.4 to 46.1)	1.2 (-14.3 to 19.7)
Sickle cell disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	0.4 (-11.5 to 15.2)	-14.3 (-24.6 to -2.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.6 (-5.4 to 15.9)	-10.7 (-19.2 to -1.8)
Sickle cell trait	57.6 (52.9 to 62.4)	63.8 (57.9 to 70.5)	11.0 (3.4 to 18.5)	-14.6 (-20.5 to -8.9)	0.8 (0.5 to 1.2)	0.8 (0.5 to 1.1)	-4.5 (-2.4 to 24.2)	-17.5 (-3.7 to 5.6)
G6PD deficiency	26.4 (16.3 to 38.2)	37.6 (19.4 to 55.4)	42.3 (-29.9 to 188.8)	0.0 (-46.2 to 122.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.4 (-70.4 to 53.4)	-31.3 (-76.0 to 18.9)
G6PD trait	454.3 (413.2 to 489.6)	584.0 (531.6 to 636.1)	28.8 (11.1 to 45.8)	-1.2 (-14.7 to 11.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	17.6 (-45.9 to 275.2)	39.8 (-55.8 to 217.6)
Other hemoglobinopathies and hemolytic anemias	20.3 (18.7 to 21.7)	27.9 (25.0 to 31.5)	37.3 (21.2 to 57.2)	7.4 (-5.2 to 21.1)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.9)	25.8 (-1.7 to 69.4)	5.1 (-18.5 to 34.1)
Endocrine, metabolic, blood, and immune disorders	42.3 (39.1 to 45.7)	56.4 (51.6 to 61.1)	33.3 (17.8 to 49.8)	2.2 (-9.6 to 13.8)	1.3 (0.9 to 1.9)	1.8 (1.2 to 2.5)	35.2 (16.2 to 56.8)	3.3 (-10.6 to 18.9)
Musculoskeletal disorders	-	-	-	-	64.2 (46.1 to 86.0)	93.1 (66.1 to 123.3)	44.6 (29.7 to 62.5)	-2.9 (-13.3 to 9.8)
Rheumatoid arthritis	18.7 (17.3 to 19.9)	27.6 (25.5 to 29.9)	47.8 (33.5 to 65.5)	-1.5 (-10.9 to 10.2)	4.3 (3.0 to 5.7)	6.4 (4.5 to 8.4)	49.0 (33.7 to 67.7)	-0.6 (-10.7 to 11.7)
Osteoarthritis	156.3 (134.0 to 180.2)	244.3 (204.4 to 282.9)	54.9 (29.8 to 97.6)	-0.1 (-16.4 to 27.9)	5.4 (3.5 to 7.9)	8.4 (5.4 to 12.2)	55.3 (30.2 to 99.2)	0.3 (-16.1 to 28.4)
Low back and neck pain	-	-	-	-	44.2 (30.6 to 60.2)	60.1 (40.6 to 81.7)	35.7 (14.4 to 62.5)	-7.5 (-22.1 to 11.0)
Low back pain	179.2 (151.8 to 209.0)	230.6 (202.2 to 267.9)	29.0 (3.4 to 65.4)	-11.3 (-29.5 to 14.1)	19.8 (12.9 to 28.1)	25.5 (17.0 to 35.7)	29.1 (3.8 to 66.2)	-11.2 (-29.7 to 14.4)
Neck pain	249.1 (214.3 to 285.9)	352.9 (274.6 to 432.9)	41.2 (7.1 to 87.9)	-4.6 (-27.2 to 26.8)	24.4 (16.8 to 33.4)	34.6 (21.8 to 50.9)	41.0 (6.6 to 88.2)	-4.3 (-27.3 to 26.4)
Gout	6.3 (5.6 to 6.9)	9.8 (8.7 to 10.8)	55.6 (33.5 to 78.9)	-0.1 (-14.4 to 14.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	56.3 (27.1 to 90.3)	0.3 (-18.5 to 22.1)
Other musculoskeletal disorders	112.8 (90.9 to 134.3)	196.2 (156.3 to 235.4)	74.4 (61.1 to 85.1)	13.7 (7.0 to 19.4)	10.3 (6.8 to 14.5)	17.9 (11.7 to 25.9)	74.8 (61.2 to 86.4)	14.1 (6.5 to 20.7)
Other non-communicable diseases	-	-	-	-	65.9 (45.0 to 95.0)	86.5 (59.5 to 122.3)	46.2 (23.5 to 38.4)	-6.2 (-8.2 to 0.7)
Congenital anomalies	-	-	-	-	7.7 (5.8 to 9.9)	10.8 (8.1 to 13.7)	39.3 (23.5 to 58.1)	3.9 (-8.0 to 17.7)
Neural tube defects	2.7 (2.4 to 3.1)	2.9 (2.5 to 3.3)	5.8 (-12.9 to 28.5)	-16.0 (-30.9 to 1.8)	0.9 (0.6 to 1.2)	1.0 (0.6 to 1.3)	5.3 (-17.8 to 42.8)	-15.4 (-33.9 to 13.8)
Congenital heart anomalies	24.2 (20.9 to 28.2)	29.9 (26.0 to 35.2)	23.5 (1.2 to 52.0)	-4.2 (-21.4 to 17.9)	0.9 (0.4 to 1.6)	1.1 (0.5 to 2.0)	26.0 (4.2 to 51.5)	-1.5 (-18.5 to 17.9)
Orofacial clefts	4.7 (3.8 to 5.6)	5.6 (4.8 to 6.7)	20.6 (-7.1 to 54.2)	-7.0 (-28.4 to 18.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	16.6 (-18.3 to 28.3)	-10.0 (-36.8 to 28.3)
Down syndrome	8.6 (7.2 to 10.2)	13.0 (10.3 to 17.4)	50.0 (14.8 to 107.0)	10.1 (-16.0 to 51.6)	1.2 (0.9 to 1.6)	1.9 (1.3 to 2.8)	12.2 (20.6 to 118.7)	5.4 (-14.8 to 54.4)
Turner syndrome	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	34.5 (-17.0 to 93.2)	4.8 (-35.0 to 50.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.1 (-17.4 to 99.5)	5.4 (-35.8 to 55.7)
Klinefelter syndrome	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	50.8 (1.5 to 144.3)	16.4 (-21.7 to 88.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.8 (-3.7 to 162.0)	16.4 (-29.0 to 96.7)
Chromosomal unbalanced rearrangements	15.0 (12.5 to 19.2)	21.7 (17.8 to 26.8)	44.8 (5.4 to 94.8)	6.4 (-22.7 to 42.3)	2.1 (1.5 to 2.9)	3.2 (2.3 to 4.4)	52.7 (9.9 to 104.8)	7.7 (-22.2 to 44.9)
Other congenital anomalies	10.2 (6.8 to 13.7)	11.7 (7.2 to 17.3)	14.5 (-14.5 to 45.0)	42.5 (-35.6 to 6.7)	3.4 (1.7 to 3.6)	3.4 (2.2 to 4.9)	24.6 (11.7 to 69.3)	4.5 (-12.9 to 32.3)
Skin and subcutaneous diseases	-	-	-	-	25.2 (16.1 to 38.6)	30.8 (20.0 to 46.0)	22.6 (23.5 to 35.1)	-1.8 (-11.2 to 7.5)
Dermatitis	238.4 (191.0 to 286.1)	317.5 (252.5 to 385.1)	33.2 (28.4 to 37.9)	-0.1 (-0.2 to 0.1)	7.2 (4.6 to 10.6)	9.3 (6.0 to 13.6)	28.5 (23.2 to 34.3)	0.2 (-2.4 to 2.7)
Psoriasis	47.6 (41.4 to 54.5)	67.4 (58.0 to 77.9)	41.5 (38.3 to 44.8)	-0.0 (-0.2 to 0.1)	3.8 (2.6 to 5.3)	5.4 (3.7 to 7.6)	41.5 (35.0 to 48.6)	0.3 (-3.7 to 4.6)
Cellulitis	1.3 (0.8 to 1.8)	1.8 (1.2 to 2.6)	42.9 (25.6 to 63.9)	0.1 (-11.7 to 14.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	42.1 (17.2 to 78.2)	1.2 (-16.4 to 25.5)
Pyoderma	3.2 (2.3 to 4.5)	3.9 (2.9 to 6.0)	23.7 (-2.3 to 49.0)	-8.0 (-23.9 to 7.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.6 (-4.7 to 50.5)	-8.8 (-25.6 to 8.4)
Scabies	2.4 (2.0 to 2.8)	2.5 (2.1 to 2.8)	0.4 (-18.7 to 25.8)	-19.8 (-35.0 to 2.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.3 (-21.5 to 31.0)	-19.6 (-36.6 to 6.6)
Fungal skin diseases	242.9 (212.3 to 271.9)	335.1 (296.1 to 369.2)	37.9 (34.2 to 42.0)	-0.4 (-0.5 to -0.2)	1.4 (0.5 to 2.9)	1.9 (0.8 to 3.9)	37.9 (33.8 to 42.1)	-0.2 (-1.0 to 0.6)
Viral skin diseases	82.2 (66.2 to 98.6)	95.0 (75.5 to 114.9)	15.5 (11.0 to 20.2)	15.5 (-1.5 to 3.9)	0.7 (1.5 to 3.9)	0.9 (1.7 to 4.6)	0.8 (10.0 to 21.1)	0.8 (-2.5 to 4.2)
Acne vulgaris	608.5 (447.6 to 809.6)	559.3 (443.4 to 709.6)	-7.5 (-37.3 to 36.4)	-8.9 (-39.6 to 33.2)	6.6 (2.9 to 13.3)	6.1 (2.8 to 11.5)	-7.5 (-37.5 to 36.8)	-8.8 (-39.4 to 33.7)
Alopecia areata	5.6 (5.2 to 6.1)	7.9 (7.3 to 8.5)	40.1 (24.8 to 54.2)	-1.1 (-11.4 to 8.7)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	40.2 (21.8 to 58.8)	-0.7 (-13.9 to 12.4)
Pruritus	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.8)	46.7 (-30.5 to 132.4)	-3.2 (-52.5 to 53.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.0 (-32.8 to 148.5)	-3.9 (-53.7 to 62.5)
Urticaria	27.1 (19.7 to 36.2)	38.3 (29.0 to 47.8)	42.2 (-3.6 to 111.6)	2.2 (-28.0 to 59.2)	1.5 (0.9 to 2.5)	2.2 (1.4 to 3.3)	41.6 (-4.6 to 109.9)	6.1 (-28.2 to 58.2)
Decubitus ulcer	1.8 (1.4 to 2.1)	2.3 (1.8 to 3.0)	32.2 (-3.9 to 74.9)	-10.9 (-34.6 to 16.9)	0.2 (0.2 to 0.4)	0.3 (0.2 to 0.5)	31.4 (-5.8 to 81.8)	-11.0 (-35.5 to 22.4)
Other skin and subcutaneous diseases	251.9 (149.9 to 419.5)	372.9 (217.8 to 631.0)	48.1 (39.3 to 55.3)	-0.1 (-2.9 to 2.7)	1.5 (0.6 to 3.2)	2.2 (0.9 to 4.8)	48.4 (38.9 to 55.5)	0.1 (-2.9 to 3.2)
Sense organ diseases	-	-	-	-	22.9 (15.3 to 33.0)	31.3 (21.0 to 44.5)	36.6 (27.4 to 46.4)	-8.1 (-14.2 to -1.7)
Glaucoma	3.9 (2.7 to 5.2)	4.2 (2.8 to 5.7)	4.7 (-16.2 to 32.3)	-31.4 (-44.6 to -13.6)	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.6)	3.3 (-21.5 to 28.8)	-9.0 (-47.9 to -13.9)
Cataract	9.3 (5.7 to 12.9)	9.6 (6.2 to 14.3)	1.3 (-24.8 to 42.1)	-34.1 (-51.2 to -9.7)	0.6 (0.3 to 0.9)	0.6 (0.4 to 1.0)	5.3 (-20.5 to 44.0)	-31.6 (-48.3 to -7.0)
Macular degeneration	12.5 (8.8 to 17.3)	18.9 (13.7 to 24.5)	52.6 (22.3 to 98.8)	-2.6 (-20.9 to 24.1)	0.8 (0.5 to 1.2)	1.1 (0.7 to 1.7)	47.7 (22.2 to 83.7)	-6.3 (-22.4 to 13.8)
Uncorrected refractive error	369.2 (302.8 to 442.1)	524.4 (431.2 to 620.2)	42.9 (8.0 to 89.1)	-3.7 (-27.1 to 27.9)	5.0 (2.8 to 8.5)	6.7 (3.8 to 11.3)	35.0 (9.6 to 67.7)	-7.6 (-24.9 to 14.2)
Age-related and other hearing loss	458.6 (397.9 to 517.2)	636.3 (537.5 to 736.7)	38.8 (30.7 to 45.9)	-8.6 (-13.7 to -4.4)	13.3 (8.6 to 19.9)	18.8 (12.4 to 27.7)	41.3 (36.0 to 54.2)	-6.8 (-13.8 to 2.0)
Other vision loss	10.5 (8.3 to 13.2)	9.6 (7.3 to 12.4)	-8.2 (-22.6 to 8.3)	-37.2 (-46.6 to -27.0)	0.7 (0.5 to 1.0)	0.7 (0.5 to 1.1)	2.6 (-10.1 to 23.5)	-29.7 (-38.5 to -15.9)
Other sense organ diseases	83.7 (80.2 to 87.2)	110.1 (104.6 to 115.6)	31.7 (23.0 to 40.4)	-0.1 (-6.7 to 6.4)	2.2 (1.4 to 3.2)	2.9 (1.8 to 4.2)	31.2 (22.0 to 41.2)	-0.1 (-7.3 to 7.2)
Oral disorders	-	-	-	-	10.0 (6.5 to 14.8)	13.6 (8.6 to 20.2)	35.6 (24.7 to 47.2)	-7.5 (-15.0 to 0.4)
Deciduous caries	178.0 (168.8 to 188.0)	184.8 (173.2 to 195.8)	3.9 (-4.3 to 12.0)	-1.0 (-8.7 to 7.1)	0.0 (-0.1 to 0.1)	0.0 (0.0 to 0.1)	3.8 (-7.4 to 16.8)	-1.1 (-11.6 to 11.5)
Permanent caries	1,250.2 (1,134.1 to 1,351.6)	1,841.7 (1,705.0 to 1,963.9)	46.7 (31.2 to 67.4)	46.2 (-2.5 to 30.4)	0.7 (0.3 to 1.4)	1.1 (0.5 to 2.1)	46.5 (31.2 to 67.7)	14.3 (2.7 to 30.8)
Periodontal diseases	185.9 (168.8 to 202.8)	325.7 (295.7 to 357.7)	75.8 (51.3 to 99.4)	12.5 (-3.1 to 27.5)	1.2 (0.2 to 2.5)	2.1 (0.8 to 4.4)	76.0 (51.4 to 99.4)	12.7 (-3.0 to 27.8

Appendix Table G.4 - Ireland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	62.0 (57.7 to 66.2)	86.1 (81.4 to 90.7)	38.9 (28.2 to 51.0)	0.8 (-7.1 to 9.8)	1.8 (1.1 to 2.7)	2.5 (1.5 to 3.7)	38.8 (27.3 to 52.0)	1.9 (-7.4 to 10.7)
Injuries	-	-	-	-	35.6 (27.1 to 45.6)	33.7 (24.1 to 45.7)	-5.6 (-16.2 to 5.5)	-37.1 (-44.1 to -29.9)
Transport injuries	-	-	-	-	6.3 (4.8 to 8.1)	4.1 (2.9 to 5.4)	-36.4 (-43.1 to -28.3)	-57.4 (-62.0 to -51.9)
Road injuries	-	-	-	-	6.0 (4.6 to 7.7)	3.4 (2.4 to 4.5)	-43.9 (-49.9 to -36.7)	-62.3 (-66.4 to -57.4)
Pedestrian road injuries	-	-	-	-	1.4 (1.0 to 1.8)	0.7 (0.5 to 1.0)	-47.7 (-54.3 to -40.6)	-47.9 (-68.9 to -59.6)
Cyclist road injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.3 (0.2 to 0.4)	-57.3 (-63.3 to -50.0)	-70.3 (-74.5 to -65.2)
Motorcyclist road injuries	-	-	-	-	0.8 (0.6 to 1.1)	0.4 (0.3 to 0.5)	-56.2 (-64.0 to -47.0)	-71.6 (-76.6 to -65.4)
Motor vehicle road injuries	-	-	-	-	3.1 (2.4 to 4.0)	2.0 (1.5 to 2.6)	-35.9 (-42.6 to -28.7)	-57.3 (-61.7 to -52.4)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other transport injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.7 (0.5 to 0.9)	113.7 (92.9 to 136.1)	43.2 (29.9 to 57.9)
Unintentional injuries	-	-	-	-	28.9 (21.9 to 37.0)	29.2 (20.9 to 39.5)	1.0 (-10.6 to 12.7)	-32.7 (-40.1 to -25.1)
Falls	-	-	-	-	20.7 (15.8 to 26.3)	22.2 (15.9 to 30.1)	7.3 (-7.1 to 22.8)	-28.8 (-38.2 to -18.9)
Drowning	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-19.2 (-29.0 to -9.0)	-45.9 (-52.5 to -39.2)
Fire, heat, and hot substances	-	-	-	-	0.7 (0.5 to 1.1)	0.7 (0.4 to 1.1)	-0.1 (-19.8 to 4.5)	-38.1 (-45.5 to -28.8)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.2 (-32.6 to 1.5)	-42.9 (-53.3 to -30.2)
Exposure to mechanical forces	-	-	-	-	5.3 (4.0 to 6.9)	3.5 (2.4 to 4.8)	-34.8 (-41.2 to -27.3)	-54.2 (-58.3 to -49.0)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-48.0 (-54.7 to -39.8)	-63.9 (-68.4 to -58.2)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other exposure to mechanical forces	-	-	-	-	5.2 (3.9 to 6.8)	3.4 (2.4 to 4.7)	-35.0 (-41.4 to -27.3)	-54.3 (-58.4 to -49.1)
Adverse effects of medical treatment	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.4)	43.0 (29.4 to 56.9)	-0.2 (-9.4 to 8.8)
Animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	34.3 (21.8 to 46.9)	-5.2 (-13.5 to 4.4)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.2 (13.2 to 64.6)	-2.8 (-18.7 to 17.6)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	33.9 (20.5 to 48.3)	-5.8 (-14.9 to 4.4)
Foreign body	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	7.5 (-5.7 to 21.4)	-23.6 (-33.5 to -12.8)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.9 (-16.8 to 9.9)	-34.6 (-42.2 to -23.3)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	18.9 (6.4 to 34.0)	-12.2 (-22.2 to 0.1)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	8.4 (-7.5 to 26.6)	-23.2 (-34.7 to -9.4)
Other unintentional injuries	-	-	-	-	1.6 (1.1 to 2.1)	2.1 (1.5 to 2.9)	34.2 (16.5 to 55.5)	-13.4 (-24.7 to 0.3)
Self-harm and interpersonal violence	-	-	-	-	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.6)	8.5 (-0.9 to 18.0)	-28.6 (-34.7 to -22.4)
Self-harm	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	46.3 (28.1 to 63.7)	-6.0 (-17.0 to 6.1)
Interpersonal violence	-	-	-	-	0.3 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-17.6 (-25.5 to -8.3)	-44.8 (-50.0 to -38.5)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.9 (-13.9 to 7.2)	-37.0 (-43.6 to -30.0)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.2 (-4.3 to 14.6)	-30.9 (-36.3 to -24.2)
Assault by other means	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-23.0 (-31.0 to -13.3)	-48.0 (-53.8 to -41.5)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.9 (-67.4 to 8.9)	-52.6 (-76.6 to -15.8)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.9 (-67.4 to 8.9)	-52.6 (-76.6 to -15.8)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Israel prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
All causes	-	-	-	-	455.1 (339.8 to 584.6)	849.2 (630.4 to 1,096.0)	86.2 (78.9 to 94.4)	86.2 (4.5 to 3.9)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	27.0 (18.8 to 37.6)	46.8 (32.1 to 65.1)	72.0 (52.7 to 105.9)	6.0 (-5.9 to 27.9)
HIV/AIDS and tuberculosis	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.8)	103.9 (60.3 to 158.7)	16.9 (-7.6 to 48.6)
Tuberculosis	0.7 (0.6 to 0.7)	1.0 (1.0 to 1.1)	56.3 (49.2 to 64.0)	-10.5 (-14.4 to -6.0)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	55.7 (23.5 to 94.7)	-10.5 (-28.5 to 12.3)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	137.8 (157.0 to 529.4)	2.0 (-14.7 to 24.1)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	127.5 (30.0 to 228.7)	26.7 (-26.9 to 83.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	127.5 (30.0 to 229.6)	26.7 (-26.9 to 84.6)
HIV/AIDS resulting in other diseases	0.4 (0.2 to 0.7)	2.5 (1.0 to 4.2)	538.5 (322.4 to 786.6)	260.0 (139.8 to 396.5)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.4)	329.3 (157.0 to 531.8)	138.2 (41.7 to 248.9)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	2.4 (1.5 to 3.6)	3.8 (2.4 to 5.7)	59.1 (51.1 to 69.2)	-6.4 (-11.2 to -0.7)
Diarrheal diseases	1.9 (1.7 to 2.1)	2.9 (2.7 to 3.2)	58.0 (37.3 to 81.6)	-6.9 (-18.7 to 6.2)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	59.1 (28.6 to 86.1)	-6.8 (-23.3 to 10.0)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.3 (47.1 to 98.5)	-28.5 (-68.1 to 20.5)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.0 (-1.9 to 38.1)	-30.0 (-41.1 to -16.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.0 (-2.0 to 38.2)	-30.0 (-41.1 to -16.4)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.2 (43.5 to 109.7)	5.1 (-13.3 to 28.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.2 (43.4 to 110.0)	5.1 (-13.3 to 28.3)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.4 (-99.2 to 3,883.3)	-59.1 (-99.5 to 3,883.3)
Lower respiratory infections	0.3 (0.3 to 0.3)	0.4 (0.4 to 0.4)	41.7 (34.5 to 49.1)	-25.2 (-28.8 to -21.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	41.6 (14.2 to 76.5)	-23.9 (-37.9 to -6.2)
Upper respiratory infections	72.5 (69.1 to 75.4)	122.5 (118.0 to 127.9)	68.9 (60.1 to 79.9)	0.6 (-4.8 to 7.1)	0.9 (0.5 to 1.4)	1.4 (0.8 to 2.4)	68.5 (57.7 to 81.2)	0.5 (-5.9 to 7.9)
Otitis media	50.7 (45.5 to 55.7)	75.4 (67.2 to 84.7)	48.7 (33.8 to 66.1)	-13.1 (-21.8 to -2.0)	0.9 (0.5 to 1.5)	1.3 (0.8 to 2.2)	48.0 (32.9 to 65.4)	-13.5 (-22.2 to -2.6)
Meningitis	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	63.4 (25.2 to 124.1)	-1.7 (-24.0 to 34.4)
Pneumococcal meningitis	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	61.2 (20.1 to 104.0)	-8.3 (-31.0 to 15.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	65.7 (14.5 to 116.4)	2.0 (-31.8 to 27.3)
H influenzae type B meningitis	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.4)	61.6 (-16.4 to 206.5)	-4.6 (-49.7 to 88.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	95.3 (-20.1 to 271.6)	20.7 (-50.3 to 132.3)
Meningococcal meningitis	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.4)	51.3 (-12.5 to 158.0)	-13.7 (-47.7 to 53.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.0 (-10.6 to 217.0)	-5.3 (-46.6 to 89.8)
Other meningitis	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.5)	47.3 (5.0 to 121.1)	-13.2 (-36.2 to 34.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	54.2 (-3.7 to 182.7)	-7.1 (-41.4 to 72.2)
Encephalitis	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.8)	80.6 (49.7 to 129.8)	-9.9 (-17.8 to 27.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	95.7 (57.2 to 150.0)	8.0 (-12.9 to 39.3)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.1 (-90.0 to 975.6)	-47.6 (-94.2 to 540.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.1 (-90.2 to 990.3)	-47.6 (-94.3 to 544.9)
Whooping cough	0.6 (0.5 to 0.8)	0.8 (0.6 to 1.0)	24.6 (22.6 to 26.6)	-21.6 (-22.9 to -20.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	25.8 (1.6 to 57.2)	-20.8 (-36.1 to -1.2)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-64.6 (-79.3 to -43.2)	-79.1 (-87.9 to -66.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-64.0 (-80.7 to -39.0)	-78.6 (-88.5 to -64.0)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.2 (-81.9 to -67.4)	-94.4 (-88.6 to -79.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-94.4 (-81.9 to -67.3)	-94.4 (-88.6 to -79.4)
Varicella and herpes zoster	4.0 (3.6 to 4.4)	6.9 (6.2 to 7.6)	74.7 (46.9 to 100.0)	-0.5 (-17.1 to 15.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	85.8 (39.0 to 137.8)	-0.8 (-25.9 to 27.4)
Neglected tropical diseases and malaria	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	17.3 (-22.4 to 65.6)	-36.9 (-58.4 to -9.1)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	128.4 (-48.1 to 678.5)	38.3 (-68.5 to 370.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	133.7 (-46.9 to 689.9)	41.6 (-67.8 to 376.2)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.8 (43.3 to 175.1)	16.0 (-15.8 to 61.0)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.3 (42.9 to 148.8)	9.8 (-16.6 to 45.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.3 (42.8 to 149.5)	9.8 (-16.6 to 45.5)
Cutaneous and mucocutaneous leishmaniasis	0.4 (0.3 to 0.6)	0.8 (0.6 to 1.2)	98.3 (57.8 to 148.3)	16.0 (-8.8 to 43.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.6 (42.8 to 178.7)	16.3 (-16.8 to 63.4)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-23.7 (-74.3 to 155.7)	-59.5 (-86.3 to 37.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.9 (-73.5 to 163.6)	-57.6 (-85.7 to 44.4)
Cystic echinococcosis	0.3 (0.3 to 0.3)	0.3 (0.3 to 0.4)	20.2 (9.8 to 27.8)	-36.2 (-41.4 to -32.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.5 (-6.3 to 50.2)	-36.4 (-49.7 to -18.8)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.9 (-61.2 to 46.1)	-27.1 (-77.2 to -34.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.9 (-61.3 to 46.4)	27.1 (-77.2 to -14.6)
Intestinal nematode infections	-	-	-	-	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	222.8 (106.7 to 422.9)	86.7 (19.2 to 204.5)
Maternal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	43.3 (-0.6 to 117.3)	-13.7 (-40.4 to 31.3)
Maternal hemorrhage	2.0 (1.3 to 2.7)	3.3 (1.8 to 4.7)	65.6 (-8.0 to 167.9)	0.0 (-44.7 to 62.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	30.7 (-46.6 to 208.3)	-21.3 (-68.2 to 88.1)
Maternal sepsis and other maternal infections	0.6 (0.2 to 1.2)	0.6 (0.2 to 1.2)	-5.2 (-73.8 to 189.9)	-46.1 (-85.0 to 67.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.7 (-37.5 to 111.6)	-32.1 (-62.5 to 27.7)
Maternal hypertensive disorders	0.8 (0.5 to 1.2)	1.3 (0.8 to 1.8)	54.7 (43.5 to 67.0)	-6.2 (-13.0 to 1.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	55.2 (25.2 to 89.3)	-5.9 (-24.3 to 14.8)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.5 (44.5 to 72.3)	-4.4 (-12.9 to 4.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.5 (44.4 to 72.4)	-4.4 (-13.0 to 4.0)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	64.2 (52.9 to 77.2)	-0.7 (-7.5 to 7.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.2 (52.8 to 77.3)	-0.7 (-7.5 to 7.2)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	58.2 (-10.0 to 192.7)	-4.6 (-45.8 to 75.8)
Neonatal disorders	-	-	-	-	5.9 (4.0 to 8.3)	13.4 (8.3 to 20.8)	118.3 (56.4 to 259.3)	31.2 (-6.3 to 115.7)
Preterm birth complications	26.4 (15.5 to 46.2)	57.4 (32.4 to 107.8)	111.5 (62.7 to 215.6)	25.2 (-3.8 to 85.0)	3.4 (2.2 to 5.0)	7.8 (4.7 to 13.0)	120.3 (52.1 to 314.9)	31.7 (-8.9 to 147.5)
Neonatal encephalopathy due to birth asphyxia and trauma	5.3 (3.1 to 9.7)	5.1 (2.7 to 11.6)	-8.1 (-39.2 to 46.5)	-44.7 (-63.3 to -12.7)	1.3 (0.8 to 1.8)	1.2 (0.8 to 1.8)	-3.6 (-36.3 to 56.3)	-41.0 (-61.3 to -5.0)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.7 (88.4 to 136.9)	117.7 (20.5 to 51.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.0 (49.9 to 186.3)	36.2 (-4.1 to 83.1)
Hemolytic disease and other neonatal jaundice	1.4 (0.5 to 3.2)	1.9 (0.6 to 8.1)	-0.2 (-76.1 to 808.1)	-39.9 (-85.6 to 443.6)	0.6 (0.2 to 1.2)	0.8 (0.2 to 3.0)	4.4 (-74.8 to 741.5)	-37.4 (-84.9 to 403.6)
Other neonatal disorders	-	-	-	-	0.7 (0.4 to 1.3)	3.5 (1.7 to 6.0)	446.1 (104.8 to 913.9)	228.3 (23.1 to 508.0)
Nutritional deficiencies	-	-	-	-	17.0 (11.1 to 24.8)	26.6 (17.0 to 38.8)	56.7 (35.9 to 75.0)	-1.9 (-14.8 to 10.1)
Protein-energy malnutrition	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	229.8 (-13.3 to 432.1)	41.0 (-60.6 to 123.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	202.9 (-21.2 to 464.2)	31.3 (-63.2 to 159.1)
Iodine deficiency	85.9 (34.5 to 161.5)	79.7 (26.7 to 138.4)	-5.4 (-71.0 to 181.3)	-45.4 (83.5 to 60.6)	1.5 (0.5 to 3.2)	1.4 (0.4 to 2.8)	-5.1 (-70.8 to 182.9)	-45.3 (-83.6 to 62.6)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-

Appendix Table G.4 - Israel prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	527.7 (496.4 to 539.4)	902.4 (853.0 to 929.2)	71.5 (60.0 to 82.6)	-2.3 (-2.2 to 10.5)	15.5 (10.2 to 22.7)	25.2 (16.2 to 36.8)	63.6 (43.8 to 82.5)	3.7 (8.3 to 15.3)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-34.5 to 163.2)	-40.6 (-70.9 to 17.0)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.3 (0.7 to 2.4)	2.2 (1.3 to 4.0)	72.2 (-10.9 to 195.5)	6.0 (-42.4 to 78.3)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.4 (0.2 to 0.7)	0.7 (0.4 to 1.3)	77.3 (41.8 to 119.5)	2.8 (-17.4 to 27.6)
Syphilis	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.5)	387.9 (106.8 to 291.7)	41.5 (1.2 to 92.5)	0.1 (0.0 to 0.0)	0.1 (0.0 to 0.1)	189.1 (82.0 to 328.2)	43.5 (-10.4 to 110.8)
Chlamydial infection	62.3 (43.6 to 81.9)	125.9 (94.0 to 157.1)	106.5 (24.5 to 217.3)	25.9 (-23.5 to 90.5)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.6)	78.5 (17.1 to 176.8)	8.5 (-30.8 to 66.6)
Gonococcal infection	17.2 (11.8 to 24.7)	24.8 (16.6 to 35.5)	43.0 (-22.1 to 156.2)	-9.3 (50.0 to 61.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	38.1 (-15.3 to 109.3)	-12.7 (-46.6 to 30.1)
Trichomoniasis	13.2 (8.9 to 19.6)	21.5 (14.8 to 30.2)	72.6 (-11.3 to 159.8)	1.7 (-46.9 to 49.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	72.7 (-18.6 to 174.0)	1.8 (-50.9 to 58.7)
Genital herpes	359.6 (322.3 to 397.9)	648.7 (599.5 to 699.7)	81.1 (58.1 to 105.4)	-4.6 (-16.7 to 7.6)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	78.0 (52.9 to 104.2)	4.7 (-17.6 to 9.0)
Other sexually transmitted diseases	0.7 (0.4 to 1.0)	0.8 (0.5 to 1.1)	6.0 (-31.9 to 68.7)	-38.7 (-60.6 to -2.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.5 (-0.8 to 147.2)	-7.8 (-41.3 to 44.9)
Hepatitis	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	46.2 (26.5 to 67.2)	-14.5 (-26.6 to -1.9)
Hepatitis A	3.9 (3.7 to 4.2)	5.9 (5.0 to 6.3)	50.4 (48.9 to 51.8)	-8.0 (-9.2 to -6.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	54.9 (37.1 to 75.7)	-6.6 (-17.3 to 5.2)
Hepatitis B	64.4 (51.5 to 78.7)	70.9 (52.6 to 90.9)	8.7 (-22.2 to 59.4)	-38.9 (-56.3 to -21.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	18.6 (-28.6 to 100.9)	-34.7 (-61.0 to 11.6)
Hepatitis C	85.3 (76.0 to 94.4)	103.6 (93.6 to 114.6)	21.9 (4.4 to 41.1)	-35.4 (-44.7 to -25.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.5 (4.3 to 107.1)	-22.2 (-44.8 to 11.4)
Hepatitis E	-	-	-	-	0.0 (-15.4 to 51.2)	0.0 (-50.8 to -10.4)	-	-
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.1 (61.4 to 145.5)	-7.0 (-21.8 to 20.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.5 (61.7 to 146.3)	-7.0 (-21.9 to 20.0)
Other infectious diseases	26.6 (22.0 to 47.6)	44.5 (35.2 to 70.8)	61.6 (-13.1 to 186.0)	1.9 (-43.7 to 77.5)	0.7 (0.4 to 1.8)	1.4 (0.8 to 2.9)	72.3 (-33.1 to 293.5)	11.1 (-56.0 to 149.6)
Non-communicable diseases	-	-	-	-	390.0 (290.8 to 500.4)	750.6 (557.7 to 969.2)	92.2 (84.2 to 100.7)	2.4 (-1.9 to 7.0)
Neoplasms	-	-	-	-	6.0 (4.5 to 7.8)	13.6 (10.0 to 17.5)	128.1 (113.0 to 143.1)	6.6 (-0.5 to 13.6)
Esophageal cancer	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	79.9 (26.4 to 155.9)	-19.9 (-43.2 to 12.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	71.4 (28.3 to 133.3)	-23.0 (-41.4 to 3.5)
Stomach cancer	1.4 (1.2 to 1.7)	2.2 (1.8 to 2.6)	51.5 (24.8 to 81.5)	-31.6 (-43.2 to -18.5)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	40.3 (16.4 to 69.8)	-36.2 (-47.1 to -23.3)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	100.3 (88.6 to 261.3)	19.7 (-13.1 to 65.7)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	235.1 (61.8 to 725.3)	59.4 (-23.2 to 300.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	190.6 (49.2 to 538.6)	38.2 (-30.0 to 208.3)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.1)	0.3 (0.1 to 0.4)	504.6 (205.8 to 1,108.0)	176.0 (40.6 to 440.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	412.3 (177.9 to 824.3)	133.2 (24.3 to 320.8)
Liver cancer due to alcohol use	0.1 (0.0 to 0.1)	0.2 (0.0 to 0.2)	39.1 (-36.2 to 194.7)	-36.8 (-71.5 to 32.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.2 (-42.5 to 129.5)	-46.2 (-73.9 to 4.6)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.5 (0.0 to 0.0)	8.5 (-51.0 to 167.9)	-49.5 (-77.1 to 25.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.2 (-50.5 to 120.2)	2.1 (-77.2 to 1.6)
Larynx cancer	0.5 (0.4 to 0.7)	1.1 (0.8 to 1.4)	124.7 (63.4 to 199.5)	2.7 (-25.7 to 36.2)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	104.7 (44.9 to 173.4)	-6.3 (-33.6 to 24.7)
Tracheal, bronchus and lung cancer	2.0 (1.8 to 2.2)	4.3 (3.8 to 4.8)	117.7 (86.6 to 150.9)	0.1 (-14.3 to 15.0)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.7)	103.0 (72.3 to 136.9)	-6.2 (-21.1 to 9.7)
Breast cancer	21.9 (19.8 to 24.1)	47.5 (44.1 to 50.8)	116.7 (92.8 to 143.5)	-0.9 (-12.0 to 11.8)	1.3 (0.9 to 1.7)	2.3 (1.6 to 3.3)	85.6 (59.7 to 111.9)	-14.2 (-26.4 to -2.2)
Cervical cancer	1.5 (1.3 to 1.9)	2.1 (1.2 to 3.2)	63.2 (-18.1 to 127.2)	-7.2 (-58.9 to 15.9)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	20.4 (-20.7 to 21.0)	-0.4 (-6.3 to 13.2)
Uterine cancer	1.7 (1.3 to 2.5)	4.6 (2.8 to 6.0)	174.7 (27.8 to 298.9)	26.8 (-42.3 to 82.9)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	162.1 (20.0 to 285.7)	20.9 (-45.1 to 77.2)
Prostate cancer	10.9 (9.4 to 12.5)	35.4 (30.8 to 42.8)	225.3 (165.0 to 299.7)	46.1 (-19.8 to 79.9)	0.7 (0.5 to 1.0)	2.3 (1.6 to 3.3)	206.8 (143.0 to 309.1)	38.7 (10.0 to 84.0)
Colon and rectum cancer	8.5 (7.9 to 9.3)	17.9 (16.2 to 19.6)	111.3 (81.9 to 138.2)	-2.6 (-16.3 to 8.7)	0.7 (0.5 to 1.0)	1.4 (1.0 to 1.8)	91.9 (65.8 to 118.1)	-11.4 (-23.9 to -0.1)
Lip and oral cavity cancer	1.0 (0.8 to 1.2)	1.9 (1.5 to 2.4)	101.6 (47.8 to 161.1)	8.8 (-31.6 to 19.9)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	95.7 (40.8 to 157.4)	-10.1 (-35.1 to 13.8)
Nasopharynx cancer	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	9.3 (-40.0 to 43.5)	54.8 (-70.1 to -28.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.6 (-39.4 to 38.9)	55.6 (-69.9 to -29.9)
Other pharynx cancer	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	73.8 (12.6 to 166.8)	-19.1 (-47.7 to 25.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	67.8 (10.1 to 151.7)	-22.3 (-49.1 to 18.4)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	10.9 (-18.3 to 69.8)	-51.1 (-63.8 to -24.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	10.5 (-21.7 to 71.4)	50.8 (-64.3 to -24.5)
Pancreatic cancer	0.4 (0.3 to 0.5)	0.9 (0.8 to 1.1)	126.5 (72.3 to 194.3)	2.0 (-22.1 to 32.5)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	112.2 (67.8 to 166.8)	-3.6 (-23.9 to 20.9)
Malignant skin melanoma	2.4 (3.4 to 6.6)	6.9 (9.5 to 19.9)	181.8 (107.8 to 248.5)	52.2 (-1.4 to 71.7)	0.3 (0.2 to 0.4)	0.8 (0.5 to 1.2)	155.8 (97.0 to 234.7)	29.6 (-4.3 to 65.4)
Non-melanoma skin cancer	2.1 (1.4 to 3.0)	5.7 (3.7 to 8.5)	169.8 (40.1 to 395.5)	21.1 (-35.9 to 122.4)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	214.4 (99.2 to 371.0)	37.4 (-11.9 to 102.9)
Ovarian cancer	1.7 (1.4 to 2.0)	2.5 (2.1 to 3.1)	52.3 (21.2 to 97.5)	-28.5 (-43.0 to -7.1)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	44.9 (10.0 to 96.3)	-31.7 (-47.9 to -8.5)
Testicular cancer	0.6 (0.4 to 0.9)	1.1 (0.8 to 1.7)	85.8 (18.6 to 188.4)	5.3 (-32.8 to 63.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	82.5 (11.1 to 196.9)	2.8 (-37.2 to 67.2)
Kidney cancer	3.7 (1.3 to 1.8)	9.3 (4.8 to 6.8)	150.9 (204.4 to 345.0)	13.2 (-42.1 to 107.2)	0.3 (0.1 to 0.2)	0.7 (0.3 to 0.5)	134.7 (177.6 to 324.7)	60.9 (29.2 to 97.3)
Bladder cancer	3.1 (3.1 to 4.3)	7.8 (7.8 to 11.3)	154.3 (104.1 to 223.8)	13.2 (-8.0 to 45.7)	0.3 (0.2 to 0.4)	0.7 (0.5 to 0.9)	134.7 (89.0 to 201.2)	6.2 (-14.5 to 36.0)
Brain and nervous system cancer	1.2 (1.0 to 1.5)	3.3 (2.7 to 3.9)	174.7 (124.2 to 229.8)	45.3 (-19.0 to 74.4)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	163.0 (108.6 to 222.6)	38.0 (9.5 to 69.4)
Thyroid cancer	3.0 (2.4 to 3.7)	6.6 (5.1 to 8.2)	122.4 (71.3 to 192.1)	12.6 (-13.7 to 49.0)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	116.0 (63.6 to 186.1)	8.3 (-17.4 to 44.5)
Mesothelioma	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	228.6 (59.4 to 328.6)	52.2 (-26.8 to 99.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	246.7 (54.3 to 346.1)	59.7 (-28.0 to 107.2)
Hodgkin lymphoma	0.9 (0.7 to 1.3)	1.4 (0.9 to 1.9)	44.9 (-1.6 to 115.4)	-15.8 (-43.4 to 25.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	40.1 (-3.6 to 103.8)	-19.7 (-45.1 to 17.3)
Non-Hodgkin lymphoma	3.0 (2.4 to 4.9)	8.2 (5.4 to 10.6)	179.2 (65.0 to 258.7)	33.4 (-22.4 to 73.5)	0.2 (0.1 to 0.4)	0.6 (0.3 to 0.8)	161.3 (53.4 to 240.0)	24.6 (-27.7 to 63.7)
Multiple myeloma	0.7 (0.5 to 1.1)	1.8 (1.2 to 2.6)	160.8 (66.4 to 294.1)	19.2 (-24.2 to 79.4)	0.1 (0.1 to 0.2)	0.1 (0.2 to 0.5)	149.2 (61.0 to 278.9)	13.9 (-27.4 to 73.1)
Leukemia	2.4 (2.1 to 2.8)	6.9 (6.0 to 7.7)	181.4 (132.7 to 236.4)	41.1 (-16.5 to 67.7)	0.3 (0.2 to 0.4)	0.8 (0.5 to 1.0)	165.8 (118.0 to 219.4)	29.6 (5.5 to 56.1)
Other neoplasms	3.6 (3.0 to 4.6)	14.3 (10.8 to 17.5)	306.5 (172.9 to 436.2)	103.1 (39.1 to 163.7)	0.2 (0.2 to 0.3)	0.9 (0.6 to 1.3)	282.9 (156.4 to 414.5)	89.9 (28.7 to 150.5)
Cardiovascular diseases	-	-	-	-	13.8 (9.6 to 18.7)	27.8 (19.6 to 37.3)	101.5 (67.8 to 141.6)	-7.8 (-23.1 to 10.8)
Rheumatic heart disease	0.4 (0.4 to 0.4)	0.7 (0.7 to 0.7)	91.6 (75.4 to 109.7)	-6.3 (-14.5 to 2.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	85.0 (38.1 to 180.3)	-9.5 (-32.8 to 37.6)
Ischemic heart disease	92.6 (78.0 to 111.5)	167.2 (147.0 to 192.2)	82.6 (42.2 to 120.7)	-17.5 (-36.4 to -0.1)	5.5 (3.5 to 8.0)	9.5 (6.4 to 13.2)	79.9 (31.5 to 117.8)	-22.1 (-41.5 to -1.7)
Cerebrovascular disease	-	-	-	-	2.5 (1.7 to 3.3)	5.2 (3.6 to 6.9)	106.8 (72.8 to 145.3)	-3.2 (-19.2 to 15.0)
Ischemic stroke	15.4 (12.8 to 17.6)	31.8 (27.0 to 36.0)	106.3 (73.1 to 147.3)	-4.4 (-19.8 to 14.8)	2.2 (1.5 to 3.0)	4.5 (3.1 to 6.1)	105.9 (70.1 to 146.0)	-3.9 (-20.3 to 14.7)
Hemorrhagic stroke	2.2 (1.8 to 2.5)	4.6 (3.9 to 5.5)	111.7 (68.7 to 165.3)	0.8 (-18.3 to 26.8)	0.3 (0.2 to 0.4)	0.7 (0.4 to 0.9)	110.1 (63.7 to 164.8)	1.2 (-20.8 to 28.0)
Hypertensive heart disease	4.7 (4.0 to 5.3)	12.1 (10.9 to 13.2)	160.1 (123.2 to 205.7)	16.7 (0.0 to 37.1)	0.5 (0.3 to 0.7)	1.3 (0.9 to 1.8)	159.2 (118.6 to 207.1)	17.1 (-1.1 to 38.8)
Cardiomyopathy and myocarditis	4.8 (4.0 to 5.9)	8.0 (7.3 to 8.8)	66.8 (34.4 to 105.8)	-21.2 (-36.3 to -2.9)	0.9 (0.3 to 0.7)	0.9 (0.6 to 1.2)	69.9 (33.4 to 108.4)	20.9 (-36.6 to -1.2)
Atrial fibrillation and flutter	12.9 (11.6 to 14.5)	22.1 (17.4 to 26.2)	71.2 (34.4 to 106.6)	-21.7 (-38.9 to -4.5)	1.0 (0.7 to 1.4)	1.7 (1.1 to 2.4)	69.7 (33.2 to 105.8)	-21.8 (-39.3 to -4.5)
Peripheral vascular disease	111.6 (80.4 to 133.9)	254.3 (193.4 to 308.0)	123.9 (69.0 to 239.0)	1.1 (-23.9 to 54.1)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.5)	80.1 (-10.5 to 320.7)	-22.8 (-62.3 to 71.9)
Endocarditis	0.2 (0.1 to 0.2)	0.7 (0.5 to 0.8)	302.1 (175.5 to 462.2)	93.6 (33.9 to 170.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	247.9 (107.9 to 434.0)	67.9 (0.8 to 154.3)
Other cardiovascular and circulatory diseases	50.1 (29.2 to 71.8)	127.1 (79.1 to 163.8)	152.8 (41.7 to 349.4)	17.7 (-33.9 to 107.6)	3.5 (1.8 to 5.6)	8.9 (4.9 to 13.2)	153.0 (60.8 to 354.1)	17.7 (-33.8 to 110.7)
Chronic respiratory diseases	-	-	-	-	15.2 (10.3 to 21.2)	30.4 (20.5 to 43.4)	99.5 (40.8 to 158.8)	2.4 (-15.7 to 34.9)
Chronic obstructive pulmonary disease	235.0 (187.2 to 275.7)	476.4 (388.0 to 567.7)	103.6 (77.5 to 132.3)	-0.3 (

Appendix Table G.4 - Israel prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	60.8	-22.0
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.6 (30.5 to 48.9)	-33.1 (-38.3 to -29.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	(50.6 to 76.7)	(-27.2 to -14.2)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.0	41.8	-33.0
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	68.4 (53.5 to 93.4)	-57.4 (-24.2 to -5.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.3 (54.4 to 94.0)	-17.1 (-23.8 to -4.8)
Asthma	97.1 (82.7 to 111.0)	182.0 (140.1 to 220.6)	87.7 (42.6 to 138.9)	6.3 (-18.9 to 34.6)	4.3 (2.7 to 6.1)	7.9 (4.7 to 11.9)	84.8 (40.7 to 137.6)	5.6 (-19.7 to 34.9)
Interstitial lung disease and pulmonary sarcoidosis	0.3 (0.2 to 0.3)	0.4 (0.4 to 0.5)	57.5 (26.9 to 106.8)	-23.5 (-38.8 to 0.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	58.6 (25.3 to 107.1)	-22.8 (-39.0 to 0.5)
Other chronic respiratory diseases	-	-	-	-	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.8)	35.3 (-5.6 to 103.8)	-33.2 (-53.7 to 1.0)
Cirrhosis	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	69.4 (45.6 to 99.1)	-15.3 (-27.1 to -0.2)
Cirrhosis due to hepatitis B	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	75.7 (-6.1 to 214.5)	-12.8 (52.6 to 56.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.2 to 228.7)	(-52.1 to 63.0)
Cirrhosis due to hepatitis C	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	117.9 (62.4 to 309.5)	8.1 (-19.9 to 102.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	119.2 (44.4 to 333.5)	10.1 (-28.5 to 116.6)
Cirrhosis due to alcohol use	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	0.0 (-45.8 to 52.2)	-51.5 (-74.1 to -25.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	1.0 (-49.3 to 72.6)	-50.7 (-75.4 to -16.3)
Cirrhosis due to other causes	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	131.1 (25.7 to 294.8)	26.8 (-31.7 to 121.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	131.1 (25.3 to 295.8)	26.8 (-32.1 to 121.7)
Digestive diseases	-	-	-	-	4.3 (2.9 to 5.9)	9.4 (6.5 to 12.9)	120.4 (81.7 to 161.7)	11.8 (-8.1 to 33.5)
Peptic ulcer disease	12.0 (10.4 to 13.6)	8.4 (6.8 to 10.4)	-29.6 (-45.3 to -11.9)	-70.9 (-77.1 to -63.7)	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	4.2 (-19.2 to 25.1)	-55.7 (-65.4 to -46.1)
Gastritis and duodenitis	1.9 (1.6 to 2.2)	1.6 (1.3 to 1.8)	-18.4 (-35.1 to 2.2)	-59.6 (-68.0 to -49.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-3.0 (-33.1 to 32.5)	-50.8 (-66.6 to -30.9)
Appendicitis	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.3)	31.2 (15.7 to 51.7)	-17.6 (-26.8 to -6.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	34.6 (-7.6 to 90.4)	-16.2 (-41.9 to 15.5)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	105.6 (42.7 to 202.8)	11.0 (-19.4 to 59.2)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	105.9 (32.9 to 216.3)	12.4 (-24.0 to 67.9)
Inguinal, femoral, and abdominal hernia	13.7 (11.9 to 15.9)	25.0 (21.8 to 29.1)	82.6 (49.7 to 120.6)	-16.0 (-31.5 to 1.3)	0.1 (0.1 to 0.3)	0.3 (0.1 to 0.5)	82.5 (48.9 to 120.3)	-15.5 (-31.6 to 1.6)
Inflammatory bowel disease	12.1 (9.8 to 14.4)	25.7 (20.5 to 30.9)	114.1 (59.4 to 178.6)	10.3 (-18.1 to 43.6)	2.6 (1.6 to 3.6)	5.4 (3.5 to 7.7)	112.5 (57.2 to 177.7)	10.3 (-18.5 to 43.7)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.9 (63.1 to 176.7)	-4.0 (-24.1 to 26.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.2 (36.4 to 215.5)	-2.2 (-34.8 to 45.9)
Gallbladder and biliary diseases	4.3 (3.5 to 4.9)	10.7 (9.5 to 12.2)	150.7 (105.5 to 214.9)	21.3 (-0.2 to 52.8)	0.4 (0.3 to 0.6)	1.1 (0.7 to 1.6)	148.9 (102.3 to 214.3)	21.2 (-0.7 to 52.6)
Pancreatitis	0.8 (0.8 to 0.9)	1.8 (1.7 to 1.8)	114.3 (102.4 to 136.6)	9.4 (3.3 to 16.6)	0.3 (0.2 to 0.3)	0.5 (0.3 to 0.7)	113.0 (80.7 to 147.4)	9.4 (-7.1 to 27.8)
Other digestive diseases	-	-	-	-	0.2 (0.2 to 0.4)	1.4 (0.9 to 2.0)	509.8 (214.8 to 689.1)	208.9 (59.8 to 301.9)
Neurological disorders	-	-	-	-	44.2 (29.3 to 59.9)	88.0 (60.0 to 138.6)	99.9 (70.8 to 130.2)	4.3 (-10.8 to 19.5)
Alzheimer disease and other dementias	56.0 (49.5 to 62.2)	138.2 (115.8 to 160.2)	146.1 (100.1 to 198.4)	0.2 (-18.6 to 20.7)	8.0 (5.8 to 10.3)	20.3 (14.3 to 27.2)	151.3 (103.5 to 207.6)	1.2 (-18.3 to 23.4)
Parkinson disease	4.4 (3.7 to 5.2)	9.4 (7.8 to 11.2)	113.0 (92.2 to 128.4)	-2.2 (-10.7 to 4.6)	0.5 (0.4 to 0.7)	1.1 (0.7 to 1.5)	111.9 (87.6 to 135.3)	-2.0 (-12.8 to 8.4)
Epilepsy	15.1 (11.3 to 18.9)	24.2 (16.9 to 31.1)	58.9 (8.0 to 132.2)	-8.5 (-38.4 to 33.4)	6.1 (3.8 to 8.8)	10.0 (6.1 to 14.5)	64.6 (8.7 to 146.9)	-4.8 (-37.3 to 44.0)
Multiple sclerosis	2.0 (1.7 to 2.3)	5.0 (4.2 to 5.8)	157.1 (106.7 to 210.6)	34.4 (8.1 to 61.8)	0.6 (0.4 to 0.9)	1.6 (1.1 to 2.2)	153.6 (100.7 to 223.7)	33.2 (5.9 to 69.3)
Migraine	65.2 (50.1 to 76.0)	108.1 (85.1 to 131.8)	77.1 (32.8 to 132.6)	1.2 (-24.6 to 31.8)	2.1 (1.2 to 3.1)	46.9 (21.2 to 59.1)	70.1 (31.2 to 132.1)	2.2 (-25.2 to 32.5)
Tension-type headache	861.0 (647.8 to 1,092.9)	1,915.8 (1,611.1 to 2,308.6)	122.1 (67.2 to 207.7)	24.8 (-7.1 to 71.1)	1.3 (0.6 to 2.5)	2.9 (1.4 to 5.4)	121.9 (65.8 to 209.4)	25.1 (-8.1 to 71.5)
Medication overuse headache	27.5 (18.0 to 38.0)	76.3 (51.2 to 104.5)	178.7 (112.5 to 271.2)	50.5 (15.6 to 101.9)	4.3 (2.5 to 6.8)	11.9 (6.9 to 18.7)	177.5 (111.8 to 272.8)	50.7 (16.0 to 103.0)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.8 (30.7 to 165.9)	-1.8 (-29.2 to 45.4)	2.2 (1.5 to 3.1)	3.3 (2.2 to 4.6)	46.6 (10.1 to 99.8)	-39.3 (-54.3 to -16.5)
Mental and substance use disorders	-	-	-	-	84.7 (60.0 to 112.1)	149.6 (104.7 to 199.1)	76.3 (67.5 to 85.8)	1.6 (-3.0 to 7.8)
Schizophrenia	10.0 (7.8 to 12.4)	17.8 (13.6 to 22.1)	77.8 (65.1 to 89.6)	-4.2 (-10.7 to 1.9)	4.4 (4.5 to 8.5)	11.4 (7.9 to 15.3)	77.6 (61.0 to 93.1)	-4.1 (-13.0 to 4.6)
Alcohol use disorders	47.3 (42.2 to 52.9)	71.5 (63.5 to 80.8)	51.3 (40.7 to 63.1)	-12.8 (-18.7 to -6.0)	4.8 (3.1 to 6.8)	7.2 (4.7 to 10.3)	51.0 (39.1 to 64.6)	-12.7 (-19.4 to -5.0)
Drug use disorders	-	-	-	-	8.8 (5.7 to 12.6)	14.6 (9.4 to 21.0)	66.7 (41.4 to 94.1)	-2.2 (-16.6 to 13.8)
Opioid use disorders	11.4 (6.7 to 17.6)	18.8 (11.0 to 28.7)	63.4 (44.4 to 90.2)	-6.8 (-17.4 to 7.7)	4.8 (2.5 to 7.2)	7.8 (4.1 to 12.9)	64.6 (42.2 to 93.8)	-6.2 (-19.2 to 9.5)
Cocaine use disorders	6.0 (4.5 to 7.5)	10.7 (8.1 to 13.1)	76.8 (19.6 to 166.4)	0.8 (-28.3 to 57.1)	0.5 (0.5 to 1.0)	1.5 (0.9 to 2.2)	76.9 (15.9 to 175.4)	4.7 (-30.9 to 62.2)
Amphetamine use disorders	8.0 (6.4 to 9.6)	13.1 (11.1 to 15.6)	62.8 (28.8 to 122.1)	-1.1 (-21.4 to 34.0)	1.0 (0.6 to 1.6)	1.7 (1.0 to 2.7)	62.5 (25.6 to 127.2)	-0.7 (-23.3 to 38.3)
Cannabis use disorders	7.9 (7.2 to 8.5)	12.3 (11.2 to 13.3)	56.7 (47.2 to 65.7)	1.2 (-4.9 to 7.1)	0.2 (0.2 to 0.3)	0.4 (0.2 to 0.5)	57.0 (34.4 to 84.6)	1.5 (-12.7 to 19.0)
Other drug use disorders	-	-	-	-	1.9 (1.1 to 2.8)	3.2 (2.0 to 4.8)	71.5 (19.6 to 142.4)	3.4 (-28.0 to 46.1)
Depressive disorders	-	-	-	-	30.4 (18.4 to 47.0)	59.5 (36.4 to 89.4)	94.3 (76.0 to 124.7)	8.6 (-1.0 to 25.2)
Major depressive disorder	119.2 (82.4 to 167.1)	238.3 (160.8 to 330.6)	98.1 (75.4 to 135.7)	10.5 (-1.1 to 31.5)	24.4 (14.1 to 39.1)	48.6 (28.2 to 76.7)	97.4 (74.1 to 135.7)	11.1 (-1.3 to 31.6)
Dysthymia	61.9 (52.0 to 71.9)	113.7 (95.8 to 131.7)	83.8 (80.4 to 87.2)	0.1 (0.0 to 0.2)	6.0 (3.9 to 8.8)	10.9 (7.1 to 16.2)	83.0 (77.5 to 89.1)	0.1 (-2.4 to 2.6)
Bipolar disorder	27.9 (23.7 to 32.4)	49.7 (42.7 to 57.1)	78.0 (67.6 to 88.6)	0.2 (-4.9 to 5.4)	5.7 (3.5 to 8.5)	10.1 (6.3 to 15.0)	77.5 (65.3 to 91.1)	0.2 (-6.3 to 7.5)
Anxiety disorders	79.7 (64.7 to 95.4)	138.4 (111.9 to 162.9)	71.2 (67.3 to 75.2)	7.3 (-0.0 to 1.1)	30.4 (4.8 to 10.6)	59.5 (8.3 to 18.1)	94.3 (63.7 to 128.0)	8.6 (-3.4 to 3.7)
Eating disorders	-	-	-	-	4.0 (1.6 to 5.3)	4.9 (2.6 to 8.5)	59.3 (49.6 to 69.4)	1.6 (-3.8 to 7.9)
Anorexia nervosa	1.8 (1.0 to 2.8)	3.2 (1.7 to 5.0)	75.0 (52.7 to 105.7)	10.5 (-3.5 to 30.8)	0.4 (0.2 to 0.7)	0.7 (0.3 to 1.2)	74.8 (45.1 to 118.1)	10.7 (-7.4 to 38.6)
Bulimia nervosa	12.5 (6.8 to 22.8)	19.7 (10.5 to 35.7)	56.8 (51.9 to 61.2)	0.2 (0.0 to 0.4)	2.7 (1.3 to 4.8)	4.2 (2.0 to 7.6)	56.8 (46.6 to 67.4)	0.2 (-5.8 to 6.2)
Autistic spectrum disorders	-	-	-	-	5.2 (3.6 to 7.1)	8.7 (6.1 to 11.9)	65.5 (62.9 to 73.9)	0.1 (-3.1 to 3.3)
Autism	13.3 (12.6 to 14.1)	22.5 (21.2 to 23.8)	68.8 (68.0 to 69.8)	-0.1 (-0.1 to -0.1)	3.3 (2.2 to 4.5)	5.5 (3.7 to 7.6)	68.3 (60.5 to 76.5)	0.1 (-4.5 to 4.9)
Asperger syndrome	19.0 (17.8 to 20.2)	32.1 (30.0 to 34.1)	68.8 (67.9 to 69.7)	-0.1 (-0.1 to -0.1)	1.9 (1.3 to 2.6)	3.2 (2.2 to 4.4)	68.7 (61.9 to 75.3)	0.2 (-3.7 to 3.9)
Attention-deficit/hyperactivity disorder	29.8 (25.6 to 34.1)	43.6 (37.5 to 49.8)	46.5 (46.2 to 46.6)	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.8)	46.3 (36.3 to 56.9)	0.1 (-6.8 to 7.3)
Conduct disorder	6.0 (4.1 to 56.8)	70.1 (59.3 to 81.2)	43.1 (42.1 to 43.8)	0.2 (0.2 to 0.2)	5.9 (3.6 to 8.9)	8.5 (5.2 to 12.8)	4.4 (38.0 to 50.0)	0.4 (-3.4 to 4.9)
Idiopathic intellectual disability	28.1 (16.7 to 40.7)	34.8 (14.2 to 55.0)	23.5 (-36.3 to 113.3)	2.7 (-62.6 to 25.9)	1.7 (0.9 to 2.6)	2.1 (0.8 to 3.6)	22.5 (37.0 to 113.8)	-27.4 (-62.7 to 26.8)
Other mental and substance use disorders	69.8 (65.8 to 73.9)	129.6 (122.0 to 136.9)	85.5 (83.8 to 87.1)	-0.2 (-0.4 to -0.1)	5.2 (3.5 to 7.1)	9.6 (6.6 to 12.9)	84.8 (78.1 to 91.4)	0.1 (-3.6 to 4.4)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	43.5 (31.6 to 57.5)	86.1 (62.3 to 114.4)	97.7 (85.1 to 112.8)	4.3 (-2.5 to 11.7)
Diabetes mellitus	147.6 (119.3 to 174.2)	390.3 (313.9 to 475.0)	163.9 (114.4 to 233.4)	29.4 (4.6 to 62.2)	10.2 (6.7 to 14.3)	27.0 (17.8 to 38.8)	164.8 (115.4 to 225.0)	28.4 (3.8 to 56.9)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.7 (36.0 to 52.5)	-14.5 (-19.8 to -10.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.7 (36.0 to 52.5)	-14.5 (-19.8 to -10.4)
Chronic kidney disease	-	-	-	-	15.1 (10.4 to 20.4)	28.6 (19.3 to 38.4)	89.6 (79.9 to 100.2)	-2.2 (-6.8 to 2.6)
Chronic kidney disease due to diabetes mellitus	64.5 (41.9 to 89.1)	200.6 (141.1 to 286.1)	213.7 (138.5 to 294.0)	53.3 (17.2 to 92.8)	4.1 (2.6 to 5.8)	11.6 (7.3 to 16.6)	183.5 (128.0 to 254.4)	40.0 (-12.0 to 75.5)
Chronic kidney disease due to hypertension	38.5 (28.5 to 54.0)	43.1 (29.6 to 60.7)	-	-40.9 (-32.2 to 39.4)	4.3 (2.6 to 6.2)	2.6 (1.7 to 3.7)	-	-40.0 (-76.1 to -59.7)
Chronic kidney disease due to glomerulonephritis	61.2 (39.2 to 92.6)	48.0 (34.4 to 64.2)	71.2 (-43.3 to 13.3)	-21.1 (-71.6 to -42.4)	1.2 (0.7 to 1.8)	2.5 (1.6 to 3.5)	110.3 (55.7 to 189.5)	17.6 (-13.0 to 62.3)
Chronic kidney disease due to other causes	113.3 (74.8 to 173.6)	243.1 (172.2 to 330.9)	112.8 (76.7 to 179.5)	11.7 (-6.8 to 45.0)	11.7 (3.8 to 7.8)	11.9 (8.2 to 16.2)	116.6 (77.5 to 173.7)	14.8 (-7.7 to 44.9)
Urinary diseases and male infertility	-	-	-	-	3.5 (2.2 to 5.1)	5.8 (3.7 to 8.4)	65.8 (49.1 to 95.5)	-20.8 (-28.8 to -6.4)

Appendix Table G.4 - Israel prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.3 (0.3 to 0.3)	0.8 (0.7 to 0.8)	162.1 (138.9 to 188.2)	47.4 (34.7 to 62.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	162.0 (93.4 to 250.2)	0.0 (9.9 to 96.2)
Urolithiasis	81.4 (58.9 to 98.3)	109.3 (36.9 to 171.7)	33.2 (-52.3 to 89.4)	-31.1 (-77.9 to -9.2)	0.6 (0.4 to 0.9)	0.9 (0.3 to 1.6)	53.5 (-36.9 to 96.5)	-25.7 (-69.8 to -4.6)
Benign prostatic hyperplasia	57.5 (52.9 to 62.1)	118.6 (112.6 to 123.9)	107.1 (87.4 to 125.1)	-3.6 (-12.6 to 4.4)	2.0 (1.3 to 2.8)	4.2 (2.7 to 5.9)	107.1 (87.2 to 125.8)	-3.3 (-12.5 to 5.4)
Male infertility due to other causes	27.5 (21.8 to 35.2)	43.4 (32.9 to 54.9)	58.3 (8.8 to 116.0)	-5.4 (-34.9 to 29.1)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.6)	59.0 (9.2 to 118.1)	-4.9 (-34.6 to 30.5)
Other urinary diseases	-	-	-	-	0.5 (0.2 to 0.8)	0.3 (0.1 to 0.8)	0.7 (65.5 to 73.3)	-76.1 (-83.3 to -16.2)
Gynecological diseases	-	-	-	-	4.8 (3.1 to 7.4)	8.6 (5.5 to 13.3)	81.3 (55.2 to 106.2)	2.3 (-12.3 to 16.6)
Uterine fibroids	145.7 (123.6 to 169.2)	271.7 (231.5 to 315.2)	86.5 (85.2 to 87.9)	0.2 (0.2 to 0.3)	1.2 (0.6 to 2.3)	2.3 (1.1 to 4.2)	89.0 (68.9 to 109.7)	2.0 (-6.7 to 13.1)
Polycystic ovarian syndrome	70.0 (59.6 to 81.1)	125.4 (106.8 to 146.5)	80.2 (43.4 to 124.7)	5.3 (-16.0 to 31.6)	0.7 (0.3 to 1.2)	1.2 (0.6 to 2.2)	81.0 (44.2 to 126.7)	5.9 (-15.5 to 32.8)
Female infertility due to other causes	2.4 (0.4 to 8.7)	4.6 (0.6 to 12.3)	154.1 (-76.7 to 1,790.8)	50.9 (-86.4 to 996.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	154.2 (-71.2 to 2,022.4)	60.8 (-83.0 to 1,130.9)
Endometriosis	11.5 (8.4 to 15.2)	20.1 (15.1 to 25.2)	75.3 (14.5 to 154.3)	1.3 (-34.1 to 47.5)	1.1 (0.6 to 1.6)	1.9 (1.2 to 2.8)	74.7 (12.1 to 155.1)	1.3 (-35.3 to 47.6)
Genital prolapse	227.4 (205.2 to 250.7)	427.2 (379.3 to 473.7)	87.9 (61.4 to 118.4)	-1.5 (-15.4 to 14.4)	0.7 (0.3 to 1.4)	1.4 (0.7 to 2.6)	87.4 (60.7 to 118.3)	-1.6 (-15.7 to 15.0)
Premenstrual syndrome	108.1 (75.9 to 140.2)	182.9 (113.7 to 229.8)	71.2 (8.0 to 160.8)	2.6 (-35.3 to 56.5)	0.9 (0.5 to 1.5)	1.5 (0.8 to 2.5)	70.5 (6.1 to 157.6)	2.5 (-36.2 to 53.7)
Other gynecological diseases	7.9 (6.9 to 14.1)	14.0 (11.5 to 18.4)	74.6 (34.4 to 142.4)	2.4 (-16.7 to 40.8)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.6)	81.4 (14.6 to 245.7)	4.1 (-27.2 to 99.4)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	8.0 (5.4 to 11.4)	12.2 (8.1 to 17.5)	51.9 (40.1 to 88.8)	-6.2 (-13.9 to 15.4)
Thalassemias	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	66.5 (48.2 to 100.0)	7.8 (-4.0 to 29.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.3 (45.2 to 149.1)	19.5 (-5.2 to 59.9)
Thalassemia trait	73.5 (67.2 to 82.3)	129.2 (122.1 to 139.9)	76.0 (64.6 to 87.1)	2.4 (-4.1 to 8.7)	2.4 (1.6 to 3.5)	4.0 (2.7 to 5.7)	65.4 (52.8 to 83.9)	-0.4 (-8.0 to 10.5)
Sickle cell disorders	2.0 (1.7 to 2.2)	3.2 (2.9 to 3.4)	55.1 (37.7 to 82.4)	-2.7 (-14.2 to 14.7)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	59.2 (33.6 to 88.8)	-1.1 (-17.1 to 17.2)
Sickle cell trait	305.6 (294.0 to 318.4)	502.6 (485.8 to 538.8)	64.2 (57.0 to 77.3)	4.3 (-8.0 to 2.8)	6.5 (3.0 to 6.6)	6.5 (4.3 to 9.6)	49.0 (22.9 to 96.2)	-10.2 (-22.8 to 21.5)
G6PD deficiency	266.8 (214.9 to 323.5)	414.2 (302.3 to 552.8)	54.6 (6.3 to 129.4)	-10.1 (-38.2 to 33.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	10.1 (-38.3 to 66.4)	-33.0 (-62.1 to 1.0)
G6PD trait	853.6 (826.4 to 881.2)	1,456.9 (1,414.8 to 1,497.0)	70.6 (63.7 to 78.0)	-1.3 (-5.2 to 3.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	30.0 (-37.2 to 153.9)	-15.7 (-58.3 to 56.1)
Other hemoglobinopathies and hemolytic anemias	26.4 (23.8 to 28.9)	46.1 (42.4 to 50.1)	73.6 (56.2 to 100.4)	0.6 (-9.1 to 14.7)	0.6 (0.4 to 0.9)	1.1 (0.7 to 1.6)	66.2 (41.3 to 99.6)	0.7 (-14.2 to 20.7)
Endocrine, metabolic, blood, and immune disorders	59.6 (56.6 to 63.1)	110.9 (100.8 to 164.0)	80.9 (67.3 to 173.4)	1.9 (-5.0 to 53.1)	1.9 (1.3 to 2.7)	3.8 (2.6 to 6.5)	97.5 (70.2 to 237.1)	5.4 (-3.7 to 86.3)
Musculoskeletal disorders	-	-	-	-	103.3 (73.2 to 140.1)	210.9 (148.9 to 283.7)	103.2 (76.2 to 135.3)	6.7 (-6.9 to 23.9)
Rheumatoid arthritis	4.7 (4.2 to 5.3)	17.8 (15.9 to 20.3)	277.9 (216.6 to 363.1)	87.2 (57.6 to 129.5)	1.1 (0.7 to 1.5)	4.1 (2.8 to 5.6)	275.1 (213.9 to 362.7)	88.5 (57.6 to 132.3)
Osteoarthritis	151.4 (125.5 to 173.7)	329.8 (279.5 to 379.6)	118.5 (70.8 to 189.3)	-0.4 (-22.4 to 23.7)	5.2 (3.3 to 7.5)	11.3 (7.2 to 16.8)	117.6 (70.2 to 168.6)	-0.2 (-22.4 to 23.9)
Low back and neck pain	-	-	-	-	84.4 (58.3 to 115.9)	167.5 (112.6 to 233.0)	97.5 (65.5 to 135.0)	5.4 (-1.3 to 25.8)
Low back pain	550.2 (480.5 to 623.2)	1,095.5 (926.1 to 1,271.4)	99.2 (59.6 to 146.1)	6.0 (-15.3 to 31.2)	61.4 (41.4 to 87.6)	121.5 (79.3 to 174.3)	98.2 (58.4 to 146.3)	6.1 (-15.1 to 32.1)
Neck pain	234.3 (192.1 to 271.7)	471.2 (361.7 to 601.7)	100.3 (45.1 to 175.3)	6.3 (-22.8 to 46.2)	23.0 (15.5 to 31.9)	46.1 (29.3 to 68.1)	99.4 (44.3 to 175.1)	5.9 (-23.1 to 47.0)
Gout	6.8 (6.1 to 7.5)	14.2 (12.8 to 15.8)	108.5 (80.2 to 147.0)	-0.9 (-14.8 to 17.5)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	107.7 (88.6 to 155.0)	-0.7 (-19.8 to 22.4)
Other musculoskeletal disorders	135.9 (109.1 to 162.7)	302.0 (243.4 to 358.9)	122.2 (106.0 to 138.1)	12.4 (4.0 to 20.4)	12.4 (8.3 to 17.7)	27.6 (18.3 to 39.5)	121.6 (105.9 to 138.6)	12.5 (4.3 to 21.1)
Other non-communicable diseases	-	-	-	-	75.0 (49.4 to 109.1)	134.7 (90.6 to 192.9)	79.8 (69.7 to 89.8)	-4.6 (-9.5 to 0.3)
Congenital anomalies	-	-	-	-	6.2 (4.3 to 8.2)	14.0 (9.7 to 19.4)	127.2 (89.2 to 175.6)	30.2 (8.4 to 59.1)
Neural tube defects	2.0 (1.7 to 2.4)	2.5 (2.1 to 2.9)	27.5 (-2.9 to 60.5)	-22.5 (-41.1 to -2.3)	0.7 (0.4 to 0.9)	0.8 (0.6 to 1.2)	27.5 (-11.9 to 81.9)	-22.1 (-46.1 to 10.8)
Congenital heart anomalies	46.1 (37.7 to 59.4)	65.0 (53.1 to 79.9)	42.0 (2.1 to 83.9)	-16.0 (-39.6 to 8.9)	1.6 (0.7 to 2.6)	2.3 (0.9 to 4.1)	43.4 (5.0 to 84.2)	-14.7 (-37.5 to 9.7)
Orofacial clefts	4.3 (3.7 to 5.1)	5.6 (4.8 to 6.5)	30.5 (6.1 to 62.6)	-22.6 (-37.1 to -3.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	20.3 (-2.1 to 61.7)	-28.5 (-45.9 to -4.5)
Down syndrome	4.6 (3.7 to 6.0)	8.6 (6.9 to 10.9)	85.9 (41.9 to 149.2)	4.3 (-20.4 to 39.5)	0.6 (0.4 to 0.9)	1.2 (0.9 to 1.7)	97.5 (48.7 to 167.3)	6.0 (-20.3 to 44.3)
Turner syndrome	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	76.8 (13.8 to 182.9)	5.7 (-32.0 to 69.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.8 (11.9 to 186.3)	4.7 (-33.1 to 71.4)
Klinefelter syndrome	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	82.5 (17.7 to 177.8)	7.7 (-30.5 to 63.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.2 (8.3 to 195.7)	5.9 (-36.8 to 74.3)
Chromosomal unbalanced rearrangements	10.3 (8.9 to 11.9)	19.5 (16.2 to 24.4)	88.2 (48.3 to 147.9)	4.7 (-16.5 to 39.6)	1.4 (1.0 to 1.8)	2.8 (2.0 to 3.8)	104.4 (57.5 to 166.6)	7.3 (-15.2 to 43.2)
Other congenital anomalies	13.1 (8.4 to 18.0)	19.6 (12.2 to 28.7)	50.6 (21.9 to 82.4)	-14.4 (-31.1 to 1.9)	1.8 (1.1 to 3.0)	6.8 (4.2 to 10.1)	274.0 (145.1 to 499.9)	117.5 (43.1 to 247.3)
Skin and subcutaneous diseases	-	-	-	-	30.1 (18.7 to 45.7)	48.1 (30.7 to 74.0)	60.5 (41.5 to 78.1)	-4.9 (-15.6 to 5.1)
Dermatitis	257.4 (201.9 to 315.0)	442.2 (348.4 to 538.6)	71.7 (68.9 to 75.3)	-0.0 (-0.0 to 0.0)	6.6 (4.1 to 9.5)	11.2 (7.1 to 16.3)	70.3 (64.8 to 76.2)	0.1 (-2.4 to 2.7)
Psoriasis	57.1 (49.4 to 65.5)	103.7 (89.8 to 119.0)	81.5 (78.6 to 85.0)	-0.0 (-0.0 to 0.0)	4.6 (3.2 to 6.5)	8.4 (5.7 to 11.6)	81.0 (72.7 to 90.1)	0.1 (-3.9 to 4.5)
Cellulitis	4.1 (3.5 to 4.9)	7.4 (6.2 to 8.9)	82.2 (67.5 to 100.0)	-4.0 (-11.1 to 3.8)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	80.6 (56.3 to 106.7)	4.2 (-16.2 to 8.8)
Pyoderma	2.1 (1.7 to 2.5)	3.4 (2.9 to 4.2)	65.5 (59.1 to 71.3)	-5.0 (-7.8 to -2.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.0 (45.6 to 85.9)	-4.9 (-15.9 to 7.2)
Scabies	3.2 (2.6 to 3.7)	4.1 (3.3 to 4.8)	30.1 (3.8 to 60.7)	-22.1 (-38.2 to -3.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	30.3 (0.6 to 64.1)	-22.1 (-39.4 to -2.4)
Fungal skin diseases	292.5 (254.0 to 329.4)	529.5 (463.5 to 591.4)	81.3 (77.7 to 84.6)	1.6 (-0.1 to 3.0)	1.5 (0.7 to 3.5)	3.0 (1.2 to 5.1)	80.6 (78.9 to 84.6)	0.1 (-0.9 to 0.9)
Viral skin diseases	109.4 (87.2 to 131.9)	176.9 (142.0 to 212.3)	61.9 (57.1 to 66.0)	0.7 (-1.6 to 2.8)	3.4 (2.0 to 5.2)	5.5 (3.2 to 8.5)	61.3 (54.9 to 67.5)	0.7 (-2.8 to 4.2)
Acne vulgaris	849.9 (631.9 to 1,062.3)	1,073.7 (731.9 to 1,419.1)	27.7 (-18.5 to 84.0)	-16.0 (-46.4 to 21.7)	9.2 (4.1 to 17.7)	11.6 (5.3 to 23.0)	27.6 (-18.3 to 84.7)	-16.1 (-46.3 to 21.9)
Alopecia areata	6.7 (6.2 to 7.3)	12.5 (11.6 to 13.3)	85.2 (67.3 to 104.6)	0.1 (-9.2 to 10.7)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	84.4 (62.2 to 107.1)	0.3 (-11.7 to 13.4)
Pruritus	0.5 (0.3 to 0.6)	0.9 (0.6 to 1.2)	101.9 (16.4 to 211.6)	4.9 (-41.7 to 59.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.5 (12.1 to 226.0)	-4.3 (-43.7 to 67.9)
Urticaria	35.8 (26.1 to 48.5)	60.6 (42.9 to 78.2)	67.6 (21.0 to 154.3)	-4.4 (-32.4 to 42.5)	2.1 (1.3 to 3.2)	3.6 (2.1 to 5.4)	65.5 (19.2 to 154.6)	-7.0 (-32.7 to 41.4)
Decubitus ulcer	2.1 (1.8 to 2.5)	4.9 (4.3 to 5.5)	133.1 (91.7 to 180.6)	7.5 (-10.9 to 29.8)	0.3 (0.2 to 0.4)	0.7 (0.5 to 0.9)	130.8 (87.7 to 183.0)	8.0 (-12.3 to 32.7)
Other skin and subcutaneous diseases	275.7 (167.9 to 445.8)	540.1 (317.1 to 900.3)	95.2 (81.8 to 107.1)	-0.4 (-3.6 to 2.6)	1.6 (0.7 to 3.4)	3.1 (1.3 to 6.8)	94.7 (81.1 to 106.5)	-0.3 (-3.8 to 3.0)
Sense organ diseases	-	-	-	-	27.0 (18.0 to 39.1)	51.2 (34.3 to 73.6)	89.7 (78.6 to 102.2)	-9.5 (-14.6 to -4.4)
Glaucoma	5.3 (4.0 to 7.0)	8.2 (5.8 to 10.5)	53.7 (13.4 to 118.8)	-29.2 (-47.7 to -0.7)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.7)	0.4 (20.9 to 112.9)	-25.8 (-43.8 to -9.9)
Cataract	18.4 (12.6 to 26.1)	32.0 (19.7 to 48.9)	72.4 (23.0 to 163.0)	-28.9 (-49.0 to 9.4)	1.2 (0.7 to 1.7)	2.0 (1.2 to 3.2)	68.0 (28.7 to 127.3)	-30.7 (-47.0 to -5.9)
Macular degeneration	22.8 (15.4 to 31.8)	49.3 (34.3 to 66.8)	117.3 (75.7 to 176.9)	-4.4 (-21.9 to 20.8)	0.9 (0.6 to 1.5)	2.1 (1.2 to 3.3)	122.6 (82.2 to 177.7)	-3.4 (-20.4 to 20.5)
Uncorrected refractive error	44.6 (36.8 to 51.7)	820.6 (662.9 to 959.1)	84.6 (39.6 to 136.9)	8.2 (-30.8 to 39.4)	6.5 (3.7 to 10.7)	11.4 (6.4 to 19.1)	74.3 (43.6 to 110.6)	-12.1 (-28.2 to 6.5)
Age-related and other hearing loss	490.9 (424.7 to 554.1)	953.2 (813.7 to 1,090.0)	94.4 (84.7 to 102.8)	-8.9 (-13.4 to -5.0)	14.2 (9.2 to 21.1)	28.8 (19.0 to 41.9)	103.2 (87.3 to 124.8)	-6.8 (-13.8 to 0.8)
Other vision loss	21.1 (15.0 to 27.7)	25.6 (18.6 to 35.3)	20.5 (-3.3 to 49.9)	-40.0 (-52.1 to -26.7)	1.1 (0.7 to 1.6)	1.5 (0.9 to 2.3)	34.5 (12.0 to 62.1)	-33.4 (-44.5 to -21.0)
Other sense organ diseases	106.2 (101.4 to 110.7)	186.6 (178.2 to 195.1)	75.7 (65.6 to 86.6)	-0.2 (-6.0 to 5.7)	2.8 (1.7 to 4.2)	4.9 (3.0 to 7.3)	74.9 (63.1 to 87.4)	-0.2 (-6.7 to 6.9)
Oral disorders	-	-	-	-	11.8 (7.4 to 17.8)	21.4 (13.4 to 32.9)	81.2 (66.9 to 94.2)	-8.9 (-16.4 to -2.2)
Deciduous caries	266.3 (256.1 to 275.6)	402.3 (385.1 to 418.6)	51.2 (42.8 to 59.8)	-2.1 (-7.6 to 3.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	51.5 (36.2 to 67.6)	-2.0 (-11.9 to 8.3)
Permanent caries	2,045.8 (1,878.2 to 2,233.8)	3,542.0 (3,252.5 to 3,783.						

Appendix Table G.4 - Israel prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.								
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	223.7 (202.8 to 244.8)	394.7 (351.7 to 432.2)	76.9 (53.8 to 100.2)	-17.5 (-28.4 to -6.7)	6.1 (4.1 to 8.5)	10.7 (7.2 to 14.8)	76.1 (53.0 to 99.5)	-17.5 (-28.5 to -6.4)
Other oral disorders	75.5 (71.1 to 79.7)	135.1 (128.5 to 142.0)	78.9 (66.9 to 93.5)	0.2 (-6.4 to 8.5)	1.4 (1.4 to 3.3)	5.9 (2.5 to 5.9)	318.9 (65.6 to 93.9)	0.0 (-6.9 to 9.1)
Injuries	-	-	-	-	38.1 (29.0 to 48.3)	51.8 (37.5 to 69.3)	35.8 (21.1 to 50.9)	-33.0 (-40.2 to -25.6)
Transport injuries	-	-	-	-	6.5 (4.9 to 8.4)	6.7 (4.9 to 8.9)	3.2 (-7.8 to 16.1)	-46.8 (-52.3 to -40.2)
Road injuries	-	-	-	-	6.1 (4.6 to 7.9)	5.8 (4.2 to 7.7)	-5.2 (-15.3 to 6.9)	-51.1 (-56.2 to -44.8)
Pedestrian road injuries	-	-	-	-	1.4 (1.0 to 1.8)	1.3 (0.9 to 1.8)	-5.2 (-16.5 to 7.4)	-51.6 (-57.3 to -45.4)
Cyclist road injuries	-	-	-	-	0.3 (0.3 to 0.4)	0.4 (0.3 to 0.5)	5.4 (-10.0 to 22.9)	-44.8 (-52.6 to -35.6)
Motorcyclist road injuries	-	-	-	-	0.6 (0.4 to 0.8)	0.8 (0.6 to 1.1)	31.3 (7.6 to 60.5)	-31.7 (-43.9 to -16.8)
Motor vehicle road injuries	-	-	-	-	3.8 (2.8 to 4.9)	3.4 (2.5 to 4.4)	-11.5 (-20.7 to -1.1)	-54.1 (-58.9 to -49.8)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.8 (-53.3 to -36.4)	-71.9 (-75.8 to -67.1)
Other transport injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.9 (0.7 to 1.3)	137.1 (109.6 to 168.1)	19.5 (5.7 to 35.4)
Unintentional injuries	-	-	-	-	30.3 (23.1 to 38.5)	44.0 (31.7 to 59.0)	45.1 (29.4 to 60.8)	-29.5 (-37.2 to -21.4)
Falls	-	-	-	-	22.1 (16.7 to 28.0)	34.5 (24.8 to 45.9)	56.1 (36.2 to 76.1)	-26.3 (-35.8 to -16.5)
Drowning	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	2.8 (0.1 to 16.1)	-46.5 (-52.6 to -39.6)
Fire, heat, and hot substances	-	-	-	-	0.8 (0.5 to 1.2)	0.9 (0.5 to 1.5)	19.2 (2.8 to 40.2)	-38.0 (-46.2 to -27.5)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.5 (-49.8 to -13.5)	-63.1 (-72.1 to -52.3)
Exposure to mechanical forces	-	-	-	-	6.2 (4.6 to 8.1)	4.9 (3.5 to 6.6)	-21.5 (-29.0 to -11.8)	-57.1 (-61.1 to -52.0)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	6.3 (-18.0 to 9.0)	-48.5 (-55.2 to -40.9)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	70.2 (44.0 to 93.8)	-10.5 (-24.2 to 1.7)
Other exposure to mechanical forces	-	-	-	-	6.1 (4.5 to 8.0)	4.7 (3.4 to 6.4)	-22.1 (-29.8 to -12.3)	-57.4 (-61.5 to -52.2)
Adverse effects of medical treatment	-	-	-	-	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	86.0 (71.1 to 101.8)	-4.5 (-12.5 to 3.9)
Animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	89.0 (69.5 to 109.2)	3.8 (-6.2 to 14.8)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	87.7 (54.3 to 128.8)	5.1 (-13.6 to 28.4)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	89.0 (66.3 to 112.5)	3.5 (-8.2 to 15.8)
Foreign body	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.5)	44.6 (26.9 to 67.1)	-20.7 (-31.1 to -7.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	27.6 (8.9 to 52.3)	-33.0 (-42.7 to -19.9)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	53.5 (35.5 to 71.4)	-12.7 (-23.8 to -1.5)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	47.5 (24.1 to 76.8)	-19.0 (-32.2 to -2.3)
Other unintentional injuries	-	-	-	-	0.7 (0.5 to 0.9)	2.7 (1.9 to 3.8)	317.7 (260.4 to 382.1)	98.0 (70.6 to 129.7)
Self-harm and interpersonal violence	-	-	-	-	0.5 (0.4 to 0.7)	0.6 (0.4 to 0.8)	17.3 (6.8 to 28.5)	-39.3 (-44.6 to -33.5)
Self-harm	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	50.7 (32.7 to 71.5)	-23.7 (-32.6 to -13.0)
Interpersonal violence	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	2.3 (-7.2 to 13.2)	-46.5 (-51.4 to -40.9)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	17.5 (6.7 to 28.1)	-39.0 (-44.6 to -33.5)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	23.2 (13.6 to 34.4)	-35.7 (-40.6 to -30.2)
Assault by other means	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	6.4 (-16.6 to 5.8)	-50.9 (-56.2 to -44.6)
Forces of nature, war, and legal intervention	-	-	-	-	0.8 (0.3 to 1.6)	0.4 (0.2 to 0.8)	-38.0 (-60.8 to -11.0)	-57.4 (-73.0 to -38.9)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	0.8 (0.3 to 1.6)	0.4 (0.2 to 0.8)	-38.2 (-60.9 to -11.3)	-57.5 (-73.0 to -39.0)

Appendix Table G.4 - Italy prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	7,548.0 (5,675.5 to 9,689.6)	9,078.8 (6,773.2 to 11,621.8)	20.2 (16.7 to 24.6)	20.2 (-3.9 to 2.9)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	294.3 (202.2 to 421.9)	285.9 (198.2 to 400.0)	-2.5 (-13.9 to 9.1)	-3.3 (-13.0 to 7.1)
HIV/AIDS and tuberculosis	-	-	-	-	12.7 (6.5 to 21.4)	10.4 (6.4 to 16.0)	-15.3 (-43.2 to 17.9)	-31.4 (-53.5 to -4.8)
Tuberculosis	10.7 (10.2 to 11.3)	9.7 (9.1 to 10.3)	-9.8 (-14.3 to -5.7)	-19.5 (-23.3 to -15.8)	3.2 (2.2 to 4.5)	2.9 (2.0 to 4.0)	-10.9 (-25.9 to 9.3)	-19.7 (-33.5 to -1.2)
HIV/AIDS	-	-	-	-	9.4 (3.8 to 17.5)	7.6 (4.0 to 12.4)	-17.0 (-50.3 to 34.6)	-35.9 (-61.2 to 5.5)
HIV/AIDS resulting in mycobacterial infection	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-68.0 (-82.5 to -50.0)	-73.2 (-85.1 to -58.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-68.0 (-82.6 to 50.0)	-73.2 (-85.1 to -58.0)
HIV/AIDS resulting in other diseases	67.7 (37.3 to 100.1)	97.8 (58.9 to 147.8)	43.4 (7.0 to 108.2)	8.1 (-19.8 to 56.5)	9.4 (3.8 to 17.5)	7.5 (4.0 to 12.4)	-16.9 (-50.2 to 35.2)	-35.7 (-61.1 to 5.9)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	31.6 (20.2 to 47.8)	31.6 (20.3 to 47.4)	-0.1 (-7.0 to 7.5)	-8.6 (-14.1 to -2.0)
Diarrheal diseases	20.1 (18.1 to 22.3)	20.3 (17.9 to 22.8)	0.9 (-14.2 to 18.8)	-16.0 (-32.0 to 4.5)	3.2 (2.1 to 4.4)	3.1 (2.1 to 4.4)	3.4 (-1.1 to 21.5)	25.1 (-35.2 to 7.9)
Intestinal infectious diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-21.1 (-37.1 to 4.5)	-22.6 (-37.8 to -7.3)
Typhoid fever	0.6 (0.6 to 0.7)	0.5 (0.4 to 0.5)	-19.2 (-28.5 to -7.4)	-21.3 (-30.6 to -8.4)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-19.2 (-28.5 to -7.4)	-21.3 (-30.6 to -8.4)
Paratyphoid fever	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.3)	10.8 (-15.2 to 41.9)	13.9 (-10.9 to 39.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.8 (-15.3 to 42.3)	13.9 (-11.0 to 39.7)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-51.4 (-84.3 to 36.4)	-52.7 (-84.6 to 36.4)
Lower respiratory infections	6.5 (6.2 to 6.7)	6.8 (6.5 to 7.1)	4.9 (0.1 to 11.0)	-23.5 (-27.0 to -19.4)	0.6 (0.4 to 0.9)	0.7 (0.5 to 0.9)	4.5 (-11.9 to 23.5)	-22.0 (-33.5 to -8.0)
Upper respiratory infections	855.3 (815.8 to 902.7)	899.7 (859.1 to 937.3)	5.4 (-1.6 to 12.1)	0.8 (-6.0 to 7.1)	10.0 (5.6 to 16.6)	10.4 (5.8 to 17.2)	5.0 (-2.5 to 12.4)	1.0 (-6.3 to 8.0)
Otitis media	715.6 (633.4 to 811.9)	664.5 (588.3 to 749.7)	-7.1 (-21.6 to 10.4)	-14.1 (-24.4 to -0.1)	13.4 (7.9 to 21.3)	12.3 (7.0 to 19.7)	-8.7 (-22.5 to 8.5)	-15.4 (-25.9 to -1.7)
Meningitis	-	-	-	-	1.7 (1.1 to 2.6)	1.9 (1.2 to 2.7)	8.0 (-14.5 to 36.8)	1.1 (-21.6 to 30.4)
Pneumococcal meningitis	5.7 (3.6 to 9.6)	6.0 (3.6 to 10.1)	5.2 (-20.6 to 33.1)	-10.2 (-33.0 to 14.2)	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.8)	4.1 (-24.9 to 46.5)	7.2 (-33.5 to 38.8)
H influenzae type B meningitis	3.2 (1.0 to 7.7)	3.2 (1.0 to 7.4)	2.2 (-36.9 to 86.0)	-4.9 (-41.9 to 83.1)	0.4 (0.2 to 0.7)	0.5 (0.2 to 0.8)	5.1 (-41.3 to 128.1)	13.2 (-45.4 to 129.1)
Meningococcal meningitis	2.1 (0.6 to 5.5)	2.2 (0.7 to 5.8)	6.8 (-35.7 to 51.4)	-7.3 (-43.2 to 43.2)	0.3 (0.1 to 0.6)	0.3 (0.2 to 0.6)	10.0 (-38.9 to 64.9)	-0.5 (-46.5 to 58.4)
Other meningitis	3.4 (1.6 to 7.2)	3.5 (1.6 to 7.9)	2.3 (-23.7 to 37.0)	-5.1 (-26.3 to 31.1)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.8)	6.7 (-25.8 to 58.1)	1.1 (-28.5 to 55.1)
Encephalitis	3.6 (1.5 to 10.0)	4.2 (1.8 to 12.0)	16.7 (-3.2 to 42.6)	-2.6 (-17.4 to 23.4)	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.9)	18.9 (-2.5 to 50.3)	2.5 (-16.7 to 32.6)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.2 (-93.7 to 407.3)	-49.9 (-94.1 to 312.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.2 (-93.8 to 410.2)	-49.9 (-94.3 to 315.7)
Whooping cough	2.7 (2.1 to 3.5)	1.6 (1.2 to 2.1)	-41.2 (-43.2 to -39.2)	-41.5 (-43.4 to -39.4)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-41.2 (-54.9 to -25.4)	-41.4 (-55.3 to -25.5)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-72.5 (-83.3 to -60.0)	-77.2 (-86.6 to -67.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-74.2 (-84.7 to -48.8)	-79.1 (-87.7 to -53.6)
Measles	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-44.5 (-46.9 to -41.7)	-44.5 (-46.4 to -41.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.5 (-46.9 to -41.7)	-43.9 (-46.4 to -41.1)
Varicella and herpes zoster	46.7 (41.6 to 52.3)	55.2 (49.2 to 62.5)	18.5 (1.0 to 39.6)	0.5 (-11.7 to 13.2)	1.9 (1.2 to 3.1)	2.4 (1.5 to 3.7)	24.0 (0.0 to 55.9)	1.9 (-17.2 to 25.3)
Neglected tropical diseases and malaria	-	-	-	-	1.1 (0.7 to 1.6)	0.6 (0.4 to 0.9)	-44.7 (-61.8 to -15.4)	-53.1 (-67.1 to -29.0)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.6 (-72.9 to 278.8)	19.6 (-73.5 to 276.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.6 (-72.1 to 289.7)	23.2 (-72.4 to 285.5)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.2 (-40.7 to -12.8)	-35.2 (-46.6 to -20.5)
Visceral leishmaniasis	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-29.9 (-42.4 to -13.5)	-37.0 (-48.7 to -21.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.9 (-42.5 to -13.5)	-37.0 (-48.7 to -21.4)
Cutaneous and mucocutaneous leishmaniasis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-4.5 (-23.4 to 20.6)	-10.1 (-26.1 to 11.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.5 (-23.4 to 20.7)	-10.1 (-26.1 to 11.3)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	1.1 (0.4 to 2.2)	0.6 (0.3 to 1.1)	-43.6 (-77.8 to 30.5)	-54.4 (-81.3 to 7.8)	0.4 (0.2 to 0.9)	0.2 (0.1 to 0.5)	-39.7 (-76.1 to 45.3)	-50.0 (-80.2 to 21.7)
Cystic echinococcosis	6.8 (5.9 to 7.6)	3.5 (3.3 to 3.7)	-48.6 (-55.4 to -41.6)	-56.3 (-62.2 to -51.8)	0.6 (0.4 to 0.9)	0.3 (0.2 to 0.5)	-47.1 (-59.8 to -29.0)	-54.9 (-64.3 to -42.1)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.0 (-60.9 to 11.3)	-16.1 (-65.6 to 2.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.0 (-60.9 to 11.6)	-16.1 (-65.9 to 2.1)
Intestinal nematode infections	-	-	-	-	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.1 (-35.9 to 25.7)	-24.5 (-44.7 to 13.6)
Maternal disorders	-	-	-	-	0.8 (0.5 to 1.1)	0.9 (0.5 to 1.3)	11.8 (-12.3 to 43.1)	17.4 (-8.5 to 49.6)
Maternal hemorrhage	7.1 (5.3 to 8.9)	8.0 (5.3 to 10.7)	11.2 (-21.5 to 56.2)	19.5 (-17.3 to 66.8)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	12.4 (-49.4 to 103.9)	22.6 (-46.7 to 121.3)
Maternal sepsis and other maternal infections	2.5 (1.7 to 3.6)	2.5 (1.6 to 3.7)	0.0 (-33.8 to 37.9)	-18.6 (-44.7 to 13.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.9 (-30.8 to 26.3)	-11.7 (-33.0 to 14.3)
Maternal hypertensive disorders	6.4 (4.2 to 9.3)	7.4 (4.8 to 10.8)	17.2 (1.4 to 33.4)	19.5 (5.7 to 33.2)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	16.4 (-13.6 to 52.9)	19.1 (-10.4 to 52.8)
Obstructed labor	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	5.4 (-4.2 to 15.9)	14.0 (4.0 to 25.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	5.4 (-4.2 to 16.1)	14.0 (3.8 to 25.5)
Complications of abortion	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.3)	15.9 (5.9 to 25.1)	20.8 (11.0 to 30.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.9 (5.9 to 25.2)	20.8 (10.8 to 30.5)
Other maternal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	8.1 (-34.6 to 62.5)	13.9 (-32.1 to 70.8)
Neonatal disorders	-	-	-	-	54.2 (38.4 to 70.8)	71.1 (47.9 to 96.1)	30.2 (-3.9 to 72.0)	24.5 (-8.3 to 65.2)
Preterm birth complications	258.4 (191.4 to 356.8)	331.7 (240.2 to 464.1)	28.3 (4.6 to 56.1)	20.8 (-1.6 to 46.1)	31.4 (22.0 to 41.7)	42.7 (29.9 to 58.1)	35.3 (6.7 to 76.1)	29.8 (2.0 to 69.1)
Neonatal encephalopathy due to birth asphyxia and trauma	58.5 (34.0 to 112.4)	34.9 (17.6 to 79.3)	-42.5 (-63.6 to -10.5)	-45.2 (-64.9 to -16.4)	13.7 (9.3 to 19.6)	8.4 (5.4 to 12.8)	-8.4 (-41.3 to -1.2)	-40.2 (-63.2 to -4.1)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	58.3 (40.7 to 92.7)	56.9 (39.4 to 90.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.3 (15.9 to 116.3)	57.3 (14.8 to 114.4)
Hemolytic disease and other neonatal jaundice	11.0 (3.0 to 25.6)	11.1 (1.8 to 24.1)	-4.0 (-86.9 to 490.5)	-6.9 (-87.5 to 477.5)	4.7 (1.2 to 10.8)	4.8 (0.7 to 10.9)	-1.3 (-86.0 to 515.4)	-6.3 (-86.8 to 484.0)
Other neonatal disorders	-	-	-	-	4.4 (2.8 to 7.6)	15.1 (5.4 to 23.8)	286.7 (8.2 to 456.5)	269.5 (2.5 to 439.8)
Nutritional deficiencies	-	-	-	-	180.2 (114.1 to 270.4)	157.4 (100.9 to 238.8)	-11.8 (-28.3 to 2.6)	-8.4 (-26.5 to 3.8)
Protein-energy malnutrition	0.1 (0.0 to 0.3)	1.1 (0.1 to 2.3)	1,514.1 (1,17.0 to 2,658.0)	658.5 (45.7 to 1,119.7)	0.3 (0.0 to 0.0)	0.1 (0.0 to 0.3)	1,238.9 (46.8 to 2,367.4)	941.9 (-63.6 to 1,009.8)
Iodine deficiency	3,251.4 (2,349.7 to 4,521.7)	1,642.7 (1,157.8 to 2,226.7)	-49.0 (-69.8 to -19.9)	-51.8 (-71.3 to -25.5)	57.7 (31.9 to 98.8)	29.0 (16.2 to 51.0)	-48.1 (-70.1 to -19.9)	-51.7 (-71.2 to -25.4)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-

Appendix Table G.4 - Italy prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	5,577.5 (5,382.2 to 5,754.6)	6,294.6 (5,780.8 to 6,526.3)	13.1 (3.5 to 18.8)	5.5 (-3.3 to 11.8)	122.5 (79.9 to 181.0)	128.2 (80.3 to 190.1)	5.3 (-17.0 to 13.8)	5.9 (-18.2 to 13.8)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	164.2 (-59.6 to 413.8)	25.8 (-71.9 to 134.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	13.7 (8.3 to 24.3)	14.0 (8.2 to 24.8)	0.2 (-35.4 to 79.2)	1.2 (-43.6 to 116.4)
Sexually transmitted diseases excluding HIV	-	-	-	-	5.3 (2.8 to 10.0)	5.1 (2.7 to 9.6)	-0.9 (-20.1 to 16.6)	-10.9 (-25.9 to 12.2)
Syphilis	2.9 (2.6 to 3.3)	4.6 (4.1 to 5.2)	58.9 (30.1 to 88.8)	19.2 (-3.1 to 44.0)	0.5 (0.3 to 0.8)	0.8 (0.5 to 1.2)	58.2 (14.1 to 116.0)	18.4 (-14.9 to 65.6)
Chlamydial infection	643.5 (487.7 to 796.0)	495.4 (342.1 to 660.7)	-22.7 (-49.6 to 17.7)	-15.8 (-47.3 to 30.9)	1.9 (0.9 to 3.6)	1.3 (0.6 to 2.6)	-30.2 (-58.4 to 25.7)	-24.4 (-56.7 to 39.4)
Gonococcal infection	177.4 (114.5 to 265.7)	130.2 (69.2 to 193.6)	-24.1 (-70.2 to 45.6)	-7.6 (-65.8 to 79.4)	0.7 (0.3 to 1.2)	0.5 (0.2 to 1.0)	-21.3 (-55.2 to 23.7)	-7.4 (-49.3 to 49.3)
Trichomoniasis	145.6 (80.5 to 222.2)	163.4 (86.8 to 232.4)	18.7 (-56.4 to 133.8)	18.7 (-60.8 to 147.8)	0.2 (0.1 to 0.6)	0.3 (0.1 to 0.6)	22.1 (-65.7 to 163.0)	24.0 (-68.4 to 179.5)
Genital herpes	7,004.3 (6,490.0 to 7,553.8)	7,903.3 (7,268.8 to 8,570.0)	12.9 (1.5 to 25.6)	-6.6 (-16.1 to 4.0)	1.8 (0.4 to 4.4)	2.0 (0.6 to 4.9)	10.5 (-9.9 to 24.4)	46.5 (-1.3 to 5.2)
Other sexually transmitted diseases	8.5 (6.5 to 10.8)	5.7 (4.3 to 7.4)	-32.2 (-45.8 to -16.0)	-39.1 (-50.5 to -24.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-23.3 (-45.0 to 6.3)	-17.5 (-47.1 to 6.6)
Hepatitis	-	-	-	-	2.3 (1.4 to 3.3)	2.1 (1.4 to 3.1)	-0.8 (-15.6 to 7.6)	-10.0 (-19.7 to 1.3)
Hepatitis A	46.2 (44.8 to 47.5)	44.4 (43.2 to 45.6)	-3.7 (-4.0 to -3.4)	-3.3 (-3.7 to -2.9)	1.4 (0.9 to 2.1)	1.4 (0.9 to 2.0)	-0.2 (-13.0 to 10.1)	-2.0 (-12.9 to 10.5)
Hepatitis B	1,150.1 (1,037.2 to 1,250.1)	924.6 (841.3 to 1,012.3)	-19.6 (-29.0 to -8.2)	-28.7 (-37.7 to -18.6)	0.7 (0.4 to 1.0)	0.6 (0.3 to 0.9)	-9.4 (-38.1 to 29.8)	23.9 (-46.9 to 7.2)
Hepatitis C	1,671.0 (1,547.9 to 1,793.3)	1,601.6 (1,481.0 to 1,730.6)	-4.2 (-13.5 to 7.0)	-21.3 (-28.9 to -12.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	8.0 (-38.6 to 34.1)	25.3 (-46.3 to 2.7)
Hepatitis E	-	-	-	-	30.0 (9.9 to 73.6)	30.7 (8.2 to 63.4)	-	-
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.7 (3.9 to 58.7)	-7.0 (-24.0 to 20.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.8 (4.0 to 61.4)	-7.3 (-24.3 to 21.4)
Other infectious diseases	241.9 (201.3 to 375.6)	258.3 (215.9 to 434.9)	5.2 (-37.1 to 90.8)	3.4 (-42.6 to 114.0)	6.2 (3.6 to 13.6)	6.7 (3.7 to 16.3)	5.8 (-51.1 to 189.7)	11.2 (-55.6 to 230.4)
Non-communicable diseases	-	-	-	-	4,881.0 to 8,359.7	6,121.1 to 10,384.3	(20.0 to 29.4)	(-0.9 to 6.8)
Neoplasms	-	-	-	-	113.1 (84.2 to 145.1)	172.3 (125.5 to 223.9)	52.4 (40.2 to 64.7)	3.0 (-4.7 to 11.2)
Esophageal cancer	4.7 (3.7 to 5.7)	4.6 (3.5 to 6.5)	-3.3 (-30.4 to 50.9)	-33.1 (-51.7 to 5.1)	0.7 (0.5 to 1.0)	0.7 (0.4 to 1.0)	-0.8 (-31.6 to 46.2)	-34.9 (-52.0 to 2.4)
Stomach cancer	57.2 (49.8 to 65.9)	52.5 (42.9 to 63.3)	-8.0 (-23.5 to 11.3)	-41.6 (-51.3 to -30.7)	6.1 (4.4 to 8.0)	5.3 (3.8 to 7.1)	-13.2 (-27.6 to 6.6)	-44.4 (-53.5 to -33.0)
Liver cancer	-	-	-	-	2.9 (1.3 to 2.7)	3.2 (2.0 to 4.9)	7.8 (12.5 to 14.9)	7.9 (23.4 to 69.6)
Liver cancer due to hepatitis B	2.1 (1.4 to 2.9)	3.5 (2.0 to 5.9)	65.3 (-8.2 to 225.8)	19.8 (-34.4 to 138.1)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.7)	45.8 (-13.5 to 175.2)	6.0 (-37.9 to 98.6)
Liver cancer due to hepatitis C	3.3 (2.2 to 4.5)	17.8 (11.9 to 26.0)	421.4 (230.3 to 788.3)	252.5 (120.0 to 511.7)	0.5 (0.3 to 0.7)	2.0 (1.2 to 3.1)	332.0 (185.0 to 599.8)	193.8 (90.5 to 379.5)
Liver cancer due to alcohol use	8.2 (5.9 to 10.9)	5.5 (3.2 to 9.1)	-35.6 (-60.5 to 19.6)	-57.1 (-73.7 to -20.5)	1.1 (0.7 to 1.5)	0.6 (0.3 to 1.1)	-11.4 (-65.1 to 5.8)	-60.8 (-76.7 to -29.5)
Liver cancer due to other causes	1.1 (0.7 to 1.6)	0.7 (0.4 to 1.1)	-40.3 (-69.7 to 15.2)	-60.0 (-78.7 to -22.0)	0.2 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-44.5 (-70.0 to 0.4)	42.9 (-78.9 to -33.3)
Larynx cancer	24.0 (17.4 to 29.6)	20.1 (15.2 to 26.4)	-16.4 (-36.6 to 12.0)	-40.1 (-54.2 to -17.9)	2.4 (1.5 to 3.4)	1.9 (1.2 to 2.8)	-22.5 (-42.1 to 4.1)	-44.7 (-58.7 to -25.0)
Tracheal, bronchus and lung cancer	63.4 (58.0 to 69.1)	75.9 (64.5 to 86.7)	20.0 (-0.6 to 40.0)	-18.4 (-32.6 to -5.2)	8.9 (6.5 to 11.3)	10.2 (7.3 to 13.3)	15.1 (-5.1 to 34.7)	-21.6 (-35.6 to -8.0)
Breast cancer	387.1 (355.3 to 419.4)	643.0 (602.0 to 690.3)	66.1 (49.2 to 84.5)	10.3 (-0.3 to 22.6)	20.5 (14.1 to 28.3)	30.3 (20.7 to 42.0)	46.7 (29.1 to 65.8)	-1.3 (-12.7 to 11.3)
Cervical cancer	19.2 (15.9 to 26.4)	29.1 (16.6 to 40.1)	71.3 (-22.5 to 131.4)	1.4 (-4.1 to 7.0)	2.1 (0.9 to 2.1)	2.1 (1.0 to 3.3)	11.0 (-21.9 to 34.1)	21.0 (-46.5 to -5.2)
Uterine cancer	38.5 (30.1 to 58.9)	73.5 (42.4 to 97.9)	104.3 (-17.0 to 179.5)	47.4 (-38.3 to 107.5)	2.5 (1.6 to 4.0)	4.7 (2.5 to 7.0)	99.8 (-24.3 to 178.7)	44.2 (-43.8 to 104.3)
Prostate cancer	154.2 (131.0 to 178.8)	359.5 (300.0 to 430.5)	132.1 (92.2 to 186.6)	50.8 (24.8 to 83.2)	12.0 (8.6 to 16.1)	27.2 (18.5 to 38.2)	126.8 (84.0 to 184.7)	44.3 (18.2 to 78.7)
Colon and rectum cancer	173.4 (163.5 to 184.2)	296.0 (259.7 to 334.6)	70.9 (47.7 to 94.7)	13.0 (-1.9 to 27.9)	14.2 (10.5 to 18.5)	23.2 (16.5 to 30.5)	63.4 (40.5 to 86.3)	7.3 (-7.0 to 20.8)
Lip and oral cavity cancer	22.6 (18.5 to 27.2)	23.9 (18.9 to 29.9)	5.3 (-21.3 to 43.4)	-26.3 (-42.9 to 20.0)	2.0 (1.5 to 2.7)	2.1 (1.4 to 2.9)	1.9 (-21.9 to 34.1)	-28.3 (-46.5 to -5.2)
Nasopharynx cancer	4.0 (2.9 to 5.6)	2.6 (1.9 to 3.9)	-34.2 (-56.6 to -3.1)	-49.2 (-65.6 to -25.6)	0.4 (0.2 to 0.5)	0.2 (0.1 to 0.4)	0.2 (-5.6 to 6.2)	-50.6 (-66.4 to -28.9)
Other pharynx cancer	9.0 (6.3 to 12.4)	8.4 (5.8 to 12.9)	-8.8 (-42.0 to 55.3)	-32.0 (-56.4 to 17.6)	0.8 (0.5 to 1.1)	0.8 (0.5 to 1.2)	-7.4 (-39.5 to 56.8)	-31.0 (-54.5 to 15.1)
Gallbladder and biliary tract cancer	3.9 (3.1 to 5.1)	4.4 (2.9 to 5.7)	12.9 (-20.6 to 54.9)	-28.5 (-49.1 to -4.3)	0.9 (0.6 to 1.3)	1.0 (0.6 to 1.5)	10.3 (-24.6 to 56.1)	-28.7 (-50.5 to -2.9)
Pancreatic cancer	7.5 (6.5 to 8.6)	13.4 (10.9 to 16.1)	77.8 (39.9 to 123.1)	17.0 (-7.9 to 46.6)	1.4 (1.0 to 1.9)	2.3 (1.6 to 3.2)	67.7 (33.2 to 113.2)	11.6 (-10.3 to 39.9)
Malignant skin melanoma	40.6 (30.1 to 56.7)	74.2 (50.2 to 103.8)	83.6 (37.9 to 128.0)	25.3 (4.0 to 70.0)	8.1 (1.6 to 3.7)	4.3 (2.6 to 6.9)	76.1 (31.5 to 121.0)	33.2 (-1.9 to 64.2)
Non-melanoma skin cancer	36.4 (28.6 to 47.4)	68.9 (52.3 to 87.2)	90.5 (34.3 to 159.3)	18.9 (-15.4 to 62.2)	0.8 (0.5 to 1.3)	1.9 (1.1 to 3.0)	137.5 (67.8 to 250.4)	42.3 (3.9 to 104.1)
Ovarian cancer	19.7 (16.9 to 22.8)	29.0 (22.7 to 35.3)	48.1 (13.5 to 83.3)	4.9 (-17.8 to 30.8)	2.4 (1.7 to 3.3)	3.5 (2.3 to 4.9)	43.9 (6.2 to 91.5)	2.2 (-23.8 to 34.8)
Testicular cancer	10.1 (7.2 to 15.0)	10.9 (6.3 to 16.3)	8.4 (-38.4 to 74.6)	2.5 (-43.5 to 70.8)	0.6 (0.4 to 1.0)	0.6 (0.3 to 1.1)	0.9 (-41.8 to 72.0)	-0.8 (-47.7 to 66.7)
Kidney cancer	42.1 (36.8 to 47.4)	77.1 (63.1 to 92.3)	82.7 (49.3 to 123.3)	27.1 (4.5 to 53.9)	3.0 (2.1 to 4.0)	5.2 (3.5 to 7.2)	78.3 (42.0 to 116.8)	22.6 (-1.0 to 49.2)
Bladder cancer	109.7 (94.5 to 125.5)	141.9 (112.8 to 171.1)	28.8 (4.0 to 60.0)	-16.8 (-31.8 to 2.0)	8.1 (5.8 to 10.7)	10.1 (6.9 to 14.1)	10.1 (-0.3 to 56.3)	-19.3 (-34.9 to -0.7)
Brain and nervous system cancer	17.8 (14.4 to 20.4)	25.3 (20.4 to 30.3)	41.7 (18.1 to 73.0)	8.5 (-9.8 to 32.6)	1.8 (1.2 to 2.5)	2.5 (1.7 to 3.4)	36.4 (8.6 to 67.3)	4.7 (-14.5 to 28.1)
Thyroid cancer	33.1 (26.1 to 39.3)	42.3 (32.4 to 58.4)	26.1 (-5.0 to 83.0)	-0.9 (-23.4 to 46.0)	1.9 (1.2 to 2.9)	2.4 (1.6 to 3.8)	23.9 (-6.6 to 81.3)	-3.6 (-27.5 to 44.6)
Mesothelioma	2.5 (2.0 to 3.2)	2.7 (2.1 to 4.5)	5.5 (-15.3 to 75.6)	0.5 (-4.3 to 18.5)	0.6 (0.3 to 0.7)	0.6 (0.3 to 1.0)	0.6 (-21.4 to 87.5)	-2.8 (-45.1 to 27.9)
Hodgkin lymphoma	14.7 (10.7 to 19.3)	11.8 (8.7 to 15.9)	-20.3 (-40.6 to 8.4)	-27.7 (-48.1 to 1.1)	1.2 (0.8 to 1.7)	0.9 (0.6 to 1.4)	-21.9 (-41.3 to 2.9)	-31.1 (-49.0 to -5.5)
Non-Hodgkin lymphoma	54.1 (40.6 to 78.7)	92.1 (53.1 to 119.7)	78.4 (-16.3 to 128.8)	23.7 (-40.9 to 55.3)	3.9 (2.5 to 5.9)	6.4 (3.5 to 9.3)	73.0 (-19.4 to 121.5)	20.2 (-43.8 to 50.7)
Multiple myeloma	12.7 (8.6 to 18.8)	19.6 (13.1 to 29.2)	54.2 (0.6 to 131.9)	5.7 (-29.9 to 58.0)	2.5 (1.5 to 4.0)	3.7 (2.2 to 5.7)	48.6 (-3.6 to 127.3)	1.9 (-33.1 to 55.3)
Leukemia	28.4 (24.8 to 32.0)	48.3 (36.1 to 52.9)	55.8 (24.8 to 92.7)	1.8 (-17.7 to 23.6)	3.7 (2.7 to 4.9)	5.6 (3.8 to 7.4)	48.0 (16.7 to 85.9)	-2.8 (-21.0 to 20.4)
Other neoplasms	56.4 (48.3 to 69.5)	143.6 (107.2 to 176.1)	157.3 (83.0 to 232.9)	82.2 (33.6 to 127.6)	4.0 (2.8 to 5.5)	9.5 (6.2 to 13.4)	139.9 (65.6 to 215.1)	70.1 (23.9 to 112.6)
Cardiovascular diseases	-	-	-	-	281.8 (198.3 to 386.0)	382.7 (264.3 to 518.5)	36.2 (11.9 to 61.2)	-9.4 (-25.6 to 7.3)
Rheumatic heart disease	9.7 (9.0 to 10.3)	13.0 (12.2 to 13.8)	34.7 (21.7 to 47.3)	-3.2 (-12.0 to 4.9)	1.0 (0.6 to 1.4)	1.4 (0.9 to 1.9)	32.4 (2.1 to 104.5)	-6.1 (-30.1 to 48.1)
Ischemic heart disease	1,582.4 (1,316.6 to 1,905.0)	1,116.0 (822.8 to 2,429.2)	34.8 (8.7 to 62.7)	-11.6 (-29.0 to 8.0)	-11.6 (68.9 to 146.7)	-11.6 (90.0 to 186.7)	26.7 (-1.9 to 58.1)	28.7 (-34.8 to 2.9)
Cerebrovascular disease	-	-	-	-	53.4 (36.9 to 71.0)	66.2 (45.2 to 88.8)	23.1 (-0.3 to 57.1)	-14.0 (-28.6 to 7.0)
Ischemic stroke	310.4 (264.4 to 356.3)	376.7 (308.3 to 439.1)	19.6 (-3.6 to 57.2)	-17.6 (-31.5 to 4.0)	44.0 (30.5 to 59.7)	53.4 (36.5 to 72.8)	20.0 (-2.7 to 55.9)	-16.3 (-30.7 to 5.4)
Hemorrhagic stroke	64.9 (54.5 to 74.8)	88.9 (74.4 to 104.6)	37.0 (9.2 to 78.4)	-3.3 (-20.5 to 21.5)	9.4 (6.3 to 12.7)	12.8 (8.7 to 17.4)	35.8 (6.3 to 75.2)	-2.8 (-21.7 to 21.9)
Hypertensive heart disease	125.2 (109.2 to 140.9)	194.3 (170.8 to 221.1)	55.0 (29.8 to 86.0)	0.7 (-15.9 to 18.3)	13.3 (9.1 to 18.4)	20.6 (14.1 to 28.7)	55.0 (29.0 to 88.2)	0.3 (-15.8 to 20.1)
Cardiomyopathy and myocarditis	123.0 (105.4 to 142.6)	136.7 (123.1 to 153.6)	11.0 (-6.6 to 35.4)	-25.2 (-36.4 to -9.0)	1.0 (0.6 to 1.8)	1.4 (0.7 to 1.9)	14.4 (-6.8 to 35.3)	24.8 (-36.0 to 8.8)
Atrial fibrillation and flutter	332.9 (267.9 to 410.7)	318.2 (244.0 to 387.8)	-2.1 (-32.4 to 23.8)	-39.4 (-57.2 to -23.3)	25.5 (16.6 to 36.3)	24.0 (15.3 to 35.2)	-3.4 (-33.9 to 23.1)	-39.5 (-57.5 to -22.1)
Peripheral vascular disease	2,286.7 (1,846.2 to 2,841.0)	3,629.6 (2,755.1 to 4,492.7)	58.3 (15.8 to 120.5)	4.6 (-24.3 to 48.3)	2.4 (0.8 to 5.1)	5.0 (2.2 to 10.4)	122.1 (-9.6 to 392.9)	44.3 (-47.1 to 198.8)
Endocarditis	1.5 (1.2 to 2.0)	5.6 (4.8 to 6.5)	261.7 (189.2 to 343.6)	172.1 (122.3 to 237.1)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.7)	158.3 (93.0 to 243.8)	94.8 (50.0 to 156.5)
Other cardiovascular and circulatory diseases	998.9 (750.3 to 1,456.6)	1,685.8 (1,000.1 to 2,236.0)	67.8 (-6.6 to 205.6)	57.9 (-35.9 to 105.4)	67.8 (35.6 to 110.9)	69.7 (62.3 to 177.2)	11.5 (-6.9 to 210.2)	25.1 (-36.4 to 108

Appendix Table G.4 - Italy prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumonia	-	-	-	-	0.1	0.1	1.9	-28.0
Silicosis	0.3	0.3	9.6	-23.3	0.1	0.1	(-2.7 to 6.4)	(-31.1 to -24.8)
Asbestosis	(0.3 to 0.3)	(0.3 to 0.3)	(3.8 to 14.8)	(-27.2 to -19.6)	0.0	0.0	(3.7 to 14.9)	(-27.3 to -19.6)
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.1	0.1	-20.5	-40.5	0.0	0.0	-20.5	-40.5
Asthma	(0.1 to 0.1)	(0.1 to 0.1)	(-24.3 to -17.1)	(-43.4 to -37.3)	137.6	143.6	4.3	-1.1
Interstitial lung disease and pulmonary sarcoidosis	3.6	6.8	85.9	39.4	(89.0 to 196.4)	(94.1 to 203.7)	(2.0 to 11.5)	(-7.6 to 6.3)
Other chronic respiratory diseases	-	-	-	-	9.3	1.7	-81.9	-86.6
Cirrhosis	-	-	-	-	(5.7 to 14.4)	(1.0 to 2.6)	(-86.6 to -74.9)	(-90.0 to -81.6)
Cirrhosis due to hepatitis B	5.1	4.6	-9.7	-33.6	(5.5 to 10.8)	(3.5 to 7.1)	(-42.3 to -26.7)	(-56.9 to -44.6)
Cirrhosis due to hepatitis C	18.9	15.6	-18.6	-39.7	3.1	2.5	-19.4	-39.3
Cirrhosis due to alcohol use	22.0	9.7	-56.4	-80.2	(1.6 to 4.7)	(1.5 to 3.7)	(-49.9 to 33.7)	(-64.7 to 1.3)
Cirrhosis due to other causes	(17.1 to 27.1)	(6.6 to 13.6)	(-71.5 to -34.6)	(-80.2 to -51.7)	2.5	0.3	(-72.7 to -32.7)	(-81.6 to -49.9)
Digestive diseases	(1.3 to 3.8)	(1.3 to 2.7)	(-58.6 to 49.7)	(-64.4 to 19.2)	66.9	84.1	25.6	-3.0
Peptic ulcer disease	341.5	159.4	-53.5	-73.8	10.9	6.1	-44.3	-68.1
Gastritis and duodenitis	131.4	74.6	-43.2	-58.4	(7.5 to 15.3)	(4.0 to 8.4)	(-51.0 to -31.7)	(-72.2 to -60.3)
Appendicitis	2.5	1.8	-26.6	-10.5	0.8	0.6	-24.6	-10.0
Paralytic ileus and intestinal obstruction	(2.1 to 2.9)	(1.7 to 1.9)	(-36.4 to -12.3)	(-24.5 to 6.8)	(0.5 to 1.2)	(0.4 to 0.9)	(-46.0 to 9.4)	(-38.4 to 36.7)
Inguinal, femoral, and abdominal hernia	367.7	476.5	29.5	-14.3	3.7	4.8	28.8	-13.8
Inflammatory bowel disease	(322.5 to 420.0)	(417.5 to 556.9)	(7.7 to 59.2)	(-27.5 to 2.8)	(1.8 to 7.0)	(2.4 to 8.9)	(7.6 to 59.1)	(-26.6 to 3.6)
Vascular intestinal disorders	0.4	0.6	64.2	5.7	0.1	0.2	53.0	1.5
Gallbladder and biliary diseases	127.4	185.9	45.3	-13.2	13.2	19.0	44.4	8.9
Pancreatitis	10.6	18.8	77.1	35.3	3.1	5.9	74.8	35.4
Other digestive diseases	-	-	-	-	6.0	10.4	74.1	34.2
Neurological disorders	-	-	-	-	865.6	1,122.1	29.8	4.2
Alzheimer disease and other dementias	1,073.9	1,957.3	83.0	0.5	(600.0 to 1,177.4)	(776.7 to 1,516.7)	(17.7 to 43.1)	(-4.6 to 14.4)
Parkinson disease	98.3	149.9	52.4	-2.2	11.3	17.2	51.3	-1.8
Epilepsy	(88.0 to 108.3)	(136.1 to 163.1)	(45.9 to 59.4)	(-6.5 to 2.2)	(7.9 to 15.3)	(12.1 to 23.0)	(39.4 to 65.9)	(-9.9 to 7.6)
Multiple sclerosis	52.4	106.8	103.9	67.6	17.1	34.6	102.1	67.3
Migraine	13,770.3	14,854.6	7.5	-0.9	465.5	500.1	8.4	0.4
Tension-type headache	(23,710.9 to 29,245.8)	(14,713.5 to 16,901.5)	(-47.1 to -31.0)	(-52.3 to -36.7)	39.7	23.6	(-40.7 to -30.9)	(-52.2 to -36.0)
Medication overuse headache	516.4	947.9	82.4	56.3	80.0	146.2	82.1	57.0
Other neurological disorders	(341.0 to 701.9)	(631.8 to 1,253.9)	(48.0 to 131.6)	(27.2 to 94.4)	(45.5 to 126.7)	(80.6 to 221.9)	(46.9 to 130.2)	(27.1 to 94.3)
Mental and substance use disorders	0.1	0.1	28.4	9.9	25.0	30.0	18.8	-30.0
Schizophrenia	(0.1 to 0.2)	(0.1 to 0.2)	(9.8 to 74.0)	(-22.4 to 46.3)	(17.6 to 33.3)	(20.4 to 41.4)	(-12.1 to 63.0)	(-47.0 to -5.0)
Alcohol use disorders	165.5	189.0	14.1	-0.6	1,452.3	1,501.9	3.6	-1.5
Drug use disorders	(128.6 to 199.9)	(146.5 to 228.8)	(7.4 to 21.5)	(-6.9 to 6.0)	(1,042.2 to 1,903.2)	(1,071.1 to 1,960.9)	(-3.2 to 8.9)	(-5.9 to 2.3)
Opioid use disorders	493.3	478.4	-3.3	49.1	105.0	119.7	14.0	14.0
Cocaine use disorders	(455.5 to 532.3)	(444.5 to 512.7)	(-7.8 to 1.8)	(-8.1 to 1.9)	(33.0 to 69.4)	(31.8 to 67.5)	(-9.4 to 3.5)	(-9.2 to 3.7)
Amphetamine use disorders	-	-	-	-	157.1	156.1	-0.6	2.3
Cannabis use disorders	245.0	251.7	2.9	1.0	(112.4 to 206.0)	(109.9 to 204.2)	(-9.5 to 8.3)	(-6.7 to 11.8)
Other drug use disorders	(199.2 to 288.5)	(206.6 to 293.6)	(5.8 to 11.6)	(-6.6 to 9.6)	101.6	104.3	2.7	1.3
Depressive disorders	184.1	108.4	-40.2	0.2	(70.5 to 134.8)	(72.9 to 138.9)	(-6.9 to 12.9)	(-7.7 to 11.8)
Major depressive disorder	2,036.0	2,154.2	6.2	-4.3	142.4	142.2	-0.2	9.2
Dysthymia	(87.7 to 119.6)	(89.2 to 117.5)	(19.0 to 24.0)	(-11.6 to 37.8)	(8.9 to 20.4)	(8.9 to 20.4)	(-20.3 to 26.4)	(-12.6 to 40.1)
Bipolar disorder	85.5	75.0	-12.2	-1.1	11.1	9.7	-12.7	-1.0
Anxiety disorders	(77.1 to 94.0)	(67.8 to 81.7)	(-23.3 to 0.6)	(-14.0 to 14.2)	(7.0 to 16.1)	(6.0 to 14.3)	(-27.9 to 3.6)	(-18.7 to 18.7)
Eating disorders	160.4	130.9	-18.3	0.1	4.6	3.8	-18.4	0.4
Anorexia nervosa	(142.6 to 177.1)	(116.8 to 144.3)	(-23.3 to -13.1)	(-6.3 to 6.8)	25.5	24.1	-5.4	5.0
Bulimia nervosa	-	-	-	-	(16.2 to 37.0)	(15.4 to 36.0)	(-3.6 to 32.6)	(-24.0 to 47.7)
Autistic spectrum disorders	-	-	-	-	505.2	537.3	6.6	3.8
Autism	162.9	172.3	5.8	0.4	(334.5 to 713.8)	(341.7 to 775.6)	(-11.1 to 21.8)	(-16.2 to 7.4)
Asperger syndrome	(153.4 to 172.1)	(161.7 to 183.3)	(4.7 to 6.9)	(0.4 to 0.5)	409.5	430.1	5.3	-4.1
Attention-deficit/hyperactivity disorder	233.3	246.6	5.8	0.6	(262.1 to 600.4)	(260.3 to 660.9)	(-16.2 to 23.2)	(-19.6 to 8.9)
Conduct disorder	(217.5 to 249.5)	(229.2 to 264.9)	(4.7 to 6.7)	(0.5 to 0.6)	95.7	107.2	12.2	-1.4
Idiopathic intellectual disability	341.2	262.5	-23.0	0.4	(63.7 to 136.0)	(71.2 to 153.1)	(3.4 to 20.5)	(-8.6 to 4.9)
Other mental and substance use disorders	(371.1 to 515.7)	(403.6 to 547.2)	(6.6 to 13.1)	(-6.0 to 3.8)	88.8	94.7	6.7	-0.6
Diabetes, urogenital, blood, and endocrine diseases	2,869.3	3,007.7	4.9	-2.1	(54.7 to 133.0)	(58.1 to 140.0)	(-0.9 to 14.4)	(-7.1 to 6.0)
Diabetes mellitus	(2,550.2 to 3,193.2)	(2,669.1 to 3,363.9)	(-1.9 to 11.6)	(-7.2 to 4.6)	(177.1 to 361.1)	(185.2 to 375.7)	(-3.2 to 11.3)	(-1.4 to 5.7)
Acute glomerulonephritis	63.6	58.5	-7.9	8.5	67.0	56.4	-15.8	1.4
Bulimia nervosa	(45.6 to 83.6)	(41.8 to 76.4)	(-21.5 to 7.1)	(-7.8 to 26.7)	(43.5 to 96.0)	(36.6 to 80.9)	(-3.2 to 6.6)	(-3.2 to 6.6)
Autistic spectrum disorders	255.4	210.5	-17.5	-0.3	13.4	12.3	-7.6	8.9
Autism	(204.6 to 310.9)	(164.2 to 259.4)	(-22.4 to -13.0)	(-4.0 to -0.2)	53.6	44.1	(-17.8 to -11.8)	(-4.2 to 4.0)
Asperger syndrome	-	-	-	-	62.6	65.9	5.2	0.7
Attention-deficit/hyperactivity disorder	162.9	172.3	5.8	0.4	(43.6 to 85.0)	(45.7 to 89.1)	(1.6 to 8.9)	(-2.6 to 4.2)
Conduct disorder	233.3	246.6	5.8	0.6	39.6	41.6	5.2	0.7
Idiopathic intellectual disability	(217.5 to 249.5)	(229.2 to 264.9)	(4.7 to 6.7)	(0.5 to 0.6)	23.1	24.3	5.3	0.8
Other mental and substance use disorders	341.2	262.5	-23.0	0.4	(16.0 to 31.9)	(16.9 to 33.5)	(0.8 to 9.6)	(-3.4 to 4.9)
Diabetes, urogenital, blood, and endocrine diseases	43.9	324.6	25.1	0.3	4.1	3.2	-22.7	0.7
Diabetes mellitus	(36.1 to 508.0)	(273.6 to 377.4)	(-26.5 to -23.8)	(0.3 to 0.4)	(2.4 to 6.4)	(1.9 to 5.0)	(-27.4 to -17.8)	(-5.4 to 7.0)
Acute glomerulonephritis	614.4	527.4	-10.9	-17.1	(10.3 to 0.4)	(32.0 to 78.7)	(23.9 to 58.4)	(-28.2 to -21.6)
Chronic kidney disease	344.4	315.4	-8.5	-12.0	20.3	18.5	-7.1	-12.0
Chronic kidney disease due to diabetes mellitus	(206.6 to 504.7)	(189.9 to 456.7)	(-48.6 to 61.1)	(-51.9 to 52.9)	(11.0 to 33.7)	(9.9 to 28.5)	(-49.5 to 61.9)	(52.1 to 53.5)
Chronic kidney disease due to hypertension	1,102.2	1,274.7	15.7	0.4	81.1	93.1	14.7	0.6
Chronic kidney disease due to glomerulonephritis	(1,036.4 to 1,166.0)	(1,202.2 to 1,348.0)	(13.4 to 17.8)	(0.2 to 0.5)	(55.7 to 108.8)	(63.5 to 125.0)	(10.4 to 19.4)	(-3.3 to 4.2)
Chronic kidney disease due to other causes	-	-	-	-	584.3	752.0	28.9	2.7
Urinary diseases and male infertility	-	-	-	-	(422.4 to 768.0)	(543.4 to 980.7)	(20.9 to 36.7)	(-3.0 to 8.2)
Diabetes mellitus	1,448.1	2,093.7	44.2	10.0	109.9	156.3	42.2	7.3
Acute glomerulonephritis	(1,101.5 to 1,836.3)	(1,586.8 to 2,649.1)	(8.1 to 31.1)	(-16.1 to 41.9)	(72.0 to 158.9)	(101.2 to 224.9)	(7.3 to 37.5)	(-17.5 to 37.5)
Chronic kidney disease	0.1	0.1	-10.9	-17.1	0.0	0.0	-10.9	-17.1
Chronic kidney disease due to diabetes mellitus	(0.1 to 0.1)	(0.1 to 0.1)	(-18.3 to -4.3)	(-23.2 to -11.7)	(0.0 to 0.0)	(0.0 to 0.0)	(-18.4 to -4.2)	(-23.2 to -11.7)
Chronic kidney disease due to hypertension	494.3	530.0	13.2	-22.1	(144.9 to 303.4)	(185.4 to 388.0)	(21.1 to 35.0)	(-3.4 to 4.3)
Chronic kidney disease due to glomerulonephritis	396.6	487.4	22.7	-8.0	43.0	47.3	9.3	-17.0
Chronic kidney disease due to other causes	(312.8 to 527.9)	(386.2 to 642.1)	(0.3 to 56.5)	(-24.9 to 14.1)	(25.3 to 64.6)	(29.5 to 66.5)	(-14.5 to 53.0)	(-34.7 to 14.8)
Urinary diseases and male infertility	614.4	527.4	-10.9	-21.4	59.1	46.5	(-21.0 to -36.3)	(-52.0 to -18.6)
Diabetes mellitus	(888.2 to 1,108.8)	(370.6 to 717.4)	(-45.3 to 29.0)	(-56.0 to -7.2)	(12.4 to 30.6)	(28.7 to 69.0)	(70.5 to 241.4)	(34.3 to 162.8)
Acute glomerulonephritis	1,405.1	1,934.1	41.3	0.9	99.7	144.4	45.2	10.3
Chronic kidney disease	(999.0 to 2,087.0)	(1,429.6 to 2,642.5)	(-1.2 to 81.7)	(-25.8 to 26.0)	(64.3 to 140.4)	(91.6 to 200.4)	(22.3 to 70.0)	(-3.7 to 27.8)
Chronic kidney disease due to diabetes mellitus	-	-	-	-	61.4	104.6	70.0	24.1
Chronic kidney disease due to hypertension	-	-	-	-	(39.9 to 86.6)	(69.5 to 147.8)	(54.5 to 88.8)	(12.5 to 38.1)

Appendix Table G.4 - Italy prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	8.9 (8.3 to 9.3)	13.4 (12.7 to 14.2)	50.2 (40.3 to 63.8)	-25.6 (16.2 to 38.1)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	49.3 (22.9 to 86.2)	26.3 (4.0 to 59.7)
Urolithiasis	1,131.7 (949.8 to 1,376.3)	2,883.5 (2,119.3 to 4,121.6)	149.8 (110.0 to 210.1)	83.4 (55.4 to 131.6)	8.0 (5.1 to 11.9)	20.2 (11.9 to 32.7)	148.3 (107.8 to 203.7)	84.2 (54.5 to 127.7)
Benign prostatic hyperplasia	1,394.7 (1,278.3 to 1,518.2)	2,161.0 (2,027.3 to 2,289.2)	55.0 (40.7 to 70.9)	9.2 (-0.6 to 20.4)	49.6 (31.8 to 69.6)	76.9 (50.4 to 108.8)	54.9 (40.8 to 71.4)	10.0 (0.0 to 21.5)
Male infertility due to other causes	234.8 (176.6 to 322.0)	242.9 (182.6 to 319.4)	5.8 (-37.6 to 50.9)	2.7 (-39.6 to 44.6)	1.6 (0.6 to 3.1)	1.6 (0.6 to 3.4)	4.3 (-38.9 to 50.8)	2.2 (-41.5 to 47.2)
Other urinary diseases	-	-	-	-	-	5.5 (1.1 to 3.2)	117.7 (79.0 to 295.5)	21.7 (31.6 to 195.5)
Gynecological diseases	-	-	-	-	68.1 (42.7 to 108.3)	78.6 (49.3 to 125.0)	15.2 (3.8 to 27.9)	1.6 (-8.3 to 13.9)
Uterine fibroids	2,378.7 (2,103.0 to 2,637.5)	3,017.4 (2,664.5 to 3,346.6)	26.9 (25.7 to 28.0)	-0.4 (-0.4 to -0.3)	19.2 (9.7 to 36.1)	24.3 (12.3 to 45.3)	26.4 (19.9 to 39.1)	1.4 (-4.6 to 14.8)
Polycystic ovarian syndrome	967.9 (833.2 to 1,119.0)	1,078.7 (915.5 to 1,222.0)	11.6 (-10.3 to 36.8)	2.5 (-17.3 to 25.9)	9.3 (4.3 to 17.2)	10.3 (4.8 to 19.2)	12.0 (-9.3 to 36.1)	3.2 (-16.2 to 24.8)
Female infertility due to other causes	83.9 (29.4 to 149.5)	87.3 (21.1 to 178.0)	4.7 (-75.7 to 207.4)	-13.2 (-78.6 to 145.3)	0.4 (0.1 to 1.1)	0.5 (0.1 to 1.2)	9.2 (-73.9 to 194.3)	-11.3 (-77.1 to 138.0)
Endometriosis	123.4 (80.1 to 159.2)	147.6 (120.8 to 175.0)	19.6 (-16.3 to 82.1)	5.1 (-26.3 to 60.0)	11.3 (6.2 to 17.4)	13.5 (8.9 to 18.9)	20.1 (-17.2 to 87.2)	6.0 (-26.4 to 65.9)
Genital prolapse	3,804.3 (3,447.6 to 4,175.4)	4,281.7 (3,882.7 to 4,669.6)	12.3 (-1.5 to 29.2)	-4.8 (-17.0 to 10.4)	12.0 (5.8 to 22.7)	13.5 (6.6 to 25.0)	12.1 (-2.1 to 29.1)	-4.6 (-17.0 to 11.0)
Premenstrual syndrome	1,544.4 (1,131.9 to 1,937.9)	1,553.3 (1,030.9 to 2,015.1)	2.2 (-32.1 to 47.8)	1.1 (-32.6 to 46.8)	12.9 (7.4 to 20.3)	12.9 (7.2 to 20.4)	0.5 (-33.6 to 48.1)	0.5 (-32.8 to 48.1)
Other gynecological diseases	148.6 (130.5 to 168.3)	148.4 (119.1 to 187.6)	-1.2 (-17.8 to 34.6)	-5.8 (-23.0 to 23.0)	3.0 (2.0 to 4.3)	3.5 (2.2 to 5.9)	13.3 (-10.4 to 101.3)	7.5 (-14.2 to 83.3)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	102.2 (67.9 to 146.7)	103.2 (69.3 to 149.0)	1.0 (-6.6 to 9.0)	5.6 (-12.7 to 2.7)
Thalassemias	9.7 (9.0 to 10.4)	7.8 (7.2 to 8.4)	-19.7 (-23.8 to -14.8)	-5.9 (-10.5 to -0.6)	0.7 (0.4 to 1.0)	0.6 (0.4 to 0.8)	-18.9 (-40.4 to 11.8)	-7.4 (-32.3 to 27.2)
Thalassemia trait	3,065.8 (2,989.1 to 3,147.3)	3,202.7 (3,109.2 to 3,296.6)	4.5 (1.6 to 7.5)	-4.0 (-6.5 to -1.5)	84.6 (56.3 to 121.8)	84.1 (57.2 to 120.4)	-0.2 (-9.2 to 4.3)	-7.4 (-14.8 to -3.7)
Sickle cell disorders	1.7 (1.4 to 1.9)	1.6 (1.3 to 1.8)	-5.4 (-25.3 to 17.4)	-1.9 (-21.6 to 24.6)	0.3 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-3.0 (-16.9 to 9.9)	1.1 (-15.8 to 15.5)
Sickle cell trait	1,132.5 (1,070.2 to 1,192.6)	1,183.1 (1,107.4 to 1,243.5)	4.6 (0.4 to 8.5)	9.8 (-8.1 to 0.1)	9.9 (6.2 to 14.6)	9.6 (5.8 to 14.1)	6.9 (-15.7 to 12.9)	6.9 (-19.2 to 9.1)
G6PD deficiency	3,298.4 (3,014.0 to 3,596.6)	3,480.2 (3,121.0 to 3,892.1)	5.4 (-7.9 to 22.5)	2.8 (-14.9 to 12.9)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.3)	-4.9 (-53.0 to 85.3)	-11.7 (-55.6 to 72.3)
G6PD trait	8,252.1 (8,043.7 to 8,470.9)	8,869.2 (8,611.9 to 9,113.5)	7.4 (3.7 to 11.3)	-2.4 (-5.9 to 1.1)	0.5 (0.1 to 0.8)	0.6 (0.2 to 0.9)	14.7 (-60.5 to 313.1)	15.0 (-65.0 to 299.4)
Other hemoglobinopathies and hemolytic anemias	321.5 (287.2 to 363.7)	416.7 (379.2 to 505.5)	28.8 (12.0 to 60.2)	7.6 (-12.5 to 47.6)	6.1 (3.7 to 9.4)	8.0 (4.9 to 13.5)	28.0 (-9.2 to 118.2)	21.7 (-18.4 to 125.6)
Endocrine, metabolic, blood, and immune disorders	686.8 (645.7 to 731.4)	796.6 (747.0 to 904.0)	15.9 (3.9 to 32.8)	15.9 (-15.6 to 24.5)	24.9 (14.2 to 29.9)	24.6 (16.4 to 34.7)	2.6 (-0.0 to 45.2)	2.6 (-21.3 to 46.1)
Musculoskeletal disorders	-	-	-	-	1,709.0 (1,199.1 to 2,272.9)	2,333.6 (1,644.3 to 3,072.3)	36.9 (-1.2 to 33.9)	12.4 (-1.2 to 33.9)
Rheumatoid arthritis	173.4 (157.8 to 191.0)	275.1 (250.4 to 298.9)	59.2 (39.2 to 81.4)	15.0 (2.0 to 29.9)	39.3 (27.7 to 52.5)	61.9 (44.0 to 82.3)	57.8 (37.0 to 81.9)	15.7 (2.0 to 32.5)
Osteoarthritis	2,120.2 (1,844.8 to 2,372.7)	3,058.2 (2,670.3 to 3,383.0)	44.6 (19.4 to 71.9)	-2.8 (-19.8 to 16.1)	72.3 (46.5 to 107.9)	103.4 (67.6 to 147.9)	43.6 (18.9 to 71.4)	-2.8 (-20.0 to 16.6)
Low back and neck pain	-	-	-	-	1,337.7 (916.7 to 1,795.2)	1,812.9 (1,258.8 to 2,434.4)	35.9 (15.1 to 62.0)	22.6 (-4.2 to 40.8)
Low back pain	7,488.5 (6,355.8 to 8,556.6)	10,409.8 (9,488.3 to 11,577.2)	38.6 (17.7 to 68.8)	13.9 (-4.5 to 43.4)	822.0 (548.7 to 1,160.5)	1,133.7 (769.4 to 1,570.3)	37.5 (16.4 to 68.2)	14.1 (-4.5 to 46.1)
Neck pain	5,304.2 (4,271.1 to 6,334.9)	7,029.6 (5,757.1 to 8,261.2)	33.5 (1.2 to 65.6)	11.0 (-15.0 to 41.0)	515.7 (336.6 to 729.2)	679.3 (455.0 to 955.5)	32.8 (1.3 to 64.9)	11.0 (-15.0 to 41.6)
Gout	87.5 (78.5 to 96.0)	113.9 (102.0 to 126.2)	30.4 (13.7 to 50.1)	-6.9 (-18.8 to 7.2)	2.7 (1.8 to 3.7)	3.5 (2.4 to 4.8)	29.9 (53.0 to 58.3)	-6.1 (-23.5 to 15.3)
Other musculoskeletal disorders	2,834.6 (2,432.7 to 3,230.9)	3,882.8 (3,425.7 to 4,399.3)	37.2 (17.4 to 47.1)	12.8 (5.5 to 20.6)	257.0 (173.9 to 360.3)	351.9 (240.7 to 487.9)	38.9 (27.6 to 47.1)	36.9 (5.7 to 21.4)
Other non-communicable diseases	-	-	-	-	1,175.0 (797.7 to 1,684.6)	1,438.4 (997.5 to 2,020.5)	22.6 (-9.7 to 4.4)	-4.4 (-9.7 to 4.4)
Congenital anomalies	-	-	-	-	91.6 (65.2 to 122.2)	102.0 (71.9 to 138.7)	11.1 (-3.9 to 29.0)	-0.0 (-13.6 to 17.4)
Neural tube defects	11.4 (9.9 to 13.0)	9.9 (8.6 to 12.1)	-13.1 (-27.5 to 7.7)	-15.6 (-29.8 to 5.1)	3.8 (2.5 to 3.8)	3.4 (2.2 to 4.7)	-11.8 (-35.2 to 20.2)	-14.4 (-36.4 to 18.5)
Congenital heart anomalies	501.4 (402.8 to 612.0)	499.4 (386.3 to 655.8)	-0.5 (-27.6 to 36.3)	-6.9 (-31.7 to 26.7)	17.2 (7.2 to 30.6)	17.3 (7.2 to 31.3)	0.6 (-24.4 to 34.9)	-5.1 (-27.8 to 26.4)
Orofacial clefts	54.4 (45.8 to 63.8)	51.5 (41.3 to 62.6)	-5.5 (-27.8 to 24.7)	-13.0 (-33.5 to 15.2)	0.6 (0.3 to 0.8)	0.5 (0.3 to 0.8)	0.5 (-33.9 to 23.9)	-17.6 (-39.1 to 13.9)
Down syndrome	77.7 (62.5 to 99.8)	90.4 (74.7 to 110.6)	16.5 (-13.5 to 54.1)	2.0 (-24.2 to 34.6)	11.6 (8.3 to 15.8)	14.4 (10.3 to 19.7)	24.2 (-9.8 to 65.7)	3.7 (-24.6 to 38.3)
Turner syndrome	2.5 (1.9 to 3.3)	2.7 (2.2 to 3.4)	11.3 (-20.8 to 49.0)	7.0 (-24.1 to 42.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	9.9 (-22.8 to 53.4)	6.6 (-25.2 to 48.1)
Klinefelter syndrome	2.0 (1.4 to 2.8)	2.8 (1.8 to 4.1)	44.6 (-7.5 to 120.3)	35.9 (-15.1 to 106.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.5 (-23.6 to 139.6)	35.9 (-26.2 to 124.2)
Chromosomal unbalanced rearrangements	117.3 (99.8 to 140.1)	133.3 (107.1 to 165.4)	13.9 (-12.4 to 44.5)	0.0 (-23.4 to 26.5)	17.5 (12.5 to 22.6)	21.2 (14.9 to 28.3)	1.4 (-7.5 to 55.7)	1.4 (-22.2 to 29.8)
Other congenital anomalies	182.6 (119.6 to 253.1)	174.7 (110.0 to 241.5)	-4.1 (-24.9 to 19.1)	-15.5 (-32.5 to 5.4)	40.9 (26.3 to 58.8)	45.2 (28.3 to 65.5)	9.8 (-11.0 to 37.6)	2.6 (-17.4 to 29.0)
Skin and subcutaneous diseases	-	-	-	-	379.3 (243.1 to 581.5)	400.2 (262.0 to 605.7)	5.6 (-6.2 to 18.4)	-1.4 (-12.6 to 12.8)
Dermatitis	3,356.1 (2,615.6 to 4,101.7)	3,627.1 (2,843.8 to 4,436.5)	8.1 (3.7 to 12.2)	-0.0 (-4.1 to -0.0)	79.5 (48.9 to 115.5)	85.2 (52.3 to 123.9)	7.3 (3.0 to 10.8)	2.1 (-2.6 to 2.4)
Psoriasis	865.0 (746.3 to 997.0)	990.3 (847.8 to 1,141.6)	14.4 (11.8 to 17.4)	0.1 (-0.1 to 0.2)	69.4 (47.4 to 96.7)	78.9 (53.6 to 110.7)	13.9 (8.2 to 19.3)	0.2 (-4.1 to 4.5)
Cellulitis	15.7 (12.7 to 19.4)	17.6 (14.7 to 22.1)	13.0 (-3.0 to 27.0)	-4.4 (-15.8 to 6.9)	1.1 (0.7 to 1.6)	1.2 (0.8 to 1.8)	12.2 (-10.0 to 40.5)	-3.7 (-22.1 to 20.9)
Pyoderma	26.4 (22.3 to 31.1)	29.4 (24.9 to 34.8)	11.2 (5.5 to 18.6)	2.1 (-2.3 to 6.7)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.4)	10.0 (-3.0 to 25.2)	1.7 (-9.6 to 14.7)
Scabies	40.1 (33.2 to 47.3)	32.9 (27.3 to 38.6)	-17.9 (-36.6 to 7.1)	-18.4 (-36.9 to 3.3)	1.0 (0.6 to 1.7)	0.8 (0.5 to 1.4)	-18.0 (-38.7 to 9.2)	-18.1 (-38.5 to 6.2)
Fungal skin diseases	4,307.1 (3,824.4 to 4,745.0)	5,026.4 (4,456.9 to 5,484.4)	16.4 (14.1 to 19.5)	16.4 (10.2 to 20.4)	23.9 (17.3 to 30.7)	27.6 (11.3 to 57.7)	16.1 (13.3 to 19.0)	1.4 (-0.4 to 1.4)
Viral skin diseases	1,149.7 (906.6 to 1,410.1)	1,124.2 (899.8 to 1,355.2)	-2.3 (-7.0 to 3.8)	0.6 (-1.4 to 2.8)	35.2 (20.8 to 55.2)	34.3 (20.2 to 53.0)	-2.8 (-7.6 to 3.6)	0.7 (-2.4 to 3.9)
Acne vulgaris	8,138.1 (5,597.0 to 10,390.9)	6,311.6 (4,476.4 to 8,129.3)	-24.7 (-51.9 to 25.5)	-7.9 (-41.1 to 50.2)	88.1 (40.1 to 169.3)	68.0 (30.0 to 130.2)	-24.8 (-52.0 to 25.9)	-8.0 (-41.2 to 50.6)
Alopecia areata	99.1 (90.7 to 107.1)	123.4 (112.1 to 135.4)	24.7 (10.0 to 39.7)	1.3 (-9.8 to 13.9)	3.3 (2.1 to 4.8)	4.0 (2.5 to 6.1)	23.7 (6.7 to 40.4)	1.7 (-11.5 to 15.3)
Pruritus	9.7 (5.2 to 10.5)	9.4 (6.2 to 13.2)	-3.1 (-29.4 to 112.9)	0.1 (-43.8 to 63.2)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	20.6 (-33.2 to 125.1)	-3.6 (-45.6 to 70.9)
Urticaria	745.7 (583.8 to 951.9)	932.0 (709.1 to 1,131.4)	25.2 (-9.8 to 76.8)	2.4 (-26.4 to 47.0)	43.6 (26.2 to 68.6)	53.8 (32.6 to 79.7)	23.6 (-11.0 to 77.9)	2.4 (-26.6 to 47.8)
Decubitus ulcer	41.8 (32.8 to 48.6)	70.6 (59.2 to 81.2)	67.8 (35.0 to 129.0)	6.2 (-13.0 to 43.5)	5.8 (3.9 to 8.2)	9.8 (6.8 to 13.3)	66.2 (31.5 to 127.4)	6.7 (-13.6 to 45.2)
Other skin and subcutaneous diseases	4,881.8 (2,727.0 to 8,467.0)	6,265.7 (3,261.8 to 11,580.7)	27.5 (15.6 to 38.3)	0.8 (-2.1 to 4.1)	28.3 (11.3 to 63.6)	36.1 (13.6 to 84.7)	27.0 (14.9 to 38.2)	1.0 (-2.3 to 4.7)
Sense organ diseases	-	-	-	-	564.0 (381.6 to 900.1)	761.1 (529.6 to 1,061.5)	35.0 (25.0 to 46.1)	-8.7 (-14.6 to -3.1)
Glaucoma	122.8 (95.9 to 161.1)	140.5 (104.6 to 176.8)	16.2 (-14.5 to 46.0)	-25.2 (-44.5 to -6.2)	11.8 (7.6 to 18.0)	13.1 (8.4 to 19.2)	11.5 (-16.3 to 45.4)	-29.3 (-46.3 to -10.6)
Cataract	387.6 (281.9 to 484.4)	463.7 (327.9 to 616.7)	16.9 (-12.6 to 83.9)	-32.0 (-49.9 to 3.6)	21.4 (13.8 to 30.5)	25.6 (16.1 to 38.1)	16.8 (-11.6 to 74.7)	-33.0 (-49.9 to -2.2)
Macular degeneration	339.2 (269.7 to 428.8)	511.0 (398.5 to 643.0)	50.3 (12.3 to 108.0)	-7.9 (-31.1 to 27.3)	23.0 (15.7 to 31.8)	35.6 (24.5 to 50.6)	53.1 (24.7 to 102.4)	-11.2 (-28.3 to 17.6)
Uncorrected refractive error	11,146.7 (10,035.8 to 12,246.6)	14,256.9 (13,013.8 to 15,464.3)	27.0 (12.5 to 45.8)	4.5 (-17.2 to 8.9)	148.4 (87.1 to 245.7)	182.2 (103.4 to 304.7)	22.4 (11.3 to 35.4)	-8.8 (-17.8 to 1.6)
Age-related and other hearing loss	9,708.7 (8,298.0 to 10,982.6)	12,991.6 (11,382.0 to 14,636.1)	34.0 (28.7 to 40.9)	-8.3 (-13.0 to -4.0)	298.6 (199.0 to 433.4)	298.6 (291.1 to 622.1)	6.7 (27.9 to 67.7)	6.7 (-16.3 to 3.7)
Other vision loss	322.2 (249.8 to 419.0)	319.1 (243.4 to 424.5)	-1.8 (-15.9 to 17.5)	-30.0 (-39.4 to -18.3)	25.3 (17.3 to 35.7)	27.4 (18.5 to 39.1)	8.0 (-3.7 to 21.7)	-3.2 (-31.8 to -14.9)
Other sense organ diseases	1,364.0							

Appendix Table G.4 - Italy prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	2,076.1 (1,876.0 to 2,282.0)	2,878.1 (2,601.5 to 3,127.0)	38.6 (20.8 to 58.8)	<-1 (-18.4 to 8.0)	56.0 (38.2 to 79.0)	77.3 (51.8 to 106.6)	37.8 (18.1 to 58.8)	-5.8 (-18.6 to 8.6)
Other oral disorders	1,106.4 (1,047.6 to 1,166.8)	1,235.4 (1,168.6 to 1,298.5)	11.8 (2.5 to 20.4)	0.4 (-7.9 to 8.0)	32.1 (20.1 to 47.9)	35.7 (22.2 to 53.4)	11.4 (1.8 to 20.2)	0.5 (-8.1 to 9.0)
Injuries	-	-	-	-	722.2 (551.9 to 922.5)	671.8 (484.8 to 896.6)	-7.3 (-17.1 to 4.6)	-35.1 (-41.7 to -27.3)
Transport injuries	-	-	-	-	129.1 (96.7 to 164.8)	86.0 (62.2 to 113.9)	-33.6 (-40.5 to -26.0)	-48.3 (-53.7 to -42.3)
Road injuries	-	-	-	-	121.8 (91.2 to 155.0)	75.3 (54.7 to 99.2)	-38.3 (-44.9 to -31.3)	-51.6 (-56.7 to -45.8)
Pedestrian road injuries	-	-	-	-	19.5 (14.6 to 25.3)	12.7 (9.0 to 17.2)	-35.2 (-42.3 to -27.3)	-51.9 (-57.3 to -46.0)
Cyclist road injuries	-	-	-	-	11.1 (8.3 to 14.4)	6.4 (4.6 to 8.5)	-42.4 (-50.3 to -33.7)	-54.7 (-61.0 to -47.6)
Motorcyclist road injuries	-	-	-	-	26.0 (19.2 to 33.0)	16.0 (11.4 to 21.5)	-38.7 (-48.1 to -27.4)	-50.5 (-58.4 to -41.5)
Motor vehicle road injuries	-	-	-	-	64.8 (48.9 to 81.9)	40.1 (29.6 to 52.2)	-38.4 (-43.7 to -31.6)	-51.4 (-55.8 to -45.9)
Other road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.2 (0.1 to 0.2)	-57.7 (-63.1 to -51.5)	-66.4 (-70.7 to -61.3)
Other transport injuries	-	-	-	-	7.3 (5.4 to 9.6)	10.7 (7.5 to 14.6)	45.6 (30.7 to 61.0)	8.7 (-2.1 to 20.4)
Unintentional injuries	-	-	-	-	585.3 (445.7 to 748.1)	580.3 (418.1 to 775.0)	-1.2 (-11.9 to 11.8)	-31.7 (-39.0 to -23.3)
Falls	-	-	-	-	436.9 (331.5 to 555.5)	464.4 (334.3 to 613.7)	5.9 (-7.5 to 22.6)	-28.3 (-37.8 to -17.4)
Drowning	-	-	-	-	0.7 (0.5 to 0.9)	0.5 (0.4 to 0.7)	-23.1 (-31.8 to -13.3)	-41.0 (-47.5 to -33.1)
Fire, heat, and hot substances	-	-	-	-	10.5 (6.5 to 16.3)	8.0 (4.6 to 13.1)	-24.8 (-34.6 to -13.9)	-44.1 (-51.6 to -35.4)
Poisonings	-	-	-	-	0.7 (0.5 to 1.0)	0.4 (0.3 to 0.6)	-43.4 (-52.8 to -32.5)	-54.1 (-62.0 to -44.7)
Exposure to mechanical forces	-	-	-	-	83.4 (61.9 to 108.5)	53.5 (37.7 to 73.6)	-35.9 (-42.9 to -28.7)	-47.2 (-53.0 to -40.9)
Unintentional firearm injuries	-	-	-	-	0.8 (0.6 to 1.1)	0.5 (0.4 to 0.7)	-40.3 (-48.4 to -32.2)	-49.0 (-56.0 to -42.0)
Unintentional suffocation	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	54.3 (33.4 to 74.6)	19.4 (2.8 to 35.3)
Other exposure to mechanical forces	-	-	-	-	82.3 (61.1 to 107.2)	52.6 (37.0 to 72.4)	-36.1 (-43.1 to -28.9)	-47.4 (-53.2 to -41.1)
Adverse effects of medical treatment	-	-	-	-	3.3 (2.1 to 4.9)	4.4 (2.7 to 6.4)	32.4 (18.9 to 45.5)	1.0 (-8.1 to 10.3)
Animal contact	-	-	-	-	2.8 (2.1 to 3.8)	3.1 (2.2 to 4.4)	8.3 (-1.0 to 19.5)	-10.6 (-18.2 to -1.1)
Venomous animal contact	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	8.7 (-7.3 to 27.7)	-6.9 (-21.0 to 9.9)
Non-venomous animal contact	-	-	-	-	2.4 (1.8 to 3.3)	2.7 (1.8 to 3.8)	8.1 (-2.1 to 20.2)	-11.2 (-19.4 to -1.6)
Foreign body	-	-	-	-	3.1 (2.1 to 4.2)	2.9 (1.9 to 4.2)	-5.7 (-16.8 to 4.5)	-19.7 (-31.1 to -9.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.5 (0.4 to 0.6)	0.4 (0.3 to 0.5)	-19.6 (-36.5 to -4.8)	-39.8 (-53.1 to -28.8)
Foreign body in eyes	-	-	-	-	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.7)	-3.3 (-13.4 to 8.1)	-12.3 (-23.2 to 0.3)
Foreign body in other body part	-	-	-	-	2.1 (1.4 to 3.0)	2.0 (1.3 to 3.1)	-3.0 (-17.2 to 9.8)	-16.5 (-31.0 to -3.7)
Other unintentional injuries	-	-	-	-	43.8 (31.4 to 59.6)	43.1 (29.5 to 60.7)	-2.2 (-13.9 to 11.4)	-33.1 (-40.1 to -24.3)
Self-harm and interpersonal violence	-	-	-	-	7.7 (5.8 to 9.9)	5.3 (3.8 to 7.2)	-30.5 (-36.2 to -23.8)	-45.6 (-50.2 to -40.6)
Self-harm	-	-	-	-	2.2 (1.6 to 2.9)	1.9 (1.3 to 2.6)	-12.5 (-21.6 to -2.7)	-33.1 (-40.6 to -25.4)
Interpersonal violence	-	-	-	-	5.5 (4.2 to 7.0)	3.4 (2.5 to 4.6)	-37.7 (-43.7 to -30.8)	-50.3 (-55.2 to -44.8)
Assault by firearm	-	-	-	-	1.3 (1.0 to 1.7)	0.8 (0.6 to 1.0)	-40.5 (-45.9 to -35.0)	-53.9 (-58.1 to -49.7)
Assault by sharp object	-	-	-	-	0.5 (0.4 to 0.7)	0.4 (0.3 to 0.6)	-11.0 (-18.7 to -2.7)	-29.4 (-35.8 to -22.9)
Assault by other means	-	-	-	-	3.7 (2.8 to 4.7)	2.2 (1.6 to 3.0)	-40.3 (-47.2 to -32.4)	-51.8 (-57.4 to -45.4)
Forces of nature, war, and legal intervention	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-1.0 (-21.6 to 27.1)	-24.3 (-40.9 to -2.0)
Exposure to forces of nature	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-1.0 (-21.6 to 27.1)	-24.3 (-40.9 to -2.0)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Jamaica prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	216.9 (161.1 to 283.3)	289.1 (214.3 to 375.1)	33.1 (30.0 to 37.4)	33.1 (-0.1 to 5.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	30.6 (20.9 to 43.2)	37.2 (25.2 to 54.7)	20.1 (9.0 to 45.0)	13.3 (2.5 to 37.7)
HIV/AIDS and tuberculosis	-	-	-	-	0.7 (0.3 to 1.2)	0.9 (0.6 to 1.2)	27.4 (21.8 to 124.7)	-4.1 (-43.1 to 70.9)
Tuberculosis	0.6 (0.6 to 0.7)	0.5 (0.5 to 0.6)	-15.7 (-21.6 to -8.9)	-37.2 (-41.5 to -32.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-16.3 (-30.1 to 1.4)	-37.3 (-47.5 to -25.2)
HIV/AIDS	-	-	-	-	0.5 (0.2 to 1.0)	0.7 (0.5 to 1.0)	42.5 (23.0 to 261.1)	8.1 (-43.3 to 176.1)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.0 (-76.1 to 21.5)	-67.1 (-82.9 to -33.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.0 (-76.2 to 21.8)	-67.1 (-83.1 to -13.0)
HIV/AIDS resulting in other diseases	5.0 (2.0 to 8.2)	9.5 (7.4 to 12.1)	90.1 (23.0 to 323.5)	49.7 (-3.4 to 236.3)	0.5 (0.2 to 1.0)	0.7 (0.5 to 1.0)	43.1 (-22.8 to 265.9)	8.6 (-43.2 to 181.4)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	4.0 (2.8 to 5.7)	3.7 (2.5 to 5.3)	-8.4 (-15.1 to -0.1)	-12.6 (-18.7 to -5.1)
Diarrheal diseases	7.6 (7.1 to 8.2)	7.2 (6.7 to 7.6)	-6.3 (-14.6 to 3.0)	1.7 (-6.8 to 11.6)	1.2 (0.8 to 1.7)	1.2 (0.8 to 1.6)	-7.4 (-16.2 to 3.3)	1.1 (-8.3 to 12.0)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.6 to -14.4	(-61.2 to -19.9)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.1 (-36.5 to -9.3)	-28.7 (-40.8 to -15.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.1 (-36.6 to -9.3)	-28.7 (-40.9 to -15.6)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.3 (-38.8 to -6.0)	-26.8 (-41.1 to -9.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.3 (-38.8 to -5.9)	-26.8 (-41.2 to -9.7)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-94.3 (-99.8 to 45.9)	-94.7 (-99.9 to 45.9)
Lower respiratory infections	1.6 (1.2 to 2.1)	1.3 (1.0 to 1.5)	-21.4 (-43.3 to 9.6)	-23.2 (-45.4 to 2.6)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-22.5 (-44.4 to 18.0)	-23.7 (-45.4 to 5.0)
Upper respiratory infections	123.8 (111.1 to 136.6)	134.4 (121.6 to 147.7)	8.3 (-5.3 to 26.1)	-3.8 (-16.1 to 11.9)	1.5 (0.8 to 2.5)	1.6 (0.9 to 2.6)	7.9 (-6.1 to 25.8)	-4.0 (-16.3 to 12.3)
Otitis media	28.2 (26.5 to 30.0)	27.0 (25.3 to 28.4)	-4.4 (-10.6 to 3.1)	-12.0 (-17.7 to -5.5)	0.5 (0.3 to 0.9)	0.5 (0.3 to 0.8)	-5.8 (-13.5 to 2.2)	-13.0 (-19.8 to -6.2)
Meningitis	-	-	-	-	0.5 (0.3 to 0.7)	0.2 (0.1 to 0.3)	-55.8 (-66.0 to -45.0)	-60.8 (-69.5 to -51.3)
Pneumococcal meningitis	2.4 (1.4 to 4.1)	1.0 (0.6 to 1.6)	-58.9 (-67.9 to -48.1)	-66.1 (-73.2 to -57.3)	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.1)	-66.7 (-71.1 to -43.8)	-62.3 (-74.3 to -51.7)
H influenzae type B meningitis	1.0 (0.3 to 2.3)	0.4 (0.1 to 0.9)	-61.4 (-73.0 to -42.9)	-66.8 (-76.6 to -49.2)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-60.1 (-73.4 to -30.1)	-63.8 (-75.0 to -37.1)
Meningococcal meningitis	0.2 (0.1 to 0.5)	0.1 (0.0 to 0.2)	-54.9 (-68.9 to -31.4)	-62.3 (-73.4 to -41.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.4 (-71.0 to -17.4)	-58.9 (-73.0 to -32.2)
Other meningitis	1.1 (0.5 to 2.2)	0.5 (0.2 to 1.0)	-53.4 (-63.5 to -43.4)	-59.7 (-68.2 to -49.1)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-51.2 (-63.3 to -34.2)	-56.1 (-66.8 to -40.7)
Encephalitis	0.1 (0.1 to 0.7)	0.3 (0.1 to 0.7)	-0.2 (-13.3 to 19.1)	-22.7 (-31.7 to -5.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	5.3 (-17.2 to 32.2)	-16.9 (-33.6 to 4.2)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.8 (-94.6 to 831.6)	-44.1 (-93.6 to 665.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.8 (-94.7 to 839.1)	-44.1 (-94.0 to 681.6)
Whooping cough	0.8 (0.6 to 1.0)	0.4 (0.3 to 0.5)	-51.7 (-53.3 to -50.1)	-41.7 (-43.6 to -39.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-51.7 (-59.3 to -43.8)	-41.8 (-50.8 to -32.4)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.3 (-90.1 to -80.1)	-82.6 (-91.3 to -64.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-81.6 (-91.5 to -62.0)	-83.3 (-92.0 to -66.2)
Measles	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	1.8 (1.6 to 2.0)	1.9 (1.6 to 2.2)	3.8 (-11.7 to 27.3)	-0.7 (-17.9 to 25.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	32.5 (-8.2 to 98.9)	-1.0 (-32.4 to 51.9)
Neglected tropical diseases and malaria	-	-	-	-	4.9 (2.8 to 7.9)	11.0 (5.8 to 19.8)	117.6 (47.9 to 272.5)	102.9 (33.2 to 253.9)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.9 (-47.4 to 76.4)	-15.5 (-53.3 to 56.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.5 (-47.2 to 78.7)	-15.4 (-53.2 to 58.0)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.3 (-31.7 to 51.1)	-14.9 (-41.7 to 28.3)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.6 (-52.5 to 73.3)	-9.9 (-50.9 to 70.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.6 (-52.5 to 73.4)	-9.9 (-51.0 to 70.9)
Cutaneous and mucocutaneous leishmaniasis	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	2.3 (-27.0 to 58.3)	-15.2 (-39.6 to 29.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.4 (-32.4 to 60.5)	-15.4 (-43.1 to 33.3)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.2 (0.1 to 0.5)	0.2 (0.1 to 0.4)	-25.2 (-72.4 to 89.2)	-43.7 (-77.6 to 35.0)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-22.5 (-71.2 to 98.7)	-40.9 (-77.1 to 47.4)
Cystic echinococcosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-8.2 (-17.1 to 0.5)	-38.1 (-44.0 to -32.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.9 (-28.5 to 17.6)	-37.2 (-51.8 to -19.2)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.7 (0.3 to 1.6)	4.0 (1.5 to 8.9)	470.8 (469.1 to 472.9)	392.9 (391.4 to 394.7)	0.1 (0.0 to 0.3)	0.6 (0.2 to 1.6)	467.5 (383.2 to 562.4)	393.7 (321.1 to 468.3)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.1 (-49.5 to 11.9)	-34.5 (-53.0 to -0.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.1 (-49.6 to 12.2)	-34.3 (-53.0 to -0.6)
Intestinal nematode infections	-	-	-	-	3.6 (1.9 to 6.2)	9.3 (4.3 to 18.0)	148.7 (50.0 to 362.2)	123.2 (32.2 to 326.2)
Ascariasis	476.7 (405.7 to 559.3)	727.2 (601.1 to 877.3)	52.6 (17.4 to 97.4)	28.9 (-2.3 to 68.9)	1.1 (0.5 to 2.2)	0.9 (0.4 to 2.1)	-23.9 (-62.0 to 88.2)	-23.9 (-63.2 to 87.9)
Trichuriasis	875.6 (771.7 to 990.3)	1,590.9 (1,446.3 to 1,739.3)	81.7 (55.2 to 112.9)	52.9 (23.3 to 81.5)	1.9 (0.8 to 3.5)	7.6 (3.3 to 15.6)	299.1 (98.6 to 759.1)	238.7 (62.8 to 670.1)
Hookworm disease	152.1 (137.4 to 192.4)	197.3 (162.6 to 231.5)	21.7 (-5.0 to 55.0)	0.6 (-22.5 to 29.2)	0.7 (0.3 to 1.1)	0.7 (0.4 to 1.4)	21.7 (-36.7 to 108.6)	0.1 (-48.3 to 90.7)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	30.2 (23.9 to 36.7)	27.5 (25.9 to 29.6)	-8.5 (-24.7 to 14.6)	-5.7 (-21.4 to 16.4)	1.1 (0.7 to 1.6)	1.0 (0.6 to 1.4)	-7.5 (-19.4 to 27.5)	-0.8 (-13.4 to 35.2)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.4 (-29.3 to 2.7)	-23.9 (-36.6 to -9.6)
Maternal hemorrhage	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.2 (-11.4 to 0.6)	-18.8 (-23.8 to -14.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.9 (-12.6 to 10.7)	-15.0 (-25.2 to -6.5)
Maternal sepsis and other maternal infections	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-10.4 (-30.5 to 11.7)	-34.2 (-49.6 to -38.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.0 (-40.2 to -2.7)	-36.9 (-50.1 to -21.4)
Maternal hypertensive disorders	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.4)	-15.6 (-21.8 to -8.1)	-24.2 (-30.1 to -17.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.2 (-38.2 to 14.0)	-24.7 (-43.9 to 1.6)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.5 (-49.0 to 51.0)	-21.6 (-51.5 to 35.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.5 (-49.0 to 53.3)	-21.6 (-51.6 to 36.1)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.1 (-50.4 to 47.5)	-21.7 (-54.5 to 23.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.1 (-50.4 to 47.6)	-21.7 (-54.9 to 23.9)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.7 (-51.3 to 31.6)	-25.8 (-56.4 to 16.9)
Neonatal disorders	-	-	-	-	3.3 (2.3 to 4.3)	4.9 (3.4 to 6.7)	47.3 (15.1 to 94.5)	32.2 (3.6 to 75.0)
Preterm birth complications	12.9 (8.6 to 18.9)	28.7 (19.3 to 43.5)	122.2 (83.7 to 173.5)	95.0 (61.1 to 139.9)	1.4 (0.9 to 1.9)	2.8 (2.0 to 3.9)	104.8 (59.1 to 167.0)	81.6 (41.4 to 135.4)
Neonatal encephalopathy due to birth asphyxia and trauma	11.2 (3.8 to 28.1)	9.3 (3.3 to 23.0)	-16.1 (-39.1 to 16.8)	-26.1 (-46.5 to 3.4)	1.1 (0.7 to 1.6)	0.9 (0.5 to 1.4)	-13.4 (-49.8 to 33.1)	-21.1 (-53.7 to 21.4)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.2 (36.4 to 86.4)	61.2 (66.4 to 127.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.5 (35.4 to 94.8)	97.5 (65.2 to 137.7)
Hemolytic disease and other neonatal jaundice	1.6 (0.9 to 2.6)	1.9 (1.1 to 3.7)	23.7 (-50.6 to 174.1)	9.9 (-56.1 to 142.1)	0.6 (0.3 to 1.0)	0.7 (0.4 to 1.4)	22.6 (-50.9 to 168.6)	9.3 (-55.8 to 139.3)
Other neonatal disorders	-	-	-	-	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.7)	75.2 (-7.5 to 225.9)	57.2 (-16.9 to 193.5)
Nutritional deficiencies	-	-	-	-	16.3 (10.9 to 23.4)	15.3 (10.2 to 22.1)	-6.1 (-9.4 to -3.5)	-8.9 (-12.0 to -6.6)
Protein-energy malnutrition	5.1 (3.6 to 7.0)	2.7 (1.5 to 4.5)	-48.0 (-71.5 to -6.0)	-38.5 (-65.9 to 10.3)	0.5 (0.4 to 1.0)	0.3 (0.2 to 0.6)	-48.0 (-72.2 to -4.2)	-38.5 (-66.8 to 11.3)
Iodine deficiency	2.6 (2.0 to 3.2)	2.0 (1.5 to 2.5)	-24.9 (-47.8 to 7.0)	-40.4 (-58.7 to -15.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-25.1 (-48.8 to 7.1)	-40.5 (-59.7 to -13.8)
Vitamin A deficiency	1.1 (0.8 to 1.5)	0.5 (0.4 to 0.7)	-52.2 (-61.3 to -42.0)	-54.1 (-62.3 to -44.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-52.7 (-62.7 to -40.7)	-55.5 (-64.7 to -45.2)

Appendix Table G.4 - Jamaica prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	487.1 (480.5 to 493.9)	491.4 (487.2 to 495.4)	0.9 (-0.8 to 2.5)	-7.2 (-8.7 to -5.8)	15.6 (10.4 to 22.6)	14.9 (9.9 to 21.6)	-4.2 (-6.9 to -2.3)	-4.2 (-10.3 to -5.8)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (-64.4 to 208.3)	0.0 (-57.5 to 259.0)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.4 (0.8 to 2.1)	1.4 (0.9 to 2.2)	4.3 (-5.2 to 19.9)	-3.0 (-11.6 to 8.2)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.5 (0.3 to 0.9)	0.6 (0.3 to 1.0)	16.0 (2.2 to 30.8)	-7.4 (-17.0 to 3.1)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	38.1 (17.5 to 63.6)	-8.0 (-21.4 to 8.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-1.3 to 88.4)	0.0 (-33.6 to 26.2)
Chlamydial infection	63.9 (53.4 to 75.1)	70.0 (60.1 to 81.2)	9.9 (-12.0 to 37.8)	-7.6 (-25.5 to 14.7)	0.3 (0.1 to 0.4)	0.3 (0.2 to 0.5)	13.3 (6.4 to 37.0)	-6.0 (-22.0 to 12.9)
Gonococcal infection	7.3 (5.5 to 8.9)	8.0 (6.3 to 9.5)	8.0 (-22.1 to 56.6)	-7.0 (-32.6 to 32.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-6.9 (-36.8 to 35.0)	-20.5 (-45.6 to 12.5)
Trichomoniasis	17.8 (10.8 to 27.4)	18.0 (12.7 to 25.7)	-0.4 (-36.5 to 73.6)	-15.9 (-43.8 to 37.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-4.5 (-44.7 to 76.9)	-18.9 (-50.5 to 38.2)
Genital herpes	512.2 (484.3 to 540.2)	690.6 (652.1 to 725.3)	34.5 (23.1 to 45.6)	-3.8 (-11.8 to 4.1)	0.1 (0.0 to 0.3)	0.1 (0.1 to 0.4)	11.6 (17.1 to 43.5)	-3.9 (-12.8 to 4.8)
Other sexually transmitted diseases	0.5 (0.4 to 0.7)	0.6 (0.4 to 0.8)	8.5 (-4.9 to 25.3)	-23.2 (-32.3 to -11.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (5.0 to 79.7)	0.6 (-27.5 to 37.0)
Hepatitis	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	8.4 (-3.3 to 22.3)	-8.1 (-18.4 to 4.0)
Hepatitis A	3.0 (2.8 to 3.1)	2.9 (2.8 to 3.0)	-0.9 (-1.6 to -0.2)	-3.9 (-4.1 to -3.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	10.2 (-1.3 to 23.0)	-2.3 (-11.8 to 8.9)
Hepatitis B	33.0 (28.6 to 38.3)	26.9 (22.1 to 31.3)	-18.7 (-34.9 to 2.4)	-34.1 (-46.1 to -17.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.4 (-41.6 to 72.0)	-24.4 (-59.2 to 28.9)
Hepatitis C	37.9 (33.8 to 42.2)	37.0 (33.2 to 40.8)	-2.5 (-15.2 to 12.3)	-8.6 (-38.1 to -38.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.2 (-29.9 to 26.5)	-27.4 (-49.2 to -2.6)
Hepatitis E	-	-	16.5 (3.6 to 32.8)	1.2 (-10.2 to 14.5)	-	-	-	-
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.7 (-38.6 to 657.4)	8.8 (-57.7 to 433.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.4 (-39.6 to 940.0)	9.6 (-58.2 to 620.1)
Other infectious diseases	21.6 (17.1 to 26.6)	20.2 (18.4 to 21.9)	-6.3 (-16.2 to 8.2)	-6.3 (-15.6 to 7.8)	0.8 (0.5 to 1.1)	0.7 (0.5 to 1.1)	-3.9 (-16.9 to 24.5)	1.3 (-12.3 to 29.6)
Non-communicable diseases	-	-	-	-	175.5 (131.5 to 228.7)	240.5 (180.1 to 310.6)	37.1 (33.7 to 40.5)	2.6 (0.3 to 5.3)
Neoplasms	-	-	-	-	1.6 (1.2 to 2.2)	3.5 (2.4 to 4.8)	111.4 (70.0 to 163.3)	48.5 (18.8 to 86.3)
Esophageal cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	42.6 (0.9 to 109.9)	-0.8 (-29.7 to 45.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.0 (-2.8 to 108.7)	-1.2 (-32.3 to 44.8)
Stomach cancer	0.8 (0.7 to 0.9)	0.7 (0.6 to 0.9)	-9.2 (-30.7 to 19.6)	-36.2 (-51.5 to -16.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-10.8 (-33.5 to 17.7)	-37.4 (-53.6 to -17.8)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-0.1 to 0.0)	0.0 (-257.1 to 219.2)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	422.1 (177.5 to 870.6)	260.0 (88.4 to 571.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	408.0 (196.2 to 753.7)	250.3 (-49.8 to 498.8)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	1,408.0 (715.8 to 2,868.8)	943.3 (463.5 to 1,939.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,357.4 (753.9 to 2,477.5)	911.6 (491.2 to 1,668.2)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	116.7 (17.4 to 281.7)	51.4 (-17.4 to 166.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.5 (30.7 to 233.2)	47.8 (-8.1 to 132.5)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.2 (0.0 to 285.0)	42.3 (-31.0 to 165.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.1 (6.5 to 233.4)	21.5 (-26.6 to 130.0)
Larynx cancer	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	73.5 (18.1 to 152.3)	17.0 (-20.1 to 70.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.5 (19.2 to 169.6)	20.5 (-19.8 to 81.9)
Tracheal, bronchus and lung cancer	0.4 (0.3 to 0.4)	0.7 (0.5 to 0.9)	76.8 (37.3 to 130.7)	20.1 (-6.7 to 57.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	74.8 (30.3 to 126.7)	18.7 (-11.6 to 55.7)
Breast cancer	3.5 (3.0 to 4.1)	6.5 (4.6 to 8.6)	83.5 (30.7 to 156.7)	15.0 (-18.3 to 60.9)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.8)	84.1 (32.1 to 153.4)	16.3 (-16.3 to 60.2)
Cervical cancer	2.1 (1.5 to 2.6)	2.0 (1.3 to 3.0)	-8.3 (-38.7 to 52.3)	-41.1 (-60.0 to -2.6)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	9.7 (-38.8 to 50.0)	32.8 (-59.4 to -2.7)
Uterine cancer	0.6 (0.4 to 0.9)	1.4 (0.7 to 2.2)	155.3 (11.8 to 356.5)	67.9 (-26.5 to 198.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	153.4 (11.0 to 344.1)	67.0 (-27.4 to 195.1)
Prostate cancer	3.2 (2.2 to 4.9)	13.2 (7.3 to 19.7)	309.3 (151.5 to 554.4)	198.1 (82.7 to 379.6)	0.3 (0.2 to 0.5)	1.2 (0.6 to 1.9)	261.2 (127.5 to 457.9)	164.6 (66.3 to 307.1)
Colon and rectum cancer	1.7 (1.5 to 1.9)	3.3 (2.7 to 3.9)	96.1 (53.9 to 144.6)	36.4 (7.4 to 69.5)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	87.2 (44.8 to 136.6)	30.4 (1.2 to 64.6)
Lip and oral cavity cancer	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	40.4 (-2.2 to 103.2)	4.8 (-33.5 to 37.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	38.1 (-5.6 to 101.2)	-6.6 (-35.6 to 35.0)
Nasopharynx cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	30.2 (-12.6 to 109.0)	-12.4 (-42.0 to 39.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.5 (-12.8 to 96.2)	-14.6 (-41.8 to 31.6)
Other pharynx cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	46.5 (-11.8 to 126.9)	-5.6 (-42.4 to 47.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.1 (-9.7 to 120.5)	-6.8 (-41.4 to 44.2)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-52.6 (-73.1 to 27.6)	-66.9 (-81.2 to -10.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.9 (-72.3 to 33.0)	-65.8 (-80.6 to -7.4)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	481.3 (321.2 to 678.4)	306.4 (192.0 to 442.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	429.3 (294.5 to 611.6)	270.6 (176.8 to 392.9)
Malignant skin melanoma	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.5)	20.5 (-15.1 to 112.8)	16.9 (-42.1 to 48.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.9 (-17.7 to 107.2)	-18.1 (-43.1 to 44.9)
Non-melanoma skin cancer	0.5 (0.4 to 0.6)	0.8 (0.7 to 1.1)	74.7 (34.1 to 131.2)	18.1 (-9.3 to 56.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	146.1 (51.9 to 290.7)	70.6 (6.0 to 170.1)
Ovarian cancer	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.6)	351.6 (209.5 to 553.3)	213.1 (116.7 to 353.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	335.3 (185.9 to 564.0)	204.3 (100.4 to 361.7)
Testicular cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	399.5 (45.1 to 1,063.4)	287.1 (-19.3 to 757.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	362.8 (-4.9 to 1,008.5)	258.1 (-30.5 to 737.1)
Kidney cancer	0.5 (0.3 to 0.4)	0.3 (0.3 to 0.5)	33.7 (-0.3 to 80.7)	-2.7 (-27.9 to 34.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.9 (-2.2 to 84.2)	-4.7 (-30.1 to 34.1)
Bladder cancer	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-4.3 (-32.6 to 26.6)	-32.1 (-52.3 to 7.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.8 (-33.7 to 52.9)	-31.8 (-52.7 to 8.8)
Brain and nervous system cancer	0.1 (0.1 to 0.1)	0.3 (0.1 to 0.4)	236.2 (35.9 to 496.8)	236.2 (26.1 to 437.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	287.8 (39.1 to 497.4)	236.3 (18.9 to 396.5)
Thyroid cancer	0.7 (0.5 to 0.9)	1.5 (1.0 to 2.2)	108.6 (46.9 to 205.4)	45.7 (2.6 to 112.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	104.5 (43.2 to 201.2)	43.6 (0.1 to 112.0)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	133.3 (64.3 to 230.0)	64.7 (16.0 to 133.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	140.7 (66.9 to 245.4)	70.9 (18.4 to 145.5)
Hodgkin lymphoma	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	500.9 (31.9 to 907.0)	437.1 (15.6 to 785.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	494.3 (30.5 to 882.1)	425.4 (10.7 to 745.1)
Non-Hodgkin lymphoma	0.8 (0.6 to 1.0)	1.6 (1.1 to 2.1)	114.5 (46.3 to 196.6)	54.4 (4.5 to 114.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	108.3 (41.7 to 193.5)	48.5 (-1.9 to 107.6)
Multiple myeloma	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	116.2 (39.2 to 257.0)	45.9 (-7.1 to 138.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	107.4 (31.2 to 240.2)	39.2 (-12.6 to 130.7)
Leukemia	0.5 (0.4 to 0.7)	0.9 (0.6 to 1.3)	62.1 (5.1 to 151.3)	50.2 (3.1 to 126.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	79.8 (27.9 to 156.7)	52.8 (10.5 to 113.5)
Other neoplasms	2.0 (1.6 to 2.5)	4.7 (3.5 to 6.5)	135.0 (70.3 to 234.0)	97.5 (48.0 to 173.7)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	132.5 (71.0 to 221.6)	89.4 (43.9 to 158.7)
Cardiovascular diseases	-	-	-	-	3.0 (2.2 to 4.1)	5.3 (3.7 to 7.0)	75.4 (46.5 to 106.1)	23.8 (3.5 to 45.8)
Rheumatic heart disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	37.5 (19.6 to 57.0)	-5.9 (-18.7 to 8.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (18.8 to 60.5)	-5.6 (-19.0 to 10.4)
Ischemic heart disease	16.9 (14.6 to 19.5)	40.8 (34.3 to 49.6)	140.0 (89.5 to 209.1)	68.7 (33.0 to 116.8)	0.8 (0.5 to 1.1)	2.1 (1.3 to 3.1)	174.9 (106.0 to 278.8)	93.9 (39.7 to 167.9)
Cerebrovascular disease	-	-	-	-	0.9 (0.6 to 1.1)	1.2 (0.8 to 1.6)	2.7 (9.9 to 76.3)	2.7 (-23.5 to 23.8)
Ischemic stroke	4.4 (3.7 to 5.2)	6.2 (5.2 to 7.4)	39.4 (8.0 to 79.9)	-2.0 (-24.3 to 27.3)	0.6 (0.4 to 0.9)	0.9 (0.6 to 1.2)	39.2 (6.7 to 79.7)	-2.3 (-25.0 to 26.9)
Hemorrhagic stroke	1.4 (1.1 to 1.8)	2.0 (1.6 to 2.6)	40.6 (0.3 to 100.7)	-3.9 (-31.9 to 39.7)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	39.7 (0.6 to 102.5)	-4.4 (-32.3 to 40.7)
Hypertensive heart disease	2.2 (2.0 to 2.4)	2.6 (2.3 to 2.8)	16.7 (1.4 to 33.1)	-18.9 (-29.4 to -7.2)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	16.9 (0.4 to 35.8)	-18.8 (-30.5 to -5.4)
Cardiomyopathy and myocarditis	0.8 (0.7 to 0.9)	1.1 (1.0 to 1.2)	47.2 (25.1 to 69.9)	2.1 (-14.0 to 18.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	46.2 (21.0 to 74.6)	1.1 (-16.7 to 21.9)
Atrial fibrillation and flutter	6.4 (4.9 to 7.8)	10.4 (8.0 to 12.7)	61.2 (18.0 to 125.2)	16.4 (-14.0 to 60.2)	0.5 (0.3 to 0.7)	0.8 (0.5 to 1.1)	61.7 (19.7 to 126.6)	16.4 (-13.3 to 61.3)
Peripheral vascular disease	65.5 (52.6 to 79.3)	102.5 (83.8 to 122.5)	56.2 (17.3 to 107.6)	0.3 (-23.9 to 34.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	24.7 (-37.6 to 129.5)	-9.0 (-54.7 to 68.8)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	6.3 (-15.9 to 31.9)	-23.4 (-39.1 to -4.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.4 (-16.8 to 29.3)	-23.7 (-41.1 to -6.4)
Other cardiovascular and circulatory diseases	7.6 (4.0 to 13.0)	10.3 (8.5 to 13.1)	40.3 (-24.0 to 162.4)	4.5 (-48.3 to 80.9)	0.5 (0.3 to 1.0)	0.7 (0.5 to 1.1)	39.9 (-24.6 to 161.7)	-5.2 (-48.0 to 78.6)
Chronic respiratory diseases	-	-	-	-	13.2 (9.1 to 18.3)	18.3 (12.6 to 25.5)	37.3 (20.5 to 66.0)	-0.9 (-12.8 to 19.7)
Chronic obstructive pulmonary disease	96.4 (91.9 to 100.6)	140.8 (134.0 to 147.9)	46.0 (41.9 to 51.6)	-0.7 (-3.5 to 3.1)	5.8 (3.7 to 8.3)	9.0 (5.8 to 12.8)	54.0 (28.9 to 88.9)	4.9 (-12.8 to 29.7)

</

Appendix Table G.4 - Jamaica prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.4 (34.3 to 45.7)	40.4 (-7.6 to -0.1)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.3 (25.0 to 33.8)	-10.9 (-13.9 to -7.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.2 (24.9 to 33.8)	-11.0 (-14.0 to -8.0)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.1 (38.6 to 56.4)	1.8 (-4.5 to 7.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.8 (38.4 to 56.4)	1.7 (-4.7 to 7.3)
Asthma	154.6 (132.8 to 178.9)	197.7 (167.4 to 228.3)	26.8 (4.4 to 60.0)	-2.6 (-20.1 to 22.6)	6.8 (4.3 to 9.8)	8.7 (5.4 to 12.6)	26.3 (4.1 to 60.6)	-2.7 (-20.3 to 22.9)
Interstitial lung disease and pulmonary sarcoidosis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	56.5 (15.4 to 106.7)	11.7 (-18.7 to 49.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.0 (15.4 to 107.0)	11.5 (-19.0 to 48.6)
Other chronic respiratory diseases	-	-	-	-	0.6 (0.4 to 1.1)	0.6 (0.3 to 1.1)	-3.7 (-41.9 to 67.9)	-34.2 (-60.6 to 15.1)
Cirrhosis	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	39.5 (20.2 to 63.8)	2.6 (-11.8 to 19.0)
Cirrhosis due to hepatitis B	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	23.7 (-37.2 to 175.4)	-12.1 (55.2 to 92.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.3 (-40.8 to 171.8)	-12.2 (57.8 to 93.5)
Cirrhosis due to hepatitis C	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	72.4 (14.3 to 138.4)	24.9 (-16.8 to 70.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	69.3 (7.4 to 142.7)	23.2 (22.2 to 79.3)
Cirrhosis due to alcohol use	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	21.3 (-14.1 to 69.2)	-19.5 (-43.5 to 11.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.4 (-20.2 to 82.3)	20.4 (-47.0 to 20.9)
Cirrhosis due to other causes	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	40.8 (9.1 to 73.9)	22.7 (-6.2 to 54.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.6 (-7.6 to 96.4)	19.1 (-19.3 to 67.6)
Digestive diseases	-	-	-	-	3.3 (2.3 to 4.6)	4.7 (3.3 to 6.4)	41.7 (32.5 to 53.9)	3.1 (-3.7 to 11.3)
Peptic ulcer disease	18.5 (16.3 to 20.3)	13.8 (12.6 to 15.1)	-24.9 (-33.6 to -15.1)	-47.8 (-54.5 to -39.9)	0.7 (0.5 to 0.9)	0.5 (0.4 to 0.8)	-17.9 (-27.8 to -4.9)	-43.8 (-50.6 to -34.3)
Gastritis and duodenitis	47.8 (45.9 to 49.7)	62.8 (59.9 to 66.1)	31.4 (23.8 to 39.0)	-1.3 (-6.9 to 4.3)	1.6 (1.1 to 2.3)	2.1 (1.4 to 2.9)	25.4 (15.9 to 37.6)	-2.9 (-10.0 to 5.7)
Appendicitis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	10.1 (-14.9 to 45.0)	-5.8 (-26.3 to 21.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.3 (-18.7 to 57.2)	-4.7 (-28.5 to 29.2)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.5 (-5.3 to 63.1)	0.0 (-5.5 to 41.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.8 (-12.0 to 83.1)	14.5 (-16.9 to 56.7)
Inguinal, femoral, and abdominal hernia	9.3 (8.3 to 10.6)	7.9 (6.4 to 9.6)	-15.2 (-34.9 to 5.7)	-38.1 (-53.2 to -22.3)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-14.5 (-34.4 to 6.3)	-37.7 (-53.0 to -22.3)
Inflammatory bowel disease	2.7 (2.6 to 2.8)	4.8 (4.6 to 4.9)	78.8 (69.8 to 88.2)	0.6 (17.8 to 30.4)	1.0 (0.4 to 0.8)	1.4 (0.7 to 1.4)	78.2 (64.6 to 94.3)	23.6 (14.3 to 34.0)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.6 (-10.1 to 98.4)	-0.3 (-35.4 to 45.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.6 (-10.1 to 98.5)	-0.3 (35.4 to 45.6)
Gallbladder and biliary diseases	1.5 (1.3 to 1.7)	1.5 (1.3 to 1.7)	-0.6 (-15.0 to 16.4)	-33.3 (-43.7 to -21.4)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-4.4 (-17.7 to 17.8)	-34.0 (-45.0 to -21.0)
Pancreatitis	0.1 (0.1 to 0.1)	0.3 (0.3 to 0.3)	113.2 (99.7 to 128.1)	50.9 (41.5 to 61.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	110.1 (66.0 to 175.4)	49.5 (18.3 to 94.1)
Other digestive diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.7 (0.5 to 1.0)	505.3 (295.8 to 643.7)	341.3 (189.8 to 443.4)
Neurological disorders	-	-	-	-	15.2 (10.4 to 20.5)	20.7 (14.2 to 28.2)	36.7 (18.7 to 57.5)	4.3 (8.2 to 19.8)
Alzheimer disease and other dementias	18.5 (16.4 to 20.6)	25.3 (22.3 to 28.3)	36.4 (14.9 to 65.0)	-0.9 (-16.1 to 19.8)	2.7 (1.9 to 3.5)	3.7 (2.7 to 4.9)	36.2 (14.5 to 65.8)	-4.1 (-16.6 to 20.1)
Parkinson disease	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.4)	38.0 (30.0 to 47.6)	-1.6 (-6.8 to 5.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	39.0 (16.6 to 69.8)	-1.3 (-17.9 to 20.0)
Epilepsy	5.5 (3.7 to 7.5)	8.3 (5.4 to 11.3)	50.4 (-11.3 to 146.6)	25.9 (-25.7 to 108.9)	1.9 (1.1 to 2.9)	2.9 (1.7 to 4.4)	52.5 (-11.7 to 158.5)	29.1 (-26.4 to 118.3)
Multiple sclerosis	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.4)	178.1 (149.2 to 211.5)	86.5 (66.4 to 109.3)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	170.7 (120.3 to 223.2)	82.2 (47.5 to 117.6)
Migraine	228.4 (193.8 to 263.8)	281.3 (241.6 to 323.0)	23.5 (0.5 to 50.8)	4.6 (-22.5 to 16.2)	7.8 (4.7 to 11.8)	9.6 (5.7 to 14.4)	41.6 (0.6 to 50.2)	-1.1 (-22.9 to 19.9)
Tension-type headache	454.3 (368.9 to 526.5)	607.4 (568.8 to 647.0)	33.9 (12.4 to 66.0)	2.2 (-13.3 to 22.8)	0.7 (0.3 to 1.2)	0.9 (0.5 to 1.6)	33.6 (11.8 to 65.7)	2.3 (-13.8 to 24.1)
Medication overuse headache	9.7 (6.1 to 13.4)	19.2 (12.2 to 26.1)	99.4 (46.7 to 161.8)	43.5 (5.6 to 90.8)	1.5 (0.9 to 2.4)	3.0 (1.7 to 4.7)	98.2 (45.7 to 160.3)	43.1 (3.9 to 89.7)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.1 (-12.8 to 72.4)	-0.4 (-29.9 to 41.9)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	9.5 (-26.0 to 67.5)	-20.9 (-46.6 to 20.7)
Mental and substance use disorders	-	-	-	-	54.9 (39.1 to 72.6)	69.4 (49.8 to 91.0)	26.6 (22.5 to 30.6)	-0.2 (-2.7 to 2.2)
Schizophrenia	5.5 (5.0 to 6.0)	7.9 (7.2 to 8.7)	43.6 (37.0 to 50.8)	-0.3 (-4.5 to 4.1)	3.6 (2.6 to 4.4)	5.1 (3.8 to 6.2)	42.4 (33.0 to 52.6)	-0.6 (-6.7 to 5.8)
Alcohol use disorders	11.8 (10.9 to 12.7)	16.8 (15.6 to 18.0)	43.2 (35.7 to 50.4)	7.4 (2.3 to 12.2)	1.2 (0.8 to 1.6)	1.6 (1.1 to 2.4)	43.4 (33.1 to 53.7)	7.6 (0.5 to 14.6)
Drug use disorders	-	-	-	-	4.0 (2.7 to 5.5)	5.0 (3.3 to 6.8)	22.6 (5.3 to 43.0)	0.8 (-12.9 to 16.7)
Opioid use disorders	1.5 (0.8 to 2.4)	2.2 (1.1 to 3.6)	52.5 (31.6 to 75.2)	0.5 (-8.8 to 13.4)	0.6 (0.3 to 1.1)	0.9 (0.4 to 1.5)	52.0 (25.6 to 81.5)	1.2 (-13.4 to 17.8)
Cocaine use disorders	7.8 (7.2 to 8.4)	9.4 (8.5 to 10.3)	20.8 (8.8 to 36.5)	1.1 (-10.6 to 14.0)	1.3 (0.7 to 1.6)	1.3 (0.8 to 1.9)	20.6 (3.7 to 40.3)	1.3 (-12.8 to 17.3)
Amphetamine use disorders	4.2 (3.9 to 4.6)	4.8 (4.4 to 5.1)	12.3 (0.8 to 24.6)	0.1 (-9.7 to 10.3)	0.6 (0.3 to 0.8)	0.6 (0.4 to 0.9)	12.1 (6.0 to 32.2)	0.2 (-15.4 to 17.3)
Cannabis use disorders	5.3 (4.3 to 6.3)	6.1 (4.9 to 7.1)	13.9 (12.3 to 15.8)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	13.9 (-1.7 to 33.4)	0.4 (-12.8 to 16.5)
Other drug use disorders	-	-	-	-	1.7 (1.0 to 2.4)	1.9 (1.2 to 2.8)	17.6 (-12.9 to 63.8)	0.6 (-25.2 to 40.5)
Depressive disorders	-	-	-	-	20.6 (13.7 to 29.2)	26.4 (17.4 to 37.0)	28.7 (20.4 to 36.3)	0.7 (-6.2 to 4.2)
Major depressive disorder	87.2 (70.2 to 103.4)	111.4 (87.0 to 131.9)	27.9 (18.8 to 35.7)	-0.6 (-7.1 to 5.0)	18.0 (11.6 to 25.7)	22.8 (14.7 to 32.6)	27.2 (17.8 to 35.5)	-0.8 (-7.1 to 4.9)
Dysthymia	26.5 (22.2 to 31.0)	37.2 (31.3 to 43.1)	40.3 (34.6 to 47.7)	0.0 (-0.1 to 0.1)	2.5 (1.7 to 3.7)	3.6 (2.3 to 5.2)	39.9 (33.5 to 48.1)	-0.2 (-2.5 to 2.3)
Bipolar disorder	16.4 (13.8 to 18.9)	21.5 (18.5 to 24.5)	30.6 (24.1 to 38.2)	-0.1 (-4.3 to 4.5)	3.4 (2.1 to 5.1)	4.4 (2.7 to 6.6)	30.1 (21.7 to 39.8)	-0.2 (-6.1 to 6.0)
Anxiety disorders	133.0 (90.0 to 172.1)	168.7 (116.7 to 214.8)	27.0 (19.2 to 35.0)	0.1 (-0.3 to 0.1)	12.3 (7.3 to 18.4)	15.5 (9.6 to 23.0)	26.4 (17.8 to 34.8)	0.3 (-2.2 to 1.7)
Eating disorders	-	-	-	-	0.8 (0.4 to 1.2)	0.8 (0.5 to 1.3)	8.1 (-1.2 to 18.6)	-0.2 (-7.7 to 8.2)
Anorexia nervosa	0.6 (0.4 to 0.8)	0.7 (0.5 to 0.8)	13.7 (1.7 to 25.7)	4.7 (-5.7 to 15.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	12.7 (8.2 to 43.3)	3.9 (-14.5 to 31.4)
Bulimia nervosa	3.0 (2.0 to 4.4)	3.2 (2.1 to 4.7)	7.2 (3.0 to 12.5)	-0.9 (-1.5 to -0.2)	0.6 (0.4 to 1.0)	0.7 (0.4 to 1.1)	7.1 (-2.4 to 19.0)	-1.1 (-8.8 to 7.6)
Autistic spectrum disorders	-	-	-	-	2.8 (1.9 to 3.8)	3.2 (2.2 to 4.4)	15.9 (11.9 to 20.2)	0.0 (-3.1 to 3.5)
Autism	7.1 (6.7 to 7.4)	8.3 (7.9 to 8.7)	16.9 (16.3 to 17.6)	0.2 (0.2 to 0.2)	1.8 (1.2 to 2.4)	2.0 (1.4 to 2.8)	16.0 (10.2 to 22.2)	0.1 (-4.6 to 5.0)
Asperger syndrome	10.3 (9.7 to 11.0)	12.0 (11.3 to 12.8)	16.3 (15.4 to 17.2)	0.2 (0.2 to 0.3)	1.0 (0.7 to 1.4)	1.2 (0.8 to 1.7)	15.6 (10.3 to 20.6)	0.0 (-4.1 to 4.0)
Attention-deficit/hyperactivity disorder	19.9 (18.3 to 21.3)	20.3 (18.6 to 21.6)	0.5 (1.5 to 1.7)	0.5 (0.5 to 0.6)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	1.7 (-5.3 to 8.6)	0.5 (-6.3 to 7.3)
Conduct disorder	26.6 (24.8 to 28.4)	27.7 (25.9 to 29.6)	4.4 (3.9 to 4.9)	0.5 (0.5 to 0.6)	3.2 (2.0 to 4.7)	3.3 (2.1 to 4.9)	4.1 (-4.0 to 4.5)	0.3 (-4.0 to 4.5)
Idiopathic intellectual disability	6.9 (3.3 to 11.2)	7.4 (3.8 to 11.4)	7.4 (-26.3 to 59.9)	6.8 (-37.4 to 35.8)	0.3 (0.1 to 0.6)	0.4 (0.2 to 0.6)	6.5 (-26.0 to 59.8)	-9.1 (-37.2 to 37.0)
Other mental and substance use disorders	34.2 (32.0 to 36.3)	46.2 (43.5 to 48.8)	35.2 (32.9 to 37.5)	0.2 (0.0 to 0.4)	2.6 (1.7 to 3.4)	3.4 (2.3 to 4.6)	34.5 (29.0 to 40.6)	0.1 (-3.4 to 3.8)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	17.0 (11.7 to 23.7)	27.0 (18.7 to 37.3)	58.6 (42.6 to 75.8)	16.9 (4.6 to 31.1)
Diabetes mellitus	91.5 (77.0 to 105.6)	192.3 (160.4 to 221.0)	110.2 (69.0 to 156.8)	40.0 (12.0 to 113)	6.6 (4.3 to 9.2)	14.0 (9.2 to 19.5)	113.4 (72.2 to 160.8)	38.3 (11.7 to 70.8)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.8 (2.9 to 21.0)	9.6 (2.9 to 18.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.8 (2.8 to 21.1)	9.6 (2.8 to 21.0)
Chronic kidney disease	-	-	-	-	3.1 (2.2 to 4.3)	4.1 (2.9 to 5.4)	30.9 (12.9 to 52.9)	-1.1 (-15.9 to 18.7)
Chronic kidney disease due to diabetes mellitus	56.2 (39.4 to 79.8)	80.2 (52.0 to 117.1)	42.8 (12.2 to 87.3)	-2.9 (-24.8 to 27.4)	0.7 (0.5 to 0.9)	1.0 (0.6 to 1.3)	39.5 (8.7 to 86.6)	-5.2 (-26.0 to 29.3)
Chronic kidney disease due to hypertension	39.9 (29.0 to 60.0)	56.2 (38.8 to 82.4)	38.7 (10.5 to 91.1)	1.1 (-10.6 to 47.9)	1.1 (0.8 to 1.5)	1.5 (1.0 to 1.9)	26.7 (5.1 to 54.7)	-4.9 (-21.0 to 14.8)
Chronic kidney disease due to glomerulonephritis	95.0 (65.5 to 135.1)	122.5 (87.5 to 175.4)	30.5 (-0.2 to 62.6)	0.5 (-23.8 to 19.1)	0.5 (0.3 to 0.7)	0.7 (0.5 to 1.0)	41.1 (-3.3 to 97.3)	14.0 (-25.3 to 59.6)
Chronic kidney disease due to other causes	67.2 (44.3 to 94.3)	82.5 (52.4 to 128.6)	21.6 (-12.6 to 64.5)	-2.2 (-30.2 to 30.7)	0.8 (0.5 to 1.1)	1.0 (0.7 to 1.3)	22.8 (-5.6 to 59.9)	-2.4 (-26.6 to 29.8)
Urinary diseases and male infertility	-	-	-	-	0.9 (0.5 to 1.3)	1.2 (0.8 to 1.7)	39.5 (26.8 to 57.6)	1.9 (-6.6 to 14.6)

Appendix Table G.4 - Jamaica prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.5 (0.5 to 0.6)	0.9 (0.8 to 0.9)	65.5 (49.2 to 83.6)	11.6 (19.6 to 44.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.9 (32.6 to 102.5)	31.8 (6.5 to 59.6)
Urolithiasis	16.4 (11.7 to 21.8)	29.8 (19.8 to 43.8)	74.9 (47.8 to 139.3)	20.5 (-0.1 to 61.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	72.4 (47.9 to 127.1)	19.3 (1.4 to 55.1)
Benign prostatic hyperplasia	15.5 (14.3 to 17.0)	21.2 (19.6 to 22.9)	35.9 (21.9 to 54.2)	-1.5 (-11.6 to 11.3)	0.6 (0.4 to 0.8)	0.8 (0.5 to 1.1)	36.1 (21.5 to 54.5)	-1.5 (-11.9 to 11.5)
Male infertility due to other causes	20.6 (16.3 to 25.0)	24.8 (19.9 to 30.2)	21.0 (-11.5 to 61.4)	-1.5 (-27.8 to 30.5)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.3)	20.0 (-12.7 to 61.4)	-0.8 (-27.8 to 32.8)
Other urinary diseases	-	-	-	-	0.3 (0.0 to 0.1)	0.1 (0.0 to 0.1)	39.6 (-3.6 to 130.3)	5.2 (-31.7 to 59.7)
Gynecological diseases	-	-	-	-	2.9 (1.9 to 4.4)	3.9 (2.5 to 6.0)	34.9 (18.9 to 49.5)	-0.6 (-11.7 to 10.6)
Uterine fibroids	36.8 (33.1 to 40.1)	64.3 (58.5 to 69.5)	74.5 (71.3 to 78.3)	2.2 (2.1 to 2.3)	0.5 (0.3 to 0.9)	0.8 (0.5 to 1.4)	47.6 (28.7 to 61.3)	-3.3 (-15.7 to 4.7)
Polycystic ovarian syndrome	41.1 (35.7 to 46.0)	58.4 (52.0 to 64.8)	42.1 (20.6 to 70.0)	4.1 (-11.0 to 23.6)	0.4 (0.2 to 0.8)	0.6 (0.3 to 1.1)	41.2 (19.6 to 68.4)	4.1 (-10.6 to 23.6)
Female infertility due to other causes	22.4 (17.8 to 27.6)	29.1 (18.7 to 40.4)	28.0 (-16.4 to 101.6)	-4.5 (-38.1 to 49.7)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	25.1 (-17.0 to 96.5)	-5.2 (-36.3 to 48.6)
Endometriosis	3.8 (3.2 to 4.4)	5.6 (4.7 to 6.4)	45.3 (17.7 to 80.9)	5.7 (-15.3 to 30.9)	0.4 (0.2 to 0.5)	0.5 (0.3 to 0.7)	44.7 (16.1 to 79.6)	5.4 (-15.7 to 30.7)
Genital prolapse	107.6 (86.6 to 126.9)	171.3 (145.6 to 195.8)	59.1 (27.1 to 106.9)	5.1 (-15.2 to 34.9)	0.3 (0.2 to 0.7)	0.5 (0.3 to 1.0)	58.5 (26.1 to 110.2)	4.9 (-15.7 to 35.9)
Premenstrual syndrome	112.1 (89.5 to 137.6)	133.3 (98.5 to 167.5)	19.3 (-15.9 to 59.9)	-3.0 (-32.4 to 34.9)	0.9 (0.6 to 1.5)	1.1 (0.6 to 1.8)	19.7 (-17.6 to 59.8)	-3.2 (-33.3 to 34.5)
Other gynecological diseases	7.0 (5.5 to 8.5)	8.3 (7.2 to 9.6)	19.0 (-5.6 to 52.9)	-7.4 (-27.1 to 17.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	11.9 (-14.4 to 76.7)	-10.3 (-32.9 to 37.4)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	2.9 (1.9 to 4.1)	3.1 (2.1 to 4.5)	8.8 (1.7 to 18.5)	0.9 (-6.0 to 9.6)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.4 (-12.6 to 2.3)	1.0 (-6.7 to 9.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.8 (-16.4 to -1.1)	-2.4 (-8.8 to 6.7)
Thalassemia trait	22.2 (20.7 to 23.7)	25.9 (24.2 to 27.6)	16.7 (12.2 to 21.7)	-0.5 (-4.3 to 3.9)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.8)	12.6 (4.1 to 28.6)	1.0 (-13.2 to 15.4)
Sickle cell disorders	5.0 (4.5 to 5.3)	5.7 (5.4 to 6.0)	13.2 (4.7 to 27.2)	2.8 (-4.5 to 14.3)	0.6 (0.4 to 0.8)	0.7 (0.5 to 0.9)	19.9 (6.4 to 34.3)	4.1 (-6.4 to 15.9)
Sickle cell trait	253.7 (247.3 to 260.4)	319.9 (303.0 to 318.7)	25.5 (20.1 to 24.9)	1.2 (2.4 to 6.6)	1.4 (0.8 to 1.8)	1.4 (0.9 to 2.0)	9.4 (-4.2 to 28.2)	3.5 (-9.4 to 23.5)
G6PD deficiency	136.5 (115.1 to 156.0)	196.0 (172.1 to 216.5)	43.6 (18.6 to 77.1)	22.7 (1.4 to 51.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.4 (-53.4 to 53.2)	-23.8 (-57.9 to 30.3)
G6PD trait	430.8 (421.1 to 439.9)	506.0 (491.3 to 519.1)	17.5 (12.9 to 21.4)	-0.1 (-4.1 to 3.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.7 (-68.7 to 623.3)	9.0 (-66.6 to 423.5)
Other hemoglobinopathies and hemolytic anemias	20.5 (18.6 to 22.4)	21.1 (19.1 to 23.0)	2.9 (-9.6 to 16.6)	-8.7 (-19.1 to 3.0)	0.6 (0.4 to 0.8)	0.5 (0.3 to 0.8)	-6.3 (-24.5 to 12.0)	-8.7 (-27.4 to 8.4)
Endocrine, metabolic, blood, and immune disorders	7.2 (19.4 to 24.9)	22.9 (20.8 to 24.9)	219.9 (-10.4 to 19.0)	3.5 (-16.2 to 9.1)	0.7 (0.5 to 1.0)	0.7 (0.5 to 1.0)	2.4 (-20.2 to 22.0)	4.4 (-21.0 to 18.6)
Musculoskeletal disorders	-	-	-	-	27.4 (19.6 to 36.3)	41.6 (29.6 to 54.9)	51.2 (41.0 to 62.6)	3.8 (-2.7 to 10.9)
Rheumatoid arthritis	5.0 (4.7 to 5.2)	9.5 (9.1 to 9.9)	91.5 (79.9 to 104.8)	39.1 (30.0 to 48.7)	1.2 (0.8 to 1.6)	2.2 (1.6 to 3.0)	89.3 (74.9 to 106.4)	37.8 (27.2 to 50.1)
Osteoarthritis	74.4 (71.6 to 77.1)	115.0 (111.1 to 118.8)	54.6 (47.1 to 62.9)	1.5 (-3.4 to 7.0)	6.5 (3.2 to 6.5)	7.4 (4.9 to 7.4)	54.6 (47.0 to 62.8)	1.2 (-3.9 to 6.7)
Low back and neck pain	-	-	-	-	16.7 (11.5 to 22.9)	23.6 (16.1 to 32.1)	41.1 (25.2 to 57.7)	0.4 (-11.8 to 11.6)
Low back pain	92.6 (83.0 to 103.7)	128.8 (115.4 to 144.6)	38.7 (21.6 to 61.1)	-0.8 (-13.4 to 13.6)	10.3 (6.9 to 14.6)	14.3 (9.4 to 20.3)	38.3 (20.5 to 60.4)	-1.0 (-13.6 to 13.7)
Neck pain	64.6 (55.3 to 74.1)	94.6 (81.3 to 107.3)	46.7 (17.8 to 79.7)	1.5 (-17.2 to 24.6)	6.4 (4.2 to 9.1)	9.3 (6.2 to 12.9)	46.0 (16.4 to 79.9)	1.1 (-18.4 to 24.2)
Gout	0.7 (0.7 to 0.8)	1.1 (1.0 to 1.2)	46.1 (27.9 to 65.8)	-3.9 (-16.3 to 9.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.3 (14.6 to 84.1)	-4.5 (-25.2 to 22.0)
Other musculoskeletal disorders	55.2 (44.8 to 67.7)	95.8 (77.2 to 115.6)	73.4 (59.0 to 89.1)	11.7 (2.4 to 21.5)	5.0 (3.3 to 7.3)	8.7 (5.7 to 12.4)	11.3 (58.0 to 88.8)	1.3 (-2.1 to 20.6)
Other non-communicable diseases	-	-	-	-	39.7 (26.8 to 57.2)	50.0 (33.9 to 72.1)	26.1 (22.1 to 30.1)	-4.8 (-7.5 to -1.9)
Congenital anomalies	-	-	-	-	2.5 (1.8 to 3.3)	3.6 (2.6 to 4.8)	42.9 (26.2 to 67.6)	21.2 (7.1 to 41.9)
Neural tube defects	0.7 (0.6 to 0.8)	0.8 (0.7 to 0.8)	5.9 (-13.8 to 28.4)	-3.4 (-21.7 to 17.1)	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	7.7 (-22.5 to 48.7)	-0.5 (-28.5 to 36.9)
Congenital heart anomalies	11.2 (9.6 to 13.7)	16.1 (14.6 to 17.9)	44.3 (14.7 to 76.3)	28.1 (1.8 to 56.4)	0.4 (0.2 to 0.7)	0.6 (0.2 to 1.0)	46.8 (15.3 to 79.1)	31.7 (3.6 to 60.6)
Orofacial clefts	2.1 (1.6 to 2.7)	2.7 (2.3 to 3.3)	27.7 (-4.6 to 70.6)	17.7 (-11.9 to 56.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	6.3 (-28.2 to 57.3)	-1.9 (-32.6 to 44.6)
Down syndrome	2.2 (2.0 to 2.5)	3.0 (2.6 to 3.5)	32.6 (9.4 to 62.9)	11.4 (-8.0 to 36.4)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	41.5 (15.9 to 78.2)	13.7 (-7.2 to 42.6)
Turner syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	19.5 (-15.9 to 77.0)	4.0 (-26.8 to 54.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.3 (-17.6 to 83.2)	4.0 (-28.9 to 58.6)
Klinefelter syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	20.0 (-15.6 to 72.3)	3.2 (-27.4 to 48.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.0 (-1.8 to 80.8)	2.7 (-27.9 to 47.9)
Chromosomal unbalanced rearrangements	4.0 (3.5 to 4.6)	5.5 (4.4 to 6.8)	36.5 (8.8 to 74.8)	14.7 (-10.3 to 47.1)	0.7 (0.4 to 0.7)	0.7 (0.5 to 1.0)	16.5 (12.8 to 36.9)	16.5 (-9.7 to 50.2)
Other congenital anomalies	9.8 (8.2 to 11.4)	10.4 (8.7 to 12.0)	6.1 (-2.7 to 15.7)	-12.0 (-19.0 to -4.4)	1.1 (0.7 to 1.6)	1.7 (1.1 to 2.3)	50.4 (22.2 to 103.6)	27.4 (4.0 to 69.6)
Skin and subcutaneous diseases	-	-	-	-	12.1 (7.7 to 18.4)	14.6 (9.4 to 22.0)	20.4 (13.4 to 30.1)	-0.3 (-6.0 to 6.8)
Dermatitis	107.7 (88.2 to 128.4)	136.2 (111.1 to 162.1)	26.6 (22.1 to 30.3)	-0.0 (-0.1 to 0.0)	2.9 (1.8 to 4.2)	3.6 (2.2 to 5.2)	22.0 (17.0 to 26.9)	-0.2 (-15.6 to 2.7)
Psoriasis	18.2 (16.0 to 20.4)	24.1 (21.1 to 27.2)	32.4 (29.4 to 35.5)	1.5 (-0.0 to 0.1)	0.0 (1.0 to 2.1)	2.0 (1.3 to 2.8)	31.7 (24.0 to 40.1)	-0.3 (-4.9 to 4.9)
Cellulitis	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	2.1 (-12.7 to 17.0)	-14.4 (-26.9 to -3.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.5 (-19.2 to 28.9)	-14.1 (-30.6 to 4.2)
Pyoderma	0.9 (0.7 to 1.0)	1.2 (1.0 to 1.5)	43.2 (32.8 to 52.4)	22.5 (17.0 to 28.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.8 (22.0 to 63.5)	22.4 (7.7 to 38.4)
Scabies	30.2 (25.6 to 34.9)	33.8 (29.1 to 39.6)	12.5 (-10.2 to 36.6)	-0.2 (-19.7 to 21.1)	0.8 (0.4 to 1.3)	0.9 (0.5 to 1.4)	11.9 (-10.5 to 36.3)	-0.5 (-19.9 to 21.6)
Fungal skin diseases	189.8 (129.9 to 222.6)	216.8 (167.4 to 283.0)	14.2 (22.1 to 33.9)	0.1 (0.0 to 0.1)	1.2 (0.4 to 2.1)	1.2 (0.5 to 2.7)	27.3 (12.5 to 33.7)	-0.1 (-1.0 to 0.8)
Viral skin diseases	51.9 (39.2 to 64.7)	54.4 (41.1 to 67.8)	4.8 (0.3 to 11.1)	-0.0 (-2.0 to 2.1)	0.6 (0.9 to 2.5)	1.7 (1.0 to 2.6)	4.3 (-0.8 to 11.4)	-2.5 (-3.5 to 2.9)
Acne vulgaris	183.0 (130.9 to 228.3)	199.8 (149.3 to 270.1)	6.4 (-22.3 to 77.7)	-2.4 (-27.8 to 57.9)	2.0 (0.9 to 3.7)	2.2 (1.0 to 4.2)	6.4 (-22.4 to 78.7)	-2.6 (-28.2 to 58.3)
Alopecia areata	2.1 (1.9 to 2.3)	2.7 (2.5 to 2.9)	28.4 (11.5 to 45.8)	0.1 (-13.4 to 13.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	27.8 (6.8 to 50.1)	-0.5 (-15.6 to 16.5)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.5 (7.0 to 73.4)	2.6 (-21.2 to 30.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.2 (6.8 to 73.4)	2.6 (-2.3 to 30.4)
Urticaria	23.5 (17.6 to 31.2)	31.2 (23.5 to 40.9)	32.5 (-8.7 to 92.2)	2.5 (-28.7 to 46.2)	1.4 (0.8 to 2.1)	1.8 (1.1 to 2.8)	31.6 (9.1 to 90.7)	2.3 (-29.3 to 46.9)
Decubitus ulcer	0.4 (0.3 to 0.4)	0.4 (0.3 to 0.5)	6.4 (-18.7 to 36.7)	-24.4 (-42.1 to -2.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	5.7 (-23.4 to 42.6)	-24.8 (-45.5 to 1.7)
Other skin and subcutaneous diseases	135.5 (86.7 to 214.4)	187.6 (118.9 to 294.7)	38.6 (25.6 to 52.3)	-1.1 (-6.0 to 3.7)	0.8 (0.3 to 1.7)	1.1 (0.5 to 2.4)	38.2 (25.0 to 52.8)	-1.3 (-6.1 to 3.6)
Sense organ diseases	-	-	-	-	17.5 (12.0 to 24.3)	21.5 (14.8 to 30.3)	23.3 (16.9 to 29.8)	-10.7 (-14.6 to -6.0)
Glaucoma	3.5 (2.9 to 4.2)	4.1 (3.3 to 5.0)	14.3 (0.2 to 32.2)	-18.9 (-29.7 to -8.8)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	17.8 (-1.6 to 38.6)	-17.1 (-31.5 to -2.9)
Cataract	19.7 (15.0 to 24.2)	19.7 (15.4 to 23.9)	-0.6 (-10.2 to 12.3)	-29.2 (-36.0 to -19.9)	1.1 (0.7 to 1.5)	1.1 (0.7 to 1.5)	-0.1 (-11.7 to 10.1)	-28.7 (-36.7 to -21.7)
Macular degeneration	3.5 (2.6 to 4.4)	6.2 (4.7 to 8.0)	76.0 (46.0 to 117.8)	13.3 (-6.0 to 39.2)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	71.4 (43.8 to 108.9)	11.1 (-6.7 to 35.3)
Uncorrected refractive error	219.9 (207.2 to 233.5)	299.2 (281.4 to 317.2)	36.0 (24.5 to 47.7)	-3.7 (-11.3 to 4.1)	3.4 (2.0 to 5.5)	4.2 (2.5 to 6.9)	24.4 (16.3 to 34.4)	-9.9 (-15.2 to -3.5)
Age-related and other hearing loss	328.6 (309.8 to 347.7)	433.6 (407.9 to 462.2)	31.8 (27.5 to 37.8)	-9.3 (-12.0 to -6.7)	10.6 (7.3 to 14.6)	13.5 (9.1 to 18.8)	27.6 (18.4 to 38.0)	-9.2 (-15.1 to -1.9)
Other vision loss	7.1 (6.1 to 8.4)	6.3 (5.3 to 7.5)	-11.3 (-21.6 to -1.7)	-33.1 (-39.2 to -26.5)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.7)	-5.9 (-16.8 to 6.6)	-31.6 (-38.4 to -23.9)
Other sense organ diseases	56.1 (53.5 to 58.8)	63.6 (60.8 to 66.3)	13.4 (6.6 to 20.6)	-1.0 (-6.6 to 5.3)	1.5 (0.9 to 2.2)	1.7 (1.0 to 2.5)	12.6 (5.0 to 21.1)	-1.1 (-7.9 to 5.9)
Oral disorders	-	-	-	-	7.6 (4.7 to 11.6)	10.3 (6.3 to 15.6)	34.9 (30.7 to 39.2)	-4.3 (-7.2 to -1.2)
Deciduous caries	191.1 (182.2 to 200.6)	165.3 (157.4 to 173.4)	-13.5 (-19.3 to -7.0)	-0.3 (-7.1 to 7.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.1 (-21.3 to -5.1)	0.5 (-9.3 to 9.4)
Permanent caries	1,027.3 (986.6 to 1,067.4)	1,261.2 (1,215.2 to 1,308.9)	22.8 (16.1 to 30.0)	0.7 (-4.3 to 6.1)	1.0 (0.6 to 1.0)	1.2 (0.6 to 2.4)	22.3 (15.4 to 29.5)	0.5 (-4.8 to 5.9)
Periodontal diseases	224.6 (214.2 to 235.5)	332.7 (316.4 to 349.3)	48.1 (38.3 to 58.7)	-1.8 (-8.5 to 5.5)	1.5 (0.6 to 3.1)	2.2 (0.		

Appendix Table G.4 - Jamaica prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	142.7 (138.4 to 146.8)	194.9 (188.5 to 201.5)	36.5 (30.4 to 42.9)	-6.4 (-10.6 to -1.9)	3.9 (2.7 to 5.4)	5.3 (3.6 to 7.3)	36.2 (30.0 to 42.8)	6.8 (-11.1 to -2.1)
Other oral disorders	38.0 (35.9 to 40.3)	48.9 (46.3 to 51.5)	28.6 (18.4 to 39.5)	-0.5 (-8.3 to 7.7)	1.1 (0.7 to 1.7)	1.4 (0.9 to 2.1)	28.1 (17.4 to 39.9)	-0.8 (-8.2 to 7.9)
Injuries	-	-	-	-	10.9 (8.3 to 14.1)	11.4 (8.2 to 15.3)	3.8 (-6.3 to 14.8)	25.1 (-32.4 to -17.2)
Transport injuries	-	-	-	-	2.5 (1.8 to 3.2)	3.1 (2.2 to 4.2)	25.3 (9.0 to 44.2)	-9.9 (-21.4 to 3.2)
Road injuries	-	-	-	-	2.2 (1.7 to 2.9)	2.8 (2.0 to 3.8)	27.5 (6.1 to 41.5)	-11.8 (-23.5 to 1.6)
Pedestrian road injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.7 (0.5 to 1.0)	2.6 (-12.8 to 20.6)	-23.9 (-35.0 to -11.4)
Cyclist road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	35.9 (19.5 to 54.1)	-0.6 (-12.4 to 12.2)
Motorcyclist road injuries	-	-	-	-	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.4)	16.5 (-0.3 to 35.3)	-18.2 (-29.8 to -5.1)
Motor vehicle road injuries	-	-	-	-	1.1 (0.8 to 1.4)	1.5 (1.1 to 2.0)	39.4 (16.1 to 56.9)	-3.9 (-17.5 to 11.4)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	7.9 (-6.6 to 25.0)	-23.3 (-33.6 to -11.7)
Other transport injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	55.6 (35.7 to 77.1)	9.8 (-4.3 to 24.7)
Unintentional injuries	-	-	-	-	7.7 (5.8 to 9.9)	7.5 (5.5 to 10.0)	-2.2 (-10.7 to 7.0)	-29.1 (-35.2 to -22.4)
Falls	-	-	-	-	3.5 (2.6 to 4.4)	3.3 (2.3 to 4.4)	-6.1 (-17.3 to 7.1)	-33.3 (-41.2 to -24.2)
Drowning	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-18.6 (-30.4 to -5.7)	-40.4 (-48.8 to -30.9)
Fire, heat, and hot substances	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-25.5 (-35.2 to -14.0)	-44.2 (-51.2 to -35.8)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.4 (-30.0 to 0.1)	-34.4 (-44.8 to -22.1)
Exposure to mechanical forces	-	-	-	-	2.8 (2.2 to 3.7)	2.5 (1.8 to 3.4)	-12.5 (-18.9 to -5.6)	-33.6 (-38.3 to -28.6)
Unintentional firearm injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	58.2 (38.3 to 81.9)	14.1 (-0.0 to 30.4)
Unintentional suffocation	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	32.6 (15.4 to 49.7)	-1.8 (-13.7 to 10.3)
Other exposure to mechanical forces	-	-	-	-	2.6 (2.0 to 3.4)	2.2 (1.6 to 2.9)	-17.9 (-23.7 to -11.4)	-37.6 (-41.9 to -32.8)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	69.3 (59.3 to 79.3)	23.3 (15.8 to 30.8)
Animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	61.8 (47.6 to 79.3)	20.2 (9.9 to 31.9)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.8 (44.4 to 87.5)	21.6 (8.4 to 39.0)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	60.6 (44.7 to 79.2)	19.0 (7.3 to 31.9)
Foreign body	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	3.5 (-6.5 to 15.0)	-23.2 (-30.2 to -15.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.4 (-33.8 to -5.3)	-39.8 (-49.0 to -28.1)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.1 (1.0 to 31.1)	-10.5 (-20.8 to 2.3)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	16.7 (5.8 to 29.6)	-15.8 (-23.0 to -7.0)
Other unintentional injuries	-	-	-	-	0.9 (0.6 to 1.1)	1.3 (0.9 to 1.7)	50.6 (38.5 to 63.3)	1.1 (-6.8 to 9.3)
Self-harm and interpersonal violence	-	-	-	-	0.6 (0.4 to 0.7)	0.6 (0.4 to 0.8)	6.1 (-6.5 to 21.9)	-25.8 (-34.8 to -15.2)
Self-harm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	1.8 (-9.6 to 15.3)	-31.0 (-38.4 to -22.0)
Interpersonal violence	-	-	-	-	0.5 (0.4 to 0.6)	0.5 (0.4 to 0.7)	6.9 (-6.3 to 23.1)	-24.9 (-34.3 to -14.0)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	48.6 (32.7 to 65.9)	3.5 (-7.6 to 15.3)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	14.1 (-1.6 to 32.1)	-20.4 (-31.5 to -8.0)
Assault by other means	-	-	-	-	0.3 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-17.0 (-28.5 to -1.7)	-41.4 (-49.7 to -30.9)
Forces of nature, war, and legal intervention	-	-	-	-	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.3)	-40.9 (-55.1 to 49.0)	-59.5 (-69.5 to 2.7)
Exposure to forces of nature	-	-	-	-	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.2)	-52.3 (-63.9 to 0.4)	-67.1 (-75.2 to -30.5)
Collective violence and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.1)	-	-

Appendix Table G.4 - Japan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	12,274.4 (9,114.9 to 15,846.5)	15,803.0 (11,773.6 to 20,442.0)	28.8 (25.6 to 31.6)	28.8 (-1.5 to 2.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	827.5 (562.4 to 1,181.0)	789.0 (543.2 to 1,124.1)	-4.5 (-9.9 to 1.4)	3.0 (-2.4 to 8.9)
HIV/AIDS and tuberculosis	-	-	-	-	12.7 (8.5 to 17.4)	10.7 (7.3 to 14.5)	-15.9 (-27.9 to -1.6)	-35.8 (-45.2 to -24.7)
Tuberculosis	40.9 (38.0 to 43.8)	35.0 (32.0 to 38.0)	-14.5 (-20.2 to -8.1)	-36.8 (-40.2 to -33.2)	12.4 (8.3 to 17.1)	10.4 (7.0 to 14.1)	-16.9 (-28.9 to -2.4)	-36.9 (-46.4 to -25.4)
HIV/AIDS	-	-	-	-	6.1 (0.1 to 0.5)	0.3 (0.1 to 0.5)	-95.2 (-102.1 to -11.1)	36.3 (18.5 to 92.0)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.3 (-65.2 to -18.1)	-48.1 (-70.0 to -29.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.3 (-65.2 to -17.9)	-48.1 (-70.1 to -29.4)
HIV/AIDS resulting in other diseases	1.4 (0.8 to 2.2)	3.8 (1.8 to 5.7)	168.8 (100.7 to 249.6)	136.6 (77.9 to 209.7)	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.5)	52.8 (-10.1 to 112.5)	38.8 (-18.3 to 93.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	72.3 (46.1 to 108.5)	68.1 (44.4 to 100.6)	-5.7 (-10.9 to -0.1)	-11.5 (-16.1 to -6.8)
Diarrheal diseases	38.4 (34.4 to 42.5)	44.5 (39.2 to 49.8)	16.3 (-2.6 to 35.8)	0.7 (-15.0 to 16.9)	6.1 (4.0 to 8.7)	6.9 (4.6 to 9.7)	13.2 (8.4 to 17.6)	13.2 (18.7 to 23.0)
Intestinal infectious diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-	-29.4 (-48.2 to -4.2)
Typhoid fever	0.7 (0.6 to 0.8)	0.5 (0.4 to 0.6)	-25.3 (-43.4 to -0.9)	-26.6 (-44.0 to 0.6)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-25.3 (-43.4 to -0.9)	-26.6 (-44.1 to 0.6)
Paratyphoid fever	0.5 (0.3 to 0.6)	0.4 (0.3 to 0.5)	-17.8 (-39.2 to 15.0)	-14.7 (-37.4 to 17.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.8 (-39.2 to 15.1)	-14.7 (-37.5 to 18.3)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-	-57.1 (-84.2 to -12.3)
Lower respiratory infections	84.9 (78.1 to 91.1)	81.5 (68.1 to 95.2)	-3.8 (-20.8 to 14.7)	-5.6 (-60.5 to -43.8)	8.5 (5.7 to 11.8)	7.9 (5.2 to 11.1)	-6.6 (-25.3 to 12.8)	-51.9 (-61.9 to -42.2)
Upper respiratory infections	2,234.2 (2,104.0 to 2,358.9)	2,075.5 (1,975.5 to 2,192.3)	-7.2 (-13.2 to 0.2)	-1.3 (-8.1 to 6.7)	26.3 (14.8 to 44.6)	24.3 (13.8 to 40.3)	-7.8 (-14.5 to 0.8)	-1.3 (-8.9 to 7.8)
Otitis media	1,279.6 (1,204.3 to 1,348.7)	1,115.7 (1,047.0 to 1,193.2)	-12.9 (-19.2 to -4.6)	-11.0 (-16.3 to -4.4)	23.3 (13.9 to 37.1)	20.3 (11.7 to 32.9)	-13.3 (-20.9 to -5.1)	-11.9 (-18.5 to -5.1)
Meningitis	-	-	-	-	1.5 (1.0 to 2.1)	1.6 (1.1 to 2.2)	7.5 (-20.8 to 44.7)	10.2 (-20.3 to 54.7)
Pneumococcal meningitis	4.6 (2.9 to 7.7)	5.1 (3.2 to 8.5)	10.0 (-7.5 to 28.4)	-0.3 (-15.6 to 15.9)	0.5 (0.3 to 0.7)	0.5 (0.4 to 0.7)	0.5 (-13.4 to 31.0)	9.2 (-16.3 to 31.9)
H influenzae type B meningitis	3.0 (0.9 to 6.9)	3.0 (1.0 to 7.1)	-0.7 (-46.2 to 96.6)	0.6 (-39.6 to 123.7)	0.4 (0.2 to 0.7)	0.4 (0.2 to 0.7)	0.4 (-47.8 to 131.4)	17.1 (-42.5 to 162.1)
Meningococcal meningitis	0.5 (0.2 to 1.2)	0.6 (0.2 to 1.6)	16.7 (-19.7 to 71.1)	-2.0 (-30.6 to 47.9)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	0.1 (-17.8 to 61.9)	-0.6 (-29.8 to 48.7)
Other meningitis	3.9 (1.9 to 8.3)	3.8 (1.8 to 8.3)	-8.8 (-29.9 to 52.6)	-5.3 (-28.2 to 70.7)	0.5 (0.3 to 0.8)	0.5 (0.3 to 1.0)	0.5 (-34.4 to 96.8)	1.5 (-33.4 to 120.8)
Encephalitis	6.5 (2.8 to 17.3)	7.9 (3.4 to 22.5)	21.4 (-1.7 to 44.7)	1.7 (-16.1 to 28.5)	0.9 (0.6 to 1.3)	1.1 (0.7 to 1.6)	24.1 (-1.4 to 55.0)	9.2 (-16.4 to 38.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	57.3 (-95.2 to 269.0)	0.0 (0.0 to 0.0)	-	-
Whooping cough	16.5 (12.9 to 21.2)	0.8 (0.6 to 1.1)	-95.2 (-96.0 to -94.2)	-94.0 (-95.0 to -92.8)	0.8 (0.5 to 1.3)	0.0 (0.0 to 0.1)	-95.2 (-97.1 to -92.8)	-94.0 (-96.4 to -91.0)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	66.7 (-83.5 to -45.2)	0.0 (0.0 to 0.0)	-	-
Measles	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-93.6 (-94.6 to -92.8)	-91.9 (-93.1 to -90.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-93.6 (-94.6 to -92.8)	-91.9 (-93.1 to -90.8)
Varicella and herpes zoster	113.1 (100.3 to 128.2)	129.9 (112.3 to 150.1)	14.6 (-0.3 to 34.1)	-5.6 (-15.6 to 6.2)	4.7 (2.8 to 7.3)	5.8 (3.5 to 9.4)	26.6 (3.6 to 57.7)	-2.6 (-18.4 to 18.2)
Neglected tropical diseases and malaria	-	-	-	-	3.1 (1.9 to 4.8)	3.2 (1.8 to 5.8)	0.8 (-25.5 to 43.8)	0.8 (-40.2 to -4.2)
Malaria	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-18.1 (-75.1 to 575.4)	-5.7 (-72.2 to 668.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-18.8 (-75.2 to 608.2)	-8.5 (-72.3 to 692.7)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.4 (0.2 to 0.7)	0.1 (0.0 to 0.1)	-81.4 (-91.4 to -39.8)	-85.9 (-93.8 to -51.3)	0.2 (0.1 to 0.3)	0.0 (0.0 to 0.1)	-80.1 (-91.0 to -31.7)	-84.8 (-93.5 to -46.9)
Cystic echinococcosis	17.2 (16.3 to 18.3)	13.2 (12.0 to 14.8)	-24.0 (-28.9 to -10.4)	-41.8 (-49.0 to -28.9)	1.6 (1.1 to 2.3)	1.2 (0.8 to 1.8)	-24.5 (-40.6 to -2.3)	-41.3 (-54.6 to -22.6)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	1.7 (-1.9 to 16.8)	0.0 (0.0 to 0.0)	1.7 (-36.5 to 19.8)	-1.9 (-39.7 to 16.9)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	106.8 (85.5 to 132.2)	146.9 (118.7 to 178.0)	37.2 (4.5 to 81.9)	4.4 (-21.1 to 35.9)	1.3 (0.5 to 2.6)	2.0 (0.7 to 4.2)	45.5 (-13.4 to 125.1)	5.4 (-29.9 to 51.1)
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-60.1 to 560.3)	0.0 (-58.3 to 534.6)
Maternal disorders	-	-	-	-	1.3 (0.7 to 2.0)	1.3 (0.8 to 2.1)	1.1 (-22.4 to 36.3)	7.3 (-18.2 to 44.5)
Maternal hemorrhage	10.3 (8.1 to 12.6)	13.2 (9.4 to 16.9)	28.3 (-15.5 to 82.4)	32.5 (-12.9 to 89.1)	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.7)	9.7 (-42.1 to 102.3)	17.3 (-39.4 to 118.7)
Maternal sepsis and other maternal infections	10.3 (6.8 to 13.8)	6.6 (2.9 to 10.1)	-36.0 (-70.9 to -1.7)	-31.1 (-65.7 to 7.4)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-31.9 (-54.2 to -7.3)	-27.0 (-49.1 to -3.3)
Maternal hypertensive disorders	10.7 (5.7 to 16.8)	10.2 (4.7 to 16.2)	-5.0 (-30.8 to 23.6)	-0.8 (-21.0 to 25.0)	0.5 (0.2 to 1.0)	0.5 (0.2 to 0.9)	-4.8 (-37.9 to 37.6)	-0.1 (-30.2 to 40.4)
Obstructed labor	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-11.9 (-42.2 to 31.3)	-6.9 (-40.1 to 39.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-11.9 (-42.2 to 31.5)	-6.9 (-40.3 to 39.6)
Complications of abortion	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-2.4 (-31.0 to 38.4)	2.2 (-27.1 to 44.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.4 (-31.1 to 38.7)	2.2 (-27.3 to 45.3)
Other maternal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	26.0 (-14.5 to 92.0)	33.3 (-9.2 to 101.7)
Neonatal disorders	-	-	-	-	97.4 (65.5 to 136.6)	130.9 (87.7 to 185.0)	34.7 (5.0 to 88.1)	42.8 (0.3 to 101.5)
Preterm birth complications	393.5 (277.9 to 536.9)	585.1 (402.0 to 841.7)	47.2 (16.9 to 88.2)	49.3 (17.7 to 92.3)	50.8 (33.8 to 70.7)	70.9 (48.8 to 99.3)	38.4 (3.3 to 93.4)	46.3 (8.9 to 105.3)
Neonatal encephalopathy due to birth asphyxia and trauma	91.5 (46.1 to 187.3)	58.8 (24.3 to 153.2)	-36.6 (-69.4 to 3.3)	-32.6 (-66.6 to 13.7)	20.5 (12.9 to 31.2)	12.3 (7.2 to 18.9)	-39.4 (-65.7 to 4.3)	-33.4 (-62.6 to 15.2)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	19.3 (4.6 to 39.3)	43.8 (25.1 to 67.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.6 (-14.5 to 65.7)	46.6 (-2.7 to 99.8)
Hemolytic disease and other neonatal jaundice	25.0 (8.1 to 51.8)	30.2 (11.8 to 84.7)	17.0 (-63.9 to 258.1)	17.0 (-60.7 to 298.1)	8.7 (2.8 to 16.6)	10.7 (4.3 to 27.4)	26.7 (-55.9 to 216.2)	26.7 (-53.2 to 245.5)
Other neonatal disorders	-	-	-	-	17.4 (10.2 to 29.6)	37.0 (19.6 to 58.0)	124.4 (0.6 to 265.6)	138.8 (6.9 to 292.9)
Nutritional deficiencies	-	-	-	-	596.1 (394.7 to 875.1)	535.5 (356.3 to 784.8)	-10.1 (-12.8 to -7.7)	-0.5 (-3.0 to 1.4)
Protein-energy malnutrition	1.2 (0.6 to 2.9)	5.4 (1.9 to 9.0)	498.6 (37.3 to 743.7)	149.9 (-41.1 to 239.7)	0.1 (0.1 to 0.4)	0.6 (0.2 to 1.2)	446.6 (19.6 to 845.6)	134.7 (-45.4 to 300.3)
Iodine deficiency	895.3 (483.6 to 1,311.6)	495.6 (219.2 to 705.2)	-45.0 (-77.9 to 15.6)	-52.2 (-77.2 to 15.0)	16.0 (7.5 to 28.1)	7.9 (3.2 to 15.2)	-52.2 (-77.7 to 14.8)	-52.3 (-77.0 to 15.9)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron deficiency anemia	20,665.1 (20,428.7 to 20,902.3)	20,622.1 (20,408.6 to 20,806.3)	-0.2 (-1.6 to 1.0)	1.3 (0.1 to 2.4)	579.8 (382.9 to 846.3)	526.9 (348.7 to 772.6)	-9.0 (-11.6 to -7.2)	0.6 (-1.7 to 2.0)

Appendix Table G.4 - Japan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.1	0.2	38.5	-46.5
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	(0.0 to 0.2)	(0.1 to 0.3)	(-21.1 to 139.8)	(-65.0 to -0.3)
Sexually transmitted diseases excluding HIV	-	-	-	-	44.7	39.3	-11.9	-1.3
Syphilis	7.0	11.5	65.7	12.5	1.3	2.1	63.3	12.4
Chlamydial infection	3,232.0	2,540.0	-21.4	-11.3	(0.8 to 3.1)	(1.4 to 3.1)	(17.4 to 124.6)	(-20.7 to 55.8)
Gonococcal infection	255.4	171.5	-33.1	-14.2	(5.1 to 17.2)	(4.0 to 13.8)	(-4.2 to 9.8)	(-31.8 to 35.1)
Trichomoniasis	471.7	499.0	5.8	20.2	(0.6 to 2.2)	(0.4 to 1.5)	(-52.5 to 4.6)	(-42.4 to 31.2)
Genital herpes	12,145.9	14,332.9	18.1	-1.6	(1.0 to 7.6)	(1.1 to 9.0)	(3.9 to 27.2)	(-11.0 to 9.0)
Other sexually transmitted diseases	21.7	14.4	-33.6	-27.8	(-9.6 to 7.5)	(-8.2 to 6.0)	(-15.2 to 15.7)	(-39.3 to 40.3)
Hepatitis	-	-	-	-	4.8	4.0	-17.2	-16.6
Hepatitis A	93.8	81.6	-13.0	-5.2	(3.1 to 7.1)	(2.6 to 5.8)	(-26.3 to -6.5)	(-25.6 to -6.8)
Hepatitis B	2,941.9	1,937.0	-34.1	-38.8	(1.8 to 4.3)	(1.6 to 3.8)	(-20.0 to 0.3)	(-14.7 to 7.1)
Hepatitis C	2,376.6	2,345.8	-1.0	-28.0	(1.0 to 4.4)	(0.7 to 1.7)	(-49.9 to -10.7)	(-53.7 to -19.5)
Hepatitis E	17.4	16.8	-3.5	-8.8	(0.2 to 0.5)	(0.2 to 0.5)	(-36.3 to 57.7)	(-47.6 to 12.9)
Leprosy	0.0	0.0	10.2	-26.1	0.0	0.0	20.1	-19.1
Other infectious diseases	752.2	679.7	-9.7	0.7	(0.0 to 0.0)	(0.0 to 0.0)	(-36.3 to 935.1)	(-61.1 to 571.1)
Non-communicable diseases	-	-	-	-	10,513.3	14,076.1	33.9	3.7
Neoplasms	-	-	-	-	(7,728.6 to 13,610.3)	(10,488.0 to 18,146.6)	(99.2 to 101.1)	(1.3 to 6.0)
Esophageal cancer	16.5	29.1	77.5	-3.7	(109.8 to 192.1)	(217.0 to 381.5)	(79.9 to 115.5)	(-0.5 to 18.9)
Stomach cancer	217.3	248.9	14.2	40.4	(1.7 to 3.4)	(2.8 to 5.8)	(22.9 to 126.3)	(-32.8 to 26.4)
Liver cancer	193.4 to 245.2	209.0 to 298.3	(-4.4 to 37.9)	(-50.5 to -29.5)	(16.7 to 30.7)	(18.0 to 34.7)	(9.5 to 31.3)	(-52.5 to -32.5)
Liver cancer due to hepatitis B	7.8	9.4	15.9	-38.1	(4.3 to 9.7)	(6.4 to 15.7)	(-4.0 to 140.4)	(-49.4 to 32.4)
Liver cancer due to hepatitis C	19.0	53.3	175.8	41.1	(0.7 to 1.8)	(0.8 to 2.5)	(-34.2 to 142.7)	(-67.0 to 55.0)
Liver cancer due to alcohol use	14.3	8.5	-42.6	-69.5	(1.7 to 3.9)	(4.4 to 11.1)	(66.9 to 334.0)	(-17.3 to 139.9)
Liver cancer due to other causes	5.7	2.3	-59.5	-77.8	(1.1 to 3.2)	(0.7 to 2.1)	(-66.7 to 16.0)	(-82.4 to -36.2)
Larynx cancer	17.4	16.8	-3.5	-4.6	(0.5 to 1.3)	(0.2 to 0.6)	(-77.7 to -18.8)	(-78.1 to -53.8)
Tracheal, bronchus and lung cancer	84.9	173.7	104.2	0.5	(1.0 to 2.2)	(1.0 to 2.4)	(-22.9 to 41.7)	(-57.0 to -22.8)
Breast cancer	368.3	928.3	151.5	46.9	(8.7 to 15.7)	(16.8 to 30.3)	(61.7 to 127.0)	(-19.1 to 11.6)
Cervical cancer	53.2	52.3	-1.2	-23.4	17.4	40.7	136.1	45.6
Uterine cancer	44.6 to 66.5	38.5 to 66.3	(-27.3 to 30.7)	(-46.5 to 1.6)	(2.8 to 5.6)	(2.5 to 7.7)	(-28.6 to 29.6)	(-47.0 to 1.7)
Prostate cancer	81.9	320.8	298.7	85.0	(1.7 to 4.0)	(1.9 to 6.0)	(-25.0 to 120.1)	(-43.7 to 69.7)
Colon and rectum cancer	299.5	718.5	139.8	28.3	7.1	26.4	272.9	72.9
Lip and oral cavity cancer	23.6	51.3	118.6	24.7	(0.5 to 9.9)	(1.7 to 36.1)	(184.5 to 376.6)	(32.6 to 123.3)
Nasopharynx cancer	3.9	4.7	22.4	-21.4	24.5	56.8	132.2	22.5
Other pharynx cancer	10.4	24.4	145.4	17.6	(17.9 to 31.8)	(40.8 to 74.5)	(102.3 to 164.8)	(7.1 to 38.7)
Gallbladder and biliary tract cancer	12.9	21.8	67.9	24.5	2.1	4.5	109.9	19.6
Pancreatic cancer	15.4	34.9	126.7	12.7	(0.6 to 1.4)	(1.0 to 3.1)	(8.6 to 25.1)	(-31.9 to 112.2)
Malignant skin melanoma	4.9	10.7	118.6	37.9	(2.1 to 4.4)	(4.4 to 8.5)	(70.4 to 166.4)	(-13.1 to 34.5)
Non-melanoma skin cancer	330.1 to 749.9	(616.5 to 1,475.1)	(6.8 to 255.3)	(53.6 to 81.3)	(2.6 to 12.1)	(5.7 to 22.8)	(192.2 to 256.9)	(-45.5 to 81.0)
Ovarian cancer	26.3	41.4	57.0	10.6	3.2	5.0	54.5	7.7
Testicular cancer	8.4	8.3	-1.5	1.5	(3.3 to 7.1)	(3.3 to 7.1)	(9.7 to 111.6)	(-21.4 to 45.3)
Kidney cancer	34.9	86.2	146.8	39.5	(0.3 to 0.8)	(0.3 to 0.8)	(-36.9 to 64.5)	(-38.5 to 66.4)
Bladder cancer	50.9 to 69.9	(100.9 to 158.6)	(66.9 to 178.3)	(16.5 to 32.1)	(1.8 to 3.5)	(4.1 to 8.5)	(87.0 to 201.4)	(33.8 to 66.8)
Brain and nervous system cancer	9.0	13.1	45.4	13.4	0.9	1.4	46.7	11.3
Thyroid cancer	41.9 to 64.1	(58.8 to 97.6)	(16.4 to 95.7)	(-15.4 to 39.8)	(0.6 to 1.3)	(0.9 to 1.9)	(18.4 to 80.7)	(-9.7 to 36.7)
Mesothelioma	0.7	2.0	192.2	50.6	2.0	4.4	113.2	58.0
Hodgkin lymphoma	2.4 to 4.7	(3.1 to 6.8)	(-0.2 to 85.5)	(-19.8 to 44.7)	(0.2 to 0.2)	(0.2 to 0.7)	(75.0 to 467.5)	(-11.9 to 171.0)
Non-Hodgkin lymphoma	38.9 to 73.0	(81.3 to 159.6)	(51.3 to 227.3)	(-13.3 to 75.6)	(2.6 to 5.9)	(5.6 to 13.1)	(-1.7 to 81.8)	(-25.7 to 30.8)
Multiple myeloma	9.4	21.8	130.9	19.1	4.0	9.2	134.5	30.6
Leukemia	27.9	44.2	58.3	-5.1	(2.2 to 3.2)	(2.4 to 6.9)	(33.4 to 239.5)	(-29.0 to 70.9)
Other neoplasms	84.0	305.2	266.1	116.5	(2.6 to 4.9)	(4.0 to 8.0)	(24.1 to 105.4)	(-24.2 to 17.6)
Cardiovascular diseases	-	-	-	-	528.7	1,122.9	113.5	13.8
Rheumatic heart disease	31.2	54.3	74.3	4.1	(86.5 to 722.3)	(773.5 to 1,528.2)	(66.3 to 164.7)	(-11.8 to 41.0)
Ischemic heart disease	2,345.4	4,757.6	103.2	5.1	3.5	5.9	68.7	0.3
Cerebrovascular disease	-	-	-	-	172.2	357.8	108.0	6.1
Ischemic stroke	703.2	1,322.6	87.9	-2.4	(111.5 to 249.8)	(239.7 to 503.6)	(61.7 to 171.5)	(-17.0 to 39.9)
Hemorrhagic stroke	235.8	453.7	91.1	9.7	18.3	25.0	86.6	1.2
Hypertensive heart disease	339.5	806.8	138.7	14.7	(96.0 to 184.5)	(178.1 to 341.8)	(49.8 to 143.1)	(-19.1 to 26.1)
Cardiomyopathy and myocarditis	210.8	400.8	102.5	14.4	10.3	19.0	85.3	-2.1
Atrial fibrillation and flutter	1,359.4	2,260.7	68.3	-5.9	(23.1 to 22.5)	(71.7 to 141.5)	(46.8 to 141.1)	(-23.3 to 22.8)
Peripheral vascular disease	13.9	21.6	47.9	-18.5	(3.1 to 6.1)	(6.3 to 13.3)	(58.0 to 172.9)	(-22.2 to 28.4)
Other cardiovascular and circulatory diseases	1,514.5	3,940.4	172.5	53.6	(0.6 to 1.3)	(0.9 to 1.9)	(18.4 to 80.7)	(-9.7 to 36.7)
Chronic respiratory diseases	-	-	-	-	528.7	1,122.9	113.5	13.8
Chronic obstructive pulmonary disease	4,360.3	6,355.5	46.0	-0.3	(4.1 to 8.4)	(13.5 to 28.4)	(142.2 to 346.0)	(-54.0 to 145.9)
Pneumoconiosis	-	-	-	-	0.9	1.2	37.6	-15.6

Appendix Table G.4 - Japan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	1.4 (1.3 to 1.5)	1.7 (1.6 to 1.8)	23.4 (16.9 to 32.1)	-28.1 (-31.3 to -23.8)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	24.0 (17.5 to 33.1)	24.0 (-31.3 to -23.4)
Asbestosis	0.6 (0.6 to 0.7)	1.2 (1.2 to 1.3)	92.1 (83.8 to 100.6)	12.2 (8.0 to 16.8)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	93.7 (85.3 to 102.6)	12.8 (8.5 to 17.5)
Coal workers pneumoconiosis	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-	-
Other pneumoconiosis	2.5 (2.2 to 2.8)	3.2 (2.9 to 3.6)	27.8 (20.3 to 36.8)	-17.1 (-21.7 to -12.9)	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.9)	30.0 (22.0 to 39.5)	-16.1 (-20.8 to -11.8)
Asthma	7,633.0 (7,093.4 to 8,099.6)	8,699.4 (6,462.7 to 7,462.5)	12.4 (-16.9 to 0.3)	9.2 (-18.2 to 0.0)	338.1 (218.7 to 484.6)	405.5 (197.6 to 437.0)	9.6 (-18.5 to -0.5)	9.4 (-18.6 to 0.2)
Interstitial lung disease and pulmonary sarcoidosis	9.7 (7.9 to 11.8)	13.6 (10.3 to 16.6)	39.8 (2.7 to 83.6)	-7.7 (-32.5 to 19.2)	1.3 (0.8 to 2.1)	1.9 (1.1 to 2.8)	40.2 (0.5 to 87.4)	-7.4 (-32.7 to 21.6)
Other chronic respiratory diseases	-	-	-	-	12.6 (8.0 to 18.9)	7.8 (4.7 to 12.2)	-37.4 (-54.0 to -17.8)	-57.6 (-68.6 to -44.8)
Cirrhosis	-	-	-	-	7.7 (5.3 to 10.8)	6.9 (4.8 to 9.7)	-9.9 (-20.7 to 3.4)	-33.4 (-41.7 to -23.2)
Cirrhosis due to hepatitis B	7.3 (5.8 to 8.8)	6.8 (4.9 to 9.4)	-8.6 (-37.6 to 37.0)	-35.2 (-55.9 to -2.2)	1.2 (0.7 to 1.8)	1.1 (0.6 to 1.8)	9.9 (-45.9 to 43.0)	-35.1 (-61.0 to 2.8)
Cirrhosis due to hepatitis C	20.6 (16.6 to 24.9)	20.8 (15.0 to 25.6)	1.0 (-31.8 to 42.5)	-28.4 (-51.1 to 1.0)	3.4 (2.2 to 5.0)	3.4 (2.0 to 5.1)	0.1 (-36.1 to 48.1)	-28.1 (-54.2 to 6.3)
Cirrhosis due to alcohol use	13.9 (10.8 to 16.8)	7.3 (5.3 to 9.9)	-47.5 (-64.9 to -23.8)	-64.1 (-76.0 to -47.5)	2.3 (1.4 to 3.3)	1.2 (0.7 to 1.9)	-47.9 (-68.1 to -19.1)	-63.8 (-78.0 to -44.1)
Cirrhosis due to other causes	4.6 (3.5 to 6.1)	7.6 (4.9 to 10.7)	65.0 (-0.8 to 153.2)	32.0 (-16.7 to 97.6)	0.8 (0.5 to 1.2)	1.3 (0.7 to 2.1)	58.7 (-7.9 to 164.1)	28.6 (-22.7 to 106.7)
Digestive diseases	-	-	-	-	124.8 (88.1 to 167.0)	144.6 (103.3 to 191.9)	16.1 (9.0 to 23.3)	-29.0 (-33.9 to -23.5)
Peptic ulcer disease	1,076.2 (984.4 to 1,166.9)	1,011.7 (958.4 to 1,073.8)	-6.3 (-14.3 to 5.0)	-61.2 (-64.2 to -57.1)	38.3 (26.3 to 54.7)	45.5 (31.0 to 63.9)	19.0 (8.2 to 31.6)	-47.8 (-52.2 to -41.9)
Gastritis and duodenitis	300.8 (270.4 to 330.8)	122.7 (110.6 to 134.1)	-59.2 (-63.8 to -53.6)	-73.1 (-76.6 to -69.0)	14.3 (9.5 to 20.4)	7.0 (4.6 to 10.1)	-50.9 (-59.0 to -39.8)	-67.5 (-73.5 to -59.4)
Appendicitis	3.9 (3.4 to 4.4)	2.4 (2.1 to 2.7)	-39.9 (-50.3 to -28.0)	-30.5 (-43.4 to -14.0)	1.3 (0.8 to 1.8)	0.8 (0.5 to 1.1)	-38.7 (-52.9 to -19.3)	-28.7 (-46.9 to -4.6)
Paralytic ileus and intestinal obstruction	2.0 (1.8 to 2.1)	3.6 (3.3 to 3.9)	81.7 (62.4 to 106.5)	15.1 (-0.4 to 46.5)	0.6 (0.4 to 0.8)	1.1 (0.7 to 1.5)	74.0 (27.7 to 130.7)	16.1 (-12.8 to 58.0)
Inguinal, femoral, and abdominal hernia	394.4 (331.8 to 471.6)	672.9 (557.3 to 801.6)	71.5 (34.0 to 117.2)	-12.5 (-29.9 to 11.6)	4.1 (1.9 to 7.8)	6.8 (3.3 to 13.1)	68.1 (32.7 to 114.6)	-22.5 (-29.6 to 11.3)
Inflammatory bowel disease	129.5 (122.0 to 137.1)	122.9 (116.6 to 129.1)	-5.1 (-11.8 to 2.5)	-22.9 (-28.4 to -16.5)	27.7 (18.9 to 37.7)	25.8 (17.7 to 35.4)	-6.9 (-15.8 to 4.1)	-23.1 (-31.1 to -13.5)
Vascular intestinal disorders	1.3 (1.0 to 1.7)	2.4 (1.7 to 3.4)	87.2 (30.9 to 198.5)	-4.8 (-30.6 to 46.4)	0.4 (0.2 to 0.6)	0.7 (0.4 to 1.2)	84.0 (10.4 to 231.1)	-3.7 (-37.2 to 61.9)
Gallbladder and biliary diseases	187.7 (167.9 to 211.0)	234.5 (200.3 to 270.7)	24.9 (4.8 to 48.7)	-24.6 (-36.6 to -11.4)	19.8 (13.1 to 27.5)	24.2 (15.9 to 34.1)	22.6 (1.7 to 46.2)	-25.2 (-37.3 to -10.9)
Pancreatitis	51.9 (31.3 to 34.4)	51.9 (49.3 to 54.3)	0.0 (-47.1 to 68.7)	57.5 (13.3 to 29.0)	9.8 (6.6 to 13.4)	15.3 (10.2 to 20.6)	54.9 (32.7 to 78.9)	20.6 (3.5 to 40.2)
Other digestive diseases	-	-	-	-	8.7 (5.9 to 12.0)	17.5 (11.3 to 24.4)	103.6 (55.7 to 143.5)	23.9 (-6.3 to 47.5)
Neurological disorders	-	-	-	-	869.4 (597.3 to 1,195.5)	1,250.5 (866.1 to 1,660.2)	44.5 (28.0 to 61.6)	0.7 (-9.6 to 8.8)
Alzheimer disease and other dementias	1,210.8 (1,138.3 to 1,276.7)	3,163.8 (2,719.8 to 3,554.5)	162.2 (121.4 to 198.6)	-2.0 (-16.3 to 11.1)	183.4 (133.9 to 234.3)	489.1 (341.3 to 646.0)	167.4 (123.9 to 206.5)	-2.4 (-17.2 to 11.4)
Parkinson disease	96.2 (85.6 to 107.4)	208.0 (180.4 to 228.1)	112.0 (99.5 to 123.9)	-12.2 (-0.9 to 9.8)	11.6 (8.0 to 15.9)	24.0 (16.6 to 32.9)	107.7 (85.7 to 129.7)	3.5 (-6.7 to 14.2)
Epilepsy	109.0 (80.6 to 137.6)	106.2 (74.1 to 137.5)	-2.6 (-36.9 to 44.7)	-10.4 (-41.7 to 32.9)	43.9 (27.0 to 63.4)	44.3 (26.1 to 64.4)	1.3 (-36.2 to 50.7)	-5.2 (-40.3 to 41.1)
Multiple sclerosis	8.0 (7.5 to 8.6)	15.4 (14.3 to 16.5)	91.5 (73.8 to 114.2)	68.2 (52.9 to 88.0)	2.9 (2.0 to 3.7)	5.3 (3.7 to 7.0)	5.3 (58.2 to 124.0)	63.4 (39.6 to 97.3)
Migraine	13,121.4 (11,948.6 to 14,325.5)	12,241.2 (10,618.4 to 13,584.5)	-6.5 (-20.4 to 6.8)	-6.1 (-19.2 to 7.7)	451.2 (266.5 to 678.3)	416.3 (249.9 to 624.9)	-7.3 (-21.3 to 6.0)	-6.3 (-18.9 to 7.1)
Tension-type headache	20,267.6 (18,960.7 to 21,546.7)	61.1 (27,978.2 to 37,981.2)	61.1 (37.4 to 88.0)	5.6 (31.7 to 77.3)	30.8 (15.0 to 53.4)	89.2 (23.5 to 89.2)	28.5 (32.7 to 86.6)	8.5 (36.1 to 77.5)
Medication overuse headache	503.6 (335.9 to 681.0)	846.7 (557.2 to 1,154.4)	70.8 (25.8 to 115.2)	56.4 (18.3 to 95.5)	79.6 (45.5 to 125.5)	132.5 (74.6 to 205.4)	68.7 (25.2 to 113.5)	36.1 (17.7 to 96.2)
Other neurological disorders	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	31.8 (-0.3 to 75.4)	9.6 (-16.5 to 44.0)	66.1 (44.7 to 90.4)	89.7 (61.3 to 122.6)	36.6 (3.4 to 74.7)	-48.0 (-60.5 to -34.2)
Mental and substance use disorders	-	-	-	-	2,527.9 (1,809.3 to 3,327.0)	2,543.7 (1,811.6 to 3,351.5)	0.6 (-3.2 to 4.4)	-0.3 (-2.9 to 2.6)
Schizophrenia	428.5 (40.1 to 457.1)	499.1 (408.8 to 474.5)	2.5 (-2.0 to 7.2)	-1.7 (-6.1 to 8.1)	278.5 (207.7 to 336.7)	283.0 (209.4 to 341.6)	1.7 (-4.6 to 7.7)	-1.8 (-8.1 to 4.3)
Alcohol use disorders	1,115.0 (999.9 to 1,227.3)	1,211.0 (1,106.1 to 1,318.0)	8.7 (0.8 to 16.9)	17.2 (8.6 to 26.1)	121.4 (73.7 to 160.2)	117.1 (79.8 to 175.7)	9.7 (-0.7 to 17.1)	17.0 (7.8 to 27.2)
Drug use disorders	-	-	-	-	262.8 (178.6 to 350.7)	239.5 (164.7 to 317.6)	-8.9 (-17.6 to 1.5)	-0.9 (-11.1 to 11.3)
Opioid use disorders	318.2 (255.6 to 389.3)	302.5 (250.3 to 364.2)	-4.8 (-12.8 to 3.8)	0.6 (-8.8 to 10.4)	134.1 (90.0 to 185.3)	127.0 (86.5 to 172.4)	-5.0 (-14.8 to 5.9)	0.7 (-10.8 to 12.7)
Cocaine use disorders	200.4 (172.9 to 224.5)	170.9 (151.2 to 191.5)	-15.3 (-27.8 to 3.4)	-8.3 (-23.0 to 14.0)	27.7 (17.1 to 41.2)	23.5 (15.2 to 33.8)	-2.2 (-31.3 to 5.5)	-8.2 (-26.2 to 16.6)
Amphetamine use disorders	248.5 (208.2 to 280.1)	229.3 (202.8 to 253.4)	-8.0 (-23.1 to 11.4)	-8.0 (-16.6 to 25.4)	32.7 (20.0 to 49.4)	29.0 (18.6 to 44.7)	-3.7 (-26.3 to 12.8)	-2.2 (-18.8 to 29.1)
Cannabis use disorders	237.3 (211.7 to 261.6)	184.1 (166.1 to 201.1)	-22.5 (-23.9 to -20.7)	0.2 (0.1 to 0.3)	6.9 (4.5 to 10.3)	5.4 (3.5 to 7.9)	-22.5 (-31.9 to -12.0)	0.1 (-12.3 to 13.9)
Other drug use disorders	-	-	-	-	61.4 (37.3 to 91.8)	53.9 (33.6 to 79.2)	-11.7 (-35.3 to 19.2)	-2.2 (-28.9 to 32.7)
Depressive disorders	-	-	-	-	915.9 (592.5 to 1,325.5)	985.3 (630.8 to 1,424.7)	7.7 (-2.5 to 17.5)	-1.1 (-7.9 to 5.6)
Major depressive disorder	3,460.7 (2,524.4 to 4,542.0)	3,759.9 (2,647.6 to 4,953.6)	8.6 (-4.2 to 21.8)	-1.4 (-8.4 to 7.0)	715.5 (433.3 to 1,078.8)	762.0 (457.6 to 1,147.0)	6.9 (5.9 to 19.9)	-1.3 (-9.1 to 7.2)
Dysthymia	2,086.8 (1,752.7 to 2,424.1)	2,327.5 (1,963.3 to 2,714.6)	11.8 (2.2 to 20.1)	0.2 (-6.1 to 5.8)	202.5 (134.4 to 289.6)	223.2 (148.7 to 323.9)	10.3 (0.7 to 18.7)	0.0 (-6.9 to 6.2)
Bipolar disorder	851.8 (686.4 to 996.1)	854.7 (703.9 to 988.6)	0.4 (-6.1 to 6.8)	-1.9 (-7.9 to 3.9)	175.0 (107.1 to 265.5)	173.6 (106.6 to 263.8)	-0.7 (-8.4 to 6.7)	-1.9 (-9.0 to 5.2)
Anxiety disorders	3,181.3 (2,533.4 to 3,878.5)	3,177.1 (2,522.4 to 3,834.9)	-0.1 (-5.7 to 6.4)	-0.2 (-0.3 to -0.0)	293.8 (186.2 to 426.1)	289.8 (187.1 to 418.0)	-1.3 (-7.2 to 5.4)	-0.2 (-3.3 to 2.7)
Eating disorders	-	-	-	-	31.6 (19.5 to 48.3)	24.7 (15.2 to 37.9)	-20.0 (-28.8 to -14.2)	0.2 (-1.5 to 9.6)
Anorexia nervosa	49.9 (38.4 to 62.5)	39.4 (32.0 to 48.5)	-21.2 (-29.4 to -9.7)	1.0 (-8.9 to 16.0)	10.6 (6.9 to 15.8)	8.4 (5.5 to 12.5)	-21.0 (-32.5 to -3.6)	1.4 (-13.3 to 24.2)
Bulimia nervosa	98.7 (63.0 to 149.0)	76.3 (48.5 to 115.9)	-23.0 (-27.2 to -18.1)	-0.6 (-0.7 to -0.5)	21.0 (11.5 to 34.6)	16.3 (8.8 to 27.3)	-22.8 (-30.9 to -14.1)	-0.6 (-9.0 to 10.3)
Autistic spectrum disorders	-	-	-	-	146.3 (103.0 to 198.5)	142.4 (100.6 to 194.5)	-2.6 (-6.3 to 1.2)	0.5 (-3.5 to 4.5)
Autism	378.9 (358.3 to 402.2)	372.7 (352.6 to 395.6)	-1.6 (-5.5 to 1.8)	0.5 (-3.5 to 3.6)	93.4 (63.8 to 129.5)	90.8 (62.1 to 126.1)	0.8 (-8.2 to 2.5)	0.5 (-5.2 to 6.1)
Asperger syndrome	529.3 (492.0 to 565.5)	522.4 (484.9 to 560.4)	-1.3 (-2.9 to 0.2)	0.8 (0.8 to 0.9)	52.9 (36.6 to 73.3)	51.6 (35.8 to 71.6)	-2.4 (-6.0 to 1.6)	0.7 (-3.1 to 4.8)
Attention-deficit/hyperactivity disorder	577.1 (530.0 to 622.4)	380.6 (349.3 to 411.0)	-34.1 (-34.3 to -33.9)	0.1 (0.0 to 0.1)	7.0 (4.2 to 10.8)	4.6 (2.7 to 7.2)	-34.2 (-38.8 to -29.1)	-0.1 (-7.2 to 7.7)
Conduct disorder	807.3 (736.5 to 879.8)	515.6 (471.2 to 562.8)	-36.2 (-36.6 to -35.8)	0.0 (-0.0 to 0.0)	97.7 (61.0 to 143.8)	62.4 (38.7 to 90.5)	-36.1 (-39.1 to -33.1)	0.1 (-4.4 to 4.8)
Idiopathic intellectual disability	555.5 (419.9 to 698.6)	428.8 (287.9 to 565.1)	-23.4 (-36.9 to -11.9)	-21.8 (-34.5 to -10.4)	33.2 (21.6 to 47.0)	25.1 (14.7 to 36.6)	-23.9 (-30.5 to -11.7)	-21.1 (-35.4 to -9.4)
Other mental and substance use disorders	2,318.9 (2,187.1 to 2,449.6)	2,600.0 (2,446.3 to 2,757.8)	12.1 (9.3 to 14.9)	6.7 (0.6 to 0.9)	173.7 (118.0 to 234.4)	192.0 (130.3 to 260.6)	10.5 (6.1 to 15.2)	0.7 (-2.8 to 4.4)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	1,048.4 (741.5 to 1,408.5)	1,773.0 (1,261.8 to 2,401.1)	69.5 (52.0 to 85.8)	24.0 (12.5 to 34.1)
Diabetes mellitus	4,956.4 (4,241.0 to 5,713.0)	11,532.7 (9,910.3 to 13,232.5)	133.0 (91.0 to 184.2)	74.5 (42.5 to 110.1)	384.5 (258.0 to 542.7)	895.1 (600.2 to 1,265.0)	133.2 (91.7 to 181.7)	69.1 (39.6 to 104.0)
Acute glomerulonephritis	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	3.1 (-5.7 to 13.3)	-21.5 (-26.8 to -15.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.1 (-5.8 to 13.4)	-21.5 (-26.8 to -15.5)
Chronic kidney disease	-	-	-	-	171.3 (123.5 to 224.4)	241.8 (168.0 to 326.0)	40.7 (16.8 to 71.8)	5.3 (-7.9 to 21.5)
Chronic kidney disease due to diabetes mellitus	2,481.8 (1,489.5 to 4,415.3)	5,746.9 (4,503.8 to 7,107.0)	139.6 (50.0 to 268.3)	71.4 (6.4 to 163.5)	32.1 (21.7 to 45.2)	96.4 (64.3 to 136.5)	197.5 (131.4 to 293.1)	117.0 (67.9 to 181.3)
Chronic kidney disease due to hypertension	3,226.5 (2,140.3 to 5,005.9)	2,523.3 (1,827.4 to 3,407.3)	-20.0 (-53.0 to 21.1)	-30.6 (-59.5 to 0.4)	33.1 (20.7 to 46.9)	7.5 (2.3 to 54.3)	7.5 (-25.3 to 57.5)	-23.1 (-42.6 to 8.6)
Chronic kidney disease due to glomerulonephritis	2,617.2 (1,573.1 to 4,201.6)	2,149.2 (1,516.4 to 2,990.1)	-16.0 (-46.9 to 25.8)	-38.2 (-60.8 to -9.8)	47.0 (33.3 to 64.0)	45.2 (29.7 to 64.5)	-4.8 (-27.5 to 30.0)	-8.8 (-31.4 to 9.4)
Chronic kidney disease due to other causes	4,466.9 (3,083.2 to 6,888.7)	3,776.6 (2,714.7 to 4,887.7						

Appendix Table G.4 - Japan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Urolithiasis	2,785.1 (2,295.8 to 3,358.5)	1,293.1 (666.8 to 2,012.9)	-51.3 (-75.9 to -32.5)	-11.2 (-36.4 to -60.4)	22.8 (14.2 to 34.8)	11.1 (5.4 to 18.9)	-48.2 (-71.7 to -31.9)	-47.9 (-81.8 to -57.5)
Benign prostatic hyperplasia	4,304.0 (3,931.3 to 4,667.3)	8,795.0 (8,040.2 to 9,420.8)	105.0 (80.6 to 127.8)	6.6 (-5.6 to 18.5)	156.4 (100.3 to 221.4)	316.6 (206.4 to 448.3)	103.1 (78.8 to 126.5)	6.6 (-5.7 to 18.8)
Male infertility due to other causes	290.0 (211.5 to 363.3)	263.8 (185.3 to 344.3)	-9.8 (-38.9 to 34.2)	-1.5 (-32.2 to 48.5)	1.9 (0.8 to 4.0)	1.7 (0.7 to 3.7)	-9.1 (-40.2 to 37.6)	-0.5 (-32.6 to 51.0)
Other urinary diseases	-	-	-	-	4.0 (2.1 to 6.5)	1.4 (0.6 to 2.6)	-65.8 (-77.7 to -41.4)	-77.5 (-85.3 to -62.5)
Gynecological diseases	-	-	-	-	169.7 (110.9 to 261.7)	148.4 (94.7 to 227.8)	-12.9 (-30.4 to -3.0)	-12.9 (-12.7 to 6.9)
Uterine fibroids	5,019.4 (4,607.5 to 5,432.8)	4,542.4 (4,167.0 to 4,916.5)	-9.4 (-9.7 to -9.2)	-1.1 (-1.1 to -1.1)	58.7 (33.0 to 99.5)	54.2 (30.7 to 91.8)	-7.6 (-11.1 to -3.9)	0.9 (-2.7 to 4.5)
Polycystic ovarian syndrome	1,719.6 (1,550.3 to 1,875.9)	1,554.6 (1,418.6 to 1,704.5)	-9.6 (-20.7 to 2.4)	1.2 (-12.1 to 15.5)	16.2 (7.4 to 30.1)	14.6 (6.9 to 27.5)	-10.1 (-21.1 to 2.1)	0.5 (-12.6 to 14.8)
Female infertility due to other causes	99.3 (16.0 to 240.8)	66.6 (9.8 to 189.3)	-40.6 (-90.9 to 436.8)	-35.7 (-88.6 to 452.7)	0.5 (0.1 to 1.5)	0.3 (0.0 to 1.1)	-39.4 (-90.2 to 433.8)	-33.9 (-89.9 to 434.8)
Endometriosis	377.7 (315.7 to 437.6)	310.1 (253.1 to 369.6)	-19.0 (-35.2 to 6.3)	-10.0 (-27.7 to 17.5)	35.2 (22.8 to 49.2)	28.9 (18.3 to 41.2)	-18.6 (-36.3 to 5.9)	-10.1 (-29.2 to 17.4)
Genital prolapse	6,122.7 (5,280.3 to 7,058.6)	6,412.5 (5,523.1 to 7,284.5)	4.6 (-14.2 to 28.4)	-0.6 (-19.1 to 24.2)	19.6 (9.4 to 37.5)	20.4 (9.6 to 38.8)	4.0 (-14.7 to 28.6)	0.5 (-20.0 to 23.7)
Premenstrual syndrome	3,047.8 (1,674.7 to 4,125.5)	2,160.9 (1,625.6 to 2,750.7)	-29.9 (-53.2 to 22.5)	-15.7 (-43.3 to 49.5)	25.8 (12.2 to 44.6)	18.3 (10.2 to 29.6)	-30.0 (-53.2 to 25.1)	-14.7 (-43.5 to 48.9)
Other gynecological diseases	463.7 (394.5 to 530.1)	392.5 (375.3 to 411.3)	-15.5 (-26.7 to -0.7)	-0.7 (-14.2 to 16.0)	13.8 (8.8 to 19.9)	11.7 (8.0 to 16.6)	-15.9 (-26.9 to 12.2)	-1.4 (-14.3 to 31.7)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	78.0 (53.0 to 114.6)	64.4 (56.6 to 121.8)	7.9 (-1.4 to 20.1)	1.5 (-6.0 to 13.2)
Thalassemias	6.4 (5.2 to 7.5)	4.9 (4.1 to 6.1)	-18.4 (-39.5 to -7.0)	3.8 (-20.8 to 16.8)	0.7 (0.5 to 1.0)	0.5 (0.4 to 0.8)	-11.8 (-41.9 to -1.7)	2.2 (-24.6 to 24.6)
Thalassemia trait	2,972.4 (2,761.3 to 3,208.6)	3,043.5 (2,810.2 to 3,303.4)	2.4 (-1.6 to 6.5)	-0.9 (-4.6 to 3.2)	53.3 (35.8 to 77.8)	54.4 (36.6 to 79.4)	2.7 (-9.4 to 13.8)	-0.6 (-10.9 to 10.4)
Sickle cell disorders	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-19.5 (-35.6 to -4.5)	-0.8 (-20.2 to 17.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.7 (-44.3 to -1.2)	-3.3 (-31.0 to 19.6)
Sickle cell trait	33.8 (31.6 to 34.2)	34.8 (32.6 to 35.2)	2.9 (2.8 to 2.9)	0.8 (0.7 to 0.8)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-3.0 (-4.3 to -0.3)	-6.2 (-11.2 to -1.2)
G6PD deficiency	220.4 (179.1 to 259.1)	380.5 (281.9 to 377.2)	49.7 (19.3 to 92.2)	43.7 (14.8 to 84.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	46.7 (45.1 to 60.5)	46.7 (38.6 to 51.3)
G6PD trait	6,928.3 (6,569.3 to 7,247.7)	7,289.4 (6,962.2 to 7,640.4)	5.1 (-1.4 to 12.7)	-0.5 (-6.6 to 6.7)	0.6 (0.3 to 0.9)	0.4 (0.1 to 0.7)	-32.3 (-76.0 to 70.2)	-31.2 (-70.6 to 67.0)
Other hemoglobinopathies and hemolytic anemias	1,015.3 (902.4 to 1,127.3)	1,353.1 (1,252.9 to 1,475.6)	32.7 (19.5 to 51.1)	5.5 (-6.8 to 22.5)	23.1 (14.7 to 34.3)	28.6 (18.6 to 42.1)	22.1 (3.2 to 63.4)	8.4 (-7.8 to 47.9)
Endocrine, metabolic, blood, and immune disorders	1,790.9 (1,670.1 to 1,905.0)	2,166.5 (2,051.0 to 2,281.8)	20.9 (12.3 to 31.0)	2.7 (-4.4 to 10.8)	58.8 (40.1 to 81.8)	71.0 (47.9 to 97.8)	20.7 (10.2 to 33.8)	4.5 (-4.7 to 15.0)
Musculoskeletal disorders	-	-	-	-	2,891.2 (2,091.9 to 3,827.8)	3,929.2 (2,841.8 to 5,172.8)	7.0 (2.8 to 43.4)	7.0 (2.8 to 12.0)
Rheumatoid arthritis	314.2 (301.8 to 326.8)	466.5 (447.1 to 486.0)	48.5 (40.1 to 57.7)	-8.6 (-13.5 to -3.3)	73.9 (52.0 to 98.1)	107.3 (76.9 to 140.4)	45.2 (34.2 to 57.4)	-8.7 (-15.6 to -1.7)
Osteoarthritis	8,548.9 (8,251.6 to 8,843.1)	14,077.9 (13,547.8 to 14,569.9)	64.6 (56.4 to 72.8)	-5.3 (-10.2 to -0.6)	300.1 (197.6 to 432.9)	487.2 (320.4 to 698.3)	62.4 (53.9 to 71.1)	-5.5 (-10.7 to -0.6)
Low back and neck pain	-	-	-	-	1,769.3 (1,225.9 to 2,422.0)	2,312.5 (1,599.6 to 3,119.2)	31.0 (21.1 to 41.7)	10.2 (1.5 to 19.4)
Low back pain	10,475.1 (9,905.6 to 11,095.8)	13,016.9 (12,440.3 to 13,633.3)	24.4 (15.5 to 34.3)	0.1 (-6.9 to 8.3)	1,176.0 (800.7 to 1,632.7)	1,436.1 (964.2 to 1,995.6)	22.1 (13.4 to 32.2)	-0.1 (-7.6 to 8.4)
Neck pain	5,993.5 (5,189.3 to 6,695.3)	8,958.5 (8,013.5 to 9,921.1)	50.0 (27.5 to 75.7)	30.9 (11.5 to 52.9)	593.3 (400.9 to 849.2)	876.4 (601.5 to 1,215.6)	48.3 (25.3 to 74.1)	30.9 (10.9 to 53.0)
Gout	76.9 (62.4 to 90.2)	128.5 (111.2 to 148.3)	65.0 (36.7 to 119.3)	8.3 (-12.0 to 39.2)	2.5 (1.6 to 3.6)	4.1 (2.7 to 5.7)	62.1 (20.9 to 128.3)	8.2 (-19.8 to 50.0)
Other musculoskeletal disorders	8,072.3 (6,563.6 to 9,451.6)	11,125.0 (9,266.0 to 12,977.2)	38.0 (27.8 to 49.1)	5.2 (-0.6 to 10.7)	745.4 (490.7 to 1,066.5)	1,018.2 (677.7 to 1,435.2)	36.6 (26.4 to 47.4)	5.3 (-0.4 to 11.5)
Other non-communicable diseases	-	-	-	-	1,791.9 (1,201.0 to 2,508.2)	2,310.0 (1,586.0 to 3,250.9)	31.3 (25.4 to 37.1)	-2.1 (-5.8 to 1.7)
Congenital anomalies	-	-	-	-	158.8 (109.4 to 214.3)	169.2 (120.7 to 226.1)	6.8 (-7.4 to 23.2)	1.0 (-11.8 to 10.3)
Neural tube defects	39.5 (34.6 to 46.5)	32.8 (28.6 to 39.3)	-16.5 (-33.0 to 3.7)	-7.5 (-25.9 to 14.5)	12.8 (8.4 to 18.0)	10.8 (7.4 to 14.9)	-15.8 (-37.9 to 14.0)	-5.8 (-31.1 to 27.2)
Congenital heart anomalies	1,226.5 (1,055.3 to 1,454.5)	1,001.7 (813.9 to 1,266.9)	-18.1 (-38.3 to 4.7)	-16.5 (-36.8 to 6.8)	44.1 (18.6 to 77.5)	36.4 (15.3 to 64.7)	-17.2 (-36.7 to 3.2)	-14.2 (-34.6 to 6.7)
Crofacial clefts	247.3 (201.1 to 295.2)	290.4 (194.9 to 365.7)	6.8 (-24.8 to 16.1)	-6.6 (-24.7 to 16.3)	2.3 (1.6 to 3.4)	2.1 (1.3 to 3.1)	-7.9 (-30.2 to 25.9)	-6.8 (-30.9 to 26.3)
Down syndrome	126.2 (104.2 to 161.0)	152.8 (124.7 to 186.3)	21.0 (-8.2 to 56.1)	7.3 (-18.3 to 38.5)	19.1 (13.3 to 26.2)	25.4 (18.1 to 34.5)	8.0 (0.4 to 17.7)	8.0 (-1.8 to 38.8)
Turner syndrome	6.5 (5.1 to 8.5)	5.9 (4.9 to 6.9)	-8.2 (-32.9 to 22.0)	-1.7 (-28.1 to 30.6)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.2)	-9.1 (-37.8 to 23.0)	-1.8 (-31.0 to 33.5)
Klinefelter syndrome	4.4 (3.3 to 6.0)	5.9 (4.6 to 8.0)	33.1 (-17.1 to 117.1)	34.8 (-16.1 to 119.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	26.3 (-24.3 to 113.9)	35.3 (-18.9 to 126.9)
Chromosomal unbalanced rearrangements	210.1 (172.8 to 257.3)	240.0 (206.6 to 279.5)	14.6 (-8.6 to 42.5)	1.3 (-18.3 to 24.9)	31.7 (22.2 to 42.8)	39.8 (29.0 to 52.8)	25.9 (-0.2 to 60.4)	1.9 (-19.1 to 29.4)
Other congenital anomalies	214.9 (160.8 to 245.9)	196.9 (145.0 to 239.0)	-8.4 (-28.4 to 11.2)	-6.2 (-32.4 to 1.9)	49.5 (31.7 to 67.5)	54.9 (33.9 to 79.6)	11.0 (-7.5 to 38.2)	14.8 (-6.1 to 42.2)
Skin and subcutaneous diseases	-	-	-	-	745.5 (497.7 to 1,131.5)	768.5 (512.7 to 1,138.6)	3.3 (-4.5 to 11.3)	0.1 (-6.1 to 8.3)
Dermatitis	7,696.0 (6,365.9 to 8,963.3)	7,467.7 (6,220.7 to 8,590.0)	-3.0 (-5.5 to -0.2)	0.0 (-0.0 to 0.1)	209.7 (135.2 to 301.9)	202.0 (130.1 to 290.9)	-3.7 (-7.0 to 0.2)	-2.1 (-2.5 to 2.3)
Psoriasis	1,776.2 (1,559.2 to 1,986.6)	1,997.7 (1,741.8 to 2,251.6)	12.3 (7.5 to 18.2)	0.2 (-0.1 to 0.3)	145.1 (98.7 to 205.5)	161.2 (109.8 to 229.2)	11.2 (4.3 to 18.0)	11.2 (-3.7 to 4.8)
Cellulitis	67.6 (53.7 to 88.9)	90.8 (72.1 to 118.2)	34.2 (15.1 to 53.5)	4.7 (-11.1 to 11.2)	6.2 (3.0 to 7.0)	6.2 (3.9 to 9.5)	0.7 (-9.3 to 9.1)	-0.7 (-16.1 to 18.3)
Pyoderma	84.2 (64.5 to 110.8)	86.8 (64.6 to 115.2)	3.1 (-8.2 to 17.4)	-11.4 (-15.2 to -6.8)	0.5 (0.2 to 1.0)	0.5 (0.2 to 1.0)	1.9 (-13.4 to 17.8)	-11.5 (-20.4 to -1.6)
Scabies	73.7 (63.8 to 86.5)	56.4 (47.8 to 67.5)	-23.5 (-39.2 to -7.7)	-20.5 (-36.3 to 0.9)	1.9 (1.0 to 3.0)	1.4 (0.8 to 2.3)	-23.9 (-40.5 to -2.9)	-20.3 (-37.5 to 2.2)
Fungal skin diseases	8,139.0 (6,660.1 to 9,566.3)	9,491.7 (7,803.5 to 10,871.7)	16.7 (11.0 to 22.5)	0.5 (-0.3 to 0.6)	45.6 (18.6 to 96.7)	52.7 (21.5 to 111.8)	15.6 (9.9 to 21.1)	0.4 (-0.5 to 1.4)
Viral skin diseases	2,593.0 (2,092.3 to 3,097.8)	2,283.5 (1,873.0 to 2,731.6)	-12.1 (-15.7 to -7.4)	-12.1 (-2.9 to 12.1)	49.8 (47.0 to 125.4)	40.7 (41.4 to 109.3)	-22.1 (-16.8 to -7.6)	-7.0 (-3.9 to 2.5)
Acne vulgaris	11,865.6 (7,259.8 to 15,267.0)	8,489.8 (6,489.6 to 10,927.0)	-29.2 (-50.5 to 13.2)	-3.6 (-34.8 to 56.8)	128.6 (55.8 to 249.0)	92.1 (40.5 to 170.6)	-29.3 (-50.6 to 14.2)	-3.5 (-35.0 to 57.7)
Alopecia areata	211.5 (196.5 to 228.7)	262.7 (236.0 to 289.7)	24.1 (11.0 to 39.4)	-0.2 (-9.5 to 10.1)	7.1 (4.5 to 10.6)	8.6 (5.5 to 13.1)	22.1 (6.6 to 40.8)	0.3 (-12.0 to 13.6)
Pruritus	55.0 (44.3 to 69.6)	75.3 (55.1 to 97.6)	35.9 (-5.5 to 97.8)	1.0 (-26.5 to 41.9)	0.6 (0.3 to 1.1)	0.8 (0.3 to 1.5)	34.2 (-7.6 to 98.5)	0.9 (-30.0 to 44.6)
Urticaria	912.2 (642.7 to 1,183.8)	1,274.0 (883.2 to 1,625.9)	40.5 (-16.2 to 116.9)	34.4 (-34.5 to 88.4)	54.1 (32.0 to 84.1)	74.3 (43.6 to 112.0)	38.6 (-18.6 to 114.1)	14.8 (-35.2 to 90.5)
Decubitus ulcer	80.0 (67.5 to 90.5)	156.4 (124.1 to 195.1)	95.7 (50.8 to 152.5)	-9.4 (-27.9 to 14.5)	11.6 (7.8 to 16.3)	22.2 (14.6 to 32.5)	91.1 (43.4 to 151.1)	-9.4 (-29.5 to 17.0)
Other skin and subcutaneous diseases	9,506.0 (5,600.8 to 15,874.6)	13,140.8 (6,349.9 to 25,393.6)	35.5 (5.1 to 64.8)	0.9 (-2.7 to 3.4)	55.9 (22.7 to 128.7)	76.4 (26.3 to 187.3)	34.0 (4.4 to 63.6)	0.7 (-2.8 to 3.6)
Sense organ diseases	-	-	-	-	599.0 (393.2 to 854.9)	1,004.9 (678.6 to 1,411.1)	67.5 (59.4 to 79.9)	-7.4 (-11.6 to -2.9)
Glaucoma	128.1 (96.1 to 158.2)	206.2 (147.7 to 267.4)	59.7 (34.9 to 92.5)	-35.3 (-33.0 to -44.2)	15.3 (9.8 to 22.6)	27.3 (17.1 to 40.7)	77.9 (48.3 to 113.3)	-18.8 (-31.0 to -5.1)
Cataract	35.3 (24.7 to 49.2)	54.4 (26.7 to 84.3)	51.5 (-17.4 to 141.7)	-37.5 (-65.3 to 0.6)	2.5 (1.5 to 3.7)	4.1 (1.5 to 6.9)	63.0 (-1.5 to 156.0)	-34.6 (-59.1 to 4.4)
Macular degeneration	57.7 (38.7 to 83.0)	130.5 (89.9 to 177.5)	125.2 (74.7 to 193.0)	6.6 (-16.0 to 36.1)	4.3 (2.6 to 6.6)	10.4 (6.1 to 16.1)	139.8 (90.9 to 203.9)	2.3 (-1.8 to 28.7)
Uncorrected refractive error	4,989.1 (4,570.2 to 5,401.7)	7,247.5 (6,793.7 to 7,734.5)	45.4 (31.4 to 61.4)	-4.7 (-14.3 to 6.1)	69.6 (40.3 to 114.4)	97.2 (56.5 to 162.9)	39.5 (28.3 to 52.0)	-7.2 (-14.9 to 0.9)
Age-related and other hearing loss	18,958.4 (18,000.9 to 19,969.3)	30,462.1 (29,362.7 to 31,650.6)	60.7 (55.7 to 66.4)	-7.9 (-10.9 to -5.1)	408.2 (267.3 to 592.6)	743.7 (497.1 to 1,055.5)	81.8 (69.3 to 102.0)	-7.8 (-13.9 to -0.8)
Other vision loss	261.5 (198.0 to 319.5)	367.8 (269.8 to 468.2)	39.9 (25.4 to 58.0)	-20.0 (-25.5 to -13.2)	22.9 (14.9 to 32.7)	33.7 (21.4 to 48.8)	37.7 (27.8 to 69.1)	-17.6 (-25.6 to -7.8)
Other sense organ diseases	2,885.4 (2,750.2 to 3,014.3)	3,410.3 (3,228.4 to 3,586.4)	18.2 (10.6 to 27.0)	-0.3 (-5.7				

Appendix Table G.4 - Japan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	2,374.1 (2,237.2 to 2,502.1)	2,544.9 (2,419.7 to 2,686.5)	7.0 (-0.5 to 18.4)	-4.1 (-7.1 to 9.9)	69.6 (43.3 to 102.2)	74.0 (46.6 to 110.4)	6.1 (-2.0 to 17.0)	0.0 (-7.9 to 9.9)
Injuries	-	-	-	-	933.6 (706.7 to 1,203.4)	937.9 (674.5 to 1,257.9)	0.2 (-10.7 to 12.4)	-37.6 (-44.1 to -30.0)
Transport injuries	-	-	-	-	245.9 (185.7 to 316.1)	134.7 (96.6 to 179.7)	-45.5 (-51.4 to -38.5)	-62.1 (-66.0 to -57.5)
Road injuries	-	-	-	-	225.5 (170.4 to 289.7)	113.2 (81.2 to 150.4)	-50.0 (-55.2 to -43.7)	-65.4 (-68.9 to -61.2)
Pedestrian road injuries	-	-	-	-	39.4 (29.3 to 51.2)	24.8 (17.6 to 33.5)	-37.2 (-43.9 to -29.4)	-40.6 (-44.5 to -55.6)
Cyclist road injuries	-	-	-	-	34.3 (25.8 to 44.3)	15.2 (11.0 to 20.3)	-55.7 (-61.0 to -49.2)	-71.1 (-74.5 to -67.0)
Motorcyclist road injuries	-	-	-	-	54.0 (39.8 to 70.3)	19.0 (13.5 to 25.5)	-65.0 (-70.4 to -58.3)	-72.9 (-77.1 to -67.8)
Motor vehicle road injuries	-	-	-	-	96.5 (73.0 to 123.8)	53.8 (39.2 to 70.5)	-44.5 (-49.7 to -38.5)	-61.0 (-64.4 to -56.9)
Other road injuries	-	-	-	-	1.3 (1.0 to 1.7)	0.4 (0.3 to 0.5)	-70.0 (-73.7 to -65.1)	-76.7 (-79.7 to -73.0)
Other transport injuries	-	-	-	-	20.4 (15.2 to 26.8)	21.4 (15.3 to 29.4)	4.9 (-6.7 to 18.9)	-23.4 (-31.8 to -13.2)
Unintentional injuries	-	-	-	-	668.4 (507.1 to 866.6)	779.2 (560.9 to 1,048.8)	16.3 (4.3 to 29.6)	-29.2 (-36.3 to -21.1)
Falls	-	-	-	-	450.0 (339.4 to 577.0)	584.4 (421.0 to 784.1)	29.7 (13.1 to 47.7)	-27.2 (-36.2 to -17.0)
Drowning	-	-	-	-	3.7 (1.1 to 6.2)	3.3 (2.4 to 4.4)	-10.4 (-22.1 to 1.4)	-40.4 (-47.7 to -32.8)
Fire, heat, and hot substances	-	-	-	-	25.2 (16.1 to 38.7)	27.1 (15.6 to 43.9)	7.0 (-6.5 to 21.6)	-19.7 (-29.1 to -8.9)
Poisonings	-	-	-	-	1.1 (0.8 to 1.5)	0.6 (0.4 to 0.8)	-45.5 (-53.5 to -36.1)	-55.8 (-62.8 to -47.9)
Exposure to mechanical forces	-	-	-	-	158.4 (117.1 to 209.8)	114.4 (81.0 to 157.5)	-28.0 (-34.4 to -20.7)	-42.5 (-47.3 to -36.8)
Unintentional firearm injuries	-	-	-	-	1.5 (1.1 to 2.0)	1.0 (0.7 to 1.4)	-32.6 (-40.4 to -23.1)	-40.1 (-46.6 to -32.3)
Unintentional suffocation	-	-	-	-	0.7 (0.6 to 1.0)	0.9 (0.6 to 1.2)	17.7 (1.9 to 33.9)	-37.7 (-27.8 to -7.1)
Other exposure to mechanical forces	-	-	-	-	156.2 (115.3 to 206.8)	112.6 (79.7 to 154.9)	-28.2 (-34.5 to -20.9)	-42.6 (-47.5 to -36.9)
Adverse effects of medical treatment	-	-	-	-	6.0 (3.7 to 8.8)	8.9 (5.6 to 13.3)	49.9 (34.5 to 64.3)	2.1 (-6.9 to 10.8)
Animal contact	-	-	-	-	6.5 (4.7 to 8.7)	7.1 (4.9 to 9.9)	9.0 (0.6 to 19.1)	-13.8 (-20.2 to -5.7)
Venomous animal contact	-	-	-	-	1.2 (0.9 to 1.6)	1.2 (0.9 to 1.7)	4.5 (-7.5 to 17.0)	-13.9 (-24.5 to -4.0)
Non-venomous animal contact	-	-	-	-	5.3 (3.8 to 7.3)	5.9 (4.0 to 8.3)	10.0 (1.2 to 20.8)	-13.7 (-20.5 to -4.9)
Foreign body	-	-	-	-	6.4 (4.5 to 8.7)	6.0 (4.1 to 8.4)	-6.7 (-14.3 to 1.2)	-20.8 (-29.7 to -13.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	1.3 (1.0 to 1.6)	1.2 (0.9 to 1.5)	-8.8 (-14.7 to 9.3)	-30.9 (-39.5 to -18.7)
Foreign body in eyes	-	-	-	-	1.8 (1.1 to 2.8)	1.7 (1.0 to 2.6)	-9.0 (-17.3 to 4.6)	-22.2 (-24.3 to -0.5)
Foreign body in other body part	-	-	-	-	3.3 (2.3 to 4.7)	3.1 (1.9 to 4.5)	-7.4 (-16.9 to 1.2)	-21.9 (-32.4 to -13.8)
Other unintentional injuries	-	-	-	-	11.1 (7.9 to 15.1)	27.2 (18.6 to 38.0)	144.6 (117.0 to 175.2)	38.1 (22.7 to 54.1)
Self-harm and interpersonal violence	-	-	-	-	19.2 (14.2 to 24.9)	16.7 (12.1 to 22.6)	-13.2 (-20.7 to -4.3)	-34.3 (-39.9 to -27.8)
Self-harm	-	-	-	-	7.9 (5.7 to 10.4)	9.9 (7.0 to 13.4)	25.4 (13.5 to 37.8)	-3.7 (-12.8 to 5.7)
Interpersonal violence	-	-	-	-	11.4 (8.5 to 14.6)	6.9 (4.9 to 9.3)	-39.8 (-45.7 to -32.1)	-54.1 (-58.5 to -48.4)
Assault by firearm	-	-	-	-	0.8 (0.6 to 1.0)	0.5 (0.4 to 0.7)	-37.9 (-45.3 to -30.9)	-55.5 (-60.8 to -50.3)
Assault by sharp object	-	-	-	-	1.8 (1.3 to 2.4)	1.2 (0.9 to 1.7)	-31.2 (-36.9 to -24.3)	-47.2 (-51.6 to -42.0)
Assault by other means	-	-	-	-	8.8 (6.6 to 11.3)	5.1 (3.7 to 6.9)	-41.7 (-48.0 to -33.6)	-55.3 (-60.2 to -49.1)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.1)	7.3 (3.3 to 14.3)	14,487.7 (7,100.1 to 26,941.3)	6,140.4 (3,095.9 to 10,872.4)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.1)	7.3 (3.3 to 14.3)	14,487.7 (7,100.1 to 26,941.3)	6,140.4 (3,095.9 to 10,872.4)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Jordan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	297.5 (215.3 to 389.5)	726.9 (538.7 to 956.2)	144.2 (135.2 to 156.2)	144.2 (-3.3 to 4.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	51.9 (35.7 to 72.6)	98.2 (69.4 to 132.6)	89.0 (72.3 to 110.7)	-2.6 (-11.5 to 8.6)
HIV/AIDS and tuberculosis	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	0.4 (0.15 to 0.73)	-40.4 (-52.9 to -35.7)
Tuberculosis	0.7 (0.6 to 0.8)	1.0 (0.9 to 1.1)	42.7 (33.7 to 52.2)	-44.0 (-47.0 to -40.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	41.9 (15.6 to 73.3)	-44.4 (-87.4 to 0.0)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (1.153 to 41.955.1)	877.4 (332.9 to 14,687.5)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,293.2 (519.1 to 20,465.5)	359.1 (103.1 to 6,896.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,293.2 (513.8 to 20,729.1)	359.1 (102.6 to 6,973.1)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	2,080.3 (780.8 to 31,921.7)	686.0 (229.3 to 11,714.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	2,706.1 (1,152.5 to 42,523.2)	883.1 (332.6 to 15,064.3)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	7.0 (6.5 to 12.5)	10.9 (10.4 to 20.4)	14.8 (51.9 to 71.2)	-14.6 (-19.0 to -10.0)
Diarrheal diseases	42.6 (40.2 to 45.2)	66.9 (62.9 to 71.0)	57.4 (47.3 to 67.8)	-15.1 (-20.2 to -9.8)	7.0 (4.7 to 9.7)	10.9 (7.4 to 15.2)	56.7 (46.8 to 68.1)	15.1 (-20.4 to -9.2)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.1 (12.9 to 89.5)	24.9 (-40.6 to -5.6)
Typhoid fever	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.4)	46.8 (15.1 to 86.8)	-24.3 (-39.7 to -5.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	48.2 (12.5 to 97.3)	-23.7 (-40.6 to -2.5)
Paratyphoid fever	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	51.0 (14.1 to 90.1)	-21.3 (-39.6 to -0.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.0 (14.1 to 90.3)	21.2 (-39.9 to -0.2)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (99.3 to 389.9)	-84.3 (-99.7 to 389.9)
Lower respiratory infections	2.5 (2.2 to 2.9)	3.1 (2.8 to 3.5)	22.9 (1.9 to 46.2)	-27.6 (-37.8 to -15.9)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	22.6 (1.7 to 55.5)	-27.9 (-40.6 to -12.7)
Upper respiratory infections	58.4 (53.9 to 64.4)	124.8 (117.4 to 132.9)	113.9 (89.0 to 138.9)	2.7 (-8.4 to 14.7)	0.7 (0.4 to 1.1)	1.5 (0.8 to 2.5)	113.7 (89.3 to 139.3)	2.9 (-8.5 to 15.5)
Otitis media	43.5 (40.3 to 46.6)	76.7 (70.7 to 83.7)	76.6 (59.6 to 93.6)	-10.5 (-20.5 to -1.6)	0.8 (0.5 to 1.3)	1.4 (0.8 to 2.3)	75.1 (58.9 to 92.8)	-11.1 (-20.5 to -2.1)
Meningitis	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	29.4 (27 to 54.7)	-41.1 (-51.3 to -29.3)
Pneumococcal meningitis	0.9 (0.6 to 1.4)	1.4 (0.8 to 2.2)	45.5 (17.8 to 81.9)	-38.0 (-49.8 to -24.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	46.9 (15.9 to 91.5)	35.2 (-47.1 to -18.2)
H influenzae type B meningitis	0.6 (0.2 to 1.2)	0.7 (0.3 to 1.4)	9.5 (-30.7 to 42.0)	-50.0 (-66.4 to -35.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	3.8 (-47.5 to 58.2)	-49.7 (-73.6 to -23.9)
Meningococcal meningitis	0.3 (0.1 to 0.7)	0.4 (0.1 to 0.9)	23.5 (-11.0 to 75.3)	-47.3 (-60.5 to -22.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	21.9 (9.7 to 98.3)	-46.0 (-59.1 to -17.3)
Other meningitis	0.4 (0.2 to 0.7)	0.6 (0.3 to 1.1)	41.7 (12.4 to 75.8)	-36.6 (-48.8 to -21.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	44.2 (9.2 to 90.2)	-34.2 (-48.7 to -14.1)
Encephalitis	0.8 (0.4 to 1.9)	1.5 (0.6 to 3.4)	71.8 (44.8 to 96.4)	-24.6 (-34.2 to -14.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	75.8 (39.0 to 112.4)	-21.5 (-35.8 to -7.0)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.0 (-91.3 to 1,770.2)	-33.6 (-94.2 to 579.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.0 (-91.5 to 1,818.9)	-33.6 (-94.3 to 581.1)
Whooping cough	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-35.9 (-39.9 to -31.8)	-62.2 (-64.5 to -59.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.4 (-55.2 to -12.1)	-62.5 (-73.6 to -48.3)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-69.2 (-83.1 to -50.1)	-85.5 (-91.8 to -77.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-66.1 (-81.0 to -42.5)	-83.3 (-90.4 to -72.6)
Measles	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.2)	54.0 (-62.0 to -43.5)	-72.9 (-77.6 to -66.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.9 (-75.5 to -34.9)	-73.4 (-85.5 to -55.8)
Varicella and herpes zoster	2.8 (2.5 to 2.9)	5.4 (4.9 to 6.1)	97.1 (74.7 to 125.7)	5.1 (-12.7 to 30.2)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	173.9 (101.1 to 271.7)	10.0 (-22.6 to 55.7)
Neglected tropical diseases and malaria	-	-	-	-	3.4 (1.9 to 6.0)	4.5 (2.8 to 7.5)	34.9 (9.0 to 97.0)	-19.7 (-45.9 to 21.8)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	211.3 (39.7 to 578.7)	51.2 (-31.7 to 217.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	181.6 (38.0 to 440.1)	35.1 (-33.1 to 157.4)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.1 (6.3 to 341.2)	-5.5 (-41.2 to 79.8)
Visceral leishmaniasis	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	87.5 (-4.9 to 486.9)	-1.6 (-46.5 to 128.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.3 (-5.9 to 490.7)	-2.1 (-46.8 to 124.1)
Cutaneous and mucocutaneous leishmaniasis	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	75.8 (50.1 to 105.0)	-13.7 (-25.6 to -0.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.8 (21.4 to 164.2)	-13.3 (-36.6 to 16.9)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	12.8 (5.0 to 29.3)	30.2 (11.8 to 69.2)	136.2 (128.0 to 144.3)	0.4 (-2.0 to 3.4)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.6)	118.8 (67.0 to 158.1)	0.5 (-18.0 to 16.3)
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.4 (-99.8 to -98.1)	-99.8 (-99.9 to -99.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.4 (-99.8 to -97.9)	-99.8 (-99.9 to -99.2)
Cystic echinococcosis	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.4)	207.3 (174.4 to 241.2)	19.5 (8.0 to 28.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	205.8 (142.3 to 282.8)	18.8 (-7.4 to 52.0)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.2 (-70.5 to -1.9)	67.2 (-86.6 to -54.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.2 (-70.6 to -1.6)	67.2 (-86.6 to -54.5)
Intestinal nematode infections	-	-	-	-	1.6 (0.7 to 3.7)	3.6 (0.7 to 3.6)	1.6 (-57.8 to 138.5)	0.4 (-73.3 to 48.4)
Ascariasis	496.6 (396.4 to 638.7)	1,425.5 (1,074.3 to 1,910.1)	185.1 (92.9 to 311.3)	30.2 (-11.0 to 95.1)	1.4 (0.5 to 3.4)	1.2 (0.4 to 3.1)	-13.0 (-68.0 to 143.5)	-43.6 (-80.3 to 66.9)
Trichuriasis	129.4 (99.0 to 168.5)	409.1 (304.5 to 536.3)	215.8 (113.3 to 370.5)	39.5 (-10.5 to 115.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	413.0 (-26.3 to 3,407.0)	120.9 (-72.4 to 1,703.7)
Hookworm disease	64.8 (52.2 to 82.4)	128.7 (92.4 to 156.6)	86.3 (30.1 to 156.6)	0.2 (-44.1 to 18.7)	0.3 (0.1 to 0.3)	0.3 (0.2 to 0.6)	86.9 (-13.3 to 175.7)	-18.5 (-56.2 to 36.6)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	46.4 (35.0 to 58.1)	76.1 (68.4 to 84.9)	63.9 (30.5 to 116.9)	-5.9 (-23.5 to 20.8)	1.6 (0.9 to 2.4)	2.6 (1.7 to 3.8)	55.4 (30.1 to 137.8)	-4.8 (-20.2 to 45.4)
Maternal disorders	-	-	-	-	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.7)	63.1 (29.8 to 106.3)	-44.3 (-54.8 to -33.4)
Maternal hemorrhage	0.8 (0.7 to 0.9)	1.7 (1.2 to 2.2)	118.8 (46.6 to 189.7)	37.3 (-51.1 to -4.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	101.4 (5.8 to 217.6)	31.1 (-63.5 to 7.4)
Maternal sepsis and other maternal infections	1.7 (1.0 to 2.4)	2.6 (1.6 to 3.7)	49.4 (13.6 to 94.3)	-59.2 (-68.7 to -48.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	23.7 (-36.7 to 116.1)	-59.9 (-79.2 to -32.7)
Maternal hypertensive disorders	2.1 (0.8 to 3.8)	3.5 (1.3 to 6.2)	65.8 (42.4 to 92.8)	-43.0 (-48.3 to -39.9)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	64.4 (34.7 to 98.2)	-43.7 (-51.3 to -35.1)
Obstructed labor	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	38.8 (-11.2 to 112.5)	-51.8 (-68.8 to -29.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	36.2 (-34.3 to 169.6)	-52.2 (-75.7 to -6.5)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	114.6 (12.8 to 277.3)	-36.3 (-64.5 to 10.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	114.6 (12.5 to 279.7)	-36.3 (-64.5 to 10.7)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	76.2 (14.3 to 162.0)	-39.8 (-62.0 to -12.1)
Neonatal disorders	-	-	-	-	8.1 (4.8 to 12.2)	27.1 (18.1 to 37.9)	238.0 (126.0 to 407.2)	67.0 (12.0 to 150.3)
Preterm birth complications	33.0 (23.5 to 43.6)	142.8 (106.3 to 185.1)	334.1 (243.3 to 467.5)	105.1 (63.3 to 164.6)	4.0 (2.6 to 5.7)	17.8 (11.9 to 24.7)	341.1 (210.8 to 520.3)	113.7 (53.6 to 197.4)
Neonatal encephalopathy due to birth asphyxia and trauma	7.2 (3.7 to 11.8)	17.7 (11.1 to 26.2)	149.4 (29.7 to 400.1)	26.7 (-34.6 to 159.1)	1.7 (0.9 to 2.7)	4.1 (2.4 to 6.4)	146.4 (36.0 to 339.2)	26.2 (-30.2 to 124.6)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	182.7 (159.1 to 188.7)	73.5 (58.9 to 77.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.2 (142.2 to 224.0)	69.6 (48.6 to 98.8)
Hemolytic disease and other neonatal jaundice	5.4 (1.3 to 11.8)	10.8 (3.3 to 28.5)	112.5 (-51.3 to 788.8)	4.9 (-75.9 to 345.7)	1.5 (0.4 to 3.2)	2.7 (0.8 to 7.0)	94.4 (-49.2 to 615.5)	-3.9 (-75.1 to 259.9)
Other neonatal disorders	-	-	-	-	0.9 (0.3 to 1.8)	2.5 (1.3 to 4.4)	180.0 (17.6 to 674.2)	39.1 (-41.6 to 282.5)
Nutritional deficiencies	-	-	-	-	29.0 (19.0 to 42.4)	47.8 (31.8 to 69.4)	64.4 (54.3 to 76.0)	-16.2 (-22.1 to -9.5)
Protein-energy malnutrition	9.3 (5.1 to 15.7)	9.5 (4.1 to 20.1)	-5.8 (-62.0 to 166.4)	44.7 (77.6 to 56.2)	1.2 (0.5 to 2.1)	1.2 (0.5 to 2.6)	44.5 (-62.6 to 162.4)	-44.5 (-77.8 to 53.5)
Iodine deficiency	213.1 (155.5 to 280.2)	245.5 (167.2 to 319.0)	14.7 (-26.9 to 81.0)	-53.5 (-70.8 to -24.4)	3.8 (2.1 to 6.5)	4.4 (2.4 to 7.3)	14.3 (-26.6 to 80.3)	-53.6 (-70.7 to -23.6)
Vitamin A deficiency	3.3 (1.9 to 5.1)	3.2 (1.8 to 4.9)	-4.4 (-29.4 to 30.8)	-52.6 (-64.6 to -38.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-6.6 (-33.6 to 24.3)	-64.5 (-66.5 to -42.8)

Appendix Table G.4 - Jordan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	703.4 (691.8 to 715.3)	1,345.2 (1,330.5 to 1,359.9)	91.2 (87.6 to 94.8)	-6.5 (-7.6 to -3.3)	23.4 (15.7 to 33.9)	41.6 (27.6 to 60.6)	77.8 (72.0 to 81.8)	77.8 (-8.8 to -3.6)
Other nutritional deficiencies	-	-	-	-	0.4 (0.2 to 1.0)	0.4 (0.1 to 1.2)	-1.5 (-70.1 to 180.4)	-48.3 (-82.3 to 63.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.8 (1.1 to 2.7)	3.3 (2.1 to 5.0)	85.0 (51.6 to 120.4)	-8.0 (-22.3 to 4.2)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.4 (0.2 to 0.7)	1.1 (0.6 to 1.9)	157.8 (102.5 to 220.5)	-3.4 (-21.1 to 16.7)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	65.9 (39.7 to 100.8)	-41.6 (-48.7 to -41.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.4 (31.8 to 130.1)	-99.8 (-55.1 to -18.1)
Chlamydial infection	25.7 (18.8 to 34.2)	70.4 (52.6 to 83.9)	173.4 (101.4 to 282.8)	5.1 (-19.6 to 44.3)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	167.0 (61.4 to 383.6)	3.2 (-35.9 to 77.1)
Gonococcal infection	15.5 (12.1 to 19.1)	35.5 (27.7 to 43.1)	127.3 (69.0 to 203.8)	-8.5 (-29.6 to 21.0)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	125.1 (48.8 to 224.9)	-10.5 (-38.3 to 28.1)
Trichomoniasis	10.5 (5.8 to 14.4)	29.4 (21.5 to 39.2)	179.0 (76.1 to 398.7)	3.2 (-32.3 to 59.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	175.6 (69.5 to 475.7)	3.8 (-34.7 to 79.2)
Genital herpes	386.5 (367.6 to 405.0)	1,137.3 (1,087.0 to 1,186.7)	194.1 (176.1 to 214.4)	-0.3 (-6.0 to 7.5)	0.1 (0.0 to 0.3)	0.3 (0.1 to 0.7)	127.5 (166.5 to 212.5)	0.5 (-6.9 to 8.8)
Other sexually transmitted diseases	0.5 (0.4 to 0.7)	1.5 (1.1 to 2.0)	187.9 (143.9 to 249.3)	-17.8 (-30.1 to -1.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	225.7 (118.4 to 415.0)	4.9 (-27.9 to 58.1)
Hepatitis	-	-	-	-	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	91.6 (64.6 to 120.9)	-24.0 (-35.8 to -11.8)
Hepatitis A	4.6 (4.4 to 4.9)	8.1 (7.8 to 8.4)	74.7 (73.8 to 75.7)	-7.4 (-7.7 to -7.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.3)	98.2 (75.2 to 125.2)	-4.1 (-14.1 to 7.6)
Hepatitis B	214.4 (173.0 to 254.8)	285.7 (232.9 to 345.3)	35.8 (-3.3 to 72.2)	-41.9 (-51.0 to -26.7)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	65.6 (15.1 to 127.1)	-44.2 (-60.2 to -28.5)
Hepatitis C	40.5 (37.0 to 44.0)	77.5 (69.5 to 85.5)	91.2 (66.7 to 118.9)	-24.6 (-33.3 to -14.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.7 (43.9 to 132.5)	-20.6 (-42.2 to 11.6)
Hepatitis E	0.5 (0.3 to 0.6)	1.5 (1.0 to 2.0)	197.6 (108.7 to 379.4)	16.8 (-17.1 to 94.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	203.4 (88.4 to 411.3)	17.1 (-26.2 to 98.8)
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	32.8 (25.6 to 40.9)	55.2 (45.0 to 66.8)	68.3 (32.8 to 113.8)	-6.6 (-24.0 to 15.5)	1.1 (0.7 to 1.7)	1.8 (1.1 to 2.7)	57.5 (10.8 to 107.4)	-5.9 (-32.9 to 23.6)
Non-communicable diseases	-	-	-	-	236.1 (172.1 to 307.9)	614.6 (453.2 to 808.1)	160.0 (149.9 to 173.2)	2.4 (-1.5 to 7.3)
Neoplasms	-	-	-	-	0.9 (0.6 to 1.2)	2.3 (1.6 to 3.1)	166.6 (109.2 to 227.8)	4.7 (-17.2 to 28.1)
Esophageal cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	90.5 (19.2 to 175.5)	-21.9 (-50.5 to 14.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.2 (30.9 to 150.7)	-23.2 (-45.9 to 5.0)
Stomach cancer	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	54.2 (10.8 to 116.6)	-36.3 (-53.7 to -12.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	54.2 (9.8 to 118.7)	-36.8 (-55.0 to -11.6)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	145.6 (63.9 to 248.6)	7.7 (-26.8 to 51.5)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	105.3 (-21.2 to 353.9)	-15.2 (-66.6 to 87.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.3 (-17.0 to 304.5)	-17.2 (-66.1 to 69.3)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	402.9 (157.0 to 955.1)	120.3 (17.7 to 359.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	388.4 (175.0 to 832.9)	113.2 (23.6 to 310.2)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.5 (-38.5 to 207.3)	-35.3 (-71.0 to 37.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.4 (-33.9 to 177.4)	-35.3 (-69.4 to 27.0)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.6 (-26.8 to 227.3)	-22.0 (-68.6 to 49.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.6 (-25.3 to 198.7)	33.5 (-67.6 to 37.7)
Larynx cancer	0.2 (0.2 to 0.3)	0.7 (0.4 to 1.1)	185.9 (68.6 to 439.1)	4.6 (-37.3 to 117.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	121.9 (31.7 to 286.1)	-16.5 (-51.0 to 52.4)
Tracheal, bronchus and lung cancer	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.7)	123.4 (50.7 to 220.3)	-6.8 (-36.5 to 31.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	122.1 (45.2 to 219.2)	-7.9 (-38.0 to 30.8)
Breast cancer	1.8 (1.3 to 2.4)	6.2 (4.1 to 8.2)	239.0 (114.0 to 389.7)	16.2 (-23.7 to 64.3)	0.2 (0.1 to 0.2)	0.5 (0.3 to 0.7)	216.9 (99.7 to 355.6)	9.6 (-29.0 to 54.7)
Cervical cancer	0.4 (0.3 to 0.6)	0.7 (0.4 to 0.9)	52.9 (-13.2 to 132.2)	17.6 (-68.6 to 42.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	46.1 (-12.3 to 144.7)	46.1 (-68.7 to -18.1)
Uterine cancer	0.3 (0.2 to 0.6)	0.5 (0.3 to 0.8)	40.3 (-20.0 to 152.9)	-45.8 (-69.5 to -4.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	42.1 (-17.9 to 150.0)	-44.8 (-68.0 to -4.1)
Prostate cancer	0.4 (0.2 to 0.6)	2.1 (1.3 to 3.1)	445.1 (225.2 to 798.7)	130.7 (39.3 to 275.0)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	315.5 (161.0 to 555.2)	77.8 (12.1 to 184.2)
Colon and rectum cancer	1.0 (0.8 to 1.1)	2.9 (2.4 to 3.5)	202.6 (129.5 to 299.6)	17.8 (-9.4 to 52.0)	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	185.5 (115.8 to 274.4)	10.6 (-15.7 to 42.3)
Lip and oral cavity cancer	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.7)	120.8 (45.3 to 261.9)	-11.9 (-43.6 to 44.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	115.0 (41.4 to 262.8)	-14.5 (-45.0 to 37.7)
Nasopharynx cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	75.9 (7.7 to 178.5)	-29.7 (-56.5 to 7.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.9 (6.8 to 163.9)	-30.6 (-56.1 to 4.1)
Other pharynx cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	117.6 (16.5 to 265.7)	-13.3 (-53.9 to 48.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.7 (16.6 to 238.4)	-16.6 (-54.7 to 33.9)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	69.4 (2.8 to 177.6)	-29.1 (-58.3 to 13.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.7 (1.6 to 164.2)	-30.9 (-58.2 to 9.6)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	280.7 (162.4 to 436.5)	55.9 (8.0 to 116.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	269.1 (166.3 to 390.3)	49.3 (8.2 to 96.4)
Malignant skin melanoma	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	169.6 (74.3 to 283.5)	5.5 (-36.5 to 34.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	151.8 (63.2 to 264.6)	-11.4 (-41.6 to 27.3)
Non-melanoma skin cancer	0.4 (0.3 to 0.5)	1.2 (1.0 to 1.5)	210.3 (145.1 to 296.2)	21.4 (-3.6 to 56.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	223.3 (123.7 to 373.0)	27.9 (-12.4 to 86.4)
Ovarian cancer	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.5)	176.4 (74.1 to 328.7)	5.5 (-33.2 to 64.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	176.9 (69.0 to 356.6)	6.0 (-38.2 to 77.9)
Testicular cancer	0.2 (0.1 to 0.3)	0.6 (0.3 to 0.9)	266.7 (99.0 to 566.7)	25.0 (-28.8 to 123.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	259.2 (81.5 to 575.2)	21.4 (-34.2 to 121.9)
Kidney cancer	0.4 (0.1 to 0.1)	0.3 (0.3 to 0.4)	302.7 (98.0 to 342.0)	25.9 (-19.8 to 83.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	194.9 (90.3 to 328.6)	19.8 (-23.3 to 75.2)
Bladder cancer	0.4 (0.3 to 0.6)	26.5 (0.4 to 0.7)	65.5 (-16.1 to 91.0)	-43.5 (-61.7 to -16.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	24.8 (-16.8 to 90.1)	24.8 (-63.0 to -18.9)
Brain and nervous system cancer	0.2 (0.2 to 0.4)	0.8 (0.6 to 1.0)	230.3 (110.9 to 381.3)	48.6 (-1.9 to 102.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	226.7 (113.4 to 368.1)	39.7 (-7.5 to 93.3)
Thyroid cancer	0.5 (0.4 to 0.7)	1.2 (0.7 to 1.7)	109.3 (21.7 to 263.1)	-25.9 (-54.2 to 22.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	101.7 (18.0 to 247.5)	-28.0 (-56.0 to 17.8)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	863.2 (282.2 to 164.5)	15.6 (-43.5 to 25.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.4 (35.8 to 163.8)	-11.4 (-44.8 to 24.6)
Hodgkin lymphoma	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	164.5 (36.2 to 385.2)	26.2 (-30.0 to 119.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	154.0 (20.2 to 381.7)	16.3 (-34.1 to 100.4)
Non-Hodgkin lymphoma	0.7 (0.5 to 1.0)	2.1 (1.5 to 2.8)	205.8 (98.6 to 348.3)	29.1 (-19.1 to 90.7)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	197.8 (89.1 to 336.4)	23.3 (-23.2 to 83.2)
Multiple myeloma	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	163.3 (58.0 to 323.0)	2.1 (-38.5 to 62.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	149.3 (48.9 to 302.3)	-3.5 (-42.5 to 56.9)
Leukemia	0.8 (0.6 to 1.0)	2.0 (1.5 to 2.6)	166.0 (83.9 to 385.3)	32.3 (-5.1 to 78.0)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	161.1 (85.5 to 245.9)	22.2 (-12.4 to 60.8)
Other neoplasms	0.9 (0.6 to 1.3)	2.8 (2.1 to 3.7)	232.7 (85.8 to 406.1)	44.9 (-10.7 to 106.1)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	214.6 (79.2 to 368.3)	30.9 (-18.3 to 83.3)
Cardiovascular diseases	-	-	-	-	4.8 (3.2 to 6.8)	12.2 (8.2 to 16.9)	154.4 (97.2 to 213.4)	2.8 (-17.4 to 23.6)
Rheumatic heart disease	7.8 (6.0 to 9.8)	20.9 (14.5 to 26.8)	173.5 (73.4 to 272.7)	7.2 (-26.6 to 39.8)	0.4 (0.3 to 0.6)	1.2 (0.7 to 1.8)	188.1 (90.8 to 302.9)	20.6 (-15.5 to 69.6)
Ischemic heart disease	22.0 (17.9 to 27.5)	42.5 (37.3 to 49.2)	92.7 (54.4 to 150.4)	-16.7 (-32.9 to 8.1)	1.2 (0.8 to 1.8)	2.5 (1.7 to 3.6)	181.4 (58.8 to 173.0)	-12.9 (-34.1 to 16.2)
Cerebrovascular disease	-	-	-	-	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.6)	177.7 (122.2 to 254.9)	3.1 (-18.9 to 33.5)
Ischemic stroke	0.8 (0.7 to 0.9)	2.2 (1.8 to 2.6)	177.7 (121.4 to 247.6)	3.2 (-18.2 to 31.1)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	177.7 (120.2 to 260.1)	3.4 (-19.1 to 34.4)
Hemorrhagic stroke	0.1 (0.1 to 0.1)	0.3 (0.3 to 0.4)	179.7 (104.5 to 294.3)	2.9 (-23.6 to 47.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	179.3 (105.4 to 290.1)	2.5 (-23.2 to 48.1)
Hypertensive heart disease	2.3 (1.9 to 2.7)	8.7 (7.5 to 10.1)	277.9 (199.0 to 378.1)	68.8 (25.9 to 105.8)	0.3 (0.2 to 0.4)	1.0 (0.6 to 1.3)	276.0 (197.1 to 375.9)	59.5 (25.4 to 102.8)
Cardiomyopathy and myocarditis	1.8 (1.5 to 2.1)	5.4 (4.8 to 6.0)	204.6 (140.0 to 279.6)	31.6 (-1.2 to 67.9)	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.8)	203.8 (132.5 to 290.0)	31.5 (-2.6 to 70.1)
Atrial fibrillation and flutter	2.7 (1.9 to 4.0)	4.5 (3.3 to 5.9)	74.7 (0.9 to 171.0)	-29.2 (-59.2 to 23.8)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	80.5 (1.1 to 177.8)	-27.8 (-59.3 to 23.1)
Peripheral vascular disease	32.4 (21.8 to 44.4)	101.8 (66.9 to 130.8)	214.7 (101.0 to 363.3)	27.1 (-17.1 to 71.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	60.2 (-20.6 to 249.7)	-15.0 (-55.6 to 70.8)
Endocarditis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	198.9 (99.1 to 329.1)	50.4 (-0.8 to 116.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	204.0 (93.3 to 351.3)	53.0 (-5.8 to 132.2)
Other cardiovascular and circulatory diseases	33.7 (25.4 to 46.4)	87.6 (53.9 to 115.2)	166.8 (58.6 to 282.9)	6.4 (-34.6 to 50.5)	2.4 (1.4 to 3.7)	6.1 (3.5 to 9.1)	165.8 (57.0 to 281.6)	6.3 (-35.7 to 51.4)
Chronic respiratory diseases	-	-	-	-	15.6 (10.7 to 21.3)	32.8 (22.2 to 45.1)	109.6 (57.0 to 154.6)	-13.5 (-24.3 to 1.7)
Chronic obstructive pulmonary disease	96.2 (90.7 to 101.7)	268.8 (252.9 to 284.2)	179.2					

Appendix Table G.4 - Jordan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	149.7	-
Silicosis	0.0	0.0	125.5	-17.9	(0.0 to 0.0)	(0.0 to 0.0)	(141.0 to 158.3)	(-12.0 to -5.7)
Asbestosis	-	-	0.0	0.0	0.0	0.0	125.2	-18.1
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	(-22.3 to -13.3)
Other pneumoconiosis	0.0	0.1	163.8	-2.7	0.0	0.0	164.4	-2.3
Asthma	193.5	321.2	66.8	-26.5	8.5	14.1	66.2	-26.9
Interstitial lung disease and pulmonary sarcoidosis	0.2	0.5	178.8	4.8	0.0	0.1	181.9	3.7
Other chronic respiratory diseases	-	-	-	-	0.6	0.6	-13.6	(-79.6 to -0.4)
Cirrhosis	-	-	-	-	0.2	0.3	52.5	-30.0
Cirrhosis due to hepatitis B	0.4	0.5	37.5	-42.0	(0.1 to 0.3)	(0.2 to 0.4)	(31.3 to 75.9)	(-38.9 to -21.0)
Cirrhosis due to hepatitis C	0.3	0.7	113.9	-8.2	0.1	0.1	114.2	-7.7
Cirrhosis due to alcohol use	0.1	0.1	5.7	-54.6	(0.0 to 0.1)	(0.0 to 0.1)	(21.7 to 279.7)	(-45.1 to 75.5)
Cirrhosis due to other causes	0.4	0.5	24.3	-29.5	(0.0 to 0.1)	(0.0 to 0.1)	(-47.2 to 107.2)	(-78.7 to -8.8)
Digestive diseases	-	-	-	-	1.9	4.2	123.0	-12.2
Peptic ulcer disease	9.7	9.1	-5.4	-52.7	0.3	0.4	18.6	-42.0
Gastritis and duodenitis	9.6	9.8	1.5	-48.6	0.5	0.5	4.1	44.8
Appendicitis	0.2	0.4	98.5	-18.2	0.1	0.1	97.2	-17.7
Paralytic ileus and intestinal obstruction	0.0	0.1	155.2	7.2	0.0	0.0	160.9	8.9
Inguinal, femoral, and abdominal hernia	6.0	14.5	139.7	-1.7	0.1	0.2	142.6	-1.0
Inflammatory bowel disease	2.1	8.5	310.1	45.6	0.4	1.8	311.4	46.1
Vascular intestinal disorders	0.0	0.0	122.8	2.1	0.0	0.0	123.4	1.4
Gallbladder and biliary diseases	0.9	2.3	145.5	0.3	0.1	0.2	146.8	4.0
Pancreatitis	0.5	1.3	163.6	-7.3	0.1	0.4	163.7	-7.8
Other digestive diseases	-	-	-	-	0.3	0.5	115.4	-15.1
Neurological disorders	-	-	-	-	21.9	61.1	180.6	12.2
Alzheimer disease and other dementias	12.9	26.8	108.3	1.7	1.9	3.7	104.2	2.0
Parkinson disease	0.7	1.7	133.8	-2.7	0.1	0.2	136.1	-2.6
Epilepsy	16.1	34.9	116.6	1.1	5.3	12.1	129.9	8.5
Multiple sclerosis	0.4	1.4	217.3	3.9	0.1	0.5	220.2	6.1
Migraine	284.0	782.4	182.5	5.3	9.7	26.6	180.3	5.4
Tension-type headache	500.6	1,324.4	164.9	3.7	5.1	14.9	165.2	4.1
Medication overuse headache	21.6	90.9	319.7	49.9	3.4	14.3	319.7	49.6
Other neurological disorders	0.0	0.0	130.2	2.5	0.7	1.8	140.2	13.2
Mental and substance use disorders	-	-	-	-	74.4	197.2	164.6	3.3
Schizophrenia	6.3	19.5	207.3	-1.0	4.1	12.5	207.5	-0.8
Alcohol use disorders	13.6	33.7	149.0	-6.4	1.3	3.3	149.8	-6.4
Drug use disorders	-	-	-	-	9.4	36.0	287.6	21.0
Opioid use disorders	17.8	76.0	336.7	27.5	7.4	31.5	335.0	26.9
Cocaine use disorders	1.8	2.9	103.3	-24.4	(0.2 to 0.5)	(0.5 to 1.3)	(92.7 to 289.2)	(-28.7 to 38.4)
Amphetamine use disorders	4.5	9.0	99.3	-15.4	0.6	1.2	97.4	-16.7
Cannabis use disorders	5.1	11.7	127.4	-1.3	0.1	0.3	127.9	-1.2
Other drug use disorders	-	-	-	-	0.9	2.1	125.0	-9.8
Depressive disorders	-	-	-	-	4.0	25.4	172.1	4.6
Major depressive disorder	110.5	300.3	171.4	5.0	22.8	61.8	170.3	5.3
Dysthymia	26.8	76.8	186.1	0.6	2.6	7.4	186.1	0.6
Bipolar disorder	19.0	53.0	178.4	-0.9	3.9	10.8	178.3	-0.9
Anxiety disorders	124.2	307.2	150.3	1.2	11.5	28.3	149.0	1.3
Eating disorders	-	-	-	-	0.5	1.1	147.5	8.0
Anorexia nervosa	0.5	1.3	158.4	20.3	0.1	0.3	157.5	19.2
Bulimia nervosa	1.7	4.0	144.0	4.4	0.3	0.9	144.8	4.5
Autistic spectrum disorders	-	-	-	-	4.0	8.6	113.0	-1.1
Autism	10.1	21.6	114.3	-1.3	2.5	5.3	113.3	-1.1
Asperger syndrome	15.2	32.4	112.4	-1.6	1.5	3.2	112.0	-1.5
Attention-deficit/hyperactivity disorder	27.4	44.8	63.8	-1.9	0.3	0.5	64.0	-1.6
Conduct disorder	51.0	81.5	59.8	-1.7	6.1	9.8	60.1	-1.1
Idiopathic intellectual disability	102.2	180.0	76.1	-16.9	3.0	8.8	75.4	-16.9
Other mental and substance use disorders	39.7	111.6	181.3	-1.2	3.0	8.3	181.2	-1.0
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	30.5	91.6	200.8	17.2
Diabetes mellitus	181.7	611.6	238.6	23.1	16.5	57.9	251.0	24.1
Acute glomerulonephritis	0.0	0.0	27.4	-32.8	0.0	0.0	27.4	-32.8
Chronic kidney disease	-	-	-	-	2.9	7.2	146.6	-0.0
Chronic kidney disease due to diabetes mellitus	23.5	69.5	198.2	14.7	0.6	1.8	201.4	12.9
Chronic kidney disease due to hypertension	18.9	34.5	85.4	-21.5	0.8	1.7	112.9	-24.7
Chronic kidney disease due to glomerulonephritis	28.1	57.7	105.2	-25.9	0.6	1.0	76.9	-9.3
Chronic kidney disease due to other causes	34.7	98.6	183.6	22.3	1.0	2.7	180.3	22.7
Urinary diseases and male infertility	-	-	-	-	1.3	3.6	174.0	7.9

Appendix Table G.4 - Jordan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.6 (0.6 to 0.7)	1.5 (1.4 to 1.6)	154.9 (128.9 to 182.2)	0.0 (-1.5 to 16.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	155.0 (96.7 to 227.1)	155.0 (12.2 to 30.2)
Urolithiasis	26.5 (16.4 to 43.9)	106.5 (58.8 to 204.3)	285.6 (214.6 to 403.4)	43.1 (20.7 to 80.9)	0.2 (0.1 to 0.3)	0.8 (0.4 to 1.6)	342.4 (268.6 to 497.0)	68.2 (42.3 to 117.2)
Benign prostatic hyperplasia	21.9 (20.0 to 23.7)	51.1 (46.2 to 55.8)	133.9 (105.5 to 160.1)	-1.6 (-12.9 to 9.8)	0.8 (0.5 to 1.1)	1.8 (1.2 to 2.6)	135.9 (107.3 to 164.3)	-1.2 (-13.2 to 10.9)
Male infertility due to other causes	21.3 (14.4 to 30.8)	59.0 (39.3 to 84.9)	178.0 (58.2 to 380.1)	-6.3 (-45.5 to 59.2)	0.1 (0.1 to 0.3)	0.4 (0.2 to 0.9)	177.1 (52.3 to 386.3)	-5.9 (-46.3 to 61.3)
Other urinary diseases	-	-	-	-	0.2 (0.1 to 0.4)	0.5 (0.2 to 0.9)	182.4 (21.5 to 409.1)	6.8 (-5.2 to 104.7)
Gynecological diseases	-	-	-	-	3.3 (2.1 to 4.8)	10.9 (7.0 to 16.2)	231.9 (162.5 to 311.3)	6.4 (-11.4 to 30.2)
Uterine fibroids	40.1 (36.3 to 43.6)	142.0 (128.0 to 154.8)	254.1 (250.5 to 257.6)	0.6 (0.3 to 0.8)	0.7 (0.4 to 1.1)	2.2 (1.3 to 3.6)	236.9 (219.1 to 254.9)	-1.7 (-6.5 to 2.9)
Polycystic ovarian syndrome	52.3 (47.3 to 57.2)	165.2 (149.4 to 181.2)	215.9 (172.1 to 262.5)	0.8 (-11.8 to 14.9)	0.5 (0.2 to 1.0)	1.6 (0.8 to 3.0)	217.4 (174.6 to 265.8)	1.6 (-11.0 to 15.0)
Female infertility due to other causes	5.2 (2.5 to 8.7)	22.6 (13.8 to 31.3)	344.8 (129.8 to 856.4)	0.0 (-22.0 to 246.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.3)	365.4 (112.9 to 774.2)	49.9 (-20.8 to 226.2)
Endometriosis	4.1 (3.6 to 4.8)	14.5 (12.2 to 16.5)	251.6 (180.9 to 325.8)	5.7 (-15.7 to 28.2)	0.4 (0.3 to 0.5)	1.3 (0.9 to 1.9)	250.2 (178.4 to 334.1)	5.7 (-15.8 to 30.8)
Genital prolapse	96.9 (81.5 to 112.8)	306.7 (254.5 to 358.0)	216.6 (142.5 to 302.8)	1.9 (-18.7 to 27.2)	0.3 (0.1 to 0.6)	1.0 (0.4 to 1.8)	218.1 (140.1 to 306.7)	2.0 (-19.2 to 27.3)
Premenstrual syndrome	135.0 (87.4 to 192.0)	463.2 (283.6 to 622.5)	240.3 (74.3 to 529.0)	18.3 (-34.1 to 115.3)	1.1 (0.6 to 1.9)	3.9 (2.0 to 6.3)	241.6 (73.9 to 533.2)	19.0 (-35.1 to 116.1)
Other gynecological diseases	8.5 (5.7 to 11.1)	23.6 (22.0 to 25.1)	176.3 (114.9 to 310.1)	-0.6 (-22.3 to 44.6)	0.2 (0.1 to 0.4)	0.7 (0.5 to 1.0)	174.1 (128.9 to 512.7)	-1.4 (-16.9 to 112.6)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	5.1 (3.4 to 7.4)	9.5 (6.3 to 13.9)	85.8 (69.9 to 102.3)	-0.9 (-11.7 to 8.9)
Thalassemias	1.1 (0.9 to 1.3)	2.1 (1.8 to 2.4)	82.4 (68.9 to 101.5)	1.2 (-6.5 to 12.9)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	82.5 (24.9 to 170.3)	-0.9 (-31.5 to 46.0)
Thalassemia trait	171.5 (157.6 to 186.3)	367.8 (340.0 to 400.3)	114.4 (106.7 to 123.0)	-3.8 (-4.7 to 2.8)	3.8 (2.6 to 5.5)	7.4 (4.9 to 10.8)	94.4 (72.0 to 112.7)	3.3 (-12.3 to 13.9)
Sickle cell disorders	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	61.8 (51.8 to 76.7)	-16.2 (-20.8 to -10.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.5 (55.0 to 83.5)	-15.0 (-21.4 to -8.6)
Sickle cell trait	52.8 (45.6 to 59.0)	87.8 (74.8 to 100.0)	66.4 (51.0 to 77.3)	-23.5 (-30.6 to -18.5)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	66.4 (-12.2 to 107.1)	32.6 (-49.1 to 21.1)
G6PD deficiency	216.2 (190.5 to 241.7)	378.5 (320.3 to 431.1)	75.5 (44.4 to 111.4)	-19.4 (-33.7 to -3.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	49.2 (14.3 to 97.9)	-25.2 (-38.2 to -7.8)
G6PD trait	641.8 (624.3 to 656.7)	1,421.9 (1,376.9 to 1,457.9)	121.5 (113.2 to 129.8)	1.6 (-2.3 to 5.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	85.7 (87.0 to 3,078.2)	8.0 (90.5 to 948.1)
Other hemoglobinopathies and hemolytic anemias	29.2 (23.5 to 33.7)	54.6 (48.1 to 60.5)	87.0 (56.0 to 135.0)	-7.6 (-19.7 to 9.3)	0.8 (0.5 to 1.3)	1.4 (0.9 to 2.2)	69.5 (111.1 to 160.6)	-8.1 (-34.5 to 38.8)
Endocrine, metabolic, blood, and immune disorders	41.2 (35.1 to 46.5)	76.8 (69.7 to 82.7)	86.7 (63.6 to 118.6)	4.5 (-15.4 to 4.9)	1.4 (0.9 to 2.1)	2.6 (1.7 to 3.6)	80.2 (52.1 to 131.4)	-3.9 (-15.3 to 16.5)
Musculoskeletal disorders	-	-	-	-	38.7 (26.9 to 52.5)	110.8 (75.9 to 153.5)	184.3 (145.2 to 240.4)	1.9 (-11.3 to 16.3)
Rheumatoid arthritis	2.8 (2.5 to 3.0)	4.9 (4.4 to 5.3)	77.5 (56.9 to 98.6)	-29.0 (-37.4 to -19.1)	0.7 (0.5 to 0.9)	1.2 (0.8 to 1.6)	77.9 (50.4 to 107.2)	-29.1 (-38.5 to -17.5)
Osteoarthritis	56.0 (52.4 to 59.3)	150.2 (140.5 to 160.2)	167.8 (146.8 to 190.7)	0.5 (-6.8 to 8.2)	3.4 (2.4 to 4.6)	9.2 (6.4 to 12.7)	170.1 (148.0 to 193.3)	0.5 (-6.8 to 8.4)
Low back and neck pain	-	-	-	-	29.7 (20.0 to 41.8)	84.1 (55.7 to 120.6)	106.6 (131.3 to 258.0)	1.0 (-16.9 to 21.2)
Low back pain	186.7 (141.5 to 231.2)	525.1 (418.6 to 654.1)	177.5 (115.0 to 280.1)	1.7 (-22.7 to 30.6)	20.8 (13.2 to 30.6)	58.5 (36.3 to 88.2)	177.9 (115.1 to 282.4)	1.6 (-22.5 to 31.5)
Neck pain	91.3 (76.3 to 107.0)	261.4 (218.8 to 299.8)	187.8 (134.8 to 244.9)	0.6 (-19.6 to 26.2)	8.9 (5.9 to 12.7)	25.5 (17.2 to 36.5)	188.1 (135.5 to 245.7)	0.6 (-19.6 to 25.4)
Gout	1.1 (0.9 to 1.2)	3.2 (2.7 to 3.6)	194.5 (136.1 to 260.4)	4.0 (-16.0 to 25.6)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	197.1 (121.2 to 292.6)	4.4 (-22.4 to 36.2)
Other musculoskeletal disorders	55.0 (41.5 to 68.4)	179.9 (139.6 to 219.2)	226.7 (200.4 to 257.7)	11.5 (4.1 to 19.6)	5.0 (3.1 to 7.4)	16.5 (10.5 to 23.8)	227.8 (200.2 to 251.3)	11.5 (3.8 to 19.7)
Other non-communicable diseases	-	-	-	-	47.2 (31.9 to 68.5)	102.1 (69.5 to 147.2)	116.3 (105.6 to 127.2)	-7.3 (-10.6 to -3.7)
Congenital anomalies	-	-	-	-	3.8 (2.6 to 5.2)	9.2 (6.3 to 12.4)	145.8 (96.7 to 198.3)	20.4 (-2.4 to 44.7)
Neural tube defects	0.9 (0.8 to 1.0)	1.9 (1.6 to 2.2)	115.0 (76.7 to 167.6)	7.8 (-11.5 to 34.1)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	120.4 (57.3 to 213.0)	11.5 (-19.3 to 56.0)
Congenital heart anomalies	18.2 (15.0 to 22.0)	50.7 (42.9 to 61.7)	180.4 (114.1 to 259.3)	38.0 (5.3 to 77.8)	0.6 (0.3 to 1.1)	1.8 (0.8 to 3.1)	186.9 (122.4 to 263.7)	43.3 (11.5 to 81.3)
Orofacial clefts	3.7 (2.8 to 4.8)	9.9 (8.0 to 12.5)	165.7 (90.3 to 287.6)	37.5 (-2.0 to 101.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	10.0 (40.5 to 224.6)	10.0 (-26.7 to 65.1)
Down syndrome	4.7 (3.7 to 5.9)	12.2 (9.8 to 16.6)	158.1 (88.4 to 261.4)	25.8 (-8.3 to 76.6)	0.6 (0.4 to 0.8)	1.5 (1.0 to 2.2)	169.1 (96.2 to 278.3)	31.4 (-4.4 to 84.8)
Turner syndrome	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	148.0 (74.1 to 255.6)	15.7 (-18.4 to 66.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	157.4 (72.3 to 277.8)	16.2 (-22.9 to 69.0)
Klinefelter syndrome	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	112.2 (39.4 to 223.3)	-1.3 (-35.2 to 50.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	151.8 (63.9 to 282.7)	-2.5 (-36.0 to 49.0)
Chromosomal unbalanced rearrangements	4.1 (3.2 to 5.0)	10.8 (8.6 to 13.6)	160.9 (94.0 to 280.3)	21.1 (-5.8 to 84.7)	0.5 (0.3 to 0.7)	1.4 (0.9 to 1.9)	171.1 (97.2 to 257.6)	32.4 (-3.8 to 92.8)
Other congenital anomalies	8.6 (7.2 to 9.9)	17.6 (14.4 to 21.3)	105.3 (75.6 to 141.7)	-11.8 (-25.6 to 4.3)	1.7 (1.1 to 2.8)	3.8 (2.4 to 5.5)	120.3 (39.2 to 219.8)	5.3 (-31.4 to 50.8)
Skin and subcutaneous diseases	-	-	-	-	19.1 (11.7 to 29.2)	41.1 (25.5 to 62.9)	115.8 (93.3 to 139.4)	0.3 (-7.9 to 9.4)
Dermatitis	177.9 (139.6 to 218.4)	421.2 (330.6 to 515.1)	136.7 (126.9 to 147.3)	-0.2 (-0.4 to 0.0)	6.1 (3.6 to 9.2)	13.6 (7.9 to 20.2)	121.3 (105.6 to 135.0)	0.0 (-2.6 to 2.7)
Psoriasis	15.4 (13.1 to 20.3)	42.7 (33.2 to 53.5)	160.0 (149.7 to 170.4)	0.0 (-0.1 to 0.2)	3.5 (0.9 to 2.0)	3.5 (2.2 to 5.1)	158.8 (136.3 to 181.1)	-0.1 (-6.0 to 5.6)
Cellulitis	0.7 (0.6 to 0.8)	1.3 (1.0 to 1.6)	86.2 (58.5 to 121.6)	-13.5 (-23.2 to -1.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	86.5 (45.5 to 143.0)	-12.4 (-30.3 to 8.7)
Pyoderma	2.8 (2.2 to 3.6)	4.9 (3.9 to 6.3)	73.6 (59.6 to 90.0)	-7.8 (-13.3 to -1.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	73.4 (49.0 to 100.8)	-7.8 (-18.6 to 3.4)
Scabies	12.0 (9.9 to 15.1)	25.9 (21.6 to 31.7)	115.3 (58.7 to 185.0)	0.4 (-28.0 to 32.7)	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.1)	114.4 (56.6 to 185.4)	0.3 (-28.2 to 33.0)
Fungal skin diseases	182.0 (135.3 to 230.8)	441.5 (338.0 to 555.0)	142.7 (126.6 to 162.5)	0.6 (-0.8 to 0.4)	1.0 (0.4 to 2.2)	2.5 (1.0 to 5.3)	182.4 (126.5 to 162.5)	-0.6 (-1.5 to 0.3)
Viral skin diseases	81.9 (64.2 to 98.4)	153.9 (115.2 to 190.7)	87.5 (76.3 to 98.8)	0.1 (-1.8 to 1.9)	2.5 (1.5 to 3.9)	4.8 (2.7 to 7.5)	87.3 (74.3 to 99.6)	0.3 (-3.0 to 3.6)
Acne vulgaris	491.1 (375.6 to 621.0)	948.7 (692.5 to 1,169.0)	95.2 (29.3 to 174.2)	1.0 (-30.6 to 39.0)	5.3 (2.5 to 10.2)	10.3 (4.7 to 20.3)	95.4 (28.3 to 174.0)	1.1 (-31.0 to 38.8)
Alopecia areata	4.2 (3.6 to 4.7)	9.9 (8.6 to 11.5)	135.5 (96.1 to 188.8)	-0.6 (-17.4 to 23.4)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	135.8 (93.2 to 195.0)	-0.2 (-18.0 to 24.5)
Pruritus	0.7 (0.4 to 0.9)	1.7 (1.2 to 2.6)	157.5 (62.6 to 419.2)	2.1 (-36.9 to 111.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	158.1 (58.5 to 417.6)	2.0 (-37.3 to 109.5)
Urticaria	22.4 (14.0 to 31.4)	54.5 (35.9 to 73.5)	140.6 (57.6 to 313.1)	5.7 (-28.5 to 60.2)	1.3 (0.7 to 2.2)	3.2 (1.8 to 4.9)	139.7 (54.0 to 317.2)	5.5 (-29.6 to 62.3)
Decubitus ulcer	0.4 (0.4 to 0.5)	0.8 (0.6 to 1.0)	83.1 (46.2 to 142.5)	-17.6 (-35.8 to 17.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	88.2 (47.0 to 151.0)	-16.7 (-37.0 to 19.9)
Other skin and subcutaneous diseases	135.5 (93.1 to 194.6)	349.0 (236.7 to 498.0)	157.6 (134.5 to 183.5)	0.8 (-2.1 to 3.9)	0.8 (0.3 to 1.6)	2.1 (0.9 to 4.2)	158.1 (133.7 to 183.3)	0.8 (-2.3 to 4.2)
Sense organ diseases	-	-	-	-	18.6 (12.8 to 26.3)	37.5 (25.5 to 53.3)	101.5 (90.7 to 114.1)	-14.6 (-20.8 to -10.6)
Glaucoma	7.6 (5.5 to 10.6)	16.9 (13.1 to 21.7)	125.1 (74.3 to 188.6)	-17.9 (-35.8 to 8.8)	0.6 (0.3 to 0.9)	1.2 (0.8 to 1.8)	117.1 (72.8 to 175.0)	-17.1 (-37.1 to 8.7)
Cataract	26.8 (19.2 to 34.7)	46.8 (30.5 to 62.8)	75.4 (45.6 to 100.8)	-22.1 (-34.7 to -12.7)	2.0 (1.2 to 3.0)	3.6 (2.1 to 5.3)	73.3 (50.8 to 103.2)	-20.7 (-31.2 to -8.6)
Macular degeneration	4.6 (2.8 to 7.5)	9.0 (5.8 to 13.6)	98.6 (29.3 to 223.8)	-19.0 (-49.9 to 30.8)	0.3 (0.2 to 0.5)	0.6 (0.3 to 0.9)	89.2 (28.6 to 217.6)	-18.7 (-46.8 to 31.1)
Uncorrected refractive error	258.1 (222.0 to 299.5)	582.7 (504.2 to 661.6)	126.7 (81.4 to 176.1)	6.4 (-24.4 to 10.5)	6.0 (3.6 to 9.1)	12.3 (7.9 to 18.6)	104.7 (80.9 to 132.0)	-14.6 (-25.1 to -4.6)
Age-related and other hearing loss	219.9 (205.4 to 235.8)	517.8 (478.4 to 562.5)	135.5 (123.3 to 147.4)	-9.8 (-13.0 to -6.8)	6.1 (4.1 to 8.6)	12.5 (8.4 to 18.5)	112.7 (93.5 to 132.5)	-11.4 (-16.4 to -6.2)
Other vision loss	20.1 (15.3 to 26.2)	36.2 (28.2 to 47.5)	79.2 (52.5 to 112.7)	1.5 (-37.3 to -13.3)	2.1 (0.9 to 2.3)	2.6 (1.6 to 4.0)	74.9 (45.3 to 108.1)	-29.1 (-39.6 to -14.9)
Other sense organ diseases	78.5 (74.2 to 82.3)	161.1 (153.5 to 169.7)	105.0 (92.4 to 120.9)	0.1 (-5.6 to 6.8)	2.1 (1.3 to 3.1)	4.3 (2.6 to 6.4)	104.9 (89.7 to 122.2)	0.4 (-6.3 to 8.0)
Oral disorders	-	-	-	-	5.7 (3.6 to 8.7)	14.3 (8.7 to 21.7)	148.3 (133.4 to 164.8)	-3.9 (-10.0 to 3.5)
Deciduous caries	388.5 (372.2 to 404.9)	619.4 (591.5 to 646.4)	59.3 (54.2 to 65.5)	0.2 (-3.0 to 4.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.5)	59.6 (49.5 to 70.3)	0.3 (-5.9 to 7.0

Appendix Table G.4 - Jordan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	95.4 (87.7 to 102.6)	229.2 (211.6 to 246.7)	140.0 (117.0 to 168.8)	-7.0 (-15.6 to 3.7)	2.6 (1.7 to 3.6)	6.3 (4.3 to 8.7)	141.5 (117.8 to 171.8)	-7.0 (-15.7 to 3.8)
Other oral disorders	47.4 (44.4 to 50.5)	118.8 (112.3 to 125.6)	150.5 (128.6 to 174.6)	0.1 (-8.4 to 8.4)	1.4 (0.9 to 2.1)	3.5 (2.2 to 5.2)	149.9 (128.5 to 175.5)	-0.0 (-8.3 to 9.0)
Injuries	-	-	-	-	9.5 (7.2 to 12.1)	14.2 (10.3 to 19.0)	48.7 (34.5 to 65.7)	41.4 (-46.9 to -34.8)
Transport injuries	-	-	-	-	3.8 (2.8 to 4.9)	4.7 (3.3 to 6.4)	22.7 (7.3 to 41.1)	-1.9 (-57.5 to -45.3)
Road injuries	-	-	-	-	2.9 (2.1 to 3.7)	1.5 (2.1 to 4.0)	7.2 (-12.4 to 18.5)	53.4 (-63.2 to -51.7)
Pedestrian road injuries	-	-	-	-	0.8 (0.6 to 1.1)	0.8 (0.6 to 1.1)	-4.8 (-19.6 to 14.1)	-58.2 (-63.7 to -51.4)
Cyclist road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	12.0 (-0.3 to 26.0)	-53.9 (-58.6 to -49.0)
Motorcyclist road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-13.2 (-25.2 to 1.8)	-65.9 (-70.4 to -60.8)
Motor vehicle road injuries	-	-	-	-	1.4 (1.0 to 1.8)	1.5 (1.1 to 2.0)	7.2 (-8.8 to 26.6)	-96.5 (-62.5 to -49.3)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.7 (-47.5 to -28.1)	-77.0 (-80.1 to -73.5)
Other transport injuries	-	-	-	-	0.9 (0.7 to 1.2)	1.8 (1.3 to 2.4)	87.2 (66.4 to 111.5)	-35.4 (-42.5 to -26.7)
Unintentional injuries	-	-	-	-	5.3 (4.0 to 6.7)	8.6 (6.3 to 11.5)	62.9 (49.6 to 78.5)	-35.7 (-40.8 to -29.7)
Falls	-	-	-	-	1.8 (1.4 to 2.3)	3.1 (2.2 to 4.3)	72.6 (53.3 to 95.8)	-33.0 (-40.8 to -24.2)
Drowning	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	13.0 (-4.3 to 32.8)	-53.7 (-60.1 to -46.1)
Fire, heat, and hot substances	-	-	-	-	0.5 (0.4 to 0.7)	0.6 (0.5 to 0.8)	12.1 (-3.0 to 30.2)	-56.0 (-61.7 to -49.6)
Poisonings	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	48.4 (19.6 to 84.3)	-39.3 (-49.9 to -27.3)
Exposure to mechanical forces	-	-	-	-	1.6 (1.2 to 2.1)	2.6 (1.8 to 3.4)	59.4 (46.7 to 73.4)	-36.9 (-41.2 to -32.1)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	27.9 (11.9 to 46.4)	53.4 (-58.8 to -47.1)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.6 (80.7 to 144.1)	-16.0 (-25.6 to -4.0)
Other exposure to mechanical forces	-	-	-	-	1.5 (1.1 to 2.0)	2.4 (1.8 to 3.3)	60.3 (47.7 to 74.6)	-36.3 (-40.6 to -31.4)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	163.0 (146.1 to 181.8)	9.7 (2.3 to 17.7)
Animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	38.9 (18.9 to 57.5)	-41.6 (-48.4 to -34.9)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	48.0 (21.1 to 74.9)	-39.8 (-49.4 to -29.7)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	31.3 (10.4 to 52.5)	-43.2 (-50.0 to -35.6)
Foreign body	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	79.1 (61.2 to 98.9)	-26.7 (-33.3 to -19.5)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.5 (-23.2 to 19.3)	-53.1 (-61.3 to -43.0)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	125.1 (101.2 to 157.5)	-9.3 (-17.9 to 0.9)
Foreign body in other body part	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	98.0 (76.7 to 122.5)	-23.2 (-30.9 to -14.2)
Other unintentional injuries	-	-	-	-	0.9 (0.7 to 1.2)	1.7 (1.2 to 2.2)	85.0 (66.8 to 102.9)	-28.6 (-35.0 to -22.4)
Self-harm and interpersonal violence	-	-	-	-	0.4 (0.3 to 0.5)	0.7 (0.5 to 1.0)	72.6 (50.7 to 98.3)	-35.2 (-42.9 to -26.0)
Self-harm	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	39.7 (21.9 to 59.7)	-51.3 (-57.0 to -45.1)
Interpersonal violence	-	-	-	-	0.4 (0.3 to 0.5)	0.7 (0.5 to 0.9)	77.8 (54.7 to 105.9)	-32.0 (-40.6 to -21.8)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	119.7 (94.1 to 147.2)	-15.5 (-24.7 to -5.7)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	114.6 (85.0 to 150.7)	-20.4 (-30.6 to -7.6)
Assault by other means	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.5)	53.5 (31.4 to 80.5)	-41.0 (-49.3 to -30.8)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	6,969.9 (3,918.9 to 13,909.5)	2,829.1 (1,519.6 to 5,997.1)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.3 (66.8 to 165.3)	-9.3 (-28.9 to 17.1)
Collective violence and legal intervention	-	-	-	-	-	0.1 (0.1 to 0.3)	-	-

Appendix Table G.4 - Kazakhstan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,523.3 (1,137.5 to 1,975.9)	1,607.0 (1,191.9 to 2,090.9)	5.4 (2.8 to 8.3)	-3.0 (-5.3 to -0.6)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	157.8 (109.7 to 222.5)	139.4 (97.1 to 190.0)	-11.3 (-21.2 to 0.0)	-7.1 (-17.2 to 4.7)
HIV/AIDS and tuberculosis	-	-	-	-	10.0 (6.7 to 13.6)	13.7 (8.9 to 20.8)	34.0 (12.5 to 88.1)	21.1 (1.9 to 69.5)
Tuberculosis	31.4 (30.0 to 32.7)	35.3 (33.9 to 36.8)	12.2 (8.1 to 16.4)	1.5 (-2.0 to 5.1)	6.6 to 13.0 (0.0 to 15.0)	7.4 to 14.7 (7.4 to 14.7)	12.8 (5.2 to 21.3)	2.3 (-4.4 to 9.5)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.1)	2.8 (0.6 to 8.1)	1,181.6 (56.1 to 32,280.2)	1,065.9 (41.5 to 28,772.1)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.2)	0.3 (0.1 to 1.0)	1,040.4 (22.0 to 0.0)	921.3 (7.4 to 0.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.4)	974.2 (4.3 to nan)	855.3 (-6.2 to nan)
HIV/AIDS resulting in other diseases	2.9 (0.0 to 13.1)	22.1 (6.8 to 56.9)	961.6 (36.9 to 0.0)	875.1 (23.8 to 0.0)	0.3 (0.0 to 1.5)	2.7 (0.5 to 8.0)	1,235.7 (52.2 to nan)	1,099.1 (36.7 to nan)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	24.6 (17.3 to 33.7)	19.0 (13.2 to 25.9)	-22.9 (-27.8 to -17.7)	-20.0 (-25.0 to -14.8)
Diarrheal diseases	57.0 (53.7 to 60.2)	47.6 (44.8 to 50.3)	-16.8 (-23.6 to -9.9)	-11.7 (-18.9 to -4.5)	9.3 (6.3 to 12.8)	7.7 (5.2 to 10.5)	-18.9 (-24.8 to -8.7)	-14.2 (-19.5 to -2.9)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-60.9 (-76.0 to -40.6)	-59.7 (-75.1 to -39.3)
Typhoid fever	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-36.8 (-46.7 to -23.3)	-35.3 (-45.2 to -22.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.8 (-46.8 to -23.2)	-35.3 (-45.2 to -22.3)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.8 (-46.9 to -19.4)	-32.3 (-44.6 to -16.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.8 (-47.0 to -19.2)	-32.3 (-44.6 to -16.6)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-87.2 (-97.9 to -50.0)	-86.8 (-97.9 to -48.5)
Lower respiratory infections	2.7 (2.2 to 3.1)	2.7 (2.3 to 3.1)	1.3 (-24.3 to 32.0)	10.5 (16.0 to 40.5)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	0.6 (-25.8 to 36.2)	9.4 (-17.9 to 45.9)
Upper respiratory infections	367.4 (343.3 to 390.5)	346.7 (325.6 to 372.3)	-6.1 (-14.3 to 3.2)	-5.5 (-13.7 to 3.9)	4.3 (2.5 to 7.2)	4.1 (2.3 to 6.7)	-6.0 (-14.7 to 3.8)	-5.2 (-13.9 to 4.7)
Otitis media	204.5 (189.1 to 221.2)	184.7 (172.3 to 197.9)	-10.0 (-16.7 to -2.7)	-9.6 (-16.0 to -2.3)	4.2 (2.5 to 6.7)	3.7 (2.2 to 5.9)	-11.3 (-18.4 to -3.2)	-9.7 (-16.8 to -1.6)
Meningitis	-	-	-	-	4.1 (2.7 to 5.6)	2.1 (1.4 to 3.0)	-48.2 (-58.9 to -33.3)	-48.6 (-58.8 to -33.9)
Pneumococcal meningitis	16.4 (10.2 to 25.1)	9.0 (5.5 to 14.7)	-46.5 (-55.0 to -28.5)	-49.4 (-57.2 to -32.8)	1.6 (1.1 to 2.2)	0.8 (0.6 to 1.2)	-46.9 (-61.2 to -14.7)	-48.2 (-61.7 to -18.0)
H influenzae type B meningitis	10.7 (4.1 to 21.6)	5.1 (1.7 to 10.8)	-52.7 (-68.1 to -40.0)	-53.7 (-68.0 to -39.3)	1.4 (0.8 to 2.1)	0.7 (0.4 to 1.1)	-50.4 (-69.3 to -24.2)	-49.4 (-68.5 to -23.2)
Meningococcal meningitis	3.5 (1.1 to 8.2)	1.7 (0.5 to 4.2)	-53.5 (-69.3 to -19.8)	-55.4 (-70.0 to -20.7)	0.5 (0.3 to 0.8)	0.2 (0.1 to 0.4)	-57.1 (-70.4 to -7.9)	-57.8 (-70.5 to -9.7)
Other meningitis	5.0 (2.4 to 9.6)	2.9 (1.5 to 5.8)	-41.3 (-55.8 to -26.2)	-43.1 (-56.3 to -28.3)	0.6 (0.4 to 1.0)	0.4 (0.2 to 0.5)	-41.1 (-61.1 to -15.4)	-41.8 (-60.8 to -16.4)
Encephalitis	5.6 (2.5 to 13.8)	4.9 (2.2 to 12.2)	-12.4 (-28.1 to 1.2)	-12.4 (-32.1 to -5.0)	0.7 (0.5 to 0.9)	0.7 (0.5 to 0.9)	-12.0 (-23.9 to 12.9)	-12.0 (-27.3 to 6.4)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-89.2 (-98.8 to -9.8)	-89.3 (-98.7 to -14.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-89.2 (-98.8 to -9.6)	-89.3 (-98.7 to -12.2)
Whooping cough	27.1 (20.7 to 35.3)	1.7 (1.3 to 2.2)	-93.7 (-94.7 to -92.5)	-92.9 (-94.0 to -91.6)	1.4 (0.8 to 2.2)	0.1 (0.0 to 0.1)	-93.7 (-95.1 to -92.0)	-92.9 (-94.4 to -91.0)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.2 (-88.5 to -61.3)	-74.7 (-90.0 to -47.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-68.9 (-88.8 to -58.6)	-73.7 (-90.0 to -45.2)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-73.2 (-79.4 to -66.6)	-69.4 (-76.4 to -61.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-73.2 (-79.4 to -66.6)	-69.4 (-76.6 to -61.8)
Varicella and herpes zoster	10.4 (9.8 to 11.1)	9.6 (9.1 to 10.3)	-8.1 (-15.0 to 0.7)	-2.2 (-10.7 to 8.0)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	2.6 (-17.8 to 31.5)	-2.7 (-22.3 to 24.5)
Neglected tropical diseases and malaria	-	-	-	-	16.5 (8.7 to 30.1)	7.9 (4.6 to 13.8)	-51.0 (-70.1 to -18.2)	-45.7 (-67.1 to -9.8)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.8 (-80.3 to 175.9)	-34.8 (-79.2 to 185.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.6 (-80.2 to 183.9)	-33.4 (-79.1 to 195.1)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.9 (-58.0 to -29.9)	-45.9 (-57.9 to -27.3)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.0 (-54.8 to -4.6)	-33.6 (-52.0 to -1.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.0 (-54.8 to -4.2)	-33.6 (-52.0 to -1.6)
Cutaneous and mucocutaneous leishmaniasis	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-49.8 (-64.0 to -27.9)	-49.0 (-63.9 to -25.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.8 (-64.1 to -27.9)	-49.0 (-63.9 to -25.8)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.3 (0.1 to 0.7)	0.1 (0.0 to 0.2)	-86.3 (-95.1 to -47.7)	-87.3 (-95.2 to -49.8)	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-84.7 (-94.5 to -42.8)	-85.8 (-94.7 to -45.0)
Cystic echinococcosis	0.8 (0.7 to 0.9)	0.8 (0.7 to 0.9)	-0.8 (-14.0 to 12.4)	-7.6 (-17.6 to 2.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-2.1 (-22.4 to 23.0)	-7.6 (-26.5 to 16.1)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.4 (-68.7 to 6.8)	-15.3 (-68.3 to 7.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.4 (-68.7 to 7.0)	-15.3 (-68.3 to 7.4)
Intestinal nematode infections	-	-	-	-	11.6 (5.0 to 23.5)	3.9 (1.6 to 8.9)	-67.5 (-85.3 to -23.6)	-64.3 (-83.7 to -15.5)
Ascariasis	4,106.2 (2,983.8 to 5,804.4)	3,931.0 (2,542.7 to 5,782.7)	-5.1 (-45.8 to 56.1)	-5.5 (-45.8 to 58.3)	11.5 (5.0 to 23.5)	3.8 (1.5 to 8.8)	-67.8 (-85.6 to -23.4)	-64.6 (-83.9 to -15.5)
Trichuriasis	-	-	-	-	7.6 (-58.8 to 168.0)	-2.3 (-62.6 to 143.7)	-	-
Hookworm disease	12.1 (6.8 to 20.3)	13.6 (8.0 to 21.7)	14.4 (-44.5 to 133.3)	4.0 (-49.6 to 112.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-23.1 (-75.3 to 196.4)	-29.1 (-77.8 to 193.7)
Food-borne trematodiasis	29.0 (20.3 to 38.5)	30.4 (21.0 to 41.7)	4.0 (-28.2 to 55.5)	-7.0 (-35.5 to 39.0)	0.7 (0.3 to 1.3)	0.8 (0.3 to 1.4)	7.3 (-27.2 to 65.5)	-6.9 (-36.6 to 41.4)
Other neglected tropical diseases	133.0 (95.2 to 180.0)	107.0 (87.6 to 125.3)	-18.2 (-41.7 to 9.1)	-4.6 (-32.3 to 27.2)	4.1 (2.1 to 7.0)	3.2 (1.9 to 4.8)	-19.0 (-46.1 to 37.4)	-3.3 (-35.9 to 66.0)
Maternal disorders	-	-	-	-	0.4 (0.3 to 0.7)	0.4 (0.2 to 0.6)	-14.7 (-37.5 to 10.6)	-19.7 (-40.5 to 4.6)
Maternal hemorrhage	2.9 (2.6 to 3.3)	3.7 (2.6 to 4.6)	23.8 (-12.6 to 67.0)	19.0 (-15.4 to 59.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	12.6 (-36.7 to 76.7)	7.1 (-40.2 to 67.5)
Maternal sepsis and other maternal infections	12.5 (7.9 to 18.5)	9.2 (5.5 to 14.0)	-27.4 (-38.3 to -13.9)	-34.2 (-45.3 to -21.3)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-37.3 (-59.3 to -3.0)	-41.4 (-61.1 to -8.7)
Maternal hypertensive disorders	1.0 (0.6 to 1.7)	1.0 (0.6 to 1.6)	-1.9 (-13.4 to 12.4)	-7.6 (-18.3 to 7.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-2.7 (-31.3 to 39.3)	-8.2 (-35.1 to 31.9)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.8 (-33.2 to 31.2)	-12.3 (-36.4 to 23.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.8 (-33.3 to 31.3)	-12.3 (-36.4 to 23.8)
Complications of abortion	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-0.8 (-16.3 to 18.9)	-5.3 (-20.3 to 13.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.3 (-51.9 to 90.8)	-5.3 (-52.9 to 84.3)
Other maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-12.8 (-51.4 to 65.8)	-18.0 (-54.2 to 56.3)
Neonatal disorders	-	-	-	-	15.0 (9.8 to 22.3)	22.4 (14.5 to 36.7)	48.9 (-2.0 to 126.7)	53.2 (-1.4 to 134.1)
Preterm birth complications	31.6 (23.3 to 43.4)	68.2 (51.3 to 91.2)	115.6 (76.9 to 156.2)	115.6 (77.9 to 156.5)	3.7 (2.5 to 5.3)	7.8 (5.3 to 10.8)	110.3 (55.7 to 175.6)	114.0 (58.4 to 179.7)
Neonatal encephalopathy due to birth asphyxia and trauma	26.8 (12.2 to 61.9)	22.7 (11.0 to 46.8)	-14.1 (-46.6 to 41.2)	-13.3 (-44.7 to 44.3)	5.7 (3.0 to 9.6)	5.6 (3.2 to 9.0)	-1.4 (-51.4 to 86.4)	3.1 (-50.1 to 95.7)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	179.8 (151.3 to 213.8)	179.8 (178.8 to 248.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	183.6 (125.4 to 248.3)	214.5 (150.1 to 286.4)
Hemolytic disease and other neonatal jaundice	10.5 (5.6 to 17.9)	14.1 (5.5 to 33.8)	23.6 (-57.2 to 253.7)	25.9 (-56.3 to 261.2)	4.1 (2.0 to 6.9)	5.5 (2.1 to 13.7)	27.3 (-57.8 to 257.1)	30.4 (-56.6 to 266.1)
Other neonatal disorders	-	-	-	-	1.5 (0.7 to 3.1)	3.5 (1.6 to 6.9)	123.9 (-3.2 to 483.0)	130.6 (-1.0 to 498.7)
Nutritional deficiencies	-	-	-	-	83.0 (49.9 to 119.2)	68.4 (44.9 to 99.8)	-17.8 (-27.9 to -3.7)	-12.0 (-22.3 to 3.4)
Protein-energy malnutrition	40.4 (16.3 to 79.6)	24.6 (9.8 to 50.0)	-39.7 (-81.8 to 100.3)	-31.8 (-79.3 to 125.8)	31.8 (1.8 to 10.4)	3.1 (1.1 to 6.9)	-37.7 (-82.2 to 101.4)	-31.9 (-79.8 to 127.2)
Iodine deficiency	466.3 (94.7 to 902.2)	272.5 (75.0 to 558.2)	-45.1 (-82.9 to 272.3)	-49.1 (-83.5 to 241.9)	8.4 (1.6 to 18.4)	4.9 (1.3 to 11.1)	-45.2 (-82.5 to 262.7)	-49.2 (-83.4 to 240.4)
Vitamin A deficiency	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-

Appendix Table G-4. Kazakhstan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes								
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	2,191.5 (2,010.5 to 2,247.8)	1,991.2 (1,945.5 to 2,046.2)	-9.9 (-13.0 to -1.4)	-	68.9 (45.2 to 101.9)	60.0 (40.0 to 87.1)	-13.5 (-17.9 to -0.7)	-13.5 (-11.2 to 6.5)
Other nutritional deficiencies	-	-	-	-	0.6 (0.2 to 1.4)	0.5 (0.1 to 1.1)	-0.1 (-0.8 to 0.7)	-0.1 (-0.8 to 0.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	8.3 (5.2 to 13.2)	7.6 (4.6 to 11.9)	-0.7 (-2.3 to 1.4)	-0.7 (-2.2 to 2.8)
Sexually transmitted diseases excluding HIV	-	-	-	-	4.1 (2.3 to 7.0)	1.5 (2.4 to 7.2)	-2.6 (-11.7 to 16.8)	-2.6 (-16.6 to 9.3)
Syphilis	0.4 (0.4 to 0.5)	0.3 (0.3 to 0.4)	-20.5 (-33.2 to -5.1)	-27.9 (-38.8 to -14.0)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-0.1 (-0.8 to 0.7)	-0.1 (-0.8 to 0.7)
Chlamydial infection	506.8 (436.1 to 571.5)	545.8 (483.9 to 603.8)	7.4 (-8.9 to 28.0)	1.9 (-13.3 to 21.1)	2.2 (1.2 to 3.7)	2.3 (1.3 to 3.7)	5.5 (-15.0 to 29.5)	-1.7 (-19.2 to 22.3)
Gonococcal infection	103.1 (79.6 to 122.7)	96.0 (78.9 to 118.8)	-7.7 (-30.6 to 27.5)	-10.1 (-32.6 to 24.0)	0.6 (0.3 to 1.0)	0.6 (0.3 to 0.9)	-0.5 (-3.9 to 30.8)	-11.6 (-37.0 to 27.2)
Trichomoniasis	230.5 (166.6 to 326.7)	215.8 (161.8 to 277.2)	-5.4 (-37.8 to 35.9)	-11.5 (-41.0 to 26.5)	0.7 (0.2 to 0.9)	0.4 (0.1 to 0.8)	-0.3 (-4.1 to 42.1)	-11.0 (-44.5 to 32.2)
Genital herpes	2,516.1 (2,421.3 to 2,594.7)	2,852.1 (2,739.7 to 2,927.0)	12.1 (7.3 to 37.8)	1.6 (-5.7 to 3.2)	0.7 (0.2 to 1.6)	0.7 (0.2 to 1.8)	1.3 (3.6 to 18.4)	-1.2 (-7.1 to 4.8)
Other sexually transmitted diseases	5.0 (3.7 to 6.5)	4.7 (3.5 to 6.1)	-7.0 (-17.5 to 8.4)	-17.0 (-26.9 to -3.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-0.4 (-26.0 to 38.4)	-0.4 (-30.4 to 25.4)
Hepatitis	-	-	-	-	1.5 (1.0 to 2.2)	1.3 (0.8 to 1.9)	-0.2 (-2.7 to 0.1)	-0.2 (-3.2 to 6.3)
Hepatitis A	19.0 (18.4 to 19.7)	16.2 (15.6 to 16.7)	-15.3 (-15.3 to -15.3)	-9.5 (-10.0 to -9.0)	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.6)	-0.1 (-1.7 to 0.4)	-0.1 (-1.9 to 6.7)
Hepatitis B	1,888.2 (1,489.6 to 1,888.2)	1,210.7 (1,027.4 to 1,392.8)	-35.4 (-42.1 to -22.0)	-32.2 (-44.3 to -16.3)	0.8 (0.5 to 1.3)	0.7 (0.4 to 1.0)	-0.1 (-3.0 to 3.9)	-0.1 (-4.5 to 6.5)
Hepatitis C	1,275.2 (1,150.1 to 1,389.8)	1,052.7 (955.1 to 1,149.3)	-17.5 (-27.8 to -6.3)	-18.0 (-34.8 to -15.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-0.1 (-40.2 to 4.4)	-0.1 (-4.1 to 1.8)
Hepatitis E	1.7 (1.5 to 1.9)	1.8 (1.6 to 1.9)	5.9 (-9.6 to 19.6)	2.7 (-14.9 to 13.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	4.9 (-26.2 to 45.2)	-2.2 (-30.3 to 33.4)
Leprosy	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-
Other infectious diseases	90.1 (72.5 to 115.2)	74.9 (58.8 to 90.1)	-16.6 (-40.0 to 10.7)	-4.1 (-31.1 to 27.0)	2.7 (1.5 to 4.4)	2.1 (1.2 to 3.2)	-0.6 (-5.7 to 17.1)	-0.6 (-4.7 to 38.0)
Non-communicable diseases	-	-	-	-	1,228.7 (914.7 to 1,592.2)	1,362.3 (1,013.0 to 1,771.3)	11.0 (7.6 to 14.4)	11.0 (-1.8 to 3.9)
Neoplasms	-	-	-	-	12.9 (9.5 to 16.8)	17.4 (12.4 to 22.6)	33.0 (16.5 to 63.4)	15.9 (2.1 to 42.7)
Esophageal cancer	4.1 (2.8 to 5.2)	3.0 (2.1 to 4.4)	-27.1 (-55.0 to 25.8)	-42.0 (-61.1 to 5.7)	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.7)	-0.1 (-5.4 to 26.1)	-0.1 (-6.0 to 6.1)
Stomach cancer	9.3 (8.0 to 10.5)	7.2 (6.1 to 8.6)	-22.1 (-37.6 to 0.2)	-34.1 (-46.5 to -13.6)	1.2 (0.8 to 1.6)	0.9 (0.6 to 1.2)	-0.3 (-3.9 to 3.8)	-0.3 (-4.8 to 17.2)
Liver cancer	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	5.0 (9.0 to 71.6)	7.0 (20.5 to 48.5)
Liver cancer due to hepatitis B	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	11.7 (-33.1 to 88.9)	-4.8 (-42.6 to 59.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	9.7 (-27.8 to 64.4)	-6.4 (-38.0 to 38.8)
Liver cancer due to hepatitis C	0.1 (0.1 to 0.2)	0.5 (0.3 to 0.7)	216.9 (99.6 to 413.9)	174.4 (68.9 to 342.6)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	201.8 (106.7 to 334.5)	159.6 (79.3 to 275.1)
Liver cancer due to alcohol use	0.4 (0.3 to 0.6)	0.1 (0.3 to 0.6)	-75.0 (-35.9 to 78.6)	-6.8 (-42.1 to 55.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	2.8 (-28.5 to 62.8)	-10.3 (-37.9 to 38.8)
Liver cancer due to other causes	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-50.0 (-65.6 to 18.9)	-36.4 (-70.4 to 4.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-0.3 (-6.3 to 1.9)	47.1 (-6.8 to 12.5)
Larynx cancer	2.1 (1.5 to 2.8)	1.8 (1.3 to 2.7)	-15.4 (-44.5 to 32.8)	-27.6 (-52.3 to 10.6)	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.4)	0.2 (-4.2 to 47.5)	-14.9 (-50.4 to 23.3)
Tracheal, bronchus and lung cancer	8.4 (7.3 to 9.5)	6.9 (5.8 to 8.4)	-18.6 (-33.6 to 3.3)	-29.2 (-42.1 to -10.2)	1.4 (1.0 to 1.8)	1.1 (0.8 to 1.5)	-0.3 (-3.5 to 1.2)	-0.6 (-4.3 to 13.0)
Breast cancer	22.3 (18.8 to 25.6)	60.7 (54.6 to 67.1)	272.2 (129.1 to 231.4)	143.8 (107.7 to 200.5)	1.7 (1.2 to 2.2)	3.7 (2.6 to 5.0)	119.0 (78.7 to 170.9)	93.4 (58.4 to 136.7)
Cervical cancer	13.2 (9.7 to 15.9)	13.9 (10.2 to 18.4)	4.9 (-22.1 to 46.0)	4.0 (-35.2 to 18.6)	1.1 (0.7 to 1.4)	1.0 (0.7 to 1.5)	1.1 (-24.5 to 43.9)	-16.2 (-37.6 to 16.8)
Uterine cancer	6.8 (3.2 to 9.5)	5.0 (3.1 to 10.2)	-26.9 (-60.3 to 99.6)	-37.9 (-65.6 to 62.9)	0.5 (0.2 to 0.7)	0.3 (0.2 to 0.7)	-0.3 (-60.2 to 99.8)	-47.7 (-65.6 to 65.7)
Prostate cancer	6.2 (4.9 to 7.7)	12.9 (9.6 to 18.0)	101.9 (52.7 to 217.3)	74.9 (31.0 to 167.8)	0.6 (0.4 to 0.8)	1.3 (0.8 to 2.1)	136.5 (66.3 to 319.2)	105.0 (45.8 to 256.1)
Colon and rectum cancer	13.4 (12.1 to 14.7)	22.0 (19.2 to 25.3)	62.4 (38.0 to 95.5)	41.4 (19.5 to 69.2)	1.2 (0.9 to 1.6)	1.2 (1.4 to 2.5)	58.0 (33.4 to 90.2)	38.2 (17.0 to 66.6)
Lip and oral cavity cancer	3.8 (2.8 to 5.1)	4.8 (3.3 to 6.2)	25.6 (-11.3 to 74.2)	6.4 (-24.2 to 47.4)	0.4 (0.2 to 0.5)	0.5 (0.3 to 0.7)	24.9 (9.8 to 71.3)	7.0 (-22.1 to 44.1)
Nasopharynx cancer	0.9 (0.6 to 1.1)	0.4 (0.3 to 0.6)	-56.8 (-70.3 to -25.2)	-43.8 (-75.0 to -36.6)	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-6.2 to 29.2)	-0.1 (-7.4 to -39.8)
Other pharynx cancer	1.0 (0.6 to 1.5)	1.0 (0.7 to 1.5)	-3.3 (-43.8 to 61.8)	-18.8 (-52.9 to 33.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-0.1 (-3.8 to 54.0)	-19.2 (-47.9 to 27.8)
Gallbladder and biliary tract cancer	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-18.8 (-47.4 to 29.7)	-31.6 (-56.4 to 10.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-0.1 (-49.9 to 28.0)	-33.2 (-58.1 to 9.1)
Pancreatic cancer	0.1 (0.1 to 0.2)	1.0 (0.8 to 1.2)	598.2 (444.4 to 816.1)	507.8 (379.8 to 697.3)	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	534.1 (416.0 to 705.6)	458.6 (342.7 to 592.6)
Malignant skin melanoma	4.9 (3.8 to 6.3)	6.0 (4.6 to 8.4)	21.4 (-5.4 to 71.9)	21.4 (-19.3 to 44.9)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	34.3 (8.5 to 67.1)	32.1 (-22.7 to 41.7)
Non-melanoma skin cancer	5.8 (4.5 to 7.2)	8.8 (6.8 to 10.6)	50.1 (11.0 to 108.1)	27.4 (-7.0 to 78.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	87.4 (41.3 to 150.1)	57.7 (17.1 to 114.2)
Ovarian cancer	2.0 (1.6 to 2.5)	3.7 (2.7 to 5.2)	83.5 (36.4 to 166.6)	52.5 (15.8 to 122.9)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	78.4 (27.4 to 170.8)	49.3 (6.4 to 125.3)
Testicular cancer	0.8 (0.5 to 1.5)	1.2 (0.8 to 2.1)	48.1 (-12.5 to 130.2)	32.5 (-18.9 to 102.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.1 (-15.9 to 128.8)	0.1 (-21.5 to 97.6)
Kidney cancer	3.9 (2.3 to 3.6)	6.4 (7.0 to 10.1)	65.3 (128.0 to 276.1)	39.8 (100.2 to 225.1)	0.3 (0.1 to 0.3)	0.5 (0.4 to 0.9)	61.0 (117.8 to 263.6)	36.2 (89.0 to 211.8)
Bladder cancer	0.5 (3.2 to 4.7)	2.3 (5.1 to 8.2)	33.0 (33.0 to 107.7)	13.5 (13.5 to 73.0)	0.2 (0.2 to 0.5)	0.7 (0.3 to 0.7)	28.6 (28.6 to 102.8)	10.3 (10.3 to 70.8)
Brain and nervous system cancer	0.5 (0.4 to 0.9)	2.3 (1.1 to 3.0)	471.1 (44.2 to 631.1)	456.8 (39.4 to 606.0)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.4)	475.2 (40.1 to 627.0)	448.1 (32.5 to 581.2)
Thyroid cancer	4.8 (3.6 to 6.9)	9.4 (5.8 to 12.4)	105.2 (6.7 to 183.7)	82.2 (-6.1 to 151.9)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.8)	102.1 (4.5 to 184.1)	79.5 (-7.9 to 149.5)
Mesothelioma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-62.1 (-25.8 to 18.2)	-21.2 (-36.9 to -1.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.1 (-24.6 to 18.2)	-0.1 (-35.9 to 1.1)
Hodgkin lymphoma	1.4 (0.6 to 2.1)	1.9 (1.1 to 2.7)	31.3 (-16.2 to 108.9)	27.6 (-17.2 to 102.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	26.3 (-18.7 to 103.8)	21.9 (-19.3 to 93.9)
Non-Hodgkin lymphoma	4.2 (3.1 to 5.2)	5.5 (4.1 to 7.2)	29.7 (-0.5 to 79.1)	21.4 (-5.5 to 62.8)	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	28.1 (-1.4 to 75.8)	18.6 (-7.3 to 60.0)
Multiple myeloma	0.4 (0.3 to 0.6)	0.5 (0.4 to 0.8)	19.8 (-28.0 to 126.9)	0.5 (-40.1 to 90.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	15.4 (-31.3 to 118.6)	-1.1 (-43.6 to 86.5)
Leukemia	6.2 (5.2 to 7.4)	9.5 (5.5 to 8.2)	53.2 (-12.0 to 37.1)	13.2 (-7.8 to 41.1)	0.6 (0.4 to 0.9)	0.7 (0.5 to 1.0)	16.6 (-6.6 to 47.8)	16.1 (-7.2 to 46.3)
Other neoplasms	10.9 (5.9 to 15.0)	10.5 (6.5 to 18.5)	-3.8 (-51.5 to 165.6)	-41.1 (-57.0 to 141.6)	0.8 (0.4 to 1.3)	0.7 (0.4 to 1.4)	-0.1 (-54.5 to 146.8)	-0.1 (-60.1 to 124.3)
Cardiovascular diseases	-	-	-	-	16.1 (10.9 to 22.4)	17.0 (11.5 to 23.6)	5.7 (-16.0 to 33.5)	-7.8 (-26.1 to 15.6)
Rheumatic heart disease	2.1 (1.9 to 2.4)	2.3 (2.0 to 2.7)	10.0 (-11.2 to 32.4)	-5.2 (-23.3 to 15.1)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	13.1 (-13.3 to 48.6)	-2.9 (-25.1 to 28.2)
Ischemic heart disease	131.5 (111.1 to 160.4)	140.2 (124.4 to 160.4)	6.8 (-16.4 to 32.7)	8.8 (-25.0 to 16.3)	6.5 (4.2 to 9.8)	6.6 (4.5 to 9.3)	1.4 (-24.5 to 35.6)	-0.1 (-30.9 to 19.1)
Cerebrovascular disease	-	-	-	-	1.8 (1.3 to 2.5)	2.1 (1.4 to 2.8)	14.1 (-28.3 to 39.9)	-2.6 (-23.3 to 18.2)
Ischemic stroke	6.8 (5.8 to 7.9)	7.7 (6.5 to 8.8)	14.1 (-9.9 to 39.8)	-3.7 (-23.3 to 20.3)	1.0 (0.7 to 1.5)	1.2 (0.8 to 1.6)	14.4 (-11.4 to 44.0)	-3.4 (-24.9 to 22.7)
Hemorrhagic stroke	5.1 (4.3 to 6.1)	5.8 (4.8 to 6.8)	13.8 (-13.2 to 44.7)	-2.2 (-26.1 to 25.2)	0.8 (0.5 to 1.1)	0.9 (0.6 to 1.2)	13.4 (-14.7 to 48.0)	-2.6 (-27.0 to 27.0)
Hypertensive heart disease	16.7 (14.7 to 18.7)	19.5 (17.3 to 21.6)	16.3 (-1.5 to 37.6)	0.1 (-15.5 to 19.1)	1.8 (1.2 to 2.5)	2.1 (1.5 to 3.0)	17.1 (-1.4 to 40.7)	0.6 (-15.9 to 21.2)
Cardiomyopathy and myocarditis	9.7 (8.3 to 11.0)	11.9 (10.8 to 13.0)	22.9 (4.8 to 46.0)	5.8 (-9.4 to 28.3)	1.0 (0.7 to 1.3)	1.2 (0.8 to 1.7)	1.2 (-3.3 to 50.8)	8.4 (-11.1 to 32.2)
Atrial fibrillation and flutter	0.7 (0.5 to 0.9)	2.6 (1.9 to 3.4)	292.2 (114.8 to 422.0)	213.9 (80.6 to 317.2)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	278.7 (101.8 to 476.6)	205.4 (69.2 to 349.3)
Peripheral vascular disease	302.3 (201.2 to 390.7)	403.0 (295.9 to 523.0)	34.8 (-11.6 to 106.3)	11.8 (-24.2 to 70.1)	0.4 (0.1 to 0.7)	0.3 (0.1 to 0.6)	-0.9 (-56.2 to 58.0)	-25.8 (-59.2 to 45.1)
Endocarditis	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-36.3 (-54.3 to -6.3)	-43.9 (-61.1 to -16.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-0.1 (-58.5 to 1.3)	-0.1 (-64.6 to 6.5)
Other cardiovascular and circulatory diseases	60.3 (33.4 to 100.4)	60.2 (34.7 to 94.6)	-0.2 (-52.4 to 111.2)	-1.9 (-60.3 to 81.6)	4.3 (2.1 to 7.6)	4.2 (2.0 to 7.3)	-0.1 (-52.0 to 110.1)	-0.1 (-60.0 to 82.9)
Chronic respiratory diseases	-	-	-	-	41.1 (27.0 to 57.5)	44.1 (29.7 to 61.0)	7.8 (-9.8 to 30.4)	-2.2 (-19.7 to 14.8)
Chronic obstructive pulmonary disease	541.9 (517.2 to 567.0)	620.6 (591.0 to 650.2)	14.1 (10.9 to 17.3)	-0.7 (-3.4 to 2.0)	33.8 (21.6 to 48.2)	36.1 (23.5 to 50.3)	7.2 (-10.6 to 37.8)	-6.

Appendix Table G.4 - Kazakhstan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	6.4 (3.5 to 9.2)	-
Silicosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	11.7 (6.8 to 17.2)	-2.7 (-7.1 to 1.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.8 (6.7 to 17.3)	-2.8 (-7.3 to 1.7)
Asbestosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	17.4 (13.3 to 21.8)	1.5 (-1.9 to 5.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.8 (13.5 to 22.6)	1.6 (-1.9 to 5.8)
Coal workers pneumoconiosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	18.0 (13.4 to 22.2)	0.9 (-2.9 to 4.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.3 (13.6 to 22.5)	1.0 (-2.7 to 4.5)
Other pneumoconiosis	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	-6.0 (-9.7 to -1.9)	-17.8 (-21.0 to -14.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.7 (-9.7 to -14.5)	47.7 (-21.0 to -14.1)
Asthma	135.7 (97.5 to 175.8)	149.0 (121.6 to 179.5)	7.4 (-21.1 to 75.3)	1.4 (-23.2 to 55.8)	6.0 (3.4 to 9.2)	6.5 (4.1 to 9.7)	6.1 (-22.5 to 76.0)	1.4 (-24.1 to 56.3)
Interstitial lung disease and pulmonary sarcoidosis	1.5 (1.1 to 1.9)	1.6 (1.3 to 2.2)	9.7 (-24.4 to 64.4)	-2.4 (-32.1 to 43.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	10.2 (-23.3 to 62.8)	-2.4 (-31.7 to 42.3)
Other chronic respiratory diseases	-	-	-	-	1.1 (0.6 to 1.8)	1.1 (0.7 to 1.9)	6.4 (-25.4 to 45.1)	-7.3 (-34.4 to 25.7)
Cirrhosis	-	-	-	-	1.6 (1.1 to 2.2)	2.6 (1.8 to 3.6)	63.0 (46.7 to 81.5)	44.4 (30.4 to 60.1)
Cirrhosis due to hepatitis B	4.1 (3.3 to 4.8)	6.5 (5.0 to 7.7)	57.4 (14.8 to 100.6)	39.3 (1.8 to 77.1)	0.7 (0.4 to 1.0)	1.1 (0.7 to 1.6)	57.4 (13.0 to 106.7)	39.3 (-0.2 to 84.0)
Cirrhosis due to hepatitis C	2.3 (1.7 to 2.9)	3.8 (2.8 to 5.0)	65.7 (10.9 to 150.4)	40.1 (5.3 to 111.4)	0.4 (0.2 to 0.6)	0.6 (0.4 to 1.0)	66.6 (8.0 to 168.7)	41.5 (7.6 to 125.2)
Cirrhosis due to alcohol use	1.7 (1.3 to 2.3)	3.0 (2.0 to 3.9)	71.0 (14.2 to 154.3)	43.6 (-3.1 to 108.5)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	71.3 (8.5 to 173.6)	44.3 (-7.9 to 122.5)
Cirrhosis due to other causes	1.5 (1.1 to 1.9)	2.5 (2.0 to 3.1)	68.8 (30.8 to 131.8)	70.1 (31.3 to 132.8)	0.3 (0.1 to 0.4)	0.4 (0.3 to 0.6)	66.9 (14.2 to 148.8)	70.6 (15.1 to 149.3)
Digestive diseases	-	-	-	-	13.0 (9.3 to 17.4)	15.6 (11.1 to 20.5)	19.7 (11.6 to 28.0)	5.8 (-1.6 to 12.8)
Peptic ulcer disease	111.8 (103.8 to 119.2)	92.2 (88.0 to 96.7)	-17.9 (-23.0 to -12.4)	-28.7 (-33.4 to -23.0)	3.3 (2.3 to 4.7)	2.8 (1.8 to 3.9)	-16.7 (-29.0 to -7.2)	-26.1 (-35.7 to -18.5)
Gastritis and duodenitis	25.2 (22.2 to 27.9)	25.5 (21.9 to 29.5)	0.6 (-14.1 to 19.5)	2.2 (-12.1 to 20.2)	1.5 (1.0 to 2.2)	1.5 (1.0 to 2.2)	-3.7 (-21.9 to 32.3)	3.0 (-15.5 to 37.4)
Appendicitis	1.6 (1.3 to 1.9)	1.4 (1.2 to 1.7)	-9.4 (-28.7 to 17.0)	-5.7 (-25.8 to 22.7)	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.7)	-9.5 (-36.1 to 33.2)	-5.5 (-33.1 to 38.5)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.2)	15.6 (-2.9 to 56.9)	11.9 (-1.7 to 44.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	17.2 (-11.5 to 70.5)	15.4 (-13.2 to 57.5)
Inguinal, femoral, and abdominal hernia	58.3 (51.4 to 66.4)	59.1 (51.3 to 69.0)	0.9 (-16.0 to 22.6)	-12.0 (-27.7 to 8.8)	0.6 (0.3 to 1.1)	0.6 (0.3 to 1.2)	1.5 (-16.5 to 23.2)	-11.0 (-27.5 to 8.7)
Inflammatory bowel disease	18.7 (17.9 to 19.5)	28.9 (27.8 to 30.0)	54.4 (45.7 to 62.7)	35.0 (27.5 to 42.1)	4.0 (2.7 to 5.4)	6.1 (4.2 to 8.4)	54.5 (42.1 to 67.8)	35.5 (24.8 to 46.8)
Vascular intestinal disorders	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	18.6 (-21.6 to 118.6)	7.4 (-33.6 to 115.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.4 (-27.3 to 127.0)	5.5 (-39.9 to 118.9)
Gallbladder and biliary diseases	15.7 (13.8 to 17.6)	14.7 (12.9 to 16.7)	-6.5 (-22.0 to 10.7)	-18.8 (-32.9 to -5.0)	1.6 (1.1 to 2.3)	1.5 (1.0 to 2.1)	-6.0 (-22.8 to 11.9)	-48.7 (-43.0 to -3.2)
Pancreatitis	3.8 (3.6 to 4.0)	6.4 (6.1 to 6.7)	69.8 (59.3 to 82.3)	46.5 (37.5 to 57.4)	1.1 (0.7 to 1.5)	1.9 (1.3 to 2.6)	70.8 (41.1 to 98.1)	70.8 (28.6 to 70.3)
Other digestive diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.7 (0.4 to 0.9)	113.8 (63.8 to 161.4)	87.7 (44.3 to 128.4)
Neurological disorders	-	-	-	-	137.3 (92.3 to 190.8)	146.6 (103.7 to 220.8)	157.1 (111.1 to 207.1)	14.6 (-4.9 to 19.2)
Alzheimer disease and other dementias	85.7 (74.5 to 96.9)	95.5 (83.4 to 107.7)	10.9 (-7.1 to 32.3)	0.1 (-17.2 to 20.3)	12.4 (8.6 to 16.3)	13.8 (9.8 to 18.3)	11.6 (-4.4 to 33.2)	1.2 (-17.5 to 22.3)
Parkinson disease	5.5 (4.6 to 6.3)	6.4 (5.5 to 7.4)	17.2 (11.0 to 21.6)	0.7 (-4.8 to 4.7)	0.7 (0.4 to 0.9)	0.8 (0.5 to 1.1)	17.9 (3.4 to 35.0)	1.1 (-11.1 to 15.2)
Epilepsy	61.5 (41.8 to 81.4)	62.4 (41.7 to 83.8)	1.0 (-39.0 to 65.0)	-0.9 (-40.0 to 61.7)	19.3 (11.3 to 29.1)	21.6 (12.4 to 32.7)	11.2 (-31.6 to 88.1)	9.8 (-32.6 to 85.4)
Multiple sclerosis	4.3 (3.9 to 4.7)	6.3 (5.8 to 6.9)	45.3 (27.8 to 64.5)	25.5 (10.4 to 41.9)	1.4 (1.0 to 1.9)	2.1 (1.4 to 2.7)	43.9 (17.0 to 75.6)	24.5 (1.9 to 50.3)
Migraine	2,402.9 (2,140.9 to 2,696.8)	2,534.5 (2,231.6 to 2,784.9)	5.1 (-10.2 to 24.4)	1.0 (-16.0 to 14.6)	5.1 (4.4 to 123.2)	86.6 (51.1 to 130.0)	-1.1 (-10.3 to 24.4)	-1.1 (-15.9 to 15.7)
Tension-type headache	3,547.8 (3,289.5 to 3,805.3)	3,909.9 (3,462.2 to 4,369.8)	9.5 (-4.9 to 25.7)	1.5 (-11.9 to 16.6)	5.4 (2.6 to 9.5)	5.9 (2.8 to 10.5)	9.4 (-4.7 to 27.2)	1.4 (-11.6 to 17.7)
Medication overuse headache	96.0 (65.0 to 128.1)	163.2 (111.9 to 215.7)	70.5 (37.8 to 100.9)	50.4 (22.9 to 77.1)	15.1 (8.7 to 23.3)	25.6 (14.5 to 39.4)	70.6 (38.2 to 102.2)	50.5 (22.9 to 78.6)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.4 (-21.9 to 43.7)	-0.1 (-25.8 to 36.3)	0.6 (0.4 to 0.8)	0.7 (0.5 to 1.0)	23.2 (-11.4 to 57.9)	10.6 (-20.6 to 43.1)
Mental and substance use disorders	-	-	-	-	338.9 (243.8 to 443.6)	357.6 (257.2 to 464.8)	5.6 (-3.3 to 10.0)	-1.0 (-3.3 to 1.0)
Schizophrenia	46.1 (42.2 to 49.7)	52.6 (48.1 to 56.6)	13.7 (9.5 to 18.0)	-0.2 (-3.7 to 3.6)	29.7 (21.8 to 35.9)	33.8 (24.8 to 41.1)	14.0 (6.9 to 20.3)	0.2 (-5.4 to 5.7)
Alcohol use disorders	183.4 (164.2 to 204.4)	186.8 (163.7 to 213.3)	1.3 (-6.3 to 10.1)	-8.3 (-15.2 to -0.4)	18.4 (12.0 to 26.2)	18.7 (11.9 to 26.7)	1.3 (-7.9 to 11.1)	-8.3 (-16.2 to 0.7)
Drug use disorders	-	-	-	-	20.9 (14.6 to 27.9)	22.1 (15.1 to 29.8)	5.4 (-5.5 to 17.8)	-0.6 (-10.9 to 10.8)
Opioid use disorders	19.7 (14.5 to 25.0)	21.7 (16.8 to 27.2)	9.9 (-1.2 to 22.9)	0.8 (-9.1 to 11.7)	8.2 (5.2 to 11.5)	9.1 (5.9 to 12.7)	10.2 (-4.1 to 27.4)	1.5 (-10.9 to 14.9)
Cocaine use disorders	12.6 (11.2 to 14.1)	12.9 (11.2 to 14.7)	1.5 (-15.6 to 20.7)	1.5 (-21.4 to 11.9)	1.8 (1.1 to 2.6)	1.8 (1.1 to 2.6)	5.2 (-20.4 to 25.8)	5.5 (-25.2 to 17.7)
Amphetamine use disorders	31.4 (28.8 to 34.3)	32.9 (30.4 to 35.2)	4.7 (-6.4 to 17.0)	0.8 (-9.6 to 12.3)	4.2 (2.6 to 6.1)	4.3 (2.8 to 6.4)	4.1 (-11.7 to 21.6)	0.3 (-14.8 to 17.1)
Cannabis use disorders	29.1 (26.9 to 31.4)	29.3 (27.1 to 31.7)	0.3 (-0.4 to 1.1)	-0.2 (-0.2 to 0.1)	0.8 (0.6 to 1.2)	0.9 (0.6 to 1.3)	0.4 (-12.0 to 16.0)	-0.3 (-12.6 to 15.4)
Other drug use disorders	-	-	-	-	6.1 (3.8 to 8.8)	6.1 (3.8 to 8.9)	2.7 (-24.4 to 37.2)	-1.9 (-27.8 to 30.8)
Depressive disorders	-	-	-	-	142.5 (86.9 to 185.1)	142.5 (93.8 to 200.3)	6.3 (3.1 to 13.2)	0.2 (-4.9 to 3.9)
Major depressive disorder	537.6 (431.7 to 627.4)	580.1 (458.1 to 687.1)	7.7 (1.5 to 13.3)	-0.4 (-6.0 to 4.2)	110.7 (71.2 to 157.3)	119.0 (76.3 to 170.2)	7.4 (1.3 to 13.3)	-0.3 (-6.0 to 4.7)
Dysthymia	215.6 (178.2 to 251.5)	244.0 (202.4 to 284.6)	12.7 (11.1 to 14.9)	-0.1 (-0.3 to 0.0)	20.8 (13.4 to 30.4)	23.5 (15.2 to 34.2)	12.9 (9.4 to 16.1)	0.2 (-2.3 to 2.4)
Bipolar disorder	107.2 (92.4 to 121.6)	118.4 (103.2 to 133.4)	9.9 (3.5 to 17.6)	-0.5 (-6.0 to 5.6)	21.9 (13.4 to 32.8)	24.1 (14.9 to 36.0)	9.9 (2.1 to 18.6)	-0.3 (-6.9 to 7.2)
Anxiety disorders	475.5 (388.1 to 570.5)	502.2 (405.7 to 599.1)	5.0 (2.4 to 7.9)	5.0 (-0.2 to 0.0)	44.0 (29.6 to 63.6)	46.2 (30.9 to 67.2)	6.3 (1.0 to 8.9)	0.2 (-2.6 to 2.8)
Eating disorders	-	-	-	-	4.1 (2.5 to 6.4)	4.2 (2.5 to 6.5)	0.8 (-7.5 to 9.2)	1.4 (-6.8 to 9.7)
Anorexia nervosa	1.3 (1.0 to 1.7)	1.4 (1.1 to 1.8)	6.6 (-3.3 to 18.3)	8.8 (-0.9 to 20.4)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	7.2 (-23.0 to 46.8)	9.7 (-21.1 to 50.3)
Bulimia nervosa	18.1 (12.9 to 24.3)	18.2 (12.8 to 24.7)	0.1 (-2.6 to 2.8)	0.5 (0.4 to 0.5)	3.8 (2.3 to 6.0)	3.9 (2.3 to 6.1)	0.3 (-8.7 to 9.3)	0.7 (-7.8 to 8.9)
Autistic spectrum disorders	-	-	-	-	19.1 (13.1 to 26.0)	19.2 (13.3 to 26.2)	0.2 (-3.0 to 3.6)	0.3 (-2.8 to 3.4)
Autism	48.9 (46.3 to 51.4)	49.3 (46.7 to 51.9)	0.5 (0.2 to 0.9)	0.1 (0.1 to 0.2)	12.1 (8.1 to 16.7)	12.2 (8.2 to 16.7)	0.3 (-4.5 to 5.1)	0.4 (-4.3 to 4.8)
Asperger syndrome	69.7 (65.3 to 73.9)	70.1 (65.7 to 74.8)	0.3 (-0.2 to 0.8)	0.2 (0.1 to 0.2)	7.0 (4.9 to 9.8)	7.0 (4.8 to 9.8)	0.2 (-3.6 to 4.5)	0.2 (-3.3 to 4.5)
Attention-deficit/hyperactivity disorder	94.6 (87.1 to 102.0)	81.4 (74.8 to 87.8)	-14.2 (-14.7 to -14.0)	0.3 (0.2 to 0.3)	1.2 (0.7 to 1.8)	1.0 (0.6 to 1.5)	-14.0 (-20.2 to -7.5)	0.6 (-6.4 to 8.2)
Conduct disorder	137.9 (130.0 to 146.2)	114 (107.1 to 121.1)	-17.6 (-18.2 to -16.9)	5.0 (0.2 to 0.3)	16.7 (10.6 to 24.3)	17.8 (8.7 to 20.2)	-17.3 (-23.3 to -11.4)	0.1 (-4.2 to 5.1)
Idiopathic intellectual disability	254.8 (208.3 to 308.9)	218.8 (176.9 to 268.7)	-14.5 (-23.7 to -4.3)	-14.2 (-23.8 to -4.2)	12.5 (8.2 to 18.0)	10.7 (6.9 to 15.5)	-14.6 (-24.5 to -3.8)	-14.1 (-24.0 to -3.8)
Other mental and substance use disorders	251.4 (235.8 to 266.5)	287.4 (270.5 to 303.9)	13.9 (12.9 to 15.0)	0.0 (-0.2 to 0.2)	18.8 (12.9 to 25.3)	21.5 (14.5 to 29.0)	14.1 (9.9 to 18.5)	0.3 (-3.0 to 3.6)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	145.9 (102.6 to 197.8)	185.6 (128.9 to 254.7)	27.6 (14.4 to 39.7)	15.7 (3.9 to 26.8)
Diabetes mellitus	783.0 (672.0 to 912.0)	1,226.7 (1,053.2 to 1,398.0)	56.6 (29.4 to 86.7)	36.5 (11.3 to 64.0)	61.3 (41.0 to 85.8)	95.1 (63.5 to 133.5)	55.3 (27.1 to 85.7)	34.6 (9.4 to 60.0)
Acute glomerulonephritis	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-46.3 (-48.8 to -43.5)	-44.2 (-46.7 to -41.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.3 (-48.8 to -43.5)	-44.2 (-46.7 to -41.7)
Chronic kidney disease	-	-	-	-	35.6 (25.5 to 47.9)	38.9 (27.7 to 51.9)	10.9 (5.1 to 23.0)	2.4 (-11.8 to 13.6)
Chronic kidney disease due to diabetes mellitus	152.3 (101.3 to 236.1)	206.0 (124.0 to 343.7)	34.6 (-4.1 to 81.5)	13.2 (-17.6 to 52.1)	5.2 (3.5 to 7.3)	7.1 (4.6 to 10.2)	39.3 (2.0 to 87.8)	17.0 (-16.0 to 59.7)
Chronic kidney disease due to hypertension	288.4 (168.6 to 456.4)	290.2 (168.2 to 496.3)	0.4 (-25.9 to 30.3)	-3.1 (-30.5 to 23.8)	9.5 (6.5 to 13.2)	4.3 (2.8 to 6.2)	-54.8 (-65.3 to -40.3)	-59.5 (-68.9 to -47.3)
Chronic kidney disease due to glomerulonephritis	298.7 (194.3 to 449.6)	185.8 (144.7 to 229.2)	-38.9 (-54.3 to -18.4)	5.0 (-57.2 to 24.1)	9.7 (6.3 to 12.7)	9.7 (7.4 to 14.5)	9.1 (-8.7 to 28.7)	11.3 (-12.9 to 43.2)
Chronic kidney disease due to other causes	391.1 (236.5 to 608.6)	541.4 (344.7 to 822.5)	36.9 (7.0 to 85.1)	35.6 (9.4 to 78.6)	11.7 (8.0 to 16.3)	16.7 (11.2 to 23.2)	42.8 (9.1 to 86.5)	36.6 (4.9 to 77.9)
Urinary diseases and male infertility	-	-	-	-	7.9 (5.2 to 11.3)	9.8 (6.5 to 13.9)	24.5 (13.2 to 36.0)	10.2 (0.6 to 20.8)

Appendix Table G-4. Kazakhstan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	4.3 (3.9 to 4.6)	5.5 (5.1 to 6.0)	29.2 (15.5 to 45.8)	29.2 (13.7 to 43.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	28.9 (5.6 to 61.5)	28.9 (4.8 to 57.3)
Urolithiasis	98.2 (78.0 to 132.4)	120.5 (92.6 to 172.8)	21.9 (10.2 to 40.4)	5.7 (-3.9 to 19.3)	1.1 (0.7 to 1.5)	1.3 (0.8 to 1.9)	21.6 (10.1 to 38.7)	7.6 (-1.7 to 21.1)
Benign prostatic hyperplasia	167.7 (154.9 to 179.1)	212.0 (195.3 to 227.6)	25.8 (13.2 to 40.1)	10.3 (-0.9 to 23.0)	6.0 (3.9 to 8.5)	7.6 (5.0 to 10.6)	26.4 (13.7 to 41.3)	10.7 (-0.7 to 23.7)
Male infertility due to other causes	91.8 (72.9 to 113.4)	89.7 (69.9 to 113.5)	-2.1 (-30.0 to 32.6)	-7.1 (-33.5 to 25.9)	0.6 (0.3 to 1.3)	0.6 (0.2 to 1.2)	-2.7 (-30.7 to 36.3)	-7.8 (-34.2 to 28.9)
Other urinary diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	17.3 (28.3 to 191.0)	18.8 (15.3 to 160.9)
Gynecological diseases	-	-	-	-	19.3 (12.5 to 29.3)	22.0 (14.1 to 33.9)	14.4 (-3.3 to 32.8)	0.5 (-14.9 to 16.0)
Uterine fibroids	317.8 (287.3 to 345.6)	403.2 (367.9 to 436.2)	26.4 (25.0 to 28.1)	1.3 (1.3 to 1.3)	4.3 (2.5 to 7.2)	4.9 (2.8 to 8.4)	14.3 (6.1 to 21.3)	-4.3 (-11.0 to 1.1)
Polycystic ovarian syndrome	277.5 (246.6 to 309.7)	323.2 (291.5 to 355.1)	16.2 (-0.9 to 35.7)	2.2 (-12.6 to 18.4)	2.7 (1.3 to 5.1)	3.1 (1.4 to 5.9)	15.6 (-1.6 to 34.5)	2.3 (-12.2 to 18.4)
Female infertility due to other causes	46.9 (26.3 to 67.1)	48.9 (29.8 to 71.5)	3.7 (-4.1 to 89.9)	0.8 (-4.2 to 85.3)	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.6)	17.8 (-4.2 to 89.3)	18.8 (-4.3 to 87.5)
Endometriosis	28.7 (23.7 to 33.8)	35.7 (30.6 to 40.9)	24.5 (-1.7 to 58.0)	7.2 (-14.2 to 35.1)	2.7 (1.7 to 3.8)	3.3 (2.2 to 4.7)	24.1 (4.0 to 59.5)	7.2 (-16.9 to 35.7)
Genital prolapse	789.6 (685.4 to 881.9)	910.5 (793.3 to 1,033.3)	14.5 (-3.4 to 38.3)	-1.1 (-16.5 to 18.5)	2.5 (1.2 to 4.8)	2.9 (1.4 to 5.5)	14.6 (-4.0 to 38.3)	-0.9 (-16.3 to 18.6)
Premenstrual syndrome	628.4 (419.4 to 829.8)	705.9 (426.6 to 1,065.5)	12.6 (-42.0 to 85.9)	2.8 (-47.3 to 67.7)	5.3 (2.9 to 8.4)	5.9 (2.9 to 10.8)	13.0 (-42.5 to 85.8)	2.8 (-47.5 to 70.2)
Other gynecological diseases	52.7 (44.4 to 61.5)	56.7 (51.8 to 61.7)	7.2 (-7.2 to 27.2)	-2.6 (-15.6 to 15.2)	1.5 (1.0 to 2.2)	1.6 (1.1 to 2.2)	1.5 (-15.9 to 34.2)	-8.3 (-23.8 to 20.7)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	15.1 (9.9 to 21.4)	14.0 (24.5 to 6.4)	6.8 (-17.6 to 14.3)	0.0 (-17.6 to 14.3)
Thalassemias	1.0 (0.2 to 2.3)	0.8 (0.1 to 2.0)	-15.5 (-27.6 to -3.4)	-4.4 (-18.5 to 9.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-16.6 (-50.9 to 34.8)	-5.6 (-45.2 to 54.8)
Thalassemia trait	447.2 (319.1 to 682.9)	451.0 (315.2 to 702.0)	1.1 (-10.0 to 7.7)	-0.2 (-9.6 to 6.3)	12.8 (8.5 to 18.4)	12.2 (8.0 to 17.3)	-4.9 (-23.7 to 9.3)	1.7 (-17.2 to 16.6)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.6 (-11.8 to 7.4)	4.7 (-6.2 to 14.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.9 (-18.4 to 4.2)	1.3 (-13.2 to 10.9)
Sickle cell trait	21.4 (20.4 to 24.0)	21.4 (19.6 to 23.0)	-3.3 (-18.1 to 5.7)	4.2 (-18.8 to 4.4)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-22.2 (-63.9 to 37.6)	7.4 (-56.1 to 60.3)
G6PD deficiency	23.7 (22.4 to 25.2)	27.6 (26.1 to 29.0)	16.0 (6.9 to 26.1)	14.1 (5.2 to 23.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.2 (-13.6 to 26.9)	21.4 (-5.5 to 36.1)
G6PD trait	1,863.9 (1,842.6 to 1,882.9)	1,921.8 (1,896.3 to 1,945.2)	2.7 (1.1 to 4.5)	0.2 (-1.4 to 1.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	39.0 (-66.4 to 1,024.9)	54.4 (-64.0 to 913.7)
Other hemoglobinopathies and hemolytic anemias	72.7 (59.9 to 87.6)	63.1 (57.9 to 69.7)	-13.6 (-32.6 to 14.0)	-7.4 (-27.1 to 21.1)	1.9 (1.0 to 2.9)	1.5 (0.9 to 2.2)	-20.5 (-48.8 to 31.5)	-12.5 (-42.0 to 41.5)
Endocrine, metabolic, blood, and immune disorders	200.0 (179.7 to 215.7)	176.3 (169.1 to 182.7)	-12.3 (-18.6 to -2.8)	-8.9 (-17.2 to -2.3)	6.7 (4.6 to 9.5)	5.8 (3.9 to 8.0)	-9.7 (-21.4 to 1.5)	-13.0 (-19.8 to 1.9)
Musculoskeletal disorders	-	-	-	-	285.8 (203.9 to 380.6)	329.2 (232.1 to 435.7)	15.5 (6.0 to 23.4)	1.0 (-6.7 to 7.8)
Rheumatoid arthritis	26.4 (25.4 to 27.5)	35.3 (33.7 to 36.9)	33.2 (25.3 to 40.9)	21.9 (14.6 to 29.3)	6.3 (4.4 to 8.3)	8.4 (5.9 to 11.1)	32.9 (22.5 to 44.8)	21.7 (12.6 to 32.2)
Osteoarthritis	578.4 (553.1 to 602.8)	690.6 (664.0 to 717.7)	19.0 (12.1 to 25.6)	0.3 (-5.2 to 5.8)	35.4 (24.9 to 48.9)	42.3 (29.9 to 57.9)	19.7 (12.2 to 26.4)	0.6 (-5.3 to 6.2)
Low back and neck pain	-	-	-	-	240.4 (149.6 to 290.7)	240.4 (166.7 to 324.5)	12.6 (0.0 to 23.2)	46.6 (-11.3 to 8.5)
Low back pain	1,338.9 (1,261.1 to 1,420.3)	1,500.9 (1,408.5 to 1,584.2)	11.8 (1.9 to 21.4)	-1.4 (-9.4 to 6.7)	149.4 (101.7 to 206.3)	167.1 (110.6 to 228.6)	11.9 (2.0 to 21.8)	-1.2 (-9.3 to 7.2)
Neck pain	660.6 (539.7 to 787.7)	745.4 (636.0 to 852.1)	12.9 (-13.9 to 46.1)	-0.5 (-24.2 to 27.9)	65.1 (42.5 to 93.3)	73.3 (48.3 to 103.4)	12.9 (-14.3 to 46.0)	-0.3 (-24.2 to 28.5)
Gout	9.1 (8.5 to 9.6)	11.0 (10.3 to 11.6)	20.8 (9.9 to 31.2)	2.3 (-6.4 to 10.7)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	21.3 (-2.1 to 47.7)	2.6 (-15.9 to 23.3)
Other musculoskeletal disorders	319.9 (241.1 to 398.6)	412.7 (318.7 to 509.4)	28.5 (17.9 to 40.8)	8.2 (-0.0 to 18.4)	29.2 (18.7 to 42.9)	37.7 (24.5 to 54.9)	79.3 (17.7 to 42.4)	25.3 (-0.1 to 19.2)
Other non-communicable diseases	-	-	-	-	234.1 (156.6 to 334.6)	236.1 (157.3 to 340.5)	0.9 (-2.6 to 3.9)	-7.1 (-9.9 to -4.8)
Congenital anomalies	-	-	-	-	14.4 (10.4 to 18.8)	15.4 (11.3 to 19.7)	7.3 (-6.4 to 22.7)	7.6 (-6.2 to 23.8)
Neural tube defects	4.0 (3.4 to 4.7)	4.3 (3.8 to 4.9)	6.4 (-12.7 to 33.6)	11.9 (-8.2 to 40.4)	1.3 (0.8 to 1.8)	1.4 (0.9 to 2.0)	8.4 (-22.4 to 56.2)	14.5 (-14.8 to 63.7)
Congenital heart anomalies	64.1 (52.6 to 76.5)	87.0 (73.2 to 105.4)	34.8 (5.2 to 79.0)	38.3 (7.4 to 77.2)	2.2 (0.9 to 3.8)	3.0 (1.3 to 5.2)	35.3 (7.2 to 74.6)	39.3 (10.3 to 79.2)
Orofacial clefts	9.8 (7.3 to 12.9)	12.3 (10.3 to 15.0)	29.0 (-11.2 to 74.2)	36.2 (-6.1 to 84.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	0.2 (-25.6 to 71.9)	18.8 (-21.8 to 79.8)
Down syndrome	14.4 (12.3 to 16.8)	16.4 (13.9 to 20.5)	12.0 (-8.4 to 51.0)	11.5 (-9.2 to 49.7)	1.8 (1.3 to 2.4)	2.1 (1.5 to 2.9)	16.8 (-6.4 to 56.4)	13.9 (-9.7 to 52.2)
Turner syndrome	0.6 (0.4 to 0.8)	0.6 (0.5 to 0.8)	7.6 (-33.7 to 71.1)	8.0 (-33.8 to 71.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.7 (-36.8 to 79.7)	7.7 (-37.3 to 78.4)
Klinefelter syndrome	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	8.1 (-31.3 to 55.9)	8.2 (-31.3 to 55.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.1 (-27.4 to 65.9)	7.4 (-32.1 to 54.9)
Chromosomal unbalanced rearrangements	22.0 (17.6 to 27.9)	24.9 (20.4 to 30.1)	13.1 (-18.9 to 51.3)	2.6 (-19.0 to 50.8)	2.8 (1.9 to 3.9)	2.9 (2.2 to 4.4)	15.4 (-15.4 to 60.0)	15.4 (-17.9 to 56.8)
Other congenital anomalies	55.6 (47.0 to 64.5)	49.0 (41.8 to 56.0)	-12.2 (-21.9 to -6.6)	-15.1 (-24.5 to -3.6)	6.2 (4.1 to 8.8)	5.5 (3.8 to 7.7)	-11.0 (-28.5 to 12.6)	-10.6 (-27.4 to 13.3)
Skin and subcutaneous diseases	-	-	-	-	69.8 (45.6 to 104.4)	67.8 (43.5 to 102.8)	-3.0 (-10.8 to 5.4)	-6.9 (-14.3 to 1.3)
Dermatitis	641.8 (518.1 to 776.0)	684.8 (551.3 to 828.4)	6.3 (4.4 to 8.3)	-0.0 (-0.1 to 0.0)	15.4 (9.4 to 22.8)	16.2 (9.9 to 24.2)	5.3 (1.4 to 8.8)	0.3 (-2.8 to 3.0)
Psoriasis	124.8 (110.2 to 139.6)	136.3 (120.0 to 152.7)	8.8 (7.6 to 10.3)	0.0 (-0.1 to 0.1)	8.8 (6.9 to 14.4)	11.1 (7.6 to 15.5)	0.3 (2.2 to 15.4)	0.3 (-5.1 to 5.9)
Cellulitis	5.8 (4.7 to 7.1)	5.4 (4.2 to 7.2)	-8.3 (-17.1 to 5.6)	-8.3 (-16.4 to 4.2)	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.6)	-0.4 (-26.8 to 16.4)	-7.4 (-25.8 to 13.9)
Pyoderma	15.9 (13.2 to 18.9)	17.2 (14.2 to 21.0)	7.7 (2.1 to 13.8)	9.0 (4.5 to 13.6)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	7.9 (-2.0 to 19.4)	9.4 (-0.0 to 19.5)
Scabies	46.9 (40.1 to 56.8)	43.5 (37.3 to 51.4)	-8.0 (-26.9 to 19.4)	-6.9 (-25.8 to 20.6)	1.2 (0.7 to 2.0)	1.1 (0.6 to 1.8)	-8.1 (-27.4 to 19.2)	-6.8 (-26.4 to 20.2)
Fungal skin diseases	1,192.8 (915.8 to 1,579.9)	1,261.0 (972.7 to 1,674.5)	5.5 (1.7 to 8.8)	5.5 (-0.1 to 11.1)	6.7 (2.7 to 14.9)	7.1 (2.9 to 15.7)	6.5 (1.4 to 9.1)	0.2 (-4.7 to 11.0)
Viral skin diseases	368.4 (284.3 to 451.6)	348.9 (262.5 to 434.6)	-5.7 (-9.2 to -3.0)	-0.0 (-1.6 to 1.6)	11.4 (6.4 to 17.9)	10.8 (6.0 to 17.0)	-5.7 (-9.7 to 2.0)	-0.2 (-2.8 to 3.3)
Acne vulgaris	400.1 (328.1 to 490.1)	393.4 (301.8 to 478.2)	-1.5 (-33.3 to 29.9)	4.2 (-29.0 to 35.9)	4.3 (2.0 to 8.3)	4.3 (2.0 to 8.1)	-1.4 (-32.9 to 29.9)	4.3 (-29.4 to 36.5)
Alopecia areata	17.7 (15.5 to 19.8)	19.3 (16.8 to 21.5)	8.9 (-10.3 to 28.8)	2.3 (-16.0 to 21.4)	0.6 (0.4 to 0.9)	1.0 (0.4 to 1.0)	8.9 (-11.7 to 32.3)	2.2 (-16.9 to 25.2)
Pruritus	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	9.2 (-12.4 to 37.5)	0.5 (-19.0 to 25.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.2 (-12.5 to 37.7)	0.5 (-19.0 to 25.8)
Urticaria	235.8 (177.0 to 296.4)	173.5 (112.6 to 245.6)	-26.8 (-54.2 to 11.1)	-31.5 (-54.9 to 2.9)	14.1 (8.5 to 21.0)	10.3 (5.5 to 16.8)	-27.2 (-54.9 to 10.2)	-32.1 (-55.9 to 2.4)
Decubitus ulcer	0.8 (0.7 to 1.0)	1.0 (0.8 to 1.2)	17.5 (-16.6 to 50.4)	13.7 (-20.3 to 50.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	19.3 (-18.1 to 58.8)	14.5 (-22.2 to 55.7)
Other skin and subcutaneous diseases	886.7 (568.4 to 1,409.1)	973.8 (622.6 to 1,530.5)	9.2 (2.3 to 18.1)	-3.0 (-6.8 to 0.9)	5.2 (2.3 to 11.0)	5.7 (2.4 to 12.1)	9.3 (2.1 to 18.7)	-2.9 (-6.8 to 1.3)
Sense organ diseases	-	-	-	-	112.6 (74.6 to 161.3)	112.0 (74.7 to 160.4)	-0.5 (-5.3 to 3.7)	-0.3 (-13.9 to -6.8)
Glaucoma	21.8 (18.3 to 26.0)	20.6 (17.3 to 24.6)	-5.0 (-19.0 to 9.6)	-16.0 (-28.5 to -1.5)	1.5 (1.0 to 2.1)	1.6 (1.0 to 2.2)	1.3 (-12.0 to 16.9)	-10.8 (-22.8 to 3.5)
Cataract	136.8 (106.9 to 164.8)	110.5 (85.9 to 134.4)	-20.7 (-32.2 to 0.7)	-30.9 (-40.5 to -14.9)	4.6 (2.8 to 7.0)	3.7 (2.3 to 5.7)	-19.6 (-30.9 to 0.4)	-29.9 (-39.1 to -14.5)
Macular degeneration	38.5 (28.9 to 52.9)	48.9 (37.0 to 62.0)	31.0 (-14.7 to 67.4)	10.6 (-29.7 to 41.3)	1.2 (0.7 to 2.0)	1.5 (0.9 to 2.4)	27.4 (-15.0 to 63.1)	7.5 (-29.6 to 36.8)
Uncorrected refractive error	1,165.7 (1,099.0 to 1,234.8)	1,201.1 (1,117.1 to 1,287.1)	2.5 (-5.2 to 11.4)	-8.2 (-14.9 to -0.7)	19.4 (11.6 to 31.4)	18.8 (11.1 to 30.9)	-3.6 (-8.6 to 2.7)	-12.5 (-16.7 to -7.1)
Age-related and other hearing loss	2,232.8 (1,959.0 to 2,480.5)	2,385.3 (2,084.4 to 2,657.6)	6.3 (1.8 to 12.2)	-7.7 (-11.1 to -3.9)	71.1 (47.3 to 100.5)	72.9 (47.9 to 102.7)	8.6 (-4.5 to 9.4)	8.6 (-13.5 to -3.2)
Other vision loss	102.8 (88.9 to 117.8)	73.3 (63.2 to 85.4)	-28.6 (-37.5 to -21.0)	-32.7 (-41.7 to -25.2)	4.7 (3.2 to 6.8)	3.5 (2.3 to 5.0)	5.7 (-33.2 to -16.5)	3.5 (-38.3 to -22.2)
Other sense organ diseases	377.0 (358.5 to 395.2)	379.6 (362.8 to 396.9)	0.3 (-6.2 to 7.8)	-0.1 (-6.3 to 6.9)	10.0 (6.1 to 14.8)	10.0 (6.2 to 15.0)	0.0 (-6.8 to 7.9)	-0.1 (-6.7 to 7.8)
Oral disorders	-	-	-	-	37.3 (21.9 to 58.7)	40.9 (24.0 to 64.9)	9.6 (5.9 to 13.3)	-1.9 (-5.1 to 1.2)
Deciduous caries	1,492.1 (1,460.6 to 1,520.9)	1,275.1 (1,252.3 to 1,301.3)	-14.9 (-17.1 to -12.2)	0.5 (-2.1 to 3.6)	0.5 (0.2 to 1.1)	0.5 (0.2 to 1.0)	0.5 (-18.9 to -9.1)	0.5 (-1.3 to 6.9)
Permanent caries	8,632.0 (8,393.4 to 8,823.4)	9						

Appendix Table G.4 - Kazakhstan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.								
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	479.2 (459.8 to 497.8)	529.1 (507.8 to 552.0)	10.1 (3.8 to 17.0)	-5.9 (-10.6 to -0.4)	13.2 (8.9 to 18.3)	14.6 (9.9 to 20.2)	10.4 (3.7 to 17.4)	5.6 (-10.8 to -0.2)
Other oral disorders	274.3 (258.2 to 288.7)	295.4 (279.5 to 312.2)	7.1 (-1.0 to 17.1)	-0.5 (-8.1 to 8.1)	8.1 (5.0 to 12.2)	8.6 (5.4 to 12.8)	7.1 (-1.3 to 17.7)	-0.4 (-8.1 to 8.7)
Injuries	-	-	-	-	138.8 (104.6 to 180.7)	105.4 (74.9 to 143.3)	-24.4 (-31.6 to -15.9)	-32.4 (-38.7 to -25.1)
Transport injuries	-	-	-	-	33.1 (24.7 to 43.1)	16.2 (11.4 to 22.1)	-51.4 (-57.0 to -44.3)	-56.1 (-61.0 to -50.2)
Road injuries	-	-	-	-	26.7 (20.0 to 34.7)	12.3 (8.6 to 16.8)	-54.2 (-60.0 to -46.9)	-58.4 (-63.8 to -52.3)
Pedestrian road injuries	-	-	-	-	5.3 (3.9 to 6.8)	2.4 (1.7 to 3.3)	-55.0 (-61.6 to -47.8)	-58.5 (-64.1 to -52.3)
Cyclist road injuries	-	-	-	-	3.2 (2.4 to 4.1)	1.6 (1.2 to 2.2)	-48.8 (-54.3 to -43.1)	-54.0 (-58.8 to -49.1)
Motorcyclist road injuries	-	-	-	-	2.7 (2.0 to 3.5)	1.2 (0.9 to 1.7)	-53.4 (-59.5 to -46.3)	-58.4 (-63.5 to -52.4)
Motor vehicle road injuries	-	-	-	-	15.4 (11.4 to 19.7)	7.0 (4.9 to 9.6)	-54.8 (-61.3 to -46.9)	-59.0 (-64.8 to -52.4)
Other road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.1)	-61.1 (-66.0 to -55.4)	-65.0 (-69.2 to -60.3)
Other transport injuries	-	-	-	-	6.4 (4.8 to 8.3)	3.9 (2.7 to 5.3)	-39.4 (-45.4 to -31.9)	-46.6 (-51.9 to -40.1)
Unintentional injuries	-	-	-	-	103.3 (77.9 to 133.8)	85.7 (61.2 to 116.1)	-17.3 (-24.6 to -9.1)	-26.8 (-33.2 to -19.5)
Falls	-	-	-	-	70.8 (52.6 to 92.2)	57.5 (40.5 to 79.1)	-18.4 (-27.0 to -8.7)	-28.7 (-36.8 to -20.3)
Drowning	-	-	-	-	1.2 (0.9 to 1.6)	0.5 (0.4 to 0.7)	-55.7 (-61.8 to -48.2)	-58.5 (-63.9 to -51.8)
Fire, heat, and hot substances	-	-	-	-	3.2 (2.5 to 4.1)	2.1 (1.5 to 2.8)	-36.1 (-44.6 to -28.0)	-41.0 (-48.6 to -33.7)
Poisonings	-	-	-	-	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-39.0 (-47.3 to -29.2)	-42.7 (-50.2 to -33.7)
Exposure to mechanical forces	-	-	-	-	19.4 (14.6 to 25.5)	15.4 (11.2 to 20.9)	-20.7 (-26.2 to -14.7)	-26.1 (-31.0 to -21.0)
Unintentional firearm injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.3)	-34.2 (-44.2 to -22.3)	-37.6 (-46.8 to -26.7)
Unintentional suffocation	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-6.4 (-15.9 to 4.8)	-10.0 (-18.8 to 0.2)
Other exposure to mechanical forces	-	-	-	-	18.9 (14.1 to 24.7)	15.0 (10.9 to 20.2)	-20.6 (-26.1 to -14.6)	-26.1 (-30.9 to -21.0)
Adverse effects of medical treatment	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	13.1 (6.5 to 20.4)	2.5 (-4.1 to 9.5)
Animal contact	-	-	-	-	0.9 (0.6 to 1.1)	0.8 (0.6 to 1.1)	-9.0 (-16.9 to 0.3)	-13.4 (-20.5 to -4.9)
Venomous animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-4.4 (-18.2 to 7.2)	-11.6 (-22.4 to 0.4)
Non-venomous animal contact	-	-	-	-	0.6 (0.4 to 0.7)	0.5 (0.4 to 0.7)	-10.3 (-19.0 to 1.0)	-14.3 (-22.0 to -4.4)
Foreign body	-	-	-	-	0.9 (0.7 to 1.2)	0.7 (0.5 to 0.9)	-22.8 (-30.0 to -13.8)	-27.6 (-34.1 to -19.8)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.3 (0.3 to 0.4)	0.2 (0.1 to 0.3)	-42.0 (-51.5 to -29.3)	-44.3 (-53.2 to -32.7)
Foreign body in eyes	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-3.5 (-8.7 to 4.0)	-8.6 (-15.3 to -2.3)
Foreign body in other body part	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.5)	-16.0 (-23.8 to -6.2)	-22.4 (-29.3 to -14.5)
Other unintentional injuries	-	-	-	-	6.2 (4.6 to 8.2)	7.8 (5.6 to 10.4)	24.0 (13.7 to 34.6)	7.0 (-1.4 to 15.9)
Self-harm and interpersonal violence	-	-	-	-	2.4 (1.8 to 3.1)	1.8 (1.3 to 2.4)	-26.1 (-33.5 to -16.6)	-35.0 (-41.8 to -26.9)
Self-harm	-	-	-	-	1.1 (0.8 to 1.4)	1.0 (0.7 to 1.3)	-13.0 (-22.9 to -1.9)	-24.3 (-32.4 to -14.9)
Interpersonal violence	-	-	-	-	1.3 (1.0 to 1.7)	0.8 (0.6 to 1.1)	-37.0 (-44.4 to -27.4)	-44.1 (-50.4 to -36.0)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-28.3 (-35.1 to -20.9)	-35.9 (-41.6 to -29.7)
Assault by sharp object	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-31.8 (-40.4 to -21.4)	-39.6 (-46.9 to -30.8)
Assault by other means	-	-	-	-	0.9 (0.7 to 1.2)	0.6 (0.4 to 0.8)	-39.6 (-47.1 to -29.7)	-46.5 (-52.9 to -38.0)
Forces of nature, war, and legal intervention	-	-	-	-	-	1.7 (0.7 to 3.3)	-	-
Exposure to forces of nature	-	-	-	-	-	1.7 (0.7 to 3.3)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Kenya prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
All causes	-	-	-	-	2,051.8 (1,503.6 to 2,735.2)	4,082.7 (2,987.8 to 5,351.6)	99.0 (93.6 to 104.8)	99.0 (-2.6 to 2.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	544.4 (373.0 to 779.4)	1,027.0 (732.0 to 1,437.8)	88.4 (78.8 to 102.4)	8.8 (1.1 to 20.5)
HIV/AIDS and tuberculosis	-	-	-	-	50.2 (34.7 to 67.3)	253.0 (170.3 to 340.9)	402.1 (334.3 to 489.9)	135.0 (98.5 to 184.5)
Tuberculosis	88.6 (81.5 to 95.7)	188.6 (177.0 to 201.7)	112.3 (101.3 to 126.7)	-6.6 (-11.4 to -1.3)	27.1 (18.7 to 36.7)	57.8 (39.1 to 78.0)	112.9 (99.0 to 130.3)	-6.5 (-11.9 to -0.3)
HIV/AIDS	-	-	-	-	23.1 (15.8 to 30.9)	195.2 (130.3 to 266.0)	745.3 (591.3 to 915.2)	336.2 (245.2 to 435.8)
HIV/AIDS resulting in mycobacterial infection	7.2 (4.4 to 10.2)	34.6 (22.3 to 46.5)	379.0 (306.6 to 476.6)	119.2 (84.2 to 166.9)	2.7 (1.4 to 4.2)	12.9 (7.4 to 19.3)	377.7 (293.2 to 488.9)	118.5 (79.9 to 171.9)
HIV/AIDS resulting in other diseases	245.9 (219.5 to 275.0)	1,483.8 (1,399.3 to 1,572.4)	505.1 (435.8 to 568.6)	219.6 (180.6 to 255.8)	20.3 (13.7 to 27.6)	182.3 (119.4 to 252.3)	795.1 (614.7 to 1,000.0)	365.0 (261.2 to 492.9)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	100.1 (71.6 to 134.8)	143.9 (101.5 to 195.9)	43.9 (33.8 to 53.5)	-18.5 (-24.1 to -13.0)
Diarrheal diseases	283.0 (267.4 to 298.5)	408.1 (392.5 to 423.8)	44.1 (34.8 to 53.8)	-11.5 (-17.0 to -5.9)	46.0 (31.1 to 64.3)	66.2 (44.8 to 91.0)	44.0 (33.3 to 54.7)	-14.8 (-17.4 to -5.2)
Intestinal infectious diseases	-	-	-	-	1.2 (0.8 to 1.9)	1.4 (0.9 to 2.0)	1.4 (-1.8 to 4.8)	13.8 (-5.1 to 21.4)
Typhoid fever	6.4 (5.6 to 7.3)	7.8 (6.9 to 8.7)	22.0 (1.4 to 45.6)	-33.6 (-44.3 to -20.5)	0.9 (0.5 to 1.3)	1.1 (0.7 to 1.5)	22.3 (-6.4 to 63.4)	-33.1 (-46.9 to -13.5)
Paratyphoid fever	2.4 (2.0 to 2.8)	3.5 (2.9 to 4.0)	46.4 (11.0 to 82.2)	-18.9 (-38.1 to -0.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	46.7 (3.3 to 101.1)	-18.6 (-39.7 to 4.9)
Other intestinal infectious diseases	-	-	-	-	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.3)	-37.8 (-61.6 to -11.8)	-66.1 (-78.6 to -47.7)
Lower respiratory infections	8.6 (7.4 to 10.0)	10.6 (9.2 to 11.8)	22.3 (2.1 to 50.4)	-24.3 (-32.4 to -14.4)	0.9 (0.6 to 1.3)	1.1 (0.7 to 1.6)	22.4 (-4.7 to 59.4)	-24.4 (-35.6 to -10.2)
Upper respiratory infections	1,643.6 (1,542.1 to 1,757.3)	3,007.5 (2,837.6 to 3,176.4)	83.1 (66.7 to 99.1)	-2.4 (-9.9 to 6.3)	19.3 (10.8 to 32.5)	35.3 (19.8 to 58.8)	83.0 (66.4 to 100.0)	-2.3 (-9.7 to 6.8)
Otitis media	404.9 (364.8 to 442.3)	679.0 (625.0 to 736.8)	67.3 (51.9 to 87.4)	-8.7 (-16.5 to 2.2)	8.3 (5.0 to 13.3)	14.0 (8.3 to 22.3)	67.5 (49.6 to 90.5)	-8.2 (-17.3 to 4.3)
Meningitis	-	-	-	-	22.2 (15.1 to 31.1)	23.2 (16.1 to 31.7)	5.5 (-14.9 to 26.9)	-43.4 (-53.1 to -32.2)
Pneumococcal meningitis	94.8 (57.5 to 140.9)	105.1 (67.2 to 151.9)	10.5 (-10.9 to 38.4)	-42.0 (-52.3 to -29.2)	5.7 (5.7 to 12.1)	6.9 (6.9 to 14.7)	5.5 (-17.1 to 78.6)	-53.0 (-55.7 to -11.0)
H influenzae type B meningitis	33.7 (13.1 to 63.0)	25.7 (11.5 to 46.0)	-22.5 (-47.1 to 16.0)	-59.1 (-71.8 to -40.5)	3.8 (2.4 to 5.7)	3.3 (2.0 to 5.0)	-13.7 (-45.3 to 40.2)	-53.0 (-70.1 to -25.0)
Meningococcal meningitis	8.6 (3.3 to 17.8)	8.1 (3.4 to 15.7)	-3.7 (-38.2 to 53.3)	-47.0 (-65.2 to -21.9)	1.2 (0.7 to 1.8)	1.2 (0.7 to 1.9)	1.5 (-33.3 to 70.3)	-43.5 (-62.2 to -13.7)
Other meningitis	71.4 (34.4 to 128.3)	67.8 (33.7 to 124.6)	-5.0 (-23.3 to 17.3)	-48.6 (-57.7 to -37.1)	8.7 (5.4 to 13.4)	8.3 (5.5 to 12.0)	-3.1 (-39.4 to 30.5)	-47.1 (-65.8 to -30.3)
Encephalitis	9.8 (1.8 to 8.0)	6.7 (3.1 to 14.1)	-31.7 (-56.9 to 99.6)	-92.2 (-12.1 to -40.0)	0.9 (0.3 to 0.7)	0.9 (0.6 to 1.2)	76.0 (51.6 to 116.0)	-9.2 (-20.0 to 6.4)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-92.5 to 3,734.4)	36.0 (93.5 to 1,227.4)	-14.3 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.0 (92.6 to 3,771.2)	-14.3 (-93.6 to 1,244.2)
Whooping cough	12.7 (10.0 to 16.3)	23.3 (18.2 to 29.8)	83.0 (81.4 to 84.7)	13.1 (12.1 to 14.1)	0.6 (0.4 to 1.0)	1.2 (0.7 to 1.8)	83.5 (61.8 to 110.6)	13.4 (-0.4 to 30.3)
Tetanus	0.5 (0.3 to 0.9)	0.0 (0.1 to 0.3)	-67.5 (-82.9 to -23.5)	-81.3 (-90.3 to -56.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (-70.4 to -8.1)	-47.1 (-60.4 to -7.4)
Measles	6.7 (5.2 to 8.5)	0.9 (0.7 to 1.1)	-86.4 (-89.6 to -83.0)	-91.9 (-93.6 to -89.5)	0.6 (0.4 to 1.0)	0.1 (0.0 to 0.1)	86.6 (92.0 to -79.7)	-91.8 (-95.0 to -87.6)
Varicella and herpes zoster	14.4 (13.0 to 15.7)	29.0 (26.5 to 31.9)	101.3 (79.2 to 132.8)	2.9 (-16.2 to 27.8)	0.3 (0.2 to 0.5)	0.6 (0.4 to 1.0)	114.3 (51.3 to 210.6)	2.8 (-28.5 to 46.6)
Neglected tropical diseases and malaria	-	-	-	-	164.0 (93.6 to 285.5)	285.9 (157.2 to 519.2)	73.7 (61.6 to 85.5)	-11.4 (-17.2 to -5.3)
Malaria	3,200.6 (3,067.4 to 3,334.3)	3,204.6 (3,075.3 to 3,341.2)	0.1 (-3.0 to 3.4)	-45.7 (-47.4 to -43.6)	36.2 (23.9 to 52.9)	37.7 (25.5 to 55.0)	4.8 (-6.9 to 13.9)	4.8 (-4.7 to -36.1)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	800.9 (416.7 to 1,427.3)	612.2 (330.9 to 1,079.0)
Visceral leishmaniasis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	88.6 (26.3 to 175.7)	4.5 (-27.6 to 41.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.6 (25.9 to 175.8)	4.5 (-27.9 to 41.8)
Cutaneous and mucocutaneous leishmaniasis	0.2 (0.1 to 0.3)	4.4 (2.7 to 7.1)	2,207.7 (1,329.6 to 3,552.6)	1,532.3 (990.3 to 2,712.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	2,117.8 (1,264.3 to 3,545.6)	1,456.3 (914.9 to 2,627.3)
African trypanosomiasis	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-87.0 (-91.7 to -80.6)	-94.0 (-96.2 to -91.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-85.7 (-90.7 to -78.9)	-93.4 (-95.1 to -90.3)
Schistosomiasis	10,003.0 (6,624.2 to 13,396.2)	20,348.6 (13,584.5 to 27,143.2)	103.2 (100.8 to 105.8)	1.2 (0.5 to 2.1)	92.2 (43.8 to 187.3)	193.9 (95.0 to 389.8)	110.5 (98.5 to 124.0)	4.5 (1.4 to 10.0)
Cysticercosis	4.8 (2.5 to 8.0)	12.8 (6.1 to 23.7)	151.3 (34.0 to 595.0)	19.3 (-34.4 to 141.0)	1.3 (0.6 to 2.3)	3.6 (1.5 to 6.7)	156.4 (34.3 to 672.0)	21.4 (-33.9 to 166.2)
Cystic echinococcosis	7.6 (6.8 to 8.5)	9.7 (8.7 to 10.6)	30.9 (10.6 to 48.8)	-24.5 (-31.6 to -15.6)	0.7 (0.5 to 1.0)	0.9 (0.6 to 1.3)	26.6 (-1.0 to 63.4)	-25.1 (-37.2 to -9.6)
Lymphatic filariasis	215.1 (186.1 to 245.1)	166.1 (131.8 to 205.7)	-22.9 (-38.3 to -6.2)	-61.4 (-68.5 to -33.1)	5.6 (3.0 to 9.2)	7.9 (4.3 to 13.1)	41.4 (33.6 to 77.5)	-35.3 (-54.2 to -17.7)
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	47.5 (31.0 to 66.0)	20.4 (11.3 to 29.9)	-57.6 (-68.1 to -45.3)	-78.4 (-84.5 to -71.8)	2.8 (1.6 to 4.3)	1.3 (0.7 to 2.0)	-53.6 (-64.5 to -41.9)	-76.3 (-82.0 to -69.7)
Dengue	0.3 (0.0 to 1.0)	2.6 (0.4 to 9.1)	823.2 (812.5 to 835.7)	389.1 (383.5 to 395.8)	0.0 (0.0 to 0.2)	0.4 (0.1 to 1.7)	814.3 (687.1 to 1,022.9)	385.3 (342.1 to 458.8)
Yellow fever	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-	-73.0 (-68.2 to -19.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.2 (-68.2 to -19.1)	-73.0 (-81.8 to -59.9)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-14.2 to 69.1)	0.0 (0.0 to 0.0)	0.0 (-14.3 to 69.3)	-
Intestinal nematode infections	-	-	-	-	5.6 (3.3 to 8.8)	11.4 (6.9 to 17.9)	104.6 (57.4 to 144.1)	6.2 (-13.7 to 26.4)
Ascariasis	1,151.6 (804.5 to 1,659.7)	2,170.0 (1,499.8 to 3,105.2)	89.5 (10.1 to 214.6)	-1.4 (-46.6 to 79.1)	0.3 (0.2 to 0.6)	0.6 (0.3 to 1.0)	81.2 (32.7 to 143.6)	-0.5 (-30.6 to 39.6)
Trichuriasis	860.0 (587.6 to 1,237.9)	1,607.7 (1,110.3 to 2,325.3)	85.1 (8.8 to 221.0)	-1.6 (-49.1 to 67.4)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.6)	79.7 (-5.2 to 253.8)	-2.3 (-56.8 to 118.6)
Hookworm disease	1,283.4 (958.8 to 1,735.1)	2,486.3 (1,789.7 to 3,381.3)	94.9 (23.2 to 204.4)	94.9 (-42.1 to 87.8)	0.4 (3.0 to 8.0)	0.4 (6.4 to 16.2)	106.3 (57.3 to 151.1)	6.2 (-14.6 to 28.7)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	340.1 (257.8 to 425.5)	473.2 (419.9 to 527.5)	38.9 (10.5 to 84.8)	-21.2 (-36.2 to 2.0)	19.5 (11.1 to 34.1)	28.7 (16.0 to 53.9)	44.8 (12.7 to 101.2)	-18.0 (-41.3 to 21.1)
Maternal disorders	-	-	-	-	5.8 (4.0 to 7.8)	8.6 (6.0 to 11.8)	48.6 (25.6 to 73.3)	-31.1 (-41.0 to -19.9)
Maternal hemorrhage	6.5 (5.5 to 7.5)	13.1 (9.3 to 16.9)	102.5 (41.3 to 183.0)	-11.3 (-35.9 to 21.0)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	54.4 (-23.8 to 157.8)	-30.0 (-63.1 to 11.8)
Maternal sepsis and other maternal infections	10.5 (6.9 to 13.5)	13.5 (9.5 to 17.4)	27.1 (11.8 to 53.5)	-45.8 (-51.9 to -35.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	16.8 (-25.6 to 88.3)	16.8 (-63.8 to -18.0)
Maternal hypertensive disorders	8.8 (4.5 to 14.6)	13.4 (7.0 to 22.3)	51.5 (33.9 to 68.3)	-30.4 (-39.2 to -23.4)	0.4 (0.2 to 0.8)	0.7 (0.3 to 1.2)	50.8 (24.5 to 85.2)	-31.0 (-42.6 to -16.0)
Obstructed labor	10.9 (9.6 to 12.2)	16.1 (14.2 to 18.2)	48.3 (36.2 to 61.4)	-30.7 (-36.3 to -24.6)	3.6 (2.4 to 4.9)	5.3 (3.6 to 7.5)	48.2 (26.5 to 72.4)	-30.6 (-40.5 to -19.9)
Complications of abortion	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	64.5 (-17.8 to 199.1)	-28.7 (-60.1 to 23.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.5 (-17.9 to 159.2)	-28.7 (-60.1 to 24.3)
Other maternal disorders	-	-	-	-	1.4 (0.8 to 2.0)	2.1 (1.3 to 3.0)	49.7 (-1.0 to 132.8)	-30.7 (-53.5 to 7.8)
Neonatal disorders	-	-	-	-	18.2 (11.6 to 27.8)	62.4 (41.7 to 85.9)	245.5 (137.1 to 412.4)	91.4 (31.7 to 182.8)
Preterm birth complications	72.9 (51.0 to 104.2)	286.2 (212.2 to 381.5)	293.8 (231.9 to 373.4)	107.2 (75.6 to 146.7)	6.4 (4.2 to 9.0)	30.3 (20.5 to 41.2)	371.2 (240.2 to 550.0)	154.7 (85.9 to 247.8)
Neonatal encephalopathy due to birth asphyxia and trauma	112.5 (16.7 to 355.2)	182.4 (40.1 to 530.2)	68.4 (30.2 to 220.6)	-11.5 (-31.6 to 70.1)	6.8 (2.8 to 13.2)	17.4 (8.6 to 29.2)	153.1 (28.5 to 608.9)	38.4 (-27.4 to 308.4)
Neonatal sepsis and other neonatal infections	0.3 (0.1 to 0.5)	0.7 (0.2 to 1.6)	171.5 (134.2 to 232.3)	72.2 (48.6 to 110.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	72.1 (131.7 to 239.1)	72.1 (46.9 to 115.1)
Hemolytic disease and other neonatal jaundice	8.3 (3.7 to 16.3)	23.1 (9.3 to 49.4)	176.3 (16.9 to 585.8)	53.8 (-35.0 to 281.4)	3.2 (1.3 to 6.6)	8.9 (3.3 to 18.8)	173.6 (9.9 to 576.5)	50.3 (-39.1 to 274.9)
Other neonatal disorders	-	-	-	-	1.7 (0.7 to 3.3)	5.7 (3.0 to 10.3)	254.2 (58.9 to 669.2)	96.6 (-12.3 to 323.5)
Nutritional deficiencies	-	-	-	-	189.2 (125.0 to 268.4)	245.3 (162.2 to 355.9)	29.0 (18.4 to 44.9)	-30.2 (-35.1 to -22.9)
Protein-energy malnutrition	151.1 (89.4 to 242.2)	218.7 (108.6 to 408.0)	39.7 (-36.8 to 236.9)	-14.4 (-54.8 to 73.4)	18.7 (9.2 to 33.4)	27.0 (11.4 to 50.8)	14.4 (-36.6 to 242.2)	-14.4 (-55.8 to 78.2)
Iodine deficiency	318.7 (264.8 to 376.1)	378.6 (304.0 to 448.0)	18.9 (-10.0 to 54.7)	-41.7 (-56.7 to -21.4)	5.7 (3.4 to 9.3)	6.8 (4.0 to 11.2)	19.0 (-9.7 to 57.2)	-41.8 (-57.3 to -21.0)
Vitamin A deficiency	30.7 (21.0 to 41.1)	25.4 (16.0 to 35.1)	-18.0 (-32.9 to 3.1)	-56.2 (-64.9 to -42.1)	1.3 (0.8 to 2.1)	1.1 (0.6 to 1.8)	-18.7 (-36.0 to 6.7)	-55.4 (-66.4 to -40.3)

Appendix Table G.4 - Kenya prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	4,538.6 (4,427.9 to 4,642.6)	6,119.5 (5,855.3 to 6,397.4)	34.6 (28.8 to 41.0)	-30.8 (-33.5 to -27.7)	163.4 (109.2 to 234.0)	210.3 (140.5 to 306.1)	28.7 (22.7 to 37.4)	28.7 (-34.1 to -25.2)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	64.8 (-41.7 to 361.5)	0.7 (-59.1 to 152.2)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	17.0 (10.6 to 26.3)	27.9 (17.4 to 44.0)	62.7 (43.1 to 94.5)	-12.9 (-23.3 to 2.0)
Sexually transmitted diseases excluding HIV	-	-	-	-	6.4 (3.6 to 11.3)	12.8 (7.0 to 23.6)	97.1 (56.2 to 170.1)	-9.1 (-25.7 to 18.5)
Syphilis	2.5 (2.2 to 2.9)	3.2 (2.8 to 3.7)	27.9 (6.0 to 52.8)	-42.2 (-50.7 to -32.0)	0.3 (0.3 to 0.7)	0.6 (0.4 to 0.9)	28.7 (5.2 to 68.2)	42.0 (-54.9 to -27.2)
Chlamydial infection	479.1 (360.7 to 578.9)	1,044.5 (844.5 to 1,282.0)	114.7 (66.3 to 225.6)	0.8 (-21.4 to 57.3)	2.6 (1.2 to 4.8)	5.3 (2.6 to 9.5)	95.2 (26.9 to 301.7)	-6.9 (-38.2 to 100.0)
Gonococcal infection	164.4 (101.6 to 224.3)	315.8 (226.6 to 421.6)	89.4 (17.9 to 256.8)	-10.3 (-41.5 to 57.3)	0.9 (0.4 to 1.7)	1.7 (0.9 to 3.1)	87.8 (5.5 to 246.7)	-11.4 (-47.6 to 54.9)
Trichomoniasis	299.3 (215.1 to 407.0)	689.4 (490.1 to 908.6)	133.3 (41.2 to 289.0)	2.5 (-32.1 to 64.9)	0.5 (0.2 to 1.1)	1.2 (0.5 to 2.7)	139.9 (33.3 to 306.6)	4.3 (-35.7 to 68.9)
Genital herpes	6,124.8 (5,384.7 to 6,785.3)	13,098.4 (11,531.5 to 14,528.8)	112.2 (84.8 to 158.0)	-2.7 (-12.3 to 13.2)	1.8 (0.6 to 4.1)	3.8 (1.3 to 8.9)	110.9 (80.2 to 159.3)	-2.2 (-13.7 to 14.6)
Other sexually transmitted diseases	8.0 (5.5 to 10.8)	14.7 (10.2 to 19.8)	84.5 (61.4 to 108.9)	-21.6 (-31.0 to -11.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	85.0 (29.4 to 168.2)	-18.4 (-38.7 to 10.9)
Hepatitis	-	-	-	-	1.5 (0.9 to 2.1)	2.5 (1.6 to 3.6)	71.2 (53.1 to 92.3)	-16.3 (-26.7 to -5.5)
Hepatitis A	43.9 (41.4 to 46.5)	75.1 (71.4 to 78.8)	70.8 (69.4 to 72.3)	-0.8 (-0.9 to -0.7)	0.8 (0.5 to 1.2)	1.5 (0.9 to 2.1)	84.9 (62.4 to 107.5)	0.8 (-10.2 to 13.1)
Hepatitis B	1,294.6 (1,168.8 to 1,424.3)	1,559.0 (1,396.5 to 1,787.4)	19.5 (3.3 to 41.6)	-38.8 (-46.3 to -29.5)	0.5 (0.3 to 0.7)	0.7 (0.4 to 1.0)	39.2 (20.0 to 63.5)	-34.6 (-52.7 to -16.7)
Hepatitis C	483.5 (435.2 to 536.5)	701.3 (629.2 to 773.8)	45.1 (24.5 to 66.7)	-28.7 (-37.0 to -20.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	42.0 (10.8 to 78.6)	-27.3 (-45.2 to 0.5)
Hepatitis E	4.6 (3.1 to 6.3)	10.0 (6.1 to 13.4)	112.7 (48.8 to 201.8)	2.7 (-24.5 to 45.7)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	119.0 (44.4 to 238.7)	3.4 (-27.7 to 59.5)
Leprosy	0.5 (0.4 to 0.8)	0.7 (0.6 to 0.9)	36.8 (7.5 to 82.8)	-32.0 (-45.0 to -11.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	38.3 (0.1 to 108.5)	-31.5 (-49.9 to 0.2)
Other infectious diseases	233.1 (181.3 to 286.7)	322.1 (280.4 to 365.6)	37.6 (18.8 to 65.6)	-23.8 (-34.0 to -8.5)	9.1 (5.6 to 13.4)	12.5 (8.0 to 38.8)	37.0 (15.2 to 74.4)	-17.9 (-30.9 to 2.7)
Non-communicable diseases	-	-	-	-	1,435.1 (1,058.1 to 1,863.5)	2,927.5 (2,157.4 to 3,786.5)	104.2 (97.6 to 109.8)	-1.2 (-3.9 to 1.5)
Neoplasms	-	-	-	-	5.9 (4.2 to 7.8)	12.5 (8.8 to 17.0)	108.9 (73.9 to 160.1)	1.7 (-14.9 to 29.1)
Esophageal cancer	2.4 (1.8 to 3.2)	4.6 (3.3 to 6.2)	87.6 (27.1 to 174.1)	-5.5 (-36.1 to 36.4)	0.4 (0.2 to 0.5)	0.7 (0.5 to 1.0)	88.3 (37.0 to 161.2)	-5.0 (-32.0 to 29.8)
Stomach cancer	2.1 (1.7 to 2.6)	2.5 (2.0 to 3.2)	20.7 (-10.1 to 67.5)	-40.8 (-56.5 to -17.2)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	22.1 (8.0 to 67.0)	-40.2 (-55.7 to -16.9)
Liver cancer	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	89.3 (37.0 to 157.7)	7.6 (-34.2 to 24.8)
Liver cancer due to hepatitis B	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.5)	32.7 (-42.1 to 208.5)	-37.8 (73.5 to 55.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	23.7 (-36.4 to 189.7)	-41.5 (-71.1 to 53.5)
Liver cancer due to hepatitis C	0.1 (0.0 to 0.1)	0.5 (0.3 to 0.8)	572.4 (214.0 to 1,294.1)	218.7 (46.9 to 549.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	533.6 (223.8 to 1,108.8)	199.4 (52.2 to 455.1)
Liver cancer due to alcohol use	0.2 (0.2 to 0.3)	0.4 (0.2 to 0.6)	44.2 (-22.6 to 157.5)	-29.5 (-62.0 to 23.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	40.8 (-13.7 to 125.4)	-61.3 (-36.7 to 9.0)
Liver cancer due to other causes	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	43.7 (-20.1 to 152.4)	-32.6 (-63.5 to 26.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	36.9 (-11.7 to 111.3)	-35.9 (-59.7 to 4.7)
Larynx cancer	0.9 (0.7 to 1.4)	1.7 (1.1 to 2.8)	83.3 (12.7 to 193.3)	-10.3 (-45.0 to 43.3)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	83.1 (8.7 to 190.4)	-10.9 (-46.5 to 41.2)
Tracheal, bronchus and lung cancer	0.6 (0.5 to 0.7)	1.1 (0.8 to 1.4)	82.2 (36.7 to 144.7)	-8.6 (-30.8 to 21.8)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	85.8 (35.3 to 163.3)	-6.8 (-32.1 to 30.4)
Breast cancer	12.9 (8.0 to 16.3)	32.0 (21.9 to 42.8)	148.4 (73.8 to 265.6)	1.1 (-18.0 to 71.2)	2.6 (0.7 to 1.6)	6.8 (1.6 to 3.8)	127.2 (63.5 to 236.0)	7.6 (-22.1 to 59.8)
Cervical cancer	9.4 (6.8 to 12.5)	14.5 (10.1 to 21.5)	53.7 (-3.6 to 145.3)	-39.2 (55.6 to 15.7)	1.2 (0.5 to 1.2)	2.8 (0.7 to 1.9)	29.9 (-3.8 to 147.9)	-29.9 (-55.9 to 13.6)
Uterine cancer	1.2 (0.7 to 1.9)	1.8 (1.1 to 3.1)	55.1 (-12.1 to 165.8)	-25.7 (56.3 to 24.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	55.4 (-10.4 to 178.7)	-25.1 (-36.5 to 30.2)
Prostate cancer	3.8 (2.4 to 6.0)	16.6 (10.2 to 28.0)	330.1 (164.1 to 600.9)	126.5 (42.5 to 255.5)	0.4 (0.2 to 0.6)	1.4 (0.8 to 2.5)	277.0 (146.6 to 492.4)	99.4 (31.4 to 205.1)
Colon and rectum cancer	3.8 (3.3 to 4.3)	7.6 (6.2 to 9.5)	100.5 (57.8 to 161.9)	-1.6 (-21.8 to 28.0)	0.3 (0.2 to 0.5)	0.7 (0.5 to 0.9)	96.3 (53.0 to 161.4)	-2.9 (-24.0 to 29.6)
Lip and oral cavity cancer	3.6 (2.5 to 4.8)	6.2 (4.4 to 9.0)	72.8 (14.4 to 166.7)	-17.6 (-46.3 to 30.4)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	73.2 (15.3 to 165.5)	-17.3 (-45.0 to 29.8)
Nasopharynx cancer	1.1 (0.6 to 1.3)	1.6 (1.0 to 2.3)	65.0 (8.8 to 167.9)	-26.8 (-54.6 to 17.8)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	62.8 (2.0 to 154.1)	-27.3 (-52.5 to 16.1)
Other pharynx cancer	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	58.7 (-10.1 to 175.6)	-23.8 (-57.8 to 36.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	61.6 (-2.0 to 164.1)	-21.3 (-54.3 to 29.4)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	67.5 (6.1 to 169.5)	-14.0 (-46.3 to 38.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	62.2 (5.7 to 162.9)	-17.4 (-47.1 to 39.5)
Pancreatic cancer	0.3 (0.2 to 0.3)	0.5 (0.4 to 0.7)	98.6 (46.0 to 184.1)	-0.2 (-26.2 to 42.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	99.6 (48.9 to 170.1)	0.0 (-25.2 to 36.0)
Malignant skin melanoma	1.1 (0.8 to 1.5)	2.6 (1.9 to 3.6)	136.6 (61.6 to 264.9)	-15.3 (-23.6 to 73.9)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	124.7 (59.9 to 253.9)	12.7 (-26.6 to 70.6)
Non-melanoma skin cancer	1.4 (1.1 to 1.8)	3.9 (3.1 to 4.9)	170.3 (113.7 to 253.2)	28.2 (-0.0 to 74.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	203.3 (110.4 to 333.5)	46.7 (-6.3 to 123.9)
Ovarian cancer	1.1 (0.7 to 1.6)	2.3 (1.5 to 3.5)	112.1 (35.2 to 233.3)	0.5 (-35.7 to 57.9)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	110.5 (31.5 to 244.6)	0.2 (-37.7 to 64.6)
Testicular cancer	0.3 (0.2 to 0.6)	0.8 (0.4 to 1.5)	153.4 (39.8 to 351.4)	6.9 (-37.1 to 77.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	147.1 (28.0 to 376.9)	4.7 (-38.9 to 85.7)
Kidney cancer	1.1 (0.7 to 1.7)	2.0 (1.3 to 3.4)	84.3 (9.4 to 226.7)	6.6 (-26.2 to 55.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	88.3 (7.4 to 232.9)	4.2 (-27.0 to 54.4)
Bladder cancer	1.1 (0.8 to 1.4)	1.8 (1.3 to 2.4)	70.1 (19.0 to 141.1)	-16.4 (-41.3 to 19.1)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	68.1 (18.9 to 139.1)	-16.6 (-41.4 to 18.2)
Brain and nervous system cancer	1.1 (0.8 to 1.4)	2.5 (1.7 to 3.5)	120.0 (59.7 to 218.9)	-6.2 (-30.7 to 28.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	102.7 (46.9 to 178.9)	-14.1 (-37.6 to 20.9)
Thyroid cancer	1.5 (1.0 to 2.2)	3.0 (1.9 to 4.6)	105.1 (34.3 to 213.6)	-9.8 (-41.9 to 45.1)	0.1 (0.1 to 0.1)	0.3 (0.1 to 0.3)	103.7 (30.9 to 215.1)	-9.2 (-42.9 to 44.5)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	87.3 (28.6 to 176.1)	-13.6 (-39.8 to 24.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.2)	87.1 (29.5 to 168.6)	-13.4 (-39.6 to 25.9)
Hodgkin lymphoma	0.6 (0.4 to 0.9)	1.8 (1.1 to 2.8)	190.4 (71.1 to 377.8)	46.0 (-19.0 to 162.0)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	156.8 (63.0 to 301.4)	26.9 (-28.9 to 122.4)
Non-Hodgkin lymphoma	2.8 (1.8 to 4.0)	5.8 (3.8 to 8.0)	105.9 (41.9 to 197.7)	11.5 (-24.8 to 67.6)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.7)	104.6 (40.9 to 190.9)	8.0 (-25.7 to 62.2)
Multiple myeloma	0.5 (0.3 to 0.7)	1.1 (0.7 to 1.6)	114.9 (39.8 to 253.8)	7.2 (-32.3 to 79.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.4)	112.8 (35.3 to 237.3)	5.3 (-36.4 to 74.0)
Leukemia	1.3 (0.9 to 1.8)	2.3 (1.5 to 3.5)	89.0 (18.1 to 209.3)	1.3 (-31.4 to 45.4)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	70.7 (19.1 to 151.7)	-10.0 (-36.8 to 24.6)
Other neoplasms	7.5 (5.7 to 10.2)	22.4 (14.4 to 31.4)	197.8 (87.1 to 347.3)	47.1 (4.7 to 100.8)	0.5 (0.3 to 0.8)	1.4 (0.8 to 2.2)	189.8 (89.1 to 301.9)	33.4 (-1.5 to 79.4)
Cardiovascular diseases	-	-	-	-	29.3 (19.8 to 41.8)	54.6 (37.4 to 75.7)	88.0 (46.6 to 130.7)	-7.3 (-25.7 to 13.2)
Rheumatic heart disease	108.9 (88.2 to 131.0)	173.7 (144.8 to 207.0)	59.0 (19.8 to 121.3)	-21.6 (-38.8 to 5.0)	5.8 (3.6 to 8.4)	8.6 (5.4 to 12.9)	49.2 (14.5 to 108.4)	-29.3 (-44.9 to -4.7)
Ischemic heart disease	176.9 (139.4 to 224.4)	260.7 (210.3 to 322.0)	48.2 (8.4 to 100.5)	-25.5 (-43.7 to 0.4)	9.7 (6.1 to 14.7)	14.2 (8.9 to 20.6)	48.7 (-0.9 to 115.5)	-23.3 (-46.4 to 7.8)
Cerebrovascular disease	-	-	-	-	6.1 (0.7 to 1.5)	2.4 (1.6 to 3.3)	123.0 (68.7 to 195.7)	4.4 (-21.8 to 35.0)
Ischemic stroke	5.1 (4.3 to 6.2)	11.5 (9.1 to 14.0)	122.2 (70.1 to 194.3)	4.8 (-19.9 to 37.1)	0.8 (0.5 to 1.2)	1.8 (1.2 to 2.5)	122.9 (68.4 to 197.8)	4.3 (-22.0 to 38.7)
Hemorrhagic stroke	1.6 (1.3 to 2.0)	3.7 (2.9 to 4.6)	127.4 (60.3 to 204.4)	4.5 (-24.3 to 35.4)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	127.9 (60.2 to 207.8)	3.8 (-25.9 to 37.3)
Hypertensive heart disease	30.7 (24.8 to 37.4)	81.0 (65.8 to 96.4)	164.5 (95.4 to 255.7)	31.3 (-5.6 to 76.9)	3.3 (2.2 to 4.9)	8.8 (5.8 to 12.6)	165.6 (93.3 to 257.2)	31.8 (-5.6 to 76.5)
Cardiomyopathy and myocarditis	18.8 (14.8 to 22.5)	40.0 (31.5 to 50.9)	109.5 (61.4 to 191.3)	0.2 (-29.6 to 52.3)	2.1 (1.3 to 3.0)	4.4 (2.7 to 6.4)	109.8 (58.8 to 199.1)	0.0 (-30.0 to 53.6)
Atrial fibrillation and flutter	8.2 (5.9 to 10.8)	26.5 (15.6 to 37.6)	215.0 (91.3 to 441.4)	6.5 (-4.6 to 20.7)	0.6 (0.4 to 0.9)	2.0 (1.1 to 3.2)	214.2 (91.3 to 439.6)	6.8 (-4.3 to 203.9)
Peripheral vascular disease	282.6 (185.6 to 378.5)	555.7 (409.8 to 725.8)	97.4 (30.4 to 203.1)	-6.7 (-37.2 to 47.0)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.5)	21.9 (-42.4 to 208.1)	-21.9 (-68.5 to 75.3)
Endocarditis	0.6 (0.4 to 0.9)	1.3 (0.9 to 2.0)	119.9 (66.6 to 220.3)	16.8 (-27.3 to 91.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	133.9 (62.0 to 256.8)	22.6 (-28.8 to 112.3)
Other cardiovascular and circulatory diseases	93.2 (44.3 to 169.2)	196.1 (110.5 to 276.1)	119.1 (-1.8 to 369.9)	8.3 (-60.4 to 111.9)	6.5 (2.8 to 12.3)	13.8 (7.0 to 22.3)	130.0 (60.3 to 374.3)	-7.9 (-60.5 to 113.9)
Chronic respiratory diseases	-							

Appendix Table G.4 - Kenya prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	103.9 (97.1 to 110.3)	6.7 (-9.9 to -3.9)
Silicosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	91.2 (82.4 to 99.5)	-12.5 (-16.3 to -9.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (82.2 to 99.4)	-12.5 (-16.3 to -9.0)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	115.8 (107.1 to 125.8)	-0.2 (-3.8 to 4.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	115.7 (107.0 to 126.0)	-0.3 (-3.9 to 4.0)
Asthma	956.8 (819.7 to 1,091.1)	1,529.5 (1,275.1 to 1,790.1)	60.3 (28.5 to 97.5)	-14.4 (-27.9 to 0.1)	42.5 (26.9 to 61.9)	67.7 (43.6 to 100.2)	59.5 (26.7 to 98.5)	-14.7 (-28.2 to -0.2)
Interstitial lung disease and pulmonary sarcoidosis	0.4 (0.3 to 0.6)	1.0 (0.7 to 1.2)	122.5 (45.9 to 226.4)	5.7 (-27.1 to 42.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	124.4 (48.4 to 224.6)	5.9 (-26.9 to 41.8)
Other chronic respiratory diseases	-	-	-	-	20.7 (11.1 to 34.4)	38.6 (21.6 to 64.8)	86.8 (26.6 to 177.1)	-13.8 (-41.8 to 26.9)
Cirrhosis	-	-	-	-	1.6 (1.1 to 2.3)	2.9 (2.0 to 4.0)	75.7 (52.7 to 102.3)	41.1 (-21.0 to -0.3)
Cirrhosis due to hepatitis B	2.4 (1.8 to 3.1)	4.1 (2.9 to 5.3)	72.8 (10.2 to 156.5)	-12.8 (-43.6 to 26.6)	0.4 (0.2 to 0.6)	0.7 (0.4 to 1.1)	73.3 (-1.4 to 171.3)	-12.5 (-46.1 to 31.9)
Cirrhosis due to hepatitis C	1.1 (0.6 to 1.6)	3.7 (2.4 to 5.0)	241.3 (85.5 to 663.8)	59.9 (-18.1 to 223.7)	0.2 (0.1 to 0.3)	0.6 (0.3 to 0.9)	236.0 (76.7 to 683.4)	59.7 (-20.2 to 236.5)
Cirrhosis due to alcohol use	2.8 (2.3 to 3.3)	3.7 (2.6 to 4.8)	32.4 (-10.2 to 86.1)	0.5 (-57.3 to -11.6)	0.6 (0.3 to 0.7)	0.6 (0.3 to 0.9)	33.7 (-15.8 to 96.8)	-39.8 (-58.8 to -10.7)
Cirrhosis due to other causes	3.5 (3.1 to 4.0)	5.8 (4.9 to 6.7)	64.4 (29.8 to 103.5)	-1.2 (-29.8 to 30.8)	0.6 (0.4 to 0.9)	1.0 (0.6 to 1.5)	68.8 (11.1 to 135.1)	-1.8 (-33.7 to 44.1)
Digestive diseases	-	-	-	-	27.2 (19.3 to 37.1)	55.0 (38.8 to 75.3)	102.7 (85.4 to 120.3)	-1.4 (-8.7 to 6.0)
Peptic ulcer disease	107.5 (96.4 to 118.2)	170.0 (151.8 to 187.1)	57.5 (34.5 to 86.5)	-26.2 (-35.5 to -12.8)	4.0 (2.7 to 5.7)	6.5 (4.4 to 9.2)	61.7 (32.7 to 90.6)	-26.8 (-39.0 to -15.9)
Gastritis and duodenitis	274.0 (253.9 to 293.7)	501.8 (470.3 to 529.7)	82.9 (68.4 to 100.6)	-6.0 (-14.3 to 4.2)	12.9 (8.8 to 18.5)	24.1 (16.2 to 34.7)	87.2 (64.8 to 112.4)	-2.9 (-11.8 to 7.2)
Appendicitis	2.8 (2.0 to 3.5)	5.8 (4.4 to 7.2)	112.2 (37.4 to 214.8)	0.7 (-27.3 to 49.5)	0.8 (0.5 to 1.3)	1.8 (1.0 to 2.7)	110.1 (23.5 to 242.9)	2.0 (-33.7 to 59.8)
Paralytic ileus and intestinal obstruction	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.9)	80.3 (-0.1 to 151.9)	-4.4 (-20.0 to 9.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	80.4 (5.4 to 181.7)	4.4 (-28.0 to 25.2)
Inguinal, femoral, and abdominal hernia	40.8 (33.5 to 52.7)	124.6 (106.1 to 145.1)	207.0 (129.2 to 299.6)	183.9 (127.0 to 253.2)	0.4 (0.2 to 0.8)	1.3 (0.6 to 2.4)	198.5 (120.1 to 294.1)	181.3 (126.3 to 252.0)
Inflammatory bowel disease	19.1 (18.2 to 20.1)	52.2 (49.9 to 54.7)	172.3 (155.1 to 191.0)	25.1 (18.2 to 32.6)	4.1 (2.8 to 5.6)	11.1 (7.6 to 15.2)	172.9 (145.8 to 200.8)	25.1 (15.2 to 35.6)
Vascular intestinal disorders	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	81.5 (36.4 to 147.7)	-4.2 (-37.5 to 33.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.0 (36.7 to 151.7)	-2.5 (-37.0 to 41.8)
Gallbladder and biliary diseases	6.2 (5.5 to 6.9)	14.9 (13.2 to 16.6)	138.9 (104.8 to 181.8)	0.7 (-1.3 to 3.8)	1.6 (1.0 to 2.2)	3.5 (1.0 to 2.4)	138.5 (96.5 to 189.8)	16.9 (-3.2 to 40.3)
Pancreatitis	3.4 (3.2 to 3.6)	8.0 (7.6 to 8.5)	138.5 (119.1 to 158.9)	4.5 (-3.8 to 13.3)	1.0 (0.7 to 1.4)	2.4 (1.6 to 3.3)	137.4 (97.3 to 182.6)	4.4 (-10.9 to 21.5)
Other digestive diseases	-	-	-	-	3.1 (2.0 to 4.8)	6.1 (3.9 to 9.1)	94.7 (46.1 to 147.7)	-5.0 (-28.3 to 21.4)
Neurological disorders	-	-	-	-	80.2 (52.7 to 112.6)	186.8 (124.2 to 265.3)	133.4 (75.2 to 189.7)	9.3 (-11.4 to 28.9)
Alzheimer disease and other dementias	32.8 (29.0 to 36.7)	65.9 (58.7 to 74.1)	100.3 (71.6 to 139.5)	1.5 (-14.0 to 20.8)	4.6 (3.3 to 6.1)	9.3 (6.6 to 12.0)	106.6 (70.5 to 139.9)	1.8 (-13.6 to 22.6)
Parkinson disease	1.7 (1.0 to 2.4)	3.3 (1.9 to 4.7)	95.9 (77.6 to 116.4)	-3.0 (-11.6 to 5.4)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	97.5 (64.3 to 139.6)	-2.8 (-18.0 to 17.6)
Epilepsy	33.8 (19.3 to 52.5)	69.5 (40.1 to 109.8)	104.0 (-3.1 to 329.4)	6.1 (-50.3 to 126.6)	10.3 (5.1 to 17.4)	21.5 (10.9 to 37.1)	105.7 (-4.6 to 339.8)	7.8 (-49.5 to 128.5)
Multiple sclerosis	0.8 (0.7 to 0.9)	2.2 (1.9 to 2.4)	162.4 (117.4 to 207.5)	14.6 (-2.7 to 32.9)	0.3 (0.2 to 0.4)	0.8 (0.5 to 1.0)	159.9 (110.6 to 211.7)	13.9 (7.5 to 36.6)
Migraine	1,210.8 (870.1 to 1,560.0)	2,780.4 (1,817.7 to 3,616.1)	426.3 (39.1 to 245.2)	6.3 (-29.6 to 48.3)	41.5 (33.0 to 45.5)	94.4 (49.1 to 149.0)	185.2 (37.2 to 245.5)	9.4 (-31.4 to 49.8)
Tension-type headache	2,534.4 (2,334.2 to 2,754.1)	5,798.6 (5,299.5 to 6,278.1)	129.0 (101.2 to 160.7)	5.0 (-4.4 to 15.7)	3.8 (1.9 to 6.6)	8.8 (4.3 to 15.2)	128.6 (101.0 to 162.3)	5.1 (-5.1 to 16.3)
Medication overuse headache	96.9 (62.6 to 133.6)	291.8 (187.5 to 410.3)	200.8 (113.5 to 309.2)	42.5 (2.7 to 97.8)	15.3 (8.4 to 24.1)	45.9 (24.5 to 74.2)	199.9 (110.6 to 309.9)	42.6 (2.2 to 97.8)
Other neurological disorders	0.0 (0.0 to 0.0)	0.1 (0.0 to 1.1)	83.8 (36.6 to 153.0)	-6.7 (-29.8 to 26.1)	4.2 (2.7 to 6.4)	6.9 (4.4 to 10.2)	66.3 (13.0 to 136.9)	-16.9 (-43.4 to 19.1)
Mental and substance use disorders	-	-	-	-	502.9 (353.9 to 688.5)	1,030.3 (724.1 to 1,399.8)	104.9 (97.7 to 112.2)	-0.9 (-4.2 to 2.6)
Schizophrenia	42.6 (39.0 to 46.3)	97.4 (88.6 to 105.4)	128.3 (118.2 to 139.4)	0.3 (-3.8 to 4.9)	0.3 (0.1 to 0.3)	0.3 (0.2 to 0.6)	128.5 (113.3 to 144.5)	0.3 (-5.8 to 6.6)
Alcohol use disorders	220.2 (202.3 to 240.8)	433.4 (401.9 to 467.6)	96.8 (86.7 to 107.1)	-9.2 (-13.5 to -4.6)	21.7 (14.3 to 30.8)	42.7 (28.2 to 59.9)	97.2 (83.9 to 110.2)	-9.3 (-14.8 to -3.7)
Drug use disorders	-	-	-	-	25.9 (17.0 to 36.3)	58.1 (37.8 to 80.7)	124.3 (101.1 to 151.3)	-0.1 (-9.6 to 10.4)
Opioid use disorders	32.6 (21.1 to 47.8)	75.6 (47.3 to 111.1)	132.9 (108.7 to 153.0)	-1.5 (-10.9 to 7.1)	13.4 (7.8 to 21.2)	31.2 (17.0 to 49.8)	132.6 (104.6 to 159.8)	-1.7 (-12.6 to 9.3)
Cocaine use disorders	8.0 (8.0 to 12.0)	23.5 (19.4 to 27.9)	340.6 (78.7 to 208.4)	3.3 (-17.8 to 28.2)	1.3 (0.8 to 2.0)	3.2 (2.0 to 4.7)	140.3 (69.9 to 229.5)	3.9 (-21.6 to 36.4)
Amphetamine use disorders	34.8 (32.2 to 37.2)	73.6 (67.5 to 78.7)	111.1 (89.0 to 136.0)	4.6 (-7.9 to 13.1)	1.9 (2.8 to 7.0)	9.6 (6.0 to 14.5)	110.8 (78.6 to 151.6)	2.0 (-12.6 to 19.7)
Cannabis use disorders	20.4 (16.3 to 24.3)	42.3 (34.5 to 50.0)	106.8 (89.0 to 125.1)	2.8 (-5.3 to 10.5)	0.6 (0.4 to 0.9)	1.2 (0.8 to 1.8)	105.9 (61.9 to 159.6)	2.0 (-17.2 to 25.7)
Other drug use disorders	-	-	-	-	6.0 (3.7 to 8.9)	12.9 (7.8 to 19.1)	115.0 (56.6 to 192.5)	1.6 (-26.2 to 37.5)
Depressive disorders	-	-	-	-	250.7 (160.7 to 371.5)	510.3 (322.8 to 749.7)	104.0 (89.5 to 116.7)	-1.6 (-7.7 to 4.2)
Major depressive disorder	1,114.6 (860.8 to 1,370.0)	2,258.3 (1,722.9 to 2,786.7)	102.9 (87.4 to 116.5)	-1.7 (-8.5 to 4.6)	230.9 (146.7 to 346.1)	466.7 (295.0 to 696.3)	102.6 (86.8 to 116.1)	-1.8 (-8.5 to 4.6)
Dysthymia	205.2 (168.5 to 245.1)	451.9 (370.7 to 542.2)	120.0 (116.8 to 123.3)	0.1 (-0.0 to 0.3)	19.8 (12.8 to 29.0)	43.6 (28.3 to 63.7)	120.0 (112.8 to 127.0)	0.1 (-2.3 to 2.4)
Bipolar disorder	117.9 (100.0 to 135.5)	258.6 (221.1 to 296.2)	119.2 (103.6 to 134.0)	-0.4 (-5.8 to 5.3)	24.1 (14.9 to 36.6)	52.7 (32.4 to 79.5)	119.1 (101.0 to 138.6)	-0.3 (-7.0 to 6.5)
Anxiety disorders	523.3 (310.2 to 786.0)	1,072.9 (636.5 to 1,605.4)	105.2 (92.7 to 114.8)	0.0 (-0.2 to 0.2)	49.4 (24.8 to 80.2)	99.0 (51.3 to 165.2)	105.0 (90.2 to 116.8)	0.1 (-3.0 to 3.8)
Eating disorders	-	-	-	-	5.8 (3.4 to 8.9)	11.7 (6.9 to 18.6)	101.9 (83.2 to 120.3)	-0.2 (-8.5 to 8.6)
Anorexia nervosa	4.1 (3.0 to 5.3)	8.2 (6.1 to 10.8)	101.6 (77.8 to 128.2)	2.7 (-9.2 to 15.1)	0.9 (0.5 to 1.3)	1.8 (1.0 to 2.7)	101.2 (55.0 to 159.5)	2.6 (-19.9 to 30.3)
Bulimia nervosa	23.2 (15.9 to 33.8)	47.0 (31.8 to 68.6)	101.8 (94.5 to 107.8)	-0.6 (-0.8 to -0.5)	4.9 (2.8 to 7.8)	9.9 (5.6 to 16.1)	101.9 (82.4 to 122.5)	-0.5 (-9.2 to 8.6)
Autistic spectrum disorders	-	-	-	-	28.1 (19.2 to 38.5)	55.6 (37.0 to 73.1)	90.3 (83.3 to 98.3)	0.1 (-2.9 to 3.7)
Autism	71.7 (68.1 to 75.5)	137.0 (129.9 to 144.2)	90.8 (90.2 to 91.4)	-0.0 (-0.0 to 0.0)	17.8 (11.8 to 24.3)	33.9 (22.7 to 46.4)	90.6 (79.9 to 102.1)	0.1 (-4.5 to 5.1)
Asperger syndrome	103.3 (96.8 to 109.3)	196.7 (184.4 to 208.3)	90.2 (89.4 to 91.1)	0.0 (-0.0 to 0.0)	10.4 (7.2 to 14.5)	19.7 (13.7 to 27.5)	90.3 (82.4 to 99.0)	0.1 (-3.5 to 4.2)
Attention-deficit/hyperactivity disorder	184.3 (170.2 to 199.3)	319.8 (294.8 to 345.4)	73.4 (72.8 to 73.7)	0.1 (0.1 to 0.1)	2.2 (1.3 to 3.4)	3.9 (2.3 to 6.0)	73.8 (60.8 to 87.2)	0.4 (-7.0 to 7.9)
Conduct disorder	270.2 (254.6 to 286.3)	464.4 (437.6 to 492.0)	71.7 (71.2 to 72.2)	0.1 (0.1 to 0.1)	32.5 (20.2 to 47.0)	55.8 (35.3 to 81.2)	71.7 (64.5 to 80.1)	0.4 (-4.1 to 5.1)
Idiopathic intellectual disability	343.0 (160.4 to 470.9)	750.5 (469.4 to 974.4)	117.4 (85.1 to 204.8)	15.4 (-2.3 to 68.4)	16.8 (7.0 to 26.4)	36.8 (20.7 to 54.9)	117.5 (85.5 to 151.9)	15.3 (-11.7 to 30.6)
Other mental and substance use disorders	257.2 (239.5 to 274.5)	575.1 (536.0 to 612.4)	123.4 (122.1 to 124.6)	-0.1 (-0.2 to 0.1)	19.2 (13.1 to 26.0)	43.1 (29.4 to 58.1)	123.6 (113.8 to 134.4)	0.1 (-3.5 to 4.0)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	114.0 (79.3 to 155.5)	242.0 (169.4 to 329.9)	112.7 (97.3 to 127.1)	5.6 (-2.7 to 14.5)
Diabetes mellitus	251.2 (201.5 to 296.0)	691.1 (582.4 to 828.2)	174.1 (116.3 to 251.1)	25.8 (-9.9 to 60.7)	18.6 (12.0 to 27.4)	51.3 (33.7 to 72.3)	175.2 (116.5 to 250.7)	26.8 (-3.2 to 64.7)
Acute glomerulonephritis	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.4)	47.3 (39.4 to 62.6)	-0.0 (-1.9 to -9.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.3 (39.4 to 62.6)	-0.0 (-1.9 to -9.8)
Chronic kidney disease	-	-	-	-	34.6 (24.4 to 45.6)	72.7 (51.9 to 96.8)	110.3 (90.5 to 133.7)	1.3 (-10.3 to 10.7)
Chronic kidney disease due to diabetes mellitus	268.9 (164.4 to 410.3)	528.9 (328.8 to 763.0)	99.6 (39.9 to 167.9)	-4.1 (-36.3 to 27.0)	4.1 (2.7 to 5.6)	8.3 (5.3 to 12.1)	102.4 (46.7 to 167.9)	-5.0 (-30.7 to 27.3)
Chronic kidney disease due to hypertension	918.5 (582.9 to 1,490.9)	1,812.8 (1,103.5 to 3,197.0)	95.8 (65.4 to 135.5)	4.7 (-11.6 to 27.2)	10.2 (6.9 to 13.8)	22.4 (15.1 to 30.3)	119.7 (76.0 to 184.5)	0.8 (-15.7 to 18.4)
Chronic kidney disease due to glomerulonephritis	725.5 (520.3 to 1,076.4)	1,159.1 (1,046.7 to 2,375.0)	110.0 (65.8 to 154.8)	11.3 (-17.0 to 19.8)	12.8 (8.8 to 17.4)	28.8 (18.7 to 35.9)	186.6 (77.0 to 315.1)	6.6 (-11.7 to 30.6)
Chronic kidney disease due to other causes	592.4 (350.1 to 1,069.0)	1,145.3 (717.6 to 1,741.9)	95.9 (47.4 to 172.5)	-4.4 (-29.9 to 20.6)	7.5 (5.2 to 10.5)	15.6 (10.5 to 22.3)	108.6 (59.3 to 175.5)	-2.9 (-23.3 to 26.9)
Urinary diseases and male infertility	-	-	-	-	5.9 (3.8 to 8.5)	11.6 (7.5 to 16.5)	95.3 (71.7 to 121.0)	-3.3 (-13.8 to 8.4)

Appendix Table G.4 - Kenya prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	4.3 (4.0 to 4.5)	9.1 (8.5 to 9.6)	112.4 (94.5 to 131.8)	0.1 (0.3 to 15.7)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	111.6 (67.6 to 169.5)	111.6 (10.3 to 29.7)
Urolithiasis	46.7 (36.8 to 59.8)	77.3 (59.2 to 97.5)	65.3 (50.7 to 82.7)	-21.1 (-28.6 to -14.2)	0.5 (0.3 to 0.6)	1.0 (0.6 to 1.3)	111.7 (84.6 to 140.7)	-4.8 (-14.4 to 4.9)
Benign prostatic hyperplasia	128.0 (116.3 to 139.2)	245.9 (224.4 to 266.6)	92.3 (69.3 to 117.6)	-2.9 (-14.0 to 9.2)	4.6 (3.0 to 6.5)	8.8 (5.7 to 12.4)	92.9 (69.8 to 119.7)	-2.6 (-13.7 to 10.2)
Male infertility due to other causes	88.6 (51.1 to 142.8)	169.9 (107.3 to 249.1)	91.4 (6.6 to 298.5)	-19.6 (56.2 to 70.7)	0.5 (0.2 to 1.2)	1.1 (0.4 to 2.2)	94.1 (-1.2 to 292.1)	-18.0 (56.5 to 76.2)
Other urinary diseases	-	-	-	-	-	-	-	-
Gynecological diseases	-	-	-	-	19.2 (12.5 to 29.2)	38.4 (23.7 to 57.3)	99.7 (61.2 to 150.1)	-10.8 (-26.6 to 9.3)
Uterine fibroids	288.3 (258.7 to 315.4)	676.2 (607.5 to 738.5)	134.3 (133.6 to 135.1)	-1.7 (-1.8 to -1.6)	4.0 (2.3 to 6.7)	7.3 (4.0 to 12.6)	81.5 (56.8 to 103.4)	-21.8 (-32.4 to -13.5)
Polycystic ovarian syndrome	296.1 (266.8 to 331.0)	676.9 (603.2 to 760.7)	129.2 (94.8 to 166.7)	-0.2 (-13.7 to 14.3)	2.9 (1.3 to 5.5)	6.5 (3.0 to 12.1)	127.6 (94.8 to 163.4)	-0.8 (-13.7 to 13.8)
Female infertility due to other causes	91.4 (61.0 to 126.2)	189.2 (110.3 to 261.9)	109.4 (9.2 to 240.3)	-11.2 (55.6 to 47.5)	0.5 (0.2 to 1.0)	1.0 (0.3 to 2.1)	109.5 (7.4 to 224.2)	-1.7 (55.5 to 46.3)
Endometriosis	30.3 (25.4 to 35.5)	61.0 (51.5 to 71.4)	100.6 (60.2 to 152.9)	-12.9 (-29.4 to 8.1)	2.8 (1.8 to 4.0)	5.6 (3.7 to 8.1)	100.3 (54.2 to 156.5)	-13.4 (-31.7 to 8.7)
Genital prolapse	506.0 (423.4 to 583.0)	1,209.6 (1,031.9 to 1,391.3)	136.6 (96.3 to 195.1)	3.9 (-12.1 to 27.8)	1.6 (0.8 to 3.0)	3.8 (1.9 to 7.4)	136.7 (93.7 to 201.4)	3.9 (-12.5 to 27.8)
Premenstrual syndrome	734.6 (432.4 to 1,005.1)	1,521.3 (918.6 to 2,116.7)	108.1 (9.5 to 299.4)	-2.3 (-49.7 to 95.5)	6.2 (3.1 to 10.1)	12.7 (6.5 to 21.7)	107.6 (8.4 to 304.0)	-2.3 (-49.1 to 98.8)
Other gynecological diseases	44.3 (31.3 to 57.6)	58.6 (48.7 to 72.6)	31.2 (-3.3 to 86.9)	-41.0 (0.6 to 1.9)	1.3 (0.6 to 1.9)	1.4 (0.8 to 2.1)	31.0 (-35.3 to 116.6)	-51.7 (-69.3 to -9.9)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	25.4 (17.2 to 38.2)	54.8 (36.6 to 78.0)	107.2 (88.1 to 136.5)	13.5 (3.5 to 28.5)
Thalassemias	0.2 (0.0 to 0.4)	0.3 (0.1 to 0.6)	48.5 (8.2 to 108.0)	-13.1 (-36.3 to 19.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.4 (16.2 to 74.0)	-9.0 (-32.3 to 1.3)
Thalassemia trait	202.8 (117.5 to 301.3)	361.9 (221.8 to 534.4)	75.2 (51.3 to 112.4)	-7.8 (-21.3 to 11.8)	4.3 (2.6 to 6.3)	8.1 (5.1 to 12.0)	89.1 (56.5 to 136.7)	5.4 (1.3 to 26.7)
Sickle cell disorders	22.0 (18.0 to 25.3)	56.0 (49.1 to 61.5)	153.8 (116.6 to 207.1)	39.4 (18.9 to 68.6)	2.4 (1.6 to 3.5)	6.3 (4.4 to 8.6)	161.1 (103.7 to 221.9)	37.0 (10.2 to 67.3)
Sickle cell trait	2,407.3 (2,219.7 to 2,578.4)	5,323.9 (4,982.9 to 5,617.7)	120.5 (112.3 to 131.4)	16.4 (11.7 to 21.8)	13.4 (8.7 to 19.4)	32.1 (20.7 to 46.5)	139.9 (100.4 to 193.2)	29.9 (9.2 to 67.0)
G6PD deficiency	3,050.2 (2,644.2 to 3,483.6)	6,376.5 (5,606.8 to 7,155.9)	108.4 (76.3 to 149.7)	9.9 (-7.1 to 31.6)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.7)	59.0 (-30.6 to 257.1)	-15.6 (-64.3 to 69.8)
G6PD trait	5,460.7 (5,361.3 to 5,545.8)	10,335.8 (10,119.4 to 10,549.7)	89.1 (83.9 to 93.9)	-0.1 (-2.8 to 2.5)	0.2 (0.0 to 0.3)	0.4 (0.1 to 0.6)	94.2 (61.4 to 1,191.3)	9.4 (-76.2 to 633.2)
Other hemoglobinopathies and hemolytic anemias	173.3 (136.8 to 204.9)	225.4 (191.2 to 256.0)	29.7 (6.5 to 68.0)	-35.3 (-45.2 to -20.9)	5.8 (3.3 to 8.9)	7.5 (4.7 to 11.2)	27.9 (-5.8 to 97.1)	-30.2 (-48.3 to 4.8)
Endocrine, metabolic, blood, and immune disorders	259.0 (228.8 to 288.7)	375.9 (318.1 to 438.5)	45.1 (12.3 to 81.1)	-21.2 (-35.3 to -6.4)	9.3 (5.8 to 13.6)	13.3 (8.4 to 19.5)	44.1 (5.9 to 80.3)	-47.4 (-35.4 to -1.8)
Musculoskeletal disorders	-	-	-	-	225.9 (159.1 to 302.5)	507.8 (356.1 to 674.2)	125.2 (104.5 to 143.5)	2.1 (-5.3 to 9.0)
Rheumatoid arthritis	43.6 (41.7 to 45.7)	84.3 (80.6 to 88.1)	93.2 (80.9 to 105.3)	-10.3 (-16.2 to -4.7)	10.4 (7.3 to 13.8)	20.1 (14.3 to 26.8)	93.5 (76.6 to 111.3)	-10.2 (-17.1 to -3.1)
Osteoarthritis	356.3 (343.5 to 368.6)	780.7 (750.4 to 811.7)	118.9 (106.8 to 130.1)	2.3 (-3.0 to 7.0)	21.7 (15.1 to 29.7)	47.7 (33.2 to 65.2)	119.8 (107.4 to 131.3)	7.7 (-3.2 to 7.7)
Low back and neck pain	-	-	-	-	163.9 (113.0 to 223.2)	321.0 (256.6 to 494.2)	123.7 (98.2 to 153.7)	2.7 (8.6 to 13.7)
Low back pain	853.5 (792.0 to 910.0)	1,853.4 (1,733.0 to 1,971.3)	116.9 (96.2 to 140.7)	0.1 (-9.0 to 9.1)	95.2 (63.1 to 134.7)	206.8 (137.5 to 281.6)	117.1 (97.1 to 141.6)	0.2 (-8.8 to 9.7)
Neck pain	697.5 (576.5 to 859.3)	1,678.2 (1,421.4 to 1,944.6)	141.7 (77.1 to 202.2)	6.7 (-17.8 to 33.2)	68.7 (45.4 to 100.8)	165.2 (110.8 to 230.2)	141.7 (77.7 to 202.7)	6.6 (-17.8 to 33.2)
Gout	2.7 (2.3 to 3.0)	5.7 (5.1 to 6.4)	113.3 (81.9 to 161.9)	-4.1 (-17.7 to 17.0)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	116.7 (66.8 to 183.5)	-2.7 (-25.6 to 28.6)
Other musculoskeletal disorders	327.0 (249.2 to 406.7)	744.6 (553.2 to 938.6)	127.0 (110.7 to 146.3)	8.4 (-5.0 to 10.3)	127.0 (19.0 to 43.8)	67.7 (42.2 to 100.8)	47.7 (105.2 to 146.9)	3.1 (-5.3 to 10.3)
Other non-communicable diseases	-	-	-	-	329.2 (215.8 to 482.8)	604.1 (400.9 to 879.3)	84.1 (71.7 to 93.1)	-7.3 (-11.9 to -4.3)
Congenital anomalies	-	-	-	-	24.8 (17.2 to 33.5)	48.9 (36.1 to 64.4)	97.0 (75.0 to 127.4)	2.7 (8.7 to 17.5)
Neural tube defects	4.7 (4.1 to 5.5)	13.0 (11.5 to 14.8)	177.2 (122.8 to 241.6)	54.8 (24.2 to 91.2)	1.2 (0.8 to 1.8)	3.7 (2.5 to 5.1)	195.2 (107.7 to 331.5)	67.2 (20.0 to 137.4)
Congenital heart anomalies	41.9 (33.8 to 53.1)	135.7 (106.8 to 173.1)	225.0 (133.8 to 346.0)	80.9 (25.5 to 148.5)	1.5 (0.7 to 2.6)	4.6 (1.9 to 8.3)	206.6 (122.7 to 330.9)	74.1 (26.4 to 146.9)
Orofacial clefts	5.9 (4.2 to 7.8)	21.3 (16.6 to 27.8)	263.7 (147.0 to 428.7)	111.4 (41.7 to 209.1)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	236.9 (108.5 to 420.2)	94.9 (22.6 to 196.2)
Down syndrome	16.6 (13.6 to 20.6)	36.7 (31.2 to 43.4)	122.4 (67.7 to 192.0)	19.3 (-9.5 to 56.4)	1.9 (1.3 to 2.7)	4.3 (3.1 to 5.9)	124.5 (65.7 to 203.3)	19.2 (-10.5 to 61.1)
Turner syndrome	0.7 (0.5 to 0.9)	1.4 (1.1 to 1.8)	114.9 (50.7 to 210.9)	12.4 (-21.7 to 61.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.4 (45.2 to 224.2)	11.7 (-25.8 to 66.1)
Klinefelter syndrome	0.7 (0.5 to 1.0)	1.3 (1.0 to 1.8)	88.1 (20.8 to 173.4)	-0.8 (-36.5 to 43.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.0 (31.2 to 199.7)	-0.1 (-36.2 to 45.1)
Chromosomal unbalanced rearrangements	27.2 (21.7 to 34.0)	61.4 (50.2 to 78.5)	123.6 (69.8 to 196.9)	3.2 (-8.5 to 50.7)	7.2 (2.2 to 4.4)	12.7 (5.0 to 10.1)	125.7 (67.1 to 210.5)	21.4 (-10.2 to 65.0)
Other congenital anomalies	166.1 (121.0 to 197.4)	274.7 (204.8 to 340.1)	64.7 (45.8 to 89.6)	-14.2 (-24.0 to -2.1)	16.9 (10.7 to 23.6)	28.8 (19.1 to 40.1)	69.6 (48.6 to 101.5)	-11.6 (-22.1 to 3.1)
Skin and subcutaneous diseases	-	-	-	-	123.8 (76.9 to 190.6)	224.0 (142.6 to 345.1)	84.0 (55.6 to 99.9)	-2.7 (-17.2 to 5.2)
Dermatitis	870.1 (710.5 to 1,057.7)	1,740.5 (1,414.0 to 2,128.8)	99.7 (94.7 to 105.0)	0.0 (-0.1 to 0.1)	31.5 (20.7 to 44.8)	61.0 (39.4 to 87.5)	93.7 (84.2 to 103.0)	0.1 (-2.8 to 3.0)
Psoriasis	131.5 (113.9 to 150.5)	273.6 (235.4 to 314.8)	107.8 (105.0 to 110.7)	0.0 (-0.1 to 0.1)	4.0 (7.3 to 15.3)	8.0 (15.2 to 31.6)	107.7 (93.4 to 123.0)	0.1 (-5.3 to 5.3)
Cellulitis	4.6 (3.7 to 5.8)	9.1 (7.3 to 11.5)	94.7 (66.2 to 142.6)	2.0 (-10.5 to 25.5)	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.0)	94.8 (42.4 to 168.4)	2.8 (-19.3 to 35.6)
Pyoderma	41.7 (30.6 to 54.0)	68.2 (51.3 to 87.4)	63.6 (52.2 to 77.7)	-4.2 (-10.6 to 2.9)	0.2 (0.1 to 0.5)	0.4 (0.1 to 0.9)	63.9 (45.5 to 84.5)	-4.1 (-13.7 to 6.3)
Scabies	790.6 (578.1 to 1,090.3)	1,014.1 (671.5 to 1,424.1)	30.0 (-24.6 to 109.9)	-29.1 (-63.4 to 11.8)	20.5 (10.5 to 35.9)	26.3 (13.0 to 46.7)	29.8 (-24.0 to 107.9)	-29.1 (-63.2 to 12.2)
Fungal skin diseases	2,085.6 (1,723.0 to 2,443.9)	3,908.4 (3,186.4 to 4,616.4)	87.3 (80.1 to 92.7)	87.3 (-0.0 to 1.1)	87.3 (4.9 to 24.9)	87.1 (0.9 to 46.6)	87.1 (80.3 to 93.1)	21.4 (-0.8 to 0.9)
Viral skin diseases	583.8 (440.8 to 726.5)	1,058.6 (767.7 to 1,356.1)	81.2 (70.3 to 90.1)	-0.0 (-3.1 to 3.2)	18.1 (10.3 to 29.0)	32.8 (18.4 to 53.6)	80.8 (68.5 to 92.0)	0.0 (-4.0 to 3.9)
Acne vulgaris	1,671.4 (1,060.7 to 2,349.8)	2,847.9 (1,868.2 to 4,262.0)	65.1 (-5.7 to 186.0)	-11.4 (47.6 to 49.9)	18.1 (7.6 to 36.2)	30.8 (12.9 to 63.2)	65.6 (-5.5 to 187.0)	-11.3 (47.9 to 49.8)
Alopecia areata	20.2 (17.7 to 22.9)	39.6 (34.5 to 44.6)	95.3 (66.4 to 136.6)	-1.0 (-15.9 to 16.6)	0.7 (0.4 to 1.0)	1.3 (0.8 to 2.0)	94.4 (58.1 to 147.0)	-1.0 (-18.8 to 19.3)
Pruritus	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	103.0 (59.6 to 157.9)	0.4 (-23.5 to 30.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.0 (59.6 to 157.9)	0.4 (-23.6 to 30.7)
Urticaria	86.3 (55.6 to 122.7)	240.3 (128.3 to 339.9)	175.3 (45.2 to 433.2)	30.7 (-35.3 to 139.0)	5.1 (2.8 to 8.1)	14.2 (6.9 to 23.1)	175.3 (43.8 to 443.5)	30.6 (-34.6 to 148.8)
Decubitus ulcer	2.4 (2.1 to 2.7)	5.2 (4.4 to 5.9)	114.5 (76.4 to 152.6)	3.0 (-19.7 to 31.2)	0.4 (0.2 to 0.5)	0.8 (0.5 to 1.1)	116.3 (70.1 to 164.1)	3.1 (-23.5 to 35.8)
Other skin and subcutaneous diseases	1,041.7 (718.1 to 1,432.6)	1,889.7 (1,295.5 to 2,594.6)	81.3 (66.3 to 97.5)	-9.8 (-18.3 to -3.5)	6.2 (2.7 to 12.5)	11.2 (5.0 to 23.0)	81.2 (66.2 to 97.9)	-9.8 (-11.1 to -3.3)
Sense organ diseases	-	-	-	-	143.8 (96.5 to 203.2)	254.5 (168.5 to 362.6)	77.0 (64.8 to 88.3)	-11.3 (-15.7 to -7.1)
Glaucoma	13.3 (10.5 to 16.3)	24.1 (18.6 to 30.1)	82.2 (38.8 to 136.2)	-0.1 (-30.3 to 10.9)	0.9 (0.6 to 1.2)	1.6 (1.0 to 2.3)	79.0 (34.9 to 123.5)	-10.5 (-30.9 to 10.4)
Cataract	66.1 (51.9 to 79.5)	106.9 (81.0 to 134.2)	60.7 (34.9 to 92.3)	-19.1 (-31.7 to -2.4)	4.2 (2.9 to 5.9)	6.9 (4.4 to 9.9)	62.6 (35.4 to 91.1)	-18.2 (-30.7 to -3.3)
Macular degeneration	21.0 (15.6 to 26.6)	63.3 (45.4 to 84.0)	196.6 (120.7 to 330.6)	39.2 (-0.0 to 104.1)	1.1 (0.7 to 1.6)	3.1 (1.9 to 4.8)	185.9 (113.9 to 297.2)	33.3 (-1.8 to 86.4)
Uncorrected refractive error	1,701.6 (1,586.3 to 1,817.5)	3,324.4 (3,097.5 to 3,563.7)	95.1 (77.7 to 115.0)	4.0 (-10.7 to 3.7)	27.4 (16.6 to 43.0)	49.1 (28.4 to 79.5)	78.4 (66.0 to 93.4)	-12.6 (-17.6 to -6.2)
Age-related and other hearing loss	2,780.1 (2,491.5 to 3,059.6)	5,321.5 (4,720.5 to 5,904.1)	91.1 (82.0 to 100.1)	-7.7 (-10.3 to -4.5)	91.1 (61.8 to 131.2)	87.1 (106.5 to 235.4)	87.1 (58.6 to 92.6)	11.0 (-18.4 to 4.9)
Other vision loss	34.0 (28.5 to 40.5)	43.8 (36.3 to 52.5)	28.4 (14.4 to 44.8)	-30.4 (-38.5 to -22.8)	2.4 (1.6 to 3.4)	3.4 (2.2 to 5.0)	39.1 (17.5 to 61.0)	-4.0 (-35.3 to -13.7)
Other sense organ diseases	561.5 (528.3 to 594.0)	1,029.3 (970.7 to 1,083.8)	82.8 (70.7 to 99.3)	0.1 (-5.7 to 6.5)	15.0 (9.2 to 22.4)	27.5 (17.0 to 40.7)	82.6 (68.8 to 99.4)	0.2 (-6.3 to 7.0)
Oral disorders	-	-	-	-	36.7 (21.0 to 59.5)	76.7 (43.6		

Appendix Table G.4 - Kenya prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	338.1 (316.4 to 360.6)	661.4 (612.9 to 704.6)	95.9 (77.2 to 115.3)	-7.2 (-15.4 to 1.4)	9.3 (6.3 to 12.9)	18.2 (12.1 to 25.3)	96.6 (77.0 to 116.3)	-7.0 (-15.2 to 1.8)
Other oral disorders	321.0 (302.7 to 340.1)	656.3 (616.1 to 701.3)	104.4 (87.8 to 122.9)	-0.8 (-8.4 to 7.4)	9.4 (5.9 to 14.1)	19.3 (11.9 to 28.7)	104.4 (85.8 to 122.1)	-0.8 (-8.8 to 7.2)
Injuries	-	-	-	-	72.2 (55.4 to 92.5)	128.2 (97.1 to 166.3)	77.2 (69.8 to 85.5)	-12.0 (-15.1 to -8.8)
Transport injuries	-	-	-	-	22.9 (17.2 to 29.3)	39.8 (30.1 to 52.0)	74.2 (64.2 to 84.2)	-13.4 (-17.4 to -9.1)
Road injuries	-	-	-	-	20.3 (15.2 to 25.0)	35.6 (26.9 to 46.4)	75.7 (64.9 to 86.6)	-12.8 (-16.9 to -8.0)
Pedestrian road injuries	-	-	-	-	6.9 (5.2 to 9.0)	10.9 (8.2 to 14.3)	57.9 (43.2 to 71.7)	-18.5 (-24.1 to -12.6)
Cyclist road injuries	-	-	-	-	1.8 (1.4 to 2.4)	2.8 (2.1 to 3.7)	51.5 (39.3 to 66.5)	-22.5 (-28.9 to -15.6)
Motorcyclist road injuries	-	-	-	-	2.2 (1.7 to 2.9)	3.6 (2.7 to 4.7)	61.5 (48.2 to 75.5)	-22.2 (-27.9 to -16.1)
Motor vehicle road injuries	-	-	-	-	9.0 (6.8 to 11.6)	18.3 (13.5 to 23.7)	99.4 (83.5 to 117.8)	-3.0 (-9.3 to 5.1)
Other road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	8.3 (1.2 to 15.8)	-47.9 (-51.2 to -44.4)
Other transport injuries	-	-	-	-	2.6 (1.9 to 3.4)	4.2 (3.1 to 5.5)	62.3 (51.6 to 73.7)	-18.3 (-23.9 to -12.8)
Unintentional injuries	-	-	-	-	45.1 (34.5 to 57.8)	79.6 (60.5 to 103.6)	76.4 (69.1 to 84.2)	-12.3 (-15.6 to -8.8)
Falls	-	-	-	-	19.3 (14.6 to 24.8)	37.2 (27.9 to 48.8)	92.4 (80.9 to 104.5)	-8.7 (-13.9 to -3.5)
Drowning	-	-	-	-	1.0 (0.7 to 1.3)	1.3 (1.0 to 1.7)	29.9 (16.1 to 45.0)	-32.3 (-38.3 to -25.8)
Fire, heat, and hot substances	-	-	-	-	5.4 (4.2 to 6.9)	7.8 (5.9 to 10.1)	43.9 (31.4 to 59.3)	-24.8 (-30.3 to -18.0)
Poisonings	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	42.0 (19.6 to 69.5)	-28.3 (-37.9 to -17.8)
Exposure to mechanical forces	-	-	-	-	10.9 (8.3 to 14.2)	18.8 (14.1 to 24.8)	72.3 (63.3 to 81.6)	-12.9 (-16.7 to -8.8)
Unintentional firearm injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.8 (0.6 to 1.0)	113.6 (93.2 to 133.7)	1.3 (-7.6 to 10.7)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	122.4 (103.1 to 142.5)	10.8 (2.4 to 19.2)
Other exposure to mechanical forces	-	-	-	-	10.4 (7.8 to 13.6)	17.7 (13.3 to 23.5)	70.2 (61.5 to 79.7)	-13.8 (-17.7 to -9.7)
Adverse effects of medical treatment	-	-	-	-	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.0)	115.7 (102.5 to 130.0)	8.8 (1.8 to 16.2)
Animal contact	-	-	-	-	1.9 (1.4 to 2.5)	2.9 (2.1 to 3.8)	50.8 (39.1 to 63.8)	-25.4 (-29.7 to -20.9)
Venomous animal contact	-	-	-	-	0.8 (0.6 to 1.1)	1.3 (0.9 to 1.8)	55.3 (37.4 to 76.7)	-24.1 (-31.4 to -15.4)
Non-venomous animal contact	-	-	-	-	1.1 (0.8 to 1.5)	1.6 (1.1 to 2.2)	47.1 (34.1 to 59.5)	-26.5 (-30.6 to -21.8)
Foreign body	-	-	-	-	0.8 (0.6 to 1.1)	1.5 (1.1 to 1.9)	82.6 (72.1 to 92.9)	-9.3 (-13.5 to -4.3)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	58.6 (37.1 to 80.1)	-11.1 (-20.3 to -1.5)
Foreign body in eyes	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	96.8 (76.8 to 121.5)	-3.2 (-11.9 to 6.1)
Foreign body in other body part	-	-	-	-	0.5 (0.4 to 0.6)	0.9 (0.7 to 1.1)	86.8 (77.0 to 99.8)	-10.3 (-15.4 to -3.8)
Other unintentional injuries	-	-	-	-	5.3 (3.9 to 6.9)	9.3 (6.9 to 12.2)	75.9 (61.0 to 94.2)	-12.5 (-19.7 to -4.7)
Self-harm and interpersonal violence	-	-	-	-	3.7 (2.8 to 4.6)	6.7 (5.1 to 8.6)	83.1 (72.2 to 93.7)	-10.6 (-15.4 to -5.8)
Self-harm	-	-	-	-	0.4 (0.3 to 0.5)	0.8 (0.6 to 1.1)	108.9 (92.9 to 126.4)	-5.5 (-11.7 to 1.0)
Interpersonal violence	-	-	-	-	3.3 (2.5 to 4.1)	5.8 (4.4 to 7.5)	79.8 (68.2 to 90.9)	-11.5 (-16.6 to -6.2)
Assault by firearm	-	-	-	-	0.6 (0.4 to 0.8)	1.1 (0.8 to 1.5)	92.1 (77.9 to 106.8)	-5.3 (-11.7 to 1.2)
Assault by sharp object	-	-	-	-	0.5 (0.4 to 0.6)	1.0 (0.7 to 1.3)	111.0 (93.1 to 133.5)	0.9 (-7.2 to 11.5)
Assault by other means	-	-	-	-	2.2 (1.7 to 2.8)	3.7 (2.8 to 4.7)	69.6 (56.1 to 81.7)	-16.2 (-22.4 to -10.5)
Forces of nature, war, and legal intervention	-	-	-	-	0.7 (0.3 to 1.4)	2.1 (0.9 to 5.0)	198.7 (132.2 to 297.9)	51.1 (14.3 to 104.2)
Exposure to forces of nature	-	-	-	-	0.2 (0.1 to 0.4)	0.6 (0.2 to 1.0)	142.3 (71.3 to 240.5)	18.5 (-20.1 to 66.1)
Collective violence and legal intervention	-	-	-	-	0.5 (0.2 to 1.1)	1.6 (0.6 to 3.6)	227.1 (160.8 to 317.9)	64.0 (26.4 to 111.8)

Appendix Table G.4 - Kiritabi prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	6.2 (4.5 to 8.2)	9.5 (7.0 to 12.4)	53.5 (45.4 to 61.9)	-1.0 (-5.9 to 4.1)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.8 (1.2 to 2.7)	2.4 (1.6 to 3.5)	29.9 (9.4 to 57.2)	-6.5 (-23.6 to 16.1)
HIV/AIDS and tuberculosis	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	108.9 (93.3 to 125.1)	25.5 (17.0 to 33.8)
Tuberculosis	0.1 (0.1 to 0.1)	0.3 (0.3 to 0.3)	110.2 (100.3 to 119.8)	26.0 (20.7 to 31.4)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	110.8 (94.7 to 126.9)	26.7 (18.2 to 34.7)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.9 (51.1 to 178.0)	-14.2 (-70.1 to 66.9)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.7 (-49.2 to 218.8)	-25.0 (-70.1 to 82.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.7 (-49.3 to 219.7)	-25.0 (-70.1 to 83.5)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.7 (-46.1 to 298.1)	-3.5 (-64.2 to 150.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.7 (-53.7 to 182.4)	-29.6 (-71.6 to 70.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-9.2 (-18.9 to -0.1)	-29.7 (-37.2 to -23.4)
Diarrheal diseases	0.4 (0.4 to 0.5)	0.4 (0.3 to 0.4)	-10.9 (-21.9 to 2.4)	-21.6 (-30.1 to -11.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-11.0 (-22.9 to 10.0)	-21.4 (-30.7 to -10.2)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-31.0 to 22.7)	-11.9 (-47.1 to -7.5)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.0 (-26.0 to 8.7)	-32.2 (-43.3 to -18.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.3 (-29.2 to 15.7)	-31.4 (-45.1 to -13.6)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.0 (-43.4 to -9.2)	-45.3 (-56.6 to -32.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.9 (-45.9 to -4.9)	-45.6 (-58.1 to -29.7)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	337.4 (90.7 to 9,640.5)	230.9 (-93.0 to 7,396.7)
Lower respiratory infections	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-25.4 (-40.3 to -9.9)	-34.7 (-45.5 to -22.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.0 (-42.2 to -9.6)	-35.2 (-47.1 to -22.4)
Upper respiratory infections	2.2 (2.1 to 2.3)	3.0 (2.9 to 3.2)	38.2 (28.7 to 48.6)	-1.0 (-7.5 to 6.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	37.9 (27.8 to 49.4)	-0.9 (-8.0 to 6.7)
Otitis media	1.0 (0.9 to 1.1)	1.2 (1.1 to 1.3)	21.0 (12.1 to 30.3)	-11.8 (-18.1 to -5.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.7 (10.9 to 30.6)	-11.6 (-18.5 to -4.0)
Meningitis	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-25.9 (-40.7 to -6.5)	-46.5 (-56.9 to -33.9)
Pneumococcal meningitis	0.5 (0.3 to 0.7)	0.4 (0.2 to 0.6)	-19.5 (-34.3 to -5.1)	-44.6 (-53.6 to -35.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-23.9 (-44.7 to -2.0)	-45.8 (-59.5 to -32.1)
H influenzae type B meningitis	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-30.6 (-54.7 to -2.8)	-51.9 (-67.5 to -32.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.6 (-62.9 to 23.5)	-53.7 (-72.9 to -11.0)
Meningococcal meningitis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-21.4 (-46.4 to 4.8)	-46.4 (-60.4 to -29.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.8 (-53.6 to 22.1)	-46.8 (-64.8 to -19.8)
Other meningitis	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-22.8 (-42.2 to -2.6)	-44.7 (-57.6 to -29.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.0 (-51.0 to 17.2)	-44.1 (-62.9 to -14.2)
Encephalitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	38.3 (14.1 to 47.6)	-44.0 (-23.0 to -2.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.2 (10.1 to 62.2)	-10.1 (-24.4 to 6.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.0 (-94.5 to 781.4)	-48.9 (-95.0 to 478.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.0 (-94.5 to 805.5)	-48.9 (-95.1 to 478.8)
Whooping cough	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.8 (-66.0 to -61.4)	-63.3 (-65.6 to -61.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.6 (-70.0 to -56.9)	-63.2 (-69.6 to -56.3)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.6 (-95.8 to -65.2)	-93.4 (-97.1 to -76.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-87.8 (-94.2 to -73.1)	-91.4 (-95.4 to -82.4)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-79.6 (-83.1 to -75.3)	-79.7 (-83.3 to -75.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.4 (-86.1 to -70.4)	-79.5 (-86.2 to -70.7)
Varicella and herpes zoster	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	29.4 (16.9 to 44.8)	-1.1 (-13.6 to 13.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.0 (24.8 to 89.2)	-2.0 (-19.6 to 23.4)
Neglected tropical diseases and malaria	-	-	-	-	0.9 (0.6 to 1.5)	1.2 (0.7 to 2.0)	30.0 (5.9 to 83.6)	-11.8 (-39.1 to 29.8)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.6 (-38.1 to 140.8)	-11.9 (-54.3 to 77.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.7 (-39.1 to 137.6)	-12.1 (-54.7 to 73.3)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.2 (2.5 to 63.8)	1.5 (-18.6 to 27.3)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.4 (-57.3 to 105.2)	-3.4 (55.0 to 70.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.4 (-57.4 to 106.1)	-3.4 (-55.2 to 71.8)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.8 (4.1 to 71.1)	2.2 (-19.6 to 31.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.8 (4.0 to 71.6)	2.2 (-19.7 to 31.1)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-68.5 (-89.4 to -13.8)	-79.3 (-92.0 to -49.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-66.0 (-88.5 to -7.6)	-77.6 (-91.6 to -43.8)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.0 (6.7 to 43.9)	-35.5 (-41.7 to -24.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.0 (-3.4 to 59.3)	-34.4 (-46.3 to -18.3)
Lymphatic filariasis	3.1 (2.3 to 4.1)	1.5 (1.0 to 2.2)	-52.1 (-66.6 to -34.6)	-70.1 (-79.0 to -59.6)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	52.0 (-33.8 to 55.4)	-1.4 (-62.1 to -4.9)
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-56.2 (-77.3 to -16.2)	-76.1 (-87.9 to -52.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.8 (-75.6 to -20.7)	-76.3 (-87.1 to -55.4)
Dengue	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	603.7 (597.9 to 610.4)	388.3 (384.3 to 393.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	601.5 (477.9 to 787.5)	389.1 (310.3 to 493.7)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.1 (-63.1 to -13.2)	-59.9 (-73.8 to -40.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.1 (-63.2 to -12.6)	-59.9 (-73.8 to -40.0)
Intestinal nematode infections	-	-	-	-	0.8 (0.4 to 1.3)	1.1 (0.5 to 1.8)	34.6 (-7.1 to 101.5)	-3.6 (-38.7 to 53.1)
Ascariasis	-	-	-	-	-2.9 (-33.8 to 298.7)	-	-	-
Trichuriasis	57.4 (52.3 to 63.0)	79.9 (72.8 to 87.6)	39.2 (22.6 to 58.4)	-3.7 (-16.1 to 11.3)	0.7 (0.4 to 1.3)	1.0 (0.5 to 1.8)	34.9 (-8.6 to 104.7)	-3.8 (-39.7 to 55.8)
Hookworm disease	5.7 (3.9 to 8.6)	8.0 (5.5 to 11.8)	40.4 (-21.4 to 137.0)	5.4 (-49.7 to 67.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	45.8 (-13.5 to 143.9)	2.3 (-43.5 to 78.8)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	0.8 (0.6 to 1.1)	0.9 (0.7 to 1.0)	5.8 (-18.7 to 44.8)	-9.3 (-30.0 to 24.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.1 (-18.4 to 69.5)	-10.8 (-30.3 to 49.4)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Maternal hemorrhage	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	6.3 (-26.1 to 33.8)	-26.7 (-48.1 to -7.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.4 (-41.5 to 30.2)	-31.6 (-60.1 to -10.1)
Maternal sepsis and other maternal infections	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-29.3 (-49.6 to -15.2)	-56.1 (-68.8 to -47.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.6 (-64.6 to 11.2)	-58.0 (-75.8 to -29.7)
Maternal hypertensive disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.1 (-19.1 to 7.9)	-36.8 (-42.7 to -24.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.4 (-29.0 to 16.1)	-37.1 (-49.7 to -20.1)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.6 (-75.7 to 11.6)	-59.6 (-82.5 to -25.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.2 (-78.5 to 60.0)	-58.8 (-85.1 to 5.5)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.0 (-42.2 to 60.4)	-35.7 (-59.9 to 10.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.0 (-42.2 to 60.9)	-35.7 (-59.9 to 10.9)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.6 (-48.1 to 48.5)	-40.1 (-64.4 to 0.4)
Neonatal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	185.7 (69.6 to 411.5)	115.8 (29.4 to 285.4)
Preterm birth complications	0.3 (0.1 to 0.6)	1.0 (0.5 to 1.9)	213.6 (156.9 to 300.0)	121.0 (80.3 to 181.2)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	303.8 (183.6 to 473.9)	200.5 (111.1 to 327.3)
Neonatal encephalopathy due to birth asphyxia and trauma	0.4 (0.1 to 0.9)	0.4 (0.1 to 1.0)	14.5 (-10.8 to 61.6)	-19.4 (-37.4 to 15.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.5 (3.2 to 213.4)	30.2 (-18.5 to 139.8)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	137.0 (136.6 to 149.4)	150.6 (150.2 to 163.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	150.6 (110.8 to 178.7)	139.4 (122.9 to 194.7)
Hemolytic disease and other neonatal jaundice	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	49.3 (-51.1 to 353.1)	15.2 (-61.7 to 253.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.7 (-52.1 to 352.2)	15.1 (-63.1 to 241.2)
Other neonatal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	199.8 (30.8 to 649.3)	127.5 (0.1 to 468.8)
Nutritional deficiencies	-	-	-	-	0.5 (0.3 to 0.7)	0.5 (0.4 to 0.8)	8.1 (-1.0 to 16.2)	-14.2 (-20.2 to -8.7)
Protein-energy malnutrition	0.5 (0.3 to 0.7)	0.4 (0.2 to 0.6)	-22.2 (-57.4 to 45.7)	-2.8 (-54.5 to 34.8)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.1 (-57.8 to 48.4)	-21.8 (-54.9 to 39.8)
Iodine deficiency	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	1.2 (-19.6 to 30.4)	-36.3 (-50.3 to -16.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.0 (-21.0 to 34.1)	-35.2 (-51.2 to -15.7)
Vitamin A deficiency	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-22.4 (-37.3 to -3.5)	-42.4 (-52.7 to -30.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.7 (-38.7 to -7.6)	-44.7 (-54.1 to -33.8)

Appendix Table G.4 - Kiritabi prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	12.9 (12.6 to 13.1)	15.0 (14.8 to 15.3)	16.8 (13.8 to 19.7)	-11.4 (-13.9 to -9.0)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	13.4 (7.6 to 15.4)	13.4 (-17.2 to 10.6)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-49.9 to 272.6)	0.0 (-48.3 to 254.4)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	33.7 (17.7 to 54.0)	-6.6 (-17.6 to 7.0)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	52.5 (35.2 to 74.7)	-2.8 (-12.5 to 9.6)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.1 (-14.6 to 18.6)	39.4 (46.8 to -29.8)	0.0 (0.0 to 0.0)	0.1 (-28.9 to 40.8)	1.1 (-54.3 to -17.5)	38.2 (-14.4 to 14.6)
Chlamydial infection	3.6 (2.3 to 5.0)	5.4 (4.5 to 6.4)	50.9 (6.1 to 143.1)	-2.7 (30.3 to 57.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.9 (31.0 to 79.6)	-1.4 (-14.4 to 14.6)
Gonococcal infection	0.5 (0.3 to 0.7)	0.8 (0.5 to 1.0)	67.2 (-5.9 to 255.7)	9.0 (-37.2 to 120.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.8 (5.9 to 157.4)	4.8 (28.9 to 60.1)
Trichomoniasis	0.8 (0.4 to 1.1)	1.1 (0.8 to 1.6)	48.4 (-22.7 to 187.9)	0.3 (-45.2 to 84.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.4 (-28.8 to 211.8)	-1.1 (-48.1 to 95.2)
Genital herpes	9.5 (9.3 to 9.7)	15.4 (15.0 to 15.8)	61.8 (56.5 to 69.4)	-2.3 (-5.3 to 1.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.8 (56.6 to 71.8)	-2.3 (-7.1 to 3.5)
Other sexually transmitted diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.8 (5.7 to 40.1)	-27.7 (-35.0 to -14.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.7 (6.2 to 59.7)	23.2 (-39.9 to -2.5)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.3 (-30.1 to 24.9)	-42.6 (-58.1 to -19.7)
Hepatitis A	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	22.8 (21.6 to 24.0)	-3.2 (-3.3 to -3.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.2 (27.5 to 59.9)	-0.2 (-10.1 to 10.6)
Hepatitis B	13.9 (10.0 to 18.7)	8.3 (6.9 to 9.9)	-38.5 (-58.1 to -14.9)	-59.7 (-72.3 to -44.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.8 (-56.6 to 5.7)	-58.4 (-74.5 to -31.8)
Hepatitis C	2.2 (1.9 to 2.5)	2.6 (2.3 to 2.9)	19.1 (-0.4 to 40.7)	26.8 (-38.0 to -34.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.3 (-13.4 to 55.4)	-22.8 (-43.3 to 5.5)
Hepatitis E	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.2 (56.1 to 118.5)	14.4 (-0.4 to 40.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.3 (43.2 to 141.7)	15.1 (9.0 to 50.6)
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	383.8 (25.0 to 1,019.7)	172.0 (-28.2 to 591.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	356.7 (-4.4 to 2,322.1)	149.5 (-43.7 to 1,362.7)
Other infectious diseases	0.6 (0.4 to 0.7)	0.7 (0.5 to 0.7)	6.6 (-15.5 to 36.3)	-10.3 (-28.3 to 14.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.8 (0.8 to 82.0)	17.3 (-15.7 to 63.4)
Non-communicable diseases	-	-	-	-	4.2 (3.1 to 5.4)	6.9 (5.0 to 8.8)	63.6 (58.7 to 69.0)	5.9 (-2.1 to 3.7)
Neoplasms	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	126.6 (17.0 to 311.5)	53.3 (-23.7 to 174.9)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	166.6 (91.5 to 264.0)	49.0 (13.7 to 96.4)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	226.1 (117.6 to 373.8)	89.2 (29.6 to 168.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	213.3 (114.3 to 351.8)	80.5 (26.0 to 155.1)
Stomach cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	226.1 (117.6 to 373.8)	89.2 (29.6 to 168.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	213.3 (114.3 to 351.8)	80.5 (26.0 to 155.1)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	467.4 (152.2 to 1,357.7)	242.9 (52.2 to 822.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	446.0 (164.0 to 1,222.6)	225.6 (52.2 to 724.8)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	933.8 (309.4 to 2,414.5)	522.3 (129.0 to 1,406.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	892.1 (318.4 to 2,046.4)	500.5 (140.6 to 1,199.7)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.1 (-7.6 to 389.6)	13.9 (-49.2 to 183.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.4 (2.2 to 330.2)	8.6 (-47.6 to 161.5)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.3 (-0.6 to 463.6)	39.6 (-41.2 to 254.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	119.7 (6.1 to 390.0)	34.2 (-36.8 to 223.3)
Larynx cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-94.2 (-98.1 to -89.5)	-97.0 (-99.1 to -94.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-91.6 (-96.7 to -84.4)	-95.7 (-98.5 to -91.8)
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.0 (26.8 to 185.5)	9.4 (-24.5 to 56.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.7 (23.9 to 188.3)	7.7 (-28.0 to 56.0)
Breast cancer	0.1 (0.1 to 0.1)	0.5 (0.3 to 0.7)	353.7 (174.1 to 623.4)	172.4 (69.8 to 314.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	298.4 (127.1 to 551.3)	131.9 (35.7 to 269.9)
Cervical cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	48.8 (-51.8 to 68.8)	-8.0 (-70.3 to -2.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.1 (-50.0 to 66.2)	49.1 (-69.0 to -2.7)
Uterine cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.3 (-70.6 to 208.9)	-41.4 (83.5 to 80.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.9 (-71.5 to 207.6)	-61.8 (-83.9 to 68.7)
Prostate cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.4 (-27.4 to 638.0)	-19.5 (-59.5 to 307.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.2 (-30.5 to 608.7)	-21.1 (-61.7 to 290.8)
Colon and rectum cancer	0.0 (0.0 to 0.0)	0.3 (0.2 to 0.3)	810.1 (479.4 to 1,264.4)	290.6 (153.4 to 460.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	807.3 (480.5 to 1,277.1)	298.1 (156.7 to 467.5)
Lip and oral cavity cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.0)	99.4 (15.1 to 242.1)	21.5 (-31.0 to 114.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.4 (19.1 to 247.3)	22.7 (-32.4 to 118.0)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.0 (-4.2 to 191.7)	-3.1 (-41.6 to 69.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.1 (-4.5 to 179.4)	-4.5 (-41.2 to 60.5)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.6 (1.4 to 247.5)	1.9 (-42.8 to 83.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.1 (3.9 to 225.2)	1.5 (-40.1 to 74.0)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.1 (-61.8 to 126.5)	-50.3 (-78.7 to 27.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.5 (-60.9 to 120.3)	-52.2 (-78.3 to 25.5)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	210.1 (99.3 to 363.7)	77.5 (18.0 to 163.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	208.6 (109.4 to 343.6)	77.1 (22.8 to 152.6)
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	476.5 (202.7 to 856.4)	243.9 (90.8 to 473.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	464.1 (185.9 to 796.2)	215.6 (71.2 to 420.5)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	213.2 (126.3 to 362.0)	79.4 (27.4 to 162.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	265.3 (133.8 to 480.6)	115.7 (32.9 to 249.7)
Ovarian cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.7 (-30.8 to 158.4)	-16.1 (-56.6 to 55.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.8 (-30.1 to 159.1)	-16.1 (-55.3 to 56.8)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.6 (-26.6 to 336.7)	12.0 (-50.9 to 163.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.6 (-30.0 to 327.2)	8.4 (-49.9 to 157.5)
Kidney cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	159.1 (49.6 to 343.8)	60.2 (-1.5 to 179.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	160.2 (50.8 to 366.7)	54.8 (-7.0 to 171.3)
Bladder cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	12.4 (-13.7 to 86.2)	-39.1 (-55.5 to 4.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.5 (-14.6 to 87.6)	-39.1 (-55.9 to 5.3)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.4 (11.2 to 221.3)	29.2 (-16.8 to 104.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.3 (13.8 to 225.2)	21.6 (-22.8 to 97.9)
Thyroid cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	132.3 (27.7 to 298.6)	43.3 (-19.4 to 140.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.1 (20.8 to 299.7)	40.6 (-23.0 to 145.0)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	132.1 (41.4 to 277.0)	70.9 (-3.6 to 167.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	141.8 (51.2 to 274.1)	77.0 (5.0 to 170.1)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	312.5 (60.7 to 661.6)	187.1 (23.5 to 384.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	288.0 (56.6 to 602.3)	151.6 (10.1 to 317.8)
Non-Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	711.2 (39.0 to 1,352.9)	505.1 (-8.2 to 947.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	708.0 (36.3 to 1,382.7)	498.8 (-11.3 to 970.8)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	277.3 (77.8 to 622.3)	123.6 (3.3 to 343.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	270.3 (80.3 to 596.5)	119.6 (4.8 to 331.5)
Leukemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	720.1 (334.0 to 1,272.2)	477.4 (242.8 to 763.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	496.7 (372.6 to 1,080.3)	388.7 (188.7 to 600.0)
Other neoplasms	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	985.0 (111.7 to 1,886.4)	699.4 (57.6 to 1,254.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	956.6 (108.2 to 1,701.9)	604.3 (49.7 to 1,031.7)
Cardiovascular diseases	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	81.3 (54.2 to 112.7)	10.6 (-4.3 to 27.8)
Rheumatic heart disease	3.4 (2.9 to 3.9)	5.2 (4.6 to 5.8)	52.3 (26.6 to 88.9)	-5.4 (-20.7 to 14.6)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.4)	52.2 (26.5 to 88.7)	-5.4 (-20.6 to 14.6)
Ischemic heart disease	0.3 (0.2 to 0.3)	0.5 (0.4 to 0.6)	84.8 (43.2 to 154.2)	0.2 (-21.2 to 38.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	93.2 (88.4 to 98.0)	3.5 (-16.5 to 39.0)
Cerebrovascular disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.5 (53.0 to 135.8)	6.1 (-10.8 to 37.4)
Ischemic stroke	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	88.3 (58.2 to 148.3)	5.7 (-12.0 to 39.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.8 (53.9 to 149.9)	6.1 (-13.3 to 42.2)
Hemorrhagic stroke	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	87.8 (59.5 to 132.5)	7.0 (-10.6 to 34.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.6 (57.3 to 132.6)	7.5 (-11.5 to 34.9)
Hypertensive heart disease	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	112.7 (74.9 to 159.2)	13.3 (-6.8 to 39.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.1 (73.9 to 164.9)	13.2 (-7.4 to 40.5)
Cardiomyopathy and myocarditis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	142.9 (103.8 to 188.1)	39.4 (15.2 to 68.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	145.2 (101.6 to 199.3)	40.8 (15.1 to 72.9)
Atrial fibrillation and flutter	0.0 (0.0 to 0.0)	0.2 (0.2 to 0.2)	364.3 (256.5 to 577.7)	113.3 (52.2 to 232.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	371.8 (263.0 to 600.1)	116.2 (55.5 to 240.7)
Peripheral vascular disease	0.7 (0.5 to 1.0)	1.4 (0.9 to 1.8)	104.8 (-3.6 to 214.4)	10.4 (-38.0 to 53.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.9 (-30.4 to 201.5)	-12.1 (-57.5 to 66.0)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.2 (12.2 to 89.7)	-5.9 (-28.4 to 24.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.2 (15.0 to 99.9)	-3.2 (-31.6 to 33.6)
Other cardiovascular and circulatory diseases	0.4 (0.2 to 0.5)	1.1 (0.6 to 1.6)	190.5 (42.5 to 420.2)	69.8 (-22.8 to 199.9)	0.1 (0.0 to 0.0)	0.1 (0.0 to 0.1)	192.2 (44.7 to 416.8)	60.9 (-22.5 to 199.3)
Chronic respiratory diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	61.1 (37.4 to 85.8)	-5.9 (-19.3 to 7.3)
Chronic obstructive pulmonary								

Appendix Table G.4 - Kiribati prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	195.7	62.5
Silicosis	0.0	0.0	57.0	-14.2	0.0	0.0	(175.7 to 213.0)	(50.2 to 73.1)
Asbestosis	-	-	0.0	0.0	0.0	0.0	56.9	-14.3
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	249.6	99.4	0.0	0.0	247.0	97.2
Asthma	1.0	1.5	58.4	-7.1	0.0	0.1	57.7	-7.1
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	67.4	-3.0	0.0	0.0	68.4	-2.9
Other chronic respiratory diseases	-	-	-	-	0.1	0.1	42.1	-17.6
Cirrhosis	-	-	-	-	0.0	0.0	4.4	-2.5
Cirrhosis due to hepatitis B	0.0	0.0	22.1	-21.5	0.0	0.0	(4.5 to 20.8)	(-40.8 to -23.1)
Cirrhosis due to hepatitis C	0.0	0.0	10.9	-28.2	0.0	0.0	11.0	-27.9
Cirrhosis due to alcohol use	0.0	0.0	-32.7	-60.1	0.0	0.0	(-34.6 to 106.6)	(58.0 to 42.2)
Cirrhosis due to other causes	0.0	0.0	-8.3	-28.6	0.0	0.0	(-59.8 to 5.1)	(-75.7 to -38.5)
Digestive diseases	-	-	-	-	0.1	0.1	31.1	-20.2
Peptic ulcer disease	0.6	0.6	6.9	-39.9	0.0	0.0	6.0	-37.3
Gastritis and duodenitis	0.6	0.7	19.3	-27.5	0.0	0.0	16.5	-24.8
Appendicitis	0.0	0.0	16.7	-27.3	0.0	0.0	15.4	-27.2
Paralytic ileus and intestinal obstruction	0.0	0.0	43.6	-21.1	0.0	0.0	41.9	-3.5
Inguinal, femoral, and abdominal hernia	0.2	0.3	45.1	-13.6	0.0	0.0	45.0	-13.2
Inflammatory bowel disease	0.0	0.0	55.0	-8.3	0.0	0.0	54.1	-8.7
Vascular intestinal disorders	0.0	0.0	110.3	88.7	0.0	0.0	(28.0 to 85.2)	(-22.7 to 8.2)
Gallbladder and biliary diseases	0.0	0.0	50.5	-11.3	0.0	0.0	51.1	-11.1
Pancreatitis	0.0	0.0	74.1	5.5	0.0	0.0	73.9	5.6
Other digestive diseases	-	-	-	-	0.0	0.0	66.9	3.2
Neurological disorders	-	-	-	-	0.2	0.3	70.3	5.9
Alzheimer disease and other dementias	0.2	0.3	85.3	3.7	0.0	0.0	(43.2 to 102.3)	(8.6 to 22.4)
Parkinson disease	0.0	0.0	81.1	0.1	0.0	0.0	81.4	0.2
Epilepsy	0.2	0.3	44.4	0.5	0.1	0.1	55.5	8.8
Multiple sclerosis	0.0	0.0	203.3	78.1	0.0	0.0	203.3	78.1
Migraine	7.4	7.4	55.1	-2.2	0.3	0.3	55.3	-2.4
Tension-type headache	8.7	14.2	61.7	-3.3	0.0	0.0	(116.5 to 111.2)	(-29.0 to 29.8)
Medication overuse headache	0.2	0.5	151.6	51.3	0.0	0.1	151.2	51.5
Other neurological disorders	0.0	0.0	50.1	1.2	0.0	0.0	79.7	-1.3
Mental and substance use disorders	-	-	-	-	1.1	1.7	59.4	0.9
Schizophrenia	0.2	0.3	63.4	-0.2	0.1	0.2	(55.1 to 63.6)	(-1.5 to 3.4)
Alcohol use disorders	0.4	1.0	113.5	35.3	0.0	0.1	114.9	36.5
Drug use disorders	-	-	-	-	0.1	0.2	43.0	-6.1
Opioid use disorders	0.1	0.1	57.8	1.1	0.0	0.0	57.0	1.7
Cocaine use disorders	0.1	0.1	55.7	-4.4	0.0	0.0	(35.5 to 82.0)	(-10.4 to 16.3)
Amphetamine use disorders	0.3	0.3	31.0	-13.0	0.0	0.0	31.6	-12.7
Cannabis use disorders	0.2	0.4	58.2	0.2	0.0	0.0	58.5	0.5
Other drug use disorders	-	-	-	-	0.0	0.1	36.2	-9.9
Depressive disorders	-	-	-	-	0.3	0.5	63.7	0.3
Major depressive disorder	1.2	2.0	62.4	-0.0	0.3	0.4	62.4	0.3
Dysthymia	0.7	1.2	68.4	-0.1	0.1	0.1	68.5	0.1
Bipolar disorder	0.3	0.6	61.6	0.5	0.1	0.1	61.5	0.4
Anxiety disorders	1.7	2.7	57.2	0.2	0.2	0.2	57.1	-0.1
Eating disorders	-	-	-	-	0.0	0.0	43.6	-5.0
Anorexia nervosa	0.0	0.0	37.4	-9.5	0.0	0.0	37.9	-9.2
Bulimia nervosa	0.0	0.0	49.9	-0.2	0.0	0.0	48.6	-0.9
Autistic spectrum disorders	-	-	-	-	0.1	0.1	44.8	0.4
Autism	0.2	0.3	44.8	0.2	0.1	0.1	44.5	0.3
Asperger syndrome	0.3	0.5	44.0	0.2	0.0	0.0	43.7	0.3
Attention-deficit/hyperactivity disorder	0.5	0.7	41.1	0.5	0.0	0.0	41.0	0.4
Conduct disorder	0.5	0.7	48.3	0.5	0.1	0.1	49.1	0.5
Idiopathic intellectual disability	0.2	0.3	39.9	-1.0	0.0	0.0	40.2	-1.4
Other mental and substance use disorders	1.0	1.6	60.9	0.1	0.1	0.1	60.8	0.2
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	0.4	0.7	71.0	9.4
Diabetes mellitus	2.4	4.8	102.4	18.0	0.1	0.3	(56.7 to 85.6)	(-1.6 to 19.8)
Acute glomerulonephritis	0.0	0.0	50.6	10.6	0.0	0.0	(11.6 to 71.0)	(-25.7 to 12.1)
Chronic kidney disease	0.0	0.0	41.6	5.0	0.0	0.0	41.5	0.3
Chronic kidney disease due to diabetes mellitus	0.3	0.6	130.4	37.8	0.0	0.0	141.8	44.3
Chronic kidney disease due to hypertension	0.4	0.3	33.5	-51.9	0.0	0.0	(68.4 to 223.4)	(1.0 to 97.2)
Chronic kidney disease due to glomerulonephritis	0.4	0.8	44.5	6.5	0.0	0.0	(27.5 to 113.2)	(-16.8 to 33.3)
Chronic kidney disease due to other causes	1.2	2.0	71.4	9.6	0.0	0.0	71.0	0.0
Urinary diseases and male infertility	-	-	-	-	0.0	0.0	69.3	-0.7

Appendix Table G.4 - Kiribati prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.9 (72.6 to 107.1)	25.8 (15.9 to 36.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.0 (50.2 to 141.6)	26.4 (3.6 to 54.1)
Urolithiasis	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	0.2 (24.8 to 80.2)	-16.0 (-29.7 to -2.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.8 (41.6 to 78.9)	-5.8 (-14.7 to 4.6)
Benign prostatic hyperplasia	0.3 (0.3 to 0.4)	0.6 (0.6 to 0.7)	83.6 (60.9 to 114.3)	0.7 (-11.5 to 16.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.3 (61.3 to 114.9)	1.2 (-11.3 to 17.5)
Male infertility due to other causes	0.6 (0.4 to 0.7)	0.8 (0.7 to 1.0)	43.1 (10.0 to 90.4)	-2.2 (-24.5 to 30.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.2 (9.4 to 91.9)	-2.2 (-25.3 to 30.2)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-1.8 to 164.2)	-18.3 (-40.7 to 59.3)
Gynecological diseases	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	56.2 (39.1 to 75.4)	4.1 (-13.5 to 7.1)
Uterine fibroids	1.2 (1.1 to 1.3)	2.1 (2.0 to 2.3)	80.3 (78.4 to 82.6)	0.3 (0.2 to 0.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.4 (45.0 to 68.6)	-7.5 (-14.8 to -2.3)
Polycystic ovarian syndrome	0.9 (0.8 to 1.0)	1.5 (1.3 to 1.7)	62.8 (36.0 to 91.0)	0.7 (-14.4 to 16.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.9 (35.6 to 91.5)	1.0 (-14.7 to 17.6)
Female infertility due to other causes	0.6 (0.5 to 0.7)	1.0 (0.8 to 1.2)	62.7 (18.1 to 115.9)	0.1 (-20.8 to 47.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.1 (17.6 to 111.6)	9.1 (-20.7 to 45.8)
Endometriosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	60.8 (29.6 to 96.9)	0.8 (-18.7 to 23.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.0 (28.3 to 101.7)	0.9 (-19.3 to 27.2)
Genital prolapse	2.8 (2.4 to 3.2)	4.6 (4.1 to 5.2)	65.7 (35.3 to 99.4)	-2.2 (-16.8 to 15.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.9 (34.3 to 101.6)	-2.1 (-17.2 to 16.5)
Premenstrual syndrome	2.0 (1.3 to 2.7)	3.0 (1.9 to 4.1)	47.4 (-10.5 to 128.7)	-6.3 (-42.6 to 49.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.9 (-11.5 to 132.1)	-6.2 (-42.9 to 51.6)
Other gynecological diseases	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.3)	44.3 (10.3 to 94.4)	-10.7 (-32.7 to 23.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.4 (11.6 to 151.4)	-12.5 (-31.9 to 64.2)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	36.2 (21.5 to 53.9)	5.2 (8.0 to 20.3)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.5 (0.8 to 30.6)	-4.4 (-16.2 to 8.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.7 (-28.0 to 84.3)	-10.0 (-39.6 to 52.0)
Thalassemia trait	2.8 (1.9 to 4.4)	4.1 (2.7 to 6.5)	44.7 (38.2 to 52.8)	1.4 (-2.6 to 9.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	43.3 (26.1 to 61.3)	9.7 (5.3 to 26.0)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.6 (-42.2 to -13.4)	-42.4 (-55.1 to -33.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.6 (-49.2 to -11.3)	-44.6 (-60.9 to -31.9)
Sickle cell trait	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	15.6 (-28.4 to -4.4)	-41.7 (-50.5 to -34.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.4 (-37.6 to 116.2)	14 (-46.4 to 82.4)
G6PD deficiency	7.5 (5.1 to 9.9)	10.6 (7.0 to 14.4)	42.2 (-23.8 to 133.4)	-1.0 (-46.7 to 62.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.0 (-55.1 to 118.7)	-18.2 (-65.2 to 72.4)
G6PD trait	15.6 (14.4 to 16.6)	23.0 (21.6 to 24.3)	46.9 (35.6 to 61.5)	1.9 (-6.0 to 12.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.5 (82.4 to 3,162.3)	22.0 (-85.5 to 1,645.8)
Other hemoglobinopathies and hemolytic anemias	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.5)	11.9 (-12.8 to 52.6)	-12.0 (-31.1 to 16.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.8 (-17.7 to 84.8)	-14.4 (-33.5 to 49.6)
Endocrine, metabolic, blood, and immune disorders	0.8 (0.7 to 0.9)	1.0 (0.9 to 1.0)	26.5 (11.4 to 47.4)	-1.9 (-13.4 to 10.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.7 (3.5 to 62.5)	-2.5 (-16.6 to 21.4)
Musculoskeletal disorders	-	-	-	-	0.8 (0.6 to 1.1)	1.4 (1.0 to 1.8)	73.7 (59.3 to 94.2)	0.8 (-7.0 to 11.4)
Rheumatoid arthritis	0.1 (0.0 to 0.1)	0.2 (0.2 to 0.2)	220.2 (200.3 to 241.0)	91.6 (78.7 to 105.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	220.3 (187.8 to 255.0)	91.6 (74.2 to 110.7)
Osteoarthritis	0.9 (0.9 to 0.9)	1.6 (1.6 to 1.7)	85.6 (74.1 to 97.1)	0.2 (-5.6 to 6.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	85.9 (74.0 to 97.7)	0.4 (-5.7 to 6.6)
Low back and neck pain	-	-	-	-	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.3)	71.0 (52.8 to 99.2)	1.4 (-10.2 to 17.0)
Low back pain	3.2 (3.0 to 3.4)	5.5 (5.1 to 5.8)	70.4 (54.7 to 88.5)	1.4 (-6.8 to 10.4)	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.9)	70.3 (54.4 to 88.6)	1.4 (-6.6 to 11.2)
Neck pain	2.2 (1.6 to 2.7)	3.8 (2.9 to 4.7)	73.9 (28.0 to 154.0)	1.0 (-25.2 to 43.6)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	73.2 (28.0 to 156.8)	1.3 (-24.9 to 44.2)
Gout	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	94.3 (75.3 to 113.2)	6.6 (-4.0 to 16.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.0 (56.7 to 138.9)	6.6 (-12.6 to 30.4)
Other musculoskeletal disorders	1.5 (1.2 to 1.8)	2.5 (1.9 to 3.0)	66.3 (52.5 to 81.4)	4.1 (-14.0 to 0.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	66.0 (51.7 to 82.7)	7.8 (-13.9 to 0.8)
Other non-communicable diseases	-	-	-	-	1.0 (0.7 to 1.4)	1.5 (1.0 to 2.2)	50.2 (42.3 to 60.7)	-5.7 (-9.6 to -1.2)
Congenital anomalies	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	101.5 (24.8 to 266.1)	49.9 (5.4 to 166.1)
Neural tube defects	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	119.2 (66.4 to 177.8)	75.2 (32.4 to 121.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	132.9 (49.3 to 235.3)	89.0 (21.0 to 170.5)
Congenital heart anomalies	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	156.4 (85.3 to 288.8)	100.9 (44.3 to 207.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	133.4 (63.1 to 254.9)	87.8 (31.4 to 105.7)
Orofacial clefts	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	151.2 (57.9 to 288.4)	105.9 (29.1 to 220.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.6 (39.6 to 267.2)	89.2 (14.5 to 201.9)
Down syndrome	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	72.4 (33.0 to 120.8)	28.1 (-1.0 to 64.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.2 (36.2 to 141.2)	32.5 (0.3 to 77.0)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.2 (20.7 to 127.4)	21.3 (-11.6 to 65.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.4 (21.7 to 133.9)	21.7 (-13.5 to 67.1)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.4 (-1.1 to 133.3)	8.4 (-30.0 to 65.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.7 (-10.9 to 165.3)	6.7 (-38.9 to 75.5)
Chromosomal unbalanced rearrangements	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	81.5 (44.4 to 142.3)	89.9 (6.8 to 79.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.1 (50.0 to 156.9)	39.1 (9.0 to 86.8)
Other congenital anomalies	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.4)	25.7 (12.6 to 37.9)	-13.2 (-21.6 to -5.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	102.4 (5.2 to 334.4)	49.5 (-19.4 to 211.9)
Skin and subcutaneous diseases	-	-	-	-	0.4 (0.3 to 0.6)	0.6 (0.4 to 1.0)	47.4 (37.2 to 64.0)	-1.2 (-7.8 to 7.4)
Dermatitis	3.9 (3.2 to 4.8)	5.8 (4.7 to 7.1)	49.2 (46.1 to 51.8)	-0.0 (-0.1 to 0.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	44.2 (37.4 to 50.5)	0.1 (-2.5 to 2.9)
Psoriasis	0.4 (0.4 to 0.5)	0.7 (0.6 to 0.8)	60.1 (57.9 to 63.3)	0.0 (-0.0 to 0.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	60.2 (49.7 to 72.2)	0.2 (-5.4 to 6.1)
Cellulitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.3 (2.0 to 39.8)	-11.8 (-21.4 to 2.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.9 (-14.6 to 51.2)	-11.7 (-29.5 to 10.2)
Pyoderma	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-42.8 (-52.6 to -30.8)	-51.9 (-59.0 to -43.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.0 (-54.2 to -29.4)	-51.9 (-60.7 to -42.1)
Scabies	1.6 (1.2 to 2.2)	1.9 (1.4 to 2.7)	21.6 (-23.1 to 87.1)	-16.8 (-46.3 to 24.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	21.6 (-23.5 to 85.8)	-16.5 (-46.4 to 24.8)
Fungal skin diseases	7.2 (6.0 to 8.4)	11.2 (9.4 to 12.9)	56.1 (52.7 to 59.1)	0.0 (-0.0 to 0.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	56.0 (52.2 to 59.2)	0.1 (-0.7 to 0.9)
Viral skin diseases	1.6 (1.2 to 2.0)	2.1 (1.6 to 2.7)	35.5 (29.5 to 42.0)	0.2 (-2.1 to 2.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	35.5 (28.5 to 43.2)	0.3 (-3.3 to 3.8)
Acne vulgaris	4.8 (3.5 to 6.5)	7.8 (5.3 to 11.9)	54.0 (0.7 to 199.2)	1.2 (-32.9 to 93.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	54.3 (0.1 to 199.3)	1.3 (-32.9 to 92.9)
Alopecia areata	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	57.9 (26.3 to 93.5)	2.5 (-17.1 to 27.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.0 (23.9 to 99.1)	2.9 (-17.1 to 28.6)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.2 (25.9 to 97.2)	-1.1 (-21.4 to 24.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.8 (14.9 to 117.5)	-1.8 (-26.4 to 31.9)
Urticaria	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.3)	61.6 (11.5 to 142.3)	-0.4 (-31.5 to 55.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	61.8 (10.8 to 145.5)	-0.3 (-30.8 to 55.4)
Decubitus ulcer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.9 (8.4 to 75.0)	-11.3 (-30.9 to 16.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.9 (0.3 to 80.8)	-11.9 (-35.9 to 18.5)
Other skin and subcutaneous diseases	4.1 (2.9 to 5.8)	6.8 (4.6 to 9.8)	63.4 (51.8 to 75.7)	-2.1 (-6.6 to 2.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	63.2 (51.5 to 75.6)	-2.1 (-6.5 to 2.7)
Sense organ diseases	-	-	-	-	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.9)	50.0 (38.3 to 52.1)	-11.3 (-14.0 to -7.9)
Glaucoma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	46.8 (25.1 to 73.9)	-14.7 (-29.5 to 4.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.8 (2.5 to 64.1)	-14.7 (-46.4 to -5.2)
Cataract	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	43.3 (11.3 to 89.9)	-18.5 (-36.2 to 6.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.7 (14.9 to 90.8)	-16.9 (-33.0 to 6.1)
Macular degeneration	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	76.4 (39.7 to 117.9)	-3.7 (-28.6 to 23.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.4 (39.1 to 109.3)	-5.8 (-28.7 to 18.2)
Uncorrected refractive error	4.2 (3.9 to 4.6)	6.6 (6.1 to 7.1)	55.4 (40.2 to 74.2)	7.0 (-14.7 to 2.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	41.5 (31.5 to 52.6)	-14.3 (-19.1 to -8.1)
Age-related and other hearing loss	8.0 (7.4 to 8.5)	12.6 (11.7 to 13.6)	57.8 (50.9 to 64.1)	-8.9 (-12.1 to -6.1)	0.2 (0.2 to 0.4)	0.2 (0.2 to 0.5)	56.0 (38.3 to 58.8)	0.1 (-13.4 to -5.3)
Other vision loss	0.4 (0.3 to 0.4)	0.5 (0.3 to 0.6)	29.9 (14.0 to 47.0)	-18.6 (-29.1 to -7.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.3 (13.6 to 43.3)	-20.8 (-28.9 to -11.4)
Other sense organ diseases	1.7 (1.6 to 1.7)	2.3 (2.2 to 2.4)	38.3 (28.8 to 46.7)	0.4 (-5.9 to 5.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	38.1 (26.8 to 47.6)	0.8 (-6.4 to 7.1)
Oral disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	46.4 (35.9 to 53.6)	-14.2 (-18.0 to -9.3)
Deciduous caries	8.5 (8.4 to 8							

Appendix Table G.4 - Kiribati prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	0.7 (0.7 to 0.8)	0.9 (0.8 to 0.9)	19.5 (9.7 to 30.3)	-34.1 (-39.2 to -28.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.6 (9.3 to 30.9)	-34.0 (-39.5 to -28.7)
Other oral disorders	1.1 (1.0 to 1.2)	1.7 (1.6 to 1.8)	57.4 (44.4 to 71.0)	-0.8 (-8.0 to 7.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	57.1 (43.2 to 71.6)	-0.7 (-8.6 to 7.7)
Injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	48.4 (34.5 to 63.3)	-7.3 (-15.2 to 1.0)
Transport injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	47.6 (31.3 to 68.2)	-6.2 (-15.4 to 4.5)
Road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	46.4 (29.4 to 67.6)	-5.4 (-15.0 to 6.4)
Pedestrian road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.5 (25.1 to 69.0)	-3.0 (-14.3 to 10.3)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.3 (39.6 to 75.7)	1.0 (-9.1 to 12.1)
Motorcyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.1 (22.1 to 60.9)	-11.6 (-21.7 to 0.2)
Motor vehicle road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.0 (31.2 to 76.0)	-1.5 (-13.0 to 12.6)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.8 (28.4 to 68.5)	8.1 (-18.1 to 3.5)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.9 (37.2 to 69.7)	-8.8 (-18.2 to 1.3)
Unintentional injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	55.7 (44.0 to 68.2)	-4.3 (-11.2 to 3.0)
Falls	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	37.3 (23.3 to 52.2)	-16.6 (-24.5 to -8.2)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.9 (6.3 to 25.9)	-29.1 (-38.0 to -19.0)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.8 (-15.1 to 11.2)	-35.2 (-42.7 to -27.0)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.0 (-20.2 to 14.3)	-37.7 (-47.0 to -27.4)
Exposure to mechanical forces	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.2 (72.0 to 99.8)	16.0 (8.6 to 24.2)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.0 (-3.1 to 21.5)	31.6 (-38.1 to -23.9)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.3 (41.0 to 71.4)	-0.5 (-8.8 to 8.9)
Other exposure to mechanical forces	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.1 (78.3 to 107.5)	20.1 (12.6 to 28.7)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.2 (67.9 to 88.1)	10.2 (3.9 to 16.6)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.4 (35.7 to 63.0)	-6.8 (-14.2 to 0.6)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.8 (39.7 to 81.9)	-0.6 (-11.3 to 11.5)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.2 (26.7 to 54.6)	-12.0 (-19.7 to -4.2)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.5 (28.8 to 52.8)	-9.3 (-15.7 to -1.6)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.5 (-22.2 to 13.4)	-32.5 (-42.6 to -20.8)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.5 (31.5 to 52.0)	-7.9 (-14.5 to -1.2)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.6 (49.7 to 83.3)	0.8 (-8.0 to 10.3)
Other unintentional injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.5 (74.8 to 107.8)	17.3 (9.3 to 27.1)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.9 (-2.5 to 23.4)	-32.9 (-39.4 to -24.7)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.8 (-4.9 to 23.3)	-34.9 (-42.3 to -26.9)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.7 (-3.8 to 24.3)	-31.8 (-39.0 to -23.0)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.8 (12.9 to 37.7)	-20.5 (-27.3 to -13.3)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.8 (7.8 to 39.1)	-24.6 (-32.8 to -14.7)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.8 (-11.1 to 17.7)	-35.9 (-43.4 to -26.8)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.3 (-66.7 to -54.7)	-71.8 (-75.8 to -66.6)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.3 (-66.7 to -54.7)	-71.8 (-75.8 to -66.6)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Kuwait prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	195.8 (145.8 to 255.6)	334.8 (249.8 to 436.7)	71.3 (61.2 to 78.1)	46.7 (-14.9 to -2.3)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	24.8 (17.0 to 34.9)	31.8 (22.2 to 43.3)	27.9 (17.5 to 41.2)	-12.7 (-19.2 to -4.0)
HIV/AIDS and tuberculosis	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	90.6 (61.7 to 124.9)	-6.9 (-18.1 to 8.8)
Tuberculosis	0.9 (0.8 to 0.9)	1.4 (1.4 to 1.5)	61.1 (54.0 to 68.4)	-19.1 (-22.1 to -16.2)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	61.7 (38.4 to 87.2)	-18.8 (-28.4 to -9.4)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	1,609.5 (672.9 to 4,290.5)	757.7 (293.1 to 2,183.9)
HIV/AIDS resulting in mycobacterial infection	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.1)	0.9 (0.6 to 1.2)	1,862.6 (837.5 to 4,889.0)	918.1 (396.6 to 2,531.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	1,609.5 (672.9 to 4,290.5)	757.7 (293.1 to 2,183.9)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	3.5 (3.5 to 6.8)	4.3 (4.4 to 8.5)	25.0 (14.3 to 36.7)	-18.7 (-24.9 to -12.0)
Diarrheal diseases	21.4 (19.5 to 23.1)	26.7 (24.7 to 28.7)	24.7 (11.1 to 39.7)	-17.9 (-26.1 to -9.2)	0.0 (2.3 to 4.9)	0.0 (3.0 to 6.0)	15.5 (10.5 to 40.6)	22.0 (-26.3 to 8.3)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.0 (-13.0 to 47.9)	-40.2 (-40.2 to -1.2)
Typhoid fever	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	16.5 (9.9 to 46.1)	-21.1 (-37.6 to -2.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.7 (-12.6 to 49.1)	-21.2 (-38.7 to -0.4)
Paratyphoid fever	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	19.5 (-13.1 to 59.7)	-20.0 (-40.1 to 6.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.5 (-13.2 to 59.9)	20.0 (-40.1 to 6.0)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.2 (-99.5 to 3,160.9)	-77.9 (-99.6 to 2,209.8)
Lower respiratory infections	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.8)	21.1 (-27.4 to 83.3)	-22.0 (-47.5 to 10.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	22.0 (-28.6 to 88.5)	22.4 (-4.9 to 10.8)
Upper respiratory infections	41.6 (37.0 to 45.7)	65.0 (57.1 to 72.1)	56.8 (34.2 to 81.4)	-0.2 (-14.2 to 15.3)	0.3 (0.3 to 0.8)	0.8 (0.4 to 1.3)	56.4 (33.7 to 82.1)	-0.2 (-14.3 to 15.8)
Otitis media	24.6 (23.0 to 26.3)	34.5 (31.7 to 38.0)	39.9 (26.0 to 57.9)	-7.0 (-16.0 to 4.0)	0.5 (0.3 to 0.7)	0.6 (0.4 to 1.0)	37.7 (23.1 to 55.7)	-8.2 (-17.7 to 2.9)
Meningitis	-	-	-	-	0.4 (0.2 to 0.6)	0.3 (0.2 to 0.4)	-24.3 (-42.8 to -3.8)	-54.4 (-64.8 to -42.9)
Pneumococcal meningitis	1.4 (0.8 to 2.3)	1.2 (0.7 to 2.1)	-15.5 (-37.4 to 19.2)	-52.2 (-63.7 to -31.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-13.8 (-38.2 to 18.6)	-50.4 (-62.6 to -33.2)
H influenzae type B meningitis	0.7 (0.2 to 1.8)	0.4 (0.1 to 1.1)	-40.8 (-66.7 to 3.2)	-64.5 (-78.7 to -37.4)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-40.7 (-69.1 to 28.2)	-62.8 (-79.8 to -22.7)
Meningococcal meningitis	0.5 (0.1 to 1.2)	0.3 (0.1 to 0.9)	-31.6 (-69.8 to 21.9)	-58.8 (-79.1 to -34.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-28.0 (-71.6 to 37.7)	-56.0 (-80.2 to -10.9)
Other meningitis	0.5 (0.3 to 1.1)	0.4 (0.2 to 0.9)	-20.2 (-43.4 to 10.2)	-53.8 (-66.7 to -36.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-19.3 (-46.7 to 19.5)	-52.8 (-68.1 to -30.3)
Encephalitis	0.4 (0.2 to 1.1)	0.5 (0.2 to 1.4)	25.1 (-0.2 to 58.9)	-25.7 (-40.0 to -6.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	25.9 (5.3 to 83.9)	-20.1 (-35.0 to 5.0)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.6 (-90.6 to 711.6)	-38.3 (-93.5 to 460.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.6 (-90.6 to 724.2)	-38.3 (-93.5 to 461.9)
Whooping cough	0.4 (0.3 to 0.5)	0.1 (0.1 to 0.1)	-74.0 (-76.5 to -71.3)	-82.4 (-84.1 to -80.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-74.3 (-81.4 to -65.3)	-82.7 (-87.4 to -76.4)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.6 (-73.3 to 9.2)	-50.3 (-83.3 to -35.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.1 (-71.3 to 18.6)	-49.2 (-82.0 to -26.8)
Measles	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.0)	-75.5 (-79.6 to -70.5)	-21.1 (-85.1 to -78.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-75.4 (-81.8 to -66.1)	-82.0 (-86.6 to -75.4)
Varicella and herpes zoster	1.4 (1.2 to 1.5)	2.1 (1.8 to 2.4)	51.0 (28.8 to 81.8)	2.1 (-17.4 to 25.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	91.2 (26.6 to 177.2)	5.1 (-31.5 to 51.9)
Neglected tropical diseases and malaria	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (31.4 to 180.0)	12.4 (-14.5 to 64.5)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.4 (4.9 to 315.4)	31.5 (-33.9 to 160.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.3 (15.5 to 321.8)	37.3 (-28.0 to 166.8)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.2 (-1.5 to 248.3)	2.2 (-34.6 to 125.2)
Visceral leishmaniasis	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	42.2 (-24.2 to 236.9)	-0.5 (-46.1 to 120.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.9 (-25.6 to 247.6)	-0.5 (-48.2 to 126.0)
Cutaneous and mucocutaneous leishmaniasis	1.0 (0.5 to 1.7)	1.7 (1.1 to 2.5)	60.9 (2.1 to 275.9)	1.7 (-33.2 to 140.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.0 (0.6 to 279.4)	2.8 (-34.9 to 140.3)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-75.9 (-91.5 to -21.7)	-88.8 (-95.6 to -69.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-72.9 (-90.6 to -9.4)	-87.2 (-95.0 to -65.9)
Cystic echinococcosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	189.2 (154.0 to 229.3)	57.0 (42.3 to 76.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	182.8 (106.1 to 288.9)	55.7 (17.8 to 107.2)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.1 (-73.1 to 6.0)	52.2 (-84.0 to -35.4)
Intestinal nematode infections	-	-	-	-	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.4 (-24.9 to 188.0)	2.0 (-46.1 to 81.8)
Maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	87.3 (42.5 to 147.0)	-7.1 (-28.8 to 20.3)
Maternal hemorrhage	0.3 (0.3 to 0.4)	0.8 (0.6 to 1.0)	140.5 (66.6 to 257.0)	15.8 (-19.7 to 74.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	119.0 (6.7 to 301.4)	7.7 (-48.4 to 103.4)
Maternal sepsis and other maternal infections	0.7 (0.4 to 1.0)	0.8 (0.4 to 1.2)	12.7 (-28.8 to 72.6)	-46.8 (-67.8 to -15.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.2 (-53.5 to 123.0)	44.9 (-76.5 to 13.0)
Maternal hypertensive disorders	0.6 (0.2 to 1.1)	1.2 (0.4 to 2.2)	92.3 (57.4 to 129.7)	-4.4 (-19.5 to 11.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	92.5 (50.0 to 143.3)	-4.5 (-24.4 to 17.3)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	96.2 (20.3 to 231.3)	-4.3 (-41.5 to 59.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.8 (-27.3 to 439.3)	-3.6 (-63.7 to 162.2)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.7 (24.5 to 283.7)	10.6 (-40.5 to 83.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.7 (24.4 to 284.0)	10.6 (-40.7 to 84.0)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.9 (-0.7 to 363.1)	3.1 (-50.6 to 129.3)
Neonatal disorders	-	-	-	-	3.2 (2.0 to 4.8)	5.5 (3.6 to 8.3)	72.0 (8.7 to 193.3)	7.8 (-31.4 to 82.0)
Preterm birth complications	9.5 (5.6 to 16.2)	20.1 (12.5 to 32.2)	106.9 (52.5 to 230.7)	26.4 (-5.2 to 101.0)	1.4 (0.9 to 2.1)	3.1 (2.0 to 4.9)	117.2 (39.5 to 307.5)	34.2 (-13.7 to 152.0)
Neonatal encephalopathy due to birth asphyxia and trauma	3.1 (1.7 to 5.6)	3.2 (1.8 to 5.7)	1.5 (-52.7 to 107.6)	-35.9 (-69.4 to 28.2)	1.0 (0.5 to 1.6)	1.1 (0.6 to 1.8)	9.4 (-45.1 to 124.9)	-30.5 (-65.0 to 41.1)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	442.9 (106.4 to 228.8)	31.9 (12.1 to 78.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	151.8 (78.3 to 243.9)	36.8 (-3.2 to 86.7)
Hemolytic disease and other neonatal jaundice	1.7 (0.6 to 4.5)	2.9 (1.1 to 6.0)	83.9 (-43.0 to 441.5)	17.5 (-63.3 to 244.5)	0.2 (0.2 to 1.5)	0.6 (0.4 to 2.2)	90.2 (-26.5 to 440.0)	20.2 (-54.4 to 242.6)
Other neonatal disorders	-	-	-	-	0.2 (0.0 to 0.5)	0.2 (0.1 to 0.4)	-44.7 (-79.2 to 428.6)	-65.0 (-86.7 to 231.2)
Nutritional deficiencies	-	-	-	-	14.9 (9.9 to 22.0)	17.2 (11.2 to 25.2)	15.5 (6.8 to 24.1)	-16.0 (-22.4 to -10.4)
Protein-energy malnutrition	4.2 (1.7 to 8.8)	2.0 (0.8 to 4.0)	52.5 (-86.2 to 50.0)	-58.1 (-90.6 to -0.1)	0.3 (0.2 to 1.2)	0.3 (0.1 to 0.5)	52.3 (86.2 to 53.8)	67.9 (-90.6 to 2.8)
Iodine deficiency	47.2 (20.0 to 82.1)	65.9 (39.5 to 98.0)	41.6 (-37.0 to 244.9)	-21.5 (-64.4 to 101.9)	0.8 (0.3 to 1.7)	1.2 (0.6 to 2.1)	41.6 (-37.6 to 245.0)	-21.1 (-64.5 to 102.6)
Vitamin A deficiency	1.7 (1.0 to 2.5)	1.4 (0.8 to 2.1)	-18.9 (-40.6 to 11.6)	-46.6 (-61.1 to -28.9)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-15.5 (-43.0 to 14.6)	-45.5 (-63.3 to -28.3)

Appendix Table G.4 - Kuwait prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	429.7 (424.4 to 434.3)	565.5 (559.2 to 571.7)	31.6 (29.3 to 33.8)	-11.4 (-13.0 to -9.6)	13.2 (8.8 to 19.1)	15.6 (10.3 to 22.8)	17.7 (14.4 to 21.3)	-22.7 (-14.9 to -9.8)
Other nutritional deficiencies	-	-	-	-	0.2 (0.1 to 0.6)	0.1 (0.0 to 0.3)	-39.8 (-87.0 to 144.5)	-58.8 (-91.1 to 66.8)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.4 (0.9 to 2.1)	2.1 (1.3 to 3.3)	55.3 (28.4 to 92.2)	-3.0 (-19.9 to 17.6)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.6 (0.3 to 0.9)	1.2 (0.7 to 1.9)	109.6 (51.8 to 183.7)	8.1 (-19.4 to 43.4)
Syphilis	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	25.3 (-16.7 to 55.3)	-39.5 (-51.3 to -28.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.8 (-20.9 to 86.5)	-38.3 (-56.4 to -13.0)
Chlamydial infection	46.4 (35.8 to 58.5)	95.8 (73.9 to 117.8)	106.9 (40.9 to 192.5)	9.4 (-23.9 to 54.4)	0.4 (0.2 to 0.6)	0.8 (0.4 to 1.3)	126.7 (40.8 to 246.9)	18.2 (-26.0 to 77.6)
Gonococcal infection	16.9 (13.7 to 20.0)	27.3 (23.2 to 31.1)	61.9 (28.6 to 105.5)	-9.0 (-27.1 to 15.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	92.5 (36.0 to 183.1)	4.2 (-26.3 to 50.1)
Trichomoniasis	8.2 (5.1 to 10.9)	12.3 (9.7 to 15.1)	49.0 (3.1 to 157.9)	-21.3 (-45.3 to 36.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.9 (-11.4 to 203.4)	-23.3 (-52.3 to 60.5)
Genital herpes	275.4 (258.6 to 293.7)	514.0 (477.3 to 544.5)	87.0 (69.4 to 102.7)	-5.7 (-15.1 to 2.3)	0.7 (0.0 to 0.2)	0.1 (0.0 to 0.3)	82.8 (63.5 to 101.1)	-6.1 (-15.6 to 2.7)
Other sexually transmitted diseases	0.5 (0.3 to 0.6)	0.6 (0.4 to 0.8)	25.0 (-3.8 to 52.1)	-39.0 (-53.8 to -24.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.6 (4.8 to 157.9)	-18.8 (-44.2 to 26.5)
Hepatitis	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.4)	40.8 (11.5 to 74.2)	-22.9 (-39.1 to -5.9)
Hepatitis A	2.1 (2.0 to 2.2)	2.9 (2.8 to 3.1)	38.5 (37.6 to 39.4)	-8.4 (-9.6 to -7.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	52.1 (33.5 to 74.2)	-6.3 (-16.4 to 6.0)
Hepatitis B	172.9 (134.3 to 207.0)	394.3 (351.0 to 440.6)	118.8 (-14.5 to 57.6)	-36.8 (-50.5 to -11.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	25.8 (-18.1 to 91.3)	-35.6 (-58.2 to -5.5)
Hepatitis C	100.7 (89.0 to 111.9)	140.2 (123.1 to 158.2)	39.3 (17.2 to 66.0)	-23.6 (-34.7 to -11.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.1 (-2.9 to 82.7)	-20.8 (-42.5 to 8.3)
Hepatitis E	0.3 (0.2 to 0.4)	0.8 (0.6 to 1.0)	124.1 (56.4 to 312.3)	22.7 (-9.9 to 128.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.3 (37.9 to 349.7)	24.0 (-21.2 to 144.7)
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	139.9 (1.9 to 672.0)	14.0 (-44.1 to 255.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.6 (-4.1 to 694.8)	9.3 (-47.7 to 252.5)
Other infectious diseases	19.4 (16.2 to 22.7)	24.5 (20.2 to 28.0)	26.5 (2.0 to 56.1)	-8.0 (-26.1 to 12.2)	0.6 (0.4 to 0.9)	0.7 (0.4 to 1.1)	14.8 (-20.2 to 67.3)	-6.9 (-35.1 to 34.4)
Non-communicable diseases	-	-	-	-	158.0 (117.1 to 207.1)	295.2 (219.2 to 384.0)	86.8 (79.8 to 93.7)	1.2 (-1.8 to 4.2)
Neoplasms	-	-	-	-	0.5 (0.4 to 0.7)	1.1 (0.8 to 1.5)	99.0 (80.3 to 124.4)	7.9 (-1.7 to 18.8)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.9 (10.1 to 163.0)	-10.2 (-44.0 to 42.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.0 (25.3 to 137.2)	-8.9 (-39.3 to 32.3)
Stomach cancer	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	63.7 (38.6 to 93.5)	-17.8 (-32.8 to -0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.7 (33.4 to 92.1)	-20.1 (-36.8 to 2.3)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	215.7 (2,438.0 to 4,174.3)	2,569.5 (1,885.1 to 3,482.2)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	2,731.0 (1,245.1 to 5,411.5)	2,342.4 (1,031.3 to 4,614.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,708.5 (1,274.0 to 5,142.6)	2,333.2 (1,050.4 to 4,346.9)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	8,609.4 (4,123.9 to 17,637.6)	5,862.7 (2,970.3 to 10,223.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8,371.3 (4,215.5 to 16,085.9)	5,428.0 (2,857.8 to 8,976.8)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,118.8 (792.1 to 4,508.5)	1,695.5 (636.2 to 3,685.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,064.4 (829.9 to 4,148.9)	1,603.4 (585.4 to 3,325.4)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,283.9 (611.2 to 2,242.7)	1,174.3 (449.4 to 2,084.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,300.4 (636.1 to 2,206.0)	1,156.6 (471.4 to 1,995.2)
Larynx cancer	0.3 (0.2 to 0.4)	0.8 (0.7 to 0.9)	153.5 (78.4 to 214.0)	38.1 (-5.8 to 83.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	129.2 (68.9 to 191.8)	25.9 (-11.0 to 62.2)
Tracheal, bronchus and lung cancer	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.2)	40.9 (18.4 to 71.5)	-24.5 (-37.2 to -6.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.4 (11.3 to 74.4)	-26.4 (-42.2 to -7.2)
Breast cancer	1.3 (1.0 to 1.5)	3.1 (2.5 to 3.7)	134.4 (86.6 to 195.4)	34.3 (7.8 to 62.6)	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	127.6 (80.3 to 194.2)	29.4 (2.7 to 59.6)
Cervical cancer	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	47.5 (-14.8 to 57.3)	-17.5 (-52.3 to -17.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.4 (-13.3 to 65.4)	-46.0 (-52.7 to -14.9)
Uterine cancer	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.6)	257.2 (29.8 to 456.6)	88.6 (-35.9 to 192.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	245.1 (26.2 to 467.5)	77.2 (-36.4 to 185.4)
Prostate cancer	0.2 (0.1 to 0.3)	0.9 (0.6 to 1.3)	444.5 (259.1 to 730.6)	156.0 (69.1 to 288.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	346.0 (204.9 to 550.9)	112.3 (43.9 to 201.6)
Colon and rectum cancer	1.1 (1.0 to 1.2)	1.7 (1.5 to 1.9)	57.3 (35.2 to 80.9)	-30.4 (-41.3 to -19.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	44.2 (26.2 to 71.0)	-35.4 (-47.1 to -22.6)
Lip and oral cavity cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	57.0 (14.1 to 125.2)	-17.6 (-42.1 to 18.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.6 (10.1 to 124.6)	-19.3 (-44.8 to 18.7)
Nasopharynx cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.3 (-32.2 to 57.1)	-45.6 (-63.2 to -16.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.1 (-31.7 to 47.2)	-46.8 (-63.4 to -20.2)
Other pharynx cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	38.9 (56.8 to 77.5)	47.9 (-77.7 to -8.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.3 (-57.0 to 81.4)	67.8 (-78.0 to -8.0)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.1 (-30.6 to 72.6)	-55.5 (-68.9 to -20.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.8 (-33.2 to 66.5)	55.5 (-69.3 to -19.0)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	124.1 (73.4 to 188.3)	8.3 (-18.6 to 45.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	120.4 (83.3 to 170.8)	6.9 (-19.6 to 42.2)
Malignant skin melanoma	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	26.5 (45.9 to 67.9)	59.9 (-70.4 to -3.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.0 (-48.4 to 69.7)	59.9 (-72.6 to 0.5)
Non-melanoma skin cancer	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	68.7 (31.4 to 116.4)	-12.4 (-32.5 to 18.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	173.1 (100.0 to 278.6)	33.3 (-5.2 to 90.5)
Ovarian cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	35.2 (5.6 to 95.9)	-27.1 (-47.0 to 5.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.1 (-11.9 to 105.8)	-28.6 (-51.5 to 6.3)
Testicular cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	115.8 (16.5 to 283.8)	7.1 (-37.2 to 86.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	114.1 (7.5 to 306.5)	6.8 (-41.1 to 89.9)
Kidney cancer	0.6 (0.1 to 0.1)	0.9 (0.2 to 0.4)	199.3 (128.0 to 288.3)	61.3 (21.8 to 114.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	191.0 (118.3 to 289.3)	53.2 (14.3 to 108.7)
Bladder cancer	0.2 (0.2 to 0.3)	0.7 (0.5 to 1.0)	190.1 (109.9 to 353.3)	40.5 (-4.5 to 135.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	224.9 (120.4 to 491.2)	48.8 (-3.3 to 190.7)
Brain and nervous system cancer	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	80.9 (38.9 to 147.2)	17.8 (-5.9 to 57.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.2 (44.8 to 154.9)	15.8 (-6.4 to 54.0)
Thyroid cancer	0.3 (0.2 to 0.4)	0.7 (0.5 to 1.0)	142.4 (62.4 to 245.8)	34.6 (-13.3 to 82.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	140.5 (57.5 to 247.7)	30.7 (-16.0 to 79.3)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.9 (19.3 to 44.6)	45.2 (-9.2 to 24.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.7 (-15.8 to 49.5)	43.2 (-57.3 to -22.4)
Hodgkin lymphoma	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	96.7 (34.1 to 183.6)	34.1 (-6.4 to 84.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.6 (34.5 to 176.3)	30.2 (-9.9 to 82.2)
Non-Hodgkin lymphoma	0.5 (0.4 to 0.6)	1.0 (0.8 to 1.3)	109.0 (63.1 to 189.3)	21.7 (-4.4 to 65.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	106.0 (55.4 to 189.7)	17.4 (-9.3 to 61.3)
Multiple myeloma	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	93.4 (13.1 to 264.6)	-2.0 (-42.8 to 91.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.3 (7.2 to 264.2)	-4.7 (-47.1 to 97.0)
Leukemia	0.6 (0.5 to 0.7)	0.9 (0.7 to 1.0)	47.3 (18.2 to 83.1)	2.3 (-18.6 to 19.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	52.4 (25.2 to 83.3)	-4.8 (-22.6 to 18.8)
Other neoplasms	0.6 (0.4 to 0.8)	1.3 (0.9 to 2.0)	83.8 (43.4 to 279.5)	24.9 (-3.3 to 146.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	80.0 (37.0 to 265.3)	16.4 (-10.2 to 130.8)
Cardiovascular diseases	-	-	-	-	3.3 (2.2 to 4.7)	6.5 (4.3 to 9.1)	96.3 (49.0 to 154.7)	8.8 (-13.3 to 33.1)
Rheumatic heart disease	5.0 (3.6 to 6.7)	10.1 (7.6 to 12.4)	103.4 (40.0 to 196.3)	4.2 (-23.0 to 51.3)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	108.8 (48.3 to 201.2)	13.0 (-17.1 to 62.6)
Ischemic heart disease	11.0 (8.6 to 15.2)	17.4 (15.3 to 20.1)	61.7 (13.8 to 104.4)	-13.4 (-35.7 to 6.0)	0.7 (0.4 to 1.1)	1.1 (0.8 to 1.6)	62.0 (14.5 to 114.9)	-11.1 (-37.0 to 14.8)
Cerebrovascular disease	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	108.7 (66.8 to 152.2)	3.7 (-17.1 to 30.9)
Ischemic stroke	0.5 (0.4 to 0.6)	1.0 (0.9 to 1.2)	115.0 (71.4 to 171.7)	6.5 (-15.5 to 35.6)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	115.1 (67.3 to 175.5)	6.4 (-16.5 to 36.9)
Hemorrhagic stroke	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	82.0 (25.1 to 155.9)	-10.6 (-34.9 to 22.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.9 (24.8 to 155.0)	-10.0 (-33.7 to 23.6)
Hypertensive heart disease	1.5 (1.2 to 1.7)	3.8 (3.3 to 4.4)	154.3 (105.3 to 227.4)	41.1 (11.1 to 83.2)	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.6)	152.5 (102.1 to 227.0)	40.0 (12.0 to 84.8)
Cardiomyopathy and myocarditis	1.6 (1.4 to 1.8)	3.3 (3.0 to 3.7)	110.5 (75.5 to 153.3)	21.1 (-1.9 to 51.3)	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.5)	109.8 (70.8 to 159.7)	20.9 (-3.7 to 54.0)
Atrial fibrillation and flutter	0.6 (0.4 to 0.8)	3.9 (3.2 to 4.8)	535.2 (364.4 to 813.9)	150.3 (67.0 to 280.2)	0.0 (0.0 to 0.1)	0.3 (0.2 to 0.4)	526.9 (346.9 to 807.2)	150.9 (67.2 to 276.7)
Peripheral vascular disease	18.1 (12.6 to 23.3)	39.2 (26.8 to 51.6)	113.1 (42.7 to 256.7)	8.9 (-19.1 to 59.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	147.1 (-24.2 to 474.5)	-6.5 (-71.9 to 111.7)
Endocarditis	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	148.3 (69.3 to 256.7)	24.1 (-14.0 to 69.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	142.4 (62.0 to 229.4)	22.0 (-19.8 to 77.8)
Other cardiovascular and circulatory diseases	25.6 (18.3 to 37.3)	48.4 (30.0 to 64.3)	83.7 (15.0 to 195.9)	7.7 (-35.3 to 56.6)	1.8 (1.1 to 2.8)	3.4 (2.0 to 5.1)	93.7 (13.5 to 199.0)	7.7 (-35.4 to 58.8)
Chronic respiratory diseases	-	-	-	-	11.5 (8.0 to 15.9)	19.1 (13.2 to 26.3)	65.7	

Appendix Table G.4 - Kuwait prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.1 (84.3 to 99.8)	93.1 (-9.2 to -1.7)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.9 (68.1 to 88.5)	-12.7 (-17.4 to -7.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.8 (67.9 to 88.5)	-12.7 (-17.4 to -7.4)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.3 (90.7 to 109.5)	-3.0 (-3.9 to 4.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	100.3 (90.8 to 110.4)	0.2 (-3.9 to 5.2)
Asthma	137.5 (123.0 to 154.4)	186.0 (145.0 to 219.5)	36.7 (31.1 to 67.4)	-16.1 (-33.6 to -0.5)	6.1 (3.9 to 8.9)	8.2 (5.0 to 12.4)	36.1 (23.6 to 67.1)	-16.2 (-34.3 to -0.3)
Interstitial lung disease and pulmonary sarcoidosis	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	100.9 (37.5 to 187.6)	-1.3 (-28.8 to 34.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	101.7 (38.2 to 189.8)	-1.1 (-29.2 to 36.9)
Other chronic respiratory diseases	-	-	-	-	0.5 (0.3 to 0.7)	0.6 (0.4 to 1.0)	30.4 (4.2 to 80.1)	-33.2 (-50.4 to -9.1)
Cirrhosis	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	80.7 (51.0 to 117.0)	6.4 (-10.1 to 27.8)
Cirrhosis due to hepatitis B	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	79.3 (-20.8 to 222.9)	8.2 (50.0 to 97.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (-24.8 to 245.5)	8.2 (53.3 to 105.1)
Cirrhosis due to hepatitis C	0.2 (0.1 to 0.2)	0.3 (0.1 to 0.5)	57.4 (-25.4 to 306.7)	-9.4 (-51.7 to 134.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	60.0 (-32.3 to 329.5)	-8.1 (-53.4 to 140.2)
Cirrhosis due to alcohol use	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	33.3 (-36.3 to 223.3)	-20.0 (-56.1 to 67.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.3 (-40.4 to 253.3)	21.2 (-59.5 to 77.3)
Cirrhosis due to other causes	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	141.6 (52.2 to 337.9)	60.9 (2.0 to 194.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	147.7 (35.4 to 366.3)	59.2 (-12.5 to 196.3)
Digestive diseases	-	-	-	-	1.1 (0.8 to 1.4)	1.9 (1.4 to 2.6)	81.0 (65.9 to 103.7)	-11.8 (-20.0 to -2.6)
Peptic ulcer disease	4.1 (3.4 to 4.7)	3.4 (2.6 to 4.0)	-19.6 (-37.5 to 5.2)	-53.7 (-60.9 to -43.5)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-8.2 (-33.0 to 22.2)	-51.9 (-60.2 to -39.5)
Gastritis and duodenitis	5.1 (4.4 to 5.8)	4.1 (3.4 to 4.7)	-19.9 (-35.1 to -5.1)	-49.8 (-57.5 to -41.5)	0.2 (0.2 to 0.2)	0.2 (0.1 to 0.3)	-2.7 (-37.3 to 16.9)	-44.6 (-53.8 to -28.6)
Appendicitis	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	49.2 (-15.8 to 128.8)	-18.5 (-50.6 to 17.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	50.7 (-24.1 to 170.1)	-17.2 (-53.8 to 35.4)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	131.5 (49.6 to 277.0)	-13.9 (-14.8 to 57.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	132.6 (35.7 to 307.7)	15.2 (-20.9 to 77.1)
Inguinal, femoral, and abdominal hernia	2.9 (2.6 to 3.4)	5.7 (4.8 to 6.8)	93.5 (53.4 to 139.8)	0.2 (-24.2 to 30.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	93.3 (51.2 to 140.9)	0.2 (-25.2 to 32.3)
Inflammatory bowel disease	1.5 (1.4 to 1.7)	4.4 (3.9 to 4.8)	184.4 (150.9 to 223.6)	44.1 (28.3 to 60.7)	0.3 (0.2 to 0.5)	0.9 (0.6 to 1.3)	184.6 (144.1 to 232.3)	44.2 (27.0 to 65.5)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.2 (11.4 to 138.1)	-9.3 (-42.0 to 36.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.0 (11.3 to 140.6)	-7.3 (-42.3 to 41.4)
Gallbladder and biliary diseases	0.5 (0.4 to 0.6)	0.9 (0.8 to 1.1)	80.4 (44.8 to 127.4)	0.1 (-19.7 to 19.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	78.8 (36.6 to 133.0)	-4.5 (-22.0 to 20.6)
Pancreatitis	0.4 (0.4 to 0.4)	0.7 (0.7 to 0.8)	89.4 (66.6 to 110.8)	-7.3 (-15.3 to 1.6)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	89.7 (51.8 to 138.3)	-7.4 (-22.4 to 10.8)
Other digestive diseases	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	140.3 (76.4 to 198.2)	17.3 (-13.2 to 44.4)
Neurological disorders	-	-	-	-	15.5 (10.1 to 21.5)	28.3 (18.9 to 40.1)	82.6 (45.1 to 123.2)	-5.0 (-23.2 to 12.0)
Alzheimer disease and other dementias	3.5 (3.1 to 4.1)	8.9 (7.8 to 10.2)	152.4 (107.8 to 208.8)	-1.3 (-18.8 to 20.7)	0.5 (0.3 to 0.6)	1.2 (0.9 to 1.6)	153.7 (109.5 to 209.8)	-1.8 (-19.4 to 20.0)
Parkinson disease	0.5 (0.2 to 0.6)	1.0 (0.5 to 1.4)	125.2 (108.0 to 148.6)	0.8 (-6.4 to 9.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	122.7 (93.9 to 160.1)	0.4 (-9.9 to 12.0)
Epilepsy	8.6 (6.5 to 10.6)	12.2 (8.6 to 16.0)	40.9 (-4.1 to 106.2)	-13.7 (-41.2 to 24.9)	3.1 (1.9 to 4.4)	4.9 (3.0 to 7.2)	56.2 (5.4 to 131.2)	-4.0 (-35.7 to 41.5)
Multiple sclerosis	0.2 (0.2 to 0.3)	0.8 (0.7 to 0.9)	246.5 (171.9 to 337.0)	0.1 (43.9 to 117.2)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	236.7 (145.8 to 355.8)	71.8 (31.7 to 125.7)
Migraine	291.1 (171.8 to 311.5)	385.2 (215.5 to 486.7)	60.8 (-2.1 to 138.8)	-2.4 (-46.0 to 23.8)	8.2 (4.5 to 12.9)	13.4 (6.9 to 20.9)	60.7 (21.1 to 139.5)	-12.2 (-46.8 to 24.4)
Tension-type headache	359.5 (331.9 to 386.1)	649.1 (439.4 to 829.8)	81.1 (18.0 to 137.1)	-0.2 (-30.4 to 22.8)	0.5 (0.3 to 1.0)	1.0 (0.4 to 1.8)	81.2 (30.9 to 227.7)	-0.5 (-30.9 to 27.7)
Medication overuse headache	16.8 (11.3 to 22.7)	45.0 (29.8 to 59.5)	169.4 (109.9 to 224.6)	43.6 (15.7 to 74.9)	2.7 (1.5 to 4.1)	7.1 (4.1 to 10.7)	169.4 (109.7 to 227.8)	43.6 (15.7 to 76.2)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.8 (-2.8 to 120.7)	-12.0 (-38.4 to 26.7)	0.4 (0.2 to 0.5)	0.5 (0.3 to 0.7)	36.8 (-7.0 to 103.0)	-49.1 (-66.6 to -23.4)
Mental and substance use disorders	-	-	-	-	60.3 (42.1 to 82.4)	110.6 (78.2 to 149.3)	88.4 (71.5 to 95.1)	-1.7 (-6.3 to 2.5)
Schizophrenia	5.6 (5.1 to 6.1)	11.5 (10.3 to 12.5)	103.7 (93.2 to 116.5)	0.2 (-4.2 to 5.2)	0.2 (2.7 to 4.4)	1.2 (5.4 to 9.1)	104.6 (88.9 to 119.9)	0.4 (-6.1 to 6.6)
Alcohol use disorders	9.8 (8.7 to 11.0)	16.2 (13.9 to 18.6)	65.1 (50.5 to 82.5)	-16.9 (-22.9 to -9.5)	1.0 (0.6 to 1.4)	1.6 (1.0 to 2.3)	65.0 (47.2 to 85.6)	-17.3 (-25.6 to -7.6)
Drug use disorders	-	-	-	-	14.6 (9.7 to 19.8)	30.5 (20.6 to 41.7)	109.5 (85.7 to 137.6)	-2.7 (-13.4 to 9.2)
Opioid use disorders	32.3 (24.9 to 40.7)	67.9 (51.1 to 87.3)	110.6 (84.4 to 139.5)	-3.2 (-14.7 to 8.3)	13.5 (8.9 to 18.5)	28.4 (18.9 to 39.3)	111.2 (84.9 to 141.6)	-3.1 (-14.7 to 9.8)
Cocaine use disorders	1.7 (1.4 to 2.1)	3.5 (2.7 to 4.4)	98.5 (46.5 to 171.0)	3.2 (-22.2 to 30.7)	0.2 (0.1 to 0.4)	0.5 (0.3 to 0.7)	98.9 (39.9 to 188.6)	3.6 (-25.6 to 47.0)
Amphetamine use disorders	2.1 (1.6 to 2.5)	3.8 (2.9 to 4.5)	82.4 (35.8 to 154.2)	-1.8 (-25.9 to 34.9)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.8)	83.6 (30.6 to 164.6)	-1.6 (-28.3 to 39.4)
Cannabis use disorders	3.3 (2.6 to 4.0)	6.0 (4.8 to 7.1)	80.4 (69.7 to 92.9)	4.2 (3.4 to 5.1)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	81.3 (51.8 to 116.4)	4.7 (-10.9 to 21.9)
Other drug use disorders	-	-	-	-	0.5 (0.3 to 0.8)	1.0 (0.6 to 1.4)	89.5 (32.4 to 177.0)	0.5 (-30.0 to 48.3)
Depressive disorders	-	-	-	-	19.6 (10.5 to 31.2)	35.3 (18.7 to 56.9)	81.0 (56.8 to 99.7)	0.5 (-10.6 to 7.7)
Major depressive disorder	84.7 (47.5 to 121.5)	152.4 (81.5 to 223.9)	80.3 (53.1 to 100.5)	-0.4 (-11.2 to 9.0)	17.5 (8.9 to 28.4)	31.5 (15.5 to 51.7)	79.9 (52.4 to 100.8)	-0.3 (-11.4 to 9.3)
Dysthymia	20.6 (16.3 to 24.8)	39.3 (30.7 to 47.7)	90.3 (85.9 to 94.0)	-2.1 (-3.0 to -1.1)	2.0 (1.3 to 3.0)	3.8 (2.4 to 5.7)	90.2 (82.5 to 98.0)	-2.0 (-4.7 to 0.8)
Bipolar disorder	14.9 (12.8 to 16.9)	28.4 (24.4 to 32.2)	94.0 (78.8 to 104.1)	-2.7 (-7.0 to 2.4)	3.0 (1.9 to 4.6)	5.8 (3.6 to 8.7)	90.7 (76.3 to 106.4)	-2.6 (-8.2 to 3.7)
Anxiety disorders	86.0 (37.9 to 122.3)	143.5 (69.5 to 207.6)	67.6 (50.9 to 82.7)	57.4 (-6.5 to -1.9)	19.6 (3.2 to 12.9)	35.3 (5.8 to 21.7)	81.0 (49.9 to 83.9)	0.5 (-7.5 to -0.7)
Eating disorders	-	-	-	-	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	54.1 (34.8 to 75.0)	-9.7 (-19.8 to 1.6)
Anorexia nervosa	0.4 (0.2 to 0.6)	0.6 (0.4 to 0.9)	63.9 (41.3 to 95.9)	2.2 (-10.3 to 20.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	64.2 (23.9 to 119.2)	2.0 (-21.4 to 37.3)
Bulimia nervosa	1.2 (0.8 to 1.6)	1.7 (1.2 to 2.5)	50.7 (40.6 to 63.3)	-13.5 (-17.1 to -10.4)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.6)	51.2 (27.8 to 74.5)	-13.5 (-25.0 to -1.7)
Autistic spectrum disorders	-	-	-	-	2.5 (1.7 to 3.4)	4.3 (3.0 to 5.9)	72.7 (66.5 to 79.2)	4.9 (0.6 to 7.6)
Autism	6.3 (6.0 to 6.6)	10.8 (10.3 to 11.4)	72.3 (71.4 to 73.3)	3.6 (3.4 to 3.8)	1.6 (1.0 to 2.1)	2.7 (1.8 to 3.7)	71.7 (62.6 to 81.1)	3.6 (-1.1 to 8.7)
Asperger syndrome	9.4 (8.8 to 10.0)	16.5 (15.4 to 17.5)	74.8 (73.3 to 76.2)	4.6 (4.4 to 4.8)	0.9 (0.7 to 1.3)	1.7 (1.1 to 2.3)	74.6 (67.1 to 82.2)	4.8 (1.0 to 8.7)
Attention-deficit/hyperactivity disorder	13.4 (11.1 to 15.8)	16.2 (13.3 to 19.1)	20.9 (19.2 to 22.1)	3.7 (3.2 to 4.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	20.6 (11.6 to 30.9)	3.6 (-4.2 to 12.0)
Conduct disorder	24.8 (20.5 to 28.7)	28 (23.2 to 32.8)	13.0 (11.4 to 15.3)	-9.9 (-23.7 to 2.7)	3.0 (1.8 to 4.5)	3.4 (2.1 to 5.1)	13.5 (8.3 to 18.9)	3.1 (-1.0 to 7.7)
Idiopathic intellectual disability	46.2 (38.6 to 55.9)	69.4 (56.6 to 83.8)	50.3 (35.5 to 68.3)	4.0 (-18.4 to 2.7)	2.3 (1.5 to 3.2)	3.4 (2.3 to 4.7)	50.3 (31.7 to 68.6)	-7.9 (-19.1 to 3.4)
Other mental and substance use disorders	31.0 (29.0 to 33.0)	65.3 (60.8 to 69.9)	110.8 (106.8 to 114.7)	4.5 (3.2 to 5.8)	2.3 (1.6 to 3.2)	4.9 (3.3 to 6.7)	111.0 (100.9 to 121.3)	4.6 (0.4 to 8.7)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	20.4 (14.1 to 28.1)	45.7 (30.9 to 61.9)	123.4 (89.4 to 160.9)	24.2 (5.6 to 46.9)
Diabetes mellitus	155.2 (131.3 to 184.8)	396.1 (345.6 to 446.5)	156.0 (104.7 to 216.7)	34.6 (8.1 to 69.3)	11.9 (7.7 to 16.9)	31.7 (21.1 to 43.4)	168.2 (107.0 to 240.0)	38.0 (9.8 to 75.3)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.2 (-5.3 to 10.6)	0.0 (-31.6 to -22.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (5.4 to 10.8)	27.2 (-31.6 to -22.6)
Chronic kidney disease	-	-	-	-	1.8 (1.3 to 2.5)	3.3 (2.3 to 4.5)	81.8 (65.9 to 101.9)	0.8 (-6.1 to 10.4)
Chronic kidney disease due to diabetes mellitus	12.6 (8.3 to 20.4)	26.3 (16.7 to 39.0)	107.6 (52.8 to 188.6)	9.6 (-20.9 to 46.5)	0.3 (0.2 to 0.5)	0.7 (0.5 to 1.0)	100.4 (42.3 to 192.4)	10.5 (-19.6 to 45.6)
Chronic kidney disease due to hypertension	11.2 (7.7 to 15.7)	15.3 (11.3 to 20.6)	37.8 (4.2 to 81.2)	-20.8 (-37.5 to 0.3)	0.6 (0.4 to 0.8)	0.9 (0.6 to 1.3)	56.1 (20.0 to 105.4)	-22.4 (-40.1 to -3.8)
Chronic kidney disease due to glomerulonephritis	18.7 (12.7 to 27.0)	29.5 (18.2 to 43.8)	57.3 (14.2 to 111.7)	4.9 (-45.7 to 4.8)	0.4 (0.2 to 0.4)	0.4 (0.2 to 0.6)	31.9 (4.9 to 91.0)	-17.8 (-40.1 to 13.4)
Chronic kidney disease due to other causes	21.8 (13.9 to 30.7)	47.0 (31.4 to 63.7)	116.2 (70.7 to 198.5)	18.3 (-4.0 to 65.8)	0.3 (0.4 to 0.8)	1.3 (0.9 to 1.9)	116.1 (72.2 to 191.7)	23.5 (1.4 to 61.8)
Urinary diseases and male infertility	-	-	-	-	0.8 (0.5 to 1.2)	2.0 (1.2 to 3.1)	140.6 (114.2 to 177.1)	17.1 (6.4 to 29.9)

Appendix Table G.4 - Kuwait prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.4 (0.3 to 0.4)	0.7 (0.6 to 0.7)	76.6 (58.4 to 97.6)	4.8 (-8.6 to 9.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.9 (38.7 to 128.3)	0.4 (-17.3 to 21.5)
Urolithiasis	16.8 (10.1 to 27.8)	44.7 (22.2 to 87.0)	152.2 (95.8 to 247.5)	30.8 (6.5 to 66.3)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.9)	151.9 (111.0 to 243.6)	40.9 (18.8 to 80.2)
Benign prostatic hyperplasia	10.1 (9.2 to 10.9)	22.0 (20.4 to 23.7)	118.8 (97.8 to 145.6)	6.7 (-3.1 to 19.6)	0.4 (0.2 to 0.5)	0.8 (0.5 to 1.1)	116.8 (95.3 to 143.8)	6.1 (-4.0 to 19.1)
Male infertility due to other causes	18.8 (12.3 to 25.3)	44.6 (29.8 to 64.5)	136.8 (34.9 to 283.5)	12.6 (-35.8 to 84.7)	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.6)	135.1 (31.5 to 298.2)	12.3 (-37.1 to 91.1)
Other urinary diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.7)	190.5 (121.1 to 307.2)	66.5 (21.3 to 124.8)
Gynecological diseases	-	-	-	-	3.0 (1.9 to 4.4)	4.6 (2.9 to 6.9)	56.5 (31.4 to 86.5)	-18.9 (-31.4 to -3.5)
Uterine fibroids	35.7 (32.1 to 39.1)	62.4 (56.1 to 68.2)	74.7 (73.9 to 75.7)	-9.5 (-10.2 to -8.8)	0.5 (0.3 to 0.9)	0.8 (0.5 to 1.4)	62.8 (52.1 to 73.4)	-17.4 (-24.3 to -11.8)
Polycystic ovarian syndrome	45.8 (42.0 to 49.5)	74.0 (66.1 to 81.6)	61.7 (41.6 to 83.1)	-18.0 (-27.4 to -7.6)	0.4 (0.2 to 0.8)	0.7 (0.3 to 1.4)	61.4 (41.4 to 83.9)	-18.2 (-27.5 to -7.3)
Female infertility due to other causes	6.1 (2.0 to 12.5)	9.1 (2.5 to 20.7)	38.5 (-60.0 to 502.5)	-27.8 (-78.5 to 188.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	38.8 (-56.7 to 420.0)	-27.0 (-76.3 to 162.8)
Endometriosis	3.7 (3.1 to 4.3)	6.0 (5.7 to 7.6)	79.1 (43.1 to 128.2)	-12.2 (29.3 to 10.2)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	78.4 (42.8 to 131.6)	-12.7 (-29.1 to 12.0)
Genital prolapse	91.9 (70.9 to 115.6)	154.4 (117.7 to 187.9)	70.2 (12.0 to 136.8)	-8.8 (-34.7 to 19.1)	0.5 (0.1 to 0.6)	0.8 (0.2 to 0.9)	69.2 (11.3 to 137.8)	-8.7 (-35.5 to 19.3)
Premenstrual syndrome	136.9 (91.7 to 178.0)	196.9 (142.0 to 270.7)	43.6 (-4.3 to 128.2)	-24.9 (-50.0 to 22.3)	1.2 (0.6 to 1.8)	1.7 (0.9 to 2.8)	43.6 (-4.1 to 129.1)	-24.9 (-50.0 to 23.8)
Other gynecological diseases	5.7 (4.4 to 7.0)	8.0 (7.4 to 8.6)	38.5 (11.5 to 81.9)	-23.9 (-38.1 to -0.5)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	38.8 (9.6 to 133.7)	-27.2 (-40.1 to 26.7)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	2.2 (1.5 to 3.2)	3.0 (2.0 to 4.4)	37.3 (23.9 to 55.7)	-1.9 (-14.8 to 10.5)
Thalassemias	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	38.1 (24.0 to 55.9)	0.3 (-9.7 to 12.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.1 (-0.8 to 86.6)	-1.6 (-28.5 to 35.8)
Thalassemia trait	56.7 (52.8 to 61.6)	89.8 (83.1 to 98.1)	58.1 (49.7 to 67.7)	-3.2 (-8.1 to 2.5)	1.3 (0.8 to 1.9)	1.8 (1.2 to 2.6)	34.4 (12.0 to 59.4)	-3.3 (-24.3 to 12.2)
Sickle cell disorders	0.2 (0.2 to 0.2)	0.4 (0.4 to 0.5)	99.6 (70.4 to 144.3)	31.9 (11.0 to 60.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	110.3 (78.5 to 148.9)	29.9 (10.9 to 53.6)
Sickle cell trait	53.1 (45.9 to 59.8)	108.2 (95.0 to 117.0)	99.9 (85.9 to 114.4)	-21.8 (-31.3 to 10.5)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	65.2 (30.6 to 109.7)	20.0 (-5.5 to 51.8)
G6PD deficiency	105.0 (92.9 to 118.4)	191.5 (168.8 to 216.6)	81.8 (56.1 to 112.9)	9.7 (-5.9 to 28.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.7 (-19.1 to 76.9)	-13.9 (-43.9 to 12.8)
G6PD trait	329.0 (312.3 to 343.3)	481.1 (464.0 to 497.5)	46.3 (38.7 to 55.1)	-5.6 (-10.5 to 0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.4 (-67.9 to 1,482.2)	4.4 (-74.7 to 833.1)
Other hemoglobinopathies and hemolytic anemias	19.4 (18.2 to 22.1)	28.1 (25.2 to 31.0)	44.9 (23.2 to 67.6)	-8.3 (-19.7 to 3.3)	0.5 (0.3 to 0.7)	0.6 (0.4 to 1.0)	24.2 (-13.5 to 76.4)	-11.9 (-36.7 to 20.3)
Endocrine, metabolic, blood, and immune disorders	24.5 (22.8 to 27.0)	33.4 (31.8 to 34.9)	36.3 (22.9 to 49.9)	-9.8 (-17.2 to -1.8)	0.8 (0.5 to 1.1)	1.0 (0.7 to 1.4)	26.6 (12.8 to 46.9)	-10.6 (-19.7 to 1.7)
Musculoskeletal disorders	-	-	-	-	12.8 (12.6 to 24.4)	24.3 (25.0 to 47.0)	90.1 (72.4 to 116.4)	-2.4 (-8.3 to 8.4)
Rheumatoid arthritis	2.4 (2.2 to 2.6)	2.5 (2.2 to 2.7)	2.2 (-10.0 to 15.7)	-43.8 (-49.8 to -37.3)	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.8)	1.6 (-14.2 to 20.3)	43.9 (-51.1 to -35.4)
Osteoarthritis	29.7 (28.0 to 31.4)	60.7 (56.9 to 64.6)	104.7 (88.1 to 123.0)	-0.2 (-7.1 to 7.2)	1.8 (1.3 to 2.5)	3.7 (2.6 to 5.2)	104.1 (86.7 to 122.4)	-0.1 (-7.0 to 7.4)
Low back and neck pain	-	-	-	-	12.8 (8.7 to 17.5)	24.3 (16.7 to 32.9)	90.1 (59.5 to 120.0)	-2.4 (-16.6 to 9.5)
Low back pain	52.6 (41.0 to 62.3)	94.9 (79.7 to 110.8)	81.9 (40.8 to 136.5)	-7.9 (-25.0 to 10.0)	5.9 (3.8 to 8.5)	10.7 (7.0 to 15.2)	81.4 (39.9 to 135.7)	-7.7 (-24.9 to 11.3)
Neck pain	69.9 (59.8 to 80.2)	137.5 (115.9 to 159.5)	98.6 (59.3 to 137.6)	1.4 (-16.2 to 22.2)	6.9 (4.7 to 9.8)	13.6 (8.9 to 19.1)	97.8 (58.9 to 137.8)	1.2 (-16.2 to 21.8)
Gout	0.6 (0.4 to 0.7)	1.4 (1.1 to 1.6)	139.8 (83.2 to 219.6)	19.3 (-5.4 to 51.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	138.9 (59.4 to 255.8)	19.1 (-14.2 to 64.3)
Other musculoskeletal disorders	31.4 (23.2 to 42.5)	72.5 (53.2 to 94.3)	130.8 (105.6 to 159.5)	22.8 (11.7 to 33.8)	2.9 (1.8 to 4.4)	6.7 (4.0 to 10.1)	28.8 (105.2 to 159.8)	10.2 (11.3 to 33.9)
Other non-communicable diseases	-	-	-	-	27.1 (18.1 to 39.5)	46.4 (31.6 to 66.7)	71.5 (62.9 to 81.3)	-5.6 (-10.2 to -1.8)
Congenital anomalies	-	-	-	-	2.2 (1.6 to 2.9)	5.1 (3.5 to 7.1)	128.5 (87.2 to 175.5)	39.1 (14.6 to 66.4)
Neural tube defects	0.6 (0.5 to 0.8)	1.1 (0.9 to 1.3)	71.2 (32.5 to 114.8)	8.9 (-15.8 to 36.4)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	77.3 (23.8 to 154.4)	13.1 (-20.4 to 61.4)
Congenital heart anomalies	15.1 (12.9 to 17.6)	28.1 (23.4 to 33.9)	85.4 (49.9 to 132.1)	17.8 (-4.9 to 47.3)	0.6 (0.2 to 0.9)	1.1 (0.5 to 1.8)	88.5 (53.4 to 131.0)	20.5 (-3.2 to 47.7)
Orofacial clefts	0.4 (2.2 to 4.1)	1.1 (2.9 to 5.3)	43.5 (-10.4 to 100.1)	-5.8 (-41.2 to 31.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	43.5 (-38.7 to 66.0)	29.4 (-59.5 to 7.0)
Down syndrome	3.4 (2.5 to 4.5)	5.8 (4.9 to 6.9)	70.3 (25.1 to 138.7)	7.1 (-21.5 to 49.4)	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.0)	74.9 (26.7 to 147.3)	9.7 (-20.5 to 56.9)
Turner syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	42.7 (2.2 to 106.5)	-7.7 (-33.4 to 33.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.5 (-0.2 to 115.5)	-9.3 (-37.4 to 34.4)
Klinefelter syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	77.6 (26.4 to 171.6)	3.9 (-26.2 to 58.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	110.3 (48.7 to 220.7)	8.5 (-22.8 to 66.0)
Chromosomal unbalanced rearrangements	34.4 (2.6 to 4.4)	72.5 (43.3 to 76.2)	130.8 (12.0 to 138.7)	22.8 (-29.7 to 50.6)	2.9 (0.3 to 0.6)	6.7 (0.5 to 1.0)	28.8 (14.7 to 144.3)	10.2 (-28.3 to 54.1)
Other congenital anomalies	5.7 (4.8 to 6.6)	9.5 (7.9 to 11.3)	66.0 (40.9 to 94.4)	-4.0 (-18.4 to 11.3)	0.6 (0.4 to 0.8)	2.2 (1.4 to 3.3)	266.7 (158.4 to 418.9)	120.5 (55.6 to 211.2)
Skin and subcutaneous diseases	-	-	-	-	10.9 (6.8 to 17.0)	18.0 (11.1 to 28.1)	65.8 (48.0 to 85.5)	1.9 (-7.5 to 14.0)
Dermatitis	108.0 (89.7 to 124.6)	192.8 (155.6 to 226.1)	78.4 (72.1 to 84.4)	0.8 (0.1 to 1.4)	3.1 (2.0 to 4.5)	5.2 (3.3 to 7.7)	69.7 (60.4 to 78.0)	0.4 (-2.6 to 3.2)
Psoriasis	11.9 (9.2 to 15.0)	22.1 (16.8 to 28.2)	85.7 (80.9 to 90.1)	1.0 (-0.7 to 0.5)	1.8 (0.6 to 1.4)	1.8 (1.2 to 2.7)	85.5 (70.3 to 99.7)	0.0 (-6.3 to 6.4)
Cellulitis	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.8)	42.3 (24.5 to 60.0)	-15.0 (-22.7 to -5.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	41.8 (8.0 to 86.9)	-14.9 (-30.5 to 7.1)
Pyoderma	1.5 (1.2 to 1.9)	2.1 (1.6 to 2.7)	37.8 (24.2 to 51.9)	-6.9 (-12.4 to -0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.5 (17.9 to 61.2)	-6.8 (-17.4 to 5.2)
Scabies	7.4 (6.0 to 9.0)	11.6 (9.5 to 15.1)	58.5 (19.3 to 108.4)	-2.1 (-24.5 to 24.0)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	58.4 (18.6 to 110.7)	-2.1 (-24.5 to 24.8)
Fungal skin diseases	124.8 (94.7 to 156.9)	228.4 (171.2 to 290.3)	82.8 (73.2 to 93.2)	8.9 (1.3 to 2.5)	0.7 (0.3 to 1.5)	1.3 (0.5 to 2.8)	82.8 (72.5 to 93.5)	2.0 (-0.9 to 3.1)
Viral skin diseases	44.7 (34.1 to 54.8)	62.8 (44.3 to 82.2)	40.0 (27.3 to 51.8)	-0.2 (-2.6 to 2.0)	1.4 (0.8 to 2.2)	1.9 (1.1 to 3.1)	39.8 (27.1 to 52.2)	0.9 (-3.9 to 3.6)
Acne vulgaris	264.4 (196.4 to 341.1)	398.5 (306.4 to 495.2)	48.9 (9.4 to 118.9)	4.4 (-23.1 to 52.3)	2.9 (2.3 to 5.7)	4.3 (1.9 to 8.5)	49.4 (9.4 to 119.6)	4.7 (-23.4 to 52.5)
Alopecia areata	2.8 (2.4 to 3.2)	4.9 (4.1 to 5.7)	76.9 (42.6 to 116.3)	0.7 (-17.5 to 20.9)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	75.8 (40.6 to 121.4)	0.2 (-17.8 to 21.2)
Pruritus	0.4 (0.2 to 0.5)	1.0 (0.6 to 1.6)	180.0 (67.9 to 312.5)	61.8 (-1.4 to 275.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	180.2 (65.7 to 541.4)	61.1 (-2.1 to 288.7)
Urticaria	16.5 (10.7 to 24.4)	31.3 (20.4 to 42.6)	92.4 (-2.2 to 231.3)	7.9 (-40.4 to 77.8)	1.0 (0.5 to 1.6)	1.9 (1.0 to 3.0)	92.0 (-2.7 to 233.5)	7.4 (-41.0 to 78.9)
Decubitus ulcer	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.4)	75.7 (34.2 to 140.7)	-16.7 (-48.8 to 34.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	74.9 (31.6 to 142.7)	-17.2 (-49.8 to 36.0)
Other skin and subcutaneous diseases	89.6 (62.6 to 122.6)	170.1 (115.8 to 238.6)	89.3 (74.8 to 104.3)	1.4 (-3.1 to 5.5)	0.5 (0.2 to 1.1)	1.0 (0.4 to 2.0)	89.3 (74.5 to 104.5)	1.4 (-3.1 to 5.6)
Sense organ diseases	-	-	-	-	10.6 (7.1 to 15.3)	17.0 (11.6 to 24.2)	60.9 (51.8 to 73.7)	-14.6 (-19.6 to -9.1)
Glaucoma	5.2 (3.3 to 7.9)	8.6 (5.8 to 11.8)	67.4 (26.7 to 121.0)	-21.1 (-41.5 to 5.8)	0.4 (0.2 to 0.7)	0.6 (0.4 to 1.0)	70.6 (32.3 to 122.2)	-20.6 (-36.6 to 7.3)
Cataract	9.7 (6.4 to 12.9)	17.6 (12.6 to 23.4)	86.1 (32.5 to 128.4)	-22.4 (-33.1 to -10.6)	0.7 (0.4 to 1.1)	1.3 (0.8 to 1.9)	79.6 (25.7 to 145.2)	-23.4 (-35.7 to -1.9)
Macular degeneration	2.6 (1.7 to 4.0)	3.6 (2.0 to 5.6)	41.9 (-10.1 to 115.7)	-25.1 (-51.5 to 18.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	45.9 (-4.1 to 125.1)	-23.0 (-47.6 to 13.4)
Uncorrected refractive error	140.4 (114.3 to 164.7)	240.6 (201.4 to 280.7)	71.5 (35.0 to 132.0)	-7.3 (-24.7 to 17.3)	3.5 (2.0 to 5.1)	5.4 (3.4 to 8.1)	59.9 (37.6 to 80.0)	-16.1 (-24.7 to -3.5)
Age-related and other hearing loss	142.2 (129.7 to 156.6)	251.4 (228.1 to 278.8)	76.4 (67.3 to 87.8)	-9.8 (-13.0 to -6.7)	3.6 (2.3 to 5.2)	6.1 (3.9 to 8.8)	71.0 (56.1 to 85.5)	-10.0 (-15.6 to -5.3)
Other vision loss	14.0 (10.8 to 18.1)	20.6 (15.2 to 27.0)	45.7 (27.9 to 72.5)	-21.6 (-31.9 to -10.0)	1.1 (0.7 to 1.6)	1.6 (0.9 to 2.5)	50.0 (24.9 to 75.9)	-20.3 (-36.6 to -6.2)
Other sense organ diseases	44.3 (42.0 to 46.7)	67.6 (64.1 to 71.0)	52.4 (41.1 to 64.3)	-1.3 (-7.3 to 5.6)	1.2 (0.7 to 1.8)	1.8 (1.1 to 2.7)	51.5 (39.6 to 66.5)	-1.2 (-7.9 to 6.7)
Oral disorders	-	-	-	-	3.4 (2.0 to 5.4)	6.3 (3.7 to 10.0)	83.8 (72.5 to 94.1)	4.7 (-11.2 to 2.4)
Deciduous caries	194.4 (188.0 to 200.3)	222.0 (216.4 to 228.3)	14.2 (10.0 to 18.8)	0.8 (-2.8 to 5.1)	0.8 (0.0 to 0.2)	0.1 (0.0 to 0.2)	14.3 (6.5 to 21.6)	1.0 (-6.0 to 7.4)
Permanent caries	695.7 (627.8 to 777.1)	1,219.9 (1,057.1 to 1,335.2)	76.1 (49.2 to 104.2)	2.7 (-11.7 to 18.9)	0.7 (0.3 to 1.3)	1.2 (0.5 to 2.3)	75.9 (49.0 to 104.4)	2.8 (-11.5 to 18.9)
Periodontal diseases	96.1 (87.9 to 104.5)	199.3 (175.2 to 220.3)	108.3 (79.1 to 135.9)	5.0 (-11.1 to 18.8)	0.6 (0.3 to 1.3)	1.3 (0.5 to 2.7)	108.5 (78.8 to 137.1)	5.0 (-11.0 to 19.1)

Appendix Table G.4 - Kuwait prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	36.9 (33.3 to 40.3)	69.3 (62.0 to 76.1)	88.1 (61.7 to 115.3)	-9.5 (-20.1 to 2.2)	1.0 (0.7 to 1.4)	1.9 (1.3 to 2.8)	87.3 (60.2 to 114.5)	-8.7 (-20.5 to 2.2)
Other oral disorders	33.4 (31.4 to 35.5)	59.1 (55.5 to 62.7)	76.3 (64.2 to 88.4)	-1.4 (-6.9 to 4.7)	1.0 (0.6 to 1.5)	1.7 (1.1 to 2.6)	76.2 (63.4 to 89.5)	-1.3 (-7.2 to 5.4)
Injuries	-	-	-	-	13.0 (7.5 to 23.4)	7.9 (5.7 to 10.6)	-34.8 (-65.3 to -6.0)	-71.3 (-84.8 to -55.4)
Transport injuries	-	-	-	-	3.3 (2.4 to 4.2)	3.3 (2.3 to 4.5)	0.5 (-13.5 to 18.2)	-45.8 (-52.7 to -37.4)
Road injuries	-	-	-	-	3.1 (2.3 to 4.0)	2.9 (2.0 to 3.9)	6.4 (-21.5 to 8.0)	-90.1 (-56.6 to -42.2)
Pedestrian road injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.6 (0.4 to 0.8)	-19.3 (-33.1 to -3.5)	-54.0 (-60.6 to -46.7)
Cyclist road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	15.7 (1.6 to 32.6)	-38.7 (-45.9 to -31.1)
Motorcyclist road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-15.2 (-28.6 to 0.2)	-55.5 (-61.7 to -47.9)
Motor vehicle road injuries	-	-	-	-	1.7 (1.3 to 2.2)	1.6 (1.1 to 2.2)	5.7 (-20.5 to 13.3)	-49.2 (-56.4 to -40.5)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.1 (-54.5 to -36.0)	-71.5 (-75.4 to -67.1)
Other transport injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.5 (0.3 to 0.6)	154.0 (122.4 to 195.0)	21.0 (6.9 to 40.7)
Unintentional injuries	-	-	-	-	2.8 (2.2 to 3.7)	4.1 (3.0 to 5.5)	43.6 (31.7 to 57.3)	-26.4 (-32.9 to -19.2)
Falls	-	-	-	-	1.1 (0.8 to 1.4)	1.7 (1.2 to 2.3)	50.7 (33.9 to 71.8)	-27.1 (-35.6 to -16.7)
Drowning	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-18.0 (-30.7 to -1.3)	-54.6 (-61.1 to -46.7)
Fire, heat, and hot substances	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	1.9 (-15.1 to 19.6)	-41.2 (-49.2 to -31.9)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.9 (-11.7 to 39.9)	-36.5 (-48.7 to -23.2)
Exposure to mechanical forces	-	-	-	-	1.0 (0.8 to 1.4)	1.3 (0.9 to 1.7)	24.7 (15.7 to 35.8)	-33.6 (-38.7 to -28.2)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-28.9 (-38.7 to -17.2)	-65.3 (-69.7 to -60.1)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.9 (44.7 to 94.2)	-7.4 (-17.7 to 6.0)
Other exposure to mechanical forces	-	-	-	-	1.0 (0.7 to 1.3)	1.2 (0.9 to 1.7)	26.8 (15.7 to 38.3)	-32.3 (-37.5 to -26.8)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	104.3 (87.2 to 120.9)	14.6 (6.4 to 22.6)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	36.7 (16.1 to 59.9)	-19.6 (-30.4 to -7.6)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.4 (12.9 to 79.6)	-19.2 (-34.2 to 0.9)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.2 (10.6 to 57.1)	-20.5 (-31.0 to -6.8)
Foreign body	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	37.8 (23.4 to 54.3)	-24.3 (-31.1 to -16.5)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.1 (-36.5 to -0.6)	-48.4 (-57.9 to -37.4)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.9 (47.6 to 89.5)	-9.0 (-17.9 to 1.8)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	48.2 (31.5 to 68.1)	-21.3 (-29.4 to -12.5)
Other unintentional injuries	-	-	-	-	0.3 (0.2 to 0.3)	0.6 (0.4 to 0.8)	144.9 (116.8 to 176.4)	5.3 (-4.2 to 16.6)
Self-harm and interpersonal violence	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	5.7 (-17.7 to 9.2)	-48.2 (-54.7 to -40.4)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.2 (38.7 to 85.3)	-20.1 (-30.3 to -8.6)
Interpersonal violence	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-14.4 (-26.0 to 0.0)	-52.4 (-58.7 to -45.1)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	20.0 (6.6 to 35.6)	-34.3 (-41.2 to -26.3)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	16.3 (0.1 to 36.3)	-38.3 (-46.5 to -28.4)
Assault by other means	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-40.7 (-50.3 to -28.7)	-65.9 (-71.0 to -59.5)
Forces of nature, war, and legal intervention	-	-	-	-	6.7 (2.1 to 16.5)	0.3 (0.1 to 0.7)	-95.7 (-97.9 to -90.0)	-96.8 (-98.5 to -92.9)
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	6.7 (2.1 to 16.5)	0.3 (0.1 to 0.7)	-95.7 (-97.9 to -90.0)	-96.8 (-98.5 to -92.9)

Appendix Table G.4 - Kyrgyzstan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	379.4 (279.2 to 492.5)	488.4 (360.8 to 636.7)	28.7 (24.7 to 33.1)	23 (5.2 to 0.6)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	51.7 (35.4 to 72.5)	58.3 (40.9 to 80.4)	12.1 (1.7 to 28.3)	-5.7 (-14.9 to 7.9)
HIV/AIDS and tuberculosis	-	-	-	-	1.9 (1.3 to 2.5)	3.8 (2.5 to 5.5)	96.1 (66.0 to 166.2)	38.7 (17.3 to 87.4)
Tuberculosis	5.9 (5.6 to 6.2)	9.8 (9.4 to 10.3)	66.0 (57.8 to 74.2)	17.3 (12.3 to 22.4)	1.8 (1.2 to 2.5)	3.0 (2.1 to 4.1)	66.3 (53.2 to 81.3)	17.6 (9.3 to 27.0)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.2)	0.7 (0.2 to 2.1)	1,213.4 (158.3 to 6,004.8)	863.4 (91.5 to 4,332.9)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	1,292.3 (125.8 to 6,438.5)	898.1 (60.8 to 4,506.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	1,221.9 (81.5 to 6,729.0)	833.6 (28.3 to 4,757.8)
HIV/AIDS resulting in other diseases	0.6 (0.1 to 1.5)	5.9 (1.4 to 13.6)	932.1 (114.2 to 4,231.6)	654.0 (56.8 to 3,050.4)	0.1 (0.0 to 0.2)	0.7 (0.1 to 2.0)	1,230.2 (122.5 to 6,817.9)	868.1 (67.2 to 4,002.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	7.5 (5.3 to 10.1)	7.3 (5.2 to 10.0)	-2.5 (-9.9 to 4.3)	-19.0 (-25.0 to -13.5)
Diarrheal diseases	19.0 (17.9 to 20.2)	19.9 (18.7 to 21.0)	4.5 (-4.2 to 14.1)	-9.3 (-16.7 to -0.9)	3.1 (2.1 to 4.3)	3.2 (2.2 to 4.5)	4.2 (5.2 to 15.4)	9.3 (-17.5 to -0.2)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.4 (-72.2 to 7.4)	-35.7 (-76.7 to -10.1)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.4 (-36.0 to -7.3)	-35.7 (-46.4 to -23.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.4 (-36.0 to -7.1)	-35.7 (-46.5 to -23.7)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.8 (-34.8 to 1.1)	-32.9 (-45.0 to -15.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.8 (-34.8 to 1.2)	-32.9 (-45.0 to -15.3)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-55.1 (-80.0 to 36.3)	-62.5 (-89.8 to 14.0)
Lower respiratory infections	2.4 (1.9 to 3.0)	1.1 (0.9 to 1.5)	-54.8 (-68.5 to -35.1)	-56.0 (-69.2 to -39.2)	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-54.3 (-69.5 to -31.5)	-55.6 (-69.9 to -36.2)
Upper respiratory infections	68.2 (62.2 to 75.0)	87.1 (80.3 to 95.7)	27.7 (12.6 to 46.3)	2.8 (-9.3 to 16.4)	0.8 (0.4 to 1.4)	1.0 (0.6 to 1.7)	27.4 (11.1 to 45.7)	2.8 (-10.3 to 16.8)
Otitis media	56.2 (51.2 to 60.8)	64.5 (59.6 to 69.5)	14.6 (6.4 to 25.0)	-8.9 (-15.6 to -1.1)	1.2 (0.7 to 1.8)	1.3 (0.8 to 2.1)	12.7 (2.9 to 23.8)	-9.1 (-16.9 to -0.5)
Meningitis	-	-	-	-	1.6 (1.1 to 2.3)	0.9 (0.6 to 1.3)	-43.1 (-56.0 to -29.6)	-54.5 (-64.3 to -43.8)
Pneumococcal meningitis	5.9 (3.7 to 8.8)	3.6 (2.2 to 5.4)	-38.4 (-48.9 to -27.9)	-51.9 (-60.2 to -44.1)	0.6 (0.4 to 0.8)	0.3 (0.2 to 0.5)	-42.0 (-56.3 to -20.4)	-54.2 (-64.8 to -38.6)
H influenzae type B meningitis	4.6 (2.0 to 8.2)	2.5 (1.1 to 4.6)	-44.6 (-57.5 to -24.1)	-56.3 (-65.7 to -40.7)	0.6 (0.3 to 1.0)	0.3 (0.2 to 0.5)	-44.5 (-64.3 to -9.4)	-55.0 (-70.8 to -28.2)
Meningococcal meningitis	1.4 (0.6 to 3.0)	0.8 (0.3 to 1.7)	-46.2 (-69.1 to -25.4)	-57.6 (-74.2 to -42.0)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-53.4 (-73.2 to -15.6)	-62.2 (-77.5 to -35.0)
Other meningitis	1.9 (1.0 to 3.2)	1.2 (0.6 to 2.0)	-37.5 (-48.5 to -23.6)	-49.8 (-59.2 to -38.1)	0.2 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-49.8 (-66.3 to -16.5)	-51.2 (-64.3 to -33.1)
Encephalitis	1.7 (0.8 to 3.6)	2.1 (1.0 to 4.5)	25.5 (12.9 to 43.3)	25.4 (12.9 to 43.3)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	27.3 (8.2 to 50.8)	-1.4 (-16.2 to 16.8)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.1 (-97.1 to 330.4)	-63.0 (-96.8 to 237.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.1 (-97.1 to 336.1)	-63.0 (-96.8 to 238.6)
Whooping cough	4.4 (3.4 to 5.7)	6.1 (4.7 to 7.9)	39.0 (36.4 to 41.6)	26.9 (24.6 to 29.3)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	39.2 (25.3 to 49.8)	27.2 (17.8 to 37.0)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.1 (-50.1 to -8.4)	-50.0 (-62.4 to -37.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.0 (-50.0 to -5.6)	-49.5 (-61.9 to -36.0)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.8 (-100.0 to -92.0)	-99.8 (-100.0 to -92.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.8 (-100.0 to -91.9)	-99.8 (-100.0 to -92.5)
Varicella and herpes zoster	3.1 (3.0 to 3.3)	3.4 (3.3 to 3.7)	10.3 (2.5 to 18.9)	-1.9 (-11.4 to 7.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	21.5 (-4.1 to 53.7)	-1.6 (-22.8 to 23.2)
Neglected tropical diseases and malaria	-	-	-	-	5.2 (3.0 to 8.8)	3.2 (2.0 to 5.2)	-37.9 (-50.9 to -18.5)	-44.0 (-56.3 to -25.7)
Malaria	0.5 (0.5 to 0.5)	0.6 (0.6 to 0.6)	24.9 (19.1 to 31.5)	-0.1 (-3.9 to 3.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.4 (4.1 to 50.7)	4.7 (9.3 to 29.8)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.5 (1.4 to 128.8)	23.1 (-15.8 to 85.2)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	21.7 (-38.1 to 144.5)	2.3 (-42.7 to 90.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.7 (-38.3 to 144.6)	2.3 (-42.8 to 91.6)
Cutaneous and mucocutaneous leishmaniasis	0.4 (0.2 to 0.6)	0.6 (0.3 to 0.9)	66.6 (12.4 to 163.2)	32.1 (-11.2 to 105.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.7 (1.1 to 191.6)	33.3 (-19.3 to 128.9)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-67.2 (-91.4 to 32.8)	-72.8 (-93.2 to 11.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-66.1 (-91.2 to 39.3)	-72.1 (-93.3 to 21.9)
Cystic echinococcosis	1.8 (1.6 to 2.1)	1.1 (1.0 to 1.3)	-36.8 (-47.6 to -26.0)	-54.4 (-61.3 to -45.5)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-36.7 (-51.2 to -19.3)	-54.0 (-63.6 to -40.8)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.1 (0.0 to 0.2)	0.4 (0.1 to 1.4)	517.5 (510.2 to 525.9)	394.0 (388.1 to 400.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	496.8 (342.0 to 670.3)	376.4 (268.9 to 498.9)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.4 (-41.6 to 23.7)	-23.2 (-46.0 to 5.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.4 (-41.7 to 23.8)	-23.2 (-46.0 to 5.7)
Intestinal nematode infections	-	-	-	-	3.5 (1.7 to 6.3)	1.6 (0.8 to 2.9)	-55.3 (-69.9 to -31.0)	-59.2 (-73.0 to -35.3)
Ascariasis	1,112.3 (820.9 to 1,577.7)	1,353.7 (918.3 to 1,934.9)	22.6 (-27.5 to 95.3)	-0.6 (-44.9 to 65.2)	3.4 (1.7 to 6.3)	1.5 (0.8 to 2.8)	-55.6 (-70.2 to -31.2)	-59.5 (-73.2 to -35.6)
Trichuriasis	-	-	-	-	41.2 (-48.1 to 280.4)	0.5 (-63.1 to 171.3)	-	-
Hookworm disease	3.0 (1.7 to 4.8)	4.2 (2.4 to 7.0)	40.6 (-33.0 to 208.5)	0.1 (-52.4 to 119.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.7 (-43.0 to 133.5)	9.9 (-64.9 to 79.2)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	44.9 (32.7 to 58.0)	43.4 (37.1 to 50.1)	-3.5 (-22.7 to 30.4)	-9.8 (-28.0 to 21.1)	1.6 (0.9 to 2.3)	1.5 (0.9 to 2.2)	-6.8 (-27.6 to 47.0)	-10.7 (-31.0 to 43.3)
Maternal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-3.0 (-27.6 to 24.6)	-32.6 (-49.2 to -14.2)
Maternal hemorrhage	0.9 (0.7 to 1.1)	1.4 (0.9 to 1.9)	47.7 (-6.5 to 115.9)	5.4 (-33.1 to 53.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	39.7 (-33.2 to 130.0)	-1.0 (-51.7 to 58.6)
Maternal sepsis and other maternal infections	4.6 (2.8 to 6.8)	3.4 (2.2 to 5.0)	-24.1 (-38.7 to -9.5)	-49.4 (-59.0 to -39.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-33.5 (-56.0 to -2.6)	-53.6 (-67.6 to -33.3)
Maternal hypertensive disorders	0.4 (0.2 to 0.6)	0.5 (0.2 to 0.8)	18.8 (-1.5 to 39.0)	-16.5 (-31.1 to -2.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.5 (-17.0 to 64.7)	-17.9 (-41.3 to 14.7)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.5 (-26.8 to 64.1)	-25.5 (-47.3 to 15.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.9 (-26.8 to 64.5)	-25.5 (-47.3 to 15.5)
Complications of abortion	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	13.3 (-5.1 to 35.2)	-19.4 (-31.9 to -4.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.7 (-48.7 to 127.3)	-20.5 (-61.6 to 57.3)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.5 (-42.0 to 81.3)	-30.5 (-58.9 to 26.7)
Neonatal disorders	-	-	-	-	4.4 (2.8 to 6.3)	11.3 (7.3 to 16.5)	160.8 (58.7 to 319.3)	114.5 (30.9 to 243.9)
Preterm birth complications	12.5 (7.4 to 22.1)	37.3 (22.8 to 61.5)	200.4 (123.4 to 310.8)	139.1 (79.8 to 225.4)	1.5 (0.9 to 2.2)	5.1 (3.0 to 8.0)	245.6 (96.3 to 479.6)	178.0 (58.7 to 363.4)
Neonatal encephalopathy due to birth asphyxia and trauma	9.1 (3.3 to 25.3)	11.1 (6.0 to 22.1)	34.5 (-25.6 to 155.8)	7.5 (-41.2 to 111.8)	1.4 (0.8 to 2.4)	2.8 (1.6 to 4.1)	96.3 (3.9 to 307.3)	64.2 (-13.5 to 240.5)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.8 (26.2 to 59.5)	33.9 (13.5 to 43.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.9 (13.2 to 96.9)	29.6 (1.9 to 77.2)
Hemolytic disease and other neonatal jaundice	2.7 (1.0 to 5.0)	6.0 (3.0 to 11.6)	117.5 (-15.2 to 699.6)	77.1 (-30.7 to 550.4)	1.0 (0.4 to 2.0)	2.3 (1.1 to 4.6)	117.0 (-14.5 to 680.3)	75.3 (-30.7 to 537.7)
Other neonatal disorders	-	-	-	-	0.5 (0.2 to 0.8)	1.2 (0.7 to 2.0)	150.6 (15.0 to 456.8)	105.3 (-6.2 to 353.2)
Nutritional deficiencies	-	-	-	-	30.0 (19.0 to 44.0)	29.6 (18.9 to 44.2)	-1.8 (-14.6 to 12.8)	-16.8 (-27.2 to -4.3)
Protein-energy malnutrition	14.0 (6.0 to 27.0)	13.3 (4.9 to 29.8)	-7.8 (-70.6 to 214.7)	-15.9 (-73.1 to 187.5)	1.9 (0.7 to 3.6)	1.7 (0.5 to 4.1)	-7.7 (-69.6 to 21.5)	-15.7 (-72.2 to 189.0)
Iodine deficiency	214.1 (120.3 to 312.3)	186.6 (80.8 to 316.5)	-14.6 (-66.3 to 105.6)	-37.1 (-75.7 to 54.6)	3.9 (1.8 to 7.1)	3.4 (1.5 to 6.5)	-14.6 (-66.3 to 103.8)	-37.2 (-75.4 to 54.2)
Vitamin A deficiency	4.7 (3.9 to 5.7)	2.8 (2.3 to 3.4)	-40.1 (-47.2 to -32.2)	-50.4 (-56.1 to -44.4)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-41.1 (-49.7 to -31.5)	-51.1 (-58.2 to -43.3)

Appendix Table G.4 - Kyrgyzstan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	716.7 (704.9 to 728.7)	757.1 (739.9 to 773.9)	5.7 (2.6 to 8.5)	-11.8 (-14.6 to -9.3)	23.2 (15.4 to 33.6)	23.3 (15.5 to 34.2)	0.7 (-3.5 to 3.7)	-12.7 (-16.7 to -10.0)
Other nutritional deficiencies	-	-	-	-	1.1 (0.3 to 3.6)	1.1 (0.3 to 2.8)	7.1 (-7.6 to 331.3)	-2.0 (-78.7 to 294.3)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.6 (1.6 to 3.9)	3.0 (1.8 to 4.6)	15.8 (1.0 to 29.5)	-7.7 (-18.1 to 2.2)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.0 (0.6 to 1.7)	1.4 (0.8 to 2.3)	33.6 (15.6 to 56.6)	-5.7 (-18.0 to 8.0)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-14.5 (-29.2 to 7.3)	-32.0 (-43.3 to -18.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.1 (-35.1 to 20.2)	-90.1 (-49.9 to -3.6)
Chlamydial infection	130.4 (112.0 to 147.0)	190.6 (163.6 to 216.4)	45.8 (21.2 to 81.4)	1.3 (-15.2 to 23.7)	0.6 (0.3 to 0.9)	0.8 (0.4 to 1.3)	43.2 (15.6 to 80.7)	-0.6 (-51.0 to 22.7)
Gonococcal infection	25.6 (20.5 to 30.0)	31.8 (25.3 to 37.8)	25.1 (7.1 to 68.6)	-12.1 (-32.9 to 16.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	23.6 (-18.2 to 79.8)	-12.2 (-41.5 to 24.5)
Trichomoniasis	58.3 (37.1 to 82.4)	59.8 (46.9 to 74.2)	4.4 (-34.4 to 62.4)	-23.2 (-48.8 to 14.2)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	0.2 (-40.5 to 63.7)	-25.3 (-53.1 to 13.6)
Genital herpes	594.5 (575.3 to 614.4)	813.4 (787.0 to 838.7)	36.8 (11.0 to 43.3)	-2.4 (-6.3 to 2.0)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.5)	37.0 (27.5 to 46.2)	-2.1 (-7.6 to 3.8)
Other sexually transmitted diseases	1.2 (0.9 to 1.5)	1.5 (1.1 to 2.0)	27.4 (11.3 to 45.1)	-15.7 (-26.6 to -3.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (1.9 to 87.9)	39.2 (-28.4 to 28.9)
Hepatitis	-	-	-	-	0.4 (0.2 to 0.6)	0.4 (0.3 to 0.6)	12.5 (8.2 to 31.8)	-16.5 (-35.1 to 0.4)
Hepatitis A	6.3 (6.0 to 6.6)	7.3 (7.0 to 7.6)	15.7 (14.8 to 16.6)	-0.7 (-0.8 to -0.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	4.9 (12.8 to 41.0)	0.4 (-9.3 to 12.5)
Hepatitis B	442.1 (385.1 to 507.0)	405.7 (338.8 to 476.3)	-8.5 (-25.4 to 12.7)	-23.3 (-43.6 to -4.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	4.9 (-29.3 to 44.5)	-24.5 (-51.3 to 5.1)
Hepatitis C	316.4 (284.6 to 349.9)	308.9 (275.8 to 339.5)	-2.2 (-15.6 to 12.7)	25.4 (-35.7 to -16.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	6.4 (-30.5 to 22.1)	25.6 (-44.9 to -1.0)
Hepatitis E	0.4 (0.4 to 0.5)	0.6 (0.5 to 0.7)	34.3 (17.1 to 53.6)	-3.3 (-16.3 to 10.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.4 (-7.5 to 85.4)	-4.7 (-31.8 to 31.1)
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	31.1 (24.7 to 38.7)	30.2 (23.1 to 37.0)	-3.0 (-26.5 to 21.9)	-10.9 (-32.0 to 11.6)	1.1 (0.7 to 1.7)	1.1 (0.7 to 1.7)	1.1 (-27.9 to 24.9)	-5.0 (-31.8 to 18.8)
Non-communicable diseases	-	-	-	-	295.3 (217.9 to 382.7)	400.9 (297.4 to 521.0)	35.8 (31.1 to 40.6)	1.5 (-1.8 to 5.0)
Neoplasms	-	-	-	-	1.9 (1.4 to 2.5)	2.3 (1.7 to 3.0)	23.3 (8.7 to 42.4)	-2.2 (-13.4 to 14.0)
Esophageal cancer	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.5)	-22.1 (-47.5 to 37.3)	-32.9 (-54.0 to 16.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-19.7 (-44.1 to 34.7)	-30.9 (-51.7 to 12.8)
Stomach cancer	1.6 (1.4 to 1.8)	1.2 (1.0 to 1.4)	-24.8 (-39.9 to -5.0)	-37.8 (-49.8 to -21.4)	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-22.9 (-38.8 to -3.5)	-36.5 (-48.8 to -20.4)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	30.1 (-0.6 to 68.7)	11.9 (-15.8 to 45.9)
Liver cancer due to hepatitis B	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	17.4 (-28.6 to 83.6)	-2.1 (-39.9 to 54.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.1 (-19.1 to 58.6)	-4.2 (-32.9 to 33.5)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	222.5 (89.9 to 427.7)	176.2 (59.5 to 344.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	213.8 (112.3 to 350.1)	169.7 (81.3 to 289.2)
Liver cancer due to alcohol use	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	19.8 (-26.2 to 90.9)	4.6 (-35.1 to 65.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.0 (-18.8 to 61.7)	2.0 (-28.2 to 41.7)
Liver cancer due to other causes	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	35.6 (-64.5 to 12.8)	-46.4 (-71.1 to -4.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.9 (-60.2 to -2.6)	-48.0 (-67.3 to -17.0)
Larynx cancer	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-33.4 (-59.5 to 56.5)	-46.0 (-66.6 to 26.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.7 (-55.0 to 56.1)	-43.6 (-63.3 to 27.2)
Tracheal, bronchus and lung cancer	0.9 (0.7 to 1.0)	0.6 (0.5 to 0.7)	-30.8 (-44.6 to -13.2)	-41.1 (-52.6 to -26.9)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-28.9 (-43.7 to -8.9)	-39.5 (-51.7 to -24.3)
Breast cancer	2.9 (2.3 to 3.5)	6.4 (5.5 to 7.3)	118.4 (67.5 to 187.5)	73.8 (33.2 to 128.4)	0.4 (0.2 to 0.3)	0.4 (0.3 to 0.6)	71.4 (37.4 to 124.5)	30.7 (5.5 to 72.2)
Cervical cancer	2.5 (1.9 to 3.1)	3.3 (2.3 to 4.3)	31.2 (-7.4 to 78.6)	9.4 (-33.6 to 20.9)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.4)	29.8 (-8.0 to 78.6)	-10.3 (-34.6 to 21.5)
Uterine cancer	0.9 (0.6 to 1.3)	1.2 (0.7 to 1.8)	36.3 (-16.9 to 117.4)	2.7 (-37.0 to 56.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	35.9 (-17.4 to 120.3)	2.6 (-36.2 to 58.3)
Prostate cancer	0.8 (0.6 to 1.1)	1.6 (1.2 to 2.3)	89.2 (38.9 to 166.1)	73.5 (27.1 to 142.7)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	102.6 (46.7 to 214.2)	87.5 (35.9 to 189.3)
Colon and rectum cancer	1.7 (1.5 to 1.9)	1.8 (1.5 to 2.0)	3.6 (-11.2 to 23.7)	-16.6 (-28.0 to -0.5)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	1.9 (-15.1 to 24.9)	-17.1 (-30.3 to 1.7)
Lip and oral cavity cancer	0.7 (0.4 to 0.9)	0.6 (0.4 to 0.8)	-9.3 (-40.4 to 48.6)	-26.8 (-50.2 to 21.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-7.4 (-39.7 to 53.4)	-24.4 (-50.8 to 24.5)
Nasopharynx cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-9.1 (-40.5 to 37.4)	-30.5 (-54.1 to 2.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.6 (-38.0 to 32.9)	-29.6 (-51.4 to 2.2)
Other pharynx cancer	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	15.0 (-36.2 to 110.9)	-6.1 (-47.1 to 69.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.0 (-23.3 to 89.6)	-2.8 (-37.1 to 51.0)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.1 (-49.9 to 28.1)	-28.4 (-58.0 to 9.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.7 (-49.8 to 21.8)	-29.1 (-57.9 to 4.9)
Pancreatic cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	19.6 (-10.8 to 58.7)	1.8 (-23.6 to 34.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.1 (-4.3 to 52.0)	1.5 (-19.7 to 30.4)
Malignant skin melanoma	0.4 (0.3 to 0.6)	0.7 (0.5 to 0.9)	58.2 (21.2 to 110.8)	22.8 (-6.7 to 62.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	56.0 (18.1 to 109.8)	23.1 (-8.5 to 66.6)
Non-melanoma skin cancer	2.2 (1.8 to 2.5)	3.4 (2.6 to 4.2)	57.5 (17.6 to 99.2)	30.7 (-3.8 to 66.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	86.5 (40.6 to 153.3)	52.7 (12.5 to 109.5)
Ovarian cancer	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.6)	25.8 (9.1 to 79.3)	-7.2 (-31.6 to 32.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	26.3 (-13.0 to 88.7)	-6.2 (-34.8 to 39.8)
Testicular cancer	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	57.5 (-15.0 to 185.8)	10.4 (-38.6 to 94.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.0 (-19.8 to 178.7)	8.4 (-40.7 to 90.7)
Kidney cancer	0.4 (0.2 to 0.4)	0.5 (0.4 to 0.6)	17.0 (33.6 to 134.2)	44.7 (11.0 to 87.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	79.1 (36.4 to 135.6)	46.0 (11.2 to 91.9)
Bladder cancer	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.3)	-19.6 (-39.9 to 26.2)	-29.4 (-47.1 to 7.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.8 (-36.9 to 27.9)	-26.2 (-45.1 to 8.7)
Brain and nervous system cancer	0.3 (0.2 to 0.4)	0.6 (0.5 to 0.8)	154.5 (39.2 to 234.5)	92.9 (12.2 to 150.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	150.2 (37.2 to 224.7)	86.6 (9.2 to 136.3)
Thyroid cancer	0.7 (0.5 to 1.0)	0.9 (0.6 to 1.3)	27.5 (-17.6 to 86.1)	-9.4 (-40.8 to 32.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	24.9 (-19.3 to 81.0)	-11.2 (-40.5 to 30.5)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.0 (20.3 to 86.7)	22.8 (-3.5 to 49.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.0 (20.2 to 82.7)	19.3 (-3.6 to 46.3)
Hodgkin lymphoma	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	20.3 (-24.7 to 101.0)	-8.0 (-40.0 to 61.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.5 (-26.4 to 94.3)	-13.3 (-42.8 to 59.2)
Non-Hodgkin lymphoma	0.3 (0.2 to 0.4)	0.3 (0.3 to 0.4)	7.9 (-20.9 to 75.8)	-13.7 (-36.9 to 40.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.1 (-19.7 to 80.7)	-13.2 (-35.8 to 41.8)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.0 (-33.2 to 124.8)	-13.7 (-50.1 to 69.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.4 (-31.1 to 112.1)	-16.0 (-48.8 to 57.4)
Leukemia	1.0 (0.8 to 1.3)	0.8 (0.6 to 1.0)	-16.1 (-39.7 to 14.2)	-22.8 (-42.3 to 3.6)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-7.6 (-29.8 to 23.1)	-18.9 (-37.6 to 7.3)
Other neoplasms	1.2 (1.0 to 1.6)	2.1 (1.6 to 2.6)	69.0 (18.1 to 127.9)	32.6 (-0.2 to 79.6)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	62.6 (19.4 to 116.3)	26.2 (-4.2 to 69.6)
Cardiovascular diseases	-	-	-	-	3.6 (2.5 to 5.0)	4.0 (2.7 to 5.5)	10.6 (-13.7 to 41.8)	-6.0 (-25.6 to 17.8)
Rheumatic heart disease	0.5 (0.4 to 0.6)	0.6 (0.5 to 0.6)	16.0 (-3.3 to 41.7)	-6.6 (-21.8 to 15.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	19.8 (-7.4 to 63.9)	-4.2 (-26.7 to 30.8)
Ischemic heart disease	31.0 (26.0 to 37.3)	33.5 (30.3 to 37.0)	8.3 (-13.1 to 33.7)	-3.9 (-22.1 to 17.4)	1.5 (1.0 to 2.2)	1.6 (1.0 to 2.2)	2.5 (-23.9 to 38.6)	-7.0 (-28.7 to 21.8)
Cerebrovascular disease	-	-	-	-	0.4 (0.3 to 0.6)	0.5 (0.4 to 0.7)	27.7 (11.1 to 60.8)	0.6 (-21.3 to 26.0)
Ischemic stroke	1.5 (1.3 to 1.8)	1.9 (1.6 to 2.2)	22.4 (-4.2 to 56.0)	-1.0 (-23.7 to 25.8)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	23.7 (-5.1 to 60.9)	-0.3 (-24.5 to 28.5)
Hemorrhagic stroke	1.2 (0.9 to 1.4)	1.5 (1.3 to 1.8)	32.5 (1.1 to 71.0)	1.3 (-22.6 to 32.0)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	33.2 (-0.6 to 76.1)	1.6 (-23.7 to 34.0)
Hypertensive heart disease	3.8 (3.4 to 4.3)	4.4 (4.0 to 4.9)	16.4 (-1.1 to 38.3)	0.9 (-14.0 to 20.7)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	17.5 (-0.8 to 39.3)	1.9 (-14.5 to 21.6)
Cardiomyopathy and myocarditis	2.8 (2.5 to 3.1)	3.5 (3.2 to 3.8)	25.9 (9.6 to 44.6)	5.1 (-8.7 to 22.5)	0.4 (0.2 to 0.4)	0.4 (0.2 to 0.5)	26.5 (8.9 to 48.7)	6.0 (-9.4 to 25.5)
Atrial fibrillation and flutter	0.1 (0.1 to 0.2)	0.5 (0.4 to 0.7)	242.8 (125.1 to 400.9)	134.0 (57.7 to 240.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	242.5 (101.3 to 455.4)	132.6 (41.7 to 265.8)
Peripheral vascular disease	68.2 (50.1 to 88.3)	79.5 (59.3 to 99.1)	16.4 (-17.2 to 63.3)	-0.5 (-30.3 to 42.3)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-24.4 (-58.6 to 45.0)	-29.4 (-61.7 to 35.3)
Endocarditis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	20.2 (-39.6 to 7.0)	-33.5 (-49.2 to -9.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.8 (-36.3 to 13.7)	-3.5 (-48.4 to -4.1)
Other cardiovascular and circulatory diseases	11.5 (5.3 to 21.2)	12.4 (6.2 to 21.3)	3.8 (-58.8 to 179.2)	-7.8 (-68.2 to 121.4)	0.8 (0.3 to 1.5)	0.9 (0.4 to 1.6)	3.5 (-59.0 to 184.9)	-17.3 (-68.0 to 123.7)
Chronic respiratory diseases	-	-	-	-	12.8 (8.8 to 17.7)	16.8 (11.5 to 22.7)	31.3 (16.3 to 49.7)	-3.8 (-14.1 to 10.4)
Chronic obstructive pulmonary disease	126.3 (120.2 to 132.1)	167.7 (159.8 to 175.4)	32.8 (28.9 to 37.3)	-0.7 (-3.4 to 2.3)	7.9 (5.1 to 11.3)	10.1 (6.6 to 14.1)	27.1 (8.9 to 54.2)	-4.1 (-18.1 to 16.0)

Appendix Table G.4 - Kyrgyzstan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumonia	-	-	-	-	0.0	0.0	18.4	-
Silicosis	0.0	0.0	23.4	-1.4	0.0	0.0	23.4	-1.0
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Coal workers pneumoconiosis	0.0	0.0	35.7	2.0	0.0	0.0	35.7	2.4
Other pneumoconiosis	0.1	0.1	9.2	5.7	0.2	0.2	46.4	-1.6
Asthma	107.8	147.9	37.5	-3.1	4.7	6.5	38.0	-2.7
Interstitial lung disease and pulmonary sarcoidosis	0.4	0.5	30.5	-4.7	0.0	0.1	29.7	-5.6
Other chronic respiratory diseases	-	-	-	-	0.1	0.1	-27.9	-45.8
Cirrhosis	-	-	-	-	0.5	0.9	64.9	27.2
Cirrhosis due to hepatitis B	1.4	2.1	59.0	22.3	0.2	0.4	58.7	22.2
Cirrhosis due to hepatitis C	0.8	1.3	70.2	25.0	0.1	0.2	69.3	26.0
Cirrhosis due to alcohol use	0.5	0.9	70.7	29.3	0.1	0.3	70.7	29.2
Cirrhosis due to other causes	0.6	1.0	72.1	48.0	0.1	0.2	71.1	46.3
Digestive diseases	-	-	-	-	3.1	4.4	43.0	6.6
Peptic ulcer disease	25.3	20.6	-18.5	-38.5	0.7	0.6	-13.9	-33.0
Gastritis and duodenitis	6.1	7.7	25.9	10.5	0.3	0.4	26.5	15.3
Appendicitis	0.4	0.5	15.7	-6.7	0.1	0.2	14.4	-7.5
Paralytic ileus and intestinal obstruction	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inguinal, femoral, and abdominal hernia	10.8	11.7	9.4	-10.5	0.1	0.1	10.0	-9.9
Inflammatory bowel disease	4.4	8.3	87.2	35.2	0.9	1.8	88.8	36.2
Vascular intestinal disorders	0.0	0.0	0.0	-3.1	0.0	0.0	0.0	-2.7
Gallbladder and biliary diseases	3.6	3.6	-1.5	-18.9	0.4	0.4	-0.9	-18.4
Pancreatitis	0.9	1.8	105.1	46.8	0.3	0.5	105.4	47.0
Other digestive diseases	-	-	-	-	0.3	0.4	79.2	33.2
Neurological disorders	-	-	-	-	34.9	49.6	42.3	7.1
Alzheimer disease and other dementias	19.9	21.9	10.3	-0.6	2.9	3.2	11.0	0.1
Parkinson disease	1.3	1.5	15.9	0.9	0.2	0.2	16.8	1.3
Epilepsy	17.6	23.9	36.2	7.2	5.8	8.0	40.4	10.6
Multiple sclerosis	0.7	1.4	83.7	26.3	0.3	0.5	82.4	25.7
Migraine	597.4	888.5	48.1	11.1	20.6	27.9	35.0	3.0
Tension-type headache	880.0	1,233.5	39.1	0.6	1.4	1.9	39.7	0.9
Medication overuse headache	23.0	48.1	111.2	50.8	3.6	7.6	112.4	51.5
Other neurological disorders	0.0	0.0	33.1	6.5	0.2	0.4	62.8	42.8
Mental and substance use disorders	-	-	-	-	86.6	119.4	37.9	0.9
Schizophrenia	10.9	15.7	44.6	-0.4	7.0	10.2	45.0	0.1
Alcohol use disorders	52.2	90.8	74.1	19.8	5.2	9.2	74.9	20.4
Drug use disorders	-	-	-	-	5.3	7.6	42.5	-0.3
Opioid use disorders	4.7	6.8	44.5	0.8	2.0	2.9	45.1	1.5
Cocaine use disorders	2.2	4.4	96.7	36.7	0.4	0.6	51.8	5.8
Amphetamine use disorders	8.4	12.2	44.8	1.1	1.1	1.6	45.3	1.3
Cannabis use disorders	7.9	11.0	38.9	0.0	0.2	0.3	39.3	0.3
Other drug use disorders	-	-	-	-	1.6	2.2	41.1	-1.6
Depressive disorders	-	-	-	-	32.9	45.4	38.0	0.3
Major depressive disorder	134.9	185.0	37.4	0.2	27.9	38.3	37.5	0.4
Dysthymia	51.7	72.4	40.1	5.0	7.0	7.0	40.6	-0.2
Bipolar disorder	26.2	37.2	41.8	-0.0	5.4	7.6	42.5	0.4
Anxiety disorders	122.8	169.6	38.4	11.4	11.4	15.2	33.4	-0.1
Eating disorders	-	-	-	-	1.5	1.5	37.6	0.6
Anorexia nervosa	0.4	0.5	47.5	10.2	0.1	0.1	47.1	10.5
Bulimia nervosa	4.9	6.7	37.0	-0.1	1.0	1.4	36.8	-0.0
Autistic spectrum disorders	-	-	-	-	5.2	6.7	27.9	1.8
Autism	13.3	16.9	27.2	0.5	3.3	4.2	27.3	0.8
Asperger syndrome	19.1	24.2	27.0	1.9	2.4	2.4	27.2	0.8
Attention-deficit/hyperactivity disorder	28.7	33.0	15.0	0.3	0.4	0.4	15.2	0.5
Conduct disorder	41.9	47.4	13.1	0.3	0.5	0.8	13.4	0.1
Idiopathic intellectual disability	63.3	65.3	3.4	-17.6	3.1	3.2	3.4	-17.5
Other mental and substance use disorders	60.9	90.0	47.8	0.3	4.6	6.8	48.2	0.6
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	35.3	51.0	44.5	9.1
Diabetes mellitus	182.4	307.0	68.6	19.1	14.1	23.6	66.6	19.0
Acute glomerulonephritis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Chronic kidney disease	-	-	-	-	8.5	11.1	30.6	0.1
Chronic kidney disease due to diabetes mellitus	39.9	55.8	40.1	4.0	1.4	1.9	41.4	4.1
Chronic kidney disease due to hypertension	77.3	99.8	28.6	0.6	2.3	1.2	-45.5	-58.9
Chronic kidney disease due to glomerulonephritis	75.0	56.9	-24.1	-48.5	2.1	2.3	49.9	14.7
Chronic kidney disease due to other causes	103.3	160.6	55.1	31.9	2.7	4.7	73.8	41.1
Urinary diseases and male infertility	-	-	-	-	2.0	2.6	29.7	16.3

Appendix Table G.4 - Kyrgyzstan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.2 (1.1 to 1.3)	1.9 (1.7 to 2.1)	61.0 (39.8 to 83.9)	27.3 (12.0 to 42.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	59.2 (29.4 to 102.1)	5.2 (4.5 to 55.6)
Urolithiasis	26.6 (21.5 to 34.2)	34.2 (27.4 to 44.2)	28.5 (13.3 to 49.2)	1.5 (-10.0 to 18.3)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	26.1 (13.2 to 40.1)	-3.2 (-12.2 to 8.2)
Benign prostatic hyperplasia	41.9 (38.4 to 45.1)	53.4 (49.8 to 57.4)	27.6 (15.1 to 43.0)	1.5 (7.9 to 33.8)	1.5 (1.0 to 2.1)	1.9 (1.2 to 2.7)	28.3 (15.3 to 43.6)	20.4 (8.5 to 34.7)
Male infertility due to other causes	25.4 (19.6 to 32.2)	35.9 (27.7 to 44.5)	41.7 (1.6 to 98.2)	0.8 (-27.2 to 40.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.5)	43.3 (5.2 to 103.3)	1.4 (-25.6 to 42.7)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-36.9 to 43.3)	0.0 (-50.6 to 9.8)
Gynecological diseases	-	-	-	-	4.6 (3.0 to 7.0)	7.1 (4.5 to 10.6)	51.9 (30.6 to 81.7)	0.1 (-13.4 to 16.0)
Uterine fibroids	69.0 (52.1 to 75.3)	118.5 (107.9 to 128.3)	71.7 (69.0 to 74.8)	1.5 (1.4 to 1.6)	1.1 (0.6 to 1.7)	1.6 (0.9 to 2.7)	48.0 (37.4 to 58.3)	-7.1 (-13.3 to -1.2)
Polycystic ovarian syndrome	65.9 (58.4 to 72.9)	100.5 (90.5 to 111.1)	52.7 (31.8 to 76.9)	0.2 (-12.8 to 14.2)	0.6 (0.3 to 1.2)	1.0 (0.5 to 1.9)	52.9 (31.3 to 76.6)	0.7 (-12.4 to 14.5)
Female infertility due to other causes	20.4 (13.2 to 27.9)	31.6 (23.0 to 41.0)	55.6 (1.4 to 143.5)	11.2 (-26.9 to 77.4)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	38.3 (2.0 to 144.5)	0.9 (-77.3 to 75.2)
Endometriosis	6.7 (5.5 to 7.9)	11.1 (9.6 to 12.8)	65.7 (29.8 to 111.4)	5.4 (-17.0 to 34.3)	0.6 (0.4 to 0.9)	1.0 (0.7 to 1.4)	66.1 (28.0 to 117.7)	6.9 (-16.9 to 38.9)
Genital prolapse	182.7 (159.3 to 206.4)	258.3 (219.2 to 293.3)	41.5 (15.2 to 69.8)	-2.7 (-19.6 to 15.4)	0.6 (0.3 to 1.1)	0.8 (0.4 to 1.6)	41.9 (14.7 to 70.2)	-2.7 (-19.7 to 16.1)
Premenstrual syndrome	145.5 (81.9 to 200.8)	231.0 (148.1 to 315.0)	57.4 (-13.5 to 219.5)	6.9 (-41.7 to 102.3)	1.2 (0.6 to 2.1)	1.9 (1.0 to 3.2)	57.3 (-14.2 to 218.6)	6.8 (-9.0 to 105.3)
Other gynecological diseases	13.8 (11.7 to 16.4)	19.3 (18.0 to 20.8)	40.3 (19.7 to 64.0)	-5.7 (-19.2 to 10.1)	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	35.5 (14.4 to 80.9)	-2.0 (-23.6 to 20.1)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	3.9 (2.6 to 5.8)	4.6 (3.1 to 6.6)	17.0 (3.4 to 35.9)	2.0 (-11.1 to 20.3)
Thalassemias	0.3 (0.1 to 0.7)	0.3 (0.1 to 0.8)	6.0 (-2.7 to 17.3)	-5.8 (-13.8 to 3.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.7 (-35.2 to 80.3)	-4.3 (-42.6 to 56.8)
Thalassemia trait	121.3 (83.8 to 187.5)	153.1 (104.8 to 238.2)	26.2 (20.2 to 32.0)	0.1 (-4.2 to 5.6)	3.1 (2.1 to 4.6)	3.9 (2.6 to 5.5)	23.8 (8.8 to 44.2)	7.4 (-6.7 to 27.2)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.5 (16.5 to 38.0)	7.5 (-3.4 to 16.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.2 (18.9 to 42.4)	12.0 (-1.1 to 20.2)
Sickle cell trait	3.0 (1.9 to 3.9)	3.9 (2.5 to 4.9)	28.5 (18.2 to 39.0)	1.8 (-6.7 to 9.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	16.0 (-25.9 to 73.3)	-3.7 (-37.3 to 36.8)
G6PD deficiency	8.6 (7.9 to 9.1)	12.8 (12.3 to 13.4)	49.3 (38.2 to 63.3)	18.1 (9.4 to 29.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.4 (74.7 to 106.2)	63.1 (51.6 to 82.0)
G6PD trait	501.4 (494.7 to 505.7)	632.4 (625.2 to 639.8)	26.1 (24.6 to 28.5)	-0.8 (-2.0 to 1.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.0 (-79.8 to 677.6)	33.8 (-81.9 to 504.8)
Other hemoglobinopathies and hemolytic anemias	24.9 (17.9 to 30.2)	23.7 (20.7 to 26.9)	-4.8 (-23.2 to 31.4)	0.8 (-3.2 to 14.2)	0.8 (0.4 to 1.2)	0.7 (0.4 to 1.0)	-11.8 (-41.5 to 62.2)	-21.6 (-47.3 to 46.3)
Endocrine, metabolic, blood, and immune disorders	59.5 (52.7 to 65.3)	60.9 (57.1 to 64.3)	2.5 (-7.5 to 15.4)	-14.0 (-21.8 to -4.2)	2.1 (1.4 to 3.0)	2.1 (1.4 to 3.0)	0.4 (-9.4 to 12.1)	45.5 (-22.0 to -0.4)
Musculoskeletal disorders	-	-	-	-	58.1 (41.3 to 76.9)	80.6 (56.0 to 108.1)	38.7 (23.1 to 54.1)	2.4 (-8.5 to 12.4)
Rheumatoid arthritis	6.5 (6.3 to 6.8)	11.3 (11.0 to 11.7)	73.4 (64.6 to 83.1)	30.2 (23.7 to 37.2)	1.6 (1.1 to 2.1)	2.7 (2.0 to 3.7)	74.1 (60.0 to 89.2)	30.5 (21.0 to 41.3)
Osteoarthritis	131.1 (125.6 to 136.4)	166.2 (158.8 to 174.0)	26.8 (19.4 to 34.0)	-0.1 (-5.6 to 5.3)	8.0 (5.7 to 10.9)	10.3 (7.2 to 14.1)	27.7 (20.0 to 35.3)	0.2 (-5.4 to 5.7)
Low back and neck pain	-	-	-	-	41.8 (28.6 to 56.7)	57.7 (39.0 to 78.3)	38.2 (16.8 to 59.7)	1.1 (-14.4 to 15.7)
Low back pain	238.2 (203.7 to 270.0)	325.6 (269.9 to 375.8)	36.9 (8.5 to 68.9)	2.1 (-17.1 to 22.8)	26.6 (17.9 to 37.8)	36.5 (23.8 to 51.6)	37.7 (9.1 to 69.9)	2.3 (-16.8 to 23.2)
Neck pain	153.7 (128.3 to 181.0)	214.1 (178.8 to 244.2)	39.0 (12.9 to 73.3)	-1.6 (-21.3 to 23.6)	15.2 (10.0 to 21.8)	21.2 (14.0 to 29.9)	39.3 (12.5 to 74.2)	-1.6 (-20.9 to 24.3)
Gout	2.1 (2.0 to 2.2)	2.9 (2.7 to 3.1)	36.6 (25.7 to 48.8)	3.8 (-4.0 to 12.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	38.2 (10.7 to 69.5)	4.1 (-15.2 to 27.5)
Other musculoskeletal disorders	72.8 (54.9 to 90.3)	105.8 (81.8 to 131.1)	45.3 (32.9 to 59.0)	7.2 (-0.7 to 16.0)	6.7 (4.3 to 9.8)	9.7 (6.3 to 14.4)	65.6 (33.5 to 60.7)	7.6 (-1.1 to 17.1)
Other non-communicable diseases	-	-	-	-	58.4 (38.8 to 83.9)	71.8 (48.1 to 103.5)	22.7 (17.7 to 28.1)	-4.6 (-7.5 to -0.8)
Congenital anomalies	-	-	-	-	3.4 (2.5 to 4.6)	5.9 (4.2 to 7.8)	71.3 (43.0 to 107.5)	37.7 (15.5 to 66.7)
Neural tube defects	0.7 (0.6 to 0.8)	1.5 (1.3 to 1.8)	132.5 (74.3 to 194.0)	94.5 (46.4 to 145.9)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	153.7 (65.3 to 278.2)	114.5 (39.4 to 213.9)
Congenital heart anomalies	9.2 (7.0 to 12.7)	25.7 (21.3 to 30.0)	186.9 (88.0 to 285.3)	136.1 (53.5 to 217.7)	0.3 (0.1 to 0.5)	0.9 (0.4 to 1.5)	176.6 (82.2 to 269.0)	128.8 (49.8 to 207.4)
Orofacial clefts	1.3 (0.9 to 1.8)	3.9 (3.2 to 4.8)	199.5 (106.5 to 358.4)	157.0 (76.2 to 293.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	249.0 (61.1 to 295.5)	114.5 (38.4 to 241.3)
Down syndrome	3.3 (2.7 to 4.1)	5.3 (4.3 to 6.4)	60.3 (17.4 to 120.1)	29.8 (-4.9 to 78.4)	0.4 (0.3 to 0.6)	0.7 (0.5 to 0.9)	63.9 (19.4 to 132.7)	33.1 (-3.3 to 88.0)
Turner syndrome	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.2)	46.3 (3.6 to 102.7)	15.2 (-18.5 to 58.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.3 (2.3 to 111.2)	16.0 (-21.7 to 60.9)
Klinefelter syndrome	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	33.0 (-11.3 to 104.0)	5.6 (-29.6 to 61.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.9 (-2.2 to 122.5)	4.8 (-30.2 to 61.1)
Chromosomal unbalanced rearrangements	5.0 (3.9 to 6.2)	8.0 (6.9 to 9.4)	62.3 (24.7 to 107.7)	31.4 (1.1 to 58.1)	0.6 (0.4 to 0.9)	1.0 (0.7 to 1.3)	65.8 (17.0 to 117.4)	34.8 (0.6 to 76.0)
Other congenital anomalies	14.7 (12.2 to 16.9)	16.1 (13.5 to 18.6)	10.2 (-3.8 to 24.4)	-14.2 (-25.0 to -3.5)	1.9 (1.3 to 2.6)	2.8 (1.9 to 4.0)	48.6 (17.0 to 98.5)	18.8 (-7.2 to 58.0)
Skin and subcutaneous diseases	-	-	-	-	18.1 (11.7 to 27.0)	22.8 (14.9 to 34.5)	26.2 (14.8 to 39.1)	-3.8 (-12.4 to 6.5)
Dermatitis	163.3 (133.1 to 196.3)	220.7 (177.7 to 266.9)	35.1 (32.6 to 37.8)	-0.1 (-0.1 to -0.0)	4.0 (2.4 to 5.9)	5.3 (3.2 to 7.9)	33.1 (28.2 to 37.6)	0.2 (-2.0 to 3.0)
Psoriasis	31.2 (27.7 to 34.8)	42.1 (37.1 to 47.4)	35.2 (33.0 to 37.3)	0.0 (-0.1 to 0.2)	2.6 (1.7 to 3.6)	3.5 (2.3 to 4.9)	42.2 (27.4 to 44.8)	0.2 (-4.8 to 5.8)
Cellulitis	1.6 (1.3 to 2.0)	1.8 (1.4 to 2.3)	11.5 (-2.3 to 24.9)	-6.5 (-16.4 to 3.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	11.4 (-11.6 to 40.7)	-6.4 (-24.6 to 16.2)
Pyoderma	4.5 (3.7 to 5.3)	5.8 (4.8 to 7.0)	28.3 (21.3 to 36.6)	9.1 (4.7 to 13.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	28.5 (16.3 to 43.4)	9.4 (0.6 to 19.5)
Scabies	12.9 (11.0 to 15.2)	15.4 (12.9 to 18.2)	17.7 (-6.3 to 52.9)	-1.7 (-25.2 to 20.7)	0.3 (0.2 to 0.6)	0.4 (0.2 to 0.7)	17.7 (-6.7 to 54.6)	-6.7 (-24.9 to 11.8)
Fungal skin diseases	307.1 (233.0 to 404.9)	402.9 (308.7 to 537.4)	31.4 (27.4 to 35.1)	0.2 (0.0 to 0.4)	2.3 (0.7 to 3.8)	2.3 (0.9 to 5.1)	31.3 (17.4 to 35.5)	0.3 (-0.6 to 1.2)
Viral skin diseases	106.2 (82.5 to 128.5)	127.5 (96.8 to 158.5)	19.9 (14.2 to 25.2)	0.0 (-1.8 to 2.0)	3.3 (1.9 to 5.1)	4.0 (2.2 to 6.3)	19.9 (13.6 to 26.3)	3.5 (-3.0 to 3.5)
Acne vulgaris	111.6 (88.5 to 137.4)	153.7 (120.2 to 187.9)	37.8 (-1.6 to 91.8)	4.3 (-24.1 to 43.9)	1.2 (0.6 to 2.3)	1.7 (0.7 to 3.1)	37.4 (-2.5 to 92.3)	4.2 (-24.8 to 44.7)
Alopecia areata	4.6 (4.0 to 5.1)	6.0 (5.2 to 6.7)	30.3 (10.0 to 58.9)	0.6 (-16.0 to 21.8)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	30.9 (6.5 to 63.9)	0.9 (-17.0 to 25.0)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.5 (0.6 to 65.7)	0.8 (-22.5 to 27.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.5 (0.5 to 65.9)	-0.8 (-22.5 to 27.1)
Urticaria	56.4 (35.9 to 74.1)	62.5 (41.2 to 87.6)	8.7 (-32.6 to 88.6)	-18.5 (-47.7 to 42.6)	3.4 (1.7 to 5.3)	3.7 (2.0 to 6.2)	9.4 (-32.8 to 87.2)	-18.5 (-47.8 to 42.5)
Decubitus ulcer	0.2 (0.2 to 0.2)	0.3 (0.2 to 0.3)	40.4 (3.1 to 71.0)	10.4 (-21.9 to 41.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	42.4 (1.2 to 81.8)	11.4 (-24.0 to 48.3)
Other skin and subcutaneous diseases	212.8 (139.1 to 328.6)	273.1 (186.1 to 395.8)	29.0 (14.8 to 44.5)	-2.0 (-7.3 to 4.2)	1.3 (0.5 to 2.6)	1.6 (0.7 to 3.3)	29.3 (15.1 to 44.7)	-1.9 (-7.2 to 4.5)
Sense organ diseases	-	-	-	-	27.8 (18.6 to 39.8)	31.4 (20.9 to 45.1)	12.7 (7.2 to 18.6)	-9.4 (-12.9 to -5.4)
Glaucoma	5.0 (4.2 to 5.8)	5.4 (4.5 to 6.3)	6.9 (-5.4 to 29.1)	-18.0 (-28.7 to -1.0)	0.4 (0.2 to 0.5)	0.5 (0.2 to 0.5)	5.6 (-10.6 to 31.6)	-15.0 (-26.6 to 5.1)
Cataract	31.2 (24.4 to 38.0)	24.9 (18.9 to 30.9)	-20.3 (-36.8 to -3.9)	-30.6 (-44.3 to -18.1)	1.1 (0.7 to 1.6)	0.9 (0.5 to 1.3)	-19.3 (-34.3 to -2.8)	-29.7 (-42.2 to -16.4)
Macular degeneration	8.7 (6.6 to 11.1)	11.9 (8.9 to 15.6)	35.8 (1.6 to 84.3)	7.4 (-19.6 to 45.2)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	33.0 (0.8 to 78.0)	5.8 (-20.4 to 40.3)
Uncorrected refractive error	344.0 (315.4 to 371.5)	428.3 (384.5 to 469.5)	24.8 (9.3 to 40.5)	-1.4 (-12.4 to 10.2)	5.4 (3.1 to 8.9)	6.4 (3.7 to 10.6)	18.8 (6.7 to 28.4)	-7.4 (-15.3 to 1.1)
Age-related and other hearing loss	521.2 (458.1 to 579.7)	617.3 (536.6 to 692.6)	18.3 (13.0 to 25.6)	-7.6 (-11.0 to -3.9)	16.9 (11.2 to 23.7)	19.2 (12.7 to 27.3)	13.7 (6.1 to 21.4)	-8.3 (-13.0 to -3.3)
Other vision loss	23.6 (21.1 to 26.9)	20.7 (17.8 to 23.7)	-12.5 (-21.2 to -2.3)	-32.1 (-39.3 to -22.1)	1.1 (0.7 to 1.6)	0.9 (0.6 to 1.4)	1.1 (-25.1 to -3.0)	-14.4 (-38.7 to -23.5)
Other sense organ diseases	103.6 (98.3 to 108.3)	124.6 (119.2 to 129.9)	20.3 (12.6 to 28.2)	0.2 (-5.9 to				

Appendix Table G.4 - Kyrgyzstan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	110.4 (105.6 to 114.8)	124.2 (118.6 to 129.7)	12.5 (6.4 to 19.1)	-6.3 (-11.2 to -1.3)	3.0 (2.1 to 4.2)	3.4 (2.3 to 4.8)	13.2 (6.6 to 19.8)	4.1 (-11.2 to -0.6)
Other oral disorders	69.2 (65.4 to 73.1)	93.3 (87.7 to 99.3)	34.7 (24.0 to 46.9)	-0.4 (-8.0 to 7.8)	1.3 to 3.1 (1.7 to 4.2)	2.0 (1.7 to 4.2)	29.3 (23.2 to 47.7)	-8.8 (-8.4 to 8.4)
Injuries	-	-	-	-	32.3 (24.4 to 41.9)	29.3 (21.0 to 39.7)	-9.8 (-18.4 to -0.5)	-31.4 (-38.0 to -24.5)
Transport injuries	-	-	-	-	6.5 (4.9 to 8.5)	4.3 (3.0 to 5.8)	-34.6 (-42.3 to -25.1)	-49.7 (-55.4 to -42.9)
Road injuries	-	-	-	-	5.7 (4.2 to 7.4)	3.5 (2.5 to 4.8)	-38.5 (-46.0 to -29.3)	-52.2 (-57.9 to -45.6)
Pedestrian road injuries	-	-	-	-	1.2 (0.9 to 1.5)	0.7 (0.5 to 1.0)	-42.8 (-51.1 to -33.1)	-53.7 (-59.9 to -46.6)
Cyclist road injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.5 (0.3 to 0.6)	-35.1 (-41.5 to -27.8)	-49.2 (-54.1 to -43.7)
Motorcyclist road injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.3 (0.2 to 0.5)	-37.2 (-45.2 to -27.4)	-53.0 (-58.9 to -45.9)
Motor vehicle road injuries	-	-	-	-	3.2 (2.4 to 4.2)	2.0 (1.4 to 2.7)	-37.6 (-46.0 to -27.3)	-52.2 (-58.4 to -44.7)
Other road injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-45.7 (-52.5 to -37.2)	-58.1 (-63.3 to -52.1)
Other transport injuries	-	-	-	-	0.9 (0.6 to 1.1)	0.8 (0.6 to 1.1)	-9.1 (-18.7 to 3.2)	-33.1 (-40.1 to -24.3)
Unintentional injuries	-	-	-	-	25.3 (19.0 to 32.8)	24.5 (17.7 to 33.1)	-3.2 (-12.1 to 5.9)	-26.9 (-33.7 to -20.0)
Falls	-	-	-	-	17.0 (12.8 to 22.2)	16.5 (11.6 to 22.5)	-3.2 (-13.7 to 7.3)	-27.5 (-35.8 to -19.5)
Drowning	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.2)	-48.0 (-55.0 to -38.7)	-59.2 (-64.5 to -52.6)
Fire, heat, and hot substances	-	-	-	-	0.7 (0.6 to 1.0)	0.6 (0.4 to 0.8)	-21.2 (-30.4 to -9.7)	-39.9 (-46.9 to -31.3)
Poisonings	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-22.1 (-33.5 to -9.3)	-41.7 (-49.2 to -32.9)
Exposure to mechanical forces	-	-	-	-	4.4 (3.3 to 5.8)	4.4 (3.2 to 6.0)	0.3 (-6.3 to 8.3)	-23.0 (-28.0 to -17.2)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-19.2 (-31.9 to -4.4)	-38.8 (-48.3 to -28.4)
Unintentional suffocation	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	6.3 (-5.2 to 19.3)	-18.5 (-27.0 to -8.9)
Other exposure to mechanical forces	-	-	-	-	4.3 (3.2 to 5.6)	4.3 (3.1 to 5.8)	0.6 (-5.9 to 8.7)	-22.7 (-27.7 to -17.0)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	30.8 (23.4 to 40.2)	2.3 (-4.0 to 10.1)
Animal contact	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	8.4 (-0.8 to 19.4)	-15.1 (-22.1 to -6.6)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	12.8 (-0.5 to 30.2)	-13.3 (-22.4 to -0.3)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	5.8 (-4.8 to 18.0)	-16.4 (-24.4 to -7.5)
Foreign body	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-7.1 (-16.0 to 2.6)	-27.0 (-33.8 to -19.6)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-31.5 (-42.8 to -17.8)	-44.3 (-53.2 to -33.7)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	19.9 (11.0 to 28.6)	-8.9 (-16.1 to -2.5)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	1.8 (-8.4 to 12.3)	-20.6 (-27.9 to -12.9)
Other unintentional injuries	-	-	-	-	2.2 (1.6 to 2.8)	2.2 (1.6 to 3.0)	1.3 (-6.3 to 10.5)	-21.4 (-27.1 to -14.3)
Self-harm and interpersonal violence	-	-	-	-	0.5 (0.4 to 0.7)	0.4 (0.3 to 0.6)	-17.4 (-25.8 to -7.1)	-40.2 (-46.2 to -32.6)
Self-harm	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-5.4 (-15.4 to 6.4)	-32.4 (-39.3 to -24.2)
Interpersonal violence	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-26.8 (-35.3 to -15.7)	-46.3 (-52.5 to -38.2)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.1 (-23.2 to -6.6)	-36.7 (-42.5 to -30.5)
Assault by sharp object	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-15.1 (-25.3 to -1.6)	-38.3 (-45.6 to -28.6)
Assault by other means	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-31.2 (-39.8 to -19.9)	-49.5 (-55.8 to -41.5)
Forces of nature, war, and legal intervention	-	-	-	-	0.0	0.0 (0.0 to 0.1)	-	-
Exposure to forces of nature	-	-	-	-	0.0	0.0 (0.0 to 0.1)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Laos prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	393.0 (277.2 to 499.5)	592.1 (432.2 to 772.4)	54.6 (47.4 to 61.3)	7.4 (-12.2 to -3.8)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	119.8 (79.7 to 171.0)	143.5 (95.2 to 200.7)	19.6 (10.3 to 31.3)	-20.5 (-26.9 to -12.2)
HIV/AIDS and tuberculosis	-	-	-	-	2.8 (1.9 to 3.8)	7.6 (5.0 to 12.5)	161.1 (142.5 to 272.8)	49.7 (39.7 to 103.7)
Tuberculosis	9.0 (8.5 to 9.5)	22.3 (21.4 to 23.1)	147.3 (137.2 to 158.8)	42.9 (36.7 to 49.9)	2.7 (1.9 to 3.7)	6.7 (4.6 to 9.1)	147.7 (133.4 to 163.4)	43.2 (35.5 to 51.7)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.4)	0.9 (0.1 to 4.8)	1,368.1 (194.2 to 5,891.9)	709.1 (60.7 to 3,180.3)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.9)	1,074.8 (108.4 to 5,307.4)	550.7 (12.6 to 2,971.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.3)	972.8 (75.0 to 5,125.7)	482.8 (9.1 to 2,746.7)
HIV/AIDS resulting in other diseases	0.8 (0.0 to 3.7)	7.8 (1.5 to 33.5)	1,688.7 (350.6 to 7,081.0)	957.4 (158.6 to 4,160.6)	0.1 (0.0 to 0.4)	0.8 (0.1 to 4.7)	1,413.3 (189.2 to 8,668.4)	761.1 (59.1 to 6,096.6)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	6.0 (9.9 to 18.9)	5.0 (8.2 to 16.1)	-16.6 (-26.7 to -5.3)	-39.5 (-45.8 to -32.8)
Diarrheal diseases	37.3 (32.1 to 42.8)	22.3 (19.3 to 25.9)	-40.1 (-51.3 to -26.7)	-53.1 (-61.1 to -44.2)	6.0 (4.0 to 8.5)	5.0 (2.4 to 5.3)	-29.9 (-51.6 to -26.6)	-52.8 (-61.2 to -43.6)
Intestinal infectious diseases	-	-	-	-	0.4 (0.2 to 0.7)	0.2 (0.1 to 0.3)	-48.6 (-67.5 to -9.5)	-6.3 (-7.7 to -40.4)
Typhoid fever	2.3 (1.5 to 3.1)	1.3 (0.9 to 1.7)	-47.1 (-64.7 to -8.7)	-63.4 (-75.6 to -37.9)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-46.0 (-66.0 to -3.7)	-62.2 (-75.9 to -34.3)
Paratyphoid fever	1.5 (1.0 to 2.0)	0.7 (0.5 to 0.9)	-55.2 (-71.0 to -25.3)	-69.5 (-80.6 to -50.7)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-54.6 (-70.9 to -19.9)	-68.8 (-80.4 to -46.7)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-57.8 (-85.7 to -11.3)	-71.0 (-90.1 to -21.8)
Lower respiratory infections	2.2 (1.8 to 2.6)	2.5 (2.1 to 2.9)	10.6 (-13.0 to 43.6)	5.6 (-15.1 to 31.8)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	9.9 (-16.9 to 47.9)	4.2 (-18.2 to 35.6)
Upper respiratory infections	155.5 (139.5 to 172.8)	233.5 (203.0 to 263.1)	50.7 (26.9 to 76.3)	-2.9 (-18.7 to 14.3)	1.8 (1.0 to 3.1)	2.8 (1.5 to 4.8)	50.9 (26.5 to 77.7)	-2.7 (-18.3 to 15.2)
Otitis media	58.4 (54.4 to 62.6)	74.7 (69.9 to 80.0)	28.0 (18.3 to 38.6)	-15.2 (-21.5 to -7.8)	1.1 (0.7 to 1.8)	1.5 (0.9 to 2.4)	30.0 (17.4 to 44.2)	-13.6 (-21.3 to -4.9)
Meningitis	-	-	-	-	3.1 (2.1 to 4.4)	2.5 (1.6 to 3.4)	-21.0 (-33.3 to -6.9)	-49.3 (-57.6 to -41.3)
Pneumococcal meningitis	14.3 (8.9 to 20.8)	11.2 (6.8 to 17.6)	-22.6 (-40.3 to 4.8)	-51.9 (-61.9 to -34.9)	1.3 (0.9 to 2.0)	1.0 (0.6 to 1.5)	-25.1 (-47.3 to 1.6)	-52.3 (-65.4 to -36.8)
H influenzae type B meningitis	7.7 (2.9 to 14.0)	5.2 (2.0 to 9.6)	-31.8 (-51.1 to -11.9)	-58.2 (-69.9 to -46.2)	0.8 (0.5 to 1.2)	0.6 (0.4 to 0.9)	-20.3 (-49.8 to 10.9)	-49.4 (-67.3 to -29.9)
Meningococcal meningitis	1.2 (0.4 to 2.5)	0.9 (0.3 to 2.0)	-24.8 (-46.8 to 3.4)	-54.6 (-67.9 to -36.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-20.4 (-44.7 to 23.6)	-51.2 (-65.2 to -27.8)
Other meningitis	7.7 (3.9 to 13.6)	5.0 (3.2 to 10.5)	-33.5 (-40.0 to 5.1)	-51.1 (-61.9 to -34.4)	0.9 (0.6 to 1.4)	0.8 (0.5 to 1.1)	-15.3 (-41.9 to 34.1)	-44.5 (-60.9 to -15.6)
Encephalitis	1.5 (0.7 to 3.1)	1.8 (0.8 to 3.8)	17.8 (-3.2 to 34.2)	-27.7 (-41.0 to -14.4)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	25.2 (8.1 to 50.7)	21.3 (-31.2 to 6.5)
Diphtheria	0.0 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-	-	0.0 (-98.0 to 294.0)	0.0 (0.0 to 0.0)	-	-
Whooping cough	9.2 (7.0 to 12.0)	7.1 (5.5 to 9.1)	-22.9 (-24.7 to -21.0)	-31.8 (-33.4 to -30.1)	0.5 (0.3 to 0.7)	0.4 (0.2 to 0.6)	-22.3 (-28.2 to -16.7)	-31.4 (-36.7 to -26.3)
Tetanus	6.0 (2.6 to 15.7)	0.4 (0.2 to 0.8)	-93.2 (-97.6 to -88.1)	-95.7 (-98.6 to -89.2)	0.2 (0.1 to 0.4)	0.0 (0.0 to 0.0)	-90.9 (-95.2 to -82.1)	-93.7 (-96.4 to -87.8)
Measles	2.0 (1.4 to 2.6)	0.1 (0.1 to 0.2)	-92.8 (-95.2 to -89.4)	-92.8 (-95.9 to -91.0)	0.0 (0.1 to 0.3)	0.0 (0.0 to 0.0)	-92.8 (-96.5 to -87.5)	-93.9 (-97.0 to -89.4)
Varicella and herpes zoster	4.5 (4.1 to 4.8)	6.8 (6.3 to 7.5)	53.3 (36.6 to 73.0)	-1.3 (-14.2 to 15.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	65.6 (35.1 to 108.9)	-1.6 (-19.8 to 23.7)
Neglected tropical diseases and malaria	-	-	-	-	35.6 (21.2 to 54.2)	50.8 (28.7 to 79.1)	42.2 (16.9 to 69.5)	-11.5 (-25.9 to 4.6)
Malaria	126.7 (117.7 to 135.5)	204.3 (191.8 to 217.5)	61.6 (51.9 to 70.3)	0.2 (-6.0 to 5.5)	1.1 (0.7 to 1.5)	1.6 (1.1 to 2.4)	54.4 (35.7 to 79.4)	0.1 (9.9 to 18.3)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.2 (111.1 to 127.0)	-6.6 (-31.5 to 25.0)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.7 (-56.6 to 293.1)	-4.0 (-60.3 to 140.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.7 (-56.8 to 295.6)	-4.0 (-60.3 to 141.3)
Cutaneous and mucocutaneous leishmaniasis	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.8)	61.0 (28.3 to 101.1)	-6.6 (-23.8 to 15.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.2 (111.1 to 127.4)	-6.6 (-31.6 to 25.1)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	55.6 (20.8 to 120.0)	8.8 (0.7 to 55.1)	-84.2 (-97.5 to 6.6)	-97.8 (-98.6 to -38.2)	0.4 (0.2 to 1.1)	0.1 (0.0 to 0.3)	-83.8 (-92.2 to -16.7)	-89.9 (-95.0 to -48.6)
Cysticercosis	3.0 (1.8 to 4.6)	1.9 (0.6 to 3.9)	-36.7 (-80.6 to 58.7)	-69.7 (-87.3 to -21.9)	0.7 (0.4 to 1.3)	0.5 (0.1 to 1.1)	-42.4 (-80.9 to 70.9)	-68.2 (-87.4 to -15.4)
Cystic echinococcosis	0.7 (0.6 to 0.7)	0.7 (0.7 to 0.8)	9.1 (-4.2 to 21.8)	-36.2 (-44.1 to -29.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	10.0 (-17.1 to 40.6)	-36.3 (-49.8 to -20.9)
Lymphatic filariasis	2.3 (1.4 to 3.4)	1.4 (0.8 to 2.4)	-37.2 (-61.2 to 1.9)	-62.4 (-75.8 to -45.2)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	21.3 (-24.7 to 103.5)	-32.6 (-57.7 to 8.9)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	1.0 (0.3 to 2.0)	0.4 (0.2 to 0.9)	-51.6 (-76.8 to -17.4)	-73.8 (-87.1 to -52.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-49.4 (-72.8 to -15.6)	-72.9 (-85.0 to -51.8)
Dengue	0.8 (0.3 to 1.7)	5.9 (2.4 to 12.9)	678.0 (672.4 to 684.5)	386.3 (382.8 to 390.4)	0.1 (0.0 to 0.3)	1.0 (0.3 to 2.3)	682.2 (543.7 to 882.7)	388.6 (318.9 to 496.6)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.0 (-67.1 to 42.1)	63.3 (-78.4 to -15.0)
Intestinal nematode infections	-	-	-	-	9.5 (5.3 to 16.5)	8.1 (4.6 to 13.6)	-14.4 (-31.7 to 6.9)	-38.9 (-52.2 to -21.7)
Ascariasis	1,207.2 (906.4 to 1,628.6)	1,180.0 (765.6 to 1,723.6)	-2.8 (-41.0 to 60.8)	-38.0 (-64.5 to 8.5)	4.1 (2.0 to 7.7)	2.2 (1.1 to 3.9)	2.2 (-63.7 to -21.2)	-58.3 (-71.6 to -36.7)
Trichuriasis	982.0 (761.9 to 1,254.4)	1,079.3 (703.1 to 1,605.7)	8.1 (-32.2 to 76.8)	-30.8 (-58.7 to 20.6)	2.8 (1.4 to 4.9)	1.8 (0.8 to 3.6)	-36.5 (-64.5 to 15.6)	-54.5 (-76.7 to -13.3)
Hookworm disease	618.3 (451.2 to 836.0)	966.8 (674.4 to 1,361.2)	53.6 (-1.8 to 142.8)	53.6 (-43.2 to 59.4)	2.6 (1.5 to 4.3)	4.1 (2.5 to 6.5)	57.7 (15.3 to 106.2)	2.2 (-30.3 to 36.7)
Food-borne trematodiasis	788.5 (631.9 to 922.1)	1,373.0 (1,074.6 to 1,678.8)	78.3 (43.0 to 118.5)	-0.8 (-20.4 to 21.2)	9.4 (9.4 to 33.0)	35.9 (17.4 to 60.5)	84.3 (49.4 to 126.5)	1.1 (-17.1 to 22.3)
Other neglected tropical diseases	92.7 (72.4 to 113.9)	95.6 (89.1 to 104.1)	3.4 (-16.2 to 33.5)	-28.7 (-40.7 to -11.7)	4.1 (2.5 to 6.5)	3.4 (2.2 to 4.9)	-15.7 (-39.4 to 20.8)	-44.3 (-64.6 to -20.9)
Maternal disorders	-	-	-	-	0.2 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-21.4 (-47.8 to 18.2)	-60.8 (-73.6 to -42.4)
Maternal hemorrhage	2.4 (2.0 to 2.9)	2.1 (1.3 to 2.9)	-10.1 (-46.7 to 27.5)	-54.6 (-72.9 to -35.0)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-21.6 (-62.9 to 46.6)	-40.4 (-80.6 to -30.1)
Maternal sepsis and other maternal infections	2.3 (1.5 to 3.4)	1.6 (1.0 to 2.6)	-29.0 (-49.7 to -4.7)	-45.5 (-76.3 to -50.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-30.1 (-62.5 to 36.7)	-55.9 (-79.7 to -38.9)
Maternal hypertensive disorders	1.2 (0.6 to 2.1)	1.1 (0.5 to 1.9)	-6.2 (-21.2 to 13.8)	-53.2 (-61.0 to -43.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-7.2 (-29.1 to 19.5)	-53.7 (-64.2 to -40.7)
Obstructed labor	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-37.0 (-73.8 to 8.7)	-69.1 (-86.4 to -48.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.0 (-74.5 to 36.0)	-66.9 (-86.4 to -32.9)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-66.5 to 91.3)	-53.3 (-83.0 to -8.0)
Neonatal disorders	-	-	-	-	2.3 (1.3 to 3.8)	11.1 (7.1 to 16.5)	383.8 (196.1 to 730.5)	228.1 (96.0 to 489.9)
Preterm birth complications	13.7 (6.2 to 28.6)	61.6 (30.5 to 126.5)	354.6 (218.1 to 534.2)	179.7 (93.3 to 297.3)	0.8 (0.4 to 1.4)	5.5 (3.2 to 8.4)	577.7 (299.3 to 1,084.1)	360.2 (171.5 to 706.8)
Neonatal encephalopathy due to birth asphyxia and trauma	26.8 (5.0 to 70.4)	31.9 (9.3 to 74.7)	25.0 (-24.4 to 141.0)	-24.7 (-55.1 to 64.0)	0.7 (0.3 to 1.4)	1.8 (1.0 to 3.0)	159.2 (50.8 to 437.1)	74.1 (-4.6 to 293.0)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hemolytic disease and other neonatal jaundice	0.6 (0.2 to 1.3)	5.0 (1.5 to 11.5)	597.1 (151.9 to 2,960.4)	415.9 (86.1 to 2,226.2)	0.2 (0.1 to 0.5)	1.7 (0.5 to 4.0)	587.5 (161.4 to 2,842.5)	414.0 (88.7 to 2,112.2)
Other neonatal disorders	-	-	-	-	0.6 (0.2 to 1.3)	2.1 (0.8 to 4.7)	273.6 (50.7 to 849.1)	156.6 (0.1 to 573.0)
Nutritional deficiencies	-	-	-	-	61.0 (41.3 to 88.0)	57.5 (38.1 to 83.8)	-5.6 (-13.7 to 1.4)	-39.0 (-42.6 to -35.3)
Protein-energy malnutrition	37.7 (23.1 to 57.1)	27.2 (15.4 to 44.6)	-28.8 (-64.6 to 43.6)	-37.1 (-68.2 to 25.0)	3.7 (2.5 to 6.2)	3.4 (1.6 to 6.6)	-28.6 (-64.2 to 43.8)	-37.0 (-68.0 to 25.0)
Iodine deficiency	34.4 (13.6 to 57.1)	40.8 (16.4 to 64.7)	21.1 (-59.4 to 214.9)	-33.8 (-77.1 to 10.2)	0.6 (0.2 to 1.6)	0.7 (0.3 to 1.4)	21.1 (-58.2 to 213.4)	-34.0 (-77.3 to 66.7)
Vitamin A deficiency	1.8 (1.2 to 2.5)	1.5 (0.9 to 2.1)	-21.2 (-37.3 to 0.8)	-47.3 (-57.2 to -33.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-24.3 (-40.7 to -3.4)	-49.3 (-59.0 to -36.7)

Appendix Table G.4 - Laos prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	1,524.7 (1,505.2 to 1,544.3)	1,661.7 (1,650.4 to 1,674.2)	9.0 (7.5 to 10.5)	-2.4 (-33.3 to -31.5)	53.9 (36.3 to 77.6)	52.3 (34.8 to 75.6)	-3.2 (-5.7 to -0.7)	-3.2 (-40.6 to -37.3)
Other nutritional deficiencies	-	-	-	-	1.7 (0.4 to 5.9)	1.0 (0.3 to 2.6)	-38.8 (-78.7 to 86.9)	-38.8 (-81.1 to 64.3)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	3.9 (2.5 to 5.6)	4.6 (2.9 to 6.8)	18.6 (6.8 to 36.3)	-25.0 (-31.7 to -16.1)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.8 (0.5 to 1.3)	1.5 (0.8 to 2.4)	87.1 (59.0 to 118.4)	-1.2 (-13.4 to 12.8)
Syphilis	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-5.4 (-16.1 to 10.2)	-44.4 (-50.5 to -36.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.8 (-26.2 to 28.4)	44.1 (-56.9 to -24.9)
Chlamydial infection	106.7 (76.5 to 153.6)	230.3 (163.8 to 298.2)	111.8 (50.8 to 224.3)	13.6 (-17.9 to 70.9)	0.5 (0.3 to 0.9)	1.0 (0.6 to 1.7)	95.1 (56.2 to 145.1)	4.7 (-13.7 to 28.1)
Gonococcal infection	16.7 (11.6 to 22.9)	31.0 (20.5 to 44.9)	88.9 (13.4 to 180.0)	2.8 (-35.6 to 47.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	89.3 (29.4 to 177.2)	2.3 (-28.4 to 43.6)
Trichomoniasis	12.6 (6.9 to 18.2)	22.6 (15.3 to 32.3)	75.8 (-2.0 to 272.9)	-5.3 (-48.3 to 87.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	72.2 (-21.0 to 319.3)	-6.6 (-57.3 to 115.4)
Genital herpes	373.1 (355.1 to 391.5)	622.4 (597.7 to 663.1)	69.8 (57.4 to 80.4)	-8.9 (-15.5 to -3.2)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	68.8 (53.2 to 85.0)	-8.9 (-16.6 to -1.6)
Other sexually transmitted diseases	0.8 (0.5 to 1.1)	1.0 (0.7 to 1.4)	30.0 (6.5 to 70.1)	-3.8 (-46.2 to -12.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.7 (3.5 to 147.3)	15.0 (-42.9 to 24.8)
Hepatitis	-	-	-	-	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.9)	24.9 (1.4 to 52.8)	-30.3 (-45.2 to -10.7)
Hepatitis A	7.6 (7.2 to 8.0)	9.6 (9.2 to 9.9)	25.9 (24.2 to 27.8)	-6.5 (-6.8 to -6.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	58.7 (42.0 to 79.1)	4.8 (-6.5 to 17.5)
Hepatitis B	784.2 (687.3 to 879.5)	766.1 (621.9 to 892.3)	-1.5 (-26.4 to 20.2)	-40.9 (-51.6 to -27.9)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	11.0 (-2.0 to 51.5)	-39.6 (-57.6 to -15.2)
Hepatitis C	133.2 (119.9 to 146.9)	157.5 (153.0 to 181.9)	25.7 (10.6 to 43.2)	-27.7 (-35.5 to -18.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.7 (-29.0 to 56.6)	-25.6 (-44.3 to -0.4)
Hepatitis E	0.9 (0.8 to 1.1)	1.2 (1.0 to 1.5)	30.7 (0.3 to 73.4)	-27.8 (-44.3 to 0.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	31.7 (-10.3 to 93.0)	-27.6 (-50.1 to 6.3)
Leprosy	0.8 (0.5 to 1.1)	0.9 (0.7 to 1.1)	14.8 (-5.9 to 45.7)	-31.4 (-42.7 to -14.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	15.5 (9.8 to 53.6)	-31.2 (-44.2 to -11.6)
Other infectious diseases	68.9 (55.8 to 82.3)	71.6 (64.3 to 80.0)	3.9 (-8.1 to 19.6)	-30.9 (-38.1 to -21.6)	2.5 (1.6 to 3.6)	2.4 (1.6 to 3.5)	-3.6 (-17.9 to 16.9)	-34.1 (-43.8 to -20.6)
Non-communicable diseases	-	-	-	-	237.8 (175.4 to 308.3)	419.6 (309.9 to 543.7)	76.4 (69.6 to 83.6)	0.2 (-3.1 to 3.7)
Neoplasms	-	-	-	-	1.2 (0.7 to 2.0)	3.2 (1.7 to 5.2)	160.6 (69.5 to 317.7)	48.1 (-2.2 to 132.6)
Esophageal cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	97.3 (13.3 to 250.9)	11.4 (-34.0 to 91.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.1 (15.0 to 219.1)	6.8 (-33.7 to 75.3)
Stomach cancer	0.5 (0.3 to 0.8)	0.8 (0.5 to 1.3)	69.3 (4.4 to 188.7)	-2.2 (-39.0 to 62.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	64.9 (2.1 to 179.1)	-5.5 (-39.7 to 58.2)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	297.4 (130.7 to 596.8)	132.4 (93.3 to 299.4)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.3)	347.5 (39.9 to 964.3)	161.3 (-17.5 to 504.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	340.4 (42.0 to 867.1)	159.4 (-14.3 to 453.2)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.3)	1,043.7 (386.4 to 4,309.0)	528.4 (176.1 to 2,158.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	950.3 (386.0 to 4,153.4)	465.5 (176.4 to 2,086.2)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.4 (-48.1 to 236.6)	-27.3 (-68.2 to 91.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.7 (-46.9 to 205.4)	-28.3 (-67.4 to 78.4)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	76.8 (-25.6 to 276.7)	5.4 (-57.2 to 122.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.9 (-23.5 to 244.4)	2.2 (-55.4 to 101.0)
Larynx cancer	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	75.3 (5.2 to 211.2)	4.3 (-36.3 to 77.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	78.4 (7.1 to 224.5)	6.4 (-34.8 to 83.3)
Tracheal, bronchus and lung cancer	0.6 (0.3 to 1.0)	1.3 (0.8 to 2.1)	109.8 (29.9 to 264.8)	24.3 (-21.4 to 106.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	101.6 (23.3 to 243.9)	19.2 (-23.5 to 97.4)
Breast cancer	1.7 (1.0 to 3.0)	8.8 (5.7 to 14.3)	422.7 (213.0 to 787.1)	197.9 (80.9 to 403.3)	0.1 (0.1 to 0.3)	0.6 (0.3 to 1.0)	310.5 (145.4 to 633.3)	127.3 (37.5 to 299.5)
Cervical cancer	2.7 (1.5 to 4.6)	4.8 (2.4 to 8.4)	74.8 (-1.4 to 231.3)	5.2 (-45.9 to 74.4)	0.2 (0.1 to 0.4)	0.2 (0.2 to 0.7)	72.5 (-1.8 to 236.3)	-5.2 (-46.6 to 70.1)
Uterine cancer	0.7 (0.3 to 1.3)	1.6 (0.7 to 3.0)	128.1 (13.0 to 398.7)	27.5 (-36.2 to 169.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	121.5 (9.9 to 374.0)	23.4 (-37.7 to 159.1)
Prostate cancer	0.4 (0.2 to 0.6)	1.7 (1.0 to 2.8)	390.1 (177.9 to 818.8)	188.8 (64.5 to 438.2)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	369.7 (153.4 to 799.8)	173.3 (47.9 to 424.0)
Colon and rectum cancer	0.8 (0.5 to 1.2)	2.5 (1.5 to 4.0)	232.1 (107.3 to 454.6)	81.3 (16.8 to 187.2)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	202.3 (88.3 to 400.2)	66.7 (6.9 to 161.6)
Lip and oral cavity cancer	0.8 (0.4 to 1.4)	1.7 (0.9 to 2.9)	105.1 (20.3 to 255.4)	18.4 (-27.8 to 100.6)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	102.6 (20.1 to 249.5)	16.3 (-28.5 to 94.2)
Nasopharynx cancer	0.3 (0.1 to 0.5)	0.3 (0.2 to 0.8)	61.8 (-11.1 to 204.9)	-12.2 (51.5 to 63.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	56.0 (-12.0 to 189.0)	-14.6 (-51.4 to 59.7)
Other pharynx cancer	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.7)	67.7 (-14.7 to 243.5)	-3.7 (-49.2 to 91.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	60.1 (-14.3 to 208.6)	-8.9 (-50.7 to 74.5)
Gallbladder and biliary tract cancer	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	68.2 (-9.7 to 212.4)	-6.4 (-48.8 to 68.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.6 (-15.5 to 187.4)	-12.2 (-49.8 to 60.0)
Pancreatic cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	139.7 (46.7 to 298.6)	34.8 (-16.3 to 117.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	126.7 (40.1 to 268.4)	25.5 (-21.6 to 99.3)
Malignant skin melanoma	0.1 (0.1 to 0.3)	0.4 (0.2 to 0.6)	172.6 (50.3 to 427.0)	46.7 (-17.2 to 175.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	159.5 (42.6 to 406.2)	39.8 (-21.2 to 167.9)
Non-melanoma skin cancer	0.3 (0.2 to 0.4)	0.7 (0.5 to 1.0)	172.3 (83.0 to 340.2)	47.3 (-0.2 to 140.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	240.8 (116.3 to 450.7)	81.4 (10.3 to 212.1)
Ovarian cancer	0.1 (0.1 to 0.3)	0.6 (0.3 to 1.1)	317.6 (108.1 to 703.4)	126.2 (10.9 to 342.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	294.2 (99.9 to 703.8)	114.2 (33.3 to 338.4)
Testicular cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	225.6 (62.6 to 568.8)	69.1 (-14.5 to 248.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	206.6 (47.1 to 598.0)	58.1 (-20.9 to 234.5)
Kidney cancer	0.1 (0.1 to 0.3)	0.2 (0.3 to 0.8)	181.5 (52.8 to 382.5)	46.7 (7.4 to 220.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	178.8 (49.1 to 373.3)	68.6 (-1.4 to 203.9)
Bladder cancer	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	108.2 (27.9 to 237.1)	12.6 (-28.0 to 79.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	97.2 (23.3 to 225.0)	7.0 (-31.1 to 72.1)
Brain and nervous system cancer	0.3 (0.1 to 0.8)	0.6 (0.4 to 1.1)	156.1 (5.1 to 337.9)	50.0 (-19.5 to 159.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	144.4 (19.9 to 336.6)	39.4 (-17.6 to 141.6)
Thyroid cancer	0.5 (0.2 to 1.0)	1.4 (0.7 to 2.8)	192.3 (58.2 to 465.5)	52.2 (-17.2 to 197.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	171.5 (46.7 to 441.7)	40.4 (-23.6 to 179.7)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.3 (-19.1 to 156.1)	20.3 (-53.1 to 42.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	39.4 (-18.6 to 153.8)	-20.4 (-53.4 to 41.0)
Hodgkin lymphoma	0.3 (0.1 to 0.6)	0.7 (0.4 to 1.2)	117.5 (21.2 to 332.6)	41.3 (-15.3 to 154.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	114.8 (24.2 to 323.4)	34.5 (-18.6 to 129.7)
Non-Hodgkin lymphoma	0.3 (0.2 to 0.7)	1.4 (0.8 to 2.3)	361.3 (121.6 to 700.3)	174.3 (39.5 to 455.2)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	324.1 (109.7 to 699.6)	144.0 (28.7 to 415.0)
Multiple myeloma	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	162.3 (43.6 to 425.3)	46.2 (-20.1 to 189.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	148.9 (40.3 to 379.3)	36.3 (-21.7 to 158.3)
Leukemia	0.5 (0.3 to 1.3)	1.6 (1.0 to 2.7)	228.6 (68.0 to 485.6)	121.1 (30.2 to 257.7)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	209.7 (84.5 to 391.2)	89.6 (19.8 to 195.6)
Other neoplasms	1.0 (0.4 to 2.9)	3.7 (2.0 to 7.0)	325.5 (85.6 to 615.7)	136.7 (42.5 to 298.7)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.5)	280.2 (82.5 to 548.5)	105.5 (27.3 to 239.1)
Cardiovascular diseases	-	-	-	-	8.4 (5.7 to 11.4)	17.5 (12.0 to 24.3)	109.2 (74.2 to 145.3)	20.3 (1.0 to 39.4)
Rheumatic heart disease	81.9 (71.1 to 93.9)	135.2 (114.2 to 154.1)	65.9 (33.7 to 103.3)	-4.0 (-20.8 to 14.3)	4.0 (2.5 to 6.0)	6.6 (4.4 to 9.9)	66.3 (34.4 to 104.9)	-3.2 (-20.0 to 16.6)
Ischemic heart disease	16.5 (13.7 to 20.2)	33.6 (26.9 to 42.3)	105.0 (43.4 to 176.2)	15.4 (-17.7 to 51.8)	1.1 (0.8 to 1.6)	2.3 (1.5 to 3.4)	104.8 (48.1 to 176.3)	15.7 (-15.9 to 52.0)
Cerebrovascular disease	-	-	-	-	0.9 (0.6 to 1.2)	1.6 (1.1 to 2.1)	79.8 (54.2 to 116.9)	2.4 (-12.6 to 23.2)
Ischemic stroke	2.8 (2.4 to 3.2)	5.2 (4.5 to 6.0)	81.7 (51.9 to 125.2)	3.4 (-13.6 to 30.8)	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.1)	82.1 (51.6 to 129.3)	3.7 (-13.3 to 31.3)
Hemorrhagic stroke	3.2 (2.8 to 3.7)	5.8 (5.1 to 6.7)	76.7 (52.1 to 117.1)	-0.0 (-14.6 to 21.2)	0.5 (0.3 to 0.7)	0.9 (0.6 to 1.2)	77.6 (49.7 to 119.0)	0.8 (-14.7 to 22.9)
Hypertensive heart disease	4.2 (3.7 to 4.8)	7.5 (6.5 to 8.5)	76.5 (46.7 to 108.7)	0.3 (-18.0 to 19.6)	0.5 (0.3 to 0.6)	0.8 (0.6 to 1.1)	77.2 (47.2 to 111.5)	0.4 (-17.8 to 20.0)
Cardiomyopathy and myocarditis	2.0 (1.7 to 2.3)	3.8 (3.4 to 4.2)	91.1 (57.5 to 130.1)	12.4 (-9.8 to 38.5)	0.4 (0.1 to 0.3)	0.4 (0.3 to 0.6)	90.0 (54.9 to 134.5)	0.0 (-11.0 to 40.2)
Atrial fibrillation and flutter	1.2 (0.9 to 1.6)	2.4 (1.9 to 3.1)	87.2 (35.9 to 198.9)	6.0 (-24.9 to 68.2)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	88.1 (33.0 to 204.9)	5.8 (-25.1 to 72.2)
Peripheral vascular disease	84.4 (67.8 to 101.7)	143.6 (113.6 to 176.7)	70.6 (26.4 to 129.9)	-5.5 (-27.1 to 23.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	40.1 (-32.8 to 182.0)	-23.6 (-58.9 to 35.6)
Endocarditis	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	57.0 (-21.6 to 111.3)	-3.5 (-57.8 to 30.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.1 (-20.8 to 153.3)	-0.4 (-58.5 to 50.1)
Other cardiovascular and circulatory diseases	21.4 (12.4 to 32.6)	76.1 (41.1 to 107.1)	353.0 (78.0 to 528.0)	15.1 (-3.6 to 267.5)	1.5 (0.8 to 2.5)	5.4 (2.7 to 8.6)	253.3 (79.4 to 538.4)	101.7 (-2.4 to 269.8)
Chronic respiratory diseases	-	-	-	-	13.9 (9.1 to 20.2)	22.6 (15.3 to 31.7)	63.6 (36.8 to 88.2)	-

Appendix Table G.4 - Laos prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	162.3 (144.0 to 179.5)	42.0 (30.9 to 52.4)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.4 (51.3 to 66.4)	-11.2 (-15.0 to -6.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.5 (50.4 to 65.8)	-11.4 (-15.5 to -6.8)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.3 (48.3 to 60.2)	-15.2 (-18.2 to -12.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.9 (47.6 to 60.1)	-15.1 (-18.3 to -12.1)
Other pneumoconiosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	29.5 (24.8 to 27.5)	88.4 (91.1 to 106.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	23.9 (23.2 to 27.6)	29.7 (8.4 to 107.7)
Asthma	29.8 (23.0 to 37.3)	65.6 (53.2 to 80.9)	119.8 (62.1 to 201.0)	18.7 (-12.7 to 55.1)	1.3 (0.8 to 1.9)	2.9 (1.8 to 4.3)	120.8 (62.0 to 209.3)	18.9 (-12.8 to 56.6)
Interstitial lung disease and pulmonary sarcoidosis	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	91.2 (38.1 to 169.2)	11.1 (-19.9 to 56.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	91.2 (39.5 to 169.2)	10.5 (-18.7 to 55.0)
Other chronic respiratory diseases	-	-	-	-	3.5 (1.5 to 6.6)	2.8 (1.4 to 4.9)	-17.6 (-47.3 to 33.6)	-53.8 (-70.6 to -26.8)
Cirrhosis	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	2.2 (10.2 to 42.0)	-24.9 (-33.4 to -15.9)
Cirrhosis due to hepatitis B	0.5 (0.3 to 0.7)	0.7 (0.4 to 1.0)	26.9 (-31.2 to 126.5)	-24.4 (56.4 to 38.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	25.7 (-36.4 to 136.9)	-24.7 (59.5 to 41.4)
Cirrhosis due to hepatitis C	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.8)	52.1 (-12.2 to 181.7)	-7.5 (-49.8 to 77.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	53.8 (-15.7 to 204.5)	-5.5 (51.6 to 90.3)
Cirrhosis due to alcohol use	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	-1.1 (-41.6 to 47.5)	-44.9 (-66.4 to -17.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-3.0 (-43.2 to 51.6)	-44.9 (-69.9 to -16.7)
Cirrhosis due to other causes	0.3 (0.2 to 0.4)	0.3 (0.3 to 0.5)	29.5 (9.5 to 94.0)	29.5 (-37.7 to 41.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	31.2 (-16.3 to 123.9)	-8.1 (-42.7 to 54.0)
Digestive diseases	-	-	-	-	4.0 (2.7 to 5.7)	4.5 (3.0 to 6.3)	13.0 (6.1 to 32.5)	-33.7 (-41.6 to -26.2)
Peptic ulcer disease	25.4 (19.9 to 28.2)	21.8 (16.3 to 25.8)	-14.1 (-29.0 to 3.7)	-47.8 (-55.1 to -38.0)	0.9 (0.6 to 1.4)	0.8 (0.5 to 1.2)	-9.6 (-28.7 to 10.3)	-46.8 (-55.6 to -36.9)
Gastritis and duodenitis	35.6 (31.8 to 38.4)	40.5 (36.3 to 44.4)	14.0 (-1.2 to 32.4)	-30.2 (-38.0 to -20.7)	1.4 (1.0 to 2.0)	1.6 (1.0 to 2.3)	9.2 (-10.3 to 28.0)	-32.0 (-40.1 to -23.0)
Appendicitis	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	42.4 (-4.7 to 110.7)	-19.0 (-43.7 to 13.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	42.0 (-13.0 to 132.3)	-17.9 (-49.4 to 26.3)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	39.1 (-35.0 to 105.0)	-0.1 (-33.7 to 23.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.8 (-35.8 to 129.6)	1.3 (-37.1 to 35.6)
Inguinal, femoral, and abdominal hernia	32.8 (23.7 to 55.2)	40.8 (31.3 to 68.3)	17.5 (-35.9 to 158.7)	-19.1 (-37.5 to 16.7)	0.3 (0.2 to 0.8)	0.4 (0.2 to 0.9)	16.5 (-36.7 to 161.0)	-19.3 (-38.4 to 18.6)
Inflammatory bowel disease	0.6 (0.6 to 0.6)	1.1 (1.0 to 1.1)	81.6 (69.0 to 94.9)	-0.0 (-6.8 to 7.4)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	82.7 (54.5 to 116.3)	0.8 (-13.7 to 18.0)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.0 (31.7 to 134.7)	-5.8 (-34.6 to 37.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.5 (24.5 to 147.2)	-4.7 (-41.7 to 57.8)
Gallbladder and biliary diseases	1.0 (0.9 to 1.1)	1.2 (1.1 to 1.3)	23.5 (5.8 to 44.4)	-2.6 (-33.1 to -11.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	23.4 (10.1 to 50.7)	-22.7 (-35.1 to -8.9)
Pancreatitis	0.7 (0.7 to 0.8)	1.5 (1.5 to 1.6)	111.3 (95.3 to 128.4)	15.0 (6.5 to 23.9)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.6)	113.2 (79.5 to 151.0)	16.0 (1.0 to 33.5)
Other digestive diseases	-	-	-	-	0.7 (0.4 to 1.2)	0.7 (0.4 to 1.0)	-3.9 (-37.7 to 51.6)	-43.8 (-62.3 to -12.8)
Neurological disorders	-	-	-	-	24.6 (15.7 to 35.5)	47.3 (30.8 to 67.8)	96.6 (44.7 to 141.0)	7.7 (-13.9 to 27.7)
Alzheimer disease and other dementias	11.7 (10.0 to 13.3)	21.8 (18.5 to 25.3)	85.8 (51.5 to 130.6)	-0.3 (-20.0 to 23.2)	1.6 (1.1 to 2.1)	3.1 (2.2 to 4.1)	90.3 (53.0 to 135.9)	0.3 (-20.5 to 23.9)
Parkinson disease	1.2 (1.0 to 1.3)	2.1 (1.8 to 2.4)	78.7 (70.5 to 86.9)	1.5 (-3.0 to 6.6)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	79.9 (60.2 to 102.6)	2.2 (-8.5 to 14.5)
Epilepsy	19.1 (14.2 to 24.1)	33.1 (24.5 to 42.1)	73.9 (16.5 to 151.4)	6.4 (-28.3 to 52.8)	5.1 (3.2 to 7.6)	9.5 (6.0 to 13.7)	88.7 (22.6 to 178.7)	15.4 (-33.3 to 69.9)
Multiple sclerosis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	238.0 (203.8 to 279.5)	0.0 (62.5 to 101.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	238.0 (203.6 to 279.8)	80.4 (62.4 to 101.8)
Migraine	41.0 (30.2 to 529.4)	765.5 (525.2 to 1,005.6)	91.5 (18.6 to 176.5)	4.5 (-32.3 to 47.4)	1.1 (7.8 to 22.7)	5.1 (13.6 to 42.1)	44.1 (17.3 to 179.4)	1.1 (-31.9 to 49.3)
Tension-type headache	806.8 (726.0 to 893.9)	1,433.6 (1,321.6 to 1,534.6)	77.6 (56.2 to 101.1)	0.5 (-9.5 to 11.9)	1.2 (0.6 to 2.1)	2.2 (1.1 to 3.8)	78.2 (55.9 to 102.6)	1.0 (-9.3 to 12.7)
Medication overuse headache	11.9 (8.1 to 16.1)	33.0 (22.5 to 43.3)	178.8 (128.7 to 232.5)	51.8 (26.3 to 82.4)	1.9 (1.1 to 2.8)	5.2 (3.0 to 8.0)	180.1 (128.2 to 238.0)	52.8 (25.0 to 83.7)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.8 (17.5 to 117.7)	-0.3 (-27.2 to 36.3)	0.5 (0.3 to 1.3)	0.8 (0.5 to 1.5)	82.4 (0.1 to 177.0)	-2.4 (-46.8 to 49.1)
Mental and substance use disorders	-	-	-	-	65.8 (47.0 to 98.2)	119.2 (85.4 to 158.9)	81.3 (73.7 to 87.8)	0.6 (-2.9 to 3.8)
Schizophrenia	11.0 (9.5 to 12.6)	20.7 (17.8 to 23.6)	88.1 (79.7 to 97.1)	0.3 (-4.0 to 5.1)	7.1 (5.0 to 8.9)	13.4 (9.6 to 16.7)	89.7 (76.8 to 102.5)	1.3 (-4.9 to 7.9)
Alcohol use disorders	26.3 (23.3 to 29.8)	48.2 (42.9 to 54.2)	83.6 (71.3 to 95.4)	-0.7 (-6.4 to 5.5)	2.6 (1.7 to 3.7)	4.8 (3.1 to 6.9)	84.6 (69.9 to 99.6)	-0.3 (-7.6 to 6.8)
Drug use disorders	-	-	-	-	11.2 (7.5 to 16.1)	21.2 (13.8 to 30.1)	88.2 (59.5 to 122.9)	1.2 (-13.3 to 18.3)
Opioid use disorders	3.8 (3.0 to 4.8)	7.2 (5.6 to 9.0)	87.5 (70.7 to 107.3)	-1.2 (-9.9 to 8.4)	1.6 (1.1 to 2.2)	3.0 (2.0 to 4.2)	89.4 (66.3 to 116.3)	-0.4 (-12.1 to 12.7)
Cocaine use disorders	5.1 (2.8 to 3.3)	5.7 (5.3 to 6.1)	87.2 (65.7 to 108.4)	0.6 (-10.9 to 9.7)	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.1)	87.3 (53.5 to 130.0)	-0.3 (-17.3 to 19.9)
Amphetamine use disorders	32.2 (28.8 to 35.8)	60.2 (53.8 to 66.5)	87.2 (61.5 to 113.5)	1.4 (-11.9 to 15.3)	4.2 (2.6 to 6.3)	8.0 (4.9 to 11.7)	88.3 (60.7 to 116.6)	1.9 (-12.4 to 16.7)
Cannabis use disorders	9.0 (5.9 to 11.9)	16.6 (11.0 to 21.7)	83.8 (81.5 to 87.1)	-0.2 (-0.3 to -0.2)	0.3 (0.1 to 0.4)	0.5 (0.3 to 0.8)	84.7 (61.0 to 112.4)	0.5 (-12.0 to 13.8)
Other drug use disorders	-	-	-	-	4.7 (2.9 to 7.1)	8.9 (5.3 to 13.4)	87.4 (35.9 to 157.6)	1.5 (-26.4 to 38.9)
Depressive disorders	-	-	-	-	17.3 (10.8 to 25.4)	31.9 (20.0 to 47.0)	84.9 (76.7 to 94.2)	0.9 (-3.7 to 6.4)
Major depressive disorder	65.3 (42.4 to 87.1)	120.2 (77.7 to 159.9)	83.7 (75.0 to 95.3)	0.2 (-4.5 to 8.0)	13.4 (7.5 to 20.7)	24.7 (13.9 to 38.2)	84.7 (74.8 to 96.8)	1.0 (-4.9 to 8.7)
Dysthymia	40.3 (34.5 to 46.1)	74.4 (63.6 to 85.2)	84.5 (83.0 to 86.1)	0.1 (0.0 to 0.1)	3.9 (2.6 to 5.6)	7.2 (4.7 to 10.4)	85.3 (80.3 to 90.6)	0.5 (-1.8 to 2.8)
Bipolar disorder	20.3 (16.3 to 24.1)	38.1 (31.0 to 44.8)	86.9 (75.5 to 101.4)	0.5 (-5.1 to 6.8)	4.1 (2.5 to 6.4)	7.8 (4.7 to 12.0)	88.3 (72.7 to 107.2)	1.3 (-6.2 to 9.7)
Anxiety disorders	94.8 (88.2 to 153.9)	172.3 (69.7 to 279.1)	82.2 (74.7 to 87.0)	0.2 (-0.0 to 0.3)	17.3 (3.2 to 15.9)	31.9 (5.8 to 28.3)	84.9 (73.0 to 92.1)	0.9 (-2.2 to 3.9)
Eating disorders	-	-	-	-	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.2)	82.0 (58.0 to 110.5)	0.8 (-1.8 to 15.6)
Anorexia nervosa	1.1 (0.9 to 1.4)	2.0 (1.5 to 2.5)	79.6 (62.6 to 102.6)	0.7 (-8.7 to 12.4)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	80.2 (48.0 to 121.6)	1.5 (-17.0 to 23.3)
Bulimia nervosa	1.0 (0.6 to 1.4)	1.8 (1.2 to 2.6)	84.2 (80.5 to 87.0)	0.5 (0.3 to 0.7)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	84.3 (54.1 to 122.0)	0.5 (-16.5 to 20.4)
Autistic spectrum disorders	-	-	-	-	5.1 (3.5 to 6.9)	8.2 (5.6 to 11.1)	61.5 (55.4 to 67.4)	0.5 (-2.8 to 3.7)
Autism	13.0 (12.3 to 13.6)	20.9 (19.8 to 22.0)	61.1 (60.4 to 61.8)	-0.1 (-0.1 to -0.1)	3.2 (2.1 to 4.4)	5.2 (3.5 to 7.2)	61.8 (52.9 to 70.7)	0.5 (-4.1 to 5.4)
Asperger syndrome	18.6 (17.5 to 19.7)	29.8 (28.0 to 31.6)	60.1 (59.2 to 61.1)	-0.1 (-0.2 to -0.1)	1.9 (1.3 to 2.6)	3.0 (2.1 to 4.2)	60.7 (53.6 to 68.0)	0.4 (-3.3 to 4.5)
Attention-deficit/hyperactivity disorder	32.6 (30.0 to 34.7)	49.5 (45.6 to 52.8)	52.1 (51.5 to 52.4)	0.1 (0.1 to 0.1)	0.4 (0.2 to 0.6)	0.6 (0.4 to 0.9)	52.7 (41.3 to 63.8)	0.5 (-7.0 to 8.1)
Conduct disorder	31.0 (31.1 to 34.9)	50.6 (47.6 to 53.6)	53.3 (52.1 to 54.4)	0.0 (0.0 to 0.1)	4.0 (2.5 to 5.7)	6.1 (3.8 to 8.8)	54.4 (46.9 to 62.1)	0.3 (-4.1 to 5.7)
Idiopathic intellectual disability	20.7 (7.3 to 41.9)	20.8 (8.3 to 47.0)	82.2 (-64.2 to 169.8)	0.4 (-75.4 to 83.1)	1.0 (0.3 to 2.3)	1.0 (0.4 to 2.4)	0.3 (-64.5 to 173.2)	-31.4 (-75.7 to 81.2)
Other mental and substance use disorders	51.8 (48.3 to 55.1)	98.3 (91.5 to 104.6)	89.7 (89.2 to 90.2)	-0.0 (-0.1 to 0.0)	3.9 (2.6 to 5.2)	7.4 (5.0 to 10.0)	90.8 (82.6 to 98.8)	0.5 (-3.1 to 4.3)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	25.9 (18.0 to 35.8)	45.1 (30.9 to 62.4)	73.3 (60.9 to 90.6)	6.4 (-3.1 to 19.2)
Diabetes mellitus	94.0 (78.9 to 111.9)	240.4 (198.7 to 286.9)	155.6 (105.5 to 221.0)	42.7 (12.2 to 82.0)	5.9 (3.7 to 8.6)	15.3 (9.7 to 22.2)	159.5 (101.0 to 232.4)	44.4 (10.2 to 87.3)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.5 (-8.0 to 2.0)	-33.9 (-36.6 to -30.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.9 (-8.0 to 2.0)	-3.5 (-36.6 to -30.9)
Chronic kidney disease	-	-	-	-	3.5 (2.4 to 4.9)	5.7 (3.9 to 8.0)	63.6 (47.7 to 79.7)	-3.4 (-11.5 to 5.2)
Chronic kidney disease due to diabetes mellitus	11.8 (7.5 to 17.4)	34.8 (22.5 to 51.8)	194.6 (104.7 to 321.0)	73.7 (11.7 to 143.4)	0.3 (0.2 to 0.5)	0.8 (0.5 to 1.3)	177.8 (112.6 to 289.9)	88.0 (16.7 to 123.3)
Chronic kidney disease due to hypertension	31.1 (18.4 to 53.0)	17.4 (11.6 to 25.6)	43.1 (-59.8 to -17.6)	-60.9 (-70.6 to -45.6)	0.7 (0.5 to 1.1)	1.2 (0.8 to 1.8)	63.7 (20.3 to 119.8)	-5.6 (-31.6 to 21.0)
Chronic kidney disease due to glomerulonephritis	30.5 (19.9 to 47.7)	46.6 (29.4 to 72.7)	54.7 (8.6 to 107.7)	44.1 (-32.3 to 23.4)	0.3 (0.4 to 1.0)	0.3 (0.2 to 0.5)	48.9 (-64.5 to -26.3)	47.7 (-78.1 to -53.0)
Chronic kidney disease due to other causes	90.4 (59.6 to 137.7)	163.1 (104.9 to 259.9)	80.7 (49.6 to 114.7)	5.4 (-12.6 to 23.9)	1.8 (1.2 to 2.6)	3.3 (2.2 to 4.8)	84.1 (53.6 to 121.3)	3.6 (-17.6 to 21.5)
Urinary diseases and male infertility	-	-	-	-	1.4 (0.9 to 2.0)	2.5 (1.6 to 3.6)	82.2 (60.9 to 104.5)	5.9 (-6.2 to 18.9)

Appendix Table G.4 - Laos prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.7 (0.6 to 0.7)	1.4 (1.3 to 1.5)	111.9 (94.3 to 130.2)	25.8 (16.2 to 35.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	112.0 (66.7 to 173.4)	126.7 (4.5 to 53.9)
Urolithiasis	15.2 (11.5 to 20.2)	27.7 (21.4 to 36.5)	82.1 (51.2 to 123.8)	2.7 (-13.0 to 27.1)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	75.9 (55.1 to 98.6)	0.7 (-9.4 to 12.6)
Benign prostatic hyperplasia	25.2 (22.9 to 27.5)	45.7 (41.2 to 49.7)	81.6 (56.5 to 106.1)	6.3 (-7.5 to 20.7)	0.9 (0.6 to 1.3)	1.6 (1.0 to 2.3)	82.2 (57.3 to 107.2)	7.2 (-6.8 to 21.4)
Male infertility due to other causes	17.2 (11.7 to 23.4)	31.4 (22.1 to 41.4)	84.0 (41.1 to 198.2)	-5.4 (41.0 to 52.7)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	86.9 (13.4 to 211.7)	-3.5 (-41.1 to 58.4)
Other urinary diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	86.6 (17.5 to 176.9)	26.6 (32.8 to 56.7)
Gynecological diseases	-	-	-	-	4.4 (2.9 to 6.4)	8.0 (5.3 to 12.0)	83.3 (55.5 to 114.3)	-6.7 (-18.5 to 6.5)
Uterine fibroids	61.4 (55.7 to 67.4)	121.2 (110.1 to 133.1)	97.5 (97.2 to 97.8)	1.2 (1.1 to 1.2)	1.3 (0.8 to 2.0)	2.0 (1.2 to 3.2)	56.1 (43.6 to 67.0)	-20.4 (-27.0 to -14.5)
Polycystic ovarian syndrome	49.9 (42.8 to 57.0)	95.4 (80.4 to 110.1)	92.6 (53.3 to 132.3)	-0.5 (-19.6 to 18.7)	0.5 (0.2 to 1.0)	0.9 (0.4 to 1.8)	92.7 (52.4 to 132.1)	-0.2 (-19.5 to 19.3)
Female infertility due to other causes	15.3 (6.2 to 28.4)	26.9 (6.2 to 53.9)	65.4 (-50.2 to 448.9)	-32.3 (-74.7 to 209.6)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.4)	64.2 (-48.0 to 423.6)	-12.6 (-74.9 to 191.7)
Endometriosis	6.2 (5.2 to 7.2)	11.8 (10.1 to 13.6)	89.9 (55.3 to 136.8)	0.8 (-19.1 to 23.2)	0.6 (0.4 to 0.8)	1.1 (0.7 to 1.5)	90.3 (53.2 to 143.6)	-0.8 (-19.8 to 25.6)
Genital prolapse	147.5 (125.8 to 170.3)	277.1 (235.1 to 315.0)	87.4 (52.9 to 127.7)	-0.5 (-16.1 to 17.3)	0.5 (0.2 to 0.9)	0.9 (0.4 to 1.7)	88.3 (52.3 to 129.4)	-0.3 (-16.4 to 18.0)
Premenstrual syndrome	107.7 (74.9 to 146.3)	271.3 (173.5 to 364.7)	157.5 (44.9 to 306.0)	29.1 (-25.1 to 97.1)	0.9 (0.5 to 1.5)	2.3 (1.2 to 3.8)	157.2 (42.1 to 310.5)	29.2 (-26.7 to 99.9)
Other gynecological diseases	17.2 (12.4 to 22.0)	23.0 (20.4 to 25.6)	34.3 (4.0 to 85.3)	-28.6 (-44.3 to -2.3)	0.6 (0.3 to 0.9)	0.7 (0.5 to 1.0)	15.8 (7.9 to 93.5)	-38.1 (-51.1 to 1.7)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	7.9 (5.3 to 11.3)	10.4 (6.9 to 15.2)	32.5 (23.0 to 43.1)	-15.8 (-22.9 to -8.2)
Thalassemias	8.3 (7.3 to 9.4)	11.9 (10.5 to 13.1)	42.4 (32.1 to 55.5)	1.2 (-5.9 to 10.3)	0.6 (0.4 to 0.9)	0.8 (0.5 to 1.2)	36.4 (10.8 to 69.6)	-0.3 (-20.8 to 22.7)
Thalassemia trait	426.1 (402.1 to 451.3)	685.2 (647.1 to 724.7)	60.7 (55.9 to 66.2)	0.7 (-2.4 to 4.1)	4.8 (3.2 to 6.9)	7.4 (4.9 to 10.7)	54.6 (38.9 to 68.8)	1.2 (-9.7 to 10.6)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.7 (-20.7 to 38.6)	-21.1 (-45.1 to -5.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.9 (-15.6 to 100.9)	10.1 (-43.5 to 36.4)
Sickle cell trait	7.4 (5.3 to 9.3)	10.2 (6.2 to 12.3)	44.1 (-0.4 to 62.0)	-9.8 (-37.6 to 1.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	22.4 (-36.9 to 223.6)	-28.9 (-60.1 to 111.2)
G6PD deficiency	175.9 (145.6 to 209.7)	190.1 (155.4 to 224.5)	8.3 (-17.6 to 42.5)	-32.3 (-48.5 to -11.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.7 (3.1 to 17.2)	-28.0 (-31.5 to -25.2)
G6PD trait	671.2 (626.7 to 714.1)	1,052.2 (1,006.5 to 1,098.1)	56.7 (45.0 to 70.1)	-2.1 (-9.5 to 6.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	28.7 (-86.4 to 131.3)	-31.8 (-91.9 to 20.2)
Other hemoglobinopathies and hemolytic anemias	76.1 (70.4 to 82.9)	79.8 (71.5 to 88.1)	-36.8 (-6.8 to 17.3)	-4.4 (-43.4 to -29.6)	2.4 (1.6 to 3.4)	2.1 (1.3 to 3.1)	-11.2 (-28.8 to 4.0)	-46.3 (-57.0 to -38.2)
Endocrine, metabolic, blood, and immune disorders	81.0 (72.1 to 89.3)	94.9 (84.0 to 104.6)	17.2 (4.2 to 34.5)	-24.2 (-33.1 to -14.0)	2.9 (1.9 to 4.2)	3.1 (2.1 to 4.5)	29.6 (-10.4 to 27.5)	-29.6 (-39.6 to -19.9)
Musculoskeletal disorders	-	-	-	-	40.8 (28.9 to 54.6)	76.2 (53.8 to 101.3)	87.0 (73.5 to 99.5)	2.7 (-4.0 to 8.8)
Rheumatoid arthritis	3.5 (3.3 to 3.8)	8.4 (8.0 to 8.9)	138.5 (117.2 to 160.8)	34.0 (22.9 to 48.5)	0.8 (0.6 to 1.1)	2.0 (1.4 to 2.7)	138.4 (112.8 to 168.2)	34.7 (20.7 to 51.1)
Osteoarthritis	41.2 (38.9 to 43.7)	76.9 (72.1 to 81.8)	86.8 (71.5 to 103.1)	3.6 (-4.3 to 12.1)	2.5 (1.8 to 3.4)	4.7 (3.3 to 6.4)	87.6 (71.7 to 105.1)	3.9 (-4.6 to 13.0)
Low back and neck pain	-	-	-	-	32.9 (23.0 to 44.4)	60.3 (41.6 to 81.7)	84.4 (68.6 to 97.9)	0.5 (-7.5 to 8.2)
Low back pain	212.8 (199.8 to 225.5)	391.0 (366.9 to 411.7)	83.7 (68.7 to 99.6)	1.1 (-7.0 to 8.8)	23.8 (16.3 to 33.3)	43.9 (29.7 to 61.1)	84.6 (69.3 to 101.9)	1.7 (-6.8 to 9.9)
Neck pain	92.6 (76.1 to 109.4)	165.5 (127.8 to 198.9)	76.7 (48.8 to 121.4)	-3.2 (-18.6 to 22.2)	9.1 (6.0 to 13.1)	16.4 (10.5 to 24.0)	77.7 (48.9 to 123.6)	-3.0 (-18.0 to 22.9)
Gout	1.6 (1.4 to 1.8)	3.0 (2.6 to 3.4)	89.4 (58.5 to 130.7)	3.9 (-13.3 to 25.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	91.4 (48.5 to 146.1)	5.6 (-18.2 to 34.4)
Other musculoskeletal disorders	49.8 (29.9 to 65.3)	99.3 (71.7 to 123.7)	97.3 (72.8 to 171.5)	6.6 (-6.0 to 42.0)	4.5 (2.5 to 6.9)	9.1 (5.8 to 13.3)	91.7 (73.6 to 177.2)	4.1 (-5.8 to 44.0)
Other non-communicable diseases	-	-	-	-	53.0 (35.3 to 76.3)	83.7 (56.3 to 121.4)	58.3 (49.9 to 64.9)	-6.9 (-10.6 to -3.8)
Congenital anomalies	-	-	-	-	3.4 (2.1 to 5.3)	5.7 (3.8 to 8.3)	69.4 (41.6 to 106.8)	13.1 (-5.1 to 38.1)
Neural tube defects	0.1 (0.1 to 0.2)	0.8 (0.7 to 0.9)	449.2 (308.8 to 591.0)	320.0 (210.6 to 432.6)	0.0 (0.0 to 0.1)	0.2 (0.2 to 0.3)	568.4 (356.6 to 815.2)	431.2 (262.6 to 619.1)
Congenital heart anomalies	1.6 (1.1 to 2.3)	12.1 (9.7 to 15.3)	659.7 (394.2 to 1,126.8)	475.7 (267.7 to 837.8)	0.1 (0.0 to 0.1)	0.4 (0.2 to 0.8)	469.8 (206.7 to 840.2)	325.3 (137.6 to 602.6)
Orofacial clefts	0.2 (0.1 to 0.4)	2.4 (1.7 to 3.0)	895.1 (530.7 to 1,625.4)	747.0 (421.5 to 1,408.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	823.6 (455.2 to 1,549.5)	675.8 (355.6 to 1,310.8)
Down syndrome	1.7 (1.3 to 2.2)	5.3 (4.4 to 6.7)	210.9 (124.8 to 333.2)	119.1 (57.3 to 207.4)	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.9)	222.8 (126.9 to 362.0)	128.5 (61.4 to 231.7)
Turner syndrome	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	166.0 (88.5 to 324.1)	75.4 (23.8 to 178.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	172.8 (90.3 to 346.8)	74.3 (21.3 to 185.6)
Klinefelter syndrome	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	65.3 (11.6 to 146.3)	4.7 (-24.4 to 56.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.9 (8.3 to 180.5)	3.6 (-36.1 to 60.0)
Chromosomal unbalanced rearrangements	2.4 (1.8 to 3.2)	7.2 (6.1 to 8.5)	197.2 (104.3 to 314.2)	109.9 (42.8 to 196.5)	0.3 (0.2 to 0.4)	0.9 (0.6 to 1.2)	209.4 (102.2 to 347.2)	120.8 (45.0 to 220.6)
Other congenital anomalies	21.1 (15.1 to 28.4)	28.0 (20.4 to 36.9)	33.2 (11.7 to 53.8)	-16.4 (-29.6 to -4.1)	2.8 (1.5 to 4.7)	3.5 (2.0 to 5.6)	25.4 (1.3 to 53.1)	-18.9 (-34.7 to -1.4)
Skin and subcutaneous diseases	-	-	-	-	20.0 (12.7 to 30.3)	33.4 (21.5 to 50.9)	67.5 (55.3 to 77.0)	0.1 (-7.3 to 5.1)
Dermatitis	188.5 (159.9 to 220.8)	321.3 (271.8 to 377.4)	70.5 (67.1 to 73.2)	0.0 (-0.0 to 0.1)	5.8 (3.7 to 8.4)	9.7 (6.1 to 14.0)	66.6 (56.9 to 72.9)	0.5 (-2.3 to 3.3)
Psoriasis	27.6 (21.9 to 33.6)	48.8 (38.6 to 59.9)	77.1 (74.8 to 79.3)	4.0 (-0.1 to 0.0)	2.2 (1.5 to 3.3)	4.0 (2.6 to 5.9)	78.3 (66.3 to 89.7)	0.6 (-4.6 to 6.1)
Cellulitis	0.9 (0.7 to 1.1)	1.5 (1.2 to 1.8)	59.0 (33.4 to 86.0)	0.8 (-17.4 to 19.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	60.3 (17.7 to 108.9)	0.8 (-23.0 to 27.2)
Pyoderma	7.2 (5.1 to 9.3)	4.5 (3.6 to 5.8)	-36.7 (-47.3 to -23.5)	-51.8 (-59.0 to -43.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-36.6 (-48.6 to -22.5)	-51.7 (-60.3 to -42.6)
Scabies	66.4 (53.6 to 80.2)	69.0 (59.6 to 82.2)	4.3 (-17.4 to 32.3)	-36.9 (-49.5 to -20.3)	1.7 (0.9 to 2.8)	1.8 (1.0 to 2.9)	4.3 (-17.3 to 32.0)	-36.9 (-49.2 to -19.7)
Fungal skin diseases	455.7 (352.8 to 562.7)	772.0 (600.2 to 946.5)	69.8 (64.2 to 74.5)	9.1 (-0.2 to 40.0)	2.6 (1.0 to 5.5)	4.4 (2.7 to 9.5)	69.9 (60.3 to 74.9)	0.2 (-0.5 to 0.6)
Viral skin diseases	101.7 (76.5 to 125.9)	152.3 (113.6 to 191.1)	50.1 (42.0 to 56.5)	0.1 (-2.0 to 2.1)	3.2 (1.8 to 5.0)	4.7 (2.7 to 7.5)	50.2 (40.9 to 58.3)	0.5 (-3.0 to 4.0)
Acne vulgaris	101.2 (62.9 to 137.1)	230.6 (146.1 to 302.8)	131.0 (39.8 to 273.5)	31.2 (-16.1 to 104.1)	1.1 (0.5 to 2.1)	2.5 (1.1 to 4.8)	130.8 (39.4 to 272.2)	31.4 (-16.2 to 106.3)
Alopecia areata	4.8 (4.3 to 5.4)	8.2 (7.2 to 9.2)	70.1 (43.8 to 100.3)	0.6 (-14.3 to 19.6)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	70.1 (38.3 to 108.4)	1.1 (-15.9 to 22.6)
Pruritus	0.6 (0.5 to 0.7)	1.1 (0.9 to 1.3)	69.8 (38.9 to 113.0)	2.5 (-22.3 to 24.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.2 (27.6 to 127.6)	-1.9 (-26.2 to 30.7)
Urticaria	29.2 (19.2 to 41.6)	59.5 (38.2 to 78.3)	108.3 (3.8 to 233.1)	12.4 (37.8 to 69.3)	1.7 (0.9 to 2.9)	3.6 (1.9 to 5.6)	109.2 (3.8 to 235.2)	13.6 (-39.0 to 71.6)
Decubitus ulcer	0.5 (0.4 to 0.5)	0.7 (0.6 to 0.9)	54.2 (21.3 to 98.0)	-0.8 (-27.0 to 38.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	51.5 (16.3 to 99.2)	-0.2 (-28.6 to 39.8)
Other skin and subcutaneous diseases	222.5 (154.8 to 319.2)	388.4 (268.9 to 555.4)	74.6 (66.7 to 82.1)	-0.6 (-3.4 to 2.0)	1.3 (0.6 to 2.7)	2.3 (1.0 to 4.7)	75.1 (67.2 to 83.2)	-0.3 (-3.2 to 2.6)
Sense organ diseases	-	-	-	-	25.1 (16.5 to 36.7)	37.2 (24.1 to 55.3)	68.2 (38.3 to 97.4)	-11.8 (-16.1 to -7.8)
Glaucoma	2.8 (1.8 to 3.9)	4.8 (3.3 to 6.7)	69.9 (19.7 to 142.5)	-5.8 (-34.9 to 31.3)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	70.2 (25.9 to 123.3)	-4.3 (-27.2 to 25.0)
Cataract	15.5 (9.5 to 21.9)	22.3 (15.1 to 30.7)	43.7 (20.7 to 77.7)	-20.4 (-31.4 to -6.6)	0.9 (0.5 to 1.5)	1.4 (0.8 to 2.2)	49.9 (27.2 to 74.6)	-17.9 (-29.8 to -7.5)
Macular degeneration	1.3 (0.7 to 2.1)	3.2 (2.0 to 4.7)	148.5 (61.6 to 280.6)	37.0 (-6.9 to 108.5)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	138.0 (60.8 to 250.7)	22.5 (-10.4 to 83.8)
Uncorrected refractive error	194.4 (175.2 to 213.4)	302.5 (276.3 to 328.9)	55.6 (38.4 to 75.7)	9.4 (-18.1 to 14.4)	3.5 (2.1 to 5.4)	5.2 (3.2 to 8.3)	49.9 (38.1 to 64.9)	-32.0 (-17.8 to -44.4)
Age-related and other hearing loss	480.6 (430.5 to 526.6)	756.9 (677.2 to 841.3)	57.6 (50.7 to 63.9)	-9.6 (-12.7 to -6.6)	16.6 (10.3 to 25.1)	24.7 (15.4 to 38.0)	48.5 (34.8 to 62.8)	-11.6 (-17.4 to -5.8)
Other vision loss	20.1 (16.0 to 24.7)	24.9 (19.1 to 30.7)	23.8 (8.6 to 41.7)	-24.8 (-36.0 to -14.2)	1.2 (0.8 to 1.7)	1.4 (0.9 to 2.1)	22.4 (7.7 to 39.5)	-2.7 (-33.5 to -15.1)
Other sense organ diseases	99.9 (94.6 to 105.5)	151.5 (144.2 to 158.7)	51.7 (40.6 to 63.1)	0.1 (-7.1 to 6.9)	2.7 (1.7 to 4.0)	4.0 (2.5 to 6.0)	51.7 (38.9 to 65.8)	0.5 (-7.1 to 8.1)
Oral disorders	-	-	-	-	4.4 (2.6 to 7.0)	7.4 (4.3 to 11.8)	65.9 (55.6 to 76.9)	-8.6 (-15.4 to -1.9)
Deciduous caries	519.6 (489.6 to 550.4)	666.7 (636.6 to 696.3)	28.6 (19.1 to 36.6)	1.9 (-5.5 to 8.3)	1.9 (0.1 to 4.0)	0.3 (0.1 to 0.5)	28.8 (17.6 to 40.0)	2.1 (-6.9 to 10.8)
Permanent caries	1,091.2 (990.6 to 1,186.0)	1,926.5 (1,693.7 to 2,133.4)	76.8 (51.9 to 105.2)	2.6 (-11.3 to 19.9)				

Appendix Table G.4 - Laos prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	31.2 (27.3 to 34.8)	39.2 (33.9 to 44.3)	25.7 (5.4 to 50.2)	-29.7 (-40.5 to -15.8)	0.9 (0.6 to 1.2)	1.1 (0.7 to 1.5)	26.0 (5.2 to 51.2)	26.0 (-40.5 to -15.3)
Other oral disorders	61.5 (57.7 to 65.1)	108.0 (100.7 to 114.1)	75.7 (61.0 to 91.4)	-0.7 (-7.9 to 7.9)	1.8 (1.1 to 2.7)	3.2 (2.0 to 4.8)	76.2 (60.1 to 93.6)	-0.3 (-8.0 to 8.3)
Injuries	-	-	-	-	25.3 (15.4 to 44.7)	29.0 (21.3 to 38.9)	20.0 (-18.0 to 50.2)	31.4 (-51.5 to -13.1)
Transport injuries	-	-	-	-	6.1 (4.6 to 7.9)	11.8 (9.0 to 15.3)	94.5 (85.4 to 104.6)	12.6 (8.1 to 17.8)
Road injuries	-	-	-	-	5.4 (4.1 to 7.0)	10.7 (8.1 to 13.9)	98.7 (87.8 to 109.6)	15.5 (10.0 to 21.2)
Pedestrian road injuries	-	-	-	-	0.8 (0.6 to 1.0)	1.6 (1.2 to 2.1)	103.5 (85.4 to 122.7)	21.5 (13.1 to 30.4)
Cyclist road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.8)	66.3 (53.8 to 81.0)	2.1 (-5.2 to 10.6)
Motorcyclist road injuries	-	-	-	-	2.4 (1.8 to 3.1)	4.1 (3.1 to 5.4)	74.8 (61.4 to 94.2)	2.3 (-4.6 to 12.4)
Motor vehicle road injuries	-	-	-	-	1.9 (1.4 to 2.4)	4.3 (3.3 to 5.6)	131.8 (113.8 to 154.2)	32.5 (22.8 to 44.1)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	73.3 (60.3 to 87.6)	-3.7 (-9.7 to 3.3)
Other transport injuries	-	-	-	-	0.7 (0.5 to 0.9)	1.1 (0.8 to 1.5)	62.7 (52.0 to 74.0)	-7.3 (-13.5 to -1.5)
Unintentional injuries	-	-	-	-	6.6 (5.0 to 8.5)	11.5 (8.8 to 14.9)	74.5 (67.4 to 81.0)	1.8 (-1.6 to 5.2)
Falls	-	-	-	-	1.6 (1.2 to 2.0)	3.1 (2.3 to 4.1)	97.7 (87.6 to 108.5)	12.6 (7.0 to 18.6)
Drowning	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.6)	16.6 (4.6 to 30.4)	-29.3 (-35.3 to -22.4)
Fire, heat, and hot substances	-	-	-	-	0.7 (0.5 to 0.8)	0.7 (0.5 to 0.9)	6.0 (-3.9 to 16.9)	-37.6 (-42.5 to -32.1)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	23.9 (3.3 to 46.9)	-27.1 (-37.5 to -16.1)
Exposure to mechanical forces	-	-	-	-	2.8 (2.1 to 3.7)	4.7 (3.5 to 6.2)	67.4 (54.4 to 78.7)	-4.2 (-9.9 to 1.3)
Unintentional firearm injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	44.2 (33.3 to 55.8)	-19.3 (-24.6 to -13.2)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	78.5 (60.9 to 98.9)	7.5 (-1.8 to 17.9)
Other exposure to mechanical forces	-	-	-	-	2.6 (1.9 to 3.4)	4.3 (3.2 to 5.7)	68.8 (55.1 to 80.8)	-3.3 (-9.7 to 2.7)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	74.6 (66.5 to 83.3)	2.2 (-2.6 to 7.8)
Animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	52.7 (42.1 to 65.1)	-9.2 (-14.5 to -3.2)
Venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	54.4 (37.4 to 73.2)	-10.1 (-18.6 to -1.4)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	52.0 (37.8 to 67.2)	-8.2 (-14.2 to -1.1)
Foreign body	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	86.1 (75.9 to 96.2)	9.8 (4.6 to 14.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.6 (63.5 to 107.9)	14.6 (5.4 to 25.1)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	71.1 (60.6 to 82.2)	0.4 (-4.5 to 6.0)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	99.8 (86.3 to 111.5)	12.9 (4.8 to 19.8)
Other unintentional injuries	-	-	-	-	0.8 (0.6 to 1.1)	2.0 (1.5 to 2.6)	145.8 (123.8 to 166.2)	39.8 (28.4 to 50.7)
Self-harm and interpersonal violence	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	14.0 (8.2 to 21.2)	-35.4 (-38.2 to -32.0)
Self-harm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	8.4 (0.4 to 17.2)	-41.2 (-45.1 to -36.8)
Interpersonal violence	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.3)	16.4 (9.1 to 25.6)	-32.0 (-36.1 to -27.8)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.8 (0.8 to 18.3)	-33.8 (-38.5 to -29.2)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	30.3 (16.4 to 44.0)	-25.7 (-33.3 to -18.6)
Assault by other means	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	13.8 (4.8 to 26.2)	-33.7 (-38.4 to -27.6)
Forces of nature, war, and legal intervention	-	-	-	-	12.3 (3.9 to 31.3)	5.3 (1.8 to 12.6)	-56.6 (-63.4 to -50.4)	-69.4 (-75.2 to -63.9)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.3)	602.4 (325.7 to 1,248.0)	241.7 (122.0 to 529.0)
Collective violence and legal intervention	-	-	-	-	12.3 (3.9 to 31.2)	5.1 (1.7 to 12.4)	-57.7 (-64.4 to -51.7)	-69.9 (-75.7 to -64.4)

Appendix Table G.4 - Latvia prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
All causes	-	-	-	-	296.0 (219.2 to 383.7)	250.5 (186.5 to 325.3)	-15.4 (-17.4 to -13.5)	-4.7 (-4.5 to -0.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	18.9 (13.1 to 26.7)	12.3 (8.7 to 17.0)	-35.2 (-41.1 to -27.6)	-4.7 (-13.3 to 5.8)
HIV/AIDS and tuberculosis	-	-	-	-	0.9 (0.6 to 1.3)	1.0 (0.7 to 1.5)	5.8 (-11.3 to 46.5)	33.4 (12.1 to 83.6)
Tuberculosis	2.9 (2.8 to 3.1)	2.0 (1.9 to 2.2)	-30.8 (-34.2 to -27.1)	-13.4 (-17.5 to -8.9)	0.9 (0.6 to 1.2)	0.6 (0.4 to 0.8)	-30.6 (-36.6 to -24.4)	-12.7 (-20.3 to -4.8)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.1)	0.4 (0.2 to 0.8)	75.2 (38.3 to 155.8)	98.9 (51.8 to 202.6)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	518.9 (243.3 to 1,084.4)	684.5 (339.9 to 1,394.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	518.9 (242.9 to 1,085.0)	684.5 (339.5 to 1,397.6)
HIV/AIDS resulting in other diseases	0.3 (0.2 to 0.7)	3.0 (2.2 to 4.6)	825.7 (452.0 to 1,583.1)	1,067.7 (598.6 to 2,019.0)	0.0 (0.0 to 0.1)	0.4 (0.2 to 0.8)	767.1 (381.8 to 1,611.9)	994.1 (509.9 to 2,084.3)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	2.9 (2.0 to 4.3)	1.9 (1.3 to 2.7)	-35.9 (-39.9 to -31.6)	-11.0 (-16.7 to -5.2)
Diarrheal diseases	4.4 (4.0 to 4.8)	3.2 (2.9 to 3.5)	-27.1 (-35.7 to -18.2)	-1.7 (-13.0 to 11.2)	0.0 (0.5 to 1.0)	0.5 (0.3 to 0.7)	-8.1 (-17.3 to -1.9)	-14.9 (-14.2 to 13.4)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.0 (-53.0 to -11.5)	-14.0 (-37.1 to 20.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.0 (-53.0 to -11.5)	-14.0 (-37.1 to 20.7)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.9 (-56.6 to -1.4)	-12.6 (-37.6 to 32.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.9 (-56.7 to -1.2)	-12.6 (-37.7 to 32.8)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Lower respiratory infections	0.6 (0.5 to 0.6)	0.3 (0.3 to 0.3)	-42.3 (-45.4 to -38.7)	-8.5 (-13.7 to -2.5)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-42.6 (-50.1 to -32.4)	-9.1 (-21.4 to 8.2)
Upper respiratory infections	89.3 (81.1 to 97.5)	61.3 (55.5 to 67.6)	-31.5 (-39.2 to -21.9)	-4.4 (-14.8 to 9.6)	1.0 (0.6 to 1.7)	0.7 (0.4 to 1.2)	-31.8 (-39.7 to -21.5)	-4.4 (-15.1 to 10.1)
Otitis media	35.6 (33.1 to 38.4)	22.5 (21.0 to 24.1)	-36.9 (-41.8 to -31.2)	-11.3 (-17.8 to -4.5)	0.7 (0.4 to 1.1)	0.4 (0.3 to 0.7)	-38.3 (-43.5 to -32.7)	-12.1 (-19.1 to -4.3)
Meningitis	-	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.1)	-77.0 (-83.5 to -68.9)	-69.1 (-78.4 to -57.7)
Pneumococcal meningitis	1.0 (0.6 to 1.6)	0.3 (0.2 to 0.4)	-74.3 (-78.7 to -67.7)	-68.9 (-74.5 to -61.2)	0.0 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-75.7 (-83.2 to -65.5)	-68.5 (-78.7 to -54.8)
H influenzae type B meningitis	0.6 (0.2 to 1.4)	0.1 (0.0 to 0.3)	-81.5 (-90.0 to -72.9)	-75.1 (-86.1 to -59.1)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-81.0 (-91.5 to -65.8)	-72.3 (-87.8 to -48.5)
Meningococcal meningitis	0.2 (0.1 to 0.6)	0.1 (0.0 to 0.1)	-76.4 (-85.9 to -66.4)	-69.9 (-81.0 to -53.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-75.6 (-87.1 to -62.2)	-67.6 (-83.0 to -45.6)
Other meningitis	0.4 (0.2 to 0.8)	0.0 (0.0 to 0.2)	-73.6 (-81.1 to -65.5)	-66.8 (-75.4 to -53.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-73.3 (-82.4 to -57.2)	-65.0 (-77.4 to -42.4)
Encephalitis	0.8 (0.4 to 2.1)	0.7 (0.3 to 1.9)	-13.5 (-33.2 to -6.8)	-18.6 (-18.8 to 12.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-18.8 (-33.0 to 1.8)	-6.8 (-17.9 to 25.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-71.7 (-96.4 to 112.3)	-61.4 (-94.3 to 165.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-71.7 (-96.4 to 114.4)	-61.4 (-94.4 to 166.7)
Whooping cough	0.5 (0.4 to 0.7)	0.1 (0.1 to 0.2)	-73.1 (-74.3 to -71.8)	-54.5 (-56.6 to -52.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-73.1 (-77.7 to -68.0)	-54.5 (-62.3 to -45.9)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.2 (-77.9 to -59.3)	-54.7 (-70.7 to -40.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.3 (-78.4 to -60.1)	-54.9 (-72.1 to -39.5)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.4 (-100.0 to -81.1)	-98.9 (-100.0 to -67.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.4 (-100.0 to -81.0)	-98.9 (-100.0 to -67.1)
Varicella and herpes zoster	1.5 (1.4 to 1.7)	1.1 (1.0 to 1.2)	-27.5 (-36.8 to -16.9)	-1.4 (-10.8 to 9.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-15.7 (-34.3 to 9.8)	-2.2 (-21.9 to 24.5)
Neglected tropical diseases and malaria	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-81.1 (-87.8 to -70.4)	-77.3 (-85.4 to -65.5)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.1 (-77.2 to 164.4)	-8.9 (-66.3 to 288.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.7 (-76.9 to 173.0)	-6.6 (-66.4 to 302.1)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.2 (0.1 to 0.3)	0.0 (0.0 to 0.0)	-91.3 (-96.7 to -69.2)	-90.4 (-96.4 to -68.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-89.9 (-96.4 to -63.7)	-89.1 (-96.1 to -61.7)
Cystic echinococcosis	0.5 (0.5 to 0.7)	0.1 (0.1 to 0.2)	-74.7 (-78.4 to -70.1)	-69.0 (-73.6 to -62.9)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-74.4 (-80.4 to -67.5)	-68.4 (-75.0 to -60.0)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.2 (-59.5 to -33.7)	-28.0 (-51.2 to -17.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.2 (-59.5 to -33.7)	-28.0 (-51.2 to -17.0)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-60.6 (-72.7 to -35.0)	-49.2 (-65.6 to -18.7)
Maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-46.9 (-57.5 to -34.2)	-26.8 (-41.1 to -9.1)
Maternal hemorrhage	0.3 (0.3 to 0.4)	0.2 (0.1 to 0.3)	-38.6 (-58.7 to -11.7)	-14.2 (-41.9 to 23.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.5 (-68.1 to 4.0)	-13.9 (-54.3 to 42.3)
Maternal sepsis and other maternal infections	1.3 (0.8 to 2.0)	0.5 (0.3 to 0.8)	-59.7 (-70.5 to -46.1)	-46.0 (-58.9 to -28.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.2 (-76.1 to -49.0)	-51.4 (-67.7 to -30.6)
Maternal hypertensive disorders	0.4 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-38.7 (-46.3 to -29.8)	-16.1 (-26.6 to -3.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.1 (-53.4 to -20.0)	-16.9 (-36.1 to 9.6)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.4 (-58.3 to -41.3)	-33.0 (-42.5 to -18.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.4 (-58.3 to -41.2)	-33.0 (-42.5 to -18.6)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.6 (-37.5 to -18.7)	-1.9 (-14.3 to 12.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.5 (-56.5 to 25.9)	2.7 (-41.4 to 79.6)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Neonatal disorders	-	-	-	-	4.1 (2.7 to 5.9)	2.5 (1.6 to 3.6)	-41.0 (-58.4 to -5.4)	-16.2 (-40.6 to 34.3)
Preterm birth complications	10.4 (7.8 to 13.6)	8.5 (6.5 to 11.3)	-18.2 (-30.8 to -2.0)	11.8 (5.7 to 34.7)	1.1 (0.8 to 1.6)	1.1 (0.7 to 1.4)	-10.6 (-31.6 to 19.7)	26.7 (-1.4 to 70.6)
Neonatal encephalopathy due to birth asphyxia and trauma	3.1 (1.5 to 6.7)	1.2 (0.6 to 2.7)	-63.0 (-79.5 to -27.3)	-47.5 (-70.5 to 5.8)	0.7 (0.4 to 1.2)	0.3 (0.2 to 0.5)	-59.9 (-78.5 to -8.1)	-41.3 (-68.9 to 33.4)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.1 (-7.2 to 11.7)	66.0 (46.6 to 76.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.4 (-21.2 to 43.5)	61.8 (21.4 to 126.7)
Hemolytic disease and other neonatal jaundice	2.0 (1.0 to 4.0)	1.4 (0.7 to 3.0)	-33.3 (-74.0 to 74.8)	-33.8 (-63.1 to 143.2)	0.8 (0.4 to 1.4)	0.5 (0.2 to 1.1)	-31.4 (-72.2 to 74.1)	-2.9 (-59.1 to 146.1)
Other neonatal disorders	-	-	-	-	1.4 (0.6 to 2.4)	0.6 (0.3 to 1.2)	-65.1 (-81.3 to 65.4)	-50.4 (-73.6 to 134.6)
Nutritional deficiencies	-	-	-	-	9.8 (6.4 to 14.5)	6.2 (4.1 to 9.1)	-36.5 (-42.6 to -29.1)	-1.2 (-10.6 to 9.8)
Protein-energy malnutrition	2.5 (1.0 to 5.5)	1.0 (0.4 to 2.1)	-58.7 (-88.2 to 27.7)	-29.9 (-80.0 to 115.4)	0.3 (0.1 to 0.8)	0.1 (0.0 to 0.3)	-30.3 (-87.8 to 31.0)	-30.7 (-79.4 to 121.8)
Iodine deficiency	46.6 (22.2 to 72.4)	23.1 (11.6 to 36.9)	-51.2 (-79.6 to 26.3)	-51.2 (-71.8 to 63.1)	0.8 (0.3 to 1.5)	0.4 (0.2 to 0.8)	-51.4 (-79.8 to 25.8)	-35.8 (-71.6 to 62.7)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron-deficiency anemia	293.6 (288.5 to 299.2)	202.8 (198.0 to 207.6)	-30.9 (-32.8 to -28.9)	0.9 (-1.6 to 3.5)	8.4 (5.6 to 12.3)	5.5 (3.6 to 8.0)	-35.1 (-38.1 to -32.9)	0.8 (-2.9 to 4.0)

Appendix Table G.4 - Latvia prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.2 (0.1 to 0.5)	0.2 (0.1 to 0.5)	7.2 (-73.4 to 310.5)	82.7 (-54.7 to 601.6)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.0 (0.6 to 1.6)	0.6 (0.4 to 1.1)	-36.8 (-45.8 to -26.6)	-6.4 (-23.6 to 10.9)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.5 (0.2 to 0.8)	0.3 (0.2 to 0.6)	-28.7 (-36.6 to -21.4)	-5.4 (-16.5 to 6.2)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-29.9 (-39.3 to -18.6)	-31.2 (-41.3 to -19.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.5 to -6.4 (-48.9 to -7.5)	-31.4 (-48.9 to -7.5)
Chlamydial infection	65.1 (56.3 to 73.5)	48.9 (39.2 to 51.5)	-31.0 (-42.8 to -16.4)	-2.1 (-19.2 to 19.7)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-31.5 (-44.6 to -17.5)	76.2 (21.7 to 18.3)
Gonococcal infection	14.5 (11.5 to 17.6)	8.4 (6.9 to 10.5)	-41.3 (-55.1 to -23.7)	-13.3 (-34.0 to 13.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-42.7 (-57.6 to -22.3)	-15.1 (-37.8 to 14.8)
Trichomoniasis	33.1 (25.4 to 46.1)	23.8 (17.5 to 31.2)	-26.7 (-54.5 to 4.2)	2.7 (-39.4 to 49.9)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-28.0 (-57.2 to 6.2)	1.0 (-42.9 to 54.1)
Genital herpes	479.3 (465.2 to 494.2)	411.7 (401.0 to 422.5)	-14.1 (-17.3 to -10.8)	-1.0 (-4.8 to 3.1)	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.3)	-15.4 (-20.4 to -10.8)	-0.7 (-6.1 to 5.3)
Other sexually transmitted diseases	0.9 (0.7 to 1.1)	0.5 (0.4 to 0.6)	-46.6 (-52.8 to -38.6)	-27.8 (-36.3 to -17.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.6 (-54.4 to -19.7)	-16.8 (-38.5 to 9.9)
Hepatitis	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-39.4 (-47.8 to -29.6)	-19.7 (-30.4 to -8.1)
Hepatitis A	2.3 (2.3 to 2.4)	1.5 (1.4 to 1.5)	-37.5 (-37.8 to -37.3)	-9.7 (-10.8 to -8.6)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-32.7 (-40.2 to -25.4)	-7.0 (-17.1 to 3.5)
Hepatitis B	102.7 (96.0 to 109.4)	49.4 (46.3 to 52.5)	-51.8 (-56.0 to -47.9)	-38.2 (-43.9 to -32.9)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-47.7 (-63.0 to -29.1)	-35.6 (-53.3 to -11.5)
Hepatitis C	66.3 (59.8 to 71.6)	43.1 (39.6 to 47.4)	-35.2 (-42.3 to -25.2)	-25.3 (-34.0 to -14.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.2 (-54.7 to -5.5)	-27.9 (-45.8 to 2.5)
Hepatitis E	-	-	-	-	19.3 (19.5 to 80.2)	-	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	10.7 (8.1 to 12.9)	6.5 (5.0 to 7.9)	-39.4 (-52.8 to -18.9)	-0.1 (-25.5 to 36.4)	0.4 (0.2 to 0.6)	0.2 (0.1 to 0.3)	-44.4 (-63.3 to -17.8)	-3.7 (-38.5 to 45.2)
Non-communicable diseases	-	-	-	-	251.0 (184.5 to 323.7)	224.4 (165.3 to 291.2)	-10.6 (-12.9 to -8.3)	2.2 (-0.4 to 4.8)
Neoplasms	-	-	-	-	3.1 (2.3 to 4.0)	4.0 (2.9 to 5.2)	27.6 (6.2 to 47.0)	27.6 (1.8 to 40.5)
Esophageal cancer	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	20.9 (-15.8 to 60.8)	22.2 (-14.2 to 63.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.2 (-22.2 to 63.1)	16.8 (-20.4 to 62.6)
Stomach cancer	1.9 (1.6 to 2.3)	1.3 (1.1 to 1.5)	-32.5 (-42.5 to -20.5)	-36.0 (-46.1 to -24.9)	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-34.7 (-45.1 to -21.5)	-38.3 (-48.0 to -26.3)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.2 (-29.6 to 68.3)	13.5 (-34.1 to 56.2)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.3 (-41.8 to 138.3)	19.6 (-42.1 to 135.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.2 (-41.3 to 108.1)	14.3 (-42.5 to 102.4)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	150.2 (31.9 to 330.0)	133.5 (22.0 to 300.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	134.3 (31.8 to 266.9)	116.7 (21.6 to 236.5)
Liver cancer due to alcohol use	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	5.0 (-43.5 to 83.1)	-3.8 (-48.3 to 66.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.1 (-42.7 to 53.7)	-7.3 (-48.1 to 38.3)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.3 (-74.8 to 15.2)	-49.1 (-76.1 to 15.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.3 (-73.5 to -4.1)	-51.5 (-74.8 to -11.7)
Larynx cancer	0.5 (0.3 to 0.7)	0.3 (0.2 to 0.5)	-28.2 (-49.7 to 9.7)	-23.8 (-46.2 to 14.8)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-26.1 (-45.3 to 4.0)	-22.5 (-42.5 to 8.1)
Tracheal, bronchus and lung cancer	1.8 (1.6 to 2.0)	1.5 (1.4 to 1.7)	-14.0 (-26.3 to 0.4)	-16.3 (-28.6 to -2.5)	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-15.4 (-27.2 to -1.6)	-17.5 (-29.2 to -5.0)
Breast cancer	5.8 (4.9 to 7.2)	8.9 (7.6 to 10.4)	54.0 (20.4 to 87.7)	49.8 (18.2 to 82.1)	0.4 (0.3 to 0.6)	0.5 (0.4 to 0.7)	24.0 (8.1 to 48.4)	21.5 (-9.3 to 45.3)
Cervical cancer	1.7 (1.4 to 2.0)	0.9 (0.7 to 1.2)	-44.3 (-60.3 to -26.9)	-41.3 (-58.0 to -22.4)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-43.3 (-62.8 to -24.0)	-40.4 (-60.3 to -20.3)
Uterine cancer	2.0 (1.7 to 2.5)	2.0 (1.2 to 2.7)	0.3 (-45.4 to 37.5)	3.1 (-44.0 to 39.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	2.3 (-45.6 to 39.8)	2.3 (-44.4 to 39.7)
Prostate cancer	2.9 (2.3 to 3.7)	6.1 (4.5 to 7.7)	112.7 (47.6 to 195.1)	94.1 (35.5 to 173.2)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	146.8 (49.0 to 242.3)	123.7 (34.5 to 209.5)
Colon and rectum cancer	3.8 (3.6 to 4.1)	5.9 (5.4 to 6.5)	53.9 (36.9 to 70.7)	39.5 (24.6 to 54.7)	0.3 (0.3 to 0.4)	0.5 (0.4 to 0.7)	48.1 (29.7 to 68.0)	33.1 (17.1 to 50.2)
Lip and oral cavity cancer	0.7 (0.6 to 0.8)	1.0 (0.6 to 1.4)	60.8 (-26.2 to 116.8)	64.6 (-26.6 to 122.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	59.1 (-27.9 to 114.3)	62.0 (-27.7 to 118.6)
Nasopharynx cancer	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-65.8 (-79.8 to -15.3)	-63.3 (-78.3 to -8.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-66.0 (-78.4 to -16.0)	-64.4 (-77.0 to -9.0)
Other pharynx cancer	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	5.8 (-45.1 to 89.4)	13.3 (-41.5 to 102.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.3 (-44.0 to 69.3)	9.3 (-40.7 to 79.0)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-18.4 (-40.8 to 6.6)	-26.2 (-45.7 to -4.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.8 (-43.5 to 1.5)	-29.1 (-47.9 to -8.0)
Pancreatic cancer	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.4)	33.5 (8.1 to 63.4)	22.0 (-1.0 to 48.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	27.4 (0.2 to 56.4)	17.9 (-6.4 to 44.8)
Malignant skin melanoma	0.8 (0.6 to 1.2)	1.0 (0.6 to 1.3)	33.4 (-22.9 to 74.3)	37.9 (-20.0 to 80.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	30.4 (-25.1 to 70.0)	33.6 (-23.6 to 72.1)
Non-melanoma skin cancer	1.9 (1.5 to 2.4)	3.3 (2.7 to 4.0)	70.8 (29.6 to 139.9)	48.4 (13.9 to 105.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	106.1 (30.2 to 319.0)	75.3 (14.4 to 243.5)
Ovarian cancer	0.8 (0.6 to 1.0)	1.0 (0.8 to 1.2)	37.9 (-21.3 to 75.0)	38.3 (-18.4 to 75.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	37.8 (-24.8 to 83.9)	37.2 (-23.1 to 83.4)
Testicular cancer	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-6.9 (-59.3 to 80.9)	21.2 (-50.5 to 144.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.4 (-59.8 to 63.2)	12.7 (-52.3 to 116.8)
Kidney cancer	1.0 (0.8 to 1.3)	2.2 (1.8 to 2.5)	120.4 (67.8 to 209.0)	118.6 (68.7 to 199.2)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	112.8 (59.2 to 206.2)	109.6 (56.2 to 195.5)
Bladder cancer	1.3 (1.1 to 1.8)	2.2 (1.6 to 2.7)	76.5 (-2.1 to 121.9)	62.5 (-9.8 to 102.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	79.5 (-3.4 to 126.1)	59.4 (-11.5 to 104.3)
Brain and nervous system cancer	0.4 (0.4 to 0.6)	0.6 (0.4 to 0.7)	42.9 (-24.8 to 84.1)	65.1 (-14.8 to 116.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	38.8 (-26.2 to 84.5)	57.8 (-17.1 to 108.4)
Thyroid cancer	0.8 (0.6 to 1.1)	0.9 (0.6 to 1.2)	27.5 (-23.8 to 76.2)	38.0 (-17.0 to 92.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	24.7 (-26.2 to 77.5)	33.1 (-21.2 to 88.2)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.7 (-48.7 to 44.5)	1.3 (-49.3 to 39.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.1 (-46.5 to 60.5)	12.7 (-47.1 to 55.0)
Hodgkin lymphoma	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-20.2 (-51.5 to 5.7)	20.2 (-41.0 to 38.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-22.5 (-54.0 to 3.0)	-2.8 (-44.5 to 32.3)
Non-Hodgkin lymphoma	0.7 (0.5 to 1.1)	1.2 (0.5 to 1.4)	88.1 (-34.6 to 144.9)	82.4 (-31.5 to 139.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	80.0 (-37.5 to 137.1)	75.0 (-35.0 to 131.2)
Multiple myeloma	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	36.5 (-23.7 to 117.2)	31.3 (-26.0 to 109.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	29.2 (-30.1 to 126.5)	25.1 (-31.2 to 115.6)
Leukemia	1.2 (1.1 to 1.4)	1.2 (1.0 to 1.4)	0.4 (-23.4 to 20.5)	2.2 (-24.4 to 24.6)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	1.4 (-20.5 to 23.1)	0.4 (-22.6 to 22.0)
Other neoplasms	2.2 (1.9 to 2.7)	4.2 (3.3 to 5.0)	92.5 (46.0 to 135.6)	92.2 (46.5 to 132.6)	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.4)	79.3 (30.8 to 123.3)	76.6 (32.3 to 118.8)
Cardiovascular diseases	-	-	-	-	3.2 (2.2 to 4.4)	2.9 (2.1 to 3.9)	-8.9 (-25.7 to 12.4)	-13.2 (-28.8 to 6.3)
Rheumatic heart disease	0.8 (0.8 to 0.9)	0.8 (0.7 to 0.8)	-10.1 (-18.0 to -1.8)	-6.0 (-13.9 to 2.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-5.9 (-26.4 to 27.2)	-5.6 (-25.9 to 27.9)
Ischemic heart disease	41.9 (35.7 to 50.9)	40.7 (36.6 to 46.4)	-2.4 (-23.0 to 21.7)	-11.3 (-29.1 to 10.1)	1.6 (0.9 to 2.4)	1.2 (0.8 to 1.8)	-21.3 (-47.0 to 15.1)	-28.8 (-51.7 to 4.2)
Cerebrovascular disease	-	-	-	-	1.1 (0.6 to 1.3)	1.0 (0.7 to 1.4)	6.8 (-11.6 to 32.5)	9.4 (-8.6 to 35.6)
Ischemic stroke	6.1 (5.2 to 7.1)	6.6 (5.5 to 7.6)	8.0 (-9.8 to 33.2)	9.2 (-8.9 to 34.9)	0.9 (0.6 to 1.2)	1.0 (0.7 to 1.4)	7.4 (-11.7 to 32.4)	9.4 (-9.4 to 35.2)
Hemorrhagic stroke	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.5)	5.7 (-40.5 to 57.6)	14.1 (-33.5 to 68.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	4.6 (-41.1 to 53.7)	13.1 (-34.6 to 67.9)
Hypertensive heart disease	1.0 (0.8 to 1.1)	1.0 (0.9 to 1.1)	2.9 (-13.7 to 24.6)	-11.7 (-25.5 to 6.9)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	2.7 (-18.6 to 29.3)	-11.0 (-29.6 to 11.4)
Cardiomyopathy and myocarditis	1.3 (1.1 to 1.6)	1.2 (1.1 to 1.3)	-8.0 (-22.6 to 8.4)	-11.8 (-25.8 to 3.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-5.3 (-23.3 to 14.8)	-10.6 (-27.2 to 8.0)
Atrial fibrillation and flutter	0.5 (0.3 to 0.7)	1.6 (1.1 to 2.3)	204.4 (105.6 to 514.9)	204.4 (90.3 to 451.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	226.4 (97.1 to 508.5)	204.3 (83.6 to 456.6)
Peripheral vascular disease	99.2 (81.4 to 123.8)	107.7 (85.9 to 137.1)	7.4 (-21.0 to 56.8)	0.4 (-24.7 to 46.6)	0.2 (0.1 to 0.3)	0.2 (0.0 to 0.2)	-33.2 (-74.9 to 64.3)	-48.5 (-80.9 to 26.5)
Endocarditis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	446.3 (285.1 to 709.3)	542.3 (353.8 to 866.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	244.5 (129.9 to 439.4)	310.4 (173.5 to 531.3)
Other cardiovascular and circulatory diseases	2.5 (1.0 to 5.0)	1.9 (0.7 to 4.2)	-25.0 (-78.0 to 146.8)	-28.7 (-79.1 to 140.2)	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.3)	-24.6 (-77.8 to 151.4)	-28.3 (-79.0 to 143.7)
Chronic respiratory diseases	-	-	-	-	10.7 (7.3 to 14.5)	9.3 (6.3 to 12.7)	-13.9 (-21.3 to -3.2)	0.3 (-7.7 to 11.1)
Chronic obstructive pulmonary disease	102.9 (98.2 to 107.6)	97.5 (92.7 to 102.3)	-5.3 (-8.0 to -2.4)	0.1 (-2.7 to 3.0)	6.4 (4.2 to 9.0)	5.9 (3.8 to 8.3)	-8.2 (-19.0 to 9.6)	-1.9 (-13.6 to 16.7)
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.5 (-27.9 to -21.4)	-22.8 (-25.8 to -19.8)

Appendix Table G.4 - Latvia prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.4 (-13.8 to -3.9)	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.0 (-14.8 to -4.2)	-
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.3 (-34.6 to -28.2)	-28.8 (-31.9 to -25.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.5 (-34.7 to -28.2)	-28.9 (-32.1 to -25.8)
Asthma	94.8 (87.7 to 102.1)	72.2 (66.6 to 77.8)	-23.7 (-31.8 to -15.4)	-2.7 (-9.7 to 14.9)	2.2 (2.7 to 5.9)	3.2 (2.0 to 4.5)	-34.4 (-32.8 to -15.4)	-3.2 (-9.7 to 16.0)
Interstitial lung disease and pulmonary sarcoidosis	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.3)	21.8 (-11.5 to 68.4)	46.6 (6.7 to 104.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	20.8 (-11.9 to 65.2)	44.2 (5.9 to 98.4)
Other chronic respiratory diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	35.7 (3.7 to 80.8)	42.6 (9.4 to 89.1)
Cirrhosis	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	20.6 (7.0 to 37.3)	44.0 (26.7 to 64.0)
Cirrhosis due to hepatitis B	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-6.7 (-50.1 to 44.1)	11.0 (-39.4 to 69.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	7.2 (-48.6 to 53.6)	10.5 (-38.2 to 81.1)
Cirrhosis due to hepatitis C	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.6)	134.7 (58.6 to 321.6)	180.7 (84.9 to 398.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	131.7 (45.1 to 371.9)	177.4 (73.9 to 451.9)
Cirrhosis due to alcohol use	0.5 (0.4 to 0.5)	1.1 (0.4 to 0.6)	16.7 (-25.9 to 27.9)	0.1 (-15.8 to 48.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.8 (-28.6 to 34.7)	16.7 (-18.8 to 56.4)
Cirrhosis due to other causes	0.2 (0.2 to 0.2)	0.2 (0.1 to 0.2)	-8.8 (-38.5 to 22.2)	21.5 (-19.9 to 60.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.9 (-44.3 to 38.8)	21.0 (-27.7 to 82.0)
Digestive diseases	-	-	-	-	3.5 (2.5 to 4.5)	3.0 (2.2 to 4.0)	-14.4 (-19.7 to -8.6)	-2.6 (-8.9 to 4.5)
Peptic ulcer disease	22.1 (21.5 to 22.7)	10.0 (9.7 to 10.4)	-54.6 (-56.5 to -52.6)	-56.1 (-58.2 to -53.9)	0.8 (0.5 to 1.1)	0.3 (0.2 to 0.5)	-57.0 (-60.9 to -53.1)	-59.4 (-63.2 to -55.1)
Gastritis and duodenitis	8.1 (7.7 to 8.4)	5.7 (4.9 to 6.2)	-29.2 (-37.7 to -23.5)	-12.9 (-29.6 to -5.6)	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-38.3 (-46.9 to -29.4)	-16.3 (-32.3 to -0.4)
Appendicitis	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-33.8 (-42.4 to -23.6)	0.2 (-13.8 to 16.7)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-33.4 (-50.7 to -10.0)	0.5 (-27.5 to 40.3)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.7 (7.0 to 25.9)	25.4 (15.7 to 33.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.7 (-6.0 to 38.4)	23.4 (8.0 to 41.1)
Inguinal, femoral, and abdominal hernia	6.1 (5.4 to 7.0)	5.0 (4.4 to 5.8)	-17.3 (-27.8 to -4.1)	-19.7 (-29.2 to -8.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-19.2 (-27.8 to -3.4)	-8.1 (-28.8 to -6.5)
Inflammatory bowel disease	5.6 (5.3 to 5.8)	6.0 (5.8 to 6.2)	6.9 (1.2 to 13.1)	21.9 (15.5 to 29.2)	1.2 (0.8 to 1.6)	1.3 (0.9 to 1.7)	6.1 (-1.2 to 14.3)	22.1 (13.4 to 31.7)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.2 (-25.3 to 57.2)	-4.3 (-31.8 to 35.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.4 (-37.7 to 82.6)	-3.6 (-38.6 to 54.7)
Gallbladder and biliary diseases	4.6 (4.1 to 5.2)	4.0 (3.5 to 4.5)	-13.9 (-28.0 to 2.2)	-9.7 (-24.2 to 6.9)	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.6)	-14.3 (-29.1 to 3.7)	-9.7 (-25.0 to 7.9)
Pancreatitis	1.4 (1.4 to 1.5)	1.6 (1.5 to 1.7)	11.4 (4.4 to 18.9)	25.8 (17.6 to 34.1)	0.5 (0.3 to 0.6)	0.5 (0.3 to 0.6)	11.3 (-1.2 to 24.3)	26.7 (12.1 to 42.0)
Other digestive diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	55.5 (8.2 to 102.1)	76.9 (23.3 to 131.2)
Neurological disorders	-	-	-	-	30.2 (20.3 to 41.8)	28.9 (19.8 to 39.1)	-4.4 (-13.2 to 7.3)	10.7 (0.4 to 22.9)
Alzheimer disease and other dementias	29.8 (25.8 to 33.8)	37.8 (32.1 to 43.2)	27.5 (2.3 to 52.4)	1.1 (-19.5 to 21.0)	4.4 (3.1 to 5.8)	5.7 (4.1 to 7.4)	30.1 (3.7 to 56.2)	1.8 (-19.0 to 21.9)
Parkinson disease	1.6 (1.4 to 1.8)	1.8 (1.6 to 2.1)	14.0 (7.6 to 20.4)	0.5 (-4.8 to 5.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	13.3 (-1.4 to 32.3)	0.6 (-12.5 to 16.9)
Epilepsy	5.3 (3.7 to 7.2)	3.8 (2.5 to 5.3)	-27.8 (-57.8 to 16.2)	-5.5 (-44.6 to 52.4)	1.6 (0.9 to 2.6)	1.2 (0.7 to 1.9)	-25.3 (-57.6 to 26.8)	-0.9 (-44.2 to 67.4)
Multiple sclerosis	1.8 (1.6 to 2.0)	1.9 (1.7 to 2.1)	7.0 (7.0 to 24.0)	28.9 (11.3 to 49.4)	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.8)	6.8 (-11.1 to 27.6)	29.3 (7.6 to 54.8)
Migraine	455.1 (417.6 to 493.9)	351.8 (320.0 to 383.6)	-22.7 (-31.0 to -13.5)	-40.9 (-11.8 to 11.3)	15.4 (9.1 to 22.8)	11.9 (7.3 to 17.5)	-23.0 (-31.2 to -13.4)	-0.5 (-11.9 to 12.4)
Tension-type headache	787.0 (739.5 to 833.1)	601.2 (532.5 to 662.4)	-23.6 (-33.3 to -14.2)	-1.0 (-13.7 to 12.1)	0.9 (0.6 to 1.2)	0.9 (0.4 to 1.6)	-40.6 (-32.5 to -13.9)	-0.6 (-13.5 to 12.9)
Medication overuse headache	39.8 (26.3 to 54.6)	51.4 (33.6 to 69.6)	28.8 (0.7 to 67.1)	54.6 (21.5 to 98.6)	6.2 (3.6 to 9.9)	8.0 (4.4 to 12.5)	28.2 (0.2 to 66.4)	55.1 (22.5 to 99.2)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.5 (-35.3 to 29.9)	7.8 (-22.1 to 50.3)	0.6 (0.4 to 0.8)	0.4 (0.3 to 0.5)	-33.4 (-51.8 to -12.7)	-44.2 (-59.0 to -27.3)
Mental and substance use disorders	-	-	-	-	56.6 (41.2 to 73.4)	44.5 (32.3 to 57.5)	-21.4 (-23.4 to -19.1)	1.0 (-1.4 to 3.9)
Schizophrenia	8.8 (8.1 to 9.5)	7.0 (6.5 to 7.6)	-20.3 (-23.4 to -16.9)	-0.7 (-4.6 to 3.7)	5.7 (4.2 to 6.8)	4.5 (3.3 to 5.5)	-20.4 (-24.6 to -15.3)	-0.4 (-5.6 to 6.2)
Alcohol use disorders	65.0 (59.1 to 72.3)	55.5 (50.3 to 60.8)	-14.4 (-20.1 to -9.0)	-11.1 (-3.9 to 18.1)	6.5 (4.3 to 9.2)	5.5 (3.6 to 7.9)	-14.3 (-20.1 to -8.3)	11.5 (3.9 to 19.4)
Drug use disorders	-	-	-	-	3.9 (2.7 to 5.1)	2.8 (1.9 to 3.7)	-27.9 (-35.8 to -17.6)	0.3 (-10.8 to 15.5)
Opioid use disorders	4.6 (4.0 to 5.2)	3.4 (3.0 to 3.9)	-25.8 (-31.0 to -20.8)	0.9 (-6.3 to 7.5)	1.9 (1.3 to 2.5)	1.4 (1.0 to 1.9)	-25.6 (-32.3 to -18.4)	1.4 (-8.0 to 11.2)
Cocaine use disorders	2.0 (1.4 to 2.5)	1.6 (1.2 to 1.9)	-21.2 (-46.2 to 20.5)	0.3 (-27.7 to 75.0)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-21.1 (-48.0 to 19.7)	12.2 (-30.2 to 75.4)
Amphetamine use disorders	4.8 (3.9 to 5.7)	3.2 (2.8 to 3.6)	-33.6 (-46.6 to -16.8)	-5.8 (-24.4 to 10.4)	0.4 (0.4 to 0.4)	0.4 (0.3 to 0.6)	-24.0 (-48.3 to -19.2)	6.0 (-28.0 to 22.5)
Cannabis use disorders	4.2 (3.6 to 4.7)	2.8 (2.5 to 3.2)	-32.6 (-36.8 to -27.7)	1.5 (-5.0 to 9.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-32.7 (-42.4 to -21.0)	1.6 (-13.5 to 19.7)
Other drug use disorders	-	-	-	-	0.9 (0.6 to 1.3)	0.6 (0.4 to 1.0)	-29.3 (-49.3 to 0.6)	0.2 (-28.5 to 42.8)
Depressive disorders	-	-	-	-	18.9 (12.6 to 26.1)	15.6 (10.4 to 21.5)	-17.2 (-22.8 to -10.8)	0.6 (-6.2 to 7.4)
Major depressive disorder	71.6 (58.1 to 85.4)	59.2 (50.1 to 68.7)	-17.2 (-24.4 to -8.8)	0.4 (-7.8 to 9.2)	14.6 (9.4 to 21.0)	11.5 (7.8 to 16.7)	-17.8 (-24.7 to -9.4)	0.9 (-7.9 to 9.6)
Dysthymia	45.0 (37.3 to 52.5)	38.2 (31.9 to 44.3)	-15.2 (-17.3 to -12.8)	-0.5 (-0.6 to -0.3)	4.3 (2.8 to 6.3)	3.6 (2.4 to 5.4)	-15.6 (-18.4 to -12.5)	-0.2 (-2.6 to 2.0)
Bipolar disorder	19.8 (17.4 to 22.3)	15.9 (14.1 to 17.7)	-19.8 (-23.9 to -15.7)	0.1 (-5.1 to 4.7)	4.0 (2.5 to 6.0)	3.2 (2.0 to 4.7)	-20.0 (-25.2 to -14.6)	0.4 (-6.4 to 7.2)
Anxiety disorders	71.0 (62.3 to 78.7)	54.7 (48.3 to 60.5)	-22.9 (-24.3 to -21.4)	-0.4 (-0.5 to -0.4)	6.5 (4.4 to 9.1)	5.0 (3.4 to 6.9)	-23.5 (-26.0 to -20.8)	-0.3 (-3.2 to 3.0)
Eating disorders	-	-	-	-	0.5 (0.4 to 0.9)	0.4 (0.2 to 0.6)	-9.0 (-39.3 to -28.3)	0.5 (-6.9 to 8.5)
Anorexia nervosa	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.2)	-30.0 (-36.7 to -22.8)	8.1 (-1.4 to 19.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-29.8 (-47.7 to -7.9)	8.8 (-18.1 to 41.3)
Bulimia nervosa	2.6 (1.8 to 3.4)	1.7 (1.2 to 2.3)	-34.4 (-36.2 to -32.8)	-0.4 (-0.6 to -0.3)	0.5 (0.3 to 0.8)	0.4 (0.2 to 0.6)	-34.4 (-40.4 to -28.3)	0.2 (-8.5 to 8.2)
Autistic spectrum disorders	-	-	-	-	3.0 (2.1 to 4.0)	2.2 (1.5 to 2.9)	-27.0 (-29.2 to -24.4)	0.8 (-2.5 to 4.5)
Autism	7.7 (7.3 to 8.1)	5.7 (5.3 to 6.0)	-26.5 (-27.0 to -26.0)	0.5 (0.5 to 0.6)	1.9 (1.3 to 2.6)	1.4 (0.9 to 1.9)	-26.9 (-30.4 to -23.2)	0.8 (-1.0 to 5.8)
Asperger syndrome	10.9 (10.2 to 11.6)	8.0 (7.4 to 8.5)	-26.8 (-27.4 to -26.1)	0.7 (0.7 to 0.7)	1.1 (0.8 to 1.5)	0.8 (0.5 to 1.1)	-27.0 (-29.7 to -24.1)	1.0 (-2.7 to 5.0)
Attention-deficit/hyperactivity disorder	11.5 (10.6 to 12.4)	6.3 (5.8 to 6.8)	-45.3 (-45.7 to -45.1)	-0.1 (-0.0 to -0.0)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-45.3 (-49.2 to -41.4)	-0.1 (-7.1 to 7.4)
Conduct disorder	16.6 (15.6 to 17.6)	8.6 (8.1 to 9.2)	-48.0 (-48.3 to -47.4)	-0.1 (-0.1 to -0.1)	2.0 (1.3 to 2.9)	1.0 (0.7 to 1.5)	-47.9 (-50.3 to -45.6)	-0.1 (-4.3 to 4.4)
Idiopathic intellectual disability	40.5 (33.7 to 49.0)	25.5 (21.0 to 31.0)	-37.0 (-43.4 to -30.8)	-1.9 (-2.1 to -1.5)	2.1 (1.3 to 2.8)	1.2 (0.8 to 1.7)	-37.3 (-44.3 to -30.9)	-13.7 (-23.3 to -5.0)
Other mental and substance use disorders	48.1 (45.2 to 50.9)	40.3 (37.9 to 42.6)	-16.2 (-17.3 to -15.2)	0.4 (0.3 to 0.6)	3.6 (2.4 to 4.8)	3.0 (2.0 to 4.0)	-16.5 (-19.5 to -13.5)	0.8 (-2.8 to 4.8)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	25.6 (18.1 to 34.0)	23.8 (17.1 to 31.9)	-6.8 (-15.3 to 2.8)	6.3 (-2.5 to 15.6)
Diabetes mellitus	118.4 (93.6 to 142.9)	120.8 (97.6 to 145.8)	2.9 (-20.6 to 29.8)	17.4 (-8.4 to 44.3)	9.7 (6.3 to 13.8)	10.1 (6.7 to 14.5)	4.7 (-17.4 to 31.4)	17.3 (-7.4 to 42.6)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-72.2 (-74.4 to -70.0)	-58.3 (-61.4 to -55.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-72.2 (-74.4 to -70.0)	-88.3 (-61.5 to -55.1)
Chronic kidney disease	-	-	-	-	7.3 (5.3 to 9.7)	6.4 (4.5 to 8.3)	-13.2 (-20.4 to -6.4)	-1.6 (-9.0 to 5.7)
Chronic kidney disease due to diabetes mellitus	36.3 (22.4 to 53.3)	25.5 (16.8 to 38.6)	-29.5 (-51.4 to 0.2)	-28.6 (-48.8 to -2.2)	1.2 (0.7 to 1.8)	0.8 (0.5 to 1.1)	-32.4 (-50.5 to -10.4)	-27.7 (-46.1 to -5.3)
Chronic kidney disease due to hypertension	48.0 (33.5 to 65.6)	41.0 (27.4 to 60.8)	-14.8 (-36.9 to 14.5)	-1.0 (-25.1 to 29.5)	1.7 (1.2 to 2.3)	0.8 (0.6 to 1.1)	-52.8 (-62.5 to -37.9)	-49.2 (-59.4 to -35.3)
Chronic kidney disease due to glomerulonephritis	50.2 (35.9 to 75.3)	30.0 (23.2 to 39.4)	-39.7 (-54.0 to -21.2)	-32.1 (-46.0 to -14.8)	1.8 (1.2 to 2.3)	1.5 (1.1 to 2.1)	-14.1 (-29.8 to 6.8)	5.6 (-11.3 to 32.3)
Chronic kidney disease due to other causes	80.2 (57.4 to 112.6)	97.8 (74.8 to 137.1)	21.8 (-2.4 to 55.6)	20.7 (10.3 to 62.6)	2.7 (1.9 to 3.6)	3.2 (2.2 to 4.3)	20.4 (11.1 to 48.2)	34.1 (13.2 to 62.9)
Urinary diseases and male infertility	-	-	-	-	2.4 (1.6 to 3.4)	2.8 (1.8 to 3.9)	17.2 (7.7 to 28.7)	9.0 (0.4 to 19.8)
Interstitial nephritis and urinary tract infections	1.0 (1.0 to 1.1)	0.9 (0.8 to 0.9)	-15.2 (-21.0 to -8.5)	10.5 (2.1 to 20.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-15.7 (-28.6 to -0.9)	10.6 (6.2 to 31.8)

Appendix Table G.4 - Latvia prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Urolithiasis	20.9 (13.3 to 30.3)	19.6 (12.2 to 28.8)	-6.2 (-18.8 to 9.0)	0.2 (-2.8 to 5.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-8.7 (-19.5 to 3.5)	-8.7 (-19.7 to 5.8)
Benign prostatic hyperplasia	56.0 (51.2 to 60.1)	68.3 (64.7 to 71.8)	21.8 (11.5 to 34.9)	9.7 (0.6 to 21.7)	2.0 (1.3 to 2.9)	2.5 (1.6 to 3.5)	22.2 (11.9 to 35.3)	10.4 (1.3 to 22.4)
Male infertility due to other causes	15.7 (12.7 to 18.6)	11.5 (8.9 to 14.2)	-27.4 (-46.8 to 1.5)	0.2 (-26.6 to 40.6)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-27.6 (-46.8 to 2.1)	0.1 (-26.7 to 41.4)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.1)	61.1 (0.0 to 121.2)	-	67.0 (-24.1 to 130.6)
Gynecological diseases	-	-	-	-	3.3 (2.1 to 5.1)	2.6 (1.7 to 4.0)	-20.9 (-31.3 to -10.5)	4.9 (-9.4 to 19.4)
Uterine fibroids	64.8 (59.3 to 70.0)	50.8 (46.6 to 54.8)	-21.6 (-22.0 to -21.2)	-1.1 (-1.1 to -1.1)	0.7 (0.4 to 1.3)	0.6 (0.3 to 1.0)	-21.1 (-25.9 to -14.7)	1.6 (-4.2 to 9.9)
Polycystic ovarian syndrome	47.1 (42.5 to 52.3)	33.4 (30.4 to 36.7)	-28.8 (-39.2 to -18.4)	-3.0 (-17.3 to 11.5)	0.5 (0.2 to 0.9)	0.3 (0.1 to 0.6)	-29.0 (-39.1 to -18.6)	-2.9 (-17.4 to 11.2)
Female infertility due to other causes	11.8 (7.9 to 16.4)	8.3 (5.5 to 11.5)	-29.2 (-55.2 to 10.0)	-1.4 (-38.1 to 52.5)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-30.0 (-56.5 to 10.2)	-2.3 (-39.9 to 52.6)
Endometriosis	5.1 (4.4 to 5.9)	3.9 (3.3 to 4.5)	-23.9 (-38.0 to -7.7)	2.9 (-16.9 to 25.2)	0.5 (0.3 to 0.7)	0.4 (0.2 to 0.5)	-24.0 (-38.4 to -5.6)	2.7 (-16.9 to 27.9)
Genital prolapse	161.9 (145.7 to 179.1)	132.5 (117.3 to 148.3)	-18.3 (-30.2 to -5.0)	-1.6 (-17.1 to 15.4)	0.5 (0.2 to 1.0)	0.4 (0.2 to 0.8)	-18.4 (-30.8 to -5.1)	-1.4 (-17.3 to 15.7)
Premenstrual syndrome	99.6 (59.9 to 138.9)	82.9 (58.3 to 107.3)	-16.4 (-45.1 to 28.4)	15.1 (-24.0 to 77.5)	0.8 (0.4 to 1.4)	0.7 (0.4 to 1.1)	-16.4 (-46.3 to 29.9)	14.9 (-25.3 to 77.5)
Other gynecological diseases	7.7 (6.9 to 8.5)	5.8 (5.4 to 6.2)	-24.7 (-33.3 to -14.2)	2.8 (-9.5 to 17.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-18.4 (-35.0 to 8.8)	12.3 (-9.5 to 39.8)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	1.7 (1.2 to 2.5)	1.2 (0.8 to 1.7)	-31.5 (-37.7 to -25.3)	-1.0 (-9.8 to 11.6)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.3 (-43.0 to -32.1)	7.9 (-0.0 to 19.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	4.3 (-29.0 to 48.8)
Thalassemia trait	44.8 (42.4 to 47.7)	34.7 (32.6 to 37.2)	-22.5 (-26.1 to -17.4)	2.3 (-2.2 to 7.2)	1.4 (1.0 to 2.0)	1.0 (0.6 to 1.4)	-32.7 (-37.2 to -21.9)	-2.5 (-9.7 to 8.6)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	2.6 (-5.4 to 57.2)	0.0 (0.0 to 0.0)	-	3.2 (-37.0 to 12.8)
Sickle cell trait	1.2 (1.1 to 1.4)	0.9 (0.9 to 1.0)	-24.3 (-28.6 to -20.9)	-0.0 (-6.9 to 8.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-7.1 (-60.0 to 83.5)
G6PD deficiency	4.4 (3.9 to 5.0)	3.4 (3.2 to 3.7)	-23.1 (-32.1 to -12.8)	23.1 (-9.9 to 16.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	34.4 (-18.0 to 83.7)
G6PD trait	283.8 (281.0 to 287.2)	218.1 (215.3 to 220.1)	-23.1 (-24.5 to -22.0)	-1.2 (-3.0 to 0.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	6.4 (-74.2 to 148.5)
Other hemoglobinopathies and hemolytic anemias	10.6 (8.9 to 12.1)	8.6 (7.3 to 9.5)	-18.8 (-33.4 to -5.5)	2.8 (-16.8 to 31.0)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-24.9 (-47.5 to 18.9)	6.8 (-24.9 to 74.9)
Endocrine, metabolic, blood, and immune disorders	33.3 (31.4 to 35.5)	22.3 (21.3 to 23.4)	-33.0 (-37.9 to -27.3)	-10.7 (-18.0 to -2.8)	1.1 (0.8 to 1.6)	0.7 (0.5 to 1.0)	-35.3 (-46.8 to -27.8)	-11.3 (-19.3 to -0.6)
Musculoskeletal disorders	-	-	-	-	68.4 (48.9 to 89.5)	64.3 (46.3 to 84.4)	-5.7 (-12.3 to 0.9)	3.2 (-4.5 to 10.3)
Rheumatoid arthritis	13.8 (13.1 to 14.4)	12.9 (12.4 to 13.6)	-6.0 (-11.5 to 0.9)	-5.2 (-10.5 to 1.2)	3.2 (2.3 to 4.2)	3.0 (2.1 to 4.0)	-5.7 (-13.2 to 0.1)	-5.0 (-11.3 to 1.9)
Osteoarthritis	162.8 (156.4 to 169.1)	172.8 (165.8 to 179.3)	6.2 (0.3 to 12.3)	1.0 (-4.6 to 6.8)	9.9 (7.1 to 13.5)	10.5 (7.4 to 14.2)	5.8 (-0.0 to 12.1)	1.2 (-4.5 to 7.4)
Low back and neck pain	-	-	-	-	48.1 (33.3 to 64.1)	42.9 (30.0 to 57.9)	-10.4 (-19.4 to -1.6)	1.6 (-8.4 to 11.9)
Low back pain	321.4 (297.4 to 346.8)	290.3 (267.7 to 313.6)	-9.6 (-18.9 to 0.5)	0.8 (-9.2 to 11.6)	35.5 (23.8 to 48.7)	31.9 (21.7 to 44.0)	-10.1 (-18.8 to 0.5)	1.1 (-8.7 to 12.2)
Neck pain	129.6 (108.5 to 150.2)	113.3 (95.2 to 131.4)	-12.4 (-29.0 to 7.9)	2.0 (-17.6 to 26.4)	12.7 (8.4 to 17.7)	11.0 (7.4 to 15.4)	-12.8 (-29.2 to 8.4)	2.3 (-17.3 to 27.5)
Gout	1.9 (1.7 to 2.0)	1.9 (1.8 to 2.0)	0.5 (-8.7 to 10.6)	3.5 (-6.1 to 13.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-0.0 (-18.7 to 23.6)	3.6 (-16.0 to 27.3)
Other musculoskeletal disorders	78.3 (59.0 to 97.0)	87.4 (71.0 to 104.5)	11.4 (-1.5 to 23.7)	19.3 (10.1 to 31.4)	7.1 (4.6 to 10.3)	7.9 (5.2 to 11.4)	11.2 (1.1 to 24.1)	19.8 (9.9 to 33.0)
Other non-communicable diseases	-	-	-	-	49.6 (33.4 to 71.1)	48.4 (29.4 to 62.1)	-4.9 (-15.9 to -9.2)	-2.4 (-8.6 to -1.5)
Congenital anomalies	-	-	-	-	3.4 (2.5 to 4.6)	2.8 (2.0 to 3.7)	-19.3 (-28.7 to -7.1)	3.3 (-9.1 to 20.1)
Neural tube defects	0.6 (0.5 to 0.7)	0.3 (0.2 to 0.4)	-53.6 (-63.4 to -39.0)	-32.8 (-46.6 to -11.5)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.1)	-51.8 (-66.6 to -31.6)	-29.8 (-51.7 to -0.1)
Congenital heart anomalies	15.2 (13.4 to 17.7)	12.7 (10.6 to 15.0)	-16.0 (-34.3 to 1.4)	13.5 (-11.2 to 35.9)	0.5 (0.2 to 0.9)	0.4 (0.2 to 0.8)	-12.9 (-31.7 to 3.1)	18.8 (-6.1 to 40.2)
Orofacial clefts	2.0 (1.6 to 2.5)	1.8 (1.6 to 2.1)	-10.1 (-29.4 to 17.5)	17.3 (-9.9 to 52.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.8 (-50.4 to -5.9)	-10.6 (-35.1 to 23.5)
Down syndrome	2.9 (2.4 to 3.5)	2.7 (2.2 to 3.4)	-0.5 (-28.0 to 19.8)	0.0 (-10.1 to 49.3)	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	2.3 (-22.0 to 34.9)	5.7 (-7.6 to 58.4)
Turner syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-25.0 (-44.7 to 0.4)	5.4 (-21.5 to 41.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.8 (-46.7 to 4.8)	4.8 (-24.9 to 49.3)
Klinefelter syndrome	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-5.8 (-39.7 to 40.6)	30.4 (-16.4 to 94.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.1 (-44.0 to 48.0)	29.8 (-23.4 to 101.6)
Chromosomal unbalanced rearrangements	4.4 (3.6 to 5.5)	4.0 (3.2 to 4.8)	-8.2 (-32.5 to 14.5)	14.1 (-15.8 to 42.3)	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.8)	2.0 (-2.4 to 30.4)	19.3 (-11.9 to 51.4)
Other congenital anomalies	12.6 (10.4 to 14.6)	8.2 (6.8 to 9.7)	-34.9 (-41.6 to -24.5)	24.2 (-25.1 to 3.2)	1.7 (1.2 to 2.4)	1.2 (0.8 to 1.7)	-30.4 (-41.6 to -13.4)	6.4 (-22.1 to 17.7)
Skin and subcutaneous diseases	-	-	-	-	13.3 (8.7 to 19.6)	10.0 (6.5 to 14.8)	-24.3 (-31.3 to -16.6)	-1.2 (-10.2 to 7.7)
Dermatitis	127.2 (105.0 to 149.8)	97.0 (80.3 to 113.6)	-23.7 (-25.2 to -21.8)	-0.1 (-0.1 to 0.0)	3.6 (2.3 to 5.2)	2.7 (1.7 to 3.8)	-25.2 (-28.2 to -22.4)	0.0 (-2.7 to 2.8)
Psoriasis	23.6 (20.9 to 26.3)	19.4 (17.1 to 21.7)	-18.0 (-19.7 to -15.7)	0.0 (-0.1 to 0.1)	1.9 (1.3 to 2.7)	1.9 (1.1 to 2.2)	-8.3 (-25.5 to -13.4)	0.4 (-4.8 to 5.8)
Cellulitis	1.5 (1.2 to 1.7)	1.2 (1.0 to 1.4)	-18.9 (-27.2 to -8.4)	18.7 (1.4 to 23.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-12.0 (-32.0 to -3.4)	12.0 (-6.3 to 32.8)
Pyoderma	2.7 (2.2 to 3.3)	3.1 (2.5 to 3.9)	14.2 (7.1 to 22.3)	41.8 (35.4 to 48.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (3.2 to 24.3)	41.9 (30.9 to 53.7)
Scabies	7.7 (6.6 to 9.0)	5.7 (4.6 to 6.8)	-26.7 (-42.2 to -5.3)	3.8 (-17.0 to 34.4)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-26.6 (-43.1 to -4.8)	4.2 (-18.3 to 35.3)
Fungal skin diseases	216.1 (169.9 to 281.0)	173.3 (136.5 to 220.3)	-29.9 (-33.2 to -16.0)	-9.9 (0.1 to 0.4)	1.2 (0.5 to 2.6)	1.0 (0.4 to 2.1)	-10.0 (-23.6 to -16.3)	0.4 (-0.5 to 1.3)
Viral skin diseases	52.0 (39.6 to 64.5)	35.0 (26.0 to 44.2)	-32.7 (-35.3 to -29.9)	32.7 (-1.7 to 17.7)	0.0 (0.9 to 2.5)	0.0 (0.6 to 1.7)	-1.1 (-36.2 to -29.6)	0.1 (-3.1 to 3.2)
Acne vulgaris	75.2 (60.9 to 90.2)	46.0 (38.2 to 54.0)	-38.6 (-53.3 to -20.3)	-6.6 (-24.8 to 30.0)	0.8 (0.4 to 1.6)	0.5 (0.2 to 0.9)	-38.6 (-53.5 to -19.8)	-0.5 (-24.8 to 30.7)
Alopecia areata	3.4 (2.9 to 3.9)	2.9 (2.5 to 3.3)	-14.2 (-30.1 to 6.7)	0.5 (-16.1 to 21.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-14.7 (-31.2 to 5.9)	0.9 (-16.9 to 22.2)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.8 (-32.1 to 11.6)	0.0 (0.0 to 0.0)	-	0.8 (-21.9 to 27.1)
Urticaria	41.5 (26.5 to 58.1)	29.5 (22.0 to 38.0)	-29.2 (-53.1 to 22.7)	-10.7 (-44.8 to 46.2)	2.4 (1.3 to 4.1)	1.7 (1.0 to 2.7)	-29.3 (-53.4 to 22.1)	-10.0 (-44.4 to 47.2)
Decubitus ulcer	0.5 (0.4 to 0.6)	0.8 (0.7 to 1.0)	82.0 (39.6 to 133.5)	70.3 (34.8 to 112.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	78.1 (33.7 to 138.4)	69.1 (30.2 to 121.9)
Other skin and subcutaneous diseases	204.2 (120.5 to 346.5)	182.0 (98.7 to 324.2)	-11.7 (-21.5 to -1.4)	-1.9 (-6.4 to 3.3)	1.2 (0.5 to 2.6)	1.1 (0.4 to 2.5)	-12.0 (-22.0 to -1.6)	-1.6 (-6.4 to 3.8)
Sense organ diseases	-	-	-	-	26.5 (17.6 to 38.3)	24.7 (16.7 to 35.7)	-6.6 (-11.5 to -1.3)	-9.0 (-13.5 to -4.4)
Glaucoma	4.0 (3.2 to 5.0)	3.6 (2.9 to 4.5)	-10.0 (-25.6 to 5.4)	-10.8 (-24.7 to 2.2)	0.2 (0.2 to 0.4)	0.2 (0.2 to 0.4)	-2.8 (-19.0 to 23.0)	-7.2 (-21.8 to 12.0)
Cataract	39.4 (29.5 to 47.5)	34.1 (25.3 to 43.6)	-13.5 (-28.1 to 0.8)	-26.1 (-38.3 to -13.6)	1.5 (0.9 to 2.2)	1.3 (0.8 to 2.0)	-12.0 (-26.7 to 14.3)	-25.6 (-37.8 to -14.3)
Macular degeneration	9.8 (7.4 to 13.1)	11.2 (8.5 to 14.5)	13.3 (-9.4 to 52.3)	11.4 (-11.8 to 46.3)	0.4 (0.2 to 0.6)	0.4 (0.3 to 0.6)	15.4 (-8.1 to 53.1)	10.7 (-12.6 to 44.3)
Uncorrected refractive error	365.2 (322.7 to 405.7)	347.4 (315.1 to 378.2)	-4.9 (-16.0 to 9.4)	-2.8 (-14.8 to 12.2)	5.3 (3.0 to 8.8)	4.7 (2.7 to 7.9)	-10.8 (-18.9 to -0.9)	-7.5 (-15.7 to 3.2)
Age-related and other hearing loss	596.3 (493.5 to 611.8)	516.6 (465.8 to 561.5)	-13.1 (-10.8 to -3.0)	-7.4 (-10.9 to -3.3)	16.6 (11.1 to 23.4)	16.1 (11.0 to 22.5)	-3.0 (-9.7 to 4.4)	-8.7 (-15.2 to -2.4)
Other vision loss	17.6 (14.7 to 21.4)	11.4 (9.4 to 14.2)	-35.6 (-43.2 to -26.4)	-7.8 (-36.0 to -18.8)	0.6 (0.5 to 1.2)	0.6 (0.4 to 0.8)	-11.0 (-38.6 to -20.9)	0.6 (-3.5 to 15.8)
Other sense organ diseases	64.3 (61.7 to 67.2)	51.7 (48.9 to 54.6)	-19.6 (-24.7 to -13.8)	-0.0 (-5.9 to 6.4)	1.7 (1.0 to 2.5)	1.3 (0.8 to 2.0)	-20.3 (-26.1 to -14.0)	-2.0 (-6.6 to 7.8)
Oral disorders	-	-	-	-	6.4 (4.0 to 9.8)	5.9 (3.7 to 8.9)	-7.6 (-11.4 to -4.0)	-1.9 (-5.3 to 1.8)
Deciduous caries	163.0 (159.0 to 167.2)	85.9 (83.1 to 88.5)	-47.3 (-49.3 to -45.4)	-2.3 (-6.0 to 1.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-	-2.5 (-9.4 to 5.5)
Permanent caries	1,189.5 (1,081.1 to 1,284.3)	925.1 (854.0 to 996.3)	-21.9 (-30.5 to -14.7)	21.9 (-8.8 to 12.2)	0.5 (0.3 to 1.4)	0.5 (0.2 to 1.0)	-22.1 (-30.7 to -14.4)	2.5 (-9.6 to 13.2)
Periodontal diseases	187.4 (177.1 to 197.0)	169.2 (160.8 to 177.1)	-9.8 (-15.8 to -2.8)	0.7 (-6.4 to 9.1)	1.2 (0.5 to 2.5)	1.1 (0.4 to 2.3)	-9.9 (-16.2 to -2.7)	1.0 (-6.5 to 9.0)
Edentulism and severe tooth loss	108.3 (104.2 to 112.6)	112.2 (108.2 to 116.1)	3.7 (-1.6 to 9.3)	-5.3 (-10.3 to -0.1)	3.0 (2.0 to 4.1)	3.1 (2.1 to 4.2)	3.4 (-2.3 to 9.4)	-5.0 (-10.3 to 0.5)

Appendix Table G.4 - Latvia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	50.2 (47.4 to 52.9)	39.9 (37.9 to 42.2)	-20.5 (-25.8 to -13.9)	-4.4 (-7.1 to 8.2)	1.5 (0.9 to 2.2)	1.2 (0.7 to 1.7)	-20.8 (-26.4 to -13.7)	-0.3 (-7.4 to 9.0)
Injuries	-	-	-	-	26.1 (19.7 to 33.8)	13.8 (9.9 to 18.6)	-47.3 (-52.3 to -42.1)	-43.9 (-49.1 to -38.1)
Transport injuries	-	-	-	-	10.8 (8.0 to 13.9)	3.9 (2.7 to 5.3)	-64.3 (-68.6 to -59.7)	-61.0 (-65.8 to -55.8)
Road injuries	-	-	-	-	9.2 (6.9 to 11.9)	3.3 (2.3 to 4.5)	-64.4 (-68.9 to -59.7)	-61.3 (-66.2 to -56.1)
Pedestrian road injuries	-	-	-	-	2.1 (1.6 to 2.7)	0.8 (0.6 to 1.1)	-63.0 (-67.7 to -57.5)	-61.9 (-66.8 to -56.0)
Cyclist road injuries	-	-	-	-	1.4 (1.0 to 1.8)	0.5 (0.4 to 0.7)	-62.8 (-66.5 to -58.5)	-59.2 (-63.2 to -54.4)
Motorcyclist road injuries	-	-	-	-	0.7 (0.6 to 1.0)	0.3 (0.2 to 0.3)	-66.3 (-70.8 to -61.1)	-61.4 (-66.5 to -55.3)
Motor vehicle road injuries	-	-	-	-	4.9 (3.6 to 6.3)	1.7 (1.2 to 2.3)	-65.1 (-69.9 to -59.6)	-61.5 (-66.8 to -55.6)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-75.8 (-78.8 to -72.5)	-73.4 (-76.7 to -69.7)
Other transport injuries	-	-	-	-	1.6 (1.2 to 2.1)	0.6 (0.4 to 0.8)	-63.3 (-67.4 to -58.6)	-59.2 (-63.8 to -54.1)
Unintentional injuries	-	-	-	-	14.7 (11.0 to 19.1)	9.6 (7.0 to 12.9)	-34.6 (-39.6 to -29.4)	-30.8 (-36.1 to -25.5)
Falls	-	-	-	-	6.5 (4.9 to 8.4)	4.5 (3.2 to 6.0)	-31.5 (-39.2 to -23.7)	-31.5 (-38.8 to -23.5)
Drowning	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.1)	-63.4 (-68.2 to -57.7)	-59.5 (-64.5 to -53.2)
Fire, heat, and hot substances	-	-	-	-	0.7 (0.5 to 0.9)	0.4 (0.3 to 0.5)	-43.9 (-50.9 to -36.5)	-36.5 (-44.2 to -28.3)
Poisonings	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-53.1 (-58.5 to -47.1)	-41.6 (-48.7 to -33.3)
Exposure to mechanical forces	-	-	-	-	3.8 (2.8 to 5.0)	2.1 (1.6 to 2.9)	-43.6 (-47.1 to -39.7)	-34.9 (-39.1 to -30.6)
Unintentional firearm injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-64.9 (-70.4 to -58.5)	-56.6 (-63.3 to -48.9)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.6 (-50.6 to -38.1)	-37.0 (-44.0 to -29.5)
Other exposure to mechanical forces	-	-	-	-	3.7 (2.7 to 4.8)	2.1 (1.5 to 2.8)	-43.2 (-46.8 to -39.4)	-34.5 (-38.7 to -30.3)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-9.9 (-7.0 to 7.2)	9.3 (2.9 to 17.5)
Animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-29.0 (-35.3 to -22.3)	-17.0 (-24.0 to -9.6)
Venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-27.9 (-35.9 to -19.3)	-13.4 (-23.9 to -2.5)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-29.6 (-36.3 to -21.9)	-18.8 (-26.0 to -10.5)
Foreign body	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-35.5 (-41.2 to -28.4)	-26.1 (-33.0 to -18.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-48.2 (-55.8 to -38.3)	-42.4 (-50.8 to -31.5)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.3 (-26.0 to -16.2)	-2.3 (-10.8 to 5.4)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-29.1 (-35.3 to -22.0)	-20.8 (-27.7 to -13.3)
Other unintentional injuries	-	-	-	-	3.0 (2.2 to 3.9)	2.2 (1.6 to 3.0)	-25.7 (-31.4 to -19.8)	-22.1 (-28.0 to -16.2)
Self-harm and interpersonal violence	-	-	-	-	0.7 (0.5 to 0.8)	0.3 (0.2 to 0.4)	-51.1 (-56.2 to -45.0)	-45.3 (-50.8 to -38.7)
Self-harm	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.2)	-46.3 (-51.4 to -40.2)	-39.3 (-45.0 to -32.4)
Interpersonal violence	-	-	-	-	0.3 (0.3 to 0.4)	0.2 (0.1 to 0.2)	-55.6 (-60.7 to -49.0)	-50.8 (-56.4 to -43.6)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.3 (-60.1 to -51.4)	-50.9 (-55.0 to -45.2)
Assault by sharp object	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-51.3 (-56.4 to -44.5)	-46.1 (-51.7 to -38.4)
Assault by other means	-	-	-	-	0.3 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-56.4 (-61.7 to -49.4)	-51.8 (-57.6 to -44.1)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Lebanon prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	384.5 (260.7 to 557.6)	545.9 (404.8 to 703.8)	45.6 (7.7 to 74.0)	45.6 (-47.8 to -14.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	32.7 (22.7 to 45.6)	47.1 (32.8 to 64.9)	43.8 (32.1 to 59.8)	-2.8 (-10.3 to 7.7)
HIV/AIDS and tuberculosis	-	-	-	-	0.3 (0.2 to 0.4)	0.7 (0.3 to 2.1)	116.7 (62.0 to 535.0)	-0.9 (-25.5 to 189.9)
Tuberculosis	0.8 (0.7 to 0.9)	1.3 (1.2 to 1.4)	60.1 (51.3 to 71.3)	-27.3 (-31.4 to -22.6)	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	66.4 (40.8 to 96.6)	-23.5 (-34.8 to -10.0)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.1)	0.3 (0.0 to 1.7)	1,156.5 (86.2 to 14,034.0)	447.7 (-17.3 to 6,178.9)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	758.0 (-11.3 to 9,080.1)	256.3 (-61.8 to 3,715.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	758.0 (-12.6 to 9,269.0)	256.3 (-62.8 to 3,771.7)
HIV/AIDS resulting in other diseases	0.2 (0.0 to 0.7)	2.6 (0.4 to 11.2)	2,476.2 (224.6 to 25,469.8)	1,044.5 (49.9 to 11,035.0)	0.0 (0.0 to 0.1)	0.3 (0.0 to 1.7)	1,156.5 (85.1 to 14,378.2)	448.3 (-17.8 to 6,233.9)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	7.5 (5.2 to 10.2)	7.9 (5.6 to 10.7)	5.5 (-3.2 to 15.0)	-20.5 (-26.3 to -14.0)
Diarrheal diseases	33.0 (30.7 to 35.4)	32.2 (29.7 to 34.8)	-2.4 (-12.1 to 8.3)	-20.7 (-28.4 to -12.6)	3.9 (3.6 to 7.3)	5.2 (3.5 to 7.1)	-9.9 (-13.0 to 8.3)	-19.9 (-27.8 to -11.2)
Intestinal infectious diseases	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	0.1 (-48.4 to -1.7)	-27.5 (-65.8 to -35.4)
Typhoid fever	0.4 (0.4 to 0.5)	0.4 (0.3 to 0.4)	-15.1 (-31.8 to 3.6)	-43.6 (-54.0 to -31.7)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-13.5 (-34.6 to 17.0)	-42.6 (-55.5 to -24.4)
Paratyphoid fever	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-16.6 (-33.9 to 2.3)	-42.6 (-53.7 to -30.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.5 (-36.4 to 7.6)	-42.7 (-55.8 to -27.9)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-72.3 (-90.9 to -16.8)	-81.4 (-94.0 to -44.3)
Lower respiratory infections	0.7 (0.5 to 0.9)	1.1 (0.4 to 1.8)	60.8 (-30.4 to 215.5)	2.0 (54.2 to 93.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	58.5 (-33.5 to 225.4)	2.7 (-54.3 to 97.2)
Upper respiratory infections	53.9 (47.3 to 59.8)	88.3 (80.2 to 97.7)	63.7 (40.8 to 94.0)	-0.1 (-14.2 to 18.4)	0.6 (0.4 to 1.1)	1.0 (0.6 to 1.7)	64.1 (40.5 to 95.8)	0.8 (-13.6 to 20.1)
Otitis media	32.5 (30.3 to 35.3)	44.0 (40.0 to 48.3)	35.6 (19.9 to 53.2)	-11.4 (-21.6 to -0.4)	0.6 (0.3 to 1.0)	0.8 (0.5 to 1.3)	35.8 (19.5 to 54.0)	-10.9 (-21.2 to 0.1)
Meningitis	-	-	-	-	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.5)	-25.8 (-44.3 to -3.4)	-57.6 (-68.1 to -45.4)
Pneumococcal meningitis	2.1 (1.3 to 3.4)	1.6 (0.9 to 2.7)	-21.7 (-45.1 to 1.8)	-59.6 (-71.6 to -48.0)	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-19.0 (-42.2 to 13.9)	-56.1 (-68.5 to -37.6)
H influenzae type B meningitis	1.3 (0.4 to 2.7)	0.8 (0.3 to 1.8)	-36.9 (-68.7 to -0.8)	-64.5 (-82.6 to -42.2)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-34.9 (-73.8 to 19.5)	-61.1 (-84.1 to -29.7)
Meningococcal meningitis	0.6 (0.2 to 1.5)	0.4 (0.1 to 1.0)	-32.1 (-56.0 to -3.0)	-63.6 (-75.6 to -47.7)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-32.5 (-57.9 to 4.2)	-62.0 (-75.5 to -41.2)
Other meningitis	0.8 (0.4 to 1.6)	0.7 (0.3 to 1.3)	-19.4 (-41.7 to 4.6)	-55.3 (-67.9 to -41.9)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-12.1 (-36.3 to 17.6)	-49.9 (-63.6 to -33.1)
Encephalitis	0.7 (0.3 to 1.6)	1.0 (0.4 to 2.4)	45.7 (21.0 to 70.9)	-24.2 (-35.7 to -10.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	50.0 (24.3 to 92.7)	-18.9 (-33.5 to 1.4)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.9 (-93.5 to 708.1)	-41.9 (-95.2 to 540.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.9 (-93.6 to 720.9)	-41.9 (-95.3 to 545.8)
Whooping cough	0.4 (0.3 to 0.5)	0.9 (0.7 to 1.1)	128.5 (114.0 to 144.3)	152.6 (136.6 to 170.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	127.6 (93.2 to 182.2)	151.6 (113.1 to 211.4)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-78.6 (-89.4 to -59.5)	-87.6 (-93.8 to -76.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-75.7 (-88.3 to -48.9)	-85.2 (-92.5 to -69.4)
Measles	0.9 (0.7 to 1.3)	0.1 (0.1 to 0.1)	-91.6 (-94.3 to -87.4)	-90.7 (-93.7 to -86.1)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	91.6 (-95.1 to -86.0)	-90.7 (-94.7 to -84.3)
Varicella and herpes zoster	2.0 (1.8 to 2.3)	3.1 (2.7 to 3.6)	51.9 (26.7 to 78.3)	6.6 (-12.0 to 27.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	136.8 (69.0 to 229.9)	15.4 (-17.5 to 59.6)
Neglected tropical diseases and malaria	-	-	-	-	1.0 (0.6 to 1.6)	1.3 (0.8 to 1.8)	19.1 (1.7 to 79.4)	0.4 (-13.9 to 48.7)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.6 (-15.1 to 403.6)	23.1 (-49.9 to 194.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.5 (-5.3 to 372.9)	22.7 (-44.6 to 177.3)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	60.0 (5.4 to 141.0)	2.1 (-30.8 to 57.8)
Visceral leishmaniasis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	33.2 (-32.3 to 123.0)	-1.8 (51.6 to 45.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.3 (-31.8 to 123.5)	-2.2 (-51.9 to 49.6)
Cutaneous and mucocutaneous leishmaniasis	1.4 (0.8 to 2.1)	2.3 (1.4 to 3.6)	76.5 (-0.8 to 172.6)	6.5 (-38.5 to 69.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	77.8 (-1.4 to 177.8)	8.7 (-38.6 to 73.8)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Cysticercosis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-73.3 (-93.5 to -24.3)	-88.0 (-96.9 to -64.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-71.3 (-93.0 to -16.3)	-87.0 (-96.9 to -61.0)
Cystic echinococcosis	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.4)	63.8 (43.3 to 83.6)	-24.8 (-33.6 to -15.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	68.4 (31.2 to 116.3)	-21.7 (-38.6 to 1.5)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.3 (65.2 to 11.4)	-56.9 (-79.1 to -35.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.3 (-65.4 to 11.4)	56.9 (-79.1 to -35.3)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.8 (70.4 to 151.4)	-3.5 (-20.7 to 16.7)
Ascariasis	-	-	117.7 (25.2 to 254.6)	1.7 (-41.5 to 65.5)	-	-	-	-
Trichuriasis	-	-	112.1 (19.6 to 259.0)	-1.0 (-44.1 to 67.7)	-	-	-	-
Hookworm disease	1.8 (1.3 to 2.5)	3.9 (2.8 to 5.3)	113.1 (40.2 to 229.9)	0.5 (-34.6 to 54.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.8 (70.4 to 151.4)	3.5 (-20.7 to 16.7)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	29.4 (22.2 to 37.5)	37.1 (33.8 to 40.9)	25.9 (-1.3 to 66.3)	1.8 (-19.3 to 32.2)	1.0 (0.6 to 1.5)	1.2 (0.8 to 1.7)	17.3 (-1.4 to 83.3)	2.5 (-13.6 to 58.8)
Maternal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-11.6 (-35.7 to 11.9)	-58.0 (-69.3 to -47.0)
Maternal hemorrhage	0.6 (0.5 to 0.7)	0.5 (0.3 to 0.7)	-13.2 (-45.6 to 20.2)	-58.6 (-73.8 to -43.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.4 (-57.7 to 66.2)	-56.3 (-78.5 to -19.1)
Maternal sepsis and other maternal infections	1.5 (0.8 to 2.3)	1.0 (0.7 to 1.5)	-30.5 (-47.0 to 2.6)	-69.7 (-76.5 to -54.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.4 (-64.1 to 25.2)	-69.6 (-82.5 to -45.6)
Maternal hypertensive disorders	1.2 (0.4 to 2.1)	1.1 (0.4 to 2.0)	-7.2 (-18.4 to 10.8)	-56.0 (-60.9 to -49.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-6.4 (-25.9 to 17.4)	-55.8 (-64.9 to -45.3)
Obstructed labor	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-25.8 (-57.8 to 14.9)	-64.7 (-79.4 to -46.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.4 (-60.7 to 56.8)	-61.5 (-80.9 to -25.9)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.0 (-37.1 to 99.3)	-48.8 (-71.4 to -9.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.0 (-37.2 to 99.5)	-48.8 (-71.5 to -8.6)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.1 (-50.4 to 77.7)	56.5 (-76.2 to -15.6)
Neonatal disorders	-	-	-	-	4.2 (2.6 to 6.7)	9.2 (6.0 to 13.4)	121.5 (38.7 to 260.7)	35.9 (-14.5 to 118.7)
Preterm birth complications	12.5 (9.0 to 16.8)	37.2 (27.7 to 49.3)	197.5 (128.9 to 301.5)	75.1 (35.1 to 133.5)	1.6 (1.0 to 2.3)	4.8 (3.2 to 6.9)	197.7 (117.1 to 338.4)	79.8 (31.8 to 162.8)
Neonatal encephalopathy due to birth asphyxia and trauma	5.7 (3.1 to 10.3)	6.6 (3.4 to 11.7)	16.9 (-43.8 to 147.9)	-27.1 (-65.0 to -53.8)	1.4 (0.8 to 2.5)	1.8 (1.0 to 2.9)	26.9 (-34.4 to 154.4)	-19.7 (-58.8 to 59.7)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	295.5 (29.5 to 116.3)	37.6 (37.6 to 129.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	206.6 (20.6 to 138.3)	153.2 (28.2 to 153.2)
Hemolytic disease and other neonatal jaundice	2.7 (0.8 to 7.0)	5.0 (0.7 to 15.1)	55.0 (-73.9 to 1,183.1)	-5.2 (-84.3 to 682.4)	0.8 (0.2 to 1.9)	1.4 (0.2 to 4.0)	59.1 (-66.0 to 907.0)	-3.6 (-79.5 to 509.6)
Other neonatal disorders	-	-	-	-	0.4 (0.2 to 0.8)	1.2 (0.6 to 2.4)	231.4 (24.8 to 641.6)	103.3 (-23.3 to 356.1)
Nutritional deficiencies	-	-	-	-	18.3 (12.2 to 26.5)	25.7 (17.0 to 37.1)	40.9 (33.0 to 48.0)	-5.0 (-10.2 to 0.8)
Protein-energy malnutrition	3.9 (1.5 to 8.6)	3.9 (1.4 to 8.7)	-2.4 (-72.0 to 247.8)	10.9 (-68.3 to 289.1)	0.5 (0.2 to 1.1)	0.5 (0.2 to 1.1)	2.1 (-73.2 to 259.2)	10.8 (-69.6 to 305.1)
Iodine deficiency	111.1 (96.6 to 127.0)	124.1 (101.1 to 149.5)	12.4 (-16.2 to 42.4)	-44.8 (-59.1 to -29.2)	2.0 (1.2 to 3.2)	2.2 (1.3 to 3.6)	13.7 (-15.5 to 44.1)	-43.8 (-58.1 to -28.4)
Vitamin A deficiency	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-

Appendix Table G.4 - Lebanon prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	504.6 (495.7 to 513.9)	801.5 (790.2 to 812.9)	58.9 (55.2 to 62.3)	-0.2 (-2.3 to 2.6)	15.7 (10.4 to 22.7)	22.8 (15.2 to 33.2)	46.0 (41.0 to 49.8)	46.0 (3.2 to 3.0)
Other nutritional deficiencies	-	-	-	-	0.1 (0.0 to 0.4)	0.1 (0.0 to 0.4)	4.4 (-75.6 to 384.7)	19.2 (-72.0 to 448.6)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.4 (0.9 to 2.1)	2.2 (1.4 to 3.5)	61.5 (30.4 to 96.4)	0.3 (-17.3 to 19.1)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.5 (0.2 to 0.8)	1.0 (0.5 to 1.8)	121.5 (47.6 to 228.0)	5.5 (-27.9 to 55.9)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	41.3 (19.3 to 67.9)	-40.3 (-48.1 to -29.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.7 (9.6 to 105.6)	47.7 (-53.2 to -13.3)
Chlamydial infection	47.2 (26.8 to 68.6)	106.5 (66.3 to 152.9)	129.2 (23.6 to 313.3)	12.4 (-39.3 to 100.1)	0.2 (0.1 to 0.4)	0.5 (0.2 to 1.0)	147.6 (27.7 to 525.0)	21.7 (-48.0 to 209.3)
Gonococcal infection	15.2 (10.2 to 20.0)	28.0 (21.2 to 35.3)	84.3 (29.6 to 204.6)	-9.3 (-35.1 to 45.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	93.2 (30.9 to 202.5)	-5.0 (-34.2 to 47.8)
Trichomoniasis	11.1 (7.6 to 14.4)	20.9 (14.7 to 27.4)	90.0 (21.7 to 189.1)	-8.4 (-39.5 to 36.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	92.7 (15.2 to 202.0)	-7.8 (-42.0 to 45.4)
Genital herpes	395.1 (371.9 to 419.1)	855.8 (785.3 to 876.2)	112.6 (92.6 to 128.4)	4.6 (-13.5 to 2.8)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.5)	112.8 (90.3 to 133.7)	-2.8 (-13.0 to 7.1)
Other sexually transmitted diseases	0.6 (0.5 to 0.8)	0.9 (0.7 to 1.2)	54.0 (32.4 to 83.9)	-32.7 (-42.3 to -19.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.7 (31.8 to 219.8)	10.9 (-39.3 to 40.6)
Hepatitis	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	45.1 (17.4 to 85.2)	-26.0 (-41.1 to -3.9)
Hepatitis A	3.6 (3.5 to 3.7)	5.0 (4.9 to 5.1)	38.3 (36.1 to 40.3)	-4.1 (-4.2 to -4.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	72.1 (52.2 to 91.6)	0.2 (-11.1 to 11.7)
Hepatitis B	237.0 (180.3 to 301.5)	282.2 (222.9 to 352.8)	18.8 (-15.2 to 71.4)	-38.5 (-55.5 to -12.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	29.9 (-15.3 to 107.1)	-39.0 (-59.9 to -2.7)
Hepatitis C	136.1 (121.9 to 151.0)	217.8 (196.0 to 244.0)	60.1 (39.2 to 84.3)	-24.2 (-33.8 to -13.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.2 (42.7 to 51.9)	24.1 (-4.9 to 4.7)
Hepatitis E	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-5.1 (-27.1 to 17.8)	-51.9 (-62.1 to -40.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.5 (-31.3 to 37.6)	-51.6 (-65.6 to -33.0)
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	481.8 (68.0 to 5,022.1)	149.1 (-27.5 to 2,271.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	490.3 (67.9 to 5,814.1)	152.4 (-27.4 to 2,558.8)
Other infectious diseases	21.1 (16.7 to 25.8)	28.4 (23.9 to 33.2)	34.1 (7.2 to 67.4)	2.0 (-17.7 to 25.9)	0.7 (0.4 to 1.1)	0.9 (0.6 to 1.4)	27.5 (5.1 to 81.5)	5.6 (-20.2 to 50.3)
Non-communicable diseases	-	-	-	-	199.5 (150.6 to 257.0)	446.0 (335.8 to 573.3)	123.3 (115.2 to 133.0)	82.1 (4.3 to 13.2)
Neoplasms	-	-	-	-	1.7 (1.2 to 2.3)	4.6 (3.1 to 6.3)	172.0 (114.5 to 246.5)	21.2 (-4.1 to 53.4)
Esophageal cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	77.2 (21.2 to 167.1)	-25.1 (-48.6 to 12.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.4 (31.2 to 153.4)	-23.4 (-45.2 to 8.7)
Stomach cancer	0.7 (0.6 to 0.9)	1.1 (0.8 to 1.4)	43.9 (5.5 to 101.7)	-38.3 (-54.3 to -14.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	49.4 (8.5 to 108.7)	-35.8 (-53.2 to -10.1)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (-37.4 to 30.9)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.4 (7.3 to 361.8)	-4.3 (-51.5 to 105.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.4 (13.4 to 327.0)	-5.8 (-49.5 to 86.8)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	270.3 (106.6 to 598.1)	57.9 (-10.9 to 194.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	257.8 (113.6 to 522.7)	51.7 (-8.1 to 162.2)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-3.2 (-58.9 to 92.7)	-57.0 (-82.0 to -16.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.3 (-59.1 to 81.7)	-57.1 (-81.9 to -21.0)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.8 (-51.9 to 121.0)	-53.4 (-78.7 to 1.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.0 (-50.5 to 99.6)	54.8 (-78.1 to -8.2)
Larynx cancer	0.8 (0.6 to 1.1)	1.1 (0.7 to 1.7)	43.4 (6.2 to 120.7)	-37.0 (-57.9 to -4.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	47.7 (-2.2 to 132.0)	-35.0 (-56.5 to 1.8)
Tracheal, bronchus and lung cancer	0.8 (0.6 to 1.0)	1.8 (1.4 to 2.3)	129.4 (65.9 to 229.2)	1.4 (-26.1 to 44.8)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	142.0 (75.5 to 253.9)	7.2 (-21.9 to 55.0)
Breast cancer	3.8 (2.9 to 4.9)	11.3 (7.7 to 14.8)	197.9 (87.5 to 329.4)	31.0 (-17.7 to 89.4)	0.3 (0.2 to 0.4)	0.9 (0.5 to 1.3)	190.6 (83.8 to 317.0)	27.9 (-19.3 to 84.8)
Cervical cancer	0.7 (0.5 to 1.0)	0.7 (0.5 to 1.0)	9.0 (-40.9 to 68.5)	-11.2 (-73.4 to -44.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	48.0 (-38.5 to 88.0)	-48.0 (-72.7 to -15.8)
Uterine cancer	0.9 (0.5 to 1.4)	1.4 (0.8 to 2.0)	44.6 (-12.0 to 146.0)	-35.8 (-61.1 to 8.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	45.2 (-14.8 to 150.6)	-35.9 (-61.4 to 10.4)
Prostate cancer	1.6 (1.0 to 2.5)	9.3 (5.3 to 14.6)	486.0 (262.4 to 842.7)	133.4 (44.6 to 276.2)	0.2 (0.1 to 0.3)	0.9 (0.5 to 1.4)	392.6 (218.0 to 662.3)	92.9 (25.2 to 201.6)
Colon and rectum cancer	1.8 (1.5 to 2.1)	5.8 (4.6 to 7.1)	223.3 (150.3 to 328.5)	37.9 (6.3 to 82.5)	0.1 (0.1 to 0.2)	0.5 (0.3 to 0.6)	219.9 (145.9 to 327.5)	36.1 (4.9 to 81.7)
Lip and oral cavity cancer	0.4 (0.3 to 0.5)	0.7 (0.5 to 1.0)	81.4 (22.6 to 196.6)	-20.4 (-45.4 to 27.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	81.1 (22.1 to 194.5)	-21.1 (-46.6 to 28.0)
Nasopharynx cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	93.1 (12.4 to 243.4)	-11.7 (-47.9 to 58.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (11.6 to 211.0)	-15.7 (-48.5 to 43.2)
Other pharynx cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	70.1 (1.6 to 200.1)	-24.1 (-54.2 to 33.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.6 (-2.1 to 190.7)	-26.1 (-56.2 to 27.5)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	87.8 (8.6 to 210.5)	-23.1 (-56.2 to 28.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.9 (10.8 to 211.2)	-23.1 (-55.6 to 29.9)
Pancreatic cancer	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	191.8 (111.2 to 305.9)	23.1 (-9.8 to 70.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	181.5 (105.2 to 282.1)	19.9 (-13.1 to 62.1)
Malignant skin melanoma	0.4 (0.1 to 0.3)	0.5 (0.4 to 0.7)	0.5 (90.6 to 292.6)	0.5 (-16.3 to 69.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (82.5 to 286.1)	37.1 (-21.4 to 67.1)
Non-melanoma skin cancer	0.4 (0.3 to 0.5)	2.6 (2.3 to 3.0)	613.0 (395.2 to 931.1)	188.6 (98.5 to 314.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	408.9 (259.3 to 612.0)	102.7 (189.2 to 189.2)
Ovarian cancer	0.4 (0.3 to 0.5)	0.9 (0.6 to 1.3)	124.7 (45.4 to 251.6)	2.0 (-33.9 to 59.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	129.2 (44.1 to 272.1)	3.7 (-34.0 to 68.1)
Testicular cancer	0.3 (0.2 to 0.5)	0.8 (0.4 to 1.4)	166.2 (42.9 to 395.5)	22.5 (-32.9 to 125.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	158.0 (36.4 to 404.0)	18.5 (-36.5 to 122.7)
Kidney cancer	0.4 (0.3 to 0.6)	1.2 (0.8 to 1.6)	156.4 (72.5 to 277.3)	22.4 (-16.9 to 80.6)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	155.1 (73.6 to 281.1)	19.8 (-18.2 to 75.3)
Bladder cancer	0.4 (0.3 to 0.5)	0.7 (0.5 to 0.9)	62.8 (11.1 to 140.9)	-32.0 (-53.7 to -0.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	65.3 (12.1 to 138.8)	-31.1 (-53.3 to -0.2)
Brain and nervous system cancer	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.3)	79.1 (14.6 to 150.6)	-2.2 (-36.2 to 36.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	84.3 (23.0 to 159.0)	-5.4 (-36.9 to 34.7)
Thyroid cancer	1.1 (0.7 to 1.6)	2.2 (1.5 to 2.9)	94.3 (21.8 to 197.1)	-13.5 (-44.4 to 32.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	88.4 (19.3 to 189.5)	-16.1 (-46.3 to 29.3)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.1 (37.5 to 194.3)	-10.3 (-39.8 to 32.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.1 (37.5 to 194.3)	102.1 (-39.7 to 33.6)
Hodgkin lymphoma	0.7 (0.4 to 1.1)	1.5 (0.8 to 2.2)	102.9 (24.0 to 245.6)	2.5 (-35.5 to 71.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	93.0 (22.2 to 224.2)	-3.3 (-37.3 to 57.4)
Non-Hodgkin lymphoma	1.4 (1.1 to 2.1)	4.8 (3.1 to 6.5)	254.4 (76.3 to 429.4)	72.1 (-19.4 to 153.1)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	256.1 (76.5 to 422.9)	71.0 (-19.6 to 148.1)
Multiple myeloma	0.1 (0.1 to 0.2)	0.3 (0.3 to 0.6)	229.9 (78.9 to 512.7)	40.2 (-25.1 to 165.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	226.2 (76.9 to 516.2)	38.7 (-25.7 to 163.4)
Leukemia	0.4 (0.3 to 0.5)	1.5 (1.1 to 1.9)	309.5 (154.3 to 510.9)	147.4 (60.1 to 248.3)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	365.6 (208.0 to 529.1)	443.7 (72.5 to 237.7)
Other neoplasms	0.5 (0.4 to 0.7)	1.5 (1.0 to 2.0)	194.0 (68.2 to 337.4)	58.3 (-2.8 to 130.4)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	184.2 (66.1 to 313.8)	44.3 (-7.8 to 107.1)
Cardiovascular diseases	-	-	-	-	5.6 (3.9 to 7.7)	13.4 (9.2 to 18.5)	140.1 (92.1 to 197.5)	9.3 (-10.8 to 34.4)
Rheumatic heart disease	7.7 (5.7 to 9.4)	16.3 (12.3 to 19.8)	109.8 (46.6 to 210.7)	0.5 (-30.0 to 46.4)	0.4 (0.2 to 0.6)	1.0 (0.6 to 1.4)	138.2 (70.4 to 262.4)	14.6 (-17.4 to 72.8)
Ischemic heart disease	29.3 (24.1 to 36.1)	63.0 (53.3 to 74.3)	116.5 (63.9 to 174.8)	-7.4 (-29.6 to 16.9)	1.5 (1.0 to 2.2)	3.6 (2.3 to 5.1)	112.2 (67.1 to 215.0)	2.4 (-26.1 to 36.7)
Cerebrovascular disease	-	-	-	-	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.6)	150.7 (95.2 to 213.3)	8.1 (-15.4 to 35.3)
Ischemic stroke	1.0 (0.9 to 1.2)	2.4 (2.1 to 2.8)	141.1 (93.5 to 200.5)	3.2 (-17.1 to 27.2)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.5)	151.8 (96.7 to 219.5)	8.8 (-15.6 to 37.2)
Hemorrhagic stroke	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	134.7 (67.1 to 241.4)	3.1 (-27.1 to 50.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	136.5 (65.7 to 242.8)	3.2 (-27.2 to 50.4)
Hypertensive heart disease	3.1 (2.1 to 3.9)	10.0 (7.5 to 13.2)	224.4 (116.5 to 414.4)	42.5 (-9.9 to 129.6)	0.3 (0.2 to 0.5)	1.1 (0.7 to 1.6)	235.8 (126.3 to 429.7)	48.6 (-6.6 to 138.5)
Cardiomyopathy and myocarditis	2.5 (2.1 to 3.0)	7.2 (5.5 to 9.4)	190.1 (115.7 to 287.3)	34.8 (-0.3 to 82.3)	0.3 (0.2 to 0.4)	0.8 (0.5 to 1.2)	201.7 (119.8 to 305.6)	201.7 (2.5 to 94.3)
Atrial fibrillation and flutter	4.1 (2.7 to 5.9)	12.3 (9.4 to 16.2)	201.4 (98.7 to 379.3)	13.7 (-25.3 to 82.9)	0.3 (0.2 to 0.4)	0.9 (0.6 to 1.4)	224.1 (112.2 to 421.4)	22.7 (-19.7 to 97.0)
Peripheral vascular disease	49.1 (37.2 to 61.5)	128.6 (92.1 to 169.5)	161.6 (75.0 to 279.3)	7.4 (-25.6 to 50.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	130.1 (22.0 to 350.7)	-18.1 (-56.4 to 61.3)
Endocarditis	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	143.9 (57.7 to 286.6)	13.2 (-25.4 to 81.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	150.4 (50.2 to 320.3)	17.8 (-29.5 to 102.2)
Other cardiovascular and circulatory diseases	97.1 (72.6 to 51.6)	78.5 (50.1 to 102.8)	116.4 (31.0 to 208.5)	11.1 (-37.8 to 47.0)	2.5 (1.6 to 3.8)	5.5 (3.1 to 8.3)	124.4 (35.9 to 218.1)	5.3 (-35.6 to 51.3)
Chronic respiratory diseases	-	-	-	-	12.8 (8.7 to 17.3)	29.2 (20.1 to 39.8)	128.3 (102.3 to 159.9)	8.7 (-3.8 to 23.1)
Chronic obstructive pulmonary disease								

Appendix Table G.4 - Lebanon prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	120.3	-5.0
Silicosis	0.0	0.0	108.5	-12.0	0.0	0.0	107.8	-12.3
Asbestosis	-	-	0.0	0.0	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.1	228.1	0.3	0.0	0.0	128.6	0.1
Asthma	113.2	225.5	97.8	3.5	4.9	9.8	98.3	5.0
Interstitial lung disease and pulmonary sarcoidosis	0.2	0.6	131.1	1.6	0.0	0.1	132.3	3.0
Other chronic respiratory diseases	-	-	-	-	0.6	0.9	42.6	-36.3
Cirrhosis	-	-	-	-	0.2	0.3	62.4	-19.9
Cirrhosis due to hepatitis B	0.3	0.6	87.8	-9.7	0.1	0.1	92.2	-7.1
Cirrhosis due to hepatitis C	0.4	0.6	61.4	-25.0	0.1	0.2	154.4	42.4
Cirrhosis due to alcohol use	0.1	0.2	18.9	-46.9	0.0	0.0	24.3	-43.8
Cirrhosis due to other causes	0.2	0.3	22.1	-20.5	0.0	0.1	23.5	-19.1
Digestive diseases	-	-	-	-	1.9	4.0	113.8	-2.1
Peptic ulcer disease	9.0	12.9	42.4	-39.6	0.3	0.6	67.6	-29.7
Gastritis and duodenitis	9.1	9.8	7.3	-46.2	0.4	0.5	11.6	-39.3
Appendicitis	0.2	0.3	50.4	-23.3	0.1	0.1	53.7	-20.7
Paralytic ileus and intestinal obstruction	0.0	0.1	93.4	0.0	0.0	0.0	93.0	7.9
Inguinal, femoral, and abdominal hernia	7.7	16.2	110.1	-8.3	0.1	0.2	116.6	-4.1
Inflammatory bowel disease	2.5	7.8	208.9	40.2	0.5	1.6	218.5	45.8
Vascular intestinal disorders	0.0	0.0	135.3	-1.2	0.0	0.0	135.7	0.6
Gallbladder and biliary diseases	1.1	2.5	119.5	-1.1	0.1	0.3	124.4	4.4
Pancreatitis	0.6	1.1	100.1	-9.0	0.2	0.3	107.6	-5.0
Other digestive diseases	-	-	-	-	0.2	0.5	147.8	13.6
Neurological disorders	-	-	-	-	20.4	48.1	134.9	11.2
Alzheimer disease and other dementias	17.8	48.1	170.1	-0.1	2.3	6.9	121.6	6.8
Parkinson disease	1.6	4.0	158.6	2.9	0.2	0.5	174.4	9.8
Epilepsy	13.0	22.4	72.3	-1.9	4.1	7.7	87.7	8.6
Multiple sclerosis	0.5	2.0	306.9	83.3	0.2	0.7	312.8	85.4
Migraine	271.4	364.6	106.2	1.6	9.0	11.5	110.5	1.4
Tension-type headache	474.7	936.9	95.4	-4.8	5.7	11.4	97.6	-3.3
Medication overuse headache	22.9	72.1	217.5	47.6	3.5	11.3	224.9	51.6
Other neurological disorders	0.0	0.0	87.4	0.8	0.4	0.4	24.4	-54.3
Mental and substance use disorders	-	-	-	-	65.2	138.8	112.4	6.1
Schizophrenia	7.0	15.4	121.4	-0.3	4.0	9.9	130.4	4.0
Alcohol use disorders	11.8	23.4	97.7	-5.3	1.1	2.3	102.4	-3.1
Drug use disorders	-	-	-	-	8.9	25.0	179.2	26.4
Opioid use disorders	18.9	53.4	181.5	25.4	7.6	22.2	192.7	30.1
Cocaine use disorders	2.1	4.5	119.6	1.6	0.3	0.6	124.5	6.0
Amphetamine use disorders	2.7	5.0	84.2	-7.4	0.3	0.7	89.3	-4.8
Cannabis use disorders	3.6	7.0	97.3	0.4	0.1	0.2	99.1	1.4
Other drug use disorders	-	-	-	-	0.6	1.3	106.4	1.1
Depressive disorders	-	-	-	-	19.3	42.3	119.7	6.5
Major depressive disorder	82.4	176.4	114.5	4.3	16.4	36.0	119.3	7.6
Dysthymia	30.4	65.6	115.9	-1.7	2.8	6.3	120.7	0.8
Bipolar disorder	19.2	40.5	111.8	-2.0	3.8	8.2	117.5	1.1
Anxiety disorders	152.4	289.0	90.5	-1.4	13.8	26.5	92.9	0.9
Eating disorders	-	-	-	-	0.4	0.8	102.9	4.3
Anorexia nervosa	0.5	1.0	114.4	14.8	0.1	0.2	116.8	16.4
Bulimia nervosa	1.4	2.8	95.6	-1.0	0.3	0.6	98.5	0.7
Autistic spectrum disorders	-	-	-	-	3.1	5.6	80.7	4.8
Autism	8.0	14.2	78.6	1.6	1.9	3.5	81.3	4.4
Asperger syndrome	11.9	21.1	77.8	2.1	1.2	2.1	79.6	4.2
Attention-deficit/hyperactivity disorder	17.6	24.4	38.9	-1.6	0.2	0.3	39.5	-1.1
Conduct disorder	32.8	45	39.6	4.8	3.9	5.5	29.5	-0.1
Idiopathic intellectual disability	74.5	116.7	56.4	-10.6	3.6	5.7	57.9	-9.1
Other mental and substance use disorders	39.6	90.1	127.6	2.0	2.9	6.7	134.2	5.5
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	26.2	66.0	150.7	20.8
Diabetes mellitus	135.9	400.7	192.5	32.9	12.8	39.9	208.9	37.5
Acute glomerulonephritis	0.0	0.0	12.6	-26.3	0.0	0.0	12.6	-26.3
Chronic kidney disease	-	-	-	-	2.8	6.1	117.0	5.4
Chronic kidney disease due to diabetes mellitus	26.9	66.5	149.4	1.6	1.0	1.6	157.3	17.7
Chronic kidney disease due to hypertension	16.3	24.6	50.9	-24.8	0.8	1.5	76.8	-19.0
Chronic kidney disease due to glomerulonephritis	31.1	51.6	65.8	0.4	0.6	0.6	55.3	-15.4
Chronic kidney disease due to other causes	39.3	92.2	138.5	15.2	1.0	2.4	147.5	26.6
Urinary diseases and male infertility	-	-	-	-	1.5	4.3	179.1	18.7

Appendix Table G.4 - Lebanon prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.6 (0.5 to 0.6)	1.2 (1.1 to 1.3)	107.0 (86.4 to 125.1)	0.0 (-6.3 to 11.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	108.1 (66.9 to 157.5)	4.5 (-14.2 to 25.9)
Urolithiasis	33.7 (24.8 to 46.6)	92.7 (51.4 to 171.2)	151.2 (90.2 to 290.2)	0.2 (-16.8 to 69.4)	0.2 (0.1 to 0.3)	0.6 (0.3 to 1.2)	194.9 (128.4 to 342.9)	31.0 (1.5 to 95.1)
Benign prostatic hyperplasia	31.0 (28.5 to 33.5)	78.3 (72.7 to 84.5)	152.1 (125.6 to 187.0)	1.0 (-6.9 to 18.7)	1.0 (0.7 to 1.5)	2.8 (1.8 to 3.9)	165.2 (135.0 to 207.2)	10.5 (-2.5 to 27.9)
Male infertility due to other causes	20.3 (14.1 to 27.1)	45.6 (32.0 to 61.7)	124.2 (42.8 to 276.7)	2.7 (-34.0 to 69.8)	0.1 (0.1 to 0.3)	0.3 (0.1 to 0.6)	123.6 (37.6 to 291.1)	3.0 (-36.0 to 76.0)
Other urinary diseases	-	-	-	-	0.1 (0.0 to 0.2)	0.5 (0.2 to 1.1)	380.4 (119.7 to 795.4)	102.9 (-2.9 to 298.4)
Gynecological diseases	-	-	-	-	4.4 (2.8 to 6.5)	9.1 (5.8 to 13.5)	105.6 (73.6 to 142.4)	-6.4 (-19.4 to 9.7)
Uterine fibroids	49.6 (45.0 to 53.9)	100.2 (90.7 to 108.9)	101.8 (101.1 to 102.5)	-13.8 (-14.3 to -13.4)	0.7 (0.4 to 1.2)	1.5 (0.9 to 2.5)	106.8 (95.7 to 120.4)	-10.1 (-14.9 to -4.2)
Polycystic ovarian syndrome	56.0 (51.2 to 60.5)	113.7 (102.0 to 125.2)	103.1 (76.7 to 131.4)	-9.0 (-20.6 to 3.2)	0.5 (0.3 to 1.0)	1.1 (0.5 to 2.2)	105.3 (79.8 to 137.0)	-8.0 (-18.9 to 5.1)
Female infertility due to other causes	13.8 (7.1 to 21.6)	30.6 (14.9 to 46.6)	122.2 (51.1 to 422.4)	-2.3 (-60.0 to 140.1)	0.2 (0.0 to 0.2)	0.2 (0.1 to 0.4)	125.1 (-3.2 to 422.8)	-0.7 (-58.1 to 132.0)
Endometriosis	4.8 (4.1 to 5.6)	10.2 (8.7 to 11.8)	113.4 (74.5 to 162.6)	-5.5 (-22.5 to 15.4)	0.4 (0.3 to 0.6)	0.9 (0.6 to 1.3)	116.6 (71.8 to 170.1)	-4.4 (-23.4 to 18.5)
Genital prolapse	148.2 (117.5 to 176.0)	291.8 (226.8 to 352.0)	96.0 (48.9 to 158.1)	-13.0 (-32.2 to 13.5)	0.5 (0.2 to 0.9)	0.9 (0.4 to 1.8)	98.9 (50.4 to 163.1)	-11.6 (-31.7 to 15.1)
Premenstrual syndrome	230.8 (172.2 to 290.2)	464.4 (339.2 to 570.9)	101.0 (39.7 to 184.6)	-4.7 (-32.7 to 34.3)	1.9 (1.1 to 3.0)	3.9 (2.3 to 6.1)	103.6 (40.1 to 190.1)	-3.4 (-32.9 to 37.3)
Other gynecological diseases	7.9 (6.1 to 9.8)	15.9 (14.8 to 17.1)	101.2 (60.4 to 161.8)	-6.5 (-25.5 to 21.8)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	105.4 (72.9 to 242.2)	-4.3 (-20.5 to 58.0)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	3.7 (2.5 to 5.4)	5.3 (3.6 to 7.5)	42.5 (29.6 to 59.8)	-4.8 (-14.8 to 7.0)
Thalassemias	0.5 (0.4 to 0.6)	0.7 (0.6 to 0.8)	38.8 (26.4 to 54.0)	0.2 (-8.4 to 10.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	44.3 (1.0 to 104.7)	-0.0 (-30.6 to 42.3)
Thalassemia trait	113.9 (106.6 to 121.8)	199.0 (186.7 to 210.6)	74.6 (68.1 to 82.0)	-0.7 (-4.4 to 3.5)	2.6 (1.7 to 3.8)	3.7 (2.5 to 5.3)	44.2 (24.0 to 64.2)	-4.3 (-19.4 to 8.9)
Sickle cell disorders	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.4)	46.5 (25.8 to 97.7)	-3.9 (-17.1 to 29.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	67.0 (35.0 to 99.1)	-1.1 (-19.0 to 17.8)
Sickle cell trait	91.0 (85.0 to 97.9)	148.4 (138.1 to 159.7)	63.1 (56.2 to 70.0)	-7.2 (-11.1 to -3.3)	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.9)	61.2 (9.3 to 118.1)	28.3 (-26.8 to 58.4)
G6PD deficiency	39.4 (26.6 to 52.5)	63.1 (40.8 to 85.0)	58.0 (1.3 to 168.6)	-10.3 (-42.5 to 52.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.7 (26.2 to 39.9)	-14.7 (-18.6 to -11.5)
G6PD trait	293.9 (183.6 to 418.8)	590.5 (370.7 to 751.8)	102.5 (24.8 to 227.1)	14.0 (-29.7 to 84.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.4 (-88.3 to 196.7)	-39.8 (-91.5 to 115.9)
Other hemoglobinopathies and hemolytic anemias	21.1 (17.1 to 24.2)	37.0 (33.2 to 40.3)	75.7 (47.9 to 122.4)	4.4 (-11.2 to 28.1)	0.5 (0.3 to 0.8)	0.8 (0.5 to 1.2)	48.2 (21.1 to 140.0)	2.2 (-28.3 to 62.0)
Endocrine, metabolic, blood, and immune disorders	30.7 (26.5 to 34.2)	48.7 (45.7 to 51.3)	58.0 (40.7 to 83.6)	-2.2 (-12.0 to 12.1)	1.0 (0.7 to 1.4)	1.5 (1.0 to 2.1)	49.9 (29.7 to 93.6)	4.3 (-15.2 to 25.1)
Musculoskeletal disorders	-	-	-	-	25.0 (17.8 to 33.1)	59.8 (42.9 to 79.9)	138.8 (122.7 to 158.3)	6.9 (-0.1 to 15.5)
Rheumatoid arthritis	5.0 (4.7 to 5.4)	9.9 (9.3 to 10.5)	99.1 (80.4 to 117.8)	-10.6 (-19.2 to -2.3)	1.1 (0.8 to 1.5)	2.3 (1.6 to 3.1)	104.8 (80.5 to 130.4)	-7.1 (-18.1 to 4.7)
Osteoarthritis	67.6 (64.3 to 71.0)	157.4 (148.8 to 165.7)	133.0 (115.2 to 149.2)	-2.6 (-9.9 to 3.9)	3.9 (2.8 to 5.4)	9.5 (6.6 to 13.6)	141.4 (121.0 to 162.9)	1.4 (-7.1 to 10.7)
Low back and neck pain	-	-	-	-	17.8 (12.5 to 23.7)	40.3 (28.4 to 53.8)	225.5 (104.5 to 150.5)	31.4 (-6.5 to 13.5)
Low back pain	78.6 (72.5 to 85.2)	172.2 (159.9 to 184.5)	118.7 (99.0 to 144.6)	-0.4 (-8.6 to 11.4)	8.5 (5.7 to 11.7)	19.1 (12.9 to 26.4)	125.0 (103.1 to 153.1)	3.5 (-6.4 to 15.6)
Neck pain	98.4 (90.0 to 108.6)	218.5 (192.8 to 239.4)	122.9 (85.9 to 156.9)	0.1 (-15.8 to 15.6)	9.3 (6.5 to 12.9)	21.3 (14.6 to 29.6)	128.8 (90.1 to 164.0)	3.4 (-12.9 to 19.5)
Gout	1.3 (1.2 to 1.6)	3.4 (2.8 to 3.8)	149.4 (100.8 to 205.4)	6.8 (-13.2 to 31.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	156.7 (92.8 to 238.1)	11.1 (-16.1 to 45.4)
Other musculoskeletal disorders	24.4 (19.3 to 38.9)	82.6 (51.3 to 131.6)	231.1 (140.6 to 357.6)	41.9 (3.9 to 97.3)	2.4 (1.4 to 3.6)	7.5 (4.0 to 13.1)	48.4 (155.3 to 373.0)	48.4 (11.6 to 105.6)
Other non-communicable diseases	-	-	-	-	40.6 (27.3 to 58.7)	81.8 (55.0 to 117.4)	101.4 (91.8 to 110.6)	1.3 (-3.2 to 6.2)
Congenital anomalies	-	-	-	-	2.6 (1.9 to 3.3)	6.9 (4.8 to 9.5)	166.9 (118.9 to 224.8)	55.2 (28.0 to 89.3)
Neural tube defects	0.7 (0.6 to 0.9)	1.4 (1.2 to 1.8)	101.4 (55.5 to 171.4)	24.4 (-4.0 to 68.0)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.7)	107.3 (42.1 to 228.2)	29.2 (-11.2 to 105.4)
Congenital heart anomalies	13.1 (10.9 to 16.0)	35.6 (30.4 to 43.4)	170.7 (106.3 to 253.5)	63.7 (25.0 to 114.2)	0.5 (0.2 to 0.8)	1.3 (0.5 to 2.3)	177.5 (113.4 to 259.0)	71.2 (33.4 to 122.9)
Orofacial clefts	2.4 (1.8 to 3.3)	6.0 (4.5 to 8.0)	149.2 (61.2 to 303.4)	55.8 (1.2 to 152.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	69.8 (2.2 to 187.5)	6.7 (-35.0 to 77.7)
Down syndrome	4.2 (3.2 to 5.4)	9.5 (7.4 to 12.4)	125.1 (65.2 to 231.8)	30.1 (-4.5 to 91.6)	0.5 (0.4 to 0.7)	1.3 (0.9 to 1.9)	149.0 (78.9 to 268.1)	40.6 (0.7 to 106.0)
Turner syndrome	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	85.6 (40.0 to 150.1)	6.8 (-19.7 to 44.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.3 (37.1 to 173.7)	5.9 (-23.6 to 49.7)
Klinefelter syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	81.9 (35.0 to 149.6)	5.5 (-21.8 to 44.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.7 (55.1 to 191.6)	7.7 (-20.5 to 48.1)
Chromosomal unbalanced rearrangements	9.9 (3.3 to 4.7)	8.3 (6.8 to 10.1)	111.6 (62.9 to 173.1)	2.2 (-6.2 to 57.9)	0.5 (0.4 to 0.7)	1.2 (0.8 to 1.5)	132.5 (79.1 to 209.4)	31.5 (1.5 to 73.5)
Other congenital anomalies	7.3 (6.2 to 8.6)	12.4 (10.2 to 15.1)	69.2 (36.0 to 102.6)	-10.3 (-28.2 to 6.8)	0.9 (0.6 to 1.2)	2.7 (1.6 to 4.3)	209.1 (108.2 to 376.1)	78.7 (20.9 to 178.3)
Skin and subcutaneous diseases	-	-	-	-	18.8 (12.3 to 27.8)	34.4 (22.3 to 51.5)	83.5 (68.9 to 97.4)	2.4 (-5.0 to 8.9)
Dermatitis	207.6 (177.5 to 240.1)	383.8 (325.5 to 442.6)	85.0 (78.8 to 90.8)	0.2 (-0.1 to 0.5)	8.3 (5.3 to 12.0)	14.7 (9.4 to 21.5)	77.8 (66.6 to 86.4)	7.8 (-0.7 to 5.1)
Psoriasis	16.2 (12.7 to 20.1)	33.7 (26.3 to 42.0)	108.1 (103.5 to 112.2)	0.0 (-0.5 to 0.5)	1.3 (0.8 to 1.9)	2.7 (1.7 to 4.0)	113.0 (98.1 to 129.7)	3.1 (-3.3 to 10.8)
Cellulitis	0.6 (0.5 to 0.7)	0.9 (0.8 to 1.2)	56.9 (38.6 to 78.5)	-1.7 (-22.4 to -3.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	58.8 (27.7 to 98.5)	-11.0 (-26.4 to 8.5)
Pyoderma	2.1 (1.7 to 2.6)	2.8 (2.3 to 3.8)	36.6 (20.2 to 53.2)	-7.2 (-12.7 to -0.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.7 (15.2 to 59.8)	-6.0 (-16.8 to 5.8)
Scabies	11.3 (8.2 to 15.4)	18.5 (14.4 to 23.8)	67.2 (10.2 to 150.6)	-5.3 (-34.9 to 39.5)	0.3 (0.1 to 0.5)	0.5 (0.3 to 0.8)	68.0 (17.0 to 150.1)	-3.7 (-34.9 to 42.1)
Fungal skin diseases	169.8 (131.7 to 208.4)	345.2 (270.1 to 424.5)	103.4 (95.3 to 112.3)	0.7 (-0.3 to 1.3)	0.9 (0.4 to 2.0)	1.9 (0.8 to 4.1)	166.0 (97.0 to 116.6)	2.6 (-1.0 to 5.6)
Viral skin diseases	58.9 (45.2 to 71.9)	88.8 (65.7 to 114.0)	50.5 (39.3 to 62.4)	0.0 (-2.0 to 2.1)	1.8 (1.1 to 2.9)	2.7 (1.6 to 4.3)	51.0 (38.1 to 64.2)	0.9 (-2.4 to 5.1)
Acne vulgaris	330.4 (261.6 to 401.0)	609.3 (466.5 to 759.1)	85.6 (38.9 to 147.9)	8.6 (-17.9 to 43.9)	3.6 (1.7 to 6.9)	6.6 (2.9 to 13.2)	86.4 (38.6 to 150.3)	9.1 (-17.3 to 45.1)
Alopecia areata	3.8 (3.3 to 4.3)	7.3 (6.3 to 8.3)	94.7 (69.3 to 124.5)	-0.2 (-12.7 to 15.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	97.4 (65.0 to 135.0)	2.6 (-13.1 to 20.6)
Pruritus	0.6 (0.4 to 0.8)	1.1 (0.6 to 2.1)	75.2 (-11.3 to 371.8)	-3.7 (-58.2 to 135.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.5 (-8.5 to 375.2)	-13.7 (-57.1 to 140.9)
Urticaria	24.7 (18.2 to 32.1)	46.7 (33.2 to 59.7)	89.3 (19.4 to 176.5)	-4.8 (-42.2 to 32.7)	1.4 (0.8 to 2.2)	2.7 (1.6 to 4.1)	91.3 (20.1 to 187.4)	-4.8 (-40.8 to 37.2)
Decubitus ulcer	0.5 (0.4 to 0.6)	1.0 (0.6 to 1.3)	96.5 (12.7 to 192.4)	-1.7 (-56.8 to 21.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	104.1 (14.6 to 199.9)	-17.1 (-54.5 to 28.5)
Other skin and subcutaneous diseases	163.5 (107.3 to 250.4)	348.8 (223.0 to 542.7)	112.8 (99.0 to 125.9)	0.3 (-3.3 to 4.0)	0.9 (0.4 to 1.9)	2.0 (0.9 to 4.3)	116.5 (101.1 to 132.8)	2.7 (-1.6 to 8.3)
Sense organ diseases	-	-	-	-	13.0 (8.7 to 18.4)	26.8 (17.8 to 38.4)	105.4 (95.1 to 116.3)	-6.8 (-10.9 to -1.5)
Glaucoma	3.1 (2.2 to 4.5)	5.8 (4.0 to 8.8)	90.5 (36.5 to 176.6)	-20.0 (-42.2 to 26.7)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.4)	83.6 (37.3 to 169.2)	-22.8 (-41.9 to 20.3)
Cataract	11.2 (7.7 to 16.7)	24.8 (16.4 to 33.6)	125.2 (72.1 to 208.8)	-10.7 (-32.0 to 24.3)	0.5 (0.3 to 0.9)	1.3 (0.7 to 1.9)	130.2 (78.6 to 207.9)	-8.8 (-29.6 to 22.1)
Macular degeneration	2.5 (1.4 to 3.7)	4.4 (2.7 to 7.0)	73.2 (11.0 to 214.2)	-2.4 (-51.0 to 39.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	79.0 (16.6 to 211.2)	-22.9 (-49.0 to 37.4)
Uncorrected refractive error	216.0 (201.9 to 230.3)	452.7 (421.5 to 484.4)	109.6 (93.3 to 128.7)	3.8 (-11.7 to 25.0)	3.0 (1.9 to 4.9)	6.1 (3.4 to 10.2)	102.8 (88.7 to 120.0)	-5.3 (-14.4 to 2.6)
Age-related and other hearing loss	274.2 (256.9 to 292.6)	579.2 (541.4 to 620.5)	111.3 (103.3 to 119.5)	-8.8 (-11.9 to -5.6)	7.2 (4.9 to 10.0)	9.9 (10.5 to 21.9)	116.6 (102.9 to 133.6)	-7.1 (-13.1 to -2.5)
Other vision loss	7.3 (5.6 to 9.3)	11.4 (8.5 to 14.6)	55.8 (26.8 to 93.6)	-23.3 (-40.4 to 0.2)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.8)	57.7 (30.9 to 92.7)	-0.2 (-39.8 to -3.0)
Other sense organ diseases	63.8 (61.2 to 66.8)	105.3 (100.0 to 110.1)	65.0 (54.5 to 74.8)	-0.5 (-6.5 to 5.6)	1.7 (1.0 to 2.5)	2.8 (1.7 to 4.1)	65.3 (53.9 to 77.5)	1.3 (-5.2 to 9.1)
Oral disorders	-	-	-	-	6.2 (3.9 to 9.4)	2.5 (8.6 to 20.6)	119.6 (103.7 to 136.8)	-0.9 (-8.2 to 7.3)
Deciduous caries	293.8 (284.1 to 302.5)	287.5 (279.7 to 294.5)	-2.1 (-5.9 to 2.1)	1.4 (-2.6 to 5.6)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	1.5 (-1.1 to 4.1)	1.5 (-4.8 to 7.8)
Permanent caries	838.4 (752.7 to 940.6)	1,605.9 (1,394.0 to 1,793.6)	90.8 (63.2 to 125.8)	-1.1 (-15.2 to 16				

Appendix Table G.4 - Lebanon prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	119.4 (110.7 to 129.1)	266.1 (243.4 to 286.8)	123.0 (98.9 to 148.7)	-7.4 (-17.3 to 2.8)	3.1 (2.1 to 4.4)	7.2 (4.8 to 10.1)	131.1 (104.9 to 160.0)	-3.5 (-14.1 to 8.2)
Other oral disorders	44.7 (42.2 to 47.0)	89.5 (84.1 to 94.2)	99.9 (85.1 to 116.4)	-1.2 (-8.3 to 6.2)	1.3 (0.8 to 1.9)	2.6 (1.6 to 3.9)	102.7 (86.9 to 119.5)	0.6 (-6.9 to 8.8)
Injuries	-	-	-	-	152.2 (66.6 to 310.6)	52.8 (28.3 to 97.2)	-64.3 (-76.7 to -47.6)	-82.8 (-88.7 to -74.6)
Transport injuries	-	-	-	-	4.2 (3.2 to 5.4)	5.0 (3.6 to 6.8)	19.2 (3.7 to 37.7)	-44.3 (-51.2 to -36.1)
Road injuries	-	-	-	-	3.8 (2.9 to 4.9)	4.3 (3.1 to 5.8)	46.8 (17.7 to 31.2)	-45.4 (-53.6 to -39.1)
Pedestrian road injuries	-	-	-	-	0.9 (0.7 to 1.1)	0.9 (0.6 to 1.2)	1.3 (-13.8 to 19.7)	-51.1 (-58.0 to -43.0)
Cyclist road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	39.5 (24.2 to 56.2)	-36.2 (-43.0 to -28.7)
Motorcyclist road injuries	-	-	-	-	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	0.6 (-13.1 to 17.1)	-53.4 (-59.7 to -46.1)
Motor vehicle road injuries	-	-	-	-	1.6 (1.6 to 2.7)	2.4 (1.7 to 3.3)	17.0 (0.4 to 39.2)	45.4 (-53.2 to -36.2)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.3 (-44.7 to -24.1)	-69.8 (-73.9 to -64.9)
Other transport injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.7 (0.5 to 0.9)	73.0 (54.0 to 97.2)	-21.3 (-30.1 to -10.6)
Unintentional injuries	-	-	-	-	4.3 (3.2 to 5.5)	7.0 (5.1 to 9.3)	63.6 (49.6 to 78.5)	-24.9 (-31.4 to -18.1)
Falls	-	-	-	-	1.6 (1.2 to 2.1)	2.9 (2.1 to 3.9)	79.1 (57.8 to 101.9)	-22.7 (-32.5 to -12.2)
Drowning	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-3.5 (-16.8 to 14.1)	-53.0 (-59.2 to -44.9)
Fire, heat, and hot substances	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	1.2 (-13.6 to 17.4)	-51.3 (-57.9 to -44.0)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	14.6 (6.1 to 39.4)	-41.6 (-51.9 to -29.4)
Exposure to mechanical forces	-	-	-	-	1.2 (0.9 to 1.6)	1.9 (1.4 to 2.5)	56.4 (42.7 to 71.1)	-24.4 (-30.5 to -17.5)
Unintentional firearm injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	23.1 (7.5 to 42.0)	-43.2 (-50.0 to -34.9)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.4 (79.0 to 129.6)	-2.5 (-13.1 to 9.8)
Other exposure to mechanical forces	-	-	-	-	1.1 (0.9 to 1.5)	1.8 (1.3 to 2.4)	57.7 (43.7 to 72.8)	-23.5 (-29.9 to -16.7)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	139.0 (123.6 to 154.6)	12.5 (5.0 to 20.2)
Animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	74.3 (55.1 to 94.9)	-14.5 (-23.3 to -5.3)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	77.6 (51.6 to 104.7)	-13.2 (-25.3 to -0.3)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	71.0 (49.0 to 93.9)	-15.8 (-25.4 to -6.0)
Foreign body	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	59.3 (43.8 to 75.5)	-22.3 (-29.4 to -14.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.6 (-24.2 to 13.5)	-50.7 (-58.5 to -40.3)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	81.4 (62.9 to 101.1)	-7.9 (-16.4 to 2.2)
Foreign body in other body part	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	75.6 (57.4 to 95.9)	-18.2 (-26.1 to -9.2)
Other unintentional injuries	-	-	-	-	0.8 (0.6 to 1.1)	1.4 (1.0 to 1.9)	72.9 (57.0 to 90.2)	-20.5 (-27.4 to -12.9)
Self-harm and interpersonal violence	-	-	-	-	0.6 (0.5 to 0.8)	0.5 (0.3 to 0.6)	-19.5 (-29.8 to -6.9)	-62.1 (-66.9 to -56.5)
Self-harm	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	86.5 (61.1 to 112.5)	-17.6 (-28.4 to -6.5)
Interpersonal violence	-	-	-	-	0.5 (0.4 to 0.7)	0.4 (0.3 to 0.5)	-28.9 (-38.0 to -16.7)	-66.4 (-70.6 to -60.9)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-15.3 (-24.4 to -4.8)	-60.0 (-64.1 to -55.2)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-17.1 (-29.4 to -2.9)	-61.2 (-66.6 to -54.8)
Assault by other means	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-37.8 (-47.0 to -26.1)	-70.5 (-74.7 to -65.2)
Forces of nature, war, and legal intervention	-	-	-	-	143.2 (58.5 to 301.5)	40.3 (17.5 to 83.8)	-71.5 (-81.6 to -57.6)	-86.2 (-91.0 to -79.2)
Exposure to forces of nature	-	-	-	-	3.0 (1.5 to 5.4)	2.0 (0.9 to 4.0)	-35.8 (-44.6 to -24.3)	-68.6 (-73.1 to -62.3)
Collective violence and legal intervention	-	-	-	-	140.2 (56.7 to 297.0)	38.4 (16.5 to 80.1)	-72.3 (-82.1 to -58.6)	-86.5 (-91.3 to -79.6)

Appendix Table G.4 - Lesotho prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	149.7 (110.4 to 194.5)	228.1 (171.0 to 293.7)	53.5 (45.6 to 59.7)	34.7 (9.5 to 20.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	33.5 (23.3 to 45.8)	70.9 (51.9 to 90.8)	112.9 (80.4 to 151.3)	106.2 (69.5 to 152.5)
HIV/AIDS and tuberculosis	-	-	-	-	2.8 (1.9 to 3.8)	39.0 (26.7 to 51.0)	1,305.1 (1,048.5 to 1,591.1)	858.1 (662.2 to 1,081.4)
Tuberculosis	7.7 (6.8 to 8.6)	19.3 (17.9 to 20.7)	150.5 (129.7 to 173.6)	59.3 (46.2 to 74.3)	2.3 (1.6 to 3.2)	5.8 (4.0 to 7.9)	149.4 (126.3 to 173.8)	57.6 (43.3 to 73.1)
HIV/AIDS	-	-	-	-	0.4 (0.3 to 0.6)	33.2 (22.7 to 43.8)	7,800.2 (5,569.2 to 9,712.7)	5,925.7 (4,428.8 to 8,017.5)
HIV/AIDS resulting in mycobacterial infection	0.2 (0.1 to 0.3)	8.5 (6.5 to 9.9)	4,066.7 (2,810.7 to 6,030.5)	2,765.4 (1,879.3 to 4,150.3)	0.1 (0.0 to 0.1)	3.1 (2.0 to 4.4)	4,002.0 (2,688.1 to 6,158.3)	2,708.7 (1,788.4 to 4,182.5)
HIV/AIDS resulting in other diseases	5.0 (4.0 to 6.4)	206.9 (189.6 to 220.2)	4,072.0 (3,182.0 to 5,092.3)	3,160.8 (2,460.6 to 3,997.4)	0.4 (0.2 to 0.5)	30.1 (20.5 to 40.3)	7,991.5 (5,951.7 to 11,116.4)	6,721.3 (4,880.7 to 9,576.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	5.1 (3.6 to 6.8)	5.0 (3.6 to 6.7)	-1.9 (-9.3 to 6.6)	-15.8 (-23.3 to -9.0)
Diarrheal diseases	16.6 (15.4 to 17.7)	15.3 (14.4 to 16.2)	-8.0 (-15.9 to 1.2)	-15.0 (-21.6 to -7.7)	2.7 (1.8 to 3.8)	2.5 (1.7 to 3.5)	-8.3 (-16.5 to 1.7)	-15.4 (-22.3 to -6.9)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (-49.7 to -4.1)	0.0 (-58.2 to -25.7)
Typhoid fever	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-23.3 (-40.4 to -3.3)	-38.6 (-51.1 to -23.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.8 (-42.1 to 2.5)	-38.1 (-51.3 to -18.5)
Paratyphoid fever	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-4.5 (-26.8 to 28.9)	-21.9 (-39.3 to 2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.0 (-29.1 to 33.7)	-21.5 (-40.6 to 4.7)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-82.6 (-97.5 to -13.0)	-85.8 (-98.0 to -28.4)
Lower respiratory infections	1.5 (1.3 to 1.7)	1.8 (1.6 to 2.0)	19.6 (1.4 to 43.0)	5.6 (9.4 to 24.2)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	18.8 (3.3 to 46.1)	5.6 (-10.6 to 27.1)
Upper respiratory infections	36.7 (33.3 to 39.7)	43.2 (39.0 to 46.8)	17.5 (4.1 to 34.5)	-7.6 (-18.0 to 5.5)	0.4 (0.2 to 0.7)	0.5 (0.3 to 0.9)	16.9 (3.3 to 34.8)	-8.2 (-18.6 to 5.8)
Otitis media	29.7 (26.9 to 32.4)	35.6 (32.4 to 39.2)	19.4 (10.4 to 30.6)	-5.9 (-13.5 to 2.7)	0.5 (0.3 to 0.9)	0.6 (0.4 to 1.0)	19.5 (8.2 to 33.5)	-5.3 (-14.1 to 4.7)
Meningitis	-	-	-	-	1.1 (0.7 to 1.5)	1.0 (0.7 to 1.4)	-6.4 (-27.0 to 23.6)	-27.5 (-41.9 to -5.8)
Pneumococcal meningitis	2.2 (1.4 to 3.3)	2.1 (1.3 to 3.3)	-4.3 (-26.6 to 24.3)	-34.5 (-43.3 to -0.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	6.7 (-29.0 to 21.0)	26.6 (-43.0 to -6.2)
H influenzae type B meningitis	3.2 (1.4 to 5.5)	2.6 (1.1 to 4.7)	-16.1 (-41.2 to 13.8)	-36.2 (-54.3 to -13.8)	0.4 (0.2 to 0.7)	0.3 (0.2 to 0.5)	-15.0 (-51.9 to 45.3)	-33.3 (-62.2 to 9.3)
Meningococcal meningitis	1.7 (0.6 to 3.8)	1.7 (0.6 to 3.5)	-1.9 (-24.9 to 31.1)	-25.3 (-43.3 to -3.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	3.0 (-23.7 to 64.0)	-22.6 (-40.3 to 14.9)
Other meningitis	2.3 (1.2 to 4.0)	2.3 (1.3 to 3.9)	-0.5 (-21.8 to 25.9)	-21.8 (-39.6 to 3.4)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	2.1 (-23.4 to 35.5)	-20.7 (-37.9 to 2.1)
Encephalitis	0.3 (0.1 to 0.6)	0.4 (0.2 to 0.8)	31.7 (13.2 to 46.3)	11.0 (-13.7 to 12.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	29.9 (13.5 to 56.1)	0.8 (-12.1 to 17.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.6 (84.3 to 2,447.8)	85.5 (81.8 to 1,776.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.6 (84.5 to 2,519.4)	85.5 (81.9 to 783.7)
Whooping cough	1.0 (0.8 to 1.3)	1.1 (0.8 to 1.3)	3.0 (2.7 to 3.2)	2.6 (2.4 to 2.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	2.8 (7.4 to 14.3)	2.5 (7.7 to 14.0)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-71.6 (-82.7 to -39.4)	-77.8 (-87.1 to -51.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.5 (-83.5 to -52.6)	-76.6 (-87.7 to -63.6)
Measles	0.3 (0.2 to 0.4)	0.1 (0.0 to 0.1)	-79.5 (-85.1 to -71.1)	-79.5 (-85.2 to -71.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-79.5 (-88.2 to -66.5)	-79.6 (-88.3 to -66.6)
Varicella and herpes zoster	1.0 (0.9 to 1.1)	1.4 (1.2 to 1.5)	35.8 (15.6 to 59.6)	4.3 (-19.1 to 31.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	35.2 (-10.1 to 92.6)	3.2 (-33.7 to 50.3)
Neglected tropical diseases and malaria	-	-	-	-	4.8 (3.1 to 7.2)	5.9 (3.8 to 8.9)	23.6 (10.0 to 38.1)	-3.0 (-16.2 to 8.4)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.2 (-54.8 to 157.0)	-17.6 (-67.0 to 89.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.9 (-54.6 to 159.0)	-17.1 (-66.8 to 90.8)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.1 (-19.0 to 144.5)	12.3 (-31.2 to 83.9)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.0 (-18.5 to 144.3)	12.2 (-30.6 to 82.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.0 (-19.2 to 144.4)	12.2 (-31.2 to 83.8)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,429.3 (914.8 to 2,083.7)	1,477.5 (1,029.9 to 2,148.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,429.3 (912.3 to 2,084.4)	1,477.5 (1,028.5 to 2,162.5)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	2.0 (1.0 to 3.1)	2.8 (1.5 to 4.5)	36.6 (-38.0 to 184.6)	-9.2 (-54.2 to 69.6)	0.5 (0.2 to 0.9)	0.8 (0.4 to 1.3)	41.3 (-38.0 to 191.8)	-7.3 (-54.7 to 73.3)
Cystic echinococcosis	0.7 (0.6 to 0.7)	0.6 (0.5 to 0.7)	-14.7 (-28.8 to 13.2)	-37.1 (-44.3 to -22.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-13.6 (-34.0 to 20.9)	-35.8 (-47.3 to -17.9)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.0 (-45.1 to 51.8)	-21.2 (-51.0 to 27.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.0 (-45.2 to 52.1)	21.2 (-51.1 to 27.8)
Intestinal nematode infections	-	-	-	-	3.3 (1.9 to 5.2)	4.2 (2.5 to 6.6)	28.6 (19.9 to 37.0)	-0.1 (-7.3 to 6.6)
Ascariasis	285.2 (189.8 to 417.7)	365.7 (239.5 to 569.2)	27.1 (-29.6 to 127.4)	-1.1 (-52.7 to 69.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	22.0 (6.2 to 38.1)	-0.7 (-15.3 to 14.0)
Trichuriasis	696.6 (529.8 to 893.2)	903.8 (671.4 to 1,204.0)	29.4 (-12.7 to 91.2)	-0.2 (-37.4 to 59.8)	1.7 (0.9 to 2.8)	2.1 (1.1 to 3.4)	25.4 (14.3 to 36.3)	-0.6 (-10.6 to 9.8)
Hookworm disease	312.5 (228.4 to 429.4)	418.1 (288.8 to 580.2)	33.1 (-19.6 to 115.5)	33.1 (-44.4 to 72.6)	0.7 (0.9 to 2.2)	1.9 (1.2 to 2.9)	33.4 (16.9 to 47.0)	0.7 (-10.9 to 10.5)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	25.9 (20.0 to 31.9)	25.6 (24.0 to 27.8)	-1.0 (-20.6 to 28.7)	-12.6 (-28.7 to 10.5)	0.9 (0.6 to 1.4)	0.9 (0.6 to 1.3)	-2.9 (-15.7 to 41.1)	-11.5 (-22.9 to 27.9)
Maternal disorders	-	-	-	-	0.6 (0.4 to 0.8)	0.5 (0.4 to 0.7)	-10.2 (-20.2 to 8.8)	-40.8 (-47.0 to -34.1)
Maternal hemorrhage	1.3 (1.2 to 1.5)	1.1 (0.8 to 1.4)	-17.3 (-44.8 to 13.0)	-51.6 (-67.2 to -35.1)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-25.5 (-63.4 to 23.8)	-97.4 (-78.5 to -30.3)
Maternal sepsis and other maternal infections	0.4 (0.2 to 0.6)	0.3 (0.2 to 0.5)	-16.3 (-29.3 to -6.2)	-46.5 (-54.5 to -40.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.1 (-44.7 to 47.2)	-46.1 (-63.9 to -17.1)
Maternal hypertensive disorders	0.3 (0.2 to 0.6)	0.3 (0.2 to 0.5)	-8.6 (-21.2 to 2.6)	-47.6 (-53.9 to -40.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.8 (-28.4 to 15.4)	-47.5 (-57.5 to -34.3)
Obstructed labor	1.4 (1.2 to 1.5)	1.2 (1.1 to 1.4)	-7.6 (-13.3 to -1.3)	-37.6 (-41.3 to -33.8)	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	-8.5 (-19.1 to 3.1)	-38.6 (-45.1 to -31.7)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-7.0 (-42.9 to 49.0)	-40.9 (-64.2 to -5.3)
Neonatal disorders	-	-	-	-	2.6 (1.4 to 4.1)	3.5 (2.1 to 5.1)	38.3 (-14.9 to 127.9)	4.2 (-35.1 to 68.3)
Preterm birth complications	6.4 (3.5 to 11.5)	15.0 (8.6 to 25.3)	134.3 (86.4 to 201.3)	80.4 (44.8 to 126.4)	0.7 (0.4 to 1.1)	1.4 (0.8 to 2.1)	98.2 (26.5 to 256.8)	47.1 (-5.6 to 162.5)
Neonatal encephalopathy due to birth asphyxia and trauma	9.6 (1.7 to 28.2)	11.6 (1.7 to 34.8)	19.7 (-24.7 to 54.2)	6.8 (-39.4 to 14.7)	0.7 (0.3 to 1.3)	0.7 (0.3 to 1.3)	2.4 (-54.7 to 139.3)	-24.1 (-63.9 to 78.0)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	158.0 (133.2 to 182.6)	0.0 (0.0 to 0.0)	158.0 (120.4 to 201.0)	150.4 (118.7 to 198.7)
Hemolytic disease and other neonatal jaundice	0.7 (0.3 to 1.2)	0.8 (0.2 to 1.8)	29.2 (-76.1 to 246.6)	-8.9 (-82.7 to 153.1)	0.3 (0.1 to 0.5)	0.3 (0.1 to 0.7)	30.9 (-76.2 to 252.9)	-7.6 (-82.2 to 153.8)
Other neonatal disorders	-	-	-	-	0.9 (0.3 to 2.2)	1.1 (0.4 to 2.1)	26.3 (-50.1 to 192.7)	-4.8 (-62.7 to 117.0)
Nutritional deficiencies	-	-	-	-	16.3 (10.8 to 23.9)	15.4 (10.3 to 22.4)	-5.7 (-11.3 to -0.0)	-23.6 (-27.0 to -18.9)
Protein-energy malnutrition	6.4 (3.2 to 11.8)	4.2 (1.6 to 9.1)	-36.1 (-78.1 to 80.4)	-34.8 (-76.3 to 72.8)	0.8 (0.3 to 1.6)	0.5 (0.2 to 1.3)	-35.9 (-78.6 to 80.7)	35.4 (-76.7 to 72.9)
Iodine deficiency	140.6 (124.2 to 156.9)	118.1 (97.9 to 143.1)	-16.2 (-31.6 to 5.6)	-38.2 (-50.6 to -21.8)	2.5 (1.5 to 4.1)	2.1 (1.2 to 3.4)	-16.9 (-32.6 to 5.3)	-38.8 (-51.2 to -21.8)
Vitamin A deficiency	2.8 (2.1 to 3.5)	1.8 (1.3 to 2.3)	-35.2 (-45.1 to -26.5)	-49.2 (-57.9 to -41.9)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-37.1 (-47.8 to -26.5)	-50.5 (-59.9 to -42.3)

Appendix Table G.4 - Lesotho prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	384.8 (379.0 to 390.3)	398.1 (393.6 to 402.1)	3.5 (1.8 to 5.1)	-17.8 (-19.0 to -16.7)	12.9 (8.6 to 18.7)	12.7 (8.5 to 18.4)	-1.3 (-4.7 to 0.4)	-1.3 (-21.2 to -17.1)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.3 (0.8 to 2.1)	1.6 (1.0 to 2.5)	18.3 (2.4 to 48.7)	-10.9 (-24.8 to 8.9)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.5 (0.3 to 0.9)	0.8 (0.4 to 1.4)	42.7 (-1.8 to 124.1)	-7.5 (-31.1 to 34.5)
Syphilis	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-6.6 (-22.7 to 12.3)	-32.2 (-42.7 to -19.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-33.6 (-47.6 to -14.2)
Chlamydial infection	55.7 (41.1 to 77.7)	80.9 (55.1 to 115.6)	44.1 (-2.9 to 152.4)	-8.4 (-36.0 to 53.3)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.7)	46.5 (-34.1 to 209.8)	-4.6 (-54.0 to 84.8)
Gonococcal infection	13.1 (9.0 to 18.0)	24.1 (17.0 to 33.6)	83.4 (3.6 to 205.7)	15.2 (-31.8 to 82.6)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	77.0 (-12.0 to 204.4)	12.3 (-41.5 to 91.0)
Trichomoniasis	42.3 (23.1 to 62.6)	60.3 (33.6 to 93.5)	35.9 (-21.4 to 130.2)	-12.4 (-44.2 to 74.5)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	29.9 (-28.8 to 222.0)	-15.9 (-48.6 to 89.9)
Genital herpes	372.7 (349.3 to 397.0)	309.3 (475.3 to 539.5)	366.8 (24.2 to 488.7)	-4.4 (-13.0 to 3.1)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	17.2 (23.1 to 51.4)	-4.9 (-14.3 to 3.7)
Other sexually transmitted diseases	0.7 (0.5 to 1.0)	2.2 (0.5 to 1.1)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.2 (-24.7 to 64.7)	2.7 (-48.8 to 1.0)
Hepatitis	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	3.1 (-17.9 to 30.7)	-28.2 (-44.9 to -3.0)
Hepatitis A	2.9 (2.7 to 3.0)	3.1 (3.0 to 3.2)	7.4 (6.2 to 8.8)	-5.0 (-5.2 to -4.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	30.7 (15.8 to 48.5)	3.9 (-7.7 to 16.9)
Hepatitis B	200.1 (160.9 to 249.2)	165.1 (129.7 to 198.8)	-16.8 (-41.2 to 7.1)	-38.3 (-57.0 to -20.2)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-13.0 (-48.3 to 34.6)	-39.2 (-60.3 to -3.5)
Hepatitis C	38.0 (34.1 to 42.0)	38.1 (34.0 to 42.3)	0.3 (-12.7 to 16.2)	26.1 (-35.1 to -15.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.6 (-28.3 to 30.4)	-25.3 (-46.1 to 5.6)
Hepatitis E	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.4)	19.4 (-3.6 to 49.0)	-20.0 (-35.1 to -1.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.8 (-14.4 to 69.9)	-19.0 (-41.7 to 10.2)
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.9 (-27.4 to 395.2)	3.9 (-43.1 to 261.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.9 (-29.5 to 430.1)	4.7 (-45.5 to 291.8)
Other infectious diseases	18.2 (14.4 to 22.3)	18.2 (16.3 to 19.9)	-0.2 (-10.7 to 14.4)	-14.3 (-22.7 to -5.1)	0.7 (0.4 to 1.0)	0.7 (0.4 to 1.0)	1.7 (-1.8 to 29.9)	-8.5 (-22.1 to 12.9)
Non-communicable diseases	-	-	-	-	109.2 (81.2 to 140.9)	148.1 (109.5 to 191.1)	35.5 (32.1 to 39.2)	1.6 (-4.2 to 1.0)
Neoplasms	-	-	-	-	0.5 (0.3 to 0.6)	0.9 (0.6 to 1.2)	90.7 (51.2 to 149.9)	43.8 (13.6 to 87.9)
Esophageal cancer	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	32.0 (9.8 to 93.3)	3.7 (-29.5 to 50.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	32.0 (-7.2 to 91.2)	3.6 (-27.7 to 46.6)
Stomach cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	-	-	0.0 (-3.0 to 75.2)	0.0 (-29.2 to 29.8)	0.0 (-1.0 to 83.5)	-2.2 (-28.8 to 36.0)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-1.0 to 112.6)	0.0 (-29.9 to 57.2)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.1 (-28.2 to 250.2)	9.3 (-47.8 to 163.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.5 (-23.0 to 229.0)	8.5 (-44.1 to 152.0)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	156.0 (34.0 to 485.7)	90.4 (-3.2 to 320.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	153.1 (39.4 to 431.4)	84.7 (-0.0 to 285.6)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.5 (-52.7 to 80.0)	-33.5 (-63.9 to 33.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.5 (-47.4 to 65.4)	-32.3 (-60.3 to 28.5)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.7 (-55.5 to 73.7)	-35.4 (-69.0 to 23.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.2 (-51.9 to 56.8)	-36.2 (-66.0 to 14.8)
Larynx cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	34.2 (-11.4 to 102.9)	6.3 (-29.4 to 58.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.9 (-12.6 to 106.1)	8.2 (-30.2 to 60.9)
Tracheal, bronchus and lung cancer	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	44.3 (0.0 to 96.0)	12.4 (-20.1 to 52.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	41.4 (-2.9 to 95.2)	10.3 (-22.2 to 48.9)
Breast cancer	0.5 (0.3 to 0.7)	1.0 (0.7 to 1.5)	69.3 (16.7 to 301.0)	31.9 (-9.4 to 184.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	63.3 (12.0 to 290.2)	27.3 (-13.4 to 173.2)
Cervical cancer	0.4 (0.2 to 0.5)	0.8 (0.6 to 1.2)	126.4 (44.6 to 287.2)	4.0 (-2.1 to 144.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	121.5 (41.5 to 272.5)	44.0 (-6.3 to 142.5)
Uterine cancer	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	53.1 (-31.1 to 193.5)	19.1 (-44.4 to 126.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.6 (-27.9 to 198.7)	22.3 (-42.4 to 126.7)
Prostate cancer	0.6 (0.3 to 1.0)	2.0 (1.2 to 3.1)	224.1 (78.1 to 699.7)	152.7 (38.1 to 524.8)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	206.2 (72.8 to 643.8)	135.2 (34.2 to 482.3)
Colon and rectum cancer	0.3 (0.3 to 0.4)	0.5 (0.4 to 0.6)	59.5 (22.1 to 105.8)	20.7 (-6.4 to 57.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	58.7 (20.6 to 107.0)	19.1 (-9.4 to 59.0)
Lip and oral cavity cancer	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	47.9 (-13.8 to 122.1)	15.8 (-30.3 to 75.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	52.2 (-8.1 to 129.4)	18.8 (-26.3 to 78.5)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.9 (-25.2 to 102.8)	-14.6 (-47.7 to 37.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.5 (-22.4 to 98.1)	-13.8 (-45.7 to 36.6)
Other pharynx cancer	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	9.4 (-44.2 to 135.4)	-9.5 (-53.6 to 91.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.0 (-40.9 to 128.5)	-8.2 (-50.8 to 87.6)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.4 (-33.1 to 58.6)	-19.9 (-48.7 to 21.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.6 (-33.4 to 45.4)	-24.1 (-49.1 to 13.8)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.4 (-10.5 to 73.5)	-3.8 (-30.4 to 36.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.0 (-8.9 to 78.0)	-4.1 (-30.0 to 41.3)
Malignant skin melanoma	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	57.1 (9.7 to 176.1)	13.9 (-21.4 to 85.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.4 (11.8 to 173.3)	56.3 (-20.7 to 82.8)
Non-melanoma skin cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	171.9 (89.2 to 281.9)	84.1 (28.6 to 153.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	234.1 (103.2 to 417.1)	115.7 (29.8 to 235.4)
Ovarian cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	105.6 (-4.3 to 345.3)	38.8 (-30.8 to 190.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.3 (-7.0 to 362.9)	40.8 (-35.3 to 212.1)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	96.8 (14.8 to 247.4)	24.6 (-23.4 to 110.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.0 (16.0 to 246.9)	29.7 (-22.3 to 107.5)
Kidney cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	96.5 (14.9 to 209.8)	19.7 (-8.4 to 141.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.4 (11.8 to 204.2)	46.0 (-11.7 to 131.1)
Bladder cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	51.8 (7.8 to 113.0)	7.0 (-24.8 to 51.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.6 (9.2 to 121.7)	8.5 (-25.4 to 55.7)
Brain and nervous system cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	43.8 (0.8 to 129.2)	13.8 (-17.1 to 67.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.5 (1.4 to 116.5)	11.1 (-18.5 to 59.4)
Thyroid cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	68.5 (-0.3 to 340.4)	11.9 (-33.2 to 136.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.5 (3.0 to 322.3)	18.8 (-30.2 to 130.9)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.9 (-26.1 to 75.9)	11.8 (-42.3 to 36.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.5 (-24.1 to 80.3)	9.8 (-41.8 to 41.2)
Hodgkin lymphoma	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	227.7 (9.1 to 312.1)	142.2 (9.1 to 312.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	210.9 (45.2 to 433.6)	125.2 (9.7 to 267.5)
Non-Hodgkin lymphoma	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	88.0 (18.6 to 307.1)	36.1 (-11.7 to 183.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.5 (19.9 to 285.9)	33.1 (-12.0 to 165.5)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	38.8 (-11.5 to 138.6)	9.6 (-30.5 to 88.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.4 (-14.8 to 137.0)	8.4 (-32.8 to 84.7)
Leukemia	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	41.3 (-16.7 to 173.5)	12.1 (-25.9 to 95.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.8 (-7.4 to 142.7)	2.2 (-27.9 to 74.2)
Other neoplasms	0.4 (0.2 to 0.5)	0.9 (0.6 to 1.4)	129.3 (47.9 to 347.6)	60.3 (9.5 to 193.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	113.5 (43.4 to 329.0)	44.5 (2.3 to 172.5)
Cardiovascular diseases	-	-	-	-	2.2 (1.6 to 3.1)	3.1 (2.1 to 4.3)	38.4 (7.8 to 71.3)	0.7 (-18.8 to 23.2)
Rheumatic heart disease	1.1 (1.1 to 1.2)	1.5 (1.4 to 1.6)	34.1 (22.5 to 46.3)	-0.6 (-8.0 to 7.3)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	23.3 (-1.1 to 54.3)	-7.6 (-27.1 to 17.0)
Ischemic heart disease	14.0 (11.3 to 17.3)	13.5 (11.7 to 15.7)	-3.4 (-22.9 to 23.0)	-22.1 (-37.0 to -2.2)	0.8 (0.5 to 1.2)	0.8 (0.5 to 1.1)	21.9 (-25.3 to 29.2)	21.9 (-38.9 to 2.0)
Cerebrovascular disease	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.3)	25.1 (2.5 to 57.4)	2.6 (-21.3 to 23.5)
Ischemic stroke	1.1 (0.9 to 1.2)	1.3 (1.2 to 1.6)	26.0 (2.5 to 59.4)	-1.1 (-19.8 to 26.8)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	24.0 (1.5 to 56.6)	-2.5 (-21.2 to 25.3)
Hemorrhagic stroke	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.4)	26.0 (-0.6 to 66.6)	-4.3 (-25.3 to 27.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	26.9 (-2.8 to 66.8)	-4.2 (-28.2 to 29.5)
Hypertensive heart disease	1.3 (1.0 to 1.5)	2.0 (1.5 to 2.6)	52.1 (0.1 to 142.4)	12.5 (-26.7 to 77.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	50.1 (-1.1 to 139.0)	11.5 (-26.3 to 75.5)
Cardiomyopathy and myocarditis	4.6 (3.6 to 5.6)	8.5 (6.8 to 10.2)	86.0 (40.1 to 148.8)	15.6 (-15.5 to 58.6)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	85.3 (39.2 to 146.3)	16.0 (-15.1 to 59.8)
Atrial fibrillation and flutter	44.5 (34.2 to 56.4)	58.1 (43.9 to 75.6)	31.2 (-10.6 to 72.8)	3.1 (-29.3 to 35.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	54.3 (-29.5 to 196.9)	-1.6 (-53.1 to 85.5)
Endocarditis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	35.0 (-56.8 to -0.2)	-47.4 (-66.8 to -8.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.7 (-59.9 to 6.6)	-48.1 (-70.3 to -3.3)
Other cardiovascular and circulatory diseases	5.6 (3.6 to 11.1)	12.5 (5.4 to 19.0)	32.7 (-28.0 to 300.5)	33.7 (-49.2 to 191.4)	0.5 (0.2 to 0.8)	0.9 (0.3 to 1.5)	92.3 (-27.7 to 297.2)	35.6 (-49.7 to 190.7)
Chronic respiratory diseases	-	-	-	-	6.8 (4.6 to 9.5)	9.0 (6.1 to 12.4)	34.4 (10.8 to 50.5)	-0.8 (-16.7 to 10.4)
Chronic obstructive pulmonary disease	60.1 (57.5 to 62.6)	78.9 (75.6 to 82.4)	31.2 (27.1 to 35.3)	-1.1 (-4.2 to 2.2)	5.4 (3.7 to 7.7)	7.3 (4.8 to 10.2)	35.4 (12.7 to 50.9)	0.9 (-15.0 to 13.4)

Appendix Table G.4 - Lesotho prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	26.1	-6.6
Silicosis	0.0	0.0	16.9	-12.3	0.0	0.0	17.0	-12.3
Asbestosis	-	-	0.0	0.0	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	34.3	-1.1	0.0	0.0	34.5	-0.9
Asthma	23.7	29.5	22.6	-16.7	1.0	1.3	22.6	-17.3
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.1	52.8	11.6	0.0	0.0	50.9	10.7
Other chronic respiratory diseases	-	-	-	-	0.1	0.1	39.4	2.2
Cirrhosis	-	-	-	-	0.2	0.4	36.0	2.4
Cirrhosis due to hepatitis B	0.1	0.2	44.6	11.8	0.0	0.0	42.1	10.0
Cirrhosis due to hepatitis C	0.1	0.1	59.4	10.3	0.0	0.0	57.2	8.8
Cirrhosis due to alcohol use	0.2	0.2	14.2	-15.0	0.0	0.0	13.4	-16.1
Cirrhosis due to other causes	0.2	0.3	53.8	28.5	0.0	0.0	52.7	27.1
Digestive diseases	-	-	-	-	1.9	2.8	43.2	4.5
Peptic ulcer disease	10.4	11.7	12.6	-20.9	0.4	0.5	16.7	-19.8
Gastritis and duodenitis	17.6	24.7	39.7	9.0	0.8	1.0	35.9	8.9
Appendicitis	0.2	0.3	56.4	6.9	0.1	0.1	56.5	7.3
Paralytic ileus and intestinal obstruction	0.0	0.0	23.5	-4.0	0.0	0.0	22.2	4.3
Inguinal, femoral, and abdominal hernia	4.7	4.6	0.3	-23.4	0.0	0.0	-0.3	-23.7
Inflammatory bowel disease	1.5	2.6	73.9	25.2	0.3	0.6	72.2	23.6
Vascular intestinal disorders	0.0	0.0	11.6	-20.4	0.0	0.0	15.0	-14.7
Gallbladder and biliary diseases	0.5	0.5	66.6	0.1	0.1	0.1	65.7	18.3
Pancreatitis	0.3	0.4	49.8	6.3	0.1	0.1	47.9	4.7
Other digestive diseases	-	-	-	-	0.2	0.4	72.5	26.3
Neurological disorders	-	-	-	-	6.7	9.9	48.3	4.5
Alzheimer disease and other dementias	3.4	5.3	55.0	6.0	0.5	0.7	57.4	5.7
Parkinson disease	0.1	0.2	31.1	-0.1	0.0	0.0	29.2	-0.6
Epilepsy	2.3	3.2	40.7	6.9	0.7	1.0	44.0	9.5
Multiple sclerosis	0.1	0.2	54.7	9.7	0.0	0.1	53.1	7.7
Migraine	110.1	151.7	37.5	-2.2	3.8	5.1	34.4	-3.7
Tension-type headache	191.1	291.3	51.1	4.5	0.3	0.4	51.2	4.1
Medication overuse headache	7.5	14.6	95.7	39.6	1.2	2.3	93.4	38.2
Other neurological disorders	0.0	0.0	21.2	-6.2	0.3	0.3	10.6	-25.5
Mental and substance use disorders	-	-	-	-	41.7	57.1	37.0	-3.4
Schizophrenia	3.1	4.5	44.7	-1.4	2.0	2.9	42.8	-3.5
Alcohol use disorders	18.2	43.0	136.3	50.6	1.8	4.3	137.4	10.2
Drug use disorders	-	-	-	-	1.9	2.9	51.6	-1.2
Opioid use disorders	2.3	3.5	45.5	-0.8	1.0	1.4	42.5	-3.0
Cocaine use disorders	0.6	0.8	56.3	1.1	0.1	0.2	53.7	0.0
Amphetamine use disorders	2.5	4.1	64.1	2.8	0.3	0.5	62.6	1.7
Cannabis use disorders	2.3	3.5	53.9	1.3	0.1	0.1	52.6	0.5
Other drug use disorders	-	-	-	-	0.4	0.7	59.0	0.3
Depressive disorders	-	-	-	-	17.4	22.6	29.6	7.2
Major depressive disorder	77.7	100.9	29.7	-6.6	15.9	20.5	28.6	-7.9
Dysthymia	15.9	22.6	42.3	1.5	2.2	3.0	41.1	-1.5
Bipolar disorder	8.7	13.0	51.4	-0.4	1.8	2.6	49.4	-2.1
Anxiety disorders	62.9	88.3	40.5	-0.6	5.8	8.1	39.4	-1.6
Eating disorders	-	-	-	-	0.4	0.6	51.1	-3.7
Anorexia nervosa	0.3	0.4	46.9	-2.2	0.1	0.1	45.1	-3.2
Bulimia nervosa	1.6	2.4	53.0	-3.1	0.3	0.5	52.0	-4.0
Autistic spectrum disorders	-	-	-	-	1.9	2.5	30.8	0.1
Autism	4.9	6.4	31.7	0.7	1.2	1.6	30.6	-0.2
Asperger syndrome	7.0	9.2	31.5	1.0	0.7	0.9	31.0	0.5
Attention-deficit/hyperactivity disorder	12.2	15.2	24.3	-0.4	0.1	0.2	24.2	-0.5
Conduct disorder	18.1	22.5	24.3	0.6	2.2	2.7	24.3	-0.5
Idiopathic intellectual disability	10.6	11.9	14.4	-16.4	4.9	5.6	14.3	-16.5
Other mental and substance use disorders	19.2	29.2	51.6	0.4	1.4	2.2	50.4	-0.9
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	8.7	11.1	26.3	-3.6
Diabetes mellitus	37.3	51.6	38.5	5.0	2.6	3.4	32.4	2.1
Acute glomerulonephritis	0.0	0.0	1.5	0.9	0.0	0.0	1.5	0.9
Chronic kidney disease	-	-	-	-	2.7	3.5	29.8	-1.9
Chronic kidney disease due to diabetes mellitus	23.0	29.5	29.6	2.5	0.3	0.4	28.4	0.0
Chronic kidney disease due to hypertension	67.7	86.4	26.2	-0.3	0.9	1.1	32.7	-2.1
Chronic kidney disease due to glomerulonephritis	60.4	79.9	32.7	0.2	0.9	1.2	29.5	0.3
Chronic kidney disease due to other causes	43.8	56.4	28.9	-3.4	0.6	0.7	27.5	-5.7
Urinary diseases and male infertility	-	-	-	-	0.5	0.7	30.4	-2.5

Appendix Table G.4 - Lesotho prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.3 (0.3 to 0.3)	0.4 (0.4 to 0.5)	41.9 (29.2 to 57.3)	0.0 (-2.3 to 17.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.4 (12.4 to 80.6)	41.4 (12.9 to 29.1)
Urolithiasis	3.4 (2.4 to 4.5)	4.1 (3.0 to 5.2)	18.3 (4.4 to 35.7)	-11.9 (-21.6 to 0.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (22.4 to 59.4)	1.5 (-8.2 to 13.2)
Benign prostatic hyperplasia	11.5 (10.5 to 12.5)	13.7 (12.5 to 14.9)	19.5 (5.2 to 34.5)	-6.4 (-17.5 to 4.9)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	17.9 (3.5 to 33.0)	-7.1 (-18.3 to 4.8)
Male infertility due to other causes	5.5 (4.2 to 6.8)	9.9 (7.5 to 12.8)	81.6 (23.3 to 162.0)	12.7 (-22.5 to 62.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	80.6 (21.6 to 164.0)	11.1 (-23.6 to 61.6)
Other urinary diseases	-	-	-	-	0.0	0.0	117.2	58.5
Gynecological diseases	-	-	-	-	1.6	2.1	37.6 to 243.4	0.6 to 148.7
Uterine fibroids	23.8 (21.5 to 25.9)	30.1 (27.0 to 32.9)	26.6 (25.0 to 28.1)	-4.7 (-5.3 to -4.0)	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.7)	14.9 (-0.3 to 25.8)	-19.7 (-30.4 to -10.8)
Polycystic ovarian syndrome	22.2 (20.0 to 24.5)	31.8 (28.2 to 35.3)	43.4 (22.6 to 65.4)	-7.6 (-19.0 to 5.1)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.6)	42.9 (22.0 to 65.1)	-8.4 (-20.0 to 4.4)
Female infertility due to other causes	10.7 (7.9 to 13.4)	13.1 (10.5 to 16.4)	21.5 (9.8 to 71.2)	-24.0 (-46.2 to 9.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	20.2 (7.0 to 73.3)	-22.8 (-45.6 to 10.0)
Endometriosis	2.2 (1.9 to 2.6)	2.9 (2.4 to 3.4)	28.8 (3.3 to 62.2)	-18.1 (-32.5 to 0.7)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	27.9 (-0.1 to 63.5)	-18.9 (-34.5 to 2.7)
Genital prolapse	51.5 (43.9 to 58.9)	70.5 (57.4 to 82.5)	37.3 (6.4 to 68.1)	0.7 (-18.9 to 22.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	36.3 (5.4 to 69.0)	0.1 (-19.8 to 22.3)
Premenstrual syndrome	50.8 (32.0 to 65.3)	77.4 (41.3 to 119.3)	51.9 (-23.2 to 201.4)	-6.4 (-49.3 to 83.7)	0.4 (0.2 to 0.7)	0.6 (0.3 to 1.2)	50.0 (-26.2 to 194.2)	-7.9 (-50.6 to 81.3)
Other gynecological diseases	4.5 (3.6 to 5.5)	5.3 (4.7 to 5.8)	17.3 (-7.7 to 53.8)	-34.2 (-39.1 to -2.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	10.0 (-14.0 to 27.1)	-32.4 (-49.8 to 10.4)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.7	0.7	2.9	-13.6
Thalassemias	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-59.9 (-80.8 to -40.2)	-71.7 (-88.5 to -54.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.1 (-81.1 to -41.7)	-72.5 (-88.5 to -56.0)
Thalassemia trait	7.3 (5.0 to 9.6)	8.8 (6.0 to 11.4)	27.9 (-15.3 to 30.0)	-0.6 (-34.3 to 1.3)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	18.8 (2.3 to 39.6)	-0.5 (-12.2 to 13.7)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.4 (1.5 to 20.5)	-10.2 (-18.1 to -2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.6 (12.8 to 42.7)	0.7 (-12.1 to 12.4)
Sickle cell trait	4.0 (3.7 to 4.2)	5.5 (5.1 to 6.0)	38.0 (27.4 to 60.9)	39.0 (-1.2 to 24.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.3 (-42.3 to 198.3)	11.6 (-45.3 to 137.9)
G6PD deficiency	25.7 (25.0 to 26.4)	34.8 (33.9 to 35.7)	35.3 (29.8 to 39.6)	4.9 (0.7 to 8.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.4 (24.0 to 47.6)	14.3 (4.7 to 22.7)
G6PD trait	182.7 (180.9 to 184.8)	227.8 (225.1 to 230.4)	24.7 (22.2 to 26.6)	-3.2 (-5.1 to -1.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.7 (-74.2 to 135.2)	-22.7 (-74.8 to 75.9)
Other hemoglobinopathies and hemolytic anemias	16.0 (13.7 to 17.6)	16.4 (14.1 to 17.9)	2.3 (-10.5 to 19.4)	-20.5 (-28.6 to -10.1)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.7)	-3.2 (-26.4 to 31.1)	-18.8 (-35.6 to 5.7)
Endocrine, metabolic, blood, and immune disorders	20.9 (19.1 to 22.5)	21.8 (19.3 to 23.9)	4.5 (-9.8 to 18.0)	-4.4 (-23.2 to -6.3)	0.7 (0.5 to 1.0)	0.7 (0.5 to 1.1)	2.5 (-16.3 to 23.1)	-12.3 (-25.0 to 1.5)
Musculoskeletal disorders	-	-	-	-	20.1	28.5	41.1	1.9
Rheumatoid arthritis	5.4 (5.1 to 5.8)	8.3 (7.9 to 8.7)	53.4 (40.1 to 65.5)	4.5 (-4.7 to 13.0)	1.3 (0.9 to 1.7)	1.9 (1.4 to 2.6)	53.4 (38.1 to 67.6)	4.4 (-5.8 to 14.0)
Osteoarthritis	35.2 (33.7 to 36.6)	45.7 (43.9 to 47.5)	29.4 (22.6 to 37.9)	2.5 (-2.9 to 8.9)	2.1 (1.5 to 2.9)	2.7 (1.9 to 3.7)	28.2 (21.1 to 36.9)	1.9 (-3.6 to 8.3)
Low back and neck pain	-	-	-	-	14.4	21.0	45.2	2.6
Low back pain	73.3 (67.0 to 79.2)	101.0 (92.8 to 109.1)	37.8 (23.6 to 55.4)	-0.1 (-10.7 to 12.3)	8.1 (5.5 to 11.2)	11.1 (7.5 to 15.5)	36.5 (22.1 to 53.2)	-1.2 (-11.6 to 11.3)
Neck pain	64.1 (52.3 to 75.7)	101.9 (88.6 to 115.6)	59.0 (33.0 to 96.8)	9.6 (-6.8 to 32.1)	6.3 (4.1 to 8.8)	9.9 (6.8 to 13.9)	58.4 (31.8 to 95.3)	8.6 (-7.8 to 31.5)
Gout	0.3 (0.3 to 0.3)	0.4 (0.3 to 0.4)	22.2 (6.5 to 38.1)	-6.3 (-18.3 to 4.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.9 (-2.9 to 53.7)	-7.3 (-26.4 to 18.0)
Other musculoskeletal disorders	26.0 (19.8 to 32.8)	31.8 (25.1 to 38.4)	22.4 (11.0 to 33.7)	-1.6 (-10.9 to 6.9)	2.3 (1.5 to 3.4)	2.8 (1.9 to 4.1)	3.1 (8.7 to 33.8)	-3.1 (-12.7 to 6.6)
Other non-communicable diseases	-	-	-	-	20.5	25.7	25.1	-6.7
Congenital anomalies	-	-	-	-	1.0	1.1	4.6	-24.4
Neural tube defects	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	1.5 (-29.2 to 44.7)	-24.2 (-47.1 to 8.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-0.1 (-42.9 to 75.0)	-23.6 (-56.0 to 33.4)
Congenital heart anomalies	2.2 (1.5 to 3.0)	2.4 (1.5 to 3.3)	8.9 (-34.7 to 69.0)	-22.0 (-53.4 to 22.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	5.4 (-34.1 to 63.6)	-21.8 (-51.2 to 19.9)
Orofacial clefts	0.3 (0.1 to 0.4)	0.3 (0.2 to 0.4)	1.9 (-54.9 to 127.4)	-19.5 (-65.0 to 83.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.0 (-55.9 to 123.6)	-19.5 (-65.5 to 77.9)
Down syndrome	1.1 (0.9 to 1.3)	1.1 (1.0 to 1.3)	2.4 (-17.9 to 38.4)	-32.0 (-45.4 to -8.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-2.7 (-23.6 to 34.1)	-37.7 (-50.8 to -14.2)
Turner syndrome	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	11.4 (-27.3 to 74.4)	-25.7 (-51.5 to 16.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.8 (-27.6 to 84.6)	-27.0 (-53.0 to 18.8)
Klinefelter syndrome	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	17.6 (-25.0 to 85.2)	-11.4 (-43.4 to 39.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.8 (-13.9 to 111.5)	-8.1 (-42.0 to 44.8)
Chromosomal unbalanced rearrangements	1.7 (1.4 to 2.2)	1.7 (1.4 to 2.2)	0.5 (-26.1 to 48.4)	-23.3 (-50.9 to -1.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	0.2 (-30.4 to 44.2)	-29.6 (-55.7 to -9.3)
Other congenital anomalies	4.3 (3.3 to 5.3)	5.0 (3.9 to 6.1)	16.9 (2.5 to 34.9)	-12.8 (-22.3 to 3.7)	0.5 (0.3 to 0.8)	0.6 (0.4 to 0.9)	10.7 (-13.2 to 36.9)	-16.2 (-32.1 to 0.6)
Skin and subcutaneous diseases	-	-	-	-	7.9	10.7	35.7	0.3
Dermatitis	65.8 (55.0 to 77.4)	90.6 (74.6 to 107.4)	37.6 (34.2 to 40.4)	-0.0 (-0.3 to 0.4)	2.0 (1.3 to 2.8)	2.7 (1.7 to 3.8)	33.7 (27.9 to 39.5)	-0.8 (-3.5 to 2.4)
Psoriasis	10.4 (8.9 to 11.8)	14.5 (12.4 to 16.7)	39.4 (36.5 to 42.3)	0.1 (-0.2 to 0.3)	0.8 (0.6 to 1.2)	1.2 (0.8 to 1.7)	1.0 (29.2 to 48.4)	-1.0 (-6.1 to 4.5)
Cellulitis	0.3 (0.3 to 0.4)	0.4 (0.3 to 0.5)	29.4 (4.5 to 52.6)	-0.8 (-22.7 to 19.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.0 (-5.1 to 71.6)	-1.4 (-27.0 to 29.9)
Pyoderma	2.7 (2.0 to 3.4)	2.9 (2.2 to 3.7)	8.6 (0.2 to 19.7)	-4.3 (-10.6 to 3.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.5 (-3.4 to 23.0)	-4.6 (-12.8 to 5.8)
Scabies	16.0 (14.3 to 17.9)	18.1 (16.2 to 20.2)	13.1 (-3.1 to 32.5)	-14.2 (-25.8 to 0.7)	0.4 (0.2 to 0.7)	0.5 (0.3 to 0.8)	13.1 (-4.1 to 32.8)	-14.4 (-26.4 to 0.7)
Fungal skin diseases	180.4 (136.6 to 235.8)	246.1 (183.5 to 323.0)	34.9 (31.0 to 40.6)	34.4 (0.2 to 67.0)	1.4 (0.4 to 2.2)	1.4 (0.5 to 2.3)	34.5 (30.4 to 40.4)	0.0 (-0.2 to 0.8)
Viral skin diseases	31.6 (24.4 to 38.1)	39.5 (29.6 to 49.5)	25.4 (17.0 to 33.1)	0.1 (-2.5 to 2.5)	1.0 (0.6 to 1.5)	1.2 (0.7 to 1.9)	25.0 (15.2 to 33.6)	-0.2 (-3.8 to 4.0)
Acne vulgaris	152.2 (118.3 to 183.6)	199.4 (160.3 to 245.9)	31.4 (-3.3 to 77.0)	-8.2 (-30.6 to 21.7)	1.6 (0.7 to 3.2)	2.2 (1.0 to 4.1)	31.3 (-3.0 to 77.6)	-8.4 (-30.8 to 21.4)
Alopecia areata	1.4 (1.3 to 1.6)	1.9 (1.7 to 2.1)	31.3 (9.1 to 51.9)	-0.7 (-17.7 to 15.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	30.9 (5.1 to 59.8)	-0.5 (-19.0 to 19.5)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.9 (5.1 to 67.5)	-0.6 (-22.0 to 32.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.9 (5.1 to 67.5)	-0.6 (-21.1 to 32.7)
Urticaria	6.8 (4.0 to 9.1)	14.3 (9.7 to 18.2)	108.4 (45.7 to 229.4)	36.7 (5.4 to 123.5)	0.4 (0.2 to 0.6)	0.8 (0.5 to 1.3)	108.0 (45.8 to 228.8)	37.1 (-4.5 to 121.1)
Decubitus ulcer	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.3)	53.5 (19.5 to 95.4)	8.7 (-16.9 to 42.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	52.3 (13.7 to 99.8)	8.5 (-20.5 to 47.0)
Other skin and subcutaneous diseases	83.9 (56.9 to 123.0)	112.2 (75.8 to 162.8)	33.3 (26.4 to 43.3)	0.5 (-1.9 to 2.8)	0.5 (0.2 to 0.7)	0.7 (0.3 to 1.4)	33.0 (25.5 to 42.8)	-0.0 (-2.8 to 2.6)
Sense organ diseases	-	-	-	-	8.8	10.3	17.8	-10.1
Glaucoma	4.6 (3.8 to 5.6)	4.5 (3.6 to 5.5)	-3.9 (-16.7 to 13.7)	-29.5 (-40.4 to -15.6)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	11.0 (-6.2 to 32.6)	-18.9 (-32.4 to -0.5)
Cataract	8.0 (6.1 to 10.0)	8.4 (6.6 to 10.1)	4.0 (-11.2 to 24.2)	-23.1 (-34.1 to -9.6)	0.6 (0.4 to 0.9)	0.6 (0.4 to 0.9)	0.5 (-13.2 to 23.4)	-26.6 (-35.2 to -10.7)
Macular degeneration	2.5 (1.9 to 3.2)	2.8 (2.1 to 3.4)	11.7 (-8.9 to 43.8)	-9.3 (-25.6 to 18.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	13.1 (-7.2 to 40.9)	-12.7 (-26.3 to 9.0)
Uncorrected refractive error	182.4 (162.7 to 202.6)	227.2 (202.8 to 251.3)	24.4 (8.3 to 43.9)	4.7 (-16.2 to 8.8)	2.7 (1.6 to 4.4)	3.2 (1.9 to 5.5)	16.2 (5.3 to 30.7)	-11.5 (-19.2 to -2.6)
Age-related and other hearing loss	180.8 (161.1 to 200.4)	217.6 (190.6 to 241.9)	20.4 (15.8 to 24.6)	-7.1 (-9.6 to -3.9)	3.6 (2.3 to 5.5)	4.5 (2.9 to 6.7)	22.5 (12.3 to 32.3)	-5.0 (-10.4 to 1.6)
Other vision loss	5.1 (4.4 to 6.2)	5.6 (4.8 to 6.6)	8.6 (-1.8 to 19.5)	-20.5 (-29.0 to -10.6)	0.4 (0.2 to 0.5)	0.4 (0.2 to 0.5)	4.5 (-10.8 to 21.1)	-22.3 (-33.9 to -9.9)
Other sense organ diseases	38.6 (36.5 to 40.7)	46.4 (44.1 to 48.7)	20.3 (11.0 to 28.9)	-0.5 (-6.6 to 5.9)	1.0 (0.6 to 1.5)	1.2 (0.8 to 1.8)	19.6 (10.3 to 29.6)	-0.9 (-7.6 to 6.5)
Oral disorders	-	-	-	-	2.8	3.6	27.2	-5.0
Deciduous caries	141.2 (135.0 to 147.9)	144.5 (138.6 to 150.9)	2.4 (-3.5 to 8.3)	-0.8 (-6.6 to 5.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.1 (-6.0 to 11.8)	2.5 (-8.9 to 8.2)
Permanent caries	527.8 (493.2 to 568.8)	720.5 (669.7 to 779.0)	36.3 (22.8 to 52.0)	-1.9 (-11.6 to 8.8)	0.5 (0.2 to 1.0)	0.7 (0.3 to 1.4)	35.6 (22.3 to 51.6)	-2.5 (-12.1 to 7.9)
Periodontal diseases	32.0 (30.2 to 33.6)	43.4 (41.1 to 45.6)	35.8 (26.6 to 46.5)	-1.2 (-7.9 to 6.5)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.6)	35.4 (25.3 to 46.2)	-1.9 (-9.1 to 6.0)

Appendix Table G.4 - Lesotho prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Edentulism and severe tooth loss	49.0 (44.9 to 53.5)	58.6 (54.0 to 63.2)	19.3 (6.8 to 35.3)	-6.6 (-16.3 to 5.2)	1.3 (0.9 to 1.9)	1.6 (1.1 to 2.2)	18.2 (6.1 to 34.3)	-7.2 (-16.6 to 4.9)
Other oral disorders	23.7 (22.3 to 25.0)	32.7 (30.9 to 34.8)	38.0 (27.5 to 50.8)	-0.7 (-8.1 to 7.1)	0.7 (0.4 to 1.0)	1.0 (0.6 to 1.4)	37.7 (26.7 to 50.8)	-1.3 (-9.0 to 6.9)
Injuries	-	-	-	-	7.0 (5.3 to 9.0)	9.1 (6.8 to 11.9)	30.0 (22.9 to 37.8)	-6.6 (-12.1 to -0.5)
Transport injuries	-	-	-	-	1.7 (1.3 to 2.2)	2.7 (2.0 to 3.6)	62.6 (50.4 to 75.4)	23.1 (14.3 to 32.9)
Road injuries	-	-	-	-	1.5 (1.1 to 1.9)	2.3 (1.7 to 3.1)	59.4 (46.9 to 73.2)	26.4 (11.5 to 30.6)
Pedestrian road injuries	-	-	-	-	0.3 (0.3 to 0.5)	0.5 (0.3 to 0.6)	36.8 (21.9 to 51.8)	4.6 (-5.3 to 14.9)
Cyclist road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	46.7 (34.2 to 60.1)	14.9 (5.4 to 25.5)
Motorcyclist road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	48.2 (34.1 to 63.4)	11.4 (0.7 to 23.5)
Motor vehicle road injuries	-	-	-	-	0.7 (0.5 to 0.9)	1.3 (0.9 to 1.6)	34.6 (62.6 to 97.7)	24.6 (22.1 to 48.2)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.3 (-9.2 to 10.4)	-28.2 (-34.2 to -20.5)
Other transport injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	84.1 (69.8 to 98.8)	41.0 (30.8 to 52.1)
Unintentional injuries	-	-	-	-	4.7 (3.6 to 6.1)	5.4 (4.1 to 7.1)	14.9 (8.6 to 21.6)	-18.8 (-23.5 to -13.5)
Falls	-	-	-	-	2.7 (2.0 to 3.5)	2.6 (1.9 to 3.4)	-3.7 (-10.0 to 3.5)	-31.3 (-36.0 to -26.1)
Drowning	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-18.5 (-27.2 to -8.7)	-37.5 (-43.5 to -30.7)
Fire, heat, and hot substances	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.6)	29.1 (17.1 to 41.3)	-1.5 (-10.1 to 7.6)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.7 (-13.1 to 19.2)	-22.8 (-32.4 to -12.4)
Exposure to mechanical forces	-	-	-	-	0.9 (0.7 to 1.2)	1.5 (1.1 to 1.9)	60.6 (52.6 to 70.3)	18.8 (13.2 to 25.8)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	104.6 (86.4 to 125.7)	48.2 (34.7 to 63.3)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.9 (51.6 to 84.3)	24.3 (11.8 to 34.5)
Other exposure to mechanical forces	-	-	-	-	0.9 (0.7 to 1.1)	1.4 (1.0 to 1.8)	58.6 (50.5 to 68.4)	17.3 (11.8 to 24.3)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	70.2 (61.7 to 80.6)	28.4 (21.3 to 36.7)
Animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	14.5 (6.6 to 23.1)	-14.1 (-19.9 to -8.1)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	20.2 (7.0 to 35.2)	-10.4 (-19.1 to -0.8)
Non-venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	10.5 (2.6 to 18.5)	-16.7 (-22.3 to -10.5)
Foreign body	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	20.0 (11.6 to 27.9)	-10.4 (-15.9 to -4.7)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.4 (-4.4 to 17.5)	-17.3 (-25.5 to -8.3)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.8 (17.0 to 45.5)	-6.0 (-13.3 to 4.0)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	24.6 (15.6 to 33.5)	-8.7 (-15.5 to -2.0)
Other unintentional injuries	-	-	-	-	0.5 (0.3 to 0.6)	0.6 (0.4 to 0.7)	24.3 (14.5 to 35.0)	-8.8 (-15.7 to -1.0)
Self-harm and interpersonal violence	-	-	-	-	0.5 (0.4 to 0.7)	0.9 (0.7 to 1.2)	76.1 (63.5 to 90.5)	28.7 (19.0 to 40.2)
Self-harm	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	108.5 (91.5 to 129.6)	46.8 (35.1 to 60.1)
Interpersonal violence	-	-	-	-	0.5 (0.4 to 0.6)	0.9 (0.6 to 1.1)	73.6 (60.6 to 88.0)	27.1 (17.3 to 38.5)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	84.2 (69.8 to 98.2)	37.1 (26.8 to 48.5)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	103.1 (86.9 to 123.5)	46.1 (33.5 to 61.8)
Assault by other means	-	-	-	-	0.3 (0.3 to 0.4)	0.5 (0.4 to 0.7)	62.8 (48.8 to 78.7)	19.3 (8.6 to 31.4)
Forces of nature, war, and legal intervention	-	-	-	-	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-79.0 (-90.5 to -49.7)	-77.9 (-89.9 to -50.6)
Exposure to forces of nature	-	-	-	-	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-92.8 (-96.7 to -85.1)	-91.9 (-96.2 to -84.0)
Collective violence and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-

Appendix Table G.4 - Usheria prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	252.1 (183.8 to 331.8)	466.6 (337.7 to 616.1)	85.7 (73.4 to 94.0)	85.7 (-14.1 to -4.8)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	105.0 (68.0 to 148.5)	175.1 (116.9 to 245.8)	66.8 (56.3 to 79.0)	-19.4 (-25.5 to -12.4)
HIV/AIDS and tuberculosis	-	-	-	-	2.2 (1.5 to 2.9)	9.0 (6.1 to 12.9)	309.0 (239.5 to 441.2)	86.8 (55.1 to 157.0)
Tuberculosis	6.3 (5.8 to 6.9)	16.8 (15.9 to 18.0)	164.9 (146.6 to 186.3)	21.0 (13.0 to 30.2)	1.9 (1.3 to 2.6)	5.1 (3.5 to 6.8)	166.4 (145.6 to 190.3)	21.8 (12.7 to 32.6)
HIV/AIDS	-	-	-	-	0.3 (0.1 to 0.4)	3.9 (2.3 to 6.9)	1,488.2 (678.3 to 3,058.5)	655.1 (276.7 to 1,562.7)
HIV/AIDS resulting in mycobacterial infection	0.1 (0.0 to 0.1)	0.9 (0.4 to 1.4)	1,306.7 (618.5 to 2,744.7)	591.4 (245.7 to 1,370.4)	0.0 (0.0 to 0.0)	0.3 (0.1 to 0.6)	1,275.2 (595.1 to 2,940.2)	570.4 (233.8 to 1,391.5)
HIV/AIDS resulting in other diseases	3.0 (1.8 to 4.5)	21.4 (17.7 to 26.6)	633.9 (357.7 to 1,118.2)	268.2 (123.0 to 529.3)	0.2 (0.1 to 0.4)	3.6 (2.1 to 6.6)	1,432.6 (649.3 to 3,376.8)	659.9 (260.5 to 1,747.5)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	12.4 (8.8 to 16.6)	18.3 (13.0 to 25.0)	48.1 (28.6 to 69.5)	-22.2 (-30.9 to -12.4)
Diarrheal diseases	31.2 (25.7 to 36.4)	60.0 (51.1 to 68.9)	91.5 (53.0 to 145.1)	8.9 (-10.5 to 33.5)	5.3 (3.3 to 7.1)	9.6 (6.4 to 13.8)	91.1 (52.2 to 146.1)	-8.6 (-10.9 to 34.6)
Intestinal infectious diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	0.1 (-0.2 to 0.1)	-2.8 (-63.3 to -35.1)
Typhoid fever	0.6 (0.5 to 0.7)	0.6 (0.5 to 0.7)	-0.1 (-25.8 to 28.5)	-48.4 (-61.8 to -33.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	1.8 (-28.3 to 39.5)	47.4 (-62.9 to -29.0)
Paratyphoid fever	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.6)	25.8 (0.1 to 59.1)	-35.3 (-48.6 to -17.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.0 (-4.2 to 68.9)	-34.5 (-49.4 to -13.6)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.2 (-97.2 to -32.2)	-81.2 (-93.5 to -44.9)
Lower respiratory infections	1.9 (1.6 to 2.3)	2.8 (2.0 to 3.7)	42.7 (-2.7 to 98.0)	-9.1 (32.7 to 104.9)	0.2 (0.1 to 0.3)	0.3 (-3.9 to 104.9)	42.3 (3.9 to 104.9)	-10.2 (-34.7 to 18.9)
Upper respiratory infections	96.9 (85.8 to 108.7)	172.3 (158.7 to 185.9)	78.1 (55.1 to 105.1)	-9.1 (-21.1 to 4.3)	1.1 (0.6 to 1.9)	2.0 (1.1 to 3.4)	77.9 (54.5 to 105.3)	-9.0 (-21.3 to 4.7)
Otitis media	46.6 (41.7 to 51.5)	85.8 (77.8 to 95.4)	83.7 (68.4 to 107.0)	-8.3 (-16.8 to 2.8)	1.0 (0.6 to 1.5)	1.8 (1.1 to 2.8)	84.5 (65.7 to 107.4)	-7.6 (-17.2 to 4.0)
Meningitis	-	-	-	-	4.5 (3.0 to 6.3)	4.1 (2.8 to 5.6)	-8.8 (-27.4 to 19.9)	-51.5 (-60.6 to -38.2)
Pneumococcal meningitis	18.2 (11.4 to 27.8)	18.7 (11.8 to 28.1)	3.0 (-21.0 to 36.1)	-46.5 (-58.8 to -29.2)	1.6 (1.0 to 2.2)	1.6 (1.1 to 2.2)	5.1 (-21.2 to 38.7)	-45.6 (-57.6 to -28.9)
H influenzae type B meningitis	9.3 (3.7 to 16.8)	7.6 (3.6 to 13.8)	-17.5 (-42.2 to 20.6)	-57.3 (-70.4 to -38.8)	1.0 (0.6 to 1.6)	0.8 (0.5 to 1.3)	0.8 (-49.2 to 53.6)	-21.7 (-73.5 to -23.4)
Meningococcal meningitis	10.0 (3.8 to 21.4)	8.8 (3.7 to 18.2)	-11.5 (-30.7 to 14.1)	-53.3 (-63.5 to -40.1)	1.2 (0.7 to 1.8)	1.0 (0.6 to 1.5)	1.0 (-46.0 to 16.2)	-15.8 (-69.5 to -40.8)
Other meningitis	5.5 (3.6 to 8.2)	5.2 (3.3 to 7.8)	-5.0 (-25.3 to 19.0)	-44.3 (-57.4 to -29.3)	0.7 (0.5 to 1.0)	0.6 (0.4 to 0.9)	0.6 (-3.1 to 17.7)	-9.5 (-60.6 to -31.6)
Encephalitis	0.4 (0.2 to 0.9)	0.9 (0.4 to 1.8)	100.9 (84.1 to 130.9)	0.1 (-8.1 to 14.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	0.1 (-74.2 to 133.8)	-1.9 (-13.0 to 12.2)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-72.5 (-98.9 to 700.1)	-80.8 (-98.9 to 224.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-72.5 (-98.9 to 707.7)	-80.8 (-99.0 to 229.8)
Whooping cough	6.5 (4.9 to 8.4)	6.0 (4.6 to 7.7)	-6.9 (-9.8 to -4.0)	-44.7 (-46.4 to -43.0)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	-6.9 (-13.5 to 0.2)	-44.7 (-48.6 to -40.3)
Tetanus	0.3 (0.1 to 0.6)	0.1 (0.0 to 0.1)	-76.9 (-91.9 to -27.9)	-88.2 (-96.2 to -62.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-62.1 (-79.8 to -23.1)	-78.7 (-89.5 to -58.9)
Measles	1.1 (0.8 to 1.4)	0.1 (0.1 to 0.2)	-98.5 (-91.2 to -85.3)	-93.3 (-94.8 to -91.4)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.0)	0.1 (-93.6 to -82.1)	-98.6 (-96.2 to -89.5)
Varicella and herpes zoster	1.3 (1.2 to 1.5)	2.8 (2.5 to 3.1)	105.2 (78.0 to 134.2)	1.0 (-20.1 to 22.3)	1.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	105.1 (41.7 to 176.9)	-0.4 (-34.1 to 39.4)
Neglected tropical diseases and malaria	-	-	-	-	71.4 (42.1 to 106.3)	100.1 (58.9 to 151.5)	39.7 (25.1 to 56.7)	-31.9 (-40.0 to -23.0)
Malaria	1,128.8 (1,044.1 to 1,211.1)	1,866.2 (1,710.2 to 2,021.2)	65.5 (56.2 to 75.1)	-18.8 (-23.9 to -13.4)	10.4 (6.9 to 14.9)	15.9 (10.8 to 22.9)	53.8 (45.7 to 66.6)	-20.2 (-24.3 to -15.4)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.1	0.0	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	163.3 (43.1 to 967.7)	30.7 (-29.9 to 312.1)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.6 (23.9 to 163.5)	-2.4 (-31.8 to 35.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.6 (23.2 to 164.5)	-2.4 (-31.9 to 35.4)
Cutaneous and mucocutaneous leishmaniasis	2.0 (0.6 to 3.3)	5.3 (2.9 to 8.8)	164.9 (44.6 to 924.3)	30.1 (-29.1 to 299.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	163.3 (43.1 to 969.5)	30.7 (-29.9 to 312.4)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	1,251.2 (613.9 to 1,909.9)	1,622.8 (783.8 to 2,579.0)	27.3 (14.6 to 59.4)	-38.9 (-44.9 to -23.4)	12.8 (4.9 to 27.4)	17.0 (6.5 to 37.7)	29.9 (16.5 to 60.7)	-37.1 (-42.9 to -22.5)
Cysticercosis	2.0 (0.9 to 4.0)	5.4 (2.9 to 8.8)	162.5 (11.5 to 642.5)	11.9 (-47.3 to 181.1)	0.5 (0.2 to 1.1)	1.4 (0.7 to 2.6)	177.7 (16.0 to 685.0)	17.9 (-45.7 to 200.8)
Cystic echinococcosis	0.6 (0.6 to 0.7)	0.8 (0.7 to 0.8)	18.0 (5.7 to 39.7)	-33.1 (-39.2 to -26.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	19.2 (-6.8 to 55.1)	-33.0 (-43.7 to -19.9)
Lymphatic filariasis	118.8 (82.7 to 153.7)	124.8 (84.4 to 171.4)	5.6 (-32.5 to 65.5)	-48.3 (-63.9 to -25.4)	3.6 (1.6 to 6.3)	3.6 (2.4 to 9.3)	47.9 (-6.5 to 129.7)	-28.4 (-54.9 to 12.7)
Onchocerciasis	645.4 (443.8 to 901.6)	798.7 (449.5 to 1,332.5)	19.8 (-0.0 to 48.3)	-45.5 (-53.7 to -27.7)	19.5 (19.5 to 63.1)	30.1 (20.6 to 90.8)	51.2 (-3.0 to 58.8)	-35.9 (-51.1 to -21.8)
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.0	0.0	-
Dengue	0.3 (0.1 to 0.6)	2.8 (1.1 to 6.1)	878.7 (869.5 to 889.4)	384.7 (380.1 to 390.0)	0.0 (0.0 to 0.1)	0.4 (0.2 to 1.1)	880.0 (669.7 to 1,186.0)	384.8 (294.1 to 505.3)
Yellow fever	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-45.6 (-47.4 to -29.5)	-73.2 (-78.2 to -66.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.6 (-57.4 to -29.4)	-73.2 (-78.2 to -66.7)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-54.0 to 102.4)	0.0 (-54.0 to 102.4)	0.0 (-54.2 to 102.9)	0.0 (-65.4 to 10.8)
Intestinal nematode infections	-	-	-	-	3.1 (1.9 to 4.9)	6.1 (3.7 to 9.4)	98.5 (71.0 to 126.2)	-1.6 (-16.6 to 13.9)
Ascariasis	328.3 (220.3 to 481.9)	649.6 (445.5 to 959.8)	98.9 (13.7 to 245.2)	-2.0 (-49.3 to 92.0)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	96.0 (57.7 to 142.6)	-0.8 (-23.6 to 29.4)
Trichuriasis	371.8 (246.7 to 550.0)	729.3 (485.5 to 1,117.8)	94.1 (9.2 to 245.9)	-4.0 (-52.2 to 92.6)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.4)	101.4 (54.2 to 174.9)	0.2 (-27.0 to 43.2)
Hookworm disease	592.3 (436.7 to 811.2)	1,205.8 (885.6 to 1,639.9)	102.8 (32.3 to 210.7)	2.8 (-39.8 to 65.7)	0.4 (1.7 to 4.4)	5.5 (3.4 to 8.4)	98.8 (68.0 to 128.9)	-1.6 (-17.8 to 15.1)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.0	0.0	-
Other neglected tropical diseases	25.7 (19.7 to 32.2)	58.6 (53.5 to 64.6)	129.3 (81.1 to 202.0)	28.2 (4.4 to 61.8)	1.8 (1.0 to 3.2)	2.7 (1.7 to 4.1)	53.6 (0.9 to 115.2)	-36.2 (-62.8 to 1.6)
Maternal disorders	-	-	-	-	0.5 (0.3 to 0.8)	1.0 (0.6 to 1.5)	102.7 (74.6 to 155.8)	-6.2 (-18.8 to 15.9)
Maternal hemorrhage	0.9 (0.7 to 1.1)	1.7 (1.2 to 2.4)	91.2 (32.8 to 183.5)	-16.6 (-41.1 to 21.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	99.8 (78.8 to 261.4)	-14.6 (-52.5 to 53.3)
Maternal sepsis and other maternal infections	0.8 (0.5 to 1.2)	1.5 (0.9 to 2.0)	75.5 (46.7 to 129.1)	-22.0 (-34.7 to 0.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.9 (-16.1 to 325.2)	-25.5 (-60.4 to 73.2)
Maternal hypertensive disorders	0.7 (0.3 to 1.4)	1.2 (0.4 to 2.1)	58.8 (44.3 to 82.1)	-28.4 (-33.8 to -16.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	59.0 (33.1 to 96.7)	-28.3 (-39.6 to -11.1)
Obstructed labor	1.0 (0.6 to 1.4)	2.1 (1.4 to 2.8)	109.5 (83.2 to 150.7)	-1.7 (-13.8 to 16.2)	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.1)	109.6 (76.5 to 164.6)	-1.9 (-16.8 to 23.1)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.3 (-11.5 to 183.7)	-30.0 (-60.3 to 13.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.3 (106.2 to 220.9)	-30.0 (-39.4 to 43.1)
Other maternal disorders	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	106.2 (32.9 to 220.9)	5.5 (-39.4 to 43.1)
Neonatal disorders	-	-	-	-	1.0 (0.5 to 1.9)	6.2 (4.1 to 9.4)	531.7 (231.8 to 1,080.8)	245.8 (66.9 to 570.2)
Preterm birth complications	6.2 (2.7 to 12.2)	31.5 (18.3 to 53.3)	414.0 (298.2 to 646.7)	148.7 (95.5 to 256.9)	0.3 (0.2 to 0.5)	3.4 (2.0 to 5.4)	969.0 (530.3 to 1,852.0)	451.4 (220.2 to 921.9)
Neonatal encephalopathy due to birth asphyxia and trauma	15.8 (1.1 to 50.5)	18.7 (3.3 to 55.4)	30.0 (-19.9 to 231.6)	-37.0 (-61.8 to 67.6)	0.5 (0.2 to 1.2)	1.3 (0.6 to 2.5)	208.1 (49.3 to 628.5)	61.5 (-28.7 to 403.8)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	73.2 (60.8 to 100.6)	7.7 (-0.1 to 24.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.2 (55.3 to 104.5)	8.3 (-3.5 to 27.1)
Hemolytic disease and other neonatal jaundice	0.3 (0.1 to 0.7)	2.5 (1.3 to 4.6)	704.3 (195.7 to 2,263.0)	398.6 (76.3 to 1,358.9)	0.1 (0.1 to 0.3)	0.9 (0.4 to 1.8)	700.1 (191.2 to 2,266.9)	389.0 (73.1 to 1,355.9)
Other neonatal disorders	-	-	-	-	0.1 (0.0 to 0.2)	0.6 (0.2 to 1.1)	555.8 (101.7 to 1,928.1)	250.7 (4.0 to 1,045.5)
Nutritional deficiencies	-	-	-	-	16.2 (10.9 to 23.0)	37.6 (25.3 to 55.5)	132.2 (110.5 to 159.5)	25.4 (13.0 to 40.4)
Protein-energy malnutrition	9.9 (5.0 to 19.0)	21.9 (10.2 to 42.0)	118.9 (-19.6 to 479.3)	27.7 (-46.9 to 185.3)	2.7 (0.5 to 2.4)	2.7 (1.0 to 5.6)	122.4 (-19.8 to 486.8)	29.4 (-46.3 to 196.7)
Iodine deficiency	70.0 (31.0 to 115.4)	92.0 (52.2 to 176.7)	30.2 (-38.5 to 189.2)	-35.6 (-71.7 to 54.6)	1.3 (0.5 to 2.4)	1.7 (0.8 to 3.4)	29.3 (-38.6 to 187.4)	-35.8 (-71.3 to 54.4)
Vitamin A deficiency	4.8 (3.3 to 6.7)	5.3 (3.3 to 7.4)	9.2 (-13.7 to 45.7)	-42.8 (-54.7 to -25.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	9.1 (-11.2 to 46.4)	-42.9 (-53.5 to -24.5)

Appendix Table G.4 - Liberia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	364.3 (352.8 to 373.2)	899.8 (876.0 to 926.7)	147.0 (137.0 to 156.9)	34.1 (29.3 to 39.3)	13.5 (9.0 to 19.4)	33.0 (22.3 to 47.4)	144.4 (132.8 to 157.7)	35.4 (28.5 to 44.6)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-28.9 to 637.6)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.4 (0.9 to 2.1)	2.8 (1.8 to 4.2)	98.4 (71.5 to 126.1)	-6.5 (-17.9 to 5.4)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.4 (0.2 to 0.7)	0.8 (0.4 to 1.4)	94.0 (56.8 to 145.6)	-10.9 (-26.3 to 8.4)
Syphilis	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.3)	18.0 (-0.3 to 40.5)	-42.9 (-50.8 to -34.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	17.1 (9.3 to 56.1)	43.4 (-54.1 to -28.5)
Chlamydial infection	29.8 (20.0 to 40.0)	63.7 (42.8 to 86.7)	117.4 (33.0 to 230.4)	2.2 (-37.6 to 51.2)	0.1 (0.1 to 0.3)	0.3 (0.1 to 0.5)	95.0 (17.3 to 262.3)	-8.3 (-44.0 to 63.3)
Gonococcal infection	9.9 (7.4 to 13.0)	17.1 (10.5 to 23.2)	71.6 (9.8 to 163.7)	-19.6 (-47.4 to 21.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	79.1 (11.6 to 184.6)	-16.7 (-46.2 to 30.3)
Trichomoniasis	23.3 (10.1 to 42.2)	60.1 (28.6 to 90.8)	193.7 (-14.1 to 521.9)	28.6 (-58.3 to 150.6)	0.0 (0.0 to 0.1)	0.2 (0.0 to 0.2)	202.6 (-25.5 to 635.9)	31.9 (-63.7 to 190.3)
Genital herpes	329.2 (293.8 to 361.3)	695.0 (636.8 to 756.1)	110.6 (85.8 to 142.8)	0.6 (-13.4 to 13.5)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.5)	111.1 (83.6 to 147.5)	-1.3 (-13.9 to 15.2)
Other sexually transmitted diseases	0.9 (0.6 to 1.2)	1.5 (1.0 to 2.0)	71.8 (48.7 to 107.0)	-23.3 (-34.0 to -7.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.1 (23.8 to 172.9)	-18.0 (-41.7 to 17.6)
Hepatitis	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	38.2 (11.0 to 67.5)	-36.6 (-52.1 to -21.0)
Hepatitis A	3.9 (3.7 to 4.1)	7.5 (7.1 to 7.8)	91.4 (90.0 to 92.6)	0.4 (0.4 to 0.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	103.9 (81.1 to 131.7)	-0.5 (-10.8 to 12.3)
Hepatitis B	436.9 (371.9 to 508.3)	500.3 (429.8 to 562.9)	14.4 (-9.9 to 40.3)	-45.3 (-54.2 to -34.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	10.0 (-2.0 to 51.5)	47.5 (-64.3 to -28.5)
Hepatitis C	148.4 (131.4 to 165.4)	227.8 (202.8 to 253.5)	54.2 (32.7 to 78.1)	-26.1 (-35.4 to -15.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.3 (4.5 to 86.7)	-27.1 (-44.4 to -0.4)
Hepatitis E	0.8 (0.6 to 1.1)	1.5 (1.1 to 1.9)	74.2 (22.3 to 159.0)	-15.0 (-38.7 to 17.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	76.7 (15.9 to 171.7)	-14.7 (-41.2 to 22.3)
Leprosy	0.3 (0.2 to 0.4)	0.3 (0.3 to 0.4)	25.9 (-4.8 to 78.2)	-36.5 (-50.9 to -12.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.5 (-13.7 to 84.3)	-38.3 (-54.3 to -9.7)
Other infectious diseases	18.1 (14.6 to 21.9)	42.5 (36.6 to 49.0)	134.0 (95.2 to 183.7)	30.0 (10.4 to 53.0)	0.7 (0.4 to 1.1)	1.6 (1.0 to 2.4)	126.2 (80.3 to 188.3)	25.8 (-9.9 to 57.9)
Non-communicable diseases	-	-	-	-	125.0 (92.0 to 161.6)	265.9 (196.2 to 344.8)	112.8 (104.2 to 121.7)	0.3 (-3.9 to 4.5)
Neoplasms	0.0	0.1	100.9	1.4	0.5 (0.3 to 0.6)	1.0 (0.7 to 1.3)	106.4 (63.1 to 152.9)	7.1 (-13.1 to 30.0)
Esophageal cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	100.9 (28.5 to 207.5)	1.4 (-34.0 to 50.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.0 (37.8 to 200.8)	3.9 (-30.5 to 47.5)
Stomach cancer	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.4)	78.7 (31.7 to 138.3)	-8.4 (-32.3 to 19.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	81.6 (35.7 to 139.1)	-7.3 (-30.6 to 20.4)
Liver cancer	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	68.6 (20.6 to 139.4)	-16.2 (-39.6 to 17.5)
Liver cancer due to hepatitis B	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	85.4 (-12.6 to 305.9)	-6.6 (-55.4 to 104.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	82.8 (-11.7 to 276.2)	-6.9 (-53.2 to 90.5)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	494.0 (170.4 to 1,965.2)	205.7 (44.5 to 787.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	448.3 (169.9 to 1,752.4)	175.6 (37.3 to 686.4)
Liver cancer due to alcohol use	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-22.4 (-61.3 to 64.4)	-61.8 (-80.3 to -21.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.0 (-57.0 to 51.7)	-59.9 (-77.7 to -27.1)
Liver cancer due to other causes	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	11.7 (-41.3 to 117.4)	-46.3 (-72.1 to 6.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.3 (-34.9 to 92.3)	0.3 (-69.8 to -2.8)
Larynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-2.4 (-38.8 to 115.3)	-48.5 (66.5 to 10.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-33.0 to 134.3)	-44.2 (-63.8 to 17.9)
Tracheal, bronchus and lung cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	71.3 (26.6 to 122.3)	-12.6 (-34.8 to 12.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.7 (32.1 to 141.6)	-7.8 (-33.1 to 24.6)
Breast cancer	0.7 (0.5 to 0.9)	1.6 (1.2 to 2.3)	130.7 (55.4 to 243.2)	8.0 (-26.3 to 63.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	125.7 (48.6 to 236.2)	6.1 (-28.6 to 60.2)
Cervical cancer	1.1 (0.8 to 1.5)	1.9 (1.3 to 2.6)	68.2 (4.7 to 161.4)	-13.3 (-45.3 to 35.1)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	74.2 (12.2 to 178.9)	-10.1 (-41.4 to 40.1)
Uterine cancer	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	92.1 (1.1 to 250.7)	-3.2 (-47.8 to 71.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.8 (0.3 to 256.5)	0.3 (-48.2 to 74.5)
Prostate cancer	0.3 (0.2 to 0.6)	1.7 (1.1 to 2.7)	419.8 (218.3 to 722.7)	141.9 (55.7 to 272.0)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	356.7 (194.9 to 607.0)	114.8 (40.6 to 224.3)
Colon and rectum cancer	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	84.0 (42.7 to 130.4)	-10.0 (-29.6 to 11.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	91.9 (50.5 to 141.1)	-5.4 (-26.2 to 20.9)
Lip and oral cavity cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	88.9 (30.1 to 166.9)	6.8 (-35.6 to 35.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.4 (35.6 to 169.7)	-4.5 (-33.3 to 39.9)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.5 (14.3 to 176.3)	-17.1 (-45.4 to 28.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.6 (17.1 to 161.9)	-17.4 (-43.6 to 22.0)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.4 (-13.3 to 172.8)	-26.2 (-57.0 to 31.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.8 (1.2 to 169.4)	-20.8 (-49.6 to 35.6)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.2 (21.9 to 178.7)	-13.6 (-42.5 to 32.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.4 (29.4 to 167.3)	-10.4 (-37.2 to 28.8)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.1 (60.1 to 208.8)	11.9 (-19.2 to 54.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	135.7 (61.1 to 208.3)	16.1 (-12.9 to 53.5)
Malignant skin melanoma	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	139.9 (71.4 to 230.3)	19.1 (-18.4 to 53.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	156.9 (86.6 to 234.2)	12.3 (-21.0 to 56.5)
Non-melanoma skin cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	122.5 (42.7 to 240.2)	6.1 (-30.2 to 66.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	140.8 (69.6 to 252.0)	11.9 (-29.3 to 77.9)
Ovarian cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	79.4 (7.9 to 201.5)	-5.5 (-44.4 to 59.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.5 (7.3 to 228.2)	-0.6 (-45.8 to 80.2)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	76.6 (-9.8 to 219.4)	-19.1 (-56.1 to 42.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.2 (-7.8 to 256.9)	-15.0 (-65.2 to 56.3)
Kidney cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	82.7 (-41.4 to 85.9)	-0.7 (-55.4 to -8.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.2 (-29.7 to 89.6)	-38.5 (-49.9 to 3.7)
Bladder cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	74.1 (20.7 to 167.0)	-14.7 (-41.5 to 29.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.4 (21.1 to 168.6)	-13.0 (-40.7 to 32.4)
Brain and nervous system cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	189.3 (72.0 to 374.2)	44.8 (1.8 to 99.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	197.1 (92.3 to 344.5)	38.7 (1.7 to 85.9)
Thyroid cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	25.3 (-28.0 to 125.8)	-36.7 (-64.2 to 13.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.2 (-23.3 to 141.0)	-31.5 (-61.2 to 27.2)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	126.6 (57.0 to 217.3)	6.1 (-29.1 to 53.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.5 (54.9 to 217.4)	3.5 (-29.5 to 53.2)
Hodgkin lymphoma	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	122.0 (29.1 to 300.3)	34.7 (-15.9 to 111.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	138.3 (46.1 to 284.8)	36.9 (-12.9 to 110.6)
Non-Hodgkin lymphoma	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	46.0 (-7.2 to 128.5)	-15.7 (-40.6 to 26.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.9 (9.5 to 147.7)	-8.1 (-34.9 to 35.7)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	120.9 (35.8 to 259.9)	6.4 (-38.6 to 76.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.8 (32.8 to 243.2)	5.0 (-39.8 to 73.2)
Leukemia	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	88.2 (-9.1 to 275.8)	-12.2 (-44.0 to 43.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.6 (24.5 to 198.0)	-12.2 (-36.7 to 25.1)
Other neoplasms	0.7 (0.4 to 1.3)	1.1 (0.7 to 1.6)	83.7 (-26.5 to 219.6)	-7.5 (-43.8 to 39.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	88.9 (-15.0 to 202.6)	-8.3 (-41.0 to 35.1)
Cardiovascular diseases	-	-	-	-	3.6 (2.5 to 5.0)	7.0 (4.6 to 10.1)	97.5 (48.8 to 152.4)	-4.7 (-25.9 to 20.9)
Rheumatic heart disease	25.4 (20.6 to 32.2)	42.0 (31.5 to 54.0)	67.3 (15.6 to 131.9)	-19.4 (-39.9 to 9.2)	1.2 (0.8 to 1.8)	2.1 (1.2 to 3.2)	71.5 (20.8 to 136.4)	-15.2 (-35.8 to 12.4)
Ischemic heart disease	15.6 (12.4 to 19.9)	23.0 (18.5 to 28.1)	49.5 (2.4 to 94.4)	-22.8 (-44.4 to -3.6)	0.7 (0.4 to 1.1)	0.9 (0.6 to 1.5)	29.7 (-23.6 to 94.9)	-31.9 (-56.8 to -3.1)
Cerebrovascular disease	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	105.4 (59.7 to 165.0)	-2.3 (-23.7 to 25.3)
Ischemic stroke	0.9 (0.7 to 1.0)	1.8 (1.5 to 2.1)	104.2 (60.5 to 160.8)	-2.1 (-23.2 to 24.4)	0.1 (0.0 to 0.2)	0.3 (0.2 to 0.4)	106.1 (57.8 to 164.2)	-1.7 (-24.0 to 25.4)
Hemorrhagic stroke	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.6)	97.8 (56.5 to 172.2)	-6.0 (-27.6 to 28.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	100.4 (53.7 to 178.1)	-5.4 (-28.6 to 31.1)
Hypertensive heart disease	3.1 (2.1 to 4.1)	6.2 (4.6 to 7.9)	102.8 (37.7 to 198.6)	6.9 (-35.9 to 36.6)	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.0)	102.3 (38.2 to 198.1)	-7.1 (-36.2 to 36.9)
Cardiomyopathy and myocarditis	2.1 (1.6 to 2.9)	3.8 (2.9 to 4.8)	83.2 (19.7 to 163.7)	-12.0 (-48.5 to 40.2)	0.2 (0.1 to 0.4)	0.4 (0.3 to 0.6)	82.2 (19.1 to 163.5)	-12.1 (-48.5 to 41.8)
Atrial fibrillation and flutter	0.3 (0.2 to 0.3)	1.3 (0.9 to 1.7)	386.4 (249.9 to 618.3)	128.2 (46.8 to 300.1)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	378.5 (231.4 to 629.8)	127.7 (43.2 to 298.1)
Peripheral vascular disease	31.9 (24.1 to 41.5)	63.3 (45.6 to 86.1)	97.0 (18.4 to 200.5)	-9.3 (-42.5 to 39.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	102.5 (-32.8 to 233.9)	-11.2 (-65.9 to 53.6)
Endocarditis	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	25.1 (-21.1 to 93.4)	-32.6 (-65.2 to 33.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.8 (-19.7 to 125.5)	-30.9 (-65.8 to 39.0)
Other cardiovascular and circulatory diseases	11.8 (7.5 to 17.5)	35.0 (16.8 to 54.2)	192.7 (37.4 to 482.4)	24.0 (-37.5 to 184.3)	0.8 (0.5 to 1.3)	2.4 (1.1 to 4.1)	193.8 (37.9 to 486.3)	34.2 (-38.4 to 185.1)
Chronic respiratory diseases	-	-	-	-	7.4 (5.1 to 10.4)	17.7 (12.3 to 24.1)	136.1 (104.1 to 190.5)	5.2 (-7.4 to 23.8)
Chronic obstructive pulmonary disease	66.1 (62.5 to 69.7)	1						

Appendix Table G.4 - Tuberculosis prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	101.0	-5.2
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.0 (81.2 to 99.5)	-10.4 (-14.8 to -5.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.6 (80.8 to 99.4)	-10.5 (-14.8 to -5.5)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.4 (103.5 to 120.6)	0.4 (-3.2 to 4.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.4 (103.0 to 120.8)	0.6 (-3.4 to 4.6)
Asthma	24.4 (15.8 to 31.9)	105.3 (77.5 to 136.1)	320.6 (175.7 to 647.1)	59.4 (9.2 to 151.2)	1.0 (0.5 to 1.7)	4.6 (2.8 to 7.0)	327.7 (177.4 to 663.0)	61.3 (11.5 to 156.6)
Interstitial lung disease and pulmonary sarcoidosis	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	121.6 (49.4 to 223.4)	3.2 (-26.4 to 41.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	121.2 (51.1 to 218.5)	3.0 (-26.1 to 40.6)
Other chronic respiratory diseases	-	-	-	-	1.1 (0.6 to 1.8)	1.5 (0.9 to 2.5)	35.9 (-4.6 to 100.3)	-35.1 (-54.3 to -5.3)
Cirrhosis	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	69.0 (49.0 to 93.4)	15.1 (-23.6 to -5.4)
Cirrhosis due to hepatitis B	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.7)	34.6 (-31.2 to 103.7)	-28.3 (-62.1 to 8.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	34.1 (-34.2 to 115.0)	-28.0 (-62.4 to 13.6)
Cirrhosis due to hepatitis C	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	129.0 (9.6 to 632.6)	8.9 (-47.0 to 237.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	128.6 (0.9 to 652.6)	7.7 (-48.0 to 247.1)
Cirrhosis due to alcohol use	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.5)	35.2 (-15.3 to 123.3)	-33.8 (-54.9 to 11.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	37.3 (-21.1 to 125.1)	-33.2 (-57.1 to 10.7)
Cirrhosis due to other causes	0.3 (0.2 to 0.3)	0.5 (0.4 to 0.6)	106.2 (49.3 to 179.4)	18.0 (-16.4 to 62.7)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	104.6 (34.6 to 215.3)	18.5 (-20.4 to 74.5)
Digestive diseases	-	-	-	-	2.6 (1.8 to 3.6)	5.5 (3.8 to 7.4)	109.1 (83.7 to 139.7)	4.0 (-6.5 to 17.1)
Peptic ulcer disease	10.2 (8.4 to 11.9)	18.8 (14.7 to 22.1)	84.1 (45.9 to 128.3)	-9.2 (-24.1 to 10.6)	0.4 (0.2 to 0.5)	0.7 (0.5 to 1.0)	101.1 (54.3 to 158.6)	-1.6 (-19.6 to 20.8)
Gastritis and duodenitis	25.0 (21.8 to 27.7)	53.1 (45.7 to 59.7)	112.9 (77.5 to 152.7)	9.2 (-8.4 to 29.4)	1.1 (0.7 to 1.6)	2.1 (1.4 to 3.1)	97.1 (55.2 to 139.3)	4.1 (-15.3 to 21.2)
Appendicitis	0.3 (0.2 to 0.3)	0.6 (0.4 to 0.8)	120.5 (35.0 to 209.5)	2.2 (-35.2 to 35.5)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	123.1 (31.5 to 233.3)	3.2 (-36.2 to 46.5)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	82.1 (16.0 to 161.1)	-2.6 (-15.5 to 14.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.1 (13.2 to 190.5)	-2.2 (-24.9 to 28.1)
Inguinal, femoral, and abdominal hernia	9.0 (7.1 to 12.1)	13.4 (11.6 to 15.6)	52.3 (6.3 to 90.2)	-19.4 (-35.2 to 1.6)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	51.4 (2.9 to 90.2)	-19.6 (-35.5 to 1.1)
Inflammatory bowel disease	1.9 (1.8 to 2.0)	5.2 (5.0 to 5.4)	168.2 (154.1 to 183.1)	26.2 (20.2 to 32.8)	0.4 (0.3 to 0.5)	1.1 (0.7 to 1.5)	170.0 (147.2 to 195.5)	26.7 (17.7 to 36.7)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	220.4 (120.2 to 351.4)	12.2 (-25.0 to 61.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	218.7 (117.5 to 356.5)	12.3 (-33.7 to 87.2)
Gallbladder and biliary diseases	0.6 (0.5 to 0.7)	1.4 (1.3 to 1.6)	140.5 (102.5 to 181.4)	9.1 (-9.6 to 27.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	125.3 (97.8 to 152.4)	9.3 (-10.3 to 30.3)
Pancreatitis	0.3 (0.3 to 0.3)	0.8 (0.7 to 0.8)	135.3 (117.2 to 154.1)	9.6 (0.7 to 18.0)	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	137.9 (98.7 to 182.5)	10.7 (-5.4 to 29.8)
Other digestive diseases	-	-	-	-	0.4 (0.3 to 0.7)	0.9 (0.5 to 1.4)	89.6 (32.2 to 197.0)	-5.3 (-33.6 to 45.4)
Neurological disorders	-	-	-	-	9.0 (6.0 to 12.5)	19.7 (13.2 to 27.4)	118.9 (92.0 to 156.6)	1.2 (-14.9 to 18.0)
Alzheimer disease and other dementias	2.5 (2.2 to 2.8)	5.4 (4.7 to 6.1)	119.3 (75.1 to 156.7)	-1.4 (-18.3 to 19.6)	0.3 (0.2 to 0.4)	0.7 (0.5 to 1.0)	121.6 (78.6 to 161.2)	2.4 (-19.1 to 19.6)
Parkinson disease	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	111.4 (98.8 to 129.4)	1.1 (-4.3 to 7.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.0 (72.7 to 159.5)	1.0 (-16.4 to 21.7)
Epilepsy	4.6 (2.6 to 7.4)	9.2 (5.1 to 14.5)	100.8 (-11.3 to 305.0)	0.8 (-56.0 to 105.2)	1.3 (0.6 to 2.2)	2.7 (1.4 to 4.6)	110.3 (-6.9 to 339.9)	5.3 (-53.4 to 117.1)
Multiple sclerosis	0.1 (0.1 to 0.1)	0.3 (0.3 to 0.3)	143.2 (108.8 to 185.9)	13.3 (-0.8 to 31.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	142.0 (93.5 to 201.7)	12.1 (-9.2 to 40.2)
Migraine	146.1 (135.4 to 158.1)	298.2 (272.8 to 325.4)	104.2 (81.2 to 131.1)	-9.9 (-13.0 to 0.1)	4.9 (3.0 to 7.2)	10.9 (5.9 to 14.9)	185.0 (79.7 to 133.7)	-2.6 (-13.6 to 11.1)
Tension-type headache	251.1 (231.2 to 272.2)	560.2 (506.6 to 614.7)	122.8 (97.3 to 153.1)	3.5 (-6.7 to 15.1)	0.4 (0.2 to 0.7)	0.8 (0.4 to 1.5)	123.5 (96.1 to 156.6)	4.0 (-6.6 to 16.8)
Medication overuse headache	9.7 (6.2 to 13.5)	28.9 (19.0 to 39.7)	195.5 (123.3 to 319.5)	39.7 (5.4 to 100.2)	1.5 (0.8 to 2.4)	4.5 (2.6 to 6.9)	196.0 (123.3 to 325.6)	39.8 (6.0 to 101.0)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.6 (37.7 to 151.6)	-7.6 (-30.4 to 24.3)	0.5 (0.3 to 1.3)	0.7 (0.4 to 1.2)	67.1 (-20.7 to 182.6)	-26.4 (-64.2 to 30.2)
Mental and substance use disorders	-	-	-	-	38.2 (26.7 to 50.7)	61.7 (57.1 to 107.8)	113.9 (103.5 to 124.5)	1.3 (-4.2 to 6.7)
Schizophrenia	4.2 (3.9 to 4.6)	9.2 (8.4 to 10.0)	117.0 (107.5 to 126.7)	0.5 (-3.6 to 4.7)	0.5 (1.9 to 3.2)	2.5 (4.2 to 7.0)	118.8 (103.0 to 133.5)	1.2 (-5.3 to 7.2)
Alcohol use disorders	10.5 (9.8 to 11.2)	25.9 (24.3 to 27.6)	146.8 (135.7 to 158.4)	16.7 (11.8 to 22.1)	1.0 (0.7 to 1.4)	2.5 (1.6 to 3.5)	149.7 (133.6 to 167.4)	17.7 (10.2 to 25.4)
Drug use disorders	-	-	-	-	2.5 (1.6 to 3.4)	5.4 (3.6 to 7.6)	117.9 (92.5 to 149.0)	0.3 (-10.5 to 13.2)
Opioid use disorders	3.4 (2.3 to 4.8)	7.4 (4.8 to 11.1)	116.5 (89.7 to 147.2)	-1.3 (-13.1 to 10.6)	1.4 (0.8 to 2.0)	3.0 (1.7 to 4.8)	119.9 (71.6 to 154.8)	-0.1 (-14.1 to 14.1)
Cocaine use disorders	1.0 (0.8 to 1.2)	2.3 (1.9 to 2.6)	134.9 (77.3 to 188.4)	2.1 (-17.3 to 26.5)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	128.6 (87.2 to 207.2)	4.0 (-21.8 to 35.3)
Amphetamine use disorders	3.2 (2.9 to 3.4)	6.7 (6.2 to 7.1)	109.7 (87.5 to 136.8)	-0.7 (-10.6 to 10.5)	0.4 (0.3 to 0.6)	0.9 (0.5 to 1.3)	112.7 (76.9 to 154.1)	0.6 (-15.1 to 19.5)
Cannabis use disorders	1.4 (1.1 to 1.8)	3.1 (2.4 to 3.7)	111.5 (109.8 to 113.6)	0.4 (0.3 to 0.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	113.1 (69.9 to 168.4)	1.3 (-18.2 to 24.3)
Other drug use disorders	-	-	-	-	0.5 (0.3 to 0.8)	1.2 (0.7 to 1.7)	114.2 (58.3 to 193.4)	0.5 (-25.2 to 36.1)
Depressive disorders	-	-	-	-	2.5 (9.4 to 22.6)	5.1 (20.2 to 48.0)	103.7 (91.2 to 137.8)	0.9 (-11.1 to 12.3)
Major depressive disorder	65.8 (45.4 to 89.5)	138.6 (98.2 to 182.8)	112.0 (87.2 to 140.8)	-0.5 (-13.2 to 14.6)	13.3 (7.9 to 20.4)	28.1 (17.0 to 43.4)	113.1 (87.9 to 141.9)	-0.2 (-12.9 to 14.6)
Dysthymia	20.0 (16.2 to 24.0)	42.6 (34.4 to 51.4)	113.0 (111.3 to 114.6)	-0.1 (-0.2 to 0.0)	1.9 (1.2 to 2.8)	4.1 (2.6 to 5.9)	114.0 (108.0 to 120.8)	0.3 (-2.0 to 2.9)
Bipolar disorder	11.3 (9.8 to 12.8)	24.3 (20.7 to 27.6)	114.5 (103.7 to 130.8)	-0.3 (-4.6 to 5.8)	2.3 (1.4 to 3.4)	4.9 (3.0 to 7.3)	115.9 (101.7 to 135.1)	0.4 (-5.8 to 7.6)
Anxiety disorders	48.1 (40.0 to 57.4)	100.2 (83.0 to 119.1)	108.3 (106.1 to 110.3)	4.4 (-0.3 to -0.1)	9.2 (2.9 to 6.2)	9.2 (6.1 to 13.1)	109.3 (101.5 to 116.9)	0.3 (-3.0 to 3.4)
Eating disorders	-	-	-	-	0.5 (0.3 to 0.8)	1.1 (0.6 to 1.7)	111.3 (93.6 to 129.3)	-0.1 (-8.2 to 8.4)
Anorexia nervosa	0.3 (0.3 to 0.5)	0.8 (0.6 to 1.0)	115.6 (92.1 to 139.6)	2.5 (-8.1 to 14.4)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	117.0 (69.5 to 179.0)	3.3 (-18.9 to 31.9)
Bulimia nervosa	2.1 (1.4 to 3.0)	4.3 (3.0 to 6.3)	109.5 (107.0 to 112.3)	-1.2 (-1.4 to -1.1)	0.4 (0.2 to 0.7)	0.9 (0.5 to 1.4)	110.0 (91.8 to 130.7)	-1.0 (-9.0 to 8.7)
Autistic spectrum disorders	-	-	-	-	2.5 (1.7 to 3.4)	5.1 (3.5 to 7.0)	103.7 (96.0 to 112.4)	0.9 (-2.3 to 4.4)
Autism	6.5 (6.2 to 6.9)	13.2 (12.6 to 13.9)	103.1 (102.7 to 103.5)	0.4 (0.4 to 0.4)	1.6 (1.1 to 2.2)	3.2 (2.2 to 4.4)	103.7 (92.8 to 116.1)	0.9 (-3.8 to 5.6)
Asperger syndrome	9.4 (8.8 to 9.9)	19.0 (17.8 to 20.1)	102.6 (102.1 to 103.3)	0.5 (0.5 to 0.5)	0.9 (0.7 to 1.3)	1.9 (1.3 to 2.6)	103.3 (94.2 to 113.3)	1.0 (-3.0 to 5.2)
Attention-deficit/hyperactivity disorder	15.5 (14.3 to 16.7)	31.3 (28.9 to 33.8)	102.2 (102.0 to 102.4)	0.6 (0.6 to 0.6)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	103.0 (87.2 to 119.0)	1.0 (-6.6 to 8.7)
Conduct disorder	22.6 (21.3 to 23.9)	45.9 (43.3 to 48.6)	103.3 (103.1 to 103.4)	0.6 (0.5 to 0.6)	2.7 (1.7 to 3.9)	5.5 (3.5 to 7.9)	103.7 (94.8 to 113.6)	1.1 (-3.5 to 5.6)
Idiopathic intellectual disability	53.7 (25.4 to 77.2)	119.0 (81.5 to 152.9)	118.4 (79.5 to 252.9)	8.6 (-11.7 to 89.5)	2.6 (1.1 to 4.2)	5.8 (3.5 to 8.5)	119.1 (79.4 to 254.8)	9.3 (-11.8 to 88.7)
Other mental and substance use disorders	25.4 (23.7 to 27.0)	54.6 (50.9 to 57.9)	115.0 (114.2 to 115.8)	0.1 (0.0 to 0.3)	1.9 (1.3 to 2.5)	4.0 (2.7 to 5.4)	116.0 (106.7 to 124.8)	0.5 (-3.2 to 4.0)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	13.8 (9.8 to 18.8)	31.9 (22.4 to 43.2)	130.6 (113.9 to 145.3)	16.6 (5.8 to 26.5)
Diabetes mellitus	31.6 (25.3 to 39.5)	108.5 (89.7 to 129.3)	246.0 (155.2 to 337.9)	63.8 (17.3 to 118.8)	2.2 (1.5 to 3.2)	7.6 (5.0 to 10.9)	239.6 (156.3 to 339.5)	61.3 (17.1 to 114.3)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.6 (14.8 to 37.9)	-30.4 (-35.5 to -25.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.6 (14.7 to 37.9)	30.4 (-35.5 to -25.5)
Chronic kidney disease	-	-	-	-	3.4 (2.4 to 4.5)	6.8 (4.8 to 9.2)	102.0 (81.4 to 122.7)	-1.4 (-10.8 to 7.3)
Chronic kidney disease due to diabetes mellitus	18.9 (12.2 to 28.3)	40.4 (24.7 to 58.8)	109.3 (59.3 to 222.0)	3.7 (-22.2 to 60.2)	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.0)	116.6 (57.3 to 209.8)	4.7 (-23.2 to 56.8)
Chronic kidney disease due to hypertension	93.7 (56.2 to 171.6)	189.9 (120.1 to 317.4)	102.1 (68.9 to 162.3)	2.4 (-20.0 to 30.1)	1.1 (0.7 to 1.6)	2.2 (1.5 to 3.1)	101.0 (62.0 to 146.9)	-4.2 (-20.1 to 15.2)
Chronic kidney disease due to glomerulonephritis	78.1 (50.2 to 116.5)	159.7 (110.6 to 231.6)	105.5 (58.8 to 153.7)	0.5 (-19.3 to 18.7)	1.2 (0.8 to 1.6)	2.5 (1.7 to 3.1)	102.3 (70.7 to 149.6)	1.9 (-16.4 to 26.8)
Chronic kidney disease due to other causes	62.2 (36.3 to 106.2)	121.6 (73.6 to 198.1)	94.5 (56.6 to 160.1)	-3.0 (-26.7 to 29.4)	0.8 (0.5 to 1.0)	1.5 (1.0 to 2.0)	91.1 (52.3 to 164.1)	-7.1 (-26.3 to 26.8)
Urinary diseases and male infertility	-	-	-	-	0.7 (0.4 to 1.0)	1.4 (0.9 to 2.1)	108.6 (88.9 to 131.4)	-1.2 (-9.7 to 8.9)

Appendix Table G.4 - Usheria prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.4 (0.4 to 0.4)	0.9 (0.8 to 0.9)	122.1 (104.1 to 142.7)	-4.6 (-7.7 to -1.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	122.2 (75.2 to 185.2)	7.1 (-11.5 to 30.3)
Urolithiasis	4.5 (3.2 to 5.9)	7.8 (6.0 to 10.1)	74.5 (52.8 to 114.0)	-14.9 (-24.8 to 2.2)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	113.5 (88.4 to 148.0)	0.7 (-9.3 to 14.0)
Benign prostatic hyperplasia	12.8 (11.8 to 14.0)	26.4 (24.2 to 28.5)	105.3 (83.0 to 130.7)	-0.9 (-10.4 to 10.4)	0.4 (0.3 to 0.6)	0.9 (0.6 to 1.3)	105.1 (83.4 to 130.5)	-1.0 (-11.0 to 10.1)
Male infertility due to other causes	26.3 (21.6 to 32.0)	57.4 (47.4 to 69.2)	119.7 (66.9 to 187.8)	-2.2 (-26.9 to 28.8)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.7)	118.9 (66.9 to 185.9)	-2.0 (-24.9 to 29.2)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.5 (4.2 to 229.4)	-12.9 (50.1 to 54.8)
Gynecological diseases	-	-	-	-	1.9 (1.2 to 3.0)	4.8 (3.1 to 7.3)	144.7 (113.9 to 184.5)	11.9 (-1.3 to 28.7)
Uterine fibroids	31.5 (28.6 to 34.3)	68.0 (61.5 to 74.1)	115.5 (114.8 to 116.1)	-0.8 (-0.9 to -0.6)	0.4 (0.2 to 0.7)	1.1 (0.6 to 1.7)	152.3 (133.3 to 215.4)	16.8 (7.5 to 43.4)
Polycystic ovarian syndrome	29.1 (25.7 to 32.7)	64.2 (57.6 to 71.5)	121.4 (83.7 to 161.4)	0.1 (-15.3 to 17.2)	0.3 (0.1 to 0.5)	0.6 (0.3 to 1.2)	121.2 (83.2 to 162.2)	0.1 (-15.3 to 16.9)
Female infertility due to other causes	27.5 (21.7 to 34.1)	58.2 (42.5 to 75.0)	112.5 (42.2 to 197.5)	-	0.1 (0.1 to 0.3)	0.3 (0.1 to 0.6)	110.5 (43.0 to 197.0)	-5.2 (-36.4 to 34.9)
Endometriosis	2.9 (2.4 to 3.4)	5.9 (5.0 to 6.8)	102.5 (63.4 to 156.6)	-8.8 (-25.9 to 13.4)	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.8)	104.0 (63.9 to 160.3)	-8.3 (-25.5 to 15.5)
Genital prolapse	70.7 (59.7 to 80.4)	150.2 (131.2 to 173.3)	112.3 (76.1 to 160.4)	0.1 (-14.9 to 17.7)	0.2 (0.1 to 0.4)	0.5 (0.2 to 0.9)	113.2 (76.1 to 162.3)	0.3 (-15.4 to 18.5)
Premenstrual syndrome	62.9 (44.8 to 81.9)	175.6 (123.1 to 229.5)	180.5 (83.6 to 332.9)	30.2 (-14.2 to 96.8)	0.5 (0.3 to 0.8)	1.5 (0.8 to 2.4)	179.7 (83.1 to 340.4)	31.0 (-13.7 to 98.7)
Other gynecological diseases	3.4 (2.1 to 4.8)	10.1 (6.5 to 13.9)	193.6 (68.2 to 368.2)	36.4 (-20.9 to 110.8)	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.5)	198.9 (29.5 to 554.3)	40.0 (-40.2 to 190.3)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	4.8 (3.2 to 6.9)	9.5 (6.4 to 13.6)	98.2 (83.0 to 114.3)	4.5 (-5.5 to 13.4)
Thalassemias	1.1 (0.9 to 1.2)	2.0 (1.7 to 2.2)	84.6 (69.2 to 103.5)	-2.3 (-10.1 to 7.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	82.9 (12.6 to 200.0)	-2.6 (-40.5 to 61.7)
Thalassemia trait	142.3 (131.0 to 152.1)	293.9 (272.7 to 312.1)	106.4 (97.2 to 115.8)	3.0 (-1.6 to 7.7)	2.8 (1.9 to 4.0)	5.3 (3.6 to 7.7)	93.4 (70.5 to 114.8)	1.1 (-14.5 to 13.5)
Sickle cell disorders	2.3 (2.0 to 2.6)	4.9 (4.4 to 5.3)	112.5 (86.8 to 144.9)	11.2 (-1.7 to 27.8)	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.7)	114.6 (78.2 to 161.2)	9.6 (-7.7 to 30.8)
Sickle cell trait	251.1 (236.1 to 265.4)	512.1 (483.2 to 539.8)	104.0 (98.5 to 109.5)	1.2 (-1.0 to 4.5)	1.8 (0.8 to 1.8)	2.3 (1.4 to 3.3)	89.9 (37.9 to 128.7)	0.1 (-29.8 to 27.7)
G6PD deficiency	262.5 (204.7 to 321.9)	443.4 (331.1 to 533.4)	69.8 (21.1 to 131.8)	-15.2 (-39.8 to 16.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	90.9 (30.8 to 236.0)	11.4 (-22.3 to 83.3)
G6PD trait	501.7 (464.5 to 526.4)	988.7 (905.0 to 1,042.2)	97.7 (76.0 to 119.3)	-1.0 (-11.9 to 9.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	89.0 (-35.5 to 546.9)	-1.7 (-66.4 to 286.6)
Other hemoglobinopathies and hemolytic anemias	16.1 (13.6 to 18.7)	41.1 (35.5 to 46.7)	155.0 (110.8 to 213.6)	37.7 (16.1 to 62.1)	0.5 (0.3 to 0.7)	1.2 (0.8 to 1.8)	146.4 (89.6 to 237.6)	36.7 (1.0 to 78.9)
Endocrine, metabolic, blood, and immune disorders	22.0 (18.3 to 25.2)	49.5 (40.2 to 58.7)	124.3 (73.8 to 191.3)	19.2 (-1.0 to 42.2)	0.8 (0.5 to 1.1)	1.8 (1.0 to 2.6)	125.4 (51.4 to 209.4)	20.0 (-10.8 to 53.0)
Musculoskeletal disorders	-	-	-	-	23.3 (16.2 to 31.5)	48.7 (33.4 to 65.7)	109.6 (75.5 to 147.2)	-2.2 (-15.1 to 12.0)
Rheumatoid arthritis	2.7 (2.6 to 2.8)	4.1 (3.9 to 4.2)	49.3 (40.9 to 59.1)	-32.6 (-36.7 to -28.2)	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.3)	51.0 (36.0 to 66.8)	-32.2 (-38.1 to -26.2)
Osteoarthritis	38.7 (37.1 to 40.1)	81.2 (77.7 to 84.8)	110.0 (97.7 to 123.5)	1.7 (-3.6 to 7.7)	2.3 (1.6 to 3.1)	4.9 (3.4 to 6.6)	110.2 (97.8 to 124.8)	1.7 (-3.8 to 8.0)
Low back and neck pain	-	-	-	-	17.5 (11.9 to 24.1)	37.7 (25.0 to 51.6)	115.5 (70.7 to 164.9)	0.5 (-17.4 to 20.5)
Low back pain	103.6 (85.7 to 122.9)	220.0 (173.7 to 269.6)	113.2 (58.0 to 175.9)	1.4 (-22.5 to 25.6)	11.3 (7.3 to 16.4)	24.1 (14.9 to 35.1)	113.7 (58.0 to 179.8)	1.8 (-22.7 to 26.9)
Neck pain	64.7 (53.1 to 76.0)	139.8 (116.8 to 160.9)	115.7 (67.8 to 182.6)	-0.8 (-22.0 to 24.7)	6.2 (4.1 to 8.7)	13.6 (9.0 to 19.1)	116.8 (68.0 to 184.5)	-0.4 (-22.2 to 25.5)
Gout	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.4)	103.2 (73.8 to 138.3)	-2.9 (-16.4 to 13.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.4 (61.5 to 155.7)	-2.9 (-23.2 to 23.9)
Other musculoskeletal disorders	31.7 (23.8 to 40.5)	58.0 (32.6 to 79.1)	86.2 (24.2 to 114.9)	-12.8 (-44.7 to 2.2)	2.8 (1.8 to 4.2)	5.2 (2.7 to 8.2)	87.1 (24.3 to 117.8)	-12.1 (-44.0 to 2.6)
Other non-communicable diseases	-	-	-	-	26.4 (17.3 to 38.9)	52.5 (34.5 to 77.8)	98.6 (88.6 to 110.3)	-5.5 (-9.5 to -1.1)
Congenital anomalies	-	-	-	-	1.2 (0.7 to 1.8)	3.3 (2.3 to 4.6)	186.7 (113.0 to 262.0)	45.2 (11.9 to 86.4)
Neural tube defects	0.1 (0.1 to 0.1)	0.9 (0.8 to 1.1)	1,005.0 (771.5 to 1,287.8)	560.1 (407.3 to 740.3)	0.0 (0.0 to 0.0)	0.2 (0.2 to 0.3)	1,278.4 (873.8 to 1,859.8)	773.4 (523.5 to 1,132.7)
Congenital heart anomalies	0.6 (0.5 to 0.9)	8.9 (7.1 to 11.2)	1,293.1 (821.4 to 1,885.4)	745.2 (441.1 to 1,146.2)	0.0 (0.0 to 0.0)	0.3 (0.1 to 0.5)	840.1 (439.9 to 1,418.5)	444.5 (227.8 to 714.8)
Orofacial clefts	0.1 (0.0 to 0.1)	1.3 (1.0 to 1.8)	1,474.1 (988.7 to 3,021.1)	1,202.1 (639.1 to 2,169.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,586.9 (894.9 to 2,787.9)	1,089.2 (585.2 to 1,997.8)
Down syndrome	0.7 (0.6 to 0.9)	3.3 (2.7 to 4.0)	368.0 (246.7 to 538.7)	151.4 (86.4 to 246.1)	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.5)	371.5 (241.7 to 567.2)	152.2 (82.8 to 252.2)
Turner syndrome	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	256.5 (125.7 to 455.1)	81.7 (15.1 to 186.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	261.4 (126.4 to 460.2)	82.0 (13.9 to 184.2)
Klinefelter syndrome	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	100.1 (29.4 to 200.1)	-0.3 (-35.6 to 48.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.3 (36.2 to 216.0)	1.0 (-34.9 to 50.6)
Chromosomal unbalanced rearrangements	1.1 (0.9 to 1.5)	5.4 (4.3 to 6.8)	156.6 (216.4 to 553.8)	0.6 (-68.9 to 254.6)	0.1 (0.1 to 0.2)	0.6 (0.4 to 0.9)	159.7 (110.5 to 575.8)	0.5 (-69.1 to 265.5)
Other congenital anomalies	9.7 (7.0 to 12.9)	17.9 (13.3 to 23.5)	85.7 (55.3 to 118.6)	-8.0 (-21.7 to 9.0)	0.9 (0.5 to 1.5)	1.7 (1.0 to 2.9)	90.4 (41.0 to 156.0)	-4.0 (-28.6 to 30.5)
Skin and subcutaneous diseases	-	-	-	-	9.2 (5.7 to 14.3)	19.1 (11.8 to 30.6)	106.5 (90.7 to 122.8)	0.9 (-6.3 to 9.5)
Dermatitis	89.4 (70.6 to 111.7)	186.4 (145.5 to 234.6)	108.3 (106.1 to 110.5)	-0.1 (-0.2 to 0.0)	2.5 (1.6 to 3.7)	5.3 (3.3 to 7.6)	106.8 (98.9 to 115.0)	0.4 (-2.4 to 3.1)
Psoriasis	13.8 (10.9 to 16.6)	29.1 (22.8 to 35.0)	110.2 (108.8 to 111.5)	0.0 (-0.1 to 0.1)	1.1 (0.7 to 1.6)	2.3 (1.5 to 3.4)	111.2 (92.2 to 126.5)	0.5 (-4.8 to 5.8)
Cellulitis	0.4 (0.3 to 0.5)	0.8 (0.6 to 1.0)	100.2 (74.9 to 131.5)	-0.9 (-13.4 to 15.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	99.7 (52.3 to 169.8)	-0.6 (-21.5 to 26.6)
Pyoderma	3.7 (2.8 to 4.8)	6.6 (4.9 to 8.4)	75.7 (63.0 to 90.2)	-4.2 (-10.5 to 3.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	75.7 (58.0 to 95.3)	-4.1 (-12.7 to 6.3)
Scabies	22.0 (19.5 to 24.9)	37.3 (31.4 to 44.0)	67.7 (36.7 to 111.2)	-14.8 (-30.6 to 4.7)	0.6 (0.3 to 0.9)	1.0 (0.5 to 1.6)	68.1 (37.3 to 113.5)	-14.6 (-30.5 to 1.7)
Fungal skin diseases	259.8 (181.8 to 350.0)	529.9 (378.0 to 727.7)	107.5 (104.1 to 111.3)	0.2 (0.1 to 0.2)	2.9 (1.5 to 4.2)	2.9 (1.1 to 6.6)	168.2 (104.0 to 112.5)	0.5 (-0.3 to 1.3)
Viral skin diseases	32.0 (24.8 to 39.6)	62.2 (47.7 to 77.3)	94.5 (81.7 to 106.8)	-0.7 (-6.4 to 4.4)	0.7 (0.6 to 1.5)	1.9 (1.1 to 3.0)	95.1 (80.7 to 109.4)	-0.4 (-6.7 to 5.9)
Acne vulgaris	129.4 (92.6 to 172.8)	277.2 (194.4 to 377.2)	114.9 (40.4 to 219.4)	5.7 (-31.2 to 54.9)	1.4 (0.6 to 2.6)	3.0 (1.3 to 5.7)	115.5 (39.8 to 221.0)	5.9 (-31.1 to 55.5)
Alopecia areata	1.8 (1.7 to 2.0)	3.8 (3.4 to 4.3)	107.6 (77.4 to 142.7)	-0.0 (-15.1 to 18.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	107.4 (66.9 to 155.9)	-0.0 (-17.5 to 20.6)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.6 (50.1 to 159.0)	3.8 (-27.4 to 27.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.6 (50.1 to 153.2)	-3.8 (-27.4 to 27.1)
Urticaria	8.3 (4.6 to 11.8)	19.5 (13.9 to 26.0)	136.7 (34.6 to 354.5)	14.5 (-33.5 to 129.5)	0.5 (0.2 to 0.8)	1.1 (0.7 to 1.7)	156.7 (35.5 to 353.3)	14.5 (-34.1 to 129.1)
Decubitus ulcer	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.4)	130.3 (79.7 to 179.4)	9.0 (-19.5 to 43.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	127.1 (73.8 to 187.7)	7.2 (-22.6 to 47.6)
Other skin and subcutaneous diseases	110.3 (75.0 to 158.1)	224.9 (151.9 to 321.8)	103.6 (97.3 to 110.3)	-1.6 (-4.5 to 1.6)	0.6 (0.3 to 1.3)	1.3 (0.6 to 2.7)	104.3 (97.0 to 111.5)	-1.4 (-4.3 to 2.0)
Sense organ diseases	-	-	-	-	13.6 (8.9 to 19.9)	24.9 (16.3 to 36.3)	81.1 (70.4 to 100.4)	-11.6 (-16.5 to -5.8)
Glaucoma	2.2 (1.6 to 3.0)	4.3 (3.1 to 5.9)	93.8 (49.3 to 150.2)	-7.9 (-25.6 to 18.0)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	105.9 (65.5 to 167.5)	-2.9 (-20.7 to 24.8)
Cataract	9.1 (6.4 to 12.1)	14.8 (10.2 to 20.2)	58.4 (23.9 to 119.6)	-29.9 (-43.9 to -11.3)	0.7 (0.4 to 1.1)	1.3 (0.8 to 1.9)	70.1 (37.9 to 122.5)	-26.0 (-39.2 to -11.9)
Macular degeneration	1.8 (1.0 to 3.0)	7.5 (4.9 to 11.3)	324.0 (169.2 to 499.0)	103.1 (34.1 to 189.3)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.7)	305.5 (167.5 to 479.0)	84.7 (26.7 to 154.1)
Uncorrected refractive error	184.3 (141.2 to 219.9)	372.6 (284.2 to 466.1)	101.0 (51.0 to 172.8)	-1.9 (-25.9 to 24.2)	3.7 (2.3 to 5.7)	6.7 (4.2 to 10.5)	81.9 (57.3 to 116.6)	-11.8 (-22.8 to 1.7)
Age-related and other hearing loss	285.5 (215.9 to 292.7)	496.5 (424.6 to 563.7)	91.8 (82.1 to 103.4)	-6.2 (-10.0 to -2.1)	7.1 (4.2 to 10.8)	11.6 (7.6 to 20.0)	81.1 (60.5 to 103.5)	-11.6 (-18.5 to -4.0)
Other vision loss	5.8 (4.7 to 7.5)	9.2 (7.2 to 11.5)	57.5 (35.7 to 77.2)	-18.9 (-28.3 to -9.5)	0.5 (0.3 to 0.7)	0.8 (0.5 to 1.2)	70.4 (41.2 to 95.7)	-13.4 (-24.5 to -1.9)
Other sense organ diseases	51.1 (48.4 to 53.9)	99.5 (94.0 to 104.8)	94.8 (79.0 to 109.6)	-0.3 (-6.8 to 6.4)	1.4 (0.8 to 2.0)	2.6 (1.6 to 3.9)	94.8 (77.6 to 113.0)	-0.0 (-6.8 to 7.7)
Oral disorders	-	-	-	-	2.4 (1.3 to 4.0)	5.1 (2.8 to 8.6)	111.6 (98.2 to 124.1)	1.2 (-5.3 to 7.7)
Deciduous caries	215.2 (204.2 to 227.3)	399.4 (376.4 to 421.4)	85.6 (72.8 to 99.3)	-0.4 (-7.4 to 6.7)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	86.1 (69.5 to 103.8)	-0.2 (-9.3 to 9.4)
Permanent caries	528.0 (482.3 to 583.9)	1,124.9 (1,012.1 to 1,282.						

Appendix Table G.4 - Liberia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	7.2 (6.6 to 7.9)	16.2 (14.7 to 17.6)	123.7 (100.1 to 152.3)	5.8 (-5.1 to 17.6)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	124.6 (98.9 to 156.2)	6.0 (5.4 to 18.5)
Other oral disorders	30.4 (28.7 to 32.2)	63.7 (60.0 to 67.3)	108.9 (94.2 to 126.4)	-0.6 (-7.1 to 6.5)	0.9 (0.6 to 1.3)	1.8 (1.2 to 2.8)	109.7 (93.6 to 128.3)	-0.2 (-7.0 to 7.3)
Injuries	-	-	-	-	22.0 (12.5 to 41.3)	25.6 (15.9 to 43.1)	18.3 (-22.2 to 73.0)	-26.5 (-50.3 to 5.3)
Transport injuries	-	-	-	-	2.9 (2.2 to 3.7)	4.8 (3.6 to 6.2)	64.9 (56.3 to 74.4)	-16.5 (-20.2 to -12.5)
Road injuries	-	-	-	-	2.7 (2.0 to 3.4)	4.4 (3.3 to 5.6)	62.5 (53.5 to 72.4)	-18.2 (-22.0 to -14.0)
Pedestrian road injuries	-	-	-	-	0.7 (0.5 to 0.9)	1.0 (0.8 to 1.3)	46.7 (33.7 to 64.6)	-23.6 (-29.2 to -16.8)
Cyclist road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	34.9 (25.4 to 45.3)	-28.0 (-33.0 to -23.1)
Motorcyclist road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.7)	38.0 (26.7 to 49.9)	-32.1 (-37.2 to -26.9)
Motor vehicle road injuries	-	-	-	-	1.3 (1.0 to 1.7)	2.4 (1.8 to 3.1)	84.1 (70.1 to 99.9)	-8.6 (-14.6 to -1.9)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	27.3 (18.8 to 37.4)	-40.0 (-43.2 to -35.9)
Other transport injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	92.1 (80.4 to 104.2)	2.7 (-4.1 to 9.3)
Unintentional injuries	-	-	-	-	4.1 (3.1 to 5.3)	7.6 (5.7 to 9.8)	84.9 (79.7 to 90.9)	-10.8 (-13.5 to -8.0)
Falls	-	-	-	-	1.6 (1.2 to 2.1)	3.2 (2.4 to 4.2)	101.5 (91.3 to 110.3)	-8.5 (-13.3 to -3.9)
Drowning	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	46.4 (30.9 to 61.3)	-27.0 (-33.3 to -20.9)
Fire, heat, and hot substances	-	-	-	-	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	55.9 (41.9 to 72.1)	-20.1 (-26.1 to -14.1)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.4 (25.3 to 78.1)	-27.3 (-37.1 to -16.6)
Exposure to mechanical forces	-	-	-	-	1.3 (1.0 to 1.7)	2.3 (1.7 to 3.0)	75.1 (66.1 to 84.1)	-13.2 (-17.4 to -9.2)
Unintentional firearm injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	74.8 (61.1 to 90.2)	-15.2 (-21.3 to -8.4)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	133.3 (108.5 to 163.3)	14.5 (4.2 to 26.4)
Other exposure to mechanical forces	-	-	-	-	1.2 (0.9 to 1.6)	2.2 (1.6 to 2.8)	74.5 (65.1 to 83.7)	-13.4 (-17.9 to -9.3)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	123.6 (112.6 to 135.3)	15.3 (9.3 to 21.3)
Animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	77.0 (66.1 to 89.5)	-11.7 (-16.6 to -6.7)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	78.0 (58.8 to 98.3)	-12.4 (-20.6 to -3.8)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	76.5 (66.4 to 88.4)	-11.1 (-15.6 to -6.3)
Foreign body	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	96.9 (86.3 to 108.8)	-2.9 (-7.9 to 2.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.7 (50.0 to 95.3)	-9.0 (-17.3 to 1.6)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	104.4 (84.1 to 127.7)	-1.4 (-9.6 to 7.8)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	106.3 (93.3 to 119.6)	-1.2 (-7.4 to 5.5)
Other unintentional injuries	-	-	-	-	0.6 (0.5 to 0.8)	1.1 (0.9 to 1.5)	80.7 (68.6 to 92.1)	-10.7 (-15.9 to -5.4)
Self-harm and interpersonal violence	-	-	-	-	1.2 (0.1 to 0.2)	0.3 (0.3 to 0.4)	86.2 (78.2 to 94.5)	-9.6 (-13.2 to -5.7)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	107.9 (91.5 to 123.2)	-2.1 (-8.8 to 4.0)
Interpersonal violence	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	82.5 (73.8 to 90.9)	-11.4 (-15.1 to -7.3)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	89.2 (77.3 to 103.6)	-7.8 (-13.6 to -1.3)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	119.1 (105.7 to 134.9)	4.3 (-1.9 to 11.7)
Assault by other means	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	72.6 (60.9 to 83.4)	-16.2 (-21.1 to -11.0)
Forces of nature, war, and legal intervention	-	-	-	-	14.8 (5.9 to 33.8)	12.8 (4.5 to 30.4)	-15.0 (-56.4 to 68.6)	-36.9 (-67.9 to 23.7)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.2 (-45.7 to -33.6)	-62.7 (-66.6 to -58.6)
Collective violence and legal intervention	-	-	-	-	14.8 (5.9 to 33.8)	12.8 (4.5 to 30.4)	-14.9 (-56.4 to 68.8)	-36.9 (-67.9 to 24.0)

Appendix Table G.4 - Libya prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	393.3 (278.9 to 497.6)	645.6 (480.3 to 835.3)	68.6 (60.7 to 75.9)	68.6 (4.0 to 4.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	60.3 (41.8 to 84.0)	78.1 (55.1 to 107.9)	29.5 (17.7 to 41.4)	0.4 (-8.6 to 10.0)
HIV/AIDS and tuberculosis	-	-	-	-	0.6 (0.4 to 0.8)	0.9 (0.6 to 1.2)	51.2 (32.0 to 72.4)	-13.4 (-22.6 to -2.5)
Tuberculosis	1.9 (1.8 to 1.9)	2.7 (2.6 to 2.8)	47.0 (41.9 to 52.7)	-15.8 (-18.4 to -12.7)	0.6 (0.4 to 0.8)	0.8 (0.6 to 1.1)	45.9 (27.9 to 65.2)	-15.9 (-24.8 to -6.3)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	886.2 (806.3 to 33,078.9)	886.2 (390.1 to 17,538.4)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,285.1 (583.5 to 23,514.0)	629.7 (260.1 to 12,088.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,285.1 (581.0 to 24,934.3)	629.7 (260.1 to 12,866.7)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.4)	1,376.1 (617.1 to 25,860.4)	720.1 (301.7 to 13,774.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	1,718.9 (803.6 to 35,858.0)	889.5 (389.2 to 19,304.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	12.0 (8.4 to 16.5)	12.1 (8.4 to 16.4)	0.8 (-7.5 to 9.1)	-18.1 (-24.1 to -12.1)
Diarrheal diseases	54.3 (50.6 to 58.2)	52.4 (48.9 to 56.0)	-3.5 (-12.9 to 6.0)	-19.1 (-26.4 to -11.7)	8.9 (5.9 to 12.3)	8.5 (5.7 to 11.9)	1.2 (-13.5 to 5.9)	-19.1 (-26.6 to -11.4)
Intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	5.5 (-26.3 to 19.3)	-26.3 (-40.6 to -8.9)
Typhoid fever	0.3 (0.3 to 0.4)	0.3 (0.3 to 0.4)	-3.6 (-21.7 to 16.4)	-24.7 (-37.3 to -8.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-3.4 (-25.8 to 23.7)	-24.5 (-39.6 to -4.5)
Paratyphoid fever	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-2.1 (-22.5 to 32.5)	-24.3 (-39.7 to 1.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.1 (-22.5 to 32.5)	-24.3 (-39.9 to 1.7)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-76.1 (-99.0 to 145.2)	-81.6 (-99.2 to 93.8)
Lower respiratory infections	1.3 (0.7 to 2.4)	2.5 (1.9 to 3.4)	122.6 (6.9 to 290.9)	43.7 (-10.9 to 129.3)	0.1 (0.1 to 0.3)	0.3 (0.2 to 0.4)	117.5 (-11.6 to 288.5)	43.5 (14.0 to 132.9)
Upper respiratory infections	86.4 (77.5 to 95.8)	119.1 (107.7 to 131.0)	38.0 (19.4 to 59.8)	-0.5 (-13.1 to 15.3)	1.0 (0.6 to 1.8)	1.4 (0.8 to 2.3)	37.7 (18.2 to 59.5)	-0.4 (-13.7 to 15.9)
Otitis media	54.3 (50.7 to 57.7)	63.8 (59.0 to 69.7)	17.0 (7.8 to 29.8)	-10.3 (-17.6 to 0.0)	1.0 (0.6 to 1.6)	1.2 (0.7 to 1.9)	16.0 (5.9 to 29.8)	-11.0 (-18.3 to -0.9)
Meningitis	-	-	-	-	0.7 (0.4 to 1.0)	0.5 (0.3 to 0.7)	-33.1 (-46.8 to -19.9)	-52.2 (-60.6 to -38.7)
Pneumococcal meningitis	2.8 (1.7 to 4.7)	2.0 (1.2 to 3.4)	-28.6 (-48.7 to 1.3)	-52.6 (-66.1 to -32.4)	0.2 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-30.6 (-48.3 to 2.2)	-51.8 (-63.3 to -30.8)
H influenzae type B meningitis	1.6 (0.5 to 3.7)	0.9 (0.3 to 2.0)	-42.6 (-58.4 to 0.3)	-60.4 (-71.3 to -25.9)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-39.4 (-64.3 to 11.8)	-55.9 (-73.6 to -19.0)
Meningococcal meningitis	0.8 (0.2 to 2.1)	0.5 (0.2 to 1.3)	-36.2 (-61.7 to -11.5)	-56.4 (-73.8 to -36.7)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-38.6 (-65.7 to -3.2)	-55.9 (-74.8 to -33.9)
Other meningitis	1.1 (0.6 to 2.1)	0.9 (0.4 to 1.6)	-23.4 (-43.6 to 2.0)	-43.9 (-57.4 to -25.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-25.3 (-48.0 to 9.8)	-44.4 (-60.0 to -17.9)
Encephalitis	0.8 (0.3 to 2.2)	1.0 (0.4 to 2.7)	22.4 (0.2 to 45.1)	-11.1 (-31.1 to -5.5)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	18.6 (6.6 to 52.6)	21.5 (-36.9 to -1.5)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.4 (-93.9 to 596.2)	-50.8 (-94.4 to 348.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.4 (-93.9 to 600.5)	-50.8 (-94.4 to 348.8)
Whooping cough	0.8 (0.6 to 1.0)	0.2 (0.1 to 0.2)	-80.5 (-82.5 to -78.4)	-81.7 (-83.6 to -79.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-80.8 (-86.9 to -73.4)	-81.9 (-87.6 to -75.1)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.2 (-96.0 to -81.6)	-92.9 (-97.2 to -86.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-87.3 (-92.6 to -72.0)	-90.3 (-94.2 to -79.6)
Measles	0.5 (0.4 to 0.7)	0.1 (0.0 to 0.1)	-88.2 (-90.9 to -84.6)	-88.8 (-91.4 to -85.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	-88.1 (-91.6 to -82.9)	-88.7 (-92.0 to -83.8)
Varicella and herpes zoster	3.3 (3.0 to 3.6)	4.4 (3.9 to 5.0)	34.5 (17.6 to 54.3)	5.2 (-13.3 to 27.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	88.0 (36.6 to 174.4)	8.1 (-21.8 to 55.8)
Neglected tropical diseases and malaria	-	-	-	-	5.7 (3.2 to 10.0)	5.6 (3.0 to 11.0)	-1.6 (-20.9 to 23.6)	-33.2 (-46.1 to -17.5)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.6 (-18.8 to 299.4)	36.6 (-40.8 to 184.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.7 (-23.2 to 263.4)	25.9 (-44.8 to 164.4)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	34.6 (8.3 to 69.8)	3.6 (-16.2 to 30.3)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.5 (-21.1 to 167.8)	20.6 (-31.3 to 112.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.5 (-21.1 to 168.6)	20.6 (-31.3 to 112.3)
Cutaneous and mucocutaneous leishmaniasis	2.6 (2.0 to 3.6)	3.6 (2.7 to 4.7)	35.2 (13.1 to 67.1)	4.1 (-12.7 to 28.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	34.7 (8.0 to 70.4)	3.6 (-16.3 to 30.3)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	217.7 (88.9 to 465.9)	343.6 (143.1 to 735.5)	57.8 (52.1 to 63.6)	57.8 (-2.2 to 3.9)	1.8 (0.7 to 4.2)	2.7 (1.1 to 6.6)	54.7 (24.9 to 90.1)	1.9 (-14.3 to 23.6)
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-89.2 (-97.4 to -59.4)	-93.5 (-98.4 to -79.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-88.4 (-97.1 to -54.9)	-93.0 (-98.2 to -77.0)
Cystic echinococcosis	0.3 (0.3 to 0.4)	0.4 (0.4 to 0.5)	24.1 (12.4 to 44.1)	-24.4 (-30.6 to -14.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	25.0 (-4.3 to 68.5)	-24.9 (-40.9 to -1.3)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	6.8 (3.5 to 11.0)	3.2 (1.6 to 5.5)	-52.9 (-66.6 to -39.9)	-79.3 (-85.5 to -69.5)	0.5 (0.2 to 0.9)	0.2 (0.1 to 0.4)	-54.1 (-68.1 to -37.8)	-80.0 (-86.2 to -71.6)
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.1 (-71.0 to -13.4)	-66.1 (-79.3 to -35.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.1 (-71.1 to -13.3)	-66.1 (-79.3 to -35.6)
Intestinal nematode infections	-	-	-	-	1.1 (0.4 to 2.6)	1.1 (0.0 to 0.1)	0.0 (-98.0 to -91.5)	-95.9 (-98.0 to -91.6)
Ascariasis	317.2 (217.9 to 455.8)	63.0 (36.8 to 104.1)	-80.3 (-89.4 to -62.9)	-85.6 (-92.8 to -71.4)	1.1 (0.4 to 2.5)	0.0 (0.0 to 0.0)	0.0 (-98.4 to -95.5)	-98.4 (-99.4 to -95.6)
Trichuriasis	197.1 (129.4 to 290.6)	42.3 (26.3 to 65.6)	-78.9 (-88.4 to -58.9)	-85.1 (-92.4 to -69.8)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-90.4 (-97.5 to -54.1)	-92.4 (-98.4 to -64.3)
Hookworm disease	2.7 (1.5 to 4.3)	4.4 (2.5 to 7.1)	63.0 (-24.4 to 263.9)	73.5 (-57.1 to 107.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (15.0 to 114.9)	0.2 (-31.3 to 24.9)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	56.2 (41.8 to 71.3)	62.7 (59.1 to 67.0)	11.7 (-11.7 to 48.4)	-1.5 (-20.3 to 26.5)	2.2 (1.3 to 3.3)	2.5 (1.5 to 4.1)	13.8 (-1.4 to 68.3)	3.1 (-10.8 to 48.9)
Maternal disorders	-	-	-	-	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	-1.7 (-23.2 to 23.2)	-49.5 (-60.5 to -37.5)
Maternal hemorrhage	1.0 (0.9 to 1.2)	1.2 (0.8 to 1.5)	11.9 (-20.4 to 48.4)	-43.3 (-58.6 to -23.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-41.5 to 66.3)	47.0 (-6.6 to 13.8)
Maternal sepsis and other maternal infections	2.1 (1.3 to 3.0)	1.4 (0.8 to 2.3)	-31.9 (-52.6 to -6.5)	-47.6 (-77.5 to -55.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-67.0 to 18.2)	-38.2 (-82.7 to -40.5)
Maternal hypertensive disorders	2.1 (0.8 to 3.7)	2.2 (0.8 to 4.2)	6.4 (-8.5 to 20.8)	-45.4 (-52.4 to -40.2)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	6.3 (-14.9 to 28.0)	45.2 (-54.9 to -35.6)
Obstructed labor	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-4.4 (-34.9 to 42.2)	-50.4 (-66.7 to -28.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-3.6 (-56.3 to 99.5)	-49.9 (-76.6 to 1.7)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.4 (-28.7 to 87.3)	-45.9 (-66.0 to -6.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.4 (-28.8 to 87.9)	-45.9 (-66.0 to -5.7)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-0.6 (-53.8 to 95.5)	-48.6 (-76.6 to -2.0)
Neonatal disorders	-	-	-	-	8.2 (5.0 to 12.6)	17.5 (11.0 to 24.8)	116.2 (41.2 to 234.2)	60.6 (4.7 to 146.7)
Preterm birth complications	23.6 (14.4 to 36.7)	63.1 (41.8 to 92.3)	166.4 (82.5 to 295.8)	89.8 (32.0 to 180.5)	3.2 (1.7 to 5.3)	8.3 (5.2 to 13.3)	160.6 (60.2 to 359.0)	89.8 (18.0 to 233.4)
Neonatal encephalopathy due to birth asphyxia and trauma	10.9 (6.0 to 17.3)	13.5 (8.0 to 19.7)	25.6 (-30.8 to 126.8)	7.0 (-48.7 to 69.9)	2.3 (1.2 to 3.9)	2.9 (1.6 to 6.4)	26.6 (-33.2 to 132.5)	-4.2 (-49.7 to 74.6)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.0 (-14.9 to 57.1)	14.7 (-19.3 to 48.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.7 (-17.5 to 77.5)	14.7 (-21.8 to 68.2)
Hemolytic disease and other neonatal jaundice	7.4 (3.6 to 13.7)	18.0 (6.9 to 33.3)	155.1 (-34.4 to 561.4)	86.5 (-52.2 to 387.6)	1.8 (0.9 to 3.5)	4.2 (1.5 to 8.2)	139.2 (-35.7 to 456.8)	75.2 (-52.8 to 305.2)
Other neonatal disorders	-	-	-	-	0.9 (0.4 to 1.5)	2.1 (1.1 to 3.9)	152.1 (26.4 to 464.2)	86.7 (-6.1 to 316.2)
Nutritional deficiencies	-	-	-	-	31.3 (20.8 to 45.5)	38.6 (25.9 to 55.7)	23.0 (12.9 to 35.8)	-0.5 (-8.2 to 10.1)
Protein-energy malnutrition	9.7 (3.9 to 20.3)	13.5 (4.8 to 30.1)	37.6 (-57.1 to 352.1)	29.5 (-50.4 to 321.9)	1.2 (0.4 to 2.6)	1.7 (0.5 to 3.8)	1.7 (-58.0 to 361.6)	29.3 (-60.2 to 330.5)
Iodine deficiency	111.8 (55.8 to 198.0)	116.1 (63.4 to 202.8)	1.5 (-52.9 to 162.7)	-36.7 (-70.7 to 80.4)	2.0 (0.9 to 4.0)	2.1 (1.0 to 4.0)	0.8 (-53.2 to 162.3)	-36.7 (-70.5 to 81.1)
Vitamin A deficiency	2.5 (1.4 to 3.3)	1.7 (1.1 to 2.4)	-31.7 (-46.8 to -6.3)	-47.4 (-58.2 to -31.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-33.2 (-50.8 to -6.3)	-49.4 (-62.3 to -32.3)

Appendix Table G.4 - Libya prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	849.4 (834.9 to 863.8)	1,133.7 (1,122.5 to 1,144.4)	33.4 (30.8 to 36.1)	27.6 (0.8 to 2.7)	27.6 (18.4 to 40.0)	34.2 (22.8 to 49.7)	24.2 (20.0 to 26.9)	24.2 (-0.9 to 4.2)
Other nutritional deficiencies	-	-	-	-	0.4 (0.1 to 1.0)	0.5 (0.1 to 1.4)	46.6 (-64.2 to 531.1)	37.8 (-65.8 to 485.4)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.4 (1.5 to 3.6)	3.1 (2.0 to 5.0)	33.8 (8.8 to 62.5)	-0.1 (-19.7 to 17.5)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.6 (0.3 to 1.2)	1.1 (0.6 to 2.1)	90.8 (16.2 to 186.1)	11.4 (-30.0 to 61.3)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	18.4 (5.2 to 41.0)	-42.0 (-52.7 to -33.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.7 (-13.2 to 62.7)	40.8 (-56.2 to -21.7)
Chlamydial infection	61.1 (35.2 to 98.2)	121.5 (82.7 to 177.9)	97.9 (-4.0 to 329.2)	22.1 (-40.8 to 164.4)	0.2 (0.1 to 0.6)	0.5 (0.2 to 1.1)	129.2 (-12.9 to 506.2)	40.6 (-47.4 to 260.9)
Gonococcal infection	27.6 (19.8 to 35.4)	40.1 (29.5 to 51.6)	42.1 (-10.0 to 127.5)	-9.8 (-41.4 to 41.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	39.0 (3.1 to 111.3)	-13.7 (-35.0 to 29.0)
Trichomoniasis	15.5 (7.7 to 25.7)	32.7 (19.7 to 49.4)	129.8 (-7.5 to 401.2)	19.0 (-44.4 to 155.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	144.4 (-15.7 to 578.0)	26.9 (-48.9 to 237.7)
Genital herpes	501.5 (468.0 to 528.6)	947.2 (889.3 to 1,003.8)	88.4 (73.6 to 104.9)	-1.3 (-9.6 to 7.5)	0.1 (0.0 to 0.3)	0.3 (0.1 to 0.6)	89.5 (63.9 to 101.8)	-1.3 (-11.0 to 8.1)
Other sexually transmitted diseases	0.7 (0.5 to 1.0)	1.3 (0.9 to 1.7)	78.3 (53.1 to 111.2)	-10.2 (-23.3 to 6.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.3 (40.0 to 217.1)	12.8 (-21.5 to 67.9)
Hepatitis	-	-	-	-	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.7)	31.0 (-1.2 to 60.8)	-21.5 (-41.4 to -1.1)
Hepatitis A	5.2 (4.9 to 5.4)	6.5 (6.2 to 6.7)	25.6 (24.7 to 26.4)	-2.1 (-2.2 to -1.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	39.5 (24.3 to 58.3)	-1.5 (-11.4 to 10.8)
Hepatitis B	346.3 (270.9 to 425.3)	332.8 (235.3 to 409.0)	-3.9 (-36.3 to 35.1)	-39.3 (-60.4 to -15.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	19.0 (-34.4 to 86.2)	-35.4 (-64.2 to 3.0)
Hepatitis C	223.8 (200.9 to 252.0)	278.4 (250.0 to 309.2)	24.2 (6.7 to 45.4)	-29.1 (-38.4 to -18.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.8 (-7.9 to 71.8)	19.7 (-41.2 to 10.2)
Hepatitis E	0.7 (0.4 to 1.0)	1.3 (0.9 to 1.8)	72.4 (14.4 to 186.7)	4.8 (-29.7 to 76.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	77.8 (5.2 to 212.0)	7.5 (-36.5 to 86.7)
Leprosy	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	40.7 (-42.2 to 579.7)	-25.4 (-67.0 to 295.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.4 (-41.7 to 962.8)	-18.5 (-66.3 to 519.4)
Other infectious diseases	39.7 (30.9 to 49.2)	46.0 (41.5 to 51.2)	15.7 (1.1 to 46.5)	-1.9 (-13.6 to 20.4)	1.4 (0.9 to 2.1)	1.6 (1.0 to 2.3)	10.8 (-7.0 to 55.1)	0.9 (-15.4 to 37.4)
Non-communicable diseases	-	-	-	-	308.9 (226.4 to 399.9)	548.0 (405.8 to 707.8)	78.0 (68.8 to 85.8)	1.9 (-3.0 to 5.4)
Neoplasms	-	-	-	-	1.4 (1.0 to 2.0)	3.1 (2.1 to 4.1)	113.2 (66.4 to 178.5)	9.1 (-14.2 to 42.0)
Esophageal cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	92.3 (18.8 to 214.3)	-7.3 (-43.3 to 52.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.5 (30.5 to 192.4)	-6.0 (-37.5 to 44.4)
Stomach cancer	0.4 (0.3 to 0.5)	0.7 (0.6 to 0.9)	75.1 (27.8 to 138.1)	-14.7 (-36.8 to 15.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	74.7 (26.6 to 139.6)	-14.7 (-37.9 to 17.5)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	114.2 (46.9 to 219.1)	3.8 (-29.0 to 55.6)
Liver cancer due to hepatitis B	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	148.2 (25.0 to 392.8)	24.8 (-37.7 to 148.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	139.7 (27.4 to 353.0)	20.3 (-38.4 to 129.7)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	409.2 (150.9 to 1,477.7)	146.5 (19.1 to 726.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	376.8 (150.5 to 1,289.1)	125.7 (16.2 to 636.0)
Liver cancer due to alcohol use	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-22.7 (-65.2 to 73.3)	-64.0 (-83.1 to -21.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.7 (-62.2 to 70.8)	-63.8 (-82.3 to -23.4)
Liver cancer due to other causes	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	7.9 (-50.6 to 187.9)	-44.8 (-74.9 to 63.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.2 (-50.3 to 165.8)	-46.4 (-75.4 to 54.5)
Larynx cancer	0.5 (0.3 to 0.7)	0.9 (0.6 to 1.2)	65.5 (8.5 to 160.7)	-16.5 (-45.1 to 29.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	70.1 (9.2 to 171.9)	-15.6 (-44.2 to 31.4)
Tracheal, bronchus and lung cancer	0.8 (0.6 to 1.0)	1.3 (1.0 to 1.7)	68.8 (15.4 to 150.6)	-17.1 (-42.3 to 22.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	72.0 (19.0 to 154.2)	-15.3 (-40.4 to 23.6)
Breast cancer	2.0 (1.4 to 2.8)	5.7 (4.1 to 7.7)	181.3 (75.7 to 340.7)	33.1 (-13.8 to 106.4)	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.7)	176.4 (70.6 to 342.2)	31.3 (-17.0 to 107.4)
Cervical cancer	1.0 (0.6 to 1.4)	1.6 (1.0 to 2.3)	63.2 (-4.4 to 168.7)	-20.0 (-51.9 to 27.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	65.4 (-21.2 to 177.7)	-19.1 (-51.4 to 32.1)
Uterine cancer	0.4 (0.2 to 0.7)	0.6 (0.4 to 1.2)	73.6 (-4.6 to 200.7)	-12.4 (-52.7 to 51.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	74.1 (5.7 to 219.4)	-12.5 (-52.8 to 57.0)
Prostate cancer	0.6 (0.4 to 1.0)	2.8 (1.7 to 4.4)	326.3 (147.2 to 680.9)	84.4 (4.5 to 240.4)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.5)	268.7 (122.2 to 539.8)	54.6 (-8.4 to 171.3)
Colon and rectum cancer	2.0 (1.6 to 2.5)	4.5 (3.6 to 5.5)	120.3 (65.4 to 204.5)	6.6 (-18.7 to 43.9)	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.5)	117.4 (60.9 to 199.2)	4.7 (-21.3 to 43.3)
Lip and oral cavity cancer	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.8)	95.0 (30.2 to 185.9)	-2.8 (-31.0 to 40.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	93.9 (28.7 to 181.0)	-3.5 (-33.8 to 39.6)
Nasopharynx cancer	0.4 (0.2 to 0.6)	0.6 (0.3 to 0.8)	52.0 (-10.7 to 147.3)	-14.4 (-47.6 to 34.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	55.2 (-7.2 to 138.2)	-15.2 (-46.0 to 32.0)
Other pharynx cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	67.6 (-10.4 to 200.6)	-15.5 (-52.7 to 50.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.5 (-5.9 to 196.6)	-16.2 (-51.2 to 44.0)
Gallbladder and biliary tract cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	70.0 (-7.2 to 183.2)	-19.7 (-57.5 to 34.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.7 (-10.1 to 184.5)	-20.2 (-58.4 to 41.5)
Pancreatic cancer	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	129.7 (58.7 to 227.6)	6.2 (-26.0 to 49.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	133.6 (67.4 to 227.1)	8.6 (-22.1 to 50.4)
Malignant skin melanoma	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	131.7 (57.3 to 276.6)	20.6 (-16.5 to 92.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	126.6 (47.9 to 263.8)	15.9 (-22.5 to 84.9)
Non-melanoma skin cancer	0.2 (0.2 to 0.3)	0.7 (0.5 to 0.9)	214.7 (132.7 to 306.7)	42.7 (5.2 to 89.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	307.4 (171.7 to 507.3)	78.2 (11.8 to 176.1)
Ovarian cancer	0.3 (0.2 to 0.4)	0.8 (0.6 to 1.1)	176.8 (57.8 to 373.1)	41.5 (-19.2 to 138.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	175.2 (47.8 to 403.7)	39.9 (-23.0 to 157.9)
Testicular cancer	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	97.4 (10.3 to 252.9)	3.8 (-41.7 to 78.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.5 (4.2 to 269.3)	3.7 (-43.3 to 87.5)
Kidney cancer	0.6 (0.5 to 0.8)	1.0 (0.9 to 1.6)	71.3 (30.8 to 200.2)	-16.8 (-26.0 to 79.4)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	73.1 (34.1 to 211.8)	-16.0 (-27.7 to 84.3)
Bladder cancer	0.6 (0.4 to 0.8)	1.0 (0.8 to 1.3)	71.6 (19.2 to 136.5)	5.3 (-41.4 to 14.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	73.3 (21.3 to 143.7)	2.8 (-40.3 to 16.0)
Brain and nervous system cancer	0.8 (0.4 to 0.8)	1.5 (0.7 to 1.3)	91.4 (21.2 to 142.4)	-2.2 (-24.9 to 50.3)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.2)	89.8 (19.9 to 150.3)	-3.5 (-29.6 to 50.5)
Thyroid cancer	0.9 (0.5 to 1.1)	1.5 (1.1 to 2.1)	69.2 (28.7 to 192.8)	17.4 (-32.7 to 44.7)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	84.6 (30.4 to 193.2)	14.6 (-32.9 to 42.2)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.3 (12.3 to 157.1)	45.0 (-45.0 to 29.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	126.6 (51.9 to 162.3)	15.9 (-44.8 to 30.3)
Hodgkin lymphoma	0.7 (0.3 to 1.1)	1.2 (0.6 to 1.7)	66.7 (3.2 to 169.2)	11.4 (-27.6 to 76.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	66.8 (13.1 to 168.7)	9.0 (-28.7 to 72.3)
Non-Hodgkin lymphoma	1.0 (0.7 to 1.5)	2.3 (1.7 to 3.0)	122.2 (47.7 to 263.4)	26.9 (-17.1 to 114.8)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	121.7 (44.9 to 269.1)	24.8 (-19.8 to 116.8)
Multiple myeloma	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	122.5 (48.4 to 247.8)	9.0 (-28.1 to 67.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	120.2 (45.5 to 239.2)	7.7 (-29.8 to 68.9)
Leukemia	0.9 (0.7 to 1.1)	1.5 (1.2 to 1.8)	75.2 (27.0 to 141.1)	17.4 (-13.2 to 58.9)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	84.6 (36.9 to 153.8)	14.6 (-15.0 to 58.0)
Other neoplasms	1.0 (0.7 to 1.6)	2.3 (1.7 to 3.3)	142.6 (59.6 to 241.0)	58.5 (12.8 to 122.8)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	140.1 (65.2 to 237.3)	49.6 (7.0 to 104.3)
Cardiovascular diseases	-	-	-	-	6.8 (4.6 to 9.6)	12.5 (8.4 to 17.4)	83.5 (43.5 to 130.5)	0.6 (-19.3 to 24.3)
Rheumatic heart disease	10.9 (7.5 to 13.6)	19.2 (15.0 to 24.3)	74.8 (20.4 to 169.6)	1.4 (-26.1 to 45.7)	0.6 (0.3 to 0.9)	1.1 (0.7 to 1.6)	88.2 (31.8 to 187.6)	12.9 (-17.2 to 66.3)
Ischemic heart disease	28.9 (23.6 to 36.8)	46.7 (40.7 to 54.4)	60.8 (22.4 to 119.2)	-19.4 (-37.2 to 7.9)	1.7 (1.1 to 2.6)	2.7 (1.8 to 3.9)	59.9 (15.3 to 135.5)	-16.3 (-38.8 to 21.2)
Cerebrovascular disease	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	79.5 (34.8 to 134.6)	-10.5 (-33.0 to 20.2)
Ischemic stroke	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.6)	84.8 (38.2 to 138.9)	-8.7 (-32.0 to 21.0)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	85.8 (37.1 to 141.8)	-8.2 (-32.5 to 22.3)
Hemorrhagic stroke	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	51.5 (0.3 to 130.9)	-24.4 (-50.3 to 24.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.9 (0.8 to 132.8)	-24.0 (-50.2 to 25.3)
Hypertensive heart disease	3.2 (2.4 to 4.2)	8.6 (6.3 to 11.0)	173.7 (82.8 to 276.5)	43.9 (8.0 to 100.4)	0.4 (0.2 to 0.5)	0.9 (0.6 to 1.4)	170.8 (83.4 to 273.9)	43.0 (-9.5 to 98.8)
Cardiomyopathy and myocarditis	3.1 (2.6 to 3.8)	6.9 (5.4 to 8.9)	117.4 (61.9 to 182.4)	23.6 (-9.6 to 67.3)	0.3 (0.2 to 0.5)	0.8 (0.5 to 1.1)	116.3 (58.5 to 186.6)	23.6 (-10.7 to 68.2)
Atrial fibrillation and flutter	3.8 (2.8 to 5.0)	10.7 (8.5 to 13.2)	178.9 (98.2 to 316.8)	15.2 (-20.1 to 70.1)	0.3 (0.2 to 0.4)	0.8 (0.5 to 1.2)	179.7 (101.1 to 317.8)	16.1 (-19.7 to 72.4)
Peripheral vascular disease	41.9 (30.4 to 57.7)	109.4 (81.7 to 140.0)	163.3 (67.3 to 269.4)	22.6 (-17.6 to 65.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	112.2 (24.5 to 391.1)	-20.0 (-50.6 to 72.1)
Endocarditis	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	77.3 (3.1 to 153.7)	4.4 (-41.0 to 50.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.4 (4.8 to 164.4)	5.1 (-40.7 to 59.0)
Other cardiovascular and circulatory diseases	49.2 (35.4 to 68.5)	84.7 (53.6 to 112.9)	75.2 (7.9 to 166.3)	5.9 (-38.6 to 51.8)	1.0 (0.1 to 5.3)	1.3 (3.4 to 9.1)	79.9 (5.8 to 160.8)	1.3 (-38.8 to 51.8)
Chronic respiratory diseases	-	-	-	-	16.3 (10.9 to 22.8)	28.8 (19.5 to 39.6)	77.0 (42.2 to 111.3)	-1.4 (-21.5 to 16.5)
Chronic obstructive pulmonary disease	142.1 (134.0 to 150.6)	269.1 (2						

Appendix Table G.4 - Libya prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumonia	-	-	-	-	0.0	0.0	(70.3 to 84.0)	(-15.3 to -8.0)
Silicosis	0.0	0.0	60.1	-22.2	0.0	0.0	(50.6 to 68.2)	(-27.2 to -17.9)
Asbestosis	(0.0 to 0.0)	(0.0 to 0.0)	(51.6 to 68.3)	(-26.7 to -17.9)	(0.0 to 0.0)	(0.0 to 0.0)		
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.1	87.4	-4.5	0.0	0.0	88.1	-3.9
Asthma	146.6	190.5	26.0	-22.5	6.4	8.3	24.6	-22.8
Interstitial lung disease and pulmonary sarcoidosis	(109.2 to 177.5)	(140.0 to 255.4)	(10.4 to 96.7)	(-44.4 to 14.3)	(3.9 to 9.7)	(5.0 to 13.2)	(-11.3 to 95.9)	(-44.9 to 14.4)
Other chronic respiratory diseases	0.3	0.6	93.6	1.3	0.0	0.1	93.0	1.6
Cirrhosis	(0.2 to 0.4)	(0.4 to 0.7)	(39.3 to 176.0)	(-26.6 to 48.4)	(0.0 to 0.1)	(0.0 to 0.1)	(39.2 to 176.7)	(-26.5 to 49.0)
Cirrhosis due to hepatitis B	0.5	0.7	38.5	-14.2	0.1	0.1	(-24.7 to 58.0)	(-61.6 to -19.5)
Cirrhosis due to hepatitis C	0.4	0.8	94.2	17.4	0.1	0.1	(23.5 to 243.5)	(51.9 to 95.7)
Cirrhosis due to alcohol use	0.2	0.1	-12.3	-51.1	0.0	0.0	(-34.2 to 400.9)	(-57.1 to 152.3)
Cirrhosis due to other causes	(0.1 to 0.3)	(0.1 to 0.2)	(-56.9 to 84.0)	(-75.9 to -2.2)	(0.0 to 0.0)	(0.0 to 0.0)	(-60.2 to 84.3)	(-77.0 to -0.1)
Digestive diseases	0.4	0.4	-9.4	-23.5	0.1	0.1	-12.1	-25.8
Peptic ulcer disease	7.5	10.6	42.9	-37.6	0.3	0.5	59.1	-28.1
Gastritis and duodenitis	12.1	9.8	-18.8	-48.4	0.6	0.5	(-17.7)	-43.0
Appendicitis	0.3	0.4	23.0	-22.6	0.1	0.1	25.0	-20.8
Paralytic ileus and intestinal obstruction	0.0	0.1	73.9	3.4	0.0	0.0	73.9	5.4
Inguinal, femoral, and abdominal hernia	7.7	12.7	63.8	-14.4	0.1	0.1	62.5	-14.1
Inflammatory bowel disease	(6.5 to 8.9)	(10.7 to 14.9)	(31.1 to 109.4)	(-34.2 to 12.9)	(0.0 to 0.2)	(0.1 to 0.2)	(29.3 to 108.6)	(-34.4 to 13.1)
Vascular intestinal disorders	2.3	7.1	212.3	65.4	0.5	1.5	210.4	66.0
Gallbladder and biliary diseases	0.0	0.0	88.1	-5.7	0.0	0.0	89.2	-2.5
Pancreatitis	(1.0 to 1.4)	(2.0 to 2.8)	(56.3 to 137.8)	(-17.8 to 26.4)	(0.1 to 0.2)	(0.2 to 0.3)	(50.5 to 144.2)	(-20.2 to 26.9)
Other digestive diseases	0.7	1.2	72.4	-9.3	0.2	0.4	71.5	-9.4
Neurological disorders	(0.7 to 0.8)	(1.1 to 1.3)	(57.5 to 90.6)	(-16.0 to -0.9)	(0.1 to 0.3)	(0.2 to 0.5)	(42.1 to 110.1)	(-23.8 to 7.8)
Alzheimer disease and other dementias	-	-	-	-	0.2	0.5	98.4	5.8
Parkinson disease	-	-	-	-	(0.2 to 0.3)	(0.3 to 0.7)	(51.7 to 155.2)	(-18.3 to 35.3)
Epilepsy	14.2	34.0	138.1	-2.2	24.8	47.9	94.1	6.2
Multiple sclerosis	(12.0 to 15.9)	(28.7 to 39.1)	(95.5 to 199.5)	(-21.2 to 22.8)	(1.6 to 2.6)	(3.4 to 6.3)	(100.8 to 209.4)	(-20.4 to 23.3)
Migraine	1.0	2.3	122.4	3.8	0.1	0.3	120.6	3.5
Tension-type headache	(0.9 to 1.2)	(1.9 to 2.7)	(104.0 to 139.1)	(-4.4 to 11.5)	(0.1 to 0.2)	(0.2 to 0.4)	(93.0 to 150.5)	(-7.6 to 16.0)
Medication overuse headache	8.2	10.7	31.4	-7.0	2.7	3.8	39.9	0.6
Other neurological disorders	(6.5 to 9.5)	(8.9 to 12.4)	(8.8 to 69.4)	(-28.8 to 20.0)	(1.8 to 3.7)	(2.5 to 5.2)	(4.7 to 86.4)	(-25.6 to 34.5)
Mental and substance use disorders	0.2	0.7	354.4	129.2	0.1	0.2	319.9	113.0
Schizophrenia	(0.1 to 0.2)	(0.4 to 1.0)	(173.9 to 573.0)	(39.8 to 231.0)	(0.0 to 0.1)	(0.1 to 0.4)	(157.1 to 545.6)	(29.5 to 221.1)
Alcohol use disorders	400.4	889.8	70.7	-13.7	23.0	47.8	105.9	-1.9
Drug use disorders	(314.9 to 492.4)	(460.8 to 894.8)	(5.7 to 154.3)	(-32.6 to 43.6)	(7.6 to 21.2)	(12.4 to 37.4)	(4.4 to 154.6)	(-32.8 to 44.9)
Opioid use disorders	684.2	1,112.2	63.6	-3.0	1.0	1.7	62.8	-1.9
Cocaine use disorders	(628.5 to 738.7)	(728.1 to 1,427.6)	(3.4 to 111.9)	(-37.4 to 24.3)	(0.5 to 1.8)	(0.7 to 3.3)	(3.4 to 114.1)	(-37.4 to 25.6)
Amphetamine use disorders	29.7	85.9	190.3	61.4	4.7	13.5	189.4	61.6
Cannabis use disorders	(19.8 to 39.7)	(57.4 to 115.6)	(134.7 to 255.0)	(32.0 to 96.7)	(2.6 to 7.2)	(7.6 to 20.8)	(133.9 to 255.6)	(32.0 to 97.9)
Other drug use disorders	0.0	0.0	35.1	-9.7	0.6	0.5	-10.5	-64.3
Depressive disorders	(0.0 to 0.0)	(0.0 to 0.0)	(-2.1 to 95.5)	(-33.6 to 24.6)	(0.4 to 0.9)	(0.3 to 0.7)	(-42.3 to 37.7)	(-77.0 to -45.3)
Major depressive disorder	9.5	18.3	93.5	-0.4	104.0	167.6	61.3	-3.2
Dysthymia	(8.5 to 10.3)	(16.7 to 19.8)	(84.2 to 103.6)	(-4.5 to 3.9)	(71.4 to 142.4)	(115.7 to 230.2)	(53.4 to 69.4)	(-6.8 to 0.2)
Bipolar disorder	17.9	29.8	66.4	-4.2	6.1	11.7	93.4	0.3
Anxiety disorders	(15.7 to 20.4)	(26.5 to 33.3)	(55.5 to 78.4)	(-9.7 to 2.2)	(1.1 to 2.5)	(1.9 to 4.2)	(52.7 to 82.8)	(-11.3 to 4.3)
Eating disorders	-	-	-	-	16.9	25.9	52.3	-21.2
Anorexia nervosa	34.6	52.6	51.6	-23.8	(10.1 to 25.8)	(15.4 to 39.5)	(29.6 to 79.4)	(-31.9 to -8.5)
Bulimia nervosa	(21.0 to 50.5)	(32.4 to 81.9)	(26.4 to 78.8)	(-35.8 to -11.1)	(8.1 to 22.4)	(12.1 to 34.8)	(15.0 to 81.0)	(-36.5 to -10.5)
Autistic spectrum disorders	3.4	5.7	64.4	0.5	64.4	0.8	65.2	-3.4
Autism	(2.8 to 4.1)	(4.5 to 6.8)	(23.7 to 118.8)	(-26.8 to 25.2)	(0.3 to 0.7)	(0.5 to 1.2)	(25.2 to 132.8)	(-30.4 to 34.2)
Asperger syndrome	5.4	8.4	54.7	-2.3	0.7	1.1	56.0	-1.7
Attention-deficit/hyperactivity disorder	(4.4 to 6.6)	(6.7 to 10.0)	(15.4 to 102.8)	(-25.9 to 26.0)	(0.4 to 1.1)	(0.6 to 1.7)	(10.1 to 112.2)	(-29.6 to 31.8)
Conduct disorder	6.5	9.8	49.3	-1.8	0.2	0.3	49.5	-1.3
Idiopathic intellectual disability	(5.0 to 8.0)	(7.7 to 11.7)	(43.3 to 56.9)	(-2.2 to -1.5)	(0.1 to 0.3)	(0.2 to 0.4)	(26.7 to 78.3)	(-16.0 to 15.7)
Other mental and substance use disorders	-	-	-	-	1.2	1.9	62.5	-0.8
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	(0.7 to 1.8)	(1.2 to 2.9)	(12.3 to 130.6)	(-30.5 to 39.8)
Diabetes mellitus	152.2	373.3	156.9	-3.3	35.5	60.5	70.9	0.4
Acute glomerulonephritis	(20.0 to 56.5)	(34.3 to 95.8)	(53.8 to 89.8)	(-5.4 to 12.7)	31.8	53.7	68.6	0.1
Chronic kidney disease	(90.3 to 217.1)	(153.3 to 369.8)	(50.6 to 90.2)	(-6.3 to 15.0)	(16.9 to 51.4)	(28.8 to 87.0)	(48.9 to 89.5)	(-6.6 to 15.0)
Chronic kidney disease due to diabetes mellitus	37.8	72.4	91.2	2.4	3.7	7.0	90.6	2.3
Chronic kidney disease due to hypertension	(30.7 to 44.9)	(58.3 to 86.2)	(85.6 to 97.8)	(1.7 to 3.0)	(2.3 to 5.4)	(4.4 to 10.2)	(82.8 to 99.3)	(-0.3 to 4.9)
Chronic kidney disease due to glomerulonephritis	26.7	48.0	80.0	-0.2	5.4	9.7	79.6	-0.3
Chronic kidney disease due to other causes	(23.2 to 30.2)	(41.9 to 53.8)	(70.4 to 89.6)	(-4.8 to 4.3)	(3.4 to 8.2)	(6.0 to 14.7)	(67.2 to 92.8)	(-6.2 to 6.4)
Diabetes, urogenital, blood, and endocrine diseases	152.2	373.3	156.9	-3.3	35.5	60.5	70.9	0.4
Diabetes mellitus	(73.9 to 239.4)	(137.2 to 385.7)	(48.3 to 85.3)	(2.1 to 4.3)	(6.3 to 25.1)	(11.3 to 40.2)	(46.9 to 84.8)	(-5.8 to 5.8)
Acute glomerulonephritis	-	-	-	-	0.6	1.0	60.9	8.5
Chronic kidney disease	-	-	-	-	(0.4 to 0.9)	(0.6 to 1.5)	(39.3 to 84.9)	(-4.1 to 22.6)
Chronic kidney disease due to diabetes mellitus	0.7	1.2	70.3	18.6	0.2	0.3	70.1	19.2
Chronic kidney disease due to hypertension	(0.4 to 1.1)	(0.8 to 1.8)	(45.5 to 95.6)	(5.6 to 37.0)	(0.1 to 0.3)	(0.1 to 0.4)	(25.9 to 122.9)	(-9.6 to 55.3)
Chronic kidney disease due to glomerulonephritis	2.2	3.4	58.5	5.4	0.5	0.7	58.2	5.2
Chronic kidney disease due to other causes	(1.5 to 3.1)	(2.3 to 4.9)	(49.8 to 69.4)	(4.4 to 6.8)	(0.3 to 0.7)	(0.4 to 1.2)	(37.1 to 83.9)	(-7.3 to 19.5)
Urinary diseases and male infertility	-	-	-	-	3.2	7.2	40.0	-3.7
Urinary diseases and male infertility	12.9	18.3	41.2	-2.9	(3.6 to 7.0)	(5.0 to 9.8)	(35.0 to 45.1)	(-6.1 to 0.2)
Urinary diseases and male infertility	(12.2 to 13.7)	(17.3 to 19.3)	(40.3 to 42.2)	(-3.0 to -2.7)	(2.2 to 4.5)	(3.0 to 6.2)	(33.2 to 47.9)	(-7.2 to 1.8)
Urinary diseases and male infertility	19.5	27.2	39.5	-3.7	2.0	2.7	39.1	-3.6
Urinary diseases and male infertility	(18.3 to 20.7)	(25.5 to 28.9)	(38.4 to 40.6)	(-3.9 to -3.6)	(1.4 to 2.7)	(1.9 to 3.8)	(32.8 to 45.7)	(-7.4 to 0.3)
Urinary diseases and male infertility	31.9	35.2	10.1	-0.3	0.4	0.4	10.2	-0.3
Urinary diseases and male infertility	(26.3 to 37.6)	(29.1 to 41.4)	(9.5 to 10.5)	(-0.4 to -0.2)	(0.2 to 0.6)	(0.2 to 0.7)	(1.9 to 18.0)	(-7.5 to 6.9)
Urinary diseases and male infertility	59.2	64.0	7.9	0.1	7.1	7.7	8.1	0.1
Urinary diseases and male infertility	(49.2 to 68.7)	(52.9 to 74.4)	(6.8 to 9.1)	(-0.1 to 0.0)	(4.4 to 10.8)	(4.7 to 11.7)	(3.5 to 12.9)	(-3.8 to 4.2)
Urinary diseases and male infertility	112.0	154.6	38.1	-3.4	5.5	7.5	37.5	3.4
Urinary diseases and male infertility	(94.5 to 134.6)	(126.9 to 188.7)	(26.0 to 49.7)	(-11.9 to 4.6)	(3.7 to 7.9)	(5.0 to 10.7)	(25.2 to 49.7)	(-12.0 to 5.1)
Urinary diseases and male infertility	56.1	101.8	81.7	-2.7	4.2	7.6	81.0	-2.7
Urinary diseases and male infertility	(52.3 to 59.6)	(95.5 to 107.8)	(79.4 to 84.2)	(-3.3 to -2.1)	(2.8 to 5.7)	(5.1 to 10.2)	(73.5 to 88.5)	(-6.3 to 9.0)
Urinary diseases and male infertility	-	-	-	-	40.4	84.0	108.0	15.0
Urinary diseases and male infertility	283.3	656.1	131.7	20.1	(27.9 to 56.6)	(56.8 to 115.8)	(76.6 to 142.1)	(-3.8 to 36.5)
Urinary diseases and male infertility	(242.2 to 334.3)	(559.2 to 748.5)	(88.9 to 189.9)	(-2.4 to 52.7)	23.4	55.0	135.2	18.2
Urinary diseases and male infertility	0.0	0.0	4.3	-23.4	0.0	0.0	(82.7 to 202.4)	(-7.9 to 52.5)
Urinary diseases and male infertility	(0.0 to 0.0)	(0.0 to 0.0)	(-10.9 to 2.4)	(-27.9 to -19.0)	(0.0 to 0.0)	(0.0 to 0.0)	(-10.9 to 2.4)	(-27.9 to -19.0)
Urinary diseases and male infertility	29.6	62.3	110.3	9.1	3.6	6.3	74.2	2.6
Urinary diseases and male infertility	(19.2 to 45.9)	(41.6 to 89.5)	(58.4 to 189.4)	(-20.3 to 46.3)	(2.5 to 4.9)	(4.4 to 8.5)	(54.7 to 99.4)	(-7.2 to 14.4)
Urinary diseases and male infertility	23.2	29.2	25.6	-21.3	1.0	1.6	55.6	-1.6
Urinary diseases and male infertility	(15.9 to 32.9)	(20.9 to 40.5)	(-1.9 to 65.4)	(-38.1 to -1.1)	(0.6 to 1.5)	(1.1 to 2.3)	(19.5 to 108.5)	(-34.5 to 8.9)
Urinary diseases and male infertility	38.9	59.8	53.0	19.4	0.6	0.8	59.1	-19.1
Urinary diseases and male infertility	(26.1 to 53.9)	(41.4 to 83.4)	(15.1 to 118.4)	(-40.1 to 8.5)	(0.4 to 0.9)	(0.5 to 1.1)	(-12.7 to 78.3)	(-40.5 to 17.8)
Urinary diseases and male infertility	46.4	97.4	109.8	23.8	1.2	2.4	103.6	26.1
Urinary diseases and male infertility	(32.4 to 64.1)	(68.9 to 134.2)	(64.0 to 163.5)	(-1.7 to 50.4)	(0.8 to 1.7)	(1.7 to 3.4)	(62.8 to 152.8)	(3.2 to 51.9)
Urinary diseases and male infertility	-	-	-	-	1.6	3.9	144.1	18.0
Urinary diseases and male infertility	-	-	-	-	(1.0 to 2.4)	(2.5 to 5.7)	(116.8 to 181.0)	(6.2 to 34.4)

Appendix Table G.4 - Libya prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.8 (0.7 to 0.9)	1.4 (1.3 to 1.5)	76.4 (61.5 to 94.1)	6.3 (0.4 to 17.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	75.9 (38.8 to 123.7)	8.2 (9.8 to 32.5)
Urolithiasis	27.9 (16.8 to 43.8)	102.7 (73.1 to 154.9)	251.2 (196.5 to 457.8)	68.5 (39.0 to 151.6)	0.2 (0.1 to 0.3)	0.8 (0.4 to 1.2)	288.8 (201.9 to 390.9)	90.2 (57.7 to 154.2)
Benign prostatic hyperplasia	28.5 (26.2 to 30.8)	57.3 (52.6 to 61.8)	100.4 (79.9 to 126.4)	-4.6 (-14.3 to 7.8)	1.0 (0.7 to 1.4)	2.0 (1.3 to 2.9)	100.6 (79.3 to 126.6)	-4.1 (-14.3 to 8.5)
Male infertility due to other causes	31.7 (22.3 to 42.7)	49.4 (32.6 to 69.0)	53.7 (1.2 to 139.8)	-15.9 (4.4 to 28.1)	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.8)	52.3 (3.0 to 140.2)	-15.9 (-45.8 to 29.0)
Other urinary diseases	-	-	-	-	0.1 (0.1 to 0.3)	0.7 (0.4 to 1.3)	49.0 (288.3 to 715.0)	0.7 (107.5 to 328.7)
Gynecological diseases	-	-	-	-	4.9 (3.2 to 7.3)	10.1 (6.3 to 15.6)	108.1 (60.3 to 152.5)	13.6 (8.9 to 35.6)
Uterine fibroids	56.4 (50.9 to 61.4)	139.0 (125.6 to 151.2)	146.3 (144.2 to 148.9)	17.8 (17.5 to 18.1)	0.9 (0.5 to 1.4)	2.0 (1.2 to 3.3)	133.8 (116.3 to 146.2)	15.3 (6.9 to 21.0)
Polycystic ovarian syndrome	72.8 (66.1 to 79.3)	151.5 (134.6 to 167.1)	108.0 (82.1 to 141.6)	13.1 (-0.6 to 30.4)	1.7 (0.3 to 1.3)	5.8 (0.7 to 2.8)	107.3 (80.7 to 141.8)	12.9 (-0.8 to 30.6)
Female infertility due to other causes	8.2 (3.5 to 13.7)	22.6 (10.8 to 37.0)	180.8 (7.4 to 646.8)	55.2 (-43.5 to 334.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.3)	159.9 (6.4 to 585.6)	46.2 (-41.1 to 289.2)
Endometriosis	5.9 (5.0 to 6.8)	13.8 (11.8 to 15.8)	131.7 (88.8 to 184.9)	19.6 (-1.1 to 45.8)	0.5 (0.3 to 0.8)	1.3 (0.8 to 1.8)	129.6 (86.5 to 185.6)	19.0 (-3.7 to 48.2)
Genital prolapse	166.1 (133.2 to 193.9)	363.5 (290.3 to 434.7)	117.4 (72.4 to 194.3)	9.7 (-11.6 to 46.0)	0.5 (0.3 to 1.0)	1.2 (0.5 to 2.2)	116.8 (70.4 to 195.2)	9.5 (-12.0 to 46.6)
Premenstrual syndrome	225.2 (159.3 to 299.7)	417.1 (240.8 to 587.0)	87.1 (-7.2 to 220.9)	10.6 (-42.8 to 91.6)	1.9 (1.0 to 3.1)	3.5 (1.8 to 6.1)	85.9 (-7.0 to 214.0)	10.0 (-42.8 to 89.5)
Other gynecological diseases	10.2 (8.0 to 12.2)	19.5 (17.9 to 21.2)	91.6 (56.4 to 144.6)	10.8 (-9.2 to 40.7)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	87.6 (55.1 to 139.9)	8.0 (-10.9 to 71.5)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	5.3 (3.5 to 7.6)	6.6 (4.4 to 9.6)	24.5 (17.4 to 36.2)	0.1 (-7.2 to 9.7)
Thalassemias	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.6)	21.5 (5.4 to 42.0)	-3.9 (-17.3 to 12.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	25.9 (-4.4 to 72.1)	-3.9 (-26.4 to 31.8)
Thalassemia trait	103.0 (91.8 to 115.4)	146.5 (132.1 to 161.8)	42.1 (36.2 to 48.6)	-2.2 (-6.2 to 2.3)	2.4 (1.6 to 3.6)	3.1 (2.1 to 4.6)	29.0 (11.9 to 47.2)	3.3 (-14.0 to 17.4)
Sickle cell disorders	1.6 (1.3 to 1.8)	2.1 (1.8 to 2.4)	31.8 (9.4 to 68.1)	4.0 (-13.1 to 31.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	44.5 (15.3 to 74.2)	7.3 (-12.8 to 27.8)
Sickle cell trait	276.0 (259.2 to 292.4)	383.3 (355.7 to 406.2)	39.0 (33.2 to 44.0)	-4.5 (-8.5 to -1.0)	1.6 (1.0 to 2.3)	1.9 (1.2 to 2.9)	28.8 (-0.1 to 39.2)	2.9 (-17.2 to 14.3)
G6PD deficiency	93.8 (69.6 to 119.4)	177.6 (144.4 to 214.7)	89.2 (37.2 to 165.4)	30.1 (-5.5 to 82.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.3 (52.5 to 74.8)	25.2 (16.2 to 31.5)
G6PD trait	476.4 (434.6 to 509.3)	615.8 (547.8 to 677.6)	29.3 (12.8 to 45.7)	-9.9 (-21.4 to 1.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.0 (-74.5 to 414.9)	-18.9 (-77.7 to 302.2)
Other hemoglobinopathies and hemolytic anemias	36.2 (31.2 to 41.2)	48.9 (44.5 to 53.2)	35.1 (19.0 to 57.0)	-2.6 (-12.5 to 9.3)	1.0 (0.6 to 1.5)	1.2 (0.8 to 1.8)	20.8 (-1.3 to 62.2)	-2.4 (-21.3 to 28.4)
Endocrine, metabolic, blood, and immune disorders	50.3 (43.3 to 55.5)	45.7 (60.7 to 69.5)	30.5 (17.0 to 52.4)	1.7 (-11.1 to 7.9)	2.1 (1.1 to 2.4)	2.1 (1.4 to 2.9)	22.6 (56.5 to 57.0)	1.5 (-14.8 to 17.1)
Musculoskeletal disorders	-	-	-	-	54.3 (37.8 to 73.1)	107.2 (73.2 to 145.6)	98.1 (67.2 to 144.4)	3.2 (-10.7 to 19.9)
Rheumatoid arthritis	5.3 (4.9 to 5.7)	9.2 (8.6 to 9.8)	73.3 (58.3 to 91.6)	-5.3 (-13.8 to 5.3)	1.3 (0.9 to 1.7)	2.2 (1.5 to 2.9)	71.8 (52.8 to 94.9)	-5.7 (-15.6 to 6.8)
Osteoarthritis	76.1 (71.9 to 80.9)	164.7 (153.7 to 174.6)	116.1 (98.6 to 135.4)	1.4 (-6.2 to 9.9)	4.6 (3.3 to 6.3)	10.0 (7.0 to 13.6)	115.3 (97.2 to 135.5)	1.4 (-6.2 to 10.0)
Low back and neck pain	-	-	-	-	41.9 (28.1 to 58.4)	81.0 (53.5 to 113.9)	94.3 (52.9 to 156.6)	2.8 (-15.0 to 25.5)
Low back pain	266.6 (207.8 to 324.5)	501.3 (373.3 to 618.9)	88.0 (33.6 to 177.0)	1.1 (-26.1 to 37.6)	29.8 (18.8 to 43.1)	55.6 (33.5 to 81.5)	87.0 (32.0 to 175.9)	0.9 (-26.3 to 38.7)
Neck pain	124.3 (105.5 to 143.0)	260.1 (223.1 to 298.7)	108.8 (68.4 to 159.9)	8.0 (-13.1 to 34.5)	12.2 (8.2 to 17.2)	25.4 (17.0 to 35.9)	107.7 (66.1 to 159.8)	8.0 (-13.5 to 34.7)
Gout	1.7 (1.4 to 1.9)	3.0 (2.6 to 3.5)	85.2 (46.1 to 122.3)	-9.7 (-28.1 to 7.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	85.3 (36.9 to 142.6)	-9.3 (-31.8 to 18.0)
Other musculoskeletal disorders	70.4 (52.6 to 88.3)	153.3 (113.7 to 197.9)	118.6 (84.1 to 145.8)	7.3 (-8.9 to 18.8)	6.4 (4.1 to 9.4)	13.9 (8.8 to 20.9)	118.1 (84.2 to 147.5)	4.4 (-8.7 to 18.7)
Other non-communicable diseases	-	-	-	-	58.4 (39.3 to 84.8)	93.8 (64.7 to 134.9)	60.6 (27.4 to 93.8)	-4.9 (-8.8 to -0.8)
Congenital anomalies	-	-	-	-	4.3 (3.1 to 5.9)	9.4 (6.3 to 13.1)	120.6 (74.5 to 184.9)	55.4 (23.0 to 98.4)
Neural tube defects	1.2 (1.0 to 1.5)	1.8 (1.5 to 2.2)	43.3 (13.6 to 95.8)	7.0 (-14.8 to 46.0)	0.2 (0.2 to 0.5)	0.5 (0.4 to 0.8)	49.0 (7.4 to 120.1)	12.5 (-18.5 to 65.7)
Congenital heart anomalies	21.0 (17.5 to 25.2)	45.7 (39.1 to 54.7)	117.6 (74.1 to 177.1)	60.6 (27.4 to 104.7)	0.7 (0.3 to 1.3)	1.6 (0.7 to 2.9)	127.7 (78.2 to 182.5)	66.1 (33.4 to 110.3)
Orofacial clefts	3.8 (2.8 to 5.0)	7.5 (5.6 to 10.3)	98.3 (35.2 to 200.1)	53.7 (5.0 to 132.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	40.6 (-12.3 to 135.5)	9.5 (-31.0 to 79.9)
Down syndrome	6.3 (5.0 to 7.8)	11.5 (9.3 to 14.8)	80.2 (33.2 to 160.2)	27.9 (-5.0 to 84.8)	0.8 (0.5 to 1.1)	1.5 (1.0 to 2.1)	90.5 (38.9 to 178.5)	32.9 (-2.5 to 93.2)
Turner syndrome	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	71.9 (26.2 to 139.2)	22.1 (-10.2 to 70.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.4 (26.0 to 164.2)	23.2 (-11.7 to 78.5)
Klinefelter syndrome	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	30.8 (-8.7 to 86.7)	-10.5 (-37.5 to 27.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.1 (-1.8 to 129.7)	-13.2 (-41.9 to 38.0)
Chromosomal unbalanced rearrangements	6.0 (5.1 to 7.3)	10.0 (7.8 to 12.7)	69.1 (21.7 to 122.7)	10.7 (-13.6 to 58.7)	0.7 (0.5 to 1.0)	1.3 (0.9 to 1.8)	70.2 (16.0 to 139.9)	25.0 (-11.6 to 68.8)
Other congenital anomalies	11.4 (9.5 to 13.2)	15.7 (12.9 to 18.6)	35.9 (20.8 to 66.3)	-12.4 (-22.1 to 7.0)	1.6 (1.0 to 2.8)	4.4 (2.6 to 6.7)	170.1 (75.0 to 324.9)	87.1 (23.0 to 195.0)
Skin and subcutaneous diseases	-	-	-	-	24.3 (14.9 to 37.4)	34.7 (21.8 to 55.2)	42.6 (27.4 to 61.9)	-1.5 (-10.0 to 8.9)
Dermatitis	236.1 (185.3 to 288.6)	366.2 (289.5 to 446.4)	55.2 (49.5 to 60.4)	-0.5 (-1.1 to 0.1)	7.9 (4.7 to 11.8)	11.6 (6.8 to 17.3)	46.1 (37.0 to 54.4)	-0.1 (-2.6 to 2.5)
Psoriasis	22.6 (17.9 to 28.2)	39.0 (30.4 to 48.8)	72.5 (67.4 to 78.2)	0.0 (-0.6 to 0.6)	1.8 (1.2 to 2.7)	3.2 (2.0 to 4.7)	71.6 (59.3 to 84.7)	0.0 (-5.4 to 6.2)
Cellulitis	0.9 (0.7 to 1.0)	1.1 (0.8 to 1.4)	28.6 (7.8 to 50.6)	-15.6 (-25.0 to -1.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	27.3 (5.0 to 63.7)	-14.3 (-33.3 to 6.0)
Pyoderma	3.4 (2.7 to 4.4)	4.0 (3.2 to 5.2)	16.2 (6.0 to 27.6)	-8.2 (-13.5 to -1.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	15.4 (0.2 to 33.6)	-8.3 (-18.3 to 3.1)
Scabies	15.5 (13.1 to 19.9)	22.3 (18.2 to 27.1)	43.2 (8.4 to 88.2)	-0.1 (-25.9 to 32.1)	0.4 (0.2 to 0.7)	0.6 (0.3 to 1.0)	43.2 (6.6 to 89.6)	-0.2 (-25.9 to 32.3)
Fungal skin diseases	252.2 (184.7 to 309.3)	399.6 (310.2 to 495.7)	63.3 (54.0 to 74.1)	63.3 (-1.9 to 40.9)	1.4 (0.5 to 2.9)	2.2 (0.9 to 4.8)	62.4 (53.1 to 73.7)	-1.4 (-2.1 to 0.4)
Viral skin diseases	100.0 (77.1 to 120.3)	124.4 (93.0 to 155.7)	24.1 (16.9 to 31.8)	0.0 (-2.1 to 2.3)	3.1 (1.8 to 4.8)	3.9 (2.2 to 6.1)	23.8 (15.9 to 32.9)	0.1 (-3.4 to 3.8)
Acne vulgaris	584.7 (438.9 to 729.5)	713.4 (521.5 to 929.3)	19.7 (-15.3 to 98.1)	-6.3 (-33.7 to 12.7)	6.4 (2.9 to 12.7)	7.7 (3.5 to 14.7)	19.5 (-15.6 to 97.9)	-6.3 (-33.7 to 51.3)
Alopecia areata	5.5 (4.7 to 6.3)	8.7 (7.6 to 10.1)	60.5 (34.3 to 88.8)	0.3 (-15.8 to 17.8)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	60.2 (30.6 to 92.6)	0.4 (-16.9 to 19.1)
Pruritus	0.9 (0.5 to 1.5)	1.5 (0.7 to 2.4)	70.7 (-27.0 to 308.2)	8.9 (-60.4 to 174.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.2 (-29.4 to 305.2)	-4.2 (-60.7 to 182.1)
Urticaria	29.9 (16.1 to 45.8)	52.0 (37.3 to 68.3)	74.4 (4.6 to 231.6)	0.1 (-33.1 to 56.5)	1.8 (0.8 to 3.1)	3.1 (1.8 to 4.8)	73.0 (2.8 to 233.5)	0.7 (-33.4 to 57.2)
Decubitus ulcer	0.5 (0.4 to 0.6)	0.9 (0.7 to 1.1)	85.3 (39.9 to 146.3)	-9.3 (-34.4 to 26.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	83.5 (35.6 to 145.8)	-8.8 (-35.7 to 28.9)
Other skin and subcutaneous diseases	188.1 (129.0 to 270.0)	333.3 (222.0 to 492.2)	77.2 (61.6 to 90.8)	-1.2 (-4.9 to 3.2)	1.1 (0.5 to 3.2)	2.0 (0.9 to 4.0)	76.2 (60.4 to 90.7)	-1.2 (-5.3 to 3.2)
Sense organ diseases	-	-	-	-	22.2 (15.1 to 31.1)	35.4 (24.1 to 49.6)	59.4 (50.0 to 68.7)	-14.8 (-19.2 to -10.4)
Glaucoma	14.0 (11.2 to 17.1)	23.2 (18.2 to 29.6)	65.1 (37.9 to 97.2)	-20.9 (-33.2 to -4.7)	1.1 (0.8 to 1.6)	1.9 (1.2 to 2.8)	62.4 (39.6 to 94.0)	-23.0 (-33.8 to -8.2)
Cataract	15.9 (10.2 to 21.5)	33.8 (23.9 to 42.7)	113.6 (64.6 to 176.4)	-4.4 (-24.7 to 17.9)	1.3 (0.8 to 2.0)	2.6 (1.6 to 3.7)	98.4 (56.5 to 151.9)	-11.7 (-29.0 to 6.7)
Macular degeneration	5.9 (4.1 to 8.2)	9.8 (6.2 to 13.6)	66.2 (10.6 to 117.3)	-19.8 (-44.9 to 5.6)	0.4 (0.3 to 0.7)	0.7 (0.4 to 1.1)	59.5 (5.5 to 109.3)	-23.8 (-47.0 to 8.8)
Uncorrected refractive error	311.3 (267.0 to 353.3)	525.9 (454.2 to 609.7)	69.1 (39.0 to 109.0)	5.7 (-2.9 to 16.4)	7.3 (4.8 to 10.6)	10.9 (7.1 to 16.3)	48.8 (33.4 to 68.4)	-17.7 (-25.8 to -6.8)
Age-related and other hearing loss	303.5 (281.8 to 326.4)	536.5 (499.4 to 577.9)	77.0 (68.5 to 85.3)	-10.5 (-13.8 to -7.4)	7.9 (5.2 to 11.4)	13.8 (9.1 to 19.9)	74.4 (62.3 to 88.1)	-11.7 (-16.5 to -7.1)
Other vision loss	17.8 (14.7 to 22.0)	22.5 (18.1 to 27.1)	27.8 (8.9 to 41.0)	-27.0 (-35.9 to -19.2)	1.5 (1.0 to 2.1)	1.9 (1.3 to 2.7)	27.1 (11.5 to 41.2)	-29.9 (-37.8 to -21.7)
Other sense organ diseases	98.3 (93.1 to 103.8)	137.3 (131.1 to 143.6)	39.7 (29.2 to 50.4)	0.7 (-5.7 to 7.2)	2.6 (1.6 to 3.9)	3.6 (2.2 to 5.4)	38.6 (26.7 to 50.8)	0.5 (-6.5 to 7.9)
Oral disorders	-	-	-	-	7.7 (4.9 to 12.1)	14.2 (8.7 to 22.1)	85.5 (74.7 to 96.8)	0.3 (-6.4 to 6.0)
Deciduous caries	468.8 (441.0 to 491.9)	477.7 (455.1 to 501.7)	2.0 (-5.6 to 9.9)	0.1 (-7.3 to 7.9)	0.1 (0.1 to 0.4)	0.2 (0.1 to 0.4)	0.1 (-7.1 to 10.8)	-0.1 (-8.8 to 8.7)
Permanent caries	1571.4 (1,452.3 to 1,719.5)	2,695.2 (2,498.0 to 2,871.2)	70.9 (56.2 to 91.9)	8.8 (-0.2 to 20.8)	1.6 (0.7 to 3.0)	2.7 (1		

Appendix Table G.4 - Libya prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	106.6 (97.7 to 115.4)	221.7 (200.8 to 243.5)	108.2 (87.0 to 130.2)	-1.4 (-11.5 to 9.0)	2.9 (2.0 to 4.1)	6.1 (4.1 to 8.5)	107.3 (85.8 to 129.4)	-1.4 (-11.5 to 9.1)
Other oral disorders	63.9 (59.5 to 67.6)	106.7 (101.0 to 112.4)	66.6 (54.6 to 82.5)	0.4 (-6.2 to 9.6)	1.9 (1.2 to 2.8)	3.1 (2.0 to 4.6)	65.9 (53.1 to 84.0)	0.6 (-6.5 to 10.5)
Injuries	-	-	-	-	14.1 (10.7 to 18.1)	18.6 (13.0 to 26.2)	30.6 (12.5 to 58.4)	-26.6 (-36.5 to -12.4)
Transport injuries	-	-	-	-	6.3 (4.8 to 8.2)	6.1 (4.3 to 8.3)	-3.8 (-17.4 to 11.5)	-44.2 (-51.4 to -36.1)
Road injuries	-	-	-	-	5.8 (4.4 to 7.5)	5.2 (3.7 to 7.1)	9.7 (23.0 to 5.1)	47.3 (-54.3 to -39.4)
Pedestrian road injuries	-	-	-	-	1.4 (1.0 to 1.8)	1.1 (0.8 to 1.5)	-22.4 (-35.0 to -7.1)	-51.9 (-59.0 to -43.9)
Cyclist road injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.6 (0.5 to 0.9)	17.2 (4.4 to 32.5)	-33.3 (-40.5 to -25.6)
Motorcyclist road injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.5 (0.4 to 0.7)	-21.4 (-33.0 to -7.7)	-55.8 (-61.8 to -48.5)
Motor vehicle road injuries	-	-	-	-	3.1 (2.4 to 4.0)	3.0 (2.1 to 4.0)	5.7 (-20.8 to 11.5)	45.8 (-53.6 to -36.8)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-47.7 (-55.3 to -38.8)	-69.9 (-74.1 to -65.3)
Other transport injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.9 (0.6 to 1.2)	60.6 (40.9 to 83.2)	-14.2 (-23.9 to -2.3)
Unintentional injuries	-	-	-	-	6.1 (4.6 to 7.8)	7.9 (5.7 to 10.6)	29.4 (17.9 to 42.3)	-28.1 (-34.3 to -21.4)
Falls	-	-	-	-	2.2 (1.6 to 2.8)	3.1 (2.2 to 4.3)	43.5 (27.0 to 62.6)	-26.2 (-34.8 to -16.3)
Drowning	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-29.9 (-40.0 to -17.2)	-46.5 (-63.5 to -50.9)
Fire, heat, and hot substances	-	-	-	-	0.5 (0.4 to 0.7)	0.4 (0.3 to 0.6)	-21.6 (-33.1 to -7.9)	-52.2 (-58.2 to -44.8)
Poisonings	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-11.2 (-30.2 to 11.2)	-44.8 (-55.2 to -32.8)
Exposure to mechanical forces	-	-	-	-	1.9 (1.4 to 2.5)	2.4 (1.7 to 3.2)	25.2 (14.1 to 37.4)	-27.1 (-32.5 to -20.9)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-1.8 (-14.2 to 13.3)	-46.5 (-52.8 to -38.7)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.8 (43.9 to 91.1)	-0.3 (-13.7 to 11.3)
Other exposure to mechanical forces	-	-	-	-	1.8 (1.4 to 2.3)	2.3 (1.6 to 3.1)	26.2 (15.0 to 38.6)	-26.2 (-31.8 to -19.9)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	96.9 (82.3 to 112.5)	14.0 (5.2 to 23.7)
Animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	39.9 (17.6 to 51.5)	-20.0 (-28.5 to -11.4)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	37.7 (16.2 to 61.9)	-18.3 (-29.6 to -5.9)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	31.2 (13.9 to 50.7)	-21.3 (-30.1 to -11.3)
Foreign body	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	24.1 (10.9 to 37.6)	-26.9 (-34.2 to -19.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.0 (-46.9 to -15.2)	-53.5 (-62.3 to -43.8)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	47.1 (33.4 to 63.9)	-11.5 (-19.6 to -1.6)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	37.0 (21.7 to 53.5)	-23.7 (-31.2 to -15.7)
Other unintentional injuries	-	-	-	-	1.0 (0.8 to 1.3)	1.4 (1.0 to 1.9)	40.7 (28.8 to 54.2)	-23.2 (-29.4 to -16.3)
Self-harm and interpersonal violence	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	9.0 (-4.4 to 27.0)	-37.3 (-44.5 to -27.8)
Self-harm	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	80.3 (56.6 to 110.5)	-7.8 (-19.4 to 6.5)
Interpersonal violence	-	-	-	-	0.3 (0.3 to 0.4)	0.3 (0.2 to 0.5)	-2.7 (-16.0 to 14.2)	-43.1 (-50.4 to -33.9)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	14.7 (0.9 to 28.2)	-32.6 (-39.9 to -25.2)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	20.4 (3.6 to 43.3)	-31.8 (-40.9 to -19.2)
Assault by other means	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-16.4 (-29.1 to 0.3)	-50.6 (-57.8 to -41.5)
Forces of nature, war, and legal intervention	-	-	-	-	1.3 (0.4 to 3.3)	4.2 (1.7 to 9.3)	246.0 (86.7 to 477.3)	70.8 (-10.7 to 197.4)
Exposure to forces of nature	-	-	-	-	-	-	-	-
Collective violence and legal intervention	-	-	-	-	1.3 (0.4 to 3.3)	4.2 (1.7 to 9.3)	246.0 (86.7 to 477.3)	70.8 (-10.7 to 197.4)

Appendix Table G.4 - Lithuania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	409.5 (305.3 to 533.7)	375.0 (281.1 to 485.6)	-8.5 (-10.4 to -6.1)	-1.4 (-3.3 to 0.8)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	24.9 (17.2 to 34.6)	16.1 (11.3 to 22.3)	-35.1 (-39.3 to -31.1)	-6.4 (-12.2 to -0.6)
HIV/AIDS and tuberculosis	-	-	-	-	1.3 (0.9 to 1.8)	1.3 (0.9 to 1.8)	-4.1 (-14.5 to 12.7)	10.9 (-1.6 to 30.9)
Tuberculosis	4.0 (3.8 to 4.2)	3.4 (3.3 to 3.6)	-14.5 (-18.0 to -10.6)	-2.8 (-6.8 to 1.6)	1.2 (0.8 to 1.7)	1.0 (0.7 to 1.4)	-14.8 (-21.6 to -8.1)	-2.3 (-10.6 to 5.6)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.6)	133.9 (39.3 to 260.9)	182.3 (69.6 to 341.4)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.2 (19.0 to 197.1)	139.3 (41.7 to 250.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.2 (18.7 to 197.4)	139.3 (41.5 to 251.2)
HIV/AIDS resulting in other diseases	0.7 (0.4 to 1.2)	1.5 (0.9 to 2.6)	114.1 (33.8 to 214.3)	171.7 (69.1 to 301.9)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.5)	135.2 (37.5 to 266.6)	183.5 (68.1 to 349.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	4.2 (2.8 to 6.0)	2.9 (1.9 to 4.1)	-31.1 (-35.9 to -25.9)	-8.0 (-14.0 to -0.6)
Diarrheal diseases	6.4 (5.9 to 6.9)	4.8 (4.4 to 5.1)	-25.7 (-34.5 to -17.0)	-2.1 (-13.8 to 9.6)	1.0 (0.7 to 1.4)	0.8 (0.5 to 1.0)	-26.8 (-37.0 to -16.7)	-2.2 (-15.0 to 11.8)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-72.7 (-72.7 to -16.3)	-
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.8 (-50.3 to -25.3)	-23.4 (-36.8 to -6.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.8 (-50.4 to -25.0)	-23.4 (-36.8 to -6.3)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.7 (-52.3 to -18.2)	-21.4 (-37.1 to 3.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.7 (-52.3 to -18.2)	-21.4 (-37.2 to 3.8)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-84.9 (-99.3 to -56.2)	-81.0 (-99.1 to 75.8)
Lower respiratory infections	0.8 (0.7 to 0.8)	0.4 (0.4 to 0.4)	-45.7 (-49.2 to -42.5)	-15.6 (-21.3 to -10.4)	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-45.9 (-53.4 to -35.8)	-15.9 (-28.4 to 0.1)
Upper respiratory infections	124.8 (113.2 to 137.5)	89.8 (81.8 to 98.1)	-27.9 (-37.0 to -18.2)	-2.5 (-14.0 to 10.4)	1.5 (0.8 to 2.5)	1.0 (0.6 to 1.7)	-28.3 (-37.3 to -18.3)	-2.2 (-14.2 to 10.7)
Otitis media	49.7 (46.3 to 53.3)	33.0 (30.6 to 35.5)	-33.8 (-39.0 to -27.3)	-10.9 (-17.5 to -3.1)	1.0 (0.6 to 1.6)	0.6 (0.4 to 1.0)	-35.3 (-41.2 to -28.7)	-11.4 (-19.2 to -2.8)
Meningitis	-	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-54.1 (-63.7 to -39.2)	-40.3 (-52.7 to -17.9)
Pneumococcal meningitis	1.0 (0.6 to 1.6)	0.5 (0.2 to 0.9)	-47.0 (-55.6 to -36.8)	-39.3 (-48.9 to -27.8)	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-90.6 (-64.2 to -36.7)	-38.7 (-55.5 to -20.1)
H influenzae type B meningitis	0.6 (0.2 to 1.3)	0.2 (0.1 to 0.6)	-61.0 (-75.6 to -29.9)	-50.1 (-65.5 to 0.8)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-62.1 (-76.8 to -10.7)	-46.4 (-67.7 to 32.5)
Meningococcal meningitis	0.2 (0.1 to 0.6)	0.1 (0.0 to 0.3)	-48.8 (-68.7 to -22.4)	-37.3 (-59.5 to 6.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-45.6 (-69.8 to -11.6)	-28.1 (-61.3 to 22.7)
Other meningitis	0.4 (0.2 to 0.9)	0.2 (0.1 to 0.5)	-52.1 (-68.0 to -34.2)	-43.1 (-59.0 to -18.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-55.6 (-72.1 to -21.8)	-44.4 (-64.3 to 0.3)
Encephalitis	1.8 (0.8 to 4.8)	1.6 (0.6 to 4.3)	-15.5 (-32.5 to -4.2)	-7.0 (-24.0 to 7.8)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-7.3 (-35.4 to 4.2)	-4.6 (-25.4 to 20.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.7 (-96.6 to 211.2)	-64.4 (-95.3 to 241.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.7 (-96.6 to 213.6)	-64.4 (-95.3 to 251.9)
Whooping cough	1.0 (0.8 to 1.2)	0.2 (0.1 to 0.2)	-80.2 (-81.5 to -78.8)	-67.1 (-69.3 to -64.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-80.2 (-83.6 to -76.3)	-67.1 (-72.6 to -60.7)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.1 (-77.0 to -53.3)	-60.2 (-73.7 to -49.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.4 (-77.6 to -53.3)	-60.5 (-74.0 to -49.5)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-75.9 (-84.3 to -66.0)	-59.0 (-73.3 to -42.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-75.9 (-84.3 to -66.0)	-59.0 (-73.3 to -42.0)
Varicella and herpes zoster	2.1 (2.0 to 2.3)	1.6 (1.5 to 1.8)	-24.4 (-33.0 to -14.5)	-1.1 (-10.9 to 7.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-2.2 (-27.9 to 16.3)	-1.7 (-21.5 to 22.8)
Neglected tropical diseases and malaria	-	-	-	-	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-65.6 (-84.0 to -31.8)	-61.5 (-81.4 to -26.3)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.2 (-91.1 to 202.7)	24.9 (-87.5 to 340.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.0 (-91.0 to 207.0)	27.2 (-87.3 to 340.8)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Visceral leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Cysticercosis	0.2 (0.1 to 0.4)	0.0 (0.0 to 0.1)	-86.6 (-95.8 to -54.1)	-86.0 (-95.8 to -49.7)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-84.6 (-95.4 to -40.8)	-84.1 (-95.3 to -36.3)
Cystic echinococcosis	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.2)	-25.5 (-34.8 to -14.9)	-15.7 (-27.3 to -4.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.8 (-43.5 to -4.2)	-16.1 (-36.3 to 9.6)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.3 (-63.6 to -20.9)	-11.9 (-57.3 to 1.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.3 (-63.6 to -20.8)	-11.9 (-57.3 to 1.1)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Ascariasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trichuriasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Hookworm disease	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.6 (-68.0 to 0.4)	-7.0 (-60.1 to 28.1)
Maternal disorders	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-57.1 (-70.4 to -48.0)	-35.5 (-55.6 to -21.7)
Maternal hemorrhage	2.2 (2.0 to 2.5)	1.1 (0.7 to 1.4)	-50.7 (-66.7 to -34.5)	-24.9 (-49.3 to -0.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-54.6 (-79.7 to -41.2)	-30.1 (-68.6 to -9.5)
Maternal sepsis and other maternal infections	1.9 (1.2 to 3.0)	0.7 (0.4 to 1.0)	-62.7 (-74.7 to -50.3)	-50.7 (-66.1 to -35.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.7 (-80.1 to -58.1)	-59.0 (-72.2 to -40.4)
Maternal hypertensive disorders	0.8 (0.5 to 1.1)	0.4 (0.2 to 0.5)	-53.8 (-59.1 to -47.2)	-31.0 (-39.0 to -20.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-54.1 (-64.0 to -41.6)	-31.6 (-46.3 to -12.5)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.3 (-66.9 to -54.1)	-41.3 (-49.7 to -30.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.3 (-66.9 to -54.1)	-41.3 (-49.7 to -30.3)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.4 (-53.5 to -40.2)	-21.0 (-30.2 to -10.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.0 (-75.7 to 10.7)	-21.7 (-64.5 to 68.0)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.0 (-73.5 to -26.5)	-33.9 (-60.2 to 10.6)
Neonatal disorders	-	-	-	-	3.7 (2.5 to 5.0)	2.4 (1.6 to 3.1)	-35.6 (-50.5 to -19.4)	-11.4 (-31.9 to 11.1)
Preterm birth complications	14.5 (11.2 to 18.6)	11.7 (9.0 to 15.3)	-19.4 (-30.6 to -6.3)	5.6 (-9.0 to 22.6)	1.6 (1.1 to 2.2)	1.4 (1.0 to 1.9)	-13.5 (-31.9 to 6.9)	18.1 (-6.5 to 46.6)
Neonatal encephalopathy due to birth asphyxia and trauma	3.6 (1.9 to 7.7)	1.4 (0.7 to 3.3)	-61.7 (-77.9 to -36.1)	-46.6 (-69.2 to -9.8)	0.9 (0.5 to 1.5)	0.4 (0.2 to 0.6)	-58.8 (-77.5 to -26.5)	-41.3 (-68.2 to 5.7)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.9 (44.8 to 68.1)	153.4 (130.9 to 168.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.8 (70.6 to 119.6)	150.0 (70.6 to 250.2)
Hemolytic disease and other neonatal jaundice	1.2 (0.4 to 3.2)	0.4 (0.2 to 0.7)	-66.2 (-91.0 to 0.5)	-52.9 (-87.7 to 38.4)	0.4 (0.2 to 1.2)	0.2 (0.1 to 0.3)	-64.1 (-90.3 to 6.1)	50.4 (-86.5 to 46.1)
Other neonatal disorders	-	-	-	-	0.7 (0.4 to 1.1)	0.4 (0.2 to 0.7)	-38.7 (-67.0 to 13.3)	-15.8 (-54.7 to 58.2)
Nutritional deficiencies	-	-	-	-	14.1 (9.4 to 20.7)	8.7 (5.8 to 12.7)	-38.5 (-43.4 to -32.5)	-5.4 (-13.1 to 3.8)
Protein-energy malnutrition	3.2 (1.3 to 6.2)	1.6 (0.6 to 3.0)	-52.1 (-84.2 to 53.6)	-20.9 (-73.9 to 153.6)	0.4 (0.1 to 0.9)	0.2 (0.1 to 0.4)	-51.6 (-83.8 to 55.6)	-20.2 (-73.3 to 157.1)
Iodine deficiency	72.6 (43.2 to 111.1)	38.3 (12.6 to 49.5)	-47.3 (-82.8 to -19.9)	-62.3 (-77.4 to -1.8)	1.3 (0.6 to 2.4)	0.5 (0.2 to 1.0)	-52.2 (-82.9 to -20.2)	52.2 (-77.4 to -0.3)
Vitamin A deficiency	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Iron-deficiency anemia	416.1 (408.6 to 422.9)	290.4 (283.1 to 296.7)	-30.2 (-32.1 to -28.4)	-0.5 (-3.0 to 1.9)	12.2 (8.0 to 17.7)	7.8 (5.1 to 11.4)	-36.1 (-39.2 to -34.1)	-1.8 (-5.1 to 1.6)

Appendix Table G.4 - Lithuania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.2 (0.1 to 0.6)	0.2 (0.1 to 0.5)	-6.6 (-78.0 to 256.5)	-54.8 (-63.6 to 491.2)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.4 (0.8 to 2.3)	0.9 (0.5 to 1.5)	-36.7 (-46.9 to -27.2)	-8.3 (-26.8 to 8.1)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.6 (0.3 to 1.2)	0.5 (0.2 to 0.9)	-25.7 (-33.7 to -15.3)	-3.5 (-14.8 to 11.3)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-9.0 (-23.6 to 13.6)	-18.9 (-32.1 to 1.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-18.3 (-40.3 to 14.0)
Chlamydial infection	91.7 (80.3 to 103.9)	66.6 (57.9 to 74.8)	-27.4 (-40.1 to -12.2)	2.8 (-16.6 to 23.4)	0.3 (0.1 to 0.5)	0.2 (0.1 to 0.3)	-28.4 (-40.4 to -13.9)	5.7 (-16.9 to 21.2)
Gonococcal infection	21.0 (17.1 to 25.1)	12.3 (9.7 to 15.3)	-40.9 (-57.2 to -23.2)	-12.7 (-36.6 to 14.5)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-43.4 (-61.1 to -23.5)	-16.4 (-42.7 to 13.1)
Trichomoniasis	51.4 (37.4 to 66.1)	35.1 (25.4 to 49.0)	-33.4 (-56.7 to 18.9)	-7.0 (-41.1 to 70.7)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-34.5 (-60.1 to 26.2)	-8.3 (-46.1 to 80.9)
Genital herpes	626.0 (608.4 to 643.0)	582.7 (567.5 to 598.8)	-7.0 (-10.5 to -3.2)	0.4 (-3.4 to 4.6)	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.4)	-8.9 (-14.2 to -4.0)	0.6 (-4.7 to 6.6)
Other sexually transmitted diseases	1.1 (0.8 to 1.4)	0.8 (0.6 to 1.1)	-23.0 (-31.2 to -13.1)	1.7 (-9.4 to 14.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.7 (-39.7 to 41.4)	5.7 (-20.2 to 40.0)
Hepatitis	-	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-37.8 (-44.2 to -30.9)	-20.8 (-28.9 to -12.2)
Hepatitis A	3.3 (3.2 to 3.4)	2.1 (2.1 to 2.2)	-35.5 (-35.6 to -35.4)	-9.0 (-10.0 to -8.0)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-30.4 (-37.6 to -22.0)	-6.4 (-16.8 to 4.8)
Hepatitis B	143.3 (134.7 to 152.0)	72.0 (67.9 to 76.3)	-49.8 (-53.6 to -45.3)	0.1 (-44.0 to -33.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-88.0 (-58.9 to -36.4)	-38.6 (-51.3 to -25.3)
Hepatitis C	94.0 (85.7 to 101.9)	62.3 (57.1 to 67.5)	-33.8 (-41.1 to -24.5)	-29.3 (-36.7 to -19.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.4 (-51.5 to 3.7)	-23.9 (-45.2 to 4.7)
Hepatitis E	-	-	-	-	13.3 (22.3 to 53.7)	-	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	15.7 (13.1 to 18.7)	9.4 (7.0 to 11.9)	-39.8 (-54.4 to -22.1)	-1.1 (-30.4 to 33.3)	0.6 (0.3 to 0.9)	0.3 (0.2 to 0.4)	-48.2 (-68.7 to -26.9)	-8.9 (-48.6 to 28.5)
Non-communicable diseases	-	-	-	-	353.3 (260.9 to 459.0)	340.2 (253.4 to 439.4)	-3.8 (-4.0 to -0.7)	2.5 (0.1 to 5.2)
Neoplasms	-	-	-	-	4.2 (3.1 to 5.4)	5.8 (4.3 to 7.4)	38.7 (23.7 to 50.9)	21.1 (8.0 to 31.8)
Esophageal cancer	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	38.4 (-19.1 to 87.4)	28.3 (-25.8 to 73.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	33.2 (-19.6 to 86.0)	23.2 (-28.0 to 71.8)
Stomach cancer	2.8 (2.4 to 3.3)	2.0 (1.7 to 2.4)	-28.8 (-40.0 to -13.5)	-39.4 (-48.6 to -26.5)	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-30.1 (-41.5 to -15.9)	-40.3 (-49.8 to -28.2)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	39.0 (-5.7 to 86.7)	15.4 (-22.2 to 54.3)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.8 (-47.8 to 208.4)	25.8 (-53.6 to 164.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.1 (-46.4 to 164.9)	18.7 (-54.0 to 131.2)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	197.4 (67.6 to 411.7)	146.6 (39.8 to 328.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	181.1 (67.0 to 359.8)	131.9 (40.0 to 280.8)
Liver cancer due to alcohol use	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	21.3 (-28.5 to 95.5)	-0.8 (-41.5 to 60.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.5 (-27.5 to 69.6)	-4.3 (-41.3 to 37.9)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.5 (-69.8 to 14.6)	-47.6 (-73.6 to -4.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.1 (-67.6 to 21.1)	-50.0 (-72.3 to -15.3)
Larynx cancer	0.6 (0.4 to 0.8)	0.5 (0.3 to 0.7)	-16.0 (-47.8 to 21.1)	-24.0 (-50.9 to 15.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-18.0 (-40.5 to 16.0)	-21.9 (-43.5 to 9.7)
Tracheal, bronchus and lung cancer	2.4 (2.2 to 2.7)	2.3 (2.0 to 2.6)	-7.2 (-21.7 to 11.0)	-18.0 (-30.9 to -1.7)	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	-7.8 (-32.5 to 9.7)	-18.3 (-31.8 to -3.0)
Breast cancer	6.3 (5.1 to 7.6)	12.7 (10.9 to 14.6)	99.5 (60.2 to 156.1)	70.8 (39.4 to 117.4)	0.5 (0.4 to 0.7)	0.8 (0.5 to 1.0)	42.9 (17.3 to 76.3)	25.0 (4.1 to 53.7)
Cervical cancer	2.7 (2.1 to 3.2)	1.6 (1.3 to 2.1)	-39.7 (-52.8 to -21.0)	-40.9 (-54.2 to -22.6)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-39.5 (-54.1 to -18.2)	-40.6 (-55.3 to -20.5)
Uterine cancer	2.7 (2.1 to 3.6)	3.1 (2.2 to 4.2)	13.2 (-21.0 to 59.6)	3.2 (-27.0 to 48.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	3.1 (-21.9 to 60.1)	21.1 (-28.7 to 46.5)
Prostate cancer	5.0 (4.2 to 6.3)	11.0 (8.4 to 13.6)	121.3 (60.2 to 189.7)	80.0 (29.6 to 134.5)	0.4 (0.3 to 0.6)	1.1 (0.7 to 1.5)	151.2 (65.7 to 239.0)	102.9 (31.9 to 173.6)
Colon and rectum cancer	5.3 (5.0 to 5.8)	8.5 (7.7 to 9.4)	59.4 (42.2 to 80.7)	31.5 (17.9 to 47.7)	0.5 (0.3 to 0.6)	0.7 (0.5 to 0.9)	55.8 (36.7 to 77.1)	27.3 (11.9 to 45.0)
Lip and oral cavity cancer	1.0 (0.8 to 1.3)	1.6 (1.0 to 2.1)	43.5 (-5.3 to 115.0)	43.5 (-12.4 to 100.3)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	52.4 (-5.9 to 111.6)	40.9 (-14.6 to 96.6)
Nasopharynx cancer	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.1)	-67.6 (-80.0 to -7.4)	-68.6 (-80.6 to -7.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.7 (-78.2 to -48.6)	-69.0 (-80.0 to -11.4)
Other pharynx cancer	0.4 (0.3 to 0.7)	0.6 (0.3 to 0.9)	26.5 (-33.6 to 126.6)	23.1 (-36.0 to 118.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	21.1 (-32.0 to 115.5)	25.8 (-34.8 to 108.5)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-21.9 (-42.1 to 4.7)	-37.3 (-53.1 to -16.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-23.7 (-44.0 to 6.3)	-37.7 (-53.3 to -15.2)
Pancreatic cancer	0.4 (0.3 to 0.4)	0.5 (0.4 to 0.6)	28.0 (3.4 to 56.3)	5.4 (-14.3 to 29.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	23.3 (-1.2 to 49.0)	3.0 (-17.1 to 24.7)
Malignant skin melanoma	1.0 (0.8 to 1.5)	1.7 (1.0 to 2.2)	66.3 (8.5 to 131.1)	66.3 (5.0 to 122.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	67.0 (5.5 to 125.9)	59.7 (1.0 to 114.9)
Non-melanoma skin cancer	2.6 (2.1 to 3.1)	4.1 (3.3 to 5.1)	59.8 (20.1 to 118.3)	25.8 (-3.3 to 72.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	101.4 (43.7 to 190.1)	58.3 (14.7 to 118.0)
Ovarian cancer	1.2 (1.0 to 1.4)	1.6 (1.3 to 1.9)	38.0 (-2.3 to 72.3)	28.7 (-8.3 to 59.5)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	34.8 (-7.3 to 77.5)	24.9 (-13.9 to 64.0)
Testicular cancer	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.4)	-44.4 (-47.7 to 41.5)	11.1 (-34.0 to 93.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.8 (-48.4 to 37.3)	6.5 (-37.6 to 80.7)
Kidney cancer	1.1 (1.0 to 1.3)	2.9 (2.4 to 3.5)	156.2 (104.3 to 217.9)	132.4 (87.6 to 187.8)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	151.1 (93.6 to 218.5)	126.3 (76.6 to 185.7)
Bladder cancer	0.7 (1.6 to 2.3)	1.9 (2.2 to 3.5)	219.0 (135.9 to 94.1)	21.0 (-5.5 to 57.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	48.9 (11.3 to 92.3)	20.7 (-9.1 to 54.9)
Brain and nervous system cancer	0.7 (0.6 to 0.8)	0.9 (0.6 to 1.1)	38.9 (-4.5 to 70.4)	44.8 (0.8 to 80.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	34.2 (-9.2 to 71.7)	38.3 (-3.1 to 75.6)
Thyroid cancer	1.2 (1.0 to 1.7)	1.6 (1.1 to 2.2)	34.2 (-8.3 to 91.2)	40.2 (-5.0 to 98.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	31.2 (-8.9 to 89.1)	33.6 (-8.8 to 91.3)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.9 (-46.8 to 9.1)	-30.0 (-52.2 to -4.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.2 (-44.6 to 18.2)	-24.1 (-50.2 to 3.3)
Hodgkin lymphoma	0.7 (0.4 to 0.8)	0.4 (0.3 to 0.6)	-36.0 (-54.8 to -4.0)	-21.4 (-44.2 to 1.7)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-38.6 (-55.0 to -10.0)	-26.5 (-46.6 to 8.1)
Non-Hodgkin lymphoma	0.9 (0.6 to 1.3)	1.3 (0.7 to 1.7)	61.8 (-29.0 to 118.2)	48.0 (-30.5 to 99.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	57.9 (-32.6 to 113.6)	43.9 (-36.9 to 92.7)
Multiple myeloma	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	54.1 (-1.1 to 131.5)	34.8 (-12.3 to 102.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	48.0 (-6.8 to 131.7)	28.6 (-16.7 to 101.7)
Leukemia	1.9 (1.6 to 2.1)	1.8 (1.5 to 2.2)	-5.3 (-19.3 to 18.5)	-8.8 (-26.2 to 8.9)	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-3.3 (-17.1 to 27.0)	-8.2 (-25.8 to 12.1)
Other neoplasms	2.2 (1.8 to 2.8)	4.6 (3.4 to 5.5)	113.6 (49.2 to 175.7)	102.6 (43.4 to 154.6)	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.4)	102.6 (40.0 to 161.9)	90.4 (33.8 to 144.2)
Cardiovascular diseases	-	-	-	-	6.4 (4.5 to 8.7)	10.1 (7.1 to 14.0)	57.2 (27.9 to 96.4)	29.4 (4.4 to 62.5)
Rheumatic heart disease	1.0 (0.9 to 1.0)	0.9 (0.8 to 0.9)	-7.6 (-16.8 to 2.1)	-12.2 (-20.3 to -3.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-1.3 (-20.3 to 38.5)	-5.8 (-23.8 to 31.4)
Ischemic heart disease	49.8 (43.2 to 58.0)	56.3 (50.1 to 63.9)	13.3 (-5.4 to 36.5)	-8.8 (-23.4 to 11.3)	2.8 (1.9 to 3.9)	3.9 (2.7 to 5.5)	41.4 (15.0 to 72.9)	10.1 (-10.0 to 36.4)
Cerebrovascular disease	-	-	-	-	1.1 (0.7 to 1.5)	1.2 (0.9 to 1.7)	15.1 (-7.2 to 52.7)	6.1 (-14.3 to 38.8)
Ischemic stroke	6.6 (5.6 to 7.8)	7.8 (6.4 to 9.3)	17.1 (-4.8 to 55.0)	7.0 (-13.8 to 38.6)	1.0 (0.7 to 1.4)	1.2 (0.8 to 1.6)	15.9 (-6.5 to 53.7)	6.9 (-14.3 to 38.7)
Hemorrhagic stroke	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	3.2 (-37.7 to 85.3)	1.6 (-36.6 to 85.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	3.6 (-37.5 to 86.4)	2.4 (-36.6 to 86.7)
Hypertensive heart disease	5.5 (4.7 to 6.3)	12.4 (10.9 to 13.9)	125.1 (89.9 to 163.5)	72.0 (45.4 to 100.4)	0.6 (0.4 to 0.8)	1.3 (0.9 to 1.9)	124.3 (86.8 to 162.7)	71.9 (43.5 to 101.7)
Cardiomyopathy and myocarditis	4.2 (3.6 to 4.8)	7.8 (7.1 to 8.6)	87.1 (60.0 to 126.8)	55.2 (31.5 to 86.1)	0.4 (0.3 to 0.6)	0.8 (0.6 to 1.2)	91.0 (59.9 to 133.9)	58.7 (33.0 to 93.1)
Atrial fibrillation and flutter	1.0 (0.7 to 1.3)	4.4 (3.2 to 6.1)	347.6 (218.8 to 632.8)	262.4 (149.8 to 513.3)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.5)	263.1 (199.3 to 642.2)	263.1 (143.3 to 516.7)
Peripheral vascular disease	124.6 (96.0 to 154.4)	156.5 (118.8 to 196.8)	25.5 (-8.5 to 72.5)	2.2 (-27.4 to 40.0)	2.2 (0.1 to 0.4)	2.2 (0.1 to 0.4)	-27.0 (-64.3 to 98.3)	-51.1 (-76.5 to 30.6)
Endocarditis	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	83.7 (20.7 to 148.0)	81.2 (21.4 to 131.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.7 (-9.5 to 125.2)	45.4 (-11.3 to 108.4)
Other cardiovascular and circulatory diseases	16.2 (7.2 to 29.9)	30.8 (15.2 to 56.0)	85.6 (-26.5 to 425.9)	62.9 (-36.2 to 371.5)	1.1 (0.5 to 2.3)	2.2 (1.0 to 4.1)	88.4 (-24.5 to 427.2)	64.2 (-35.8 to 376.0)
Chronic respiratory diseases	-	-	-	-	14.4 (10.0 to 19.5)	13.2 (9.1 to 18.0)	-8.3 (-22.6 to 10.2)	-5.1 (-19.6 to 12.8)
Chronic obstructive pulmonary disease	138.5 (131.9 to 145.2)	142.6 (135.6 to 149.1)	3.0 (0.1 to 6.0)	-1.0 (-3.4 to 1.7)	8.8 (5.7 to 12.4)	9.1 (5.9 to 12.9)	3.8 (-18.7 to 35.5)	0.8 (-2.5 to 31.4)
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.7 (-26.2 to -18.4)	-27.8 (-30.8 to -24.2)

Appendix Table G.4 - Lithuania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.4 (-7.1 to 2.9)	-11.2 (-15.4 to -6.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.9 (-5.8 to 5.1)	-10.2 (-14.2 to -5.0)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-34.7 (-37.3 to -31.6)	-37.6 (-39.9 to -34.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.7 (-36.4 to -30.5)	-36.6 (-39.0 to -33.4)
Asthma	90.9 (113.0 to 133.4)	90.9 (80.7 to 100.8)	0.0 (-36.4 to -15.5)	0.0 (-26.0 to 11.9)	5.4 (3.5 to 7.7)	3.9 (2.5 to 5.6)	-29.9 (-30.0 to -16.6)	-12.5 (-26.7 to 11.5)
Interstitial lung disease and pulmonary sarcoidosis	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.2)	-4.5 (-26.2 to 40.6)	5.3 (-18.3 to 57.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.9 (-24.1 to 42.1)	6.5 (-17.2 to 56.9)
Other chronic respiratory diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-18.2 (-42.4 to 10.8)	-21.2 (-44.1 to 5.8)
Cirrhosis	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	49.4 (34.2 to 69.2)	65.3 (47.4 to 87.1)
Cirrhosis due to hepatitis B	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	12.8 (-37.6 to 68.4)	24.7 (-30.5 to 87.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	10.5 (-4.7 to 75.5)	22.8 (-35.7 to 95.6)
Cirrhosis due to hepatitis C	0.3 (0.2 to 0.5)	1.1 (0.8 to 1.3)	213.5 (101.1 to 429.9)	240.3 (118.2 to 478.7)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	213.5 (93.9 to 448.3)	243.7 (109.1 to 505.6)
Cirrhosis due to alcohol use	0.8 (0.7 to 0.9)	1.0 (0.7 to 1.2)	19.2 (-10.0 to 63.2)	26.4 (-7.0 to 76.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	18.8 (-12.5 to 65.9)	26.9 (-8.9 to 78.4)
Cirrhosis due to other causes	0.3 (0.3 to 0.4)	0.4 (0.3 to 0.5)	10.1 (-26.2 to 44.9)	36.9 (-7.0 to 79.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	8.8 (-32.4 to 56.8)	36.3 (-14.2 to 95.1)
Digestive diseases	-	-	-	-	4.6 (3.3 to 6.0)	5.0 (3.6 to 6.5)	8.7 (3.0 to 15.1)	15.4 (8.8 to 22.2)
Peptic ulcer disease	29.4 (28.6 to 30.2)	17.6 (17.1 to 18.1)	-40.2 (-42.3 to -38.0)	-48.8 (-50.8 to -46.5)	1.0 (0.7 to 1.4)	0.6 (0.4 to 0.8)	-40.5 (-44.8 to -36.0)	-50.9 (-54.7 to -45.5)
Gastritis and duodenitis	4.6 (4.2 to 5.0)	7.1 (6.2 to 8.0)	54.0 (35.6 to 78.4)	97.6 (77.9 to 124.7)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	40.3 (19.4 to 60.8)	112.4 (79.3 to 146.3)
Appendicitis	0.3 (0.3 to 0.3)	0.2 (0.2 to 0.2)	-31.0 (-39.4 to -19.1)	-0.8 (-12.8 to 17.6)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-30.1 (-48.1 to -5.4)	-0.1 (-26.8 to 38.8)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	19.5 (10.8 to 29.4)	19.2 (11.5 to 28.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.0 (-6.4 to 45.5)	18.8 (1.0 to 39.4)
Inguinal, femoral, and abdominal hernia	11.9 (10.3 to 13.7)	12.5 (11.0 to 14.1)	5.8 (-11.4 to 24.3)	8.7 (-22.4 to 6.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	5.0 (-11.2 to 23.9)	8.5 (-22.1 to 6.1)
Inflammatory bowel disease	7.5 (7.2 to 7.8)	8.6 (8.3 to 9.0)	15.1 (9.7 to 21.8)	21.5 (15.6 to 28.8)	1.6 (1.1 to 2.1)	1.8 (1.2 to 2.5)	14.5 (6.7 to 22.5)	22.1 (13.4 to 30.9)
Vascular intestinal disorders	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-24.9 to 101.0)	-1.9 (-38.2 to 51.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.2 (-32.4 to 116.4)	-4.5 (-42.0 to 66.6)
Gallbladder and biliary diseases	7.3 (6.5 to 8.2)	7.7 (7.0 to 8.4)	5.2 (-9.6 to 21.5)	0.6 (-13.0 to 16.2)	0.8 (0.5 to 1.1)	0.8 (0.5 to 1.1)	4.0 (-10.9 to 22.0)	0.6 (-13.8 to 18.1)
Pancreatitis	1.9 (1.8 to 2.0)	2.8 (2.7 to 2.9)	48.6 (34.7 to 58.5)	48.6 (39.6 to 58.5)	0.8 (0.4 to 0.8)	0.8 (0.6 to 1.1)	42.1 (27.7 to 59.9)	48.9 (32.9 to 67.9)
Other digestive diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	148.7 (83.8 to 230.3)	159.8 (93.1 to 247.1)
Neurological disorders	-	-	-	-	40.4 (27.9 to 55.8)	41.1 (28.1 to 55.7)	1.7 (-6.8 to 12.7)	10.1 (0.7 to 20.9)
Alzheimer disease and other dementias	38.4 (33.5 to 43.4)	54.8 (47.2 to 62.8)	42.6 (18.1 to 75.0)	0.0 (-17.0 to 22.4)	5.7 (4.0 to 7.6)	8.2 (5.8 to 10.8)	44.8 (19.3 to 78.0)	0.5 (-17.2 to 23.1)
Parkinson disease	2.1 (1.8 to 2.3)	2.6 (2.3 to 3.0)	28.4 (22.0 to 34.9)	0.2 (-4.3 to 4.7)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	27.5 (13.0 to 45.4)	0.6 (-1.1 to 14.5)
Epilepsy	7.2 (4.7 to 9.9)	5.5 (3.6 to 7.6)	-23.5 (-56.5 to 31.4)	-4.3 (-45.4 to 65.3)	2.2 (1.3 to 3.4)	1.7 (1.0 to 2.7)	-20.4 (-56.0 to 44.6)	0.7 (-44.7 to 82.9)
Multiple sclerosis	2.4 (2.1 to 2.7)	2.8 (2.4 to 3.1)	15.3 (-0.8 to 33.1)	29.1 (10.0 to 50.0)	0.8 (0.5 to 1.1)	0.9 (0.6 to 1.2)	14.6 (-5.3 to 38.9)	28.9 (6.3 to 55.5)
Migraine	690.0 (577.0 to 682.4)	525.7 (488.8 to 563.3)	-16.6 (-25.2 to -6.6)	0.7 (-10.5 to 12.6)	21.4 (12.8 to 31.5)	17.7 (10.7 to 26.5)	-17.2 (-26.0 to -7.0)	0.8 (-10.7 to 13.6)
Tension-type headache	1,356.4 (1,284.5 to 1,425.1)	1,110.3 (1,047.3 to 1,170.5)	-18.2 (-24.1 to -11.4)	1.7 (-6.2 to 9.7)	2.1 (1.0 to 3.6)	1.1 (0.7 to 1.7)	-8.5 (-24.0 to -11.5)	0.4 (-6.0 to 10.6)
Medication overuse headache	46.5 (31.7 to 62.8)	62.7 (41.6 to 84.4)	33.7 (9.7 to 77.1)	51.6 (23.1 to 100.1)	7.3 (4.2 to 11.0)	9.7 (5.4 to 14.8)	33.1 (7.9 to 76.0)	52.4 (22.3 to 99.6)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.0 (-30.8 to 33.2)	6.9 (-21.8 to 44.7)	0.8 (0.5 to 1.1)	0.8 (0.5 to 1.1)	1.7 (-25.8 to 35.8)	-24.0 (-44.4 to 0.7)
Mental and substance use disorders	-	-	-	-	92.3 (64.7 to 125.4)	76.0 (52.9 to 103.4)	-17.8 (-21.0 to -13.3)	1.2 (-1.9 to 4.6)
Schizophrenia	12.0 (10.0 to 12.9)	10.1 (9.3 to 10.9)	-15.7 (-18.9 to -12.3)	-0.5 (-4.5 to 3.7)	7.6 (5.7 to 9.3)	6.4 (4.8 to 7.7)	-15.9 (-21.0 to -10.8)	-0.2 (-5.9 to 5.5)
Alcohol use disorders	99.6 (90.1 to 109.7)	79.7 (73.1 to 86.6)	-20.0 (-24.7 to -14.5)	9.9 (-4.9 to 8.0)	2.0 (6.5 to 14.3)	7.9 (5.2 to 11.2)	-20.0 (-24.9 to -14.6)	1.2 (-5.0 to 8.7)
Drug use disorders	-	-	-	-	5.2 (3.7 to 6.8)	3.9 (2.7 to 5.0)	-25.1 (-34.1 to -13.6)	4.7 (-7.9 to 20.8)
Opioid use disorders	6.6 (5.9 to 7.2)	4.9 (4.5 to 5.3)	-26.3 (-30.1 to -21.5)	1.7 (-4.0 to 8.0)	2.8 (2.0 to 3.5)	2.0 (1.5 to 2.6)	-26.1 (-32.2 to -18.9)	2.0 (-6.3 to 11.8)
Cocaine use disorders	2.7 (2.0 to 3.5)	2.4 (2.0 to 2.8)	-11.9 (-33.7 to 22.7)	-11.9 (-7.4 to 72.9)	0.4 (0.2 to 0.6)	0.3 (0.0 to 0.5)	-11.2 (-36.3 to 29.3)	24.3 (-10.6 to 82.9)
Amphetamine use disorders	4.3 (4.3 to 6.9)	6.9 (3.5 to 4.8)	60.2 (-44.6 to -0.7)	28.7 (-22.5 to 41.9)	0.8 (0.4 to 1.1)	0.5 (0.3 to 0.8)	29.2 (-45.7 to 3.6)	0.4 (-23.7 to 48.3)
Cannabis use disorders	4.7 (4.1 to 5.2)	3.4 (3.0 to 3.7)	-28.3 (-32.9 to -22.7)	3.2 (-3.4 to 11.4)	0.1 (-0.1 to 0.2)	0.1 (0.1 to 0.1)	-28.0 (-39.7 to -13.9)	3.6 (-13.6 to 24.3)
Other drug use disorders	-	-	-	-	1.1 (0.7 to 1.7)	0.9 (0.5 to 1.3)	-23.6 (-47.6 to 12.8)	7.7 (-26.6 to 59.8)
Depressive disorders	-	-	-	-	39.0 (23.1 to 60.3)	34.1 (19.8 to 52.3)	-12.7 (-19.7 to -2.8)	2.6 (-3.7 to 11.0)
Major depressive disorder	162.6 (104.7 to 226.9)	143.0 (88.5 to 201.1)	-12.5 (-20.5 to -9.9)	3.1 (-4.3 to 12.7)	33.2 (18.4 to 52.7)	28.3 (15.4 to 46.0)	-13.1 (-21.4 to -1.7)	3.1 (-4.2 to 12.8)
Dysthymia	60.5 (50.0 to 70.6)	54.9 (45.9 to 63.8)	-9.3 (-12.6 to -5.7)	-0.2 (-0.3 to -0.1)	5.8 (3.8 to 8.5)	5.2 (3.4 to 7.7)	-9.9 (-13.5 to -5.9)	-0.1 (-2.3 to 2.2)
Bipolar disorder	27.2 (24.0 to 30.5)	22.7 (20.1 to 25.2)	-16.6 (-20.7 to -12.2)	-0.2 (-4.9 to 5.1)	5.5 (3.4 to 8.2)	4.6 (2.9 to 6.7)	-17.1 (-21.9 to -11.6)	0.0 (-6.0 to 6.9)
Anxiety disorders	98.1 (85.9 to 109.0)	79.9 (71.0 to 88.4)	-18.5 (-20.5 to -16.4)	-0.3 (-0.3 to -0.2)	9.0 (6.1 to 12.6)	7.2 (4.9 to 10.1)	-19.3 (-22.0 to -16.1)	-0.1 (-2.9 to 2.9)
Eating disorders	-	-	-	-	0.9 (0.5 to 1.4)	0.6 (0.4 to 0.9)	-34.0 (-39.0 to -28.7)	0.6 (-7.0 to 8.7)
Anorexia nervosa	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-29.2 (-34.9 to -22.6)	8.0 (-0.8 to 17.8)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-29.3 (-45.1 to -7.5)	8.2 (-16.5 to 41.4)
Bulimia nervosa	3.8 (2.7 to 5.0)	2.5 (1.8 to 3.3)	-34.7 (-35.5 to -33.8)	-0.4 (-0.4 to -0.3)	0.8 (0.5 to 1.3)	0.5 (0.3 to 0.8)	-34.6 (-40.2 to -29.1)	-0.3 (-8.5 to 8.0)
Autistic spectrum disorders	-	-	-	-	4.2 (2.9 to 5.7)	3.2 (2.2 to 4.3)	-24.2 (-26.4 to -21.7)	0.8 (-2.4 to 4.3)
Autism	10.9 (10.3 to 11.4)	8.3 (7.8 to 8.8)	-23.6 (-24.2 to -22.9)	0.3 (0.3 to 0.4)	2.7 (1.8 to 3.6)	2.0 (1.4 to 2.8)	-24.1 (-27.3 to -20.2)	0.8 (-3.7 to 5.8)
Asperger syndrome	15.4 (14.4 to 16.3)	11.7 (10.9 to 12.5)	-23.9 (-24.7 to -23.2)	0.4 (0.4 to 0.5)	1.5 (1.1 to 2.1)	1.2 (0.8 to 1.6)	-24.3 (-27.4 to -21.4)	0.8 (-3.3 to 4.7)
Attention-deficit/hyperactivity disorder	17.1 (15.8 to 18.5)	10.2 (9.4 to 11.0)	-40.6 (-40.7 to -40.5)	0.4 (0.4 to 0.4)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-40.5 (-44.8 to -35.7)	0.6 (-6.7 to 8.7)
Conduct disorder	24.8 (23.3 to 26.3)	14.9 (14.0 to 15.8)	-40.0 (-40.5 to -39.5)	0.4 (0.4 to 0.4)	3.0 (1.9 to 4.4)	1.8 (1.1 to 2.6)	-40.0 (-42.5 to -37.0)	0.5 (-3.7 to 5.2)
Idiopathic intellectual disability	56.6 (40.0 to 70.7)	38.3 (31.7 to 46.3)	-31.7 (-40.3 to -28.8)	-11.1 (-20.7 to -5.1)	2.5 (1.9 to 4.1)	1.9 (1.2 to 2.6)	-31.1 (-40.7 to -28.7)	-11.1 (-20.8 to -3.4)
Other mental and substance use disorders	65.8 (61.9 to 69.6)	57.9 (54.5 to 61.1)	-12.0 (-13.5 to -10.6)	0.2 (0.0 to 0.4)	4.9 (3.3 to 6.6)	4.3 (2.9 to 5.7)	-12.6 (-15.7 to -9.4)	0.5 (-2.7 to 3.8)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	33.6 (24.0 to 45.5)	34.7 (24.9 to 46.3)	2.9 (-6.7 to 14.4)	9.4 (0.3 to 20.4)
Diabetes mellitus	144.0 (117.4 to 174.1)	174.6 (143.5 to 207.4)	21.2 (5.8 to 54.4)	27.4 (1.0 to 63.3)	11.8 (7.7 to 16.7)	14.6 (9.8 to 20.3)	23.2 (-2.4 to 56.3)	26.5 (1.7 to 58.5)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.6 (-59.9 to -53.2)	-42.9 (-47.0 to -39.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.6 (-60.0 to -53.2)	-42.9 (-47.0 to -39.1)
Chronic kidney disease	-	-	-	-	9.4 (6.7 to 12.6)	8.8 (6.3 to 11.4)	-8.8 (-18.6 to 4.6)	0.4 (-11.8 to 8.6)
Chronic kidney disease due to diabetes mellitus	47.9 (34.3 to 66.4)	50.5 (33.9 to 73.4)	5.4 (-25.3 to 46.4)	-3.2 (-31.2 to 31.4)	1.5 (1.0 to 2.3)	1.5 (1.0 to 2.2)	0.8 (-24.1 to 37.2)	-2.9 (-27.3 to 31.1)
Chronic kidney disease due to hypertension	72.1 (47.8 to 107.3)	66.0 (44.1 to 94.1)	-8.7 (-30.3 to 18.6)	-3.3 (-25.5 to 25.5)	2.5 (1.8 to 3.5)	1.0 (0.6 to 1.4)	-61.7 (-72.7 to -45.0)	-61.7 (-72.4 to -46.0)
Chronic kidney disease due to glomerulonephritis	74.1 (55.3 to 101.3)	43.0 (34.0 to 55.8)	-41.7 (-54.2 to -23.9)	-36.9 (-50.0 to -21.0)	2.4 (1.7 to 3.3)	2.5 (1.7 to 3.4)	2.8 (-18.3 to 30.2)	18.5 (-3.8 to 49.7)
Chronic kidney disease due to other causes	91.2 (64.2 to 121.2)	122.4 (88.7 to 175.7)	33.8 (5.2 to 68.9)	28.6 (8.5 to 66.9)	2.9 (2.0 to 3.9)	3.8 (2.7 to 5.0)	29.9 (6.3 to 61.0)	34.4 (13.1 to 66.4)
Urinary diseases and male infertility	-	-	-	-	3.6 (2.4 to 5.1)	4.5 (3.0 to 6.4)	23.7 (15.8 to 33.9)	3.6 (-3.0 to 11.9)
Interstitial nephritis and urinary tract infections	1.4 (1.3 to 1.4)	1.2 (1.2 to 1.3)	-10.5 (-16.0 to -3.1)	11.3 (3.8 to 20.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-11.0 (-24.1 to 4.9)	11.6 (5.2 to 32.4)

Appendix Table G.4 - Lithuania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Urolithiasis	25.0 (16.7 to 34.9)	28.6 (19.3 to 40.6)	15.2 (-2.9 to 32.7)	15.2 (-16.4 to 12.2)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	12.5 (-0.9 to 25.7)	12.5 (-9.3 to 13.5)
Benign prostatic hyperplasia	88.5 (82.5 to 94.4)	112.4 (106.9 to 118.1)	26.9 (17.5 to 37.4)	2.3 (-5.1 to 11.0)	3.2 (2.1 to 4.4)	4.0 (2.6 to 5.7)	27.1 (17.5 to 38.2)	3.2 (-4.6 to 11.9)
Male infertility due to other causes	23.3 (18.7 to 28.7)	16.1 (13.0 to 19.5)	-30.5 (-48.7 to -7.2)	1.5 (-25.1 to 35.3)	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.2)	-31.1 (-49.6 to -7.5)	0.8 (-26.4 to 35.4)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	248.3 (7.7 to 365.0)	244.4 (0.7 to 341.0)
Gynecological diseases	-	-	-	-	4.8 (3.0 to 7.1)	3.8 (2.4 to 5.9)	-20.0 (-31.1 to -7.9)	7.5 (-12.1 to 18.5)
Uterine fibroids	86.4 (79.0 to 93.4)	75.7 (69.6 to 81.4)	-12.5 (-13.6 to -11.3)	-0.8 (-0.8 to -0.7)	1.0 (0.6 to 1.7)	0.9 (0.5 to 1.5)	-14.9 (-22.4 to -9.5)	1.5 (-6.8 to 8.2)
Polycystic ovarian syndrome	66.0 (58.1 to 73.1)	49.0 (44.1 to 54.5)	-26.0 (-36.3 to -13.4)	-1.7 (-15.7 to 15.5)	0.6 (0.3 to 1.2)	0.5 (0.2 to 0.9)	-26.0 (-35.8 to -13.2)	-1.3 (-14.8 to 16.1)
Female infertility due to other causes	17.3 (11.9 to 23.2)	12.8 (8.3 to 17.5)	-26.1 (-55.2 to 18.5)	7.3 (-34.9 to 71.9)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-26.1 (-55.5 to 18.9)	7.9 (-35.3 to 72.0)
Endometriosis	7.1 (6.0 to 8.3)	5.6 (4.8 to 6.3)	-20.8 (-36.6 to -2.3)	4.6 (-16.1 to 29.3)	0.7 (0.4 to 0.9)	0.5 (0.3 to 0.7)	-21.0 (-38.0 to -6.6)	4.9 (-17.8 to 31.7)
Genital prolapse	214.1 (190.1 to 239.2)	190.4 (169.6 to 213.7)	-11.4 (-24.5 to 3.8)	0.0 (-15.3 to 17.8)	0.0 (0.3 to 1.3)	0.6 (0.3 to 1.1)	-11.4 (-25.4 to 3.4)	0.1 (-15.7 to 18.0)
Premenstrual syndrome	154.6 (108.8 to 203.9)	118.4 (79.0 to 154.2)	-25.1 (-54.2 to 21.9)	4.5 (-36.1 to 67.5)	1.3 (0.7 to 2.1)	1.0 (0.5 to 1.7)	-25.2 (-54.2 to 21.9)	3.9 (-36.4 to 66.3)
Other gynecological diseases	12.8 (11.4 to 13.9)	10.2 (9.6 to 10.8)	-20.6 (-27.9 to -11.2)	1.9 (-7.3 to 14.1)	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-22.3 (-34.1 to -3.8)	1.2 (-14.6 to 25.8)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	2.5 (1.6 to 3.6)	1.8 (1.2 to 2.6)	-28.1 (-37.7 to -16.3)	0.3 (-8.4 to 13.3)
Thalassemias	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-38.7 (-45.0 to -27.8)	7.0 (-4.0 to 26.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.8 (-52.1 to -17.4)	6.7 (-17.1 to 45.8)
Thalassemia trait	62.4 (59.4 to 66.6)	50.9 (47.6 to 54.4)	-18.6 (-21.8 to -14.5)	2.5 (-1.3 to 7.1)	2.1 (1.4 to 3.0)	1.5 (1.0 to 2.1)	-28.5 (-33.3 to -20.7)	0.1 (-6.7 to 9.0)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.0 (-39.3 to -22.5)	1.1 (-6.1 to 18.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.4 (-39.3 to -16.6)	-0.2 (-6.8 to 26.6)
Sickle cell trait	1.7 (1.5 to 1.9)	1.3 (1.3 to 1.4)	-20.8 (-33.0 to -18.4)	0.0 (-14.9 to 6.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.5 (-72.0 to -8.8)	-19.6 (-57.7 to 56.4)
G6PD deficiency	6.2 (5.5 to 6.9)	5.0 (4.6 to 5.3)	-20.0 (-30.2 to -7.9)	1.6 (-11.4 to 17.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.8 (-39.7 to 25.1)	11.9 (-12.2 to 63.6)
G6PD trait	389.8 (386.1 to 394.3)	316.0 (311.8 to 319.6)	-18.9 (-20.4 to -17.5)	-0.9 (-2.7 to 0.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.0 (-82.3 to 141.0)	7.3 (-80.7 to 286.3)
Other hemoglobinopathies and hemolytic anemias	14.6 (11.3 to 17.5)	12.1 (10.2 to 14.3)	-17.5 (-36.5 to 13.7)	1.9 (-23.0 to 42.9)	0.4 (0.2 to 0.6)	0.3 (0.2 to 0.4)	-25.5 (-50.5 to 48.3)	2.1 (-31.9 to 102.8)
Endocrine, metabolic, blood, and immune disorders	46.7 (43.9 to 49.6)	35.7 (34.6 to 37.1)	-23.5 (-28.4 to -17.9)	-4.1 (-11.2 to 3.5)	1.6 (1.1 to 2.2)	1.2 (0.8 to 1.7)	-25.3 (-38.8 to -17.4)	-5.0 (-13.2 to 5.4)
Musculoskeletal disorders	-	-	-	-	92.3 (65.4 to 123.4)	89.2 (66.9 to 123.0)	-2.0 (-5.2 to 7.3)	2.0 (-4.6 to 8.6)
Rheumatoid arthritis	18.5 (17.8 to 19.3)	19.6 (18.7 to 20.5)	5.8 (0.4 to 12.4)	-2.3 (-8.0 to 3.2)	4.3 (3.1 to 5.7)	4.5 (3.2 to 5.9)	4.6 (-2.9 to 11.7)	4.6 (-9.3 to 4.1)
Osteoarthritis	208.3 (200.3 to 216.7)	248.4 (239.0 to 257.2)	19.2 (12.9 to 26.2)	1.1 (-4.2 to 6.9)	12.7 (9.0 to 17.3)	15.0 (10.5 to 20.3)	18.6 (12.2 to 25.7)	1.1 (-4.3 to 7.3)
Low back and neck pain	-	-	-	-	64.7 (44.7 to 88.4)	61.8 (42.5 to 83.5)	-4.3 (-13.0 to 4.5)	1.2 (-10.7 to 10.7)
Low back pain	432.3 (396.8 to 464.5)	417.0 (386.0 to 447.2)	-3.7 (-13.9 to 7.7)	-0.7 (-10.9 to 11.3)	47.8 (32.2 to 66.4)	45.6 (30.4 to 63.3)	-4.6 (-14.6 to 6.9)	-0.5 (-10.9 to 12.0)
Neck pain	173.1 (143.0 to 204.5)	166.1 (135.4 to 194.3)	-4.2 (-24.7 to 21.3)	4.7 (-17.5 to 32.8)	16.9 (11.1 to 24.6)	16.1 (10.8 to 23.0)	-4.6 (-25.1 to 20.7)	5.1 (-17.5 to 33.1)
Gout	2.5 (2.3 to 2.7)	2.7 (2.6 to 2.9)	9.2 (0.0 to 20.3)	0.1 (-7.5 to 11.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	7.7 (-10.7 to 33.8)	0.8 (-16.3 to 24.5)
Other musculoskeletal disorders	116.0 (91.6 to 140.3)	130.4 (106.0 to 157.2)	12.4 (4.2 to 21.6)	9.6 (2.7 to 17.3)	10.5 (6.9 to 15.2)	11.8 (7.8 to 16.9)	11.7 (2.9 to 21.1)	9.6 (2.0 to 17.9)
Other non-communicable diseases	-	-	-	-	64.9 (44.0 to 92.4)	60.7 (41.8 to 86.3)	-8.3 (-10.0 to -2.2)	6.3 (-10.0 to -2.8)
Congenital anomalies	-	-	-	-	5.2 (3.8 to 6.7)	4.2 (3.0 to 5.5)	-19.9 (-27.9 to -6.3)	-0.0 (-10.7 to 17.9)
Neural tube defects	1.0 (0.8 to 1.2)	0.5 (0.4 to 0.6)	-52.1 (-63.1 to -34.6)	-31.0 (-46.6 to -5.6)	0.3 (0.2 to 0.5)	0.1 (0.1 to 0.2)	-51.2 (-67.1 to -25.1)	-29.1 (-52.1 to 8.5)
Congenital heart anomalies	26.1 (21.8 to 31.5)	18.4 (15.7 to 21.7)	-29.2 (-44.8 to -11.0)	-6.5 (-26.7 to 17.5)	0.9 (0.4 to 1.6)	0.7 (0.3 to 1.2)	-28.8 (-43.4 to -11.6)	-3.9 (-22.7 to 18.7)
Crofacial clefts	3.6 (2.9 to 4.3)	2.8 (2.3 to 3.8)	-21.1 (-41.4 to 5.0)	2.0 (-24.2 to 35.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-31.5 (-52.2 to -16.6)	-11.2 (-38.7 to 27.9)
Down syndrome	4.3 (3.5 to 5.1)	3.9 (3.2 to 4.7)	-9.1 (-29.9 to 19.2)	8.2 (-15.9 to 42.0)	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.8)	0.6 (-24.0 to 33.1)	0.8 (-14.8 to 47.9)
Turner syndrome	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-27.5 (-50.0 to 9.5)	-0.3 (-31.6 to 50.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.0 (-52.1 to 11.3)	-0.6 (-33.5 to 52.8)
Klinefelter syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-11.4 (-48.7 to 32.6)	17.9 (-31.6 to 76.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.7 (-50.7 to 35.0)	16.3 (-33.7 to 84.0)
Chromosomal unbalanced rearrangements	6.4 (5.5 to 7.7)	5.7 (4.9 to 6.6)	-12.0 (-31.1 to 8.5)	5.2 (-17.5 to 29.2)	0.9 (0.6 to 1.2)	0.9 (0.6 to 1.2)	-2.9 (-24.4 to 20.1)	8.1 (-15.7 to 32.8)
Other congenital anomalies	17.5 (14.3 to 20.3)	12.0 (10.1 to 14.1)	-31.6 (-37.8 to -23.3)	21.6 (-24.3 to 6.2)	2.4 (1.7 to 3.3)	1.9 (1.2 to 2.6)	-27.0 (-35.1 to -10.1)	0.6 (-15.9 to 31.0)
Skin and subcutaneous diseases	-	-	-	-	17.3 (11.4 to 25.6)	13.5 (8.8 to 19.9)	-22.1 (-29.5 to -15.8)	-4.8 (-13.2 to 3.2)
Dermatitis	156.0 (126.7 to 185.9)	126.5 (102.8 to 149.1)	-18.9 (-21.0 to -16.2)	-0.0 (-0.1 to 0.0)	3.8 (2.4 to 5.5)	3.0 (1.9 to 4.4)	-19.5 (-26.6 to -12.4)	0.1 (-2.8 to 2.7)
Psoriasis	32.2 (28.5 to 35.9)	28.1 (24.7 to 31.3)	-12.9 (-15.4 to -10.0)	0.0 (-0.0 to 0.1)	0.0 (1.8 to 3.7)	2.3 (1.5 to 3.2)	-0.2 (-18.4 to 8.6)	0.2 (-5.3 to 5.5)
Cellulitis	1.9 (1.6 to 2.3)	1.7 (1.4 to 2.0)	-12.4 (-21.2 to -2.3)	0.1 (-3.6 to 23.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-13.2 (-27.9 to 4.3)	12.5 (-6.0 to 33.8)
Pyoderma	4.5 (3.7 to 5.7)	5.5 (4.5 to 6.9)	21.5 (13.5 to 29.5)	42.5 (35.9 to 48.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	20.5 (10.0 to 31.9)	42.7 (32.3 to 54.5)
Scabies	11.0 (9.3 to 13.3)	8.3 (6.8 to 10.2)	-24.9 (-41.9 to -0.3)	1.8 (-22.4 to 35.7)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.4)	-25.4 (-42.9 to -1.6)	1.9 (-23.2 to 34.6)
Fungal skin diseases	297.3 (232.9 to 388.8)	253.1 (200.9 to 319.8)	-14.8 (-19.1 to -9.9)	0.1 (0.1 to 0.2)	1.7 (0.7 to 3.6)	1.4 (0.6 to 3.1)	-15.3 (-19.5 to -10.3)	0.3 (-0.6 to 1.2)
Viral skin diseases	74.6 (56.4 to 93.0)	51.8 (39.4 to 64.3)	-30.6 (-33.8 to -26.3)	0.1 (-1.8 to 1.8)	1.6 (1.3 to 3.6)	1.6 (0.9 to 2.5)	-31.1 (-34.6 to -26.3)	-0.1 (-2.9 to 3.3)
Acne vulgaris	110.2 (89.2 to 130.1)	74.5 (61.0 to 86.7)	-32.8 (-46.9 to -12.9)	2.4 (-20.7 to 34.8)	1.2 (0.5 to 2.3)	0.8 (0.4 to 1.5)	-32.9 (-47.0 to -12.6)	2.4 (-20.3 to 34.6)
Alopecia areata	4.7 (4.1 to 5.3)	4.2 (3.7 to 4.7)	-10.7 (-24.5 to 5.3)	-1.3 (-16.3 to 15.4)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-11.0 (-27.2 to 7.9)	-0.4 (-18.8 to 20.5)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.7 (-27.4 to 21.9)	-0.2 (-21.2 to 29.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.7 (-27.5 to 21.9)	-0.2 (-21.3 to 29.7)
Urticaria	60.6 (44.9 to 77.5)	38.9 (27.2 to 52.5)	-34.9 (-59.2 to -3.7)	-26.5 (-52.2 to 11.3)	3.6 (2.1 to 5.4)	2.3 (1.3 to 3.6)	-35.4 (-59.4 to -3.9)	-26.2 (-52.3 to 11.4)
Decubitus ulcer	0.5 (0.3 to 0.7)	0.8 (0.6 to 1.0)	79.4 (11.0 to 178.3)	49.9 (-5.9 to 120.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	72.6 (3.4 to 178.8)	46.6 (-8.9 to 124.2)
Other skin and subcutaneous diseases	267.2 (160.2 to 446.0)	255.6 (141.3 to 449.8)	-5.1 (-15.7 to 5.1)	-3.5 (-7.4 to 0.5)	1.6 (0.6 to 3.5)	1.5 (0.6 to 3.5)	-5.5 (-16.2 to 4.5)	-3.4 (-7.4 to 0.9)
Sense organ diseases	-	-	-	-	33.6 (22.5 to 48.2)	21.1 (23.4 to 48.7)	34.3 (-3.2 to 8.9)	2.1 (-14.2 to -4.6)
Glaucoma	5.5 (4.4 to 7.1)	5.3 (4.1 to 6.9)	-3.1 (-18.9 to 16.0)	-11.0 (-25.4 to 2.9)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.5)	8.9 (-8.4 to 32.7)	-6.6 (-19.4 to 10.7)
Cataract	49.0 (36.8 to 59.9)	48.1 (35.8 to 59.8)	-1.7 (-16.2 to 12.4)	-26.6 (-36.5 to -14.8)	1.9 (1.2 to 2.8)	1.9 (1.2 to 2.8)	-0.0 (-13.9 to 14.7)	-25.8 (-31.2 to -14.5)
Macular degeneration	13.1 (9.3 to 17.8)	16.7 (11.2 to 23.7)	27.3 (-2.7 to 67.1)	11.2 (-13.5 to 39.2)	0.5 (0.3 to 0.8)	0.6 (0.4 to 1.0)	28.2 (-0.9 to 68.1)	10.4 (-13.6 to 38.8)
Uncorrected refractive error	368.8 (325.5 to 406.6)	372.8 (303.6 to 455.8)	0.5 (-17.7 to 26.7)	-5.1 (-21.5 to 19.8)	5.8 (3.4 to 9.4)	5.5 (3.2 to 9.0)	-6.5 (-17.6 to 8.8)	-9.9 (-20.2 to 4.0)
Age-related and other hearing loss	726.3 (645.1 to 797.4)	745.7 (673.3 to 810.5)	2.6 (-1.7 to 7.8)	-7.6 (-11.0 to -3.2)	21.6 (14.4 to 30.4)	23.2 (15.8 to 32.2)	7.2 (0.1 to 15.6)	-9.2 (-15.6 to -2.9)
Other vision loss	24.6 (20.7 to 30.9)	17.2 (14.0 to 21.1)	-29.5 (-40.5 to -19.3)	1.2 (-36.3 to -38.4)	0.9 (0.7 to 1.6)	0.9 (0.6 to 1.2)	-23.6 (-33.6 to -11.7)	-23.1 (-31.5 to -14.8)
Other sense organ diseases	88.0 (83.9 to 92.0)	75.1 (71.1 to 78.7)	-14.6 (-20.3 to -8.5)	0.5 (-6.2 to 7.1)	2.3 (1.4 to 3.4)	2.0 (1.2 to 2.8)	-15.7 (-21.8 to -9.1)	0.5 (-6.3 to 8.4)
Oral disorders	-	-	-	-	8.7 (5.3 to 13.4)	7.7 (5.4 to 13.1)	-8.7 (-4.7 to 4.0)	-2.0 (-5.4 to 1.3)
Deciduous caries	275.5 (270.8 to 279.3)	143.5 (141.5 to 145.5)	-47.9 (-48.9 to -46.8)	0.6 (-1.3 to 2.7)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-47.9 (-51.2 to -44.4)	0.6 (-5.6 to 7.3)
Permanent caries	2,085.4 (2,036.9 to 2,132.8)	1,648.2 (1,596.9 to 1,694.8)	-21.2 (-23.6 to -19.0)	21.2 (-3.7 to 2.6)	0.4 (0.6 to 2.4)	0.4 (0.4 to 1.9)	-21.5 (-24.2 to -19.1)	0.1 (-4.1 to 3.2)
Periodontal diseases	249.1 (237.3 to 261.8)	244.9 (233.8 to 256.1)	-1.7 (-8.6 to 5.3)	0.3 (-6.5 to 7.9)	1.6 (0.7 to 3.3)	1.6 (0.6 to 3.3)	-2.1 (-9.0 to 5.2)	0.4 (-6.6 to 8.2)
Edentulism and severe tooth loss	138.7 (133.2 to 143.9)	161.6 (155.6 to 168.1)	16.5 (10.6 to 23.3)	-4.8 (-9.7 to 0.9)	3.8 (2.6 to 5.3)	4.4 (3.0 to 6.1)	16.1 (9.5 to 22.9)	1.7 (-9.9 to 12.7)

Appendix Table G.4 - Lithuania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	68.8 (64.8 to 72.6)	57.6 (54.6 to 60.7)	-16.3 (-22.8 to -9.0)	-0.5 (-8.4 to 8.2)	2.0 (1.3 to 3.0)	1.7 (1.1 to 2.5)	-16.6 (-23.5 to -8.4)	-0.3 (-9.0 to 8.2)
Injuries	-	-	-	-	31.3 (23.7 to 40.7)	18.7 (13.4 to 25.2)	-40.6 (-46.2 to -34.6)	-41.5 (-46.8 to -35.6)
Transport injuries	-	-	-	-	10.9 (8.1 to 14.0)	4.2 (3.0 to 5.8)	-61.4 (-66.1 to -56.2)	-60.5 (-65.2 to -55.1)
Road injuries	-	-	-	-	9.2 (6.9 to 11.9)	3.4 (2.4 to 4.6)	-63.0 (-67.6 to -57.6)	-62.2 (-66.8 to -56.6)
Pedestrian road injuries	-	-	-	-	2.1 (1.5 to 2.6)	0.8 (0.6 to 1.1)	-60.3 (-65.4 to -54.5)	-61.8 (-66.8 to -56.1)
Cyclist road injuries	-	-	-	-	1.4 (1.1 to 1.9)	0.6 (0.4 to 0.7)	-61.4 (-65.6 to -56.9)	-60.3 (-64.7 to -55.7)
Motorcyclist road injuries	-	-	-	-	0.9 (0.6 to 1.1)	0.3 (0.2 to 0.4)	-68.6 (-72.9 to -63.8)	-66.2 (-70.8 to -61.1)
Motor vehicle road injuries	-	-	-	-	4.8 (3.6 to 6.2)	1.8 (1.3 to 2.4)	-63.2 (-68.4 to -57.3)	-61.8 (-67.2 to -55.5)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.0)	-75.5 (-78.6 to -72.1)	-75.0 (-78.2 to -71.4)
Other transport injuries	-	-	-	-	1.7 (1.2 to 2.2)	0.8 (0.6 to 1.1)	-52.5 (-57.8 to -46.7)	-51.1 (-56.6 to -45.3)
Unintentional injuries	-	-	-	-	19.6 (14.9 to 25.4)	14.0 (10.1 to 18.8)	-28.9 (-34.6 to -22.8)	-30.8 (-36.2 to -24.9)
Falls	-	-	-	-	8.6 (6.5 to 11.1)	6.5 (4.6 to 8.7)	-24.8 (-33.0 to -15.4)	-31.3 (-38.8 to -22.9)
Drowning	-	-	-	-	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-59.5 (-64.9 to -53.6)	-58.3 (-63.8 to -52.5)
Fire, heat, and hot substances	-	-	-	-	0.8 (0.6 to 1.1)	0.5 (0.4 to 0.7)	-36.2 (-44.0 to -27.7)	-33.0 (-41.0 to -24.1)
Poisonings	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-48.7 (-54.6 to -42.1)	-39.8 (-47.2 to -31.2)
Exposure to mechanical forces	-	-	-	-	5.1 (3.8 to 6.7)	3.1 (2.2 to 4.1)	-40.0 (-44.0 to -35.4)	-35.4 (-39.5 to -30.6)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-63.6 (-69.1 to -56.4)	-58.0 (-64.1 to -49.9)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-41.3 (-46.9 to -34.5)	-37.6 (-43.4 to -30.8)
Other exposure to mechanical forces	-	-	-	-	5.0 (3.7 to 6.6)	3.0 (2.2 to 4.1)	-39.6 (-43.5 to -35.0)	-35.0 (-39.1 to -30.1)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	4.6 (-2.5 to 12.4)	7.1 (0.6 to 14.4)
Animal contact	-	-	-	-	0.3 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-24.4 (-30.4 to -17.0)	-17.4 (-23.4 to -10.1)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-22.9 (-30.4 to -12.6)	-13.0 (-22.0 to -1.3)
Non-venomous animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-25.0 (-32.1 to -16.9)	-19.6 (-27.0 to -11.3)
Foreign body	-	-	-	-	0.3 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-31.2 (-38.0 to -23.9)	-27.0 (-34.1 to -19.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-42.9 (-51.7 to -32.1)	-41.4 (-50.0 to -30.6)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-18.5 (-23.3 to -13.2)	-3.9 (-13.0 to 3.5)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-24.9 (-32.1 to -17.5)	-22.3 (-29.3 to -14.7)
Other unintentional injuries	-	-	-	-	4.0 (3.0 to 5.3)	3.2 (2.4 to 4.3)	-19.4 (-25.3 to -13.2)	-22.3 (-28.0 to -16.4)
Self-harm and interpersonal violence	-	-	-	-	0.9 (0.7 to 1.1)	0.5 (0.4 to 0.7)	-43.7 (-49.3 to -36.4)	-41.9 (-47.5 to -34.7)
Self-harm	-	-	-	-	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-37.0 (-43.1 to -29.6)	-34.4 (-40.5 to -27.0)
Interpersonal violence	-	-	-	-	0.4 (0.3 to 0.6)	0.2 (0.2 to 0.3)	-50.0 (-55.9 to -42.4)	-48.9 (-54.8 to -41.4)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.9 (-55.3 to -45.5)	-48.8 (-53.1 to -43.5)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-43.6 (-50.2 to -35.8)	-42.3 (-48.8 to -34.0)
Assault by other means	-	-	-	-	0.3 (0.3 to 0.4)	0.2 (0.1 to 0.2)	-51.3 (-57.3 to -43.2)	-50.4 (-56.4 to -42.4)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Luxembourg prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	50.2 (37.7 to 64.8)	72.7 (54.7 to 93.7)	45.0 (39.2 to 50.4)	45.0 (-4.8 to 3.6)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.1 (1.5 to 3.0)	2.9 (2.0 to 4.1)	36.7 (20.7 to 65.6)	-2.2 (-12.7 to 16.5)
HIV/AIDS and tuberculosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.4 (14.9 to 71.3)	-3.0 (-20.5 to 18.9)
Tuberculosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	21.7 (16.3 to 27.7)	-14.2 (-18.2 to -10.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.9 (1.0 to 46.4)	-14.7 (-31.1 to 4.4)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,083.2 (423.7 to 4,039.0)	683.6 (248.8 to 2,624.3)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	459.4 (134.4 to 1,967.0)	289.9 (61.0 to 1,332.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	459.4 (131.3 to 1,995.8)	289.9 (60.6 to 1,344.5)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	1,337.7 (622.9 to 4,490.2)	837.1 (366.4 to 2,905.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,085.5 (423.8 to 4,122.8)	684.4 (249.0 to 2,678.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	14.1 (2.6 to 26.4)	-19.7 (-27.7 to -11.3)
Diarrheal diseases	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	33.4 (12.3 to 59.3)	-5.1 (-24.3 to 16.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.9 (7.9 to 66.1)	-4.9 (-26.2 to 22.6)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.9 (-61.6 to 97.4)	27.3 (-73.1 to 35.8)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.6 (-38.0 to 77.6)	-24.8 (-54.6 to 18.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.6 (-38.3 to 77.9)	-24.8 (-54.6 to 18.8)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.4 (-13.0 to 125.9)	1.8 (-35.8 to 53.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.4 (-14.0 to 126.1)	1.8 (-36.1 to 54.0)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.2 (-96.8 to 526.6)	-59.7 (-97.8 to 331.2)
Lower respiratory infections	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	10.1 (1.5 to 18.5)	-26.1 (-32.1 to -20.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.9 (5.6 to 28.1)	-25.8 (-36.5 to -13.5)
Upper respiratory infections	5.7 (5.5 to 6.0)	8.1 (7.7 to 8.4)	41.2 (31.4 to 48.7)	1.2 (-5.8 to 6.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	40.9 (30.4 to 50.2)	1.1 (-6.2 to 7.8)
Otitis media	4.8 (4.3 to 5.4)	5.8 (5.1 to 6.7)	22.5 (5.4 to 47.0)	-13.8 (-24.9 to 0.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	21.8 (4.3 to 46.1)	-14.1 (-26.1 to 0.4)
Meningitis	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-32.3 (-50.1 to -15.2)	-53.7 (-66.8 to -41.1)
Pneumococcal meningitis	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-14.0 (-36.6 to 16.8)	-41.5 (-57.4 to -22.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.2 (-35.3 to 35.1)	35.3 (-56.8 to -6.1)
H influenzae type B meningitis	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-46.4 (-69.7 to -18.6)	-63.2 (-79.4 to -43.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.4 (-69.3 to -12.9)	-63.2 (-79.4 to -39.8)
Meningococcal meningitis	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-39.3 (-61.4 to 5.5)	-58.4 (-73.6 to -26.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.3 (-59.4 to 21.2)	-55.1 (-72.7 to -15.6)
Other meningitis	0.2 (0.1 to 0.4)	0.2 (0.0 to 0.3)	-39.2 (-60.6 to -13.6)	-57.6 (-72.4 to -40.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.1 (-64.6 to -5.4)	-57.5 (-75.4 to -33.9)
Encephalitis	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	34.5 (-0.0 to 78.8)	-48.4 (-29.9 to 26.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.4 (6.3 to 89.8)	3.2 (-26.9 to 33.6)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.7 (-93.6 to 267.3)	-69.3 (-96.0 to 150.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.7 (-93.8 to 269.1)	-69.3 (-96.0 to 151.4)
Whooping cough	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-79.9 (-82.2 to -77.4)	-84.7 (-86.5 to -82.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-80.0 (-86.8 to -71.1)	-84.8 (-90.1 to -78.0)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.3 (-70.3 to 4.5)	-52.0 (-80.2 to -27.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.2 (-72.7 to -2.2)	-53.5 (-81.4 to -33.0)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.3 (-100.0 to -94.2)	-99.9 (-100.0 to -95.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.9 (-100.0 to -94.0)	-99.9 (-100.0 to -95.5)
Varicella and herpes zoster	0.3 (0.3 to 0.4)	0.4 (0.4 to 0.5)	43.3 (11.2 to 78.6)	0.4 (-19.1 to 20.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.2 (3.1 to 103.1)	0.5 (-28.6 to 35.5)
Neglected tropical diseases and malaria	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.2 (-46.7 to -15.3)	-54.8 (-65.4 to -43.1)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.2 (-60.7 to 332.6)	-7.9 (-72.1 to 207.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.8 (-59.5 to 349.9)	-5.3 (-71.1 to 221.7)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.0 (-83.6 to 10.8)	-69.4 (-87.9 to -14.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.2 (-81.8 to 30.0)	-65.8 (-86.7 to -1.3)
Cystic echinococcosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-28.2 (-38.8 to -19.3)	-54.1 (-60.5 to -46.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.8 (-44.0 to -12.5)	-53.9 (-64.1 to -41.1)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.0 (-57.9 to 47.1)	-21.7 (-72.9 to -7.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.0 (-58.0 to 47.1)	21.7 (-72.9 to -7.0)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	116.2 (-33.6 to 194.9)	37.4 (-55.8 to 83.9)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.5 (-24.6 to 103.0)	-2.5 (-40.1 to 58.7)
Maternal hemorrhage	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	30.0 (-48.1 to 335.6)	3.2 (-59.5 to 233.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.0 (-72.6 to 259.3)	-14.5 (-77.6 to 191.2)
Maternal sepsis and other maternal infections	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	70.0 (-76.7 to 843.8)	22.3 (-81.7 to 553.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.1 (-33.2 to 163.3)	2.2 (-47.9 to 97.2)
Maternal hypertensive disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.7 (24.8 to 50.5)	8.1 (-1.8 to 18.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.7 (8.7 to 120.5)	10.3 (-28.4 to 70.2)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.8 (2.3 to 48.7)	-1.3 (-17.7 to 18.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.8 (2.2 to 48.8)	-1.3 (-18.0 to 18.1)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.5 (24.0 to 44.0)	5.1 (-2.4 to 13.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.5 (23.9 to 44.0)	5.1 (-2.4 to 13.4)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.1 (-38.6 to 151.2)	-4.3 (-51.9 to 95.3)
Neonatal disorders	-	-	-	-	0.5 (0.3 to 0.7)	0.7 (0.5 to 1.3)	45.8 (4.5 to 176.4)	2.4 (-32.9 to 94.1)
Preterm birth complications	1.7 (1.2 to 2.5)	2.9 (2.0 to 4.2)	67.1 (27.7 to 119.7)	18.5 (-9.4 to 55.1)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.5)	80.8 (37.3 to 144.6)	28.0 (-2.9 to 73.5)
Neonatal encephalopathy due to birth asphyxia and trauma	0.4 (0.2 to 0.8)	0.3 (0.1 to 0.7)	-29.8 (-54.1 to 20.9)	-50.4 (-67.4 to -15.5)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-20.2 (-48.5 to 26.8)	-43.9 (-63.9 to -11.4)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17,435.4 (5,286.4 to 187,164.0)	13,518.2 (4,083.2 to 145,331.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17,067.2 (4,947.1 to 188,736.7)	13,223.3 (3,819.7 to 146,552.6)
Hemolytic disease and other neonatal jaundice	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.3)	42.4 (-57.1 to 458.0)	0.2 (-69.8 to 287.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	45.5 (-55.5 to 474.9)	2.4 (-68.7 to 300.7)
Other neonatal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.7)	20.0 (-46.8 to 391.4)	-16.0 (-62.8 to 245.8)
Nutritional deficiencies	-	-	-	-	1.2 (0.8 to 1.8)	1.7 (1.1 to 2.5)	39.1 (12.6 to 54.1)	0.2 (-18.3 to 10.6)
Protein-energy malnutrition	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,492.9 (-36.3 to 4,601.3)	1,080.8 (-62.5 to 1,939.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,081.5 (-47.7 to 4,067.2)	909.9 (-68.1 to 1,731.8)
Iodine deficiency	6.8 (3.2 to 13.4)	5.4 (1.5 to 12.2)	24.5 (-79.0 to 110.5)	45.3 (83.5 to 47.5)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.2)	24.9 (-79.1 to 110.6)	45.5 (-83.5 to 48.9)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron-deficiency anemia	43.5 (41.6 to 44.9)	64.2 (58.6 to 66.6)	47.8 (33.8 to 56.2)	4.0 (-6.6 to 10.1)	1.1 (0.7 to 1.6)	1.6 (1.0 to 2.3)	45.6 (16.0 to 60.0)	3.4 (-16.4 to 14.7)

Appendix Table G.4 - Luxembourg prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.0	0.0	178.8	29.6
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.1	0.1	(63.3 to 438.8)	(-77.2 to 135.4)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.0	0.1	32.1	-4.6
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.4 (47.6 to 196.4)	41.9 (-3.2 to 102.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	(11.9 to 71.1)	(-19.2 to 25.5)
Chlamydial infection	6.2 (3.8 to 8.8)	6.2 (4.6 to 7.7)	26.1 (-15.6 to 79.0)	5.6 (-37.2 to 35.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.3	-2.1
Gonococcal infection	1.2 (0.8 to 1.8)	1.9 (1.2 to 2.6)	49.6 (-10.9 to 160.9)	18.3 (-32.5 to 112.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.0	7.7
Trichomoniasis	1.1 (0.8 to 1.5)	1.8 (1.2 to 2.5)	59.2 (-2.7 to 167.7)	21.9 (-29.8 to 108.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.5	26.5
Genital herpes	47.0 (41.6 to 51.9)	63.3 (55.2 to 71.2)	34.0 (15.3 to 61.4)	-8.0 (-21.3 to 10.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.2	-7.6
Other sexually transmitted diseases	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	51.8 (3.6 to 132.6)	11.2 (-23.7 to 68.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.5	(2.3 to 80.1)
Hepatitis	-	-	-	-	0.0	0.0	15.3	-18.0
Hepatitis A	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.4)	24.1 (21.3 to 26.7)	-12.1 (-14.2 to -10.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (11.6 to 42.1)	-10.7 (-21.1 to 0.9)
Hepatitis B	5.4 (4.4 to 6.8)	5.2 (3.6 to 6.7)	-2.8 (-32.2 to 28.7)	-31.9 (-53.4 to -8.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-38.8 to 32.6)	-8.2 (-57.6 to -7.9)
Hepatitis C	8.1 (7.2 to 9.1)	8.7 (7.8 to 9.6)	7.8 (-8.1 to 25.3)	-26.3 (-37.6 to -14.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.7	-24.8
Hepatitis E	-	-	70.9 (-30.0 to 178.3)	22.1 (-50.6 to 104.8)	-	-	-	(-48.7 to 8.5)
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	1.7 (1.5 to 2.0)	2.5 (2.2 to 4.7)	43.8 (15.6 to 170.7)	1.0 (-21.4 to 102.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	29.5	-5.9
Non-communicable diseases	-	-	-	-	43.6 (32.8 to 56.5)	65.3 (49.0 to 84.2)	49.8	2.7
Neoplasms	-	-	-	-	1.0 (0.7 to 1.3)	1.5 (1.1 to 1.9)	48.5	4.2
Esophageal cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	62.4 (17.7 to 130.4)	6.2 (-23.4 to 50.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.5	-1.4
Stomach cancer	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.4)	8.7 (-10.0 to 34.0)	-31.6 (-42.9 to -16.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.3	-37.5
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	209.4	104.2
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	560.1 (178.6 to 1,433.6)	337.1 (83.6 to 896.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	456.5	267.2
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	524.2 (171.3 to 1,362.3)	310.4 (73.6 to 883.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	418.6	240.2
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.4 (-43.0 to 400.0)	0.1 (-63.5 to 226.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.7	-12.2
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.4 (-51.1 to 222.2)	-21.3 (-67.8 to 98.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.8	-27.9
Larynx cancer	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-36.6 (-44.2 to 42.1)	-44.5 (-63.6 to -6.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.7	(-53.1 to 173.3)
Tracheal, bronchus and lung cancer	0.5 (0.5 to 0.6)	0.7 (0.6 to 0.8)	36.1 (12.3 to 62.0)	-9.6 (-25.3 to 7.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	23.2	-18.1
Breast cancer	3.6 (3.3 to 4.0)	5.8 (5.3 to 6.3)	58.9 (40.0 to 81.5)	1.2 (-11.0 to 15.7)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	43.0	-9.1
Cervical cancer	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-18.6 (-43.0 to 18.7)	-62.7 (-62.7 to -22.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	(-43.6 to 19.1)
Uterine cancer	0.8 (0.5 to 1.0)	0.7 (0.5 to 1.1)	-14.1 (-41.4 to 97.5)	-31.6 (-61.7 to 27.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	45.1	(-63.1 to 21.9)
Prostate cancer	1.5 (1.2 to 1.7)	3.6 (2.8 to 4.6)	144.1 (79.1 to 228.4)	58.5 (18.3 to 113.8)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	107.9	34.0
Colon and rectum cancer	1.7 (1.5 to 1.9)	2.8 (2.4 to 3.2)	64.1 (41.6 to 92.7)	5.8 (-8.7 to 24.4)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	52.7	-1.6
Lip and oral cavity cancer	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	0.6 (-28.6 to 36.9)	-34.7 (-53.6 to -11.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.3	-37.6
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.1 (-68.5 to -5.5)	-66.7 (-79.1 to -40.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.6	-88.1
Other pharynx cancer	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	8.7 (-32.1 to 96.6)	-27.5 (-55.3 to 31.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	(-69.2 to -42.8)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.2 (-60.4 to 61.7)	-64.0 (-75.5 to -2.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.6	-64.5
Pancreatic cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	96.5 (55.0 to 152.5)	25.5 (-0.7 to 59.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.5	12.6
Malignant skin melanoma	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.0)	76.0 (21.7 to 128.7)	14.8 (-20.8 to 49.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	70.8	11.1
Non-melanoma skin cancer	0.3 (0.2 to 0.4)	0.7 (0.5 to 1.0)	159.7 (50.9 to 415.4)	61.5 (-6.1 to 222.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	194.3	80.9
Ovarian cancer	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.4)	34.6 (0.4 to 97.7)	-12.6 (-34.9 to 26.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	29.0	-16.2
Testicular cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-32.3 (-60.4 to 45.0)	-50.9 (-71.4 to 6.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.6	-52.5
Kidney cancer	0.3 (0.2 to 0.3)	0.5 (0.4 to 0.6)	98.1 (53.9 to 150.2)	30.8 (-1.2 to 64.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.7	22.0
Bladder cancer	1.1 (0.9 to 1.2)	1.4 (1.1 to 1.6)	29.0 (4.6 to 56.6)	-16.6 (-31.9 to 2.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	10.6	-28.2
Brain and nervous system cancer	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	32.6 (1.7 to 90.8)	-14.4 (-34.7 to 23.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.2	-16.1
Thyroid cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	-0.6 (-30.3 to 136.4)	-28.5 (-48.6 to 59.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.6	(-36.5 to 21.8)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.4 (-1.9 to 130.1)	11.6 (-38.1 to 47.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.7	13.7
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.4 (54.6 to 26.1)	-49.9 (-67.0 to -9.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.9	-52.6
Non-Hodgkin lymphoma	0.3 (0.3 to 0.6)	0.8 (0.4 to 1.0)	150.7 (1.3 to 236.5)	63.8 (-32.8 to 118.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	134.0	52.8
Multiple myeloma	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	86.9 (15.1 to 201.5)	23.5 (-22.4 to 95.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.8	15.4
Leukemia	0.3 (0.2 to 0.3)	0.5 (0.4 to 0.5)	97.5 (53.0 to 151.5)	21.2 (-5.5 to 52.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	80.7	12.7
Other neoplasms	0.3 (0.3 to 0.4)	1.1 (0.8 to 1.4)	264.0 (141.1 to 376.4)	123.8 (54.7 to 188.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	233.6	108.0
Cardiovascular diseases	-	-	-	-	1.8 (1.2 to 2.4)	2.8 (1.9 to 3.7)	56.6	1.6
Rheumatic heart disease	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	46.8 (34.6 to 59.9)	-1.3 (-9.7 to 7.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.3	-4.4
Ischemic heart disease	8.9 (7.5 to 11.1)	12.7 (10.8 to 14.9)	44.2 (8.1 to 78.3)	-6.6 (-30.6 to 15.5)	0.6 (0.4 to 0.8)	0.7 (0.5 to 1.1)	36.7	-12.8
Cerebrovascular disease	-	-	-	-	0.4 (0.3 to 0.6)	0.7 (0.5 to 0.9)	67.7	6.0
Ischemic stroke	2.5 (2.1 to 2.9)	4.0 (3.4 to 4.6)	62.4 (28.9 to 92.9)	6.7 (-14.5 to 26.4)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.8)	61.2	6.5
Hemorrhagic stroke	0.5 (0.3 to 0.7)	0.7 (0.5 to 1.1)	59.2 (-3.7 to 167.7)	4.9 (-35.0 to 72.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	57.7	4.6
Hypertensive heart disease	0.7 (0.6 to 0.8)	1.3 (1.2 to 1.4)	75.1 (44.2 to 108.6)	10.4 (-8.8 to 31.9)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	74.4	10.8
Cardiomyopathy and myocarditis	0.7 (0.6 to 0.8)	0.9 (0.8 to 1.0)	27.4 (3.6 to 54.3)	-16.2 (-31.6 to 1.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	27.0	-15.8
Atrial fibrillation and flutter	0.0 (0.0 to 0.1)	0.3 (0.2 to 0.6)	961.8 (349.6 to 4,125.4)	511.8 (179.4 to 2,356.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	914.7	493.8
Peripheral vascular disease	14.1 (11.4 to 17.7)	23.1 (17.4 to 29.5)	63.2 (11.4 to 150.8)	3.8 (-30.8 to 60.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.0	-23.9
Endocarditis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	249.8 (151.9 to 368.5)	146.2 (73.3 to 229.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	232.4	131.1
Other cardiovascular and circulatory diseases	8.7 (5.5 to 12.2)	14.8 (9.7 to 18.7)	70.2 (1.8 to 183.4)	10.2 (-33.2 to 82.0)	0.6 (0.3 to 0.9)	1.0 (0.6 to 1.5)	70.0	10.4
Chronic respiratory diseases	-	-	-	-	1.7 (1.1 to 2.4)	2.6 (1.8 to 3.6)	56.3	4.1
Chronic obstructive pulmonary disease	28.1 (22.9 to 33.8)	42.2 (34.7 to 51.4)	50.0 (32.2 to 75.0)	-0.5 (-12.1 to 15.9)	1.2 (0.8 to 1.8)	2.0 (1.3 to 2.8)	63.6	8.1
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.2	-31.8
	-	-	-	-	0.0	0.0	(-3.3 to 10.4)	(-35.9 to -26.8)

Appendix Table G.4 - Luxembourg prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.9 (-1.7 to 10.7)	-31.2 (-35.0 to -26.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.0 (-9.9 to 11.9)	-30.6 (-34.5 to -25.9)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.7 (-7.6 to 7.4)	-34.1 (-38.5 to -28.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.9 (-4.4 to 11.5)	-32.0 (-36.5 to -26.0)
Asthma	10.4 (8.5 to 12.4)	18.6 (11.6 to 17.6)	80.7 (10.1 to 85.4)	88.1 (26.1 to 25.0)	0.6 (0.3 to 0.7)	0.6 (0.4 to 0.9)	-5.1 (8.7 to 84.2)	-5.1 (-26.6 to 25.7)
Interstitial lung disease and pulmonary sarcoidosis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	72.6 (27.4 to 137.3)	15.7 (-14.8 to 57.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.6 (14.8 to 140.8)	15.9 (-15.3 to 58.5)
Other chronic respiratory diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.3 (-6.6 to 85.4)	-11.7 (-37.8 to 21.8)
Cirrhosis	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	20.8 (8.6 to 33.8)	-19.3 (-27.6 to -10.8)
Cirrhosis due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	16.6 (-33.1 to 121.9)	22.4 (55.7 to 49.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.7 (-36.0 to 127.1)	-22.5 (-57.3 to 52.7)
Cirrhosis due to hepatitis C	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	58.9 (1.4 to 121.6)	4.9 (-32.6 to 46.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.9 (0.2 to 130.0)	5.1 (-33.4 to 52.2)
Cirrhosis due to alcohol use	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-26.3 (-50.4 to 15.8)	-51.2 (-67.1 to -22.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.3 (-53.6 to 20.9)	-51.0 (-68.7 to -19.9)
Cirrhosis due to other causes	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	66.4 (1.4 to 301.4)	13.3 (-29.0 to 162.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.9 (-7.0 to 295.2)	13.8 (-35.7 to 157.7)
Digestive diseases	-	-	-	-	0.6 (0.4 to 0.9)	1.0 (0.7 to 1.3)	50.1 (27.5 to 80.1)	1.8 (-13.8 to 22.8)
Peptic ulcer disease	3.4 (3.2 to 3.5)	1.7 (1.5 to 2.0)	-48.2 (-56.3 to -40.5)	-70.4 (-74.6 to -66.3)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-37.0 (-45.4 to -27.6)	-63.3 (-68.4 to -58.1)
Gastritis and duodenitis	0.7 (0.6 to 0.8)	0.5 (0.4 to 0.5)	-31.6 (-40.3 to -20.9)	-54.8 (-60.6 to -48.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.5 (-25.0 to 4.9)	-41.6 (-51.6 to -31.6)
Appendicitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.7 (-11.6 to 18.8)	-23.6 (-34.6 to -10.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.9 (-24.5 to 45.6)	-22.8 (-44.7 to 12.6)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.4 (64.9 to 103.8)	19.4 (3.8 to 40.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.6 (39.7 to 125.2)	19.4 (-4.6 to 49.3)
Inguinal, femoral, and abdominal hernia	2.4 (2.1 to 2.7)	3.4 (3.0 to 3.9)	38.7 (17.4 to 75.2)	-10.0 (-23.4 to 12.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	39.2 (16.8 to 75.3)	9.6 (-23.0 to 12.4)
Inflammatory bowel disease	1.5 (1.2 to 1.7)	2.7 (2.3 to 3.1)	84.7 (43.2 to 142.7)	25.7 (-3.1 to 65.8)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	84.4 (43.0 to 143.0)	25.9 (-2.8 to 66.1)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.2 (-8.3 to 151.0)	0.3 (-38.9 to 58.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.0 (-16.5 to 154.5)	2.4 (-41.5 to 62.3)
Gallbladder and biliary diseases	0.7 (0.6 to 0.8)	0.9 (0.8 to 1.0)	27.6 (3.2 to 59.6)	-13.4 (-30.0 to 7.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	28.1 (2.0 to 63.5)	-12.9 (-30.1 to 10.4)
Pancreatitis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	70.8 (62.0 to 81.0)	0.0 (9.5 to 22.0)	0.0 (0.0 to 0.0)	0.0 (0.1 to 0.2)	71.5 (39.7 to 144.8)	16.0 (-5.8 to 65.7)
Other digestive diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	89.3 (39.7 to 144.8)	28.5 (-5.8 to 65.7)
Neurological disorders	-	-	-	-	5.2 (3.5 to 7.2)	8.4 (5.6 to 11.4)	60.8 (41.5 to 83.2)	10.3 (-2.8 to 25.7)
Alzheimer disease and other dementias	5.6 (4.5 to 7.0)	9.7 (7.6 to 11.6)	71.5 (24.3 to 132.2)	-1.1 (-27.2 to 32.1)	0.8 (0.5 to 1.1)	1.9 (1.0 to 1.9)	76.5 (27.0 to 138.2)	0.2 (-26.9 to 34.8)
Parkinson disease	0.5 (0.3 to 0.6)	0.7 (0.4 to 1.0)	56.3 (39.0 to 67.0)	0.1 (-10.6 to 7.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	56.1 (35.8 to 74.2)	0.5 (-11.5 to 12.4)
Epilepsy	1.1 (0.7 to 1.5)	0.9 (0.5 to 1.5)	-17.9 (-57.6 to 60.5)	-41.9 (-70.1 to 13.2)	0.4 (0.3 to 0.7)	0.4 (0.2 to 0.7)	-9.9 (-54.2 to 78.9)	-36.5 (-67.3 to 25.9)
Multiple sclerosis	0.3 (0.2 to 0.4)	0.7 (0.5 to 0.8)	118.0 (40.6 to 231.9)	47.9 (-4.7 to 127.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.3)	116.5 (40.2 to 235.3)	47.8 (-3.9 to 129.9)
Migraine	82.3 (70.3 to 94.5)	130.4 (118.1 to 143.0)	59.0 (33.4 to 90.6)	14.2 (-4.5 to 36.0)	2.8 (1.7 to 4.2)	4.4 (2.6 to 6.6)	59.3 (33.1 to 91.3)	14.6 (-4.1 to 36.7)
Tension-type headache	118.5 (92.9 to 147.9)	164.8 (157.4 to 172.0)	39.5 (11.2 to 76.5)	1.0 (-19.5 to 27.8)	1.3 (0.1 to 0.4)	0.2 (0.1 to 0.4)	39.6 (11.0 to 76.8)	1.5 (-19.6 to 27.1)
Medication overuse headache	4.0 (2.7 to 5.4)	8.7 (5.8 to 11.5)	117.5 (78.1 to 165.5)	50.1 (24.0 to 82.2)	0.6 (0.4 to 1.0)	1.3 (0.8 to 2.1)	117.7 (77.5 to 165.9)	50.4 (23.5 to 82.8)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.2 (-7.0 to 107.1)	-3.8 (-34.3 to 43.7)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	5.9 (-29.5 to 69.0)	-37.0 (-57.5 to 0.2)
Mental and substance use disorders	-	-	-	-	9.8 (6.9 to 13.1)	13.7 (9.6 to 18.3)	40.3 (36.9 to 44.0)	0.6 (-2.2 to 3.2)
Schizophrenia	1.2 (0.9 to 1.4)	1.6 (1.3 to 2.0)	42.3 (32.7 to 55.4)	-0.8 (-7.2 to 5.5)	0.7 (0.5 to 1.0)	1.0 (0.7 to 1.4)	42.4 (31.2 to 57.8)	-0.7 (-8.5 to 9.4)
Alcohol use disorders	5.6 (5.1 to 6.2)	7.9 (7.3 to 8.7)	41.5 (33.5 to 50.0)	1.5 (-4.6 to 7.6)	0.6 (0.4 to 0.8)	0.8 (0.5 to 1.1)	41.5 (32.1 to 51.0)	1.6 (-5.5 to 8.5)
Drug use disorders	-	-	-	-	1.2 (0.8 to 1.5)	1.5 (1.1 to 2.0)	31.8 (20.2 to 46.1)	-1.5 (-10.7 to 9.4)
Opioid use disorders	2.0 (1.6 to 2.3)	2.6 (2.1 to 3.1)	31.9 (20.1 to 43.6)	-1.7 (-10.9 to 6.5)	0.8 (0.6 to 1.1)	1.1 (0.7 to 1.5)	31.9 (19.4 to 45.3)	-1.8 (-11.4 to 8.2)
Cocaine use disorders	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.8)	44.6 (-1.1 to 104.8)	7.3 (-27.7 to 54.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	44.8 (-3.6 to 110.7)	7.6 (-29.1 to 59.6)
Amphetamine use disorders	0.8 (0.6 to 0.9)	1.1 (0.8 to 1.1)	25.4 (-1.7 to 61.7)	5.6 (-27.1 to 24.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	24.4 (-3.6 to 65.3)	0.1 (-28.2 to 27.0)
Cannabis use disorders	0.8 (0.7 to 0.9)	1.1 (0.9 to 1.2)	31.4 (29.9 to 33.1)	-0.1 (-0.1 to -0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.9 (15.6 to 50.7)	0.2 (-12.5 to 14.3)
Other drug use disorders	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	32.0 (-6.7 to 95.7)	-0.8 (-30.5 to 47.0)
Depressive disorders	-	-	-	-	3.2 (1.6 to 5.1)	4.6 (2.4 to 7.2)	45.7 (35.3 to 52.2)	3.2 (-6.2 to 8.5)
Major depressive disorder	12.6 (5.5 to 18.7)	18.3 (8.4 to 27.3)	47.2 (34.0 to 55.3)	3.9 (-8.0 to 10.0)	2.5 (1.1 to 4.3)	3.7 (1.6 to 6.2)	46.9 (34.0 to 55.3)	4.1 (-7.4 to 10.5)
Dysthymia	6.5 (5.5 to 7.6)	9.2 (7.8 to 10.7)	41.6 (38.6 to 44.7)	-0.4 (-0.7 to -0.1)	0.6 (0.4 to 0.9)	0.9 (0.6 to 1.3)	41.5 (37.0 to 46.1)	-0.2 (-2.7 to 2.1)
Bipolar disorder	3.0 (2.5 to 3.5)	4.1 (3.5 to 4.8)	37.9 (30.2 to 45.2)	-0.7 (-5.8 to 4.8)	0.6 (0.4 to 0.9)	0.8 (0.5 to 1.2)	37.9 (28.3 to 47.0)	-0.4 (-7.1 to 6.5)
Anxiety disorders	20.3 (11.3 to 28.5)	28.2 (15.9 to 40.1)	39.3 (33.0 to 43.5)	-0.5 (-1.1 to -0.1)	1.8 (0.9 to 2.9)	2.6 (1.3 to 4.0)	39.1 (32.2 to 44.6)	-0.3 (-2.6 to 1.9)
Eating disorders	-	-	-	-	0.3 (0.1 to 0.5)	0.4 (0.2 to 0.7)	41.2 (24.0 to 42.9)	0.6 (-1.7 to 12.1)
Anorexia nervosa	0.4 (0.2 to 0.7)	0.5 (0.2 to 1.0)	49.9 (28.5 to 74.8)	15.4 (0.9 to 34.9)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	49.4 (26.0 to 78.4)	15.2 (-2.3 to 36.7)
Bulimia nervosa	1.0 (0.5 to 1.8)	1.3 (0.7 to 2.2)	26.8 (22.5 to 31.8)	0.4 (0.3 to 0.6)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.5)	26.9 (19.4 to 35.8)	0.7 (-5.0 to 5.5)
Autistic spectrum disorders	-	-	-	-	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.8)	41.3 (36.7 to 46.1)	0.8 (-2.6 to 4.2)
Autism	1.1 (1.0 to 1.2)	1.5 (1.5 to 1.6)	41.4 (41.0 to 41.9)	0.6 (0.6 to 0.7)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	41.2 (34.6 to 48.0)	0.6 (-3.7 to 5.8)
Asperger syndrome	1.6 (1.5 to 1.7)	2.2 (2.1 to 2.4)	41.7 (41.2 to 42.2)	0.8 (0.7 to 0.9)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	41.5 (36.0 to 47.1)	0.9 (-3.1 to 4.9)
Attention-deficit/hyperactivity disorder	1.8 (1.5 to 2.1)	2.4 (2.0 to 2.9)	37.9 (37.6 to 38.6)	0.3 (0.3 to 0.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.0 (29.2 to 48.2)	0.3 (-6.3 to 7.6)
Conduct disorder	2.5 (2.1 to 2.9)	3.5 (3.0 to 4.1)	41.9 (40.4 to 42.9)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	42.2 (36.4 to 48.0)	0.4 (-3.5 to 4.5)
Idiopathic intellectual disability	1.8 (1.0 to 2.8)	2.1 (1.1 to 3.3)	15.3 (-40.7 to 120.5)	-18.8 (-57.8 to 55.8)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	15.4 (-41.9 to 122.7)	-18.5 (-58.6 to 55.3)
Other mental and substance use disorders	7.5 (7.1 to 7.9)	10.7 (10.1 to 11.3)	42.4 (40.9 to 44.1)	0.5 (0.2 to 0.8)	0.6 (0.4 to 0.7)	0.8 (0.5 to 1.1)	42.2 (36.9 to 47.4)	0.7 (-3.0 to 4.2)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	4.6 (3.2 to 6.1)	7.6 (5.5 to 10.2)	66.5 (49.9 to 86.3)	11.3 (0.7 to 24.0)
Diabetes mellitus	22.8 (18.1 to 28.7)	45.1 (34.9 to 56.9)	97.1 (47.5 to 170.0)	31.9 (0.1 to 79.6)	1.6 (1.0 to 2.4)	3.2 (2.0 to 4.6)	95.3 (48.2 to 160.4)	30.3 (-0.2 to 73.3)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.6 (25.9 to 60.3)	-14.1 (-22.0 to -1.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.6 (25.9 to 60.5)	-14.1 (-22.0 to -1.8)
Chronic kidney disease	-	-	-	-	1.6 (1.1 to 2.1)	2.4 (1.6 to 3.2)	48.7 (42.3 to 55.5)	-0.0 (-4.3 to 4.1)
Chronic kidney disease due to diabetes mellitus	4.4 (2.8 to 6.5)	7.9 (5.2 to 11.9)	81.2 (30.6 to 174.0)	19.9 (-12.2 to 81.0)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	82.8 (24.6 to 146.0)	21.1 (-17.1 to 61.6)
Chronic kidney disease due to hypertension	4.2 (3.2 to 5.5)	5.7 (3.4 to 7.9)	33.6 (-4.0 to 88.6)	-10.7 (-33.9 to 26.4)	0.5 (0.3 to 0.7)	0.2 (0.1 to 0.4)	-47.2 (-61.2 to -29.9)	-64.0 (-73.0 to -52.7)
Chronic kidney disease due to glomerulonephritis	6.6 (3.9 to 9.9)	5.2 (3.8 to 7.0)	-19.5 (-40.8 to 9.6)	-44.6 (-58.2 to -27.5)	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.7)	175.1 (87.0 to 327.9)	75.0 (19.1 to 162.7)
Chronic kidney disease due to other causes	14.2 (9.9 to 19.5)	23.7 (16.9 to 32.8)	66.3 (37.4 to 98.8)	11.1 (-6.3 to 30.7)	0.7 (0.5 to 1.0)	1.2 (0.8 to 1.7)	70.5 (34.0 to 110.5)	13.8 (-9.3 to 39.4)
Urinary diseases and male infertility	-	-	-	-	0.5 (0.3 to 0.7)	0.9 (0.6 to 1.2)	69.5 (47.4 to 97.6)	13.5 (-1.3 to 33.7)
Interstitial nephritis and urinary tract infections	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	94.7 (79.1 to 112.1)	38.3 (26.5 to 51.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.1 (54.4 to 143.4)	38.3 (9.8 to 73.1)

Appendix Table G.4 - Luxembourg prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Urolithiasis	5.6 (3.8 to 7.6)	11.7 (8.4 to 17.1)	111.9 (74.2 to 150.7)	21.8 (14.3 to 64.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	115.6 (79.7 to 151.4)	39.7 (19.4 to 65.3)
Benign prostatic hyperplasia	10.7 (10.0 to 11.4)	19.2 (18.1 to 20.5)	80.3 (62.6 to 94.9)	21.1 (9.4 to 31.2)	0.4 (0.2 to 0.5)	0.7 (0.4 to 0.9)	80.0 (62.0 to 94.9)	21.6 (9.7 to 31.4)
Male infertility due to other causes	2.0 (1.4 to 2.6)	2.4 (1.7 to 3.3)	26.1 (-26.4 to 97.2)	-3.0 (-43.6 to 54.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.8 (-27.7 to 101.6)	-3.5 (-44.0 to 56.2)
Other urinary diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-23.0 (-56.7 to 242.5)	-49.3 (-71.3 to 124.5)
Gynecological diseases	-	-	-	-	0.5 (0.3 to 0.7)	0.7 (0.4 to 1.1)	46.5 (25.6 to 76.3)	1.1 (-13.5 to 21.9)
Uterine fibroids	15.4 (13.1 to 17.9)	24.4 (20.9 to 28.3)	58.1 (56.5 to 59.7)	1.0 (0.9 to 1.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	51.9 (34.6 to 85.3)	-2.2 (-13.2 to 21.2)
Polycystic ovarian syndrome	6.8 (5.8 to 7.8)	9.7 (8.3 to 11.1)	43.7 (17.6 to 77.1)	1.4 (-17.6 to 25.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	43.8 (16.7 to 77.4)	2.0 (-18.0 to 25.7)
Female infertility due to other causes	0.3 (0.0 to 1.0)	0.5 (0.0 to 1.5)	69.3 (-86.4 to 1,639.7)	29.9 (-89.7 to 1,279.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.2 (-87.4 to 1,689.6)	18.6 (-90.5 to 1,291.7)
Endometriosis	1.1 (0.8 to 1.4)	1.6 (1.1 to 2.0)	38.5 (-3.8 to 111.8)	-1.4 (-31.6 to 47.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	38.8 (-4.7 to 110.3)	-1.1 (-31.4 to 48.6)
Genital prolapse	25.5 (22.9 to 28.1)	35.6 (32.0 to 39.3)	39.3 (19.4 to 63.6)	-3.9 (-18.1 to 12.8)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	39.4 (17.6 to 63.8)	-3.8 (-19.1 to 13.4)
Premenstrual syndrome	10.2 (7.1 to 13.3)	14.7 (10.4 to 19.3)	44.4 (-12.5 to 128.9)	6.2 (-33.6 to 69.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	43.9 (-13.5 to 130.4)	5.9 (-34.8 to 70.6)
Other gynecological diseases	0.9 (0.7 to 1.6)	1.5 (1.1 to 3.3)	49.0 (-13.5 to 342.8)	6.1 (-36.8 to 185.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	62.3 (-50.0 to 911.7)	13.1 (-64.6 to 524.0)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	34.3 (22.4 to 56.2)	-7.6 (-14.6 to 5.0)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.9 (13.5 to 40.3)	-3.8 (-13.4 to 6.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.5 (9.5 to 35.3)	1.8 (-34.3 to 34.9)
Thalassemia trait	5.7 (5.1 to 6.4)	8.1 (7.1 to 9.4)	40.1 (31.5 to 55.3)	-1.1 (-6.7 to 7.5)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.4)	43.5 (26.7 to 68.6)	-1.6 (-11.1 to 12.4)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.8 (-10.6 to 46.1)	-10.6 (-35.5 to 10.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.5 (6.8 to 45.0)	-7.4 (-22.3 to 9.0)
Sickle cell trait	3.9 (3.6 to 4.3)	3.9 (3.0 to 4.2)	-0.9 (-7.3 to 4.7)	-29.8 (-34.3 to -26.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-13.1 (-31.0 to 11.1)	-39.4 (-52.4 to -22.7)
G6PD deficiency	5.8 (2.3 to 5.2)	6.6 (4.6 to 8.8)	75.2 (2.5 to 204.2)	23.9 (-27.7 to 116.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.7 (8.8 to 111.9)	15.2 (-22.6 to 59.9)
G6PD trait	51.3 (46.4 to 55.9)	69.6 (61.4 to 77.0)	36.3 (18.1 to 57.4)	-3.4 (-16.3 to 11.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.0 (-38.2 to 163.6)	-4.6 (-55.5 to 87.5)
Other hemoglobinopathies and hemolytic anemias	2.3 (2.1 to 2.5)	3.5 (3.2 to 4.2)	51.4 (33.8 to 81.4)	4.4 (-8.4 to 28.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	40.2 (3.0 to 112.9)	0.2 (-22.7 to 57.6)
Endocrine, metabolic, blood, and immune disorders	3.5 (3.3 to 4.3)	5.7 (5.3 to 6.9)	61.4 (39.0 to 95.2)	10.6 (-9.0 to 43.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	64.0 (28.1 to 129.7)	13.6 (-17.6 to 78.3)
Musculoskeletal disorders	-	-	-	-	11.3 (8.1 to 15.0)	16.7 (11.7 to 22.1)	46.1 (29.4 to 70.2)	-0.2 (-11.0 to 17.1)
Rheumatoid arthritis	0.4 (0.3 to 0.4)	0.8 (0.7 to 0.9)	112.3 (77.8 to 159.1)	41.6 (20.3 to 69.9)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	111.9 (74.5 to 160.6)	41.9 (18.3 to 72.5)
Osteoarthritis	21.5 (18.1 to 24.6)	31.8 (25.2 to 36.7)	49.9 (13.0 to 79.1)	-3.7 (-27.6 to 15.2)	0.7 (0.5 to 1.1)	1.1 (0.7 to 1.6)	49.7 (12.5 to 79.0)	-3.5 (-27.8 to 15.7)
Low back and neck pain	-	-	-	-	9.1 (6.4 to 12.3)	13.1 (9.1 to 17.9)	42.5 (21.9 to 72.3)	-2.1 (-17.1 to 19.2)
Low back pain	55.1 (46.7 to 62.4)	80.3 (69.3 to 92.1)	45.7 (22.5 to 81.2)	0.2 (-16.9 to 24.8)	6.0 (4.1 to 8.5)	8.8 (5.8 to 12.4)	45.3 (22.6 to 80.7)	0.5 (-16.9 to 25.9)
Neck pain	31.5 (27.0 to 36.3)	44.4 (35.1 to 54.3)	40.3 (7.7 to 81.3)	-3.8 (-26.4 to 24.1)	3.1 (2.0 to 4.3)	4.3 (2.8 to 6.3)	40.1 (6.8 to 80.2)	-3.4 (-26.4 to 23.9)
Gout	0.8 (0.7 to 0.9)	1.3 (1.1 to 1.4)	57.8 (33.3 to 87.4)	4.0 (-12.4 to 23.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	57.1 (26.1 to 96.2)	4.1 (-17.0 to 30.0)
Other musculoskeletal disorders	14.7 (11.9 to 17.6)	24.5 (19.3 to 29.6)	66.4 (52.9 to 78.6)	13.6 (4.9 to 21.3)	1.3 (0.9 to 1.9)	2.2 (1.5 to 3.2)	66.8 (52.5 to 79.1)	14.0 (4.9 to 21.7)
Other non-communicable diseases	-	-	-	-	7.7 (5.2 to 10.9)	11.0 (7.6 to 15.4)	44.3 (37.3 to 52.7)	-1.1 (-6.7 to 5.4)
Congenital anomalies	-	-	-	-	0.7 (0.5 to 1.0)	1.4 (0.9 to 2.1)	91.9 (53.7 to 140.9)	37.0 (9.8 to 73.9)
Neural tube defects	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	41.9 (11.2 to 82.7)	-0.2 (-22.0 to 28.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	43.6 (3.0 to 101.5)	1.1 (-27.5 to 42.5)
Congenital heart anomalies	3.2 (2.6 to 4.0)	3.3 (2.6 to 4.0)	6.4 (-22.4 to 40.6)	-24.4 (-44.9 to -0.2)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	9.4 (-18.6 to 40.3)	-21.8 (-41.5 to 0.0)
Crofacial clefts	0.6 (0.5 to 0.8)	0.7 (0.5 to 1.0)	20.6 (-31.6 to 72.1)	-15.2 (-51.9 to 21.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.0 (-36.9 to 69.7)	-21.0 (-55.7 to 20.7)
Down syndrome	0.5 (0.4 to 0.7)	0.8 (0.6 to 1.1)	55.1 (7.8 to 112.0)	8.3 (-25.1 to 48.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	59.4 (10.0 to 119.9)	9.8 (-24.5 to 50.8)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.4 (-5.7 to 122.5)	0.1 (-33.1 to 57.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.6 (-11.8 to 122.3)	0.4 (-37.2 to 58.6)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.3 (21.8 to 147.1)	21.8 (-14.0 to 74.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.8 (5.3 to 163.9)	20.4 (-23.5 to 87.7)
Chromosomal unbalanced rearrangements	1.0 (0.8 to 1.4)	1.5 (1.2 to 2.0)	48.4 (3.3 to 109.8)	3.4 (-28.1 to 45.9)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	51.8 (5.9 to 116.3)	4.7 (-27.6 to 49.2)
Other congenital anomalies	1.2 (0.8 to 1.6)	1.4 (0.9 to 2.1)	19.0 (-5.5 to 60.0)	-17.1 (-33.9 to 12.1)	0.4 (0.2 to 0.6)	0.9 (0.5 to 1.4)	143.2 (79.3 to 241.8)	74.8 (28.7 to 145.1)
Skin and subcutaneous diseases	-	-	-	-	2.7 (1.8 to 4.1)	3.7 (2.4 to 5.5)	37.3 (25.5 to 49.6)	-2.0 (-11.7 to 7.8)
Dermatitis	28.1 (20.8 to 34.9)	39.4 (29.4 to 48.8)	40.2 (37.6 to 42.3)	-0.1 (-0.3 to -0.1)	0.9 (0.5 to 1.3)	1.2 (0.7 to 1.8)	39.2 (35.4 to 43.1)	0.1 (-2.5 to 2.3)
Psoriasis	5.8 (5.0 to 6.7)	8.3 (7.1 to 9.6)	43.0 (40.7 to 45.2)	0.1 (-0.2 to 0.3)	0.5 (0.3 to 0.6)	0.7 (0.4 to 0.9)	42.9 (37.0 to 49.2)	0.3 (-3.7 to 4.4)
Cellulitis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	39.5 (28.4 to 52.0)	0.0 (-11.0 to 4.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.6 (13.9 to 71.2)	0.5 (-20.1 to 17.4)
Pyoderma	0.5 (0.4 to 0.5)	0.6 (0.5 to 0.8)	39.9 (31.8 to 49.1)	-5.4 (-11.3 to 1.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.4 (27.0 to 51.7)	-5.8 (-14.2 to 3.5)
Scabies	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.3)	7.7 (-11.9 to 46.7)	-21.5 (-35.2 to 5.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.2 (-14.2 to 47.3)	-21.5 (-36.9 to 6.2)
Fungal skin diseases	28.5 (25.2 to 31.4)	41.3 (36.7 to 45.3)	45.0 (44.0 to 46.1)	0.4 (0.2 to 0.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.5)	44.9 (43.3 to 46.8)	0.6 (-0.5 to 1.6)
Viral skin diseases	7.6 (5.8 to 9.4)	10.5 (8.3 to 12.8)	38.9 (34.0 to 45.2)	0.4 (-1.9 to 2.7)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	38.8 (31.1 to 46.0)	0.5 (-2.9 to 3.8)
Acne vulgaris	51.3 (36.4 to 67.4)	61.4 (46.4 to 78.7)	17.5 (-19.8 to 100.0)	-10.2 (-39.3 to 54.5)	0.6 (0.2 to 1.1)	0.7 (0.3 to 1.2)	17.6 (-20.0 to 99.7)	-10.3 (-39.4 to 55.2)
Alopecia areata	0.7 (0.6 to 0.7)	1.0 (0.9 to 1.1)	46.7 (31.0 to 65.3)	-0.1 (-10.5 to 11.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.5 (28.4 to 69.3)	0.3 (-12.5 to 14.6)
Pruritus	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	59.2 (9.5 to 156.1)	7.7 (-36.8 to 74.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.8 (-12.7 to 166.2)	6.4 (-40.4 to 77.8)
Urticaria	3.4 (2.2 to 4.6)	4.8 (3.4 to 6.6)	44.4 (9.9 to 138.3)	1.6 (-38.1 to 58.8)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	44.4 (-10.6 to 137.3)	-1.4 (-39.2 to 59.7)
Decubitus ulcer	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	50.0 (7.0 to 140.9)	-4.8 (-39.0 to 48.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	50.4 (8.4 to 138.8)	-3.8 (-39.2 to 48.1)
Other skin and subcutaneous diseases	32.2 (18.8 to 55.4)	47.5 (27.7 to 80.6)	47.6 (41.4 to 54.7)	0.6 (-2.6 to 4.3)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.6)	47.5 (40.8 to 55.0)	0.7 (-2.6 to 4.6)
Sense organ diseases	-	-	-	-	2.9 (1.9 to 4.1)	4.1 (2.8 to 6.0)	44.4 (35.5 to 55.1)	-7.1 (-13.3 to -1.4)
Glaucoma	0.5 (0.4 to 0.7)	0.6 (0.4 to 0.8)	14.3 (5.6 to 42.6)	-37.9 (-40.3 to -10.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	10.9 (-8.7 to 41.6)	-8.8 (-42.0 to -10.1)
Cataract	1.2 (0.8 to 1.8)	1.5 (0.9 to 2.4)	26.5 (-8.3 to 75.3)	-25.9 (-47.2 to 2.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	31.8 (-3.5 to 68.4)	-22.8 (-44.2 to -2.0)
Macular degeneration	1.8 (1.3 to 2.5)	2.6 (1.8 to 3.6)	46.3 (12.8 to 91.3)	-10.3 (-28.7 to 15.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	46.4 (20.8 to 81.6)	-12.8 (-26.5 to 7.2)
Uncorrected refractive error	43.8 (35.9 to 52.1)	61.9 (52.1 to 74.9)	41.2 (9.3 to 85.6)	-7.0 (-28.3 to 22.9)	0.6 (0.3 to 1.0)	0.8 (0.5 to 1.4)	35.3 (12.2 to 67.3)	-10.3 (-26.4 to 10.3)
Age-related and other hearing loss	60.9 (52.2 to 69.2)	85.7 (73.4 to 98.7)	40.7 (34.0 to 47.3)	-8.0 (-12.9 to -3.5)	1.7 (1.1 to 2.5)	2.6 (1.7 to 3.8)	50.8 (38.3 to 62.6)	-4.6 (-13.2 to 4.2)
Other vision loss	1.3 (1.0 to 1.7)	1.3 (1.0 to 1.7)	2.9 (-18.1 to 13.3)	-36.7 (-45.9 to -27.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-27.4 (-6.1 to 24.8)	-27.4 (-37.8 to -16.9)
Other sense organ diseases	9.0 (8.6 to 9.4)	12.8 (12.3 to 13.5)	42.1 (33.8 to 52.5)	-0.8 (-6.5 to 6.4)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	41.8 (32.8 to 53.4)	-0.6 (-7.0 to 7.3)
Oral disorders	-	-	-	-	1.3 (0.8 to 2.0)	1.8 (1.1 to 2.7)	31.2 (20.2 to 43.2)	-10.6 (-17.8 to -2.8)
Deciduous caries	12.6 (1.8 to 13.4)	17.4 (16.0 to 18.6)	37.6 (23.6 to 52.8)	-0.8 (-10.9 to 10.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.5 (21.0 to 57.3)	-0.9 (-12.8 to 13.4)
Permanent caries	188.7 (135.6 to 164.5)	307.4 (183.6 to 232.1)	40.3 (17.4 to 65.0)	40.3 (-16.6 to 17.7)	0.6 (0.0 to 0.2)	0.1 (0.1 to 0.2)	40.2 (17.2 to 65.0)	-0.1 (-16.9 to 17.4)
Periodontal diseases	38.8 (33.1 to 44.0)	58.9 (51.5 to 67.3)	51.5 (28.5 to 80.0)	2.1 (-13.2 to 20.9)	0.3 (0.1 to 0.5)	0.4 (0.2 to 0.8)	51.7 (28.6 to 80.2)	2.2 (-13.0 to 20.9)
Edentulism and severe tooth loss	28.7 (26.0 to 31.2)	34.8 (31.3 to 38.4)	21.0 (6.1 to 41.4)	-20.2 (-30.1 to -6.7)	0.8 (0.5 to 1.1)	0.9 (0.6 to 1.3)	20.5 (5.1 to 41.3)	-0.1 (-30.5 to 6.2)

Appendix Table G.4 - Luxembourg prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	7.4 (7.0 to 7.8)	10.5 (9.9 to 11.0)	41.7 (30.7 to 52.6)	-4.2 (-7.8 to 7.7)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	41.5 (30.8 to 52.9)	-0.1 (-7.6 to 7.6)
Injuries	-	-	-	-	4.5 (3.4 to 5.7)	4.6 (3.3 to 6.0)	1.3 (-8.6 to 12.9)	-34.2 (-40.4 to -27.1)
Transport injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.5 (0.4 to 0.7)	-8.0 (-16.7 to 2.2)	-38.9 (-44.9 to -32.1)
Road injuries	-	-	-	-	0.5 (0.4 to 0.6)	0.4 (0.3 to 0.6)	-12.9 (-21.5 to -2.9)	-42.1 (-48.0 to -35.3)
Pedestrian road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-26.4 (-35.4 to -16.6)	-52.1 (-58.0 to -45.6)
Cyclist road injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-59.0 (-64.2 to -52.6)	-72.7 (-76.2 to -68.3)
Motorcyclist road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-35.2 (-46.7 to -24.1)	-57.0 (-64.9 to -49.5)
Motor vehicle road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	13.5 (2.5 to 26.2)	-24.3 (-31.7 to -15.5)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-66.0 (-70.2 to -61.2)	-77.1 (-80.1 to -73.8)
Other transport injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	34.5 (22.9 to 48.6)	-10.4 (-18.0 to -1.1)
Unintentional injuries	-	-	-	-	3.9 (3.0 to 5.0)	4.0 (2.9 to 5.3)	2.9 (-7.7 to 15.0)	-33.4 (-39.9 to -26.1)
Falls	-	-	-	-	2.7 (2.1 to 3.5)	3.1 (2.3 to 4.2)	13.3 (-0.5 to 29.8)	-26.9 (-35.5 to -16.9)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.4 (-34.0 to -13.6)	-49.7 (-56.3 to -42.5)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-16.0 (-27.0 to -3.9)	-47.8 (-55.1 to -40.1)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.7 (-45.9 to -20.1)	-55.8 (-63.8 to -45.5)
Exposure to mechanical forces	-	-	-	-	0.7 (0.5 to 0.9)	0.5 (0.3 to 0.6)	-32.1 (-38.9 to -23.3)	-53.6 (-58.3 to -47.4)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.9 (-2.1 to 29.0)	-21.6 (-32.1 to -10.5)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.3 (-28.6 to -5.2)	-44.8 (-52.6 to -36.1)
Other exposure to mechanical forces	-	-	-	-	0.7 (0.5 to 0.9)	0.5 (0.3 to 0.6)	-32.4 (-39.3 to -23.5)	-53.8 (-58.5 to -47.5)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.6 (36.9 to 64.1)	2.3 (-7.2 to 10.5)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.4 (21.4 to 44.6)	-10.6 (-18.5 to -2.0)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.1 (8.4 to 49.5)	-11.4 (-24.9 to 4.8)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.4 (20.7 to 46.7)	-10.3 (-19.1 to -1.0)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.5 (3.9 to 31.3)	-18.3 (-28.6 to -8.5)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.7 (5.8 to 36.9)	-24.2 (-33.6 to -12.3)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.0 (9.6 to 41.7)	-11.3 (-22.8 to 1.5)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.2 (2.0 to 33.9)	-18.9 (-31.5 to -6.1)
Other unintentional injuries	-	-	-	-	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-14.9 (-25.3 to -1.5)	-43.8 (-50.7 to -34.8)
Self-harm and interpersonal violence	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-9.1 (-16.9 to 0.2)	-39.1 (-44.3 to -32.8)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.9 (-4.8 to 19.3)	-28.4 (-36.2 to -19.5)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.8 (-30.2 to -14.3)	-47.8 (-52.8 to -42.1)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.3 (-33.0 to -19.7)	-50.7 (-55.2 to -46.4)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.3 (-0.9 to 18.5)	-27.8 (-33.6 to -20.3)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.5 (-33.2 to -16.2)	-49.4 (-54.8 to -43.1)
Forces of nature, war, and legal intervention	-	-	-	-	-	-	-	-
Exposure to forces of nature	-	-	-	-	-	-	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Macedonia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	208.7 (155.3 to 270.9)	247.8 (185.6 to 320.3)	18.6 (15.4 to 22.0)	8.9 (5.8 to 0.8)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	17.3 (12.1 to 24.2)	15.1 (10.5 to 20.6)	-13.0 (-21.7 to -1.6)	-2.9 (-12.1 to 8.9)
HIV/AIDS and tuberculosis	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	0.0 (-2.1 to 24.6)	-8.9 (-18.7 to 2.4)
Tuberculosis	0.9 (0.8 to 0.9)	0.9 (0.9 to 1.0)	9.5 (4.5 to 14.6)	-10.6 (-14.4 to -6.7)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	0.0 (-3.8 to 22.9)	0.0 (-20.0 to 1.0)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (38.6 to 1,040.0)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	362.9 (16.3 to 935.6)	275.1 (5.3 to 759.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (65.3 to 943.1)	0.0 (5.5 to 760.0)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	537.8 (89.0 to 1,193.1)	451.8 (60.6 to 1,030.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	513.3 (64.3 to 1,258.6)	418.9 (38.0 to 1,069.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	1.9 (1.4 to 2.6)	1.6 (1.1 to 2.2)	-18.6 (-24.2 to -13.1)	-1.4 (-17.4 to -4.7)
Diarrheal diseases	5.9 (5.4 to 6.4)	4.8 (4.5 to 5.1)	-18.2 (-26.7 to -9.3)	-7.3 (-16.9 to 4.0)	0.9 (0.6 to 1.3)	0.8 (0.5 to 1.1)	-13.3 (-17.8 to -8.6)	-2.2 (-17.3 to 4.8)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (52.2 to 16.0)	0.0 (-48.8 to 22.1)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.4 (-41.3 to 7.6)	-14.9 (-37.1 to 12.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.4 (-41.3 to 7.8)	-14.9 (-37.3 to 12.4)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.1 (-39.3 to 7.3)	-12.4 (-34.1 to 14.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.1 (-39.3 to 7.4)	-12.4 (-34.2 to 14.4)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.1 (-98.7 to 3,817.3)	-41.0 (-98.7 to 3,885.4)
Lower respiratory infections	0.8 (0.7 to 0.9)	0.5 (0.4 to 0.6)	-39.1 (-52.1 to -18.9)	-30.6 (-45.7 to -3.1)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-39.6 (-54.4 to -17.0)	-29.7 (-48.1 to 1.1)
Upper respiratory infections	20.1 (19.3 to 21.0)	19.9 (19.0 to 20.8)	-1.2 (-7.7 to 4.4)	-1.0 (-7.7 to 4.4)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.4)	-1.6 (-9.0 to 5.7)	-0.7 (-8.3 to 6.5)
Otitis media	22.0 (20.3 to 23.6)	20.0 (18.4 to 21.3)	-9.1 (-16.7 to -1.3)	-6.4 (-14.0 to 0.6)	0.4 (0.3 to 0.7)	0.4 (0.2 to 0.6)	-12.2 (-19.9 to -3.7)	-8.3 (-16.1 to -0.1)
Meningitis	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-58.5 (-65.9 to -47.0)	-58.1 (-65.9 to -46.2)
Pneumococcal meningitis	0.6 (0.3 to 0.9)	0.2 (0.1 to 0.4)	-57.1 (-72.8 to -40.7)	-61.0 (-75.4 to -46.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-58.1 (-72.9 to -40.9)	-59.5 (-73.9 to -42.5)
H influenzae type B meningitis	0.2 (0.1 to 0.5)	0.1 (0.0 to 0.2)	-60.3 (-75.8 to -32.6)	-61.7 (-75.5 to -30.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-58.0 (-79.9 to -18.4)	-56.0 (-78.9 to -13.2)
Meningococcal meningitis	0.2 (0.0 to 0.4)	0.1 (0.0 to 0.1)	-62.5 (-79.8 to -11.6)	-64.2 (-79.8 to -6.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.0 (-80.0 to 30.1)	-56.4 (-80.2 to 33.7)
Other meningitis	0.3 (0.1 to 0.6)	0.1 (0.0 to 0.2)	-58.5 (-70.5 to -43.8)	-60.0 (-71.3 to -44.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-58.2 (-75.5 to -31.5)	-57.9 (-75.0 to -30.0)
Encephalitis	0.2 (0.1 to 0.6)	0.3 (0.1 to 0.6)	13.0 (-6.3 to 32.8)	9.0 (-19.4 to 17.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.9 (-9.9 to 42.0)	2.2 (-20.6 to 25.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.2 (-96.0 to 169.5)	-65.8 (-95.8 to 160.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-66.2 (-96.0 to 171.6)	-65.8 (-95.8 to 162.3)
Whooping cough	0.7 (0.5 to 0.9)	0.3 (0.2 to 0.4)	-57.0 (-58.0 to -56.0)	-33.5 (-35.0 to -31.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-57.1 (-62.5 to -50.2)	-33.6 (-41.9 to -22.9)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-72.2 (-82.7 to -56.0)	-73.7 (-83.9 to -58.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.9 (-79.4 to -56.1)	-69.4 (-80.9 to -57.8)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-97.9 (-100.0 to -95.7)	-96.7 (-99.9 to -93.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-97.9 (-100.0 to -95.7)	-96.7 (-99.9 to -93.4)
Varicella and herpes zoster	1.2 (1.1 to 1.2)	1.0 (0.9 to 1.1)	-10.6 (-20.9 to -0.3)	-3.6 (-12.2 to 6.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	14.4 (-12.5 to 46.1)	-3.1 (-24.1 to 22.4)
Neglected tropical diseases and malaria	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-49.2 (-69.9 to -9.5)	-57.7 (-74.3 to -26.9)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.7 (-62.1 to 213.7)	11.3 (-59.9 to 232.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.0 (-61.2 to 218.4)	14.0 (-59.0 to 236.1)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.4 (-53.0 to 38.7)	-18.8 (-51.8 to 52.1)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.1 (-52.9 to 40.2)	-19.4 (-52.5 to 55.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.1 (-53.5 to 40.3)	-19.4 (-52.5 to 55.4)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.5 (-58.3 to 87.0)	2.2 (-56.7 to 81.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.5 (-58.4 to 87.3)	2.2 (-57.1 to 81.6)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-50.5 (-82.9 to 45.0)	-60.8 (-85.9 to 13.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-46.2 (-83.4 to 70.2)	-56.6 (-85.9 to 36.1)
Cystic echinococcosis	0.4 (0.3 to 0.4)	0.2 (0.2 to 0.2)	-52.4 (-58.2 to -49.2)	-59.9 (-65.3 to -57.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-53.5 (-64.5 to -41.9)	-60.6 (-69.7 to -51.5)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.9 (-54.4 to -5.4)	-25.4 (-57.7 to -7.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.0 (-54.4 to -5.4)	25.4 (-57.8 to -7.9)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Ascariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trichuriasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hookworm disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.4 (-69.8 to -27.3)	-50.4 (-68.7 to -19.3)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-44.0 (-57.4 to -23.6)	-44.7 (-57.8 to -24.7)
Maternal hemorrhage	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-15.2 (-41.7 to 13.7)	-16.9 (-42.8 to 11.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.0 (-82.0 to 32.6)	-41.8 (-82.1 to 29.3)
Maternal sepsis and other maternal infections	0.5 (0.3 to 0.8)	0.2 (0.1 to 0.3)	-60.9 (-75.5 to -40.6)	-63.1 (-76.9 to -44.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.2 (-78.4 to -38.1)	-63.9 (-78.2 to -39.5)
Maternal hypertensive disorders	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-39.1 (-47.7 to -23.2)	-39.7 (-48.1 to -24.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.7 (-54.7 to -13.8)	-39.5 (-54.9 to -15.1)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.6 (-70.9 to 130.9)	-32.2 (-71.1 to 128.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.6 (-70.9 to 131.6)	-32.2 (-71.2 to 129.7)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.3 (-61.9 to 47.0)	-33.1 (-62.3 to 45.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.8 (-66.7 to 88.4)	-28.4 (-67.2 to 88.8)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.8 (-64.2 to 6.4)	-40.8 (-64.8 to 5.1)
Neonatal disorders	-	-	-	-	4.2 (2.9 to 6.0)	4.2 (2.8 to 6.0)	-2.2 (-32.5 to 51.0)	0.1 (-30.9 to 54.1)
Preterm birth complications	11.3 (7.3 to 17.9)	15.3 (9.6 to 23.4)	35.0 (5.8 to 70.2)	33.0 (5.1 to 68.4)	1.5 (1.0 to 2.3)	2.0 (1.3 to 3.0)	33.6 (7.3 to 97.8)	35.5 (6.0 to 101.2)
Neonatal encephalopathy due to birth asphyxia and trauma	4.4 (2.3 to 9.2)	1.9 (1.0 to 3.8)	-56.0 (-76.8 to -18.7)	-54.9 (-76.3 to -15.9)	1.0 (0.6 to 1.6)	0.5 (0.3 to 0.8)	-50.3 (-74.0 to -20.9)	-47.5 (-72.5 to 2.2)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.1 (66.2 to 115.2)	92.1 (160.6 to 237.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.0 (65.2 to 37.0)	92.1 (57.7 to 481.6)
Hemolytic disease and other neonatal jaundice	1.6 (1.0 to 2.5)	2.0 (1.0 to 3.1)	22.9 (-34.1 to 155.8)	24.3 (-32.8 to 159.8)	0.6 (0.3 to 1.1)	0.7 (0.4 to 1.2)	25.2 (-33.8 to 162.6)	27.5 (-32.4 to 167.8)
Other neonatal disorders	-	-	-	-	1.1 (0.5 to 1.9)	0.9 (0.5 to 2.0)	-28.7 (-62.8 to 179.9)	-27.1 (-61.9 to 184.8)
Nutritional deficiencies	-	-	-	-	9.9 (6.6 to 14.5)	8.2 (5.4 to 11.9)	-17.4 (-21.3 to -13.1)	-2.2 (-6.3 to 2.5)
Protein-energy malnutrition	1.3 (0.9 to 1.7)	1.0 (0.7 to 1.4)	-20.7 (-50.4 to 26.3)	24.5 (-22.1 to 98.2)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-20.6 (-49.3 to 27.6)	24.7 (-20.3 to 100.2)
Iodine deficiency	19.7 (8.0 to 34.6)	11.2 (3.4 to 21.5)	-46.4 (-83.5 to 108.6)	-51.2 (-84.5 to 88.5)	0.4 (0.1 to 0.7)	0.2 (0.1 to 0.4)	-46.5 (-83.9 to 109.7)	-50.9 (-84.7 to 91.9)
Vitamin A deficiency	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-

Appendix Table G.4 - Macedonia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	332.1 (328.6 to 336.0)	309.9 (305.1 to 314.9)	-6.7 (-8.5 to -4.7)	-1.4 (-3.3 to 0.6)	9.4 (6.2 to 13.6)	7.8 (5.1 to 11.4)	-16.8 (-19.6 to -13.9)	-1.9 (-4.6 to 0.8)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	115.4 (31.2 to 436.4)	238.5 (8.2 to 742.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.9 (0.5 to 1.3)	0.8 (0.5 to 1.3)	-11.1 (-25.2 to 4.0)	-2.1 (20.0 to 15.6)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.3 (0.2 to 0.6)	0.4 (0.2 to 0.7)	4.4 (-7.8 to 17.6)	-4.3 (-15.2 to 7.9)
Syphilis	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	21.1 (2.5 to 43.1)	-12.8 (-25.4 to 2.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.4 (-9.6 to 62.4)	-11.1 (33.8 to 19.8)
Chlamydial infection	49.8 (44.0 to 55.9)	49.9 (44.4 to 55.5)	0.4 (-16.2 to 21.0)	-2.6 (-18.6 to 18.0)	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.3)	1.3 (-16.4 to 19.9)	-1.6 (-19.0 to 17.0)
Gonococcal infection	11.8 (9.6 to 14.4)	10.5 (8.4 to 12.6)	-11.6 (-32.4 to 18.0)	-10.5 (-31.5 to 19.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-14.7 (-34.7 to 19.8)	-13.5 (-34.2 to 21.1)
Trichomoniasis	23.7 (17.4 to 32.1)	26.6 (21.3 to 33.3)	12.6 (-22.2 to 69.4)	6.3 (-26.9 to 61.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	13.0 (-27.6 to 88.1)	6.7 (-30.8 to 79.0)
Genital herpes	394.3 (304.4 to 363.8)	398.2 (361.0 to 429.1)	18.1 (4.4 to 33.5)	-6.3 (-17.1 to 5.0)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	15.8 (0.7 to 32.1)	61.1 (-12.2 to 6.7)
Other sexually transmitted diseases	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-18.9 (-36.8 to 0.6)	-25.6 (-41.7 to -7.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-35.4 to 46.1)	-4.1 (-40.5 to 34.7)
Hepatitis	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-7.4 (-19.0 to 5.6)	-12.8 (-23.8 to -1.1)
Hepatitis A	1.9 (1.9 to 2.0)	1.7 (1.6 to 1.7)	-13.3 (-13.6 to -13.2)	-6.2 (-6.9 to -5.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-4.0 (-14.4 to 7.8)	-4.5 (-15.6 to 7.1)
Hepatitis B	48.3 (38.3 to 58.8)	39.0 (32.1 to 47.3)	-19.4 (-41.6 to 21.1)	-28.4 (-47.9 to 7.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.2 (-39.7 to 19.9)	-27.8 (-48.7 to 2.1)
Hepatitis C	32.1 (28.8 to 35.8)	30.1 (27.2 to 33.2)	-6.2 (-18.3 to 8.0)	-25.5 (-35.1 to -14.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.6 (-31.3 to 41.2)	-20.3 (-43.9 to 10.1)
Hepatitis E	-	-	4.5 (-7.7 to 18.8)	-2.6 (-13.8 to 10.4)	-	-	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	13.9 (11.5 to 16.0)	11.7 (10.1 to 13.3)	-16.5 (-30.7 to 3.6)	-0.9 (-19.3 to 24.8)	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.5)	-23.5 (-46.3 to 5.6)	1.6 (-30.6 to 41.5)
Non-communicable diseases	-	-	-	-	167.6 (124.6 to 218.1)	257.7 (156.0 to 272.9)	53.7 (22.0 to 29.9)	1.2 (-1.7 to 4.5)
Neoplasms	-	-	-	-	1.4 (1.0 to 1.8)	2.5 (1.8 to 3.2)	80.7 (60.6 to 99.0)	26.5 (11.5 to 39.3)
Esophageal cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	47.2 (2.4 to 96.4)	-4.9 (-33.6 to 26.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.4 (5.5 to 88.8)	-5.2 (-31.6 to 21.2)
Stomach cancer	0.8 (0.7 to 0.9)	0.9 (0.7 to 1.0)	6.3 (-11.9 to 28.2)	-31.1 (-42.7 to -16.9)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	7.3 (-11.7 to 29.5)	-30.5 (-42.8 to -16.2)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-16.2 to 105.8)	27.5 (-47.3 to 29.6)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-11.1 (-55.5 to 84.8)	-41.9 (-71.2 to 19.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.7 (-52.3 to 69.6)	-43.0 (-69.0 to 8.4)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	128.6 (9.2 to 425.8)	43.7 (-30.2 to 229.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	122.5 (21.9 to 393.6)	38.9 (-23.2 to 206.5)
Liver cancer due to alcohol use	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	11.7 (-36.3 to 126.8)	-30.5 (-60.4 to 36.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.7 (-30.1 to 102.8)	-33.1 (-55.7 to 24.6)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.6 (-67.7 to 27.8)	-60.0 (-78.3 to -45.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.5 (-65.4 to 13.5)	-41.4 (-76.9 to -24.3)
Larynx cancer	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	0.3 (-6.7 to 99.1)	35.7 (-35.4 to 34.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-2.0 to 99.0)	37.8 (-32.6 to 33.9)
Tracheal, bronchus and lung cancer	0.7 (0.6 to 0.8)	1.3 (1.1 to 1.5)	88.8 (53.0 to 132.5)	26.4 (2.5 to 55.6)	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	92.6 (57.1 to 132.9)	29.1 (5.6 to 55.8)
Breast cancer	1.8 (1.5 to 2.3)	6.8 (5.9 to 7.6)	275.9 (193.5 to 362.2)	172.2 (113.1 to 234.5)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	122.8 (74.6 to 183.3)	60.5 (25.4 to 103.5)
Cervical cancer	1.1 (0.9 to 1.4)	2.1 (0.9 to 1.4)	91.1 (-29.8 to 38.2)	-21.2 (-45.8 to 7.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-20.4 (-30.3 to 44.5)	-41.4 (-46.0 to 10.7)
Uterine cancer	0.8 (0.6 to 1.0)	1.2 (0.8 to 1.6)	49.8 (-1.2 to 120.0)	6.5 (-29.1 to 55.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	50.4 (-2.7 to 127.4)	6.9 (-2.0 to 59.6)
Prostate cancer	1.3 (1.0 to 1.6)	3.4 (2.7 to 4.1)	166.7 (94.9 to 241.8)	58.0 (16.0 to 106.0)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	186.6 (100.4 to 283.7)	69.5 (17.8 to 129.5)
Colon and rectum cancer	1.3 (1.2 to 1.5)	3.3 (3.0 to 3.7)	146.3 (113.6 to 181.2)	62.2 (40.9 to 84.5)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	141.2 (106.9 to 182.8)	58.2 (35.3 to 85.1)
Lip and oral cavity cancer	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	35.0 (0.1 to 88.5)	-9.8 (-31.2 to 23.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	35.3 (0.3 to 85.2)	-10.2 (-33.2 to 22.1)
Nasopharynx cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-11.7 (-39.2 to 28.2)	-34.1 (-54.4 to -9.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.9 (-35.0 to 25.5)	-33.6 (-51.9 to -9.3)
Other pharynx cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	58.2 (-12.6 to 170.9)	10.1 (-38.2 to 87.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.7 (0.6 to 153.1)	11.1 (-30.6 to 73.0)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	39.1 (-15.0 to 91.3)	-12.0 (-46.5 to 21.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.7 (-16.9 to 83.8)	-13.8 (-48.3 to 18.6)
Pancreatic cancer	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	102.1 (59.1 to 150.1)	28.7 (1.0 to 59.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	96.2 (58.1 to 141.8)	25.7 (0.5 to 55.3)
Malignant skin melanoma	0.9 (0.6 to 1.2)	1.5 (1.1 to 2.4)	67.7 (27.0 to 128.8)	21.6 (-2.4 to 65.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	64.1 (26.7 to 126.2)	37.8 (-9.2 to 60.5)
Non-melanoma skin cancer	1.0 (0.7 to 1.4)	2.2 (1.5 to 3.1)	134.5 (16.2 to 260.1)	48.5 (-29.3 to 131.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	223.3 (106.9 to 461.8)	99.6 (21.7 to 264.9)
Ovarian cancer	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.6)	29.5 (29.2 to 130.0)	29.5 (-4.8 to 68.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	77.3 (23.6 to 146.7)	30.3 (8.6 to 78.9)
Testicular cancer	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.6)	-11.7 (-46.2 to 52.9)	-18.9 (-50.6 to 39.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.8 (-46.5 to 46.8)	-20.2 (-51.2 to 31.7)
Kidney cancer	0.2 (0.1 to 0.2)	0.5 (0.4 to 0.6)	176.6 (109.6 to 270.3)	95.7 (48.9 to 161.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	174.8 (103.5 to 277.3)	91.2 (43.9 to 163.7)
Bladder cancer	0.7 (0.6 to 0.8)	1.1 (0.9 to 1.3)	68.8 (27.6 to 111.6)	9.2 (-17.7 to 35.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	68.9 (28.7 to 116.3)	8.0 (-17.2 to 37.5)
Brain and nervous system cancer	0.5 (0.4 to 0.6)	0.7 (0.6 to 0.8)	44.6 (14.5 to 79.5)	21.6 (-4.5 to 53.7)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	48.6 (17.1 to 88.2)	20.9 (-3.8 to 52.0)
Thyroid cancer	0.5 (0.4 to 0.6)	0.6 (0.4 to 0.9)	19.1 (-10.7 to 82.8)	-3.7 (-27.5 to 46.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	20.2 (-12.4 to 82.5)	-3.9 (-29.6 to 44.7)
Mesothelioma	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	85.6 (88.9 to 56.2)	89.2 (92.4 to 47.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.6 (88.1 to 63.5)	89.5 (91.9 to 8.5)
Hodgkin lymphoma	0.3 (0.3 to 0.5)	0.4 (0.3 to 0.5)	6.6 (-26.3 to 54.6)	-2.7 (-33.1 to 40.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.4 (-26.0 to 46.1)	-6.7 (-33.6 to 30.6)
Non-Hodgkin lymphoma	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.6)	43.8 (-18.7 to 122.2)	13.5 (-36.0 to 74.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	46.1 (-16.9 to 129.1)	13.9 (-35.0 to 72.8)
Multiple myeloma	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	100.7 (9.1 to 248.7)	38.4 (-24.8 to 137.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.6 (7.9 to 228.1)	29.5 (-27.0 to 121.5)
Leukemia	0.6 (0.5 to 0.7)	0.7 (0.6 to 0.9)	13.4 (-8.8 to 58.2)	3.8 (-23.5 to 36.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	41.0 (9.9 to 77.7)	12.3 (-11.9 to 40.7)
Other neoplasms	0.9 (0.7 to 1.1)	2.0 (1.4 to 2.6)	134.8 (54.7 to 215.9)	89.3 (25.0 to 154.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	126.0 (48.7 to 211.2)	77.5 (18.7 to 143.9)
Cardiovascular diseases	-	-	-	-	3.2 (2.2 to 4.5)	5.2 (3.6 to 7.1)	63.3 (26.8 to 99.3)	3.4 (-19.0 to 26.0)
Rheumatic heart disease	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.4)	46.7 (11.3 to 90.6)	-1.0 (-24.1 to 27.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	45.1 (1.0 to 99.2)	-1.5 (-30.0 to 33.7)
Ischemic heart disease	22.3 (19.3 to 26.4)	33.2 (29.1 to 38.6)	48.7 (19.4 to 81.4)	-7.4 (-24.2 to 12.7)	1.2 (0.8 to 1.7)	1.7 (1.2 to 2.5)	51.5 (15.3 to 90.6)	-7.0 (-27.8 to 15.1)
Cerebrovascular disease	-	-	-	-	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.9)	54.0 (13.9 to 99.7)	5.7 (-20.5 to 36.6)
Ischemic stroke	2.3 (1.9 to 2.7)	3.5 (2.8 to 4.2)	57.0 (17.2 to 105.0)	4.9 (-21.0 to 36.9)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.7)	55.7 (14.6 to 107.3)	4.9 (-22.0 to 38.8)
Hemorrhagic stroke	0.5 (0.4 to 0.6)	0.7 (0.6 to 0.9)	44.3 (8.1 to 95.8)	5.1 (-20.9 to 40.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	43.5 (5.0 to 100.8)	5.5 (-22.2 to 45.9)
Hypertensive heart disease	3.1 (2.7 to 3.4)	5.8 (5.3 to 6.4)	89.4 (63.6 to 119.0)	10.1 (-4.5 to 27.0)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	89.8 (63.7 to 123.6)	11.0 (-4.3 to 29.6)
Cardiomyopathy and myocarditis	4.4 (3.0 to 3.9)	4.4 (4.0 to 4.8)	29.0 (7.9 to 50.9)	-22.8 (-35.4 to -9.5)	0.4 (0.2 to 0.5)	0.5 (0.3 to 0.6)	28.9 (7.8 to 52.0)	-2.6 (-35.6 to -9.1)
Atrial fibrillation and flutter	0.2 (0.1 to 0.3)	1.7 (0.6 to 2.8)	755.5 (349.5 to 1571.7)	411.9 (174.3 to 915.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	747.6 (332.3 to 1576.7)	409.7 (170.4 to 912.1)
Peripheral vascular disease	49.6 (38.5 to 62.0)	81.1 (64.6 to 97.6)	64.2 (21.5 to 117.6)	1.0 (-23.4 to 34.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	58.9 (-37.7 to 334.9)	-13.8 (-34.0 to 133.0)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.3 (9.7 to 170.4)	18.5 (-17.9 to 96.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.6 (21.5 to 191.9)	35.0 (-7.7 to 113.4)
Other cardiovascular and circulatory diseases	11.8 (7.3 to 20.7)	20.5 (11.1 to 29.1)	80.5 (-21.1 to 225.2)	21.8 (-47.0 to 123.4)	0.8 (0.4 to 1.5)	1.4 (0.7 to 2.3)	81.6 (-21.7 to 232.4)	21.2 (-47.3 to 125.9)
Chronic respiratory diseases	-	-	-	-	8.7 (5.9 to 12.0)	11.2 (7.7 to 15.4)	30.8 (9.3 to 50.4)	2.1 (-15.3 to 17.7)
Chronic obstructive pulmonary disease	91.1 (86.5 to 95.0)	124.1 (118.5 to 129.6)	36.0 (32.5 to 41.1)	-1.3 (-3.7 to 2.0)	5.6 (3.6 to 7.9)	7.2 (4.7 to 10.4)	30.4 (1.8 to 58.1)	-4.6 (-25.9 to 15.3)

Appendix Table G.4 - Macedonia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.5 (2.9 to 21.4)	-22.9 (-28.9 to -17.2)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.1 (32.8 to 48.2)	-5.1 (-11.1 to -0.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.6 (33.2 to 49.0)	-5.0 (-11.0 to -0.1)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.7 (-15.8 to 5.2)	-33.5 (-40.4 to -27.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.0 (-15.6 to 6.1)	-33.1 (-40.2 to -25.5)
Asthma	65.3 (54.2 to 78.0)	89.2 (82.1 to 96.2)	37.8 (10.7 to 70.1)	21.1 (-2.2 to 49.0)	2.9 (1.8 to 4.3)	3.9 (2.5 to 5.7)	37.6 (10.4 to 70.6)	22.1 (-1.5 to 51.2)
Interstitial lung disease and pulmonary sarcoidosis	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	35.6 (-16.1 to 96.8)	3.0 (-35.4 to 47.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	36.1 (-15.1 to 94.8)	2.7 (-35.1 to 46.4)
Other chronic respiratory diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-51.2 (-68.5 to -30.5)	-64.3 (-76.6 to -49.4)
Cirrhosis	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	10.1 (5.5 to 31.7)	-7.9 (-20.6 to 9.5)
Cirrhosis due to hepatitis B	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	41.9 (7.8 to 114.0)	13.6 (25.4 to 70.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-	12.7 (-14.7 to 134.4)
Cirrhosis due to hepatitis C	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	10.3 (-26.0 to 74.1)	-15.0 (-44.0 to 35.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	8.8 (-30.8 to 79.8)	-15.8 (-47.0 to 41.2)
Cirrhosis due to alcohol use	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-19.1 (-48.6 to 45.0)	-41.4 (-62.2 to 3.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.6 (-52.9 to 46.5)	-42.1 (-64.7 to 6.9)
Cirrhosis due to other causes	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.3)	15.4 (-13.4 to 49.4)	13.6 (-13.0 to 42.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	13.6 (-20.3 to 61.5)	12.4 (-20.0 to 57.7)
Digestive diseases	-	-	-	-	1.7 (1.2 to 2.2)	2.1 (1.5 to 2.8)	23.3 (19.8 to 39.3)	-7.1 (-14.6 to 0.6)
Peptic ulcer disease	9.0 (8.2 to 9.5)	7.0 (5.2 to 8.1)	-22.2 (-42.4 to -8.7)	-53.6 (-65.6 to -46.4)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-6.4 (-22.6 to 12.8)	-43.8 (-52.2 to -32.4)
Gastritis and duodenitis	0.6 (0.6 to 0.7)	0.6 (0.5 to 0.7)	-2.1 (-17.3 to 15.9)	-18.4 (-31.5 to -2.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-11.5 (-34.1 to 19.1)	-24.1 (-44.9 to 4.1)
Appendicitis	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-34.3 (-54.3 to -5.5)	-30.0 (-51.6 to 1.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.7 (-58.2 to 9.0)	-28.6 (-57.0 to 20.0)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.3 (-0.9 to 62.8)	3.9 (-18.9 to 41.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.5 (-7.9 to 70.2)	3.8 (-25.1 to 49.6)
Inguinal, femoral, and abdominal hernia	9.0 (7.8 to 10.4)	11.9 (9.8 to 14.0)	31.4 (8.3 to 65.8)	-12.7 (-28.5 to 9.0)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	31.1 (7.2 to 66.8)	-11.9 (-28.2 to 10.3)
Inflammatory bowel disease	2.4 (2.3 to 2.6)	4.4 (4.3 to 4.6)	82.4 (71.9 to 94.2)	41.3 (33.3 to 50.4)	0.5 (0.3 to 0.7)	0.9 (0.6 to 1.3)	81.3 (67.9 to 97.9)	41.7 (31.3 to 54.1)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.3 (12.8 to 151.6)	6.6 (-29.3 to 60.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.3 (12.6 to 151.8)	6.6 (-29.7 to 60.9)
Gallbladder and biliary diseases	3.7 (3.2 to 4.2)	3.9 (3.2 to 4.5)	3.9 (-16.7 to 28.4)	7.4 (-41.0 to -9.6)	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	7.0 (-17.2 to 28.5)	24.0 (-11.1 to -9.3)
Pancreatitis	0.5 (0.5 to 0.6)	0.9 (0.8 to 0.9)	64.9 (50.5 to 78.8)	24.5 (14.2 to 34.5)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	64.4 (41.1 to 93.9)	25.4 (7.9 to 46.9)
Other digestive diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-56.4 (-64.3 to -33.0)	-68.8 (-74.6 to -51.9)
Neurological disorders	-	-	-	-	18.6 (12.5 to 26.1)	23.7 (16.2 to 32.5)	27.8 (13.6 to 44.7)	6.1 (-5.5 to 19.8)
Alzheimer disease and other dementias	12.1 (10.6 to 13.6)	22.3 (19.2 to 25.3)	85.0 (49.8 to 123.3)	0.8 (-18.7 to 21.4)	1.7 (1.2 to 2.2)	3.2 (2.3 to 4.2)	89.5 (53.5 to 129.3)	2.1 (-17.8 to 23.8)
Parkinson disease	1.0 (0.7 to 1.4)	1.7 (1.1 to 2.3)	65.2 (53.5 to 85.7)	-1.6 (-8.2 to 9.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	66.5 (42.9 to 91.3)	-0.5 (-13.1 to 13.9)
Epilepsy	9.5 (6.1 to 13.3)	9.6 (6.3 to 13.3)	1.9 (-39.9 to 74.0)	-3.8 (-43.3 to 61.1)	2.8 (1.5 to 4.6)	2.9 (1.7 to 4.5)	5.6 (-40.1 to 86.1)	0.6 (-43.1 to 75.3)
Multiple sclerosis	0.8 (0.5 to 1.0)	1.3 (0.9 to 1.6)	67.4 (2.0 to 147.5)	34.7 (-18.0 to 97.5)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	66.6 (-2.4 to 153.1)	34.9 (-20.3 to 103.8)
Migraine	289.1 (261.4 to 315.8)	321 (297.5 to 346.1)	11.1 (-0.9 to 25.4)	0.7 (-11.4 to 12.3)	9.9 (5.8 to 14.6)	10.5 (6.5 to 16.1)	9.6 (-2.5 to 25.3)	0.6 (-11.9 to 12.8)
Tension-type headache	373.7 (342.3 to 405.7)	422.0 (388.7 to 456.1)	12.9 (0.6 to 26.9)	0.3 (-10.6 to 13.0)	0.6 (0.3 to 1.0)	0.6 (0.3 to 1.1)	12.8 (-0.3 to 27.6)	0.7 (-10.7 to 13.7)
Medication overuse headache	19.2 (12.6 to 26.2)	33.7 (21.2 to 47.9)	73.3 (25.3 to 137.2)	43.3 (5.6 to 93.7)	3.0 (1.7 to 4.7)	5.3 (2.9 to 8.6)	72.3 (26.7 to 136.0)	43.9 (7.0 to 94.3)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.4 (-10.4 to 75.0)	4.3 (-21.7 to 45.3)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-28.2 (-48.8 to 2.5)	-59.8 (-71.4 to -41.7)
Mental and substance use disorders	-	-	-	-	41.6 (30.3 to 54.1)	45.8 (33.3 to 59.4)	10.2 (7.6 to 12.9)	-1.2 (-3.2 to 1.1)
Schizophrenia	6.3 (5.8 to 6.8)	7.5 (6.9 to 8.1)	19.1 (13.8 to 24.9)	-0.7 (-5.0 to 4.0)	4.1 (3.0 to 4.9)	4.8 (3.5 to 5.8)	18.8 (11.1 to 26.1)	-0.4 (-6.7 to 5.6)
Alcohol use disorders	13.8 (12.1 to 15.6)	14.0 (12.4 to 15.6)	1.4 (-5.9 to 9.7)	-12.3 (-18.7 to -5.3)	1.4 (0.9 to 2.0)	1.4 (0.9 to 2.0)	1.3 (-7.6 to 10.7)	-11.9 (-19.6 to -4.1)
Drug use disorders	-	-	-	-	2.3 (1.4 to 3.3)	2.3 (1.4 to 3.3)	0.8 (-15.6 to 18.7)	-5.7 (-21.2 to 10.7)
Opioid use disorders	2.2 (1.1 to 3.7)	2.4 (1.2 to 4.1)	9.3 (-2.3 to 33.2)	-1.4 (-11.4 to 20.5)	0.9 (0.4 to 1.6)	1.0 (0.5 to 1.8)	10.3 (-5.6 to 35.3)	-0.6 (-14.5 to 23.5)
Cocaine use disorders	1.3 (0.9 to 1.6)	1.4 (1.1 to 1.7)	5.1 (-25.7 to 46.0)	0.2 (-32.7 to 34.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	4.2 (-29.0 to 48.0)	2.6 (-34.5 to 37.6)
Amphetamine use disorders	3.5 (2.9 to 4.1)	3.2 (2.7 to 3.7)	-9.1 (-28.0 to 15.6)	-12.8 (-30.6 to 11.3)	0.5 (0.3 to 0.7)	0.4 (0.2 to 0.7)	-10.0 (-30.7 to 19.2)	-13.4 (-33.4 to 15.1)
Cannabis use disorders	2.6 (2.3 to 3.0)	2.6 (2.2 to 2.9)	-1.7 (-3.0 to -0.2)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-1.7 (-17.7 to 15.0)	0.1 (-16.0 to 16.8)
Other drug use disorders	-	-	-	-	0.7 (0.4 to 1.0)	0.6 (0.4 to 1.0)	-4.9 (-34.1 to 34.6)	-9.3 (-37.1 to 28.3)
Depressive disorders	-	-	-	-	15.6 (10.6 to 21.6)	18.0 (12.4 to 24.9)	15.8 (10.5 to 21.6)	0.1 (-4.3 to 4.1)
Major depressive disorder	62.9 (54.5 to 70.5)	72.5 (62.6 to 82.2)	15.3 (9.0 to 21.3)	-0.3 (-5.1 to 4.2)	12.9 (8.7 to 18.0)	14.8 (9.9 to 20.6)	14.8 (8.0 to 21.3)	-0.1 (-5.3 to 5.0)
Dysthymia	27.7 (23.1 to 32.5)	34.1 (28.3 to 39.8)	23.1 (19.4 to 27.3)	-0.0 (-0.1 to 0.1)	2.7 (1.7 to 3.9)	3.3 (2.1 to 4.8)	22.6 (17.9 to 28.1)	0.2 (-2.1 to 2.5)
Bipolar disorder	14.1 (11.3 to 16.7)	16.5 (13.4 to 19.7)	17.0 (9.4 to 24.3)	-0.4 (-6.4 to 6.1)	2.9 (1.7 to 4.4)	3.3 (2.0 to 5.0)	16.3 (7.4 to 25.1)	-0.2 (-7.3 to 7.5)
Anxiety disorders	70.5 (59.0 to 82.1)	77.9 (65.4 to 90.0)	10.5 (6.9 to 14.1)	6.5 (-0.2 to 0.1)	6.5 (4.4 to 9.2)	7.1 (4.8 to 10.1)	9.7 (5.3 to 14.5)	0.0 (-2.5 to 2.8)
Eating disorders	-	-	-	-	0.5 (0.3 to 0.8)	0.5 (0.3 to 0.8)	-4.5 (-12.0 to 3.5)	0.1 (-7.6 to 8.3)
Anorexia nervosa	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-4.0 (-15.1 to 6.0)	2.5 (-8.9 to 12.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-4.9 (-27.9 to 27.5)	1.7 (-23.3 to 36.1)
Bulimia nervosa	2.2 (1.6 to 3.0)	2.1 (1.5 to 2.9)	-4.3 (-6.6 to -2.5)	-0.3 (-0.3 to -0.2)	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.7)	-4.3 (-12.2 to 3.6)	-0.1 (-8.0 to 8.3)
Autistic spectrum disorders	-	-	-	-	2.4 (1.7 to 3.2)	2.4 (1.7 to 3.3)	1.7 (-1.7 to 5.4)	0.3 (-2.8 to 3.9)
Autism	6.2 (5.8 to 6.5)	6.3 (6.0 to 6.7)	2.6 (1.9 to 3.5)	0.2 (0.1 to 0.2)	1.5 (1.0 to 2.1)	1.5 (1.0 to 2.1)	1.7 (-2.9 to 6.9)	0.3 (-4.2 to 5.4)
Asperger syndrome	8.8 (8.2 to 9.3)	9.0 (8.4 to 9.6)	2.3 (1.3 to 3.3)	0.2 (0.2 to 0.2)	0.9 (0.6 to 1.2)	0.9 (0.6 to 1.2)	1.7 (-2.7 to 5.7)	0.5 (-3.7 to 4.4)
Attention-deficit/hyperactivity disorder	10.8 (9.9 to 11.7)	8.4 (7.7 to 9.1)	-22.3 (-22.8 to -22.1)	0.3 (0.3 to 0.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-22.4 (-28.4 to -15.9)	0.2 (-7.3 to 8.4)
Conduct disorder	15.8 (14.9 to 16.8)	12 (11.6 to 12.9)	-23.5 (-24.3 to -22.9)	0.1 (0.1 to 0.3)	1.5 (1.2 to 2.8)	1.5 (0.9 to 2.1)	-23.7 (-26.7 to -20.3)	0.1 (-3.9 to 4.6)
Idiopathic intellectual disability	29.2 (22.5 to 36.0)	25.7 (18.7 to 32.1)	-12.0 (-23.4 to 1.7)	-14.8 (-25.8 to -1.4)	1.4 (0.9 to 2.1)	1.2 (0.8 to 1.8)	-12.5 (-24.6 to 1.2)	-14.7 (-26.0 to -1.4)
Other mental and substance use disorders	34.5 (32.5 to 36.6)	41.7 (39.3 to 44.1)	20.9 (19.5 to 22.1)	-0.1 (-0.2 to 0.1)	2.6 (1.8 to 3.5)	3.1 (2.1 to 4.2)	20.3 (16.0 to 24.9)	0.2 (-3.2 to 3.8)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	18.7 (13.3 to 25.2)	25.1 (17.8 to 33.9)	34.1 (22.3 to 49.1)	7.3 (-2.1 to 18.1)
Diabetes mellitus	103.3 (85.5 to 121.2)	153.2 (125.5 to 182.9)	47.7 (21.9 to 82.6)	15.8 (-3.5 to 42.5)	7.3 (4.8 to 10.3)	11.2 (7.3 to 16.1)	54.7 (24.1 to 93.7)	16.3 (-6.2 to 43.6)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.4 (-46.4 to -32.5)	-29.4 (-36.5 to -22.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.4 (-46.5 to -32.5)	-29.4 (-36.6 to -22.8)
Chronic kidney disease	-	-	-	-	5.1 (3.7 to 6.7)	6.7 (4.9 to 8.9)	32.0 (19.4 to 44.0)	4.8 (-3.6 to 13.8)
Chronic kidney disease due to diabetes mellitus	28.0 (19.5 to 41.1)	40.9 (28.8 to 58.3)	45.6 (15.5 to 88.1)	4.5 (-16.4 to 32.3)	0.7 (0.5 to 1.0)	1.1 (0.8 to 1.4)	49.9 (20.7 to 86.4)	8.2 (-12.5 to 34.1)
Chronic kidney disease due to hypertension	47.8 (30.5 to 73.8)	45.6 (31.8 to 62.8)	-4.2 (-24.0 to 27.2)	-15.1 (-33.6 to 10.9)	1.6 (1.1 to 2.1)	1.5 (1.0 to 1.9)	-8.6 (-22.6 to 12.0)	-28.0 (-38.0 to -11.8)
Chronic kidney disease due to glomerulonephritis	60.3 (41.5 to 88.9)	52.9 (37.0 to 77.0)	-11.0 (-27.4 to 7.9)	-18.5 (-39.6 to -12.5)	2.8 (0.8 to 1.5)	1.1 (0.8 to 1.5)	-18.5 (-18.7 to 32.2)	-11.1 (-28.3 to 13.4)
Chronic kidney disease due to other causes	72.9 (51.7 to 106.1)	120.1 (83.9 to 162.7)	64.2 (36.2 to 108.9)	34.4 (15.8 to 61.3)	1.7 (1.2 to 2.3)	3.1 (2.2 to 4.2)	78.7 (49.7 to 119.6)	40.9 (20.3 to 72.6)
Urinary diseases and male infertility	-	-	-	-	1.2 (0.8 to 1.7)	1.2 (1.1 to 2.6)	48.4 (25.4 to 76.4)	-6.8 (-21.7 to 11.6)

Appendix Table G.4 - Macedonia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.3)	2.6 (-15.5 to 24.4)	0.0 (-21.3 to 14.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.7 (-24.5 to 40.2)	5.0 (-29.5 to 30.5)
Urolithiasis	16.3 (10.3 to 23.6)	22.0 (15.6 to 31.1)	36.5 (9.4 to 63.1)	-8.1 (-25.8 to 5.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	29.1 (10.3 to 47.6)	-8.3 (-20.9 to 3.3)
Benign prostatic hyperplasia	25.3 (21.0 to 29.7)	39.3 (33.9 to 45.5)	56.1 (26.2 to 94.0)	-7.2 (-25.8 to 14.5)	0.9 (0.6 to 1.3)	1.4 (0.9 to 2.0)	56.8 (25.8 to 94.7)	-6.7 (-25.4 to 16.5)
Male infertility due to other causes	8.0 (5.7 to 10.5)	8.4 (6.1 to 11.3)	5.7 (-30.5 to 56.5)	2.4 (-32.6 to 51.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	2.7 (-30.6 to 58.4)	6.2 (-32.9 to 53.3)
Other urinary diseases	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	39.3 (0.3 to 71.7)	6.7 (-27.5 to 24.2)
Gynecological diseases	-	-	-	-	2.5 (1.6 to 3.7)	2.7 (1.7 to 4.2)	12.2 (-7.2 to 29.6)	0.4 (-16.8 to 16.4)
Uterine fibroids	44.4 (40.3 to 48.1)	53.1 (48.6 to 57.5)	19.7 (18.7 to 20.9)	-1.1 (-1.1 to -1.1)	0.6 (0.3 to 0.9)	0.6 (0.4 to 1.1)	13.0 (6.2 to 18.5)	-3.5 (-8.8 to 0.9)
Polycystic ovarian syndrome	35.8 (31.7 to 39.9)	39.8 (36.2 to 43.7)	11.7 (-2.5 to 28.1)	2.5 (-10.4 to 17.3)	0.3 (0.2 to 0.6)	0.4 (0.2 to 0.7)	11.1 (-2.4 to 27.3)	2.3 (-9.9 to 17.0)
Female infertility due to other causes	4.8 (1.4 to 9.1)	5.2 (1.7 to 10.1)	9.9 (-9.4 to 36.9)	6.5 (-70.6 to 255.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	9.6 (-68.8 to 267.7)	6.7 (-69.7 to 259.5)
Endometriosis	3.8 (3.2 to 4.4)	4.4 (3.7 to 5.0)	16.1 (-6.0 to 42.7)	5.2 (-14.5 to 28.7)	0.4 (0.2 to 0.5)	0.4 (0.3 to 0.6)	15.8 (7.1 to 46.3)	5.0 (-15.6 to 32.0)
Genital prolapse	104.2 (92.1 to 114.8)	128.1 (114.0 to 142.5)	23.4 (4.8 to 44.1)	0.0 (-15.8 to 16.6)	0.3 (0.2 to 0.6)	0.4 (0.2 to 0.8)	22.8 (3.7 to 43.7)	-0.1 (-16.0 to 17.0)
Premenstrual syndrome	78.5 (47.3 to 115.4)	81.2 (54.0 to 109.8)	6.0 (-43.1 to 82.8)	1.6 (-44.7 to 75.2)	0.7 (0.3 to 1.1)	0.7 (0.4 to 1.2)	5.9 (-43.5 to 82.0)	1.9 (-1.2 to 74.0)
Other gynecological diseases	6.6 (5.5 to 7.9)	7.2 (6.2 to 8.3)	8.3 (-12.6 to 37.3)	-1.8 (-20.5 to 23.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	8.5 (-20.5 to 56.2)	-4.1 (-28.1 to 40.1)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	1.8 (1.2 to 2.6)	1.7 (1.1 to 2.4)	7.1 (-13.8 to 6.1)	-3.3 (-10.8 to 9.1)
Thalassemias	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-24.9 (-30.8 to -17.0)	-0.1 (-8.6 to 10.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.6 (-44.0 to 6.3)	0.1 (-27.9 to 41.3)
Thalassemia trait	49.1 (45.0 to 54.0)	49.7 (44.5 to 55.2)	0.9 (-4.8 to 8.4)	-3.6 (-8.8 to 3.4)	1.3 (0.9 to 2.0)	1.3 (0.9 to 1.8)	-5.1 (-13.6 to 10.0)	-3.0 (-11.8 to 11.0)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.2 (-40.5 to -13.7)	-8.2 (-31.4 to 1.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.9 (-40.3 to -6.6)	-10.0 (-32.8 to 5.0)
Sickle cell trait	7.2 (5.2 to 9.7)	6.9 (4.9 to 9.7)	-2.0 (-29.0 to 8.5)	-2.0 (-32.0 to 3.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-24.8 (-47.0 to 7.6)	-14.8 (-45.5 to 19.7)
G6PD deficiency	24.7 (18.5 to 31.1)	21.6 (11.4 to 29.4)	-10.9 (-54.8 to 33.9)	-14.4 (-56.6 to 28.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.7 (-8.1 to 10.1)	8.3 (-8.8 to 18.0)
G6PD trait	269.2 (247.8 to 286.8)	280.6 (257.7 to 300.1)	4.1 (-6.6 to 16.9)	-1.2 (-11.3 to 11.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.6 (-53.1 to 138.0)	-5.4 (-54.0 to 153.4)
Other hemoglobinopathies and hemolytic anemias	16.5 (15.8 to 18.2)	17.3 (15.5 to 19.1)	5.7 (-8.4 to 20.3)	0.4 (-14.0 to 14.0)	0.3 (0.2 to 0.6)	0.3 (0.2 to 0.5)	-9.2 (-35.9 to 10.3)	-1.0 (-28.4 to 21.5)
Endocrine, metabolic, blood, and immune disorders	26.6 (24.7 to 28.4)	29.7 (28.2 to 31.3)	11.4 (3.4 to 21.1)	0.9 (1.6 to 18.7)	0.9 (0.6 to 1.3)	0.9 (0.6 to 1.3)	9.7 (-1.8 to 20.5)	10.5 (1.4 to 23.5)
Musculoskeletal disorders	-	-	-	-	44.0 (30.6 to 58.4)	58.6 (41.0 to 78.1)	32.9 (23.2 to 45.1)	1.7 (-5.4 to 10.9)
Rheumatoid arthritis	0.8 (0.7 to 0.9)	2.0 (1.8 to 2.2)	139.5 (107.4 to 181.6)	97.7 (71.6 to 132.1)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.6)	132.1 (95.3 to 186.5)	93.7 (63.0 to 136.7)
Osteoarthritis	82.5 (79.3 to 86.3)	130.3 (125.4 to 135.0)	57.9 (49.5 to 66.2)	2.1 (-3.1 to 7.2)	5.0 (3.6 to 6.9)	7.9 (5.6 to 10.8)	57.6 (48.8 to 66.1)	2.5 (-3.0 to 7.5)
Low back and neck pain	-	-	-	-	35.0 (24.0 to 47.3)	44.5 (30.6 to 60.4)	27.9 (15.7 to 42.2)	0.2 (-8.3 to 11.9)
Low back pain	237.8 (216.8 to 257.9)	305.0 (280.0 to 330.9)	27.6 (14.7 to 48.6)	-0.4 (-10.4 to 16.0)	26.4 (17.9 to 36.4)	33.7 (22.6 to 47.1)	26.9 (13.9 to 47.4)	-0.1 (-10.2 to 16.0)
Neck pain	86.8 (71.1 to 102.1)	110.8 (94.3 to 127.9)	26.6 (0.9 to 66.1)	-0.2 (-19.8 to 31.7)	8.5 (5.7 to 12.1)	10.8 (7.2 to 15.2)	26.0 (0.5 to 67.3)	0.0 (-20.0 to 32.0)
Gout	0.9 (0.9 to 1.0)	1.3 (1.2 to 1.4)	44.6 (31.5 to 58.8)	-0.9 (-9.3 to 8.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	43.5 (16.1 to 80.5)	-0.9 (-19.3 to 23.9)
Other musculoskeletal disorders	41.0 (29.8 to 52.3)	61.4 (47.3 to 75.9)	49.6 (36.0 to 66.7)	9.0 (0.4 to 20.5)	7.7 (2.4 to 5.6)	5.6 (3.6 to 8.2)	9.4 (35.3 to 67.0)	4.4 (0.3 to 21.2)
Other non-communicable diseases	-	-	-	-	29.8 (19.5 to 43.5)	36.4 (24.2 to 52.9)	22.3 (17.3 to 27.7)	-4.0 (-7.7 to -0.3)
Congenital anomalies	-	-	-	-	2.0 (1.5 to 2.6)	2.8 (2.1 to 3.7)	40.6 (23.3 to 65.4)	32.5 (15.7 to 57.1)
Neural tube defects	0.5 (0.5 to 0.7)	0.6 (0.5 to 0.7)	5.5 (-16.0 to 34.5)	10.6 (-11.8 to 41.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	7.3 (-24.7 to 53.9)	13.4 (-20.1 to 64.4)
Congenital heart anomalies	8.7 (7.2 to 10.7)	14.6 (12.5 to 17.5)	67.0 (29.6 to 117.3)	66.5 (28.9 to 116.7)	0.3 (0.1 to 0.5)	0.5 (0.2 to 0.9)	76.8 (35.2 to 129.4)	78.4 (36.2 to 131.1)
Orofacial clefts	1.5 (1.2 to 1.8)	2.7 (2.2 to 3.4)	88.1 (32.6 to 151.0)	98.1 (32.0 to 150.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.8 (-28.3 to 60.7)	9.8 (-27.9 to 59.9)
Down syndrome	1.7 (1.5 to 1.9)	2.4 (1.9 to 3.1)	44.0 (5.7 to 86.9)	31.5 (-3.5 to 70.9)	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	62.0 (17.0 to 115.2)	39.0 (1.4 to 82.9)
Turner syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	10.2 (-25.0 to 83.2)	10.7 (-24.8 to 84.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.1 (-27.4 to 86.2)	10.9 (-27.6 to 86.0)
Klinefelter syndrome	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	14.0 (-35.4 to 100.5)	11.3 (-36.9 to 95.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.0 (-33.7 to 104.9)	11.3 (-37.0 to 95.9)
Chromosomal unbalanced rearrangements	0.0 (2.8 to 4.1)	0.0 (3.7 to 5.9)	40.3 (1.4 to 89.2)	4.6 (-6.3 to 77.7)	0.7 (0.3 to 0.6)	0.7 (0.5 to 1.0)	35.1 (-2.6 to 84.2)	0.2 (-2.6 to 84.2)
Other congenital anomalies	6.8 (5.5 to 8.0)	6.7 (5.5 to 7.9)	-1.6 (-10.6 to 7.6)	-10.9 (-18.6 to -2.0)	0.9 (0.6 to 1.2)	1.1 (0.7 to 1.5)	21.3 (-1.0 to 72.3)	18.4 (-3.5 to 69.7)
Skin and subcutaneous diseases	-	-	-	-	9.4 (6.2 to 13.9)	9.7 (6.4 to 14.2)	4.0 (-4.8 to 12.5)	-4.3 (-12.0 to 3.3)
Dermatitis	89.5 (75.0 to 105.1)	98.4 (82.6 to 114.8)	9.8 (7.6 to 12.8)	0.0 (-0.0 to 0.0)	2.2 (1.4 to 3.2)	2.4 (1.5 to 3.4)	7.7 (3.6 to 12.1)	0.0 (-2.0 to 2.7)
Psoriasis	16.6 (14.6 to 18.7)	19.6 (17.2 to 22.1)	18.0 (15.6 to 21.2)	0.0 (-0.1 to 0.1)	1.4 (0.9 to 1.9)	1.6 (1.1 to 2.2)	19.6 (10.7 to 24.1)	0.3 (-4.5 to 5.8)
Cellulitis	0.3 (0.2 to 0.4)	0.3 (0.3 to 0.5)	6.1 (-5.7 to 23.4)	-1.3 (-9.9 to 6.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.8 (-17.2 to 29.8)	-1.1 (-20.0 to 19.8)
Pyoderma	2.0 (1.7 to 2.6)	2.0 (1.6 to 2.6)	-0.4 (-10.7 to 7.9)	-2.8 (-7.7 to 2.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.5 (-13.1 to 10.2)	-2.8 (-11.0 to 6.8)
Scabies	3.8 (3.4 to 4.1)	3.4 (3.1 to 3.8)	-8.8 (-20.9 to 3.0)	-10.5 (-21.4 to 1.7)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-9.8 (-21.8 to 4.3)	-10.1 (-22.1 to 3.4)
Fungal skin diseases	157.6 (122.0 to 207.9)	179.5 (140.9 to 233.5)	14.0 (8.2 to 20.4)	14.0 (0.0 to 21.0)	0.9 (0.4 to 2.0)	1.0 (0.4 to 2.2)	13.4 (7.6 to 20.0)	0.2 (-0.6 to 1.0)
Viral skin diseases	43.3 (33.0 to 53.1)	39.5 (29.8 to 49.9)	-8.8 (-13.4 to -4.4)	0.2 (-1.6 to 2.1)	1.3 (0.8 to 2.1)	1.2 (0.7 to 1.9)	-9.3 (-14.1 to -4.3)	0.2 (-2.8 to 3.4)
Acne vulgaris	55.1 (41.7 to 68.6)	55.8 (45.6 to 69.5)	1.2 (-26.4 to 38.8)	10.7 (-20.9 to 50.8)	0.6 (0.3 to 1.2)	0.6 (0.3 to 1.2)	1.4 (-27.0 to 38.8)	10.6 (-21.2 to 50.9)
Alopecia areata	2.4 (2.1 to 2.7)	2.7 (2.4 to 3.1)	15.6 (-4.7 to 38.8)	-2.4 (-18.7 to 15.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	15.4 (-7.1 to 41.0)	-2.2 (-21.0 to 18.7)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.4 (-7.7 to 57.3)	-4.1 (-25.8 to 25.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.4 (-7.7 to 57.5)	-4.1 (-25.8 to 25.4)
Urticaria	33.7 (24.9 to 43.0)	29.0 (22.7 to 38.5)	-13.8 (-39.0 to 25.2)	-22.5 (-45.1 to 10.6)	2.0 (1.2 to 3.1)	1.7 (1.0 to 2.6)	-14.1 (-39.3 to 24.8)	-22.0 (-45.1 to 11.3)
Decubitus ulcer	0.3 (0.2 to 0.3)	0.5 (0.4 to 0.6)	83.5 (31.0 to 139.3)	23.2 (-10.5 to 61.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	78.3 (26.2 to 139.5)	22.4 (-12.2 to 67.1)
Other skin and subcutaneous diseases	127.4 (81.1 to 199.2)	163.0 (96.6 to 272.9)	26.6 (14.2 to 41.2)	-3.5 (-8.0 to 1.7)	0.7 (0.3 to 1.6)	0.9 (0.4 to 2.1)	26.2 (14.1 to 40.6)	-3.2 (-7.7 to 2.0)
Sense organ diseases	-	-	-	-	13.9 (9.0 to 20.2)	17.8 (11.8 to 26.2)	28.2 (28.7 to 35.9)	-9.5 (-14.2 to -5.0)
Glaucoma	2.2 (1.8 to 2.6)	2.4 (1.9 to 2.8)	10.3 (-10.6 to 32.2)	-19.6 (-34.4 to -4.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	14.6 (-7.1 to 35.3)	-20.4 (-34.8 to -6.8)
Cataract	18.1 (14.5 to 22.0)	23.1 (18.0 to 28.2)	27.3 (7.8 to 53.2)	-26.6 (-36.8 to -13.5)	0.6 (0.4 to 0.9)	0.8 (0.5 to 1.2)	28.6 (9.8 to 52.4)	-25.8 (-35.7 to -13.5)
Macular degeneration	5.6 (4.1 to 7.1)	9.2 (6.9 to 11.6)	63.4 (25.0 to 123.2)	9.0 (-17.4 to 46.4)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	62.9 (26.7 to 116.1)	7.2 (-17.2 to 39.7)
Uncorrected refractive error	170.8 (140.4 to 201.5)	225.6 (181.6 to 267.0)	33.6 (1.4 to 66.0)	-2.2 (-24.2 to 20.0)	2.6 (1.5 to 4.4)	3.2 (1.8 to 5.5)	22.5 (11.1 to 42.7)	-8.2 (-22.8 to 7.0)
Age-related and other hearing loss	390.8 (291.2 to 367.1)	439.5 (389.6 to 482.9)	32.7 (26.7 to 39.5)	-8.1 (-11.4 to -4.3)	8.7 (5.6 to 12.5)	11.7 (7.8 to 16.7)	8.8 (26.3 to 45.9)	-8.8 (-14.2 to -2.6)
Other vision loss	12.3 (10.7 to 14.1)	10.0 (8.5 to 11.7)	-19.0 (-29.0 to -6.8)	-34.5 (-41.7 to -25.4)	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.6)	0.5 (-22.9 to -0.2)	-31.1 (-39.9 to -24.9)
Other sense organ diseases	46.0 (43.9 to 48.1)	49.2 (46.9 to 51.5)	7.1 (-0.3 to 14.4)	0.3 (-6.3 to 6.6)	1.2 (0.8 to 1.8)	1.2 (0.8 to 1.9)	6.1 (-1.9 to 13.8)	0.5 (-7.2 to 7.8)
Oral disorders	-	-	-	-	4.5 (2.7 to 7.1)	6.1 (3.6 to 9.4)	34.2 (27.6 to 41.4)	-0.6 (-4.7 to 4.2)
Deciduous caries	149.0 (142.8 to 155.4)	96.9 (92.6 to 101.6)	-34.9 (-39.0 to -31.6)	0.1 (-6.2 to 5.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (-40.6 to -29.2)	0.0 (-8.7 to 8.8)
Permanent caries	814.7 (740.4 to 894.6)	908.7 (811.0 to 1,008.0)	12.0 (-2.8 to 25.8)	3.7 (-10.1 to 16.1)	0.5 (0.2 to 0.9)	0.5 (0.2 to 1.0)	11.5 (-3.4 to 25.1)	3.8 (-10.6 to 16.2)
Periodontal diseases	203.1 (187.7 to 220.2)	269.9 (249.5 to 291.7)	32.3 (19.5 to 49.6)	-1.3 (-10.6 to 11.7)	1.3 (0.5 to 2.7)	1.8 (0.7 to 3.6)	32.1 (19.2 to 49.4)	-1.0 (-

Appendix Table G.4 - Macedonia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	59.3 (57.0 to 61.5)	93.0 (88.6 to 97.4)	56.8 (47.3 to 66.6)	-2.0 (-7.8 to 3.9)	1.6 (1.1 to 2.2)	2.5 (1.7 to 3.5)	55.5 (46.6 to 67.4)	-15 (-7.6 to 4.8)
Other oral disorders	36.2 (34.1 to 38.1)	41.3 (39.4 to 43.5)	14.1 (5.9 to 24.1)	-0.4 (-7.6 to 8.2)	1.1 (0.7 to 1.6)	1.2 (0.8 to 1.8)	13.5 (5.1 to 24.2)	-0.5 (-7.8 to 8.6)
Injuries	-	-	-	-	23.8 (17.9 to 30.8)	21.9 (15.6 to 29.5)	-8.4 (-17.9 to 2.2)	-33.4 (-40.4 to -25.5)
Transport injuries	-	-	-	-	2.9 (2.2 to 3.8)	1.9 (1.3 to 2.6)	-35.2 (-44.0 to -25.2)	-49.0 (-55.6 to -41.4)
Road injuries	-	-	-	-	2.4 (1.8 to 3.1)	1.6 (1.1 to 2.1)	-35.2 (-44.4 to -24.5)	-48.7 (-55.7 to -40.7)
Pedestrian road injuries	-	-	-	-	0.5 (0.4 to 0.6)	0.3 (0.2 to 0.4)	-40.8 (-50.7 to -28.6)	-52.6 (-60.3 to -43.4)
Cyclist road injuries	-	-	-	-	0.5 (0.3 to 0.6)	0.3 (0.2 to 0.3)	-44.6 (-51.9 to -37.3)	-56.5 (-62.0 to -51.0)
Motorcyclist road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-47.1 (-55.5 to -37.7)	-58.0 (-64.4 to -50.7)
Motor vehicle road injuries	-	-	-	-	1.1 (0.8 to 1.4)	0.9 (0.6 to 1.2)	-24.2 (-36.6 to -9.8)	-39.9 (-49.4 to -29.1)
Other road injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-71.1 (-75.3 to -66.3)	-77.7 (-80.8 to -74.2)
Other transport injuries	-	-	-	-	0.6 (0.4 to 0.7)	0.4 (0.3 to 0.5)	-35.0 (-42.6 to -26.7)	-49.9 (-55.6 to -43.5)
Unintentional injuries	-	-	-	-	20.6 (15.5 to 26.7)	19.8 (14.1 to 26.7)	-4.3 (-13.9 to 6.2)	-31.3 (-38.5 to -23.3)
Falls	-	-	-	-	15.8 (11.8 to 20.3)	16.1 (11.4 to 21.7)	1.7 (-9.3 to 14.6)	-29.5 (-37.8 to -20.2)
Drowning	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-41.3 (-50.3 to -31.8)	-52.9 (-59.7 to -45.7)
Fire, heat, and hot substances	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-16.9 (-28.1 to -4.4)	-30.4 (-39.4 to -20.4)
Poisonings	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-43.2 (-52.3 to -33.6)	-50.3 (-58.4 to -41.9)
Exposure to mechanical forces	-	-	-	-	2.4 (1.8 to 3.1)	2.0 (1.4 to 2.7)	-17.1 (-23.9 to -8.9)	-30.1 (-35.3 to -24.0)
Unintentional firearm injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-45.0 (-54.2 to -34.6)	-54.4 (-61.6 to -46.0)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.8 (-56.3 to -42.1)	-56.0 (-61.7 to -49.3)
Other exposure to mechanical forces	-	-	-	-	2.3 (1.7 to 3.0)	2.0 (1.4 to 2.7)	-16.2 (-22.9 to -8.0)	-29.3 (-34.6 to -23.2)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.5 (24.0 to 49.2)	4.2 (-4.3 to 14.8)
Animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	1.3 (-9.8 to 13.4)	-13.3 (-22.0 to -3.6)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	9.2 (-5.7 to 28.6)	-6.4 (-19.4 to 10.3)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-2.7 (-14.7 to 10.3)	-16.8 (-26.5 to -6.3)
Foreign body	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-13.8 (-22.5 to -3.7)	-29.3 (-35.9 to -20.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-35.6 (-47.1 to -20.8)	-45.2 (-54.6 to -33.2)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.4 (-1.8 to 11.2)	-9.4 (-15.8 to -3.4)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-5.3 (-15.1 to 5.6)	-25.0 (-32.3 to -17.1)
Other unintentional injuries	-	-	-	-	1.9 (1.4 to 2.5)	1.2 (0.9 to 1.7)	-35.1 (-40.7 to -29.1)	-50.1 (-54.0 to -45.7)
Self-harm and interpersonal violence	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-26.4 (-34.8 to -16.5)	-48.0 (-50.2 to -36.9)
Self-harm	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-23.1 (-32.5 to -13.4)	-42.6 (-49.5 to -35.6)
Interpersonal violence	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-29.5 (-38.7 to -18.3)	-45.4 (-52.2 to -37.1)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.6 (-20.8 to -2.4)	-33.0 (-39.0 to -25.7)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.7 (-19.5 to 8.0)	-27.6 (-37.1 to -16.6)
Assault by other means	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-36.9 (-45.6 to -26.3)	-50.9 (-57.6 to -43.2)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Madagascar prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,184.0 (869.6 to 1,555.7)	2,297.0 (1,682.2 to 3,008.5)	94.1 (87.9 to 100.8)	4.9 (-7.5 to 1.8)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	374.6 (255.7 to 555.1)	666.3 (460.0 to 965.6)	77.7 (67.1 to 92.2)	-11.6 (-19.0 to -2.5)
HIV/AIDS and tuberculosis	-	-	-	-	9.2 (5.5 to 13.8)	29.0 (17.8 to 56.8)	214.0 (161.1 to 339.8)	54.3 (28.2 to 116.1)
Tuberculosis	25.7 (22.6 to 29.5)	72.6 (68.0 to 77.9)	183.4 (152.3 to 217.9)	40.1 (24.6 to 55.7)	7.7 (5.1 to 10.6)	22.0 (14.9 to 29.8)	185.3 (151.9 to 222.2)	41.0 (24.5 to 58.0)
HIV/AIDS	-	-	-	-	1.3 (0.1 to 5.7)	7.0 (1.3 to 32.1)	738.7 (117.4 to 2,002.7)	36.7 (8.2 to 1,021.9)
HIV/AIDS resulting in mycobacterial infection	0.2 (0.0 to 1.2)	1.4 (0.2 to 6.9)	1,042.6 (174.2 to 2,994.2)	494.4 (38.6 to 1,532.2)	0.1 (0.0 to 0.5)	0.5 (0.1 to 2.7)	968.6 (138.8 to 4,031.7)	449.4 (23.2 to 1,886.8)
HIV/AIDS resulting in other diseases	16.6 (1.0 to 72.1)	38.0 (6.3 to 169.3)	309.8 (20.2 to 1,014.5)	105.9 (-40.7 to 447.5)	1.4 (0.1 to 5.4)	6.5 (0.7 to 31.8)	741.6 (94.2 to 2,339.2)	331.4 (-5.2 to 1,211.7)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	48.5 (34.9 to 65.3)	69.4 (49.5 to 93.9)	42.9 (33.2 to 54.2)	-22.8 (-27.9 to -16.9)
Diarrheal diseases	137.0 (127.0 to 147.3)	213.9 (198.4 to 231.2)	56.3 (40.6 to 73.7)	-8.3 (-16.4 to 0.4)	22.0 (14.8 to 30.5)	55.8 (22.9 to 47.8)	58.8 (40.2 to 74.3)	9.4 (-16.9 to 0.8)
Intestinal infectious diseases	-	-	-	-	0.8 (0.5 to 1.3)	0.9 (0.6 to 1.3)	9.4 (-18.7 to 43.6)	4.3 (-57.2 to -27.3)
Typhoid fever	4.2 (3.7 to 4.8)	5.1 (4.5 to 5.8)	22.5 (0.1 to 47.9)	-36.7 (-48.6 to -22.9)	0.6 (0.4 to 0.8)	0.7 (0.5 to 1.0)	24.3 (8.6 to 62.2)	-35.7 (-51.6 to -16.8)
Paratyphoid fever	1.6 (1.3 to 1.8)	2.4 (1.9 to 2.7)	51.2 (20.9 to 88.9)	-22.8 (-37.8 to -2.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	52.7 (15.0 to 103.0)	-22.0 (-39.9 to 2.9)
Other intestinal infectious diseases	-	-	-	-	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.2)	-49.9 (-68.5 to -34.4)	-72.2 (-83.3 to -56.7)
Lower respiratory infections	8.8 (7.3 to 10.4)	11.5 (9.0 to 13.9)	33.9 (-10.9 to 76.3)	-15.6 (-33.7 to 2.9)	0.9 (0.6 to 1.3)	1.2 (0.8 to 1.8)	33.0 (-12.8 to 82.0)	-16.0 (-35.1 to 6.1)
Upper respiratory infections	616.0 (573.3 to 662.3)	1,105.9 (1,024.1 to 1,188.0)	80.5 (60.7 to 100.0)	-8.0 (-17.3 to 2.1)	7.2 (4.1 to 12.1)	12.9 (7.3 to 21.5)	80.7 (60.8 to 100.4)	-7.7 (-17.1 to 2.7)
Otitis media	208.2 (189.0 to 229.3)	352.0 (324.8 to 384.2)	69.7 (52.3 to 89.5)	-14.5 (-23.3 to -3.6)	4.3 (2.6 to 7.0)	7.3 (4.4 to 11.6)	69.3 (49.8 to 91.7)	-14.3 (-24.0 to -2.6)
Meningitis	-	-	-	-	11.6 (7.7 to 16.0)	11.1 (7.6 to 15.1)	-3.5 (-18.1 to 15.6)	-49.5 (-56.5 to -40.9)
Pneumococcal meningitis	42.6 (26.4 to 62.7)	41.9 (26.0 to 60.0)	-0.1 (-22.8 to 19.9)	-48.3 (-58.1 to -37.8)	3.8 (2.5 to 5.1)	3.9 (2.7 to 5.4)	4.9 (-18.9 to 36.7)	-46.1 (-56.7 to -32.3)
H influenzae type B meningitis	27.2 (11.3 to 48.2)	24.3 (11.3 to 41.6)	-10.1 (-31.6 to 25.5)	-53.9 (-64.7 to -38.5)	3.1 (1.9 to 4.8)	3.0 (1.9 to 4.5)	-5.4 (-35.3 to 65.0)	-51.7 (-65.9 to -17.0)
Meningococcal meningitis	6.7 (2.4 to 13.9)	6.2 (2.4 to 12.5)	-7.3 (-40.7 to 29.3)	-49.2 (-67.6 to -30.6)	0.9 (0.5 to 1.5)	0.8 (0.5 to 1.3)	-7.1 (-40.0 to 38.6)	-49.6 (-67.1 to -27.2)
Other meningitis	31.9 (16.2 to 55.7)	27.3 (14.3 to 47.7)	-13.4 (-33.6 to 10.5)	-54.0 (-64.2 to -42.0)	3.8 (2.4 to 5.6)	3.4 (2.1 to 5.0)	-10.4 (-36.2 to 27.7)	-52.3 (-64.7 to -33.9)
Encephalitis	2.0 (0.9 to 4.1)	3.6 (1.7 to 7.2)	83.6 (60.8 to 108.6)	-7.2 (-17.3 to 3.6)	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.6)	85.1 (58.5 to 117.7)	-7.5 (-20.9 to 5.6)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-	-	-
Whooping cough	13.6 (10.6 to 17.5)	10.1 (7.9 to 13.0)	-25.3 (-29.1 to -21.5)	-55.0 (-57.2 to -52.6)	0.7 (0.4 to 1.1)	0.5 (0.3 to 0.8)	-25.4 (-34.5 to -15.3)	-54.9 (-64.2 to -48.8)
Tetanus	0.4 (0.2 to 0.8)	0.1 (0.1 to 0.2)	-68.9 (-88.6 to -20.8)	-83.3 (-93.7 to -56.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.8 (-73.4 to 6.0)	-71.2 (-84.2 to -40.0)
Measles	6.7 (4.8 to 9.1)	1.9 (1.5 to 2.3)	-72.1 (-77.1 to -65.7)	-83.7 (-86.6 to -80.0)	0.6 (0.3 to 1.0)	0.2 (0.1 to 0.3)	22.4 (80.4 to -61.0)	43.9 (-88.5 to 77.2)
Varicella and herpes zoster	7.2 (6.5 to 8.1)	14.7 (13.6 to 16.3)	104.0 (78.5 to 134.5)	1.4 (-16.1 to 28.5)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	103.4 (45.7 to 190.7)	0.3 (-27.7 to 50.5)
Neglected tropical diseases and malaria	-	-	-	-	210.9 (132.0 to 332.4)	279.3 (173.0 to 442.6)	32.0 (20.6 to 45.2)	-31.7 (-40.6 to -22.7)
Malaria	7,217.2 (6,914.6 to 7,515.0)	7,499.0 (7,164.5 to 7,815.6)	4.3 (0.6 to 7.6)	-47.0 (-48.8 to -45.2)	63.9 (42.4 to 92.2)	65.7 (43.9 to 95.1)	2.8 (-1.8 to 9.1)	-46.2 (-48.8 to -42.6)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	149.0 (27.0 to 453.9)	38.0 (-23.5 to 166.0)
Visceral leishmaniasis	1.0 (0.5 to 1.7)	2.1 (1.2 to 3.5)	108.6 (2.3 to 392.6)	4.4 (-44.4 to 117.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	107.9 (-2.5 to 402.5)	4.7 (-47.1 to 115.9)
Cutaneous and mucocutaneous leishmaniasis	0.1 (0.1 to 0.2)	3.0 (1.8 to 4.6)	2,546.3 (1,645.1 to 4,101.0)	1,596.9 (1,006.4 to 2,498.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	2,446.1 (1,456.2 to 3,940.9)	1,514.7 (898.5 to 2,458.7)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	6,877.2 (4,149.7 to 9,771.1)	10,738.3 (6,486.9 to 15,487.2)	55.3 (46.8 to 75.1)	-34.1 (-28.2 to -34.4)	71.8 (32.2 to 144.7)	114.0 (50.6 to 231.1)	57.7 (40.0 to 79.5)	-22.5 (-29.7 to -12.5)
Cysticercosis	5.8 (2.5 to 10.8)	17.8 (9.4 to 33.8)	209.4 (25.8 to 601.0)	37.5 (-38.9 to 166.5)	1.5 (0.6 to 3.1)	4.9 (2.4 to 10.1)	223.0 (27.9 to 650.3)	44.3 (-39.4 to 188.8)
Cystic echinococcosis	3.5 (3.0 to 4.5)	5.2 (4.5 to 5.8)	59.0 (0.0 to 82.3)	0.2 (-36.0 to 12.1)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.7)	54.8 (-4.7 to 97.2)	-0.9 (-38.7 to 20.7)
Lymphatic filariasis	1,222.5 (945.1 to 1,506.1)	1,124.0 (843.5 to 1,437.0)	-8.4 (-29.8 to 24.6)	-51.8 (-62.2 to -35.3)	29.8 (15.6 to 51.2)	45.1 (23.0 to 78.0)	53.2 (-4.6 to 121.2)	-24.6 (-52.8 to 7.3)
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.4 (0.1 to 1.1)	3.8 (1.0 to 10.7)	864.1 (852.4 to 877.7)	384.8 (378.9 to 391.6)	0.1 (0.0 to 0.2)	0.6 (0.1 to 1.8)	806.5 (619.6 to 1,039.4)	351.7 (272.4 to 446.0)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-36.0 to 90.3)	0.0 (0.0 to 0.0)	20.4 (-36.4 to 90.4)	32.9 (-56.9 to -4.8)
Intestinal nematode infections	-	-	-	-	37.8 (21.9 to 61.3)	35.0 (20.5 to 56.8)	37.8 (-14.9 to -0.2)	-3.0 (-58.1 to -50.2)
Ascariasis	7,645.2 (6,010.0 to 9,500.1)	6,479.1 (5,122.2 to 8,212.4)	-15.3 (-38.1 to 19.9)	-58.3 (-72.0 to -36.8)	15.9 (8.9 to 26.7)	13.8 (7.8 to 23.0)	-13.3 (-22.4 to -3.4)	-57.1 (-62.4 to -51.2)
Trichuriasis	7,388.3 (5,693.3 to 9,467.3)	6,087.6 (4,699.1 to 7,824.6)	-17.4 (-43.6 to 17.8)	-59.1 (-74.2 to -36.3)	11.9 (6.7 to 20.1)	10.1 (5.7 to 16.7)	-15.3 (-25.2 to -3.6)	-58.2 (-64.0 to -51.3)
Hookworm disease	2,422.9 (1,801.2 to 3,315.3)	2,689.0 (1,971.9 to 3,686.9)	11.3 (-27.3 to 72.9)	45.5 (-66.5 to -8.3)	10.0 (6.1 to 15.5)	11.1 (6.8 to 17.2)	45.2 (-6.1 to 26.9)	-45.2 (-53.6 to -37.0)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	140.3 (116.8 to 166.1)	346.1 (317.2 to 384.1)	148.4 (105.5 to 199.6)	33.7 (12.9 to 55.5)	5.6 (3.3 to 8.4)	13.4 (8.6 to 19.5)	135.1 (96.7 to 212.1)	23.8 (2.5 to 64.3)
Maternal disorders	-	-	-	-	4.5 (3.0 to 6.3)	7.4 (4.8 to 10.6)	65.3 (38.7 to 92.5)	-21.0 (-32.8 to -8.2)
Maternal hemorrhage	3.4 (2.8 to 3.9)	5.0 (3.2 to 6.8)	47.6 (-7.2 to 113.7)	-33.0 (-57.8 to -3.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	65.7 (-26.9 to 170.9)	-35.7 (-68.5 to 17.7)
Maternal sepsis and other maternal infections	6.0 (4.0 to 8.4)	6.6 (4.2 to 9.7)	11.0 (-3.0 to 24.5)	-49.8 (-56.5 to -43.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	4.4 (-33.9 to 58.2)	-51.2 (-67.2 to -30.0)
Maternal hypertensive disorders	5.1 (2.6 to 8.4)	7.2 (3.7 to 11.8)	42.4 (25.7 to 61.3)	-33.1 (-40.8 to -24.9)	0.3 (0.1 to 0.5)	0.4 (0.2 to 0.7)	42.8 (21.3 to 73.4)	-33.1 (-43.0 to -18.6)
Obstructed labor	9.0 (7.3 to 11.0)	14.8 (11.8 to 18.2)	64.6 (46.8 to 82.3)	-20.8 (-29.3 to -11.9)	2.9 (1.9 to 4.3)	4.8 (3.1 to 7.1)	65.1 (41.8 to 92.0)	-20.5 (-31.4 to -8.3)
Complications of abortion	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	48.6 (-27.6 to 167.6)	-32.7 (-64.3 to 14.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.6 (-27.9 to 168.6)	-32.7 (-64.3 to 14.7)
Other maternal disorders	-	-	-	-	1.0 (0.6 to 1.6)	1.9 (1.1 to 2.9)	79.8 (17.9 to 154.5)	-14.7 (-43.7 to 20.4)
Neonatal disorders	-	-	-	-	7.1 (4.3 to 11.6)	37.9 (25.5 to 55.1)	443.8 (240.6 to 752.6)	195.4 (77.8 to 364.6)
Preterm birth complications	37.5 (17.7 to 71.1)	162.4 (92.7 to 281.3)	340.7 (258.5 to 487.0)	118.7 (77.2 to 187.0)	2.5 (1.5 to 3.8)	17.6 (11.4 to 25.9)	603.5 (378.1 to 1,056.0)	265.9 (150.2 to 495.2)
Neonatal encephalopathy due to birth asphyxia and trauma	60.9 (5.6 to 200.7)	84.6 (17.6 to 249.9)	54.4 (0.8 to 265.6)	-23.5 (-50.3 to 95.4)	2.2 (0.8 to 5.1)	7.6 (3.7 to 12.7)	267.9 (85.5 to 704.6)	103.8 (-7.0 to 427.0)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.5)	98.9 (78.4 to 133.0)	30.6 (17.1 to 52.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	96.4 (66.1 to 132.6)	28.9 (9.1 to 52.7)
Hemolytic disease and other neonatal jaundice	2.6 (1.2 to 4.8)	12.2 (6.4 to 22.4)	384.9 (73.6 to 1,142.3)	186.0 (-0.6 to 619.0)	1.0 (0.4 to 2.0)	4.7 (2.3 to 8.7)	375.3 (70.8 to 1,142.1)	175.3 (8.1 to 603.8)
Other neonatal disorders	-	-	-	-	1.4 (0.6 to 3.0)	7.9 (3.3 to 18.9)	461.0 (155.2 to 1,110.2)	206.5 (31.2 to 558.0)
Nutritional deficiencies	-	-	-	-	84.9 (57.2 to 122.1)	222.7 (148.2 to 318.4)	160.6 (134.7 to 201.2)	36.3 (25.3 to 54.9)
Protein-energy malnutrition	80.3 (51.5 to 123.4)	292.7 (156.8 to 493.9)	256.5 (76.3 to 637.3)	91.3 (-0.5 to 272.8)	9.7 (6.3 to 16.1)	36.2 (16.3 to 66.3)	293.3 (76.6 to 648.4)	96.4 (0.1 to 287.7)
Iodine deficiency	342.4 (271.8 to 410.5)	461.0 (378.5 to 548.5)	35.3 (2.1 to 79.6)	-34.8 (-52.4 to -9.8)	5.1 (3.7 to 9.7)	8.3 (5.0 to 13.8)	35.9 (2.6 to 79.7)	-34.5 (-50.2 to -9.5)
Vitamin A deficiency	26.2 (16.2 to 44.5)	31.3 (16.7 to 52.5)	16.4 (-11.2 to 65.3)	-41.4 (-55.1 to -20.7)	1.3 (0.7 to 2.2)	1.5 (0.7 to 2.7)	13.3 (-12.7 to 48.5)	-42.0 (-54.4 to -26.6)

Appendix Table G.4 - Madagascar prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	1,933.7 (1,851.6 to 2,010.2)	5,075.1 (4,928.5 to 5,273.4)	163.0 (150.7 to 176.3)	-9.2 (33.7 to 46.2)	67.7 (45.3 to 97.6)	176.5 (117.5 to 253.5)	160.5 (143.5 to 179.0)	160.5 (33.6 to 53.1)
Other nutritional deficiencies	-	-	-	-	0.0	0.0	-	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	(0.0 to 0.1)	(0.1 to 0.5)	(36.5 to 1,114.0)	(-22.0 to 512.5)
Sexually transmitted diseases excluding HIV	-	-	-	-	9.4 (6.0 to 14.5)	20.6 (13.0 to 31.5)	117.9 (92.9 to 152.0)	4.4 (-8.1 to 19.7)
Syphilis	1.6 (1.5 to 1.8)	1.8 (1.6 to 2.1)	14.4 (-1.9 to 35.9)	-44.0 (-51.2 to -34.8)	67.7 (1.6 to 5.2)	176.5 (3.3 to 10.8)	160.5 (61.0 to 162.7)	14.7 (-43.8 to 73.2)
Chlamydial infection	215.3 (119.9 to 293.6)	437.4 (300.3 to 587.6)	101.1 (37.4 to 219.6)	-2.8 (-32.2 to 45.4)	1.1 (0.4 to 2.1)	2.4 (1.1 to 4.6)	117.8 (25.8 to 309.5)	3.3 (-37.5 to 81.1)
Gonococcal infection	99.1 (67.1 to 138.3)	196.3 (137.1 to 262.1)	102.3 (22.6 to 205.2)	-2.3 (-39.9 to 44.0)	0.6 (0.3 to 1.0)	1.1 (0.6 to 1.9)	90.5 (25.8 to 205.6)	-7.9 (-37.0 to 45.2)
Trichomoniasis	146.0 (91.6 to 270.1)	379.9 (192.2 to 620.6)	155.6 (38.9 to 375.6)	16.4 (-30.3 to 98.4)	0.2 (0.1 to 0.6)	0.6 (0.2 to 1.6)	163.4 (27.2 to 456.2)	17.7 (-37.0 to 123.3)
Genital herpes	2,516.3 (2,108.5 to 3,021.3)	5,650.5 (4,544.9 to 6,805.4)	126.2 (74.6 to 188.5)	4.9 (-17.1 to 26.2)	0.7 (0.2 to 1.7)	1.6 (0.5 to 3.8)	127.8 (71.0 to 194.6)	5.3 (-18.1 to 30.8)
Other sexually transmitted diseases	5.3 (3.7 to 7.1)	9.0 (6.2 to 12.4)	71.2 (50.4 to 94.1)	-22.0 (-32.0 to -10.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	73.6 (24.0 to 136.1)	-18.6 (-38.6 to 7.6)
Hepatitis	-	-	-	-	1.4 (0.8 to 2.0)	2.5 (1.5 to 3.6)	80.2 (43.6 to 130.5)	-13.5 (-35.0 to 16.5)
Hepatitis A	21.4 (20.2 to 22.6)	40.3 (38.3 to 42.2)	88.8 (87.6 to 90.0)	0.2 (0.1 to 0.2)	0.9 (0.2 to 0.6)	1.5 (0.5 to 1.1)	99.6 (77.0 to 125.5)	-0.2 (-10.8 to 11.2)
Hepatitis B	2,153.2 (1,692.2 to 2,691.0)	3,670.7 (3,143.2 to 4,210.0)	71.3 (33.6 to 128.8)	-16.8 (-34.2 to 7.6)	0.2 (0.5 to 1.4)	1.5 (0.9 to 2.4)	71.0 (20.1 to 147.6)	-17.7 (-43.6 to 25.1)
Hepatitis C	110.0 (100.4 to 120.0)	151.0 (145.3 to 178.6)	46.7 (28.9 to 67.9)	-28.4 (-36.0 to -19.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.8 (16.3 to 86.2)	-23.2 (-47.6 to 7.3)
Hepatitis E	2.3 (1.6 to 2.9)	4.8 (3.4 to 6.5)	107.5 (45.6 to 258.9)	-0.7 (-28.4 to 72.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	108.6 (32.1 to 287.7)	-0.2 (-35.2 to 84.2)
Leprosy	6.1 (4.6 to 7.5)	10.4 (9.2 to 11.7)	72.3 (44.8 to 111.4)	-12.7 (-25.2 to 4.6)	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.9)	77.9 (48.1 to 122.6)	-10.5 (-24.2 to 8.8)
Other infectious diseases	101.3 (87.0 to 116.2)	251.2 (224.1 to 276.1)	148.9 (115.6 to 189.5)	32.5 (18.1 to 50.0)	4.7 (2.9 to 7.3)	11.3 (7.1 to 17.3)	136.8 (97.2 to 207.6)	23.6 (-2.7 to 68.9)
Non-communicable diseases	-	-	-	-	769.8 (565.5 to 993.5)	1,565.1 (1,157.2 to 2,009.5)	109.5 (96.8 to 109.9)	2.0 (-4.8 to 1.3)
Neoplasms	-	-	-	-	2.8 (1.9 to 3.7)	6.2 (4.0 to 8.7)	120.6 (67.3 to 187.9)	14.3 (-10.8 to 46.7)
Esophageal cancer	1.1 (0.7 to 1.5)	1.8 (1.2 to 2.7)	69.5 (9.5 to 172.9)	-15.4 (-44.0 to 31.9)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	70.8 (13.6 to 164.8)	-14.7 (-42.7 to 29.7)
Stomach cancer	0.6 (0.5 to 0.7)	1.0 (0.8 to 1.4)	72.0 (24.4 to 134.4)	-10.1 (-34.9 to 21.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	75.1 (23.8 to 140.3)	-8.8 (-34.5 to 24.1)
Liver cancer	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.1)	96.1 (30.3 to 168.3)	45.9 (-32.9 to 32.0)
Liver cancer due to hepatitis B	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	82.0 (-29.1 to 391.5)	-8.5 (-67.4 to 147.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	78.3 (-25.2 to 333.8)	-10.2 (-66.7 to 127.5)
Liver cancer due to hepatitis C	0.1 (0.0 to 0.1)	0.5 (0.2 to 0.8)	418.6 (157.2 to 978.7)	141.9 (24.3 to 394.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	387.1 (167.3 to 858.9)	127.5 (28.6 to 334.6)
Liver cancer due to alcohol use	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-13.4 (-54.4 to 64.3)	-55.5 (-76.5 to -38.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-14.4 (-50.9 to 46.1)	-55.3 (-73.3 to -24.1)
Liver cancer due to other causes	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	193.2 (-37.3 to 154.4)	-40.6 (-69.4 to 31.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.9 (-35.8 to 124.4)	42.2 (-67.9 to 15.6)
Larynx cancer	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.5)	38.5 (-8.8 to 112.5)	-28.2 (-52.3 to 9.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	38.5 (-8.2 to 111.5)	-28.0 (-53.3 to 9.7)
Tracheal, bronchus and lung cancer	0.3 (0.3 to 0.4)	0.6 (0.4 to 0.8)	67.9 (22.8 to 131.5)	-12.0 (-34.3 to 21.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	73.2 (23.2 to 148.1)	-9.5 (-34.4 to 28.6)
Breast cancer	4.0 (2.3 to 5.4)	11.9 (6.2 to 17.8)	189.9 (84.7 to 366.9)	38.7 (9.4 to 116.8)	0.4 (0.2 to 0.5)	1.0 (0.5 to 1.6)	170.7 (68.0 to 318.4)	30.1 (-16.1 to 95.4)
Cervical cancer	5.4 (3.5 to 7.2)	9.2 (5.1 to 14.4)	67.8 (-3.7 to 191.0)	6.6 (-50.7 to 41.1)	0.5 (0.3 to 0.7)	1.6 (0.4 to 1.3)	69.9 (21.9 to 155.5)	-15.1 (-47.3 to 42.7)
Uterine cancer	0.7 (0.4 to 1.2)	1.3 (0.7 to 2.3)	83.0 (-3.9 to 259.2)	-8.4 (-50.7 to 67.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	86.1 (-1.8 to 248.3)	-6.6 (-48.0 to 71.7)
Prostate cancer	2.9 (1.7 to 4.3)	11.6 (6.9 to 18.3)	291.8 (138.8 to 570.9)	100.6 (25.8 to 231.6)	0.3 (0.2 to 0.5)	1.0 (0.6 to 1.7)	235.3 (115.8 to 434.5)	75.7 (15.5 to 169.7)
Colon and rectum cancer	1.8 (1.5 to 2.1)	4.3 (3.1 to 5.5)	138.7 (75.1 to 218.9)	16.7 (-12.0 to 51.9)	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.6)	131.2 (69.9 to 212.1)	13.6 (-14.7 to 49.9)
Lip and oral cavity cancer	1.0 (0.7 to 1.3)	1.8 (1.2 to 2.6)	87.7 (24.5 to 183.5)	-5.2 (-35.0 to 42.8)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	88.2 (25.4 to 182.9)	-4.4 (-34.9 to 43.2)
Nasopharynx cancer	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	41.4 (-15.4 to 166.3)	-32.0 (-59.6 to 24.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	32.3 (-13.0 to 149.6)	-32.3 (-57.7 to 18.0)
Other pharynx cancer	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	57.8 (-11.5 to 201.0)	-19.7 (-54.0 to 49.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	59.0 (-1.6 to 182.3)	-18.5 (-49.2 to 42.0)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	108.1 (40.7 to 216.0)	2.6 (-30.5 to 58.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.9 (43.4 to 190.2)	-0.2 (-28.6 to 46.9)
Pancreatic cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	81.0 (26.6 to 150.7)	-10.6 (-36.0 to 24.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	82.3 (37.8 to 144.5)	-9.6 (-31.8 to 19.2)
Malignant skin melanoma	0.4 (0.4 to 0.7)	0.8 (0.9 to 2.1)	154.7 (76.6 to 277.2)	23.9 (-13.2 to 85.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	148.0 (72.3 to 271.0)	21.4 (-15.8 to 79.4)
Non-melanoma skin cancer	0.7 (0.5 to 0.8)	1.6 (1.2 to 2.0)	136.9 (77.3 to 223.9)	18.7 (-11.3 to 65.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	158.3 (78.9 to 282.1)	33.5 (-14.7 to 103.0)
Ovarian cancer	0.4 (0.3 to 0.7)	0.8 (0.4 to 1.3)	78.8 (5.8 to 192.3)	-9.1 (-45.4 to 46.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	80.3 (3.4 to 208.6)	-7.9 (-47.1 to 59.8)
Testicular cancer	0.2 (0.1 to 0.4)	0.6 (0.3 to 1.0)	192.8 (63.2 to 427.9)	31.9 (-25.2 to 128.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	177.4 (40.3 to 425.8)	24.3 (-33.0 to 123.9)
Kidney cancer	0.7 (0.4 to 1.2)	0.9 (0.6 to 1.5)	27.6 (-35.0 to 159.0)	8.5 (-40.9 to 41.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	44.5 (-22.6 to 184.2)	0.9 (-33.0 to 46.4)
Bladder cancer	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.9)	48.8 (0.6 to 130.8)	-23.2 (-48.1 to 17.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	49.6 (2.6 to 128.7)	-22.5 (-47.4 to 19.4)
Brain and nervous system cancer	0.4 (0.3 to 0.5)	1.1 (0.6 to 1.5)	162.8 (66.3 to 294.2)	29.2 (-8.2 to 75.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	155.8 (71.9 to 268.6)	22.5 (-12.0 to 66.2)
Thyroid cancer	0.5 (0.3 to 0.8)	1.0 (0.5 to 1.6)	89.0 (-4.3 to 260.4)	-8.7 (-54.3 to 71.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	85.5 (-7.3 to 254.1)	-10.7 (-55.2 to 65.4)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.9 (22.3 to 182.7)	2.4 (-35.4 to 41.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.4 (23.1 to 187.7)	-1.4 (-31.4 to 50.0)
Hodgkin lymphoma	0.7 (0.4 to 1.0)	1.5 (0.9 to 2.7)	125.9 (39.9 to 299.0)	30.8 (-15.3 to 114.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	120.7 (41.7 to 259.1)	22.5 (-21.2 to 95.7)
Non-Hodgkin lymphoma	1.8 (1.1 to 2.5)	3.1 (2.0 to 4.5)	75.6 (5.6 to 187.7)	2.8 (-30.7 to 55.2)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	83.3 (16.0 to 194.9)	3.8 (-28.8 to 57.7)
Multiple myeloma	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	122.2 (38.4 to 241.1)	10.5 (-30.4 to 68.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	117.9 (34.3 to 231.5)	8.2 (-36.3 to 68.3)
Leukemia	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.1)	101.7 (12.9 to 232.7)	8.9 (-27.0 to 60.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	102.4 (37.0 to 203.8)	4.9 (-27.4 to 50.1)
Other neoplasms	3.9 (2.6 to 6.0)	9.6 (5.8 to 13.8)	161.5 (12.2 to 319.1)	32.9 (-16.2 to 96.0)	0.3 (0.2 to 0.4)	0.7 (0.4 to 1.0)	155.9 (25.2 to 294.3)	25.7 (-15.3 to 80.9)
Cardiovascular diseases	-	-	-	-	20.1 (13.6 to 27.8)	37.8 (25.3 to 53.0)	87.3 (50.7 to 131.5)	-7.1 (-26.0 to 15.0)
Rheumatic heart disease	125.7 (100.5 to 146.3)	247.4 (190.3 to 297.7)	98.5 (47.5 to 166.3)	-2.8 (-23.1 to 19.8)	6.2 (3.9 to 9.1)	11.9 (7.4 to 18.1)	92.9 (45.1 to 155.7)	-7.9 (-26.5 to 14.4)
Ischemic heart disease	111.8 (86.7 to 145.3)	150.8 (123.2 to 196.4)	166.3 (-1.2 to 90.3)	-28.1 (-46.7 to -0.3)	5.9 (3.6 to 8.6)	7.3 (4.5 to 10.9)	36.3 (15.0 to 92.9)	-33.6 (-53.9 to 1.6)
Cerebrovascular disease	-	-	-	-	0.6 (0.4 to 0.9)	1.3 (0.9 to 1.8)	111.8 (71.6 to 177.8)	4.0 (-15.1 to 38.2)
Ischemic stroke	3.1 (2.5 to 3.8)	6.7 (5.5 to 7.9)	111.9 (72.5 to 172.3)	4.1 (-15.1 to 37.7)	0.5 (0.3 to 0.7)	1.0 (0.7 to 1.4)	112.5 (71.1 to 179.5)	4.8 (-15.7 to 39.4)
Hemorrhagic stroke	0.9 (0.7 to 1.1)	1.8 (1.4 to 2.2)	114.0 (62.2 to 187.9)	3.9 (-19.6 to 43.4)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	112.3 (61.2 to 184.9)	2.5 (-20.4 to 40.1)
Hypertensive heart disease	15.4 (11.8 to 19.4)	36.1 (27.0 to 45.7)	134.7 (60.7 to 249.2)	21.2 (-2.3 to 83.3)	1.6 (1.0 to 2.4)	3.9 (2.4 to 5.9)	156.3 (63.1 to 251.3)	22.4 (-21.7 to 85.3)
Cardiomyopathy and myocarditis	10.8 (8.6 to 13.5)	29.3 (21.1 to 38.5)	173.8 (82.5 to 291.2)	35.8 (-20.7 to 114.6)	1.2 (0.7 to 1.7)	3.2 (2.0 to 4.7)	176.7 (81.5 to 302.2)	37.4 (-20.4 to 117.6)
Atrial fibrillation and flutter	5.6 (4.2 to 7.0)	16.7 (11.6 to 23.1)	197.2 (86.1 to 380.2)	1.2 (-5.6 to 197.1)	0.4 (0.3 to 0.6)	1.7 (0.7 to 1.9)	199.3 (87.9 to 375.0)	61.5 (-2.8 to 192.3)
Peripheral vascular disease	176.5 (126.4 to 225.3)	302.7 (147.9 to 448.9)	70.2 (2.2 to 168.7)	-14.6 (-48.6 to 31.5)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	21.6 (-62.1 to 173.3)	-31.7 (-77.6 to 43.1)
Endocarditis	0.4 (0.3 to 0.7)	0.8 (0.4 to 1.5)	95.0 (5.7 to 224.3)	-4.2 (-56.4 to 93.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	106.3 (0.9 to 267.0)	-0.4 (-59.6 to 114.9)
Other cardiovascular and circulatory diseases	59.7 (31.8 to 101.0)	126.0 (60.9 to 197.4)	117.2 (8.6 to 354.5)	4.4 (-62.0 to 117.9)	1.7 (1.9 to 7.3)	8.8 (4.1 to 14.9)	118.3 (8.5 to 363.8)	3.2 (-61.3 to 119.2)
Chronic respiratory diseases	-	-	-	-	60.1 (39.5 to 85.2)	112.3 (75.1 to 156.9)	87.2 (53.8 to 125.0)	-14.9

Appendix Table G.4 - Madagascar prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	-	-
Silicosis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	76.5 (68.0 to 85.1)	-15.3 (-19.1 to -11.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (84.4 to 97.5)	-15.3 (-118.2 to -5.8)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.0	0.0	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	106.2 (98.7 to 115.4)	-1.2 (-4.6 to 3.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.8 (96.6 to 114.3)	-1.7 (-5.1 to 2.9)
Asthma	168.3 (128.1 to 238.3)	569.7 (425.3 to 734.7)	242.2 (117.0 to 431.2)	32.3 (-6.6 to 83.2)	7.2 (4.1 to 11.6)	24.9 (15.0 to 37.6)	248.8 (118.1 to 449.7)	35.1 (-5.9 to 86.7)
Interstitial lung disease and pulmonary sarcoidosis	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.6)	119.4 (42.7 to 229.3)	5.9 (-26.8 to 55.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	120.5 (44.4 to 227.9)	6.2 (-26.3 to 54.2)
Other chronic respiratory diseases	-	-	-	-	21.8 (12.2 to 35.5)	22.4 (13.0 to 36.1)	2.1 (-32.3 to 58.1)	-51.0 (-67.8 to -23.3)
Cirrhosis	-	-	-	-	0.9 (0.6 to 1.3)	1.5 (1.1 to 2.1)	64.8 (44.9 to 87.2)	15.0 (-24.4 to -5.4)
Cirrhosis due to hepatitis B	1.5 (0.9 to 2.1)	2.5 (1.6 to 3.4)	66.0 (-13.0 to 195.7)	-12.4 (51.2 to 47.5)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.7)	67.5 (-16.0 to 208.4)	-11.7 (-52.1 to 55.2)
Cirrhosis due to hepatitis C	0.9 (0.6 to 1.3)	1.7 (1.1 to 2.5)	80.8 (-2.0 to 284.9)	-13.5 (-49.0 to 88.3)	0.2 (0.1 to 0.2)	0.3 (0.1 to 0.5)	86.0 (-6.4 to 285.4)	-12.1 (-51.1 to 94.6)
Cirrhosis due to alcohol use	1.5 (1.1 to 2.0)	1.9 (1.4 to 2.6)	31.4 (-14.9 to 96.3)	-33.0 (-56.4 to -3.6)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	32.3 (-17.4 to 109.3)	-32.9 (-57.2 to 0.5)
Cirrhosis due to other causes	1.7 (1.4 to 2.1)	3.1 (2.5 to 3.9)	76.5 (29.8 to 154.8)	5.2 (-25.6 to 63.3)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.8)	77.4 (19.8 to 179.0)	5.1 (-30.2 to 68.1)
Digestive diseases	-	-	-	-	13.7 (9.4 to 18.8)	28.2 (19.8 to 38.7)	106.3 (85.6 to 127.1)	5.1 (-5.8 to 14.5)
Peptic ulcer disease	80.5 (68.0 to 90.6)	130.3 (103.9 to 152.8)	63.5 (34.6 to 97.1)	-16.0 (-30.6 to 0.6)	2.8 (1.8 to 3.9)	4.9 (3.3 to 7.0)	79.0 (42.6 to 117.4)	-8.4 (-26.1 to 8.6)
Gastritis and duodenitis	127.7 (108.2 to 143.4)	256.2 (231.3 to 280.2)	101.4 (75.2 to 137.8)	3.2 (-11.3 to 24.3)	5.5 (3.6 to 8.0)	11.0 (7.4 to 15.9)	98.6 (65.3 to 127.8)	4.6 (-13.7 to 17.0)
Appendicitis	1.4 (1.1 to 1.8)	3.1 (2.4 to 4.1)	115.8 (44.5 to 212.4)	2.4 (-28.4 to 41.9)	0.4 (0.3 to 0.7)	0.9 (0.6 to 1.4)	117.2 (32.1 to 241.1)	3.5 (-33.1 to 56.1)
Paralytic ileus and intestinal obstruction	0.2 (0.1 to 0.3)	0.3 (0.3 to 0.4)	79.3 (28.5 to 170.2)	-4.3 (-16.2 to 10.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	90.6 (12.9 to 199.5)	2.6 (-26.0 to 27.1)
Inguinal, femoral, and abdominal hernia	28.5 (22.0 to 40.1)	80.8 (69.4 to 92.8)	195.3 (97.8 to 277.0)	0.3 (106.6 to 241.2)	0.8 (0.1 to 0.6)	0.8 (0.4 to 1.6)	187.1 (90.7 to 275.3)	166.5 (102.7 to 239.2)
Inflammatory bowel disease	10.4 (9.9 to 10.9)	27.4 (26.2 to 28.6)	163.9 (148.5 to 181.9)	25.6 (18.9 to 33.2)	2.2 (1.5 to 3.0)	5.8 (3.9 to 8.0)	166.3 (141.2 to 191.3)	26.6 (16.6 to 36.7)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	93.1 (37.8 to 162.8)	-4.6 (-39.5 to 37.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.3 (35.1 to 162.4)	-6.9 (-45.5 to 44.5)
Gallbladder and biliary diseases	9.4 (8.0 to 3.8)	7.9 (7.1 to 8.8)	131.9 (96.8 to 184.3)	0.4 (-0.8 to 4.4)	0.8 (0.2 to 1.2)	0.8 (0.6 to 1.2)	133.0 (93.0 to 197.5)	19.6 (-1.1 to 47.6)
Pancreatitis	1.8 (1.7 to 1.9)	4.2 (3.9 to 4.2)	126.6 (110.5 to 146.9)	4.8 (-2.4 to 13.7)	0.2 (0.4 to 0.7)	1.2 (0.8 to 1.7)	127.3 (93.0 to 174.5)	5.6 (-9.2 to 25.1)
Other digestive diseases	-	-	-	-	1.5 (0.9 to 2.5)	2.6 (1.6 to 4.8)	68.5 (26.2 to 153.8)	-14.7 (-36.5 to 31.3)
Neurological disorders	-	-	-	-	44.8 (29.8 to 64.7)	97.9 (63.0 to 140.7)	120.0 (58.3 to 186.1)	6.1 (-17.9 to 30.8)
Alzheimer disease and other dementias	17.4 (15.2 to 19.4)	34.4 (30.3 to 38.8)	97.2 (71.8 to 138.1)	1.4 (-11.9 to 24.6)	2.3 (1.7 to 3.1)	4.7 (3.4 to 6.2)	99.1 (73.5 to 141.8)	2.2 (-11.6 to 25.2)
Parkinson disease	0.9 (0.6 to 1.3)	1.8 (1.2 to 2.5)	92.9 (78.2 to 110.7)	-1.3 (-7.8 to 6.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	94.7 (64.7 to 136.0)	-0.7 (-15.9 to 18.3)
Epilepsy	27.3 (15.8 to 43.4)	60.0 (32.8 to 96.0)	124.3 (11.1 to 346.6)	8.7 (-44.7 to 117.1)	7.9 (4.3 to 13.5)	18.2 (9.1 to 31.8)	129.7 (12.8 to 363.0)	13.1 (-44.3 to 125.2)
Multiple sclerosis	0.8 (0.8 to 0.9)	2.1 (1.9 to 2.4)	150.0 (111.5 to 196.7)	0.3 (-1.0 to 35.7)	0.3 (0.2 to 0.4)	0.7 (0.5 to 1.0)	148.6 (94.1 to 215.1)	15.8 (-6.6 to 45.3)
Migraine	647.5 (486.2 to 928.9)	1,210.5 (777.1 to 1,747.8)	88.7 (2.5 to 190.6)	-7.2 (-42.8 to 39.2)	21.9 (12.1 to 36.3)	41.0 (20.3 to 68.0)	88.2 (13.3 to 193.7)	-6.6 (-43.4 to 41.6)
Tension-type headache	1,325.0 (1,224.2 to 1,427.8)	3,011.4 (2,760.4 to 3,258.2)	128.1 (105.8 to 153.9)	5.8 (-3.0 to 15.6)	2.0 (1.0 to 3.5)	4.5 (2.2 to 8.0)	129.2 (105.0 to 156.4)	6.4 (-0.2 to 17.1)
Medication overuse headache	52.3 (33.1 to 71.2)	158.3 (103.7 to 219.3)	199.9 (132.7 to 317.4)	40.7 (10.2 to 102.4)	8.1 (4.5 to 12.5)	24.8 (14.1 to 38.6)	202.3 (133.7 to 324.9)	41.9 (10.4 to 104.8)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.5 (34.3 to 153.2)	-8.4 (-33.9 to 23.8)	2.2 (1.3 to 3.8)	3.7 (2.3 to 5.5)	70.5 (6.3 to 153.4)	-14.1 (-46.8 to 29.3)
Mental and substance use disorders	-	-	-	-	260.6 (180.7 to 351.4)	544.6 (383.1 to 734.1)	109.1 (102.9 to 115.7)	1.2 (-2.0 to 4.1)
Schizophrenia	23.4 (21.3 to 25.3)	50.2 (45.8 to 54.3)	114.8 (105.4 to 124.2)	0.9 (-3.3 to 5.0)	14.8 (10.7 to 17.9)	32.0 (23.4 to 38.6)	116.0 (102.0 to 131.0)	1.5 (-4.3 to 8.2)
Alcohol use disorders	118.5 (109.9 to 128.1)	217.1 (200.9 to 232.9)	83.9 (74.3 to 94.2)	-11.5 (-16.3 to -6.8)	11.5 (7.7 to 16.1)	21.2 (14.2 to 29.8)	84.3 (71.9 to 97.5)	-11.3 (-16.9 to -5.5)
Drug use disorders	-	-	-	-	13.8 (9.1 to 18.9)	29.3 (19.3 to 40.8)	113.2 (90.4 to 139.8)	0.9 (-8.7 to 12.6)
Opioid use disorders	17.5 (11.2 to 26.1)	39.1 (25.9 to 55.9)	125.6 (99.6 to 146.8)	2.7 (-7.4 to 12.4)	7.1 (4.0 to 11.1)	16.0 (9.4 to 24.7)	126.1 (96.1 to 153.6)	3.1 (-9.2 to 15.4)
Cocaine use disorders	5.5 (4.4 to 6.4)	12.0 (9.9 to 13.9)	119.6 (68.8 to 181.3)	0.7 (-18.6 to 27.8)	0.6 (0.5 to 1.1)	1.6 (1.0 to 2.4)	118.7 (62.5 to 201.2)	3.3 (-21.8 to 35.7)
Amphetamine use disorders	18.4 (17.1 to 19.8)	35.3 (32.9 to 38.1)	93.0 (74.3 to 114.1)	-4.9 (-13.6 to 4.6)	2.4 (1.5 to 3.5)	4.6 (2.8 to 6.8)	93.3 (65.7 to 128.9)	-4.5 (-17.6 to 11.5)
Cannabis use disorders	14.9 (11.0 to 18.2)	30.5 (22.6 to 37.1)	105.2 (104.3 to 106.4)	0.0 (-0.0 to 0.1)	0.4 (0.3 to 0.7)	0.9 (0.5 to 1.4)	106.3 (71.1 to 146.6)	0.2 (-15.1 to 18.6)
Other drug use disorders	-	-	-	-	3.1 (2.0 to 4.7)	6.3 (4.0 to 9.4)	100.9 (50.8 to 185.6)	-1.9 (-26.8 to 36.1)
Depressive disorders	-	-	-	-	125.1 (78.8 to 185.0)	262.9 (169.1 to 389.1)	110.3 (98.5 to 124.0)	1.6 (-3.5 to 7.3)
Major depressive disorder	562.6 (427.7 to 696.9)	1,172.4 (908.0 to 1,448.7)	109.3 (96.4 to 123.9)	1.1 (-4.7 to 7.4)	114.6 (71.8 to 171.4)	240.6 (152.0 to 358.9)	110.2 (97.3 to 125.4)	1.7 (-4.0 to 8.0)
Dysthymia	111.1 (91.4 to 132.6)	233.1 (192.7 to 277.9)	110.6 (108.4 to 113.2)	0.5 (0.3 to 0.8)	10.6 (6.8 to 15.4)	22.3 (14.4 to 32.6)	111.7 (105.1 to 117.8)	1.0 (-1.5 to 3.4)
Bipolar disorder	62.6 (53.2 to 71.3)	130.5 (111.5 to 147.6)	108.9 (97.8 to 122.0)	0.1 (-4.5 to 5.4)	12.6 (7.7 to 19.0)	26.4 (16.3 to 40.1)	110.1 (95.0 to 127.8)	0.6 (-5.8 to 7.4)
Anxiety disorders	342.1 (137.0 to 570.8)	707.7 (283.9 to 1,165.3)	107.7 (104.4 to 111.9)	0.4 (0.1 to 1.5)	31.1 (11.4 to 56.3)	64.9 (23.8 to 116.8)	108.7 (101.4 to 116.0)	1.0 (-1.7 to 3.6)
Eating disorders	-	-	-	-	2.9 (1.7 to 4.5)	5.9 (3.5 to 9.3)	105.3 (88.2 to 125.6)	0.7 (-7.7 to 10.2)
Anorexia nervosa	2.0 (1.5 to 2.6)	4.2 (3.2 to 5.5)	114.6 (91.2 to 133.7)	5.1 (-6.1 to 13.9)	0.4 (0.3 to 0.6)	0.9 (0.6 to 1.4)	113.9 (68.2 to 174.1)	4.6 (-17.5 to 33.3)
Bulimia nervosa	11.7 (8.0 to 17.1)	23.7 (16.2 to 34.6)	103.0 (102.0 to 104.1)	-0.3 (-0.4 to -0.2)	2.4 (1.4 to 4.0)	5.0 (2.9 to 8.1)	103.3 (85.8 to 125.4)	-0.1 (-8.6 to 10.0)
Autistic spectrum disorders	-	-	-	-	13.7 (9.5 to 18.6)	27.4 (19.2 to 37.2)	99.7 (92.4 to 108.4)	0.2 (-3.3 to 3.6)
Autism	35.5 (33.6 to 37.3)	70.5 (66.8 to 74.2)	99.4 (99.1 to 99.8)	-0.4 (-0.4 to -0.4)	8.7 (5.8 to 11.9)	17.3 (11.6 to 23.8)	100.1 (89.5 to 111.7)	0.1 (-4.3 to 5.1)
Asperger syndrome	51.1 (47.9 to 54.1)	101.1 (94.7 to 107.1)	98.7 (98.3 to 99.3)	-0.5 (-0.6 to -0.5)	5.1 (3.5 to 7.0)	10.1 (7.0 to 13.9)	99.3 (90.2 to 108.8)	0.0 (-4.0 to 3.8)
Attention-deficit/hyperactivity disorder	85.7 (79.1 to 92.6)	169.5 (156.4 to 183.1)	98.6 (98.5 to 98.6)	0.0 (0.0 to 0.0)	1.0 (0.6 to 1.6)	2.1 (1.2 to 3.1)	99.2 (84.6 to 115.5)	0.4 (-7.3 to 8.4)
Conduct disorder	126.6 (119.3 to 134.0)	250.7 (236.4 to 265.7)	98.3 (98.0 to 99.0)	0.0 (-0.0 to -0.0)	15.0 (9.4 to 21.8)	30.0 (18.8 to 43.7)	99.8 (90.5 to 109.2)	0.3 (-4.1 to 5.1)
Idiopathic intellectual disability	181.8 (86.0 to 251.0)	427.3 (283.5 to 558.7)	132.3 (92.7 to 268.3)	20.2 (-1.5 to 103.2)	8.8 (3.8 to 13.7)	20.8 (12.7 to 30.8)	132.4 (91.5 to 257.6)	20.1 (-1.8 to 101.8)
Other mental and substance use disorders	139.1 (129.7 to 148.1)	292.0 (272.4 to 310.2)	110.6 (109.7 to 111.5)	-0.4 (-0.7 to -0.2)	10.2 (10.0 to 13.7)	21.7 (14.8 to 29.0)	111.9 (102.2 to 121.2)	0.3 (-3.6 to 4.1)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	51.9 (36.4 to 69.6)	112.9 (80.4 to 151.1)	117.3 (103.3 to 133.6)	5.9 (-1.2 to 15.5)
Diabetes mellitus	90.9 (71.6 to 119.0)	225.3 (190.6 to 271.3)	152.1 (83.2 to 232.4)	16.8 (-16.3 to 52.5)	6.8 (4.3 to 9.9)	17.2 (11.4 to 24.6)	155.8 (85.4 to 246.0)	17.8 (-15.6 to 60.1)
Acute glomerulonephritis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	49.5 (40.6 to 59.1)	-17.7 (-21.3 to -13.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.5 (40.5 to 59.2)	-17.7 (-21.3 to -13.2)
Chronic kidney disease	-	-	-	-	18.0 (12.9 to 23.9)	36.7 (26.0 to 48.2)	103.3 (86.5 to 125.7)	1.6 (-7.0 to 12.3)
Chronic kidney disease due to diabetes mellitus	151.7 (95.0 to 251.0)	271.5 (187.8 to 415.4)	80.0 (31.4 to 154.7)	-11.7 (-34.0 to 26.9)	2.3 (1.5 to 3.3)	4.2 (2.8 to 6.0)	81.5 (40.2 to 154.4)	-10.8 (-31.8 to 24.9)
Chronic kidney disease due to hypertension	450.1 (303.0 to 737.5)	950.4 (625.7 to 1,524.9)	111.3 (73.3 to 164.7)	8.0 (-9.8 to 36.8)	5.4 (3.8 to 7.4)	11.8 (8.4 to 15.5)	118.4 (81.0 to 160.1)	5.9 (-8.0 to 24.5)
Chronic kidney disease due to glomerulonephritis	391.4 (270.6 to 580.5)	842.6 (573.4 to 1,287.8)	116.5 (76.4 to 166.6)	0.4 (-13.0 to 22.3)	0.4 (4.2 to 8.4)	11.3 (0.0 to 17.3)	111.4 (76.3 to 159.1)	9.4 (-10.1 to 35.7)
Chronic kidney disease due to other causes	319.7 (199.7 to 547.1)	589.2 (346.0 to 944.7)	86.6 (41.9 to 141.0)	-8.6 (-30.0 to 18.3)	4.1 (2.9 to 5.6)	7.6 (5.2 to 10.5)	86.4 (45.8 to 131.6)	-7.3 (-29.1 to 16.8)
Urinary diseases and male infertility	-	-	-	-	3.6 (2.3 to 5.1)	6.6 (4.2 to 9.6)	83.7 (61.1 to 105.6)	-7.0 (-18.0 to 3.3)

Appendix Table G.4 - Madagascar prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	2.2 (2.0 to 2.3)	4.7 (4.4 to 4.9)	115.1 (96.9 to 136.9)	0.1 (0.1 to 17.0)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	117.0 (73.4 to 178.2)	117.0 (9.9 to 342)
Urolithiasis	28.1 (21.1 to 37.3)	40.3 (28.1 to 51.2)	45.3 (18.1 to 71.2)	-26.2 (-39.1 to -12.7)	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.7)	95.0 (66.7 to 124.0)	-8.6 (-20.8 to 3.1)
Benign prostatic hyperplasia	77.6 (71.0 to 83.6)	135.5 (123.0 to 147.6)	75.4 (55.2 to 97.1)	-7.9 (-18.7 to 3.1)	2.7 (1.8 to 3.8)	4.8 (3.1 to 6.8)	77.0 (56.5 to 99.1)	-7.1 (-18.2 to 4.0)
Male infertility due to other causes	70.6 (46.9 to 99.1)	149.9 (107.6 to 208.0)	116.1 (82.9 to 246.3)	-0.1 (-39.3 to 63.3)	0.4 (0.2 to 1.0)	1.0 (0.4 to 2.1)	124.8 (26.1 to 251.0)	4.7 (-39.4 to 65.0)
Other urinary diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	95.0 (8.2 to 126.0)	-8.0 (-56.7 to 6.3)
Gynecological diseases	-	-	-	-	9.6 (6.0 to 14.2)	22.2 (13.9 to 33.9)	130.1 (93.7 to 180.0)	6.4 (-8.8 to 26.1)
Uterine fibroids	162.9 (146.7 to 177.7)	364.7 (330.0 to 396.7)	124.7 (123.4 to 126.0)	-1.2 (-1.3 to -1.2)	1.8 (1.0 to 3.1)	4.8 (2.7 to 7.9)	167.8 (135.7 to 231.4)	21.3 (6.8 to 45.3)
Polycystic ovarian syndrome	157.1 (141.9 to 173.9)	351.2 (313.8 to 390.5)	124.2 (91.2 to 161.8)	2.0 (-11.9 to 17.2)	1.5 (0.7 to 2.9)	3.4 (1.6 to 6.5)	125.1 (91.5 to 163.0)	2.5 (-10.8 to 18.5)
Female infertility due to other causes	67.1 (47.0 to 89.9)	135.5 (97.8 to 182.1)	100.0 (31.4 to 222.0)	0.7 (-4.1 to 45.5)	0.7 (0.1 to 0.7)	0.7 (0.3 to 1.6)	62.0 (34.4 to 231.8)	-8.0 (-38.9 to 49.9)
Endometriosis	16.0 (13.4 to 18.5)	31.3 (26.9 to 36.2)	95.8 (58.4 to 146.6)	-10.1 (-26.3 to 12.0)	1.5 (1.0 to 2.1)	2.9 (1.9 to 4.1)	96.3 (53.3 to 151.4)	-9.8 (-28.7 to 13.9)
Genital prolapse	277.4 (232.9 to 322.2)	626.7 (531.1 to 719.5)	125.1 (82.1 to 191.4)	5.9 (-11.7 to 32.7)	0.9 (0.4 to 1.6)	2.0 (0.9 to 3.8)	125.7 (82.1 to 194.3)	6.5 (-11.8 to 33.4)
Premenstrual syndrome	396.0 (243.4 to 535.5)	842.0 (572.7 to 1,132.5)	108.1 (30.0 to 277.8)	-2.2 (-38.7 to 80.0)	3.3 (1.6 to 5.4)	7.0 (3.8 to 11.9)	109.7 (30.4 to 282.4)	-1.4 (-38.9 to 85.3)
Other gynecological diseases	12.3 (8.0 to 16.5)	46.8 (31.0 to 63.3)	276.1 (152.7 to 501.6)	77.2 (23.8 to 171.8)	0.3 (0.1 to 0.5)	1.4 (0.6 to 2.1)	325.8 (99.5 to 994.1)	96.4 (-1.5 to 329.3)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	9.9 (6.5 to 14.0)	20.6 (13.7 to 29.7)	109.4 (84.9 to 136.9)	10.4 (-2.2 to 25.8)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.8 (42.2 to 156.8)	-8.8 (-25.0 to 30.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.3 (38.9 to 161.3)	-9.0 (-25.7 to 32.1)
Thalassemia trait	33.3 (23.1 to 42.7)	66.9 (45.0 to 84.4)	98.1 (95.1 to 141.0)	0.0 (-1.0 to 22.0)	0.6 (0.4 to 0.9)	1.2 (0.7 to 1.7)	98.0 (62.8 to 133.0)	4.7 (-12.9 to 22.7)
Sickle cell disorders	8.4 (6.8 to 9.7)	18.4 (15.0 to 21.0)	120.8 (68.3 to 176.3)	17.4 (-7.8 to 43.9)	0.9 (0.6 to 1.3)	2.0 (1.3 to 2.8)	119.7 (68.1 to 182.7)	15.6 (9.1 to 43.8)
Sickle cell trait	1,126.1 (1,045.8 to 1,207.6)	2,190.4 (2,027.2 to 2,346.8)	95.1 (86.7 to 105.2)	-16.5 (-5.8 to 3.5)	5.2 (3.4 to 7.5)	9.9 (6.3 to 14.4)	98.5 (51.4 to 130.2)	0.0 (-15.5 to 23.3)
G6PD deficiency	700.7 (590.4 to 814.3)	1,971.2 (1,611.4 to 2,342.1)	180.4 (121.1 to 262.6)	41.2 (11.3 to 82.2)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	157.0 (94.9 to 215.8)	32.0 (6.7 to 50.8)
G6PD trait	2,643.4 (2,557.8 to 2,706.4)	5,237.2 (5,068.9 to 5,388.9)	99.0 (90.7 to 106.6)	1.5 (-2.8 to 5.3)	0.1 (0.0 to 0.2)	0.2 (0.0 to 0.3)	91.8 (-70.3 to 890.3)	-0.6 (-82.5 to 499.8)
Other hemoglobinopathies and hemolytic anemias	98.7 (80.0 to 111.9)	245.3 (221.3 to 273.1)	149.4 (117.9 to 207.8)	27.4 (12.5 to 47.6)	2.9 (1.7 to 4.4)	7.2 (4.3 to 10.8)	143.3 (87.7 to 251.9)	27.1 (-3.3 to 70.6)
Endocrine, metabolic, blood, and immune disorders	113.7 (94.6 to 138.6)	277.8 (223.9 to 321.8)	133.9 (82.9 to 206.8)	4.2 (0.2 to 43.3)	9.7 (5.8 to 14.2)	9.9 (4.8 to 14.2)	133.8 (47.8 to 256.4)	20.1 (-14.9 to 62.7)
Musculoskeletal disorders	-	-	-	-	22.8 (8.3 to 161.5)	266.5 (189.1 to 360.2)	117.4 (94.1 to 138.6)	3.9 (-5.6 to 12.6)
Rheumatoid arthritis	25.0 (24.1 to 26.0)	45.3 (43.4 to 47.3)	81.9 (72.0 to 91.9)	-12.1 (-17.0 to -6.9)	5.9 (4.2 to 7.8)	10.7 (7.6 to 14.2)	82.5 (68.0 to 98.7)	-11.4 (-18.0 to -4.7)
Osteoarthritis	202.7 (194.3 to 210.8)	427.2 (410.7 to 444.9)	111.5 (100.3 to 123.0)	3.2 (-1.8 to 8.4)	12.1 (8.4 to 16.6)	25.9 (18.1 to 35.2)	113.4 (102.0 to 125.7)	4.1 (-1.1 to 9.6)
Low back and neck pain	-	-	-	-	98.9 (61.8 to 119.7)	190.4 (132.6 to 261.9)	114.6 (84.6 to 145.2)	1.8 (-11.1 to 14.9)
Low back pain	474.9 (437.1 to 512.1)	975.7 (890.3 to 1,074.7)	106.4 (81.9 to 135.3)	-1.3 (-11.7 to 12.8)	52.0 (35.1 to 72.4)	107.9 (72.7 to 150.2)	107.3 (82.9 to 137.8)	-0.6 (-11.1 to 13.8)
Neck pain	381.8 (320.3 to 447.9)	844.8 (677.8 to 1,013.5)	122.7 (67.0 to 188.6)	4.1 (-20.7 to 33.8)	36.9 (25.3 to 52.3)	82.6 (54.7 to 117.0)	124.2 (67.3 to 190.1)	4.5 (-20.3 to 34.6)
Gout	1.5 (1.3 to 1.7)	3.1 (2.7 to 3.5)	107.5 (73.6 to 156.0)	-1.4 (-16.9 to 21.3)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	110.4 (61.5 to 174.4)	0.0 (-24.2 to 31.5)
Other musculoskeletal disorders	178.2 (134.0 to 224.2)	495.7 (329.4 to 540.5)	148.8 (127.3 to 165.2)	17.2 (7.6 to 26.6)	17.2 (10.1 to 23.4)	39.5 (24.9 to 57.6)	17.8 (128.4 to 168.3)	47.4 (8.1 to 27.4)
Other non-communicable diseases	-	-	-	-	192.0 (130.5 to 272.5)	357.3 (241.0 to 509.0)	85.6 (77.6 to 95.9)	-8.7 (-12.7 to -4.3)
Congenital anomalies	-	-	-	-	12.6 (8.6 to 17.1)	30.1 (21.0 to 40.0)	137.9 (105.8 to 175.3)	21.7 (3.9 to 40.2)
Neural tube defects	1.2 (1.0 to 1.4)	6.9 (5.9 to 8.1)	488.7 (365.9 to 638.6)	244.6 (169.7 to 336.3)	0.3 (0.2 to 0.4)	2.0 (1.3 to 2.7)	593.3 (417.7 to 884.1)	318.4 (211.8 to 489.5)
Congenital heart anomalies	9.8 (6.9 to 13.5)	72.5 (60.0 to 90.1)	642.0 (396.4 to 1,030.1)	331.1 (181.0 to 570.4)	0.4 (0.1 to 0.6)	2.4 (1.0 to 4.4)	581.7 (351.8 to 976.5)	299.8 (161.6 to 525.7)
Orofacial clefts	1.2 (0.8 to 1.7)	11.6 (8.1 to 15.4)	910.9 (460.7 to 1,478.4)	0.0 (-25.4 to 95.6)	0.2 (0.0 to 0.0)	0.2 (0.1 to 0.3)	779.9 (350.7 to 1,400.2)	465.9 (188.8 to 868.3)
Down syndrome	5.9 (5.1 to 7.0)	18.9 (15.8 to 22.6)	221.9 (150.3 to 304.2)	76.5 (37.1 to 121.7)	0.7 (0.5 to 0.9)	2.2 (1.6 to 3.0)	228.2 (149.1 to 323.5)	82.1 (37.5 to 134.6)
Turner syndrome	0.3 (0.2 to 0.4)	0.7 (0.5 to 1.0)	174.6 (69.6 to 315.9)	43.3 (-11.9 to 118.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	177.1 (73.5 to 332.7)	43.0 (-10.9 to 119.9)
Klinefelter syndrome	0.4 (0.3 to 0.5)	0.7 (0.5 to 0.9)	89.9 (26.7 to 168.8)	-4.5 (-36.0 to 35.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.5 (33.0 to 182.3)	-3.3 (-35.3 to 38.1)
Chromosomal unbalanced rearrangements	9.9 (7.8 to 12.1)	31.7 (27.4 to 38.7)	79.5 (151.1 to 341.2)	221.7 (37.7 to 145.3)	3.7 (0.8 to 1.6)	3.7 (2.6 to 5.0)	237.5 (152.0 to 361.3)	81.8 (40.3 to 158.1)
Other congenital anomalies	103.6 (83.9 to 121.6)	189.9 (148.9 to 220.3)	85.3 (51.7 to 113.6)	-6.6 (-24.3 to 7.7)	10.2 (6.6 to 14.2)	19.6 (12.4 to 28.0)	92.1 (63.0 to 130.4)	-2.1 (-19.4 to 16.9)
Skin and subcutaneous diseases	-	-	-	-	52.9 (33.6 to 80.3)	104.5 (67.1 to 157.2)	97.1 (82.0 to 113.7)	-1.4 (-8.1 to 6.5)
Dermatitis	446.7 (344.8 to 574.7)	907.9 (696.0 to 1,176.1)	103.9 (101.6 to 106.1)	0.1 (0.0 to 0.2)	15.9 (9.9 to 23.5)	32.1 (19.8 to 47.2)	101.9 (94.1 to 109.9)	0.5 (-2.3 to 3.8)
Psoriasis	68.8 (59.4 to 78.7)	141.5 (122.3 to 162.5)	106.4 (105.2 to 108.1)	-0.0 (-0.2 to 0.1)	5.5 (3.8 to 7.8)	11.5 (7.8 to 16.4)	107.7 (94.3 to 122.7)	0.8 (-4.5 to 6.3)
Cellulitis	2.3 (1.8 to 3.0)	4.6 (3.6 to 5.9)	97.5 (78.9 to 118.4)	0.8 (-8.0 to 9.1)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	97.8 (53.2 to 157.9)	0.3 (-17.8 to 23.6)
Pyoderma	19.9 (14.7 to 25.6)	34.8 (26.2 to 44.6)	75.7 (63.3 to 89.6)	-4.2 (-10.6 to 2.9)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.4)	74.7 (56.5 to 97.8)	-4.3 (-13.5 to 7.0)
Scabies	197.6 (140.9 to 282.4)	330.1 (242.8 to 464.4)	64.3 (15.4 to 178.0)	-17.7 (-46.8 to 35.4)	5.0 (2.7 to 8.9)	8.5 (4.2 to 15.0)	65.4 (113.1 to 179.6)	-17.5 (-46.7 to 36.0)
Fungal skin diseases	1,947.9 (725.2 to 1,417.1)	2,110.7 (1,463.2 to 2,863.8)	102.0 (99.6 to 105.4)	102.0 (-0.2 to 0.1)	19.9 (2.3 to 13.0)	11.9 (4.7 to 26.5)	102.6 (93.2 to 106.7)	0.4 (-0.4 to 1.2)
Viral skin diseases	278.8 (206.2 to 352.3)	543.9 (403.6 to 687.5)	95.8 (88.9 to 103.4)	0.0 (-2.9 to 3.3)	8.6 (4.9 to 13.9)	16.8 (9.6 to 27.0)	95.9 (86.5 to 106.3)	0.3 (-3.6 to 4.4)
Acne vulgaris	518.7 (332.8 to 677.8)	860.1 (521.3 to 1,280.5)	63.5 (-5.7 to 189.9)	-16.8 (53.1 to 41.2)	5.6 (2.3 to 10.5)	9.3 (3.8 to 19.2)	63.5 (-5.6 to 190.8)	-16.7 (53.4 to 41.8)
Alopecia areata	10.4 (9.2 to 11.7)	20.8 (18.4 to 23.4)	100.6 (71.0 to 137.4)	-0.7 (-16.4 to 16.5)	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.1)	101.7 (64.9 to 145.4)	-0.6 (-17.5 to 19.8)
Pruritus	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	99.3 (60.6 to 154.7)	-2.5 (-23.2 to 27.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.3 (60.0 to 155.0)	-2.5 (-23.4 to 27.2)
Urticaria	42.5 (27.4 to 63.1)	112.7 (73.2 to 154.2)	178.6 (49.5 to 352.5)	26.1 (31.8 to 98.5)	2.5 (1.4 to 4.1)	6.6 (3.6 to 10.5)	178.6 (49.9 to 356.4)	26.6 (-31.5 to 100.6)
Decubitus ulcer	1.3 (1.1 to 1.5)	2.7 (2.3 to 3.2)	105.5 (64.8 to 166.8)	0.9 (-22.3 to 54.9)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	107.5 (64.1 to 171.0)	1.6 (-23.7 to 57.6)
Other skin and subcutaneous diseases	541.2 (375.3 to 792.9)	1,041.3 (714.7 to 1,480.8)	93.3 (81.5 to 104.0)	-6.0 (-12.6 to -1.8)	3.1 (1.4 to 6.4)	6.1 (2.8 to 12.3)	94.0 (82.3 to 105.4)	-5.5 (-11.8 to -1.0)
Sense organ diseases	-	-	-	-	108.8 (72.3 to 145.8)	178.7 (121.8 to 250.6)	70.5 (58.1 to 83.4)	-4.4 (-19.7 to -8.8)
Glaucoma	20.0 (14.0 to 26.7)	33.9 (22.6 to 45.6)	69.8 (33.4 to 112.7)	-15.9 (-39.0 to 5.6)	1.9 (1.1 to 3.1)	3.1 (1.8 to 4.8)	63.1 (18.1 to 103.7)	-18.6 (-42.6 to 9.4)
Cataract	92.2 (62.5 to 121.9)	138.7 (86.9 to 194.0)	51.8 (17.8 to 99.1)	-23.4 (-33.6 to 1.5)	6.8 (3.9 to 10.1)	10.3 (5.7 to 15.8)	53.5 (26.3 to 78.4)	-22.1 (-32.6 to -10.4)
Macular degeneration	15.0 (8.0 to 22.7)	33.9 (16.4 to 51.7)	125.4 (45.8 to 342.6)	10.5 (-27.9 to 99.3)	0.8 (0.4 to 1.3)	1.7 (0.8 to 2.8)	119.1 (39.0 to 304.9)	7.4 (-29.8 to 78.9)
Uncorrected refractive error	92.6 (761.1 to 1,107.9)	1,756.3 (1,371.4 to 2,103.5)	91.6 (43.0 to 144.1)	-5.9 (-21.5 to 20.7)	18.4 (17.7 to 27.9)	32.6 (20.3 to 50.9)	76.9 (51.4 to 107.3)	-13.0 (-23.0 to 0.9)
Age-related and other hearing loss	1,735.3 (1,608.1 to 1,860.5)	3,211.6 (2,933.2 to 3,502.5)	85.5 (75.6 to 98.5)	-7.7 (-11.1 to -3.9)	66.6 (44.6 to 93.4)	115.5 (75.3 to 160.4)	69.0 (51.5 to 86.0)	-13.5 (-21.7 to -7.3)
Other vision loss	35.8 (27.0 to 46.9)	51.1 (37.2 to 69.6)	43.3 (17.1 to 74.1)	-29.6 (-44.9 to -14.3)	3.1 (1.8 to 4.6)	4.5 (2.6 to 7.3)	48.4 (17.3 to 76.2)	-5.5 (-44.1 to -9.4)
Other sense organ diseases	273.5 (257.9 to 287.3)	528.0 (501.0 to 553.0)	93.4 (79.4 to 110.6)	-0.3 (-6.2 to 7.1)	7.2 (4.5 to 10.7)	14.0 (8.6 to 20.9)	93.7 (78.9 to 112.5)	0.0 (-6.1 to 8.7)
Oral disorders	-	-	-	-	21.7 (12.4 to 35.2)	44.1 (24.9 to 72.4)	103.2 (95.6 to 110.8)	-1.8 (-5.4 to 2.0)

Appendix Table G.4 - Madagascar prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.								
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	191.7 (177.4 to 205.1)	361.4 (337.2 to 386.5)	89.1 (71.1 to 110.2)	-4.2 (-14.5 to 2.8)	5.2 (3.5 to 7.1)	9.9 (6.6 to 13.6)	99.8 (71.9 to 112.1)	-5.6 (-14.0 to 4.0)
Other oral disorders	166.0 (156.2 to 176.3)	340.7 (320.8 to 360.6)	105.9 (89.4 to 123.9)	-0.5 (-7.6 to 7.6)	4.8 (3.0 to 7.2)	10.0 (6.2 to 15.1)	106.4 (89.2 to 126.2)	-0.1 (-8.1 to 8.6)
Injuries	-	-	-	-	39.7 (30.2 to 50.9)	65.6 (50.1 to 84.5)	65.5 (60.2 to 70.3)	-15.7 (-18.1 to -13.5)
Transport injuries	-	-	-	-	15.3 (11.5 to 19.6)	20.7 (15.6 to 26.9)	35.6 (29.6 to 42.4)	-29.0 (-31.5 to -26.5)
Road injuries	-	-	-	-	13.5 (10.2 to 17.3)	18.5 (13.9 to 23.9)	37.0 (30.0 to 44.3)	-28.9 (-31.8 to -26.3)
Pedestrian road injuries	-	-	-	-	4.7 (3.5 to 6.0)	6.0 (4.5 to 7.8)	27.6 (17.5 to 38.7)	-31.7 (-35.8 to -27.5)
Cyclist road injuries	-	-	-	-	1.2 (0.9 to 1.6)	1.5 (1.1 to 1.9)	21.9 (13.2 to 30.9)	-34.1 (-38.8 to -29.9)
Motorcyclist road injuries	-	-	-	-	1.5 (1.1 to 1.9)	1.7 (1.3 to 2.3)	15.7 (5.9 to 24.1)	-41.9 (-46.2 to -38.3)
Motor vehicle road injuries	-	-	-	-	5.9 (4.4 to 7.6)	9.1 (6.8 to 11.8)	54.8 (41.3 to 66.2)	-21.1 (-27.4 to -16.7)
Other road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-13.3 (-18.6 to -6.9)	-56.2 (-58.6 to -53.5)
Other transport injuries	-	-	-	-	1.8 (1.4 to 2.3)	2.3 (1.7 to 3.0)	26.5 (19.9 to 32.6)	-29.2 (-33.2 to -25.5)
Unintentional injuries	-	-	-	-	23.0 (17.5 to 29.6)	41.6 (31.6 to 54.0)	81.0 (74.7 to 86.9)	-9.0 (-11.8 to -6.0)
Falls	-	-	-	-	9.8 (7.4 to 12.6)	19.5 (14.6 to 25.1)	98.8 (88.6 to 109.8)	-4.0 (-8.9 to 1.5)
Drowning	-	-	-	-	0.5 (0.4 to 0.7)	0.7 (0.5 to 1.0)	45.5 (33.3 to 60.5)	-25.1 (-30.3 to -19.1)
Fire, heat, and hot substances	-	-	-	-	2.7 (2.1 to 3.5)	4.5 (3.4 to 5.8)	64.1 (49.5 to 81.1)	-17.3 (-23.3 to -10.4)
Poisonings	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	43.9 (24.2 to 69.6)	-27.9 (-36.0 to -18.3)
Exposure to mechanical forces	-	-	-	-	5.5 (4.2 to 7.1)	9.7 (7.3 to 12.7)	76.1 (67.7 to 83.0)	-11.7 (-15.4 to -8.5)
Unintentional firearm injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	119.5 (101.4 to 138.7)	7.5 (-0.7 to 15.7)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	133.5 (114.9 to 155.4)	15.7 (7.9 to 24.4)
Other exposure to mechanical forces	-	-	-	-	5.2 (4.0 to 6.8)	9.1 (6.9 to 11.9)	73.7 (65.4 to 80.8)	-12.8 (-16.6 to -9.6)
Adverse effects of medical treatment	-	-	-	-	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.5)	113.6 (102.0 to 126.3)	9.9 (3.2 to 17.6)
Animal contact	-	-	-	-	1.2 (0.9 to 1.6)	1.6 (1.2 to 2.1)	37.3 (26.9 to 47.7)	-29.8 (-33.8 to -25.6)
Venomous animal contact	-	-	-	-	0.5 (0.4 to 0.7)	0.7 (0.5 to 1.0)	37.0 (22.2 to 54.8)	-31.3 (-38.1 to -23.7)
Non-venomous animal contact	-	-	-	-	0.7 (0.5 to 0.9)	0.9 (0.7 to 1.2)	37.3 (26.2 to 46.7)	-28.8 (-32.6 to -24.8)
Foreign body	-	-	-	-	0.4 (0.3 to 0.5)	0.8 (0.6 to 1.1)	93.8 (83.0 to 106.6)	-3.5 (-8.4 to 2.0)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	82.1 (56.3 to 112.3)	-0.9 (-11.7 to 10.9)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	104.0 (83.9 to 124.4)	0.2 (-8.0 to 9.5)
Foreign body in other body part	-	-	-	-	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.6)	95.1 (83.4 to 109.7)	-4.9 (-10.9 to 1.9)
Other unintentional injuries	-	-	-	-	2.7 (2.0 to 3.5)	4.4 (3.3 to 5.8)	65.5 (53.1 to 80.2)	-11.5 (-17.0 to -4.0)
Self-harm and interpersonal violence	-	-	-	-	0.9 (0.7 to 1.1)	2.2 (1.7 to 2.8)	149.8 (137.3 to 162.2)	25.2 (19.6 to 30.4)
Self-harm	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	106.0 (90.6 to 123.0)	-1.3 (-7.9 to 6.2)
Interpersonal violence	-	-	-	-	0.7 (0.5 to 0.9)	1.8 (1.4 to 2.3)	163.2 (147.5 to 177.5)	36.5 (29.2 to 42.9)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.3 to 0.4)	172.5 (154.1 to 191.7)	40.3 (32.1 to 49.9)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	201.5 (176.3 to 229.6)	52.9 (41.0 to 66.6)
Assault by other means	-	-	-	-	0.5 (0.3 to 0.6)	1.2 (0.9 to 1.5)	152.2 (133.6 to 169.7)	31.5 (22.5 to 39.0)
Forces of nature, war, and legal intervention	-	-	-	-	0.5 (0.2 to 0.9)	1.0 (0.5 to 1.9)	111.3 (65.6 to 166.8)	9.6 (-16.1 to 38.8)
Exposure to forces of nature	-	-	-	-	0.4 (0.2 to 0.7)	0.8 (0.4 to 1.5)	103.8 (67.3 to 143.2)	9.7 (-11.4 to 30.3)
Collective violence and legal intervention	-	-	-	-	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.6)	140.7 (38.8 to 519.4)	7.0 (-35.8 to 199.9)

Appendix Table G.4 - Malawi prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,004.4 (735.3 to 1,307.2)	1,554.6 (1,139.4 to 2,019.0)	55.1 (49.2 to 60.8)	55.1 (-12.2 to -4.8)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	374.4 (262.4 to 512.7)	498.7 (353.8 to 666.6)	33.1 (22.2 to 45.8)	-20.3 (-29.2 to -8.8)
HIV/AIDS and tuberculosis	-	-	-	-	74.3 (46.3 to 103.2)	142.7 (95.1 to 200.3)	91.6 (55.4 to 154.3)	20.5 (5.0 to 59.0)
Tuberculosis	22.1 (20.4 to 23.9)	30.2 (28.0 to 32.5)	36.8 (29.3 to 43.7)	-18.9 (-23.3 to -14.9)	6.7 (4.5 to 9.0)	9.2 (6.2 to 12.5)	38.2 (27.9 to 48.3)	-18.0 (-23.7 to -12.6)
HIV/AIDS	-	-	-	-	67.6 (40.9 to 95.0)	133.5 (88.0 to 188.4)	24.0 (17.1 to 31.5)	24.0 (3.8 to 69.9)
HIV/AIDS resulting in mycobacterial infection	7.3 (5.3 to 9.1)	9.0 (6.4 to 11.3)	22.1 (5.7 to 49.3)	-23.5 (-34.1 to -6.0)	2.7 (1.7 to 3.9)	3.3 (2.0 to 4.8)	23.4 (2.6 to 54.1)	-22.6 (-33.3 to -3.4)
HIV/AIDS resulting in other diseases	503.8 (395.4 to 562.8)	951.4 (882.3 to 1,030.5)	85.2 (68.1 to 142.9)	22.7 (10.5 to 59.0)	64.9 (38.2 to 91.7)	130.2 (85.1 to 184.1)	99.3 (58.3 to 181.9)	26.0 (3.2 to 75.9)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	54.7 (39.2 to 73.3)	65.0 (46.3 to 88.7)	18.9 (9.8 to 28.3)	26.7 (-3.2 to 21.1)
Diarrheal diseases	188.8 (176.1 to 201.1)	207.3 (193.9 to 220.6)	10.0 (0.5 to 20.0)	31.1 (-36.5 to -25.3)	30.4 (20.8 to 42.2)	33.6 (22.5 to 45.9)	10.5 (0.2 to 20.8)	-30.8 (-36.8 to -24.5)
Intestinal infectious diseases	-	-	-	-	0.5 (0.3 to 0.7)	0.3 (0.2 to 0.4)	-0.7 (-55.4 to -24.8)	-40.7 (-72.8 to -57.1)
Typhoid fever	2.5 (2.2 to 2.8)	1.6 (1.4 to 1.8)	-35.0 (-44.1 to -23.8)	-62.1 (-67.6 to -55.4)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-32.8 (-48.1 to -13.6)	-60.5 (-68.1 to -51.3)
Paratyphoid fever	0.9 (0.8 to 1.1)	0.8 (0.6 to 0.9)	-8.3 (-34.1 to -8.8)	-52.4 (-61.7 to -41.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-18.1 (-38.0 to 4.8)	-52.3 (-63.1 to -40.2)
Other intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-81.8 (-90.7 to -65.1)	-89.4 (-94.4 to -79.8)
Lower respiratory infections	9.9 (8.5 to 11.5)	13.1 (10.6 to 15.3)	31.4 (7.0 to 70.6)	-16.3 (-28.2 to 0.7)	1.0 (0.7 to 1.5)	1.4 (0.9 to 2.0)	32.2 (2.9 to 76.0)	-15.8 (-29.4 to 3.6)
Upper respiratory infections	740.2 (700.5 to 775.2)	1,240.9 (1,183.1 to 1,302.3)	67.7 (57.2 to 80.6)	-1.3 (-7.6 to 6.0)	8.7 (4.8 to 14.6)	14.6 (8.2 to 24.1)	68.5 (57.3 to 81.5)	-0.9 (-7.4 to 6.7)
Otitis media	166.2 (151.0 to 179.5)	254.8 (232.2 to 278.4)	52.7 (39.0 to 72.6)	-12.5 (-20.4 to -1.9)	3.4 (2.0 to 5.4)	5.2 (3.1 to 8.3)	52.2 (35.7 to 73.8)	-12.5 (-21.8 to -1.7)
Meningitis	-	-	-	-	9.9 (6.9 to 13.4)	9.2 (6.4 to 12.3)	-7.4 (-24.9 to 11.8)	-44.7 (-53.9 to -33.1)
Pneumococcal meningitis	34.3 (21.9 to 49.7)	29.4 (18.7 to 41.9)	-14.7 (-38.3 to 11.6)	-48.2 (-61.3 to -32.5)	3.0 (2.1 to 4.4)	3.0 (2.0 to 4.4)	2.7 (-36.9 to 35.9)	41.8 (-60.7 to 21.7)
H influenzae type B meningitis	19.4 (8.3 to 35.8)	14.9 (6.7 to 25.3)	-22.7 (-44.4 to 8.9)	-54.1 (-66.4 to -37.7)	2.2 (1.3 to 3.4)	1.8 (1.2 to 2.6)	-15.4 (-51.6 to 40.1)	-50.1 (-70.6 to -17.7)
Meningococcal meningitis	4.6 (1.9 to 9.5)	3.7 (1.6 to 7.7)	-18.9 (-43.7 to 11.2)	-48.1 (-62.2 to -32.3)	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.7)	-16.6 (-38.0 to 23.4)	47.4 (-59.4 to -28.9)
Other meningitis	34.8 (18.5 to 59.4)	29.3 (17.2 to 47.6)	-15.7 (-31.4 to 6.1)	-49.1 (-58.3 to -36.4)	4.1 (2.8 to 5.8)	3.9 (2.5 to 5.8)	-4.6 (-34.4 to 33.7)	-43.1 (-58.1 to -21.5)
Encephalitis	1.7 (0.8 to 3.5)	2.7 (1.3 to 5.4)	53.0 (38.6 to 70.6)	0.2 (-17.1 to -1.8)	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.5)	97.5 (30.6 to 86.5)	-9.6 (-20.3 to 4.4)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	54.2 (97.6 to 579.1)	0.0 (0.0 to 0.0)	-34.7 (97.7 to 1,634.8)	-54.2 (97.5 to 585.5)
Whooping cough	4.1 (3.2 to 5.2)	3.5 (2.7 to 4.5)	-13.9 (-16.9 to -10.8)	-44.7 (-46.7 to -42.8)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-13.7 (-27.2 to 3.9)	-44.6 (-53.6 to -33.0)
Tetanus	0.5 (0.2 to 0.9)	0.2 (0.1 to 0.3)	-70.0 (-91.6 to -27.9)	-81.6 (-94.9 to -54.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-65.3 (-84.7 to -35.8)	-76.6 (-90.0 to -58.6)
Measles	1.8 (1.5 to 2.3)	0.1 (0.1 to 0.1)	-95.0 (-96.8 to -92.0)	-95.9 (-98.0 to -95.0)	0.2 (0.1 to 0.3)	0.0 (0.0 to 0.0)	-94.8 (-96.8 to -91.5)	-96.7 (-98.0 to -94.7)
Varicella and herpes zoster	6.0 (5.5 to 6.6)	10.7 (9.9 to 11.7)	79.8 (57.2 to 102.6)	2.0 (-17.5 to 26.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	77.4 (25.0 to 146.7)	1.2 (-29.9 to 49.8)
Neglected tropical diseases and malaria	-	-	-	-	152.5 (98.7 to 228.8)	148.6 (97.5 to 221.2)	-2.4 (-15.1 to 13.8)	47.3 (-56.2 to -36.3)
Malaria	5,337.3 (5,086.5 to 5,583.2)	6,838.9 (6,514.6 to 7,144.6)	28.3 (23.3 to 33.3)	-26.8 (-29.8 to -23.6)	49.5 (33.2 to 71.1)	69.2 (46.5 to 99.4)	39.8 (32.2 to 53.4)	21.4 (-26.2 to -17.2)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.1	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	79.0 (-15.1 to 238.1)	26.2 (-34.0 to 121.4)
Visceral leishmaniasis	0.4 (0.3 to 0.6)	0.7 (0.3 to 1.1)	53.8 (-37.4 to 195.9)	-1.6 (57.3 to 80.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	53.2 (-38.4 to 200.7)	-1.2 (57.7 to 82.2)
Cutaneous and mucocutaneous leishmaniasis	0.1 (0.0 to 0.1)	0.0 (0.6 to 1.4)	1,105.8 (669.0 to 1,819.0)	914.6 (519.1 to 1,451.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,069.7 (599.6 to 1,805.2)	863.1 (474.5 to 1,403.1)
African trypanosomiasis	1.2 (0.6 to 2.1)	0.1 (0.0 to 0.2)	-91.3 (-93.0 to -88.5)	-94.9 (-95.9 to -93.3)	0.3 (0.1 to 0.6)	0.0 (0.0 to 0.1)	-90.5 (-92.8 to -86.5)	-94.3 (-95.7 to -91.9)
Schistosomiasis	4,889.3 (3,213.7 to 6,812.6)	4,777.0 (1,558.9 to 5,026.8)	-2.7 (-59.9 to -13.0)	-70.1 (-77.1 to -50.0)	29.5 (23.5 to 95.7)	29.5 (13.0 to 62.1)	43.9 (54.5 to -3.5)	41.8 (-74.1 to -44.9)
Cysticercosis	2.1 (0.8 to 3.8)	3.7 (2.0 to 6.0)	83.8 (-17.7 to 335.2)	-4.9 (-55.3 to 100.2)	0.6 (0.2 to 1.1)	1.1 (0.5 to 1.9)	95.4 (-13.3 to 354.9)	0.8 (-54.4 to 119.0)
Cystic echinococcosis	4.1 (3.9 to 4.5)	4.0 (3.5 to 4.5)	-2.7 (-14.5 to 12.8)	-59.9 (-63.5 to -56.1)	0.4 (0.3 to 0.5)	0.4 (0.2 to 0.5)	-1.2 (-20.0 to 22.8)	-59.0 (-65.5 to -51.6)
Lymphatic filariasis	1,313.7 (913.0 to 1,645.7)	468.1 (329.9 to 644.5)	-65.0 (-74.7 to -47.5)	-77.2 (-83.1 to -68.6)	31.3 (16.3 to 56.7)	30.2 (15.7 to 50.8)	-1.5 (-41.6 to 48.5)	-40.7 (-64.4 to -13.6)
Onchocerciasis	184.6 (104.8 to 321.6)	82.6 (43.6 to 133.8)	-55.2 (-73.5 to -30.3)	-54.2 (-84.8 to -59.4)	5.4 (5.4 to 18.5)	5.0 (2.3 to 13.0)	6.4 (-67.0 to -11.0)	68.1 (81.4 to -45.3)
Trachoma	7.2 (3.8 to 12.2)	4.2 (2.0 to 6.7)	-41.6 (-67.5 to 6.9)	-70.8 (-83.6 to -50.9)	0.5 (0.3 to 1.0)	0.3 (0.1 to 0.6)	-39.7 (-69.5 to 13.2)	-70.5 (-84.1 to -46.5)
Dengue	0.5 (0.2 to 1.2)	4.1 (1.4 to 10.2)	748.8 (738.5 to 760.8)	390.3 (384.3 to 397.2)	0.1 (0.0 to 0.2)	0.7 (0.2 to 1.8)	704.5 (569.8 to 850.4)	355.5 (291.4 to 424.5)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.1 (-51.4 to 44.5)	43.1 (-63.8 to -20.7)
Intestinal nematode infections	-	-	-	-	4.0 (2.5 to 6.0)	3.6 (2.1 to 5.6)	-10.2 (-30.4 to 9.5)	-50.4 (-60.0 to -38.6)
Ascariasis	820.9 (545.2 to 1,213.1)	522.1 (346.4 to 764.2)	-35.5 (-64.4 to 5.8)	-63.0 (-82.0 to -32.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-37.5 (-59.9 to -5.9)	-63.5 (-77.6 to -40.7)
Trichuriasis	903.3 (594.1 to 1,369.6)	553.3 (372.6 to 842.7)	-38.7 (-65.9 to 10.2)	-64.4 (-82.1 to -27.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.5 (-61.2 to 8.7)	-64.0 (-79.5 to -31.4)
Hookworm disease	1,102.4 (748.6 to 1,543.9)	984.7 (680.3 to 1,449.0)	-11.8 (-47.1 to 56.2)	-49.0 (-72.2 to -1.1)	3.9 (2.4 to 5.9)	3.6 (2.1 to 5.5)	9.8 (-30.1 to 10.5)	-50.2 (-60.0 to -38.2)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	122.8 (89.1 to 155.8)	178.6 (160.5 to 197.7)	46.1 (15.4 to 98.3)	-15.3 (-32.1 to 11.4)	5.4 (3.4 to 8.1)	7.2 (4.7 to 10.3)	32.0 (9.3 to 88.2)	-25.3 (-40.8 to 3.9)
Maternal disorders	-	-	-	-	3.2 (2.2 to 4.4)	4.4 (3.0 to 6.0)	38.6 (18.0 to 61.7)	-20.9 (-31.9 to -8.8)
Maternal hemorrhage	3.9 (3.4 to 4.5)	6.4 (4.8 to 8.1)	62.8 (19.6 to 114.8)	-10.7 (-33.8 to 16.1)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.4)	48.3 (-5.9 to 116.9)	21.9 (-50.0 to 14.4)
Maternal sepsis and other maternal infections	5.8 (3.8 to 7.5)	5.3 (3.4 to 6.9)	-8.7 (-21.5 to 2.2)	-44.4 (-52.3 to -38.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-2.2 (-35.2 to 44.6)	-43.6 (-60.6 to -20.1)
Maternal hypertensive disorders	4.3 (2.1 to 7.2)	5.8 (2.9 to 9.6)	36.5 (16.6 to 49.7)	-25.5 (-35.6 to -18.6)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.5)	35.0 (12.6 to 64.2)	-26.4 (-37.6 to -11.6)
Obstructed labor	6.1 (5.5 to 6.9)	8.4 (7.6 to 9.3)	38.0 (25.9 to 51.7)	-20.1 (-26.7 to -12.8)	2.0 (1.3 to 2.8)	2.8 (1.8 to 3.8)	38.8 (20.1 to 61.5)	-19.8 (-29.9 to -7.6)
Complications of abortion	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	61.0 (-40.7 to 231.6)	-14.6 (-60.5 to 57.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.0 (-40.8 to 231.6)	-14.6 (-60.5 to 57.7)
Other maternal disorders	-	-	-	-	0.8 (0.5 to 1.1)	1.1 (0.7 to 1.5)	41.4 (5.2 to 109.3)	-20.1 (-46.3 to 18.3)
Neonatal disorders	-	-	-	-	5.0 (2.9 to 9.1)	24.6 (16.6 to 34.6)	413.4 (194.2 to 701.2)	214.7 (61.8 to 414.1)
Preterm birth complications	38.2 (24.3 to 56.5)	148.5 (108.9 to 197.2)	293.0 (222.6 to 384.1)	120.0 (81.6 to 169.7)	1.6 (1.0 to 2.4)	12.8 (8.6 to 17.6)	705.4 (476.8 to 1,096.7)	367.4 (225.4 to 598.1)
Neonatal encephalopathy due to birth asphyxia and trauma	66.8 (4.9 to 227.6)	70.6 (11.5 to 220.3)	15.6 (-23.4 to 167.7)	-34.6 (51.8 to -54.6)	2.0 (0.6 to 5.1)	4.3 (2.0 to 8.0)	131.0 (24.9 to 437.0)	33.7 (-31.0 to 285.1)
Neonatal sepsis and other neonatal infections	0.1 (0.1 to 0.3)	0.3 (0.1 to 0.6)	84.2 (71.9 to 136.8)	28.0 (19.4 to 64.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (62.7 to 139.4)	85.6 (13.1 to 66.4)
Hemolytic disease and other neonatal jaundice	1.2 (0.6 to 2.0)	6.9 (3.2 to 11.5)	482.8 (122.4 to 1,314.4)	335.1 (60.4 to 989.3)	0.4 (0.2 to 0.8)	2.6 (1.1 to 4.5)	510.9 (132.6 to 1,365.4)	348.7 (64.3 to 1,042.7)
Other neonatal disorders	-	-	-	-	1.0 (0.4 to 2.1)	4.9 (2.1 to 9.2)	401.4 (99.5 to 1,019.0)	202.2 (13.5 to 598.7)
Nutritional deficiencies	-	-	-	-	77.4 (51.8 to 112.2)	102.7 (68.3 to 147.2)	32.9 (22.3 to 42.0)	-22.2 (-27.0 to -16.8)
Protein-energy malnutrition	50.3 (31.0 to 78.4)	49.4 (28.9 to 77.5)	-2.4 (-51.3 to 91.9)	-28.8 (59.9 to 19.8)	6.1 (3.2 to 10.7)	6.0 (3.0 to 10.6)	4.6 (-52.3 to 98.5)	29.1 (-60.9 to 23.2)
Iodine deficiency	238.6 (196.1 to 279.5)	266.0 (218.0 to 313.0)	11.7 (-16.0 to 46.1)	-36.0 (-53.6 to -13.1)	4.3 (2.5 to 6.8)	4.8 (2.9 to 7.7)	12.7 (-14.7 to 47.5)	-35.4 (-53.0 to -12.9)
Vitamin A deficiency	13.7 (9.8 to 18.4)	13.0 (8.7 to 18.4)	-4.5 (-25.9 to 14.8)	-44.5 (-57.7 to -30.6)	0.8 (0.5 to 1.2)	0.7 (0.4 to 1.1)	-12.1 (-33.5 to 12.9)	-46.9 (-60.9 to -29.7)

Appendix Table G.4 - Malawi prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	1,683.3 (1,608.2 to 1,754.3)	2,437.2 (2,386.5 to 2,499.8)	44.7 (38.6 to 52.2)	-18.1 (-21.1 to -14.6)	66.2 (44.3 to 96.3)	91.2 (60.4 to 131.2)	37.8 (26.8 to 45.2)	37.8 (-24.8 to -14.5)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	1.9 (-70.2 to 182.4)	-26.2 (-75.8 to 87.9)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	7.3 (4.6 to 11.4)	10.7 (6.7 to 16.5)	46.3 (27.9 to 66.5)	-13.2 (-24.5 to -3.6)
Sexually transmitted diseases excluding HIV	-	-	-	-	2.4 (1.3 to 4.4)	3.9 (2.1 to 7.4)	64.8 (41.5 to 93.9)	-6.6 (-17.2 to 6.9)
Syphilis	1.1 (1.0 to 1.3)	1.1 (0.9 to 1.3)	-2.1 (-20.6 to 20.5)	-41.1 (-50.9 to -30.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	2.4 (-27.4 to 30.0)	41.1 (-5.6 to -25.1)
Chlamydial infection	92.1 (76.2 to 109.4)	152.3 (121.7 to 185.0)	65.4 (16.8 to 114.6)	-4.6 (-31.2 to 20.9)	0.5 (0.3 to 0.9)	0.9 (0.5 to 1.5)	71.4 (112.0 to 158.5)	-1.7 (-32.1 to 38.3)
Gonococcal infection	106.1 (85.0 to 126.5)	169.7 (136.6 to 205.1)	59.8 (24.5 to 104.8)	-12.0 (-29.7 to 9.9)	0.4 (0.2 to 0.7)	0.7 (0.3 to 1.2)	71.3 (0.1 to 147.1)	-5.1 (-42.7 to 36.5)
Trichomoniasis	121.1 (73.3 to 173.7)	223.8 (134.5 to 313.7)	87.6 (-2.2 to 231.8)	4.9 (-39.8 to 68.4)	0.2 (0.1 to 0.5)	0.4 (0.1 to 0.9)	91.1 (-5.6 to 249.2)	5.1 (-42.7 to 73.1)
Genital herpes	3,365.9 (3,113.2 to 3,627.0)	5,786.9 (5,239.7 to 6,256.5)	71.7 (53.8 to 90.4)	-7.5 (-7.5 to 8.8)	1.0 (0.3 to 2.3)	1.7 (0.6 to 4.0)	78.8 (52.1 to 98.8)	1.3 (-8.5 to 12.3)
Other sexually transmitted diseases	3.6 (2.5 to 4.8)	4.8 (3.3 to 6.5)	33.0 (16.4 to 50.3)	-19.6 (-29.2 to -9.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	46.1 (4.0 to 112.9)	15.4 (-41.0 to 18.1)
Hepatitis	-	-	-	-	0.9 (0.5 to 1.3)	1.4 (0.9 to 2.2)	69.8 (37.1 to 99.2)	-0.4 (-22.6 to 22.2)
Hepatitis A	18.3 (17.2 to 19.4)	29.0 (27.4 to 30.5)	58.4 (57.8 to 59.1)	-2.8 (-3.1 to -2.5)	0.3 (0.2 to 0.5)	0.5 (0.4 to 0.8)	76.7 (55.6 to 98.5)	4.5 (-7.2 to 16.5)
Hepatitis B	1,118.9 (927.5 to 1,316.4)	1,879.8 (1,500.2 to 2,220.2)	69.2 (27.8 to 107.5)	1.4 (-25.9 to 19.2)	0.5 (0.3 to 0.7)	0.8 (0.5 to 1.2)	70.5 (13.3 to 128.2)	0.5 (-32.6 to 37.2)
Hepatitis C	299.5 (240.2 to 300.5)	372.5 (330.5 to 414.3)	38.3 (18.6 to 62.1)	-20.7 (-31.3 to -7.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	39.0 (6.0 to 86.1)	-17.7 (-32.9 to 12.0)
Hepatitis E	1.8 (1.3 to 2.2)	2.7 (1.5 to 3.7)	48.9 (-13.3 to 126.1)	-16.2 (-46.9 to 26.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	49.0 (-18.9 to 145.7)	-15.6 (-50.2 to 37.0)
Leprosy	1.6 (1.2 to 2.1)	2.0 (1.8 to 2.2)	27.0 (5.4 to 59.5)	0.1 (-35.7 to -7.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	27.5 (-0.6 to 67.0)	-23.7 (-38.2 to -3.5)
Other infectious diseases	85.1 (64.5 to 106.2)	122.3 (110.1 to 135.5)	44.0 (23.1 to 75.6)	-17.6 (-28.3 to -4.6)	2.4 (2.4 to 6.0)	5.2 (3.4 to 7.5)	31.1 (4.5 to 61.6)	-25.1 (-46.6 to -7.2)
Non-communicable diseases	-	-	-	-	595.6 (436.8 to 766.5)	1,015.2 (741.4 to 1,309.2)	70.4 (64.1 to 76.5)	-2.7 (-6.0 to 0.5)
Neoplasms	-	-	-	-	2.0 (1.4 to 2.6)	4.1 (2.8 to 5.6)	111.5 (70.7 to 158.8)	26.9 (2.9 to 55.9)
Esophageal cancer	1.1 (0.8 to 1.5)	2.4 (1.6 to 3.2)	109.7 (39.6 to 207.5)	23.0 (-17.2 to 77.6)	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.5)	112.4 (53.2 to 204.0)	25.6 (-9.5 to 76.0)
Stomach cancer	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	87.6 (39.2 to 157.8)	8.9 (-19.1 to 50.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.3 (44.7 to 152.8)	11.5 (-17.1 to 52.0)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	99.2 (40.6 to 147.5)	10.3 (-18.2 to 45.8)
Liver cancer due to hepatitis B	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	111.8 (-4.6 to 360.3)	20.3 (-43.9 to 176.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.5 (0.7 to 342.6)	19.1 (-43.1 to 166.9)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	407.8 (122.4 to 907.6)	167.8 (30.8 to 442.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	404.3 (131.0 to 819.8)	164.8 (34.6 to 396.1)
Liver cancer due to alcohol use	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-2.1 (-43.9 to 85.7)	-43.2 (-67.4 to 6.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.3 (-40.7 to 65.1)	-42.7 (-65.2 to -2.6)
Liver cancer due to other causes	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	101.3 (-35.4 to 85.0)	-37.2 (-54.0 to 9.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.7 (-30.9 to 66.9)	-37.8 (-61.0 to -1.5)
Larynx cancer	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	119.8 (52.7 to 209.7)	20.2 (-16.0 to 67.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	124.8 (54.0 to 212.4)	22.6 (-14.7 to 73.4)
Tracheal, bronchus and lung cancer	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	125.2 (62.7 to 205.4)	23.0 (-8.9 to 64.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	121.2 (60.5 to 199.4)	21.6 (-11.1 to 66.8)
Breast cancer	2.0 (1.2 to 2.5)	4.1 (2.6 to 5.3)	110.4 (47.3 to 187.6)	24.9 (-10.6 to 69.0)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	97.1 (37.0 to 172.7)	18.7 (-14.7 to 63.9)
Cervical cancer	4.9 (3.7 to 6.6)	7.8 (5.0 to 10.8)	60.8 (-8.0 to 143.4)	3.9 (-43.8 to 47.6)	0.7 (0.3 to 0.6)	0.7 (0.4 to 1.0)	61.4 (-45.5 to 145.7)	-1.3 (-43.7 to 47.2)
Uterine cancer	0.3 (0.2 to 0.6)	0.4 (0.2 to 0.7)	35.5 (-22.4 to 129.5)	-17.4 (-51.8 to 41.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	41.1 (-18.9 to 141.7)	-13.9 (-47.4 to 17.1)
Prostate cancer	0.7 (0.4 to 1.2)	4.2 (2.5 to 6.8)	480.9 (235.4 to 1,074.9)	195.4 (77.3 to 473.8)	0.1 (0.0 to 0.1)	0.4 (0.2 to 0.7)	443.7 (229.6 to 960.3)	178.8 (75.3 to 421.3)
Colon and rectum cancer	0.5 (0.4 to 0.6)	1.2 (1.0 to 1.4)	129.0 (80.1 to 189.8)	31.1 (4.2 to 65.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	120.4 (69.5 to 181.6)	25.8 (-2.9 to 63.2)
Lip and oral cavity cancer	0.5 (0.3 to 0.6)	0.9 (0.6 to 1.2)	89.7 (30.5 to 170.4)	13.7 (-21.7 to 63.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	91.5 (33.4 to 169.6)	14.5 (-20.0 to 62.2)
Nasopharynx cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	62.2 (2.8 to 164.2)	-3.8 (-41.2 to 56.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.5 (6.4 to 160.3)	-4.2 (-37.2 to 53.2)
Other pharynx cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	84.6 (6.7 to 229.2)	3.8 (-43.4 to 85.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.9 (17.7 to 230.6)	8.7 (-36.9 to 90.9)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.9 (7.9 to 166.3)	-2.5 (-38.9 to 54.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.7 (8.9 to 149.4)	-5.0 (-37.9 to 44.5)
Pancreatic cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	92.5 (39.0 to 170.0)	5.5 (-23.3 to 46.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.0 (48.1 to 152.6)	6.1 (-17.5 to 38.1)
Malignant skin melanoma	0.7 (0.5 to 0.9)	1.5 (1.0 to 2.0)	117.6 (52.9 to 200.0)	26.5 (-10.8 to 78.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	117.4 (51.0 to 208.1)	26.4 (-12.8 to 78.8)
Non-melanoma skin cancer	0.5 (0.4 to 0.6)	1.2 (1.0 to 1.5)	168.1 (112.0 to 240.6)	48.5 (13.4 to 90.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	219.3 (127.5 to 367.3)	73.6 (4.3 to 172.1)
Ovarian cancer	0.4 (0.2 to 0.5)	0.7 (0.4 to 1.1)	85.1 (19.5 to 176.6)	4.5 (-30.9 to 49.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	86.9 (17.3 to 181.0)	4.8 (-32.9 to 56.0)
Testicular cancer	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	172.3 (62.2 to 366.0)	42.3 (-12.7 to 137.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	172.1 (63.9 to 375.0)	45.9 (-13.5 to 152.0)
Kidney cancer	1.0 (0.6 to 2.0)	1.9 (0.9 to 3.6)	95.5 (-30.5 to 334.6)	16.7 (-44.9 to 115.4)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	100.8 (-28.9 to 336.5)	20.3 (-40.4 to 98.4)
Bladder cancer	1.0 (0.7 to 1.3)	1.9 (1.3 to 2.4)	95.5 (38.1 to 174.8)	16.7 (-16.4 to 61.6)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	100.8 (44.4 to 182.9)	20.3 (-12.0 to 66.6)
Brain and nervous system cancer	0.2 (0.1 to 0.4)	0.5 (0.3 to 0.8)	117.5 (24.9 to 256.9)	0.0 (-8.0 to 84.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	105.7 (25.7 to 209.4)	27.3 (-5.6 to 74.3)
Thyroid cancer	0.5 (0.3 to 0.8)	0.9 (0.6 to 1.4)	74.8 (6.5 to 170.4)	-0.2 (-39.9 to 59.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	76.6 (8.8 to 180.3)	0.0 (-38.9 to 59.4)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.2 (27.0 to 162.6)	0.6 (-30.6 to 50.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.7 (31.1 to 170.9)	2.6 (-29.7 to 54.2)
Hodgkin lymphoma	0.4 (0.3 to 0.6)	0.5 (0.5 to 1.2)	94.3 (19.8 to 218.6)	34.2 (-12.0 to 103.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	97.9 (29.5 to 200.3)	32.7 (-11.3 to 97.2)
Non-Hodgkin lymphoma	3.0 (2.1 to 4.3)	6.9 (3.7 to 11.2)	132.0 (18.4 to 314.2)	29.4 (-16.0 to 91.7)	0.2 (0.1 to 0.3)	0.5 (0.2 to 0.8)	120.8 (26.5 to 264.3)	24.6 (-12.7 to 72.8)
Multiple myeloma	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	94.3 (21.1 to 214.5)	9.7 (-32.9 to 76.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	90.9 (26.6 to 193.5)	8.0 (-29.8 to 69.3)
Leukemia	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	99.2 (20.6 to 227.5)	0.0 (-24.0 to 55.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	79.5 (26.0 to 147.0)	-0.7 (-27.9 to 33.6)
Other neoplasms	3.7 (2.2 to 8.2)	9.0 (6.2 to 12.9)	169.1 (17.1 to 348.5)	36.9 (-11.9 to 96.0)	0.2 (0.1 to 0.5)	0.6 (0.4 to 0.9)	155.4 (23.6 to 293.0)	29.0 (-9.6 to 78.8)
Cardiovascular diseases	-	-	-	-	15.0 (10.3 to 21.1)	26.2 (17.6 to 36.7)	75.2 (40.5 to 113.9)	-6.0 (-24.9 to 13.2)
Rheumatic heart disease	99.8 (82.0 to 117.2)	168.7 (137.1 to 196.8)	69.3 (30.7 to 122.8)	-4.6 (-23.2 to 19.5)	4.9 (3.1 to 7.2)	8.2 (5.1 to 12.3)	66.2 (28.3 to 119.3)	-8.9 (-28.6 to 15.9)
Ischemic heart disease	76.1 (59.9 to 96.4)	99.2 (78.2 to 125.6)	29.3 (-0.7 to 75.1)	-30.3 (-44.7 to -7.6)	3.5 (2.4 to 5.9)	4.7 (2.8 to 7.3)	19.1 (-15.8 to 75.4)	-35.2 (-62.3 to -6.3)
Cerebrovascular disease	-	-	-	-	0.5 (0.3 to 0.6)	0.8 (0.6 to 1.1)	82.3 (41.8 to 128.0)	1.7 (-21.3 to 27.0)
Ischemic stroke	2.1 (1.8 to 2.6)	3.9 (3.2 to 4.7)	85.3 (41.8 to 126.9)	2.2 (-20.2 to 24.9)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	84.4 (40.0 to 133.8)	2.5 (-22.6 to 28.9)
Hemorrhagic stroke	0.7 (0.6 to 0.9)	1.2 (1.0 to 1.6)	75.8 (30.6 to 132.9)	-2.0 (-26.3 to 28.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	76.4 (31.5 to 132.7)	-0.7 (-26.5 to 31.5)
Hypertensive heart disease	11.8 (9.2 to 15.1)	24.6 (16.5 to 32.5)	108.9 (32.1 to 206.1)	7.0 (-35.1 to 56.5)	1.3 (0.8 to 1.9)	2.7 (1.6 to 4.0)	109.6 (31.5 to 207.6)	8.6 (-34.3 to 58.4)
Cardiomyopathy and myocarditis	8.5 (7.0 to 10.4)	21.2 (15.4 to 28.2)	146.8 (65.1 to 263.1)	36.5 (-15.8 to 115.2)	0.9 (0.6 to 1.3)	2.3 (1.4 to 3.6)	149.1 (65.0 to 274.1)	38.6 (-14.1 to 120.1)
Atrial fibrillation and flutter	2.8 (2.1 to 3.5)	9.6 (6.9 to 13.0)	247.6 (141.2 to 383.1)	75.6 (12.8 to 162.3)	0.2 (0.1 to 0.3)	0.7 (0.4 to 1.1)	245.8 (136.9 to 394.4)	78.2 (14.3 to 168.1)
Peripheral vascular disease	118.6 (75.3 to 160.4)	218.2 (135.6 to 297.6)	90.0 (1.6 to 198.8)	-1.3 (-43.8 to 47.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	90.8 (-7.7 to 323.3)	-2.3 (-57.1 to 78.8)
Endocarditis	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	13.3 (-34.6 to 107.7)	-37.8 (-67.5 to 32.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	13.7 (-37.1 to 127.3)	-0.0 (-70.6 to 47.9)
Other cardiovascular and circulatory diseases	46.1 (23.4 to 80.8)	94.2 (48.4 to 138.7)	113.3 (-14.4 to 316.7)	7.2 (-58.6 to 126.2)	1.2 (1.5 to 5.8)	6.6 (3.0 to 11.0)	116.2 (-13.6 to 317.4)	8.7 (-58.2 to 131.2)
Chronic respiratory diseases	-	-	-	-	48.9 (31.4 to 70.7)	73.4 (49.6 to 103.6)	50.5 (21.4 to 90.2)	-14.8 (-30.6

Appendix Table G.4 - Malawi prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.2 (65.9 to 76.8)	-4.6 (-7.6 to -1.9)
Silicosis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	64.4 (56.8 to 72.1)	-9.3 (-13.6 to -5.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.2 (56.4 to 72.2)	-9.4 (-13.7 to -5.5)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	78.7 (71.3 to 86.6)	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.5 (70.4 to 86.2)	0.4 (-3.4 to 4.6)
Asthma	170.1 (112.0 to 232.4)	349.0 (282.8 to 428.7)	103.5 (93.6 to 219.5)	14.5 (11.0 to 56.1)	7.4 (4.1 to 12.0)	15.3 (9.4 to 22.5)	105.4 (84.4 to 228.4)	15.6 (11.4 to 59.4)
Interstitial lung disease and pulmonary sarcoidosis	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.4)	102.4 (34.3 to 180.2)	11.9 (-19.6 to 49.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	101.7 (36.0 to 176.4)	11.5 (-19.4 to 48.4)
Other chronic respiratory diseases	-	-	-	-	17.6 (9.3 to 28.9)	16.0 (8.9 to 28.3)	-9.5 (-40.3 to 40.4)	47.4 (-6.4 to -18.2)
Cirrhosis	-	-	-	-	0.8 (0.5 to 1.1)	1.1 (0.8 to 1.6)	48.2 (30.4 to 68.9)	-3.3 (-18.7 to 11.6)
Cirrhosis due to hepatitis B	1.2 (0.7 to 1.7)	1.7 (1.2 to 2.4)	53.8 (-20.4 to 139.0)	0.0 (49.6 to 54.6)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.5)	53.6 (-21.4 to 153.8)	0.4 (-50.3 to 63.8)
Cirrhosis due to hepatitis C	0.7 (0.4 to 1.0)	1.2 (0.8 to 1.8)	65.6 (-1.7 to 223.9)	-4.3 (47.7 to 99.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	66.2 (-4.4 to 235.6)	-3.9 (-49.2 to 100.9)
Cirrhosis due to alcohol use	1.2 (0.9 to 1.5)	1.5 (1.1 to 1.8)	20.1 (-19.0 to 71.2)	-28.6 (-53.5 to 0.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	20.5 (-21.9 to 80.5)	28.3 (-54.0 to 5.4)
Cirrhosis due to other causes	1.5 (1.2 to 1.9)	2.1 (2.1 to 2.9)	62.3 (25.0 to 108.4)	10.0 (-20.0 to 49.1)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	61.9 (10.8 to 141.0)	10.8 (-24.3 to 60.3)
Digestive diseases	-	-	-	-	11.6 (8.0 to 15.8)	19.9 (13.9 to 27.3)	71.8 (55.6 to 87.7)	-0.5 (-9.8 to 8.3)
Peptic ulcer disease	58.5 (50.2 to 65.6)	77.2 (71.8 to 82.4)	31.9 (14.2 to 54.5)	-25.1 (-35.0 to -13.6)	2.1 (1.3 to 2.9)	2.8 (1.9 to 4.1)	38.6 (10.5 to 61.5)	-21.5 (-34.3 to -9.5)
Gastritis and duodenitis	114.0 (101.8 to 124.6)	183.3 (169.9 to 196.7)	60.7 (43.4 to 81.7)	-5.6 (-16.9 to 7.7)	4.9 (3.3 to 7.1)	8.4 (5.6 to 12.0)	72.1 (44.8 to 92.8)	2.0 (-11.1 to 15.2)
Appendicitis	1.2 (1.0 to 1.5)	2.0 (1.4 to 2.7)	58.3 (30.0 to 127.0)	-8.6 (-31.5 to 28.3)	0.2 (0.2 to 0.6)	0.6 (0.3 to 0.9)	60.7 (3.3 to 148.5)	-7.5 (-36.3 to 37.1)
Paralytic ileus and intestinal obstruction	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	62.6 (9.5 to 170.6)	-3.6 (-16.2 to 13.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	63.2 (-3.4 to 177.2)	-2.9 (-27.2 to 31.5)
Inguinal, femoral, and abdominal hernia	15.3 (12.5 to 20.4)	42.6 (35.1 to 51.0)	180.4 (105.1 to 272.9)	0.2 (-117.9 to 258.3)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.8)	171.8 (96.9 to 271.5)	178.5 (113.9 to 254.4)
Inflammatory bowel disease	8.4 (8.0 to 8.8)	18.1 (17.3 to 19.0)	116.1 (102.9 to 130.1)	25.9 (18.7 to 33.4)	1.8 (1.2 to 2.4)	3.8 (2.6 to 5.2)	118.1 (96.7 to 142.0)	27.2 (16.8 to 38.1)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.9 (22.8 to 136.9)	-3.8 (-33.2 to 32.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.2 (23.7 to 140.8)	-0.3 (-32.9 to 42.2)
Gallbladder and biliary diseases	2.7 (2.4 to 3.1)	5.7 (5.1 to 6.4)	109.2 (75.6 to 146.0)	0.3 (-1.9 to 37.3)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	110.8 (70.8 to 158.2)	16.8 (-2.5 to 39.8)
Pancreatitis	1.5 (1.4 to 1.6)	2.7 (2.6 to 2.9)	84.3 (70.6 to 99.6)	4.8 (-2.6 to 13.1)	0.8 (0.3 to 0.6)	0.8 (0.5 to 1.1)	86.3 (58.1 to 121.9)	6.2 (-8.5 to 23.6)
Other digestive diseases	-	-	-	-	1.6 (0.8 to 2.5)	2.3 (1.4 to 3.4)	45.2 (1.9 to 114.2)	-15.7 (-40.8 to 22.8)
Neurological disorders	-	-	-	-	34.1 (22.3 to 49.2)	59.9 (38.5 to 89.4)	71.9 (35.9 to 151.5)	-3.2 (-18.3 to 18.5)
Alzheimer disease and other dementias	11.7 (10.4 to 13.3)	25.1 (22.2 to 28.3)	114.6 (79.6 to 154.9)	0.4 (-14.6 to 20.2)	1.6 (1.1 to 2.1)	3.5 (2.5 to 4.6)	120.2 (84.0 to 164.9)	1.9 (-13.7 to 21.9)
Parkinson disease	0.7 (0.4 to 0.9)	1.3 (0.8 to 1.9)	95.6 (74.2 to 119.3)	-0.2 (-9.0 to 9.0)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	98.6 (60.6 to 142.3)	2.0 (-16.4 to 23.0)
Epilepsy	13.7 (7.7 to 21.9)	22.1 (12.4 to 35.2)	62.9 (-22.6 to 227.5)	-4.4 (-55.5 to 86.3)	4.2 (2.1 to 7.2)	7.0 (3.5 to 11.8)	70.2 (-17.8 to 246.2)	-3.2 (-52.7 to 94.0)
Multiple sclerosis	0.6 (0.5 to 0.7)	1.1 (1.0 to 1.3)	91.4 (62.3 to 123.8)	14.7 (-1.2 to 32.9)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.5)	90.4 (48.6 to 143.0)	13.8 (-10.3 to 44.9)
Migraine	519.6 (334.1 to 710.2)	798.8 (476.4 to 1,233.3)	53.2 (-6.3 to 269.4)	-31.2 (-39.9 to 82.9)	17.5 (9.3 to 30.0)	27.7 (13.0 to 47.5)	12.8 (-7.6 to 27.5)	-12.8 (-40.2 to 87.5)
Tension-type headache	1,089.3 (1,014.3 to 1,167.6)	2,041.4 (1,865.5 to 2,204.2)	88.0 (66.8 to 109.9)	4.5 (-4.9 to 13.7)	1.6 (0.8 to 2.8)	3.1 (1.5 to 5.3)	89.9 (53.8 to 113.9)	5.5 (-1.5 to 16.1)
Medication overuse headache	42.6 (27.2 to 57.8)	100.6 (67.5 to 139.9)	133.3 (76.7 to 218.5)	42.7 (3.5 to 84.8)	6.6 (3.6 to 10.3)	15.7 (8.9 to 24.4)	135.5 (78.0 to 221.9)	43.1 (5.4 to 87.1)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.9 (20.8 to 121.6)	-6.4 (-32.2 to 26.9)	2.3 (1.3 to 5.5)	3.0 (1.8 to 4.9)	38.9 (-27.8 to 100.5)	-33.8 (-65.3 to -6.4)
Mental and substance use disorders	-	-	-	-	210.2 (146.5 to 284.3)	365.0 (252.5 to 500.3)	73.7 (68.3 to 78.7)	0.4 (-2.9 to 3.0)
Schizophrenia	19.3 (17.6 to 20.8)	32.5 (29.7 to 35.3)	68.5 (61.0 to 76.3)	1.1 (-3.3 to 5.4)	1.1 (8.9 to 14.7)	1.1 (15.1 to 25.2)	70.6 (59.5 to 83.0)	2.2 (-4.2 to 8.8)
Alcohol use disorders	97.2 (89.7 to 104.4)	153.9 (143.4 to 166.1)	58.1 (50.7 to 67.1)	-8.1 (-11.9 to -3.3)	9.5 (6.3 to 13.4)	15.1 (10.1 to 21.4)	59.9 (49.9 to 70.1)	-7.1 (-12.5 to -1.7)
Drug use disorders	-	-	-	-	11.2 (7.4 to 15.3)	19.5 (12.8 to 27.2)	73.9 (55.8 to 98.2)	2.8 (-7.5 to 14.8)
Opioid use disorders	14.0 (8.8 to 20.5)	23.9 (15.2 to 36.2)	68.6 (54.0 to 95.6)	3.6 (-5.5 to 17.8)	5.6 (3.2 to 8.9)	9.8 (5.5 to 15.6)	71.3 (53.1 to 102.0)	5.2 (-6.0 to 21.5)
Cocaine use disorders	4.6 (3.8 to 5.3)	7.6 (6.2 to 9.4)	63.9 (27.4 to 119.7)	0.1 (-20.0 to 26.7)	0.6 (0.4 to 0.9)	0.9 (0.6 to 1.6)	64.8 (18.4 to 133.6)	-0.3 (-24.8 to 33.8)
Amphetamine use disorders	15.2 (14.0 to 16.3)	26.7 (24.5 to 29.1)	75.4 (56.4 to 99.3)	-2.6 (-12.4 to 9.5)	2.0 (1.2 to 2.9)	3.5 (2.2 to 5.2)	77.1 (49.6 to 113.6)	-1.7 (-16.7 to 16.8)
Cannabis use disorders	11.9 (8.8 to 14.4)	21.5 (15.9 to 26.3)	81.2 (79.0 to 82.9)	0.5 (0.4 to 0.7)	0.3 (0.2 to 0.5)	0.6 (0.4 to 1.0)	82.1 (53.8 to 118.0)	1.1 (-13.7 to 19.1)
Other drug use disorders	-	-	-	-	2.6 (1.6 to 3.9)	4.6 (2.8 to 6.8)	73.7 (25.4 to 141.0)	-1.8 (-28.7 to 35.6)
Depressive disorders	-	-	-	-	11.3 (63.6 to 146.4)	19.8 (108.1 to 254.0)	75.5 (61.9 to 81.1)	2.0 (-6.8 to 4.1)
Major depressive disorder	443.4 (330.6 to 557.3)	756.0 (551.7 to 957.2)	70.7 (59.9 to 80.3)	-1.3 (-8.4 to 3.7)	90.5 (57.4 to 135.5)	155.6 (97.7 to 234.0)	72.2 (61.0 to 82.4)	-0.5 (-7.6 to 4.5)
Dysthymia	91.2 (75.1 to 109.0)	154.8 (127.1 to 184.9)	69.8 (67.1 to 72.2)	-0.6 (-0.9 to -0.4)	8.7 (5.6 to 12.7)	14.9 (9.6 to 21.8)	71.0 (65.5 to 76.8)	0.1 (-2.4 to 2.7)
Bipolar disorder	51.3 (43.9 to 58.5)	88.0 (74.9 to 100.2)	72.1 (61.0 to 81.4)	-0.4 (-5.5 to 4.4)	10.3 (6.4 to 15.5)	17.9 (10.8 to 26.9)	73.5 (58.7 to 86.7)	0.6 (-6.3 to 6.9)
Anxiety disorders	281.6 (111.6 to 467.3)	482.9 (193.7 to 812.8)	71.6 (67.2 to 74.4)	-1.0 (-1.5 to -0.5)	99.2 (2.3 to 46.3)	170.5 (16.1 to 46.3)	72.0 (66.3 to 79.3)	-0.5 (-2.8 to 2.3)
Eating disorders	-	-	-	-	9.2 (1.4 to 3.7)	4.1 (2.5 to 6.6)	78.8 (64.2 to 94.6)	-1.0 (-8.6 to 7.9)
Anorexia nervosa	1.6 (1.2 to 2.0)	2.9 (2.2 to 3.9)	86.2 (65.1 to 103.9)	3.1 (-8.2 to 12.9)	0.3 (0.2 to 0.5)	0.6 (0.4 to 1.0)	86.7 (42.1 to 134.5)	3.9 (-21.2 to 30.1)
Bulimia nervosa	9.5 (6.5 to 13.9)	16.7 (11.4 to 24.5)	76.3 (72.9 to 78.8)	-2.3 (-2.9 to -1.9)	2.0 (1.2 to 3.2)	3.5 (2.0 to 5.7)	77.7 (62.3 to 95.5)	-1.6 (-9.9 to 8.2)
Autistic spectrum disorders	-	-	-	-	11.3 (7.8 to 15.4)	19.8 (13.7 to 26.9)	75.5 (68.7 to 82.7)	2.0 (-1.4 to 5.7)
Autism	29.0 (27.5 to 30.5)	50.5 (47.9 to 53.1)	74.1 (73.9 to 74.2)	1.0 (1.0 to 1.1)	7.1 (4.8 to 9.8)	12.5 (8.3 to 17.1)	75.4 (65.5 to 86.4)	2.0 (-3.1 to 7.2)
Asperger syndrome	41.7 (39.1 to 44.2)	72.6 (68.1 to 77.0)	74.2 (73.9 to 74.4)	1.3 (1.3 to 1.4)	4.1 (2.9 to 5.8)	7.3 (5.0 to 10.2)	75.5 (67.8 to 83.7)	2.2 (-1.7 to 6.1)
Attention-deficit/hyperactivity disorder	69.6 (64.3 to 75.3)	124.7 (115.1 to 134.7)	79.1 (79.0 to 79.2)	0.4 (0.4 to 0.4)	0.8 (0.5 to 1.3)	1.5 (0.9 to 2.3)	80.4 (67.4 to 94.7)	1.1 (-5.7 to 9.1)
Conduct disorder	101.9 (96.1 to 107.9)	182.2 (171.7 to 193.0)	78.5 (78.3 to 79.4)	0.3 (0.3 to 0.3)	12.2 (7.7 to 17.5)	22.0 (13.8 to 32.2)	80.1 (71.6 to 88.1)	1.0 (-3.6 to 5.5)
Idiopathic intellectual disability	152.9 (95.6 to 223.8)	306.7 (187.0 to 404.6)	97.2 (60.8 to 237.0)	7.5 (-5.1 to 104.6)	16.4 (5.1 to 26.1)	15.0 (8.4 to 22.5)	98.2 (61.5 to 121.9)	16.5 (5.4 to 106.9)
Other mental and substance use disorders	111.8 (104.1 to 118.9)	195.9 (182.6 to 208.9)	75.3 (74.1 to 76.4)	0.9 (0.6 to 1.2)	8.2 (5.6 to 11.0)	14.6 (9.9 to 19.5)	76.9 (68.9 to 84.5)	1.8 (-2.0 to 5.4)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	41.7 (29.5 to 56.1)	72.8 (51.3 to 97.6)	74.4 (60.7 to 87.6)	2.9 (-6.0 to 11.8)
Diabetes mellitus	80.6 (67.8 to 95.2)	179.3 (150.9 to 208.0)	123.2 (76.4 to 177.9)	28.6 (-1.7 to 65.1)	28.6 (4.0 to 8.5)	132.2 (8.7 to 38.9)	119.4 (70.3 to 183.2)	25.4 (-4.9 to 66.4)
Acute glomerulonephritis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	23.2 (12.8 to 32.5)	-23.9 (-29.3 to -19.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.2 (12.8 to 32.6)	-23.9 (-29.3 to -19.5)
Chronic kidney disease	-	-	-	-	14.4 (10.3 to 19.3)	25.5 (18.5 to 33.5)	76.5 (58.4 to 98.0)	0.6 (-8.1 to 12.0)
Chronic kidney disease due to diabetes mellitus	117.5 (73.6 to 173.3)	195.6 (129.7 to 288.3)	68.5 (9.4 to 144.6)	-0.6 (-33.0 to 43.0)	1.8 (1.2 to 2.6)	3.0 (2.0 to 4.2)	69.0 (15.7 to 130.1)	0.2 (-28.9 to 34.5)
Chronic kidney disease due to hypertension	378.7 (235.9 to 620.3)	670.5 (415.3 to 1,055.9)	77.6 (42.1 to 117.4)	4.3 (-22.6 to 28.1)	5.5 (3.0 to 5.8)	8.1 (5.6 to 10.8)	88.0 (55.0 to 129.1)	3.6 (-12.8 to 22.7)
Chronic kidney disease due to glomerulonephritis	313.5 (226.6 to 452.6)	578.2 (390.6 to 890.6)	71.6 (47.0 to 131.9)	1.9 (-19.3 to 24.5)	1.9 (3.5 to 7.1)	9.1 (6.5 to 12.2)	90.3 (40.4 to 121.0)	6.6 (-19.3 to 31.4)
Chronic kidney disease due to other causes	254.4 (153.1 to 422.1)	412.1 (263.1 to 710.6)	63.2 (28.5 to 104.5)	-8.7 (-27.1 to 14.1)	3.2 (3.2 to 4.3)	5.3 (3.7 to 7.2)	64.3 (20.2 to 107.5)	1.8 (-28.0 to 18.4)
Urinary diseases and male infertility	-	-	-	-	2.4 (1.6 to 3.5)	4.6 (3.0 to 6.6)	88.6 (65.3 to 111.8)	1.3 (-9.2 to 12.2)

Appendix Table G.4 - Malawi prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.8 (1.6 to 1.9)	3.3 (3.1 to 3.5)	85.6 (68.2 to 103.8)	0.1 (-1.9 to 15.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	85.9 (42.4 to 136.8)	7.5 (-12.6 to 29.4)
Urolithiasis	19.9 (15.5 to 26.3)	27.2 (20.2 to 35.9)	35.9 (18.2 to 59.5)	0.2 (-32.0 to -12.8)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	68.1 (47.2 to 93.8)	-4.6 (-15.1 to 7.3)
Benign prostatic hyperplasia	48.4 (44.2 to 52.1)	97.2 (87.7 to 105.5)	100.7 (77.6 to 127.2)	2.2 (-8.6 to 14.6)	1.7 (1.1 to 2.4)	3.5 (2.2 to 4.9)	103.3 (79.1 to 129.8)	3.9 (-7.1 to 16.5)
Male infertility due to other causes	47.4 (30.3 to 68.3)	72.2 (46.1 to 108.9)	51.9 (-16.7 to 176.4)	-9.7 (-51.3 to 64.0)	0.3 (0.1 to 0.6)	0.4 (0.2 to 0.9)	55.1 (-13.9 to 193.7)	-9.2 (-50.5 to 71.3)
Other urinary diseases	-	-	-	-	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	22.0 (-20.9 to 103.5)	-30.0 (55.5 to 13.8)
Gynecological diseases	-	-	-	-	8.6 (5.5 to 13.0)	13.3 (8.5 to 20.1)	53.0 (30.5 to 81.5)	-9.6 (-22.1 to 6.0)
Uterine fibroids	144.7 (130.4 to 157.9)	213.6 (191.9 to 233.2)	47.7 (46.7 to 48.7)	-5.1 (-5.3 to -4.9)	2.0 (1.1 to 3.3)	2.8 (1.6 to 4.7)	37.4 (21.0 to 78.9)	-15.8 (-25.5 to 7.2)
Polycystic ovarian syndrome	138.3 (121.4 to 155.7)	226.4 (200.7 to 252.9)	63.6 (39.4 to 94.9)	-3.5 (-15.7 to 13.5)	1.3 (0.6 to 2.5)	2.2 (1.0 to 4.1)	64.3 (40.7 to 94.8)	-3.4 (-15.9 to 13.2)
Female infertility due to other causes	69.5 (44.8 to 92.9)	76.1 (49.8 to 106.3)	8.5 (-31.9 to 88.1)	-35.2 (-59.6 to -11.8)	0.3 (0.1 to 0.7)	0.4 (0.1 to 0.8)	22.0 (-32.0 to 86.6)	-36.1 (-59.2 to 11.8)
Endometriosis	13.9 (11.6 to 16.1)	19.9 (16.7 to 23.3)	44.7 (14.8 to 81.1)	-12.5 (-29.4 to 8.5)	1.3 (0.8 to 1.8)	1.8 (1.2 to 2.6)	45.6 (12.5 to 85.1)	-12.1 (-30.6 to 10.4)
Genital prolapse	235.2 (195.3 to 277.3)	399.7 (339.8 to 463.0)	70.2 (32.5 to 114.8)	1.4 (-17.5 to 23.0)	0.7 (0.4 to 1.4)	1.3 (0.6 to 2.4)	71.3 (33.1 to 116.2)	1.5 (-17.5 to 24.1)
Premenstrual syndrome	291.1 (204.4 to 390.5)	489.7 (282.2 to 664.6)	65.3 (-6.0 to 183.2)	-3.4 (-4.2 to 66.1)	2.4 (1.4 to 3.9)	4.1 (2.1 to 6.9)	66.3 (-6.6 to 188.4)	-2.9 (-44.7 to 67.7)
Other gynecological diseases	17.9 (11.9 to 24.0)	27.7 (19.8 to 36.7)	53.9 (6.8 to 142.1)	-13.3 (-36.9 to 31.9)	0.6 (0.3 to 0.9)	0.8 (0.4 to 1.2)	37.3 (-28.6 to 189.2)	-26.2 (-58.8 to 46.6)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	6.5 (4.3 to 9.4)	10.9 (7.2 to 15.7)	67.9 (48.3 to 96.0)	-3.9 (-14.7 to 13.9)
Thalassemias	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	46.3 (8.2 to 93.0)	-15.2 (-35.9 to 10.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.6 (13.5 to 101.5)	-9.7 (-33.0 to 15.3)
Thalassemia trait	45.4 (36.4 to 54.8)	80.6 (66.6 to 96.5)	72.7 (71.1 to 130.8)	0.4 (-0.3 to 35.3)	0.9 (0.6 to 1.3)	1.8 (1.1 to 2.6)	100.8 (66.5 to 144.2)	15.9 (-1.1 to 37.5)
Sickle cell disorders	2.4 (1.7 to 2.8)	4.7 (3.7 to 5.5)	98.8 (43.8 to 187.7)	17.6 (-15.9 to 59.0)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.8)	107.0 (47.7 to 179.8)	21.4 (-8.0 to 55.8)
Sickle cell trait	567.1 (521.1 to 609.9)	990.5 (916.5 to 1,055.9)	74.5 (67.7 to 83.7)	1.7 (-2.2 to 7.1)	2.8 (1.8 to 4.1)	5.3 (3.3 to 7.7)	85.6 (39.1 to 139.5)	3.9 (-16.1 to 41.6)
G6PD deficiency	1,716.5 (1,508.3 to 1,973.1)	2,564.8 (2,151.4 to 2,924.6)	49.7 (19.6 to 83.9)	-12.6 (-30.0 to 7.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	41.2 (-26.1 to 170.6)	-24.0 (-59.1 to 46.5)
G6PD trait	2,421.5 (2,400.5 to 2,430.0)	4,056.6 (3,973.7 to 4,090.8)	67.8 (64.7 to 69.7)	-2.4 (-4.2 to -1.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	66.5 (-74.7 to 622.9)	-7.7 (-84.9 to 371.3)
Other hemoglobinopathies and hemolytic anemias	64.7 (50.3 to 75.6)	86.9 (74.3 to 98.0)	34.1 (13.7 to 73.0)	-27.6 (-37.3 to -11.3)	2.3 (1.4 to 3.5)	3.0 (1.9 to 4.4)	31.5 (63.3 to 92.1)	-25.7 (-40.4 to 6.5)
Endocrine, metabolic, blood, and immune disorders	98.2 (81.7 to 113.5)	143.5 (116.9 to 165.5)	46.1 (10.5 to 89.0)	45.8 (-31.3 to 2.7)	3.8 (2.2 to 5.5)	5.4 (3.3 to 8.1)	42.5 (2.8 to 114.4)	-35.6 (-36.7 to 13.4)
Musculoskeletal disorders	-	-	-	-	102.4 (73.6 to 135.6)	181.3 (128.1 to 240.1)	76.6 (60.1 to 96.7)	2.3 (-5.6 to 11.9)
Rheumatoid arthritis	20.2 (19.4 to 21.1)	31.6 (30.2 to 33.1)	56.0 (46.5 to 66.6)	-13.0 (-18.2 to -7.4)	4.8 (3.3 to 6.3)	7.5 (5.3 to 10.0)	57.4 (43.9 to 72.8)	-11.9 (-18.7 to -4.8)
Osteoarthritis	156.2 (149.6 to 162.9)	286.5 (275.9 to 297.8)	83.4 (74.3 to 94.7)	1.7 (-3.0 to 7.2)	9.4 (6.6 to 13.0)	17.4 (12.1 to 23.4)	84.0 (74.0 to 95.4)	2.6 (-2.4 to 8.3)
Low back and neck pain	-	-	-	-	76.4 (54.2 to 104.0)	133.7 (92.9 to 179.3)	74.4 (53.0 to 101.5)	1.2 (-10.0 to 14.7)
Low back pain	405.2 (378.2 to 432.6)	698.6 (653.8 to 739.1)	72.9 (56.9 to 89.2)	-0.5 (-8.9 to 8.2)	44.5 (30.3 to 61.2)	77.4 (52.8 to 106.7)	73.8 (57.7 to 90.7)	0.6 (-8.3 to 9.6)
Neck pain	328.6 (264.9 to 390.9)	574.4 (461.5 to 692.3)	74.5 (36.6 to 132.4)	1.0 (-19.3 to 32.4)	31.9 (21.0 to 44.8)	56.3 (36.5 to 81.2)	75.7 (36.6 to 135.6)	1.7 (-19.1 to 32.8)
Gout	1.1 (0.9 to 1.3)	2.0 (1.8 to 2.2)	75.3 (50.0 to 110.3)	-2.2 (-16.6 to 15.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	77.3 (40.0 to 128.6)	-0.3 (-22.0 to 28.0)
Other musculoskeletal disorders	130.5 (97.4 to 165.9)	251.2 (194.2 to 312.2)	93.4 (75.8 to 110.2)	12.6 (2.6 to 20.9)	11.7 (7.5 to 17.3)	22.6 (14.7 to 33.2)	84.2 (76.0 to 113.8)	1.7 (-3.5 to 22.5)
Other non-communicable diseases	-	-	-	-	129.0 (84.2 to 189.4)	211.4 (139.9 to 311.7)	63.9 (56.0 to 70.9)	-7.9 (-11.4 to -4.4)
Congenital anomalies	-	-	-	-	15.7 (5.0 to 11.3)	15.7 (10.5 to 22.2)	101.3 (74.8 to 136.6)	13.5 (-1.1 to 33.6)
Neural tube defects	0.4 (0.3 to 0.5)	3.0 (2.5 to 3.5)	661.5 (470.5 to 961.9)	435.0 (287.7 to 662.1)	0.1 (0.1 to 0.1)	0.8 (0.5 to 1.1)	779.8 (461.0 to 1,276.6)	552.6 (312.5 to 907.2)
Congenital heart anomalies	3.2 (2.2 to 4.7)	30.1 (21.8 to 40.8)	857.6 (453.8 to 1,423.7)	578.9 (277.7 to 1,008.7)	0.1 (0.3 to 0.2)	1.0 (0.4 to 1.9)	627.5 (304.8 to 1,144.5)	397.3 (182.2 to 753.7)
Orofacial clefts	0.3 (0.2 to 0.5)	4.2 (2.9 to 5.5)	1,167.8 (640.2 to 1,949.2)	913.0 (462.3 to 1,644.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	1,067.0 (553.1 to 2,122.6)	835.5 (404.0 to 1,712.3)
Down syndrome	2.8 (2.2 to 3.6)	10.8 (9.1 to 13.0)	291.5 (186.4 to 415.6)	150.2 (82.2 to 236.1)	0.3 (0.2 to 0.5)	1.2 (0.9 to 1.7)	296.3 (181.3 to 461.1)	153.8 (81.4 to 259.7)
Turner syndrome	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.6)	202.4 (98.7 to 380.5)	80.1 (17.5 to 191.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	205.1 (99.5 to 391.9)	80.0 (16.3 to 200.0)
Klinefelter syndrome	0.3 (0.2 to 0.3)	0.5 (0.3 to 0.6)	78.9 (24.9 to 173.0)	5.0 (-26.9 to 60.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.5 (26.7 to 177.2)	7.2 (-25.3 to 64.1)
Chromosomal unbalanced rearrangements	4.7 (3.7 to 5.9)	18.3 (15.1 to 21.8)	188.3 (192.8 to 416.8)	185.5 (87.4 to 233.4)	0.5 (0.3 to 0.7)	2.1 (1.4 to 2.9)	295.2 (183.3 to 441.6)	155.0 (85.6 to 247.3)
Other congenital anomalies	68.9 (50.0 to 85.0)	104.0 (73.7 to 133.1)	50.0 (31.1 to 76.6)	-11.9 (-22.7 to 3.0)	6.7 (4.1 to 10.0)	10.4 (6.1 to 16.1)	55.0 (31.3 to 87.3)	-10.5 (-24.1 to 8.2)
Skin and subcutaneous diseases	-	-	-	-	45.5 (28.5 to 70.9)	79.4 (50.3 to 123.8)	75.7 (59.2 to 86.8)	1.0 (-7.2 to 7.0)
Dermatitis	368.4 (283.7 to 475.7)	632.7 (489.1 to 812.8)	71.8 (70.4 to 73.4)	-0.1 (-0.5 to 0.2)	13.2 (8.2 to 19.5)	22.9 (14.2 to 33.7)	73.8 (67.5 to 80.6)	0.5 (-2.5 to 3.5)
Psoriasis	55.9 (48.2 to 64.1)	96.7 (83.7 to 110.7)	73.1 (71.6 to 74.4)	0.0 (-0.1 to 0.2)	4.5 (3.1 to 6.3)	7.9 (5.3 to 11.2)	74.9 (62.1 to 87.4)	1.1 (-4.9 to 7.1)
Cellulitis	1.9 (1.4 to 2.4)	3.4 (2.7 to 4.2)	81.6 (55.8 to 110.6)	5.9 (-11.9 to 24.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	81.0 (36.1 to 142.2)	6.7 (-18.3 to 35.7)
Pyoderma	16.6 (12.2 to 21.5)	26.1 (19.5 to 33.5)	57.2 (47.4 to 69.1)	-4.1 (-10.5 to 3.1)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	57.3 (41.7 to 76.0)	-4.0 (-12.9 to 6.7)
Scabies	163.9 (118.9 to 221.4)	205.3 (160.9 to 264.1)	25.8 (-11.2 to 78.5)	-26.6 (-50.4 to 3.3)	4.2 (2.1 to 7.5)	5.3 (2.9 to 9.4)	26.8 (10.8 to 79.0)	-26.3 (-50.2 to 1.6)
Fungal skin diseases	1,050.2 (751.8 to 1,494.2)	1,839.2 (1,316.9 to 2,614.5)	75.2 (73.7 to 76.6)	75.2 (0.3 to 0.8)	0.5 (0.3 to 0.7)	10.4 (7.3 to 13.3)	45.9 (73.9 to 79.3)	1.0 (-0.2 to 3.9)
Viral skin diseases	229.3 (171.7 to 287.4)	400.7 (296.6 to 508.4)	74.7 (68.5 to 81.8)	0.2 (-2.8 to 3.2)	2.3 (4.0 to 11.2)	12.4 (7.0 to 20.1)	75.7 (66.9 to 84.4)	0.8 (-3.5 to 4.8)
Acne vulgaris	475.4 (330.1 to 759.8)	903.1 (552.9 to 1,290.7)	102.0 (-13.5 to 232.9)	10.2 (-51.7 to 76.3)	5.1 (2.1 to 10.2)	9.8 (4.1 to 20.3)	103.2 (-13.4 to 235.7)	11.3 (-51.2 to 78.0)
Alopecia areata	8.2 (7.2 to 9.3)	14.4 (12.7 to 16.1)	76.4 (50.6 to 104.5)	0.9 (-12.7 to 16.6)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	76.6 (46.1 to 112.9)	1.6 (-14.2 to 21.2)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.3 (39.2 to 116.5)	1.5 (-19.5 to 29.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.9 (38.9 to 116.6)	1.5 (-19.8 to 29.3)
Urticaria	35.7 (21.9 to 50.5)	84.2 (57.8 to 111.8)	134.0 (21.2 to 312.5)	30.5 (-20.5 to 109.6)	2.1 (1.1 to 3.5)	5.0 (2.8 to 8.0)	137.3 (19.7 to 326.2)	32.3 (-21.0 to 113.2)
Decubitus ulcer	1.0 (0.9 to 1.2)	1.9 (1.6 to 2.1)	87.8 (50.5 to 129.4)	-2.2 (-26.3 to 29.1)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	87.8 (46.1 to 135.8)	0.3 (-26.7 to 36.1)
Other skin and subcutaneous diseases	467.9 (316.1 to 664.5)	783.1 (528.4 to 1,121.0)	67.3 (60.1 to 75.2)	-4.1 (-8.3 to -0.6)	2.7 (1.2 to 5.5)	4.6 (2.1 to 9.3)	68.2 (60.2 to 76.8)	-3.4 (-7.7 to 0.4)
Sense organ diseases	-	-	-	-	59.7 (38.5 to 87.2)	88.4 (57.1 to 130.3)	48.0 (35.9 to 59.5)	-14.8 (-20.6 to -10.0)
Glaucoma	9.0 (6.8 to 11.7)	10.7 (8.0 to 13.9)	20.6 (-3.2 to 47.9)	-35.9 (-48.9 to -20.4)	1.0 (0.6 to 1.6)	1.0 (0.6 to 1.4)	4.8 (2.5 to 7.1)	-4.8 (-6.0 to -33.4)
Cataract	36.1 (26.9 to 45.0)	50.7 (34.6 to 65.4)	40.4 (12.3 to 74.3)	-24.7 (-36.5 to -8.5)	2.8 (1.8 to 4.0)	4.1 (2.5 to 6.0)	45.6 (20.4 to 86.6)	-21.4 (-32.8 to -2.4)
Macular degeneration	4.8 (2.5 to 8.1)	10.7 (7.3 to 15.6)	123.4 (29.3 to 312.8)	22.5 (-28.1 to 109.8)	0.3 (0.1 to 0.5)	0.6 (0.4 to 1.0)	119.1 (27.2 to 298.6)	16.5 (-28.5 to 93.3)
Uncorrected refractive error	406.5 (377.6 to 436.1)	653.4 (608.3 to 706.0)	60.4 (46.3 to 77.7)	-8.6 (-15.2 to -0.0)	9.0 (6.0 to 13.0)	13.0 (8.4 to 19.5)	45.0 (35.6 to 57.6)	-19.0 (-24.5 to -12.2)
Age-related and other hearing loss	1,193.4 (1,007.9 to 1,350.7)	1,887.6 (1,570.4 to 2,151.3)	58.0 (50.0 to 68.4)	-7.3 (-10.6 to -3.5)	39.2 (24.1 to 59.0)	57.4 (34.3 to 87.6)	46.0 (28.9 to 62.6)	-13.4 (-20.6 to -6.4)
Other vision loss	14.7 (12.0 to 18.2)	19.4 (15.5 to 23.8)	31.8 (13.8 to 51.5)	-20.4 (-32.2 to -8.0)	1.4 (0.9 to 2.1)	1.9 (1.2 to 2.8)	34.4 (14.3 to 62.0)	-18.7 (-29.8 to -1.5)
Other sense organ diseases	227.1 (216.2 to 238.6)	387.0 (365.9 to 409.4)	70.4 (58.0 to 83.6)	-1				

Appendix Table G.4 - Malawi prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	144.2 (133.8 to 154.7)	249.0 (233.4 to 264.9)	72.8 (58.0 to 90.1)	-6.6 (-14.3 to 1.6)	3.9 (2.6 to 5.5)	6.8 (4.5 to 9.5)	73.5 (58.3 to 91.0)	-5.7 (-13.6 to 3.0)
Other oral disorders	135.9 (126.9 to 143.9)	232.7 (218.1 to 247.9)	71.2 (56.2 to 87.0)	-1.1 (-8.8 to 7.2)	4.0 (2.5 to 5.9)	6.8 (4.2 to 10.2)	72.1 (56.5 to 89.1)	-0.5 (-8.5 to 8.3)
Injuries	-	-	-	-	33.5 (25.5 to 42.9)	40.8 (30.7 to 53.7)	21.7 (14.3 to 29.6)	-25.6 (-29.9 to -20.9)
Transport injuries	-	-	-	-	14.6 (11.1 to 18.7)	13.8 (10.1 to 18.3)	-5.5 (-13.1 to 3.7)	-38.2 (-42.6 to -32.9)
Road injuries	-	-	-	-	13.0 (9.9 to 16.6)	12.1 (8.9 to 16.1)	-7.1 (-15.1 to 2.3)	-39.1 (-43.5 to -33.9)
Pedestrian road injuries	-	-	-	-	4.4 (3.2 to 5.6)	3.7 (2.7 to 5.0)	-14.6 (-23.7 to -4.3)	-42.8 (-47.9 to -37.1)
Cyclist road injuries	-	-	-	-	1.2 (0.9 to 1.5)	1.1 (0.8 to 1.5)	-3.5 (-10.6 to 5.2)	-36.8 (-41.3 to -31.2)
Motorcyclist road injuries	-	-	-	-	1.6 (1.2 to 2.0)	1.3 (0.9 to 1.8)	-17.1 (-25.9 to -8.0)	-46.1 (-51.3 to -40.5)
Motor vehicle road injuries	-	-	-	-	5.7 (4.3 to 7.3)	5.8 (4.3 to 7.6)	9.8 (4.2 to 13.3)	-33.9 (-39.8 to -27.5)
Other road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-38.4 (-43.7 to -32.0)	-61.8 (-64.7 to -58.3)
Other transport injuries	-	-	-	-	1.6 (1.2 to 2.1)	1.8 (1.3 to 2.3)	7.9 (-0.7 to 18.0)	-31.6 (-36.4 to -25.0)
Unintentional injuries	-	-	-	-	17.7 (13.5 to 22.8)	24.5 (18.5 to 32.1)	38.5 (31.8 to 45.0)	-18.9 (-23.4 to -14.4)
Falls	-	-	-	-	7.4 (5.6 to 9.6)	11.3 (8.3 to 15.0)	51.4 (40.8 to 64.4)	-16.9 (-23.7 to -9.6)
Drowning	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	1.5 (-0.2 to 14.7)	-36.6 (-42.8 to -29.3)
Fire, heat, and hot substances	-	-	-	-	1.7 (1.3 to 2.2)	1.9 (1.4 to 2.5)	14.0 (0.9 to 26.8)	-30.8 (-37.4 to -25.1)
Poisonings	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	18.9 (1.6 to 41.2)	-29.5 (-37.8 to -19.3)
Exposure to mechanical forces	-	-	-	-	4.3 (3.3 to 5.6)	6.0 (4.5 to 8.0)	40.4 (32.8 to 48.5)	-15.3 (-19.6 to -10.5)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	56.2 (41.7 to 74.5)	-5.3 (-13.9 to 5.5)
Unintentional suffocation	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	81.1 (64.2 to 102.8)	7.6 (-0.8 to 18.1)
Other exposure to mechanical forces	-	-	-	-	4.1 (3.1 to 5.3)	5.7 (4.2 to 7.6)	39.2 (31.6 to 47.3)	-16.0 (-20.4 to -11.2)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	86.7 (76.2 to 99.7)	9.9 (3.2 to 17.3)
Animal contact	-	-	-	-	1.0 (0.8 to 1.4)	1.1 (0.8 to 1.5)	8.6 (-0.9 to 18.3)	-33.4 (-38.2 to -28.6)
Venomous animal contact	-	-	-	-	0.5 (0.3 to 0.6)	0.5 (0.4 to 0.7)	10.6 (-3.3 to 25.6)	-32.6 (-40.1 to -25.1)
Non-venomous animal contact	-	-	-	-	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.8)	7.0 (-3.4 to 17.8)	-33.9 (-38.8 to -28.3)
Foreign body	-	-	-	-	0.3 (0.3 to 0.4)	0.5 (0.4 to 0.6)	45.9 (36.0 to 56.1)	-13.8 (-19.1 to -7.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	18.8 (2.0 to 37.1)	-22.7 (-31.9 to -13.6)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	62.4 (46.5 to 81.9)	-5.2 (-13.8 to 3.1)
Foreign body in other body part	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	49.1 (37.7 to 61.7)	-13.6 (-20.0 to -6.0)
Other unintentional injuries	-	-	-	-	2.4 (1.8 to 3.1)	3.0 (2.2 to 3.9)	27.2 (14.3 to 39.3)	-20.2 (-27.8 to -13.0)
Self-harm and interpersonal violence	-	-	-	-	1.2 (0.9 to 1.5)	2.4 (1.8 to 3.2)	99.8 (83.3 to 118.8)	27.7 (17.9 to 39.1)
Self-harm	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	47.5 (34.2 to 62.6)	-13.0 (-20.6 to -4.8)
Interpersonal violence	-	-	-	-	1.0 (0.8 to 1.3)	2.1 (1.6 to 2.8)	109.1 (91.3 to 130.0)	37.2 (26.2 to 50.2)
Assault by firearm	-	-	-	-	0.2 (0.1 to 0.2)	0.5 (0.3 to 0.6)	137.4 (119.6 to 161.0)	53.8 (42.9 to 68.6)
Assault by sharp object	-	-	-	-	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	150.4 (127.9 to 181.8)	58.6 (44.2 to 77.6)
Assault by other means	-	-	-	-	0.7 (0.5 to 0.9)	1.3 (1.0 to 1.7)	91.5 (72.9 to 112.1)	26.7 (15.1 to 39.8)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	731.1 (564.8 to 1,194.5)	436.1 (325.5 to 718.7)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	731.1 (564.8 to 1,194.5)	436.1 (325.5 to 718.7)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Malaysia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,481.3 (1,094.3 to 1,945.1)	2,633.2 (1,941.5 to 3,424.2)	77.8 (72.3 to 83.6)	-2.1 (-4.8 to 0.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	334.9 (225.2 to 480.4)	399.7 (271.5 to 580.3)	19.3 (5.8 to 35.9)	-20.2 (-29.2 to -9.4)
HIV/AIDS and tuberculosis	-	-	-	-	10.1 (6.9 to 13.6)	24.6 (16.7 to 33.9)	142.4 (116.2 to 177.9)	13.8 (2.4 to 29.8)
Tuberculosis	30.7 (28.6 to 32.9)	59.2 (55.0 to 63.3)	93.4 (83.4 to 105.7)	-8.0 (-12.7 to -1.9)	9.4 (6.4 to 12.7)	18.0 (12.4 to 24.3)	92.6 (77.2 to 108.6)	-8.0 (-14.6 to -0.6)
HIV/AIDS	-	-	-	-	0.8 (0.3 to 1.7)	6.6 (3.7 to 11.1)	88.8 (360.5 to 1,785.8)	399.7 (146.9 to 924.2)
HIV/AIDS resulting in mycobacterial infection	0.1 (0.0 to 0.2)	0.8 (0.4 to 1.4)	755.5 (312.3 to 1,617.7)	315.0 (99.4 to 737.1)	0.0 (0.0 to 0.1)	0.3 (0.1 to 0.6)	675.4 (257.7 to 1,511.5)	272.8 (74.4 to 673.7)
HIV/AIDS resulting in other diseases	6.3 (2.6 to 13.5)	46.5 (36.3 to 62.1)	763.6 (261.3 to 1,524.3)	383.8 (104.3 to 802.9)	0.7 (0.2 to 1.7)	6.3 (3.5 to 10.6)	857.3 (352.3 to 2,034.2)	411.4 (143.0 to 1,083.9)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	28.4 (19.8 to 39.4)	30.7 (20.5 to 44.6)	7.8 (-3.9 to 20.8)	-28.0 (-35.6 to -19.8)
Diarrheal diseases	39.9 (30.6 to 48.3)	32.1 (27.4 to 37.2)	-19.1 (-37.8 to 9.4)	-37.4 (-51.0 to -17.1)	6.5 (4.1 to 9.6)	5.2 (3.3 to 7.5)	-19.7 (-31.1 to 13.2)	-37.2 (-51.6 to -14.9)
Intestinal infectious diseases	-	-	-	-	0.7 (0.4 to 1.1)	0.7 (0.4 to 1.0)	-11.2 (-42.4 to 43.2)	-36.9 (-58.5 to 1.5)
Typhoid fever	4.2 (3.2 to 5.5)	4.0 (2.8 to 5.4)	-4.2 (-38.6 to 48.9)	-32.1 (-56.1 to 4.2)	0.6 (0.3 to 0.9)	0.5 (0.3 to 0.8)	-3.7 (-38.6 to 57.8)	-32.0 (55.9 to 12.4)
Paratyphoid fever	2.7 (2.0 to 3.5)	2.0 (1.3 to 2.6)	-25.0 (-52.9 to 11.8)	-46.5 (-65.0 to -19.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-24.6 (-53.7 to 19.6)	-46.2 (-65.9 to -13.9)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-74.8 (-94.4 to -11.1)	-82.1 (-96.0 to -37.7)
Lower respiratory infections	7.2 (5.5 to 9.9)	5.4 (4.5 to 6.3)	-22.9 (-42.2 to 1.5)	-40.7 (-52.1 to -26.8)	0.7 (0.4 to 1.2)	0.6 (0.4 to 0.8)	-24.5 (-45.9 to 4.5)	-41.4 (-54.2 to -23.9)
Upper respiratory infections	638.7 (573.4 to 705.8)	997.8 (900.3 to 1,111.6)	57.0 (35.7 to 79.1)	1.3 (-13.1 to 16.3)	7.5 (4.2 to 12.4)	11.7 (6.5 to 19.8)	56.3 (35.1 to 78.7)	1.5 (-13.8 to 17.0)
Otitis media	233.2 (218.0 to 250.2)	296.1 (278.0 to 315.9)	26.9 (16.7 to 38.6)	-15.9 (-22.5 to -8.2)	4.4 (2.6 to 7.2)	5.7 (3.4 to 9.1)	29.3 (17.3 to 43.3)	-14.1 (-21.7 to -5.0)
Meningitis	-	-	-	-	6.6 (4.5 to 9.2)	4.6 (3.1 to 6.3)	-31.1 (-45.8 to -15.2)	-57.6 (-66.3 to -48.8)
Pneumococcal meningitis	32.8 (18.5 to 53.8)	24.1 (14.7 to 39.2)	-27.2 (-44.8 to 4.0)	-58.1 (-68.1 to -40.6)	2.1 (1.8 to 4.1)	2.1 (1.4 to 3.0)	-24.3 (-45.3 to 6.0)	-54.6 (-66.3 to -38.8)
H influenzae type B meningitis	14.5 (4.6 to 31.1)	7.4 (2.6 to 16.5)	-49.0 (-66.7 to -23.1)	-69.5 (-79.9 to -53.5)	1.5 (0.9 to 2.3)	1.0 (0.6 to 1.5)	-36.7 (-61.0 to -1.1)	-60.0 (-74.9 to -38.1)
Meningococcal meningitis	2.8 (0.9 to 6.7)	1.9 (0.6 to 4.7)	-33.9 (-56.7 to 4.6)	-63.5 (-75.3 to -44.9)	0.4 (0.2 to 0.6)	0.3 (0.1 to 0.4)	-31.7 (-54.0 to 12.0)	-61.6 (-72.6 to -41.6)
Other meningitis	16.3 (7.7 to 31.7)	10.0 (4.9 to 20.4)	-39.3 (-53.9 to -22.6)	-63.4 (-72.0 to -52.5)	2.0 (1.2 to 2.9)	1.2 (0.8 to 1.8)	-35.9 (-53.7 to -11.1)	-59.8 (-70.0 to -45.2)
Encephalitis	5.1 (2.2 to 12.2)	6.8 (3.0 to 16.9)	33.2 (-1.3 to 64.5)	-55.1 (-44.5 to -7.5)	0.7 (0.5 to 0.9)	1.0 (0.7 to 1.4)	44.3 (11.4 to 86.6)	-17.0 (-36.1 to 5.6)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Whooping cough	6.0 (4.7 to 7.7)	1.7 (1.3 to 2.1)	-72.5 (-74.7 to -70.1)	-73.9 (-76.0 to -71.6)	0.3 (0.2 to 0.5)	0.1 (0.0 to 0.1)	-72.3 (-77.8 to -66.1)	-73.7 (-79.0 to -67.7)
Tetanus	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-81.9 (-89.3 to -80.3)	-88.0 (-92.6 to -75.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-82.4 (-90.6 to -64.0)	-87.9 (-93.6 to -77.5)
Measles	3.2 (2.5 to 4.0)	0.8 (0.6 to 1.1)	-73.6 (-78.9 to -66.7)	-75.2 (-80.2 to -68.8)	0.3 (0.2 to 0.5)	0.1 (0.0 to 0.1)	-87.6 (-82.8 to -89.9)	-75.3 (-84.0 to -62.2)
Varicella and herpes zoster	18.2 (16.5 to 20.2)	29.7 (27.2 to 32.7)	63.6 (43.6 to 87.5)	0.0 (-14.3 to 17.5)	0.6 (0.4 to 0.9)	1.1 (0.7 to 1.8)	86.1 (49.5 to 133.8)	-0.2 (-19.7 to 25.8)
Neglected tropical diseases and malaria	-	-	-	-	101.4 (59.0 to 162.2)	198.0 (117.7 to 316.2)	96.8 (53.8 to 147.7)	21.2 (-7.0 to 55.0)
Malaria	654.1 (582.7 to 736.2)	917.5 (821.2 to 1,020.3)	40.9 (27.7 to 52.9)	-14.2 (-22.1 to -6.8)	5.7 (3.8 to 8.2)	13.3 (8.7 to 19.9)	135.8 (106.7 to 163.2)	51.7 (34.1 to 68.8)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.7 (13.6 to 80.4)	-0.2 (-21.3 to 26.6)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.9 (-53.7 to 637.1)	37.7 (-60.0 to 369.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.9 (-54.3 to 637.5)	37.7 (-60.0 to 370.5)
Cutaneous and mucocutaneous leishmaniasis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	42.1 (13.9 to 80.2)	-0.9 (-21.7 to 25.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.1 (13.9 to 80.5)	-0.9 (-21.8 to 25.7)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	1.3 (0.6 to 2.8)	0.3 (0.1 to 0.7)	-77.6 (-92.5 to -27.3)	-89.9 (-96.9 to -65.7)	0.4 (0.2 to 0.8)	0.1 (0.0 to 0.3)	-73.2 (-91.3 to -7.6)	-87.9 (-96.3 to -56.5)
Cystic echinococcosis	2.0 (1.8 to 2.2)	3.4 (3.1 to 3.7)	74.7 (41.1 to 93.5)	-0.2 (-19.0 to 8.1)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.5)	72.1 (25.8 to 125.6)	-1.9 (-25.9 to 23.4)
Lymphatic filariasis	27.6 (19.5 to 39.4)	12.5 (7.2 to 20.9)	-55.4 (-71.5 to -34.6)	-76.9 (-85.1 to -66.5)	1.1 (0.4 to 2.3)	1.1 (0.4 to 2.3)	-6.6 (-47.1 to 64.3)	-56.2 (-77.0 to -26.4)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	8.1 (2.8 to 18.8)	64.4 (22.1 to 149.8)	696.7 (696.6 to 696.8)	391.6 (391.6 to 391.7)	1.3 (0.4 to 3.5)	10.5 (3.2 to 27.5)	694.6 (592.9 to 806.9)	391.3 (332.4 to 453.2)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Intestinal nematode infections	-	-	-	-	84.1 (46.1 to 139.2)	167.0 (96.0 to 275.6)	99.9 (51.9 to 159.2)	21.3 (-10.7 to 60.2)
Ascariasis	7,520.1 (6,147.6 to 9,156.0)	12,763.3 (9,801.9 to 16,447.1)	70.8 (22.2 to 136.1)	2.0 (-28.3 to 43.6)	27.7 (14.1 to 50.3)	32.6 (16.7 to 59.3)	17.4 (-22.6 to 84.8)	-22.3 (50.1 to 24.2)
Trichuriasis	8,677.9 (7,251.7 to 10,356.7)	15,018.0 (12,505.6 to 17,961.6)	73.4 (35.6 to 125.6)	2.5 (-20.3 to 35.1)	39.6 (19.1 to 72.9)	31.0 (46.3 to 157.1)	125.7 (37.0 to 256.3)	31.0 (-22.3 to 108.2)
Hookworm disease	3,483.4 (2,774.4 to 4,371.7)	6,391.0 (4,923.5 to 8,224.4)	82.8 (28.6 to 158.2)	7.6 (-25.8 to 54.4)	16.8 (10.3 to 26.3)	175.7 (28.5 to 71.0)	64.9 (105.6 to 259.2)	64.9 (20.6 to 120.9)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	247.5 (195.5 to 301.6)	179.5 (154.7 to 205.2)	-27.6 (-43.2 to 0.3)	-44.3 (-55.5 to -24.6)	8.5 (5.0 to 12.5)	5.7 (3.5 to 8.4)	-34.3 (-48.4 to -0.1)	-46.4 (-57.9 to -20.1)
Maternal disorders	-	-	-	-	1.0 (0.6 to 1.5)	1.4 (0.7 to 2.3)	46.9 (-19.1 to 121.1)	-17.1 (54.3 to 24.8)
Maternal hemorrhage	18.3 (9.4 to 11.4)	34.0 (23.2 to 44.8)	231.0 (123.9 to 337.1)	87.4 (25.8 to 145.7)	0.4 (0.3 to 0.6)	0.8 (0.3 to 1.4)	105.9 (-18.2 to 230.7)	15.4 (54.3 to 83.7)
Maternal sepsis and other maternal infections	7.6 (4.6 to 11.5)	4.6 (2.6 to 7.3)	-38.7 (-57.1 to -25.0)	-47.7 (-77.4 to -40.5)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-42.6 (-68.1 to 6.8)	-68.4 (-81.5 to -43.2)
Maternal hypertensive disorders	3.4 (1.6 to 5.7)	3.5 (1.7 to 5.7)	0.2 (-5.9 to 18.6)	-40.3 (-45.7 to -31.8)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	2.5 (-20.5 to 32.4)	-40.9 (-54.2 to -23.7)
Obstructed labor	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-29.8 (-60.3 to 31.9)	-59.9 (-77.1 to -26.1)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-26.7 (-66.1 to 91.7)	-58.2 (-80.6 to 7.3)
Complications of abortion	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	16.2 (-31.6 to 99.5)	-34.8 (-60.8 to 12.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.2 (-31.7 to 100.5)	-34.8 (-60.9 to 13.3)
Other maternal disorders	-	-	-	-	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.5)	36.2 (-39.0 to 221.5)	-23.3 (65.4 to 80.4)
Neonatal disorders	-	-	-	-	31.4 (19.1 to 48.1)	41.7 (27.1 to 61.8)	32.3 (-13.4 to 115.9)	-14.5 (43.5 to 39.7)
Preterm birth complications	80.0 (46.9 to 132.6)	169.1 (101.6 to 291.2)	112.2 (40.2 to 207.1)	33.1 (-10.7 to 90.5)	11.2 (6.1 to 18.0)	25.6 (16.0 to 39.2)	130.5 (18.8 to 325.5)	47.2 (-24.2 to 167.8)
Neonatal encephalopathy due to birth asphyxia and trauma	35.7 (17.5 to 69.2)	27.5 (11.8 to 59.8)	-24.1 (-52.6 to 16.1)	-51.6 (-69.8 to -25.9)	5.3 (3.4 to 7.7)	4.5 (2.8 to 6.4)	-15.4 (-47.5 to 34.2)	-43.7 (-64.9 to -12.1)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	80.6 (27.9 to 115.3)	76.4 (24.9 to 110.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.4 (25.6 to 146.6)	78.7 (22.7 to 140.8)
Hemolytic disease and other neonatal jaundice	6.5 (2.0 to 13.1)	4.8 (1.9 to 10.2)	-32.2 (-72.0 to 118.1)	-56.1 (-81.7 to 41.4)	2.5 (0.7 to 5.2)	2.5 (0.7 to 4.3)	-27.5 (-70.0 to 133.7)	-53.5 (-80.5 to 50.7)
Other neonatal disorders	-	-	-	-	12.4 (4.2 to 23.4)	9.6 (4.8 to 17.9)	-26.8 (-68.2 to 252.5)	-52.5 (-79.3 to 128.4)
Nutritional deficiencies	-	-	-	-	151.5 (100.0 to 217.2)	90.9 (60.6 to 130.4)	-40.0 (-47.3 to -31.4)	-55.6 (-60.0 to -49.4)
Protein-energy malnutrition	143.0 (81.4 to 223.0)	94.1 (51.5 to 161.1)	-35.3 (-68.9 to 43.5)	-38.0 (-70.2 to 37.3)	38.0 (8.6 to 31.9)	17.9 (5.9 to 22.7)	11.8 (-68.9 to 43.3)	-37.7 (-70.1 to 37.3)
Iodine deficiency	78.4 (61.5 to 96.8)	50.9 (32.6 to 71.9)	-35.4 (-59.3 to -2.1)	-47.4 (-79.4 to -50.7)	1.4 (0.8 to 2.3)	0.9 (0.5 to 1.7)	-34.7 (-59.4 to -0.5)	-67.0 (-79.3 to -49.9)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-

Appendix Table G.4 - Malaysia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	4,068.7 (4,017.6 to 4,114.6)	2,729.5 (2,582.1 to 2,850.1)	-32.8 (-36.7 to -29.8)	-55.1 (-57.7 to -53.2)	128.1 (85.3 to 185.2)	75.5 (50.2 to 110.7)	-41.0 (-47.4 to -36.6)	-41.0 (-57.8 to -24.2)
Other nutritional deficiencies	-	-	-	-	4.1 (1.7 to 8.5)	2.6 (1.0 to 5.2)	-37.6 (-73.5 to 52.7)	-40.2 (-74.6 to 46.3)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	11.1 (7.0 to 16.6)	12.3 (7.6 to 19.3)	10.5 (-2.8 to 27.8)	-27.0 (-34.8 to -16.8)
Sexually transmitted diseases excluding HIV	-	-	-	-	3.9 (2.2 to 6.4)	6.8 (3.8 to 11.1)	72.3 (46.5 to 102.1)	-4.9 (-18.1 to 10.7)
Syphilis	0.6 (0.5 to 0.7)	0.7 (0.6 to 0.8)	13.2 (9.4 to 39.5)	-42.6 (-52.9 to -32.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	15.4 (-17.7 to 64.4)	42.0 (-57.4 to -20.7)
Chlamydial infection	563.4 (330.0 to 778.0)	1,032.3 (680.0 to 1,431.0)	86.9 (13.6 to 192.0)	5.8 (-35.3 to 66.8)	2.7 (1.4 to 4.5)	4.7 (2.5 to 7.6)	75.2 (40.0 to 122.5)	-1.1 (-20.5 to 24.3)
Gonococcal infection	81.0 (45.2 to 116.8)	136.7 (76.6 to 188.7)	65.1 (-13.1 to 273.4)	-4.2 (-48.7 to 114.1)	0.5 (0.3 to 0.8)	0.9 (0.5 to 1.5)	72.1 (18.0 to 151.2)	-0.7 (-31.4 to 42.6)
Trichomoniasis	71.5 (48.5 to 97.5)	110.0 (60.9 to 172.0)	52.5 (-20.2 to 156.2)	-16.6 (-54.7 to 39.1)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.4)	53.9 (-36.5 to 166.7)	-14.8 (-62.8 to 46.5)
Genital herpes	1,708.4 (1,622.9 to 1,796.5)	3,107.5 (2,923.7 to 3,281.1)	82.3 (68.2 to 97.2)	-8.9 (-15.7 to -1.5)	0.5 (0.1 to 1.1)	0.8 (0.3 to 2.0)	57.0 (6.1 to 96.9)	-8.9 (-16.9 to -0.5)
Other sexually transmitted diseases	2.8 (2.0 to 3.8)	4.2 (3.2 to 5.3)	52.5 (31.7 to 77.1)	-18.4 (-29.8 to -5.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	71.7 (11.1 to 166.7)	6.7 (-38.6 to 40.6)
Hepatitis	-	-	-	-	0.8 (0.5 to 1.1)	1.1 (0.7 to 1.6)	42.6 (28.1 to 57.6)	-13.6 (-22.0 to -5.0)
Hepatitis A	24.1 (23.2 to 25.1)	29.0 (28.0 to 30.2)	20.7 (20.5 to 20.9)	-13.8 (-14.5 to -13.1)	0.6 (0.4 to 0.8)	0.8 (0.5 to 1.2)	45.2 (29.0 to 61.4)	-7.3 (-17.2 to 2.6)
Hepatitis B	209.1 (189.1 to 228.0)	255.1 (213.2 to 256.6)	12.6 (-2.1 to 38.5)	-34.6 (-42.7 to -26.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	29.7 (-10.2 to 84.6)	-31.8 (-52.0 to -3.1)
Hepatitis C	431.7 (388.8 to 474.7)	617.4 (551.7 to 695.5)	43.1 (24.2 to 68.5)	-25.2 (-34.4 to -13.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	38.6 (4.6 to 80.3)	-24.9 (-45.2 to 1.9)
Hepatitis E	2.2 (1.6 to 3.3)	3.2 (2.4 to 3.7)	46.0 (-15.7 to 100.9)	-18.7 (-52.5 to 10.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	45.8 (-19.8 to 129.6)	-19.7 (-54.8 to 23.7)
Leprosy	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.3)	53.2 (11.8 to 122.2)	-26.7 (-45.1 to 6.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.8 (6.1 to 154.7)	-24.1 (-50.1 to 26.9)
Other infectious diseases	181.6 (147.9 to 217.6)	131.4 (114.6 to 150.1)	-28.0 (-39.2 to -13.9)	-47.0 (-55.1 to -37.4)	6.4 (4.0 to 9.4)	4.5 (2.9 to 6.8)	-30.7 (-45.0 to -13.0)	-45.9 (-57.1 to -32.0)
Non-communicable diseases	-	-	-	-	1,079.4 (802.4 to 1,390.1)	2,138.4 (1,594.3 to 2,768.6)	98.0 (92.8 to 104.2)	3.4 (0.7 to 6.4)
Neoplasms	-	-	-	-	7.8 (5.6 to 10.3)	23.7 (17.1 to 31.1)	205.5 (174.1 to 240.3)	40.2 (26.5 to 56.1)
Esophageal cancer	0.4 (0.3 to 0.5)	0.9 (0.7 to 1.2)	138.6 (80.5 to 219.2)	2.5 (-24.2 to 38.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	132.5 (77.9 to 201.0)	-0.6 (-25.9 to 34.5)
Stomach cancer	2.5 (2.2 to 2.9)	5.1 (4.4 to 5.9)	101.9 (63.6 to 149.4)	-10.5 (-28.5 to 12.8)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.7)	86.6 (48.6 to 133.7)	-17.0 (-34.8 to 5.7)
Liver cancer	-	-	-	-	0.2 (0.1 to 0.2)	0.5 (0.3 to 0.7)	174.0 (111.4 to 280.5)	37.1 (-10.9 to 62.3)
Liver cancer due to hepatitis B	0.6 (0.4 to 0.8)	2.3 (1.6 to 3.0)	289.2 (149.7 to 520.8)	66.5 (7.9 to 169.4)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	224.7 (130.0 to 390.0)	40.0 (-3.1 to 110.5)
Liver cancer due to hepatitis C	0.1 (0.0 to 0.1)	0.6 (0.3 to 0.9)	761.9 (305.3 to 1,544.2)	270.8 (82.6 to 642.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	616.8 (253.9 to 1,155.4)	209.1 (59.9 to 473.7)
Liver cancer due to alcohol use	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	0.3 (-16.6 to 203.8)	-31.1 (-63.4 to 30.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	34.5 (-25.2 to 152.5)	-40.7 (-67.6 to 14.3)
Liver cancer due to other causes	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	74.8 (-14.7 to 214.8)	-22.4 (-61.6 to 43.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	54.5 (-19.2 to 156.7)	31.6 (-63.7 to 16.2)
Larynx cancer	1.2 (0.9 to 1.6)	2.4 (1.8 to 3.4)	89.7 (45.0 to 156.7)	-16.4 (-36.7 to 13.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	93.3 (41.5 to 169.3)	-15.2 (-39.6 to 19.1)
Tracheal, bronchus and lung cancer	4.2 (3.7 to 4.7)	10.6 (9.3 to 12.1)	151.5 (110.1 to 207.3)	9.8 (-8.2 to 34.6)	0.6 (0.5 to 0.8)	1.5 (1.1 to 1.9)	136.7 (92.0 to 190.0)	3.2 (-15.1 to 27.1)
Breast cancer	19.1 (16.4 to 22.2)	95.2 (83.3 to 107.5)	401.3 (309.3 to 502.8)	132.1 (91.2 to 174.3)	1.4 (1.0 to 2.0)	5.9 (4.0 to 8.1)	310.3 (223.0 to 410.7)	83.3 (46.3 to 128.3)
Cervical cancer	7.1 (5.5 to 8.8)	9.6 (7.3 to 12.4)	35.3 (2.5 to 82.9)	97.4 (-51.7 to -47.1)	0.5 (0.3 to 0.8)	0.7 (0.5 to 1.1)	87.2 (11.2 to 92.4)	-46.7 (-53.4 to -12.9)
Uterine cancer	2.9 (1.9 to 4.9)	9.8 (5.7 to 14.1)	246.7 (84.0 to 490.3)	47.4 (-21.3 to 143.2)	0.2 (0.1 to 0.3)	0.6 (0.3 to 1.0)	239.5 (77.8 to 486.6)	42.2 (-25.6 to 144.9)
Prostate cancer	3.8 (2.6 to 5.3)	22.0 (13.7 to 31.0)	483.2 (311.6 to 711.5)	148.7 (74.3 to 254.9)	0.2 (0.2 to 0.6)	2.1 (1.2 to 3.1)	452.3 (290.8 to 692.8)	137.8 (65.8 to 249.2)
Colon and rectum cancer	8.7 (7.8 to 9.6)	31.4 (27.8 to 35.4)	261.1 (208.2 to 324.0)	56.9 (32.1 to 87.7)	0.8 (0.5 to 1.0)	2.6 (1.9 to 3.4)	237.4 (181.5 to 304.4)	46.8 (21.7 to 80.2)
Lip and oral cavity cancer	2.9 (2.1 to 3.6)	6.1 (4.7 to 7.8)	112.4 (57.6 to 189.8)	-7.1 (-31.0 to 26.2)	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.8)	108.7 (54.1 to 181.9)	-9.3 (-33.7 to 24.7)
Nasopharynx cancer	3.9 (2.8 to 5.4)	6.2 (4.6 to 8.5)	56.9 (6.7 to 133.6)	-28.1 (-49.8 to 6.2)	0.4 (0.2 to 0.6)	0.6 (0.4 to 0.9)	59.2 (6.6 to 123.2)	29.7 (-50.4 to 3.4)
Other pharynx cancer	0.8 (0.6 to 1.1)	1.8 (1.3 to 2.4)	123.9 (44.2 to 233.0)	-5.1 (-38.5 to 41.4)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	114.7 (46.1 to 208.3)	-9.0 (-38.2 to 36.5)
Gallbladder and biliary tract cancer	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	44.3 (-11.0 to 110.9)	-36.8 (-62.0 to -4.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	36.0 (-15.6 to 95.9)	40.7 (-65.0 to -9.7)
Pancreatic cancer	0.3 (0.3 to 0.4)	1.0 (0.8 to 1.1)	212.7 (146.2 to 298.9)	32.5 (2.1 to 69.6)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	195.5 (139.4 to 269.1)	23.6 (-3.2 to 59.8)
Malignant skin melanoma	0.9 (0.7 to 1.1)	2.4 (1.8 to 3.2)	179.7 (107.3 to 290.9)	2.4 (-2.5 to 87.2)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	98.2 (72.8 to 289.4)	26.5 (-9.0 to 82.6)
Non-melanoma skin cancer	2.2 (1.8 to 2.7)	9.2 (7.8 to 10.9)	320.2 (234.2 to 435.9)	80.0 (40.5 to 133.4)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.4)	371.9 (235.7 to 556.6)	102.7 (32.6 to 200.0)
Ovarian cancer	2.1 (1.7 to 2.6)	5.9 (4.6 to 7.5)	177.7 (98.6 to 296.0)	26.6 (-8.0 to 80.7)	0.3 (0.2 to 0.4)	0.7 (0.5 to 1.0)	170.7 (86.9 to 302.6)	22.7 (16.2 to 82.2)
Testicular cancer	0.8 (0.5 to 1.2)	2.2 (1.4 to 3.3)	167.1 (66.5 to 337.9)	40.1 (-10.1 to 122.5)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	163.9 (53.2 to 354.0)	36.2 (-16.0 to 123.7)
Kidney cancer	1.4 (1.1 to 1.6)	6.0 (4.9 to 7.2)	342.9 (235.7 to 476.5)	104.3 (58.9 to 166.5)	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.6)	320.5 (213.1 to 452.4)	90.7 (43.3 to 151.3)
Bladder cancer	1.5 (1.2 to 1.8)	5.7 (4.6 to 7.0)	288.7 (197.6 to 410.2)	63.5 (25.2 to 115.3)	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.6)	256.9 (171.4 to 376.2)	50.7 (13.2 to 105.7)
Brain and nervous system cancer	1.0 (0.8 to 1.4)	2.0 (1.6 to 2.7)	95.4 (43.6 to 161.6)	12.0 (-13.0 to 47.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	98.0 (50.7 to 164.9)	8.5 (-14.9 to 43.0)
Thyroid cancer	3.8 (2.9 to 5.3)	14.5 (9.3 to 19.8)	285.7 (138.7 to 489.0)	80.0 (10.1 to 167.2)	0.2 (0.1 to 0.4)	0.8 (0.5 to 1.3)	273.8 (127.8 to 473.5)	70.8 (3.1 to 157.9)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.2 (5.9 to 105.1)	-35.3 (-53.1 to -4.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.2 (11.9 to 111.1)	31.1 (-49.9 to -0.4)
Hodgkin lymphoma	0.9 (0.7 to 1.2)	2.0 (1.5 to 2.5)	113.2 (48.1 to 209.8)	17.6 (-15.8 to 64.0)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	105.0 (41.8 to 201.0)	10.4 (-20.0 to 59.0)
Non-Hodgkin lymphoma	4.5 (3.7 to 5.8)	15.3 (11.2 to 18.2)	244.3 (130.2 to 337.6)	70.0 (9.6 to 115.8)	0.3 (0.2 to 0.5)	1.1 (0.7 to 1.6)	231.6 (116.7 to 332.1)	61.2 (1.2 to 110.7)
Multiple myeloma	0.3 (0.2 to 0.4)	0.9 (0.6 to 1.2)	178.8 (89.2 to 306.2)	17.3 (-20.2 to 67.9)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	164.2 (77.1 to 304.6)	10.6 (-26.7 to 72.2)
Leukemia	4.5 (3.4 to 6.0)	9.3 (7.7 to 11.1)	110.2 (49.4 to 185.2)	30.7 (0.4 to 68.1)	0.5 (0.3 to 0.7)	1.1 (0.7 to 1.4)	115.7 (66.3 to 177.8)	21.0 (-5.1 to 54.0)
Other neoplasms	5.1 (3.8 to 7.6)	24.7 (19.2 to 30.1)	403.6 (205.7 to 599.3)	186.7 (83.7 to 288.1)	0.4 (0.2 to 0.5)	1.6 (1.1 to 2.4)	370.6 (197.5 to 551.4)	155.1 (66.9 to 243.8)
Cardiovascular diseases	-	-	-	-	34.0 (23.3 to 47.3)	96.8 (64.8 to 134.1)	186.5 (125.8 to 247.4)	29.9 (5.5 to 53.2)
Rheumatic heart disease	213.2 (159.6 to 278.5)	410.9 (308.2 to 491.3)	94.9 (18.5 to 190.7)	3.2 (-33.0 to 42.1)	10.8 (6.5 to 16.8)	21.2 (12.9 to 31.7)	96.7 (23.0 to 192.1)	3.4 (-31.2 to 39.5)
Ischemic heart disease	93.3 (78.2 to 114.3)	268.2 (226.6 to 320.1)	187.2 (117.4 to 281.9)	15.8 (-10.5 to 52.8)	6.5 (4.3 to 9.3)	18.7 (12.1 to 27.3)	182.6 (113.9 to 273.3)	13.6 (-12.8 to 50.8)
Cerebrovascular disease	-	-	-	-	4.4 (3.1 to 6.0)	11.4 (7.9 to 14.9)	156.1 (109.1 to 209.0)	10.4 (-10.0 to 33.5)
Ischemic stroke	13.8 (11.7 to 15.7)	36.6 (31.6 to 41.1)	165.3 (113.7 to 227.1)	12.0 (-10.3 to 39.5)	2.1 (1.4 to 2.9)	5.4 (3.6 to 7.5)	163.5 (107.6 to 229.6)	11.4 (-12.0 to 38.7)
Hemorrhagic stroke	15.8 (13.7 to 18.1)	39.7 (34.2 to 45.6)	151.7 (107.1 to 203.8)	9.5 (-10.6 to 33.4)	2.4 (1.6 to 3.2)	5.9 (4.0 to 8.1)	150.1 (100.6 to 209.3)	8.9 (-12.2 to 34.5)
Hypertensive heart disease	19.7 (17.1 to 22.3)	48.5 (42.3 to 54.9)	146.9 (104.9 to 196.7)	1.5 (-15.6 to 22.1)	2.2 (1.5 to 3.2)	5.4 (3.7 to 7.7)	145.7 (103.4 to 195.6)	1.1 (-16.0 to 21.5)
Cardiomyopathy and myocarditis	10.3 (8.9 to 11.9)	23.8 (21.2 to 26.4)	131.0 (96.3 to 180.9)	6.8 (-12.0 to 31.7)	1.1 (0.7 to 1.6)	2.6 (1.7 to 3.6)	129.7 (90.7 to 183.8)	6.2 (-13.8 to 32.8)
Atrial fibrillation and flutter	9.9 (8.4 to 11.8)	62.0 (55.6 to 69.2)	525.3 (416.5 to 658.1)	167.0 (118.8 to 229.2)	0.8 (0.5 to 1.1)	4.9 (3.3 to 6.9)	524.5 (406.1 to 664.2)	165.5 (116.6 to 233.0)
Peripheral vascular disease	398.2 (316.6 to 490.4)	906.4 (734.2 to 1,095.6)	130.1 (65.9 to 199.9)	-5.3 (-29.2 to 22.2)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.9)	136.8 (1.0 to 347.1)	0.2 (-54.3 to 97.5)
Endocarditis	1.6 (1.2 to 2.3)	3.9 (2.8 to 4.8)	153.6 (49.2 to 272.0)	21.6 (-29.2 to 82.4)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.7)	155.8 (36.8 to 311.9)	24.2 (-34.8 to 99.2)
Other cardiovascular and circulatory diseases	194.4 (70.7 to 160.6)	451.0 (226.0 to 649.5)	235.1 (92.5 to 614.6)	90.8 (-11.2 to 230.5)	7.8 (4.2 to 12.7)	22.3 (14.8 to 51.0)	3	

Appendix Table G.4 - Malaysia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	254.7 (229.5 to 277.2)	57.1 (43.5 to 70.1)
Silicosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	100.0 (88.4 to 111.0)	-12.1 (-17.0 to -6.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	98.9 (87.1 to 110.3)	-12.5 (-17.4 to -7.1)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.3 (0.3 to 0.3)	1.3 (1.2 to 1.4)	326.6 (310.8 to 350.8)	98.4 (90.7 to 108.9)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	318.9 (297.6 to 344.1)	92.6 (80.2 to 107.7)
Asthma	843.1 (754.5 to 926.5)	1,244.8 (1,055.6 to 1,443.6)	47.9 (19.2 to 78.2)	-10.0 (-26.5 to 6.7)	37.5 (24.1 to 54.3)	55.3 (34.5 to 82.0)	47.5 (18.4 to 77.2)	-10.0 (-26.9 to 7.2)
Interstitial lung disease and pulmonary sarcoidosis	1.2 (0.9 to 1.4)	2.6 (2.0 to 3.2)	122.5 (61.2 to 200.6)	6.3 (-22.9 to 41.3)	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.5)	123.2 (62.1 to 207.0)	4.9 (-24.3 to 43.8)
Other chronic respiratory diseases	-	-	-	-	4.1 (2.4 to 6.4)	4.4 (2.7 to 6.7)	9.3 (-23.4 to 47.9)	-48.9 (-64.3 to -30.6)
Cirrhosis	-	-	-	-	1.0 (0.7 to 1.3)	1.4 (1.0 to 2.0)	48.5 (27.9 to 72.8)	24.7 (-34.9 to -13.7)
Cirrhosis due to hepatitis B	2.9 (2.4 to 3.4)	4.2 (3.6 to 4.9)	48.0 (17.7 to 84.3)	-26.0 (-40.3 to -8.4)	0.5 (0.3 to 0.7)	0.7 (0.5 to 1.0)	48.0 (10.9 to 93.3)	26.1 (-43.6 to 6.2)
Cirrhosis due to hepatitis C	0.8 (0.4 to 1.3)	1.7 (1.0 to 2.4)	114.1 (7.0 to 474.0)	5.4 (-52.2 to 157.5)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.5)	111.9 (-6.2 to 451.8)	3.5 (-53.6 to 150.0)
Cirrhosis due to alcohol use	1.2 (0.7 to 1.7)	1.5 (1.1 to 1.9)	17.4 (-26.6 to 140.8)	-44.4 (-64.3 to 9.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	16.3 (-30.3 to 145.3)	45.2 (-65.8 to 13.0)
Cirrhosis due to other causes	0.8 (0.6 to 1.0)	1.1 (0.9 to 1.4)	36.8 (3.2 to 85.3)	-11.1 (-33.8 to 21.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	36.9 (-6.0 to 116.3)	-10.9 (-39.8 to 39.2)
Digestive diseases	-	-	-	-	13.2 (9.1 to 18.2)	20.2 (14.2 to 28.0)	53.3 (39.4 to 70.5)	27.7 (-33.0 to -21.4)
Peptic ulcer disease	102.2 (90.3 to 110.4)	107.9 (99.4 to 116.6)	5.5 (-5.0 to 20.3)	-52.1 (-56.1 to -47.3)	3.3 (2.2 to 4.7)	3.6 (2.4 to 5.2)	9.0 (-9.9 to 35.1)	-52.7 (-58.9 to -45.8)
Gastritis and duodenitis	148.9 (136.7 to 158.6)	192.7 (179.5 to 204.7)	29.4 (18.3 to 42.3)	-33.1 (-37.6 to -28.2)	5.7 (3.8 to 8.2)	8.3 (5.6 to 12.1)	45.6 (24.2 to 72.5)	23.6 (-30.6 to -12.8)
Appendicitis	1.3 (1.0 to 1.7)	1.7 (1.3 to 2.3)	30.7 (-11.2 to 94.9)	-26.0 (-48.3 to 4.6)	0.4 (0.2 to 0.7)	0.5 (0.3 to 0.8)	32.6 (-19.3 to 113.3)	-24.4 (-51.8 to 17.2)
Paralytic ileus and intestinal obstruction	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	60.6 (22.5 to 126.6)	-2.6 (-17.1 to 20.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	69.5 (12.9 to 138.7)	2.1 (-27.1 to 34.0)
Inguinal, femoral, and abdominal hernia	42.0 (36.6 to 48.3)	79.0 (66.1 to 94.7)	87.7 (53.2 to 133.4)	-9.7 (-27.1 to 16.4)	0.4 (0.2 to 0.8)	0.8 (0.4 to 1.5)	86.0 (52.2 to 133.1)	-10.3 (-27.8 to 16.1)
Inflammatory bowel disease	1.7 (1.6 to 1.8)	3.6 (3.4 to 3.9)	113.7 (97.1 to 133.8)	4.6 (-3.4 to 13.3)	0.4 (0.2 to 0.5)	0.8 (0.5 to 1.1)	112.6 (72.8 to 162.4)	4.6 (-14.5 to 26.8)
Vascular intestinal disorders	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	94.2 (35.9 to 168.4)	-12.9 (-43.0 to 29.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.2 (35.2 to 179.7)	-11.4 (-46.1 to 43.3)
Gallbladder and biliary diseases	1.4 (3.9 to 4.9)	7.1 (6.3 to 7.9)	61.4 (34.5 to 85.5)	-18.4 (-30.2 to -7.4)	0.5 (0.3 to 0.7)	0.7 (0.5 to 1.1)	59.4 (30.7 to 91.7)	19.0 (-31.1 to 5.4)
Pancreatitis	3.6 (3.4 to 3.8)	6.5 (8.1 to 8.9)	136.0 (119.1 to 155.3)	14.6 (6.7 to 23.3)	1.1 (0.7 to 1.5)	2.5 (1.7 to 3.5)	134.0 (96.7 to 175.4)	14.1 (-1.6 to 32.2)
Other digestive diseases	-	-	-	-	1.3 (0.9 to 2.0)	2.8 (1.9 to 4.0)	113.1 (50.0 to 165.5)	0.4 (-29.8 to 23.1)
Neurological disorders	-	-	-	-	97.4 (66.5 to 135.2)	202.0 (139.1 to 278.3)	107.4 (77.7 to 141.1)	9.9 (-3.4 to 24.2)
Alzheimer disease and other dementias	63.3 (55.5 to 70.9)	158.4 (134.4 to 180.5)	150.1 (110.0 to 197.5)	4.5 (-12.7 to 23.5)	9.0 (6.4 to 12.0)	22.4 (15.8 to 29.8)	149.3 (108.4 to 194.4)	4.4 (-13.1 to 23.3)
Parkinson disease	5.4 (4.7 to 6.1)	13.2 (11.4 to 14.8)	143.8 (132.1 to 156.8)	1.4 (-3.5 to 6.7)	0.7 (0.4 to 0.9)	1.6 (1.1 to 2.2)	143.8 (117.1 to 176.6)	1.0 (-9.1 to 13.6)
Epilepsy	84.0 (59.6 to 107.0)	128.8 (90.5 to 169.8)	53.3 (-2.6 to 135.1)	-6.3 (-40.3 to 41.2)	26.3 (15.7 to 38.2)	44.7 (26.2 to 66.8)	69.7 (6.0 to 160.0)	5.0 (-34.0 to 60.5)
Multiple sclerosis	0.1 (0.1 to 0.1)	0.4 (0.4 to 0.4)	273.4 (232.1 to 317.4)	82.9 (62.8 to 104.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	273.4 (232.0 to 317.9)	82.9 (62.7 to 104.1)
Migraine	1,293.4 (1,074.8 to 1,529.6)	1,652.9 (2,208.5 to 3,183.0)	105.7 (60.1 to 167.8)	-10.6 (-12.7 to 38.3)	44.7 (26.1 to 68.8)	46.7 (54.0 to 138.9)	105.6 (59.1 to 166.6)	10.9 (-13.0 to 39.6)
Tension-type headache	3,828.4 (3,459.1 to 4,202.2)	7,122.3 (6,670.6 to 7,585.5)	86.1 (66.2 to 109.7)	1.3 (-8.5 to 12.3)	5.8 (2.8 to 10.4)	10.8 (5.3 to 19.0)	85.6 (59.2 to 110.6)	1.2 (-8.3 to 12.5)
Medication overuse headache	58.0 (38.8 to 75.9)	176.5 (120.6 to 236.2)	204.9 (156.2 to 262.0)	55.0 (29.8 to 82.2)	9.2 (5.2 to 14.1)	28.0 (16.0 to 43.7)	205.1 (152.8 to 266.6)	55.2 (29.9 to 85.1)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.2 (32.9 to 147.1)	1.6 (-23.8 to 41.2)	1.7 (1.1 to 2.4)	3.0 (2.0 to 4.2)	80.8 (29.0 to 154.8)	-24.4 (-45.9 to 6.8)
Mental and substance use disorders	-	-	-	-	399.1 (245.6 to 443.2)	618.9 (448.1 to 816.1)	82.6 (76.5 to 88.9)	-0.5 (-3.4 to 2.5)
Schizophrenia	57.2 (49.1 to 65.4)	111.7 (96.7 to 127.1)	96.0 (86.3 to 104.9)	-0.6 (-4.8 to 4.0)	37.4 (26.6 to 47.0)	72.9 (52.1 to 91.5)	95.1 (82.4 to 107.8)	0.6 (-6.5 to 5.6)
Alcohol use disorders	107.4 (96.5 to 118.9)	174.7 (157.6 to 192.1)	62.9 (53.8 to 72.2)	-12.3 (-16.9 to -7.5)	10.7 (7.1 to 15.3)	17.4 (11.6 to 25.1)	62.4 (50.2 to 74.4)	-12.5 (-18.8 to -6.5)
Drug use disorders	-	-	-	-	37.0 (24.7 to 52.1)	64.0 (42.7 to 91.1)	73.4 (40.3 to 112.7)	-1.8 (-19.6 to 18.8)
Opioid use disorders	21.1 (16.5 to 25.8)	37.9 (30.0 to 46.2)	80.2 (67.8 to 95.8)	-2.4 (-9.1 to 5.2)	8.9 (5.7 to 12.3)	16.0 (10.7 to 22.1)	80.5 (60.9 to 105.8)	-2.3 (-12.7 to 9.6)
Cocaine use disorders	18.8 (13.8 to 15.9)	26.1 (24.4 to 27.8)	76.5 (60.5 to 94.6)	1.3 (-9.9 to 8.2)	2.0 (1.3 to 0.3)	3.6 (2.3 to 5.3)	77.5 (48.2 to 114.4)	-0.7 (-17.5 to 19.5)
Amphetamine use disorders	86.4 (68.4 to 103.7)	145.4 (117.2 to 171.2)	69.6 (28.2 to 119.7)	-2.3 (-25.4 to 25.0)	11.4 (6.8 to 17.3)	19.2 (11.6 to 28.9)	68.3 (26.7 to 120.6)	-2.8 (-26.0 to 26.0)
Cannabis use disorders	41.9 (28.7 to 53.5)	71.0 (49.7 to 89.8)	69.8 (66.8 to 74.9)	-1.7 (-1.9 to -1.5)	1.2 (0.7 to 1.9)	2.1 (1.1 to 3.2)	70.3 (47.3 to 96.4)	-1.4 (-14.1 to 12.5)
Other drug use disorders	-	-	-	-	13.5 (8.1 to 20.5)	23.1 (13.7 to 35.7)	72.1 (18.0 to 145.0)	-1.2 (-31.8 to 40.0)
Depressive disorders	-	-	-	-	90.0 (56.5 to 130.0)	176.7 (110.6 to 255.1)	96.9 (83.0 to 109.5)	0.9 (-4.7 to 7.2)
Major depressive disorder	341.6 (230.3 to 451.5)	664.9 (450.7 to 873.5)	95.6 (79.8 to 114.4)	1.0 (-5.9 to 9.0)	70.7 (41.4 to 107.3)	137.4 (81.9 to 206.2)	94.8 (78.3 to 111.1)	1.0 (-6.2 to 9.4)
Dysthymia	198.3 (168.9 to 226.9)	405.1 (347.5 to 460.3)	104.5 (100.5 to 109.7)	0.7 (0.5 to 0.9)	19.3 (12.6 to 27.9)	39.3 (25.8 to 56.4)	103.9 (96.8 to 111.1)	0.7 (-1.7 to 3.0)
Bipolar disorder	104.2 (85.4 to 121.2)	197.4 (163.4 to 228.0)	89.8 (78.9 to 100.5)	-0.3 (-4.9 to 4.8)	21.4 (12.8 to 32.5)	40.6 (25.1 to 61.3)	89.3 (76.3 to 104.8)	-0.2 (-6.0 to 6.5)
Anxiety disorders	795.3 (549.6 to 1,030.7)	1,467.3 (1,055.0 to 1,887.5)	84.5 (77.9 to 95.6)	1.5 (1.2 to 1.8)	73.8 (44.3 to 112.7)	136.0 (83.6 to 204.6)	84.1 (75.7 to 95.3)	1.5 (-0.7 to 3.9)
Eating disorders	-	-	-	-	2.1 (1.3 to 3.1)	3.6 (2.2 to 5.4)	71.4 (48.5 to 95.3)	3.6 (-10.0 to 17.9)
Anorexia nervosa	5.1 (4.0 to 6.5)	8.7 (6.7 to 10.9)	69.6 (50.9 to 89.0)	3.7 (-7.3 to 15.7)	1.1 (0.7 to 1.7)	1.9 (1.1 to 2.8)	69.4 (38.4 to 110.2)	3.9 (-15.2 to 27.9)
Bulimia nervosa	4.6 (3.0 to 6.7)	7.9 (5.1 to 11.6)	73.7 (70.2 to 76.3)	3.0 (2.7 to 3.4)	1.0 (0.5 to 1.6)	1.7 (0.9 to 2.8)	74.2 (43.7 to 110.6)	3.4 (-14.6 to 24.6)
Autistic spectrum disorders	-	-	-	-	22.2 (15.3 to 30.1)	35.2 (24.4 to 47.7)	58.8 (53.4 to 64.4)	-1.7 (-4.7 to 1.3)
Autism	56.5 (53.6 to 59.4)	90.2 (85.4 to 95.0)	59.8 (58.8 to 61.0)	-1.7 (-1.8 to -1.6)	14.0 (9.4 to 19.3)	22.4 (14.9 to 30.5)	59.5 (51.8 to 68.1)	-1.5 (-6.0 to 3.2)
Asperger syndrome	81.0 (76.0 to 85.8)	128.0 (119.9 to 136.0)	58.2 (56.9 to 59.5)	-2.2 (-2.2 to -2.1)	8.1 (5.6 to 11.3)	12.8 (8.9 to 17.9)	57.8 (51.0 to 64.4)	-2.1 (-5.9 to 1.6)
Attention-deficit/hyperactivity disorder	128.5 (118.4 to 136.9)	173.9 (159.8 to 185.7)	35.6 (34.9 to 36.0)	-2.1 (-2.3 to -2.0)	1.6 (0.9 to 2.4)	3.2 (1.3 to 3.2)	36.1 (26.6 to 46.9)	-1.7 (-8.5 to 6.0)
Conduct disorder	129.4 (121.9 to 137.0)	178.3 (167.8 to 189.0)	38.0 (37.0 to 38.9)	-1.7 (-1.8 to -1.6)	15.6 (9.8 to 22.5)	21.6 (13.6 to 31.6)	38.4 (31.6 to 45.7)	-1.1 (-6.1 to 3.9)
Idiopathic intellectual disability	158.2 (100.4 to 225.5)	221.8 (121.4 to 326.7)	41.2 (-15.7 to 120.5)	-1.4 (-4.8 to 43.4)	7.8 (4.4 to 11.9)	10.9 (5.3 to 17.8)	40.7 (45.5 to 6.6)	-1.8 (-48.3 to 40.7)
Other mental and substance use disorders	261.0 (244.0 to 277.1)	506.7 (475.4 to 537.0)	94.5 (92.7 to 96.3)	-0.9 (-1.2 to -0.6)	19.7 (13.4 to 26.7)	38.1 (26.0 to 51.3)	93.7 (86.4 to 102.9)	-1.1 (-4.4 to 2.9)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	123.1 (85.9 to 166.9)	295.7 (205.1 to 410.0)	139.7 (117.3 to 168.5)	24.8 (12.7 to 39.0)
Diabetes mellitus	841.6 (743.4 to 950.4)	2,535.2 (2,204.1 to 2,894.8)	201.7 (159.0 to 254.7)	45.2 (25.4 to 69.0)	52.6 (34.3 to 74.4)	166.6 (110.0 to 237.3)	211.9 (155.2 to 281.7)	45.4 (20.9 to 76.4)
Acute glomerulonephritis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-11.2 (-17.8 to -5.0)	-35.0 (-40.0 to -31.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.2 (-17.8 to -5.0)	-35.6 (-40.0 to -31.3)
Chronic kidney disease	-	-	-	-	19.4 (13.8 to 26.6)	41.4 (29.4 to 56.3)	113.7 (94.4 to 135.7)	13.3 (3.4 to 25.6)
Chronic kidney disease due to diabetes mellitus	45.4 (29.2 to 66.7)	214.0 (138.5 to 300.5)	371.6 (251.5 to 572.3)	128.8 (71.4 to 221.2)	1.5 (0.9 to 2.1)	7.2 (4.8 to 10.9)	394.9 (255.2 to 565.2)	140.9 (76.5 to 227.4)
Chronic kidney disease due to hypertension	125.8 (76.3 to 205.7)	111.4 (82.7 to 156.8)	-9.0 (-34.8 to 21.7)	-41.9 (-55.3 to -25.7)	3.6 (2.4 to 5.1)	8.4 (5.4 to 11.9)	130.1 (78.8 to 193.2)	23.7 (-1.8 to 52.9)
Chronic kidney disease due to glomerulonephritis	125.8 (100.4 to 199.0)	205.6 (117.3 to 314.3)	63.4 (15.9 to 119.2)	3.2 (-28.6 to 24.7)	61.4 (21.1 to 45.1)	2.3 (5.1 to 3.2)	29.9 (-45.5 to 6.6)	54.6 (-65.3 to -42.4)
Chronic kidney disease due to other causes	417.4 (279.3 to 624.2)	729.2 (502.6 to 1,013.5)	74.7 (49.8 to 107.0)	-4.9 (-20.7 to 7.4)	11.2 (8.0 to 15.4)	23.6 (17.0 to 31.9)	112.2 (84.5 to 141.5)	5.4 (-9.1 to 26.7)
Urinary diseases and male infertility	-	-	-	-	7.5 (5.0 to 10.8)	20.2 (13.2 to 28.6)	167.7 (139.3 to 197.3)	17.9 (6.5 to 31.2)

Appendix Table G.4 - Malaysia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	3.0 (2.8 to 3.2)	6.8 (6.3 to 7.2)	128.4 (108.5 to 149.0)	26.5 (15.3 to 36.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	125.0 (76.7 to 185.1)	25.7 (3.4 to 53.3)
Urolithiasis	67.8 (49.4 to 92.1)	164.9 (122.5 to 228.1)	135.7 (97.7 to 214.8)	9.1 (-7.8 to 33.8)	1.0 (0.7 to 1.4)	2.2 (1.4 to 3.1)	109.8 (85.1 to 145.5)	4.3 (-6.2 to 19.0)
Benign prostatic hyperplasia	126.2 (114.6 to 136.4)	324.1 (297.6 to 351.3)	156.9 (127.1 to 190.6)	7.9 (-4.6 to 22.1)	4.6 (3.0 to 6.5)	11.7 (7.6 to 16.5)	156.1 (125.3 to 189.9)	7.4 (-5.7 to 21.7)
Male infertility due to other causes	71.9 (49.9 to 97.0)	133.9 (85.3 to 191.4)	86.4 (11.2 to 209.5)	4.5 (-38.5 to 79.6)	0.5 (0.2 to 1.0)	0.8 (0.3 to 1.8)	80.6 (8.0 to 199.1)	1.5 (-39.1 to 69.2)
Other urinary diseases	-	-	-	-	-	-	-	-
Gynecological diseases	-	-	-	-	20.9 (13.6 to 31.0)	34.6 (21.8 to 52.7)	66.2 (39.9 to 92.4)	-12.4 (-25.3 to 0.3)
Uterine fibroids	320.3 (290.1 to 352.5)	698.2 (638.5 to 763.2)	118.3 (116.2 to 120.5)	5.8 (5.8 to 5.8)	5.1 (3.0 to 8.3)	6.4 (3.2 to 11.3)	21.4 (-3.1 to 65.1)	-38.2 (-50.4 to -16.7)
Polycystic ovarian syndrome	260.0 (214.6 to 304.3)	470.2 (388.2 to 548.5)	80.6 (41.1 to 129.8)	-3.2 (-23.8 to 22.6)	2.6 (1.1 to 4.9)	4.6 (2.2 to 8.6)	81.9 (43.1 to 128.8)	-2.3 (-22.9 to 22.5)
Female infertility due to other causes	101.2 (54.0 to 146.5)	191.5 (110.2 to 283.1)	92.3 (-0.3 to 250.6)	3.7 (-47.9 to 96.0)	0.5 (0.2 to 1.2)	1.0 (0.4 to 2.2)	284.2 (0.9 to 262.7)	38.9 (-46.8 to 95.4)
Endometriosis	31.6 (26.4 to 36.6)	61.7 (52.2 to 71.9)	95.6 (54.1 to 145.0)	4.4 (-17.2 to 29.7)	2.9 (1.9 to 4.2)	5.8 (3.8 to 8.2)	96.3 (49.7 to 149.9)	4.8 (-19.3 to 32.0)
Genital prolapse	741.4 (636.1 to 846.3)	1,543.0 (1,351.4 to 1,761.2)	109.2 (73.2 to 152.7)	2.6 (-13.6 to 20.6)	2.4 (1.1 to 4.5)	4.9 (2.3 to 9.4)	109.1 (72.0 to 152.7)	2.5 (-13.5 to 20.9)
Premenstrual syndrome	685.0 (494.9 to 888.6)	1,330.5 (877.0 to 1,755.0)	99.8 (13.8 to 199.5)	10.7 (-35.9 to 63.9)	5.8 (3.2 to 9.4)	11.2 (6.2 to 18.5)	99.3 (12.1 to 198.2)	10.4 (-36.4 to 63.4)
Other gynecological diseases	54.3 (42.3 to 66.7)	35.9 (28.9 to 43.5)	-34.0 (-51.2 to -8.2)	-43.3 (-73.0 to -49.0)	1.6 (1.0 to 2.4)	0.6 (0.4 to 1.1)	-61.0 (-75.0 to -27.5)	-78.1 (-85.5 to -59.4)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	14.8 (9.9 to 21.5)	26.9 (17.8 to 38.8)	82.4 (64.4 to 105.5)	19.9 (6.5 to 35.8)
Thalassemias	3.5 (3.2 to 4.0)	4.8 (4.3 to 5.3)	35.8 (26.9 to 48.1)	1.5 (-4.9 to 10.7)	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	13.3 (9.2 to 45.3)	-16.2 (-32.6 to 6.9)
Thalassemia trait	644.8 (600.3 to 688.1)	1,045.5 (993.2 to 1,106.3)	62.3 (57.1 to 68.2)	-0.7 (-3.8 to 3.1)	9.0 (6.0 to 13.2)	22.4 (14.9 to 32.4)	150.8 (117.5 to 178.9)	65.8 (41.1 to 84.6)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.4 (32.6 to 188.0)	9.7 (-7.9 to 101.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.5 (36.5 to 280.5)	21.1 (-7.6 to 162.3)
Sickle cell trait	41.9 (22.4 to 55.6)	69.8 (51.3 to 89.7)	63.5 (32.6 to 156.7)	0.1 (-18.9 to 56.9)	0.2 (0.1 to 0.4)	0.6 (0.2 to 1.0)	198.2 (5.2 to 1,032.3)	95.3 (-28.7 to 644.2)
G6PD deficiency	801.2 (737.8 to 871.2)	1,348.8 (1,248.3 to 1,455.9)	68.6 (50.4 to 88.5)	3.2 (-7.9 to 15.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-7.7 (-33.3 to 81.5)	-36.7 (-53.2 to 17.9)
G6PD trait	2,995.8 (2,937.2 to 3,051.7)	5,014.0 (4,900.3 to 5,126.4)	67.5 (63.2 to 72.9)	1.7 (-0.9 to 5.0)	0.4 (0.0 to 0.2)	0.4 (0.1 to 0.6)	199.0 (27.2 to 10,910.5)	97.2 (-49.9 to 5,396.0)
Other hemoglobinopathies and hemolytic anemias	185.4 (168.1 to 203.7)	132.7 (117.1 to 147.9)	-28.3 (-38.9 to -18.2)	-55.7 (-61.1 to -49.2)	5.0 (3.2 to 7.3)	3.0 (1.8 to 4.5)	-40.0 (-56.2 to -22.6)	-59.4 (-70.3 to -47.0)
Endocrine, metabolic, blood, and immune disorders	236.7 (205.9 to 260.0)	243.3 (218.6 to 265.8)	2.7 (-9.1 to 20.6)	-32.5 (-39.6 to -22.5)	2.7 (5.3 to 11.2)	8.0 (5.3 to 11.4)	30.5 (-18.0 to 28.0)	-30.8 (-42.4 to -14.0)
Musculoskeletal disorders	-	-	-	-	168.6 (119.0 to 225.7)	349.2 (246.6 to 468.1)	107.5 (91.6 to 123.0)	0.1 (-6.7 to 6.7)
Rheumatoid arthritis	10.3 (9.4 to 11.1)	32.9 (30.8 to 35.2)	221.6 (189.1 to 258.2)	55.7 (39.4 to 74.8)	2.5 (1.7 to 3.3)	7.9 (5.5 to 10.6)	217.8 (176.8 to 266.8)	54.8 (36.2 to 77.5)
Osteoarthritis	171.8 (161.9 to 181.9)	437.5 (413.7 to 460.4)	154.7 (135.4 to 175.7)	6.8 (-1.2 to 15.1)	10.6 (7.5 to 14.4)	27.1 (18.9 to 36.6)	154.2 (133.6 to 175.4)	6.6 (-1.5 to 15.5)
Low back and neck pain	-	-	-	-	255.5 (89.9 to 173.4)	917.8 (177.3 to 350.4)	97.7 (79.1 to 118.1)	-1.8 (-10.5 to 8.1)
Low back pain	744.9 (700.2 to 789.3)	1,505.9 (1,427.8 to 1,591.2)	102.1 (87.6 to 119.8)	-0.5 (-6.8 to 7.5)	84.1 (55.9 to 116.5)	169.5 (114.6 to 236.4)	101.3 (85.9 to 120.1)	-0.6 (-7.1 to 7.9)
Neck pain	455.6 (375.8 to 555.0)	867.8 (707.1 to 1,046.2)	92.0 (46.4 to 140.6)	-4.7 (-26.2 to 18.5)	45.3 (30.1 to 65.2)	86.0 (56.8 to 120.8)	91.5 (45.1 to 140.5)	-4.7 (-26.6 to 19.0)
Gout	8.9 (7.7 to 10.2)	20.0 (17.3 to 22.9)	124.6 (82.5 to 176.4)	0.2 (-17.8 to 23.1)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	124.2 (65.9 to 199.0)	0.1 (-24.6 to 32.2)
Other musculoskeletal disorders	279.9 (202.9 to 356.9)	628.8 (458.4 to 804.1)	423.9 (106.4 to 150.7)	-1.4 (-8.7 to 9.5)	25.9 (16.2 to 38.3)	58.1 (36.6 to 86.7)	123.7 (105.2 to 151.8)	-1.5 (-9.5 to 9.7)
Other non-communicable diseases	-	-	-	-	205.3 (135.4 to 298.3)	365.5 (243.8 to 530.5)	78.1 (72.1 to 83.8)	-5.2 (-7.5 to -2.3)
Congenital anomalies	-	-	-	-	16.2 (11.7 to 21.0)	31.0 (22.2 to 40.8)	91.3 (66.8 to 120.8)	19.8 (5.1 to 37.5)
Neural tube defects	5.2 (4.6 to 5.9)	7.8 (6.7 to 9.4)	50.0 (24.1 to 85.5)	-1.0 (-18.0 to 22.2)	1.7 (1.1 to 2.3)	2.6 (1.7 to 3.7)	54.8 (15.9 to 112.8)	2.8 (-23.2 to 41.2)
Congenital heart anomalies	83.2 (74.0 to 94.2)	165.1 (139.4 to 194.5)	98.5 (64.6 to 138.1)	27.7 (5.4 to 53.7)	3.0 (1.3 to 5.3)	6.3 (2.6 to 11.0)	104.5 (72.1 to 145.7)	33.0 (11.8 to 60.3)
Orofacial clefts	19.7 (16.4 to 24.2)	35.9 (29.5 to 50.5)	80.9 (35.3 to 170.0)	20.8 (-9.6 to 80.6)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	40.7 (-7.2 to 118.9)	-6.1 (-37.3 to 44.8)
Down syndrome	19.3 (16.2 to 23.4)	35.9 (30.5 to 45.9)	85.9 (44.8 to 142.3)	12.7 (-12.6 to 47.5)	2.4 (1.7 to 3.3)	4.9 (3.5 to 6.7)	100.7 (53.2 to 166.1)	16.3 (-12.2 to 53.7)
Turner syndrome	0.6 (0.5 to 0.9)	1.1 (0.9 to 1.4)	76.4 (20.2 to 132.6)	10.6 (-24.7 to 46.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.6 (17.5 to 145.8)	9.2 (-27.1 to 50.8)
Klinefelter syndrome	0.6 (0.4 to 0.9)	0.9 (0.8 to 1.2)	52.5 (4.4 to 132.0)	-5.2 (-35.2 to 44.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.8 (-7.0 to 176.6)	-6.5 (-45.6 to 58.9)
Chromosomal unbalanced rearrangements	25.8 (21.0 to 32.8)	49.4 (42.0 to 58.9)	83.7 (40.4 to 143.7)	11.0 (-14.6 to 48.4)	3.3 (2.3 to 4.5)	6.7 (4.8 to 9.1)	14.4 (51.0 to 168.3)	14.4 (-13.2 to 54.9)
Other congenital anomalies	41.1 (33.4 to 49.3)	64.0 (52.0 to 77.0)	55.9 (39.7 to 73.4)	-7.1 (-16.2 to 3.5)	5.4 (3.5 to 7.9)	10.2 (6.5 to 14.8)	88.7 (39.9 to 153.3)	24.8 (-6.8 to 66.4)
Skin and subcutaneous diseases	-	-	-	-	86.4 (55.2 to 132.3)	149.7 (96.2 to 230.0)	73.3 (63.8 to 82.9)	1.2 (-3.5 to 7.5)
Dermatitis	831.0 (716.6 to 958.0)	1,454.1 (1,245.8 to 1,676.3)	75.0 (71.6 to 79.4)	0.1 (-0.1 to 0.3)	23.9 (15.6 to 34.3)	40.6 (26.4 to 58.4)	69.5 (62.5 to 77.3)	0.3 (-2.4 to 3.1)
Psoriasis	130.5 (102.9 to 160.6)	246.5 (192.1 to 302.1)	88.8 (84.3 to 95.6)	0.0 (-0.2 to 0.2)	10.7 (7.1 to 15.8)	10.7 (13.2 to 29.8)	80.6 (76.5 to 101.0)	-0.1 (-4.8 to 5.4)
Cellulitis	4.0 (3.2 to 5.1)	7.0 (5.6 to 8.6)	75.9 (53.5 to 96.6)	0.5 (-10.5 to 12.6)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	74.3 (34.8 to 117.2)	0.3 (-19.5 to 23.3)
Pyoderma	27.6 (20.3 to 35.7)	18.0 (14.2 to 23.2)	-34.7 (-46.7 to -19.9)	-51.9 (-59.1 to -43.1)	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.2)	-34.7 (-48.1 to -19.6)	-51.9 (-60.5 to -42.7)
Scabies	195.3 (178.4 to 215.7)	279.0 (248.6 to 317.5)	42.7 (21.7 to 67.0)	-14.1 (-25.7 to -0.5)	5.0 (2.9 to 8.0)	7.2 (4.0 to 11.6)	42.7 (22.1 to 67.3)	-14.2 (-25.6 to -0.3)
Fungal skin diseases	2,066.6 (1,610.6 to 2,529.3)	3,563.2 (2,852.4 to 4,276.6)	72.8 (65.6 to 79.8)	11.7 (-0.9 to 43.5)	6.7 (4.6 to 25.3)	20.7 (8.1 to 43.2)	75.5 (62.2 to 79.4)	14.4 (-1.4 to 31.0)
Viral skin diseases	407.9 (304.9 to 507.9)	585.0 (425.7 to 748.7)	43.7 (35.3 to 51.4)	-0.1 (-1.5 to 1.5)	12.7 (7.2 to 20.7)	18.2 (10.2 to 29.2)	43.4 (33.9 to 52.1)	0.1 (-2.7 to 3.6)
Acne vulgaris	544.2 (425.6 to 661.0)	954.8 (767.3 to 1,120.3)	75.0 (37.0 to 137.7)	9.3 (-14.0 to 47.7)	5.9 (2.7 to 11.4)	10.4 (4.7 to 20.1)	75.0 (37.4 to 139.1)	9.2 (-13.8 to 48.3)
Alopecia areata	22.4 (19.6 to 25.1)	40.7 (36.1 to 45.7)	82.4 (54.4 to 115.9)	0.1 (-14.7 to 16.9)	0.8 (0.5 to 1.1)	1.4 (0.9 to 2.1)	81.2 (50.0 to 118.9)	0.5 (-15.6 to 18.7)
Pruritus	2.9 (2.3 to 3.4)	5.6 (4.7 to 6.6)	91.3 (55.5 to 152.2)	0.8 (-21.4 to 31.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	91.3 (43.5 to 163.3)	-0.5 (-26.0 to 37.7)
Urticaria	143.7 (94.8 to 195.2)	295.6 (223.8 to 367.8)	105.0 (34.1 to 230.4)	11.4 (-20.0 to 86.3)	8.6 (4.6 to 13.8)	17.7 (10.6 to 27.4)	104.4 (32.4 to 233.2)	11.2 (-21.0 to 86.6)
Decubitus ulcer	2.2 (1.9 to 2.6)	4.2 (3.5 to 5.1)	86.9 (48.6 to 139.4)	-2.8 (-26.8 to 33.4)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	82.5 (42.0 to 139.0)	-4.2 (-29.5 to 34.0)
Other skin and subcutaneous diseases	1,064.3 (738.7 to 1,504.9)	2,151.4 (1,460.7 to 3,106.0)	101.9 (85.6 to 118.3)	0.9 (-1.8 to 4.3)	6.3 (2.8 to 12.7)	12.7 (5.6 to 25.9)	101.3 (84.4 to 118.6)	0.8 (-2.1 to 5.5)
Sense organ diseases	-	-	-	-	82.8 (55.9 to 118.9)	148.6 (98.4 to 213.5)	9.3 (70.3 to 88.7)	-11.7 (-15.0 to -8.7)
Glaucoma	5.4 (4.1 to 7.0)	11.3 (8.3 to 14.6)	112.8 (50.4 to 180.7)	-2.2 (-28.0 to 29.8)	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.0)	100.5 (52.5 to 169.6)	-10.6 (-29.8 to 20.1)
Cataract	75.7 (56.3 to 97.6)	150.0 (112.2 to 185.4)	98.3 (69.3 to 138.3)	-19.9 (-29.6 to -8.1)	4.5 (2.9 to 6.5)	8.8 (5.6 to 12.6)	95.5 (70.3 to 130.8)	-20.9 (-28.9 to -9.6)
Macular degeneration	8.9 (6.2 to 12.2)	22.9 (15.7 to 32.5)	154.7 (86.3 to 263.0)	2.9 (-23.6 to 42.9)	0.5 (0.3 to 0.8)	1.3 (0.8 to 1.9)	138.6 (80.3 to 225.0)	-5.7 (-26.5 to 22.7)
Uncorrected refractive error	696.7 (643.0 to 751.8)	1,260.7 (1,162.1 to 1,348.9)	81.3 (64.2 to 100.0)	-11.9 (-19.4 to -4.5)	14.6 (9.4 to 21.8)	24.8 (15.6 to 37.4)	69.3 (59.0 to 81.6)	-16.7 (-21.1 to -11.8)
Age-related and other hearing loss	1,999.4 (1,870.2 to 2,132.0)	3,958.1 (3,737.8 to 4,253.1)	98.3 (89.0 to 106.3)	-9.5 (-12.8 to -6.4)	98.3 (29.9 to 66.6)	45.5 (55.3 to 127.2)	90.0 (74.1 to 103.3)	-8.7 (-13.7 to -3.8)
Other vision loss	107.5 (91.4 to 124.1)	150.3 (123.5 to 177.8)	40.7 (17.2 to 62.7)	-26.5 (-39.5 to -16.2)	6.3 (4.3 to 8.7)	9.3 (6.2 to 13.2)	48.0 (25.3 to 73.4)	-27.4 (-38.8 to -17.6)
Other sense organ diseases	410.7 (391.2 to 431.3)	653.3 (622.4 to 684.7)	59.4 (48.5 to 70.2)	0.5 (-5.6 to 6.7)	11.0 (6.8 to 16.4)	17.4 (10.7 to 25.9)	58.8 (46.2 to 71.5)	0.7 (-6.0 to 7.9)
Oral disorders	-	-	-	-	19.9 (11.7 to 31.5)	36.3 (21.2 to 58.3)	82.4 (72.5 to 91.9)	-7.4 (-12.8 to -2.3)
Deciduous caries	2,125.3 (2,069.2 to 2,176.3)	2,254.4 (2,1						

Appendix Table G.4 - Malaysia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	115.4 (102.9 to 128.5)	204.2 (182.8 to 224.5)	77.1 (51.8 to 105.1)	-25.6 (-35.8 to -14.1)	3.2 (2.1 to 4.5)	5.6 (3.8 to 8.0)	76.6 (50.5 to 104.7)	25.9 (-36.2 to -14.1)
Other oral disorders	288.8 (271.4 to 306.5)	531.8 (497.9 to 561.3)	85.1 (67.0 to 99.3)	0.6 (-8.3 to 8.2)	8.5 (5.3 to 12.7)	15.7 (9.8 to 23.5)	84.3 (66.8 to 100.4)	0.5 (-8.3 to 8.6)
Injuries	-	-	-	-	67.0 (50.9 to 86.2)	95.1 (68.2 to 128.1)	41.3 (25.9 to 59.1)	-26.4 (-33.6 to -18.0)
Transport injuries	-	-	-	-	36.6 (27.5 to 47.6)	52.9 (37.6 to 71.8)	43.5 (25.2 to 65.6)	-24.6 (-33.4 to -14.5)
Road injuries	-	-	-	-	12.6 (9.3 to 16.2)	19.6 (11.9 to 23.4)	56.5 (38.8 to 82.9)	-25.7 (-34.8 to -15.2)
Pedestrian road injuries	-	-	-	-	4.6 (3.4 to 6.0)	6.7 (4.8 to 9.1)	43.8 (21.5 to 68.7)	-22.6 (-33.1 to -11.1)
Cyclist road injuries	-	-	-	-	2.2 (1.6 to 2.9)	3.3 (2.3 to 4.4)	47.3 (30.2 to 65.3)	-24.4 (-32.4 to -15.7)
Motorcyclist road injuries	-	-	-	-	13.5 (10.1 to 17.6)	17.0 (11.9 to 23.4)	24.8 (6.9 to 47.4)	-34.2 (-42.8 to -23.6)
Motor vehicle road injuries	-	-	-	-	12.6 (9.3 to 16.2)	19.6 (14.0 to 26.5)	56.4 (38.8 to 82.9)	-25.5 (-32.2 to -4.7)
Other road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	16.8 (1.5 to 37.6)	-42.1 (-49.0 to -32.8)
Other transport injuries	-	-	-	-	3.5 (2.6 to 4.6)	6.2 (4.4 to 8.3)	73.6 (54.6 to 96.7)	-15.6 (-25.0 to -4.6)
Unintentional injuries	-	-	-	-	27.7 (21.1 to 35.8)	39.4 (28.7 to 52.5)	42.1 (30.7 to 55.8)	-26.6 (-32.4 to -19.9)
Falls	-	-	-	-	8.0 (6.0 to 10.3)	12.3 (8.7 to 16.8)	54.7 (35.6 to 74.4)	-26.9 (-35.8 to -17.5)
Drowning	-	-	-	-	0.8 (0.6 to 1.0)	0.7 (0.5 to 0.9)	-12.1 (-25.4 to 5.2)	-50.4 (-57.7 to -41.7)
Fire, heat, and hot substances	-	-	-	-	2.1 (1.6 to 2.7)	1.8 (1.3 to 2.5)	-14.6 (-26.6 to 0.2)	-54.1 (-59.8 to -47.0)
Poisonings	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	2.2 (-13.8 to 23.2)	-43.7 (-51.5 to -33.6)
Exposure to mechanical forces	-	-	-	-	12.3 (9.3 to 16.1)	15.6 (11.3 to 21.2)	26.3 (15.0 to 38.9)	-32.0 (-37.4 to -26.1)
Unintentional firearm injuries	-	-	-	-	0.9 (0.6 to 1.1)	0.8 (0.6 to 1.1)	4.1 (-1.4 to 9.5)	-48.9 (-54.4 to -42.4)
Unintentional suffocation	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	34.0 (20.2 to 52.7)	-23.9 (-31.2 to -15.0)
Other exposure to mechanical forces	-	-	-	-	11.1 (8.4 to 14.6)	14.3 (10.4 to 19.6)	28.4 (16.6 to 41.2)	-30.9 (-36.4 to -24.9)
Adverse effects of medical treatment	-	-	-	-	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.0)	109.5 (97.8 to 121.5)	8.3 (2.4 to 14.3)
Animal contact	-	-	-	-	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.8)	37.7 (20.4 to 54.9)	-23.1 (-31.5 to -14.5)
Venomous animal contact	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	37.0 (15.0 to 61.0)	-24.0 (-35.3 to -12.3)
Non-venomous animal contact	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	38.8 (17.4 to 59.7)	-22.0 (-31.8 to -12.0)
Foreign body	-	-	-	-	0.3 (0.3 to 0.4)	0.5 (0.4 to 0.7)	51.0 (37.0 to 67.4)	-18.4 (-25.4 to -10.5)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	9.2 (-10.1 to 32.6)	-34.6 (-44.8 to -22.0)
Foreign body in eyes	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	62.9 (52.6 to 75.2)	-10.5 (-17.0 to -3.9)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	73.9 (56.0 to 94.5)	-12.6 (-21.1 to -3.5)
Other unintentional injuries	-	-	-	-	3.3 (2.4 to 4.3)	7.1 (5.1 to 9.4)	115.7 (91.6 to 140.5)	9.8 (-2.1 to 21.1)
Self-harm and interpersonal violence	-	-	-	-	2.0 (1.5 to 2.5)	2.6 (1.9 to 3.6)	32.1 (15.9 to 52.6)	-31.2 (-39.3 to -21.3)
Self-harm	-	-	-	-	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	-2.2 (-13.8 to 12.2)	-53.1 (-58.4 to -46.6)
Interpersonal violence	-	-	-	-	1.5 (1.2 to 2.0)	2.2 (1.6 to 3.0)	41.9 (22.9 to 65.8)	-24.1 (-33.7 to -12.6)
Assault by firearm	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	58.6 (41.8 to 79.5)	-13.7 (-21.9 to -3.4)
Assault by sharp object	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	55.0 (34.2 to 81.9)	-18.4 (-29.0 to -5.5)
Assault by other means	-	-	-	-	1.1 (0.8 to 1.4)	1.5 (1.1 to 2.0)	35.4 (16.0 to 59.9)	-27.2 (-37.2 to -15.2)
Forces of nature, war, and legal intervention	-	-	-	-	0.7 (0.2 to 1.9)	0.2 (0.1 to 0.4)	-73.8 (-84.5 to -57.5)	-86.2 (-91.9 to -77.8)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-2.7 (-36.0 to 67.9)	-57.9 (-70.2 to -31.7)
Collective violence and legal intervention	-	-	-	-	0.7 (0.2 to 1.8)	0.1 (0.1 to 0.3)	-77.5 (-86.4 to -65.1)	-87.8 (-92.7 to -80.7)

Appendix Table G.4 - Maldives prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	17.6 (12.9 to 23.5)	28.9 (21.4 to 37.8)	64.9 (51.2 to 74.4)	46 (-12.3 to -5.1)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	4.6 (3.0 to 6.8)	3.4 (2.3 to 4.7)	-24.8 (-43.3 to -11.3)	-43.8 (-52.9 to -35.6)
HIV/AIDS and tuberculosis	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	40.7 (28.9 to 52.5)	-34.9 (-39.7 to -29.8)
Tuberculosis	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.3)	40.2 (33.4 to 47.0)	-35.2 (-38.7 to -31.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	40.2 (28.5 to 52.1)	-35.1 (-39.9 to -30.0)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-23.3 to 126.3)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.4 (-43.6 to 85.9)	-49.9 (-75.3 to -18.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.4 (-43.7 to 86.4)	-49.9 (-75.4 to -18.6)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	175.4 (40.5 to 292.7)	45.0 (-25.5 to 104.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	213.7 (60.6 to 369.2)	53.7 (-22.5 to 129.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.2 (0.3 to 0.6)	0.1 (0.2 to 0.5)	-40.5 (-23.3 to 3.4)	-27.6 (-35.7 to -18.4)
Diarrheal diseases	1.4 (1.1 to 1.6)	0.8 (0.7 to 0.9)	-40.5 (-51.6 to -24.5)	-44.8 (-54.1 to -31.6)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-40.5 (-52.0 to -24.3)	-27.6 (-34.6 to -20.4)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-2.4 to 13.7)	0.0 (-7.0 to -21.5)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.0 (-55.8 to 16.4)	-45.3 (-64.5 to -19.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.8 (-57.0 to 20.2)	-44.7 (-65.3 to -16.4)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.5 (-65.3 to -9.7)	-54.7 (-72.1 to -34.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-6.6 to -6.3)	-41.2 (-72.0 to -32.0)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-93.8 (-99.1 to 258.7)	-93.1 (-99.3 to 208.1)
Lower respiratory infections	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	45.1 (11.3 to 106.9)	31.3 (1.9 to 88.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (5.0 to 107.2)	0.0 (-0.1 to 90.6)
Upper respiratory infections	5.5 (5.1 to 5.8)	8.9 (8.2 to 9.6)	63.6 (47.1 to 79.5)	7.6 (-2.9 to 18.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	63.7 (46.6 to 80.6)	7.9 (-3.0 to 18.8)
Otitis media	3.1 (2.9 to 3.4)	3.6 (3.4 to 3.9)	16.0 (6.1 to 26.6)	-16.4 (-23.5 to -9.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	17.5 (5.6 to 30.0)	-14.8 (-22.5 to -6.4)
Meningitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.6 (-55.2 to -36.4)	-66.6 (-71.7 to -60.2)
Pneumococcal meningitis	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-54.0 (-64.9 to -40.7)	-74.4 (-79.6 to -65.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-5.6 to -31.6)	-66.7 (-73.0 to -59.2)
H influenzae type B meningitis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-62.4 (-73.3 to -46.0)	-77.2 (-83.6 to -66.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.6 (-65.9 to -29.1)	-68.2 (-76.9 to -53.0)
Meningococcal meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.2 (-67.0 to -21.8)	-71.1 (-82.4 to -51.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-59.4 to -2.1)	-35.7 (-78.9 to -42.5)
Other meningitis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-55.5 (-65.0 to -42.9)	-72.3 (-78.2 to -63.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-59.2 to -29.6)	-47.0 (-74.1 to -54.4)
Encephalitis	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	22.9 (-6.5 to 45.7)	-29.6 (-46.5 to -17.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.0 (10.6 to 65.9)	-22.0 (-33.2 to -3.8)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.2 (-98.9 to 172.3)	-86.0 (-98.8 to 70.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-85.2 (-98.9 to 181.8)	-86.0 (-98.8 to 74.8)
Whooping cough	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-73.5 (-75.4 to -71.5)	-69.8 (-71.9 to -67.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-73.4 (-79.4 to -66.0)	-69.6 (-76.6 to -61.3)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.0 (-99.2 to -88.1)	-98.1 (-99.5 to -92.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-94.8 (-98.4 to -84.5)	-96.4 (-98.9 to -90.5)
Measles	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-60.3 (-65.3 to -55.5)	-55.6 (-60.7 to -49.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-60.4 (-70.9 to -46.9)	-55.1 (-67.0 to -40.0)
Varicella and herpes zoster	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.4)	48.5 (32.6 to 69.2)	0.5 (-12.2 to 15.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.9 (43.7 to 120.9)	1.1 (-17.4 to 23.1)
Neglected tropical diseases and malaria	-	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-20.1 (-37.1 to 19.0)	-34.1 (-47.5 to -4.3)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.8 (-27.4 to 226.1)	11.5 (-54.0 to 113.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.1 (-26.9 to 230.1)	12.9 (-53.4 to 115.6)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.5 (-3.8 to 50.2)	2.1 (-19.2 to 25.0)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.5 (-76.2 to 74.4)	-29.4 (-73.2 to 61.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.5 (-76.3 to 76.3)	-29.4 (-73.2 to 61.7)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.5 (-6.6 to 54.0)	2.8 (-17.2 to 28.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.5 (-0.7 to 54.1)	2.8 (-17.3 to 28.0)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-96.5 (-99.0 to -78.5)	-98.3 (-99.6 to -91.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-96.1 (-98.9 to -75.9)	-98.1 (-99.5 to -90.2)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.5 (-32.7 to -16.8)	-56.9 (-60.4 to -50.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.0 (-42.1 to -1.7)	-55.6 (-63.8 to -43.6)
Lymphatic filariasis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-42.7 (-55.4 to -25.6)	-70.5 (-76.7 to -62.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.2 (-23.6 to 62.4)	-49.8 (-67.9 to -30.3)
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.5)	676.1 (668.8 to 684.5)	389.8 (385.2 to 395.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	673.9 (513.6 to 923.2)	390.4 (307.7 to 519.5)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-65.4 (-80.9 to -41.2)	-63.1 (-87.6 to -75.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-65.4 (-80.9 to -41.2)	-83.1 (-87.6 to -75.8)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	156.5 (99.1 to 204.5)	19.6 (-8.8 to 42.2)
Ascariasis	-	-	109.5 (27.9 to 264.4)	-1.8 (-40.1 to 71.0)	-	-	-	-
Trichuriasis	-	-	115.7 (30.6 to 241.5)	1.1 (-38.9 to 60.2)	-	-	-	-
Hookworm disease	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	112.9 (36.3 to 234.4)	0.2 (-36.2 to 56.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	156.5 (99.1 to 204.5)	19.6 (-8.8 to 42.2)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	4.4 (3.4 to 5.3)	3.1 (2.6 to 3.7)	-30.0 (-43.7 to -8.8)	-44.6 (-54.1 to -31.3)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-40.2 (-54.0 to -13.6)	-49.2 (-60.8 to -30.4)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.1 (-38.3 to 34.5)	-61.0 (-72.7 to -41.0)
Maternal hemorrhage	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	35.0 (-7.8 to 99.0)	-39.6 (-59.3 to -9.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.4 (-45.7 to 114.7)	54.0 (-75.4 to 4.3)
Maternal sepsis and other maternal infections	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-41.9 (-57.9 to -28.2)	-76.9 (-82.7 to -70.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.0 (-71.4 to -7.9)	-78.0 (-86.7 to -63.8)
Maternal hypertensive disorders	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-8.8 (-19.4 to 7.8)	-61.4 (-65.7 to -53.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.5 (-30.8 to 19.2)	-62.3 (-70.1 to -50.5)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.1 (-72.6 to 32.2)	-70.8 (-88.2 to -48.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.6 (-72.0 to 96.8)	-68.4 (-88.4 to -26.4)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.3 (-33.9 to 99.9)	-59.1 (-73.0 to -24.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.3 (-34.0 to 106.2)	-59.1 (-73.1 to -24.0)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.1 (-54.8 to 82.3)	-61.7 (-80.3 to -22.4)
Neonatal disorders	-	-	-	-	0.2 (0.1 to 0.4)	0.5 (0.4 to 0.8)	122.5 (31.2 to 337.1)	60.7 (-5.6 to 222.2)
Preterm birth complications	0.4 (0.3 to 0.6)	1.6 (1.2 to 2.2)	263.3 (190.2 to 360.3)	140.8 (90.0 to 206.7)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	331.5 (221.4 to 499.0)	203.6 (125.4 to 318.2)
Neonatal encephalopathy due to birth asphyxia and trauma	1.0 (0.3 to 2.0)	0.8 (0.4 to 1.5)	-17.4 (-56.1 to 65.9)	-46.1 (-73.3 to 15.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	71.2 (4.3 to 208.3)	27.0 (-21.9 to 126.6)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.4 (-31.5 to 4.2)	0.6 (-20.4 to 21.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-51.3 to 72.7)	-13.3 (-43.4 to 100.7)
Hemolytic disease and other neonatal jaundice	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	132.8 (-6.7 to 715.6)	69.0 (-31.6 to 489.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	132.6 (-9.4 to 717.8)	66.3 (-34.7 to 486.6)
Other neonatal disorders	-	-	-	-	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	61.2 (-43.6 to 644.3)	17.4 (-59.2 to 450.5)
Nutritional deficiencies	-	-	-	-	3.5 (2.2 to 5.4)	2.0 (1.3 to 3.0)	-40.7 (-58.1 to -26.6)	-55.3 (-64.2 to -47.3)
Protein-energy malnutrition	2.6 (1.6 to 3.9)	1.6 (0.9 to 2.4)	-40.0 (-67.9 to 12.9)	-30.6 (-62.8 to 30.5)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-39.7 (-67.5 to 12.8)	-30.2 (-62.4 to 30.3)
Iodine deficiency	2.2 (1.6 to 2.7)	2.5 (1.7 to 3.4)	15.5 (-31.3 to 74.3)	-44.8 (-66.9 to -17.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	15.9 (-31.9 to 75.9)	-44.5 (-67.7 to -16.1)
Vitamin A deficiency	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-23.9 (-41.3 to -0.1)	-45.9 (-58.6 to -28.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.4 (-40.8 to -2.4)	-47.1 (-59.0 to -34.2)

Appendix Table G.4 - Maldives prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	69.9 (67.7 to 71.1)	53.8 (50.8 to 57.0)	-23.1 (-27.7 to -18.1)	-51.4 (-54.4 to -48.2)	2.4 (1.6 to 3.5)	1.5 (1.0 to 2.2)	-37.5 (-44.3 to -34.3)	-57.5 (-62.2 to -55.1)
Other nutritional deficiencies	-	-	-	-	0.7 (0.1 to 2.1)	0.3 (0.1 to 0.6)	-57.2 (-88.3 to 68.6)	-50.4 (-86.5 to 94.8)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	1.1 (-14.7 to 22.5)	-35.0 (-44.6 to -24.7)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	106.9 (74.6 to 144.2)	-5.4 (-18.6 to 10.4)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.3 (-2.0 to 33.9)	-47.1 (-53.7 to -39.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.9 (-15.3 to 56.8)	46.9 (-59.8 to -28.8)
Chlamydial infection	5.4 (3.2 to 8.1)	11.6 (8.2 to 16.4)	111.2 (15.3 to 295.5)	-7.7 (-45.1 to 79.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	112.2 (64.5 to 170.9)	-1.3 (-21.5 to 24.2)
Gonococcal infection	1.0 (0.5 to 1.4)	1.9 (1.3 to 2.6)	96.6 (12.8 to 264.2)	-6.2 (-43.5 to 63.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	118.4 (40.3 to 221.3)	2.3 (-32.6 to 48.2)
Trichomoniasis	0.5 (0.3 to 0.8)	1.2 (0.7 to 1.8)	118.5 (27.8 to 270.2)	-10.0 (-45.7 to 51.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.9 (16.7 to 330.5)	-9.0 (-50.3 to 77.8)
Genital herpes	17.3 (16.6 to 18.1)	34.8 (32.7 to 36.8)	101.3 (87.7 to 115.3)	9.8 (-16.0 to -3.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.2 (79.7 to 115.5)	-9.7 (-16.8 to -2.5)
Other sexually transmitted diseases	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	25.4 (5.8 to 54.5)	-50.8 (-58.6 to -39.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.6 (30.3 to 188.6)	-19.8 (-43.3 to 16.8)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.9 (6.8 to 74.1)	-32.4 (-46.3 to -4.9)
Hepatitis A	0.4 (0.3 to 0.4)	0.4 (0.4 to 0.4)	2.5 (0.8 to 4.3)	-15.5 (-15.9 to -14.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.5 (28.2 to 63.0)	-4.0 (-14.7 to 6.6)
Hepatitis B	20.4 (16.1 to 25.6)	23.6 (17.8 to 29.1)	15.7 (-19.3 to 70.0)	-38.6 (-55.6 to -11.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.7 (-15.9 to 111.1)	-43.0 (-60.6 to -6.3)
Hepatitis C	5.3 (4.7 to 5.9)	7.3 (6.5 to 8.1)	39.3 (17.8 to 63.9)	-29.1 (-39.1 to -17.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.8 (9.8 to 52.3)	-30.3 (-48.6 to -3.7)
Hepatitis E	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.5 (-14.5 to 52.0)	-41.1 (-53.5 to -22.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.8 (-20.8 to 78.3)	-41.8 (-58.7 to -13.4)
Leprosy	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	39.6 (-36.9 to 474.8)	-31.3 (-67.2 to 198.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.2 (-38.2 to 1,031.1)	-25.4 (-67.5 to 479.8)
Other infectious diseases	3.2 (2.6 to 3.8)	2.3 (2.0 to 2.7)	-28.4 (-41.1 to -11.6)	-47.6 (-56.3 to -36.9)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-37.2 (-54.9 to -19.5)	-50.6 (-63.3 to -38.6)
Non-communicable diseases	-	-	-	-	12.5 (9.2 to 16.3)	25.0 (18.4 to 32.5)	99.8 (90.8 to 109.1)	0.2 (-4.0 to 3.9)
Neoplasms	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	123.2 (83.8 to 151.4)	-7.3 (-16.4 to 2.0)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.7 (1.2 to 254.3)	-12.7 (-59.6 to 53.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.2 (10.2 to 225.6)	-10.6 (-58.4 to 39.2)
Stomach cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	128.7 (70.6 to 188.7)	3.5 (-22.7 to 31.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.5 (54.2 to 160.3)	-7.6 (-32.4 to 20.0)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,447.1 (730.4 to 2,128.5)	659.6 (324.0 to 990.0)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,494.3 (638.1 to 2,969.5)	701.3 (292.6 to 1,434.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,302.2 (604.6 to 2,308.8)	593.9 (255.7 to 1,131.1)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4,087.7 (1,288.2 to 11,694.0)	1,818.0 (673.8 to 5,111.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3,572.0 (1,155.8 to 9,609.6)	1,577.8 (596.4 to 4,176.5)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	552.4 (193.3 to 1,211.4)	198.8 (36.5 to 492.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	484.5 (169.3 to 995.1)	162.5 (-26.4 to 390.6)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	488.6 (184.4 to 1,142.3)	32.7 (-55.7 to 63.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	438.3 (171.8 to 966.6)	194.2 (-47.1 to 522.7)
Larynx cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	67.2 (42.7 to 102.4)	-35.5 (-45.0 to -22.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.4 (39.3 to 107.1)	-33.7 (-44.6 to -18.8)
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	299.3 (211.7 to 772.5)	97.4 (53.4 to 310.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	261.5 (174.1 to 677.7)	77.0 (33.1 to 259.6)
Breast cancer	0.1 (0.0 to 0.1)	0.4 (0.3 to 0.5)	640.9 (251.4 to 884.1)	249.6 (84.4 to 374.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	485.9 (168.8 to 712.7)	158.7 (-25.5 to 260.5)
Cervical cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	30.4 (-71.0 to 102.1)	32.7 (-85.2 to 21.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.9 (-70.2 to 109.7)	-11.4 (-85.2 to 61.0)
Uterine cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	21.7 (-68.1 to 142.1)	-58.0 (-82.0 to 26.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.6 (-68.2 to 141.9)	-59.5 (-81.7 to 24.6)
Prostate cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	1,743.6 (131.5 to 3,492.0)	648.6 (-10.9 to 1,311.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,482.3 (86.0 to 2,985.4)	471.5 (-32.2 to 1,088.9)
Colon and rectum cancer	0.3 (0.3 to 0.3)	0.7 (0.6 to 0.7)	152.2 (132.2 to 170.2)	-6.1 (-13.4 to 1.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	148.0 (127.3 to 170.5)	-6.3 (-13.8 to 2.0)
Lip and oral cavity cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	70.1 (-18.2 to 210.7)	-20.4 (-61.3 to 40.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.9 (-19.2 to 202.0)	-24.6 (-62.8 to 30.0)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.9 (-54.0 to 11.0)	-70.9 (-80.0 to -51.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-73.3 (-55.6 to 3.2)	-73.3 (-81.0 to -55.7)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.2 (-45.0 to 69.5)	-51.5 (-72.0 to -18.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.2 (-46.6 to 58.7)	-55.3 (-73.3 to -26.5)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	143.6 (11.1 to 265.6)	6.5 (-45.8 to 57.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	127.9 (9.1 to 224.6)	-1.8 (-48.1 to 40.5)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	381.6 (258.3 to 530.3)	105.8 (54.7 to 169.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	352.7 (263.2 to 459.8)	90.8 (51.6 to 136.9)
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	39.0 (-4.2 to 164.1)	35.0 (55.5 to 16.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.5 (-8.6 to 155.4)	21.5 (-58.1 to 9.4)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	83.7 (20.5 to 194.0)	-25.1 (-53.1 to 16.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.0 (-3.2 to 254.5)	-39.6 (-66.4 to 36.6)
Ovarian cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,238.4 (746.8 to 2,205.2)	607.5 (363.0 to 1,097.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,088.3 (609.3 to 2,040.1)	514.8 (281.4 to 998.7)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	122.4 (39.3 to 337.1)	-15.5 (-46.9 to 73.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.8 (16.8 to 290.5)	-28.5 (-58.9 to 54.7)
Kidney cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	151.2 (48.2 to 346.7)	74.7 (11.5 to 165.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	153.6 (49.9 to 340.9)	60.3 (3.9 to 140.5)
Bladder cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	89.4 (67.8 to 117.2)	-36.9 (-44.1 to -26.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.1 (61.5 to 115.5)	-37.1 (-45.0 to -26.2)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	270.2 (21.2 to 436.1)	88.9 (-40.1 to 168.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	273.5 (22.3 to 441.9)	78.8 (-43.3 to 157.0)
Thyroid cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	174.1 (2.3 to 316.2)	26.4 (-48.7 to 87.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	152.2 (-6.9 to 320.2)	14.5 (-52.9 to 80.9)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.3 (56.6 to 293.2)	9.8 (-18.5 to 90.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	127.8 (72.2 to 302.2)	14.4 (-12.9 to 90.3)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.3 (-62.5 to 113.0)	53.7 (-69.7 to 17.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.2 (-70.9 to 103.6)	-57.6 (-72.3 to 0.7)
Non-Hodgkin lymphoma	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	17.7 (-40.7 to 261.7)	-39.4 (-68.7 to 88.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.0 (-43.8 to 237.7)	-45.0 (-71.0 to 69.0)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	182.0 (31.0 to 364.3)	20.9 (-44.2 to 94.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	165.3 (28.8 to 324.3)	11.0 (-45.0 to 77.1)
Leukemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	292.3 (139.7 to 470.0)	124.7 (54.0 to 207.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	274.6 (138.5 to 413.8)	79.6 (22.5 to 145.7)
Other neoplasms	0.2 (0.1 to 0.4)	0.2 (0.2 to 0.3)	54.9 (-51.5 to 215.9)	15.3 (-51.7 to 107.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.1 (-44.7 to 212.9)	3.0 (-52.2 to 84.6)
Cardiovascular diseases	-	-	-	-	0.4 (0.3 to 0.5)	0.9 (0.6 to 1.3)	153.5 (102.4 to 206.2)	20.3 (-2.0 to 43.5)
Rheumatic heart disease	2.4 (1.8 to 2.8)	4.6 (3.7 to 5.9)	93.6 (44.7 to 154.1)	-0.9 (-24.6 to 28.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	98.3 (51.8 to 158.2)	1.9 (-21.5 to 31.0)
Ischemic heart disease	0.9 (0.7 to 1.2)	2.3 (1.9 to 2.7)	146.8 (85.1 to 220.6)	4.1 (-19.5 to 34.8)	0.1 (0.0 to 0.1)	0.4 (0.1 to 0.2)	148.4 (87.1 to 223.2)	8.3 (-16.9 to 39.7)
Cerebrovascular disease	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	135.7 (84.7 to 196.6)	3.0 (-17.4 to 31.1)
Ischemic stroke	0.1 (0.1 to 0.2)	0.3 (0.3 to 0.4)	148.8 (89.6 to 215.6)	4.6 (-18.2 to 34.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	146.1 (86.9 to 214.4)	5.2 (-18.9 to 34.8)
Hemorrhagic stroke	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.4)	130.0 (81.2 to 195.0)	1.0 (-19.4 to 29.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	125.9 (77.6 to 193.1)	0.4 (-19.5 to 31.0)
Hypertensive heart disease	0.2 (0.2 to 0.2)	0.5 (0.5 to 0.6)	156.3 (115.4 to 207.3)	14.8 (-9.9 to 39.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	154.5 (112.1 to 207.9)	15.4 (-4.4 to 40.3)
Cardiomyopathy and myocarditis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	105.7 (120.7 to 221.3)	-32.8 (-6.0 to 58.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.1 (117.9 to 228.0)	-32.0 (-4.9 to 63.2)
Atrial fibrillation and flutter	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	105.7 (42.6 to 182.5)	-32.8 (-55.1 to -3.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.1 (39.0 to 188.3)	-32.0 (-55.4 to -2.6)
Peripheral vascular disease	4.4 (3.7 to 5.4)	9.1 (6.8 to 11.3)	103.8 (49.7 to 171.8)	-8.8 (-32.2 to 17.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	205.5 (23.2 to 692.6)	-10.1 (-60.9 to 91.4)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	257.0 (87.9 to 511.3)	102.6 (12.1 to 243.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	280.6 (86.9 to 665.8)	111.9 (7.0 to 321.9)
Other cardiovascular and circulatory diseases	1.5 (1.0 to 2.0)	4.9 (2.5 to 6.9)	321.8 (60.2 to 449.1)	67.0 (-18.8 to 183.3)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.6)	255.4 (89.7 to 452.4)	68.0 (-18.1 to 186.5)
Chronic respiratory diseases	-	-	-	-	0.8 (0.5 to 1.1)	1.5 (1.0 to 2.1)	103.9 (71.4 to 141.0)	-6.2 (-17.5 to 6

Appendix Table G.4 - Maldives prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	244.1	45.9
Silicosis	0.0	0.0	85.2	-23.4	0.0	0.0	(218.3 to 270.7)	(33.1 to 59.0)
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	83.5	-23.8
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	327.8	91.7	0.0	0.0	317.2	86.5
Asthma	3.2	8.2	172.5	22.1	0.1	0.4	173.7	22.9
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	132.1	10.3	0.0	0.0	132.6	9.5
Other chronic respiratory diseases	-	-	-	-	0.1	0.1	-39.2	-71.7
Cirrhosis	-	-	-	-	0.0	0.0	40.1	-27.1
Cirrhosis due to hepatitis B	0.0	0.0	60.8	-18.7	0.0	0.0	(14.1 to 72.7)	(-40.8 to -9.5)
Cirrhosis due to hepatitis C	0.0	0.0	55.3	-21.6	0.0	0.0	59.0	-18.5
Cirrhosis due to alcohol use	0.0	0.0	19.2	-45.6	0.0	0.0	19.4	-21.5
Cirrhosis due to other causes	0.0	0.0	25.1	-10.0	0.0	0.0	(-47.8 to 124.7)	(-73.1 to -0.2)
Digestive diseases	-	-	-	-	0.2	0.2	24.7	-11.2
Peptic ulcer disease	0.6	0.6	4.4	-54.1	0.0	0.0	(-25.7 to 110.5)	(-47.6 to 46.2)
Gastritis and duodenitis	1.7	2.1	22.9	-34.7	0.1	0.1	31.1	-36.4
Appendicitis	0.0	0.0	64.4	-15.7	0.0	0.0	65.9	-14.7
Paralytic ileus and intestinal obstruction	0.0	0.0	16.9	-39.2	0.0	0.0	(4.3 to 217.7)	(-45.2 to 57.0)
Inguinal, femoral, and abdominal hernia	0.4	0.7	73.6	-17.4	0.0	0.0	72.5	-16.9
Inflammatory bowel disease	0.0	0.0	84.9	-12.8	0.0	0.0	84.9	-12.4
Vascular intestinal disorders	0.0	0.0	120.1	-0.3	0.0	0.0	(49.9 to 127.0)	(-27.3 to 6.6)
Gallbladder and biliary diseases	0.0	0.1	40.2	-38.1	0.0	0.0	112.8	-1.8
Pancreatitis	0.0	0.1	151.4	12.9	0.0	0.0	(53.8 to 195.7)	(-38.2 to 56.9)
Other digestive diseases	-	-	-	-	0.0	0.0	150.8	13.6
Neurological disorders	-	-	-	-	0.0	0.0	(115.4 to 194.7)	(-1.3 to 31.3)
Alzheimer disease and other dementias	0.5	1.5	231.0	8.2	0.1	0.2	12.7	45.4
Parkinson disease	0.1	0.1	145.0	-0.4	0.0	0.0	(-18.3 to 62.1)	(-60.9 to -21.9)
Epilepsy	1.0	1.7	65.3	5.1	0.3	0.6	132.3	4.8
Multiple sclerosis	0.0	0.0	308.4	86.6	0.0	0.0	(82.8 to 203.3)	(-14.4 to 27.8)
Migraine	16.9	43.2	152.6	18.5	0.6	1.5	251.0	9.6
Tension-type headache	38.7	79.1	103.0	1.8	0.1	0.1	(82.8 to 203.3)	(-11.6 to 33.1)
Medication overuse headache	0.6	1.9	228.5	55.1	0.1	0.3	144.0	0.3
Other neurological disorders	0.0	0.0	68.8	2.6	0.1	0.1	(113.4 to 177.4)	(-10.4 to 12.1)
Mental and substance use disorders	-	-	-	-	3.1	6.1	77.4	13.0
Schizophrenia	0.5	1.2	120.1	-2.4	0.2	0.2	(17.0 to 187.6)	(-26.0 to 78.4)
Alcohol use disorders	1.1	1.6	44.2	-31.0	0.1	0.2	308.4	86.6
Drug use disorders	-	-	-	-	0.4	0.6	(264.9 to 360.5)	(-67.9 to 108.5)
Opioid use disorders	0.2	0.4	142.1	0.2	0.1	0.2	142.7	0.4
Cocaine use disorders	0.1	0.3	107.9	5.4	0.0	0.0	(112.8 to 180.0)	(-10.8 to 14.8)
Amphetamine use disorders	1.0	1.2	15.0	-39.1	0.1	0.2	109.2	2.9
Cannabis use disorders	0.4	0.9	100.3	-0.6	0.0	0.0	(71.6 to 155.6)	(-18.8 to 17.5)
Other drug use disorders	-	-	-	-	0.2	0.2	15.1	-39.3
Depressive disorders	-	-	-	-	0.1	0.1	(-15.1 to 69.7)	(-53.4 to -13.2)
Major depressive disorder	3.2	7.2	125.4	6.3	0.7	1.5	102.2	-0.1
Dysthymia	1.9	4.3	123.3	2.1	0.2	0.4	(73.4 to 138.4)	(-13.4 to 14.4)
Bipolar disorder	1.0	2.2	120.5	1.1	0.2	0.5	29.2	-33.0
Anxiety disorders	1.5	9.5	113.3	2.2	0.9	1.9	(-12.6 to 87.6)	(-64.2 to -5.5)
Eating disorders	-	-	-	-	0.0	0.0	52.9	-24.1
Anorexia nervosa	0.1	0.1	94.2	3.1	0.0	0.0	(22.1 to 93.5)	(-38.0 to -6.7)
Bulimia nervosa	0.0	0.1	103.2	0.0	0.0	0.0	142.7	0.4
Autistic spectrum disorders	-	-	-	-	0.3	0.4	(86.2 to 104.1)	(-5.7 to 0.5)
Autism	0.7	1.1	59.5	-1.9	0.2	0.3	121.6	-1.8
Asperger syndrome	1.0	1.5	57.4	-2.4	0.1	0.2	105.5 to 138.8	(-8.6 to 5.2)
Attention-deficit/hyperactivity disorder	1.7	2.2	32.0	0.2	0.0	0.0	44.7	-30.9
Conduct disorder	1.6	2.2	34.4	0.2	0.0	0.0	52.9	-24.1
Idiopathic intellectual disability	1.9	2.3	18.2	-11.9	0.1	0.1	(25.5 to 63.5)	(-38.6 to -23.1)
Other mental and substance use disorders	2.6	5.7	122.5	-1.8	0.2	0.4	102.2	-0.1
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	2.0	3.8	102.2	-0.1
Diabetes mellitus	8.2	24.7	199.1	44.6	0.5	1.6	(73.4 to 138.4)	(-13.4 to 14.4)
Acute glomerulonephritis	0.0	0.0	41.8	-53.4	0.0	0.0	29.2	-33.0
Chronic kidney disease	0.5	1.9	252.8	78.1	0.1	0.2	(111.6 to 140.3)	(0.1 to 11.9)
Chronic kidney disease due to diabetes mellitus	0.3	0.9	161.8	32.5	0.0	0.0	126.4	6.7
Chronic kidney disease due to hypertension	1.7	2.6	54.4	-47.9	0.1	0.1	(108.2 to 146.3)	(-0.7 to 14.9)
Chronic kidney disease due to glomerulonephritis	1.5	2.6	64.4	-47.9	0.0	0.0	123.2	2.6
Chronic kidney disease due to other causes	4.5	8.5	92.1	10.2	0.1	0.2	(115.7 to 131.8)	(0.2 to 5.1)
Urinary diseases and male infertility	-	-	-	-	0.1	0.2	99.8	2.6

Appendix Table G.4 - Maldives prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	135.7 (115.8 to 156.4)	30.6 (20.3 to 39.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	134.2 (80.1 to 198.6)	30.8 (6.4 to 58.1)
Urolithiasis	0.7 (0.5 to 0.9)	1.8 (1.4 to 2.6)	181.3 (134.5 to 236.9)	17.8 (0.9 to 36.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	136.4 (108.2 to 170.4)	11.7 (-0.6 to 26.2)
Benign prostatic hyperplasia	1.6 (1.4 to 1.7)	3.4 (3.1 to 3.7)	114.6 (89.7 to 145.9)	-11.7 (-21.6 to 1.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	113.4 (87.9 to 144.3)	-11.2 (-21.3 to 2.6)
Male infertility due to other causes	1.3 (1.0 to 1.8)	3.4 (2.5 to 4.4)	163.5 (63.7 to 271.3)	4.2 (-34.7 to 45.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	165.2 (59.1 to 277.0)	6.0 (-35.1 to 46.9)
Other urinary diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-0.1 to 0.1)	-0.4 (-86.9 to 47.9)
Gynecological diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	115.4 (82.8 to 152.5)	-9.5 (-22.9 to 4.9)
Uterine fibroids	2.8 (2.6 to 3.1)	7.3 (6.6 to 8.0)	159.6 (157.3 to 162.1)	5.8 (5.7 to 5.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	69.2 (50.7 to 90.9)	-31.2 (-39.1 to -22.0)
Polycystic ovarian syndrome	2.4 (2.0 to 2.8)	5.6 (4.6 to 6.5)	139.1 (83.9 to 194.9)	-1.0 (-21.6 to 21.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	140.2 (84.8 to 197.7)	-0.4 (-21.3 to 22.3)
Female infertility due to other causes	1.8 (1.3 to 2.5)	5.5 (4.3 to 6.8)	194.9 (117.2 to 335.6)	8.0 (-13.9 to 25.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	194.3 (114.0 to 328.7)	19.0 (-14.4 to 73.0)
Endometriosis	0.3 (0.2 to 0.3)	0.7 (0.6 to 0.8)	154.1 (107.0 to 217.1)	4.5 (-15.1 to 29.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	154.8 (101.0 to 223.1)	4.9 (-16.3 to 31.7)
Genital prolapse	6.8 (5.9 to 7.7)	16.2 (14.0 to 18.5)	137.7 (93.9 to 191.6)	7.4 (-9.6 to 26.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	139.2 (93.6 to 192.3)	7.7 (-9.8 to 27.2)
Premenstrual syndrome	6.5 (4.4 to 8.6)	16.7 (11.4 to 23.4)	157.7 (54.4 to 329.7)	11.4 (-35.3 to 84.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	157.9 (53.0 to 334.4)	12.2 (-35.1 to 90.6)
Other gynecological diseases	0.7 (0.5 to 0.9)	0.8 (0.7 to 0.9)	5.2 (-20.2 to 59.0)	-51.6 (-63.2 to -27.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.5 (-24.8 to 95.5)	-57.1 (-65.7 to -13.2)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.8 (0.5 to 1.1)	1.2 (0.8 to 1.7)	48.8 (31.3 to 70.1)	4.2 (-12.5 to 19.7)
Thalassemias	0.6 (0.5 to 0.7)	0.7 (0.6 to 0.8)	19.3 (12.3 to 28.6)	4.6 (-1.5 to 13.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	13.0 (7.7 to 33.5)	2.7 (-16.2 to 21.7)
Thalassemia trait	35.8 (33.7 to 38.1)	58.9 (55.8 to 62.2)	64.5 (59.8 to 70.3)	3.4 (0.4 to 7.1)	0.6 (0.4 to 0.9)	1.0 (0.7 to 1.5)	67.8 (44.4 to 92.7)	19.5 (-4.0 to 37.3)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.1 (-72.6 to -12.7)	-64.3 (-79.6 to -35.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.4 (-73.0 to 25.0)	-60.7 (-80.9 to -10.3)
Sickle cell trait	0.5 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-30.7 (-58.7 to 27.9)	-65.5 (-74.0 to -19.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.0 (-63.2 to 65.3)	-39.8 (-74.7 to 14.7)
G6PD deficiency	25.3 (13.9 to 35.9)	40.1 (26.4 to 56.2)	54.5 (-7.3 to 204.5)	-2.8 (-41.7 to 93.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.0 (-58.2 to 51.3)	-35.0 (-70.6 to -5.3)
G6PD trait	39.9 (35.1 to 43.7)	64.2 (54.6 to 71.2)	60.3 (33.1 to 91.8)	3.1 (-14.4 to 23.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.5 (-88.5 to 294.1)	-31.8 (-91.3 to 157.7)
Other hemoglobinopathies and hemolytic anemias	3.5 (3.0 to 3.9)	2.7 (2.4 to 3.0)	-22.6 (-33.0 to -9.3)	-55.4 (-61.1 to -49.4)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-39.2 (-56.0 to -13.4)	-62.5 (-71.3 to -49.8)
Endocrine, metabolic, blood, and immune disorders	3.8 (3.4 to 4.3)	3.7 (3.3 to 3.9)	-5.0 (-16.5 to 7.7)	-37.2 (-44.3 to -29.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-14.0 (-27.6 to 5.2)	-39.0 (-47.5 to -26.0)
Musculoskeletal disorders	-	-	-	-	1.9 (1.3 to 2.6)	4.2 (2.9 to 5.6)	124.4 (95.9 to 155.3)	3.6 (-8.3 to 16.9)
Rheumatoid arthritis	0.2 (0.2 to 0.2)	0.5 (0.5 to 0.5)	135.1 (119.5 to 152.5)	12.7 (4.7 to 20.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	134.7 (111.9 to 159.9)	13.1 (3.4 to 23.8)
Osteoarthritis	1.9 (1.8 to 2.0)	4.6 (4.3 to 4.9)	139.8 (120.9 to 164.4)	5.0 (-3.3 to 15.3)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	139.5 (119.2 to 164.9)	5.6 (-2.5 to 16.4)
Low back and neck pain	-	-	-	-	1.4 (0.9 to 1.9)	3.0 (2.1 to 4.2)	156.2 (78.9 to 158.4)	-0.1 (-16.3 to 18.2)
Low back pain	8.6 (7.3 to 10.0)	18.4 (14.9 to 21.6)	113.5 (66.6 to 168.8)	-2.2 (-21.8 to 20.9)	1.0 (0.6 to 1.4)	2.1 (1.3 to 3.0)	113.9 (67.6 to 169.5)	-1.6 (-21.3 to 21.8)
Neck pain	4.4 (3.4 to 5.3)	9.6 (7.2 to 12.1)	120.7 (65.1 to 181.2)	1.9 (-23.7 to 31.5)	0.4 (0.3 to 0.6)	1.0 (0.6 to 1.4)	121.6 (64.6 to 182.9)	2.6 (-23.6 to 32.2)
Gout	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	147.1 (102.7 to 199.9)	10.8 (-9.4 to 33.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	145.6 (89.7 to 229.2)	11.0 (-13.8 to 45.0)
Other musculoskeletal disorders	3.4 (2.4 to 4.4)	8.5 (6.0 to 10.7)	149.0 (126.3 to 178.1)	15.2 (7.9 to 25.7)	0.3 (0.2 to 0.5)	0.8 (0.5 to 1.2)	150.3 (126.2 to 181.6)	15.3 (8.1 to 26.4)
Other non-communicable diseases	-	-	-	-	3.0 (2.0 to 4.3)	5.2 (3.5 to 7.4)	73.4 (65.8 to 85.1)	-6.9 (-10.5 to -2.3)
Congenital anomalies	-	-	-	-	0.2 (0.2 to 0.4)	0.5 (0.4 to 0.7)	118.9 (72.3 to 193.8)	57.9 (24.7 to 108.1)
Neural tube defects	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	222.3 (158.7 to 301.4)	148.6 (99.5 to 209.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	249.4 (150.0 to 386.6)	173.7 (96.6 to 272.2)
Congenital heart anomalies	0.3 (0.2 to 0.5)	1.6 (1.4 to 1.8)	380.1 (245.6 to 556.6)	255.1 (153.4 to 387.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	378.6 (242.2 to 560.8)	258.1 (155.9 to 397.1)
Orofacial clefts	0.1 (0.1 to 0.1)	0.3 (0.3 to 0.4)	420.3 (291.1 to 620.5)	329.1 (224.8 to 497.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	194.4 (149.6 to 433.7)	194.4 (106.9 to 333.7)
Down syndrome	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	134.6 (81.3 to 204.6)	70.1 (31.8 to 122.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	155.3 (98.4 to 234.1)	87.8 (45.5 to 148.8)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	118.6 (43.4 to 227.1)	45.7 (-4.0 to 118.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	130.1 (46.9 to 255.0)	43.5 (-7.3 to 121.2)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.7 (4.3 to 153.8)	2.5 (-34.1 to 60.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.1 (14.8 to 245.5)	3.6 (-40.9 to 75.6)
Chromosomal unbalanced rearrangements	0.0 (0.2 to 0.3)	0.1 (0.4 to 0.6)	129.0 (78.0 to 199.9)	129.0 (29.1 to 117.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	147.8 (90.4 to 227.9)	82.7 (40.7 to 141.3)
Other congenital anomalies	1.1 (0.8 to 1.5)	1.4 (1.0 to 1.9)	30.6 (8.7 to 49.0)	-17.9 (-30.9 to -6.8)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	84.2 (37.8 to 174.2)	29.4 (-2.3 to 89.5)
Skin and subcutaneous diseases	-	-	-	-	1.1 (0.7 to 1.7)	1.8 (1.1 to 2.8)	67.9 (59.0 to 83.9)	-2.1 (-6.8 to 4.7)
Dermatitis	9.4 (8.0 to 10.9)	17.1 (14.3 to 20.1)	82.1 (73.8 to 89.2)	0.3 (0.0 to 0.5)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	69.1 (54.9 to 79.9)	0.7 (-1.7 to 3.7)
Psoriasis	1.4 (1.1 to 1.6)	2.7 (2.1 to 3.3)	99.1 (93.6 to 104.3)	40.0 (-0.5 to 0.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	99.8 (86.0 to 114.6)	0.6 (-4.4 to 6.0)
Cellulitis	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	68.5 (42.4 to 94.3)	1.1 (-14.6 to 18.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.6 (26.4 to 120.6)	1.2 (-21.2 to 28.7)
Pyoderma	0.4 (0.3 to 0.5)	0.2 (0.2 to 0.3)	-43.6 (-54.7 to -29.9)	-51.9 (-59.1 to -43.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.0 (-55.6 to -28.2)	-52.0 (-60.0 to -42.1)
Scabies	2.5 (2.2 to 2.8)	3.3 (2.9 to 3.7)	30.9 (10.3 to 58.0)	-21.3 (-33.2 to -6.2)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	30.9 (10.1 to 58.6)	-21.1 (-33.3 to -5.7)
Fungal skin diseases	2.7 (1.7 to 2.8)	40.6 (31.8 to 49.1)	793.1 (66.1 to 91.2)	79.3 (-0.7 to 61.2)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.5)	79.3 (66.2 to 91.4)	-0.1 (-0.6 to 0.8)
Viral skin diseases	5.3 (4.0 to 6.6)	7.1 (5.2 to 9.1)	33.5 (19.7 to 46.0)	0.1 (-2.1 to 2.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	33.9 (19.3 to 46.7)	0.6 (-3.0 to 4.1)
Acne vulgaris	11.4 (7.8 to 14.9)	18.6 (14.2 to 24.6)	64.2 (12.9 to 135.5)	-6.5 (-35.6 to 32.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	64.5 (13.1 to 137.2)	-6.3 (-35.5 to 33.1)
Alopecia areata	0.2 (0.2 to 0.3)	0.4 (0.4 to 0.5)	83.5 (52.3 to 119.1)	-0.5 (-16.6 to 19.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.3 (49.1 to 126.6)	0.8 (-16.5 to 21.7)
Pruritus	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	88.3 (44.1 to 137.3)	2.3 (-27.1 to 23.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.6 (36.5 to 156.0)	-3.1 (-29.3 to 31.2)
Urticaria	1.8 (1.3 to 2.2)	3.3 (2.6 to 4.3)	88.3 (32.3 to 191.7)	-3.9 (-31.1 to 45.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	88.6 (32.5 to 194.0)	-3.4 (-31.2 to 47.2)
Decubitus ulcer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	107.6 (70.6 to 162.6)	-14.1 (-32.6 to 15.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.6 (56.8 to 165.4)	-13.5 (-35.8 to 21.3)
Other skin and subcutaneous diseases	11.5 (8.1 to 16.2)	22.4 (15.3 to 32.1)	95.4 (80.3 to 110.2)	-1.3 (-3.8 to 1.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	95.3 (79.5 to 110.9)	-0.8 (-3.7 to 2.1)
Sense organ diseases	-	-	-	-	1.4 (1.0 to 2.1)	2.4 (1.6 to 3.5)	68.1 (54.9 to 81.8)	-14.4 (-18.6 to -9.9)
Glaucoma	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	139.5 (55.9 to 237.7)	3.0 (-33.3 to 43.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	139.9 (57.3 to 230.8)	-0.8 (-37.9 to 28.0)
Cataract	1.1 (0.8 to 1.5)	2.1 (1.4 to 2.8)	97.2 (40.0 to 154.7)	-26.9 (-41.5 to -11.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	116.1 (51.2 to 183.1)	-21.9 (-37.5 to -2.5)
Macular degeneration	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	172.0 (70.5 to 346.9)	28.6 (-14.8 to 99.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	176.7 (82.4 to 333.2)	15.0 (-16.6 to 67.2)
Uncorrected refractive error	13.4 (10.6 to 16.5)	22.5 (16.9 to 28.1)	67.3 (18.1 to 129.0)	-15.0 (-38.9 to 13.0)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.7)	63.9 (36.3 to 96.8)	-16.5 (-31.4 to -2.6)
Age-related and other hearing loss	24.2 (21.7 to 26.4)	45.1 (40.6 to 49.7)	86.7 (77.9 to 94.4)	-10.4 (-13.7 to -7.5)	0.8 (0.5 to 1.3)	1.4 (0.9 to 2.2)	71.5 (51.1 to 90.3)	-12.5 (-18.5 to -6.9)
Other vision loss	1.5 (1.1 to 1.9)	2.2 (1.7 to 2.9)	42.2 (20.0 to 74.0)	-26.9 (-40.7 to -11.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	42.8 (25.4 to 68.7)	-29.4 (-42.7 to -17.1)
Other sense organ diseases	5.2 (4.9 to 5.6)	7.5 (7.2 to 7.9)	43.9 (33.5 to 54.5)	1.2 (-5.5 to 8.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	43.3 (31.9 to 54.3)	1.6 (-5.8 to 8.6)
Oral disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	88.5 (76.0 to 99.6)	-7.2 (-13.9 to -0.3)
Deciduous caries	28.3 (26.6 to 29.9)	25.7 (24.1 to 27.2)	-9.6 (-16.8 to -1.2)	-0.9 (-8.5 to 8.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.3 (18.2 to 0.7)	-0.5 (-10.3 to 10.3)
Permanent caries	53.5 (48.7 to 59.9)	102.5 (89.8 to 116.3)	89.7 (67.8 to 124.1)	3.3 (-7.9 to 23.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	89.9 (67.4 to 124.2)	3.7 (-2.8 to 24.0)
Periodontal diseases	4.5 (3.9 to 5.1)	10.0 (8.8 to 11.5)	123.6 (83.5 to 173.4)	2.4 (-16.8 to 27.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	124.2 (83.5 to 173.6)	2.6 (

Appendix Table G.4 - Maldives prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	1.3 (1.2 to 1.5)	2.2 (1.9 to 2.5)	68.1 (44.5 to 103.8)	-29.7 (-39.1 to -15.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	67.8 (43.2 to 101.5)	-29.1 (-39.6 to -15.2)
Other oral disorders	-	-	94.2 (78.3 to 110.2)	0.1 (-7.1 to 7.6)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	94.3 (78.3 to 111.7)	0.5 (-6.8 to 8.3)
Injuries	-	-	-	-	0.5 (0.4 to 0.7)	7.0 (0.4 to 0.8)	-46.3 (-2.2 to 17.8)	-63.9 (-50.5 to -41.3)
Transport injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-17.8 (-27.9 to -6.6)	-56.4 (-61.3 to -50.5)
Road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-39.4 (-30.0 to -46.6)	-55.5 (-60.6 to -49.2)
Pedestrian road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.3 (-36.9 to -10.9)	-57.2 (-62.9 to -50.6)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.9 (-19.0 to 2.5)	-51.1 (-56.3 to -44.7)
Motorcyclist road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-29.5 (-39.8 to -17.2)	-60.8 (-65.8 to -54.9)
Motor vehicle road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-19.6 (-21.6 to 10.5)	-59.6 (-56.7 to -41.3)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.9 to -6.7)	(-64.9 to -54.0)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.5 (-22.8 to -0.4)	-59.1 (-64.1 to -53.5)
Unintentional injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	18.6 (9.8 to 28.0)	41.3 (-45.5 to -36.9)
Falls	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	63.1 (45.0 to 83.6)	-28.6 (-36.8 to -19.1)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.1 (-48.1 to -28.5)	-67.1 (-71.5 to -62.1)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.3 (-43.0 to -22.0)	-63.2 (-67.9 to -58.3)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.0 (-53.3 to -27.0)	-68.8 (-73.7 to -62.3)
Exposure to mechanical forces	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	4.3 (-4.0 to 12.4)	-48.3 (-51.7 to -44.8)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.4 (-32.6 to -14.0)	-63.9 (-67.6 to -59.4)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.2 (1.2 to 27.9)	-39.3 (-45.4 to -33.4)
Other exposure to mechanical forces	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	6.0 (2.4 to 14.5)	47.4 (-50.8 to -43.8)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.5 (77.7 to 100.2)	-4.4 (-9.8 to 0.8)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.7 (-10.1 to 13.1)	-48.3 (-53.1 to -42.8)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.5 (-9.0 to 22.0)	-47.0 (-53.0 to -39.8)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.7 (-14.8 to 11.0)	-49.4 (-54.7 to -43.2)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.8 (44.1 to 74.3)	-17.8 (-24.2 to -9.6)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.4 (-7.2 to 37.5)	-31.4 (-42.0 to -19.2)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.4 (57.1 to 81.0)	-10.5 (-17.1 to -3.6)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.5 (63.2 to 103.5)	-15.0 (-23.0 to -5.3)
Other unintentional injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	48.8 (33.7 to 65.3)	-26.9 (-33.2 to -19.6)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.0 (-27.8 to -5.9)	-98.8 (-63.5 to -53.3)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.9 (-25.7 to -4.4)	-62.5 (-66.5 to -57.6)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.5 (-29.2 to -5.7)	-57.4 (-62.5 to -51.4)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.1 (-16.0 to 4.6)	-49.5 (-53.9 to -44.1)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.1 (-15.6 to 12.3)	-51.1 (-56.8 to -44.4)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.9 (-35.2 to -12.1)	-60.4 (-65.4 to -54.2)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Malaria prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	830.0 (602.9 to 1,107.6)	1,381.0 (997.5 to 1,813.9)	66.6 (59.3 to 73.2)	9.1 (-13.0 to -6.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	328.7 (225.0 to 467.3)	459.1 (317.5 to 639.1)	39.8 (27.2 to 53.8)	-34.6 (-40.9 to -27.7)
HIV/AIDS and tuberculosis	-	-	-	-	5.7 (3.8 to 8.0)	16.6 (10.9 to 23.6)	188.9 (129.8 to 271.5)	51.8 (21.0 to 100.2)
Tuberculosis	12.8 (11.9 to 13.8)	20.4 (19.1 to 21.9)	59.8 (51.7 to 68.3)	-12.5 (-16.8 to -8.3)	3.9 (2.6 to 5.3)	6.3 (4.3 to 8.5)	62.2 (50.0 to 76.0)	-11.7 (-18.1 to -5.3)
HIV/AIDS	-	-	-	-	1.3 (0.9 to 1.4)	10.4 (6.1 to 16.4)	213.3 (221.6 to 912.1)	472.3 (73.1 to 455.7)
HIV/AIDS resulting in mycobacterial infection	0.3 (0.1 to 0.5)	0.9 (0.5 to 1.5)	260.4 (105.3 to 494.4)	98.6 (11.4 to 227.5)	0.1 (0.0 to 0.2)	0.4 (0.2 to 0.6)	256.5 (89.1 to 578.3)	98.4 (26 to 279.7)
HIV/AIDS resulting in other diseases	18.7 (9.7 to 32.0)	77.1 (58.8 to 95.7)	325.3 (152.3 to 584.1)	135.3 (39.6 to 280.1)	1.7 (0.8 to 3.3)	10.0 (5.9 to 16.1)	486.5 (221.2 to 973.6)	219.3 (72.3 to 492.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	54.3 (38.9 to 72.6)	70.6 (50.5 to 94.3)	29.9 (20.3 to 41.6)	33.3 (-38.3 to -27.2)
Diarrheal diseases	140.8 (128.9 to 152.2)	207.4 (191.0 to 221.9)	47.6 (31.3 to 64.8)	-34.5 (-31.1 to -16.1)	22.5 (15.4 to 31.4)	38.4 (22.4 to 46.3)	48.4 (32.3 to 65.1)	24.2 (-31.5 to -15.6)
Intestinal infectious diseases	-	-	-	-	0.7 (0.5 to 1.0)	0.5 (0.3 to 0.8)	26.4 (45.5 to -1.7)	-26.4 (-71.2 to -49.3)
Typhoid fever	3.4 (3.0 to 3.9)	2.7 (2.2 to 3.3)	-19.6 (-37.1 to 3.2)	-58.0 (-66.9 to -45.4)	0.4 (0.3 to 0.6)	0.4 (0.2 to 0.6)	-17.9 (-40.9 to 12.3)	-56.6 (-67.9 to -41.2)
Paratyphoid fever	2.2 (1.9 to 2.6)	2.3 (1.8 to 2.9)	3.6 (-22.3 to 33.9)	-48.0 (-62.2 to -32.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	5.2 (-24.9 to 46.6)	47.4 (-62.7 to -26.8)
Other intestinal infectious diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.0 (0.0 to 0.1)	-74.4 (-85.8 to -46.7)	-86.3 (-92.5 to -72.5)
Lower respiratory infections	7.9 (6.8 to 9.2)	15.9 (13.7 to 18.6)	100.9 (61.1 to 148.5)	8.9 (-6.4 to 27.4)	0.8 (0.5 to 1.2)	1.7 (1.1 to 2.4)	102.5 (59.2 to 155.1)	9.6 (-8.7 to 31.0)
Upper respiratory infections	360.0 (326.4 to 391.3)	726.5 (673.5 to 799.4)	102.0 (80.6 to 129.7)	3.7 (-7.4 to 17.7)	4.2 (2.3 to 7.1)	8.6 (4.8 to 14.2)	103.0 (81.5 to 132.4)	4.3 (-7.4 to 18.7)
Otitis media	172.1 (152.3 to 190.5)	310.7 (284.9 to 341.8)	80.8 (64.6 to 99.3)	-7.4 (-16.3 to 3.5)	3.6 (2.1 to 5.7)	6.5 (3.9 to 10.5)	82.4 (65.4 to 101.7)	-6.8 (-15.9 to 4.7)
Meningitis	-	-	-	-	20.6 (13.9 to 28.5)	18.9 (12.6 to 26.1)	8.5 (-21.3 to 7.9)	49.9 (-57.3 to -41.8)
Pneumococcal meningitis	86.5 (52.6 to 132.1)	80.6 (51.5 to 117.8)	-5.1 (-32.0 to 23.8)	-48.0 (-62.3 to -32.1)	7.9 (5.0 to 11.9)	7.7 (5.3 to 10.6)	-2.2 (-31.7 to 38.5)	47.2 (-62.9 to -26.4)
H influenzae type B meningitis	33.4 (15.5 to 60.6)	25.6 (10.8 to 46.0)	-22.5 (-50.3 to 6.8)	-58.9 (-74.0 to -43.2)	3.9 (2.4 to 6.4)	3.0 (1.8 to 4.6)	-21.3 (-60.1 to 28.1)	-59.7 (-79.2 to -34.6)
Meningococcal meningitis	48.1 (18.2 to 98.3)	42.7 (14.4 to 86.8)	-12.4 (-29.9 to 19.1)	-50.3 (-61.3 to -34.9)	5.9 (3.3 to 9.1)	5.4 (2.9 to 8.3)	-9.3 (-30.5 to 23.6)	49.2 (-60.0 to -33.6)
Other meningitis	23.8 (15.4 to 36.1)	21.9 (14.5 to 32.8)	-7.6 (-29.2 to 22.7)	-49.0 (-61.9 to -29.0)	2.9 (2.0 to 4.1)	2.7 (1.9 to 4.0)	-4.7 (-27.5 to 23.0)	47.4 (-60.8 to -30.9)
Encephalitis	1.7 (0.8 to 3.5)	3.0 (1.4 to 6.0)	71.9 (53.8 to 91.6)	2.2 (-16.6 to 1.3)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.5)	9.9 (59.4 to 114.6)	-3.9 (-16.5 to 9.3)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-77.7 (-99.4 to 567.9)	-86.9 (-99.4 to 567.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-77.7 (-99.4 to 569.1)	-86.9 (-99.4 to 157.4)
Whooping cough	20.0 (15.3 to 26.1)	8.0 (6.3 to 10.3)	-60.0 (-63.8 to -55.9)	-79.8 (-81.7 to -77.8)	1.0 (0.6 to 1.6)	0.4 (0.2 to 0.6)	-59.9 (-65.3 to -53.9)	-79.8 (-82.5 to -76.8)
Tetanus	0.5 (0.3 to 0.8)	0.1 (0.1 to 0.3)	-69.3 (-86.4 to -43.4)	-83.9 (-92.0 to -71.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-71.7 (-84.9 to -57.1)	-85.1 (-90.2 to -77.8)
Measles	5.3 (3.8 to 7.2)	0.7 (0.5 to 0.9)	-87.2 (-91.1 to -83.4)	-93.9 (-95.6 to -91.7)	0.5 (0.3 to 0.8)	0.1 (0.0 to 0.1)	92.9 (93.0 to 90.3)	92.9 (-96.5 to -90.2)
Varicella and herpes zoster	5.0 (4.6 to 5.5)	10.2 (9.3 to 11.1)	103.5 (76.5 to 136.6)	4.5 (-17.6 to 35.0)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	85.9 (29.0 to 173.7)	3.9 (-29.9 to 58.5)
Neglected tropical diseases and malaria	-	-	-	-	133.9 (85.6 to 199.6)	110.9 (72.4 to 167.6)	-17.4 (-31.6 to 4.2)	-64.2 (-70.6 to -53.4)
Malaria	4,928.9 (4,584.3 to 5,289.0)	7,234.2 (6,717.6 to 7,830.5)	47.1 (38.0 to 55.8)	-26.1 (-31.5 to -21.0)	45.1 (30.2 to 64.6)	66.5 (44.7 to 96.3)	47.6 (38.9 to 55.6)	27.4 (-32.4 to -22.8)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	93.4 (40.2 to 176.1)	7.0 (-25.4 to 59.2)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.8 (34.2 to 176.9)	-6.4 (-27.2 to 29.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.8 (34.1 to 177.0)	-6.4 (-27.3 to 29.9)
Cutaneous and mucocutaneous leishmaniasis	2.2 (1.4 to 3.3)	4.2 (2.8 to 6.1)	93.5 (45.9 to 168.1)	6.7 (-23.1 to 56.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	93.4 (40.2 to 176.5)	7.0 (-25.4 to 59.3)
African trypanosomiasis	0.1 (0.0 to 0.4)	-	-100.0 (-100.0 to 0.0)	-100.0 (-100.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-100.0 (-100.0 to nan)	-100.0 (-100.0 to nan)
Schistosomiasis	4,232.7 (2,963.4 to 5,561.5)	1,225.7 (516.9 to 3,719.7)	-71.0 (-86.2 to -16.1)	-88.0 (-92.8 to -58.6)	44.3 (21.1 to 85.9)	13.7 (4.8 to 44.4)	47.3 (83.1 to -7.6)	87.0 (-91.0 to -54.0)
Cysticercosis	1.4 (0.4 to 3.6)	2.1 (0.8 to 4.8)	65.8 (-64.9 to 559.0)	-22.6 (-83.6 to 133.7)	0.4 (0.1 to 0.9)	0.6 (0.2 to 1.3)	78.3 (-66.1 to 621.4)	-17.6 (-83.0 to 166.7)
Cystic echinococcosis	2.2 (2.0 to 2.4)	2.3 (2.1 to 2.5)	6.4 (-12.3 to 17.1)	-39.5 (-46.2 to -34.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	5.6 (-19.7 to 36.8)	-39.3 (-49.4 to -27.2)
Lymphatic filariasis	205.9 (149.3 to 295.6)	95.8 (53.6 to 172.1)	-54.2 (-70.2 to -34.8)	-70.2 (-80.1 to -58.6)	8.9 (3.1 to 19.5)	7.9 (3.0 to 17.8)	-9.1 (-51.5 to 31.5)	-46.0 (-69.8 to -22.6)
Onchocerciasis	163.0 (111.5 to 228.9)	0.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	14.5 (7.2 to 24.4)	14.5 (7.2 to 24.4)	100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Trachoma	40.4 (24.6 to 56.1)	31.2 (20.0 to 45.3)	-22.3 (-41.7 to 0.7)	-50.0 (-62.1 to -35.7)	2.6 (1.4 to 4.1)	2.0 (1.1 to 3.2)	-22.4 (-40.0 to 2.8)	-49.3 (-61.5 to -29.2)
Dengue	0.5 (0.2 to 1.1)	4.3 (1.4 to 10.3)	845.5 (823.2 to 847.6)	386.8 (380.9 to 393.7)	0.1 (0.0 to 0.2)	0.7 (0.2 to 1.9)	798.2 (599.7 to 1,015.8)	357.6 (284.9 to 440.4)
Yellow fever	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-49.6 (-62.6 to -28.0)	-73.7 (-79.7 to -64.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.6 (-62.6 to -27.9)	-73.7 (-79.8 to -64.4)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.6 to 63.5	-62.7 to -14.5	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-40.0 to 64.3)	0.0 (-62.8 to -14.4)
Intestinal nematode infections	-	-	-	-	5.8 (3.5 to 8.9)	5.9 (3.6 to 9.0)	2.3 (-15.2 to 21.6)	48.4 (-58.1 to -37.3)
Ascariasis	69.1 (45.6 to 104.0)	61.2 (41.3 to 89.6)	-10.6 (-50.5 to 49.0)	-55.2 (-78.4 to -32.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.2 (-46.7 to 63.5)	-54.5 (-75.8 to -8.1)
Trichuriasis	193.1 (123.0 to 301.7)	158.1 (103.3 to 242.8)	-18.1 (-55.5 to 57.1)	-58.4 (-80.0 to -8.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.2 (-48.6 to 44.0)	-57.0 (-77.2 to -19.4)
Hookworm disease	1,441.1 (1,008.9 to 2,017.2)	1,533.6 (1,106.1 to 2,068.0)	5.6 (-35.3 to 66.1)	-45.9 (-70.7 to -6.8)	5.8 (3.5 to 8.9)	5.9 (3.6 to 9.0)	9.3 (-15.2 to 21.6)	48.4 (-58.1 to -37.3)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	149.8 (109.4 to 190.8)	301.8 (280.9 to 330.4)	102.8 (58.1 to 177.2)	2.6 (-18.4 to 35.3)	12.0 (6.2 to 23.5)	13.4 (8.9 to 19.8)	18.3 (-30.2 to 73.2)	-58.0 (-78.1 to -30.1)
Maternal disorders	-	-	-	-	3.1 (1.8 to 4.6)	4.7 (2.9 to 7.1)	52.1 (30.5 to 80.0)	-23.2 (-34.7 to -10.7)
Maternal hemorrhage	3.0 (1.9 to 3.9)	6.2 (3.3 to 9.2)	109.8 (51.1 to 259.8)	3.0 (-48.1 to 75.1)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.5)	101.8 (-7.8 to 285.9)	0.8 (-52.6 to 84.2)
Maternal sepsis and other maternal infections	3.8 (2.3 to 5.6)	6.6 (4.2 to 8.8)	73.3 (40.9 to 137.7)	-16.0 (-32.1 to 15.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	59.1 (-6.6 to 170.2)	-22.1 (-50.3 to 29.5)
Maternal hypertensive disorders	3.3 (1.3 to 5.8)	6.3 (2.5 to 10.7)	90.0 (76.1 to 108.3)	-8.4 (-14.5 to 0.8)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.6)	90.4 (61.7 to 119.9)	-8.3 (-20.4 to 5.5)
Obstructed labor	6.7 (4.3 to 9.0)	9.5 (6.2 to 12.9)	42.2 (23.9 to 56.3)	-27.0 (-36.9 to -19.2)	2.2 (1.2 to 3.4)	3.1 (1.8 to 4.8)	43.4 (22.1 to 66.5)	-26.7 (-37.8 to -16.1)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	160.2 (15.4 to 457.3)	18.2 (-39.0 to 123.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	160.2 (14.3 to 458.1)	18.2 (-39.2 to 125.5)
Other maternal disorders	-	-	-	-	0.5 (0.3 to 0.8)	0.8 (0.5 to 1.3)	63.8 (-0.1 to 176.6)	-19.5 (-50.9 to 34.0)
Neonatal disorders	-	-	-	-	3.9 (2.0 to 7.5)	13.8 (8.7 to 20.4)	275.4 (133.7 to 505.9)	105.1 (14.2 to 249.0)
Preterm birth complications	22.9 (10.6 to 42.8)	99.4 (50.1 to 175.3)	338.4 (271.7 to 446.4)	123.1 (89.9 to 172.0)	1.1 (0.6 to 1.8)	7.4 (4.3 to 11.7)	584.6 (356.4 to 1,071.7)	260.8 (145.9 to 514.0)
Neonatal encephalopathy due to birth asphyxia and trauma	67.8 (4.3 to 220.0)	91.3 (9.0 to 289.5)	40.2 (7.9 to 128.5)	-28.7 (-45.8 to 14.8)	2.0 (0.6 to 5.2)	3.5 (1.4 to 7.8)	78.7 (25.9 to 258.3)	-11.1 (-35.0 to 99.0)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.3)	0.4 (0.1 to 1.0)	245.8 (213.6 to 266.0)	82.5 (65.5 to 93.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	82.5 (211.8 to 276.7)	245.8 (64.5 to 98.8)
Hemolytic disease and other neonatal jaundice	0.9 (0.3 to 1.7)	1.0 (1.6 to 7.4)	385.1 (57.2 to 1,386.1)	189.2 (-12.1 to 886.5)	0.3 (0.1 to 0.7)	1.6 (0.6 to 3.0)	395.9 (60.7 to 1,480.9)	198.5 (-12.3 to 947.1)
Other neonatal disorders	-	-	-	-	0.4 (0.2 to 1.0)	1.2 (0.6 to 2.4)	196.0 (30.7 to 631.2)	59.7 (-34.5 to 310.5)
Nutritional deficiencies	-	-	-	-	120.5 (82.8 to 171.0)	229.2 (154.3 to 324.4)	89.8 (73.3 to 112.4)	-4.3 (-10.4 to 3.9)
Protein-energy malnutrition	102.9 (61.1 to 161.9)	203.3 (93.8 to 369.6)	89.6 (-18.1 to 339.2)	4.5 (-55.6 to 111.9)	12.6 (6.4 to 21.8)	25.0 (9.9 to 49.2)	91.6 (-7.9 to 345.6)	3.4 (-56.0 to 113.1)
Iodine deficiency	285.1 (164.4 to 429.5)	284.1 (152.9 to 437.6)	1.7 (-54.7 to 117.4)	-48.2 (-77.8 to 19.4)	5.1 (2.3 to 9.5)	5.1 (2.3 to 9.6)	2.9 (-54.1 to 119.6)	47.9 (77.5 to 19.8)
Vitamin A deficiency	20.3 (15.0 to 25.7)	23.5 (16.7 to 30.2)	14.3 (-5.8 to 40.2)	-34.8 (-45.9 to -18.5)	1.1 (0.6 to 1.6)	1.3 (0.7 to 1.9)	18.4 (-4.9 to 48.1)	-32.4 (-44.7 to -13.9)

Appendix Table G.4 - Malaria prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	2 437.1 (2 348.4 to 2 535.3)	4 860.6 (4 823.4 to 4 902.5)	99.8 (92.8 to 107.8)	2.6 (-0.1 to 7.0)	101.7 (68.8 to 145.1)	197.8 (133.4 to 281.7)	94.5 (86.2 to 99.0)	197.8 (5.4 to 1.6)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	119.5 (-35.4 to 550.4)	8.8 (-65.9 to 214.0)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	7.3 (4.8 to 10.7)	13.2 (8.7 to 19.2)	79.4 (65.4 to 102.9)	-13.2 (-20.4 to -3.1)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.5 (0.9 to 2.6)	2.6 (1.5 to 4.6)	72.3 (35.9 to 115.8)	-13.1 (-28.8 to 3.1)
Syphilis	0.9 (0.8 to 1.0)	0.9 (0.8 to 1.0)	0.3 (-16.7 to 18.3)	-41.4 (-50.0 to -32.6)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	94.9 (-23.9 to 31.4)	40.9 (-53.8 to -25.8)
Chlamydial infection	111.6 (81.0 to 150.5)	212.5 (149.4 to 306.5)	93.1 (22.0 to 185.2)	-6.3 (-39.7 to 35.9)	0.5 (0.3 to 0.9)	1.0 (0.5 to 1.7)	96.2 (13.4 to 196.2)	-3.7 (-41.4 to 43.9)
Gonococcal infection	36.0 (24.7 to 47.3)	74.2 (55.5 to 97.3)	105.4 (43.8 to 213.2)	-1.8 (-29.9 to 45.3)	0.3 (0.1 to 0.4)	0.5 (0.3 to 0.9)	95.3 (9.6 to 257.5)	-6.2 (-45.0 to 64.4)
Trichomoniasis	109.3 (63.9 to 158.6)	166.9 (80.1 to 283.6)	41.7 (-27.4 to 236.6)	-21.0 (-56.5 to 51.6)	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.8)	36.3 (-35.4 to 250.0)	-23.6 (-59.9 to 59.8)
Genital herpes	1 280.9 (1 183.6 to 1 374.8)	1 283.4 (2 018.9 to 2 358.3)	71.6 (54.0 to 89.3)	6.8 (-16.2 to 3.0)	0.6 (0.1 to 0.8)	0.6 (0.2 to 1.4)	74.9 (54.1 to 95.3)	64.4 (-16.4 to 4.6)
Other sexually transmitted diseases	3.3 (2.3 to 4.5)	4.9 (3.6 to 6.5)	49.9 (28.8 to 73.4)	-27.3 (-38.0 to -15.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	61.6 (12.2 to 133.6)	21.5 (-43.2 to 9.9)
Hepatitis	-	-	-	-	1.1 (0.7 to 1.7)	1.5 (0.9 to 2.2)	34.3 (12.8 to 58.4)	-31.8 (-44.0 to -17.6)
Hepatitis A	15.1 (14.3 to 16.0)	28.3 (26.7 to 29.9)	87.2 (87.0 to 87.5)	-2.1 (-2.2 to -1.8)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	95.8 (74.1 to 123.4)	3.6 (-7.6 to 16.6)
Hepatitis B	1 623.6 (1 335.8 to 1 878.9)	1 682.7 (1 458.2 to 1 941.0)	3.2 (-14.8 to 28.4)	-46.2 (-54.8 to -33.6)	0.7 (0.4 to 1.1)	0.7 (0.4 to 1.1)	4.8 (-2.8 to 38.7)	-43.2 (-57.5 to -24.3)
Hepatitis C	572.4 (499.5 to 642.4)	759.0 (657.5 to 848.2)	32.8 (11.4 to 58.2)	-25.5 (-35.8 to -13.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	36.9 (18.2 to 82.5)	-21.5 (-39.7 to 2.1)
Hepatitis E	3.4 (2.3 to 4.3)	6.1 (4.0 to 8.1)	79.8 (30.6 to 144.0)	-8.7 (-32.6 to 18.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	77.4 (22.1 to 152.4)	-9.3 (-36.7 to 24.9)
Leprosy	1.4 (0.9 to 2.0)	1.1 (0.9 to 1.3)	-16.6 (-35.7 to 10.4)	-41.6 (-53.7 to -24.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-11.4 (-34.5 to 26.0)	-38.4 (-13.1 to -14.6)
Other infectious diseases	109.0 (84.4 to 138.4)	218.3 (205.7 to 232.3)	100.7 (85.4 to 219.0)	1.7 (-8.3 to 12.4)	4.7 (3.0 to 6.6)	9.1 (6.0 to 13.0)	93.7 (77.5 to 129.7)	-3.9 (-12.0 to 13.4)
Non-communicable diseases	-	-	-	-	475.5 (345.7 to 612.3)	878.0 (641.8 to 1 142.1)	95.2 (80.8 to 90.3)	21.5 (0.2 to 4.9)
Neoplasms	-	-	-	-	2.1 (1.5 to 2.8)	4.4 (3.0 to 6.0)	103.4 (66.3 to 152.5)	26.6 (2.8 to 57.8)
Esophageal cancer	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	82.0 (23.9 to 159.8)	19.5 (-17.9 to 71.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	74.4 (26.7 to 137.7)	14.7 (-16.3 to 60.9)
Stomach cancer	1.6 (1.3 to 1.9)	2.4 (1.9 to 3.1)	53.5 (13.3 to 112.3)	4.2 (-23.1 to 44.2)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	54.2 (15.6 to 114.5)	5.4 (-21.0 to 44.0)
Liver cancer	-	-	-	-	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.8)	61.3 (16.5 to 125.9)	1.8 (-26.8 to 40.6)
Liver cancer due to hepatitis B	0.8 (0.6 to 1.1)	1.6 (0.9 to 2.4)	86.5 (-2.9 to 256.1)	11.7 (-43.1 to 119.0)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.4)	82.5 (1.4 to 221.7)	9.3 (-41.9 to 95.9)
Liver cancer due to hepatitis C	0.3 (0.2 to 0.5)	1.1 (0.6 to 1.8)	271.3 (74.2 to 660.0)	153.7 (20.7 to 411.3)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	246.3 (82.1 to 593.4)	132.6 (25.4 to 358.9)
Liver cancer due to alcohol use	0.4 (0.2 to 0.6)	0.3 (0.1 to 0.5)	-33.8 (-69.1 to 41.4)	-56.1 (-79.9 to -8.9)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-32.6 (-65.8 to 33.3)	-55.2 (-78.8 to -14.3)
Liver cancer due to other causes	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.7)	-12.2 (-50.2 to 55.0)	-48.7 (-71.1 to -7.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	34.0 (-47.3 to 37.5)	49.0 (-69.1 to -18.1)
Larynx cancer	0.2 (0.2 to 0.3)	0.4 (0.2 to 0.6)	95.0 (9.6 to 119.5)	3.9 (-27.1 to 49.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	53.2 (7.3 to 115.7)	2.3 (-29.0 to 46.6)
Tracheal, bronchus and lung cancer	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.4)	53.0 (17.6 to 105.9)	2.6 (-20.8 to 35.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	51.2 (15.1 to 107.2)	1.7 (-23.1 to 37.6)
Breast cancer	2.3 (1.9 to 2.8)	7.0 (5.2 to 9.6)	204.0 (114.1 to 327.1)	84.6 (31.4 to 165.2)	0.2 (0.2 to 0.3)	0.6 (0.4 to 0.9)	167.9 (89.7 to 278.6)	65.3 (15.9 to 139.9)
Cervical cancer	4.8 (3.5 to 6.2)	8.3 (5.5 to 11.6)	74.2 (14.9 to 156.8)	6.7 (-29.1 to 57.4)	0.4 (0.3 to 0.6)	0.7 (0.4 to 1.1)	75.9 (17.1 to 153.1)	7.4 (-28.4 to 56.0)
Uterine cancer	0.4 (0.3 to 0.7)	0.8 (0.4 to 1.3)	82.4 (5.4 to 211.3)	14.4 (-34.6 to 102.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	79.0 (5.2 to 208.7)	13.5 (-36.0 to 101.1)
Prostate cancer	1.0 (0.6 to 1.5)	3.4 (2.2 to 5.5)	260.2 (103.1 to 521.7)	161.6 (55.9 to 354.2)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	201.9 (83.6 to 416.7)	124.4 (38.6 to 292.7)
Colon and rectum cancer	1.0 (0.9 to 1.1)	2.5 (2.0 to 3.0)	151.8 (99.8 to 219.9)	52.6 (19.4 to 93.8)	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	132.6 (81.8 to 204.2)	40.9 (8.1 to 83.3)
Lip and oral cavity cancer	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.9)	74.6 (22.3 to 149.4)	11.5 (-23.2 to 61.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	70.0 (21.2 to 136.9)	9.0 (-23.8 to 58.1)
Nasopharynx cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	99.1 (27.1 to 215.6)	8.1 (-31.0 to 68.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.0 (26.5 to 189.3)	5.1 (-29.0 to 54.7)
Other pharynx cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	53.7 (-9.4 to 167.8)	3.8 (-36.2 to 78.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.2 (-2.8 to 140.3)	2.6 (-33.2 to 66.2)
Gallbladder and biliary tract cancer	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	71.9 (17.7 to 166.6)	14.2 (-23.7 to 72.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.5 (14.0 to 139.1)	7.4 (-26.2 to 60.5)
Pancreatic cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	113.5 (52.7 to 200.2)	37.9 (-0.8 to 98.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.7 (57.5 to 174.2)	32.6 (-0.2 to 81.8)
Malignant skin melanoma	0.4 (0.3 to 0.5)	0.9 (0.7 to 1.2)	119.2 (55.0 to 213.0)	19.2 (-5.1 to 99.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	111.7 (47.0 to 212.8)	31.1 (-7.7 to 95.4)
Non-melanoma skin cancer	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.0)	69.4 (19.8 to 203.0)	11.7 (-22.8 to 87.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	110.9 (47.7 to 213.4)	35.4 (-15.3 to 106.8)
Ovarian cancer	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.7)	144.2 (65.0 to 256.9)	49.9 (2.8 to 120.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	139.1 (54.7 to 265.9)	45.5 (6.5 to 131.7)
Testicular cancer	0.1 (0.0 to 0.1)	0.3 (0.1 to 0.4)	226.5 (76.1 to 489.1)	61.2 (-11.1 to 191.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	206.6 (58.1 to 496.2)	49.4 (-18.5 to 182.7)
Kidney cancer	0.3 (0.2 to 0.4)	0.7 (0.5 to 1.0)	152.2 (70.7 to 277.0)	69.2 (17.3 to 148.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	117.3 (61.5 to 273.6)	68.3 (11.6 to 141.7)
Bladder cancer	0.7 (0.5 to 0.9)	1.1 (0.7 to 1.5)	55.2 (7.8 to 128.5)	-1.4 (-31.6 to 42.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	53.8 (7.5 to 119.6)	-1.6 (-31.5 to 37.7)
Brain and nervous system cancer	0.3 (0.1 to 0.5)	0.8 (0.4 to 1.1)	167.8 (57.6 to 309.7)	43.4 (2.1 to 93.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	160.8 (67.7 to 281.6)	37.2 (-0.8 to 81.2)
Thyroid cancer	0.5 (0.3 to 0.7)	1.4 (0.8 to 1.9)	156.5 (75.0 to 271.4)	43.5 (-3.9 to 111.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	143.6 (62.6 to 261.8)	37.5 (-9.7 to 111.6)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.9 (-1.4 to 108.3)	47.7 (-36.6 to 39.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.5 (-40.2 to 108.2)	5.2 (-38.0 to 39.1)
Hodgkin lymphoma	0.5 (0.3 to 0.7)	1.5 (0.9 to 2.2)	184.8 (87.3 to 367.9)	63.4 (9.1 to 152.7)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	166.1 (74.8 to 330.0)	51.4 (1.3 to 130.8)
Non-Hodgkin lymphoma	0.6 (0.5 to 0.9)	1.6 (1.2 to 2.1)	157.0 (66.1 to 261.1)	44.2 (6.8 to 91.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	147.8 (66.3 to 243.2)	37.4 (3.8 to 85.9)
Multiple myeloma	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	122.2 (30.3 to 270.8)	46.2 (-18.8 to 148.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.6 (24.3 to 238.9)	38.0 (-23.4 to 138.1)
Leukemia	0.3 (0.2 to 0.4)	0.8 (0.6 to 1.0)	167.2 (81.5 to 300.4)	49.1 (0.0 to 122.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	152.8 (66.4 to 220.8)	31.6 (-10.1 to 87.0)
Other neoplasms	2.2 (1.4 to 5.1)	6.1 (4.0 to 10.3)	190.8 (50.3 to 363.5)	37.1 (-14.3 to 113.4)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	169.9 (53.5 to 305.6)	25.9 (-19.0 to 96.2)
Cardiovascular diseases	-	-	-	-	17.2 (11.7 to 23.8)	28.7 (19.1 to 40.5)	67.1 (37.8 to 99.5)	2.1 (-16.7 to 21.8)
Rheumatic heart disease	166.7 (143.8 to 186.9)	279.4 (232.3 to 320.8)	68.5 (34.1 to 107.7)	-9.6 (-25.5 to 8.9)	7.9 (5.0 to 11.9)	13.6 (8.5 to 20.0)	70.7 (37.0 to 106.9)	-6.5 (-23.2 to 12.5)
Ischemic heart disease	60.7 (41.5 to 86.9)	63.0 (52.3 to 77.0)	5.2 (-31.0 to 53.6)	-20.4 (-45.1 to 11.4)	2.3 (1.4 to 4.9)	2.5 (1.5 to 3.8)	-11.2 (-53.4 to 55.2)	-30.9 (-61.2 to 14.0)
Cerebrovascular disease	-	-	-	-	0.7 (0.5 to 0.9)	1.1 (0.7 to 1.5)	51.6 (23.6 to 84.7)	-4.1 (-20.5 to 20.2)
Ischemic stroke	3.6 (3.2 to 4.1)	5.4 (4.7 to 6.2)	48.3 (22.2 to 81.1)	-3.8 (-19.9 to 20.0)	0.5 (0.4 to 0.7)	0.8 (0.6 to 1.1)	50.4 (21.6 to 87.2)	-2.5 (-20.3 to 23.3)
Hemorrhagic stroke	1.0 (0.9 to 1.2)	1.5 (1.2 to 1.8)	50.3 (16.3 to 91.2)	-10.1 (-32.1 to 16.7)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	54.0 (16.4 to 98.3)	-8.5 (-32.7 to 20.4)
Hypertensive heart disease	12.7 (8.7 to 17.9)	19.0 (13.2 to 24.9)	49.7 (-7.7 to 142.4)	-1.5 (-38.2 to 53.2)	1.4 (0.8 to 2.2)	2.1 (1.3 to 3.1)	51.8 (-6.7 to 145.2)	0.2 (-37.0 to 56.3)
Cardiomyopathy and myocarditis	0.9 (6.0 to 11.1)	4.2 (9.2 to 17.1)	340.0 (-6.3 to 140.5)	205.8 (-41.1 to 71.8)	0.1 (0.5 to 1.4)	0.3 (0.8 to 2.1)	337.0 (-6.3 to 142.8)	205.9 (-40.7 to 74.3)
Atrial fibrillation and flutter	0.7 (0.7 to 1.3)	2.3 (2.9 to 5.7)	181.6 (181.6 to 563.5)	23.1 (36.1 to 406.0)	0.1 (0.0 to 0.1)	0.2 (0.2 to 0.5)	10.6 (176.9 to 579.2)	10.6 (39.7 to 408.7)
Peripheral vascular disease	131.1 (93.0 to 172.2)	165.7 (113.4 to 249.5)	23.1 (-18.2 to 36.3)	-10.7 (-39.8 to 59.3)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	70.7 (-41.6 to 468.4)	10.6 (-59.0 to 384.5)
Endocarditis	0.8 (0.5 to 1.2)	1.0 (0.6 to 1.5)	30.6 (-10.4 to 95.6)	-23.0 (-54.9 to 36.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	29.9 (-19.2 to 110.9)	-21.7 (-56.6 to 48.6)
Other cardiovascular and circulatory diseases	45.1 (29.5 to 67.5)	107.3 (54.1 to 167.0)	130.6 (13.9 to 346.3)	40.7 (-30.9 to 180.7)	3.2 (1.8 to 5.1)	7.6 (3.5 to 13.0)	132.6 (15.4 to 357.9)	42.6 (-29.8 to 185.9)
Chronic respiratory diseases	-	-	-	-	30.5 (20.3 to 43.6)	51.5 (34.3 to 72.0)	68.2 (45.7 to 93.5)	-1.9

Appendix Table G.4 - Malignant prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.2 (51.0 to 62.9)	-4.1 (-7.3 to -1.0)
Silicosis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	43.1 (36.5 to 50.2)	-9.2 (-13.1 to -4.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.9 (36.1 to 50.3)	-9.2 (-13.3 to -4.4)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	70.3 (63.5 to 77.5)	0.9 (-2.6 to 4.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.6 (63.2 to 78.5)	1.2 (-2.8 to 5.0)
Asthma	56.4 (43.3 to 69.8)	109.0 (84.5 to 138.6)	93.4 (42.7 to 166.7)	0.1 (-20.1 to 23.3)	2.5 (1.5 to 3.7)	4.8 (3.0 to 7.5)	95.9 (42.4 to 178.9)	1.3 (-18.3 to 26.0)
Interstitial lung disease and pulmonary sarcoidosis	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	98.1 (42.5 to 163.3)	7.8 (-17.7 to 37.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	96.5 (43.1 to 161.8)	7.6 (-17.3 to 37.2)
Other chronic respiratory diseases	-	-	-	-	7.1 (3.8 to 12.3)	11.1 (6.5 to 17.6)	56.6 (9.7 to 120.0)	-7.2 (-35.0 to 31.7)
Cirrhosis	-	-	-	-	0.7 (0.5 to 1.0)	1.0 (0.7 to 1.4)	46.6 (27.7 to 64.6)	-16.6 (-25.1 to -7.1)
Cirrhosis due to hepatitis B	1.7 (1.4 to 2.0)	1.6 (1.1 to 2.4)	-1.9 (-36.0 to 41.4)	-40.8 (-59.9 to -14.4)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	4.9 (3.7 to 52.3)	-40.4 (-60.9 to -11.3)
Cirrhosis due to hepatitis C	0.7 (0.4 to 1.0)	1.4 (0.8 to 2.1)	102.5 (-2.3 to 247.3)	25.5 (-34.4 to 101.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	106.1 (-3.8 to 258.0)	26.1 (-34.9 to 109.9)
Cirrhosis due to alcohol use	0.8 (0.6 to 1.1)	1.0 (0.7 to 1.4)	29.2 (-23.8 to 87.2)	-29.2 (-53.1 to 14.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	18.0 (-25.4 to 93.0)	28.2 (-53.3 to 13.8)
Cirrhosis due to other causes	1.0 (0.8 to 1.2)	2.0 (1.6 to 2.5)	105.9 (53.4 to 163.8)	19.2 (-15.9 to 60.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	107.3 (34.9 to 208.6)	19.2 (-23.1 to 75.8)
Digestive diseases	-	-	-	-	11.0 (7.6 to 15.2)	18.9 (13.4 to 26.1)	71.9 (49.9 to 95.1)	-1.8 (-12.6 to 9.1)
Peptic ulcer disease	54.1 (44.1 to 61.7)	67.0 (53.0 to 78.4)	24.6 (1.2 to 50.8)	-17.8 (-30.9 to -3.3)	2.1 (1.4 to 3.0)	2.7 (1.8 to 3.9)	27.0 (-0.1 to 57.1)	-17.8 (-33.4 to -0.5)
Gastritis and duodenitis	95.6 (82.2 to 106.2)	166.6 (140.7 to 190.7)	74.1 (44.4 to 112.5)	2.3 (-13.3 to 23.9)	4.3 (2.9 to 6.3)	7.2 (4.9 to 10.3)	67.0 (35.8 to 105.6)	-4.2 (-21.1 to 13.5)
Appendicitis	0.9 (0.7 to 1.2)	2.0 (1.5 to 2.6)	117.6 (56.7 to 235.1)	10.5 (-20.5 to 69.1)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	120.0 (42.8 to 259.8)	11.2 (-25.6 to 76.8)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	111.8 (45.4 to 186.9)	4.7 (-8.6 to 18.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	113.3 (33.6 to 229.3)	6.2 (-18.3 to 38.5)
Inguinal, femoral, and abdominal hernia	46.9 (35.6 to 71.3)	58.7 (47.8 to 77.6)	30.7 (-24.1 to 97.0)	-18.0 (-38.2 to 4.8)	0.5 (0.2 to 1.0)	0.6 (0.3 to 1.2)	32.7 (-24.7 to 101.6)	-17.1 (-37.6 to 5.9)
Inflammatory bowel disease	7.2 (6.9 to 7.5)	16.4 (15.7 to 17.2)	127.4 (114.6 to 143.3)	26.6 (19.7 to 33.9)	1.5 (1.0 to 2.1)	3.5 (2.4 to 4.8)	130.9 (109.6 to 153.6)	28.0 (18.0 to 39.2)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	159.2 (79.2 to 256.5)	15.9 (-20.2 to 88.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	157.2 (74.9 to 263.0)	14.1 (-29.7 to 107.4)
Gallbladder and biliary diseases	2.5 (2.2 to 2.9)	4.7 (4.2 to 5.3)	86.4 (59.5 to 120.2)	0.3 (-5.5 to 31.0)	0.5 (0.2 to 0.4)	0.5 (0.3 to 0.7)	89.1 (55.6 to 131.3)	11.6 (-7.2 to 36.2)
Pancreatitis	1.2 (1.1 to 1.3)	2.4 (2.3 to 2.6)	100.4 (86.5 to 118.4)	9.7 (2.1 to 20.1)	0.4 (0.2 to 0.5)	0.7 (0.5 to 1.0)	103.4 (70.6 to 143.1)	11.0 (-5.2 to 30.4)
Other digestive diseases	-	-	-	-	1.6 (1.0 to 2.6)	2.9 (1.9 to 4.5)	80.9 (23.8 to 163.1)	3.2 (-28.3 to 49.4)
Neurological disorders	-	-	-	-	33.8 (22.6 to 46.9)	67.7 (44.8 to 94.4)	99.8 (71.6 to 131.8)	8.2 (-4.2 to 22.0)
Alzheimer disease and other dementias	12.2 (10.5 to 13.8)	17.7 (15.5 to 20.3)	45.5 (19.7 to 75.9)	-1.8 (-17.6 to 18.1)	1.6 (1.2 to 2.2)	2.5 (1.8 to 3.2)	49.9 (23.3 to 82.1)	4.1 (-1.6 to 20.8)
Parkinson disease	0.6 (0.5 to 0.7)	0.8 (0.7 to 1.0)	40.4 (32.0 to 49.1)	0.1 (-5.6 to 5.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	42.4 (16.9 to 74.1)	1.5 (-16.5 to 21.8)
Epilepsy	18.3 (10.3 to 29.1)	30.5 (16.5 to 47.8)	66.7 (-21.4 to 238.3)	-11.9 (-59.1 to 80.4)	5.1 (2.6 to 8.9)	9.0 (4.5 to 15.7)	79.4 (-18.5 to 261.4)	-5.7 (-56.3 to 91.0)
Multiple sclerosis	0.4 (0.4 to 0.5)	0.9 (0.8 to 1.0)	107.0 (72.7 to 142.0)	12.2 (-4.6 to 28.7)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	103.8 (61.0 to 157.7)	9.5 (-13.5 to 40.8)
Migraine	541.0 (500.2 to 584.4)	999.8 (915.1 to 1,093.9)	85.4 (62.9 to 106.6)	18.4 (-15.0 to 8.5)	18.4 (10.9 to 27.4)	25.5 (20.9 to 51.1)	89.1 (63.6 to 112.0)	2.1 (-15.0 to 9.9)
Tension-type headache	936.8 (864.7 to 1,004.3)	1,862.6 (1,684.7 to 2,015.8)	99.5 (77.0 to 123.6)	3.2 (-6.9 to 13.0)	2.2 (0.7 to 2.5)	2.8 (1.3 to 5.0)	101.4 (67.8 to 125.9)	4.0 (-6.7 to 14.4)
Medication overuse headache	35.2 (23.0 to 48.3)	99.5 (64.3 to 137.0)	182.4 (114.0 to 278.2)	51.8 (11.5 to 102.5)	5.5 (3.1 to 8.8)	15.7 (8.7 to 24.8)	185.6 (116.8 to 288.0)	53.1 (13.2 to 104.8)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.1 (32.4 to 135.5)	-4.9 (-30.8 to 27.3)	1.6 (1.0 to 3.3)	2.8 (1.7 to 4.9)	71.0 (7.0 to 149.7)	12.0 (-30.7 to 66.5)
Mental and substance use disorders	-	-	-	-	144.7 (100.5 to 196.9)	285.9 (199.5 to 389.1)	97.4 (89.5 to 105.8)	3.4 (-0.6 to 7.5)
Schizophrenia	15.3 (14.0 to 16.6)	29.1 (26.5 to 31.6)	90.2 (82.7 to 100.1)	-0.0 (-3.6 to 5.0)	9.7 (7.1 to 11.9)	18.8 (13.7 to 22.8)	93.4 (79.6 to 106.5)	1.1 (-5.0 to 7.5)
Alcohol use disorders	36.4 (34.0 to 39.0)	80.6 (75.3 to 86.3)	122.1 (111.8 to 134.8)	14.6 (9.4 to 20.6)	3.5 (2.3 to 4.9)	7.8 (5.1 to 11.2)	125.1 (110.7 to 142.8)	15.8 (9.4 to 24.1)
Drug use disorders	-	-	-	-	8.9 (5.9 to 12.4)	18.2 (12.1 to 25.1)	105.3 (83.3 to 129.6)	3.0 (-7.6 to 14.2)
Opioid use disorders	11.4 (7.8 to 16.6)	23.5 (15.4 to 34.0)	105.8 (80.2 to 125.0)	3.2 (-9.9 to 12.8)	4.7 (2.8 to 7.4)	9.7 (5.7 to 15.0)	109.0 (78.3 to 132.6)	4.2 (-10.0 to 17.0)
Cocaine use disorders	2.9 (2.9 to 4.2)	7.5 (6.2 to 8.6)	144.4 (64.3 to 166.5)	0.5 (-15.8 to 27.4)	0.5 (0.3 to 0.7)	1.0 (0.6 to 1.5)	116.6 (60.9 to 185.9)	6.9 (-18.4 to 37.2)
Amphetamine use disorders	11.7 (10.7 to 12.6)	23.0 (21.3 to 25.0)	96.7 (76.0 to 120.3)	-1.0 (-11.4 to 9.7)	1.5 (0.9 to 2.3)	3.0 (1.9 to 4.5)	98.9 (68.5 to 135.8)	0.1 (-14.3 to 18.5)
Cannabis use disorders	5.3 (4.1 to 6.5)	10.5 (8.2 to 12.8)	98.9 (96.5 to 101.4)	0.7 (0.5 to 0.9)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	100.1 (58.7 to 152.2)	1.5 (-1.7 to 25.0)
Other drug use disorders	-	-	-	-	2.0 (1.3 to 3.0)	4.1 (2.6 to 6.1)	102.6 (46.6 to 177.8)	1.6 (-26.3 to 40.1)
Depressive disorders	-	-	-	-	9.4 (33.6 to 94.3)	18.5 (65.0 to 188.2)	96.8 (77.1 to 112.7)	2.1 (-4.3 to 12.2)
Major depressive disorder	258.6 (145.9 to 368.0)	502.7 (280.2 to 726.6)	94.7 (73.6 to 113.9)	3.8 (-5.9 to 12.7)	52.6 (27.4 to 85.5)	103.7 (53.7 to 172.4)	96.9 (75.5 to 116.6)	4.6 (-4.9 to 14.3)
Dysthymia	74.6 (60.6 to 89.3)	136.8 (109.7 to 165.8)	83.8 (78.0 to 88.8)	-0.6 (-0.9 to -0.3)	7.1 (4.6 to 10.2)	13.2 (8.5 to 19.2)	85.9 (78.3 to 93.3)	0.3 (-2.1 to 2.6)
Bipolar disorder	41.1 (35.7 to 46.6)	78.9 (66.7 to 90.5)	92.5 (78.5 to 104.8)	-0.8 (-6.8 to 4.5)	8.3 (5.1 to 12.4)	16.1 (9.8 to 24.3)	94.6 (84.8 to 110.0)	0.1 (-7.1 to 6.6)
Anxiety disorders	180.0 (150.2 to 214.2)	341.9 (282.9 to 408.7)	90.3 (87.2 to 93.2)	0.3 (-0.6 to -0.1)	16.5 (10.7 to 23.6)	31.8 (21.1 to 45.1)	82.3 (78.4 to 100.0)	0.5 (-2.7 to 3.6)
Eating disorders	-	-	-	-	1.8 (1.1 to 2.9)	3.7 (2.2 to 5.8)	100.4 (84.9 to 118.5)	-0.7 (-7.9 to 7.9)
Anorexia nervosa	1.3 (0.9 to 1.7)	2.6 (1.9 to 3.3)	102.9 (81.9 to 127.4)	1.6 (-8.6 to 13.3)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.9)	105.2 (60.0 to 162.8)	2.5 (-18.6 to 30.8)
Bulimia nervosa	7.5 (5.1 to 10.9)	14.8 (10.2 to 21.6)	98.0 (95.1 to 100.9)	-2.2 (-2.6 to -1.8)	1.6 (0.9 to 2.5)	3.1 (1.8 to 5.1)	99.6 (81.9 to 119.2)	-1.4 (-9.3 to 7.5)
Autistic spectrum disorders	-	-	-	-	9.4 (6.5 to 12.8)	18.5 (12.9 to 25.1)	96.8 (89.0 to 104.7)	4.1 (-1.3 to 5.3)
Autism	24.2 (22.9 to 25.5)	47.0 (44.6 to 49.5)	94.7 (94.4 to 95.1)	1.0 (0.9 to 1.0)	5.9 (4.0 to 8.2)	11.7 (7.8 to 16.1)	96.6 (85.8 to 108.0)	1.9 (-2.7 to 6.5)
Asperger syndrome	34.8 (32.6 to 36.8)	67.8 (63.6 to 72.8)	95.3 (94.9 to 95.7)	1.3 (1.2 to 1.3)	3.5 (2.4 to 4.8)	6.8 (4.7 to 9.5)	97.0 (88.0 to 105.7)	2.1 (-1.7 to 6.3)
Attention-deficit/hyperactivity disorder	59.5 (55.0 to 64.4)	114.7 (105.9 to 124.0)	93.1 (92.9 to 93.3)	0.4 (0.4 to 0.4)	0.7 (0.4 to 1.1)	1.4 (0.8 to 2.1)	94.2 (79.8 to 108.5)	1.0 (-6.4 to 8.4)
Conduct disorder	87.7 (82.7 to 92.9)	167.0 (157.6 to 177.0)	90.3 (90.7 to 91.1)	0.3 (-0.3 to 0.3)	10.5 (6.6 to 15.2)	20.5 (12.7 to 29.3)	93.5 (84.0 to 102.0)	1.5 (-3.1 to 6.0)
Idiopathic intellectual disability	184.9 (70.8 to 268.3)	341.9 (226.2 to 530.0)	90.3 (71.1 to 265.0)	11.1 (-11.4 to 99.9)	11.1 (3.3 to 14.5)	19.3 (10.2 to 29.5)	112.0 (84.0 to 271.0)	2.2 (-10.7 to 102.3)
Other mental and substance use disorders	91.7 (85.9 to 97.5)	176.4 (164.3 to 187.9)	92.6 (90.9 to 94.4)	0.8 (0.6 to 1.1)	6.8 (4.6 to 9.1)	13.3 (9.0 to 18.0)	94.9 (87.4 to 103.8)	1.8 (-1.6 to 5.6)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	50.4 (35.2 to 67.1)	101.2 (71.5 to 136.6)	100.8 (88.9 to 114.1)	13.7 (5.9 to 22.7)
Diabetes mellitus	91.1 (75.1 to 112.5)	296.4 (240.7 to 354.3)	225.6 (159.3 to 316.9)	88.6 (46.3 to 141.7)	6.9 (4.8 to 9.7)	21.2 (13.9 to 30.5)	207.8 (142.9 to 293.9)	85.0 (44.6 to 138.5)
Acute glomerulonephritis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	26.9 (14.1 to 38.1)	0.0 (-38.8 to -29.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.9 (14.1 to 38.2)	33.9 (-38.8 to -29.1)
Chronic kidney disease	-	-	-	-	13.2 (9.3 to 17.7)	23.5 (16.9 to 31.2)	78.4 (63.2 to 97.2)	-0.6 (-8.1 to 7.7)
Chronic kidney disease due to diabetes mellitus	78.0 (50.1 to 133.1)	121.9 (75.8 to 189.3)	60.1 (6.2 to 120.3)	0.3 (-36.1 to 41.3)	1.2 (0.8 to 1.8)	2.0 (1.3 to 2.9)	58.1 (13.0 to 123.6)	-2.9 (-30.9 to 39.4)
Chronic kidney disease due to hypertension	349.9 (218.1 to 611.0)	656.8 (417.8 to 1,183.3)	88.4 (44.5 to 163.5)	4.4 (-17.1 to 40.5)	3.2 (3.0 to 6.1)	7.9 (5.5 to 10.7)	79.9 (49.5 to 113.3)	-1.2 (-17.0 to 16.8)
Chronic kidney disease due to glomerulonephritis	302.9 (215.0 to 439.2)	569.1 (382.6 to 928.2)	84.9 (46.6 to 157.4)	4.5 (-18.5 to 28.6)	4.6 (3.1 to 6.3)	8.3 (5.8 to 11.3)	82.7 (45.1 to 135.8)	2.7 (-16.6 to 34.7)
Chronic kidney disease due to other causes	239.5 (136.0 to 404.7)	431.7 (247.9 to 712.9)	79.9 (35.5 to 146.8)	-3.6 (-24.2 to 23.8)	3.0 (2.0 to 4.3)	5.3 (3.7 to 7.2)	80.7 (48.1 to 134.2)	-4.0 (-25.0 to 26.3)
Urinary diseases and male infertility	-	-	-	-	2.9 (1.8 to 4.2)	4.5 (2.8 to 6.7)	53.9 (36.6 to 78.4)	0.7 (-9.2 to 13.0)

Appendix Table G.4 - Malignant prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.5 (1.4 to 1.6)	3.1 (2.9 to 3.3)	101.6 (84.0 to 120.2)	0.1 (-2.1 to 15.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	103.2 (60.6 to 160.4)	7.4 (-10.9 to 31.1)
Urolithiasis	18.8 (14.2 to 23.1)	25.0 (19.3 to 32.0)	32.3 (17.9 to 56.2)	-13.8 (-22.5 to -0.7)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	88.2 (65.1 to 116.6)	11.3 (0.3 to 24.8)
Benign prostatic hyperplasia	58.6 (53.3 to 64.1)	78.0 (71.6 to 84.8)	33.3 (18.1 to 53.1)	-1.3 (-11.8 to 11.5)	2.1 (1.4 to 3.0)	2.8 (1.8 to 4.0)	34.5 (19.0 to 54.2)	-0.1 (-10.9 to 13.2)
Male infertility due to other causes	89.0 (69.1 to 111.5)	190.5 (153.7 to 233.1)	115.8 (55.1 to 208.8)	3.3 (-25.4 to 48.3)	0.6 (0.2 to 1.2)	1.2 (0.5 to 2.5)	114.5 (55.9 to 207.2)	2.8 (-25.3 to 46.2)
Other urinary diseases	-	-	-	-	0.3 (0.0 to 0.1)	0.5 (0.0 to 0.1)	79.0 (-3.8 to 250.2)	1.5 (-44.0 to 96.8)
Gynecological diseases	-	-	-	-	9.1 (6.0 to 13.3)	17.9 (11.7 to 26.2)	95.0 (73.6 to 120.7)	-2.2 (-11.6 to 9.7)
Uterine fibroids	117.2 (106.4 to 127.2)	210.6 (189.6 to 229.8)	80.1 (78.2 to 81.7)	-5.0 (-5.1 to -5.0)	2.7 (1.7 to 4.0)	4.9 (3.2 to 7.5)	84.3 (69.6 to 110.6)	-5.0 (-12.9 to 7.7)
Polycystic ovarian syndrome	105.4 (95.3 to 117.2)	208.8 (184.8 to 232.6)	98.5 (72.7 to 129.0)	-3.4 (-15.8 to 10.3)	1.0 (0.5 to 1.9)	2.0 (1.0 to 3.8)	100.5 (72.5 to 131.3)	-2.9 (-15.6 to 11.0)
Female infertility due to other causes	84.6 (66.5 to 103.6)	145.1 (108.9 to 186.9)	71.5 (22.2 to 143.0)	-15.5 (-40.9 to 21.2)	0.4 (0.2 to 0.9)	0.7 (0.3 to 1.6)	71.2 (20.6 to 141.3)	15.4 (-40.6 to 20.9)
Endometriosis	10.5 (8.9 to 12.0)	19.3 (16.4 to 22.2)	83.5 (50.6 to 129.2)	-10.6 (-26.4 to 10.7)	1.0 (0.6 to 1.4)	1.8 (1.2 to 2.6)	85.4 (48.8 to 135.5)	-10.0 (-27.7 to 13.9)
Genital prolapse	268.7 (236.4 to 301.4)	469.8 (406.5 to 531.2)	74.8 (44.9 to 111.9)	-1.6 (-15.6 to 15.5)	0.8 (0.4 to 1.6)	1.5 (0.7 to 2.8)	76.0 (45.8 to 112.7)	-1.0 (-15.9 to 16.8)
Premenstrual syndrome	241.7 (175.4 to 314.6)	524.6 (381.7 to 676.0)	116.1 (48.3 to 229.0)	5.5 (-28.8 to 57.4)	2.0 (1.1 to 3.2)	4.4 (2.5 to 7.1)	117.8 (47.3 to 233.2)	6.7 (-28.1 to 60.3)
Other gynecological diseases	30.2 (13.6 to 46.9)	63.6 (53.4 to 74.5)	111.1 (35.8 to 361.8)	5.4 (-31.9 to 126.9)	1.2 (0.5 to 1.9)	2.5 (1.4 to 3.6)	103.3 (55.1 to 471.8)	1.1 (-24.1 to 175.7)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	13.4 (9.1 to 18.6)	24.7 (16.9 to 34.8)	84.6 (69.1 to 103.6)	9.3 (-12.9 to 5.5)
Thalassemias	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	95.1 (83.2 to 112.7)	-1.9 (-8.4 to 6.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.2 (77.2 to 107.6)	-4.2 (-12.0 to 3.6)
Thalassemia trait	73.8 (68.7 to 79.1)	143.9 (135.5 to 153.4)	95.1 (89.3 to 104.1)	1.5 (-1.6 to 6.1)	1.0 (1.0 to 2.0)	2.7 (1.8 to 3.9)	84.0 (55.4 to 121.1)	-6.1 (-21.4 to 13.1)
Sickle cell disorders	24.9 (22.5 to 26.9)	49.9 (45.8 to 53.9)	101.2 (80.8 to 122.7)	1.7 (-8.5 to 11.7)	2.6 (1.8 to 3.5)	5.1 (3.6 to 6.9)	98.1 (72.8 to 135.6)	1.3 (-10.4 to 18.2)
Sickle cell trait	1,109.9 (1,029.6 to 1,182.6)	2,078.7 (1,921.6 to 2,221.0)	87.6 (81.8 to 94.4)	-2.4 (-5.4 to 1.1)	9.4 (3.6 to 7.6)	9.5 (6.2 to 13.7)	79.6 (44.5 to 107.0)	9.3 (-19.9 to 5.3)
G6PD deficiency	355.9 (308.6 to 403.2)	685.0 (587.5 to 781.3)	93.3 (57.8 to 136.5)	0.5 (-17.9 to 22.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	84.1 (40.5 to 140.8)	-4.9 (-17.7 to 10.6)
G6PD trait	1,132.1 (1,075.4 to 1,183.8)	2,095.1 (1,955.9 to 2,216.5)	85.5 (71.2 to 100.1)	-3.5 (-10.9 to 4.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	91.5 (25.9 to 180.1)	-0.5 (-30.5 to 40.9)
Other hemoglobinopathies and hemolytic anemias	111.0 (90.8 to 132.4)	208.0 (190.8 to 227.4)	88.1 (56.6 to 132.3)	-0.4 (-16.8 to 21.8)	3.9 (2.4 to 5.6)	7.2 (4.8 to 10.5)	83.5 (60.0 to 150.1)	-4.7 (-18.8 to 34.0)
Endocrine, metabolic, blood, and immune disorders	125.9 (106.5 to 144.2)	241.2 (187.8 to 287.5)	91.7 (42.6 to 160.2)	5.0 (-22.3 to 27.4)	9.4 (2.9 to 7.3)	9.4 (5.8 to 13.6)	89.9 (34.7 to 173.3)	-2.0 (-27.0 to 31.4)
Musculoskeletal disorders	-	-	-	-	76.1 (54.4 to 101.4)	133.9 (94.0 to 177.3)	75.3 (63.0 to 93.6)	1.0 (-4.8 to 9.3)
Rheumatoid arthritis	11.3 (10.9 to 11.8)	13.5 (12.9 to 14.1)	19.1 (12.0 to 26.9)	-34.5 (-38.7 to -30.0)	2.7 (1.9 to 3.5)	3.2 (2.3 to 4.3)	21.6 (10.5 to 33.4)	-33.7 (-39.4 to -28.1)
Osteoarthritis	164.6 (157.7 to 170.7)	248.0 (237.6 to 258.0)	51.1 (42.0 to 59.8)	1.4 (-4.2 to 7.0)	10.0 (7.0 to 13.5)	15.2 (10.7 to 20.7)	52.7 (45.1 to 61.5)	2.5 (-3.5 to 8.4)
Low back and neck pain	-	-	-	-	51.0 (35.4 to 69.0)	93.7 (64.6 to 126.1)	62.9 (64.7 to 111.1)	0.7 (-8.5 to 14.0)
Low back pain	246.4 (232.7 to 260.2)	443.1 (417.4 to 473.6)	80.0 (66.0 to 96.2)	1.2 (-6.7 to 10.3)	2.2 (1.8 to 3.7)	49.7 (33.5 to 69.3)	82.8 (67.9 to 99.1)	2.4 (-5.8 to 11.1)
Neck pain	244.7 (200.5 to 286.2)	445.9 (381.2 to 510.3)	81.0 (45.0 to 141.6)	-2.2 (-19.7 to 26.8)	23.8 (15.7 to 34.1)	44.0 (29.0 to 63.0)	82.9 (46.6 to 144.8)	-1.1 (-19.5 to 28.7)
Gout	0.7 (0.6 to 0.8)	1.1 (0.9 to 1.2)	58.1 (35.3 to 87.3)	-1.3 (-15.6 to 16.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	60.5 (25.8 to 104.2)	-0.4 (-22.8 to 26.5)
Other musculoskeletal disorders	139.3 (107.3 to 174.3)	238.4 (181.7 to 296.7)	71.5 (57.8 to 87.2)	6.7 (-2.4 to 14.0)	12.5 (8.0 to 18.2)	21.7 (13.8 to 32.2)	89.9 (58.8 to 91.2)	7.1 (-1.1 to 16.0)
Other non-communicable diseases	-	-	-	-	106.9 (70.5 to 155.2)	184.9 (123.3 to 270.2)	72.9 (65.0 to 81.2)	-2.7 (-6.2 to 0.9)
Congenital anomalies	-	-	-	-	4.1 (2.5 to 6.4)	8.9 (5.9 to 12.7)	118.4 (70.0 to 179.9)	15.6 (-10.4 to 48.7)
Neural tube defects	0.2 (0.2 to 0.3)	1.3 (1.1 to 1.6)	443.8 (310.6 to 615.1)	230.7 (145.6 to 342.9)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.5)	474.9 (307.2 to 715.8)	261.0 (157.9 to 406.3)
Congenital heart anomalies	2.1 (1.5 to 3.0)	12.1 (8.4 to 16.3)	463.2 (246.9 to 818.9)	241.1 (106.6 to 481.3)	0.1 (0.0 to 0.2)	0.4 (0.2 to 0.8)	334.2 (133.8 to 640.0)	149.5 (35.4 to 334.2)
Orofacial clefts	0.2 (0.2 to 0.3)	7.4 (0.8 to 1.8)	258.7 (229.8 to 794.9)	98.2 (100.8 to 487.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	447.0 (197.9 to 793.7)	254.8 (86.7 to 491.9)
Down syndrome	2.1 (1.6 to 2.6)	7.4 (6.0 to 9.1)	258.7 (162.2 to 409.4)	98.2 (44.7 to 185.0)	0.2 (0.2 to 0.4)	0.9 (0.6 to 1.2)	261.2 (152.2 to 436.7)	101.5 (42.9 to 200.2)
Turner syndrome	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	215.7 (115.2 to 440.0)	65.7 (12.0 to 191.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	220.1 (116.8 to 452.0)	67.1 (12.0 to 195.4)
Klinefelter syndrome	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	93.4 (25.5 to 203.7)	0.8 (-34.7 to 59.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.7 (31.7 to 221.6)	2.8 (-33.4 to 63.3)
Chromosomal unbalanced rearrangements	3.4 (2.7 to 4.2)	12.1 (10.3 to 14.0)	362.3 (169.5 to 377.9)	89.4 (46.4 to 166.9)	0.4 (0.2 to 0.6)	1.4 (1.0 to 1.9)	259.7 (160.3 to 334.3)	101.5 (46.6 to 178.3)
Other congenital anomalies	35.4 (26.0 to 47.7)	62.1 (46.5 to 79.8)	76.4 (47.5 to 111.0)	-6.3 (-21.0 to 10.7)	3.3 (1.8 to 5.5)	5.8 (3.5 to 9.4)	77.9 (30.3 to 141.8)	-6.2 (-32.3 to 27.5)
Skin and subcutaneous diseases	-	-	-	-	35.3 (21.9 to 55.4)	66.5 (40.8 to 108.2)	88.1 (71.4 to 106.4)	0.6 (-8.3 to 9.0)
Dermatitis	316.1 (249.5 to 389.3)	606.8 (473.6 to 754.3)	92.2 (89.8 to 94.9)	-0.2 (-0.4 to 0.1)	8.7 (5.5 to 12.8)	16.7 (10.5 to 25.0)	93.5 (86.4 to 100.6)	0.6 (-2.2 to 3.2)
Psoriasis	50.9 (41.9 to 62.7)	94.6 (77.2 to 116.8)	86.2 (81.7 to 90.5)	0.0 (-0.1 to 0.2)	4.1 (2.7 to 6.0)	7.8 (5.1 to 11.3)	88.3 (76.0 to 101.6)	1.0 (-4.4 to 6.4)
Cellulitis	1.5 (1.2 to 1.9)	2.8 (2.2 to 3.6)	88.5 (57.9 to 118.5)	-4.6 (-20.6 to 10.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	90.0 (37.4 to 160.9)	-4.3 (-25.6 to 24.5)
Pyoderma	13.9 (10.2 to 17.9)	25.1 (18.7 to 32.4)	81.2 (70.5 to 94.6)	-4.1 (-10.5 to 3.0)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	82.3 (64.7 to 103.8)	-3.5 (-12.6 to 6.8)
Scabies	156.0 (125.8 to 190.1)	214.2 (166.2 to 270.8)	37.3 (1.2 to 87.1)	-23.8 (-46.4 to 3.7)	4.0 (2.2 to 6.6)	5.5 (2.9 to 9.4)	37.6 (18.0 to 87.8)	-23.6 (-46.3 to 4.7)
Fungal skin diseases	939.3 (678.5 to 1,305.1)	1,794.9 (1,286.2 to 2,527.0)	91.4 (87.6 to 95.0)	0.4 (-0.2 to 0.5)	1.4 (0.2 to 1.1)	3.4 (3.9 to 22.8)	102.6 (88.5 to 96.4)	1.0 (-0.2 to 1.8)
Viral skin diseases	116.8 (92.2 to 141.4)	222.9 (172.9 to 276.5)	91.2 (78.0 to 104.6)	-1.8 (-7.2 to 3.2)	3.6 (2.2 to 5.4)	6.9 (4.2 to 10.6)	92.3 (73.3 to 108.3)	-1.2 (-7.7 to 5.1)
Acne vulgaris	438.1 (317.2 to 615.5)	937.3 (624.1 to 1,259.7)	112.5 (31.8 to 227.5)	10.8 (-29.4 to 65.9)	4.7 (2.1 to 8.8)	10.1 (4.4 to 20.6)	113.7 (32.7 to 231.6)	11.4 (-29.2 to 67.6)
Alopecia areata	6.9 (6.2 to 7.6)	13.4 (11.8 to 15.0)	94.9 (66.6 to 126.8)	2.9 (-13.0 to 19.3)	0.2 (0.1 to 0.4)	0.5 (0.3 to 0.7)	96.7 (59.6 to 138.9)	3.9 (-15.5 to 23.7)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.1 (44.2 to 126.3)	0.2 (-21.8 to 24.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.1 (44.2 to 126.7)	-0.2 (-22.0 to 24.3)
Urticaria	30.8 (15.1 to 52.6)	65.1 (39.5 to 94.6)	122.3 (7.6 to 346.5)	21.8 (-37.2 to 116.6)	1.8 (0.8 to 3.4)	3.9 (2.0 to 6.5)	123.0 (81.1 to 360.8)	23.2 (-38.1 to 122.0)
Decubitus ulcer	0.7 (0.6 to 0.8)	1.2 (1.0 to 1.4)	87.3 (45.9 to 135.0)	7.7 (-21.5 to 53.3)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	90.0 (45.3 to 139.3)	9.7 (-20.0 to 57.2)
Other skin and subcutaneous diseases	450.1 (304.4 to 664.8)	745.6 (504.5 to 1,060.4)	66.6 (50.6 to 81.7)	-4.5 (-10.7 to -0.2)	2.6 (1.2 to 5.6)	4.4 (2.0 to 9.9)	68.0 (51.6 to 83.0)	-3.8 (-9.8 to 0.8)
Sense organ diseases	-	-	-	-	58.1 (38.9 to 84.3)	92.7 (62.4 to 134.1)	59.3 (49.9 to 69.9)	-6.7 (-9.0 to 3.3)
Glaucoma	11.6 (9.1 to 14.4)	31.7 (25.6 to 39.0)	175.6 (115.6 to 233.6)	62.0 (27.7 to 99.4)	1.0 (0.7 to 1.5)	2.5 (1.7 to 3.6)	147.1 (91.7 to 205.9)	45.0 (11.0 to 82.6)
Cataract	40.9 (30.7 to 51.0)	75.3 (54.2 to 94.9)	83.5 (49.1 to 133.6)	22.1 (0.4 to 50.0)	4.3 (2.7 to 6.2)	7.4 (4.6 to 10.8)	70.0 (36.3 to 118.7)	13.4 (-6.9 to 42.4)
Macular degeneration	3.2 (2.1 to 4.5)	20.0 (14.7 to 26.4)	544.7 (310.1 to 908.1)	309.8 (170.2 to 516.2)	0.2 (0.1 to 0.3)	1.2 (0.7 to 1.8)	448.9 (247.6 to 739.6)	224.0 (116.6 to 379.1)
Uncorrected refractive error	664.0 (607.3 to 725.4)	997.5 (905.7 to 1,095.1)	50.7 (33.7 to 68.9)	-12.5 (-20.7 to -3.7)	17.1 (11.5 to 24.1)	24.2 (16.3 to 35.1)	41.7 (31.1 to 52.8)	-17.4 (-21.4 to -12.1)
Age-related and other hearing loss	1,012.3 (863.6 to 1,139.5)	1,555.4 (1,314.2 to 1,770.5)	53.9 (45.9 to 63.1)	-5.9 (-9.5 to -2.1)	27.7 (16.8 to 41.9)	42.2 (25.0 to 66.1)	51.8 (33.8 to 73.1)	-10.7 (-17.9 to -3.5)
Other vision loss	26.5 (21.7 to 32.4)	54.0 (45.2 to 64.5)	105.8 (74.4 to 134.1)	27.7 (8.5 to 44.7)	2.8 (1.7 to 4.1)	5.6 (3.6 to 8.0)	103.4 (66.8 to 136.8)	13.2 (1.1 to 41.7)
Other sense organ diseases	191.5 (181.9 to 201.3)	362.3 (342.8 to 382.6)	89.6 (76.2 to 104.8)	-0.3 (-5.8 to 5.9)	5.1 (3.1 to 7.5)	9.7 (5.9 to 14.4)	91.1 (74.3 to 108.9)	0.5 (-6.2 to 7.9)
Oral disorders	-	-	-	-	9.4 (5.2 to 15.6)	16.9 (9.2 to 27.9)	78.2 (61.9 to 91.1)	-2.3 (-8.1 to 6.0)
Deciduous caries	800.4 (763.5 to 837.7)	1,584.0 (1,507.7 to 1,664.6)	98.7 (85.7 to 111.6)	0.2 (-6.3 to 6.7)	0.2 (0.1 to 0.6)	0.6		

Appendix Table G.4 - Malt prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	34.1 (31.1 to 36.7)	44.5 (41.1 to 47.8)	31.0 (16.4 to 46.1)	-12.4 (-21.7 to -2.8)	0.9 (0.6 to 1.3)	1.2 (0.8 to 1.7)	33.5 (16.7 to 49.4)	-11.5 (-21.1 to -1.2)
Other oral disorders	113.2 (106.9 to 121.1)	211.3 (198.4 to 223.8)	86.8 (75.4 to 99.9)	-0.9 (-6.4 to 5.7)	3.3 (2.0 to 4.9)	6.2 (3.9 to 9.3)	88.5 (75.4 to 103.0)	-0.1 (-6.2 to 7.3)
Injuries	-	-	-	-	27.8 (21.3 to 35.6)	43.9 (33.8 to 56.6)	58.3 (52.7 to 63.2)	-7.6 (-10.2 to -4.9)
Transport injuries	-	-	-	-	10.0 (7.6 to 13.1)	15.5 (11.7 to 20.0)	54.5 (47.7 to 61.8)	-9.5 (-12.9 to -5.9)
Road injuries	-	-	-	-	8.3 (6.8 to 11.6)	13.6 (10.3 to 17.6)	51.9 (44.5 to 59.5)	-11.3 (-14.8 to -7.5)
Pedestrian road injuries	-	-	-	-	2.3 (1.7 to 3.0)	3.3 (2.4 to 4.2)	40.0 (29.3 to 53.0)	-16.3 (-21.2 to -10.9)
Cyclist road injuries	-	-	-	-	0.8 (0.6 to 1.0)	1.0 (0.7 to 1.3)	23.2 (15.9 to 32.4)	-22.1 (-26.7 to -16.6)
Motorcyclist road injuries	-	-	-	-	1.3 (1.0 to 1.7)	1.7 (1.3 to 2.2)	27.7 (18.4 to 36.2)	-27.0 (-31.4 to -22.4)
Motor vehicle road injuries	-	-	-	-	4.4 (3.3 to 5.6)	7.5 (5.7 to 9.7)	72.2 (59.9 to 85.6)	-0.9 (-7.3 to 5.3)
Other road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	13.1 (5.3 to 19.8)	-36.9 (-40.5 to -33.6)
Other transport injuries	-	-	-	-	1.1 (0.8 to 1.4)	1.9 (1.4 to 2.5)	75.9 (65.3 to 86.4)	4.9 (-2.0 to 11.5)
Unintentional injuries	-	-	-	-	16.1 (12.4 to 20.7)	26.2 (20.0 to 33.8)	63.1 (59.2 to 67.8)	-6.2 (-8.5 to -3.3)
Falls	-	-	-	-	6.4 (4.9 to 8.3)	10.9 (8.2 to 14.1)	68.8 (60.8 to 77.0)	-3.1 (-7.5 to 1.4)
Drowning	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	38.1 (24.3 to 54.2)	-21.9 (-28.2 to -15.0)
Fire, heat, and hot substances	-	-	-	-	1.0 (0.8 to 1.3)	1.5 (1.1 to 1.9)	46.5 (34.5 to 59.9)	-16.7 (-22.1 to -10.6)
Poisonings	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	39.0 (13.2 to 66.2)	-25.3 (-37.3 to -13.3)
Exposure to mechanical forces	-	-	-	-	5.0 (3.8 to 6.5)	8.1 (6.2 to 10.7)	62.8 (55.8 to 69.5)	-9.1 (-12.6 to -5.5)
Unintentional firearm injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.4)	59.2 (46.9 to 72.2)	-10.7 (-17.0 to -3.7)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	113.9 (89.1 to 138.8)	19.5 (6.7 to 31.6)
Other exposure to mechanical forces	-	-	-	-	4.7 (3.6 to 6.2)	7.7 (5.9 to 10.1)	62.4 (55.3 to 69.6)	-9.3 (-13.1 to -5.5)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	92.0 (79.1 to 104.2)	15.4 (7.5 to 23.5)
Animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	62.6 (51.4 to 73.9)	-7.5 (-12.7 to -2.1)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	63.5 (43.5 to 85.6)	-8.5 (-18.3 to 1.7)
Non-venomous animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	61.9 (53.8 to 70.4)	-6.7 (-10.8 to -2.1)
Foreign body	-	-	-	-	0.3 (0.3 to 0.4)	0.6 (0.4 to 0.7)	78.3 (69.4 to 87.8)	1.7 (-2.9 to 6.6)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	69.4 (49.1 to 91.2)	-0.5 (-9.0 to 8.0)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	90.9 (70.7 to 112.7)	0.1 (-9.5 to 8.5)
Foreign body in other body part	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.4)	78.0 (67.0 to 89.9)	3.0 (-3.7 to 9.7)
Other unintentional injuries	-	-	-	-	2.5 (1.9 to 3.2)	3.9 (2.9 to 5.0)	56.6 (47.5 to 69.5)	-7.5 (-12.9 to -0.6)
Self-harm and interpersonal violence	-	-	-	-	0.7 (0.5 to 0.9)	1.1 (0.9 to 1.4)	70.8 (63.0 to 77.6)	-5.0 (-9.0 to -1.4)
Self-harm	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	81.8 (66.6 to 96.6)	4.3 (-3.0 to 11.6)
Interpersonal violence	-	-	-	-	0.6 (0.4 to 0.7)	1.0 (0.7 to 1.2)	68.8 (60.1 to 76.7)	-7.2 (-11.4 to -3.2)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	72.3 (60.3 to 83.6)	-4.6 (-10.4 to 1.1)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	95.2 (83.4 to 108.0)	6.2 (-0.2 to 13.4)
Assault by other means	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.8)	61.6 (52.0 to 72.1)	-11.3 (-16.2 to -5.9)
Forces of nature, war, and legal intervention	-	-	-	-	1.0 (0.4 to 2.3)	1.0 (0.4 to 2.5)	5.7 (-40.2 to 103.2)	-15.9 (52.9 to 62.0)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.3)	2,837.0 (1,376.9 to 6,649.8)	1,359.3 (647.5 to 3,103.5)
Collective violence and legal intervention	-	-	-	-	1.0 (0.4 to 2.3)	0.9 (0.3 to 2.3)	-6.9 (-53.2 to 86.8)	-23.1 (-61.6 to 54.8)

Appendix Table G.4 - Malta prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
All causes	-	-	-	-	44.1 (33.1 to 56.8)	59.1 (44.2 to 76.5)	34.0 (29.6 to 39.1)	-1.8 (-5.1 to 1.9)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.2 (1.6 to 3.1)	2.2 (1.5 to 3.0)	-3.7 (-12.1 to 4.4)	1.4 (-7.5 to 8.7)
HIV/AIDS and tuberculosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.1 (8.6 to 31.7)	-3.0 (-20.3 to 14.7)
Tuberculosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	14.2 (9.4 to 20.1)	-1.1 (-5.1 to 3.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.1 (-6.9 to 37.8)	-0.1 (-18.9 to 21.0)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-48.0 to 44.7)	-31.7 (-60.7 to 16.7)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.3 (-77.1 to -7.1)	-58.2 (-80.9 to -38.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.3 (-77.2 to -6.4)	-58.2 (-80.9 to -17.5)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	43.9 (-2.4 to 128.4)	12.0 (-25.0 to 83.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.5 (-48.0 to 44.8)	-31.7 (-60.7 to 17.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.2 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-21.1 (-31.2 to -10.3)	-29.2 (-38.8 to -20.2)
Diarrheal diseases	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-8.0 (-28.2 to 10.5)	-11.5 (-34.9 to 10.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-31.7 to 12.9)	-10.9 (-36.8 to 13.9)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-78.3 to 12.7)	-33.8 (-77.8 to 9.7)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.8 (-54.4 to 2.8)	-33.6 (-53.9 to -2.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.8 (-54.4 to 3.0)	-33.6 (-53.9 to -2.0)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.9 (-41.3 to 35.8)	-8.3 (-35.9 to 40.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.9 (-41.4 to 36.3)	-8.3 (-42.3 to 40.4)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-98.0 to 362.2)	-42.7 (-98.0 to 378.4)
Lower respiratory infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.4 (-15.8 to 11.8)	-21.4 (-31.7 to -10.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.0 (-22.4 to 18.4)	-20.0 (-34.9 to -1.4)
Upper respiratory infections	5.9 (5.6 to 6.1)	6.4 (6.1 to 6.7)	8.8 (2.5 to 16.4)	1.8 (-4.1 to 8.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	8.2 (0.8 to 17.0)	2.0 (-5.1 to 10.1)
Otitis media	5.1 (4.4 to 5.8)	4.8 (4.2 to 5.5)	-3.9 (-20.0 to 12.5)	-15.0 (-27.7 to -1.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-3.9 (-20.6 to 12.5)	-15.4 (-27.7 to -2.3)
Meningitis	-	-	-	-	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-60.4 (-70.3 to -46.1)	-65.2 (-74.1 to -52.9)
Pneumococcal meningitis	0.3 (0.2 to 0.5)	0.1 (0.1 to 0.3)	-55.4 (-68.9 to -38.3)	-65.5 (-76.4 to -52.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.9 (-69.8 to -40.5)	-62.3 (-75.2 to -50.0)
H influenzae type B meningitis	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.2)	-71.5 (-86.2 to -47.7)	-75.1 (-87.3 to -53.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (-86.4 to -44.0)	-73.8 (-87.3 to -47.5)
Meningococcal meningitis	0.1 (0.1 to 0.4)	0.1 (0.0 to 0.2)	-55.6 (-73.3 to -35.0)	-65.0 (-78.3 to -45.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-72.8 to -22.7)	-53.5 (-68.3 to -33.5)
Other meningitis	0.3 (0.1 to 0.5)	0.1 (0.1 to 0.3)	-58.0 (-72.3 to -40.9)	-64.8 (-74.6 to -46.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (-72.7 to -24.8)	-56.2 (-75.6 to -30.6)
Encephalitis	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	42.9 (8.1 to 84.2)	5.2 (-18.9 to 39.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.9 (20.0 to 99.6)	16.2 (-9.0 to 52.6)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.4 (-94.4 to 318.3)	-55.7 (-94.8 to 339.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-94.4 to 322.3)	-55.7 (-94.8 to 343.4)
Whooping cough	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-72.8 (-74.1 to -71.3)	-57.5 (-59.7 to -55.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-72.7 (-77.2 to -68.1)	-57.4 (-64.4 to -50.3)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.0 (-73.6 to -27.6)	-53.5 (-78.2 to -36.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.1 (-72.3 to -28.7)	-52.4 (-76.5 to -36.2)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-66.0 (-100.0 to 88.0)	-65.9 (-100.0 to 193.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-65.9 (-100.0 to 89.1)	-46.9 (-100.0 to 195.0)
Varicella and herpes zoster	0.3 (0.3 to 0.3)	0.4 (0.3 to 0.4)	14.4 (-6.6 to 38.9)	-1.2 (-16.6 to 16.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.3 (5.6 to 86.5)	-2.5 (-25.6 to 29.1)
Neglected tropical diseases and malaria	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-53.1 to -14.4)	-36.5 (-64.1 to -35.8)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.5 (-75.3 to 483.0)	3.6 (-76.2 to 468.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.3 (-75.1 to 496.6)	6.3 (-76.2 to 473.0)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.5 (19.6 to 175.4)	71.0 (-0.2 to 152.8)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.3 (22.8 to 181.7)	72.6 (2.8 to 158.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.0 (19.7 to 179.6)	73.4 (0.7 to 157.8)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.0 (-52.6 to 88.0)	-15.5 (-61.4 to 52.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.0 (-52.7 to 88.1)	-15.5 (-61.7 to 53.3)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-65.9 (-84.2 to -0.1)	-75.5 (-88.9 to -34.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.2 (-83.3 to 9.2)	-73.7 (-88.1 to -27.7)
Cystic echinococcosis	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-39.3 (-43.9 to -35.5)	-56.2 (-59.0 to -51.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-51.7 to -25.1)	-55.6 (-63.9 to -45.7)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.1 (-62.1 to 14.4)	-16.8 (-46.6 to -9.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.1 (-62.2 to 14.4)	-16.8 (-66.7 to -0.8)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Ascariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trichuriasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hookworm disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.0 (49.1 to 143.9)	78.4 (28.6 to 129.4)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.7 (-66.8 to -10.1)	-39.4 (-66.2 to -9.0)
Maternal hemorrhage	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-12.7 (-52.9 to 60.2)	-10.1 (-51.3 to 66.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.1 (-77.2 to 8.6)	-37.8 (-78.8 to 9.6)
Maternal sepsis and other maternal infections	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-59.5 (-88.3 to 51.6)	-56.2 (-87.1 to 56.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.4 (-78.2 to -11.2)	-56.9 (-77.0 to -5.1)
Maternal hypertensive disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.9 (-43.9 to -31.2)	-35.7 (-42.4 to -29.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.5 (-54.9 to -11.4)	-35.9 (-53.9 to -10.7)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.7 (-76.4 to 108.9)	-30.7 (-76.0 to 128.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.7 (-76.4 to 109.4)	-30.7 (-76.0 to 128.9)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.5 (-38.4 to -24.1)	-29.8 (-36.9 to -22.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.5 (-38.4 to -24.1)	-29.8 (-36.9 to -22.2)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-68.8 to 18.2)	-
Neonatal disorders	-	-	-	-	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.7)	61.1 (24.9 to 104.2)	51.0 (17.2 to 92.7)
Preterm birth complications	1.8 (1.3 to 2.6)	3.4 (2.5 to 4.7)	85.2 (49.7 to 127.4)	67.2 (35.3 to 105.5)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.5)	84.1 (49.4 to 135.6)	71.4 (39.2 to 120.5)
Neonatal encephalopathy due to birth asphyxia and trauma	0.4 (0.3 to 0.9)	0.1 (0.2 to 0.9)	-3.8 (-32.5 to 26.3)	-10.1 (-36.2 to 18.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-5.2 (-38.1 to 32.4)	-8.3 (-40.2 to 28.3)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.1 (-35.0 to 2,092.0)	150.9 (0.6 to 3,292.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.1 (-35.0 to 2,111.5)	150.9 (0.6 to 3,323.1)
Hemolytic disease and other neonatal jaundice	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-28.1 (-89.6 to 139.1)	-33.2 (-90.3 to 119.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-23.1 (-88.9 to 154.5)	-29.7 (-89.7 to 135.4)
Other neonatal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	3,039.2 (60.2 to 5,756.4)	2,835.7 (51.2 to 5,345.3)
Nutritional deficiencies	-	-	-	-	1.4 (0.9 to 2.1)	1.2 (0.8 to 1.8)	-14.8 (-28.7 to -5.2)	-2.2 (-20.2 to 7.0)
Protein-energy malnutrition	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.4 (-72.4 to -20.1)	-57.4 (-73.4 to -41.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-72.5 to -19.8)	0.0 (-79.4 to -41.2)
Iodine deficiency	6.8 (2.0 to 12.9)	5.7 (3.2 to 9.4)	-15.6 (-65.9 to 208.4)	-28.4 (-70.8 to 156.9)	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.2)	-14.8 (-65.9 to 215.9)	-28.2 (-70.8 to 162.9)
Vitamin A deficiency	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-

Appendix Table G.4 - Malta prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	47.7 (46.6 to 48.7)	47.4 (44.0 to 48.8)	-0.2 (-7.8 to 3.6)	-1.3 (-8.8 to 5.2)	1.3 (0.9 to 1.9)	1.1 (0.7 to 1.6)	-14.5 (-27.6 to -9.9)	-14.5 (-17.5 to 4.6)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-	-
Sexually transmitted diseases excluding HIV	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-	-
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	126.7 (77.4 to 186.6)	48.5 (14.1 to 81.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Chlamydial infection	7.9 (5.1 to 11.4)	8.0 (5.9 to 10.2)	2.4 (-36.4 to 52.8)	-1.7 (-39.8 to 49.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Gonococcal infection	1.1 (0.7 to 1.5)	1.1 (0.8 to 1.5)	-0.8 (-38.4 to 53.1)	-1.8 (-42.2 to 56.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trichomoniasis	1.0 (0.6 to 1.6)	1.2 (0.8 to 1.5)	17.2 (-30.9 to 117.3)	17.4 (-35.6 to 116.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Genital herpes	44.5 (38.6 to 51.0)	57.6 (50.1 to 65.1)	29.4 (5.6 to 56.5)	5.4 (-23.4 to 15.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other sexually transmitted diseases	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-31.5 (-52.8 to -1.8)	-28.8 (-50.9 to 1.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hepatitis A	0.3 (0.3 to 0.3)	0.3 (0.3 to 0.3)	-8.1 (-8.2 to -8.1)	-8.3 (-9.4 to -7.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hepatitis B	5.2 (4.3 to 6.5)	4.2 (3.1 to 5.4)	-18.3 (-44.3 to 11.0)	-34.8 (-54.8 to -12.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hepatitis C	6.5 (5.9 to 7.3)	7.0 (6.2 to 7.9)	7.1 (-9.6 to 26.1)	-24.7 (-36.0 to -11.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hepatitis E	-	-	61.2 (6.5 to 147.6)	41.4 (-6.1 to 113.8)	-	-	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	2.1 (1.8 to 2.6)	1.8 (1.6 to 2.6)	-13.0 (-33.6 to 36.4)	1.5 (-24.7 to 69.1)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-28.5 (-53.8 to 56.0)	-6.6 (-41.6 to 112.5)
Non-communicable diseases	-	-	-	-	28.3 (28.3 to 48.7)	39.5 (39.5 to 68.6)	39.9 (34.0 to 45.3)	142.3 (-2.8 to 5.4)
Neoplasms	-	-	-	-	0.4 (0.3 to 0.5)	0.8 (0.6 to 1.0)	99.6 (77.7 to 122.2)	10.0 (-2.0 to 22.8)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.6 (26.3 to 168.9)	-5.5 (-33.7 to 41.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.8 (30.2 to 140.1)	-9.5 (-32.5 to 25.9)
Stomach cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	38.8 (13.7 to 74.3)	-27.4 (-40.9 to -8.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.1 (2.7 to 59.8)	-32.9 (-46.2 to -16.1)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.2 (112.2 to 112.2)	10.2 (10.2 to 10.2)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.0 (-26.7 to 379.7)	-0.4 (-59.3 to 161.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.9 (-28.0 to 328.6)	-7.9 (-60.8 to 130.8)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	343.1 (142.9 to 855.5)	129.6 (24.1 to 397.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	309.1 (140.8 to 717.9)	112.3 (23.3 to 325.3)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.2 (-44.4 to 156.2)	-38.2 (-71.6 to 30.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.8 (-46.2 to 116.6)	-42.1 (-72.3 to 10.0)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	334.4 (-72.3 to 58.6)	-62.4 (-84.7 to -33.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.4 (-71.3 to 39.5)	44.5 (-84.2 to -22.0)
Larynx cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	63.3 (17.6 to 137.3)	-15.3 (-38.5 to 21.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.0 (5.7 to 112.5)	-22.7 (-44.7 to 8.8)
Tracheal, bronchus and lung cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	91.8 (52.5 to 138.7)	-2.3 (-22.2 to 20.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	80.3 (44.7 to 121.3)	-7.9 (-26.0 to 13.0)
Breast cancer	1.2 (1.0 to 1.4)	2.6 (2.4 to 2.9)	121.4 (87.6 to 162.7)	19.6 (0.7 to 42.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	76.1 (51.3 to 108.0)	-2.5 (-16.2 to 14.9)
Cervical cancer	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	37.4 (-55.4 to -14.5)	-5.0 (-67.7 to -38.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.1 (-6.7 to -37.0)	44.5 (-67.6 to -37.0)
Uterine cancer	0.3 (0.3 to 0.4)	0.8 (0.4 to 1.2)	166.9 (20.9 to 296.1)	40.0 (-35.7 to 105.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	160.5 (-36.8 to 103.1)	36.4 (-36.8 to 103.1)
Prostate cancer	0.4 (0.3 to 0.5)	1.3 (1.1 to 1.6)	222.2 (162.3 to 315.1)	55.4 (24.6 to 102.5)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	206.9 (145.1 to 286.8)	49.8 (18.9 to 90.9)
Colon and rectum cancer	0.4 (0.4 to 0.5)	1.2 (1.0 to 1.3)	171.9 (132.7 to 218.9)	43.6 (23.3 to 68.7)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	150.7 (111.4 to 195.8)	32.7 (12.4 to 56.6)
Lip and oral cavity cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	78.3 (29.6 to 145.0)	-0.6 (-21.6 to 35.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.8 (21.5 to 134.5)	-5.2 (-32.7 to 29.6)
Nasopharynx cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	30.1 (-54.9 to 21.5)	-52.9 (-70.0 to -38.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-55.3 to 12.8)	54.3 (-69.9 to -23.2)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	265.1 (48.1 to 525.2)	97.6 (-20.6 to 233.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	253.4 (41.6 to 485.1)	89.5 (-23.6 to 212.7)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.9 (-16.2 to 65.7)	-38.3 (-56.1 to -11.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.3 (-20.3 to 66.1)	40.0 (-59.3 to -12.1)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	158.0 (96.7 to 245.6)	33.3 (1.7 to 81.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	135.2 (61.6 to 195.6)	21.6 (-5.8 to 53.8)
Malignant skin melanoma	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	195.6 (67.6 to 222.8)	49.0 (9.8 to 102.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	180.5 (85.3 to 217.7)	44.6 (7.1 to 99.2)
Non-melanoma skin cancer	0.3 (0.2 to 0.3)	0.7 (0.6 to 0.8)	150.9 (104.1 to 207.9)	32.1 (7.7 to 61.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	165.2 (110.4 to 240.6)	40.3 (10.3 to 79.8)
Ovarian cancer	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	120.2 (57.6 to 196.5)	24.6 (-10.5 to 68.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.1 (45.3 to 195.6)	20.0 (-16.6 to 67.4)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.3 (-40.4 to 103.4)	1.8 (-48.1 to 85.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.5 (-47.6 to 132.7)	4.0 (-54.7 to 110.3)
Kidney cancer	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	181.4 (120.4 to 254.8)	57.8 (24.2 to 98.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	161.5 (105.5 to 236.0)	45.7 (14.8 to 87.1)
Bladder cancer	0.5 (0.5 to 0.6)	0.8 (0.7 to 0.9)	51.2 (24.9 to 85.1)	-22.4 (-35.6 to -5.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	35.0 (9.8 to 69.1)	-30.5 (-43.4 to -13.0)
Brain and nervous system cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	56.1 (24.8 to 94.2)	13.6 (-10.0 to 41.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.4 (22.4 to 88.8)	8.8 (-12.1 to 33.2)
Thyroid cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	86.2 (-4.0 to 191.5)	43.1 (-23.7 to 127.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.9 (-4.1 to 188.5)	41.3 (-25.3 to 121.5)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	144.5 (45.4 to 234.5)	27.8 (-22.6 to 75.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	137.5 (37.3 to 237.6)	24.2 (-26.6 to 73.6)
Hodgkin lymphoma	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	84.8 (-12.6 to 176.9)	45.5 (-30.2 to 117.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.2 (-31.0 to 161.2)	38.9 (-38.4 to 103.6)
Non-Hodgkin lymphoma	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	159.9 (57.5 to 241.5)	58.9 (-2.4 to 106.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	141.5 (45.3 to 223.1)	48.2 (-9.3 to 96.3)
Multiple myeloma	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	177.4 (56.7 to 351.8)	40.9 (-19.5 to 127.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	151.3 (43.1 to 328.4)	28.2 (-27.5 to 115.8)
Leukemia	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	88.5 (27.6 to 98.4)	9.6 (-11.7 to 37.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.1 (22.8 to 95.4)	2.7 (-18.8 to 28.9)
Other neoplasms	0.2 (0.2 to 0.3)	0.7 (0.5 to 0.9)	230.4 (142.7 to 316.8)	114.0 (57.9 to 171.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	203.2 (120.5 to 287.8)	94.8 (43.3 to 145.1)
Cardiovascular diseases	-	-	-	-	1.3 (0.9 to 1.7)	2.6 (1.7 to 3.4)	98.4 (58.4 to 143.4)	5.2 (-15.7 to 28.6)
Rheumatic heart disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.6 (15.6 to 104.5)	-12.2 (-33.1 to 14.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.0 (4.3 to 130.1)	-12.2 (-39.1 to 28.5)
Ischemic heart disease	6.5 (5.4 to 7.7)	11.9 (10.1 to 14.0)	86.6 (42.9 to 127.4)	0.7 (-27.3 to 14.1)	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.0)	79.9 (35.0 to 123.9)	-9.3 (-31.3 to 12.1)
Cerebrovascular disease	-	-	-	-	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	96.5 (58.7 to 138.2)	3.4 (-16.7 to 25.2)
Ischemic stroke	1.7 (1.4 to 1.9)	3.4 (2.8 to 4.0)	99.0 (62.2 to 153.6)	2.8 (-16.0 to 31.3)	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.7)	99.7 (60.9 to 152.5)	3.5 (-16.2 to 30.9)
Hemorrhagic stroke	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.9)	75.2 (9.1 to 185.8)	-3.5 (-38.8 to 56.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	73.2 (10.1 to 183.1)	-3.1 (-37.6 to 54.6)
Hypertensive heart disease	0.6 (0.5 to 0.7)	1.3 (1.1 to 1.4)	124.1 (84.3 to 169.7)	14.0 (-5.5 to 37.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	125.4 (86.3 to 171.6)	14.9 (-4.9 to 38.4)
Cardiomyopathy and myocarditis	0.6 (0.5 to 0.7)	0.9 (0.8 to 1.0)	44.2 (18.9 to 82.7)	-23.6 (-37.0 to -2.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	44.6 (18.9 to 85.2)	-23.3 (-37.1 to -1.8)
Atrial fibrillation and flutter	0.2 (0.1 to 0.3)	0.8 (0.5 to 1.1)	315.2 (203.9 to 518.6)	106.7 (50.9 to 203.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	319.7 (203.1 to 546.4)	108.5 (50.6 to 218.6)
Peripheral vascular disease	9.9 (6.6 to 12.8)	20.4 (15.0 to 24.8)	102.3 (45.6 to 244.1)	6.4 (-23.8 to 77.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.8 (-12.8 to 294.1)	-13.6 (-56.5 to 96.3)
Endocarditis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	173.8 (77.2 to 324.7)	55.8 (5.0 to 141.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	137.3 (54.0 to 297.6)	35.6 (-10.9 to 124.3)
Other cardiovascular and circulatory diseases	6.2 (3.7 to 9.0)	13.2 (8.6 to 16.8)	114.8 (23.0 to 273.4)	21.3 (-30.9 to 111.1)	0.4 (0.2 to 0.7)	0.9 (0.5 to 1.4)	115.0 (23.6 to 278.2)	21.4 (-30.9 to 112.4)
Chronic respiratory diseases	-	-	-	-	2.4 (1.6 to 3.2)	3.1 (2.1 to 4.3)	31.7 (14.5 to 57.3)	-3.3 (-15.5 to 14.6)
Chronic obstructive pulmonary disease	21.7 (17.7 to 25.8)	35.6 (29.2 to 42.3)	63.4 (42.5 to 87.3)	0.3 (-11.2 to 13.7)	1.0 (0.6 to 1.4)	1.6 (1.0 to 2.5)	65.1 (26.1 to 115.3)	1.8 (-20.8 to 35.6)

Appendix Table G.4 - Malta prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	35.4	-22.6
Silicosis	0.0	0.0	21.0	-33.2	0.0	0.0	(16.5 to 50.7)	(-33.8 to -13.2)
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	(13.2 to 26.6)	(-37.5 to -30.3)
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	48.3	-56.7	0.0	0.0	41.7	-17.7
Asthma	29.4	33.8	15.1	-2.2	1.3	1.5	14.2	-1.9
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.1	126.0	31.0	0.0	0.0	120.2	27.8
Other chronic respiratory diseases	-	-	-	-	0.1	0.0	-86.5	-91.6
Cirrhosis	-	-	-	-	0.0	0.0	75.4	-39.3
Cirrhosis due to hepatitis B	0.0	0.0	-1.5	-38.2	0.0	0.0	(-19.6 to 11.8)	(-48.4 to -28.6)
Cirrhosis due to hepatitis C	0.0	0.0	20.1	-24.4	0.0	0.0	47.8 to 86.9)	(66.4 to 20.0)
Cirrhosis due to alcohol use	0.0	0.0	-31.2	-58.5	0.0	0.0	(-38.8 to 189.9)	(61.1 to 84.2)
Cirrhosis due to other causes	0.0	0.0	4.6	-21.1	0.0	0.0	(-65.7 to 37.3)	(-79.6 to -17.8)
Digestive diseases	-	-	-	-	0.5	0.8	52.2	1.5
Peptic ulcer disease	2.3	1.1	-52.6	-73.6	0.1	0.0	-46.0	-69.8
Gastritis and duodenitis	0.9	1.2	31.3	-13.9	0.0	0.1	43.3	4.4
Appendicitis	0.0	0.0	27.4	-27.9	0.0	0.0	-26.6	-27.3
Paralytic ileus and intestinal obstruction	0.0	0.0	95.4	-27.8	0.0	0.0	88.8	26.0
Inguinal, femoral, and abdominal hernia	1.7	2.7	59.8	-13.3	0.0	0.0	59.6	-12.9
Inflammatory bowel disease	1.2	2.0	66.3	14.1	0.3	0.4	64.5	13.9
Vascular intestinal disorders	0.0	0.0	184.2	54.6	0.0	0.0	173.0	49.9
Gallbladder and biliary diseases	0.3	0.6	76.8	0.0	0.1	0.1	75.4	9.3
Pancreatitis	0.1	0.1	56.2	7.5	0.0	0.0	53.4	7.1
Other digestive diseases	-	-	-	-	0.1	0.1	123.6	49.3
Neurological disorders	-	-	-	-	3.9	5.1	31.9	-1.6
Alzheimer disease and other dementias	3.5	6.8	96.9	2.9	0.5	1.0	96.5	3.6
Parkinson disease	0.3	0.6	100.0	0.4	0.0	0.1	100.8	1.1
Epilepsy	1.3	1.5	7.4	-10.5	0.5	0.6	11.8	-5.0
Multiple sclerosis	0.1	0.2	133.6	68.0	0.0	0.1	128.0	65.7
Migraine	56.6	69.4	23.2	-3.3	1.3	2.1	58.3	-8.1
Tension-type headache	77.7	116.8	48.8	21.7	0.1	0.2	47.8	21.9
Medication overuse headache	2.6	5.2	99.3	52.2	0.4	0.8	98.1	52.4
Other neurological disorders	0.0	0.0	40.5	3.2	0.4	0.3	-16.9	-56.2
Mental and substance use disorders	-	-	-	-	9.1	10.6	17.4	-0.1
Schizophrenia	1.1	1.3	26.2	-0.5	0.7	0.8	25.0	0.4
Alcohol use disorders	1.4	2.8	97.4	66.9	0.1	0.3	96.5	66.7
Drug use disorders	-	-	-	-	1.1	1.2	7.6	1.2
Opioid use disorders	1.9	1.9	3.9	-1.0	0.8	0.8	3.6	-1.0
Cocaine use disorders	0.5	0.6	13.9	0.1	0.5	0.6	13.9	4.4
Amphetamine use disorders	0.6	0.8	21.8	7.7	0.1	0.1	22.1	8.5
Cannabis use disorders	0.6	0.6	6.4	0.9	0.0	0.0	6.4	0.8
Other drug use disorders	-	-	-	-	0.2	0.2	19.0	7.4
Depressive disorders	-	-	-	-	0.1	0.2	16.3 to 66.3)	(24.9 to 51.1)
Major depressive disorder	12.7	15.2	19.7	-3.5	2.6	3.1	18.5	-3.5
Dysthymia	5.9	7.5	28.0	-0.7	0.6	0.7	27.1	-0.7
Bipolar disorder	2.8	3.3	19.0	-1.5	0.6	0.7	18.2	-1.4
Anxiety disorders	19.2	22.7	18.4	1.7	1.7	2.1	17.4	-0.8
Eating disorders	-	-	-	-	0.3	0.3	6.9	7.4
Anorexia nervosa	0.2	0.3	35.3	39.2	0.1	0.1	35.8	39.2
Bulimia nervosa	1.0	1.0	0.2	-0.3	0.2	0.2	-0.3	-0.2
Autistic spectrum disorders	-	-	-	-	0.4	0.5	10.7	1.3
Autism	1.1	1.2	11.5	1.0	0.3	0.3	10.3	1.2
Asperger syndrome	1.6	1.8	12.3	1.3	0.2	0.2	11.4	1.4
Attention-deficit/hyperactivity disorder	2.2	1.9	-14.5	0.3	0.0	0.0	-14.6	0.4
Conduct disorder	1.1	1.6	43.8	0.4	0.3	0.3	-14.0	0.2
Idiopathic intellectual disability	2.0	2.7	34.3	-23.9	0.1	0.1	-15.4	-24.1
Other mental and substance use disorders	6.6	8.6	31.7	0.8	0.5	0.6	30.8	1.0
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	4.3	6.7	58.7	6.1
Diabetes mellitus	26.2	49.7	89.8	12.7	1.8	3.4	92.8	13.5
Acute glomerulonephritis	0.0	0.0	-14.7	-24.7	0.0	0.0	-14.7	-24.7
Chronic kidney disease	-	-	-	-	1.3	1.9	44.1	-1.2
Chronic kidney disease due to diabetes mellitus	3.2	7.7	140.3	37.6	0.2	0.4	105.6	25.8
Chronic kidney disease due to hypertension	3.7	4.6	23.8	-11.0	0.4	0.6	48.4	-64.4
Chronic kidney disease due to glomerulonephritis	5.3	4.3	-18.3	-5.7	0.2	0.3	64.0	-64.0
Chronic kidney disease due to other causes	11.4	18.8	65.9	9.3	0.6	1.0	64.9	13.7
Urinary diseases and male infertility	-	-	-	-	0.2	0.4	105.9	10.1

Appendix Table G.4 - Malta prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.1 (50.6 to 89.3)	29.8 (16.0 to 46.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.9 (37.7 to 103.3)	28.9 (5.8 to 60.3)
Urolithiasis	4.2 (2.9 to 5.6)	9.7 (5.7 to 15.0)	124.6 (69.7 to 181.7)	29.2 (2.1 to 64.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	119.8 (71.8 to 176.6)	32.1 (7.7 to 66.2)
Benign prostatic hyperplasia	3.9 (3.6 to 4.2)	8.2 (7.7 to 8.8)	113.2 (92.6 to 135.4)	4.4 (-5.6 to 15.1)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	114.5 (93.8 to 138.1)	4.9 (-5.1 to 16.2)
Male infertility due to other causes	2.0 (1.4 to 2.7)	1.9 (1.4 to 2.5)	-6.2 (-38.8 to 38.9)	3.5 (-33.2 to 53.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.7 (-39.3 to 41.4)	3.7 (-33.6 to 56.4)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.1 (14.8 to 166.5)	2.5 (-28.3 to 58.2)
Gynecological diseases	-	-	-	-	0.5 (0.3 to 0.8)	0.5 (0.3 to 0.8)	4.5 (-10.0 to 22.3)	-3.7 (-15.8 to 13.4)
Uterine fibroids	15.2 (12.9 to 17.6)	16.8 (14.4 to 19.4)	10.7 (8.8 to 12.6)	-3.6 (-3.8 to -3.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	7.6 (-1.2 to 23.9)	-5.5 (-13.2 to 9.0)
Polycystic ovarian syndrome	6.7 (5.5 to 7.8)	7.1 (6.2 to 8.0)	5.6 (-14.0 to 30.4)	4.4 (-14.7 to 29.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	5.9 (-14.2 to 32.0)	5.2 (-14.4 to 30.4)
Female infertility due to other causes	0.5 (0.0 to 1.6)	0.6 (0.1 to 1.4)	23.5 (-82.4 to 998.9)	48.8 (80.3 to 1,082.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.7 (81.8 to 1,067.3)	40.1 (-80.3 to 1,092.4)
Endometriosis	1.2 (0.9 to 1.6)	1.1 (0.8 to 1.4)	-10.2 (-42.1 to 33.4)	-8.9 (-40.4 to 34.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-9.8 (-42.7 to 35.7)	8.6 (-41.0 to 37.8)
Genital prolapse	22.6 (20.1 to 25.0)	28.5 (25.7 to 31.3)	26.3 (9.4 to 45.2)	-5.9 (-18.4 to 6.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	25.6 (9.1 to 44.4)	-5.8 (-18.7 to 6.9)
Premenstrual syndrome	10.3 (7.6 to 13.6)	10.1 (7.2 to 13.7)	-3.0 (-36.5 to 67.5)	-2.7 (-36.7 to 66.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-2.8 (-36.8 to 68.9)	-2.5 (-36.7 to 67.0)
Other gynecological diseases	0.9 (0.8 to 1.0)	0.9 (0.8 to 1.6)	2.8 (-17.4 to 92.5)	-3.1 (-23.0 to 70.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.6 (-30.7 to 259.3)	-0.0 (-39.0 to 202.8)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.4 (0.2 to 0.5)	0.4 (0.2 to 0.5)	5.3 (-3.3 to 21.0)	5.6 (-2.4 to 24.4)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.4 (-21.2 to 25.3)	14.8 (-3.3 to 54.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.3 (-36.7 to 42.0)	23.8 (-22.4 to 78.6)
Thalassemia trait	8.3 (6.5 to 10.7)	10.4 (9.1 to 12.6)	25.3 (13.8 to 47.6)	9.6 (-0.3 to 29.4)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	14.1 (3.8 to 27.9)	14.2 (4.5 to 25.7)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.9 (-32.6 to -3.5)	-10.1 (-26.4 to 8.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.5 (-24.2 to 0.3)	-7.4 (-18.9 to 8.8)
Sickle cell trait	4.0 (3.7 to 4.4)	3.8 (3.4 to 4.2)	-5.1 (-14.5 to 2.0)	-16.6 (-24.7 to -9.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-8.4 (-60.5 to -16.9)	32.2 (-60.0 to -2.0)
G6PD deficiency	11.6 (7.0 to 16.2)	14.9 (8.8 to 20.5)	26.8 (-23.5 to 158.2)	11.0 (-32.8 to 126.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.5 (-40.3 to 45.4)	-4.7 (-42.8 to 48.9)
G6PD trait	58.3 (53.2 to 62.9)	65.3 (59.2 to 71.0)	12.0 (-0.2 to 25.4)	-3.2 (-13.8 to 8.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.6 (-55.1 to 166.7)	-10.1 (-52.0 to 195.9)
Other hemoglobinopathies and hemolytic anemias	2.2 (2.1 to 2.4)	2.8 (2.5 to 3.5)	24.5 (10.2 to 58.9)	6.2 (-7.9 to 36.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	8.8 (-13.6 to 91.9)	5.0 (-16.4 to 78.5)
Endocrine, metabolic, blood, and immune disorders	4.1 (3.8 to 4.4)	4.9 (4.7 to 5.1)	20.9 (9.6 to 32.4)	4.2 (-8.5 to 13.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	20.7 (4.3 to 36.6)	1.2 (-12.9 to 17.8)
Musculoskeletal disorders	-	-	-	-	9.6 (6.6 to 13.0)	14.2 (10.1 to 19.1)	47.9 (29.9 to 69.9)	4.6 (-8.3 to 20.0)
Rheumatoid arthritis	0.2 (0.2 to 0.2)	1.3 (1.1 to 1.5)	590.0 (458.2 to 750.5)	351.9 (273.4 to 445.9)	0.0 (0.0 to 0.1)	0.3 (0.2 to 0.4)	566.0 (437.8 to 740.9)	342.1 (262.2 to 447.7)
Osteoarthritis	15.5 (13.0 to 18.5)	28.5 (24.0 to 33.0)	84.0 (47.5 to 130.1)	-1.3 (-21.1 to 22.8)	0.5 (0.3 to 0.8)	1.0 (0.6 to 1.4)	83.9 (46.8 to 131.1)	-1.3 (-21.4 to 23.1)
Low back and neck pain	-	-	-	-	7.9 (5.3 to 10.9)	11.1 (7.6 to 15.2)	41.0 (20.3 to 65.6)	3.1 (-12.8 to 21.1)
Low back pain	46.3 (38.9 to 54.5)	67.7 (58.8 to 77.6)	47.6 (16.4 to 80.7)	5.9 (-17.2 to 29.2)	5.1 (3.3 to 7.5)	7.4 (4.9 to 10.4)	46.2 (14.6 to 78.8)	6.0 (-17.8 to 30.0)
Neck pain	28.1 (24.0 to 32.6)	37.9 (30.9 to 44.9)	35.4 (4.4 to 71.1)	-0.4 (-22.0 to 26.1)	2.7 (1.8 to 3.9)	3.7 (2.4 to 5.3)	34.5 (3.5 to 69.6)	-0.2 (-22.0 to 26.2)
Gout	0.6 (0.6 to 0.7)	1.2 (1.0 to 1.3)	79.9 (54.5 to 110.4)	2.6 (-11.8 to 19.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.7 (43.8 to 121.1)	3.2 (-17.0 to 26.8)
Other musculoskeletal disorders	12.1 (9.8 to 14.3)	19.7 (15.8 to 23.8)	63.0 (50.3 to 77.0)	3.3 (-0.6 to 12.3)	1.8 (0.7 to 1.6)	1.8 (1.2 to 2.5)	61.7 (49.0 to 76.0)	5.6 (-1.1 to 12.6)
Other non-communicable diseases	-	-	-	-	6.6 (4.5 to 9.4)	9.0 (6.2 to 12.8)	35.9 (27.8 to 45.8)	-1.0 (-8.3 to 2.9)
Congenital anomalies	-	-	-	-	1.0 (0.7 to 1.3)	1.3 (0.9 to 1.8)	30.7 (10.9 to 53.9)	8.5 (-8.1 to 29.8)
Neural tube defects	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.2)	-23.9 (-37.9 to -6.6)	-26.8 (-40.4 to -10.2)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-23.5 (-40.6 to 0.7)	-25.6 (-41.9 to -1.7)
Congenital heart anomalies	4.2 (3.5 to 5.0)	4.7 (4.1 to 5.6)	12.1 (-11.0 to 45.7)	1.0 (-19.7 to 31.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	11.7 (9.1 to 43.4)	2.9 (-16.1 to 31.4)
Orofacial clefts	0.6 (0.5 to 0.7)	0.7 (0.6 to 0.9)	11.5 (-14.7 to 40.1)	-0.8 (-24.2 to 24.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.3 (-26.7 to 38.5)	8.5 (-34.6 to 24.8)
Down syndrome	0.9 (0.7 to 1.0)	1.1 (1.0 to 1.3)	33.2 (6.0 to 66.6)	2.0 (-18.3 to 27.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	51.1 (20.0 to 90.5)	3.6 (-17.3 to 29.6)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.5 (-33.8 to 82.6)	1.5 (-38.6 to 69.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.8 (-36.2 to 84.4)	0.6 (-39.7 to 73.4)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.8 (-17.7 to 72.3)	5.6 (-26.3 to 54.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.9 (-32.7 to 74.7)	3.7 (-36.9 to 68.1)
Chromosomal unbalanced rearrangements	1.4 (1.1 to 1.7)	2.0 (1.7 to 2.4)	43.9 (13.3 to 86.8)	0.2 (-13.1 to 43.0)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.4)	11.1 (26.2 to 112.9)	11.7 (-12.7 to 46.3)
Other congenital anomalies	1.1 (0.7 to 1.6)	1.2 (0.7 to 1.6)	2.7 (-17.7 to 24.8)	-16.5 (-32.7 to -0.0)	0.5 (0.3 to 0.7)	0.6 (0.3 to 0.9)	26.5 (-7.7 to 71.4)	15.5 (-15.0 to 57.2)
Skin and subcutaneous diseases	-	-	-	-	2.4 (1.5 to 3.7)	2.7 (1.7 to 4.1)	14.0 (0.7 to 31.8)	-1.3 (-13.2 to 15.4)
Dermatitis	22.3 (17.1 to 27.8)	24.7 (19.3 to 30.4)	11.1 (7.7 to 15.3)	-0.1 (-0.2 to 0.1)	0.5 (0.3 to 0.8)	0.6 (0.4 to 0.8)	11.2 (6.8 to 16.4)	-0.2 (-2.6 to 2.6)
Psoriasis	5.2 (4.5 to 6.0)	6.8 (5.8 to 7.8)	30.2 (25.1 to 37.5)	0.2 (-0.1 to 0.4)	0.4 (0.3 to 0.6)	0.5 (0.4 to 0.8)	29.1 (21.4 to 37.8)	0.3 (-3.8 to 4.7)
Cellulitis	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.2)	38.7 (23.9 to 59.2)	0.3 (-7.4 to 9.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.9 (11.1 to 68.1)	0.3 (-16.4 to 19.9)
Pyoderma	0.6 (0.5 to 0.7)	0.5 (0.4 to 0.7)	-13.3 (-19.3 to -4.7)	-20.2 (-23.9 to -15.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.1 (-22.2 to -3.3)	-20.0 (-26.5 to -12.7)
Scabies	0.3 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-13.1 (-33.8 to 17.5)	-19.3 (-38.7 to 7.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.5 (-34.9 to 19.0)	-19.4 (-39.6 to 10.3)
Fungal skin diseases	25.8 (22.6 to 28.7)	34.1 (30.2 to 37.3)	32.0 (26.7 to 36.9)	32.0 (0.5 to 10.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	11.1 (25.8 to 36.1)	11.7 (-0.0 to 1.8)
Viral skin diseases	8.3 (6.5 to 10.1)	8.2 (6.5 to 10.1)	-0.8 (-5.6 to 5.6)	0.4 (-1.9 to 3.0)	0.3 (0.1 to 0.4)	0.3 (0.1 to 0.4)	-1.6 (-6.8 to 5.3)	4.0 (-2.8 to 4.0)
Acne vulgaris	61.4 (37.8 to 78.7)	56.8 (43.0 to 69.6)	-9.7 (-39.8 to 52.5)	-6.4 (-41.2 to 62.0)	0.7 (0.3 to 1.3)	0.6 (0.3 to 1.2)	-9.8 (-40.1 to 52.3)	-6.4 (-41.2 to 62.3)
Alopecia areata	0.6 (0.6 to 0.7)	0.8 (0.7 to 0.8)	30.9 (16.6 to 43.9)	0.3 (-10.3 to 10.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.4 (13.0 to 46.8)	-0.0 (-12.6 to 14.3)
Pruritus	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	40.3 (-36.2 to 146.1)	-13.6 (-60.3 to 50.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.4 (-39.8 to 156.1)	-12.9 (-61.5 to 61.5)
Urticaria	2.5 (1.7 to 3.4)	3.6 (2.6 to 4.7)	40.2 (-18.7 to 124.9)	8.7 (-35.2 to 69.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	39.1 (-22.7 to 124.3)	9.9 (-36.4 to 69.5)
Decubitus ulcer	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.4)	76.6 (37.8 to 140.8)	-4.3 (-25.0 to 31.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	75.5 (34.9 to 147.5)	-4.1 (-25.7 to 35.3)
Other skin and subcutaneous diseases	25.1 (15.5 to 40.4)	39.6 (21.8 to 69.4)	56.3 (31.3 to 78.7)	0.9 (-1.8 to 4.1)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.5)	55.7 (30.7 to 78.2)	1.1 (-1.9 to 4.3)
Sense organ diseases	-	-	-	-	2.2 (1.5 to 3.2)	3.4 (2.3 to 5.0)	56.1 (43.1 to 69.8)	-7.6 (-14.2 to -1.3)
Glaucoma	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	17.9 (-11.0 to 58.2)	-30.1 (-48.4 to -9.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	19.2 (-15.9 to 55.8)	-30.5 (-51.0 to -11.1)
Cataract	0.8 (0.5 to 1.1)	1.1 (0.7 to 1.6)	37.9 (0.2 to 89.0)	-28.7 (-48.3 to -1.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	41.5 (2.7 to 89.9)	-26.5 (-46.8 to -2.3)
Macular degeneration	1.1 (0.8 to 1.6)	2.1 (1.5 to 2.9)	85.0 (42.8 to 144.5)	-4.3 (-25.7 to 25.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	75.8 (41.5 to 121.0)	-8.2 (-25.8 to 14.5)
Uncorrected refractive error	37.2 (30.3 to 44.4)	56.6 (44.7 to 69.4)	53.6 (11.0 to 98.8)	-5.5 (-31.3 to 21.1)	0.5 (0.3 to 0.9)	0.7 (0.4 to 1.1)	43.2 (11.1 to 75.3)	-9.3 (-29.0 to 11.3)
Age-related and other hearing loss	43.7 (37.5 to 49.9)	74.7 (62.9 to 86.7)	71.3 (58.6 to 80.1)	-7.5 (-12.4 to -3.6)	1.2 (0.8 to 1.8)	2.1 (1.4 to 3.2)	5.8 (52.8 to 92.4)	5.8 (-13.9 to 3.9)
Other vision loss	1.0 (0.8 to 1.3)	1.0 (0.8 to 1.3)	-3.3 (-18.3 to 13.7)	-37.7 (-47.7 to -29.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	10.6 (-5.1 to 30.2)	-30.6 (-39.6 to -19.7)
Other sense organ diseases	8.7 (8.3 to 9.1)	10.5 (10.0 to 11.0)	21.0 (14.0 to 29.0)	-0.3 (-6.2 to 6.0)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.4)	19.2 (11.8 to 28.1)	-0.1 (-6.8 to 7.1)
Oral disorders	-	-	-	-	1.1 (0.7 to 1.6)	1.6 (1.0 to 2.4)	48.4 (36.1 to 63.0)	-8.6 (-15.9 to 0.4)
Deciduous caries	18.2 (16.9 to 19.4)	11.8 (11.1 to 12.5)	-35.1 (-41.1 to -28.4)	-0.4 (-9.6 to 9.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.2 (-43.0 to -11.1)	-0.7 (-12.8 to 13.0)
Permanent caries	142.6 (132.1 to 156.5)	166.8 (150.6 to 180.9)	17.1 (2.9 to 32.0)	0.0 (-11.7 to 12.7)	0.0 (0.0 to 0.2)	0.1 (0.0 to 0.2)	16.3 (2.2 to 31.2)	-0.1 (-12.0 to 12.7)
Periodontal diseases	32.6 (28.9 to 37.4)	51.8 (46.4 to 58.2)	59.0 (33.8 to 88.9)	4.1 (-11.9 to 23.2)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.7)	58.3 (32.6 to 88.0)	4.2 (-12.2 to 23.3)

Appendix Table G.4 - Malta prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	20.3 (18.3 to 22.2)	32.4 (29.2 to 35.6)	59.1 (39.4 to 82.6)	-16.6 (-26.9 to -4.2)	0.6 (0.4 to 0.8)	0.9 (0.6 to 1.2)	58.7 (39.2 to 82.8)	-16.6 (-26.8 to -3.9)
Other oral disorders	6.8 (6.5 to 7.2)	8.5 (8.1 to 9.0)	24.9 (15.7 to 35.3)	-0.5 (-8.2 to 6.9)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.4)	24.2 (14.5 to 34.5)	-0.4 (-8.1 to 7.7)
Injuries	-	-	-	-	3.9 (2.9 to 5.0)	4.0 (2.9 to 5.5)	3.8 (-6.2 to 14.6)	-31.9 (-38.5 to -24.5)
Transport injuries	-	-	-	-	0.6 (0.5 to 0.8)	0.5 (0.4 to 0.7)	-14.9 (-24.0 to -4.0)	-39.5 (-45.7 to -32.0)
Road injuries	-	-	-	-	0.6 (0.4 to 0.8)	0.5 (0.3 to 0.6)	-21.3 (-29.6 to -10.8)	-43.8 (-49.5 to -36.5)
Pedestrian road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-18.8 (-28.0 to -8.2)	-45.3 (-51.1 to -38.3)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.3 (-45.3 to -24.2)	-56.6 (-62.7 to -48.8)
Motorcyclist road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-21.1 (-35.6 to -3.7)	-40.1 (-50.9 to -27.0)
Motor vehicle road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-22.4 (-30.7 to -13.2)	-43.2 (-48.8 to -36.7)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.9 (-39.8 to -20.4)	-53.2 (-59.0 to -46.3)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	77.6 (59.0 to 98.9)	19.4 (7.7 to 34.5)
Unintentional injuries	-	-	-	-	3.2 (2.4 to 4.2)	3.5 (2.5 to 4.7)	7.7 (-2.4 to 18.7)	-30.3 (-37.0 to -22.8)
Falls	-	-	-	-	2.2 (1.7 to 2.8)	2.5 (1.8 to 3.3)	15.1 (2.9 to 29.6)	-29.1 (-36.7 to -19.8)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.6 (-2.2 to 13.8)	-27.7 (-35.8 to -20.0)
Fire, heat, and hot substances	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	2.6 (-11.3 to 17.7)	-22.5 (-32.5 to -11.2)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-68.8 (-76.8 to -58.1)	-75.6 (-82.0 to -67.2)
Exposure to mechanical forces	-	-	-	-	0.6 (0.4 to 0.7)	0.5 (0.3 to 0.6)	-18.6 (-27.5 to -7.2)	-37.8 (-44.4 to -29.8)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-59.8 (-64.7 to -54.4)	-68.1 (-71.8 to -63.9)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.4 (-22.6 to 8.1)	-30.3 (-40.8 to -18.1)
Other exposure to mechanical forces	-	-	-	-	0.5 (0.4 to 0.7)	0.5 (0.3 to 0.6)	-18.2 (-27.3 to -6.8)	-37.5 (-44.2 to -29.6)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.5 (38.1 to 68.5)	0.4 (-8.9 to 9.7)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.9 (17.4 to 44.9)	-2.4 (-11.9 to 8.7)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.4 (2.7 to 49.1)	-4.2 (-19.7 to 16.3)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.3 (17.7 to 47.2)	-2.1 (-12.1 to 9.7)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.9 (-2.6 to 23.0)	-13.8 (-24.6 to -1.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.7 (6.0 to 54.7)	-4.7 (-23.5 to 14.5)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.8 (-7.2 to 14.4)	-11.6 (-22.5 to 0.5)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.5 (-8.6 to 25.4)	-15.9 (-29.5 to -0.4)
Other unintentional injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	3.2 (-9.4 to 16.3)	-35.6 (-43.4 to -27.9)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.7 (-34.5 to -20.2)	-49.2 (-53.7 to -44.2)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.8 (-35.3 to -15.1)	-49.7 (-55.8 to -42.5)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.1 (-35.5 to -19.8)	-49.1 (-54.2 to -43.4)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.3 (-36.2 to -21.5)	-54.0 (-58.1 to -49.2)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.3 (-2.5 to 20.4)	-26.7 (-33.0 to -18.5)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.4 (-38.4 to -21.4)	-49.6 (-55.0 to -43.1)
Forces of nature, war, and legal intervention	-	-	-	-	-	-	-	-
Exposure to forces of nature	-	-	-	-	-	-	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Marshall Islands prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
All causes	-	-	-	-	3.5 (2.6 to 4.6)	5.6 (4.1 to 7.3)	58.9 (50.8 to 68.5)	-1.4 (-5.7 to 3.9)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.8 (0.6 to 1.3)	1.2 (0.8 to 1.7)	37.4 (16.9 to 65.7)	-2.6 (-21.8 to 23.8)
HIV/AIDS and tuberculosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	76.1 (62.4 to 94.4)	6.5 (-0.8 to 16.4)
Tuberculosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	66.1 (59.1 to 73.5)	0.2 (-3.6 to 4.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.3 (53.9 to 78.5)	0.2 (-5.7 to 7.2)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,130.9 (353.5 to 2,082.3)	68.9 (180.2 to 1,284.2)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	974.1 (296.9 to 1,817.1)	565.6 (138.4 to 1,080.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	974.1 (295.9 to 1,821.8)	565.6 (107.6 to 1,083.6)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	814.9 (266.4 to 1,570.7)	497.9 (144.4 to 983.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,133.9 (346.9 to 2,135.1)	686.7 (176.7 to 1,338.3)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	6.7 (-1.8 to 16.2)	-20.4 (-26.1 to -13.7)
Diarrheal diseases	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.3)	5.5 (-6.6 to 21.3)	-12.4 (-22.3 to -1.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	5.0 (-1.1 to 11.5)	-12.5 (-22.8 to -0.6)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-21.8 to 34.7)	-17.8 (-41.9 to -0.2)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.4 (-15.9 to 15.0)	-27.8 (-38.1 to -16.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.6 (-20.4 to 23.2)	-27.0 (-40.4 to -11.1)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.4 (-35.8 to 1.0)	-41.6 (-53.5 to -25.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.9 (-37.6 to 8.9)	-41.1 (-54.3 to -23.1)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.0 (-82.4 to 8,226.8)	473.1 (-87.0 to 5,346.4)
Lower respiratory infections	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-9.2 (-28.5 to 20.9)	-21.4 (-34.2 to -3.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.8 (-32.0 to 21.8)	-21.8 (-36.0 to -4.2)
Upper respiratory infections	1.4 (1.4 to 1.5)	2.0 (1.9 to 2.1)	40.9 (31.6 to 51.5)	-1.9 (-8.4 to 5.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.6 (31.1 to 52.5)	-1.9 (-8.7 to 5.3)
Otitis media	0.7 (0.6 to 0.7)	0.8 (0.8 to 0.9)	24.9 (15.8 to 34.9)	-12.2 (-18.6 to -5.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.7 (14.7 to 35.7)	-11.9 (-18.5 to -3.9)
Meningitis	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-6.9 (-22.8 to 20.1)	-35.1 (-45.1 to -19.0)
Pneumococcal meningitis	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-2.3 (-18.2 to 20.3)	-35.0 (-44.4 to -22.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.3 (-25.5 to 36.3)	-2.8 (-47.1 to -11.6)
H influenzae type B meningitis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-11.3 (-35.1 to 56.2)	-40.9 (-55.7 to 0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.4 (-40.0 to 108.9)	-34.4 (-57.9 to 44.3)
Meningococcal meningitis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	5.8 (-20.3 to 44.6)	-32.0 (-47.4 to -3.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.3 (-27.1 to 65.8)	-27.9 (-49.5 to 9.6)
Other meningitis	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-6.9 (-31.4 to 12.5)	-34.8 (-50.3 to -20.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.5 (-41.5 to 11.7)	-39.1 (-57.4 to -21.1)
Encephalitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.0 (13.9 to 55.5)	-2.5 (-24.0 to 1.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.9 (8.8 to 66.2)	-9.8 (-26.0 to 7.6)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.1 (-93.3 to 852.1)	-32.8 (-93.5 to 436.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.1 (-93.3 to 887.6)	-32.8 (-93.5 to 466.3)
Whooping cough	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-65.0 (-67.6 to -62.3)	-68.0 (-70.3 to -65.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-64.8 (-71.1 to -57.8)	-67.8 (-73.5 to -61.4)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-71.4 (-89.6 to -21.1)	-81.0 (-93.0 to -46.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-73.6 (-91.2 to -34.3)	-81.9 (-92.9 to -59.5)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.0 (-76.0 to -62.4)	-73.4 (-78.7 to -66.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.0 (-78.9 to -57.8)	-73.2 (-81.1 to -62.6)
Varicella and herpes zoster	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	35.8 (23.4 to 50.9)	-1.1 (-14.4 to 13.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.5 (27.7 to 92.7)	-1.8 (-20.0 to 20.9)
Neglected tropical diseases and malaria	-	-	-	-	0.3 (0.2 to 0.6)	0.5 (0.3 to 0.8)	41.6 (-3.4 to 122.5)	-3.8 (-39.7 to 63.9)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.2 (-34.1 to 147.0)	-8.8 (-53.8 to 75.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.8 (-33.7 to 136.3)	-9.0 (-53.1 to 69.6)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.0 (7.9 to 80.5)	4.1 (-24.5 to 37.6)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.1 (-39.3 to 153.7)	-2.7 (-42.9 to 78.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.1 (-39.6 to 155.3)	-2.7 (-43.1 to 78.5)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.7 (10.2 to 85.4)	4.5 (-25.7 to 39.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.7 (10.2 to 85.6)	4.5 (-25.7 to 39.6)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.2 (-72.3 to 38.5)	-69.5 (-86.6 to -36.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.1 (-74.1 to 59.3)	-67.4 (-86.3 to -26.6)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.6 (-32.1 to -15.1)	-57.4 (-61.7 to -54.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.3 (-37.1 to -1.7)	-56.9 (-64.9 to -48.1)
Lymphatic filariasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.0 (-50.1 to 5.5)	-57.9 (-70.3 to -37.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.9 (-23.2 to 76.0)	-38.3 (-59.0 to -0.6)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	624.7 (622.9 to 626.8)	389.5 (388.3 to 390.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	624.1 (520.1 to 748.3)	389.9 (329.0 to 464.5)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.2 (-44.5 to 52.3)	-42.1 (-64.5 to -0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.2 (-44.7 to 53.0)	-42.1 (-64.5 to 0.2)
Intestinal nematode infections	-	-	-	-	0.3 (0.2 to 0.6)	0.4 (0.2 to 0.8)	38.1 (8.8 to 122.6)	-6.1 (-43.0 to 66.4)
Ascariasis	2.4 (1.5 to 3.7)	3.2 (2.1 to 4.7)	33.6 (-24.0 to 141.4)	-6.9 (-51.2 to 78.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-98.7 to -74.8)	-95.7 (-98.9 to -78.0)
Trichuriasis	31.1 (27.0 to 36.0)	46.4 (39.8 to 53.5)	49.3 (19.7 to 81.4)	0.2 (-2.4 to 25.9)	0.2 (0.1 to 0.5)	0.3 (0.2 to 0.6)	42.7 (-17.5 to 155.3)	-3.4 (-50.0 to 93.7)
Hookworm disease	10.8 (8.1 to 14.2)	16.7 (12.3 to 22.8)	54.7 (0.5 to 138.8)	0.1 (-36.3 to 64.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	39.6 (-5.9 to 106.5)	-3.5 (-41.0 to 55.8)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.5 (0.3 to 0.6)	0.6 (0.5 to 0.7)	26.2 (-5.2 to 73.8)	0.1 (-25.7 to 39.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.1 (-8.2 to 115.1)	2.5 (-28.8 to 77.5)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.0 (-37.2 to 5.1)	-45.2 (-59.7 to -32.1)
Maternal hemorrhage	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-6.9 (-31.0 to 18.0)	-38.6 (-55.4 to -23.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.5 (-45.5 to 10.0)	-42.6 (-64.4 to -20.2)
Maternal sepsis and other maternal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.1 (-22.6 to 36.3)	-46.1 (-55.4 to -21.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.5 (-56.8 to 43.2)	-51.5 (-71.6 to -16.7)
Maternal hypertensive disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.1 (-21.0 to 3.4)	-44.5 (-48.3 to -32.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.9 (-30.4 to 12.5)	-44.5 (-55.2 to -29.3)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.2 (-73.5 to 93.2)	-57.9 (-83.0 to 16.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.3 (-73.6 to 160.9)	-56.0 (-62.8 to 62.3)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.8 (-47.0 to 56.8)	-43.3 (-65.6 to -3.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.8 (-47.0 to 56.8)	-43.3 (-65.7 to -3.0)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.9 (-49.8 to 48.5)	-46.5 (-67.5 to -3.9)
Neonatal disorders	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	77.0 (-10.6 to 181.1)	28.2 (-35.0 to 102.3)
Preterm birth complications	0.2 (0.1 to 0.4)	0.7 (0.3 to 1.3)	202.4 (120.6 to 304.6)	111.1 (57.8 to 179.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	189.5 (58.1 to 355.8)	105.2 (15.1 to 219.5)
Neonatal encephalopathy due to birth asphyxia and trauma	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.5)	26.3 (-2.7 to 58.6)	-13.7 (-32.4 to 14.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.8 (-14.2 to 134.5)	-1.3 (-37.6 to 55.8)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.4 (75.7 to 108.9)	94.7 (72.4 to 105.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.7 (74.2 to 121.2)	95.5 (71.0 to 117.1)
Hemolytic disease and other neonatal jaundice	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	49.6 (-49.8 to 373.2)	5.1 (-63.5 to 224.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.6 (-50.4 to 322.4)	4.9 (-63.6 to 198.4)
Other neonatal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	29.9 (-56.4 to 242.1)	-6.6 (-68.7 to 142.0)
Nutritional deficiencies	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.5)	34.1 (27.6 to 39.4)	-0.5 (-5.2 to 3.2)
Protein-energy malnutrition	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	8.9 (-41.1 to 105.8)	-11.6 (-48.7 to 50.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.3 (-21.6 to 108.8)	-10.6 (-48.5 to 55.9)
Iodine deficiency	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.1 (-20.5 to 31.7)	-37.7 (-51.8 to -17.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.2 (-22.4 to 35.2)	-36.8 (-52.5 to -14.6)
Vitamin A deficiency	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-22.6 (-37.3 to -6.2)	-45.0 (-54.8 to -35.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.4 (-41.2 to -10.8)	-48.4 (-57.7 to -38.5)

Appendix Table G.4 - Marshall Islands prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
Iron-deficiency anemia	7.0 (6.8 to 7.1)	9.5 (9.3 to 9.6)	36.4 (32.6 to 40.2)	-2.9 to 3.3	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	36.1 (30.8 to 40.2)	40.7 (-1.0 to 3.8)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-41.5 to 266.4)	20.7 (-50.6 to 191.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	41.7 (25.2 to 60.8)	-6.6 (-17.1 to 5.1)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.8 (36.7 to 73.0)	-3.3 (-13.1 to 7.3)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.3 (-7.1 to 22.6)	-38.0 (-44.8 to -31.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.3 (-22.7 to 51.7)	-38.1 (-54.5 to -17.8)
Chlamydial infection	2.9 (2.1 to 3.6)	4.0 (3.0 to 5.2)	35.6 (-2.1 to 91.0)	-12.5 (36.9 to 22.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.0 (27.6 to 74.1)	-4.5 (-17.7 to 10.0)
Gonococcal infection	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	44.2 (-14.8 to 138.7)	-6.4 (-42.0 to 49.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.0 (12.7 to 120.2)	3.5 (-25.3 to 40.8)
Trichomoniasis	0.4 (0.2 to 0.7)	0.9 (0.5 to 1.3)	110.2 (18.1 to 353.5)	22.8 (-29.1 to 144.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	120.2 (9.5 to 483.7)	28.4 (-33.7 to 212.0)
Genital herpes	5.4 (5.3 to 5.6)	9.1 (8.8 to 9.4)	67.6 (60.2 to 73.9)	-3.0 (-7.0 to 0.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.8 (52.2 to 75.9)	-3.0 (8.4 to 2.5)
Other sexually transmitted diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.3 (5.3 to 35.3)	-31.1 (-39.6 to -22.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.2 (5.3 to 63.3)	-26.6 (-43.0 to -3.6)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.7 (-36.5 to 19.4)	-43.7 (-63.7 to -27.0)
Hepatitis A	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	28.8 (27.9 to 29.6)	-3.4 (-3.5 to -3.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.9 (28.2 to 62.6)	-1.1 (-11.3 to 10.5)
Hepatitis B	8.4 (5.8 to 11.1)	5.4 (4.1 to 6.6)	-36.7 (-57.8 to -2.8)	-58.8 (-71.1 to -48.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.9 (-68.9 to 2.3)	-93.7 (-81.9 to -37.8)
Hepatitis C	1.4 (1.2 to 1.5)	1.7 (1.5 to 1.8)	22.3 (2.8 to 45.7)	-27.5 (-37.4 to -17.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.2 (-14.9 to 56.4)	-27.0 (-47.8 to 0.7)
Hepatitis E	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.2 (50.6 to 111.7)	12.1 (-5.1 to 34.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.6 (39.1 to 132.5)	11.9 (-10.2 to 45.0)
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	228.6 (-7.1 to 560.0)	84.6 (-45.4 to 310.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	256.9 (-21.3 to 1,678.5)	97.0 (-53.1 to 1,012.5)
Other infectious diseases	0.3 (0.3 to 0.4)	0.4 (0.3 to 0.5)	27.8 (-1.6 to 65.3)	0.5 (-23.0 to 30.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.1 (8.0 to 107.0)	17.3 (-13.2 to 66.0)
Non-communicable diseases	-	-	-	-	1.9 (1.9 to 3.3)	3.2 (3.2 to 5.5)	59.7 (59.7 to 75.0)	32.3 (-4.0 to 3.1)
Neoplasms	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	173.7 (79.3 to 310.5)	32.3 (-6.7 to 84.9)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	156.5 (28.6 to 371.6)	31.5 (-34.7 to 140.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	164.6 (34.3 to 381.5)	36.6 (-32.7 to 147.6)
Stomach cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	146.6 (66.0 to 252.8)	28.1 (-11.6 to 80.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	150.3 (67.0 to 258.5)	30.8 (-12.0 to 88.6)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	350.1 (152.2 to 1,491.1)	146.2 (89.9 to 780.9)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	444.6 (162.9 to 2,245.3)	209.3 (46.4 to 1,274.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	428.4 (175.5 to 2,153.9)	196.1 (52.4 to 1,710.4)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	940.5 (249.6 to 4,167.8)	462.0 (97.2 to 1,233.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	898.8 (280.1 to 3,894.6)	429.6 (105.3 to 1,953.4)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.6 (-11.0 to 529.5)	0.5 (-55.2 to 255.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.9 (-9.3 to 486.6)	-2.4 (-56.6 to 228.2)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	177.2 (14.8 to 968.2)	57.2 (-36.5 to 484.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	167.4 (17.7 to 877.7)	51.5 (-33.7 to 453.1)
Larynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.3 (-36.8 to 86.3)	-48.5 (-70.1 to -12.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.6 (-32.6 to 90.8)	-47.1 (-68.8 to -12.0)
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.5 (33.6 to 203.9)	11.5 (-26.8 to 53.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.7 (33.1 to 209.3)	11.7 (-27.2 to 55.7)
Breast cancer	0.1 (0.1 to 0.1)	0.3 (0.1 to 0.4)	199.1 (57.6 to 475.4)	58.3 (-13.9 to 201.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	218.3 (68.9 to 512.0)	69.8 (-6.2 to 220.0)
Cervical cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	96.3 (6.9 to 257.8)	98.8 (-42.0 to 73.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.4 (5.4 to 248.3)	51.5 (-41.5 to 71.6)
Uterine cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	160.1 (1.4 to 486.5)	34.0 (-44.7 to 194.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	158.9 (5.7 to 507.5)	33.2 (-43.2 to 194.1)
Prostate cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	253.3 (89.1 to 531.5)	80.6 (-0.3 to 210.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	254.2 (95.3 to 530.4)	80.1 (2.2 to 216.7)
Colon and rectum cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.7 (37.5 to 181.4)	-32.5 (-49.6 to 23.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.1 (38.3 to 183.8)	-30.6 (-48.6 to 25.9)
Lip and oral cavity cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.0)	78.6 (2.5 to 205.3)	-4.6 (-44.3 to 62.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.9 (10.6 to 203.1)	-3.9 (-42.1 to 58.9)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.6 (6.6 to 215.8)	3.7 (-39.2 to 72.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.4 (6.0 to 195.6)	1.3 (-38.7 to 62.0)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.2 (-25.8 to 164.5)	-24.8 (-59.3 to 36.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.8 (-20.8 to 166.2)	-23.0 (-57.5 to 33.8)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.0 (-15.2 to 186.9)	-14.9 (-56.0 to 51.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.8 (-17.6 to 164.3)	-18.6 (-57.1 to 39.2)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	219.8 (96.9 to 398.1)	70.7 (-5.1 to 166.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	228.4 (108.4 to 402.2)	74.9 (-10.0 to 168.0)
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	195.2 (66.6 to 483.8)	58.8 (-64.1 to 194.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	195.2 (57.4 to 449.8)	50.7 (-14.3 to 174.8)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	240.0 (122.1 to 421.2)	64.1 (-11.2 to 142.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	282.9 (115.4 to 569.1)	83.4 (3.3 to 204.9)
Ovarian cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	156.5 (-0.8 to 615.1)	39.7 (-42.3 to 269.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	157.3 (-2.7 to 610.3)	39.3 (-43.2 to 267.3)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.6 (-9.4 to 253.0)	11.4 (-43.0 to 103.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.0 (-13.8 to 256.1)	9.5 (-44.0 to 94.7)
Kidney cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.0 (9.1 to 298.9)	19.7 (-37.2 to 123.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.5 (9.1 to 316.9)	37.5 (-39.5 to 118.3)
Bladder cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	250.6 (112.5 to 629.6)	43.3 (-30.8 to 224.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	267.1 (120.7 to 661.8)	45.8 (-29.3 to 237.0)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.1 (15.7 to 213.2)	28.1 (-18.3 to 89.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.4 (13.3 to 218.4)	24.4 (-23.9 to 84.8)
Thyroid cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.0 (4.4 to 286.3)	16.8 (-38.1 to 116.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.2 (5.7 to 292.4)	16.3 (-39.4 to 107.8)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	131.0 (34.7 to 270.3)	33.6 (-21.4 to 109.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	131.3 (39.5 to 265.6)	34.2 (-18.2 to 108.8)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	186.0 (51.6 to 455.0)	79.2 (2.6 to 212.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	176.7 (35.7 to 399.6)	63.0 (-6.8 to 172.2)
Non-Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	256.7 (58.5 to 579.7)	114.7 (-8.5 to 302.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	258.3 (59.2 to 613.7)	109.5 (-11.6 to 297.2)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	167.4 (43.6 to 424.3)	39.9 (-25.8 to 185.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	165.1 (43.7 to 424.9)	37.1 (-25.2 to 182.5)
Leukemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	239.8 (90.7 to 472.4)	128.1 (49.0 to 237.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	250.4 (117.9 to 434.6)	109.1 (35.2 to 204.0)
Other neoplasms	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	299.3 (107.2 to 690.2)	190.0 (38.6 to 403.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	304.9 (105.4 to 663.6)	176.0 (28.7 to 359.5)
Cardiovascular diseases	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	108.9 (64.5 to 158.3)	18.0 (-2.9 to 39.8)
Rheumatic heart disease	1.2 (0.9 to 1.6)	2.1 (1.7 to 2.6)	74.0 (25.9 to 145.0)	3.1 (-22.2 to 38.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	72.7 (25.5 to 143.9)	1.8 (-21.7 to 36.2)
Ischemic heart disease	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	106.1 (57.8 to 176.1)	1.9 (-21.7 to 31.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.0 (65.1 to 175.7)	3.5 (-18.8 to 33.6)
Cerebrovascular disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.3 (49.2 to 121.0)	-7.8 (-25.9 to 11.1)
Ischemic stroke	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.7 (47.3 to 127.2)	-9.5 (-27.5 to 12.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.2 (46.8 to 129.9)	-9.1 (-27.1 to 13.9)
Hemorrhagic stroke	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	79.8 (44.9 to 120.1)	-7.2 (-27.4 to 12.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.7 (44.9 to 121.4)	-7.2 (-27.3 to 13.3)
Hypertensive heart disease	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	118.9 (77.1 to 166.1)	9.6 (-13.2 to 32.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.8 (75.2 to 170.8)	9.3 (-12.1 to 33.9)
Cardiomyopathy and myocarditis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	124.5 (87.8 to 163.2)	25.4 (3.7 to 49.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	124.9 (85.9 to 168.7)	26.0 (4.1 to 52.3)
Atrial fibrillation and flutter	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	648.4 (402.3 to 895.0)	207.1 (91.0 to 325.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	655.8 (401.6 to 911.5)	209.9 (96.3 to 327.8)
Peripheral vascular disease	0.3 (0.2 to 0.4)	0.8 (0.6 to 1.1)	145.6 (51.9 to 269.2)	13.3 (-22.3 to 55.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.4 (-32.3 to 255.2)	-31.5 (-66.7 to 54.2)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.1 (5.9 to 96.8)	-15.3 (-39.0 to 26.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.1 (-2.1 to 108.2)	-14.7 (-42.3 to 34.9)
Other cardiovascular and circulatory diseases	0.2 (0.1 to 0.3)	0.6 (0.3 to 1.0)	212.2 (40.2 to 504.9)	65.8 (-26.2 to 230.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	216.6 (38.4 to 494.6)	66.6 (-26.4 to 230.2)
Chronic respiratory diseases	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	52.9 (33.1 to 82.7)	-11.3 (-21.5 to 2.3)
Chronic obstructive pulmonary disease	1.0 (0.9 to 1.0)	1.7 (1.6 to 1.8)	80.3 (75.3 to 85.7)	-0.3 (-3.0 to 2.3)	0.1 (

Appendix Table G.4 - Marshall Islands prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	204.7	58.6
Silicosis	0.0	0.0	65.3	-15.9	(0.0 to 0.0)	(0.0 to 0.0)	(186.4 to 223.2)	(46.8 to 69.8)
Asbestosis	-	-	0.0	0.0	-	-	64.6	-16.0
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	264.6	98.7	(0.0 to 0.0)	(0.0 to 0.0)	257.7	94.4
Asthma	0.8	1.0	16.5	-3.4	(0.0 to 0.0)	(0.0 to 0.0)	15.4	-23.8
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	79.4	-1.3	(0.0 to 0.0)	(0.0 to 0.0)	79.5	-1.2
Other chronic respiratory diseases	-	-	-	-	0.0	0.0	6.3	-40.2
Cirrhosis	-	-	-	-	0.0	0.0	1.3	-28.7
Cirrhosis due to hepatitis B	0.0	0.0	32.6	-15.6	(0.0 to 0.0)	(0.0 to 0.0)	(3.0 to 27.9)	(-36.8 to -20.1)
Cirrhosis due to hepatitis C	0.0	0.0	2.9	-34.8	(0.0 to 0.0)	(0.0 to 0.0)	4.4	-34.5
Cirrhosis due to alcohol use	0.0	0.0	-22.2	-54.7	(0.0 to 0.0)	(0.0 to 0.0)	(-52.7 to 114.8)	(66.1 to 23.3)
Cirrhosis due to other causes	0.0	0.0	-4.7	-2.2	(0.0 to 0.0)	(0.0 to 0.0)	(-52.6 to 21.7)	(-71.3 to -29.8)
Digestive diseases	-	-	-	-	0.0	0.1	73.9	4.9
Peptic ulcer disease	0.3	0.3	38.5	-19.7	(0.0 to 0.0)	(0.0 to 0.0)	34.3	-24.7
Gastritis and duodenitis	0.3	0.4	24.5	-24.8	(0.0 to 0.0)	(0.0 to 0.0)	21.8	-20.1
Appendicitis	0.0	0.0	15.7	-27.9	(0.0 to 0.0)	(0.0 to 0.0)	15.2	-27.5
Paralytic ileus and intestinal obstruction	0.0	0.0	28.4	-2.2	(0.0 to 0.0)	(0.0 to 0.0)	27.3	-8.0
Inguinal, femoral, and abdominal hernia	0.1	0.2	56.9	-12.8	(0.0 to 0.0)	(0.0 to 0.0)	56.6	-12.5
Inflammatory bowel disease	0.0	0.0	59.3	-8.8	(0.0 to 0.0)	(0.0 to 0.0)	(38.3 to 80.2)	(-23.1 to 2.0)
Vascular intestinal disorders	0.0	0.0	92.4	51.0	(0.0 to 0.0)	(0.0 to 0.0)	(31.5 to 89.6)	(-23.2 to 6.7)
Gallbladder and biliary diseases	0.0	0.0	78.3	6.1	(0.0 to 0.0)	(0.0 to 0.0)	77.6	2.3
Pancreatitis	0.0	0.0	84.4	5.4	(0.0 to 0.0)	(0.0 to 0.0)	(48.5 to 110.5)	(-18.8 to 9.4)
Other digestive diseases	-	-	-	-	0.0	0.0	202.7	85.3
Neurological disorders	-	-	-	-	0.2	0.3	69.8	-3.6
Alzheimer disease and other dementias	0.1	0.2	118.8	2.3	(0.1 to 0.3)	(0.2 to 0.5)	(40.4 to 103.6)	(-17.5 to 13.9)
Parkinson disease	0.0	0.0	102.5	-0.5	(0.0 to 0.0)	(0.0 to 0.0)	(86.3 to 158.6)	(-15.0 to 20.1)
Epilepsy	0.1	0.2	47.3	-0.4	(0.0 to 0.0)	(0.0 to 0.0)	(81.9 to 126.5)	(-9.6 to 10.1)
Multiple sclerosis	0.0	0.0	215.1	78.8	(0.0 to 0.0)	(0.0 to 0.0)	215.1	78.8
Migraine	4.5	4.5	59.6	4.1	(0.0 to 0.0)	(0.0 to 0.0)	(176.0 to 252.8)	(57.9 to 98.9)
Tension-type headache	2.3 to 3.4	3.4 to 5.6	(16.3 to 120.4)	(-25.2 to 35.2)	(0.1 to 0.2)	(0.1 to 0.2)	(14.8 to 119.4)	(-26.1 to 35.4)
Medication overuse headache	5.8	8.9	55.4	-5.9	(0.0 to 0.0)	(0.0 to 0.0)	54.4	-6.2
Other neurological disorders	0.1	0.3	162.4	52.7	(0.0 to 0.0)	(0.0 to 0.1)	162.8	52.7
Mental and substance use disorders	0.0	0.0	53.0	2.1	(0.0 to 0.0)	(0.0 to 0.0)	1.5	-53.3
Schizophrenia	0.1	0.2	71.4	-0.4	(0.1 to 0.1)	(0.1 to 0.1)	(58.4 to 66.9)	(-1.4 to 3.4)
Alcohol use disorders	0.3	0.6	115.4	34.2	(0.0 to 0.0)	(0.0 to 0.0)	(62.0 to 82.9)	(-5.3 to 5.8)
Drug use disorders	-	-	-	-	0.1	0.1	50.3	-3.5
Opioid use disorders	0.0	0.1	70.3	-0.1	(0.0 to 0.0)	(0.0 to 0.0)	(26.8 to 78.1)	(-17.2 to 13.3)
Cocaine use disorders	0.0	0.1	52.4 to 88.8	(-10.1 to 10.4)	(0.0 to 0.0)	(0.0 to 0.0)	(48.4 to 93.1)	(-17.0 to 13.0)
Amphetamine use disorders	0.1	0.2	40.8	-6.1	(0.0 to 0.0)	(0.0 to 0.0)	40.2	-6.3
Cannabis use disorders	0.2	0.2	49.4	-0.1	(0.0 to 0.0)	(0.0 to 0.0)	49.4	0.1
Other drug use disorders	-	-	-	-	0.0	0.0	43.4	-5.3
Depressive disorders	-	-	-	-	0.2	0.3	65.9	0.2
Major depressive disorder	0.8	1.3	65.3	0.1	(0.1 to 0.2)	(0.2 to 0.4)	(54.2 to 75.3)	(-5.9 to 5.8)
Dysthymia	0.4	0.8	74.7	0.3	(0.0 to 0.1)	(0.0 to 0.1)	(69.0 to 80.8)	(-2.0 to 3.0)
Bipolar disorder	0.2	0.3	67.3	-0.0	(0.0 to 0.1)	(0.0 to 0.1)	(52.5 to 80.5)	(-7.2 to 6.7)
Anxiety disorders	1.1	1.7	59.2	0.3	(0.1 to 0.1)	(0.1 to 0.2)	(45.9 to 65.2)	(-2.5 to 3.5)
Eating disorders	-	-	-	-	0.0	0.0	40.4	-5.6
Anorexia nervosa	0.0	0.0	32.0	-10.7	(0.0 to 0.0)	(0.0 to 0.0)	(22.2 to 80.4)	(-17.0 to 19.7)
Bulimia nervosa	0.0	0.0	49.8	0.0	(0.0 to 0.0)	(0.0 to 0.0)	50.3	0.4
Autistic spectrum disorders	-	-	-	-	0.1	0.1	47.5	-0.2
Autism	0.1	0.2	48.1	-0.3	(0.0 to 0.1)	(0.1 to 0.1)	(42.3 to 53.2)	(-3.4 to 3.2)
Asperger syndrome	0.2	0.3	47.3	-0.3	(0.0 to 0.0)	(0.0 to 0.1)	(40.0 to 56.1)	(-4.9 to 4.9)
Attention-deficit/hyperactivity disorder	0.3	0.5	37.4	0.1	(0.0 to 0.0)	(0.0 to 0.0)	(40.7 to 53.4)	(-3.9 to 3.4)
Conduct disorder	0.4	0.5	37.6	0.1	(0.0 to 0.0)	(0.0 to 0.0)	(27.6 to 48.4)	(-7.0 to 8.2)
Idiopathic intellectual disability	0.3 to 0.4	0.5 to 0.5	(37.5 to 37.5)	(0.1 to 0.1)	(0.0 to 0.1)	(0.0 to 0.1)	(31.0 to 45.4)	(-4.8 to 5.7)
Other mental and substance use disorders	0.6	1.0	69.3	-0.3	(0.0 to 0.1)	(0.1 to 0.1)	(62.1 to 76.4)	(-3.7 to 3.4)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	0.3	0.4	71.8	6.1
Diabetes mellitus	1.5	3.0	94.9	10.7	(0.2 to 0.4)	(0.3 to 0.6)	(57.6 to 84.7)	(-3.7 to 16.2)
Acute glomerulonephritis	0.0	0.0	55.7	8.8	(0.0 to 0.0)	(0.0 to 0.0)	(66.6 to 145.6)	(-6.0 to 36.9)
Chronic kidney disease	0.0	0.0	46.3 to 64.6	(3.4 to 14.0)	(0.0 to 0.0)	(0.0 to 0.0)	(46.3 to 64.6)	(3.4 to 14.1)
Chronic kidney disease due to diabetes mellitus	0.1	0.4	158.6	48.2	(0.0 to 0.0)	(0.0 to 0.1)	(43.5 to 75.1)	(-8.2 to 10.5)
Chronic kidney disease due to hypertension	0.3	0.2	31.7	-53.7	(0.0 to 0.0)	(0.0 to 0.0)	(88.8 to 214.6)	(10.0 to 98.6)
Chronic kidney disease due to glomerulonephritis	0.3	0.5	38.0	-12.6	(0.0 to 0.0)	(0.0 to 0.0)	(16.8 to 106.2)	(-26.9 to 22.4)
Chronic kidney disease due to other causes	0.7	1.3	80.3	9.2	(0.0 to 0.0)	(0.0 to 0.0)	(-61.5 to -21.7)	(-72.5 to -45.7)
Urinary diseases and male infertility	-	-	-	-	0.0	0.0	90.1	1.3
	-	-	-	-	0.0	0.0	(68.7 to 114.7)	(-10.0 to 12.8)

Appendix Table G.4 - Marshall Islands prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.6 (79.4 to 113.9)	26.0 (16.3 to 38.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.3 (53.7 to 149.1)	26.3 (4.6 to 53.7)
Urolithiasis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	64.7 (40.7 to 100.6)	-12.9 (-25.6 to 6.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.8 (43.9 to 83.1)	-8.1 (-16.9 to 3.0)
Benign prostatic hyperplasia	0.2 (0.2 to 0.2)	0.4 (0.4 to 0.4)	103.0 (74.0 to 134.9)	0.4 (-13.9 to 13.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.9 (73.9 to 134.5)	0.5 (-13.6 to 14.1)
Male infertility due to other causes	0.3 (0.3 to 0.4)	0.6 (0.5 to 0.7)	65.2 (22.7 to 127.2)	1.1 (-25.0 to 36.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.5 (20.1 to 129.6)	0.7 (-26.5 to 39.5)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.6 (45.0 to 184.4)	16.5 (-15.3 to 63.3)
Gynecological diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	64.9 (45.2 to 90.0)	-2.7 (-12.8 to 10.4)
Uterine fibroids	0.7 (0.6 to 0.8)	1.3 (1.2 to 1.4)	83.2 (82.2 to 84.4)	1.1 (1.0 to 1.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.6 (62.0 to 84.9)	-0.9 (-8.5 to 4.8)
Polycystic ovarian syndrome	0.6 (0.5 to 0.6)	0.9 (0.8 to 1.0)	65.9 (43.6 to 94.6)	-1.6 (-13.8 to 13.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.9 (43.7 to 95.4)	-1.5 (-13.4 to 14.4)
Female infertility due to other causes	0.3 (0.3 to 0.4)	0.6 (0.5 to 0.8)	81.1 (38.9 to 142.3)	9.6 (-16.0 to 48.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.8 (37.4 to 136.0)	8.5 (-16.9 to 43.6)
Endometriosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	71.7 (37.2 to 116.5)	0.8 (-19.3 to 25.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.1 (36.4 to 117.7)	0.6 (-19.7 to 26.9)
Genital prolapse	1.6 (1.4 to 1.8)	2.7 (2.3 to 3.1)	67.1 (36.1 to 104.2)	-4.0 (-19.9 to 13.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.7 (36.0 to 103.9)	-4.2 (-20.2 to 14.2)
Premenstrual syndrome	1.3 (0.9 to 1.7)	1.9 (1.2 to 2.5)	45.5 (-10.9 to 164.7)	-11.0 (-44.0 to 51.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.7 (-11.7 to 163.3)	-10.9 (-44.1 to 52.4)
Other gynecological diseases	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	61.2 (23.1 to 118.7)	-0.2 (-24.8 to 37.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.2 (20.2 to 192.5)	-0.0 (-26.2 to 87.3)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	35.9 (22.5 to 52.9)	0.1 (-10.5 to 14.3)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.8 (-3.8 to 41.1)	-5.2 (-26.4 to 10.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.8 (-27.5 to 82.2)	-10.9 (-42.3 to 37.4)
Thalassemia trait	1.9 (1.3 to 2.9)	2.8 (1.9 to 4.3)	49.8 (42.8 to 61.9)	1.4 (-3.4 to 9.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	36.7 (21.6 to 54.2)	0.0 (-12.2 to 15.1)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.3 (-40.4 to -0.7)	-33.5 (-55.9 to -26.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.3 (-46.6 to 8.9)	-33.2 (-61.2 to -19.2)
Sickle cell trait	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.1 (-19.8 to 16.3)	-28.9 (-45.7 to -21.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.0 (-43.6 to 44.0)	33.2 (-55.2 to 5.7)
G6PD deficiency	2.6 (1.7 to 3.5)	4.4 (3.4 to 5.7)	65.7 (9.7 to 199.7)	12.0 (-25.8 to 102.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.3 (-15.4 to 183.4)	12.3 (-35.1 to 75.5)
G6PD trait	9.5 (8.8 to 10.0)	14.2 (12.9 to 15.1)	49.5 (34.5 to 64.3)	1.4 (-8.8 to 11.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.2 (83.4 to 1,424.8)	1.4 (-87.7 to 1,028.9)
Other hemoglobinopathies and hemolytic anemias	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.4)	36.6 (5.6 to 92.4)	1.2 (-22.0 to 38.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.4 (-3.5 to 148.8)	1.8 (-25.7 to 96.3)
Endocrine, metabolic, blood, and immune disorders	0.5 (0.4 to 0.5)	0.6 (0.6 to 0.7)	42.0 (24.0 to 69.2)	2.1 (-8.9 to 16.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.2 (24.6 to 87.1)	3.6 (-7.5 to 26.6)
Musculoskeletal disorders	-	-	-	-	0.5 (0.3 to 0.6)	0.8 (0.6 to 1.1)	82.2 (60.5 to 102.4)	1.3 (-9.3 to 11.3)
Rheumatoid arthritis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	220.2 (202.5 to 240.8)	83.8 (73.5 to 95.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	217.4 (187.0 to 255.5)	83.3 (68.3 to 101.3)
Osteoarthritis	0.5 (0.5 to 0.5)	1.0 (0.9 to 1.0)	99.9 (88.8 to 112.0)	1.2 (-4.2 to 6.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	99.7 (88.1 to 113.1)	1.4 (-4.5 to 7.0)
Low back and neck pain	-	-	-	-	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.8)	77.6 (49.1 to 106.4)	1.9 (-14.3 to 16.5)
Low back pain	1.9 (1.8 to 2.1)	3.4 (3.1 to 3.6)	73.6 (55.6 to 94.7)	0.2 (-8.4 to 10.0)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.5)	73.4 (53.9 to 94.7)	0.2 (-8.5 to 10.3)
Neck pain	1.3 (1.0 to 1.5)	2.3 (1.6 to 2.9)	84.4 (16.9 to 173.0)	1.9 (-33.1 to 49.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	84.2 (16.3 to 174.9)	1.9 (-33.7 to 49.2)
Gout	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.5 (80.4 to 118.3)	3.6 (-5.3 to 14.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.9 (57.5 to 142.0)	3.6 (-14.4 to 23.4)
Other musculoskeletal disorders	0.8 (0.6 to 1.0)	1.5 (1.2 to 1.8)	81.5 (68.0 to 98.7)	4.3 (-10.7 to 4.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	81.4 (66.6 to 98.8)	4.1 (-11.2 to 4.5)
Other non-communicable diseases	-	-	-	-	0.6 (0.4 to 0.9)	1.0 (0.7 to 1.4)	50.7 (41.4 to 71.4)	-7.7 (-11.7 to 0.1)
Congenital anomalies	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	56.2 (-7.9 to 281.9)	10.7 (-32.6 to 162.7)
Neural tube defects	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.5 (31.4 to 108.5)	21.7 (-3.5 to 52.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.2 (20.1 to 147.7)	26.5 (-9.3 to 80.5)
Congenital heart anomalies	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	90.5 (45.9 to 144.7)	35.9 (4.3 to 77.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.2 (42.9 to 145.6)	34.9 (4.9 to 81.8)
Orofacial clefts	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.1 (40.6 to 165.1)	44.6 (4.3 to 99.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.8 (14.2 to 170.5)	31.4 (-13.5 to 97.1)
Down syndrome	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	56.2 (19.7 to 106.0)	7.6 (-17.8 to 42.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.9 (20.0 to 114.9)	8.6 (-19.7 to 45.8)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.1 (-5.1 to 105.2)	0.0 (-34.7 to 43.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.6 (-7.4 to 117.1)	-0.2 (-37.7 to 48.4)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.1 (10.2 to 134.0)	9.3 (-25.2 to 59.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.8 (4.2 to 184.4)	8.9 (-33.8 to 84.4)
Chromosomal unbalanced rearrangements	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	53.9 (19.3 to 111.4)	0.0 (-18.3 to 45.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.7 (18.4 to 118.7)	5.4 (-20.1 to 48.8)
Other congenital anomalies	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.2)	28.0 (14.4 to 42.7)	-13.7 (-22.0 to -4.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	52.5 (-30.6 to 398.5)	9.0 (-48.9 to 244.9)
Skin and subcutaneous diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	47.3 (36.3 to 62.6)	-2.1 (-8.7 to 7.3)
Dermatitis	2.5 (2.0 to 3.1)	3.8 (3.1 to 4.7)	53.2 (50.3 to 56.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	48.1 (41.6 to 54.1)	0.1 (-2.5 to 2.8)
Psoriasis	0.3 (0.2 to 0.3)	0.4 (0.4 to 0.5)	64.2 (62.3 to 66.8)	0.0 (-0.1 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	63.8 (52.8 to 74.9)	-0.0 (-5.5 to 5.6)
Cellulitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.3 (2.6 to 31.1)	-15.6 (-24.3 to -7.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.9 (-12.9 to 58.5)	-15.4 (-32.4 to 3.6)
Pyoderma	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-40.7 (-50.2 to -28.1)	-51.9 (-59.0 to -42.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.8 (-50.9 to -27.6)	-51.9 (-60.2 to -42.6)
Scabies	1.1 (0.8 to 1.7)	1.3 (0.9 to 1.9)	16.3 (-25.9 to 86.0)	-21.1 (-51.6 to 26.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	16.5 (-25.8 to 86.2)	-21.0 (-52.1 to 26.5)
Fungal skin diseases	4.5 (3.8 to 5.3)	7.2 (6.0 to 8.3)	58.2 (54.5 to 61.8)	0.0 (-0.1 to 0.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	58.0 (54.6 to 62.0)	0.0 (-0.7 to 0.7)
Viral skin diseases	1.1 (0.8 to 1.3)	1.5 (1.1 to 1.8)	38.6 (32.9 to 43.9)	0.0 (-1.8 to 2.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	38.2 (31.4 to 45.2)	-0.0 (-3.2 to 3.4)
Acne vulgaris	3.5 (2.5 to 4.5)	4.7 (3.4 to 6.7)	33.6 (9.5 to 106.1)	-7.8 (-36.8 to 40.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	34.1 (9.6 to 106.7)	-7.7 (-36.8 to 41.5)
Alopecia areata	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	65.2 (36.7 to 105.9)	3.3 (-12.6 to 27.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.8 (31.6 to 108.9)	4.3 (-15.3 to 29.8)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.4 (28.6 to 109.2)	2.3 (-23.7 to 27.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.1 (17.6 to 122.3)	-1.9 (-28.5 to 32.9)
Urticaria	0.3 (0.2 to 0.5)	0.6 (0.5 to 0.8)	76.3 (17.7 to 253.1)	8.3 (-25.6 to 110.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	76.8 (17.2 to 253.4)	8.3 (-27.4 to 112.9)
Decubitus ulcer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.2 (69.8 to 151.8)	26.2 (0.9 to 50.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.7 (57.1 to 159.4)	25.3 (-3.3 to 59.6)
Other skin and subcutaneous diseases	2.5 (1.8 to 3.5)	4.2 (2.9 to 6.0)	68.4 (57.8 to 80.6)	-2.2 (-6.0 to 2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	68.1 (57.1 to 80.4)	-2.1 (-5.9 to 3.3)
Sense organ diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.6 (0.3 to 0.6)	50.5 (43.1 to 57.6)	0.0 (-15.2 to -9.6)
Glaucoma	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	58.5 (30.2 to 88.8)	-13.6 (-29.5 to 4.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.9 (12.2 to 95.3)	-11.5 (-41.8 to 4.4)
Cataract	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	39.1 (7.4 to 96.0)	-32.0 (-44.0 to -10.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.9 (16.1 to 82.7)	-32.4 (-41.4 to -15.3)
Macular degeneration	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	69.3 (36.2 to 109.3)	-11.7 (-31.0 to 7.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.4 (35.3 to 101.5)	-13.4 (-32.3 to 1.9)
Uncorrected refractive error	2.5 (2.3 to 2.8)	4.1 (3.8 to 4.4)	60.4 (45.4 to 78.5)	6.8 (-14.4 to 11.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	47.0 (37.1 to 59.5)	-14.2 (-18.9 to -7.9)
Age-related and other hearing loss	4.7 (4.3 to 5.0)	7.7 (7.1 to 8.3)	64.2 (57.1 to 70.4)	-9.2 (-12.4 to -6.5)	0.0 (0.1 to 0.2)	0.2 (0.2 to 0.3)	54.7 (43.3 to 64.9)	-10.0 (-13.6 to -6.2)
Other vision loss	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	30.4 (16.5 to 51.6)	-20.3 (-31.0 to -6.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.2 (15.9 to 50.5)	-20.9 (-31.3 to -9.9)
Other sense organ diseases	1.1 (1.0 to 1.1)	1.6 (1.5 to 1.6)	44.3 (34.1 to 54.6)	0.0 (-6.3 to 6.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	43.8 (32.0 to 55.8)	0.0 (-6.9 to 7.2)
Oral disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	54.2 (46.9 to 62.2)	-13.7 (-18.6 to -9.1)
Deciduous caries	5.9 (5.7 to 6.0)	7.4 (7.2 to 7.5)	25.6 (22.2 to 29.0)	-0.1 (-2.7 to 2.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.7 (18.6 to 33.4)	0.0 (-5.4 to 6.0)
Permanent caries	13.9 (13.1 to 14.6)	22.2 (21.1 to 23.3)	59.4 (48.4 to 72.1)	1.7 (-4.4 to 8.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.3 (48.4 to 72.2)	1.8 (-4.5 to 1.2)
Periodontal diseases	0.3 (0.3 to 0.3)	0.6 (0.5 to 0.6)	88.5 (72.5 to 105.2)	2.0 (-5.8 to 10.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.3 (72.2 to 105.7)	2.0 (-6.0 to 10.7)

Appendix Table G.4 - Marshall Islands prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	0.4 (0.4 to 0.4)	0.5 (0.5 to 0.5)	32.2 (20.1 to 43.5)	-34.1 (-39.4 to -29.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.2 (19.7 to 44.3)	-34.0 (-39.7 to -28.7)
Other oral disorders	0.7 (0.6 to 0.7)	1.1 (1.0 to 1.2)	62.7 (51.1 to 76.3)	0.2 (-6.5 to 7.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.6 (49.7 to 76.8)	0.2 (-7.1 to 8.0)
Injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	41.3 (27.1 to 57.4)	-15.4 (-23.1 to -6.5)
Transport injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	34.8 (17.6 to 54.1)	-18.1 (-27.6 to -7.9)
Road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	34.2 (16.4 to 54.8)	-27.6 (-27.6 to -7.0)
Pedestrian road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.7 (17.7 to 59.8)	-13.5 (-24.3 to -2.2)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.5 (27.3 to 60.4)	-12.8 (-21.9 to -3.2)
Motorcyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.1 (11.9 to 50.7)	-21.7 (-31.6 to -10.9)
Motor vehicle road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.6 (17.3 to 58.2)	-20.3 (-26.5 to -3.8)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.1 (18.3 to 55.7)	-20.6 (-29.6 to -10.3)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.6 to 56.3 (22.6 to 56.3)	-10.3 (-29.1 to -10.5)
Unintentional injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	51.7 (39.9 to 64.8)	-10.3 (-17.1 to -3.3)
Falls	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.8 (22.0 to 53.4)	-21.1 (-29.2 to -12.0)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.7 (3.6 to 29.1)	-29.8 (-38.4 to -19.9)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.0 (-18.3 to 8.3)	-40.3 (-47.5 to -32.5)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.5 (-11.9 to 29.7)	-32.4 (-42.3 to -20.6)
Exposure to mechanical forces	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.8 (66.2 to 92.6)	8.8 (1.9 to 16.3)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.0 (-3.3 to 15.7)	-35.5 (-42.6 to -27.5)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.3 (36.9 to 69.1)	-5.4 (-13.9 to 4.1)
Other exposure to mechanical forces	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.3 (72.9 to 100.0)	12.8 (5.8 to 20.4)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.1 (65.2 to 87.5)	5.5 (-0.6 to 11.8)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.1 (27.3 to 55.8)	-15.2 (-22.5 to -7.7)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.8 (31.3 to 70.1)	-9.9 (-19.7 to 0.6)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.5 (20.2 to 49.6)	-19.6 (-27.1 to -11.5)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.5 (18.0 to 41.0)	-19.3 (-25.8 to -12.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.9 (-23.3 to 13.1)	-34.0 (-44.3 to -22.5)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.4 (35.3 to 55.9)	-9.4 (-15.9 to -2.9)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.6 (30.6 to 59.4)	-16.8 (-23.8 to -8.1)
Other unintentional injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.5 (68.5 to 104.6)	11.6 (1.7 to 21.8)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.2 (-3.3 to 25.3)	-34.6 (-42.2 to -26.2)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.2 (8.1 to 41.5)	-29.1 (-37.7 to -20.2)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.0 (-8.2 to 21.3)	-36.7 (-44.3 to -27.7)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.6 (6.9 to 32.2)	-27.4 (-34.2 to -20.3)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.9 (3.0 to 38.1)	-30.2 (-38.7 to -19.1)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.3 (-14.8 to 15.0)	-40.3 (-48.2 to -31.3)
Forces of nature, war, and legal intervention	-	-	-	-	-	-	-	-
Exposure to forces of nature	-	-	-	-	-	-	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Mauritania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	215.5 (154.3 to 281.9)	381.3 (277.8 to 499.3)	78.6 (73.6 to 84.0)	78.6 (-11.2 to -6.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	73.6 (50.8 to 103.9)	98.6 (69.1 to 137.1)	33.7 (27.9 to 42.0)	31.4 (-34.6 to -26.9)
HIV/AIDS and tuberculosis	-	-	-	-	2.1 (1.4 to 3.1)	5.5 (3.4 to 10.1)	11.0 (114.0 to 291.9)	11.0 (0.9 to 7.3)
Tuberculosis	6.8 (6.2 to 7.3)	14.6 (13.6 to 15.7)	116.0 (103.3 to 131.9)	1.8 (-3.6 to 8.8)	2.0 (1.4 to 2.8)	4.4 (3.0 to 6.0)	117.7 (102.6 to 134.2)	2.6 (-4.0 to 7.9)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.5)	1.0 (0.2 to 5.2)	1,398.3 (244.5 to 4,720.3)	962.3 (61.0 to 1,187.8)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.1)	0.2 (0.0 to 1.0)	669.8 (42.9 to 3,089.8)	252.5 (-36.3 to 1,396.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.4)	641.2 (18.4 to 3,767.0)	231.1 (-45.0 to 1,669.7)
HIV/AIDS resulting in other diseases	1.0 (0.1 to 4.4)	6.6 (1.4 to 29.9)	1,258.1 (189.1 to 4,743.8)	598.0 (44.8 to 2,400.2)	0.1 (0.0 to 0.4)	0.9 (0.1 to 4.9)	1,509.4 (239.3 to 6,457.4)	669.6 (60.7 to 3,318.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	7.3 (9.9 to 18.7)	7.4 (11.5 to 22.0)	1.2 (4.4 to 32.6)	43.7 (-41.9 to -28.1)
Diarrheal diseases	45.8 (40.2 to 51.2)	46.0 (40.2 to 53.0)	0.3 (-15.9 to 20.7)	-44.1 (-52.1 to -34.3)	7.3 (4.9 to 10.3)	7.4 (5.0 to 10.4)	1.2 (-16.0 to 21.8)	43.7 (-52.2 to -33.7)
Intestinal infectious diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.1)	-61.6 (-71.9 to -50.8)	-79.1 (-84.7 to -73.1)
Typhoid fever	1.2 (1.0 to 1.4)	0.5 (0.5 to 0.6)	-54.9 (-63.6 to -45.8)	-75.8 (-80.4 to -70.2)	0.2 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-53.3 (-64.3 to -40.1)	-74.6 (-80.2 to -67.7)
Paratyphoid fever	0.8 (0.7 to 0.9)	0.4 (0.4 to 0.5)	-45.8 (-57.3 to -30.1)	-71.0 (-77.5 to -62.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-44.5 (-59.0 to -24.8)	-70.2 (-77.8 to -60.6)
Other intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-91.0 (-96.9 to -75.1)	-95.1 (-98.3 to -47.3)
Lower respiratory infections	2.1 (1.8 to 2.4)	2.9 (2.4 to 3.6)	40.3 (3.6 to 79.6)	-16.3 (-31.3 to 1.1)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	41.4 (3.9 to 87.0)	-15.8 (-32.1 to 5.3)
Upper respiratory infections	116.3 (104.7 to 127.1)	221.4 (197.0 to 246.9)	91.3 (63.1 to 117.9)	0.5 (-13.7 to 14.9)	1.4 (0.8 to 2.3)	2.6 (1.5 to 4.3)	92.3 (63.4 to 120.2)	1.1 (-13.7 to 16.5)
Otitis media	44.4 (39.6 to 48.4)	78.6 (70.7 to 86.9)	77.1 (59.5 to 97.3)	-6.5 (-17.5 to 4.4)	0.9 (0.5 to 1.5)	1.6 (1.0 to 2.6)	77.3 (58.3 to 100.4)	-5.9 (-16.8 to 6.5)
Meningitis	-	-	-	-	3.3 (2.3 to 4.7)	3.8 (2.5 to 5.4)	14.4 (-7.9 to 42.5)	-40.6 (-51.0 to -26.7)
Pneumococcal meningitis	14.3 (8.8 to 22.4)	16.2 (9.5 to 26.1)	12.8 (-17.1 to 64.6)	-41.8 (-56.9 to -17.1)	1.6 (0.8 to 1.7)	1.6 (0.9 to 2.5)	27.6 (-13.8 to 97.1)	34.4 (-55.0 to -2.8)
H influenzae type B meningitis	5.9 (2.3 to 11.1)	6.5 (2.7 to 11.8)	11.6 (-19.7 to 54.3)	-42.8 (-58.7 to -21.9)	0.6 (0.4 to 1.0)	0.8 (0.5 to 1.3)	27.6 (-18.3 to 90.6)	-33.5 (-56.2 to -1.0)
Meningococcal meningitis	8.0 (2.9 to 16.8)	7.0 (2.5 to 15.3)	-13.3 (-34.7 to 17.7)	-54.3 (-65.3 to -40.3)	1.0 (0.6 to 1.5)	0.9 (0.5 to 1.4)	-13.8 (-40.6 to 28.4)	-54.2 (-67.1 to -35.7)
Other meningitis	3.8 (2.5 to 5.8)	4.2 (2.7 to 6.5)	8.1 (-16.2 to 46.8)	-41.3 (-55.1 to -19.2)	0.5 (0.3 to 0.7)	0.5 (0.4 to 0.8)	13.9 (-11.9 to 74.7)	-37.0 (-51.0 to -3.4)
Encephalitis	0.4 (0.2 to 0.8)	0.7 (0.3 to 1.4)	83.0 (62.3 to 104.7)	6.7 (-16.2 to 2.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	97.4 (56.5 to 122.9)	-5.3 (-19.2 to 9.9)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.0 (-96.8 to 788.5)	-69.8 (-97.4 to 266.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.0 (-96.9 to 810.0)	-69.8 (-97.5 to 272.9)
Whooping cough	4.4 (3.4 to 5.7)	4.5 (3.5 to 5.8)	3.3 (0.1 to 6.5)	-38.4 (-40.3 to -36.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	4.0 (-3.5 to 12.6)	-38.0 (-42.5 to -32.9)
Tetanus	0.3 (0.1 to 0.5)	0.2 (0.1 to 0.6)	-33.9 (-75.0 to 104.4)	-67.0 (-87.2 to 3.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.8 (-70.7 to 47.1)	-70.0 (-83.8 to -31.2)
Measles	1.0 (0.8 to 1.4)	0.2 (0.1 to 0.2)	-84.7 (-85.5 to -79.7)	-91.0 (-93.2 to -88.0)	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	94.6 (-90.6 to -76.7)	-90.9 (-94.4 to -86.3)
Varicella and herpes zoster	1.3 (1.1 to 1.4)	2.5 (2.3 to 2.9)	99.4 (74.3 to 136.6)	1.1 (-18.0 to 28.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	106.5 (50.0 to 204.5)	-0.2 (-30.0 to 47.0)
Neglected tropical diseases and malaria	-	-	-	-	19.1 (11.5 to 30.3)	14.1 (8.0 to 24.3)	-27.2 (-36.3 to -13.1)	-62.2 (-67.1 to -54.7)
Malaria	998.8 (537.0 to 1,366.6)	280.1 (142.1 to 472.3)	-73.1 (-83.3 to -52.6)	-85.7 (-92.0 to -74.8)	8.7 (5.8 to 12.5)	1.9 (1.3 to 2.7)	78.3 (-80.9 to -74.3)	89.4 (-90.8 to -87.3)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	84.4 (-42.7 to 314.2)	-11.7 (-72.6 to 99.8)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.9 (38.8 to 160.4)	4.0 (-23.7 to 34.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.9 (38.6 to 160.9)	4.0 (-23.9 to 34.2)
Cutaneous and mucocutaneous leishmaniasis	2.5 (1.2 to 3.9)	4.5 (1.9 to 7.8)	81.8 (-42.7 to 319.0)	-12.3 (-72.8 to 97.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	84.4 (-42.7 to 314.3)	-11.7 (-72.6 to 99.9)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	714.4 (435.4 to 1,017.0)	824.9 (502.5 to 1,241.1)	13.8 (1.6 to 38.1)	-43.1 (-49.2 to -30.9)	7.1 (3.3 to 13.7)	8.1 (3.6 to 16.2)	12.0 (-1.4 to 40.4)	-43.9 (-50.0 to -30.2)
Cysticercosis	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	35.5 (-62.2 to 568.5)	-40.0 (-85.4 to 167.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-58.9 to 708.8)	-32.4 (-82.9 to 233.1)
Cystic echinococcosis	0.5 (0.5 to 0.6)	0.8 (0.7 to 0.9)	58.6 (23.3 to 83.9)	-19.1 (-34.4 to -4.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	56.7 (17.8 to 98.5)	-18.7 (-35.4 to 1.4)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	7.2 (3.6 to 12.3)	5.0 (2.7 to 8.1)	-34.0 (-61.8 to 39.7)	-68.5 (-79.9 to -32.2)	0.5 (0.2 to 0.9)	0.3 (0.2 to 0.6)	-34.5 (-59.4 to 45.3)	-68.4 (-78.9 to -27.7)
Dengue	0.1 (0.0 to 0.2)	0.6 (0.1 to 1.7)	835.8 (824.5 to 849.0)	388.2 (382.3 to 395.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.3)	786.7 (600.1 to 993.6)	357.1 (271.5 to 452.5)
Yellow fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.8 (-68.9 to -16.3)	-73.1 (-87.7 to -57.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.8 (-69.1 to -15.9)	-73.1 (-82.7 to -57.8)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.2 (-0.6 to 119.3)	-14.7 (-45.8 to 18.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.2 (-1.2 to 119.4)	-14.7 (-46.0 to 18.5)
Intestinal nematode infections	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	89.5 (23.3 to 179.8)	-1.3 (-34.1 to 45.8)
Ascariasis	13.5 (9.6 to 18.9)	26.3 (17.7 to 38.3)	93.7 (16.6 to 219.5)	-0.6 (-45.5 to 86.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.9 (-18.0 to 314.4)	-0.6 (-59.3 to 153.8)
Trichuriasis	54.4 (37.8 to 75.3)	106.1 (73.5 to 148.1)	96.2 (16.9 to 222.5)	3.4 (-44.1 to 89.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.4 (-12.1 to 301.1)	-0.4 (-57.6 to 144.2)
Hookworm disease	62.1 (45.6 to 82.8)	122.4 (88.8 to 172.5)	97.9 (28.2 to 202.7)	0.7 (-38.9 to 67.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	89.8 (23.2 to 180.3)	-1.7 (-34.6 to 47.7)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	43.2 (32.6 to 53.6)	74.6 (69.7 to 82.3)	72.8 (37.1 to 130.6)	-9.7 (-27.1 to 15.0)	1.5 (2.5 to 4.0)	3.2 (2.1 to 4.7)	29.3 (-2.0 to 77.9)	-41.1 (-60.2 to -16.4)
Maternal disorders	-	-	-	-	0.8 (0.5 to 1.2)	1.1 (0.6 to 1.6)	34.1 (16.0 to 57.8)	-36.2 (-44.6 to -26.0)
Maternal hemorrhage	0.7 (0.5 to 0.9)	1.6 (1.0 to 2.1)	125.5 (37.8 to 241.3)	2.9 (-35.6 to 53.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	95.4 (-0.9 to 248.0)	8.4 (-53.6 to 59.7)
Maternal sepsis and other maternal infections	1.0 (0.7 to 1.4)	1.2 (0.8 to 1.6)	-50.3 (-7.3 to 28.1)	-50.3 (-58.3 to -43.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.9 (-41.0 to 105.7)	47.8 (-70.5 to -8.2)
Maternal hypertensive disorders	0.7 (0.2 to 1.2)	1.0 (0.4 to 1.9)	58.5 (45.5 to 76.5)	-26.1 (-32.3 to -16.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	59.0 (34.3 to 92.1)	-25.6 (-37.2 to -8.8)
Obstructed labor	1.8 (1.2 to 2.4)	2.2 (1.5 to 3.0)	26.3 (14.0 to 42.4)	-39.4 (-46.2 to -32.4)	0.6 (0.3 to 0.9)	0.7 (0.4 to 1.1)	27.4 (10.1 to 49.5)	39.0 (-47.4 to 29.3)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.1 (8.0 to 216.7)	-19.3 (-50.2 to 39.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.1 (7.9 to 216.9)	-19.3 (-50.3 to 40.0)
Other maternal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	42.3 (-6.1 to 131.0)	-32.5 (-55.5 to 10.2)
Neonatal disorders	-	-	-	-	2.3 (1.3 to 3.7)	8.2 (5.7 to 11.8)	270.4 (135.5 to 457.1)	103.4 (30.4 to 209.6)
Preterm birth complications	7.9 (4.2 to 13.7)	33.3 (19.9 to 54.9)	320.6 (230.8 to 517.2)	117.6 (74.9 to 208.5)	0.8 (0.4 to 1.3)	4.0 (2.4 to 6.3)	403.7 (196.7 to 990.6)	172.1 (63.3 to 469.4)
Neonatal encephalopathy due to birth asphyxia and trauma	13.3 (2.1 to 39.8)	23.0 (5.6 to 63.0)	82.8 (46.3 to 214.4)	6.1 (-24.9 to 70.0)	0.8 (0.4 to 1.5)	2.3 (1.4 to 3.7)	176.1 (71.3 to 419.0)	53.0 (-6.9 to 203.3)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	138.6 (228.5 to 310.5)	138.6 (103.8 to 154.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	138.6 (227.6 to 327.2)	138.2 (103.2 to 165.0)
Hemolytic disease and other neonatal jaundice	0.9 (0.4 to 1.7)	3.2 (1.6 to 6.5)	231.9 (57.4 to 866.1)	85.5 (-12.9 to 435.7)	0.3 (0.1 to 0.6)	1.2 (0.6 to 2.6)	229.3 (53.5 to 902.6)	84.1 (-14.3 to 445.3)
Other neonatal disorders	-	-	-	-	0.3 (0.1 to 0.9)	0.7 (0.3 to 1.4)	138.5 (-22.5 to 515.4)	31.2 (-57.6 to 243.5)
Nutritional deficiencies	-	-	-	-	33.5 (22.5 to 47.2)	50.2 (33.9 to 72.1)	49.8 (40.2 to 60.7)	-24.3 (-28.3 to -19.3)
Protein-energy malnutrition	25.0 (17.5 to 34.6)	25.8 (12.5 to 45.5)	0.3 (-52.4 to 101.2)	37.9 (-68.5 to 19.3)	3.1 (1.8 to 4.9)	3.2 (1.3 to 6.0)	3.2 (-53.0 to 105.8)	31.8 (-69.0 to 20.4)
Iodine deficiency	123.3 (94.4 to 154.8)	142.2 (99.6 to 204.9)	12.6 (-24.4 to 82.0)	-45.2 (-63.2 to -7.7)	2.2 (1.3 to 3.6)	2.6 (1.4 to 4.5)	13.4 (-23.0 to 83.2)	44.7 (-62.9 to -7.1)
Vitamin A deficiency	6.0 (4.5 to 7.8)	5.0 (3.7 to 6.4)	-17.0 (-32.6 to -2.6)	-56.6 (-65.9 to -49.0)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.4)	-17.7 (-33.3 to -0.8)	-56.7 (-65.6 to -48.1)

Appendix Table G.4 - Mauritania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	694.8 (676.9 to 710.6)	1,204.3 (1,186.7 to 1,222.6)	73.4 (68.6 to 77.7)	-44.4 (-16.7 to -12.3)	27.9 (18.8 to 39.7)	44.2 (29.6 to 63.7)	58.4 (52.1 to 64.1)	58.4 (-23.9 to -17.9)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-61.0 to 246.8)	-28.0 (-74.9 to 108.6)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.0 (1.3 to 2.9)	3.3 (2.1 to 4.8)	63.5 (50.5 to 83.6)	-18.1 (-25.1 to -8.7)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.4 (0.2 to 0.6)	0.8 (0.4 to 1.3)	109.9 (54.3 to 164.3)	-3.5 (-25.0 to 17.3)
Syphilis	0.2 (0.2 to 0.2)	0.3 (0.2 to 0.3)	20.3 (1.6 to 44.2)	-43.3 (-50.8 to -34.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-8.0 to 62.0)	43.2 (-5.5 to -27.5)
Chlamydial infection	28.1 (20.8 to 36.3)	59.0 (36.1 to 80.2)	114.2 (15.4 to 234.1)	1.2 (-43.5 to 58.2)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.5)	126.2 (19.0 to 274.8)	10.3 (-38.0 to 75.1)
Gonococcal infection	10.3 (7.3 to 13.8)	19.6 (12.2 to 26.1)	94.2 (8.5 to 203.0)	-5.2 (-46.0 to 43.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	94.6 (-8.3 to 224.2)	-4.5 (53.4 to 52.7)
Trichomoniasis	17.3 (9.2 to 34.0)	55.7 (33.4 to 83.4)	242.3 (29.3 to 638.8)	41.3 (-36.5 to 196.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	269.9 (17.7 to 799.7)	49.7 (-41.9 to 241.8)
Genital herpes	309.2 (280.2 to 329.2)	637.4 (589.7 to 687.4)	109.7 (85.9 to 134.3)	-2.1 (-13.4 to 9.3)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	188.7 (82.6 to 238.2)	-1.6 (-13.4 to 12.0)
Other sexually transmitted diseases	0.9 (0.6 to 1.2)	1.5 (1.1 to 2.1)	75.1 (50.1 to 114.8)	-23.1 (-34.2 to -7.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.4 (21.9 to 160.9)	19.1 (-41.6 to 13.7)
Hepatitis	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	39.3 (16.2 to 69.2)	-34.4 (-46.5 to -18.6)
Hepatitis A	3.6 (3.4 to 3.8)	6.0 (5.8 to 6.3)	67.6 (66.4 to 69.0)	-3.6 (-3.8 to -3.3)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	87.5 (65.9 to 113.9)	3.0 (-8.6 to 17.4)
Hepatitis B	399.6 (333.9 to 476.3)	471.1 (412.2 to 528.5)	18.0 (-6.3 to 50.7)	-41.7 (-50.0 to -28.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	17.5 (-1.7 to 60.3)	-44.8 (-59.9 to -25.0)
Hepatitis C	136.1 (119.8 to 151.6)	199.7 (174.3 to 225.4)	46.8 (24.3 to 73.5)	27.4 (-37.7 to -15.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.9 (9.0 to 87.3)	-25.3 (-43.5 to -3.3)
Hepatitis E	0.6 (0.4 to 0.8)	1.1 (0.8 to 1.4)	85.9 (10.5 to 171.1)	-5.0 (-42.0 to 34.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.9 (7.8 to 188.2)	-6.2 (-44.5 to 40.5)
Leprosy	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.4)	51.4 (1.2 to 162.1)	-24.8 (-47.7 to 27.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.7 (-1.2 to 188.1)	-23.1 (-48.3 to 36.5)
Other infectious diseases	31.9 (24.8 to 39.3)	53.7 (49.9 to 57.6)	68.7 (40.3 to 82.9)	-13.9 (-25.7 to -7.9)	1.3 (0.9 to 1.9)	2.1 (1.3 to 3.0)	56.1 (42.7 to 81.2)	-19.0 (-27.0 to -7.5)
Non-communicable diseases	-	-	-	-	130.3 (95.2 to 168.8)	287.9 (196.1 to 347.2)	105.5 (100.4 to 111.4)	0.3 (-2.4 to 3.0)
Neoplasms	-	-	-	-	0.4 (0.3 to 0.6)	1.2 (0.8 to 1.8)	179.7 (111.3 to 262.4)	30.9 (2.5 to 69.6)
Esophageal cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	113.2 (31.9 to 233.8)	3.3 (-34.2 to 61.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	110.7 (35.2 to 226.3)	1.6 (-35.2 to 58.4)
Stomach cancer	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.4)	74.7 (28.4 to 142.2)	-13.6 (-36.5 to 18.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	76.6 (28.5 to 146.0)	-13.2 (-35.7 to 20.5)
Liver cancer	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	104.1 (32.5 to 191.8)	3.9 (-34.5 to 34.6)
Liver cancer due to hepatitis B	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	146.8 (25.4 to 381.3)	14.9 (-41.2 to 121.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	142.2 (34.2 to 338.0)	12.5 (-37.2 to 114.7)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	342.4 (87.3 to 1,033.2)	115.2 (5.6 to 430.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	305.9 (79.1 to 852.6)	96.8 (-10.6 to 348.3)
Liver cancer due to alcohol use	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-7.9 (-60.2 to 112.8)	-54.3 (-78.6 to -2.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.2 (-54.9 to 107.0)	-53.5 (-76.3 to -6.3)
Liver cancer due to other causes	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	19.2 (-41.7 to 132.3)	44.3 (-72.9 to 77.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.4 (-38.6 to 114.2)	-44.9 (-70.4 to 0.3)
Larynx cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	14.0 (-33.5 to 226.4)	-44.3 (-67.7 to 57.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.7 (-21.2 to 224.4)	-36.5 (-61.8 to 54.2)
Tracheal, bronchus and lung cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	102.1 (49.6 to 189.6)	-1.6 (-25.5 to 38.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.6 (47.9 to 188.6)	-1.7 (-27.7 to 38.2)
Breast cancer	0.5 (0.4 to 0.7)	2.3 (1.4 to 3.4)	328.3 (168.8 to 543.3)	86.3 (22.1 to 175.1)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	277.5 (136.4 to 463.6)	64.9 (7.5 to 149.2)
Cervical cancer	1.1 (0.7 to 1.4)	2.1 (1.3 to 3.1)	95.6 (15.1 to 239.4)	6.6 (-43.5 to 56.6)	0.0 (0.1 to 0.1)	0.2 (0.1 to 0.3)	86.9 (14.5 to 234.9)	-5.5 (-43.2 to 56.7)
Uterine cancer	0.2 (0.1 to 0.4)	0.6 (0.3 to 1.0)	180.9 (44.6 to 459.1)	33.2 (-28.4 to 150.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	175.6 (43.0 to 438.6)	29.2 (-28.5 to 140.8)
Prostate cancer	0.3 (0.2 to 0.6)	2.0 (1.3 to 3.3)	516.1 (288.7 to 895.7)	202.7 (93.9 to 378.3)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	415.5 (236.2 to 707.6)	157.3 (69.9 to 293.1)
Colon and rectum cancer	0.3 (0.3 to 0.4)	0.7 (0.5 to 0.9)	114.2 (54.0 to 184.8)	-13.8 (-37.6 to 12.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	109.7 (51.8 to 179.7)	-12.9 (-36.1 to 15.5)
Lip and oral cavity cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	150.5 (66.0 to 251.6)	19.2 (-20.7 to 73.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	146.0 (62.0 to 260.4)	36.2 (-23.0 to 76.4)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.6 (40.6 to 272.6)	1.7 (-35.5 to 68.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.4 (36.7 to 240.0)	2.4 (-36.7 to 53.1)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.0 (15.6 to 256.7)	-4.3 (-43.6 to 63.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	100.4 (23.9 to 225.3)	-4.2 (-40.0 to 52.6)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	179.4 (84.0 to 336.4)	26.9 (-15.5 to 100.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	166.4 (79.5 to 292.5)	21.4 (-17.2 to 81.6)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	266.1 (163.5 to 414.3)	73.7 (-24.8 to 138.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	258.8 (165.7 to 377.1)	68.8 (-26.0 to 125.4)
Malignant skin melanoma	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	199.4 (85.8 to 370.3)	35.9 (-12.2 to 122.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	186.2 (77.5 to 371.8)	29.3 (-16.0 to 115.7)
Non-melanoma skin cancer	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	205.3 (94.7 to 474.2)	36.6 (-10.4 to 148.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	243.0 (139.9 to 415.0)	58.3 (-1.9 to 151.7)
Ovarian cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	180.1 (69.2 to 379.1)	31.2 (-18.0 to 118.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	177.9 (65.1 to 391.6)	30.7 (-21.8 to 128.6)
Testicular cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	258.9 (97.2 to 581.5)	65.5 (-10.0 to 210.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	245.5 (66.6 to 577.6)	55.7 (-19.8 to 195.3)
Kidney cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	159.3 (69.7 to 338.3)	22.7 (-15.1 to 80.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	149.0 (59.3 to 307.7)	16.5 (-20.6 to 68.3)
Bladder cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	105.6 (38.9 to 202.9)	-6.5 (-35.9 to 40.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.6 (37.5 to 192.7)	-8.6 (-37.7 to 37.0)
Brain and nervous system cancer	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.2)	344.4 (183.3 to 554.5)	108.1 (46.7 to 180.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	323.9 (185.9 to 494.4)	89.5 (34.2 to 150.6)
Thyroid cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	154.6 (34.4 to 411.3)	18.4 (-36.9 to 135.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	141.6 (28.6 to 394.8)	11.5 (-39.7 to 126.4)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.1 (41.9 to 220.1)	0.7 (-33.2 to 49.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.7 (39.7 to 216.4)	0.0 (-35.1 to 51.3)
Hodgkin lymphoma	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.5)	282.2 (136.4 to 551.3)	94.6 (21.6 to 215.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	248.2 (116.5 to 458.0)	76.3 (10.4 to 172.7)
Non-Hodgkin lymphoma	0.2 (0.1 to 0.3)	0.7 (0.4 to 0.9)	233.2 (120.9 to 387.5)	63.6 (12.6 to 136.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	221.6 (118.0 to 370.9)	54.6 (8.5 to 121.2)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	226.0 (92.0 to 439.9)	54.4 (-10.0 to 165.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	205.1 (77.2 to 392.6)	43.0 (-18.9 to 145.3)
Leukemia	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	279.9 (130.5 to 527.6)	67.5 (11.4 to 149.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	229.8 (125.0 to 384.2)	38.9 (-3.1 to 105.7)
Other neoplasms	0.5 (0.3 to 0.6)	2.0 (1.2 to 2.8)	314.2 (135.2 to 568.2)	88.0 (16.9 to 187.6)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	285.5 (126.4 to 500.9)	66.1 (3.8 to 156.3)
Cardiovascular diseases	-	-	-	-	3.3 (2.2 to 4.5)	6.8 (4.5 to 9.7)	108.8 (64.2 to 163.7)	4.0 (-18.0 to 30.8)
Rheumatic heart disease	23.0 (17.2 to 29.6)	38.4 (27.8 to 47.8)	67.8 (21.9 to 125.0)	-14.7 (-37.4 to 11.0)	1.1 (0.7 to 1.7)	1.9 (1.2 to 3.0)	73.6 (25.9 to 132.4)	-8.0 (-32.2 to 19.0)
Ischemic heart disease	14.3 (10.5 to 17.7)	22.0 (18.5 to 26.9)	51.2 (16.6 to 129.2)	-21.8 (-38.1 to 10.4)	0.7 (0.4 to 1.1)	0.9 (0.5 to 1.4)	32.1 (-12.9 to 133.9)	-32.7 (-53.1 to 11.7)
Cerebrovascular disease	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	116.5 (77.7 to 163.3)	2.9 (-14.9 to 26.4)
Ischemic stroke	0.8 (0.7 to 0.9)	1.8 (1.5 to 2.0)	119.2 (79.7 to 167.1)	3.7 (-14.4 to 28.6)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	120.6 (78.4 to 173.2)	5.1 (-15.0 to 31.5)
Hemorrhagic stroke	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.6)	103.8 (58.4 to 155.7)	-4.5 (-24.9 to 19.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	103.8 (56.1 to 166.0)	-4.4 (-26.0 to 23.4)
Hypertensive heart disease	2.8 (2.0 to 3.6)	5.8 (4.0 to 7.7)	104.6 (35.5 to 214.0)	4.4 (-35.5 to 46.9)	0.3 (0.2 to 0.5)	0.6 (0.4 to 1.0)	105.9 (36.9 to 216.3)	-3.5 (-35.9 to 48.8)
Cardiomyopathy and myocarditis	1.9 (1.4 to 2.5)	4.1 (2.9 to 5.8)	113.0 (24.1 to 255.2)	6.5 (-44.0 to 89.1)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.7)	114.8 (24.5 to 268.4)	7.7 (-45.0 to 92.9)
Atrial fibrillation and flutter	0.2 (0.2 to 0.3)	1.2 (0.8 to 1.7)	406.6 (220.6 to 687.5)	168.0 (17.4 to 393.4)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	398.9 (212.9 to 705.0)	171.8 (19.7 to 398.0)
Peripheral vascular disease	30.7 (22.4 to 39.7)	59.3 (35.2 to 79.2)	94.9 (12.3 to 185.6)	-7.6 (-38.2 to 33.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	116.6 (12.5 to 339.8)	8.9 (-46.9 to 114.4)
Endocarditis	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.4)	27.6 (-24.1 to 108.0)	-36.6 (-65.6 to 15.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.9 (-26.7 to 130.9)	-34.7 (-67.0 to 32.0)
Other cardiovascular and circulatory diseases	10.5 (6.5 to 16.0)	34.1 (16.0 to 51.5)	227.0 (46.6 to 534.2)	5.8 (-33.9 to 219.5)	0.7 (0.4 to 1.2)	2.4 (1.0 to 4.2)	230.4 (47.7 to 546.9)	57.8 (-33.6 to 227.6)
Chronic respiratory diseases	-	-	-	-	9.4 (6.2 to 13.2)	19.1 (12.8 to 26.2)	103.0 (77.8 to 140.3)	-5.1

Appendix Table G.4 - Mauritania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	106.3	-3.6
Silicosis	0.0	0.0	96.7	-8.3	0.0	0.0	(99.0 to 113.2)	(-6.8 to -0.2)
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	96.7	-8.3
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	114.0	1.4	0.0	0.0	114.8	1.6
Asthma	53.4	118.9	(104.7 to 123.5)	(-2.7 to 5.7)	2.3	5.2	123.4	7.7
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.1	119.4	5.7	0.0	0.0	119.5	5.8
Other chronic respiratory diseases	-	-	-	-	1.8	2.8	63.0	23.5
Cirrhosis	0.4	0.5	19.9	-39.2	0.1	0.1	18.9	-38.9
Cirrhosis due to hepatitis B	0.2	0.4	109.7	6.6	0.0	0.1	105.6	5.9
Cirrhosis due to hepatitis C	0.2	0.3	52.3	-26.5	0.0	0.0	52.7	-26.0
Cirrhosis due to alcohol use	0.2	0.5	106.9	18.4	0.0	0.1	108.1	18.3
Cirrhosis due to other causes	0.2	0.3	50.1 to 183.7	(-17.3 to 65.1)	0.0	0.1	36.3 to 220.2	(-22.3 to 78.1)
Digestive diseases	-	-	-	-	2.6	4.9	92.8	8.7
Peptic ulcer disease	11.3	18.2	60.3	-22.7	0.4	0.7	52.1	-26.6
Gastritis and duodenitis	23.0	46.0	100.3	-0.5	1.0	1.9	87.1	-4.9
Appendicitis	0.2	0.5	133.6	11.3	0.1	0.2	137.7	13.1
Paralytic ileus and intestinal obstruction	0.0	0.1	91.5	-17.9 to 49.7	0.0	0.1	60.2 to 273.4	(-22.3 to 67.6)
Inguinal, femoral, and abdominal hernia	8.8	16.7	88.5	-11.6	0.1	0.2	89.7	-10.6
Inflammatory bowel disease	1.8	4.9	168.3	26.5	0.4	1.0	169.5	27.1
Vascular intestinal disorders	0.0	0.0	161.3	-3.3	0.0	0.0	164.3	-1.3
Gallbladder and biliary diseases	0.6	1.4	143.5	9.1	0.1	0.1	149.6	12.1
Pancreatitis	0.3	0.7	137.7	10.2	0.1	0.2	139.5	11.5
Other digestive diseases	-	-	-	-	0.4	0.6	48.2	-29.8
Neurological disorders	-	-	-	-	8.5	18.7	120.4	8.2
Alzheimer disease and other dementias	2.6	5.4	112.1	2.6	0.3	0.8	115.5	3.9
Parkinson disease	0.1	0.3	104.7	0.5	0.0	0.0	107.1	1.1
Epilepsy	4.5	8.5	85.7	-1.5	1.2	2.5	101.2	7.2
Multiple sclerosis	0.1	0.3	146.6	12.5	0.0	0.1	144.1	11.0
Migraine	139.4	276.0	98.7	2.3	4.7	9.8	94.6 to 209.9	(-12.7 to 41.0)
Tension-type headache	243.1	521.1	114.0	2.7	0.4	0.8	115.2	3.4
Medication overuse headache	9.1	28.1	210.7	45.4	1.4	4.4	213.2	46.9
Other neurological disorders	0.0	0.0	82.9	-7.5	0.3	0.7	111.7	-0.8
Mental and substance use disorders	-	-	-	-	40.6	83.6	106.0	1.7
Schizophrenia	4.0	8.8	118.8	0.4	2.6	5.7	120.5	1.2
Alcohol use disorders	9.5	22.5	135.9	14.9	0.9	2.2	138.9	16.1
Drug use disorders	-	-	-	-	2.4	5.2	115.3	0.8
Opioid use disorders	3.2	7.3	129.6	1.8	1.3	3.0	131.3	2.6
Cocaine use disorders	0.8	1.1	79.2 to 161.3	(-15.2 to 18.2)	0.1	0.2	66.4 to 184.9	(-20.6 to 28.3)
Amphetamine use disorders	3.2	6.0	86.8	-5.1	0.4	0.8	89.4	-3.9
Cannabis use disorders	1.4	2.9	98.1	0.3	0.0	0.1	98.6	0.4
Other drug use disorders	-	-	-	-	0.5	1.1	96.5	-2.4
Depressive disorders	-	-	-	-	17.7	37.8	112.6	3.0
Major depressive disorder	77.9	164.8	111.2	2.5	15.9	33.9	112.6	3.5
Dysthymia	19.2	40.7	111.6	-0.6	1.8	3.9	113.2	0.1
Bipolar disorder	11.0	23.0	109.0	-0.9	2.2	4.7	110.8	0.0
Anxiety disorders	45.8	92.3	97.4	0.3	8.5	18.2	98.2	0.3
Eating disorders	-	-	-	-	0.5	1.0	98.1	0.7
Anorexia nervosa	0.3	0.7	100.0	2.9	0.1	0.1	101.1	3.7
Bulimia nervosa	2.0	4.0	95.6	-0.6	0.4	0.8	97.1	0.2
Autistic spectrum disorders	-	-	-	-	2.4	4.7	94.7	1.6
Autism	6.2	12.1	93.7	0.7	1.5	3.0	94.9	1.6
Asperger syndrome	9.0	17.3	93.4	1.0	0.9	1.7	94.3	1.6
Attention-deficit/hyperactivity disorder	15.2	27.4	80.4	0.0	0.2	0.3	81.2	0.5
Conduct disorder	22.3	40.1	80.0	0.0	2.5	4.8	81.5	0.5
Idiopathic intellectual disability	59.3	99.4	68.6	-9.6	2.9	4.8	69.2	-9.2
Other mental and substance use disorders	24.5	52.5	114.3	0.8	1.8	3.9	115.5	1.5
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	12.1	25.7	112.3	6.0
Diabetes mellitus	28.1	94.9	236.4	55.7	2.0	6.8	237.0	55.3
Acute glomerulonephritis	0.0	0.0	15.3	-37.5	0.0	0.0	15.3	-37.5
Chronic kidney disease	-	-	-	-	3.3	6.5	98.8	-3.9
Chronic kidney disease due to diabetes mellitus	19.4	39.0	103.3	1.8	0.3	0.7	102.9	-1.9
Chronic kidney disease due to hypertension	90.2	176.5	100.1	4.7	1.1	2.2	93.4	-8.6
Chronic kidney disease due to glomerulonephritis	75.6	154.4	105.0	1.1	0.5	1.1	110.0	8.9
Chronic kidney disease due to other causes	55.7	105.6	87.0	-9.0	0.7	1.3	84.4	-13.1
Urinary diseases and male infertility	-	-	-	-	0.6	1.3	108.3	1.0

Appendix Table G.4 - Mauritania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.4 (0.4 to 0.4)	0.8 (0.8 to 0.9)	112.9 (95.1 to 134.5)	0.0 (-1.6 to 14.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.6 (70.2 to 173.4)	0.0 (-12.3 to 28.8)
Urolithiasis	4.4 (3.4 to 5.6)	7.4 (5.6 to 9.5)	73.8 (38.5 to 94.5)	-15.7 (-31.1 to -7.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	126.8 (97.3 to 160.0)	7.3 (-4.3 to 19.0)
Benign prostatic hyperplasia	11.9 (11.0 to 12.9)	23.9 (21.9 to 25.9)	99.7 (79.5 to 124.1)	-0.7 (-10.3 to 10.5)	0.4 (0.3 to 0.6)	0.9 (0.6 to 1.2)	101.2 (80.3 to 126.0)	0.4 (-9.5 to 11.3)
Male infertility due to other causes	23.6 (18.7 to 29.6)	52.8 (41.9 to 63.7)	124.8 (65.6 to 196.8)	4.0 (-24.4 to 37.8)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.7)	123.5 (62.8 to 197.7)	4.2 (-24.2 to 37.8)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	194.7 (89.8 to 253.7)	30.8 (-8.7 to 81.4)
Gynecological diseases	-	-	-	-	2.4 (1.6 to 3.5)	5.0 (3.2 to 7.5)	113.1 (89.9 to 145.0)	-4.4 (-14.4 to 8.5)
Uterine fibroids	29.8 (27.0 to 32.5)	65.9 (59.6 to 71.7)	120.7 (120.0 to 121.5)	-5.6 (-5.8 to -5.4)	0.7 (0.4 to 1.0)	1.3 (0.8 to 2.0)	92.5 (75.2 to 115.3)	-16.6 (-24.3 to -7.2)
Polycystic ovarian syndrome	28.1 (25.3 to 31.1)	60.0 (52.5 to 67.0)	113.1 (82.4 to 151.7)	-4.1 (-16.7 to 13.1)	0.3 (0.1 to 0.5)	0.6 (0.3 to 1.1)	114.0 (82.1 to 153.9)	-3.4 (-16.3 to 13.6)
Female infertility due to other causes	16.5 (12.2 to 21.6)	39.7 (29.0 to 53.6)	136.6 (59.9 to 252.0)	2.6 (-31.3 to 59.6)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.5)	136.5 (59.6 to 255.5)	3.1 (-30.9 to 59.4)
Endometriosis	2.8 (2.4 to 3.3)	5.7 (4.9 to 6.6)	100.8 (63.7 to 147.8)	-11.1 (-26.7 to 9.5)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	102.0 (62.0 to 153.5)	-10.3 (-26.8 to 11.4)
Genital prolapse	67.0 (58.3 to 76.1)	143.8 (125.1 to 163.9)	114.7 (75.7 to 161.0)	-1.2 (-17.0 to 18.1)	0.5 (0.1 to 0.4)	0.5 (0.2 to 0.9)	116.5 (75.5 to 161.9)	-0.6 (-17.0 to 18.2)
Premenstrual syndrome	70.2 (49.8 to 88.3)	175.1 (133.8 to 223.6)	146.9 (72.8 to 282.6)	16.9 (-19.3 to 84.2)	0.6 (0.3 to 0.9)	1.9 (0.9 to 2.3)	148.4 (73.7 to 284.9)	17.9 (-19.0 to 85.4)
Other gynecological diseases	7.6 (4.3 to 11.0)	16.3 (14.7 to 17.9)	113.9 (53.3 to 273.4)	-1.5 (-29.4 to 70.3)	0.3 (0.1 to 0.4)	0.5 (0.4 to 0.8)	87.1 (48.2 to 290.5)	-14.1 (-31.8 to 73.9)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	2.4 (1.6 to 3.5)	3.9 (2.6 to 5.5)	57.6 (46.6 to 77.8)	-22.2 (-28.2 to -10.6)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.5 (57.9 to 94.7)	0.9 (-12.4 to 9.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.6 (61.0 to 99.8)	3.4 (-10.5 to 12.3)
Thalassemia trait	19.3 (15.7 to 23.5)	37.1 (30.4 to 44.9)	92.0 (82.9 to 99.2)	-0.2 (-4.9 to 3.5)	0.4 (0.2 to 0.5)	0.7 (0.4 to 1.0)	76.1 (46.0 to 115.4)	-7.2 (-23.0 to 13.7)
Sickle cell disorders	1.2 (1.0 to 1.4)	2.3 (1.8 to 2.5)	80.4 (47.1 to 121.1)	-0.3 (-17.8 to 19.2)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	90.1 (49.4 to 140.6)	3.8 (-15.2 to 26.5)
Sickle cell trait	152.2 (149.7 to 173.1)	309.3 (278.0 to 320.5)	85.1 (79.2 to 93.6)	-3.8 (-6.9 to 0.7)	0.8 (0.5 to 1.1)	1.3 (0.9 to 1.9)	71.1 (46.2 to 109.0)	21.3 (-21.3 to 15.7)
G6PD deficiency	113.8 (79.3 to 154.3)	209.7 (143.9 to 266.7)	84.8 (13.4 to 199.8)	-3.9 (-41.2 to 55.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.3 (54.9 to 123.1)	-3.2 (-13.1 to 7.4)
G6PD trait	451.2 (415.3 to 479.1)	851.9 (767.0 to 914.2)	89.4 (67.2 to 108.0)	-2.2 (-13.7 to 7.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.9 (-35.0 to 210.3)	-15.4 (-68.7 to 61.2)
Other hemoglobinopathies and hemolytic anemias	33.7 (28.8 to 38.3)	51.4 (46.6 to 57.0)	52.1 (32.5 to 78.4)	-26.3 (-35.6 to -16.0)	1.1 (0.7 to 1.7)	1.6 (1.0 to 2.4)	38.1 (20.0 to 79.0)	-58.6 (-47.8 to -18.8)
Endocrine, metabolic, blood, and immune disorders	35.4 (31.1 to 39.3)	59.5 (51.5 to 66.6)	68.6 (40.8 to 95.6)	-5.3 (-26.3 to -4.6)	1.4 (0.9 to 2.0)	2.2 (1.5 to 3.2)	58.7 (21.6 to 95.2)	-20.4 (-33.9 to -5.5)
Musculoskeletal disorders	-	-	-	-	18.6 (17.3 to 21.3)	40.2 (37.4 to 70.3)	151.4 (101.9 to 136.0)	0.7 (-4.8 to 9.2)
Rheumatoid arthritis	2.8 (2.7 to 2.9)	3.8 (3.7 to 4.0)	37.9 (28.8 to 46.7)	-37.2 (-41.0 to -33.0)	0.7 (0.5 to 0.9)	0.9 (0.6 to 1.2)	39.8 (26.2 to 55.3)	-36.4 (-41.8 to -30.5)
Osteoarthritis	37.0 (35.5 to 38.5)	79.3 (76.3 to 82.5)	114.2 (103.1 to 127.1)	1.5 (-3.3 to 7.1)	2.2 (1.5 to 3.0)	4.8 (3.4 to 6.7)	116.1 (104.5 to 130.0)	2.4 (-2.5 to 8.4)
Low back and neck pain	-	-	-	-	18.6 (13.0 to 25.4)	40.2 (27.8 to 55.0)	151.4 (97.5 to 138.4)	0.7 (-7.6 to 10.7)
Low back pain	113.5 (106.4 to 120.1)	240.2 (226.3 to 254.7)	111.6 (95.0 to 130.7)	-0.0 (-7.0 to 7.9)	12.6 (8.4 to 17.4)	26.8 (17.9 to 37.5)	113.1 (96.2 to 133.2)	0.8 (-6.3 to 9.1)
Neck pain	62.4 (49.9 to 74.3)	136.6 (114.5 to 156.8)	119.2 (70.8 to 185.3)	0.2 (-21.5 to 28.5)	6.1 (4.1 to 8.6)	13.4 (9.0 to 19.0)	121.1 (72.3 to 189.0)	0.7 (-21.1 to 30.3)
Gout	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.4)	116.0 (82.0 to 161.7)	0.0 (-15.3 to 17.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.8 (71.2 to 173.9)	-0.1 (-22.7 to 27.6)
Other musculoskeletal disorders	28.3 (19.9 to 37.3)	68.1 (51.4 to 86.1)	138.8 (115.0 to 188.1)	10.4 (-0.7 to 30.0)	2.5 (1.5 to 3.8)	6.2 (3.9 to 9.2)	141.3 (115.2 to 193.4)	11.4 (-0.3 to 32.0)
Other non-communicable diseases	-	-	-	-	29.3 (19.0 to 43.2)	55.2 (35.7 to 82.3)	87.9 (79.4 to 101.1)	-5.9 (-9.9 to -1.5)
Congenital anomalies	-	-	-	-	1.5 (1.0 to 2.1)	3.2 (2.2 to 4.5)	117.8 (77.5 to 171.9)	18.6 (-3.6 to 47.1)
Neural tube defects	0.3 (0.3 to 0.4)	0.9 (0.8 to 1.0)	187.5 (139.8 to 249.4)	64.4 (36.2 to 99.9)	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	206.2 (129.3 to 304.9)	77.3 (34.2 to 128.6)
Congenital heart anomalies	2.6 (1.9 to 3.4)	8.6 (6.5 to 11.2)	234.7 (119.6 to 415.5)	88.2 (22.7 to 195.1)	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.5)	212.5 (105.9 to 370.0)	77.7 (17.1 to 168.5)
Orofacial clefts	0.3 (0.2 to 0.5)	1.2 (0.8 to 1.6)	254.4 (112.1 to 470.0)	109.8 (24.6 to 244.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.9 (97.9 to 463.3)	10.9 (18.4 to 239.1)
Down syndrome	1.2 (1.0 to 1.5)	3.0 (2.5 to 3.7)	144.9 (86.9 to 229.3)	35.3 (2.9 to 82.2)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.5)	151.3 (89.9 to 251.1)	39.0 (4.3 to 94.2)
Turner syndrome	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	116.6 (50.9 to 220.0)	14.9 (-19.7 to 72.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	121.7 (46.0 to 237.9)	15.8 (-23.7 to 76.8)
Klinefelter syndrome	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	85.5 (31.7 to 177.6)	-2.0 (-30.6 to 45.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.7 (40.7 to 198.8)	-1.5 (-30.2 to 48.3)
Chromosomal unbalanced rearrangements	0.0 (1.6 to 2.5)	0.0 (4.2 to 5.7)	143.7 (85.2 to 225.8)	0.6 (-2.7 to 79.7)	0.2 (0.2 to 0.3)	0.7 (0.4 to 0.8)	148.8 (86.5 to 238.7)	39.4 (5.0 to 86.7)
Other congenital anomalies	9.3 (6.8 to 12.5)	16.8 (12.6 to 21.9)	81.3 (49.0 to 119.4)	-5.4 (-23.2 to 14.3)	0.9 (0.5 to 1.5)	1.7 (0.9 to 2.9)	85.3 (34.0 to 163.7)	-0.4 (-28.4 to 40.7)
Skin and subcutaneous diseases	-	-	-	-	10.2 (6.2 to 16.5)	19.6 (12.0 to 31.7)	90.1 (71.2 to 127.8)	-1.6 (-9.4 to 14.6)
Dermatitis	85.9 (67.4 to 107.2)	172.9 (134.8 to 217.8)	101.4 (97.3 to 104.6)	-0.1 (-0.3 to 0.0)	2.5 (1.5 to 3.6)	4.9 (3.0 to 7.1)	98.4 (90.5 to 105.8)	0.6 (-2.3 to 3.3)
Psoriasis	13.3 (10.5 to 15.9)	27.3 (21.3 to 33.0)	105.3 (102.4 to 108.2)	0.0 (-0.1 to 0.2)	1.1 (0.7 to 1.6)	2.2 (1.5 to 3.2)	106.8 (93.5 to 121.0)	0.9 (-4.4 to 6.4)
Cellulitis	0.4 (0.3 to 0.5)	0.7 (0.6 to 0.9)	91.6 (61.7 to 126.6)	-3.8 (-19.4 to 15.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	91.0 (42.2 to 156.6)	-2.9 (-25.0 to 24.0)
Pyoderma	3.5 (2.6 to 4.4)	5.9 (4.4 to 7.5)	69.6 (57.9 to 83.2)	-4.2 (-10.5 to 3.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	70.0 (53.3 to 90.6)	-3.5 (-12.8 to 6.6)
Scabies	35.3 (26.2 to 48.6)	34.1 (28.1 to 41.1)	-1.8 (-31.2 to 36.1)	-47.6 (-65.5 to -24.2)	0.9 (0.5 to 1.6)	0.9 (0.5 to 1.4)	-1.7 (-31.5 to 36.8)	-47.3 (-63.9 to -24.0)
Fungal skin diseases	242.8 (175.4 to 339.2)	478.8 (346.7 to 669.0)	96.0 (90.8 to 103.2)	0.2 (-0.1 to 0.3)	1.4 (0.9 to 1.9)	2.7 (1.0 to 6.1)	96.7 (91.3 to 104.3)	0.7 (-0.1 to 1.4)
Viral skin diseases	30.2 (23.6 to 37.5)	55.6 (43.0 to 68.9)	83.9 (72.3 to 95.3)	-0.4 (-6.0 to 5.2)	0.5 (0.5 to 1.5)	1.7 (1.0 to 2.8)	84.6 (70.8 to 99.3)	0.1 (-6.4 to 7.0)
Acne vulgaris	205.3 (119.5 to 283.9)	407.7 (284.1 to 549.5)	88.7 (20.7 to 317.4)	1.9 (-32.6 to 120.8)	2.2 (0.9 to 4.4)	4.4 (2.0 to 8.8)	89.3 (21.5 to 320.3)	2.3 (-32.6 to 121.1)
Alopecia areata	1.8 (1.6 to 2.0)	3.5 (3.1 to 3.9)	98.7 (68.4 to 135.1)	-0.2 (-14.7 to 17.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	100.2 (63.2 to 145.9)	0.5 (-17.2 to 21.3)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	100.2 (58.8 to 147.1)	1.0 (-23.8 to 23.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	100.2 (58.6 to 147.3)	-1.0 (-23.8 to 23.9)
Urticaria	7.9 (5.4 to 10.9)	21.6 (14.2 to 31.0)	175.5 (68.6 to 419.6)	24.4 (-28.0 to 125.0)	0.5 (0.3 to 0.7)	1.3 (0.7 to 2.1)	176.5 (70.3 to 432.9)	26.6 (-27.3 to 128.0)
Decubitus ulcer	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.4)	126.5 (83.9 to 190.7)	11.2 (-19.2 to 52.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	126.5 (80.7 to 197.1)	11.6 (-21.4 to 56.3)
Other skin and subcutaneous diseases	110.3 (74.7 to 158.0)	215.9 (146.2 to 310.0)	95.8 (85.9 to 106.6)	-4.8 (-10.0 to -1.3)	0.6 (0.3 to 1.3)	1.3 (0.6 to 2.6)	96.7 (86.8 to 107.8)	-4.1 (-9.4 to -0.4)
Sense organ diseases	-	-	-	-	15.3 (10.1 to 22.3)	27.7 (18.1 to 41.0)	80.6 (68.2 to 92.8)	-9.9 (-14.7 to -5.6)
Glaucoma	3.1 (2.5 to 4.0)	5.8 (4.3 to 7.4)	84.4 (34.4 to 147.9)	-7.4 (-27.7 to 18.1)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	96.2 (50.6 to 153.8)	-1.5 (-24.7 to 25.8)
Cataract	12.5 (9.3 to 16.3)	20.4 (14.0 to 26.2)	58.8 (24.5 to 140.6)	-17.4 (-34.9 to 13.4)	1.1 (0.7 to 1.5)	1.7 (1.1 to 2.5)	65.2 (26.7 to 121.0)	-15.1 (-34.0 to 6.0)
Macular degeneration	2.9 (2.0 to 3.9)	10.3 (7.1 to 13.8)	255.9 (147.2 to 433.1)	74.5 (22.3 to 166.9)	0.2 (0.1 to 0.3)	0.6 (0.4 to 1.0)	248.9 (146.0 to 424.5)	67.4 (18.8 to 152.9)
Uncorrected refractive error	289.2 (270.9 to 307.2)	564.1 (523.0 to 601.1)	94.7 (76.9 to 113.4)	-8.6 (-11.0 to 3.6)	5.1 (3.2 to 7.9)	9.2 (5.7 to 14.4)	79.8 (68.8 to 94.2)	-11.2 (-16.0 to -5.6)
Age-related and other hearing loss	246.9 (208.2 to 278.9)	475.0 (403.9 to 538.4)	92.8 (81.3 to 103.3)	-6.3 (-10.3 to -2.7)	6.9 (4.0 to 10.6)	12.3 (7.4 to 19.1)	79.4 (56.6 to 102.8)	-10.7 (-18.1 to -3.3)
Other vision loss	7.6 (6.2 to 9.2)	10.7 (8.7 to 13.1)	42.0 (23.1 to 60.0)	-26.6 (-37.0 to -15.5)	0.6 (0.4 to 1.0)	1.0 (0.6 to 1.4)	50.5 (25.4 to 77.8)	-22.9 (-35.0 to -6.6)
Other sense organ diseases	48.0 (45.3 to 50.7)	90.1 (85.2 to 95.4)	87.8 (72.5 to 103.5)	-0.4 (-7.6 to 6.8)	1.3 (0.8 to 1.9)	2.4 (1.5 to 3.6)	88.6 (73.1 to 106.2)	0.1 (-7.3 to 7.5)
Oral disorders	-	-	-	-	2.3 (1.3 to 3.9)	4.8 (2.6 to 8.0)	105.4 (91.0 to 121.8)	0.5 (-7.2 to 9.3)
Deciduous caries	197.1 (186.6 to 207.4)	343.0 (326.9 to 350.9)	73.4 (62.2 to 88.7)	0.1 (-6.3 to 8.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.0)	74.0 (50.8 to 93.2)	0.3 (-8.0 to 11.5)
Permanent caries	522.1 (476.9 to 578.4)	1,030.8 (924.1 to 1,146.0)	97.6 (73.3 to 126.3)	-1.4 (-13.4 to 12.7)	0.5 (0.2 to 1.0)	1.0 (0.5 to 2.0)		

Appendix Table G.4 - Mauritania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	5.8 (5.3 to 6.2)	11.3 (10.5 to 12.1)	95.4 (78.3 to 116.6)	-7.0 (-14.8 to 2.6)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	97.1 (78.5 to 120.2)	-6.2 (-14.2 to 3.9)
Other oral disorders	29.3 (27.4 to 31.0)	59.2 (55.8 to 62.7)	101.4 (85.7 to 119.8)	-0.9 (-8.1 to 7.4)	0.9 (0.5 to 1.3)	1.7 (1.1 to 2.6)	102.4 (85.3 to 121.6)	-0.2 (-7.9 to 8.6)
Injuries	-	-	-	-	9.6 (6.6 to 14.6)	14.8 (11.2 to 19.3)	58.4 (13.4 to 86.0)	-21.0 (-41.3 to -7.6)
Transport injuries	-	-	-	-	2.8 (2.1 to 3.5)	5.7 (4.2 to 7.3)	106.0 (97.0 to 115.4)	-0.1 (-3.8 to 3.8)
Road injuries	-	-	-	-	2.5 (1.9 to 3.2)	5.3 (3.9 to 6.8)	108.3 (98.3 to 118.5)	11.1 (-3.4 to 4.8)
Pedestrian road injuries	-	-	-	-	0.6 (0.5 to 0.8)	1.2 (0.9 to 1.5)	93.0 (78.8 to 110.3)	-4.8 (-10.4 to 2.0)
Cyclist road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	73.1 (63.0 to 83.1)	-12.7 (-17.6 to -7.9)
Motorcyclist road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.7 (0.5 to 0.9)	79.5 (65.2 to 91.8)	-14.3 (-20.5 to -9.2)
Motor vehicle road injuries	-	-	-	-	1.3 (1.0 to 1.6)	3.0 (2.2 to 3.8)	131.8 (114.4 to 150.2)	11.1 (3.5 to 18.9)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	54.1 (45.2 to 64.8)	-29.7 (-33.4 to -25.7)
Other transport injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	79.5 (67.8 to 93.3)	-7.9 (-14.1 to -1.6)
Unintentional injuries	-	-	-	-	4.0 (3.0 to 5.1)	7.4 (5.7 to 9.6)	87.5 (81.8 to 93.5)	-6.7 (-9.5 to -3.7)
Falls	-	-	-	-	1.6 (1.2 to 2.0)	3.2 (2.4 to 4.2)	105.7 (96.0 to 115.6)	-3.2 (-7.3 to 2.2)
Drowning	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	45.9 (31.2 to 61.5)	-24.3 (-30.5 to -17.8)
Fire, heat, and hot substances	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	54.9 (39.3 to 70.9)	-19.4 (-26.0 to -13.2)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.0 (22.9 to 74.5)	-26.3 (-36.2 to -14.6)
Exposure to mechanical forces	-	-	-	-	1.3 (1.0 to 1.6)	2.2 (1.7 to 2.9)	76.0 (67.5 to 84.9)	-10.1 (-13.7 to -6.0)
Unintentional firearm injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	78.7 (65.6 to 94.5)	-11.8 (-17.9 to -5.0)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	131.5 (100.9 to 160.1)	18.0 (4.5 to 30.1)
Other exposure to mechanical forces	-	-	-	-	1.2 (0.9 to 1.5)	2.1 (1.6 to 2.7)	75.2 (66.6 to 84.3)	-10.3 (-14.2 to -6.1)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	121.6 (110.2 to 134.6)	15.2 (9.1 to 22.0)
Animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	76.2 (63.5 to 88.1)	-9.4 (-14.7 to -4.6)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	77.4 (58.0 to 99.1)	-10.2 (-18.7 to -1.1)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	75.0 (62.9 to 86.0)	-8.8 (-13.9 to -4.5)
Foreign body	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	98.0 (86.0 to 108.9)	0.1 (-5.0 to 4.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.2 (46.6 to 94.4)	-4.9 (-14.3 to 4.5)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.0 (81.3 to 124.1)	0.7 (-8.2 to 9.4)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	109.7 (96.6 to 123.9)	1.5 (-4.6 to 8.3)
Other unintentional injuries	-	-	-	-	0.6 (0.5 to 0.8)	1.1 (0.8 to 1.4)	84.7 (71.0 to 97.3)	-7.6 (-13.7 to -1.6)
Self-harm and interpersonal violence	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	85.7 (76.4 to 93.0)	-8.1 (-12.0 to -4.8)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	113.6 (95.1 to 131.2)	0.4 (-6.6 to 7.5)
Interpersonal violence	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	81.0 (70.9 to 88.5)	-10.1 (-14.4 to -6.4)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	86.8 (73.1 to 98.8)	-7.0 (-13.2 to -1.8)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	117.5 (104.2 to 131.3)	5.5 (-0.8 to 12.1)
Assault by other means	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	71.3 (59.0 to 81.6)	-14.7 (-20.0 to -9.8)
Forces of nature, war, and legal intervention	-	-	-	-	2.7 (0.6 to 7.5)	1.4 (0.4 to 3.5)	-48.6 (-55.6 to -27.8)	-66.9 (-71.1 to -55.0)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.1)	-	-	-
Collective violence and legal intervention	-	-	-	-	2.7 (0.6 to 7.5)	1.3 (0.3 to 3.5)	-50.6 (-56.4 to -34.4)	-67.5 (-71.5 to -58.3)

Appendix Table G.4 - Malaria prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
All causes	-	-	-	-	89.4 (66.4 to 116.7)	123.3 (90.9 to 160.0)	38.0 (27.8 to 42.5)	38.0 (5.2 to 0.2)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	11.5 (8.0 to 15.9)	9.2 (6.4 to 12.7)	-20.4 (-27.8 to -12.1)	-21.1 (-28.1 to -13.4)
HIV/AIDS and tuberculosis	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	35.4 (15.9 to 57.8)	-16.1 (-27.6 to -2.8)
Tuberculosis	0.8 (0.7 to 0.8)	0.7 (0.7 to 0.8)	-4.3 (-10.0 to 2.2)	-40.8 (-44.5 to -36.7)	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-4.8 (-15.3 to 6.3)	-40.4 (-46.6 to -33.8)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	3,342.7 (1,055.8 to 7,893.8)	463.4 (711.7 to 6,036.9)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,135.4 (290.1 to 3,003.8)	703.4 (148.8 to 1,947.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,135.4 (288.9 to 3,014.1)	703.4 (148.7 to 1,961.1)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.1)	1.3 (0.9 to 1.8)	5,598.0 (2,494.8 to 10,368.6)	4,342.3 (1,886.3 to 8,196.1)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	3,373.9 (1,055.5 to 8,523.2)	2,501.5 (715.6 to 6,657.5)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	1.4 (1.0 to 2.1)	1.3 (0.9 to 1.9)	-10.4 (-23.1 to 3.5)	-15.7 (-27.8 to -2.4)
Diarrheal diseases	2.1 (1.2 to 2.9)	1.6 (1.2 to 2.2)	-21.4 (-50.7 to 51.5)	-16.5 (-46.7 to 61.3)	0.3 (0.2 to 0.6)	0.3 (0.2 to 0.4)	-22.0 (-50.8 to 53.2)	-15.7 (-46.5 to 62.7)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Typhoid fever	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-27.2 (-49.8 to 15.2)	-28.8 (-48.7 to 8.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.1 (-50.7 to 21.6)	-28.3 (-49.7 to 16.5)
Paratyphoid fever	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-44.5 (-60.6 to -8.8)	-42.2 (-58.9 to -9.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.5 (-60.7 to -8.7)	-42.2 (-58.9 to -9.6)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Lower respiratory infections	0.4 (0.3 to 0.5)	0.7 (0.5 to 0.8)	68.9 (22.0 to 122.0)	25.6 (-7.1 to 61.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	53.6 (19.0 to 120.6)	24.5 (9.7 to 64.0)
Upper respiratory infections	36.4 (31.7 to 40.9)	39.7 (35.3 to 43.7)	8.8 (8.2 to 30.3)	0.2 (-14.7 to 18.9)	0.4 (0.2 to 0.7)	0.5 (0.3 to 0.8)	8.6 (8.6 to 29.5)	0.4 (-15.1 to 19.4)
Otitis media	13.4 (12.5 to 14.4)	11.8 (11.1 to 12.6)	-12.0 (-18.6 to -4.1)	-16.4 (-22.5 to -9.7)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.4)	-11.4 (-19.4 to -2.2)	-14.9 (-22.1 to -6.7)
Meningitis	-	-	-	-	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-42.3 (-65.5 to -25.1)	-50.0 (-61.8 to -36.0)
Pneumococcal meningitis	1.2 (0.7 to 1.9)	0.7 (0.4 to 1.2)	-41.4 (-58.5 to -11.9)	-55.0 (-67.4 to -33.9)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-45.1 (-66.7 to -20.3)	-54.3 (-71.7 to -35.3)
H influenzae type B meningitis	0.5 (0.2 to 1.1)	0.3 (0.1 to 0.6)	-49.1 (-70.8 to -20.8)	-56.9 (-74.1 to -31.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-48.8 (-69.4 to 7.4)	-52.0 (-70.7 to -4.7)
Meningococcal meningitis	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-28.7 (-54.6 to 15.0)	-49.0 (-66.0 to -15.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.6 (-49.0 to 29.5)	-42.0 (-60.1 to -0.2)
Other meningitis	0.5 (0.2 to 0.9)	0.3 (0.1 to 0.7)	-37.2 (-55.0 to -8.9)	-48.0 (-62.4 to -27.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-33.4 (-54.2 to 1.0)	-41.4 (-58.5 to -12.6)
Encephalitis	0.3 (0.1 to 0.8)	0.3 (0.1 to 0.8)	-3.8 (-28.4 to 11.1)	-27.9 (-45.6 to -14.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	2.9 (-14.2 to 22.7)	-28.1 (-33.1 to -4.9)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.4 (-92.0 to 384.8)	-36.2 (-93.7 to 385.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.4 (-92.1 to 386.9)	-36.2 (-93.7 to 394.1)
Whooping cough	0.3 (0.2 to 0.3)	0.1 (0.1 to 0.1)	-68.0 (-69.6 to -66.4)	-53.5 (-55.8 to -51.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-68.0 (-73.7 to -61.4)	-53.5 (-61.8 to -43.8)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-94.2 (-97.3 to -90.4)	-95.0 (-97.7 to -91.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-94.0 (-96.9 to -88.7)	-94.6 (-97.2 to -90.4)
Measles	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-67.5 (-71.4 to -63.1)	-54.0 (-59.5 to -47.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.4 (-76.7 to -53.7)	-53.9 (-67.2 to -34.1)
Varicella and herpes zoster	1.1 (1.0 to 1.2)	1.3 (1.2 to 1.5)	24.5 (8.5 to 45.7)	0.1 (-12.7 to 15.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	44.4 (17.0 to 81.3)	-0.3 (-18.4 to 23.6)
Neglected tropical diseases and malaria	-	-	-	-	0.7 (0.4 to 0.9)	0.7 (0.4 to 1.2)	1.8 (-31.6 to 70.3)	-2.4 (-34.0 to 61.4)
Malaria	0.0 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-78.3 (-99.4 to 26.4)	-80.5 (-99.4 to 17.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.1 (-89.1 to 111.2)	-18.2 (-90.4 to 98.3)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.1 (-9.9 to 40.4)	1.3 (-21.1 to 26.8)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.6 (-67.5 to 79.5)	-5.1 (-62.1 to 118.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.6 (-67.8 to 79.7)	-5.1 (-62.2 to 118.2)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.0 (-9.2 to 42.2)	2.0 (-21.1 to 27.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.0 (-9.2 to 42.3)	2.0 (-21.2 to 27.2)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	10.3 (4.2 to 22.6)	14.1 (6.2 to 29.1)	37.6 (29.5 to 56.9)	10.9 (3.8 to 27.0)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	56.3 (15.0 to 140.8)	31.9 (-2.6 to 102.0)
Cysticercosis	0.5 (0.2 to 0.9)	0.0 (0.0 to 0.1)	-90.2 (-96.1 to -65.0)	-93.0 (-97.3 to -75.5)	0.1 (0.0 to 0.3)	0.0 (0.0 to 0.0)	-89.5 (-95.9 to -59.6)	-92.4 (-97.1 to -70.2)
Cystic echinococcosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-41.8 (-47.5 to -36.7)	-58.9 (-64.1 to -55.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.9 (-53.9 to -25.2)	-58.3 (-66.6 to -48.0)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.3 (0.1 to 0.8)	1.9 (0.7 to 4.4)	470.1 (468.8 to 471.7)	395.0 (393.8 to 396.3)	0.1 (0.0 to 0.1)	0.3 (0.1 to 0.8)	466.4 (393.8 to 548.6)	396.4 (338.0 to 460.7)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-55.5 (-56.1 to -8.6)	-55.5 (-71.4 to -43.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.0 (-56.1 to -8.6)	-55.5 (-71.4 to -43.3)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Ascariasis	-	-	34.2 (-16.8 to 121.7)	1.0 (-37.4 to 66.7)	-	-	-	-
Trichuriasis	-	-	34.7 (-21.1 to 134.0)	1.4 (-40.7 to 76.0)	-	-	-	-
Hookworm disease	0.8 (0.6 to 1.1)	1.0 (0.7 to 1.4)	30.9 (-17.1 to 105.3)	1.5 (-37.6 to 54.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.7 (-62.9 to -1.9)	-54.4 (-70.2 to -20.5)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	10.7 (8.5 to 13.3)	7.2 (5.7 to 11.6)	-35.0 (-50.1 to 14.5)	-25.4 (-42.6 to 33.0)	0.4 (0.2 to 0.5)	0.2 (0.1 to 0.4)	-41.0 (-58.3 to 35.1)	-29.0 (-49.5 to 62.3)
Maternal disorders	-	-	-	-	0.7 (0.5 to 0.9)	0.7 (0.5 to 1.0)	5.7 (-7.3 to 20.6)	-10.8 (-21.8 to 1.5)
Maternal hemorrhage	0.5 (0.4 to 0.5)	1.1 (0.9 to 1.3)	138.3 (86.4 to 194.8)	134.6 (84.6 to 189.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.4 (-11.3 to 144.4)	53.4 (-11.1 to 139.4)
Maternal sepsis and other maternal infections	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-37.2 (-54.1 to 4.2)	-48.5 (-62.8 to -9.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.7 (-71.3 to -7.2)	-52.1 (-72.7 to -15.3)
Maternal hypertensive disorders	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.2)	-32.5 (-38.0 to -19.3)	-32.2 (-36.5 to -21.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.3 (-49.0 to -5.9)	-31.5 (-48.8 to -6.9)
Obstructed labor	1.6 (1.5 to 1.8)	1.7 (1.6 to 1.9)	7.7 (1.4 to 15.2)	-11.9 (-17.2 to -5.7)	0.5 (0.4 to 0.7)	0.6 (0.4 to 0.8)	7.5 (-1.8 to 18.8)	-11.5 (-19.1 to -2.3)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.6 (-59.3 to 55.1)	-23.3 (-58.9 to 48.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.6 (-59.3 to 55.3)	-23.3 (-58.9 to 48.5)
Other maternal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-3.7 (-48.5 to 71.5)	-12.1 (-53.3 to 57.2)
Neonatal disorders	-	-	-	-	1.2 (0.8 to 1.6)	2.0 (1.3 to 2.9)	68.4 (13.5 to 147.5)	58.0 (6.5 to 133.0)
Preterm birth complications	4.6 (2.6 to 7.3)	10.0 (5.7 to 18.2)	116.0 (60.3 to 212.2)	91.9 (43.7 to 178.6)	0.6 (0.4 to 0.9)	1.2 (0.8 to 1.9)	108.3 (33.3 to 262.3)	91.4 (23.5 to 236.6)
Neonatal encephalopathy due to birth asphyxia and trauma	2.7 (1.3 to 5.0)	2.4 (1.0 to 5.1)	-14.3 (-39.1 to 22.3)	-22.1 (-44.2 to 10.4)	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.5)	-14.2 (-48.8 to 22.2)	-16.4 (-50.2 to 17.9)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.4 (19.7 to 73.8)	107.5 (86.2 to 170.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.2 (8.2 to 74.5)	110.4 (68.4 to 171.4)
Hemolytic disease and other neonatal jaundice	0.4 (0.2 to 0.8)	0.5 (0.2 to 1.0)	3.3 (-67.9 to 306.5)	-3.0 (-70.1 to 276.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	7.5 (-66.5 to 313.4)	0.6 (-68.8 to 283.2)
Other neonatal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.4)	462.7 (33.7 to 955.9)	426.9 (24.8 to 900.0)
Nutritional deficiencies	-	-	-	-	6.7 (4.9 to 9.8)	3.7 (2.3 to 5.5)	-45.4 (-57.1 to -38.8)	-39.6 (-52.3 to -31.9)
Protein-energy malnutrition	7.3 (4.4 to 11.0)	2.8 (1.5 to 4.7)	-61.8 (-81.4 to -23.9)	-4.6 (-73.1 to 10.3)	0.4 (0.3 to 0.6)	0.4 (0.2 to 0.7)	-61.7 (-73.3 to -44.2)	-44.2 (-73.3 to 11.1)
Iodine deficiency	15.8 (7.7 to 27.4)	12.6 (4.8 to 22.1)	-25.1 (-68.5 to 121.2)	-40.8 (-74.8 to 71.8)	0.3 (0.1 to 0.6)	0.2 (0.1 to 0.4)	-25.1 (-68.7 to 120.4)	-40.7 (-74.9 to 71.6)
Vitamin A deficiency	0.5 (0.3 to 0.8)	0.3 (0.1 to 0.4)	-43.7 (-58.6 to -29.7)	-45.6 (-59.8 to -32.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.9 (-59.0 to -30.0)	-47.9 (-61.7 to -35.3)

Appendix Table G.4 - Mauritius prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	185.7 (182.8 to 188.4)	120.7 (106.6 to 125.8)	-34.7 (-43.1 to -31.8)	-34.8 (-43.4 to -32.0)	5.5 (3.6 to 8.0)	3.0 (1.9 to 4.6)	-43.9 (-58.7 to -40.8)	-38.9 (-54.9 to -35.9)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.8)	-13.9 (-23.8 to 7.9)	-19.8 (-30.7 to 4.5)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.4)	8.6 (7.4 to 27.2)	-4.4 (-18.3 to 11.1)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.0 (-18.0 to 12.2)	-44.3 (-50.7 to -33.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Chlamydial infection	34.1 (23.2 to 46.8)	36.3 (23.1 to 51.2)	6.3 (-35.9 to 82.6)	-0.6 (-40.0 to 69.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	8.0 (-11.1 to 34.9)	0.2 (-18.0 to 25.3)
Gonococcal infection	5.2 (3.0 to 7.5)	5.0 (3.3 to 6.6)	-5.4 (-44.8 to 77.0)	-6.4 (-45.2 to 73.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-2.6 (-40.0 to 52.6)	-5.4 (-41.6 to 46.2)
Trichomoniasis	4.2 (2.6 to 6.0)	4.6 (3.1 to 6.4)	16.0 (-44.4 to 104.1)	-3.4 (-54.5 to 63.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.8 (-50.7 to 128.4)	-2.9 (-59.0 to 85.2)
Genital herpes	113.8 (107.8 to 119.3)	151.0 (143.5 to 159.7)	32.5 (23.6 to 43.3)	8.9 (-15.2 to -1.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	28.0 (14.2 to 42.0)	9.0 (-16.6 to -0.1)
Other sexually transmitted diseases	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-22.7 (-38.7 to 2.3)	-37.0 (-49.5 to -16.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.0 (-37.7 to 50.9)	-19.0 (-46.7 to 25.5)
Hepatitis	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-11.5 (-35.7 to 16.7)	-30.6 (-49.9 to -8.2)
Hepatitis A	1.3 (1.2 to 1.3)	1.0 (1.0 to 1.0)	-21.6 (-22.4 to -20.9)	-21.2 (-22.7 to -19.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.8 (-19.0 to 4.0)	-13.6 (-24.2 to -2.5)
Hepatitis B	108.6 (78.2 to 135.7)	89.3 (65.6 to 114.9)	-17.1 (-44.5 to 16.6)	-36.2 (-57.2 to -11.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-14.4 (-49.9 to 39.1)	-38.6 (-63.8 to -1.6)
Hepatitis C	32.3 (28.2 to 35.9)	33.7 (29.6 to 37.7)	4.0 (-12.6 to 23.7)	-28.3 (-39.5 to -16.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.2 (-24.2 to 38.0)	29.5 (-48.3 to -6.2)
Hepatitis E	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-16.6 (-41.4 to 10.1)	-26.0 (-46.7 to -5.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.9 (-46.5 to 28.1)	-26.2 (-52.5 to 6.9)
Leprosy	0.4 (0.0 to 1.3)	0.3 (0.1 to 0.8)	-4.6 (-48.8 to 360.4)	-46.6 (-68.4 to 196.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-2.8 (-46.2 to 582.9)	-44.1 (-68.9 to 308.1)
Other infectious diseases	7.9 (6.4 to 9.6)	5.3 (4.4 to 7.8)	-34.3 (-46.7 to -3.4)	-27.6 (-41.3 to 8.4)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-35.7 (-52.2 to 12.8)	-25.8 (-45.5 to 32.6)
Non-communicable diseases	-	-	-	-	75.4 (56.2 to 97.4)	110.6 (81.6 to 143.4)	46.8 (42.3 to 51.9)	0.0 (-2.6 to 3.1)
Neoplasms	-	-	-	-	0.6 (0.4 to 0.8)	1.5 (1.1 to 2.0)	158.3 (118.6 to 189.9)	29.0 (9.0 to 45.1)
Esophageal cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	100.5 (47.2 to 165.7)	-4.2 (-29.6 to 27.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.0 (39.5 to 150.4)	-9.1 (-34.0 to 20.9)
Stomach cancer	0.2 (0.2 to 0.3)	0.4 (0.4 to 0.5)	83.4 (52.2 to 120.0)	-13.5 (-28.2 to 3.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	67.6 (35.9 to 105.0)	-21.4 (-36.4 to -4.3)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	609.5 (1,075.3 to 1,733.2)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,616.0 (925.0 to 2,868.2)	778.8 (423.0 to 1,447.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,400.5 (844.6 to 2,310.4)	650.7 (437.0 to 1,132.4)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	4,095.3 (2,054.0 to 8,185.5)	1,764.0 (876.5 to 3,709.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3,382.0 (1,823.7 to 6,449.6)	1,427.7 (757.8 to 2,817.7)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	534.6 (252.2 to 1,024.3)	209.2 (72.4 to 437.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	452.2 (221.5 to 812.0)	163.8 (54.2 to 328.0)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	679.1 (286.4 to 1,433.8)	299.3 (91.5 to 693.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	579.8 (281.7 to 1,236.0)	245.4 (86.6 to 598.8)
Larynx cancer	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	35.8 (5.6 to 71.4)	-32.6 (-47.3 to -13.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.6 (7.1 to 83.2)	-30.8 (-47.5 to -10.3)
Tracheal, bronchus and lung cancer	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.5)	111.8 (78.3 to 154.5)	3.3 (-13.1 to 24.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	95.0 (61.8 to 139.0)	-5.1 (-21.3 to 15.8)
Breast cancer	1.1 (1.0 to 1.3)	6.4 (5.3 to 7.4)	471.5 (347.0 to 583.3)	214.1 (141.8 to 274.8)	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.6)	359.8 (242.4 to 467.2)	143.9 (81.0 to 204.3)
Cervical cancer	0.6 (0.5 to 0.7)	1.5 (0.9 to 0.8)	15.5 (-21.9 to 38.0)	6.1 (-57.6 to -25.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	45.2 (-25.4 to -43.1)	-45.2 (-59.7 to -23.9)
Uterine cancer	0.5 (0.3 to 0.7)	0.9 (0.6 to 1.4)	82.4 (28.8 to 155.5)	-14.2 (-38.0 to 16.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	79.4 (-1.2 to 153.6)	-17.1 (-40.5 to 14.9)
Prostate cancer	0.5 (0.4 to 0.7)	3.1 (1.8 to 4.2)	547.7 (325.8 to 812.3)	208.1 (100.2 to 336.9)	0.0 (0.0 to 0.1)	0.3 (0.2 to 0.4)	516.9 (294.3 to 755.6)	187.6 (81.0 to 303.3)
Colon and rectum cancer	1.6 (1.4 to 1.7)	1.9 (1.7 to 2.1)	18.3 (3.5 to 36.8)	-49.7 (-56.3 to -41.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	12.9 (5.5 to 35.2)	-51.0 (-59.2 to -40.8)
Lip and oral cavity cancer	0.2 (0.2 to 0.3)	0.6 (0.4 to 0.7)	160.3 (49.2 to 252.6)	28.8 (-27.7 to 73.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	149.7 (41.0 to 242.6)	23.0 (-29.9 to 67.2)
Nasopharynx cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	23.2 (-10.5 to 75.3)	-28.6 (-48.1 to -0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-12.0 to 61.5)	32.7 (-49.7 to -8.8)
Other pharynx cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	165.1 (68.4 to 295.4)	28.7 (-17.5 to 91.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	147.5 (61.5 to 266.0)	18.8 (-22.5 to 73.1)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.7 (-4.5 to 88.0)	-40.5 (-56.9 to -14.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.5 (-10.0 to 75.1)	42.4 (-60.2 to -17.4)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	165.9 (115.2 to 222.6)	25.3 (0.7 to 53.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	147.2 (100.0 to 200.1)	16.0 (-7.9 to 43.3)
Malignant skin melanoma	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	83.2 (50.3 to 142.1)	15.5 (-10.3 to 44.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.1 (37.1 to 126.9)	41.2 (-18.9 to 45.1)
Non-melanoma skin cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	123.3 (41.4 to 244.0)	7.7 (-31.7 to 61.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.8 (49.6 to 276.4)	3.2 (-31.7 to 87.1)
Ovarian cancer	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.3)	175.6 (115.9 to 265.5)	50.4 (18.1 to 96.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	165.5 (94.0 to 276.9)	44.0 (5.1 to 104.0)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	134.3 (41.5 to 257.6)	81.2 (12.5 to 169.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	126.6 (30.8 to 273.5)	68.3 (-6.6 to 166.3)
Kidney cancer	0.1 (0.1 to 0.1)	0.3 (0.3 to 0.3)	148.2 (191.8 to 320.0)	80.3 (51.2 to 117.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	224.8 (159.7 to 302.5)	64.5 (31.7 to 104.2)
Bladder cancer	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	107.5 (56.7 to 229.9)	-0.1 (-23.9 to 58.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.6 (36.1 to 204.1)	-10.2 (-33.2 to 42.9)
Brain and nervous system cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	79.4 (32.0 to 133.7)	32.3 (-0.8 to 71.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.3 (31.9 to 131.1)	27.1 (-7.3 to 59.5)
Thyroid cancer	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	164.7 (72.5 to 254.5)	58.8 (4.9 to 111.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	160.0 (69.3 to 254.0)	51.1 (0.0 to 103.9)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	674.4 (41.1 to 99.1)	57.9 (-31.1 to -1.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.9 (46.8 to 104.4)	16.0 (-29.6 to -0.2)
Hodgkin lymphoma	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	28.2 (5.4 to 154.8)	1.7 (-23.3 to 95.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.8 (-14.4 to 140.9)	-7.1 (-33.6 to 82.0)
Non-Hodgkin lymphoma	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.5)	409.0 (81.5 to 545.9)	222.7 (14.5 to 303.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	385.6 (74.2 to 521.4)	196.3 (5.7 to 275.5)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	369.9 (84.1 to 1,099.0)	132.6 (-9.5 to 499.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	325.6 (67.3 to 951.5)	105.9 (-21.3 to 422.6)
Leukemia	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.4)	80.5 (36.4 to 162.2)	50.9 (14.3 to 114.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	82.1 (52.2 to 150.4)	41.2 (13.8 to 81.2)
Other neoplasms	0.3 (0.2 to 0.4)	1.4 (0.9 to 1.7)	430.8 (186.8 to 619.1)	263.1 (100.0 to 381.4)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	394.2 (165.3 to 564.5)	219.4 (72.7 to 324.9)
Cardiovascular diseases	-	-	-	-	2.3 (1.6 to 3.1)	5.5 (3.8 to 7.6)	143.9 (95.9 to 192.4)	30.2 (6.8 to 53.7)
Rheumatic heart disease	14.3 (11.1 to 18.0)	20.5 (17.0 to 24.1)	44.9 (7.2 to 90.2)	2.7 (-21.9 to 31.0)	0.7 (0.5 to 1.1)	1.1 (0.7 to 1.6)	49.6 (12.4 to 96.1)	3.3 (-20.8 to 30.4)
Ischemic heart disease	6.1 (5.2 to 7.4)	16.8 (14.1 to 20.0)	173.5 (116.1 to 246.9)	22.1 (-6.6 to 54.9)	1.2 (-3.6 to 54.9)	1.2 (0.8 to 1.6)	168.4 (115.8 to 244.2)	20.4 (-3.5 to 53.5)
Cerebrovascular disease	-	-	-	-	0.3 (0.2 to 0.4)	0.7 (0.5 to 0.9)	123.0 (87.9 to 170.5)	7.5 (-8.7 to 28.3)
Ischemic stroke	0.9 (0.8 to 1.1)	2.2 (1.9 to 2.5)	136.3 (98.3 to 189.2)	9.2 (-8.1 to 32.8)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	133.9 (93.5 to 192.4)	8.9 (-8.7 to 34.5)
Hemorrhagic stroke	1.1 (0.9 to 1.2)	2.3 (2.0 to 2.6)	116.7 (81.8 to 164.6)	6.0 (-11.2 to 29.2)	0.2 (0.1 to 0.2)	0.5 (0.2 to 0.5)	115.1 (76.4 to 163.2)	6.0 (-11.8 to 31.0)
Hypertensive heart disease	1.4 (1.2 to 1.6)	3.1 (2.8 to 3.6)	120.8 (84.0 to 162.7)	0.8 (-15.7 to 21.0)	0.2 (0.0 to 0.2)	0.4 (0.2 to 0.5)	126.6 (80.8 to 163.2)	0.9 (-16.0 to 21.7)
Cardiomyopathy and myocarditis	0.7 (0.6 to 0.8)	1.5 (1.3 to 1.6)	120.3 (81.0 to 167.5)	19.5 (-4.1 to 47.5)	0.2 (0.0 to 0.1)	0.5 (0.1 to 0.2)	119.4 (73.1 to 172.7)	19.0 (-7.2 to 49.0)
Atrial fibrillation and flutter	1.0 (0.9 to 1.2)	3.8 (3.4 to 4.3)	280.1 (219.9 to 349.9)	65.3 (36.9 to 97.2)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	278.7 (212.2 to 349.6)	65.5 (36.0 to 98.3)
Peripheral vascular disease	27.2 (21.9 to 33.5)	58.4 (46.5 to 71.9)	115.7 (54.5 to 190.6)	-0.1 (-25.7 to 29.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	136.1 (4.3 to 672.0)	-6.8 (-59.6 to 178.4)
Endocarditis	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	106.4 (17.8 to 192.9)	23.1 (-2.9 to 73.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.6 (13.3 to 217.6)	23.0 (-32.3 to 90.0)
Other cardiovascular and circulatory diseases	6.8 (4.2 to 10.4)	24.4 (11.5 to 35.6)	369.4 (58.6 to 561.4)	101.9 (-14.0 to 275.6)	0.5 (0.3 to 0.8)	1.7 (0.7 to 2.8)	270.0 (61.6 to 564.2)	102.5 (-12.3 to 274.5)
Chronic respiratory diseases	-	-	-	-	5.2 (3.5 to 7.1)	7.3 (5.0 to 10.2)	40.7 (25.7 to 60.8)	-13.2 (-21.5 to -1.6)
Chronic obstructive pulmonary disease	33.2 (30.5 to 36.1)	56.8 (52.6 to 61.2)	71.1 (62.7 to 78.9)	-1.2 (-5.4 to 3.0)</				

Appendix Table G.4 - Mauritius prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	195.4 (174.7 to 214.6)	61.5 (49.2 to 74.5)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.6 (69.7 to 89.6)	-7.9 (-13.0 to -2.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.7 (68.6 to 88.8)	-8.4 (-13.4 to -3.1)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	253.9 (236.0 to 272.0)	101.1 (92.2 to 110.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	240.3 (219.7 to 263.7)	92.9 (79.9 to 107.1)
Asthma	27.9 (23.1 to 32.3)	25.7 (21.4 to 29.8)	-7.9 (-24.4 to 13.6)	-29.4 (-41.4 to -12.9)	1.2 (0.8 to 1.8)	1.1 (0.7 to 1.6)	-8.7 (-25.1 to 13.2)	-29.5 (-41.9 to -13.1)
Interstitial lung disease and pulmonary sarcoidosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	79.2 (25.4 to 155.6)	2.8 (-26.7 to 43.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.1 (24.8 to 151.6)	3.1 (-27.9 to 44.2)
Other chronic respiratory diseases	-	-	-	-	0.7 (0.4 to 1.1)	0.5 (0.3 to 0.8)	-23.6 (-45.5 to 1.8)	-56.2 (-68.8 to -41.8)
Cirrhosis	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	25.2 (10.5 to 40.7)	-20.6 (-29.5 to -11.5)
Cirrhosis due to hepatitis B	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	21.4 (-29.4 to 85.0)	-24.0 (54.6 to 16.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	19.3 (-29.4 to 90.2)	24.0 (55.2 to 20.1)
Cirrhosis due to hepatitis C	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	107.2 (6.8 to 279.1)	30.2 (-37.0 to 138.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	104.4 (-12.1 to 290.4)	28.4 (-40.9 to 145.6)
Cirrhosis due to alcohol use	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-47.3 (-49.9 to 38.5)	-8.3 (-71.0 to -20.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.4 (-53.0 to 45.8)	-47.3 (-72.7 to -17.1)
Cirrhosis due to other causes	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	29.1 (-9.0 to 85.7)	6.0 (-24.9 to 49.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.3 (-20.3 to 103.2)	6.6 (-33.2 to 65.0)
Digestive diseases	-	-	-	-	0.9 (0.6 to 1.2)	1.1 (0.8 to 1.5)	28.5 (19.3 to 35.3)	-26.3 (-30.8 to -22.3)
Peptic ulcer disease	7.3 (6.6 to 7.9)	6.5 (5.9 to 7.0)	-10.5 (-20.7 to 0.9)	-57.6 (-60.6 to -54.1)	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-5.3 (-18.9 to 6.1)	-55.4 (-60.0 to -50.4)
Gastritis and duodenitis	9.7 (9.1 to 10.1)	12.1 (11.7 to 12.4)	24.0 (18.1 to 32.9)	-27.1 (-30.1 to -23.5)	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.7)	22.6 (12.9 to 30.6)	-21.0 (-26.1 to -15.9)
Appendicitis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-15.6 (-39.5 to 30.1)	-26.9 (-48.2 to 10.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.9 (-45.8 to 50.3)	-26.0 (-52.4 to 24.4)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.0 (53.3 to 118.0)	6.8 (-10.6 to 27.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.7 (44.8 to 124.0)	6.7 (-19.3 to 40.4)
Inguinal, femoral, and abdominal hernia	2.4 (2.1 to 2.8)	4.0 (3.4 to 4.7)	69.7 (38.3 to 104.4)	-8.7 (-26.1 to 11.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	68.1 (36.4 to 102.6)	-8.6 (-26.0 to 11.2)
Inflammatory bowel disease	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.3)	73.2 (58.2 to 90.1)	8.6 (-0.6 to 18.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	71.2 (41.3 to 110.5)	8.9 (-9.0 to 31.3)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.5 (39.2 to 192.1)	5.4 (-32.6 to 53.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.2 (28.3 to 201.1)	3.2 (-40.4 to 76.0)
Gallbladder and biliary diseases	0.3 (0.3 to 0.3)	0.4 (0.4 to 0.4)	33.0 (15.2 to 55.1)	-25.4 (-35.5 to -14.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	31.8 (8.0 to 59.6)	25.8 (-38.4 to -11.9)
Pancreatitis	0.2 (0.2 to 0.3)	0.4 (0.4 to 0.5)	84.4 (72.7 to 99.3)	15.7 (8.2 to 24.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	83.1 (55.6 to 116.4)	16.1 (0.2 to 34.6)
Other digestive diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	111.9 (78.1 to 147.2)	21.0 (1.8 to 40.9)
Neurological disorders	-	-	-	-	7.5 (4.9 to 10.5)	11.7 (7.8 to 16.2)	54.9 (29.0 to 94.2)	10.9 (-6.3 to 37.0)
Alzheimer disease and other dementias	4.1 (3.4 to 4.7)	10.0 (8.6 to 11.4)	146.6 (96.0 to 207.1)	-0.5 (-22.5 to 25.6)	0.6 (0.4 to 0.8)	1.4 (1.0 to 1.9)	151.6 (98.9 to 213.1)	-0.2 (-23.0 to 25.3)
Parkinson disease	0.4 (0.3 to 0.4)	0.9 (0.8 to 1.0)	125.6 (114.7 to 136.0)	2.4 (-1.9 to 7.4)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	123.6 (99.0 to 151.6)	2.3 (-8.7 to 13.7)
Epilepsy	4.9 (3.5 to 6.3)	5.6 (3.9 to 7.3)	12.9 (-29.3 to 79.3)	-2.6 (-38.2 to 51.5)	1.6 (1.0 to 2.3)	1.9 (1.2 to 2.9)	22.7 (-24.3 to 95.8)	6.9 (-34.4 to 67.9)
Multiple sclerosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	172.5 (145.0 to 204.1)	80.4 (61.8 to 100.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	172.5 (144.8 to 204.3)	80.4 (61.5 to 100.8)
Migraine	123.0 (93.8 to 150.3)	180.1 (141.9 to 224.9)	48.4 (6.2 to 114.5)	9.6 (-17.2 to 62.3)	4.3 (2.4 to 6.6)	6.2 (3.5 to 9.6)	10.0 (5.2 to 114.6)	10.0 (-17.5 to 64.8)
Tension-type headache	242.9 (221.0 to 264.3)	316.2 (296.3 to 337.0)	30.5 (16.7 to 43.9)	1.1 (-9.0 to 11.1)	0.5 (0.2 to 0.7)	0.5 (0.2 to 0.8)	29.6 (15.3 to 43.6)	1.0 (-9.4 to 11.8)
Medication overuse headache	3.8 (2.6 to 5.1)	8.4 (5.7 to 10.9)	118.9 (83.5 to 162.3)	50.1 (26.2 to 78.5)	0.6 (0.3 to 1.0)	1.3 (0.8 to 2.1)	117.4 (79.9 to 160.6)	50.7 (26.8 to 79.3)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.9 (-0.7 to 82.5)	1.0 (-24.1 to 36.3)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	234.7 (51.1 to 377.3)	37.3 (-36.5 to 97.3)
Mental and substance use disorders	-	-	-	-	20.1 (14.8 to 26.6)	25.3 (18.1 to 33.5)	25.8 (15.5 to 30.8)	-1.5 (-5.0 to 1.9)
Schizophrenia	3.8 (3.2 to 4.3)	5.2 (4.5 to 6.0)	38.6 (30.9 to 45.4)	-0.5 (-4.9 to 4.2)	2.5 (1.7 to 3.1)	3.4 (2.4 to 4.3)	37.6 (27.9 to 47.1)	0.5 (-6.8 to 6.5)
Alcohol use disorders	10.7 (9.7 to 11.8)	13.3 (12.3 to 14.5)	24.8 (16.6 to 34.0)	-4.9 (-10.4 to 1.7)	1.1 (0.7 to 1.5)	1.3 (0.9 to 1.9)	23.9 (15.3 to 34.5)	-4.9 (-10.9 to 2.8)
Drug use disorders	-	-	-	-	2.4 (1.6 to 3.4)	2.6 (1.8 to 3.6)	6.2 (-13.0 to 29.7)	-0.9 (-18.7 to 21.1)
Opioid use disorders	1.3 (1.0 to 1.6)	1.6 (1.3 to 2.0)	21.3 (11.9 to 32.9)	-0.4 (-8.2 to 8.3)	0.6 (0.4 to 0.8)	0.7 (0.5 to 0.9)	21.4 (7.6 to 38.2)	0.3 (-11.2 to 12.7)
Cocaine use disorders	0.9 (0.9 to 1.0)	1.0 (1.0 to 1.1)	9.1 (-1.1 to 19.9)	0.1 (-10.0 to 8.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	9.1 (9.9 to 29.5)	0.7 (-17.4 to 18.4)
Amphetamine use disorders	5.7 (4.6 to 6.9)	5.7 (4.7 to 6.9)	1.0 (-24.3 to 33.8)	-0.8 (-25.0 to 31.0)	0.8 (0.5 to 1.1)	0.8 (0.5 to 1.2)	0.5 (-24.7 to 34.2)	-1.3 (-26.0 to 30.9)
Cannabis use disorders	2.6 (1.8 to 3.4)	2.7 (2.0 to 3.4)	2.1 (-1.2 to 8.9)	-0.3 (-0.4 to -0.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	2.5 (-10.3 to 20.3)	-0.1 (-12.2 to 14.8)
Other drug use disorders	-	-	-	-	0.9 (0.5 to 1.4)	0.9 (0.5 to 1.4)	1.5 (-30.3 to 48.0)	-1.1 (-31.2 to 44.1)
Depressive disorders	-	-	-	-	5.9 (3.7 to 8.7)	8.3 (5.1 to 12.2)	38.8 (28.4 to 50.8)	-1.1 (-6.0 to 5.2)
Major depressive disorder	22.4 (15.0 to 29.7)	30.6 (19.9 to 40.5)	36.8 (22.9 to 52.3)	-1.7 (-7.6 to 5.6)	4.6 (2.7 to 7.0)	6.3 (3.6 to 9.6)	35.7 (21.8 to 51.0)	-1.3 (-7.9 to 6.6)
Dysthymia	13.3 (11.4 to 15.1)	20.1 (17.5 to 22.7)	51.5 (45.2 to 59.2)	-0.4 (-0.5 to -0.3)	1.3 (0.8 to 1.9)	1.9 (1.3 to 2.8)	50.6 (42.8 to 59.2)	-0.3 (-2.5 to 2.0)
Bipolar disorder	6.8 (5.6 to 7.9)	8.9 (7.6 to 10.2)	31.5 (22.5 to 41.3)	-0.7 (-5.9 to 4.6)	1.4 (0.8 to 2.1)	1.8 (1.1 to 2.7)	30.7 (20.4 to 42.0)	-0.4 (-7.0 to 6.5)
Anxiety disorders	29.2 (12.3 to 46.2)	37.5 (18.0 to 57.4)	29.3 (10.6 to 58.8)	2.2 (-0.8 to 0.1)	2.7 (1.0 to 4.8)	3.5 (1.6 to 6.0)	28.9 (9.4 to 57.0)	-0.1 (-2.9 to 2.8)
Eating disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-3.8 (-16.9 to 11.0)	0.5 (-12.8 to 15.5)
Anorexia nervosa	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-4.7 (-13.4 to 7.0)	0.2 (-9.3 to 11.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-5.0 (-22.6 to 18.9)	-0.0 (-18.2 to 24.8)
Bulimia nervosa	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-3.3 (-6.3 to 2.3)	0.9 (0.6 to 1.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-3.0 (-19.3 to 17.7)	0.8 (-15.8 to 23.1)
Autistic spectrum disorders	-	-	-	-	1.3 (0.9 to 1.8)	1.5 (1.0 to 2.0)	13.0 (9.5 to 17.0)	0.4 (-2.6 to 3.8)
Autism	3.3 (3.1 to 3.5)	3.7 (3.6 to 4.0)	14.0 (13.0 to 15.2)	0.2 (0.2 to 0.3)	0.8 (0.6 to 1.1)	0.9 (0.6 to 1.3)	13.0 (7.8 to 18.9)	0.4 (-4.1 to 5.3)
Asperger syndrome	4.7 (4.4 to 5.0)	5.3 (5.0 to 5.7)	13.5 (12.1 to 14.9)	0.3 (0.2 to 0.3)	0.5 (0.3 to 0.7)	0.5 (0.4 to 0.7)	12.8 (7.8 to 17.9)	0.4 (-3.7 to 4.8)
Attention-deficit/hyperactivity disorder	7.0 (6.4 to 7.4)	6.0 (5.5 to 6.4)	-14.4 (-14.5 to -14.3)	-0.2 (-0.3 to -0.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-14.3 (-20.4 to -7.3)	-0.2 (-7.4 to 7.9)
Conduct disorder	7.1 (6.7 to 7.5)	6.1 (5.8 to 6.5)	-13.6 (-13.8 to -13.5)	0.1 (-0.1 to -0.1)	0.9 (0.5 to 1.3)	0.7 (0.5 to 1.1)	-13.3 (-17.9 to -8.8)	0.1 (-5.0 to 5.6)
Idiopathic intellectual disability	9.3 (5.6 to 13.4)	6.1 (2.3 to 10.2)	-33.6 (-73.8 to 19.6)	-11.2 (-76.5 to 5.9)	0.5 (0.2 to 0.7)	0.3 (0.1 to 0.5)	-34.1 (-73.9 to 18.5)	-41.1 (-76.5 to 6.0)
Other mental and substance use disorders	17.2 (16.1 to 18.3)	23.5 (22.1 to 24.9)	36.5 (33.2 to 39.6)	0.2 (-0.0 to 0.4)	1.3 (0.9 to 1.8)	1.8 (1.2 to 2.4)	35.6 (29.2 to 41.8)	0.4 (-3.4 to 3.9)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	9.0 (6.2 to 12.5)	14.9 (10.0 to 21.0)	65.5 (48.4 to 86.6)	10.5 (-1.7 to 24.3)
Diabetes mellitus	80.7 (68.7 to 92.7)	157.0 (131.1 to 187.4)	94.2 (58.4 to 141.9)	13.6 (-7.5 to 40.6)	4.4 (2.9 to 6.3)	8.6 (5.5 to 12.6)	95.5 (58.1 to 143.7)	13.0 (8.7 to 38.9)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.7 (-15.2 to -0.9)	-13.0 (-17.9 to -6.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.7 (-15.3 to -0.9)	-13.0 (-17.9 to -6.4)
Chronic kidney disease	-	-	-	-	1.1 (0.8 to 1.5)	1.7 (1.1 to 2.3)	52.5 (37.8 to 69.3)	6.7 (-1.5 to 17.7)
Chronic kidney disease due to diabetes mellitus	3.8 (2.5 to 5.6)	10.8 (7.1 to 15.1)	187.2 (101.4 to 327.1)	63.1 (12.3 to 125.9)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	168.9 (89.9 to 283.4)	57.5 (12.6 to 114.6)
Chronic kidney disease due to hypertension	7.4 (4.5 to 12.1)	4.4 (3.4 to 5.5)	-38.5 (-61.0 to -12.8)	-49.9 (-64.8 to -35.5)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.6)	52.6 (14.7 to 98.0)	4.9 (-18.8 to 36.5)
Chronic kidney disease due to glomerulonephritis	8.5 (5.7 to 12.3)	10.7 (6.3 to 16.6)	25.3 (-7.8 to 78.2)	29.2 (-31.4 to 16.1)	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.1)	42.1 (74.5 to -42.0)	68.6 (-78.0 to -53.9)
Chronic kidney disease due to other causes	23.3 (15.5 to 33.4)	33.9 (23.4 to 46.5)	44.8 (21.6 to 80.5)	6.4 (-7.5 to 28.7)	0.6 (0.4 to 0.8)	1.0 (0.6 to 1.3)	63.8 (41.6 to 105.6)	16.4 (-0.6 to 42.7)
Urinary diseases and male infertility	-	-	-	-	0.4 (0.3 to 0.6)	0.9 (0.6 to 1.3)	119.8 (95.9 to 146.5)	13.9 (1.9 to 27.5)

Appendix Table G.4 - Mauritius prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.3)	67.7 (53.7 to 82.4)	24.1 (14.8 to 34.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.4 (34.9 to 107.7)	24.1 (3.0 to 52.8)
Urolithiasis	4.5 (3.2 to 5.9)	9.2 (6.4 to 13.2)	105.5 (84.1 to 130.3)	4.5 (5.9 to 15.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	69.5 (50.3 to 94.0)	4.3 (5.4 to 15.1)
Benign prostatic hyperplasia	7.8 (7.0 to 8.4)	19.1 (17.6 to 20.7)	145.3 (121.3 to 179.9)	13.0 (1.3 to 28.1)	0.3 (0.2 to 0.4)	0.7 (0.4 to 1.0)	144.4 (120.3 to 179.4)	12.8 (1.1 to 28.5)
Male infertility due to other causes	6.1 (4.2 to 8.7)	6.3 (4.4 to 8.6)	6.6 (-38.9 to 71.9)	-3.4 (45.0 to 56.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	4.6 (-39.5 to 69.1)	-4.6 (-45.0 to 55.2)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	175.3 (43.6 to 272.3)	74.8 (6.7 to 131.7)
Gynecological diseases	-	-	-	-	1.3 (0.8 to 2.0)	1.5 (0.9 to 2.3)	12.6 (-4.0 to 29.7)	-10.3 (-23.1 to 2.7)
Uterine fibroids	22.3 (20.3 to 24.4)	33.1 (30.3 to 36.0)	48.4 (46.4 to 50.5)	-1.2 (-1.3 to -1.1)	0.3 (0.2 to 0.5)	0.3 (0.1 to 0.5)	-3.9 (-21.7 to 32.9)	-32.7 (-44.5 to -7.2)
Polycystic ovarian syndrome	17.8 (15.2 to 20.9)	19.6 (15.2 to 23.2)	10.1 (-14.0 to 36.7)	-7.8 (-28.3 to 14.7)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	10.5 (-13.7 to 37.2)	-7.1 (-27.1 to 15.5)
Female infertility due to other causes	5.2 (1.7 to 10.1)	7.6 (2.7 to 14.0)	49.3 (-66.2 to 515.5)	29.8 (-71.4 to 473.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	28.7 (-63.7 to 482.9)	31.1 (-68.0 to 450.1)
Endometriosis	2.1 (1.7 to 2.4)	2.5 (2.2 to 2.9)	23.4 (-0.4 to 52.3)	0.3 (-18.8 to 23.5)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	0.8 (2.4 to 55.0)	0.8 (-20.0 to 25.7)
Genital prolapse	50.4 (44.4 to 56.8)	73.8 (65.0 to 83.5)	46.0 (24.0 to 76.1)	-3.9 (-17.1 to 15.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	45.9 (23.5 to 75.4)	-3.7 (-17.5 to 15.7)
Premenstrual syndrome	43.0 (31.3 to 56.6)	51.5 (36.4 to 67.9)	21.8 (-26.6 to 80.4)	10.4 (-33.1 to 62.0)	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.7)	22.3 (-26.2 to 81.3)	11.0 (-34.1 to 63.4)
Other gynecological diseases	2.9 (2.1 to 3.8)	2.2 (1.7 to 2.7)	-26.0 (-44.3 to 2.4)	-37.6 (-52.9 to -13.6)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-64.3 (-77.0 to -30.3)	-70.2 (-80.6 to -42.5)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	1.4 (0.9 to 2.0)	1.9 (1.2 to 2.7)	35.9 (25.2 to 46.1)	29.4 (19.1 to 39.4)
Thalassemias	0.4 (0.2 to 0.6)	0.3 (0.2 to 0.6)	-5.1 (-12.8 to 3.9)	6.6 (-1.5 to 16.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.2 (-27.1 to 39.3)	7.1 (-20.6 to 53.8)
Thalassemia trait	67.0 (50.1 to 86.7)	80.1 (63.7 to 102.1)	19.3 (14.3 to 28.5)	1.9 (-2.1 to 10.0)	1.1 (0.7 to 1.6)	1.7 (1.1 to 2.4)	51.5 (36.5 to 62.3)	43.1 (28.7 to 53.0)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.8 (-16.5 to 25.0)	7.1 (-11.5 to 30.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.0 (-21.0 to 61.9)	13.1 (-18.4 to 63.2)
Sickle cell trait	1.5 (0.8 to 2.0)	1.8 (1.1 to 2.4)	17.2 (-10.9 to 51.4)	0.0 (-23.9 to 30.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.2 (-20.9 to 482.7)	44.6 (-23.4 to 449.1)
G6PD deficiency	39.5 (29.7 to 49.3)	49.1 (33.0 to 63.2)	24.0 (-21.2 to 88.1)	6.0 (-32.6 to 61.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.5 (-63.8 to -10.4)	-40.2 (-66.4 to -14.5)
G6PD trait	159.0 (137.6 to 181.7)	187.0 (149.5 to 214.8)	18.7 (9.4 to 43.0)	-0.4 (-24.0 to 20.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.4 (38.1 to 306.7)	81.4 (-41.3 to 259.3)
Other hemoglobinopathies and hemolytic anemias	8.2 (7.0 to 9.6)	5.8 (5.1 to 7.2)	-29.5 (-41.6 to -7.0)	-35.9 (-47.4 to -14.1)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-41.4 (-56.6 to 3.4)	-40.3 (-55.6 to 6.7)
Endocrine, metabolic, blood, and immune disorders	11.6 (10.3 to 12.8)	11.0 (9.9 to 13.0)	-5.4 (-16.7 to 12.4)	-17.1 (-27.7 to 0.3)	0.4 (0.3 to 0.5)	0.4 (0.2 to 0.5)	-4.4 (-22.9 to 17.9)	-18.0 (-32.9 to 6.8)
Musculoskeletal disorders	-	-	-	-	13.3 (9.3 to 17.8)	21.0 (14.8 to 28.0)	57.1 (43.2 to 74.1)	-2.0 (-9.9 to 7.6)
Rheumatoid arthritis	0.7 (0.6 to 0.7)	2.0 (1.9 to 2.2)	203.2 (167.2 to 236.9)	75.6 (55.7 to 96.4)	0.2 (0.1 to 0.2)	0.5 (0.3 to 0.6)	196.7 (157.7 to 243.2)	74.9 (52.8 to 101.4)
Osteoarthritis	14.2 (13.4 to 15.0)	30.6 (28.7 to 32.5)	115.6 (97.7 to 134.2)	2.5 (-6.4 to 10.7)	0.9 (0.6 to 1.2)	2.6 (1.3 to 2.6)	114.9 (96.5 to 133.7)	2.5 (-6.2 to 11.0)
Low back and neck pain	-	-	-	-	10.0 (6.8 to 13.5)	14.5 (9.8 to 20.0)	45.7 (27.8 to 68.1)	44.6 (-14.2 to 10.5)
Low back pain	61.1 (57.5 to 65.1)	93.6 (88.5 to 98.5)	53.5 (40.3 to 65.9)	0.1 (-7.9 to 7.6)	6.9 (4.6 to 9.6)	10.5 (7.0 to 14.6)	52.1 (38.5 to 64.3)	0.1 (-7.8 to 7.8)
Neck pain	30.3 (24.2 to 36.5)	40.8 (27.7 to 57.9)	30.4 (-8.5 to 110.7)	-12.8 (-38.1 to 36.9)	3.0 (1.9 to 4.3)	4.0 (2.4 to 6.7)	29.2 (9.5 to 108.3)	-13.0 (-38.7 to 37.0)
Gout	0.6 (0.5 to 0.6)	1.1 (1.0 to 1.3)	100.9 (63.8 to 137.5)	8.0 (-10.6 to 27.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	98.1 (50.2 to 159.4)	8.1 (-17.2 to 40.6)
Other musculoskeletal disorders	25.0 (18.6 to 31.3)	43.9 (33.2 to 54.8)	75.8 (63.1 to 89.2)	4.9 (-9.7 to 0.8)	2.3 (1.5 to 3.4)	4.0 (2.6 to 5.9)	74.9 (62.0 to 89.7)	-4.1 (-9.6 to 1.9)
Other non-communicable diseases	-	-	-	-	16.4 (11.0 to 23.5)	22.2 (15.1 to 31.7)	35.2 (27.8 to 42.4)	-7.5 (-10.6 to -4.1)
Congenital anomalies	-	-	-	-	1.3 (0.9 to 1.8)	1.7 (1.2 to 2.2)	29.9 (9.5 to 56.4)	14.9 (-2.7 to 37.1)
Neural tube defects	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.3)	-2.4 (-21.5 to 17.1)	-4.0 (-22.8 to 15.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-3.4 (-27.6 to 27.9)	-4.0 (-27.6 to 26.5)
Congenital heart anomalies	4.0 (3.3 to 4.7)	5.6 (4.7 to 6.7)	41.2 (10.3 to 79.5)	30.9 (2.1 to 66.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	42.8 (13.4 to 81.0)	34.5 (6.7 to 70.1)
Orofacial clefts	0.9 (0.7 to 1.2)	1.2 (1.1 to 1.5)	34.7 (1.4 to 75.6)	29.4 (-3.2 to 69.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.6 (-25.7 to 58.5)	4.4 (-28.7 to 49.8)
Down syndrome	1.0 (0.9 to 1.3)	1.5 (1.2 to 2.0)	46.0 (5.9 to 104.3)	20.7 (-12.9 to 67.9)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	66.2 (17.3 to 136.7)	26.8 (-11.2 to 79.6)
Turner syndrome	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	11.0 (-27.9 to 54.9)	2.7 (-33.3 to 43.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.8 (-28.8 to 64.8)	2.5 (-34.0 to 52.3)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	15.3 (-17.7 to 72.9)	2.0 (-27.1 to 52.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.5 (-30.5 to 93.6)	2.3 (-37.6 to 67.5)
Chromosomal unbalanced rearrangements	1.5 (1.2 to 1.7)	2.0 (1.6 to 2.5)	23.0 (6.9 to 83.6)	4.0 (-11.4 to 51.5)	0.0 (0.1 to 0.2)	0.0 (0.2 to 0.4)	19.5 (21.2 to 111.9)	19.5 (-8.1 to 59.9)
Other congenital anomalies	5.4 (4.0 to 7.2)	5.1 (3.8 to 6.7)	-5.1 (-22.0 to 10.9)	-18.0 (-32.2 to -4.5)	0.7 (0.4 to 1.2)	0.8 (0.5 to 1.2)	16.8 (9.6 to 60.8)	9.6 (-15.7 to 47.4)
Skin and subcutaneous diseases	-	-	-	-	5.7 (3.6 to 8.8)	6.8 (4.3 to 10.4)	20.4 (12.0 to 28.4)	0.4 (-5.6 to 6.0)
Dermatitis	52.7 (44.3 to 62.0)	63.9 (54.4 to 74.6)	21.5 (17.1 to 25.6)	-0.1 (-0.1 to 0.0)	1.6 (1.0 to 2.2)	1.8 (1.1 to 2.6)	16.4 (10.2 to 22.2)	0.1 (-2.6 to 2.8)
Psoriasis	8.4 (6.6 to 10.3)	11.5 (8.9 to 14.2)	37.3 (30.8 to 47.3)	0.0 (-0.2 to 0.1)	0.7 (0.5 to 1.0)	0.9 (0.6 to 1.4)	36.3 (25.5 to 48.5)	0.0 (-5.0 to 5.3)
Cellulitis	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.4)	38.3 (21.2 to 63.2)	2.1 (-9.9 to 14.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.4 (7.5 to 78.3)	2.4 (-17.7 to 27.3)
Pyoderma	1.4 (1.1 to 1.8)	0.7 (0.6 to 1.0)	-49.8 (-59.2 to -38.6)	-51.8 (-59.0 to -42.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.2 (-60.7 to -37.4)	-52.0 (-59.9 to -42.1)
Scabies	11.4 (10.5 to 12.4)	11.6 (10.4 to 13.1)	2.4 (-11.7 to 19.1)	-12.0 (-23.5 to 2.0)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	1.9 (-13.3 to 19.2)	-12.0 (-23.8 to 2.4)
Fungal skin diseases	126.0 (99.0 to 152.6)	154.9 (124.6 to 183.6)	23.0 (16.7 to 30.2)	0.7 (-0.1 to 1.5)	0.7 (0.3 to 1.5)	0.9 (0.4 to 1.8)	22.4 (16.5 to 29.7)	0.0 (-0.7 to 0.7)
Viral skin diseases	22.1 (16.3 to 28.0)	21.7 (15.8 to 27.7)	-2.5 (-7.7 to 4.9)	0.0 (-1.9 to 2.2)	0.0 (0.4 to 1.1)	0.7 (0.4 to 1.1)	-2.7 (-8.8 to 5.0)	0.1 (-3.0 to 3.8)
Acne vulgaris	63.1 (46.6 to 78.8)	61.9 (46.5 to 80.5)	-2.3 (-31.8 to 34.5)	4.7 (-27.3 to 44.3)	0.7 (0.3 to 1.3)	0.7 (0.3 to 1.3)	-2.2 (-32.3 to 34.1)	4.9 (-27.3 to 43.9)
Alopecia areata	1.3 (1.2 to 1.5)	1.9 (1.7 to 2.2)	42.2 (17.6 to 68.6)	2.0 (-13.8 to 19.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	41.1 (13.6 to 71.8)	2.3 (-16.4 to 21.4)
Pruritus	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	56.3 (11.9 to 105.0)	4.0 (-22.7 to 35.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.9 (4.7 to 111.9)	3.3 (-27.7 to 42.3)
Urticaria	9.4 (7.0 to 12.2)	13.4 (9.1 to 17.5)	43.8 (-11.3 to 113.8)	4.6 (-33.8 to 48.1)	0.6 (0.3 to 0.9)	0.8 (0.5 to 1.3)	41.7 (-13.0 to 114.2)	4.4 (-34.1 to 50.0)
Decubitus ulcer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	99.0 (57.5 to 154.5)	8.5 (-18.7 to 44.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	92.6 (49.1 to 152.9)	7.3 (-19.7 to 46.0)
Other skin and subcutaneous diseases	70.5 (48.3 to 102.1)	109.8 (70.1 to 170.3)	55.3 (33.8 to 79.2)	-0.3 (-3.2 to 2.3)	0.4 (0.2 to 0.9)	0.6 (0.3 to 1.4)	54.2 (33.3 to 78.5)	-0.2 (-3.3 to 2.6)
Sense organ diseases	-	-	-	-	8.1 (5.4 to 11.9)	11.0 (7.9 to 17.2)	36.5 (17.5 to 58.8)	-13.8 (-17.9 to -10.0)
Glaucoma	1.5 (1.2 to 1.9)	2.1 (1.6 to 2.7)	41.7 (4.3 to 88.4)	-19.6 (-38.9 to 6.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	50.2 (34.5 to 85.9)	-19.9 (-36.8 to 11.9)
Cataract	7.2 (5.4 to 9.3)	13.4 (9.5 to 17.0)	87.1 (35.6 to 121.9)	-22.0 (-39.3 to -8.6)	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.2)	93.7 (47.3 to 123.7)	-20.5 (-35.8 to -10.3)
Macular degeneration	0.8 (0.5 to 1.1)	1.8 (1.2 to 2.7)	131.1 (46.9 to 297.4)	8.4 (-30.5 to 79.3)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	126.7 (51.4 to 264.5)	1.4 (-30.7 to 53.2)
Uncorrected refractive error	69.0 (63.1 to 74.5)	107.5 (98.3 to 116.8)	55.6 (40.4 to 72.9)	-8.9 (-16.6 to 0.3)	1.3 (0.8 to 2.0)	1.9 (1.2 to 2.9)	42.5 (32.2 to 54.9)	-15.4 (-20.4 to -8.9)
Age-related and other hearing loss	157.7 (140.3 to 171.5)	256.9 (235.6 to 279.8)	63.1 (54.4 to 72.1)	-9.5 (-12.7 to -6.5)	5.2 (3.2 to 7.8)	7.7 (5.0 to 11.5)	49.1 (30.6 to 70.0)	-12.1 (-18.3 to -6.2)
Other vision loss	8.6 (6.8 to 10.6)	9.0 (6.9 to 11.4)	32.1 (9.8 to 33.8)	2.4 (-41.0 to -15.9)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.8)	7.3 (-5.1 to 36.7)	-34.3 (-41.1 to -21.1)
Other sense organ diseases	23.3 (22.2 to 24.3)	28.3 (27.1 to 29.5)	21.7 (14.0 to 30.0)	-0.0 (-6.0 to 6.9)	0.6 (0.4 to 0.9)	0.7 (0.5 to 1.1)	20.7 (11.9 to 29.5)	0.2 (-7.0 to 7.5)
Oral disorders	-	-	-	-	1.3 (0.8 to 2.1)	1.8 (1.1 to 2.9)	40.9 (31.1 to 50.7)	-6.1 (-12.5 to 0.5)
Deciduous caries	81.4 (76.2 to 85.9)	62.3 (58.4 to 65.1)	-23.2 (-29.8 to -17.1)	0.2 (-8.7 to 8.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-23.4 (-30.7 to -15.2)	-0.1 (-9.4 to 10.7)
Permanent caries	305.6 (277.7 to 336.0)	380.8 (343.8 to 423.5)	24.0 (8.4 to 45.7)	1.9 (-11.4 to 19.4)	0.3 (0.1 to 0.6)	0.4 (0.2 to 0.7)	23.8 (7.9 to 44.7)	1.9 (-11.6 to 19.7)
Periodontal diseases	29.8 (26.1 to 33.7)	56.0 (48.9 to 62.7)	88.3 (56.6 to 119.9)	6.6 (-11.4 to 25.2)	0.2 (0.1 to 0.4)	0.4 (0.1 to 0.8)	87.2 (56.0 to 119.1)	6.7 (-11.3 to

Appendix Table G.4 - Mauritius prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	8.7 (7.6 to 9.7)	13.6 (11.9 to 15.3)	57.9 (33.2 to 83.9)	-26.1 (-37.3 to -13.6)	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	57.4 (31.7 to 84.2)	26.1 (-37.6 to -13.6)
Other oral disorders	18.2 (17.1 to 19.3)	23.8 (22.6 to 25.1)	30.8 (20.2 to 41.2)	-0.2 (-7.7 to 7.5)	0.5 (0.3 to 0.8)	0.7 (0.4 to 1.0)	30.3 (19.5 to 41.5)	-0.2 (-7.8 to 7.6)
Injuries	-	-	-	-	2.5 (1.9 to 3.3)	3.5 (2.5 to 4.8)	38.1 (25.4 to 52.6)	-13.1 (-20.4 to -4.7)
Transport injuries	-	-	-	-	1.0 (0.7 to 1.3)	1.6 (1.1 to 2.3)	67.7 (47.3 to 91.6)	2.7 (-8.5 to 15.2)
Road injuries	-	-	-	-	0.3 (0.2 to 0.4)	1.5 (1.1 to 2.1)	66.5 (45.9 to 91.3)	2.7 (-8.7 to 15.7)
Pedestrian road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	64.2 (40.5 to 90.8)	0.2 (-12.6 to 14.0)
Cyclist road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	64.5 (44.4 to 85.0)	-6.9 (-17.7 to 4.6)
Motorcyclist road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.9)	56.4 (34.1 to 81.4)	-3.1 (-15.3 to 10.4)
Motor vehicle road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	81.3 (55.4 to 114.3)	14.0 (-0.8 to 31.8)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.5 (3.7 to 37.8)	-30.3 (-38.5 to -20.8)
Other transport injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	81.4 (60.4 to 106.5)	1.6 (-10.9 to 15.7)
Unintentional injuries	-	-	-	-	1.4 (1.1 to 1.8)	1.7 (1.2 to 2.2)	16.1 (6.8 to 25.4)	-25.2 (-31.0 to -19.6)
Falls	-	-	-	-	0.5 (0.4 to 0.6)	0.8 (0.5 to 1.0)	52.4 (35.6 to 70.2)	-12.2 (-22.0 to -1.8)
Drowning	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-15.3 (-28.0 to -0.1)	-46.0 (-53.3 to -37.4)
Fire, heat, and hot substances	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-16.2 (-23.4 to -8.7)	-43.9 (-47.9 to -39.9)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.2 (-19.1 to 24.0)	-28.9 (-40.8 to -11.7)
Exposure to mechanical forces	-	-	-	-	0.5 (0.4 to 0.7)	0.4 (0.3 to 0.5)	-25.3 (-32.2 to -18.1)	-46.1 (-50.4 to -41.4)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.8 (-48.4 to -32.2)	-57.3 (-62.4 to -51.9)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.9 (-21.6 to 2.2)	-34.1 (-41.1 to -25.1)
Other exposure to mechanical forces	-	-	-	-	0.5 (0.3 to 0.6)	0.3 (0.2 to 0.5)	-24.6 (-31.6 to -17.4)	-45.6 (-50.1 to -40.8)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.8 (48.6 to 67.6)	2.3 (-3.7 to 8.6)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.5 (19.5 to 66.3)	8.7 (-7.1 to 25.8)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.8 (19.0 to 79.3)	10.2 (-9.4 to 33.9)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.9 (15.1 to 64.0)	7.8 (-8.8 to 24.6)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.6 (8.9 to 33.6)	-17.2 (-24.4 to -9.6)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.9 (-26.3 to 11.2)	-34.1 (-44.9 to -20.7)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.2 (14.6 to 33.0)	-8.3 (-15.4 to -1.8)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.5 (25.5 to 55.3)	-12.1 (-20.1 to -3.6)
Other unintentional injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	56.7 (38.0 to 77.2)	-4.1 (-14.0 to 7.8)
Self-harm and interpersonal violence	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-7.6 (-18.4 to 5.2)	-39.2 (-45.9 to -31.5)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.4 (-37.6 to -17.8)	-54.7 (-60.4 to -48.6)
Interpersonal violence	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	0.3 (-12.5 to 15.7)	-33.0 (-41.0 to -23.7)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.3 (-0.7 to 26.8)	-23.8 (-31.8 to -15.2)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.2 (-8.9 to 24.5)	-29.2 (-37.8 to -17.2)
Assault by other means	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-3.1 (-16.7 to 12.3)	-35.5 (-43.9 to -26.2)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	8,935.8 (2,520.0 to 31,174.8)	8,514.6 (2,486.5 to 29,383.9)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	8,935.8 (2,520.0 to 31,174.8)	8,514.6 (2,486.5 to 29,383.9)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Mexico prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	7,343.6 (5,408.5 to 9,532.7)	11,978.7 (8,839.5 to 15,567.4)	63.1 (60.2 to 66.1)	-0.3 (-1.5 to 1.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1,016.4 (713.2 to 1,400.3)	1,115.9 (798.7 to 1,513.9)	9.8 (6.3 to 14.3)	-13.0 (-15.9 to -9.8)
HIV/AIDS and tuberculosis	-	-	-	-	16.8 (11.3 to 23.6)	25.0 (17.3 to 35.0)	51.7 (12.3 to 83.3)	-12.1 (-35.7 to 5.1)
Tuberculosis	33.2 (31.9 to 34.5)	42.9 (41.3 to 44.7)	29.8 (26.9 to 32.3)	-24.4 (-25.9 to -22.9)	10.2 (7.0 to 13.7)	13.1 (9.0 to 17.6)	28.8 (23.8 to 33.3)	-24.5 (-27.2 to -21.9)
HIV/AIDS	-	-	-	-	6.7 (3.5 to 11.9)	8.7 (7.4 to 18.2)	9.8 (5.2 to 18.6)	6.7 (4.5 to 66.5)
HIV/AIDS resulting in mycobacterial infection	5.1 (2.3 to 9.5)	5.3 (1.8 to 10.5)	9.7 (-60.7 to 96.1)	-41.6 (-79.3 to 5.2)	1.9 (0.8 to 4.0)	2.0 (0.6 to 4.2)	10.0 (-61.1 to 97.1)	-41.1 (-79.4 to 6.4)
HIV/AIDS resulting in other diseases	47.6 (30.5 to 73.4)	121.2 (96.3 to 153.3)	166.7 (55.0 to 279.8)	65.2 (-4.2 to 135.2)	4.7 (2.2 to 9.7)	9.9 (6.1 to 15.9)	135.5 (-3.8 to 284.3)	39.1 (-45.4 to 135.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	217.6 (150.4 to 298.9)	214.2 (145.8 to 298.5)	-1.8 (-6.0 to 3.6)	-17.2 (-19.7 to -14.3)
Diarrheal diseases	724.6 (712.1 to 737.1)	656.3 (646.2 to 666.9)	-9.1 (-11.2 to -7.0)	-15.8 (-17.6 to -13.9)	118.8 (80.8 to 165.5)	107.0 (73.1 to 148.4)	-10.0 (-12.1 to -7.7)	-16.1 (-18.1 to -14.1)
Intestinal infectious diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-0.1 (-1.3 to 2.8)	-38.0 (-62.1 to -44.3)
Typhoid fever	0.5 (0.4 to 0.5)	0.4 (0.4 to 0.4)	-14.9 (-18.2 to -11.3)	-34.3 (-37.0 to -31.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-14.9 (-18.2 to -11.2)	-34.3 (-37.0 to -31.4)
Paratyphoid fever	0.2 (0.2 to 0.2)	0.0 (0.2 to 0.2)	-16.1 (-20.0 to -10.9)	-33.9 (-37.3 to -29.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.1 (-20.1 to -10.9)	-33.8 (-37.2 to -29.8)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-0.1 (-1.7 to 4.2)	-90.6 (-93.5 to -86.9)
Lower respiratory infections	52.9 (45.4 to 59.7)	33.9 (31.1 to 37.5)	-34.8 (-42.6 to -28.4)	-50.1 (-55.5 to -45.4)	5.5 (3.5 to 8.0)	3.1 (2.3 to 5.0)	-35.8 (-41.9 to -29.2)	-50.3 (-55.9 to -45.4)
Upper respiratory infections	4,225.9 (4,123.2 to 4,335.4)	5,699.9 (5,539.0 to 5,852.8)	35.4 (30.0 to 40.4)	0.2 (-3.8 to 3.9)	49.9 (28.0 to 82.6)	67.3 (37.5 to 112.2)	34.9 (29.5 to 39.9)	0.4 (-3.0 to 3.9)
Otitis media	1,147.8 (1,098.1 to 1,191.9)	1,318.1 (1,273.9 to 1,362.3)	15.1 (12.4 to 18.4)	-12.5 (-14.4 to -10.5)	21.9 (13.0 to 35.3)	24.8 (14.8 to 39.8)	12.9 (8.8 to 17.2)	-13.6 (-16.4 to -10.7)
Meningitis	-	-	-	-	13.1 (9.0 to 18.5)	6.7 (4.7 to 9.2)	-48.7 (-52.5 to -44.2)	-61.8 (-64.8 to -58.3)
Pneumococcal meningitis	64.4 (40.5 to 103.2)	33.0 (20.8 to 53.3)	-48.6 (-51.3 to -46.1)	-65.0 (-66.7 to -63.2)	6.0 (4.2 to 8.3)	3.1 (2.2 to 4.1)	-48.3 (-51.3 to -44.5)	-62.3 (-64.6 to -59.4)
H influenzae type B meningitis	27.2 (10.1 to 58.1)	11.5 (4.6 to 25.0)	-57.6 (-63.1 to -47.9)	-70.0 (-73.0 to -60.7)	3.3 (2.2 to 4.9)	1.5 (1.0 to 2.2)	-55.1 (-60.9 to -40.3)	-65.7 (-70.4 to -54.5)
Meningococcal meningitis	4.6 (1.7 to 10.9)	2.4 (0.9 to 5.8)	-48.0 (-54.5 to -42.6)	-64.5 (-67.9 to -56.6)	0.6 (0.4 to 1.0)	0.3 (0.2 to 0.5)	-47.4 (-53.2 to -40.3)	-61.9 (-66.5 to -54.9)
Other meningitis	24.0 (12.0 to 47.9)	12.7 (6.6 to 25.8)	-46.5 (-51.6 to -41.8)	-62.1 (-65.4 to -54.1)	3.1 (2.1 to 4.5)	1.8 (1.2 to 2.5)	-43.3 (-50.3 to -37.1)	-57.4 (-62.6 to -51.7)
Encephalitis	7.1 (3.3 to 17.4)	11.4 (5.5 to 28.8)	62.9 (46.3 to 72.0)	62.9 (-3.1 to 16.8)	1.0 (0.7 to 1.3)	1.6 (1.1 to 2.2)	68.5 (56.5 to 81.1)	13.3 (5.3 to 22.0)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Whooping cough	115.2 (88.6 to 149.1)	18.7 (14.6 to 23.9)	-83.7 (-85.4 to -81.7)	-83.4 (-85.2 to -81.4)	5.8 (3.4 to 9.3)	0.9 (0.5 to 1.5)	-93.6 (-85.6 to -81.5)	-83.3 (-85.4 to -81.2)
Tetanus	0.7 (0.6 to 0.8)	0.0 (0.0 to 0.0)	-96.5 (-96.3 to -94.4)	-96.8 (-97.3 to -95.9)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-93.2 (-94.8 to -90.7)	-94.9 (-96.1 to -93.0)
Measles	1.9 (1.9 to 1.9)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.2 (0.1 to 0.2)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	65.2 (64.0 to 66.9)	82.3 (80.2 to 84.4)	26.5 (22.8 to 30.4)	-1.2 (-5.0 to 3.1)	1.3 (0.8 to 2.1)	2.3 (1.4 to 3.5)	72.0 (55.9 to 89.5)	-2.1 (-9.4 to 6.3)
Neglected tropical diseases and malaria	-	-	-	-	117.9 (82.5 to 167.5)	107.5 (75.0 to 146.7)	-8.5 (-23.3 to 8.0)	-31.9 (-42.7 to -19.2)
Malaria	0.5 (0.4 to 0.6)	1.1 (0.9 to 1.4)	103.0 (65.2 to 147.6)	50.4 (20.9 to 81.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	139.1 (102.8 to 175.7)	84.7 (57.9 to 110.4)
Chagas disease	1,005.9 (986.7 to 1,026.5)	1,584.8 (1,551.2 to 1,621.9)	58.1 (53.3 to 63.1)	1.4 (-1.6 to 4.7)	7.8 (5.3 to 11.0)	14.8 (9.9 to 20.8)	88.3 (80.5 to 95.6)	8.3 (-2.9 to 4.2)
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Visceral leishmaniasis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	7.3 (9.2 to 25.2)	-12.6 (-25.7 to 1.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.3 (9.4 to 25.3)	-12.5 (-25.6 to 1.6)
Cutaneous and mucocutaneous leishmaniasis	0.7 (0.6 to 0.8)	0.6 (0.5 to 0.7)	-12.7 (-25.1 to 0.2)	-41.5 (-50.3 to -32.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.3 (-25.1 to 2.0)	-40.7 (-50.7 to -30.9)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Cysticercosis	110.1 (91.0 to 135.1)	80.5 (65.4 to 99.6)	-26.0 (-47.3 to -3.9)	-54.6 (-67.0 to -42.3)	32.3 (21.2 to 44.2)	26.7 (18.0 to 37.7)	-17.0 (-42.3 to 11.8)	-49.0 (-63.4 to -32.7)
Cystic echinococcosis	3.7 (3.3 to 4.2)	4.2 (3.7 to 4.7)	13.9 (12.2 to 15.7)	-37.2 (-38.4 to -36.4)	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	15.7 (9.6 to 22.2)	35.9 (-39.5 to -32.1)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	10.4 (6.5 to 14.8)	4.3 (2.8 to 6.1)	-58.5 (-67.4 to -49.4)	-81.3 (-85.5 to -77.0)	0.5 (0.3 to 0.8)	0.2 (0.1 to 0.4)	-54.9 (-63.9 to -45.8)	-79.8 (-84.0 to -75.7)
Dengue	5.7 (2.1 to 13.3)	39.4 (14.3 to 90.5)	590.6 (583.9 to 598.1)	395.9 (390.7 to 401.7)	0.9 (0.3 to 2.4)	6.4 (2.1 to 16.4)	579.3 (538.4 to 639.6)	390.6 (363.5 to 426.1)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Intestinal nematode infections	-	-	-	-	44.9 (23.5 to 80.4)	29.0 (14.3 to 50.8)	-29.0 (-56.6 to -0.8)	-45.1 (-64.2 to -14.9)
Ascariasis	11,604.9 (10,155.3 to 13,220.4)	14,694.0 (12,339.4 to 17,558.8)	26.3 (2.5 to 58.9)	-9.9 (-28.5 to 14.6)	30.8 (15.5 to 56.6)	10.5 (4.8 to 20.0)	-66.3 (-79.5 to -36.5)	-69.1 (-81.2 to -42.3)
Trichuriasis	11,380.6 (9,788.5 to 13,179.5)	16,589.1 (14,123.4 to 19,321.5)	46.3 (17.5 to 80.3)	2.7 (-19.0 to 29.5)	13.5 (6.1 to 25.3)	18.2 (8.2 to 34.4)	34.2 (-29.5 to 163.9)	-2.7 (-52.2 to 93.7)
Hookworm disease	199.4 (171.9 to 231.2)	28.5 (23.0 to 34.2)	-85.7 (-88.7 to -81.9)	-85.7 (-92.3 to -47.4)	0.6 (0.4 to 1.1)	0.3 (0.2 to 0.4)	0.3 (-71.6 to -28.6)	0.3 (-80.0 to -45.1)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	883.7 (844.1 to 923.6)	849.2 (834.0 to 865.9)	-3.7 (-8.1 to 1.1)	-15.9 (-19.5 to -11.9)	31.0 (20.5 to 45.2)	29.8 (19.7 to 43.3)	-4.1 (-8.4 to 2.6)	-13.0 (-16.8 to -6.9)
Maternal disorders	-	-	-	-	1.1 (0.7 to 1.6)	1.0 (0.6 to 1.5)	-4.1 (-8.7 to 1.0)	-33.1 (-36.2 to -29.7)
Maternal hemorrhage	2.6 (2.4 to 2.7)	4.7 (4.5 to 4.9)	82.2 (72.6 to 94.9)	27.3 (20.1 to 35.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	5.3 (-16.5 to 8.2)	-34.6 (-42.4 to -25.2)
Maternal sepsis and other maternal infections	3.6 (2.5 to 5.3)	4.2 (2.9 to 6.3)	17.5 (6.1 to 30.1)	-33.1 (-39.2 to -25.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-3.5 (-11.5 to 9.9)	-37.1 (-40.8 to -31.2)
Maternal hypertensive disorders	10.4 (6.9 to 14.7)	10.6 (7.2 to 14.9)	2.3 (-1.1 to 6.8)	-28.6 (-31.6 to -25.5)	0.5 (0.3 to 0.8)	0.5 (0.3 to 0.8)	2.5 (-3.9 to 10.0)	-28.5 (-33.0 to -23.2)
Obstructed labor	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	4.8 (2.8 to 7.2)	-23.7 (-25.1 to -22.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	5.1 (-2.2 to 13.0)	-23.5 (-28.6 to -18.0)
Complications of abortion	0.9 (0.6 to 1.2)	0.3 (0.6 to 1.2)	-7.7 (-2.6 to 1.1)	-30.2 (-31.4 to -28.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	1.3 (-11.5 to 15.5)	-29.6 (-37.4 to -19.7)
Other maternal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-26.1 (-31.4 to -18.7)	-48.4 (-52.1 to -43.4)
Neonatal disorders	-	-	-	-	102.0 (73.7 to 129.7)	222.5 (161.7 to 283.0)	118.5 (97.6 to 138.5)	64.8 (49.2 to 80.6)
Preterm birth complications	273.1 (215.9 to 353.3)	773.9 (634.2 to 959.8)	185.8 (151.9 to 220.1)	108.0 (82.2 to 133.5)	39.7 (28.1 to 52.1)	117.7 (84.5 to 153.9)	197.5 (160.8 to 234.3)	121.4 (93.6 to 148.9)
Neonatal encephalopathy due to birth asphyxia and trauma	292.9 (119.5 to 632.8)	269.7 (126.7 to 547.1)	-6.8 (-31.6 to 31.4)	-32.6 (-51.1 to -13.7)	31.7 (22.8 to 43.0)	41.4 (31.0 to 52.7)	30.1 (11.7 to 53.1)	0.1 (-14.8 to 18.6)
Neonatal sepsis and other neonatal infections	0.4 (0.1 to 0.8)	0.7 (0.2 to 1.4)	75.5 (71.5 to 78.2)	89.4 (85.1 to 92.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	0.1 (68.1 to 82.8)	75.9 (81.5 to 97.4)
Hemolytic disease and other neonatal jaundice	55.1 (43.4 to 67.5)	100.6 (85.2 to 119.2)	82.6 (38.3 to 142.5)	36.3 (2.6 to 79.8)	21.0 (14.4 to 28.5)	39.6 (28.0 to 50.8)	89.7 (41.7 to 152.3)	41.9 (5.8 to 88.4)
Other neonatal disorders	-	-	-	-	9.5 (6.6 to 13.3)	23.7 (16.0 to 32.8)	148.8 (105.0 to 196.6)	88.7 (54.1 to 125.4)
Nutritional deficiencies	-	-	-	-	519.3 (346.0 to 740.1)	495.8 (329.9 to 720.0)	-4.4 (-8.8 to -1.2)	-23.3 (-26.5 to -21.1)
Protein-energy malnutrition	252.9 (157.0 to 372.7)	100.1 (57.2 to 170.1)	-60.7 (-79.8 to -21.9)	-62.0 (-78.7 to -33.0)	6.0 (16.7 to 52.5)	12.2 (6.1 to 23.0)	61.6 (-80.5 to 21.8)	62.5 (-79.2 to -31.3)
Iodine deficiency	852.9 (754.4 to 956.8)	817.6 (713.6 to 908.6)	-4.0 (-17.9 to 14.2)	-38.4 (-47.5 to -25.8)	15.3 (9.3 to 23.9)	14.7 (8.8 to 23.3)	-4.4 (-18.2 to 13.8)	-38.4 (-47.6 to -26.1)
Vitamin A deficiency	21.6 (15.5 to 27.8)	11.7 (8.5 to 14.8)	-45.6 (-52.8 to -36.4)	-56.5 (-61.7 to -49.0)	0.9 (0.5 to 1.4)	0.5 (0.3 to 0.7)	-46.6 (-52.4 to -39.1)	-58.3 (-62.6 to -52.3)

Appendix Table G.4 - Mexico prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	14,364.3 (14,309.5 to 14,414.8)	15,210.8 (15,167.9 to 15,251.2)	6.2 (5.7 to 6.6)	-19.0 (-19.4 to -18.7)	466.9 (310.5 to 677.8)	467.1 (309.4 to 679.3)	0.0 (-0.9 to 1.1)	-19.6 (-20.2 to -19.0)
Other nutritional deficiencies	-	-	-	-	4.9 (2.3 to 10.3)	1.3 (0.6 to 2.7)	-74.0 (-88.0 to -42.8)	-74.8 (-87.2 to -49.9)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	41.8 (26.9 to 63.3)	49.9 (31.5 to 79.1)	19.0 (13.5 to 26.3)	-10.1 (-12.7 to -7.6)
Sexually transmitted diseases excluding HIV	-	-	-	-	16.1 (9.5 to 27.8)	23.4 (13.4 to 41.3)	45.0 (38.2 to 52.6)	-7.0 (-10.3 to -3.8)
Syphilis	1.7 (1.6 to 1.7)	2.2 (2.2 to 2.3)	32.0 (27.5 to 38.4)	-32.5 (-35.0 to -29.9)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	37.5 (27.8 to 47.6)	-29.9 (-35.1 to -24.3)
Chlamydial infection	2,084.2 (1,941.0 to 2,259.9)	2,913.3 (2,676.0 to 3,150.9)	40.7 (21.6 to 56.0)	-5.1 (-18.3 to 5.4)	9.0 (5.3 to 14.2)	12.7 (7.5 to 20.4)	41.6 (33.4 to 49.3)	-5.6 (-10.7 to -0.7)
Gonococcal infection	346.9 (326.7 to 370.5)	432.4 (402.3 to 466.5)	24.9 (13.5 to 39.1)	-11.9 (-19.9 to -1.9)	2.1 (1.2 to 3.4)	2.5 (1.5 to 4.0)	19.2 (8.9 to 31.0)	-17.1 (-24.2 to -9.3)
Trichomoniasis	557.8 (505.8 to 604.5)	799.5 (738.9 to 870.1)	43.9 (28.7 to 61.7)	-9.0 (-18.1 to 1.4)	1.0 (0.4 to 2.1)	1.4 (0.5 to 2.9)	41.0 (25.0 to 60.0)	-9.7 (-19.0 to 1.7)
Genital herpes	13,127.2 (12,950.2 to 13,288.9)	23,398.8 (23,024.9 to 23,619.3)	78.2 (75.1 to 81.2)	-1.5 (-3.2 to 0.2)	3.6 (1.1 to 8.6)	6.2 (2.0 to 14.9)	71.0 (62.4 to 78.6)	-1.4 (-3.4 to 0.3)
Other sexually transmitted diseases	8.0 (6.5 to 10.1)	10.1 (8.3 to 12.4)	25.6 (19.2 to 34.8)	-28.1 (-32.0 to -23.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	45.0 (36.0 to 54.4)	-10.9 (-17.5 to -4.5)
Hepatitis	-	-	-	-	4.3 (2.8 to 6.2)	5.3 (3.4 to 7.7)	24.2 (19.4 to 29.3)	-16.6 (-20.6 to -12.6)
Hepatitis A	112.4 (107.8 to 117.2)	128.0 (123.6 to 132.6)	14.2 (13.5 to 14.9)	-6.6 (-6.8 to -6.3)	2.7 (1.7 to 3.9)	3.4 (2.2 to 5.0)	28.6 (24.9 to 32.5)	-3.3 (-5.9 to -0.4)
Hepatitis B	2,725.9 (2,576.1 to 2,800.4)	2,990.9 (2,421.1 to 2,813.9)	-4.7 (-14.0 to 5.4)	-38.3 (-44.2 to -31.5)	1.4 (0.9 to 2.0)	1.6 (1.0 to 2.4)	15.9 (3.8 to 29.4)	-33.2 (-41.0 to -25.0)
Hepatitis C	1,786.9 (1,736.1 to 1,836.7)	2,236.6 (2,183.0 to 2,293.6)	25.6 (21.2 to 30.1)	-26.8 (-29.3 to -24.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	22.8 (15.1 to 30.5)	-25.7 (-31.2 to -20.2)
Hepatitis E	-	-	-	-	-	-	-	-
Leprosy	0.6 (0.5 to 0.7)	0.6 (0.6 to 0.7)	11.6 (1.6 to 20.6)	-42.2 (-47.4 to -37.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	15.0 (3.4 to 26.9)	-40.4 (-46.8 to -34.0)
Other infectious diseases	622.9 (603.9 to 642.4)	606.7 (591.3 to 624.0)	-2.4 (-6.1 to 1.4)	-17.2 (-20.0 to -14.3)	21.4 (14.1 to 30.8)	21.1 (13.8 to 30.9)	-1.3 (-6.0 to 4.4)	-11.8 (-15.0 to -6.9)
Non-communicable diseases	-	-	-	-	4,458.7 (4,458.7 to 7,813.3)	7,813.3 (7,870.1 to 13,683.5)	75.8 (72.3 to 79.0)	3.1 (2.4 to 5.2)
Neoplasms	-	-	-	-	37.3 (27.2 to 49.0)	97.8 (70.7 to 127.3)	162.9 (142.5 to 181.7)	37.8 (27.0 to 48.1)
Esophageal cancer	1.4 (1.1 to 1.7)	3.2 (2.5 to 3.9)	124.8 (80.7 to 181.2)	5.7 (-15.6 to 33.3)	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.7)	122.0 (93.1 to 155.0)	4.5 (-9.5 to 20.2)
Stomach cancer	17.6 (16.1 to 19.0)	34.7 (31.8 to 37.5)	98.3 (77.7 to 120.0)	-6.7 (-17.0 to 3.8)	1.9 (1.4 to 2.5)	3.7 (2.7 to 4.8)	92.3 (75.4 to 110.9)	-9.5 (-17.8 to -0.6)
Liver cancer	-	-	-	-	0.6 (0.4 to 0.8)	1.4 (1.0 to 1.9)	125.2 (84.3 to 172.8)	7.1 (12.9 to 30.2)
Liver cancer due to hepatitis B	0.7 (0.5 to 0.9)	1.8 (1.3 to 2.4)	157.7 (70.6 to 285.6)	25.7 (-17.3 to 88.6)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	148.1 (101.8 to 209.6)	20.3 (-2.8 to 51.2)
Liver cancer due to hepatitis C	0.7 (0.5 to 1.0)	4.0 (2.9 to 5.2)	442.0 (243.4 to 725.6)	152.5 (59.3 to 287.1)	0.1 (0.1 to 0.2)	0.7 (0.5 to 0.9)	394.5 (289.5 to 561.6)	128.8 (78.9 to 207.1)
Liver cancer due to alcohol use	1.1 (0.8 to 1.4)	1.4 (1.0 to 1.8)	-39.6 (-17.8 to 27.8)	-39.6 (-61.5 to -8.9)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	27.7 (0.5 to 99.8)	-39.9 (-53.2 to -24.9)
Liver cancer due to other causes	0.9 (0.6 to 1.2)	0.8 (0.5 to 1.1)	-7.1 (-43.6 to 46.3)	-55.1 (-72.9 to -28.5)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-10.2 (-31.0 to 15.9)	-26.6 (-66.8 to -44.2)
Larynx cancer	7.1 (5.6 to 9.0)	11.5 (9.3 to 15.8)	62.6 (30.3 to 106.6)	-21.8 (-37.5 to -0.4)	0.7 (0.4 to 0.9)	1.1 (0.7 to 1.6)	66.3 (35.4 to 109.5)	-20.2 (-35.7 to 1.1)
Tracheal, bronchus and lung cancer	9.1 (8.2 to 9.9)	15.9 (14.4 to 17.5)	76.5 (55.5 to 99.4)	-15.6 (-25.7 to -4.6)	1.4 (1.0 to 1.8)	2.4 (1.7 to 3.1)	71.1 (57.3 to 85.6)	-18.1 (-25.0 to -10.9)
Breast cancer	51.8 (46.5 to 57.8)	160.2 (144.9 to 179.7)	210.1 (169.2 to 255.3)	50.2 (31.4 to 72.5)	3.9 (2.9 to 5.2)	12.0 (8.6 to 16.0)	203.7 (167.5 to 245.5)	47.4 (30.2 to 67.2)
Cervical cancer	79.7 (61.0 to 90.8)	83.2 (71.2 to 114.2)	3.8 (-13.5 to 53.3)	-9.6 (-57.0 to -23.0)	1.8 (4.0 to 8.1)	6.3 (4.3 to 9.2)	49.3 (19.1 to 54.5)	-49.3 (-56.3 to -22.0)
Uterine cancer	12.5 (8.3 to 16.7)	25.4 (18.2 to 37.9)	101.9 (49.4 to 178.1)	-3.3 (-28.1 to 32.2)	0.8 (0.5 to 1.3)	1.7 (1.0 to 2.7)	100.6 (49.4 to 175.0)	-3.7 (-28.0 to 30.6)
Prostate cancer	41.5 (29.8 to 57.9)	219.0 (149.0 to 294.7)	430.4 (302.4 to 596.8)	149.3 (88.5 to 227.4)	4.0 (2.6 to 5.7)	18.7 (11.6 to 27.2)	373.8 (269.6 to 495.5)	122.0 (71.4 to 178.2)
Colon and rectum cancer	22.0 (20.9 to 23.3)	78.2 (73.0 to 83.4)	257.7 (229.1 to 284.5)	70.4 (56.5 to 83.6)	1.8 (1.3 to 2.4)	6.3 (4.6 to 8.2)	241.8 (216.3 to 266.1)	62.9 (50.4 to 75.0)
Lip and oral cavity cancer	6.9 (5.4 to 8.7)	14.8 (11.4 to 18.9)	115.9 (69.6 to 174.2)	1.1 (-18.8 to 33.0)	0.6 (0.1 to 0.9)	1.3 (0.9 to 1.9)	113.3 (73.3 to 165.2)	2.8 (-17.7 to 29.1)
Nasopharynx cancer	5.0 (0.4 to 0.6)	0.5 (0.8 to 1.3)	129.5 (71.9 to 202.5)	20.5 (-10.8 to 57.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	126.3 (74.6 to 183.1)	17.7 (-9.6 to 47.4)
Other pharynx cancer	1.4 (1.1 to 1.8)	2.9 (2.1 to 3.7)	104.4 (47.3 to 177.5)	-2.8 (-30.9 to 33.1)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	101.2 (52.8 to 162.0)	-4.8 (-28.5 to 25.4)
Gallbladder and biliary tract cancer	1.6 (1.4 to 2.0)	2.3 (1.9 to 3.0)	42.2 (11.7 to 85.8)	-33.2 (-47.7 to -12.1)	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.8)	38.0 (12.6 to 78.4)	-34.9 (-46.8 to -15.3)
Pancreatic cancer	2.3 (2.0 to 2.5)	5.5 (4.9 to 6.2)	144.1 (111.4 to 183.5)	0.4 (0.1 to 0.4)	0.4 (0.3 to 0.5)	1.0 (0.7 to 1.3)	140.0 (115.5 to 161.9)	13.8 (9.9 to 24.6)
Malignant skin melanoma	4.1 to 7.1 (4.1 to 7.1)	13.9 to 21.7 (13.9 to 21.7)	175.8 to 344.5 (175.8 to 344.5)	39.1 to 128.9 (39.1 to 128.9)	0.2 to 0.5 (0.2 to 0.5)	0.7 to 1.6 (0.7 to 1.6)	166.4 to 325.1 (166.4 to 325.1)	133.7 to 118.5 (133.7 to 118.5)
Non-melanoma skin cancer	18.6 (15.7 to 22.4)	64.4 (52.9 to 85.0)	243.8 (188.7 to 328.5)	58.2 (31.9 to 101.5)	0.8 (0.5 to 1.1)	3.1 (2.0 to 4.7)	309.0 (217.0 to 445.9)	90.8 (42.8 to 155.6)
Ovarian cancer	6.4 (5.7 to 7.2)	18.1 (15.8 to 20.6)	185.0 (140.5 to 236.7)	52.3 (28.5 to 79.2)	0.8 (0.6 to 1.1)	2.3 (1.6 to 3.0)	179.5 (139.0 to 227.4)	49.8 (27.5 to 74.1)
Testicular cancer	14.0 (9.4 to 20.7)	32.6 (20.1 to 45.6)	137.0 (52.2 to 261.8)	0.9 (-2.5 to 125.0)	0.9 (0.5 to 1.4)	3.0 (1.1 to 3.1)	132.8 (52.1 to 246.2)	46.7 (-1.3 to 116.6)
Kidney cancer	11.2 (10.0 to 12.5)	35.5 (31.5 to 39.4)	219.6 (175.2 to 268.0)	89.5 (53.7 to 106.1)	0.8 (0.5 to 1.1)	2.5 (1.8 to 3.4)	218.3 (173.9 to 261.9)	73.1 (49.0 to 96.5)
Bladder cancer	2.6 (2.3 to 3.1)	6.3 (5.3 to 7.3)	142.6 (99.8 to 188.9)	12.7 (-7.9 to 35.5)	0.2 (0.2 to 0.3)	0.6 (0.4 to 0.8)	139.8 (104.1 to 176.6)	11.3 (-6.1 to 29.4)
Brain and nervous system cancer	6.5 (5.3 to 8.7)	14.7 (11.3 to 17.0)	132.4 (76.0 to 174.2)	62.4 (23.9 to 89.1)	0.6 (0.4 to 0.9)	1.5 (1.0 to 2.0)	141.5 (85.6 to 176.9)	58.9 (22.0 to 80.6)
Thyroid cancer	32.2 (26.1 to 41.2)	93.2 (68.9 to 115.0)	189.6 (137.0 to 254.5)	48.4 (19.9 to 83.2)	1.8 (1.2 to 2.7)	5.3 (3.3 to 7.7)	185.1 (133.4 to 247.7)	45.3 (17.5 to 79.5)
Mesothelioma	0.4 (0.3 to 0.4)	0.5 (0.4 to 0.5)	23.4 (13.0 to 37.9)	-40.0 (-44.9 to -32.9)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	29.8 (21.5 to 43.9)	36.9 (-0.9 to -30.3)
Hodgkin lymphoma	10.1 (7.9 to 12.0)	14.7 (12.0 to 20.2)	41.5 (11.6 to 111.8)	0.7 (-21.5 to 49.6)	0.8 (0.6 to 1.2)	1.2 (0.8 to 1.8)	42.7 (14.8 to 107.3)	-3.2 (-21.8 to 39.2)
Non-Hodgkin lymphoma	15.4 (12.8 to 22.2)	51.5 (36.1 to 61.5)	268.7 (101.1 to 351.0)	121.6 (14.4 to 171.4)	1.1 (0.8 to 1.8)	3.7 (2.3 to 5.3)	265.0 (96.7 to 339.1)	112.6 (9.2 to 156.2)
Multiple myeloma	1.6 (1.2 to 2.1)	4.9 (3.6 to 6.2)	211.4 (118.3 to 334.3)	48.2 (3.1 to 107.2)	0.3 (0.2 to 0.5)	1.0 (0.6 to 1.4)	196.6 (116.3 to 296.1)	41.0 (2.1 to 89.9)
Leukemia	27.0 (22.8 to 32.1)	50.2 (43.2 to 57.2)	87.3 (54.5 to 125.1)	48.0 (21.1 to 88.5)	2.6 (1.8 to 3.5)	5.2 (3.7 to 6.8)	99.2 (71.6 to 128.7)	28.6 (22.6 to 58.7)
Other neoplasms	47.8 (41.0 to 62.8)	171.4 (128.9 to 196.9)	277.2 (136.7 to 357.2)	157.9 (65.2 to 209.6)	3.1 (2.0 to 4.4)	11.0 (7.0 to 15.4)	280.2 (142.6 to 352.3)	148.3 (59.9 to 197.5)
Cardiovascular diseases	-	-	-	-	63.8 (44.8 to 88.2)	214.4 (149.5 to 288.4)	239.5 (172.6 to 291.8)	61.1 (36.6 to 81.7)
Rheumatic heart disease	1.6 (1.6 to 1.6)	3.2 (3.1 to 3.2)	97.7 (94.0 to 101.6)	1.2 (-0.8 to 3.3)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.5)	96.9 (82.7 to 108.3)	1.0 (-6.6 to 7.3)
Ischemic heart disease	513.3 (487.6 to 541.0)	2,029.6 (1,918.7 to 2,162.8)	298.2 (265.6 to 330.9)	79.7 (65.8 to 93.8)	26.4 (18.0 to 36.3)	119.2 (81.4 to 164.0)	352.4 (308.4 to 401.3)	104.0 (85.2 to 124.6)
Cerebrovascular disease	-	-	-	-	10.0 (7.0 to 13.0)	21.1 (14.8 to 27.5)	110.8 (100.6 to 124.1)	3.3 (-2.0 to 10.2)
Ischemic stroke	16.3 (15.5 to 17.0)	36.9 (35.0 to 38.8)	126.7 (111.7 to 148.0)	7.6 (0.2 to 18.0)	2.5 (1.7 to 3.3)	5.6 (3.9 to 7.5)	126.4 (110.3 to 145.9)	7.6 (-0.2 to 17.2)
Hemorrhagic stroke	49.6 (47.6 to 51.4)	102.4 (98.9 to 106.0)	107.5 (97.0 to 120.7)	1.9 (-3.5 to 8.6)	7.5 (5.2 to 10.0)	15.5 (10.8 to 20.5)	105.8 (94.3 to 119.3)	1.7 (-4.1 to 8.2)
Hypertensive heart disease	43.8 (41.5 to 45.9)	104.3 (99.4 to 108.8)	139.1 (127.8 to 150.0)	12.0 (6.5 to 17.0)	4.8 (3.4 to 6.5)	11.4 (8.1 to 15.6)	137.9 (125.5 to 149.0)	11.7 (5.8 to 17.1)
Cardiomyopathy and myocarditis	22.6 (21.1 to 24.2)	49.2 (46.0 to 52.4)	117.6 (107.3 to 131.2)	10.8 (5.2 to 17.9)	2.5 (1.7 to 3.5)	5.5 (3.8 to 7.4)	116.3 (104.4 to 130.5)	10.8 (4.7 to 18.7)
Atrial fibrillation and flutter	48.9 (46.5 to 51.9)	194.0 (183.4 to 204.2)	299.4 (263.7 to 329.5)	79.8 (63.8 to 93.1)	3.7 (2.6 to 4.9)	14.8 (10.3 to 20.0)	305.6 (269.6 to 334.1)	82.9 (65.8 to 96.2)
Peripheral vascular disease	1,511.8 (1,416.3 to 1,593.3)	3,350.4 (3,167.9 to 3,533.3)	122.0 (105.5 to 141.6)	2.9 (-3.5 to 11.7)	0.9 (0.4 to 1.6)	1.7 (0.8 to 3.0)	97.8 (69.3 to 129.3)	-11.9 (-24.7 to 1.6)
Endocarditis	1.4 (1.1 to 1.7)	1.7 (1.3 to 2.1)	22.8 (10.4 to 45.6)	-24.0 (-33.5 to -11.6)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	26.8 (15.3 to 52.7)	-26.8 (-32.7 to -8.6)
Other cardiovascular and circulatory diseases	215.3 (115.2 to 400.7)	567.2 (294.7 to 818.5)	177.8 (111.0 to 431.5)	27.1 (-42.6 to 165.8)	15.3 (7.2 to 29.6)	40.2		

Appendix Table G.4 - Mexico prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumococcosis	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	76.9 (75.2 to 78.6)	76.9 (10.7 to -8.9)
Silicosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-15.6 (67.8 to 71.9)	-15.6 (-16.4 to -14.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.8 (67.8 to 72.0)	-15.6 (-16.5 to -14.4)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumococcosis	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	88.5 (86.2 to 90.6)	-5.3 (-6.3 to -4.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.5 (86.1 to 90.6)	-5.4 (-6.4 to -4.4)
Other pneumococcosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	76.3 (74.1 to 78.8)	0.0 (-8.4 to -6.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.3 (73.9 to 78.9)	-7.2 (-8.4 to -6.6)
Asthma	2,857.2 (2,677.4 to 3,057.0)	5,705.4 (5,487.2 to 6,023.0)	100.0 (87.3 to 115.7)	16.4 (9.7 to 26.7)	125.7 (81.6 to 178.4)	252.0 (164.3 to 355.5)	100.1 (87.3 to 115.7)	17.3 (10.5 to 27.3)
Interstitial lung disease and pulmonary sarcoidosis	1.4 (1.3 to 1.5)	2.8 (2.6 to 2.9)	102.4 (89.3 to 117.4)	2.4 (-5.1 to 9.7)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	103.2 (89.8 to 118.1)	2.5 (-5.1 to 9.9)
Other chronic respiratory diseases	-	-	-	-	23.5 (15.5 to 34.3)	20.0 (13.1 to 29.6)	-14.6 (-23.4 to -5.1)	-55.2 (-59.5 to -50.2)
Cirrhosis	-	-	-	-	5.7 (4.0 to 7.8)	8.5 (5.9 to 11.7)	48.6 (43.9 to 53.0)	-18.2 (-20.5 to -16.2)
Cirrhosis due to hepatitis B	0.9 (0.7 to 1.0)	1.8 (1.7 to 2.0)	109.8 (85.9 to 152.3)	11.1 (-0.7 to 33.0)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	106.7 (80.4 to 147.1)	9.3 (-4.2 to 31.1)
Cirrhosis due to hepatitis C	11.1 (10.0 to 12.1)	18.7 (17.7 to 19.7)	69.6 (51.1 to 88.3)	-7.4 (-17.0 to 2.5)	1.8 (1.2 to 2.6)	3.1 (2.1 to 4.2)	68.0 (48.4 to 88.2)	-7.9 (-17.8 to 2.9)
Cirrhosis due to alcohol use	15.8 (14.9 to 16.7)	20.3 (19.4 to 21.2)	29.0 (20.6 to 39.4)	2.6 (-37.5 to -27.8)	2.6 (1.8 to 3.6)	3.3 (2.3 to 4.6)	28.4 (18.5 to 40.2)	33.4 (-38.3 to 3.8)
Cirrhosis due to other causes	6.7 (6.3 to 7.1)	10.5 (9.9 to 11.2)	57.5 (46.2 to 69.9)	4.1 (-4.0 to 13.3)	1.1 (0.8 to 1.6)	1.8 (1.2 to 2.5)	56.2 (39.8 to 75.3)	27.5 (-6.8 to 16.0)
Digestive diseases	-	-	-	-	65.0 (46.3 to 86.8)	114.8 (82.1 to 153.1)	76.9 (69.4 to 83.7)	-9.7 (-14.1 to -5.7)
Peptic ulcer disease	545.6 (537.7 to 554.0)	611.7 (604.7 to 618.5)	12.6 (10.6 to 14.4)	-46.0 (-46.9 to -45.1)	18.7 (12.8 to 26.1)	21.1 (14.6 to 29.4)	13.3 (10.6 to 16.1)	-45.1 (-46.3 to -43.9)
Gastritis and duodenitis	246.6 (242.1 to 251.2)	400.6 (394.4 to 407.0)	63.0 (59.5 to 66.6)	-9.4 (-11.5 to -7.3)	11.4 (7.7 to 16.1)	18.0 (12.3 to 25.4)	58.3 (52.6 to 64.2)	-9.0 (-11.6 to -6.4)
Appendicitis	3.7 (3.6 to 3.8)	4.4 (4.2 to 4.5)	18.2 (13.5 to 24.2)	-12.0 (-15.3 to -8.0)	1.2 (0.8 to 1.6)	1.4 (0.9 to 1.9)	19.4 (8.6 to 33.7)	-11.4 (-18.3 to -2.6)
Paralytic ileus and intestinal obstruction	1.1 (1.0 to 1.2)	1.3 (1.2 to 1.4)	20.6 (9.0 to 38.4)	4.0 (-3.7 to 15.3)	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	20.1 (6.9 to 40.5)	4.1 (-5.5 to 17.5)
Inguinal, femoral, and abdominal hernia	186.2 (181.4 to 191.3)	296.0 (287.9 to 304.7)	59.5 (53.2 to 66.0)	-20.2 (-23.5 to -16.7)	1.9 (1.0 to 3.6)	3.1 (1.5 to 5.8)	59.2 (52.5 to 66.1)	-19.8 (-23.2 to -16.1)
Inflammatory bowel disease	87.1 (85.8 to 88.5)	198.5 (195.7 to 201.5)	128.8 (125.7 to 131.8)	24.0 (22.4 to 25.6)	18.6 (12.9 to 25.3)	42.4 (29.1 to 57.7)	127.8 (122.7 to 132.7)	24.2 (21.8 to 26.6)
Vascular intestinal disorders	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.3)	113.7 (99.2 to 127.5)	9.1 (1.3 to 16.3)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	106.6 (90.6 to 124.2)	4.8 (-4.2 to 14.6)
Gallbladder and biliary diseases	50.7 (49.1 to 52.2)	95.7 (93.4 to 98.2)	89.6 (82.1 to 96.3)	-2.2 (-5.7 to 0.9)	5.4 (3.7 to 7.3)	10.1 (7.0 to 13.7)	88.4 (80.0 to 96.0)	-2.4 (-6.2 to 1.3)
Pancreatitis	4.1 (4.0 to 4.1)	12.4 (12.3 to 12.5)	206.0 (200.9 to 210.9)	66.6 (63.8 to 69.1)	1.2 (0.8 to 1.6)	3.7 (2.5 to 5.0)	203.5 (184.0 to 224.6)	66.4 (56.2 to 77.2)
Other digestive diseases	-	-	-	-	6.3 (4.4 to 8.6)	14.5 (9.9 to 20.1)	132.1 (108.1 to 150.5)	18.1 (5.1 to 27.8)
Neurological disorders	-	-	-	-	520.2 (355.6 to 711.9)	907.4 (625.0 to 1,223.4)	74.5 (53.1 to 100.1)	2.7 (-8.3 to 14.8)
Alzheimer disease and other dementias	376.6 (358.9 to 393.0)	829.5 (797.8 to 860.2)	121.1 (109.0 to 134.1)	0.1 (-5.4 to 6.0)	53.9 (39.4 to 68.6)	120.1 (89.1 to 152.6)	123.0 (110.4 to 136.2)	0.3 (-5.4 to 6.0)
Parkinson disease	5.9 (4.9 to 6.9)	12.9 (11.0 to 14.9)	119.1 (113.1 to 126.5)	1.9 (-0.7 to 4.9)	0.7 (0.5 to 1.0)	1.6 (1.0 to 2.1)	118.8 (107.6 to 130.8)	2.4 (-3.3 to 7.6)
Epilepsy	425.6 (287.7 to 579.7)	598.2 (392.1 to 832.4)	41.2 (-12.8 to 131.5)	-2.6 (-40.0 to 59.9)	138.2 (81.1 to 215.8)	216.7 (125.3 to 341.5)	56.3 (-5.1 to 155.6)	8.6 (-33.9 to 78.7)
Multiple sclerosis	3.7 (3.6 to 3.7)	13.2 (13.0 to 13.3)	258.4 (250.8 to 266.0)	9.4 (8.8 to 96.5)	1.3 (0.9 to 1.7)	4.5 (3.3 to 5.7)	243.7 (227.9 to 260.0)	84.7 (76.3 to 93.4)
Migraine	6,447.0 (6,261.6 to 7,012.3)	10,564.9 (9,812.7 to 11,214.8)	59.3 (46.9 to 71.5)	-3.2 (-10.1 to 3.7)	228.3 (138.9 to 337.8)	862.1 (214.7 to 540.7)	28.9 (46.1 to 70.5)	-3.1 (-10.2 to 3.8)
Tension-type headache	15,985.6 (15,284.5 to 16,741.6)	26,498.4 (26,031.2 to 26,969.2)	66.3 (59.2 to 74.4)	2.4 (-1.9 to 7.0)	24.3 (11.8 to 42.2)	40.4 (19.6 to 70.8)	66.1 (58.4 to 74.2)	2.7 (-2.0 to 7.5)
Medication overuse headache	338.5 (231.4 to 435.1)	854.7 (582.4 to 1,085.4)	153.8 (139.9 to 170.9)	42.2 (35.0 to 51.2)	53.5 (30.9 to 81.5)	134.9 (78.6 to 206.2)	152.7 (138.8 to 170.4)	42.3 (34.8 to 51.7)
Other neurological disorders	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.2)	44.3 (31.7 to 58.8)	-6.7 (-14.3 to 2.6)	20.1 (14.4 to 25.9)	27.2 (19.5 to 35.2)	35.5 (20.9 to 50.7)	-39.1 (-45.6 to -32.3)
Mental and substance use disorders	-	-	-	-	2,043.6 (1,431.9 to 2,735.2)	3,112.9 (2,173.3 to 4,208.0)	52.4 (48.0 to 57.2)	-2.0 (-3.1 to -1.0)
Schizophrenia	191.9 (176.4 to 206.3)	345.4 (318.5 to 370.4)	80.7 (78.1 to 83.4)	-0.5 (-1.5 to 0.5)	124.2 (91.0 to 149.9)	223.6 (164.2 to 271.0)	80.1 (76.6 to 83.8)	-0.5 (-2.0 to 1.0)
Alcohol use disorders	1,380.7 (1,277.6 to 1,499.3)	1,638.2 (1,501.4 to 1,780.9)	19.1 (15.9 to 22.4)	-27.1 (-29.1 to -25.2)	138.3 (93.5 to 199.4)	164.3 (109.8 to 236.5)	18.8 (15.4 to 22.0)	-27.1 (-29.2 to -25.2)
Drug use disorders	-	-	-	-	111.0 (74.0 to 149.4)	172.8 (116.4 to 231.9)	55.5 (47.9 to 64.5)	0.4 (-3.9 to 5.4)
Opioid use disorders	49.1 (23.7 to 83.8)	95.0 (46.4 to 157.1)	95.0 (84.6 to 106.8)	3.1 (-0.1 to 7.1)	20.4 (9.2 to 36.6)	39.5 (17.9 to 69.2)	94.3 (83.5 to 108.6)	3.3 (-0.9 to 8.0)
Cocaine use disorders	160.0 (149.1 to 171.1)	359.9 (246.6 to 272.8)	62.8 (50.8 to 78.4)	17.7 (5.0 to 10.6)	17.7 (14.3 to 31.1)	32.0 (23.7 to 50.4)	62.9 (50.4 to 78.7)	2.0 (-5.1 to 11.4)
Amphetamine use disorders	166.3 (163.0 to 169.6)	218.1 (214.2 to 222.1)	31.8 (28.4 to 35.3)	-3.7 (-6.1 to -1.3)	21.9 (13.7 to 31.9)	28.9 (18.2 to 42.2)	31.5 (26.4 to 37.0)	-3.8 (-7.3 to 0.2)
Cannabis use disorders	78.7 (59.6 to 95.8)	107.0 (83.8 to 128.0)	36.7 (32.7 to 41.4)	-0.2 (-0.4 to -0.1)	2.3 (1.4 to 3.5)	3.1 (1.9 to 4.8)	36.9 (28.5 to 45.2)	-0.3 (-4.9 to 4.8)
Other drug use disorders	-	-	-	-	44.4 (29.7 to 60.6)	65.4 (44.3 to 88.6)	47.3 (35.9 to 60.0)	-0.5 (-8.1 to 7.7)
Depressive disorders	-	-	-	-	102.5 (467.7 to 1,201.9)	142.0 (743.2 to 1,903.9)	142.0 (51.3 to 71.4)	-0.7 (-1.4 to 3.2)
Major depressive disorder	3,368.2 (2,219.5 to 4,497.1)	5,369.5 (3,393.3 to 7,220.8)	59.9 (48.3 to 71.0)	1.2 (-1.7 to 3.5)	698.8 (398.4 to 1,090.3)	1,111.2 (611.9 to 1,725.8)	58.9 (47.0 to 70.0)	1.2 (-1.7 to 3.6)
Dysthymia	852.2 (691.2 to 1,007.4)	1,530.5 (1,264.7 to 1,808.9)	80.1 (73.1 to 89.4)	0.8 (0.5 to 1.1)	82.5 (53.4 to 120.4)	148.1 (95.3 to 216.9)	79.4 (72.1 to 88.8)	0.8 (0.1 to 1.4)
Bipolar disorder	615.7 (494.9 to 725.9)	1,023.3 (838.3 to 1,206.6)	66.8 (61.7 to 73.5)	0.3 (-1.0 to 2.0)	126.2 (75.7 to 194.7)	209.5 (125.8 to 320.5)	65.9 (60.7 to 73.6)	0.3 (-1.3 to 2.4)
Anxiety disorders	3,528.6 (2,314.2 to 4,654.4)	5,492.3 (3,635.3 to 7,064.4)	56.2 (45.7 to 68.9)	0.6 (0.3 to 1.0)	327.1 (190.9 to 501.1)	506.2 (306.5 to 762.1)	69.9 (44.9 to 68.0)	1.2 (-0.0 to 1.3)
Eating disorders	-	-	-	-	27.7 (16.4 to 43.3)	37.9 (22.6 to 58.9)	36.2 (30.6 to 43.1)	1.5 (-0.6 to 3.8)
Anorexia nervosa	21.4 (16.4 to 27.3)	29.7 (22.8 to 38.1)	39.7 (32.7 to 45.7)	6.5 (3.1 to 9.3)	4.6 (2.9 to 6.8)	6.4 (4.1 to 9.7)	39.4 (30.1 to 49.6)	6.5 (0.5 to 13.3)
Bulimia nervosa	109.3 (72.9 to 158.5)	148.0 (97.7 to 216.2)	35.7 (29.9 to 42.8)	0.5 (0.2 to 1.0)	23.2 (13.1 to 37.3)	31.5 (17.9 to 51.2)	35.7 (28.8 to 43.4)	0.6 (-1.7 to 2.8)
Autistic spectrum disorders	-	-	-	-	102.5 (71.5 to 138.9)	142.0 (98.7 to 193.0)	142.0 (37.1 to 40.0)	-0.7 (-1.5 to 0.1)
Autism	258.4 (244.2 to 272.4)	359.5 (339.4 to 378.1)	39.6 (38.8 to 40.5)	-0.8 (-0.9 to -0.8)	64.3 (43.3 to 88.5)	89.2 (60.1 to 122.2)	38.9 (36.8 to 40.9)	-0.6 (-1.8 to 0.5)
Asperger syndrome	380.1 (356.5 to 402.7)	524.3 (491.0 to 556.3)	38.4 (37.3 to 39.5)	-1.1 (-1.1 to -1.0)	38.2 (26.4 to 53.6)	52.7 (36.6 to 73.4)	37.9 (36.0 to 39.8)	-0.9 (-1.8 to 0.1)
Attention-deficit/hyperactivity disorder	790.9 (724.6 to 843.4)	892.6 (817.6 to 952.2)	13.2 (12.8 to 13.4)	0.3 (0.3 to 0.4)	9.7 (5.7 to 14.7)	10.9 (6.4 to 16.7)	13.3 (11.4 to 15.2)	0.6 (-1.0 to 2.2)
Conduct disorder	1,067.0 (997.1 to 1,138.0)	1,194.8 (1,113.9 to 1,277.4)	12.4 (11.9 to 12.8)	0.5 (0.3 to 0.8)	128.9 (80.9 to 185.9)	145.1 (90.5 to 210.5)	12.6 (11.3 to 13.9)	0.3 (-0.3 to 1.3)
Idiopathic intellectual disability	1,626.1 (1,296.0 to 1,970.4)	1,846.5 (1,520.4 to 2,241.5)	13.6 (5.8 to 24.2)	-18.2 (-23.8 to -10.0)	80.0 (51.4 to 114.5)	90.7 (59.8 to 128.7)	13.2 (14.3 to 23.8)	-18.1 (-23.8 to -8.8)
Other mental and substance use disorders	1,155.8 (1,080.0 to 1,228.6)	1,978.3 (1,860.6 to 2,093.4)	71.8 (69.4 to 74.2)	-1.0 (-1.3 to -0.7)	86.8 (58.9 to 117.1)	148.6 (100.8 to 199.1)	71.3 (68.1 to 74.2)	0.8 (-1.8 to 0.1)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	546.2 (378.9 to 750.7)	1,204.0 (834.6 to 1,638.0)	120.6 (113.1 to 128.1)	27.9 (23.0 to 33.2)
Diabetes mellitus	3,512.0 (3,226.8 to 3,749.2)	9,903.2 (9,341.6 to 10,410.3)	183.2 (168.9 to 199.4)	52.4 (43.3 to 63.4)	244.3 (166.9 to 335.5)	699.6 (482.2 to 947.7)	186.4 (170.9 to 203.9)	48.0 (-0.8 to 57.9)
Acute glomerulonephritis	1.854.9 (0.3 to 0.4)	0.3 (0.3 to 0.3)	-26.6 (-6.5 to 1.2)	-26.6 (-28.7 to -24.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.6 (-6.5 to 1.2)	-26.6 (-28.7 to -24.4)
Chronic kidney disease	-	-	-	-	117.5 (84.8 to 153.8)	205.4 (148.9 to 267.4)	74.8 (68.9 to 82.2)	8.0 (4.7 to 12.0)
Chronic kidney disease due to diabetes mellitus	1,368.2 (963.4 to 1,923.0)	2,736.2 (1,958.3 to 3,835.9)	101.2 (82.6 to 115.8)	5.2 (-0.8 to 11.1)	21.8 (15.8 to 28.4)	45.0 (32.4 to 59.3)	106.7 (93.2 to 119.7)	9.8 (2.8 to 16.5)
Chronic kidney disease due to hypertension	1,433.7 (931.4 to 2,297.8)	2,351.6 (1,613.1 to 3,463.8)	65.1 (43.5 to 93.5)	9.9 (2.8 to 17.5)	29.6 (21.4 to 38.1)	52.9 (38.5 to 69.5)	78.6 (70.1 to 90.5)	3.9 (-1.1 to 10.7)
Chronic kidney disease due to glomerulonephritis	1,854.9 (1,296.0 to 2,557.3)	3,009.7 (2,175.7 to 4,199.9)	62.6 (46.6 to 79.8)	36.6 (-9.7 to 2.7)	62.6 (19.1 to 35.6)	62.6 (32.0 to 58.5)	67.8 (57.1 to 80.8)	37.1 (9.5 to 24.7)
Chronic kidney disease due to other causes								

Appendix Table G.4 - Mexico prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	18.9 (18.4 to 19.5)	28.5 (27.7 to 29.6)	51.5 (44.4 to 58.6)	0.6 (-4.0 to 3.9)	0.6 (0.4 to 0.9)	1.0 (0.6 to 1.4)	50.2 (40.8 to 61.0)	-0.6 (-6.3 to 5.5)
Urolithiasis	542.1 (37.4 to 855.8)	1,297.0 (848.4 to 2,009.7)	146.4 (105.9 to 162.1)	18.7 (-1.8 to 30.2)	3.0 (1.6 to 5.1)	8.3 (4.5 to 14.7)	182.2 (151.2 to 205.2)	42.6 (23.3 to 54.2)
Benign prostatic hyperplasia	278.8 (274.6 to 283.8)	600.8 (594.4 to 607.3)	116.4 (112.1 to 120.0)	1.7 (-0.3 to 3.4)	10.0 (6.5 to 14.0)	21.6 (14.1 to 30.3)	116.5 (112.1 to 120.7)	1.8 (-0.3 to 3.8)
Male infertility due to other causes	295.3 (276.2 to 315.5)	459.2 (431.3 to 488.5)	56.5 (41.4 to 69.9)	-5.1 (-14.2 to 2.8)	1.9 (0.8 to 3.9)	2.9 (1.2 to 5.8)	55.3 (39.4 to 69.1)	-4.6 (-14.4 to 3.8)
Other urinary diseases	-	-	-	-	1.1 (0.5 to 1.7)	2.8 (1.5 to 4.7)	40.6 (130.1 to 296.7)	17.0 (15.3 to 104.4)
Gynecological diseases	-	-	-	-	97.6 (63.8 to 146.1)	168.3 (109.3 to 251.3)	72.4 (65.3 to 78.5)	0.1 (-2.8 to 3.1)
Uterine fibroids	1,339.1 (1,204.0 to 1,458.1)	2,872.7 (2,609.8 to 3,116.9)	115.3 (112.4 to 118.6)	7.4 (7.2 to 7.7)	18.6 (10.8 to 31.5)	32.8 (18.3 to 56.5)	75.3 (65.0 to 85.0)	-6.9 (-11.0 to -3.0)
Polycystic ovarian syndrome	1,290.6 (1,251.4 to 1,329.3)	2,312.3 (2,245.3 to 2,376.7)	79.8 (72.5 to 87.2)	5.2 (1.2 to 9.4)	12.4 (5.8 to 23.5)	22.3 (10.4 to 41.6)	79.7 (72.3 to 87.1)	5.6 (1.5 to 9.7)
Female infertility due to other causes	225.0 (187.5 to 267.2)	94.5 (59.3 to 522.0)	94.5 (54.6 to 137.8)	6.4 (-15.4 to 29.9)	1.2 (0.4 to 2.5)	2.2 (0.9 to 4.7)	40.6 (54.5 to 137.3)	6.6 (-15.2 to 30.3)
Endometriosis	137.8 (132.6 to 143.0)	252.7 (253.7 to 272.6)	91.1 (81.5 to 102.3)	9.4 (3.9 to 15.5)	12.8 (8.6 to 17.5)	24.4 (16.4 to 33.7)	90.8 (80.6 to 104.0)	3.5 (3.7 to 16.6)
Genital prolapse	4,538.3 (4,370.8 to 4,727.7)	8,886.5 (8,574.5 to 9,192.5)	96.7 (86.9 to 106.4)	3.8 (-0.7 to 8.8)	14.5 (7.0 to 27.1)	28.4 (13.8 to 53.2)	96.2 (86.1 to 106.4)	3.8 (-0.9 to 8.8)
Premenstrual syndrome	3,777.5 (3,568.4 to 3,969.7)	6,045.4 (5,618.3 to 6,406.6)	60.7 (48.6 to 74.3)	0.9 (-6.6 to 10.2)	31.9 (20.1 to 47.8)	51.1 (32.0 to 76.1)	60.2 (48.1 to 74.0)	0.8 (-6.6 to 10.3)
Other gynecological diseases	237.2 (231.1 to 243.3)	306.3 (300.4 to 311.7)	29.7 (25.8 to 33.9)	-17.1 (-19.6 to -14.4)	6.3 (4.2 to 9.0)	6.9 (4.7 to 9.8)	10.9 (4.1 to 18.3)	-7.1 (-31.5 to -22.3)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	49.8 (33.3 to 72.4)	71.6 (47.6 to 104.5)	43.5 (40.3 to 47.1)	17.0 (14.5 to 19.7)
Thalassemias	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.7)	8.5 (0.9 to 23.9)	-2.5 (-9.8 to 11.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	14.0 (3.8 to 21.9)	1.9 (-7.5 to 9.5)
Thalassemia trait	602.6 (471.6 to 723.8)	888.1 (719.2 to 1,050.2)	47.4 (42.9 to 58.2)	4.4 (0.6 to 11.5)	16.9 (11.4 to 24.2)	28.7 (19.4 to 41.2)	69.9 (64.3 to 76.5)	31.0 (27.0 to 35.8)
Sickle cell disorders	4.7 (2.0 to 7.1)	6.3 (2.6 to 9.8)	34.6 (24.7 to 41.6)	4.4 (-3.5 to 9.3)	0.6 (0.2 to 1.2)	0.9 (0.3 to 1.7)	37.6 (24.4 to 47.6)	1.9 (-7.7 to 10.6)
Sickle cell trait	1,658.3 (1,072.1 to 2,305.3)	2,340.2 (1,539.0 to 3,302.1)	42.4 (34.9 to 45.2)	0.8 (-4.8 to 3.4)	17.0 (11.4 to 24.8)	26.2 (17.1 to 38.3)	30.7 (46.9 to 59.5)	30.7 (25.8 to 35.4)
G6PD deficiency	811.2 (776.8 to 847.7)	1,170.9 (1,102.7 to 1,232.2)	44.8 (35.2 to 54.0)	2.1 (-4.6 to 8.6)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	60.6 (48.8 to 73.4)	26.7 (18.7 to 35.4)
G6PD trait	9,331.6 (9,149.1 to 9,489.3)	13,453.3 (13,172.6 to 13,751.4)	44.6 (41.0 to 48.7)	1.3 (-1.3 to 4.1)	0.3 (0.2 to 0.4)	0.3 (0.4 to 1.1)	165.5 (115.7 to 235.1)	131.5 (90.3 to 187.7)
Other hemoglobinopathies and hemolytic anemias	543.8 (531.8 to 556.1)	575.5 (566.5 to 585.6)	6.0 (3.1 to 9.4)	-21.3 (-23.2 to -19.0)	14.8 (9.9 to 21.5)	14.9 (9.8 to 21.9)	0.1 (-4.4 to 5.3)	-16.7 (-20.5 to -12.4)
Endocrine, metabolic, blood, and immune disorders	657.1 (642.2 to 672.7)	729.9 (712.1 to 733.5)	10.3 (7.3 to 13.3)	-15.7 (-17.7 to -13.7)	20.5 (13.7 to 29.4)	22.5 (15.3 to 31.7)	9.8 (5.0 to 14.8)	-20.5 (-14.0 to -6.9)
Musculoskeletal disorders	-	-	-	-	1,160.8 (825.0 to 1,534.3)	2,257.3 (1,609.3 to 2,978.6)	94.3 (88.3 to 101.9)	3.2 (0.7 to 6.7)
Rheumatoid arthritis	258.9 (255.7 to 262.2)	510.8 (504.4 to 517.2)	98.1 (94.4 to 101.8)	4.3 (2.3 to 6.3)	61.1 (43.8 to 80.8)	119.5 (85.7 to 157.8)	95.7 (91.7 to 99.8)	3.8 (1.7 to 6.0)
Osteoarthritis	1,975.4 (1,957.6 to 1,992.9)	4,323.2 (4,284.6 to 4,363.1)	119.7 (117.2 to 122.7)	2.1 (0.9 to 3.4)	120.7 (84.3 to 163.9)	264.6 (185.5 to 359.9)	119.3 (116.6 to 122.2)	3.0 (0.8 to 3.3)
Low back and neck pain	-	-	-	-	770.9 (533.6 to 1,042.9)	1,363.5 (954.2 to 1,847.6)	66.4 (68.8 to 87.1)	2.1 (5.6 to 3.8)
Low back pain	4,965.3 (4,716.2 to 5,300.9)	8,817.3 (8,424.9 to 9,195.8)	77.9 (67.2 to 89.2)	-1.3 (-6.4 to 4.3)	556.5 (373.5 to 774.5)	986.4 (674.7 to 1,353.7)	76.9 (66.1 to 88.3)	-1.2 (-6.4 to 4.4)
Neck pain	2,171.6 (2,062.4 to 2,276.7)	3,822.3 (3,561.0 to 4,122.3)	76.3 (60.8 to 93.7)	-3.7 (-12.3 to 7.1)	214.4 (148.5 to 294.4)	377.1 (257.6 to 522.7)	75.5 (59.8 to 93.1)	-3.8 (-12.6 to 6.7)
Gout	28.4 (27.2 to 29.6)	59.9 (57.7 to 61.9)	111.6 (99.7 to 125.5)	1.4 (-4.3 to 6.7)	0.9 (0.6 to 1.2)	1.4 (1.3 to 2.6)	110.9 (96.0 to 125.7)	1.4 (-5.5 to 8.6)
Other musculoskeletal disorders	2,857.8 (1,869.7 to 2,674.0)	5,546.8 (4,626.5 to 6,512.9)	445.2 (136.9 to 296.6)	19.0 (14.7 to 24.0)	207.7 (136.9 to 296.6)	407.7 (335.3 to 725.0)	64.9 (135.6 to 155.8)	64.9 (14.5 to 23.8)
Other non-communicable diseases	-	-	-	-	1,276.7 (878.5 to 1,827.6)	2,030.0 (1,392.6 to 2,906.9)	58.9 (55.4 to 62.8)	-5.6 (-7.3 to -3.8)
Congenital anomalies	-	-	-	-	109.1 (80.2 to 141.2)	178.1 (130.8 to 229.6)	63.0 (51.9 to 76.5)	17.6 (9.3 to 27.4)
Neural tube defects	27.1 (25.8 to 28.5)	40.2 (38.4 to 42.7)	48.7 (38.7 to 61.7)	16.3 (8.3 to 26.6)	8.5 (6.0 to 11.0)	13.1 (9.1 to 17.1)	53.9 (39.8 to 72.7)	21.8 (10.4 to 36.6)
Congenital heart anomalies	941.1 (324.0 to 360.9)	772.1 (746.0 to 800.5)	127.1 (113.1 to 142.5)	72.5 (61.7 to 84.6)	12.0 (5.9 to 20.2)	27.8 (12.1 to 47.1)	131.1 (115.2 to 147.4)	78.1 (66.9 to 90.5)
Orofacial clefts	62.6 (58.8 to 66.8)	127.6 (121.9 to 134.2)	104.9 (89.5 to 118.3)	64.6 (52.0 to 75.4)	1.0 (0.6 to 1.4)	1.5 (1.0 to 2.1)	24.8 (30.2 to 70.2)	24.8 (12.2 to 36.5)
Down syndrome	100.8 (96.6 to 106.1)	175.6 (167.2 to 184.2)	75.2 (63.9 to 85.5)	25.6 (17.3 to 33.1)	12.4 (9.3 to 16.0)	23.4 (17.7 to 29.5)	89.1 (75.4 to 103.0)	30.3 (21.4 to 39.0)
Turner syndrome	3.1 (2.9 to 3.3)	4.9 (4.6 to 5.2)	58.1 (45.1 to 73.8)	15.5 (6.0 to 27.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	60.9 (46.2 to 79.2)	15.7 (5.6 to 28.5)
Klinefelter syndrome	2.4 (2.3 to 2.6)	3.4 (3.2 to 3.6)	39.2 (27.0 to 50.6)	-0.6 (-9.3 to 7.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.6 (36.4 to 63.5)	-1.7 (-10.6 to 6.4)
Chromosomal unbalanced rearrangements	135.6 (131.0 to 142.9)	298.1 (226.7 to 250.0)	75.0 (64.3 to 85.6)	45.2 (17.9 to 33.4)	16.7 (12.3 to 21.5)	31.7 (23.6 to 40.1)	30.5 (36.7 to 103.2)	30.5 (22.6 to 39.4)
Other congenital anomalies	395.8 (336.8 to 452.8)	509.2 (433.4 to 590.5)	29.3 (19.7 to 37.9)	-12.9 (-19.2 to -7.1)	58.4 (40.7 to 81.0)	80.5 (54.6 to 109.4)	37.3 (25.4 to 53.6)	-1.9 (-10.3 to 10.2)
Skin and subcutaneous diseases	-	-	-	-	423.1 (272.5 to 640.7)	613.7 (398.0 to 926.2)	45.2 (41.0 to 49.0)	-0.4 (-2.3 to 1.3)
Dermatitis	4,326.6 (3,466.0 to 5,316.4)	6,559.4 (5,263.7 to 7,984.2)	52.4 (46.5 to 57.1)	-0.0 (-0.2 to 0.1)	134.8 (82.7 to 199.4)	193.7 (120.2 to 283.2)	44.0 (37.3 to 49.6)	0.1 (-0.5 to 0.8)
Psoriasis	638.5 (552.8 to 708.4)	1,035.4 (902.5 to 1,168.6)	62.8 (61.8 to 69.5)	-0.0 (-0.2 to 0.1)	51.6 (34.8 to 72.1)	84.5 (57.6 to 119.1)	64.4 (59.9 to 69.1)	0.0 (-1.3 to 1.3)
Cellulitis	3.8 (3.3 to 4.4)	5.9 (5.0 to 7.1)	55.1 (45.1 to 66.7)	-0.5 (-5.0 to 3.8)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	54.7 (44.7 to 66.0)	0.6 (-5.4 to 3.9)
Pyoderma	22.2 (19.1 to 26.1)	31.5 (26.9 to 37.5)	42.1 (35.3 to 51.4)	-0.3 (-1.4 to 0.8)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.4)	41.4 (32.3 to 52.3)	-0.2 (-3.6 to 3.4)
Scabies	1,038.1 (1,003.3 to 1,072.7)	1,280.2 (1,242.0 to 1,315.7)	23.7 (18.4 to 29.5)	-8.0 (-11.8 to -4.0)	26.9 (15.3 to 43.0)	33.2 (18.9 to 52.8)	23.2 (18.0 to 29.2)	-8.1 (-11.9 to -3.9)
Fungal skin diseases	6,021.2 (4,531.7 to 7,963.8)	9,277.2 (7,142.2 to 12,254.6)	55.2 (44.7 to 65.3)	45.4 (-0.6 to 40.2)	34.0 (16.4 to 74.8)	52.4 (21.1 to 116.9)	64.5 (44.3 to 64.8)	-0.4 (-0.6 to 0.0)
Viral skin diseases	1,659.2 (1,290.6 to 1,986.6)	2,031.5 (1,575.9 to 2,489.1)	22.7 (17.2 to 27.8)	0.0 (-0.5 to 0.5)	0.0 (0.0 to 81.3)	63.3 (37.0 to 101.9)	22.5 (16.9 to 27.6)	0.2 (-0.8 to 1.1)
Acne vulgaris	4,661.1 (4,290.8 to 4,972.0)	6,171.7 (5,730.3 to 6,600.6)	33.2 (21.0 to 48.5)	5.6 (-4.0 to 17.3)	50.5 (23.9 to 94.7)	67.2 (31.4 to 124.8)	33.2 (20.9 to 48.4)	5.5 (-4.0 to 17.4)
Alopecia areata	72.1 (70.6 to 73.8)	114.0 (111.4 to 116.5)	58.6 (53.9 to 63.2)	-1.6 (-4.4 to 1.4)	2.4 (1.6 to 3.6)	3.8 (2.4 to 5.7)	57.6 (51.1 to 64.2)	-1.5 (-5.5 to 2.4)
Pruritus	0.2 (0.2 to 0.3)	0.4 (0.4 to 0.4)	66.9 (57.7 to 78.4)	-2.1 (-8.8 to 4.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.9 (55.7 to 78.5)	-2.1 (-8.8 to 4.8)
Urticaria	748.0 (661.5 to 830.5)	1,140.1 (1,044.9 to 1,226.2)	54.7 (33.9 to 68.2)	-3.6 (-14.7 to 5.0)	44.7 (28.6 to 65.3)	67.7 (43.5 to 96.5)	53.1 (32.7 to 66.8)	-3.8 (-15.1 to 4.5)
Decubitus ulcer	9.7 (9.2 to 10.1)	21.5 (20.6 to 22.9)	123.7 (106.8 to 141.7)	1.4 (1.6 to 22.0)	1.4 (1.0 to 1.9)	3.1 (2.2 to 4.2)	119.8 (102.3 to 136.9)	10.7 (0.7 to 21.5)
Other skin and subcutaneous diseases	4,183.8 (2,823.1 to 6,220.3)	7,471.8 (4,810.9 to 11,596.3)	79.1 (63.1 to 92.9)	-0.8 (-1.7 to 0.0)	24.6 (10.8 to 51.4)	44.0 (19.2 to 91.9)	78.3 (62.1 to 92.1)	-0.8 (-1.7 to 0.1)
Sense organ diseases	-	-	-	-	945.8 (376.5 to 761.4)	883.3 (606.3 to 1,238.9)	61.8 (55.1 to 68.9)	-11.7 (-14.2 to -9.2)
Glaucoma	121.3 (102.9 to 138.3)	189.1 (161.6 to 217.1)	56.7 (46.0 to 67.4)	-20.8 (-25.5 to -15.8)	8.8 (6.0 to 12.1)	14.2 (9.6 to 19.5)	69.9 (50.7 to 70.9)	-20.2 (-24.8 to -15.3)
Cataract	442.5 (361.8 to 525.3)	690.6 (563.3 to 825.3)	56.8 (44.5 to 68.8)	-28.0 (-33.6 to -22.2)	30.1 (20.5 to 41.8)	48.7 (33.2 to 68.8)	61.7 (52.9 to 69.4)	-26.2 (-30.2 to -22.6)
Macular degeneration	151.2 (122.5 to 183.3)	345.2 (285.0 to 408.4)	128.8 (112.5 to 146.4)	7.5 (-0.6 to 16.1)	7.1 (4.7 to 10.1)	16.2 (11.0 to 22.8)	126.5 (111.2 to 142.9)	6.3 (-1.3 to 14.1)
Uncorrected refractive error	6,885.3 (6,632.5 to 7,135.5)	12,093.3 (11,638.0 to 12,412.5)	75.6 (68.3 to 83.0)	-2.9 (-6.6 to 11.2)	114.4 (70.3 to 181.4)	184.0 (111.3 to 299.6)	60.3 (53.3 to 68.9)	-0.5 (-13.9 to 5.4)
Age-related and other hearing loss	9,479.7 (8,817.6 to 10,174.2)	16,659.9 (15,621.8 to 17,878.6)	76.2 (69.7 to 84.9)	9.7 (-12.4 to -6.0)	55.2 (213.0 to 430.4)	84.5 (353.4 to 720.0)	64.5 (56.6 to 79.6)	-0.2 (-3.9 to 4.5)
Other vision loss	304.1 (263.9 to 348.9)	342.9 (299.4 to 392.0)	13.3 (5.8 to 21.0)	-33.8 (-37.1 to -30.0)	23.1 (15.9 to 31.6)	27.6 (18.8 to 37.6)	19.9 (11.6 to 28.2)	19.9 (-36.9 to -29.5)
Other sense organ diseases	1,974.3 (1,951.0 to 1,996.4)	2,760.9 (2,						

Appendix Table G.4 - Mexico prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Edentulism and severe tooth loss	2,601.5 (2,584.9 to 2,618.5)	5,071.6 (5,040.1 to 5,102.2)	95.7 (94.0 to 97.4)	-7.4 (-8.2 to -6.7)	71.8 (48.5 to 98.9)	140.1 (94.9 to 192.7)	95.3 (93.3 to 97.1)	-7.5 (-8.4 to -6.7)
Other oral disorders	1,342.1 (1,322.6 to 1,361.1)	2,126.6 (2,097.6 to 2,154.5)	59.0 (56.1 to 62.0)	-0.5 (-2.2 to 1.3)	39.5 (24.9 to 59.3)	62.6 (39.5 to 93.4)	58.4 (55.4 to 61.5)	-0.5 (-2.2 to 1.4)
Injuries	-	-	-	-	308.5 (235.4 to 397.4)	285.7 (207.4 to 385.1)	-7.9 (-16.4 to 1.8)	-47.5 (-52.3 to -42.0)
Transport injuries	-	-	-	-	89.9 (67.7 to 115.9)	71.0 (50.5 to 96.3)	-21.6 (-31.2 to -9.7)	-55.8 (-60.9 to -49.8)
Road injuries	-	-	-	-	76.2 (57.5 to 98.0)	63.6 (45.2 to 86.3)	-17.2 (-27.5 to -4.2)	-53.5 (-59.0 to -47.0)
Pedestrian road injuries	-	-	-	-	22.6 (16.9 to 29.2)	18.6 (13.1 to 25.3)	-18.6 (-28.9 to -5.7)	-54.4 (-59.8 to -48.1)
Cyclist road injuries	-	-	-	-	5.6 (4.2 to 7.4)	5.3 (3.8 to 7.2)	-5.5 (-13.8 to 3.4)	-48.3 (-52.6 to -43.6)
Motorcyclist road injuries	-	-	-	-	5.9 (4.4 to 7.7)	4.5 (3.1 to 6.2)	-24.4 (-33.7 to -13.3)	-57.3 (-62.3 to -51.6)
Motor vehicle road injuries	-	-	-	-	39.5 (29.9 to 50.9)	38.4 (23.9 to 45.2)	-2.8 (-7.1 to -1.9)	-52.5 (-58.4 to -45.3)
Other road injuries	-	-	-	-	2.6 (2.0 to 3.4)	1.8 (1.3 to 2.5)	-30.5 (-38.7 to -20.8)	-62.0 (-66.2 to -57.3)
Other transport injuries	-	-	-	-	13.7 (10.3 to 17.8)	7.4 (5.3 to 10.0)	-46.1 (-51.5 to -39.8)	-68.7 (-71.8 to -65.3)
Unintentional injuries	-	-	-	-	200.8 (153.0 to 259.4)	195.6 (142.4 to 262.3)	-3.0 (-10.4 to 5.3)	-44.2 (-48.7 to -39.4)
Falls	-	-	-	-	68.1 (51.6 to 87.6)	83.5 (59.6 to 113.3)	21.9 (8.4 to 37.4)	-38.4 (-45.5 to -30.2)
Drowning	-	-	-	-	2.4 (1.7 to 3.0)	1.7 (1.2 to 2.3)	-29.1 (-37.4 to -18.6)	-58.8 (-63.2 to -53.2)
Fire, heat, and hot substances	-	-	-	-	9.4 (7.3 to 11.9)	7.4 (5.3 to 10.0)	-22.1 (-31.3 to -11.9)	-52.4 (-57.4 to -46.5)
Poisonings	-	-	-	-	1.0 (0.7 to 1.3)	0.7 (0.5 to 0.9)	-29.2 (-33.0 to -25.5)	-55.3 (-57.3 to -53.2)
Exposure to mechanical forces	-	-	-	-	105.6 (80.5 to 138.2)	82.4 (59.5 to 110.6)	-22.3 (-27.0 to -16.9)	-52.3 (-54.9 to -49.6)
Unintentional firearm injuries	-	-	-	-	10.9 (8.3 to 14.0)	9.3 (6.6 to 12.7)	-15.5 (-23.4 to -6.7)	-51.8 (-55.9 to -47.2)
Unintentional suffocation	-	-	-	-	2.2 (1.6 to 2.8)	4.8 (3.5 to 6.4)	121.7 (101.0 to 141.9)	32.8 (22.7 to 43.7)
Other exposure to mechanical forces	-	-	-	-	92.5 (70.1 to 121.3)	68.3 (49.3 to 92.0)	-26.4 (-30.6 to -21.6)	-54.4 (-56.8 to -52.0)
Adverse effects of medical treatment	-	-	-	-	0.5 (0.3 to 0.8)	0.8 (0.5 to 1.2)	59.9 (57.7 to 62.0)	-11.2 (-12.4 to -10.0)
Animal contact	-	-	-	-	1.7 (1.3 to 2.2)	2.0 (1.5 to 2.7)	18.4 (10.1 to 31.0)	-29.9 (-35.2 to -23.8)
Venomous animal contact	-	-	-	-	0.7 (0.5 to 0.9)	0.7 (0.5 to 1.0)	7.6 (1.3 to 14.1)	-35.5 (-39.1 to -32.0)
Non-venomous animal contact	-	-	-	-	1.0 (0.7 to 1.3)	1.3 (0.9 to 1.7)	28.0 (16.1 to 41.8)	-26.5 (-32.9 to -19.2)
Foreign body	-	-	-	-	2.6 (2.0 to 3.2)	3.0 (2.2 to 3.9)	15.9 (4.6 to 29.8)	-31.2 (-37.6 to -23.6)
Pulmonary aspiration and foreign body in airway	-	-	-	-	1.2 (0.9 to 1.5)	1.1 (0.8 to 1.4)	-9.9 (-23.0 to 7.0)	-45.9 (-53.5 to -36.6)
Foreign body in eyes	-	-	-	-	0.4 (0.2 to 0.5)	0.5 (0.3 to 0.8)	43.7 (38.0 to 50.0)	-10.4 (-15.9 to -6.3)
Foreign body in other body part	-	-	-	-	1.0 (0.8 to 1.3)	1.4 (1.0 to 1.8)	36.5 (25.2 to 49.2)	-20.9 (-26.1 to -15.1)
Other unintentional injuries	-	-	-	-	9.6 (7.2 to 12.5)	14.2 (10.4 to 18.8)	47.6 (39.6 to 55.8)	-17.4 (-21.3 to -13.3)
Self-harm and interpersonal violence	-	-	-	-	17.5 (13.4 to 22.3)	18.9 (13.5 to 25.6)	8.8 (5.3 to 22.4)	-42.0 (-48.3 to -34.1)
Self-harm	-	-	-	-	2.2 (1.7 to 2.9)	3.4 (2.4 to 4.5)	50.0 (37.9 to 64.8)	-22.1 (-28.4 to -14.6)
Interpersonal violence	-	-	-	-	15.3 (11.7 to 19.4)	15.5 (11.0 to 21.0)	0.5 (-11.6 to 16.0)	-45.0 (-51.3 to -37.1)
Assault by firearm	-	-	-	-	4.7 (3.5 to 6.1)	6.6 (4.7 to 9.0)	41.7 (29.0 to 55.9)	-24.1 (-30.3 to -17.3)
Assault by sharp object	-	-	-	-	3.1 (2.4 to 4.0)	3.2 (2.3 to 4.5)	2.1 (-10.4 to 17.2)	-44.5 (-51.0 to -36.7)
Assault by other means	-	-	-	-	7.5 (5.7 to 9.5)	5.6 (4.0 to 7.5)	-25.3 (-35.3 to -12.2)	-58.6 (-63.9 to -51.4)
Forces of nature, war, and legal intervention	-	-	-	-	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	-19.0 (-30.0 to -6.3)	-21.7 (-32.3 to -9.8)
Exposure to forces of nature	-	-	-	-	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	-20.7 (-31.3 to -8.3)	-23.2 (-33.4 to -11.5)
Collective violence and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-

Appendix Table G.4 - Moldova prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	443.9 (329.9 to 572.7)	402.9 (299.7 to 521.8)	-9.2 (-11.6 to -7.0)	-0.9 (-3.4 to 1.3)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	38.3 (26.6 to 53.7)	28.5 (20.0 to 39.1)	-25.6 (-30.3 to -20.6)	5.3 (-1.3 to 12.3)
HIV/AIDS and tuberculosis	-	-	-	-	1.5 (1.0 to 2.0)	2.4 (1.6 to 3.4)	59.2 (39.0 to 93.1)	77.5 (55.2 to 115.5)
Tuberculosis	4.5 (4.2 to 4.8)	5.7 (5.5 to 5.9)	26.9 (20.2 to 33.9)	40.8 (33.4 to 48.1)	1.4 (0.9 to 1.9)	1.8 (1.2 to 2.4)	27.2 (16.4 to 38.7)	41.7 (30.3 to 54.1)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.3)	0.7 (0.3 to 1.3)	466.8 (185.7 to 1,362.4)	465.3 (227.2 to 1,544.8)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	581.7 (263.5 to 1,469.8)	655.4 (318.2 to 1,721.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	532.9 (203.9 to 1,550.9)	627.8 (240.5 to 1,831.8)
HIV/AIDS resulting in other diseases	0.9 (0.3 to 1.8)	5.6 (3.4 to 8.5)	584.9 (251.4 to 1,517.3)	682.3 (304.8 to 1,756.9)	0.1 (0.0 to 0.3)	0.6 (0.3 to 1.3)	466.8 (179.6 to 1,434.3)	544.3 (221.3 to 1,636.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	4.4 (3.0 to 6.2)	2.9 (2.0 to 4.1)	-33.9 (-38.1 to -30.0)	-9.4 (-15.0 to -4.1)
Diarrheal diseases	8.9 (8.1 to 9.6)	5.8 (5.3 to 6.3)	-34.6 (-42.3 to -26.3)	-3.9 (-15.3 to 8.7)	1.4 (1.0 to 2.0)	0.9 (0.6 to 1.3)	-35.3 (-43.8 to -26.5)	-4.0 (-16.7 to 9.5)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.6 (-68.3 to -23.5)	-29.0 (-57.7 to 3.1)
Typhoid fever	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-40.9 (-58.0 to -22.9)	-20.6 (-44.2 to 4.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.9 (-58.0 to -22.8)	-20.6 (-44.2 to 4.2)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.7 (-64.1 to -24.2)	-21.4 (-48.5 to 3.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.7 (-64.1 to -24.2)	-21.4 (-49.0 to 4.0)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-91.1 (-99.7 to 145.5)	-88.0 (-99.5 to 233.7)
Lower respiratory infections	1.3 (1.1 to 1.5)	0.9 (0.7 to 1.2)	-27.4 (-49.5 to -4.1)	24.5 (14.8 to 68.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-27.7 (-51.1 to 1.2)	24.3 (-16.9 to 74.7)
Upper respiratory infections	68.8 (65.5 to 71.9)	52.0 (49.8 to 54.0)	-24.2 (-29.1 to -19.3)	-8.8 (-7.2 to 5.9)	0.8 (0.5 to 1.4)	0.6 (0.3 to 1.0)	-24.5 (-29.8 to -19.1)	-0.7 (-7.7 to 6.7)
Otitis media	60.1 (55.5 to 65.0)	41.6 (38.5 to 44.8)	-30.7 (-36.8 to -24.0)	-10.6 (-17.9 to -3.1)	1.2 (0.7 to 2.0)	0.8 (0.5 to 1.3)	-33.2 (-39.4 to -25.8)	-11.4 (-19.5 to -2.8)
Meningitis	-	-	-	-	0.4 (0.3 to 0.6)	0.2 (0.1 to 0.2)	-60.1 (-68.6 to -46.3)	-48.4 (-59.8 to -30.4)
Pneumococcal meningitis	1.7 (0.9 to 2.6)	0.8 (0.5 to 1.3)	-51.2 (-60.0 to -41.2)	-4.4 (-53.2 to -30.6)	0.2 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-91.1 (-70.5 to -37.9)	-88.0 (-63.0 to -22.0)
H influenzae type B meningitis	1.2 (0.4 to 2.3)	0.5 (0.2 to 0.9)	-61.0 (-71.5 to -40.2)	-51.0 (-63.7 to -23.9)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-65.6 (-78.7 to -33.7)	-53.2 (-71.2 to 17.5)
Meningococcal meningitis	0.4 (0.1 to 1.0)	0.2 (0.1 to 0.4)	-52.2 (-69.3 to -36.0)	-43.6 (-62.5 to -18.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-56.0 (-77.1 to -30.3)	-44.0 (-70.7 to -9.2)
Other meningitis	0.8 (0.3 to 1.5)	0.4 (0.2 to 0.7)	-52.4 (-63.0 to -38.8)	-42.3 (-54.8 to -25.0)	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-54.8 (-69.8 to -37.1)	-42.0 (-61.3 to -18.5)
Encephalitis	1.8 (0.8 to 4.3)	1.8 (0.8 to 4.1)	-1.2 (-14.6 to 15.8)	-1.2 (-8.0 to 26.3)	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-0.6 (-21.9 to 16.7)	5.8 (-13.4 to 29.7)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.0 (-95.5 to 192.4)	-54.0 (-94.1 to 250.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.0 (-95.5 to 194.2)	-54.0 (-94.1 to 254.8)
Whooping cough	1.9 (1.5 to 2.4)	0.6 (0.5 to 0.8)	-69.1 (-70.0 to -68.1)	-40.0 (-41.7 to -38.2)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.0)	-69.1 (-72.7 to -64.8)	-40.1 (-47.0 to -31.9)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.4 (-82.3 to -35.4)	-34.1 (-78.6 to -16.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.3 (-82.1 to -36.0)	-33.8 (-78.3 to -16.8)
Measles	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-99.2 (-99.5 to -98.9)	-98.4 (-99.0 to -97.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.2 (-99.5 to -98.5)	-98.3 (-99.1 to -97.0)
Varicella and herpes zoster	2.7 (2.5 to 2.9)	1.9 (1.7 to 2.1)	-30.6 (-38.1 to -22.7)	-9.9 (-10.3 to 8.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-11.3 (-30.0 to 11.4)	-0.6 (-20.0 to 24.0)
Neglected tropical diseases and malaria	-	-	-	-	0.4 (0.2 to 0.7)	0.1 (0.0 to 0.2)	-75.0 (-89.5 to -40.9)	-73.8 (-88.6 to -39.8)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.1 (-69.7 to 295.9)	47.6 (-58.0 to 447.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.3 (-70.2 to 286.3)	48.9 (-58.5 to 433.5)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Visceral leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Cysticercosis	1.0 (0.4 to 2.2)	0.2 (0.1 to 0.3)	-84.5 (-95.1 to -40.4)	-84.3 (-94.9 to -41.3)	0.3 (0.1 to 0.6)	0.0 (0.0 to 0.1)	-84.7 (-95.2 to -38.8)	-84.4 (-94.7 to -38.4)
Cystic echinococcosis	0.9 (0.9 to 1.0)	0.5 (0.4 to 0.5)	-48.4 (-61.1 to -42.6)	-45.3 (-58.8 to -39.7)	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-49.1 (-64.6 to -34.9)	-45.7 (-62.3 to -31.0)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.3 (-57.6 to -29.4)	-28.5 (-48.6 to -11.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.3 (-57.6 to -29.4)	-38.5 (-48.7 to -11.6)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Ascariasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trichuriasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Hookworm disease	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-65.8 (-75.7 to -55.6)	-57.6 (-70.5 to -44.9)
Maternal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.1)	-53.5 (-63.5 to -43.3)	-49.1 (-60.1 to -38.1)
Maternal hemorrhage	1.3 (1.1 to 1.4)	0.7 (0.5 to 0.9)	-44.0 (-62.2 to -22.5)	-39.3 (-59.0 to -16.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-44.7 (-70.8 to -16.6)	-40.1 (-68.0 to -9.2)
Maternal sepsis and other maternal infections	3.9 (2.3 to 5.9)	1.3 (0.8 to 2.1)	-66.4 (-71.8 to -56.7)	-59.4 (-66.1 to -47.4)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-70.8 (-79.9 to -58.4)	-66.6 (-77.0 to -52.0)
Maternal hypertensive disorders	1.0 (0.6 to 1.4)	0.5 (0.3 to 0.8)	-44.7 (-49.7 to -35.8)	-40.6 (-46.7 to -30.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-44.5 (-56.0 to -30.3)	-40.4 (-52.7 to -24.0)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.5 (-67.9 to -8.5)	-39.5 (-64.9 to 1.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.1 (-67.9 to -8.4)	-39.5 (-65.2 to 1.4)
Complications of abortion	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-42.1 (-57.4 to -9.6)	-36.7 (-53.6 to -0.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.9 (-72.0 to 21.6)	-37.3 (-69.5 to 36.4)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.1 (-74.9 to -15.8)	-49.1 (-72.7 to -7.7)
Neonatal disorders	-	-	-	-	4.7 (3.3 to 6.7)	4.4 (3.1 to 6.0)	-6.1 (-33.1 to 20.9)	29.0 (-9.0 to 63.9)
Preterm birth complications	14.2 (10.5 to 18.9)	17.2 (12.5 to 22.6)	21.0 (1.2 to 43.2)	55.7 (30.2 to 84.9)	1.6 (1.1 to 2.4)	2.0 (1.3 to 2.7)	22.0 (-12.2 to 70.8)	62.1 (16.8 to 127.4)
Neonatal encephalopathy due to birth asphyxia and trauma	7.8 (4.0 to 16.3)	3.8 (2.2 to 7.4)	-50.0 (-69.9 to -20.4)	-31.4 (-59.2 to 9.6)	1.8 (1.1 to 2.8)	1.0 (0.6 to 1.4)	-44.3 (-66.4 to -10.3)	-21.2 (-52.6 to 27.1)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.6 (-63.3 to -59.5)	-37.0 (-30.4 to -43.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.6 (-66.6 to -55.6)	-37.1 (-36.6 to -15.7)
Hemolytic disease and other neonatal jaundice	3.3 (1.6 to 6.9)	2.6 (1.5 to 4.7)	-17.7 (-71.0 to 81.3)	-17.7 (-61.0 to 145.4)	1.2 (0.6 to 2.4)	0.9 (0.5 to 1.6)	-17.4 (-67.8 to 71.4)	-11.3 (-56.3 to 130.6)
Other neonatal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.5 (0.1 to 0.9)	228.3 (-63.3 to 540.9)	344.8 (27.5 to 770.4)
Nutritional deficiencies	-	-	-	-	25.3 (16.8 to 36.6)	17.3 (11.7 to 25.2)	-31.3 (-36.3 to -26.4)	1.8 (-5.5 to 9.7)
Protein-energy malnutrition	9.2 (3.8 to 19.0)	4.7 (1.9 to 9.4)	-49.7 (-82.9 to 59.4)	-1.4 (-66.5 to 211.0)	1.2 (0.4 to 2.5)	0.6 (0.2 to 1.2)	-49.8 (-83.4 to 62.3)	-1.6 (-67.4 to 216.5)
Iodine deficiency	94.2 (58.6 to 131.9)	55.1 (32.5 to 84.5)	-41.0 (-69.6 to 8.6)	-43.0 (-63.5 to 24.9)	1.7 (0.8 to 3.0)	1.0 (0.5 to 1.8)	-42.8 (-69.6 to 7.4)	-32.5 (-63.1 to 25.2)
Vitamin A deficiency	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Iron-deficiency anemia	684.8 (676.8 to 693.1)	504.4 (500.7 to 508.5)	-26.4 (-27.6 to -25.2)	3.1 (1.4 to 4.8)	22.1 (14.7 to 32.1)	15.5 (10.3 to 22.6)	-29.8 (-31.8 to -28.6)	3.9 (1.0 to 5.7)

Appendix Table G.4 - Moldova prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.3 (0.1 to 0.8)	0.2 (0.1 to 0.5)	-21.1 (-81.0 to 166.2)	-22.1 (-62.7 to 421.5)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.8 (1.1 to 3.0)	1.2 (0.7 to 2.0)	-34.5 (-43.7 to -25.3)	-7.0 (-21.5 to 4.9)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.7 (0.4 to 1.4)	0.6 (0.3 to 1.2)	-2.7 (-24.5 to -5.4)	-2.7 (-13.2 to 8.4)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-18.4 (-28.2 to -3.8)	-18.6 (-28.4 to -4.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.0 (-38.0 to 9.4)	-18.4 (-38.3 to 9.8)
Chlamydial infection	118.7 (93.3 to 124.0)	92.5 (80.7 to 104.6)	-21.6 (-30.7 to 1.8)	-21.2 (-18.3 to 21.2)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.4)	-4.7 (-19.2 to 19.4)	-4.7 (-19.2 to 19.4)
Gonococcal infection	25.6 (21.0 to 30.0)	18.2 (15.0 to 21.4)	-29.1 (-46.5 to -8.0)	-14.1 (-35.3 to 12.0)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-32.8 (-50.1 to -9.0)	-18.6 (-40.1 to 9.9)
Trichomoniasis	56.1 (40.1 to 76.3)	47.0 (31.6 to 64.6)	-16.8 (-44.6 to 31.6)	-8.8 (-33.4 to 62.3)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-18.3 (-47.1 to 38.1)	-2.3 (-36.5 to 71.0)
Genital herpes	752.9 (728.7 to 778.2)	749.6 (719.9 to 779.8)	-0.5 (-5.3 to 5.1)	4.4 (-0.8 to 10.3)	0.2 (0.1 to 0.5)	0.2 (0.1 to 0.5)	-1.4 (-7.5 to 5.1)	4.6 (1.7 to 12.0)
Other sexually transmitted diseases	1.7 (1.2 to 2.3)	1.2 (0.9 to 1.5)	-31.0 (-41.4 to -21.8)	-16.6 (-28.1 to -5.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-22.0 (-41.3 to 5.8)	-7.2 (-29.4 to 25.0)
Hepatitis	-	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-33.8 (-40.8 to -25.9)	-17.3 (-26.0 to -7.7)
Hepatitis A	4.8 (4.6 to 4.9)	3.2 (3.1 to 3.3)	-33.1 (-34.0 to -32.3)	-0.7 (-0.7 to -0.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-24.7 (-32.7 to -16.1)	-0.3 (-11.0 to 11.2)
Hepatitis B	164.7 (154.2 to 175.2)	84.8 (80.0 to 89.9)	-48.5 (-52.7 to -43.4)	-39.0 (-43.9 to -32.7)	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-46.9 (-59.3 to -29.7)	-40.2 (-54.1 to -21.7)
Hepatitis C	87.9 (80.8 to 95.7)	60.8 (55.4 to 66.2)	-30.8 (-39.4 to -21.7)	-26.4 (-32.2 to -16.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.9 (-49.6 to -5.1)	-25.4 (-44.3 to 1.1)
Hepatitis E	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leprosy	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other infectious diseases	25.0 (22.0 to 28.8)	14.4 (12.5 to 16.4)	-42.1 (-52.8 to -31.4)	2.0 (-17.6 to 21.9)	0.5 (0.5 to 1.3)	0.4 (0.2 to 0.6)	-50.9 (-67.4 to -34.3)	-8.2 (-39.2 to 22.9)
Non-communicable diseases	-	-	-	-	374.3 (276.1 to 483.3)	356.5 (264.8 to 462.8)	-4.7 (-7.5 to 2.0)	1.9 (-0.2 to 4.7)
Neoplasms	-	-	-	-	3.3 (2.4 to 4.3)	3.2 (2.4 to 4.2)	-3.3 (-10.2 to 6.4)	3.9 (-12.4 to 3.7)
Esophageal cancer	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-19.2 (-41.2 to 20.0)	-26.4 (-45.9 to 9.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.7 (-40.1 to 23.6)	-25.2 (-44.9 to 10.7)
Stomach cancer	1.5 (1.3 to 1.7)	0.9 (0.8 to 1.1)	-39.1 (-49.5 to -26.8)	-42.6 (-52.3 to -31.2)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-38.1 (-48.5 to -25.1)	-41.7 (-51.6 to -30.0)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-	0.1 (-12.1 to 142.5)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	69.5 (-27.2 to 344.9)	62.2 (-29.9 to 318.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.0 (-24.6 to 311.7)	56.2 (-27.4 to 287.9)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	270.7 (74.8 to 705.8)	248.0 (63.7 to 648.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	248.1 (85.6 to 601.8)	226.3 (75.6 to 550.1)
Liver cancer due to alcohol use	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	42.8 (-32.1 to 167.7)	34.1 (-36.0 to 150.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.6 (-28.4 to 132.5)	29.3 (-33.6 to 117.0)
Liver cancer due to other causes	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-19.3 (-61.4 to 53.3)	-21.2 (-62.9 to 49.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.3 (-62.2 to 35.5)	-24.1 (-63.5 to 30.9)
Larynx cancer	0.5 (0.3 to 0.6)	0.4 (0.3 to 0.6)	-16.9 (-41.5 to 34.8)	-16.9 (-45.1 to 23.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-16.9 (-40.9 to 28.2)	-17.0 (-44.8 to 16.3)
Tracheal, bronchus and lung cancer	1.7 (1.4 to 1.9)	1.2 (1.0 to 1.5)	-25.8 (-40.0 to -8.1)	-30.5 (-43.4 to -34.1)	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-22.1 (-36.2 to -5.5)	-26.9 (-40.1 to -12.1)
Breast cancer	3.7 (2.9 to 4.4)	7.1 (6.0 to 8.3)	90.9 (52.3 to 135.7)	83.7 (46.3 to 127.7)	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.7)	23.4 (-1.7 to 53.1)	18.4 (-5.4 to 47.7)
Cervical cancer	4.3 (3.4 to 5.0)	2.4 (1.7 to 3.0)	-44.1 (-60.0 to -28.2)	-40.7 (-57.6 to 23.8)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-44.8 (-59.8 to -28.4)	-41.9 (-58.2 to -24.0)
Uterine cancer	1.3 (1.0 to 1.8)	1.4 (0.9 to 2.0)	8.7 (-37.6 to 64.9)	8.7 (-40.5 to 53.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	8.9 (-38.0 to 62.8)	2.1 (-41.3 to 51.6)
Prostate cancer	1.8 (1.5 to 2.4)	3.4 (2.3 to 4.4)	85.3 (21.5 to 168.4)	68.4 (12.6 to 141.2)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	101.9 (24.4 to 193.1)	82.8 (12.7 to 160.4)
Colon and rectum cancer	4.0 (3.7 to 4.3)	4.4 (4.0 to 4.8)	10.4 (-2.9 to 24.6)	2.5 (-9.2 to 15.7)	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	10.0 (-5.5 to 25.4)	1.6 (-12.0 to 15.5)
Lip and oral cavity cancer	1.4 (1.1 to 1.7)	1.3 (1.0 to 1.6)	-8.6 (-37.0 to 31.9)	-14.9 (-41.0 to 20.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-7.0 (-33.8 to 29.9)	-14.4 (-38.0 to 18.7)
Nasopharynx cancer	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.2)	-39.7 (-58.7 to -3.7)	-39.4 (-57.9 to -2.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.8 (-56.2 to -7.2)	-40.4 (-56.2 to -8.6)
Other pharynx cancer	0.3 (0.2 to 0.5)	0.5 (0.2 to 0.7)	39.0 (-40.3 to 170.8)	27.0 (-44.9 to 147.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	27.0 (-31.8 to 146.7)	45.0 (-36.3 to 121.3)
Gallbladder and biliary tract cancer	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-48.3 (-62.0 to -4.0)	-52.1 (-64.7 to -7.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-48.5 (-62.4 to -9.5)
Pancreatic cancer	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.4)	6.8 (-14.6 to 35.8)	-3.3 (-22.2 to 22.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	9.8 (-11.7 to 36.3)	-0.4 (-19.4 to 24.1)
Malignant skin melanoma	1.0 (0.7 to 1.3)	1.2 (0.8 to 1.6)	19.8 (-6.9 to 49.9)	21.2 (-5.8 to 51.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	17.6 (-6.6 to 50.8)	18.2 (-7.7 to 49.9)
Non-melanoma skin cancer	2.3 (1.8 to 2.8)	3.2 (2.5 to 3.8)	39.8 (14.1 to 89.8)	23.5 (-10.3 to 66.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	61.3 (26.4 to 127.7)	46.4 (8.8 to 100.5)
Ovarian cancer	0.8 (0.6 to 1.0)	0.5 (0.4 to 0.6)	-37.3 (-50.8 to -13.2)	-37.6 (-51.1 to -14.1)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-36.1 (-54.2 to -6.0)	-36.9 (-54.4 to -7.1)
Testicular cancer	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-33.3 (-56.7 to 61.2)	-33.3 (-49.0 to 85.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Kidney cancer	0.6 (0.5 to 0.8)	0.7 (0.6 to 0.9)	18.3 (-5.7 to 51.2)	18.9 (-5.0 to 48.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	21.3 (-5.5 to 54.0)	19.5 (-5.5 to 50.5)
Bladder cancer	0.9 (0.7 to 1.1)	0.6 (0.5 to 0.7)	-33.6 (-47.8 to -10.1)	-33.6 (-51.8 to -17.1)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-33.7 (-45.4 to -5.5)	-35.9 (-50.3 to -13.5)
Brain and nervous system cancer	0.7 (0.6 to 0.9)	0.7 (0.6 to 0.8)	-4.7 (-23.6 to 16.6)	16.1 (-7.0 to 42.4)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-1.2 (-19.8 to 20.3)	14.1 (-7.1 to 39.5)
Thyroid cancer	0.8 (0.6 to 1.4)	0.9 (0.5 to 1.2)	29.7 (-49.9 to 87.2)	40.3 (-44.6 to 100.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	30.3 (-49.8 to 90.3)	39.7 (-44.9 to 103.1)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hodgkin lymphoma	1.0 (0.7 to 1.4)	0.7 (0.5 to 1.0)	-28.7 (-50.0 to 5.5)	-34.1 (-40.1 to 26.2)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-30.1 (-50.2 to -15.5)	-17.5 (-40.5 to 16.6)
Non-Hodgkin lymphoma	0.9 (0.6 to 1.3)	0.8 (0.5 to 1.0)	-11.6 (-47.0 to 34.4)	-3.8 (-42.2 to 43.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-6.3 (-44.0 to 36.7)	-0.7 (-40.0 to 47.2)
Multiple myeloma	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	7.8 (-27.5 to 74.4)	2.8 (-30.8 to 63.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.3 (-28.2 to 69.0)	1.1 (-30.7 to 59.8)
Leukemia	1.7 (1.3 to 2.1)	0.7 (0.6 to 0.9)	-58.2 (-67.6 to -45.0)	-47.2 (-59.5 to -31.1)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-49.3 (-60.8 to -34.1)	-41.8 (-54.3 to -25.6)
Other neoplasms	1.7 (1.4 to 2.1)	2.2 (1.8 to 2.6)	27.5 (1.0 to 63.3)	43.3 (14.0 to 82.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	21.7 (-0.2 to 56.6)	21.7 (8.4 to 67.2)
Cardiovascular diseases	-	-	-	-	5.9 (4.0 to 8.0)	5.8 (4.0 to 7.8)	-2.7 (-22.7 to 21.3)	-10.3 (-27.6 to 12.3)
Rheumatic heart disease	1.0 (0.9 to 1.1)	1.0 (0.9 to 1.1)	-0.1 (-14.6 to 17.7)	-3.9 (-17.0 to 12.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	2.7 (-21.9 to 55.2)	-0.7 (-23.9 to 46.1)
Ischemic heart disease	52.4 (44.3 to 65.0)	48.9 (43.3 to 54.8)	-5.2 (-28.5 to 16.2)	-14.0 (-33.4 to 4.0)	2.6 (1.6 to 3.8)	2.2 (1.5 to 3.1)	-13.7 (-40.6 to 15.2)	-21.4 (-44.8 to 3.2)
Cerebrovascular disease	-	-	-	-	1.1 (0.9 to 1.8)	1.4 (0.9 to 1.8)	26.9 (-19.1 to 44.9)	46.4 (-22.5 to 37.9)
Ischemic stroke	8.1 (6.9 to 9.4)	8.9 (7.1 to 10.9)	10.7 (-18.8 to 43.8)	5.7 (-22.8 to 36.7)	1.2 (0.8 to 1.7)	1.4 (0.9 to 1.9)	10.6 (-18.9 to 46.7)	5.9 (-22.2 to 39.5)
Hemorrhagic stroke	0.5 (0.4 to 0.8)	0.5 (0.4 to 0.7)	-5.6 (-38.3 to 48.6)	-4.3 (-36.8 to 49.4)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-5.3 (-38.1 to 48.0)	-4.2 (-36.5 to 48.4)
Hypertensive heart disease	3.8 (3.3 to 4.3)	4.8 (4.2 to 5.4)	27.0 (7.2 to 54.3)	9.8 (-7.7 to 33.3)	0.4 (0.3 to 0.6)	0.5 (0.4 to 0.7)	26.9 (5.7 to 56.4)	10.2 (-8.0 to 36.1)
Cardiomyopathy and myocarditis	3.4 (2.9 to 4.0)	3.8 (3.5 to 4.3)	11.3 (-6.2 to 36.6)	4.5 (-11.9 to 28.9)	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.5)	12.9 (-5.8 to 40.5)	6.0 (-12.3 to 32.9)
Atrial fibrillation and flutter	0.3 (0.1 to 0.4)	0.9 (0.6 to 1.6)	233.9 (87.6 to 698.3)	224.4 (80.2 to 694.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	217.2 (74.5 to 692.0)	217.2 (70.9 to 693.8)
Peripheral vascular disease	110.2 (87.5 to 132.4)	127.8 (94.3 to 166.2)	15.4 (-22.5 to 66.2)	1.4 (-32.8 to 44.0)	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.2)	-36.0 (-72.7 to 65.0)	-47.3 (-78.4 to 35.1)
Endocarditis	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	38.7 (-31.2 to 211.0)	38.2 (-31.6 to 200.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-37.3 to 149.9)	37.7 (-36.6 to 143.9)
Other cardiovascular and circulatory diseases	14.2 (7.0 to 25.8)	13.4 (6.0 to 25.1)	-8.2 (-64.6 to 149.6)	-13.2 (-67.3 to 142.1)	1.0 (0.4 to 1.9)	0.9 (0.4 to 1.9)	-8.8 (-64.4 to 148.5)	-13.2 (-66.9 to 140.8)
Chronic respiratory diseases	-	-	-	-	14.3 (9.8 to 19.6)	13.6 (9.0 to 18.5)	-4.8 (-19.1 to 9.7)	-1.9 (-17.1 to 14.5)
Chronic obstructive pulmonary disease	139.3 (132.8 to 145.8)	139.9 (133.1 to 146.5)	0.6 (-2.6 to 3.2)	-0.4 (-3.4 to 2.1)	8.5 (5.5 to 12.1)	8.9 (5.7 to 12.9)	4.9 (-11.2 to 27.8)	4.6 (-11.8 to 26.3)
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.5 (-38.0 to -30.3)	-35.9 (-39.4 to -31.8)

Appendix Table G.4 - Moldova prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.9 (-6.9 to 3.8)	-10.4 to -0.2	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.7 (-6.8 to 4.0)	-
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-44.2 (-47.1 to -41.1)	-45.1 (-48.0 to -42.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.8 (-47.0 to -40.5)	-44.4 (-47.4 to -40.8)
Asthma	130.9 (105.8 to 154.4)	108.6 (84.3 to 134.3)	-17.2 (-40.5 to 13.0)	-13.6 (-36.4 to 26.7)	5.7 (3.6 to 8.4)	4.6 (2.9 to 6.8)	-21.9 (-41.8 to 13.4)	-14.2 (-37.5 to 27.9)
Interstitial lung disease and pulmonary sarcoidosis	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-7.2 (-37.1 to 30.6)	0.2 (-31.8 to 40.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-6.8 (-36.5 to 31.3)	1.0 (-30.9 to 41.7)
Other chronic respiratory diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-37.0 (-58.9 to -8.3)	-37.7 (-58.9 to -9.5)
Cirrhosis	-	-	-	-	0.8 (0.5 to 1.1)	0.7 (0.5 to 1.0)	-11.0 (-18.3 to -3.2)	-7.5 (-15.5 to 0.8)
Cirrhosis due to hepatitis B	1.1 (0.8 to 1.3)	0.7 (0.5 to 1.1)	-34.0 (-58.7 to 5.9)	32.3 (-57.8 to 9.7)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-34.4 (-60.0 to 12.0)	-32.4 (-59.8 to 17.7)
Cirrhosis due to hepatitis C	1.0 (0.8 to 1.3)	1.7 (1.2 to 2.2)	68.8 (9.3 to 145.6)	70.2 (9.7 to 148.8)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	68.2 (4.7 to 146.6)	70.2 (6.4 to 150.3)
Cirrhosis due to alcohol use	1.9 (1.5 to 2.2)	1.2 (0.9 to 1.6)	-35.2 (-55.0 to -12.6)	-35.8 (-55.6 to -13.3)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-34.7 (-56.1 to -9.1)	-35.3 (-56.5 to -10.3)
Cirrhosis due to other causes	0.8 (0.7 to 1.0)	0.6 (0.4 to 0.9)	-21.1 (-56.2 to 11.0)	-4.7 (-44.9 to 31.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-22.4 (-58.5 to 18.6)	-6.0 (-48.6 to 41.2)
Digestive diseases	-	-	-	-	4.5 (3.2 to 5.9)	4.4 (3.2 to 5.9)	-1.1 (-6.6 to 4.7)	1.6 (-4.5 to 7.5)
Peptic ulcer disease	33.1 (31.5 to 35.1)	26.0 (24.7 to 27.3)	-21.4 (-26.6 to -16.6)	-26.2 (-31.0 to -22.0)	1.0 (0.6 to 1.4)	0.6 (0.4 to 0.9)	-33.2 (-44.7 to -25.4)	-37.7 (-48.2 to -30.5)
Gastritis and duodenitis	3.1 (2.8 to 3.4)	2.2 (1.9 to 2.5)	-29.9 (-38.9 to -21.1)	-13.3 (-23.8 to -2.8)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-36.3 (-48.2 to -20.8)	-11.6 (-27.0 to 11.3)
Appendicitis	0.4 (0.3 to 0.4)	0.3 (0.2 to 0.3)	-24.3 (-36.9 to -6.7)	2.1 (-15.1 to 26.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-24.3 (-45.5 to 5.0)	2.8 (-26.0 to 42.9)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	20.6 (1.0 to 40.4)	28.0 (8.5 to 50.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.1 (-2.1 to 43.7)	27.2 (4.5 to 56.5)
Inguinal, femoral, and abdominal hernia	10.6 (9.0 to 12.3)	9.6 (8.1 to 11.2)	-10.3 (-27.1 to 13.1)	-16.3 (-32.3 to 6.4)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.2)	-10.0 (-27.1 to 13.1)	-15.3 (-31.8 to 7.2)
Inflammatory bowel disease	8.0 (7.7 to 8.3)	9.3 (9.0 to 9.7)	16.5 (10.5 to 23.1)	21.1 (15.0 to 28.0)	1.7 (1.2 to 2.3)	2.0 (1.4 to 2.7)	16.4 (7.9 to 25.4)	21.5 (12.7 to 30.7)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.3 (-24.8 to 73.9)	2.8 (-29.2 to 63.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.0 (-31.9 to 78.8)	2.6 (-35.4 to 74.7)
Gallbladder and biliary diseases	6.3 (5.6 to 7.0)	5.3 (4.6 to 6.0)	-15.6 (-28.2 to -2.5)	-16.5 (-29.2 to -2.9)	0.7 (0.5 to 0.9)	0.6 (0.4 to 0.8)	-16.1 (-23.2 to -2.5)	-16.5 (-29.4 to -2.8)
Pancreatitis	2.1 (2.0 to 2.2)	2.7 (2.6 to 2.8)	25.9 (17.9 to 34.5)	25.9 (22.8 to 40.0)	0.6 (0.4 to 0.9)	0.8 (0.5 to 1.1)	25.5 (11.7 to 42.9)	31.4 (17.3 to 49.2)
Other digestive diseases	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	52.7 (14.9 to 78.8)	56.6 (17.9 to 83.9)
Neurological disorders	-	-	-	-	44.4 (30.1 to 61.2)	45.1 (30.4 to 62.2)	1.4 (-9.1 to 12.8)	9.0 (-1.4 to 20.2)
Alzheimer disease and other dementias	28.9 (25.3 to 32.7)	36.3 (31.4 to 42.2)	25.6 (4.2 to 49.9)	1.0 (-16.8 to 22.4)	4.2 (3.0 to 5.6)	5.4 (3.7 to 7.1)	28.7 (5.6 to 55.1)	1.8 (-16.9 to 23.8)
Parkinson disease	1.9 (1.6 to 2.2)	2.1 (1.8 to 2.4)	13.2 (7.2 to 18.1)	13.2 (-4.9 to 4.8)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.3)	13.4 (-0.7 to 29.6)	0.9 (-11.5 to 14.1)
Epilepsy	9.5 (6.7 to 12.6)	7.8 (5.4 to 10.2)	-17.5 (-48.4 to 29.0)	1.9 (-36.2 to 59.1)	2.8 (1.6 to 4.1)	3.3 (1.3 to 3.4)	-17.0 (-50.2 to 34.9)	3.6 (-38.2 to 68.9)
Multiple sclerosis	2.6 (2.3 to 2.9)	3.2 (2.8 to 3.6)	22.3 (4.6 to 43.1)	30.1 (11.0 to 52.1)	0.9 (0.6 to 1.1)	1.1 (0.7 to 1.4)	21.3 (1.4 to 45.6)	29.5 (8.5 to 55.6)
Migraine	706.4 (641.3 to 764.8)	613.4 (559.9 to 672.5)	-13.0 (-23.6 to -1.7)	-6.6 (-13.1 to 12.7)	24.1 (14.3 to 35.2)	20.8 (12.4 to 30.7)	-13.5 (-24.3 to -0.2)	-0.5 (-13.1 to 13.7)
Tension-type headache	1,297.1 (1,144.9 to 1,314.7)	1,082.2 (969.0 to 1,198.8)	-16.2 (-23.2 to -0.1)	-16.2 (-11.9 to 14.4)	1.9 (0.9 to 3.2)	1.6 (0.8 to 2.9)	-12.2 (-23.6 to 12.2)	1.8 (-12.3 to 14.7)
Medication overuse headache	60.5 (39.8 to 81.2)	83.0 (55.5 to 113.2)	37.2 (5.6 to 73.1)	46.5 (15.3 to 84.2)	9.5 (5.4 to 15.0)	13.0 (7.3 to 20.1)	37.0 (15.3 to 73.9)	46.9 (15.1 to 86.4)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.1 (-32.5 to 29.2)	4.4 (-22.6 to 43.4)	1.0 (0.7 to 1.4)	0.7 (0.4 to 0.9)	-31.4 (-49.7 to -9.3)	-43.0 (-58.2 to -24.1)
Mental and substance use disorders	-	-	-	-	101.6 (71.2 to 136.8)	90.2 (63.5 to 122.4)	-11.3 (-14.1 to -8.0)	1.6 (-1.2 to 5.6)
Schizophrenia	13.5 (12.4 to 14.5)	12.3 (11.3 to 13.3)	-8.5 (-12.8 to -5.3)	-0.2 (-4.6 to 3.4)	8.6 (6.4 to 10.5)	7.9 (5.8 to 9.5)	-8.5 (-16.6 to -0.2)	0.2 (-6.2 to 5.8)
Alcohol use disorders	94.5 (85.4 to 104.1)	88.8 (81.1 to 97.2)	-5.9 (-11.4 to -0.6)	3.6 (-2.0 to 9.4)	9.4 (6.3 to 13.4)	8.9 (5.8 to 12.5)	-5.9 (-11.5 to -0.0)	3.9 (-2.3 to 10.1)
Drug use disorders	-	-	-	-	6.2 (4.4 to 8.0)	5.3 (3.7 to 6.9)	-14.1 (-25.3 to -2.3)	0.4 (-12.4 to 14.7)
Opioid use disorders	7.6 (6.5 to 8.7)	6.5 (5.5 to 7.5)	-15.2 (-20.9 to -8.8)	1.0 (-5.4 to 7.8)	3.2 (2.2 to 4.2)	2.7 (1.9 to 3.6)	-14.8 (-22.8 to -6.1)	1.6 (-8.1 to 11.9)
Cocaine use disorders	3.7 (2.9 to 4.5)	3.2 (2.4 to 4.1)	-14.6 (-39.8 to 21.6)	-1.6 (-31.5 to 39.5)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.7)	-6.4 (-17.7 to 24.9)	-0.6 (-34.3 to 44.2)
Amphetamine use disorders	6.8 (5.3 to 8.6)	6.0 (4.8 to 7.3)	-11.3 (-34.9 to 26.2)	0.1 (-26.5 to 45.2)	0.9 (0.5 to 1.4)	0.8 (0.5 to 1.2)	-9.2 (-23.6 to 28.2)	0.9 (-28.3 to 46.8)
Cannabis use disorders	6.9 (5.5 to 8.2)	5.8 (4.6 to 6.8)	-16.6 (-18.8 to -14.7)	0.2 (-0.2 to 0.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-16.7 (-28.3 to -2.2)	0.4 (-14.5 to 17.2)
Other drug use disorders	-	-	-	-	1.4 (0.9 to 2.1)	1.2 (0.7 to 1.9)	-13.9 (-40.4 to 22.6)	-1.3 (-31.9 to 40.7)
Depressive disorders	-	-	-	-	41.8 (24.7 to 64.6)	39.2 (23.3 to 60.5)	-6.4 (-12.9 to 2.1)	4.2 (-1.9 to 14.3)
Major depressive disorder	173.4 (105.6 to 244.2)	162.9 (104.7 to 224.8)	-6.2 (-14.0 to 4.0)	4.7 (-2.3 to 17.0)	4.7 (19.8 to 56.6)	4.7 (18.2 to 52.5)	-6.5 (-14.0 to 3.9)	5.0 (-2.3 to 17.3)
Dysthymia	65.8 (54.1 to 77.1)	61.8 (51.1 to 72.1)	-6.0 (-7.8 to -3.9)	-0.4 (-0.5 to -0.2)	6.3 (4.1 to 9.3)	5.9 (3.8 to 8.7)	-6.2 (-9.2 to -3.0)	-0.2 (-2.6 to 2.2)
Bipolar disorder	30.3 (26.6 to 34.3)	27.8 (24.5 to 31.1)	-8.4 (-12.5 to -3.5)	0.5 (-4.2 to 5.6)	6.2 (3.8 to 9.2)	5.6 (3.5 to 8.3)	-8.6 (-14.1 to -2.7)	0.6 (-5.8 to 6.9)
Anxiety disorders	112.6 (98.6 to 125.6)	95.6 (83.5 to 106.1)	-15.1 (-17.0 to -13.2)	-0.4 (-0.5 to -0.3)	10.3 (7.0 to 14.5)	8.7 (5.9 to 12.3)	-15.5 (-18.7 to -12.0)	-0.3 (-3.1 to 2.6)
Eating disorders	-	-	-	-	1.1 (0.7 to 1.6)	0.9 (0.5 to 1.4)	-9.4 (-17.0 to -1.9)	0.1 (-7.6 to 8.3)
Anorexia nervosa	0.5 (0.4 to 0.6)	0.4 (0.3 to 0.5)	-17.0 (-25.4 to -8.1)	7.3 (-2.3 to 18.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-17.0 (-36.0 to 7.1)	7.3 (-17.3 to 39.4)
Bulimia nervosa	4.5 (3.3 to 6.0)	3.7 (2.6 to 5.0)	-19.4 (-24.3 to -13.7)	-0.4 (-0.5 to -0.3)	1.0 (0.6 to 1.5)	0.8 (0.5 to 1.2)	-19.6 (-27.7 to -10.5)	0.7 (-8.7 to 8.0)
Autistic spectrum disorders	-	-	-	-	5.0 (3.5 to 6.8)	4.0 (2.7 to 5.4)	-21.6 (-24.0 to -18.9)	0.7 (-2.4 to 4.3)
Autism	13.0 (12.3 to 13.7)	10.2 (9.7 to 10.8)	-21.1 (-21.6 to -20.5)	0.5 (0.4 to 0.5)	3.2 (2.1 to 4.3)	2.5 (1.7 to 3.4)	-21.6 (-24.9 to -17.7)	0.6 (-3.9 to 5.6)
Asperger syndrome	18.4 (17.3 to 19.5)	14.5 (13.5 to 15.4)	-21.4 (-22.1 to -20.6)	0.6 (0.6 to 0.6)	1.8 (1.3 to 2.6)	1.4 (1.0 to 2.0)	-21.6 (-25.2 to -18.3)	0.9 (-3.4 to 4.8)
Attention-deficit/hyperactivity disorder	22.6 (20.8 to 24.4)	13.5 (12.4 to 14.5)	-40.4 (-41.2 to -40.1)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-40.5 (-45.0 to -36.0)	0.1 (-6.9 to 7.7)
Conduct disorder	33.0 (31.1 to 35.0)	18.6 (17.4 to 19.8)	-43.7 (-44.6 to -42.6)	0.1 (0.1 to 0.1)	4.0 (2.5 to 5.8)	2.3 (1.4 to 3.3)	-43.7 (-46.4 to -40.7)	0.1 (-4.3 to 5.0)
Idiopathic intellectual disability	67.9 (55.1 to 82.8)	46.7 (36.5 to 54.6)	-31.2 (-40.7 to -26.5)	-31.2 (-40.7 to -26.5)	3.1 (2.2 to 4.8)	2.2 (1.4 to 3.1)	-34.4 (-41.0 to -26.4)	-15.4 (-23.9 to -5.0)
Other mental and substance use disorders	71.0 (66.8 to 75.1)	68.9 (64.8 to 73.0)	-3.0 (-4.2 to -1.8)	0.3 (0.2 to 0.5)	5.3 (3.6 to 7.1)	5.1 (3.5 to 6.9)	-3.0 (-6.8 to 0.7)	0.6 (-1.1 to 4.2)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	36.2 (25.7 to 48.8)	35.3 (24.6 to 46.8)	-2.6 (-12.3 to 7.5)	6.1 (-4.0 to 16.5)
Diabetes mellitus	155.0 (123.4 to 185.0)	177.8 (143.4 to 215.4)	14.9 (-11.5 to 51.2)	20.8 (-6.1 to 59.3)	12.5 (8.3 to 17.8)	14.6 (9.3 to 20.8)	17.4 (8.9 to 51.9)	20.4 (-6.3 to 55.7)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.9 (-58.0 to -51.2)	-32.9 (-37.1 to -28.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.9 (-58.0 to -51.2)	-32.9 (-37.1 to -28.5)
Chronic kidney disease	-	-	-	-	9.4 (6.8 to 12.6)	8.2 (5.8 to 10.8)	-13.6 (-20.5 to -5.3)	-4.7 (-11.8 to 3.1)
Chronic kidney disease due to diabetes mellitus	49.5 (28.0 to 97.1)	45.6 (29.3 to 74.1)	-9.4 (-42.3 to 67.1)	-11.0 (-44.6 to 61.4)	1.1 (0.7 to 1.8)	1.3 (0.8 to 1.9)	9.3 (-21.0 to 76.8)	7.6 (-22.4 to 70.9)
Chronic kidney disease due to hypertension	121.3 (78.5 to 186.7)	99.6 (67.2 to 146.9)	-18.8 (-32.8 to 8.4)	-4.3 (-24.7 to 24.3)	3.5 (2.5 to 4.8)	1.4 (0.9 to 1.9)	-61.1 (-68.2 to -52.0)	-58.7 (-65.7 to -50.0)
Chronic kidney disease due to glomerulonephritis	146.5 (98.7 to 225.2)	62.4 (47.1 to 83.7)	-57.4 (-66.6 to -43.6)	-53.2 (-63.6 to -39.8)	2.8 (1.9 to 3.8)	2.9 (2.0 to 4.0)	5.0 (-14.9 to 35.6)	22.7 (0.7 to 56.1)
Chronic kidney disease due to other causes	89.6 (54.8 to 118.4)	98.6 (67.4 to 144.7)	10.3 (-16.8 to 64.4)	14.6 (-1.9 to 87.2)	2.6 (1.3 to 2.8)	2.6 (1.7 to 3.6)	29.6 (-0.3 to 92.5)	45.1 (13.9 to 113.7)
Urinary diseases and male infertility	-	-	-	-	3.5 (2.3 to 5.0)	4.0 (2.6 to 5.7)	13.8 (4.0 to 25.3)	4.6 (-4.1 to 14.6)
Interstitial nephritis and urinary tract infections	1.6 (1.5 to 1.7)	1.6 (1.5 to 1.7)	-2.0 (-11.1 to 6.9)	19.3 (8.0 to 30.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-2.2 (-17.7 to 16.0)	19.6 (0.4 to 41.3)

Appendix Table G.4 - Moldova prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Urolithiasis	24.0 (15.3 to 34.3)	26.5 (16.2 to 39.8)	7.6 (-7.5 to 31.3)	0.3 (-17.7 to 19.7)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	0.8 (-10.8 to 16.9)	-2.3 (-13.4 to 12.4)
Benign prostatic hyperplasia	80.1 (73.7 to 85.9)	93.5 (87.2 to 101.3)	16.7 (5.6 to 30.0)	4.2 (-5.4 to 15.7)	2.9 (1.9 to 4.1)	3.4 (2.2 to 4.8)	17.2 (6.1 to 31.1)	4.9 (-5.0 to 16.8)
Male infertility due to other causes	33.1 (26.1 to 40.8)	26.9 (21.9 to 32.3)	-18.4 (-39.0 to 9.9)	-0.5 (-25.0 to 34.3)	0.2 (0.1 to 0.5)	0.2 (0.1 to 0.4)	-17.9 (-39.1 to 12.9)	-0.7 (-26.3 to 36.0)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	51.9 (-25.9 to 99.1)	51.4 (-25.7 to 97.7)
Gynecological diseases	-	-	-	-	6.0 (3.9 to 9.0)	5.3 (3.4 to 7.9)	-11.4 (-21.8 to 11.0)	2.6 (-9.7 to 16.4)
Uterine fibroids	97.0 (88.1 to 105.2)	87.6 (80.1 to 94.8)	-9.7 (-10.7 to -8.6)	-1.2 (-1.3 to -1.2)	1.5 (0.9 to 2.5)	1.4 (0.8 to 2.3)	-9.6 (-14.7 to -5.7)	1.0 (-4.5 to 5.5)
Polycystic ovarian syndrome	79.2 (70.3 to 88.2)	65.6 (59.1 to 72.1)	-17.3 (-28.4 to -3.9)	-1.2 (-1.4 to 1.7)	0.8 (0.4 to 1.5)	0.6 (0.3 to 1.2)	-17.2 (-28.5 to -2.9)	-0.8 (-14.0 to 15.1)
Female infertility due to other causes	19.7 (12.1 to 27.9)	17.5 (12.6 to 23.0)	-10.0 (-44.7 to 47.6)	12.5 (-30.9 to 84.3)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-10.1 (-46.4 to 47.9)	11.7 (-33.7 to 84.1)
Endometriosis	8.5 (7.2 to 9.8)	7.4 (6.2 to 8.5)	-13.5 (-31.4 to 6.0)	2.5 (-18.1 to 25.1)	0.7 (0.5 to 1.1)	0.7 (0.5 to 1.0)	-13.4 (-32.4 to 7.9)	2.6 (-19.8 to 27.3)
Genital prolapse	237.3 (210.6 to 264.8)	224.0 (196.7 to 252.3)	-5.4 (-20.2 to 10.7)	-0.5 (-16.5 to 16.5)	0.8 (0.4 to 1.4)	0.7 (0.4 to 1.3)	-5.6 (-20.5 to 11.3)	0.5 (-16.9 to 16.9)
Premenstrual syndrome	176.9 (117.6 to 234.9)	156.8 (106.7 to 204.7)	-11.9 (-43.3 to 42.9)	1.5 (-32.7 to 70.4)	1.3 (0.8 to 2.4)	1.3 (0.7 to 2.1)	-11.8 (-43.9 to 44.8)	5.6 (-32.2 to 71.5)
Other gynecological diseases	17.3 (14.5 to 19.8)	15.3 (14.4 to 16.2)	-11.9 (-22.8 to 3.5)	2.1 (-10.6 to 19.7)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.7)	-11.6 (-22.7 to 20.1)	2.7 (-10.0 to 39.6)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	2.7 (1.8 to 3.9)	1.9 (1.3 to 2.7)	-31.4 (-37.6 to -25.5)	3.9 (-6.4 to 16.2)
Thalassemias	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-39.9 (-45.9 to -30.4)	3.1 (-7.1 to 18.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.2 (-53.7 to -15.8)	2.7 (-22.4 to 41.5)
Thalassemia trait	72.6 (68.4 to 77.7)	59.8 (55.8 to 63.8)	-17.5 (-20.7 to -14.9)	3.3 (-0.7 to 6.9)	2.0 (1.3 to 2.8)	1.4 (0.9 to 2.0)	-31.0 (-37.5 to -21.5)	6.6 (-4.5 to 21.2)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.1 (-37.4 to -11.1)	3.6 (-4.9 to 30.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.1 (-37.3 to -5.4)	4.1 (-7.1 to 35.7)
Sickle cell trait	2.1 (1.9 to 2.3)	1.6 (1.5 to 1.8)	-20.6 (-31.9 to -18.5)	-0.8 (-14.4 to 3.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.3 (-46.5 to -15.7)	-4.1 (-24.0 to 23.0)
G6PD deficiency	7.4 (6.6 to 8.3)	6.0 (5.6 to 6.4)	-18.8 (-28.8 to -7.8)	1.8 (-10.7 to 15.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.8 (-26.0 to 41.3)	58.5 (-20.6 to 98.7)
G6PD trait	459.0 (454.7 to 463.9)	367.8 (363.9 to 371.9)	-19.9 (-21.2 to -18.8)	-1.5 (-3.2 to -0.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.3 (-80.1 to 189.9)	21.6 (-70.7 to 322.2)
Other hemoglobinopathies and hemolytic anemias	23.2 (18.3 to 27.7)	17.9 (16.5 to 19.3)	-22.7 (-37.1 to 0.8)	3.6 (-15.9 to 33.4)	0.7 (0.4 to 1.0)	0.4 (0.3 to 0.7)	-33.3 (-52.7 to 6.3)	-4.3 (-33.4 to 52.5)
Endocrine, metabolic, blood, and immune disorders	60.9 (54.6 to 65.9)	41.0 (39.3 to 42.8)	-32.7 (-38.6 to -25.5)	-11.6 (-18.8 to -2.6)	2.1 (1.4 to 3.0)	1.3 (0.9 to 1.8)	-37.3 (-43.0 to -26.2)	-16.7 (-24.3 to -2.9)
Musculoskeletal disorders	-	-	-	-	95.6 (88.1 to 128.5)	97.1 (69.7 to 129.2)	2.0 (-6.3 to 9.3)	3.1 (-4.7 to 10.8)
Rheumatoid arthritis	15.5 (14.7 to 16.3)	15.7 (14.9 to 16.4)	1.4 (-6.0 to 9.6)	-1.7 (-8.7 to 6.3)	3.6 (2.6 to 4.8)	3.7 (2.6 to 4.9)	0.9 (-7.1 to 9.9)	-1.7 (-9.2 to 7.3)
Osteoarthritis	194.3 (185.8 to 202.8)	216.4 (207.6 to 225.3)	11.3 (5.2 to 18.3)	1.0 (-4.5 to 7.3)	11.9 (8.3 to 16.5)	13.3 (9.3 to 18.1)	11.4 (4.8 to 18.3)	1.4 (-4.4 to 7.5)
Low back and neck pain	-	-	-	-	69.0 (47.0 to 94.6)	69.4 (46.3 to 91.0)	-1.9 (-12.2 to 8.5)	1.9 (-8.4 to 12.5)
Low back pain	457.8 (417.0 to 493.8)	441.6 (406.7 to 478.7)	-3.4 (-14.3 to 8.0)	-0.7 (-11.6 to 11.4)	50.9 (34.5 to 71.9)	48.5 (33.0 to 67.4)	-4.6 (-14.4 to 7.8)	-0.4 (-11.3 to 11.8)
Neck pain	184.7 (144.2 to 216.5)	188.8 (160.5 to 221.9)	2.4 (-18.8 to 29.4)	7.8 (-13.7 to 35.7)	18.1 (11.5 to 25.5)	18.1 (12.3 to 26.3)	2.2 (-18.6 to 29.4)	8.1 (-13.6 to 36.3)
Gout	2.5 (2.4 to 2.7)	2.7 (2.5 to 2.9)	6.1 (-3.5 to 16.5)	1.0 (-8.2 to 10.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	5.8 (-13.9 to 30.9)	1.3 (-16.9 to 25.6)
Other musculoskeletal disorders	120.9 (95.0 to 146.1)	139.5 (112.6 to 170.2)	15.3 (6.2 to 24.5)	13.7 (5.8 to 22.1)	11.0 (7.2 to 15.8)	12.7 (8.4 to 18.2)	15.2 (6.1 to 25.0)	14.0 (5.9 to 22.7)
Other non-communicable diseases	-	-	-	-	67.7 (45.4 to 96.3)	61.3 (41.2 to 87.6)	-9.7 (-12.9 to -5.4)	-3.7 (-7.2 to 0.7)
Congenital anomalies	-	-	-	-	5.0 (3.6 to 6.6)	5.1 (3.6 to 6.8)	1.8 (-11.5 to 20.7)	27.5 (10.6 to 52.3)
Neural tube defects	1.0 (0.8 to 1.2)	0.7 (0.6 to 0.8)	-26.9 (-43.8 to -11.6)	1.6 (-21.5 to 23.0)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-27.6 (-48.5 to 5.4)	1.6 (-27.8 to 47.7)
Congenital heart anomalies	19.3 (16.3 to 22.9)	22.8 (18.5 to 28.2)	17.1 (-10.7 to 60.0)	54.0 (17.7 to 109.7)	0.7 (0.3 to 1.2)	0.8 (0.3 to 1.4)	17.4 (8.4 to 57.7)	57.5 (-23.1 to 111.3)
Crofacial clefts	2.6 (2.2 to 3.3)	3.4 (2.9 to 4.2)	30.1 (-2.1 to 71.1)	72.1 (29.6 to 126.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-7.4 (-34.7 to 35.6)	25.2 (-13.6 to 80.5)
Down syndrome	4.1 (3.4 to 4.9)	4.4 (3.6 to 5.3)	8.6 (-17.6 to 38.1)	30.7 (-0.4 to 66.2)	0.5 (0.4 to 0.7)	0.6 (0.5 to 0.8)	23.1 (-7.8 to 62.1)	39.6 (5.5 to 82.8)
Turner syndrome	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-18.3 (-41.8 to 24.5)	7.2 (-23.6 to 63.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.5 (-44.0 to 29.9)	7.0 (-27.3 to 66.3)
Klinefelter syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-16.8 (-39.9 to 14.2)	7.2 (-22.6 to 47.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.8 (-36.6 to 22.0)	6.9 (-22.9 to 46.6)
Chromosomal unbalanced rearrangements	6.0 (4.9 to 7.3)	6.4 (5.5 to 8.0)	6.9 (-17.3 to 42.8)	29.0 (0.1 to 71.1)	0.8 (0.5 to 1.1)	0.9 (0.7 to 1.3)	20.8 (-7.7 to 63.0)	37.4 (4.8 to 85.3)
Other congenital anomalies	20.0 (16.5 to 23.2)	14.3 (11.7 to 16.8)	-28.7 (-35.4 to -20.6)	28.7 (-23.7 to -6.0)	2.7 (1.8 to 3.7)	2.5 (1.6 to 3.5)	-9.7 (-24.7 to 18.0)	27.5 (-3.1 to 53.4)
Skin and subcutaneous diseases	-	-	-	-	21.0 (13.8 to 31.0)	17.0 (11.2 to 25.4)	-18.6 (-26.6 to -12.7)	-2.0 (-11.0 to 5.1)
Dermatitis	200.1 (163.8 to 239.2)	166.7 (136.5 to 198.5)	-16.7 (-18.3 to -15.1)	-0.0 (-0.1 to 0.0)	5.6 (3.5 to 8.2)	4.5 (2.8 to 6.5)	-19.2 (-22.7 to -15.8)	0.0 (-2.8 to 3.1)
Psoriasis	35.9 (31.7 to 40.1)	32.4 (28.6 to 36.1)	-9.8 (-11.1 to -8.0)	0.0 (-0.1 to 0.1)	2.9 (2.0 to 4.1)	2.6 (1.8 to 3.7)	-9.9 (-15.0 to -4.8)	3.3 (-5.0 to 5.9)
Cellulitis	2.4 (2.0 to 2.8)	1.9 (1.5 to 2.2)	-19.2 (-30.4 to -14.1)	23.0 (8.5 to 10.2)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-23.3 (-36.6 to -7.5)	0.4 (-15.8 to 20.8)
Pyoderma	5.4 (4.5 to 6.5)	5.7 (4.6 to 6.9)	4.5 (-2.2 to 10.6)	32.2 (26.0 to 37.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	3.7 (-6.0 to 12.9)	31.9 (-21.9 to 41.8)
Scabies	13.6 (11.7 to 15.8)	10.9 (8.9 to 13.2)	-20.4 (-37.4 to 2.4)	4.6 (-17.6 to 32.4)	0.4 (0.2 to 0.6)	0.3 (0.2 to 0.5)	-20.6 (-38.7 to 2.8)	4.5 (-19.1 to 34.2)
Fungal skin diseases	335.6 (261.1 to 442.2)	291.4 (227.7 to 381.0)	-13.1 (-17.0 to -9.1)	0.2 (0.0 to 0.3)	1.9 (0.8 to 4.1)	1.6 (0.7 to 3.5)	-13.3 (-17.4 to -9.3)	0.3 (-0.5 to 1.2)
Viral skin diseases	93.5 (72.7 to 114.3)	66.5 (49.1 to 84.5)	-29.0 (-33.7 to -24.4)	2.9 (-1.8 to 4.5)	2.1 (1.7 to 2.5)	2.1 (1.1 to 3.2)	-29.3 (-34.4 to -24.6)	0.2 (-3.1 to 3.3)
Acne vulgaris	134.6 (110.9 to 160.1)	101.4 (83.9 to 118.0)	-24.3 (-43.4 to -2.2)	0.8 (-24.1 to 29.4)	0.8 (0.7 to 2.8)	0.8 (0.5 to 2.1)	-24.2 (-43.4 to -2.7)	0.7 (-24.3 to 29.2)
Alopecia areata	5.0 (4.4 to 5.8)	4.5 (3.9 to 5.1)	-10.2 (-26.9 to 8.4)	1.5 (-17.3 to 21.8)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-10.5 (-29.8 to 9.6)	1.7 (-19.5 to 24.5)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	3.8 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	3.8 (-24.4 to 22.4)
Urticaria	64.0 (46.8 to 81.3)	47.5 (31.4 to 60.9)	-25.9 (-57.2 to 16.3)	3.1 (-50.8 to 33.3)	2.8 (2.2 to 5.7)	2.8 (1.5 to 4.4)	-24.2 (-57.5 to 17.0)	-12.9 (-50.7 to 35.5)
Decubitus ulcer	0.5 (0.4 to 0.6)	0.7 (0.6 to 0.9)	47.3 (4.3 to 102.8)	44.6 (-0.5 to 105.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	42.0 (-0.1 to 100.4)	41.6 (-4.6 to 103.7)
Other skin and subcutaneous diseases	283.2 (175.1 to 451.4)	269.9 (163.4 to 448.8)	-4.9 (-12.8 to 2.6)	-2.3 (-7.3 to 1.4)	1.7 (0.7 to 3.6)	1.6 (0.6 to 3.5)	-5.0 (-13.2 to 2.7)	-2.2 (-7.3 to 1.8)
Sense organ diseases	-	-	-	-	33.0 (21.6 to 47.7)	30.7 (20.5 to 44.3)	-6.9 (-12.1 to -0.9)	-9.4 (-14.2 to -4.0)
Glaucoma	5.2 (4.2 to 6.5)	4.8 (3.8 to 6.0)	-8.3 (-22.1 to 9.9)	-11.6 (-23.7 to 4.1)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-2.2 (-16.6 to 15.5)	-9.5 (-22.5 to 5.9)
Cataract	42.5 (32.6 to 52.4)	35.4 (25.4 to 44.6)	-16.2 (-31.0 to -3.8)	-8.1 (-41.2 to -19.1)	1.6 (1.0 to 2.4)	1.4 (0.8 to 2.1)	-14.9 (-28.3 to -4.3)	-27.7 (-39.3 to -15.7)
Macular degeneration	12.1 (8.9 to 16.3)	15.1 (11.3 to 19.3)	25.8 (-2.7 to 61.6)	12.7 (-12.8 to 43.7)	0.4 (0.3 to 0.7)	0.5 (0.3 to 0.8)	24.0 (-4.4 to 58.5)	10.0 (-15.5 to 40.5)
Uncorrected refractive error	396.0 (347.9 to 444.4)	384.8 (321.1 to 448.3)	-2.4 (-20.3 to 18.2)	-2.8 (-20.2 to 16.7)	6.2 (3.6 to 10.4)	5.6 (3.2 to 9.4)	-10.0 (-21.7 to 3.6)	-8.2 (-19.8 to 4.6)
Age-related and other hearing loss	718.2 (634.9 to 795.8)	697.7 (614.0 to 769.9)	-3.0 (-7.0 to 1.8)	-7.4 (-10.7 to -3.4)	20.6 (13.5 to 29.1)	20.0 (13.4 to 28.5)	-2.9 (-10.2 to 5.4)	-8.5 (-14.9 to -1.1)
Other vision loss	26.1 (21.4 to 32.0)	17.4 (14.3 to 21.1)	-33.7 (-41.7 to -22.4)	33.7 (-36.2 to -17.6)	1.2 (0.8 to 1.7)	1.2 (0.5 to 1.2)	-30.7 (-38.5 to -22.7)	-27.6 (-34.5 to -19.6)
Other sense organ diseases	103.4 (98.6 to 108.2)	82.9 (79.4 to 86.9)	-19.9 (-24.6 to -14.8)	0.3 (-5.6 to 6.8)	2.7 (1.7 to 4.1)	2.2 (1.3 to 3.2)	-20.6 (-25.7 to -14.5)	0.4 (-6.1 to 7.8)
Oral disorders	-	-	-	-	8.7 (5.3 to 13.5)	8.4 (5.1 to 12.8)	-4.1 (-8.1 to 0.2)	-2.4 (-6.3 to 1.5)
Deciduous caries	308.4 (293.0 to 323.8)	147.7 (139.3 to 155.8)	-52.1 (-55.5 to -48.9)	-0.4 (-7.3 to 6.5)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-52.1 (-56.6 to -47.1)	-0.3 (-9.9 to 9.9)
Permanent caries	1 937.1 (1 798.5 to 2 063.5)	1 570.9 (1 353.7 to 1 729.2)	-18.2 (-30.4 to -6.9)	-18.2 (-16.8 to 10.9)	2.9 (0.5 to 2.2)	2.1 (0.4 to 1.9)	-25.5 (-30.6 to -8.8)	2.7 (-16.8 to 11.2)
Periodontal diseases	262.1 (248.2 to 275.2)	262.8 (250.4 to 275.4)	0.2 (-6.3 to 7.3)	0.4 (-6.0 to 7.4)	1.7 (0.7 to 3.5)	1.7 (0.7 to 3.6)	0.2 (-6.1 to 7.4)	0.6 (-5.7 to 7.8)
Edentulism and severe tooth loss	128.2 (123.1 to 133.6)	134.4 (129.2 to 139.8)	4.8 (-1.3 to 10.9)	-4.9 (-10.1 to 0.3)	3.			

Appendix Table G.4 - Moldova prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.								
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	77.8 (73.9 to 82.0)	68.4 (64.5 to 72.2)	-12.2 (-19.3 to -4.8)	-8.8 (-8.3 to 7.4)	2.3 (1.4 to 3.4)	2.0 (1.3 to 3.0)	-13.3 (-19.6 to -5.0)	-0.5 (-8.6 to 7.7)
Injuries	-	-	-	-	31.3 (23.6 to 40.8)	17.9 (12.9 to 24.2)	-43.0 (-48.0 to -37.5)	-41.5 (-46.5 to -36.0)
Transport injuries	-	-	-	-	10.6 (8.0 to 13.8)	4.0 (2.8 to 5.5)	-62.7 (-67.1 to -57.3)	-61.0 (-65.5 to -55.4)
Road injuries	-	-	-	-	9.1 (6.8 to 11.8)	3.3 (2.3 to 4.5)	-63.9 (-68.4 to -58.5)	-62.1 (-66.6 to -56.6)
Pedestrian road injuries	-	-	-	-	2.1 (1.5 to 2.6)	0.7 (0.5 to 0.9)	-66.0 (-70.8 to -60.0)	-64.8 (-69.6 to -58.9)
Cyclist road injuries	-	-	-	-	1.3 (0.9 to 1.7)	0.5 (0.3 to 0.6)	-63.3 (-67.5 to -59.2)	-61.4 (-65.6 to -57.1)
Motorcyclist road injuries	-	-	-	-	0.9 (0.7 to 1.2)	0.4 (0.2 to 0.5)	-60.7 (-66.1 to -54.4)	-58.4 (-64.0 to -52.1)
Motor vehicle road injuries	-	-	-	-	4.8 (3.6 to 6.2)	1.7 (1.2 to 2.4)	-63.5 (-68.8 to -57.3)	-61.5 (-66.9 to -55.2)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-70.2 (-74.1 to -65.7)	-69.0 (-72.8 to -64.5)
Other transport injuries	-	-	-	-	1.6 (1.2 to 2.1)	0.7 (0.5 to 1.0)	-55.5 (-60.1 to -49.5)	-54.3 (-59.0 to -48.1)
Unintentional injuries	-	-	-	-	19.7 (14.9 to 25.6)	13.4 (9.7 to 18.1)	-32.3 (-37.4 to -27.1)	-31.4 (-36.4 to -26.1)
Falls	-	-	-	-	7.8 (5.8 to 10.0)	5.8 (4.1 to 7.8)	-25.9 (-33.6 to -17.7)	-28.8 (-36.2 to -20.7)
Drowning	-	-	-	-	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-58.8 (-64.4 to -52.2)	-56.4 (-62.2 to -49.7)
Fire, heat, and hot substances	-	-	-	-	0.9 (0.7 to 1.1)	0.6 (0.4 to 0.8)	-36.7 (-44.5 to -27.9)	-32.2 (-40.2 to -23.5)
Poisonings	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-47.0 (-53.6 to -39.8)	-39.2 (-46.8 to -30.5)
Exposure to mechanical forces	-	-	-	-	6.0 (4.5 to 7.9)	3.2 (2.3 to 4.4)	-46.7 (-50.3 to -42.7)	-42.8 (-46.2 to -38.7)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-64.2 (-69.9 to -57.5)	-60.6 (-66.2 to -53.5)
Unintentional suffocation	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-42.3 (-49.3 to -35.7)	-37.2 (-44.4 to -30.1)
Other exposure to mechanical forces	-	-	-	-	5.9 (4.4 to 7.7)	3.1 (2.3 to 4.3)	-46.5 (-49.9 to -42.3)	-42.5 (-45.9 to -38.4)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-2.0 (-9.1 to 5.2)	1.4 (-5.9 to 9.0)
Animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-24.8 (-31.2 to -16.9)	-17.0 (-23.5 to -9.3)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-22.7 (-30.9 to -13.1)	-13.8 (-23.3 to -2.9)
Non-venomous animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-25.8 (-32.9 to -16.9)	-18.5 (-25.8 to -9.9)
Foreign body	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-33.0 (-39.3 to -25.4)	-27.6 (-34.3 to -19.7)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-45.7 (-54.2 to -34.6)	-41.8 (-50.7 to -30.6)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-20.5 (-25.2 to -15.4)	-8.8 (-15.4 to -2.2)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-25.5 (-32.7 to -17.3)	-21.2 (-28.1 to -13.0)
Other unintentional injuries	-	-	-	-	4.0 (3.0 to 5.3)	3.2 (2.3 to 4.3)	-20.5 (-26.9 to -13.9)	-19.7 (-26.1 to -13.4)
Self-harm and interpersonal violence	-	-	-	-	0.9 (0.7 to 1.2)	0.5 (0.4 to 0.7)	-45.1 (-50.8 to -37.7)	-44.0 (-49.7 to -36.7)
Self-harm	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-34.6 (-41.3 to -26.7)	-33.8 (-40.5 to -25.8)
Interpersonal violence	-	-	-	-	0.5 (0.4 to 0.6)	0.2 (0.2 to 0.3)	-53.3 (-59.0 to -46.4)	-52.1 (-57.9 to -45.2)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-51.9 (-56.5 to -47.0)	-50.2 (-54.8 to -45.3)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-46.3 (-52.3 to -38.2)	-45.1 (-51.0 to -37.2)
Assault by other means	-	-	-	-	0.4 (0.3 to 0.5)	0.2 (0.1 to 0.2)	-54.9 (-60.9 to -47.8)	-53.8 (-59.7 to -46.7)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Mongolia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	170.4 (126.4 to 221.8)	246.9 (183.1 to 319.0)	44.9 (41.2 to 49.6)	44.9 (-5.0 to -0.3)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	21.6 (15.1 to 29.7)	22.5 (16.0 to 30.7)	3.9 (-3.0 to 14.9)	-8.2 (-13.7 to 0.4)
HIV/AIDS and tuberculosis	-	-	-	-	1.1 (0.8 to 1.5)	1.8 (1.2 to 2.4)	1.8 (44.9 to 69.4)	-1.2 (-7.7 to 5.5)
Tuberculosis	3.6 (3.4 to 3.7)	5.6 (5.4 to 5.9)	57.6 (51.3 to 65.5)	-0.9 (-4.6 to 3.2)	1.1 (0.8 to 1.5)	1.7 (1.2 to 2.4)	57.3 (45.4 to 69.4)	-1.0 (-7.5 to 5.4)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (92.9 to 645.5)	0.0 (95.7 to 308.5)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.7 (-97.4 to 499.6)	-74.9 (-98.5 to 231.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.7 (-97.4 to 500.7)	-74.9 (-98.5 to 231.6)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	30.0 (-87.1 to 899.1)	-23.1 (-91.6 to 470.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.6 (-94.1 to 701.0)	-54.5 (-96.5 to 348.3)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	4.0 (2.8 to 5.3)	3.7 (2.6 to 5.0)	-0.3 (-13.3 to -0.7)	-0.3 (-23.5 to -13.0)
Diarrheal diseases	11.1 (10.5 to 11.9)	10.6 (10.1 to 11.2)	-4.7 (-12.3 to 3.3)	-9.1 (-15.9 to -2.0)	1.8 (1.2 to 2.5)	1.7 (1.2 to 2.4)	-0.1 (-13.5 to 4.3)	-0.1 (-16.6 to -0.7)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (74.3 to 52.5)	0.0 (77.6 to 28.7)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.1 (-41.1 to -15.8)	-40.2 (-50.0 to -29.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.1 (-41.1 to -15.8)	-40.2 (-50.0 to -29.3)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.7 (-44.0 to -12.9)	-39.0 (-51.2 to -25.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.7 (-44.3 to -12.8)	-39.1 (-51.2 to -25.4)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (85.6 to 109.2)	0.0 (88.2 to 76.4)
Lower respiratory infections	1.7 (1.4 to 2.0)	1.2 (1.0 to 1.4)	-25.8 (-44.2 to -7.1)	-22.3 (-40.3 to -3.7)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-0.1 (-44.6 to -3.8)	-0.1 (-21.7 to -0.3)
Upper respiratory infections	38.8 (35.0 to 43.3)	48.3 (42.7 to 54.3)	24.2 (6.0 to 42.7)	0.1 (-14.1 to 14.8)	0.5 (0.3 to 0.8)	0.6 (0.3 to 1.0)	24.2 (6.0 to 43.8)	0.6 (-13.9 to 16.0)
Otitis media	28.7 (26.4 to 31.3)	32.4 (29.6 to 35.5)	13.2 (2.8 to 23.2)	-9.8 (-17.9 to -1.8)	0.6 (0.4 to 1.0)	0.7 (0.4 to 1.1)	9.7 (1.9 to 20.3)	-10.0 (-19.0 to -1.0)
Meningitis	-	-	-	-	0.6 (0.4 to 0.9)	0.4 (0.3 to 0.6)	-0.2 (-48.6 to -21.7)	-0.2 (-60.4 to -41.9)
Pneumococcal meningitis	2.2 (1.3 to 3.3)	1.8 (1.1 to 2.8)	-20.6 (-36.3 to -1.3)	-6.3 (-56.3 to -33.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-0.4 (-42.3 to 6.8)	-0.4 (-58.0 to -25.5)
H influenzae type B meningitis	1.6 (0.7 to 3.0)	0.9 (0.3 to 1.9)	-43.5 (-63.5 to -25.0)	-58.1 (-71.6 to -45.3)	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.2)	-0.1 (-67.7 to -16.3)	-0.1 (-74.3 to -34.1)
Meningococcal meningitis	0.5 (0.2 to 1.1)	0.4 (0.1 to 0.8)	-26.6 (-46.1 to 2.6)	-48.9 (-61.6 to -28.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-0.1 (-49.1 to 23.9)	-0.1 (-61.9 to -12.6)
Other meningitis	1.0 (0.6 to 1.5)	0.6 (0.3 to 1.0)	-42.5 (-54.7 to -26.2)	-56.6 (-64.1 to -44.5)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-0.5 (-56.2 to -25.4)	-0.5 (-65.3 to -42.5)
Encephalitis	0.8 (0.3 to 1.7)	0.8 (0.4 to 1.8)	0.9 (-10.9 to 24.5)	-21.1 (-35.1 to -10.3)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	0.1 (9.1 to 32.1)	0.1 (-32.5 to -2.3)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.6 (-98.2 to 242.3)	-73.4 (-97.9 to 143.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.6 (-98.2 to 245.9)	-73.4 (-97.9 to 146.9)
Whooping cough	3.0 (2.3 to 3.8)	0.5 (0.4 to 0.6)	-82.8 (-84.5 to -81.0)	-81.3 (-83.1 to -79.3)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.0)	-82.8 (-85.4 to -79.7)	-81.3 (-84.2 to -77.9)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.6 (-92.2 to -75.2)	-92.1 (-95.6 to -82.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-86.6 (-92.2 to -74.5)	-92.6 (-95.5 to -81.5)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -92.5)	-100.0 (-100.0 to -91.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -92.5)	-100.0 (-100.0 to -91.7)
Varicella and herpes zoster	1.6 (1.5 to 1.7)	1.7 (1.6 to 1.8)	3.6 (-2.9 to 13.8)	-0.7 (-9.5 to 10.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (4.8 to 64.8)	-1.0 (-20.8 to 25.5)
Neglected tropical diseases and malaria	-	-	-	-	2.0 (1.4 to 2.8)	1.0 (0.7 to 1.4)	-1.0 (-61.7 to -39.2)	-1.0 (-72.0 to -52.9)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.8 (-63.4 to 301.7)	0.0 (-68.2 to 245.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-62.7 to 311.7)	0.0 (-67.6 to 251.5)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.3 (-59.3 to 128.2)	-0.6 (-62.8 to 73.9)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.1 (-36.4 to 169.1)	-3.1 (-40.6 to 111.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.1 (-36.5 to 169.3)	-3.1 (-40.6 to 112.8)
Cutaneous and mucocutaneous leishmaniasis	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	22.8 (-72.0 to 117.4)	-0.9 (-73.8 to 67.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.6 (-73.9 to 147.1)	-2.3 (-74.5 to 83.3)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	1.7 (0.9 to 2.9)	0.5 (0.2 to 1.1)	-75.4 (-91.0 to -35.9)	-83.4 (-94.0 to -55.7)	0.5 (0.2 to 0.9)	0.1 (0.0 to 0.4)	-73.8 (-90.5 to -30.5)	-82.3 (-93.7 to -52.5)
Cystic echinococcosis	7.7 (6.9 to 8.7)	2.1 (1.9 to 2.5)	-72.6 (-75.6 to -66.6)	-80.7 (-82.7 to -77.0)	0.7 (0.5 to 1.0)	0.2 (0.1 to 0.3)	-72.6 (-76.5 to -66.1)	-80.8 (-83.1 to -76.8)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.4 (-85.5 to -29.0)	-72.8 (-83.5 to -44.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-74.4 (-85.6 to -28.9)	-72.8 (-83.5 to -44.2)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-60.4 to 147.6)	0.0 (-68.9 to 53.9)
Ascariasis	-	-	57.7 (-10.0 to 167.0)	-0.5 (-43.2 to 68.5)	-	-	-	-
Trichuriasis	-	-	59.0 (-11.9 to 184.3)	0.4 (-44.5 to 79.6)	-	-	-	-
Hookworm disease	1.4 (1.0 to 1.8)	2.1 (1.5 to 3.0)	56.3 (-3.5 to 141.1)	-1.3 (-39.1 to 52.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.9 (-60.4 to 147.6)	-28.5 (-68.9 to 53.9)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	23.3 (17.7 to 28.7)	19.2 (16.7 to 21.5)	-17.5 (-34.7 to 8.3)	-10.9 (-29.1 to 15.9)	0.8 (0.5 to 1.2)	0.6 (0.4 to 0.9)	-22.0 (-37.8 to 19.4)	-11.7 (-30.8 to 34.9)
Maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-0.1 (-42.7 to 15.0)	-0.1 (-62.6 to -27.1)
Maternal hemorrhage	1.2 (0.7 to 1.7)	1.3 (1.1 to 1.6)	10.3 (-20.2 to 70.1)	-30.5 (-49.1 to 4.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.2 (-58.3 to 79.5)	-41.3 (-72.7 to 17.2)
Maternal sepsis and other maternal infections	1.9 (1.2 to 2.7)	1.6 (1.0 to 2.4)	-16.1 (-34.8 to 27.1)	-55.2 (-65.4 to -26.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (-58.7 to 9.0)	0.0 (-72.7 to -35.2)
Maternal hypertensive disorders	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	1.6 (-16.1 to 19.6)	-33.4 (-44.1 to -22.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-35.0 to 38.5)	-1.4 (-56.2 to -9.6)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.2 (-27.5 to 41.5)	-34.5 (-52.2 to -10.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.2 (-27.8 to 41.5)	-34.5 (-52.3 to -10.0)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.8 (-10.6 to 26.5)	-32.3 (-42.8 to -19.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-51.3 to 133.3)	-32.5 (-66.1 to 35.9)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.0 (-52.7 to 65.2)	-44.1 (-69.1 to 4.5)
Neonatal disorders	-	-	-	-	1.7 (1.1 to 2.5)	5.1 (3.5 to 7.2)	199.9 (112.6 to 359.0)	151.4 (80.3 to 279.3)
Preterm birth complications	8.7 (5.8 to 12.6)	25.4 (18.8 to 34.4)	191.0 (140.5 to 264.0)	127.4 (89.1 to 183.1)	0.7 (0.5 to 1.1)	2.9 (2.0 to 4.1)	304.7 (164.4 to 489.5)	228.4 (118.5 to 375.7)
Neonatal encephalopathy due to birth asphyxia and trauma	3.8 (1.0 to 12.5)	4.7 (2.0 to 11.4)	36.3 (-25.0 to 188.7)	0.3 (-41.3 to 135.5)	0.4 (0.2 to 0.9)	1.0 (0.5 to 1.6)	135.9 (12.9 to 475.0)	110.1 (1.6 to 429.1)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.0 (56.6 to 89.0)	0.0 (-68.1 to 102.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.0 (43.3 to 108.7)	0.0 (53.9 to 124.0)
Hemolytic disease and other neonatal jaundice	1.1 (0.6 to 1.9)	2.3 (1.1 to 4.4)	99.8 (-24.2 to 392.7)	67.7 (-36.1 to 310.5)	0.4 (0.2 to 0.8)	0.9 (0.4 to 1.8)	102.4 (-24.6 to 385.9)	68.2 (-36.5 to 309.8)
Other neonatal disorders	-	-	-	-	0.1 (0.0 to 0.2)	0.3 (0.2 to 0.6)	219.9 (58.0 to 591.1)	166.4 (33.1 to 480.5)
Nutritional deficiencies	-	-	-	-	11.5 (7.5 to 16.9)	9.5 (6.3 to 14.0)	-17.3 (-24.3 to -9.7)	-18.1 (-24.0 to -10.4)
Protein-energy malnutrition	3.6 (1.6 to 6.9)	2.4 (0.9 to 5.1)	-32.4 (-79.2 to 99.0)	-26.8 (-77.4 to 114.7)	0.5 (0.2 to 1.0)	0.3 (0.2 to 0.7)	-0.3 (-79.7 to 99.0)	-0.3 (-77.9 to 115.5)
Iodine deficiency	40.1 (29.2 to 51.4)	31.7 (19.7 to 46.3)	-19.7 (-55.2 to 19.3)	-45.7 (-69.4 to -16.9)	0.7 (0.4 to 1.2)	0.6 (0.3 to 1.0)	-20.3 (-55.2 to 19.6)	-45.6 (-69.1 to -17.0)
Vitamin A deficiency	2.4 (2.0 to 2.9)	1.4 (1.1 to 1.7)	-42.8 (-49.3 to -34.0)	-50.9 (-56.0 to -44.6)	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-43.7 (-52.6 to -33.6)	-52.0 (-58.7 to -44.4)

Appendix Table G.4 - Mongolia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	305.2 (297.7 to 313.0)	280.7 (273.4 to 294.6)	-8.1 (-12.3 to -2.8)	-13.6 (-17.5 to -8.5)	10.0 (6.6 to 14.5)	8.5 (5.6 to 12.5)	-15.7 (-19.0 to -6.8)	-15.7 (-17.6 to -4.9)
Other nutritional deficiencies	-	-	-	-	0.2 (0.1 to 0.7)	0.1 (0.0 to 0.3)	-50.6 (-88.2 to 95.9)	-46.1 (-87.1 to 111.2)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.2 (0.8 to 1.9)	1.4 (0.9 to 2.3)	15.4 (3.7 to 33.8)	-9.0 (-17.3 to 0.7)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.5 (0.3 to 0.9)	0.8 (0.5 to 1.4)	50.9 (30.8 to 79.1)	-3.1 (-14.3 to 12.2)
Syphilis	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	19.8 (-2.1 to 47.5)	36.1 (-38.0 to -12.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.6 (-6.2 to 67.6)	-25.5 (-44.6 to 2.3)
Chlamydial infection	67.0 (57.4 to 76.8)	103.9 (89.6 to 118.2)	54.3 (27.0 to 92.9)	0.8 (-15.6 to 24.6)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.7)	53.2 (25.4 to 92.2)	-0.5 (-17.3 to 22.5)
Gonococcal infection	14.3 (11.3 to 17.5)	19.6 (15.6 to 23.9)	37.6 (1.0 to 87.5)	-5.6 (-30.3 to 27.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	35.2 (7.5 to 89.2)	-7.1 (-36.2 to 29.5)
Trichomoniasis	30.5 (19.0 to 44.3)	46.5 (30.5 to 65.0)	49.1 (-10.6 to 184.6)	-7.7 (-40.5 to 60.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	46.6 (-18.4 to 201.6)	-8.0 (-45.5 to 73.2)
Genital herpes	263.2 (254.0 to 274.1)	447.7 (433.8 to 461.6)	70.5 (60.7 to 79.0)	1.2 (-5.7 to 8.1)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	66.7 (53.1 to 78.4)	-1.3 (-6.9 to 4.9)
Other sexually transmitted diseases	0.5 (0.4 to 0.7)	0.9 (0.7 to 1.2)	70.9 (45.3 to 102.5)	-7.2 (-22.7 to 12.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.4 (15.2 to 115.1)	5.7 (-28.3 to 25.5)
Hepatitis	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	11.2 (-6.6 to 36.5)	-24.3 (-37.5 to -5.2)
Hepatitis A	3.4 (3.3 to 3.6)	3.5 (3.4 to 3.6)	2.8 (1.2 to 4.5)	-3.1 (-3.2 to -3.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	19.2 (5.8 to 34.6)	0.2 (-10.9 to 12.2)
Hepatitis B	221.0 (193.1 to 252.3)	201.6 (170.0 to 232.1)	-8.4 (-27.2 to 12.8)	-35.0 (-47.7 to -20.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	6.6 (-25.3 to 66.3)	-36.2 (-55.3 to 0.7)
Hepatitis C	169.7 (151.5 to 189.0)	186.5 (169.5 to 203.4)	10.1 (-4.8 to 26.5)	-27.5 (-36.6 to -18.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.1 (-19.3 to 38.7)	22.3 (-40.1 to 0.4)
Hepatitis E	0.3 (0.3 to 0.4)	0.3 (0.3 to 0.4)	8.6 (-5.8 to 34.1)	-26.3 (-36.8 to -8.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.3 (-21.3 to 56.7)	-26.2 (-47.6 to 3.0)
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	15.9 (12.6 to 19.0)	13.2 (11.4 to 15.0)	-16.6 (-30.3 to 2.4)	-12.1 (-26.6 to 7.6)	0.5 (0.3 to 0.8)	0.4 (0.3 to 0.6)	-19.0 (-37.8 to 9.2)	-9.2 (-31.6 to 22.3)
Non-communicable diseases	-	-	-	-	138.2 (99.0 to 174.6)	209.1 (154.4 to 269.0)	51.7 (50.9 to 61.5)	1.2 (-1.3 to 4.4)
Neoplasms	-	-	-	-	1.3 (0.9 to 1.7)	1.8 (1.3 to 2.5)	41.1 (18.7 to 76.3)	-7.0 (-20.1 to 11.8)
Esophageal cancer	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	44.0 (-1.5 to 109.9)	2.4 (-30.2 to 50.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	44.8 (8.1 to 99.3)	3.0 (-24.2 to 42.4)
Stomach cancer	1.0 (0.9 to 1.2)	1.3 (1.1 to 1.6)	28.2 (0.4 to 64.9)	-15.8 (-34.5 to 8.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	29.6 (20.0 to 66.0)	-13.6 (-31.9 to 8.4)
Liver cancer	-	-	-	-	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	110.0 (50.8 to 198.4)	42.9 (3.4 to 101.8)
Liver cancer due to hepatitis B	0.4 (0.2 to 0.5)	0.8 (0.5 to 1.1)	108.8 (24.9 to 256.5)	34.4 (-18.8 to 130.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	106.3 (40.8 to 220.2)	34.5 (-9.9 to 106.3)
Liver cancer due to hepatitis C	0.1 (0.1 to 0.2)	0.6 (0.4 to 0.9)	380.2 (168.0 to 712.0)	231.9 (82.5 to 460.6)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	362.3 (200.5 to 601.9)	217.0 (105.2 to 391.5)
Liver cancer due to alcohol use	0.4 (0.2 to 0.5)	0.7 (0.4 to 0.9)	75.5 (6.7 to 201.4)	24.0 (-25.7 to 114.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	72.4 (17.8 to 173.4)	21.2 (-17.3 to 94.5)
Liver cancer due to other causes	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	6.1 (-46.3 to 95.3)	-28.8 (-65.9 to 33.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.8 (-38.9 to 72.2)	-29.9 (-59.9 to 17.2)
Larynx cancer	0.1 (0.1 to 0.2)	0.1 (0.2 to 0.3)	77.6 (27.9 to 147.5)	16.6 (-14.8 to 65.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.4 (43.4 to 157.2)	31.8 (-5.5 to 78.2)
Tracheal, bronchus and lung cancer	0.5 (0.4 to 0.6)	0.5 (0.4 to 0.6)	8.4 (-14.7 to 39.7)	-21.7 (-37.3 to -0.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	10.7 (-12.6 to 39.9)	-20.2 (-35.5 to 0.7)
Breast cancer	0.5 (0.3 to 0.6)	1.5 (1.3 to 1.8)	226.1 (134.0 to 393.1)	115.4 (49.8 to 228.7)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	132.5 (67.4 to 243.3)	40.9 (3.2 to 110.4)
Cervical cancer	1.6 (1.1 to 2.1)	2.3 (1.6 to 3.3)	43.6 (-2.8 to 114.2)	40.9 (-4.7 to 15.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	44.2 (-3.1 to 110.4)	-20.1 (-44.3 to 17.4)
Uterine cancer	0.5 (0.3 to 0.8)	0.8 (0.5 to 1.2)	44.3 (-15.7 to 145.1)	-18.5 (-51.7 to 39.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	43.6 (-16.4 to 146.4)	-18.5 (-51.5 to 41.0)
Prostate cancer	0.3 (0.2 to 0.4)	0.6 (0.5 to 1.0)	118.8 (59.0 to 221.4)	53.1 (13.7 to 113.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	149.5 (71.1 to 305.8)	75.3 (23.2 to 181.1)
Colon and rectum cancer	0.8 (0.6 to 1.0)	0.8 (0.7 to 0.9)	-2.3 (-26.1 to 35.8)	-35.5 (-50.5 to -11.6)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-3.6 (-27.4 to 35.5)	-35.3 (-51.2 to -11.4)
Lip and oral cavity cancer	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.5)	1.1 (-33.8 to 124.2)	-34.4 (-56.9 to 44.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	1.4 (-32.9 to 48.6)	-33.9 (-57.2 to 48.6)
Nasopharynx cancer	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-19.6 (-53.2 to 61.0)	56.9 (-75.0 to -11.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.4 (-53.3 to 52.9)	57.2 (-74.0 to -16.4)
Other pharynx cancer	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-47.5 (-71.1 to 64.7)	46.0 (-80.9 to -0.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.7 (-67.1 to 70.6)	64.5 (-78.0 to 3.4)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.7 (-57.4 to 34.8)	-46.7 (-67.3 to -11.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.6 (-55.1 to 29.8)	46.3 (-65.7 to 14.0)
Pancreatic cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	58.8 (13.4 to 115.5)	7.3 (-21.3 to 43.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.9 (-22.8 to 104.9)	6.7 (-17.4 to 39.4)
Malignant skin melanoma	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	46.8 (-33.7 to 106.8)	1.3 (-33.7 to 21.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.6 (-56.8 to 101.7)	0.6 (-72.5 to 22.0)
Non-melanoma skin cancer	0.7 (0.5 to 0.9)	1.5 (1.2 to 1.9)	109.0 (56.9 to 196.8)	35.6 (-0.1 to 88.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	171.1 (92.3 to 270.0)	72.4 (12.5 to 136.4)
Ovarian cancer	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	89.7 (21.0 to 189.0)	9.3 (-29.8 to 65.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.9 (11.8 to 197.5)	7.8 (-35.9 to 70.9)
Testicular cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	460.8 (47.7 to 1,402.6)	203.7 (-26.4 to 688.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	431.8 (48.1 to 1,527.7)	196.9 (-27.5 to 760.2)
Kidney cancer	0.4 (0.1 to 0.2)	0.3 (0.2 to 0.3)	46.8 (7.4 to 99.9)	1.3 (-25.3 to 39.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.6 (8.0 to 99.4)	0.6 (-26.6 to 35.3)
Bladder cancer	1.4 (1.2 to 1.6)	1.2 (1.0 to 1.5)	-12.2 (-31.2 to 9.6)	-37.5 (-51.2 to -21.7)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-11.6 (-30.9 to 12.0)	-37.0 (-51.1 to -20.4)
Brain and nervous system cancer	0.1 (0.1 to 0.3)	0.4 (0.3 to 0.5)	234.5 (53.5 to 375.7)	157.2 (23.7 to 244.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	252.3 (70.3 to 392.1)	156.1 (20.4 to 238.9)
Thyroid cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	113.8 (41.0 to 224.0)	56.1 (-19.9 to 130.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.2 (38.1 to 248.7)	58.1 (-4.0 to 145.9)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.0 (-75.3 to -47.9)	0.0 (-83.2 to -64.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-65.6 (-74.6 to -43.0)	73.7 (-82.4 to -58.9)
Hodgkin lymphoma	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	48.2 (-9.3 to 160.5)	4.5 (-38.3 to 100.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.4 (-17.6 to 153.3)	-4.2 (-44.4 to 93.9)
Non-Hodgkin lymphoma	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	65.1 (11.7 to 168.6)	14.2 (-21.1 to 96.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.6 (14.0 to 167.3)	12.0 (-21.5 to 92.8)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.3 (-69.5 to 243.7)	-53.3 (-82.2 to 101.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.1 (-68.1 to 217.2)	-53.2 (-81.3 to 91.5)
Leukemia	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.1)	81.9 (8.4 to 212.2)	59.9 (4.9 to 153.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	79.0 (16.6 to 153.2)	98.1 (0.3 to 97.4)
Other neoplasms	1.6 (0.7 to 2.4)	1.6 (1.1 to 2.5)	25.0 (-50.1 to 211.2)	-54.3 (-69.1 to 90.0)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	-30.1 (-52.1 to 196.1)	57.3 (-70.7 to 80.9)
Cardiovascular diseases	-	-	-	-	1.5 (1.0 to 2.1)	1.9 (1.3 to 2.7)	25.6 (1.4 to 57.0)	-12.4 (-28.3 to 7.7)
Rheumatic heart disease	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.3)	40.6 (18.2 to 68.7)	-6.7 (-22.0 to 14.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.1 (14.3 to 96.8)	-3.4 (-25.2 to 28.0)
Ischemic heart disease	12.8 (10.9 to 14.8)	15.4 (13.8 to 17.4)	19.8 (1.1 to 49.8)	-12.2 (-25.8 to 5.3)	0.6 (0.4 to 0.9)	0.7 (0.5 to 1.0)	10.6 (-12.0 to 48.2)	-16.0 (-32.1 to 6.2)
Cerebrovascular disease	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	50.6 (19.9 to 80.8)	5.6 (-24.7 to 15.2)
Ischemic stroke	0.6 (0.5 to 0.6)	0.8 (0.7 to 1.0)	49.4 (18.1 to 94.7)	-3.9 (-24.5 to 28.6)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	51.2 (18.7 to 98.5)	-3.0 (-23.9 to 28.7)
Hemorrhagic stroke	0.6 (0.5 to 0.7)	0.8 (0.7 to 1.0)	46.9 (14.4 to 79.1)	-10.1 (-28.8 to 11.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	47.8 (13.2 to 84.1)	-9.8 (-29.9 to 12.8)
Hypertensive heart disease	1.5 (1.4 to 1.7)	2.0 (1.8 to 2.3)	33.4 (14.5 to 55.8)	-2.6 (-17.1 to 13.7)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	34.7 (14.2 to 59.9)	-2.0 (-17.1 to 14.8)
Cardiomyopathy and myocarditis	1.0 (0.9 to 1.1)	1.6 (1.4 to 1.7)	56.3 (34.6 to 82.3)	9.2 (-7.6 to 30.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	57.5 (31.4 to 89.1)	9.9 (-9.4 to 33.9)
Atrial fibrillation and flutter	0.2 (0.2 to 0.2)	1.0 (0.9 to 1.2)	447.9 (337.6 to 577.8)	148.5 (99.8 to 208.3)	0.0 (0.0 to 0.0)	0.0 (0.1 to 0.1)	455.8 (318.4 to 650.3)	151.7 (90.9 to 235.1)
Peripheral vascular disease	25.1 (19.4 to 31.4)	45.6 (32.6 to 59.3)	83.2 (19.0 to 138.1)	20.2 (-13.3 to 55.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	1.9 (-50.4 to 86.1)	-10.9 (-59.9 to 55.3)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.8 (-17.5 to 77.5)	-9.3 (-40.7 to 29.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.2 (-26.7 to 91.4)	-13.8 (-48.7 to 51.2)
Other cardiovascular and circulatory diseases	6.5 (3.1 to 9.1)	6.2 (3.2 to 10.5)	6.4 (-50.6 to 140.5)	-29.8 (-68.4 to 60.6)	0.4 (0.2 to 0.7)	0.4 (0.2 to 0.8)	5.9 (-50.7 to 145.3)	29.4 (-68.1 to 61.7)
Chronic respiratory diseases	-	-	-	-	5.4 (3.6 to 7.6)	7.5 (5.1 to 10.4)	40.4 (15.0 to 60.0)	-14.6 (-29.1 to -2.5)
Chronic obstructive pulmonary disease	54.5 (51.9 to 57.1)	87.8 (83.4 to 92.3)	61.0 (56.3 to 66.0)	-1.4 (-4.1 to 1.4)	3.4 (2.1 to 4.8)	5.2 (3.5 to 7.4)	56.1 (30.4 to 81.1)	-3.7 (-21.1 to 13.6)

Appendix Table G.4 - Mongolia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumonia	-	-	-	-	0.0	0.0	43.1	-12.6
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.1 (38.7 to 51.8)	-9.3 (-13.6 to -5.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.9 (37.4 to 46.9)	-9.4 (-15.3 to -10.0)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.3 (59.5 to 73.5)	-1.6 (-5.3 to 2.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.6 (59.9 to 73.8)	-1.7 (-5.5 to 2.1)
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.2 (23.3 to 36.8)	-3.1 (-22.7 to -4.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.6 (23.6 to 37.2)	-19.9 (-22.6 to -15.0)
Asthma	21.5 (15.4 to 29.4)	36.7 (27.1 to 48.7)	70.4 (41.1 to 175.2)	-2.8 (-33.6 to 44.9)	0.9 (0.5 to 1.5)	1.6 (1.0 to 2.5)	70.7 (31.1 to 177.8)	-2.5 (-34.1 to 47.8)
Interstitial lung disease and pulmonary sarcoidosis	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	57.7 (3.4 to 129.6)	-3.5 (-35.8 to 37.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	58.0 (4.6 to 128.6)	-3.6 (-34.7 to 37.2)
Other chronic respiratory diseases	-	-	-	-	1.0 (0.6 to 1.7)	0.6 (0.4 to 0.9)	-42.1 (-63.4 to -13.2)	-63.5 (-76.8 to -45.8)
Cirrhosis	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	85.1 (66.1 to 105.2)	25.7 (13.8 to 37.4)
Cirrhosis due to hepatitis B	0.6 (0.5 to 0.7)	1.1 (0.9 to 1.4)	85.3 (39.7 to 141.0)	23.7 (-3.8 to 62.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	83.7 (34.8 to 152.9)	23.8 (-6.0 to 67.3)
Cirrhosis due to hepatitis C	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	80.1 (17.6 to 181.2)	14.5 (-22.6 to 80.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	82.5 (9.9 to 196.2)	15.4 (-25.4 to 86.5)
Cirrhosis due to alcohol use	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	111.2 (26.9 to 271.4)	25.3 (-19.2 to 111.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	114.1 (21.1 to 292.1)	26.1 (-22.4 to 116.9)
Cirrhosis due to other causes	0.3 (0.2 to 0.3)	0.5 (0.4 to 0.6)	69.1 (24.0 to 122.5)	41.6 (5.3 to 84.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	65.8 (13.5 to 146.5)	39.8 (-3.1 to 101.7)
Digestive diseases	-	-	-	-	1.8 (1.3 to 2.5)	2.7 (1.9 to 3.6)	46.5 (28.1 to 67.3)	-4.7 (-17.0 to 7.2)
Peptic ulcer disease	13.2 (12.4 to 13.8)	15.0 (14.2 to 15.7)	13.2 (6.6 to 19.5)	-24.2 (-27.7 to -20.9)	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	0.5 (-9.0 to 12.0)	-32.9 (-37.7 to -26.6)
Gastritis and duodenitis	3.1 (2.7 to 3.4)	3.6 (3.2 to 4.0)	16.8 (1.6 to 36.7)	4.1 (-7.0 to 17.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	6.6 (-13.7 to 28.9)	0.8 (-14.7 to 17.2)
Appendicitis	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.3)	12.3 (-12.3 to 56.8)	-5.9 (-24.8 to 27.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	13.9 (-23.0 to 71.0)	-4.4 (-33.7 to 40.4)
Paralytic ileus and intestinal obstruction	0.2 (0.0 to 0.6)	0.1 (0.0 to 0.2)	-38.0 (-89.3 to 95.1)	-14.0 (-86.7 to 82.6)	0.0 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-17.2 (-89.7 to 105.6)	-33.7 (-87.1 to 88.8)
Inguinal, femoral, and abdominal hernia	6.4 (5.2 to 8.0)	6.9 (5.9 to 8.0)	7.5 (-15.5 to 38.3)	-21.4 (-35.8 to -1.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	7.7 (-15.6 to 40.7)	-20.6 (-35.4 to 0.3)
Inflammatory bowel disease	2.0 (1.9 to 2.0)	4.5 (4.3 to 4.7)	127.3 (115.8 to 140.3)	34.7 (27.9 to 42.1)	0.4 (0.3 to 0.6)	1.0 (0.7 to 1.3)	128.1 (109.3 to 149.9)	35.4 (24.8 to 45.8)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.2 (7.5 to 115.8)	14.7 (-35.2 to 67.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.2 (-7.5 to 116.1)	14.7 (-35.3 to 68.1)
Gallbladder and biliary diseases	1.5 (1.3 to 1.7)	1.8 (1.5 to 2.1)	22.0 (-0.1 to 47.8)	-17.4 (-31.0 to 0.7)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	22.0 (1.8 to 50.9)	-17.4 (-32.1 to 1.9)
Pancreatitis	0.4 (0.4 to 0.4)	1.0 (0.9 to 1.0)	156.4 (138.9 to 174.8)	47.5 (38.1 to 58.0)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	158.3 (128.9 to 200.1)	48.1 (29.9 to 71.3)
Other digestive diseases	-	-	-	-	0.3 (0.2 to 0.7)	0.4 (0.3 to 0.6)	31.4 (-28.9 to 152.1)	-15.8 (-53.9 to 62.0)
Neurological disorders	-	-	-	-	16.1 (10.6 to 22.3)	26.0 (17.3 to 36.1)	61.3 (42.2 to 84.1)	8.6 (-2.8 to 21.1)
Alzheimer disease and other dementias	6.6 (5.8 to 7.5)	8.5 (7.6 to 9.5)	28.1 (7.9 to 53.2)	0.6 (-15.7 to 20.8)	0.9 (0.7 to 1.2)	1.2 (0.9 to 1.6)	28.6 (8.2 to 53.4)	1.3 (-15.8 to 23.2)
Parkinson disease	0.5 (0.4 to 0.6)	0.7 (0.6 to 0.8)	37.8 (29.9 to 46.0)	-0.7 (-5.5 to 5.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	40.1 (22.7 to 60.3)	0.3 (-11.4 to 13.7)
Epilepsy	8.7 (5.9 to 11.7)	11.8 (8.1 to 16.0)	36.0 (-18.0 to 117.2)	3.5 (-37.0 to 64.3)	2.8 (1.7 to 4.2)	4.0 (2.4 to 6.2)	46.3 (-9.9 to 136.1)	11.7 (-30.8 to 79.8)
Multiple sclerosis	0.4 (0.4 to 0.4)	0.9 (0.9 to 1.0)	131.6 (103.9 to 164.7)	26.2 (11.1 to 43.1)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	128.2 (84.4 to 184.6)	25.0 (1.0 to 52.6)
Migraine	281.4 (247.7 to 312.5)	495.0 (384.6 to 487.9)	75.4 (30.5 to 80.5)	1.7 (-13.0 to 15.3)	1.8 (0.9 to 14.3)	1.8 (8.8 to 22.2)	84.3 (29.9 to 80.0)	1.8 (-12.9 to 15.7)
Tension-type headache	433.7 (397.5 to 468.2)	670.1 (569.3 to 797.0)	54.7 (29.3 to 80.5)	1.3 (-13.7 to 17.2)	1.0 (0.3 to 1.2)	1.0 (0.5 to 1.8)	54.5 (28.3 to 81.9)	1.2 (-14.5 to 17.4)
Medication overuse headache	10.4 (7.0 to 13.9)	26.0 (17.7 to 35.0)	148.8 (101.0 to 207.7)	47.6 (19.4 to 81.8)	1.7 (0.9 to 2.6)	4.1 (2.4 to 6.5)	149.0 (98.4 to 213.4)	47.5 (19.0 to 83.4)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.7 (-3.1 to 89.9)	1.2 (-24.4 to 37.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	54.2 (18.9 to 102.9)	11.3 (-15.0 to 48.4)
Mental and substance use disorders	-	-	-	-	41.1 (29.3 to 54.2)	64.3 (46.3 to 83.9)	56.4 (51.9 to 61.4)	4.0 (1.4 to 6.3)
Schizophrenia	4.9 (4.5 to 5.3)	8.8 (8.0 to 9.6)	80.3 (71.0 to 88.9)	-0.3 (-4.6 to 3.7)	3.2 (2.3 to 3.9)	5.8 (4.2 to 7.0)	79.9 (67.9 to 93.4)	-0.0 (-5.8 to 6.2)
Alcohol use disorders	19.3 (16.7 to 22.2)	61.7 (55.8 to 68.9)	220.4 (187.2 to 255.5)	87.8 (70.9 to 105.4)	1.9 (1.3 to 2.8)	6.2 (4.1 to 9.0)	221.6 (186.6 to 257.6)	88.7 (70.5 to 107.2)
Drug use disorders	-	-	-	-	2.7 (1.8 to 3.6)	4.2 (2.9 to 5.7)	57.8 (38.8 to 79.9)	0.1 (-1.0 to 12.9)
Opioid use disorders	2.1 (1.6 to 2.8)	4.0 (2.9 to 5.1)	86.6 (68.5 to 107.3)	1.1 (-7.9 to 13.2)	0.9 (0.6 to 1.3)	1.7 (1.1 to 2.4)	85.8 (61.7 to 113.8)	1.2 (-10.4 to 16.2)
Cocaine use disorders	1.3 (1.3 to 1.9)	2.1 (2.1 to 2.8)	53.2 (24.0 to 85.5)	0.2 (-19.9 to 15.1)	0.3 (0.1 to 0.3)	0.3 (0.2 to 0.5)	52.2 (15.1 to 100.1)	-3.7 (-25.3 to 23.4)
Amphetamine use disorders	4.4 (4.0 to 4.8)	6.3 (5.8 to 6.8)	41.7 (26.6 to 59.1)	0.8 (-9.9 to 12.4)	0.6 (0.4 to 0.9)	0.8 (0.5 to 1.2)	41.4 (19.8 to 67.3)	0.7 (-14.1 to 18.4)
Cannabis use disorders	4.2 (3.8 to 4.6)	5.6 (5.2 to 6.1)	34.5 (32.2 to 36.9)	0.4 (0.3 to 0.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	33.7 (15.6 to 57.2)	0.1 (-12.5 to 16.4)
Other drug use disorders	-	-	-	-	0.8 (0.5 to 1.2)	1.2 (0.7 to 1.8)	43.3 (5.5 to 98.6)	-1.2 (-27.3 to 35.6)
Depressive disorders	-	-	-	-	15.3 (10.1 to 21.4)	23.8 (15.6 to 33.5)	55.8 (47.2 to 64.7)	1.1 (-4.4 to 5.9)
Major depressive disorder	62.3 (49.7 to 73.5)	96.0 (77.1 to 113.4)	54.1 (44.4 to 64.3)	1.2 (-4.6 to 6.3)	13.0 (8.3 to 18.6)	20.0 (12.7 to 28.7)	53.6 (43.6 to 63.6)	1.3 (-5.3 to 7.0)
Dysthymia	23.4 (19.0 to 27.4)	39.3 (32.0 to 46.0)	68.1 (61.8 to 74.5)	0.3 (0.1 to 0.4)	2.3 (1.5 to 3.3)	3.8 (2.4 to 5.6)	68.2 (60.4 to 75.9)	0.4 (-1.9 to 2.8)
Bipolar disorder	12.1 (10.2 to 13.9)	20.2 (17.5 to 23.1)	66.5 (56.9 to 78.1)	0.2 (-4.0 to 5.5)	2.5 (1.5 to 3.8)	4.2 (2.5 to 6.3)	66.7 (55.0 to 80.7)	0.4 (-5.6 to 7.1)
Anxiety disorders	60.0 (48.7 to 72.2)	85.7 (68.4 to 103.3)	42.6 (33.7 to 52.4)	0.1 (-0.1 to 0.2)	15.3 (3.7 to 8.2)	23.8 (5.3 to 11.6)	55.8 (24.7 to 53.7)	1.1 (-2.7 to 3.1)
Eating disorders	-	-	-	-	0.6 (0.4 to 0.9)	0.5 (0.5 to 1.3)	36.9 (32.4 to 50.3)	-0.6 (-8.3 to 8.5)
Anorexia nervosa	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	42.9 (29.0 to 57.8)	7.9 (-1.2 to 19.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	43.1 (3.4 to 95.2)	8.3 (-20.6 to 47.1)
Bulimia nervosa	2.6 (1.9 to 3.4)	3.5 (2.5 to 4.8)	36.7 (30.2 to 43.0)	-1.2 (-1.3 to -1.0)	0.5 (0.3 to 0.9)	0.7 (0.4 to 1.2)	36.3 (23.7 to 50.6)	-1.2 (-8.8 to 8.5)
Autistic spectrum disorders	-	-	-	-	2.6 (1.8 to 3.6)	3.4 (2.3 to 4.7)	25.0 (24.5 to 34.0)	0.2 (-2.9 to 3.5)
Autism	6.7 (6.3 to 7.0)	8.7 (8.2 to 9.1)	29.8 (29.0 to 30.7)	0.0 (-0.0 to 0.1)	1.7 (1.1 to 2.3)	2.2 (1.4 to 2.9)	29.2 (22.8 to 36.0)	0.1 (-4.1 to 5.1)
Asperger syndrome	9.6 (9.0 to 10.1)	12.4 (11.6 to 13.2)	29.3 (28.1 to 30.5)	1.0 (-0.0 to 0.1)	1.0 (0.7 to 1.3)	1.2 (0.9 to 1.8)	28.9 (23.1 to 34.9)	0.2 (-3.8 to 4.4)
Attention-deficit/hyperactivity disorder	15.8 (14.5 to 17.0)	15.3 (14.1 to 16.6)	-2.6 (-3.5 to -2.1)	0.7 (0.6 to 0.7)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-2.6 (-9.9 to 4.7)	0.8 (-6.7 to 5.5)
Conduct disorder	23.1 (21.8 to 24.5)	21.6 (20.3 to 22.9)	-6.7 (-7.6 to -5.7)	0.6 (0.6 to 0.6)	2.9 (1.8 to 4.1)	2.6 (1.7 to 3.8)	0.7 (-11.2 to -2.1)	0.7 (-4.0 to 5.5)
Idiopathic intellectual disability	32.3 (25.0 to 40.0)	31.0 (23.0 to 40.1)	-4.0 (-21.4 to 11.3)	-24.4 (-37.8 to -11.3)	1.6 (1.0 to 2.3)	1.5 (1.0 to 2.2)	4.1 (-21.3 to 11.0)	-24.2 (-38.0 to -11.5)
Other mental and substance use disorders	28.6 (26.6 to 30.5)	49.0 (45.8 to 51.9)	71.1 (69.0 to 73.4)	-0.3 (-0.5 to -0.1)	2.2 (1.5 to 2.9)	3.7 (2.5 to 5.0)	71.4 (63.9 to 78.4)	-0.1 (-3.7 to 3.3)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	15.1 (10.7 to 20.3)	25.6 (17.9 to 34.7)	70.4 (54.1 to 85.7)	9.6 (-1.4 to 21.4)
Diabetes mellitus	73.2 (60.9 to 84.2)	163.9 (141.5 to 187.2)	124.5 (79.8 to 174.6)	30.8 (4.5 to 66.2)	5.6 (3.7 to 7.9)	12.6 (8.3 to 17.6)	123.9 (79.0 to 172.3)	28.2 (4.0 to 61.7)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.5 (-39.8 to -30.9)	-40.8 (-43.7 to -37.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-39.8 to -30.9)	-35.5 (-43.8 to -37.2)
Chronic kidney disease	-	-	-	-	4.7 (3.4 to 6.3)	6.2 (4.4 to 8.2)	31.4 (14.5 to 49.0)	-7.2 (-17.1 to 4.4)
Chronic kidney disease due to diabetes mellitus	23.7 (14.5 to 39.5)	36.6 (23.0 to 61.8)	54.2 (6.7 to 127.4)	-4.9 (-34.8 to 47.3)	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.4)	77.6 (20.0 to 159.2)	5.6 (-26.5 to 58.7)
Chronic kidney disease due to hypertension	54.8 (30.4 to 79.3)	59.3 (33.6 to 90.6)	6.4 (-21.9 to 56.1)	-19.0 (-40.5 to 13.1)	1.2 (0.9 to 1.6)	0.6 (0.4 to 0.9)	47.7 (-61.8 to -28.7)	-64.6 (-72.7 to -52.9)
Chronic kidney disease due to glomerulonephritis	52.4 (31.9 to 81.3)	38.3 (29.0 to 59.1)	-25.7 (-44.8 to 0.5)	25.7 (-63.9 to -33.9)	1.3 (0.9 to 1.7)	1.8 (1.3 to 2.4)	39.1 (14.1 to 82.1)	3.7 (-14.0 to 32.5)
Chronic kidney disease due to other causes	72.9 (42.6 to 110.3)	109.1 (69.1 to 154.9)	49.8 (16.2 to 106.9)	18.5 (-7.1 to 53.3)	1.7 (1.2 to 2.3)	2.8 (1.9 to 3.8)	66.4 (36.1 to 110.3)	25.8 (4.5 to 54.9)
Urinary diseases and male infertility	-	-	-	-	0.9 (0.6 to 1.3)	1.3 (0.8 to 1.8)	41.0 (25.7 to 56.4)	-0.4 (-11.3 to 10.6)

Appendix Table G.4 - Mongolia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.6 (0.5 to 0.6)	0.9 (0.8 to 1.0)	61.1 (41.6 to 84.1)	27.4 (13.8 to 43.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.5 (26.4 to 104.4)	27.5 (1.5 to 56.2)
Urolithiasis	10.5 (8.3 to 14.0)	18.5 (14.2 to 25.7)	76.4 (55.4 to 105.6)	7.9 (4.4 to 21.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	74.5 (54.1 to 97.1)	8.8 (-1.8 to 20.1)
Benign prostatic hyperplasia	19.8 (18.0 to 21.6)	25.5 (23.2 to 27.3)	29.1 (12.6 to 46.0)	-3.3 (-15.6 to 8.9)	0.7 (0.5 to 1.0)	0.9 (0.6 to 1.3)	30.0 (13.3 to 46.7)	-2.9 (-15.3 to 9.4)
Male infertility due to other causes	10.3 (8.0 to 13.0)	18.4 (14.6 to 23.0)	77.2 (27.0 to 150.4)	3.4 (-26.9 to 45.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	76.9 (27.1 to 147.0)	3.5 (-26.0 to 45.3)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	245.5 (56.1 to 454.3)	112.4 (2.3 to 245.6)
Gynecological diseases	-	-	-	-	1.9 (1.2 to 2.9)	3.6 (2.3 to 5.5)	90.6 (65.3 to 122.7)	3.8 (-10.1 to 20.4)
Uterine fibroids	32.2 (29.0 to 35.1)	68.3 (62.1 to 74.1)	112.2 (109.3 to 115.2)	0.3 (0.1 to 0.4)	0.7 (0.2 to 0.6)	0.7 (0.4 to 1.2)	98.3 (79.3 to 117.9)	-0.9 (-10.1 to 8.3)
Polycystic ovarian syndrome	32.5 (28.8 to 36.1)	57.3 (51.4 to 63.6)	76.6 (52.2 to 103.4)	-3.1 (-15.0 to 10.1)	0.3 (0.1 to 0.6)	0.6 (0.3 to 1.1)	76.4 (52.5 to 101.7)	-2.7 (-14.5 to 10.8)
Female infertility due to other causes	6.4 (1.7 to 12.0)	12.7 (5.3 to 21.1)	102.2 (-25.9 to 642.3)	21.3 (-54.9 to 401.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	245.5 (26.5 to 560.4)	112.4 (-55.3 to 360.3)
Endometriosis	3.3 (2.8 to 3.9)	6.4 (5.3 to 7.3)	91.6 (53.0 to 135.9)	2.8 (-17.6 to 25.0)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	91.4 (50.3 to 136.9)	3.0 (-19.5 to 26.3)
Genital prolapse	81.0 (69.6 to 91.7)	145.2 (125.1 to 165.8)	79.3 (47.8 to 118.6)	0.7 (-15.8 to 19.2)	0.3 (0.1 to 0.5)	0.5 (0.2 to 0.9)	79.2 (47.5 to 120.7)	0.7 (-15.6 to 20.5)
Premenstrual syndrome	66.8 (46.8 to 88.8)	133.8 (93.2 to 175.6)	102.4 (29.3 to 226.3)	12.9 (-27.8 to 80.9)	0.6 (0.3 to 0.9)	1.1 (0.6 to 1.8)	100.7 (27.8 to 228.1)	13.4 (-28.1 to 81.2)
Other gynecological diseases	3.8 (3.3 to 4.6)	6.5 (5.6 to 7.4)	69.0 (32.7 to 107.0)	-3.2 (-28.7 to 19.1)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	92.1 (12.8 to 188.7)	0.7 (-43.1 to 51.3)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.9 (0.6 to 1.3)	0.9 (0.6 to 1.4)	3.8 (-14.7 to 5.6)	-4.8 (-14.7 to 5.6)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.2 (-1.2 to 43.5)	14.2 (-0.4 to 44.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.5 (1.7 to 50.0)	18.4 (2.5 to 50.7)
Thalassemia trait	19.8 (11.5 to 28.6)	26.0 (14.4 to 38.4)	31.0 (21.3 to 36.6)	1.2 (-5.6 to 5.3)	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.9)	13.5 (0.4 to 25.1)	-2.0 (-12.3 to 7.0)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.3 (11.7 to 309.3)	6.6 (-0.5 to 84.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.7 (-0.1 to 123.2)	-0.1 (-13.6 to 94.5)
Sickle cell trait	3.3 (2.2 to 3.9)	4.1 (3.4 to 4.9)	20.7 (8.9 to 90.8)	6.6 (-15.9 to 47.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.3 (-35.2 to 130.0)	18.9 (-39.3 to 86.6)
G6PD deficiency	3.5 (3.2 to 3.7)	5.2 (4.9 to 5.4)	49.3 (38.2 to 60.5)	14.8 (6.3 to 23.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.8 (18.5 to 23.5)	5.8 (3.4 to 8.2)
G6PD trait	246.8 (244.3 to 249.8)	321.5 (318.3 to 324.1)	30.2 (28.5 to 32.4)	0.8 (-0.5 to 2.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.5 (-62.0 to 218.7)	8.4 (-65.5 to 154.4)
Other hemoglobinopathies and hemolytic anemias	11.4 (10.0 to 12.8)	9.9 (8.9 to 10.9)	-13.1 (-25.8 to 2.4)	-18.5 (-29.7 to -5.3)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-16.5 (-33.5 to 12.1)	-12.6 (-31.5 to 13.7)
Endocrine, metabolic, blood, and immune disorders	27.9 (26.0 to 29.7)	27.6 (25.9 to 29.1)	-1.0 (-11.1 to 8.8)	-13.7 (-21.4 to -6.0)	1.0 (0.6 to 1.4)	1.0 (0.6 to 1.4)	9.8 (-15.0 to 11.3)	-12.3 (-23.1 to -2.8)
Musculoskeletal disorders	-	-	-	-	24.8 (17.2 to 33.4)	42.3 (29.4 to 57.0)	69.9 (41.3 to 99.5)	2.0 (-7.1 to 12.5)
Rheumatoid arthritis	2.5 (2.4 to 2.7)	4.4 (4.1 to 4.6)	73.7 (59.6 to 86.2)	18.9 (10.8 to 27.3)	0.6 (0.4 to 0.8)	1.1 (0.7 to 1.4)	72.7 (54.7 to 93.5)	18.7 (8.1 to 30.7)
Osteoarthritis	50.3 (48.2 to 52.6)	82.1 (78.7 to 85.6)	63.2 (52.3 to 73.3)	2.3 (-4.0 to 8.2)	3.1 (2.2 to 4.3)	5.1 (3.6 to 7.0)	64.5 (53.0 to 74.8)	2.6 (-4.1 to 8.5)
Low back and neck pain	-	-	-	-	18.4 (12.4 to 25.3)	30.8 (20.9 to 42.3)	67.4 (41.3 to 99.5)	0.1 (-12.5 to 15.6)
Low back pain	103.6 (90.2 to 118.0)	169.2 (146.9 to 190.4)	63.3 (36.1 to 94.3)	-0.5 (-14.2 to 17.1)	11.7 (7.7 to 16.5)	19.1 (12.8 to 27.3)	64.0 (36.3 to 95.3)	-0.1 (-14.2 to 17.8)
Neck pain	67.8 (53.7 to 81.2)	118.2 (98.2 to 140.6)	71.7 (32.0 to 139.3)	-0.6 (-21.7 to 34.1)	6.7 (4.3 to 9.7)	11.8 (7.6 to 16.9)	71.9 (32.1 to 140.4)	-0.7 (-21.6 to 34.9)
Gout	0.9 (0.9 to 1.0)	1.5 (1.4 to 1.6)	66.7 (53.7 to 81.3)	-1.7 (-9.2 to 6.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	68.5 (34.9 to 108.3)	-1.3 (-19.1 to 19.2)
Other musculoskeletal disorders	29.5 (22.1 to 36.6)	56.5 (43.2 to 70.7)	92.2 (77.3 to 109.2)	9.1 (1.0 to 17.7)	2.7 (1.7 to 4.0)	5.2 (3.3 to 7.7)	98.2 (77.2 to 111.2)	0.1 (0.9 to 18.7)
Other non-communicable diseases	-	-	-	-	26.7 (17.7 to 38.5)	36.4 (24.2 to 52.8)	36.4 (30.5 to 42.2)	-5.1 (-8.0 to -2.5)
Congenital anomalies	-	-	-	-	1.5 (1.0 to 2.0)	2.7 (1.9 to 3.5)	82.5 (50.8 to 122.6)	43.8 (19.9 to 74.8)
Neural tube defects	0.2 (0.2 to 0.3)	0.6 (0.5 to 0.7)	144.1 (87.7 to 215.3)	118.0 (67.4 to 182.5)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	159.7 (82.8 to 285.2)	137.1 (67.9 to 248.4)
Congenital heart anomalies	3.6 (2.6 to 4.9)	10.6 (8.9 to 13.1)	193.6 (113.7 to 321.4)	149.2 (81.3 to 257.1)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	180.4 (105.7 to 253.2)	139.1 (78.4 to 236.8)
Orofacial clefts	0.5 (0.3 to 0.6)	1.4 (1.1 to 1.7)	206.2 (107.0 to 400.7)	183.0 (89.5 to 368.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	148.4 (70.9 to 346.5)	148.3 (57.7 to 314.3)
Down syndrome	1.5 (1.2 to 1.8)	2.4 (2.0 to 3.0)	67.2 (27.7 to 118.3)	33.6 (0.9 to 75.4)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	73.2 (28.4 to 127.8)	36.0 (0.9 to 81.5)
Turner syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	49.5 (12.8 to 305.8)	17.4 (-11.4 to 61.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.5 (14.8 to 122.1)	18.0 (-12.2 to 67.9)
Klinefelter syndrome	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	39.5 (-1.8 to 87.0)	7.6 (-24.3 to 44.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.7 (16.5 to 123.2)	8.7 (-23.4 to 45.8)
Chromosomal unbalanced rearrangements	0.0 (1.8 to 2.9)	0.0 (3.0 to 4.4)	43.5 (23.3 to 119.6)	3.8 (-1.0 to 75.5)	0.0 (0.2 to 0.4)	0.0 (0.3 to 0.6)	3.8 (26.4 to 130.1)	33.9 (-1.3 to 79.7)
Other congenital anomalies	7.2 (6.1 to 8.4)	8.3 (7.2 to 9.5)	15.6 (1.4 to 30.5)	-15.1 (-24.8 to -4.7)	0.8 (0.5 to 1.2)	1.3 (0.9 to 1.8)	64.6 (23.2 to 129.9)	28.4 (-1.2 to 78.1)
Skin and subcutaneous diseases	-	-	-	-	8.8 (5.8 to 13.2)	11.9 (7.6 to 17.9)	34.6 (23.0 to 47.2)	-2.4 (-10.3 to 5.9)
Dermatitis	78.9 (64.4 to 94.4)	118.3 (94.3 to 144.5)	50.0 (42.5 to 56.4)	0.0 (-0.0 to 0.1)	2.0 (1.2 to 2.9)	2.8 (1.7 to 4.2)	44.4 (36.7 to 50.8)	0.2 (-2.6 to 3.0)
Psoriasis	14.7 (13.0 to 16.4)	22.5 (19.7 to 25.4)	52.9 (48.7 to 56.9)	0.0 (-0.1 to 0.1)	1.2 (0.8 to 1.7)	1.9 (1.2 to 2.6)	52.8 (42.2 to 63.3)	0.2 (-5.3 to 6.2)
Cellulitis	0.8 (0.6 to 1.0)	1.0 (0.8 to 1.2)	19.1 (1.6 to 36.0)	-5.9 (-17.3 to 7.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	18.2 (9.5 to 53.2)	-5.3 (-24.6 to 17.6)
Pyoderma	2.2 (1.9 to 2.7)	2.8 (2.3 to 3.5)	26.4 (17.7 to 37.1)	8.8 (4.3 to 13.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.4 (12.6 to 43.3)	9.2 (0.2 to 18.6)
Scabies	6.4 (5.5 to 7.6)	7.6 (6.5 to 8.8)	17.9 (-5.9 to 48.9)	-6.9 (-24.5 to 15.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	17.8 (-6.1 to 51.0)	-6.8 (-25.0 to 17.6)
Fungal skin diseases	148.4 (111.6 to 196.3)	210.2 (160.5 to 283.1)	41.8 (29.9 to 52.9)	0.0 (-0.1 to 0.2)	0.8 (0.3 to 1.8)	1.2 (0.5 to 2.7)	41.7 (28.5 to 52.7)	0.1 (-0.7 to 1.0)
Viral skin diseases	55.4 (43.2 to 66.7)	62.8 (46.7 to 78.9)	13.1 (4.9 to 20.6)	0.2 (-1.6 to 2.0)	1.7 (1.0 to 2.7)	2.0 (1.1 to 3.1)	12.8 (3.8 to 20.7)	0.2 (-3.1 to 3.5)
Acne vulgaris	61.2 (46.0 to 76.0)	77.1 (63.7 to 93.2)	26.2 (-6.4 to 73.2)	5.2 (-21.6 to 43.2)	0.7 (0.3 to 1.3)	0.8 (0.4 to 1.6)	26.3 (-6.7 to 73.8)	5.0 (-21.5 to 43.3)
Alopecia areata	2.1 (1.9 to 2.4)	3.1 (2.7 to 3.5)	45.6 (21.0 to 70.1)	0.3 (-15.7 to 17.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	45.7 (16.8 to 75.7)	1.0 (-18.1 to 20.6)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.5 (12.6 to 81.4)	3.8 (-25.2 to 21.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.5 (12.5 to 81.4)	-3.8 (-25.2 to 21.5)
Urticaria	25.9 (19.8 to 32.6)	33.4 (24.0 to 44.0)	29.2 (-20.7 to 103.8)	-12.4 (-41.2 to 31.5)	1.6 (1.0 to 2.3)	2.0 (1.2 to 3.2)	28.3 (-21.7 to 105.4)	-13.1 (-41.7 to 32.5)
Decubitus ulcer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	41.1 (10.1 to 80.7)	-2.6 (-23.8 to 33.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.8 (11.9 to 86.7)	-0.6 (-25.4 to 42.9)
Other skin and subcutaneous diseases	93.9 (63.5 to 141.1)	143.4 (96.8 to 204.7)	53.0 (37.5 to 70.8)	-1.3 (-5.1 to 2.6)	0.6 (0.2 to 1.2)	0.8 (0.4 to 1.7)	53.0 (37.2 to 71.4)	-1.0 (-5.2 to 2.7)
Sense organ diseases	-	-	-	-	12.4 (8.1 to 17.6)	15.8 (10.4 to 22.7)	28.0 (28.3 to 35.2)	-10.8 (-14.1 to -7.6)
Glaucoma	2.4 (2.1 to 2.8)	3.1 (2.7 to 3.6)	29.0 (12.2 to 45.0)	-19.5 (-32.1 to -6.7)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	25.6 (7.2 to 50.1)	-18.0 (-31.5 to -1.0)
Cataract	11.2 (8.7 to 13.7)	11.6 (9.2 to 13.8)	3.3 (-13.5 to 25.5)	-26.1 (-36.1 to -13.5)	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	0.8 (-13.9 to 23.3)	-27.2 (-36.2 to -13.7)
Macular degeneration	3.6 (2.7 to 4.8)	5.7 (4.4 to 7.1)	56.2 (20.9 to 101.7)	1.9 (-23.6 to 27.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	52.9 (19.1 to 96.8)	-0.0 (-23.0 to 23.5)
Uncorrected refractive error	151.9 (137.2 to 167.2)	205.5 (185.4 to 225.1)	34.5 (18.4 to 55.1)	6.9 (-18.1 to 5.8)	2.6 (1.5 to 4.1)	3.2 (1.9 to 5.2)	25.9 (15.4 to 39.2)	-11.6 (-19.4 to -3.2)
Age-related and other hearing loss	217.6 (190.4 to 242.9)	317.1 (271.7 to 358.4)	45.4 (37.5 to 55.5)	-7.9 (-11.3 to -3.8)	7.1 (4.6 to 10.0)	9.5 (6.1 to 13.6)	8.9 (22.1 to 46.1)	34.4 (-13.7 to -4.0)
Other vision loss	11.8 (10.3 to 13.5)	11.3 (10.0 to 13.0)	-4.2 (-12.8 to 7.2)	-34.4 (-40.0 to -24.4)	0.6 (0.4 to 0.9)	0.6 (0.4 to 0.9)	-5.3 (-17.5 to 5.6)	-34.4 (-41.5 to -25.4)
Other sense organ diseases	50.9 (48.2 to 53.4)	61.5 (58.4 to 64.9)	21.2 (11.7 to 30.2)	0.6 (-6.7 to 7.3)	1.4 (0.8 to 2.0)	1.6 (1.0 to 2.5)	20.6 (11.0 to 30.3)	0.7 (-6.8 to 8.1)
Oral disorders	-	-	-	-	4.1 (2.4 to 6.5)	6.0 (3.5 to 9.8)	48.5 (45.1 to 54.9)	-1.7 (-4.9 to 1.8)
Deciduous caries	258.6 (253.3 to 263.2)	256.8 (221.7 to 231.2)	-12.3 (-14.9 to -9.7)	0.3 (-2.6 to 3.2)	0.3 (0.1 to 0.2)	0.2 (0.0 to 0.2)	0.1 (-1.1 to 0.9)	0.1 (-5.5 to 6.5)
Permanent caries	1,119.5 (1,077.8 to 1,158.5)	1,562.5 (1,516.6 to 1,604.5)	39.4 (34.2 to 46.5)	-0.2 (-3.6 to 4.1)	1.1 (0.5 to 2.2)	1.6 (0.7 to 3.0)	39.1 (33.5 to 46.3)	-0.1 (-3.7 to 4.3)
Periodontal diseases	104.9 (99.6 to 110.5)	187.8 (177.5 to 198.1)	78.7 (65.6 to 93.8)	0.7 (-6.4 to 8.1)	0.5 (0.3 to 1.4)			

Appendix Table G.4 - Mongolia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	42.8 (41.0 to 44.5)	60.7 (57.7 to 63.6)	42.1 (33.2 to 50.9)	-4.8 (-10.2 to 0.7)	1.2 (0.8 to 1.6)	1.7 (1.1 to 2.3)	43.1 (33.7 to 52.3)	-4.5 (-10.0 to 1.4)
Other oral disorders	33.0 (30.9 to 35.1)	49.8 (47.0 to 52.6)	51.1 (39.2 to 63.7)	0.4 (-6.8 to 8.0)	15.2 (11.0 to 18.8)	15.2 (10.9 to 20.6)	50.7 (38.3 to 64.0)	0.4 (-7.1 to 8.8)
Injuries	-	-	-	-	14.5 (11.0 to 18.8)	15.2 (10.9 to 20.6)	5.0 (-9.3 to 18.3)	-32.3 (-40.8 to -23.9)
Transport injuries	-	-	-	-	2.4 (1.8 to 3.1)	2.4 (1.7 to 3.3)	-0.3 (-12.9 to 14.9)	-32.9 (-40.7 to -23.3)
Road injuries	-	-	-	-	2.2 (1.7 to 2.9)	2.0 (1.4 to 2.8)	-0.3 (-20.0 to 7.0)	-36.9 (-44.5 to -27.5)
Pedestrian road injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.4 (0.3 to 0.6)	-22.2 (-33.5 to -7.8)	-42.0 (-49.4 to -32.9)
Cyclist road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	8.0 (-4.6 to 21.2)	-24.8 (-33.0 to -15.9)
Motorcyclist road injuries	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	8.8 (-6.2 to 26.2)	-30.3 (-39.6 to -20.0)
Motor vehicle road injuries	-	-	-	-	1.3 (1.0 to 1.7)	1.2 (0.9 to 1.7)	6.1 (-18.4 to 10.3)	-37.1 (-45.4 to -28.8)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.3 (-31.5 to -9.3)	-45.9 (-52.5 to -38.3)
Other transport injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	76.6 (56.0 to 100.0)	4.4 (-7.4 to 18.7)
Unintentional injuries	-	-	-	-	10.8 (8.1 to 14.0)	12.4 (8.9 to 16.7)	14.6 (4.1 to 25.8)	-27.2 (-33.9 to -20.4)
Falls	-	-	-	-	7.2 (5.4 to 9.4)	8.3 (5.9 to 11.3)	15.3 (2.6 to 28.3)	-28.3 (-36.4 to -20.2)
Drowning	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-36.4 (-45.8 to -25.9)	-56.3 (-62.4 to -49.7)
Fire, heat, and hot substances	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.2)	-41.8 (-46.7 to -36.3)	-60.3 (-63.5 to -56.8)
Poisonings	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-9.9 (-23.8 to 7.2)	-38.7 (-47.0 to -28.2)
Exposure to mechanical forces	-	-	-	-	2.0 (1.5 to 2.6)	2.4 (1.7 to 3.2)	20.8 (11.2 to 30.6)	-19.7 (-25.3 to -14.5)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.7 (-22.6 to 8.9)	-39.7 (-49.0 to -29.4)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.1 (-3.0 to 25.6)	-21.6 (-29.6 to -13.0)
Other exposure to mechanical forces	-	-	-	-	1.9 (1.4 to 2.5)	2.3 (1.7 to 3.1)	21.5 (11.8 to 31.4)	-19.3 (-24.9 to -14.0)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.9 (36.8 to 56.0)	1.3 (-5.9 to 8.3)
Animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	19.0 (6.8 to 32.2)	-14.9 (-22.7 to -6.7)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	25.1 (8.1 to 44.7)	-12.7 (-23.8 to -1.0)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	15.4 (3.2 to 31.0)	-16.2 (-23.7 to -6.7)
Foreign body	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	4.5 (-5.7 to 16.3)	-27.2 (-33.7 to -19.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-24.7 (-37.2 to -8.5)	-44.1 (-52.4 to -33.6)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.3 (23.5 to 40.2)	-9.7 (-16.5 to -3.6)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	17.0 (4.3 to 30.8)	-21.6 (-28.9 to -13.4)
Other unintentional injuries	-	-	-	-	0.9 (0.7 to 1.2)	1.1 (0.8 to 1.5)	26.0 (16.4 to 36.2)	-18.1 (-23.6 to -11.8)
Self-harm and interpersonal violence	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	14.1 (3.3 to 28.0)	-33.0 (-39.1 to -25.3)
Self-harm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	20.7 (8.1 to 35.0)	-30.5 (-37.6 to -22.6)
Interpersonal violence	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	7.8 (5.0 to 24.6)	-35.3 (-42.7 to -25.9)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.9 (5.6 to 30.3)	-28.0 (-34.4 to -20.5)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.2 (4.5 to 38.6)	-29.3 (-37.5 to -18.0)
Assault by other means	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	4.3 (-8.8 to 22.3)	-37.5 (-45.0 to -27.2)
Forces of nature, war, and legal intervention	-	-	-	-	1.1 (0.3 to 2.7)	0.2 (0.1 to 0.4)	-84.2 (-93.6 to -62.9)	-87.3 (-94.7 to -70.9)
Exposure to forces of nature	-	-	-	-	1.1 (0.3 to 2.7)	0.2 (0.1 to 0.4)	-84.2 (-93.6 to -62.9)	-87.3 (-94.7 to -70.9)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Montenegro prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	65.7 (49.1 to 85.0)	73.2 (54.8 to 95.0)	11.5 (8.4 to 14.4)	4.3 (-6.8 to -1.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	4.8 (3.3 to 6.7)	4.4 (3.1 to 6.1)	-0.4 (-1.6 to 1.1)	0.9 (-7.7 to 10.6)
HIV/AIDS and tuberculosis	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	0.0 (-1.9 to 1.9)	17.6 (2.0 to 34.5)
Tuberculosis	0.2 (0.2 to 0.2)	0.3 (0.2 to 0.3)	36.1 (29.7 to 42.5)	15.3 (10.2 to 20.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	0.0 (-1.8 to 1.8)	15.7 (1.7 to 32.3)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.1 (-24.0 to 636.9)	122.1 (-33.6 to 555.8)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	171.4 (-22.4 to 762.2)	136.1 (-32.6 to 637.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	171.4 (-22.5 to 777.2)	136.1 (-33.5 to 654.1)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.1 (-36.0 to 557.5)	96.1 (-41.8 to 513.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	145.0 (-25.2 to 648.0)	121.7 (-34.0 to 581.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.5 (0.4 to 0.7)	0.2 (0.3 to 0.6)	-0.3 (-1.8 to -0.7)	-9.6 (-15.6 to -3.1)
Diarrheal diseases	1.6 (1.5 to 1.7)	1.4 (1.3 to 1.5)	-12.0 (-20.2 to -3.6)	-8.0 (-16.6 to 1.5)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-0.1 (-1.9 to -2.7)	-1.0 (-7.5 to 3.2)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-8.5 to -6.1)	-50.2 (-85.3 to -5.3)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.4 (-61.2 to -8.2)	-33.6 (-59.4 to -7.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-6.1 to -8.0)	-33.6 (-59.7 to -7.8)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.7 (-58.3 to -6.5)	-32.4 (-55.8 to -4.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-5.8 to -6.5)	-32.4 (-55.8 to -4.8)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-91.8 (-99.3 to 378.0)	-91.7 (-99.3 to 396.2)
Lower respiratory infections	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.3)	-16.8 (-43.4 to 26.4)	-16.3 (-41.0 to 26.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-17.1 (-43.7 to 28.3)	-15.6 (-43.2 to 28.9)
Upper respiratory infections	6.0 (5.7 to 6.3)	5.9 (5.6 to 6.1)	-1.8 (-8.7 to 4.7)	-0.1 (-7.3 to 6.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-2.2 (-10.0 to 5.7)	-0.3 (-8.3 to 7.8)
Otitis media	6.5 (6.1 to 7.0)	6.0 (5.5 to 6.4)	-9.2 (-15.2 to -1.3)	-6.0 (-12.0 to 1.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-0.1 (-1.9 to -3.4)	-7.4 (-14.8 to 0.7)
Meningitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.8 (-61.1 to -36.4)	-48.5 (-61.3 to -36.1)
Pneumococcal meningitis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	45.4 (-62.3 to -29.1)	50.7 (-65.9 to -36.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.9 (-62.6 to -22.6)	-46.0 (-63.6 to -25.0)
H influenzae type B meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.1 (-66.4 to -27.1)	-51.2 (-66.8 to -22.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-69.1 to -12.3)	-43.2 (-67.3 to -5.6)
Meningococcal meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.9 (-76.3 to -40.9)	-64.3 (-77.5 to -42.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-62.6 (-81.4 to -39.1)	-63.3 (-81.5 to -39.5)
Other meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.3 (-61.7 to -22.7)	-47.6 (-63.7 to -25.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-65.9 to -13.3)	-43.8 (-66.1 to -13.2)
Encephalitis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-32.0 (-47.3 to -12.7)	-32.0 (-54.5 to -21.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.8 (-36.1 to -6.5)	-21.5 (-43.2 to -15.7)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.8 (-94.2 to 234.2)	-58.5 (-94.4 to 213.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.8 (-94.5 to 216.3)	-58.5 (-94.4 to 216.3)
Whooping cough	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-52.7 (-54.3 to -51.2)	-41.5 (-43.4 to -39.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.8 (-59.0 to -45.3)	-41.4 (-49.1 to -32.4)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.8 (-81.0 to -40.9)	-61.7 (-81.6 to -39.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-59.5 (-80.0 to -36.9)	-58.9 (-79.9 to -35.5)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -99.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -99.9)	-100.0 (-100.0 to -99.9)
Varicella and herpes zoster	0.3 (0.3 to 0.4)	0.3 (0.3 to 0.4)	-5.0 (-16.1 to 7.3)	-3.3 (-12.1 to 7.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.5 (-13.4 to 45.9)	-2.7 (-24.9 to 23.8)
Neglected tropical diseases and malaria	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-49.0 (-77.6 to 7.6)	-57.5 (-81.2 to -12.6)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.7 (-66.0 to 123.6)	-19.2 (-64.0 to 139.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.4 (-66.3 to 128.4)	-18.7 (-63.9 to 143.1)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.4 (-25.1 to 44.8)	10.4 (-23.2 to 55.9)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.0 (-24.9 to 47.0)	10.3 (-21.7 to 58.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.0 (-25.4 to 47.0)	10.3 (-22.1 to 59.8)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.7 (-51.1 to 115.7)	8.2 (-51.7 to 103.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.7 (-51.4 to 116.0)	8.2 (-51.7 to 103.1)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.1 (0.1 to 0.3)	0.0 (0.0 to 0.1)	-67.5 (-89.7 to -1.5)	-73.5 (-91.5 to -22.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-67.0 (-89.9 to 0.4)	-72.8 (-91.5 to -17.4)
Cystic echinococcosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	28.1 (7.5 to 39.4)	5.8 (-10.7 to 14.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.1 (-3.5 to 57.3)	4.4 (-19.7 to 29.3)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.0 (-42.1 to 13.9)	-18.8 (-45.5 to 11.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.0 (-42.2 to 14.1)	-18.8 (-45.6 to 12.1)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.8 (-65.4 to -15.0)	-43.3 (-63.3 to -8.2)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.3 (-41.2 to -3.9)	-18.1 (-36.0 to 3.4)
Maternal hemorrhage	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-27.6 (-46.0 to -2.0)	-21.1 (-41.2 to 6.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.2 (-74.0 to 29.0)	-40.4 (-71.6 to 38.6)
Maternal sepsis and other maternal infections	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-25.3 (-48.1 to -0.8)	-25.6 (-47.7 to -9.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.3 (-59.1 to 9.4)	-28.5 (-56.1 to 18.2)
Maternal hypertensive disorders	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-16.7 (-28.7 to 2.6)	-9.1 (-21.0 to 10.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.6 (-38.1 to 17.0)	-8.4 (-31.6 to 26.6)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.4 (-74.3 to 129.7)	-21.0 (-72.5 to 149.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.4 (-74.6 to 129.9)	-21.0 (-72.7 to 151.2)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.5 (-56.5 to 28.4)	-13.4 (-53.6 to 40.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.5 (-56.5 to 28.7)	-13.4 (-53.7 to 40.9)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.2 (-54.1 to 35.9)	-13.4 (-50.2 to 46.8)
Neonatal disorders	-	-	-	-	1.0 (0.6 to 1.5)	1.0 (0.7 to 1.5)	0.0 (-30.3 to 54.8)	9.9 (-27.6 to 60.2)
Preterm birth complications	3.4 (2.1 to 5.4)	3.8 (2.4 to 5.9)	10.2 (-14.9 to 47.9)	10.8 (-14.2 to 49.7)	0.4 (0.3 to 0.7)	0.5 (0.3 to 0.7)	22.8 (-21.6 to 90.0)	27.1 (-18.8 to 96.4)
Neonatal encephalopathy due to birth asphyxia and trauma	0.9 (0.5 to 1.7)	0.4 (0.2 to 0.9)	-53.4 (-76.3 to -12.1)	-51.5 (-74.8 to -8.1)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-49.6 (-74.8 to 1.6)	-46.3 (-73.3 to 9.5)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.5 (19.5 to 46.2)	63.3 (46.1 to 78.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.0 (-4.9 to 94.4)	61.4 (16.2 to 137.7)
Hemolytic disease and other neonatal jaundice	0.5 (0.2 to 0.8)	0.5 (0.3 to 1.0)	6.7 (-51.4 to 192.0)	9.9 (-50.2 to 202.8)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	6.8 (-51.3 to 189.9)	11.0 (-49.6 to 199.1)
Other neonatal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	29.8 (-47.5 to 216.5)	34.1 (-45.6 to 226.4)
Nutritional deficiencies	-	-	-	-	2.9 (2.0 to 4.3)	2.6 (1.7 to 3.8)	-11.3 (-15.9 to -7.1)	1.3 (-4.3 to 6.2)
Protein-energy malnutrition	0.7 (0.5 to 1.0)	0.5 (0.4 to 0.7)	-24.3 (-52.2 to 24.6)	-6.2 (-40.7 to 54.2)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-24.5 (-51.1 to 23.8)	6.5 (-41.8 to 53.3)
Iodine deficiency	5.9 (2.2 to 12.4)	4.3 (2.2 to 6.8)	-25.5 (-71.5 to 103.2)	-27.6 (-72.7 to 94.8)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-25.9 (-71.5 to 102.0)	-27.8 (-72.3 to 93.6)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-

Appendix Table G.4 - Montenegro prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	95.4 (94.2 to 96.7)	93.0 (91.7 to 94.3)	-2.5 (-4.5 to -0.4)	-2.5 (-0.3 to 4.7)	2.7 (1.8 to 3.9)	2.4 (1.6 to 3.5)	-9.6 (-12.5 to -7.2)	-3.2 (0.1 to 5.9)
Other nutritional deficiencies	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-0.1 (-0.2 to 0.1)	-0.1 (-0.2 to 0.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.4)	-12.1 (-23.3 to 3.4)	-3.0 (-17.0 to 14.6)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.2)	-0.5 (-15.2 to 9.9)	-4.7 (-16.1 to 8.7)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.2 (-2.1 to 36.8)	-10.8 (-24.4 to 4.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.1 (-13.8 to 54.0)	-11.1 (-33.1 to 17.3)
Chlamydial infection	14.8 (12.6 to 16.7)	14.0 (12.5 to 15.6)	-6.3 (-19.6 to 17.1)	-1.3 (-15.1 to 23.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-5.6 (-23.2 to 15.1)	-0.5 (-19.2 to 21.2)
Gonococcal infection	3.4 (2.7 to 4.2)	3.0 (2.4 to 3.6)	-13.6 (-36.6 to 22.5)	-4.8 (-30.2 to 35.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.9 (-43.9 to 19.9)	-12.0 (-38.2 to 31.9)
Trichomoniasis	7.0 (4.6 to 10.1)	6.5 (4.6 to 8.4)	-5.4 (-36.2 to 34.5)	-4.4 (-35.3 to 35.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.4 (-45.1 to 39.3)	-6.6 (-44.2 to 41.2)
Genital herpes	102.5 (92.9 to 112.0)	113.5 (102.9 to 125.5)	10.8 (-3.5 to 27.6)	6.5 (-18.3 to 7.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	5.4 (-5.4 to 25.3)	6.3 (-18.2 to 7.8)
Other sexually transmitted diseases	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-14.8 (-32.7 to 4.4)	-16.9 (-34.6 to 2.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.2 (-35.3 to 53.5)	-5.3 (-37.4 to 50.0)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.4 (-30.7 to -7.1)	-20.7 (-30.4 to -8.0)
Hepatitis A	0.6 (0.6 to 0.6)	0.5 (0.5 to 0.5)	-16.7 (-16.8 to -16.6)	-9.0 (-9.6 to -8.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.6 (-19.7 to 0.5)	-5.0 (-15.7 to 5.3)
Hepatitis B	16.1 (12.5 to 19.4)	10.8 (8.1 to 13.6)	-31.8 (-52.0 to -11.8)	-36.6 (-55.8 to -17.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.9 (-58.8 to -5.9)	-45.0 (-63.8 to -15.1)
Hepatitis C	10.0 (9.0 to 11.1)	8.9 (8.0 to 9.8)	-10.6 (-23.1 to 3.5)	-14.7 (-35.8 to -13.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.1 (-38.3 to 19.4)	-30.6 (-49.0 to -6.1)
Hepatitis E	-	-	-9.1 (-21.0 to 5.2)	-9.3 (-20.4 to 4.4)	-	-	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	4.0 (3.3 to 4.5)	3.6 (3.1 to 4.1)	-9.9 (-23.2 to 9.1)	2.4 (-15.1 to 25.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-17.1 (-38.9 to 15.3)	2.2 (-26.2 to 42.7)
Non-communicable diseases	-	-	-	-	53.2 (39.8 to 68.9)	62.4 (46.5 to 80.8)	17.4 (13.7 to 20.8)	0.3 (-3.3 to 2.6)
Neoplasms	-	-	-	-	0.8 (0.6 to 1.1)	0.8 (0.6 to 1.1)	6.5 (-7.5 to 22.5)	-26.0 (-35.3 to -14.9)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	144.0 (21.6 to 265.7)	68.4 (-15.6 to 152.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	134.2 (17.3 to 250.0)	59.5 (-19.2 to 138.6)
Stomach cancer	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	1.7 (-22.0 to 36.4)	-28.9 (-45.2 to -5.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.0 (-21.3 to 40.7)	-27.3 (-44.3 to -2.2)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.0 (-14.4 to 81.5)	-17.5 (-43.0 to 22.2)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.8 (-54.9 to 113.4)	-33.7 (-69.3 to 42.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.9 (-50.5 to 91.4)	-34.8 (-66.7 to 26.4)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	149.4 (30.7 to 378.1)	65.2 (-13.9 to 219.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	137.4 (40.3 to 299.5)	58.3 (-5.2 to 167.8)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.7 (-43.6 to 109.8)	-26.0 (-62.6 to 41.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.3 (-35.9 to 81.1)	-26.6 (-57.2 to 21.9)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.2 (-71.0 to 20.9)	-9.5 (-40.1 to -17.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.2 (-68.9 to 3.9)	40.5 (-78.6 to -29.2)
Larynx cancer	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-3.4 (-31.7 to 35.5)	-30.8 (-51.4 to -3.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.1 (-17.4 to 61.8)	-19.0 (-41.3 to 13.4)
Tracheal, bronchus and lung cancer	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.7)	45.0 (12.0 to 92.5)	-1.5 (-23.5 to 29.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	47.0 (13.4 to 90.8)	-0.2 (-22.6 to 29.6)
Breast cancer	0.6 (0.4 to 0.9)	2.5 (2.2 to 2.9)	309.2 (192.7 to 447.9)	194.0 (110.4 to 292.9)	0.2 (0.0 to 0.1)	0.2 (0.1 to 0.2)	130.7 (63.8 to 221.1)	66.4 (18.3 to 131.9)
Cervical cancer	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	29.1 (-18.5 to 101.4)	7.4 (-32.9 to 68.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.9 (-19.8 to 101.9)	8.9 (-33.0 to 71.3)
Uterine cancer	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	0.4 (-39.1 to 76.8)	-29.2 (-56.3 to 26.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.9 (-38.4 to 84.4)	-28.8 (-55.9 to 31.7)
Prostate cancer	0.5 (0.4 to 0.7)	1.4 (1.2 to 1.8)	156.6 (99.0 to 242.5)	62.9 (24.9 to 116.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	148.8 (87.4 to 239.0)	58.5 (19.3 to 114.7)
Colon and rectum cancer	3.1 (2.7 to 3.6)	0.9 (0.8 to 1.1)	-69.8 (-74.8 to -62.6)	-79.6 (-83.0 to -75.0)	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.1)	-68.6 (-74.3 to -60.4)	-78.8 (-82.8 to -73.4)
Lip and oral cavity cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	36.5 (-10.1 to 108.4)	-1.3 (-34.4 to 52.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.5 (-11.3 to 114.1)	0.3 (-33.9 to 53.7)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.1 (-48.1 to 36.7)	-11.1 (-57.4 to 7.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-45.8 to 31.4)	-11.6 (-56.3 to 1.9)
Other pharynx cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-63.4 (-82.1 to 108.3)	-73.2 (-86.8 to 53.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.3 (-80.2 to 108.1)	-73.4 (-85.4 to 54.0)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.6 (-27.0 to 109.7)	-8.9 (-50.2 to 41.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.5 (-26.0 to 102.5)	-8.9 (-49.9 to 40.3)
Pancreatic cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	58.5 (19.1 to 109.3)	6.6 (-19.8 to 40.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.9 (18.6 to 112.2)	7.8 (-19.6 to 44.0)
Malignant skin melanoma	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	60.0 (-3.2 to 164.9)	21.1 (-26.4 to 100.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.4 (-7.7 to 152.0)	16.9 (-30.1 to 97.4)
Non-melanoma skin cancer	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	105.8 (14.8 to 250.6)	43.7 (-20.3 to 144.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	132.6 (20.1 to 315.6)	65.2 (-14.5 to 203.2)
Ovarian cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	71.6 (12.7 to 160.6)	27.4 (-15.6 to 93.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.6 (7.9 to 169.9)	28.3 (-20.9 to 101.0)
Testicular cancer	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	25.0 (-9.5 to 34.0)	-23.6 (-58.4 to 39.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.8 (-60.0 to 36.6)	-24.6 (-59.3 to 38.4)
Kidney cancer	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	77.1 (15.8 to 162.0)	26.2 (-16.2 to 84.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.8 (17.1 to 163.3)	23.8 (-15.8 to 86.5)
Bladder cancer	0.9 (0.8 to 1.1)	0.6 (0.5 to 0.8)	-33.4 (-50.3 to -9.8)	-56.1 (-67.3 to -40.0)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-36.4 (-53.6 to -8.6)	-57.8 (-69.3 to -39.7)
Brain and nervous system cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	49.1 (13.3 to 95.0)	16.5 (-11.3 to 51.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.9 (10.3 to 92.7)	14.2 (-14.6 to 49.3)
Thyroid cancer	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	58.2 (0.3 to 144.2)	25.5 (-20.1 to 93.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.3 (-1.2 to 150.6)	24.7 (-21.3 to 95.0)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.2 (-72.5 to 43.8)	6.5 (-81.3 to 9.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.2 (-70.4 to 46.5)	66.3 (-79.7 to 3.5)
Hodgkin lymphoma	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	31.6 (-14.4 to 115.0)	12.6 (-27.1 to 79.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.9 (-5.5 to 110.7)	14.0 (-20.8 to 75.0)
Non-Hodgkin lymphoma	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	29.8 (-11.6 to 93.2)	-1.7 (-32.7 to 49.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.9 (-10.4 to 98.6)	-2.0 (-32.3 to 50.8)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.1 (-34.3 to 176.1)	-3.0 (-54.1 to 94.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.2 (-34.5 to 167.6)	-4.2 (-54.8 to 92.2)
Leukemia	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	0.1 (-25.2 to 40.0)	3.5 (-44.9 to 43.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.6 (-19.8 to 52.5)	-20.7 (-41.8 to 10.0)
Other neoplasms	0.3 (0.2 to 0.4)	0.3 (0.3 to 0.5)	13.0 (-31.8 to 129.3)	-4.8 (-45.4 to 101.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.2 (-28.6 to 125.1)	-6.3 (-43.0 to 92.6)
Cardiovascular diseases	-	-	-	-	1.1 (0.8 to 1.5)	1.7 (1.2 to 2.4)	60.1 (26.9 to 91.8)	10.5 (-11.8 to 32.5)
Rheumatic heart disease	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	43.7 (5.0 to 92.8)	1.8 (-25.5 to 35.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.0 (-2.0 to 98.6)	0.1 (-29.9 to 39.2)
Ischemic heart disease	7.1 (6.2 to 8.4)	10.1 (9.0 to 11.3)	41.6 (13.6 to 74.9)	4.3 (-22.5 to 17.1)	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	41.1 (9.0 to 84.0)	-5.1 (-25.0 to 22.8)
Cerebrovascular disease	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	41.4 (12.2 to 84.9)	2.9 (-17.9 to 33.7)
Ischemic stroke	0.7 (0.6 to 0.8)	1.0 (0.9 to 1.2)	45.0 (16.4 to 89.1)	3.2 (-16.7 to 34.1)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	44.8 (14.6 to 91.2)	3.4 (-18.1 to 36.8)
Hemorrhagic stroke	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.3)	31.3 (-2.4 to 81.2)	0.7 (-24.6 to 37.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	29.3 (-6.3 to 78.5)	-0.0 (-26.8 to 38.4)
Hypertensive heart disease	1.1 (1.0 to 1.2)	1.8 (1.6 to 2.0)	68.5 (45.3 to 94.6)	10.1 (-5.3 to 27.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	70.7 (46.2 to 98.8)	11.1 (-4.7 to 28.7)
Cardiomyopathy and myocarditis	1.2 (1.1 to 1.4)	1.4 (1.3 to 1.6)	16.8 (-1.0 to 38.4)	-23.1 (-34.7 to -8.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	17.6 (-1.3 to 39.6)	-22.7 (-35.0 to -8.0)
Atrial fibrillation and flutter	0.6 (0.6 to 0.7)	2.5 (2.1 to 2.9)	305.8 (229.6 to 379.9)	177.3 (126.3 to 227.0)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	311.4 (232.1 to 398.1)	182.1 (128.5 to 240.3)
Peripheral vascular disease	17.0 (12.7 to 21.7)	24.4 (19.0 to 32.7)	41.6 (5.7 to 117.4)	-3.8 (-28.8 to 48.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-31.1 (-71.8 to 69.2)	-52.4 (-80.9 to 16.7)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.9 (-11.4 to 87.4)	-1.0 (-30.9 to 43.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.7 (-13.8 to 84.4)	-5.2 (-31.8 to 41.7)
Other cardiovascular and circulatory diseases	0.4 (2.0 to 6.4)	6.0 (3.2 to 8.7)	85.5 (-26.6 to 233.4)	37.6 (-45.9 to 150.3)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.7)	87.1 (-26.7 to 234.7)	38.4 (-45.7 to 151.9)
Chronic respiratory diseases	-	-	-	-	2.8 (1.8 to 3.8)	3.0 (2.1 to 4.2)	9.5 (-9.1 to 34.4)	-13.9 (-29.3 to 6.6)
Chronic obstructive pulmonary disease	28.1 (26.9 to 29.4)	36.0 (34.3 to 37.5)	27.7 (24.3 to 31.6)	-0.9 (-3.4 to 1.9)	1.6 (1.1 to 2.3)	2.1 (1.4 to 3.0)	29.4 (9.3 to 58.8)	0.9 (-15.4 to 24.2)

Appendix Table G.4 - Montenegro prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	5.2	-22.5
					(0.0 to 0.0)	(0.0 to 0.0)	(-2.2 to 13.1)	(-27.6 to -17.0)
Silicosis	0.0	0.0	36.8	-1.7	0.0	0.0	37.3	-1.4
	(0.0 to 0.0)	(0.0 to 0.0)	(29.1 to 44.0)	(-7.3 to 3.3)	(0.0 to 0.0)	(0.0 to 0.0)	(29.7 to 44.7)	(-7.0 to 3.8)
Asbestosis	0.0	0.0	33.4	-2.3	0.0	0.0	34.1	-1.9
	(0.0 to 0.0)	(0.0 to 0.0)	(27.0 to 40.1)	(-7.1 to 2.2)	(0.0 to 0.0)	(0.0 to 0.0)	(27.5 to 40.8)	(-6.8 to 2.5)
Coal workers pneumoconiosis	-	-	0.0	-	0.0	-	-	-
			(0.0 to 0.0)	(0.0 to 0.0)				
Other pneumoconiosis	0.0	0.0	38.8	-9.5	0.0	0.0	-19.0	-39.2
	(0.0 to 0.0)	(0.0 to 0.0)	(-27.4 to -9.9)	(-44.6 to -33.5)	(0.0 to 0.0)	(0.0 to 0.0)	(-26.9 to -9.6)	(-44.3 to -33.1)
Asthma	13.7	16.4	20.0	-2.8	0.6	0.7	19.3	-2.6
	(10.2 to 17.4)	(12.9 to 20.0)	(-15.7 to 75.3)	(-32.1 to 43.7)	(0.4 to 0.9)	(0.4 to 1.0)	(-16.3 to 75.7)	(-32.8 to 43.9)
Interstitial lung disease and pulmonary sarcoidosis	0.1	0.1	33.1	6.1	0.0	0.0	33.0	5.7
	(0.1 to 0.1)	(0.1 to 0.1)	(-8.7 to 102.0)	(-26.8 to 61.7)	(0.0 to 0.0)	(0.0 to 0.0)	(-9.1 to 101.2)	(-26.6 to 60.7)
Other chronic respiratory diseases	-	-	-	-	0.5	0.2	-62.3	-70.9
					(0.3 to 0.8)	(0.1 to 0.3)	(-75.6 to -45.7)	(-81.3 to -57.8)
Cirrhosis	0.0	0.0	-	-	0.0	0.0	13.3	-13.3
					(0.0 to 0.0)	(0.0 to 0.0)	(-17.6 to 21.5)	(-27.5 to 5.7)
Cirrhosis due to hepatitis B	0.0	0.1	25.5	4.8	0.0	0.0	23.2	3.8
	(0.0 to 0.1)	(0.0 to 0.1)	(-22.3 to 90.4)	(-35.5 to 57.8)	(0.0 to 0.0)	(0.0 to 0.0)	(-30.3 to 109.6)	(-41.4 to 76.5)
Cirrhosis due to hepatitis C	0.1	0.1	-0.5	-16.3	0.0	0.0	-0.0	-15.6
	(0.0 to 0.1)	(0.0 to 0.1)	(-42.6 to 80.1)	(-51.9 to 49.5)	(0.0 to 0.0)	(0.0 to 0.0)	(-46.8 to 88.4)	(-54.6 to 56.1)
Cirrhosis due to alcohol use	0.1	0.0	-28.4	-44.7	0.0	0.0	-27.9	-44.1
	(0.0 to 0.1)	(0.0 to 0.1)	(-51.1 to 18.2)	(-61.9 to -7.6)	(0.0 to 0.0)	(0.0 to 0.0)	(-57.2 to 24.6)	(-66.2 to -3.4)
Cirrhosis due to other causes	0.1	0.1	1.7	1.9	0.0	0.0	0.5	1.6
	(0.0 to 0.1)	(0.0 to 0.1)	(-22.6 to 52.5)	(-21.4 to 50.5)	(0.0 to 0.0)	(0.0 to 0.0)	(-34.2 to 56.1)	(-33.1 to 54.3)
Digestive diseases	-	-	-	-	0.5	0.7	35.2	4.0
					(0.4 to 0.7)	(0.5 to 1.0)	(25.7 to 44.8)	(-4.0 to 11.9)
Peptic ulcer disease	3.6	3.2	-10.3	-38.7	0.1	0.1	3.3	-29.7
	(3.4 to 3.8)	(3.0 to 3.5)	(-17.4 to -1.2)	(-43.5 to -32.7)	(0.1 to 0.2)	(0.1 to 0.2)	(-7.8 to 17.4)	(-37.0 to -20.4)
Gastritis and duodenitis	0.2	0.2	9.8	-5.9	0.0	0.0	2.6	-11.3
	(0.2 to 0.2)	(0.2 to 0.3)	(-5.4 to 26.7)	(-20.9 to 10.8)	(0.0 to 0.0)	(0.0 to 0.0)	(-23.2 to 30.7)	(-35.8 to 16.1)
Appendicitis	0.0	0.0	-14.7	-9.3	0.0	0.0	-13.7	-7.9
	(0.0 to 0.0)	(0.0 to 0.0)	(-45.9 to 28.9)	(-44.4 to 45.0)	(0.0 to 0.0)	(0.0 to 0.0)	(-48.5 to 36.8)	(-47.5 to 51.1)
Paralytic ileus and intestinal obstruction	0.0	0.0	-16.1	-31.4	0.0	0.0	-16.8	-30.8
	(0.0 to 0.0)	(0.0 to 0.0)	(-45.8 to 21.0)	(-59.1 to 7.8)	(0.0 to 0.0)	(0.0 to 0.0)	(-49.8 to 26.6)	(-60.6 to 12.1)
Inguinal, femoral, and abdominal hernia	2.8	3.6	28.0	-7.9	0.0	0.0	28.0	-7.5
	(2.4 to 3.3)	(3.0 to 4.2)	(-1.1 to 62.7)	(-28.6 to 16.9)	(0.0 to 0.1)	(0.0 to 0.1)	(-1.0 to 62.6)	(-27.9 to 16.7)
Inflammatory bowel disease	0.8	1.4	73.1	42.7	0.2	0.3	72.6	43.3
	(0.7 to 0.8)	(1.3 to 1.4)	(62.3 to 83.1)	(34.1 to 50.5)	(0.1 to 0.2)	(0.2 to 0.4)	(58.3 to 86.5)	(32.0 to 55.3)
Vascular intestinal disorders	0.0	0.0	47.3	2.1	0.0	0.0	48.8	1.8
	(0.0 to 0.0)	(0.0 to 0.0)	(12.9 to 90.9)	(-20.6 to 32.1)	(0.0 to 0.0)	(0.0 to 0.0)	(-2.5 to 122.0)	(-34.7 to 54.6)
Gallbladder and biliary diseases	1.3	1.5	17.8	-2.4	0.1	0.2	17.8	-11.8
	(1.1 to 1.4)	(1.3 to 1.7)	(-3.5 to 41.6)	(-27.7 to 5.3)	(0.1 to 0.2)	(0.1 to 0.2)	(-4.5 to 41.0)	(-21.7 to 5.6)
Pancreatitis	0.1	0.2	63.6	30.1	0.0	0.1	64.2	31.3
	(0.1 to 0.1)	(0.2 to 0.2)	(50.7 to 78.7)	(19.6 to 42.1)	(0.0 to 0.1)	(0.0 to 0.1)	(39.9 to 96.1)	(12.2 to 56.4)
Other digestive diseases	-	-	-	-	0.0	0.0	81.7	40.2
					(0.0 to 0.0)	(0.0 to 0.0)	(15.8 to 154.7)	(-10.4 to 96.9)
Neurological disorders	-	-	-	-	5.8	7.0	20.2	7.3
					(4.0 to 8.0)	(4.8 to 9.6)	(6.8 to 34.8)	(-4.6 to 20.1)
Alzheimer disease and other dementias	5.0	7.2	45.0	-0.7	0.7	1.0	45.2	0.6
	(4.4 to 5.7)	(6.4 to 8.1)	(20.6 to 73.0)	(-17.4 to 18.1)	(0.5 to 0.9)	(0.7 to 1.4)	(20.5 to 74.6)	(-1.6 to 20.9)
Parkinson disease	0.4	0.5	51.9	-1.0	0.0	0.1	53.4	-0.0
	(0.2 to 0.5)	(0.4 to 0.7)	(39.1 to 65.7)	(-8.1 to 6.9)	(0.0 to 0.1)	(0.0 to 0.1)	(34.4 to 75.9)	(-11.4 to 13.8)
Epilepsy	3.0	2.8	-5.9	-9.5	0.9	0.8	-5.4	-7.4
	(2.0 to 4.3)	(1.8 to 4.1)	(-46.5 to 59.8)	(-48.6 to 54.7)	(0.5 to 1.4)	(0.4 to 1.3)	(-48.6 to 69.2)	(-50.8 to 65.6)
Multiple sclerosis	0.2	0.4	75.2	50.1	0.1	0.1	74.8	50.8
	(0.1 to 0.3)	(0.3 to 0.5)	(-1.6 to 173.4)	(-15.9 to 132.5)	(0.0 to 0.1)	(0.1 to 0.2)	(-1.5 to 176.8)	(-15.3 to 140.5)
Migraine	87.6	92.5	5.4	0.7	3.1	3.1	3.1	0.0
	(80.1 to 94.6)	(84.4 to 101.4)	(-6.7 to 18.3)	(-12.3 to 12.1)	(1.8 to 4.4)	(1.9 to 4.6)	(-7.1 to 18.4)	(-12.3 to 12.5)
Tension-type headache	114.6	121.7	6.2	0.2	0.2	0.2	6.3	0.7
	(103.7 to 126.2)	(111.2 to 131.8)	(-7.6 to 20.1)	(-12.7 to 13.0)	(0.1 to 0.3)	(0.1 to 0.3)	(-7.5 to 20.5)	(-12.4 to 14.3)
Medication overuse headache	5.9	10.3	74.7	53.9	0.9	1.6	74.7	55.1
	(3.9 to 8.1)	(6.8 to 14.4)	(36.7 to 135.4)	(20.5 to 106.5)	(0.5 to 1.4)	(0.9 to 2.5)	(36.8 to 136.8)	(21.0 to 108.7)
Other neurological disorders	0.0	0.0	21.8	6.8	0.0	0.0	-65.7	-75.9
	(0.0 to 0.0)	(0.0 to 0.0)	(-11.2 to 68.4)	(-20.0 to 45.2)	(0.0 to 0.1)	(0.0 to 0.0)	(-75.9 to -44.4)	(-83.0 to -60.7)
Mental and substance use disorders	-	-	-	-	12.8	13.3	3.5	-2.1
					(9.3 to 16.7)	(9.6 to 17.3)	(0.9 to 6.3)	(-4.4 to 0.1)
Schizophrenia	1.9	2.1	11.4	-1.1	1.2	1.4	11.2	-0.5
	(1.7 to 2.1)	(1.9 to 2.3)	(7.3 to 16.5)	(-4.6 to 3.5)	(0.9 to 1.5)	(1.0 to 1.6)	(4.4 to 18.2)	(-6.8 to 5.9)
Alcohol use disorders	4.9	4.0	-18.0	-24.7	0.5	0.4	-18.4	-24.7
	(4.3 to 5.5)	(3.5 to 4.6)	(-24.4 to -11.2)	(-30.6 to -18.6)	(0.3 to 0.7)	(0.3 to 0.6)	(-25.8 to -10.5)	(-31.7 to -17.3)
Drug use disorders	-	-	-	-	0.7	0.6	-9.7	-8.1
					(0.5 to 1.0)	(0.4 to 0.9)	(-23.8 to 5.9)	(-22.8 to 8.3)
Opioid use disorders	0.7	0.6	-3.2	-5.4	0.3	0.3	-3.6	-5.6
	(0.3 to 1.1)	(0.3 to 1.1)	(-15.1 to 12.0)	(-18.0 to 9.1)	(0.1 to 0.5)	(0.1 to 0.5)	(-1.9 to 13.9)	(-19.7 to 10.9)
Cocaine use disorders	0.4	0.4	-6.1	-4.9	0.1	0.1	-9.0	-5.3
	(0.3 to 0.5)	(0.3 to 0.5)	(-36.5 to 26.7)	(-37.2 to 30.0)	(0.0 to 0.1)	(0.0 to 0.1)	(-41.7 to 33.3)	(-41.2 to 35.7)
Amphetamine use disorders	1.1	0.9	-15.6	-11.9	0.1	0.1	-16.2	-12.2
	(0.9 to 1.3)	(0.8 to 1.1)	(-32.8 to 10.6)	(-30.3 to 15.9)	(0.1 to 0.2)	(0.1 to 0.2)	(-35.1 to 11.8)	(-32.2 to 17.7)
Cannabis use disorders	0.9	0.9	-8.1	-0.1	0.0	0.0	-8.5	-0.5
	(0.7 to 1.1)	(0.7 to 1.0)	(-9.5 to -6.2)	(-0.2 to -0.0)	(0.0 to 0.0)	(0.0 to 0.0)	(-20.3 to 8.2)	(-13.6 to 17.3)
Other drug use disorders	-	-	-	-	0.2	0.2	-14.6	-11.5
					(0.1 to 0.3)	(0.1 to 0.3)	(-39.0 to 22.1)	(-36.6 to 27.3)
Depressive disorders	-	-	-	-	4.8	5.2	9.1	0.3
					(3.3 to 6.6)	(3.6 to 7.3)	(3.7 to 15.4)	(-4.8 to 4.6)
Major depressive disorder	19.4	21.0	8.5	-0.7	4.0	4.3	7.8	-0.4
	(16.7 to 21.7)	(18.0 to 23.9)	(2.2 to 15.6)	(-5.7 to 4.9)	(2.6 to 5.5)	(2.8 to 6.0)	(1.4 to 15.4)	(-5.8 to 5.6)
Dysthymia	8.6	9.9	15.5	-0.3	0.8	0.9	15.1	-0.1
	(7.1 to 10.0)	(8.2 to 11.5)	(11.5 to 20.0)	(-0.5 to -0.2)	(0.5 to 1.2)	(0.6 to 1.4)	(10.4 to 20.3)	(-2.2 to 2.4)
Bipolar disorder	4.3	4.7	7.9	-2.0	0.9	0.9	7.1	-1.7
	(3.5 to 5.1)	(3.8 to 5.5)	(2.0 to 14.1)	(-7.1 to 3.7)	(0.5 to 1.3)	(0.6 to 1.4)	(0.2 to 14.8)	(-8.5 to 5.1)
Anxiety disorders	21.6	22.8	5.4	-0.4	2.0	2.1	9.0	0.0
	(18.1 to 25.1)	(19.2 to 26.2)	(2.3 to 8.8)	(-0.5 to -0.2)	(1.3 to 2.8)	(1.4 to 3.0)	(0.5 to 9.3)	(-2.6 to 2.6)
Eating disorders	-	-	-	-	0.2	0.1	-10.7	0.8
					(0.1 to 0.2)	(0.1 to 0.2)	(-17.9 to -2.8)	(-7.1 to 9.6)
Anorexia nervosa	0.1	0.1	-11.2	0.8	0.0	0.0	-10.3	1.6
	(0.1 to 0.1)	(0.1 to 0.1)	(-19.8 to -3.2)	(-9.0 to 9.5)	(0.0 to 0.0)	(0.0 to 0.0)	(-33.2 to 18.4)	(-23.7 to 34.4)
Bulimia nervosa	0.7	0.6	-10.6	0.8	0.1	0.1	-10.6	0.8
	(0.5 to 0.9)	(0.4 to 0.8)	(-12.1 to -9.1)	(0.6 to 1.0)	(0.1 to 0.2)	(0.1 to 0.2)	(-18.3 to -2.3)	(-7.6 to 10.0)
Autistic spectrum disorders	-	-	-	-	0.7	0.7	-0.7	0.6
					(0.5 to 1.0)	(0.5 to 1.0)	(-4.1 to 2.8)	(-2.8 to 3.9)
Autism	1.8	1.8	-0.1	0.3	0.5	0.5	-0.6	0.6
	(1.7 to 1.9)	(1.7 to 1.9)	(-0.8 to 0.6)	(0.3 to 0.4)	(0.3 to 0.6)	(0.3 to 0.6)	(-5.5 to 4.4)	(-4.3 to 5.5)
Asperger syndrome	2.6	2.6	-0.2	0.4	0.3	0.3	-0.7	0.6
	(2.5 to 2.8)	(2.5 to 2.8)	(-1.1 to 0.6)	(0.4 to 0.5)	(0.2 to 0.4)	(0.2 to 0.4)	(-4.8 to 3.3)	(-3.5 to 4.5)
Attention-deficit/hyperactivity disorder	3.3	2.6	-20.2	0.3	0.0	0.0	-20.2	0.3
	(3.0 to 3.5)	(2.4 to 2.8)	(-20.4 to -20.1)	(0.3 to 0.4)	(0.0 to 0.1)	(0.0 to 0.0)	(-26.3 to -14.0)	(-7.2 to 8.1)
Conduct disorder	4.8	3.1	-35.8	0.3	0.5	0.5	-20.7	0.5
	(4.5 to 5.1)	(3.6 to 4.0)	(-21.3 to -50.5)	(0.3 to 0.4)	(0.4 to 0.8)	(0.3 to 0.7)	(-24.6 to -17.3)	(-4.3 to 4.9)
Idiopathic intellectual disability	9.5	8.1	-14.7	-14.9	0.5	0.4	-15.1	-14.7
	(7.6 to 11.5)	(6.3 to 10.0)	(-25.0 to -4.9)	(-24.7 to -5.0)	(0.3 to 0.7)	(0.3 to 0.6)	(-25.1 to -5.0)	(-24.6 to -4.5)
Other mental and substance use disorders	10.6	11.9	11.7	0.2	0.8	0.9	11.3	0.5
	(10.0 to 11.3)	(11.2 to 12.6)	(10.1 to 13.2)	(-0.0 to 0.4)	(0.5 to 1.1)	(0.6 to 1.2)	(7.1 to 15.7)	(-3.1 to

Appendix Table G.4 - Montenegro prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	14.3 (9.1 to 48.2)	0.0 (-15.4 to 39.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.2 (-18.1 to 62.4)	12.2 (-22.7 to 55.7)
Urolithiasis	6.1 (4.7 to 8.0)	6.3 (4.5 to 8.6)	4.8 (-25.1 to 27.5)	-23.6 (-42.9 to -7.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	9.1 (-14.1 to 25.6)	9.1 (-32.8 to -5.5)
Benign prostatic hyperplasia	7.5 (6.4 to 8.4)	13.0 (11.0 to 14.8)	72.8 (41.2 to 114.4)	12.2 (-8.4 to 39.2)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	73.7 (42.4 to 116.7)	13.0 (-7.4 to 40.8)
Male infertility due to other causes	2.4 (1.8 to 3.0)	2.3 (1.7 to 3.1)	0.3 (-34.5 to 45.1)	7.2 (-30.3 to 55.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.2 (-35.2 to 41.7)	7.7 (-30.9 to 51.7)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-7.2 to 108.0)	0.0 (-27.7 to 61.1)
Gynecological diseases	-	-	-	-	0.7 (0.5 to 1.1)	0.8 (0.5 to 1.2)	6.2 (-7.0 to 23.0)	1.8 (-10.6 to 18.7)
Uterine fibroids	13.2 (12.1 to 14.4)	15.1 (13.8 to 16.3)	13.7 (12.7 to 14.8)	-0.6 (-0.8 to -0.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	14.3 (8.2 to 20.7)	4.0 (-0.9 to 10.2)
Polycystic ovarian syndrome	10.6 (9.6 to 11.6)	10.9 (9.8 to 12.1)	2.7 (-11.0 to 18.9)	0.9 (-12.6 to 16.9)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	2.7 (-11.5 to 18.5)	1.5 (-12.6 to 17.2)
Female infertility due to other causes	1.3 (0.4 to 2.6)	1.6 (0.3 to 3.2)	24.5 (-80.9 to 366.4)	30.5 (-79.8 to 392.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-80.4 to 348.4)	0.0 (-78.6 to 370.5)
Endometriosis	1.1 (0.9 to 1.3)	1.2 (1.1 to 1.4)	13.2 (-8.0 to 40.0)	9.4 (-11.3 to 34.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	13.3 (-10.0 to 41.8)	9.5 (-12.5 to 36.2)
Genital prolapse	32.2 (28.7 to 35.6)	37.1 (32.7 to 41.4)	15.4 (-2.1 to 36.0)	-0.4 (-16.0 to 18.1)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	15.3 (-2.3 to 36.5)	-0.0 (-16.3 to 19.3)
Premenstrual syndrome	23.3 (13.7 to 32.0)	22.3 (14.8 to 30.2)	-4.3 (-38.7 to 66.5)	-2.4 (-37.3 to 68.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-5.9 (-39.7 to 68.8)	-2.0 (-3.7 to 70.6)
Other gynecological diseases	2.0 (1.7 to 2.3)	2.0 (1.6 to 2.3)	-0.2 (-19.2 to 28.3)	-2.7 (-20.4 to 24.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-1.2 (-29.0 to 44.8)	-3.7 (-30.5 to 40.0)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.6 (0.4 to 0.9)	0.6 (0.4 to 0.8)	7.2 (-12.8 to 6.3)	-4.2 (-10.4 to 8.7)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.6 (-30.6 to -11.1)	0.2 (-13.4 to 10.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.4 (-42.6 to 37.9)	9.0 (-29.0 to 75.2)
Thalassemia trait	16.4 (12.4 to 21.1)	16.7 (12.5 to 21.5)	1.9 (-5.4 to 8.3)	-0.3 (-7.4 to 6.3)	0.4 (0.3 to 0.7)	0.4 (0.3 to 0.6)	-6.4 (-13.7 to 9.3)	-4.5 (-12.0 to 10.4)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.7 (-29.9 to 21.0)	9.7 (-19.9 to 37.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.6 (-39.5 to 53.0)	10.9 (-32.0 to 68.9)
Sickle cell trait	3.5 (1.7 to 5.6)	3.5 (1.7 to 5.6)	2.0 (-27.6 to 32.6)	0.1 (-28.7 to 30.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.5 (-44.4 to 12.5)	-19.2 (-39.1 to 22.9)
G6PD deficiency	7.3 (5.5 to 9.1)	6.1 (3.9 to 8.8)	-16.8 (-49.1 to 35.7)	-17.9 (-49.9 to 34.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-14.5 to 1.7)	4.9 (-13.6 to 10.0)
G6PD trait	82.4 (76.3 to 88.6)	84.2 (77.0 to 91.3)	2.2 (-7.7 to 14.5)	-1.4 (-11.0 to 10.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.2 (-58.3 to 63.1)	-15.6 (-53.4 to 70.9)
Other hemoglobinopathies and hemolytic anemias	4.8 (4.3 to 5.4)	5.2 (4.7 to 5.7)	9.0 (-4.9 to 28.6)	3.7 (-10.3 to 21.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-4.3 (-28.0 to 40.2)	1.9 (-21.5 to 46.1)
Endocrine, metabolic, blood, and immune disorders	8.0 (7.6 to 8.4)	4.0 (7.9 to 8.2)	-50.0 (-2.5 to 11.7)	0.3 (-5.3 to 8.5)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	0.9 (-8.9 to 9.9)	0.4 (-7.5 to 10.5)
Musculoskeletal disorders	-	-	-	-	14.0 (9.9 to 18.7)	17.4 (12.3 to 23.2)	24.8 (13.8 to 33.3)	1.5 (-7.3 to 8.0)
Rheumatoid arthritis	1.3 (1.2 to 1.4)	1.9 (1.7 to 2.0)	39.3 (25.3 to 51.8)	8.6 (-1.9 to 18.5)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	38.4 (23.4 to 52.9)	9.1 (-2.4 to 20.6)
Osteoarthritis	28.0 (26.9 to 29.0)	40.1 (38.6 to 41.6)	43.2 (35.9 to 51.3)	0.3 (-4.6 to 6.0)	1.7 (1.2 to 2.3)	2.4 (1.7 to 3.3)	43.8 (36.2 to 52.5)	0.9 (-4.3 to 6.9)
Low back and neck pain	-	-	-	-	10.9 (7.5 to 14.9)	13.0 (9.0 to 17.7)	19.4 (6.2 to 30.6)	0.3 (-10.6 to 9.0)
Low back pain	75.0 (69.4 to 81.0)	89.6 (81.3 to 96.9)	20.0 (4.2 to 32.1)	-0.1 (-13.1 to 9.9)	8.3 (5.6 to 11.6)	9.9 (6.7 to 13.7)	19.5 (3.8 to 31.8)	0.1 (-13.1 to 10.2)
Neck pain	26.5 (22.0 to 31.4)	31.8 (27.4 to 37.0)	20.3 (-2.7 to 46.9)	0.9 (-18.1 to 23.0)	2.6 (1.8 to 3.6)	3.1 (2.2 to 4.3)	19.9 (-3.3 to 46.6)	1.2 (-18.2 to 23.6)
Gout	0.3 (0.3 to 0.3)	0.4 (0.4 to 0.4)	39.9 (27.4 to 53.5)	2.6 (-6.3 to 12.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-9.5 to 74.9)	2.6 (-18.8 to 27.7)
Other musculoskeletal disorders	11.9 (8.4 to 15.4)	17.2 (13.0 to 21.4)	45.0 (19.8 to 61.8)	11.7 (1.4 to 24.1)	1.6 (0.7 to 1.6)	1.6 (1.0 to 2.3)	6.3 (-29.8 to 62.6)	0.4 (-1.6 to 25.3)
Other non-communicable diseases	-	-	-	-	9.5 (6.3 to 13.8)	11.0 (7.4 to 16.1)	15.5 (10.8 to 19.8)	0.0 (-7.4 to -0.5)
Congenital anomalies	-	-	-	-	0.6 (0.4 to 0.8)	0.8 (0.6 to 1.1)	35.5 (16.5 to 63.1)	30.4 (11.2 to 57.6)
Neural tube defects	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-0.2 (-23.5 to 30.2)	7.0 (-17.8 to 40.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	2.4 (-30.6 to 45.3)	10.1 (-25.5 to 57.0)
Congenital heart anomalies	3.0 (2.5 to 3.5)	3.4 (2.6 to 4.4)	13.4 (-14.5 to 61.0)	14.5 (-13.4 to 62.5)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	17.9 (-10.9 to 65.7)	20.3 (-9.2 to 68.2)
Orofacial clefts	0.5 (0.4 to 0.7)	0.6 (0.5 to 0.8)	18.5 (-13.8 to 64.3)	19.0 (-13.5 to 65.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.6 (-45.3 to 21.4)	-17.1 (-44.8 to 21.3)
Down syndrome	0.6 (0.4 to 0.7)	0.7 (0.6 to 0.9)	26.9 (-5.5 to 75.8)	17.5 (-12.5 to 63.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	40.5 (-2.2 to 98.8)	22.7 (-10.7 to 72.2)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.5 (-40.0 to 51.7)	2.6 (-38.3 to 56.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-42.5 to 57.7)	1.7 (-40.5 to 63.1)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.9 (-31.9 to 66.0)	10.2 (-31.6 to 66.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.3 (-31.7 to 68.5)	6.2 (-37.2 to 68.7)
Chromosomal unbalanced rearrangements	1.0 (0.8 to 1.3)	1.2 (1.0 to 1.5)	21.5 (-10.5 to 68.6)	2.5 (-17.0 to 55.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	0.2 (-3.1 to 87.5)	0.2 (-14.4 to 63.4)
Other congenital anomalies	2.0 (1.7 to 2.4)	2.0 (1.6 to 2.3)	-4.2 (-13.2 to 8.2)	-9.6 (-18.4 to 1.8)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	46.4 (13.1 to 105.6)	47.0 (13.6 to 107.9)
Skin and subcutaneous diseases	-	-	-	-	2.9 (1.9 to 4.3)	2.9 (1.9 to 4.3)	-1.3 (-8.8 to 6.3)	-5.3 (-12.6 to 1.7)
Dermatitis	28.3 (23.8 to 33.5)	29.4 (24.8 to 34.5)	4.1 (2.1 to 6.3)	-0.1 (-0.2 to 0.0)	0.7 (0.5 to 1.1)	0.8 (0.5 to 1.1)	2.3 (-1.3 to 6.4)	0.1 (-2.6 to 2.8)
Psoriasis	5.1 (4.5 to 5.7)	5.7 (5.0 to 6.4)	12.1 (9.5 to 15.4)	0.0 (-0.1 to 0.1)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.6)	11.5 (5.2 to 18.3)	0.2 (-4.9 to 5.9)
Cellulitis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	13.2 (0.0 to 27.1)	5.6 (-5.2 to 15.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.2 (-9.3 to 37.5)	5.2 (-13.0 to 29.6)
Pyoderma	0.7 (0.6 to 0.9)	0.7 (0.6 to 0.9)	0.1 (-6.8 to 6.9)	-5.6 (-10.9 to -1.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.1 (-10.2 to 9.8)	-5.2 (-13.4 to 2.7)
Scabies	1.2 (1.1 to 1.4)	1.0 (0.9 to 1.1)	-18.1 (-28.2 to -6.7)	-16.7 (-26.5 to -5.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-18.4 (-29.0 to 14.6)	-16.6 (-27.4 to -3.4)
Fungal skin diseases	48.2 (37.5 to 63.4)	52.5 (41.8 to 67.7)	8.7 (3.9 to 15.0)	8.7 (-0.1 to 10.3)	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.6)	6.4 (3.4 to 5.6)	0.3 (-0.2 to 1.2)
Viral skin diseases	12.9 (9.9 to 16.0)	11.5 (9.1 to 14.7)	-8.6 (-11.9 to -4.9)	0.1 (-1.8 to 1.9)	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.6)	-8.9 (-12.9 to -4.6)	0.5 (-2.8 to 3.5)
Acne vulgaris	16.3 (12.5 to 20.1)	15.5 (13.0 to 18.3)	-4.9 (-28.6 to 34.2)	8.3 (-19.2 to 54.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-4.8 (-29.0 to 35.0)	8.4 (-19.4 to 55.2)
Alopecia areata	0.7 (0.6 to 0.8)	0.8 (0.7 to 0.9)	15.5 (-3.9 to 37.2)	2.9 (-13.5 to 20.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.9 (-7.2 to 39.4)	3.2 (-16.5 to 25.6)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.4 (-13.5 to 58.7)	0.0 (-26.9 to 30.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.4 (-13.7 to 58.9)	-3.0 (-26.9 to 31.5)
Urticaria	10.6 (8.5 to 12.9)	8.4 (6.2 to 10.5)	-20.7 (-44.7 to 9.5)	-26.3 (-49.2 to 2.1)	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.7)	-21.1 (-45.2 to 10.3)	-25.8 (-49.4 to 3.6)
Decubitus ulcer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	49.8 (12.1 to 94.7)	14.5 (-14.1 to 46.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.4 (10.2 to 102.4)	14.7 (-14.5 to 54.3)
Other skin and subcutaneous diseases	40.4 (24.8 to 64.7)	48.9 (28.5 to 83.4)	20.2 (8.0 to 32.5)	-3.7 (-8.2 to 0.5)	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.6)	20.1 (7.6 to 32.6)	-3.4 (-7.9 to 0.1)
Sense organ diseases	-	-	-	-	4.6 (3.0 to 6.7)	5.5 (3.6 to 8.1)	20.1 (13.2 to 26.4)	-8.3 (-13.5 to -3.9)
Glaucoma	0.7 (0.6 to 0.8)	0.7 (0.6 to 0.9)	2.1 (-14.4 to 28.0)	-19.2 (-31.5 to -0.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.7 (-10.3 to 29.9)	-18.4 (-30.8 to -1.6)
Cataract	6.6 (5.3 to 7.8)	7.3 (5.5 to 9.2)	10.9 (-13.1 to 30.4)	-25.4 (-41.2 to -12.6)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	12.7 (-9.6 to 32.1)	-24.3 (-39.0 to -11.8)
Macular degeneration	1.8 (1.4 to 2.3)	2.8 (2.0 to 3.7)	50.4 (12.4 to 104.8)	4.6 (-22.2 to 42.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	49.6 (12.5 to 99.6)	4.8 (-22.3 to 40.1)
Uncorrected refractive error	55.1 (46.9 to 65.9)	71.4 (59.8 to 84.1)	31.1 (-1.8 to 55.8)	2.2 (-21.9 to 29.0)	0.8 (0.5 to 1.4)	1.0 (0.6 to 1.7)	19.3 (-1.1 to 39.5)	-5.2 (-21.7 to 10.7)
Age-related and other hearing loss	106.4 (94.1 to 117.5)	132.7 (118.0 to 145.5)	24.7 (19.1 to 31.2)	-8.0 (-11.4 to -4.1)	2.9 (1.9 to 4.1)	3.6 (2.4 to 5.1)	23.8 (15.8 to 31.9)	8.8 (-13.8 to -2.6)
Other vision loss	3.8 (3.3 to 4.4)	3.1 (2.6 to 3.7)	-20.2 (-28.2 to -4.5)	-31.9 (-38.5 to -20.4)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-12.8 (-21.8 to 1.7)	-29.5 (-36.2 to -19.6)
Other sense organ diseases	14.0 (13.4 to 14.7)	15.0 (14.3 to 15.8)	7.0 (-0.2 to 14.3)	-0.2 (-6.5 to 6.6)	0.4 (0.2 to 0.5)	0.4 (0.2 to 0.6)	6.2 (-1.5 to 14.3)	0.1 (-6.7 to 7.6)
Oral disorders	-	-	-	-	1.4 (0.8 to 2.2)	1.8 (1.1 to 2.8)	26.9 (20.8 to 32.8)	-0.5 (-4.5 to 4.4)
Deciduous caries	42.2 (40.5 to 43.9)	32.2 (31.0 to 33.6)	-24.0 (-27.9 to -19.1)	-0.2 (-5.2 to 6.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-30.2 to 36.4)	0.0 (-8.2 to 9.8)
Permanent caries	257.9 (231.1 to 283.7)	256.1 (233.9 to 285.5)	-1.0 (-14.8 to 14.6)	-4.0 (-17.1 to 11.1)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.3)	-1.2 (-15.3 to 14.6)	-3.8 (-17.3 to 11.6)
Periodontal diseases	62.5 (57.9 to 67.2)	79.5 (72.9 to 86.1)	27.4 (12.8 to 41.5)	1.1 (-10.5 to 12.4)	0.4 (0.2 to 0.8)	0.5 (0.2 to 1.1)	27.3 (12.8 to 41.6)	1.5 (-10.2 to 12.7)

Appendix Table G.4 - Montenegro prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	19.5 (18.8 to 20.2)	28.3 (27.2 to 29.5)	45.4 (37.8 to 53.5)	-1.6 (-6.6 to 4.0)	0.5 (0.4 to 0.7)	0.8 (0.5 to 1.1)	46.0 (38.1 to 54.4)	-0.9 (-6.3 to 4.8)
Other oral disorders	11.0 (10.4 to 11.6)	11.9 (11.3 to 12.6)	8.2 (0.4 to 18.8)	-0.7 (-7.7 to 9.0)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	7.9 (4.0 to 18.5)	-0.5 (-8.1 to 9.2)
Injuries	-	-	-	-	7.7 (5.8 to 9.9)	6.4 (4.6 to 8.6)	-17.4 (-25.8 to -7.4)	-34.8 (-41.1 to -26.9)
Transport injuries	-	-	-	-	0.9 (0.7 to 1.2)	0.6 (0.4 to 0.9)	-30.9 (-40.1 to -20.4)	-43.2 (-50.6 to -34.8)
Road injuries	-	-	-	-	0.4 (0.6 to 1.0)	0.5 (0.4 to 0.7)	-32.3 (-41.7 to -21.6)	-42.3 (-51.8 to -35.5)
Pedestrian road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-27.7 (-38.8 to -15.1)	-40.8 (-49.8 to -30.7)
Cyclist road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-51.9 (-57.2 to -46.0)	-60.5 (-64.7 to -55.7)
Motorcyclist road injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-27.1 (-38.8 to -14.4)	-38.4 (-47.9 to -27.6)
Motor vehicle road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-30.3 (-40.8 to -17.7)	-42.3 (-50.7 to -32.1)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.5 (-62.7 to -48.9)	-64.0 (-69.1 to -57.9)
Other transport injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-25.2 (-34.3 to -14.4)	-39.1 (-46.4 to -30.5)
Unintentional injuries	-	-	-	-	6.7 (5.0 to 8.6)	5.7 (4.1 to 7.6)	-15.5 (-23.8 to -5.5)	-33.8 (-40.1 to -25.9)
Falls	-	-	-	-	5.3 (4.0 to 6.9)	4.8 (3.4 to 6.4)	-11.2 (-20.8 to 0.9)	-31.4 (-38.8 to -22.2)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.9 (-40.0 to -18.2)	-41.6 (-49.4 to -32.1)
Fire, heat, and hot substances	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-47.9 (-54.8 to -39.3)	-55.2 (-61.4 to -48.0)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.3 (-47.7 to -23.0)	-42.9 (-52.7 to -29.3)
Exposure to mechanical forces	-	-	-	-	0.9 (0.6 to 1.1)	0.5 (0.4 to 0.7)	-37.3 (-42.9 to -29.7)	-45.3 (-49.5 to -38.4)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.3 (-60.5 to -44.9)	-45.3 (-65.6 to -52.2)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-55.8 (-61.8 to -49.5)	-62.0 (-67.1 to -56.9)
Other exposure to mechanical forces	-	-	-	-	0.8 (0.6 to 1.1)	0.5 (0.4 to 0.7)	-36.9 (-42.4 to -29.7)	-44.9 (-49.5 to -38.4)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.8 (10.2 to 30.4)	-3.0 (-10.8 to 5.5)
Animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-14.9 (-23.6 to -5.7)	-25.0 (-32.1 to -17.2)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.0 (-27.7 to -2.5)	-25.1 (-35.3 to -13.1)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.3 (-23.4 to -4.2)	-24.8 (-32.6 to -16.2)
Foreign body	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-18.4 (-26.5 to -9.1)	-29.8 (-36.8 to -22.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.3 (-49.5 to -25.4)	-46.5 (-55.3 to -34.7)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.5 (-7.7 to 6.0)	-9.7 (-17.2 to -3.4)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.3 (-19.7 to -0.1)	-25.3 (-32.6 to -17.2)
Other unintentional injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-23.2 (-29.2 to -15.5)	-40.3 (-44.7 to -34.5)
Self-harm and interpersonal violence	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-16.2 (-25.7 to -5.7)	-32.8 (-40.8 to -24.8)
Self-harm	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-3.3 (-13.6 to 10.5)	-23.0 (-31.6 to -13.3)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.2 (-41.6 to -23.0)	-45.3 (-52.0 to -37.2)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.9 (-20.8 to -3.2)	-29.1 (-35.8 to -22.1)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.3 (-25.2 to -0.3)	-30.0 (-38.6 to -18.9)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.1 (-51.0 to -33.6)	-53.1 (-59.4 to -45.4)
Forces of nature, war, and legal intervention	-	-	-	-	-	-	-	-
Exposure to forces of nature	-	-	-	-	-	-	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Morocco prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	2,275.2 (1,658.4 to 2,968.5)	3,489.8 (2,584.4 to 4,555.6)	53.3 (47.9 to 59.4)	14 (-4.3 to 1.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	-	-	-	-
HIV/AIDS and tuberculosis	-	-	-	-	4.7 (3.2 to 6.4)	7.9 (5.5 to 10.7)	68.3 (50.7 to 92.0)	2.5 (-6.7 to 14.2)
Tuberculosis	15.3 (14.8 to 15.8)	24.0 (23.3 to 24.6)	56.7 (51.6 to 61.4)	-4.9 (-8.0 to -2.5)	4.7 (3.2 to 6.4)	7.3 (4.9 to 9.8)	56.0 (40.4 to 75.5)	-5.0 (-12.5 to 4.4)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.6 (0.3 to 1.2)	3,995.4 (1,901.2 to 6,601.7)	127.9 (1,099.0 to 4,067.5)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,845.5 (804.5 to 3,517.2)	1,013.1 (416.0 to 1,959.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,845.5 (800.9 to 3,527.5)	1,013.1 (414.0 to 1,967.5)
HIV/AIDS resulting in other diseases	0.1 (0.1 to 0.3)	7.7 (4.5 to 11.4)	5,488.4 (2,957.4 to 8,543.7)	3,527.9 (1,893.0 to 5,515.1)	0.0 (0.0 to 0.0)	0.6 (0.3 to 1.2)	3,718.0 (1,905.1 to 6,718.6)	2,196.4 (1,101.9 to 4,184.3)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	79.1 (56.3 to 107.6)	71.6 (50.1 to 97.5)	-9.6 (-15.1 to -3.4)	-21.5 (-26.1 to -16.3)
Diarrheal diseases	310.8 (294.8 to 325.8)	281.5 (266.7 to 295.7)	-9.3 (-15.7 to -2.6)	-17.0 (-22.5 to -11.2)	50.5 (34.3 to 70.6)	45.6 (30.9 to 63.2)	-9.7 (-16.5 to -2.7)	-17.0 (-22.9 to -10.8)
Intestinal infectious diseases	-	-	-	-	0.6 (0.4 to 0.8)	0.4 (0.2 to 0.5)	-0.4 (-48.9 to -13.7)	-0.4 (-55.1 to -27.2)
Typhoid fever	2.9 (2.4 to 3.4)	2.1 (1.8 to 2.5)	-26.6 (-41.3 to -8.6)	-37.3 (-49.5 to -22.9)	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-26.5 (-44.1 to -4.0)	-37.3 (-50.6 to -19.7)
Paratyphoid fever	1.5 (1.2 to 1.8)	1.1 (0.9 to 1.4)	-26.0 (-44.9 to -1.7)	-36.2 (-52.7 to -13.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-26.3 (-46.0 to 3.1)	-36.1 (-53.2 to -11.9)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	-79.5 (-86.4 to -59.0)	-79.5 (-88.3 to -45.3)
Lower respiratory infections	19.3 (17.0 to 22.0)	18.0 (15.5 to 20.7)	-7.1 (-22.7 to 14.5)	-10.6 (-25.6 to 8.7)	2.0 (1.4 to 2.9)	1.9 (1.2 to 2.7)	-8.1 (-25.9 to 16.0)	-11.5 (-28.1 to 10.7)
Upper respiratory infections	585.3 (542.6 to 625.4)	753.9 (707.7 to 798.7)	29.2 (17.1 to 42.9)	2.0 (-7.6 to 12.8)	6.9 (3.8 to 11.3)	8.9 (5.0 to 15.1)	28.8 (15.8 to 43.4)	2.2 (-8.2 to 13.1)
Otitis media	304.5 (281.6 to 328.0)	332.9 (307.0 to 363.6)	9.2 (0.0 to 20.7)	-8.0 (-15.9 to 1.6)	5.6 (3.3 to 9.1)	6.1 (3.5 to 9.8)	7.7 (2.2 to 19.2)	-9.3 (-17.1 to 0.2)
Meningitis	-	-	-	-	11.3 (7.6 to 16.0)	7.1 (4.6 to 10.5)	-38.0 (-49.9 to -17.3)	-53.6 (-61.1 to -38.1)
Pneumococcal meningitis	58.8 (34.2 to 91.5)	40.5 (23.5 to 63.1)	-32.7 (-45.7 to -3.9)	-53.2 (-62.3 to -34.8)	5.1 (3.3 to 7.5)	3.6 (2.2 to 6.4)	-21.1 (-54.1 to 21.8)	-49.9 (-64.6 to -13.2)
H influenzae type B meningitis	22.6 (7.1 to 45.3)	9.9 (3.3 to 20.5)	-56.9 (-70.6 to -33.9)	-67.9 (-78.3 to -49.8)	2.2 (1.4 to 3.4)	1.1 (0.6 to 1.7)	-1.1 (-69.7 to -15.6)	-53.7 (-75.4 to -34.6)
Meningococcal meningitis	16.4 (4.7 to 36.1)	9.5 (2.7 to 21.3)	-43.0 (-57.3 to -25.1)	-60.7 (-69.0 to -48.9)	1.9 (1.0 to 3.2)	1.1 (0.6 to 1.9)	1.1 (-59.1 to -11.5)	-43.6 (-69.0 to -37.7)
Other meningitis	15.9 (9.8 to 25.5)	10.8 (5.8 to 19.1)	-34.1 (-47.3 to -12.9)	-50.4 (-59.3 to -36.4)	2.0 (1.3 to 2.9)	1.3 (0.8 to 2.0)	1.3 (-48.9 to -10.2)	-49.9 (-59.5 to -34.6)
Encephalitis	7.4 (3.1 to 16.2)	7.9 (3.3 to 18.3)	6.8 (-12.3 to 21.5)	-27.8 (-39.0 to -17.9)	6.8 (0.6 to 1.3)	1.0 (0.7 to 1.4)	9.9 (-11.0 to 33.3)	-23.7 (-36.1 to -8.0)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-	-	-
Whooping cough	10.1 (7.9 to 12.9)	0.8 (0.6 to 1.1)	-91.9 (-93.1 to -90.6)	-91.8 (-93.0 to -90.4)	0.5 (0.3 to 0.8)	0.0 (0.0 to 0.1)	-91.9 (-94.4 to -88.8)	-91.8 (-94.3 to -88.6)
Tetanus	3.4 (2.1 to 5.5)	0.0 (0.0 to 0.1)	-98.7 (-99.3 to -97.5)	-99.0 (-99.5 to -98.1)	0.0 (0.1 to 0.4)	0.0 (0.0 to 0.0)	-97.6 (-98.8 to -94.9)	-97.9 (-99.0 to -95.6)
Measles	2.3 (1.8 to 2.8)	0.3 (0.2 to 0.4)	-88.6 (-91.9 to -83.6)	-88.2 (-91.6 to -82.9)	0.2 (0.1 to 0.3)	0.0 (0.0 to 0.0)	-88.3 (-92.2 to -81.9)	-87.8 (-91.9 to -81.2)
Varicella and herpes zoster	18.9 (17.2 to 20.5)	24.0 (21.5 to 26.7)	26.5 (10.8 to 48.9)	5.9 (-10.1 to 31.1)	0.4 (0.2 to 0.6)	0.7 (0.4 to 1.1)	84.7 (35.3 to 173.0)	10.1 (-19.3 to 65.6)
Neglected tropical diseases and malaria	-	-	-	-	19.6 (12.0 to 29.7)	14.7 (9.4 to 21.8)	-24.5 (-39.2 to -4.8)	-37.7 (-48.6 to -26.6)
Malaria	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-74.1 (-88.3 to -48.3)	-83.1 (-92.4 to -66.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-16.7 to 246.6)	24.2 (-40.9 to 153.8)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.2 (0.1 to 0.4)	0.6 (0.3 to 1.1)	181.8 (107.4 to 270.5)	58.6 (21.6 to 105.1)
Visceral leishmaniasis	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	29.6 (5.5 to 68.3)	17.7 (-3.5 to 47.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.6 (5.0 to 68.5)	17.7 (-3.5 to 47.5)
Cutaneous and mucocutaneous leishmaniasis	19.4 (13.4 to 29.0)	55.0 (42.0 to 72.4)	188.4 (110.3 to 276.7)	58.6 (23.6 to 103.0)	0.2 (0.1 to 0.4)	0.6 (0.3 to 1.1)	188.1 (109.3 to 280.4)	59.5 (21.6 to 107.8)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	57.2 (22.4 to 122.3)	83.1 (32.3 to 176.7)	45.6 (40.7 to 50.9)	45.6 (-2.3 to 4.5)	0.5 (0.2 to 1.1)	0.7 (0.2 to 1.5)	32.7 (-1.6 to 61.1)	-3.9 (-25.9 to 14.4)
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cystic echinococcosis	3.5 (3.2 to 3.8)	3.2 (2.9 to 3.5)	-7.3 (-18.5 to -0.1)	-48.5 (-54.2 to -44.0)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-9.3 (-29.6 to 15.7)	-48.9 (-59.5 to -36.0)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	33.0 (21.1 to 49.1)	20.2 (12.0 to 30.1)	-38.8 (-55.7 to -18.5)	-70.2 (-78.7 to -59.1)	2.2 (1.2 to 3.3)	1.3 (0.7 to 2.2)	-37.5 (-54.6 to -20.8)	-69.8 (-78.0 to -60.9)
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-70.7 to -41.5)	0.0 (-78.4 to -60.0)	-	-
Intestinal nematode infections	-	-	-	-	4.1 (1.7 to 8.4)	1.2 (0.6 to 2.1)	-70.9 (-83.9 to -44.5)	-69.4 (-82.7 to -42.1)
Ascariasis	1,762.2 (1,340.1 to 2,279.4)	2,673.1 (1,963.3 to 3,591.0)	52.7 (-0.4 to 122.8)	15.8 (-27.3 to 72.0)	4.0 (1.7 to 8.3)	0.9 (0.4 to 1.8)	-77.7 (-88.1 to -53.1)	-76.3 (-87.2 to -49.8)
Trichuriasis	860.8 (614.1 to 1,221.5)	1,956.0 (1,366.2 to 2,866.8)	131.0 (36.1 to 275.9)	73.2 (-2.1 to 186.0)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.4)	525.9 (179.0 to 1,423.0)	420.3 (107.3 to 1,200.6)
Hookworm disease	15.2 (10.1 to 21.9)	24.5 (16.3 to 35.8)	62.5 (-9.8 to 178.0)	62.5 (-44.2 to 72.1)	0.5 (0.0 to 0.1)	0.1 (0.1 to 0.2)	70.3 (32.7 to 102.2)	5.1 (-17.6 to 24.6)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	348.5 (268.9 to 431.8)	325.3 (276.8 to 374.8)	-6.1 (-24.9 to 20.6)	-10.1 (-27.0 to 13.0)	12.3 (7.3 to 18.3)	10.7 (6.7 to 15.7)	-14.0 (-34.2 to 24.0)	-11.6 (-32.4 to 26.6)
Maternal disorders	-	-	-	-	1.5 (0.8 to 2.4)	1.5 (0.8 to 2.5)	2.4 (-18.8 to 26.4)	-32.3 (-45.5 to -18.6)
Maternal hemorrhage	5.1 (4.3 to 6.1)	7.4 (5.1 to 10.1)	45.0 (-3.8 to 102.3)	-7.5 (-37.9 to 27.5)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.4)	34.3 (-29.0 to 108.5)	-12.8 (-53.5 to 36.6)
Maternal sepsis and other maternal infections	15.4 (10.9 to 20.8)	12.5 (8.5 to 17.6)	-18.8 (-33.4 to -2.4)	-55.7 (-63.4 to -46.6)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-30.7 (-61.9 to 17.9)	-56.2 (-74.2 to -25.1)
Maternal hypertensive disorders	13.4 (5.0 to 24.3)	13.7 (5.3 to 25.5)	2.1 (-11.7 to 19.8)	-31.0 (-42.5 to -22.0)	0.7 (0.2 to 1.4)	0.7 (0.2 to 1.4)	1.6 (-17.2 to 25.1)	-31.7 (-44.4 to -16.5)
Obstructed labor	0.6 (0.4 to 1.0)	0.6 (0.4 to 0.9)	-	-	0.2 (-36.9 to 33.4)	0.2 (-56.9 to 13.3)	-2.2 (-53.8 to 82.7)	-38.8 (-68.3 to 17.5)
Complications of abortion	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	20.5 (-28.7 to 103.5)	-25.8 (-56.3 to 24.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.5 (-28.7 to 104.1)	-25.8 (-56.3 to 24.5)
Other maternal disorders	-	-	-	-	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	13.6 (-35.8 to 104.0)	-24.7 (-58.1 to 33.4)
Neonatal disorders	-	-	-	-	37.3 (22.7 to 57.4)	91.9 (58.9 to 134.8)	150.3 (48.0 to 282.9)	108.8 (25.7 to 218.4)
Preterm birth complications	115.1 (65.1 to 191.2)	351.5 (235.6 to 522.7)	208.5 (111.9 to 384.3)	142.7 (70.5 to 277.3)	14.1 (7.1 to 24.2)	45.9 (29.3 to 67.6)	164.2 (95.4 to 281.7)	164.2 (59.5 to 454.5)
Neonatal encephalopathy due to birth asphyxia and trauma	49.5 (22.8 to 93.0)	93.4 (51.2 to 151.2)	96.2 (-13.8 to 311.2)	63.8 (-30.4 to 251.2)	10.2 (5.0 to 17.5)	21.1 (11.8 to 33.5)	111.9 (-2.5 to 326.8)	85.0 (-14.6 to 268.0)
Neonatal sepsis and other neonatal infections	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.6)	17.0 (15.5 to 21.8)	15.1 (13.7 to 19.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	17.0 (6.8 to 28.4)	15.5 (5.1 to 26.4)
Hemolytic disease and other neonatal jaundice	25.7 (11.6 to 50.4)	81.4 (26.1 to 179.7)	222.6 (-22.5 to 772.0)	170.0 (-35.5 to 636.7)	7.6 (3.5 to 13.5)	20.4 (7.8 to 43.9)	167.3 (-17.6 to 596.0)	118.9 (-32.4 to 481.1)
Other neonatal disorders	-	-	-	-	5.3 (2.3 to 11.2)	4.4 (2.3 to 8.2)	-14.1 (-67.5 to 122.3)	-28.8 (-72.8 to 86.7)
Nutritional deficiencies	-	-	-	-	213.5 (140.0 to 307.3)	215.9 (143.3 to 314.5)	1.1 (-9.8 to 13.9)	-13.4 (-23.3 to -2.7)
Protein-energy malnutrition	71.5 (43.8 to 109.2)	89.6 (30.6 to 196.4)	17.2 (-59.0 to 204.0)	18.4 (-58.5 to 208.2)	8.9 (4.6 to 15.1)	11.2 (3.5 to 26.5)	18.1 (-59.6 to 204.1)	19.7 (-58.9 to 207.6)
Iodine deficiency	973.7 (415.4 to 1,728.0)	1,011.2 (457.8 to 1,590.0)	11.4 (-63.1 to 147.9)	-24.6 (-75.3 to 72.0)	17.5 (6.6 to 34.9)	18.2 (7.3 to 34.6)	10.8 (-62.8 to 145.3)	-25.0 (-75.2 to 71.9)
Vitamin A deficiency	28.3 (19.5 to 37.5)	16.3 (10.4 to 22.1)	-42.6 (-63.5 to -29.5)	-52.8 (-62.4 to -39.9)	1.4 (0.8 to 2.2)	0.8 (0.4 to 1.3)	-44.2 (-56.3 to -27.9)	-45.7 (-66.0 to -42.4)

Appendix Table G.4 - Morocco prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	5,629.5 (5,544.8 to 5,713.5)	6,158.4 (6,058.2 to 6,256.4)	9.5 (6.9 to 12.0)	-12.2 (-14.5 to -10.0)	182.2 (121.4 to 264.3)	181.6 (120.7 to 263.3)	-0.2 (-4.0 to 2.2)	-13.1 (-16.6 to -10.7)
Other nutritional deficiencies	-	-	-	-	3.5 (1.3 to 7.9)	4.2 (1.1 to 11.1)	15.3 (-68.3 to 270.6)	16.8 (-67.5 to 276.0)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	14.6 (9.1 to 21.9)	16.2 (10.1 to 25.1)	10.6 (-6.9 to 34.1)	-8.6 (-22.5 to 7.7)
Sexually transmitted diseases excluding HIV	-	-	-	-	4.0 (2.3 to 6.9)	6.1 (3.3 to 10.9)	54.7 (4.7 to 111.0)	1.4 (-28.5 to 37.1)
Syphilis	0.7 (0.6 to 0.8)	0.8 (0.7 to 0.9)	14.1 (5.0 to 31.7)	-41.9 (-50.7 to -34.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	40.7 (-12.5 to 54.4)	40.7 (-55.9 to -20.9)
Chlamydial infection	476.2 (372.0 to 612.7)	751.4 (524.1 to 1,014.7)	58.2 (0.8 to 122.5)	9.4 (-30.8 to 50.6)	2.1 (1.1 to 3.9)	3.2 (1.6 to 6.3)	59.8 (-19.8 to 190.0)	11.1 (-43.2 to 99.3)
Gonococcal infection	125.0 (96.1 to 158.3)	169.0 (131.3 to 211.3)	36.2 (8.0 to 88.9)	-3.2 (-32.9 to 32.3)	0.8 (0.4 to 1.4)	1.7 (0.6 to 2.7)	28.6 (-13.4 to 92.9)	-9.1 (-37.1 to 35.0)
Trichomoniasis	114.4 (70.0 to 185.1)	195.9 (143.0 to 265.2)	78.7 (-11.5 to 208.0)	12.0 (-39.1 to 83.7)	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.7)	87.8 (-19.1 to 272.1)	17.8 (-4.2 to 115.0)
Genital herpes	2,330.9 (2,243.2 to 2,412.7)	3,952.6 (3,806.1 to 4,072.7)	70.0 (60.1 to 78.2)	3.5 (-9.3 to 1.3)	1.0 (0.2 to 1.5)	2.0 (0.3 to 2.5)	64.9 (48.4 to 77.2)	-3.2 (-10.3 to 2.8)
Other sexually transmitted diseases	5.0 (3.6 to 6.8)	6.5 (4.9 to 8.8)	29.7 (10.0 to 52.6)	-28.3 (-39.4 to -16.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	60.6 (7.0 to 141.0)	3.8 (-33.9 to 43.1)
Hepatitis	-	-	-	-	2.0 (1.2 to 3.0)	2.3 (1.5 to 3.4)	16.2 (-11.8 to 47.4)	-22.2 (-44.5 to 5.2)
Hepatitis A	38.5 (36.7 to 40.2)	39.6 (38.4 to 40.8)	3.1 (1.6 to 4.7)	-4.3 (-4.4 to 4.1)	0.8 (0.5 to 1.2)	1.0 (0.6 to 1.4)	19.0 (6.4 to 34.0)	0.1 (-10.7 to 11.8)
Hepatitis B	1,902.0 (1,470.8 to 2,415.0)	1,918.0 (1,476.0 to 2,340.8)	0.6 (-28.3 to 42.1)	-32.4 (-52.3 to -14.0)	1.0 (0.5 to 1.6)	1.0 (0.6 to 1.6)	2.6 (-45.0 to 69.5)	-39.8 (-69.8 to 10.9)
Hepatitis C	1,172.1 (1,015.2 to 1,337.9)	1,349.7 (1,197.0 to 1,501.7)	15.5 (-3.2 to 35.8)	-30.6 (-41.4 to -19.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	20.2 (-12.5 to 63.4)	21.2 (-44.1 to 10.0)
Hepatitis E	3.5 (1.9 to 5.5)	7.8 (5.0 to 10.4)	129.3 (2.1 to 387.5)	58.2 (-32.2 to 244.1)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	132.8 (-4.4 to 422.3)	58.2 (-35.4 to 249.6)
Leprosy	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.3)	29.7 (-5.0 to 100.2)	-30.5 (-47.7 to 6.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.1 (-9.4 to 112.8)	-28.9 (-52.1 to 16.2)
Other infectious diseases	250.4 (199.7 to 303.2)	243.0 (198.1 to 291.0)	-2.8 (-22.5 to 22.3)	-11.4 (-28.1 to 9.1)	8.6 (5.2 to 12.6)	7.7 (4.7 to 11.5)	-9.6 (-38.5 to 23.3)	-9.6 (-37.8 to 23.6)
Non-communicable diseases	-	-	-	-	1,325.1 to 2,331.7	2,195.4 to 3,859.9	57.4 to 71.5	-2.3 to 4.6
Neoplasms	-	-	-	-	7.0 (5.0 to 9.3)	17.4 (11.9 to 24.1)	145.4 (100.1 to 206.4)	33.4 (8.6 to 69.3)
Esophageal cancer	0.3 (0.2 to 0.4)	0.7 (0.5 to 0.9)	108.4 (39.1 to 216.2)	14.6 (-26.3 to 76.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	106.5 (48.3 to 183.9)	11.6 (-24.8 to 57.6)
Stomach cancer	2.2 (1.8 to 2.7)	5.3 (4.2 to 6.6)	134.5 (81.4 to 215.2)	35.0 (4.7 to 80.7)	0.3 (0.2 to 0.4)	0.7 (0.5 to 0.9)	128.3 (72.4 to 215.9)	30.7 (-1.3 to 76.8)
Liver cancer	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	479.2 (301.1 to 732.7)	255.1 (145.5 to 414.6)
Liver cancer due to hepatitis B	0.1 (0.1 to 0.1)	0.5 (0.3 to 0.8)	458.7 (184.9 to 1,004.2)	235.1 (64.3 to 592.8)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	459.8 (225.6 to 889.0)	236.8 (87.1 to 513.6)
Liver cancer due to hepatitis C	0.1 (0.0 to 0.1)	0.8 (0.5 to 1.1)	1,167.2 (576.2 to 2,367.1)	660.0 (292.0 to 1,377.1)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	1,211.4 (615.3 to 1,959.6)	611.9 (306.4 to 1,139.9)
Liver cancer due to alcohol use	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	205.3 (61.5 to 475.2)	85.9 (-2.3 to 255.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	204.9 (77.6 to 407.8)	84.1 (7.5 to 215.5)
Liver cancer due to other causes	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	175.5 (11.5 to 544.3)	65.7 (-30.0 to 419.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	175.5 (27.7 to 480.6)	83.9 (-22.8 to 359.3)
Larynx cancer	1.8 (1.2 to 2.3)	2.3 (1.6 to 3.4)	30.3 (-12.9 to 109.3)	-35.1 (-55.2 to 1.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	33.3 (-11.7 to 113.2)	-34.2 (-55.7 to 2.8)
Tracheal, bronchus and lung cancer	2.8 (2.2 to 3.4)	6.3 (4.9 to 8.2)	121.5 (68.8 to 213.7)	17.3 (-10.1 to 61.1)	0.5 (0.3 to 0.7)	1.1 (0.7 to 1.6)	115.5 (61.9 to 200.0)	13.9 (-14.0 to 56.4)
Breast cancer	12.7 (10.1 to 15.5)	37.7 (27.2 to 51.7)	197.3 (104.2 to 326.3)	44.0 (1.5 to 107.1)	1.2 (0.8 to 1.6)	3.2 (2.0 to 4.8)	175.4 (92.8 to 296.3)	34.7 (-3.0 to 94.2)
Cervical cancer	10.7 (8.1 to 14.0)	17.6 (11.5 to 25.0)	62.1 (6.3 to 153.9)	17.5 (-47.3 to 22.8)	0.4 (0.1 to 0.3)	0.9 (0.7 to 2.1)	69.9 (6.6 to 162.0)	-20.9 (-47.9 to 25.5)
Uterine cancer	3.6 (2.3 to 5.7)	9.0 (4.3 to 14.3)	147.2 (24.4 to 362.2)	22.5 (-38.4 to 122.0)	0.2 (0.1 to 0.4)	0.6 (0.3 to 1.0)	142.7 (18.5 to 365.7)	19.6 (-41.2 to 123.3)
Prostate cancer	4.2 (2.6 to 6.9)	23.8 (13.5 to 35.4)	476.5 (235.9 to 892.6)	188.0 (53.8 to 398.0)	0.5 (0.3 to 0.8)	2.3 (1.2 to 3.7)	402.3 (179.3 to 730.4)	151.0 (25.0 to 320.0)
Colon and rectum cancer	4.0 (3.4 to 4.6)	11.3 (9.1 to 14.0)	181.3 (121.4 to 265.1)	49.2 (18.0 to 90.7)	0.4 (0.3 to 0.5)	1.0 (0.7 to 1.4)	170.5 (110.5 to 251.4)	41.9 (12.8 to 87.7)
Lip and oral cavity cancer	2.1 (1.5 to 2.8)	4.3 (3.0 to 5.8)	105.9 (42.0 to 204.0)	7.8 (-30.0 to 58.6)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	104.5 (38.3 to 200.2)	7.3 (-32.8 to 55.1)
Nasopharynx cancer	1.6 (1.1 to 2.2)	1.9 (1.3 to 2.8)	17.6 (-24.7 to 95.9)	-39.4 (-61.2 to -0.5)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	13.7 (-25.8 to 83.2)	41.5 (-61.8 to -7.3)
Other pharynx cancer	0.6 (0.4 to 0.8)	1.1 (0.7 to 1.6)	87.4 (8.5 to 220.6)	-0.5 (-42.3 to 71.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	84.0 (11.3 to 198.5)	-1.9 (-40.1 to 57.5)
Gallbladder and biliary tract cancer	0.2 (0.2 to 0.3)	0.6 (0.4 to 0.8)	150.9 (40.9 to 288.4)	32.9 (-30.8 to 112.1)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	130.7 (33.0 to 252.5)	22.1 (-34.4 to 93.4)
Pancreatic cancer	0.3 (0.2 to 0.3)	1.0 (0.8 to 1.3)	252.4 (168.2 to 380.9)	95.7 (48.7 to 163.5)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	237.4 (166.7 to 346.1)	81.8 (-37.7 to 139.9)
Malignant skin melanoma	0.6 (0.5 to 0.8)	2.2 (1.6 to 2.9)	362.8 (138.2 to 430.0)	85.8 (20.4 to 166.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	262.1 (114.2 to 401.2)	71.8 (7.8 to 153.2)
Non-melanoma skin cancer	2.0 (1.5 to 2.6)	6.9 (5.1 to 9.6)	251.0 (154.0 to 385.6)	65.1 (19.3 to 132.8)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	253.2 (140.1 to 416.7)	65.6 (9.2 to 147.5)
Ovarian cancer	1.0 (0.8 to 1.4)	2.3 (1.7 to 3.3)	127.9 (51.9 to 246.4)	25.6 (-18.7 to 91.9)	0.1 (0.1 to 0.2)	0.5 (0.2 to 0.5)	129.3 (43.7 to 271.6)	26.3 (-23.8 to 105.0)
Testicular cancer	0.7 (0.4 to 1.1)	2.0 (1.1 to 3.2)	193.2 (52.0 to 315.8)	74.5 (-9.7 to 268.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	183.9 (42.5 to 316.7)	68.9 (-19.6 to 261.9)
Kidney cancer	1.8 (0.6 to 1.3)	3.2 (1.6 to 2.6)	74.2 (52.8 to 291.9)	-4.4 (-28.0 to 153.0)	0.2 (0.0 to 0.1)	0.2 (0.1 to 0.3)	74.3 (73.2 to 304.8)	-7.0 (-29.1 to 151.5)
Bladder cancer	1.4 (1.4 to 2.3)	2.3 (2.3 to 4.3)	150.8 (22.8 to 345.6)	83.3 (-35.1 to 33.0)	0.3 (0.1 to 0.2)	0.6 (0.2 to 0.4)	157.3 (25.1 to 143.0)	77.2 (-33.2 to 30.7)
Brain and nervous system cancer	2.5 (1.8 to 4.0)	6.2 (4.6 to 7.9)	150.8 (53.6 to 270.2)	83.3 (16.5 to 156.0)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	157.3 (66.3 to 268.9)	77.2 (11.2 to 144.2)
Thyroid cancer	3.0 (2.0 to 4.3)	6.1 (4.4 to 8.7)	101.2 (25.9 to 224.7)	3.4 (-33.7 to 59.9)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	97.5 (22.4 to 224.8)	-0.1 (-35.6 to 55.2)
Mesothelioma	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	140.9 (122.6 to 384.3)	103.8 (27.3 to 201.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	289.7 (113.3 to 385.6)	100.5 (25.9 to 197.4)
Hodgkin lymphoma	2.5 (1.7 to 3.6)	3.6 (2.6 to 4.8)	42.3 (-12.5 to 131.0)	6.5 (-30.3 to 59.2)	0.3 (0.1 to 0.3)	0.3 (0.2 to 0.4)	43.5 (8.9 to 119.8)	1.8 (-30.7 to 45.3)
Non-Hodgkin lymphoma	3.2 (2.3 to 4.2)	7.2 (5.4 to 9.6)	128.2 (59.7 to 236.7)	36.3 (-4.5 to 93.7)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	119.5 (53.7 to 223.9)	29.2 (-10.2 to 84.6)
Multiple myeloma	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.9)	107.7 (97.5 to 662.5)	107.7 (0.3 to 324.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	278.3 (91.8 to 642.1)	94.5 (-3.2 to 297.9)
Leukemia	2.0 (1.5 to 3.0)	6.2 (4.7 to 7.9)	214.2 (94.4 to 347.6)	154.7 (57.7 to 218.1)	0.2 (0.2 to 0.4)	0.7 (0.5 to 1.0)	194.5 (104.6 to 300.6)	105.1 (43.8 to 175.2)
Other neoplasms	8.7 (5.9 to 14.3)	17.9 (13.4 to 23.2)	116.3 (11.5 to 231.7)	34.7 (-16.2 to 92.4)	0.6 (0.4 to 1.1)	1.3 (0.8 to 1.8)	111.7 (19.7 to 209.6)	22.1 (-19.0 to 70.1)
Cardiovascular diseases	-	-	-	-	39.0 (26.4 to 55.1)	70.3 (47.9 to 98.4)	80.2 (43.8 to 124.3)	3.3 (-17.3 to 28.1)
Rheumatic heart disease	67.8 (55.4 to 81.1)	108.1 (80.7 to 131.3)	61.6 (11.4 to 112.3)	3.2 (-24.9 to 34.3)	3.6 (2.2 to 5.3)	6.3 (4.1 to 9.1)	78.2 (26.5 to 139.0)	15.5 (-14.8 to 55.7)
Ischemic heart disease	175.3 (140.0 to 214.3)	276.3 (240.6 to 324.1)	58.6 (18.3 to 105.2)	-17.4 (-37.3 to 6.5)	9.9 (6.2 to 14.5)	16.0 (10.7 to 22.6)	63.9 (13.1 to 124.6)	-12.6 (-38.6 to 21.1)
Cerebrovascular disease	-	-	-	-	1.2 (0.8 to 1.6)	2.4 (1.6 to 3.3)	103.5 (58.1 to 152.6)	5.3 (-20.8 to 28.9)
Ischemic stroke	6.6 (5.7 to 7.7)	13.5 (11.5 to 15.3)	106.2 (54.9 to 148.9)	5.0 (-21.2 to 26.1)	1.0 (0.7 to 1.4)	2.1 (1.4 to 2.9)	104.5 (55.4 to 156.2)	5.0 (-22.3 to 29.0)
Hemorrhagic stroke	1.0 (0.8 to 1.3)	2.0 (1.6 to 2.6)	99.4 (41.4 to 186.6)	6.0 (-26.3 to 56.7)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	99.0 (41.1 to 186.4)	6.2 (-26.2 to 54.8)
Hypertensive heart disease	18.8 (15.1 to 22.4)	53.6 (44.1 to 62.6)	185.9 (114.4 to 273.9)	53.8 (12.7 to 103.1)	2.1 (1.4 to 3.1)	5.9 (4.0 to 8.2)	184.2 (112.4 to 269.8)	52.9 (11.5 to 101.1)
Cardiomyopathy and myocarditis	15.1 (12.8 to 17.2)	35.5 (31.1 to 40.3)	134.9 (95.9 to 188.6)	39.7 (11.1 to 75.4)	1.7 (1.1 to 2.4)	3.9 (2.6 to 5.4)	135.7 (91.4 to 188.8)	40.1 (10.3 to 76.7)
Atrial fibrillation and flutter	12.8 (8.6 to 20.4)	28.6 (20.5 to 41.5)	140.0 (13.4 to 264.8)	0.5 (-52.2 to 56.6)	1.0 (0.6 to 1.7)	2.2 (1.3 to 3.7)	142.2 (14.1 to 273.6)	1.8 (-52.1 to 59.9)
Peripheral vascular disease	279.6 (167.9 to 377.3)	681.0 (469.3 to 873.4)	149.3 (37.4 to 330.8)	16.3 (-27.6 to 98.8)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.6)	53.7 (-20.0 to 223.9)	-34.8 (-66.5 to 30.9)
Endocarditis	1.3 (1.0 to 1.7)	2.7 (2.1 to 3.3)	117.7 (50.4 to 189.3)	35.9 (-4.8 to 86.5)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	131.9 (48.1 to 234.9)	42.0 (-9.9 to 110.9)
Other cardiovascular and circulatory diseases	274.9 (209.0 to 367.9)	469.6 (289.0 to 616.9)	73.3 (7.3 to 147.3)	9.9 (-34.5 to 49.8)	1.4 (1.0 to 2.3)	5.0 (3.0 to 8.7)	73.1 (7.8 to 149.6)	5.0 (-35.2 to

Appendix Table G.4 - Morocco prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	78.5 (72.7 to 84.7)	-
Silicosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	69.0 (61.0 to 78.2)	-14.8 (-18.8 to -10.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	69.0 (60.8 to 78.2)	-14.8 (-18.9 to -10.1)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.2 (0.2 to 0.2)	0.4 (0.4 to 0.4)	84.1 (76.8 to 91.9)	-1.8 (-5.4 to 2.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	83.9 (76.6 to 91.6)	-1.9 (-5.5 to 1.9)
Asthma	625.9 (506.0 to 745.0)	585.8 (453.4 to 712.0)	-5.8 (-32.6 to 30.2)	-29.4 (-47.3 to -9.1)	27.7 (17.3 to 39.9)	25.6 (15.1 to 38.3)	-7.0 (-34.0 to 30.1)	-30.0 (-47.9 to -8.0)
Interstitial lung disease and pulmonary sarcoidosis	1.5 (1.2 to 1.9)	2.9 (2.3 to 3.7)	93.5 (46.1 to 164.0)	6.0 (-21.6 to 43.3)	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.6)	96.0 (46.2 to 166.0)	5.6 (-22.1 to 43.3)
Other chronic respiratory diseases	-	-	-	-	6.3 (3.7 to 10.2)	10.1 (6.2 to 15.3)	59.9 (14.6 to 115.0)	-14.0 (-38.0 to 17.0)
Cirrhosis	-	-	-	-	1.7 (1.1 to 2.4)	1.9 (1.3 to 2.7)	14.0 (-0.4 to 31.0)	23.4 (-32.7 to -13.8)
Cirrhosis due to hepatitis B	3.2 (1.4 to 5.3)	3.4 (1.9 to 5.1)	10.6 (-50.5 to 184.9)	-34.7 (69.0 to 54.7)	0.5 (0.2 to 0.9)	0.6 (0.3 to 1.0)	9.8 (-50.6 to 183.8)	35.0 (-70.0 to 53.5)
Cirrhosis due to hepatitis C	3.1 (1.8 to 4.9)	5.3 (3.3 to 7.0)	73.7 (-11.0 to 243.2)	12.6 (-44.2 to 114.3)	0.5 (0.2 to 0.9)	0.9 (0.5 to 1.3)	71.0 (-15.0 to 246.1)	11.1 (-45.8 to 116.4)
Cirrhosis due to alcohol use	1.1 (0.7 to 1.6)	0.8 (0.5 to 1.3)	-29.5 (-56.8 to 19.9)	-60.4 (-76.3 to -34.6)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-28.5 (-59.9 to 28.3)	60.1 (-77.8 to -29.2)
Cirrhosis due to other causes	2.9 (2.1 to 4.1)	2.3 (1.7 to 3.1)	-20.7 (-47.6 to 33.6)	-28.6 (-53.2 to 21.8)	0.5 (0.3 to 0.8)	0.4 (0.2 to 0.6)	-20.4 (-51.6 to 36.5)	-28.3 (-56.8 to 22.4)
Digestive diseases	-	-	-	-	15.7 (11.8 to 22.7)	25.4 (18.3 to 33.8)	52.4 (34.5 to 70.5)	-13.8 (-22.6 to -4.2)
Peptic ulcer disease	77.6 (64.5 to 90.7)	79.2 (65.2 to 93.5)	2.3 (-12.9 to 21.7)	-47.2 (-53.4 to -40.0)	2.9 (1.9 to 4.3)	3.2 (2.2 to 4.7)	12.6 (-12.7 to 41.4)	-42.1 (-51.9 to -30.4)
Gastritis and duodenitis	83.7 (71.9 to 95.1)	67.6 (58.2 to 76.8)	-19.2 (-31.8 to -4.8)	-46.9 (-54.4 to -37.2)	3.6 (2.3 to 5.4)	3.1 (2.0 to 4.7)	-14.1 (-32.5 to 18.7)	-37.9 (-48.2 to -19.0)
Appendicitis	1.6 (1.1 to 2.1)	2.0 (1.3 to 2.8)	25.9 (-6.4 to 90.6)	-15.2 (-35.6 to 26.4)	0.5 (0.3 to 0.8)	0.6 (0.3 to 1.0)	26.3 (-20.2 to 113.5)	-12.8 (-43.2 to 39.2)
Paralytic ileus and intestinal obstruction	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	53.0 (3.5 to 123.0)	2.9 (-20.0 to 38.6)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	53.8 (-2.3 to 151.5)	3.9 (-23.8 to 52.3)
Inguinal, femoral, and abdominal hernia	106.9 (86.2 to 147.9)	141.8 (116.9 to 168.2)	35.6 (9.1 to 85.1)	-18.0 (-36.4 to 11.7)	1.1 (0.5 to 2.3)	1.5 (0.7 to 2.8)	34.5 (-11.3 to 83.4)	-17.9 (-36.7 to 10.4)
Inflammatory bowel disease	17.6 (16.3 to 19.0)	45.2 (41.3 to 49.3)	156.5 (128.3 to 188.4)	44.4 (29.4 to 62.9)	3.8 (2.5 to 5.1)	9.6 (6.5 to 13.3)	154.9 (119.8 to 195.0)	44.4 (25.6 to 66.1)
Vascular intestinal disorders	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	92.7 (36.7 to 175.6)	1.2 (-33.9 to 50.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.2 (31.8 to 176.5)	4.0 (-36.5 to 69.4)
Gallbladder and biliary diseases	7.9 (6.8 to 9.1)	14.1 (12.1 to 16.4)	78.5 (46.0 to 121.3)	-6.6 (-24.4 to 10.6)	0.8 (0.5 to 1.2)	1.5 (1.0 to 2.0)	78.8 (40.7 to 126.5)	-5.7 (-25.3 to 22.0)
Pancreatitis	4.1 (3.9 to 4.4)	6.7 (6.3 to 7.1)	62.3 (48.3 to 77.8)	-8.0 (-15.0 to -0.1)	1.2 (0.8 to 1.7)	2.0 (1.3 to 2.8)	59.6 (33.6 to 92.3)	-8.7 (-22.1 to 7.6)
Other digestive diseases	-	-	-	-	2.7 (1.6 to 4.0)	3.8 (2.5 to 5.2)	40.3 (5.5 to 84.9)	-19.9 (-39.3 to 4.8)
Neurological disorders	-	-	-	-	178.0 (116.4 to 249.1)	307.4 (206.0 to 425.5)	72.9 (44.4 to 109.6)	4.7 (-10.7 to 22.7)
Alzheimer disease and other dementias	91.0 (78.3 to 106.7)	204.2 (178.4 to 232.9)	124.8 (82.0 to 174.0)	-1.0 (-19.4 to 22.6)	12.6 (9.0 to 16.7)	28.9 (20.5 to 37.9)	129.4 (86.9 to 182.3)	-1.1 (-18.8 to 22.4)
Parkinson disease	8.8 (4.7 to 12.5)	18.2 (9.4 to 25.5)	109.9 (85.6 to 130.6)	0.4 (-11.0 to 10.7)	1.0 (0.5 to 1.6)	2.2 (1.0 to 3.4)	107.8 (77.0 to 140.7)	0.3 (-14.8 to 14.5)
Epilepsy	118.5 (98.2 to 136.6)	152.7 (124.0 to 176.7)	29.2 (0.8 to 62.4)	-2.0 (-22.8 to 22.0)	34.0 (22.6 to 47.7)	49.2 (32.4 to 68.2)	44.9 (10.5 to 89.2)	11.1 (-14.8 to 44.4)
Multiple sclerosis	3.5 (2.4 to 4.7)	11.2 (7.6 to 15.3)	218.0 (93.4 to 434.5)	69.1 (8.0 to 185.2)	1.2 (0.7 to 1.7)	3.7 (2.2 to 5.9)	216.8 (89.6 to 437.1)	69.7 (4.5 to 187.7)
Migraine	2,565.4 (1,891.4 to 3,267.7)	3,987.1 (3,107.3 to 5,046.8)	53.7 (7.8 to 128.4)	1.6 (-28.0 to 45.4)	87.8 (46.4 to 139.3)	135.7 (77.1 to 210.7)	56.1 (7.1 to 128.2)	1.1 (-28.5 to 44.6)
Tension-type headache	4,046.7 (3,733.4 to 4,351.9)	6,278.8 (4,618.5 to 7,728.4)	56.2 (14.4 to 95.1)	1.4 (-22.2 to 26.1)	6.1 (2.9 to 9.9)	9.5 (4.3 to 17.6)	54.9 (13.3 to 96.4)	1.1 (-22.5 to 27.0)
Medication overuse headache	187.8 (125.4 to 253.0)	466.0 (312.7 to 626.6)	149.1 (106.7 to 201.3)	49.2 (21.2 to 79.9)	29.5 (17.3 to 45.4)	73.0 (41.0 to 112.0)	147.7 (105.6 to 199.6)	49.1 (21.2 to 81.9)
Other neurological disorders	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	38.4 (-6.1 to 101.7)	-1.1 (-31.2 to 44.4)	5.8 (3.6 to 8.5)	5.1 (3.4 to 7.3)	-11.2 (-42.8 to 39.6)	-61.5 (-75.7 to -39.1)
Mental and substance use disorders	-	-	-	-	581.8 (397.8 to 812.5)	864.5 (594.1 to 1,188.7)	48.7 (40.2 to 58.1)	-1.7 (-4.8 to 1.3)
Schizophrenia	55.3 (50.2 to 60.0)	98.7 (90.4 to 106.3)	78.6 (69.8 to 86.9)	-0.3 (-4.7 to 3.6)	35.5 (26.0 to 43.4)	63.1 (46.9 to 76.3)	78.0 (65.5 to 91.2)	0.1 (-6.5 to 5.8)
Alcohol use disorders	158.8 (142.4 to 176.1)	242.2 (219.3 to 265.5)	52.6 (43.8 to 62.2)	-1.0 (-6.5 to 5.7)	15.8 (10.5 to 22.6)	24.0 (16.0 to 34.3)	52.2 (41.4 to 65.3)	-0.8 (-7.4 to 6.4)
Drug use disorders	-	-	-	-	72.1 (41.0 to 117.4)	109.8 (63.4 to 177.4)	52.0 (33.7 to 77.1)	-7.3 (-17.4 to 4.7)
Opioid use disorders	134.9 (72.4 to 221.2)	213.8 (119.5 to 356.2)	58.7 (38.2 to 88.4)	-7.4 (-18.6 to 5.3)	55.9 (27.6 to 99.0)	88.6 (45.2 to 155.1)	58.7 (36.9 to 89.1)	-7.4 (-18.8 to 5.7)
Cocaine use disorders	19.6 (15.1 to 24.6)	28.3 (22.7 to 34.7)	46.3 (5.3 to 95.2)	2.7 (-27.6 to 26.5)	3.9 (1.7 to 4.2)	5.9 (2.4 to 9.9)	65.8 (-10.5 to 102.8)	-2.7 (-30.7 to 32.8)
Amphetamine use disorders	36.7 (28.7 to 45.3)	45.2 (36.7 to 53.8)	23.6 (9.9 to 69.0)	-9.5 (-32.8 to 21.6)	4.8 (2.8 to 7.2)	5.9 (3.6 to 9.2)	23.9 (-10.8 to 73.2)	-9.3 (-33.3 to 24.6)
Cannabis use disorders	38.7 (29.7 to 47.2)	52.2 (41.0 to 62.6)	35.2 (31.2 to 39.9)	-0.2 (-0.3 to -0.1)	1.1 (0.6 to 1.7)	1.5 (0.9 to 2.3)	35.3 (15.4 to 61.2)	0.2 (-13.7 to 17.3)
Other drug use disorders	-	-	-	-	7.5 (4.6 to 11.1)	9.9 (6.1 to 14.8)	31.3 (9.2 to 90.9)	-6.9 (-34.7 to 33.7)
Depressive disorders	-	-	-	-	291.1 (111.9 to 315.2)	380.0 (170.6 to 497.5)	30.3 (36.6 to 78.2)	0.2 (-7.4 to 6.2)
Major depressive disorder	845.8 (509.5 to 1,211.1)	1,323.6 (738.8 to 1,935.2)	56.5 (32.0 to 80.2)	-1.3 (-8.0 to 6.5)	174.3 (94.7 to 288.0)	271.3 (138.3 to 451.5)	55.4 (30.8 to 79.1)	-1.2 (-8.7 to 7.0)
Dysthymia	229.6 (186.6 to 273.3)	397.7 (322.9 to 473.2)	73.3 (66.3 to 82.6)	-0.1 (-0.3 to 0.1)	22.1 (14.1 to 32.4)	38.3 (24.2 to 55.9)	72.5 (64.5 to 83.3)	0.0 (-2.6 to 2.6)
Bipolar disorder	159.1 (135.5 to 180.6)	256.3 (224.0 to 288.3)	61.4 (51.8 to 71.3)	-1.3 (-5.9 to 3.3)	32.4 (20.1 to 48.9)	52.0 (32.2 to 77.6)	60.6 (49.4 to 73.5)	-1.2 (-6.9 to 5.2)
Anxiety disorders	998.3 (450.8 to 1,443.6)	1,466.6 (754.6 to 2,066.0)	47.6 (31.8 to 67.7)	0.1 (-0.2 to 0.5)	92.2 (37.6 to 150.3)	134.9 (62.5 to 217.5)	47.0 (30.6 to 68.4)	0.3 (-1.9 to 2.6)
Eating disorders	-	-	-	-	3.6 (2.1 to 5.6)	4.9 (2.9 to 7.6)	36.9 (20.8 to 54.1)	5.1 (-6.5 to 18.5)
Anorexia nervosa	3.4 (2.2 to 5.0)	5.2 (3.4 to 7.4)	51.2 (32.5 to 74.1)	20.4 (7.7 to 35.5)	0.7 (0.4 to 1.2)	1.1 (0.6 to 1.8)	51.9 (14.9 to 101.5)	20.7 (-7.8 to 58.7)
Bulimia nervosa	13.5 (9.1 to 19.1)	17.9 (12.2 to 25.4)	32.6 (28.0 to 38.4)	1.1 (0.8 to 1.5)	2.8 (1.6 to 4.6)	3.8 (2.2 to 6.1)	32.9 (15.6 to 51.6)	1.1 (-10.7 to 14.7)
Autistic spectrum disorders	-	-	-	-	29.1 (20.3 to 39.6)	38.0 (26.1 to 51.3)	30.3 (25.2 to 35.1)	0.2 (-3.3 to 3.7)
Autism	73.4 (69.5 to 77.5)	96.3 (91.3 to 101.6)	31.4 (30.5 to 32.5)	0.1 (0.1 to 0.1)	18.1 (12.1 to 24.9)	23.7 (15.8 to 32.4)	30.5 (23.5 to 37.6)	0.2 (-4.6 to 5.0)
Asperger syndrome	109.8 (103.0 to 116.4)	143.3 (134.2 to 152.1)	30.6 (29.3 to 31.9)	0.1 (0.1 to 0.1)	11.0 (7.5 to 15.4)	14.3 (9.9 to 20.1)	30.1 (24.6 to 36.0)	0.3 (-3.4 to 4.3)
Attention-deficit/hyperactivity disorder	181.7 (149.9 to 214.2)	183.7 (151.6 to 216.4)	1.3 (0.7 to 1.6)	0.2 (0.2 to 0.2)	2.2 (1.3 to 3.5)	2.2 (1.3 to 3.5)	1.3 (-6.5 to 9.4)	0.3 (-7.4 to 8.2)
Conduct disorder	335.9 (271.9 to 389.3)	340.1 (281.5 to 397.5)	1.3 (-0.3 to 3.1)	0.2 (0.2 to 0.3)	1.3 (0.6 to 2.4)	1.6 (0.6 to 3.1)	1.6 (-2.9 to 6.1)	0.4 (-3.6 to 4.8)
Idiopathic intellectual disability	777.1 (650.9 to 942.6)	902.3 (735.7 to 1,105.7)	16.4 (4.7 to 27.6)	-9.5 (-18.7 to -0.4)	38.0 (24.9 to 54.1)	44.0 (29.1 to 62.2)	15.7 (4.0 to 27.6)	-9.5 (-19.1 to -0.3)
Other mental and substance use disorders	324.1 (301.8 to 345.4)	552.5 (518.1 to 584.9)	70.7 (67.8 to 73.8)	0.1 (-0.2 to 0.4)	24.2 (16.4 to 32.6)	41.2 (27.9 to 54.9)	70.1 (62.7 to 77.0)	0.2 (-3.2 to 4.0)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	189.2 (132.9 to 261.1)	350.0 (239.9 to 487.7)	84.3 (64.2 to 113.1)	13.4 (-0.8 to 31.0)
Diabetes mellitus	827.0 (649.4 to 1,021.5)	2,028.9 (1,602.9 to 2,519.1)	144.2 (86.5 to 224.0)	30.7 (0.1 to 73.1)	70.8 (45.1 to 102.5)	176.8 (115.9 to 259.3)	149.7 (91.4 to 236.3)	28.1 (-2.6 to 70.5)
Acute glomerulonephritis	0.2 (0.2 to 0.2)	0.1 (0.1 to 0.2)	-14.9 (-21.4 to -8.7)	-28.9 (-34.0 to -24.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.9 (-21.4 to -8.7)	-28.9 (-34.0 to -24.6)
Chronic kidney disease	-	-	-	-	22.2 (15.6 to 30.2)	34.8 (25.0 to 47.0)	57.1 (42.2 to 72.5)	-1.8 (-10.2 to 6.1)
Chronic kidney disease due to diabetes mellitus	138.8 (93.2 to 212.2)	304.8 (187.0 to 456.0)	115.2 (57.6 to 228.8)	15.5 (-17.4 to 70.2)	3.4 (2.2 to 4.9)	7.1 (4.6 to 10.1)	108.1 (54.3 to 206.8)	13.1 (-18.1 to 59.5)
Chronic kidney disease due to hypertension	200.2 (132.9 to 289.9)	247.2 (172.3 to 349.0)	25.1 (9.4 to 63.1)	-15.6 (-35.5 to 6.4)	6.3 (4.5 to 8.5)	8.6 (5.8 to 12.1)	34.5 (17.1 to 82.5)	-24.1 (-38.5 to 7.2)
Chronic kidney disease due to glomerulonephritis	244.3 (167.2 to 346.8)	329.2 (229.7 to 481.0)	35.3 (2.9 to 84.1)	15.3 (-4.2 to 43.0)	5.4 (3.8 to 8.0)	6.5 (4.4 to 9.1)	17.4 (-11.8 to 47.8)	-13.5 (-34.9 to 7.8)
Chronic kidney disease due to other causes	267.5 (188.5 to 366.2)	511.7 (353.1 to 723.0)	91.1 (44.0 to 158.0)	15.3 (-9.9 to 62.5)	6.9 (4.8 to 9.6)	12.6 (8.7 to 17.3)	85.2 (35.4 to 132.2)	18.0 (-8.9 to 47.7)
Urinary diseases and male infertility	-	-	-	-	9.1 (5.8 to 13.3)	19.4 (12.2 to 28.5)	111.3 (84.0 to 145.2)	11.4 (-0.5 to 28.4)

Appendix Table G.4 - Morocco prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	814.7 (749.4 to 880.9)	1,508.4 (1,391.4 to 1,616.0)	85.7 (65.8 to 105.5)	-7.7 (-17.2 to 2.2)	22.5 (15.2 to 31.7)	41.6 (28.2 to 58.4)	85.2 (65.1 to 105.0)	-7.6 (-17.1 to 2.3)
Other oral disorders	376.9 (356.8 to 399.7)	574.3 (543.3 to 605.0)	52.7 (41.3 to 64.4)	-0.1 (-7.2 to 7.1)	11.1 (6.9 to 16.7)	16.8 (10.5 to 25.0)	51.7 (40.2 to 64.0)	-0.3 (-7.5 to 7.5)
Injuries	-	-	-	-	100.4 (73.2 to 135.2)	112.3 (84.1 to 146.2)	13.6 (8.2 to 26.8)	-32.6 (-46.4 to -24.3)
Transport injuries	-	-	-	-	38.4 (28.7 to 49.6)	49.4 (36.8 to 64.7)	28.4 (18.3 to 39.3)	-22.5 (-27.8 to -16.8)
Road injuries	-	-	-	-	32.9 (24.8 to 42.4)	42.8 (31.9 to 56.1)	30.2 (19.6 to 41.9)	-20.8 (-26.8 to -14.5)
Pedestrian road injuries	-	-	-	-	8.5 (6.3 to 11.0)	9.3 (6.9 to 12.2)	9.6 (3.6 to 22.7)	-28.6 (-35.6 to -21.8)
Cyclist road injuries	-	-	-	-	3.2 (2.4 to 4.1)	5.1 (3.8 to 6.7)	60.6 (48.3 to 74.7)	-5.8 (-12.5 to 1.7)
Motorcyclist road injuries	-	-	-	-	4.0 (3.0 to 5.2)	4.5 (3.2 to 5.9)	10.2 (0.8 to 22.6)	-35.1 (-41.2 to -28.5)
Motor vehicle road injuries	-	-	-	-	16.8 (12.5 to 21.7)	23.8 (17.7 to 31.0)	41.4 (26.6 to 56.6)	-15.6 (-23.5 to -7.8)
Other road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-32.5 (-38.2 to -26.0)	-60.2 (-63.1 to -57.0)
Other transport injuries	-	-	-	-	5.6 (4.2 to 7.2)	6.6 (4.9 to 8.7)	17.5 (8.8 to 27.7)	-32.4 (-37.2 to -26.6)
Unintentional injuries	-	-	-	-	41.3 (31.4 to 53.3)	52.7 (39.8 to 69.3)	27.5 (20.2 to 34.7)	-23.6 (-27.6 to -19.9)
Falls	-	-	-	-	13.8 (10.4 to 17.6)	20.8 (15.5 to 27.3)	51.0 (39.5 to 62.1)	-18.3 (-24.8 to -12.3)
Drowning	-	-	-	-	1.1 (0.8 to 1.4)	0.9 (0.7 to 1.2)	-12.8 (-23.2 to -2.1)	-44.3 (-50.4 to -38.1)
Fire, heat, and hot substances	-	-	-	-	3.1 (2.4 to 4.0)	2.3 (1.7 to 3.0)	-27.8 (-35.3 to -19.5)	-51.6 (-56.1 to -47.0)
Poisonings	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.5)	-11.4 (-27.8 to 8.1)	-39.7 (-49.6 to -28.1)
Exposure to mechanical forces	-	-	-	-	14.9 (11.3 to 19.4)	18.3 (13.6 to 24.3)	23.1 (13.8 to 32.3)	-21.6 (-25.7 to -17.0)
Unintentional firearm injuries	-	-	-	-	0.7 (0.5 to 0.8)	0.7 (0.5 to 1.0)	7.8 (2.0 to 19.1)	-36.6 (-41.5 to -30.7)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	69.0 (51.6 to 87.6)	5.6 (-3.7 to 15.2)
Other exposure to mechanical forces	-	-	-	-	14.0 (10.7 to 18.5)	17.3 (12.9 to 23.1)	23.4 (14.0 to 32.9)	-21.0 (-25.4 to -16.4)
Adverse effects of medical treatment	-	-	-	-	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	86.3 (74.1 to 99.5)	13.0 (5.5 to 22.7)
Animal contact	-	-	-	-	0.7 (0.5 to 0.9)	0.8 (0.6 to 1.0)	15.0 (3.9 to 26.1)	-25.1 (-31.3 to -19.3)
Venomous animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	16.7 (1.7 to 34.4)	-24.5 (-33.8 to -14.7)
Non-venomous animal contact	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	13.2 (1.3 to 25.4)	-26.1 (-31.4 to -19.9)
Foreign body	-	-	-	-	0.8 (0.6 to 1.0)	1.1 (0.8 to 1.4)	33.4 (24.4 to 43.9)	-16.1 (-20.9 to -10.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-10.8 (-22.8 to 4.0)	-36.3 (-43.3 to -28.1)
Foreign body in eyes	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	44.1 (29.0 to 60.6)	-5.2 (-13.2 to 4.5)
Foreign body in other body part	-	-	-	-	0.4 (0.3 to 0.6)	0.6 (0.5 to 0.8)	47.2 (35.9 to 61.4)	-13.2 (-18.9 to -6.1)
Other unintentional injuries	-	-	-	-	6.3 (4.7 to 8.1)	7.6 (5.7 to 10.0)	21.0 (11.2 to 31.6)	-29.2 (-34.8 to -24.2)
Self-harm and interpersonal violence	-	-	-	-	2.1 (1.6 to 2.7)	3.9 (2.9 to 5.1)	85.1 (71.5 to 100.9)	9.2 (2.0 to 17.8)
Self-harm	-	-	-	-	0.9 (0.7 to 1.2)	1.4 (1.0 to 1.8)	50.3 (35.4 to 66.6)	-17.8 (-25.2 to -9.9)
Interpersonal violence	-	-	-	-	1.2 (0.9 to 1.5)	2.5 (1.9 to 3.3)	112.1 (94.2 to 133.4)	35.9 (24.9 to 48.5)
Assault by firearm	-	-	-	-	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.7)	126.1 (104.9 to 150.7)	46.9 (34.2 to 61.0)
Assault by sharp object	-	-	-	-	0.2 (0.2 to 0.3)	0.6 (0.4 to 0.8)	153.4 (126.0 to 185.5)	56.2 (41.0 to 73.9)
Assault by other means	-	-	-	-	0.7 (0.6 to 0.9)	1.4 (1.1 to 1.8)	95.3 (75.3 to 118.1)	26.1 (14.2 to 39.3)
Forces of nature, war, and legal intervention	-	-	-	-	18.5 (6.1 to 46.6)	6.2 (2.5 to 14.0)	-65.4 (-72.5 to -54.8)	-78.2 (-82.8 to -71.3)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.6 (0.3 to 1.1)	-	-
Collective violence and legal intervention	-	-	-	-	18.5 (6.1 to 46.6)	5.6 (2.1 to 13.1)	-68.6 (-74.3 to -61.0)	-80.1 (-83.8 to -74.6)

Appendix Table G.4 - Mozambique prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,444.1 (1,055.7 to 1,894.6)	2,698.5 (1,993.7 to 3,505.0)	87.7 (76.8 to 96.5)	0.3 (-6.3 to 4.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	458.5 (315.3 to 670.8)	967.7 (700.3 to 1,314.3)	111.7 (88.8 to 139.7)	24.6 (7.2 to 47.0)
HIV/AIDS and tuberculosis	-	-	-	-	21.6 (14.8 to 29.2)	294.9 (203.0 to 396.0)	1,274.0 (984.7 to 1,621.3)	584.0 (433.3 to 774.8)
Tuberculosis	60.9 (54.3 to 68.2)	99.7 (88.2 to 112.0)	64.2 (53.5 to 77.0)	-18.4 (-23.8 to -12.0)	18.2 (12.3 to 24.8)	30.1 (20.4 to 41.6)	65.2 (52.2 to 79.3)	-18.1 (-24.4 to -11.2)
HIV/AIDS	-	-	-	-	3.4 (2.3 to 4.8)	264.8 (180.4 to 358.6)	7,696.2 (5,778.5 to 10,376.1)	1,173.9 (3,086.3 to 5,836.6)
HIV/AIDS resulting in mycobacterial infection	1.2 (0.6 to 1.8)	30.4 (21.2 to 39.0)	2,604.0 (1,943.4 to 3,543.0)	1,304.7 (951.3 to 1,783.1)	0.4 (0.2 to 0.7)	11.1 (6.9 to 16.5)	2,575.3 (1,809.8 to 3,711.0)	1,286.5 (896.5 to 1,905.5)
HIV/AIDS resulting in other diseases	37.3 (31.2 to 46.9)	1,612.8 (1,375.1 to 1,812.2)	4,253.5 (3,358.5 to 5,392.8)	2,261.7 (1,786.6 to 2,898.3)	3.0 (1.9 to 3.3)	253.7 (170.5 to 344.4)	8,441.2 (6,184.1 to 11,726.6)	4,670.0 (3,315.8 to 6,755.7)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	54.6 (40.0 to 73.2)	76.4 (54.5 to 102.4)	39.6 (27.7 to 52.5)	-25.8 (-31.8 to -19.9)
Diarrheal diseases	140.0 (125.5 to 154.7)	227.5 (210.4 to 244.4)	62.6 (44.3 to 87.8)	-10.2 (-19.1 to 1.8)	22.5 (15.3 to 31.0)	36.8 (24.8 to 51.2)	63.6 (43.5 to 89.7)	-10.0 (-19.6 to 1.9)
Intestinal infectious diseases	-	-	-	-	0.8 (0.5 to 1.1)	0.8 (0.5 to 1.2)	5.7 (20.2 to 37.7)	-44.3 (-57.0 to -28.3)
Typhoid fever	4.0 (3.5 to 4.5)	4.6 (3.9 to 5.2)	15.2 (-6.4 to 40.3)	-39.2 (-50.3 to -25.4)	0.5 (0.3 to 0.8)	0.6 (0.4 to 0.9)	17.2 (-12.2 to 52.7)	-38.2 (-51.8 to -20.9)
Paratyphoid fever	1.5 (1.3 to 1.7)	2.1 (1.7 to 2.5)	43.9 (12.2 to 79.1)	-24.2 (-40.3 to -6.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	43.4 (5.0 to 94.6)	-24.1 (-42.6 to -1.7)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.1 to 0.3)	0.1 (0.0 to 0.2)	-58.4 (-70.0 to -47.5)	-73.7 (-83.8 to -57.3)
Lower respiratory infections	8.9 (7.6 to 10.3)	10.5 (7.5 to 12.7)	19.7 (-17.9 to 51.1)	-28.9 (-43.6 to -15.1)	0.9 (0.6 to 1.3)	5.8 (0.7 to 1.7)	20.3 (-19.4 to 56.5)	-28.9 (-45.5 to -12.3)
Upper respiratory infections	513.8 (483.7 to 544.1)	919.0 (872.8 to 970.1)	79.8 (67.3 to 95.9)	-4.1 (-10.8 to 3.2)	6.0 (3.4 to 10.0)	10.8 (6.0 to 17.6)	79.9 (66.4 to 97.1)	-3.9 (-11.1 to 4.0)
Otitis media	235.3 (215.7 to 256.4)	399.5 (364.8 to 433.3)	70.2 (54.7 to 87.3)	-11.1 (-19.6 to -2.6)	4.8 (2.9 to 7.7)	8.2 (4.8 to 13.1)	69.4 (51.9 to 90.8)	-11.4 (-20.4 to -1.2)
Meningitis	-	-	-	-	17.2 (11.6 to 23.7)	16.4 (11.2 to 22.8)	-4.6 (-21.8 to 17.4)	-48.3 (-56.9 to -37.7)
Pneumococcal meningitis	59.7 (38.9 to 86.3)	58.2 (37.6 to 84.4)	-2.2 (-25.4 to 27.1)	-46.2 (-58.6 to -30.3)	5.5 (3.5 to 8.0)	5.8 (3.9 to 8.1)	6.8 (-21.2 to 39.8)	-41.9 (-55.9 to -25.8)
H influenzae type B meningitis	36.6 (17.3 to 63.6)	30.7 (14.7 to 53.3)	-14.6 (-40.8 to 20.1)	-55.4 (-68.6 to -38.0)	3.8 (2.3 to 5.8)	3.8 (2.3 to 5.9)	2.6 (-39.4 to 67.2)	-45.8 (-67.5 to -24.5)
Meningococcal meningitis	9.4 (4.0 to 18.4)	8.6 (3.4 to 17.0)	-6.6 (-34.6 to 23.0)	-49.1 (-64.5 to -30.4)	1.2 (0.7 to 2.0)	1.2 (0.7 to 1.8)	-4.8 (-31.5 to 30.8)	-47.3 (-62.1 to -29.3)
Other meningitis	53.9 (31.3 to 87.6)	45.2 (24.2 to 78.7)	-15.6 (-36.5 to 6.2)	-54.0 (-65.3 to -41.1)	6.6 (4.2 to 10.1)	5.6 (3.7 to 8.1)	-12.9 (-42.9 to 18.6)	-52.9 (-67.8 to -37.8)
Encephalitis	2.8 (1.4 to 5.4)	4.3 (2.0 to 8.8)	53.0 (30.2 to 73.5)	-18.7 (-32.6 to -8.4)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.7)	62.5 (39.5 to 85.9)	-16.2 (-26.0 to -3.4)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-75.1 (-98.7 to 43.2)	-83.4 (-98.9 to 117.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-75.1 (-98.9 to 450.8)	-83.4 (-98.9 to 125.7)
Whooping cough	30.3 (23.2 to 39.3)	22.0 (17.2 to 28.1)	-26.7 (-30.7 to -22.7)	-59.6 (-61.7 to -57.3)	1.5 (0.9 to 2.4)	1.1 (0.6 to 1.8)	-26.7 (-33.5 to -19.0)	-59.5 (-63.3 to -55.2)
Tetanus	1.8 (0.8 to 5.2)	0.3 (0.2 to 0.6)	-78.5 (-94.4 to -46.5)	-87.3 (-96.9 to -69.7)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-72.1 (-84.7 to -53.6)	-81.9 (-91.3 to -72.0)
Measles	4.4 (3.4 to 5.6)	2.6 (1.9 to 3.5)	-40.4 (-50.3 to -26.7)	-57.7 (-73.0 to -40.3)	0.4 (0.2 to 0.6)	0.2 (0.1 to 0.4)	-39.7 (-59.1 to -15.6)	-47.3 (-77.8 to -54.3)
Varicella and herpes zoster	8.6 (7.9 to 9.5)	17.0 (15.6 to 18.5)	99.0 (73.0 to 125.8)	1.1 (-18.0 to 25.0)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	91.8 (33.5 to 165.1)	-0.4 (-31.6 to 44.2)
Neglected tropical diseases and malaria	-	-	-	-	206.3 (130.0 to 326.6)	306.0 (195.5 to 487.7)	47.9 (37.9 to 61.7)	-20.1 (-27.6 to -8.1)
Malaria	7,269.6 (6,967.9 to 7,580.1)	8,848.9 (8,469.5 to 9,229.7)	22.3 (18.1 to 26.7)	-36.7 (-38.7 to -34.5)	68.1 (45.2 to 98.5)	85.0 (57.2 to 121.8)	25.1 (14.7 to 34.1)	-36.6 (-41.0 to -32.8)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	89.5 (11.2 to 247.0)	-3.8 (-33.7 to 44.4)
Visceral leishmaniasis	1.0 (0.6 to 1.7)	2.0 (0.9 to 3.7)	94.4 (1.2 to 288.5)	1.7 (-39.0 to 67.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	93.3 (-2.6 to 299.7)	0.6 (-40.4 to 67.0)
Cutaneous and mucocutaneous leishmaniasis	1.8 (1.1 to 2.9)	3.1 (2.0 to 4.7)	75.7 (8.1 to 171.0)	-13.0 (-46.6 to 36.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	75.3 (1.5 to 194.4)	-12.6 (-46.9 to 42.4)
African trypanosomiasis	0.1 (0.0 to 0.2)	-	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.1)	-	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Schistosomiasis	7,975.7 (6,052.0 to 9,834.4)	11,509.7 (8,751.4 to 14,296.1)	43.8 (35.9 to 61.2)	-25.2 (-29.2 to -15.9)	82.2 (41.5 to 154.6)	120.8 (60.3 to 235.8)	45.7 (30.9 to 66.8)	-24.8 (-31.4 to -14.0)
Cysticercosis	2.9 (1.3 to 5.5)	5.1 (2.9 to 8.2)	84.8 (-19.6 to 318.3)	-5.8 (-53.3 to 117.7)	0.7 (0.3 to 1.5)	1.4 (0.7 to 2.5)	94.0 (-18.8 to 360.1)	0.7 (-52.1 to 126.2)
Cystic echinococcosis	4.1 (3.7 to 4.4)	12.0 (11.1 to 13.3)	195.0 (163.3 to 237.5)	15.9 (4.3 to 30.7)	0.4 (0.2 to 0.5)	1.1 (0.8 to 1.6)	199.3 (144.9 to 275.7)	20.3 (0.7 to 44.5)
Lymphatic filariasis	882.0 (598.7 to 1,240.4)	1,313.2 (966.2 to 1,704.9)	54.7 (-7.4 to 152.0)	-17.9 (-44.1 to 28.7)	22.2 (11.3 to 40.1)	41.1 (22.1 to 71.0)	81.4 (20.5 to 224.7)	5.9 (-28.7 to 79.5)
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	26.7 (7.1 to 50.7)	20.0 (7.2 to 48.4)	-29.2 (-72.5 to 117.2)	-64.0 (84.7 to 11.2)	1.7 (0.5 to 3.6)	1.2 (0.4 to 3.3)	-30.3 (-73.7 to 77.6)	-65.2 (-85.3 to -9.7)
Dengue	0.6 (0.2 to 1.6)	5.7 (1.7 to 14.7)	817.7 (806.5 to 830.7)	382.9 (377.0 to 389.7)	0.1 (0.0 to 0.3)	0.9 (0.2 to 2.4)	765.1 (609.4 to 935.4)	347.1 (275.8 to 419.8)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-43.4 to 25.8)	0.0 (0.0 to 0.0)	-18.4 (-43.7 to 26.0)	-48.6 (-62.2 to -28.2)
Intestinal nematode infections	-	-	-	-	21.6 (12.9 to 34.2)	40.3 (23.7 to 64.4)	86.5 (70.1 to 105.0)	-2.7 (-12.8 to 7.1)
Ascariasis	1,475.6 (1,308.8 to 1,662.0)	2,762.9 (2,444.5 to 3,097.2)	88.5 (59.4 to 120.5)	-0.8 (-19.9 to 18.0)	0.6 (0.4 to 1.1)	1.2 (0.7 to 2.0)	86.4 (59.3 to 120.7)	-0.8 (-18.8 to 19.6)
Trichuriasis	3,758.2 (3,420.5 to 4,141.6)	7,035.9 (6,361.7 to 7,796.7)	87.7 (64.4 to 116.4)	-1.2 (-16.1 to 18.0)	8.3 (4.6 to 14.0)	15.6 (8.4 to 26.3)	88.3 (63.7 to 114.5)	-0.6 (-16.2 to 17.9)
Hookworm disease	2,236.9 (2,383.4 to 2,907.3)	4,932.4 (4,461.8 to 5,406.9)	87.8 (64.6 to 116.5)	-17.2 (-16.7 to 17.4)	12.6 (7.8 to 19.2)	23.6 (14.4 to 36.8)	86.0 (62.4 to 109.2)	-3.8 (-16.3 to 8.5)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	198.8 (139.0 to 260.0)	329.0 (310.8 to 352.3)	66.4 (26.7 to 136.4)	-14.3 (-34.4 to 19.7)	9.2 (5.6 to 13.8)	14.0 (9.1 to 20.6)	49.1 (25.7 to 118.9)	-25.0 (-41.2 to 6.6)
Maternal disorders	-	-	-	-	5.0 (3.4 to 7.1)	7.2 (4.8 to 10.1)	42.6 (22.6 to 64.2)	-28.5 (-38.2 to -18.4)
Maternal hemorrhage	3.9 (2.7 to 5.1)	4.9 (3.1 to 6.8)	27.2 (-25.2 to 111.7)	-41.6 (-64.7 to -4.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	15.1 (-46.5 to 139.0)	-47.4 (-73.8 to -6.0)
Maternal sepsis and other maternal infections	7.3 (4.9 to 9.3)	8.9 (6.1 to 11.5)	23.0 (11.3 to 38.5)	-39.7 (-45.2 to -32.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	22.3 (-17.5 to 87.5)	-41.3 (-58.8 to -15.3)
Maternal hypertensive disorders	5.7 (2.9 to 9.4)	9.0 (4.5 to 14.8)	59.7 (33.6 to 82.3)	-28.1 (-39.7 to -17.7)	0.3 (0.1 to 0.5)	0.4 (0.2 to 0.9)	60.3 (28.5 to 93.3)	-27.4 (-41.8 to -12.6)
Obstructed labor	10.6 (8.7 to 12.8)	14.9 (12.2 to 18.1)	41.3 (27.7 to 56.2)	-27.9 (-35.6 to -20.0)	3.4 (2.3 to 4.9)	4.9 (3.2 to 7.1)	42.0 (22.5 to 65.9)	-27.6 (-37.4 to -15.8)
Complications of abortion	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	85.0 (4.8 to 283.7)	-1.4 (-52.5 to 52.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.0 (4.8 to 283.9)	-1.4 (-52.6 to 52.7)
Other maternal disorders	-	-	-	-	1.1 (0.7 to 1.6)	1.5 (1.0 to 2.3)	47.0 (-2.3 to 113.2)	-27.4 (-51.1 to 4.5)
Neonatal disorders	-	-	-	-	7.9 (4.4 to 14.6)	38.1 (25.8 to 52.0)	404.4 (186.0 to 675.7)	161.9 (38.5 to 317.4)
Preterm birth complications	58.1 (36.5 to 90.3)	243.6 (171.2 to 342.7)	324.9 (253.3 to 423.6)	113.7 (78.1 to 161.7)	2.6 (1.5 to 3.9)	20.5 (13.4 to 29.1)	686.1 (458.8 to 1,159.5)	286.6 (180.8 to 520.2)
Neonatal encephalopathy due to birth asphyxia and trauma	104.8 (6.8 to 355.0)	116.7 (17.3 to 369.8)	22.8 (-21.8 to 179.9)	-38.0 (-60.9 to -45.5)	3.0 (0.9 to 7.9)	6.8 (3.1 to 12.0)	150.4 (30.6 to 483.0)	22.5 (-36.2 to 255.7)
Neonatal sepsis and other neonatal infections	0.2 (0.1 to 0.4)	0.6 (0.2 to 1.1)	170.0 (155.8 to 206.9)	0.1 (-53.3 to 83.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	177.0 (149.2 to 213.6)	66.0 (49.4 to 88.0)
Hemolytic disease and other neonatal jaundice	1.5 (0.7 to 2.8)	10.0 (4.8 to 15.7)	578.0 (181.9 to 1,558.2)	318.5 (69.5 to 920.0)	0.6 (0.2 to 1.1)	3.8 (1.6 to 6.5)	602.3 (189.1 to 1,594.3)	326.1 (68.6 to 941.9)
Other neonatal disorders	-	-	-	-	1.8 (0.7 to 3.9)	6.9 (3.3 to 12.0)	309.7 (79.2 to 839.8)	112.0 (-12.0 to 394.5)
Nutritional deficiencies	-	-	-	-	151.4 (102.8 to 215.6)	226.3 (151.9 to 329.2)	49.6 (39.3 to 60.8)	-23.4 (-27.8 to -17.6)
Protein-energy malnutrition	87.9 (49.8 to 147.6)	106.8 (64.3 to 165.7)	24.1 (-41.6 to 158.2)	-9.0 (-63.5 to 32.3)	20.6 (5.2 to 19.0)	11.2 (6.7 to 22.6)	26.0 (-0.7 to 162.0)	-38.2 (-64.0 to 34.5)
Iodine deficiency	597.4 (514.2 to 677.5)	681.7 (564.6 to 805.9)	14.8 (-9.5 to 40.8)	-40.7 (-54.5 to -25.3)	10.7 (6.4 to 16.9)	12.3 (7.5 to 19.2)	15.5 (-9.1 to 42.3)	-40.3 (-54.4 to -24.7)
Vitamin A deficiency	29.5 (17.4 to 48.8)	29.2 (17.5 to 46.2)	-3.0 (-24.3 to 43.4)	-50.0 (-60.5 to -28.5)	1.4 (0.8 to 2.4)	1.4 (0.8 to 2.3)	-5.3 (-23.5 to 26.8)	-49.7 (-58.6 to -33.7)

Appendix Table G.4 - Mozambique prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	83.3	-3.0
Silicosis	0.1	0.1	74.5	-6.7	(0.0 to 0.0)	(0.0 to 0.1)	(77.8 to 89.2)	(5.9 to 0.1)
Asbestosis	-	-	0.0	0.0	0.0	0.0	74.2	-6.8
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.1	0.1	91.8	0.9	0.0	0.0	91.2	0.5
Asthma	184.2	320.5	(85.4 to 99.8)	(-2.4 to 4.9)	7.8	13.7	77.7	-6.3
Interstitial lung disease and pulmonary sarcoidosis	0.2	0.6	134.2	21.6	(4.4 to 12.6)	(7.9 to 21.4)	(12.6 to 155.0)	(37.2 to 27.7)
Other chronic respiratory diseases	-	-	-	-	16.2	17.8	132.9	21.0
Cirrhosis	-	-	-	-	(7.9 to 29.8)	(9.1 to 30.3)	(-30.5 to 68.4)	(-62.4 to -10.0)
Cirrhosis due to hepatitis B	1.7	2.8	72.9	-2.2	(0.7 to 1.5)	(1.1 to 2.4)	(35.9 to 78.1)	(-24.5 to 5.1)
Cirrhosis due to hepatitis C	1.1	1.8	69.3	-7.5	0.3	0.5	74.8	-1.7
Cirrhosis due to alcohol use	1.7	1.9	-41.0	0.3	(0.1 to 0.3)	(0.2 to 0.5)	(-10.1 to 214.1)	(54.2 to 65.1)
Cirrhosis due to other causes	2.1	3.6	69.7	4.3	(0.2 to 0.4)	(0.2 to 0.5)	(-32.7 to 71.4)	(-62.7 to -9.1)
Digestive diseases	-	-	-	-	17.7	32.9	86.2	-4.5
Peptic ulcer disease	89.5	135.3	51.7	-21.6	(12.4 to 24.3)	(23.1 to 45.0)	(65.9 to 104.3)	(-13.9 to 3.8)
Gastritis and duodenitis	166.9	299.0	80.2	-5.3	3.4	5.3	56.0	-21.1
Appendicitis	1.7	3.4	102.1	2.3	(2.3 to 4.9)	(3.6 to 7.5)	(22.8 to 89.9)	(-35.1 to -8.5)
Paralytic ileus and intestinal obstruction	0.2	0.4	79.9	-2.5	(5.0 to 10.6)	(8.9 to 19.0)	(48.1 to 108.9)	(-19.4 to 6.6)
Inguinal, femoral, and abdominal hernia	31.8	100.7	223.7	161.6	(0.3 to 0.8)	(0.6 to 1.6)	(23.0 to 228.0)	(-35.3 to 61.8)
Inflammatory bowel disease	12.2	29.2	140.6	25.8	(0.1 to 0.1)	(0.1 to 0.2)	(13.9 to 168.9)	(-25.6 to 25.0)
Vascular intestinal disorders	0.0	0.1	80.1	-3.6	(0.2 to 0.7)	(0.5 to 2.0)	(126.8 to 300.4)	(113.3 to 220.4)
Gallbladder and biliary diseases	4.2	9.5	125.6	15.9	(1.7 to 3.5)	(4.3 to 8.4)	(120.3 to 165.9)	(16.2 to 37.1)
Pancreatitis	2.1	4.4	108.8	5.6	0.0	0.0	36.8	175.6
Other digestive diseases	-	-	-	-	(0.0 to 0.0)	(0.0 to 0.0)	(36.8 to 175.6)	(35.2 to 82.4)
Neurological disorders	-	-	-	-	50.4	104.9	108.0	2.9
Alzheimer disease and other dementias	21.1	43.0	104.2	-1.3	(31.8 to 72.3)	(68.3 to 151.8)	(40.5 to 182.1)	(-23.8 to 26.7)
Parkinson disease	1.1	2.2	89.3	-0.5	2.9	5.8	108.4	-1.1
Epilepsy	26.1	49.9	90.2	-1.4	(2.0 to 3.6)	(4.1 to 7.6)	(77.5 to 148.5)	(-16.1 to 18.4)
Multiple sclerosis	1.0	2.1	120.8	14.1	(0.1 to 0.2)	(0.1 to 0.4)	(53.6 to 128.0)	(-18.4 to 19.8)
Migraine	730.9	1,481.2	102.2	9.2	(3.5 to 12.5)	(7.4 to 25.9)	(-4.3 to 375.8)	(-50.8 to 142.2)
Tension-type headache	1,561.8	3,233.1	108.1	4.2	(-3.7 to 32.1)	(0.2 to 4.0)	(70.6 to 177.0)	(-11.9 to 42.9)
Medication overuse headache	62.8	172.2	174.9	42.2	2.9	5.8	91.2	-4.7
Other neurological disorders	0.0	0.0	77.4	-7.6	(43.8 to 48.7)	(12.9 to 40.9)	(-1.0 to 236.9)	(-45.6 to 49.8)
Mental and substance use disorders	-	-	-	-	2.3	4.1	109.1	4.6
Schizophrenia	26.9	52.2	95.8	-0.0	(-4.7 to 13.6)	(2.4 to 8.7)	(84.8 to 134.5)	(-4.6 to 14.8)
Alcohol use disorders	128.0	237.8	87.0	-5.8	9.7	26.7	175.7	43.2
Drug use disorders	-	-	-	-	(5.6 to 15.3)	(15.2 to 43.0)	(110.6 to 265.2)	(7.1 to 95.1)
Opioid use disorders	19.0	37.6	98.8	-0.2	(2.0 to 6.8)	(2.6 to 6.5)	(-23.7 to 100.1)	(-62.9 to -3.7)
Cocaine use disorders	5.9	12.3	109.3	0.8	298.9	567.2	89.9	-2.1
Amphetamine use disorders	20.3	40.6	100.9	1.1	(208.4 to 405.1)	(391.9 to 767.3)	(82.9 to 96.5)	(-5.2 to 1.3)
Cannabis use disorders	16.7	32.6	96.9	0.7	16.8	32.8	95.6	0.4
Other drug use disorders	-	-	-	-	(10.0 to 20.3)	(19.9 to 41.7)	(79.1 to 123.8)	(-9.6 to 10.8)
Depressive disorders	-	-	-	-	7.6	15.2	98.4	-0.3
Major depressive disorder	649.3	1,182.5	83.2	-4.5	(4.5 to 11.7)	(8.3 to 23.3)	(74.8 to 122.8)	(-11.4 to 11.5)
Dysthymia	131.1	251.0	92.4	-0.8	109.3	217.7	109.3	2.7
Bipolar disorder	70.7	138.9	97.5	-0.9	(10.9 to 27.8)	(15.0 to 24.0)	(47.0 to 188.3)	(-24.8 to 35.3)
Anxiety disorders	401.2	770.3	93.1	-1.2	1.1	2.6	102.2	1.3
Eating disorders	-	-	-	-	(-0.0 to 11.9)	(1.6 to 3.9)	(69.8 to 137.5)	(-13.4 to 18.8)
Anorexia nervosa	2.3	4.5	97.5	-0.4	0.5	0.9	96.5	0.2
Bulimia nervosa	13.3	25.8	94.5	-3.0	(0.3 to 0.7)	(0.5 to 1.5)	(66.3 to 137.2)	(-13.9 to 18.1)
Autistic spectrum disorders	-	-	-	-	3.4	7.0	104.8	2.3
Autism	41.1	78.8	92.4	1.3	(2.1 to 5.0)	(4.3 to 10.3)	(50.7 to 183.0)	(-24.1 to 38.9)
Asperger syndrome	58.9	113.0	92.8	1.7	14.0	28.0	94.4	4.1
Attention-deficit/hyperactivity disorder	104.4	193.3	86.1	0.6	(1.9 to 5.0)	(3.8 to 9.8)	(78.9 to 115.0)	(-9.9 to 6.9)
Conduct disorder	155.1	282.6	83.1	0.4	0.0	0.0	92.9	1.6
Idiopathic intellectual disability	67.4 to 312.7	(251.1 to 598.5)	(68.0 to 309.3)	(-12.8 to 121.3)	(0.3 to 17.0)	(11.5 to 33.0)	(75.4 to 313.9)	(-12.9 to 120.4)
Other mental and substance use disorders	153.1	307.5	101.8	1.0	11.2	22.7	102.4	1.2
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	68.6	127.7	85.9	-0.9
Diabetes mellitus	124.5	265.5	114.0	13.5	(48.1 to 92.7)	(90.4 to 171.9)	(74.7 to 98.5)	(-8.0 to 7.0)
Acute glomerulonephritis	0.2	0.2	47.0	-17.0	9.6	20.5	114.2	16.5
Chronic kidney disease	0.1 to 0.2	(0.2 to 0.3)	(35.4 to 56.8)	(-21.1 to -12.4)	(6.1 to 13.9)	(13.6 to 29.1)	(63.1 to 182.0)	(-15.2 to 60.4)
Chronic kidney disease due to diabetes mellitus	197.9	343.4	76.4	-2.8	0.0	0.0	47.0	-17.0
Chronic kidney disease due to hypertension	538.9	1,028.3	92.8	3.1	(1.8 to 4.1)	(3.1 to 7.1)	(25.7 to 141.4)	(-31.5 to 31.5)
Chronic kidney disease due to glomerulonephritis	475.1	919.1	91.9	7.1	(4.5 to 9.9)	(8.7 to 16.9)	(56.5 to 129.5)	(-17.3 to 19.2)
Chronic kidney disease due to other causes	377.2	710.8	91.9	-2.9	(19.6 to 28.9)	(5.0 to 9.6)	(57.7 to 137.9)	(-17.0 to 24.0)
Urinary diseases and male infertility	-	-	-	-	2.2	4.1	88.8	-1.5
	-	-	-	-	3.9	7.6	94.3	3.2
	-	-	-	-	(2.5 to 5.6)	(4.8 to 10.8)	(68.3 to 124.0)	(-9.6 to 15.7)

Appendix Table G.4 - Mozambique prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes								
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	238.5 (223.1 to 254.8)	416.0 (385.4 to 443.1)	75.0 (59.5 to 94.0)	-6.5 (-14.5 to 2.5)	6.4 (4.4 to 8.9)	11.2 (7.6 to 15.5)	75.4 (59.0 to 94.8)	-6.2 (-14.4 to 3.4)
Other oral disorders	195.3 (184.1 to 206.5)	370.1 (349.4 to 389.4)	90.6 (75.7 to 105.7)	-0.9 (-8.5 to 5.9)	5.7 (3.5 to 8.5)	10.8 (6.8 to 16.1)	91.0 (74.7 to 106.4)	-0.8 (-8.9 to 6.1)
Injuries	-	-	-	-	117.5 (61.8 to 218.6)	97.6 (66.3 to 144.1)	-13.8 (-36.6 to 16.5)	-47.6 (-59.2 to -32.7)
Transport injuries	-	-	-	-	10.4 (7.8 to 13.4)	19.7 (14.8 to 25.5)	90.2 (83.2 to 97.3)	4.4 (0.8 to 8.0)
Road injuries	-	-	-	-	8.2 (6.2 to 10.6)	16.7 (12.5 to 21.5)	103.8 (95.9 to 112.2)	10.0 (6.0 to 14.2)
Pedestrian road injuries	-	-	-	-	2.8 (2.1 to 3.6)	5.5 (4.1 to 7.1)	96.6 (86.1 to 109.1)	6.9 (2.3 to 11.9)
Cyclist road injuries	-	-	-	-	0.8 (0.6 to 1.1)	1.4 (1.0 to 1.8)	66.8 (56.3 to 78.0)	-6.0 (-11.7 to 1.4)
Motorcyclist road injuries	-	-	-	-	0.9 (0.7 to 1.2)	1.6 (1.2 to 2.1)	79.0 (69.2 to 90.7)	-2.8 (-8.1 to 3.2)
Motor vehicle road injuries	-	-	-	-	3.5 (2.7 to 4.5)	8.0 (6.0 to 10.3)	128.0 (112.5 to 142.2)	21.6 (13.9 to 28.2)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	10.7 (4.1 to 18.0)	-41.2 (-44.7 to -38.0)
Other transport injuries	-	-	-	-	2.2 (1.7 to 2.8)	3.1 (2.3 to 3.9)	39.1 (30.9 to 48.6)	-18.2 (-23.4 to -12.3)
Unintentional injuries	-	-	-	-	21.4 (16.5 to 27.4)	38.1 (28.8 to 49.7)	77.8 (71.5 to 83.8)	-7.3 (-11.1 to -3.7)
Falls	-	-	-	-	9.0 (6.8 to 11.7)	17.2 (12.8 to 22.5)	90.3 (79.5 to 100.3)	-6.9 (-13.0 to -1.4)
Drowning	-	-	-	-	0.5 (0.4 to 0.6)	0.8 (0.5 to 1.0)	53.0 (37.5 to 69.6)	-16.1 (-23.6 to -7.8)
Fire, heat, and hot substances	-	-	-	-	2.6 (2.0 to 3.3)	4.5 (3.4 to 5.9)	73.3 (57.8 to 92.7)	-3.9 (-11.3 to 4.8)
Poisonings	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	39.2 (16.9 to 67.2)	-25.1 (-35.2 to -12.7)
Exposure to mechanical forces	-	-	-	-	6.4 (4.9 to 8.4)	10.9 (8.2 to 14.3)	70.0 (61.7 to 77.8)	-7.3 (-11.8 to -3.5)
Unintentional firearm injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	98.8 (83.1 to 114.2)	5.5 (-2.0 to 13.7)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	105.7 (87.0 to 127.6)	10.0 (1.5 to 20.1)
Other exposure to mechanical forces	-	-	-	-	6.1 (4.6 to 8.0)	10.3 (7.7 to 13.5)	68.5 (60.0 to 76.4)	-8.1 (-12.7 to -4.3)
Adverse effects of medical treatment	-	-	-	-	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	103.2 (91.1 to 115.9)	9.8 (2.9 to 17.5)
Animal contact	-	-	-	-	0.8 (0.6 to 1.0)	1.0 (0.8 to 1.4)	32.3 (23.8 to 41.0)	-28.0 (-31.7 to -24.3)
Venomous animal contact	-	-	-	-	0.3 (0.3 to 0.5)	0.5 (0.3 to 0.6)	35.1 (20.6 to 50.1)	-27.2 (-34.2 to -20.4)
Non-venomous animal contact	-	-	-	-	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.8)	30.0 (22.3 to 37.8)	-28.6 (-31.9 to -25.2)
Foreign body	-	-	-	-	0.5 (0.4 to 0.6)	0.9 (0.6 to 1.1)	77.7 (68.1 to 87.2)	-5.8 (-10.0 to -1.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	63.8 (42.8 to 88.3)	-9.1 (-17.1 to 0.5)
Foreign body in eyes	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	89.1 (69.2 to 112.9)	-2.2 (-10.7 to 6.7)
Foreign body in other body part	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.6)	78.3 (67.6 to 89.7)	-5.8 (-11.0 to 0.5)
Other unintentional injuries	-	-	-	-	1.3 (1.0 to 1.7)	2.3 (1.7 to 3.0)	73.3 (61.7 to 86.8)	-5.7 (-11.0 to 0.7)
Self-harm and interpersonal violence	-	-	-	-	2.3 (1.8 to 2.9)	4.2 (3.2 to 5.4)	78.1 (69.7 to 88.4)	-1.8 (-6.4 to 3.4)
Self-harm	-	-	-	-	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.6)	131.7 (113.6 to 152.0)	20.0 (11.4 to 28.8)
Interpersonal violence	-	-	-	-	2.1 (1.6 to 2.7)	3.7 (2.8 to 4.8)	73.1 (64.4 to 84.0)	-4.5 (-9.1 to 0.9)
Assault by firearm	-	-	-	-	0.4 (0.3 to 0.5)	0.7 (0.5 to 0.9)	82.4 (69.1 to 96.7)	1.0 (-5.8 to 8.3)
Assault by sharp object	-	-	-	-	0.3 (0.2 to 0.4)	0.7 (0.5 to 0.9)	107.1 (90.5 to 125.2)	12.4 (3.4 to 21.9)
Assault by other means	-	-	-	-	1.4 (1.1 to 1.8)	2.3 (1.8 to 3.0)	63.0 (52.8 to 75.4)	-9.9 (-15.2 to -3.7)
Forces of nature, war, and legal intervention	-	-	-	-	83.4 (31.3 to 184.9)	35.7 (14.0 to 77.8)	-56.9 (-60.7 to -52.6)	-68.3 (-71.2 to -64.9)
Exposure to forces of nature	-	-	-	-	6.8 (3.0 to 13.9)	3.5 (1.6 to 7.5)	-49.0 (-52.7 to -44.3)	-65.0 (-67.8 to -61.3)
Collective violence and legal intervention	-	-	-	-	76.6 (27.7 to 171.3)	32.2 (12.1 to 70.9)	-57.7 (-61.2 to -53.8)	-68.6 (-71.5 to -65.1)

Appendix Table G.4 - Myanmar prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	3,996.1 (2,909.5 to 5,230.4)	4,991.9 (3,677.6 to 6,498.4)	25.3 (17.1 to 31.5)	25.3 (18.4 to 34.4)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1,000.6 (679.2 to 1,415.9)	721.0 (505.4 to 1,006.6)	-28.2 (-34.3 to -18.6)	-39.1 (-44.6 to -31.6)
HIV/AIDS and tuberculosis	-	-	-	-	37.4 (25.1 to 52.2)	86.2 (54.4 to 157.5)	115.1 (88.5 to 244.6)	31.3 (22.3 to 103.9)
Tuberculosis	117.5 (112.5 to 123.1)	232.3 (223.6 to 240.9)	97.7 (90.3 to 105.1)	21.5 (16.7 to 26.5)	35.6 (24.4 to 47.6)	70.7 (48.2 to 95.1)	98.4 (88.1 to 109.8)	22.3 (16.1 to 29.1)
HIV/AIDS	-	-	-	-	41.3 (0.1 to 7.4)	15.5 (2.5 to 78.3)	37.4 (245.6 to 3,524.4)	78.4 (128.6 to 2,236.5)
HIV/AIDS resulting in mycobacterial infection	0.3 (0.0 to 1.3)	2.8 (0.2 to 18.4)	1,138.5 (209.1 to 3,631.4)	639.4 (79.9 to 2,144.7)	0.3 (0.0 to 0.5)	1.1 (0.1 to 7.2)	1,031.6 (112.7 to 3,588.8)	573.4 (27.6 to 2,110.3)
HIV/AIDS resulting in other diseases	20.3 (1.4 to 91.2)	109.3 (25.5 to 445.3)	987.6 (169.8 to 3,016.6)	647.3 (81.9 to 2,033.4)	1.7 (0.1 to 6.6)	14.5 (1.7 to 77.3)	1,208.5 (226.0 to 4,142.1)	793.3 (121.1 to 2,758.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	114.5 (80.8 to 153.4)	82.1 (57.3 to 113.7)	-28.3 (-36.3 to -19.7)	-36.0 (-43.0 to -28.8)
Diarrheal diseases	256.0 (226.9 to 285.6)	149.8 (138.4 to 161.2)	-41.5 (-48.7 to -32.3)	-40.8 (-47.3 to -32.3)	41.3 (27.5 to 58.3)	24.3 (16.6 to 34.3)	-41.3 (-49.2 to -31.1)	-46.1 (-47.2 to -30.7)
Intestinal infectious diseases	-	-	-	-	2.8 (1.7 to 4.4)	1.7 (1.0 to 2.6)	-1.1 (-7.7 to 5.5)	-4.0 (-6.1 to -21.0)
Typhoid fever	16.2 (11.9 to 20.8)	9.6 (7.2 to 12.5)	-41.3 (-56.8 to -10.8)	-46.6 (-60.6 to -19.8)	2.1 (1.3 to 3.2)	1.3 (0.8 to 2.0)	-40.2 (-57.6 to -9.5)	-45.3 (-61.0 to -17.2)
Paratyphoid fever	10.1 (7.4 to 13.2)	5.0 (3.7 to 6.3)	-50.4 (-65.1 to -31.3)	-53.8 (-67.9 to -35.6)	0.5 (0.3 to 0.8)	0.3 (0.2 to 0.4)	-49.3 (-65.8 to -25.9)	-52.9 (-68.5 to -31.1)
Other intestinal infectious diseases	-	-	-	-	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.3)	-0.1 (-67.5 to 39.4)	-35.4 (-70.9 to 27.8)
Lower respiratory infections	9.6 (8.2 to 11.2)	10.7 (8.8 to 12.9)	10.3 (-13.7 to 42.5)	11.8 (-10.6 to 40.9)	1.0 (0.7 to 1.5)	1.1 (0.7 to 1.7)	8.4 (-20.9 to 46.2)	10.4 (-15.8 to 42.7)
Upper respiratory infections	1,501.7 (1,344.6 to 1,654.9)	1,786.2 (1,574.0 to 1,983.2)	18.8 (1.9 to 38.8)	-0.3 (-14.9 to 16.5)	17.6 (9.8 to 29.4)	21.0 (11.6 to 35.1)	19.1 (1.9 to 39.9)	0.4 (-14.5 to 17.4)
Otitis media	575.7 (537.8 to 615.9)	554.0 (519.4 to 591.7)	-3.8 (-11.8 to 5.3)	-14.7 (-21.6 to -7.2)	11.7 (7.1 to 18.7)	11.3 (7.0 to 18.2)	-3.5 (-12.9 to 7.4)	-13.0 (-21.1 to -3.5)
Meningitis	-	-	-	-	34.5 (22.4 to 49.2)	17.4 (11.5 to 24.4)	-48.8 (-60.9 to -38.1)	-59.3 (-68.2 to -50.9)
Pneumococcal meningitis	141.4 (86.3 to 219.7)	84.3 (51.2 to 127.0)	-40.2 (-59.4 to -8.3)	-55.5 (-69.2 to -32.9)	14.0 (8.7 to 22.3)	7.4 (4.9 to 10.6)	-45.0 (-66.1 to -26.3)	-56.9 (-72.7 to -43.3)
H influenzae type B meningitis	83.4 (40.2 to 144.7)	38.0 (13.3 to 71.4)	-55.3 (-68.8 to -39.8)	-65.2 (-75.2 to -53.8)	8.4 (5.4 to 12.3)	4.1 (2.4 to 6.4)	-51.7 (-69.2 to -28.9)	-59.2 (-73.6 to -40.0)
Meningococcal meningitis	15.9 (6.4 to 29.7)	8.5 (2.8 to 17.3)	-47.8 (-62.7 to -28.2)	-63.5 (-74.0 to -50.4)	2.1 (1.1 to 3.4)	1.1 (0.6 to 1.9)	-46.0 (-59.3 to -25.5)	-61.4 (-70.4 to -47.1)
Other meningitis	83.7 (45.7 to 138.9)	41.4 (18.1 to 73.8)	-50.5 (-64.9 to -36.8)	-62.1 (-72.8 to -52.3)	10.0 (6.3 to 15.1)	4.8 (3.0 to 7.2)	-51.7 (-66.6 to -32.7)	-61.6 (-72.2 to -47.0)
Encephalitis	18.5 (9.2 to 36.9)	18.5 (8.2 to 37.1)	-2.1 (-19.0 to 9.6)	-2.1 (-42.8 to 42.1)	2.1 (1.5 to 3.0)	2.3 (1.6 to 3.2)	-0.3 (-9.9 to 18.7)	-21.6 (-32.9 to -13.1)
Diphtheria	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-45.4 (-95.5 to 518.9)	-50.3 (-95.4 to 383.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.4 (-95.5 to 520.9)	-50.3 (-95.4 to 393.9)
Whooping cough	19.4 (15.2 to 24.8)	14.8 (11.6 to 18.9)	-23.9 (-24.2 to -23.7)	-9.5 (-9.8 to -9.2)	1.0 (0.6 to 1.6)	0.7 (0.4 to 1.2)	-23.6 (-31.9 to -13.7)	-9.0 (-18.8 to 2.7)
Tetanus	5.8 (2.7 to 10.7)	0.2 (0.2 to 0.8)	-93.5 (-97.6 to -78.6)	-94.7 (-98.1 to -82.5)	0.2 (0.1 to 0.4)	0.0 (0.0 to 0.0)	-99.6 (-95.7 to -77.7)	-91.1 (-96.1 to -81.0)
Measles	6.3 (5.0 to 7.9)	1.7 (1.3 to 2.2)	-73.2 (-77.8 to -68.0)	-73.2 (-73.6 to -61.9)	0.6 (0.3 to 0.9)	0.2 (0.1 to 0.2)	-97.0 (-82.3 to -61.3)	-47.9 (-79.0 to -5.6)
Varicella and herpes zoster	43.0 (39.2 to 47.5)	53.1 (48.2 to 58.3)	23.9 (7.2 to 40.1)	-0.1 (-15.3 to 13.8)	1.5 (0.9 to 2.3)	2.0 (1.2 to 3.2)	41.4 (10.0 to 75.1)	-0.6 (-22.3 to 23.1)
Neglected tropical diseases and malaria	-	-	-	-	348.2 (213.8 to 536.2)	196.2 (124.0 to 297.8)	-43.4 (-53.4 to -31.8)	-54.4 (-61.6 to -45.8)
Malaria	6,529.2 (6,018.0 to 7,119.9)	7,785.9 (7,268.4 to 8,440.9)	19.1 (11.9 to 28.1)	-6.0 (-12.3 to 0.7)	65.0 (40.2 to 101.2)	73.5 (47.6 to 108.5)	15.3 (-7.7 to 31.2)	-1.8 (-23.7 to 11.0)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.0	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.4 (24.5 to 106.3)	16.7 (-12.1 to 49.8)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.0 (-80.3 to 40.8)	-21.7 (-77.7 to 47.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.0 (-80.3 to 41.0)	-21.7 (-77.7 to 47.5)
Cutaneous and mucocutaneous leishmaniasis	1.3 (1.0 to 1.7)	2.1 (1.5 to 2.7)	61.9 (30.0 to 99.7)	16.6 (-5.2 to 42.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.9 (24.7 to 106.9)	16.8 (-12.0 to 50.2)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.0	-	-
Cysticercosis	20.8 (7.6 to 34.0)	6.0 (2.0 to 17.2)	-77.0 (-91.5 to 63.6)	-86.9 (-94.8 to -7.4)	5.4 (1.9 to 9.5)	1.7 (0.5 to 5.1)	-74.7 (-91.6 to 76.9)	-85.5 (-94.7 to 2.1)
Cystic echinococcosis	7.3 (6.8 to 7.8)	7.8 (6.8 to 8.6)	8.7 (-10.3 to 21.6)	-26.8 (-41.9 to -21.1)	0.7 (0.4 to 1.0)	0.7 (0.5 to 1.0)	9.3 (-17.2 to 38.6)	-26.3 (-44.9 to -9.2)
Lymphatic filariasis	1,058.7 (773.2 to 1,512.8)	574.1 (365.3 to 955.4)	-46.6 (-58.4 to -31.8)	-64.5 (-71.8 to -54.6)	46.7 (16.0 to 103.4)	42.4 (16.6 to 91.5)	-8.8 (-34.1 to 21.3)	-44.4 (-62.1 to -28.8)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.0	-	-
Trachoma	96.9 (64.3 to 133.8)	41.6 (28.8 to 55.4)	-57.7 (-69.2 to -34.6)	-75.5 (-81.6 to -62.1)	6.1 (3.6 to 9.3)	2.6 (1.7 to 3.9)	-70.0 (-67.3 to -36.1)	-75.0 (-81.1 to -63.6)
Dengue	5.6 (2.3 to 12.5)	34.7 (14.1 to 76.3)	516.8 (510.9 to 523.5)	398.6 (393.9 to 404.1)	0.9 (0.3 to 2.3)	5.7 (2.0 to 13.9)	517.0 (396.0 to 697.7)	401.5 (311.0 to 537.9)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.0	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	2.7 (-41.6 to 69.3)	-35.5 (-61.5 to 3.4)	2.7 (0.0 to 0.0)	2.7 (0.0 to 0.0)	0.0 (-41.7 to 69.8)	35.5 (-61.5 to 3.6)
Intestinal nematode infections	-	-	-	-	199.0 (108.0 to 326.6)	55.8 (28.1 to 102.6)	-72.2 (-81.0 to -58.3)	-76.0 (-83.8 to -63.7)
Ascariasis	18,081.6 (14,229.9 to 22,825.5)	10,271.5 (6,310.9 to 15,604.1)	-43.8 (-66.8 to -7.7)	-54.8 (-74.0 to -25.7)	72.6 (37.7 to 125.8)	16.2 (7.0 to 33.7)	-78.6 (-87.6 to -60.5)	-79.9 (-88.4 to -63.0)
Trichuriasis	20,387.3 (16,520.2 to 25,647.6)	12,157.3 (8,337.8 to 16,932.9)	-41.2 (-62.2 to -11.2)	-53.5 (-70.6 to -29.0)	115.4 (62.3 to 190.8)	28.4 (11.4 to 61.3)	-76.6 (-88.2 to -54.3)	-80.4 (-90.4 to -60.8)
Hookworm disease	2,971.0 (2,056.2 to 4,230.6)	3,255.2 (1,950.7 to 5,154.3)	8.0 (-42.2 to 95.0)	17.4 (-56.6 to 54.1)	11.0 (6.3 to 17.3)	11.2 (5.5 to 20.4)	9.9 (-37.3 to 63.1)	33.8 (-53.0 to 24.9)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.0	-	-
Other neglected tropical diseases	687.2 (542.0 to 840.3)	429.1 (382.6 to 476.5)	-37.8 (-49.2 to -20.6)	-38.6 (-48.9 to -23.9)	24.4 (15.1 to 35.7)	13.8 (9.0 to 20.1)	-44.4 (-54.5 to -20.8)	-40.6 (-51.1 to -17.0)
Maternal disorders	-	-	-	-	1.7 (1.0 to 2.6)	1.8 (1.1 to 2.7)	5.3 (-30.7 to 55.5)	-29.8 (-52.3 to 1.4)
Maternal hemorrhage	15.8 (13.8 to 18.1)	26.1 (17.4 to 34.2)	66.0 (8.0 to 119.2)	8.5 (-28.7 to 43.3)	0.7 (0.4 to 1.1)	0.9 (0.5 to 1.4)	34.3 (-34.7 to 138.2)	-11.0 (-56.6 to 51.8)
Maternal sepsis and other maternal infections	13.0 (8.2 to 18.3)	10.2 (6.4 to 14.8)	-22.6 (-43.4 to 18.8)	-52.0 (-64.7 to -38.0)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-36.3 (-62.4 to 14.1)	-57.5 (-74.6 to -23.0)
Maternal hypertensive disorders	7.3 (3.6 to 12.2)	6.3 (3.2 to 10.1)	-13.3 (-24.1 to 14.4)	-41.2 (-46.9 to -32.9)	0.4 (0.2 to 0.7)	0.3 (0.1 to 0.6)	-14.2 (-34.5 to 12.7)	-41.8 (-54.5 to -25.0)
Obstructed labor	0.4 (0.2 to 0.7)	0.3 (0.1 to 0.5)	-34.7 (-71.5 to 26.3)	-56.3 (-80.8 to -13.8)	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.2)	-32.5 (-71.8 to 85.0)	-54.4 (-81.3 to 21.4)
Complications of abortion	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	17.3 (-39.8 to 96.8)	-26.8 (-61.3 to 23.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.3 (-40.5 to 97.3)	-26.8 (-61.3 to 23.5)
Other maternal disorders	-	-	-	-	0.3 (0.1 to 0.6)	0.3 (0.2 to 0.5)	4.6 (-52.5 to 172.1)	-30.6 (-68.3 to 78.0)
Neonatal disorders	-	-	-	-	26.3 (15.4 to 39.5)	82.4 (53.8 to 122.0)	213.0 (88.1 to 423.0)	172.4 (64.4 to 354.2)
Preterm birth complications	137.3 (65.4 to 258.1)	447.2 (223.2 to 871.1)	228.6 (132.6 to 365.0)	163.2 (86.6 to 271.5)	11.0 (6.4 to 17.3)	47.5 (28.7 to 73.3)	324.8 (164.1 to 641.9)	261.5 (129.2 to 539.6)
Neonatal encephalopathy due to birth asphyxia and trauma	191.8 (47.2 to 453.2)	384.4 (66.6 to 420.3)	1.3 (-40.3 to 91.0)	-20.1 (-54.2 to 56.7)	7.2 (3.2 to 13.1)	15.3 (9.3 to 22.9)	113.4 (24.3 to 362.8)	89.9 (7.2 to 300.4)
Neonatal sepsis and other neonatal infections	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.6)	53.3 (22.0 to 88.1)	53.6 (49.6 to 81.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	27.4 (13.4 to 59.7)	56.2 (39.0 to 95.8)
Hemolytic disease and other neonatal jaundice	14.0 (4.2 to 28.6)	33.7 (15.8 to 64.2)	154.9 (-35.6 to 823.7)	128.6 (-43.1 to 748.9)	5.4 (1.5 to 11.6)	12.7 (5.8 to 25.1)	152.8 (-33.4 to 780.3)	125.4 (-41.7 to 689.7)
Other neonatal disorders	-	-	-	-	2.7 (0.7 to 5.9)	6.9 (2.7 to 17.9)	160.7 (4.1 to 569.6)	126.1 (-10.4 to 486.5)
Nutritional deficiencies	-	-	-	-	440.7 (297.1 to 620.9)	244.4 (161.9 to 357.1)	-46.6 (-48.2 to -40.6)	-49.7 (-52.6 to -46.2)
Protein-energy malnutrition	255.9 (175.4 to 348.6)	124.2 (68.4 to 203.9)	-52.5 (-75.1 to -5.9)	-43.1 (-69.9 to 11.7)	31.8 (17.8 to 51.6)	15.6 (7.4 to 29.6)	-52.0 (-75.3 to -4.4)	-42.5 (-69.8 to 13.1)
Iodine deficiency	472.3 (215.5 to 791.7)	346.9 (171.2 to 581.4)	-26.1 (-66.2 to 67.3)	-50.6 (-77.1 to 8.5)	8.4 (3.5 to 16.9)	6.2 (2.6 to 11.9)	-26.2 (-66.9 to 66.1)	-50.8 (-77.1 to 8.7)
Vitamin A deficiency	20.8 (13.6 to 28.1)	11.8 (7.7 to 16.5)	-43.5 (-52.7 to -32.2)	-46.9 (-56.0 to -38.4)	1.0 (0.6 to 1.6)	0.6 (0.3 to 1.0)	-42.1 (-53.5 to -28.6)	-38.2 (-50.0 to -38.2)

Appendix Table G.4 - Myanmar prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	372.6 (323.8 to 430.7)	461.5 (408.0 to 510.5)	24.9 (2.4 to 46.3)	-28.0 (-40.7 to -16.6)	10.2 (6.6 to 14.5)	12.7 (8.4 to 18.0)	25.9 (2.8 to 49.4)	-27.4 (-40.6 to -15.0)
Other oral disorders	669.9 (629.3 to 708.8)	966.5 (914.4 to 1,020.6)	44.1 (33.5 to 57.0)	-0.7 (-7.2 to 8.2)	19.6 (12.4 to 30.0)	28.4 (17.6 to 42.7)	44.5 (32.6 to 58.3)	0.0 (-7.3 to 9.1)
Injuries	-	-	-	-	331.1 (179.2 to 654.4)	256.5 (170.5 to 384.7)	-18.7 (-46.5 to 13.0)	-48.6 (-66.2 to -28.0)
Transport injuries	-	-	-	-	42.0 (31.4 to 54.4)	63.2 (46.5 to 83.6)	50.4 (39.3 to 62.9)	-3.0 (-9.1 to 3.9)
Road injuries	-	-	-	-	35.1 (26.2 to 45.4)	54.7 (40.2 to 72.0)	56.8 (43.6 to 69.5)	1.6 (-5.3 to 9.3)
Pedestrian road injuries	-	-	-	-	5.1 (3.8 to 6.6)	7.6 (5.5 to 10.0)	49.4 (33.2 to 66.5)	1.8 (-7.3 to 11.1)
Cyclist road injuries	-	-	-	-	2.4 (1.8 to 3.2)	3.5 (2.5 to 4.6)	42.4 (31.0 to 55.9)	-4.9 (-12.6 to 4.8)
Motorcyclist road injuries	-	-	-	-	15.3 (11.4 to 19.8)	22.3 (16.4 to 29.6)	45.3 (32.3 to 60.1)	-6.2 (-13.9 to 2.5)
Motor vehicle road injuries	-	-	-	-	12.1 (9.0 to 15.8)	21.1 (15.4 to 27.9)	76.0 (55.1 to 95.3)	13.4 (2.0 to 25.4)
Other road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	36.4 (24.1 to 49.7)	-15.6 (-22.3 to -8.0)
Other transport injuries	-	-	-	-	6.9 (5.2 to 9.0)	8.5 (6.2 to 11.2)	22.5 (12.6 to 33.6)	-25.0 (-30.7 to -18.5)
Unintentional injuries	-	-	-	-	73.2 (56.2 to 94.7)	94.2 (69.7 to 124.0)	28.5 (21.3 to 35.5)	-15.3 (-19.0 to -11.5)
Falls	-	-	-	-	22.4 (16.9 to 29.1)	34.2 (25.0 to 45.3)	52.7 (42.5 to 62.6)	-5.6 (-11.8 to 0.2)
Drowning	-	-	-	-	3.2 (2.4 to 4.2)	2.3 (1.7 to 3.1)	-28.5 (-37.7 to -18.9)	-48.9 (-54.8 to -42.9)
Fire, heat, and hot substances	-	-	-	-	5.0 (3.8 to 6.3)	3.9 (2.8 to 5.1)	-22.3 (-30.5 to -13.7)	-45.7 (-50.7 to -40.4)
Poisonings	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	-7.4 (-21.0 to 8.1)	-35.7 (-44.5 to -25.9)
Exposure to mechanical forces	-	-	-	-	31.0 (23.4 to 40.5)	35.3 (25.9 to 47.3)	13.7 (4.9 to 22.3)	-24.0 (-28.6 to -19.2)
Unintentional firearm injuries	-	-	-	-	2.0 (1.5 to 2.6)	1.8 (1.3 to 2.5)	-9.6 (-16.8 to -1.0)	-41.4 (-45.8 to -36.4)
Unintentional suffocation	-	-	-	-	0.7 (0.5 to 0.9)	0.7 (0.5 to 1.0)	12.3 (0.9 to 24.7)	-20.7 (-27.4 to -12.8)
Other exposure to mechanical forces	-	-	-	-	28.3 (21.3 to 37.0)	32.7 (24.0 to 43.9)	15.4 (6.1 to 24.5)	-22.8 (-27.7 to -17.5)
Adverse effects of medical treatment	-	-	-	-	0.7 (0.5 to 1.1)	1.1 (0.7 to 1.6)	54.8 (44.1 to 64.6)	3.0 (-3.8 to 9.8)
Animal contact	-	-	-	-	1.4 (1.1 to 1.8)	1.5 (1.1 to 2.0)	8.7 (0.4 to 18.1)	-25.0 (-30.6 to -19.3)
Venomous animal contact	-	-	-	-	0.7 (0.5 to 0.9)	0.7 (0.5 to 1.0)	10.9 (-2.6 to 26.0)	-24.6 (-33.4 to -15.1)
Non-venomous animal contact	-	-	-	-	0.7 (0.5 to 1.0)	0.8 (0.6 to 1.1)	6.7 (-3.6 to 17.5)	-25.5 (-31.0 to -19.5)
Foreign body	-	-	-	-	0.2 (0.5 to 0.9)	0.2 (0.8 to 1.3)	15.8 (34.3 to 52.2)	-14.1 (-8.8 to 0.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	38.2 (3.6 to 31.8)	-4.6 (-21.9 to -4.4)
Foreign body in eyes	-	-	-	-	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	38.2 (29.1 to 47.6)	-4.6 (-10.1 to 1.0)
Foreign body in other body part	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.6)	64.2 (52.2 to 78.5)	2.0 (-5.1 to 10.0)
Other unintentional injuries	-	-	-	-	8.5 (6.3 to 11.0)	14.6 (10.8 to 19.4)	72.3 (52.7 to 92.2)	8.4 (-3.1 to 19.3)
Self-harm and interpersonal violence	-	-	-	-	5.9 (4.4 to 7.5)	4.3 (3.2 to 5.7)	-26.8 (-32.2 to -20.6)	-93.3 (-56.5 to -49.8)
Self-harm	-	-	-	-	1.0 (0.7 to 1.2)	0.8 (0.6 to 1.1)	-12.0 (-19.2 to -2.7)	-48.3 (-52.1 to -43.2)
Interpersonal violence	-	-	-	-	4.9 (3.7 to 6.3)	3.5 (2.6 to 4.6)	-29.5 (-35.3 to -23.3)	-54.5 (-57.9 to -50.9)
Assault by firearm	-	-	-	-	0.5 (0.4 to 0.7)	0.4 (0.3 to 0.5)	-26.3 (-32.7 to -19.5)	-51.0 (-54.9 to -47.0)
Assault by sharp object	-	-	-	-	1.0 (0.8 to 1.3)	0.8 (0.6 to 1.1)	-21.1 (-28.1 to -11.7)	-50.1 (-54.1 to -44.3)
Assault by other means	-	-	-	-	3.4 (2.5 to 4.3)	2.3 (1.7 to 3.0)	-32.5 (-38.9 to -26.2)	-56.3 (-60.1 to -52.6)
Forces of nature, war, and legal intervention	-	-	-	-	210.0 (66.7 to 543.7)	94.8 (37.8 to 212.6)	-53.2 (-67.5 to -20.6)	-70.3 (-79.0 to -50.8)
Exposure to forces of nature	-	-	-	-	31.8 (12.5 to 71.7)	63.0 (22.5 to 150.9)	-	-
Collective violence and legal intervention	-	-	-	-	210.0 (66.7 to 543.7)	94.8 (37.8 to 212.6)	-69.4 (-75.2 to -61.0)	-79.1 (-83.3 to -72.9)

Appendix Table G.4 - Namibia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	129.3 (95.0 to 168.7)	232.7 (172.6 to 302.8)	80.0 (74.9 to 85.2)	3.7 (1.1 to 6.2)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	33.6 (23.6 to 45.8)	60.5 (44.1 to 81.2)	80.0 (65.6 to 99.0)	20.8 (11.3 to 34.6)
HIV/AIDS and tuberculosis	-	-	-	-	3.9 (2.7 to 5.3)	21.9 (15.4 to 29.0)	455.5 (379.8 to 559.3)	191.4 (151.2 to 247.5)
Tuberculosis	10.9 (10.1 to 11.8)	22.1 (20.6 to 23.7)	101.8 (91.2 to 114.2)	5.1 (4.0 to 10.7)	3.4 (2.3 to 4.6)	6.7 (4.6 to 9.1)	100.6 (88.1 to 113.2)	4.6 (1.1 to 10.6)
HIV/AIDS	-	-	-	-	0.6 (0.4 to 0.8)	15.5 (10.5 to 20.7)	3,266.1 (2,037.5 to 5,199.1)	1,448.8 (1,147.0 to 1,861.0)
HIV/AIDS resulting in mycobacterial infection	0.4 (0.2 to 0.6)	5.6 (3.4 to 7.6)	1,326.7 (985.9 to 1,727.2)	65.5 (47.0 to 86.3)	0.2 (0.1 to 0.3)	2.1 (1.1 to 3.2)	1,303.0 (955.1 to 1,741.1)	643.2 (456.1 to 870.3)
HIV/AIDS resulting in other diseases	5.6 (4.6 to 7.2)	143.5 (125.6 to 162.5)	2,477.1 (2,007.5 to 2,935.6)	1,481.8 (1,192.7 to 1,774.6)	0.4 (0.3 to 0.6)	13.0 (8.8 to 18.2)	2,995.0 (2,283.8 to 3,864.1)	1,798.5 (1,344.5 to 2,390.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	4.5 (3.2 to 6.1)	5.5 (3.9 to 7.5)	22.3 (13.9 to 30.9)	-13.9 (-18.9 to -9.1)
Diarrheal diseases	15.8 (14.8 to 16.7)	17.8 (16.8 to 19.0)	13.2 (3.7 to 23.1)	-13.8 (-20.8 to -7.0)	2.6 (1.7 to 3.6)	2.9 (2.0 to 4.0)	18.4 (3.0 to 24.1)	-28.3 (-21.3 to -6.0)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-11.9 (-36.3 to 16.2)	-43.4 (-58.6 to -25.9)
Typhoid fever	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	-3.0 (-26.4 to 19.0)	-37.7 (-53.0 to -24.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.6 (-28.7 to 26.4)	-37.0 (-53.6 to -19.7)
Paratyphoid fever	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	19.2 (9.8 to 56.6)	-22.1 (-40.2 to 1.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.3 (-11.5 to 64.9)	-22.1 (-41.9 to 3.4)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.2 (-99.7 to -45.8)	-94.2 (-99.8 to -45.8)
Lower respiratory infections	0.9 (0.7 to 1.0)	1.2 (1.0 to 1.4)	37.8 (6.8 to 75.2)	-9.9 (-17.0 to 17.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	38.6 (13.3 to 74.9)	-0.2 (-19.6 to 21.7)
Upper respiratory infections	44.3 (41.4 to 47.1)	70.4 (66.6 to 74.8)	58.9 (46.4 to 74.4)	0.4 (-7.6 to 9.3)	0.5 (0.3 to 0.9)	0.8 (0.5 to 1.4)	58.7 (45.0 to 73.8)	0.3 (-7.9 to 9.4)
Otitis media	26.5 (24.1 to 29.1)	39.5 (36.0 to 43.0)	48.8 (36.2 to 64.0)	-6.5 (-14.1 to 3.2)	0.5 (0.3 to 0.8)	0.7 (0.4 to 1.2)	49.1 (34.9 to 65.0)	-5.8 (-14.2 to 3.7)
Meningitis	-	-	-	-	0.7 (0.4 to 0.9)	0.8 (0.5 to 1.1)	19.6 (-2.4 to 47.4)	-26.7 (-38.5 to -11.6)
Pneumococcal meningitis	1.5 (0.9 to 2.4)	1.8 (1.1 to 2.9)	20.9 (-2.5 to 51.4)	-37.4 (-40.8 to -9.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	18.4 (9.4 to 56.6)	-28.3 (-44.1 to -7.9)
H influenzae type B meningitis	1.7 (0.6 to 3.5)	1.8 (0.7 to 3.8)	7.5 (-21.7 to 52.6)	-35.1 (-51.3 to -8.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	14.0 (-30.1 to 76.3)	-29.9 (-55.4 to 7.9)
Meningococcal meningitis	1.1 (0.3 to 2.5)	1.3 (0.5 to 3.0)	28.2 (-6.2 to 91.9)	-24.6 (-42.7 to 16.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	40.0 (-10.9 to 127.8)	-17.7 (-44.5 to 29.5)
Other meningitis	1.6 (0.9 to 2.8)	1.8 (1.0 to 3.3)	15.5 (-7.5 to 45.9)	-28.3 (-42.4 to -9.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	11.4 (-14.4 to 50.2)	-30.1 (-46.0 to -7.8)
Encephalitis	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.8)	76.5 (50.4 to 101.0)	9.6 (-11.1 to 15.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	79.3 (48.5 to 118.7)	4.9 (-11.4 to 23.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.9 (-94.7 to 810.4)	-47.5 (-94.6 to 392.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.9 (-94.7 to 815.2)	-47.5 (-94.6 to 393.6)
Whooping cough	1.3 (1.0 to 1.7)	0.8 (0.6 to 1.0)	-40.4 (-43.1 to -37.6)	-50.6 (-52.8 to -48.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-40.3 (-47.5 to -31.8)	-50.5 (-56.5 to -43.5)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.4 (-90.4 to -67.2)	-89.4 (-93.6 to -79.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-79.7 (-90.2 to -53.6)	-86.8 (-92.3 to -74.1)
Measles	0.3 (0.3 to 0.4)	0.0 (0.0 to 0.0)	-94.3 (-96.2 to -91.6)	-95.4 (-96.9 to -93.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-94.1 (-96.2 to -90.8)	-95.2 (-97.0 to -92.6)
Varicella and herpes zoster	0.9 (0.8 to 1.0)	1.5 (1.3 to 1.6)	68.6 (44.0 to 93.9)	1.7 (-17.9 to 25.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	78.2 (20.9 to 150.8)	-0.1 (-32.6 to 42.6)
Neglected tropical diseases and malaria	-	-	-	-	5.2 (3.5 to 7.6)	6.5 (4.3 to 9.5)	24.5 (12.1 to 37.5)	-26.2 (-35.6 to -16.6)
Malaria	232.8 (154.6 to 353.9)	257.0 (119.1 to 517.4)	-1.0 (-52.3 to 135.3)	-35.4 (-68.9 to 54.1)	2.2 (1.4 to 3.2)	2.4 (1.6 to 3.5)	12.5 (-3.0 to 20.8)	-25.9 (-35.8 to -20.3)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.1 (11.7 to 204.4)	19.6 (-21.8 to 86.6)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.1 (11.7 to 203.4)	19.6 (-21.7 to 86.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.1 (11.7 to 204.4)	19.6 (-21.8 to 86.6)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.2 (22.1 to 204.2)	7.9 (-23.0 to 80.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.2 (22.1 to 204.5)	7.9 (-23.1 to 81.7)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	8.9 (3.4 to 19.5)	15.5 (5.9 to 33.9)	74.8 (69.9 to 82.1)	0.6 (-1.8 to 4.2)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	72.6 (33.3 to 103.9)	1.3 (-17.4 to 16.7)
Cysticercosis	1.7 (0.4 to 2.8)	1.7 (0.8 to 2.9)	-3.6 (-63.4 to 230.0)	-46.9 (-79.0 to 62.3)	0.5 (0.1 to 0.9)	0.5 (0.2 to 0.9)	1.5 (-60.6 to 248.4)	-43.5 (-77.7 to 79.1)
Cystic echinococcosis	0.4 (0.4 to 0.5)	0.8 (0.6 to 0.9)	79.8 (53.6 to 94.0)	-8.8 (-19.8 to -1.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	78.0 (40.0 to 117.7)	-8.9 (-25.3 to 7.9)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	4.8 (3.2 to 6.5)	3.2 (2.2 to 4.5)	-33.6 (-49.1 to -14.1)	-63.4 (-72.3 to -52.5)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-37.1 (-50.2 to -19.2)	-65.4 (-72.8 to -55.3)
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.8 (-40.0 to 13.7)	-42.1 (-59.1 to -23.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.8 (-40.2 to 14.0)	-42.1 (-59.2 to -23.4)
Intestinal nematode infections	-	-	-	-	1.1 (0.7 to 1.7)	1.8 (1.1 to 2.9)	67.6 (45.0 to 91.7)	0.8 (-12.1 to 13.9)
Ascariasis	27.7 (16.8 to 42.5)	46.3 (27.5 to 77.5)	66.4 (-17.0 to 220.3)	3.3 (-54.6 to 125.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.9 (8.7 to 99.9)	-2.3 (-33.2 to 37.9)
Trichuriasis	65.8 (42.6 to 104.0)	107.4 (65.5 to 174.5)	63.6 (-15.0 to 207.0)	0.6 (-53.6 to 112.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.0 (-1.6 to 144.6)	-2.7 (-42.2 to 61.2)
Hookworm disease	27.7 (16.4 to 348.1)	403.3 (273.7 to 589.4)	69.7 (-0.6 to 182.0)	1.8 (-46.2 to 78.6)	1.8 (0.7 to 1.7)	1.8 (1.1 to 2.8)	69.6 (45.0 to 92.0)	0.8 (-12.2 to 14.1)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	24.4 (19.2 to 29.8)	30.1 (28.1 to 32.6)	23.5 (0.8 to 55.9)	-15.5 (-29.4 to 3.2)	1.1 (0.6 to 1.8)	1.4 (0.8 to 2.3)	25.6 (3.8 to 68.4)	-13.3 (-32.1 to 14.2)
Maternal disorders	-	-	-	-	0.5 (0.4 to 0.7)	0.6 (0.4 to 0.8)	18.0 (5.0 to 33.7)	-36.3 (-43.0 to -28.4)
Maternal hemorrhage	1.1 (1.0 to 1.3)	1.4 (1.0 to 1.7)	22.9 (-12.5 to 58.0)	-40.0 (-57.2 to -22.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	8.2 (-44.8 to 69.9)	-46.1 (-72.3 to -15.1)
Maternal sepsis and other maternal infections	0.4 (0.3 to 0.5)	0.4 (0.2 to 0.6)	11.2 (-22.7 to 38.8)	-43.5 (-60.2 to -29.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.3 (-31.5 to 69.1)	-43.1 (-62.3 to -15.4)
Maternal hypertensive disorders	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	8.0 (-1.8 to 34.9)	-44.6 (-48.5 to -39.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.7 (-14.3 to 32.5)	-44.7 (-55.7 to -32.1)
Obstructed labor	1.2 (1.1 to 1.3)	1.5 (1.3 to 1.6)	20.2 (12.5 to 28.4)	-34.4 (-38.6 to -30.5)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	19.3 (6.6 to 35.1)	-34.6 (-41.6 to -26.9)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.6 (-31.4 to 125.1)	-35.6 (-62.6 to 57.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.6 (-31.5 to 125.4)	-35.6 (-62.7 to 0.4)
Other maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	21.9 (-21.1 to 84.4)	-34.5 (-57.2 to -0.4)
Neonatal disorders	-	-	-	-	2.4 (1.4 to 4.0)	5.7 (3.6 to 8.8)	132.8 (48.6 to 287.1)	48.2 (-4.5 to 145.9)
Preterm birth complications	5.5 (3.2 to 9.5)	18.7 (11.2 to 30.5)	239.0 (164.1 to 352.2)	111.6 (67.7 to 178.2)	0.6 (0.4 to 0.9)	2.2 (1.4 to 3.3)	257.0 (108.4 to 499.2)	125.7 (33.7 to 275.5)
Neonatal encephalopathy due to birth asphyxia and trauma	6.3 (1.4 to 18.3)	7.9 (2.4 to 21.6)	30.2 (-1.0 to 121.7)	-20.4 (-40.1 to 36.4)	0.6 (0.3 to 0.9)	1.0 (0.6 to 1.5)	72.0 (16.4 to 218.6)	8.6 (-25.2 to 108.3)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	124.9 (111.9 to 141.0)	99.9 (88.3 to 114.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.9 (97.5 to 159.0)	99.7 (75.5 to 130.2)
Hemolytic disease and other neonatal jaundice	0.6 (0.3 to 1.2)	1.3 (0.4 to 2.4)	98.0 (-44.9 to 374.0)	22.9 (-65.7 to 190.3)	0.2 (0.1 to 0.5)	0.5 (0.2 to 1.0)	101.1 (-44.7 to 381.2)	23.3 (-65.9 to 197.2)
Other neonatal disorders	-	-	-	-	1.0 (0.3 to 2.2)	2.0 (0.7 to 4.1)	105.4 (-5.0 to 344.1)	31.3 (-40.3 to 182.9)
Nutritional deficiencies	-	-	-	-	15.7 (10.6 to 22.6)	18.4 (12.3 to 27.1)	17.5 (5.2 to 31.2)	-24.7 (-31.8 to -16.8)
Protein-energy malnutrition	10.4 (5.1 to 19.2)	9.1 (2.7 to 21.7)	-20.3 (-78.4 to 157.8)	32.6 (-80.9 to 108.1)	1.3 (0.6 to 2.6)	1.1 (0.3 to 2.9)	1.1 (-78.3 to 162.5)	-32.7 (-80.9 to 114.5)
Iodine deficiency	75.4 (55.4 to 94.1)	82.1 (51.0 to 114.9)	10.5 (-37.7 to 71.1)	-37.3 (-65.7 to -3.3)	1.4 (0.8 to 2.2)	1.5 (0.7 to 2.7)	9.6 (-37.8 to 68.7)	-37.4 (-65.5 to -2.8)
Vitamin A deficiency	1.4 (1.1 to 1.7)	1.2 (0.9 to 1.6)	-10.0 (-25.6 to 5.2)	-40.1 (-50.5 to -30.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-16.5 (-33.1 to 0.3)	-45.2 (-55.9 to -34.0)

Appendix Table G.4 - Namibia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	380.0 (374.7 to 385.1)	488.2 (484.4 to 492.1)	28.5 (26.8 to 30.1)	-20.4 (-21.4 to -19.4)	13.0 (8.7 to 18.7)	15.7 (10.5 to 22.7)	21.3 (18.2 to 23.9)	-22.6 (-24.3 to -20.8)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	97.5 (57.0 to 139.9)	64.8 (-62.4 to 553.8)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.2 (0.8 to 1.9)	1.8 (1.1 to 2.8)	47.1 (22.8 to 77.5)	-7.7 (-23.1 to 8.6)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.5 (0.3 to 0.9)	0.8 (0.5 to 1.5)	76.1 (19.5 to 158.3)	-3.7 (-30.8 to 30.6)
Syphilis	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	23.4 (1.4 to 48.0)	-34.6 (-44.2 to -23.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.0 (9.4 to 64.2)	-35.0 (-49.5 to -16.2)
Chlamydial infection	48.4 (34.1 to 65.6)	90.9 (60.8 to 115.5)	88.7 (22.1 to 189.0)	2.9 (-28.4 to 58.1)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.6)	98.6 (-25.0 to 330.8)	13.1 (-56.1 to 132.6)
Gonococcal infection	17.2 (11.4 to 21.6)	30.4 (21.4 to 42.1)	76.3 (14.9 to 181.9)	-1.8 (-34.7 to 50.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	65.9 (-9.2 to 165.6)	-7.4 (-47.6 to 42.5)
Trichomoniasis	41.1 (17.5 to 60.5)	71.8 (38.8 to 111.4)	68.1 (-5.5 to 259.8)	-7.3 (-42.9 to 77.7)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	62.8 (-17.5 to 278.4)	-9.7 (-48.8 to 84.5)
Genital herpes	310.7 (292.3 to 329.0)	553.3 (518.3 to 582.8)	78.3 (64.3 to 93.0)	-5.1 (-12.5 to 2.3)	0.1 (0.0 to 0.2)	0.2 (0.0 to 0.4)	5.8 (59.3 to 92.7)	-5.5 (-13.9 to 2.5)
Other sexually transmitted diseases	0.5 (0.4 to 0.7)	0.9 (0.6 to 1.2)	65.4 (38.7 to 99.5)	-17.1 (-30.4 to -1.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.1 (19.3 to 155.1)	-12.6 (-35.7 to 22.8)
Hepatitis	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	63.0 (29.4 to 103.9)	-5.6 (-29.1 to 22.7)
Hepatitis A	2.2 (2.1 to 2.3)	2.9 (2.8 to 3.1)	34.0 (32.9 to 35.3)	-6.9 (-7.0 to -6.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	55.0 (37.4 to 73.6)	-1.8 (-11.9 to 9.0)
Hepatitis B	98.2 (83.6 to 118.3)	157.7 (127.5 to 198.2)	60.7 (18.9 to 109.5)	-5.6 (-29.0 to -23.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	77.2 (81.1 to 183.7)	-4.2 (-44.1 to 54.1)
Hepatitis C	30.8 (27.2 to 34.5)	38.1 (33.6 to 42.5)	23.8 (4.9 to 44.8)	-30.6 (-40.4 to 4.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.9 (1.2 to 59.3)	-23.7 (-43.2 to 6.4)
Hepatitis E	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.4)	48.9 (21.8 to 86.5)	-18.4 (-33.5 to 2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.8 (6.4 to 110.5)	-18.7 (-41.5 to 13.3)
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	133.2 (20.1 to 536.0)	22.6 (-34.3 to 242.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	133.5 (15.6 to 570.7)	22.7 (-38.0 to 252.6)
Other infectious diseases	17.6 (13.8 to 21.5)	21.7 (19.6 to 23.7)	23.7 (10.0 to 39.0)	-17.9 (-25.9 to -10.4)	0.7 (0.4 to 1.0)	0.8 (0.5 to 1.2)	25.1 (78.1 to 47.8)	-12.0 (-24.2 to 3.9)
Non-communicable diseases	-	-	-	-	99.7 (66.2 to 116.4)	163.5 (120.2 to 211.0)	82.3 (77.9 to 86.9)	1.4 (-1.1 to 3.8)
Neoplasms	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	100.1 (38.3 to 189.4)	10.2 (-22.9 to 58.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.8 (35.4 to 181.2)	8.6 (-24.8 to 52.4)
Esophageal cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	75.1 (21.7 to 154.7)	-3.1 (-32.5 to 43.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.1 (18.0 to 153.4)	-5.3 (-35.7 to 43.3)
Stomach cancer	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	100.1 (21.7 to 154.7)	10.2 (-32.5 to 43.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.8 (18.0 to 153.4)	8.6 (-35.7 to 43.3)
Liver cancer	0.0 (0.0 to 0.0)	0.0 (0.1 to 0.1)	100.1 (21.7 to 154.7)	10.2 (-32.5 to 43.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.8 (18.0 to 153.4)	8.6 (-35.7 to 43.3)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	301.9 (64.6 to 1,074.6)	126.2 (-15.9 to 567.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	275.2 (64.0 to 926.5)	108.3 (-14.8 to 489.7)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	440.4 (153.3 to 1,031.3)	187.7 (36.7 to 515.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	401.4 (147.0 to 946.7)	168.3 (33.1 to 461.8)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.6 (-25.9 to 150.0)	-22.3 (-58.0 to 36.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.2 (-25.0 to 111.1)	-28.2 (-57.8 to 18.1)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.3 (-31.9 to 117.4)	-31.3 (-64.1 to 20.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.4 (-30.0 to 84.0)	35.6 (-63.4 to 3.2)
Larynx cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	111.5 (49.8 to 192.6)	13.0 (-20.0 to 57.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	110.4 (40.7 to 199.5)	12.8 (-25.8 to 61.8)
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	112.4 (65.6 to 179.4)	15.3 (-8.8 to 48.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.0 (52.8 to 186.7)	11.8 (-16.2 to 52.8)
Breast cancer	0.4 (0.2 to 0.5)	1.2 (0.8 to 1.6)	197.3 (111.9 to 402.8)	58.8 (14.9 to 159.9)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	180.0 (102.0 to 367.3)	51.2 (10.3 to 140.4)
Cervical cancer	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	101.3 (31.2 to 221.9)	3.3 (-30.0 to 63.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	100.5 (30.8 to 211.6)	3.4 (-31.2 to 63.3)
Uterine cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	103.2 (23.9 to 236.2)	10.1 (-31.6 to 73.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.1 (21.5 to 232.7)	9.1 (-38.3 to 78.3)
Prostate cancer	0.1 (0.1 to 0.3)	0.7 (0.4 to 1.3)	351.7 (168.5 to 845.9)	157.0 (60.5 to 422.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	309.2 (149.3 to 751.9)	136.0 (45.2 to 373.6)
Colon and rectum cancer	0.3 (0.1 to 0.4)	0.3 (0.3 to 0.4)	15.7 (-24.9 to 117.8)	-54.6 (-72.9 to -3.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.0 (-23.9 to 121.4)	-51.3 (-71.0 to -0.4)
Lip and oral cavity cancer	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	108.9 (45.3 to 191.8)	14.6 (-20.7 to 58.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	108.5 (45.1 to 191.1)	13.0 (-20.2 to 60.3)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	90.4 (21.6 to 199.6)	5.5 (-31.5 to 61.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.3 (25.7 to 184.3)	0.7 (-30.7 to 47.7)
Other pharynx cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	96.9 (10.6 to 237.4)	9.4 (-35.8 to 85.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.4 (14.4 to 239.3)	9.1 (-35.3 to 83.7)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.9 (-11.6 to 161.2)	-9.9 (-51.3 to 51.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.7 (-14.6 to 147.3)	-14.9 (-52.4 to 40.0)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	97.2 (48.7 to 163.2)	12.7 (-14.6 to 51.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.4 (47.3 to 153.7)	9.2 (-18.5 to 45.9)
Malignant skin melanoma	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	140.5 (67.5 to 246.3)	29.2 (-10.2 to 86.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	135.7 (64.1 to 240.8)	26.8 (-14.0 to 81.7)
Non-melanoma skin cancer	0.1 (0.1 to 0.2)	0.5 (0.4 to 0.7)	312.9 (190.8 to 476.9)	107.7 (44.2 to 189.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	349.8 (186.4 to 579.6)	122.4 (38.1 to 248.0)
Ovarian cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	227.3 (84.6 to 455.5)	72.9 (0.5 to 190.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	212.7 (76.9 to 494.6)	65.4 (-5.6 to 217.0)
Testicular cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	137.0 (36.0 to 295.4)	21.1 (-27.9 to 97.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	143.7 (39.1 to 324.5)	26.1 (-25.5 to 111.1)
Kidney cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	156.9 (77.0 to 269.8)	59.0 (8.8 to 116.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	158.0 (73.4 to 271.5)	48.6 (-3.7 to 115.0)
Bladder cancer	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.1)	59.9 (-77.9 to 6.2)	-81.8 (-90.7 to -54.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-69.7 (-84.2 to -13.1)	-9.7 (-93.1 to -61.0)
Brain and nervous system cancer	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	102.0 (42.5 to 186.7)	26.5 (-5.3 to 65.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.1 (47.9 to 176.0)	20.5 (-8.1 to 59.1)
Thyroid cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	164.7 (71.3 to 316.0)	39.7 (-6.4 to 108.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	162.4 (68.5 to 319.8)	37.2 (-8.8 to 109.2)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.1 (19.8 to 145.7)	6.0 (-35.3 to 38.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.3 (21.5 to 145.7)	5.2 (-33.8 to 37.3)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	188.6 (75.5 to 360.5)	79.2 (11.8 to 182.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	185.4 (79.7 to 342.9)	67.7 (8.9 to 154.1)
Non-Hodgkin lymphoma	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	163.8 (74.6 to 408.2)	49.3 (1.6 to 189.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	159.1 (72.1 to 396.8)	43.9 (-2.6 to 176.5)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.2 (52.8 to 250.6)	24.2 (-15.7 to 88.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.9 (48.5 to 225.4)	20.7 (-20.4 to 76.9)
Leukemia	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	138.6 (68.3 to 246.8)	39.4 (2.2 to 112.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	127.5 (67.9 to 240.7)	28.7 (-7.1 to 93.5)
Other neoplasms	0.6 (0.4 to 0.8)	1.8 (1.3 to 2.4)	213.7 (116.1 to 347.5)	105.2 (51.5 to 181.1)	0.0 (0.0 to 1.1)	0.1 (0.1 to 0.2)	205.4 (115.1 to 326.5)	89.2 (39.5 to 164.2)
Cardiovascular diseases	-	-	-	-	1.5 (1.0 to 2.1)	2.9 (1.9 to 4.1)	88.9 (41.0 to 140.7)	3.4 (-18.8 to 30.2)
Rheumatic heart disease	1.0 (0.9 to 1.0)	1.7 (1.6 to 1.8)	71.6 (57.2 to 87.2)	-0.6 (-7.8 to 7.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	64.8 (29.0 to 108.8)	-5.1 (-26.2 to 20.7)
Ischemic heart disease	9.7 (7.6 to 12.5)	13.0 (10.8 to 15.7)	34.7 (0.8 to 75.7)	-21.6 (-39.8 to 1.9)	0.6 (0.3 to 0.9)	0.8 (0.5 to 1.1)	5.4 (4.0 to 12.1)	-20.8 (-40.6 to 6.5)
Cerebrovascular disease	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	80.4 (44.2 to 121.8)	-3.0 (-24.3 to 22.0)
Ischemic stroke	0.8 (0.7 to 0.9)	1.4 (1.2 to 1.6)	80.4 (42.5 to 119.7)	-3.2 (-25.7 to 21.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	80.2 (41.1 to 124.5)	-3.3 (-25.4 to 23.3)
Hemorrhagic stroke	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	80.9 (38.0 to 133.1)	-2.8 (-26.3 to 26.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	81.9 (33.7 to 138.7)	-2.8 (-27.8 to 29.6)
Hypertensive heart disease	1.0 (0.7 to 1.3)	2.1 (1.4 to 2.7)	114.8 (39.6 to 225.8)	19.1 (-22.2 to 78.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	113.7 (40.7 to 224.8)	18.7 (-23.3 to 79.0)
Cardiomyopathy and myocarditis	1.1 (0.9 to 1.5)	1.9 (1.6 to 2.2)	64.7 (14.3 to 127.2)	-3.4 (-37.3 to 37.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	63.5 (12.6 to 125.0)	-3.9 (-38.1 to 37.7)
Atrial fibrillation and flutter	1.9 (1.5 to 2.5)	4.8 (3.5 to 6.3)	146.5 (62.0 to 270.9)	27.2 (-21.6 to 102.1)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.5)	146.1 (61.9 to 273.8)	28.6 (-21.0 to 104.2)
Peripheral vascular disease	36.6 (26.6 to 46.9)	61.6 (44.8 to 81.4)	65.9 (20.1 to 140.5)	-5.7 (-32.0 to 30.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	66.3 (-26.5 to 277.5)	-9.2 (-59.4 to 99.3)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.3 (-15.3 to 52.0)	-30.8 (-49.0 to -3.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.5 (-19.2 to 56.6)	-30.0 (-53.4 to 0.3)
Other cardiovascular and circulatory diseases	5.0 (2.8 to 8.6)	13.2 (5.3 to 20.8)	157.3 (6.5 to 462.3)	41.9 (-51.0 to 201.9)	0.0 (0.2 to 0.7)	0.9 (0.3 to 1.6)	159.0 (-8.7 to 454.3)	41.9 (-51.9 to 204.3)
Chronic respiratory diseases	-	-	-	-	5.9 (4.1 to 8.2)	11.7 (8.0 to		

Appendix Table G.4 - Namibia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumonia	-	-	-	-	0.0	0.0	75.3	-
Silicosis	0.0	0.0	65.1	-11.6	0.0	0.0	(69.1 to 80.8)	(-9.4 to -3.3)
Asbestosis	-	-	0.0	0.0	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	88.3	-0.7	0.0	0.0	84.3	(-0.5 to 3.6)
Asthma	21.1	59.0	179.3	43.5	0.9	2.6	180.0	44.2
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.1	93.0	7.7	0.0	0.0	93.7	8.0
Other chronic respiratory diseases	-	-	-	-	0.3	0.5	44.8	-20.9
Cirrhosis	-	-	-	-	0.1	0.1	74.3	-3.1
Cirrhosis due to hepatitis B	0.1	0.2	79.4	0.7	0.0	0.0	76.6	-1.4
Cirrhosis due to hepatitis C	0.1	0.1	86.0	-1.4	0.0	0.0	84.6	-1.4
Cirrhosis due to alcohol use	0.2	0.3	54.0	-18.1	0.0	0.0	54.0	-18.4
Cirrhosis due to other causes	0.2	0.3	93.0	27.8	0.0	0.0	90.0	26.7
Digestive diseases	-	-	-	-	1.6	2.8	77.7	2.3
Peptic ulcer disease	8.4	10.3	22.5	-33.0	0.3	0.4	28.7	-32.7
Gastritis and duodenitis	15.0	25.3	68.5	1.4	0.6	1.1	64.8	2.2
Appendicitis	0.2	0.3	96.5	11.7	0.0	0.1	95.7	11.9
Paralytic ileus and intestinal obstruction	0.0	0.0	54.9	-4.9	0.0	0.0	51.9	4.9
Inguinal, femoral, and abdominal hernia	3.5	4.9	39.0	-22.3	0.0	0.1	39.4	-22.1
Inflammatory bowel disease	1.3	3.0	134.3	25.4	0.3	0.6	133.2	25.0
Vascular intestinal disorders	0.0	0.0	65.8	-4.5	0.0	0.0	63.3	-6.7
Gallbladder and biliary diseases	0.4	0.9	130.6	0.0	0.1	0.1	130.6	19.4
Pancreatitis	0.2	0.5	101.1	5.7	0.1	0.1	99.1	5.4
Other digestive diseases	-	-	-	-	0.2	0.3	109.3	15.0
Neurological disorders	-	-	-	-	5.8	11.2	91.1	6.4
Alzheimer disease and other dementias	2.4	4.6	87.7	3.7	0.3	0.6	90.4	4.2
Parkinson disease	0.1	0.2	77.5	-0.5	0.0	0.0	78.9	0.6
Epilepsy	2.0	3.3	63.0	-0.9	0.6	1.1	70.7	4.3
Multiple sclerosis	0.1	0.3	117.0	11.1	0.0	0.1	114.7	9.8
Migraine	97.5	172.8	76.6	0.8	3.3	5.9	70.7	-1.1
Tension-type headache	172.2	326.9	89.6	3.5	0.3	0.5	89.2	3.5
Medication overuse headache	6.5	16.9	159.9	43.3	1.0	2.6	159.3	42.5
Other neurological disorders	0.0	0.0	55.2	-6.7	0.2	0.3	51.2	-17.8
Mental and substance use disorders	-	-	-	-	33.5	60.7	79.4	1.0
Schizophrenia	2.8	5.4	91.5	-1.2	1.8	3.4	89.7	-1.9
Alcohol use disorders	16.7	41.8	150.8	35.7	1.7	4.2	151.6	36.0
Drug use disorders	-	-	-	-	1.8	3.4	91.4	-0.0
Opioid use disorders	2.2	4.4	99.0	-0.5	0.9	1.8	96.5	-1.2
Cocaine use disorders	0.6	1.2	94.7	0.2	0.2	0.2	94.2	1.2
Amphetamine use disorders	2.3	4.3	84.9	3.0	0.3	0.6	84.6	2.9
Cannabis use disorders	2.1	3.6	76.0	0.1	0.1	0.1	77.7	0.9
Other drug use disorders	-	-	-	-	0.4	0.7	85.8	1.5
Depressive disorders	-	-	-	-	12.5	23.0	84.0	1.7
Major depressive disorder	54.3	100.2	84.7	2.4	11.2	20.5	83.6	2.0
Dysthymia	13.8	26.1	88.3	0.3	1.3	2.5	87.6	0.0
Bipolar disorder	7.8	14.7	87.6	0.1	1.6	3.0	86.4	-0.4
Anxiety disorders	55.8	97.8	75.0	0.2	5.2	9.0	74.4	-0.2
Eating disorders	-	-	-	-	0.4	0.6	67.6	-2.5
Anorexia nervosa	0.3	0.4	74.8	2.0	0.1	0.1	75.3	2.4
Bulimia nervosa	1.5	2.6	75.1	-0.4	0.3	0.5	74.3	-0.6
Autistic spectrum disorders	-	-	-	-	1.7	2.7	62.8	-0.4
Autism	4.3	7.1	63.4	-0.3	1.1	1.7	62.9	-0.5
Asperger syndrome	6.2	10.1	62.5	-0.4	0.6	1.0	62.5	-0.3
Attention-deficit/hyperactivity disorder	10.6	16.3	53.0	0.0	0.1	0.2	53.4	0.3
Conduct disorder	15.7	24.1	53.7	0.0	1.1	2.9	54.2	0.1
Idiopathic intellectual disability	75.3	107.6	42.8	-1.1	3.7	5.3	42.6	-1.1
Other mental and substance use disorders	17.3	32.7	89.2	-0.3	1.3	2.4	88.8	-0.6
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	7.0	12.9	84.8	6.2
Diabetes mellitus	21.1	52.9	149.7	34.4	1.4	3.5	143.0	30.2
Acute glomerulonephritis	0.0	0.0	11.6	-20.7	0.0	0.0	11.6	-20.7
Chronic kidney disease	-	-	-	-	2.3	4.0	77.0	1.4
Chronic kidney disease due to diabetes mellitus	19.1	33.7	76.1	-3.2	0.3	0.5	80.8	0.2
Chronic kidney disease due to hypertension	59.1	97.6	65.0	0.8	0.7	1.3	81.7	1.8
Chronic kidney disease due to glomerulonephritis	50.1	88.4	75.0	0.9	0.8	1.3	69.1	1.5
Chronic kidney disease due to other causes	36.5	63.9	76.0	5.0	0.5	0.9	85.1	6.5
Urinary diseases and male infertility	-	-	-	-	0.4	0.7	79.7	1.3

Appendix Table G.4 - Namibia prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.3 (0.2 to 0.3)	0.5 (0.5 to 0.5)	80.0 (64.6 to 101.2)	0.0 (-1.9 to 17.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.8 (42.4 to 133.3)	6.1 (-12.4 to 30.8)
Urolithiasis	2.8 (2.1 to 3.6)	4.5 (3.4 to 5.7)	60.4 (34.2 to 98.6)	-13.3 (-26.5 to 2.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	94.1 (70.1 to 122.4)	3.8 (-8.1 to 15.4)
Benign prostatic hyperplasia	8.6 (7.9 to 9.4)	14.7 (13.4 to 15.9)	70.3 (50.2 to 91.4)	-1.2 (-12.7 to 11.1)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	69.6 (49.5 to 91.8)	-1.4 (-12.8 to 10.9)
Male infertility due to other causes	3.3 (2.4 to 4.3)	6.1 (4.6 to 8.1)	86.3 (27.5 to 179.8)	-1.6 (-32.8 to 47.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	82.0 (23.6 to 174.0)	-3.9 (-34.3 to 46.2)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	44.8 (83.4 to 313.1)	24.1 (-0.3 to 120.2)
Gynecological diseases	-	-	-	-	1.4 (0.9 to 2.1)	2.7 (1.8 to 4.1)	95.7 (65.2 to 134.0)	0.6 (-14.0 to 17.7)
Uterine fibroids	21.0 (18.9 to 22.9)	42.9 (38.9 to 46.7)	104.9 (103.7 to 106.1)	0.6 (0.4 to 0.7)	0.4 (0.2 to 0.6)	0.6 (0.4 to 1.0)	69.7 (44.1 to 83.3)	-15.5 (-28.9 to -8.5)
Polycystic ovarian syndrome	19.9 (17.9 to 21.9)	40.8 (36.1 to 45.1)	105.4 (74.8 to 137.8)	3.4 (-10.3 to 18.3)	0.1 (0.1 to 0.4)	0.4 (0.2 to 0.7)	104.3 (74.4 to 136.6)	3.2 (-10.5 to 18.2)
Female infertility due to other causes	5.0 (3.3 to 7.0)	7.6 (4.8 to 10.6)	54.2 (-12.9 to 151.5)	-23.9 (-56.8 to 30.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	52.4 (-13.5 to 144.9)	24.1 (-56.7 to 28.4)
Endometriosis	2.1 (1.8 to 2.4)	3.7 (3.1 to 4.3)	77.6 (38.5 to 120.6)	-9.8 (-28.9 to 11.2)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	76.2 (34.9 to 128.4)	-10.7 (-31.3 to 14.4)
Genital prolapse	43.3 (36.3 to 50.2)	87.8 (72.6 to 101.6)	100.8 (64.0 to 159.3)	4.2 (-13.5 to 31.6)	0.1 (0.1 to 0.3)	0.3 (0.1 to 0.5)	100.5 (62.8 to 158.0)	3.9 (-14.2 to 30.6)
Premenstrual syndrome	41.1 (19.7 to 60.8)	104.0 (75.1 to 140.3)	156.7 (46.6 to 426.9)	37.0 (-21.0 to 169.6)	0.3 (0.1 to 0.6)	0.9 (0.5 to 1.4)	155.9 (45.0 to 416.5)	35.9 (-21.5 to 168.2)
Other gynecological diseases	4.5 (3.5 to 5.6)	6.9 (4.9 to 8.9)	50.8 (8.1 to 105.1)	-20.0 (-40.9 to 7.0)	0.1 (0.1 to 0.2)	0.2 (0.0 to 0.3)	43.0 (-32.1 to 123.3)	-25.6 (-63.8 to 11.4)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.8 (0.5 to 1.1)	1.0 (0.7 to 1.5)	33.2 (15.0 to 66.0)	-15.6 (-25.0 to 2.0)
Thalassemias	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-54.9 (-70.3 to -36.0)	-73.4 (-83.7 to -60.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-55.9 (-69.3 to -41.6)	-73.8 (-83.0 to -64.7)
Thalassemia trait	9.5 (7.1 to 12.0)	14.8 (11.0 to 19.2)	61.8 (29.9 to 67.3)	-0.5 (-20.4 to 3.1)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	59.1 (36.6 to 87.4)	2.8 (-1.1 to 20.0)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	54.3 (45.4 to 64.3)	0.2 (-5.2 to 6.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.8 (53.6 to 77.1)	5.2 (-1.9 to 13.3)
Sickle cell trait	20.3 (17.7 to 22.7)	33.8 (29.3 to 37.7)	65.9 (58.7 to 73.2)	1.9 (-2.3 to 6.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	65.4 (11.5 to 182.3)	75.3 (-23.6 to 77.6)
G6PD deficiency	40.2 (38.9 to 41.8)	67.4 (65.1 to 69.7)	67.5 (60.2 to 75.6)	3.0 (-1.5 to 7.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.2 (34.2 to 102.4)	8.9 (-6.0 to 21.6)
G6PD trait	174.9 (173.1 to 176.9)	280.2 (277.0 to 282.9)	60.2 (57.8 to 62.6)	-1.4 (-2.9 to 0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.3 (-60.8 to 113.3)	-30.1 (-75.3 to 17.7)
Other hemoglobinopathies and hemolytic anemias	17.0 (14.5 to 18.9)	20.9 (18.8 to 22.7)	23.4 (9.3 to 44.5)	-26.2 (-32.8 to -17.2)	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.9)	18.1 (-6.2 to 58.7)	-26.5 (-39.1 to -6.5)
Endocrine, metabolic, blood, and immune disorders	20.0 (18.7 to 21.5)	26.1 (22.8 to 28.9)	30.4 (9.3 to 56.9)	-17.3 (-28.1 to -4.8)	0.7 (0.5 to 1.0)	0.9 (0.6 to 1.2)	26.7 (20.9 to 60.2)	-16.7 (-30.5 to 1.8)
Musculoskeletal disorders	-	-	-	-	12.2 (11.8 to 12.7)	24.0 (22.8 to 42.7)	95.5 (89.0 to 110.3)	2.7 (-3.7 to 9.6)
Rheumatoid arthritis	4.2 (4.0 to 4.5)	7.7 (7.2 to 8.2)	82.3 (66.5 to 100.0)	-6.3 (-14.2 to 1.2)	1.0 (0.7 to 1.3)	1.8 (1.3 to 2.4)	82.3 (65.6 to 103.6)	-6.5 (-14.8 to 2.6)
Osteoarthritis	26.6 (25.5 to 27.7)	50.9 (48.9 to 53.0)	91.1 (81.1 to 102.2)	2.5 (-2.6 to 8.1)	1.6 (1.1 to 2.2)	3.2 (2.1 to 4.2)	90.8 (80.7 to 102.8)	2.4 (-2.8 to 8.3)
Low back and neck pain	-	-	-	-	8.5 (8.5 to 16.5)	12.2 (16.6 to 32.2)	95.5 (77.5 to 118.4)	2.7 (-5.5 to 13.5)
Low back pain	60.3 (56.9 to 63.6)	110.5 (104.1 to 116.6)	83.5 (68.9 to 98.2)	-1.0 (-8.4 to 7.5)	6.7 (4.6 to 9.3)	12.2 (8.3 to 17.1)	82.6 (68.4 to 98.3)	-1.3 (-8.6 to 7.1)
Neck pain	56.2 (46.5 to 64.0)	119.4 (102.1 to 135.2)	111.4 (77.1 to 162.5)	7.8 (-8.5 to 32.5)	5.5 (3.7 to 7.8)	11.7 (7.8 to 16.3)	111.1 (76.2 to 160.0)	7.7 (-8.8 to 32.5)
Gout	0.2 (0.2 to 0.3)	0.4 (0.4 to 0.5)	76.7 (54.8 to 104.1)	-5.1 (-15.8 to 8.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.1 (39.9 to 130.0)	-5.3 (-26.2 to 24.5)
Other musculoskeletal disorders	19.9 (15.3 to 25.0)	38.4 (29.5 to 47.1)	99.1 (76.8 to 110.7)	4.0 (-5.5 to 11.9)	1.8 (1.2 to 2.7)	3.5 (2.2 to 5.0)	92.1 (75.2 to 112.2)	3.5 (-5.9 to 12.8)
Other non-communicable diseases	-	-	-	-	17.2 (11.2 to 25.7)	28.7 (18.6 to 42.5)	66.5 (59.6 to 73.9)	-4.2 (-7.2 to -1.0)
Congenital anomalies	-	-	-	-	1.1 (0.8 to 1.5)	2.2 (1.5 to 3.2)	97.8 (62.3 to 165.5)	17.6 (-2.1 to 53.9)
Neural tube defects	0.3 (0.2 to 0.3)	0.6 (0.5 to 0.6)	100.2 (53.9 to 149.7)	28.0 (-1.6 to 60.2)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	113.4 (44.2 to 202.7)	37.3 (-5.6 to 93.1)
Congenital heart anomalies	3.6 (2.8 to 4.4)	8.8 (6.9 to 11.0)	147.2 (76.0 to 236.3)	55.2 (9.7 to 112.3)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.5)	142.9 (72.6 to 228.4)	54.6 (9.8 to 108.5)
Orofacial clefts	0.4 (0.3 to 0.6)	1.1 (0.9 to 1.4)	163.0 (80.1 to 310.3)	0.0 (-17.8 to 17.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.2 (45.5 to 248.7)	47.3 (-4.6 to 130.6)
Down syndrome	1.0 (0.8 to 1.2)	1.7 (1.4 to 2.2)	79.0 (36.4 to 138.7)	8.5 (-17.2 to 46.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	78.7 (33.6 to 144.1)	6.9 (-19.6 to 44.4)
Turner syndrome	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	70.0 (21.5 to 130.4)	1.0 (-27.7 to 37.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.4 (16.6 to 143.8)	0.4 (-31.9 to 42.6)
Klinefelter syndrome	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	51.8 (8.7 to 133.3)	-7.2 (-33.6 to 42.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.5 (18.8 to 155.5)	-6.4 (-33.1 to 44.4)
Chromosomal unbalanced rearrangements	1.8 (1.5 to 2.3)	3.1 (2.6 to 3.9)	72.2 (22.0 to 128.2)	4.2 (-26.2 to 39.2)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	71.4 (21.3 to 132.1)	2.2 (-27.8 to 39.9)
Other congenital anomalies	3.8 (2.9 to 4.8)	5.6 (4.4 to 6.9)	46.4 (29.0 to 77.5)	-13.5 (-23.7 to 7.1)	0.6 (0.4 to 0.8)	1.1 (0.7 to 2.0)	98.4 (48.3 to 218.8)	16.7 (-10.3 to 81.4)
Skin and subcutaneous diseases	-	-	-	-	7.0 (4.4 to 11.2)	11.7 (7.3 to 18.8)	66.8 (53.2 to 82.0)	-1.0 (-7.7 to 5.3)
Dermatitis	58.7 (48.9 to 69.4)	102.5 (84.4 to 122.0)	74.6 (71.5 to 77.6)	0.1 (0.0 to 0.1)	1.8 (1.1 to 2.5)	3.0 (1.9 to 4.3)	69.5 (62.7 to 75.5)	-0.1 (-3.0 to 2.9)
Psoriasis	0.1 (7.8 to 10.5)	16.3 (13.9 to 19.0)	79.5 (77.3 to 81.7)	-0.7 (-0.1 to 0.1)	0.7 (0.5 to 1.1)	1.3 (0.9 to 1.9)	78.7 (67.6 to 89.6)	0.3 (-5.4 to 5.1)
Cellulitis	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.6)	66.2 (41.8 to 95.0)	-1.7 (-16.1 to 17.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	67.5 (27.4 to 120.4)	-1.0 (-21.7 to 26.1)
Pyoderma	2.4 (1.7 to 3.0)	3.2 (2.5 to 4.1)	36.6 (25.7 to 49.6)	-4.3 (-10.6 to 2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.0 (21.5 to 54.1)	-4.4 (-13.3 to 5.3)
Scabies	13.9 (12.3 to 15.7)	20.2 (18.1 to 22.4)	44.8 (24.3 to 70.3)	-12.6 (-24.3 to 1.6)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.8)	44.3 (22.8 to 70.1)	-12.8 (-24.8 to 1.9)
Fungal skin diseases	158.6 (119.6 to 207.8)	269.8 (204.7 to 354.9)	69.5 (65.7 to 75.5)	0.9 (-0.1 to 0.9)	1.5 (0.3 to 2.0)	1.5 (0.6 to 3.4)	69.6 (65.1 to 75.2)	-0.1 (-0.8 to 0.5)
Viral skin diseases	27.9 (21.5 to 34.1)	43.0 (32.8 to 53.0)	53.9 (45.9 to 60.5)	-0.2 (-2.7 to 2.2)	0.9 (0.5 to 1.3)	1.3 (0.8 to 2.1)	53.7 (45.2 to 62.3)	-0.2 (-4.1 to 3.3)
Acne vulgaris	140.7 (108.4 to 181.5)	202.4 (147.2 to 269.1)	43.1 (-0.7 to 120.3)	-14.5 (-39.9 to 25.3)	1.5 (0.7 to 2.9)	2.2 (1.0 to 4.2)	42.9 (-0.7 to 121.2)	-14.8 (-40.3 to 26.3)
Alopecia areata	1.2 (1.1 to 1.4)	2.1 (1.9 to 2.4)	71.3 (45.9 to 99.0)	0.8 (-13.7 to 16.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	70.9 (39.9 to 105.1)	0.4 (-16.0 to 18.4)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.1 (32.6 to 117.5)	0.8 (-23.4 to 26.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.1 (32.5 to 117.5)	-0.8 (-23.5 to 25.9)
Urticaria	6.2 (4.0 to 8.2)	15.6 (9.7 to 20.3)	149.4 (65.1 to 317.3)	21.8 (-22.5 to 92.8)	0.4 (0.2 to 0.6)	0.9 (0.5 to 1.5)	150.9 (64.8 to 334.9)	22.9 (-22.6 to 96.9)
Decubitus ulcer	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	95.0 (50.1 to 149.6)	6.6 (-21.6 to 44.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	94.2 (46.2 to 153.9)	6.8 (-23.4 to 47.9)
Other skin and subcutaneous diseases	71.1 (48.8 to 101.0)	127.0 (86.8 to 177.4)	78.6 (70.7 to 88.0)	-0.4 (-3.2 to 3.1)	0.4 (0.2 to 0.9)	0.7 (0.3 to 1.5)	78.2 (70.0 to 88.2)	-0.5 (-3.5 to 3.1)
Sense organ diseases	-	-	-	-	6.9 (4.5 to 10.2)	11.0 (7.1 to 16.2)	99.7 (51.8 to 97.0)	11.0 (-11.4 to -3.4)
Glaucoma	2.9 (2.5 to 3.3)	4.2 (3.4 to 5.1)	43.5 (24.2 to 68.7)	-17.3 (-29.4 to 0.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	57.8 (31.8 to 86.6)	-9.5 (-23.6 to 11.4)
Cataract	4.0 (2.9 to 4.8)	6.7 (5.3 to 8.0)	66.6 (35.2 to 115.2)	-5.7 (-23.2 to 18.3)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	58.2 (25.2 to 112.3)	-11.1 (-28.5 to 14.5)
Macular degeneration	1.1 (0.9 to 1.4)	2.6 (2.0 to 3.2)	133.8 (76.2 to 208.7)	28.8 (-3.5 to 67.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	121.2 (67.5 to 183.4)	19.6 (-8.4 to 51.8)
Uncorrected refractive error	146.5 (135.6 to 157.0)	245.2 (228.3 to 263.1)	67.2 (52.3 to 84.2)	4.9 (-12.7 to 12.9)	2.2 (1.3 to 3.6)	3.5 (2.0 to 5.0)	55.7 (45.5 to 68.6)	-11.4 (-16.8 to -5.1)
Age-related and other hearing loss	147.5 (130.6 to 164.6)	248.6 (215.7 to 279.4)	68.4 (61.6 to 75.5)	-7.3 (-10.1 to -4.1)	3.0 (1.9 to 4.5)	4.9 (3.0 to 7.5)	65.4 (50.1 to 76.8)	-4.7 (-11.4 to 1.8)
Other vision loss	3.9 (3.3 to 4.5)	5.6 (4.7 to 6.6)	44.1 (26.0 to 57.7)	-12.3 (-24.2 to -2.7)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	32.7 (5.3 to 52.7)	19.3 (-36.4 to -7.5)
Other sense organ diseases	33.3 (31.5 to 35.0)	51.7 (49.3 to 54.3)	55.2 (44.7 to 67.0)	-0.2 (-6.3 to 6.5)	0.9 (0.5 to 1.3)	1.4 (0.8 to 2.0)	54.9 (42.4 to 68.1)	-0.1 (-7.0 to 7.1)
Oral disorders	-	-	-	-	2.2 (1.3 to 3.4)	3.7 (2.3 to 5.8)	70.5 (60.0 to 77.8)	-6.7 (-11.2 to -2.5)
Deciduous caries	122.8 (117.3 to 128.4)	161.9 (154.4 to 168.7)	32.2 (23.5 to 39.4)	-1.0 (-7.4 to 4.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to		

Appendix Table G.4 - Namibia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	31.2 (29.5 to 32.7)	49.8 (47.0 to 52.9)	59.7 (47.9 to 73.4)	-12.4 (-18.6 to -5.5)	0.9 (0.6 to 1.2)	1.4 (0.9 to 1.9)	59.8 (47.1 to 73.4)	-22.4 (-19.0 to -5.4)
Other oral disorders	20.8 (19.5 to 21.8)	37.0 (34.9 to 39.0)	78.3 (64.7 to 93.7)	-0.0 (-7.5 to 7.5)	0.5 (0.4 to 0.9)	1.1 (0.7 to 1.6)	77.7 (63.0 to 94.0)	-0.3 (-7.7 to 7.6)
Injuries	-	-	-	-	6.1 (4.6 to 7.8)	8.7 (6.4 to 11.7)	43.1 (29.5 to 58.9)	-20.6 (-27.8 to -12.2)
Transport injuries	-	-	-	-	1.7 (1.3 to 2.2)	2.4 (1.7 to 3.2)	38.0 (21.0 to 58.8)	-17.7 (-27.0 to -6.8)
Road injuries	-	-	-	-	1.5 (1.2 to 2.0)	2.0 (1.5 to 2.8)	35.2 (16.2 to 53.4)	-20.5 (-29.7 to -9.9)
Pedestrian road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	10.5 (5.9 to 29.5)	-30.8 (-39.7 to -20.5)
Cyclist road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	32.6 (18.8 to 48.0)	-19.9 (-27.6 to -11.1)
Motorcyclist road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	28.7 (11.0 to 48.7)	-26.3 (-36.0 to -16.1)
Motor vehicle road injuries	-	-	-	-	0.7 (0.6 to 1.0)	1.1 (0.8 to 1.5)	47.4 (26.8 to 73.1)	-12.4 (-23.7 to 0.6)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.4 (-23.4 to 2.8)	-49.8 (-56.1 to -42.9)
Other transport injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	82.1 (61.7 to 105.6)	6.2 (-5.6 to 19.2)
Unintentional injuries	-	-	-	-	3.9 (3.0 to 5.1)	5.5 (4.0 to 7.3)	39.2 (27.9 to 51.5)	-24.9 (-31.1 to -17.9)
Falls	-	-	-	-	2.2 (1.7 to 2.8)	2.6 (1.9 to 3.6)	19.4 (7.1 to 32.6)	-36.2 (-42.8 to -29.0)
Drowning	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-13.5 (-25.6 to 3.1)	-46.4 (-53.4 to -37.6)
Fire, heat, and hot substances	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	50.2 (34.4 to 68.4)	-9.8 (-18.4 to 0.1)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.5 (5.6 to 46.9)	-26.5 (-36.3 to -16.6)
Exposure to mechanical forces	-	-	-	-	0.8 (0.6 to 1.1)	1.5 (1.1 to 2.0)	86.4 (74.3 to 98.9)	8.5 (1.8 to 15.5)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	129.8 (103.4 to 163.5)	29.3 (13.8 to 47.4)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.9 (74.9 to 118.8)	13.9 (3.1 to 27.0)
Other exposure to mechanical forces	-	-	-	-	0.8 (0.6 to 1.0)	1.4 (1.0 to 1.9)	84.6 (72.5 to 97.0)	7.5 (0.7 to 14.6)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	124.3 (112.2 to 137.1)	27.3 (20.5 to 34.7)
Animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	30.2 (19.6 to 42.4)	-23.7 (-29.4 to -17.0)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	39.2 (23.5 to 57.0)	-19.1 (-27.2 to -10.1)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	23.5 (11.3 to 36.7)	-26.9 (-33.6 to -19.5)
Foreign body	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	36.0 (23.4 to 50.4)	-19.9 (-27.0 to -12.5)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.5 (-19.0 to 19.5)	-35.7 (-45.4 to -22.9)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.2 (42.8 to 79.4)	-8.8 (-17.6 to 1.6)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	48.4 (33.5 to 65.6)	-16.1 (-24.3 to -7.3)
Other unintentional injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	52.3 (41.9 to 65.3)	-14.4 (-20.0 to -7.1)
Self-harm and interpersonal violence	-	-	-	-	0.4 (0.3 to 0.5)	0.8 (0.6 to 1.1)	95.9 (73.2 to 127.3)	12.2 (-0.4 to 29.1)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	142.9 (116.9 to 172.2)	28.0 (15.1 to 42.9)
Interpersonal violence	-	-	-	-	0.4 (0.3 to 0.5)	0.7 (0.5 to 1.0)	91.8 (68.9 to 123.2)	10.8 (-2.3 to 28.0)
Assault by firearm	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	123.5 (102.2 to 149.2)	28.0 (16.7 to 41.9)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	136.0 (108.8 to 174.8)	31.7 (16.7 to 52.1)
Assault by other means	-	-	-	-	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.6)	72.5 (50.5 to 101.7)	0.5 (-12.1 to 16.9)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	250.4 (82.4 to 569.8)	110.7 (13.1 to 297.9)
Exposure to forces of nature	-	-	-	-	-	-	-	-
Collective violence and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.0 (-0.8 to 162.6)	5.7 (-34.7 to 66.5)

Appendix Table G.4 - Nepal prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,729.7 (1,262.1 to 2,255.3)	2,732.6 (2,026.1 to 3,564.3)	58.1 (53.1 to 62.8)	4.9 (-7.2 to -2.4)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	451.3 (313.7 to 630.9)	507.8 (356.8 to 701.9)	12.6 (6.1 to 20.5)	-23.4 (-28.1 to -17.5)
HIV/AIDS and tuberculosis	-	-	-	-	9.1 (6.2 to 12.5)	17.7 (11.3 to 31.8)	80.4 (60.9 to 213.8)	2.8 (-7.7 to 75.2)
Tuberculosis	29.8 (27.6 to 32.2)	48.4 (45.5 to 51.7)	63.2 (54.2 to 72.8)	-6.8 (-12.4 to -1.1)	9.0 (6.1 to 12.1)	14.6 (10.1 to 19.7)	63.0 (50.5 to 76.0)	-6.6 (-13.4 to 1.1)
HIV/AIDS	-	-	-	-	0.2 (0.0 to 0.7)	3.1 (0.5 to 15.0)	3,269.2 (597.6 to 13,314.8)	3,913.9 (312.0 to 8,077.4)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.1)	0.4 (0.0 to 2.1)	2,640.7 (352.4 to 11,888.3)	1,480.5 (157.3 to 6,932.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.8)	2,374.7 (205.0 to 10,926.9)	1,315.5 (69.6 to 3,361.0)
HIV/AIDS resulting in other diseases	1.3 (0.1 to 4.8)	20.1 (4.9 to 83.5)	3,389.8 (641.4 to 13,626.6)	2,090.3 (362.3 to 8,819.3)	0.2 (0.0 to 0.7)	3.0 (0.4 to 14.9)	3,459.4 (548.9 to 22,993.4)	2,044.2 (283.9 to 14,092.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	77.4 (55.0 to 104.5)	71.5 (50.7 to 96.7)	-7.5 (-13.9 to -1.1)	-29.5 (-34.0 to -24.9)
Diarrheal diseases	260.1 (243.2 to 276.4)	240.2 (225.5 to 254.9)	-7.2 (-15.2 to 1.5)	-22.2 (-28.3 to -15.8)	42.1 (28.7 to 58.0)	38.9 (26.4 to 54.2)	-7.5 (-15.7 to 2.0)	-22.2 (-28.6 to -14.8)
Intestinal infectious diseases	-	-	-	-	2.7 (1.7 to 3.9)	1.7 (1.1 to 2.4)	1.7 (-5.2 to -19.3)	-35.9 (-64.5 to -42.8)
Typhoid fever	14.8 (12.3 to 17.7)	10.2 (8.4 to 11.8)	-30.2 (-46.9 to -13.8)	-50.5 (-61.5 to -39.5)	1.9 (1.3 to 2.9)	1.4 (0.9 to 2.0)	-29.7 (-47.8 to -9.5)	-49.5 (-62.0 to -35.6)
Paratyphoid fever	9.0 (7.1 to 11.1)	5.7 (4.4 to 7.2)	-36.6 (-54.6 to -11.2)	-52.9 (-66.2 to -35.4)	0.5 (0.3 to 0.7)	0.3 (0.2 to 0.5)	-36.2 (-57.0 to -5.3)	-52.4 (-67.4 to -33.0)
Other intestinal infectious diseases	-	-	-	-	0.3 (0.1 to 0.5)	0.0 (0.0 to 0.1)	-88.5 (-95.9 to -81.3)	-91.6 (-96.5 to -81.3)
Lower respiratory infections	14.0 (12.7 to 15.3)	13.8 (12.5 to 15.0)	-1.1 (-11.9 to 11.5)	-16.5 (-25.5 to -6.7)	1.5 (1.0 to 2.1)	1.4 (1.0 to 2.1)	-1.2 (-16.0 to 16.6)	-16.1 (-27.0 to -3.4)
Upper respiratory infections	486.4 (459.8 to 511.1)	705.2 (677.6 to 735.1)	45.2 (36.3 to 55.2)	-4.0 (-9.7 to 2.1)	5.7 (3.2 to 9.6)	8.3 (4.6 to 13.9)	45.6 (34.9 to 57.1)	-3.6 (-10.3 to 3.1)
Otitis media	346.9 (317.7 to 377.7)	416.9 (384.4 to 449.6)	20.4 (10.0 to 32.2)	-17.5 (-24.9 to -9.1)	7.0 (4.2 to 11.1)	8.3 (4.9 to 13.3)	18.7 (7.8 to 31.3)	-18.4 (-25.8 to -9.6)
Meningitis	-	-	-	-	14.3 (9.7 to 19.7)	10.4 (7.3 to 14.2)	-27.2 (-41.3 to -9.9)	-51.5 (-60.6 to -40.7)
Pneumococcal meningitis	71.2 (44.6 to 107.2)	51.9 (30.3 to 85.5)	-29.5 (-51.3 to 16.1)	-56.0 (-68.8 to -25.4)	6.1 (4.2 to 8.6)	5.0 (3.3 to 7.5)	-19.0 (-45.8 to 22.9)	-47.6 (-63.8 to -23.7)
H influenzae type B meningitis	37.4 (16.1 to 68.9)	20.2 (7.8 to 38.4)	-47.9 (-61.6 to -18.2)	-67.7 (-75.6 to -47.3)	3.8 (2.4 to 5.6)	2.2 (1.4 to 3.3)	-41.5 (-60.3 to -10.3)	-60.8 (-73.1 to -40.9)
Meningococcal meningitis	5.6 (2.2 to 11.7)	4.1 (1.5 to 9.1)	-29.4 (-52.6 to 12.9)	-55.9 (-70.5 to -28.0)	0.7 (0.4 to 1.0)	0.5 (0.3 to 0.8)	-24.0 (-46.5 to 10.2)	-51.5 (-66.2 to -29.2)
Other meningitis	33.4 (17.0 to 59.9)	21.9 (11.1 to 40.1)	-34.2 (-55.3 to -5.5)	-56.8 (-70.9 to -37.6)	3.7 (2.4 to 5.4)	2.7 (1.7 to 4.0)	-28.0 (-50.4 to 5.0)	-50.9 (-66.1 to -31.0)
Encephalitis	0.7 (4.6 to 19.9)	12.6 (5.8 to 26.3)	29.5 (14.4 to 42.3)	-24.4 (-31.2 to -14.9)	1.6 (0.8 to 1.6)	1.6 (1.1 to 2.2)	35.6 (14.8 to 60.8)	-47.2 (-29.2 to -7.7)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Whooping cough	30.7 (23.6 to 39.8)	5.3 (4.1 to 6.8)	-82.7 (-84.6 to -80.7)	-82.7 (-84.5 to -80.6)	1.5 (0.9 to 2.5)	0.3 (0.2 to 0.4)	-82.7 (-85.4 to -79.2)	-82.6 (-85.4 to -79.3)
Tetanus	22.7 (9.4 to 46.2)	1.3 (0.7 to 2.1)	-93.6 (-98.2 to -86.2)	-95.8 (-98.8 to -90.6)	0.8 (0.4 to 1.4)	0.1 (0.1 to 0.1)	-84.8 (-93.5 to -59.0)	-89.2 (-95.5 to -70.6)
Measles	14.9 (8.8 to 6.2)	0.2 (0.1 to 0.3)	-95.9 (-97.4 to -93.6)	-95.9 (-97.5 to -93.9)	0.4 (0.3 to 0.7)	0.0 (0.0 to 0.0)	-95.8 (-97.4 to -93.2)	-96.0 (-97.6 to -93.6)
Varicella and herpes zoster	14.6 (13.3 to 16.0)	19.4 (17.4 to 21.7)	32.7 (14.2 to 54.9)	-2.0 (-22.1 to 20.3)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	62.1 (8.7 to 139.6)	-2.7 (-36.9 to 40.4)
Neglected tropical diseases and malaria	-	-	-	-	91.9 (58.0 to 142.0)	87.9 (55.3 to 133.0)	4.1 (-18.2 to 11.9)	-39.4 (-49.4 to -27.5)
Malaria	36.1 (22.2 to 64.7)	46.9 (29.0 to 72.6)	32.2 (-22.4 to 100.5)	-13.7 (-47.5 to 31.4)	0.5 (0.3 to 0.8)	0.5 (0.3 to 0.8)	4.9 (-30.4 to 56.1)	-31.4 (-52.6 to -2.0)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Leishmaniasis	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	47.7 (4.7 to 125.8)	-0.8 (-31.1 to 49.7)
Visceral leishmaniasis	0.8 (0.5 to 1.2)	1.0 (0.7 to 1.5)	25.8 (-3.0 to 66.9)	-5.9 (-24.4 to 18.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	25.6 (8.7 to 78.1)	-5.7 (-27.9 to 25.5)
Cutaneous and mucocutaneous leishmaniasis	4.8 (2.4 to 8.0)	8.4 (5.1 to 12.7)	77.2 (-5.7 to 271.1)	2.9 (-41.3 to 102.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	77.5 (-7.5 to 289.9)	4.8 (-42.2 to 110.9)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Cysticercosis	4.7 (2.6 to 7.5)	4.5 (2.3 to 8.2)	-1.4 (-56.3 to 88.5)	-43.2 (-72.4 to 0.6)	1.2 (0.6 to 2.1)	1.4 (0.6 to 2.6)	14.2 (-51.5 to 129.2)	-33.8 (-69.3 to 24.2)
Cystic echinococcosis	3.1 (2.7 to 3.5)	3.2 (2.9 to 3.4)	0.9 (-14.4 to 20.8)	-41.6 (-48.2 to -34.5)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	2.2 (-23.5 to 35.7)	41.2 (-53.3 to -26.2)
Lymphatic filariasis	268.1 (195.0 to 380.4)	129.1 (77.1 to 225.7)	-52.6 (-66.3 to -35.3)	-70.3 (-78.8 to -60.6)	12.2 (4.1 to 27.1)	10.9 (4.4 to 23.3)	-5.7 (-46.6 to 29.7)	-45.6 (-68.8 to -21.4)
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	12.5 (9.5 to 15.7)	5.7 (4.3 to 7.4)	-54.2 (-65.7 to -36.1)	-78.0 (-83.4 to -69.4)	0.8 (0.5 to 1.1)	0.4 (0.2 to 0.5)	-52.9 (-64.1 to -36.4)	-77.6 (-82.6 to -70.2)
Dengue	1.8 (0.7 to 4.1)	13.5 (5.2 to 30.3)	649.2 (641.0 to 658.8)	382.2 (376.9 to 388.3)	0.3 (0.1 to 0.7)	2.2 (0.8 to 5.5)	650.6 (483.2 to 889.0)	382.4 (286.0 to 518.6)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-79.8 to -10.5)	0.0 (-84.9 to -42.3)	-	-
Intestinal nematode infections	-	-	-	-	64.7 (36.6 to 102.8)	76.4 (33.6 to 92.4)	-6.7 (-24.8 to 12.6)	-76.4 (-52.4 to -25.2)
Ascariasis	5,116.2 (3,913.3 to 6,652.0)	5,436.5 (3,622.9 to 8,044.2)	5.4 (-34.0 to 71.8)	-32.1 (-60.4 to 16.4)	15.3 (7.6 to 29.7)	4.6 (2.1 to 8.7)	4.6 (-81.3 to -51.2)	-76.9 (-86.0 to -59.0)
Trichuriasis	3,740.5 (2,735.6 to 5,106.5)	5,082.4 (3,469.2 to 7,368.9)	34.6 (-17.6 to 120.6)	-15.6 (-50.6 to 46.0)	7.6 (3.4 to 14.3)	7.1 (3.2 to 14.4)	-7.9 (-51.1 to 17.1)	-44.3 (-72.6 to 8.7)
Hookworm disease	6,789.0 (5,578.4 to 8,250.1)	8,502.5 (6,415.4 to 11,207.5)	25.4 (-10.1 to 75.2)	-21.9 (-47.4 to 12.5)	39.8 (23.3 to 63.6)	46.0 (27.4 to 71.9)	15.5 (-9.0 to 45.5)	-38.4 (-45.5 to -7.1)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	377.5 (302.7 to 454.6)	401.9 (378.8 to 436.9)	6.4 (-11.5 to 32.2)	-23.7 (-34.7 to -8.7)	13.8 (8.6 to 20.0)	14.3 (9.5 to 21.1)	2.4 (-9.8 to 39.8)	-25.5 (-34.0 to -10.0)
Maternal disorders	-	-	-	-	11.1 (7.6 to 15.4)	14.5 (9.4 to 19.9)	31.3 (10.6 to 51.1)	-22.0 (-33.8 to -10.1)
Maternal hemorrhage	4.0 (3.0 to 4.9)	4.8 (3.1 to 6.5)	21.3 (-22.3 to 72.2)	-39.1 (-54.1 to -0.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	0.6 (-46.1 to 62.9)	-38.2 (-66.4 to 0.7)
Maternal sepsis and other maternal infections	12.6 (8.5 to 17.5)	8.6 (5.3 to 13.1)	-33.5 (-50.5 to -10.0)	-60.7 (-71.2 to -40.5)	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.2)	-45.7 (-66.9 to -12.4)	-45.7 (-79.1 to -48.8)
Maternal hypertensive disorders	11.2 (6.1 to 18.6)	8.2 (4.5 to 14.0)	-26.8 (-34.5 to -21.1)	-56.7 (-61.8 to -52.6)	0.6 (0.3 to 1.0)	0.4 (0.2 to 0.8)	-27.2 (-38.5 to -14.1)	-56.9 (-63.6 to -48.8)
Obstructed labor	24.0 (20.5 to 27.9)	32.0 (27.5 to 36.4)	33.7 (23.0 to 44.3)	-21.2 (-27.7 to -14.7)	7.9 (5.2 to 10.9)	10.6 (6.9 to 14.8)	34.3 (21.3 to 49.7)	-20.7 (-28.3 to -11.6)
Complications of abortion	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	28.1 (-41.9 to 171.7)	-26.5 (-65.5 to 47.7)	0.1 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other maternal disorders	-	-	-	-	2.2 (1.2 to 3.5)	3.1 (1.8 to 4.7)	45.8 (-21.7 to 141.0)	-12.7 (-53.0 to 45.7)
Neonatal disorders	-	-	-	-	13.7 (8.6 to 20.2)	64.2 (43.6 to 87.6)	369.9 (217.6 to 625.4)	240.5 (124.2 to 433.1)
Preterm birth complications	52.9 (35.0 to 76.9)	231.0 (172.3 to 298.9)	339.0 (240.8 to 488.6)	188.1 (122.7 to 285.9)	3.7 (2.3 to 5.5)	29.7 (19.6 to 42.5)	694.6 (436.0 to 1,131.4)	464.7 (286.1 to 768.2)
Neonatal encephalopathy due to birth asphyxia and trauma	165.7 (40.9 to 317.5)	156.6 (74.6 to 252.3)	-5.6 (-32.3 to 125.3)	-39.2 (-56.6 to -22.9)	5.8 (2.8 to 10.4)	16.6 (10.8 to 24.0)	191.2 (59.0 to 476.8)	105.7 (10.4 to 338.8)
Neonatal sepsis and other neonatal infections	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.5)	34.4 (25.4 to 45.7)	57.0 (46.6 to 70.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	15.5 (17.7 to 51.8)	33.7 (37.5 to 77.3)
Hemolytic disease and other neonatal jaundice	5.5 (2.3 to 9.8)	31.6 (14.4 to 58.4)	478.4 (103.9 to 1,745.7)	346.6 (56.7 to 1,334.3)	1.9 (0.8 to 3.6)	9.3 (4.5 to 16.8)	395.4 (94.2 to 1,368.0)	272.4 (46.2 to 1,008.8)
Other neonatal disorders	-	-	-	-	2.2 (1.1 to 4.1)	8.5 (4.3 to 14.8)	304.2 (77.1 to 788.0)	191.2 (27.2 to 536.8)
Nutritional deficiencies	-	-	-	-	233.7 (156.3 to 333.8)	235.4 (157.1 to 339.6)	0.9 (-5.9 to 6.3)	-31.1 (-34.7 to -28.0)
Protein-energy malnutrition	149.2 (84.8 to 243.9)	132.0 (85.3 to 190.8)	-9.7 (-54.4 to 74.5)	-9.7 (-53.1 to 66.3)	9.7 (8.7 to 33.3)	9.9 (8.8 to 26.9)	18.5 (-54.5 to 75.4)	9.4 (-53.6 to 68.0)
Iodine deficiency	216.6 (174.5 to 261.1)	214.4 (175.0 to 253.2)	-1.1 (-23.2 to 33.0)	-39.7 (-54.3 to -17.6)	3.9 (2.3 to 6.3)	3.9 (2.3 to 6.2)	-1.5 (-24.0 to 35.2)	-39.7 (-54.6 to -16.4)
Vitamin A deficiency	11.1 (8.3 to 14.3)	8.2 (6.0 to 10.6)	-25.7 (-33.8 to -15.0)	-48.3 (-53.4 to -41.6)	0.5 (0.3 to 0.8)	0.4 (0.2 to 0.6)	-28.6 (-39.9 to -14.3)	-50.9 (-57.8 to -42.0)

Appendix Table G.4 - Nepal prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	6,094.2 (6,015.5 to 6,172.5)	6,730.1 (6,689.6 to 6,773.5)	10.7 (9.2 to 12.1)	-27.1 (-28.2 to -26.0)	214.0 (209.7 to 301.9)	214.0 (142.3 to 310.1)	2.0 (-0.2 to 4.2)	-32.2 (-33.7 to -30.4)
Other nutritional deficiencies	-	-	-	-	1.2 (0.3 to 2.9)	0.7 (0.3 to 1.8)	-35.9 (-77.0 to 140.4)	-37.2 (-77.0 to 134.8)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	14.4 (9.3 to 21.4)	16.7 (10.9 to 25.0)	14.6 (4.1 to 37.4)	-22.6 (-29.2 to -11.6)
Sexually transmitted diseases excluding HIV	-	-	-	-	3.3 (2.0 to 5.6)	4.8 (2.8 to 8.4)	46.4 (26.4 to 67.1)	-16.0 (-26.5 to -5.1)
Syphilis	1.7 (1.5 to 2.0)	1.1 (1.0 to 1.3)	35.5 (-46.2 to -22.4)	-63.1 (-68.8 to -46.9)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-43.2 (-51.7 to -13.2)	-49.3 (-71.8 to -52.2)
Chlamydial infection	229.4 (206.0 to 250.8)	380.1 (343.0 to 417.3)	66.4 (44.2 to 88.3)	-0.3 (-12.6 to 11.6)	1.2 (0.7 to 1.9)	1.8 (1.0 to 3.0)	51.3 (24.0 to 81.5)	-9.1 (-24.5 to 7.8)
Gonococcal infection	80.4 (62.0 to 99.6)	121.1 (97.0 to 149.6)	50.5 (11.1 to 110.6)	-9.0 (-30.9 to 24.1)	0.7 (0.3 to 1.1)	0.9 (0.5 to 1.6)	45.9 (-11.1 to 115.7)	-12.2 (-43.9 to 23.3)
Trichomoniasis	178.8 (123.0 to 233.1)	300.7 (213.3 to 409.9)	64.9 (10.3 to 170.6)	-1.6 (-32.3 to 58.8)	0.3 (0.1 to 0.7)	0.5 (0.2 to 1.2)	68.2 (6.5 to 195.5)	0.6 (-33.5 to 70.3)
Genital herpes	2,669.7 (2,384.0 to 2,918.9)	4,517.8 (4,126.0 to 4,948.8)	69.6 (49.7 to 92.6)	5.4 (-15.8 to 6.7)	0.7 (0.2 to 1.7)	1.2 (0.4 to 2.9)	68.5 (46.9 to 93.5)	-4.9 (-16.5 to 8.3)
Other sexually transmitted diseases	4.3 (3.2 to 5.5)	4.1 (3.2 to 5.2)	-4.9 (-20.8 to 13.1)	-45.2 (-54.5 to -35.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	40.9 (6.3 to 122.6)	-18.1 (-44.6 to 27.6)
Hepatitis	-	-	-	-	1.0 (0.7 to 1.5)	1.4 (0.9 to 2.0)	33.8 (15.4 to 50.5)	-16.6 (-28.9 to -6.1)
Hepatitis A	30.9 (29.3 to 32.4)	38.5 (37.0 to 39.9)	24.8 (23.2 to 26.5)	-4.7 (-4.9 to -4.4)	0.6 (0.4 to 0.9)	0.9 (0.6 to 1.3)	54.2 (36.5 to 73.1)	3.7 (-7.5 to 16.1)
Hepatitis B	500.2 (436.1 to 568.3)	497.3 (447.0 to 549.5)	-0.6 (-15.3 to 16.8)	-37.4 (-45.9 to -27.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	15.5 (-5.9 to 56.6)	-31.0 (-51.9 to -8.0)
Hepatitis C	95.4 (85.4 to 105.1)	122.7 (111.3 to 133.8)	28.9 (12.5 to 47.2)	-25.8 (-34.5 to -15.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.3 (-0.5 to 55.2)	-25.4 (-20.8 to -2.5)
Hepatitis E	8.7 (7.1 to 10.4)	8.5 (5.3 to 11.9)	0.4 (-38.9 to 36.3)	-40.1 (-61.4 to -16.8)	0.3 (0.1 to 0.4)	0.2 (0.1 to 0.4)	0.4 (-43.0 to 44.9)	-39.9 (-64.1 to -12.4)
Leprosy	4.9 (3.9 to 5.9)	6.6 (5.8 to 7.6)	34.4 (15.1 to 59.9)	-27.6 (-36.8 to -16.6)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	40.7 (17.0 to 70.8)	-24.6 (-36.0 to -11.4)
Other infectious diseases	278.9 (222.9 to 331.9)	295.7 (275.6 to 315.5)	6.1 (-7.0 to 28.9)	-26.2 (-34.2 to -14.2)	9.8 (6.2 to 14.5)	10.1 (6.7 to 14.7)	1.5 (-10.4 to 32.2)	-27.1 (-35.6 to -7.9)
Non-communicable diseases	-	-	-	-	878.4 (878.4 to 1,569.5)	2,116.5 (1,548.9 to 2,736.1)	75.2 (71.0 to 79.8)	-0.1 (-2.5 to 2.3)
Neoplasms	-	-	-	-	4.7 (3.2 to 6.4)	9.3 (6.4 to 12.6)	98.5 (49.1 to 150.1)	6.5 (-18.2 to 32.1)
Esophageal cancer	1.3 (0.9 to 1.8)	2.3 (1.5 to 3.8)	77.0 (16.8 to 180.3)	-9.4 (-39.8 to 40.1)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	73.6 (15.3 to 157.7)	-11.9 (-40.5 to 30.5)
Stomach cancer	1.4 (1.1 to 1.7)	2.0 (1.6 to 2.6)	49.1 (6.5 to 100.9)	-22.0 (-43.6 to 6.2)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	49.1 (7.1 to 102.2)	-22.1 (-43.0 to 7.2)
Liver cancer	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	166.0 (80.3 to 288.3)	33.5 (8.3 to 91.1)
Liver cancer due to hepatitis B	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.5)	157.2 (2.2 to 462.0)	33.9 (-45.4 to 192.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	149.2 (14.8 to 419.7)	28.3 (-41.4 to 171.2)
Liver cancer due to hepatitis C	0.1 (0.0 to 0.1)	0.4 (0.3 to 0.6)	503.2 (181.4 to 1,611.2)	181.9 (35.5 to 722.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	475.0 (187.7 to 1,450.4)	166.9 (40.1 to 623.0)
Liver cancer due to alcohol use	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	31.5 (-39.8 to 164.8)	-34.2 (-69.8 to 29.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.4 (-34.4 to 135.6)	-36.4 (-67.6 to 15.3)
Liver cancer due to other causes	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	69.2 (-18.0 to 254.8)	-10.3 (56.1 to 90.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.1 (-15.1 to 197.2)	-11.1 (55.3 to 57.6)
Larynx cancer	5.6 (4.7 to 6.6)	10.6 (9.1 to 12.1)	88.0 (56.4 to 129.9)	-4.4 (-22.8 to 15.7)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	80.9 (44.4 to 122.9)	-8.9 (-26.1 to 12.5)
Tracheal, bronchus and lung cancer	1.0 (0.7 to 1.3)	1.9 (1.4 to 2.0)	95.3 (38.5 to 172.8)	1.4 (-27.4 to 39.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	93.2 (30.6 to 172.2)	0.3 (-31.5 to 37.1)
Breast cancer	7.2 (4.9 to 9.5)	19.8 (13.2 to 27.3)	173.7 (82.3 to 306.9)	44.5 (-12.2 to 110.8)	0.7 (0.4 to 1.0)	1.6 (1.0 to 2.4)	146.6 (67.4 to 271.0)	30.1 (-11.6 to 91.1)
Cervical cancer	8.6 (5.1 to 12.0)	9.9 (6.0 to 14.3)	15.2 (-27.9 to 79.5)	-35.6 (-59.7 to -0.3)	0.7 (0.4 to 1.0)	0.8 (0.4 to 1.2)	27.4 (-2.6 to 88.3)	-35.4 (-60.3 to 3.2)
Uterine cancer	0.9 (0.5 to 1.4)	1.6 (0.8 to 2.7)	85.0 (2.2 to 223.4)	-1.3 (-44.5 to 70.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	81.1 (0.6 to 230.1)	-4.0 (-46.4 to 66.2)
Prostate cancer	1.0 (0.4 to 1.7)	4.1 (2.1 to 7.3)	297.9 (114.0 to 761.3)	87.0 (4.9 to 313.0)	0.1 (0.0 to 0.2)	0.4 (0.2 to 0.7)	235.6 (83.4 to 657.5)	59.3 (-13.1 to 250.3)
Colon and rectum cancer	2.3 (1.8 to 2.7)	6.1 (4.9 to 7.5)	172.8 (105.9 to 252.5)	34.6 (1.7 to 75.0)	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.8)	146.6 (87.5 to 224.3)	21.7 (-8.8 to 60.9)
Lip and oral cavity cancer	4.6 (3.2 to 6.9)	10.4 (6.8 to 15.2)	124.7 (45.2 to 246.7)	17.1 (-21.3 to 77.9)	0.4 (0.1 to 0.6)	0.9 (0.5 to 1.4)	121.5 (41.3 to 238.9)	14.8 (-25.5 to 75.4)
Nasopharynx cancer	1.1 (0.7 to 1.5)	1.4 (0.9 to 2.0)	32.8 (-19.4 to 125.1)	-26.7 (55.2 to 21.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	30.2 (-17.8 to 107.7)	-29.1 (55.0 to 12.4)
Other pharynx cancer	1.2 (0.7 to 1.8)	3.0 (1.7 to 4.8)	148.6 (36.1 to 364.2)	27.7 (-29.6 to 134.9)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.5)	145.8 (32.5 to 322.1)	25.5 (-30.0 to 114.4)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	155.4 (65.2 to 276.1)	0.3 (-15.4 to 87.8)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	144.6 (62.7 to 237.8)	23.5 (-15.7 to 69.7)
Pancreatic cancer	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.4)	82.7 (24.9 to 154.0)	-8.0 (-36.1 to 26.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	77.9 (29.5 to 134.0)	-10.9 (-34.4 to 16.5)
Malignant skin melanoma	0.4 (0.3 to 0.6)	1.0 (0.7 to 1.6)	120.6 (45.4 to 213.2)	14.6 (-22.8 to 64.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	115.5 (44.3 to 221.1)	10.1 (-24.2 to 63.2)
Non-melanoma skin cancer	0.5 (0.4 to 0.7)	1.3 (1.0 to 1.6)	147.6 (83.4 to 233.2)	19.8 (-14.0 to 64.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	162.0 (66.2 to 310.2)	21.6 (-31.7 to 109.5)
Ovarian cancer	0.9 (0.5 to 1.5)	2.6 (1.4 to 4.3)	182.3 (75.6 to 345.8)	51.0 (-4.3 to 131.0)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	173.3 (62.9 to 343.9)	44.5 (-12.7 to 136.1)
Testicular cancer	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.1)	101.9 (4.1 to 281.6)	15.8 (-38.7 to 114.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	90.1 (-8.7 to 279.1)	7.9 (-46.4 to 111.5)
Kidney cancer	0.5 (0.3 to 0.6)	0.9 (0.6 to 1.4)	99.8 (23.0 to 201.7)	25.5 (-14.6 to 77.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	109.2 (33.4 to 192.6)	18.6 (-17.4 to 69.1)
Bladder cancer	0.6 (0.5 to 0.9)	1.1 (0.8 to 1.5)	72.4 (19.8 to 151.2)	-13.7 (39.4 to 25.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	71.2 (19.1 to 143.5)	-15.3 (-40.0 to 24.0)
Brain and nervous system cancer	1.2 (0.6 to 1.8)	2.1 (1.3 to 2.7)	79.2 (-3.4 to 167.0)	10.7 (-29.7 to 62.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	79.3 (7.8 to 164.0)	6.7 (-30.5 to 54.8)
Thyroid cancer	1.1 (0.5 to 1.6)	2.1 (1.2 to 3.3)	102.0 (18.4 to 239.5)	7.0 (-35.0 to 78.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	91.1 (11.6 to 228.6)	-1.3 (-38.3 to 67.6)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.0 (-4.2 to 114.1)	0.0 (-49.6 to 14.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.6 (-31.1 to 119.4)	23.9 (-49.3 to 15.8)
Hodgkin lymphoma	1.6 (1.1 to 2.5)	1.9 (1.3 to 3.1)	20.3 (-36.6 to 130.6)	-15.1 (50.9 to 49.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	23.5 (3.0 to 131.6)	-17.8 (50.0 to 46.0)
Non-Hodgkin lymphoma	1.4 (1.0 to 1.9)	2.9 (1.9 to 4.3)	100.8 (30.5 to 235.7)	16.0 (-25.9 to 94.1)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.4)	94.7 (29.0 to 225.4)	9.7 (-29.3 to 82.3)
Multiple myeloma	0.2 (0.1 to 0.4)	0.5 (0.3 to 0.7)	129.9 (20.8 to 313.1)	17.4 (-37.5 to 107.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	118.4 (20.5 to 289.7)	11.1 (-39.2 to 96.7)
Leukemia	2.0 (1.4 to 2.9)	3.6 (2.3 to 4.8)	89.2 (8.4 to 170.7)	25.8 (-17.6 to 79.9)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	81.6 (19.7 to 147.4)	13.2 (-22.7 to 55.7)
Other neoplasms	4.2 (2.7 to 7.4)	9.3 (5.1 to 12.8)	151.7 (-21.2 to 294.1)	55.2 (-27.5 to 137.8)	0.3 (0.2 to 0.5)	0.6 (0.3 to 1.0)	144.8 (8.3 to 282.5)	37.1 (-23.9 to 109.9)
Cardiovascular diseases	-	-	-	-	22.3 (14.2 to 32.9)	55.0 (30.9 to 83.7)	147.1 (49.2 to 271.2)	22.0 (-24.7 to 80.4)
Rheumatic heart disease	54.0 (47.4 to 60.7)	89.1 (78.0 to 101.2)	65.0 (38.6 to 97.3)	-1.0 (-16.2 to 15.6)	3.5 (2.4 to 5.0)	5.8 (3.8 to 8.2)	62.9 (30.4 to 98.5)	-5.4 (-24.4 to 15.2)
Ischemic heart disease	113.0 (89.6 to 143.4)	172.2 (151.8 to 200.3)	53.7 (12.8 to 102.7)	-22.5 (-41.3 to 0.7)	6.3 (3.9 to 9.4)	9.4 (6.2 to 13.4)	59.3 (45.0 to 115.1)	-23.7 (-45.0 to 9.0)
Cerebrovascular disease	-	-	-	-	3.7 (2.4 to 5.0)	7.1 (5.0 to 9.5)	94.7 (50.5 to 148.3)	1.4 (-20.6 to 31.9)
Ischemic stroke	16.0 (13.3 to 19.1)	31.7 (27.4 to 36.6)	97.9 (56.9 to 154.3)	0.9 (-20.9 to 32.2)	2.4 (1.6 to 3.3)	4.7 (3.2 to 6.4)	98.2 (54.4 to 157.5)	1.7 (-21.1 to 34.6)
Hemorrhagic stroke	8.3 (7.0 to 9.9)	15.8 (12.9 to 18.3)	90.7 (47.6 to 142.5)	0.2 (-23.4 to 29.2)	1.3 (0.8 to 1.8)	2.4 (1.6 to 3.3)	87.9 (44.8 to 143.5)	-0.3 (-24.2 to 32.0)
Hypertensive heart disease	6.7 (4.6 to 9.2)	16.7 (11.9 to 22.2)	148.1 (63.4 to 312.9)	14.1 (-24.4 to 96.9)	0.7 (0.4 to 1.1)	1.8 (1.1 to 2.8)	149.1 (64.1 to 311.1)	14.9 (-25.3 to 102.2)
Cardiomyopathy and myocarditis	6.4 (5.3 to 7.6)	14.0 (11.4 to 16.9)	120.2 (62.7 to 192.6)	11.3 (-18.1 to 52.2)	0.7 (0.4 to 1.0)	1.5 (1.0 to 2.1)	121.7 (62.3 to 205.6)	12.5 (-18.0 to 56.9)
Atrial fibrillation and flutter	1.6 (1.2 to 2.2)	1.9 (1.3 to 2.7)	14.7 (-26.3 to 91.4)	-38.9 (-62.0 to 1.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	13.2 (-30.0 to 96.8)	-39.7 (-62.7 to 1.7)
Peripheral vascular disease	381.0 (291.5 to 473.8)	654.4 (445.9 to 849.9)	70.1 (12.5 to 166.6)	-11.9 (-40.2 to 36.7)	0.1 (0.1 to 0.3)	0.3 (0.1 to 0.6)	103.3 (-3.4 to 381.3)	-20.8 (55.0 to 87.0)
Endocarditis	0.3 (0.2 to 0.5)	0.8 (0.5 to 1.1)	129.7 (60.3 to 222.9)	27.2 (-15.0 to 95.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	147.4 (58.6 to 280.0)	32.0 (-18.4 to 123.4)
Other cardiovascular and circulatory diseases	101.2 (29.9 to 181.3)	409.6 (111.7 to 684.1)	308.4 (2.7 to 1,403.0)	88.5 (-49.1 to 563.4)	7.1 (1.9 to 13.8)	28.5 (7.6 to 53.4)	314.4 (0.7 to 1,424.1)	90.6 (-49.7 to 586.0)
Chronic respiratory diseases	-	-	-	-	97.7 (66.4 to 132.3)	170.5 (115.		

Appendix Table G.4 - Nepal prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	3.3 (3.1 to 3.6)	5.7 (5.3 to 6.1)	70.2 (51.8 to 89.8)	0.1 (-3.3 to 13.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	71.1 (33.3 to 117.3)	15.1 (-15.1 to 25.5)
Urolithiasis	51.5 (38.9 to 65.2)	90.9 (60.4 to 121.0)	76.0 (37.6 to 114.7)	0.5 (-25.3 to 9.8)	1.0 (0.3 to 0.7)	1.0 (0.7 to 1.5)	109.4 (82.4 to 140.8)	19.1 (4.7 to 34.4)
Benign prostatic hyperplasia	129.9 (117.3 to 141.4)	276.5 (249.6 to 302.9)	112.7 (87.2 to 146.9)	-0.0 (-11.3 to 15.3)	4.6 (3.0 to 6.5)	9.9 (6.4 to 14.1)	113.6 (88.9 to 148.7)	0.7 (-10.4 to 17.0)
Male infertility due to other causes	62.8 (47.1 to 82.2)	92.7 (64.3 to 122.8)	48.3 (-5.8 to 115.6)	-11.0 (-42.8 to 29.9)	0.4 (0.2 to 0.9)	0.6 (0.3 to 1.4)	49.1 (-8.0 to 125.3)	-10.7 (-44.3 to 34.9)
Other urinary diseases	-	-	-	-	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.6)	113.4 (44.1 to 486.9)	3.1 (-17.4 to 239.2)
Gynecological diseases	-	-	-	-	19.4 (12.6 to 29.1)	33.7 (21.9 to 50.5)	74.2 (47.1 to 102.3)	1.4 (-12.9 to 16.8)
Uterine fibroids	295.5 (268.0 to 320.9)	540.6 (489.5 to 587.4)	83.3 (82.9 to 83.8)	3.2 (2.7 to 3.5)	5.3 (3.2 to 8.4)	7.7 (4.4 to 12.7)	46.4 (30.2 to 59.4)	-17.0 (-26.5 to -9.3)
Polycystic ovarian syndrome	283.0 (253.2 to 312.2)	500.7 (441.4 to 562.9)	77.1 (50.8 to 107.8)	3.2 (-12.1 to 20.1)	2.7 (1.3 to 5.2)	4.9 (2.3 to 9.2)	78.6 (51.8 to 109.5)	4.1 (-10.5 to 20.9)
Female infertility due to other causes	39.6 (25.2 to 56.2)	72.1 (45.1 to 99.3)	82.2 (4.8 to 218.4)	15.5 (-31.1 to 101.6)	0.3 (0.1 to 0.6)	0.5 (0.2 to 1.1)	268.9 (-2.3 to 197.2)	9.1 (-37.3 to 85.0)
Endometriosis	28.4 (24.2 to 33.1)	54.3 (46.2 to 61.9)	90.9 (54.4 to 140.9)	11.1 (-10.2 to 40.3)	2.6 (1.7 to 3.7)	5.0 (3.3 to 7.0)	90.4 (51.7 to 144.9)	11.3 (-11.4 to 42.7)
Genital prolapse	549.8 (485.7 to 619.2)	990.1 (874.7 to 1,113.7)	80.4 (53.0 to 114.6)	2.3 (-13.1 to 20.9)	1.7 (0.8 to 3.3)	3.2 (1.5 to 5.9)	80.8 (53.5 to 115.2)	2.7 (-13.0 to 21.4)
Premenstrual syndrome	558.6 (376.6 to 775.2)	1,179.8 (752.9 to 1,620.1)	114.5 (22.6 to 239.5)	32.6 (-23.0 to 109.9)	4.7 (2.6 to 7.9)	9.9 (5.3 to 16.9)	115.1 (20.8 to 238.0)	31.9 (-24.4 to 107.3)
Other gynecological diseases	68.3 (49.4 to 86.8)	89.6 (77.6 to 101.1)	32.2 (0.1 to 85.8)	-21.9 (-41.0 to 8.5)	2.0 (1.1 to 3.0)	2.4 (1.5 to 3.5)	19.3 (-9.3 to 121.2)	-30.0 (-46.9 to 30.1)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	14.4 (9.5 to 20.6)	17.7 (11.4 to 25.7)	22.6 (8.5 to 40.1)	-19.7 (-27.2 to -8.6)
Thalassemias	1.2 (1.0 to 1.4)	1.6 (1.4 to 2.0)	33.6 (14.4 to 70.7)	-1.3 (-14.6 to 23.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	31.6 (-0.5 to 76.4)	-1.1 (-23.3 to 28.8)
Thalassemia trait	395.7 (373.8 to 418.0)	619.6 (588.5 to 653.9)	57.0 (51.7 to 62.0)	2.0 (-1.4 to 5.3)	5.3 (3.5 to 7.6)	8.7 (5.8 to 12.5)	65.9 (46.4 to 86.4)	10.9 (-1.8 to 23.5)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.6 (4.2 to 29.0)	-15.1 (-24.3 to -6.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.9 (17.3 to 61.1)	-0.1 (-15.4 to 17.0)
Sickle cell trait	92.7 (84.3 to 99.6)	125.8 (116.2 to 135.6)	35.4 (22.5 to 48.6)	-11.9 (-20.4 to -3.4)	0.3 (0.1 to 0.5)	0.4 (0.2 to 0.7)	47.9 (-33.2 to 216.2)	9.8 (-47.4 to 137.2)
G6PD deficiency	139.1 (116.9 to 164.9)	169.2 (132.3 to 208.4)	21.4 (-7.9 to 64.4)	-21.1 (-40.1 to 6.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.3 (26.4 to 47.6)	-9.7 (-14.6 to -1.2)
G6PD trait	1,905.6 (1,722.2 to 2,048.9)	3,237.2 (2,960.7 to 3,538.9)	69.8 (52.0 to 92.3)	9.6 (-1.9 to 24.1)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.2)	18.5 (-57.5 to 129.5)	-37.5 (-75.7 to 14.0)
Other hemoglobinopathies and hemolytic anemias	299.1 (263.7 to 324.5)	317.7 (287.8 to 345.5)	6.2 (-3.1 to 21.5)	-33.1 (-38.9 to -25.9)	8.6 (5.4 to 12.5)	8.2 (5.1 to 12.1)	-4.6 (-23.3 to 22.0)	-38.9 (-49.9 to -23.1)
Endocrine, metabolic, blood, and immune disorders	330.1 (294.9 to 356.0)	372.9 (333.1 to 406.2)	16.8 (2.5 to 33.3)	-23.3 (-30.5 to -12.6)	16.8 (7.3 to 15.4)	12.1 (8.3 to 17.5)	39.5 (-6.3 to 137.5)	23.5 (-34.1 to -8.4)
Musculoskeletal disorders	-	-	-	-	241.6 (203.7 to 389.8)	297.7 (372.2 to 708.5)	78.3 (68.8 to 94.9)	0.5 (-5.5 to 7.8)
Rheumatoid arthritis	29.1 (27.0 to 31.3)	44.3 (41.3 to 47.8)	52.4 (37.0 to 70.7)	-18.2 (-26.5 to -7.9)	6.8 (4.8 to 9.0)	10.4 (7.3 to 13.9)	52.3 (35.4 to 73.7)	-18.1 (-26.7 to -6.2)
Osteoarthritis	259.3 (246.6 to 271.9)	513.9 (490.4 to 538.3)	98.5 (85.6 to 112.7)	-0.7 (-6.5 to 5.7)	15.8 (11.2 to 21.4)	42.1 (22.3 to 41.2)	98.7 (85.3 to 113.5)	-0.2 (-6.2 to 6.6)
Low back and neck pain	-	-	-	-	241.6 (164.3 to 329.1)	297.7 (297.1 to 582.4)	78.3 (62.1 to 93.4)	0.5 (-8.4 to 8.5)
Low back pain	1,789.9 (1,664.9 to 1,908.5)	3,142.3 (2,956.0 to 3,326.7)	76.2 (59.4 to 92.4)	-1.0 (-9.6 to 7.0)	199.6 (134.1 to 276.9)	351.5 (239.6 to 486.1)	76.3 (59.2 to 92.6)	-0.5 (-9.3 to 7.8)
Neck pain	429.2 (376.5 to 484.9)	793.9 (667.7 to 903.7)	85.4 (49.7 to 127.4)	3.9 (-15.3 to 26.8)	42.1 (28.8 to 58.8)	78.3 (52.4 to 109.7)	85.6 (50.1 to 128.1)	4.5 (-15.3 to 28.1)
Gout	1.4 (1.3 to 1.6)	2.9 (2.6 to 3.3)	103.8 (72.0 to 138.8)	6.0 (-10.4 to 24.0)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	102.7 (55.3 to 159.6)	6.0 (-19.2 to 35.6)
Other musculoskeletal disorders	316.9 (244.9 to 396.3)	883.8 (539.5 to 842.2)	116.4 (99.6 to 135.6)	14.5 (5.4 to 24.5)	28.8 (18.4 to 42.5)	62.6 (40.5 to 91.5)	117.3 (99.4 to 137.5)	15.6 (-5.7 to 25.8)
Other non-communicable diseases	-	-	-	-	230.3 (153.4 to 333.8)	386.3 (253.9 to 562.1)	67.8 (60.1 to 75.4)	-5.5 (-9.0 to -2.2)
Congenital anomalies	-	-	-	-	8.6 (5.9 to 11.8)	23.8 (17.1 to 31.5)	177.2 (124.7 to 249.7)	85.7 (49.9 to 133.9)
Neural tube defects	1.0 (0.8 to 1.2)	6.2 (5.3 to 7.2)	541.9 (417.0 to 688.3)	401.1 (302.5 to 520.0)	0.2 (0.2 to 0.3)	2.0 (1.3 to 2.7)	702.9 (487.2 to 989.9)	546.6 (374.2 to 766.1)
Congenital heart anomalies	11.9 (7.7 to 17.1)	117.7 (100.3 to 141.7)	909.6 (576.0 to 1,490.2)	666.7 (411.5 to 1,137.9)	0.5 (0.2 to 0.8)	4.0 (1.7 to 7.0)	757.6 (479.7 to 1,238.7)	544.6 (330.3 to 925.7)
Orofacial clefts	1.4 (0.8 to 2.0)	18.8 (14.6 to 24.2)	1,293.9 (765.5 to 2,155.4)	1,098.6 (633.1 to 1,866.5)	0.0 (0.0 to 0.0)	0.3 (0.2 to 0.5)	917.2 (604.7 to 1,972.2)	917.2 (505.1 to 1,684.8)
Down syndrome	10.6 (8.3 to 13.4)	33.7 (29.3 to 39.7)	220.1 (143.5 to 317.4)	132.1 (75.6 to 205.1)	1.2 (0.8 to 1.7)	4.2 (3.0 to 5.7)	239.5 (153.4 to 356.2)	146.7 (83.9 to 231.3)
Turner syndrome	0.4 (0.3 to 0.6)	1.1 (0.8 to 1.4)	166.9 (79.4 to 288.5)	84.0 (23.1 to 168.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	171.9 (78.1 to 293.7)	83.2 (18.8 to 167.1)
Klinefelter syndrome	0.5 (0.4 to 0.6)	0.7 (0.5 to 0.9)	44.9 (5.4 to 110.4)	-4.0 (-30.3 to 39.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.8 (83.0 to 118.6)	-6.7 (-32.2 to 36.2)
Chromosomal unbalanced rearrangements	13.0 (10.6 to 15.7)	40.4 (33.8 to 49.7)	307.4 (141.2 to 322.9)	49.6 (74.4 to 206.2)	1.5 (1.0 to 2.1)	5.0 (3.5 to 6.8)	198.3 (150.5 to 353.3)	188.3 (81.9 to 230.3)
Other congenital anomalies	58.4 (44.2 to 71.1)	77.7 (59.6 to 93.1)	33.7 (17.7 to 52.7)	-16.3 (-25.8 to -5.1)	5.1 (3.0 to 7.7)	8.3 (5.2 to 12.9)	60.2 (23.8 to 136.1)	2.4 (-20.1 to 48.8)
Skin and subcutaneous diseases	-	-	-	-	80.0 (50.9 to 121.7)	135.3 (84.8 to 208.3)	69.6 (51.8 to 85.0)	3.4 (-6.3 to 12.7)
Dermatitis	500.0 (388.2 to 609.7)	823.4 (644.0 to 999.7)	65.1 (63.3 to 67.1)	0.2 (-0.1 to 0.5)	12.9 (8.1 to 19.2)	21.3 (13.6 to 31.9)	65.0 (58.4 to 72.4)	0.8 (-2.4 to 4.4)
Psoriasis	105.6 (88.3 to 126.1)	179.7 (149.2 to 215.0)	70.4 (68.4 to 72.7)	0.0 (-0.3 to 0.2)	8.6 (5.7 to 12.4)	14.7 (9.9 to 21.2)	70.7 (59.6 to 82.6)	0.5 (-5.1 to 6.4)
Cellulitis	4.4 (3.6 to 5.4)	5.9 (4.5 to 7.7)	35.1 (12.4 to 55.2)	-17.5 (-29.9 to -6.8)	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	35.7 (29.9 to 75.7)	-16.5 (-33.8 to 4.8)
Pyoderma	28.3 (20.5 to 36.8)	26.1 (20.2 to 33.5)	-7.1 (-19.2 to 6.1)	-28.9 (-36.6 to -20.7)	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.3)	-7.6 (-21.7 to 8.3)	-28.9 (-38.9 to -18.3)
Scabies	202.0 (177.1 to 232.8)	270.6 (240.3 to 304.0)	34.0 (13.1 to 57.5)	-12.3 (-24.5 to 3.4)	7.0 (2.9 to 8.5)	5.2 (4.0 to 11.4)	34.0 (12.6 to 59.1)	-12.0 (-24.4 to 4.3)
Fungal skin diseases	815.5 (590.9 to 1,083.6)	1,378.4 (1,016.2 to 1,808.7)	69.4 (64.8 to 74.1)	46.6 (-0.8 to 30.3)	6.6 (1.8 to 9.9)	7.7 (3.1 to 16.8)	69.4 (64.2 to 74.8)	-0.3 (-2.0 to 1.5)
Viral skin diseases	464.2 (387.7 to 542.2)	660.9 (551.5 to 779.3)	42.8 (36.5 to 48.9)	-2.4 (-4.0 to 0.7)	14.3 (8.8 to 21.3)	20.5 (12.8 to 30.5)	42.9 (35.2 to 50.6)	-2.0 (-5.2 to 1.1)
Acne vulgaris	1,666.5 (1,308.7 to 2,099.1)	2,944.9 (2,188.8 to 3,668.7)	79.7 (17.8 to 140.5)	10.9 (-24.5 to 46.9)	18.0 (8.1 to 33.8)	32.0 (14.7 to 61.0)	80.4 (18.1 to 142.2)	10.9 (-24.4 to 48.1)
Alopecia areata	14.8 (13.5 to 16.6)	24.1 (22.3 to 26.3)	64.1 (41.2 to 84.8)	-0.4 (-12.8 to 12.1)	0.5 (0.3 to 0.8)	0.8 (0.5 to 1.2)	63.2 (36.1 to 93.0)	-0.1 (-15.2 to 15.4)
Pruritus	1.1 (0.8 to 1.4)	1.8 (1.4 to 2.2)	61.4 (22.1 to 123.4)	0.0 (-29.5 to 33.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.2 (13.9 to 139.9)	-6.0 (-34.2 to 40.8)
Urticaria	188.8 (144.0 to 237.2)	387.8 (284.9 to 505.2)	103.1 (41.5 to 209.6)	11.2 (-18.2 to 62.5)	11.2 (7.0 to 16.6)	23.1 (13.1 to 35.4)	103.8 (42.3 to 216.3)	12.1 (-18.2 to 64.5)
Decubitus ulcer	2.0 (1.7 to 2.3)	4.1 (3.4 to 4.9)	110.0 (77.6 to 156.2)	9.2 (-13.3 to 41.1)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	107.5 (67.4 to 160.2)	10.0 (-15.8 to 45.4)
Other skin and subcutaneous diseases	671.4 (455.0 to 993.9)	1,194.4 (784.7 to 1,811.9)	77.6 (67.1 to 89.2)	-1.7 (-5.7 to 3.0)	3.9 (1.8 to 8.2)	7.0 (3.1 to 14.7)	78.0 (66.8 to 90.1)	-1.3 (-5.4 to 3.7)
Sense organ diseases	-	-	-	-	107.0 (73.4 to 148.2)	165.2 (112.7 to 232.1)	94.5 (45.2 to 62.8)	-13.8 (-17.7 to -10.1)
Glaucoma	17.5 (14.9 to 20.9)	26.9 (22.9 to 31.2)	54.1 (30.9 to 82.4)	-16.7 (-29.8 to -2.5)	1.2 (0.8 to 1.7)	2.0 (1.4 to 2.8)	63.7 (38.8 to 93.4)	-11.5 (-24.9 to 5.5)
Cataract	101.7 (88.8 to 112.9)	171.6 (152.4 to 190.0)	68.9 (54.8 to 85.5)	-19.4 (-25.4 to -12.4)	6.0 (4.1 to 8.2)	10.2 (7.1 to 14.0)	71.3 (57.4 to 86.1)	-19.0 (-25.1 to -12.8)
Macular degeneration	11.1 (8.8 to 13.9)	27.4 (21.2 to 36.7)	146.4 (81.8 to 244.8)	22.7 (-6.8 to 67.7)	0.7 (0.4 to 1.0)	1.6 (1.0 to 2.2)	135.9 (81.1 to 215.2)	12.2 (-10.8 to 47.7)
Uncorrected refractive error	1,121.7 (1,050.0 to 1,182.2)	1,843.1 (1,378.8 to 1,949.3)	64.8 (51.6 to 78.2)	-9.5 (-15.9 to -2.8)	26.2 (17.5 to 38.7)	40.0 (26.7 to 58.9)	52.5 (45.4 to 61.4)	-15.9 (-19.4 to -11.4)
Age-related and other hearing loss	1,777.9 (1,579.3 to 1,965.3)	3,006.1 (2,670.4 to 3,316.9)	69.5 (59.8 to 80.6)	-8.8 (-12.6 to -4.2)	57.2 (38.3 to 81.1)	89.0 (59.8 to 127.3)	55.8 (39.5 to 70.7)	-13.3 (-19.8 to -7.3)
Other vision loss	68.2 (60.5 to 76.1)	85.6 (76.4 to 96.0)	25.6 (17.5 to 36.2)	-25.8 (-30.8 to -19.1)	4.5 (3.1 to 6.1)	5.6 (3.9 to 7.7)	24.7 (13.3 to 36.5)	-7.3 (-33.3 to -20.6)
Other sense organ diseases	425.2 (403.1 to 449.3)	636.5 (606.9 to 668.2)	49.7 (39.5 to 62.3)	0.4 (-5.6 to 7.1)	11.3 (7.0 to 16.7)	16.9 (10.4 to 25.3)	49.6 (38.2 to 63.8)	0.8 (-5.8 to 8.6)
Oral disorders	-	-	-	-	34.7 (21.5 to 52.9)	62.0 (37.9 to 94.8)	78.7 (71.7 to 86.8)	-4.3 (-8.2 to -0.2)

Appendix Table G.4 - Nepal prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	560.7 (533.7 to 590.1)	1,035.5 (987.3 to 1,080.5)	85.0 (73.3 to 97.8)	-9.1 (-14.1 to -3.6)	15.4 (10.4 to 21.0)	28.5 (19.1 to 39.4)	85.1 (73.1 to 98.3)	-8.6 (-13.8 to -2.9)
Other oral disorders	271.7 (255.8 to 288.3)	459.4 (431.0 to 491.9)	69.6 (56.4 to 84.9)	0.2 (-7.3 to 8.5)	7.9 (5.0 to 11.8)	13.5 (8.4 to 19.9)	69.8 (54.5 to 84.9)	0.6 (-7.6 to 9.0)
Injuries	-	-	-	-	70.8 (54.2 to 91.0)	108.3 (81.9 to 138.5)	51.9 (46.3 to 66.1)	-10.5 (-13.9 to -2.7)
Transport injuries	-	-	-	-	24.7 (18.6 to 32.0)	31.7 (23.9 to 41.1)	28.2 (23.7 to 32.9)	-22.8 (-25.1 to -20.4)
Road injuries	-	-	-	-	17.5 (13.2 to 22.5)	25.1 (18.8 to 32.4)	43.5 (37.4 to 50.0)	-11.9 (-15.2 to -8.4)
Pedestrian road injuries	-	-	-	-	5.5 (4.1 to 7.1)	8.0 (6.0 to 10.4)	46.1 (35.7 to 56.9)	-8.1 (-13.1 to -2.6)
Cyclist road injuries	-	-	-	-	1.9 (1.4 to 2.4)	2.5 (1.9 to 3.3)	34.5 (25.7 to 43.0)	-15.5 (-20.7 to -10.1)
Motorcyclist road injuries	-	-	-	-	3.8 (2.9 to 4.9)	4.4 (3.2 to 5.6)	14.8 (5.4 to 23.7)	-30.9 (-35.9 to -25.7)
Motor vehicle road injuries	-	-	-	-	6.0 (4.5 to 7.8)	9.8 (7.3 to 12.7)	63.8 (50.7 to 76.7)	-1.4 (-8.5 to 6.1)
Other road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	15.9 (8.2 to 22.7)	-33.2 (-37.1 to -29.5)
Other transport injuries	-	-	-	-	7.3 (5.5 to 9.4)	6.7 (5.0 to 8.7)	-8.5 (-13.8 to -2.7)	-47.3 (-50.3 to -44.0)
Unintentional injuries	-	-	-	-	42.9 (32.9 to 54.8)	65.5 (49.7 to 84.4)	52.5 (47.1 to 57.5)	-11.3 (-14.4 to -8.4)
Falls	-	-	-	-	15.3 (11.6 to 19.8)	29.4 (22.3 to 37.8)	91.8 (82.2 to 101.7)	3.9 (-1.5 to 10.0)
Drowning	-	-	-	-	2.5 (1.9 to 3.3)	3.3 (2.5 to 4.3)	31.0 (22.0 to 41.4)	-21.3 (-26.1 to -15.6)
Fire, heat, and hot substances	-	-	-	-	9.2 (7.2 to 11.6)	8.3 (6.3 to 10.5)	-10.7 (-17.5 to -2.5)	-47.2 (-50.7 to -43.1)
Poisonings	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	20.0 (-0.8 to 46.1)	-26.0 (-37.0 to -11.6)
Exposure to mechanical forces	-	-	-	-	3.6 (2.7 to 4.7)	7.7 (5.8 to 10.0)	113.8 (96.7 to 127.9)	25.2 (16.8 to 32.3)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	133.6 (117.0 to 154.2)	34.2 (25.2 to 44.9)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	142.1 (116.0 to 174.8)	43.1 (29.7 to 59.7)
Other exposure to mechanical forces	-	-	-	-	3.4 (2.6 to 4.5)	7.3 (5.5 to 9.5)	112.8 (95.1 to 127.1)	24.7 (16.1 to 32.0)
Adverse effects of medical treatment	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	66.5 (53.7 to 79.0)	-3.6 (-11.4 to 4.8)
Animal contact	-	-	-	-	3.6 (2.7 to 4.7)	2.8 (2.1 to 3.7)	-20.4 (-25.9 to -15.9)	-52.6 (-55.1 to -50.3)
Venomous animal contact	-	-	-	-	1.5 (1.1 to 2.0)	1.2 (0.9 to 1.6)	-20.0 (-27.8 to -11.3)	-52.8 (-57.1 to -48.3)
Non-venomous animal contact	-	-	-	-	2.1 (1.6 to 2.8)	1.6 (1.2 to 2.2)	-20.8 (-26.7 to -15.9)	-52.5 (-55.2 to -50.0)
Foreign body	-	-	-	-	0.7 (0.5 to 0.9)	1.2 (0.9 to 1.5)	61.5 (52.7 to 70.4)	-7.2 (-12.3 to -2.3)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	45.4 (29.1 to 60.9)	-9.8 (-18.9 to -1.9)
Foreign body in eyes	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	66.2 (51.0 to 84.6)	1.6 (-6.7 to 11.5)
Foreign body in other body part	-	-	-	-	0.5 (0.3 to 0.6)	0.8 (0.6 to 1.0)	64.4 (52.8 to 76.6)	-8.7 (-14.9 to -1.7)
Other unintentional injuries	-	-	-	-	7.5 (5.6 to 9.7)	12.1 (9.0 to 15.7)	62.4 (47.8 to 75.7)	-7.3 (-15.3 to 1.1)
Self-harm and interpersonal violence	-	-	-	-	1.7 (1.3 to 2.3)	2.8 (2.1 to 3.6)	66.6 (56.3 to 74.8)	-1.2 (-6.2 to 3.7)
Self-harm	-	-	-	-	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.4)	20.5 (10.4 to 31.5)	-31.2 (-36.7 to -25.5)
Interpersonal violence	-	-	-	-	1.4 (1.1 to 1.8)	2.5 (1.9 to 3.2)	73.2 (63.0 to 84.3)	4.5 (-1.1 to 10.7)
Assault by firearm	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	66.6 (54.1 to 79.3)	0.5 (-6.6 to 7.2)
Assault by sharp object	-	-	-	-	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.7)	82.1 (65.5 to 96.0)	7.6 (-1.8 to 15.5)
Assault by other means	-	-	-	-	0.9 (0.7 to 1.2)	1.6 (1.2 to 2.0)	72.0 (59.6 to 87.6)	4.5 (-2.5 to 13.4)
Forces of nature, war, and legal intervention	-	-	-	-	1.4 (0.8 to 2.6)	8.2 (3.6 to 17.9)	445.6 (246.0 to 925.4)	240.5 (112.9 to 546.9)
Exposure to forces of nature	-	-	-	-	1.4 (0.8 to 2.6)	1.5 (0.8 to 3.0)	6.0 (-10.4 to 22.7)	-32.7 (-41.9 to -24.2)
Collective violence and legal intervention	-	-	-	-	-	6.7 (2.7 to 15.3)	-	-

Appendix Table G.4 - Netherlands prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,897.2 (1,398.4 to 2,423.5)	2,306.8 (1,730.5 to 2,967.5)	23.3 (19.4 to 25.0)	23.3 (-2.3 to 2.1)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	85.2 (58.9 to 119.1)	100.2 (70.1 to 136.9)	18.1 (5.8 to 30.8)	7.1 (-2.9 to 17.5)
HIV/AIDS and tuberculosis	-	-	-	-	1.3 (0.9 to 2.0)	0.7 (0.9 to 2.0)	0.7 (-22.1 to 27.4)	-13.4 (-33.1 to 8.1)
Tuberculosis	2.7 (2.6 to 2.9)	2.5 (2.4 to 2.6)	-9.3 (-13.1 to -5.1)	-20.0 (-23.4 to -16.3)	0.8 (0.6 to 1.2)	0.8 (0.5 to 1.1)	-10.3 (-25.9 to 9.7)	-20.1 (-34.6 to -2.5)
HIV/AIDS	-	-	-	-	0.5 (0.2 to 1.0)	0.6 (0.3 to 1.1)	21.6 (-32.5 to 92.2)	-1.0 (-45.0 to 58.2)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.2 (-74.9 to -18.1)	-54.6 (-76.9 to -23.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.2 (-75.0 to -18.1)	-54.6 (-77.0 to -23.6)
HIV/AIDS resulting in other diseases	4.1 (2.3 to 6.4)	7.6 (3.5 to 12.5)	83.2 (10.6 to 164.2)	47.6 (-10.9 to 118.6)	0.5 (0.2 to 1.0)	0.6 (0.2 to 1.1)	21.8 (-32.4 to 93.3)	-0.8 (-45.0 to 59.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	9.7 (6.4 to 14.2)	1.2 (6.4 to 14.5)	1.2 (-9.4 to 10.1)	-11.6 (-20.2 to -3.7)
Diarrheal diseases	4.9 (4.4 to 5.6)	5.1 (4.6 to 5.6)	2.0 (-12.8 to 18.8)	-11.9 (-27.8 to 6.1)	0.8 (0.5 to 1.1)	0.8 (0.5 to 1.1)	1.2 (-17.3 to 23.9)	-11.7 (-30.5 to 11.8)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-55.2 to 31.2)	-27.2 (-60.2 to 18.7)
Typhoid fever	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-20.5 (-32.8 to -2.0)	-28.4 (-39.2 to -11.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.5 (-32.8 to -2.0)	-28.4 (-39.2 to -11.6)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.7 (-16.8 to 45.5)	5.6 (-21.0 to 30.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.7 (-17.0 to 45.9)	5.6 (-21.1 to 31.0)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.6 (-96.9 to 740.5)	-49.4 (-97.2 to 669.6)
Lower respiratory infections	6.7 (4.8 to 8.7)	9.6 (8.4 to 10.8)	40.5 (5.7 to 101.9)	11.9 (-12.1 to 57.0)	0.7 (0.4 to 1.0)	0.9 (0.6 to 1.3)	41.5 (3.9 to 102.2)	14.0 (-12.4 to 58.9)
Upper respiratory infections	226.1 (217.3 to 235.7)	251.5 (238.9 to 261.8)	10.9 (2.6 to 18.0)	0.7 (-6.9 to 7.0)	2.6 (1.5 to 4.4)	2.9 (1.7 to 4.8)	10.5 (1.7 to 18.6)	0.7 (-7.5 to 8.2)
Otitis media	183.5 (163.4 to 205.6)	190.4 (166.0 to 218.5)	3.2 (-12.7 to 20.3)	-11.0 (-23.6 to 4.6)	3.4 (2.0 to 5.4)	3.5 (2.0 to 5.6)	2.2 (-14.0 to 19.0)	-12.4 (-25.1 to 2.7)
Meningitis	-	-	-	-	1.6 (1.1 to 2.3)	1.0 (0.6 to 1.4)	-40.0 (-59.1 to -16.7)	-44.2 (-63.0 to -21.0)
Pneumococcal meningitis	4.5 (2.7 to 7.6)	2.9 (1.8 to 4.9)	-36.4 (-51.1 to -12.8)	-46.4 (-59.1 to -25.4)	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-40.0 (-58.0 to -15.6)	-46.9 (-63.2 to -24.0)
H influenzae type B meningitis	2.5 (0.7 to 5.9)	1.4 (0.4 to 3.4)	-42.2 (-75.8 to 34.3)	-47.9 (-77.0 to 31.2)	0.3 (0.2 to 0.7)	0.2 (0.1 to 0.4)	-41.1 (-77.9 to 41.7)	-44.2 (-79.3 to 38.6)
Meningococcal meningitis	2.2 (0.7 to 5.8)	1.2 (0.4 to 3.2)	-45.0 (-69.4 to 12.0)	-52.0 (-72.8 to 5.7)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-48.2 (-71.8 to 10.6)	-53.4 (-74.8 to 4.2)
Other meningitis	3.7 (1.7 to 7.8)	2.4 (1.0 to 5.2)	-35.9 (-59.1 to 5.5)	-41.9 (-60.9 to 16.1)	0.5 (0.3 to 0.8)	0.3 (0.2 to 0.6)	-36.7 (-65.0 to 26.4)	-40.2 (-66.5 to 23.3)
Encephalitis	0.7 (0.3 to 1.8)	0.8 (0.4 to 2.2)	17.5 (-2.2 to 48.0)	17.5 (-19.9 to 24.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	19.3 (-2.0 to 55.5)	-4.4 (-18.9 to 29.0)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.5 (-92.4 to 682.0)	-37.5 (-93.9 to 585.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.5 (-92.5 to 729.7)	-37.5 (-94.0 to 587.9)
Whooping cough	0.6 (0.5 to 0.8)	0.6 (0.5 to 0.8)	5.0 (4.7 to 5.2)	6.6 (6.3 to 6.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	6.4 (-17.9 to 36.3)	8.1 (-17.0 to 38.7)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.2 (-45.7 to -12.0)	-42.5 (-49.9 to -20.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.5 (-46.4 to -4.2)	-38.1 (-70.9 to -11.0)
Measles	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	15,339.1 (10,887.9 to 31,093.1)	-47.7 (-10,884.1 to 31,082.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16,330.9 (10,875.8 to 31,134.7)	16,335.1 (10,871.9 to 31,123.6)
Varicella and herpes zoster	11.4 (10.4 to 12.6)	13.4 (12.2 to 14.9)	17.4 (1.6 to 34.5)	-2.1 (-12.6 to 9.1)	0.4 (0.3 to 0.7)	0.5 (0.3 to 0.8)	23.3 (-1.1 to 51.1)	-3.0 (-21.3 to 17.4)
Neglected tropical diseases and malaria	-	-	-	-	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.2)	-51.8 (-66.3 to -20.6)	-60.7 (-72.2 to -35.8)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.8 (-31.2 to 435.5)	43.8 (-36.2 to 405.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.8 (-30.3 to 449.8)	44.7 (-35.5 to 418.0)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.3 (0.1 to 0.6)	0.1 (0.0 to 0.2)	-79.4 (-91.0 to -20.1)	-82.7 (-92.9 to -33.4)	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-77.5 (-90.5 to -10.1)	-81.3 (-92.6 to -27.3)
Cystic echinococcosis	2.1 (1.7 to 2.6)	1.3 (1.2 to 1.4)	-35.4 (-47.5 to -27.1)	-48.9 (-58.3 to -41.0)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-36.2 (-51.5 to -16.5)	-48.7 (-60.9 to -33.0)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.5 (-44.7 to 24.6)	-3.5 (-53.4 to 10.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.5 (-44.9 to 24.9)	-3.5 (-53.4 to 10.2)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	196.8 (8.6 to 270.7)	160.3 (8.0 to 224.7)
Maternal disorders	-	-	-	-	0.7 (0.5 to 1.2)	0.7 (0.4 to 1.0)	-21.4 (-40.0 to 13.7)	-3.9 (-26.5 to 37.7)
Maternal hemorrhage	12.9 (9.1 to 16.8)	8.6 (6.5 to 10.7)	-34.1 (-54.5 to 1.4)	-20.5 (-45.0 to 20.8)	0.6 (0.3 to 0.8)	0.4 (0.3 to 0.7)	-23.1 (-43.7 to 17.2)	-5.8 (-31.4 to 41.9)
Maternal sepsis and other maternal infections	0.3 (0.1 to 0.4)	0.2 (0.0 to 0.4)	-20.9 (-79.6 to 92.6)	-35.0 (-75.8 to 110.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.4 (-51.6 to 23.8)	-5.7 (-41.3 to 39.7)
Maternal hypertensive disorders	1.3 (0.7 to 2.1)	1.3 (0.6 to 2.1)	1.2 (-17.6 to 15.4)	20.5 (0.9 to 35.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.7 (-28.8 to 37.9)	20.0 (-13.5 to 64.4)
Obstructed labor	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-13.3 (-59.4 to 177.9)	4.4 (-51.0 to 232.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.3 (-59.4 to 178.0)	4.4 (-51.0 to 232.5)
Complications of abortion	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-4.7 (-48.9 to 89.9)	13.9 (-38.4 to 126.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.7 (-49.1 to 90.1)	13.9 (-38.9 to 128.1)
Other maternal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-24.4 (-56.4 to 38.4)	-7.3 (-46.9 to 68.7)
Neonatal disorders	-	-	-	-	18.1 (13.1 to 24.1)	30.3 (21.0 to 40.6)	68.3 (22.4 to 118.6)	52.9 (10.9 to 99.2)
Preterm birth complications	116.0 (82.4 to 162.0)	206.6 (145.0 to 301.3)	76.7 (50.4 to 109.2)	57.2 (33.8 to 86.3)	11.6 (8.4 to 15.9)	19.6 (13.9 to 26.4)	70.0 (27.9 to 121.1)	55.0 (16.5 to 102.3)
Neonatal encephalopathy due to birth asphyxia and trauma	18.0 (8.6 to 38.7)	13.8 (6.2 to 35.7)	-27.6 (-50.5 to 7.0)	-34.2 (-54.8 to -4.0)	3.4 (2.2 to 5.3)	2.5 (1.6 to 3.7)	-25.7 (-53.2 to 11.0)	-30.9 (-56.9 to 3.2)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.2 (52.7 to 101.2)	80.3 (61.8 to 113.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.2 (32.3 to 120.1)	82.4 (40.2 to 133.2)
Hemolytic disease and other neonatal jaundice	3.4 (1.4 to 6.1)	2.4 (0.8 to 4.4)	-29.4 (-81.6 to 79.1)	-24.2 (-83.5 to 61.8)	1.4 (0.6 to 2.6)	1.0 (0.3 to 1.9)	-24.2 (-81.1 to 84.4)	-34.4 (-83.0 to 67.7)
Other neonatal disorders	-	-	-	-	1.6 (1.0 to 3.0)	7.2 (3.3 to 11.2)	390.0 (61.8 to 691.9)	345.3 (47.0 to 622.0)
Nutritional deficiencies	-	-	-	-	50.9 (33.8 to 75.0)	53.7 (34.4 to 77.6)	6.4 (-8.8 to 16.8)	-2.3 (-13.5 to 5.1)
Protein-energy malnutrition	0.3 (0.1 to 0.4)	0.4 (0.2 to 0.8)	61.1 (-9.5 to 158.3)	-0.2 (-43.1 to 57.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	58.5 (-16.8 to 184.7)	-1.7 (-46.7 to 71.8)
Iodine deficiency	303.1 (135.0 to 564.0)	210.2 (98.5 to 358.9)	-30.0 (-75.7 to 75.2)	-24.2 (-77.8 to 59.1)	3.7 (2.2 to 11.8)	3.7 (1.4 to 7.4)	-24.8 (-75.5 to 74.3)	-34.4 (-77.8 to 58.3)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron deficiency anemia	1,762.9 (1,718.1 to 1,802.2)	2,016.6 (1,867.1 to 2,074.9)	14.0 (5.4 to 18.6)	1.6 (-4.9 to 5.4)	45.5 (30.2 to 66.6)	49.9 (31.6 to 72.5)	10.2 (-6.1 to 15.8)	0.4 (-11.1 to 4.6)

Appendix Table G.4 - Netherlands prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.3 (-31.5 to 134.5)	36.3 (55.9 to 42.3)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	4.1 (2.4 to 6.8)	4.3 (2.6 to 7.3)	4.3 (-7.7 to 33.9)	-2.5 (-14.4 to 29.8)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.8 (1.0 to 3.5)	1.9 (0.9 to 3.7)	1.9 (-13.0 to 22.2)	-1.7 (-17.7 to 17.6)
Syphilis	0.4 (0.3 to 0.4)	0.6 (0.5 to 0.8)	77.2 (21.9 to 146.0)	29.4 (-13.7 to 83.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	72.8 (5.2 to 168.8)	27.5 (-24.9 to 100.6)
Chlamydial infection	303.5 (244.8 to 354.5)	272.0 (225.4 to 316.6)	-10.0 (-31.2 to 14.2)	4.9 (-28.4 to 20.8)	0.1 (0.4 to 1.6)	0.8 (0.4 to 1.5)	-5.0 (-34.5 to 28.7)	-4.4 (-32.2 to 36.9)
Gonococcal infection	43.8 (30.9 to 59.9)	42.1 (28.5 to 55.6)	-3.2 (-46.4 to 59.3)	8.7 (-41.1 to 82.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-10.0 (-43.8 to 38.3)	0.8 (-37.9 to 53.7)
Trichomoniasis	47.2 (28.9 to 68.6)	44.0 (28.9 to 59.3)	-7.4 (-47.3 to 71.5)	-4.3 (-46.8 to 91.0)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-11.0 (-51.6 to 93.0)	-7.9 (-51.4 to 117.2)
Genital herpes	2,138.3 (1,926.3 to 2,348.5)	2,681.5 (2,446.9 to 2,917.0)	25.2 (8.9 to 41.8)	0.3 (-13.1 to 14.4)	0.6 (0.2 to 1.4)	0.7 (0.2 to 1.7)	22.2 (4.5 to 39.5)	0.4 (-14.1 to 14.9)
Other sexually transmitted diseases	2.3 (1.6 to 3.1)	2.0 (1.3 to 2.8)	-14.8 (-42.3 to 12.6)	-11.3 (-40.0 to 15.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	6.9 (-40.2 to 47.0)	-4.4 (-39.6 to 53.4)
Hepatitis	-	-	-	-	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	0.4 (-13.1 to 9.5)	-3.4 (-20.5 to 0.6)
Hepatitis A	11.3 (10.7 to 11.8)	11.3 (10.7 to 12.0)	-0.1 (-1.0 to 0.7)	-7.9 (-9.2 to -6.6)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	0.8 (-9.4 to 14.0)	-6.8 (-17.3 to 5.2)
Hepatitis B	107.1 (89.0 to 124.4)	87.1 (75.7 to 99.6)	-19.1 (-34.0 to 0.8)	-30.8 (-44.4 to -14.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-20.9 (-47.7 to 20.9)	-32.6 (-54.6 to 3.1)
Hepatitis C	73.7 (67.2 to 80.5)	67.2 (61.2 to 73.5)	-8.9 (-20.0 to 2.9)	-28.3 (-36.9 to -18.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.7 (-26.4 to 36.4)	-26.6 (-43.4 to -2.2)
Hepatitis E	-	-	-	-	15.9 (11.0 to 60.3)	-	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	70.5 (62.3 to 79.5)	79.9 (69.2 to 96.8)	11.8 (5.4 to 42.3)	1.0 (-16.1 to 28.4)	1.8 (1.1 to 2.8)	2.0 (1.2 to 3.5)	7.2 (-13.1 to 66.9)	-1.7 (-20.0 to 53.2)
Non-communicable diseases	-	-	-	-	1,680.9 (1,239.5 to 2,163.0)	2,088.9 (1,554.2 to 2,685.3)	24.3 (21.1 to 27.5)	1.3 (-1.2 to 3.7)
Neoplasms	-	-	-	-	27.0 (20.2 to 34.7)	47.4 (35.4 to 61.6)	75.6 (64.9 to 88.1)	18.5 (11.5 to 27.0)
Esophageal cancer	1.5 (1.3 to 1.8)	3.8 (2.6 to 4.8)	149.9 (75.7 to 240.2)	65.5 (16.6 to 124.9)	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.7)	131.4 (60.6 to 206.1)	53.8 (7.1 to 101.4)
Stomach cancer	7.6 (6.7 to 8.7)	9.2 (7.6 to 11.0)	19.1 (1.9 to 43.7)	-21.3 (-32.4 to -5.8)	0.9 (0.6 to 1.1)	1.0 (0.7 to 1.3)	12.3 (-6.8 to 39.1)	-25.8 (-38.0 to -8.8)
Liver cancer	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	0.2 (0.0 to 0.2)	140.8 (5.8 to 231.5)
Liver cancer due to hepatitis B	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	74.0 (-51.4 to 453.4)	19.0 (-65.6 to 269.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	73.7 (-41.3 to 424.4)	38.9 (-246.0 to 26.0)
Liver cancer due to hepatitis C	0.1 (0.1 to 0.2)	0.6 (0.3 to 0.9)	426.4 (158.3 to 978.3)	250.0 (75.4 to 613.2)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	404.1 (154.3 to 854.7)	236.5 (70.2 to 528.0)
Liver cancer due to alcohol use	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	9.9 (-46.1 to 102.6)	-27.3 (-64.6 to 30.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	8.5 (-43.4 to 80.1)	-28.2 (-62.9 to 17.0)
Liver cancer due to other causes	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	25.8 (-58.2 to 221.9)	-15.7 (-70.8 to 111.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.2 (-54.8 to 180.7)	-19.1 (-68.5 to 82.3)
Larynx cancer	3.3 (2.7 to 4.2)	3.6 (2.8 to 4.6)	8.5 (-11.5 to 37.2)	-28.9 (-41.4 to -10.5)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	3.7 (-18.9 to 32.6)	-31.3 (-46.0 to -13.0)
Tracheal, bronchus and lung cancer	15.4 (14.2 to 16.8)	22.6 (17.5 to 26.1)	49.1 (9.4 to 72.4)	-1.1 (-27.0 to 14.5)	2.4 (1.7 to 3.0)	3.2 (2.3 to 4.3)	3.2 (-5.7 to 59.0)	-8.6 (-29.6 to 5.7)
Breast cancer	98.5 (89.2 to 106.9)	181.3 (170.9 to 193.3)	82.9 (64.3 to 103.6)	21.7 (9.1 to 35.9)	5.6 (3.8 to 7.6)	9.0 (6.1 to 12.7)	61.0 (44.1 to 82.8)	7.9 (-3.6 to 22.2)
Cervical cancer	5.6 (4.2 to 6.4)	5.2 (4.2 to 6.6)	-8.3 (-28.7 to 23.6)	-29.8 (-45.2 to -6.8)	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	0.4 (-29.6 to 30.2)	-29.7 (-45.7 to -3.0)
Uterine cancer	19.4 (10.1 to 15.1)	12.3 (14.4 to 25.5)	-36.1 (8.3 to 109.8)	57.1 (-27.8 to 42.0)	1.5 (0.6 to 1.1)	1.3 (0.8 to 1.8)	8.3 (-4.2 to 110.2)	3.3 (-30.7 to 39.1)
Prostate cancer	40.5 (34.7 to 47.8)	101.0 (86.5 to 123.8)	149.4 (108.0 to 193.0)	67.6 (40.0 to 96.2)	3.6 (2.6 to 4.8)	8.4 (5.9 to 11.7)	130.9 (92.7 to 184.2)	54.3 (29.3 to 89.1)
Colon and rectum cancer	43.5 (41.1 to 45.8)	88.1 (79.7 to 97.3)	102.3 (79.1 to 125.9)	33.8 (19.1 to 48.6)	3.7 (2.7 to 4.8)	7.1 (5.1 to 9.2)	91.9 (70.3 to 114.2)	26.9 (13.3 to 41.5)
Lip and oral cavity cancer	5.9 (5.1 to 6.7)	9.9 (7.5 to 12.2)	65.8 (25.4 to 115.3)	11.3 (-15.6 to 44.6)	0.5 (0.4 to 0.7)	0.8 (0.5 to 1.1)	60.8 (20.4 to 110.0)	7.9 (-18.6 to 39.5)
Nasopharynx cancer	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.7)	-25.6 (-51.0 to 15.4)	-47.8 (-65.6 to -18.4)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-27.2 (-51.4 to 9.3)	-49.1 (-66.0 to -23.7)
Other pharynx cancer	2.2 (1.6 to 2.8)	4.0 (2.7 to 5.4)	82.7 (17.3 to 168.1)	20.7 (-22.8 to 77.0)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.5)	73.3 (11.5 to 159.1)	14.9 (-25.7 to 70.6)
Gallbladder and biliary tract cancer	0.7 (0.5 to 0.8)	2.1 (0.5 to 1.0)	21.0 (-25.2 to 45.1)	-32.9 (-50.5 to -5.3)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-1.3 (-31.5 to 41.8)	-35.1 (-54.0 to -7.4)
Pancreatic cancer	1.5 (1.3 to 1.7)	2.6 (2.1 to 3.2)	74.6 (36.0 to 124.6)	15.5 (-10.1 to 47.0)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.7)	71.1 (35.4 to 112.0)	13.1 (-9.5 to 38.9)
Malignant skin melanoma	15.8 (11.9 to 21.8)	34.2 (21.7 to 44.6)	117.6 (60.8 to 174.5)	61.7 (22.1 to 102.0)	0.9 (0.6 to 1.4)	2.0 (1.1 to 3.0)	111.7 (56.2 to 170.0)	57.5 (18.9 to 97.9)
Non-melanoma skin cancer	7.6 (6.6 to 8.9)	19.2 (17.1 to 21.9)	151.5 (110.1 to 199.5)	74.2 (46.0 to 106.3)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	167.2 (114.6 to 251.5)	82.1 (47.4 to 133.7)
Ovarian cancer	5.6 (4.6 to 6.5)	7.6 (6.2 to 9.3)	34.4 (6.4 to 78.6)	-9.1 (-27.2 to 20.9)	0.7 (0.5 to 1.0)	1.0 (0.7 to 1.3)	31.8 (-0.2 to 80.2)	-10.5 (-32.2 to 21.9)
Testicular cancer	3.6 (2.6 to 4.9)	3.9 (2.3 to 5.6)	4.3 (-29.4 to 60.0)	2.5 (-31.4 to 62.7)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	2.9 (-32.6 to 60.3)	1.0 (-33.8 to 61.5)
Kidney cancer	8.9 (7.8 to 10.0)	18.1 (15.0 to 21.3)	102.7 (64.8 to 141.9)	34.2 (10.0 to 59.1)	0.7 (0.5 to 0.9)	1.3 (0.9 to 1.7)	94.7 (59.0 to 137.0)	29.1 (6.2 to 55.9)
Bladder cancer	2.7 (13.9 to 17.9)	2.6 (2.1 to 3.2)	-3.7 (-38.8 to 103.8)	58.5 (-7.8 to 34.4)	1.2 (0.9 to 1.6)	2.0 (1.4 to 2.7)	61.1 (30.5 to 97.2)	6.2 (-13.5 to 29.4)
Brain and nervous system cancer	3.9 (3.3 to 4.6)	5.8 (4.7 to 7.0)	48.6 (26.0 to 74.8)	10.2 (-6.3 to 29.2)	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	45.5 (19.9 to 75.9)	8.2 (-9.3 to 28.8)
Thyroid cancer	3.2 (2.5 to 3.8)	4.8 (3.7 to 6.2)	47.0 (15.8 to 94.6)	14.3 (-10.8 to 50.9)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	43.5 (10.3 to 93.0)	10.2 (-16.0 to 47.5)
Mesothelioma	0.5 (0.4 to 0.7)	0.9 (0.6 to 1.2)	81.3 (22.9 to 139.2)	18.6 (-18.5 to 55.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	82.1 (14.8 to 158.1)	19.4 (-23.7 to 69.7)
Hodgkin lymphoma	2.7 (1.9 to 3.4)	2.6 (2.0 to 3.9)	-5.9 (-30.5 to 45.7)	-20.3 (-41.3 to 30.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-0.9 (-31.5 to 37.1)	-23.2 (-42.9 to 19.1)
Non-Hodgkin lymphoma	11.3 (8.3 to 15.6)	19.2 (12.7 to 26.2)	69.5 (20.8 to 121.0)	15.6 (-17.6 to 52.0)	0.8 (0.5 to 1.2)	1.4 (0.8 to 2.1)	63.8 (13.5 to 112.3)	12.0 (-21.6 to 46.8)
Multiple myeloma	1.8 (1.2 to 2.7)	3.4 (2.1 to 5.8)	91.1 (14.9 to 199.3)	27.1 (-23.9 to 97.1)	0.4 (0.2 to 0.7)	0.7 (0.4 to 1.2)	77.7 (11.8 to 179.5)	18.3 (-25.0 to 84.4)
Leukemia	4.7 (4.1 to 5.3)	8.9 (7.6 to 10.6)	91.0 (56.6 to 133.5)	27.1 (4.8 to 54.6)	0.7 (0.5 to 0.9)	1.2 (0.8 to 1.6)	79.1 (45.6 to 123.1)	20.2 (-1.3 to 47.9)
Other neoplasms	14.6 (12.4 to 17.0)	43.6 (35.8 to 54.8)	196.0 (139.0 to 282.2)	104.3 (68.8 to 156.8)	2.9 (0.7 to 1.4)	2.9 (2.0 to 4.0)	196.3 (119.5 to 256.0)	91.8 (56.2 to 140.8)
Cardiovascular diseases	-	-	-	-	43.6 (43.6 to 84.5)	49.7 (58.2 to 114.6)	14.2 (10.2 to 67.5)	8.7 (-25.4 to 13.3)
Rheumatic heart disease	1.3 (0.9 to 1.6)	1.8 (1.3 to 2.4)	45.1 (-2.1 to 111.1)	2.0 (-29.2 to 45.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	43.1 (-14.1 to 133.9)	-0.7 (-40.1 to 59.7)
Ischemic heart disease	333.9 (281.5 to 400.1)	452.1 (394.3 to 523.2)	34.2 (7.8 to 72.1)	-12.8 (-30.6 to 12.4)	21.1 (13.8 to 29.7)	26.2 (17.4 to 36.7)	24.2 (-2.4 to 59.9)	-19.6 (-37.0 to 4.7)
Cerebrovascular disease	-	-	-	-	12.4 (8.4 to 16.9)	16.5 (11.3 to 22.8)	46.5 (-0.3 to 70.9)	37.5 (-30.6 to 15.7)
Ischemic stroke	70.2 (60.0 to 82.9)	95.2 (77.6 to 109.8)	35.3 (0.4 to 74.8)	-8.3 (-31.1 to 17.6)	10.0 (6.7 to 13.7)	13.6 (9.0 to 18.7)	36.2 (1.0 to 74.9)	-7.8 (-30.3 to 17.2)
Hemorrhagic stroke	16.0 (11.3 to 20.3)	22.9 (17.9 to 27.6)	44.2 (-7.7 to 104.7)	0.5 (-34.6 to 40.5)	2.3 (1.5 to 3.4)	3.3 (2.1 to 4.7)	43.8 (-8.1 to 106.9)	0.6 (-33.6 to 42.4)
Hypertensive heart disease	20.7 (16.3 to 24.5)	34.0 (27.9 to 41.0)	62.6 (28.3 to 117.1)	8.8 (-13.9 to 43.9)	2.2 (1.5 to 3.1)	3.7 (2.5 to 5.2)	63.8 (27.8 to 118.9)	9.8 (-14.1 to 47.0)
Cardiomyopathy and myocarditis	23.6 (19.1 to 29.2)	26.3 (22.1 to 30.8)	11.1 (-16.5 to 43.7)	-23.2 (-42.1 to -1.7)	2.5 (1.7 to 3.6)	2.8 (1.9 to 3.9)	10.7 (-1.5 to 43.9)	-23.9 (-42.6 to -0.9)
Atrial fibrillation and flutter	99.0 (85.9 to 113.3)	81.7 (61.2 to 110.4)	-17.6 (-40.1 to 14.7)	-45.9 (-59.5 to -23.3)	7.6 (5.1 to 10.6)	6.3 (3.8 to 9.9)	-18.7 (-39.0 to 15.4)	-45.1 (-58.7 to -22.8)
Peripheral vascular disease	535.0 (426.4 to 656.8)	782.2 (552.8 to 987.0)	45.1 (-3.8 to 114.4)	-5.0 (-37.1 to 40.9)	0.6 (0.3 to 1.3)	0.7 (0.3 to 1.5)	27.6 (-47.0 to 139.7)	-16.8 (-65.0 to 57.9)
Endocarditis	0.6 (0.3 to 0.8)	0.7 (0.6 to 1.0)	31.6 (-19.7 to 123.0)	-3.7 (-40.4 to 61.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	29.2 (-27.4 to 138.7)	-5.1 (-46.1 to 70.8)
Other cardiovascular and circulatory diseases	228.9 (129.5 to 334.8)	395.7 (253.2 to 524.4)	72.8 (-1.5 to 224.3)	20.3 (-31.2 to 123.9)	16.1 (8.3 to 25.8)	27.9 (15.3 to 42.0)	72.0 (-3.4 to 226.7)	20.3 (-31.6 to 125.7)
Chronic respiratory diseases	-	-	-	-	55.5 (55.5 to 109.8)	71.1 (70.7 to 137.1)	28.3 (2.7 to 53.4)	1.5 (-15.2 to 19.1)
Chronic obstructive pulmonary disease	1,016.1 (931.0 to 1,097.0)	1,401.4 (1,281.6 to 1,513.7)	37.2 (30.9 to 44.6)	0.8 (-3.6 to 6.3)	48.5 (30.4 to 69.7)	64.6 (42.8 to 92.2)	32.5 (2.7 to 85.8)	-3.0 (-23.3 to 35.6)
Pneumoconiosis	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-19.0 (-29.5 to -2.3)	-43.3 (-51.0 to -32.8)

Appendix Table G.4 - Netherlands prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-4.3 (-10.0 to 1.6)	-3.4 (-37.5 to -29.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.8 (-10.7 to 1.2)	-34.0 (-37.9 to -29.9)
Asbestosis	-	-	-	-	-	-	-	-
Coal workers pneumoconiosis	-	-	-	-	-	-	-	-
Other pneumoconiosis	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-23.3 (-35.7 to -1.1)	-45.9 (-55.2 to -32.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-23.1 (-35.7 to -2.0)	-45.7 (-55.5 to -32.4)
Asthma	738.0 (690.5 to 788.1)	835.2 (792.9 to 877.5)	12.7 (3.7 to 22.0)	12.7 (8.3 to 9.2)	32.4 (21.0 to 45.9)	36.3 (23.7 to 51.6)	13.3 (2.4 to 21.8)	13.3 (8.7 to 9.4)
Interstitial lung disease and pulmonary sarcoidosis	1.7 (1.3 to 2.1)	2.4 (1.8 to 3.0)	42.3 (2.1 to 111.3)	1.7 (-2.8 to 51.0)	0.2 (0.1 to 0.4)	0.5 (0.2 to 0.5)	43.0 (-1.8 to 110.5)	2.7 (-29.1 to 50.4)
Other chronic respiratory diseases	-	-	-	-	0.6 (0.4 to 1.0)	0.6 (0.4 to 0.9)	-5.6 (-33.2 to 45.9)	-30.8 (-49.8 to 6.8)
Cirrhosis	-	-	-	-	0.7 (0.5 to 0.9)	0.8 (0.5 to 1.1)	13.9 (-3.2 to 34.7)	-17.9 (-30.1 to -3.2)
Cirrhosis due to hepatitis B	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.7)	31.8 (-22.8 to 136.5)	-5.1 (45.9 to 68.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-30.9 (-35.6 to 149.0)	-7.1 (-5.2 to 79.9)
Cirrhosis due to hepatitis C	1.6 (1.1 to 2.1)	2.3 (1.8 to 2.9)	45.0 (-0.6 to 136.6)	2.7 (29.4 to 66.4)	0.3 (0.1 to 0.4)	0.4 (0.2 to 0.5)	43.2 (-6.2 to 147.5)	1.6 (-33.7 to 73.4)
Cirrhosis due to alcohol use	1.7 (1.2 to 2.2)	1.3 (0.9 to 1.7)	-24.4 (-52.6 to 17.7)	-47.6 (-67.0 to -18.6)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	24.8 (-55.5 to 22.8)	-47.7 (-69.3 to -14.7)
Cirrhosis due to other causes	0.4 (0.3 to 0.6)	0.6 (0.5 to 0.9)	46.0 (-9.4 to 144.1)	10.5 (-26.6 to 77.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	37.9 (-17.5 to 141.1)	4.4 (-31.9 to 75.6)
Digestive diseases	-	-	-	-	28.5 (20.0 to 37.5)	36.3 (25.9 to 48.3)	27.7 (16.3 to 38.1)	-2.2 (-11.5 to 6.1)
Peptic ulcer disease	113.9 (110.0 to 117.9)	73.5 (66.6 to 80.2)	-35.7 (-41.8 to -29.9)	-58.3 (-62.2 to -54.5)	3.5 (2.4 to 4.9)	2.8 (1.9 to 3.9)	-22.2 (-28.3 to -10.2)	-49.3 (-53.4 to -40.8)
Gastritis and duodenitis	59.3 (54.9 to 63.6)	49.0 (42.0 to 55.9)	-17.8 (-27.7 to -7.8)	-42.3 (-49.2 to -35.4)	2.3 (1.5 to 3.2)	2.2 (1.5 to 3.0)	-4.2 (-14.6 to 9.2)	-32.1 (-40.1 to -21.8)
Appendicitis	0.6 (0.5 to 0.8)	0.3 (0.3 to 0.7)	-23.7 (-47.3 to 12.5)	-25.5 (-49.1 to 14.1)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-23.9 (-49.6 to 21.3)	-25.9 (-52.9 to 22.2)
Paralytic ileus and intestinal obstruction	0.4 (0.3 to 0.4)	0.6 (0.6 to 0.7)	71.4 (57.2 to 84.8)	24.4 (14.5 to 33.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	69.7 (33.5 to 116.5)	25.0 (1.0 to 53.1)
Inguinal, femoral, and abdominal hernia	50.5 (32.7 to 67.5)	70.8 (38.5 to 112.1)	42.5 (-28.5 to 119.5)	37.8 (-52.2 to 47.8)	0.5 (0.2 to 1.0)	0.7 (0.3 to 1.5)	43.3 (-29.0 to 121.5)	2.3 (-52.4 to 50.3)
Inflammatory bowel disease	69.0 (64.9 to 73.5)	95.9 (88.8 to 102.9)	38.2 (25.9 to 51.3)	8.7 (-1.7 to 19.0)	14.5 (10.0 to 19.7)	20.0 (13.6 to 27.2)	37.6 (23.9 to 50.8)	8.8 (-2.3 to 19.5)
Vascular intestinal disorders	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	29.8 (-12.4 to 94.1)	-11.9 (-39.1 to 32.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	28.0 (-23.1 to 126.4)	-12.2 (-44.4 to 50.3)
Gallbladder and biliary diseases	17.4 (13.1 to 22.8)	27.9 (20.0 to 38.3)	56.2 (11.1 to 184.8)	9.0 (-24.5 to 99.7)	1.8 (1.1 to 2.7)	2.9 (1.8 to 4.4)	56.1 (11.0 to 186.1)	9.9 (-24.0 to 99.3)
Pancreatitis	3.5 (3.3 to 3.7)	5.3 (5.0 to 5.7)	52.4 (40.5 to 64.5)	5.7 (9.3 to 28.2)	1.0 (0.7 to 1.4)	1.5 (1.0 to 2.1)	52.4 (27.1 to 79.1)	19.5 (0.8 to 41.2)
Other digestive diseases	-	-	-	-	4.5 (3.1 to 6.1)	5.9 (4.1 to 8.4)	32.6 (9.4 to 55.3)	1.4 (-16.6 to 19.3)
Neurological disorders	-	-	-	-	159.0 (110.7 to 213.7)	207.3 (144.7 to 280.1)	30.4 (18.7 to 42.2)	9.5 (-0.2 to 20.1)
Alzheimer disease and other dementias	175.9 (164.8 to 188.8)	240.8 (201.1 to 290.1)	35.3 (13.2 to 65.7)	-12.4 (-26.8 to 6.4)	26.3 (19.4 to 33.4)	35.9 (24.9 to 48.2)	35.5 (12.9 to 65.4)	-12.9 (-27.4 to 5.8)
Parkinson disease	33.7 (30.5 to 36.7)	50.0 (45.2 to 55.2)	47.5 (41.4 to 54.7)	47.5 (-5.0 to 3.7)	3.9 (2.7 to 5.3)	5.8 (4.0 to 7.8)	48.7 (38.1 to 60.2)	3.2 (-7.2 to 7.8)
Epilepsy	45.0 (32.7 to 57.0)	45.1 (30.6 to 59.3)	-0.4 (-38.0 to 54.4)	-13.2 (-45.8 to 34.4)	18.2 (11.4 to 26.5)	18.8 (11.0 to 27.5)	3.6 (-36.1 to 61.3)	-9.0 (-43.4 to 41.3)
Multiple sclerosis	12.7 (9.8 to 16.2)	23.8 (17.0 to 29.7)	88.7 (16.7 to 176.4)	52.3 (-6.2 to 124.8)	4.2 (2.7 to 5.9)	7.7 (4.9 to 10.8)	7.7 (13.7 to 177.1)	52.8 (8.2 to 127.2)
Migraine	2,298.0 (2,086.2 to 2,525.3)	2,909.2 (2,623.5 to 3,175.5)	25.6 (10.9 to 44.5)	14.7 (1.1 to 32.8)	77.9 (46.4 to 114.7)	97.7 (58.2 to 143.0)	25.2 (16.6 to 43.9)	15.1 (1.1 to 35.1)
Tension-type headache	5,557.2 (4,585.0 to 6,597.7)	6,854.7 (6,471.8 to 7,221.2)	22.8 (1.9 to 51.6)	22.8 (-4.4 to 34.4)	8.4 (4.0 to 11.9)	9.3 (5.0 to 17.9)	9.3 (14.8 to 51.7)	10.5 (8.4 to 35.2)
Medication overuse headache	76.4 (51.4 to 100.6)	136.7 (90.3 to 179.1)	79.0 (45.6 to 107.7)	47.5 (19.4 to 72.3)	11.9 (6.8 to 18.4)	21.1 (12.0 to 32.3)	78.0 (44.3 to 109.2)	47.3 (18.9 to 73.4)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	10.1 (-22.5 to 70.7)	-9.9 (-36.4 to 36.8)	8.2 (5.7 to 11.0)	10.1 (6.7 to 14.4)	21.4 (-5.8 to 64.6)	-17.6 (-35.7 to 11.3)
Mental and substance use disorders	-	-	-	-	355.2 (257.7 to 464.4)	394.1 (284.3 to 508.5)	11.0 (8.1 to 14.2)	0.9 (-1.5 to 3.5)
Schizophrenia	41.0 (34.6 to 49.2)	50.4 (42.9 to 59.4)	22.5 (14.9 to 31.9)	4.0 (-2.1 to 12.8)	26.1 (18.7 to 33.2)	31.8 (22.8 to 40.1)	21.9 (12.7 to 32.8)	4.2 (-3.5 to 14.2)
Alcohol use disorders	165.1 (150.5 to 179.0)	177.2 (162.5 to 190.6)	6.8 (0.4 to 13.0)	1.4 (-5.0 to 7.7)	16.5 (10.9 to 23.6)	17.6 (11.6 to 25.4)	6.4 (-1.0 to 13.3)	1.5 (-5.5 to 8.7)
Drug use disorders	-	-	-	-	29.0 (20.4 to 38.1)	27.8 (19.0 to 37.0)	-4.2 (-13.9 to 6.4)	-0.4 (-10.3 to 10.7)
Opioid use disorders	32.7 (24.4 to 40.7)	32.2 (24.1 to 39.9)	-1.5 (-10.5 to 6.8)	1.3 (-4.4 to 10.0)	13.6 (8.7 to 18.6)	13.3 (8.6 to 18.1)	-2.3 (-12.9 to 8.6)	1.0 (-10.3 to 13.2)
Cocaine use disorders	27.7 (23.5 to 30.2)	25.6 (23.5 to 28.1)	-8.2 (-17.9 to 3.8)	-4.4 (-14.6 to 8.6)	3.8 (2.5 to 5.5)	3.5 (2.3 to 4.9)	-3.3 (-21.7 to 8.8)	-4.4 (-18.3 to 14.2)
Amphetamine use disorders	24.2 (21.6 to 27.2)	23.7 (20.7 to 26.9)	-1.9 (-18.9 to 15.0)	1.6 (-1.7 to 1.9)	3.1 (1.9 to 4.7)	3.1 (1.9 to 4.6)	1.2 (-22.5 to 18.6)	1.2 (-20.6 to 23.5)
Cannabis use disorders	48.2 (44.2 to 51.8)	45.0 (41.6 to 48.6)	-7.2 (-11.3 to -2.1)	-1.0 (-5.5 to 4.6)	1.4 (0.9 to 2.0)	1.3 (0.9 to 1.9)	-7.0 (-17.0 to 3.8)	-1.0 (-11.5 to 11.0)
Other drug use disorders	-	-	-	-	7.0 (4.6 to 10.2)	6.7 (4.1 to 9.9)	-5.4 (-30.8 to 30.4)	-1.2 (-27.5 to 36.0)
Depressive disorders	-	-	-	-	105.3 (73.1 to 143.2)	123.2 (85.4 to 166.9)	17.1 (9.5 to 25.0)	2.8 (-2.8 to 9.2)
Major depressive disorder	394.7 (336.3 to 445.8)	473.6 (410.2 to 539.1)	19.5 (10.7 to 29.4)	4.4 (-2.3 to 12.5)	80.1 (54.5 to 110.5)	95.0 (64.5 to 128.9)	18.7 (9.8 to 29.3)	4.5 (-2.5 to 12.9)
Dysthymia	262.7 (222.2 to 303.4)	296.0 (249.9 to 349.2)	12.2 (1.0 to 22.1)	-2.1 (-11.2 to 5.2)	25.2 (16.7 to 36.3)	28.1 (18.8 to 40.1)	11.7 (0.3 to 22.2)	-2.1 (-11.1 to 5.6)
Bipolar disorder	122.8 (109.7 to 135.5)	134.0 (120.9 to 147.0)	8.6 (2.8 to 14.0)	-0.2 (-5.7 to 4.7)	24.8 (15.8 to 36.6)	26.8 (17.1 to 38.9)	8.2 (1.0 to 14.7)	-0.0 (-6.7 to 6.5)
Anxiety disorders	966.3 (851.8 to 1,073.2)	1,085.8 (982.1 to 1,185.6)	12.0 (4.6 to 19.9)	-0.7 (-6.2 to 5.3)	88.2 (59.9 to 124.6)	98.1 (66.8 to 137.6)	11.3 (3.9 to 19.7)	-0.7 (-6.7 to 5.8)
Eating disorders	-	-	-	-	11.4 (7.3 to 16.5)	10.3 (6.6 to 14.8)	-0.7 (-15.0 to -4.4)	2.4 (-3.2 to 8.1)
Anorexia nervosa	13.8 (9.3 to 18.1)	13.4 (8.5 to 18.1)	-4.0 (-18.1 to 8.4)	6.8 (-9.1 to 20.6)	2.9 (1.7 to 4.4)	2.8 (1.6 to 4.4)	-0.1 (-20.0 to 11.8)	7.0 (-11.0 to 23.8)
Bulimia nervosa	40.3 (30.6 to 50.5)	35.7 (27.3 to 44.9)	-11.8 (-13.7 to -9.7)	0.5 (0.4 to 0.7)	8.5 (5.2 to 12.5)	7.5 (4.6 to 11.0)	-11.8 (-16.7 to -6.8)	0.7 (-4.6 to 5.7)
Autistic spectrum disorders	-	-	-	-	16.7 (11.6 to 22.8)	18.5 (13.0 to 25.2)	10.7 (7.2 to 14.5)	0.1 (-3.2 to 3.6)
Autism	43.3 (40.8 to 45.7)	48.4 (45.5 to 51.3)	11.3 (10.4 to 12.3)	0.2 (0.1 to 0.2)	10.6 (7.1 to 14.5)	11.7 (7.9 to 16.1)	10.6 (5.5 to 16.1)	0.2 (-0.7 to 5.0)
Asperger syndrome	62.1 (58.0 to 66.2)	69.4 (64.6 to 74.4)	11.4 (10.3 to 12.2)	0.2 (0.2 to 0.3)	6.2 (4.3 to 8.5)	6.8 (4.8 to 9.4)	10.9 (6.5 to 15.2)	0.3 (-3.8 to 4.2)
Attention-deficit/hyperactivity disorder	66.0 (55.8 to 77.0)	66.5 (56.1 to 77.5)	0.2 (0.0 to 0.7)	-0.0 (-0.0 to 0.0)	0.8 (0.5 to 1.2)	0.8 (0.5 to 1.2)	0.2 (-6.9 to 7.8)	-0.1 (-7.1 to 6.6)
Conduct disorder	110.4 (92.7 to 129.1)	113.1 (95.3 to 131.4)	2.0 (0.6 to 3.2)	0.0 (-0.0 to 0.0)	13.3 (8.1 to 20.0)	13.5 (8.2 to 20.4)	0.0 (-2.1 to 6.8)	0.0 (-4.1 to 4.4)
Idiopathic intellectual disability	27.8 (17.7 to 43.1)	19.9 (14.5 to 28.6)	-26.9 (-46.4 to -17.3)	-34.8 (-52.3 to -17.3)	1.7 (0.9 to 2.8)	1.2 (0.7 to 1.8)	-26.9 (-40.0 to -6.3)	-44.7 (-53.5 to -16.1)
Other mental and substance use disorders	287.7 (271.2 to 304.1)	333.4 (313.6 to 352.5)	15.3 (13.3 to 17.2)	0.2 (0.0 to 0.5)	21.3 (14.5 to 28.8)	24.4 (16.6 to 32.8)	14.4 (10.6 to 18.8)	0.2 (-3.1 to 3.7)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	150.0 (106.7 to 196.4)	223.7 (162.1 to 295.2)	48.8 (36.4 to 66.1)	12.6 (3.5 to 24.4)
Diabetes mellitus	692.6 (599.7 to 800.3)	1,332.2 (1,142.8 to 1,566.3)	91.0 (51.6 to 143.6)	36.3 (8.2 to 70.9)	48.7 (32.3 to 68.5)	94.5 (63.4 to 132.1)	94.3 (53.8 to 150.1)	38.0 (9.4 to 75.9)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.8 (-11.0 to -0.6)	-18.8 (-21.5 to -12.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.8 (-11.0 to -0.6)	-18.8 (-21.5 to -12.9)
Chronic kidney disease	-	-	-	-	55.9 (36.8 to 76.4)	75.2 (50.1 to 102.1)	34.7 (26.3 to 43.9)	2.1 (-2.4 to 7.2)
Chronic kidney disease due to diabetes mellitus	124.8 (76.2 to 276.0)	161.3 (110.9 to 284.4)	31.7 (7.2 to 83.7)	-8.7 (-34.5 to 26.0)	7.5 (4.6 to 11.7)	9.2 (5.8 to 13.1)	24.1 (-13.4 to 70.2)	-10.7 (-38.0 to 19.5)
Chronic kidney disease due to hypertension	143.9 (115.7 to 185.8)	143.2 (94.3 to 246.5)	-7.8 (-27.6 to 40.8)	-7.8 (-45.0 to 1.0)	16.3 (10.3 to 23.7)	7.0 (4.5 to 9.9)	-57.1 (-65.4 to -45.6)	-66.0 (-72.3 to -57.3)
Chronic kidney disease due to glomerulonephritis	246.3 (156.1 to 455.5)	138.7 (99.3 to 237.0)	-42.7 (-58.7 to -24.6)	-54.7 (-67.2 to -41.4)	4.8 (3.0 to 6.9)	10.0 (6.4 to 14.7)	108.7 (60.5 to 183.9)	64.0 (28.6 to 118.0)
Chronic kidney disease due to other causes	705.5 (393.3 to 812.8)	863.8 (685.9 to 1,582.0)	21.4 (46.9 to 101.8)	23.3 (7.3 to 43.0)	27.3 (17.7 to 37.5)	49.0 (32.9 to 66.5)	81.1 (52.6 to 107.3)	33.9 (16.0 to 52.0)
Urinary diseases and male infertility	-	-	-	-	11.2 (7.3 to 16.0)	15.0 (9.4 to 21.6)	33.1 (15.5 to 53.2)	-8.3 (-20.5 to 5.7)
Interstitial nephritis and urinary tract infections	1.7 (1.2 to 2.2)	2.6 (2.0 to 3.4)	60.2 (4.5 to 139.1)	18.5 (-23.0 to 99.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	56.9 (-1.8 to 168.5)	18.3 (-18.7 to 117.8)

Appendix Table G.4 - Netherlands prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	284.8 (269.4 to 299.4)	331.1 (313.6 to 349.1)	15.8 (7.6 to 24.6)	-4.1 (-7.4 to 7.4)	8.3 (5.3 to 12.2)	9.6 (6.1 to 14.4)	15.3 (6.8 to 24.3)	-0.1 (-7.3 to 7.3)
Injuries	-	-	-	-	121.0 (92.3 to 156.3)	117.7 (84.0 to 157.8)	-3.2 (-13.3 to 7.3)	-27.1 (-34.4 to -19.3)
Transport injuries	-	-	-	-	28.6 (21.4 to 36.6)	23.6 (17.1 to 31.4)	-5.0 (-26.0 to -8.2)	-6.5 (-42.9 to -29.3)
Road injuries	-	-	-	-	28.1 (21.0 to 35.8)	23.2 (16.8 to 30.9)	-4.9 (-25.9 to -7.9)	-6.4 (-42.7 to -29.0)
Pedestrian road injuries	-	-	-	-	3.2 (2.4 to 4.2)	2.5 (1.8 to 3.4)	-0.7 (-30.7 to -11.5)	-0.5 (-47.4 to -32.5)
Cyclist road injuries	-	-	-	-	5.1 (3.8 to 6.5)	4.1 (3.0 to 5.5)	-1.0 (-29.0 to -5.9)	-3.0 (-44.2 to -26.3)
Motorcyclist road injuries	-	-	-	-	5.9 (4.4 to 7.6)	3.6 (2.5 to 4.9)	-2.3 (-48.9 to -28.1)	-2.4 (-59.6 to -43.2)
Motor vehicle road injuries	-	-	-	-	13.6 (10.3 to 17.2)	12.8 (9.4 to 16.9)	-0.8 (-14.0 to 4.4)	-1.1 (-34.2 to -20.5)
Other road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.2)	-0.1 (-53.5 to -39.8)	-0.1 (-64.2 to -53.7)
Other transport injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.4 (0.3 to 0.5)	-0.1 (-33.7 to -21.2)	-0.1 (-49.6 to -40.3)
Unintentional injuries	-	-	-	-	90.2 (68.4 to 116.9)	91.9 (65.7 to 123.8)	1.7 (-9.3 to 12.4)	-23.9 (-31.5 to -15.9)
Falls	-	-	-	-	59.9 (45.6 to 76.7)	57.5 (41.2 to 77.0)	-2.4 (-17.0 to 9.0)	-29.2 (-38.2 to -19.7)
Drowning	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	0.0 (-15.2 to 7.4)	-25.2 (-34.5 to -15.8)
Fire, heat, and hot substances	-	-	-	-	2.1 (1.4 to 3.3)	2.4 (1.4 to 3.9)	0.3 (-4.0 to 27.1)	-12.8 (-23.7 to 0.7)
Poisonings	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	0.0 (-12.7 to 20.1)	-15.6 (-29.3 to 0.9)
Exposure to mechanical forces	-	-	-	-	9.8 (7.3 to 12.8)	10.1 (7.2 to 13.6)	0.3 (-6.2 to 14.1)	-17.2 (-24.1 to -8.5)
Unintentional firearm injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	0.0 (-18.8 to -0.1)	-24.9 (-32.5 to -16.6)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	0.0 (-12.6 to 12.6)	-21.6 (-31.5 to -11.6)
Other exposure to mechanical forces	-	-	-	-	9.4 (7.0 to 12.4)	9.8 (7.0 to 13.2)	0.4 (-5.9 to 14.6)	-17.0 (-24.0 to -8.1)
Adverse effects of medical treatment	-	-	-	-	1.0 (0.7 to 1.5)	1.5 (0.9 to 2.2)	0.5 (-35.0 to 52.1)	10.3 (3.9 to 16.4)
Animal contact	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	0.0 (-3.6 to 13.4)	-18.9 (-24.7 to -12.2)
Venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.0 (-12.9 to 10.3)	-19.9 (-28.6 to -9.6)
Non-venomous animal contact	-	-	-	-	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	0.0 (-3.0 to 15.2)	-18.8 (-25.2 to -11.8)
Foreign body	-	-	-	-	0.4 (0.3 to 0.6)	0.4 (0.2 to 0.5)	0.0 (-24.7 to -12.3)	-30.0 (-36.6 to -24.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	0.0 (-28.9 to -5.3)	-33.6 (-42.9 to -22.2)
Foreign body in eyes	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	0.0 (-22.0 to -8.9)	-23.0 (-31.3 to -15.7)
Foreign body in other body part	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	0.0 (-27.6 to -12.8)	-30.6 (-39.0 to -24.1)
Other unintentional injuries	-	-	-	-	16.2 (11.7 to 22.0)	19.4 (13.5 to 26.9)	3.2 (-10.0 to 28.8)	-12.5 (-19.4 to -5.9)
Self-harm and interpersonal violence	-	-	-	-	2.2 (1.7 to 2.9)	2.1 (1.5 to 2.8)	-0.1 (-14.1 to 2.6)	-27.1 (-33.4 to -20.6)
Self-harm	-	-	-	-	0.8 (0.6 to 1.1)	1.1 (0.8 to 1.5)	0.3 (-13.5 to 41.5)	-1.2 (-12.3 to 9.2)
Interpersonal violence	-	-	-	-	1.4 (1.1 to 1.8)	1.0 (0.7 to 1.4)	-0.4 (-34.0 to -18.1)	-42.3 (-47.9 to -35.9)
Assault by firearm	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-0.1 (-31.4 to -16.2)	-41.5 (-46.8 to -35.2)
Assault by sharp object	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-0.1 (-27.4 to -13.8)	-38.1 (-42.6 to -32.5)
Assault by other means	-	-	-	-	1.0 (0.8 to 1.3)	0.8 (0.5 to 1.0)	-0.2 (-35.7 to -18.1)	-43.3 (-49.3 to -35.7)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-93.7 to -61.5)	-87.8 (-94.9 to -68.2)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-93.7 to -61.5)	-87.8 (-94.9 to -68.2)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - New Zealand prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	400.5 (300.0 to 514.4)	568.7 (424.4 to 733.0)	41.1 (38.3 to 45.2)	42.1 (4.0 to 0.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	16.6 (11.7 to 23.5)	21.6 (15.2 to 30.0)	29.5 (20.7 to 41.2)	5.4 (-1.5 to 14.1)
HIV/AIDS and tuberculosis	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	5.6 (-14.0 to 27.9)	-22.1 (-37.4 to -5.5)
Tuberculosis	0.5 (0.5 to 0.5)	0.6 (0.5 to 0.6)	13.7 (8.6 to 18.7)	-15.4 (-19.2 to -11.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	12.6 (9.9 to 39.4)	-15.3 (-33.0 to 5.5)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	9.9 (-41.2 to 37.2)	35.1 (-59.9 to -2.3)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-59.4 (-75.1 to -38.1)	-69.6 (-81.4 to -53.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-59.4 (-75.2 to -38.1)	-69.6 (-81.5 to -53.2)
HIV/AIDS resulting in other diseases	0.6 (0.4 to 0.8)	0.9 (0.5 to 1.3)	50.6 (7.0 to 105.5)	4.8 (-26.1 to 46.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-7.7 (-41.1 to 37.3)	-35.8 (-59.9 to -2.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	2.2 (1.5 to 3.1)	2.3 (1.5 to 3.4)	3.6 (-4.8 to 11.5)	-20.0 (-26.5 to -13.9)
Diarrheal diseases	1.8 (1.7 to 1.9)	2.3 (2.2 to 2.5)	27.5 (17.5 to 38.5)	-2.3 (-10.2 to 6.4)	0.4 (0.2 to 0.4)	0.4 (0.2 to 0.5)	26.5 (10.2 to 44.2)	-2.1 (-15.0 to 11.8)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-59.9 to 11.3)	-24.0 (-68.1 to -13.3)
Typhoid fever	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-23.0 (-38.2 to 3.5)	-39.4 (-51.1 to -19.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.0 (-38.5 to 4.7)	-39.4 (-51.1 to -19.2)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.6 (-18.8 to 38.3)	-14.7 (-33.8 to 10.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.6 (-18.9 to 38.3)	-14.7 (-33.8 to 10.1)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-81.7 (-99.6 to 1588.7)	85.8 (-99.7 to 1,226.2)
Lower respiratory infections	0.8 (0.7 to 1.0)	0.7 (0.5 to 0.9)	-15.5 (-37.7 to 22.1)	-8.4 (-61.1 to -25.9)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-15.4 (-40.2 to 25.5)	-47.6 (-61.9 to -23.2)
Upper respiratory infections	64.8 (61.4 to 68.2)	78.9 (74.8 to 83.9)	21.6 (13.3 to 32.0)	-4.2 (-10.8 to 3.7)	0.8 (0.4 to 1.3)	0.9 (0.5 to 1.5)	21.2 (12.0 to 32.4)	-4.1 (-11.7 to 4.3)
Otitis media	21.6 (20.6 to 22.7)	24.8 (23.8 to 26.0)	14.7 (8.0 to 22.3)	-10.7 (-15.6 to -5.1)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.7)	14.0 (5.1 to 22.5)	-11.7 (-18.4 to -5.3)
Meningitis	-	-	-	-	0.5 (0.3 to 0.8)	0.3 (0.2 to 0.4)	-39.9 (-54.2 to -24.8)	53.3 (-64.6 to -41.1)
Pneumococcal meningitis	2.3 (1.4 to 3.7)	1.5 (0.9 to 2.5)	-34.1 (-48.7 to -19.0)	-52.2 (-63.1 to -40.4)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	0.1 (-52.7 to -3.7)	0.1 (-64.3 to -25.6)
H influenzae type B meningitis	0.7 (0.2 to 1.6)	0.4 (0.1 to 1.0)	-42.8 (-66.7 to -9.4)	-55.8 (-73.6 to -26.0)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-42.2 (-70.3 to 3.3)	-53.3 (-75.5 to -15.5)
Meningococcal meningitis	0.5 (0.2 to 1.2)	0.3 (0.1 to 0.7)	-60.9 (-67.9 to -11.3)	-60.9 (-75.7 to -31.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-46.5 (-70.4 to 2.9)	-59.5 (-77.7 to -19.8)
Other meningitis	1.2 (0.6 to 2.6)	0.6 (0.3 to 1.4)	-46.1 (-63.6 to -29.0)	-59.5 (-71.1 to -44.4)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.1)	0.2 (-67.3 to -20.6)	0.2 (-74.6 to -37.3)
Encephalitis	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	48.3 (29.5 to 74.4)	8.5 (-8.8 to 24.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (32.3 to 82.6)	10.5 (5.9 to 30.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.0 (-95.2 to 210.9)	-69.1 (-96.3 to 137.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.0 (-95.3 to 215.9)	-69.1 (-96.4 to 141.6)
Whooping cough	1.0 (0.8 to 1.3)	0.4 (0.3 to 0.6)	-57.7 (-60.4 to -54.9)	-62.6 (-65.0 to -60.2)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-57.7 (-64.4 to -50.4)	-62.6 (-68.6 to -56.1)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.8 (-58.2 to 52.2)	-13.6 (-67.8 to 20.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.7 (-51.3 to 43.5)	-14.4 (-62.3 to 13.5)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13,500.6 (80.8 to 0.0)	-11,820.5 (58.5 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13,500.6 (80.7 to nan)	11,820.5 (58.3 to nan)
Varicella and herpes zoster	2.5 (2.3 to 2.8)	3.4 (3.1 to 3.9)	36.6 (18.3 to 59.8)	-0.5 (-12.5 to 14.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	50.1 (17.5 to 95.4)	-0.3 (-21.2 to 28.4)
Neglected tropical diseases and malaria	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-27.2 (-44.7 to 5.4)	-51.5 (-62.3 to -31.2)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.5 (-75.8 to 279.9)	-15.1 (-80.8 to 202.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.4 (-75.4 to 288.1)	-14.0 (-80.6 to 208.6)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-59.3 (-81.8 to 3.7)	-71.7 (-87.3 to -26.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.5 (-81.5 to 9.4)	-69.7 (-86.9 to -20.6)
Cystic echinococcosis	0.5 (0.5 to 0.6)	0.4 (0.4 to 0.5)	-25.0 (-38.4 to 13.5)	-50.6 (-59.2 to -28.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-23.8 (-44.0 to 19.3)	-49.1 (-61.8 to -24.0)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.3 (-43.3 to 22.1)	-19.0 (-58.1 to -8.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.3 (-43.3 to 22.2)	-19.0 (-58.1 to -8.2)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.9 (-37.2 to 85.9)	5.4 (-53.3 to 37.8)
Maternal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-17.5 (-42.7 to 22.7)	-23.4 (-47.0 to 14.9)
Maternal hemorrhage	3.0 (2.2 to 3.7)	3.0 (2.2 to 3.9)	1.9 (-26.4 to 41.9)	-4.6 (-31.9 to 33.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-37.6 (-63.8 to 38.3)	-42.3 (-66.0 to 31.7)
Maternal sepsis and other maternal infections	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-14.4 (-69.7 to 139.4)	-25.3 (-72.9 to 106.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.9 (-40.5 to 26.3)	-20.8 (-45.1 to 13.1)
Maternal hypertensive disorders	0.9 (0.4 to 1.4)	1.0 (0.5 to 1.6)	13.5 (-6.0 to 36.6)	4.7 (-12.9 to 24.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	12.3 (-12.3 to 49.6)	3.4 (-19.3 to 36.3)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.3 (-38.4 to 63.7)	-9.8 (-42.3 to 53.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.3 (-38.5 to 63.9)	-9.8 (-42.3 to 53.9)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.2 (-23.0 to 43.1)	-1.6 (-28.9 to 32.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.2 (-23.1 to 43.2)	-1.6 (-29.0 to 32.4)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-22.7 (-52.8 to 41.1)	-28.3 (-56.0 to 32.0)
Neonatal disorders	-	-	-	-	3.2 (2.3 to 4.4)	5.9 (4.1 to 7.8)	80.9 (38.9 to 140.3)	41.1 (8.5 to 86.8)
Preterm birth complications	18.6 (13.1 to 26.4)	36.0 (25.0 to 51.5)	94.5 (64.6 to 126.4)	48.8 (26.4 to 73.1)	2.0 (1.4 to 2.7)	3.9 (2.7 to 5.2)	100.3 (57.5 to 146.7)	56.1 (22.2 to 92.1)
Neonatal encephalopathy due to birth asphyxia and trauma	3.2 (1.6 to 7.1)	3.0 (1.3 to 7.2)	-10.5 (-39.1 to 33.9)	-30.2 (-51.9 to 4.7)	0.7 (0.4 to 0.9)	0.6 (0.4 to 0.9)	-6.5 (-40.5 to 58.7)	-25.9 (-52.9 to 25.6)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.4 (90.5 to 145.0)	89.2 (75.1 to 125.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.7 (45.8 to 218.8)	95.1 (34.3 to 193.8)
Hemolytic disease and other neonatal jaundice	1.0 (0.3 to 2.5)	0.7 (0.3 to 1.7)	-26.2 (-87.1 to 268.1)	-42.4 (-89.9 to 187.6)	0.4 (0.1 to 1.0)	0.3 (0.1 to 0.7)	-28.9 (-86.0 to 288.1)	-39.9 (-89.1 to 200.9)
Other neonatal disorders	-	-	-	-	0.2 (0.1 to 0.3)	1.0 (0.5 to 1.6)	437.6 (125.4 to 832.8)	320.3 (76.5 to 626.9)
Nutritional deficiencies	-	-	-	-	9.7 (6.4 to 14.2)	11.6 (7.7 to 17.1)	20.5 (13.0 to 25.7)	1.7 (-4.5 to 5.9)
Protein-energy malnutrition	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-25.6 (-55.1 to 42.1)	-63.1 (-77.3 to -30.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.7 (-69.1 to 65.6)	-63.5 (-83.7 to -19.0)
Iodine deficiency	21.8 (11.4 to 33.2)	17.5 (9.1 to 25.8)	-38.4 (-64.9 to 58.3)	-37.8 (-73.0 to 20.6)	0.4 (0.2 to 0.7)	0.3 (0.1 to 0.6)	-18.6 (-64.2 to 59.5)	-37.5 (-72.8 to 21.5)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron-deficiency anemia	357.8 (349.6 to 366.3)	462.7 (454.2 to 470.1)	29.3 (25.7 to 32.8)	2.0 (-0.9 to 4.9)	9.3 (6.2 to 13.7)	11.3 (7.5 to 16.6)	22.4 (14.4 to 27.4)	3.3 (-3.6 to 7.2)

Appendix Table G.4 - New Zealand prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.0	0.0	-45.3	-72.3
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.1	1.4	24.0	-0.8
Sexually transmitted diseases excluding HIV	-	-	-	-	0.5	0.6	29.5	0.1
Syphilis	0.2 (0.2 to 0.2)	0.4 (0.4 to 0.5)	108.0 (70.1 to 156.4)	27.1 (3.3 to 56.6)	0.0	0.1	106.6	26.9
Chlamydial infection	69.9 (52.9 to 86.3)	85.3 (68.8 to 103.7)	22.2 (-5.9 to 56.9)	1.1 (-21.1 to 41.0)	0.2	0.2	-5.2	10.7
Gonococcal infection	8.9 (6.2 to 11.6)	8.7 (6.1 to 11.8)	-1.3 (-39.6 to 66.8)	-13.4 (-46.9 to 47.2)	0.0	0.0	0.6	-11.9
Trichomoniasis	21.3 (16.6 to 26.2)	25.9 (20.6 to 31.3)	22.2 (-11.0 to 61.2)	3.1 (-24.6 to 36.6)	0.0	0.0	20.9	2.4
Genital herpes	601.3 (587.3 to 613.7)	872.3 (852.5 to 890.4)	45.2 (40.6 to 49.7)	1.3 (-2.0 to 4.4)	0.2	0.2	42.9	1.4
Other sexually transmitted diseases	0.5 (0.4 to 0.7)	0.5 (0.4 to 0.7)	-2.4 (-30.8 to 52.7)	-17.5 (-40.5 to 26.0)	0.0	0.0	24.6	3.5
Hepatitis	-	-	-	-	0.2	0.2	5.0	21.3
Hepatitis A	2.8 (2.7 to 3.0)	3.3 (3.1 to 3.4)	15.5 (14.7 to 16.2)	-7.4 (-8.5 to -6.3)	0.1	0.1	19.7	-5.9
Hepatitis B	183.7 (163.9 to 205.5)	153.1 (138.2 to 167.3)	-16.5 (-27.8 to -4.7)	-38.9 (-46.9 to -30.4)	0.1	0.1	-8.2	-34.8
Hepatitis C	19.6 (18.0 to 21.0)	22.0 (20.3 to 23.7)	12.5 (0.2 to 25.9)	-25.3 (-33.1 to -16.4)	0.0	0.0	11.2	-27.9
Hepatitis E	-	-	40.5 (13.9 to 70.7)	9.9 (-10.1 to 31.9)	-	-	-	-
Leprosy	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	46.9 (-35.2 to 770.0)	-11.1 (-61.8 to 429.9)	0.0	0.0	50.7	-8.8
Other infectious diseases	15.1 (13.4 to 17.1)	18.1 (16.5 to 19.8)	19.7 (6.7 to 36.9)	-1.7 (-13.1 to 12.9)	0.4	0.6	25.9	6.1
Non-communicable diseases	-	-	-	-	359.0 (268.3 to 461.3)	522.1 (390.8 to 672.6)	45.5	0.5
Neoplasms	-	-	-	-	6.6 (5.0 to 8.6)	11.4 (8.4 to 14.9)	71.9	1.3
Esophageal cancer	0.4 (0.3 to 0.4)	0.6 (0.4 to 0.7)	63.0 (21.6 to 115.1)	-7.2 (-30.5 to 22.2)	0.1	0.1	53.1	-12.7
Stomach cancer	1.4 (1.2 to 1.6)	1.5 (1.3 to 1.8)	7.5 (9.6 to -27.4)	-38.1 (-47.8 to -26.9)	0.2	0.2	4.1	-39.8
Liver cancer	-	-	-	-	0.0	0.0	95.0	12.8
Liver cancer due to hepatitis B	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	103.3 (-3.3 to 271.7)	21.1 (-41.7 to 119.9)	0.0	0.0	92.8	14.9
Liver cancer due to hepatitis C	0.0 (0.0 to 0.1)	0.2 (0.2 to 0.3)	442.1 (238.1 to 862.4)	212.3 (93.2 to 452.3)	0.0	0.0	400.3	185.9
Liver cancer due to alcohol use	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	8.4 (-35.7 to 122.7)	-38.0 (-63.4 to 27.1)	0.0	0.0	3.7	-40.7
Liver cancer due to other causes	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-4.3 (-47.8 to 85.2)	-43.1 (-68.9 to 6.7)	0.0	0.0	-7.7	-45.3
Larynx cancer	0.5 (0.4 to 0.6)	0.8 (0.7 to 0.9)	61.5 (20.2 to 106.2)	-6.0 (-29.5 to 20.0)	0.1	0.1	31.6	-28.2
Tracheal, bronchus and lung cancer	3.0 (2.8 to 3.3)	4.4 (3.9 to 5.0)	46.2 (27.3 to 66.2)	-15.0 (-25.6 to -3.8)	0.4	0.5	37.1	-20.6
Breast cancer	20.4 (19.3 to 21.9)	28.8 (26.0 to 31.5)	40.6 (25.1 to 56.6)	-19.0 (-27.7 to -9.7)	1.1	1.5	40.7	-18.3
Cervical cancer	2.1 (1.5 to 2.4)	1.4 (1.1 to 1.8)	-33.7 (-49.1 to -6.4)	-56.3 (-66.4 to -38.1)	0.2	0.1	-32.1	-55.2
Uterine cancer	2.2 (1.8 to 2.7)	3.7 (2.9 to 4.8)	67.9 (26.0 to 126.7)	3.1 (-27.3 to 29.6)	0.1	0.2	65.6	5.4
Prostate cancer	11.3 (10.0 to 13.3)	29.3 (24.1 to 37.4)	158.7 (107.8 to 218.9)	52.3 (23.0 to 86.1)	0.9	2.4	154.2	48.2
Colon and rectum cancer	11.7 (11.1 to 12.5)	20.3 (18.1 to 22.4)	73.4 (53.1 to 95.7)	-0.2 (-11.7 to 12.3)	1.0	1.6	64.4	-5.6
Lip and oral cavity cancer	1.3 (1.1 to 1.4)	1.6 (1.3 to 2.0)	25.8 (-1.8 to 61.6)	-25.3 (-41.4 to -4.1)	0.1	0.1	22.1	-43.4 to -5.6
Nasopharynx cancer	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-9.3 (-35.9 to 32.4)	-43.9 (-61.1 to -17.9)	0.0	0.0	-11.6	-45.4
Other pharynx cancer	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	36.6 (-15.5 to 122.9)	-11.8 (51.4 to 27.4)	0.0	0.0	0.0	-37.4
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	0.1 (-26.7 to 32.9)	-42.6 (-57.5 to -25.1)	0.0	0.0	0.0	-42.4
Pancreatic cancer	0.4 (0.3 to 0.4)	0.6 (0.5 to 0.7)	62.5 (32.8 to 101.2)	-6.9 (-23.8 to 14.9)	0.1	0.1	58.3	-9.2
Malignant skin melanoma	9.3 (6.8 to 12.3)	20.6 (13.9 to 29.1)	120.1 (83.2 to 164.1)	36.7 (14.1 to 63.1)	0.5	1.2	113.6	32.1
Non-melanoma skin cancer	29.3 (22.1 to 36.9)	55.5 (44.0 to 68.4)	89.8 (34.3 to 176.3)	9.4 (-22.9 to 59.7)	6.3	11.4	94.3	11.5
Ovarian cancer	1.0 (0.9 to 1.2)	1.8 (1.2 to 1.8)	50.4 (18.8 to 89.7)	-11.5 (-30.0 to 11.2)	0.1	0.2	47.0	-13.5
Testicular cancer	1.2 (0.9 to 1.7)	1.0 (0.7 to 1.5)	-19.7 (-45.2 to 19.5)	-35.7 (-56.1 to -2.3)	0.1	0.1	-20.0	-35.9
Kidney cancer	1.5 (1.3 to 1.7)	3.5 (2.9 to 4.1)	123.7 (86.1 to 173.7)	32.1 (9.3 to 61.1)	0.1	0.2	112.4	25.6
Bladder cancer	2.7 (2.4 to 3.1)	3.7 (3.0 to 4.4)	35.5 (12.4 to 64.8)	-21.9 (-35.4 to -4.8)	0.3	0.3	27.9	-26.5
Brain and nervous system cancer	0.9 (0.7 to 1.0)	1.3 (1.0 to 1.5)	41.6 (18.7 to 69.0)	-7.7 (-22.6 to 10.5)	0.1	0.1	40.2	-9.2
Thyroid cancer	1.2 (1.0 to 1.5)	1.6 (1.2 to 1.9)	26.9 (-1.4 to 62.2)	-18.1 (-36.0 to 3.3)	0.1	0.1	24.3	-20.4
Mesothelioma	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	191.4 (30.3 to 301.6)	67.7 (-24.5 to 128.6)	0.0	0.0	184.7	63.8
Hodgkin lymphoma	0.5 (0.4 to 0.7)	0.6 (0.4 to 0.7)	7.9 (-30.8 to 44.9)	-21.1 (-50.5 to 5.1)	0.0	0.0	6.6	-24.4
Non-Hodgkin lymphoma	2.5 (1.8 to 3.7)	4.8 (3.2 to 6.1)	97.6 (12.5 to 150.7)	18.6 (-33.6 to 50.2)	0.2	0.3	85.3	11.5
Multiple myeloma	0.7 (0.5 to 1.0)	1.3 (0.9 to 2.0)	94.1 (26.5 to 198.9)	12.3 (-26.2 to 71.9)	0.1	0.3	85.6	6.8
Leukemia	2.0 (1.8 to 2.2)	3.5 (3.0 to 4.0)	79.9 (52.0 to 111.7)	11.0 (-6.4 to 31.1)	0.2	0.3	71.7	4.4
Other neoplasms	2.8 (2.4 to 3.5)	6.4 (5.1 to 7.6)	131.1 (70.0 to 190.4)	46.2 (8.6 to 81.9)	0.2	0.6	121.3	99.4
Cardiovascular diseases	-	-	-	-	6.7 (4.7 to 8.9)	11.4 (8.0 to 15.3)	71.4	1.2
Rheumatic heart disease	2.1 (1.7 to 2.6)	3.6 (3.0 to 4.3)	70.8 (28.8 to 120.8)	4.4 (-20.7 to 33.7)	0.2	0.3	49.5	-9.1
Ischemic heart disease	56.0 (46.8 to 65.5)	106.4 (90.8 to 121.3)	90.9 (51.4 to 138.3)	9.1 (-13.2 to 36.0)	2.3	2.6	82.3	4.7
Cerebrovascular disease	-	-	-	-	1.5 (1.2 to 3.5)	2.9 (2.0 to 3.9)	27.7	-25.8
Ischemic stroke	9.6 (8.5 to 10.8)	11.4 (9.5 to 13.4)	17.9 (-4.2 to 49.4)	-30.5 (-43.5 to -12.8)	2.1 (1.7 to 3.1)	2.0 (1.1 to 2.3)	20.0	-39.2 to -10.8
Hemorrhagic stroke	6.7 (5.9 to 7.5)	8.6 (7.1 to 10.1)	28.9 (3.1 to 60.3)	-22.1 (-37.0 to -3.9)	1.0 (0.7 to 1.3)	1.3 (0.8 to 1.7)	29.8	-20.8
Hypertensive heart disease	0.8 (0.7 to 1.0)	1.6 (1.4 to 1.9)	93.7 (57.3 to 142.8)	12.0 (-8.7 to 39.8)	0.1	0.2	93.7	12.2
Cardiomyopathy and myocarditis	1.0 (0.9 to 1.2)	1.9 (1.7 to 2.1)	82.9 (53.8 to 114.5)	14.6 (-2.9 to 33.7)	0.1	0.2	84.6	16.4
Atrial fibrillation and flutter	16.3 (12.3 to 20.5)	31.5 (24.7 to 38.0)	92.7 (33.8 to 190.1)	10.5 (-23.2 to 65.6)	1.3 (0.8 to 1.8)	2.4 (1.5 to 3.5)	92.7	10.5
Peripheral vascular disease	99.5 (83.6 to 118.1)	174.8 (146.4 to 202.7)	76.0 (48.5 to 107.1)	-0.1 (-15.6 to 18.4)	0.1	0.1	137.4	28.4
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	27.3 (-22.3 to 85.6)	-19.9 (-50.1 to 15.6)	0.0	0.0	30.4	-15.3
Other cardiovascular and circulatory diseases	4.3 (2.4 to 9.6)	15.0 (5.1 to 24.7)	297.0 (-3.5 to 728.8)	158.6 (-38.5 to 439.8)	0.3 (0.1 to 0.7)	1.1 (0.3 to 1.9)	294.1	159.8
Chronic respiratory diseases	-	-	-	-	32.5 (22.3 to 44.1)	45.4 (31.4 to 61.7)	32.5	2.0
Chronic obstructive pulmonary disease	208.4 (193.8 to 221.6)	329.4 (308.6 to 349.8)	58.0 (51.6 to 63.9)	-1.5 (-5.4 to 2.2)	12.7 (8.1 to 18.3)	20.4 (12.9 to 29.2)	60.0	0.3
Pneumoconiosis	-	-	-	-	0.0	0.0	55.7	-6.2

Appendix Table G.4 - New Zealand prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	42.4 (33.8 to 49.1)	-0.0 (-20.3 to -11.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.6 (31.7 to 58.1)	-43.6 (-22.2 to -60.0)
Asbestosis	-	-	-	-	-	-	-	-
Coal workers pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.3 (56.8 to 68.5)	-0.1 (-3.5 to 3.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.4 (56.7 to 68.9)	-0.2 (-3.5 to 3.9)
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.5 (65.4 to 90.7)	0.0 (1.9 to 16.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.3 (65.2 to 90.7)	7.9 (1.6 to 16.4)
Asthma	440.4 (419.7 to 460.9)	565.9 (538.0 to 592.7)	28.3 (19.9 to 37.5)	19.4 (8.8 to 5.5)	248.7 (227.7 to 277)	248.7 (216.3 to 344.7)	-1.1 (19.2 to 36.9)	-1.1 (8.8 to 5.6)
Interstitial lung disease and pulmonary sarcoidosis	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	65.6 (25.1 to 126.2)	8.0 (-19.5 to 48.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.3 (26.6 to 126.7)	8.6 (-18.4 to 48.3)
Other chronic respiratory diseases	-	-	-	-	0.4 (0.2 to 0.7)	0.2 (0.1 to 0.3)	-53.4 (-66.0 to -34.0)	-70.8 (-78.7 to -58.9)
Cirrhosis	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	1.7 (-14.8 to 21.1)	-36.1 (-45.9 to -24.7)
Cirrhosis due to hepatitis B	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-9.4 (-41.8 to 44.8)	-42.1 (-43.5 to -9.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.3 (-48.8 to 57.3)	-42.7 (-66.9 to -2.6)
Cirrhosis due to hepatitis C	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	35.4 (1.6 to 77.8)	-15.6 (36.9 to 10.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	33.5 (8.3 to 87.7)	-16.6 (-42.2 to 17.9)
Cirrhosis due to alcohol use	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-31.3 (-53.3 to -6.5)	-58.6 (-71.9 to -43.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-30.5 (-56.9 to 3.9)	-58.1 (-73.9 to -37.3)
Cirrhosis due to other causes	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	34.9 (-10.1 to 110.2)	-8.1 (-37.6 to 39.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.9 (-10.3 to 110.2)	-8.1 (-38.0 to 40.4)
Digestive diseases	-	-	-	-	5.6 (4.0 to 7.5)	9.8 (6.9 to 13.1)	72.9 (60.3 to 85.5)	13.3 (4.7 to 22.5)
Peptic ulcer disease	28.1 (25.7 to 30.3)	20.5 (19.5 to 21.5)	-27.3 (-33.8 to -17.9)	-6.6 (-64.0 to -55.8)	0.9 (0.6 to 1.3)	0.9 (0.6 to 1.3)	3.3 (-7.9 to 14.1)	-42.8 (-49.0 to -36.8)
Gastritis and duodenitis	3.5 (3.3 to 3.8)	3.3 (3.0 to 3.6)	-6.7 (-15.8 to 3.6)	-40.0 (-46.3 to -33.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	8.6 (8.5 to 30.0)	-29.6 (-41.4 to -15.2)
Appendicitis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-4.6 (-19.3 to 14.7)	-21.5 (-34.1 to -4.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-2.7 (-30.6 to 36.0)	-20.1 (-43.5 to 13.5)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	56.2 (23.1 to 90.7)	-4.6 (-24.2 to 16.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.9 (7.1 to 112.8)	-5.5 (-31.3 to 28.3)
Inguinal, femoral, and abdominal hernia	11.9 (9.9 to 14.4)	17.9 (14.8 to 21.1)	49.2 (28.6 to 76.5)	-2.5 (-24.6 to 3.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	48.4 (28.2 to 77.3)	-2.3 (-24.3 to 4.1)
Inflammatory bowel disease	13.7 (13.1 to 14.4)	26.8 (25.5 to 28.0)	94.8 (82.7 to 107.7)	30.6 (22.3 to 39.2)	2.9 (2.0 to 4.0)	5.6 (3.8 to 7.7)	94.1 (79.9 to 109.3)	30.9 (21.2 to 40.9)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	60.0 (2.9 to 129.3)	-4.9 (-38.5 to 34.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.4 (-6.4 to 154.9)	-2.7 (-41.7 to 49.9)
Gallbladder and biliary diseases	3.0 (2.7 to 3.4)	4.0 (3.6 to 4.4)	32.4 (14.7 to 53.2)	-19.9 (-30.5 to -7.4)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	31.8 (16.6 to 54.7)	-20.1 (-31.6 to -5.7)
Pancreatitis	0.8 (0.8 to 0.8)	1.2 (1.2 to 1.3)	52.2 (43.3 to 62.1)	0.2 (-5.8 to 6.4)	0.2 (0.2 to 0.3)	0.4 (0.2 to 0.5)	52.4 (32.6 to 78.1)	0.2 (-13.9 to 18.7)
Other digestive diseases	-	-	-	-	0.9 (0.6 to 1.2)	1.9 (1.3 to 2.8)	119.4 (69.1 to 171.7)	43.4 (10.4 to 78.0)
Neurological disorders	-	-	-	-	32.6 (22.4 to 43.9)	49.3 (34.3 to 65.9)	51.5 (32.8 to 69.9)	-1.2 (-13.6 to 10.4)
Alzheimer disease and other dementias	44.0 (39.3 to 49.3)	97.5 (83.2 to 109.2)	122.6 (82.2 to 158.3)	14.7 (-5.7 to 33.7)	6.5 (4.7 to 8.5)	14.7 (10.4 to 19.1)	126.5 (84.7 to 164.4)	15.2 (-4.7 to 34.6)
Parkinson disease	3.1 (2.5 to 3.8)	5.4 (4.4 to 6.4)	71.2 (59.1 to 87.0)	0.4 (-7.2 to 7.8)	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.9)	71.2 (52.6 to 90.8)	-0.2 (-10.5 to 11.2)
Epilepsy	10.2 (7.5 to 12.7)	12.7 (9.0 to 16.1)	24.9 (-16.0 to 80.8)	-6.6 (-37.0 to 35.5)	4.0 (2.5 to 5.6)	5.1 (3.3 to 7.5)	29.8 (-13.9 to 93.3)	-2.3 (-35.3 to 45.9)
Multiple sclerosis	1.0 (1.0 to 1.1)	2.4 (2.2 to 2.6)	127.2 (101.5 to 161.1)	0.3 (-33.9 to 72.7)	0.3 (0.2 to 0.4)	0.8 (0.6 to 1.0)	126.0 (84.7 to 172.9)	50.7 (23.5 to 81.4)
Migraine	447.0 (381.4 to 512.6)	528.1 (446.5 to 614.8)	18.5 (-3.0 to 44.1)	-12.4 (-28.2 to 7.4)	15.1 (8.9 to 22.8)	17.6 (10.2 to 26.9)	17.6 (-4.2 to 44.2)	-12.2 (-28.5 to 7.9)
Tension-type headache	1,059.9 (953.3 to 1,163.9)	696.8 (569.7 to 695.5)	-33.7 (-48.0 to -31.1)	-65.7 (-61.7 to -49.3)	1.5 (0.8 to 2.8)	1.0 (0.5 to 1.7)	52.4 (-47.3 to -41.4)	-55.8 (-62.3 to -49.2)
Medication overuse headache	17.4 (11.2 to 24.2)	39.3 (25.3 to 54.5)	127.9 (68.3 to 187.0)	57.9 (18.4 to 101.2)	2.7 (1.5 to 4.3)	3.7 (3.4 to 10.0)	127.5 (66.9 to 188.9)	18.1 (58.5 to 101.5)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.8 (5.4 to 94.4)	0.4 (-26.2 to 31.5)	2.0 (1.3 to 2.8)	3.2 (2.1 to 4.6)	62.5 (17.4 to 131.3)	-14.9 (-38.2 to 20.2)
Mental and substance use disorders	-	-	-	-	95.2 (67.8 to 124.4)	124.0 (88.7 to 162.0)	30.2 (26.5 to 34.0)	-0.2 (-2.8 to 2.6)
Schizophrenia	9.7 (8.9 to 10.6)	13.5 (12.3 to 14.6)	38.0 (31.7 to 44.9)	-1.9 (-6.3 to 3.4)	6.2 (4.7 to 7.5)	8.6 (6.4 to 10.3)	37.7 (29.0 to 48.3)	-1.5 (-7.9 to 5.8)
Alcohol use disorders	33.1 (30.2 to 35.8)	42.2 (38.7 to 45.6)	27.5 (21.5 to 34.3)	1.5 (-3.3 to 7.0)	3.3 (2.2 to 4.7)	4.2 (2.8 to 6.0)	17.3 (19.4 to 36.1)	27.8 (-4.7 to 9.0)
Drug use disorders	-	-	-	-	12.5 (8.7 to 16.3)	14.7 (10.1 to 19.4)	17.4 (6.9 to 30.3)	-1.8 (-10.6 to 8.8)
Opioid use disorders	11.7 (10.3 to 13.3)	14.1 (12.5 to 15.8)	20.1 (12.6 to 29.1)	-1.4 (-8.1 to 5.7)	4.9 (3.4 to 6.4)	5.8 (4.0 to 7.6)	20.4 (10.5 to 31.3)	-0.9 (-9.1 to 7.7)
Cocaine use disorders	8.0 (7.5 to 8.6)	9.6 (9.0 to 10.3)	19.6 (9.4 to 31.0)	-0.4 (-8.7 to 9.2)	1.1 (0.7 to 1.5)	1.3 (0.9 to 1.9)	19.6 (4.4 to 36.5)	-0.0 (-12.9 to 13.7)
Amphetamine use disorders	18.9 (17.6 to 20.2)	21.7 (20.4 to 23.0)	15.0 (4.9 to 25.4)	-2.8 (-11.5 to 6.0)	2.5 (1.5 to 3.6)	2.8 (1.8 to 4.1)	14.9 (1.1 to 27.4)	2.7 (-14.6 to 8.4)
Cannabis use disorders	16.2 (15.0 to 17.5)	18.6 (17.1 to 19.9)	14.8 (8.8 to 21.2)	-1.4 (-6.6 to 4.0)	0.5 (0.3 to 0.7)	0.5 (0.4 to 0.8)	15.1 (3.1 to 26.5)	-1.0 (-11.4 to 8.7)
Other drug use disorders	-	-	-	-	3.6 (2.2 to 5.2)	4.1 (2.6 to 6.0)	15.0 (-11.5 to 53.9)	-3.1 (-25.6 to 30.0)
Depressive disorders	-	-	-	-	29.5 (19.7 to 41.7)	40.1 (26.7 to 56.4)	36.0 (27.3 to 44.8)	0.1 (-6.5 to 6.5)
Major depressive disorder	117.1 (92.6 to 143.9)	159.6 (126.6 to 194.0)	36.4 (25.9 to 46.5)	-0.0 (-7.4 to 7.4)	2.7 (15.0 to 34.5)	23.8 (21.0 to 47.3)	36.0 (24.9 to 46.3)	0.3 (-7.4 to 8.1)
Dysthymia	59.1 (50.0 to 69.1)	81.1 (69.5 to 94.5)	37.1 (27.4 to 48.0)	-1.2 (-7.2 to 5.9)	5.7 (3.7 to 8.2)	7.8 (5.2 to 11.1)	36.7 (26.5 to 48.1)	-1.0 (-7.2 to 6.2)
Bipolar disorder	35.7 (31.2 to 40.2)	47.0 (40.8 to 52.8)	31.7 (25.0 to 38.8)	-0.3 (-5.2 to 4.7)	7.2 (4.5 to 10.8)	9.5 (5.9 to 14.1)	31.4 (23.5 to 39.9)	-0.2 (-6.0 to 6.2)
Anxiety disorders	234.0 (212.1 to 257.8)	308.4 (278.5 to 339.4)	31.9 (25.1 to 38.9)	0.6 (-4.2 to 5.6)	21.4 (14.6 to 29.8)	28.1 (19.2 to 39.0)	31.6 (24.6 to 38.3)	0.8 (-4.5 to 6.0)
Eating disorders	-	-	-	-	3.1 (1.8 to 4.7)	3.4 (2.0 to 5.1)	10.0 (4.9 to 15.6)	0.4 (-4.1 to 5.4)
Anorexia nervosa	1.7 (1.4 to 2.0)	2.0 (1.6 to 2.3)	16.1 (4.2 to 29.8)	3.5 (-7.0 to 15.6)	0.5 (0.2 to 0.5)	0.4 (0.3 to 0.6)	16.5 (13.1 to 36.6)	4.0 (-11.9 to 21.6)
Bulimia nervosa	12.9 (8.2 to 17.1)	14.0 (9.0 to 18.6)	8.9 (7.2 to 10.5)	-0.3 (-0.8 to 0.1)	2.7 (1.5 to 4.2)	3.0 (1.7 to 4.6)	9.2 (3.6 to 14.6)	-0.1 (-4.7 to 5.0)
Autistic spectrum disorders	-	-	-	-	4.1 (2.8 to 5.5)	5.3 (3.7 to 7.1)	29.4 (25.5 to 33.5)	0.3 (-2.7 to 3.3)
Autism	10.9 (10.4 to 11.6)	14.2 (13.5 to 15.0)	29.9 (29.1 to 30.8)	0.1 (0.1 to 0.1)	0.1 (1.8 to 3.6)	0.1 (2.3 to 4.7)	29.9 (24.2 to 35.3)	0.3 (-3.8 to 4.8)
Asperger syndrome	14.0 (13.1 to 14.9)	18.2 (17.0 to 19.4)	29.9 (28.8 to 30.9)	0.1 (0.1 to 0.2)	1.4 (1.0 to 1.9)	1.8 (1.2 to 2.5)	29.6 (24.8 to 34.6)	0.4 (-3.3 to 4.3)
Attention-deficit/hyperactivity disorder	23.9 (20.5 to 27.6)	26.6 (22.6 to 31.1)	11.8 (-1.9 to 19.8)	-0.4 (-12.6 to 6.7)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	11.5 (-4.1 to 23.4)	-0.6 (-14.4 to 10.0)
Conduct disorder	21.1 (18.1 to 24.3)	24.2 (20.7 to 27.7)	14.5 (9.6 to 19.3)	2.1 (-2.1 to 6.1)	2.5 (1.5 to 3.7)	2.9 (1.8 to 4.3)	14.6 (7.2 to 22.1)	2.2 (-4.3 to 8.8)
Idiopathic intellectual disability	11.6 (7.5 to 15.8)	11.9 (6.9 to 17.2)	2.9 (-22.0 to 29.8)	-21.3 (-39.6 to -0.9)	0.7 (0.4 to 1.0)	0.7 (0.4 to 1.1)	2.5 (-35.6 to 30.1)	-21.3 (-41.1 to 0.0)
Other mental and substance use disorders	59.5 (56.0 to 62.9)	84.1 (79.3 to 88.9)	41.4 (39.3 to 43.6)	0.3 (-0.0 to 0.5)	4.0 (3.0 to 5.9)	6.2 (4.2 to 8.3)	40.9 (32.6 to 46.3)	0.5 (-3.0 to 4.1)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	28.4 (20.1 to 37.9)	48.8 (34.1 to 66.2)	71.9 (57.0 to 88.1)	13.4 (4.1 to 23.7)
Diabetes mellitus	121.1 (96.6 to 146.0)	293.6 (249.7 to 349.8)	142.6 (86.8 to 213.0)	50.3 (16.7 to 92.9)	8.0 (5.4 to 11.4)	19.1 (12.4 to 28.1)	138.0 (82.9 to 202.1)	45.5 (12.3 to 83.3)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.6 (-8.4 to 3.3)	-23.6 (-28.6 to -19.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.6 (-8.4 to 3.4)	-23.6 (-28.6 to -19.2)
Chronic kidney disease	-	-	-	-	8.1 (5.8 to 10.9)	12.7 (9.0 to 17.0)	56.7 (46.9 to 66.4)	3.3 (-2.2 to 9.7)
Chronic kidney disease due to diabetes mellitus	97.1 (67.3 to 138.1)	249.9 (182.4 to 338.4)	159.4 (98.1 to 228.1)	61.8 (22.2 to 104.1)	2.3 (1.6 to 3.3)	6.0 (4.2 to 8.4)	164.0 (109.4 to 221.6)	64.1 (30.8 to 96.7)
Chronic kidney disease due to hypertension	69.4 (42.3 to 111.2)	95.5 (60.7 to 149.1)	35.8 (2.2 to 91.5)	-4.7 (-29.1 to 30.8)	1.6 (1.1 to 2.5)	1.6 (1.0 to 2.3)	-0.0 (-24.9 to 34.5)	-34.2 (-50.7 to -13.0)
Chronic kidney disease due to glomerulonephritis	80.3 (51.8 to 119.9)	84.9 (63.6 to 112.6)	7.5 (-20.0 to 39.9)	-26.3 (-44.7 to -4.0)	1.8 (1.2 to 2.6)	2.7 (1.9 to 3.8)	52.5 (15.8 to 103.8)	9.7 (-15.9 to 47.1)
Chronic kidney disease due to other causes	112.3 (77.8 to 153.1)	112.8 (79.9 to 149.2)	0.4 (-17.6 to 24.3)	-39.9 (-43.2 to -14.1)	2.4 (1.7 to 3.4)	2.4 (1.7 to 3.4)	31.9 (-24.7 to 23.8)	-32.5 (-46.5 to -14.3)
Urinary diseases and male infertility	-	-	-	-	2.8 (1.7 to 4.0)	5.1 (3.3 to 7.4)	84.2 (51.2 to 127.3)	8.6 (-10.9 to 32.9)
Interstitial nephritis and urinary tract infections	0.8 (0.7 to 0.9)	1.3 (1.2 to 1.5)	70.4 (41.0 to 104.0)	21.3 (1.3 to 45.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	70.2 (31.0 to 119.6)	21.9 (6.1 to 59.1)

Appendix Table G.4 - New Zealand prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Urolithiasis	17.4 (11.9 to 26.9)	28.6 (19.5 to 44.9)	67.1 (37.5 to 91.4)	-0.5 (-19.5 to 14.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	55.0 (32.3 to 75.2)	-4.0 (-19.0 to 8.2)
Benign prostatic hyperplasia	70.7 (59.4 to 82.4)	132.8 (114.8 to 152.3)	87.4 (50.9 to 136.8)	8.9 (-12.6 to 37.3)	2.5 (1.6 to 3.7)	4.7 (3.1 to 7.0)	87.4 (50.9 to 137.3)	9.2 (-12.0 to 38.0)
Male infertility due to other causes	7.1 (4.8 to 9.3)	8.2 (5.5 to 11.0)	19.5 (-32.9 to 77.0)	8.3 (-39.5 to 61.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	21.3 (-35.5 to 87.3)	10.0 (-41.6 to 69.0)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	42.9 (7.5 to 95.9)	-10.3 (-32.8 to 22.1)
Gynecological diseases	-	-	-	-	4.7 (3.1 to 6.9)	5.8 (3.7 to 8.8)	24.6 (4.1 to 44.1)	-3.2 (-19.8 to 12.6)
Uterine fibroids	92.4 (81.8 to 104.1)	141.1 (125.9 to 157.5)	52.6 (49.8 to 55.8)	3.6 (3.4 to 3.7)	0.8 (0.4 to 1.5)	1.3 (0.7 to 2.3)	54.0 (41.0 to 69.4)	8.7 (-0.6 to 19.6)
Polycystic ovarian syndrome	64.3 (58.1 to 69.8)	83.1 (75.9 to 89.9)	29.1 (13.6 to 46.4)	4.3 (-8.7 to 18.4)	0.6 (0.3 to 1.1)	0.8 (0.4 to 1.4)	29.6 (13.8 to 45.5)	5.2 (-7.8 to 18.4)
Female infertility due to other causes	0.4 (0.3 to 0.9)	0.5 (0.3 to 1.3)	20.9 (-47.3 to 237.9)	4.0 (-54.5 to 186.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.8 (-45.1 to 214.0)	8.6 (-53.4 to 161.7)
Endometriosis	12.0 (10.4 to 13.6)	14.4 (12.1 to 15.5)	14.4 (-4.4 to 40.7)	7.9 (-23.3 to 13.2)	1.1 (0.7 to 1.5)	1.3 (0.8 to 1.8)	14.6 (5.0 to 40.5)	14.6 (-23.5 to 13.9)
Genital prolapse	146.8 (123.9 to 168.9)	221.4 (190.2 to 254.8)	51.0 (20.5 to 88.8)	2.7 (-19.5 to 29.5)	0.5 (0.2 to 0.9)	0.7 (0.3 to 1.3)	51.3 (19.2 to 90.0)	3.0 (-19.5 to 29.4)
Premenstrual syndrome	180.9 (133.0 to 231.6)	187.8 (122.7 to 255.2)	6.9 (-39.9 to 62.8)	-10.6 (-52.5 to 37.9)	1.5 (0.9 to 2.4)	1.6 (0.8 to 2.7)	6.6 (-40.6 to 65.0)	-10.8 (-52.8 to 39.7)
Other gynecological diseases	7.7 (7.0 to 8.4)	9.7 (8.7 to 11.6)	25.8 (9.5 to 53.2)	-1.2 (-13.3 to 15.9)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.4)	32.0 (-1.5 to 92.5)	0.3 (-24.5 to 37.5)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	3.7 (2.5 to 5.4)	4.7 (3.1 to 6.8)	25.6 (17.2 to 35.2)	-0.6 (-6.7 to 7.5)
Thalassemias	0.4 (0.4 to 0.4)	0.4 (0.4 to 0.5)	14.0 (8.2 to 19.8)	0.3 (-4.7 to 5.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	33.5 (3.4 to 115.2)	18.1 (-15.7 to 93.9)
Thalassemia trait	129.2 (125.2 to 133.6)	168.8 (163.2 to 174.5)	30.7 (26.5 to 34.9)	-1.3 (-4.3 to 1.9)	3.3 (2.2 to 4.7)	4.1 (2.7 to 6.0)	24.4 (15.5 to 33.7)	-1.9 (-8.3 to 5.8)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.8 (-12.4 to 50.0)	6.3 (-25.9 to 27.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.9 (-6.3 to 46.6)	3.6 (-20.1 to 24.5)
Sickle cell trait	4.8 (4.6 to 5.1)	5.9 (5.4 to 6.1)	21.5 (11.1 to 29.4)	-8.2 (-15.9 to -2.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-7.7 (-4.2 to 33.4)	-27.3 (-55.6 to 6.2)
G6PD deficiency	4.4 (3.3 to 5.6)	5.1 (3.9 to 6.6)	16.4 (-17.4 to 74.6)	-12.1 (-37.6 to 31.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.2 (-3.8 to 82.6)	9.3 (-22.1 to 56.7)
G6PD trait	151.4 (131.5 to 168.9)	264.6 (236.7 to 290.8)	74.3 (48.3 to 108.2)	31.0 (11.5 to 56.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.4 (-53.2 to 245.7)	16.2 (-62.0 to 196.3)
Other hemoglobinopathies and hemolytic anemias	18.1 (16.8 to 19.4)	25.9 (23.9 to 27.7)	42.9 (29.3 to 58.8)	4.3 (-5.8 to 16.3)	0.3 (0.2 to 0.5)	0.3 (0.3 to 0.7)	39.3 (14.3 to 73.1)	11.4 (-8.0 to 36.3)
Endocrine, metabolic, blood, and immune disorders	34.8 (32.6 to 37.0)	46.7 (44.2 to 49.1)	34.3 (23.8 to 45.6)	-2.5 (-9.8 to 5.6)	1.1 (0.7 to 1.5)	1.5 (1.0 to 2.1)	35.9 (22.5 to 52.8)	-0.6 (-10.4 to 11.7)
Musculoskeletal disorders	-	-	-	-	94.8 (67.3 to 124.9)	141.4 (100.7 to 186.5)	49.3 (39.5 to 59.7)	0.5 (-6.5 to 7.8)
Rheumatoid arthritis	20.8 (19.8 to 21.7)	33.7 (32.2 to 35.2)	62.5 (52.1 to 74.9)	-1.2 (-7.2 to 6.2)	4.8 (3.4 to 6.2)	7.7 (5.5 to 10.2)	62.4 (51.3 to 75.2)	-0.5 (-7.3 to 7.3)
Osteoarthritis	123.2 (118.0 to 128.3)	220.0 (211.8 to 228.5)	78.7 (69.3 to 88.8)	2.5 (-2.9 to 8.3)	4.2 (2.8 to 6.2)	7.6 (5.0 to 10.9)	78.5 (68.6 to 88.7)	2.7 (-2.9 to 8.7)
Low back and neck pain	-	-	-	-	69.2 (47.6 to 93.0)	98.7 (68.8 to 133.0)	42.8 (29.2 to 56.3)	-1.1 (-10.9 to 8.7)
Low back pain	431.6 (405.9 to 458.0)	634.4 (598.6 to 674.8)	47.4 (34.0 to 60.1)	1.4 (-7.8 to 10.5)	47.9 (32.3 to 65.7)	70.1 (47.2 to 97.2)	46.7 (33.3 to 60.0)	1.7 (-7.8 to 10.9)
Neck pain	217.5 (183.2 to 257.8)	292.3 (238.0 to 341.9)	35.0 (5.5 to 67.3)	-9.9 (-26.7 to 15.6)	21.3 (14.3 to 30.5)	28.5 (18.7 to 40.6)	34.9 (5.3 to 67.1)	-6.4 (-26.6 to 16.1)
Gout	18.9 (17.8 to 19.9)	31.7 (29.9 to 33.7)	67.8 (55.4 to 82.7)	0.8 (-6.6 to 9.7)	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.3)	67.6 (48.8 to 88.5)	1.2 (-10.2 to 13.5)
Other musculoskeletal disorders	175.2 (156.4 to 193.3)	289.3 (256.7 to 320.7)	65.4 (51.9 to 77.6)	6.9 (-1.4 to 14.4)	16.0 (10.8 to 22.2)	26.4 (18.2 to 36.8)	65.7 (51.7 to 78.1)	7.4 (-0.8 to 15.5)
Other non-communicable diseases	-	-	-	-	56.4 (38.5 to 79.7)	80.5 (55.2 to 113.4)	42.8 (39.2 to 47.2)	4.3 (-6.9 to -1.5)
Congenital anomalies	-	-	-	-	5.3 (3.7 to 7.0)	7.5 (5.2 to 10.1)	42.2 (22.9 to 68.7)	5.5 (-9.2 to 25.5)
Neural tube defects	1.5 (1.3 to 1.8)	1.7 (1.5 to 1.9)	9.2 (-11.5 to 31.5)	-13.2 (-29.6 to 4.3)	0.5 (0.3 to 0.7)	0.5 (0.4 to 0.7)	9.3 (-21.6 to 45.5)	-12.7 (-36.6 to 16.5)
Congenital heart anomalies	31.4 (27.2 to 36.9)	38.2 (32.7 to 46.4)	21.4 (-2.7 to 49.3)	-6.7 (-25.2 to 14.4)	1.1 (0.5 to 1.9)	2.4 (0.6 to 2.4)	22.6 (-0.0 to 50.5)	-4.8 (-22.3 to 16.3)
Orofacial clefts	4.7 (4.0 to 5.4)	5.8 (4.7 to 7.1)	24.5 (-1.9 to 63.7)	-5.0 (-25.2 to 24.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	22.4 (-1.0 to 74.2)	-6.0 (-32.9 to 34.0)
Down syndrome	3.7 (3.2 to 4.3)	4.4 (4.5 to 6.7)	16.4 (17.0 to 90.4)	5.8 (-17.2 to 35.1)	0.5 (0.4 to 0.7)	0.8 (0.6 to 1.1)	5.5 (25.8 to 105.2)	57.7 (-15.9 to 37.7)
Turner syndrome	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	29.8 (-12.5 to 119.0)	1.7 (-31.5 to 71.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.2 (-17.1 to 112.8)	1.0 (-34.2 to 68.4)
Klinefelter syndrome	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	60.6 (5.9 to 138.4)	22.7 (-19.0 to 82.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.6 (-5.8 to 154.9)	22.2 (-25.4 to 104.0)
Chromosomal unbalanced rearrangements	7.5 (6.2 to 9.5)	10.7 (9.4 to 12.6)	44.1 (10.1 to 85.0)	2.0 (-22.4 to 21.6)	1.1 (0.7 to 1.4)	1.6 (1.2 to 2.1)	54.2 (16.1 to 102.8)	3.2 (-21.9 to 35.2)
Other congenital anomalies	7.0 (5.9 to 8.0)	8.2 (7.0 to 9.5)	18.0 (5.6 to 30.8)	18.9 (-22.6 to -4.7)	2.0 (1.3 to 2.9)	3.1 (1.9 to 4.7)	16.7 (15.7 to 102.9)	16.7 (-11.2 to 57.2)
Skin and subcutaneous diseases	-	-	-	-	20.6 (13.7 to 30.7)	27.6 (18.5 to 40.5)	33.9 (26.9 to 41.6)	0.4 (-4.5 to 5.5)
Dermatitis	212.4 (177.4 to 246.9)	276.0 (231.5 to 318.0)	30.0 (27.1 to 32.9)	-0.1 (-0.2 to 0.0)	6.0 (3.9 to 8.5)	7.7 (5.1 to 11.1)	29.6 (25.9 to 33.8)	0.1 (-2.2 to 2.5)
Psoriasis	55.0 (49.5 to 60.9)	78.0 (70.1 to 86.0)	41.9 (38.6 to 45.3)	-0.1 (-0.2 to 0.0)	4.4 (3.3 to 6.2)	6.3 (4.2 to 8.7)	41.5 (35.3 to 48.1)	0.2 (-3.7 to 4.0)
Cellulitis	1.7 (1.4 to 2.2)	2.5 (2.1 to 3.3)	49.4 (36.6 to 65.3)	-0.2 (-8.5 to 9.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	48.5 (26.8 to 77.0)	0.4 (-1.4 to 19.4)
Pyoderma	2.2 (1.7 to 2.9)	3.4 (2.6 to 4.6)	55.7 (43.1 to 70.8)	0.0 (-6.2 to 20.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.5 (35.0 to 75.9)	13.1 (-0.1 to 26.8)
Scabies	2.5 (2.1 to 3.2)	2.4 (2.0 to 2.8)	-27.5 (-30.4 to 20.4)	-27.5 (-45.8 to -6.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-6.3 (-29.6 to 22.2)	-27.2 (-44.9 to -4.7)
Fungal skin diseases	222.5 (185.1 to 260.0)	316.2 (266.1 to 362.8)	42.2 (38.0 to 46.5)	0.1 (-0.1 to 0.2)	1.2 (0.5 to 2.6)	1.8 (0.7 to 3.7)	41.7 (37.3 to 46.5)	0.2 (-0.8 to 1.1)
Viral skin diseases	75.7 (59.6 to 91.6)	92.4 (74.3 to 110.8)	22.0 (18.2 to 28.4)	-0.2 (-2.0 to 2.0)	2.3 (1.4 to 3.7)	2.8 (1.7 to 4.2)	21.9 (17.1 to 28.8)	-0.1 (-3.2 to 3.4)
Acne vulgaris	278.6 (225.5 to 331.8)	293.8 (249.0 to 344.3)	4.9 (-15.6 to 37.9)	-7.8 (-25.3 to 11.7)	3.0 (1.4 to 5.6)	3.2 (1.5 to 6.1)	4.9 (-15.4 to 38.2)	-7.9 (-25.4 to 22.0)
Alopecia areata	5.5 (5.1 to 5.9)	7.9 (7.2 to 8.6)	44.6 (27.9 to 61.4)	-0.5 (-11.1 to 11.1)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	43.9 (24.7 to 63.8)	-0.0 (-13.5 to 13.2)
Pruritus	1.4 (1.1 to 1.7)	2.1 (1.6 to 2.7)	53.0 (3.5 to 127.6)	-2.0 (-33.3 to 44.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.4 (1.1 to 126.0)	-1.7 (-35.2 to 44.0)
Urticaria	26.6 (19.0 to 34.4)	48.6 (31.5 to 57.9)	85.2 (44.4 to 149.5)	16.0 (-20.2 to 76.4)	1.6 (0.9 to 2.3)	2.6 (1.5 to 4.0)	64.9 (40.0 to 150.2)	16.0 (-20.3 to 78.5)
Decubitus ulcer	1.8 (1.5 to 2.2)	3.1 (2.6 to 3.7)	69.2 (29.7 to 120.2)	-3.0 (-25.3 to 25.3)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	67.2 (25.5 to 122.8)	-2.8 (-25.8 to 27.8)
Other skin and subcutaneous diseases	245.0 (146.5 to 406.6)	384.9 (219.9 to 655.2)	56.6 (43.9 to 67.4)	0.3 (-2.2 to 4.0)	1.4 (0.6 to 3.1)	2.2 (0.9 to 5.2)	56.3 (43.6 to 67.1)	0.6 (-2.5 to 4.4)
Sense organ diseases	-	-	-	-	19.5 (12.9 to 28.0)	29.6 (19.8 to 42.4)	52.4 (46.9 to 58.4)	-9.1 (-12.4 to -5.6)
Glaucoma	7.2 (6.2 to 8.3)	8.5 (7.1 to 10.0)	17.9 (2.0 to 34.3)	32.5 (-41.2 to 23.3)	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.8)	24.1 (5.8 to 42.7)	-29.4 (-39.7 to -19.4)
Cataract	4.1 (3.1 to 5.0)	4.9 (3.8 to 6.2)	18.9 (-10.7 to 71.1)	35.1 (-50.9 to -6.1)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	31.4 (3.7 to 74.6)	29.2 (43.9 to -5.8)
Macular degeneration	4.6 (3.8 to 5.7)	12.6 (10.1 to 15.2)	172.0 (118.4 to 238.6)	47.4 (18.8 to 80.6)	0.3 (0.2 to 0.5)	0.7 (0.5 to 1.0)	118.3 (83.0 to 157.7)	14.4 (-4.5 to 35.1)
Uncorrected refractive error	257.7 (228.1 to 286.6)	401.7 (349.8 to 445.6)	55.9 (35.3 to 82.7)	-3.3 (-16.6 to 13.6)	3.5 (2.0 to 5.9)	5.2 (2.9 to 8.6)	46.0 (30.6 to 64.9)	-8.2 (-17.8 to 4.0)
Age-related and other hearing loss	478.1 (457.5 to 501.5)	733.0 (704.6 to 768.7)	53.2 (48.7 to 58.3)	-9.0 (-11.6 to -5.8)	12.2 (8.1 to 17.3)	19.4 (13.1 to 27.3)	59.4 (51.1 to 67.8)	-8.7 (-13.2 to -4.3)
Other vision loss	14.8 (13.1 to 16.5)	14.0 (12.1 to 16.1)	-4.7 (-15.7 to 4.8)	-41.2 (-47.3 to -35.7)	0.7 (0.4 to 0.9)	0.6 (0.4 to 0.9)	2.6 (-13.2 to 8.0)	-40.7 (-46.9 to -34.5)
Other sense organ diseases	78.6 (75.4 to 81.9)	108.3 (103.0 to 113.2)	37.9 (29.1 to 46.2)	-0.2 (-6.5 to 5.6)	2.1 (1.3 to 3.1)	2.8 (1.8 to 4.2)	36.9 (27.5 to 46.3)	-0.1 (-7.0 to 6.8)
Oral disorders	-	-	-	-	11.0 (7.2 to 15.9)	15.7 (10.2 to 22.6)	42.6 (34.5 to 52.7)	-10.7 (-15.7 to -4.3)
Deciduous caries	110.1 (107.9 to 112.4)	125.0 (122.0 to 127.8)	13.5 (10.0 to 17.1)	0.8 (-2.3 to 4.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	13.8 (30.6 to 26.7)	1.0 (-7.9 to 12.5)
Permanent caries	889.9 (815.1 to 885.4)	1,175.2 (1,133.7 to 1,214.4)	38.3 (31.2 to 46.6)	38.3 (0.4 to 12.1)	0.7 (0.4 to 1.1)	0.7 (0.3 to 1.3)	37.9 (30.6 to 46.1)	5.7 (0.4 to 12.3)
Periodontal diseases	167.3 (157.8 to 177.9)	274.6 (260.0 to 289.1)	64.1 (52.8 to 76.2)	4.7 (-2.6 to 12.3)	1.1 (0.4 to 2.2)	1.8 (0.7 to 3.6)	63.9 (52.3 to 76.2)	4.7 (-2.6 to 12.6)
Edentulism and severe tooth loss	276.6 (260.7 to 292.7)	392.4 (365.8 to						

Appendix Table G.4 - New Zealand prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	61.7 (58.5 to 64.9)	84.4 (79.8 to 88.8)	37.1 (26.6 to 47.2)	-4.4 (-7.6 to 6.9)	1.8 (1.1 to 2.7)	2.5 (1.5 to 3.7)	36.9 (26.3 to 47.0)	-0.1 (-7.6 to 7.5)
Injuries	-	-	-	-	24.8 (18.9 to 32.0)	25.0 (18.0 to 33.8)	0.5 (-9.0 to 11.3)	-36.3 (-42.2 to -29.5)
Transport injuries	-	-	-	-	7.6 (5.7 to 9.8)	5.2 (3.7 to 6.9)	-32.2 (-39.0 to -24.0)	-55.1 (-59.4 to -49.8)
Road injuries	-	-	-	-	6.6 (5.0 to 8.4)	4.1 (3.0 to 5.5)	-37.2 (-43.8 to -29.0)	-58.1 (-62.3 to -52.6)
Pedestrian road injuries	-	-	-	-	0.6 (0.6 to 1.1)	0.6 (0.4 to 0.9)	-22.7 (-30.8 to -13.4)	-49.4 (-55.0 to -43.8)
Cyclist road injuries	-	-	-	-	0.6 (0.4 to 0.7)	0.3 (0.2 to 0.4)	-50.8 (-57.6 to -43.1)	-65.7 (-70.4 to -60.2)
Motorcyclist road injuries	-	-	-	-	1.3 (1.0 to 1.7)	0.6 (0.5 to 0.9)	-50.8 (-58.6 to -41.9)	-66.7 (-71.8 to -60.8)
Motor vehicle road injuries	-	-	-	-	3.9 (2.9 to 4.9)	2.6 (1.9 to 3.4)	-33.8 (-40.1 to -26.1)	-55.9 (-60.1 to -50.8)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.9 (-33.5 to -11.4)	-49.4 (-55.7 to -41.2)
Other transport injuries	-	-	-	-	1.0 (0.8 to 1.4)	1.0 (0.7 to 1.4)	-0.7 (-9.2 to 8.8)	-36.0 (-41.4 to -29.9)
Unintentional injuries	-	-	-	-	16.8 (12.8 to 21.6)	19.5 (13.9 to 26.3)	15.2 (4.7 to 27.1)	-27.8 (-34.3 to -20.4)
Falls	-	-	-	-	10.3 (7.9 to 13.2)	12.7 (9.0 to 16.9)	22.3 (9.0 to 37.8)	-26.5 (-34.3 to -17.1)
Drowning	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-9.1 (-20.8 to 2.6)	-39.6 (-47.7 to -32.0)
Fire, heat, and hot substances	-	-	-	-	0.6 (0.4 to 1.0)	0.7 (0.4 to 1.2)	17.7 (3.2 to 32.9)	-20.9 (-30.3 to -10.5)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.7 (-16.5 to 15.8)	-29.2 (-40.6 to -17.1)
Exposure to mechanical forces	-	-	-	-	4.7 (3.5 to 6.1)	4.4 (3.2 to 6.0)	-5.4 (-13.6 to 4.4)	-35.3 (-40.8 to -28.9)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-11.0 (-22.1 to -0.1)	-37.5 (-44.9 to -30.1)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	57.1 (36.6 to 77.4)	7.6 (5.4 to 21.5)
Other exposure to mechanical forces	-	-	-	-	4.6 (3.4 to 6.0)	4.3 (3.1 to 5.9)	-5.7 (-13.7 to 4.2)	-35.5 (-41.0 to -29.1)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	56.6 (43.9 to 71.8)	2.7 (5.0 to 12.3)
Animal contact	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	31.6 (21.9 to 41.8)	-11.9 (-18.2 to -5.2)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	22.6 (10.3 to 35.8)	-15.0 (-23.8 to -6.3)
Non-venomous animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	33.7 (23.6 to 44.7)	-11.1 (-17.6 to -4.0)
Foreign body	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	11.9 (1.3 to 21.1)	-19.8 (-29.0 to -12.4)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.2 (-12.5 to 13.2)	-31.1 (-40.0 to -22.0)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	20.0 (8.1 to 33.7)	-10.7 (-20.5 to 0.2)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	11.1 (0.6 to 21.8)	-21.2 (-30.8 to -13.2)
Other unintentional injuries	-	-	-	-	0.6 (0.4 to 0.9)	0.9 (0.6 to 1.2)	41.1 (31.0 to 51.9)	-12.6 (-18.8 to -6.1)
Self-harm and interpersonal violence	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	2.0 (-6.6 to 11.6)	-32.8 (-38.5 to -26.7)
Self-harm	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	29.3 (15.7 to 44.0)	-15.1 (-24.1 to -5.5)
Interpersonal violence	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-31.7 (-38.4 to -24.6)	-54.6 (-59.0 to -50.0)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.4 (-44.7 to -32.2)	-59.4 (-63.3 to -55.3)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.5 (-14.9 to 2.2)	-38.1 (-42.7 to -31.5)
Assault by other means	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-35.2 (-42.3 to -27.1)	-57.0 (-61.7 to -51.5)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76,655.9 (14,901.6 to 263,858.8)	71,398.9 (13,115.1 to 263,258.0)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76,655.9 (14,901.6 to 263,858.8)	71,398.9 (13,115.1 to 263,258.0)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Nicaragua prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	653.4 (429.9 to 935.3)	622.6 (454.8 to 799.3)	-3.1 (-26.1 to 21.0)	-1.1 (-59.4 to -35.1)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	49.1 (34.4 to 68.3)	55.1 (39.1 to 76.3)	12.4 (5.2 to 21.2)	-7.8 (-14.9 to 0.3)
HIV/AIDS and tuberculosis	-	-	-	-	0.6 (0.4 to 0.8)	1.9 (1.1 to 2.9)	204.7 (127.4 to 358.3)	68.4 (26.7 to 149.5)
Tuberculosis	2.1 (2.0 to 2.2)	3.0 (2.9 to 3.1)	45.3 (40.5 to 49.7)	-20.6 (-23.3 to -18.1)	0.6 (0.4 to 0.8)	0.9 (0.6 to 1.2)	58.1 (39.1 to 81.0)	-9.6 (-19.1 to 2.8)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.1)	1.0 (0.4 to 1.9)	3,889.4 (1,657.5 to 25,667.4)	1,915.3 (751.8 to 32,723.8)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	2,832.6 (1,263.3 to 19,175.5)	1,348.5 (547.6 to 9,557.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,832.6 (1,261.8 to 19,687.2)	1,348.5 (544.9 to 793.3)
HIV/AIDS resulting in other diseases	0.2 (0.0 to 0.4)	10.1 (5.9 to 16.2)	5,599.6 (2,906.5 to 28,094.2)	3,012.4 (1,544.0 to 15,443.9)	0.0 (0.0 to 0.1)	1.0 (0.4 to 1.9)	3,917.7 (1,655.1 to 29,591.8)	1,926.9 (748.7 to 15,752.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	11.5 (8.2 to 15.6)	11.0 (7.8 to 15.1)	-4.2 (-10.7 to 3.7)	-15.3 (-20.6 to -9.6)
Diarrheal diseases	41.3 (39.2 to 43.4)	36.8 (34.6 to 38.9)	-11.1 (-17.4 to -3.7)	-13.1 (-19.0 to -6.6)	6.7 (4.5 to 9.4)	6.0 (4.0 to 8.3)	-11.5 (-18.1 to -3.2)	-12.1 (-18.7 to -4.4)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.3 to -10.2	(-61.3 to -33.1)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.2 (-28.3 to 8.7)	-34.6 (-45.7 to -19.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.2 (-28.3 to 9.1)	-34.6 (-45.7 to -19.1)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.5 (-28.4 to 10.9)	-31.7 (-45.0 to -14.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.5 (-28.4 to 11.1)	-31.7 (-45.1 to -14.5)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-88.4 (-97.9 to -59.9)	-91.2 (-98.4 to -54.3)
Lower respiratory infections	4.3 (3.3 to 5.6)	4.5 (3.6 to 5.5)	5.1 (-22.2 to 44.0)	-7.7 (-26.4 to 25.8)	0.4 (0.3 to 0.7)	0.5 (0.3 to 0.7)	4.3 (-23.1 to 46.9)	-3.0 (-24.8 to 35.3)
Upper respiratory infections	143.5 (133.7 to 153.5)	205.7 (190.4 to 221.3)	43.5 (29.7 to 57.8)	2.0 (-7.6 to 11.6)	1.6 (0.9 to 2.7)	2.4 (1.4 to 4.1)	45.9 (32.2 to 61.1)	7.0 (-3.3 to 18.4)
Otitis media	57.5 (54.1 to 61.2)	68.1 (63.9 to 72.6)	18.5 (10.6 to 26.2)	-12.3 (-17.8 to -6.7)	1.1 (0.6 to 1.8)	1.3 (0.7 to 2.0)	17.6 (8.4 to 28.0)	-10.2 (-16.9 to -2.2)
Meningitis	-	-	-	-	1.3 (0.8 to 1.9)	0.7 (0.5 to 0.9)	-47.2 (-59.8 to -28.5)	-61.0 (-69.5 to -48.6)
Pneumococcal meningitis	6.1 (3.8 to 9.0)	3.2 (1.9 to 4.9)	-47.6 (-58.2 to -36.9)	-64.6 (-71.4 to -57.8)	0.6 (0.4 to 0.9)	0.3 (0.2 to 0.4)	-50.1 (-64.5 to -28.7)	-63.1 (-72.9 to -47.9)
H influenzae type B meningitis	2.8 (0.9 to 5.5)	1.3 (0.5 to 2.6)	-53.8 (-66.1 to -38.4)	-68.7 (-75.6 to -57.7)	0.3 (0.2 to 0.6)	0.2 (0.1 to 0.2)	-50.9 (-71.4 to -25.1)	-64.4 (-79.3 to -46.8)
Meningococcal meningitis	0.4 (0.2 to 1.0)	0.3 (0.1 to 0.6)	-40.7 (-56.7 to -21.3)	-60.4 (-69.9 to -47.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-41.4 (-60.6 to -4.9)	-58.3 (-70.8 to -35.6)
Other meningitis	2.3 (1.1 to 4.2)	1.4 (0.7 to 2.5)	-39.5 (-56.4 to -22.5)	-57.4 (-68.1 to -44.1)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-36.2 (-61.0 to 10.1)	-52.2 (-69.5 to -26.1)
Encephalitis	0.4 (0.2 to 0.9)	0.7 (0.3 to 1.6)	74.9 (55.4 to 100.2)	74.9 (61.1 to 127.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	79.6 (51.0 to 120.9)	12.0 (-0.3 to 40.5)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-75.8 (-98.3 to 407.4)	-77.3 (-98.1 to 225.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-75.8 (-98.3 to 410.0)	-77.3 (-98.2 to 226.7)
Whooping cough	3.1 (2.4 to 3.9)	0.2 (0.2 to 0.3)	-92.6 (-93.7 to -91.3)	-92.2 (-93.4 to -90.9)	0.2 (0.1 to 0.3)	0.0 (0.0 to 0.0)	-92.5 (-94.6 to -90.0)	-92.1 (-94.4 to -89.6)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.8 (-98.9 to -96.1)	-98.4 (-99.2 to -96.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-96.1 (-98.1 to -91.6)	-97.0 (-98.5 to -94.0)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to 0.0)	-100.0 (-100.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.7 (-100.0 to nan)	-99.7 (-100.0 to nan)
Varicella and herpes zoster	3.6 (3.3 to 3.8)	4.2 (3.8 to 4.7)	18.3 (4.7 to 35.0)	0.2 (-15.9 to 19.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	78.8 (32.3 to 146.7)	11.4 (-19.0 to 54.4)
Neglected tropical diseases and malaria	-	-	-	-	6.4 (4.0 to 9.5)	5.6 (3.7 to 8.4)	-11.5 (-38.1 to 34.1)	-27.6 (-49.6 to 10.3)
Malaria	21.0 (14.3 to 28.4)	35.7 (25.5 to 52.2)	65.5 (28.5 to 142.5)	26.4 (-2.0 to 75.2)	0.4 (0.2 to 0.6)	0.6 (0.4 to 1.1)	59.9 (12.6 to 132.5)	36.4 (-2.5 to 95.0)
Chagas disease	37.2 (35.2 to 39.3)	59.6 (56.4 to 63.3)	60.0 (47.8 to 73.9)	1.8 (-8.9 to 6.1)	0.2 (0.0 to 0.1)	0.5 (0.3 to 0.7)	113.3 (87.6 to 146.3)	11.3 (4.4 to 31.3)
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	144.1 (99.5 to 196.4)	88.6 (60.2 to 130.6)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.7 (-21.4 to 73.8)	-0.8 (-31.2 to 41.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.7 (-21.5 to 74.1)	-0.8 (-31.2 to 41.6)
Cutaneous and mucocutaneous leishmaniasis	3.4 (2.5 to 4.6)	8.1 (6.3 to 10.5)	140.4 (100.8 to 179.0)	75.8 (52.0 to 111.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	144.7 (99.9 to 198.4)	89.0 (60.4 to 131.6)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	4.3 (1.4 to 7.6)	3.3 (0.9 to 7.8)	-23.8 (-84.1 to 163.3)	-51.1 (-87.9 to 40.6)	1.1 (0.3 to 2.1)	1.0 (0.3 to 2.4)	-9.8 (-81.9 to 217.7)	-40.9 (-86.9 to 83.1)
Cystic echinococcosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	78.3 (66.1 to 125.5)	-8.8 (-16.3 to 14.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.4 (52.5 to 155.3)	1.7 (-21.1 to 39.5)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	1.0 (0.4 to 2.3)	7.2 (2.8 to 16.1)	612.2 (608.9 to 616.0)	390.5 (388.2 to 393.1)	0.2 (0.1 to 0.4)	1.2 (0.4 to 2.8)	632.0 (504.2 to 807.1)	423.0 (346.7 to 518.6)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-80.1 to -55.2	(-81.5 to -67.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-72.0 (-80.1 to -55.2)	-76.1 (-81.5 to -67.2)
Intestinal nematode infections	-	-	-	-	2.5 (1.2 to 4.8)	0.6 (0.3 to 1.1)	-76.8 (-86.4 to -58.7)	-77.7 (-87.2 to -60.9)
Ascariasis	647.1 (532.2 to 796.5)	456.4 (273.2 to 726.0)	-31.4 (-58.1 to 16.5)	-50.0 (-70.5 to -9.8)	1.8 (0.8 to 3.6)	0.2 (0.1 to 0.4)	-90.5 (-95.9 to -77.3)	-90.0 (-95.8 to -75.7)
Trichuriasis	749.1 (626.5 to 890.4)	566.2 (347.5 to 892.9)	-26.2 (-56.4 to 23.1)	-47.3 (-69.6 to -8.8)	0.6 (0.3 to 1.1)	0.3 (0.1 to 0.6)	-55.7 (-80.1 to 6.0)	-64.9 (-85.5 to -15.2)
Hookworm disease	39.7 (32.4 to 48.5)	47.5 (28.5 to 71.8)	18.0 (-30.1 to 95.4)	-19.3 (-52.7 to 38.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	9.6 (-42.8 to 93.0)	-18.1 (-50.7 to 41.2)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	51.3 (38.6 to 64.3)	50.2 (42.2 to 57.1)	-1.4 (-23.7 to 32.7)	-13.4 (-31.3 to 12.2)	1.9 (1.2 to 2.8)	1.7 (1.1 to 2.5)	-11.8 (-32.9 to 34.5)	-20.0 (-39.0 to 20.3)
Maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	5.6 (-17.5 to 45.8)	-40.5 (-53.6 to -19.3)
Maternal hemorrhage	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	50.9 (9.4 to 126.6)	-13.5 (-37.6 to 32.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.9 (-34.2 to 385.6)	18.5 (-64.7 to 147.4)
Maternal sepsis and other maternal infections	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	-40.2 (-14.6 to 46.6)	-40.2 (-57.0 to -24.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.5 (-43.8 to 71.1)	-45.0 (-66.3 to -6.7)
Maternal hypertensive disorders	0.8 (0.3 to 1.4)	0.7 (0.3 to 1.4)	-4.8 (-16.2 to 12.8)	-45.3 (-51.3 to -36.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-3.5 (-25.4 to 30.7)	-44.4 (-56.6 to -26.5)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.1 (-73.9 to 339.0)	-24.6 (-83.3 to 138.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.1 (-74.0 to 340.4)	-24.6 (-83.3 to 140.3)
Complications of abortion	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-4.1 (-38.8 to 50.9)	-44.1 (-63.4 to -15.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.1 (-53.6 to 177.2)	-41.0 (-70.8 to 35.8)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.3 (-54.8 to 33.7)	-56.9 (-74.2 to -24.0)
Neonatal disorders	-	-	-	-	3.4 (2.3 to 4.6)	8.3 (5.9 to 11.3)	150.5 (78.1 to 237.0)	88.0 (34.0 to 153.7)
Preterm birth complications	9.6 (6.6 to 13.5)	32.6 (23.7 to 43.6)	241.4 (180.3 to 319.5)	141.0 (97.6 to 197.9)	1.0 (0.7 to 1.5)	4.0 (2.7 to 5.5)	290.4 (189.6 to 450.6)	187.2 (115.3 to 302.7)
Neonatal encephalopathy due to birth asphyxia and trauma	16.4 (5.3 to 36.7)	16.6 (7.0 to 35.6)	3.2 (-27.4 to 67.5)	-28.1 (-49.5 to 16.4)	1.3 (0.7 to 2.2)	2.2 (1.4 to 3.3)	79.0 (-0.5 to 228.5)	35.9 (-24.9 to 151.5)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	19.1 (-4.8 to 14.2)	7.5 (-5.5 to 26.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.4 (-5.9 to 20.3)	19.0 (4.2 to 33.3)
Hemolytic disease and other neonatal jaundice	2.5 (1.3 to 4.7)	4.6 (2.5 to 7.9)	84.2 (-3.9 to 317.4)	34.6 (-30.3 to 207.5)	0.9 (0.4 to 1.7)	1.8 (0.9 to 3.3)	93.5 (-3.2 to 344.1)	44.8 (-28.8 to 233.0)
Other neonatal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	89.9 (7.8 to 214.5)	42.8 (-19.7 to 137.9)
Nutritional deficiencies	-	-	-	-	25.2 (16.9 to 36.8)	25.9 (17.1 to 37.7)	2.5 (-3.3 to 7.5)	-16.9 (-21.7 to -11.8)
Protein-energy malnutrition	5.9 (3.4 to 9.7)	4.2 (2.2 to 7.7)	-30.8 (-68.4 to 63.3)	-28.5 (-64.4 to 53.0)	0.7 (0.4 to 1.4)	0.5 (0.2 to 1.0)	-30.9 (-69.2 to 64.7)	-26.7 (-65.4 to 64.4)
Iodine deficiency	34.9 (17.5 to 54.2)	41.9 (23.9 to 64.4)	16.7 (-40.1 to 182.9)	-31.1 (-65.8 to 70.7)	0.6 (0.3 to 1.1)	0.7 (0.4 to 1.4)	21.2 (-39.9 to 193.1)	-27.0 (-63.9 to 85.6)
Vitamin A deficiency	1.1 (0.8 to 1.5)	0.7 (0.5 to 0.9)	-39.1 (-49.2 to -24.9)	-52.0 (-59.0 to -41.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-40.4 (-53.6 to -23.5)	-53.6 (-62.6 to -42.3)

Appendix Table G.4 - Nicaragua prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	730.9 (719.6 to 741.7)	794.1 (774.8 to 813.2)	8.6 (5.8 to 11.8)	-17.8 (-20.2 to -15.1)	23.8 (15.9 to 34.5)	24.6 (16.3 to 35.9)	3.1 (-0.9 to 7.1)	3.1 (-20.2 to -11.9)
Other nutritional deficiencies	-	-	-	-	0.0	0.0	-	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	(0.0 to 0.0)	(0.0 to 0.0)	(-79.5 to 79.2)	(-76.8 to 78.3)
Sexually transmitted diseases excluding HIV	-	-	-	-	2.0 (1.3 to 3.0)	2.4 (1.5 to 3.7)	2.4 (1.4 to 3.7)	-12.3 (-22.1 to -0.9)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	7.5 (-13.5 to 45.7)	-47.6 (-56.2 to -34.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-15.0 to 15.0)	41.3 (-56.8 to -12.5)
Chlamydial infection	75.6 (60.9 to 92.2)	113.4 (81.9 to 147.7)	50.0 (7.5 to 108.8)	-13.6 (-36.0 to 16.9)	0.3 (0.2 to 0.5)	0.6 (0.3 to 0.9)	73.6 (34.9 to 126.0)	1.6 (-19.8 to 29.8)
Gonococcal infection	13.0 (10.0 to 16.3)	17.6 (13.0 to 21.8)	37.0 (-4.6 to 91.8)	-18.5 (-40.9 to 12.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	41.7 (-5.3 to 100.9)	-15.6 (-42.1 to 14.1)
Trichomoniasis	23.3 (14.3 to 35.4)	42.3 (26.1 to 62.2)	82.0 (-3.3 to 282.8)	-1.7 (-4.4 to 83.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	82.8 (-9.1 to 301.5)	0.7 (-44.2 to 94.2)
Genital herpes	585.2 (552.6 to 618.7)	7,117.7 (1,050.7 to 1,184.2)	905.9 (75.8 to 1,075.5)	-1.0 (-8.8 to 7.2)	0.2 (0.0 to 0.4)	0.3 (0.1 to 0.7)	98.0 (76.2 to 121.9)	7.2 (-3.0 to 19.7)
Other sexually transmitted diseases	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.8)	42.6 (17.1 to 70.0)	-25.8 (-38.0 to -11.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (17.3 to 154.5)	-4.3 (-32.2 to 34.8)
Hepatitis	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	0.2 (16.8 to 48.0)	-13.8 (-23.5 to -1.9)
Hepatitis A	6.6 (6.3 to 6.9)	7.9 (7.6 to 8.2)	19.8 (18.2 to 21.4)	-2.4 (-2.5 to -2.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	43.0 (26.0 to 62.6)	2.6 (-8.3 to 15.2)
Hepatitis B	91.1 (73.6 to 108.0)	66.9 (56.5 to 75.5)	-26.4 (-43.3 to -6.4)	-53.1 (-62.0 to -40.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-14.4 (-37.3 to -24.4)	-52.3 (-65.7 to -24.4)
Hepatitis C	85.6 (75.6 to 94.9)	109.0 (98.5 to 120.5)	26.9 (9.8 to 48.1)	-38.5 (-37.0 to -38.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.7 (0.8 to 62.1)	-16.4 (-38.0 to 13.0)
Hepatitis E	-	-	-	-	-	-	-	-
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	192.9 (-18.4 to 1,546.5)	47.3 (-57.3 to 807.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	196.2 (-20.4 to 2,509.7)	47.7 (-68.1 to 1,285.3)
Other infectious diseases	35.6 (28.4 to 43.4)	35.6 (30.5 to 40.3)	0.5 (-16.9 to 20.1)	-14.8 (-27.9 to -0.5)	1.2 (0.8 to 1.8)	1.1 (0.7 to 1.6)	-14.2 (-29.9 to 6.6)	-22.4 (-36.4 to -3.9)
Non-communicable diseases	-	-	-	-	258.8 (176.4 to 304.1)	464.9 (343.6 to 599.6)	95.9 (86.2 to 110.0)	36.9 (9.3 to 26.5)
Neoplasms	-	-	-	-	1.1 (0.8 to 1.4)	2.5 (1.8 to 3.3)	129.1 (101.3 to 164.2)	26.1 (10.4 to 46.5)
Esophageal cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	128.3 (64.8 to 210.8)	6.5 (-24.7 to 47.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	142.3 (89.2 to 204.0)	15.5 (-12.0 to 47.9)
Stomach cancer	0.5 (0.5 to 0.6)	0.9 (0.7 to 1.0)	61.3 (35.0 to 100.2)	-26.7 (-39.1 to -8.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	87.1 (54.9 to 132.7)	-12.3 (-29.2 to 9.4)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	1,323.2 (1,043.8 to 1,700.4)	556.9 (415.9 to 741.0)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	1,597.8 (783.6 to 3,144.5)	780.0 (337.4 to 1,715.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,545.3 (847.8 to 2,715.7)	732.4 (359.9 to 1,502.2)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	4,315.7 (2,140.7 to 10,157.7)	1,705.5 (859.7 to 4,192.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3,681.5 (2,042.1 to 8,163.2)	1,419.9 (800.7 to 3,378.6)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	724.2 (324.9 to 1,572.8)	259.9 (84.4 to 640.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	657.4 (325.5 to 1,344.5)	226.3 (84.6 to 511.4)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	389.9 (169.7 to 855.8)	132.0 (20.0 to 372.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	375.6 (198.8 to 723.6)	222.2 (34.4 to 304.5)
Larynx cancer	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	38.1 (5.0 to 91.2)	-33.7 (-49.5 to -8.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (26.2 to 129.2)	-19.6 (-39.5 to 11.9)
Tracheal, bronchus and lung cancer	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.4)	79.7 (45.3 to 120.3)	-14.7 (-31.3 to 4.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	103.9 (63.9 to 154.0)	0.0 (-20.6 to 25.6)
Breast cancer	1.3 (1.1 to 1.5)	3.5 (2.9 to 4.3)	179.9 (118.1 to 256.8)	33.6 (5.2 to 69.2)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	180.4 (120.4 to 268.0)	35.8 (6.7 to 76.7)
Cervical cancer	4.5 (3.4 to 5.2)	8.3 (3.5 to 5.7)	48.9 (-21.3 to 44.3)	-48.9 (-60.6 to -28.7)	0.3 (0.2 to 0.4)	0.9 (0.2 to 0.5)	45.2 (-17.0 to 52.7)	-22.2 (-58.1 to -21.8)
Uterine cancer	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.8)	1.0 (-36.7 to 104.4)	-51.8 (-69.4 to -4.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	7.7 (-30.7 to 113.2)	-48.1 (-65.9 to 1.1)
Prostate cancer	1.3 (0.9 to 2.0)	6.9 (4.6 to 10.3)	453.5 (287.7 to 675.8)	149.1 (72.0 to 251.6)	0.1 (0.1 to 0.1)	0.5 (0.3 to 0.8)	510.8 (320.2 to 731.9)	171.9 (86.4 to 277.0)
Colon and rectum cancer	0.6 (0.5 to 0.7)	1.7 (1.5 to 1.9)	174.8 (134.4 to 223.4)	23.9 (5.6 to 46.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	189.7 (140.8 to 246.2)	34.1 (9.0 to 62.8)
Lip and oral cavity cancer	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.4)	82.2 (33.0 to 144.5)	-15.0 (-35.8 to 15.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.0 (53.8 to 165.5)	-2.9 (-28.1 to 29.1)
Nasopharynx cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	36.0 (-1.2 to 93.5)	-27.3 (-46.5 to 3.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (4.5 to 93.7)	-27.7 (-44.4 to 3.4)
Other pharynx cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	71.6 (9.9 to 156.7)	-18.8 (-48.2 to 22.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.1 (26.5 to 162.8)	-12.4 (-40.1 to 25.8)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-20.0 (-45.6 to 108.6)	-65.4 (-76.4 to -8.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.6 (-34.7 to 127.8)	-57.3 (-70.6 to 3.6)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.1 to 0.1)	638.2 (489.9 to 834.8)	231.8 (160.7 to 323.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	587.8 (466.5 to 746.5)	203.4 (149.9 to 279.4)
Malignant skin melanoma	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.6)	49.9 (13.0 to 125.8)	24.0 (-42.3 to 16.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.7 (14.9 to 137.4)	12.7 (-4.0 to 19.5)
Non-melanoma skin cancer	0.5 (0.4 to 0.7)	1.9 (1.5 to 2.5)	269.8 (160.1 to 414.7)	63.4 (11.6 to 129.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	324.2 (216.7 to 474.6)	89.7 (35.8 to 162.3)
Ovarian cancer	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	275.4 (188.1 to 383.9)	95.5 (50.9 to 153.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	272.3 (188.5 to 388.6)	95.0 (46.6 to 161.3)
Testicular cancer	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.4)	1,246.1 (26.0 to 2,573.0)	657.9 (-27.3 to 1,291.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,151.1 (11.0 to 2,613.5)	598.3 (-35.6 to 1,285.8)
Kidney cancer	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.4)	55.6 (24.5 to 99.1)	6.6 (-13.3 to 31.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.7 (33.6 to 130.4)	12.7 (-9.7 to 38.8)
Bladder cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	94.2 (44.4 to 161.2)	-16.2 (-39.2 to 13.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.2 (53.4 to 173.7)	-8.2 (-33.2 to 22.8)
Brain and nervous system cancer	0.1 (0.1 to 0.4)	0.8 (0.5 to 1.1)	669.8 (49.3 to 965.6)	544.8 (16.5 to 732.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	734.0 (52.4 to 1,083.9)	542.5 (11.5 to 731.4)
Thyroid cancer	0.5 (0.4 to 0.9)	1.6 (1.0 to 2.0)	216.8 (61.9 to 344.8)	61.9 (-17.8 to 123.6)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	218.9 (62.4 to 358.0)	65.4 (-15.7 to 132.0)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.0 (22.5 to 135.5)	-54.0 (-62.7 to -44.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-17.2 to 16.7)	53.1 (-60.3 to -43.2)
Hodgkin lymphoma	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.4)	650.7 (6.2 to 1,030.8)	548.2 (-15.3 to 834.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	760.3 (8.2 to 1,414.8)	596.5 (-18.7 to 872.8)
Non-Hodgkin lymphoma	0.4 (0.3 to 0.5)	0.7 (0.5 to 0.8)	80.2 (30.9 to 132.1)	22.2 (-19.5 to 59.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	92.2 (35.2 to 155.5)	26.6 (-18.1 to 68.7)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	115.6 (40.9 to 223.3)	3.7 (-32.7 to 54.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.0 (52.7 to 208.8)	4.7 (-27.6 to 47.6)
Leukemia	1.3 (1.0 to 1.8)	1.7 (1.4 to 2.1)	30.3 (-10.7 to 78.8)	14.4 (-15.8 to 47.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	22.4 (13.9 to 98.6)	22.4 (-2.3 to 53.3)
Other neoplasms	2.1 (1.5 to 3.0)	4.2 (3.3 to 5.2)	100.5 (23.5 to 217.0)	56.8 (13.7 to 128.4)	0.3 (0.1 to 0.2)	0.3 (0.2 to 0.4)	109.1 (33.0 to 219.9)	59.8 (18.3 to 124.6)
Cardiovascular diseases	-	-	-	-	2.8 (2.0 to 3.7)	9.1 (6.1 to 12.4)	225.6 (157.1 to 300.4)	73.5 (35.9 to 117.3)
Rheumatic heart disease	17.1 (16.2 to 18.0)	28.8 (27.2 to 30.3)	68.4 (56.0 to 80.6)	0.1 (-6.7 to 6.5)	0.8 (0.5 to 1.1)	1.4 (0.9 to 2.0)	4.0 (55.8 to 90.0)	4.0 (-6.8 to 16.6)
Ischemic heart disease	18.5 (15.7 to 22.6)	76.4 (59.4 to 96.3)	313.0 (206.3 to 449.1)	81.5 (33.5 to 138.0)	0.7 (0.5 to 1.1)	4.2 (2.5 to 6.2)	494.4 (293.8 to 711.9)	244.2 (72.8 to 254.4)
Cerebrovascular disease	-	-	-	-	0.3 (0.2 to 0.4)	0.8 (0.6 to 1.1)	149.1 (96.1 to 208.1)	23.2 (-4.3 to 56.1)
Ischemic stroke	0.7 (0.5 to 0.8)	1.4 (1.1 to 1.7)	114.3 (54.4 to 194.0)	-1.5 (-30.6 to 36.8)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	144.1 (78.5 to 234.4)	16.9 (-16.4 to 62.3)
Hemorrhagic stroke	1.9 (1.6 to 2.2)	4.1 (3.5 to 4.6)	119.3 (75.7 to 170.1)	5.4 (-16.3 to 31.6)	0.2 (0.2 to 0.3)	0.6 (0.4 to 0.8)	150.9 (94.7 to 212.3)	26.4 (-3.9 to 61.4)
Hypertensive heart disease	1.6 (1.4 to 1.7)	3.8 (3.4 to 4.1)	142.1 (110.4 to 173.8)	7.1 (-7.1 to 21.2)	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.5)	176.8 (133.6 to 227.3)	26.0 (-4.9 to 50.8)
Cardiomyopathy and myocarditis	2.0 (0.7 to 1.0)	2.0 (1.8 to 2.2)	136.9 (104.1 to 173.7)	20.2 (0.9 to 42.9)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	164.2 (118.4 to 220.0)	40.5 (14.2 to 73.8)
Atrial fibrillation and flutter	0.7 (0.4 to 1.2)	3.7 (2.3 to 5.6)	450.5 (106.9 to 951.2)	106.5 (-26.1 to 338.5)	0.0 (0.0 to 0.1)	0.3 (0.1 to 0.4)	552.2 (150.2 to 1,176.2)	153.6 (-9.6 to 450.7)
Peripheral vascular disease	54.3 (40.6 to 71.5)	130.5 (96.1 to 161.1)	143.2 (59.1 to 266.8)	7.8 (-24.5 to 53.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	265.0 (49.9 to 658.3)	27.7 (-49.9 to 159.4)
Endocarditis	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	91.8 (43.5 to 148.2)	19.4 (-15.1 to 49.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.3 (47.4 to 149.0)	27.7 (-13.8 to 53.8)
Other cardiovascular and circulatory diseases	10.4 (6.3 to 17.5)	35.6 (15.1 to 37.0)	164.0 (20.9 to 355.2)	28.8 (-40.3 to 121.0)	0.7 (0.4 to 1.1)	1.8 (0.9 to 2.8)	195.5 (31.0 to 385.4)	48.0 (-32.4 to 156.1)
Chronic respiratory diseases	-	-	-	-	16.0 (11.2 to 21.8)	32.7 (22.6 to 43.9)	104.1 (78.7 to 133.9)	25.3 (10.3 to 45.3)
Chronic obstructive pulmonary disease	97.4 (91.0 to 103.6)	193.2 (180.7 to 205.9)	98.5 (90.9 to 105.9)	0.9 (-2.5 to 4.8)	5.2 (3.5 to 7.1)	14.5 (9.6 to		

Appendix Table G.4 - Nicaragua prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	93.9	-4.1
Silicosis	0.0	0.0	85.4	-9.9	0.0	0.0	(88.4 to 99.3)	(-6.8 to -1.6)
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	85.7	-9.7
Coal workers pneumoconiosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Other pneumoconiosis	0.0	0.0	101.0	1.7	0.0	0.0	101.3	1.9
Asthma	230.5	392.4	69.9	8.2	9.8	17.2	76.0	16.3
Interstitial lung disease and pulmonary sarcoidosis	0.1	0.1	94.2	-0.3	0.0	0.0	95.3	0.3
Other chronic respiratory diseases	0.1	0.1	94.2	-0.3	0.0	0.0	95.3	0.3
Cirrhosis	0.0	0.1	149.8	36.2	0.0	0.0	141.5	27.0
Cirrhosis due to hepatitis B	0.0	0.1	149.8	36.2	0.0	0.0	141.5	27.0
Cirrhosis due to hepatitis C	0.3	0.7	112.4	21.1	0.0	0.1	134.2	41.0
Cirrhosis due to alcohol use	0.4	0.7	70.1	-14.7	0.1	0.1	100.3	2.8
Cirrhosis due to other causes	0.3	0.5	84.0	32.3	0.0	0.1	84.8	-9.3
Digestive diseases	18.2	21.3	16.8	-49.6	0.5	0.7	30.9	-38.2
Peptic ulcer disease	15.6	19.6	25.6	-54.1	0.4	0.5	14.4	-45.6
Gastritis and duodenitis	7.2	10.1	40.3	-24.7	0.3	0.5	54.3	-11.5
Appendicitis	0.2	0.2	30.1	-10.8	0.1	0.1	31.1	-10.1
Paralytic ileus and intestinal obstruction	0.0	0.0	98.9	34.4	0.0	0.0	92.2	32.5
Inguinal, femoral, and abdominal hernia	10.2	15.6	52.8	-25.8	0.1	0.2	68.5	-11.1
Inflammatory bowel disease	3.6	8.7	139.2	24.3	0.7	1.8	162.6	41.2
Vascular intestinal disorders	0.0	0.0	129.3	10.0	0.0	0.0	116.1	3.5
Gallbladder and biliary diseases	1.9	3.6	84.1	9.5	0.2	0.4	95.4	25.9
Pancreatitis	0.2	0.5	199.9	56.7	0.0	0.1	235.0	83.1
Other digestive diseases	0.2	0.2	181.4	219.0	0.0	0.1	430.3	165.6
Neurological disorders	12.2	32.0	162.0	0.2	1.3	4.3	234.6	25.9
Alzheimer disease and other dementias	0.2	0.5	130.7	2.3	0.0	0.1	163.7	21.3
Parkinson disease	22.6	34.0	50.2	-0.3	6.7	11.5	72.3	20.9
Epilepsy	0.1	0.4	268.8	91.3	0.0	0.1	263.9	88.2
Multiple sclerosis	0.1	0.4	238.7	75.7	0.0	0.1	216.7	63.8
Migraine	303.3	481.8	59.9	-0.5	9.6	16.4	68.9	-2.1
Tension-type headache	678.3	1,263.6	87.2	4.1	1.0	1.9	95.6	11.7
Medication overuse headache	14.4	37.6	159.5	38.0	2.1	5.9	175.2	49.0
Other neurological disorders	0.0	0.0	46.7	-6.7	0.4	0.8	77.8	-32.0
Mental and substance use disorders	8.0	15.3	90.8	-0.8	4.5	9.7	115.6	15.0
Schizophrenia	53.6	95.1	77.3	-2.7	4.8	9.4	95.1	10.4
Alcohol use disorders	48.6	86.2	76.9	-7.8	3.2	6.2	77.0	0.3
Drug use disorders	2.1	4.3	103.0	2.7	0.7	1.8	134.7	20.4
Opioid use disorders	0.0	0.0	103.0	2.7	0.0	0.0	103.0	2.7
Cocaine use disorders	0.0	0.0	103.0	2.7	0.0	0.0	103.0	2.7
Amphetamine use disorders	0.0	0.0	103.0	2.7	0.0	0.0	103.0	2.7
Cannabis use disorders	0.0	0.0	103.0	2.7	0.0	0.0	103.0	2.7
Other drug use disorders	0.0	0.0	103.0	2.7	0.0	0.0	103.0	2.7
Depressive disorders	146.7	265.0	80.1	2.4	28.5	54.3	90.6	11.6
Major depressive disorder	88.9	148.2	66.1	4.9	15.4	27.8	82.0	8.8
Dysthymia	35.4	67.6	90.7	0.2	3.2	6.4	102.8	9.2
Bipolar disorder	26.3	48.1	82.9	0.0	5.0	9.7	96.1	10.1
Anxiety disorders	155.9	266.0	71.2	0.2	13.7	24.2	71.2	7.5
Eating disorders	1.0	1.6	67.2	8.1	0.2	0.3	69.5	9.9
Anorexia nervosa	0.7	1.2	71.4	8.1	0.2	0.3	69.5	9.9
Bulimia nervosa	4.9	8.0	64.3	0.3	1.0	1.7	67.1	2.2
Autistic spectrum disorders	12.4	18.2	46.4	-0.2	2.9	4.5	52.6	8.8
Autism	11.7	17.2	45.3	-0.2	2.0	3.0	44.1	2.3
Asperger syndrome	18.4	26.7	45.1	-0.2	1.8	2.7	50.1	7.6
Attention-deficit/hyperactivity disorder	40.0	50.1	25.3	0.3	0.5	0.6	26.3	1.2
Conduct disorder	52.9	66.9	26.4	0.3	0.3	0.7	17.7	3.5
Idiopathic intellectual disability	70.7	86.8	22.5	-5.8	3.3	4.2	25.3	-10.1
Other mental and substance use disorders	48.3	92.4	91.2	-0.2	3.2	6.8	108.8	12.6
Diabetes, urogenital, blood, and endocrine diseases	127.6	348.0	172.9	44.5	7.7	23.5	203.9	59.9
Diabetes mellitus	109.4	300.8	174.2	18.3	5.1	15.8	155.6	30.1
Acute glomerulonephritis	0.0	0.0	13.4	-29.0	0.0	0.0	-	-
Chronic kidney disease	62.4	97.1	60.0	-16.4	0.7	1.8	152.4	33.6
Chronic kidney disease due to diabetes mellitus	40.6	67.5	65.5	-11.7	0.5	1.2	88.5	22.7
Chronic kidney disease due to hypertension	77.8	110.3	44.0	-5.4	1.1	2.5	122.1	31.1
Chronic kidney disease due to glomerulonephritis	58.3	90.5	55.9	-21.3	1.7	2.8	68.1	14.8
Chronic kidney disease due to other causes	114.8	141.6	27.0	-21.3	1.7	2.8	68.1	14.8
Urinary diseases and male infertility	0.0	0.0	0.0	0.0	0.5	1.6	187.2	42.4

Appendix Table G.4 - Nicaragua prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.8 (0.7 to 0.9)	1.3 (1.1 to 1.5)	61.5 (37.1 to 100.6)	0.0 (-7.6 to 21.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	66.5 (25.9 to 123.4)	10.0 (-13.1 to 38.0)
Urolithiasis	19.0 (12.2 to 29.5)	51.7 (32.2 to 78.3)	170.3 (131.8 to 229.0)	0.1 (5.3 to 54.3)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.5)	246.5 (194.3 to 330.1)	0.3 (47.5 to 120.1)
Benign prostatic hyperplasia	13.9 (12.8 to 15.4)	30.2 (25.1 to 33.9)	119.5 (75.0 to 154.9)	2.3 (-19.0 to 19.3)	0.3 (0.2 to 0.5)	1.0 (0.6 to 1.3)	181.5 (117.6 to 242.0)	33.0 (1.9 to 61.8)
Male infertility due to other causes	10.6 (7.8 to 14.1)	18.3 (14.2 to 24.0)	71.2 (20.0 to 152.8)	-7.6 (-35.3 to 37.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	82.5 (22.8 to 183.1)	0.3 (-31.7 to 55.8)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	307.8 (165.2 to 854.6)	226.3 (45.3 to 421.8)
Gynecological diseases	-	-	-	-	3.9 (2.5 to 5.8)	7.3 (4.6 to 10.9)	87.6 (64.5 to 114.6)	0.1 (-11.7 to 14.8)
Uterine fibroids	53.9 (48.3 to 58.8)	115.0 (103.5 to 125.1)	113.3 (111.4 to 115.4)	3.3 (3.2 to 3.3)	0.7 (0.4 to 1.2)	1.2 (0.6 to 2.1)	67.9 (47.7 to 92.9)	-15.4 (-25.3 to -1.9)
Polycystic ovarian syndrome	54.3 (46.0 to 61.5)	106.3 (93.1 to 120.7)	94.7 (63.1 to 141.2)	3.2 (-12.3 to 24.6)	0.5 (0.2 to 1.0)	1.0 (0.5 to 1.9)	95.7 (64.4 to 144.2)	4.0 (-10.9 to 27.0)
Female infertility due to other causes	6.1 (3.2 to 9.4)	11.6 (6.9 to 17.4)	92.3 (-11.1 to 293.8)	-1.6 (-54.0 to 104.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	94.1 (8.8 to 296.0)	-0.4 (-52.7 to 105.7)
Endometriosis	5.9 (4.9 to 6.8)	11.8 (10.0 to 13.7)	101.1 (60.6 to 150.4)	5.7 (-15.2 to 29.7)	0.5 (0.3 to 0.8)	1.1 (0.7 to 1.5)	104.8 (59.8 to 157.6)	7.6 (-15.1 to 34.4)
Genital prolapse	188.6 (161.3 to 214.8)	371.9 (311.8 to 426.5)	97.4 (58.9 to 145.0)	-1.3 (-19.2 to 19.0)	0.6 (0.3 to 1.1)	1.2 (0.6 to 2.3)	101.3 (59.5 to 152.2)	1.5 (-17.5 to 23.7)
Premenstrual syndrome	154.4 (120.0 to 192.5)	283.5 (213.2 to 359.4)	81.7 (34.4 to 158.6)	-0.3 (-25.9 to 44.8)	1.3 (0.8 to 2.0)	2.4 (1.3 to 3.8)	83.5 (33.9 to 165.1)	0.8 (-24.4 to 46.9)
Other gynecological diseases	8.4 (7.3 to 9.4)	13.6 (10.0 to 21.8)	51.8 (15.3 to 159.8)	-12.7 (-37.5 to 75.8)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.8)	36.5 (-26.5 to 248.2)	-11.1 (-57.6 to 172.3)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	2.3 (1.5 to 3.3)	3.2 (2.1 to 4.6)	37.4 (25.5 to 56.7)	11.3 (-1.0 to 26.1)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.1 (-20.7 to 23.0)	-6.9 (-32.9 to 4.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.1 (-4.1 to 21.3)	-7.7 (-18.1 to 4.5)
Thalassemia trait	30.1 (23.9 to 36.5)	44.3 (35.3 to 53.8)	47.7 (28.2 to 59.1)	1.3 (-11.9 to 11.5)	0.9 (0.6 to 1.3)	1.4 (1.0 to 2.0)	58.1 (40.7 to 88.1)	19.0 (5.4 to 42.3)
Sickle cell disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	33.2 (20.4 to 50.3)	-1.7 (-10.5 to 7.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.9 (22.9 to 46.7)	-5.5 (-17.7 to 2.1)
Sickle cell trait	51.9 (45.0 to 60.5)	75.2 (64.0 to 87.7)	44.6 (37.5 to 53.4)	-4.0 (-6.0 to 5.2)	0.5 (0.3 to 0.8)	1.0 (0.6 to 1.4)	86.4 (50.8 to 124.3)	56.5 (26.3 to 89.2)
G6PD deficiency	85.3 (70.0 to 101.7)	127.2 (75.9 to 159.6)	51.4 (-8.6 to 101.1)	3.7 (-37.1 to 37.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.9 (-22.5 to 26.8)	-25.8 (-41.6 to -7.7)
G6PD trait	508.5 (465.6 to 545.4)	746.6 (679.3 to 810.8)	46.9 (29.9 to 65.7)	-0.1 (-11.7 to 12.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	140.7 (15.6 to 611.8)	85.4 (-12.6 to 420.2)
Other hemoglobinopathies and hemolytic anemias	29.2 (25.3 to 33.2)	32.8 (29.4 to 36.4)	12.7 (5.4 to 33.5)	-15.9 (-26.8 to -4.1)	0.8 (0.5 to 1.2)	0.7 (0.4 to 1.1)	-81.1 (-34.4 to 13.7)	-16.6 (-42.2 to -5.0)
Endocrine, metabolic, blood, and immune disorders	34.9 (32.6 to 37.1)	40.3 (35.9 to 44.3)	15.0 (-0.9 to 34.0)	4.4 (-19.2 to 2.6)	1.1 (0.7 to 1.6)	1.2 (0.7 to 1.7)	11.2 (-20.8 to 26.2)	-10.2 (-25.9 to 10.2)
Musculoskeletal disorders	-	-	-	-	38.8 (27.1 to 52.9)	88.8 (60.8 to 123.6)	128.9 (89.7 to 172.8)	22.6 (2.8 to 40.9)
Rheumatoid arthritis	10.2 (9.6 to 10.9)	17.0 (15.8 to 18.2)	66.1 (51.7 to 82.0)	-12.2 (-20.3 to -2.9)	2.2 (1.6 to 2.9)	3.9 (2.8 to 5.2)	75.4 (57.3 to 98.6)	-3.0 (-13.7 to 11.9)
Osteoarthritis	72.5 (69.6 to 75.7)	163.0 (157.2 to 169.2)	124.8 (113.3 to 138.1)	1.4 (-3.5 to 7.1)	3.7 (2.7 to 5.0)	9.5 (6.7 to 12.9)	154.6 (131.1 to 185.1)	17.3 (9.7 to 31.8)
Low back and neck pain	-	-	-	-	30.6 (20.7 to 42.9)	64.7 (42.4 to 92.4)	110.0 (66.7 to 163.3)	15.2 (-9.2 to 40.1)
Low back pain	226.3 (188.2 to 270.6)	445.0 (368.4 to 529.3)	96.1 (56.6 to 146.6)	2.8 (-15.2 to 27.2)	22.7 (14.9 to 32.9)	48.7 (31.5 to 71.1)	113.8 (67.4 to 175.3)	17.4 (-5.6 to 46.9)
Neck pain	88.5 (70.1 to 110.8)	165.0 (100.9 to 223.7)	93.3 (5.2 to 170.7)	-0.0 (-41.7 to 39.0)	8.0 (5.1 to 11.7)	16.0 (8.6 to 24.6)	107.3 (10.7 to 193.3)	9.6 (-36.3 to 54.0)
Gout	1.2 (1.0 to 1.3)	2.6 (2.2 to 2.9)	118.3 (76.4 to 166.6)	4.4 (-15.6 to 27.8)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	148.9 (89.3 to 222.3)	22.7 (6.5 to 60.8)
Other musculoskeletal disorders	27.6 (22.9 to 39.3)	117.4 (64.2 to 170.3)	336.4 (151.4 to 455.4)	103.4 (18.5 to 163.4)	2.2 (1.4 to 3.5)	10.6 (5.1 to 17.4)	89.7 (20.3 to 306.6)	39.7 (46.9 to 206.6)
Other non-communicable diseases	-	-	-	-	50.8 (35.2 to 71.9)	90.7 (62.1 to 127.9)	78.5 (69.1 to 90.0)	6.9 (-0.2 to 15.8)
Congenital anomalies	-	-	-	-	4.0 (3.0 to 5.3)	8.8 (6.5 to 11.4)	118.5 (85.7 to 157.6)	54.5 (32.2 to 81.6)
Neural tube defects	1.1 (0.9 to 1.5)	2.2 (1.8 to 2.6)	46.3 (38.1 to 161.6)	4.3 (6.3 to 99.8)	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.0)	102.7 (24.8 to 233.0)	58.5 (-2.2 to 157.7)
Congenital heart anomalies	11.9 (9.5 to 14.5)	32.7 (29.0 to 37.9)	176.4 (111.7 to 255.4)	107.2 (58.7 to 167.1)	0.4 (0.2 to 0.7)	1.1 (0.5 to 2.0)	172.1 (105.8 to 253.6)	113.4 (65.6 to 177.3)
Orofacial clefts	2.6 (1.9 to 3.6)	7.2 (5.8 to 9.1)	181.2 (88.2 to 296.3)	0.0 (-48.8 to 218.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	81.5 (43.9 to 263.8)	17.4 (16.0 to 184.3)
Down syndrome	4.7 (3.8 to 5.6)	8.9 (7.0 to 11.3)	89.0 (40.8 to 161.7)	34.2 (-0.8 to 85.5)	0.5 (0.4 to 0.7)	1.1 (0.8 to 1.6)	108.2 (52.9 to 196.1)	50.1 (10.2 to 111.5)
Turner syndrome	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	78.8 (8.6 to 163.7)	24.9 (-24.2 to 85.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.4 (8.0 to 181.3)	25.2 (-26.5 to 88.4)
Klinefelter syndrome	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	48.1 (0.0 to 124.3)	2.7 (-30.6 to 54.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.8 (-14.1 to 154.9)	1.8 (-31.1 to 54.4)
Chromosomal unbalanced rearrangements	6.1 (5.2 to 7.2)	11.1 (9.3 to 13.2)	81.2 (45.3 to 134.4)	74.4 (3.1 to 66.6)	0.7 (0.5 to 0.9)	1.4 (1.0 to 1.9)	98.8 (54.5 to 158.1)	43.0 (13.4 to 87.3)
Other congenital anomalies	18.3 (15.6 to 21.2)	24.8 (21.1 to 28.8)	35.7 (24.0 to 49.0)	-12.5 (-20.0 to -4.2)	2.0 (1.3 to 2.9)	4.4 (3.0 to 5.8)	118.7 (74.9 to 186.5)	48.6 (20.3 to 90.9)
Skin and subcutaneous diseases	-	-	-	-	18.7 (12.1 to 27.8)	30.3 (19.8 to 44.9)	62.8 (44.4 to 79.5)	9.3 (-3.6 to 20.2)
Dermatitis	198.9 (160.0 to 244.8)	318.8 (254.0 to 390.3)	60.4 (55.5 to 64.9)	-0.0 (-0.1 to 0.1)	6.2 (3.8 to 9.2)	9.6 (5.9 to 14.1)	55.3 (45.3 to 65.5)	5.9 (1.6 to 12.3)
Psoriasis	27.4 (24.1 to 30.8)	47.7 (41.9 to 54.0)	74.4 (71.4 to 77.2)	0.0 (-0.1 to 0.1)	2.1 (1.4 to 2.9)	3.8 (2.6 to 5.4)	86.0 (71.3 to 101.9)	11.1 (3.1 to 21.8)
Cellulitis	0.2 (0.2 to 0.2)	0.3 (0.2 to 0.3)	54.8 (41.4 to 68.2)	-0.1 (-8.7 to 8.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.9 (40.6 to 70.2)	2.4 (-8.5 to 13.7)
Pyoderma	1.7 (1.2 to 2.4)	2.9 (2.1 to 3.9)	66.6 (42.5 to 103.1)	25.6 (9.0 to 47.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.1 (37.9 to 116.8)	33.7 (11.0 to 64.3)
Scabies	47.6 (41.8 to 54.1)	65.4 (57.5 to 73.1)	38.0 (14.7 to 64.2)	-1.9 (-17.5 to 16.4)	1.2 (0.7 to 1.9)	1.7 (0.9 to 2.7)	40.6 (15.3 to 67.0)	2.6 (-15.1 to 22.6)
Fungal skin diseases	270.9 (201.2 to 359.3)	441.0 (335.5 to 583.1)	63.0 (53.5 to 72.3)	0.1 (-0.2 to 0.0)	6.1 (4.6 to 7.4)	2.5 (1.0 to 5.5)	71.2 (57.0 to 83.5)	7.2 (3.3 to 14.8)
Viral skin diseases	84.8 (66.0 to 101.0)	109.7 (83.9 to 134.0)	29.4 (21.2 to 37.7)	0.1 (-2.3 to 2.6)	2.6 (1.5 to 4.0)	3.4 (2.0 to 5.4)	30.9 (21.4 to 41.1)	3.3 (-0.9 to 7.9)
Acne vulgaris	211.8 (128.4 to 302.6)	360.5 (220.7 to 549.3)	65.6 (-0.8 to 199.7)	8.4 (-33.3 to 94.4)	2.3 (0.9 to 4.8)	3.9 (1.6 to 8.2)	68.6 (0.5 to 204.0)	10.6 (-32.5 to 97.8)
Alopecia areata	3.2 (3.0 to 3.5)	5.3 (4.8 to 5.7)	62.3 (42.2 to 84.6)	-1.8 (-13.5 to 11.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	70.2 (41.2 to 103.1)	8.2 (-9.1 to 27.4)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.7 (34.4 to 111.6)	2.8 (-23.0 to 25.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.7 (34.4 to 111.6)	-2.8 (-23.2 to 25.7)
Urticaria	33.5 (22.4 to 47.8)	56.1 (37.5 to 77.5)	64.2 (-5.8 to 199.2)	3.4 (-44.6 to 96.1)	1.9 (1.0 to 3.2)	3.3 (1.8 to 5.3)	70.3 (-2.7 to 215.5)	13.0 (-39.9 to 114.0)
Decubitus ulcer	0.3 (0.3 to 0.4)	0.8 (0.6 to 1.0)	147.1 (75.7 to 226.9)	6.8 (-30.7 to 54.3)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	168.7 (94.4 to 254.9)	27.5 (-17.9 to 84.8)
Other skin and subcutaneous diseases	174.1 (120.7 to 254.9)	322.5 (219.1 to 483.1)	84.8 (69.4 to 99.9)	0.7 (-4.3 to 5.6)	0.9 (0.4 to 1.9)	1.8 (0.8 to 3.8)	97.5 (76.0 to 123.4)	12.1 (3.5 to 23.5)
Sense organ diseases	-	-	-	-	20.1 (14.2 to 27.6)	35.5 (24.9 to 50.0)	77.8 (65.3 to 93.5)	0.6 (-6.9 to 10.5)
Glaucoma	4.7 (4.0 to 5.6)	7.8 (6.5 to 9.4)	65.9 (45.8 to 90.1)	-21.1 (-32.4 to -8.4)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	96.3 (60.9 to 134.3)	-4.3 (-26.4 to 16.6)
Cataract	15.3 (12.1 to 18.6)	26.4 (21.1 to 32.0)	73.5 (53.6 to 92.2)	-29.4 (-36.4 to -22.8)	0.8 (0.5 to 1.1)	1.7 (1.2 to 2.4)	116.1 (79.3 to 157.5)	-13.2 (-25.9 to 2.6)
Macular degeneration	5.8 (4.5 to 7.3)	13.1 (10.5 to 15.8)	127.9 (87.6 to 172.5)	5.7 (-13.2 to 26.8)	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.8)	164.9 (114.4 to 225.4)	23.7 (-0.1 to 53.6)
Uncorrected refractive error	313.6 (266.8 to 359.5)	540.1 (455.7 to 621.2)	72.1 (40.1 to 110.9)	6.4 (-22.8 to 32.1)	4.6 (2.8 to 7.4)	7.9 (4.7 to 13.1)	71.4 (48.2 to 99.5)	-1.2 (-13.6 to 11.0)
Age-related and other hearing loss	373.9 (345.9 to 402.8)	670.7 (625.3 to 722.5)	79.3 (72.0 to 88.5)	-9.3 (-12.1 to -6.7)	10.7 (7.5 to 14.9)	20.3 (13.8 to 28.1)	89.1 (71.2 to 112.7)	3.8 (-4.8 to 16.0)
Other vision loss	13.5 (11.8 to 15.4)	15.4 (13.4 to 17.8)	14.0 (5.0 to 24.4)	-33.5 (-38.6 to -27.8)	0.9 (0.6 to 1.2)	1.2 (0.8 to 1.6)	30.2 (13.7 to 48.7)	-22.3 (-32.2 to -10.7)
Other sense organ diseases	98.6 (92.3 to 104.3)	136.0 (129.3 to 142.8)	38.1 (27.6 to 50.6)	-0.3 (-6.9 to 7.9)	2.6 (1.6 to 3.8)	3.6 (2.2 to 5.3)	40.6 (28.4 to 55.2)	6.2 (-2.2 to 16.9)
Oral disorders	-	-	-	-	7.9 (4.7 to 12.4)	15.8 (9.4 to 24.6)	98.9 (88.1 to 113.7)	7.5 (0.5 to 17.2)
Deciduous caries	411.2 (391.0 to 431.8)	417.4 (396.5 to 438.3)	1.8 (-5.8 to 8.7)	-0.2 (-7.6 to 6.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	0.3 (-7.6 to 11.6)	0.3 (-9.4 to 9.4)
Permanent caries	1,577.8 (1,493.9 to 1,672.1)	2,540.4 (2,413.7 to 2,662.4)	61.1 (49.0 to 72.0)	2.1 (-4.5 to 7.9)	1.5 (0.7 to 2.9)	2.5 (1.1 to 4.9)	65.8 (52.8 to 78.1)	7.6 (0.2 to 15.1)
Periodontal diseases	300.9 (286.1 to 316.1)	616.6 (585.9 to 651.0)	105.1 (91.5 to 120.6)	3.4 (-3.6 to 11.3)	1.8 (0.7 to 3.6)	4.0 (1.6 to 8.2)	121.9 (103.6 to 144.6)	14.5 (4.2 to 27.4)

Appendix Table G.4 - Nicaragua prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	120.8 (115.1 to 126.1)	235.7 (223.0 to 248.1)	95.5 (84.0 to 105.1)	-9.5 (-14.7 to -5.4)	2.8 (1.9 to 3.8)	6.2 (4.3 to 8.5)	121.6 (103.8 to 146.3)	5.0 (-4.3 to 17.1)
Other oral disorders	59.4 (55.6 to 62.7)	100.1 (94.2 to 105.5)	68.7 (54.7 to 82.8)	-0.5 (-7.2 to 7.2)	1.7 (1.1 to 2.5)	2.9 (1.8 to 4.3)	75.1 (59.6 to 91.7)	6.4 (-2.9 to 16.8)
Injuries	-	-	-	-	368.5 (183.8 to 642.8)	102.5 (56.9 to 180.1)	-72.1 (-80.2 to -61.2)	83.0 (-88.2 to -76.4)
Transport injuries	-	-	-	-	10.5 (7.9 to 13.5)	11.1 (7.9 to 15.0)	5.5 (-10.0 to 22.9)	-38.1 (-47.0 to -28.2)
Road injuries	-	-	-	-	10.2 (7.8 to 13.1)	10.5 (7.5 to 14.2)	2.3 (-12.9 to 19.1)	-39.9 (-48.5 to -30.2)
Pedestrian road injuries	-	-	-	-	3.1 (2.3 to 4.0)	2.7 (1.9 to 3.7)	-13.9 (-28.2 to 2.6)	-46.3 (-54.6 to -37.5)
Cyclist road injuries	-	-	-	-	0.8 (0.6 to 1.0)	1.0 (0.7 to 1.3)	24.7 (10.2 to 41.1)	-26.8 (-36.4 to -16.6)
Motorcyclist road injuries	-	-	-	-	0.9 (0.7 to 1.2)	1.0 (0.7 to 1.4)	9.9 (-7.2 to 29.3)	-36.8 (-46.8 to -26.1)
Motor vehicle road injuries	-	-	-	-	5.2 (3.9 to 6.6)	5.6 (4.0 to 7.6)	7.9 (8.6 to 28.0)	-38.3 (-47.8 to -27.2)
Other road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-18.9 (-30.4 to -5.1)	-50.4 (-57.6 to -42.3)
Other transport injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.6 (0.4 to 0.8)	139.9 (106.1 to 178.3)	32.0 (12.9 to 54.7)
Unintentional injuries	-	-	-	-	8.3 (6.4 to 10.7)	8.4 (6.2 to 11.2)	1.2 (8.7 to 13.3)	40.0 (-46.6 to -32.5)
Falls	-	-	-	-	2.1 (1.6 to 2.7)	3.4 (2.5 to 4.6)	60.4 (39.9 to 94.5)	-22.8 (-33.8 to -9.2)
Drowning	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-17.3 (-30.2 to -0.4)	-49.3 (-57.4 to -39.6)
Fire, heat, and hot substances	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-14.4 (-26.2 to 0.5)	-46.3 (-53.5 to -37.6)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.3 (-37.0 to -1.4)	-49.0 (-58.7 to -38.4)
Exposure to mechanical forces	-	-	-	-	4.9 (3.7 to 6.5)	3.6 (2.6 to 4.8)	-27.6 (-34.4 to -19.2)	-55.0 (-59.1 to -49.7)
Unintentional firearm injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	14.6 (-1.1 to 34.6)	-33.5 (-43.0 to -21.9)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	9.8 (-7.7 to 29.4)	-32.0 (-41.6 to -21.0)
Other exposure to mechanical forces	-	-	-	-	4.6 (3.5 to 6.1)	3.2 (2.4 to 4.3)	-30.2 (-36.6 to -22.1)	-56.4 (-60.2 to -51.3)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	59.8 (48.8 to 72.1)	-11.5 (-17.1 to -4.8)
Animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-42.4 (-49.3 to -33.8)	45.1 (-6.6 to -59.8)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-43.4 (-50.4 to -34.3)	-65.3 (-69.6 to -59.8)
Non-venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-41.7 (-49.8 to -32.1)	-65.1 (-69.9 to -59.4)
Foreign body	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	16.4 (1.1 to 33.8)	-23.8 (-32.9 to -13.3)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-20.2 (-35.6 to -2.0)	-43.2 (-53.7 to -31.4)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.4 (31.9 to 67.6)	-4.3 (-13.7 to 6.9)
Foreign body in other body part	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	57.6 (37.3 to 80.4)	-6.4 (-17.9 to 6.8)
Other unintentional injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.7 (0.5 to 0.9)	64.7 (46.7 to 87.4)	-17.3 (-26.6 to -4.8)
Self-harm and interpersonal violence	-	-	-	-	3.0 (2.3 to 3.8)	3.9 (2.9 to 5.2)	30.5 (12.0 to 53.8)	-26.4 (-37.8 to -12.8)
Self-harm	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	70.1 (48.7 to 98.2)	-12.5 (-24.1 to 2.1)
Interpersonal violence	-	-	-	-	2.9 (2.2 to 3.6)	3.8 (2.8 to 5.0)	29.2 (10.7 to 52.4)	-26.8 (-37.8 to -13.4)
Assault by firearm	-	-	-	-	0.8 (0.7 to 1.1)	1.6 (1.1 to 2.1)	86.3 (63.1 to 116.4)	3.5 (-10.2 to 21.3)
Assault by sharp object	-	-	-	-	0.6 (0.5 to 0.8)	0.9 (0.6 to 1.2)	34.1 (14.0 to 62.4)	-25.9 (-37.7 to -10.2)
Assault by other means	-	-	-	-	1.4 (1.1 to 1.8)	1.3 (1.0 to 1.7)	-7.3 (-21.7 to 10.2)	-46.7 (-55.4 to -36.0)
Forces of nature, war, and legal intervention	-	-	-	-	346.7 (162.8 to 623.7)	79.1 (35.8 to 155.2)	-77.4 (-84.9 to -67.8)	-85.7 (-90.3 to -79.1)
Exposure to forces of nature	-	-	-	-	14.8 (7.4 to 27.5)	6.4 (2.8 to 13.8)	-57.6 (-66.0 to -48.5)	-76.2 (-81.7 to -69.2)
Collective violence and legal intervention	-	-	-	-	331.9 (153.5 to 599.6)	72.7 (32.8 to 142.0)	-78.3 (-85.5 to -68.8)	-86.1 (-90.7 to -79.7)

Appendix Table G.4 - Niger prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	728.5 (524.6 to 967.6)	1,547.9 (1,111.4 to 2,034.1)	113.6 (106.0 to 122.4)	15.6 (-9.0 to 1.4)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	241.7 (166.0 to 337.4)	448.3 (309.6 to 614.2)	85.6 (72.7 to 99.1)	-27.3 (-34.1 to -20.9)
HIV/AIDS and tuberculosis	-	-	-	-	5.3 (3.6 to 7.2)	15.9 (10.6 to 22.4)	197.0 (151.4 to 288.3)	38.5 (17.0 to 85.9)
Tuberculosis	15.3 (14.0 to 16.7)	30.9 (28.9 to 33.2)	101.5 (88.8 to 117.1)	-3.4 (-9.3 to 2.8)	4.7 (3.2 to 6.4)	9.5 (6.4 to 12.8)	101.9 (86.6 to 120.7)	-3.1 (-10.2 to 5.0)
HIV/AIDS	-	-	-	-	0.6 (0.2 to 1.0)	6.4 (3.6 to 10.8)	1,006.2 (442.1 to 2,684.0)	486.8 (160.4 to 1,331.2)
HIV/AIDS resulting in mycobacterial infection	0.1 (0.0 to 0.2)	0.8 (0.4 to 1.4)	720.6 (296.0 to 1,979.6)	318.3 (100.8 to 962.6)	0.0 (0.0 to 0.1)	0.3 (0.1 to 0.6)	723.0 (253.6 to 2,123.0)	312.7 (79.8 to 999.2)
HIV/AIDS resulting in other diseases	5.8 (2.8 to 9.7)	41.5 (32.0 to 54.1)	634.3 (299.4 to 1,360.3)	270.8 (99.3 to 649.8)	0.5 (0.2 to 1.0)	6.1 (3.4 to 10.4)	1,030.1 (445.8 to 2,860.3)	448.8 (161.6 to 1,370.7)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	56.7 (40.1 to 76.8)	93.1 (65.0 to 126.9)	64.3 (51.0 to 77.4)	-28.6 (-34.4 to -22.8)
Diarrheal diseases	220.9 (209.6 to 231.8)	368.9 (334.3 to 404.2)	66.8 (48.5 to 84.6)	-39.4 (-36.3 to -22.3)	35.6 (24.1 to 49.7)	59.6 (40.2 to 83.9)	67.3 (49.2 to 85.1)	-29.5 (-36.5 to -22.1)
Intestinal infectious diseases	-	-	-	-	0.9 (0.6 to 1.3)	0.6 (0.4 to 0.9)	0.6 (0.4 to 0.9)	-31.9 (-49.6 to -9.3)
Typhoid fever	4.0 (3.4 to 4.6)	3.1 (2.5 to 3.7)	-21.8 (-40.4 to -2.0)	-65.7 (-74.0 to -58.3)	0.5 (0.3 to 0.8)	0.4 (0.3 to 0.6)	-19.9 (-41.9 to 5.7)	-64.7 (-73.6 to -55.0)
Paratyphoid fever	2.6 (2.2 to 3.1)	2.6 (2.1 to 3.2)	-0.9 (-27.3 to 33.2)	-58.2 (-68.9 to -41.1)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.2)	-0.2 (-29.8 to 42.0)	-57.6 (-38.7 to -76.5)
Other intestinal infectious diseases	-	-	-	-	0.2 (0.1 to 0.5)	0.0 (0.0 to 0.1)	-78.8 (-88.8 to -59.1)	-90.7 (-95.1 to -42.9)
Lower respiratory infections	7.0 (6.1 to 8.0)	10.7 (8.9 to 12.9)	53.9 (19.5 to 92.7)	-24.4 (-35.9 to -10.1)	0.7 (0.5 to 1.0)	1.1 (0.7 to 1.7)	54.9 (17.4 to 99.6)	-24.0 (-37.6 to -7.5)
Upper respiratory infections	431.0 (400.0 to 461.9)	1,012.2 (937.7 to 1,090.6)	134.8 (112.1 to 158.6)	2.4 (-6.8 to 13.0)	5.1 (2.8 to 8.6)	11.9 (6.7 to 20.2)	135.5 (112.3 to 159.6)	2.7 (-6.9 to 13.6)
Otitis media	172.9 (157.2 to 189.4)	364.2 (328.7 to 401.2)	110.7 (91.8 to 131.7)	-10.0 (-18.9 to -0.6)	3.6 (2.1 to 5.7)	7.6 (4.6 to 12.2)	112.6 (90.7 to 138.0)	-9.5 (-19.1 to 1.3)
Meningitis	-	-	-	-	8.6 (5.8 to 12.1)	10.6 (7.2 to 14.6)	21.6 (-2.8 to 60.5)	-44.0 (-54.5 to -28.7)
Pneumococcal meningitis	25.9 (16.3 to 39.0)	30.7 (20.0 to 45.7)	17.4 (-9.7 to 62.8)	-44.0 (-57.0 to -23.8)	2.7 (1.6 to 4.7)	3.1 (2.1 to 4.3)	19.7 (-28.8 to 74.4)	-45.6 (-66.6 to -24.1)
H influenzae type B meningitis	16.9 (7.7 to 30.4)	19.8 (9.1 to 34.3)	17.4 (-15.8 to 78.6)	-46.9 (-60.6 to -23.2)	1.9 (1.2 to 3.1)	2.5 (1.4 to 4.5)	26.7 (-21.1 to 153.3)	-42.9 (-64.1 to 8.6)
Meningococcal meningitis	23.1 (8.8 to 45.5)	26.4 (11.7 to 52.2)	13.7 (-4.9 to 43.9)	-46.5 (-54.9 to -32.8)	2.8 (1.6 to 4.3)	3.3 (2.0 to 5.0)	17.1 (8.5 to 65.7)	-45.7 (-55.6 to -26.0)
Other meningitis	9.9 (7.5 to 13.5)	12.1 (8.8 to 16.5)	22.2 (-2.0 to 54.7)	-39.5 (-52.3 to -22.2)	1.3 (0.8 to 1.8)	1.6 (1.1 to 2.4)	27.8 (0.4 to 79.2)	-37.2 (-51.6 to -12.0)
Encephalitis	0.8 (0.8 to 3.3)	0.2 (1.8 to 6.9)	115.3 (95.3 to 140.9)	3.2 (-11.0 to 6.1)	0.5 (0.1 to 0.3)	0.5 (0.3 to 0.6)	132.4 (90.5 to 160.4)	-2.4 (-14.3 to 11.6)
Diphtheria	0.0 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-76.0 (-99.5 to 680.9)	-88.9 (-99.5 to 120.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-76.0 (-99.5 to 687.7)	-88.9 (-99.5 to 123.1)
Whooping cough	23.5 (18.0 to 30.7)	17.0 (13.3 to 21.6)	-27.8 (-32.6 to -22.6)	-68.4 (-70.5 to -66.2)	1.2 (0.7 to 1.9)	0.8 (0.5 to 1.3)	-27.8 (-35.5 to -20.1)	-68.4 (-71.9 to -65.1)
Tetanus	4.9 (2.6 to 8.8)	3.1 (1.7 to 5.3)	-36.2 (-70.1 to 49.2)	-72.3 (-87.7 to -32.0)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.3)	-28.5 (-61.1 to 29.4)	-70.5 (-83.4 to -45.5)
Measles	6.9 (4.8 to 9.6)	0.2 (0.1 to 0.3)	-97.3 (-98.3 to -95.7)	-98.9 (-99.3 to -98.2)	0.6 (0.3 to 1.0)	0.0 (0.0 to 0.0)	97.2 (-98.3 to -95.4)	-98.8 (-99.3 to -98.0)
Varicella and herpes zoster	4.8 (4.5 to 5.3)	11.8 (10.6 to 13.0)	143.2 (112.4 to 172.5)	2.8 (-17.7 to 25.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	131.2 (52.9 to 213.3)	1.8 (-32.5 to 45.0)
Neglected tropical diseases and malaria	-	-	-	-	76.8 (48.6 to 115.2)	83.5 (55.2 to 120.4)	9.2 (-11.3 to 29.6)	-61.0 (-69.2 to -50.5)
Malaria	3,157.8 (2,871.2 to 3,429.2)	5,091.5 (4,569.7 to 5,578.1)	61.5 (47.0 to 74.9)	-30.9 (-37.2 to -24.0)	29.8 (19.9 to 42.7)	48.4 (32.6 to 68.6)	62.2 (50.2 to 75.1)	-32.0 (-37.2 to -25.7)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	253.5 (95.9 to 615.4)	56.8 (-17.3 to 214.1)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	126.1 (48.2 to 240.8)	-0.1 (-28.6 to 38.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	126.1 (48.2 to 241.1)	-0.1 (-28.7 to 38.5)
Cutaneous and mucocutaneous leishmaniasis	0.2 (0.1 to 0.4)	0.8 (0.4 to 1.2)	261.3 (111.1 to 594.5)	0.0 (-9.8 to 203.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	256.0 (96.1 to 625.9)	57.4 (-17.4 to 217.1)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Schistosomiasis	2,141.8 (1,619.0 to 2,793.7)	523.0 (188.7 to 1,686.2)	-75.7 (-91.2 to -21.8)	-91.9 (-96.1 to -66.9)	21.0 (10.3 to 38.8)	5.2 (1.6 to 20.8)	-81.9 (-89.4 to -9.5)	-92.1 (-95.4 to -61.4)
Cysticercosis	0.4 (0.1 to 1.4)	1.0 (0.4 to 2.4)	160.3 (-53.8 to 796.4)	14.1 (-76.3 to 259.7)	0.1 (0.0 to 0.3)	0.3 (0.1 to 0.7)	185.1 (-53.6 to 910.1)	21.9 (-76.5 to 291.6)
Cystic echinococcosis	1.6 (1.4 to 1.7)	2.7 (2.5 to 3.0)	72.2 (56.3 to 104.1)	-0.2 (-8.5 to 11.0)	0.1 (0.1 to 0.2)	0.1 (0.2 to 0.4)	74.3 (36.2 to 133.6)	-0.4 (-17.7 to 22.2)
Lymphatic filariasis	332.4 (243.1 to 438.8)	164.3 (111.4 to 230.7)	-50.4 (-67.9 to -25.4)	-75.9 (-83.7 to -65.0)	10.2 (4.8 to 17.8)	11.5 (5.4 to 20.7)	13.8 (-29.4 to 69.0)	-52.9 (-71.6 to -23.7)
Onchocerciasis	42.3 (29.9 to 56.5)	0.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	2.2 (1.7 to 5.1)	0.0 (-100.0 to -100.0)	100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Trachoma	16.9 (7.8 to 26.6)	19.3 (10.0 to 31.1)	12.0 (-37.1 to 169.8)	-55.9 (-74.8 to -8.6)	1.0 (0.4 to 1.7)	1.1 (0.5 to 1.9)	13.6 (-35.5 to 155.1)	-55.1 (-73.7 to -16.6)
Dengue	0.4 (0.1 to 1.0)	4.5 (1.5 to 11.2)	1,016.4 (1,002.9 to 1,032.2)	384.6 (378.7 to 391.5)	0.1 (0.0 to 0.2)	0.7 (0.2 to 2.0)	964.2 (799.6 to 1,180.7)	354.5 (297.3 to 430.5)
Yellow fever	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-41.0 (-69.5 to 28.7)	-73.7 (-84.8 to -61.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.0 (-69.6 to 29.0)	-73.7 (-84.8 to -61.5)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.0 (-33.0 to 166.6)	-63.9 (-63.9 to 12.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-33.1 to 167.4)	-30.3 (-63.9 to 12.1)
Intestinal nematode infections	-	-	-	-	1.2 (0.7 to 1.8)	1.3 (0.7 to 2.1)	14.2 (27.4 to 56.6)	-52.3 (-67.3 to -35.2)
Ascariasis	311.5 (205.6 to 447.8)	272.9 (188.2 to 400.5)	-12.9 (-48.1 to 53.2)	-62.3 (-80.9 to -24.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.9 (-40.6 to 36.7)	-61.9 (-77.1 to -39.4)
Trichuriasis	67.1 (44.0 to 108.1)	57.5 (36.9 to 87.4)	-14.0 (-54.9 to 62.0)	-62.9 (-83.4 to -15.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.8 (-66.4 to 110.7)	-62.9 (-86.8 to 1.2)
Hookworm disease	425.4 (282.4 to 642.8)	510.6 (344.1 to 761.4)	20.3 (-31.9 to 111.0)	20.3 (-73.7 to 6.0)	1.2 (0.7 to 1.8)	1.3 (0.7 to 2.1)	14.3 (-27.5 to 57.1)	-52.3 (-67.3 to -34.9)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Other neglected tropical diseases	133.4 (99.7 to 168.3)	344.2 (317.0 to 382.6)	160.7 (101.5 to 243.5)	11.7 (-11.1 to 40.1)	10.2 (5.2 to 19.3)	14.7 (9.8 to 21.5)	53.3 (-14.2 to 133.0)	-57.6 (-79.9 to -19.5)
Maternal disorders	-	-	-	-	2.2 (1.5 to 3.0)	3.7 (2.5 to 5.1)	69.8 (45.1 to 101.7)	-22.3 (-33.1 to -8.4)
Maternal hemorrhage	4.1 (3.1 to 5.1)	7.1 (5.0 to 9.6)	73.1 (18.8 to 154.4)	-16.4 (-42.9 to 22.5)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.5)	69.3 (-13.9 to 207.5)	-18.4 (-59.3 to 43.6)
Maternal sepsis and other maternal infections	3.1 (1.9 to 4.6)	8.3 (5.1 to 11.6)	165.2 (126.6 to 212.9)	26.7 (9.4 to 49.3)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	170.7 (61.4 to 356.8)	27.2 (-20.7 to 102.2)
Maternal hypertensive disorders	3.4 (1.3 to 6.1)	7.1 (2.8 to 12.9)	111.5 (94.6 to 118.9)	-2.8 (-9.7 to 1.1)	0.2 (0.1 to 0.4)	0.4 (0.1 to 0.8)	110.4 (80.4 to 145.8)	-2.8 (-16.1 to 12.3)
Obstructed labor	4.2 (3.4 to 5.0)	6.7 (5.6 to 7.7)	58.9 (44.3 to 78.7)	-27.3 (-34.3 to -18.8)	1.4 (0.9 to 2.0)	2.2 (1.4 to 3.1)	60.0 (36.5 to 90.3)	-27.2 (-36.7 to -14.6)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	96.7 (15.4 to 240.4)	-8.8 (-43.6 to 53.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.7 (15.4 to 241.9)	-8.8 (-43.6 to 53.4)
Other maternal disorders	-	-	-	-	0.4 (0.2 to 0.6)	0.7 (0.4 to 1.0)	81.0 (15.1 to 170.3)	-16.2 (-44.4 to 24.0)
Neonatal disorders	-	-	-	-	2.6 (1.2 to 5.8)	11.0 (7.0 to 16.8)	364.6 (141.5 to 717.8)	117.8 (-1.7 to 337.2)
Preterm birth complications	9.3 (5.5 to 15.1)	47.2 (31.5 to 69.9)	412.0 (319.0 to 525.5)	118.6 (80.1 to 163.8)	0.4 (0.2 to 0.6)	3.6 (2.3 to 5.3)	859.3 (550.7 to 1,321.8)	320.6 (182.4 to 541.5)
Neonatal encephalopathy due to birth asphyxia and trauma	55.2 (40.0 to 176.0)	71.5 (9.4 to 225.6)	36.3 (-14.2 to 179.8)	-11.8 (-64.2 to 23.8)	1.7 (0.6 to 4.3)	3.6 (1.5 to 7.2)	131.6 (34.6 to 451.9)	-0.2 (-45.4 to 205.3)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.7)	180.6 (171.5 to 252.3)	34.7 (30.3 to 69.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	34.7 (15.3 to 255.9)	187.7 (20.6 to 70.8)
Hemolytic disease and other neonatal jaundice	0.5 (0.3 to 1.1)	6.0 (2.8 to 10.8)	1,030.3 (314.2 to 2,286.8)	667.9 (148.1 to 1,652.1)	0.2 (0.1 to 0.4)	2.3 (1.0 to 4.2)	1,112.1 (319.6 to 2,447.4)	715.7 (153.4 to 1,806.9)
Other neonatal disorders	-	-	-	-	0.4 (0.1 to 1.0)	1.5 (0.5 to 3.2)	300.5 (65.8 to 871.1)	91.1 (-30.0 to 430.8)
Nutritional deficiencies	-	-	-	-	91.8 (61.7 to 128.7)	227.1 (151.6 to 323.0)	146.7 (128.7 to 173.7)	4.7 (-0.5 to 12.0)
Protein-energy malnutrition	76.7 (53.1 to 109.8)	203.2 (98.9 to 373.5)	158.8 (21.2 to 437.3)	9.7 (-43.7 to 121.8)	9.3 (5.2 to 14.9)	24.9 (10.3 to 49.9)	151.7 (22.6 to 450.8)	30.9 (-43.9 to 126.0)
Iodine deficiency	295.1 (258.1 to 338.6)	393.7 (337.6 to 453.1)	33.4 (7.7 to 65.5)	-40.7 (-53.3 to -24.4)	5.3 (3.2 to 8.5)	7.1 (4.3 to 11.3)	34.3 (9.0 to 65.6)	-40.5 (-52.9 to -23.9)
Vitamin A deficiency	17.0 (12.2 to 22.6)	20.4 (14.4 to 27.3)	18.9 (8.0 to 52.7)	-47.4 (-59.4 to -33.7)	0.8 (0.5 to 1.3)	1.0 (0.6 to 1.5)	21.8 (-3.6 to 53.2)	-45.7 (-57.8 to -32.9)

Appendix Table G.4 - Niger prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	1,953.6 (1,898.4 to 2,010.2)	4,978.7 (4,921.5 to 5,033.1)	155.0 (147.7 to 162.5)	21.3 (8.1 to 33.6)	76.4 (51.3 to 109.2)	194.0 (130.1 to 277.2)	154.5 (145.5 to 159.6)	154.5 (5.4 to 12.5)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	0.0 (-38.1 to 744.8)	-0.3 (-72.9 to 251.2)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	6.3 (4.0 to 9.2)	14.1 (9.2 to 20.4)	122.8 (101.2 to 154.2)	-9.9 (-19.0 to 1.5)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.3 (0.7 to 2.2)	2.3 (1.2 to 4.1)	83.1 (34.3 to 144.4)	-15.5 (-35.3 to 6.0)
Syphilis	0.8 (0.7 to 0.9)	1.0 (0.9 to 1.2)	24.5 (4.2 to 50.0)	-41.4 (-48.5 to -30.5)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	34.9 (-6.3 to 66.0)	41.2 (-53.9 to -25.1)
Chlamydial infection	60.7 (43.2 to 82.9)	157.9 (89.2 to 238.4)	155.3 (51.3 to 370.9)	14.6 (-28.9 to 107.4)	0.3 (0.1 to 0.6)	0.6 (0.2 to 1.3)	113.4 (-19.5 to 296.0)	-1.3 (-61.2 to 76.7)
Gonococcal infection	39.1 (26.9 to 52.5)	73.5 (52.3 to 96.2)	87.3 (23.5 to 182.0)	-13.4 (-42.4 to 25.1)	0.3 (0.1 to 0.4)	0.5 (0.2 to 0.8)	69.7 (6.3 to 194.6)	-21.4 (-49.5 to 28.7)
Trichomoniasis	92.2 (48.9 to 157.2)	149.8 (79.6 to 279.4)	47.5 (-18.6 to 381.4)	-21.0 (-55.3 to 94.8)	0.2 (0.0 to 0.4)	0.3 (0.1 to 0.6)	42.7 (-25.1 to 403.1)	-22.9 (-57.8 to 113.4)
Genital herpes	1,174.3 (1,072.3 to 1,274.7)	2,476.3 (2,264.8 to 2,690.3)	110.8 (85.7 to 138.5)	-3.0 (-14.7 to 9.8)	0.3 (0.1 to 0.8)	0.7 (0.2 to 1.6)	111.9 (83.8 to 142.3)	-2.6 (-15.0 to 10.2)
Other sexually transmitted diseases	3.1 (2.3 to 4.3)	5.1 (3.6 to 7.0)	61.4 (39.0 to 84.8)	-23.2 (-33.8 to -11.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	71.7 (19.8 to 147.4)	-20.1 (-41.6 to 10.4)
Hepatitis	-	-	-	-	1.1 (0.7 to 1.6)	1.7 (1.1 to 2.5)	57.2 (35.5 to 91.6)	-33.2 (-44.0 to -13.8)
Hepatitis A	15.2 (14.3 to 16.1)	34.6 (32.5 to 36.8)	127.9 (127.8 to 128.2)	-1.2 (-1.3 to -1.0)	0.2 (0.2 to 0.4)	0.6 (0.4 to 0.9)	133.8 (106.6 to 166.8)	2.3 (-9.0 to 15.6)
Hepatitis B	1,520.3 (1,163.7 to 1,811.5)	1,939.1 (1,599.1 to 2,247.1)	27.3 (0.6 to 72.0)	-44.8 (-54.4 to -29.3)	0.7 (0.4 to 1.0)	0.8 (0.5 to 1.3)	16.0 (-12.4 to 63.2)	-46.6 (-60.2 to -21.8)
Hepatitis C	495.6 (437.9 to 551.3)	855.0 (768.9 to 943.9)	72.6 (48.8 to 101.3)	-23.9 (-34.4 to -13.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	90.0 (38.4 to 156.5)	-15.6 (-36.6 to 10.7)
Hepatitis E	3.2 (2.1 to 4.3)	7.7 (5.7 to 10.5)	145.6 (55.2 to 260.3)	14.1 (-26.5 to 60.0)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	146.4 (46.7 to 277.7)	14.2 (-29.6 to 70.6)
Leprosy	2.1 (1.5 to 2.7)	3.3 (2.9 to 3.8)	61.8 (35.2 to 100.4)	-22.9 (-34.5 to -7.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	64.1 (31.2 to 110.4)	-21.6 (-35.5 to -2.3)
Other infectious diseases	94.1 (71.2 to 119.1)	243.1 (224.3 to 262.1)	158.7 (127.4 to 196.7)	11.6 (-1.5 to 27.8)	3.8 (2.4 to 5.5)	9.8 (6.4 to 14.1)	155.9 (128.0 to 208.7)	9.5 (-4.7 to 36.1)
Non-communicable diseases	-	-	-	-	455.9 (332.9 to 595.5)	1,046.6 (765.6 to 1,363.5)	129.7 (120.4 to 139.0)	1.4 (-2.4 to 6.1)
Neoplasms	-	-	-	-	1.4 (1.0 to 1.9)	3.5 (2.5 to 4.7)	154.7 (97.6 to 214.0)	17.1 (-4.0 to 44.1)
Esophageal cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	127.6 (49.0 to 239.5)	0.6 (-33.4 to 48.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	126.9 (59.6 to 231.1)	0.2 (-30.3 to 44.2)
Stomach cancer	0.6 (0.5 to 0.8)	1.2 (0.9 to 1.4)	81.2 (39.0 to 139.4)	-16.2 (-36.8 to 10.5)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	83.3 (36.2 to 138.4)	-15.3 (-36.7 to 12.7)
Liver cancer	-	-	-	-	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	102.6 (45.2 to 176.6)	6.9 (-31.7 to 25.8)
Liver cancer due to hepatitis B	0.5 (0.2 to 0.7)	0.9 (0.4 to 1.6)	97.3 (-20.5 to 259.7)	-12.3 (-63.4 to 67.1)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	100.0 (-14.4 to 232.3)	-11.9 (-60.3 to 55.9)
Liver cancer due to hepatitis C	0.1 (0.1 to 0.2)	0.7 (0.3 to 1.3)	507.7 (127.1 to 1,352.1)	174.5 (5.2 to 489.5)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	476.5 (119.9 to 1,164.6)	153.8 (1.8 to 404.1)
Liver cancer due to alcohol use	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	5.9 (-55.6 to 146.1)	-52.2 (-79.9 to 11.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	7.6 (-50.7 to 132.9)	-50.6 (-78.4 to 10.3)
Liver cancer due to other causes	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.6)	22.4 (-34.2 to 144.1)	-45.7 (-71.6 to 5.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	20.7 (-29.5 to 120.4)	45.5 (-69.1 to -1.7)
Larynx cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.3)	38.5 (-7.5 to 209.6)	-35.1 (56.3 to 38.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-6.6 to 214.3)	0.0 (-54.9 to 39.8)
Tracheal, bronchus and lung cancer	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.4)	100.9 (53.6 to 170.8)	-9.5 (-29.9 to 17.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	106.6 (53.9 to 179.3)	-6.7 (-30.2 to 25.1)
Breast cancer	1.5 (1.2 to 2.0)	5.3 (3.4 to 6.8)	241.4 (137.1 to 365.1)	48.1 (8.5 to 101.7)	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.6)	203.0 (111.0 to 316.1)	32.0 (-4.3 to 81.0)
Cervical cancer	3.7 (2.5 to 5.1)	6.0 (4.2 to 8.0)	61.3 (7.4 to 141.4)	-5.7 (-46.9 to 13.6)	0.2 (0.2 to 0.5)	0.5 (0.3 to 0.7)	65.2 (10.9 to 146.7)	-20.4 (-44.9 to 17.1)
Uterine cancer	0.6 (0.3 to 0.9)	1.4 (0.7 to 2.2)	146.1 (40.8 to 313.8)	10.2 (-36.1 to 78.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	144.6 (37.6 to 313.6)	9.5 (-36.1 to 79.0)
Prostate cancer	0.8 (0.5 to 1.3)	5.6 (3.4 to 8.9)	643.7 (268.9 to 1,196.6)	197.2 (52.9 to 407.1)	0.1 (0.0 to 0.1)	0.5 (0.3 to 0.8)	526.3 (217.5 to 937.3)	155.5 (30.0 to 327.7)
Colon and rectum cancer	0.5 (0.4 to 0.6)	1.7 (1.4 to 2.0)	217.9 (158.7 to 291.4)	34.9 (11.0 to 64.1)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	206.7 (146.0 to 278.0)	31.2 (2.7 to 62.6)
Lip and oral cavity cancer	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.7)	142.4 (62.4 to 247.8)	8.8 (-25.5 to 54.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	140.4 (69.8 to 242.2)	7.5 (-25.0 to 56.9)
Nasopharynx cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	113.3 (35.6 to 226.4)	5.4 (-38.1 to 42.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.4 (37.2 to 203.8)	8.9 (-37.6 to 34.3)
Other pharynx cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	96.4 (14.8 to 235.6)	-11.6 (-48.9 to 45.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.2 (25.9 to 221.9)	-9.5 (-43.5 to 44.0)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	158.7 (78.7 to 275.8)	5.2 (-29.0 to 52.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	153.2 (83.7 to 242.7)	3.2 (-26.2 to 42.8)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	267.0 (177.7 to 392.5)	57.3 (17.5 to 109.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	268.2 (196.7 to 360.2)	54.5 (21.4 to 96.8)
Malignant skin melanoma	0.2 (0.2 to 0.3)	0.7 (0.5 to 0.9)	189.4 (102.7 to 295.1)	22.6 (-13.0 to 60.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	181.9 (93.3 to 296.6)	19.6 (-17.5 to 69.6)
Non-melanoma skin cancer	0.3 (0.2 to 0.5)	0.8 (0.5 to 1.2)	169.1 (30.2 to 343.3)	14.8 (-37.9 to 90.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	203.3 (96.4 to 349.8)	24.6 (-23.9 to 97.0)
Ovarian cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	115.4 (35.6 to 242.4)	0.2 (-35.1 to 55.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	115.7 (28.3 to 238.1)	-0.4 (-40.1 to 53.5)
Testicular cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	204.7 (68.4 to 427.2)	39.0 (-21.0 to 131.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	196.1 (66.4 to 432.1)	32.5 (-23.2 to 132.6)
Kidney cancer	0.2 (0.2 to 0.5)	0.5 (0.3 to 0.9)	92.7 (8.7 to 316.9)	-9.9 (-39.6 to 43.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	92.9 (-4.8 to 304.5)	2.5 (-35.9 to 41.8)
Bladder cancer	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.6)	94.6 (37.7 to 206.5)	-14.1 (-40.6 to 32.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	95.5 (37.6 to 201.0)	-12.4 (-39.7 to 36.2)
Brain and nervous system cancer	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.9)	303.4 (102.3 to 507.5)	71.7 (9.3 to 129.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	299.0 (119.9 to 480.7)	61.1 (10.6 to 114.5)
Thyroid cancer	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	97.1 (10.4 to 248.1)	-12.5 (-50.3 to 54.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.4 (10.8 to 246.7)	-14.6 (-50.2 to 54.3)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	233.9 (57.4 to 221.1)	21.9 (-34.4 to 42.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	125.6 (49.9 to 333.2)	6.1 (-34.3 to 43.6)
Hodgkin lymphoma	0.3 (0.2 to 0.5)	0.9 (0.6 to 1.5)	184.4 (64.0 to 457.9)	43.4 (-7.1 to 140.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	180.8 (68.2 to 423.5)	39.8 (5.4 to 120.5)
Non-Hodgkin lymphoma	0.7 (0.4 to 1.1)	1.5 (0.9 to 2.1)	139.8 (20.6 to 279.0)	12.9 (-26.2 to 60.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	145.3 (28.2 to 263.5)	14.5 (-22.6 to 58.1)
Multiple myeloma	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	228.7 (103.5 to 417.0)	36.1 (-17.7 to 120.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	216.6 (102.9 to 370.2)	32.6 (-20.9 to 108.7)
Leukemia	0.2 (0.1 to 0.3)	0.7 (0.4 to 1.1)	240.7 (62.2 to 501.1)	21.9 (-21.8 to 82.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	201.0 (83.4 to 341.0)	8.7 (-23.0 to 51.4)
Other neoplasms	2.3 (1.3 to 6.4)	6.4 (4.4 to 9.8)	242.0 (13.1 to 453.6)	19.1 (-33.8 to 90.1)	0.1 (0.1 to 0.4)	0.4 (0.3 to 0.6)	225.3 (26.1 to 404.1)	12.4 (-33.1 to 78.0)
Cardiovascular diseases	-	-	-	-	11.4 (7.5 to 16.0)	27.2 (17.9 to 39.1)	139.9 (81.1 to 201.1)	2.7 (-18.3 to 26.8)
Rheumatic heart disease	84.6 (63.5 to 112.9)	170.3 (122.6 to 214.8)	103.9 (25.2 to 195.5)	-10.3 (-38.5 to 30.5)	4.1 (2.4 to 6.4)	8.5 (5.2 to 12.6)	110.1 (28.2 to 203.6)	-6.3 (-33.9 to 38.3)
Ischemic heart disease	47.0 (36.6 to 60.6)	85.8 (71.9 to 101.2)	84.5 (33.5 to 150.0)	-19.9 (-39.2 to 6.8)	2.3 (1.3 to 3.6)	3.6 (2.2 to 5.4)	60.8 (15.5 to 146.3)	-29.0 (-53.5 to 4.9)
Cerebrovascular disease	-	-	-	-	0.6 (0.4 to 0.8)	1.3 (0.9 to 1.7)	129.4 (83.7 to 185.1)	-0.3 (-20.6 to 27.7)
Ischemic stroke	2.8 (2.4 to 3.3)	6.5 (5.4 to 7.5)	134.3 (89.8 to 187.8)	0.9 (-21.0 to 28.2)	0.4 (0.3 to 0.6)	1.0 (0.7 to 1.4)	133.1 (86.0 to 192.0)	1.7 (-20.6 to 29.9)
Hemorrhagic stroke	0.8 (0.7 to 1.0)	1.8 (1.5 to 2.2)	115.6 (63.4 to 178.9)	-6.7 (-29.8 to 25.9)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	114.9 (62.3 to 182.7)	-5.9 (-30.1 to 27.2)
Hypertensive heart disease	8.4 (5.1 to 12.4)	22.0 (16.5 to 28.2)	134.9 (50.6 to 333.3)	6.5 (-39.6 to 61.1)	1.0 (0.6 to 1.6)	2.4 (1.5 to 3.6)	135.1 (49.9 to 333.2)	-5.3 (-39.6 to 63.4)
Cardiomyopathy and myocarditis	6.6 (4.9 to 8.6)	15.7 (11.5 to 21.4)	139.8 (64.8 to 220.9)	8.8 (-35.2 to 45.1)	0.7 (0.4 to 1.1)	1.7 (1.1 to 2.7)	139.3 (65.0 to 225.4)	4.2 (-34.7 to 47.9)
Atrial fibrillation and flutter	0.7 (0.5 to 0.9)	3.6 (2.5 to 5.3)	387.1 (219.3 to 620.7)	110.3 (-10.1 to 263.1)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.5)	381.9 (201.8 to 631.4)	112.4 (6.3 to 264.4)
Peripheral vascular disease	97.8 (70.8 to 129.2)	248.9 (168.4 to 345.5)	155.4 (45.5 to 318.7)	-2.6 (-40.2 to 42.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	128.0 (3.2 to 360.5)	-8.8 (-54.7 to 74.8)
Endocarditis	0.7 (0.5 to 1.2)	1.1 (0.7 to 1.7)	60.2 (-15.6 to 179.8)	-26.4 (-71.3 to 59.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	70.2 (-19.9 to 239.3)	-24.6 (-72.0 to 92.4)
Other cardiovascular and circulatory diseases	35.0 (21.5 to 56.6)	120.4 (60.7 to 198.8)	257.2 (67.3 to 574.3)	2.2 (-32.6 to 192.9)	2.5 (1.3 to 4.2)	9.2 (3.9 to 16.1)	270.2 (67.8 to 583.0)	53.7 (-32.0 to 195.0)
Chronic respiratory diseases	-	-	-	-				

Appendix Table G.4 - Niger prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	128.4	0.0
Silicosis	0.0	0.1	124.4	-3.0	0.0	0.0	124.3	-2.9
Asbestosis	-	-	0.0	0.0	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.1	331.1	-	0.0	0.0	131.9	3.1
Asthma	89.5	287.3	214.5	31.4	3.9	12.5	217.0	32.1
Interstitial lung disease and pulmonary sarcoidosis	0.1	0.4	149.6	9.2	0.0	0.0	149.8	9.2
Other chronic respiratory diseases	-	-	-	-	6.2	9.0	48.3	-34.3
Cirrhosis	-	-	-	-	0.6	1.1	81.4	-19.6
Cirrhosis due to hepatitis B	1.5	1.8	16.8	-41.7	0.3	0.3	17.3	-41.5
Cirrhosis due to hepatitis C	0.6	1.8	200.1	22.9	0.1	0.3	199.6	24.6
Cirrhosis due to alcohol use	0.7	1.2	57.9	-27.3	0.1	0.2	58.8	-26.3
Cirrhosis due to other causes	1.0	2.1	123.1	8.4	0.2	0.4	125.7	8.8
Digestive diseases	-	-	-	-	9.6	21.2	121.1	-2.8
Peptic ulcer disease	39.1	76.1	93.5	-16.0	1.4	2.7	90.2	-14.8
Gastritis and duodenitis	91.8	197.9	115.8	-3.5	4.0	8.5	113.3	-5.3
Appendicitis	0.9	2.5	178.9	20.1	0.3	0.8	182.4	21.4
Paralytic ileus and intestinal obstruction	0.1	0.2	104.0	0.0	0.0	0.1	105.9	0.7
Inguinal, femoral, and abdominal hernia	39.3	71.1	82.8	-11.0	0.4	0.7	81.3	-10.5
Inflammatory bowel disease	6.8	18.9	179.2	26.6	1.4	4.0	180.5	27.4
Vascular intestinal disorders	0.0	0.0	285.9	18.7	0.0	0.0	284.3	16.6
Gallbladder and biliary diseases	2.0	5.5	176.6	-6.8	0.2	0.6	150.8	8.5
Pancreatitis	1.1	2.8	144.7	10.2	0.3	0.8	144.0	11.0
Other digestive diseases	-	-	-	-	1.5	2.9	95.7	-13.4
Neurological disorders	-	-	-	-	32.1	77.0	139.7	2.2
Alzheimer disease and other dementias	7.4	19.4	159.8	-1.0	1.0	2.7	154.8	0.2
Parkinson disease	0.4	1.0	144.1	0.5	0.0	0.1	142.9	1.0
Epilepsy	16.2	37.1	129.1	0.2	4.5	10.9	142.8	7.3
Multiple sclerosis	0.4	1.0	139.5	9.9	0.2	0.4	137.2	9.1
Migraine	523.0	1,131.9	117.0	-8.4	17.9	39.0	117.4	-3.1
Tension-type headache	903.6	2,041.7	126.3	1.2	14.2	31.5	126.7	1.8
Medication overuse headache	33.1	108.6	230.3	46.9	5.2	17.2	232.1	47.7
Other neurological disorders	0.0	0.0	125.0	-3.0	1.9	3.7	105.6	-20.4
Mental and substance use disorders	-	-	-	-	146.8	340.2	131.7	3.6
Schizophrenia	15.2	32.6	115.2	0.5	9.7	21.0	116.0	1.1
Alcohol use disorders	35.0	87.7	150.5	16.2	3.4	8.5	152.5	17.2
Drug use disorders	-	-	-	-	8.9	19.5	118.4	3.2
Opioid use disorders	11.9	26.2	120.8	5.4	4.9	10.8	121.4	5.6
Cocaine use disorders	2.9	7.8	115.4	0.5	1.1	2.7	115.9	2.5
Amphetamine use disorders	11.0	23.6	113.9	-2.2	1.4	3.1	114.2	-1.9
Cannabis use disorders	5.0	11.3	125.4	1.0	0.1	0.3	125.6	1.1
Other drug use disorders	-	-	-	-	2.0	4.2	116.1	-0.4
Depressive disorders	-	-	-	-	60.3	144.7	140.2	6.2
Major depressive disorder	259.5	627.8	143.0	6.6	53.5	129.9	143.9	7.2
Dysthymia	71.1	153.3	115.9	-1.3	6.9	14.8	116.1	-0.9
Bipolar disorder	40.2	86.8	115.9	-0.2	8.2	17.8	117.0	0.4
Anxiety disorders	172.8	387.9	124.6	-1.0	16.0	36.5	125.5	16.7
Eating disorders	-	-	-	-	1.8	4.1	121.0	0.1
Anorexia nervosa	1.3	2.9	131.0	2.6	0.3	0.6	131.8	3.3
Bulimia nervosa	7.4	16.2	118.0	-1.0	1.6	3.4	119.2	-0.5
Autistic spectrum disorders	-	-	-	-	9.2	21.3	153.1	2.1
Autism	23.4	54.3	131.8	1.7	5.8	13.5	132.9	2.3
Asperger syndrome	33.7	78.5	132.6	3.4	2.3	7.9	133.5	2.7
Attention-deficit/hyperactivity disorder	55.2	134.0	142.5	1.5	0.7	1.6	142.6	1.5
Conduct disorder	80.3	196.0	144.1	1.7	9.6	23.6	145.0	2.1
Idiopathic intellectual disability	25.6	56.7	119.8	-2.5	12.3	27.5	120.5	-2.2
Other mental and substance use disorders	88.2	192.4	118.2	1.2	6.6	14.4	119.0	1.8
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	47.0	116.3	147.1	13.2
Diabetes mellitus	69.8	281.2	302.7	82.9	5.0	20.3	303.0	80.9
Acute glomerulonephritis	0.1	0.1	57.5	0.0	0.0	0.0	57.5	0.0
Chronic kidney disease	-	-	-	-	12.1	27.2	125.3	-0.0
Chronic kidney disease due to diabetes mellitus	63.8	138.5	119.0	1.4	1.1	2.3	121.3	3.9
Chronic kidney disease due to hypertension	335.1	789.8	140.0	5.0	3.9	8.7	126.6	0.5
Chronic kidney disease due to glomerulonephritis	271.3	643.6	142.9	-1.0	4.4	11.9	131.5	4.5
Chronic kidney disease due to other causes	225.3	510.9	121.5	-6.9	2.8	6.0	117.9	-9.5
Urinary diseases and male infertility	-	-	-	-	2.1	5.2	149.7	7.9

Appendix Table G.4 - Niger prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	24.9 (22.8 to 26.9)	56.5 (51.7 to 61.7)	127.9 (101.7 to 157.1)	-4.1 (-14.8 to 7.6)	0.7 (0.5 to 1.0)	1.6 (1.0 to 2.2)	128.9 (100.8 to 159.4)	-3.5 (-14.5 to 9.0)
Other oral disorders	108.6 (102.0 to 115.4)	239.9 (226.1 to 253.7)	121.3 (103.6 to 139.3)	-1.0 (-8.3 to 6.0)	3.2 (2.0 to 4.8)	7.1 (4.4 to 10.5)	122.3 (102.3 to 140.9)	-0.6 (-8.5 to 7.1)
Injuries	-	-	-	-	26.9 (20.6 to 34.4)	53.0 (40.4 to 68.1)	97.2 (88.7 to 104.1)	-7.0 (-9.9 to -4.2)
Transport injuries	-	-	-	-	11.1 (8.3 to 14.2)	20.1 (15.2 to 25.9)	81.1 (72.4 to 89.9)	-12.1 (-15.4 to -8.6)
Road injuries	-	-	-	-	10.0 (7.5 to 12.8)	18.6 (13.6 to 23.2)	80.6 (71.2 to 90.1)	-12.7 (-16.3 to -8.9)
Pedestrian road injuries	-	-	-	-	2.6 (1.9 to 3.3)	4.2 (3.2 to 5.5)	63.7 (47.0 to 79.4)	-19.8 (-25.6 to -14.4)
Cyclist road injuries	-	-	-	-	0.9 (0.6 to 1.1)	1.3 (0.9 to 1.6)	46.3 (35.5 to 57.6)	-25.9 (-31.0 to -19.9)
Motorcyclist road injuries	-	-	-	-	1.5 (1.1 to 1.9)	2.3 (1.7 to 3.0)	58.3 (47.7 to 72.8)	-23.3 (-28.2 to -17.1)
Motor vehicle road injuries	-	-	-	-	4.9 (3.7 to 6.3)	10.0 (7.5 to 12.7)	103.9 (88.8 to 119.8)	-2.5 (-8.6 to 3.8)
Other road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	43.9 (34.6 to 54.0)	-35.9 (-39.1 to -32.5)
Other transport injuries	-	-	-	-	1.1 (0.8 to 1.4)	2.1 (1.5 to 2.7)	85.4 (74.3 to 97.6)	-7.2 (-13.2 to -1.3)
Unintentional injuries	-	-	-	-	14.3 (10.9 to 18.5)	30.9 (23.6 to 39.8)	115.5 (109.7 to 121.7)	-2.2 (-4.7 to 0.8)
Falls	-	-	-	-	5.4 (4.1 to 7.0)	13.2 (9.9 to 17.2)	142.7 (130.7 to 154.7)	3.1 (-1.5 to 8.0)
Drowning	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.8)	76.3 (58.0 to 95.4)	-5.8 (-24.9 to -11.1)
Fire, heat, and hot substances	-	-	-	-	0.9 (0.6 to 1.1)	1.6 (1.2 to 2.0)	83.9 (68.0 to 101.3)	-15.0 (-20.5 to -8.1)
Poisonings	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	66.9 (39.2 to 101.6)	-25.0 (-35.3 to -12.8)
Exposure to mechanical forces	-	-	-	-	4.7 (3.6 to 6.2)	9.4 (7.1 to 12.2)	98.1 (88.6 to 106.7)	-7.1 (-11.3 to -3.1)
Unintentional firearm injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	97.8 (84.4 to 114.8)	-5.8 (-11.7 to 1.2)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	170.2 (145.1 to 199.3)	25.3 (15.7 to 36.8)
Other exposure to mechanical forces	-	-	-	-	4.5 (3.4 to 5.9)	8.8 (6.7 to 11.6)	97.3 (87.5 to 106.0)	-7.5 (-11.9 to -3.4)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.4)	148.4 (137.0 to 162.3)	15.7 (10.6 to 22.0)
Animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.6 (0.5 to 0.8)	100.3 (86.9 to 114.0)	-6.7 (-11.9 to -1.4)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	97.0 (75.3 to 119.3)	-8.4 (-17.1 to 0.4)
Non-venomous animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.5)	103.8 (90.8 to 115.4)	-5.2 (-10.6 to -0.4)
Foreign body	-	-	-	-	0.3 (0.2 to 0.4)	0.7 (0.5 to 0.9)	134.3 (121.8 to 148.7)	6.5 (1.3 to 12.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	121.5 (91.0 to 163.8)	5.1 (-4.9 to 18.4)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	129.0 (104.1 to 153.6)	1.7 (-7.2 to 10.1)
Foreign body in other body part	-	-	-	-	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	141.8 (126.7 to 158.9)	8.0 (1.4 to 15.8)
Other unintentional injuries	-	-	-	-	2.2 (1.7 to 2.9)	4.5 (3.4 to 5.9)	104.0 (92.1 to 118.2)	-6.0 (-11.4 to 0.6)
Self-harm and interpersonal violence	-	-	-	-	0.6 (0.5 to 0.8)	1.4 (1.0 to 1.7)	152.8 (103.3 to 113.0)	0.2 (-3.8 to 4.4)
Self-harm	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	140.9 (121.8 to 161.2)	11.5 (3.8 to 19.6)
Interpersonal violence	-	-	-	-	0.5 (0.4 to 0.7)	1.1 (0.9 to 1.4)	108.1 (98.0 to 119.1)	-2.4 (-6.6 to 2.3)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	113.1 (100.2 to 127.5)	-0.9 (-6.6 to 5.4)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	142.0 (126.7 to 160.9)	12.0 (5.0 to 20.5)
Assault by other means	-	-	-	-	0.4 (0.3 to 0.5)	0.7 (0.5 to 0.9)	99.2 (85.4 to 114.1)	-6.2 (-12.4 to 0.4)
Forces of nature, war, and legal intervention	-	-	-	-	0.9 (0.3 to 2.2)	0.7 (0.3 to 1.6)	-14.3 (-51.3 to 45.3)	-42.9 (-67.3 to -7.1)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	891.7 (463.8 to 2,072.5)	333.9 (162.1 to 770.9)
Collective violence and legal intervention	-	-	-	-	0.8 (0.3 to 2.1)	0.5 (0.2 to 1.4)	-34.3 (-66.7 to 14.7)	-53.1 (-75.5 to -20.5)

Appendix Table G.4 - Nigeria prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	24,663.6 (23,873.5 to 25,582.5)	38,407.2 (37,260.8 to 39,555.3)	55.3 (48.5 to 61.2)	-17.3 (-20.5 to -14.2)	940.7 (633.6 to 1,331.2)	1,397.4 (937.7 to 2,005.8)	48.5 (38.7 to 56.6)	21.6 (-25.6 to 16.5)
Other nutritional deficiencies	-	-	-	-	0.3 (0.1 to 0.7)	0.6 (0.2 to 1.5)	140.1 (-23.4 to 595.6)	33.9 (-53.7 to 274.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	78.2 (50.5 to 115.8)	121.3 (77.6 to 182.6)	54.2 (36.1 to 81.4)	-17.2 (-25.8 to -6.6)
Sexually transmitted diseases excluding HIV	-	-	-	-	21.3 (12.2 to 35.7)	36.3 (20.3 to 63.4)	69.4 (35.9 to 112.1)	-10.2 (-26.1 to 8.1)
Syphilis	10.4 (9.1 to 11.9)	10.5 (9.1 to 11.9)	0.6 (-17.3 to 21.8)	-42.1 (-50.4 to -32.8)	1.9 (1.2 to 2.7)	1.9 (1.2 to 2.8)	-0.1 (-26.6 to 35.3)	-42.1 (-55.0 to -25.7)
Chlamydial infection	1,628.9 (1,254.7 to 1,986.1)	3,079.4 (2,333.7 to 4,000.0)	88.5 (38.2 to 158.1)	-0.0 (-26.3 to 38.5)	7.7 (4.0 to 12.8)	13.5 (6.9 to 24.3)	72.1 (4.6 to 177.9)	-7.9 (-42.9 to 41.6)
Gonococcal infection	558.4 (416.1 to 691.2)	1,105.9 (775.1 to 1,432.8)	97.0 (34.1 to 181.9)	4.1 (-28.0 to 45.2)	4.2 (2.4 to 6.5)	7.6 (4.1 to 13.0)	78.4 (24.0 to 175.0)	-5.2 (-32.1 to 40.4)
Trichomoniasis	1,685.8 (1,168.0 to 2,149.6)	3,088.3 (2,166.6 to 4,164.1)	84.3 (19.3 to 157.9)	1.1 (-32.5 to 39.5)	3.0 (1.1 to 6.5)	5.4 (1.9 to 12.5)	83.3 (15.5 to 165.7)	1.0 (-34.4 to 44.2)
Genital herpes	14,805.8 (14,062.8 to 15,525.0)	26,286.8 (24,858.6 to 27,632.3)	76.5 (64.2 to 89.8)	3.4 (-10.0 to 3.6)	4.0 (1.3 to 9.4)	7.1 (2.2 to 17.0)	7.8 (62.8 to 94.7)	-3.1 (-10.5 to 4.8)
Other sexually transmitted diseases	42.4 (29.6 to 56.1)	61.1 (42.9 to 82.4)	42.9 (26.7 to 68.7)	-23.7 (-31.8 to -9.9)	0.5 (0.3 to 0.8)	0.7 (0.4 to 1.3)	48.3 (2.6 to 113.1)	-21.0 (-43.1 to 9.3)
Hepatitis	-	-	-	-	11.1 (7.1 to 16.0)	15.5 (9.8 to 22.5)	39.7 (20.9 to 57.4)	-25.4 (-36.2 to -13.2)
Hepatitis A	170.5 (161.3 to 179.8)	283.2 (269.1 to 297.6)	65.4 (64.9 to 66.2)	-4.0 (-4.2 to -3.7)	3.1 (1.9 to 4.5)	5.5 (3.5 to 8.2)	80.1 (57.8 to 103.3)	3.4 (-7.9 to 15.8)
Hepatitis B	15,242.5 (14,091.6 to 16,376.9)	18,703.3 (16,749.9 to 19,822.6)	19.2 (6.7 to 33.6)	-35.2 (-41.6 to -27.9)	6.3 (4.0 to 9.2)	7.5 (4.6 to 11.1)	18.8 (-10.4 to 47.9)	-35.4 (-51.6 to -16.3)
Hepatitis C	5,893.9 (5,379.3 to 6,403.0)	7,552.6 (6,946.6 to 8,231.0)	27.7 (14.5 to 42.5)	-28.4 (-35.1 to -21.0)	0.7 (0.4 to 1.0)	0.9 (0.6 to 1.4)	33.7 (-0.5 to 79.2)	-23.7 (-43.7 to 4.1)
Hepatitis E	35.9 (24.4 to 47.4)	53.7 (39.2 to 69.7)	43.5 (1.2 to 172.2)	-18.0 (-41.9 to 44.5)	1.0 (0.5 to 1.6)	1.5 (0.9 to 2.4)	46.6 (-1.5 to 186.6)	-16.6 (-43.7 to 50.4)
Leprosy	11.8 (9.5 to 14.3)	14.9 (13.5 to 16.6)	26.6 (11.1 to 46.4)	-24.6 (-31.7 to -15.8)	0.7 (0.4 to 1.1)	0.9 (0.6 to 1.3)	28.7 (4.7 to 63.7)	-23.4 (-45.3 to -7.6)
Other infectious diseases	1,148.4 (887.6 to 1,465.4)	1,813.7 (1,510.5 to 2,123.3)	57.0 (25.7 to 98.7)	-16.2 (-30.6 to 1.4)	45.1 (28.3 to 66.6)	68.7 (44.1 to 100.8)	51.3 (19.5 to 105.0)	-19.2 (-35.4 to 6.6)
Non-communicable diseases	-	-	-	-	6,449.3 (4,775.0 to 8,333.0)	11,673.8 (8,574.5 to 15,052.9)	80.5 (76.2 to 84.7)	0.1 (-2.4 to 2.3)
Neoplasms	-	-	-	-	19.0 (13.4 to 25.5)	43.2 (29.4 to 59.2)	126.1 (81.9 to 187.8)	33.9 (8.5 to 70.6)
Esophageal cancer	1.2 (0.7 to 1.7)	2.1 (1.4 to 3.2)	82.8 (21.2 to 169.0)	0.2 (-25.6 to 62.8)	0.3 (0.1 to 0.3)	0.3 (0.2 to 0.6)	79.9 (22.5 to 153.4)	8.8 (-23.1 to 52.3)
Stomach cancer	7.4 (5.9 to 9.1)	9.7 (7.6 to 12.7)	30.8 (-3.0 to 84.6)	-20.5 (-41.0 to 10.5)	1.0 (0.7 to 1.3)	1.3 (0.8 to 1.8)	31.0 (-3.4 to 80.4)	-20.6 (-42.2 to 10.3)
Liver cancer	-	-	-	-	2.3 (1.4 to 3.6)	3.2 (1.8 to 5.1)	39.8 (-1.1 to 95.2)	15.2 (-39.5 to 19.3)
Liver cancer due to hepatitis B	4.2 (2.3 to 6.8)	6.3 (3.7 to 10.1)	50.6 (-20.9 to 169.2)	-13.2 (-53.7 to 55.9)	0.7 (0.4 to 1.2)	1.1 (0.6 to 1.8)	53.6 (-11.6 to 146.3)	-11.8 (-49.1 to 44.2)
Liver cancer due to hepatitis C	1.1 (0.6 to 1.8)	3.9 (2.1 to 6.9)	255.9 (87.1 to 625.0)	123.3 (20.2 to 352.7)	0.2 (0.1 to 0.3)	0.7 (0.3 to 1.2)	241.4 (95.3 to 526.6)	110.1 (20.5 to 280.0)
Liver cancer due to alcohol use	5.5 (3.3 to 9.1)	6.6 (3.4 to 11.1)	18.0 (-34.2 to 116.2)	-26.4 (-57.6 to 30.3)	0.9 (0.5 to 1.5)	1.9 (0.5 to 1.9)	17.4 (-29.1 to 89.9)	-27.0 (-54.5 to 14.9)
Liver cancer due to other causes	2.6 (1.6 to 4.0)	2.2 (1.3 to 3.6)	-9.2 (-55.9 to 48.0)	-53.2 (-75.2 to -31.1)	0.4 (0.3 to 0.7)	0.4 (0.2 to 0.6)	38.6 (-52.2 to 31.7)	54.1 (-72.9 to 21.8)
Larynx cancer	1.1 (0.8 to 1.6)	9.4 (0.9 to 3.0)	754.5 (-29.3 to 169.7)	-32.6 (-55.7 to 58.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	9.4 (-29.1 to 166.5)	-30.7 (-54.7 to 54.2)
Tracheal, bronchus and lung cancer	2.2 (1.8 to 2.7)	3.5 (2.8 to 4.5)	57.8 (18.2 to 111.1)	-4.1 (-26.5 to 24.0)	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	55.7 (13.6 to 108.5)	-4.8 (-30.0 to 27.6)
Breast cancer	31.2 (21.4 to 41.7)	89.4 (62.8 to 121.5)	185.4 (96.0 to 333.6)	59.2 (10.6 to 137.5)	2.8 (1.7 to 4.0)	7.1 (4.4 to 10.7)	156.5 (75.4 to 302.6)	43.6 (0.6 to 117.7)
Cervical cancer	48.5 (34.4 to 65.3)	80.7 (56.2 to 114.5)	64.7 (14.4 to 156.3)	3.9 (-40.5 to 37.2)	4.8 (2.4 to 5.8)	6.4 (3.9 to 9.7)	31.9 (3.1 to 115.0)	8.9 (-40.2 to 36.2)
Uterine cancer	8.5 (5.4 to 13.2)	19.5 (12.1 to 31.5)	129.4 (36.6 to 291.3)	30.1 (-19.2 to 115.5)	0.6 (0.3 to 1.0)	1.3 (0.7 to 2.2)	127.0 (35.3 to 291.6)	28.5 (-12.5 to 114.6)
Prostate cancer	13.7 (8.3 to 24.5)	82.4 (50.4 to 141.0)	500.7 (266.0 to 900.0)	255.1 (126.1 to 462.4)	1.3 (0.8 to 2.5)	6.8 (3.9 to 12.2)	404.6 (218.4 to 706.8)	205.5 (101.4 to 369.2)
Colon and rectum cancer	10.7 (8.8 to 12.8)	27.2 (21.0 to 34.2)	152.8 (95.8 to 232.2)	50.9 (18.2 to 92.7)	1.0 (0.7 to 1.4)	2.4 (1.6 to 3.4)	136.8 (82.2 to 210.3)	42.6 (10.2 to 86.8)
Lip and oral cavity cancer	3.1 (2.2 to 4.3)	5.8 (4.1 to 8.2)	84.2 (28.6 to 167.7)	10.5 (-24.8 to 59.3)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.8)	83.4 (27.2 to 163.1)	9.7 (-26.1 to 56.6)
Nasopharynx cancer	0.7 (0.5 to 1.0)	1.1 (0.7 to 1.7)	54.7 (-3.6 to 146.4)	-16.5 (-46.8 to 28.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	50.1 (-4.3 to 127.1)	-18.9 (-46.3 to 20.3)
Other pharynx cancer	0.6 (0.4 to 1.0)	1.0 (0.6 to 1.6)	54.0 (-8.4 to 156.6)	-7.7 (-44.3 to 57.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	54.0 (-1.4 to 145.2)	-6.8 (-40.4 to 53.8)
Gallbladder and biliary tract cancer	0.4 (0.3 to 0.5)	0.7 (0.4 to 1.0)	77.9 (20.6 to 172.7)	2.4 (-31.9 to 53.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	68.3 (20.3 to 143.6)	-3.3 (-32.3 to 40.8)
Pancreatic cancer	0.5 (0.4 to 0.7)	1.4 (1.1 to 1.8)	162.5 (88.0 to 269.4)	58.4 (15.0 to 118.0)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	157.1 (96.2 to 242.9)	51.0 (13.8 to 98.6)
Malignant skin melanoma	2.4 (2.4 to 4.3)	9.7 (5.0 to 19.0)	96.6 (39.1 to 196.9)	9.7 (-21.9 to 66.4)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	92.1 (34.0 to 192.5)	8.6 (-25.1 to 65.0)
Non-melanoma skin cancer	4.6 (2.6 to 6.3)	10.6 (5.9 to 15.3)	121.8 (21.6 to 414.5)	20.5 (-25.8 to 178.9)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	188.5 (91.7 to 326.8)	55.2 (6.1 to 136.6)
Ovarian cancer	3.1 (2.2 to 4.2)	6.9 (4.9 to 9.6)	123.2 (47.9 to 251.9)	24.2 (-15.2 to 93.3)	0.4 (0.3 to 0.6)	0.9 (0.6 to 1.4)	122.6 (36.8 to 260.4)	23.6 (22.8 to 95.9)
Testicular cancer	0.9 (0.5 to 1.5)	2.2 (1.2 to 3.6)	144.4 (29.6 to 339.5)	29.9 (-27.9 to 124.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	139.7 (21.5 to 347.7)	27.0 (-32.2 to 127.2)
Kidney cancer	2.7 (1.8 to 4.0)	7.1 (4.5 to 11.8)	164.8 (58.9 to 358.3)	42.4 (3.8 to 104.7)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.9)	158.0 (47.4 to 345.4)	37.1 (-3.2 to 99.2)
Bladder cancer	3.5 (2.4 to 4.7)	6.4 (4.8 to 8.7)	82.9 (29.4 to 169.0)	0.4 (-31.0 to 50.7)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	79.0 (23.8 to 163.5)	-0.8 (-33.2 to 50.4)
Brain and nervous system cancer	1.9 (1.3 to 2.7)	6.0 (3.6 to 8.3)	205.2 (109.0 to 350.7)	59.8 (20.3 to 112.7)	0.2 (0.1 to 0.3)	0.6 (0.3 to 0.8)	197.4 (108.0 to 322.3)	51.2 (15.3 to 100.4)
Thyroid cancer	3.2 (1.9 to 4.8)	6.2 (4.2 to 10.0)	87.8 (8.1 to 252.2)	3.4 (-40.4 to 86.8)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	82.7 (1.5 to 255.7)	0.6 (-42.3 to 86.6)
Mesothelioma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	67.9 (14.3 to 138.5)	0.0 (-35.0 to 38.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.4 (14.5 to 136.1)	-4.3 (-34.7 to 39.2)
Hodgkin lymphoma	3.1 (2.0 to 4.6)	9.5 (5.4 to 14.7)	201.8 (85.6 to 375.3)	75.9 (11.8 to 158.0)	0.3 (0.2 to 0.4)	0.7 (0.4 to 1.2)	184.9 (75.9 to 342.4)	64.9 (5.6 to 145.6)
Non-Hodgkin lymphoma	10.5 (6.9 to 15.8)	26.5 (15.7 to 41.9)	148.4 (58.0 to 301.8)	42.6 (2.0 to 97.1)	0.8 (0.5 to 1.2)	1.9 (1.0 to 3.0)	141.6 (57.0 to 272.8)	37.1 (-1.0 to 91.3)
Multiple myeloma	0.5 (0.3 to 0.8)	1.2 (0.8 to 1.8)	139.0 (43.5 to 293.5)	36.9 (-19.3 to 129.5)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	124.7 (38.7 to 257.4)	28.3 (-24.7 to 116.7)
Leukemia	2.7 (1.9 to 3.9)	7.1 (4.6 to 11.0)	159.4 (63.6 to 342.6)	26.9 (-12.9 to 85.4)	0.3 (0.2 to 0.5)	0.8 (0.5 to 1.2)	120.6 (57.1 to 227.8)	8.9 (-21.4 to 55.5)
Other neoplasms	25.2 (16.3 to 51.3)	78.7 (51.0 to 133.3)	226.1 (76.9 to 396.6)	55.1 (2.4 to 134.6)	1.7 (1.0 to 3.3)	4.9 (2.8 to 8.4)	198.6 (78.5 to 346.8)	40.1 (6.5 to 114.6)
Cardiovascular diseases	-	-	-	-	149.6 (102.1 to 208.9)	247.5 (167.3 to 342.3)	64.5 (35.3 to 104.7)	-5.3 (-21.6 to 16.0)
Rheumatic heart disease	1,089.9 (826.0 to 1,391.0)	1,636.9 (1,184.0 to 2,080.8)	52.6 (-3.5 to 112.6)	-18.0 (-44.5 to 19.9)	52.3 (30.7 to 80.9)	78.3 (46.4 to 121.3)	53.2 (-3.1 to 111.5)	-17.4 (-43.5 to 18.0)
Ischemic heart disease	702.4 (565.4 to 895.7)	865.5 (691.0 to 1,100.8)	23.1 (-12.4 to 76.6)	-24.1 (-43.6 to 6.2)	32.4 (19.8 to 49.5)	34.6 (20.1 to 54.0)	7.3 (-34.4 to 80.7)	-32.8 (-56.7 to 9.6)
Cerebrovascular disease	-	-	-	-	7.6 (5.3 to 10.2)	13.3 (8.6 to 18.8)	77.5 (33.9 to 117.5)	-0.1 (-25.2 to 22.4)
Ischemic stroke	38.6 (33.1 to 45.1)	67.9 (56.4 to 83.2)	77.5 (35.8 to 117.1)	-0.1 (-24.4 to 22.9)	5.8 (4.0 to 8.0)	10.2 (6.5 to 14.7)	77.5 (35.1 to 122.6)	1.1 (-24.6 to 24.9)
Hemorrhagic stroke	11.4 (9.4 to 14.0)	19.2 (15.3 to 23.4)	70.3 (20.9 to 120.5)	-6.9 (-33.5 to 23.9)	1.8 (1.2 to 2.5)	3.1 (2.0 to 4.4)	72.4 (20.2 to 129.6)	-5.1 (-34.4 to 27.9)
Hypertensive heart disease	117.1 (88.0 to 136.2)	301.0 (252.7 to 353.6)	168.1 (108.6 to 256.7)	48.1 (17.0 to 88.2)	12.0 (7.8 to 17.3)	32.4 (22.1 to 44.9)	170.3 (105.3 to 261.2)	30.2 (-13.1 to 100.6)
Cardiomyopathy and myocarditis	130.4 (108.8 to 152.5)	115.6 (96.2 to 140.9)	-12.1 (-30.9 to 14.8)	-49.5 (-61.6 to -32.5)	14.1 (9.3 to 19.6)	12.4 (8.1 to 17.7)	49.8 (-32.9 to 14.6)	-19.8 (-62.3 to -32.5)
Atrial fibrillation and flutter	11.9 (8.7 to 15.3)	59.8 (45.2 to 79.8)	412.9 (229.7 to 609.9)	167.1 (54.4 to 340.4)	0.9 (0.6 to 1.4)	4.6 (2.9 to 7.0)	402.1 (222.3 to 619.7)	174.2 (57.6 to 349.6)
Peripheral vascular disease	1,220.1 (855.8 to 1,610.4)	2,385.3 (1,421.8 to 3,507.4)	92.0 (9.5 to 235.4)	-0.8 (-39.5 to 64.0)	0.9 (0.3 to 2.0)	1.3 (0.4 to 3.0)	34.7 (-42.2 to 300.7)	-15.7 (-65.3 to 146.8)
Endocarditis	8.4 (6.0 to 13.0)	11.8 (8.8 to 16.6)	43.2 (-10.2 to 103.3)	-17.2 (-53.0 to 31.3)	0.8 (0.4 to 1.3)	1.1 (0.7 to 1.8)	50.2 (-17.9 to 130.1)	-1.3 (-55.9 to 43.9)

Appendix Table G.4 - Nigeria prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	72.6 (67.1 to 78.5)	-2.4 (-5.6 to 0.9)
Silicosis	0.4 (0.4 to 0.5)	0.7 (0.6 to 0.8)	63.2 (55.8 to 71.3)	-6.5 (-10.6 to -1.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	63.3 (55.8 to 71.3)	-6.4 (-10.6 to -1.7)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.5 (0.4 to 0.5)	0.8 (0.8 to 0.9)	80.3 (72.7 to 87.6)	1.6 (-2.2 to 5.5)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	81.3 (73.4 to 89.3)	2.1 (-2.1 to 6.3)
Asthma	4,160.4 (3,550.9 to 4,778.6)	5,541.6 (5,541.6 to 7,391.9)	57.2 (27.9 to 89.4)	-6.4 (-20.9 to 8.5)	181.9 (113.7 to 268.7)	285.3 (181.3 to 419.4)	57.7 (27.3 to 89.7)	-6.5 (-21.2 to 9.0)
Interstitial lung disease and pulmonary sarcoidosis	1.9 (1.4 to 2.4)	3.9 (2.9 to 4.9)	109.6 (36.6 to 198.5)	13.6 (-19.6 to 59.4)	0.3 (0.1 to 0.4)	0.5 (0.3 to 0.8)	110.5 (39.6 to 197.3)	14.2 (-18.6 to 59.2)
Other chronic respiratory diseases	-	-	-	-	67.0 (34.7 to 113.8)	112.3 (64.9 to 184.0)	69.0 (17.3 to 146.8)	-5.1 (-34.0 to 37.4)
Cirrhosis	-	-	-	-	7.2 (5.2 to 10.5)	11.5 (8.0 to 15.8)	69.9 (32.0 to 70.8)	45.1 (-24.3 to -5.4)
Cirrhosis due to hepatitis B	17.1 (10.8 to 21.8)	17.5 (8.5 to 25.9)	1.7 (-55.5 to 103.0)	-37.0 (68.1 to 19.5)	2.8 (1.5 to 4.3)	2.8 (1.2 to 4.7)	1.5 (-57.5 to 105.1)	-37.2 (69.3 to 17.8)
Cirrhosis due to hepatitis C	9.3 (5.3 to 13.7)	14.2 (7.9 to 18.3)	52.5 (-8.7 to 162.0)	-13.8 (-48.9 to 64.0)	1.5 (0.7 to 2.5)	2.3 (1.2 to 3.6)	53.1 (-13.2 to 171.5)	-12.0 (50.3 to 64.1)
Cirrhosis due to alcohol use	10.0 (7.5 to 12.9)	16.3 (11.7 to 21.4)	61.1 (7.8 to 145.3)	-10.6 (-38.4 to 31.1)	1.6 (1.0 to 2.5)	2.6 (1.6 to 4.2)	63.5 (1.4 to 165.1)	-9.8 (-41.1 to 38.1)
Cirrhosis due to other causes	10.1 (8.2 to 12.7)	21.8 (17.6 to 26.2)	116.7 (43.9 to 184.6)	30.7 (-9.1 to 74.9)	1.1 (1.0 to 2.6)	3.7 (2.3 to 5.6)	117.1 (33.0 to 224.8)	30.2 (-17.8 to 92.2)
Digestive diseases	-	-	-	-	123.5 (85.7 to 171.0)	226.5 (157.9 to 310.0)	83.6 (61.0 to 109.2)	-1.5 (-11.5 to 10.0)
Peptic ulcer disease	490.4 (408.9 to 550.7)	712.6 (571.1 to 828.8)	45.9 (16.2 to 74.4)	-16.8 (-30.3 to -4.1)	19.4 (13.1 to 28.1)	27.0 (17.9 to 38.6)	39.3 (7.6 to 73.7)	-22.7 (-35.0 to -7.8)
Gastritis and duodenitis	1,056.1 (909.1 to 1,183.4)	1,898.8 (1,700.5 to 2,063.0)	79.4 (52.1 to 113.4)	-1.5 (-15.6 to 16.1)	48.0 (32.0 to 69.3)	82.5 (55.2 to 118.7)	73.2 (41.9 to 103.7)	-8.1 (-19.0 to 8.6)
Appendicitis	10.3 (7.5 to 13.5)	24.0 (15.3 to 31.4)	134.9 (62.0 to 221.6)	19.9 (-12.3 to 58.0)	3.1 (1.8 to 4.9)	7.2 (3.9 to 11.0)	135.8 (50.8 to 252.1)	20.2 (-19.1 to 68.2)
Paralytic ileus and intestinal obstruction	0.4 (1.0 to 2.3)	2.6 (1.9 to 3.8)	78.9 (1.7 to 257.3)	0.7 (-17.9 to 25.5)	0.4 (0.2 to 0.7)	0.8 (0.4 to 1.3)	86.0 (-8.2 to 289.8)	2.0 (-24.8 to 39.6)
Inguinal, femoral, and abdominal hernia	487.9 (409.2 to 647.7)	682.5 (572.5 to 866.5)	41.0 (-5.6 to 83.8)	-15.3 (-32.5 to 3.4)	5.1 (2.4 to 10.3)	7.1 (3.4 to 14.1)	41.5 (-7.9 to 88.1)	-15.2 (-32.1 to 3.6)
Inflammatory bowel disease	88.4 (84.3 to 92.6)	202.2 (193.2 to 210.8)	128.3 (114.0 to 142.7)	26.1 (18.9 to 33.6)	18.5 (12.7 to 25.1)	42.4 (28.5 to 58.1)	129.3 (107.2 to 152.9)	26.9 (16.4 to 37.4)
Vascular intestinal disorders	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	122.8 (55.1 to 239.5)	0.6 (-33.7 to 52.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	123.9 (53.4 to 246.4)	1.5 (-41.6 to 67.7)
Gallbladder and biliary diseases	27.0 (23.4 to 30.6)	56.8 (50.0 to 63.8)	110.7 (73.1 to 149.7)	2.8 (-9.6 to 28.3)	9.6 (1.9 to 3.9)	9.9 (4.0 to 8.5)	112.2 (67.7 to 161.9)	9.7 (9.6 to 32.0)
Pancreatitis	14.9 (14.1 to 15.8)	30.0 (28.2 to 31.8)	100.4 (85.5 to 118.1)	8.9 (8.5 to 17.9)	4.4 (2.9 to 5.9)	8.8 (5.9 to 11.8)	100.4 (66.8 to 141.9)	9.4 (-7.2 to 28.3)
Other digestive diseases	-	-	-	-	21.8 (13.2 to 34.0)	44.7 (27.3 to 69.5)	105.1 (42.2 to 205.3)	10.3 (-23.6 to 62.6)
Neurological disorders	-	-	-	-	368.2 (242.3 to 507.8)	739.1 (497.4 to 1,030.7)	100.8 (77.6 to 126.3)	8.6 (-8.6 to 23.2)
Alzheimer disease and other dementias	105.4 (90.6 to 121.2)	183.0 (159.8 to 205.2)	74.5 (39.6 to 108.3)	-0.8 (-20.6 to 21.5)	13.9 (9.8 to 18.6)	24.3 (17.4 to 31.8)	75.2 (40.1 to 111.8)	0.1 (-20.3 to 23.9)
Parkinson disease	5.8 (4.9 to 6.7)	10.1 (8.5 to 11.7)	74.4 (62.8 to 83.4)	1.6 (-5.1 to 7.1)	0.7 (0.4 to 1.0)	1.2 (0.8 to 1.7)	75.9 (44.0 to 110.8)	2.4 (-13.9 to 21.4)
Epilepsy	143.5 (82.3 to 231.3)	242.7 (133.6 to 377.8)	67.9 (-21.7 to 252.1)	-7.1 (-58.0 to 91.8)	39.7 (19.5 to 67.3)	72.1 (36.2 to 123.0)	81.5 (-16.8 to 279.2)	0.6 (-54.4 to 107.5)
Multiple sclerosis	5.4 (4.8 to 6.1)	11.4 (10.2 to 12.6)	108.6 (78.7 to 146.4)	14.6 (-1.4 to 33.2)	1.9 (1.3 to 2.5)	3.9 (2.7 to 5.2)	105.4 (65.6 to 157.6)	12.8 (9.3 to 39.2)
Migraine	6,232.8 (5,708.2 to 6,754.3)	11,858.4 (10,821.3 to 12,812.1)	90.4 (68.2 to 112.6)	8.8 (-6.6 to 17.7)	245.5 (126.3 to 312.0)	401.0 (239.5 to 589.7)	89.5 (76.8 to 114.5)	3.3 (-6.8 to 18.1)
Tension-type headache	11,445.1 (10,550.1 to 12,399.3)	22,139.1 (20,174.9 to 24,226.7)	92.4 (73.4 to 116.9)	3.8 (-5.2 to 14.8)	17.2 (8.3 to 30.4)	33.2 (16.2 to 58.7)	93.0 (67.6 to 119.6)	4.2 (-5.8 to 16.2)
Medication overuse headache	432.8 (277.5 to 620.4)	1,126.5 (751.8 to 1,557.5)	156.4 (102.4 to 252.7)	38.1 (8.6 to 94.2)	66.8 (36.9 to 105.4)	174.4 (97.0 to 275.4)	158.8 (102.3 to 259.2)	39.0 (8.9 to 94.7)
Other neurological disorders	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	71.5 (26.3 to 131.6)	-5.1 (-30.5 to 26.1)	17.4 (10.6 to 27.4)	29.0 (17.6 to 42.4)	66.9 (9.9 to 153.2)	-5.5 (-39.5 to 46.2)
Mental and substance use disorders	-	-	-	-	1,820.2 (1,281.2 to 2,376.2)	3,346.5 (2,359.9 to 4,371.6)	83.8 (75.1 to 89.0)	0.6 (-1.9 to 3.2)
Schizophrenia	195.5 (178.9 to 212.2)	360.5 (328.3 to 391.4)	83.3 (75.6 to 93.5)	-0.3 (-4.5 to 4.4)	122.6 (89.6 to 147.7)	226.7 (166.2 to 274.1)	86.6 (72.6 to 99.0)	0.2 (-6.1 to 7.5)
Alcohol use disorders	450.3 (420.4 to 480.9)	961.4 (898.7 to 1,027.9)	112.7 (102.7 to 122.8)	16.0 (10.3 to 21.1)	42.7 (28.7 to 60.4)	91.7 (62.9 to 130.7)	115.0 (100.7 to 130.6)	16.7 (9.3 to 24.6)
Drug use disorders	-	-	-	-	115.8 (78.1 to 160.3)	215.6 (140.6 to 300.8)	86.7 (66.9 to 108.6)	-0.2 (-9.6 to 10.8)
Opioid use disorders	158.3 (105.1 to 224.4)	289.3 (186.4 to 428.2)	80.9 (64.6 to 100.5)	-1.9 (-10.5 to 7.8)	63.8 (38.4 to 97.1)	116.5 (68.0 to 181.3)	81.7 (60.9 to 104.8)	-1.8 (-12.7 to 10.0)
Cocaine use disorders	45.5 (37.0 to 54.1)	90.4 (74.3 to 104.7)	98.2 (50.1 to 154.6)	5.4 (-16.2 to 31.5)	6.1 (3.7 to 9.1)	12.1 (7.7 to 18.0)	106.6 (64.0 to 173.5)	5.9 (-20.2 to 41.8)
Amphetamine use disorders	144.5 (131.8 to 156.3)	271.0 (250.9 to 292.5)	87.2 (67.8 to 107.9)	0.2 (-9.6 to 10.4)	18.6 (11.5 to 27.4)	35.0 (21.7 to 51.8)	87.7 (58.5 to 121.7)	0.2 (-14.7 to 18.1)
Cannabis use disorders	78.5 (62.6 to 93.2)	145.9 (116.7 to 173.0)	85.4 (84.3 to 86.7)	0.2 (0.1 to 0.2)	2.3 (1.3 to 3.4)	4.2 (2.5 to 6.2)	86.1 (51.9 to 132.3)	0.4 (-16.9 to 22.3)
Other drug use disorders	-	-	-	-	25.0 (15.2 to 37.4)	47.8 (29.6 to 71.7)	91.0 (38.7 to 162.6)	2.2 (-25.9 to 39.9)
Depressive disorders	-	-	-	-	764.7 (492.8 to 1,108.1)	1,378.7 (887.4 to 2,015.5)	80.2 (71.1 to 90.3)	-0.7 (-5.6 to 4.4)
Major depressive disorder	3,331.4 (2,523.8 to 4,164.0)	5,981.8 (4,468.3 to 7,584.3)	79.0 (69.5 to 89.7)	-1.2 (-7.1 to 4.3)	1,214.7 (423.3 to 990.5)	2,124.7 (754.7 to 1,824.3)	78.8 (69.6 to 91.2)	-0.8 (-6.6 to 5.1)
Dysthymia	942.2 (746.2 to 1,149.5)	1,725.0 (1,356.5 to 2,116.3)	82.4 (80.0 to 84.5)	-0.3 (-0.4 to -0.3)	89.3 (57.4 to 132.7)	164.1 (106.2 to 242.1)	83.2 (77.5 to 88.8)	0.1 (-2.3 to 2.5)
Bipolar disorder	516.0 (443.3 to 587.0)	957.2 (820.4 to 1,085.9)	85.1 (73.5 to 95.1)	-0.3 (-5.7 to 4.1)	103.3 (63.1 to 156.2)	191.8 (119.0 to 290.5)	86.0 (72.3 to 99.0)	0.0 (-6.4 to 6.1)
Anxiety disorders	2,168.9 (1,783.3 to 2,544.8)	3,954.6 (3,237.7 to 4,660.5)	81.1 (80.1 to 83.6)	0.3 (-0.3 to -0.2)	197.9 (130.1 to 281.2)	361.0 (239.5 to 515.9)	82.4 (75.7 to 89.3)	0.0 (-3.0 to 3.1)
Eating disorders	-	-	-	-	22.3 (13.6 to 35.2)	41.7 (25.4 to 65.8)	87.1 (69.9 to 104.6)	0.3 (-8.1 to 9.0)
Anorexia nervosa	15.5 (11.5 to 20.5)	29.4 (22.2 to 38.4)	89.2 (73.4 to 112.9)	2.3 (-6.2 to 15.9)	3.3 (1.9 to 5.2)	6.2 (3.8 to 9.4)	89.6 (49.1 to 151.6)	2.9 (-19.3 to 35.1)
Bulimia nervosa	91.6 (62.8 to 133.6)	170.5 (117.0 to 248.7)	85.7 (83.6 to 87.4)	-0.6 (-0.7 to -0.5)	19.1 (11.1 to 30.7)	35.5 (20.6 to 58.2)	86.5 (69.3 to 104.1)	-0.3 (-9.1 to 8.7)
Autistic spectrum disorders	-	-	-	-	113.9 (79.3 to 155.2)	208.6 (144.8 to 284.8)	83.0 (76.3 to 89.9)	1.0 (-1.1 to 4.2)
Autism	294.5 (279.4 to 309.8)	537.5 (510.0 to 565.6)	81.9 (81.9 to 82.0)	0.4 (0.4 to 0.5)	71.9 (48.4 to 98.9)	131.7 (89.1 to 182.8)	82.9 (73.2 to 93.2)	0.9 (-3.6 to 5.9)
Asperger syndrome	424.3 (397.5 to 449.2)	774.9 (726.0 to 820.8)	82.0 (81.9 to 82.2)	0.6 (0.6 to 0.6)	42.0 (28.7 to 58.4)	76.9 (53.9 to 106.9)	83.0 (75.4 to 91.6)	1.1 (-2.7 to 5.1)
Attention-deficit/hyperactivity disorder	701.8 (648.0 to 758.8)	1,262.5 (1,165.0 to 1,364.4)	79.4 (79.2 to 79.5)	0.3 (0.3 to 0.3)	8.5 (5.0 to 13.0)	15.3 (9.0 to 23.2)	79.9 (67.0 to 93.4)	0.4 (-6.7 to 8.2)
Conduct disorder	1,029.0 (970.4 to 1,090.1)	1,838.4 (1,733.0 to 1,948.1)	78.2 (78.0 to 78.4)	0.3 (0.3 to 0.3)	122.3 (77.3 to 175.6)	219.3 (136.2 to 317.3)	79.2 (75.5 to 88.0)	0.1 (-3.4 to 5.4)
Idiopathic intellectual disability	2,484.7 (1,324.8 to 3,517.6)	4,876.9 (3,251.2 to 6,309.5)	95.3 (64.3 to 168.9)	7.3 (-10.4 to 54.8)	120.6 (57.6 to 187.4)	236.8 (138.7 to 348.1)	95.8 (64.0 to 173.9)	7.7 (-10.0 to 54.1)
Other mental and substance use disorders	1,164.1 (1,086.4 to 1,236.3)	2,164.9 (2,018.3 to 2,300.1)	85.4 (84.7 to 86.0)	0.4 (0.3 to 0.5)	85.6 (58.4 to 114.9)	159.5 (109.1 to 214.9)	86.0 (78.7 to 94.3)	0.7 (-2.7 to 4.4)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	632.6 (448.8 to 864.2)	1,173.8 (836.6 to 1,591.5)	85.3 (73.5 to 98.6)	6.8 (-1.4 to 15.6)
Diabetes mellitus	631.2 (504.5 to 753.5)	2,390.8 (1,881.7 to 2,957.8)	274.4 (186.7 to 419.0)	112.7 (59.3 to 201.9)	46.8 (30.6 to 66.7)	169.4 (109.0 to 246.2)	256.8 (176.1 to 405.8)	103.5 (52.7 to 192.3)
Acute glomerulonephritis	0.9 (0.8 to 1.0)	1.1 (1.0 to 1.2)	23.6 (13.4 to 33.5)	-39.2 (-34.5 to -25.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	23.7 (13.5 to 33.7)	30.2 (-34.5 to -25.5)
Chronic kidney disease	-	-	-	-	168.9 (118.6 to 225.6)	287.7 (200.6 to 389.5)	71.0 (47.9 to 94.9)	-4.3 (-18.0 to 8.5)
Chronic kidney disease due to diabetes mellitus	1,343.5 (903.0 to 2,114.3)	1,777.6 (1,407.4 to 2,167.9)	35.3 (-12.2 to 99.1)	-17.2 (-46.8 to 15.0)	15.8 (9.9 to 23.2)	26.4 (16.8 to 38.9)	66.7 (23.0 to 126.0)	-2.4 (-30.6 to 31.4)
Chronic kidney disease due to hypertension	6,197.6 (3,794.4 to 9,110.8)	9,037.9 (6,319.7 to 13,141.1)	47.2 (-1.1 to 115.4)	-20.5 (-44.2 to 12.9)	54.9 (37.5 to 75.3)	95.2 (62.5 to 134.2)	73.9 (35.4 to 115.3)	3.1 (-22.4 to 21.9)
Chronic kidney disease due to glomerulonephritis	5,414.4 (3,361.1 to 8,185.6)	7,956.1 (5,540.6 to 10,007.5)	81.1 (-28.8 to 111.9)	-15.6 (-56.2 to 13.5)	60.1 (41.8 to 82.6)	103.7 (72.0 to 139.3)	72.5 (41.3 to 112.1)	4.0 (-23.5 to 17.1)
Chronic kidney disease due to other causes	4,067.6 (2,337.7 to 5,864.8)	5,776.6 (3,745.5 to 9,196.6)	42.4 (-5.1 to 70.9)	-20.9 (-46.4 to 5.6)	38.1 (25.8 to 52.7)	62.4 (42.1 to 86.0)	64.2 (28.4 to 106.4)	-7.9 (-28.2 to 15.9)
Urinary diseases and male infertility	-	-	-	-	27.9 (17.4 to 41.1)	50.2 (31.5 to 71.6)	79.9 (64.9 to 94.6)	5.6 (-1.0 to 11.8)

Appendix Table G.4 - Nigeria prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	295.1 (274.3 to 318.6)	432.5 (395.9 to 465.0)	46.1 (31.3 to 62.6)	-16.1 (-24.0 to -8.1)	8.0 (5.4 to 11.0)	11.7 (7.9 to 16.1)	46.9 (30.7 to 66.3)	46.9 (-23.8 to -6.4)
Other oral disorders	1,385.5 (1,304.2 to 1,461.5)	2,513.3 (2,346.9 to 2,660.2)	81.0 (66.9 to 96.2)	-0.6 (-8.0 to 7.0)	40.2 (24.9 to 60.1)	73.0 (45.6 to 110.3)	81.6 (66.1 to 98.1)	-0.3 (-8.4 to 7.8)
Injuries	-	-	-	-	461.7 (351.7 to 593.3)	830.7 (629.1 to 1,068.2)	79.7 (74.5 to 85.9)	1.3 (-1.4 to 4.1)
Transport injuries	-	-	-	-	261.9 (198.6 to 336.9)	501.6 (379.0 to 646.9)	91.2 (83.6 to 100.7)	6.2 (2.8 to 11.4)
Road injuries	-	-	-	-	250.3 (189.7 to 321.9)	479.0 (361.9 to 617.5)	91.2 (83.1 to 101.1)	6.2 (2.3 to 11.1)
Pedestrian road injuries	-	-	-	-	62.0 (46.9 to 80.0)	111.3 (83.7 to 143.7)	79.9 (65.4 to 94.3)	0.6 (-6.0 to 7.1)
Cyclist road injuries	-	-	-	-	20.2 (15.2 to 26.2)	32.2 (24.0 to 41.8)	59.6 (48.9 to 71.0)	-7.6 (-13.7 to -2.0)
Motorcyclist road injuries	-	-	-	-	42.4 (31.8 to 54.7)	68.5 (50.9 to 88.8)	61.3 (51.1 to 72.3)	-10.5 (-15.9 to -4.7)
Motor vehicle road injuries	-	-	-	-	121.3 (91.6 to 156.4)	260.9 (197.5 to 334.7)	114.4 (102.4 to 132.1)	18.4 (12.0 to 26.7)
Other road injuries	-	-	-	-	4.3 (3.2 to 5.5)	6.1 (4.6 to 7.8)	40.8 (31.8 to 49.1)	-26.3 (-30.4 to -22.4)
Other transport injuries	-	-	-	-	11.6 (8.7 to 15.0)	22.6 (17.0 to 29.3)	93.7 (82.5 to 106.8)	17.3 (10.4 to 25.2)
Unintentional injuries	-	-	-	-	191.2 (144.8 to 245.5)	309.8 (235.7 to 398.1)	61.9 (58.0 to 66.0)	-7.1 (-9.4 to -4.7)
Falls	-	-	-	-	76.4 (58.2 to 98.9)	130.9 (98.0 to 169.4)	71.2 (60.9 to 79.2)	-4.5 (-8.3 to -0.8)
Drowning	-	-	-	-	4.7 (3.5 to 6.1)	6.0 (4.5 to 7.9)	29.4 (15.6 to 42.3)	-25.0 (-31.6 to -18.8)
Fire, heat, and hot substances	-	-	-	-	12.3 (9.5 to 15.7)	17.3 (13.2 to 22.0)	40.5 (28.1 to 52.7)	-18.6 (-23.9 to -13.1)
Poisonings	-	-	-	-	0.5 (0.4 to 0.7)	0.7 (0.5 to 1.0)	31.7 (10.2 to 56.1)	-26.1 (-36.4 to -15.7)
Exposure to mechanical forces	-	-	-	-	57.8 (44.2 to 75.3)	90.2 (68.3 to 117.9)	56.2 (48.5 to 64.0)	-10.2 (-14.5 to -6.0)
Unintentional firearm injuries	-	-	-	-	2.4 (1.8 to 3.0)	3.7 (2.8 to 4.7)	54.0 (42.1 to 65.0)	-11.8 (-18.4 to -6.2)
Unintentional suffocation	-	-	-	-	0.6 (0.5 to 0.8)	1.3 (1.0 to 1.6)	109.1 (86.4 to 127.7)	18.8 (7.9 to 28.9)
Other exposure to mechanical forces	-	-	-	-	54.8 (41.7 to 71.6)	85.3 (64.3 to 111.8)	55.6 (47.7 to 64.0)	-10.4 (-14.9 to -6.0)
Adverse effects of medical treatment	-	-	-	-	1.3 (0.8 to 1.9)	2.5 (1.6 to 3.8)	97.1 (84.0 to 111.0)	15.3 (7.8 to 23.4)
Animal contact	-	-	-	-	4.2 (3.1 to 5.4)	6.5 (4.9 to 8.5)	54.7 (44.7 to 64.7)	-11.1 (-15.8 to -6.5)
Venomous animal contact	-	-	-	-	1.9 (1.4 to 2.5)	2.9 (2.1 to 3.9)	55.4 (37.0 to 73.7)	-11.5 (-20.4 to -2.6)
Non-venomous animal contact	-	-	-	-	2.3 (1.7 to 3.1)	3.6 (2.6 to 4.9)	53.9 (45.3 to 64.1)	-10.8 (-15.0 to -6.6)
Foreign body	-	-	-	-	3.9 (3.0 to 5.0)	6.9 (5.2 to 8.7)	75.1 (65.9 to 83.2)	0.0 (-4.6 to 4.4)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.9 (0.7 to 1.2)	1.5 (1.1 to 1.9)	61.1 (42.3 to 81.0)	-3.2 (-11.9 to 5.3)
Foreign body in eyes	-	-	-	-	0.8 (0.4 to 1.2)	1.4 (0.8 to 2.1)	79.6 (61.7 to 101.5)	-1.3 (-9.4 to 7.8)
Foreign body in other body part	-	-	-	-	2.2 (1.7 to 2.9)	4.0 (3.1 to 5.2)	79.1 (68.1 to 89.9)	1.3 (-4.9 to 7.5)
Other unintentional injuries	-	-	-	-	30.0 (22.7 to 38.8)	48.7 (36.8 to 62.4)	62.0 (52.2 to 72.5)	-5.5 (-10.8 to 0.1)
Self-harm and interpersonal violence	-	-	-	-	7.2 (5.5 to 9.1)	12.2 (9.3 to 15.5)	70.4 (61.8 to 78.0)	-2.1 (-6.5 to 1.9)
Self-harm	-	-	-	-	0.5 (0.4 to 0.7)	1.2 (0.9 to 1.6)	129.5 (114.3 to 146.8)	28.7 (21.4 to 37.3)
Interpersonal violence	-	-	-	-	6.7 (5.1 to 8.4)	11.0 (8.4 to 14.0)	65.9 (56.9 to 74.0)	-5.8 (-10.5 to -1.4)
Assault by firearm	-	-	-	-	1.2 (0.9 to 1.6)	2.1 (1.6 to 2.7)	73.2 (60.6 to 87.0)	-1.0 (-7.9 to 5.7)
Assault by sharp object	-	-	-	-	0.9 (0.7 to 1.1)	1.8 (1.4 to 2.3)	102.4 (91.0 to 116.1)	13.4 (7.2 to 20.7)
Assault by other means	-	-	-	-	4.6 (3.5 to 5.8)	7.1 (5.4 to 9.0)	56.5 (46.3 to 67.4)	-11.1 (-16.7 to -5.1)
Forces of nature, war, and legal intervention	-	-	-	-	1.4 (0.5 to 3.5)	7.1 (2.6 to 21.1)	384.0 (282.3 to 768.0)	158.8 (108.0 to 309.8)
Exposure to forces of nature	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.0 to 0.1)	-57.5 (-61.3 to -35.1)	-70.5 (-73.5 to -66.0)
Collective violence and legal intervention	-	-	-	-	1.3 (0.4 to 3.4)	6.7 (2.5 to 16.7)	421.6 (311.4 to 644.9)	177.6 (121.3 to 293.1)

Appendix Table G.4 - North Korea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,765.9 (1,301.2 to 2,318.6)	2,403.5 (1,775.6 to 3,157.6)	36.3 (28.3 to 45.7)	36.3 (9.5 to 1.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	329.5	339.3	3.1	-11.3
HIV/AIDS and tuberculosis	-	-	-	-	(223.9 to 472.5)	(238.0 to 463.9)	(7.8 to 16.0)	(-20.4 to -0.7)
Tuberculosis	63.0 (56.1 to 69.7)	155.2 (147.5 to 163.8)	145.9 (122.4 to 177.0)	60.8 (45.6 to 82.1)	19.4 (13.1 to 26.5)	47.6 (32.8 to 65.1)	145.2 (119.5 to 178.3)	62.8 (46.4 to 83.7)
HIV/AIDS	-	-	-	-	0.1	0.6	505.1	1,635.3
HIV/AIDS resulting in mycobacterial infection	0.0	0.1	9,154.1	6,013.2	(0.0 to 0.0)	(0.2 to 1.2)	(1,845.2 to 37,390.1)	(1,327.2 to 12,564.7)
HIV/AIDS resulting in other diseases	0.0 to 0.0	(0.1 to 0.3)	(3,747.5 to 33,487.6)	(2,434.8 to 22,244.1)	0.0	0.1	9,154.1	6,013.2
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	40.2	28.8	-28.5	-32.5
Diarrheal diseases	135.2 (124.3 to 145.7)	62.9 (56.4 to 69.0)	-53.5 (-59.2 to -47.4)	-51.5 (-57.2 to -45.1)	22.0 (14.9 to 31.0)	10.3 (6.9 to 14.7)	-34.7 (-53.3 to -46.3)	-27.0 (-56.9 to -43.7)
Intestinal infectious diseases	-	-	-	-	0.0	0.0	-17.8	-25.5
Typhoid fever	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-24.6 (-56.6 to 15.0)	-32.3 (-60.5 to 0.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.6 (-56.8 to 15.1)	-32.3 (-60.7 to 0.3)
Paratyphoid fever	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-18.2 (-58.3 to 22.8)	-24.7 (-60.8 to 12.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.2 (-58.4 to 22.9)	-24.7 (-60.9 to 12.8)
Other intestinal infectious diseases	-	-	-	-	0.0	0.0	647.3	569.4
Lower respiratory infections	36.4 (33.7 to 39.3)	51.3 (48.4 to 54.1)	41.0 (29.0 to 54.5)	30.1 (19.5 to 41.6)	3.8 (2.6 to 5.4)	5.3 (3.5 to 7.3)	36.8 (23.0 to 52.7)	26.6 (14.2 to 41.2)
Upper respiratory infections	254.6 (243.1 to 266.8)	296.0 (278.9 to 309.0)	16.1 (8.9 to 23.8)	-1.9 (-8.1 to 4.2)	3.0 (1.7 to 5.0)	3.5 (2.0 to 5.7)	15.7 (7.1 to 25.2)	-2.0 (-9.0 to 5.8)
Otitis media	256.4 (243.6 to 271.6)	255.7 (239.8 to 271.4)	-0.4 (-7.3 to 6.9)	-12.3 (-18.1 to -6.4)	5.0 (2.9 to 8.0)	5.0 (2.9 to 8.0)	-0.1 (-7.7 to 8.9)	-11.6 (-18.2 to -4.3)
Meningitis	-	-	-	-	3.1	1.7	-43.4	-52.1
Pneumococcal meningitis	10.3 (5.8 to 16.9)	7.0 (4.1 to 10.9)	-32.1 (-48.4 to -7.1)	-47.0 (-59.9 to -27.5)	(2.0 to 4.5)	(1.2 to 2.5)	(-55.8 to -26.2)	(-62.5 to -37.8)
H influenzae type B meningitis	4.6 (1.5 to 9.2)	2.3 (0.9 to 4.2)	-49.0 (-68.0 to -26.6)	-58.4 (-73.7 to -39.4)	0.5 (0.3 to 0.8)	0.2 (0.1 to 0.4)	-54.1 (-73.6 to -28.6)	-59.8 (-76.8 to -37.7)
Meningococcal meningitis	2.5 (0.7 to 5.7)	1.3 (0.4 to 2.9)	-46.7 (-61.0 to -19.7)	-58.2 (-69.8 to -33.3)	0.3 (0.2 to 0.5)	0.4 (0.1 to 0.2)	-47.9 (-65.1 to -17.3)	-57.6 (-71.6 to -32.2)
Other meningitis	13.5 (4.8 to 27.3)	7.2 (3.1 to 13.3)	-45.2 (-59.4 to -24.8)	-55.7 (-67.1 to -36.3)	1.4 (0.8 to 2.3)	0.8 (0.5 to 1.1)	-45.5 (-66.5 to -15.5)	-53.3 (-71.2 to -26.9)
Encephalitis	3.3 to 16.6	8.4 (3.8 to 17.8)	13.1 (-0.5 to 40.7)	-15.5 (-26.8 to 5.6)	0.9 (0.6 to 1.3)	1.1 (0.7 to 1.5)	14.8 (5.4 to 39.8)	-12.6 (-27.4 to 6.4)
Diphtheria	0.1 (0.0 to 0.4)	0.0 (0.0 to 0.0)	-80.8 (-98.4 to 108.1)	-82.8 (-98.5 to 101.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-80.8 (-98.5 to 109.5)	-82.8 (-98.6 to 101.9)
Whooping cough	30.2 (23.0 to 39.6)	14.6 (11.2 to 18.8)	-51.8 (-53.6 to -49.9)	-45.3 (-47.4 to -43.2)	1.5 (0.9 to 2.5)	0.7 (0.4 to 1.2)	-51.7 (-55.3 to -47.7)	-45.2 (-49.3 to -40.7)
Tetanus	0.8 (0.3 to 1.5)	0.1 (0.1 to 0.3)	-87.1 (-95.1 to -15.6)	-89.2 (-95.8 to -28.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-65.4 (-89.3 to 297.5)	-69.8 (-90.5 to 250.0)
Measles	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-42.6 (-46.5 to -38.3)	-35.7 (-40.0 to -30.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.8 (-50.9 to -32.5)	-34.8 (-44.9 to -24.5)
Varicella and herpes zoster	21.0 (19.1 to 22.9)	25.4 (23.5 to 29.8)	25.7 (11.0 to 45.7)	-0.5 (-12.6 to 16.1)	0.8 (0.5 to 1.2)	1.1 (0.7 to 1.7)	43.2 (16.0 to 77.9)	0.2 (-18.1 to 23.0)
Neglected tropical diseases and malaria	-	-	-	-	23.3 (12.6 to 41.2)	11.5 (7.4 to 17.4)	-49.0 (-69.1 to -27.5)	-55.4 (-72.7 to -36.6)
Malaria	2.0 (1.8 to 2.2)	2.6 (2.3 to 2.8)	26.7 (16.2 to 39.2)	5.5 (-3.4 to 16.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	23.8 (21.9 to 25.3)	4.4 (2.6 to 5.9)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0	0.0	14.4	-0.4
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.4 (-44.5 to 85.6)	-1.3 (50.0 to 65.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.4 (-44.8 to 86.7)	-1.3 (50.0 to 65.7)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	28.2 (1.9 to 54.5)	4.2 (-17.0 to 25.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.2 (1.8 to 54.5)	4.2 (-17.0 to 25.6)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	3.1 (1.2 to 6.0)	2.2 (1.1 to 3.9)	-30.9 (-40.8 to 151.7)	-52.0 (86.0 to 54.5)	0.9 (0.3 to 1.8)	0.6 (0.3 to 1.2)	-27.8 (-80.3 to 175.5)	-49.9 (85.6 to 74.0)
Cystic echinococcosis	4.8 (4.6 to 5.3)	4.3 (3.9 to 4.7)	-12.7 (-23.6 to 1.6)	-33.5 (-42.0 to -22.3)	0.5 (0.3 to 0.6)	0.4 (0.3 to 0.6)	-12.2 (-31.4 to 9.2)	-32.7 (-47.0 to -17.0)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-79.8 to -55.3	-84.5 to -66.1	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.0 (-79.9 to -55.2)	-77.1 (-84.5 to -65.1)
Intestinal nematode infections	-	-	-	-	13.8 (5.8 to 29.8)	2.5 (0.8 to 6.6)	-83.3 (-93.2 to -51.6)	-87.1 (-94.7 to -63.4)
Ascariasis	5,703.8 (3,987.8 to 8,098.4)	3,775.9 (2,387.7 to 5,970.5)	-34.4 (-63.3 to 15.1)	-47.9 (-70.5 to -9.3)	13.8 (5.7 to 29.7)	2.4 (0.7 to 6.5)	-84.0 (-93.7 to -52.3)	-87.6 (-95.0 to -63.9)
Trichuriasis	84.0 (48.7 to 141.2)	109.4 (61.0 to 190.0)	31.3 (-42.8 to 187.1)	4.4 (-53.2 to 124.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	215.9 (-90.4 to 16,120.6)	146.3 (-92.2 to 12,036.0)
Hookworm disease	15.9 (8.5 to 26.8)	20.7 (11.8 to 33.7)	30.6 (-38.7 to 174.0)	0.1 (-53.4 to 107.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	38.4 (11.2 to 55.2)	1.1 (-15.7 to 17.6)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	247.5 (197.2 to 300.8)	247.4 (229.3 to 267.4)	0.0 (-17.6 to 25.3)	-5.9 (-23.0 to 18.3)	8.1 (4.7 to 12.2)	8.0 (5.1 to 11.6)	-2.4 (-17.0 to 38.1)	-5.8 (-19.7 to 34.1)
Maternal disorders	-	-	-	-	0.6 (0.4 to 1.0)	0.5 (0.3 to 0.8)	-15.5 (-46.7 to 11.0)	-22.0 (-50.5 to 2.0)
Maternal hemorrhage	7.1 (6.3 to 8.2)	6.4 (4.4 to 8.7)	-10.0 (-40.9 to 20.4)	-15.1 (-44.3 to 13.8)	0.3 (0.2 to 0.5)	0.3 (0.1 to 0.4)	-14.4 (-57.9 to 35.9)	-21.0 (-61.5 to 25.3)
Maternal sepsis and other maternal infections	3.5 (2.1 to 5.2)	3.2 (1.8 to 5.1)	-5.5 (-33.8 to 13.0)	-35.0 (-54.6 to -22.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-17.2 (-60.7 to 75.7)	-32.7 (-66.8 to 42.5)
Maternal hypertensive disorders	2.6 (0.7 to 5.0)	2.4 (0.7 to 4.6)	-6.2 (-25.8 to 5.5)	-10.5 (-27.0 to -1.7)	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.3)	-6.5 (-32.3 to 31.6)	-10.5 (-34.4 to 23.6)
Obstructed labor	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.1)	-47.3 (-76.7 to 6.9)	-50.5 (-78.5 to -0.7)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-44.6 (-77.6 to 37.2)	-47.7 (-79.1 to 31.7)
Complications of abortion	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-9.0 (-47.6 to 85.2)	-14.4 (-50.7 to 72.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.8 (-57.7 to 190.8)	-2.1 (-61.2 to 180.7)
Other maternal disorders	-	-	-	-	0.1	0.1	-16.7	-23.2
Neonatal disorders	-	-	-	-	18.6 (10.8 to 27.6)	44.1 (28.5 to 67.5)	132.3 (41.3 to 323.2)	104.5 (25.2 to 274.5)
Preterm birth complications	79.4 (44.2 to 142.6)	217.9 (130.2 to 353.1)	167.7 (89.3 to 359.8)	125.8 (59.4 to 287.9)	9.2 (5.3 to 14.1)	27.6 (17.0 to 44.9)	185.8 (71.7 to 504.6)	149.1 (50.5 to 426.3)
Neonatal encephalopathy due to birth asphyxia and trauma	65.2 (22.0 to 143.3)	58.8 (29.0 to 108.5)	-6.1 (-41.6 to 70.3)	-20.8 (-51.7 to 44.8)	4.8 (2.6 to 7.8)	7.5 (4.9 to 11.4)	57.1 (-14.0 to 181.8)	41.4 (-22.8 to 152.9)
Neonatal sepsis and other neonatal infections	0.0	0.0	0.0	25.0	0.0	0.0	7.8	26.7
Hemolytic disease and other neonatal jaundice	5.3 (1.5 to 10.3)	9.9 (3.5 to 23.6)	78.1 (-51.8 to 602.9)	58.1 (-57.2 to 519.5)	1.9 (0.6 to 3.6)	2.9 (1.0 to 6.8)	46.4 (-55.3 to 404.6)	28.7 (-60.8 to 341.9)
Other neonatal disorders	-	-	-	-	2.7 (1.0 to 6.7)	6.1 (2.3 to 14.7)	134.8 (-18.9 to 477.6)	105.4 (-28.5 to 407.2)
Nutritional deficiencies	-	-	-	-	215.6 (140.0 to 323.3)	193.8 (126.9 to 283.4)	-10.4 (-20.2 to 1.9)	-20.8 (-29.4 to -10.4)
Protein-energy malnutrition	67.7 (26.2 to 136.3)	39.4 (19.9 to 68.8)	-41.1 (-77.8 to 85.9)	-33.0 (-74.7 to 107.3)	8.5 (2.8 to 17.6)	4.9 (2.2 to 10.1)	-40.7 (-77.7 to 87.4)	-32.8 (-74.4 to 107.2)
Iodine deficiency	3,361.0 (2,170.8 to 4,402.6)	2,260.5 (1,390.4 to 2,986.2)	-33.7 (-60.5 to 8.9)	-47.5 (-68.5 to -14.8)	60.6 (31.3 to 99.8)	40.6 (21.3 to 67.6)	-33.7 (-60.8 to 8.8)	-47.6 (-68.8 to -14.1)
Vitamin A deficiency	3.5 (2.2 to 5.0)	2.1 (1.3 to 3.1)	-40.6 (-51.9 to -25.4)	-48.6 (-58.3 to -35.5)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-45.1 (-61.6 to -30.6)	-54.5 (-67.5 to -41.5)

Appendix Table G.4 - North Korea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.1	0.3	154.7	46.6
Silicosis	0.1	0.2	74.6	-6.2	(0.1 to 0.2)	(0.2 to 0.5)	(136.3 to 170.4)	(34.5 to 57.3)
Asbestosis	-	-	0.0	0.0	0.0	0.0	73.8	-6.8
Coal workers pneumoconiosis	0.2	0.3	44.0	-17.4	(0.0 to 0.0)	0.0	43.7	-17.8
Other pneumoconiosis	0.4	1.3	240.7	23.0	(0.2 to 0.7)	(0.2 to 0.4)	235.8	38.2
Asthma	199.1	261.2	30.4	-17.6	(195.0 to 203.0)	(217.8 to 253.1)	28.9	-17.7
Interstitial lung disease and pulmonary sarcoidosis	1.5	2.5	66.3	-1.7	(1.2 to 1.8)	(2.0 to 3.0)	69.0	-0.1
Other chronic respiratory diseases	-	-	-	-	2.0	1.5	-24.1	-54.3
Cirrhosis	-	-	-	-	(1.0 to 3.6)	(0.8 to 2.7)	(54.1 to 15.6)	(-72.4 to -30.3)
Cirrhosis due to hepatitis B	4.5	4.4	-2.8	-34.7	(1.0 to 2.1)	(1.1 to 2.3)	(3.9 to 23.2)	(-35.0 to -18.5)
Cirrhosis due to hepatitis C	1.5	2.4	57.7	-2.2	(0.5 to 1.1)	(0.4 to 1.1)	(38.0 to 36.7)	(57.2 to -7.5)
Cirrhosis due to alcohol use	1.9	1.9	-1.1	-38.1	(0.1 to 0.4)	(0.2 to 0.7)	(-8.4 to 170.7)	(-41.4 to 65.5)
Cirrhosis due to other causes	1.0	2.1	110.0	-11.2	(0.2 to 0.5)	(0.2 to 0.5)	(-45.3 to 59.8)	(-64.3 to -1.7)
Digestive diseases	-	-	-	-	(0.1 to 0.3)	(0.1 to 0.3)	(34.4 to 92.9)	(-45.6 to 53.1)
Peptic ulcer disease	198.0	214.9	8.3	-41.9	(195.5 to 40.1)	(22.2 to 44.3)	(0.5 to 21.7)	(-40.8 to -29.2)
Gastritis and duodenitis	355.0	457.2	28.7	-26.0	(337.3 to 372.8)	(435.3 to 476.4)	(20.3 to 36.8)	(-29.7 to -22.7)
Appendicitis	1.6	1.5	-8.4	-25.6	(1.3 to 2.0)	(1.2 to 1.8)	(-30.0 to 22.7)	(-42.7 to -1.2)
Paralytic ileus and intestinal obstruction	0.3	0.5	53.9	18.1	(0.2 to 0.5)	(0.3 to 0.8)	(0.3 to 0.7)	(-39.4 to 43.2)
Inguinal, femoral, and abdominal hernia	44.8	59.3	32.2	-23.2	(44.8 to 50.3)	(49.2 to 70.5)	(7.1 to 64.1)	(-36.8 to -5.5)
Inflammatory bowel disease	4.3	6.4	48.8	-3.9	(4.1 to 4.5)	(6.0 to 6.7)	(38.9 to 60.2)	(-10.3 to 3.1)
Vascular intestinal disorders	0.1	0.1	75.0	-8.9	(0.0 to 0.1)	(0.0 to 0.1)	(0.0 to 0.1)	(20.9 to 144.7)
Gallbladder and biliary diseases	0.7	1.7	147.9	15.1	(0.5 to 1.1)	(0.7 to 1.5)	(1.0 to 2.2)	(16.1 to 86.0)
Pancreatitis	4.7	7.3	55.3	-3.0	(4.5 to 4.9)	(6.9 to 7.6)	(45.1 to 66.4)	(-9.1 to 2.0)
Other digestive diseases	-	-	-	-	5.4	3.8	-29.4	-59.1
Neurological disorders	-	-	-	-	(3.3 to 8.6)	(2.5 to 5.6)	(-50.8 to -0.8)	(-71.1 to -42.2)
Alzheimer disease and other dementias	54.4	129.5	139.6	-9.8	(46.5 to 62.3)	(97.1 to 157.7)	(66.8 to 212.5)	(-32.1 to 33.1)
Parkinson disease	17.3	36.8	113.6	-3.0	(10.3 to 23.9)	(20.0 to 52.8)	(83.0 to 129.1)	(-16.0 to 3.6)
Epilepsy	40.6	49.3	22.3	-0.5	(29.3 to 52.9)	(36.4 to 61.8)	(-20.0 to 82.4)	(-34.8 to 47.2)
Multiple sclerosis	0.5	1.2	148.4	68.9	(0.4 to 0.6)	(1.0 to 1.5)	(87.8 to 246.4)	(27.9 to 135.5)
Migraine	1,092.0	1,339.1	23.6	-9.4	(861.4 to 1,357.5)	(950.3 to 1,647.9)	(17.1 to 66.7)	(-39.0 to 23.9)
Tension-type headache	2,733.7	3,801.6	36.2	-4.1	(1,535.6 to 3,518.9)	(3,047.2 to 4,711.3)	(1.5 to 127.1)	(-29.2 to 49.9)
Medication overuse headache	73.6	151.2	103.7	41.8	(46.8 to 101.2)	(95.3 to 217.5)	(47.2 to 194.6)	(3.3 to 104.5)
Other neurological disorders	0.0	0.0	37.7	3.2	(0.0 to 0.0)	(0.0 to 0.0)	(-10.0 to 121.1)	(-31.0 to 65.4)
Mental and substance use disorders	-	-	-	-	387.7	500.9	29.0	-2.0
Schizophrenia	89.7	126.2	40.5	-0.2	(77.5 to 104.0)	(108.9 to 145.1)	(32.7 to 49.4)	(-5.5 to 5.9)
Alcohol use disorders	198.7	251.1	26.5	3.3	(175.8 to 225.2)	(226.5 to 279.1)	(17.4 to 36.7)	(-3.2 to 10.1)
Drug use disorders	-	-	-	-	32.1	36.3	13.0	-0.4
Opioid use disorders	27.6	36.7	33.3	1.5	(21.8 to 34.0)	(29.5 to 43.9)	(20.4 to 49.1)	(-6.9 to 11.9)
Cocaine use disorders	18.4	20.7	12.4	2.5	(17.1 to 19.7)	(19.2 to 22.0)	(1.4 to 23.4)	(-9.8 to 9.6)
Amphetamine use disorders	51.2	50.2	-1.8	-2.8	(47.1 to 55.2)	(46.4 to 53.8)	(-12.4 to 8.6)	(-13.3 to 7.0)
Cannabis use disorders	57.5	59.2	2.9	0.2	(49.2 to 66.2)	(51.4 to 67.1)	(0.4 to 5.4)	(0.1 to 0.2)
Other drug use disorders	-	-	-	-	9.5	9.6	2.0	-2.2
Depressive disorders	-	-	-	-	(5.8 to 14.1)	(5.9 to 14.3)	(-24.9 to 37.9)	(-27.6 to 32.9)
Major depressive disorder	487.4	625.3	26.2	-9.8	(425.1 to 509.7)	(582.6 to 688.8)	(11.5 to 54.1)	(-16.2 to -0.2)
Dysthymia	257.1	388.9	51.1	-1.2	(223.0 to 290.3)	(339.2 to 436.4)	(46.6 to 56.2)	(-1.6 to -0.9)
Bipolar disorder	106.8	139.7	30.7	-2.4	(84.2 to 129.0)	(111.9 to 167.1)	(23.5 to 39.4)	(-7.1 to 1.7)
Anxiety disorders	588.3	769.2	30.7	54.6	(503.3 to 588.3)	(769.2 to 940.9)	(51.4 to 98.4)	(-1.6 to -0.5)
Eating disorders	-	-	-	-	24.1	23.8	-1.3	7.4
Anorexia nervosa	5.4	6.2	14.9	13.7	(3.7 to 7.8)	(4.3 to 8.8)	(0.2 to 31.7)	(-3.0 to 30.6)
Bulimia nervosa	5.3	5.2	-2.3	-0.6	(2.7 to 9.9)	(2.7 to 9.8)	(-6.3 to 5.7)	(-1.0 to -0.5)
Autistic spectrum disorders	-	-	-	-	24.1	29.2	20.7	1.9
Autism	61.6	74.8	21.3	1.4	(58.4 to 64.9)	(70.9 to 78.9)	(20.5 to 22.3)	(1.3 to 1.4)
Asperger syndrome	87.6	106.3	21.2	1.8	(82.1 to 93.0)	(99.6 to 113.0)	(20.0 to 22.3)	(1.7 to 1.9)
Attention-deficit/hyperactivity disorder	129.8	126.1	-2.9	0.1	(107.0 to 151.7)	(103.9 to 147.3)	(-3.0 to -2.8)	(0.1 to 0.1)
Conduct disorder	128.7	127.0	-1.3	-1.3	(109.7 to 148.1)	(108.2 to 144.6)	(-3.5 to 0.3)	(0.1 to 0.1)
Idiopathic intellectual disability	117.7	211.1	79.3	52.0	(60.5 to 175.2)	(126.1 to 281.8)	(18.8 to 199.6)	(0.9 to 156.4)
Other mental and substance use disorders	335.7	451.9	34.5	1.1	(314.0 to 356.6)	(426.0 to 476.8)	(31.5 to 37.2)	(0.8 to 1.5)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	113.5	178.7	56.8	7.6
Diabetes mellitus	547.3	1,008.4	85.0	20.6	(434.1 to 663.4)	(804.1 to 1,224.3)	(40.0 to 132.2)	(-7.8 to 53.4)
Acute glomerulonephritis	0.2	0.2	5.5	-14.5	(0.1 to 0.2)	(0.2 to 0.2)	(-2.3 to 14.4)	(-20.0 to -7.8)
Chronic kidney disease	-	-	-	-	24.1	18.1	-27.2	50.7
Chronic kidney disease due to diabetes mellitus	68.6	201.2	192.6	62.8	(42.9 to 114.0)	(117.1 to 312.3)	(90.4 to 352.4)	(11.3 to 150.2)
Chronic kidney disease due to hypertension	238.9	144.2	-38.8	-52.1	(137.0 to 408.0)	(93.9 to 214.2)	(-53.0 to -19.0)	(-61.4 to -39.0)
Chronic kidney disease due to glomerulonephritis	177.1	222.2	26.6	-3.3	(118.0 to 249.8)	(141.9 to 320.3)	(-6.0 to 65.5)	(-31.6 to 13.2)
Chronic kidney disease due to other causes	302.5	531.0	78.1	23.9	(192.6 to 478.5)	(373.4 to 772.8)	(28.0 to 121.8)	(-5.5 to 51.0)
Urinary diseases and male infertility	-	-	-	-	5.5	13.5	147.1	30.9
	-	-	-	-	(3.6 to 7.8)	(8.9 to 19.3)	(118.6 to 177.1)	(16.6 to 45.3)

Appendix Table G.4 - North Korea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	382.0 (341.4 to 421.8)	454.4 (408.1 to 499.5)	18.6 (3.8 to 37.1)	-42.3 (-49.2 to -33.6)	10.6 (7.2 to 14.8)	12.6 (8.4 to 17.7)	18.4 (2.7 to 36.3)	-42.2 (-49.5 to -33.6)
Other oral disorders	353.8 (333.5 to 374.5)	468.1 (440.7 to 493.7)	32.1 (21.9 to 43.6)	-0.7 (-8.0 to 7.8)	10.4 (6.5 to 15.7)	13.8 (8.5 to 20.8)	31.8 (21.2 to 43.5)	-0.4 (-7.9 to 8.4)
Injuries	-	-	-	-	61.8 (46.4 to 80.7)	115.0 (73.1 to 184.0)	79.9 (38.8 to 182.5)	17.4 (-8.2 to 81.5)
Transport injuries	-	-	-	-	28.5 (21.3 to 37.5)	33.5 (23.9 to 45.8)	17.5 (7.1 to 28.7)	-21.9 (-28.1 to -15.0)
Road injuries	-	-	-	-	24.1 (18.0 to 31.8)	28.5 (20.1 to 38.5)	17.9 (7.3 to 28.3)	-22.1 (-28.1 to -15.3)
Pedestrian road injuries	-	-	-	-	6.9 (5.2 to 9.0)	9.5 (6.7 to 12.9)	37.4 (25.0 to 50.6)	-10.2 (-17.7 to -2.0)
Cyclist road injuries	-	-	-	-	2.2 (1.6 to 2.9)	2.4 (1.7 to 3.3)	7.8 (2.5 to 20.4)	-30.9 (-37.1 to -23.0)
Motorcyclist road injuries	-	-	-	-	6.5 (4.8 to 8.7)	6.9 (4.9 to 9.6)	5.6 (-4.9 to 17.8)	-29.0 (-35.5 to -21.8)
Motor vehicle road injuries	-	-	-	-	8.4 (6.3 to 10.9)	9.8 (6.7 to 12.9)	11.7 (-0.3 to 25.7)	-24.4 (-31.9 to -15.7)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	1.8 (-11.1 to 15.3)	-34.1 (-41.3 to -26.0)
Other transport injuries	-	-	-	-	4.3 (3.2 to 5.7)	5.2 (3.6 to 7.1)	20.0 (7.1 to 34.4)	-21.3 (-29.4 to -11.9)
Unintentional injuries	-	-	-	-	28.1 (21.0 to 36.5)	34.8 (25.2 to 47.0)	23.7 (13.4 to 35.7)	-19.6 (-26.3 to -12.2)
Falls	-	-	-	-	16.4 (12.3 to 21.4)	19.2 (13.6 to 26.1)	16.9 (5.1 to 30.8)	-27.8 (-35.1 to -19.2)
Drowning	-	-	-	-	2.0 (1.5 to 2.7)	0.9 (0.6 to 1.2)	-56.5 (-63.2 to -48.9)	-67.0 (-71.8 to -61.8)
Fire, heat, and hot substances	-	-	-	-	0.7 (0.6 to 0.9)	0.5 (0.4 to 0.7)	-29.7 (-35.7 to -23.3)	-51.2 (-54.8 to -47.2)
Poisonings	-	-	-	-	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.6)	-14.8 (-29.1 to 3.3)	-37.2 (-47.2 to -24.5)
Exposure to mechanical forces	-	-	-	-	5.0 (3.7 to 6.6)	8.0 (5.8 to 10.8)	60.0 (48.4 to 72.2)	13.2 (6.0 to 20.5)
Unintentional firearm injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-47.8 (-55.1 to -40.2)	-62.8 (-67.7 to -57.6)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	37.8 (22.9 to 53.1)	-1.0 (-10.7 to 9.3)
Other exposure to mechanical forces	-	-	-	-	4.7 (3.5 to 6.2)	7.7 (5.6 to 10.5)	64.6 (52.5 to 76.9)	16.3 (8.8 to 23.8)
Adverse effects of medical treatment	-	-	-	-	0.4 (0.2 to 0.5)	0.6 (0.3 to 0.8)	49.2 (35.3 to 62.1)	1.0 (-8.6 to 9.5)
Animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-7.4 (-16.1 to 2.8)	-34.7 (-40.3 to -28.5)
Venomous animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-9.0 (-21.1 to 3.7)	-35.4 (-43.4 to -26.7)
Non-venomous animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-5.9 (-15.8 to 6.4)	-34.1 (-40.5 to -26.2)
Foreign body	-	-	-	-	0.5 (0.4 to 0.7)	0.7 (0.5 to 0.9)	21.8 (10.3 to 36.0)	-17.4 (-24.4 to -8.8)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-37.1 (-50.0 to -20.8)	-52.5 (-61.1 to -41.8)
Foreign body in eyes	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	27.0 (12.4 to 42.6)	-7.9 (-17.5 to 3.8)
Foreign body in other body part	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	45.6 (28.6 to 64.2)	-6.5 (-16.1 to 4.4)
Other unintentional injuries	-	-	-	-	2.2 (1.6 to 2.9)	4.3 (3.1 to 5.8)	95.7 (77.7 to 117.7)	35.5 (23.9 to 49.9)
Self-harm and interpersonal violence	-	-	-	-	5.2 (3.9 to 6.8)	3.7 (2.6 to 5.0)	-30.2 (-37.5 to -21.1)	-52.2 (-57.0 to -46.3)
Self-harm	-	-	-	-	1.7 (1.2 to 2.3)	1.3 (0.9 to 1.8)	-23.8 (-32.9 to -13.5)	-52.4 (-57.9 to -46.1)
Interpersonal violence	-	-	-	-	3.5 (2.7 to 4.5)	2.4 (1.7 to 3.2)	-33.2 (-41.4 to -23.4)	-52.1 (-57.7 to -45.7)
Assault by firearm	-	-	-	-	0.3 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-24.8 (-33.2 to -13.9)	-45.1 (-51.0 to -38.0)
Assault by sharp object	-	-	-	-	0.8 (0.6 to 1.0)	0.7 (0.5 to 1.0)	-11.2 (-22.9 to 3.8)	-36.6 (-44.8 to -26.5)
Assault by other means	-	-	-	-	2.4 (1.8 to 3.1)	1.4 (1.0 to 1.9)	-41.4 (-49.1 to -32.1)	-57.9 (-63.0 to -51.8)
Forces of nature, war, and legal intervention	-	-	-	-	0.1 (0.0 to 0.1)	43.0 (15.6 to 100.6)	67,915.8 (54,835.8 to 81,916.2)	43,266.0 (34,345.2 to 52,806.4)
Exposure to forces of nature	-	-	-	-	0.1 (0.0 to 0.1)	43.0 (15.6 to 100.6)	67,915.8 (54,835.8 to 81,916.2)	43,266.0 (34,345.2 to 52,806.4)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Norway prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	547.7 (408.5 to 698.1)	655.2 (487.8 to 839.9)	19.6 (16.9 to 22.5)	3.4 (-4.5 to 0.1)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	22.8 (15.9 to 31.9)	28.2 (19.5 to 39.5)	23.4 (11.2 to 38.1)	3.4 (-5.8 to 14.7)
HIV/AIDS and tuberculosis	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	18.6 (5.6 to 44.6)	-1.3 (-22.3 to 19.4)
Tuberculosis	0.7 (0.7 to 0.8)	0.7 (0.7 to 0.8)	-1.3 (-5.5 to 2.4)	-14.6 (-18.2 to -11.2)	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-0.9 (-19.6 to 19.9)	-14.2 (-31.5 to 4.4)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	197.4 (4.3 to 220.1)	39.9 (-20.3 to 149.1)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.7 (-52.4 to 53.4)	-21.4 (59.1 to 31.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.7 (-52.4 to 53.6)	-21.4 (-59.2 to 32.1)
HIV/AIDS resulting in other diseases	0.4 (0.2 to 0.7)	1.4 (0.7 to 2.2)	242.7 (122.5 to 376.5)	160.0 (66.4 to 263.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	107.9 (4.3 to 221.8)	60.2 (-20.2 to 149.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	2.5 (1.6 to 3.8)	2.8 (1.8 to 4.1)	8.9 (1.6 to 16.8)	-9.6 (-15.7 to -3.9)
Diarrheal diseases	1.5 (1.3 to 1.7)	1.5 (1.3 to 1.7)	-0.5 (-15.4 to 17.8)	-17.3 (-32.1 to 0.5)	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	0.7 (-19.6 to 21.9)	-17.5 (-35.7 to 4.5)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (56.4 to 35.5)	-26.9 (-62.9 to 16.9)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.2 (-28.1 to -1.1)	-26.9 (-38.5 to -16.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-28.1 to -1.1)	-26.9 (-38.5 to -16.2)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.8 (-13.4 to 62.5)	3.7 (-23.7 to 40.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.8 (-13.4 to 62.5)	3.7 (-23.9 to 41.1)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.0 (-99.3 to 3.958.8)	-68.4 (-99.4 to 3.153.8)
Lower respiratory infections	1.1 (1.0 to 1.1)	0.9 (0.9 to 0.9)	-15.4 (-19.8 to -11.1)	-26.4 (-30.0 to -22.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-14.8 (-25.0 to -2.8)	-25.5 (-35.2 to -14.2)
Upper respiratory infections	64.3 (61.5 to 67.1)	76.3 (73.0 to 79.8)	18.7 (12.5 to 25.7)	0.3 (-4.9 to 6.3)	0.8 (0.4 to 1.2)	0.9 (0.5 to 1.5)	18.7 (11.4 to 27.3)	0.4 (-5.6 to 8.0)
Otitis media	59.6 (53.8 to 67.7)	62.6 (56.7 to 68.6)	4.7 (-9.2 to 22.5)	-14.6 (-24.7 to -2.1)	1.1 (0.6 to 1.7)	1.1 (0.6 to 1.8)	3.9 (-9.9 to 21.9)	-15.1 (-25.3 to -2.5)
Meningitis	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	3.4 (-17.8 to 35.3)	-13.3 (-31.2 to 14.7)
Pneumococcal meningitis	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	8.3 (-18.3 to 47.9)	-13.3 (-35.4 to 19.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.7 (-20.9 to 65.4)	4.5 (-36.7 to 36.7)
H influenzae type B meningitis	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.3)	-17.9 (-56.2 to 50.0)	-31.2 (-64.2 to 29.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.2 (-56.3 to 64.8)	-21.8 (-63.8 to 41.9)
Meningococcal meningitis	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.2)	-27.0 (-52.7 to 27.3)	-39.8 (-61.0 to 8.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-52.8 to 42.9)	-34.3 (-61.2 to 22.7)
Other meningitis	0.4 (0.2 to 0.9)	0.4 (0.2 to 0.9)	3.9 (-23.2 to 46.9)	-13.6 (-35.0 to 25.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	9.9 (-24.1 to 77.1)	-6.4 (-35.7 to 53.1)
Encephalitis	0.6 (0.2 to 1.6)	0.7 (0.3 to 2.1)	24.0 (-2.0 to 59.4)	24.0 (-20.3 to 30.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	20.7 (4.6 to 71.4)	6.4 (-15.6 to 42.9)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.8 (-89.8 to 585.2)	-38.0 (-91.9 to 428.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.8 (-89.8 to 586.0)	-38.0 (-91.9 to 433.7)
Whooping cough	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	3.5 (-3.0 to 4.1)	-6.3 (-6.8 to -5.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.7 (-15.0 to 25.7)	-6.2 (-23.3 to 13.9)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.9 (-60.3 to 25.8)	-31.2 (-67.7 to 5.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.4 (-63.3 to 13.3)	-36.2 (-70.7 to -4.4)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-91.6 (-97.3 to -85.2)	-92.4 (-97.6 to -86.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.6 (-97.3 to -85.1)	-92.4 (-97.6 to -86.7)
Varicella and herpes zoster	3.7 (3.2 to 4.2)	4.3 (3.7 to 5.0)	17.2 (-2.4 to 43.0)	-3.3 (-16.3 to 14.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	19.0 (8.6 to 57.3)	-4.0 (-26.5 to 25.5)
Neglected tropical diseases and malaria	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (-63.2 to -18.0)	-54.2 (-68.5 to -30.5)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.9 (-75.2 to 530.5)	-6.4 (-79.2 to 436.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.0 (-75.0 to 535.8)	-4.3 (-79.0 to 440.4)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-74.4 (-89.2 to 32.8)	-79.0 (-90.9 to 17.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-73.1 (-88.7 to 41.8)	-77.6 (-90.4 to 26.6)
Cystic echinococcosis	0.3 (0.3 to 0.4)	0.2 (0.2 to 0.2)	-37.6 (-47.9 to -29.0)	-47.2 (-55.0 to -39.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.1 (-51.8 to -15.4)	-45.6 (-57.4 to -29.3)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.5 (-49.2 to 15.4)	-17.7 (-59.3 to -4.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.5 (-49.3 to 15.5)	-17.7 (-59.3 to -4.7)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	198.9 (4.4 to 281.6)	144.6 (-25.9 to 212.2)
Maternal disorders	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	4.2 (-17.9 to 21.5)	-1.0 (-21.6 to 15.4)
Maternal hemorrhage	1.4 (1.3 to 1.6)	1.5 (1.0 to 2.0)	6.9 (-27.7 to 41.2)	1.6 (-29.9 to 33.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	1.0 (-33.7 to 22.3)	-3.5 (-35.3 to 16.4)
Maternal sepsis and other maternal infections	0.6 (0.2 to 1.0)	0.4 (0.1 to 0.8)	-26.1 (-81.4 to 140.7)	-36.0 (-83.3 to 98.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.3 (-59.9 to 37.0)	-27.5 (-53.9 to 23.2)
Maternal hypertensive disorders	0.8 (0.6 to 1.2)	0.9 (0.6 to 1.4)	11.6 (-2.0 to 22.5)	5.2 (-3.7 to 15.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	11.7 (-6.6 to 34.7)	5.2 (-12.0 to 27.6)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.1 (-1.2 to 15.7)	2.5 (-5.5 to 11.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.1 (-1.2 to 15.8)	2.5 (-5.6 to 11.0)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.2 (-1.7 to 15.7)	0.6 (-6.9 to 9.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.2 (-1.7 to 15.9)	0.6 (-6.9 to 10.1)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	8.3 (-35.4 to 86.7)	2.5 (-38.2 to 77.0)
Neonatal disorders	-	-	-	-	4.6 (3.1 to 6.4)	6.6 (4.5 to 9.1)	44.5 (-1.1 to 107.4)	19.8 (-18.0 to 71.8)
Preterm birth complications	21.9 (16.2 to 30.8)	36.6 (25.9 to 51.8)	66.7 (37.5 to 102.5)	38.5 (14.4 to 68.4)	2.5 (1.7 to 3.4)	4.1 (2.7 to 5.6)	64.5 (21.6 to 116.2)	36.7 (0.9 to 80.6)
Neonatal encephalopathy due to birth asphyxia and trauma	4.0 (2.1 to 8.6)	2.7 (1.1 to 7.7)	-37.4 (-59.1 to 6.1)	-47.9 (-65.9 to -12.5)	0.9 (0.6 to 1.3)	0.6 (0.3 to 0.9)	-35.3 (-58.9 to 9.7)	-46.1 (-61.7 to -9.3)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.1 (57.3 to 97.2)	68.4 (46.3 to 83.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.6 (5.5 to 217.4)	68.9 (-1.9 to 195.2)
Hemolytic disease and other neonatal jaundice	1.2 (0.4 to 3.5)	0.9 (0.3 to 2.2)	-25.7 (-83.7 to 295.4)	-38.5 (-86.4 to 223.5)	0.5 (0.2 to 1.4)	0.4 (0.1 to 0.9)	-38.5 (-83.1 to 320.3)	-36.8 (-85.9 to 244.0)
Other neonatal disorders	-	-	-	-	0.7 (0.4 to 1.0)	1.5 (0.8 to 2.7)	104.0 (12.8 to 415.3)	69.3 (-6.0 to 326.7)
Nutritional deficiencies	-	-	-	-	14.1 (9.1 to 20.7)	16.8 (10.7 to 25.1)	20.5 (-3.7 to 34.7)	1.4 (-19.3 to 11.2)
Protein-energy malnutrition	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	563.8 (-24.6 to 1,061.2)	357.4 (-45.1 to 663.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	521.3 (-34.0 to 1,422.6)	329.3 (-50.1 to 873.0)
Iodine deficiency	68.5 (15.5 to 131.4)	65.3 (37.1 to 109.6)	-1.9 (-67.5 to 429.4)	-14.4 (-72.9 to 338.5)	1.2 (0.3 to 2.6)	1.2 (0.5 to 2.3)	2.5 (-67.5 to 436.2)	-13.9 (-73.0 to 345.1)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron-deficiency anemia	522.0 (511.6 to 532.4)	633.6 (574.7 to 657.4)	21.7 (9.6 to 26.6)	1.3 (-9.7 to 5.7)	12.8 (8.4 to 19.0)	15.7 (9.9 to 22.9)	22.9 (-0.8 to 27.5)	3.0 (-16.9 to 7.0)

Appendix Table G.4 - Norway prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.9 (-50.9 to 150.3)	-27.1 (-63.2 to 63.5)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.2 (0.7 to 2.0)	1.5 (0.9 to 3.0)	17.4 (-3.2 to 151.1)	-0.5 (-22.7 to 146.8)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.5 (0.3 to 1.0)	0.6 (0.3 to 1.2)	19.8 (3.3 to 40.4)	3.0 (-11.7 to 22.0)
Syphilis	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.4)	76.7 (31.5 to 125.8)	36.4 (-0.5 to 79.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	74.4 (17.8 to 157.0)	35.2 (-10.1 to 101.6)
Chlamydial infection	108.1 (78.4 to 106.5)	133.7 (86.2 to 120.8)	13.5 (-7.5 to 44.2)	12.2 (-16.7 to 29.3)	0.3 (0.1 to 0.5)	0.3 (0.2 to 0.5)	17.0 (-12.5 to 46.9)	3.0 (-21.2 to 41.6)
Gonococcal infection	12.3 (8.5 to 16.6)	15.9 (11.4 to 21.3)	29.5 (-17.2 to 106.0)	22.7 (-21.8 to 97.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	12.2 (-23.6 to 72.3)	5.1 (-28.3 to 62.9)
Trichomoniasis	16.5 (11.7 to 21.9)	14.5 (9.6 to 19.8)	-13.9 (-45.4 to 40.4)	-24.9 (-53.7 to 25.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-16.1 (-51.8 to 47.2)	-26.1 (-58.8 to 33.1)
Genital herpes	600.0 (539.4 to 661.8)	728.0 (652.2 to 801.8)	21.0 (5.2 to 41.6)	-3.6 (-16.1 to 13.2)	0.2 (0.0 to 0.4)	0.2 (0.1 to 0.5)	20.1 (4.2 to 40.6)	-3.3 (-16.9 to 13.8)
Other sexually transmitted diseases	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.5)	-20.8 (-53.0 to 18.7)	-31.2 (-57.5 to 1.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.7 (-27.7 to 42.6)	-11.6 (-37.8 to 27.4)
Hepatitis	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	0.1 (-14.9 to 15.9)	-16.7 (-29.0 to -3.7)
Hepatitis A	3.0 (2.8 to 3.1)	3.2 (2.9 to 3.4)	7.1 (5.4 to 8.7)	-9.6 (-11.3 to -8.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	9.0 (-3.7 to 22.8)	-8.3 (-19.5 to 3.2)
Hepatitis B	64.8 (51.5 to 81.6)	49.0 (40.8 to 58.2)	-24.7 (-43.9 to 5.4)	-39.2 (-55.7 to -15.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-16.9 (-53.8 to 28.8)	-33.8 (-62.7 to 2.7)
Hepatitis C	96.1 (87.0 to 105.2)	79.9 (71.6 to 88.7)	-16.8 (-27.9 to -4.2)	-33.5 (-42.5 to -23.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.2 (-41.1 to 29.2)	-28.0 (-49.0 to -0.4)
Hepatitis E	-	-	-	-	-	-	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	21.2 (17.9 to 25.2)	26.7 (21.7 to 52.4)	18.1 (-5.2 to 161.9)	-0.1 (-22.1 to 144.8)	0.5 (0.3 to 0.8)	0.7 (0.4 to 2.2)	19.0 (-22.6 to 327.0)	0.5 (-36.7 to 293.1)
Non-communicable diseases	-	-	-	-	475.8 (353.6 to 607.0)	587.3 (433.6 to 752.5)	23.4 (20.5 to 26.5)	0.4 (-1.9 to 2.8)
Neoplasms	-	-	-	-	8.2 (6.2 to 10.5)	12.7 (9.3 to 16.2)	54.8 (43.5 to 65.4)	20.9 (13.0 to 28.6)
Esophageal cancer	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	41.2 (3.2 to 82.9)	8.1 (-20.8 to 40.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	41.1 (1.2 to 86.8)	8.6 (-21.3 to 40.5)
Stomach cancer	2.4 (2.1 to 2.7)	2.0 (1.7 to 2.4)	-14.9 (-26.8 to -0.9)	-33.6 (-41.9 to -23.4)	0.3 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-19.4 (-32.6 to -2.2)	-36.7 (-46.6 to -24.1)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	85.5 (10.1 to 151.1)	45.9 (-12.9 to 95.5)
Liver cancer due to hepatitis B	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	44.3 (-31.5 to 350.0)	12.9 (-44.4 to 240.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.6 (-32.8 to 319.7)	9.1 (-44.8 to 216.7)
Liver cancer due to hepatitis C	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	274.5 (80.9 to 599.3)	198.7 (41.6 to 474.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	261.4 (72.7 to 533.9)	190.0 (40.5 to 425.2)
Liver cancer due to alcohol use	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-11.9 (-60.3 to 93.0)	-30.6 (-68.8 to 53.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.2 (-60.2 to 78.4)	-33.4 (-68.9 to 39.9)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.9 (-67.9 to 59.6)	-46.8 (-73.6 to 23.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.3 (-69.3 to 55.7)	-48.5 (-74.3 to 19.2)
Larynx cancer	0.6 (0.4 to 0.7)	0.5 (0.4 to 0.6)	-30.3 (-34.6 to 15.9)	-39.0 (-50.1 to -13.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-12.7 (-37.8 to 20.8)	-32.8 (-51.9 to -9.6)
Tracheal, bronchus and lung cancer	3.5 (3.2 to 3.9)	6.1 (4.8 to 6.8)	82.6 (32.6 to 103.1)	38.7 (2.1 to 53.3)	0.5 (0.3 to 0.6)	0.8 (0.5 to 1.0)	71.4 (25.8 to 97.1)	30.4 (-3.1 to 50.3)
Breast cancer	27.8 (24.9 to 30.4)	43.1 (40.6 to 45.6)	54.7 (40.2 to 74.9)	18.6 (7.2 to 33.4)	1.4 (1.0 to 2.0)	2.0 (1.3 to 2.8)	38.0 (22.3 to 56.5)	4.7 (-6.7 to 19.6)
Cervical cancer	2.7 (2.2 to 3.1)	1.9 (1.4 to 2.3)	-29.1 (-43.1 to -12.3)	-45.2 (-56.3 to -31.9)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-28.7 (-44.0 to -7.3)	-44.3 (-56.4 to -28.8)
Uterine cancer	3.3 (1.7 to 4.0)	4.7 (2.2 to 6.0)	41.3 (3.0 to 81.9)	38.7 (-25.0 to 35.0)	0.3 (0.1 to 0.3)	0.3 (0.1 to 0.5)	38.7 (1.7 to 80.9)	2.1 (-24.6 to 34.5)
Prostate cancer	18.8 (15.9 to 21.9)	38.5 (31.8 to 45.5)	105.5 (67.4 to 150.5)	76.6 (43.2 to 113.7)	1.6 (1.1 to 2.1)	2.9 (2.1 to 4.0)	86.5 (55.1 to 124.6)	60.1 (32.8 to 93.5)
Colon and rectum cancer	15.0 (14.3 to 15.8)	26.4 (24.3 to 28.9)	76.1 (59.5 to 94.4)	36.9 (24.9 to 49.8)	1.2 (0.9 to 1.6)	2.1 (1.5 to 2.7)	67.2 (50.9 to 86.7)	30.4 (17.7 to 45.3)
Lip and oral cavity cancer	2.0 (1.8 to 2.3)	2.5 (2.0 to 3.1)	25.1 (-3.9 to 56.3)	-4.0 (-26.7 to 21.3)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	19.4 (9.5 to 52.6)	-7.9 (-29.1 to 16.9)
Nasopharynx cancer	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-50.7 (-66.4 to -6.8)	-42.2 (-74.3 to -28.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.0 (-67.4 to -32.1)	-63.8 (-74.6 to -32.4)
Other pharynx cancer	0.6 (0.5 to 0.8)	0.7 (0.5 to 1.0)	14.5 (-22.9 to 62.2)	-13.3 (-41.1 to 24.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	13.7 (-26.1 to 62.6)	-13.5 (-42.6 to 22.8)
Gallbladder and biliary tract cancer	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-5.4 (-29.6 to 26.4)	-26.2 (-44.4 to 0.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-10.5 (-36.9 to 30.3)	-29.9 (-48.9 to -0.1)
Pancreatic cancer	0.7 (0.6 to 0.8)	1.0 (0.8 to 1.1)	38.6 (17.2 to 64.9)	9.9 (-6.7 to 30.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	34.3 (9.8 to 67.5)	6.3 (-12.5 to 31.4)
Malignant skin melanoma	7.1 (5.3 to 10.2)	11.3 (7.3 to 14.8)	60.3 (19.6 to 91.3)	18.6 (-9.1 to 40.3)	0.4 (0.3 to 0.6)	0.7 (0.4 to 1.0)	56.2 (16.4 to 88.8)	16.5 (-10.6 to 39.0)
Non-melanoma skin cancer	1.9 (1.5 to 2.3)	4.2 (3.5 to 5.2)	127.3 (77.6 to 188.2)	77.9 (40.3 to 123.6)	0.2 (0.0 to 0.1)	0.2 (0.1 to 0.2)	154.4 (59.7 to 247.4)	94.8 (29.9 to 168.6)
Ovarian cancer	1.8 (1.6 to 2.0)	2.4 (2.0 to 2.8)	38.1 (13.4 to 63.7)	0.5 (-17.0 to 18.5)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	35.3 (5.7 to 70.8)	-0.9 (-21.3 to 25.5)
Testicular cancer	1.3 (0.9 to 1.9)	1.4 (0.9 to 2.0)	11.9 (-39.0 to 77.2)	-3.0 (-46.9 to 61.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	8.7 (-39.5 to 77.2)	-4.8 (-47.4 to 57.1)
Kidney cancer	2.6 (2.2 to 2.9)	4.9 (4.2 to 5.7)	90.6 (62.0 to 127.9)	45.5 (24.2 to 73.1)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	81.7 (49.7 to 120.8)	39.1 (15.2 to 67.9)
Bladder cancer	1.9 (3.2 to 4.2)	4.2 (5.3 to 7.8)	145.7 (46.6 to 119.1)	47.9 (16.1 to 72.7)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	85.3 (34.4 to 106.5)	35.7 (5.9 to 62.5)
Brain and nervous system cancer	1.2 (1.0 to 1.4)	2.3 (1.9 to 2.7)	94.7 (58.2 to 129.3)	44.3 (20.5 to 68.9)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	81.4 (43.9 to 121.6)	36.3 (11.9 to 63.2)
Thyroid cancer	1.2 (1.0 to 1.5)	1.5 (1.2 to 2.0)	20.3 (-6.1 to 72.2)	-6.6 (-27.6 to 34.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	15.5 (-12.5 to 66.6)	-9.8 (-31.3 to 31.9)
Mesothelioma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	65.4 (-21.2 to 118.2)	29.4 (-35.9 to 69.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.3 (-26.3 to 128.5)	22.4 (-40.3 to 75.1)
Hodgkin lymphoma	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.7)	0.4 (-25.2 to 53.2)	2.1 (-39.4 to 28.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	6.8 (-29.8 to 34.4)	-22.8 (-42.7 to 14.6)
Non-Hodgkin lymphoma	3.3 (2.5 to 5.0)	6.3 (3.5 to 6.7)	65.0 (-5.7 to 98.0)	26.2 (-29.4 to 52.3)	0.2 (0.2 to 0.4)	0.4 (0.2 to 0.5)	54.2 (-11.3 to 89.7)	18.9 (-32.0 to 45.8)
Multiple myeloma	0.9 (0.6 to 1.3)	1.4 (0.9 to 2.0)	52.7 (-6.0 to 140.1)	21.6 (-23.6 to 93.6)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	41.8 (-12.4 to 128.5)	13.9 (-29.4 to 81.9)
Leukemia	1.6 (1.4 to 1.8)	2.9 (2.5 to 3.3)	78.4 (49.9 to 110.3)	30.4 (5.5 to 55.1)	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	67.9 (38.4 to 109.9)	27.5 (5.7 to 53.7)
Other neoplasms	1.6 (1.4 to 2.0)	3.4 (2.7 to 4.2)	107.9 (55.7 to 161.9)	70.3 (31.3 to 109.4)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	81.8 (36.4 to 132.1)	51.0 (17.0 to 86.2)
Cardiovascular diseases	-	-	-	-	20.0 (14.1 to 26.9)	22.4 (15.8 to 29.7)	12.0 (-6.8 to 31.9)	-9.5 (-25.1 to 6.9)
Rheumatic heart disease	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	16.0 (5.8 to 27.4)	-4.8 (-12.8 to 3.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.9 (-12.3 to 56.1)	-6.0 (-26.5 to 23.9)
Ischemic heart disease	90.5 (72.8 to 115.4)	110.8 (88.2 to 126.4)	22.7 (-6.3 to 60.5)	-4.4 (-28.1 to 25.2)	5.3 (3.4 to 8.0)	5.8 (3.8 to 8.0)	10.7 (-18.3 to 54.0)	-13.6 (-37.9 to 22.4)
Cerebrovascular disease	-	-	-	-	5.1 (3.6 to 6.9)	5.9 (4.0 to 8.0)	14.9 (9.1 to 44.7)	-4.4 (-23.2 to 17.8)
Ischemic stroke	31.4 (26.5 to 36.5)	35.9 (31.1 to 42.4)	15.2 (-10.2 to 44.5)	-4.1 (-23.9 to 17.8)	4.4 (3.1 to 6.0)	5.2 (3.4 to 7.2)	16.7 (8.7 to 46.1)	-2.9 (-23.2 to 19.4)
Hemorrhagic stroke	4.7 (3.7 to 5.8)	4.9 (3.9 to 6.1)	3.1 (-22.7 to 44.4)	-14.2 (-34.9 to 17.9)	0.7 (0.4 to 1.0)	0.7 (0.5 to 1.0)	4.8 (-22.1 to 45.9)	-12.9 (-34.9 to 19.9)
Hypertensive heart disease	6.5 (5.6 to 7.4)	8.5 (7.6 to 9.4)	8.5 (8.1 to 57.5)	6.3 (-11.5 to 27.0)	0.9 (0.5 to 1.0)	0.9 (0.6 to 1.2)	31.9 (8.7 to 60.3)	7.3 (-1.3 to 29.9)
Cardiomyopathy and myocarditis	6.4 (5.2 to 7.7)	6.4 (5.9 to 7.0)	2.3 (-17.6 to 24.8)	-16.6 (-32.4 to 11.1)	0.7 (0.6 to 0.9)	0.7 (0.5 to 0.9)	2.3 (-18.3 to 28.1)	-16.7 (-37.7 to 3.5)
Atrial fibrillation and flutter	38.4 (32.4 to 44.4)	29.0 (24.1 to 34.7)	-26.1 (-39.8 to 2.4)	-39.6 (-50.8 to -17.0)	2.9 (1.9 to 4.1)	2.2 (1.5 to 3.2)	-5.5 (-40.2 to 3.3)	-39.1 (-51.3 to -15.8)
Peripheral vascular disease	169.6 (129.5 to 213.6)	242.1 (190.8 to 295.7)	42.1 (3.3 to 91.8)	10.9 (-21.2 to 47.0)	0.2 (0.1 to 0.5)	0.2 (0.1 to 0.4)	0.1 (-64.1 to 120.1)	-20.2 (-72.6 to 84.0)
Endocarditis	0.3 (0.2 to 0.5)	0.8 (0.7 to 0.9)	121.2 (62.8 to 344.7)	90.0 (34.8 to 290.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	69.3 (19.2 to 235.0)	44.1 (8.8 to 189.2)
Other cardiovascular and circulatory diseases	72.3 (45.9 to 102.2)	93.9 (59.3 to 122.2)	29.2 (-23.3 to 116.8)	3.1 (-39.0 to 72.9)	5.1 (2.8 to 8.0)	6.6 (3.6 to 9.8)	29.6 (-24.3 to 117.9)	3.6 (-39.7 to 75.1)
Chronic respiratory diseases	-	-	-	-	22.0 (15.3 to 30.0)	22.0 (18.5 to 36.3)	0.0 (-8.3 to 39.6)	0.0 (-11.2 to 14.1)
Chronic obstructive pulmonary disease	262.0 (232.5 to 289.4)	341.4 (311.0 to 375.0)	30.4 (23.4 to 38.8)	2.1 (-3.6 to 9.0)	13.3 (8.6 to 18.9)	15.5 (10.1 to 21.9)	15.3 (2.4 to 44.5)	-9.7 (-24.4 to 13.1)
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.8 (0.9 to 16.3)	-14.5 (-20.2 to -7.2)

Appendix Table G.4 - Norway prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.1 (-15.3 to -5.2)	-28.2 (-32.2 to -24.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.4 (-14.7 to -4.2)	-27.7 (-31.8 to -23.6)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.4 (5.4 to 29.6)	-8.5 (-17.2 to 2.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.0 (7.8 to 33.0)	-6.6 (-15.8 to 4.1)
Asthma	195.2 (178.2 to 212.4)	290.2 (231.6 to 270.1)	48.5 (14.2 to 43.4)	9.5 (2.6 to 23.7)	9.8 (5.6 to 12.2)	10.5 (7.1 to 15.6)	7.4 (14.5 to 43.4)	8.8 (2.6 to 24.1)
Interstitial lung disease and pulmonary sarcoidosis	0.5 (0.4 to 0.6)	0.9 (0.8 to 0.9)	92.3 (52.7 to 145.7)	54.3 (23.2 to 97.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	87.6 (46.3 to 139.6)	51.1 (19.6 to 93.0)
Other chronic respiratory diseases	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	36.1 (0.5 to 90.2)	6.2 (-21.8 to 49.5)
Cirrhosis	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	18.4 (3.9 to 35.1)	-10.9 (-22.0 to 1.9)
Cirrhosis due to hepatitis B	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	20.1 (-35.5 to 161.4)	-8.7 (51.1 to 99.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.4 (-40.7 to 177.5)	8.9 (-55.0 to 113.6)
Cirrhosis due to hepatitis C	0.5 (0.3 to 0.6)	0.7 (0.5 to 0.9)	59.6 (-5.5 to 134.7)	19.0 (-29.0 to 73.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	59.1 (-11.5 to 141.5)	17.7 (-34.6 to 78.1)
Cirrhosis due to alcohol use	0.5 (0.4 to 0.7)	0.4 (0.2 to 0.6)	-26.6 (-52.5 to 14.1)	-45.4 (-65.6 to -13.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-26.3 (-54.4 to 22.9)	-45.5 (-67.1 to -5.5)
Cirrhosis due to other causes	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	59.9 (-7.8 to 227.5)	22.1 (-28.1 to 138.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	58.3 (-17.9 to 222.2)	21.6 (-33.7 to 140.5)
Digestive diseases	-	-	-	-	8.7 (6.2 to 11.7)	11.4 (8.0 to 15.3)	30.6 (16.0 to 45.1)	7.0 (-5.3 to 18.5)
Peptic ulcer disease	36.4 (35.1 to 37.7)	9.8 (8.2 to 11.2)	-73.2 (-76.7 to -69.8)	-78.4 (-81.5 to -75.5)	1.3 (0.9 to 1.8)	0.4 (0.3 to 0.6)	-67.9 (-70.5 to -60.9)	-74.0 (-76.2 to -68.0)
Gastritis and duodenitis	3.1 (2.4 to 3.6)	2.6 (2.1 to 3.2)	-15.1 (-34.3 to 12.4)	-31.7 (-46.7 to -8.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-3.3 (-30.3 to 38.0)	-21.1 (-45.8 to 14.4)
Appendicitis	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	-7.6 (-18.3 to 6.3)	-22.4 (-31.9 to -10.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-7.0 (-32.6 to 27.7)	-22.2 (-44.7 to 10.9)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	83.7 (70.3 to 100.5)	47.8 (36.9 to 61.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.5 (38.5 to 137.3)	46.3 (17.4 to 80.6)
Inguinal, femoral, and abdominal hernia	11.7 (10.3 to 13.3)	12.2 (11.0 to 13.7)	4.6 (-11.9 to 24.0)	14.4 (-27.5 to 0.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	5.0 (-12.5 to 25.7)	14.2 (-27.6 to 1.3)
Inflammatory bowel disease	22.5 (20.4 to 24.4)	32.5 (29.7 to 35.4)	44.2 (27.0 to 62.8)	13.6 (-0.3 to 29.1)	4.7 (3.2 to 6.4)	6.8 (4.6 to 9.2)	44.6 (26.6 to 64.5)	13.8 (-0.8 to 30.4)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	36.4 (-3.2 to 94.0)	9.9 (-17.9 to 50.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.7 (-15.8 to 117.7)	11.8 (-25.9 to 65.3)
Gallbladder and biliary diseases	11.9 (10.6 to 13.2)	12.5 (10.9 to 14.1)	5.2 (-10.6 to 21.9)	-16.1 (-28.6 to -3.5)	1.2 (0.8 to 1.7)	1.3 (0.9 to 1.8)	5.2 (-1.3 to 22.7)	-16.1 (-29.1 to -3.1)
Pancreatitis	1.1 (1.0 to 1.1)	1.5 (1.4 to 1.6)	41.3 (33.0 to 49.7)	0.3 (5.3 to 18.2)	0.4 (0.2 to 0.4)	0.4 (0.3 to 0.5)	42.1 (22.5 to 61.7)	32.2 (3.8 to 30.0)
Other digestive diseases	-	-	-	-	0.9 (0.6 to 1.3)	2.1 (1.4 to 2.9)	137.9 (61.0 to 188.9)	95.4 (30.3 to 137.1)
Neurological disorders	-	-	-	-	41.2 (29.1 to 54.3)	52.7 (36.9 to 69.7)	27.8 (14.6 to 43.3)	2.8 (-7.3 to 15.3)
Alzheimer disease and other dementias	79.1 (68.8 to 89.5)	104.5 (85.9 to 123.4)	32.6 (6.3 to 61.1)	3.2 (-16.6 to 24.3)	11.6 (8.3 to 15.1)	15.7 (11.0 to 21.2)	35.7 (8.6 to 66.1)	4.8 (-16.0 to 26.6)
Parkinson disease	2.0 (1.8 to 2.3)	2.6 (2.2 to 2.9)	25.0 (15.3 to 32.3)	0.2 (-3.8 to 9.3)	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.4)	26.3 (7.1 to 46.7)	4.2 (-1.1 to 20.6)
Epilepsy	15.5 (10.7 to 20.0)	15.0 (9.7 to 21.1)	-2.9 (-41.5 to 56.8)	-19.2 (51.4 to 30.1)	6.3 (3.8 to 9.3)	6.5 (3.7 to 9.8)	1.4 (-39.9 to 66.2)	-15.6 (-49.9 to 39.1)
Multiple sclerosis	3.7 (3.5 to 3.9)	8.3 (7.9 to 8.7)	123.3 (108.0 to 141.1)	71.6 (60.4 to 85.0)	1.2 (0.9 to 1.6)	2.7 (2.0 to 3.5)	122.8 (100.8 to 149.3)	71.6 (54.4 to 91.9)
Migraine	426.5 (392.4 to 460.9)	513.5 (458.4 to 562.8)	20.8 (5.3 to 35.5)	0.6 (-12.5 to 13.2)	14.4 (8.8 to 21.2)	17.4 (10.2 to 25.9)	20.8 (4.7 to 36.4)	0.9 (-12.7 to 14.2)
Tension-type headache	921.4 (869.9 to 966.8)	762.5 (703.9 to 822.0)	-17.2 (-24.6 to -10.1)	-14.4 (-38.1 to -25.1)	1.1 (0.7 to 2.4)	1.1 (0.6 to 2.0)	-17.2 (-38.4 to -24.5)	-31.3 (-38.4 to -24.5)
Medication overuse headache	22.8 (15.5 to 29.8)	41.2 (27.9 to 53.7)	81.1 (56.7 to 107.9)	43.9 (24.2 to 63.9)	3.5 (2.1 to 5.4)	6.4 (3.7 to 9.8)	81.5 (55.2 to 108.4)	44.5 (23.7 to 65.1)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.4 (-12.7 to 89.2)	2.2 (-28.4 to 54.1)	2.4 (1.6 to 3.5)	2.6 (1.7 to 3.8)	3.8 (-30.1 to 59.1)	-17.3 (-43.6 to 25.7)
Mental and substance use disorders	-	-	-	-	118.9 (84.7 to 155.2)	138.2 (97.9 to 180.4)	16.1 (12.0 to 21.0)	-2.3 (-5.8 to 1.7)
Schizophrenia	12.0 (9.3 to 14.5)	14.9 (11.6 to 17.8)	23.7 (17.7 to 33.9)	-1.6 (-6.9 to 9.9)	7.6 (5.2 to 9.9)	9.5 (6.4 to 12.3)	24.5 (15.9 to 37.4)	-0.9 (-7.9 to 9.7)
Alcohol use disorders	78.0 (72.8 to 83.9)	86.7 (80.9 to 93.4)	11.0 (5.1 to 19.1)	-5.9 (-11.0 to 1.1)	7.8 (5.2 to 11.2)	8.7 (5.8 to 12.3)	10.9 (4.5 to 19.5)	5.8 (-11.3 to 1.9)
Drug use disorders	-	-	-	-	7.4 (4.8 to 10.6)	8.3 (5.3 to 11.3)	11.5 (-4.1 to 29.9)	-3.6 (-17.3 to 11.9)
Opioid use disorders	10.0 (5.6 to 14.8)	10.2 (6.1 to 15.1)	2.4 (-12.9 to 24.5)	-15.8 (-28.2 to -0.7)	4.1 (2.2 to 6.7)	4.2 (2.3 to 6.6)	2.5 (-13.8 to 25.4)	-15.4 (-29.0 to -0.3)
Cocaine use disorders	5.3 (4.2 to 6.4)	6.7 (5.7 to 7.7)	27.1 (-2.9 to 66.2)	13.6 (-13.3 to 49.0)	0.7 (0.4 to 1.1)	0.9 (0.6 to 1.4)	27.4 (-5.6 to 71.3)	13.6 (-16.2 to 54.4)
Amphetamine use disorders	5.2 to 7.3	6.7 to 8.6	(-1.0 to 50.0)	(-11.0 to 36.4)	0.5 to 1.2	0.6 to 1.5	21.4 to 52.6	10.1 to 38.9
Cannabis use disorders	7.0 (6.4 to 7.5)	7.6 (7.1 to 8.2)	9.6 (3.4 to 15.4)	0.9 (-5.0 to 6.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	9.6 (-6.2 to 25.9)	0.8 (-14.3 to 15.8)
Other drug use disorders	-	-	-	-	1.6 (0.9 to 2.3)	1.9 (1.2 to 2.8)	24.8 (-14.5 to 73.0)	12.3 (-23.2 to 56.7)
Depressive disorders	-	-	-	-	35.6 (24.1 to 48.9)	40.3 (26.9 to 56.7)	14.2 (1.6 to 21.7)	-5.9 (-16.4 to 0.3)
Major depressive disorder	142.9 (119.2 to 166.8)	159.2 (131.9 to 190.0)	12.3 (-2.0 to 21.4)	-7.3 (-19.4 to 0.2)	28.9 (19.4 to 40.6)	32.2 (21.1 to 46.7)	12.4 (-2.4 to 21.7)	-7.1 (-19.5 to 0.4)
Dysthymia	69.8 (59.0 to 80.6)	84.8 (71.9 to 98.4)	21.4 (18.9 to 24.0)	-0.3 (-4.5 to 0.2)	6.7 (4.4 to 9.9)	8.1 (5.4 to 12.0)	21.6 (17.8 to 25.3)	-0.1 (-2.5 to 2.1)
Bipolar disorder	31.9 (27.1 to 37.0)	37.8 (32.3 to 43.6)	18.6 (11.9 to 24.3)	-1.0 (-6.0 to 4.0)	6.4 (3.9 to 9.6)	7.6 (4.7 to 11.4)	18.6 (11.3 to 26.5)	-0.6 (-6.7 to 5.6)
Anxiety disorders	372.7 (311.8 to 444.8)	448.0 (362.8 to 537.8)	20.3 (9.8 to 30.5)	1.8 (-7.9 to 10.3)	33.9 (22.5 to 48.3)	40.8 (26.3 to 59.0)	20.4 (9.4 to 31.0)	1.9 (-7.7 to 11.3)
Eating disorders	-	-	-	-	4.0 (2.5 to 5.8)	4.4 (2.8 to 6.4)	9.3 (3.8 to 15.7)	2.6 (-2.5 to 8.3)
Anorexia nervosa	4.2 (2.9 to 5.5)	5.0 (3.4 to 6.7)	19.9 (4.4 to 36.7)	11.1 (-2.8 to 26.6)	0.9 (0.5 to 1.4)	1.1 (0.6 to 1.7)	20.2 (1.9 to 39.2)	11.4 (-5.6 to 28.6)
Bulimia nervosa	15.0 (11.0 to 18.9)	15.9 (11.5 to 20.0)	6.3 (4.9 to 7.3)	0.1 (-0.0 to 0.3)	3.2 (1.8 to 4.7)	3.4 (2.0 to 5.0)	6.2 (1.5 to 11.1)	0.1 (-4.0 to 4.7)
Autistic spectrum disorders	-	-	-	-	4.7 (3.3 to 6.3)	5.6 (3.9 to 7.6)	19.4 (15.6 to 23.6)	0.5 (-2.9 to 4.0)
Autism	12.2 (11.5 to 13.0)	14.6 (13.7 to 15.5)	19.5 (19.0 to 19.9)	0.4 (0.4 to 0.4)	3.0 (2.0 to 4.0)	3.5 (2.4 to 4.8)	19.3 (14.1 to 25.1)	0.4 (-0.1 to 5.5)
Asperger syndrome	17.4 (16.2 to 18.6)	20.8 (19.4 to 22.3)	19.7 (19.3 to 20.2)	0.5 (0.5 to 0.6)	1.7 (1.2 to 2.4)	2.1 (1.4 to 2.8)	19.5 (15.1 to 24.7)	0.6 (-3.2 to 5.0)
Attention-deficit/hyperactivity disorder	24.6 (21.0 to 27.7)	27.3 (23.3 to 30.8)	10.9 (10.8 to 11.1)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	11.1 (4.2 to 18.2)	0.2 (-5.7 to 6.4)
Conduct disorder	34.6 (29.4 to 40.6)	38.7 (33.0 to 45.2)	11.8 (11.0 to 12.5)	0.1 (0.1 to 0.1)	4.2 (2.5 to 6.1)	4.6 (2.8 to 6.8)	11.9 (7.5 to 16.2)	0.2 (-3.7 to 3.9)
Idiopathic intellectual disability	17.5 (13.0 to 23.4)	12.9 (7.4 to 19.2)	-26.4 (-50.9 to 2.4)	-38.5 (-58.8 to -14.5)	1.0 (0.9 to 1.6)	0.8 (0.4 to 1.2)	-26.6 (-51.5 to -3.6)	-38.4 (-59.2 to -13.7)
Other mental and substance use disorders	80.1 (75.5 to 84.6)	98.2 (92.5 to 103.8)	22.5 (12.2 to 24.0)	0.3 (0.2 to 0.5)	5.9 (4.0 to 8.0)	7.2 (5.0 to 9.7)	22.8 (18.5 to 27.2)	0.7 (-2.9 to 4.3)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	44.1 (31.7 to 58.2)	62.7 (44.5 to 83.7)	42.0 (28.3 to 59.5)	11.6 (1.3 to 22.7)
Diabetes mellitus	206.1 (164.7 to 262.0)	356.2 (285.5 to 446.7)	74.5 (29.7 to 128.0)	37.7 (0.7 to 79.3)	14.2 (9.5 to 21.1)	24.5 (16.0 to 35.3)	73.9 (30.0 to 133.5)	36.4 (1.4 to 81.7)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.2 (-13.4 to -1.5)	-19.5 (-24.9 to -14.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.2 (-13.5 to -1.5)	-19.5 (-24.9 to -14.4)
Chronic kidney disease	-	-	-	-	14.7 (9.4 to 20.5)	19.5 (12.6 to 26.8)	32.7 (25.4 to 41.0)	3.7 (-0.0 to 8.0)
Chronic kidney disease due to diabetes mellitus	18.3 (12.8 to 25.3)	29.4 (20.3 to 39.9)	58.3 (5.0 to 142.9)	19.8 (-14.8 to 76.7)	1.9 (1.1 to 2.9)	2.7 (1.6 to 3.9)	38.4 (4.4 to 114.4)	1.1 (-22.9 to 53.2)
Chronic kidney disease due to hypertension	35.0 (29.0 to 43.2)	46.0 (35.3 to 63.5)	28.8 (5.3 to 76.0)	1.2 (-17.6 to 39.4)	6.3 (3.9 to 9.0)	4.0 (2.4 to 6.1)	-36.5 (-49.7 to -18.0)	-49.7 (-60.3 to -36.8)
Chronic kidney disease due to glomerulonephritis	53.8 (41.1 to 70.2)	48.0 (36.4 to 68.8)	-11.0 (-34.1 to 20.1)	-23.9 (-41.9 to 2.2)	1.5 (0.9 to 2.2)	4.5 (2.8 to 6.6)	128.1 (118.4 to 136.5)	203.1 (68.9 to 209.8)
Chronic kidney disease due to other causes	63.2 (50.1 to 78.9)	108.4 (74.1 to 135.3)	65.8 (22.8 to 118.9)	25.5 (4.5 to 72.1)	8.5 (3.2 to 7.1)	8.3 (5.4 to 11.5)	30.0 (29.8 to 101.3)	30.0 (3.7 to 55.0)
Urinary diseases and male infertility	-	-	-	-	4.2 (2.7 to 5.9)	6.0 (3.9 to 8.6)	43.3 (32.3 to 58.3)	16.2 (7.2 to 28.1)
Interstitial nephritis and urinary tract infections	0.4 (0.4 to 0.5)	0.5 (0.5 to 0.6)	28.1 (18.6 to 38.6)	7.7 (-1.9 to 17.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.0 (-0.8 to 63.4)	7.4 (-16.7 to 38.8)

Appendix Table G.4 - Norway prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Urolithiasis	52.7 (28.6 to 83.0)	120.5 (58.8 to 190.6)	125.2 (101.0 to 168.2)	5.2 (55.5 to 114.9)	0.4 (0.2 to 0.8)	1.0 (0.4 to 1.8)	122.9 (89.9 to 162.1)	73.2 (45.0 to 107.2)
Benign prostatic hyperplasia	99.9 (91.4 to 107.6)	132.9 (127.7 to 137.7)	33.0 (22.1 to 46.0)	7.5 (-1.3 to 17.7)	3.5 (2.3 to 5.0)	4.7 (3.1 to 6.7)	33.2 (22.4 to 46.5)	7.6 (-0.9 to 18.1)
Male infertility due to other causes	19.6 (13.8 to 26.3)	22.2 (16.6 to 29.1)	13.2 (-28.9 to 69.3)	3.3 (-34.6 to 54.3)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.3)	13.9 (-30.6 to 71.5)	3.7 (-36.3 to 55.6)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	211.9 (50.3 to 367.1)	142.0 (15.7 to 264.0)
Gynecological diseases	-	-	-	-	5.3 (3.4 to 8.3)	6.2 (3.8 to 9.7)	16.0 (0.5 to 32.0)	-8.6 (-16.5 to 10.4)
Uterine fibroids	159.4 (135.7 to 185.2)	205.6 (176.0 to 238.3)	29.0 (27.8 to 30.2)	-0.7 (-0.7 to -0.6)	1.1 (0.7 to 2.6)	1.8 (0.9 to 3.3)	23.2 (9.7 to 51.6)	-3.3 (-15.0 to 22.6)
Polycystic ovarian syndrome	69.8 (59.8 to 80.6)	84.3 (71.2 to 96.9)	21.2 (-3.0 to 48.9)	4.9 (-16.3 to 29.9)	0.7 (0.3 to 1.2)	0.8 (0.4 to 1.5)	21.5 (-1.9 to 52.1)	5.2 (-15.3 to 32.5)
Female infertility due to other causes	5.4 (0.5 to 16.6)	5.2 (0.6 to 13.3)	6.6 (-92.2 to 865.6)	-6.3 (-93.1 to 786.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	5.2 (-92.3 to 899.0)	-4.1 (-92.8 to 827.9)
Endometriosis	11.7 (9.2 to 14.2)	11.5 (8.1 to 16.8)	-0.8 (-35.2 to 43.9)	-1.2 (-43.7 to 23.4)	1.1 (0.7 to 1.6)	1.1 (0.6 to 1.6)	0.6 (-35.0 to 43.2)	-4.0 (-44.5 to 23.8)
Genital prolapse	259.8 (234.8 to 285.4)	319.2 (286.4 to 350.0)	23.0 (6.6 to 40.7)	-4.2 (-17.8 to 10.0)	0.8 (0.4 to 1.5)	1.0 (0.5 to 1.9)	23.1 (6.5 to 41.8)	-4.0 (-18.2 to 10.4)
Premenstrual syndrome	107.6 (65.1 to 143.5)	121.1 (82.0 to 161.6)	12.9 (-27.3 to 89.9)	0.3 (-34.5 to 71.3)	0.9 (0.4 to 1.5)	1.0 (0.5 to 1.6)	11.6 (-27.3 to 91.6)	0.0 (-35.4 to 71.2)
Other gynecological diseases	14.3 (12.4 to 16.4)	17.1 (14.5 to 21.3)	20.1 (-2.3 to 49.1)	2.4 (-17.6 to 27.3)	0.4 (0.2 to 0.5)	0.4 (0.3 to 0.7)	2.0 (-10.9 to 70.0)	-2.0 (-24.9 to 50.5)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	3.9 (2.6 to 5.6)	4.5 (3.0 to 6.5)	13.7 (-9.0 to 31.1)	-5.8 (-18.0 to 6.8)
Thalassemias	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	12.3 (4.2 to 23.4)	2.2 (-5.3 to 12.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.1 (-15.6 to 54.7)	2.3 (-24.1 to 40.0)
Thalassemia trait	68.8 (64.8 to 74.0)	84.0 (79.3 to 89.9)	22.2 (17.4 to 26.9)	2.0 (-1.9 to 5.5)	2.2 (1.5 to 3.2)	2.6 (1.8 to 3.7)	18.4 (7.4 to 25.9)	-2.2 (-9.8 to 3.5)
Sickle cell disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	5.1 (-10.3 to 31.0)	-8.4 (-21.4 to 14.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.7 (-2.3 to 19.4)	-5.4 (-15.5 to 4.1)
Sickle cell trait	68.7 (62.8 to 75.0)	76.7 (70.4 to 83.2)	11.7 (6.0 to 17.3)	-6.9 (-11.6 to -2.2)	1.0 (0.7 to 1.5)	1.0 (0.6 to 1.5)	0.5 (-15.0 to 14.5)	-15.0 (-27.4 to -2.5)
G6PD deficiency	16.8 (11.0 to 25.6)	22.6 (15.0 to 30.4)	32.7 (-16.8 to 125.7)	0.0 (-30.5 to 87.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.2 (-21.3 to 37.9)	6.7 (-38.5 to 14.7)
G6PD trait	490.4 (433.4 to 540.1)	568.0 (505.6 to 619.6)	15.8 (-0.6 to 35.5)	-3.0 (-16.8 to 13.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	1.9 (-47.2 to 93.5)	-12.3 (-56.6 to 67.8)
Other hemoglobinopathies and hemolytic anemias	28.3 (25.6 to 31.9)	36.7 (32.4 to 47.1)	29.3 (1.6 to 68.2)	3.9 (-19.5 to 30.7)	0.5 (0.3 to 0.9)	0.7 (0.4 to 1.3)	27.6 (-19.6 to 124.0)	1.0 (-32.6 to 64.0)
Endocrine, metabolic, blood, and immune disorders	58.7 (54.7 to 62.6)	69.2 (65.4 to 73.7)	18.5 (6.4 to 29.5)	-2.9 (-14.6 to 7.2)	1.8 (1.2 to 2.6)	2.1 (1.5 to 2.9)	18.7 (12.6 to 32.2)	-3.1 (-18.1 to 6.8)
Musculoskeletal disorders	-	-	-	-	130.2 (91.8 to 172.6)	163.3 (116.2 to 216.3)	25.1 (19.6 to 32.3)	0.2 (-4.4 to 5.9)
Rheumatoid arthritis	16.2 (15.4 to 16.9)	21.4 (20.2 to 22.7)	32.2 (22.7 to 42.2)	6.9 (-0.5 to 14.6)	3.7 (2.7 to 4.8)	4.9 (3.5 to 6.5)	33.8 (22.9 to 45.5)	8.0 (-0.6 to 17.4)
Osteoarthritis	227.2 (212.8 to 240.1)	288.9 (269.7 to 306.1)	27.1 (17.1 to 38.8)	-1.3 (-9.5 to 7.9)	7.8 (5.2 to 11.1)	9.9 (6.6 to 14.3)	27.8 (17.5 to 39.9)	-0.9 (-9.2 to 8.3)
Low back and neck pain	-	-	-	-	104.3 (73.0 to 140.9)	129.3 (89.9 to 174.1)	23.7 (17.5 to 32.1)	-0.5 (-5.5 to 6.2)
Low back pain	638.8 (603.9 to 674.9)	797.1 (741.3 to 835.1)	23.0 (15.0 to 33.7)	-0.5 (-7.3 to 7.9)	70.6 (48.4 to 98.2)	87.1 (58.1 to 121.0)	23.2 (15.0 to 33.6)	-0.3 (-7.3 to 7.9)
Neck pain	345.6 (322.8 to 367.3)	432.9 (408.2 to 458.7)	25.4 (15.2 to 36.4)	-0.2 (-7.9 to 8.5)	33.7 (23.3 to 46.9)	42.3 (29.3 to 58.5)	25.6 (15.1 to 36.7)	0.1 (-8.0 to 9.0)
Gout	11.5 (10.7 to 12.4)	14.7 (13.6 to 15.9)	28.6 (15.2 to 42.1)	-0.6 (-11.0 to 9.7)	0.4 (0.2 to 0.5)	0.5 (0.3 to 0.6)	29.5 (9.5 to 52.1)	-0.3 (-15.5 to 17.8)
Other musculoskeletal disorders	155.6 (135.9 to 175.3)	203.7 (180.9 to 228.1)	30.9 (20.3 to 41.6)	3.4 (-4.8 to 11.3)	14.2 (9.6 to 19.9)	18.7 (12.7 to 26.1)	31.6 (20.6 to 42.4)	4.1 (-4.4 to 12.2)
Other non-communicable diseases	-	-	-	-	82.2 (55.2 to 117.9)	97.0 (65.3 to 139.7)	18.7 (12.9 to 23.5)	-2.7 (-7.2 to 2.2)
Congenital anomalies	-	-	-	-	7.3 (5.1 to 10.0)	9.1 (6.3 to 12.2)	25.2 (6.0 to 44.2)	1.8 (-13.9 to 18.0)
Neural tube defects	1.1 (0.9 to 1.2)	1.1 (0.9 to 1.3)	3.8 (-14.4 to 24.6)	-13.5 (-28.5 to 4.0)	0.4 (0.2 to 0.5)	0.4 (0.2 to 0.5)	4.9 (-22.6 to 39.2)	-12.3 (-35.5 to 17.3)
Congenital heart anomalies	48.5 (41.5 to 62.6)	49.5 (43.0 to 57.5)	3.3 (-23.0 to 30.9)	-13.7 (-35.6 to 8.9)	1.7 (0.7 to 3.0)	1.8 (0.7 to 3.1)	4.9 (-20.4 to 30.0)	-12.2 (-33.0 to 8.7)
Orofacial clefts	7.2 (5.9 to 8.5)	7.8 (7.1 to 9.1)	8.1 (-10.4 to 38.4)	-10.2 (-25.5 to 15.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	8.4 (-13.0 to 46.1)	-9.8 (-33.4 to 23.0)
Down syndrome	6.3 (5.5 to 7.4)	8.2 (6.9 to 9.7)	31.6 (6.0 to 57.6)	5.3 (-15.1 to 25.7)	0.9 (0.7 to 1.2)	1.3 (0.9 to 1.6)	6.8 (9.7 to 64.3)	36.9 (-15.1 to 28.8)
Turner syndrome	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	25.5 (-16.8 to 99.6)	4.9 (-30.4 to 66.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.1 (-21.0 to 96.5)	3.5 (-32.5 to 66.0)
Klinefelter syndrome	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	31.9 (-2.6 to 79.1)	9.4 (-19.1 to 48.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.5 (-21.8 to 96.9)	8.9 (-32.1 to 67.4)
Chromosomal unbalanced rearrangements	11.5 (9.7 to 13.9)	14.7 (12.4 to 17.8)	27.0 (-0.6 to 64.9)	1.3 (-20.6 to 22.2)	1.7 (1.2 to 2.3)	2.3 (1.6 to 2.9)	32.4 (23.9 to 71.9)	2.8 (-20.0 to 34.0)
Other congenital anomalies	10.0 (6.4 to 12.4)	9.1 (6.1 to 12.0)	-7.7 (-36.6 to 18.1)	-41.1 (-47.0 to -3.8)	2.6 (1.6 to 3.9)	3.4 (2.1 to 5.1)	30.3 (4.7 to 72.5)	10.3 (-12.4 to 44.4)
Skin and subcutaneous diseases	-	-	-	-	29.9 (19.5 to 44.4)	36.5 (23.9 to 54.6)	22.4 (11.9 to 33.2)	3.4 (-5.9 to 13.3)
Dermatitis	300.0 (241.1 to 359.2)	356.2 (287.4 to 425.1)	18.8 (17.0 to 20.7)	-0.1 (-0.1 to -0.0)	9.0 (5.9 to 13.2)	10.6 (7.0 to 15.5)	18.5 (15.6 to 22.0)	0.1 (-2.4 to 2.5)
Psoriasis	66.3 (59.0 to 74.2)	81.4 (72.0 to 90.8)	22.7 (21.0 to 24.6)	0.1 (-0.1 to 0.2)	5.3 (3.7 to 7.5)	6.6 (4.5 to 9.3)	22.8 (18.3 to 27.9)	0.3 (-3.4 to 4.6)
Cellulitis	0.5 (0.4 to 0.6)	0.5 (0.4 to 0.6)	5.6 (-5.5 to 17.0)	-0.0 (-18.6 to 3.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.6 (-8.9 to 28.4)	-7.1 (-19.9 to 8.5)
Pyoderma	5.6 (4.6 to 6.7)	7.8 (6.3 to 9.6)	38.5 (31.8 to 48.2)	8.7 (4.0 to 14.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	38.1 (27.2 to 50.7)	8.4 (-0.1 to 17.4)
Scabies	3.0 (2.6 to 3.5)	2.7 (2.2 to 3.1)	-11.2 (-34.1 to 9.9)	-23.5 (-43.5 to -4.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-11.0 (-33.9 to 12.4)	-23.3 (-43.8 to -3.0)
Fungal skin diseases	314.5 (278.7 to 346.8)	390.5 (346.6 to 429.0)	24.1 (22.8 to 25.4)	0.4 (0.2 to 0.5)	1.7 (0.7 to 3.7)	2.2 (0.9 to 4.5)	24.2 (22.6 to 26.0)	0.5 (-0.5 to 1.4)
Viral skin diseases	84.1 (73.9 to 96.2)	97.7 (86.6 to 111.3)	16.4 (12.8 to 19.4)	0.5 (-1.9 to 3.0)	2.6 (1.7 to 3.8)	3.0 (1.9 to 4.4)	16.2 (11.8 to 20.6)	0.6 (-3.0 to 4.3)
Acne vulgaris	599.8 (425.4 to 758.9)	746.0 (579.0 to 958.8)	26.9 (-2.6 to 73.4)	15.9 (-21.1 to 57.9)	6.5 (2.8 to 12.8)	8.1 (3.6 to 15.2)	27.0 (-12.9 to 74.4)	16.0 (-21.4 to 58.3)
Alopecia areata	7.4 (6.8 to 8.1)	9.2 (8.5 to 10.0)	23.8 (10.8 to 39.3)	-0.9 (-10.4 to 11.3)	0.2 (0.2 to 0.4)	0.3 (0.2 to 0.5)	24.0 (7.7 to 41.6)	-0.7 (-12.6 to 13.3)
Pruritus	1.4 (1.3 to 1.6)	1.5 (1.4 to 1.7)	6.4 (-4.6 to 22.4)	-16.1 (-24.5 to -4.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.3 (-10.4 to 29.3)	-15.6 (-30.3 to 0.9)
Urticaria	32.1 (23.2 to 43.3)	42.1 (29.9 to 57.8)	31.3 (-23.0 to 103.2)	1.9 (-38.5 to 75.1)	2.5 (1.1 to 3.0)	3.0 (1.4 to 3.9)	30.7 (-23.5 to 105.6)	2.8 (-38.5 to 75.0)
Decubitus ulcer	3.0 (2.5 to 3.5)	3.5 (2.9 to 4.2)	18.0 (-9.6 to 51.2)	-2.2 (-24.2 to 22.6)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	18.9 (-9.7 to 54.5)	-1.5 (-24.4 to 24.9)
Other skin and subcutaneous diseases	362.2 (202.1 to 642.2)	466.2 (261.3 to 806.5)	28.7 (22.8 to 36.4)	1.2 (-1.9 to 3.7)	2.1 (0.8 to 4.8)	2.7 (1.1 to 6.1)	29.0 (22.7 to 36.7)	1.4 (-1.8 to 4.1)
Sense organ diseases	-	-	-	-	28.3 (18.3 to 41.6)	32.4 (20.9 to 47.7)	14.7 (6.1 to 22.8)	-8.9 (-15.0 to -2.9)
Glaucoma	3.2 (2.2 to 4.5)	2.6 (1.8 to 3.9)	-18.1 (-33.8 to 1.7)	-34.5 (-47.4 to -17.5)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-18.6 (-37.3 to 9.8)	-34.6 (-49.7 to -11.7)
Cataract	8.8 (5.8 to 13.9)	8.3 (5.5 to 12.0)	-5.8 (-30.7 to 28.2)	-26.0 (-45.1 to -2.0)	0.5 (0.3 to 0.8)	0.4 (0.2 to 0.7)	-5.0 (-26.9 to 30.0)	-25.4 (-43.6 to -2.3)
Macular degeneration	12.9 (8.5 to 17.7)	15.7 (11.0 to 21.3)	21.8 (-0.0 to 54.4)	-6.1 (-21.4 to 17.2)	0.7 (0.4 to 1.1)	0.8 (0.5 to 1.3)	19.9 (1.9 to 45.5)	-8.1 (-21.5 to 11.2)
Uncorrected refractive error	519.1 (427.3 to 602.8)	613.8 (514.9 to 705.5)	18.0 (-6.1 to 50.0)	-8.0 (-27.2 to 17.5)	6.1 (3.1 to 10.9)	7.1 (3.6 to 12.8)	15.5 (-5.3 to 41.8)	-9.5 (-25.8 to 10.9)
Age-related and other hearing loss	732.3 (709.7 to 752.4)	827.3 (800.1 to 855.4)	13.1 (9.3 to 16.6)	-10.8 (-14.0 to -7.9)	17.7 (11.6 to 25.5)	20.3 (13.2 to 29.6)	15.1 (5.2 to 26.2)	-9.2 (-16.1 to -1.6)
Other vision loss	9.1 (6.4 to 12.5)	6.7 (4.6 to 9.4)	-25.4 (-41.4 to -12.6)	-40.6 (-52.3 to -30.6)	0.5 (0.3 to 0.8)	0.4 (0.2 to 0.6)	-17.1 (-33.0 to 0.2)	-3.1 (-46.0 to -19.5)
Other sense organ diseases	102.5 (98.1 to 107.2)	123.5 (117.8 to 128.7)	20.7 (13.2 to 28.2)	-0.2 (-6.3 to 6.0)	2.7 (1.7 to 4.0)	3.2 (2.0 to 4.8)	20.7 (12.2 to 28.8)	-0.1 (-7.1 to 6.4)
Oral disorders	-	-	-	-	16.8 (10.8 to 25.0)	19.0 (11.7 to 28.4)	13.4 (5.4 to 21.7)	-8.8 (-14.8 to -2.5)
Deciduous caries	133.7 (129.5 to 137.6)	156.0 (150.0 to 162.0)	16.6 (10.9 to 22.3)	1.3 (-3.7 to 6.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	16.7 (5.6 to 29.0)	1.3 (-8.2 to 11.9)
Permanent caries	1,463.5 (1,246.1 to 1,588.7)	1,860.1 (1,742.9 to 2,005.1)	26.8 (13.0 to 50.4)	26.8 (-5.6 to 24.9)	0.9 (0.4 to 1.7)	1.1 (0.5 to 2.1)	26.9 (12.7 to 49.2)	5.7 (-6.0 to 24.0)
Periodontal diseases	473.3 (427.4 to 514.9)	653.0 (597.3 to 713.1)	38.1 (21.4 to 56.2)	4.7 (-7.8 to 18.2)	3.1 (1.2 to 6.2)	4.2 (1.7 to 8.8)	38.1 (21.6 to 56.2)	4.7 (-8.0 to 18.5)
Edentulism and severe tooth loss	385.6 (356.4 to							

Appendix Table G.4 - Norway prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Other oral disorders	79.8 (75.8 to 83.8)	97.3 (92.0 to 102.4)	22.0 (13.6 to 31.6)	0.0 (-7.2 to 8.2)	2.3 (1.4 to 3.5)	2.8 (1.7 to 4.3)	23.0 (12.7 to 32.2)	0.3 (-7.4 to 8.7)
Injuries	-	-	-	-	49.0 (37.0 to 62.5)	39.7 (28.4 to 53.3)	-19.0 (-28.4 to -9.2)	-35.9 (-42.7 to -28.7)
Transport injuries	-	-	-	-	2.6 (2.0 to 3.4)	2.0 (1.5 to 2.7)	-23.2 (-30.8 to -15.0)	-40.3 (-46.2 to -33.8)
Road injuries	-	-	-	-	1.5 (1.2 to 2.0)	0.8 (0.6 to 1.0)	-48.6 (-53.6 to -42.8)	-60.4 (-64.4 to -55.8)
Pedestrian road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.1)	-51.2 (-56.3 to -45.0)	-62.1 (-66.3 to -57.0)
Cyclist road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-50.2 (-56.5 to -42.1)	-60.6 (-65.7 to -54.1)
Motorcyclist road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-52.8 (-60.3 to -44.8)	-64.0 (-69.8 to -57.7)
Motor vehicle road injuries	-	-	-	-	0.9 (0.7 to 1.2)	0.5 (0.4 to 0.7)	-46.5 (-51.4 to -40.9)	-58.8 (-62.7 to -54.3)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.9 (-73.7 to -65.5)	-76.1 (-79.3 to -72.4)
Other transport injuries	-	-	-	-	1.1 (0.8 to 1.4)	1.2 (0.9 to 1.7)	12.7 (1.0 to 24.6)	-11.4 (-20.6 to -2.4)
Unintentional injuries	-	-	-	-	45.7 (34.5 to 58.3)	37.1 (26.5 to 49.8)	-18.9 (-28.5 to -8.6)	-35.6 (-42.7 to -28.2)
Falls	-	-	-	-	34.3 (25.9 to 43.7)	30.0 (21.5 to 40.1)	-13.0 (-25.4 to 0.7)	-30.2 (-39.4 to -20.0)
Drowning	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-33.5 (-40.5 to -24.6)	-48.5 (-54.1 to -41.4)
Fire, heat, and hot substances	-	-	-	-	1.1 (0.7 to 1.6)	0.9 (0.5 to 1.5)	-14.0 (-24.9 to -1.5)	-32.8 (-41.7 to -23.0)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.1 (-18.9 to 15.9)	-22.6 (-37.0 to -9.0)
Exposure to mechanical forces	-	-	-	-	5.9 (4.4 to 7.8)	3.9 (2.8 to 5.4)	-33.2 (-40.9 to -24.5)	-46.7 (-52.8 to -39.5)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-41.2 (-49.5 to -32.3)	-52.4 (-58.9 to -44.9)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.3 (12.4 to 53.4)	8.0 (-9.1 to 24.4)
Other exposure to mechanical forces	-	-	-	-	5.8 (4.3 to 7.7)	3.9 (2.7 to 5.3)	-33.4 (-41.2 to -24.7)	-46.8 (-53.0 to -39.6)
Adverse effects of medical treatment	-	-	-	-	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.4)	24.7 (12.1 to 38.4)	1.5 (-8.6 to 10.9)
Animal contact	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	7.5 (-2.6 to 17.9)	-13.5 (-21.7 to -4.2)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.7 (-10.7 to 26.0)	-12.3 (-27.6 to 3.3)
Non-venomous animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	7.4 (-3.2 to 18.4)	-13.7 (-22.4 to -4.3)
Foreign body	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-1.9 (-13.3 to 11.5)	-20.0 (-30.0 to -8.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.5 (-24.7 to 1.9)	-29.0 (-40.0 to -17.6)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	5.4 (-6.0 to 18.1)	-11.8 (-22.3 to 0.3)
Foreign body in other body part	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-1.1 (-14.7 to 16.1)	-19.6 (-31.4 to -4.8)
Other unintentional injuries	-	-	-	-	3.6 (2.5 to 4.9)	1.5 (1.1 to 2.0)	-58.7 (-64.1 to -54.1)	-68.8 (-73.0 to -65.3)
Self-harm and interpersonal violence	-	-	-	-	0.7 (0.5 to 0.9)	0.6 (0.4 to 0.8)	-15.0 (-22.2 to -7.6)	-34.1 (-39.8 to -28.4)
Self-harm	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	5.9 (-5.1 to 19.0)	-17.0 (-26.2 to -6.6)
Interpersonal violence	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.3)	-11.6 (-38.3 to -24.3)	-46.9 (-52.3 to -41.2)
Assault by firearm	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-33.8 (-40.1 to -27.3)	-48.9 (-53.9 to -43.8)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-9.8 (-17.4 to -0.7)	-29.9 (-35.8 to -22.6)
Assault by other means	-	-	-	-	0.3 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-34.6 (-41.8 to -26.5)	-49.2 (-55.0 to -42.8)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Oman prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
All causes	-	-	-	-	171.7 (125.7 to 224.7)	360.8 (263.9 to 466.9)	110.6 (93.2 to 126.1)	4.0 (-9.3 to 0.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	38.0 (24.9 to 58.3)	42.9 (30.1 to 59.0)	18.8 (-24.7 to 49.4)	-27.9 (-53.1 to -11.8)
HIV/AIDS and tuberculosis	-	-	-	-	0.2 (0.1 to 0.2)	0.5 (0.3 to 0.7)	198.7 (136.4 to 300.8)	13.0 (-6.1 to 45.5)
Tuberculosis	0.5 (0.5 to 0.5)	1.0 (0.9 to 1.1)	102.5 (91.5 to 116.2)	-17.1 (-20.5 to -13.3)	0.0 (0.1 to 0.2)	0.3 (0.2 to 0.4)	103.2 (70.5 to 147.8)	-17.2 (-26.9 to -5.6)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	9,511.3 (2,891.1 to 180,001.1)	511.3 (1,067.8 to 65,857.8)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6,615.0 (1,788.3 to 145,434.0)	2,402.9 (607.7 to 56,770.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6,615.0 (1,784.6 to 151,466.1)	2,402.9 (606.3 to 58,639.2)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	1.8 (1.1 to 2.8)	12,334.6 (3,608.8 to 242,359.2)	4,720.5 (1,444.4 to 90,142.2)	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	9,529.2 (2,880.7 to 201,112.5)	3,504.6 (1,065.2 to 75,776.3)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	5.9 (4.2 to 8.1)	6.9 (4.8 to 9.3)	15.6 (5.2 to 25.7)	-18.6 (-24.8 to -12.8)
Diarrheal diseases	28.0 (26.1 to 29.7)	29.8 (27.4 to 32.1)	6.6 (-4.0 to 17.2)	-19.2 (-26.7 to -12.2)	4.6 (3.1 to 6.3)	4.8 (3.2 to 6.7)	5.3 (-5.0 to 17.4)	-19.1 (-26.9 to -11.8)
Intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-29.7 (57.6 to 1.2)	-56.9 (-72.9 to -38.6)
Typhoid fever	0.3 (0.3 to 0.4)	0.3 (0.3 to 0.4)	-11.4 (-30.5 to 12.9)	-45.6 (-56.1 to -31.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-10.0 (-34.2 to 23.7)	-44.7 (-57.7 to -25.9)
Paratyphoid fever	0.2 (0.2 to 0.2)	0.2 (0.1 to 0.2)	-10.5 (-31.9 to 14.6)	-43.8 (-55.8 to -27.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.1 (-34.7 to 23.0)	-43.4 (-57.6 to -24.6)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-79.8 (-92.3 to -49.8)	-84.1 (-95.3 to -50.9)
Lower respiratory infections	1.1 (0.7 to 1.5)	1.3 (0.7 to 1.8)	20.3 (-36.4 to 114.1)	-25.0 (58.3 to 43.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	17.1 (-39.1 to 113.0)	-24.4 (-58.9 to 40.6)
Upper respiratory infections	37.9 (33.6 to 42.2)	69.8 (59.3 to 77.4)	85.5 (50.5 to 116.4)	-0.5 (-17.7 to 15.6)	0.4 (0.2 to 0.8)	0.8 (0.4 to 1.4)	85.0 (49.1 to 116.3)	-0.3 (-17.7 to 16.2)
Otitis media	22.9 (21.4 to 24.6)	35.8 (33.0 to 38.8)	55.9 (41.3 to 72.8)	-6.1 (-14.4 to 3.3)	0.4 (0.3 to 0.7)	0.7 (0.4 to 1.1)	54.3 (38.5 to 73.2)	-7.1 (-15.8 to 3.2)
Meningitis	-	-	-	-	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-8.3 (-28.0 to 17.9)	-50.7 (-60.7 to -37.8)
Pneumococcal meningitis	0.8 (0.5 to 1.4)	0.7 (0.4 to 1.2)	-9.3 (-39.7 to 22.7)	-53.5 (-68.5 to -38.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-3.4 (-35.7 to 26.5)	-50.4 (-65.2 to -37.5)
H influenzae type B meningitis	0.4 (0.1 to 1.0)	0.3 (0.1 to 0.7)	-27.5 (-54.5 to 38.2)	-62.6 (-75.1 to -25.2)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-13.9 (-52.9 to 58.8)	-53.0 (-70.6 to -12.6)
Meningococcal meningitis	0.3 (0.1 to 0.8)	0.2 (0.1 to 0.6)	-28.5 (-53.7 to 13.6)	-62.5 (-75.7 to -37.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-23.8 (-47.4 to 37.8)	-59.6 (-72.0 to -29.2)
Other meningitis	0.4 (0.2 to 0.7)	0.3 (0.2 to 0.7)	-7.1 (-38.8 to 28.4)	-44.7 (-63.4 to -24.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	1.0 (-28.4 to 45.8)	-40.3 (-56.7 to -18.2)
Encephalitis	0.4 (0.2 to 1.0)	0.6 (0.2 to 1.6)	52.8 (17.2 to 91.3)	-25.6 (-41.8 to -6.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	69.9 (24.6 to 112.3)	-19.8 (-36.0 to 2.3)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.8 (-96.9 to 617.6)	-64.1 (-96.5 to 326.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.8 (-96.5 to 618.9)	-64.1 (-96.5 to 338.4)
Whooping cough	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-30.7 (-32.1 to -29.4)	-32.8 (-34.1 to -31.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.1 (-48.1 to -7.2)	-32.1 (-49.9 to -10.0)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.2 (-79.0 to -33.1)	-76.7 (-86.3 to -58.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.7 (-77.6 to -16.2)	-72.1 (-83.9 to -46.8)
Measles	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-62.4 (-67.6 to -56.1)	-62.9 (-68.1 to -56.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-62.4 (-74.5 to -37.4)	-61.1 (-74.7 to -39.3)
Varicella and herpes zoster	1.6 (1.4 to 1.7)	2.1 (1.8 to 2.4)	34.0 (16.9 to 57.7)	4.9 (-13.5 to 28.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	122.6 (54.1 to 221.5)	9.3 (-23.4 to 61.9)
Neglected tropical diseases and malaria	-	-	-	-	2.0 (1.3 to 2.8)	1.6 (1.1 to 2.2)	-22.0 (-31.2 to -2.9)	-62.9 (-69.0 to -53.9)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-64.4 (-80.8 to -21.7)	-84.4 (-91.5 to -65.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	194.7 (53.4 to 573.9)	39.8 (-24.3 to 213.6)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.2 (0.7 to 62.2)	-14.6 (-30.4 to 4.7)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.6 (-16.7 to 67.5)	-14.6 (-38.5 to 11.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.6 (-16.7 to 67.7)	-14.6 (-38.5 to 11.8)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.4 (20.7 to 80.6)	-14.4 (-29.6 to 6.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.4 (20.6 to 80.8)	-14.4 (-29.6 to 6.9)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	71.7 (59.8 to 114.4)	-26.0 (-31.3 to -7.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.6 (53.5 to 106.5)	-18.9 (-30.7 to -6.9)
Cysticercosis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-70.3 (-92.6 to 28.8)	-88.4 (-96.6 to -59.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-78.8 (-92.2 to 41.5)	-87.2 (-96.2 to -53.7)
Cystic echinococcosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	132.0 (111.0 to 163.7)	-1.6 (-9.5 to 7.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	135.5 (83.2 to 221.6)	0.0 (-24.6 to 35.4)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	8.1 (5.5 to 11.3)	4.9 (3.6 to 6.8)	-40.3 (-53.9 to -24.6)	-74.7 (-80.5 to -65.5)	0.8 (0.5 to 1.2)	0.5 (0.3 to 0.7)	-39.4 (-52.4 to -25.2)	-74.3 (-79.7 to -67.0)
Dengue	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.4)	466.3 (415.4 to 530.8)	187.3 (161.4 to 220.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	466.3 (415.0 to 530.9)	187.3 (161.2 to 220.0)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.2 (-54.1 to 35.6)	53.0 (-71.9 to -25.0)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	173.0 (107.7 to 234.1)	2.8 (-23.6 to 25.2)
Ascariasis	3.9 (2.7 to 5.5)	7.7 (4.5 to 12.6)	95.0 (1.1 to 259.8)	-1.6 (-49.3 to 89.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.3 (88.5 to 1,952.5)	10.6 (-91.4 to 1,326.0)
Trichuriasis	8.0 (5.4 to 12.0)	15.7 (9.2 to 27.3)	90.6 (2.7 to 304.1)	-0.7 (-49.9 to 110.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.8 (88.2 to 4,033.4)	27.3 (-91.8 to 2,604.5)
Hookworm disease	1.1 (0.6 to 1.7)	3.0 (1.7 to 4.9)	173.8 (38.4 to 499.6)	3.4 (-50.7 to 113.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	172.9 (107.8 to 234.1)	2.8 (-23.6 to 25.2)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	33.6 (26.0 to 41.3)	34.4 (32.2 to 36.8)	2.4 (-17.2 to 32.3)	-23.1 (-36.3 to -3.8)	1.2 (0.7 to 1.7)	1.0 (0.7 to 1.5)	-12.9 (-23.9 to 28.4)	-24.4 (-33.6 to 10.0)
Maternal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-3.3 (-23.2 to 19.9)	-67.4 (-74.4 to -59.7)
Maternal hemorrhage	0.4 (0.4 to 0.5)	0.6 (0.3 to 0.8)	39.0 (-19.4 to 98.8)	-52.2 (-70.3 to -33.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.8 (-54.3 to 90.9)	-63.2 (-83.1 to -37.8)
Maternal sepsis and other maternal infections	1.3 (0.8 to 1.8)	0.8 (0.5 to 1.2)	-38.5 (-57.6 to 12.5)	-73.5 (-81.8 to -52.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.7 (-67.0 to 5.7)	-77.7 (-87.2 to -62.8)
Maternal hypertensive disorders	1.2 (0.4 to 2.1)	1.2 (0.5 to 2.3)	2.2 (-14.8 to 17.3)	-65.8 (-73.7 to -56.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.7 (-18.9 to 22.6)	-66.1 (-74.4 to -55.4)
Obstructed labor	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-2.2 (-37.2 to 42.6)	-69.0 (-78.7 to -54.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.6 (-57.8 to 94.2)	-69.1 (-84.0 to -40.7)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.4 (-32.2 to 79.3)	-60.6 (-74.6 to -36.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.0 (-36.3 to 105.4)	-59.6 (-76.3 to -25.8)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.3 (-46.0 to 93.8)	-66.0 (-82.0 to -33.2)
Neonatal disorders	-	-	-	-	9.1 (2.8 to 25.2)	11.9 (6.7 to 20.2)	69.7 (-60.2 to 346.5)	-6.0 (-77.3 to 142.3)
Preterm birth complications	7.7 (5.5 to 10.7)	20.6 (15.0 to 27.8)	166.2 (102.4 to 257.5)	39.5 (7.3 to 85.3)	1.0 (0.7 to 1.4)	3.0 (2.0 to 4.2)	206.9 (121.3 to 339.3)	64.7 (20.5 to 129.9)
Neonatal encephalopathy due to birth asphyxia and trauma	3.2 (1.4 to 6.0)	3.3 (1.8 to 5.9)	3.3 (-56.2 to 154.1)	-0.8 (-75.0 to 84.3)	0.8 (0.4 to 1.4)	0.8 (0.6 to 1.7)	28.9 (-41.2 to 164.5)	-26.4 (-65.7 to 51.0)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.2 (10.5 to 52.2)	18.2 (2.7 to 41.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.9 (-9.3 to 98.9)	18.3 (-15.7 to 84.9)
Hemolytic disease and other neonatal jaundice	2.8 (1.1 to 5.8)	5.3 (1.9 to 14.7)	67.9 (-50.3 to 895.4)	-5.8 (-72.0 to 463.2)	0.9 (0.4 to 1.6)	1.8 (0.7 to 4.4)	88.9 (-31.2 to 739.6)	1.6 (-62.7 to 348.8)
Other neonatal disorders	-	-	-	-	6.5 (0.7 to 22.0)	6.1 (2.9 to 12.2)	40.0 (-78.9 to 826.1)	-22.0 (-87.9 to 393.4)
Nutritional deficiencies	-	-	-	-	19.4 (12.9 to 27.8)	19.8 (13.1 to 28.9)	2.4 (-8.1 to 13.1)	-31.6 (-36.2 to -25.2)
Protein-energy malnutrition	12.3 (6.5 to 21.8)	8.5 (3.6 to 17.2)	-32.8 (-75.9 to 69.7)	-33.8 (-76.2 to 67.3)	0.8 (0.7 to 2.9)	1.1 (0.4 to 2.3)	1.5 (-75.8 to 74.0)	-33.5 (-71.1 to 71.5)
Iodine deficiency	50.3 (28.6 to 77.2)	61.5 (34.1 to 101.2)	22.3 (-36.1 to 113.7)	-52.2 (-75.3 to -15.3)	0.9 (0.4 to 1.6)	1.1 (0.5 to 2.1)	23.1 (-35.9 to 114.7)	-52.2 (-75.3 to -14.6)
Vitamin A deficiency	2.0 (1.2 to 2.8)	1.8 (1.0 to 2.9)	-9.9 (-35.1 to 33.9)	-47.0 (-58.9 to -24.8)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-10.0 (-34.6 to 33.4)	-47.6 (-60.2 to -27.0)

Appendix Table G.4 - Oman prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	501.9 (494.8 to 509.0)	620.5 (616.3 to 624.7)	23.6 (21.7 to 25.6)	-28.4 (-29.4 to -27.4)	16.4 (10.9 to 23.8)	16.9 (11.2 to 24.7)	2.8 (-0.6 to 5.9)	2.8 (-32.6 to -29.6)
Other nutritional deficiencies	-	-	-	-	0.3 (0.1 to 0.8)	0.6 (0.2 to 1.3)	92.9 (59.7 to 770.7)	91.2 (59.6 to 763.6)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.3 (0.8 to 1.9)	2.2 (1.4 to 3.4)	63.9 (35.4 to 101.0)	-12.6 (-24.7 to 0.6)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.3 (0.1 to 0.5)	1.0 (0.5 to 1.7)	255.7 (127.8 to 444.0)	12.4 (-24.8 to 59.8)
Syphilis	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	47.5 (19.0 to 87.2)	-39.4 (-48.2 to -27.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.8 (7.2 to 129.9)	97.3 (-55.7 to -7.7)
Chlamydial infection	27.5 (17.7 to 39.5)	89.1 (59.1 to 124.3)	225.9 (86.7 to 444.1)	9.2 (-38.0 to 77.0)	0.1 (0.0 to 0.3)	0.6 (0.3 to 1.1)	344.8 (84.5 to 882.6)	38.8 (-40.4 to 195.2)
Gonococcal infection	9.9 (7.3 to 13.1)	27.8 (18.5 to 35.5)	186.4 (91.6 to 297.7)	-5.4 (-36.0 to 30.4)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	227.8 (117.7 to 388.3)	1.2 (-31.2 to 47.5)
Trichomoniasis	6.6 (4.3 to 9.7)	16.5 (9.9 to 24.1)	144.2 (50.9 to 340.2)	-11.1 (-46.2 to 43.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	136.9 (12.6 to 390.0)	-11.5 (-54.8 to 62.6)
Genital herpes	202.9 (190.2 to 214.6)	515.1 (493.1 to 549.0)	155.6 (135.7 to 177.1)	-5.7 (-13.1 to 2.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.3)	158.4 (132.7 to 184.9)	-5.4 (-14.4 to 3.3)
Other sexually transmitted diseases	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	105.3 (65.2 to 152.9)	-18.5 (-33.1 to 0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	151.8 (63.7 to 286.3)	-6.7 (-34.8 to 35.2)
Hepatitis	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	84.3 (39.1 to 131.6)	-22.3 (-42.2 to 0.3)
Hepatitis A	2.7 (2.5 to 2.8)	4.1 (4.0 to 4.3)	55.8 (53.4 to 58.1)	-5.0 (-5.1 to -4.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	110.6 (82.8 to 140.4)	-1.7 (-12.0 to 10.0)
Hepatitis B	1531 (114.7 to 201.1)	198.2 (150.4 to 243.3)	29.3 (-16.9 to 92.4)	-41.4 (-61.7 to -16.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	57.3 (8.2 to 146.5)	-36.1 (-62.0 to 4.4)
Hepatitis C	75.5 (67.3 to 84.5)	130.9 (113.6 to 148.7)	73.8 (42.6 to 104.3)	-26.4 (-39.0 to -14.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.9 (1.1 to 90.5)	-29.8 (-48.3 to -3.1)
Hepatitis E	0.2 (0.1 to 0.3)	0.8 (0.5 to 1.4)	216.1 (115.7 to 540.9)	13.3 (-19.2 to 98.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	234.4 (94.4 to 621.8)	14.9 (-27.3 to 113.7)
Leprosy	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	0.2 (-41.2 to 298.7)	-45.2 (-65.2 to 118.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.2 (-44.7 to 376.3)	-44.7 (-67.3 to 157.8)
Other infectious diseases	24.3 (19.3 to 29.3)	26.5 (23.5 to 29.8)	9.3 (-9.1 to 30.4)	-25.3 (-36.1 to -11.9)	0.9 (0.5 to 1.3)	0.9 (0.6 to 1.3)	1.0 (-17.5 to 22.2)	-21.5 (-35.4 to -5.0)
Non-communicable diseases	-	-	-	-	124.4 (92.1 to 160.5)	398.2 (224.9 to 401.2)	148.8 (129.8 to 162.4)	4.6 (-0.5 to 9.2)
Neoplasms	-	-	-	-	0.5 (0.3 to 0.7)	1.0 (0.7 to 1.3)	104.7 (54.8 to 169.6)	-2.5 (-23.7 to 23.3)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	74.2 (0.2 to 201.2)	-19.3 (-52.3 to 38.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.7 (8.6 to 187.6)	-18.8 (-48.8 to 32.0)
Stomach cancer	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	66.5 (11.8 to 140.3)	-12.9 (-39.3 to 21.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	66.7 (8.7 to 142.5)	-13.5 (-41.7 to 24.0)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	168.5 (67.9 to 309.7)	37.5 (-10.5 to 106.5)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	163.5 (8.8 to 476.5)	34.1 (-58.6 to 207.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	142.5 (-10.3 to 407.5)	24.0 (-59.5 to 164.7)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	497.5 (154.2 to 1,200.0)	199.4 (30.4 to 515.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	452.5 (146.6 to 984.6)	171.0 (-28.6 to 430.6)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.2 (-40.7 to 264.9)	-20.3 (-68.4 to 79.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.1 (-43.0 to 221.7)	-26.4 (-70.2 to 55.8)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.1 (-31.0 to 198.1)	-21.4 (-65.3 to 60.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.2 (-30.2 to 166.0)	-26.7 (-64.7 to 40.3)
Larynx cancer	0.0 (0.0 to 0.1)	0.8 (0.7 to 0.9)	1,721.1 (1,081.1 to 2,975.8)	1,085.5 (679.9 to 1,895.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	857.2 (468.6 to 1,652.8)	500.9 (266.2 to 1,003.1)
Tracheal, bronchus and lung cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	107.1 (37.6 to 204.8)	7.9 (-26.6 to 54.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	102.1 (29.4 to 205.0)	5.1 (-30.3 to 54.3)
Breast cancer	0.6 (0.4 to 0.8)	1.6 (1.1 to 2.3)	188.3 (63.9 to 390.6)	22.3 (-29.2 to 103.7)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	187.8 (65.2 to 406.4)	31.4 (-24.3 to 123.3)
Cervical cancer	0.3 (0.2 to 0.4)	4.1 (2.2 to 0.4)	61.1 (-50.3 to 72.9)	-57.1 (-76.3 to -22.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.4 (-48.1 to 79.0)	-45.3 (-76.1 to -21.4)
Uterine cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	75.4 (-18.9 to 243.9)	-14.2 (-60.5 to 66.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.4 (-21.2 to 242.7)	-16.3 (-61.2 to 62.1)
Prostate cancer	0.1 (0.1 to 0.2)	0.9 (0.5 to 1.3)	610.5 (239.7 to 1,263.7)	210.2 (51.4 to 479.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	512.6 (189.9 to 1,041.5)	166.3 (-28.9 to 394.8)
Colon and rectum cancer	1.5 (1.3 to 1.7)	1.8 (1.6 to 2.1)	21.3 (1.1 to 43.9)	-49.5 (-57.8 to -41.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	18.0 (-3.7 to 42.1)	-50.0 (-58.7 to -40.8)
Lip and oral cavity cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	99.0 (21.3 to 215.7)	3.4 (-31.1 to 58.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.4 (22.9 to 209.4)	1.8 (-34.8 to 56.1)
Nasopharynx cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	29.3 (-59.7 to 30.7)	-69.0 (-81.9 to -42.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.0 (-59.2 to 30.2)	-69.5 (-82.0 to -43.9)
Other pharynx cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	3.2 (-40.5 to 103.0)	-50.4 (-70.3 to -5.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.3 (-39.0 to 106.6)	-50.5 (-70.9 to -3.5)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.4 (4.4 to 188.1)	-16.3 (-51.4 to 33.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.8 (-0.2 to 171.8)	-20.3 (-52.8 to 25.2)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	166.5 (71.4 to 314.2)	30.4 (-13.5 to 99.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	158.8 (77.1 to 281.9)	24.8 (-13.4 to 79.3)
Malignant skin melanoma	0.4 (0.0 to 0.1)	0.1 (0.1 to 0.2)	59.4 (70.7 to 398.1)	22.8 (-25.4 to 114.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	185.5 (62.5 to 389.7)	37.7 (-32.2 to 105.8)
Non-melanoma skin cancer	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	351.5 (169.9 to 674.3)	81.2 (5.0 to 224.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	474.1 (218.4 to 1,074.7)	128.1 (-32.2 to 344.7)
Ovarian cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	106.1 (5.1 to 296.7)	2.6 (-47.5 to 97.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	100.7 (0.2 to 303.5)	-1.5 (-50.1 to 108.3)
Testicular cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	242.8 (63.0 to 617.7)	20.4 (-41.3 to 144.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	238.3 (33.4 to 735.7)	17.8 (-48.9 to 174.3)
Kidney cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	40.4 (-12.0 to 123.8)	6.0 (-39.2 to 49.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.1 (-6.9 to 147.0)	-6.0 (-39.4 to 51.7)
Bladder cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	110.0 (39.3 to 259.8)	1.5 (-31.6 to 68.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	121.9 (46.6 to 286.3)	3.9 (-30.5 to 84.0)
Brain and nervous system cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	46.1 (-17.3 to 126.3)	-3.8 (-38.6 to 45.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.5 (-4.2 to 149.1)	-2.1 (-37.2 to 44.9)
Thyroid cancer	0.3 (0.1 to 0.5)	0.5 (0.4 to 0.8)	91.1 (-7.3 to 293.1)	-26.1 (-62.8 to 54.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.9 (-8.3 to 290.4)	-29.1 (-63.4 to 57.4)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.9 (0.5 to 156.9)	30.8 (56.8 to 12.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.8 (-45.6 to 158.0)	31.0 (-57.1 to 13.9)
Hodgkin lymphoma	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	-2.2 (-48.0 to 196.8)	-54.2 (-73.8 to 48.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.2 (-0.5 to 218.8)	-55.9 (-74.8 to 52.9)
Non-Hodgkin lymphoma	0.4 (0.2 to 0.6)	1.1 (0.8 to 1.5)	213.4 (82.7 to 527.8)	71.5 (4.6 to 251.6)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	207.0 (79.4 to 531.8)	64.8 (-1.0 to 251.8)
Multiple myeloma	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	200.4 (72.3 to 404.1)	42.4 (-14.5 to 138.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	189.1 (66.8 to 404.7)	37.7 (-20.6 to 134.4)
Leukemia	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.7)	59.4 (1.2 to 129.8)	3.4 (-26.2 to 51.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	76.9 (18.9 to 161.9)	3.7 (-27.1 to 59.6)
Other neoplasms	0.5 (0.3 to 1.0)	1.3 (1.0 to 1.7)	203.5 (27.9 to 361.0)	82.2 (10.9 to 174.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	201.3 (42.6 to 357.4)	66.6 (4.3 to 140.7)
Cardiovascular diseases	-	-	-	-	2.3 (1.6 to 3.2)	6.2 (4.2 to 8.6)	167.3 (117.8 to 225.2)	23.5 (1.9 to 45.6)
Rheumatic heart disease	1.6 (1.4 to 1.9)	4.2 (3.6 to 4.8)	160.5 (117.1 to 215.3)	10.6 (-4.2 to 30.4)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	188.2 (125.5 to 297.9)	31.0 (-3.7 to 89.7)
Ischemic heart disease	8.9 (7.2 to 10.6)	17.2 (14.6 to 19.8)	94.3 (50.1 to 151.1)	-9.7 (-30.3 to 16.4)	0.5 (0.3 to 0.7)	1.0 (0.7 to 1.5)	99.8 (50.4 to 157.6)	-3.2 (-29.8 to 27.9)
Cerebrovascular disease	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	135.5 (89.4 to 186.4)	1.3 (-16.0 to 23.2)
Ischemic stroke	0.4 (0.3 to 0.4)	0.9 (0.8 to 1.1)	137.0 (97.4 to 189.2)	3.1 (-13.1 to 24.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	137.1 (89.7 to 193.4)	2.9 (-16.0 to 27.5)
Hemorrhagic stroke	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	121.5 (50.0 to 231.2)	-8.3 (-37.9 to 35.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	122.2 (50.5 to 232.3)	-7.6 (-37.0 to 36.2)
Hypertensive heart disease	1.3 (1.1 to 1.5)	3.1 (3.3 to 4.5)	195.8 (140.8 to 273.3)	51.8 (23.3 to 96.5)	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.6)	192.1 (136.0 to 272.6)	50.2 (-21.4 to 95.8)
Cardiomyopathy and myocarditis	0.8 (0.7 to 1.0)	1.9 (1.7 to 2.1)	127.8 (91.2 to 172.6)	20.0 (-2.4 to 47.6)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	126.7 (81.7 to 186.7)	20.1 (-5.9 to 53.1)
Atrial fibrillation and flutter	0.6 (0.5 to 1.0)	4.6 (3.7 to 5.6)	632.2 (350.8 to 1,013.6)	182.2 (74.5 to 360.5)	0.0 (0.0 to 0.1)	0.3 (0.2 to 0.5)	629.0 (349.1 to 1,020.3)	184.6 (75.9 to 367.8)
Peripheral vascular disease	15.5 (10.3 to 21.5)	36.2 (26.9 to 47.3)	136.1 (44.2 to 278.1)	7.3 (-28.3 to 52.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.0 (6.0 to 430.6)	-21.0 (-62.6 to 92.0)
Endocarditis	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	189.4 (95.7 to 292.2)	44.9 (-1.4 to 96.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	217.1 (109.0 to 340.8)	52.7 (-3.2 to 128.7)
Other cardiovascular and circulatory diseases	19.1 (15.1 to 23.8)	53.1 (39.1 to 66.9)	178.3 (100.3 to 271.6)	25.3 (-11.2 to 67.0)	1.4 (0.9 to 2.0)	3.8 (2.4 to 5.5)	176.6 (100.3 to 273.4)	26.1 (-11.2 to 66.8)
Chronic respiratory diseases	-	-	-	-	7.7 (5.3 to 10.5)	18.7 (12.9 to 25.5)	142.0 (112.5 to 176.9)	11.3 (-4.0 to

Appendix Table G.4 - Oman prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	139.5 (129.1 to 152.9)	-
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	118.7 (106.8 to 131.5)	-5.8 (-10.5 to -1.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	120.0 (106.4 to 135.9)	-4.5 (-10.1 to 1.4)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	447.7 (136.2 to 160.5)	1.8 (-2.5 to 6.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	151.2 (137.6 to 167.3)	4.5 (0.6 to 10.1)
Asthma	90.4 (79.0 to 101.0)	199.7 (175.3 to 226.9)	120.8 (83.1 to 166.6)	7.4 (8.4 to 24.0)	4.0 (2.5 to 5.8)	8.9 (5.7 to 13.1)	120.3 (82.9 to 167.1)	7.5 (8.2 to 24.5)
Interstitial lung disease and pulmonary sarcoidosis	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.3)	138.7 (65.9 to 222.6)	0.9 (-24.2 to 36.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	145.9 (68.0 to 238.0)	5.7 (-24.5 to 48.8)
Other chronic respiratory diseases	-	-	-	-	0.3 (0.2 to 0.5)	0.6 (0.4 to 1.0)	107.7 (48.8 to 192.6)	-8.4 (-34.6 to 28.0)
Cirrhosis	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	47.2 (25.5 to 71.5)	-15.8 (-26.3 to -3.5)
Cirrhosis due to hepatitis B	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	64.8 (-15.1 to 296.8)	-10.3 (-51.7 to 110.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	65.6 (-18.1 to 302.4)	-10.5 (-53.9 to 118.1)
Cirrhosis due to hepatitis C	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.5)	140.7 (37.1 to 358.7)	27.6 (-32.3 to 132.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	141.5 (22.8 to 419.0)	29.2 (-32.2 to 144.6)
Cirrhosis due to alcohol use	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-30.0 (-64.3 to 53.5)	-0.9 (-83.0 to -19.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.3 (-66.4 to 65.1)	-64.0 (-83.9 to -13.3)
Cirrhosis due to other causes	0.2 (0.2 to 0.2)	0.2 (0.1 to 0.2)	-12.0 (-37.7 to 19.5)	-40.1 (-59.6 to -11.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-10.4 (-42.1 to 37.6)	-39.6 (-63.3 to -4.6)
Digestive diseases	-	-	-	-	0.8 (0.6 to 1.1)	1.8 (1.3 to 2.4)	122.2 (91.4 to 154.5)	6.4 (-16.8 to 4.0)
Peptic ulcer disease	2.7 (2.1 to 3.1)	3.9 (3.3 to 4.6)	48.5 (19.7 to 81.1)	-30.7 (-44.0 to -16.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	60.1 (18.0 to 96.0)	-26.8 (-41.1 to -11.1)
Gastritis and duodenitis	4.6 (3.9 to 5.2)	4.1 (3.5 to 4.7)	-9.5 (-27.9 to 9.9)	-46.9 (-54.8 to -36.7)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-11.1 (-34.3 to 27.1)	-40.7 (-50.6 to -23.8)
Appendicitis	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	133.8 (53.3 to 252.7)	-11.7 (-37.9 to 24.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	134.0 (28.8 to 338.0)	-9.7 (-45.3 to 51.1)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	141.6 (91.0 to 201.1)	6.2 (-11.8 to 26.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	139.2 (84.8 to 211.6)	7.6 (-18.8 to 40.1)
Inguinal, femoral, and abdominal hernia	2.8 (2.3 to 3.3)	5.7 (4.8 to 6.7)	108.0 (71.2 to 152.7)	-0.9 (-20.4 to 24.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	105.7 (67.3 to 156.5)	-0.3 (-20.4 to 25.7)
Inflammatory bowel disease	1.0 (0.9 to 1.0)	3.9 (3.5 to 4.3)	313.3 (257.7 to 367.1)	59.5 (40.2 to 78.0)	0.2 (0.1 to 0.3)	0.8 (0.6 to 1.2)	314.6 (249.1 to 390.3)	60.5 (37.2 to 83.8)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.5 (52.2 to 177.4)	-12.1 (-41.8 to 22.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.0 (48.2 to 186.0)	-11.1 (-43.4 to 36.3)
Gallbladder and biliary diseases	0.4 (0.4 to 0.5)	0.9 (0.8 to 1.1)	107.9 (59.3 to 162.4)	6.4 (-24.6 to 18.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	107.8 (54.5 to 172.7)	5.2 (-26.2 to 25.8)
Pancreatitis	0.3 (0.3 to 0.3)	0.7 (0.6 to 0.8)	130.0 (95.9 to 167.9)	-0.0 (-17.8 to 0.5)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	129.5 (73.3 to 201.4)	-9.0 (-24.1 to 8.4)
Other digestive diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	68.4 (1.1 to 194.1)	-27.1 (-56.4 to 22.7)
Neurological disorders	-	-	-	-	11.9 (8.0 to 16.7)	30.6 (20.8 to 42.0)	156.5 (106.7 to 220.2)	3.1 (-14.6 to 23.2)
Alzheimer disease and other dementias	4.6 (4.0 to 5.2)	11.7 (10.2 to 13.3)	156.6 (110.8 to 208.1)	-3.2 (-19.7 to 17.5)	0.6 (0.4 to 0.8)	1.6 (1.2 to 2.1)	151.6 (116.3 to 215.9)	2.4 (-18.9 to 18.8)
Parkinson disease	0.5 (0.2 to 0.6)	1.1 (0.6 to 1.5)	137.6 (120.3 to 166.2)	1.8 (-6.0 to 8.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	136.9 (107.9 to 171.6)	2.4 (-9.3 to 15.1)
Epilepsy	8.1 (6.4 to 9.5)	15.9 (12.4 to 19.2)	96.3 (40.7 to 165.7)	-4.0 (-29.8 to 29.3)	2.8 (1.8 to 3.9)	5.9 (3.7 to 8.2)	110.4 (45.1 to 190.0)	3.7 (-27.2 to 41.7)
Multiple sclerosis	0.1 (0.1 to 0.2)	0.7 (0.5 to 0.9)	354.3 (170.6 to 593.9)	77.0 (10.9 to 157.5)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	348.3 (161.2 to 601.9)	70.9 (2.8 to 160.8)
Migraine	175.8 (132.6 to 217.3)	422.0 (299.8 to 567.2)	137.1 (60.9 to 262.8)	-2.3 (-42.8 to 27.8)	6.4 (3.4 to 9.5)	14.5 (8.1 to 23.6)	188.1 (62.9 to 352.7)	-12.2 (-42.7 to 30.0)
Tension-type headache	273.0 (247.4 to 295.0)	764.1 (538.2 to 1,100.3)	173.7 (99.6 to 310.3)	5.0 (-23.0 to 40.8)	0.4 (0.2 to 0.7)	1.2 (0.5 to 2.3)	174.0 (91.1 to 310.1)	5.3 (-24.1 to 42.1)
Medication overuse headache	12.5 (8.1 to 16.9)	44.3 (29.5 to 60.0)	257.5 (174.8 to 349.0)	45.2 (15.7 to 77.4)	2.0 (1.1 to 3.0)	7.0 (4.1 to 10.9)	260.0 (178.5 to 354.8)	45.4 (16.2 to 78.4)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.2 (14.0 to 282.6)	0.5 (-36.8 to 63.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	319.2 (114.1 to 517.7)	59.6 (-20.3 to 143.7)
Mental and substance use disorders	-	-	-	-	41.5 (28.6 to 56.9)	107.0 (73.4 to 149.5)	157.6 (139.3 to 177.3)	0.9 (-2.3 to 4.8)
Schizophrenia	4.1 (3.8 to 4.5)	11.3 (10.1 to 12.3)	171.7 (156.6 to 188.8)	0.1 (-4.0 to 5.0)	0.1 (1.9 to 3.2)	2.6 (5.4 to 9.0)	175.3 (152.0 to 200.0)	0.7 (-5.7 to 7.2)
Alcohol use disorders	6.8 (5.9 to 7.7)	22.1 (18.8 to 25.9)	223.6 (197.7 to 254.0)	4.3 (-2.0 to 11.8)	0.7 (0.4 to 1.0)	2.2 (1.4 to 3.2)	229.1 (192.8 to 270.8)	5.1 (-4.1 to 15.0)
Drug use disorders	-	-	-	-	6.9 (4.0 to 10.6)	22.4 (12.8 to 34.7)	225.2 (181.2 to 273.3)	4.0 (-6.3 to 17.4)
Opioid use disorders	14.0 (8.2 to 21.8)	45.8 (27.0 to 69.7)	227.1 (177.4 to 288.2)	6.2 (-6.1 to 21.1)	5.8 (3.1 to 9.1)	19.2 (10.2 to 31.1)	231.6 (176.7 to 294.7)	6.9 (-6.1 to 23.2)
Cocaine use disorders	1.5 (1.2 to 1.8)	4.8 (3.8 to 5.9)	221.8 (140.3 to 346.6)	4.8 (-24.0 to 35.1)	0.7 (0.1 to 0.3)	0.7 (0.4 to 1.0)	225.6 (127.1 to 364.1)	0.6 (-28.2 to 39.8)
Amphetamine use disorders	2.3 (1.8 to 2.8)	6.3 (4.4 to 8.3)	166.7 (96.1 to 292.4)	-17.0 (-37.6 to 18.5)	0.3 (0.2 to 0.5)	0.8 (0.5 to 1.3)	169.0 (86.2 to 300.2)	-16.1 (-39.7 to 21.6)
Cannabis use disorders	2.6 (2.0 to 3.1)	8.0 (6.2 to 9.7)	212.6 (192.5 to 233.1)	3.1 (-2.3 to 3.9)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	211.1 (157.8 to 281.2)	2.8 (-12.1 to 20.7)
Other drug use disorders	-	-	-	-	0.5 (0.3 to 0.8)	1.5 (0.9 to 2.4)	196.6 (99.0 to 354.2)	-8.7 (-37.7 to 37.6)
Depressive disorders	-	-	-	-	13.7 (7.8 to 22.3)	34.7 (18.5 to 56.8)	153.2 (118.8 to 178.4)	1.3 (-4.6 to 9.0)
Major depressive disorder	59.7 (34.8 to 87.3)	149.2 (79.2 to 218.5)	150.8 (111.1 to 178.4)	1.3 (-5.0 to 9.8)	12.3 (6.6 to 20.5)	30.9 (15.0 to 52.1)	152.0 (111.4 to 180.1)	1.8 (-4.9 to 10.5)
Dysthymia	15.2 (12.1 to 18.1)	39.5 (30.6 to 48.8)	161.0 (142.8 to 176.1)	-2.3 (-3.1 to -1.6)	1.5 (0.9 to 2.2)	3.8 (2.4 to 5.7)	162.6 (142.3 to 180.1)	-2.0 (-4.6 to 0.3)
Bipolar disorder	10.9 (9.3 to 12.2)	30.8 (26.1 to 35.5)	183.8 (160.3 to 206.4)	-2.0 (-7.1 to 2.9)	2.2 (1.4 to 3.3)	6.3 (3.9 to 9.6)	186.1 (158.2 to 214.4)	-1.6 (-7.6 to 4.8)
Anxiety disorders	64.4 (28.7 to 92.5)	152.9 (69.9 to 225.6)	138.5 (98.1 to 174.7)	5.9 (-4.8 to -2.2)	14.2 (2.4 to 9.7)	14.2 (5.9 to 23.3)	138.8 (97.0 to 178.2)	-3.0 (-5.7 to -0.3)
Eating disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.6 (0.3 to 0.9)	173.4 (136.2 to 213.3)	-6.8 (-17.1 to 7.4)
Anorexia nervosa	0.3 (0.2 to 0.4)	0.7 (0.4 to 1.1)	177.4 (141.8 to 228.9)	7.8 (-2.5 to 25.2)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	179.0 (106.3 to 269.2)	8.8 (-17.4 to 39.9)
Bulimia nervosa	0.8 (0.5 to 1.1)	2.1 (1.4 to 3.1)	170.5 (146.9 to 189.6)	-11.6 (-17.1 to -6.1)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	171.4 (128.6 to 218.1)	-11.6 (-22.9 to 3.2)
Autistic spectrum disorders	-	-	-	-	2.2 (1.5 to 3.1)	4.9 (3.4 to 6.6)	118.4 (109.0 to 128.6)	3.8 (0.4 to 7.7)
Autism	5.6 (5.3 to 5.9)	12.2 (11.6 to 12.9)	118.2 (116.0 to 120.3)	3.2 (3.0 to 3.3)	1.4 (0.9 to 1.9)	3.0 (2.0 to 4.2)	117.7 (104.6 to 132.3)	3.4 (-1.2 to 8.8)
Asperger syndrome	8.6 (8.0 to 9.1)	18.8 (17.5 to 19.9)	119.3 (116.1 to 122.8)	4.1 (4.0 to 4.3)	0.9 (0.6 to 1.2)	1.9 (1.3 to 2.6)	119.5 (109.0 to 131.6)	4.5 (-0.1 to 8.8)
Attention-deficit/hyperactivity disorder	12.5 (10.3 to 14.7)	20.2 (16.5 to 23.8)	62.0 (57.2 to 64.9)	3.3 (2.9 to 3.6)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.4)	61.5 (48.3 to 75.4)	3.5 (-4.3 to 11.1)
Conduct disorder	22.2 (18.5 to 25.6)	33 (27.1 to 39.3)	48.2 (39.5 to 59.7)	2.7 (-2.1 to 3.3)	0.7 (1.7 to 4.0)	4.0 (2.4 to 6.1)	48.7 (38.0 to 61.0)	3.1 (-0.7 to 7.4)
Idiopathic intellectual disability	48.1 (40.8 to 57.2)	88.5 (74.7 to 106.1)	84.1 (67.6 to 101.9)	-9.5 (-17.5 to -0.6)	2.4 (1.6 to 3.3)	4.3 (2.9 to 6.1)	83.8 (67.3 to 103.5)	9.4 (-17.4 to 0.1)
Other mental and substance use disorders	24.0 (22.4 to 25.7)	77.0 (70.0 to 83.9)	220.2 (207.8 to 233.3)	3.9 (2.7 to 5.1)	1.8 (1.2 to 2.4)	5.8 (3.9 to 7.8)	223.7 (203.6 to 245.0)	4.5 (0.4 to 8.6)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	13.7 (9.6 to 18.7)	34.4 (24.0 to 47.7)	150.9 (123.5 to 183.9)	26.5 (10.0 to 45.9)
Diabetes mellitus	71.8 (60.8 to 82.5)	255.2 (213.9 to 297.8)	255.2 (196.3 to 338.4)	56.7 (23.2 to 95.6)	5.9 (4.0 to 8.3)	19.4 (12.7 to 28.3)	223.3 (155.6 to 308.5)	47.6 (18.5 to 85.8)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.5 (-8.6 to 6.2)	-31.4 (-35.0 to -27.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.5 (-8.6 to 6.3)	-31.4 (-35.0 to -27.5)
Chronic kidney disease	-	-	-	-	1.6 (1.1 to 2.1)	3.5 (2.3 to 4.9)	117.8 (87.6 to 148.7)	-0.6 (-9.5 to 9.2)
Chronic kidney disease due to diabetes mellitus	10.9 (7.5 to 15.4)	25.0 (16.3 to 38.5)	127.8 (67.4 to 222.0)	3.1 (-21.9 to 57.9)	0.3 (0.2 to 0.4)	0.7 (0.4 to 1.0)	133.1 (66.3 to 258.9)	7.9 (-20.3 to 54.6)
Chronic kidney disease due to hypertension	9.0 (5.9 to 13.4)	15.6 (10.8 to 22.3)	73.8 (28.8 to 141.7)	-18.7 (-35.8 to -4.3)	0.5 (0.3 to 0.6)	0.9 (0.5 to 1.4)	96.2 (39.8 to 157.4)	-21.5 (-39.7 to 0.0)
Chronic kidney disease due to glomerulonephritis	15.5 (10.9 to 22.2)	29.3 (19.0 to 43.9)	88.4 (32.1 to 158.1)	6.2 (-47.3 to 40.7)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	69.6 (22.4 to 145.3)	-8.3 (-38.9 to 14.3)
Chronic kidney disease due to other causes	20.1 (14.0 to 27.7)	50.0 (34.4 to 68.3)	147.2 (84.1 to 242.6)	17.1 (-16.8 to 45.6)	0.7 (0.4 to 0.8)	1.4 (0.9 to 2.0)	146.8 (81.5 to 227.4)	18.1 (-8.3 to 55.8)
Urinary diseases and male infertility	-	-	-	-	1.7 (0.4 to 1.0)	1.8 (1.1 to 2.8)	167.9 (105.1 to 238.5)	16.0 (-6.7 to 36.2)

Appendix Table G.4 - Oman prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Edentulism and severe tooth loss	36.8 (33.5 to 39.7)	76.3 (70.4 to 82.3)	107.1 (86.0 to 132.9)	-4.4 (-17.9 to 2.0)	1.0 (0.7 to 1.4)	2.1 (1.4 to 2.9)	107.2 (85.7 to 133.1)	-8.2 (-17.8 to 2.8)
Other oral disorders	25.8 (24.3 to 27.3)	62.1 (57.9 to 67.0)	141.3 (119.0 to 167.2)	-1.2 (-8.8 to 6.8)	0.8 (0.5 to 1.1)	1.8 (1.1 to 2.7)	142.0 (118.4 to 168.4)	-1.0 (-9.2 to 7.8)
Injuries	-	-	-	-	9.2 (6.8 to 12.6)	9.7 (7.0 to 13.1)	6.9 (-18.8 to 27.6)	51.2 (-62.0 to -42.7)
Transport injuries	-	-	-	-	5.0 (3.7 to 6.4)	5.3 (3.8 to 7.1)	5.2 (-2.2 to 22.2)	-52.2 (-57.7 to -45.2)
Road injuries	-	-	-	-	4.6 (3.5 to 5.9)	4.5 (3.2 to 6.1)	2.4 (-15.2 to 13.7)	24.8 (-60.1 to -48.2)
Pedestrian road injuries	-	-	-	-	1.5 (1.1 to 1.9)	1.2 (0.9 to 1.7)	-19.1 (-30.9 to -3.7)	61.0 (-65.9 to -54.6)
Cyclist road injuries	-	-	-	-	0.4 (0.3 to 0.6)	0.5 (0.4 to 0.7)	15.5 (2.7 to 28.6)	-46.1 (-51.6 to -40.4)
Motorcyclist road injuries	-	-	-	-	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.5)	-12.0 (-24.4 to 2.3)	-60.0 (-65.0 to -54.4)
Motor vehicle road injuries	-	-	-	-	2.2 (1.6 to 2.8)	2.4 (1.7 to 3.2)	8.5 (-7.0 to 29.3)	51.2 (-57.7 to -42.9)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-46.1 (-54.0 to -36.9)	75.4 (-78.6 to -71.8)
Other transport injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.7 (0.5 to 1.0)	106.0 (82.9 to 133.9)	-19.3 (-28.3 to -9.0)
Unintentional injuries	-	-	-	-	2.6 (2.0 to 3.4)	4.1 (3.0 to 5.4)	53.1 (40.4 to 67.0)	-32.3 (-37.8 to -26.2)
Falls	-	-	-	-	0.9 (0.7 to 1.2)	1.5 (1.1 to 2.1)	69.9 (50.7 to 92.9)	-25.5 (-33.9 to -15.5)
Drowning	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	14.1 (-3.1 to 36.3)	-50.2 (-57.4 to -41.8)
Fire, heat, and hot substances	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	1.2 (-14.8 to 18.8)	-50.0 (-56.8 to -43.3)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.4 (-41.6 to -1.2)	-66.0 (-72.3 to -58.0)
Exposure to mechanical forces	-	-	-	-	1.0 (0.8 to 1.3)	1.5 (1.1 to 2.0)	49.6 (36.3 to 62.9)	-36.8 (-41.8 to -32.1)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	27.4 (10.3 to 46.0)	-49.4 (-55.8 to -42.5)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.4 (69.3 to 120.3)	-14.4 (-24.2 to -4.5)
Other exposure to mechanical forces	-	-	-	-	0.9 (0.7 to 1.2)	1.4 (1.0 to 1.9)	50.3 (37.0 to 63.9)	-36.3 (-41.4 to -31.5)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	142.2 (123.6 to 161.2)	12.6 (4.2 to 21.7)
Animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	35.0 (18.4 to 52.7)	-40.3 (-46.1 to -34.0)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	41.3 (19.1 to 67.2)	-39.7 (-47.2 to -31.0)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	30.1 (14.1 to 47.1)	-40.8 (-47.0 to -34.5)
Foreign body	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	71.5 (54.2 to 91.1)	-22.5 (-29.2 to -15.4)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.2 (-26.1 to 14.1)	-49.7 (-58.3 to -39.6)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	110.2 (83.9 to 138.3)	-8.4 (-17.6 to 2.0)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	85.2 (66.0 to 106.6)	-18.9 (-26.3 to -10.4)
Other unintentional injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	49.2 (34.0 to 67.2)	-35.4 (-40.8 to -28.8)
Self-harm and interpersonal violence	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	50.7 (31.0 to 74.0)	-27.9 (-36.2 to -17.6)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	110.5 (78.6 to 146.7)	-14.6 (-25.5 to -1.3)
Interpersonal violence	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	35.0 (17.6 to 56.7)	-32.6 (-40.7 to -22.9)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.6 (26.6 to 59.7)	-26.0 (-33.1 to -17.8)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.9 (38.8 to 92.7)	-24.0 (-34.1 to -11.5)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	26.6 (8.0 to 49.8)	-36.5 (-45.3 to -26.1)
Forces of nature, war, and legal intervention	-	-	-	-	1.5 (0.4 to 4.2)	0.3 (0.1 to 0.7)	-80.2 (-88.1 to -68.6)	-85.5 (-91.0 to -76.9)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	13.1 (-9.7 to 44.5)	40.9 (-50.0 to -28.6)
Collective violence and legal intervention	-	-	-	-	1.5 (0.4 to 4.2)	0.2 (0.1 to 0.5)	-83.5 (-89.8 to -74.6)	87.0 (-91.8 to -79.4)

Appendix Table G.4 - Pakistan prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
Pneumonia	-	-	-	-	0.5	0.9	77.6	-7.1
Silicosis	1.0	1.5	46.5	-22.1	(0.4 to 0.7)	(0.6 to 1.2)	(70.7 to 84.1)	(-10.8 to -3.8)
Asbestosis	-	-	0.0	0.0	0.2	0.3	46.1	-22.2
Coal workers pneumoconiosis	0.5	1.0	87.5	-2.0	-	0.2	86.7	-2.2
Other pneumoconiosis	1.0	2.1	106.0	2.1	(0.1 to 0.1)	(0.1 to 0.3)	(79.2 to 94.4)	(-5.9 to 1.6)
Asthma	4,067.5	5,288.8	30.0	-21.9	179.3	232.7	29.7	-22.2
Interstitial lung disease and pulmonary sarcoidosis	6.1	12.1	97.5	6.7	(114.9 to 258.4)	(147.7 to 347.6)	(37.0 to 58.7)	(-34.1 to -7.2)
Other chronic respiratory diseases	1.0	1.9	89.9	6.7	(0.5 to 1.2)	(1.0 to 2.5)	(45.3 to 172.2)	(22.5 to 44.5)
Cirrhosis	-	-	-	-	67.7	109.2	61.0	-15.1
Cirrhosis due to hepatitis B	11.1	22.0	94.9	7.4	(38.0 to 108.4)	(61.9 to 179.3)	(1.3 to 150.9)	(-46.5 to 31.7)
Cirrhosis due to hepatitis C	18.7	31.7	69.4	3.1	9.9	16.0	62.5	2.9
Cirrhosis due to alcohol use	8.0	9.5	20.7	-35.7	(6.8 to 13.8)	(11.0 to 22.3)	(41.4 to 85.4)	(-13.5 to 8.6)
Cirrhosis due to other causes	21.4	33.0	54.8	3.7	1.8	3.6	94.5	6.5
Digestive diseases	11.1	22.0	94.9	7.4	(1.0 to 2.9)	(2.1 to 5.5)	(25.1 to 229.7)	(32.5 to 76.6)
Peptic ulcer disease	525.7	720.7	37.4	-25.6	(1.9 to 4.6)	(3.1 to 7.8)	(12.6 to 147.6)	(-29.9 to 52.7)
Gastritis and duodenitis	1,970.5	1,899.3	-3.5	-40.9	1.3	1.6	21.7	-35.4
Appendicitis	24.9	30.9	23.1	-31.5	(0.7 to 2.2)	(0.9 to 2.5)	(-35.1 to 107.8)	(-63.9 to 5.1)
Paralytic ileus and intestinal obstruction	42.7	75.1	75.2	-10.5	(0.4 to 0.6)	(0.6 to 1.0)	(3.5 to 8.4)	(35.0 to 117.6)
Inguinal, femoral, and abdominal hernia	583.9	970.4	65.4	-8.7	(109.3 to 211.6)	(151.9 to 291.9)	(27.0 to 50.8)	(-27.9 to -13.6)
Inflammatory bowel disease	119.0	264.5	122.1	17.7	20.4	28.4	40.8	-25.0
Vascular intestinal disorders	0.2	0.4	87.2	0.9	(13.9 to 29.8)	(18.8 to 40.9)	(10.6 to 66.6)	(-39.3 to -11.1)
Gallbladder and biliary diseases	42.7	75.1	75.2	-10.5	81.6	82.0	0.4	-37.7
Pancreatitis	20.7	37.2	80.0	-4.9	(54.9 to 119.5)	(54.0 to 118.2)	(-10.3 to 13.4)	(-45.8 to -31.0)
Other digestive diseases	20.7	37.2	80.0	-4.9	24.9	30.9	23.1	-31.5
Neurological disorders	225.5	437.1	93.4	0.1	(20.0 to 31.6)	(22.6 to 39.6)	(-21.6 to 77.1)	(-53.5 to -5.8)
Alzheimer disease and other dementias	22.8	42.8	87.3	-0.7	1.2	1.8	48.8	0.4
Parkinson disease	542.9	886.6	64.3	-1.2	(1.1 to 1.4)	(1.6 to 2.0)	(28.2 to 79.2)	(-18.8 to 0.6)
Epilepsy	23.5	53.3	125.9	17.0	583.9	970.4	65.4	-8.7
Multiple sclerosis	23.5	53.3	125.9	17.0	(490.2 to 670.8)	(819.1 to 1,152.4)	(35.9 to 109.9)	(-27.3 to 18.6)
Migraine	15,518.2	20,099.4	87.0	1.5	119.0	264.5	122.1	17.7
Tension-type headache	31,393.6	58,315.5	86.4	0.1	(113.5 to 124.7)	(253.7 to 274.9)	(109.2 to 136.5)	(11.2 to 24.3)
Medication overuse headache	534.4	1,313.0	149.0	36.4	0.2	0.3	66.6	-0.2
Other neurological disorders	119.0	264.5	122.1	17.7	0.2	0.3	66.6	-0.2
Mental and substance use disorders	168.1	326.2	94.2	-0.4	(0.1 to 0.2)	(0.2 to 0.4)	(23.6 to 122.2)	(-26.6 to 31.8)
Schizophrenia	741.9	1,366.3	84.1	-3.6	225.5	437.1	93.4	0.1
Alcohol use disorders	663.0 to 825.0	1,206.3 to 1,539.0	(73.3 to 95.3)	(-8.7 to 1.7)	22.8	42.8	87.3	-0.7
Drug use disorders	79.4	152.1	91.7	-3.2	(20.4 to 25.2)	(38.2 to 47.5)	(79.8 to 96.0)	(-4.4 to 3.6)
Opioid use disorders	51.2 to 107.0	100.6 to 205.6	(70.5 to 113.2)	(-13.3 to 8.4)	542.9	886.6	64.3	-1.2
Cocaine use disorders	46.5 to 65.3	91.6 to 128.0	(59.4 to 152.0)	(11.7 to 24.7)	23.5	53.3	125.9	17.0
Amphetamine use disorders	167.0	330.4	97.9	2.8	23.5	53.3	125.9	17.0
Cannabis use disorders	162.1	306.7	89.2	-0.2	(414.7 to 656.2)	(663.0 to 1,059.6)	(16.3 to 126.9)	(-29.9 to 36.6)
Other drug use disorders	162.1	306.7	89.2	-0.2	23.5	53.3	125.9	17.0
Depressive disorders	3,811.1	7,154.2	87.8	2.6	167.0	330.4	97.9	2.8
Major depressive disorder	1,136.0	2,202.4	93.7	0.8	162.1	306.7	89.2	-0.2
Dysthymia	608.3	1,175.9	93.6	0.4	162.1	306.7	89.2	-0.2
Bipolar disorder	3,467.6	6,385.2	84.0	0.9	162.1	306.7	89.2	-0.2
Anxiety disorders	1,844.7 to 4,807.6	3,509.0 to 8,803.2	(77.4 to 91.6)	(0.6 to 1.4)	168.1	326.2	94.2	-0.4
Eating disorders	18.1	37.9	108.3	16.0	168.1	326.2	94.2	-0.4
Anorexia nervosa	105.9	199.0	88.2	0.4	168.1	326.2	94.2	-0.4
Bulimia nervosa	72.4 to 155.1	(134.8 to 289.5)	(83.9 to 90.9)	(0.2 to 0.5)	168.1	326.2	94.2	-0.4
Autistic spectrum disorders	344.3	569.3	65.4	-0.6	168.1	326.2	94.2	-0.4
Autism	344.3	569.3	65.4	-0.6	168.1	326.2	94.2	-0.4
Asperger syndrome	497.4	816.6	64.2	-0.9	168.1	326.2	94.2	-0.4
Attention-deficit/hyperactivity disorder	753.2	1,178.7	56.9	0.7	168.1	326.2	94.2	-0.4
Conduct disorder	1,007.6	1,609.7	60.0	0.8	168.1	326.2	94.2	-0.4
Idiopathic intellectual disability	1,538.6 to 3,115.9	(2,267.6 to 4,524.1)	(81.2 to 93.4)	(-35.9 to 16.6)	168.1	326.2	94.2	-0.4
Other mental and substance use disorders	1,414.1	2,747.5	94.0	-0.9	168.1	326.2	94.2	-0.4
Diabetes, urogenital, blood, and endocrine diseases	4,879.5	11,183.6	130.0	20.2	168.1	326.2	94.2	-0.4
Diabetes mellitus	4,188.4 to 7,720.0	(9,829.7 to 12,574.7)	(85.3 to 109.4)	(-3.8 to 47.0)	168.1	326.2	94.2	-0.4
Acute glomerulonephritis	1.2	1.3	11.5	-21.4	168.1	326.2	94.2	-0.4
Chronic kidney disease	2,588.1	4,621.1	76.4	-4.8	168.1	326.2	94.2	-0.4
Chronic kidney disease due to diabetes mellitus	3,549.4	6,232.2	73.8	-0.8	168.1	326.2	94.2	-0.4
Chronic kidney disease due to hypertension	2,267.1 to 6,291.6	(3,768.3 to 9,713.1)	(29.9 to 130.9)	(-29.9 to 28.5)	168.1	326.2	94.2	-0.4
Chronic kidney disease due to glomerulonephritis	4,709.7	8,120.8	71.6	-0.3	168.1	326.2	94.2	-0.4
Chronic kidney disease due to other causes	2,784.5 to 8,465.2	(4,968.0 to 14,181.8)	(41.7 to 113.2)	(-16.3 to 24.0)	168.1	326.2	94.2	-0.4
Urinary diseases and male infertility	-	-	-	-	168.1	326.2	94.2	-0.4

Appendix Table G.4 - Pakistan prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
Edentulism and severe tooth loss	3,554.1 (3,392.5 to 3,732.2)	6,021.2 (5,720.9 to 6,334.9)	69.4 (57.9 to 81.4)	-10.1 (-15.6 to -4.4)	97.1 (66.2 to 134.2)	165.1 (112.2 to 226.9)	70.0 (58.0 to 82.5)	70.0 (-15.2 to -3.7)
Other oral disorders	1,618.8 (1,531.1 to 1,713.0)	2,966.5 (2,776.6 to 3,147.6)	83.3 (67.1 to 99.2)	0.3 (-8.1 to 8.5)	47.4 (30.2 to 70.3)	87.1 (53.7 to 129.0)	83.6 (66.7 to 99.7)	0.5 (-8.0 to 8.8)
Injuries	-	-	-	-	670.5 (474.1 to 976.0)	961.5 (712.0 to 1,269.3)	45.8 (23.2 to 60.1)	-19.8 (-32.0 to -11.8)
Transport injuries	-	-	-	-	218.1 (163.3 to 281.9)	319.3 (241.4 to 415.9)	46.5 (41.1 to 51.6)	-20.8 (-23.3 to -18.4)
Road injuries	-	-	-	-	159.5 (119.3 to 205.8)	235.3 (177.9 to 305.6)	47.4 (41.2 to 54.0)	-19.8 (-22.9 to -16.7)
Pedestrian road injuries	-	-	-	-	49.3 (37.0 to 63.7)	74.4 (55.8 to 96.6)	50.8 (40.1 to 62.2)	-16.9 (-21.6 to -11.9)
Cyclist road injuries	-	-	-	-	16.8 (12.6 to 21.6)	23.0 (17.3 to 29.9)	37.3 (28.7 to 47.6)	-22.3 (-27.0 to -17.0)
Motorcyclist road injuries	-	-	-	-	34.4 (25.7 to 44.3)	42.0 (31.3 to 55.2)	22.1 (13.5 to 31.7)	-34.4 (-38.7 to -29.5)
Motor vehicle road injuries	-	-	-	-	56.2 (41.7 to 71.7)	92.6 (69.7 to 119.7)	64.8 (52.5 to 78.4)	-11.5 (-17.9 to -4.8)
Other road injuries	-	-	-	-	2.9 (2.1 to 3.7)	3.3 (2.4 to 4.2)	15.3 (7.6 to 22.4)	-39.5 (-43.2 to -36.0)
Other transport injuries	-	-	-	-	58.6 (43.7 to 76.1)	84.0 (63.0 to 109.9)	43.3 (35.4 to 52.5)	-23.5 (-27.6 to -18.8)
Unintentional injuries	-	-	-	-	267.7 (204.8 to 343.7)	464.9 (353.7 to 597.3)	73.8 (68.0 to 79.0)	-5.3 (-8.0 to -2.5)
Falls	-	-	-	-	80.8 (61.8 to 103.3)	148.1 (111.8 to 189.9)	83.3 (74.9 to 91.7)	-1.2 (-6.0 to 3.6)
Drowning	-	-	-	-	14.8 (11.0 to 19.2)	20.6 (15.2 to 26.3)	39.7 (28.3 to 51.4)	-19.8 (-25.1 to -13.9)
Fire, heat, and hot substances	-	-	-	-	37.9 (29.0 to 48.2)	57.4 (43.7 to 73.7)	51.1 (37.4 to 66.6)	-18.0 (-24.2 to -10.8)
Poisonings	-	-	-	-	2.4 (1.7 to 3.3)	3.4 (2.4 to 4.6)	40.8 (19.9 to 66.8)	-21.2 (-31.2 to -9.1)
Exposure to mechanical forces	-	-	-	-	23.0 (17.4 to 29.8)	56.9 (42.9 to 74.5)	147.9 (132.9 to 162.2)	34.4 (27.4 to 41.2)
Unintentional firearm injuries	-	-	-	-	0.9 (0.7 to 1.1)	2.2 (1.7 to 2.8)	149.9 (128.7 to 172.2)	32.6 (22.6 to 43.5)
Unintentional suffocation	-	-	-	-	0.2 (0.2 to 0.3)	0.6 (0.4 to 0.8)	140.2 (117.8 to 167.7)	33.4 (22.9 to 46.9)
Other exposure to mechanical forces	-	-	-	-	21.8 (16.5 to 28.4)	54.1 (40.7 to 71.0)	147.7 (132.3 to 162.7)	34.5 (27.1 to 41.7)
Adverse effects of medical treatment	-	-	-	-	1.8 (1.1 to 2.6)	3.0 (1.9 to 4.5)	67.4 (57.3 to 78.9)	-5.9 (-12.0 to 1.0)
Animal contact	-	-	-	-	12.4 (9.4 to 16.1)	12.8 (9.6 to 16.6)	3.8 (-4.3 to 11.9)	-43.5 (-46.8 to -39.8)
Venomous animal contact	-	-	-	-	5.2 (3.7 to 6.8)	5.4 (3.9 to 7.2)	5.0 (-8.0 to 19.1)	-43.9 (-50.3 to -37.1)
Non-venomous animal contact	-	-	-	-	7.2 (5.3 to 9.8)	7.4 (5.5 to 10.0)	2.8 (-7.5 to 13.5)	-43.4 (-47.6 to -38.9)
Foreign body	-	-	-	-	4.5 (3.4 to 5.8)	7.5 (5.7 to 9.7)	66.4 (57.8 to 76.4)	-9.5 (-14.2 to -4.4)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.7 (0.5 to 0.9)	1.1 (0.8 to 1.4)	52.8 (31.4 to 72.0)	-8.7 (-17.7 to -0.9)
Foreign body in eyes	-	-	-	-	0.9 (0.5 to 1.4)	1.6 (0.9 to 2.4)	77.0 (59.4 to 96.7)	0.5 (-8.1 to 9.9)
Foreign body in other body part	-	-	-	-	2.9 (2.2 to 3.7)	4.8 (3.6 to 6.2)	67.3 (54.7 to 79.4)	-11.8 (-18.2 to -5.1)
Other unintentional injuries	-	-	-	-	90.1 (68.2 to 116.8)	155.3 (115.7 to 200.1)	72.0 (60.6 to 83.6)	-6.4 (-12.4 to -0.5)
Self-harm and interpersonal violence	-	-	-	-	16.7 (12.7 to 21.2)	27.4 (21.1 to 34.7)	64.3 (56.7 to 72.2)	-12.0 (-15.7 to -8.0)
Self-harm	-	-	-	-	1.2 (0.8 to 1.5)	1.6 (1.2 to 2.1)	40.1 (28.8 to 51.4)	-27.1 (-32.4 to -21.9)
Interpersonal violence	-	-	-	-	15.5 (11.9 to 19.7)	25.8 (19.9 to 32.6)	66.2 (58.0 to 74.7)	-10.8 (-14.7 to -6.5)
Assault by firearm	-	-	-	-	2.4 (1.8 to 3.1)	3.8 (2.9 to 5.0)	58.3 (47.7 to 71.7)	-14.2 (-19.6 to -7.8)
Assault by sharp object	-	-	-	-	3.4 (2.6 to 4.3)	5.7 (4.3 to 7.4)	69.4 (55.2 to 83.1)	-10.3 (-17.7 to -3.6)
Assault by other means	-	-	-	-	9.7 (7.4 to 12.3)	16.2 (12.3 to 20.5)	67.2 (55.5 to 78.3)	-9.9 (-15.3 to -4.3)
Forces of nature, war, and legal intervention	-	-	-	-	168.0 (50.9 to 421.6)	149.8 (55.9 to 323.4)	-8.2 (-30.8 to 40.5)	-46.9 (-59.5 to -18.4)
Exposure to forces of nature	-	-	-	-	3.0 (1.0 to 6.7)	33.3 (15.9 to 63.9)	1,119.4 (685.8 to 1,630.1)	520.4 (359.1 to 742.6)
Collective violence and legal intervention	-	-	-	-	165.0 (49.7 to 416.8)	116.6 (37.3 to 269.0)	-28.7 (-42.8 to -13)	-56.8 (-65.3 to -37.7)

Appendix Table G.4 - Palestine prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	180.0 (131.4 to 236.5)	399.5 (293.0 to 520.6)	121.9 (114.0 to 129.6)	121.9 (-3.9 to 3.1)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	31.6 (21.9 to 44.2)	56.4 (39.3 to 77.8)	78.2 (63.4 to 98.3)	-5.6 (-13.7 to 5.6)
HIV/AIDS and tuberculosis	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	101.2 (64.4 to 150.8)	-10.0 (-24.4 to 9.7)
Tuberculosis	0.4 (0.3 to 0.4)	0.7 (0.6 to 0.7)	77.8 (64.3 to 90.5)	-19.0 (-25.1 to -12.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	76.5 (45.3 to 114.2)	-19.8 (-31.8 to -5.0)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	5,897.5 (2,619.0 to 74,989.4)	2,531.3 (1,064.6 to 33,906.9)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4,278.2 (1,883.8 to 53,160.2)	1,786.1 (746.1 to 23,361.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4,278.2 (1,872.3 to 53,981.6)	1,786.1 (743.7 to 24,027.6)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.2)	4,952.2 (2,267.2 to 67,493.1)	2,163.3 (961.5 to 28,876.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	5,856.6 (2,613.6 to 78,641.5)	2,536.2 (1,061.6 to 36,098.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	7.4 (5.1 to 10.0)	10.0 (7.0 to 13.6)	35.6 (23.7 to 48.0)	-22.5 (-28.4 to -16.4)
Diarrheal diseases	33.3 (30.8 to 35.8)	44.9 (41.5 to 48.2)	34.7 (21.3 to 49.5)	-19.9 (-27.6 to -12.6)	3.5 (3.7 to 7.5)	3.8 (5.0 to 10.3)	34.3 (28.7 to 50.1)	-20.1 (-27.8 to -12.0)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	13.8 (-14.7 to 49.1)	-40.4 (-53.5 to -23.4)
Typhoid fever	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.3)	23.8 (3.5 to 53.4)	-35.1 (-45.4 to -19.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	25.2 (-3.2 to 66.0)	-34.7 (-46.7 to -16.3)
Paratyphoid fever	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	29.1 (5.3 to 62.7)	-31.1 (-44.4 to -12.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.5 (2.7 to 67.9)	-30.7 (-42.1 to -11.2)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.0 (-9.7 to 19.7)	-8.4 (-7.3 to -36.8)
Lower respiratory infections	0.9 (0.6 to 1.5)	1.1 (0.6 to 1.8)	15.3 (-25.5 to 101.3)	-29.6 (54.2 to 13.1)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	13.7 (-21.1 to 100.2)	-29.9 (55.9 to 13.1)
Upper respiratory infections	44.8 (39.7 to 49.2)	88.1 (79.1 to 98.1)	97.4 (70.6 to 129.3)	-1.9 (-14.5 to 14.8)	0.5 (0.3 to 0.9)	1.0 (0.6 to 1.7)	96.3 (70.1 to 130.4)	-1.8 (-14.9 to 15.2)
Otitis media	28.0 (25.5 to 30.3)	49.4 (46.0 to 53.2)	75.8 (60.4 to 100.5)	-9.3 (-18.1 to 5.3)	0.5 (0.3 to 0.9)	0.9 (0.5 to 1.5)	74.5 (58.3 to 98.5)	-9.9 (-18.7 to 3.4)
Meningitis	-	-	-	-	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.5)	-21.9 (-37.7 to 3.0)	-61.5 (-68.7 to -50.8)
Pneumococcal meningitis	1.7 (1.0 to 2.7)	1.4 (0.8 to 2.2)	-20.3 (-41.5 to 11.6)	-62.2 (-72.5 to -49.8)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-13.7 (-38.0 to 53.7)	-58.0 (-69.1 to -31.4)
H influenzae type B meningitis	0.9 (0.3 to 1.9)	0.7 (0.2 to 1.3)	-27.0 (-55.9 to -1.4)	-64.9 (-78.7 to -52.0)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-25.3 (-50.8 to 6.6)	-62.8 (-75.2 to -47.8)
Meningococcal meningitis	0.6 (0.2 to 1.3)	0.4 (0.1 to 0.8)	-35.1 (-53.2 to -5.1)	-68.9 (-76.8 to -51.1)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-37.4 (-58.6 to 0.9)	-69.3 (-79.1 to -54.4)
Other meningitis	0.7 (0.4 to 1.2)	0.5 (0.3 to 0.9)	-23.9 (-39.3 to 0.6)	-61.8 (-70.0 to -50.8)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-22.6 (-44.9 to 3.7)	-60.9 (-70.9 to -49.3)
Encephalitis	0.6 (0.2 to 1.2)	0.9 (0.4 to 2.0)	63.7 (43.5 to 85.0)	-21.5 (-29.5 to -11.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	69.5 (40.8 to 103.5)	-27.8 (-29.1 to -3.2)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.9 (-94.9 to 1,163.9)	-42.5 (-95.0 to 390.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.9 (-94.9 to 1,199.2)	-42.5 (-95.1 to 400.2)
Whooping cough	0.5 (0.4 to 0.6)	0.3 (0.2 to 0.3)	-45.2 (-48.8 to -41.5)	-63.8 (-66.2 to -61.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.3 (-59.2 to -29.1)	-63.9 (-73.1 to -53.1)
Tetanus	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-97.4 (-99.0 to -91.6)	-98.7 (-99.5 to -95.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-96.8 (-99.2 to -89.2)	-98.3 (-99.6 to -94.0)
Measles	2.0 (1.3 to 2.9)	0.2 (0.1 to 0.2)	-91.0 (-94.4 to -85.5)	-94.3 (-96.4 to -90.7)	0.2 (0.1 to 0.3)	0.0 (0.0 to 0.0)	-91.1 (-95.0 to -84.5)	-94.3 (-96.8 to -90.1)
Varicella and herpes zoster	1.8 (1.7 to 2.0)	3.4 (3.1 to 3.6)	83.9 (67.6 to 106.9)	5.9 (-11.6 to 29.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	148.2 (82.5 to 257.9)	11.3 (-20.7 to 62.1)
Neglected tropical diseases and malaria	-	-	-	-	1.9 (1.1 to 3.3)	2.2 (1.5 to 3.2)	21.3 (-19.8 to 63.7)	-35.7 (-56.8 to -14.5)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	144.6 (16.6 to 431.9)	21.6 (-40.9 to 172.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	122.0 (18.4 to 363.1)	8.8 (-41.6 to 137.5)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-9.4 (-29.9 to 54.3)	-66.2 (-74.0 to -46.0)
Visceral leishmaniasis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	62.6 (-7.2 to 227.9)	-15.9 (50.7 to 66.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.0 (-13.0 to 235.8)	-14.8 (53.1 to 68.4)
Cutaneous and mucocutaneous leishmaniasis	10.3 (6.5 to 14.9)	9.1 (6.8 to 12.5)	-13.4 (-32.6 to 49.9)	-68.1 (-75.1 to -49.7)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-13.2 (-32.8 to 51.4)	-67.9 (-75.1 to -47.8)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-64.8 (-94.1 to 16.0)	-82.9 (-96.9 to -48.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-60.8 (-93.7 to 32.9)	-81.0 (-96.6 to -41.8)
Cystic echinococcosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	97.7 (74.4 to 136.4)	-15.0 (-23.8 to -1.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.9 (56.7 to 163.0)	-14.5 (-34.4 to 13.5)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.3 (-53.3 to 13.2)	-64.9 (-75.8 to -44.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.3 (-53.5 to 13.7)	-64.9 (-75.8 to -44.5)
Intestinal nematode infections	-	-	-	-	0.7 (0.2 to 1.6)	0.2 (0.1 to 0.4)	-75.2 (-91.4 to -27.3)	-83.7 (-94.3 to -47.5)
Ascariasis	221.9 (167.4 to 302.6)	422.0 (313.0 to 564.7)	90.8 (21.1 to 185.3)	-5.1 (-43.3 to 49.8)	0.7 (0.2 to 1.6)	0.1 (0.1 to 0.4)	-77.3 (-92.6 to -30.1)	-85.2 (-95.3 to -49.6)
Trichuriasis	-	-	-	-	-	-	-	-
Hookworm disease	1.1 (0.7 to 1.6)	2.7 (1.8 to 4.1)	143.7 (37.5 to 361.3)	1.9 (-42.7 to 93.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	158.9 (98.8 to 206.2)	7.2 (-18.3 to 26.4)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	32.2 (23.9 to 40.7)	55.2 (50.2 to 60.5)	72.5 (35.6 to 129.0)	-4.9 (-23.5 to 22.2)	1.1 (0.6 to 1.7)	1.9 (1.3 to 2.8)	70.3 (44.4 to 161.8)	-4.7 (-19.7 to 44.2)
Maternal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	29.2 (2.8 to 55.9)	-45.1 (-56.4 to -34.2)
Maternal hemorrhage	0.7 (0.6 to 0.7)	1.4 (1.0 to 1.8)	105.1 (46.2 to 171.2)	-17.6 (-41.4 to 9.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	84.8 (6.0 to 182.6)	-24.5 (-56.2 to 15.6)
Maternal sepsis and other maternal infections	1.5 (0.8 to 2.3)	1.5 (0.9 to 2.3)	-1.0 (-42.4 to 82.1)	-60.8 (-77.2 to -27.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.3 (-53.7 to 66.7)	-62.5 (-79.8 to -33.3)
Maternal hypertensive disorders	1.8 (0.7 to 3.3)	2.3 (0.8 to 4.2)	24.2 (5.6 to 41.4)	-45.8 (-55.0 to -41.1)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	23.1 (0.4 to 45.4)	-46.8 (-57.1 to -38.4)
Obstructed labor	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	18.8 (-25.4 to 76.0)	-48.7 (-65.9 to -24.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	20.1 (-41.7 to 129.8)	-47.7 (-73.9 to -2.6)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.3 (-0.7 to 204.2)	-32.8 (-59.1 to 12.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.3 (-1.3 to 204.9)	-32.8 (-59.2 to 13.1)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	29.7 (-41.0 to 147.0)	-44.8 (-75.0 to 3.9)
Neonatal disorders	-	-	-	-	3.3 (2.0 to 5.1)	10.4 (6.2 to 16.0)	220.7 (105.4 to 425.7)	68.3 (8.8 to 175.6)
Preterm birth complications	10.8 (6.6 to 17.0)	43.6 (26.9 to 67.5)	303.3 (181.4 to 493.7)	102.9 (45.7 to 194.2)	1.5 (0.9 to 2.3)	5.7 (3.4 to 8.6)	282.4 (125.1 to 548.0)	96.9 (16.8 to 234.0)
Neonatal encephalopathy due to birth asphyxia and trauma	4.2 (1.9 to 8.0)	9.2 (5.0 to 16.7)	120.0 (9.2 to 395.5)	16.1 (-41.8 to 165.7)	1.0 (0.4 to 1.9)	2.3 (1.3 to 3.9)	130.6 (19.9 to 417.5)	23.4 (-35.0 to 176.3)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	444.3 (593.0 to 751.9)	557.7 (397.8 to 512.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	668.2 (386.1 to 1,170.1)	451.8 (249.2 to 812.4)
Hemolytic disease and other neonatal jaundice	0.9 (0.3 to 2.6)	2.4 (0.7 to 8.4)	163.5 (56.3 to 1,281.3)	40.0 (-77.5 to 643.2)	0.3 (0.1 to 0.7)	0.6 (0.2 to 2.2)	145.9 (-54.3 to 995.9)	26.1 (-76.5 to 478.0)
Other neonatal disorders	-	-	-	-	0.5 (0.1 to 1.2)	1.8 (0.5 to 3.9)	273.4 (18.7 to 1,126.5)	96.2 (-38.3 to 544.4)
Nutritional deficiencies	-	-	-	-	17.5 (11.5 to 25.4)	30.8 (20.4 to 44.9)	75.7 (61.3 to 91.4)	-10.3 (-18.2 to -2.0)
Protein-energy malnutrition	4.2 (1.6 to 9.0)	9.4 (3.5 to 19.6)	125.2 (-39.3 to 624.9)	48.3 (-59.0 to 371.2)	0.5 (0.2 to 1.2)	1.2 (0.4 to 2.8)	127.3 (-38.4 to 635.1)	49.9 (-58.8 to 383.5)
Iodine deficiency	66.8 (34.5 to 105.8)	77.5 (42.0 to 125.1)	13.7 (-49.9 to 183.6)	-50.0 (-79.0 to 30.2)	1.2 (0.5 to 2.3)	1.4 (0.6 to 2.6)	13.1 (-49.9 to 186.6)	-49.7 (-79.1 to 31.0)
Vitamin A deficiency	1.5 (0.9 to 2.0)	1.6 (0.9 to 2.2)	6.0 (-17.2 to 36.0)	-47.6 (-59.6 to -31.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-1.0 (-26.0 to 30.1)	-51.6 (-64.1 to -36.8)

Appendix Table G.4 - Palestine prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	131.4	131.4
Silicosis	0.0	0.0	118.8	-15.0	0.0	0.0	(121.4 to 145.0)	(-12.3 to -2.3)
Asbestosis	-	-	0.0	0.0	-	-	115.6	-16.3
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	(-22.0 to -8.6)
Other pneumoconiosis	0.0	0.0	144.3	-1.5	0.0	0.0	140.1	-3.2
Asthma	(86.2 to 110.9)	(75.9 to 127.8)	(-26.5 to 31.0)	(-50.0 to -20.9)	(2.8 to 6.4)	(2.6 to 6.7)	(28.1 to 29.5)	(-50.9 to -22.5)
Interstitial lung disease and pulmonary sarcoidosis	0.1	0.3	145.7	2.3	0.0	0.0	148.5	1.8
Other chronic respiratory diseases	-	-	-	-	0.3	0.5	45.5	-40.8
Cirrhosis	-	-	-	-	0.1	0.2	99.5	37.4
Cirrhosis due to hepatitis B	0.2	0.3	111.1	-4.9	0.0	0.1	(37.9 to 83.2)	(-27.0 to -7.2)
Cirrhosis due to hepatitis C	0.3	0.5	81.2	-9.6	0.0	0.0	107.6	-4.7
Cirrhosis due to alcohol use	0.1	0.1	8.2	-50.0	0.0	0.0	8.0	-50.2
Cirrhosis due to other causes	0.2	0.3	25.9	-26.4	0.0	0.0	26.2	-26.2
Digestive diseases	-	-	-	-	1.0	2.4	139.6	3.5
Peptic ulcer disease	2.5	3.4	34.3	-44.4	0.1	0.2	58.8	-36.7
Gastritis and duodenitis	5.5	6.4	15.1	-44.2	0.3	0.3	15.5	-40.0
Appendicitis	0.1	0.3	81.8	-18.3	0.0	0.1	84.7	-16.7
Paralytic ileus and intestinal obstruction	0.1	0.5	211.9	79.9	0.0	0.2	214.9	84.9
Inguinal, femoral, and abdominal hernia	7.1	7.1	113.9	-11.0	0.0	0.0	113.4	-11.2
Inflammatory bowel disease	1.3	4.5	248.7	43.7	0.3	1.0	248.3	43.4
Vascular intestinal disorders	0.0	0.0	143.5	1.2	0.0	0.0	138.9	-2.9
Gallbladder and biliary diseases	0.5	1.1	134.0	-4.3	0.1	0.1	133.4	-5.0
Pancreatitis	0.3	0.7	121.3	-8.9	0.1	0.2	118.0	-9.4
Other digestive diseases	-	-	-	-	0.1	0.3	157.9	8.5
Neurological disorders	-	-	-	-	13.7	33.6	145.5	-1.0
Alzheimer disease and other dementias	4.8	13.2	174.5	-0.8	0.7	1.8	174.5	-1.6
Parkinson disease	0.5	1.3	168.0	-0.4	0.1	0.2	164.8	-1.2
Epilepsy	9.8	20.6	109.2	-0.3	3.0	7.0	131.4	10.0
Multiple sclerosis	0.2	1.1	341.8	77.0	0.1	0.4	335.3	75.9
Migraine	193.2	491.4	120.6	6.6	14.8	48.1	(170.8 to 600.4)	(14.2 to 182.5)
Tension-type headache	(147.8 to 238.0)	(298.3 to 565.8)	(50.3 to 264.7)	(-34.0 to 41.5)	(3.7 to 10.5)	(8.0 to 23.2)	(68.3 to 267.9)	(-34.2 to 42.2)
Medication overuse headache	30.4	70.7	127.3	-1.6	0.5	1.1	126.8	-1.6
Other neurological disorders	13.3	47.2	257.2	48.3	2.1	7.4	255.7	48.0
Mental and substance use disorders	0.0	0.0	113.4	1.4	0.6	0.9	47.1	49.0
Schizophrenia	4.0	9.7	144.0	-0.3	56.3	126.6	124.6	-1.6
Alcohol use disorders	9.2	21.4	133.9	0.3	0.9	2.1	135.6	0.4
Drug use disorders	-	-	-	-	5.6	11.7	109.4	-13.2
Opioid use disorders	10.5	22.1	108.6	-14.5	4.4	9.1	107.9	-14.5
Cocaine use disorders	(6.1 to 16.9)	(11.0 to 36.5)	(65.7 to 146.0)	(-32.2 to -1.3)	(2.3 to 7.2)	(4.1 to 16.0)	(63.4 to 147.9)	(-32.6 to 0.1)
Amphetamine use disorders	2.7	5.6	103.7	-9.3	0.4	0.7	104.6	-8.9
Cannabis use disorders	3.0	7.0	130.8	0.1	0.1	0.2	130.5	-0.1
Other drug use disorders	-	-	-	-	0.6	1.2	108.6	-8.3
Depressive disorders	-	-	-	-	26.0	60.3	131.9	0.4
Major depressive disorder	118.0	273.7	131.8	0.6	24.4	56.5	131.2	0.4
Dysthymia	16.4	39.6	141.9	-0.2	1.6	3.8	141.5	-0.4
Bipolar disorder	11.6	27.3	134.6	-1.3	2.4	5.6	134.1	-1.5
Anxiety disorders	(9.9 to 13.3)	(23.4 to 31.2)	(122.5 to 148.3)	(-5.4 to 3.3)	(1.4 to 3.6)	(3.5 to 8.4)	(117.3 to 151.3)	(-7.3 to 4.5)
Eating disorders	-	-	-	-	2.8	6.3	127.6	-0.3
Anorexia nervosa	0.3	0.7	149.8	11.6	0.1	0.1	148.7	11.2
Bulimia nervosa	1.0	2.4	127.2	-0.5	0.2	0.5	127.9	-0.2
Autistic spectrum disorders	-	-	-	-	2.5	5.2	108.4	0.3
Autism	6.2	12.9	109.5	0.2	1.5	3.2	108.8	0.3
Asperger syndrome	9.3	19.4	108.1	0.3	0.9	1.9	107.6	0.3
Attention-deficit/hyperactivity disorder	16.1	32.4	101.2	0.3	0.2	0.4	100.8	0.2
Conduct disorder	29.6	60.8	105.5	0.3	3.6	7.3	106.2	0.6
Idiopathic intellectual disability	70.9	136.2	92.4	6.7	3.5	6.7	91.6	6.7
Other mental and substance use disorders	23.7	57.3	141.6	0.1	1.8	4.3	141.2	0.0
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	15.4	41.5	170.2	21.3
Diabetes mellitus	93.5	299.6	223.4	36.2	7.3	23.6	226.1	33.3
Acute glomerulonephritis	0.0	0.0	10.8	-41.1	0.0	0.0	10.8	-41.1
Chronic kidney disease	-	-	-	-	1.7	3.9	126.9	1.2
Chronic kidney disease due to diabetes mellitus	11.5	30.0	159.9	8.0	0.3	0.8	158.9	9.3
Chronic kidney disease due to hypertension	10.9	17.9	65.4	-20.6	0.5	0.9	92.1	-20.6
Chronic kidney disease due to glomerulonephritis	15.7	30.7	83.0	61.7	0.3	0.5	61.7	-18.6
Chronic kidney disease due to other causes	22.8	21.6	170.9	18.4	0.6	0.7	176.5	24.2
Urinary diseases and male infertility	-	-	-	-	0.6	1.7	201.6	15.5

Appendix Table G.4 - Palestine prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	48.4 (44.2 to 52.1)	117.5 (108.4 to 127.1)	142.6 (116.6 to 172.2)	-7.4 (-16.0 to 3.0)	1.3 (0.9 to 1.9)	3.2 (2.2 to 4.5)	141.4 (116.1 to 171.0)	-7.7 (-16.2 to 2.8)
Other oral disorders	28.8 (27.3 to 30.4)	65.6 (61.6 to 69.4)	127.9 (110.1 to 146.1)	-0.2 (-7.3 to 7.0)	0.8 (0.5 to 1.3)	1.9 (1.2 to 2.9)	127.4 (108.9 to 147.4)	-0.5 (-7.7 to 7.4)
Injuries	-	-	-	-	4.8 (3.6 to 6.4)	7.4 (5.3 to 9.9)	55.9 (26.3 to 82.1)	-27.1 (-41.6 to -14.6)
Transport injuries	-	-	-	-	1.8 (1.3 to 2.3)	2.3 (1.6 to 3.1)	29.9 (10.7 to 54.0)	-8.3 (-46.7 to -28.3)
Road injuries	-	-	-	-	1.6 (1.2 to 2.0)	2.0 (1.4 to 2.7)	24.7 (5.1 to 48.6)	-46.6 (-49.4 to -30.7)
Pedestrian road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	-3.4 (-19.5 to 17.5)	-51.6 (-58.5 to -43.1)
Cyclist road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	71.6 (50.7 to 93.0)	-21.5 (-30.4 to -13.0)
Motorcyclist road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-3.2 (-18.0 to 15.9)	-54.8 (-61.2 to -46.4)
Motor vehicle road injuries	-	-	-	-	0.9 (0.7 to 1.1)	1.2 (0.9 to 1.6)	36.6 (13.8 to 68.5)	-34.8 (-45.8 to -22.3)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.5 (-38.2 to -12.2)	-68.2 (-72.9 to -62.9)
Other transport injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	80.3 (55.7 to 109.4)	-19.6 (-29.6 to -7.3)
Unintentional injuries	-	-	-	-	2.0 (1.6 to 2.6)	3.9 (2.9 to 5.2)	92.1 (74.1 to 111.1)	-13.3 (-21.5 to -5.0)
Falls	-	-	-	-	0.8 (0.6 to 1.1)	1.6 (1.1 to 2.1)	92.6 (71.1 to 117.2)	-16.9 (-27.0 to -5.6)
Drowning	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	6.3 (-19.6 to 11.1)	-56.2 (-62.1 to -48.9)
Fire, heat, and hot substances	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-26.2 (-36.9 to -13.9)	-63.8 (-68.4 to -58.9)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.1 (-31.4 to 21.1)	-58.8 (-66.8 to -47.8)
Exposure to mechanical forces	-	-	-	-	0.6 (0.4 to 0.7)	1.2 (0.9 to 1.6)	114.6 (84.5 to 141.1)	3.8 (-7.2 to 13.5)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	37.0 (18.9 to 58.2)	-40.0 (-47.5 to -31.5)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	224.7 (170.6 to 281.2)	55.6 (33.6 to 77.2)
Other exposure to mechanical forces	-	-	-	-	0.5 (0.4 to 0.7)	1.1 (0.8 to 1.5)	118.5 (86.7 to 145.7)	6.5 (-5.2 to 17.0)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	151.3 (134.9 to 170.8)	15.0 (7.0 to 24.0)
Animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	60.7 (42.0 to 81.6)	-27.0 (-34.0 to -19.1)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.4 (33.6 to 91.7)	-27.7 (-38.2 to -15.9)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	62.2 (41.4 to 81.5)	-25.9 (-33.4 to -18.8)
Foreign body	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	98.6 (77.2 to 121.2)	-1.3 (-10.7 to 8.3)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.0 (-29.0 to 9.0)	-52.4 (-60.6 to -42.7)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	123.0 (98.4 to 151.7)	4.9 (-5.8 to 15.8)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	163.9 (124.1 to 208.4)	23.7 (8.4 to 40.6)
Other unintentional injuries	-	-	-	-	0.3 (0.2 to 0.3)	0.7 (0.5 to 0.9)	173.8 (135.5 to 210.2)	22.1 (7.9 to 36.1)
Self-harm and interpersonal violence	-	-	-	-	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.6)	146.5 (114.4 to 180.3)	13.5 (-0.7 to 27.8)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	221.3 (177.3 to 273.0)	30.4 (14.3 to 48.6)
Interpersonal violence	-	-	-	-	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	139.7 (107.3 to 174.2)	11.7 (-2.9 to 26.2)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	182.9 (146.4 to 222.7)	36.2 (19.4 to 52.3)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	155.9 (119.4 to 196.3)	16.0 (1.1 to 33.6)
Assault by other means	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	116.5 (83.7 to 152.0)	-0.1 (-14.1 to 16.3)
Forces of nature, war, and legal intervention	-	-	-	-	0.8 (0.3 to 1.8)	0.7 (0.3 to 1.5)	-7.7 (-60.1 to 98.7)	-51.4 (-80.1 to 6.5)
Exposure to forces of nature	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-	-
Collective violence and legal intervention	-	-	-	-	0.8 (0.3 to 1.8)	0.6 (0.2 to 1.5)	-16.4 (-67.0 to 89.7)	-55.6 (-83.2 to 2.6)

Appendix Table G.4 - Panama prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	226.2 (165.4 to 294.8)	389.4 (287.5 to 507.0)	71.1 (67.4 to 77.9)	71.1 (-4.3 to 0.9)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	29.6 (20.7 to 41.8)	37.0 (26.1 to 50.3)	25.3 (14.2 to 37.6)	-11.8 (-20.2 to -2.9)
HIV/AIDS and tuberculosis	-	-	-	-	1.2 (0.8 to 1.6)	1.9 (1.2 to 2.7)	59.7 (15.8 to 134.0)	-11.3 (-35.1 to 29.4)
Tuberculosis	1.5 (1.4 to 1.5)	2.3 (2.2 to 2.4)	54.2 (49.7 to 59.1)	-16.0 (-18.5 to -13.3)	0.5 (0.3 to 0.6)	0.7 (0.5 to 1.0)	53.6 (37.5 to 71.0)	-15.7 (-23.5 to -6.9)
HIV/AIDS	-	-	-	-	0.7 (0.4 to 1.1)	1.2 (0.7 to 1.8)	61.2 (4.0 to 208.0)	8.2 (-45.8 to 73.7)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	11.2 (-39.2 to 110.5)	-41.5 (-68.1 to 11.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.0 (-41.5 to 126.9)	-39.1 (-68.8 to 20.8)
HIV/AIDS resulting in other diseases	5.9 (4.3 to 8.1)	11.1 (8.2 to 15.1)	85.0 (21.7 to 219.2)	10.2 (-27.6 to 89.9)	0.7 (0.4 to 1.1)	1.2 (0.7 to 1.8)	64.5 (-4.1 to 211.7)	-7.6 (-45.8 to 76.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	5.9 (4.1 to 8.2)	7.1 (4.9 to 9.9)	18.4 (9.6 to 29.3)	-13.0 (-19.2 to -5.6)
Diarrheal diseases	19.1 (17.9 to 20.3)	21.4 (20.1 to 22.9)	12.2 (2.8 to 22.6)	-11.3 (-18.5 to -3.5)	3.1 (2.1 to 4.4)	3.5 (2.3 to 4.8)	11.2 (11.1 to 23.0)	3.4 (-19.4 to -2.7)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-40.2 to 4.9)	-15.2 (-58.3 to -27.2)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.6 (-24.2 to 11.1)	-34.7 (-47.4 to -23.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-24.2 to 11.4)	-34.7 (-47.4 to -23.1)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.7 (-25.9 to 16.6)	-35.4 (-47.6 to -18.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-25.9 to 16.7)	-8.7 (-47.6 to -18.4)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-89.6 (-99.7 to 91.1)	-92.0 (-99.8 to 33.7)
Lower respiratory infections	1.9 (1.4 to 2.6)	1.4 (1.0 to 1.8)	-30.8 (-55.3 to 23.5)	-52.9 (-70.1 to -34.4)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	31.8 (57.0 to 22.9)	-53.6 (-70.6 to -14.8)
Upper respiratory infections	119.1 (106.6 to 132.4)	179.5 (159.9 to 198.0)	50.5 (27.3 to 77.1)	1.3 (-14.0 to 17.9)	1.4 (0.8 to 2.3)	2.1 (1.2 to 3.5)	50.2 (26.4 to 78.0)	1.5 (-14.2 to 19.6)
Otitis media	32.6 (30.6 to 34.6)	41.6 (39.3 to 43.7)	27.7 (18.2 to 36.9)	-12.1 (-18.1 to -6.2)	0.6 (0.4 to 1.0)	0.8 (0.5 to 1.2)	25.6 (15.2 to 36.5)	-13.3 (-20.1 to -5.8)
Meningitis	-	-	-	-	0.4 (0.3 to 0.6)	0.4 (0.2 to 0.5)	-16.4 (-30.5 to -0.4)	-43.6 (-52.9 to -32.7)
Pneumococcal meningitis	2.3 (1.3 to 3.7)	1.9 (1.2 to 3.1)	-15.9 (-31.7 to 2.7)	-47.6 (-57.4 to -35.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-11.4 (-33.7 to 26.9)	-41.4 (-55.6 to -17.0)
H influenzae type B meningitis	1.0 (0.3 to 2.2)	0.6 (0.2 to 1.3)	-41.0 (-65.0 to -14.3)	-61.5 (-76.4 to -42.1)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	0.1 (-64.1 to 6.2)	-35.9 (-74.8 to -26.2)
Meningococcal meningitis	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.3)	-24.4 (-53.5 to 10.9)	-52.9 (-69.0 to -30.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-53.4 to 28.0)	-22.8 (-67.4 to -18.1)
Other meningitis	0.8 (0.3 to 1.6)	0.7 (0.3 to 1.5)	-11.8 (-33.7 to 13.9)	-43.5 (-57.0 to -24.6)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-1.5 (-25.5 to 37.7)	-33.5 (-49.3 to -5.8)
Encephalitis	0.2 (0.1 to 0.5)	0.3 (0.2 to 0.9)	61.5 (24.2 to 93.7)	-4.8 (-24.4 to 16.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (-36.4 to 115.6)	3.4 (-16.1 to 30.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.6 (-94.6 to 822.2)	-47.5 (-95.7 to 530.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-94.7 to 837.8)	-47.5 (-95.8 to 532.8)
Whooping cough	1.7 (1.3 to 2.2)	1.2 (0.9 to 1.5)	-32.7 (-35.1 to -30.3)	-43.0 (-45.0 to -40.9)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-32.3 (-39.4 to -23.9)	-42.6 (-48.7 to -35.5)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-94.1 (-96.8 to -86.0)	-96.1 (-97.9 to -90.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-96.4 to -85.1)	-95.1 (-97.5 to -89.9)
Measles	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	1.9 (1.7 to 2.1)	2.7 (2.4 to 3.1)	44.5 (24.8 to 70.5)	-3.7 (-18.7 to 18.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	77.7 (28.3 to 158.0)	-6.3 (-34.0 to 32.7)
Neglected tropical diseases and malaria	-	-	-	-	6.6 (4.3 to 10.2)	4.6 (2.8 to 6.7)	-31.8 (-54.0 to 5.9)	-52.7 (-68.3 to -26.0)
Malaria	21.3 (10.5 to 35.2)	63.1 (28.3 to 139.0)	175.6 (58.5 to 483.3)	95.4 (10.4 to 327.4)	0.3 (0.2 to 0.5)	1.3 (0.7 to 2.2)	327.3 (156.0 to 450.6)	227.9 (98.5 to 319.9)
Chagas disease	15.9 (15.0 to 16.9)	26.2 (24.8 to 27.7)	64.2 (51.3 to 78.0)	-2.3 (-9.7 to 5.8)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	94.2 (71.1 to 121.0)	-3.0 (-13.3 to 9.7)
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	83.3 (63.6 to 105.2)	16.0 (4.8 to 29.6)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	131.1 (20.9 to 309.4)	65.5 (-11.3 to 183.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	131.1 (20.7 to 310.2)	65.5 (-11.3 to 183.3)
Cutaneous and mucocutaneous leishmaniasis	2.1 (1.7 to 2.8)	3.9 (3.1 to 5.1)	83.0 (70.1 to 98.6)	14.7 (6.9 to 24.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	82.4 (62.4 to 104.9)	15.2 (3.8 to 28.3)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	2.1 (0.7 to 4.2)	3.4 (0.9 to 7.0)	46.8 (-56.5 to 591.7)	-16.7 (-73.2 to 283.4)	0.6 (0.2 to 1.3)	1.1 (0.3 to 2.3)	59.1 (-54.4 to 672.9)	-8.4 (-71.8 to 335.8)
Cystic echinococcosis	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	113.4 (87.5 to 125.8)	3.8 (-9.0 to 9.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	110.3 (59.6 to 175.5)	3.8 (-21.4 to 38.1)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.5 (0.2 to 1.2)	4.1 (1.6 to 9.0)	656.0 (651.8 to 660.9)	393.6 (390.8 to 396.8)	0.1 (0.0 to 0.2)	0.7 (0.2 to 1.6)	655.8 (527.8 to 817.6)	394.8 (321.5 to 489.7)
Yellow fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.5 (-69.1 to -44.6)	-72.7 (-79.4 to -44.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.5 (-69.2 to -44.5)	-72.7 (-79.4 to -44.2)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.6 (-55.2 to 14.4)	-40.6 (-71.3 to -25.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.6 (-55.4 to 14.4)	-40.6 (-71.3 to -25.8)
Intestinal nematode infections	-	-	-	-	4.7 (2.7 to 7.9)	0.2 (0.1 to 0.6)	-96.4 (-98.5 to -88.2)	97.4 (-98.9 to -91.3)
Ascariasis	529.8 (423.6 to 668.6)	469.4 (340.7 to 638.3)	-12.0 (-40.3 to 31.1)	-42.3 (-61.5 to -11.3)	1.4 (0.7 to 2.8)	0.2 (0.1 to 0.6)	-83.3 (-95.6 to -59.9)	-90.5 (-96.4 to -67.5)
Trichuriasis	691.5 (553.4 to 841.4)	99.3 (2.9 to 193.3)	-99.6 (-99.8 to -99.3)	-99.7 (-99.8 to -99.5)	0.8 (0.4 to 1.8)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Hookworm disease	385.9 (313.4 to 480.0)	2.9 (1.9 to 4.0)	-99.3 (-99.5 to -98.9)	-99.5 (-99.7 to -99.3)	2.4 (1.5 to 4.0)	0.0 (0.0 to 0.0)	-99.8 (-99.9 to -99.7)	-99.8 (-99.9 to -99.8)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	20.6 (16.3 to 25.0)	27.4 (26.1 to 29.0)	33.3 (8.6 to 66.6)	2.4 (-15.5 to 25.8)	0.7 (0.5 to 1.1)	1.0 (0.6 to 1.4)	32.3 (18.5 to 87.7)	4.3 (-6.9 to 46.2)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-13.0 to 39.9)	-
Maternal hemorrhage	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	29.4 (-9.7 to 144.2)	-10.5 (-37.4 to 65.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.7 (-64.0 to 108.4)	-27.9 (-75.4 to 28.5)
Maternal sepsis and other maternal infections	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	-41.8 (-30.6 to 37.4)	-41.8 (-60.6 to -22.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.6 (-48.3 to 62.3)	-44.3 (-65.7 to -0.1)
Maternal hypertensive disorders	0.3 (0.1 to 0.7)	0.4 (0.1 to 0.7)	17.4 (12.8 to 29.5)	-18.8 (-26.5 to -13.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.5 (-11.9 to 53.7)	-20.2 (-39.1 to 4.7)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.5 (-63.3 to 163.8)	-34.2 (-74.1 to 78.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.5 (-63.4 to 164.2)	-34.2 (-74.4 to 80.3)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.9 (-31.2 to 96.1)	-18.2 (-51.5 to 32.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.8 (-46.2 to 150.4)	-18.2 (-62.0 to 65.1)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.2 (-37.6 to 59.7)	-33.5 (-57.7 to 6.9)
Neonatal disorders	-	-	-	-	3.2 (2.0 to 4.8)	6.6 (4.6 to 9.0)	110.1 (35.5 to 228.3)	42.9 (7.8 to 123.9)
Preterm birth complications	9.2 (5.4 to 15.3)	26.3 (16.6 to 42.2)	189.2 (119.7 to 287.6)	89.9 (44.4 to 154.1)	1.2 (0.7 to 1.9)	3.5 (2.2 to 5.0)	204.1 (76.3 to 388.1)	104.4 (18.7 to 223.5)
Neonatal encephalopathy due to birth asphyxia and trauma	6.6 (2.7 to 14.0)	8.3 (3.6 to 17.3)	24.9 (-4.2 to 58.8)	-17.5 (-35.5 to 12.5)	0.8 (0.5 to 1.4)	1.2 (0.8 to 1.7)	11.7 (-15.3 to 140.0)	-1.9 (-40.9 to 66.2)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	140.7 (118.7 to 171.3)	108.9 (89.8 to 135.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.9 (104.1 to 181.8)	108.9 (77.2 to 144.6)
Hemolytic disease and other neonatal jaundice	2.1 (0.6 to 4.7)	3.1 (1.5 to 5.4)	45.6 (-50.8 to 354.4)	-1.7 (-67.0 to 208.8)	0.8 (0.2 to 1.8)	1.2 (0.5 to 2.2)	48.8 (-49.1 to 368.2)	1.1 (-65.7 to 220.9)
Other neonatal disorders	-	-	-	-	0.3 (0.2 to 0.6)	0.7 (0.4 to 1.1)	116.8 (16.5 to 319.9)	47.2 (-20.2 to 187.7)
Nutritional deficiencies	-	-	-	-	11.5 (7.9 to 16.5)	15.2 (10.1 to 22.5)	32.6 (27.7 to 37.2)	-3.7 (-7.8 to -0.3)
Protein-energy malnutrition	2.2 (1.3 to 3.7)	2.2 (1.2 to 3.7)	-0.7 (-57.8 to 120.5)	-2.1 (-64.5 to 64.9)	0.3 (0.1 to 0.5)	0.3 (0.1 to 0.5)	0.3 (-58.2 to 120.4)	21.8 (-64.9 to 65.5)
Iodine deficiency	31.5 (23.5 to 40.1)	28.5 (20.2 to 37.5)	-10.5 (-39.3 to 32.4)	-44.5 (-62.5 to -16.9)	0.6 (0.3 to 0.9)	0.5 (0.3 to 0.9)	-8.8 (-40.1 to 31.2)	-44.3 (-62.9 to -17.7)
Vitamin A deficiency	0.6 (0.4 to 0.8)	0.4 (0.3 to 0.5)	-32.7 (-44.4 to -20.0)	-51.7 (-59.7 to -42.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.7 (-48.0 to -14.1)	-52.3 (-62.8 to -41.0)

Appendix Table G.4 - Panama prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	107.5	-1.7
Silicosis	0.0	0.0	106.0	-5.0	0.0	0.0	106.8	-4.5
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	107.0	0.8	0.0	0.0	107.6	1.3
Asthma	235.2	328.1	39.1	-10.4	10.4	14.5	38.3	-10.6
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.1	120.6	2.8	0.0	0.0	121.1	2.9
Other chronic respiratory diseases	-	-	-	-	0.3	0.6	76.8	-12.5
Cirrhosis	-	-	-	-	0.1	0.2	70.2	-9.1
Cirrhosis due to hepatitis B	0.0	0.0	135.0	22.0	0.0	0.0	135.0	22.0
Cirrhosis due to hepatitis C	0.2	0.4	93.5	2.2	0.0	0.1	90.1	1.7
Cirrhosis due to alcohol use	0.3	0.4	55.8	-23.2	0.0	0.0	52.6	-24.3
Cirrhosis due to other causes	0.1	0.2	76.9	14.9	0.0	0.0	74.5	14.4
Digestive diseases	-	-	-	-	1.5	3.2	113.2	-0.2
Peptic ulcer disease	13.1	16.1	22.6	-49.9	0.4	0.6	34.7	-43.0
Gastritis and duodenitis	2.3	3.8	65.4	-17.3	0.1	0.2	65.3	-17.2
Appendicitis	0.1	0.1	15.0	-21.2	0.0	0.0	18.8	-19.4
Paralytic ileus and intestinal obstruction	0.0	0.0	160.2	52.8	0.0	0.0	145.6	46.8
Inguinal, femoral, and abdominal hernia	5.6	9.9	74.5	-22.9	0.1	0.1	74.3	-22.3
Inflammatory bowel disease	2.7	6.5	141.2	24.3	0.6	1.4	140.4	24.5
Vascular intestinal disorders	0.0	0.0	118.8	-1.6	0.0	0.0	118.8	-1.6
Gallbladder and biliary diseases	1.4	2.8	100.4	0.1	0.3	0.3	100.1	-3.0
Pancreatitis	0.1	0.3	177.9	44.8	0.0	0.1	174.9	44.9
Other digestive diseases	-	-	-	-	0.1	0.4	551.9	205.4
Neurological disorders	-	-	-	-	15.6	29.0	86.1	1.7
Alzheimer disease and other dementias	12.0	30.5	152.9	-0.8	1.7	4.4	157.3	-0.3
Parkinson disease	0.2	0.5	141.4	1.5	0.0	0.1	142.3	2.3
Epilepsy	13.8	19.2	39.6	-11.4	4.4	6.8	51.7	-2.9
Multiple sclerosis	0.1	0.3	257.9	88.7	0.0	0.1	252.5	86.3
Migraine	192.5	395.5	77.4	-7.4	2.6	6.6	76.6	2.1
Tension-type headache	471.5	833.3	77.0	3.4	0.7	1.3	77.1	3.7
Medication overuse headache	10.4	26.4	154.2	37.6	1.6	4.1	153.3	37.6
Other neurological disorders	0.0	0.0	54.7	-8.1	0.5	0.7	46.9	-62.8
Mental and substance use disorders	-	-	-	-	59.4	95.9	61.7	-1.8
Schizophrenia	6.0	11.1	85.7	-0.6	3.8	7.1	85.1	-0.5
Alcohol use disorders	18.8	33.1	76.4	1.0	1.9	3.3	77.1	1.7
Drug use disorders	-	-	-	-	3.2	5.3	65.7	3.1
Opioid use disorders	1.6	3.3	102.5	5.3	0.7	1.3	102.4	6.2
Cocaine use disorders	4.7	6.7	42.9	-0.8	0.6	0.9	42.8	-0.7
Amphetamine use disorders	3.1	4.5	44.7	0.2	0.1	0.1	45.2	0.4
Other drug use disorders	-	-	-	-	1.2	1.9	56.9	1.8
Depressive disorders	-	-	-	-	24.7	40.7	63.3	3.1
Major depressive disorder	107.2	172.1	61.6	-3.6	22.2	35.4	60.8	-3.5
Dysthymia	26.1	48.6	86.5	-0.0	2.5	4.7	85.9	0.2
Bipolar disorder	18.8	32.4	72.0	-0.5	3.8	6.6	71.4	-0.2
Anxiety disorders	184.0	371.0	64.2	-0.1	9.6	15.7	64.1	0.1
Eating disorders	-	-	-	-	0.8	1.1	42.2	0.8
Anorexia nervosa	0.6	0.9	46.2	4.9	0.1	0.2	47.2	5.7
Bulimia nervosa	3.1	4.4	40.6	-0.6	0.7	0.9	41.2	-0.1
Autistic spectrum disorders	-	-	-	-	3.0	4.5	50.0	0.4
Autism	7.5	11.5	53.6	0.1	1.9	2.8	53.1	0.3
Asperger syndrome	11.1	16.9	53.0	0.1	1.1	1.7	52.7	0.5
Attention-deficit/hyperactivity disorder	21.3	27.0	26.5	0.1	0.3	0.3	26.6	0.1
Conduct disorder	28.5	35	26.0	0.0	3.4	4.3	26.4	0.4
Idiopathic intellectual disability	45.4	54.1	19.2	-21.8	2.2	2.6	19.0	-21.6
Other mental and substance use disorders	36.0	64.6	79.5	0.1	2.7	4.8	78.8	0.4
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	14.9	33.4	125.1	21.8
Diabetes mellitus	86.6	253.7	196.0	50.1	6.1	18.1	199.1	45.7
Acute glomerulonephritis	0.0	0.0	17.2	-19.0	0.0	0.0	17.2	-19.0
Chronic kidney disease	-	-	-	-	3.3	5.8	79.4	1.6
Chronic kidney disease due to diabetes mellitus	42.2	87.1	107.3	2.8	0.6	1.3	104.9	0.8
Chronic kidney disease due to hypertension	40.0	73.9	85.4	11.9	0.8	1.6	90.0	3.2
Chronic kidney disease due to glomerulonephritis	54.0	97.8	81.3	0.7	1.2	1.2	65.4	4.2
Chronic kidney disease due to other causes	67.0	111.4	69.9	-2.7	1.1	1.5	59.3	-4.5
Urinary diseases and male infertility	-	-	-	-	0.7	1.7	132.8	4.1

Appendix Table G.4 - Panama prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.5 (0.5 to 0.6)	1.0 (0.9 to 1.1)	83.0 (54.4 to 115.5)	0.0 (-5.3 to 24.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	81.1 (38.9 to 129.1)	8.4 (-15.2 to 34.0)
Urolithiasis	18.6 (12.3 to 28.5)	54.8 (31.7 to 84.3)	189.3 (116.6 to 271.6)	0.1 (-5.4 to 64.3)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.6)	216.3 (141.3 to 301.5)	46.1 (10.6 to 82.8)
Benign prostatic hyperplasia	12.9 (10.7 to 15.4)	28.4 (24.9 to 31.9)	122.1 (80.8 to 169.2)	-5.9 (-24.3 to 15.0)	1.0 (0.3 to 0.7)	1.0 (0.6 to 1.5)	121.6 (81.3 to 171.1)	-5.8 (-24.1 to 16.1)
Male infertility due to other causes	12.4 (9.5 to 15.4)	20.1 (15.8 to 24.8)	63.7 (20.4 to 124.1)	-2.0 (-27.9 to 36.0)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	59.8 (15.0 to 131.3)	-2.0 (-29.6 to 40.3)
Other urinary diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	197.4 (132.4 to 293.8)	38.9 (10.4 to 88.3)
Gynecological diseases	-	-	-	-	2.9 (1.9 to 4.3)	5.1 (3.2 to 7.7)	74.3 (53.6 to 99.6)	-1.4 (-12.3 to 13.1)
Uterine fibroids	42.2 (38.0 to 45.9)	84.7 (76.8 to 91.7)	100.6 (98.4 to 103.1)	-0.9 (-0.9 to -0.9)	0.5 (0.3 to 0.9)	1.0 (0.6 to 1.7)	88.9 (78.6 to 100.0)	-1.1 (-5.8 to 4.5)
Polycystic ovarian syndrome	38.5 (33.5 to 43.3)	68.5 (61.4 to 76.1)	77.6 (49.1 to 116.2)	1.8 (-13.4 to 23.0)	0.4 (0.2 to 0.7)	0.7 (0.3 to 1.3)	77.6 (50.2 to 116.8)	2.1 (-12.8 to 23.5)
Female infertility due to other causes	14.6 (10.9 to 18.5)	22.3 (13.7 to 32.6)	54.1 (-15.3 to 142.2)	-16.4 (-54.2 to 31.4)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	54.1 (-14.2 to 139.4)	-16.2 (-54.4 to 31.9)
Endometriosis	4.2 (3.6 to 4.9)	7.7 (6.6 to 8.9)	84.9 (46.7 to 129.0)	4.6 (-16.6 to 28.4)	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.0)	85.3 (45.5 to 132.1)	4.9 (-16.9 to 31.3)
Genital prolapse	138.4 (120.0 to 157.1)	267.0 (232.9 to 299.1)	92.9 (60.8 to 129.5)	-0.2 (-15.1 to 16.7)	0.4 (0.2 to 0.8)	0.9 (0.4 to 1.6)	92.6 (60.4 to 130.8)	-0.2 (-15.3 to 17.3)
Premenstrual syndrome	112.7 (87.8 to 138.5)	178.2 (131.2 to 227.1)	57.1 (10.4 to 134.9)	-3.9 (-33.3 to 45.4)	0.9 (0.6 to 1.5)	1.5 (0.9 to 2.4)	57.8 (8.9 to 131.6)	-3.9 (-33.8 to 42.8)
Other gynecological diseases	5.3 (4.7 to 5.9)	8.2 (7.4 to 8.9)	56.4 (36.2 to 77.5)	-4.8 (-16.8 to 8.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	47.9 (14.3 to 95.7)	-7.6 (-29.2 to 22.8)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	1.4 (0.9 to 2.0)	1.9 (1.3 to 2.8)	41.6 (32.1 to 51.9)	1.2 (-5.1 to 8.3)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.0 (1.9 to 58.6)	-1.9 (-19.9 to 25.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.8 (5.9 to 40.2)	-4.3 (-17.2 to 9.7)
Thalassemia trait	18.1 (14.2 to 23.2)	28.5 (21.3 to 36.5)	55.3 (40.1 to 81.4)	0.0 (-9.8 to 16.9)	0.5 (0.4 to 0.8)	0.8 (0.5 to 1.1)	46.8 (32.0 to 60.7)	-0.2 (-9.2 to 8.4)
Sickle cell disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	48.7 (32.4 to 73.3)	4.4 (-6.3 to 18.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.8 (38.6 to 64.9)	3.4 (-4.5 to 11.6)
Sickle cell trait	45.1 (40.4 to 49.7)	69.9 (62.2 to 77.0)	55.0 (49.1 to 60.7)	0.2 (-3.9 to 3.5)	0.6 (0.3 to 0.6)	0.6 (0.4 to 0.9)	34.7 (12.3 to 51.9)	-0.5 (-15.8 to 12.7)
G6PD deficiency	70.2 (55.7 to 83.6)	115.6 (89.1 to 143.4)	63.7 (21.4 to 126.5)	5.6 (-21.7 to 46.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.2 (4.3 to 91.0)	4.4 (-26.6 to 26.3)
G6PD trait	317.3 (292.0 to 342.2)	487.6 (445.3 to 524.0)	53.5 (37.9 to 73.0)	-1.4 (-11.4 to 11.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.2 (-50.6 to 263.1)	14.4 (-58.8 to 167.7)
Other hemoglobinopathies and hemolytic anemias	13.2 (12.2 to 14.4)	20.5 (19.4 to 21.6)	54.4 (39.0 to 71.1)	4.6 (-4.9 to 14.2)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.7)	41.5 (21.2 to 75.0)	5.1 (-9.8 to 28.7)
Endocrine, metabolic, blood, and immune disorders	16.0 (14.2 to 18.0)	25.0 (22.2 to 27.4)	56.5 (35.7 to 80.1)	0.5 (-5.6 to 21.8)	0.8 (0.3 to 0.7)	0.8 (0.5 to 1.1)	50.4 (25.8 to 86.6)	6.9 (-10.0 to 29.4)
Musculoskeletal disorders	-	-	-	-	36.5 (25.3 to 49.4)	74.1 (52.3 to 99.6)	103.2 (73.3 to 135.6)	3.8 (-10.5 to 16.6)
Rheumatoid arthritis	6.9 (6.4 to 7.3)	13.9 (12.9 to 14.9)	101.8 (82.8 to 123.4)	-1.7 (-11.2 to 8.7)	1.6 (1.1 to 2.1)	3.2 (2.3 to 4.3)	99.4 (80.7 to 121.2)	-1.8 (-11.3 to 9.3)
Osteoarthritis	61.6 (59.5 to 64.1)	145.9 (140.3 to 151.4)	137.0 (124.4 to 149.8)	3.8 (-3.5 to 7.1)	1.8 (2.6 to 5.1)	8.9 (6.2 to 12.0)	136.3 (123.3 to 150.0)	1.8 (-3.8 to 7.4)
Low back and neck pain	-	-	-	-	26.3 (17.2 to 36.7)	48.2 (32.7 to 66.3)	44.2 (46.4 to 127.5)	-2.3 (-21.4 to 16.4)
Low back pain	176.0 (144.9 to 213.5)	316.0 (275.8 to 372.6)	80.3 (37.6 to 138.2)	-4.6 (-25.9 to 20.8)	19.7 (12.5 to 28.1)	35.1 (23.4 to 50.0)	79.0 (37.2 to 138.5)	-4.6 (-25.7 to 21.6)
Neck pain	66.6 (51.2 to 82.0)	133.1 (103.7 to 173.1)	99.2 (48.0 to 179.2)	3.4 (-23.6 to 46.5)	6.6 (4.2 to 9.6)	13.1 (8.3 to 19.1)	98.7 (46.1 to 180.7)	3.7 (-23.6 to 45.7)
Gout	1.0 (0.9 to 1.1)	2.3 (1.9 to 2.6)	131.3 (81.7 to 182.4)	4.0 (-17.5 to 26.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	130.7 (69.4 to 210.3)	4.3 (-23.2 to 40.1)
Other musculoskeletal disorders	52.5 (44.1 to 62.1)	150.6 (123.7 to 179.9)	187.2 (166.6 to 206.0)	35.0 (26.1 to 43.2)	4.8 (3.2 to 6.8)	13.7 (9.1 to 19.5)	34.7 (165.5 to 205.6)	2.7 (-25.9 to 43.3)
Other non-communicable diseases	-	-	-	-	38.3 (26.1 to 55.1)	66.4 (45.5 to 95.0)	73.6 (66.9 to 79.9)	-6.7 (-9.7 to -3.8)
Congenital anomalies	-	-	-	-	3.0 (2.2 to 4.0)	5.8 (4.2 to 7.6)	90.0 (63.3 to 118.8)	21.0 (3.3 to 39.4)
Neural tube defects	0.9 (0.7 to 1.1)	1.1 (1.0 to 1.3)	31.2 (2.0 to 70.7)	-8.6 (-31.4 to 18.5)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	29.0 (-16.4 to 81.1)	-9.5 (-40.5 to 28.0)
Congenital heart anomalies	13.5 (11.0 to 16.8)	25.1 (21.2 to 30.1)	84.9 (42.6 to 141.4)	24.7 (-3.7 to 63.2)	0.5 (0.2 to 0.8)	0.9 (0.4 to 1.6)	87.1 (46.7 to 137.5)	27.9 (-0.2 to 63.4)
Orofacial clefts	2.9 (2.2 to 3.8)	4.4 (3.3 to 5.7)	55.1 (3.7 to 112.1)	8.0 (-27.5 to 48.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	30.1 (-16.9 to 96.6)	-9.3 (-41.8 to 35.8)
Down syndrome	2.9 (2.3 to 3.6)	5.2 (4.3 to 6.3)	75.3 (31.8 to 137.3)	11.2 (-16.5 to 50.7)	0.4 (0.3 to 0.5)	0.7 (0.5 to 1.0)	88.8 (40.6 to 162.3)	13.6 (-16.0 to 58.3)
Turner syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	51.8 (-13.4 to 154.0)	1.4 (-42.3 to 69.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.2 (-17.0 to 159.4)	0.1 (-44.9 to 70.6)
Klinefelter syndrome	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	55.4 (11.1 to 122.6)	1.1 (-27.7 to 45.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.3 (16.0 to 134.2)	1.5 (-27.5 to 45.6)
Chromosomal unbalanced rearrangements	4.5 (3.9 to 5.5)	7.7 (6.5 to 9.6)	70.9 (35.0 to 126.8)	6.4 (-14.3 to 47.7)	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.4)	82.2 (163.5 to 146.7)	10.5 (-13.3 to 49.8)
Other congenital anomalies	11.6 (9.8 to 13.4)	16.2 (13.7 to 18.8)	40.5 (29.3 to 52.5)	-12.6 (-19.1 to -5.6)	1.3 (0.8 to 1.9)	2.7 (1.8 to 3.8)	109.7 (66.1 to 177.6)	33.0 (8.5 to 75.3)
Skin and subcutaneous diseases	-	-	-	-	12.2 (7.8 to 18.3)	19.1 (12.6 to 29.1)	56.4 (43.7 to 71.7)	-1.5 (-9.6 to 5.8)
Dermatitis	125.7 (103.1 to 149.7)	205.4 (168.3 to 243.9)	63.3 (58.3 to 68.8)	0.0 (-0.0 to 0.1)	3.8 (2.4 to 5.5)	6.0 (3.8 to 8.8)	57.4 (50.4 to 64.9)	0.3 (-2.4 to 2.9)
Psoriasis	18.9 (16.6 to 21.3)	33.1 (28.9 to 37.5)	75.4 (71.8 to 80.1)	1.5 (-0.1 to 0.0)	0.0 (1.0 to 2.2)	2.7 (1.8 to 3.8)	74.4 (63.5 to 86.0)	0.1 (-4.9 to 5.6)
Cellulitis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	70.0 (55.5 to 86.0)	-0.9 (-11.9 to 7.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.6 (52.9 to 89.5)	-1.1 (-14.1 to 11.2)
Pyoderma	0.8 (0.6 to 1.0)	1.3 (1.0 to 1.8)	72.7 (37.9 to 125.2)	15.5 (-6.2 to 46.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.5 (31.5 to 135.0)	16.1 (-9.8 to 51.6)
Scabies	26.0 (23.0 to 29.4)	38.6 (34.7 to 43.6)	47.7 (24.9 to 78.6)	0.4 (-15.0 to 20.6)	0.7 (0.4 to 1.1)	1.0 (0.6 to 1.6)	47.5 (24.0 to 80.2)	0.4 (-15.7 to 21.7)
Fungal skin diseases	177.4 (134.4 to 233.8)	299.0 (230.1 to 390.9)	67.2 (58.7 to 77.4)	1.0 (-0.0 to 0.1)	1.7 (1.4 to 2.2)	1.7 (0.7 to 3.7)	69.3 (57.8 to 77.0)	0.2 (-0.2 to 1.0)
Viral skin diseases	46.3 (35.8 to 55.9)	63.3 (49.3 to 77.8)	36.7 (30.8 to 42.3)	0.0 (-2.4 to 2.4)	0.0 (0.8 to 2.3)	2.0 (1.1 to 3.1)	36.6 (29.3 to 44.2)	0.2 (-3.5 to 4.1)
Acne vulgaris	134.9 (89.4 to 194.4)	199.1 (127.5 to 273.3)	48.8 (-19.5 to 171.9)	10.7 (-39.9 to 95.4)	1.5 (0.6 to 2.9)	2.2 (0.9 to 4.5)	49.1 (-20.0 to 173.4)	11.5 (-40.0 to 95.7)
Alopecia areata	2.2 (2.0 to 2.4)	3.7 (3.4 to 4.1)	73.7 (51.1 to 97.5)	-0.3 (-12.9 to 13.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	72.3 (41.6 to 105.1)	-0.1 (-16.6 to 16.9)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.1 (42.6 to 128.1)	-1.4 (-24.4 to 24.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.1 (42.2 to 128.1)	-1.4 (-24.5 to 24.8)
Urticaria	23.6 (17.3 to 33.9)	32.5 (19.9 to 48.0)	37.0 (-16.5 to 134.7)	-21.6 (51.7 to 36.9)	1.4 (0.8 to 2.3)	1.9 (1.0 to 3.3)	35.3 (-17.6 to 138.0)	-22.1 (-52.6 to 36.6)
Decubitus ulcer	0.3 (0.3 to 0.4)	0.9 (0.7 to 1.1)	182.1 (101.0 to 273.6)	23.2 (-14.5 to 67.2)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	173.1 (93.2 to 278.3)	21.9 (-17.8 to 73.1)
Other skin and subcutaneous diseases	126.8 (85.3 to 188.6)	243.5 (155.4 to 383.6)	91.7 (73.4 to 109.9)	-1.5 (-5.4 to 3.0)	0.7 (0.3 to 1.6)	1.4 (0.6 to 3.0)	90.9 (72.7 to 109.2)	-1.3 (-5.4 to 3.1)
Sense organ diseases	-	-	-	-	16.7 (11.5 to 23.4)	29.9 (20.8 to 41.8)	78.7 (71.3 to 87.6)	-12.0 (-15.0 to -8.3)
Glaucoma	3.8 (3.2 to 4.5)	6.4 (5.3 to 7.8)	67.6 (46.4 to 94.2)	-22.2 (-33.0 to -9.5)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	76.4 (48.6 to 108.3)	-20.6 (-33.8 to -5.4)
Cataract	14.1 (11.3 to 17.3)	25.1 (20.0 to 30.5)	78.1 (59.0 to 99.0)	-28.4 (-35.6 to -19.2)	1.0 (0.6 to 1.4)	1.8 (1.2 to 2.5)	86.4 (65.0 to 107.9)	-25.6 (-33.7 to -17.3)
Macular degeneration	4.9 (3.8 to 6.2)	12.2 (9.5 to 14.8)	148.6 (104.0 to 202.8)	6.7 (-13.6 to 32.6)	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.8)	147.8 (102.1 to 202.6)	6.0 (-14.1 to 30.5)
Uncorrected refractive error	217.8 (180.1 to 244.4)	402.6 (358.2 to 454.0)	84.5 (58.9 to 120.9)	6.7 (-18.5 to 10.9)	3.6 (2.2 to 5.7)	6.1 (3.7 to 10.0)	71.7 (55.8 to 94.9)	-12.6 (-19.3 to -0.7)
Age-related and other hearing loss	295.8 (275.4 to 317.9)	564.9 (530.7 to 604.4)	90.8 (83.8 to 100.2)	-9.4 (-12.1 to -5.8)	9.5 (6.5 to 13.2)	17.7 (12.1 to 24.5)	106.0 (73.9 to 100.2)	-8.0 (-14.3 to -5.4)
Other vision loss	9.3 (8.0 to 10.7)	11.6 (10.0 to 13.4)	25.5 (15.2 to 38.1)	-33.8 (-38.9 to -27.4)	0.7 (0.5 to 1.0)	1.0 (0.6 to 1.3)	34.7 (22.2 to 50.8)	1.0 (-37.8 to -25.2)
Other sense organ diseases	56.6 (53.8 to 59.5)	88.1 (84.2 to 92.1)	55.6 (45.9 to 66.7)	-4.4 (-6.3 to 6.3)	1.5 (0.9 to 2.2)	2.3 (1.4 to 3.5)	54.6 (43.2 to 66.9)	-0.1 (-6.9 to 7.4)
Oral disorders	-	-	-	-	6.4 (3.8 to 10.0)	11.7 (7.0 to 18.3)	83.2 (77.0 to 89.6)	-8.6 (-12.1 to -4.8)
Deciduous caries	187.8 (178.7 to 197.0)	290.9 (219.1 to 242.2)	23.0 (14.9 to 31.4)	0.6 (-6.0 to 7.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	23.5 (12.0 to 35.1)	1.0 (-7.9 to 10.5)
Permanent caries	1,018.8 (977.1 to 1,066.4)	1,620.0 (1,526.4 to 1,698.4)	59.3 (47.6 to 68.9)	1.5 (-5.7 to 7.6)	1.0 (0.5 to 1.9)	1.6 (0.7 to 3.1)	59.0 (47.1 to 68.9)	1.7 (-5.6 to 7.8)
Periodontal diseases	234.0 (222.7 to 245.8)	489.9 (464.6 to 514.4)	109.5 (95.4 to 123.8)	5.1 (-1.9 to 12.2)	1.5 (0.6 to 3.2)	3.2 (1.3 to 6.5)	109.1 (94.9 to 123.5)	5.2 (-1.8 to 12.4)

Appendix Table G.4 - Panama prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	94.6 (92.0 to 97.1)	176.8 (172.7 to 181.0)	86.8 (80.3 to 93.7)	-18.5 (-21.4 to -15.5)	2.6 (1.8 to 3.6)	4.9 (3.3 to 6.7)	86.1 (79.3 to 93.3)	-18.5 (-21.6 to -15.5)
Other oral disorders	39.8 (37.4 to 42.1)	66.8 (63.2 to 70.3)	67.9 (54.9 to 81.6)	-1.0 (-8.4 to 6.6)	1.2 (0.7 to 1.7)	2.0 (1.2 to 3.0)	67.6 (54.4 to 82.2)	-0.9 (-8.4 to 7.2)
Injuries	-	-	-	-	11.7 (8.9 to 15.1)	12.8 (9.2 to 17.3)	8.8 (2.8 to 22.4)	43.1 (-49.0 to -36.1)
Transport injuries	-	-	-	-	4.4 (3.3 to 5.7)	4.2 (3.0 to 5.8)	-4.7 (-17.5 to 10.1)	-50.3 (-56.7 to -42.9)
Road injuries	-	-	-	-	4.1 (3.0 to 5.3)	3.7 (2.7 to 5.1)	-6.5 (-20.9 to 5.7)	-92.3 (-58.5 to -45.3)
Pedestrian road injuries	-	-	-	-	1.4 (1.0 to 1.8)	1.2 (0.8 to 1.6)	-11.6 (-24.7 to 4.0)	-53.9 (-60.0 to -46.6)
Cyclist road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	5.6 (-7.2 to 20.9)	-45.8 (-52.1 to -38.3)
Motorcyclist road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	9.1 (-6.0 to 27.7)	-44.8 (-52.1 to -35.7)
Motor vehicle road injuries	-	-	-	-	2.2 (1.6 to 2.8)	2.0 (1.5 to 2.8)	-6.5 (-20.9 to 8.8)	-90.9 (-58.4 to -43.3)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-47.8 (-55.2 to -39.5)	-72.8 (-76.4 to -68.5)
Other transport injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	38.0 (18.9 to 61.3)	-29.0 (-38.5 to -17.2)
Unintentional injuries	-	-	-	-	6.1 (4.7 to 7.9)	6.8 (5.0 to 9.2)	11.2 (1.1 to 21.7)	41.7 (-47.2 to -35.8)
Falls	-	-	-	-	2.1 (1.6 to 2.6)	2.8 (2.0 to 3.8)	37.8 (26.6 to 57.2)	-38.0 (-46.3 to -28.7)
Drowning	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-24.8 (-35.7 to -11.6)	-59.8 (-65.3 to -53.0)
Fire, heat, and hot substances	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-23.4 (-35.2 to -8.6)	-56.1 (-62.3 to -48.4)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.7 (-10.8 to 40.0)	-35.0 (-46.3 to -18.6)
Exposure to mechanical forces	-	-	-	-	3.1 (2.4 to 4.1)	2.7 (1.9 to 3.6)	-14.6 (-21.9 to -7.1)	-51.0 (-54.8 to -46.9)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-9.9 (-19.6 to 14.3)	-46.9 (-55.1 to -37.4)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.5 (35.8 to 80.1)	-8.2 (-20.0 to 3.6)
Other exposure to mechanical forces	-	-	-	-	3.0 (2.3 to 3.9)	2.5 (1.8 to 3.4)	-15.6 (-22.8 to -8.5)	-51.5 (-55.2 to -47.4)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.3 (67.7 to 92.8)	-9.0 (-15.1 to -1.9)
Animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	85.0 (67.7 to 105.3)	0.4 (-8.5 to 10.4)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	76.0 (55.8 to 100.4)	-2.7 (-13.0 to 9.5)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	91.9 (71.8 to 115.7)	2.5 (-7.5 to 14.2)
Foreign body	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	28.9 (13.8 to 46.6)	-31.3 (-38.8 to -22.5)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	1.3 (-16.7 to 22.8)	-45.4 (-54.5 to -34.9)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.5 (38.7 to 72.6)	-12.6 (-21.2 to -1.6)
Foreign body in other body part	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	49.0 (31.8 to 69.6)	-21.5 (-29.6 to -11.5)
Other unintentional injuries	-	-	-	-	0.3 (0.2 to 0.3)	0.6 (0.4 to 0.8)	136.2 (112.6 to 160.8)	23.3 (11.7 to 35.1)
Self-harm and interpersonal violence	-	-	-	-	1.1 (0.8 to 1.4)	1.7 (1.2 to 2.3)	51.3 (31.3 to 77.3)	-20.2 (-30.2 to -7.1)
Self-harm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	42.4 (26.7 to 60.8)	-29.6 (-37.3 to -21.0)
Interpersonal violence	-	-	-	-	1.0 (0.8 to 1.3)	1.6 (1.1 to 2.1)	52.0 (31.0 to 79.1)	-19.3 (-29.7 to -5.7)
Assault by firearm	-	-	-	-	0.3 (0.2 to 0.4)	0.7 (0.5 to 0.9)	121.0 (95.8 to 150.0)	15.2 (2.8 to 29.9)
Assault by sharp object	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.5)	55.7 (32.8 to 84.5)	-17.7 (-29.4 to -3.4)
Assault by other means	-	-	-	-	0.5 (0.4 to 0.6)	0.5 (0.4 to 0.7)	5.9 (-11.5 to 28.5)	-43.0 (-52.2 to -31.3)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	55.3 (22.1 to 101.0)	-14.0 (-34.7 to 11.0)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	55.3 (22.1 to 101.0)	-14.0 (-34.7 to 11.0)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Papua New Guinea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	341.4 (247.9 to 448.0)	600.0 (439.0 to 787.2)	75.9 (69.1 to 82.6)	75.9 (-7.8 to -1.4)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	101.3 (69.0 to 142.9)	147.7 (102.9 to 208.4)	45.7 (32.1 to 60.6)	45.7 (-24.7 to -4.8)
HIV/AIDS and tuberculosis	-	-	-	-	1.8 (1.2 to 2.4)	6.7 (4.6 to 9.2)	277.5 (207.4 to 391.6)	91.9 (56.0 to 152.8)
Tuberculosis	5.2 (4.9 to 5.5)	9.9 (9.5 to 10.3)	91.5 (81.6 to 101.7)	-2.6 (-6.6 to 1.7)	1.6 (1.1 to 2.2)	3.1 (2.1 to 4.1)	91.8 (75.9 to 110.4)	-1.9 (-9.3 to 5.6)
HIV/AIDS	-	-	-	-	0.2 (0.0 to 0.3)	3.6 (2.3 to 5.5)	2,293.3 (900.6 to 7,896.6)	1,677.7 (448.9 to 4,091.9)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	1,554.6 (618.1 to 5,390.0)	779.7 (276.3 to 2,715.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	1,458.3 (514.8 to 5,204.6)	715.0 (219.1 to 2,615.0)
HIV/AIDS resulting in other diseases	1.8 (0.5 to 3.4)	30.9 (25.9 to 36.6)	1,720.9 (734.7 to 6,293.8)	918.1 (368.0 to 3,425.0)	0.2 (0.0 to 0.3)	3.6 (2.2 to 5.4)	2,234.6 (897.8 to 8,102.1)	1,174.9 (441.3 to 4,305.5)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	17.4 (12.7 to 23.2)	24.5 (17.4 to 33.0)	40.8 (30.9 to 50.4)	-16.4 (-22.5 to -10.5)
Diarrheal diseases	46.0 (43.9 to 48.3)	76.0 (72.4 to 79.6)	65.6 (54.3 to 75.9)	2.2 (-4.6 to 8.4)	7.5 (5.1 to 10.3)	12.4 (8.4 to 17.3)	65.8 (52.2 to 78.1)	2.5 (-4.7 to 9.7)
Intestinal infectious diseases	-	-	-	-	0.7 (0.5 to 1.0)	0.9 (0.6 to 1.4)	32.4 (3.9 to 71.0)	9.1 (-37.9 to 1.9)
Typhoid fever	4.1 (3.6 to 4.7)	4.8 (4.2 to 5.4)	16.8 (-4.0 to 38.6)	-30.3 (-42.1 to -18.6)	0.5 (0.4 to 0.8)	0.6 (0.4 to 0.9)	16.9 (8.3 to 44.4)	-30.1 (-44.2 to -14.5)
Paratyphoid fever	2.3 (2.0 to 2.7)	2.2 (1.9 to 2.6)	-4.0 (-23.6 to 18.9)	-44.0 (-55.5 to -31.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-3.4 (-27.9 to 25.9)	-43.5 (-57.0 to -27.7)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.4)	361.8 (139.4 to 818.8)	175.5 (41.5 to 436.2)
Lower respiratory infections	8.8 (5.8 to 11.5)	9.3 (7.2 to 11.3)	4.8 (-21.1 to 56.9)	-29.2 (-43.8 to -1.5)	0.9 (0.5 to 1.4)	1.0 (0.6 to 1.4)	2.7 (-23.4 to 58.9)	-29.7 (-44.8 to -1.5)
Upper respiratory infections	127.8 (121.0 to 134.1)	220.1 (208.6 to 231.4)	72.3 (59.9 to 87.1)	-0.7 (-7.4 to 6.9)	1.5 (0.8 to 2.5)	2.6 (1.4 to 4.3)	72.5 (59.2 to 87.6)	-0.6 (-7.7 to 7.6)
Otitis media	59.8 (55.8 to 64.0)	91.3 (85.5 to 96.5)	53.0 (42.2 to 63.4)	-10.7 (-17.1 to -4.1)	1.2 (0.7 to 1.9)	1.8 (1.1 to 2.9)	52.4 (39.5 to 65.4)	-10.6 (-17.5 to -3.0)
Meningitis	-	-	-	-	5.0 (3.9 to 7.0)	4.8 (3.3 to 6.6)	-4.0 (-21.4 to 13.6)	-42.7 (-52.8 to -31.9)
Pneumococcal meningitis	26.8 (16.6 to 39.5)	26.6 (16.6 to 40.7)	-0.3 (-17.5 to 17.8)	-41.9 (-51.3 to -32.3)	2.5 (1.7 to 3.6)	2.4 (1.6 to 3.4)	5.4 (-32.7 to 25.4)	-43.4 (-58.5 to -28.1)
H influenzae type B meningitis	6.1 (2.7 to 10.8)	5.1 (2.0 to 9.7)	-17.4 (-45.3 to 16.2)	-51.9 (-67.2 to -35.5)	0.8 (0.5 to 1.2)	0.6 (0.4 to 1.0)	-21.0 (-52.8 to 44.6)	-52.4 (-71.4 to -16.1)
Meningococcal meningitis	3.1 (1.1 to 6.5)	3.1 (1.1 to 7.0)	0.4 (-22.6 to 27.9)	-42.8 (-54.2 to -28.6)	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.6)	-2.3 (-29.5 to 40.8)	-43.0 (-57.3 to -22.8)
Other meningitis	10.8 (5.7 to 19.6)	11.6 (6.2 to 20.1)	5.8 (-10.4 to 31.4)	-37.4 (-47.0 to -23.1)	1.3 (0.8 to 2.1)	1.4 (0.9 to 2.1)	4.9 (-17.1 to 52.6)	-36.8 (-50.0 to -8.3)
Encephalitis	1.1 (0.5 to 2.2)	1.7 (0.8 to 3.6)	56.3 (33.1 to 76.7)	-13.6 (-23.9 to -2.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	62.8 (30.6 to 93.0)	-8.4 (-23.3 to 7.5)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	58.1 (86.4 to 1,891.8)	-5.6 (-90.6 to 931.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.1 (86.7 to 1,903.9)	-5.6 (-90.9 to 939.6)
Whooping cough	5.2 (4.0 to 6.7)	9.0 (6.9 to 11.6)	71.5 (70.3 to 72.7)	11.4 (10.6 to 12.2)	0.3 (0.1 to 0.4)	0.4 (0.3 to 0.7)	71.9 (59.0 to 85.0)	11.6 (3.1 to 20.3)
Tetanus	0.1 (0.1 to 0.3)	0.0 (0.0 to 0.1)	-69.2 (-88.8 to -15.5)	-82.3 (-93.7 to -50.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-60.0 (-83.7 to -8.0)	-75.2 (-89.5 to -46.0)
Measles	0.6 (0.5 to 0.7)	0.6 (0.4 to 0.7)	-8.8 (-28.3 to 14.0)	-41.5 (-54.1 to -26.9)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.2 (-38.1 to 38.6)	-41.2 (-60.3 to -11.1)
Varicella and herpes zoster	4.6 (4.3 to 5.0)	7.9 (7.3 to 8.6)	70.7 (52.1 to 88.5)	-0.7 (-13.3 to 14.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	84.9 (46.9 to 131.9)	-0.5 (-19.9 to 23.0)
Neglected tropical diseases and malaria	-	-	-	-	35.6 (22.3 to 54.5)	54.7 (33.7 to 85.1)	52.7 (22.9 to 95.5)	-15.9 (-33.8 to 10.2)
Malaria	513.4 (490.8 to 539.0)	815.5 (771.9 to 862.3)	58.9 (51.7 to 64.7)	-10.9 (-14.6 to -7.8)	4.7 (2.9 to 7.2)	7.5 (4.8 to 11.3)	9.7 (44.3 to 73.0)	-9.7 (-19.5 to -2.8)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	200.0 (119.8 to 297.7)	62.9 (19.4 to 118.8)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.7 (-36.7 to 354.2)	13.4 (-55.5 to 145.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.7 (-36.8 to 354.5)	13.4 (-55.7 to 146.4)
Cutaneous and mucocutaneous leishmaniasis	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.5)	203.5 (139.9 to 275.0)	65.3 (32.2 to 100.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	201.0 (120.0 to 299.0)	63.1 (19.3 to 119.4)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	2.1 (1.2 to 3.2)	1.6 (0.8 to 2.7)	-21.3 (-65.5 to 84.4)	-56.0 (-79.2 to -11.0)	0.5 (0.3 to 0.9)	0.4 (0.2 to 0.8)	-19.6 (-65.5 to 90.9)	-55.1 (-79.6 to -2.8)
Cystic echinococcosis	0.7 (0.6 to 0.8)	1.4 (1.3 to 1.5)	96.5 (73.8 to 113.4)	12.0 (-2.9 to 22.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	94.7 (53.6 to 145.1)	11.1 (-10.8 to 35.6)
Lymphatic filariasis	176.4 (124.5 to 228.0)	232.1 (165.9 to 310.2)	30.0 (-2.3 to 112.1)	-32.2 (-47.4 to 5.2)	6.3 (2.7 to 12.0)	9.1 (3.8 to 17.2)	45.7 (14.1 to 90.2)	-27.9 (-50.2 to -3.3)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	3.6 (1.8 to 6.8)	3.2 (1.3 to 6.0)	-14.1 (-56.0 to 54.9)	-63.9 (-85.0 to -40.1)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.3)	-16.1 (-55.6 to 43.2)	-64.8 (-84.9 to -43.9)
Dengue	0.5 (0.2 to 1.0)	3.9 (1.5 to 8.8)	756.8 (747.8 to 767.3)	389.8 (384.7 to 395.8)	0.1 (0.0 to 0.2)	0.6 (0.2 to 1.5)	758.2 (571.0 to 1,030.8)	391.1 (295.9 to 519.4)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.2 (-28.4 to 86.3)	-27.1 (-58.6 to 3.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.2 (-28.4 to 86.7)	37.1 (-58.6 to 3.2)
Intestinal nematode infections	-	-	-	-	21.6 (12.1 to 36.6)	34.0 (19.3 to 58.2)	57.5 (10.4 to 131.2)	-8.3 (-40.1 to 39.6)
Ascariasis	1,038.2 (770.0 to 1,339.8)	1,686.4 (1,234.2 to 2,300.9)	62.2 (7.2 to 151.4)	-5.6 (-41.6 to 58.2)	3.5 (1.6 to 6.8)	1.9 (0.8 to 3.7)	-47.3 (-72.4 to 2.8)	-63.1 (-81.2 to -18.4)
Trichuriasis	-	-	90.1 (-23.4 to 334.0)	0.8 (-59.6 to 131.1)	-	-	-	-
Hookworm disease	2,482.9 (2,231.5 to 2,751.7)	4,470.2 (4,007.0 to 5,014.2)	80.9 (54.7 to 110.2)	0.6 (-14.9 to 19.2)	18.1 (10.2 to 30.7)	32.2 (18.0 to 54.9)	78.1 (20.0 to 169.7)	-1.0 (-37.3 to 57.0)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	58.6 (43.9 to 73.0)	73.6 (67.0 to 80.2)	25.1 (0.1 to 68.9)	-25.4 (-39.8 to -0.6)	2.1 (1.2 to 3.1)	2.7 (1.8 to 3.9)	24.1 (6.5 to 89.9)	-23.9 (-35.1 to 17.1)
Maternal disorders	-	-	-	-	0.2 (0.2 to 0.4)	0.4 (0.2 to 0.5)	39.7 (2.0 to 77.1)	-25.6 (-45.6 to -7.6)
Maternal hemorrhage	2.7 (2.4 to 3.2)	4.5 (3.1 to 5.9)	62.9 (14.4 to 322.2)	-13.4 (-39.8 to 18.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	45.3 (-14.8 to 101.2)	-22.0 (-54.4 to 6.4)
Maternal sepsis and other maternal infections	1.9 (1.3 to 2.7)	2.5 (1.8 to 3.3)	31.3 (14.1 to 47.4)	-35.6 (-44.5 to -27.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.6 (-47.0 to 108.3)	-38.1 (-70.2 to -0.7)
Maternal hypertensive disorders	1.0 (0.4 to 1.7)	1.4 (0.7 to 2.4)	47.4 (30.6 to 80.5)	-19.2 (-26.8 to -5.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	47.3 (17.6 to 91.2)	-19.3 (-34.7 to 3.9)
Obstructed labor	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-6.3 (-45.6 to 105.3)	-54.2 (-72.2 to -2.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.0 (-50.9 to 155.9)	-51.4 (-74.7 to 26.1)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	92.2 (18.3 to 200.9)	-5.7 (-38.2 to 41.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	92.2 (18.3 to 201.6)	-5.7 (-38.3 to 41.9)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	39.2 (-13.0 to 130.7)	25.9 (-53.1 to 22.6)
Neonatal disorders	-	-	-	-	6.0 (3.3 to 11.7)	13.6 (8.3 to 20.9)	134.4 (19.8 to 308.8)	40.3 (-27.8 to 142.3)
Preterm birth complications	18.6 (9.2 to 35.3)	68.1 (34.3 to 135.0)	266.0 (170.7 to 386.4)	104.6 (56.2 to 167.8)	1.5 (0.9 to 2.3)	6.0 (3.5 to 9.6)	311.7 (123.6 to 593.1)	142.0 (35.3 to 301.1)
Neonatal encephalopathy due to birth asphyxia and trauma	21.7 (5.4 to 51.9)	31.3 (9.6 to 72.3)	46.4 (15.8 to 101.3)	-18.9 (-36.1 to 12.7)	0.9 (0.4 to 1.5)	1.7 (0.9 to 2.7)	100.1 (16.8 to 275.8)	17.8 (-27.9 to 115.8)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	118.3 (182.0 to 252.7)	0.0 (-93.6 to 142.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	118.3 (169.4 to 268.8)	215.7 (84.9 to 153.2)
Hemolytic disease and other neonatal jaundice	1.9 (0.6 to 4.5)	3.9 (1.3 to 8.9)	115.8 (-55.9 to 740.6)	30.1 (-73.8 to 394.0)	0.6 (0.2 to 1.5)	1.3 (0.4 to 3.0)	114.7 (-52.3 to 751.1)	28.0 (-71.6 to 408.7)
Other neonatal disorders	-	-	-	-	3.1 (0.8 to 8.1)	4.6 (1.5 to 9.5)	63.3 (-42.0 to 291.9)	-2.2 (-64.8 to 127.9)
Nutritional deficiencies	-	-	-	-	36.7 (24.8 to 52.2)	42.8 (28.5 to 61.9)	16.7 (10.1 to 22.5)	-31.7 (-34.8 to -28.9)
Protein-energy malnutrition	24.8 (15.9 to 36.4)	18.0 (11.4 to 26.5)	-27.9 (-59.4 to 30.3)	-49.4 (-70.5 to -13.8)	3.1 (1.6 to 5.1)	2.2 (1.2 to 3.7)	-27.7 (-59.4 to 32.5)	50.0 (-70.8 to -11.5)
Iodine deficiency	1.9 (1.6 to 2.2)	2.3 (2.0 to 2.7)	22.5 (-0.5 to 53.9)	-34.6 (-47.2 to -15.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	24.7 (-2.7 to 64.7)	-33.3 (-48.3 to -11.5)
Vitamin A deficiency	5.8 (4.4 to 7.3)	5.5 (4.1 to 7.0)	-4.6 (-19.8 to 14.5)	-43.6 (-52.1 to -33.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-5.5 (-21.2 to 14.8)	44.4 (-33.6 to -33.3)

Appendix Table G.4 - Papua New Guinea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	944.2 (930.2 to 959.1)	1,193.6 (1,174.0 to 1,193.3)	25.4 (23.4 to 27.4)	-29.0 (-30.1 to -27.8)	33.0 (22.1 to 47.4)	39.9 (26.7 to 58.0)	21.3 (18.0 to 24.0)	-30.3 (-32.1 to -28.7)
Other nutritional deficiencies	-	-	-	-	0.4 (0.1 to 1.2)	0.4 (0.1 to 1.0)	-12.4 (-65.1 to 96.6)	-38.1 (-75.2 to 38.9)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	3.4 (2.2 to 5.2)	5.0 (3.2 to 7.6)	46.9 (32.7 to 61.3)	-15.4 (-22.7 to -8.3)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.5 (0.9 to 2.5)	2.6 (1.5 to 4.2)	70.2 (48.1 to 92.1)	-7.7 (-19.9 to 2.7)
Syphilis	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	15.9 (0.5 to 35.0)	39.2 (-46.5 to -11.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	16.5 (-17.4 to 60.8)	-48.9 (-53.6 to -19.7)
Chlamydial infection	255.8 (197.5 to 325.8)	381.2 (301.4 to 471.2)	48.5 (11.9 to 95.5)	-16.8 (-36.4 to 7.2)	1.0 (0.6 to 1.7)	1.8 (1.0 to 2.8)	71.5 (47.9 to 104.1)	-5.3 (-17.7 to 10.3)
Gonococcal infection	31.8 (21.4 to 44.6)	59.6 (40.0 to 79.2)	88.0 (8.6 to 233.0)	4.5 (-37.2 to 81.3)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	101.5 (39.2 to 190.1)	11.9 (-20.6 to 57.2)
Trichomoniasis	75.4 (50.5 to 105.3)	88.1 (60.4 to 119.0)	16.6 (-26.1 to 91.8)	-36.1 (-57.7 to 1.9)	0.1 (0.0 to 0.3)	0.1 (0.1 to 0.3)	9.3 (-36.9 to 95.5)	-40.0 (-63.4 to 5.2)
Genital herpes	544.2 (532.8 to 556.5)	1,057.1 (1,010.8 to 1,061.3)	90.8 (84.3 to 96.4)	3.3 (-4.4 to -0.4)	0.1 (0.0 to 0.4)	0.3 (0.1 to 0.7)	85.4 (75.2 to 95.4)	-3.2 (-7.9 to 1.7)
Other sexually transmitted diseases	1.3 (0.9 to 1.8)	1.8 (1.3 to 2.5)	38.2 (24.3 to 61.4)	-32.1 (-38.8 to -21.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.5 to 92.7)	27.8 (-47.4 to -3.5)
Hepatitis	-	-	-	-	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.7)	50.0 (34.0 to 69.1)	-20.0 (-29.8 to -7.7)
Hepatitis A	7.1 (6.7 to 7.4)	11.3 (10.8 to 11.7)	59.6 (58.7 to 60.6)	-1.4 (-1.4 to -1.3)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	69.7 (50.1 to 91.2)	1.4 (-9.4 to 14.1)
Hepatitis B	315.1 (274.3 to 351.8)	362.4 (329.1 to 401.6)	15.4 (-2.0 to 35.8)	-37.2 (-45.5 to -27.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	16.4 (-13.3 to 56.2)	-39.8 (-56.1 to -17.3)
Hepatitis C	171.2 (152.6 to 190.2)	243.7 (216.5 to 271.7)	42.0 (22.5 to 65.8)	-35.5 (-35.0 to -35.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.2 (11.0 to 81.6)	-24.5 (-43.7 to 0.2)
Hepatitis E	1.3 (1.2 to 1.5)	2.7 (2.4 to 3.1)	106.0 (71.1 to 140.7)	14.0 (-4.1 to 32.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	106.0 (61.0 to 165.7)	14.0 (-9.1 to 42.6)
Leprosy	0.5 (0.3 to 0.7)	0.8 (0.6 to 0.9)	57.4 (25.2 to 103.0)	-19.0 (-33.6 to 2.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	58.7 (17.2 to 119.8)	-18.0 (-36.6 to 8.1)
Other infectious diseases	42.0 (32.9 to 51.9)	51.7 (43.7 to 60.1)	23.3 (-1.9 to 50.2)	-27.6 (-41.8 to -12.7)	1.5 (0.9 to 2.2)	1.9 (1.2 to 2.8)	24.2 (5.1 to 47.7)	-24.8 (-42.9 to -10.0)
Non-communicable diseases	-	-	-	-	232.1 (171.3 to 299.9)	436.7 (324.3 to 569.4)	89.2 (81.3 to 95.6)	2.2 (-5.2 to 1.3)
Neoplasms	-	-	-	-	1.9 (1.1 to 3.0)	5.4 (3.0 to 9.0)	189.9 (91.3 to 352.4)	42.9 (-3.2 to 114.3)
Esophageal cancer	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.7)	158.3 (50.9 to 343.8)	24.7 (-26.0 to 105.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	154.2 (47.4 to 325.4)	21.9 (-27.4 to 100.2)
Stomach cancer	0.5 (0.3 to 0.8)	1.1 (0.7 to 1.7)	118.5 (39.3 to 245.3)	5.9 (-30.0 to 63.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	115.8 (35.7 to 239.9)	3.8 (-30.9 to 59.3)
Liver cancer	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	219.8 (85.5 to 481.4)	53.9 (-5.5 to 170.9)
Liver cancer due to hepatitis B	0.1 (0.1 to 0.2)	0.5 (0.2 to 0.9)	277.1 (80.7 to 701.2)	87.7 (-9.7 to 293.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	252.0 (85.9 to 600.9)	74.8 (-7.2 to 241.8)
Liver cancer due to hepatitis C	0.0	0.3	653.2	256.0	0.0	0.0	612.7	229.3
Liver cancer due to alcohol use	0.0	0.1	36.6	-35.6	0.0	0.0	32.6	-37.2
Liver cancer due to other causes	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	83.5 (-39.6 to 224.4)	-9.0 (-69.4 to 42.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.1 (-36.9 to 192.2)	-13.3 (-67.7 to 27.6)
Larynx cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	108.1 (-15.0 to 272.0)	8.2 (-59.1 to 84.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.9 (-13.3 to 228.8)	9.3 (-56.8 to 67.4)
Tracheal, bronchus and lung cancer	0.6 (0.4 to 1.0)	1.4 (0.8 to 2.2)	119.0 (39.4 to 259.5)	5.6 (-30.0 to 67.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	115.7 (34.8 to 250.6)	4.7 (-33.1 to 60.6)
Breast cancer	5.1 (3.0 to 8.4)	24.4 (17.3 to 37.1)	386.9 (205.4 to 681.5)	165.1 (73.7 to 310.9)	0.4 (0.2 to 0.7)	1.6 (0.9 to 2.9)	286.6 (141.2 to 529.1)	95.0 (-24.7 to 204.1)
Cervical cancer	5.3 (3.0 to 8.0)	10.6 (5.8 to 19.1)	98.4 (9.9 to 267.9)	8.8 (-46.3 to 65.9)	0.4 (0.2 to 0.7)	0.4 (0.4 to 1.5)	95.4 (10.5 to 254.8)	-7.4 (-45.3 to 58.1)
Uterine cancer	0.3 (0.1 to 0.7)	0.7 (0.3 to 1.8)	132.8 (26.8 to 351.7)	14.7 (-37.6 to 121.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	129.5 (30.9 to 349.0)	12.5 (-39.1 to 113.2)
Prostate cancer	0.8 (0.5 to 1.2)	3.4 (1.9 to 5.2)	315.0 (151.5 to 604.2)	92.8 (19.0 to 204.1)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.6)	311.4 (142.6 to 626.4)	96.1 (19.3 to 226.4)
Colon and rectum cancer	1.2 (0.8 to 1.7)	3.7 (2.3 to 5.8)	214.3 (104.7 to 409.0)	50.7 (1.5 to 132.2)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.6)	199.8 (93.2 to 376.3)	43.3 (-4.2 to 115.1)
Lip and oral cavity cancer	0.6 (0.3 to 0.9)	1.2 (0.5 to 2.0)	106.0 (15.4 to 279.6)	4.3 (-3.4 to 60.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	105.0 (23.5 to 273.7)	3.3 (-37.7 to 91.7)
Nasopharynx cancer	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.2)	118.7 (18.7 to 313.2)	10.1 (-39.3 to 106.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	101.9 (21.4 to 297.1)	6.1 (-39.7 to 95.5)
Other pharynx cancer	0.2 (0.1 to 0.4)	0.5 (0.2 to 1.0)	126.5 (13.6 to 363.8)	8.7 (-41.8 to 111.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	124.5 (17.4 to 338.4)	8.8 (-42.6 to 103.5)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	155.9 (49.1 to 361.5)	21.9 (-27.9 to 123.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	141.5 (44.8 to 333.9)	15.0 (-30.5 to 109.1)
Pancreatic cancer	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	202.8 (81.1 to 405.2)	43.2 (-10.7 to 125.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	195.6 (53.3 to 381.1)	38.7 (-13.0 to 116.7)
Malignant skin melanoma	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.7)	214.4 (70.4 to 494.8)	24.4 (-10.8 to 184.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	198.8 (88.4 to 469.3)	44.4 (-19.0 to 160.5)
Non-melanoma skin cancer	0.3 (0.2 to 0.5)	1.0 (0.7 to 1.6)	216.2 (107.2 to 361.7)	44.7 (0.0 to 107.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	227.4 (88.9 to 447.3)	51.0 (-9.6 to 152.1)
Ovarian cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	141.2 (30.2 to 356.3)	17.0 (-34.2 to 113.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	136.6 (28.9 to 347.1)	15.2 (-34.6 to 108.7)
Testicular cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	182.4 (45.6 to 452.1)	45.7 (-19.0 to 172.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	168.7 (40.7 to 495.8)	38.0 (-25.2 to 177.5)
Kidney cancer	0.8 (0.2 to 0.4)	0.8 (0.4 to 1.4)	106.1 (77.2 to 434.5)	62.2 (-3.1 to 183.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	204.9 (70.6 to 429.5)	56.2 (-5.7 to 176.2)
Bladder cancer	0.3 (0.2 to 0.4)	0.6 (0.3 to 1.0)	114.0 (40.6 to 251.1)	-8.7 (-36.5 to 39.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	103.8 (37.7 to 223.8)	-13.4 (-39.5 to 28.5)
Brain and nervous system cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.4)	148.6 (41.6 to 333.2)	36.1 (-14.5 to 124.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	149.6 (52.9 to 322.5)	31.4 (-16.1 to 112.6)
Thyroid cancer	0.7 (0.3 to 1.4)	2.2 (0.9 to 4.4)	197.3 (60.9 to 442.9)	49.8 (-17.4 to 174.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.3)	192.4 (52.7 to 447.5)	45.5 (-19.7 to 166.8)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.0 (24.1 to 283.6)	0.0 (-39.0 to 84.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.2 (23.1 to 286.7)	7.9 (-38.5 to 84.3)
Hodgkin lymphoma	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	180.4 (55.5 to 421.6)	57.7 (-10.3 to 178.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	167.8 (49.3 to 395.2)	45.8 (-14.1 to 155.5)
Non-Hodgkin lymphoma	0.3 (0.2 to 0.5)	1.0 (0.5 to 1.7)	195.5 (85.8 to 387.4)	54.6 (-2.9 to 152.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	189.2 (79.2 to 379.0)	49.0 (-7.6 to 142.3)
Multiple myeloma	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.8)	195.4 (55.9 to 415.3)	42.4 (-23.1 to 147.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	190.1 (43.1 to 457.8)	36.5 (-24.9 to 150.7)
Leukemia	0.8 (0.5 to 1.2)	2.4 (1.4 to 3.6)	188.6 (63.7 to 435.7)	66.4 (5.6 to 171.8)	0.1 (0.1 to 0.1)	0.3 (0.1 to 0.4)	182.8 (86.0 to 354.6)	52.2 (-0.1 to 132.2)
Other neoplasms	1.8 (1.2 to 2.6)	7.6 (4.2 to 12.1)	316.4 (153.0 to 588.1)	131.8 (47.4 to 272.4)	0.1 (0.1 to 0.2)	0.5 (0.3 to 0.9)	300.5 (150.2 to 546.3)	109.7 (33.0 to 231.0)
Cardiovascular diseases	-	-	-	-	9.4 (6.3 to 13.0)	20.1 (13.5 to 28.9)	114.5 (70.7 to 165.5)	11.2 (-6.4 to 31.6)
Rheumatic heart disease	116.7 (88.0 to 140.9)	203.8 (136.5 to 259.6)	76.9 (20.3 to 136.9)	-4.3 (-28.6 to 21.3)	5.6 (3.4 to 8.6)	9.8 (5.7 to 15.4)	77.3 (19.6 to 136.3)	-4.7 (-28.6 to 20.2)
Ischemic heart disease	11.4 (9.1 to 13.6)	25.9 (21.9 to 30.7)	127.6 (81.1 to 188.5)	2.0 (-17.5 to 27.4)	2.0 (0.6 to 1.2)	2.0 (1.4 to 2.9)	131.1 (90.2 to 198.4)	5.4 (-13.0 to 32.3)
Cerebrovascular disease	-	-	-	-	0.7 (0.5 to 1.0)	1.4 (1.0 to 1.9)	101.8 (70.8 to 167.6)	5.2 (-18.6 to 28.7)
Ischemic stroke	2.0 (1.7 to 2.3)	4.1 (3.5 to 4.9)	102.5 (68.6 to 171.9)	-5.8 (-20.4 to 25.7)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	103.4 (67.5 to 172.9)	-5.3 (-21.2 to 26.6)
Hemorrhagic stroke	2.7 (2.3 to 3.1)	5.5 (4.8 to 6.4)	101.1 (70.9 to 161.6)	-5.1 (-18.9 to 28.5)	0.4 (0.3 to 0.6)	0.8 (0.6 to 1.1)	101.0 (67.1 to 165.5)	-4.9 (-20.0 to 32.2)
Hypertensive heart disease	2.4 (2.1 to 2.8)	6.1 (5.2 to 7.0)	148.9 (95.8 to 211.7)	13.3 (-10.6 to 45.0)	0.3 (0.2 to 0.4)	0.7 (0.5 to 1.0)	148.6 (95.7 to 215.8)	34.1 (-11.0 to 44.9)
Cardiomyopathy and myocarditis	1.8 (1.6 to 2.1)	4.7 (4.2 to 5.2)	156.2 (121.0 to 198.3)	30.5 (9.4 to 56.3)	0.2 (0.1 to 0.3)	0.5 (0.4 to 0.7)	157.3 (118.3 to 212.6)	31.5 (8.4 to 61.6)
Atrial fibrillation and flutter	0.9 (0.6 to 1.3)	4.0 (2.9 to 6.0)	352.9 (161.2 to 562.8)	96.3 (-8.7 to 222.5)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.5)	346.8 (160.4 to 597.7)	95.4 (-8.9 to 225.7)
Peripheral vascular disease	30.8 (21.2 to 43.6)	67.4 (47.2 to 92.9)	114.1 (29.7 to 291.8)	-2.1 (-33.5 to 62.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	73.7 (-25.1 to 244.1)	-20.0 (-62.7 to 51.0)
Endocarditis	0.2 (0.2 to 0.4)	0.5 (0.3 to 0.7)	101.3 (62.3 to 151.9)	10.6 (-16.5 to 40.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	106.8 (55.5 to 183.2)	11.9 (-21.9 to 51.0)
Other cardiovascular and circulatory diseases	22.3 (15.4 to 30.7)	73.2 (40.0 to 106.9)	229.4 (72.4 to 439.4)	69.9 (-17.8 to 181.1)	1.6 (0.9 to 2.4)	5.2 (2.5 to 8.5)	220.0 (74.3 to 443.6)	61.3 (-18.5 to 180.7)
Chronic respiratory diseases	-	-	-	-	11.9 (7.9 to 16.8)	21.9 (14.6 to 30.0)	85.0 (57.9 to 123.8)	-7.4 (-20.5 to 10.7)
Chronic obstructive pulmonary disease	83.9 (79.4 to 88.8)	169.9 (161.2 to 179.5)	102.6 (96.2 to 108.3)	0.1 (-2.9 to 2.7)	7.1 (4.7 to 10.0)	14.4 (9.4 to 20.4		

Appendix Table G.4 - Papua New Guinea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	241.1 (219.8 to 260.4)	241.1 (49.9 to 72.1)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.5 (73.5 to 91.9)	-13.7 (-18.1 to -9.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.5 (72.8 to 91.0)	-14.0 (-18.4 to -9.0)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	90.2 (286.8 to 325.5)	99.0 (90.7 to 107.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	298.0 (277.6 to 317.9)	94.9 (84.5 to 105.5)
Asthma	52.8 (37.0 to 73.8)	93.2 (66.4 to 122.3)	76.3 (0.1 to 184.9)	-10.0 (-43.3 to 34.2)	2.3 (1.3 to 3.8)	4.1 (2.3 to 6.5)	76.6 (0.7 to 184.6)	-9.6 (-44.2 to 34.6)
Interstitial lung disease and pulmonary sarcoidosis	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.6)	106.8 (47.1 to 179.2)	2.4 (-22.4 to 36.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	106.7 (48.1 to 175.8)	1.7 (-25.1 to 35.3)
Other chronic respiratory diseases	-	-	-	-	2.5 (1.3 to 4.0)	3.3 (1.9 to 5.3)	35.9 (-3.9 to 90.5)	-31.2 (-51.6 to -4.0)
Cirrhosis	-	-	-	-	0.4 (0.2 to 0.5)	0.4 (0.3 to 0.6)	22.1 (7.5 to 40.6)	-32.1 (-39.0 to -23.6)
Cirrhosis due to hepatitis B	1.1 (0.9 to 1.2)	1.5 (1.3 to 1.7)	38.0 (13.0 to 68.4)	-23.3 (-35.9 to -7.5)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	36.9 (6.6 to 77.1)	-23.9 (-39.1 to -4.0)
Cirrhosis due to hepatitis C	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	37.4 (-24.2 to 118.7)	-20.8 (-54.2 to 26.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	38.0 (-32.3 to 135.3)	-20.8 (-58.0 to 35.2)
Cirrhosis due to alcohol use	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-20.4 (-43.6 to 12.8)	0.1 (-70.3 to -44.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-19.7 (-48.8 to 23.0)	-59.7 (-73.0 to -40.4)
Cirrhosis due to other causes	0.4 (0.3 to 0.5)	0.4 (0.4 to 0.6)	13.4 (-13.8 to 52.8)	-28.0 (-45.8 to -2.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	13.8 (-26.2 to 80.3)	-27.6 (-51.7 to 10.5)
Digestive diseases	-	-	-	-	3.0 (2.1 to 4.2)	4.6 (3.2 to 6.4)	51.2 (35.9 to 71.0)	-24.6 (-30.4 to -18.2)
Peptic ulcer disease	33.5 (28.7 to 37.1)	42.0 (36.7 to 46.3)	25.5 (9.0 to 43.1)	-38.8 (-45.3 to -31.0)	1.1 (0.7 to 1.5)	1.5 (1.0 to 2.1)	34.2 (12.5 to 60.7)	-34.3 (-43.7 to -25.6)
Gastritis and duodenitis	27.5 (24.7 to 29.7)	40.4 (35.9 to 44.1)	46.8 (29.1 to 67.6)	-25.9 (-33.0 to -18.3)	1.1 (0.7 to 1.5)	1.5 (1.0 to 2.2)	39.7 (13.9 to 87.1)	-27.1 (-34.6 to -11.7)
Appendicitis	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	38.8 (-4.2 to 127.1)	-25.7 (-47.2 to 9.6)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	42.3 (-16.7 to 158.3)	-23.1 (-53.3 to 27.2)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	80.7 (30.2 to 169.9)	-4.9 (-16.8 to 13.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.4 (16.7 to 190.8)	-3.9 (-27.5 to 30.5)
Inguinal, femoral, and abdominal hernia	16.1 (12.5 to 22.6)	24.7 (21.3 to 29.0)	57.7 (21.0 to 81.9)	-14.2 (-24.1 to -2.4)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.5)	56.9 (19.7 to 83.4)	-14.2 (-24.4 to -2.4)
Inflammatory bowel disease	0.6 (0.6 to 0.6)	1.1 (1.0 to 1.1)	80.2 (68.2 to 92.7)	-8.6 (-13.9 to -3.0)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	81.0 (50.7 to 121.4)	-8.1 (-21.7 to 8.5)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	138.3 (56.7 to 261.5)	95.9 (20.6 to 217.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	135.8 (53.5 to 259.0)	84.6 (4.9 to 241.1)
Gallbladder and biliary diseases	1.2 (1.1 to 1.4)	2.4 (2.1 to 2.7)	90.0 (58.1 to 122.1)	0.1 (-20.9 to 5.2)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	89.8 (56.9 to 129.0)	-7.2 (-22.3 to 7.5)
Pancreatitis	0.7 (0.6 to 0.7)	1.4 (1.3 to 1.5)	108.2 (90.6 to 128.7)	5.9 (-2.7 to 15.6)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	108.8 (73.8 to 149.6)	6.0 (-9.9 to 23.3)
Other digestive diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	128.6 (56.2 to 200.0)	15.5 (-21.0 to 47.9)
Neurological disorders	-	-	-	-	16.9 (11.2 to 23.6)	34.5 (22.6 to 47.6)	103.4 (68.8 to 140.3)	0.0 (-14.4 to 15.8)
Alzheimer disease and other dementias	6.6 (5.9 to 7.4)	15.0 (13.4 to 16.7)	126.0 (92.3 to 169.6)	0.6 (-14.9 to 21.5)	0.9 (0.7 to 1.2)	2.1 (1.5 to 2.8)	129.7 (94.7 to 173.2)	1.0 (-15.6 to 22.5)
Parkinson disease	1.3 (1.0 to 1.5)	2.8 (2.3 to 3.3)	117.1 (106.6 to 131.0)	-0.4 (-5.5 to 5.3)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	118.2 (95.3 to 143.8)	0.5 (-8.8 to 10.6)
Epilepsy	12.0 (9.0 to 15.0)	21.5 (15.7 to 26.4)	79.7 (22.1 to 156.3)	2.2 (-29.9 to 45.0)	3.5 (2.2 to 5.2)	6.5 (4.0 to 9.4)	86.9 (24.5 to 165.9)	6.6 (-28.6 to 52.2)
Multiple sclerosis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	258.6 (219.8 to 306.1)	0.0 (61.5 to 102.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	258.6 (219.5 to 306.2)	79.6 (61.5 to 102.2)
Migraine	257.3 (200.4 to 330.7)	307.1 (389.6 to 629.8)	98.4 (42.9 to 163.0)	8.7 (-25.0 to 33.2)	5.7 (5.1 to 13.4)	17.4 (10.0 to 27.2)	97.8 (43.4 to 163.6)	5.3 (-24.6 to 33.7)
Tension-type headache	486.8 (395.0 to 588.9)	929.3 (818.8 to 1,039.3)	91.4 (50.5 to 148.5)	0.6 (-19.2 to 24.1)	0.7 (0.4 to 1.3)	1.4 (0.7 to 2.5)	92.2 (50.5 to 151.1)	1.4 (-18.8 to 26.3)
Medication overuse headache	12.0 (8.2 to 15.7)	35.5 (24.3 to 46.6)	197.9 (156.0 to 241.7)	52.2 (31.6 to 74.5)	1.9 (1.1 to 3.0)	5.6 (3.2 to 8.7)	197.1 (152.3 to 245.5)	52.3 (30.5 to 77.6)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.2 (38.1 to 138.4)	5.7 (-19.7 to 36.4)	0.9 (0.5 to 1.4)	1.0 (0.7 to 1.6)	18.5 (-21.9 to 89.5)	-48.4 (-65.9 to -15.0)
Mental and substance use disorders	-	-	-	-	62.2 (49.9 to 80.9)	115.7 (83.3 to 149.7)	85.8 (80.7 to 91.1)	0.5 (-2.0 to 2.8)
Schizophrenia	10.7 (9.8 to 11.5)	21.1 (19.4 to 22.7)	97.3 (89.2 to 107.0)	-0.1 (-4.0 to 4.5)	7.0 (5.1 to 8.4)	13.8 (10.0 to 16.7)	97.9 (83.8 to 111.4)	0.4 (-5.8 to 6.6)
Alcohol use disorders	25.8 (23.3 to 28.2)	58.0 (52.6 to 63.6)	124.8 (111.1 to 140.1)	21.6 (14.9 to 29.2)	2.6 (1.7 to 3.7)	5.8 (3.8 to 8.3)	125.7 (107.9 to 144.8)	22.4 (13.3 to 31.8)
Drug use disorders	-	-	-	-	7.0 (4.6 to 9.5)	11.6 (7.9 to 15.9)	67.2 (40.4 to 97.2)	-6.6 (-20.6 to 8.6)
Opioid use disorders	3.7 (2.7 to 4.9)	7.4 (5.5 to 9.7)	100.9 (78.6 to 124.8)	0.8 (-9.7 to 12.7)	1.6 (1.0 to 2.2)	3.1 (2.0 to 4.5)	101.6 (71.0 to 133.7)	1.5 (-12.8 to 17.2)
Cocaine use disorders	3.0 (3.0 to 3.5)	5.9 (5.5 to 6.4)	82.9 (65.1 to 103.7)	0.4 (-8.4 to 10.9)	0.8 (0.3 to 0.6)	0.8 (0.5 to 1.2)	83.7 (48.0 to 125.5)	0.6 (-16.5 to 22.1)
Amphetamine use disorders	15.3 (13.1 to 17.5)	22.9 (19.9 to 26.2)	50.5 (19.6 to 86.8)	-12.7 (-29.0 to 6.8)	2.0 (1.2 to 3.0)	3.0 (1.8 to 4.6)	50.1 (18.4 to 90.6)	-12.6 (-30.4 to 9.2)
Cannabis use disorders	15.1 (13.4 to 16.9)	26.2 (23.3 to 29.0)	72.9 (71.5 to 74.5)	-0.0 (-0.1 to -0.0)	0.4 (0.3 to 0.7)	0.8 (0.5 to 1.1)	72.7 (54.5 to 92.2)	-0.0 (-9.7 to 10.7)
Other drug use disorders	-	-	-	-	2.5 (1.5 to 3.8)	3.9 (2.4 to 5.8)	55.2 (8.8 to 114.5)	-10.4 (-36.3 to 22.0)
Depressive disorders	-	-	-	-	18.1 (11.6 to 25.4)	34.8 (22.5 to 49.3)	91.9 (82.0 to 100.1)	0.5 (-3.9 to 4.6)
Major depressive disorder	69.1 (51.6 to 84.1)	131.0 (99.5 to 158.1)	89.9 (78.1 to 99.3)	0.1 (-5.5 to 5.6)	14.3 (8.9 to 20.9)	27.1 (16.9 to 39.6)	90.2 (77.5 to 100.8)	0.5 (-5.3 to 5.9)
Dysthymia	39.7 (33.9 to 45.4)	78.6 (67.3 to 90.0)	98.3 (95.7 to 101.2)	0.2 (0.1 to 0.3)	3.8 (2.5 to 5.5)	7.6 (5.0 to 11.0)	98.5 (92.1 to 105.2)	0.6 (-1.9 to 3.0)
Bipolar disorder	18.8 (15.0 to 22.2)	36.2 (29.5 to 42.5)	92.0 (80.2 to 107.3)	0.1 (-5.4 to 6.5)	3.9 (2.3 to 6.0)	7.4 (4.5 to 11.5)	91.8 (76.0 to 110.6)	0.3 (-6.6 to 8.1)
Anxiety disorders	97.7 (81.7 to 115.6)	178.9 (149.2 to 211.1)	83.1 (79.7 to 87.2)	0.2 (0.1 to 0.3)	9.1 (6.1 to 13.0)	16.6 (11.2 to 23.6)	83.0 (76.0 to 90.5)	0.5 (-2.3 to 3.6)
Eating disorders	-	-	-	-	0.5 (0.3 to 0.7)	0.7 (0.5 to 1.1)	65.7 (41.8 to 90.7)	-4.6 (-17.7 to 9.2)
Anorexia nervosa	1.2 (0.9 to 1.5)	1.8 (1.4 to 2.3)	55.4 (41.1 to 73.5)	-10.0 (-19.6 to 0.4)	0.2 (0.2 to 0.4)	0.4 (0.2 to 0.6)	57.6 (24.8 to 93.0)	-9.4 (-28.2 to 11.0)
Bulimia nervosa	1.0 (0.7 to 1.5)	1.8 (1.2 to 2.5)	74.8 (70.8 to 79.8)	-0.1 (-0.2 to -0.1)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.6)	75.2 (43.2 to 114.3)	-0.1 (-17.7 to 21.2)
Autistic spectrum disorders	-	-	-	-	5.1 (3.6 to 7.0)	9.0 (6.2 to 12.3)	75.6 (68.6 to 82.9)	0.1 (-3.2 to 3.6)
Autism	13.0 (12.3 to 13.7)	22.9 (21.7 to 24.1)	75.6 (75.2 to 76.0)	-0.2 (-0.2 to -0.2)	3.2 (2.2 to 4.5)	5.7 (3.8 to 7.9)	75.7 (66.3 to 85.1)	0.1 (-4.3 to 5.4)
Asperger syndrome	18.7 (17.6 to 19.9)	32.8 (30.8 to 34.8)	75.2 (74.6 to 75.8)	-0.2 (-0.2 to -0.2)	1.9 (1.3 to 2.6)	3.3 (2.3 to 4.6)	75.4 (67.4 to 83.7)	0.1 (-3.8 to 4.1)
Attention-deficit/hyperactivity disorder	33.3 (30.7 to 35.5)	53.6 (49.4 to 57.1)	61.0 (60.8 to 61.1)	0.2 (0.2 to 0.2)	0.4 (0.2 to 0.6)	0.7 (0.4 to 1.0)	61.4 (49.6 to 74.1)	0.4 (-6.7 to 8.4)
Conduct disorder	34.2 (31.3 to 36.2)	56.6 (51.5 to 57.9)	59.7 (59.6 to 59.9)	0.1 (0.1 to 0.1)	4.1 (2.6 to 6.0)	6.6 (4.1 to 9.6)	60.5 (52.0 to 69.6)	0.5 (-4.6 to 6.4)
Idiopathic intellectual disability	11.8 (6.7 to 19.9)	19.3 (11.0 to 32.8)	65.1 (10.3 to 129.5)	-1.3 (-31.3 to 34.5)	0.6 (0.3 to 1.1)	1.0 (0.5 to 1.8)	66.3 (9.3 to 133.2)	-1.4 (-32.8 to 35.1)
Other mental and substance use disorders	52.6 (49.0 to 56.0)	102.3 (95.6 to 108.5)	94.4 (93.1 to 95.8)	-0.2 (-0.3 to -0.1)	4.0 (2.7 to 5.3)	7.7 (5.2 to 10.4)	94.4 (86.2 to 103.0)	-0.0 (-3.9 to 3.8)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	27.6 (19.1 to 38.4)	50.0 (34.0 to 70.2)	81.6 (68.1 to 95.9)	-4.0 (-11.7 to 4.6)
Diabetes mellitus	204.6 (180.7 to 232.5)	395.8 (345.3 to 446.5)	93.8 (66.9 to 120.7)	-3.0 (-15.3 to 11.4)	12.8 (8.4 to 17.9)	24.9 (16.4 to 35.8)	94.7 (68.0 to 126.3)	-2.1 (-15.1 to 14.1)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.7 (84.7 to 114.6)	0.0 (6.9 to 20.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.7 (84.7 to 114.8)	12.5 (6.9 to 20.9)
Chronic kidney disease	-	-	-	-	2.9 (2.0 to 4.1)	5.5 (3.9 to 7.6)	87.5 (65.9 to 107.3)	-0.0 (-11.4 to 10.4)
Chronic kidney disease due to diabetes mellitus	12.6 (8.9 to 17.8)	35.7 (24.1 to 53.1)	186.6 (105.6 to 271.0)	42.4 (1.7 to 84.8)	0.3 (0.2 to 0.5)	0.8 (0.6 to 1.2)	172.7 (96.3 to 258.4)	36.7 (-1.1 to 80.4)
Chronic kidney disease due to hypertension	26.3 (16.4 to 40.8)	19.8 (13.5 to 30.0)	24.6 (46.5 to 6.8)	-55.6 (-67.3 to -39.5)	0.8 (0.5 to 1.1)	1.3 (0.9 to 1.9)	78.4 (34.8 to 130.8)	-4.7 (-27.3 to 18.9)
Chronic kidney disease due to glomerulonephritis	31.6 (21.2 to 44.0)	52.5 (33.0 to 81.4)	64.0 (23.3 to 118.4)	0.2 (-30.9 to 39.1)	0.2 (0.1 to 0.8)	0.4 (0.3 to 0.6)	64.0 (48.0 to 81.5)	0.4 (-7.6 to -41.8)
Chronic kidney disease due to other causes	63.0 (42.4 to 95.3)	137.0 (94.3 to 197.4)	115.4 (85.0 to 160.0)	9.8 (-7.1 to 36.1)	1.3 (0.9 to 1.8)	2.9 (2.0 to 4.1)	121.7 (82.1 to 170.7)	10.8 (-4.0 to 40.2)
Urinary diseases and male infertility	-	-	-	-	1.1 (0.7 to 1.6)	2.3 (1.5 to 3.3)	109.4 (86.8 to 133.5)	2.1 (-8.0 to 13.4)

Appendix Table G.4 - Papua New Guinea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	33.3 (31.2 to 35.4)	47.7 (44.9 to 50.5)	43.3 (31.7 to 54.3)	-34.2 (-39.1 to -29.3)	0.9 (0.6 to 1.3)	1.3 (0.9 to 1.8)	43.5 (31.6 to 55.9)	-34.0 (-39.0 to -28.8)
Other oral disorders	61.8 (57.9 to 65.3)	115.6 (109.8 to 121.6)	86.9 (73.0 to 103.7)	0.1 (-6.5 to 8.1)	1.8 (1.1 to 2.7)	3.4 (2.1 to 5.1)	86.7 (72.0 to 104.3)	0.1 (-6.8 to 9.1)
Injuries	-	-	-	-	8.0 (6.0 to 10.3)	15.6 (11.8 to 20.4)	96.0 (83.7 to 111.1)	6.4 (0.9 to 15.0)
Transport injuries	-	-	-	-	3.3 (2.5 to 4.3)	6.0 (4.4 to 7.9)	82.3 (70.4 to 95.8)	-0.8 (-6.1 to 5.4)
Road injuries	-	-	-	-	3.0 (2.2 to 3.9)	5.5 (4.1 to 7.3)	84.4 (71.9 to 98.3)	1.8 (-4.4 to 7.6)
Pedestrian road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.7 (0.5 to 0.9)	76.0 (59.4 to 94.3)	2.7 (-5.4 to 11.1)
Cyclist road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	95.3 (76.3 to 113.2)	6.4 (-3.7 to 16.2)
Motorcyclist road injuries	-	-	-	-	1.1 (0.9 to 1.5)	2.1 (1.6 to 2.8)	86.4 (70.8 to 102.5)	-0.6 (-7.7 to 6.8)
Motor vehicle road injuries	-	-	-	-	1.3 (1.0 to 1.7)	2.4 (1.8 to 3.1)	84.4 (67.1 to 103.7)	1.8 (-6.5 to 11.0)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	110.1 (93.1 to 126.8)	8.7 (1.0 to 15.3)
Other transport injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.6)	58.8 (45.1 to 76.6)	-19.8 (-25.9 to -11.8)
Unintentional injuries	-	-	-	-	3.6 (2.8 to 4.7)	7.3 (5.6 to 9.5)	101.8 (95.6 to 109.1)	5.2 (2.5 to 8.5)
Falls	-	-	-	-	1.6 (1.2 to 2.1)	3.2 (2.3 to 4.1)	99.8 (89.6 to 110.9)	2.8 (-1.1 to 7.4)
Drowning	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	66.3 (50.9 to 82.9)	-10.5 (-17.3 to -3.3)
Fire, heat, and hot substances	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	8.7 (6.2 to 20.9)	-41.8 (-49.5 to -35.5)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.3 (2.3 to 43.7)	-33.5 (-43.7 to -22.5)
Exposure to mechanical forces	-	-	-	-	1.0 (0.7 to 1.3)	2.2 (1.6 to 2.8)	120.1 (107.7 to 133.8)	16.6 (10.7 to 22.8)
Unintentional firearm injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	55.7 (45.7 to 69.0)	-18.3 (-23.0 to -11.9)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	99.7 (83.5 to 118.8)	6.7 (-1.1 to 15.7)
Other exposure to mechanical forces	-	-	-	-	0.9 (0.7 to 1.2)	2.0 (1.5 to 2.6)	125.6 (111.6 to 141.3)	19.6 (13.0 to 26.6)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	103.8 (90.1 to 117.8)	6.5 (-0.2 to 14.8)
Animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	110.6 (98.2 to 125.2)	8.9 (3.8 to 15.1)
Venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	119.2 (97.2 to 146.6)	13.0 (3.8 to 25.0)
Non-venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	103.8 (92.9 to 119.2)	5.6 (1.0 to 11.7)
Foreign body	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	94.5 (84.9 to 106.4)	3.2 (-1.1 to 8.3)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.5 (59.0 to 104.1)	3.8 (-5.4 to 12.6)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	84.1 (72.5 to 97.4)	-1.2 (-6.7 to 4.5)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	109.3 (95.6 to 126.2)	4.8 (-1.8 to 12.7)
Other unintentional injuries	-	-	-	-	0.5 (0.4 to 0.7)	1.1 (0.8 to 1.5)	121.3 (103.8 to 141.2)	16.2 (8.0 to 25.7)
Self-harm and interpersonal violence	-	-	-	-	0.4 (0.3 to 0.6)	0.8 (0.6 to 1.0)	84.1 (75.6 to 92.8)	-5.6 (-9.3 to -1.9)
Self-harm	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	79.0 (62.9 to 99.0)	-9.9 (-17.0 to -1.4)
Interpersonal violence	-	-	-	-	0.3 (0.2 to 0.4)	0.6 (0.5 to 0.8)	85.9 (76.5 to 94.7)	-3.9 (-8.4 to 0.1)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	82.7 (70.7 to 96.8)	-3.2 (-8.7 to 2.8)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	92.8 (78.1 to 108.8)	-1.1 (-8.5 to 6.5)
Assault by other means	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	83.9 (72.3 to 95.7)	-4.9 (-10.2 to 0.2)
Forces of nature, war, and legal intervention	-	-	-	-	0.6 (0.3 to 1.4)	1.5 (0.6 to 3.2)	151.2 (31.2 to 346.5)	78.2 (0.1 to 195.7)
Exposure to forces of nature	-	-	-	-	0.1 (0.1 to 0.3)	1.0 (0.4 to 2.0)	625.4 (515.4 to 770.9)	295.6 (234.3 to 378.7)
Collective violence and legal intervention	-	-	-	-	0.5 (0.2 to 1.1)	0.5 (0.2 to 1.3)	4.5 (-50.5 to 116.1)	-16.8 (-60.7 to 68.7)

Appendix Table G.4 - Paraguay prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	355.7 (270.5 to 475.7)	644.3 (478.2 to 836.5)	76.2 (72.9 to 79.6)	76.2 (-2.6 to 0.9)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	37.6 (26.1 to 51.9)	53.4 (38.2 to 72.0)	42.0 (32.6 to 54.4)	42.0 (-7.6 to 7.7)
HIV/AIDS and tuberculosis	-	-	-	-	1.2 (0.8 to 1.6)	2.7 (1.8 to 3.7)	130.7 (95.5 to 185.6)	24.3 (5.8 to 52.8)
Tuberculosis	3.4 (3.2 to 3.6)	5.7 (5.4 to 6.1)	69.2 (62.1 to 76.9)	-8.7 (-12.7 to -4.5)	1.0 (0.7 to 1.4)	1.8 (1.2 to 2.4)	68.4 (53.0 to 85.2)	-8.7 (-16.1 to -0.2)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.2)	0.9 (0.5 to 1.6)	794.7 (321.9 to 1,747.7)	389.6 (126.1 to 948.3)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	524.8 (173.8 to 1,251.0)	226.4 (41.1 to 631.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	524.8 (171.1 to 1,259.8)	226.4 (39.9 to 638.2)
HIV/AIDS resulting in other diseases	0.8 (0.4 to 1.4)	9.7 (6.6 to 14.4)	1,147.4 (567.4 to 2,052.4)	625.6 (293.2 to 1,152.5)	0.1 (0.0 to 0.2)	0.9 (0.5 to 1.6)	803.0 (322.1 to 1,802.0)	393.4 (125.5 to 998.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	9.4 (6.6 to 12.7)	9.9 (6.9 to 13.6)	6.1 (1.9 to 14.5)	-19.7 (-24.7 to -14.6)
Diarrheal diseases	36.9 (34.5 to 39.5)	34.3 (32.0 to 36.5)	-7.2 (-15.2 to 2.2)	-25.7 (-31.8 to -18.7)	6.1 (4.1 to 8.5)	5.6 (3.7 to 7.8)	5.0 (-16.6 to 2.2)	-26.0 (-32.8 to -18.7)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-58.0 to -21.2)	-
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.0 (-27.9 to 2.2)	-42.6 (-51.6 to -31.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.0 (-28.0 to 2.3)	-42.6 (-51.6 to -31.2)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.1 (-32.9 to 2.2)	-44.2 (-54.3 to -29.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-33.1 to 2.2)	-18.1 (-54.4 to -29.0)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-98.8 (-97.5 to -71.4)	-93.8 (-98.3 to -80.8)
Lower respiratory infections	3.0 (2.6 to 3.3)	4.0 (3.5 to 4.6)	34.0 (14.5 to 63.5)	1.6 (-10.7 to 18.9)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	32.6 (10.3 to 66.9)	1.2 (-14.9 to 21.8)
Upper respiratory infections	112.1 (107.2 to 117.1)	170.2 (162.5 to 177.9)	52.4 (42.1 to 61.0)	-2.0 (-8.4 to 3.6)	1.3 (0.7 to 2.2)	2.0 (1.1 to 3.4)	52.1 (41.0 to 62.3)	-2.0 (-8.8 to 4.5)
Otitis media	49.2 (46.4 to 52.2)	64.2 (60.8 to 67.7)	30.4 (20.3 to 40.6)	-11.7 (-18.3 to -5.1)	0.9 (0.6 to 1.5)	1.2 (0.7 to 2.0)	29.9 (18.4 to 41.7)	-11.9 (-18.9 to -4.1)
Meningitis	-	-	-	-	0.3 (0.0 to 0.5)	0.3 (0.2 to 0.5)	1.7 (-20.2 to 29.5)	-33.3 (-47.2 to -16.4)
Pneumococcal meningitis	1.0 (0.6 to 1.6)	0.9 (0.5 to 1.5)	-9.5 (-26.0 to 13.7)	-44.5 (-53.8 to -30.9)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	8.3 (-27.3 to 14.3)	-41.0 (-53.0 to -27.4)
H influenzae type B meningitis	0.9 (0.3 to 1.8)	0.8 (0.3 to 1.5)	-11.3 (-34.0 to 59.8)	-44.1 (-57.4 to 1.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-1.6 (-40.1 to 137.5)	-34.3 (-60.3 to 54.6)
Meningococcal meningitis	0.4 (0.1 to 0.9)	0.4 (0.1 to 0.9)	-0.0 (-31.8 to 26.7)	-41.8 (-55.3 to -19.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-5.0 (-42.0 to 53.6)	-39.4 (-61.2 to -3.4)
Other meningitis	0.7 (0.4 to 1.2)	0.7 (0.4 to 1.2)	0.0 (-19.2 to 32.0)	-35.0 (-48.4 to -11.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	10.3 (-23.2 to 63.8)	-25.5 (-47.8 to 10.0)
Encephalitis	0.4 (0.2 to 0.8)	0.5 (0.2 to 1.2)	15.5 (32.5 to 73.5)	-11.3 (-20.2 to 2.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	57.7 (26.2 to 90.2)	-5.6 (-22.9 to 12.7)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Whooping cough	5.1 (3.9 to 6.6)	3.5 (2.7 to 4.5)	-31.0 (-33.3 to -28.8)	-40.8 (-42.7 to -38.8)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-30.8 (-36.9 to -23.4)	-40.5 (-45.8 to -34.2)
Tetanus	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.0)	-83.3 (-90.7 to -70.7)	-89.3 (-94.1 to -81.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-79.2 (-90.4 to -60.8)	-86.2 (-93.5 to -74.2)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -99.9)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -99.9)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	3.5 (3.3 to 3.7)	4.8 (4.2 to 5.4)	36.5 (18.0 to 57.0)	-1.3 (-21.8 to 19.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	73.1 (16.2 to 149.3)	-2.8 (-37.3 to 39.9)
Neglected tropical diseases and malaria	-	-	-	-	6.8 (4.3 to 10.2)	9.3 (6.2 to 13.4)	39.0 (5.8 to 72.1)	-8.9 (-28.1 to 12.5)
Malaria	0.5 (0.4 to 0.6)	0.7 (0.6 to 0.8)	42.2 (24.8 to 59.8)	-11.0 (-22.3 to 0.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.7 (-26.9 to 100.4)	-30.0 (-54.8 to 20.0)
Chagas disease	113.2 (106.5 to 119.8)	182.2 (170.4 to 194.2)	61.0 (47.5 to 74.8)	-12.2 (-20.2 to -4.3)	1.8 (0.7 to 1.5)	1.8 (1.2 to 2.6)	7.8 (57.2 to 95.7)	1.1 (-22.2 to -3.4)
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	390.6 (192.1 to 339.0)	263.0 (192.1 to 339.0)
Visceral leishmaniasis	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	45.7 (10.0 to 90.2)	6.1 (-18.6 to 35.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.6 (8.2 to 93.8)	6.5 (-19.2 to 35.7)
Cutaneous and mucocutaneous leishmaniasis	0.6 (0.5 to 0.8)	4.1 (3.1 to 5.2)	586.6 (499.4 to 677.8)	370.0 (314.2 to 433.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	583.0 (436.8 to 745.4)	369.8 (282.9 to 472.8)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Cysticercosis	1.5 (0.5 to 2.9)	1.3 (0.5 to 2.6)	-16.4 (-64.2 to 97.2)	-53.3 (-79.0 to 3.7)	0.4 (0.1 to 0.9)	0.4 (0.1 to 0.9)	-10.2 (-62.2 to 122.4)	-49.1 (-78.2 to 17.0)
Cystic echinococcosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	50.5 (36.3 to 76.8)	-21.2 (-28.5 to -6.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.5 (35.0 to 85.0)	-17.6 (-29.5 to 2.5)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Dengue	0.9 (0.3 to 1.9)	6.6 (2.7 to 14.5)	679.1 (674.2 to 684.8)	388.4 (385.3 to 391.9)	0.1 (0.0 to 0.3)	1.1 (0.4 to 2.6)	675.7 (536.7 to 839.6)	387.7 (315.9 to 480.1)
Yellow fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Intestinal nematode infections	-	-	-	-	4.4 (2.5 to 7.1)	5.0 (3.1 to 7.6)	17.1 (-19.9 to 55.4)	-17.8 (-43.8 to 13.0)
Ascariasis	504.0 (370.6 to 680.7)	777.1 (567.1 to 1,063.6)	53.7 (-0.5 to 141.2)	-4.1 (-39.2 to 53.7)	1.2 (0.4 to 2.8)	0.3 (0.1 to 0.9)	-75.2 (-92.7 to -14.5)	-80.2 (-94.4 to -27.3)
Trichuriasis	280.3 (212.5 to 364.0)	412.3 (298.0 to 562.3)	46.5 (-4.0 to 123.5)	-9.3 (-43.1 to 43.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	16.2 (-80.6 to 650.9)	-25.9 (-90.2 to 441.8)
Hookworm disease	252.8 (206.9 to 330.3)	499.3 (334.8 to 557.6)	63.4 (15.8 to 131.4)	47.9 (-31.7 to 46.3)	3.2 (2.0 to 4.8)	4.7 (2.9 to 6.9)	49.9 (15.2 to 94.8)	3.1 (-24.7 to 40.2)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	27.7 (20.9 to 35.6)	34.4 (25.8 to 42.4)	25.3 (-10.5 to 72.8)	-2.0 (-29.6 to 34.2)	0.7 (0.4 to 1.2)	0.9 (0.5 to 1.4)	26.2 (-34.9 to 124.1)	-3.1 (-49.7 to 70.7)
Maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	12.1 (-4.3 to 31.9)	-36.0 (-45.2 to -25.2)
Maternal hemorrhage	0.5 (0.4 to 0.5)	0.7 (0.6 to 0.7)	49.3 (28.7 to 73.0)	-14.8 (-26.0 to -2.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.3 (-3.7 to 129.6)	-16.6 (-43.1 to 30.3)
Maternal sepsis and other maternal infections	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.7)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.3 (-15.9 to 20.4)	-43.2 (-52.6 to -31.6)
Maternal hypertensive disorders	1.0 (0.6 to 1.4)	1.1 (0.7 to 1.6)	10.3 (1.4 to 21.7)	-36.9 (-41.9 to -30.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	9.7 (-10.2 to 36.1)	-37.1 (-48.2 to -22.6)
Obstructed labor	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-	-	0.0 (-1.0 to 39.5)	0.0 (0.0 to 0.0)	21.2 (-22.8 to 88.0)	-31.0 (-53.9 to 2.3)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.4 (5.6 to 25.8)	-34.4 (-40.0 to -28.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.4 (5.5 to 25.8)	-34.4 (-40.0 to -28.8)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.3 (-40.1 to 48.7)	-46.5 (-65.7 to -15.9)
Neonatal disorders	-	-	-	-	4.9 (3.4 to 6.7)	11.0 (7.8 to 15.2)	121.4 (69.0 to 207.9)	44.7 (10.1 to 101.4)
Preterm birth complications	10.2 (7.5 to 13.4)	34.2 (25.8 to 44.5)	236.3 (177.2 to 309.7)	114.5 (78.4 to 159.3)	1.3 (0.9 to 1.9)	4.3 (3.0 to 5.9)	224.1 (134.0 to 346.1)	109.5 (52.5 to 188.5)
Neonatal encephalopathy due to birth asphyxia and trauma	16.1 (6.8 to 33.4)	19.9 (9.1 to 40.5)	23.8 (-6.2 to 76.0)	-21.7 (-39.7 to 10.3)	1.9 (1.2 to 3.0)	2.9 (1.9 to 4.4)	50.7 (-10.3 to 165.2)	-1.0 (-40.5 to 74.2)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	79.0 (48.5 to 118.6)	57.2 (30.4 to 92.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.8 (35.8 to 121.0)	88.8 (19.2 to 94.0)
Hemolytic disease and other neonatal jaundice	3.4 (1.7 to 5.8)	7.3 (3.0 to 13.2)	112.1 (-36.0 to 431.4)	36.2 (-59.0 to 234.8)	1.3 (0.6 to 2.3)	2.7 (1.1 to 4.8)	115.8 (-34.1 to 372.2)	38.7 (-57.1 to 206.7)
Other neonatal disorders	-	-	-	-	0.4 (0.2 to 0.6)	1.0 (0.6 to 1.6)	179.7 (53.8 to 405.9)	82.8 (1.0 to 228.2)
Nutritional deficiencies	-	-	-	-	13.5 (8.8 to 19.7)	17.4 (11.5 to 25.6)	29.5 (17.8 to 38.8)	-5.5 (-13.7 to 0.9)
Protein-energy malnutrition	2.2 (1.2 to 3.6)	3.6 (1.4 to 7.8)	52.8 (-42.8 to 355.3)	30.8 (-40.6 to 246.8)	0.3 (0.1 to 0.5)	0.4 (0.1 to 1.1)	51.5 (-46.3 to 369.4)	30.1 (-45.2 to 261.1)
Iodine deficiency	8.9 (3.3 to 14.0)	11.0 (5.0 to 16.7)	21.8 (-50.4 to 293.7)	-30.3 (-71.5 to 145.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	19.6 (-51.6 to 265.2)	-30.3 (-71.4 to 140.9)
Vitamin A deficiency	1.3 (1.0 to 1.6)	0.8 (0.6 to 1.0)	-37.0 (-44.1 to -29.5)	-55.8 (-60.4 to -50.8)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-38.8 (-50.4 to -26.0)	-57.9 (-65.0 to -49.1)

Appendix Table G.4 - Paraguay prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	95.3	-2.6
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.5 (90.9 to 106.9)	-2.6 (-6.1 to 1.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.9 to 102.5	(5.5 to 0.5)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.0	99.6	-2.3
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.0	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.1 (83.3 to 98.9)	-3.2 (-7.0 to 0.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.5	-2.8
Asthma	266.8 (252.3 to 282.2)	404.9 (378.1 to 432.8)	51.5 (39.1 to 65.2)	-5.3 (-12.1 to 2.3)	11.9 (7.8 to 17.1)	18.0 (11.7 to 25.8)	51.0 (38.0 to 64.8)	-5.4 (-12.6 to 2.4)
Interstitial lung disease and pulmonary sarcoidosis	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	91.4 (41.7 to 148.7)	-4.4 (-30.5 to 26.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.7	-4.1
Other chronic respiratory diseases	-	-	-	-	1.6 (1.0 to 2.4)	1.3 (0.8 to 2.0)	-18.1 (-43.4 to 14.5)	-58.8 (-71.7 to -42.0)
Cirrhosis	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	88.1	12.4
Cirrhosis due to hepatitis B	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	160.3 (41.5 to 395.9)	34.9 (-21.7 to 142.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	157.4	32.4
Cirrhosis due to hepatitis C	0.2 (0.2 to 0.3)	0.6 (0.4 to 0.8)	159.8 (78.2 to 311.5)	46.5 (-3.4 to 128.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	155.7	45.6
Cirrhosis due to alcohol use	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	74.5 (22.2 to 196.1)	-10.8 (-37.3 to 38.9)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	73.0	-11.6
Cirrhosis due to other causes	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	70.4 (15.1 to 117.9)	14.1 (-25.0 to 48.3)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	65.9	9.5
Digestive diseases	-	-	-	-	2.5 (1.8 to 3.3)	5.8 (4.2 to 7.7)	121.2	19.3
Peptic ulcer disease	14.3 (13.7 to 14.9)	18.2 (17.3 to 19.2)	27.6 (19.8 to 36.2)	-40.8 (-44.7 to -36.8)	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.9)	39.1	-33.4
Gastritis and duodenitis	10.4 (9.9 to 10.8)	30.9 (29.7 to 32.0)	197.9 (182.3 to 214.1)	56.2 (48.9 to 63.6)	0.6 (0.4 to 0.8)	1.4 (0.9 to 1.9)	143.3	35.6
Appendicitis	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.2)	40.5 (15.5 to 71.9)	-11.7 (-26.6 to 6.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	42.2	-10.9
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	125.0 (90.4 to 169.1)	41.5 (28.1 to 57.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	121.2	39.2
Inguinal, femoral, and abdominal hernia	17.6 (15.6 to 20.2)	29.3 (25.9 to 33.4)	67.4 (39.2 to 96.4)	-18.3 (-30.5 to -2.2)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.6)	67.2	-17.9
Inflammatory bowel disease	3.7 (3.5 to 3.8)	8.9 (8.6 to 9.2)	143.0 (131.9 to 157.3)	26.1 (20.0 to 33.4)	0.8 (0.5 to 1.1)	1.9 (1.3 to 2.6)	142.9	26.4
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.9 (35.8 to 164.7)	1.2 (-34.9 to 38.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.0	-0.8
Gallbladder and biliary diseases	2.9 (2.4 to 3.3)	6.0 (5.2 to 6.8)	105.6 (81.1 to 154.6)	0.3 (-14.8 to 23.9)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	106.7	2.3
Pancreatitis	0.2 (0.2 to 0.2)	0.6 (0.5 to 0.6)	215.4 (193.4 to 238.1)	65.8 (54.6 to 78.4)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	211.4	64.8
Other digestive diseases	-	-	-	-	0.1 (0.1 to 0.1)	0.8 (0.5 to 1.1)	857.1	382.0
Neurological disorders	-	-	-	-	23.0 (15.4 to 31.5)	43.3 (29.6 to 59.6)	88.5	2.6
Alzheimer disease and other dementias	15.7 (13.9 to 17.4)	36.9 (32.5 to 41.3)	135.4 (99.5 to 176.8)	-1.9 (-17.0 to 16.5)	2.2 (1.6 to 2.9)	5.3 (3.8 to 6.9)	139.7	-4.2
Parkinson disease	0.4 (0.3 to 0.5)	0.9 (0.7 to 1.1)	117.9 (105.1 to 135.6)	-1.6 (-7.4 to 6.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	117.7	-1.0
Epilepsy	11.0 (7.6 to 14.7)	15.2 (10.4 to 20.2)	39.4 (-14.7 to 120.8)	-16.0 (-49.0 to 33.2)	3.4 (2.0 to 5.2)	5.1 (3.0 to 7.6)	49.0	-9.4
Multiple sclerosis	0.4 (0.3 to 0.4)	1.3 (1.2 to 1.3)	254.0 (224.7 to 285.7)	83.1 (67.9 to 99.1)	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.6)	245.4	78.6
Migraine	371.1 (327.1 to 409.5)	655.6 (590.2 to 733.5)	76.6 (51.7 to 106.5)	0.4 (-14.0 to 14.4)	12.7 (7.5 to 19.1)	22.4 (13.4 to 33.4)	76.0	-0.7
Tension-type headache	1,084.2 (950.1 to 1,224.8)	1,394.2 (1,296.9 to 1,490.0)	28.7 (11.8 to 48.7)	-29.2 (-37.5 to -19.3)	1.6 (0.8 to 2.9)	2.1 (1.0 to 3.8)	28.6	-29.2
Medication overuse headache	15.2 (9.9 to 21.0)	42.8 (27.0 to 59.2)	178.0 (120.4 to 288.3)	46.7 (16.0 to 99.0)	2.4 (1.4 to 3.7)	6.8 (3.7 to 10.8)	178.0	46.7
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.9 (22.6 to 126.9)	-0.8 (-28.2 to 35.1)	0.4 (0.2 to 0.6)	1.0 (0.7 to 1.4)	186.0	18.7
Mental and substance use disorders	-	-	-	-	107.4 (77.6 to 139.4)	185.1 (132.8 to 242.3)	72.5	-1.1
Schizophrenia	9.3 (8.5 to 10.1)	17.5 (16.1 to 18.9)	88.0 (80.6 to 97.8)	-0.2 (-3.8 to 4.4)	6.0 (4.5 to 7.3)	11.3 (8.3 to 13.7)	88.0	0.1
Alcohol use disorders	49.8 (45.2 to 54.4)	86.0 (78.4 to 94.0)	72.9 (62.9 to 83.2)	-4.1 (-9.3 to 1.2)	5.0 (3.3 to 7.0)	8.6 (5.6 to 12.1)	72.8	-4.1
Drug use disorders	-	-	-	-	4.3 (2.8 to 5.9)	7.7 (5.0 to 10.6)	80.4	1.5
Opioid use disorders	2.5 (1.3 to 4.2)	4.8 (2.3 to 8.1)	88.2 (71.0 to 107.9)	0.0 (-9.2 to 10.9)	1.1 (0.5 to 1.9)	2.0 (0.9 to 3.5)	87.6	0.2
Cocaine use disorders	4.0 (4.0 to 5.0)	7.8 (6.8 to 8.7)	74.5 (47.1 to 104.3)	0.2 (-15.4 to 15.4)	0.5 (0.4 to 0.9)	1.1 (0.7 to 1.5)	74.5	0.1
Amphetamine use disorders	7.2 (6.6 to 7.8)	13.0 (12.1 to 14.0)	81.9 (60.1 to 103.5)	4.5 (-7.2 to 16.3)	0.9 (0.6 to 1.4)	1.7 (1.0 to 2.5)	82.3	4.9
Cannabis use disorders	2.9 (2.5 to 3.3)	5.0 (4.2 to 5.7)	71.9 (70.8 to 73.3)	-0.1 (-0.1 to -0.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	72.0	0.1
Other drug use disorders	-	-	-	-	1.6 (1.0 to 2.4)	2.8 (1.7 to 4.1)	76.6	1.4
Depressive disorders	-	-	-	-	32.4 (21.3 to 46.3)	57.9 (38.1 to 81.3)	78.7	0.8
Major depressive disorder	137.1 (107.8 to 159.8)	243.2 (191.3 to 284.2)	77.8 (65.6 to 88.4)	-1.1 (-7.1 to 4.4)	28.3 (18.3 to 40.9)	50.1 (32.2 to 71.9)	77.3	-0.9
Dysthymia	42.6 (34.8 to 50.8)	80.6 (65.9 to 95.7)	89.3 (86.4 to 93.0)	-0.0 (-0.2 to 0.1)	4.1 (2.7 to 6.0)	7.8 (5.1 to 11.3)	89.0	0.0
Bipolar disorder	26.3 (22.2 to 30.1)	48.2 (40.6 to 55.6)	83.3 (72.4 to 94.5)	0.0 (-5.2 to 4.8)	5.4 (3.3 to 8.1)	9.8 (6.1 to 14.8)	83.2	0.1
Anxiety disorders	313.2 (276.8 to 347.3)	547.4 (483.4 to 608.7)	74.8 (72.8 to 76.5)	0.1 (-0.0 to 0.2)	29.0 (19.8 to 40.2)	50.5 (34.4 to 70.4)	74.2	0.1
Eating disorders	-	-	-	-	1.3 (0.7 to 2.0)	2.2 (1.3 to 3.4)	71.4	1.3
Anorexia nervosa	1.0 (0.7 to 1.2)	1.7 (1.3 to 2.2)	75.8 (59.9 to 96.5)	6.7 (-2.8 to 18.8)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	75.1	6.5
Bulimia nervosa	5.0 (3.3 to 7.3)	8.5 (5.5 to 12.5)	71.0 (68.3 to 73.3)	0.4 (0.2 to 0.6)	1.1 (0.6 to 1.7)	1.8 (1.0 to 2.9)	70.7	0.2
Autistic spectrum disorders	-	-	-	-	5.1 (3.5 to 6.8)	8.1 (5.6 to 10.9)	59.1	0.0
Autism	12.8 (12.2 to 13.5)	20.5 (19.5 to 21.6)	60.2 (59.5 to 61.0)	0.0 (0.0 to 0.0)	3.2 (2.1 to 4.3)	5.1 (3.4 to 6.8)	59.4	0.0
Asperger syndrome	18.9 (17.7 to 20.0)	30.1 (28.2 to 31.9)	59.2 (58.2 to 60.3)	0.0 (0.0 to 0.1)	1.9 (1.3 to 2.6)	3.0 (2.1 to 4.2)	58.8	0.1
Attention-deficit/hyperactivity disorder	37.6 (34.8 to 40.4)	54.5 (50.4 to 58.7)	45.1 (44.6 to 45.4)	0.1 (0.1 to 0.1)	0.5 (0.3 to 0.7)	0.7 (0.4 to 1.0)	44.9	-0.0
Conduct disorder	49.7 (46.5 to 52.9)	75.3 (68.6 to 78.2)	47.5 (46.4 to 48.3)	0.1 (0.1 to 0.1)	6.0 (3.7 to 8.6)	8.8 (5.5 to 12.8)	67.4	0.2
Idiopathic intellectual disability	186.6 (141.5 to 200.9)	238.0 (202.8 to 282.6)	41.3 (31.1 to 52.6)	-11.9 (-18.2 to -4.7)	8.3 (5.5 to 11.6)	11.7 (7.7 to 16.7)	40.9	-11.9
Other mental and substance use disorders	56.3 (52.5 to 59.8)	105.2 (98.5 to 111.5)	87.0 (85.8 to 88.1)	0.0 (-0.1 to 0.1)	4.2 (2.9 to 5.7)	7.9 (5.4 to 10.7)	86.6	0.0
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	24.4 (16.9 to 33.4)	48.5 (33.6 to 66.9)	98.3	14.2
Diabetes mellitus	108.1 (92.1 to 125.5)	285.6 (237.2 to 336.8)	163.1 (109.9 to 233.4)	36.2 (7.4 to 76.4)	7.6 (5.1 to 10.7)	20.6 (13.1 to 28.6)	164.5	33.4
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.4 (-14.5 to 0.6)	-30.7 (-35.2 to -25.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.4	-30.7
Chronic kidney disease	-	-	-	-	7.6 (5.4 to 10.1)	12.3 (8.8 to 16.1)	61.8	-1.6
Chronic kidney disease due to diabetes mellitus	87.8 (57.7 to 132.2)	180.6 (124.6 to 276.6)	103.5 (68.1 to 159.0)	4.8 (-16.5 to 31.1)	1.2 (0.9 to 1.6)	2.4 (1.6 to 3.2)	90.2	-0.6
Chronic kidney disease due to hypertension	74.6 (46.3 to 126.3)	128.8 (85.9 to 204.0)	74.5 (38.5 to 113.1)	1.5 (-18.5 to 23.8)	1.9 (1.3 to 2.5)	3.2 (2.3 to 4.4)	72.4	-1.1
Chronic kidney disease due to glomerulonephritis	102.4 (66.5 to 150.1)	189.8 (119.7 to 276.3)	79.5 (28.6 to 143.4)	1.4 (-25.0 to 30.5)	1.4 (1.0 to 2.0)	2.4 (1.6 to 3.3)	64.5	5.1
Chronic kidney disease due to other causes	139.0 (94.8 to 212.6)	231.6 (156.9 to 326.9)	67.1 (30.5 to 114.3)	-1.0 (-21.3 to 21.2)	3.1 (2.1 to 4.1)	4.4 (3.1 to 5.9)	42.3	-7.0
Urinary diseases and male infertility	-	-	-	-	0.7 (0.5 to 1.1)	1.6 (1.0 to 2.4)	125.6	11.0
							100.5 to 166.1	(0.9 to 29.8)

Appendix Table G.4 - Paraguay prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	217.2 (210.4 to 224.3)	429.5 (413.4 to 444.5)	97.8 (88.1 to 107.4)	-7.2 (-11.6 to -2.9)	6.0 (4.1 to 8.4)	11.9 (8.0 to 16.5)	97.5 (87.4 to 107.7)	-7.1 (-11.6 to -2.6)
Other oral disorders	64.0 (60.1 to 67.5)	112.6 (106.5 to 118.8)	76.1 (62.9 to 90.7)	-0.4 (-7.5 to 7.7)	1.9 (1.2 to 2.8)	3.3 (2.1 to 4.9)	75.7 (61.3 to 91.4)	-0.3 (-8.1 to 8.0)
Injuries	-	-	-	-	15.8 (12.1 to 20.4)	20.7 (15.2 to 27.4)	30.2 (20.2 to 41.5)	-30.9 (-36.2 to -25.1)
Transport injuries	-	-	-	-	3.4 (2.6 to 4.4)	4.8 (3.5 to 6.4)	40.5 (25.6 to 58.6)	-25.2 (-32.9 to -16.0)
Road injuries	-	-	-	-	3.2 (2.4 to 4.1)	4.5 (3.3 to 6.0)	39.8 (24.5 to 58.6)	-25.8 (-33.3 to -16.2)
Pedestrian road injuries	-	-	-	-	1.0 (0.8 to 1.3)	1.3 (0.9 to 1.7)	24.0 (8.6 to 42.6)	-33.3 (-41.0 to -24.0)
Cyclist road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	65.6 (48.3 to 84.1)	-11.9 (-21.4 to -2.5)
Motorcyclist road injuries	-	-	-	-	0.6 (0.5 to 0.8)	1.0 (0.7 to 1.3)	50.8 (31.4 to 72.0)	-19.2 (-29.2 to -8.6)
Motor vehicle road injuries	-	-	-	-	1.3 (1.0 to 1.7)	1.9 (1.4 to 2.5)	48.8 (26.9 to 64.0)	-23.8 (-32.1 to -13.3)
Other road injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	52.6 (34.7 to 71.3)	-20.7 (-29.7 to -11.5)
Other transport injuries	-	-	-	-	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	46.5 (32.0 to 66.6)	-22.3 (-30.2 to -11.5)
Unintentional injuries	-	-	-	-	11.2 (8.6 to 14.4)	14.5 (10.7 to 19.1)	28.9 (19.6 to 38.8)	-31.0 (-36.0 to -25.4)
Falls	-	-	-	-	4.9 (3.7 to 6.3)	7.2 (5.2 to 9.7)	45.9 (31.5 to 61.3)	-27.2 (-34.6 to -19.0)
Drowning	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-12.5 (-23.5 to 0.3)	-50.6 (-56.6 to -43.8)
Fire, heat, and hot substances	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	-7.4 (-19.6 to 5.4)	-47.0 (-53.4 to -40.0)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.2 (9.0 to 35.5)	-36.3 (-46.1 to -23.7)
Exposure to mechanical forces	-	-	-	-	3.9 (3.0 to 5.1)	3.5 (2.6 to 4.7)	-10.7 (-17.3 to -3.9)	-48.8 (-52.3 to -45.2)
Unintentional firearm injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	18.3 (5.1 to 33.8)	35.0 (-42.3 to -26.6)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.1 (68.2 to 126.9)	16.4 (1.5 to 31.5)
Other exposure to mechanical forces	-	-	-	-	3.7 (2.8 to 4.8)	3.2 (2.3 to 4.3)	-12.7 (-19.3 to -6.1)	-49.8 (-58.4 to -42.2)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	102.9 (90.3 to 115.4)	8.1 (1.5 to 14.6)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	63.2 (48.4 to 78.5)	-9.5 (-17.0 to -2.2)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.0 (40.3 to 80.7)	-11.5 (-21.3 to -2.1)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.7 (52.4 to 84.2)	-7.1 (-14.7 to 1.4)
Foreign body	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	39.0 (26.4 to 52.7)	-21.4 (-28.2 to -14.5)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.8 (-2.7 to 32.3)	-36.3 (-44.4 to -26.4)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.7 (45.0 to 74.1)	-6.5 (-14.8 to 1.6)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	54.9 (41.5 to 73.0)	-13.2 (-20.1 to -4.3)
Other unintentional injuries	-	-	-	-	1.7 (1.3 to 2.2)	3.1 (2.3 to 4.1)	79.0 (64.3 to 95.9)	-7.1 (-14.7 to 1.4)
Self-harm and interpersonal violence	-	-	-	-	0.9 (0.7 to 1.2)	1.3 (0.9 to 1.7)	36.8 (22.8 to 54.5)	-28.5 (-35.8 to -19.6)
Self-harm	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	39.9 (25.8 to 56.8)	-29.5 (-36.5 to -21.3)
Interpersonal violence	-	-	-	-	0.8 (0.6 to 1.0)	1.1 (0.8 to 1.5)	36.4 (21.2 to 54.9)	-28.3 (-36.2 to -18.9)
Assault by firearm	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	82.9 (64.0 to 102.3)	-4.8 (-14.0 to 4.9)
Assault by sharp object	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	48.2 (30.8 to 70.7)	-23.2 (-32.0 to -11.9)
Assault by other means	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	6.2 (8.1 to 22.2)	-43.5 (-51.1 to -35.1)
Forces of nature, war, and legal intervention	-	-	-	-	0.3 (0.1 to 0.5)	0.1 (0.0 to 0.2)	-69.9 (-76.3 to -53.0)	-86.5 (-89.7 to -77.8)
Exposure to forces of nature	-	-	-	-	0.3 (0.1 to 0.5)	0.1 (0.0 to 0.2)	-69.9 (-76.3 to -53.0)	-86.5 (-89.7 to -77.8)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Peru prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	2,729.0 (1,940.1 to 3,682.1)	3,169.3 (2,361.0 to 4,108.7)	17.8 (5.1 to 33.3)	31.3 (-46.2 to -19.2)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	316.2 (219.7 to 436.0)	341.6 (241.3 to 473.9)	8.0 (2.0 to 15.7)	-12.5 (-17.5 to -5.7)
HIV/AIDS and tuberculosis	-	-	-	-	11.6 (7.9 to 15.8)	15.9 (10.8 to 21.4)	36.3 (21.0 to 56.5)	-12.9 (-22.4 to -0.1)
Tuberculosis	36.5 (34.8 to 38.2)	46.8 (44.2 to 49.5)	28.2 (22.7 to 34.2)	-19.6 (-22.8 to -16.2)	10.9 (7.5 to 14.6)	14.3 (9.6 to 19.0)	30.9 (20.7 to 42.0)	-16.2 (-22.3 to -9.4)
HIV/AIDS	-	-	-	-	0.0 (0.1 to 2.2)	1.6 (0.8 to 3.6)	59.2 (22.9 to 1,227.3)	59.2 (50.2 to 708.2)
HIV/AIDS resulting in mycobacterial infection	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-20.8 (-78.4 to 327.9)	-51.8 (-86.8 to 148.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-20.8 (-78.5 to 328.9)	-51.8 (-86.6 to 150.0)
HIV/AIDS resulting in other diseases	7.4 (1.2 to 21.8)	21.3 (13.2 to 43.2)	250.7 (-6.4 to 1,640.9)	129.8 (-36.7 to 1,046.3)	0.7 (0.1 to 2.1)	1.6 (0.8 to 3.6)	163.1 (22.5 to 1,404.3)	67.5 (-50.5 to 845.9)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	85.5 (59.5 to 117.6)	84.1 (57.5 to 117.7)	-1.8 (-8.3 to 6.0)	-15.5 (-20.0 to -10.8)
Diarrheal diseases	331.1 (316.4 to 344.4)	273.5 (261.0 to 286.1)	-17.4 (-22.5 to -11.9)	-34.4 (-28.9 to -39.4)	53.7 (36.3 to 74.2)	44.2 (30.0 to 61.7)	-17.8 (-23.0 to -11.7)	-23.9 (-28.7 to -18.4)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (-65.2 to -33.1)	0.0 (-72.8 to -48.0)
Typhoid fever	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-21.0 (-33.6 to -7.1)	-38.5 (-48.3 to -28.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-33.6 to -7.1)	-21.0 (-48.3 to -28.3)
Paratyphoid fever	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-22.9 (-39.3 to -5.1)	-39.8 (-51.7 to -25.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-39.4 to -5.1)	-22.9 (-51.7 to -25.4)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-87.7 (-93.3 to -77.1)	-90.5 (-94.7 to -42.4)
Lower respiratory infections	40.1 (36.4 to 43.4)	29.2 (27.2 to 31.2)	-27.2 (-34.9 to -18.6)	-37.2 (-42.8 to -30.9)	4.2 (2.8 to 5.9)	3.0 (2.0 to 4.2)	-27.8 (-36.8 to -16.8)	-35.8 (-43.1 to -27.3)
Upper respiratory infections	1,761.1 (1,668.0 to 1,844.0)	2,380.3 (2,265.6 to 2,489.1)	35.1 (26.4 to 45.5)	-0.4 (-6.3 to 6.7)	20.5 (11.5 to 34.1)	27.9 (15.5 to 46.5)	35.7 (26.6 to 46.7)	1.2 (-4.9 to 9.0)
Otitis media	265.8 (250.5 to 280.7)	305.2 (288.6 to 322.4)	14.8 (7.4 to 23.2)	-10.5 (-16.2 to -4.1)	5.1 (3.1 to 8.1)	5.8 (3.4 to 9.3)	13.1 (3.9 to 23.3)	-11.1 (-17.7 to -3.3)
Meningitis	-	-	-	-	0.8 (0.5 to 1.1)	0.6 (0.4 to 0.8)	-26.8 (-41.6 to -12.1)	-44.7 (-55.4 to -33.7)
Pneumococcal meningitis	2.9 (1.8 to 4.5)	2.2 (1.3 to 3.6)	-23.5 (-38.8 to -9.3)	-46.8 (-56.8 to -36.7)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-24.4 (-42.8 to -6.0)	-44.3 (-56.5 to -31.7)
H influenzae type B meningitis	1.6 (0.5 to 3.4)	1.1 (0.4 to 2.4)	-31.8 (-54.9 to -2.6)	-50.6 (-65.9 to -27.2)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-26.3 (-56.6 to 22.1)	-42.8 (-66.3 to -5.4)
Meningococcal meningitis	0.5 (0.2 to 1.2)	0.4 (0.1 to 0.9)	-32.9 (-53.9 to -1.7)	-52.7 (-65.4 to -31.2)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-31.2 (-57.0 to 12.6)	-49.6 (-66.5 to -18.3)
Other meningitis	1.8 (0.9 to 3.4)	1.3 (0.6 to 2.5)	-31.9 (-48.7 to -6.3)	-49.6 (-61.1 to -37.7)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.2)	-28.3 (-51.5 to 4.0)	-45.2 (-62.0 to -21.0)
Encephalitis	1.9 (0.8 to 4.4)	2.4 (1.0 to 5.6)	23.0 (0.1 to 45.3)	-18.8 (-31.1 to -1.7)	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.5)	28.6 (3.7 to 64.1)	-12.9 (-29.2 to 9.0)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.2 (-93.0 to 1,574.8)	-6.1 (-93.0 to 1,052.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.2 (-93.0 to 1,578.9)	-6.1 (-93.1 to 1,073.2)
Whooping cough	13.2 (10.3 to 16.8)	36.8 (28.2 to 47.9)	177.9 (160.1 to 197.4)	183.0 (164.9 to 202.8)	0.7 (0.4 to 1.1)	1.8 (1.1 to 2.9)	178.9 (150.9 to 208.4)	183.8 (155.6 to 214.2)
Tetanus	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.0)	-69.5 (-86.4 to -42.2)	-78.2 (-90.2 to -58.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.1 (-67.7 to 3.5)	-59.8 (-76.1 to -26.5)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	16.3 (14.9 to 17.9)	20.6 (18.3 to 23.0)	26.2 (9.0 to 48.1)	-0.3 (-17.3 to 23.4)	0.3 (0.2 to 0.5)	0.6 (0.3 to 0.9)	70.0 (22.3 to 154.9)	4.1 (-26.3 to 55.4)
Neglected tropical diseases and malaria	-	-	-	-	57.1 (37.8 to 83.8)	55.9 (36.6 to 82.8)	-2.4 (-27.1 to 31.5)	-26.8 (-43.4 to -3.6)
Malaria	60.8 (43.7 to 83.0)	77.6 (56.8 to 100.7)	29.7 (-6.3 to 72.1)	-0.8 (-28.3 to 30.9)	0.8 (0.5 to 1.3)	1.2 (0.8 to 1.9)	44.9 (12.4 to 98.0)	23.4 (-3.9 to 65.9)
Chagas disease	112.3 (105.4 to 119.4)	172.9 (163.1 to 181.7)	55.9 (42.4 to 65.5)	1.9 (-5.3 to 9.7)	1.6 (0.6 to 1.2)	1.6 (1.0 to 2.3)	8.0 (6.7 to 119.2)	8.0 (5.0 to 24.5)
Leishmaniasis	-	-	-	-	0.9 (0.4 to 1.8)	1.1 (0.5 to 2.2)	21.2 (8.9 to 33.0)	-22.9 (-30.3 to -15.7)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.1 (-4.8 to 161.9)	25.9 (-19.7 to 103.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.1 (-5.0 to 162.8)	25.9 (-19.7 to 103.7)
Cutaneous and mucocutaneous leishmaniasis	88.8 (68.7 to 115.5)	105.6 (82.9 to 134.8)	19.1 (7.5 to 30.1)	-25.8 (-32.4 to -19.9)	0.9 (0.4 to 1.8)	1.1 (0.5 to 2.2)	21.2 (8.9 to 33.0)	23.0 (-30.3 to -15.8)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	57.9 (39.1 to 82.9)	53.9 (33.2 to 83.9)	-8.4 (-53.0 to 82.3)	-39.8 (-68.2 to 20.7)	15.6 (8.9 to 24.7)	16.3 (9.1 to 27.1)	3.5 (-46.8 to 110.8)	-31.0 (-64.7 to 38.7)
Cystic echinococcosis	1.3 (1.2 to 1.5)	1.8 (1.6 to 2.2)	36.6 (25.9 to 47.1)	-24.2 (-31.7 to -18.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	41.3 (10.3 to 77.4)	20.1 (-37.7 to 0.2)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	1.9 (0.7 to 4.3)	13.0 (4.8 to 29.2)	579.5 (571.8 to 588.5)	392.1 (386.5 to 398.6)	0.3 (0.1 to 0.8)	2.1 (0.7 to 5.1)	578.8 (418.7 to 815.7)	397.2 (286.1 to 547.4)
Yellow fever	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-41.8 (-50.3 to -31.2)	-57.6 (-63.4 to -50.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.8 (-50.3 to -31.2)	-57.6 (-63.4 to -50.4)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.1 to 0.2)	0.0 (0.1 to 0.3)	-	-
Intestinal nematode infections	-	-	-	-	21.7 (10.8 to 40.2)	11.9 (5.7 to 23.0)	-45.6 (-67.8 to -8.4)	-54.5 (-73.6 to -22.4)
Ascariasis	4,859.7 (3,626.5 to 6,441.2)	4,668.3 (2,937.3 to 7,456.5)	-6.5 (-45.3 to 62.4)	-32.2 (-62.3 to 22.1)	14.6 (6.6 to 28.2)	4.6 (1.7 to 9.7)	-69.2 (-84.9 to -32.0)	-72.5 (-86.4 to -37.3)
Trichuriasis	4,862.8 (3,547.4 to 6,503.8)	5,122.5 (3,991.9 to 7,702.0)	4.2 (-34.8 to 71.7)	-26.5 (-53.3 to 26.5)	5.6 (2.5 to 11.5)	5.3 (2.0 to 12.4)	-7.9 (-60.7 to 122.4)	-32.7 (-73.0 to 66.9)
Hookworm disease	424.7 (288.8 to 611.5)	560.0 (342.2 to 892.7)	31.2 (-29.1 to 139.4)	29.4 (-53.1 to 70.4)	1.5 (0.9 to 2.4)	2.0 (1.1 to 3.2)	29.4 (-15.6 to 93.8)	0.7 (-35.9 to 46.0)
Food-borne trematodiasis	351.7 (255.5 to 457.3)	588.5 (412.1 to 803.0)	66.7 (28.6 to 119.4)	-1.8 (-2.2 to 16.6)	7.5 (2.2 to 16.6)	12.8 (1.7 to 27.7)	69.1 (15.6 to 129.6)	1.6 (-20.1 to 32.8)
Other neglected tropical diseases	256.4 (186.7 to 326.8)	245.9 (224.8 to 268.4)	-3.7 (-23.9 to 29.5)	-11.4 (-29.5 to 18.2)	9.2 (5.5 to 13.6)	8.7 (5.7 to 12.6)	-7.5 (-18.2 to 44.7)	-13.0 (-23.0 to 36.1)
Maternal disorders	-	-	-	-	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	12.3 (8.8 to 40.6)	-24.1 (-38.0 to -6.6)
Maternal hemorrhage	1.5 (1.2 to 1.7)	3.3 (2.7 to 4.0)	127.9 (83.5 to 182.1)	45.9 (18.4 to 76.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	128.7 (74.4 to 372.8)	48.7 (-29.0 to 198.3)
Maternal sepsis and other maternal infections	2.0 (1.3 to 2.9)	1.7 (1.1 to 2.4)	-13.2 (-37.1 to 5.9)	-48.5 (-62.6 to -36.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.0 (-35.6 to -1.9)	-48.9 (-58.8 to -37.0)
Maternal hypertensive disorders	3.4 (2.3 to 4.7)	3.3 (2.2 to 4.6)	-2.9 (-9.4 to 4.8)	-34.3 (-38.4 to -29.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-2.6 (-24.0 to 24.8)	-34.0 (-48.3 to -15.9)
Obstructed labor	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-1.6 (-10.7 to 7.4)	-31.3 (-37.3 to -25.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	2.9 (-36.1 to 61.0)	28.5 (-53.6 to 6.0)
Complications of abortion	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-	-34.9 (-40.1 to -29.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-33.2 (-43.0 to 92.3)	-33.2 (-60.2 to 29.7)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	13.0 (-19.7 to 69.7)	23.9 (-45.3 to 13.2)
Neonatal disorders	-	-	-	-	14.3 (8.9 to 22.1)	36.9 (25.3 to 50.6)	164.5 (66.2 to 298.9)	104.6 (29.3 to 208.5)
Preterm birth complications	35.6 (25.3 to 49.9)	121.2 (89.9 to 162.1)	243.4 (172.4 to 325.1)	152.9 (100.8 to 215.0)	3.5 (2.3 to 5.1)	14.7 (9.9 to 20.2)	322.0 (203.3 to 492.5)	220.6 (132.0 to 351.4)
Neonatal encephalopathy due to birth asphyxia and trauma	87.3 (24.5 to 197.8)	79.8 (35.0 to 156.4)	-6.2 (-39.2 to 68.7)	-31.9 (-55.7 to 24.4)	5.4 (2.8 to 9.0)	10.9 (6.9 to 15.8)	105.8 (12.6 to 268.0)	60.5 (-11.5 to 196.1)
Neonatal sepsis and other neonatal infections	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.5)	55.3 (42.8 to 83.6)	67.9 (54.4 to 98.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	67.9 (37.0 to 90.7)	51.6 (48.1 to 106.2)
Hemolytic disease and other neonatal jaundice	12.3 (4.3 to 24.4)	25.0 (12.3 to 47.6)	125.9 (-36.3 to 529.6)	73.5 (-51.4 to 387.6)	4.4 (1.5 to 9.2)	9.4 (4.3 to 18.7)	139.8 (-29.1 to 554.6)	84.2 (-45.7 to 408.6)
Other neonatal disorders	-	-	-	-	1.0 (0.5 to 1.8)	1.9 (1.1 to 3.2)	91.6 (1.3 to 281.7)	48.7 (-21.8 to 192.9)
Nutritional deficiencies	-	-	-	-	136.0 (90.4 to 195.4)	135.6 (90.2 to 197.8)	-0.2 (-3.5 to 2.0)	-16.5 (-19.2 to -14.9)
Protein-energy malnutrition	26.6 (19.1 to 36.1)	11.1 (8.4 to 14.6)	-58.4 (-71.0 to -39.4)	62.5 (-72.1 to -48.8)	3.2 (1.9 to 5.0)	3.3 (0.8 to 2.0)	1.3 (-7.1 to 38.5)	61.6 (-72.0 to -45.7)
Iodine deficiency	5.4 (3.7 to 7.3)	4.7 (3.3 to 5.9)	-11.0 (-45.2 to 35.3)	-41.9 (-64.7 to -11.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-10.3 (-44.4 to 38.3)	-41.0 (-64.0 to -9.6)
Vitamin A deficiency	14.0 (10.4 to 17.6)	8.1 (6.0 to 10.1)	-42.1 (-48.5 to -35.4)	-52.5 (-58.1 to -46.6)	0.6 (0.4 to 0.9)	0.3 (0.2 to 0.5)	-44.1 (-52.6 to -33.8)	-55.2 (-61.7 to -46.7)

Appendix Table G.4 - Peru prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	3,900.0 (3,830.3 to 3,965.2)	4,129.8 (4,076.9 to 4,183.1)	5.9 (3.7 to 8.2)	-15.0 (-16.6 to -13.3)	132.0 (87.5 to 190.3)	133.7 (89.0 to 195.3)	1.5 (-1.7 to 3.4)	-15.1 (-17.7 to -13.5)
Other nutritional deficiencies	-	-	-	-	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.2)	-0.1 (-0.3 to 0.1)	-0.2 (-0.4 to 0.0)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	11.3 (7.2 to 17.2)	12.9 (8.1 to 20.2)	13.9 (1.8 to 28.4)	-10.0 (-18.7 to -1.0)
Sexually transmitted diseases excluding HIV	-	-	-	-	4.0 (2.3 to 7.0)	5.7 (3.2 to 9.9)	40.2 (22.1 to 58.1)	-9.4 (-19.7 to 1.7)
Syphilis	1.0 (0.9 to 1.1)	1.0 (0.9 to 1.1)	-1.0 (-1.6 to 1.6)	-46.7 (-54.8 to -38.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	1.5 (-26.9 to 40.9)	-43.5 (-59.2 to -24.3)
Chlamydial infection	431.1 (363.5 to 499.1)	634.1 (528.8 to 747.3)	45.4 (18.1 to 84.3)	-2.5 (-19.9 to 23.4)	2.1 (1.2 to 3.5)	3.1 (1.7 to 5.1)	43.0 (16.0 to 77.4)	-3.8 (-20.7 to 17.9)
Gonococcal infection	64.4 (52.3 to 76.8)	78.8 (62.8 to 95.1)	22.9 (-6.7 to 58.9)	-15.6 (-35.5 to 8.4)	0.4 (0.3 to 0.7)	0.5 (0.3 to 0.8)	8.5 (-23.4 to 50.3)	-26.2 (-46.9 to 1.8)
Trichomoniasis	164.9 (116.0 to 219.1)	253.2 (165.1 to 321.3)	54.4 (-6.5 to 140.7)	5.2 (-35.3 to 56.1)	0.3 (0.1 to 0.7)	0.4 (0.2 to 1.0)	55.9 (-12.8 to 154.3)	7.0 (-39.4 to 68.3)
Genital herpes	3,459.2 (3,350.2 to 3,571.0)	5,352.4 (5,203.2 to 5,512.1)	54.7 (48.4 to 62.0)	-9.9 (-13.6 to -6.0)	1.4 (0.3 to 2.1)	1.4 (0.4 to 3.4)	9.9 (41.7 to 63.7)	-7.7 (-22.7 to -2.0)
Other sexually transmitted diseases	3.6 (2.7 to 4.7)	3.4 (2.7 to 4.4)	-3.7 (-19.2 to 10.2)	-42.8 (-52.0 to -34.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	17.7 (-13.4 to 74.8)	26.2 (-44.4 to 7.3)
Hepatitis	-	-	-	-	0.9 (0.6 to 1.4)	1.2 (0.8 to 1.7)	27.3 (14.9 to 40.7)	-8.5 (-18.0 to 0.6)
Hepatitis A	30.7 (29.5 to 32.0)	34.7 (33.6 to 35.8)	13.0 (11.9 to 14.1)	-5.4 (-5.5 to -5.2)	0.7 (0.4 to 1.0)	0.9 (0.6 to 1.3)	29.5 (15.4 to 45.7)	-0.5 (-10.8 to 11.1)
Hepatitis B	529.5 (488.4 to 576.9)	498.0 (464.3 to 528.6)	-5.8 (-15.0 to 3.7)	-34.4 (-41.5 to -29.1)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	21.3 (-7.1 to 50.6)	-23.9 (-41.9 to -5.3)
Hepatitis C	317.1 (286.3 to 346.1)	380.5 (345.6 to 418.0)	19.8 (5.6 to 37.4)	-27.5 (-36.0 to -18.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	17.0 (8.3 to 52.1)	-24.9 (-43.2 to 2.3)
Hepatitis E	-	-	-	-	-	-	-	-
Leprosy	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-2.1 (-29.5 to 84.6)	-46.5 (-61.6 to 1.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.9 (-33.0 to 102.1)	-43.3 (-63.7 to 14.6)
Other infectious diseases	174.7 (137.2 to 215.0)	169.1 (149.4 to 189.9)	-3.3 (-19.0 to 15.5)	-12.8 (-26.6 to 4.3)	6.3 (3.8 to 9.4)	6.1 (3.8 to 9.2)	-3.9 (-21.5 to 14.3)	-10.4 (-26.9 to 6.6)
Non-communicable diseases	-	-	-	-	1,488.4 (1,108.5 to 1,913.1)	2,519.9 (1,882.2 to 3,256.4)	69.9 (64.5 to 75.2)	6.1 (2.7 to 10.3)
Neoplasms	-	-	-	-	10.4 (7.6 to 13.5)	23.1 (16.3 to 32.1)	120.5 (84.4 to 168.1)	20.2 (1.0 to 47.3)
Esophageal cancer	0.3 (0.3 to 0.4)	0.5 (0.4 to 0.7)	54.6 (9.5 to 115.6)	-27.6 (-48.7 to 3.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	58.4 (18.5 to 110.4)	-24.7 (-43.9 to 2.6)
Stomach cancer	8.2 (7.3 to 9.3)	14.9 (12.2 to 18.1)	79.5 (46.9 to 126.0)	-13.5 (-30.2 to 9.1)	0.9 (0.6 to 1.1)	1.6 (1.1 to 2.1)	84.7 (48.6 to 134.1)	-10.1 (-27.4 to 15.4)
Liver cancer	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	240.0 (160.7 to 351.4)	70.0 (29.1 to 125.9)
Liver cancer due to hepatitis B	0.2 (0.1 to 0.3)	0.9 (0.6 to 1.3)	405.2 (182.9 to 805.1)	172.4 (49.3 to 397.0)	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.2)	378.3 (207.6 to 645.0)	155.7 (58.5 to 312.3)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.3 (0.2 to 0.6)	1,474.2 (646.5 to 3,305.7)	626.8 (238.2 to 1,548.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	1,365.5 (660.9 to 2,764.0)	565.6 (236.5 to 1,263.5)
Liver cancer due to alcohol use	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.8)	155.2 (46.1 to 358.8)	19.8 (-31.1 to 109.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	144.7 (55.4 to 270.0)	14.8 (-26.9 to 76.0)
Liver cancer due to other causes	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	81.3 (-10.1 to 251.8)	-6.8 (-55.1 to 84.5)	0.1 (0.0 to 0.0)	0.1 (0.0 to 0.1)	78.9 (-0.0 to 202.9)	-10.6 (-49.9 to 58.7)
Larynx cancer	0.6 (0.4 to 0.7)	0.5 (0.3 to 0.7)	-19.9 (-43.4 to 14.6)	-60.8 (-72.8 to -43.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	12.5 (-17.2 to 65.7)	-44.0 (-59.9 to -15.4)
Tracheal, bronchus and lung cancer	2.3 (2.0 to 2.6)	4.1 (3.4 to 5.0)	76.7 (42.3 to 122.2)	-13.5 (-30.1 to 8.7)	0.3 (0.3 to 0.5)	0.6 (0.4 to 0.9)	83.7 (44.2 to 132.2)	-8.6 (-28.5 to 15.8)
Breast cancer	20.7 (18.0 to 23.4)	39.5 (29.3 to 53.5)	87.5 (41.4 to 170.1)	-2.6 (-25.1 to 40.3)	1.6 (1.1 to 2.1)	2.9 (1.9 to 4.3)	79.4 (34.7 to 154.2)	-6.4 (-28.6 to 30.0)
Cervical cancer	22.3 (17.8 to 27.0)	25.4 (17.9 to 34.9)	12.3 (-17.0 to 59.1)	-89.7 (-54.9 to -15.6)	1.6 (1.1 to 2.3)	1.9 (1.2 to 2.9)	15.2 (-11.9 to 62.2)	-87.9 (-133.5 to -13.3)
Uterine cancer	5.9 (4.1 to 9.2)	10.6 (6.4 to 16.8)	78.1 (9.4 to 191.2)	-8.7 (-42.8 to 46.9)	0.4 (0.2 to 0.6)	0.7 (0.4 to 1.2)	82.8 (12.7 to 200.8)	-6.4 (-45.2 to 52.8)
Prostate cancer	11.5 (7.1 to 16.3)	62.3 (40.5 to 97.2)	441.9 (245.2 to 798.1)	151.6 (59.1 to 314.8)	1.0 (0.6 to 1.5)	4.9 (3.0 to 7.6)	397.4 (220.6 to 710.0)	130.0 (49.6 to 265.7)
Colon and rectum cancer	7.3 (6.8 to 8.0)	22.9 (19.4 to 27.7)	210.1 (160.8 to 278.7)	49.9 (26.4 to 83.0)	0.6 (0.4 to 0.7)	1.8 (1.3 to 2.4)	209.9 (155.2 to 283.7)	50.9 (24.7 to 88.8)
Lip and oral cavity cancer	1.7 (1.4 to 2.2)	3.4 (2.4 to 4.4)	94.3 (39.7 to 160.6)	4.6 (-30.1 to 31.6)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	100.4 (40.2 to 174.8)	-0.7 (-31.2 to 37.4)
Nasopharynx cancer	0.3 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-27.7 (-50.8 to 27.6)	-60.3 (-73.1 to -28.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.4 (-48.6 to 27.4)	60.4 (-72.1 to -29.4)
Other pharynx cancer	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.0)	70.9 (12.8 to 161.0)	-12.8 (-42.6 to 31.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	70.1 (17.6 to 152.4)	-14.6 (-40.9 to 28.3)
Gallbladder and biliary tract cancer	0.8 (0.6 to 1.0)	0.9 (0.7 to 1.3)	12.8 (-18.6 to 85.9)	-47.6 (-62.2 to -16.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	14.3 (-18.5 to 87.1)	45.2 (-61.0 to -10.3)
Pancreatic cancer	0.2 (0.2 to 0.2)	1.3 (1.1 to 1.7)	594.3 (442.4 to 808.7)	239.6 (165.6 to 345.8)	0.0 (0.0 to 0.1)	0.2 (0.2 to 0.3)	524.9 (395.0 to 687.1)	200.8 (136.1 to 278.8)
Malignant skin melanoma	2.4 (2.0 to 3.2)	5.3 (3.9 to 7.4)	116.0 (60.2 to 190.0)	-15.8 (-14.7 to 55.6)	0.3 (0.1 to 0.2)	0.3 (0.2 to 0.5)	115.0 (59.5 to 187.9)	14.8 (-16.6 to 53.4)
Non-melanoma skin cancer	5.2 (4.4 to 6.1)	15.2 (12.3 to 19.0)	191.3 (136.5 to 257.3)	31.1 (3.3 to 62.2)	0.2 (0.1 to 0.2)	0.5 (0.3 to 0.8)	244.8 (149.3 to 368.3)	55.9 (7.7 to 120.8)
Ovarian cancer	0.8 (0.7 to 1.0)	3.3 (2.4 to 4.4)	291.5 (183.7 to 443.3)	115.3 (56.2 to 198.8)	0.1 (0.1 to 0.2)	0.6 (0.3 to 0.6)	286.8 (160.6 to 456.8)	115.0 (44.4 to 212.9)
Testicular cancer	0.4 (0.2 to 0.7)	2.0 (0.6 to 4.0)	608.4 (38.8 to 1,503.9)	344.0 (-13.3 to 889.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.3)	539.6 (21.5 to 1,575.3)	304.6 (-22.5 to 887.7)
Kidney cancer	1.1 (1.7 to 2.1)	1.4 (4.6 to 7.3)	29.5 (138.1 to 293.0)	-39.4 (28.5 to 111.4)	0.1 (0.1 to 0.2)	0.1 (0.3 to 0.6)	36.6 (132.9 to 285.5)	-35.5 (22.4 to 103.6)
Bladder cancer	0.7 (0.8 to 1.3)	3.6 (1.1 to 2.0)	485.3 (-4.0 to 102.5)	323.9 (-55.8 to -6.9)	0.1 (0.1 to 0.1)	0.4 (0.1 to 0.2)	500.5 (1.2 to 107.0)	309.8 (-52.5 to -4.1)
Brain and nervous system cancer	0.7 (0.5 to 1.1)	12.1 (1.6 to 4.7)	1,679.7 (76.5 to 6,079.1)	609.1 (20.5 to 4,533.0)	0.1 (0.0 to 0.1)	0.4 (0.2 to 0.5)	500.5 (73.8 to 710.8)	309.8 (13.1 to 434.9)
Thyroid cancer	5.7 (4.3 to 7.5)	12.1 (8.1 to 16.9)	109.7 (48.5 to 197.5)	18.9 (-15.1 to 67.4)	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.1)	108.9 (47.5 to 198.9)	17.5 (-16.4 to 68.3)
Mesothelioma	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	86.5 (40.6 to 144.7)	86.5 (-31.7 to 19.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.0 (42.5 to 139.1)	-10.3 (-31.8 to 18.5)
Hodgkin lymphoma	0.3 (0.2 to 0.5)	1.2 (0.5 to 1.8)	408.7 (115.5 to 678.7)	320.1 (-16.4 to 518.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	472.6 (15.7 to 743.2)	350.7 (-17.8 to 538.9)
Non-Hodgkin lymphoma	5.8 (4.5 to 6.9)	11.8 (9.1 to 15.4)	100.0 (49.8 to 176.5)	17.8 (-10.9 to 59.3)	0.4 (0.3 to 0.6)	0.9 (0.6 to 1.3)	100.6 (48.8 to 173.6)	18.3 (-12.0 to 57.5)
Multiple myeloma	0.6 (0.4 to 0.8)	1.3 (0.9 to 1.9)	105.8 (20.4 to 251.9)	1.2 (-40.7 to 71.5)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	108.3 (19.0 to 259.3)	3.4 (-40.6 to 77.1)
Leukemia	7.6 (6.0 to 9.7)	10.6 (8.5 to 13.7)	41.4 (3.3 to 89.1)	12.9 (-12.4 to 43.9)	0.7 (0.5 to 1.0)	1.1 (0.7 to 1.5)	59.9 (18.7 to 102.1)	15.5 (8.4 to 45.6)
Other neoplasms	16.5 (11.8 to 20.2)	31.7 (23.4 to 48.9)	70.5 (28.0 to 275.4)	16.6 (-11.1 to 143.5)	2.0 (0.7 to 1.5)	2.0 (1.2 to 3.5)	14.9 (29.6 to 270.2)	14.9 (-13.1 to 141.3)
Cardiovascular diseases	-	-	-	-	20.2 (13.8 to 28.8)	57.1 (38.6 to 80.1)	185.9 (102.8 to 267.1)	46.4 (8.0 to 85.8)
Rheumatic heart disease	9.3 (7.5 to 11.1)	17.8 (13.9 to 22.4)	87.6 (46.7 to 164.5)	5.6 (-16.7 to 46.2)	0.8 (0.5 to 1.2)	1.5 (0.9 to 2.2)	81.0 (16.8 to 196.9)	3.6 (-32.0 to 66.2)
Ischemic heart disease	91.4 (80.3 to 106.7)	344.6 (275.3 to 415.4)	276.4 (179.6 to 400.8)	73.9 (29.6 to 130.6)	4.5 (3.3 to 6.6)	20.3 (13.6 to 29.9)	320.1 (205.5 to 480.7)	95.1 (42.1 to 169.9)
Cerebrovascular disease	-	-	-	-	1.8 (1.3 to 2.4)	2.9 (2.6 to 5.0)	110.5 (72.0 to 157.5)	8.9 (-11.9 to 34.5)
Ischemic stroke	8.9 (7.6 to 10.3)	17.6 (15.1 to 20.7)	95.2 (62.0 to 149.0)	-3.2 (-20.1 to 23.7)	1.2 (0.9 to 1.7)	2.6 (1.8 to 3.6)	108.3 (67.5 to 172.3)	5.5 (-15.2 to 37.4)
Hemorrhagic stroke	3.6 (2.9 to 4.3)	7.3 (5.9 to 9.2)	102.1 (58.2 to 161.4)	7.3 (-17.5 to 41.5)	0.5 (0.4 to 0.8)	1.1 (0.7 to 1.7)	111.1 (58.7 to 171.7)	14.5 (-14.2 to 49.9)
Hypertensive heart disease	19.9 (18.2 to 21.7)	43.9 (40.7 to 47.3)	120.8 (94.5 to 148.6)	1.7 (-10.4 to 15.0)	2.0 (1.4 to 2.7)	4.7 (3.3 to 6.3)	135.8 (105.4 to 169.7)	10.7 (4.3 to 27.4)
Cardiomyopathy and myocarditis	8.7 (7.5 to 10.1)	21.8 (20.1 to 23.5)	152.1 (112.1 to 200.3)	31.4 (7.6 to 63.4)	0.9 (0.6 to 1.2)	2.4 (1.6 to 3.3)	165.3 (115.4 to 220.9)	41.8 (13.6 to 76.7)
Atrial fibrillation and flutter	18.6 (14.7 to 23.2)	48.1 (37.5 to 60.5)	159.6 (75.4 to 281.1)	6.9 (-28.3 to 60.1)	1.2 (0.8 to 1.8)	3.5 (2.3 to 5.1)	185.3 (89.2 to 312.6)	20.8 (-21.1 to 79.8)
Peripheral vascular disease	368.6 (285.6 to 466.4)	741.6 (469.7 to 1,003.6)	99.0 (38.1 to 187.4)	-4.2 (-30.0 to 33.7)	0.2 (0.1 to 0.3)	0.4 (0.1 to 0.7)	115.8 (4.7 to 295.1)	-13.9 (-58.8 to 60.5)
Endocarditis	1.3 (1.0 to 1.8)	3.5 (2.2 to 4.3)	199.7 (59.5 to 298.2)	82.1 (-9.8 to 143.8)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	226.9 (64.8 to 376.6)	95.3 (-6.8 to 192.9)
Other cardiovascular and circulatory diseases	124.0 (74.2 to 213.7)	389.4 (140.5 to 422.5)	142.5 (4.5 to 351.3)	42.5 (-43.1 to 160.8)	8.4 (4.5 to 14.9)	20.5 (8.8 to 32.4)	151.6 (74.4 to 365.6)	42.8 (-39.5 to 175.1)
Chronic respiratory diseases	-	-	-	-	121.6 (84.7 to 165.3)	198.9 (138.2 to 270.5)	62.8 (45.9 to 87.3)	1.3 (-9.6

Appendix Table G.4 - Peru prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	84.0	-1.5
Silicosis	0.0	0.0	73.7	-9.8	(0.0 to 0.0)	(0.0 to 0.0)	(78.1 to 89.9)	(-4.4 to 1.5)
Asbestosis	-	-	0.0	0.0	0.0	0.0	73.8	-9.7
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.1	0.1	87.3	2.0	0.0	0.0	88.1	2.1
Asthma	(0.1 to 0.1)	(0.1 to 0.1)	(79.7 to 96.0)	(-1.9 to 5.6)	(0.0 to 0.0)	(0.0 to 0.0)	(80.0 to 96.2)	(-1.9 to 5.7)
Interstitial lung disease and pulmonary sarcoidosis	1.539.1	2,391.2	55.4	6.9	67.2	105.3	56.8	9.5
Other chronic respiratory diseases	(1,381.2 to 1,705.2)	(2,167.3 to 2,634.0)	(35.3 to 79.1)	(-6.1 to 22.4)	(42.9 to 95.4)	(67.7 to 151.2)	(36.0 to 81.4)	(-4.3 to 25.2)
Cirrhosis	0.6	1.2	105.7	3.8	0.1	0.2	103.6	4.6
Cirrhosis due to hepatitis B	(0.4 to 0.7)	(0.9 to 1.4)	(50.7 to 198.6)	(-26.4 to 56.9)	(0.0 to 0.1)	(0.1 to 0.2)	(44.4 to 199.2)	(-28.8 to 61.3)
Cirrhosis due to hepatitis C	-	-	-	-	9.2	4.1	-56.1	-75.6
Cirrhosis due to alcohol use	-	-	-	-	(4.9 to 15.0)	(2.5 to 6.3)	(-73.0 to -9.7)	(-84.5 to -50.2)
Cirrhosis due to other causes	-	-	-	-	0.2	1.4	4.9	75.3
Digestive diseases	0.7	1.2	68.0	-5.7	(0.5 to 1.1)	(0.9 to 1.9)	(53.8 to 104.1)	(8.1 to 21.2)
Peptic ulcer disease	(0.5 to 1.0)	(0.6 to 1.9)	(-23.6 to 221.6)	(59.0 to 94.1)	0.1	0.2	(-24.9 to 245.3)	(-59.6 to 112.7)
Gastritis and duodenitis	0.9	2.7	211.3	79.7	0.4	0.4	219.6	89.0
Appendicitis	(0.7 to 1.1)	(2.0 to 3.6)	(100.8 to 389.8)	(10.2 to 184.2)	(0.1 to 0.2)	(0.3 to 0.7)	(92.9 to 401.6)	(12.5 to 206.0)
Paralytic ileus and intestinal obstruction	1.8	2.1	14.2	-39.2	0.3	0.3	21.4	-34.6
Inguinal, femoral, and abdominal hernia	(1.6 to 2.1)	(1.6 to 2.7)	(-13.8 to 54.3)	(-54.1 to -19.0)	(0.2 to 0.4)	(0.2 to 0.5)	(-17.6 to 76.3)	(-55.2 to -6.1)
Inflammatory bowel disease	1.5	2.3	58.3	12.3	0.2	0.4	59.6	15.9
Vascular intestinal disorders	(1.2 to 1.7)	(1.9 to 2.8)	(25.9 to 105.9)	(-13.9 to 56.4)	(0.1 to 0.4)	(0.2 to 0.6)	(9.5 to 138.1)	(-20.8 to 77.1)
Peptic ulcer disease	92.8	92.6	-0.0	-50.8	3.1	3.5	11.1	-44.2
Gastritis and duodenitis	(89.0 to 97.2)	(86.1 to 99.0)	(-9.5 to 8.8)	(-55.3 to -46.6)	(2.2 to 4.3)	(2.3 to 4.8)	(-3.1 to 23.4)	(-49.8 to -37.5)
Appendicitis	116.2	307.2	164.5	52.6	4.9	11.7	137.8	41.9
Paralytic ileus and intestinal obstruction	(111.5 to 121.3)	(296.5 to 317.2)	(150.7 to 178.4)	(45.2 to 59.7)	(3.4 to 6.9)	(7.8 to 16.6)	(109.3 to 159.1)	(31.8 to 53.4)
Inguinal, femoral, and abdominal hernia	1.3	1.6	17.6	-16.5	0.4	0.5	18.8	-14.6
Inflammatory bowel disease	(1.1 to 1.5)	(1.4 to 1.8)	(-3.1 to 44.1)	(-30.9 to 0.1)	(0.3 to 0.6)	(0.3 to 0.7)	(-21.6 to 83.6)	(-41.8 to 25.8)
Vascular intestinal disorders	0.1	0.3	143.0	62.7	0.0	0.1	138.3	61.1
Peptic ulcer disease	(0.1 to 0.1)	(0.2 to 0.3)	(105.4 to 197.2)	(44.2 to 90.2)	(0.0 to 0.1)	(0.1 to 0.1)	(94.6 to 204.9)	(31.9 to 99.1)
Gastritis and duodenitis	117.6	144.6	23.6	-34.7	1.1	1.5	27.8	-29.7
Appendicitis	(105.1 to 132.0)	(130.4 to 159.5)	(6.2 to 41.0)	(-43.3 to -25.6)	(0.6 to 2.2)	(0.7 to 2.7)	(9.0 to 46.6)	(-39.5 to -19.4)
Paralytic ileus and intestinal obstruction	18.6	41.8	124.6	28.7	3.8	8.8	131.7	35.2
Inflammatory bowel disease	(17.8 to 19.4)	(40.3 to 43.4)	(113.0 to 137.6)	(21.9 to 36.3)	(2.6 to 5.2)	(6.1 to 12.0)	(110.5 to 155.3)	(23.5 to 48.5)
Vascular intestinal disorders	0.0	0.1	108.7	7.8	0.0	0.0	108.7	7.8
Peptic ulcer disease	(0.0 to 0.0)	(0.0 to 0.1)	(60.2 to 174.0)	(-21.1 to 45.1)	(0.0 to 0.0)	(0.0 to 0.0)	(60.1 to 174.0)	(-21.1 to 45.5)
Gastritis and duodenitis	23.7	37.5	59.2	-14.8	2.4	3.9	62.4	-11.4
Appendicitis	(21.3 to 26.7)	(31.7 to 42.1)	(26.4 to 86.3)	(-29.6 to -2.7)	(1.6 to 3.4)	(2.6 to 5.5)	(28.6 to 95.6)	(7.1 to 3.5)
Paralytic ileus and intestinal obstruction	1.2	3.4	197.8	71.4	1.0	1.0	206.8	87.6
Inguinal, femoral, and abdominal hernia	(1.1 to 1.2)	(3.3 to 3.6)	(179.9 to 216.6)	(60.8 to 81.9)	(0.2 to 0.5)	(0.7 to 1.4)	(140.4 to 300.7)	(42.4 to 133.0)
Inflammatory bowel disease	-	-	-	-	0.4	2.4	607.3	288.9
Vascular intestinal disorders	-	-	-	-	(0.2 to 0.7)	(1.6 to 3.4)	(213.8 to 822.3)	(76.6 to 409.6)
Neurological disorders	-	-	-	-	166.8	278.1	66.5	8.2
Alzheimer disease and other dementias	-	-	-	-	(113.0 to 230.8)	(184.6 to 378.3)	(41.3 to 94.4)	(6.8 to 24.2)
Parkinson disease	59.6	145.2	143.4	0.9	7.3	20.5	175.2	13.1
Epilepsy	(52.9 to 66.6)	(129.3 to 161.1)	(108.5 to 183.9)	(-13.8 to 17.8)	(5.3 to 9.4)	(14.6 to 26.2)	(131.0 to 227.9)	(5.7 to 35.2)
Multiple sclerosis	3.8	8.4	118.4	0.3	0.4	1.0	135.9	10.4
Migraine	(3.2 to 4.4)	(7.2 to 9.7)	(109.2 to 129.8)	(-3.7 to 5.4)	(0.3 to 0.6)	(0.6 to 1.3)	(99.6 to 177.5)	(-6.6 to 30.2)
Tension-type headache	143.6	166.2	15.6	-17.5	42.3	54.9	29.9	-5.2
Medication overuse headache	(94.6 to 197.3)	(114.1 to 226.9)	(-31.2 to 87.9)	(-50.8 to 33.9)	(24.8 to 65.0)	(32.9 to 83.3)	(-23.2 to 115.1)	(-44.4 to 54.9)
Other neurological disorders	1.0	3.2	219.3	84.9	0.4	1.1	207.3	78.0
Alzheimer disease and other dementias	(0.9 to 1.1)	(3.0 to 3.4)	(186.5 to 252.7)	(65.7 to 105.7)	(0.3 to 0.5)	(0.8 to 1.5)	(154.1 to 265.8)	(47.9 to 112.8)
Parkinson disease	2,835.1	4,611.7	61.7	6.5	95.6	157.5	64.4	8.4
Epilepsy	(2,489.6 to 3,167.6)	(4,020.9 to 5,356.8)	(39.0 to 96.6)	(-9.8 to 27.4)	(56.9 to 140.2)	(92.7 to 236.7)	(40.1 to 98.8)	(7.6 to 31.0)
Multiple sclerosis	3,337.6	5,392.2	61.3	4.3	5.0	8.2	62.5	6.2
Migraine	(3,033.8 to 3,650.5)	(4,916.3 to 5,829.2)	(42.9 to 82.4)	(-7.8 to 17.3)	(2.4 to 8.7)	(9.9 to 14.3)	(43.6 to 86.5)	(-5.8 to 21.4)
Tension-type headache	91.0	209.9	128.7	35.6	14.0	32.9	133.2	40.2
Medication overuse headache	(59.1 to 121.6)	(134.6 to 288.1)	(74.5 to 206.7)	(4.0 to 81.4)	(7.8 to 22.1)	(18.4 to 52.5)	(76.0 to 213.6)	(6.9 to 86.5)
Other neurological disorders	0.0	0.0	49.9	0.6	1.9	2.5	30.3	-45.7
Alzheimer disease and other dementias	(0.0 to 0.0)	(0.0 to 0.1)	(5.9 to 107.5)	(-28.3 to 38.1)	(1.3 to 2.7)	(1.7 to 3.4)	(-3.2 to 73.2)	(-59.2 to -28.1)
Parkinson disease	50.2	84.8	68.8	-0.7	496.1	778.0	56.8	4.0
Epilepsy	(45.8 to 54.2)	(78.0 to 91.0)	(61.8 to 76.6)	(-4.3 to 3.7)	(357.3 to 655.2)	(558.8 to 1,026.1)	(51.7 to 62.4)	(1.0 to 8.3)
Multiple sclerosis	227.1	473.3	108.2	33.9	31.1	54.4	74.2	3.8
Migraine	(208.2 to 247.0)	(440.7 to 508.7)	(97.3 to 121.5)	(27.3 to 41.4)	(14.8 to 31.8)	(31.7 to 67.6)	(99.4 to 130.8)	(30.1 to 49.5)
Tension-type headache	-	-	-	-	22.1	35.4	60.3	6.7
Medication overuse headache	-	-	-	-	(14.4 to 30.4)	(22.8 to 49.3)	(36.6 to 85.8)	(-7.5 to 22.5)
Other neurological disorders	13.4	25.6	92.2	10.5	5.3	10.6	99.1	15.9
Alzheimer disease and other dementias	(6.5 to 21.9)	(12.6 to 41.4)	(67.1 to 120.6)	(-3.4 to 23.7)	(2.3 to 9.4)	(4.8 to 18.3)	(66.3 to 137.7)	(-3.1 to 36.2)
Parkinson disease	20.5	34.7	69.8	2.8	6.8	12.5	72.8	12.5
Epilepsy	(16.3 to 26.6)	(28.2 to 41.4)	(20.0 to 124.1)	(10.5 to 42.4)	(1.7 to 4.2)	(3.0 to 7.0)	(22.9 to 131.3)	(-17.2 to 48.6)
Multiple sclerosis	40.3	54.1	34.1	-4.1	5.2	7.1	35.5	-2.6
Migraine	(37.4 to 43.2)	(50.2 to 58.1)	(21.2 to 47.5)	(-13.1 to 5.1)	(3.3 to 7.7)	(4.5 to 10.5)	(15.0 to 58.0)	(-16.7 to 12.7)
Tension-type headache	24.5	34.5	41.0	0.1	1.0	1.0	41.8	0.8
Medication overuse headache	(18.4 to 30.3)	(26.7 to 42.2)	(37.6 to 45.4)	(0.1 to 0.1)	(0.4 to 1.1)	(0.6 to 1.5)	(15.6 to 74.2)	(-17.2 to 22.1)
Other neurological disorders	-	-	-	-	8.1	12.0	48.5	3.0
Alzheimer disease and other dementias	-	-	-	-	(5.0 to 11.7)	(7.5 to 17.6)	(9.5 to 102.0)	(-24.0 to 40.7)
Parkinson disease	-	-	-	-	175.1	281.5	60.9	3.7
Epilepsy	-	-	-	-	(114.2 to 245.5)	(187.0 to 395.6)	(50.0 to 71.8)	(-2.4 to 11.3)
Multiple sclerosis	760.0	1,191.9	57.1	0.7	153.7	244.3	59.3	3.8
Migraine	(602.7 to 899.0)	(938.0 to 1,416.4)	(45.4 to 68.3)	(-5.6 to 8.5)	(97.7 to 218.9)	(158.8 to 347.4)	(46.5 to 71.6)	(-3.2 to 12.4)
Tension-type headache	228.0	388.4	70.2	-0.1	21.5	37.2	73.5	3.1
Medication overuse headache	(188.1 to 267.9)	(323.8 to 453.7)	(65.8 to 76.2)	(-0.1 to -0.1)	(14.0 to 30.9)	(24.3 to 54.2)	(66.1 to 81.7)	(-0.0 to 7.2)
Other neurological disorders	145.7	232.8	60.1	29.1	47.2	62.7	113.5	38.7
Alzheimer disease and other dementias	(120.6 to 167.4)	(198.5 to 266.0)	(49.6 to 70.0)	(-5.8 to 5.9)	(17.7 to 44.4)	(29.3 to 70.6)	(48.7 to 76.9)	(-4.8 to 11.0)
Parkinson disease	1,193.2	1,823.5	52.7	10.3	167.4	267.4	58.6	2.2
Epilepsy	(796.4 to 1,556.3)	(1,240.4 to 2,329.7)	(45.5 to 62.0)	(-0.1 to -0.1)	(63.5 to 164.6)	(101.3 to 250.8)	(45.9 to 65.6)	(-0.0 to 5.7)
Multiple sclerosis	-	-	-	-	7.2	10.1	39.8	1.4
Migraine	-	-	-	-	(4.2 to 10.9)	(5.9 to 15.3)	(28.3 to 51.6)	(-6.0 to 9.5)
Tension-type headache	5.1	7.3	42.1	6.4	1.1	1.6	43.6	7.1
Medication overuse headache	(3.9 to 6.5)	(5.5 to 9.5)	(29.5 to 59.2)	(-2.5 to 18.2)	(0.7 to 1.6)	(0.9 to 2.4)	(16.1 to 78.3)	(-13.7 to 32.5)
Other neurological disorders	29.0	40.2	38.4	-0.2	6.1	8.5	39.0	0.4
Alzheimer disease and other dementias	(18.4 to 38.1)	(25.5 to 52.7)	(34.4 to 42.5)	(-0.3 to -0.2)	(3.4 to 9.4)	(4.8 to 13.2)	(27.0 to 52.6)	(-7.8 to 9.3)
Parkinson disease	-	-	-	-	25.5	35.7	39.8	2.8
Epilepsy	-	-	-	-	(17.8 to 34.5)	(24.7 to 48.1)	(35.3 to 45.4)	(-0.9 to 6.8)
Multiple sclerosis	65.7	91.2	38.7	0.1	16.0	22.4	39.9	2.9
Migraine	(62.3 to 69.0)	(86.6 to 95.9)	(38.0 to 39.6)	(0.1 to 0.1)	(10.8 to 21.8)	(15.0 to 30.6)	(33.3 to 48.3)	(-1.7 to 8.6)
Tension-type headache	96.5	133.2	38.0	0.2	9.5	13.3	39.2	2.6
Medication overuse headache	(90.5 to 102.2)	(124.7 to 141.3)	(36.9 to 39.0)	(0.2 to 0.2)	(6.6 to 13.3)	(9.1 to 18.5)	(33.2 to 45.5)	(-1.6 to 7.5)
Other neurological disorders	191.4	222.9	16.5	0.1	2.3	2.7	17.0	0.6
Alzheimer disease and other dementias	(175.3 to 204.1)	(204.1 to 237.8)	(16.1 to 16.7)	(0.1 to 0.1)	(1.4 to 3.6)	(1.6 to 4.2)	(8.9 to 24.8)	(-6.2 to 7.2)
Parkinson disease	256.3	296.1	16.2	0.1	30.8	36.0	16.7	5.6
Epilepsy	(239.2 to 273.4)	(278.1 to 318.5)	(15.7 to 16.9)	(0.1 to 0.1)	(19.3 to 44.8)	(22.5 to 52.3)	(11.9 to 22.2)	(-3.6 to 5.3)
Multiple sclerosis	423.9	477.7	12.5	-17.4	20.6	23.3	13.1	-16.2
Migraine	(321.2 to 532.6)	(381.3 to 584.9)	(-3.1 to 34.2)	(-29.0 to -0.7)	(13.0 to 29.7)	(15.1 to 32.9)	(-2.7 to 35.0)	(-28.1 to 0.3)
Tension-type headache	301.0	500.0	66.1	0.1	21.9	37.2	70.1	4.1
Medication overuse headache	(280.9 to 319.7)	(469.5 to 529.8)	(64.3 to 67.9)	(0.1 to 0.1)	(14.8 to 29.2)	(25.2 to 50.1)	(62.5 to 79.0)	(-0.2 to 9.4)
Other neurological disorders	-	-	-	-				

Appendix Table G.4 - Peru prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	917.8 (887.6 to 950.0)	1,725.7 (1,672.1 to 1,777.7)	88.0 (79.4 to 96.4)	-8.9 (-12.9 to -5.1)	23.7 (16.3 to 32.4)	46.7 (31.8 to 64.1)	97.2 (85.2 to 111.5)	-2.3 (-8.8 to 4.6)
Other oral disorders	341.0 (321.2 to 363.0)	525.9 (492.6 to 556.0)	54.1 (41.1 to 67.9)	-0.7 (-8.4 to 8.0)	9.9 (6.1 to 14.7)	15.4 (9.5 to 23.3)	56.1 (41.6 to 70.5)	1.8 (-6.9 to 11.0)
Injuries	-	-	-	-	929.4 (483.8 to 1,723.5)	307.8 (190.2 to 509.7)	-66.1 (-75.0 to -54.8)	-81.0 (-85.8 to -74.5)
Transport injuries	-	-	-	-	30.7 (23.1 to 39.2)	32.0 (23.2 to 42.3)	3.9 (-6.3 to 17.0)	-38.1 (-43.9 to -30.5)
Road injuries	-	-	-	-	29.9 (22.5 to 38.2)	29.5 (21.7 to 39.5)	-0.4 (-10.2 to 12.5)	-40.6 (-46.2 to -33.3)
Pedestrian road injuries	-	-	-	-	12.3 (9.2 to 15.8)	10.7 (7.8 to 14.2)	-1.7 (-23.6 to -0.4)	-47.1 (-52.8 to -39.5)
Cyclist road injuries	-	-	-	-	2.0 (1.5 to 2.6)	2.4 (1.7 to 3.2)	2.1 (9.9 to 34.7)	-28.3 (-35.0 to -20.3)
Motorcyclist road injuries	-	-	-	-	3.2 (2.4 to 4.2)	3.1 (2.2 to 4.2)	-0.1 (-14.5 to 9.9)	-43.1 (-49.3 to -35.7)
Motor vehicle road injuries	-	-	-	-	11.8 (8.9 to 15.0)	13.3 (9.6 to 17.4)	1.5 (-1.7 to 25.7)	-35.2 (-42.2 to -26.8)
Other road injuries	-	-	-	-	0.6 (0.4 to 0.7)	0.5 (0.4 to 0.7)	-0.1 (-15.0 to 6.5)	-44.9 (-50.1 to -37.7)
Other transport injuries	-	-	-	-	0.8 (0.6 to 1.0)	2.1 (1.5 to 2.8)	160.0 (133.8 to 192.0)	52.7 (36.7 to 72.1)
Unintentional injuries	-	-	-	-	67.1 (51.1 to 86.0)	75.1 (56.4 to 98.6)	11.7 (4.1 to 20.1)	-32.2 (-36.7 to -27.0)
Falls	-	-	-	-	22.0 (16.8 to 28.2)	33.8 (24.9 to 44.6)	53.0 (39.1 to 68.4)	-19.8 (-27.6 to -10.8)
Drowning	-	-	-	-	0.6 (0.5 to 0.8)	0.6 (0.4 to 0.7)	-0.4 (-19.3 to 4.1)	-41.7 (-48.1 to -34.6)
Fire, heat, and hot substances	-	-	-	-	2.5 (1.9 to 3.2)	2.0 (1.5 to 2.6)	-21.5 (-30.1 to -12.1)	-49.0 (-54.0 to -43.5)
Poisonings	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	10.1 (6.8 to 27.7)	-27.6 (-37.3 to -17.0)
Exposure to mechanical forces	-	-	-	-	33.6 (25.3 to 43.8)	22.7 (16.7 to 30.4)	-32.8 (-37.5 to -27.3)	-55.8 (-58.5 to -52.5)
Unintentional firearm injuries	-	-	-	-	1.7 (1.3 to 2.2)	2.3 (1.6 to 3.0)	32.3 (17.5 to 50.2)	-16.7 (-25.7 to -6.0)
Unintentional suffocation	-	-	-	-	0.7 (0.5 to 0.9)	0.9 (0.7 to 1.3)	45.0 (25.6 to 64.5)	-2.8 (-15.3 to 9.8)
Other exposure to mechanical forces	-	-	-	-	31.3 (23.6 to 40.9)	19.5 (14.3 to 26.0)	-38.0 (-42.3 to -33.1)	-59.1 (-61.6 to -56.1)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	107.2 (95.2 to 120.6)	21.2 (14.1 to 29.7)
Animal contact	-	-	-	-	0.3 (0.3 to 0.4)	0.6 (0.4 to 0.8)	71.1 (56.2 to 87.8)	5.3 (-3.2 to 14.4)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	66.6 (47.1 to 89.5)	5.0 (-5.9 to 17.8)
Non-venomous animal contact	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	73.3 (57.5 to 92.3)	5.1 (-3.5 to 15.5)
Foreign body	-	-	-	-	0.9 (0.7 to 1.1)	1.1 (0.8 to 1.4)	19.2 (7.6 to 32.1)	-27.4 (-33.9 to -20.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.5 (0.4 to 0.6)	0.5 (0.4 to 0.7)	4.3 (-8.7 to 20.0)	-35.1 (-42.7 to -26.6)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	44.8 (25.5 to 67.9)	-6.1 (-17.4 to 7.4)
Foreign body in other body part	-	-	-	-	0.3 (0.3 to 0.4)	0.5 (0.3 to 0.6)	35.2 (23.1 to 49.2)	-20.6 (-27.3 to -12.9)
Other unintentional injuries	-	-	-	-	6.8 (5.1 to 8.7)	13.9 (10.3 to 18.3)	105.1 (88.5 to 125.4)	10.4 (1.4 to 21.5)
Self-harm and interpersonal violence	-	-	-	-	4.6 (3.5 to 5.9)	4.7 (3.5 to 6.2)	1.6 (-7.8 to 13.8)	-40.6 (-46.0 to -33.5)
Self-harm	-	-	-	-	0.8 (0.6 to 1.1)	1.0 (0.7 to 1.3)	12.8 (1.5 to 25.6)	-36.1 (-42.5 to -29.6)
Interpersonal violence	-	-	-	-	3.8 (2.9 to 4.8)	3.8 (2.8 to 5.0)	-0.9 (-10.8 to 11.7)	-41.5 (-47.2 to -34.4)
Assault by firearm	-	-	-	-	0.9 (0.7 to 1.1)	1.1 (0.8 to 1.5)	27.2 (14.5 to 40.4)	-26.3 (-33.3 to -18.7)
Assault by sharp object	-	-	-	-	0.8 (0.6 to 1.0)	0.9 (0.7 to 1.2)	12.6 (1.0 to 27.5)	-34.7 (-41.3 to -26.3)
Assault by other means	-	-	-	-	2.1 (1.6 to 2.7)	1.7 (1.3 to 2.3)	-17.6 (-26.7 to -6.5)	-50.8 (-56.3 to -44.3)
Forces of nature, war, and legal intervention	-	-	-	-	827.0 (387.6 to 1,615.6)	196.0 (88.0 to 393.2)	-76.2 (-82.4 to -69.0)	-86.2 (-89.7 to -81.6)
Exposure to forces of nature	-	-	-	-	220.3 (108.5 to 404.1)	81.5 (39.4 to 159.3)	-63.2 (-69.7 to -56.4)	-79.1 (-83.4 to -74.1)
Collective violence and legal intervention	-	-	-	-	606.7 (235.5 to 1,297.7)	114.6 (45.9 to 252.0)	-81.1 (-85.9 to -74.2)	-89.0 (-91.8 to -84.7)

Appendix Table G.4 - Philippines prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	5,871.1 (4,259.4 to 7,880.9)	8,776.5 (6,453.6 to 11,452.5)	50.9 (32.5 to 60.1)	-35.6 (-27.7 to -7.4)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1,382.5 (960.3 to 1,938.4)	1,636.2 (1,133.5 to 2,289.2)	18.4 (7.1 to 31.4)	-24.4 (-32.8 to -14.6)
HIV/AIDS and tuberculosis	-	-	-	-	81.8 (56.9 to 110.4)	151.3 (103.0 to 205.6)	84.3 (71.3 to 103.3)	2.5 (-4.4 to 11.8)
Tuberculosis	267.4 (254.1 to 280.4)	460.3 (433.4 to 488.8)	71.8 (63.9 to 81.5)	-4.3 (-8.9 to 1.1)	80.4 (55.8 to 108.0)	139.6 (96.0 to 189.8)	73.6 (62.5 to 86.4)	-2.7 (-8.8 to 3.8)
HIV/AIDS	-	-	-	-	4.1 (0.4 to 3.8)	11.7 (4.7 to 24.6)	490.3 (286.5 to 2,013.6)	756.9 (125.5 to 1,160.1)
HIV/AIDS resulting in mycobacterial infection	0.5 (0.1 to 1.3)	3.6 (1.2 to 8.0)	755.8 (247.8 to 2,140.9)	382.5 (93.3 to 1,162.1)	0.2 (0.0 to 0.5)	1.4 (0.4 to 3.3)	672.2 (206.3 to 2,041.3)	332.0 (68.8 to 1,26.5)
HIV/AIDS resulting in other diseases	14.2 (4.1 to 33.3)	77.7 (37.6 to 139.2)	484.0 (140.2 to 1,434.3)	251.6 (43.0 to 807.7)	1.2 (0.3 to 3.5)	10.3 (3.5 to 22.9)	778.2 (243.3 to 2,435.8)	432.8 (107.1 to 1,470.7)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	189.8 (133.4 to 259.8)	206.0 (142.0 to 286.6)	8.5 (-1.4 to 18.8)	-23.9 (-30.0 to -17.8)
Diarrheal diseases	542.2 (493.5 to 594.1)	484.7 (439.4 to 530.7)	-10.6 (-21.6 to 2.7)	-33.9 (-41.7 to -25.0)	88.0 (59.1 to 123.0)	78.8 (53.6 to 110.6)	78.8 (22.3 to 31.1)	-10.6 (-41.6 to -23.9)
Intestinal infectious diseases	-	-	-	-	1.8 (1.2 to 2.6)	1.6 (1.0 to 2.2)	-0.5 (-30.9 to 9.1)	-13.7 (-50.8 to -26.5)
Typhoid fever	10.3 (8.7 to 11.5)	9.5 (8.5 to 10.6)	-7.6 (-22.0 to 10.1)	-36.3 (-46.0 to -25.2)	1.4 (0.9 to 2.0)	1.3 (0.8 to 1.9)	6.4 (-27.4 to 21.5)	-35.7 (-48.1 to -19.4)
Paratyphoid fever	6.6 (5.6 to 7.7)	4.9 (4.2 to 5.6)	-26.1 (-39.4 to -8.4)	-49.1 (-57.6 to -38.2)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-25.2 (-43.3 to -0.1)	-48.7 (-60.1 to -33.3)
Other intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-82.1 (-89.4 to -69.3)	87.6 (-92.7 to -79.5)
Lower respiratory infections	28.6 (25.4 to 32.8)	40.4 (33.2 to 47.9)	40.4 (12.2 to 81.2)	18.7 (-1.2 to 44.4)	3.0 (1.9 to 4.3)	4.2 (2.7 to 6.2)	38.9 (6.5 to 85.3)	19.1 (4.5 to 46.6)
Upper respiratory infections	3,373.8 (3,241.4 to 3,529.2)	5,151.5 (4,899.3 to 5,358.2)	52.8 (43.1 to 61.9)	-2.0 (-7.9 to 3.8)	39.6 (22.2 to 66.2)	60.6 (34.4 to 101.9)	53.1 (42.9 to 63.4)	-1.3 (-7.7 to 5.0)
Otitis media	844.2 (783.4 to 905.8)	1,074.6 (1,003.1 to 1,154.4)	27.2 (18.3 to 37.7)	-15.6 (-21.9 to -8.8)	16.6 (9.8 to 27.0)	21.4 (12.7 to 34.8)	28.7 (17.7 to 42.7)	-14.3 (-21.5 to -5.2)
Meningitis	-	-	-	-	33.5 (22.2 to 47.3)	30.3 (20.3 to 42.9)	-9.1 (-27.5 to 12.7)	-39.9 (-51.5 to -26.2)
Pneumococcal meningitis	146.0 (88.2 to 223.2)	141.8 (82.0 to 227.1)	-4.8 (-25.8 to 36.8)	-40.6 (-53.4 to -15.2)	12.8 (8.4 to 17.9)	12.9 (8.3 to 18.9)	6.3 (-26.4 to 42.6)	35.5 (-52.3 to -10.1)
H influenzae type B meningitis	82.2 (30.0 to 157.6)	60.5 (23.2 to 115.3)	-26.0 (-45.2 to 1.6)	-53.3 (-64.9 to -34.3)	9.1 (5.6 to 13.5)	7.3 (4.3 to 11.5)	-20.1 (-47.7 to 25.0)	-47.3 (-64.8 to -17.4)
Meningococcal meningitis	11.6 (4.2 to 26.6)	10.0 (3.7 to 22.7)	-13.6 (-40.9 to 22.6)	-46.4 (-61.6 to -25.4)	1.5 (0.8 to 2.4)	1.2 (0.7 to 1.8)	-12.9 (-51.3 to 26.0)	-44.1 (-67.2 to -20.2)
Other meningitis	82.3 (38.4 to 147.8)	68.7 (35.5 to 122.8)	-15.7 (-37.4 to 11.5)	-45.2 (-58.8 to -25.8)	10.1 (5.9 to 16.4)	8.9 (5.4 to 14.0)	-9.0 (-47.5 to 36.8)	-38.4 (-64.1 to -9.6)
Encephalitis	18.3 (8.2 to 40.7)	24.7 (11.4 to 54.0)	34.7 (16.9 to 55.4)	-2.3 (-28.8 to -7.3)	2.3 (1.6 to 3.2)	3.3 (2.3 to 4.5)	41.8 (18.8 to 76.3)	-13.7 (-26.7 to 3.9)
Diphtheria	0.0 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-23.3 (-95.1 to 1,084.6)	-43.6 (-95.5 to 616.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.3 (-95.1 to 1,104.1)	-43.5 (-95.5 to 624.7)
Whooping cough	35.9 (28.1 to 45.8)	37.2 (29.1 to 47.5)	3.7 (2.7 to 4.8)	-15.5 (-16.3 to -14.6)	1.8 (1.0 to 2.9)	1.9 (1.1 to 3.0)	4.3 (-6.7 to 17.2)	-15.0 (-24.1 to -4.4)
Tetanus	2.7 (1.7 to 5.0)	1.1 (0.6 to 1.7)	-59.9 (-80.2 to -11.7)	-74.2 (-87.3 to -43.9)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-43.0 (-71.3 to 2.7)	-61.8 (-80.5 to -32.3)
Measles	11.4 (9.0 to 14.2)	3.9 (2.9 to 5.2)	-65.9 (-71.6 to -58.9)	-72.6 (-77.2 to -67.0)	1.0 (0.6 to 1.7)	0.4 (0.2 to 0.6)	-66.2 (-78.0 to -50.4)	-72.9 (-82.4 to -60.2)
Varicella and herpes zoster	62.0 (57.0 to 67.2)	99.2 (90.1 to 109.3)	60.0 (41.1 to 81.3)	0.6 (-12.5 to 16.9)	2.0 (1.2 to 3.1)	3.5 (2.1 to 5.3)	77.1 (43.4 to 119.3)	1.9 (-17.2 to 27.0)
Neglected tropical diseases and malaria	-	-	-	-	445.1 (263.7 to 688.0)	439.5 (261.5 to 699.5)	-1.9 (-24.4 to 32.8)	-42.4 (-57.0 to -19.2)
Malaria	2,699.3 (2,527.9 to 2,868.5)	3,921.3 (3,650.7 to 4,176.6)	45.6 (37.9 to 52.6)	-8.5 (-13.3 to -4.1)	22.6 (15.0 to 33.4)	38.7 (25.8 to 56.9)	70.7 (58.1 to 88.1)	10.8 (1.5 to 21.7)
Chagas disease	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	907.3 (650.3 to 1,188.4)	626.0 (448.7 to 839.4)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.8 (-62.1 to -3.9)	-49.1 (-67.9 to -24.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.8 (-62.3 to -3.7)	-49.1 (-68.0 to -23.8)
Cutaneous and mucocutaneous leishmaniasis	0.3 (0.2 to 0.4)	3.0 (2.7 to 3.7)	1,046.9 (793.1 to 1,345.6)	708.4 (540.5 to 940.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	1,028.5 (754.9 to 1,346.6)	683.6 (494.2 to 920.9)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	409.8 (152.9 to 987.7)	353.8 (128.0 to 947.5)	-18.7 (-33.6 to 48.1)	-51.7 (-60.5 to -12.0)	3.2 (1.3 to 7.6)	2.9 (1.0 to 7.0)	-13.5 (-35.1 to 36.0)	-48.1 (-60.5 to -17.7)
Cysticercosis	20.5 (6.5 to 38.6)	9.9 (4.3 to 17.9)	-49.0 (-81.2 to 18.4)	-76.9 (-90.9 to -51.4)	5.4 (1.6 to 11.2)	2.8 (1.1 to 5.7)	-44.5 (-80.9 to 32.8)	-74.4 (-90.6 to -44.6)
Cystic echinococcosis	7.5 (6.8 to 8.2)	9.9 (9.4 to 10.8)	31.9 (17.7 to 48.3)	-12.1 (-17.6 to -2.2)	0.7 (0.5 to 1.0)	0.9 (0.6 to 1.4)	31.7 (2.8 to 68.6)	-10.4 (-27.0 to 11.1)
Lymphatic filariasis	802.5 (521.7 to 1,185.4)	205.0 (108.3 to 365.2)	-74.8 (-85.0 to -60.3)	-85.5 (-91.2 to -77.0)	34.6 (11.3 to 75.3)	18.2 (7.3 to 40.5)	-77.1 (-73.0 to -5.0)	-71.7 (-86.4 to -50.7)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Dengue	30.0 (10.1 to 71.6)	232.4 (78.6 to 555.3)	675.0 (674.7 to 675.3)	389.2 (389.0 to 389.4)	4.9 (1.5 to 12.7)	37.9 (11.5 to 100.2)	677.6 (588.6 to 783.1)	393.4 (342.2 to 452.4)
Yellow fever	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.3 (-17.9 to 37.8)	32.0 (-48.5 to -15.9)
Intestinal nematode infections	-	-	-	-	331.0 (184.0 to 547.7)	286.1 (147.6 to 480.6)	-14.6 (-39.7 to 29.8)	-47.7 (-64.5 to -17.3)
Ascariasis	33,616.0 (30,198.8 to 37,216.0)	27,416.8 (19,381.5 to 39,219.2)	-20.4 (-43.8 to 19.3)	-51.2 (-66.6 to -25.6)	137.8 (63.2 to 259.7)	46.6 (19.4 to 100.6)	-67.1 (-84.9 to -29.2)	-80.3 (-91.6 to -54.2)
Trichuriasis	26,924.8 (23,021.2 to 31,708.1)	45,694.4 (35,864.4 to 58,416.2)	68.8 (26.2 to 133.8)	5.2 (-23.6 to 47.0)	85.1 (44.2 to 149.8)	139.1 (60.6 to 293.4)	54.9 (-13.4 to 222.8)	-2.9 (-49.8 to 114.7)
Hookworm disease	13,967.3 (16,214.3 to 22,136.1)	19,250.2 (13,997.4 to 26,072.2)	0.7 (-29.4 to 42.4)	0.7 (-58.4 to -40.4)	108.1 (61.3 to 182.6)	100.5 (57.9 to 170.1)	6.2 (-38.5 to 45.6)	-43.6 (-64.8 to -5.5)
Food-borne trematodiasis	611.3 (445.4 to 787.4)	1,067.3 (806.1 to 1,404.1)	72.9 (21.8 to 174.2)	-9.4 (-35.0 to 35.3)	6.8 (3.0 to 12.4)	12.1 (5.2 to 24.1)	77.4 (10.5 to 191.9)	-1.8 (-38.0 to 42.3)
Other neglected tropical diseases	997.1 (792.1 to 1,215.5)	1,156.2 (1,094.9 to 1,254.3)	16.2 (-4.7 to 45.5)	-19.1 (-32.4 to -1.3)	35.8 (22.1 to 53.1)	39.9 (25.9 to 58.3)	9.7 (-4.7 to 53.6)	-22.9 (-33.0 to 6.4)
Maternal disorders	-	-	-	-	3.2 (2.0 to 4.8)	3.6 (2.2 to 5.5)	13.0 (-16.4 to 46.7)	-32.6 (-49.8 to -12.8)
Maternal hemorrhage	35.6 (32.1 to 39.3)	49.1 (36.5 to 61.8)	38.3 (1.1 to 75.8)	-15.5 (-38.6 to 7.8)	1.4 (0.9 to 2.1)	1.6 (0.9 to 2.6)	13.8 (-33.0 to 67.7)	-32.6 (-60.6 to 0.0)
Maternal sepsis and other maternal infections	26.0 (16.4 to 38.7)	25.3 (15.6 to 39.0)	-1.0 (-21.7 to 12.9)	-45.3 (-56.5 to -37.4)	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.6)	-11.5 (-53.6 to 75.6)	-46.6 (-71.8 to -2.7)
Maternal hypertensive disorders	13.6 (6.9 to 22.9)	16.1 (8.4 to 26.7)	16.9 (9.5 to 37.1)	-28.8 (-34.6 to -17.1)	0.7 (0.3 to 1.3)	0.8 (0.4 to 1.5)	17.5 (-4.3 to 47.4)	-28.8 (-42.3 to -10.0)
Obstructed labor	0.8 (0.4 to 1.3)	0.6 (0.3 to 1.0)	-25.4 (-68.4 to 53.0)	-55.0 (-80.0 to -9.7)	0.2 (0.1 to 0.5)	0.2 (0.1 to 0.4)	-20.4 (-68.9 to 121.1)	-52.4 (-80.5 to 26.8)
Complications of abortion	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	20.9 (-34.8 to 122.3)	-28.6 (-59.9 to 27.5)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	20.9 (-34.8 to 122.7)	-28.6 (-59.9 to 27.9)
Other maternal disorders	-	-	-	-	0.4 (0.3 to 0.7)	0.6 (0.4 to 1.0)	17.7 (-1.6 to 92.2)	-17.9 (-41.7 to 13.3)
Neonatal disorders	-	-	-	-	71.8 (44.2 to 109.6)	165.7 (109.8 to 246.7)	129.3 (43.0 to 275.0)	52.6 (-4.2 to 148.3)
Preterm birth complications	266.6 (145.8 to 495.0)	911.1 (523.9 to 1,734.6)	239.1 (153.2 to 375.8)	118.9 (64.9 to 205.9)	29.4 (16.8 to 46.2)	102.8 (65.5 to 155.5)	239.2 (110.0 to 516.1)	123.6 (40.9 to 303.5)
Neonatal encephalopathy due to birth asphyxia and trauma	211.3 (67.2 to 482.3)	267.0 (105.6 to 597.9)	29.9 (-10.0 to 89.9)	-18.2 (-43.9 to 21.3)	14.6 (8.8 to 23.0)	26.6 (16.6 to 41.0)	82.9 (20.6 to 197.3)	22.6 (-18.0 to 101.3)
Neonatal sepsis and other neonatal infections	0.2 (0.1 to 0.4)	0.7 (0.2 to 1.5)	294.2 (239.0 to 313.4)	233.9 (187.1 to 250.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	227.0 (228.0 to 366.6)	227.0 (177.8 to 295.2)
Hemolytic disease and other neonatal jaundice	21.3 (5.8 to 41.8)	35.7 (16.3 to 78.0)	53.9 (-46.7 to 729.4)	1.6 (-64.3 to 449.7)	7.9 (2.2 to 16.0)	13.3 (5.8 to 30.2)	55.8 (-46.4 to 761.3)	2.5 (-64.5 to 456.6)
Other neonatal disorders	-	-	-	-	20.0 (8.4 to 37.4)	22.8 (11.3 to 42.7)	11.4 (-54.8 to 211.0)	-25.8 (-69.9 to 107.4)
Nutritional deficiencies	-	-	-	-	549.8 (365.0 to 787.2)	617.7 (412.2 to 894.6)	12.2 (-17.7 to 17.9)	-25.1 (-27.8 to -21.7)
Protein-energy malnutrition	263.7 (196.7 to 342.4)	287.9 (168.1 to 476.0)	5.6 (-37.9 to 95.9)	-13.7 (-47.2 to 55.8)	1.4 (19.5 to 49.6)	1.6 (18.0 to 66.8)	6.4 (-38.2 to 97.8)	-32.9 (-47.9 to 57.7)
Iodine deficiency	346.3 (315.9 to 377.2)	294.9 (231.5 to 365.1)	-15.6 (-34.5 to 8.2)	-51.4 (-62.4 to -37.0)	6.2 (3.8 to 10.0)	5.3 (3.0 to 8.7)	-15.0 (-35.3 to 10.1)	-50.7 (-62.9 to -36.1)
Vitamin A deficiency	32.3 (21.4 to 43.6)	26.4 (16.7 to 35.9)	-18.5 (-37.3 to 3.6)	-46.7 (-58.5 to -32.6)	1.3 (0.7 to 2.1)	1.0 (0.5 to 1.6)	-24.5 (-40.9 to -4.1)	-51.1 (-61.6 to -37.9)

Appendix Table G.4 - Philippines prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	393.1 (347.1 to 444.1)	616.7 (541.6 to 694.5)	57.4 (30.6 to 86.8)	-24.6 (-36.7 to -11.4)	10.6 (7.0 to 15.0)	17.0 (11.3 to 24.1)	59.3 (31.5 to 90.9)	23.4 (-36.0 to -9.8)
Other oral disorders	933.2 (885.4 to 983.8)	1,609.9 (1,517.0 to 1,703.6)	72.3 (59.8 to 87.0)	-0.3 (-7.0 to 7.8)	27.3 (17.0 to 40.6)	47.4 (29.3 to 71.3)	73.3 (60.2 to 89.3)	0.6 (-6.5 to 9.1)
Injuries	-	-	-	-	799.7 (365.4 to 1,843.8)	401.4 (252.7 to 671.2)	-46.6 (-63.9 to -20.5)	-71.1 (-79.6 to -56.4)
Transport injuries	-	-	-	-	47.7 (36.1 to 61.8)	85.4 (63.1 to 112.6)	78.8 (66.8 to 93.1)	-7.6 (-13.4 to -0.9)
Road injuries	-	-	-	-	42.6 (32.2 to 55.3)	74.5 (55.5 to 98.3)	75.4 (63.2 to 90.0)	-9.4 (-15.1 to -2.9)
Pedestrian road injuries	-	-	-	-	6.5 (4.9 to 8.3)	11.3 (8.3 to 14.8)	72.9 (56.1 to 90.8)	-10.6 (-17.9 to -2.9)
Cyclist road injuries	-	-	-	-	3.2 (2.4 to 4.1)	4.9 (3.6 to 6.5)	53.7 (41.0 to 67.5)	-22.0 (-28.4 to -14.6)
Motorcyclist road injuries	-	-	-	-	17.0 (12.9 to 22.0)	27.3 (19.9 to 36.4)	60.0 (45.8 to 76.0)	-16.6 (-23.4 to -9.2)
Motor vehicle road injuries	-	-	-	-	15.6 (11.8 to 20.4)	31.1 (22.9 to 40.7)	98.8 (79.6 to 121.1)	2.6 (-5.9 to 13.3)
Other road injuries	-	-	-	-	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	34.1 (22.7 to 46.7)	-36.4 (-41.3 to -31.0)
Other transport injuries	-	-	-	-	5.0 (3.8 to 6.6)	10.5 (7.7 to 13.9)	108.6 (88.4 to 130.7)	6.8 (-2.3 to 18.2)
Unintentional injuries	-	-	-	-	87.1 (66.5 to 112.6)	105.3 (77.8 to 138.9)	20.9 (13.4 to 27.6)	-28.7 (-32.1 to -25.2)
Falls	-	-	-	-	19.9 (15.0 to 25.8)	39.4 (29.1 to 52.4)	97.3 (82.3 to 112.8)	5.0 (-2.5 to 13.1)
Drowning	-	-	-	-	4.1 (3.0 to 5.3)	4.3 (3.1 to 5.7)	6.0 (5.7 to 18.6)	-38.7 (-44.7 to -32.2)
Fire, heat, and hot substances	-	-	-	-	4.0 (3.0 to 5.1)	3.8 (2.7 to 5.2)	-6.4 (-23.2 to 18.7)	-8.0 (-24.4 to -2.4)
Poisonings	-	-	-	-	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.4)	14.1 (-4.6 to 36.4)	-34.6 (-44.2 to -23.3)
Exposure to mechanical forces	-	-	-	-	51.0 (39.1 to 67.0)	40.5 (29.6 to 54.0)	-20.4 (-26.8 to -14.4)	-54.3 (-57.4 to -51.4)
Unintentional firearm injuries	-	-	-	-	3.2 (2.4 to 4.1)	2.1 (1.6 to 2.8)	-34.0 (-39.2 to -28.2)	-62.7 (-65.4 to -59.7)
Unintentional suffocation	-	-	-	-	1.4 (1.1 to 1.9)	1.1 (0.8 to 1.5)	-22.2 (-29.3 to -13.1)	-54.5 (-58.2 to -49.9)
Other exposure to mechanical forces	-	-	-	-	46.4 (35.2 to 61.2)	37.3 (27.3 to 49.7)	-19.4 (-26.3 to -13.1)	-53.7 (-57.0 to -50.5)
Adverse effects of medical treatment	-	-	-	-	1.0 (0.6 to 1.4)	1.8 (1.1 to 2.6)	81.3 (70.0 to 94.9)	2.6 (-3.8 to 10.0)
Animal contact	-	-	-	-	1.9 (1.4 to 2.4)	4.0 (2.9 to 5.3)	114.8 (95.0 to 135.9)	22.1 (12.0 to 32.9)
Venomous animal contact	-	-	-	-	0.9 (0.6 to 1.2)	2.0 (1.4 to 2.6)	120.7 (91.2 to 149.2)	26.2 (11.2 to 40.4)
Non-venomous animal contact	-	-	-	-	1.0 (0.7 to 1.3)	2.0 (1.4 to 2.8)	110.0 (88.6 to 131.4)	18.5 (8.9 to 28.9)
Foreign body	-	-	-	-	1.1 (0.8 to 1.4)	1.7 (1.2 to 2.2)	60.3 (50.0 to 70.7)	-6.7 (-12.2 to -1.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	33.7 (18.0 to 50.5)	-15.7 (-24.4 to -6.8)
Foreign body in eyes	-	-	-	-	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	63.1 (51.5 to 75.3)	-5.2 (-11.4 to 1.4)
Foreign body in other body part	-	-	-	-	0.4 (0.3 to 0.5)	0.7 (0.5 to 1.0)	79.0 (64.9 to 96.9)	-2.2 (-9.6 to 6.9)
Other unintentional injuries	-	-	-	-	4.0 (2.9 to 5.2)	9.6 (7.0 to 12.5)	140.6 (122.6 to 158.4)	25.3 (16.5 to 34.1)
Self-harm and interpersonal violence	-	-	-	-	12.9 (9.9 to 16.5)	12.7 (9.5 to 16.6)	-1.2 (-8.2 to 7.1)	-45.3 (-49.0 to -41.2)
Self-harm	-	-	-	-	1.5 (1.1 to 1.9)	1.3 (1.0 to 1.7)	-10.0 (-18.9 to -0.6)	-53.6 (-57.7 to -49.3)
Interpersonal violence	-	-	-	-	11.4 (8.8 to 14.5)	11.4 (8.5 to 14.9)	-0.1 (-7.7 to 8.6)	-44.1 (-48.0 to -39.8)
Assault by firearm	-	-	-	-	1.3 (1.0 to 1.7)	1.4 (1.0 to 1.8)	2.2 (-6.5 to 11.3)	-41.4 (-46.2 to -36.4)
Assault by sharp object	-	-	-	-	2.8 (2.1 to 3.6)	2.9 (2.1 to 3.9)	2.9 (-6.7 to 14.6)	-43.3 (-48.1 to -37.3)
Assault by other means	-	-	-	-	7.3 (5.6 to 9.3)	7.2 (5.4 to 9.3)	-1.7 (-10.1 to 7.9)	-44.9 (-49.5 to -39.9)
Forces of nature, war, and legal intervention	-	-	-	-	652.1 (218.0 to 1,674.3)	197.9 (83.0 to 459.0)	-69.2 (-74.8 to -55.2)	-81.7 (-85.0 to -75.0)
Exposure to forces of nature	-	-	-	-	45.9 (24.8 to 81.1)	33.2 (15.5 to 75.1)	-37.0 (-53.5 to 103.3)	-58.9 (-67.7 to 20.9)
Collective violence and legal intervention	-	-	-	-	606.2 (185.3 to 1,598.7)	164.7 (57.6 to 406.1)	-72.4 (-76.7 to -66.0)	-83.4 (-86.0 to -79.4)

Appendix Table G.4 - Poland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	4,276.6 (3,213.2 to 5,563.3)	4,915.9 (3,679.3 to 6,394.5)	14.9 (12.3 to 17.8)	14.9 (-5.1 to 0.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	276.3 (194.5 to 388.9)	218.8 (152.3 to 307.3)	-20.8 (-27.3 to -12.6)	-4.4 (-11.9 to 4.3)
HIV/AIDS and tuberculosis	-	-	-	-	5.1 (3.5 to 6.9)	6.3 (4.4 to 8.7)	24.1 (9.4 to 40.7)	2.1 (-9.8 to 16.0)
Tuberculosis	16.4 (15.7 to 17.1)	18.6 (17.6 to 19.4)	13.5 (9.2 to 17.7)	-8.0 (-11.2 to -4.4)	4.9 (3.3 to 6.7)	5.5 (3.8 to 7.5)	12.4 (0.1 to 26.9)	-7.9 (-18.5 to 4.4)
HIV/AIDS	-	-	-	-	0.2 (0.1 to 0.3)	0.8 (0.5 to 1.3)	300.1 (135.4 to 715.1)	276.8 (100.9 to 595.4)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	153.8 (21.8 to 386.6)	116.1 (5.2 to 319.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	153.8 (21.0 to 388.1)	116.1 (5.0 to 319.2)
HIV/AIDS resulting in other diseases	1.7 (1.0 to 2.6)	10.3 (6.9 to 14.3)	494.8 (268.8 to 845.7)	406.6 (213.2 to 708.7)	0.2 (0.1 to 0.3)	0.8 (0.4 to 1.3)	342.3 (135.7 to 722.3)	278.2 (101.8 to 599.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	30.0 (20.6 to 41.4)	25.7 (17.7 to 35.9)	-14.2 (-19.9 to -8.8)	-7.0 (-13.3 to -0.9)
Diarrheal diseases	95.6 (87.8 to 103.9)	81.5 (75.9 to 87.2)	-14.6 (-23.7 to -5.8)	-6.1 (-16.3 to 4.8)	15.3 (10.4 to 21.3)	12.9 (8.8 to 17.8)	-15.9 (-25.6 to -5.9)	-6.1 (-17.1 to 5.4)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-32.3 (-55.0 to -1.2)	-29.6 (-53.0 to 4.8)
Typhoid fever	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-21.4 (-41.7 to 9.1)	-18.9 (-39.6 to 15.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.4 (-41.8 to 9.3)	-18.9 (-39.6 to 15.1)
Paratyphoid fever	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-22.1 (-46.5 to 14.6)	-15.0 (-41.3 to 20.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.1 (-46.5 to 14.8)	-15.0 (-41.3 to 20.8)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-78.0 (-96.0 to -8.1)	-77.1 (-95.9 to -0.9)
Lower respiratory infections	3.2 (3.1 to 3.4)	2.3 (2.3 to 2.4)	-27.2 (-30.8 to -23.6)	-17.6 (-22.1 to -13.1)	0.3 (0.2 to 0.5)	0.2 (0.2 to 0.4)	-27.6 (-40.3 to -11.2)	-17.6 (-31.9 to 2.7)
Upper respiratory infections	374.6 (358.4 to 388.8)	357.3 (340.8 to 372.9)	-4.7 (-10.2 to 2.2)	-1.1 (-7.0 to 5.8)	4.4 (2.5 to 7.3)	4.2 (2.4 to 6.9)	-5.1 (-12.3 to 3.5)	-1.1 (-8.6 to 7.5)
Otitis media	404.2 (372.0 to 432.4)	357.7 (332.6 to 382.1)	-11.6 (-17.5 to -4.2)	-6.2 (-11.8 to 1.0)	8.2 (4.8 to 13.0)	7.0 (4.2 to 11.1)	-14.8 (-21.6 to -5.9)	-7.7 (-14.8 to 0.6)
Meningitis	-	-	-	-	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.5)	-20.6 (-35.7 to -4.6)	-19.8 (-35.3 to -2.0)
Pneumococcal meningitis	1.7 (1.0 to 2.7)	1.4 (0.8 to 2.3)	-18.6 (-41.8 to 5.1)	-36.9 (-47.3 to -6.1)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-10.4 (-31.4 to 15.5)	-14.0 (-34.1 to 12.5)
H influenzae type B meningitis	0.8 (0.3 to 1.9)	0.5 (0.2 to 1.1)	-45.9 (-64.3 to 4.3)	-45.6 (-62.6 to 11.1)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-34.7 (-63.3 to 30.6)	-28.9 (-59.4 to 42.7)
Meningococcal meningitis	0.5 (0.2 to 1.3)	0.3 (0.1 to 0.7)	-37.4 (-57.3 to 18.6)	-38.8 (-59.5 to 22.2)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-19.3 (-46.8 to 44.7)	-16.8 (-46.8 to 48.4)
Other meningitis	1.3 (0.7 to 2.7)	0.9 (0.5 to 1.9)	-30.9 (-48.6 to -7.5)	-33.0 (-48.9 to -6.8)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-26.9 (-50.6 to 11.5)	-25.2 (-49.8 to 14.0)
Encephalitis	1.1 (1.1 to 6.1)	2.5 (1.2 to 6.5)	129.1 (20.5 to 202)	129.1 (-29.7 to 6.3)	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.5)	9.6 (-3.3 to 35.4)	2.3 (-18.2 to 20.6)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-59.8 (-95.0 to 265.7)	-59.8 (-94.3 to 233.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-59.8 (-95.0 to 281.0)	-59.8 (-94.3 to 234.1)
Whooping cough	3.4 (2.7 to 4.4)	0.3 (0.2 to 0.4)	-90.6 (-91.7 to -89.3)	-86.4 (-87.9 to -84.6)	0.2 (0.1 to 0.3)	0.0 (0.0 to 0.0)	-90.7 (-94.0 to -86.1)	-86.6 (-91.3 to -79.9)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-73.2 (-79.8 to -31.7)	-76.1 (-81.8 to -48.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-73.0 (-79.9 to -31.6)	-75.8 (-81.9 to -48.4)
Measles	1.5 (1.5 to 1.6)	0.0 (0.0 to 0.0)	-99.8 (-99.9 to -99.8)	-99.8 (-99.8 to -99.7)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.0)	-99.8 (-99.9 to -99.8)	-99.8 (-99.8 to -99.7)
Varicella and herpes zoster	21.6 (20.0 to 23.3)	18.9 (17.1 to 21.0)	-12.2 (-23.0 to -1.4)	-2.2 (-10.9 to 7.3)	0.6 (0.3 to 0.9)	0.6 (0.4 to 1.0)	12.4 (-13.1 to 43.6)	-1.3 (-22.8 to 22.1)
Neglected tropical diseases and malaria	-	-	-	-	0.3 (0.1 to 0.5)	0.1 (0.1 to 0.2)	-52.9 (-78.7 to -23.8)	-60.6 (-82.1 to -38.7)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.3 (-71.4 to 181.1)	29.7 (-68.6 to 213.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.3 (-69.4 to 188.1)	35.6 (-65.6 to 220.4)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Visceral leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Cysticercosis	0.5 (0.2 to 1.3)	0.1 (0.0 to 0.2)	-84.6 (-96.0 to -41.0)	-87.2 (-96.8 to -55.7)	0.2 (0.1 to 0.4)	0.0 (0.0 to 0.1)	-83.3 (-96.0 to -32.6)	-86.1 (-96.1 to -50.7)
Cystic echinococcosis	1.1 (1.0 to 1.3)	0.9 (0.8 to 0.9)	-22.7 (-31.8 to -14.9)	-36.0 (-43.5 to -29.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-20.7 (-36.0 to -0.8)	-33.7 (-46.3 to -17.2)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.3 (-51.5 to 8.9)	-15.8 (-54.5 to 2.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.3 (-51.5 to 8.9)	-15.8 (-54.5 to 2.4)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Ascariasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trichuriasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Hookworm disease	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.9 (-46.5 to 46.4)	4.4 (-48.5 to 45.1)
Maternal disorders	-	-	-	-	0.7 (0.4 to 1.0)	0.4 (0.2 to 0.6)	-43.7 (-54.6 to -29.1)	-49.3 (-59.0 to -36.5)
Maternal hemorrhage	1.3 (1.0 to 1.6)	1.2 (1.0 to 1.3)	-10.0 (-30.1 to 19.4)	-21.1 (-40.2 to 6.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-37.3 (-62.0 to 8.1)	-36.3 (-63.5 to 9.0)
Maternal sepsis and other maternal infections	19.6 (11.7 to 30.7)	6.0 (3.8 to 8.7)	-69.4 (-76.6 to -59.6)	-69.6 (-76.6 to -59.1)	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.1)	-71.2 (-77.6 to -61.5)	-73.2 (-79.6 to -64.5)
Maternal hypertensive disorders	5.5 (3.6 to 7.9)	4.2 (2.8 to 6.3)	-24.9 (-31.0 to -11.4)	-31.9 (-40.8 to -22.1)	0.3 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-22.3 (-42.0 to 2.4)	-32.2 (-49.4 to -11.1)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.1 (-31.8 to -12.8)	-33.6 (-41.5 to -25.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.1 (-31.9 to -12.8)	-33.6 (-41.5 to -25.0)
Complications of abortion	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-9.8 (-20.6 to 3.8)	-20.9 (-30.3 to -8.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.8 (-20.6 to 3.8)	-20.9 (-30.4 to -8.6)
Other maternal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-56.8 (-67.5 to -14.9)	-51.2 (-70.7 to -21.9)
Neonatal disorders	-	-	-	-	49.0 (32.2 to 71.5)	38.4 (26.2 to 54.7)	-22.0 (-48.9 to 23.7)	-17.5 (-46.0 to 28.6)
Preterm birth complications	189.5 (145.3 to 244.0)	185.8 (144.6 to 237.8)	-1.7 (-18.7 to 18.6)	0.3 (-17.4 to 21.1)	22.3 (15.1 to 31.0)	23.7 (16.4 to 32.0)	6.5 (-22.0 to 40.3)	11.8 (-18.4 to 47.0)
Neonatal encephalopathy due to birth asphyxia and trauma	70.8 (36.3 to 139.5)	27.4 (13.3 to 57.2)	-60.4 (-82.9 to -29.6)	-57.9 (-81.5 to -24.1)	17.4 (9.7 to 29.2)	7.5 (4.1 to 13.1)	-54.6 (-80.5 to -20.5)	-50.3 (-78.5 to -12.5)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-39.3 (-22.9 to -9.6)	8.1 (3.2 to 21.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.3 (-32.4 to 11.4)	12.0 (-9.4 to 35.7)
Hemolytic disease and other neonatal jaundice	15.3 (4.7 to 34.3)	8.8 (2.2 to 43.9)	-41.8 (-91.7 to 80.4)	-59.1 (-91.3 to 830.1)	5.2 (1.7 to 11.0)	3.2 (0.8 to 15.3)	-56.7 (-90.0 to 78.6)	55.0 (-89.4 to 760.7)
Other neonatal disorders	-	-	-	-	4.1 (2.1 to 7.2)	4.0 (2.4 to 7.0)	-1.2 (-48.6 to 103.5)	4.3 (-45.9 to 112.1)
Nutritional deficiencies	-	-	-	-	176.0 (116.0 to 258.4)	135.3 (89.1 to 198.5)	-22.9 (-28.9 to -18.1)	-0.2 (-7.1 to 4.8)
Protein-energy malnutrition	26.9 (19.0 to 37.1)	16.3 (11.7 to 22.7)	-39.0 (-62.0 to -2.4)	-13.0 (-46.0 to 39.8)	3.4 (1.9 to 5.4)	2.1 (1.2 to 3.3)	-38.6 (-62.3 to -0.5)	-12.3 (-46.2 to 42.2)
Iodine deficiency	369.8 (149.0 to 897.1)	329.9 (161.4 to 667.7)	-7.4 (-75.4 to 205.1)	-13.7 (-76.3 to 173.7)	6.7 (2.2 to 17.6)	5.9 (2.4 to 12.7)	-5.6 (-75.4 to 200.9)	-13.2 (-76.9 to 172.3)
Vitamin A deficiency	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Iron deficiency anemia	5,852.4 (5,721.5 to 5,985.7)	5,360.4 (5,236.7 to 5,489.2)	-8.3 (-10.7 to -5.9)	2.4 (-0.2 to 5.2)	162.7 (107.8 to 239.3)	126.5 (83.0 to 187.2)	-22.1 (-26.3 to -19.3)	1.9 (-2.5 to 5.9)

Appendix Table G.4 - Poland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	3.2 (1.2 to 6.0)	0.8 (0.3 to 2.1)	-80.5 (-89.9 to -6.0)	-72.0 (-85.5 to 35.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	15.2 (9.2 to 24.5)	12.6 (7.4 to 20.6)	-18.1 (-29.7 to -3.7)	-2.1 (-19.4 to 15.5)
Sexually transmitted diseases excluding HIV	-	-	-	-	6.4 (3.3 to 12.5)	6.6 (3.4 to 12.3)	2.8 (-8.4 to 15.0)	-4.0 (-15.1 to 8.5)
Syphilis	0.9 (0.8 to 1.0)	1.1 (0.9 to 1.2)	24.6 (4.3 to 49.3)	-8.5 (-24.0 to 10.3)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	23.3 (9.1 to 68.3)	-8.1 (-32.2 to 24.1)
Chlamydial infection	883.1 (772.4 to 987.7)	892.4 (806.6 to 984.3)	1.3 (-13.0 to 19.9)	1.7 (-15.9 to 17.2)	1.3 (1.3 to 4.5)	2.6 (1.4 to 4.6)	1.1 (-13.7 to 22.4)	1.9 (-16.6 to 20.0)
Gonococcal infection	207.2 (166.3 to 246.6)	189.7 (150.6 to 226.1)	-9.5 (-28.9 to 22.0)	-8.7 (-28.7 to 23.2)	0.8 (0.4 to 1.5)	0.7 (0.4 to 1.3)	-13.0 (-35.9 to 18.2)	-12.5 (-36.4 to 19.1)
Trichomoniasis	503.7 (377.7 to 657.1)	547.7 (404.7 to 705.8)	10.2 (-30.2 to 57.4)	11.1 (-34.2 to 63.0)	0.9 (0.3 to 2.1)	0.9 (0.4 to 1.9)	8.6 (-34.8 to 64.0)	10.0 (-39.0 to 68.3)
Genital herpes	6,737.2 (6,093.9 to 7,312.3)	7,364.9 (6,704.7 to 8,098.3)	9.2 (-3.5 to 25.3)	-9.9 (-20.5 to 3.6)	1.7 (0.5 to 4.3)	1.9 (0.6 to 4.7)	7.6 (-6.0 to 24.1)	-9.7 (-29.9 to 4.6)
Other sexually transmitted diseases	9.1 (6.9 to 12.1)	7.5 (5.6 to 10.1)	-17.7 (-29.9 to -0.4)	-18.6 (-30.9 to -0.5)	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-8.2 (-31.6 to 29.8)	-8.6 (-35.5 to 23.2)
Hepatitis	-	-	-	-	1.3 (0.8 to 1.9)	1.1 (0.7 to 1.6)	-13.1 (-22.5 to -3.0)	-13.1 (-22.2 to -3.0)
Hepatitis A	37.6 (36.5 to 38.7)	29.3 (28.4 to 30.2)	-22.0 (-22.2 to -21.8)	-12.7 (-13.9 to -11.6)	1.0 (0.6 to 1.5)	0.9 (0.6 to 1.3)	-11.4 (-21.8 to 0.2)	-8.7 (-19.4 to 2.7)
Hepatitis B	389.6 (333.1 to 444.3)	275.3 (242.4 to 309.4)	-29.1 (-41.0 to -14.4)	-33.8 (-45.1 to -19.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-23.8 (-48.1 to 15.1)	-31.9 (-53.1 to 0.5)
Hepatitis C	495.2 (453.8 to 539.4)	445.5 (410.4 to 480.4)	-9.9 (-20.2 to 1.1)	-25.0 (-34.1 to -16.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-9.5 (-34.4 to 30.4)	-23.8 (-43.8 to 4.3)
Hepatitis E	-	-	-	-	4.9 (-9.9 to 21.6)	1.1 (-13.7 to 13.5)	-77.6 (-113.0 to -42.2)	-77.6 (-113.0 to -42.2)
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	247.5 (207.4 to 288.3)	193.4 (169.6 to 217.1)	-21.6 (-34.7 to -5.3)	1.8 (-18.8 to 26.1)	7.5 (4.5 to 11.2)	4.9 (3.1 to 7.1)	-35.7 (-54.8 to -12.1)	1.0 (-31.8 to 40.4)
Non-communicable diseases	-	-	-	-	3,496.9 (2,609.0 to 4,539.5)	4,238.3 (3,130.2 to 5,486.3)	21.3 (17.6 to 24.7)	1.6 (-1.5 to 4.3)
Neoplasms	-	-	-	-	42.5 (31.5 to 54.3)	72.4 (54.1 to 93.2)	71.4 (53.9 to 86.4)	23.2 (10.0 to 33.4)
Esophageal cancer	2.5 (2.0 to 2.9)	3.7 (2.9 to 4.7)	49.3 (15.6 to 97.8)	3.4 (-19.9 to 37.8)	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.8)	-0.7 (-7.3 to 90.1)	-0.7 (-24.6 to 28.7)
Stomach cancer	18.0 (15.5 to 20.9)	19.2 (16.5 to 22.4)	6.9 (-11.0 to 27.8)	-26.0 (-38.4 to -11.9)	2.2 (1.6 to 3.0)	2.2 (1.6 to 2.9)	-1.7 (-19.3 to 19.1)	-32.2 (-43.7 to -17.5)
Liver cancer	-	-	-	-	0.5 (0.4 to 0.8)	0.6 (0.4 to 0.8)	4.7 (-2.6 to 55.6)	-29.3 (-47.1 to 4.3)
Liver cancer due to hepatitis B	0.4 (0.4 to 1.0)	0.5 (0.2 to 0.8)	-33.7 (-73.3 to 29.5)	-52.9 (-80.9 to -7.9)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-39.6 (-72.9 to 7.3)	-57.3 (-80.7 to -24.8)
Liver cancer due to hepatitis C	0.6 (0.3 to 0.9)	1.4 (0.8 to 2.1)	123.0 (19.3 to 350.9)	50.7 (-20.0 to 202.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	107.4 (24.4 to 268.6)	39.2 (-16.1 to 145.1)
Liver cancer due to alcohol use	1.1 (0.7 to 1.5)	1.2 (0.8 to 1.9)	7.5 (-38.8 to 90.5)	-28.2 (-59.3 to 27.8)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	2.0 (-35.6 to 67.4)	-32.1 (-57.5 to 9.1)
Liver cancer due to other causes	0.5 (0.3 to 0.7)	0.3 (0.2 to 0.5)	-40.4 (-70.1 to 15.6)	-58.8 (-79.0 to -20.3)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-43.9 (-68.4 to -0.5)	-61.5 (-78.1 to -32.1)
Larynx cancer	10.7 (7.7 to 14.8)	17.5 (13.4 to 21.8)	66.4 (7.5 to 145.2)	18.8 (-22.7 to 73.3)	1.3 (0.9 to 1.8)	1.6 (1.1 to 2.2)	25.9 (-5.6 to 69.2)	9.6 (-31.7 to 18.8)
Tracheal, bronchus and lung cancer	28.9 (25.7 to 32.3)	43.0 (37.3 to 48.4)	49.5 (24.0 to 74.6)	5.5 (-12.2 to 22.6)	4.7 (3.3 to 6.1)	6.4 (4.6 to 8.2)	37.2 (15.7 to 60.2)	-3.1 (-18.1 to 12.6)
Breast cancer	54.1 (41.8 to 70.5)	168.4 (151.9 to 187.6)	212.6 (142.4 to 304.6)	119.8 (71.1 to 182.9)	4.9 (3.5 to 7.0)	9.6 (6.6 to 13.1)	96.6 (50.1 to 141.7)	39.6 (6.1 to 71.7)
Cervical cancer	37.5 (29.3 to 43.7)	25.7 (20.0 to 31.7)	-31.9 (-44.9 to -15.5)	-46.5 (-57.2 to -33.8)	2.8 (1.9 to 3.9)	1.9 (1.3 to 2.7)	-31.8 (-47.2 to -13.7)	-46.7 (-58.8 to -33.1)
Uterine cancer	13.9 (10.4 to 25.5)	35.6 (19.8 to 48.1)	180.4 (-7.5 to 304.5)	103.3 (-34.8 to 184.6)	0.9 (0.6 to 1.4)	2.3 (1.2 to 3.5)	17.9 (-13.1 to 99.5)	38.8 (-38.4 to 176.6)
Prostate cancer	35.9 (29.7 to 44.1)	91.0 (72.5 to 113.3)	153.6 (103.1 to 223.7)	75.5 (41.1 to 122.1)	3.5 (2.4 to 4.7)	8.8 (6.1 to 12.0)	152.6 (98.9 to 211.9)	72.6 (36.7 to 113.6)
Colon and rectum cancer	49.7 (46.2 to 53.4)	114.5 (103.8 to 125.0)	130.4 (106.0 to 159.2)	60.2 (43.2 to 80.1)	4.5 (3.3 to 5.9)	9.5 (6.9 to 12.2)	109.8 (83.3 to 138.7)	44.9 (27.0 to 63.7)
Lip and oral cavity cancer	10.4 (8.3 to 12.9)	17.6 (13.0 to 22.5)	68.6 (13.6 to 137.4)	19.2 (-17.8 to 67.2)	1.0 (0.7 to 1.3)	1.6 (1.0 to 2.2)	63.7 (8.1 to 121.0)	14.6 (-22.1 to 54.2)
Nasopharynx cancer	1.9 (1.3 to 2.6)	1.4 (1.0 to 2.0)	-23.5 (-49.1 to 14.7)	-42.6 (-61.2 to -15.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-25.7 (-47.4 to -4.6)	-44.7 (-60.5 to -22.8)
Other pharynx cancer	3.2 (2.1 to 4.8)	5.8 (3.6 to 8.4)	79.4 (-7.3 to 213.6)	27.2 (-33.0 to 122.2)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	67.9 (-7.7 to 171.3)	17.8 (-33.2 to 91.9)
Gallbladder and biliary tract cancer	2.3 (1.8 to 3.2)	2.6 (1.9 to 3.3)	16.2 (-19.1 to 55.0)	-22.6 (-45.8 to 2.0)	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.9)	0.6 (-22.2 to 50.5)	-26.1 (-47.8 to -0.3)
Pancreatic cancer	3.7 (3.2 to 4.3)	5.2 (4.5 to 6.0)	40.0 (14.7 to 73.1)	-4.4 (-21.5 to 18.6)	0.8 (0.5 to 1.0)	1.0 (0.7 to 1.3)	34.5 (6.8 to 63.2)	-7.3 (-25.9 to 11.7)
Malignant skin melanoma	12.8 (9.5 to 18.4)	23.4 (15.7 to 31.9)	83.8 (34.2 to 134.5)	39.6 (-2.4 to 76.9)	0.9 (0.5 to 1.4)	1.5 (0.9 to 2.3)	74.8 (26.1 to 122.5)	32.0 (-3.7 to 65.6)
Non-melanoma skin cancer	33.5 (22.3 to 44.7)	58.3 (41.0 to 79.8)	74.5 (13.1 to 176.6)	15.4 (-24.9 to 79.7)	1.5 (0.6 to 1.4)	2.5 (1.1 to 3.0)	60.0 (3.4 to 225.1)	23.8 (-34.0 to 102.5)
Ovarian cancer	12.5 (10.7 to 14.7)	18.5 (15.4 to 21.7)	47.6 (15.6 to 83.3)	9.3 (-13.4 to 36.1)	1.6 (1.1 to 2.2)	2.3 (1.6 to 3.1)	43.1 (6.1 to 87.2)	5.8 (-22.1 to 37.6)
Testicular cancer	7.7 (5.1 to 11.9)	9.7 (5.6 to 14.7)	26.8 (-29.6 to 119.7)	17.5 (-34.5 to 100.3)	0.5 (0.3 to 0.8)	0.6 (0.3 to 1.0)	11.0 (-30.8 to 106.9)	11.0 (-35.9 to 89.8)
Kidney cancer	14.7 (12.8 to 17.1)	36.7 (30.6 to 43.2)	150.3 (101.7 to 203.6)	81.1 (46.1 to 118.6)	1.1 (0.8 to 1.6)	2.6 (1.8 to 3.6)	133.4 (83.3 to 188.2)	69.1 (33.5 to 106.4)
Bladder cancer	21.3 (18.9 to 26.7)	46.0 (36.0 to 54.5)	106.7 (62.9 to 158.0)	106.7 (13.7 to 79.4)	1.8 (1.3 to 2.5)	3.5 (2.4 to 4.7)	90.4 (46.8 to 137.6)	31.7 (3.1 to 63.7)
Brain and nervous system cancer	9.0 (7.4 to 10.5)	12.8 (10.5 to 15.1)	42.7 (21.3 to 67.6)	16.2 (-1.7 to 36.1)	1.0 (0.7 to 1.3)	1.4 (0.9 to 1.9)	41.9 (15.4 to 71.4)	14.1 (-6.0 to 35.2)
Thyroid cancer	8.3 (6.6 to 11.9)	15.9 (10.9 to 20.1)	101.6 (15.4 to 173.2)	58.9 (-7.9 to 118.6)	0.5 (0.3 to 0.8)	1.0 (0.6 to 1.4)	92.6 (7.2 to 162.7)	50.2 (-14.7 to 103.5)
Mesothelioma	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	11.6 (-10.3 to 50.8)	-20.4 (-35.6 to 6.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	-11.2 (-9.8 to 51.2)	-21.0 (-35.2 to 7.3)
Hodgkin lymphoma	6.5 (4.6 to 8.4)	5.5 (4.1 to 8.5)	-16.2 (-40.7 to 28.7)	-24.4 (-46.3 to 13.8)	0.5 (0.4 to 0.9)	0.5 (0.3 to 0.7)	-25.2 (-44.2 to 19.3)	-33.2 (-50.1 to 3.9)
Non-Hodgkin lymphoma	11.0 (8.2 to 16.4)	22.0 (14.9 to 28.3)	104.9 (36.9 to 153.7)	53.9 (4.2 to 90.2)	0.9 (0.6 to 1.4)	1.6 (1.0 to 2.4)	90.1 (26.2 to 141.6)	42.9 (-4.0 to 80.0)
Multiple myeloma	2.0 (1.2 to 3.4)	4.4 (2.7 to 6.3)	122.7 (10.5 to 290.2)	57.8 (-22.8 to 174.9)	0.5 (0.2 to 0.8)	0.9 (0.5 to 1.5)	107.4 (0.2 to 287.7)	46.3 (-29.3 to 171.2)
Leukemia	10.0 (8.5 to 11.7)	16.1 (13.4 to 18.9)	59.6 (29.1 to 97.0)	21.1 (-2.4 to 49.4)	1.4 (1.0 to 1.9)	2.2 (1.5 to 2.9)	56.3 (22.1 to 99.0)	34.9 (9.2 to 43.1)
Other neoplasms	28.1 (23.7 to 33.9)	81.9 (65.4 to 98.2)	195.5 (125.8 to 260.5)	118.6 (75.3 to 163.8)	2.0 (1.4 to 2.8)	5.5 (3.6 to 7.5)	172.6 (106.7 to 238.8)	102.4 (57.8 to 146.9)
Cardiovascular diseases	-	-	-	-	74.4 (52.7 to 103.0)	137.5 (97.9 to 187.3)	86.9 (49.9 to 117.8)	27.6 (1.8 to 49.0)
Rheumatic heart disease	6.4 (6.0 to 6.9)	9.2 (8.7 to 9.8)	44.0 (30.8 to 56.8)	5.4 (-4.1 to 14.3)	0.7 (0.5 to 1.0)	1.0 (0.7 to 1.4)	41.6 (16.0 to 72.9)	4.4 (-14.4 to 26.7)
Ischemic heart disease	509.7 (446.6 to 593.8)	735.6 (667.1 to 816.0)	45.2 (21.5 to 68.0)	-1.3 (-17.0 to 14.5)	29.4 (20.0 to 40.1)	47.6 (33.4 to 63.4)	63.1 (34.3 to 91.3)	8.5 (-6.6 to 26.6)
Cerebrovascular disease	-	-	-	-	7.3 (5.0 to 10.0)	11.6 (7.8 to 15.6)	59.9 (21.2 to 102.4)	13.1 (-10.2 to 47.4)
Ischemic stroke	39.6 (33.3 to 46.4)	62.7 (51.6 to 75.2)	57.2 (21.8 to 103.1)	13.1 (-11.9 to 45.1)	5.9 (3.9 to 8.2)	9.3 (6.2 to 12.9)	57.0 (21.7 to 106.3)	13.2 (-10.1 to 48.0)
Hemorrhagic stroke	9.0 (7.4 to 11.0)	13.5 (10.7 to 16.8)	48.9 (9.5 to 106.5)	12.9 (-16.4 to 57.5)	1.4 (0.9 to 2.0)	2.1 (1.3 to 3.0)	46.5 (5.5 to 103.4)	11.9 (-17.5 to 56.6)
Hypertensive heart disease	97.0 (87.9 to 106.9)	181.8 (168.7 to 196.8)	87.4 (66.5 to 111.4)	23.4 (9.8 to 39.1)	10.4 (7.1 to 14.3)	19.4 (13.8 to 26.5)	88.0 (66.2 to 113.4)	24.7 (10.2 to 41.1)
Cardiomyopathy and myocarditis	79.2 (69.9 to 89.5)	105.2 (97.5 to 113.7)	33.3 (14.3 to 53.4)	8.7 (-21.7 to 5.2)	8.3 (5.8 to 11.5)	11.1 (7.7 to 15.0)	33.4 (13.8 to 55.0)	-8.2 (-21.8 to 7.2)
Atrial fibrillation and flutter	28.2 (25.3 to 31.5)	124.5 (98.6 to 157.9)	337.2 (245.4 to 462.3)	189.7 (129.8 to 271.5)	2.2 (1.5 to 3.0)	9.6 (6.1 to 14.4)	340.2 (238.8 to 473.4)	139.9 (129.3 to 288.3)
Peripheral vascular disease	1,135.4 (858.8 to 1,436.6)	1,735.5 (1,277.8 to 2,175.7)	52.4 (9.1 to 111.0)	2.3 (-27.5 to 41.6)	1.5 (0.9 to 4.8)	1.5 (0.6 to 3.1)	-35.6 (-73.1 to 72.9)	-62.1 (-83.9 to 9.8)
Endocarditis	0.7 (0.6 to 1.0)	2.3 (1.9 to 2.7)	216.8 (135.5 to 319.9)	144.0 (81.4 to 221.5)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	157.3 (77.5 to 250.0)	97.5 (38.5 to 167.1)
Other cardiovascular and circulatory diseases	198.2 (102.9 to 405.3)	509.4 (288.0 to 723.9)	176.4 (6.6 to 437.8)	96.1 (-25.6 to 290.8)	13.8 (6.5 to 28.0)	35.6 (17.9 to 56.2)	178.3 (4.5 to 445.8)	98.0 (-25.7 to 291.9)
Chronic respiratory diseases	-	-	-	-	113.2 (144.6 to 285.9)	146.3 (170.8 to 331.4)	28.7 (-1.1 to 31.1)	-0.5 (-14.0 to 12.8)
Chronic obstructive pulmonary disease	1,938.4 (1,846.0 to 2,027.3)	2,524.5 (2,407.6 to 2,640.3)	30.4 (26.5 to 33.8)	-0.0 (-2.9 to 2.6)	113.2 (97.2 to 159.2)	146.3 (97.2 to 210.2)	28.7 (-2.4 to 59.6)	-0.5 (-24.6 to 2

Appendix Table G.4 - Poland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	698.7 (659.8 to 737.8)	771.1 (727.6 to 815.6)	10.5 (1.6 to 19.8)	-4.1 (-8.4 to 8.1)	20.3 (12.9 to 30.6)	22.4 (14.2 to 33.2)	10.2 (0.6 to 19.8)	-0.1 (-8.6 to 8.6)
Injuries	-	-	-	-	503.4 (380.5 to 645.4)	458.8 (328.1 to 619.7)	-9.1 (-18.0 to 0.7)	-32.1 (-39.0 to -24.6)
Transport injuries	-	-	-	-	83.2 (62.6 to 108.1)	44.3 (31.4 to 60.2)	-47.0 (-52.7 to -40.2)	-58.1 (-62.5 to -52.7)
Road injuries	-	-	-	-	63.3 (47.7 to 82.6)	33.3 (23.3 to 45.5)	-47.7 (-53.4 to -40.9)	-58.7 (-63.1 to -53.4)
Pedestrian road injuries	-	-	-	-	15.7 (11.7 to 20.4)	8.0 (5.7 to 11.1)	-49.2 (-55.1 to -41.9)	-61.2 (-65.6 to -55.4)
Cyclist road injuries	-	-	-	-	12.8 (9.6 to 17.0)	6.8 (4.8 to 9.3)	-46.9 (-52.5 to -41.1)	-58.8 (-63.0 to -54.2)
Motorcyclist road injuries	-	-	-	-	5.0 (3.7 to 6.5)	2.5 (1.7 to 3.5)	-50.0 (-57.0 to -41.7)	-58.7 (-64.5 to -51.8)
Motor vehicle road injuries	-	-	-	-	29.3 (22.0 to 38.1)	15.8 (11.1 to 21.6)	-46.0 (-53.0 to -38.2)	-56.8 (-62.3 to -50.8)
Other road injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.1 (0.1 to 0.2)	-77.2 (-80.3 to -73.6)	-82.2 (-84.6 to -79.4)
Other transport injuries	-	-	-	-	19.9 (14.8 to 25.9)	11.0 (7.8 to 14.9)	-44.9 (-50.7 to -37.4)	-55.9 (-60.5 to -49.9)
Unintentional injuries	-	-	-	-	413.9 (312.4 to 529.4)	410.0 (293.1 to 553.1)	-1.2 (-11.0 to 9.4)	-26.9 (-34.3 to -18.9)
Falls	-	-	-	-	339.6 (256.6 to 432.0)	345.4 (246.7 to 466.5)	1.4 (-10.0 to 13.9)	-26.6 (-35.0 to -17.4)
Drowning	-	-	-	-	1.5 (1.1 to 2.0)	0.9 (0.6 to 1.2)	-41.7 (-48.6 to -32.3)	-53.6 (-59.8 to -46.4)
Fire, heat, and hot substances	-	-	-	-	3.2 (2.4 to 4.2)	2.4 (1.8 to 3.2)	-24.2 (-30.0 to -17.9)	-39.0 (-43.8 to -34.0)
Poisonings	-	-	-	-	1.0 (0.7 to 1.3)	0.5 (0.3 to 0.6)	-52.5 (-60.1 to -43.5)	-57.6 (-64.8 to -49.3)
Exposure to mechanical forces	-	-	-	-	62.3 (47.0 to 82.2)	38.5 (27.6 to 52.2)	-38.2 (-43.5 to -33.2)	-47.4 (-52.1 to -43.1)
Unintentional firearm injuries	-	-	-	-	0.9 (0.7 to 1.2)	0.5 (0.3 to 0.7)	-48.3 (-57.7 to -37.0)	-55.7 (-63.5 to -46.3)
Unintentional suffocation	-	-	-	-	0.4 (0.3 to 0.5)	0.2 (0.2 to 0.3)	-39.6 (-47.1 to -32.2)	-48.4 (-55.1 to -41.6)
Other exposure to mechanical forces	-	-	-	-	61.0 (46.0 to 80.4)	37.8 (27.0 to 51.3)	-38.1 (-43.4 to -33.1)	-47.3 (-52.0 to -43.0)
Adverse effects of medical treatment	-	-	-	-	0.4 (0.3 to 0.7)	0.6 (0.4 to 0.9)	33.4 (21.2 to 47.7)	5.4 (-3.7 to 16.4)
Animal contact	-	-	-	-	2.1 (1.6 to 2.8)	2.1 (1.5 to 2.7)	-1.7 (-11.3 to 9.6)	-12.9 (-21.4 to -3.3)
Venomous animal contact	-	-	-	-	0.7 (0.5 to 1.0)	0.8 (0.5 to 1.0)	2.3 (-12.3 to 17.9)	8.3 (22.0 to 5.7)
Non-venomous animal contact	-	-	-	-	1.3 (1.0 to 1.8)	1.3 (0.9 to 1.8)	-3.9 (-15.0 to 9.6)	-15.3 (-24.7 to -4.1)
Foreign body	-	-	-	-	2.9 (2.2 to 3.6)	2.5 (1.8 to 3.3)	-13.5 (-22.9 to -4.6)	-27.1 (-34.1 to -20.0)
Pulmonary aspiration and foreign body in airway	-	-	-	-	1.0 (0.7 to 1.2)	0.6 (0.5 to 0.9)	-34.5 (-45.0 to -21.0)	-44.3 (-52.9 to -33.4)
Foreign body in eyes	-	-	-	-	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.7)	0.9 (-5.1 to 7.0)	-9.2 (-16.3 to -3.1)
Foreign body in other body part	-	-	-	-	1.4 (1.1 to 1.9)	1.4 (1.0 to 1.8)	-4.3 (-15.0 to 7.1)	-21.7 (-29.7 to -12.7)
Other unintentional injuries	-	-	-	-	0.9 (0.6 to 1.1)	17.0 (12.3 to 23.1)	1,863.1 (1,626.6 to 2,097.9)	1,429.4 (1,248.6 to 1,622.4)
Self-harm and interpersonal violence	-	-	-	-	6.3 (4.7 to 8.1)	4.6 (3.3 to 6.2)	-28.1 (-35.8 to -18.9)	-42.8 (-49.0 to -35.7)
Self-harm	-	-	-	-	3.8 (2.8 to 4.9)	3.0 (2.1 to 4.0)	-20.9 (-29.6 to -10.5)	-37.4 (-44.1 to -29.3)
Interpersonal violence	-	-	-	-	2.6 (1.9 to 3.3)	1.6 (1.1 to 2.1)	-38.4 (-45.8 to -29.8)	-50.7 (-56.4 to -43.8)
Assault by firearm	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-36.0 (-41.7 to -29.6)	-49.6 (-54.0 to -44.7)
Assault by sharp object	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-24.7 (-33.7 to -13.6)	-39.4 (-46.4 to -30.6)
Assault by other means	-	-	-	-	1.9 (1.4 to 2.4)	1.1 (0.8 to 1.5)	-41.5 (-48.9 to -32.6)	-53.1 (-58.9 to -46.0)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Portugal prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,252.5 (928.7 to 1,608.4)	1,492.9 (1,105.8 to 1,917.6)	19.1 (15.2 to 24.0)	19.1 (5.4 to 2.3)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	58.0 (40.3 to 81.5)	60.2 (41.2 to 86.0)	3.6 (-4.7 to 12.4)	4.9 (-2.3 to 11.7)
HIV/AIDS and tuberculosis	-	-	-	-	2.0 (1.0 to 3.7)	5.5 (2.6 to 9.6)	170.1 (88.5 to 294.0)	115.5 (50.0 to 212.9)
Tuberculosis	2.8 (2.7 to 2.9)	3.0 (2.9 to 3.1)	5.7 (3.0 to 8.4)	-7.8 (-10.1 to -5.3)	0.6 (0.6 to 1.1)	0.9 (0.6 to 1.2)	5.5 (9.6 to 21.9)	-7.2 (-21.8 to 8.1)
HIV/AIDS	-	-	-	-	1.2 (0.3 to 2.7)	4.6 (1.8 to 8.6)	229.8 (125.9 to 694.0)	278.8 (77.0 to 525.3)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	110.9 (13.6 to 303.5)	70.6 (7.5 to 227.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	110.9 (13.6 to 305.5)	70.6 (8.0 to 230.2)
HIV/AIDS resulting in other diseases	9.7 (3.9 to 18.5)	58.5 (26.9 to 101.4)	505.3 (312.9 to 914.7)	365.3 (215.5 to 688.3)	1.2 (0.3 to 2.7)	4.6 (1.8 to 8.6)	324.7 (126.3 to 712.6)	230.5 (77.1 to 532.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	5.5 (3.5 to 8.4)	5.2 (3.3 to 7.9)	-6.0 (-13.3 to 1.4)	-11.9 (-18.8 to -4.6)
Diarrheal diseases	3.6 (3.1 to 4.1)	3.2 (2.9 to 3.6)	-9.7 (-24.9 to 7.2)	-19.0 (-37.3 to 2.8)	0.6 (0.4 to 0.8)	0.5 (0.3 to 0.7)	-10.7 (-28.3 to 10.5)	-19.3 (-40.4 to 5.9)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-59.1 to 20.8)	0.0 (-59.0 to 19.5)
Typhoid fever	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-26.8 (-39.2 to -10.7)	-28.9 (-40.6 to -11.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.8 (-39.2 to -10.6)	-28.9 (-40.7 to -11.8)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.5 (-19.6 to 40.2)	4.8 (-16.0 to 41.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.5 (-19.6 to 40.2)	4.8 (-16.1 to 41.3)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.4 (-98.5 to 1,848.7)	-9.8 (-98.5 to 1,848.4)
Lower respiratory infections	0.9 (0.9 to 1.0)	0.8 (0.8 to 0.8)	-13.1 (-17.8 to -7.3)	-32.1 (-36.0 to -27.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-13.2 (-28.2 to 3.1)	-30.8 (-41.8 to -16.7)
Upper respiratory infections	151.8 (144.7 to 159.8)	156.7 (150.0 to 163.6)	3.2 (-3.3 to 10.7)	0.5 (-6.2 to 8.4)	1.8 (1.0 to 3.0)	1.8 (1.0 to 3.1)	2.8 (-1.1 to 11.5)	0.5 (-7.3 to 9.3)
Otitis media	129.6 (112.6 to 143.7)	115.6 (102.8 to 126.8)	-11.0 (-22.2 to 4.1)	-16.0 (-25.9 to -2.3)	2.4 (1.4 to 3.8)	2.1 (1.2 to 3.4)	-11.4 (-22.6 to 3.5)	-15.9 (-25.3 to -2.4)
Meningitis	-	-	-	-	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-27.1 (-49.9 to -7.5)	-32.4 (-52.9 to -13.7)
Pneumococcal meningitis	0.7 (0.4 to 1.1)	0.6 (0.4 to 0.9)	-14.0 (-31.8 to 7.5)	-37.3 (-42.5 to -9.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-11.7 (-32.6 to 17.4)	-21.2 (-40.3 to 6.0)
H influenzae type B meningitis	0.4 (0.2 to 1.0)	0.3 (0.1 to 0.7)	-33.1 (-64.5 to 1.5)	-37.9 (-66.0 to -1.6)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-34.4 (-72.0 to 18.4)	-35.6 (-72.4 to 17.7)
Meningococcal meningitis	0.3 (0.1 to 0.9)	0.3 (0.1 to 0.7)	-24.3 (-47.8 to 12.9)	-33.3 (-54.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-21.7 (-47.7 to 22.4)	-28.3 (-52.3 to 13.8)
Other meningitis	0.8 (0.4 to 1.6)	0.5 (0.2 to 1.1)	-32.2 (-59.5 to -6.1)	-38.3 (-62.2 to -14.5)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-34.4 (-66.0 to 10.9)	-38.2 (-69.1 to 3.7)
Encephalitis	0.3 (0.2 to 0.9)	0.4 (0.2 to 1.1)	22.4 (-9.2 to 32.2)	-5.9 (-21.7 to 14.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	19.6 (-1.1 to 45.2)	2.4 (-15.7 to 25.9)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-62.3 (-96.4 to 245.1)	-65.6 (-96.5 to 203.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-62.3 (-96.5 to 251.3)	-65.6 (-96.5 to 204.5)
Whooping cough	0.7 (0.6 to 0.9)	0.2 (0.1 to 0.2)	-75.7 (-77.5 to -73.8)	-70.3 (-72.5 to -67.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-75.9 (-82.3 to -67.6)	-70.4 (-78.4 to -60.4)
Tetanus	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-94.9 (-98.2 to -87.8)	-95.3 (-98.4 to -88.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-93.7 (-97.9 to -84.9)	-94.1 (-98.1 to -85.5)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -96.7)	-100.0 (-100.0 to -95.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -96.7)	-100.0 (-100.0 to -95.9)
Varicella and herpes zoster	8.3 (7.2 to 9.4)	9.2 (7.9 to 11.0)	12.2 (-7.7 to 35.9)	-0.5 (-16.7 to 15.7)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	23.5 (-7.3 to 58.9)	-0.4 (-26.0 to 26.6)
Neglected tropical diseases and malaria	-	-	-	-	4.0 (1.2 to 9.0)	4.7 (1.2 to 10.9)	15.6 (-29.3 to 79.0)	-7.1 (-43.1 to 43.7)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.0 (-81.6 to 331.2)	-20.7 (-81.4 to 333.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.5 (-81.3 to 347.3)	-18.5 (-81.0 to 348.1)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.8 (-27.8 to 13.1)	-18.2 (-35.3 to 0.0)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.6 (-27.6 to 12.9)	-18.6 (-35.4 to 0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.6 (-27.6 to 13.0)	-18.6 (-35.4 to 0.4)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.5 (-56.2 to 94.8)	-16.5 (-58.7 to 72.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.5 (-56.2 to 95.3)	-16.5 (-58.8 to 72.6)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	1.1 (0.4 to 2.6)	0.2 (0.1 to 0.4)	-78.0 (-92.6 to -13.3)	-81.9 (-93.8 to -34.1)	0.4 (0.1 to 0.9)	0.1 (0.0 to 0.2)	-74.5 (-91.8 to 2.8)	-79.3 (-93.0 to -18.8)
Cystic echinococcosis	0.8 (0.7 to 0.8)	0.3 (0.3 to 0.4)	-63.9 (-60.9 to -52.3)	-63.9 (-66.9 to -61.5)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-53.9 (-62.0 to -44.7)	-61.9 (-67.7 to -55.4)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.0 (-68.1 to 12.4)	-11.5 (-72.7 to 3.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.0 (-68.1 to 12.4)	-11.5 (-72.7 to 3.6)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	174.0 (106.5 to 249.5)	229.0 (148.4 to 325.8)	31.4 (-14.6 to 101.5)	4.9 (-31.6 to 60.7)	3.5 (0.9 to 8.6)	4.6 (1.1 to 10.7)	29.7 (-15.6 to 102.5)	4.3 (-32.1 to 62.5)
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.3 (-41.0 to 26.5)	-32.5 (-47.8 to 15.8)
Maternal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-20.2 (-44.3 to 15.2)	-22.7 (-45.6 to 10.1)
Maternal hemorrhage	1.9 (1.2 to 2.6)	1.8 (0.9 to 2.5)	-6.4 (-50.1 to 54.3)	-8.8 (-50.3 to 48.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-33.6 (-71.7 to 48.8)	-33.6 (-71.8 to 44.0)
Maternal sepsis and other maternal infections	1.1 (0.7 to 1.7)	1.0 (0.5 to 1.5)	-8.9 (-51.9 to 38.3)	-26.6 (-61.1 to 12.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.2 (-42.3 to 5.7)	-27.8 (-46.8 to -5.7)
Maternal hypertensive disorders	1.1 (0.7 to 1.6)	0.9 (0.6 to 1.4)	-13.9 (-25.7 to -1.1)	-18.0 (-27.2 to -8.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-14.8 (-36.1 to 14.7)	-18.9 (-38.3 to 7.6)
Obstructed labor	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-15.6 (-22.8 to -6.3)	-17.6 (-24.6 to -8.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-17.7 (-62.4 to 89.7)	-19.2 (-63.1 to 82.1)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.3 (8.9 to 33.8)	16.4 (5.7 to 29.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.3 (8.9 to 33.8)	16.4 (5.6 to 29.4)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Neonatal disorders	-	-	-	-	9.4 (6.6 to 13.0)	10.9 (7.5 to 14.8)	17.5 (-13.6 to 56.6)	14.3 (-16.0 to 52.4)
Preterm birth complications	46.8 (34.6 to 65.7)	47.9 (35.1 to 67.1)	1.8 (-18.7 to 26.4)	-2.6 (-21.9 to 20.0)	5.5 (3.8 to 7.7)	6.2 (4.3 to 8.5)	11.7 (-13.6 to 54.1)	8.8 (-16.0 to 50.4)
Neonatal encephalopathy due to birth asphyxia and trauma	11.1 (6.5 to 20.7)	4.6 (2.2 to 11.8)	-61.7 (-76.7 to -26.4)	-62.3 (-77.0 to -30.7)	2.4 (1.6 to 3.2)	1.1 (0.7 to 1.5)	-54.7 (-69.0 to -32.7)	-55.1 (-69.9 to -33.1)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.9 (-9.3 to 14.7)	4.5 (-24.8 to 42.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.3 (-45.5 to 16.4)	-3.8 (-32.6 to 44.1)
Hemolytic disease and other neonatal jaundice	2.2 (0.7 to 5.9)	2.1 (0.8 to 4.1)	-4.5 (-66.8 to 325.3)	-5.6 (-67.9 to 315.1)	0.9 (0.3 to 2.5)	0.9 (0.3 to 1.9)	2.7 (-63.8 to 353.9)	-0.5 (-65.4 to 345.6)
Other neonatal disorders	-	-	-	-	0.5 (0.3 to 1.1)	2.7 (0.9 to 4.4)	569.9 (13.8 to 1,034.9)	552.6 (12.1 to 1,007.1)
Nutritional deficiencies	-	-	-	-	34.1 (22.4 to 50.3)	30.9 (20.2 to 44.9)	-9.2 (-12.6 to -5.5)	0.6 (-2.5 to 4.2)
Protein-energy malnutrition	0.4 (0.2 to 0.6)	0.3 (0.1 to 0.5)	-23.5 (-54.2 to 18.3)	-62.3 (-73.6 to -37.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-31.2 (-60.8 to 26.9)	-61.5 (-76.5 to -31.7)
Iodine deficiency	126.7 (104.9 to 150.7)	82.7 (57.0 to 108.3)	-34.5 (-56.8 to -7.8)	-39.8 (-60.2 to -16.1)	2.2 (1.4 to 3.6)	1.5 (0.8 to 2.5)	-34.4 (-57.1 to -8.1)	-39.4 (-60.4 to -15.2)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-

Appendix Table G.4 - Portugal prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	1,181.4 (1,162.9 to 1,196.5)	1,205.7 (1,180.2 to 1,227.5)	1.9 (-0.4 to 4.0)	1.9 (0.6 to 5.0)	31.8 (21.1 to 46.8)	29.4 (19.2 to 43.1)	-7.4 (-10.9 to -4.0)	-7.4 (0.1 to 6.5)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.9 (1.8 to 4.6)	2.8 (1.7 to 4.5)	-4.5 (-16.9 to 10.1)	0.7 (-34.1 to 17.8)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.1 (0.6 to 2.2)	1.3 (0.7 to 2.4)	10.8 (-10.5 to 33.5)	2.4 (-19.5 to 24.5)
Syphilis	0.4 (0.3 to 0.5)	0.8 (0.6 to 0.9)	86.4 (35.3 to 130.7)	36.4 (-3.1 to 73.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	84.3 (20.6 to 167.5)	35.9 (-12.6 to 99.0)
Chlamydial infection	190.3 (138.7 to 250.8)	193.2 (134.3 to 249.7)	2.3 (-37.6 to 61.1)	4.3 (-38.5 to 62.3)	0.5 (0.3 to 1.0)	0.6 (0.3 to 1.0)	2.3 (-33.7 to 46.3)	3.8 (-34.5 to 46.7)
Gonococcal infection	34.8 (23.5 to 47.1)	25.2 (16.4 to 36.3)	-25.4 (-60.1 to 21.6)	-16.0 (-56.9 to 42.7)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.2)	-19.7 (-48.5 to 22.1)	-12.4 (-44.6 to 37.9)
Trichomoniasis	25.9 (13.4 to 37.7)	36.2 (22.7 to 49.4)	38.3 (-22.5 to 208.8)	32.3 (-31.0 to 208.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	48.2 (-23.7 to 324.7)	44.7 (-31.4 to 336.6)
Genital herpes	1,251.3 (1,066.0 to 1,412.3)	1,511.6 (1,344.0 to 1,699.5)	20.8 (0.3 to 46.8)	3.7 (-20.6 to 17.5)	3.7 (0.1 to 0.8)	3.7 (0.1 to 0.9)	8.1 (-3.2 to 44.5)	3.7 (-21.4 to 17.4)
Other sexually transmitted diseases	2.1 (1.5 to 2.8)	1.6 (1.2 to 2.2)	-20.5 (-37.0 to -4.6)	-33.3 (-46.7 to -19.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-9.2 (-39.9 to 38.0)	-9.2 (-45.7 to 30.2)
Hepatitis	-	-	-	-	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	-4.5 (-16.3 to 9.6)	-10.6 (-22.0 to 2.6)
Hepatitis A	7.6 (7.2 to 8.0)	7.1 (6.7 to 7.5)	-6.3 (-6.4 to -6.3)	-5.4 (-6.2 to -4.5)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.3)	-2.3 (-13.1 to 9.7)	-4.3 (-15.0 to 7.9)
Hepatitis B	144.3 (114.5 to 175.0)	106.9 (79.3 to 136.5)	-26.5 (-46.5 to -4.7)	-37.4 (-54.9 to -22.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-10.2 (-42.1 to 38.0)	-26.3 (-52.8 to 13.6)
Hepatitis C	124.2 (112.9 to 135.7)	110.2 (99.7 to 120.4)	-11.1 (-22.4 to 0.6)	-27.7 (-36.8 to -17.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.8 (-34.3 to 41.3)	23.0 (-44.1 to 8.5)
Hepatitis E	-	-	140.5 (72.5 to 285.7)	132.9 (67.4 to 285.3)	-	-	-	-
Leprosy	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-
Other infectious diseases	48.5 (41.1 to 55.7)	45.1 (40.3 to 50.3)	-7.2 (-20.3 to 9.3)	3.1 (-12.4 to 24.3)	1.4 (0.9 to 2.2)	1.2 (0.8 to 1.8)	-16.5 (-31.6 to 11.2)	1.8 (-17.2 to 37.2)
Non-communicable diseases	-	-	-	-	1,345.2 (811.3 to 1,408.2)	1,345.2 (996.7 to 1,721.7)	22.4 (18.0 to 28.1)	22.4 (-3.5 to 5.1)
Neoplasms	-	-	-	-	15.2 (11.3 to 19.3)	24.9 (18.6 to 31.6)	64.3 (52.0 to 76.0)	13.9 (5.4 to 22.0)
Esophageal cancer	1.0 (0.8 to 1.3)	1.2 (0.9 to 1.5)	19.6 (-15.2 to 73.8)	-11.5 (-38.1 to 28.5)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	13.8 (-14.4 to 53.3)	-15.8 (-37.9 to 13.0)
Stomach cancer	9.1 (7.8 to 10.5)	9.3 (7.9 to 11.1)	1.6 (-15.6 to 21.4)	-30.8 (-42.2 to -17.7)	1.1 (0.8 to 1.4)	1.0 (0.7 to 1.3)	-4.6 (-21.6 to 15.6)	-35.0 (-46.3 to -22.0)
Liver cancer	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	76.9 (51.1 to 141.2)	24.4 (-18.5 to 68.7)
Liver cancer due to hepatitis B	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.5)	120.8 (-14.9 to 438.5)	60.5 (-37.1 to 291.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	103.9 (-18.1 to 370.5)	47.2 (-40.4 to 243.6)
Liver cancer due to hepatitis C	0.2 (0.1 to 0.3)	0.8 (0.6 to 1.3)	363.5 (144.0 to 809.5)	226.0 (74.8 to 542.8)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	309.6 (138.4 to 629.2)	188.1 (67.5 to 419.6)
Liver cancer due to alcohol use	0.4 (0.3 to 0.6)	0.2 (0.2 to 0.7)	-4.5 (-54.1 to 76.5)	-34.2 (-68.1 to 21.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-9.0 (-53.6 to 54.3)	-37.2 (-67.9 to 5.5)
Liver cancer due to other causes	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	29.3 (-71.6 to 65.5)	-29.7 (-79.3 to 12.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.1 (-71.8 to 51.1)	53.8 (-79.7 to 1.1)
Larynx cancer	2.2 (1.7 to 3.0)	2.8 (2.0 to 3.6)	27.8 (-3.0 to 72.1)	-9.9 (-26.6 to 30.7)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	11.0 (-20.0 to 48.4)	-15.9 (-39.8 to 12.5)
Tracheal, bronchus and lung cancer	4.1 (3.6 to 4.6)	7.2 (6.3 to 8.1)	77.1 (46.5 to 107.1)	27.4 (5.7 to 49.4)	0.7 (0.5 to 0.8)	1.1 (0.8 to 1.4)	66.8 (38.3 to 96.8)	20.2 (-0.6 to 41.9)
Breast cancer	46.5 (41.0 to 51.3)	82.7 (77.7 to 87.6)	77.0 (58.4 to 105.3)	21.4 (8.5 to 40.6)	2.7 (1.9 to 3.7)	4.0 (2.8 to 5.6)	49.9 (30.7 to 72.4)	3.3 (-10.5 to 19.0)
Cervical cancer	7.3 (6.0 to 8.9)	5.9 (4.5 to 7.4)	-18.3 (-38.2 to 5.3)	-20.5 (-54.8 to -11.1)	0.5 (0.4 to 0.6)	0.4 (0.3 to 0.6)	-18.3 (-40.6 to 6.6)	-41.0 (-55.7 to -20.0)
Uterine cancer	10.0 (7.6 to 12.5)	11.6 (8.1 to 15.0)	14.9 (-18.0 to 62.3)	-17.4 (-40.1 to 17.1)	0.7 (0.4 to 0.9)	0.7 (0.5 to 1.1)	12.9 (-20.4 to 59.8)	-19.1 (-42.8 to 14.4)
Prostate cancer	24.2 (20.4 to 29.2)	55.3 (47.1 to 68.8)	127.4 (78.1 to 190.8)	53.7 (21.1 to 96.5)	2.1 (1.5 to 2.9)	4.7 (3.3 to 6.6)	117.1 (68.8 to 185.0)	44.0 (13.2 to 88.7)
Colon and rectum cancer	23.1 (21.4 to 24.8)	47.1 (42.5 to 52.1)	103.4 (80.2 to 129.2)	39.2 (22.8 to 56.0)	2.0 (1.5 to 2.6)	3.8 (2.8 to 4.9)	90.7 (66.5 to 116.5)	29.4 (13.1 to 46.8)
Lip and oral cavity cancer	6.0 (4.8 to 7.4)	8.4 (6.5 to 10.4)	40.4 (1.1 to 88.1)	4.8 (-25.6 to 43.0)	0.5 (0.4 to 0.7)	0.7 (0.5 to 1.0)	35.2 (-0.9 to 81.2)	0.6 (-27.8 to 37.6)
Nasopharynx cancer	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.8)	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-	-
Other pharynx cancer	2.0 (1.4 to 2.9)	4.6 (2.7 to 6.7)	133.2 (12.5 to 273.0)	80.8 (-14.5 to 192.4)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.6)	124.4 (9.7 to 255.6)	74.2 (-16.8 to 180.3)
Gallbladder and biliary tract cancer	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	6.9 (-24.5 to 48.9)	-29.5 (-49.6 to -3.5)
Pancreatic cancer	0.8 (0.6 to 0.9)	1.2 (1.0 to 1.5)	62.0 (24.7 to 115.9)	9.4 (-15.5 to 46.8)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.4)	58.4 (25.2 to 101.5)	7.9 (-13.7 to 36.3)
Malignant skin melanoma	2.7 (2.7 to 5.2)	5.2 (4.6 to 9.5)	95.5 (39.6 to 146.9)	43.1 (1.4 to 79.7)	0.4 (0.1 to 0.4)	0.4 (0.3 to 0.7)	98.5 (35.3 to 140.2)	36.4 (-1.7 to 72.9)
Non-melanoma skin cancer	9.6 (6.1 to 13.8)	16.1 (10.3 to 25.5)	68.4 (-5.4 to 188.7)	8.2 (-36.2 to 80.9)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	92.6 (21.5 to 197.2)	22.7 (-20.0 to 85.8)
Ovarian cancer	2.1 (1.8 to 2.4)	3.2 (2.7 to 3.8)	55.5 (22.0 to 92.0)	11.5 (-11.7 to 38.6)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	50.5 (8.8 to 97.4)	7.9 (-20.6 to 43.0)
Testicular cancer	0.7 (0.5 to 1.1)	0.8 (0.5 to 1.2)	20.5 (-40.4 to 105.8)	5.8 (-49.1 to 84.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	15.8 (-42.6 to 104.6)	0.8 (-52.5 to 81.7)
Kidney cancer	3.8 (3.2 to 4.3)	7.4 (6.5 to 9.0)	95.5 (66.5 to 144.9)	45.0 (17.2 to 74.2)	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	104.1 (55.3 to 139.8)	47.0 (10.6 to 69.9)
Bladder cancer	7.9 (6.7 to 9.5)	14.5 (11.4 to 17.2)	85.1 (40.2 to 131.2)	25.8 (-4.4 to 55.1)	0.6 (0.4 to 0.8)	1.1 (0.7 to 1.5)	74.2 (32.7 to 120.1)	18.0 (-10.2 to 48.6)
Brain and nervous system cancer	2.7 (2.3 to 3.2)	4.3 (3.2 to 5.2)	61.8 (24.7 to 95.7)	23.0 (-2.1 to 45.9)	0.3 (0.2 to 0.4)	0.3 (0.3 to 0.6)	58.0 (17.7 to 99.8)	20.4 (-6.1 to 44.5)
Thyroid cancer	5.1 (3.3 to 6.4)	5.3 (4.1 to 7.1)	-1.8 (-28.2 to 81.0)	-25.1 (-45.6 to 37.7)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	-4.7 (-31.4 to 76.1)	-28.3 (-48.8 to 31.1)
Mesothelioma	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-68.6 (-65.9 to 70.6)	55.5 (-75.7 to 37.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-53.0 (-63.0 to 79.2)	47.0 (-78.9 to 22.7)
Hodgkin lymphoma	1.5 (1.1 to 2.2)	1.7 (1.2 to 2.4)	15.4 (-24.0 to 62.7)	-1.1 (-35.5 to 43.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	10.4 (-24.5 to 54.8)	6.8 (-33.8 to 35.2)
Non-Hodgkin lymphoma	4.6 (3.5 to 7.0)	9.9 (6.4 to 12.5)	129.7 (-2.6 to 202.4)	64.1 (-28.9 to 114.0)	0.3 (0.2 to 0.6)	0.7 (0.4 to 1.0)	118.8 (-9.5 to 192.7)	57.0 (-34.1 to 106.7)
Multiple myeloma	1.1 (0.7 to 1.7)	2.2 (1.4 to 3.2)	105.2 (15.3 to 207.2)	44.3 (-18.6 to 114.4)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.7)	94.4 (8.1 to 196.3)	36.2 (-24.1 to 103.6)
Leukemia	2.1 (1.8 to 2.6)	3.2 (2.5 to 3.8)	48.8 (13.1 to 92.8)	11.1 (-24.3 to 28.6)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.6)	46.9 (10.0 to 85.8)	4.7 (-23.1 to 25.2)
Other neoplasms	8.8 (7.0 to 10.4)	23.8 (18.8 to 29.0)	171.0 (115.2 to 243.1)	90.0 (53.8 to 139.4)	1.6 (0.4 to 0.9)	1.6 (1.1 to 2.2)	150.7 (93.5 to 212.4)	77.6 (41.2 to 122.4)
Cardiovascular diseases	-	-	-	-	46.6 (32.7 to 62.2)	61.9 (43.2 to 81.9)	32.5 (14.2 to 54.0)	-9.6 (-21.9 to 5.1)
Rheumatic heart disease	1.3 (1.2 to 1.3)	1.7 (1.6 to 1.8)	33.4 (21.8 to 46.8)	-2.2 (-10.1 to 6.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	31.2 (6.0 to 103.6)	-5.7 (-34.9 to 48.9)
Ischemic heart disease	371.9 (317.1 to 444.9)	495.8 (391.4 to 491.5)	17.0 (-2.9 to 40.3)	-20.4 (-34.4 to -4.5)	21.1 (13.9 to 29.8)	22.8 (15.2 to 31.5)	-9.8 (-12.8 to 34.2)	-27.1 (-41.8 to -8.9)
Cerebrovascular disease	-	-	-	-	12.6 (8.7 to 17.1)	18.8 (13.1 to 24.7)	48.2 (20.5 to 84.0)	1.9 (-16.7 to 25.0)
Ischemic stroke	70.9 (60.6 to 82.2)	106.0 (91.1 to 123.9)	48.0 (19.3 to 91.5)	0.3 (-18.3 to 28.1)	10.1 (6.8 to 13.9)	15.0 (10.1 to 20.2)	46.9 (18.9 to 90.1)	0.5 (-19.0 to 27.8)
Hemorrhagic stroke	17.5 (13.5 to 22.9)	27.0 (20.0 to 35.6)	53.3 (-4.2 to 140.8)	6.0 (-30.3 to 61.3)	2.5 (1.6 to 3.7)	3.9 (2.4 to 5.7)	51.2 (-3.8 to 136.3)	6.0 (-29.2 to 60.5)
Hypertensive heart disease	10.4 (8.9 to 12.0)	17.0 (15.2 to 19.3)	63.3 (35.7 to 97.4)	6.9 (-10.5 to 28.3)	1.1 (0.8 to 1.5)	1.8 (1.3 to 2.5)	62.3 (33.6 to 99.1)	7.1 (-11.3 to 31.0)
Cardiomyopathy and myocarditis	10.4 (8.5 to 13.0)	11.5 (10.5 to 12.7)	11.4 (-12.8 to 37.0)	-22.7 (-39.3 to -5.8)	1.1 (0.8 to 1.6)	1.2 (0.8 to 1.7)	1.2 (-13.9 to 38.8)	10.8 (-39.0 to -3.8)
Atrial fibrillation and flutter	34.7 (29.1 to 40.6)	43.1 (33.6 to 54.2)	25.1 (-10.2 to 62.0)	-17.9 (-40.0 to 6.2)	2.7 (1.7 to 3.8)	3.3 (2.1 to 4.8)	23.4 (-12.1 to 61.0)	18.4 (-40.7 to 6.6)
Peripheral vascular disease	357.8 (273.2 to 440.7)	579.8 (454.4 to 692.8)	61.7 (18.8 to 128.7)	10.2 (-19.4 to 57.0)	0.3 (0.1 to 0.7)	0.5 (0.2 to 1.1)	44.8 (-23.6 to 272.5)	-13.8 (-53.4 to 122.9)
Endocarditis	0.5 (0.4 to 0.7)	0.8 (0.6 to 1.0)	50.2 (2.5 to 133.5)	17.6 (-16.9 to 79.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	27.2 (-17.4 to 112.8)	-1.9 (-34.6 to 60.4)
Other cardiovascular and circulatory diseases	105.7 (61.4 to 157.2)	189.4 (115.0 to 249.5)	77.5 (0.4 to 218.7)	22.7 (-30.6 to 118.7)	7.4 (3.8 to 12.0)	13.2 (7.2 to 19.7)	77.8 (0.6 to 218.9)	22.9 (-30.4 to 120.2)
Chronic respiratory diseases	-	-	-	-	66.4 (45.8 to 89.4)	67.7 (46.8 to 91.6)	2.5 (-8.0 to 10.8)	-8.5 (-17.8 to -1.1)
Chronic obstructive pulmonary disease	478.8 (417.4 to 531.6)	633.6 (566.3 to 701.7)	31.9 (24.0 to 43.0)	-1.2 (-6.6 to 7.9)	23.3 (15.6 to 31.8)	25.2 (16.7 to 34.4)	9.6 (-14.5 to 30.5)	-17.6 (-35.1 to -2.3)

Appendix Table G.4 - Portugal prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.7 (3.9 to 17.4)	9.7 (-24.4 to -14.0)
Silicosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-2.0 (-6.6 to 2.8)	-29.7 (-33.1 to -26.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.9 (-6.6 to 2.9)	-29.7 (-33.1 to -26.4)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	27.0 (14.6 to 39.3)	6.1 (-15.3 to 3.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.9 (15.3 to 40.3)	5.7 (-14.4 to 3.4)
Asthma	917.1 (869.3 to 964.1)	970.5 (923.6 to 1,015.9)	5.7 (-1.6 to 13.7)	1.1 (-6.2 to 9.0)	40.1 (26.2 to 56.2)	42.1 (27.7 to 59.7)	4.8 (-2.8 to 13.2)	1.1 (-6.2 to 9.7)
Interstitial lung disease and pulmonary sarcoidosis	0.8 (0.6 to 1.0)	0.9 (0.8 to 1.0)	14.3 (-20.7 to 53.8)	-14.2 (-38.8 to 15.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	16.3 (-18.6 to 57.8)	-12.7 (-37.4 to 17.6)
Other chronic respiratory diseases	-	-	-	-	2.8 (1.7 to 4.5)	0.2 (0.1 to 0.3)	-92.2 (-94.1 to -89.8)	-94.1 (-95.6 to -92.3)
Cirrhosis	-	-	-	-	0.3 (0.6 to 1.3)	0.8 (0.6 to 1.2)	9.8 (19.6 to 0.7)	29.5 (-37.2 to -20.9)
Cirrhosis due to hepatitis B	0.6 (0.3 to 0.8)	0.5 (0.3 to 0.7)	-8.6 (-49.6 to 62.0)	-29.3 (-60.7 to 26.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-9.0 (-53.1 to 77.9)	-29.4 (-63.9 to 37.7)
Cirrhosis due to hepatitis C	2.0 (1.3 to 2.9)	2.5 (1.6 to 3.1)	23.2 (-23.8 to 95.2)	-5.1 (-40.2 to 48.1)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	23.0 (-26.2 to 102.5)	-4.8 (-41.8 to 54.8)
Cirrhosis due to alcohol use	2.7 (1.7 to 3.2)	1.6 (1.0 to 2.3)	-42.7 (-64.2 to 4.6)	-56.4 (-73.5 to -19.4)	0.4 (0.2 to 0.6)	0.3 (0.1 to 0.4)	-42.9 (-66.3 to 5.4)	-56.4 (-74.8 to -18.4)
Cirrhosis due to other causes	0.5 (0.3 to 0.8)	0.7 (0.4 to 0.9)	28.1 (-38.4 to 161.3)	5.8 (-48.7 to 107.5)	0.2 (0.0 to 0.2)	0.1 (0.1 to 0.2)	26.7 (-41.9 to 159.7)	4.5 (-51.0 to 103.5)
Digestive diseases	-	-	-	-	13.4 (9.6 to 18.2)	18.1 (12.7 to 24.6)	34.1 (14.4 to 61.5)	4.1 (-11.4 to 25.9)
Peptic ulcer disease	70.4 (67.6 to 72.9)	34.6 (28.4 to 41.0)	-50.7 (-60.1 to -41.0)	-70.0 (-75.3 to -64.3)	2.2 (1.5 to 3.1)	1.4 (1.0 to 2.0)	-37.1 (-43.2 to -22.0)	-60.7 (-64.9 to -51.4)
Gastritis and duodenitis	6.5 (5.2 to 7.6)	3.2 (2.6 to 3.7)	-51.1 (-62.5 to -35.6)	-64.0 (-72.5 to -52.7)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-30.2 (-50.6 to -1.2)	-47.8 (-63.5 to -25.2)
Appendicitis	0.5 (0.4 to 0.6)	0.4 (0.4 to 0.4)	-25.5 (-35.0 to -14.2)	-15.9 (-26.6 to -3.3)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-23.9 (-43.8 to 6.0)	-14.9 (-38.0 to 23.0)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	22.2 (13.9 to 47.6)	4.4 (-26.0 to 10.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	22.5 (-31.0 to 68.6)	-7.5 (-31.7 to 23.0)
Inguinal, femoral, and abdominal hernia	43.5 (37.5 to 50.4)	58.6 (52.0 to 66.6)	34.6 (10.0 to 62.8)	-9.3 (-24.2 to 8.6)	0.4 (0.2 to 0.8)	0.6 (0.3 to 1.1)	34.6 (11.0 to 63.3)	-8.5 (-23.4 to 9.8)
Inflammatory bowel disease	35.2 (29.6 to 40.9)	53.0 (44.4 to 62.1)	50.3 (17.3 to 96.7)	18.1 (-7.8 to 53.3)	7.3 (4.9 to 10.5)	11.0 (7.3 to 15.7)	50.2 (15.8 to 95.9)	18.7 (-8.0 to 53.8)
Vascular intestinal disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	49.1 (4.8 to 119.9)	0.1 (-29.5 to 40.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (-9.8 to 140.4)	-0.9 (-35.3 to 57.1)
Gallbladder and biliary diseases	13.8 (11.8 to 16.4)	20.3 (17.2 to 23.0)	47.4 (17.8 to 78.6)	7.3 (-14.1 to 28.9)	1.4 (1.0 to 2.0)	2.1 (1.4 to 2.9)	46.9 (16.9 to 79.4)	7.6 (-14.0 to 29.9)
Pancreatitis	2.3 (2.2 to 2.4)	3.6 (3.5 to 3.8)	58.9 (50.5 to 68.5)	20.6 (14.0 to 28.0)	0.7 (0.4 to 0.7)	1.0 (0.7 to 1.4)	58.4 (35.1 to 83.4)	21.1 (8.0 to 41.7)
Other digestive diseases	-	-	-	-	0.8 (0.5 to 1.1)	1.5 (1.0 to 2.1)	89.1 (45.0 to 139.2)	46.6 (11.3 to 86.9)
Neurological disorders	-	-	-	-	102.4 (70.1 to 140.7)	139.2 (96.4 to 185.2)	35.5 (16.3 to 60.3)	8.0 (-7.5 to 29.1)
Alzheimer disease and other dementias	140.1 (111.3 to 167.9)	244.1 (196.7 to 299.4)	71.9 (32.9 to 143.1)	0.4 (-21.7 to 41.8)	20.4 (13.9 to 27.3)	36.5 (25.0 to 48.9)	46.6 (34.3 to 151.3)	1.5 (-21.7 to 44.7)
Parkinson disease	9.5 (8.1 to 11.0)	14.4 (12.2 to 16.9)	51.8 (41.6 to 64.3)	1.0 (-5.3 to 9.0)	1.1 (0.8 to 1.5)	1.7 (1.1 to 2.3)	51.1 (34.1 to 69.6)	1.7 (-9.8 to 14.3)
Epilepsy	34.3 (25.4 to 43.5)	36.0 (25.9 to 44.9)	5.1 (-29.6 to 54.2)	-4.8 (-35.9 to 40.8)	13.2 (8.5 to 18.6)	14.3 (9.1 to 20.1)	7.7 (-28.5 to 62.6)	-0.9 (-34.2 to 49.7)
Multiple sclerosis	4.6 (3.3 to 5.9)	9.7 (7.2 to 12.0)	108.7 (36.5 to 226.0)	1.5 (-7.0 to 161.8)	1.5 (0.9 to 2.2)	3.1 (2.0 to 4.4)	107.7 (37.5 to 232.9)	65.9 (8.3 to 167.5)
Migraine	1,437.2 (1,142.2 to 1,768.7)	1,641.3 (1,281.1 to 2,023.6)	13.0 (-14.8 to 57.8)	48.3 (-24.1 to 41.5)	3.3 (2.7 to 9.5)	5.1 (3.1 to 7.5)	55.1 (-15.5 to 57.3)	1.1 (-24.6 to 41.2)
Tension-type headache	2,023.9 (1,358.4 to 2,843.1)	2,942.9 (2,443.0 to 3,343.6)	50.2 (-2.5 to 120.1)	33.1 (-13.1 to 96.6)	3.0 (1.3 to 5.8)	4.4 (2.1 to 7.9)	49.2 (-4.0 to 117.9)	33.3 (-14.4 to 96.8)
Medication overuse headache	72.3 (46.7 to 99.2)	130.5 (83.5 to 178.9)	82.4 (26.2 to 139.6)	53.7 (11.2 to 99.3)	11.2 (6.3 to 17.8)	20.2 (11.1 to 32.3)	82.0 (27.6 to 138.5)	53.8 (12.2 to 99.6)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.1 (-20.6 to 72.9)	-0.5 (-32.9 to 45.9)	3.3 (2.1 to 4.6)	4.0 (2.7 to 5.7)	23.5 (-14.4 to 79.8)	-25.2 (-48.2 to 8.0)
Mental and substance use disorders	-	-	-	-	253.9 (177.8 to 344.1)	280.9 (200.8 to 378.3)	10.6 (4.0 to 19.8)	0.4 (-6.6 to 8.8)
Schizophrenia	27.5 (21.6 to 33.2)	33.1 (26.1 to 39.9)	20.4 (13.2 to 26.9)	-0.6 (-7.3 to 5.1)	17.4 (12.1 to 22.9)	21.0 (14.3 to 27.3)	20.5 (12.4 to 30.0)	2.2 (-7.8 to 7.7)
Alcohol use disorders	136.2 (124.4 to 149.8)	145.7 (133.4 to 159.1)	6.9 (0.1 to 13.4)	1.9 (-4.7 to 8.1)	13.6 (9.1 to 19.5)	14.5 (9.7 to 20.9)	6.5 (-0.8 to 14.2)	1.9 (-5.5 to 9.3)
Drug use disorders	-	-	-	-	13.2 (8.7 to 18.1)	13.8 (9.1 to 19.1)	4.4 (-8.4 to 17.8)	-1.4 (-12.7 to 11.0)
Opioid use disorders	13.8 (7.7 to 22.3)	16.1 (8.8 to 26.2)	16.6 (0.7 to 31.0)	-5.9 (-16.9 to 6.4)	5.7 (2.9 to 9.5)	6.6 (3.4 to 10.8)	5.7 (-0.9 to 34.9)	-5.0 (-18.4 to 10.6)
Cocaine use disorders	11.4 (11.4 to 13.5)	13.5 (11.3 to 15.5)	19.3 (-11.3 to 11.9)	0.5 (-8.8 to 14.5)	1.7 (1.1 to 2.4)	1.7 (1.1 to 2.4)	9.9 (-17.0 to 17.6)	1.7 (-15.1 to 21.0)
Amphetamine use disorders	13.9 (12.8 to 15.0)	12.9 (12.1 to 13.7)	-7.1 (-15.8 to 2.5)	-0.1 (-9.2 to 10.7)	1.8 (1.0 to 2.7)	1.7 (1.0 to 2.4)	-7.3 (-21.6 to 9.0)	0.4 (-21.6 to 18.4)
Cannabis use disorders	17.8 (16.2 to 19.4)	15.5 (14.2 to 16.6)	-13.4 (-18.2 to -7.9)	2.1 (-3.5 to 8.8)	0.5 (0.3 to 0.8)	0.4 (0.3 to 0.7)	-13.2 (-25.2 to 0.8)	2.3 (-11.3 to 18.8)
Other drug use disorders	-	-	-	-	3.5 (2.2 to 5.1)	3.4 (2.2 to 5.0)	-3.8 (-29.5 to 29.9)	1.5 (-25.7 to 36.8)
Depressive disorders	-	-	-	-	103.4 (61.7 to 157.3)	120.5 (77.0 to 176.8)	16.2 (0.7 to 43.2)	13.3 (-13.2 to 24.8)
Major depressive disorder	435.5 (283.4 to 622.1)	508.4 (354.1 to 668.0)	16.5 (-1.2 to 50.0)	1.0 (-14.5 to 30.2)	87.7 (50.1 to 141.3)	101.7 (61.4 to 152.4)	15.6 (-2.0 to 49.0)	1.5 (-14.6 to 31.4)
Dysthymia	165.3 (139.1 to 194.8)	197.4 (168.0 to 230.8)	19.4 (11.2 to 27.3)	0.7 (-5.6 to 7.7)	15.8 (10.5 to 23.1)	18.8 (12.6 to 26.9)	18.9 (10.4 to 28.1)	0.7 (-5.8 to 8.5)
Bipolar disorder	73.4 (62.0 to 85.6)	82.2 (69.7 to 95.0)	12.0 (5.4 to 19.1)	-0.7 (-6.5 to 5.5)	14.8 (9.1 to 22.3)	16.4 (10.1 to 24.6)	11.5 (3.3 to 20.4)	-0.7 (-7.5 to 7.9)
Anxiety disorders	516.4 (285.6 to 729.2)	565.4 (339.3 to 791.9)	10.1 (-1.0 to 22.9)	0.6 (-0.8 to 0.5)	46.9 (22.7 to 74.3)	51.0 (26.9 to 80.1)	9.3 (-1.8 to 22.1)	4.5 (-2.7 to 19.9)
Eating disorders	-	-	-	-	5.4 (3.4 to 7.8)	5.2 (3.4 to 7.4)	-3.9 (-11.5 to 5.3)	7.8 (0.4 to 17.3)
Anorexia nervosa	10.6 (8.1 to 13.0)	11.5 (8.6 to 14.6)	8.8 (-2.0 to 23.2)	19.9 (9.3 to 33.2)	2.2 (1.4 to 3.3)	2.4 (1.5 to 3.7)	8.4 (-4.9 to 26.0)	20.0 (6.7 to 37.6)
Bulimia nervosa	14.9 (10.2 to 21.5)	13.1 (8.7 to 18.8)	-12.8 (-17.8 to -6.9)	-1.1 (-1.6 to -0.2)	3.1 (1.8 to 4.9)	2.7 (1.6 to 4.4)	-12.6 (-21.4 to -4.2)	-1.0 (-7.9 to 6.7)
Autistic spectrum disorders	-	-	-	-	11.0 (7.7 to 15.0)	11.5 (8.0 to 15.6)	4.4 (1.1 to 7.8)	1.1 (-2.2 to 4.6)
Autism	28.6 (27.0 to 30.2)	30.0 (28.2 to 31.9)	4.9 (3.9 to 6.1)	0.8 (0.7 to 0.8)	7.0 (4.7 to 9.5)	7.3 (4.9 to 9.9)	4.3 (-0.7 to 9.3)	1.1 (-3.7 to 6.3)
Asperger syndrome	40.8 (38.2 to 43.5)	43.0 (40.0 to 46.1)	5.2 (4.1 to 6.2)	1.0 (1.0 to 1.1)	4.0 (2.8 to 5.6)	4.2 (2.9 to 5.8)	4.7 (0.4 to 9.0)	1.3 (-3.0 to 5.6)
Attention-deficit/hyperactivity disorder	59.1 (49.0 to 69.6)	42.5 (35.3 to 50.0)	-28.1 (-28.5 to -28.0)	0.3 (0.2 to 0.3)	0.7 (0.4 to 1.1)	0.5 (0.3 to 0.8)	0.5 (-33.1 to -23.1)	0.1 (-6.6 to 7.3)
Conduct disorder	88.0 (74.0 to 102.0)	60.6 (51.2 to 70.3)	-31.1 (-32.0 to -30.5)	0.2 (0.1 to 0.2)	10.6 (6.5 to 15.8)	7.3 (4.4 to 11.0)	-31.0 (-33.8 to -28.1)	0.3 (-3.8 to 4.4)
Idiopathic intellectual disability	61.2 (35.9 to 87.3)	57.7 (34.6 to 84.9)	-5.9 (-44.7 to 60.1)	-11.7 (-47.8 to 51.1)	3.6 (1.9 to 5.8)	3.4 (1.8 to 5.5)	-7.3 (-46.6 to 60.9)	-12.0 (-48.9 to 53.7)
Other mental and substance use disorders	179.3 (168.9 to 189.7)	216.1 (203.6 to 228.2)	20.4 (18.7 to 22.1)	0.7 (0.6 to 0.9)	13.2 (9.0 to 17.7)	15.8 (10.7 to 21.1)	19.8 (15.1 to 24.6)	0.9 (-2.8 to 4.9)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	112.4 (79.8 to 151.6)	158.8 (113.6 to 207.8)	41.4 (22.9 to 60.1)	8.9 (-3.2 to 21.7)
Diabetes mellitus	650.0 (532.8 to 797.5)	1,089.6 (904.7 to 1,243.3)	68.8 (22.7 to 116.5)	26.0 (-6.1 to 63.4)	46.3 (29.7 to 67.2)	77.3 (52.1 to 106.7)	68.3 (22.8 to 116.8)	24.5 (-7.6 to 60.3)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.6 (-20.6 to -11.4)	-16.8 (-21.7 to -13.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-20.7 to -11.4)	-15.6 (-21.7 to -13.1)
Chronic kidney disease	-	-	-	-	36.7 (24.8 to 49.9)	48.5 (32.2 to 65.7)	32.0 (24.9 to 39.7)	2.3 (-2.3 to 6.9)
Chronic kidney disease due to diabetes mellitus	125.4 (80.8 to 184.7)	235.3 (161.6 to 351.5)	86.9 (32.8 to 153.6)	35.5 (2.0 to 83.5)	7.0 (4.3 to 10.6)	12.0 (7.7 to 17.5)	70.8 (31.2 to 135.9)	29.0 (-2.1 to 75.6)
Chronic kidney disease due to hypertension	103.0 (77.6 to 133.7)	87.7 (65.4 to 122.6)	-16.1 (-34.5 to 23.6)	-33.4 (-46.6 to -6.2)	11.8 (7.8 to 16.2)	5.7 (3.8 to 8.1)	-51.8 (-59.6 to -40.6)	-62.4 (-68.8 to -53.1)
Chronic kidney disease due to glomerulonephritis	194.1 (120.7 to 292.4)	107.0 (75.4 to 156.0)	-45.0 (-57.4 to -23.1)	-45.9 (-65.8 to -43.1)	2.7 (1.7 to 4.0)	4.7 (2.9 to 6.9)	69.7 (48.3 to 152.1)	32.0 (-6.1 to 98.4)
Chronic kidney disease due to other causes	321.5 (225.1 to 432.8)	550.2 (382.6 to 739.9)	69.8 (41.4 to 115.5)	27.8 (9.7 to 56.4)	15.2 (9.3 to 21.8)	26.1 (17.5 to 35.6)	70.9 (44.9 to 119.2)	32.1 (14.2 to 67.9)
Urinary diseases and male infertility	-	-	-	-	5.4 (3.4 to 7.9)	8.0 (5.0 to 11.7)	47.9 (36.0 to 63.3)	5.9 (-2.9 to 17.8)

Appendix Table G.4 - Portugal prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.0 (1.0 to 1.1)	1.7 (1.6 to 1.8)	68.4 (56.3 to 84.7)	68.4 (32.8 to 58.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	66.2 (34.0 to 112.6)	66.2 (14.7 to 85.2)
Urolithiasis	115.6 (40.4 to 191.3)	224.7 (85.0 to 339.5)	102.8 (62.8 to 159.4)	102.8 (14.7 to 80.7)	0.9 (0.3 to 1.7)	1.8 (0.6 to 3.2)	92.1 (67.5 to 139.6)	92.1 (17.9 to 67.1)
Benign prostatic hyperplasia	110.5 (101.9 to 118.5)	158.4 (150.5 to 166.7)	42.9 (30.9 to 57.9)	42.9 (-7.9 to 10.8)	3.9 (2.5 to 5.5)	5.6 (3.7 to 7.9)	42.9 (30.3 to 58.7)	42.9 (8.0 to 11.9)
Male infertility due to other causes	42.2 (31.0 to 55.1)	46.6 (34.9 to 61.6)	8.6 (-2.5 to 74.8)	8.6 (-34.1 to 55.4)	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.7)	8.8 (-28.5 to 76.2)	8.8 (-35.6 to 57.4)
Other urinary diseases	-	-	-	-	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.6)	35.1 (-49.5 to 179.6)	35.1 (-64.5 to 96.3)
Gynecological diseases	-	-	-	-	12.1 (7.6 to 18.6)	13.9 (8.7 to 21.6)	15.1 (13.3 to 30.6)	15.1 (-13.5 to 11.6)
Uterine fibroids	377.4 (322.5 to 436.5)	473.0 (404.8 to 548.1)	25.2 (24.3 to 26.1)	-2.7 (-2.7 to -2.7)	3.4 (1.8 to 6.1)	4.3 (2.2 to 7.7)	24.3 (18.1 to 35.7)	24.3 (-5.7 to 9.0)
Polycystic ovarian syndrome	160.6 (137.4 to 183.1)	187.4 (162.3 to 213.5)	16.4 (5.1 to 43.4)	1.6 (-17.6 to 24.6)	1.5 (0.7 to 2.8)	1.8 (0.8 to 3.4)	16.7 (-3.5 to 42.2)	16.7 (-16.8 to 23.6)
Female infertility due to other causes	12.6 (3.1 to 24.7)	9.8 (1.7 to 28.6)	-9.8 (-88.4 to 42.2)	-9.8 (-89.2 to 334.1)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	0.1 (-86.7 to 408.0)	0.1 (-88.4 to 309.0)
Endometriosis	26.7 (19.3 to 34.0)	28.3 (20.7 to 36.8)	4.3 (-27.3 to 57.7)	-11.3 (-37.5 to 34.2)	2.5 (1.5 to 3.7)	2.6 (1.6 to 3.9)	4.6 (-28.9 to 60.3)	4.6 (-38.7 to 36.1)
Genital prolapse	630.4 (567.6 to 700.9)	741.3 (676.7 to 818.2)	17.0 (2.6 to 36.9)	-4.2 (-16.5 to 12.4)	2.0 (1.0 to 3.8)	2.3 (1.1 to 4.4)	17.0 (2.4 to 36.9)	17.0 (-17.1 to 13.1)
Premenstrual syndrome	259.1 (177.2 to 347.7)	277.3 (175.9 to 388.8)	9.1 (-36.7 to 68.2)	3.3 (-38.1 to 60.2)	2.2 (1.2 to 3.5)	2.3 (1.2 to 3.8)	8.2 (-36.5 to 71.7)	8.2 (-38.6 to 63.3)
Other gynecological diseases	21.2 (19.5 to 23.3)	23.5 (20.8 to 26.1)	10.3 (-3.6 to 26.8)	1.4 (-11.4 to 16.7)	1.4 (0.3 to 0.6)	0.5 (0.3 to 0.8)	19.7 (-6.0 to 66.8)	11.7 (-14.6 to 52.7)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	8.6 (5.7 to 12.3)	7.7 (5.1 to 11.2)	-10.7 (-17.9 to -3.0)	-10.7 (-17.8 to -4.0)
Thalassemias	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-18.4 (-25.7 to -9.8)	0.3 (-8.5 to 10.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.2 (-31.3 to 10.2)	5.1 (-13.5 to 38.7)
Thalassemia trait	100.4 (92.7 to 110.0)	107.4 (100.1 to 116.1)	6.7 (2.7 to 11.3)	-0.7 (-4.2 to 3.3)	3.1 (2.1 to 4.4)	3.0 (2.0 to 4.3)	-2.6 (-11.3 to 5.8)	-7.4 (-15.3 to 0.2)
Sickle cell disorders	0.8 (0.6 to 0.9)	0.7 (0.6 to 0.8)	-12.5 (-21.9 to 22.9)	0.2 (-15.8 to 32.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	2.6 (-13.0 to 17.8)	5.9 (-11.1 to 22.5)
Sickle cell trait	280.2 (261.4 to 299.4)	292.0 (273.4 to 310.2)	3.9 (0.0 to 8.4)	3.9 (-6.7 to 1.2)	3.9 (2.5 to 5.6)	3.1 (2.0 to 4.5)	-20.5 (-30.0 to -11.0)	-18.7 (-28.4 to -9.7)
G6PD deficiency	64.0 (35.0 to 115.9)	77.3 (39.1 to 130.4)	18.3 (-50.8 to 191.5)	9.9 (-53.7 to 168.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-72.6 (-84.5 to -17.0)	-73.4 (-84.1 to -19.2)
G6PD trait	740.1 (366.1 to 1,152.5)	888.5 (456.6 to 1,414.6)	19.5 (-31.6 to 191.2)	9.8 (-37.1 to 167.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-3.0 (-43.3 to 112.2)	-3.1 (-48.2 to 123.8)
Other hemoglobinopathies and hemolytic anemias	61.0 (55.8 to 67.3)	70.6 (63.5 to 76.7)	15.7 (-0.5 to 35.3)	5.3 (-9.7 to 23.2)	1.5 (0.9 to 2.2)	1.4 (0.9 to 2.1)	2.2 (-27.5 to 33.4)	0.6 (-21.3 to 32.4)
Endocrine, metabolic, blood, and immune disorders	105.6 (99.7 to 111.9)	113.4 (109.5 to 117.8)	7.3 (1.1 to 14.0)	7.3 (-8.8 to 4.3)	3.4 (2.2 to 4.6)	3.4 (2.4 to 4.7)	3.9 (-4.3 to 14.5)	3.2 (-11.4 to 7.4)
Musculoskeletal disorders	-	-	-	-	290.7 (204.6 to 389.6)	367.5 (260.1 to 490.3)	25.7 (10.9 to 46.3)	1.0 (-12.2 to 18.4)
Rheumatoid arthritis	34.1 (31.2 to 37.1)	50.1 (45.3 to 56.4)	47.0 (27.1 to 70.3)	10.8 (-3.4 to 26.6)	7.9 (5.6 to 10.5)	11.5 (8.1 to 15.4)	45.6 (24.8 to 69.0)	10.7 (-3.8 to 27.2)
Osteoarthritis	531.8 (436.0 to 620.7)	780.4 (640.2 to 905.3)	47.3 (15.6 to 84.9)	1.4 (-21.7 to 28.8)	18.2 (11.7 to 27.2)	26.6 (17.0 to 39.0)	46.5 (14.6 to 84.3)	1.6 (-21.9 to 29.1)
Low back and neck pain	-	-	-	-	230.7 (158.4 to 318.5)	280.0 (193.8 to 384.4)	20.3 (2.6 to 45.7)	-1.4 (-17.3 to 19.3)
Low back pain	1,398.5 (1,177.7 to 1,690.2)	1,728.1 (1,491.1 to 1,939.3)	22.5 (-1.3 to 52.7)	-0.2 (-22.0 to 23.7)	153.9 (102.9 to 223.0)	188.7 (125.7 to 263.0)	21.8 (-1.9 to 51.8)	0.1 (-22.0 to 24.2)
Neck pain	789.6 (667.3 to 914.9)	942.5 (796.6 to 1,112.7)	19.4 (-3.7 to 50.2)	-3.4 (-20.9 to 21.7)	76.8 (51.4 to 107.1)	91.3 (61.2 to 129.0)	19.0 (-3.9 to 49.0)	-3.1 (-20.4 to 22.3)
Gout	20.6 (18.5 to 23.2)	28.5 (25.1 to 31.7)	38.1 (18.5 to 59.0)	-0.1 (-14.6 to 15.3)	0.6 (0.4 to 0.9)	0.9 (0.6 to 1.2)	37.5 (10.5 to 68.7)	0.6 (-19.0 to 23.3)
Other musculoskeletal disorders	367.7 (299.5 to 427.7)	538.4 (429.3 to 641.8)	46.1 (36.2 to 56.9)	15.6 (7.7 to 24.6)	33.3 (21.9 to 46.8)	48.6 (32.1 to 70.2)	46.9 (35.2 to 57.6)	3.2 (7.4 to 25.5)
Other non-communicable diseases	-	-	-	-	196.0 (130.2 to 283.1)	225.6 (151.4 to 324.3)	14.9 (10.1 to 21.8)	-6.5 (-10.1 to -1.3)
Congenital anomalies	-	-	-	-	14.2 (9.8 to 19.0)	15.4 (10.9 to 20.3)	8.6 (5.8 to 23.9)	-1.9 (-15.1 to 12.9)
Neural tube defects	2.2 (1.9 to 2.6)	1.7 (1.4 to 1.9)	-25.6 (-38.7 to -10.0)	-26.2 (-39.1 to -10.9)	0.7 (0.5 to 1.0)	0.6 (0.4 to 0.8)	-23.9 (-42.5 to 1.8)	-24.0 (-42.6 to 1.5)
Congenital heart anomalies	79.2 (65.0 to 107.1)	80.5 (68.1 to 95.2)	2.0 (-24.7 to 28.8)	-3.8 (-28.9 to 20.9)	2.7 (1.1 to 4.7)	2.8 (1.2 to 4.9)	4.0 (-2.9 to 29.4)	-0.6 (-25.4 to 23.1)
Orofacial clefts	7.2 (6.0 to 8.9)	7.6 (6.6 to 9.0)	5.5 (-17.9 to 36.6)	-3.0 (-24.7 to 25.6)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-11.1 (-33.8 to 20.3)	-18.0 (-39.5 to 11.1)
Down syndrome	8.7 (7.1 to 11.1)	10.8 (8.8 to 13.3)	24.7 (-6.2 to 63.3)	9.3 (-18.1 to 43.1)	1.3 (0.9 to 1.7)	1.7 (1.2 to 2.3)	35.1 (-0.8 to 76.9)	12.5 (-16.7 to 47.1)
Turner syndrome	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	6.6 (-29.6 to 69.4)	3.2 (-31.8 to 64.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.1 (-31.6 to 74.8)	2.7 (-33.6 to 69.7)
Klinefelter syndrome	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.4)	26.5 (-9.0 to 76.9)	20.7 (-13.2 to 69.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-13.9 to 91.8)	28.6 (-21.0 to 78.2)
Chromosomal unbalanced rearrangements	20.0 (15.7 to 23.9)	24.9 (20.8 to 30.6)	24.5 (-3.2 to 64.8)	9.0 (-15.0 to 43.4)	2.9 (2.0 to 3.8)	3.9 (2.8 to 5.2)	12.2 (2.7 to 20.4)	12.2 (-13.6 to 50.2)
Other congenital anomalies	30.6 (20.1 to 42.3)	28.4 (17.9 to 39.8)	-6.6 (-26.1 to 13.0)	-17.4 (-33.2 to -0.3)	6.5 (4.1 to 9.4)	6.4 (4.0 to 9.4)	-2.3 (-19.9 to 22.9)	-8.0 (-24.9 to 16.5)
Skin and subcutaneous diseases	-	-	-	-	72.7 (44.5 to 113.3)	70.9 (45.6 to 107.1)	-2.1 (-10.5 to 6.0)	-4.8 (-13.6 to 3.3)
Dermatitis	699.1 (572.3 to 822.4)	771.6 (636.5 to 919.0)	10.3 (6.3 to 13.8)	0.1 (-0.0 to 0.2)	15.9 (10.2 to 23.3)	17.2 (11.1 to 25.3)	8.1 (4.4 to 11.8)	0.1 (-2.1 to 2.4)
Psoriasis	144.8 (125.3 to 166.5)	169.3 (145.2 to 195.1)	16.7 (14.5 to 19.3)	0.1 (-0.0 to 0.2)	11.6 (7.9 to 16.2)	13.5 (9.2 to 18.8)	16.2 (11.2 to 21.4)	0.3 (-3.9 to 5.0)
Cellulitis	1.9 (1.6 to 2.4)	2.2 (1.8 to 2.7)	14.7 (9.9 to 27.0)	-2.9 (-12.1 to 7.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	14.9 (8.6 to 44.8)	-2.1 (-20.9 to 21.2)
Pyoderma	4.7 (4.0 to 5.6)	4.9 (4.1 to 5.9)	3.2 (-3.1 to 9.6)	-4.3 (-7.8 to -0.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	2.3 (-9.7 to 15.1)	-4.4 (-14.8 to 7.7)
Scabies	6.8 (5.5 to 8.1)	5.3 (4.3 to 6.4)	-22.9 (-38.8 to 2.3)	-22.5 (-38.7 to 2.8)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-22.6 (-41.0 to 4.7)	-22.6 (-40.8 to 4.8)
Fungal skin diseases	726.4 (643.5 to 805.6)	809.9 (755.5 to 930.1)	11.0 (13.9 to 20.0)	16.5 (0.4 to 32.7)	4.7 (1.6 to 8.5)	4.7 (1.9 to 9.8)	0.0 (-13.1 to 13.7)	0.2 (-0.7 to 1.6)
Viral skin diseases	230.3 (191.1 to 272.0)	216.0 (174.8 to 258.7)	-6.2 (-10.3 to -2.6)	0.7 (-1.1 to 2.4)	7.1 (4.4 to 10.5)	6.6 (4.1 to 9.9)	-6.7 (-11.4 to -2.6)	0.7 (-2.2 to 3.5)
Acne vulgaris	2,212.5 (1,767.4 to 2,579.8)	1,555.0 (1,257.4 to 1,893.9)	-29.6 (-45.3 to -9.3)	-14.3 (-34.6 to 9.9)	24.0 (11.2 to 44.1)	16.8 (7.8 to 32.0)	-29.6 (-45.5 to -9.3)	-14.3 (-34.7 to 10.4)
Alopecia areata	16.8 (15.6 to 18.0)	20.6 (19.1 to 22.2)	22.5 (10.2 to 37.2)	0.6 (-8.5 to 12.3)	0.6 (0.4 to 0.8)	0.7 (0.4 to 1.0)	21.7 (7.4 to 39.5)	0.9 (-10.8 to 15.6)
Pruritus	1.3 (0.8 to 1.8)	1.6 (1.0 to 2.2)	27.6 (-26.6 to 131.4)	2.1 (-43.4 to 80.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.1 (-30.3 to 129.0)	-2.6 (-45.1 to 79.1)
Urticaria	65.2 (45.6 to 88.7)	73.4 (57.2 to 91.1)	14.9 (-8.7 to 76.0)	-1.6 (-38.2 to 53.9)	3.8 (2.2 to 6.1)	4.3 (2.6 to 6.3)	13.7 (-30.0 to 75.8)	-1.3 (-38.6 to 55.6)
Decubitus ulcer	6.3 (5.2 to 7.6)	8.4 (6.7 to 10.4)	34.2 (-4.4 to 79.6)	-11.8 (-34.7 to 16.1)	0.9 (0.6 to 1.3)	1.2 (0.8 to 1.7)	32.2 (-6.4 to 81.1)	-11.8 (-35.7 to 18.3)
Other skin and subcutaneous diseases	780.6 (444.3 to 1,359.4)	991.3 (540.3 to 1,778.7)	26.4 (16.7 to 33.5)	-0.2 (-2.8 to 2.3)	4.5 (1.8 to 10.1)	5.7 (2.2 to 13.1)	26.0 (16.5 to 33.2)	0.0 (-8.8 to 9.5)
Sense organ diseases	-	-	-	-	75.0 (50.0 to 108.7)	86.3 (65.5 to 142.0)	31.0 (20.5 to 45.1)	8.3 (-14.4 to 0.5)
Glaucoma	12.4 (9.0 to 16.6)	13.1 (9.7 to 17.7)	7.7 (-18.7 to 35.4)	-28.0 (-46.6 to -9.6)	1.2 (0.7 to 1.8)	1.2 (0.8 to 1.9)	9.7 (-19.7 to 37.1)	-25.5 (-45.4 to -6.2)
Cataract	33.2 (21.3 to 45.1)	36.9 (21.7 to 56.2)	9.2 (-21.7 to 56.9)	-34.8 (-51.2 to -6.9)	2.1 (1.2 to 3.1)	2.4 (1.3 to 4.0)	14.8 (-12.5 to 52.1)	-31.0 (-46.4 to -9.3)
Macular degeneration	42.3 (28.9 to 60.9)	65.4 (45.6 to 88.4)	55.0 (25.7 to 94.8)	2.1 (-18.1 to 26.6)	2.6 (1.6 to 4.1)	4.0 (2.4 to 6.1)	52.4 (29.8 to 86.3)	-4.0 (-18.2 to 15.5)
Uncorrected refractive error	1,205.0 (1,000.4 to 1,429.9)	1,495.5 (1,215.6 to 1,790.1)	23.8 (-6.0 to 71.6)	-7.1 (-30.9 to 27.4)	16.0 (9.1 to 27.3)	19.1 (10.5 to 33.5)	18.9 (-3.9 to 53.0)	-10.4 (-27.3 to 14.8)
Age-related and other hearing loss	1,553.1 (1,327.7 to 1,756.3)	2,040.9 (1,770.3 to 2,306.0)	31.3 (25.9 to 37.4)	-8.2 (-13.3 to -4.3)	44.7 (29.3 to 65.9)	62.4 (41.1 to 91.4)	64.4 (27.1 to 59.2)	-4.4 (-15.1 to 3.3)
Other vision loss	33.1 (25.3 to 42.2)	28.4 (20.5 to 37.2)	-13.7 (-32.1 to -0.3)	-36.5 (-50.2 to -28.6)	2.2 (1.5 to 3.2)	2.2 (1.3 to 3.3)	-1.4 (-17.5 to 12.9)	-26.8 (-38.2 to -17.0)
Other sense organ diseases	238.6 (226.3 to 249.3)	269.5 (257.6 to 281.8)	12.7 (5.8 to 20.4)	-0.4 (-6.2 to 6.4)	6.2 (3.9 to 9.3)	6.9 (4.3 to 10.1)	11.6 (4.1 to 20.2)	-0.4 (-6.9 to 6.9)
Oral disorders	-	-	-	-	34.1 (21.5 to 50.5)	40.9 (26.0 to 61.4)	20.1 (9.6 to 31.3)	8.1 (-16.3 to 0.5)
Deciduous caries	333.1 (312.8 to 352.4)	266.7 (251.0 to 283.3)	-20.1 (-25.8 to -13.0)	0.3 (-6.8 to 9.2)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	0.1 (-28.5 to 9.5)	0.1 (-10.3 to 13.4)
Permanent caries	3,852.3 (3,425.3 to 4,213.3)	4						

Appendix Table G.4 - Portugal prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	745.9 (666.5 to 828.0)	876.8 (791.9 to 960.1)	17.6 (1.4 to 35.9)	-17.8 (-29.0 to -5.2)	20.3 (13.6 to 27.9)	23.7 (15.7 to 32.9)	17.1 (1.0 to 35.7)	-17.8 (-29.2 to -5.0)
Other oral disorders	187.5 (177.4 to 197.3)	212.8 (200.9 to 224.6)	13.4 (4.6 to 22.8)	-0.2 (-8.2 to 8.2)	5.4 (3.4 to 8.2)	6.1 (3.8 to 9.1)	13.1 (3.7 to 22.8)	0.1 (-8.5 to 8.4)
Injuries	-	-	-	-	96.7 (73.1 to 125.3)	87.5 (63.0 to 118.0)	-9.6 (-17.1 to -1.3)	-34.1 (-39.5 to -28.1)
Transport injuries	-	-	-	-	27.0 (20.5 to 34.6)	12.8 (9.3 to 17.0)	-52.7 (-56.1 to -48.9)	-63.9 (-66.4 to -61.0)
Road injuries	-	-	-	-	24.5 (18.6 to 31.3)	11.4 (8.4 to 15.1)	-53.3 (-56.7 to -49.5)	-64.3 (-66.8 to -61.4)
Pedestrian road injuries	-	-	-	-	5.3 (3.9 to 7.0)	2.7 (1.9 to 3.7)	-49.3 (-53.5 to -44.7)	-62.2 (-65.4 to -58.8)
Cyclist road injuries	-	-	-	-	3.1 (2.4 to 4.0)	1.3 (1.0 to 1.8)	-57.5 (-62.1 to -52.2)	-67.0 (-70.5 to -62.9)
Motorcyclist road injuries	-	-	-	-	4.5 (3.4 to 5.8)	1.9 (1.4 to 2.6)	-57.7 (-61.6 to -53.2)	-66.8 (-70.0 to -63.2)
Motor vehicle road injuries	-	-	-	-	11.2 (8.5 to 14.2)	5.4 (4.0 to 7.1)	-51.7 (-55.4 to -47.5)	-63.0 (-65.8 to -59.7)
Other road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.1 (0.0 to 0.1)	-80.6 (-82.3 to -78.7)	-85.0 (-86.3 to -83.4)
Other transport injuries	-	-	-	-	2.5 (1.9 to 3.3)	1.4 (1.0 to 1.9)	-45.7 (-50.4 to -41.1)	-59.4 (-62.9 to -56.0)
Unintentional injuries	-	-	-	-	68.5 (51.7 to 89.5)	73.9 (52.9 to 100.3)	7.5 (-1.1 to 17.4)	-21.7 (-27.4 to -14.6)
Falls	-	-	-	-	38.4 (29.1 to 49.0)	40.7 (29.5 to 54.0)	5.7 (-5.4 to 19.0)	-25.5 (-32.9 to -16.3)
Drowning	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-23.8 (-44.4 to -28.6)	-49.7 (-56.4 to -43.3)
Fire, heat, and hot substances	-	-	-	-	1.9 (1.1 to 3.0)	2.1 (1.2 to 3.4)	11.3 (-1.3 to 26.4)	-11.3 (-21.8 to 1.7)
Poisonings	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-55.9 (-63.7 to -46.8)	-63.7 (-70.5 to -55.9)
Exposure to mechanical forces	-	-	-	-	7.7 (5.7 to 10.2)	6.1 (4.3 to 8.4)	-20.8 (-28.0 to -11.1)	-35.3 (-40.8 to -27.3)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	32.6 (-32.5 to -15.0)	5.3 (-43.5 to -29.0)
Unintentional suffocation	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-21.0 (16.3 to 51.8)	-35.6 (-7.5 to 21.8)
Other exposure to mechanical forces	-	-	-	-	0.6 (5.6 to 9.9)	0.8 (4.2 to 8.2)	36.3 (-28.4 to -11.3)	5.5 (-41.1 to -27.3)
Adverse effects of medical treatment	-	-	-	-	0.2 (0.4 to 0.9)	0.2 (0.5 to 1.2)	21.2 (25.7 to 47.1)	-3.2 (-2.3 to 13.1)
Animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	22.2 (12.2 to 30.2)	-3.2 (-10.3 to 4.0)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.1 (3.5 to 30.8)	-2.5 (-14.0 to 10.3)
Non-venomous animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	21.9 (12.7 to 32.2)	-3.4 (-10.7 to 4.8)
Foreign body	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.5)	-8.3 (-17.2 to -0.8)	-21.4 (-30.5 to -13.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-12.3 (-24.0 to -1.0)	-29.1 (-39.2 to -18.6)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.7 (-8.3 to 8.3)	-9.1 (-19.2 to -1.0)
Foreign body in other body part	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-9.9 (-21.6 to -0.3)	-22.8 (-34.0 to -13.7)
Other unintentional injuries	-	-	-	-	19.2 (13.7 to 25.0)	23.5 (16.4 to 32.7)	22.1 (12.9 to 32.4)	-9.8 (-16.9 to -2.3)
Self-harm and interpersonal violence	-	-	-	-	1.2 (0.9 to 1.5)	0.8 (0.6 to 1.1)	-30.8 (-36.7 to -23.9)	-45.7 (-50.2 to -40.3)
Self-harm	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-20.4 (-31.6 to -8.9)	-38.7 (-47.6 to -29.3)
Interpersonal violence	-	-	-	-	0.8 (0.6 to 1.0)	0.5 (0.4 to 0.7)	-35.3 (-40.6 to -29.1)	-48.6 (-52.7 to -43.7)
Assault by firearm	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-29.8 (-35.6 to -22.3)	-45.4 (-49.8 to -39.6)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-21.4 (-28.4 to -14.0)	-37.6 (-42.9 to -31.9)
Assault by other means	-	-	-	-	0.5 (0.4 to 0.7)	0.3 (0.2 to 0.4)	-40.0 (-45.6 to -33.5)	-51.9 (-56.3 to -46.7)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	118.6 (28.0 to 162.9)	153.9 (33.1 to 214.3)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	118.6 (28.0 to 162.9)	153.9 (33.1 to 214.3)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Qatar prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	48.0 (35.7 to 62.3)	237.1 (176.1 to 307.9)	394.3 -1.3	394.3 (5.1 to 1.9)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	4.6 (3.2 to 6.3)	15.1 (10.8 to 20.8)	225.2 (195.6 to 263.3)	-7.7 (-14.5 to 0.8)
HIV/AIDS and tuberculosis	-	-	-	-	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.5)	360.2 (279.7 to 449.6)	-24.8 (-34.4 to -14.3)
Tuberculosis	0.2 (0.2 to 0.3)	1.1 (1.0 to 1.1)	349.5 (319.3 to 379.1)	-26.5 (-30.2 to -22.9)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.5)	352.9 (274.1 to 440.8)	-25.8 (-35.1 to -15.5)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	775.4 (273.6 to 6,089.4)	62.7 (-28.8 to 1,076.8)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3,148.2 (1,324.8 to 8,378.0)	424.4 (117.9 to 1,407.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3,148.2 (1,302.2 to 8,429.0)	424.4 (117.4 to 1,409.3)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	753.5 (261.5 to 5,022.8)	59.5 (-31.5 to 866.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	742.9 (231.7 to 6,429.7)	58.1 (-36.2 to 1,159.4)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	1.1 (0.8 to 1.5)	3.1 (2.1 to 4.3)	181.7 (154.8 to 212.8)	-15.6 (-21.9 to -8.6)
Diarrheal diseases	5.1 (4.7 to 5.5)	12.7 (11.5 to 14.1)	348.0 (119.3 to 182.8)	-19.2 (-26.5 to -10.6)	45.5 (0.6 to 1.2)	2.1 (1.4 to 2.9)	45.5 (116.7 to 183.4)	-19.3 (-26.8 to -9.9)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	196.4 (108.2 to 323.4)	-21.5 (-42.6 to 2.9)
Typhoid fever	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	196.4 (114.6 to 324.4)	-21.8 (-39.9 to 1.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	199.0 (112.7 to 331.3)	-21.5 (-40.7 to 4.2)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	208.2 (111.6 to 341.5)	-17.6 (-37.2 to 12.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	208.3 (111.5 to 343.1)	-17.6 (-37.3 to 12.2)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.0 (-98.0 to 5,260.0)	-74.7 (-99.4 to 1,328.4)
Lower respiratory infections	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	392.1 (78.5 to 363.1)	-5.3 (36.0 to 44.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	157.1 (68.3 to 379.7)	-7.5 (-38.2 to 44.8)
Upper respiratory infections	9.4 (8.3 to 10.5)	39.3 (32.9 to 45.6)	318.7 (242.1 to 405.7)	-1.9 (-18.9 to 15.4)	0.1 (0.1 to 0.2)	0.5 (0.3 to 0.8)	318.1 (239.3 to 409.0)	-1.9 (-18.8 to 15.5)
Otitis media	5.3 (5.0 to 5.7)	19.6 (17.4 to 21.5)	271.1 (224.5 to 318.1)	-6.5 (-15.9 to 2.1)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	266.9 (221.2 to 318.1)	-7.8 (-16.8 to 2.1)
Meningitis	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	477.4 (379.5 to 714.6)	25.4 (6.0 to 61.5)
Pneumococcal meningitis	0.0 (0.0 to 0.1)	0.4 (0.2 to 0.6)	614.5 (413.1 to 871.6)	44.8 (4.9 to 85.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	549.8 (384.8 to 973.4)	34.9 (3.7 to 100.1)
H influenzae type B meningitis	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.4)	405.5 (160.4 to 711.3)	13.0 (36.6 to 72.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	342.4 (147.7 to 620.0)	5.3 (-37.6 to 57.9)
Meningococcal meningitis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	450.1 (199.1 to 907.8)	14.6 (-40.3 to 101.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	411.6 (175.2 to 822.8)	7.4 (-47.8 to 91.6)
Other meningitis	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	632.4 (406.1 to 1,023.2)	54.7 (17.6 to 109.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	578.9 (385.2 to 982.7)	44.4 (8.1 to 100.7)
Encephalitis	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.8)	239.4 (152.3 to 343.9)	-25.8 (-41.7 to -1.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	251.4 (161.8 to 391.0)	-20.4 (-38.3 to 7.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.2 (91.1 to 1,437.4)	-54.1 (-97.0 to 458.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.2 (91.3 to 1,437.9)	-54.1 (-97.0 to 461.8)
Whooping cough	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-67.2 (-70.6 to -63.4)	-84.2 (-85.9 to -82.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.4 (-78.4 to -52.5)	-84.3 (-89.8 to -76.9)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.9 (-20.1 to 237.8)	-41.2 (-80.3 to -9.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	119.7 (-18.2 to 259.1)	-39.3 (-79.6 to -4.5)
Measles	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	86.3 (-91.1 to -78.8)	-95.3 (-95.6 to -89.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.1 (-91.1 to -77.7)	-95.1 (-95.6 to -89.0)
Varicella and herpes zoster	0.3 (0.3 to 0.3)	1.0 (0.8 to 1.2)	218.3 (152.4 to 316.2)	1.9 (14.6 to 29.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	373.0 (206.1 to 718.5)	3.4 (-25.3 to 65.5)
Neglected tropical diseases and malaria	-	-	-	-	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.5)	140.7 (85.2 to 245.8)	-3.7 (-29.3 to 37.8)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	454.4 (183.8 to 1,031.6)	21.7 (-37.5 to 146.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	471.2 (191.0 to 1,068.5)	25.2 (-36.0 to 156.7)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	218.6 (84.4 to 457.1)	-18.3 (-49.8 to 32.3)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	325.8 (72.3 to 777.4)	13.8 (-49.0 to 112.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	326.9 (70.6 to 783.5)	13.9 (-48.5 to 112.0)
Cutaneous and mucocutaneous leishmaniasis	0.3 (0.2 to 0.4)	0.8 (0.4 to 1.5)	182.7 (58.2 to 448.8)	-28.3 (-56.1 to 23.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	183.0 (47.4 to 468.7)	-28.0 (-58.2 to 26.1)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-78.8 (-92.2 to -11.4)	-95.5 (-98.3 to -85.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-76.5 (-91.8 to -2.5)	-95.1 (-98.2 to -83.9)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	168.3 (141.8 to 232.1)	-43.8 (-51.1 to -34.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	185.8 (115.9 to 295.9)	-40.5 (-54.9 to -20.6)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	157.2 (-59.7 to 260.5)	-32.9 (-49.4 to -8.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	157.2 (-59.7 to 261.1)	32.9 (-89.4 to -8.3)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	230.3 (98.6 to 574.1)	-34.0 (-60.9 to 24.6)
Ascariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trichuriasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hookworm disease	0.3 (0.3 to 0.5)	2.0 (1.4 to 2.7)	460.4 (263.6 to 788.1)	2.2 (-33.7 to 61.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	230.3 (98.6 to 574.1)	-34.0 (-60.9 to 24.6)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	4.5 (3.6 to 5.6)	12.8 (11.1 to 14.2)	182.4 (129.7 to 251.9)	-2.8 (-21.6 to 20.8)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	138.7 (80.2 to 253.8)	-1.4 (-28.7 to 45.3)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	128.8 (67.4 to 202.5)	65.8 (-7.5 to -54.4)
Maternal hemorrhage	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.5)	333.9 (192.5 to 524.4)	33.1 (-54.5 to -3.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	272.5 (78.0 to 689.1)	-42.9 (-73.5 to 21.5)
Maternal sepsis and other maternal infections	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	45.5 (-15.6 to 150.0)	-75.4 (-85.7 to -59.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.2 (-30.1 to 156.8)	77.0 (-88.7 to -60.1)
Maternal hypertensive disorders	0.2 (0.1 to 0.3)	0.5 (0.2 to 0.8)	121.2 (71.4 to 179.9)	-67.4 (-75.9 to -56.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	121.3 (64.9 to 188.3)	67.4 (-76.6 to -55.8)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.5 (19.3 to 205.5)	-73.8 (-83.6 to -53.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.6 (-32.4 to 331.5)	-73.7 (-83.8 to -35.7)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	150.5 (39.9 to 359.8)	-60.5 (-77.5 to -31.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	150.5 (39.8 to 360.1)	-60.5 (-77.5 to -31.1)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	130.0 (103.3 to 419.3)	65.4 (-83.6 to -21.0)
Neonatal disorders	-	-	-	-	0.7 (0.5 to 1.0)	3.7 (2.5 to 5.4)	426.2 (273.6 to 744.7)	21.1 (-12.8 to 87.2)
Preterm birth complications	2.3 (1.4 to 3.9)	15.9 (10.2 to 25.6)	588.9 (411.4 to 800.7)	52.8 (16.6 to 97.3)	0.3 (0.2 to 0.5)	2.4 (1.5 to 3.6)	636.1 (346.3 to 993.1)	67.2 (5.9 to 144.4)
Neonatal encephalopathy due to birth asphyxia and trauma	0.7 (0.4 to 1.1)	2.1 (1.2 to 3.6)	191.6 (66.8 to 526.3)	-33.3 (-61.7 to -33.7)	0.2 (0.1 to 0.3)	0.7 (0.4 to 1.1)	209.6 (63.6 to 584.8)	-28.4 (-61.8 to -51.4)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.4 (-75.8 to -55.4)	-83.4 (-89.1 to -79.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.4 (-78.7 to 44.9)	84.2 (-90.4 to -75.1)
Hemolytic disease and other neonatal jaundice	0.2 (0.0 to 0.4)	0.5 (0.2 to 1.4)	229.0 (-38.7 to 2,423.6)	-29.4 (-87.4 to 440.2)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.6)	249.9 (-30.7 to 2,357.6)	-25.5 (-85.1 to 438.8)
Other neonatal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.6)	451.9 (130.4 to 1,815.7)	31.5 (-45.2 to 318.6)
Nutritional deficiencies	-	-	-	-	2.3 (1.5 to 3.3)	6.1 (4.0 to 9.0)	164.7 (133.2 to 195.2)	-12.8 (-21.5 to -4.2)
Protein-energy malnutrition	0.3 (0.1 to 0.7)	0.4 (0.1 to 0.9)	47.4 (-64.5 to 433.4)	-27.5 (-82.3 to 158.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	47.5 (-65.2 to 439.2)	-38.0 (-82.8 to 160.0)
Iodine deficiency	13.3 (7.0 to 20.9)	35.0 (19.3 to 60.8)	160.2 (30.4 to 454.9)	-49.5 (-72.6 to 2.6)	0.2 (0.1 to 0.4)	0.6 (0.3 to 1.3)	162.8 (28.4 to 454.9)	-49.4 (-72.8 to 2.6)
Vitamin A deficiency	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-

Appendix Table G.4 - Qatar prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	70.4 (68.8 to 71.8)	235.0 (230.7 to 239.7)	233.8 (222.4 to 245.8)	-6.9 (-10.5 to -3.1)	2.0 (1.3 to 2.8)	5.3 (3.5 to 7.8)	170.3 (156.3 to 186.0)	-4.3 (-13.1 to -4.4)
Other nutritional deficiencies	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	77.7 (69.8 to 894.7)	-12.1 (-84.9 to 388.9)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.3 (0.2 to 0.5)	1.4 (0.9 to 2.3)	366.9 (272.1 to 495.9)	0.9 (-17.1 to 23.0)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.2 (0.1 to 0.3)	0.9 (0.5 to 1.6)	509.2 (338.0 to 765.6)	6.7 (-21.0 to 49.2)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	204.9 (129.6 to 327.8)	-48.5 (-50.2 to -28.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	225.1 (107.4 to 423.2)	-39.7 (-55.8 to -14.1)
Chlamydial infection	14.3 (10.7 to 18.4)	90.3 (70.9 to 115.6)	515.5 (342.9 to 817.6)	10.8 (20.4 to 64.6)	0.1 (0.1 to 0.2)	0.7 (0.3 to 1.2)	551.5 (305.7 to 1,004.1)	15.1 (-28.8 to 90.5)
Gonococcal infection	3.7 (2.8 to 4.7)	15.7 (11.8 to 19.7)	330.2 (188.6 to 531.2)	-23.1 (-51.7 to 19.2)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	459.9 (271.8 to 780.8)	-2.3 (-33.2 to 54.8)
Trichomoniasis	2.1 (1.3 to 2.9)	10.1 (7.2 to 13.4)	376.5 (200.4 to 722.7)	-12.6 (-46.8 to 56.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	349.3 (133.8 to 961.3)	-15.3 (-58.2 to 103.5)
Genital herpes	68.3 (63.9 to 72.4)	357.3 (329.7 to 383.9)	422.7 (368.2 to 477.4)	-5.2 (-14.5 to 4.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	419.0 (267.7 to 487.1)	44.5 (-15.4 to 5.6)
Other sexually transmitted diseases	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.3)	206.7 (149.4 to 277.2)	-46.4 (-56.7 to -33.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	311.2 (163.3 to 575.1)	-24.6 (-48.1 to 12.7)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	304.0 (195.8 to 450.9)	-23.0 (-41.1 to 2.9)
Hepatitis A	0.4 (0.4 to 0.4)	1.6 (1.5 to 1.7)	289.2 (287.5 to 290.2)	-7.2 (-8.3 to -6.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	359.0 (290.8 to 439.9)	-6.1 (-17.6 to 7.0)
Hepatitis B	43.6 (30.5 to 55.6)	152.6 (118.3 to 192.8)	246.5 (146.6 to 421.7)	-33.3 (-51.0 to -11.1)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	250.1 (106.6 to 498.7)	-36.1 (-61.2 to 8.2)
Hepatitis C	24.2 (20.8 to 27.5)	89.4 (74.9 to 105.2)	268.5 (203.5 to 357.7)	-29.3 (-40.0 to -15.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	265.5 (126.8 to 468.0)	-20.0 (-43.6 to 14.2)
Hepatitis E	0.1 (0.1 to 0.1)	0.6 (0.4 to 0.9)	651.0 (351.5 to 1,307.0)	33.6 (-16.4 to 134.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	664.2 (307.7 to 1,481.1)	34.4 (-22.4 to 149.1)
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	443.7 (49.4 to 1,208.3)	9.4 (-62.9 to 168.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	628.3 (42.5 to 4,002.2)	38.3 (-63.5 to 790.1)
Other infectious diseases	3.4 (2.8 to 4.0)	10.4 (9.1 to 11.9)	209.6 (158.4 to 272.8)	-3.0 (-21.2 to 18.7)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	198.1 (114.7 to 306.7)	4.0 (-25.8 to 34.2)
Non-communicable diseases	-	-	-	-	41.4 (30.8 to 53.6)	214.9 (158.8 to 280.2)	418.8 (392.4 to 443.7)	0.2 (-3.9 to 4.2)
Neoplasms	0.0	0.0	71.6	-53.2	0.0	0.6	231.6	-17.9
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.6 (3.0 to 235.9)	-53.2 (-73.6 to -9.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.1 (27.1 to 226.5)	-49.7 (-69.6 to -13.2)
Stomach cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	191.9 (125.0 to 280.5)	-11.2 (-32.3 to 18.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	189.5 (118.8 to 284.0)	-13.6 (-35.4 to 18.9)
Liver cancer	0.0	0.0	-	-	0.0	0.0	294.0	-14.8
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.6 (-13.9 to 477.4)	-45.7 (77.6 to 51.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.7 (-16.7 to 424.9)	-51.5 (-79.2 to 37.8)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	923.3 (358.7 to 2,443.9)	124.6 (11.6 to 393.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	794.6 (307.4 to 2,023.1)	89.4 (-5.6 to 295.7)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	162.5 (-15.6 to 537.9)	-34.1 (-73.2 to 42.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	143.6 (-19.5 to 464.3)	-38.8 (-75.4 to 23.4)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	143.8 (-13.1 to 520.6)	-44.4 (-79.1 to 37.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	118.9 (-19.6 to 433.0)	-50.0 (-81.2 to 12.9)
Larynx cancer	0.1 (0.1 to 0.1)	0.5 (0.4 to 0.5)	268.5 (198.1 to 361.2)	-15.3 (-33.5 to 7.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	287.6 (191.0 to 417.5)	-10.3 (-32.2 to 16.1)
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	173.5 (110.3 to 298.2)	-27.8 (-44.5 to -2.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	170.6 (102.9 to 313.5)	-29.7 (-47.5 to -2.0)
Breast cancer	0.8 (0.7 to 0.9)	1.4 (1.1 to 1.9)	79.9 (32.1 to 144.8)	-68.0 (-75.1 to -58.4)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	128.5 (60.4 to 222.5)	-54.3 (-66.5 to -38.9)
Cervical cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	486.1 (7.3 to 966.9)	103.8 (-68.6 to 206.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	394.9 (6.3 to 1,051.2)	-8.9 (-69.6 to 212.0)
Uterine cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	637.0 (54.8 to 1,314.3)	95.3 (-65.7 to 255.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	605.7 (44.5 to 1,259.1)	84.3 (-66.9 to 238.0)
Prostate cancer	0.0 (0.0 to 0.0)	0.3 (0.2 to 0.5)	7,557.8 (431.5 to 14,172.0)	2,280.5 (38.3 to 4,192.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6,216.7 (317.7 to 11,864.6)	1,911.1 (-9.7 to 3,873.4)
Colon and rectum cancer	0.5 (0.5 to 0.5)	2.0 (1.8 to 2.2)	299.1 (254.4 to 342.7)	-3.5 (-13.9 to 6.8)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	296.3 (243.8 to 353.5)	-5.0 (-15.8 to 5.1)
Lip and oral cavity cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	197.9 (106.8 to 346.9)	-19.9 (-47.6 to 16.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	193.7 (99.6 to 348.6)	-21.2 (-48.5 to 14.3)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	788.5 (314.7 to 1,476.0)	132.2 (8.7 to 283.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	802.3 (309.2 to 1,440.5)	132.2 (-13.2 to 267.3)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,094.1 (228.6 to 1,802.6)	246.0 (-32.4 to 448.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,066.3 (212.2 to 1,745.2)	234.6 (-35.0 to 430.3)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.7 (-14.4 to 274.0)	-64.3 (-78.4 to -4.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.6 (-13.0 to 272.3)	-63.4 (-78.4 to -3.9)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	233.4 (141.5 to 355.2)	-18.8 (-39.4 to 10.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	235.1 (157.8 to 336.7)	-18.3 (-37.8 to 10.0)
Malignant skin melanoma	0.1 (0.0 to 0.0)	0.1 (0.0 to 0.1)	480.9 (56.7 to 694.5)	89.9 (-60.4 to 76.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	418.9 (45.2 to 685.0)	-42.1 (-63.5 to 63.3)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.2)	748.2 (435.2 to 1,147.9)	74.3 (7.5 to 154.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	873.2 (373.4 to 1,528.6)	93.2 (10.0 to 209.8)
Ovarian cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	242.4 (118.9 to 439.6)	-6.9 (-36.7 to 35.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	234.3 (98.6 to 475.7)	-10.8 (-44.9 to 41.9)
Testicular cancer	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	62.3 (-30.2 to 362.3)	-70.5 (-85.6 to 83.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.7 (-40.1 to 1,067.8)	-69.6 (-87.0 to 93.9)
Kidney cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	234.0 (131.8 to 365.6)	-14.8 (-39.5 to 22.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	219.2 (113.6 to 380.0)	-18.6 (-43.2 to 17.8)
Bladder cancer	0.3 (0.3 to 0.3)	0.8 (0.8 to 0.9)	163.3 (131.8 to 202.1)	-32.8 (-41.7 to -23.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	165.2 (124.5 to 212.4)	-33.6 (-42.9 to -22.9)
Brain and nervous system cancer	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	43.9 (-7.7 to 333.2)	-53.8 (-67.9 to 25.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.4 (4.8 to 378.4)	-52.8 (-66.7 to 24.2)
Thyroid cancer	0.1 (0.0 to 0.2)	0.3 (0.2 to 0.4)	78.3 (3.8 to 596.3)	-61.3 (-76.1 to 37.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.6 (2.5 to 614.1)	-61.0 (-75.7 to 35.5)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	406.9 (259.1 to 651.5)	26.4 (-11.8 to 80.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	466.7 (26.5 to 6,447.4)	27.5 (-10.4 to 83.4)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	587.5 (217.2 to 1,024.6)	75.0 (-19.0 to 180.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	629.5 (209.3 to 1,118.3)	72.8 (-23.8 to 178.1)
Non-Hodgkin lymphoma	0.1 (0.1 to 0.1)	0.5 (0.5 to 0.8)	576.9 (327.2 to 821.5)	67.9 (-0.5 to 125.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	566.4 (305.3 to 827.8)	60.2 (-5.3 to 117.9)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,287.8 (205.3 to 2,907.7)	465.7 (-27.6 to 1,136.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,203.0 (204.4 to 2,840.5)	364.0 (-31.7 to 1,351.5)
Leukemia	0.1 (0.1 to 0.1)	0.1 (0.2 to 0.4)	254.5 (174.5 to 382.2)	82.8 (-25.6 to 23.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	254.8 (173.9 to 418.9)	8.3 (-31.1 to 24.2)
Other neoplasms	0.1 (0.1 to 0.2)	0.6 (0.4 to 0.8)	362.6 (181.2 to 594.7)	59.7 (8.8 to 123.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	360.8 (184.3 to 608.3)	49.5 (-3.5 to 113.8)
Cardiovascular diseases	-	-	-	-	0.8 (0.6 to 1.2)	3.9 (2.5 to 5.4)	363.9 (247.9 to 492.6)	-1.8 (-20.5 to 16.9)
Rheumatic heart disease	1.2 (1.0 to 1.8)	6.1 (4.6 to 7.8)	394.0 (223.0 to 634.6)	0.3 (-28.2 to 37.7)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.5)	414.2 (247.7 to 638.1)	12.3 (-19.7 to 61.7)
Ischemic heart disease	2.4 (1.9 to 3.3)	7.9 (6.6 to 9.3)	232.7 (135.9 to 342.8)	-14.4 (-38.2 to 12.8)	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.8)	264.4 (152.8 to 386.8)	-11.0 (-37.9 to 18.7)
Cerebrovascular disease	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	423.0 (284.8 to 601.7)	2.6 (-19.1 to 35.3)
Ischemic stroke	0.1 (0.1 to 0.1)	0.6 (0.5 to 0.8)	418.3 (285.6 to 576.2)	1.2 (-19.2 to 32.0)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	419.2 (275.8 to 607.5)	1.2 (-20.8 to 37.3)
Hemorrhagic stroke	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	420.6 (233.4 to 818.3)	8.3 (-27.0 to 72.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	421.5 (235.4 to 815.7)	8.3 (-27.9 to 68.7)
Hypertensive heart disease	0.3 (0.3 to 0.4)	2.0 (1.7 to 2.3)	477.3 (375.7 to 598.9)	42.0 (17.4 to 69.4)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	481.0 (362.5 to 620.0)	40.4 (-15.1 to 68.3)
Cardiomyopathy and myocarditis	0.4 (0.4 to 0.5)	2.0 (1.7 to 2.3)	344.7 (250.3 to 464.5)	4.7 (-17.7 to 32.8)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	342.3 (236.3 to 487.4)	3.9 (-19.9 to 34.4)
Atrial fibrillation and flutter	0.6 (0.5 to 0.6)	2.7 (2.3 to 3.1)	380.3 (302.1 to 490.0)	-5.0 (-21.4 to 21.9)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	392.8 (301.3 to 515.2)	-5.5 (-22.1 to 21.2)
Peripheral vascular disease	3.4 (2.2 to 5.0)	21.2 (12.5 to 33.5)	500.0 (214.9 to 1,182.7)	17.5 (-20.7 to 79.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	152.5 (20.5 to 540.9)	-13.9 (-61.2 to 112.1)
Endocarditis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	698.7 (375.6 to 1,265.9)	85.7 (6.6 to 218.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	667.3 (345.3 to 1,235.2)	0.2 (-3.5 to 176.3)
Other cardiovascular and circulatory diseases	6.5 (4.6 to 9.5)	30.7 (19.0 to 41.5)	382.8 (182.7 to 619.8)	9.8 (-41.6 to 46.2)	0.5 (0.3 to 0.7)	2.2 (1.2 to 3.3)	389.9 (181.3 to 623.6)	0.9 (-41.9 to 45.5)
Chronic respiratory diseases	-	-	-	-	1.9 (1.3			

Appendix Table G.4 - Qatar prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	399.9	-4.3
Silicosis	0.0	0.0	348.5	-17.6	0.0	0.0	(375.8 to 422.2)	(-12.4 to -4.3)
Asbestosis	0.0	0.0	(323.0 to 376.9)	(-21.6 to -12.8)	0.0	0.0	(323.0 to 377.2)	(-21.5 to -12.4)
Coal workers pneumoconiosis	0.0	0.0	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	431.2	-	0.0	0.0	432.9	-0.6
Asthma	11.2	46.5	(400.6 to 459.5)	(-5.8 to 3.8)	0.0	2.0	317.2	-4.2
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.2	(204.0 to 433.5)	(-31.9 to 24.3)	0.0	0.0	(197.8 to 435.5)	(-33.5 to 23.8)
Other chronic respiratory diseases	0.0	0.2	402.8	-4.2	0.0	0.0	406.4	-4.1
Cirrhosis	0.0	0.1	(225.7 to 769.7)	(-30.7 to 33.0)	0.0	2.0	(227.5 to 756.3)	(-30.4 to 35.9)
Cirrhosis due to hepatitis B	0.0	0.1	204.2	-26.8	0.0	0.0	206.5	-27.7
Cirrhosis due to hepatitis C	0.1	0.2	267.7	-12.4	0.0	0.0	268.9	-12.7
Cirrhosis due to alcohol use	0.0	0.0	104.2	-47.8	0.0	0.0	110.0	-47.9
Cirrhosis due to other causes	0.0	0.1	172.0	-17.8	0.0	0.0	169.4	-20.9
Digestive diseases	0.0	0.0	(54.0 to 401.4)	(-51.8 to 35.4)	0.0	1.5	(40.7 to 442.5)	(-57.6 to 51.8)
Peptic ulcer disease	0.7	1.2	84.2	-56.0	0.0	0.1	111.1	-44.5
Gastritis and duodenitis	1.0	1.9	101.2	-45.1	0.0	0.0	93.0	-37.1
Appendicitis	0.0	0.2	383.1	-13.3	0.0	0.1	394.1	-11.1
Paralytic ileus and intestinal obstruction	0.0	0.0	(186.8 to 909.6)	(-43.3 to 65.1)	0.0	0.0	(160.3 to 1,058.9)	(-47.6 to 84.7)
Inguinal, femoral, and abdominal hernia	0.7	3.1	356.5	-5.6	0.0	0.0	358.0	-5.2
Inflammatory bowel disease	0.4	3.6	711.2	48.9	0.1	0.1	718.1	49.0
Vascular intestinal disorders	0.0	0.0	(604.6 to 827.2)	(-31.2 to 67.9)	0.0	0.0	(586.2 to 876.4)	(-30.5 to 73.2)
Gallbladder and biliary diseases	0.1	0.5	350.7	-3.7	0.0	0.1	355.8	-4.3
Pancreatitis	0.1	0.6	432.4	-9.1	0.0	0.2	433.8	-9.3
Other digestive diseases	0.0	0.0	(363.3 to 509.4)	(-17.2 to -0.3)	0.0	0.3	1,531.7	174.8
Neurological disorders	0.8	2.7	254.1	1.5	0.4	17.2	404.3	-5.2
Alzheimer disease and other dementias	0.1	0.5	347.2	2.7	0.0	0.1	354.8	2.6
Parkinson disease	1.5	5.5	256.0	-21.5	0.6	2.4	283.2	-15.1
Epilepsy	0.1	0.7	782.1	72.1	0.0	0.2	776.7	66.5
Multiple sclerosis	0.1	0.6	(572.5 to 1,066.5)	(-33.5 to 122.6)	0.0	0.1	(514.7 to 1,185.3)	(-25.9 to 132.0)
Migraine	52.5	248.4	374.3	-10.1	8.5	8.5	394.9	-10.5
Tension-type headache	68.2	380.0	459.0	8.5	0.1	0.6	459.9	8.2
Medication overuse headache	3.9	29.8	661.7	48.1	0.6	4.7	663.9	48.1
Other neurological disorders	0.0	0.0	431.2	4.3	0.1	0.3	175.8	-38.0
Mental and substance use disorders	1.6	9.0	460.3	-0.3	1.0	87.1	441.3	0.4
Schizophrenia	3.4	16.0	368.6	-19.4	0.3	1.6	369.1	-19.9
Alcohol use disorders	11.8	72.5	514.0	7.2	4.9	30.3	515.8	7.6
Drug use disorders	0.5	2.3	348.8	-23.9	0.1	0.3	350.0	-23.4
Opioid use disorders	0.4	1.7	212.2 to 622.0	(-46.2 to 22.5)	0.0	0.0	(188.6 to 668.0)	(-49.2 to 27.6)
Cocaine use disorders	0.5	2.7	391.0	-14.3	0.1	0.3	388.6	-14.8
Amphetamine use disorders	0.4	1.7	(228.9 to 578.3)	(-42.4 to 17.1)	0.0	0.0	(218.9 to 610.8)	(-43.0 to 21.2)
Cannabis use disorders	0.8	4.7	466.5	3.6	0.0	0.1	465.2	3.6
Other drug use disorders	0.0	0.0	(439.6 to 490.3)	(-3.0 to 4.4)	0.0	0.0	(362.7 to 598.2)	(-12.6 to 23.6)
Depressive disorders	19.8	103.5	417.5	-0.8	21.4	21.4	418.2	-0.6
Major depressive disorder	5.0	26.8	432.9	-1.7	2.6	2.6	434.7	-1.7
Dysthymia	3.9	21.1	447.9	-2.4	0.8	4.3	449.7	-2.4
Bipolar disorder	18.2	98.5	389.0	3.8	0.7	8.2	388.7	4.0
Anxiety disorders	0.1	0.3	408.7	3.4	0.0	0.1	406.1	2.9
Eating disorders	0.2	1.0	373.5	-15.1	0.0	0.2	370.6	-15.2
Anorexia nervosa	0.0	0.0	(338.5 to 506.2)	(-8.6 to 21.6)	0.0	0.0	(274.9 to 618.6)	(-21.1 to 45.4)
Bulimia nervosa	0.1	0.3	408.7	3.4	0.0	0.1	406.1	2.9
Autistic spectrum disorders	1.6	8.0	393.3	3.0	0.4	2.0	393.1	3.4
Autism	2.5	12.5	398.6	3.8	0.3	1.3	398.0	4.0
Asperger syndrome	2.4	8.0	233.2	4.9	0.0	0.1	230.6	4.6
Attention-deficit/hyperactivity disorder	4.1	11.9	190.6	0.5	1.4	1.4	191.5	0.5
Conduct disorder	10.4	43.4	317.8	-10.5	0.5	2.1	317.1	-10.4
Idiopathic intellectual disability	9.3	56.2	503.0	3.3	0.7	4.2	505.7	3.6
Other mental and substance use disorders	0.0	0.0	(491.4 to 514.4)	(-2.3 to 4.3)	0.5	0.9	(472.4 to 540.7)	(-8.8 to 8.0)
Diabetes, urogenital, blood, and endocrine diseases	45.4	237.3	426.7	3.9	3.4	18.1	433.0	4.8
Diabetes mellitus	0.0	0.0	(121.5 to 161.3)	(-34.9 to -27.3)	0.0	0.0	(121.5 to 161.4)	(-35.0 to -27.3)
Acute glomerulonephritis	3.1	15.5	406.3	9.9	0.1	0.6	444.1	15.1
Chronic kidney disease	2.5	9.6	276.2	-20.5	0.2	0.8	348.5	-22.8
Chronic kidney disease due to diabetes mellitus	4.4	18.6	318.3	-26.2	0.1	0.3	301.3	-22.6
Chronic kidney disease due to hypertension	2.9	7.0	(195.1 to 508.4)	(-41.2 to 3.6)	0.1	0.1	(170.6 to 532.1)	(-33.4 to 19.2)
Chronic kidney disease due to glomerulonephritis	5.2	27.5	430.8	13.8	0.2	1.0	466.5	19.8
Chronic kidney disease due to other causes	0.0	0.0	(305.1 to 599.9)	(-10.6 to 43.8)	0.1	0.3	(321.9 to 668.6)	(-7.2 to 48.2)
Urinary diseases and male infertility	0.0	0.0	-	-	0.4	1.7	338.1	-7.3
					(0.2 to 0.6)	(1.0 to 2.8)	(216.2 to 522.7)	(-25.9 to 16.8)

Appendix Table G.4 - Qatar prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.4)	370.4 (322.2 to 416.1)	0.0 (-7.4 to 9.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	372.7 (235.7 to 532.0)	0.7 (-18.9 to 24.0)
Urolithiasis	4.4 (2.5 to 7.6)	22.1 (11.5 to 49.5)	371.9 (254.0 to 593.3)	10.9 (-22.1 to 37.5)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.6)	494.2 (402.8 to 687.3)	28.8 (4.2 to 62.4)
Benign prostatic hyperplasia	2.3 (2.1 to 2.5)	9.3 (8.6 to 10.0)	308.4 (264.1 to 355.5)	-1.6 (-14.2 to 10.7)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.5)	310.0 (263.5 to 360.8)	-1.6 (-14.0 to 11.1)
Male infertility due to other causes	7.7 (5.3 to 10.4)	49.4 (33.4 to 69.7)	544.5 (271.1 to 963.0)	9.2 (-36.2 to 87.4)	0.1 (0.0 to 0.1)	0.5 (0.1 to 0.7)	541.2 (259.5 to 988.4)	8.4 (-38.9 to 87.9)
Other urinary diseases	-	-	-	-	0.2 (0.0 to 0.4)	0.7 (0.1 to 0.4)	286.7 (77.3 to 700.2)	-30.6 (-63.3 to 68.6)
Gynecological diseases	-	-	-	-	0.4 (0.3 to 0.6)	1.8 (1.2 to 2.8)	342.0 (247.0 to 432.3)	-22.5 (-38.8 to -6.9)
Uterine fibroids	6.0 (5.4 to 6.6)	24.6 (21.9 to 26.9)	310.0 (305.3 to 314.6)	-23.2 (-23.8 to -22.9)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.5)	292.9 (259.3 to 321.0)	-28.1 (-34.2 to -21.8)
Polycystic ovarian syndrome	7.2 (6.6 to 7.8)	29.5 (25.4 to 33.5)	308.1 (245.3 to 379.8)	-29.4 (-37.8 to -19.1)	0.1 (0.0 to 0.1)	0.6 (0.1 to 0.6)	309.4 (245.8 to 378.2)	-29.4 (-38.4 to -19.7)
Female infertility due to other causes	1.2 (0.4 to 2.5)	5.9 (1.5 to 11.5)	356.8 (113.3 to 1,742.0)	-28.3 (-80.0 to 157.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	346.4 (27.6 to 1,516.6)	-29.6 (-78.2 to 130.2)
Endometriosis	0.6 (0.5 to 0.7)	2.8 (2.4 to 3.3)	352.4 (254.8 to 484.8)	-23.6 (-38.3 to -3.6)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.4)	354.2 (249.3 to 491.7)	-23.4 (-39.8 to -2.5)
Genital prolapse	14.3 (11.1 to 17.6)	64.8 (50.3 to 80.7)	345.8 (222.7 to 540.5)	-11.5 (-30.5 to 16.8)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.4)	345.0 (221.5 to 545.4)	-11.8 (-31.2 to 15.8)
Premenstrual syndrome	17.1 (9.4 to 24.4)	82.8 (57.2 to 111.7)	393.2 (165.4 to 785.4)	-18.5 (-55.9 to 41.2)	0.1 (0.0 to 0.3)	0.7 (0.4 to 1.2)	393.2 (163.0 to 779.6)	-18.0 (-56.3 to 40.3)
Other gynecological diseases	0.7 (0.5 to 0.9)	2.7 (2.4 to 2.9)	278.5 (206.8 to 389.3)	-30.2 (-43.5 to -10.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	212.4 (141.8 to 527.0)	-43.3 (-55.8 to 13.1)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.6 (0.4 to 0.8)	1.7 (1.2 to 2.6)	203.3 (167.0 to 240.9)	6.7 (-18.3 to 4.0)
Thalassemias	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.4)	288.8 (236.6 to 354.4)	7.7 (-2.6 to 21.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	340.2 (201.4 to 561.1)	19.8 (-14.9 to 73.5)
Thalassemia trait	21.5 (19.6 to 23.5)	95.7 (88.3 to 103.4)	344.6 (323.6 to 369.4)	-1.7 (-6.1 to 3.9)	0.4 (0.3 to 0.6)	1.3 (0.9 to 1.9)	221.7 (162.0 to 267.2)	-1.4 (-18.4 to 9.7)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	135.7 (106.8 to 204.7)	-39.9 (-48.7 to -21.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	184.7 (140.2 to 226.2)	-35.2 (-45.6 to -26.1)
Sickle cell trait	12.0 (10.3 to 13.6)	36.5 (30.5 to 41.7)	303.8 (178.4 to 233.0)	-33.5 (-39.0 to -27.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	89.7 (50.0 to 159.4)	-38.7 (-52.2 to -17.1)
G6PD deficiency	34.4 (26.3 to 43.0)	146.3 (92.9 to 185.3)	326.1 (168.3 to 543.6)	-8.9 (-41.6 to 37.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	141.3 (-0.5 to 416.3)	-27.8 (-69.9 to 58.9)
G6PD trait	56.7 (44.9 to 64.0)	180.8 (148.0 to 205.8)	218.7 (155.0 to 326.1)	-11.0 (-28.8 to 19.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	234.1 (-14.5 to 1,171.0)	12.1 (-81.1 to 318.0)
Other hemoglobinopathies and hemolytic anemias	3.6 (3.2 to 4.0)	14.4 (12.7 to 15.3)	296.8 (240.3 to 357.7)	-3.4 (-16.9 to 12.7)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	209.9 (109.6 to 343.5)	-2.7 (-31.9 to 39.7)
Endocrine, metabolic, blood, and immune disorders	4.6 (4.2 to 5.0)	16.1 (15.0 to 17.1)	250.9 (214.4 to 290.6)	-4.4 (-14.5 to 5.8)	0.1 (0.1 to 0.2)	0.5 (0.3 to 0.7)	239.1 (189.6 to 302.9)	3.1 (-12.1 to 19.5)
Musculoskeletal disorders	-	-	-	-	7.0 (4.8 to 9.7)	38.2 (26.0 to 52.5)	448.2 (351.0 to 537.2)	3.2 (-9.9 to 15.1)
Rheumatoid arthritis	0.7 (0.7 to 0.8)	3.8 (3.6 to 4.1)	432.2 (386.8 to 480.9)	2.2 (-5.7 to 11.7)	0.2 (0.1 to 0.2)	0.9 (0.6 to 1.2)	434.2 (372.3 to 516.1)	2.5 (-7.4 to 13.6)
Osteoarthritis	7.1 (6.6 to 7.6)	33.7 (31.3 to 36.2)	374.6 (328.4 to 426.0)	1.2 (-6.5 to 8.8)	0.4 (0.3 to 0.6)	1.2 (1.5 to 2.9)	377.6 (339.5 to 430.2)	1.1 (-6.3 to 9.0)
Low back and neck pain	-	-	-	-	5.7 (3.8 to 7.9)	21.4 (21.0 to 43.8)	460.8 (340.8 to 571.3)	4.6 (-12.7 to 20.6)
Low back pain	35.2 (26.6 to 44.7)	195.4 (138.8 to 255.2)	465.2 (299.1 to 630.2)	4.7 (-17.4 to 27.5)	4.0 (2.4 to 5.9)	22.1 (13.3 to 32.6)	467.1 (298.4 to 637.2)	5.1 (-17.7 to 28.1)
Neck pain	17.4 (14.8 to 20.3)	93.9 (78.1 to 109.4)	441.6 (329.1 to 570.1)	2.1 (-14.6 to 20.9)	1.7 (1.2 to 2.4)	9.3 (6.1 to 13.2)	442.2 (329.0 to 571.3)	2.1 (-15.2 to 21.0)
Gout	0.3 (0.2 to 0.3)	1.4 (1.1 to 1.7)	413.3 (284.1 to 653.1)	-0.2 (-22.2 to 33.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	418.1 (243.1 to 710.7)	0.7 (-27.8 to 40.2)
Other musculoskeletal disorders	8.1 (5.2 to 11.1)	40.2 (26.5 to 55.6)	395.6 (339.8 to 456.6)	2.5 (-10.5 to 6.7)	0.7 (0.4 to 1.2)	3.7 (2.1 to 5.9)	377.6 (341.3 to 457.8)	-2.5 (-11.7 to 7.5)
Other non-communicable diseases	-	-	-	-	6.2 (4.2 to 9.1)	28.7 (19.3 to 42.1)	362.0 (333.9 to 391.5)	-3.8 (-8.1 to 1.1)
Congenital anomalies	-	-	-	-	3.6 (0.5 to 0.9)	3.6 (2.3 to 5.1)	435.3 (314.2 to 607.5)	23.4 (-4.9 to 56.2)
Neural tube defects	0.2 (0.1 to 0.2)	0.6 (0.5 to 0.8)	309.4 (199.6 to 429.1)	-4.8 (-30.0 to 22.7)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	327.7 (167.8 to 526.6)	0.5 (-36.1 to 41.9)
Congenital heart anomalies	3.2 (2.6 to 4.0)	17.3 (14.7 to 20.0)	452.6 (320.0 to 582.5)	28.2 (-0.6 to 59.4)	0.1 (0.0 to 0.2)	0.6 (0.3 to 1.1)	477.1 (355.1 to 617.4)	34.9 (6.4 to 67.7)
Orofacial clefts	0.6 (0.4 to 0.8)	3.0 (2.4 to 4.0)	402.4 (238.8 to 668.8)	0.0 (-18.5 to 81.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	415.2 (119.8 to 506.2)	15.2 (-45.1 to 37.4)
Down syndrome	0.7 (0.6 to 1.1)	3.6 (2.7 to 4.5)	391.9 (193.3 to 619.4)	16.2 (-30.7 to 67.7)	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.6)	399.4 (196.0 to 636.2)	20.0 (-29.5 to 76.9)
Turner syndrome	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	243.7 (105.5 to 376.4)	-6.7 (-44.3 to 29.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	256.0 (99.0 to 423.5)	-9.4 (-48.8 to 27.6)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	416.4 (270.8 to 737.5)	5.5 (-24.1 to 71.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	496.8 (326.4 to 876.6)	8.1 (-22.4 to 75.5)
Chromosomal unbalanced rearrangements	0.7 (0.6 to 0.8)	3.5 (2.7 to 4.4)	404.0 (277.7 to 586.2)	3.5 (-11.5 to 60.6)	0.4 (0.1 to 0.1)	0.4 (0.3 to 0.6)	409.9 (270.3 to 611.1)	22.0 (-9.7 to 68.2)
Other congenital anomalies	1.4 (1.2 to 1.6)	6.5 (5.4 to 7.8)	370.1 (292.3 to 478.4)	-5.6 (-19.6 to 14.3)	0.3 (0.2 to 0.5)	1.8 (1.1 to 2.9)	455.7 (268.0 to 783.9)	23.8 (-16.3 to 92.4)
Skin and subcutaneous diseases	-	-	-	-	2.6 (1.6 to 4.1)	12.8 (8.0 to 19.9)	390.9 (337.5 to 438.6)	4.5 (-4.4 to 15.5)
Dermatitis	30.4 (23.5 to 37.5)	153.0 (115.6 to 190.6)	403.9 (383.5 to 421.3)	0.7 (0.1 to 1.3)	0.9 (0.5 to 1.4)	4.4 (2.4 to 6.8)	374.6 (326.4 to 407.4)	0.4 (-2.3 to 3.2)
Psoriasis	3.0 (2.3 to 3.9)	15.9 (11.8 to 20.8)	427.9 (415.2 to 440.9)	0.1 (-0.6 to 0.4)	0.2 (0.2 to 0.4)	1.3 (0.8 to 2.0)	430.3 (380.5 to 478.7)	-0.0 (-6.1 to 7.0)
Cellulitis	0.1 (0.1 to 0.1)	0.3 (0.3 to 0.5)	249.8 (197.1 to 326.9)	-17.7 (-28.7 to -5.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	261.9 (168.8 to 384.5)	-16.8 (-35.1 to 6.3)
Pyoderma	0.3 (0.3 to 0.4)	1.2 (0.9 to 1.6)	242.3 (182.3 to 300.9)	-7.1 (-13.1 to 0.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	241.4 (170.2 to 324.4)	-7.0 (-18.6 to 6.4)
Scabies	1.6 (1.3 to 2.0)	7.8 (5.8 to 11.7)	369.3 (221.2 to 671.0)	3.4 (-25.4 to 42.3)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.4)	370.4 (218.1 to 675.2)	3.3 (-25.5 to 42.8)
Fungal skin diseases	32.2 (23.9 to 41.1)	168.5 (123.7 to 219.5)	422.7 (400.4 to 446.1)	1.6 (-1.0 to 2.1)	0.2 (0.1 to 0.4)	0.9 (0.4 to 1.1)	422.8 (399.0 to 448.5)	1.8 (0.7 to 2.8)
Viral skin diseases	9.1 (6.5 to 11.8)	34.5 (21.1 to 50.2)	276.7 (214.6 to 332.5)	-0.0 (-2.4 to 2.2)	0.3 (0.2 to 0.4)	1.1 (0.5 to 1.9)	276.0 (211.3 to 335.7)	0.1 (-3.7 to 4.2)
Acne vulgaris	50.0 (37.9 to 61.5)	253.0 (182.3 to 352.9)	404.3 (221.5 to 641.2)	11.5 (-24.2 to 63.4)	0.5 (0.2 to 1.0)	2.7 (1.2 to 5.3)	406.0 (220.6 to 643.6)	11.4 (-24.5 to 64.6)
Alopecia areata	0.7 (0.6 to 0.8)	3.3 (2.6 to 4.1)	378.4 (255.0 to 509.9)	-1.7 (-20.7 to 20.0)	0.0 (0.0 to 0.0)	0.0 (0.1 to 0.2)	382.1 (247.0 to 536.2)	-1.3 (-21.8 to 23.8)
Pruritus	0.1 (0.1 to 0.2)	0.7 (0.4 to 1.1)	533.1 (200.3 to 1,463.6)	0.0 (-32.3 to 155.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	536.7 (188.6 to 1,429.4)	23.8 (-33.6 to 163.5)
Urticaria	3.6 (1.9 to 6.1)	20.9 (12.4 to 28.7)	477.6 (200.7 to 1,038.6)	16.9 (-24.5 to 96.6)	0.2 (0.1 to 0.4)	1.3 (0.6 to 2.0)	481.2 (199.0 to 1,053.1)	16.4 (-25.8 to 98.1)
Decubitus ulcer	0.0 (0.0 to 0.1)	0.2 (0.2 to 0.3)	351.7 (242.8 to 512.5)	-3.5 (-32.5 to 52.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	356.5 (237.7 to 534.6)	-4.1 (-35.3 to 55.0)
Other skin and subcutaneous diseases	22.8 (15.5 to 32.2)	117.7 (77.3 to 170.7)	415.4 (372.8 to 463.1)	1.5 (-2.0 to 5.3)	0.1 (0.1 to 0.3)	0.7 (0.3 to 1.4)	415.8 (373.4 to 464.9)	1.5 (-2.0 to 5.5)
Sense organ diseases	-	-	-	-	2.1 (1.4 to 3.1)	8.4 (5.5 to 12.5)	292.6 (266.2 to 326.0)	-12.9 (-16.5 to -8.6)
Glaucoma	1.0 (0.7 to 1.4)	3.1 (3.1 to 6.9)	344.4 (213.4 to 611.6)	-6.6 (-35.7 to 49.3)	0.0 (0.0 to 0.1)	0.3 (0.2 to 0.4)	346.7 (255.9 to 560.4)	-2.5 (-30.3 to 42.1)
Cataract	2.1 (1.5 to 2.8)	5.2 (3.4 to 7.2)	152.0 (53.4 to 240.5)	-23.7 (-39.8 to -7.7)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	155.7 (67.9 to 234.3)	-21.5 (-38.3 to -8.1)
Macular degeneration	0.4 (0.2 to 0.6)	1.7 (1.1 to 2.9)	346.5 (177.1 to 567.4)	1.4 (-38.9 to 57.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	343.9 (180.1 to 547.5)	1.0 (-36.0 to 51.4)
Uncorrected refractive error	31.8 (25.0 to 37.6)	134.5 (104.8 to 170.8)	321.2 (209.1 to 479.2)	-8.8 (-26.8 to 10.9)	0.6 (0.4 to 1.0)	2.5 (1.5 to 4.0)	291.2 (232.9 to 372.1)	-13.9 (-23.3 to -3.3)
Age-related and other hearing loss	37.2 (33.4 to 41.3)	166.2 (148.3 to 187.7)	347.0 (317.2 to 378.6)	-9.8 (-13.2 to -6.3)	0.9 (0.6 to 1.3)	3.8 (2.4 to 5.7)	311.9 (274.0 to 354.0)	-11.6 (-16.7 to -6.0)
Other vision loss	2.7 (2.1 to 3.4)	10.6 (7.9 to 13.9)	289.5 (238.3 to 355.8)	-13.5 (-28.7 to 3.7)	0.1 (0.1 to 0.2)	0.6 (0.3 to 0.8)	278.0 (222.5 to 337.5)	-16.1 (-30.2 to -2.2)
Other sense organ diseases	9.6 (9.1 to 10.1)	36.9 (34.5 to 39.4)	285.6 (252.2 to 320.3)	-0.6 (-7.5 to 6.3)	0.3 (0.2 to 0.4)	1.0 (0.6 to 1.5)	284.0 (248.0 to 323.9)	-0.7 (-7.9 to 7.1)
Oral disorders	-	-	-	-	0.8 (0.5 to 1.3)	3.9 (2.3 to 6.4)	389.4 (350.6 to 434.3)	-4.6 (-12.3 to 2.7)
Deciduous caries	37.2 (35.4 to 39.2)	72.8 (69.2 to 76.7)	95.7 (82.3 to 110.7)	-0.5 (-7.1 to 7.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	95.3 (78.8 to 115.5)	-0.7 (-9.0 to 9.5)
Permanent caries	15.7 (13.6 to 183.0)	798.8 (667.2 to 929.6)	414.2 (2					

Appendix Table G.4 - Qatar prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	7.7 (6.6 to 8.7)	32.3 (28.7 to 36.7)	315.2 (249.5 to 402.7)	-9.8 (-23.5 to 4.3)	0.2 (0.1 to 0.3)	0.9 (0.6 to 1.3)	313.3 (250.4 to 412.8)	-9.7 (-23.6 to -4.2)
Other oral disorders	7.9 (7.4 to 8.5)	40.4 (37.3 to 43.5)	408.7 (360.4 to 460.1)	-1.5 (-8.4 to 6.2)	0.2 (0.1 to 0.3)	1.2 (0.7 to 1.8)	409.4 (354.7 to 461.5)	-1.4 (-8.7 to 7.1)
Injuries	-	-	-	-	1.9 (1.4 to 2.4)	7.1 (5.1 to 9.5)	274.0 (231.1 to 323.5)	-25.5 (-33.4 to -16.7)
Transport injuries	-	-	-	-	0.8 (0.6 to 1.0)	3.0 (2.1 to 4.0)	273.0 (216.4 to 338.6)	-22.5 (-32.8 to -11.1)
Road injuries	-	-	-	-	0.7 (0.5 to 0.9)	2.5 (1.8 to 3.4)	267.6 (209.4 to 336.7)	-22.2 (-33.0 to -9.6)
Pedestrian road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.5 (0.3 to 0.7)	215.3 (157.4 to 285.4)	-29.8 (-40.5 to -17.6)
Cyclist road injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.4)	358.2 (298.7 to 426.7)	-4.5 (-15.7 to 7.3)
Motorcyclist road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	224.8 (170.0 to 293.5)	-34.7 (-44.2 to -23.3)
Motor vehicle road injuries	-	-	-	-	0.4 (0.3 to 0.5)	1.5 (1.0 to 2.0)	286.3 (221.2 to 370.4)	-18.9 (-31.4 to -3.9)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.4 (70.7 to 142.4)	-56.5 (-62.3 to -49.8)
Other transport injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.6)	305.4 (253.1 to 372.7)	-25.0 (-33.8 to -13.5)
Unintentional injuries	-	-	-	-	1.1 (0.8 to 1.4)	4.0 (2.9 to 5.3)	276.0 (241.6 to 314.8)	-27.4 (-34.0 to -20.0)
Falls	-	-	-	-	0.4 (0.3 to 0.5)	1.6 (1.1 to 2.1)	269.6 (224.6 to 317.9)	-27.5 (-36.0 to -17.6)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	132.7 (96.7 to 179.4)	-54.2 (-60.6 to -46.0)
Fire, heat, and hot substances	-	-	-	-	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	134.3 (96.5 to 177.0)	-51.6 (-58.5 to -43.9)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	100.1 (57.4 to 156.5)	-59.6 (-67.3 to -50.4)
Exposure to mechanical forces	-	-	-	-	0.3 (0.2 to 0.3)	1.3 (0.9 to 1.7)	391.9 (356.1 to 436.8)	-8.3 (-15.2 to -0.2)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	266.5 (217.0 to 322.2)	-34.5 (-42.7 to -25.4)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	487.4 (401.9 to 582.4)	11.7 (-2.3 to 25.8)
Other exposure to mechanical forces	-	-	-	-	0.2 (0.2 to 0.3)	1.2 (0.9 to 1.6)	398.7 (356.2 to 444.1)	-7.0 (-14.0 to 1.3)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	428.4 (384.1 to 484.3)	12.5 (5.2 to 20.6)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	238.2 (198.2 to 283.7)	-33.3 (-39.9 to -25.8)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	254.6 (198.6 to 323.6)	-30.1 (-39.6 to -19.8)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	223.4 (184.4 to 269.3)	-35.5 (-42.2 to -27.7)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	278.8 (237.3 to 323.1)	-23.5 (-31.0 to -16.0)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	122.6 (75.7 to 181.7)	-44.1 (-54.2 to -32.0)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	362.7 (298.6 to 439.9)	-9.0 (-19.3 to 2.5)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	297.4 (247.8 to 349.8)	-21.4 (-30.0 to -12.7)
Other unintentional injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.6 (0.4 to 0.8)	278.8 (237.3 to 324.4)	-28.9 (-34.5 to -21.5)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	227.4 (185.9 to 283.5)	-30.5 (-38.8 to -19.8)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	247.8 (199.8 to 313.7)	-35.5 (-43.5 to -24.5)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	214.0 (167.9 to 268.1)	-26.0 (-36.0 to -14.4)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	256.1 (210.2 to 306.2)	-17.3 (-27.0 to -7.0)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	306.6 (243.7 to 373.4)	-13.6 (-25.9 to -0.2)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	166.7 (120.5 to 219.1)	-33.3 (-43.5 to -21.5)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Romania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	2,620.0 (1,958.5 to 3,376.2)	2,726.8 (2,029.8 to 3,499.8)	4.0 (1.4 to 7.0)	-2.0 (-4.5 to 0.8)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	211.1 (148.7 to 286.7)	172.9 (122.1 to 236.0)	-18.8 (-25.9 to -6.3)	-1.8 (-9.9 to 13.3)
HIV/AIDS and tuberculosis	-	-	-	-	4.5 (3.0 to 6.0)	6.0 (4.2 to 8.1)	34.7 (23.0 to 48.1)	27.5 (16.6 to 40.4)
Tuberculosis	14.6 (14.1 to 15.0)	18.5 (18.0 to 19.0)	26.9 (23.2 to 30.4)	19.3 (16.0 to 22.5)	4.4 (3.0 to 5.9)	5.6 (3.8 to 7.5)	26.6 (15.8 to 38.9)	19.9 (9.6 to 32.5)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.2)	0.5 (0.3 to 0.8)	598.4 (218.2 to 2,664.1)	496.7 (185.6 to 2,415.0)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	226.6 (50.3 to 1,349.5)	192.4 (33.5 to 1,193.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	226.6 (49.7 to 1,353.4)	192.4 (33.1 to 1,194.7)
HIV/AIDS resulting in other diseases	0.7 (0.2 to 1.4)	6.2 (4.0 to 9.1)	739.8 (445.3 to 3,263.2)	651.3 (383.4 to 2,893.7)	0.1 (0.0 to 0.2)	0.5 (0.3 to 0.8)	514.4 (220.4 to 2,778.9)	453.9 (186.6 to 2,525.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	21.4 (15.1 to 29.3)	15.5 (10.8 to 21.5)	-27.4 (-32.5 to -22.0)	-16.2 (-22.6 to -9.5)
Diarrheal diseases	60.3 (55.3 to 66.6)	46.7 (43.6 to 50.2)	-22.4 (-31.1 to -12.9)	-10.0 (-20.8 to 2.9)	6.6 (6.6 to 13.5)	5.1 (5.1 to 10.2)	-32.4 (-32.4 to -13.0)	-10.1 (-20.8 to 3.7)
Intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-63.2 (-82.1 to -39.2)	-57.7 (-79.0 to -32.0)
Typhoid fever	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-36.0 (-59.5 to -12.3)	-27.3 (-53.1 to -3.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.0 (-59.5 to -11.9)	-27.3 (-53.1 to -3.0)
Paratyphoid fever	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-36.3 (-58.8 to -11.6)	-25.9 (-50.4 to -0.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.3 (-58.8 to -11.3)	-25.9 (-50.4 to 0.2)
Other intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-80.2 (-93.2 to -51.0)	-77.4 (-92.2 to -46.0)
Lower respiratory infections	4.9 (3.9 to 6.3)	2.6 (2.2 to 3.2)	-47.3 (-60.4 to -28.7)	-51.6 (-66.1 to -34.5)	0.5 (0.3 to 0.8)	0.3 (0.2 to 0.4)	-48.4 (-63.5 to -27.5)	-51.6 (-68.0 to -32.3)
Upper respiratory infections	227.5 (219.5 to 235.8)	202.2 (194.6 to 210.1)	-11.0 (-16.1 to -6.4)	-0.7 (-6.3 to 4.7)	2.7 (1.5 to 4.4)	2.4 (1.3 to 3.9)	-11.2 (-17.4 to -5.1)	-0.4 (-7.1 to 6.6)
Otitis media	246.9 (229.7 to 264.2)	202.0 (188.0 to 214.4)	-18.0 (-24.5 to -11.4)	-5.4 (-12.1 to 2.2)	5.0 (3.0 to 7.9)	4.0 (2.4 to 6.3)	-20.5 (-27.0 to -13.4)	-7.2 (-14.9 to 1.2)
Meningitis	-	-	-	-	2.4 (1.6 to 3.5)	0.6 (0.4 to 0.8)	-76.1 (-82.2 to -71.2)	-74.2 (-81.0 to -68.7)
Pneumococcal meningitis	8.7 (5.3 to 14.0)	2.2 (1.3 to 3.6)	-74.6 (-79.9 to -68.3)	-75.0 (-80.2 to -68.8)	0.8 (0.5 to 1.2)	0.2 (0.1 to 0.3)	-74.1 (-83.3 to -64.4)	-73.2 (-82.7 to -62.2)
H influenzae type B meningitis	5.3 (1.6 to 11.5)	1.0 (0.3 to 2.2)	-81.4 (-86.4 to -70.0)	-80.1 (-85.1 to -65.9)	0.6 (0.3 to 1.1)	0.1 (0.1 to 0.2)	-80.3 (-87.3 to -62.8)	-77.7 (-85.9 to -57.4)
Meningococcal meningitis	3.1 (1.1 to 7.7)	0.7 (0.2 to 1.7)	-78.1 (-84.4 to -67.3)	-77.1 (-83.9 to -64.2)	0.4 (0.2 to 0.7)	0.2 (0.1 to 0.2)	-76.0 (-85.7 to -63.1)	-74.2 (-84.6 to -59.6)
Other meningitis	4.5 (2.0 to 9.3)	1.1 (0.5 to 2.4)	-75.9 (-81.9 to -67.7)	-75.0 (-81.1 to -65.7)	0.6 (0.4 to 0.9)	0.0 (0.1 to 0.2)	-75.5 (-84.3 to -62.8)	-73.9 (-83.3 to -59.5)
Encephalitis	4.5 (1.9 to 11.1)	3.6 (1.6 to 8.8)	-20.5 (-34.0 to -4.9)	-20.8 (-34.6 to -2.2)	0.5 (0.4 to 0.8)	0.5 (0.3 to 0.7)	-18.4 (-31.1 to 5.0)	-16.5 (-32.0 to 9.3)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-94.5 to 339.6)	0.0 (0.0 to 0.0)	-	-
Whooping cough	1.5 (1.1 to 1.9)	1.9 (1.5 to 2.4)	30.2 (24.2 to 36.5)	96.9 (87.9 to 106.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	29.7 (6.4 to 63.2)	96.2 (60.6 to 145.9)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-79.8 (-88.8 to -63.2)	-78.7 (-88.4 to -61.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-72.7 (-87.6 to -52.1)	-71.0 (-86.8 to -46.7)
Measles	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-75.8 (-77.3 to -74.2)	-75.8 (-64.9 to -60.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-75.8 (-77.3 to -74.2)	-62.6 (-65.0 to -60.2)
Varicella and herpes zoster	12.8 (11.9 to 13.7)	10.7 (9.6 to 11.8)	-15.8 (-26.5 to -5.4)	-2.0 (-10.5 to 7.6)	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.6)	0.4 (-22.9 to 29.9)	-2.0 (-22.5 to 23.2)
Neglected tropical diseases and malaria	-	-	-	-	3.8 (1.3 to 7.4)	0.7 (0.4 to 1.2)	-82.5 (-90.3 to -26.5)	-83.1 (-90.8 to -32.9)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.2 (-80.2 to 75.7)	-32.4 (-77.3 to 100.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.6 (-80.1 to 77.5)	-31.6 (-77.1 to 104.4)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	12.5 (3.4 to 23.9)	1.5 (0.7 to 3.7)	-89.4 (-94.7 to -26.3)	-90.3 (-95.1 to -35.9)	3.3 (0.9 to 6.9)	0.4 (0.2 to 0.9)	-88.7 (-94.9 to -19.7)	-89.6 (-95.3 to -30.9)
Cystic echinococcosis	5.1 (4.8 to 5.8)	3.1 (2.9 to 3.4)	-38.7 (-46.0 to -30.2)	-39.0 (-46.5 to -30.4)	0.5 (0.3 to 0.7)	0.3 (0.2 to 0.4)	-38.9 (-50.3 to -23.9)	-38.7 (-50.7 to -22.7)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.9 (-61.3 to -13.0)	-47.4 (-59.2 to -9.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.9 (-61.4 to -13.0)	-47.4 (-59.2 to -9.6)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	430.4 (-54.6 to 757.6)	470.5 (-53.6 to 816.7)
Maternal disorders	-	-	-	-	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-38.3 (-55.7 to -11.9)	-31.6 (-50.0 to -3.8)
Maternal hemorrhage	0.8 (0.5 to 1.1)	1.2 (0.8 to 1.5)	55.1 (-21.0 to 184.3)	50.3 (-16.8 to 192.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-43.0 (-74.8 to 59.4)	-34.1 (-69.7 to 71.0)
Maternal sepsis and other maternal infections	5.3 (3.2 to 9.3)	2.1 (1.0 to 3.6)	-59.7 (-75.5 to -41.2)	-61.7 (-75.5 to -44.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-62.2 (-81.2 to -43.9)	-64.3 (-80.5 to -41.6)
Maternal hypertensive disorders	2.6 (1.2 to 4.4)	1.9 (1.0 to 3.2)	-25.1 (-43.0 to 17.3)	-17.1 (-34.0 to 20.7)	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.2)	-25.4 (-49.4 to 30.3)	-17.6 (-41.9 to 34.1)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.5 (-62.9 to 259.9)	17.8 (-62.2 to 271.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.5 (-63.2 to 263.4)	17.8 (-62.6 to 271.7)
Complications of abortion	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	9.3 (-45.2 to 116.2)	9.3 (-40.5 to 114.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.6 (-45.3 to 116.3)	9.3 (-40.6 to 115.4)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-	-
Neonatal disorders	-	-	-	-	45.0 (27.2 to 65.1)	52.9 (35.2 to 78.8)	14.8 (-17.0 to 91.8)	29.5 (-6.6 to 115.9)
Preterm birth complications	126.4 (74.1 to 207.2)	157.5 (95.9 to 246.1)	25.9 (-7.4 to 71.3)	37.8 (1.4 to 89.4)	15.6 (9.1 to 24.6)	20.7 (13.3 to 31.8)	33.9 (-24.2 to 132.3)	50.0 (-15.5 to 161.6)
Neonatal encephalopathy due to birth asphyxia and trauma	30.3 (14.8 to 65.3)	17.7 (8.8 to 37.0)	-40.7 (-66.9 to 2.8)	-32.5 (-62.4 to 18.1)	6.4 (3.8 to 10.5)	4.6 (2.4 to 7.8)	-28.0 (-61.5 to 32.2)	-17.1 (-55.5 to 53.5)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.9 (-32.4 to -17.1)	5.8 (-2.2 to 19.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.2 (-54.7 to 16.8)	8.2 (-34.8 to 68.9)
Hemolytic disease and other neonatal jaundice	16.6 (8.7 to 32.8)	14.7 (7.9 to 27.2)	-10.8 (-67.9 to 160.6)	0.3 (-64.0 to 194.1)	6.2 (3.1 to 12.5)	5.5 (2.8 to 10.9)	-9.6 (-67.4 to 166.4)	1.6 (-63.7 to 204.1)
Other neonatal disorders	-	-	-	-	16.8 (7.9 to 28.5)	22.1 (13.3 to 41.3)	23.7 (-21.0 to 189.6)	39.3 (-10.9 to 227.8)
Nutritional deficiencies	-	-	-	-	126.1 (83.7 to 182.7)	89.7 (59.4 to 132.5)	-28.7 (-31.8 to -26.4)	-8.4 (-12.3 to -5.3)
Protein-energy malnutrition	23.9 (17.1 to 32.1)	13.1 (9.2 to 17.9)	-45.1 (-65.4 to -14.1)	-16.3 (-47.6 to 31.0)	3.0 (1.8 to 4.8)	1.7 (0.9 to 2.7)	-45.0 (-66.3 to -14.4)	-16.3 (-48.6 to 30.3)
Iodine deficiency	76.2 (62.0 to 92.3)	43.4 (29.4 to 57.6)	-43.0 (-63.4 to -16.8)	-40.9 (-60.8 to -15.1)	1.4 (0.8 to 2.2)	0.8 (0.4 to 1.4)	-42.9 (-63.0 to -16.0)	-40.7 (-61.3 to -13.6)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron-deficiency anemia	4,219.6 (4,182.4 to 4,257.0)	3,438.4 (3,402.8 to 3,473.9)	-18.5 (-19.6 to -17.3)	-5.3 (-6.6 to -4.0)	117.7 (77.9 to 171.5)	86.4 (57.1 to 128.2)	-26.6 (-28.5 to -24.7)	-5.6 (-7.7 to -3.7)

Appendix Table G.4 - Romania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	4.0 (2.0 to 7.1)	0.9 (0.4 to 2.2)	-78.0 (-88.8 to -54.1)	-46.3 (-83.0 to -29.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	10.1 (6.1 to 15.9)	7.7 (4.6 to 13.0)	-23.3 (-33.2 to -12.7)	-6.3 (-20.2 to 8.5)
Sexually transmitted diseases excluding HIV	-	-	-	-	3.9 (2.0 to 7.4)	3.7 (1.9 to 7.1)	-6.7 (-17.9 to 4.0)	-6.3 (-17.8 to 4.9)
Syphilis	0.6 (0.5 to 0.7)	0.6 (0.6 to 0.7)	6.3 (9.7 to 27.4)	-11.9 (-25.6 to 6.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	5.5 (-24.6 to 43.9)	-11.9 (-35.5 to 19.4)
Chlamydial infection	543.7 (474.6 to 610.1)	497.8 (437.2 to 549.3)	-8.3 (-21.9 to 7.3)	2.3 (-16.7 to 14.7)	1.5 (0.8 to 2.8)	1.5 (0.8 to 2.6)	-7.6 (-25.4 to 8.6)	-2.1 (-21.6 to 15.8)
Gonococcal infection	129.9 (106.1 to 155.7)	102.7 (84.4 to 122.9)	-21.2 (-40.9 to 5.9)	-1.9 (-34.8 to 20.7)	0.5 (0.3 to 0.9)	0.4 (0.2 to 0.7)	-24.9 (-49.2 to 4.9)	-16.8 (-43.4 to 16.4)
Trichomoniasis	266.0 (191.2 to 355.0)	279.4 (232.4 to 336.7)	6.3 (-25.3 to 50.0)	3.1 (-25.7 to 44.3)	0.2 (0.2 to 1.0)	0.5 (0.2 to 1.0)	5.4 (-30.6 to 55.3)	1.8 (-30.5 to 47.9)
Genital herpes	4,156.9 (3,815.1 to 4,502.2)	4,236.9 (3,826.2 to 4,670.8)	1.9 (-9.7 to 14.4)	-7.4 (-17.8 to 4.0)	1.1 (0.3 to 2.6)	1.1 (0.3 to 2.6)	0.5 (-11.4 to 13.5)	-7.3 (-18.3 to 5.3)
Other sexually transmitted diseases	5.6 (4.0 to 7.4)	4.1 (2.8 to 5.5)	-25.6 (-43.7 to -7.8)	-30.9 (-47.8 to -13.8)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-13.6 (-41.6 to 13.7)	-16.0 (-43.9 to 32.2)
Hepatitis	-	-	-	-	1.1 (0.7 to 1.6)	0.8 (0.5 to 1.2)	-27.7 (-33.2 to -10.5)	-15.3 (-26.5 to -1.7)
Hepatitis A	24.0 (23.5 to 24.6)	18.4 (18.1 to 18.7)	-23.4 (-24.1 to -22.7)	-4.4 (-4.5 to -4.2)	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.8)	-15.8 (-24.7 to -5.1)	-1.4 (-12.1 to 11.1)
Hepatitis B	629.7 (486.4 to 764.6)	385.4 (316.2 to 459.6)	-38.9 (-52.6 to -15.2)	-38.1 (-52.4 to -14.9)	0.4 (0.2 to 0.6)	0.2 (0.1 to 0.4)	-35.9 (-55.8 to -2.3)	-39.5 (-58.6 to -8.5)
Hepatitis C	592.6 (551.6 to 637.4)	461.3 (429.1 to 492.2)	-22.1 (-29.7 to -13.3)	-27.1 (-34.0 to -18.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-17.8 (-43.3 to 18.0)	-22.5 (-44.2 to 7.1)
Hepatitis E	-	-	-	-	-	-	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	168.9 (147.4 to 192.3)	123.4 (114.4 to 133.8)	-26.8 (-35.5 to -14.2)	-4.5 (-15.9 to 13.2)	5.1 (3.3 to 7.6)	3.2 (2.0 to 4.8)	-36.0 (-51.4 to -14.6)	-4.7 (-28.7 to 29.7)
Non-communicable diseases	-	-	-	-	2,138.8 (1,598.4 to 2,755.4)	2,296.9 (1,711.6 to 2,951.0)	7.4 (4.5 to 10.8)	-0.1 (-2.8 to 3.1)
Neoplasms	-	-	-	-	211.6 (15.9 to 27.9)	30.5 (22.5 to 40.6)	14.4 (23.0 to 57.1)	22.1 (4.1 to 32.0)
Esophageal cancer	0.7 (0.6 to 1.0)	1.3 (0.8 to 1.7)	96.3 (1.9 to 169.0)	71.2 (-11.2 to 135.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	85.7 (-4.6 to 147.8)	61.5 (-17.7 to 114.8)
Stomach cancer	9.6 (8.3 to 11.2)	7.7 (6.5 to 9.1)	-20.2 (-34.3 to -6.6)	-34.3 (-46.0 to -18.8)	1.2 (0.8 to 1.6)	0.9 (0.7 to 1.2)	-22.1 (-36.2 to -1.4)	-36.0 (-47.5 to -19.1)
Liver cancer	-	-	-	-	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	166.6 (-16.2 to 355.0)	121.4 (-29.7 to 278.1)
Liver cancer due to hepatitis B	0.3 (0.2 to 0.6)	0.7 (0.3 to 1.1)	112.2 (-37.3 to 419.3)	82.8 (-45.6 to 342.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	109.0 (-34.2 to 359.2)	79.1 (-43.5 to 286.4)
Liver cancer due to hepatitis C	0.2 (0.1 to 0.3)	0.9 (0.4 to 1.5)	479.4 (78.6 to 1,328.9)	375.1 (47.0 to 1,088.0)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	450.8 (77.4 to 1,148.7)	350.6 (45.9 to 934.4)
Liver cancer due to alcohol use	0.2 (0.2 to 0.6)	0.8 (0.3 to 1.3)	125.1 (-35.6 to 425.2)	84.3 (-47.7 to 322.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	126.5 (-35.4 to 370.0)	86.4 (-47.9 to 280.0)
Liver cancer due to other causes	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.3)	-37.4 (-62.8 to 192.8)	-15.0 (-68.6 to 143.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-63.4 (-164.0 to 36.2)	11.5 (-69.4 to 109.8)
Larynx cancer	3.9 (2.7 to 5.1)	3.8 (2.5 to 5.0)	-2.6 (-32.2 to 45.5)	-2.9 (-39.2 to 29.1)	0.5 (0.3 to 0.8)	0.5 (0.3 to 0.7)	6.5 (-36.6 to 30.2)	-16.9 (-43.1 to 15.0)
Tracheal, bronchus and lung cancer	12.1 (10.7 to 13.6)	14.6 (12.6 to 17.0)	20.4 (0.5 to 45.6)	5.5 (-12.0 to 27.5)	1.9 (1.4 to 2.5)	2.3 (1.6 to 3.0)	19.1 (-1.7 to 44.7)	4.2 (-13.6 to 26.2)
Breast cancer	26.6 (21.8 to 33.2)	80.4 (69.9 to 89.9)	206.1 (136.3 to 271.0)	150.6 (93.7 to 201.4)	2.7 (1.9 to 3.8)	4.8 (3.2 to 6.5)	76.8 (36.4 to 119.6)	45.4 (12.2 to 80.2)
Cervical cancer	35.9 (30.6 to 42.2)	23.3 (15.1 to 30.7)	-35.0 (-57.6 to -11.8)	-42.6 (-62.2 to -21.3)	2.7 (1.9 to 3.8)	1.7 (1.0 to 2.6)	-42.8 (-56.9 to -9.9)	-28.8 (-61.5 to -19.8)
Uterine cancer	2.2 (1.6 to 3.7)	4.4 (2.7 to 6.0)	100.3 (-10.8 to 208.4)	82.2 (-20.7 to 173.7)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	184.8 (-13.9 to 195.8)	75.6 (-26.3 to 158.5)
Prostate cancer	16.2 (13.1 to 20.9)	35.5 (27.7 to 44.6)	119.2 (72.8 to 186.5)	70.3 (34.8 to 120.9)	1.6 (1.1 to 2.3)	3.6 (2.4 to 5.0)	119.7 (65.0 to 198.9)	67.5 (27.0 to 127.5)
Colon and rectum cancer	21.4 (19.8 to 23.1)	43.8 (40.1 to 47.9)	105.1 (82.9 to 129.3)	69.1 (50.7 to 89.5)	1.9 (1.4 to 2.5)	3.8 (2.7 to 4.9)	96.5 (70.6 to 123.4)	60.7 (38.8 to 82.4)
Lip and oral cavity cancer	10.7 (8.7 to 13.2)	20.5 (10.8 to 26.2)	95.2 (-14.1 to 170.5)	73.6 (-24.0 to 136.7)	0.9 (0.6 to 1.3)	1.7 (0.9 to 2.4)	91.5 (-15.5 to 160.7)	68.9 (-26.1 to 126.6)
Nasopharynx cancer	1.4 (1.0 to 2.0)	1.1 (0.7 to 1.6)	-15.2 (-50.7 to 30.4)	-24.2 (-55.4 to 15.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-15.0 (-48.7 to 23.5)	-24.5 (-54.3 to 9.4)
Other pharynx cancer	1.8 (1.2 to 2.9)	3.5 (1.6 to 5.6)	98.5 (-31.5 to 265.4)	79.5 (-38.0 to 226.9)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.5)	88.2 (-32.4 to 216.6)	62.2 (-39.7 to 183.8)
Gallbladder and biliary tract cancer	0.9 (0.6 to 1.1)	0.6 (0.5 to 0.8)	-35.2 (-51.9 to 5.0)	-47.9 (-61.3 to -16.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-35.6 (-52.0 to 5.0)	-48.1 (-61.4 to -14.0)
Pancreatic cancer	1.6 (1.3 to 1.8)	2.6 (2.2 to 3.1)	66.1 (33.8 to 105.1)	36.4 (10.0 to 68.0)	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	58.5 (28.6 to 98.5)	30.5 (6.4 to 63.0)
Malignant skin melanoma	6.5 (4.4 to 8.9)	9.4 (6.2 to 13.2)	44.4 (14.9 to 76.1)	24.4 (-0.3 to 51.9)	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.9)	39.5 (9.1 to 74.9)	18.9 (-6.1 to 49.5)
Non-melanoma skin cancer	17.1 (14.1 to 20.8)	30.6 (24.6 to 37.6)	79.2 (36.2 to 132.7)	79.2 (40.7 to 117.6)	0.6 (0.4 to 0.8)	1.2 (0.7 to 1.7)	105.5 (44.4 to 186.0)	49.7 (1.7 to 107.8)
Ovarian cancer	5.7 (4.9 to 6.7)	6.0 (4.8 to 7.2)	5.3 (-17.4 to 30.0)	-7.5 (-27.3 to 13.3)	0.7 (0.5 to 1.0)	0.8 (0.5 to 1.1)	4.5 (-21.2 to 39.0)	-8.6 (-30.5 to 21.7)
Testicular cancer	3.5 (2.3 to 5.1)	3.3 (1.6 to 5.3)	-4.4 (-57.5 to 70.7)	-11.2 (-60.4 to 56.7)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	-6.5 (-58.4 to 67.4)	-13.1 (-61.0 to 53.8)
Kidney cancer	3.6 (3.0 to 4.2)	6.9 (5.7 to 8.2)	90.7 (54.7 to 134.5)	67.0 (35.4 to 105.5)	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	82.0 (45.9 to 130.1)	58.8 (27.0 to 99.8)
Bladder cancer	3.0 (7.9 to 11.1)	2.2 (8.8 to 13.3)	-28.0 (-42.3 to 42.3)	-30.8 (-23.5 to 18.0)	0.3 (0.5 to 1.1)	0.3 (0.6 to 1.2)	-12.7 (-10.8 to 40.6)	-7.5 (-27.1 to 15.5)
Brain and nervous system cancer	4.2 (3.6 to 5.2)	5.9 (4.2 to 7.2)	44.3 (-1.7 to 79.9)	37.7 (-1.3 to 73.2)	0.5 (0.3 to 0.6)	0.6 (0.4 to 0.9)	44.0 (-3.3 to 82.0)	35.4 (-5.7 to 69.9)
Thyroid cancer	2.8 (2.2 to 4.2)	5.5 (2.9 to 7.8)	122.8 (-13.2 to 227.8)	98.6 (-22.4 to 193.7)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	120.6 (-15.0 to 230.1)	94.3 (-25.0 to 190.9)
Mesothelioma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	-17.3 (-34.5 to 21.0)	-28.1 (-43.2 to 5.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.2 (-34.7 to 23.4)	-9.0 (-43.3 to 8.5)
Hodgkin lymphoma	3.0 (1.9 to 3.9)	2.2 (1.5 to 3.4)	-28.0 (-50.9 to 31.5)	-30.8 (-53.4 to 22.3)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-12.7 (-52.0 to 22.8)	-35.1 (-54.7 to 15.0)
Non-Hodgkin lymphoma	5.7 (4.0 to 8.0)	9.6 (4.2 to 9.6)	28.5 (-24.6 to 83.7)	16.6 (-30.1 to 64.3)	0.6 (0.3 to 0.7)	0.6 (0.3 to 0.8)	27.3 (-27.1 to 81.1)	14.9 (-32.6 to 62.0)
Multiple myeloma	0.9 (0.6 to 1.3)	1.3 (0.8 to 1.9)	52.3 (-5.6 to 142.5)	33.8 (-17.7 to 112.7)	0.3 (0.1 to 0.3)	0.3 (0.1 to 0.4)	42.4 (-17.1 to 142.3)	24.9 (-25.9 to 110.2)
Leukemia	7.9 (6.9 to 9.1)	8.7 (6.9 to 10.5)	11.2 (-15.7 to 40.7)	2.9 (-23.4 to 34.7)	0.9 (0.6 to 1.2)	1.1 (0.8 to 1.5)	21.7 (-7.9 to 52.1)	8.5 (-18.5 to 37.2)
Other neoplasms	17.2 (14.5 to 21.2)	33.7 (23.2 to 41.4)	101.1 (32.5 to 159.5)	81.6 (22.9 to 130.6)	1.2 (0.8 to 1.7)	2.3 (1.4 to 3.2)	91.5 (23.9 to 147.5)	71.9 (13.3 to 118.5)
Cardiovascular diseases	-	-	-	-	58.4 (31.1 to 59.9)	58.4 (41.5 to 78.5)	0.0 (6.9 to 64.3)	0.0 (-15.4 to 29.7)
Rheumatic heart disease	3.4 (2.7 to 4.2)	4.0 (3.2 to 4.7)	14.6 (9.1 to 52.2)	-1.0 (-20.5 to 30.0)	0.4 (0.2 to 0.6)	0.4 (0.3 to 0.6)	13.0 (-15.7 to 56.5)	-2.1 (-26.9 to 35.5)
Ischemic heart disease	323.3 (281.0 to 378.3)	390.6 (346.6 to 446.5)	21.2 (-0.9 to 47.0)	-3.7 (-20.3 to 17.2)	17.0 (11.4 to 24.0)	22.5 (14.4 to 28.6)	20.8 (-3.4 to 52.3)	-5.1 (-24.4 to 18.0)
Cerebrovascular disease	-	-	-	-	6.1 (4.0 to 8.1)	7.1 (4.8 to 9.8)	16.2 (4.8 to 28.2)	2.1 (-21.3 to 28.2)
Ischemic stroke	32.8 (27.8 to 38.8)	39.5 (33.1 to 47.8)	21.8 (-8.4 to 51.5)	2.4 (-22.3 to 25.8)	4.9 (3.3 to 6.8)	5.9 (3.9 to 8.2)	20.3 (9.1 to 52.5)	1.7 (-22.0 to 28.2)
Hemorrhagic stroke	6.9 (5.5 to 8.7)	8.2 (6.7 to 10.1)	20.7 (-16.6 to 68.8)	5.7 (-26.0 to 46.9)	1.1 (0.7 to 1.5)	1.3 (0.8 to 1.8)	19.7 (-19.6 to 67.0)	5.1 (-27.9 to 46.3)
Hypertensive heart disease	46.1 (40.9 to 51.3)	69.7 (62.9 to 76.8)	51.3 (29.6 to 78.3)	13.0 (-3.2 to 33.4)	5.0 (3.5 to 6.9)	7.5 (5.3 to 10.2)	50.5 (27.9 to 78.7)	12.9 (-4.0 to 34.3)
Cardiomyopathy and myocarditis	54.9 (48.6 to 62.2)	54.8 (49.5 to 60.0)	-0.1 (-14.1 to 17.3)	-22.9 (-33.6 to -9.7)	5.9 (4.1 to 8.0)	5.8 (4.0 to 7.9)	-0.9 (-15.7 to 17.5)	-23.0 (-34.5 to -9.2)
Atrial fibrillation and flutter	6.4 (5.2 to 8.1)	10.2 (5.4 to 17.1)	57.9 (-17.2 to 157.3)	18.5 (-37.4 to 99.0)	0.8 (0.3 to 0.7)	0.8 (0.4 to 1.5)	18.5 (-19.0 to 167.0)	20.2 (-38.5 to 104.2)
Peripheral vascular disease	682.7 (509.6 to 941.9)	967.6 (732.8 to 1,187.3)	44.7 (-2.8 to 106.1)	14.2 (-22.3 to 58.6)	1.3 (0.5 to 2.6)	1.0 (0.4 to 2.0)	-22.4 (-61.3 to 48.7)	-47.3 (-74.2 to -6.6)
Endocarditis	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	42.8 (-13.0 to 96.3)	28.4 (-22.4 to 75.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	45.0 (-8.8 to 100.7)	32.2 (-16.9 to 81.1)
Other cardiovascular and circulatory diseases	104.5 (51.5 to 215.5)	212.1 (109.6 to 314.1)	117.4					

Appendix Table G.4 - Romania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.3)	12.7 (6.3 to 18.9)	0.0 (-10.7 to -0.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	13.0 (6.4 to 19.5)	13.0 (-10.7 to 0.1)
Asbestosis	-	-	-	-	-	-	-	-
Coal workers pneumoconiosis	-	-	-	-	-	-	-	-
Other pneumoconiosis	0.5 (0.4 to 0.6)	0.3 (0.2 to 0.4)	-40.7 (-46.7 to -34.4)	-49.8 (-54.7 to -43.9)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-40.4 (-46.7 to -32.9)	-49.7 (-54.7 to -43.7)
Asthma	640.8 (524.8 to 768.2)	620.8 (533.0 to 716.1)	-3.1 (-20.5 to 18.8)	-4.8 (-30.8 to 41.9)	27.8 (17.8 to 41.9)	26.6 (17.1 to 39.0)	-4.5 (-22.1 to 17.5)	-15.6 (-32.1 to 3.6)
Interstitial lung disease and pulmonary sarcoidosis	3.1 (2.4 to 3.9)	3.2 (2.4 to 4.1)	5.0 (-25.8 to 46.8)	-5.0 (-31.8 to 31.2)	0.4 (0.2 to 0.7)	0.4 (0.3 to 0.7)	5.1 (-24.9 to 45.9)	-4.5 (-31.2 to 31.2)
Other chronic respiratory diseases	-	-	-	-	-	-	-	-
Cirrhosis	-	-	-	-	-	-	-	-
Cirrhosis due to hepatitis B	5.9 (4.5 to 7.2)	6.9 (4.9 to 9.0)	17.9 (-24.3 to 60.9)	7.8 (-31.1 to 48.2)	1.0 (0.6 to 1.5)	1.1 (0.7 to 1.7)	16.8 (-25.8 to 65.2)	7.0 (-32.5 to 51.4)
Cirrhosis due to hepatitis C	7.5 (5.2 to 9.9)	8.0 (5.7 to 9.9)	9.0 (-29.6 to 59.1)	-0.8 (-36.6 to 43.7)	1.2 (0.7 to 1.9)	1.3 (0.8 to 1.9)	1.3 (-32.3 to 63.9)	-1.4 (-39.5 to 49.8)
Cirrhosis due to alcohol use	7.0 (5.1 to 9.0)	4.7 (3.2 to 6.3)	-34.1 (-53.0 to -4.5)	-41.5 (-58.4 to -14.8)	1.1 (0.7 to 1.7)	0.8 (0.4 to 1.2)	-33.8 (-55.9 to -3.8)	-41.0 (-61.2 to 14.4)
Cirrhosis due to other causes	5.2 (4.1 to 6.5)	6.0 (4.8 to 7.7)	13.9 (-14.0 to 57.9)	18.5 (-8.8 to 59.7)	0.9 (0.6 to 1.3)	1.0 (0.6 to 1.5)	13.0 (-18.7 to 61.7)	17.5 (-13.8 to 64.4)
Digestive diseases	-	-	-	-	-	-	-	-
Peptic ulcer disease	176.3 (165.8 to 186.8)	87.0 (67.8 to 100.9)	-50.6 (-60.2 to -41.0)	-62.2 (-69.6 to -55.3)	27.2 (19.3 to 36.3)	28.2 (20.1 to 37.1)	3.6 (-3.1 to 11.6)	-9.3 (-15.9 to -1.9)
Gastritis and duodenitis	43.1 (37.4 to 48.4)	51.7 (44.7 to 58.0)	20.1 (1.7 to 41.9)	0.8 (-15.4 to 18.1)	2.1 (1.4 to 3.0)	2.3 (1.5 to 3.3)	8.3 (-14.2 to 31.1)	-7.8 (-27.7 to 13.3)
Appendicitis	1.2 (0.9 to 1.5)	0.5 (0.4 to 0.7)	-54.3 (-66.4 to -33.0)	-43.5 (-59.1 to -15.1)	0.4 (0.2 to 0.6)	0.2 (0.1 to 0.3)	-54.4 (-69.9 to -25.8)	-44.0 (-52.1 to -5.2)
Paralytic ileus and intestinal obstruction	0.3 (0.2 to 0.7)	0.3 (0.2 to 0.4)	-	-	-	-	-	-
Inguinal, femoral, and abdominal hernia	107.4 (91.4 to 123.1)	107.2 (90.8 to 124.2)	0.4 (-19.9 to 24.6)	-16.9 (-33.3 to 1.5)	1.1 (0.5 to 2.1)	1.1 (0.5 to 2.1)	0.0 (-20.1 to 23.8)	16.5 (-32.9 to 1.8)
Inflammatory bowel disease	35.3 (33.8 to 36.9)	52.6 (50.4 to 54.9)	49.2 (40.4 to 58.3)	35.6 (27.7 to 43.5)	7.4 (5.0 to 10.1)	11.0 (7.5 to 14.9)	48.7 (36.4 to 60.5)	35.8 (25.0 to 46.4)
Vascular intestinal disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-	-	-	-	-	-
Gallbladder and biliary diseases	65.8 (57.2 to 74.9)	51.8 (43.5 to 59.1)	-21.7 (-34.5 to -4.0)	-21.7 (-43.3 to 17.6)	6.9 (4.6 to 9.5)	5.4 (3.6 to 7.6)	-22.2 (-34.7 to 41.1)	-32.7 (-43.5 to 17.0)
Pancreatitis	8.4 (8.0 to 8.9)	10.7 (10.0 to 11.2)	26.3 (17.1 to 37.0)	26.3 (3.9 to 21.2)	2.5 (1.7 to 3.3)	3.1 (2.1 to 4.2)	25.8 (8.9 to 44.8)	12.1 (2.8 to 29.6)
Other digestive diseases	-	-	-	-	-	-	-	-
Neurological disorders	-	-	-	-	-	-	-	-
Alzheimer disease and other dementias	211.9 (187.9 to 238.2)	316.1 (277.8 to 356.6)	48.7 (27.0 to 76.6)	0.2 (-14.8 to 18.9)	30.6 (21.7 to 40.0)	46.1 (33.1 to 61.3)	50.3 (28.5 to 80.1)	-0.8 (-16.0 to 18.2)
Parkinson disease	16.2 (10.9 to 21.5)	20.7 (13.7 to 27.2)	28.5 (15.9 to 36.5)	-1.9 (-10.1 to 4.3)	2.9 (1.1 to 2.8)	2.4 (1.4 to 3.6)	23.3 (9.4 to 44.6)	1.9 (-15.0 to 11.0)
Epilepsy	103.1 (65.0 to 145.6)	91.6 (58.2 to 130.5)	-11.6 (-48.7 to 55.5)	-7.7 (-45.5 to 64.9)	30.1 (16.6 to 49.0)	27.5 (14.9 to 44.5)	-9.1 (-49.9 to 67.0)	-2.2 (-46.2 to 79.2)
Multiple sclerosis	5.7 (4.9 to 6.5)	12.2 (10.2 to 14.2)	116.1 (71.5 to 172.8)	99.1 (57.6 to 151.6)	1.9 (1.3 to 2.5)	4.0 (2.8 to 5.3)	112.7 (61.9 to 178.5)	95.5 (49.2 to 156.7)
Migraine	3,411.0 (3,166.3 to 3,717.4)	3,333.9 (3,053.5 to 3,607.3)	-2.3 (-12.2 to 9.3)	-0.7 (-11.0 to 11.3)	116.1 (70.3 to 172.5)	112.9 (68.6 to 163.6)	-2.8 (-12.8 to 9.3)	-0.5 (-10.7 to 12.5)
Tension-type headache	4,465.4 (4,070.3 to 4,844.7)	4,424.9 (4,082.0 to 4,806.6)	-1.1 (-12.3 to 12.0)	-1.5 (-11.3 to 14.6)	6.7 (3.3 to 11.9)	6.7 (3.3 to 11.5)	0.5 (-12.9 to 13.0)	0.3 (-11.7 to 14.9)
Medication overuse headache	235.2 (156.3 to 322.1)	368.3 (238.4 to 523.6)	54.4 (18.5 to 110.6)	48.2 (11.8 to 101.6)	36.7 (20.6 to 57.5)	57.5 (30.9 to 92.7)	54.8 (17.7 to 111.6)	49.1 (11.3 to 104.2)
Other neurological disorders	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-	-	-	-	-	-
Mental and substance use disorders	-	-	-	-	-	-	-	-
Schizophrenia	74.9 (68.4 to 81.0)	78.9 (72.6 to 84.9)	5.4 (1.0 to 10.4)	-1.3 (-5.5 to 3.4)	47.7 (35.2 to 57.9)	50.4 (37.1 to 61.0)	5.6 (-6.9 to 12.2)	-0.8 (-6.9 to 5.3)
Alcohol use disorders	293.0 (267.5 to 318.5)	210.5 (188.5 to 232.0)	-28.1 (-33.4 to -22.4)	-31.3 (-36.7 to -25.5)	29.1 (19.5 to 41.8)	20.9 (13.9 to 29.7)	-28.2 (-34.2 to -21.8)	-31.3 (-37.1 to -24.8)
Drug use disorders	-	-	-	-	-	-	-	-
Opioid use disorders	23.0 (11.3 to 39.1)	25.1 (11.5 to 42.6)	8.7 (-1.4 to 20.7)	2.0 (-6.8 to 13.1)	9.5 (4.3 to 17.0)	10.4 (4.6 to 18.8)	9.2 (-5.2 to 26.7)	2.5 (-10.7 to 18.7)
Cocaine use disorders	13.7 (10.3 to 16.8)	14.5 (11.9 to 17.0)	5.9 (-21.3 to 49.2)	8.6 (-20.8 to 53.3)	1.9 (1.1 to 2.8)	2.0 (1.2 to 3.0)	5.7 (-25.3 to 51.1)	8.1 (-24.7 to 57.3)
Amphetamine use disorders	43.1 (34.4 to 50.8)	31.7 (25.9 to 37.1)	-25.9 (-43.4 to -6.0)	25.9 (-40.8 to 0.9)	5.6 (3.4 to 8.3)	4.1 (2.4 to 6.2)	-26.4 (-45.6 to -3.1)	21.1 (-42.5 to 4.1)
Cannabis use disorders	27.1 (24.5 to 29.8)	22.7 (20.7 to 24.7)	-16.3 (-21.2 to -11.0)	-0.7 (-6.2 to 5.4)	0.8 (0.5 to 1.2)	0.7 (0.4 to 0.9)	-16.4 (-30.2 to -0.2)	-1.0 (-17.4 to 18.6)
Other drug use disorders	-	-	-	-	-	-	-	-
Depressive disorders	-	-	-	-	-	-	-	-
Major depressive disorder	751.4 (643.5 to 848.3)	764.5 (649.3 to 869.6)	1.8 (-4.1 to 7.2)	0.7 (-4.5 to 5.3)	477.7 (401.8 to 513.8)	450.4 (371.2 to 529.5)	2.3 (-4.8 to 7.1)	0.7 (-4.3 to 5.2)
Dysthymia	348.6 (286.8 to 417.8)	374.9 (309.1 to 447.5)	7.6 (5.8 to 9.7)	-0.1 (-0.1 to 0.0)	33.4 (21.7 to 49.9)	35.8 (23.5 to 53.1)	7.2 (4.1 to 10.8)	0.0 (-2.5 to 2.6)
Bipolar disorder	179.8 (151.6 to 209.9)	189.3 (161.5 to 217.6)	5.3 (0.4 to 12.3)	36.3 (-4.2 to 66.6)	0.6 (22.6 to 53.6)	0.6 (24.2 to 57.0)	0.8 (-0.7 to 12.5)	0.8 (-5.4 to 8.2)
Anxiety disorders	789.1 (684.0 to 895.8)	753.6 (650.9 to 858.2)	-4.4 (-7.2 to -1.7)	-0.1 (-0.2 to -0.1)	72.2 (49.3 to 102.2)	72.2 (47.1 to 96.6)	68.5 (-9.2 to 13.1)	-0.0 (-2.6 to 2.6)
Eating disorders	-	-	-	-	-	-	-	-
Anorexia nervosa	2.5 (2.0 to 3.0)	2.3 (1.8 to 2.8)	-6.6 (-14.7 to 2.9)	12.5 (3.1 to 23.3)	0.5 (0.3 to 0.8)	0.5 (0.3 to 0.7)	-6.6 (-30.3 to 22.0)	12.5 (-15.2 to 44.6)
Bulimia nervosa	23.9 (17.2 to 32.2)	20.4 (14.6 to 28.1)	-14.6 (-19.2 to -10.5)	-0.6 (-0.6 to -0.5)	5.1 (3.1 to 8.0)	4.3 (2.5 to 7.0)	-14.8 (-22.9 to -6.1)	-0.6 (-8.3 to 9.1)
Autistic spectrum disorders	-	-	-	-	-	-	-	-
Autism	69.9 (66.3 to 73.8)	63.7 (60.3 to 67.3)	-8.9 (-9.4 to -8.2)	0.2 (0.2 to 0.2)	0.2 (11.5 to 23.4)	0.2 (10.3 to 21.3)	0.2 (-13.4 to 4.9)	0.2 (-4.2 to 5.2)
Asperger syndrome	99.5 (93.2 to 105.7)	90.3 (84.3 to 96.6)	-9.1 (-9.9 to -8.4)	-0.2 (0.2 to 0.2)	0.2 (6.8 to 13.7)	0.2 (6.2 to 12.3)	-0.2 (-12.7 to 5.8)	0.2 (-3.1 to 4.6)
Attention-deficit/hyperactivity disorder	118.7 (109.3 to 128.1)	73.1 (67.2 to 78.9)	-38.3 (-38.9 to -38.0)	0.2 (0.1 to 0.2)	1.5 (0.9 to 2.2)	0.9 (0.5 to 1.4)	-38.5 (-43.0 to -33.5)	0.0 (-7.2 to 7.9)
Conduct disorder	177.7 (167.4 to 189.0)	102.8 (96.6 to 109.3)	-42.1 (-42.4 to -41.8)	0.1 (0.1 to 0.1)	21.5 (13.5 to 31.3)	12.4 (7.9 to 18.1)	-42.0 (-44.4 to -39.5)	0.2 (-3.8 to 4.6)
Idiopathic intellectual disability	349.6 (270.7 to 423.7)	266.0 (196.9 to 331.4)	-23.7 (-34.4 to -14.6)	-17.0 (-28.1 to -7.3)	17.0 (11.0 to 23.9)	12.5 (8.1 to 18.1)	-23.9 (-34.8 to -15.0)	-16.8 (-28.8 to -7.2)
Other mental and substance use disorders	419.9 (396.5 to 445.0)	439.5 (414.1 to 464.5)	4.7 (3.0 to 6.6)	0.0 (-0.1 to 0.2)	0.0 (21.1 to 42.0)	0.0 (22.0 to 43.7)	0.0 (0.3 to 0.5)	0.0 (-3.1 to 4.0)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	-	-	-	-
Diabetes mellitus	1,252.1 (1,034.2 to 1,496.6)	1,622.4 (1,309.8 to 1,928.1)	30.1 (2.0 to 60.4)	20.2 (-5.3 to 47.2)	94.6 (62.2 to 129.7)	123.5 (83.1 to 170.8)	30.7 (4.5 to 60.1)	18.5 (-4.5 to 44.3)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-	-	-
Chronic kidney disease	-	-	-	-	-	-	-	-
Chronic kidney disease due to diabetes mellitus	344.8 (235.1 to 502.7)	317.8 (233.5 to 458.8)	-9.3 (-29.7 to 39.3)	-20.2 (-38.7 to 19.3)	9.2 (5.7 to 13.3)	8.4 (5.8 to 11.5)	-9.6 (-30.2 to 41.3)	-18.8 (-37.1 to 22.5)
Chronic kidney disease due to hypertension	623.2 (428.2 to 912.7)	512.9 (348.6 to 753.5)	-17.6 (-36.4 to 7.6)	-17.2 (-36.2 to 4.9)	16.9 (11.9 to 22.9)	4.7 (3.1 to 6.4)	-74.5 (-80.1 to -61.8)	-74.5 (-81.5 to -65.2)
Chronic kidney disease due to glomerulonephritis	640.6 (463.0 to 879.4)	227.7 (189.4 to 290.6)	-64.4 (-71.4 to -55.1)	-65.2 (-72.1 to -57.0)	15.2 (10.4 to 20.4)	14.9 (10.4 to 20.1)	-9.9 (-23.7 to 23.5)	-4.2 (-24.6 to 18.3)
Chronic kidney disease due to other causes	1,042.6 (663.1 to 1,490.4)	1,825.9 (1,327.7 to 2,528.5)	77.2 (45.0 to 118.1)	77.2 (36.8 to 91.2)	25.7 (17.8 to 34.5)	25.7 (35.4 to 63.7)	86.7 (60.0 to 139.7)	86.7 (44.9 to 111.7)
Urinary diseases and male infertility	-	-	-	-	-	-	-	-
Interstitial nephritis and urinary tract infections	4.6 (4.0 to 5.2)	4.5 (4.1 to 5.0)	-1.0 (-15.5 to 16.1)	4.7 (-11.5 to 24.7)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-2.2 (-23.6 to 26.9)	4.8 (-19.3 to 36.7)

Appendix Table G.4 - Romania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	431.3 (408.3 to 454.7)	432.8 (409.2 to 456.2)	0.3 (-6.5 to 8.5)	0.0 (-7.1 to 8.2)	12.6 (7.9 to 18.7)	12.6 (7.9 to 19.0)	0.1 (-7.7 to 8.2)	0.1 (-7.4 to 8.4)
Injuries	-	-	-	-	270.1 (205.0 to 350.3)	257.0 (182.9 to 347.7)	-5.3 (-14.2 to 4.5)	-18.3 (-26.1 to -10.0)
Transport injuries	-	-	-	-	33.3 (25.2 to 43.3)	17.0 (12.0 to 23.2)	-49.1 (-54.8 to -42.4)	-54.7 (-59.7 to -48.6)
Road injuries	-	-	-	-	21.0 (15.8 to 27.1)	10.9 (7.7 to 14.8)	-48.3 (-54.5 to -41.0)	-54.1 (-59.6 to -47.7)
Pedestrian road injuries	-	-	-	-	5.6 (4.2 to 7.4)	2.8 (2.0 to 3.8)	-50.5 (-57.3 to -42.3)	-56.3 (-62.6 to -49.5)
Cyclist road injuries	-	-	-	-	3.5 (2.6 to 4.6)	1.8 (1.3 to 2.5)	-48.4 (-54.0 to -41.7)	-54.1 (-59.1 to -48.2)
Motorcyclist road injuries	-	-	-	-	1.5 (1.1 to 1.9)	0.7 (0.5 to 1.0)	-48.8 (-55.7 to -41.7)	-54.0 (-60.3 to -47.5)
Motor vehicle road injuries	-	-	-	-	10.0 (7.5 to 12.9)	5.4 (3.8 to 7.4)	-46.2 (-53.7 to -37.7)	-52.0 (-58.7 to -44.3)
Other road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.1)	-70.0 (-73.5 to -66.3)	-73.8 (-76.8 to -70.6)
Other transport injuries	-	-	-	-	12.4 (9.2 to 16.2)	6.2 (4.4 to 8.3)	-50.4 (-56.0 to -43.8)	-55.7 (-60.7 to -49.7)
Unintentional injuries	-	-	-	-	233.5 (177.4 to 302.5)	237.7 (169.5 to 321.5)	1.4 (-8.1 to 11.4)	-12.8 (-21.2 to -4.4)
Falls	-	-	-	-	171.8 (130.2 to 221.5)	194.0 (137.7 to 262.7)	12.3 (-0.2 to 26.0)	-5.3 (-15.9 to 6.4)
Drowning	-	-	-	-	1.3 (1.0 to 1.7)	0.6 (0.4 to 0.9)	-50.8 (-58.2 to -43.1)	-55.5 (-62.0 to -48.5)
Fire, heat, and hot substances	-	-	-	-	3.5 (2.7 to 4.5)	2.5 (1.8 to 3.5)	-28.1 (-36.7 to -18.7)	-32.9 (-41.2 to -24.2)
Poisonings	-	-	-	-	0.8 (0.6 to 1.1)	0.4 (0.3 to 0.5)	-54.3 (-60.7 to -46.4)	-54.3 (-60.9 to -46.4)
Exposure to mechanical forces	-	-	-	-	51.1 (38.0 to 67.2)	26.2 (18.8 to 35.8)	-48.8 (-53.1 to -44.8)	-51.2 (-55.0 to -47.5)
Unintentional firearm injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.3 (0.2 to 0.4)	-53.8 (-61.7 to -44.0)	-55.3 (-62.7 to -46.0)
Unintentional suffocation	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-35.0 (-44.1 to -24.7)	-36.8 (-45.9 to -26.6)
Other exposure to mechanical forces	-	-	-	-	50.2 (37.4 to 66.1)	25.7 (18.4 to 35.2)	-48.8 (-53.1 to -44.7)	-51.2 (-55.0 to -47.6)
Adverse effects of medical treatment	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	14.4 (1.7 to 26.7)	3.4 (-7.5 to 13.8)
Animal contact	-	-	-	-	1.4 (1.0 to 1.8)	1.3 (0.9 to 1.7)	-5.1 (-14.1 to 4.4)	-7.9 (-16.6 to 0.9)
Venomous animal contact	-	-	-	-	0.6 (0.4 to 0.7)	0.5 (0.4 to 0.7)	-8.1 (-19.7 to 5.9)	-10.0 (-21.7 to 4.1)
Non-venomous animal contact	-	-	-	-	0.8 (0.6 to 1.1)	0.8 (0.6 to 1.1)	-3.5 (-13.1 to 6.8)	-6.9 (-15.7 to 2.5)
Foreign body	-	-	-	-	1.7 (1.3 to 2.1)	1.4 (1.0 to 1.8)	-16.2 (-24.5 to -6.8)	-21.7 (-29.5 to -13.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.6 (0.5 to 0.8)	0.4 (0.3 to 0.5)	-42.1 (-51.7 to -29.4)	-45.3 (-53.9 to -33.6)
Foreign body in eyes	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	0.2 (-6.4 to 8.1)	-2.1 (-8.4 to 4.5)
Foreign body in other body part	-	-	-	-	0.8 (0.6 to 1.0)	0.8 (0.5 to 1.0)	-0.4 (-11.7 to 11.7)	-9.3 (-18.9 to 1.4)
Other unintentional injuries	-	-	-	-	1.7 (1.3 to 2.2)	11.0 (7.9 to 14.7)	552.3 (466.2 to 634.3)	492.7 (418.5 to 564.4)
Self-harm and interpersonal violence	-	-	-	-	3.1 (2.4 to 4.0)	2.2 (1.6 to 3.0)	-29.6 (-37.0 to -21.1)	-37.1 (-43.6 to -29.6)
Self-harm	-	-	-	-	1.6 (1.2 to 2.1)	1.3 (0.9 to 1.7)	-22.8 (-31.2 to -13.0)	-31.5 (-39.0 to -23.0)
Interpersonal violence	-	-	-	-	1.5 (1.1 to 1.9)	0.9 (0.7 to 1.3)	-37.0 (-44.0 to -29.1)	-43.3 (-49.6 to -36.2)
Assault by firearm	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-31.9 (-38.2 to -26.0)	-39.1 (-44.6 to -33.9)
Assault by sharp object	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-29.3 (-37.3 to -19.8)	-36.2 (-43.2 to -27.8)
Assault by other means	-	-	-	-	1.1 (0.8 to 1.3)	0.6 (0.5 to 0.9)	-39.6 (-46.8 to -31.0)	-45.5 (-52.1 to -38.0)
Forces of nature, war, and legal intervention	-	-	-	-	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-50.3 (-73.1 to -29.9)	-54.3 (-77.4 to -30.5)
Exposure to forces of nature	-	-	-	-	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-50.3 (-73.1 to -29.9)	-54.3 (-77.4 to -30.5)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Russia prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
All causes	-	-	-	-	16,649.0 (12,390.6 to 21,640.1)	17,751.5 (13,136.3 to 23,055.2)	6.6 (4.1 to 9.3)	-1.8 (-4.0 to 0.8)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1,107.8 (775.3 to 1,539.3)	1,116.8 (791.3 to 1,555.9)	0.0 (-9.7 to 18.0)	11.8 (1.7 to 31.6)
HIV/AIDS and tuberculosis	-	-	-	-	62.0 (41.8 to 83.4)	116.9 (76.9 to 171.8)	83.9 (57.9 to 146.7)	73.9 (49.2 to 131.9)
Tuberculosis	182.5 (174.0 to 190.8)	212.7 (204.1 to 222.4)	16.8 (12.4 to 21.4)	10.3 (6.4 to 14.7)	55.4 (37.5 to 74.5)	65.0 (44.5 to 88.2)	17.2 (8.3 to 27.6)	11.2 (2.7 to 20.9)
HIV/AIDS	-	-	-	-	6.2 (2.9 to 12.3)	51.9 (28.5 to 95.8)	698.8 (416.8 to 1,204.8)	657.9 (390.0 to 1,121.8)
HIV/AIDS resulting in mycobacterial infection	0.6 (0.3 to 1.2)	4.7 (2.2 to 9.0)	629.4 (367.7 to 1,057.9)	596.8 (346.2 to 1,009.6)	0.3 (0.1 to 0.5)	1.8 (0.7 to 3.7)	574.3 (273.7 to 1,070.9)	545.3 (253.2 to 1,005.1)
HIV/AIDS resulting in other diseases	36.3 (19.9 to 63.5)	417.7 (321.4 to 600.0)	1,102.8 (634.6 to 1,867.5)	1,049.1 (599.8 to 1,775.4)	6.3 (2.7 to 12.0)	50.1 (26.8 to 94.6)	703.4 (407.9 to 1,253.0)	659.5 (383.7 to 1,191.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	177.6 (118.5 to 255.5)	150.2 (100.1 to 219.7)	-15.5 (-19.9 to -11.0)	-9.9 (-14.7 to -4.9)
Diarrheal diseases	239.7 (222.5 to 257.9)	214.4 (198.7 to 230.4)	-10.3 (-18.7 to 0.2)	-3.4 (-12.7 to 8.4)	38.5 (26.2 to 53.1)	34.1 (23.5 to 47.6)	-11.3 (-20.8 to 0.7)	-3.3 (-9.9 to 10.7)
Intestinal infectious diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-0.2 (-4.8 to -1.6)	-20.6 (-45.0 to 4.9)
Typhoid fever	1.5 (1.2 to 1.9)	1.2 (0.9 to 1.4)	-23.0 (-44.7 to 2.1)	-16.9 (-41.1 to 8.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-23.0 (-44.9 to 2.4)	-16.9 (-41.1 to 8.7)
Paratyphoid fever	0.8 (0.6 to 1.0)	0.6 (0.5 to 0.8)	-24.2 (-46.0 to 3.9)	-15.8 (-40.0 to 11.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-24.2 (-46.4 to 4.1)	-15.8 (-40.1 to 11.8)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-56.1 (-84.7 to 19.9)	-52.8 (-83.7 to 29.3)
Lower respiratory infections	26.8 (22.6 to 30.2)	29.1 (25.9 to 32.6)	9.9 (10.1 to 31.1)	35.1 (7.9 to 61.4)	2.9 (1.8 to 4.1)	3.1 (2.0 to 4.6)	6.6 (14.4 to 35.5)	33.5 (4.1 to 68.9)
Upper respiratory infections	5,830.1 (5,593.4 to 6,081.1)	5,420.3 (5,146.7 to 5,688.2)	-6.6 (-13.5 to -1.2)	-0.5 (-7.7 to 5.4)	68.0 (38.0 to 113.2)	63.2 (35.7 to 105.2)	-6.8 (-13.9 to -1.0)	-0.4 (-7.8 to 5.9)
Otitis media	2,002.8 (1,861.0 to 2,162.5)	1,684.1 (1,549.0 to 1,822.7)	-15.6 (-23.0 to -7.9)	-10.4 (-17.3 to -3.2)	40.1 (24.1 to 64.1)	32.9 (19.5 to 52.9)	-18.0 (-24.8 to -9.1)	-11.2 (-18.4 to -2.4)
Meningitis	-	-	-	-	14.2 (9.0 to 20.9)	6.9 (4.5 to 9.9)	-51.5 (-62.4 to -37.1)	-49.6 (-61.2 to -33.5)
Pneumococcal meningitis	59.4 (33.9 to 97.5)	31.4 (17.9 to 52.9)	-47.6 (-57.4 to -34.4)	-50.0 (-59.6 to -37.2)	5.9 (3.3 to 9.5)	2.7 (1.7 to 3.9)	-55.1 (-68.1 to -28.6)	-54.8 (-68.5 to -27.3)
H influenzae type B meningitis	34.3 (9.3 to 79.2)	14.9 (4.3 to 34.7)	-56.8 (-73.2 to -34.7)	-55.6 (-70.9 to -27.4)	4.0 (2.2 to 6.5)	1.7 (1.0 to 2.9)	-57.0 (-75.5 to -17.6)	-52.4 (-73.0 to -7.5)
Meningococcal meningitis	13.0 (3.6 to 31.9)	7.0 (1.9 to 18.2)	-46.6 (-62.8 to -13.2)	-46.9 (-62.4 to -6.1)	1.6 (0.9 to 2.7)	0.9 (0.4 to 1.6)	-46.4 (-66.1 to 2.3)	-44.6 (-65.8 to 12.9)
Other meningitis	22.5 (10.2 to 45.9)	13.6 (6.2 to 29.2)	-39.0 (-53.3 to -24.4)	-39.6 (-53.3 to -22.6)	2.7 (1.7 to 4.1)	1.6 (1.0 to 2.5)	-40.6 (-59.0 to -13.5)	-39.2 (-58.7 to -9.8)
Encephalitis	53.3 (22.8 to 139.5)	54.8 (22.5 to 148.1)	1.8 (-14.3 to 21.0)	1.8 (-19.1 to 10.2)	6.8 (4.6 to 9.7)	7.0 (4.6 to 9.8)	2.4 (-18.6 to 30.8)	3.1 (-21.7 to 22.1)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-77.0 (-96.9 to 88.0)	-75.8 (-96.9 to 75.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-77.0 (-96.9 to 90.6)	-75.8 (-96.9 to 76.8)
Whooping cough	89.6 (69.1 to 115.3)	3.5 (2.7 to 4.6)	-96.1 (-96.7 to -95.3)	-94.9 (-95.8 to -93.9)	4.5 (2.6 to 7.2)	0.2 (0.1 to 0.3)	-96.1 (-97.2 to -94.7)	-94.9 (-96.3 to -93.2)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-64.5 (-84.1 to -53.8)	-60.7 (-84.1 to -48.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.1 (-82.7 to -53.1)	-59.0 (-82.2 to -48.1)
Measles	0.5 (0.5 to 0.5)	0.1 (0.1 to 0.1)	-86.4 (-87.0 to -85.8)	-86.4 (-82.4 to -80.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-86.4 (-87.0 to -85.8)	-81.6 (-82.4 to -80.8)
Varicella and herpes zoster	85.0 (78.1 to 92.5)	75.9 (69.3 to 83.8)	-10.6 (-21.0 to 1.0)	-1.4 (-10.8 to 8.4)	2.5 (1.5 to 3.8)	2.6 (1.5 to 4.0)	-1.3 (-16.4 to 37.7)	-1.3 (-20.6 to 26.5)
Neglected tropical diseases and malaria	-	-	-	-	26.3 (14.1 to 41.9)	26.2 (13.1 to 44.4)	-1.0 (-34.6 to 38.7)	-12.1 (-41.9 to 20.5)
Malaria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-14.4 (-74.7 to 159.3)	0.1 (-71.5 to 203.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.5 (-74.4 to 168.3)	1.8 (-71.4 to 213.8)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	12.9 (5.0 to 24.6)	1.2 (0.4 to 3.1)	-90.1 (-97.7 to -69.9)	-91.8 (-98.0 to -75.0)	3.4 (1.2 to 6.7)	0.4 (0.1 to 1.0)	-88.1 (-97.4 to -61.4)	-90.0 (-97.2 to -67.8)
Cystic echinococcosis	28.2 (24.8 to 31.7)	31.3 (29.7 to 33.1)	11.1 (1.0 to 25.2)	3.0 (-7.4 to 17.7)	2.6 (1.7 to 3.8)	2.9 (1.9 to 4.2)	11.6 (-10.7 to 40.9)	3.4 (-18.4 to 34.4)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.3 (-66.7 to -16.0)	-33.5 (-66.3 to -15.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.3 (-66.7 to -16.0)	-33.5 (-66.3 to -15.0)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	879.3 (655.2 to 1,142.7)	955.6 (688.7 to 1,284.0)	9.5 (-22.7 to 56.2)	9.5 (-30.2 to 39.4)	20.2 (9.2 to 35.3)	22.9 (10.3 to 40.5)	13.4 (-24.8 to 66.4)	-0.1 (-31.8 to 45.0)
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.2 (-75.1 to -31.0)	-53.2 (-74.7 to -30.8)
Maternal disorders	-	-	-	-	4.8 (2.9 to 7.2)	4.3 (2.7 to 6.6)	-7.8 (-32.7 to 12.7)	-13.7 (-36.5 to 4.5)
Maternal hemorrhage	53.0 (47.1 to 60.7)	57.1 (39.9 to 73.6)	7.8 (-23.3 to 36.8)	1.0 (-28.0 to 27.7)	1.7 (1.1 to 2.5)	1.7 (0.8 to 2.6)	2.4 (-48.6 to 41.4)	-4.2 (-50.5 to 31.5)
Maternal sepsis and other maternal infections	70.8 (43.9 to 112.4)	45.9 (27.5 to 73.1)	-35.3 (-51.4 to -17.0)	-35.3 (-52.0 to -17.0)	0.8 (0.4 to 1.5)	0.5 (0.2 to 0.9)	-41.1 (-59.0 to -14.1)	-43.4 (-60.6 to -17.0)
Maternal hypertensive disorders	22.0 (13.5 to 32.7)	21.2 (13.2 to 31.4)	-3.9 (-16.5 to 10.4)	-12.1 (-24.3 to 1.4)	1.1 (0.5 to 1.9)	1.0 (0.5 to 1.8)	-4.7 (-25.2 to 23.3)	-12.9 (-32.0 to 12.6)
Obstructed labor	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	3.8 (-35.6 to 70.7)	-3.6 (-41.5 to 65.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.8 (-36.2 to 70.8)	-3.5 (-42.0 to 66.3)
Complications of abortion	0.9 (0.6 to 1.3)	10.4 (0.6 to 1.4)	10.4 (-19.9 to 48.9)	2.1 (-27.2 to 39.3)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	12.3 (-33.6 to 115.4)	4.5 (-41.1 to 117.4)
Other maternal disorders	-	-	-	-	1.0 (0.6 to 1.7)	1.0 (0.6 to 1.6)	-9.1 (-36.2 to 37.2)	-9.1 (-40.3 to 27.3)
Neonatal disorders	-	-	-	-	213.2 (136.5 to 309.4)	333.4 (206.5 to 535.8)	51.4 (4.0 to 168.9)	65.8 (13.9 to 194.0)
Preterm birth complications	801.4 (461.1 to 1,291.0)	955.6 (578.8 to 1,536.7)	20.8 (-9.3 to 55.3)	27.9 (-3.7 to 66.2)	96.5 (57.4 to 156.0)	121.8 (73.7 to 180.5)	29.1 (-22.0 to 99.8)	40.2 (-14.9 to 119.2)
Neonatal encephalopathy due to birth asphyxia and trauma	212.7 (105.4 to 440.1)	116.2 (58.2 to 253.4)	-47.1 (-69.9 to 3.7)	-41.2 (-66.6 to 18.8)	48.8 (26.9 to 81.5)	29.3 (16.2 to 47.8)	-42.4 (-66.0 to 19.0)	-34.4 (-60.7 to 36.1)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.3)	3.9 (-0.1 to 11.1)	23.0 (18.2 to 31.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.2 (-11.9 to 31.4)	24.6 (4.4 to 55.5)
Hemolytic disease and other neonatal jaundice	92.0 (37.1 to 170.5)	118.9 (57.9 to 266.1)	15.9 (-51.4 to 357.2)	27.3 (-46.5 to 410.3)	33.4 (13.0 to 62.7)	43.3 (19.4 to 89.9)	43.3 (-47.7 to 346.8)	30.4 (-42.4 to 393.9)
Other neonatal disorders	-	-	-	-	34.5 (16.8 to 76.9)	139.1 (61.3 to 241.9)	392.7 (114.4 to 890.5)	440.3 (23.5 to 985.9)
Nutritional deficiencies	-	-	-	-	571.6 (373.5 to 823.0)	442.6 (290.7 to 647.3)	-22.6 (-27.4 to -17.4)	-4.5 (-10.3 to 2.0)
Protein-energy malnutrition	170.2 (82.6 to 319.7)	110.3 (47.6 to 214.0)	-35.6 (-77.7 to 67.8)	-16.4 (-71.2 to 118.3)	21.3 (9.4 to 42.7)	13.9 (5.3 to 29.9)	-35.9 (-77.3 to 65.3)	-16.7 (-70.6 to 115.1)
Iodine deficiency	1,895.6 (868.2 to 2,872.3)	1,289.4 (630.9 to 1,917.4)	-32.1 (-66.0 to 50.1)	-32.1 (-66.0 to 44.2)	23.2 (13.8 to 65.4)	23.0 (10.1 to 42.4)	-32.6 (-66.2 to 49.8)	-33.0 (-65.9 to 43.4)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron deficiency anemia	17,578.6 (17,262.8 to 17,903.9)	15,044.3 (14,649.5 to 15,398.0)	-14.2 (-16.4 to -11.9)	-1.2 (-3.6 to 1.1)	515.0 (340.3 to 746.6)	404.3 (267.4 to 595.8)	-21.4 (-25.0 to -18.7)	-2.2 (-5.9 to 0.7)

Appendix Table G.4 - Russia prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Other oral disorders	2,769.8 (2,606.6 to 2,919.5)	2,875.4 (2,728.9 to 3,026.3)	4.1 (-3.2 to 12.4)	-4.0 (-6.8 to 8.0)	80.5 (50.1 to 120.4)	83.7 (52.3 to 125.1)	4.0 (-3.6 to 12.7)	0.2 (-6.9 to 8.7)
Injuries	-	-	-	-	936.9 to 1,612.1	356.2 to 660.7	(-65.0 to -55.3)	(-68.6 to -60.1)
Transport injuries	-	-	-	-	437.4 (322.9 to 564.6)	149.8 (106.3 to 203.1)	-66.0 (-70.3 to -60.6)	-69.2 (-73.0 to -64.5)
Road injuries	-	-	-	-	342.2 (252.5 to 440.7)	122.6 (86.6 to 166.5)	-64.5 (-69.2 to -58.4)	-67.9 (-72.1 to -62.5)
Pedestrian road injuries	-	-	-	-	75.5 (55.6 to 98.2)	31.3 (21.7 to 43.4)	-58.8 (-64.8 to -51.1)	-63.9 (-69.1 to -57.0)
Cyclist road injuries	-	-	-	-	48.6 (36.0 to 63.3)	16.0 (11.3 to 21.7)	-67.1 (-71.3 to -62.5)	-70.0 (-73.6 to -65.9)
Motorcyclist road injuries	-	-	-	-	29.5 (21.6 to 38.8)	12.9 (9.0 to 17.9)	-56.6 (-62.3 to -49.4)	-60.8 (-65.9 to -54.4)
Motor vehicle road injuries	-	-	-	-	184.6 (136.2 to 238.2)	61.2 (43.9 to 81.5)	-67.1 (-71.7 to -60.9)	-70.0 (-74.1 to -64.4)
Other road injuries	-	-	-	-	4.2 (3.0 to 5.2)	1.2 (0.9 to 1.7)	-69.5 (-73.5 to -64.9)	-72.8 (-76.3 to -68.7)
Other transport injuries	-	-	-	-	95.2 (70.6 to 124.0)	27.2 (19.7 to 36.4)	-71.4 (-75.1 to -67.2)	-73.9 (-77.3 to -70.1)
Unintentional injuries	-	-	-	-	771.3 (580.1 to 1,007.3)	320.7 (235.2 to 432.0)	-58.6 (-62.9 to -53.3)	-63.0 (-66.9 to -58.4)
Falls	-	-	-	-	316.9 (239.9 to 412.2)	173.1 (124.0 to 235.7)	-45.7 (-51.8 to -38.1)	-53.9 (-59.1 to -47.6)
Drowning	-	-	-	-	12.2 (9.0 to 15.9)	5.9 (4.1 to 8.1)	-52.3 (-59.1 to -44.3)	-57.1 (-63.3 to -50.3)
Fire, heat, and hot substances	-	-	-	-	33.2 (25.2 to 42.2)	20.0 (13.9 to 28.1)	-40.4 (-49.9 to -27.6)	-45.4 (-53.9 to -34.1)
Poisonings	-	-	-	-	4.4 (3.1 to 5.9)	2.7 (1.8 to 3.6)	-38.8 (-46.5 to -30.2)	-40.4 (-48.2 to -31.3)
Exposure to mechanical forces	-	-	-	-	213.4 (160.1 to 281.2)	69.2 (49.5 to 94.9)	-67.7 (-72.0 to -62.5)	-69.2 (-73.3 to -64.0)
Unintentional firearm injuries	-	-	-	-	3.8 (2.9 to 4.8)	1.3 (0.9 to 1.8)	-65.9 (-71.5 to -57.8)	-67.5 (-72.7 to -60.6)
Unintentional suffocation	-	-	-	-	2.0 (1.5 to 2.6)	0.5 (0.4 to 0.6)	-77.0 (-79.9 to -73.0)	-77.8 (-80.8 to -73.6)
Other exposure to mechanical forces	-	-	-	-	207.6 (155.6 to 273.4)	67.4 (48.0 to 92.6)	-67.7 (-72.0 to -62.5)	-69.1 (-73.3 to -63.9)
Adverse effects of medical treatment	-	-	-	-	2.1 (1.3 to 3.0)	2.4 (1.5 to 3.6)	17.8 (10.6 to 27.2)	4.0 (-2.0 to 12.1)
Animal contact	-	-	-	-	10.0 (7.4 to 13.0)	7.5 (5.4 to 10.1)	-25.1 (-31.6 to -16.3)	-29.5 (-35.4 to -22.0)
Venomous animal contact	-	-	-	-	3.2 (2.3 to 4.4)	2.7 (1.9 to 3.6)	-17.8 (-27.4 to -7.9)	-21.9 (-31.1 to -12.3)
Non-venomous animal contact	-	-	-	-	6.7 (5.0 to 8.9)	4.9 (3.4 to 6.8)	-28.6 (-36.5 to -18.5)	-33.1 (-40.1 to -24.5)
Foreign body	-	-	-	-	10.6 (8.1 to 13.5)	5.6 (4.1 to 7.4)	-47.2 (-54.5 to -38.6)	-50.6 (-57.7 to -42.6)
Pulmonary aspiration and foreign body in airway	-	-	-	-	4.3 (3.3 to 5.5)	2.7 (1.9 to 3.6)	-38.2 (-47.7 to -26.1)	-44.5 (-52.9 to -33.9)
Foreign body in eyes	-	-	-	-	1.9 (1.2 to 2.7)	1.4 (0.7 to 2.2)	-27.1 (-40.7 to -16.6)	-27.3 (-42.4 to -15.9)
Foreign body in other body part	-	-	-	-	4.4 (3.3 to 5.7)	1.6 (1.1 to 2.2)	-64.5 (-71.2 to -55.1)	-66.8 (-72.9 to -58.1)
Other unintentional injuries	-	-	-	-	168.5 (125.2 to 221.2)	34.4 (26.0 to 44.2)	-79.6 (-82.8 to -74.9)	-81.1 (-84.2 to -76.6)
Self-harm and interpersonal violence	-	-	-	-	36.2 (27.1 to 46.4)	20.1 (14.3 to 27.4)	-44.9 (-50.8 to -36.2)	-51.1 (-56.1 to -43.6)
Self-harm	-	-	-	-	16.3 (11.9 to 21.2)	12.2 (8.7 to 16.7)	-25.0 (-32.6 to -15.2)	-33.5 (-40.3 to -25.0)
Interpersonal violence	-	-	-	-	20.0 (15.3 to 25.5)	7.9 (5.7 to 10.9)	-60.9 (-66.1 to -53.3)	-65.1 (-69.7 to -58.6)
Assault by firearm	-	-	-	-	1.6 (1.2 to 2.1)	0.6 (0.4 to 0.8)	-62.9 (-67.4 to -56.4)	-66.8 (-70.8 to -61.3)
Assault by sharp object	-	-	-	-	3.2 (2.3 to 4.2)	1.6 (1.1 to 2.4)	-48.9 (-56.7 to -37.9)	-54.9 (-61.7 to -45.4)
Assault by other means	-	-	-	-	15.2 (11.5 to 19.4)	5.6 (4.1 to 7.7)	-63.3 (-68.0 to -56.1)	-67.1 (-71.2 to -60.9)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	260.9 (44.6 to 713.2)	396.5 (95.9 to 1,006.0)
Exposure to forces of nature	-	-	-	-	0.0	0.0	-	-
Collective violence and legal intervention	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	227.8 (32.7 to 633.4)	357.6 (80.5 to 923.8)

Appendix Table G.4 - Rwanda prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	637.2 (461.9 to 837.2)	1,202.9 (871.0 to 1,594.4)	86.8 (72.2 to 114.5)	11.1 (1.7 to 30.6)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	189.8 (129.9 to 268.5)	233.0 (161.9 to 331.3)	22.8 (16.2 to 30.8)	-26.5 (-31.7 to -19.0)
HIV/AIDS and tuberculosis	-	-	-	-	26.7 (18.1 to 37.5)	27.2 (18.2 to 39.6)	-0.9 (-21.4 to 42.2)	-45.8 (-58.1 to -16.2)
Tuberculosis	5.8 (5.5 to 6.1)	10.7 (10.2 to 11.2)	83.7 (75.9 to 92.7)	-2.3 (-6.0 to 1.6)	1.8 (1.2 to 2.4)	3.2 (2.2 to 4.3)	80.5 (63.5 to 99.1)	-4.2 (-12.3 to 4.1)
HIV/AIDS	-	-	-	-	24.9 (16.8 to 35.3)	23.5 (15.8 to 35.6)	-1.4 (-27.9 to 39.7)	-48.9 (-61.6 to -17.0)
HIV/AIDS resulting in mycobacterial infection	1.2 (0.9 to 1.6)	1.1 (0.6 to 1.6)	-15.2 (-37.7 to 13.0)	-53.0 (-66.1 to -35.3)	0.5 (0.3 to 0.7)	0.4 (0.2 to 0.6)	-16.9 (-44.3 to 17.1)	-53.9 (-68.8 to -35.2)
HIV/AIDS resulting in other diseases	186.0 (164.0 to 211.4)	197.6 (174.1 to 223.6)	5.3 (-8.5 to 26.2)	-36.3 (-45.4 to -21.5)	24.5 (16.5 to 34.7)	23.6 (15.5 to 35.0)	-6.4 (-28.1 to 41.0)	-48.8 (-61.7 to -16.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	36.2 (25.7 to 48.8)	42.4 (30.2 to 58.1)	16.9 (7.8 to 27.6)	-21.2 (-26.6 to -14.9)
Diarrheal diseases	119.2 (110.1 to 128.1)	137.2 (129.1 to 146.1)	14.9 (4.7 to 26.5)	-16.7 (-23.3 to -8.9)	19.4 (12.9 to 27.0)	22.2 (15.0 to 31.1)	14.7 (4.2 to 27.2)	-19.1 (-23.7 to -8.9)
Intestinal infectious diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-0.1 (-30.9 to 16.7)	-10.0 (-54.4 to -27.1)
Typhoid fever	1.5 (1.3 to 1.6)	1.4 (1.2 to 1.6)	-5.7 (-22.5 to 14.8)	-39.2 (-50.0 to -27.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-4.4 (-28.2 to 26.4)	-38.2 (-51.9 to -22.0)
Paratyphoid fever	0.5 (0.5 to 0.6)	0.6 (0.5 to 0.8)	15.6 (-11.7 to 49.1)	-25.3 (-41.8 to -6.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.8 (-15.4 to 55.8)	-25.3 (-42.8 to -2.9)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-57.2 (-77.3 to -35.5)	-72.3 (-85.3 to -47.0)
Lower respiratory infections	6.0 (5.1 to 6.9)	7.5 (6.7 to 8.5)	23.9 (3.4 to 52.5)	-15.4 (-26.1 to -0.3)	0.6 (0.4 to 0.9)	0.8 (0.5 to 1.2)	24.1 (-0.4 to 56.6)	-15.4 (-27.7 to 2.2)
Upper respiratory infections	471.2 (445.2 to 496.8)	796.8 (748.1 to 846.2)	68.8 (58.0 to 80.2)	4.7 (-2.4 to 12.2)	5.5 (3.1 to 9.2)	9.3 (5.3 to 15.7)	68.1 (56.8 to 80.5)	4.1 (-3.2 to 11.8)
Otitis media	129.1 (116.4 to 141.9)	180.0 (165.6 to 196.4)	39.5 (24.9 to 54.5)	-12.9 (-21.6 to -3.9)	2.7 (1.6 to 4.3)	3.7 (2.2 to 5.9)	38.2 (21.7 to 54.7)	-13.4 (-23.1 to -3.3)
Meningitis	-	-	-	-	7.3 (5.1 to 9.8)	5.7 (3.9 to 7.8)	-21.8 (-38.3 to 0.5)	-49.9 (-59.4 to -37.9)
Pneumococcal meningitis	25.9 (16.6 to 37.6)	20.9 (13.5 to 30.8)	-19.7 (-36.6 to 3.2)	-49.1 (-59.0 to -35.9)	2.4 (1.6 to 3.4)	2.0 (1.3 to 2.8)	-18.7 (-37.8 to 9.2)	-48.5 (-59.8 to -33.0)
H influenzae type B meningitis	15.5 (7.3 to 27.6)	12.3 (6.1 to 21.4)	-19.6 (-46.8 to 20.5)	-51.8 (-66.5 to -31.0)	1.7 (1.1 to 2.6)	1.6 (0.9 to 2.6)	-4.4 (-50.4 to 68.8)	-41.7 (-68.0 to 1.2)
Meningococcal meningitis	3.4 (1.4 to 7.1)	2.7 (1.2 to 5.8)	-20.4 (-41.8 to 3.8)	-47.5 (-61.4 to -32.7)	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.5)	-16.0 (-41.7 to 18.0)	-44.2 (-59.2 to -25.7)
Other meningitis	22.5 (12.3 to 37.7)	15.0 (7.9 to 26.6)	-33.4 (-47.4 to -17.5)	-56.5 (-65.2 to -46.6)	2.7 (1.7 to 3.9)	1.8 (1.2 to 2.5)	-34.3 (-53.8 to -10.4)	-56.6 (-68.7 to -42.7)
Encephalitis	1.2 (0.6 to 2.5)	1.8 (0.8 to 3.7)	46.3 (30.2 to 65.8)	-32.0 (-21.2 to -3.0)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	-52.0 (-77.3 to 83.5)	-10.1 (-21.6 to 4.2)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-98.0 to 236.2)	0.0 (0.0 to 0.0)	-	-
Whooping cough	2.5 (2.0 to 3.2)	0.8 (0.6 to 1.1)	-67.1 (-69.8 to -64.2)	-75.5 (-77.5 to -73.4)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-67.2 (-75.5 to -57.1)	-75.6 (-81.7 to -68.1)
Tetanus	0.6 (0.3 to 1.0)	0.1 (0.0 to 0.2)	-84.7 (-93.2 to -51.2)	-90.8 (-96.0 to -47.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-72.1 (-85.9 to -39.5)	-81.7 (-90.7 to -59.8)
Measles	1.0 (0.8 to 1.2)	0.2 (0.2 to 0.3)	-76.4 (-80.7 to -71.1)	-92.5 (-85.7 to -78.6)	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-65.3 (-85.9 to -42.8)	-42.4 (-89.5 to -7.2)
Varicella and herpes zoster	4.5 (4.1 to 5.0)	7.7 (6.9 to 8.4)	69.3 (50.2 to 91.7)	1.1 (-17.5 to 23.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	75.7 (28.8 to 138.5)	-0.9 (-30.2 to 38.3)
Neglected tropical diseases and malaria	-	-	-	-	53.4 (27.3 to 95.8)	67.0 (36.7 to 117.0)	26.6 (12.7 to 42.8)	-25.9 (-35.7 to -13.8)
Malaria	456.0 (427.4 to 488.3)	330.4 (311.2 to 351.7)	-27.7 (-31.6 to -23.1)	-55.2 (-57.5 to -52.1)	6.6 (4.3 to 9.8)	5.4 (3.7 to 7.8)	-18.1 (-27.7 to -7.0)	-47.5 (-54.3 to -40.0)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	55.8 (-21.9 to 237.9)	-3.1 (-47.5 to 73.3)
Visceral leishmaniasis	0.6 (0.3 to 0.9)	1.0 (0.4 to 1.7)	61.7 (-28.2 to 276.1)	6.6 (-50.3 to 107.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	59.9 (-33.4 to 296.9)	6.0 (-50.5 to 118.8)
Cutaneous and mucocutaneous leishmaniasis	0.8 (0.5 to 1.2)	1.0 (0.6 to 1.7)	37.0 (-9.2 to 95.4)	-26.6 (-49.9 to 5.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.2 (-13.8 to 112.9)	27.5 (-51.2 to 11.2)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	2,713.3 (758.1 to 5,328.2)	2,745.9 (844.1 to 5,540.0)	0.3 (-11.4 to 23.5)	-43.2 (-49.6 to -29.8)	28.2 (9.1 to 64.5)	30.7 (11.2 to 68.8)	9.8 (-4.1 to 34.6)	-38.8 (-46.3 to -23.9)
Cysticercosis	0.4 (0.1 to 1.1)	1.2 (0.5 to 2.0)	197.4 (-6.6 to 1,180.0)	24.9 (-61.4 to 309.6)	0.1 (0.0 to 0.3)	0.4 (0.1 to 0.6)	216.8 (-9.1 to 1,322.2)	29.3 (-61.2 to 362.7)
Cystic echinococcosis	4.0 (3.6 to 4.3)	2.8 (2.5 to 3.1)	-31.1 (-36.6 to -21.9)	-61.8 (-64.3 to -59.1)	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-31.3 (-43.0 to -15.5)	-61.9 (-67.3 to -56.4)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Dengue	0.2 (0.1 to 0.6)	1.7 (0.4 to 4.8)	715.2 (705.3 to 726.6)	396.7 (390.7 to 403.7)	0.0 (0.0 to 0.1)	0.3 (0.1 to 0.8)	670.4 (491.0 to 890.3)	360.0 (265.9 to 472.5)
Yellow fever	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-56.4 (-68.6 to -38.4)	-73.5 (-79.5 to -44.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.4 (-68.7 to -38.4)	-73.5 (-79.5 to -64.0)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-71.4 to 56.2)	0.0 (0.0 to 0.0)	-	-
Intestinal nematode infections	-	-	-	-	13.7 (8.3 to 21.4)	25.3 (15.4 to 39.4)	84.7 (69.1 to 97.7)	9.4 (0.9 to 16.8)
Ascariasis	1,567.6 (1,100.9 to 2,196.3)	2,573.8 (1,781.9 to 3,601.6)	63.6 (2.0 to 167.4)	-0.6 (-45.6 to 75.5)	2.9 (1.6 to 4.8)	4.5 (2.5 to 7.6)	57.6 (42.0 to 76.8)	-0.9 (-13.4 to 13.7)
Trichuriasis	1,135.9 (762.9 to 1,685.2)	1,872.1 (1,213.2 to 2,835.3)	63.8 (-7.0 to 184.2)	0.5 (-49.1 to 90.4)	0.9 (0.5 to 1.5)	1.4 (0.8 to 2.4)	59.3 (35.9 to 88.1)	-1.3 (-19.3 to 21.5)
Hookworm disease	1,844.3 (1,378.8 to 2,409.7)	3,087.9 (2,273.7 to 4,059.8)	69.6 (11.8 to 146.7)	0.4 (-39.2 to 62.3)	0.4 (6.3 to 15.1)	0.4 (12.2 to 29.6)	59.4 (73.7 to 111.8)	22.9 (-1.8 to 22.2)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	109.4 (85.7 to 134.0)	129.0 (117.7 to 142.7)	17.8 (-4.3 to 50.5)	-20.3 (-34.2 to -1.4)	4.2 (2.6 to 6.1)	4.6 (3.0 to 6.7)	8.0 (8.8 to 49.5)	-27.9 (-40.8 to -2.1)
Maternal disorders	-	-	-	-	0.1 (2.6 to 5.3)	0.1 (3.9 to 8.3)	26.4 (30.5 to 79.4)	-36.4 (-29.2 to -4.9)
Maternal hemorrhage	2.5 (2.1 to 2.9)	4.4 (3.5 to 5.3)	75.0 (36.4 to 118.4)	-11.5 (-29.0 to 8.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	26.4 (-30.4 to 110.0)	-36.4 (-63.5 to 6.1)
Maternal sepsis and other maternal infections	2.9 (2.0 to 3.9)	2.8 (1.9 to 3.9)	-1.1 (-24.2 to 42.0)	-49.8 (-60.5 to -22.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-5.7 (-43.6 to 49.8)	-49.3 (-68.6 to -23.1)
Maternal hypertensive disorders	3.0 (1.5 to 5.0)	3.6 (1.8 to 5.8)	19.2 (7.0 to 36.9)	-36.9 (-43.9 to -28.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	18.4 (-0.9 to 42.2)	-37.7 (-47.6 to -25.9)
Obstructed labor	8.0 (6.8 to 9.5)	12.5 (10.2 to 14.9)	55.5 (37.5 to 72.6)	-16.1 (-25.2 to -6.6)	2.7 (1.8 to 3.7)	4.1 (2.7 to 5.8)	54.7 (33.7 to 76.6)	-16.9 (-27.4 to -5.6)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-37.0 to 132.1)	0.0 (66.0 to 12.1)	-	-
Other maternal disorders	-	-	-	-	0.9 (0.5 to 1.3)	1.4 (0.9 to 2.2)	58.0 (7.6 to 146.8)	-14.9 (-42.8 to 33.5)
Neonatal disorders	-	-	-	-	4.5 (2.6 to 7.6)	19.1 (12.4 to 27.8)	332.5 (159.6 to 591.7)	200.3 (64.2 to 409.8)
Preterm birth complications	23.1 (11.8 to 41.4)	86.8 (52.8 to 140.9)	278.7 (202.9 to 416.0)	132.3 (83.2 to 219.6)	1.5 (0.9 to 2.5)	9.5 (5.9 to 14.8)	511.9 (304.0 to 931.5)	323.6 (176.5 to 603.2)
Neonatal encephalopathy due to birth asphyxia and trauma	4.0 (4.1 to 143.9)	49.2 (10.4 to 144.5)	25.0 (-19.7 to 211.3)	-26.1 (-52.8 to 92.0)	1.5 (0.6 to 3.6)	4.4 (2.2 to 7.4)	212.7 (40.7 to 695.6)	113.6 (-11.6 to 481.3)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	105.8 (95.2 to 121.8)	55.2 (47.2 to 67.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (86.7 to 127.1)	105.2 (40.8 to 71.3)
Hemolytic disease and other neonatal jaundice	1.5 (0.7 to 3.0)	6.7 (2.8 to 14.7)	315.5 (80.9 to 1,108.0)	223.9 (38.2 to 837.9)	0.6 (0.2 to 1.2)	2.6 (1.0 to 5.8)	316.1 (78.1 to 1,095.7)	217.0 (33.3 to 821.3)
Other neonatal disorders	-	-	-	-	0.9 (0.4 to 1.7)	2.7 (1.2 to 5.1)	214.7 (27.8 to 593.0)	117.8 (-14.0 to 399.9)
Nutritional deficiencies	-	-	-	-	59.7 (39.7 to 86.2)	64.3 (42.3 to 94.5)	7.9 (14.1 to 14.3)	-30.9 (-35.3 to -26.4)
Protein-energy malnutrition	34.7 (22.1 to 55.2)	29.6 (16.8 to 48.8)	-14.4 (-58.9 to 67.8)	-38.1 (-63.9 to 2.9)	4.2 (2.2 to 7.4)	3.6 (1.8 to 6.8)	-13.3 (-59.2 to 69.9)	-37.5 (-64.5 to -10.5)
Iodine deficiency	348.6 (305.7 to 394.2)	376.4 (314.6 to 432.2)	7.8 (-11.7 to 30.9)	-38.2 (-51.4 to -20.9)	6.3 (3.9 to 10.2)	6.8 (4.1 to 10.9)	6.7 (-12.7 to 29.2)	-38.6 (-51.6 to -21.8)
Vitamin A deficiency	3.8 (2.4 to 5.7)	3.4 (2.1 to 4.8)	-10.8 (-35.7 to 21.7)	-45.0 (-59.0 to -26.5)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-18.7 (-41.0 to 11.6)	-48.2 (-60.7 to -31.8)

Appendix Table G.4 - Rwanda prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	75.9	-3.9
Silicosis	0.0	0.0	67.0	-7.7	(0.0 to 0.0)	(0.0 to 0.0)	(70.0 to 81.8)	(-7.0 to -1.0)
Asbestosis	(0.0 to 0.0)	(0.0 to 0.0)	(59.3 to 74.6)	(-11.5 to -3.3)	0.0	0.0	66.9	-7.7
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.1	84.7	0.4	(0.0 to 0.0)	(0.0 to 0.0)	83.5	0.0
Asthma	246.1	613.3	152.7	28.5	10.8	26.8	151.6	27.9
Interstitial lung disease and pulmonary sarcoidosis	0.1	0.3	87.2	3.5	0.0	0.0	89.3	4.1
Other chronic respiratory diseases	-	-	(34.8 to 159.3)	(-24.5 to 37.4)	10.2	9.6	(36.6 to 160.3)	(-23.7 to 37.8)
Cirrhosis	-	-	-	-	(5.1 to 17.5)	(5.1 to 15.8)	(-4.2 to 49.6)	(-68.6 to -18.7)
Cirrhosis due to hepatitis B	1.0	0.8	-17.3	-44.2	0.5	0.7	24.3	-26.3
Cirrhosis due to hepatitis C	0.5	1.0	101.4	9.6	(0.4 to 0.8)	(0.5 to 1.0)	(7.6 to 41.2)	(-34.1 to -18.0)
Cirrhosis due to alcohol use	0.9	0.9	-39.5	0.1	0.2	0.1	-17.9	-45.1
Cirrhosis due to other causes	1.1	1.2	43.6	0.1	(0.1 to 0.2)	(0.1 to 0.2)	(-32.4 to 56.6)	(-60.7 to -14.7)
Digestive diseases	1.1	1.6	43.6	0.1	(0.1 to 0.3)	(0.2 to 0.4)	(-1.8 to 103.6)	(-28.9 to 42.1)
Peptic ulcer disease	47.4	50.4	6.3	-41.4	9.0	14.9	64.9	-11.4
Gastritis and duodenitis	85.2	131.9	54.2	-9.4	(6.3 to 12.5)	(10.6 to 20.5)	(52.8 to 80.0)	(-17.3 to -4.9)
Appendicitis	0.9	1.5	64.7	-5.2	1.7	1.8	9.1	-42.2
Paralytic ileus and intestinal obstruction	0.1	0.2	64.3	-0.6	(1.1 to 2.4)	(1.2 to 2.6)	(-7.0 to 30.1)	(-50.7 to -31.6)
Inguinal, femoral, and abdominal hernia	15.2	34.4	129.3	15.7	2.6	6.9	74.7	-0.8
Inflammatory bowel disease	5.8	13.5	131.5	25.7	(4.6 to 9.7)	(5.7 to 10.1)	(57.8 to 101.1)	(-8.7 to 8.8)
Vascular intestinal disorders	0.0	0.0	73.8	0.5	0.0	0.0	74.5	1.8
Gallbladder and biliary diseases	1.9	3.8	99.7	0.4	(0.0 to 0.0)	(0.0 to 0.0)	(28.0 to 150.3)	(-35.0 to 52.8)
Pancreatitis	1.0	2.0	98.6	4.5	0.3	0.6	95.5	3.2
Other digestive diseases	-	-	-	-	(0.2 to 0.4)	(0.4 to 0.8)	(60.4 to 131.6)	(-12.0 to 20.5)
Neurological disorders	-	-	-	-	1.2	1.6	26.5	-32.2
Alzheimer disease and other dementias	8.0	16.0	97.4	0.5	(0.6 to 1.9)	(1.0 to 2.4)	(-6.8 to 110.7)	(-50.0 to 13.7)
Parkinson disease	0.4	0.8	86.7	2.4	24.7	50.1	104.0	3.9
Epilepsy	15.4	26.8	77.3	7.9	(15.8 to 36.0)	(32.2 to 72.0)	(52.8 to 161.6)	(-15.1 to 28.5)
Multiple sclerosis	0.3	0.6	114.1	15.1	1.1	2.2	99.6	-0.4
Migraine	346.3	674.9	100.0	0.6	(0.8 to 1.5)	(1.6 to 2.9)	(70.9 to 138.3)	(-15.4 to 19.5)
Tension-type headache	772.7	1,543.3	99.8	5.1	0.1	0.1	84.3	1.7
Medication overuse headache	30.2	81.0	168.8	44.7	(0.0 to 0.1)	(0.1 to 0.2)	(51.5 to 129.5)	(-15.1 to 22.2)
Other neurological disorders	0.0	0.0	55.8	-6.9	4.6	8.4	86.6	13.6
Mental and substance use disorders	-	-	-	-	(2.3 to 7.8)	(4.2 to 14.4)	(-15.6 to 269.4)	(-48.0 to 126.2)
Schizophrenia	13.3	25.3	89.5	1.4	0.1	0.2	112.3	14.0
Alcohol use disorders	71.4	111.2	55.7	-15.8	(0.1 to 0.1)	(0.1 to 0.2)	(51.5 to 129.5)	(-15.1 to 22.2)
Drug use disorders	-	-	-	-	4.6	8.4	86.6	13.6
Opioid use disorders	9.6	19.4	100.5	4.9	(0.0 to 0.0)	(0.0 to 0.0)	(74.8 to 162.1)	(-6.5 to 38.9)
Cocaine use disorders	2.6	6.0	86.5	0.4	(0.0 to 0.0)	(0.0 to 0.0)	(8.2 to 127.7)	(-9.5 to 52.7)
Amphetamine use disorders	11.1	18.9	70.6	-6.3	(0.1 to 0.3)	(0.3 to 0.5)	(60.7 to 143.3)	(-7.6 to 36.7)
Cannabis use disorders	8.7	15.9	82.1	-0.2	0.3	0.6	95.5	3.2
Other drug use disorders	-	-	-	-	(0.2 to 0.4)	(0.4 to 0.8)	(64.4 to 131.6)	(-12.0 to 20.5)
Depressive disorders	-	-	-	-	1.2	1.6	26.5	-32.2
Major depressive disorder	322.1	618.3	91.9	5.8	(1.2 to 2.8)	(2.1 to 4.9)	(25.3 to 139.5)	(-31.0 to 29.3)
Dysthymia	63.2	118.3	87.1	0.2	8.0	14.7	84.5	-1.2
Bipolar disorder	35.9	67.7	88.7	0.6	(5.2 to 11.1)	(9.6 to 20.6)	(63.1 to 108.1)	(-11.1 to 10.4)
Anxiety disorders	201.5	369.4	83.6	0.5	3.9	7.7	94.8	1.7
Eating disorders	-	-	-	-	(4.8 to 19.6)	(4.6 to 12.3)	(72.8 to 132.3)	(-9.8 to 19.0)
Anorexia nervosa	1.2	2.3	88.6	6.0	(2.2 to 6.2)	(2.1 to 5.5)	(8.2 to 22.8)	(-3.9 to 48.8)
Bulimia nervosa	7.0	12.8	83.6	0.9	(0.3 to 0.7)	(0.5 to 1.2)	(34.6 to 153.8)	(-26.0 to 28.7)
Autistic spectrum disorders	-	-	-	-	0.3	0.5	89.6	6.2
Autism	21.9	36.1	64.6	-0.4	(0.8 to 2.4)	(1.6 to 4.4)	(66.0 to 99.5)	(-8.5 to 9.0)
Asperger syndrome	31.5	51.6	63.7	-0.5	8.6	14.0	61.1	-1.2
Attention-deficit/hyperactivity disorder	55.1	87.5	58.7	-0.1	(5.9 to 11.7)	(9.7 to 19.0)	(56.4 to 69.8)	(-4.9 to 2.2)
Conduct disorder	80.3	130.2	62.0	0.0	5.4	8.8	63.4	-1.3
Idiopathic intellectual disability	125.5	204.2	60.0	5.1	(3.7 to 7.4)	(5.9 to 12.1)	(54.4 to 73.6)	(-5.9 to 3.6)
Other mental and substance use disorders	78.2	144.4	84.6	-0.2	3.2	5.1	62.5	-1.2
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	(2.2 to 4.4)	(3.6 to 7.2)	(54.9 to 70.5)	(-5.2 to 2.8)
Diabetes mellitus	42.6	112.2	165.4	50.0	0.7	1.1	59.0	0.1
Acute glomerulonephritis	0.1	0.1	12.6	-24.6	(0.4 to 1.0)	(0.6 to 1.6)	(47.7 to 72.4)	(-6.7 to 8.2)
Chronic kidney disease	-	-	-	-	9.6	15.6	62.2	0.1
Chronic kidney disease due to diabetes mellitus	82.5	139.1	66.9	-3.7	(-0.1 to 0.0)	(0.3 to 0.7)	(55.3 to 69.7)	(-3.9 to 48.8)
Chronic kidney disease due to hypertension	268.0	468.1	74.9	6.3	6.1	9.9	69.0	4.4
Chronic kidney disease due to glomerulonephritis	188.9	313.3	68.5	-4.4	(2.6 to 9.6)	(4.2 to 15.0)	(32.3 to 142.2)	(-14.0 to 69.7)
Chronic kidney disease due to other causes	120.7 to 333.1	186.3 to 547.3	19.6 to 120.4	(-24.5 to 21.5)	2.5	4.5	81.3	-0.6
Urinary diseases and male infertility	-	-	-	-	(4.0 to 7.9)	(7.1 to 14.3)	(73.7 to 91.0)	(-5.5 to 2.6)
	-	-	-	-	27.5	49.9	81.4	7.7
	-	-	-	-	(19.4 to 37.0)	(35.5 to 67.6)	(69.7 to 96.3)	(-0.0 to 16.7)
	42.6	112.2	165.4	50.0	3.0	8.2	175.6	52.4
	(33.2 to 55.0)	(91.0 to 134.0)	(99.5 to 242.9)	(11.5 to 97.1)	(1.9 to 4.4)	(5.4 to 11.7)	(100.0 to 268.0)	(9.3 to 111.0)
	0.1	0.1	12.6	-24.6	0.0	0.0	12.6	0.0
	(0.1 to 0.1)	(0.1 to 0.1)	(0.2 to 23.4)	(-31.2 to -18.9)	(0.0 to 0.0)	(0.0 to 0.0)	(-0.3 to 23.4)	(-31.2 to -18.8)
	-	-	-	-	10.8	19.8	84.8	3.0
	-	-	-	-	(7.7 to 14.3)	(14.1 to 26.2)	(64.8 to 102.9)	(-6.1 to 12.9)
	82.5	139.1	66.9	-3.7	1.3	2.2	69.1	-2.8
	(54.8 to 119.6)	(80.4 to 217.6)	(21.8 to 125.7)	(-30.5 to 26.9)	(0.9 to 1.8)	(1.4 to 3.1)	(23.2 to 126.6)	(-34.2 to 27.4)
	268.0	468.1	74.9	6.3	3.3	6.0	83.6	-0.9
	(156.7 to 447.9)	(274.8 to 740.3)	(35.5 to 120.4)	(-12.5 to 38.0)	(2.3 to 4.5)	(4.2 to 8.1)	(47.9 to 123.1)	(-18.4 to 19.7)
	235.1	414.2	75.4	3.7	9.1	7.2	91.1	13.3
	(168.6 to 333.9)	(268.8 to 632.2)	(29.8 to 123.8)	(-19.5 to 25.0)	(2.6 to 5.0)	(4.9 to 9.7)	(55.8 to 134.7)	(-6.2 to 37.4)
	188.9	313.3	68.5	-4.4	2.5	4.5	81.3	-0.6
	(120.7 to 333.1)	(186.3 to 547.3)	(19.6 to 120.4)	(-24.5 to 21.5)	(1.6 to 3.3)	(3.1 to 6.1)	(40.0 to 136.4)	(-19.4 to 28.6)
	-	-	-	-	1.6	2.8	74.3	3.1
	-	-	-	-	(1.1 to 2.3)	(1.8 to 3.9)	(54.4 to 93.7)	(-8.6 to 14.4)

Appendix Table G.4 - Rwanda prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	96.5 (89.4 to 102.8)	165.7 (154.5 to 176.9)	71.6 (54.3 to 90.8)	-7.0 (-15.2 to 1.7)	2.7 (1.8 to 3.7)	4.5 (3.1 to 6.3)	69.2 (52.4 to 88.9)	-7.9 (-16.5 to 1.1)
Other oral disorders	98.1 (92.4 to 103.3)	173.8 (162.8 to 185.0)	76.9 (63.7 to 92.5)	-0.3 (-7.5 to 7.5)	2.9 (1.8 to 4.3)	5.1 (3.1 to 7.6)	75.8 (61.1 to 93.2)	-1.0 (-8.4 to 6.6)
Injuries	-	-	-	-	28.7 (21.9 to 36.6)	225.6 (116.3 to 418.3)	640.7 (333.3 to 1,252.2)	323.1 (145.6 to 692.9)
Transport injuries	-	-	-	-	12.6 (9.6 to 16.2)	9.4 (7.2 to 12.1)	-25.4 (-29.0 to -21.6)	-57.9 (-59.5 to -56.1)
Road injuries	-	-	-	-	11.5 (8.7 to 14.7)	8.6 (6.6 to 11.0)	-25.0 (-28.9 to -21.0)	-57.1 (-59.5 to -56.0)
Pedestrian road injuries	-	-	-	-	4.0 (3.0 to 5.1)	3.1 (2.3 to 4.0)	-22.7 (-28.9 to -16.5)	-54.9 (-57.6 to -52.3)
Cyclist road injuries	-	-	-	-	1.0 (0.7 to 1.3)	0.6 (0.5 to 0.8)	-39.2 (-43.6 to -34.5)	-65.4 (-68.0 to -62.9)
Motorcyclist road injuries	-	-	-	-	1.5 (1.1 to 2.0)	1.0 (0.7 to 1.3)	-35.9 (-40.5 to -31.5)	-63.9 (-66.0 to -61.8)
Motor vehicle road injuries	-	-	-	-	4.8 (3.6 to 6.1)	3.8 (3.0 to 4.9)	-39.8 (-26.0 to -13.2)	-56.0 (-58.8 to -53.0)
Other road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-46.3 (-49.7 to -42.4)	-69.4 (-71.1 to -67.6)
Other transport injuries	-	-	-	-	1.2 (0.9 to 1.5)	0.8 (0.6 to 1.1)	-29.3 (-34.8 to -23.6)	-58.4 (-61.6 to -55.1)
Unintentional injuries	-	-	-	-	13.7 (10.5 to 17.7)	16.2 (12.4 to 21.0)	18.0 (13.0 to 23.8)	32.2 (-34.9 to -28.9)
Falls	-	-	-	-	5.4 (4.0 to 7.1)	8.3 (6.3 to 10.9)	53.6 (44.3 to 63.6)	-17.5 (-21.8 to -12.2)
Drowning	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	6.3 (5.0 to 17.7)	-34.2 (-39.7 to -28.8)
Fire, heat, and hot substances	-	-	-	-	1.7 (1.3 to 2.1)	1.8 (1.3 to 2.3)	5.5 (-4.1 to 18.8)	-36.9 (-41.5 to -30.7)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	17.1 (0.5 to 37.7)	-32.1 (-39.5 to -23.2)
Exposure to mechanical forces	-	-	-	-	3.2 (2.4 to 4.2)	3.2 (2.4 to 4.2)	-0.7 (-7.2 to 7.8)	-45.0 (-48.6 to -40.2)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	45.8 (33.6 to 59.3)	-18.7 (-24.8 to -11.2)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	25.7 (11.7 to 39.9)	-29.2 (-36.1 to -21.9)
Other exposure to mechanical forces	-	-	-	-	3.0 (2.3 to 4.0)	3.0 (2.2 to 4.0)	-2.7 (-9.3 to 6.1)	-46.3 (-49.9 to -41.3)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	82.5 (71.4 to 93.0)	7.1 (0.7 to 13.6)
Animal contact	-	-	-	-	0.8 (0.6 to 1.0)	0.7 (0.5 to 1.0)	-5.6 (-12.8 to 1.4)	-44.9 (-48.2 to -41.4)
Venomous animal contact	-	-	-	-	0.3 (0.3 to 0.5)	0.3 (0.3 to 0.5)	-1.1 (-12.6 to 11.7)	-43.8 (-49.4 to -37.5)
Non-venomous animal contact	-	-	-	-	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.5)	-9.4 (-16.8 to -1.2)	-45.9 (-49.3 to -41.9)
Foreign body	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	16.9 (7.4 to 28.7)	-35.9 (-40.7 to -30.0)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	27.5 (10.6 to 47.0)	-14.3 (-22.5 to -6.3)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	50.1 (31.2 to 72.1)	-15.8 (-26.4 to -4.4)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	0.1 (9.5 to 11.1)	-46.4 (-51.7 to -40.9)
Other unintentional injuries	-	-	-	-	2.0 (1.5 to 2.5)	1.4 (1.0 to 1.8)	-31.3 (-37.9 to -23.2)	-60.8 (-64.5 to -56.5)
Self-harm and interpersonal violence	-	-	-	-	1.4 (1.0 to 1.8)	1.3 (1.0 to 1.7)	-4.8 (-11.3 to 1.8)	-45.1 (-48.4 to -41.7)
Self-harm	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	56.1 (43.3 to 71.4)	-14.0 (-20.2 to -6.7)
Interpersonal violence	-	-	-	-	1.3 (1.0 to 1.6)	1.1 (0.9 to 1.4)	-10.7 (-17.2 to -3.8)	-49.1 (-52.4 to -45.6)
Assault by firearm	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-5.1 (-13.3 to 4.8)	-47.1 (-51.3 to -41.6)
Assault by sharp object	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	12.3 (1.7 to 26.7)	-37.6 (-43.6 to -29.6)
Assault by other means	-	-	-	-	0.8 (0.6 to 1.1)	0.7 (0.5 to 0.9)	-17.3 (-24.3 to -10.7)	-52.5 (-56.2 to -49.1)
Forces of nature, war, and legal intervention	-	-	-	-	1.0 (0.4 to 2.3)	198.7 (91.9 to 385.5)	19,759.0 (9,801.6 to 41,132.9)	41,940.2 (20,643.8 to 88,482.4)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.1 (-35.7 to 21.7)	-13.6 (-29.5 to 21.4)
Collective violence and legal intervention	-	-	-	-	1.0 (0.4 to 2.3)	198.7 (91.9 to 385.5)	19,883.7 (9,850.8 to 41,643.3)	42,213.2 (20,697.1 to 89,358.1)

Appendix Table G.4 - Saint Lucia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	13.6 (9.9 to 17.8)	19.3 (14.3 to 25.1)	43.9 (34.8 to 49.0)	43.9 (-10.3 to -1.9)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.8 (1.8 to 4.3)	2.1 (1.4 to 2.9)	-25.8 (-39.6 to -13.6)	-37.4 (-51.3 to -25.4)
HIV/AIDS and tuberculosis	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	116.2 (62.1 to 185.1)	31.9 (-1.3 to 71.9)
Tuberculosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	38.2 (32.2 to 45.3)	-13.4 (-16.8 to -9.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.6 (22.4 to 55.5)	-12.7 (-22.1 to -2.9)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	84.0 (87.4 to 486.6)	34.0 (8.6 to 162.9)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.7 (30.0 to 322.3)	24.3 (-26.3 to 147.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.7 (29.9 to 322.4)	24.3 (26.4 to 147.3)
HIV/AIDS resulting in other diseases	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.8)	206.8 (77.8 to 505.6)	90.9 (11.5 to 267.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	207.0 (86.8 to 499.4)	84.7 (8.6 to 271.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-4.1 (-11.4 to 4.0)	-10.5 (-16.8 to -3.7)
Diarrheal diseases	1.0 (1.0 to 1.1)	1.0 (0.9 to 1.1)	-4.9 (-13.4 to 4.4)	1.1 (-7.5 to 10.9)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	6.0 (-15.6 to 4.9)	1.1 (8.5 to 11.9)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.3 (-67.4 to 9.7)	-27.0 (-71.3 to -3.5)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.8 (-28.3 to 3.0)	-25.3 (-37.1 to -11.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.8 (-28.3 to 3.0)	-25.3 (-37.1 to -10.9)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.9 (-30.9 to 5.8)	-23.5 (-38.5 to -5.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.9 (-31.0 to 5.9)	-23.5 (-38.5 to -5.4)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.8 (-98.7 to 615.6)	-54.2 (-98.9 to 533.0)
Lower respiratory infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	30.2 (-12.4 to 125.9)	-1.1 (-39.7 to 41.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.4 (-15.2 to 135.4)	2.6 (-41.5 to 50.5)
Upper respiratory infections	7.3 (6.5 to 8.0)	8.6 (7.7 to 9.6)	17.8 (3.9 to 37.3)	-4.1 (-15.6 to 11.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	17.6 (3.8 to 37.5)	-3.6 (-15.3 to 12.0)
Otitis media	1.7 (1.6 to 1.8)	1.7 (1.6 to 1.8)	2.4 (-4.1 to 8.5)	-11.7 (-17.2 to -6.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	1.0 (-7.1 to 9.4)	1.0 (-19.4 to -6.0)
Meningitis	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-60.6 (-72.4 to -51.4)	-69.1 (-78.1 to -61.9)
Pneumococcal meningitis	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.1)	-59.2 (-70.6 to -46.8)	-71.2 (-78.9 to -62.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.2 (-75.2 to -42.4)	-67.5 (-80.7 to -56.9)
H influenzae type B meningitis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-68.3 (-80.4 to -48.7)	-75.9 (-84.4 to -60.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.3 (-81.7 to -35.1)	-73.3 (-84.8 to -46.8)
Meningococcal meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-59.8 (-79.9 to -32.4)	-71.3 (-84.4 to -51.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-59.0 (-81.7 to -33.4)	-69.0 (-85.8 to -42.3)
Other meningitis	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-57.6 (-78.7 to -45.0)	-68.4 (-82.8 to -57.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.6 (-81.7 to -37.8)	-64.8 (-85.1 to -51.6)
Encephalitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.6 (-11.8 to 29.0)	-27.3 (-39.2 to -9.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.7 (-6.5 to 43.4)	-18.2 (-33.8 to -0.2)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.1 (-95.6 to 442.6)	-52.6 (-95.3 to 299.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.1 (-95.7 to 456.9)	-52.6 (-95.4 to 305.1)
Whooping cough	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-74.1 (-75.8 to -72.4)	-65.3 (-67.6 to -63.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-74.3 (-80.9 to -65.6)	-65.5 (-74.4 to -54.1)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-77.2 (-87.7 to -58.0)	-82.0 (-90.3 to -67.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-71.1 (-86.7 to -41.7)	-76.2 (-88.7 to -52.7)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	37.5 (11.5 to 69.5)	6.5 (-15.4 to 33.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.3 (8.2 to 138.1)	-1.4 (-34.6 to 43.0)
Neglected tropical diseases and malaria	-	-	-	-	1.1 (0.6 to 2.1)	0.3 (0.2 to 0.4)	-73.7 (-83.3 to -58.2)	-80.0 (-87.6 to -68.1)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.5 (-21.2 to 169.5)	11.1 (-34.8 to 120.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.1 (-18.5 to 176.3)	14.6 (-33.4 to 126.5)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.0 (-25.2 to 107.2)	-8.2 (-45.1 to 52.9)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.7 (-59.2 to 117.8)	-5.0 (-59.5 to 103.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.7 (-59.3 to 118.1)	-5.0 (-59.7 to 105.1)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.3 (-26.6 to 117.4)	-9.1 (-47.3 to 53.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.9 (-25.8 to 120.8)	-8.7 (-47.0 to 61.6)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	1.7 (0.7 to 3.6)	2.5 (1.0 to 5.3)	44.2 (40.2 to 48.7)	0.4 (-1.8 to 3.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.7 (14.1 to 62.1)	1.0 (-13.7 to 16.2)
Cysticercosis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-44.9 (-77.1 to 70.3)	-63.6 (-84.6 to -1.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.7 (-77.5 to 87.4)	-62.5 (-84.5 to 5.6)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.4 (-24.7 to -4.4)	-49.1 (-55.1 to -43.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.3 (-33.8 to 10.4)	-48.8 (-60.5 to -33.8)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.1 (0.0 to 0.1)	0.3 (0.1 to 0.7)	536.6 (535.8 to 537.6)	396.3 (395.6 to 397.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	535.3 (460.9 to 632.1)	399.3 (342.9 to 473.0)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.4 (-27.2 to 57.2)	-20.6 (-42.8 to 15.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.4 (-27.3 to 57.8)	20.6 (-42.8 to 15.9)
Intestinal nematode infections	-	-	-	-	1.0 (0.5 to 1.9)	0.1 (0.1 to 0.3)	-85.8 (-91.3 to -76.0)	-89.6 (-93.8 to -82.0)
Ascariasis	84.5 (71.2 to 98.7)	35.8 (22.2 to 55.7)	-59.4 (-74.4 to -29.3)	-70.0 (-81.1 to -48.5)	0.5 (0.2 to 0.9)	0.0 (0.0 to 0.1)	-94.3 (-97.7 to -83.6)	-95.5 (-98.2 to -86.6)
Trichuriasis	87.9 (75.7 to 101.3)	27.3 (17.4 to 43.3)	-69.9 (-80.6 to -50.3)	-78.0 (-85.8 to -63.5)	0.6 (0.3 to 1.1)	0.0 (0.0 to 0.0)	-98.4 (-99.5 to -93.9)	-98.9 (-99.6 to -95.6)
Hookworm disease	0.1 (0.1 to 0.2)	25.6 (17.5 to 38.0)	27,014.0 (13,980.4 to 52,352.3)	17,855.9 (8,988.6 to 33,731.6)	0.1 (0.0 to 0.0)	0.1 (0.1 to 0.2)	24,867.8 (16,885.8 to 42,190.4)	16,164.3 (11,011.7 to 27,059.1)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	1.9 (1.5 to 2.3)	1.7 (1.6 to 1.8)	-12.5 (-29.7 to 13.6)	-8.7 (-25.8 to 16.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-15.0 (-25.9 to 23.1)	-9.1 (-22.6 to 28.9)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Maternal hemorrhage	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.2 (4.4 to 51.6)	-17.7 (-35.1 to 7.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Maternal sepsis and other maternal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.9 (-37.2 to 16.3)	-48.0 (-63.9 to -31.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Maternal hypertensive disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.9 (-28.5 to -11.8)	-40.8 (-46.2 to -35.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.3 (-53.0 to 34.2)	-41.6 (-63.0 to -1.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.3 (-69.0 to 50.0)	-46.2 (-76.6 to 3.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Neonatal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	69.6 (3.1 to 135.2)	42.8 (-13.0 to 97.2)
Preterm birth complications	0.6 (0.3 to 1.1)	1.5 (0.8 to 3.0)	157.8 (76.5 to 234.4)	106.7 (44.1 to 167.9)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	133.7 (23.3 to 262.5)	92.4 (2.3 to 198.9)
Neonatal encephalopathy due to birth asphyxia and trauma	0.7 (0.2 to 1.8)	0.6 (0.2 to 1.5)	-9.5 (-38.3 to 34.5)	-27.1 (-49.6 to 10.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-7.8 (-49.6 to 63.1)	-20.1 (-56.7 to 42.1)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.5 (21.4 to 54.8)	89.7 (67.4 to 113.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.6 (16.7 to 64.1)	92.6 (60.9 to 126.3)
Hemolytic disease and other neonatal jaundice	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	27.5 (-54.4 to 268.9)	5.7 (-61.7 to 208.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	33.4 (-51.4 to 275.6)	11.5 (-59.5 to 211.7)
Other neonatal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	181.0 (47.9 to 396.6)	136.3 (24.7 to 317.2)
Nutritional deficiencies	-	-	-	-	1.0 (0.7 to 1.5)	0.0 (0.6 to 1.4)	-6.1 (-10.5 to -2.5)	-12.2 (-15.7 to -9.2)
Protein-energy malnutrition	0.4 (0.2 to 0.6)	0.2 (0.1 to 0.4)	-43.9 (-74.8 to 24.2)	-27.7 (-66.9 to 56.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-	-
Iodine deficiency	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-8.2 (-39.6 to 28.8)	-38.6 (-59.7 to -13.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Vitamin A deficiency	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-49.2 (-58.8 to -39.2)	-53.5 (-60.9 to -44.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.1 (-60.6 to -37.8)	-55.8 (-64.0 to -45.3)

Appendix Table G.4 - Saint Lucia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	30.3 (29.9 to 30.8)	31.3 (31.0 to 31.7)	3.4 (1.7 to 5.0)	-11.4 (-12.7 to -10.1)	1.0 (0.6 to 1.4)	0.9 (0.6 to 1.4)	-4.1 (-7.0 to -2.1)	-4.1 (-13.7 to -9.8)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-	-
Sexually transmitted diseases excluding HIV	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-	-
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.5 (35.0 to 88.4)	-11.8 (-27.1 to 1.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Chlamydial infection	3.6 (3.0 to 4.3)	4.8 (4.1 to 5.7)	31.8 (5.1 to 70.8)	-7.0 (-24.6 to 18.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Gonococcal infection	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.7)	35.7 (0.9 to 86.4)	-1.9 (-25.4 to 32.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trichomoniasis	0.9 (0.6 to 1.3)	1.2 (0.9 to 1.7)	36.0 (-19.9 to 120.9)	-11.9 (-45.6 to 38.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Genital herpes	29.9 (28.4 to 31.3)	48.2 (45.8 to 50.6)	61.4 (50.5 to 73.1)	-5.6 (-11.8 to 1.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other sexually transmitted diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	35.2 (14.9 to 54.4)	-24.2 (-35.4 to -11.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hepatitis A	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	3.7 (2.6 to 4.6)	-5.0 (-5.2 to -4.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hepatitis B	6.3 (5.1 to 8.3)	5.0 (4.1 to 6.0)	21.3 (-42.7 to 4.5)	-47.0 (-61.1 to -29.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hepatitis C	2.2 (2.0 to 2.5)	2.7 (2.4 to 3.0)	20.5 (5.4 to 40.7)	-25.2 (-34.4 to -12.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hepatitis E	-	-	17.9 (1.3 to 42.5)	-14.7 (-26.0 to 3.3)	-	-	-	-
Leprosy	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	43.1 (-27.9 to 435.7)	-19.3 (-59.1 to 212.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other infectious diseases	1.3 (1.1 to 1.7)	1.2 (1.2 to 1.3)	-8.6 (-16.7 to 8.7)	-9.5 (-16.5 to 3.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-	-
Non-communicable diseases	-	-	-	-	7.5 (7.5 to 13.1)	12.2 (12.2 to 21.2)	62.2 (57.6 to 68.0)	82.7 (63.2 to 95.5)
Neoplasms	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	129.7 (84.6 to 177.0)	33.5 (6.4 to 61.4)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.1 (1.0 to 89.1)	-20.2 (-41.7 to 9.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Stomach cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	10.1 (-17.2 to 41.7)	-37.1 (-52.9 to -18.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	503.0 (196.9 to 1,059.3)	246.6 (70.1 to 568.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,667.2 (904.5 to 3,474.3)	889.7 (461.4 to 1,936.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	157.0 (45.8 to 369.6)	45.3 (-16.8 to 166.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	146.0 (36.1 to 337.8)	40.8 (-23.3 to 151.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Larynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.9 (-22.8 to 56.8)	-39.1 (-56.5 to -12.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	63.8 (21.3 to 112.3)	-7.3 (-31.5 to 20.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Breast cancer	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	75.2 (26.4 to 150.5)	-8.1 (-34.1 to 30.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-	-
Cervical cancer	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-3.8 (-34.1 to 41.1)	48.0 (-64.8 to -24.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Uterine cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	126.6 (4.2 to 267.0)	25.2 (-42.1 to 104.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Prostate cancer	0.3 (0.2 to 0.4)	1.2 (0.8 to 1.8)	313.7 (181.6 to 529.6)	152.0 (72.4 to 279.8)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	-	-
Colon and rectum cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	106.2 (28.9 to 182.2)	17.4 (-27.7 to 60.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Lip and oral cavity cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	49.1 (5.2 to 110.7)	-16.3 (-41.1 to 18.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.6 (-9.1 to 83.6)	-29.8 (-50.6 to 1.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.3 (-5.9 to 130.2)	-20.8 (-49.6 to 24.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.0 (-66.5 to 69.0)	-67.0 (-81.0 to -3.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	593.6 (417.6 to 809.0)	289.2 (186.6 to 414.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.6 (-12.4 to 72.5)	-24.1 (-51.4 to -2.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	204.0 (113.3 to 317.5)	65.4 (16.4 to 126.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Ovarian cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	402.2 (256.9 to 600.2)	190.1 (102.7 to 306.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	463.1 (37.7 to 1,020.2)	235.0 (-17.5 to 564.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Kidney cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	38.7 (5.6 to 82.5)	-16.9 (-36.8 to 9.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Bladder cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	310.6 (158.7 to 540.1)	127.6 (41.8 to 256.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	340.3 (46.6 to 586.0)	248.0 (15.4 to 416.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Thyroid cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	106.0 (46.6 to 211.9)	16.2 (-17.4 to 73.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	181.6 (114.5 to 270.1)	59.9 (21.3 to 110.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	704.7 (17.0 to 1,257.6)	517.4 (-12.7 to 921.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Non-Hodgkin lymphoma	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	116.7 (59.5 to 195.0)	28.0 (-6.1 to 73.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	132.5 (35.3 to 280.7)	32.3 (-22.1 to 116.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leukemia	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	60.2 (2.3 to 133.1)	23.4 (-13.3 to 76.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neoplasms	0.1 (0.1 to 0.2)	0.3 (0.3 to 0.5)	166.3 (72.0 to 308.0)	84.7 (30.3 to 173.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cardiovascular diseases	-	-	-	-	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	129.0 (88.9 to 172.3)	30.5 (7.7 to 54.7)
Rheumatic heart disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.8 (43.2 to 89.1)	-4.7 (-17.4 to 11.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Ischemic heart disease	1.0 (0.8 to 1.2)	3.0 (2.5 to 3.6)	204.9 (140.0 to 291.9)	76.5 (39.8 to 128.0)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	-	-
Cerebrovascular disease	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	78.8 (48.8 to 116.1)	0.7 (-15.4 to 21.7)
Ischemic stroke	0.3 (0.2 to 0.3)	0.5 (0.4 to 0.5)	80.3 (46.6 to 119.3)	0.9 (-17.4 to 23.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-	-
Hemorrhagic stroke	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	79.0 (29.5 to 139.1)	1.3 (-28.1 to 36.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hypertensive heart disease	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	55.1 (36.0 to 77.8)	-13.4 (-24.8 to -0.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cardiomyopathy and myocarditis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	91.4 (63.2 to 123.3)	10.9 (-6.1 to 30.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Atrial fibrillation and flutter	0.3 (0.3 to 0.4)	0.8 (0.6 to 0.9)	146.1 (81.1 to 228.5)	31.4 (-5.4 to 73.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	-	-
Peripheral vascular disease	3.7 (2.9 to 4.5)	7.1 (5.2 to 8.4)	93.9 (26.7 to 156.9)	2.5 (-32.7 to 37.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.8 (21.2 to 107.2)	-10.7 (-28.9 to 21.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other cardiovascular and circulatory diseases	0.4 (0.2 to 0.8)	0.7 (0.6 to 0.9)	70.4 (-10.1 to 247.0)	3.2 (-48.8 to 97.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-	-
Chronic respiratory diseases	-	-	-	-	0.7 (0.5 to 1.0)	1.2 (0.8 to 1.7)	69.9 (38.8 to 97.8)	3.4 (-14.5 to 21.0)
Chronic obstructive pulmonary disease	5.6 (5.3 to 5.8)	9.8 (9.4 to 10.3)	76.5 (71.7 to 82.3)	-0.0 (-2.9 to 3.1)	0.3 (0.2 to 0.5)	0.7 (0.4 to 0.9)	93.7 (57.5 to 139.7)	10.4 (10.8 to 36.5)

Appendix Table G.4 - Saint Lucia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	-4.0	(-8.1 to -0.2)
Silicosis	0.0	0.0	58.1	-10.7	0.0	0.0	57.9	-10.8
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Coal workers pneumoconiosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Other pneumoconiosis	0.0	0.0	80.3	1.5	0.0	0.0	80.5	1.2
Asthma	8.0	12.0	50.4	0.3	0.3	0.5	50.1	0.6
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	83.5	7.2	0.0	0.0	83.8	6.9
Other chronic respiratory diseases	0.0	0.0	38.4	-20.3	0.0	0.0	37.9	-4.0
Cirrhosis	0.0	0.0	33.1	-22.8	0.0	0.0	34.1	-19.8
Cirrhosis due to hepatitis B	0.0	0.0	24.1	55.8	0.0	0.0	28.3	58.0
Cirrhosis due to hepatitis C	0.0	0.0	105.1	24.9	0.0	0.0	101.6	22.2
Cirrhosis due to alcohol use	0.0	0.0	23.9	-32.0	0.0	0.0	24.5	-31.5
Cirrhosis due to other causes	0.0	0.0	60.2	19.6	0.0	0.0	60.0	21.3
Digestive diseases	0.0	0.0	21.3	-11.5	0.2	0.3	68.4	2.4
Peptic ulcer disease	1.2	1.1	-10.0	-50.3	0.0	0.0	4.3	-42.4
Gastritis and duodenitis	2.8	4.4	57.9	-0.2	0.1	0.2	50.8	-0.3
Appendicitis	0.0	0.0	27.3	-3.6	0.0	0.0	27.0	-3.0
Paralytic ileus and intestinal obstruction	0.0	0.0	42.8	17.2	0.0	0.0	35.5	14.0
Inguinal, femoral, and abdominal hernia	0.4	0.3	-12.4	-51.4	0.0	0.0	-11.8	-50.6
Inflammatory bowel disease	0.1	0.3	114.7	23.7	0.0	0.1	115.1	24.4
Vascular intestinal disorders	0.0	0.0	63.6	-6.0	0.0	0.0	63.6	-6.0
Gallbladder and biliary diseases	0.1	0.1	20.8	-3.2	0.0	0.0	20.1	-3.4
Pancreatitis	0.0	0.0	162.2	51.1	0.0	0.0	161.3	50.5
Other digestive diseases	0.0	0.0	143.5	40.4	0.0	0.0	571.0	308.8
Neurological disorders	0.0	0.0	86.6	0.6	0.9	1.4	65.7	4.5
Alzheimer disease and other dementias	1.0	1.8	86.6	0.6	0.1	0.3	91.3	1.0
Parkinson disease	0.0	0.0	69.0	-1.5	0.0	0.0	69.2	-0.9
Epilepsy	0.3	0.5	60.2	19.9	0.1	0.2	63.9	24.1
Multiple sclerosis	0.0	0.0	238.3	85.8	0.0	0.0	225.8	80.1
Migraine	13.0	19.0	46.2	4.4	0.6	0.6	46.6	-3.8
Tension-type headache	26.2	40.9	55.8	2.2	0.0	0.1	55.9	2.9
Medication overuse headache	0.6	1.3	125.4	34.0	0.1	0.2	126.5	35.0
Other neurological disorders	0.0	0.0	37.0	-3.0	0.0	0.0	30.9	-30.7
Mental and substance use disorders	0.0	0.0	102.9	-29.4	3.1	4.6	50.0	0.1
Schizophrenia	0.3	0.6	75.4	-0.5	0.2	0.4	76.1	0.2
Alcohol use disorders	0.8	1.2	66.2	3.9	0.1	0.1	67.8	4.7
Drug use disorders	0.0	0.0	58.0	-0.7	0.2	0.3	48.5	-0.8
Opioid use disorders	0.1	0.2	94.7	4.0	0.0	0.1	96.0	4.8
Cocaine use disorders	0.2	0.3	55.8	-4.4	0.0	0.0	56.6	-1.0
Amphetamine use disorders	0.3	0.3	22.4	-5.5	0.0	0.0	22.4	-5.2
Cannabis use disorders	0.4	0.5	28.9	0.2	0.0	0.0	29.4	0.6
Other drug use disorders	0.0	0.0	26.9	0.1	0.1	0.1	38.3	-2.9
Depressive disorders	5.0	7.6	52.3	0.4	1.0	1.5	52.2	1.1
Major depressive disorder	1.5	2.6	70.1	0.1	0.2	0.2	70.6	0.5
Dysthymia	0.9	1.5	56.9	-0.8	0.2	0.3	57.2	-0.3
Bipolar disorder	0.6	0.8	66.7	0.1	0.1	0.1	67.8	4.7
Anxiety disorders	0.9	1.5	56.9	-0.8	0.2	0.3	57.2	-0.3
Eating disorders	0.0	0.0	28.6	5.3	0.0	0.0	29.9	6.8
Anorexia nervosa	0.0	0.0	15.0	-5.3	0.0	0.0	15.0	-5.3
Bulimia nervosa	0.2	0.2	25.5	-0.3	0.0	0.0	26.1	0.3
Autistic spectrum disorders	0.4	0.5	29.9	0.1	0.1	0.1	29.8	0.8
Autism	0.4	0.5	29.9	0.1	0.1	0.1	29.8	0.8
Asperger syndrome	0.6	0.8	66.7	0.1	0.1	0.1	67.8	4.7
Attention-deficit/hyperactivity disorder	1.2	1.2	0.0	0.4	0.0	0.0	1.1	0.9
Conduct disorder	1.6	1.6	0.0	0.2	0.2	0.2	1.7	7.3
Idiopathic intellectual disability	0.5	0.5	14.2	-11.5	0.0	0.0	14.6	-10.7
Other mental and substance use disorders	1.9	3.2	67.0	0.1	0.1	0.2	67.3	0.7
Diabetes, urogenital, blood, and endocrine diseases	1.8	3.0	64.1	-0.0	1.0	1.9	83.2	14.0
Diabetes mellitus	6.1	14.1	129.6	30.4	0.4	1.0	133.7	29.2
Acute glomerulonephritis	0.0	0.0	14.8	6.6	0.0	0.0	14.8	6.6
Chronic kidney disease	3.4	6.0	77.3	0.7	0.2	0.3	57.5	1.4
Chronic kidney disease due to diabetes mellitus	2.1	3.2	53.0	9.5	0.1	0.1	58.3	0.4
Chronic kidney disease due to hypertension	1.3	2.8	59.5	-13.9	0.0	0.0	49.9	-20.9
Chronic kidney disease due to glomerulonephritis	0.0	0.0	17.7	-25.8	0.0	0.0	19.2	-8.2
Chronic kidney disease due to other causes	0.0	0.0	44.5	-0.5	0.1	0.1	48.7	1.2
Urinary diseases and male infertility	0.0	0.0	15.1	-19.6	0.0	0.1	64.4	-0.6

Appendix Table G.4 - Saint Lucia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	92.9 (75.4 to 116.9)	31.0 (19.8 to 46.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.6 (56.5 to 137.6)	31.8 (8.3 to 60.0)
Urolithiasis	0.9 (0.7 to 1.3)	1.9 (1.2 to 3.0)	107.7 (61.6 to 189.5)	16.4 (-10.9 to 58.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.6 (55.9 to 157.9)	9.3 (-13.0 to 44.6)
Benign prostatic hyperplasia	0.9 (0.8 to 1.0)	1.5 (1.4 to 1.7)	64.9 (43.0 to 88.5)	0.3 (-12.6 to 13.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	65.2 (42.6 to 88.7)	0.7 (-12.6 to 14.1)
Male infertility due to other causes	0.9 (0.7 to 1.1)	1.4 (1.1 to 1.8)	53.8 (13.3 to 121.7)	-1.4 (-27.3 to 40.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.3 (10.8 to 122.4)	-0.1 (-27.3 to 44.1)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.7 (-12.2 to 83.1)	30.4 (-49.5 to 5.0)
Gynecological diseases	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	67.6 (49.7 to 88.7)	-0.5 (-10.6 to 12.1)
Uterine fibroids	2.1 (1.9 to 2.3)	4.5 (4.1 to 4.8)	112.7 (109.3 to 116.4)	0.5 (0.4 to 0.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	76.1 (58.8 to 94.7)	-8.2 (-16.7 to 0.7)
Polycystic ovarian syndrome	2.3 (2.0 to 2.6)	4.0 (3.5 to 4.4)	73.1 (47.4 to 107.5)	2.1 (-12.8 to 19.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	73.5 (46.2 to 107.6)	2.8 (-12.5 to 21.0)
Female infertility due to other causes	0.8 (0.5 to 1.3)	1.5 (0.8 to 2.3)	78.4 (-9.5 to 247.8)	7.3 (-45.0 to 104.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.9 (-9.9 to 245.6)	7.9 (-43.8 to 112.4)
Endometriosis	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.5)	86.5 (48.5 to 136.4)	7.1 (-14.5 to 34.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	86.9 (47.0 to 136.0)	7.4 (-14.8 to 35.5)
Genital prolapse	6.3 (5.3 to 7.5)	11.7 (10.0 to 13.5)	84.8 (50.3 to 133.9)	1.3 (-16.5 to 26.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	85.1 (51.0 to 135.6)	1.5 (-16.6 to 27.6)
Premenstrual syndrome	5.7 (4.4 to 6.9)	8.7 (6.5 to 11.0)	50.4 (7.5 to 113.6)	0.5 (-29.2 to 45.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	51.5 (7.7 to 113.9)	1.6 (-29.2 to 46.9)
Other gynecological diseases	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.6)	34.6 (8.8 to 76.5)	-13.4 (-29.8 to 12.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.6 (-2.3 to 114.4)	-14.9 (-36.2 to 41.5)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	11.4 (5.0 to 19.7)	-1.8 (-7.6 to 5.3)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.0 (-28.2 to -2.7)	-0.6 (-22.2 to 5.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.8 (-25.3 to -9.0)	-11.8 (-17.7 to -1.0)
Thalassemia trait	1.1 (1.0 to 1.3)	1.5 (1.2 to 1.7)	29.6 (13.8 to 34.5)	-0.4 (-12.6 to 3.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.4 (9.5 to 39.5)	3.4 (-8.4 to 16.6)
Sickle cell disorders	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.2)	19.4 (8.6 to 38.1)	1.9 (-7.3 to 15.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.2 (15.6 to 54.7)	5.6 (-7.6 to 20.5)
Sickle cell trait	12.1 (10.9 to 13.2)	15.7 (14.0 to 17.2)	29.6 (24.6 to 35.0)	0.6 (-4.5 to 3.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	12.6 (-0.5 to 30.2)	1.3 (-10.7 to 18.3)
G6PD deficiency	7.4 (5.8 to 9.1)	9.9 (7.6 to 12.0)	33.5 (-1.4 to 82.5)	2.6 (-24.2 to 40.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.4 (-9.2 to 64.5)	0.7 (-21.9 to 28.1)
G6PD trait	22.8 (21.3 to 24.1)	30.1 (27.5 to 32.0)	32.2 (18.8 to 44.3)	0.8 (-9.4 to 10.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.2 (-73.6 to 490.3)	2.0 (-74.6 to 345.7)
Other hemoglobinopathies and hemolytic anemias	1.3 (1.2 to 1.4)	1.4 (1.3 to 1.5)	7.4 (-1.9 to 18.8)	-12.2 (-19.5 to -4.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-9.8 (-21.6 to 7.6)	-15.3 (-25.6 to 0.2)
Endocrine, metabolic, blood, and immune disorders	1.4 (1.2 to 1.5)	5.7 (1.3 to 1.6)	5.7 (-4.8 to 20.7)	5.7 (-17.5 to 3.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	2.5 (-16.1 to 18.4)	-7.4 (-20.6 to 12.4)
Musculoskeletal disorders	-	-	-	-	1.6 (1.1 to 2.1)	2.9 (2.1 to 3.8)	79.8 (65.2 to 95.1)	2.9 (-5.1 to 11.4)
Rheumatoid arthritis	0.3 (0.3 to 0.3)	0.7 (0.6 to 0.7)	121.9 (108.0 to 136.4)	34.2 (25.0 to 43.5)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	119.9 (101.6 to 138.6)	33.9 (22.6 to 45.4)
Osteoarthritis	4.3 (4.1 to 4.5)	8.1 (7.8 to 8.5)	89.3 (79.0 to 100.5)	1.6 (-4.0 to 7.7)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	90.0 (79.2 to 101.8)	2.0 (-3.8 to 8.4)
Low back and neck pain	-	-	-	-	1.0 (0.7 to 1.3)	1.6 (1.1 to 2.2)	67.2 (45.8 to 91.0)	1.6 (-13.6 to 13.7)
Low back pain	5.5 (4.9 to 6.0)	8.9 (8.0 to 10.1)	64.4 (39.0 to 90.6)	-2.0 (-16.8 to 13.3)	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.4)	64.5 (39.0 to 91.1)	-1.6 (-16.9 to 14.2)
Neck pain	3.8 (3.3 to 4.3)	6.6 (5.5 to 7.6)	69.6 (35.5 to 116.4)	-2.2 (-21.2 to 24.2)	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.9)	70.5 (36.2 to 117.0)	-1.6 (-21.0 to 24.9)
Gout	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	76.2 (56.6 to 96.4)	-3.9 (-14.8 to 7.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.8 (39.9 to 126.6)	-3.4 (-24.0 to 23.4)
Other musculoskeletal disorders	3.2 (2.6 to 3.7)	6.4 (5.3 to 7.7)	102.1 (85.5 to 120.6)	10.1 (1.9 to 18.3)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	104.4 (86.1 to 122.8)	10.4 (1.7 to 19.2)
Other non-communicable diseases	-	-	-	-	2.3 (1.5 to 3.3)	3.4 (2.3 to 4.9)	49.0 (43.6 to 54.6)	-4.5 (-7.8 to -1.3)
Congenital anomalies	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	63.9 (42.9 to 90.0)	27.4 (10.8 to 47.9)
Neural tube defects	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	30.8 (9.8 to 62.0)	13.6 (-4.5 to 40.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.0 (-0.2 to 85.8)	17.1 (-17.1 to 64.0)
Congenital heart anomalies	0.6 (0.4 to 0.7)	1.0 (0.9 to 1.2)	73.1 (38.6 to 140.2)	42.7 (14.0 to 98.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	74.3 (38.8 to 137.1)	45.8 (15.9 to 98.5)
Orofacial clefts	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	52.4 (19.8 to 114.1)	33.4 (4.8 to 86.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.7 (-11.0 to 94.0)	13.7 (-22.0 to 70.8)
Down syndrome	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	51.7 (19.8 to 91.7)	17.1 (-7.7 to 48.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.6 (28.3 to 112.9)	21.9 (-6.1 to 56.6)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.9 (9.7 to 86.7)	8.9 (-12.8 to 49.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.6 (6.2 to 98.6)	8.3 (-18.0 to 53.9)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.8 (-18.4 to 64.8)	-2.0 (-36.3 to 28.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.7 (-8.7 to 86.5)	-2.2 (-36.9 to 28.1)
Chromosomal unbalanced rearrangements	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.4)	46.9 (16.9 to 102.0)	53.7 (-9.9 to 56.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	58.4 (29.4 to 122.7)	23.7 (-4.6 to 63.9)
Other congenital anomalies	0.6 (0.5 to 0.7)	0.7 (0.6 to 0.8)	19.2 (9.8 to 31.3)	-12.2 (-19.2 to -4.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	65.5 (32.8 to 114.6)	26.9 (2.6 to 65.5)
Skin and subcutaneous diseases	-	-	-	-	0.7 (0.5 to 1.1)	1.0 (0.6 to 1.5)	36.4 (26.5 to 49.4)	-0.7 (-7.5 to 8.1)
Dermatitis	6.2 (5.1 to 7.4)	9.2 (7.4 to 11.0)	47.2 (40.8 to 53.0)	-0.0 (-0.1 to 0.0)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	40.0 (33.3 to 46.3)	0.6 (-2.1 to 3.3)
Psoriasis	1.1 (0.9 to 1.2)	1.6 (1.4 to 1.9)	55.7 (15.9 to 60.6)	0.0 (-0.0 to 0.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	55.8 (46.6 to 66.1)	0.7 (-4.0 to 5.7)
Cellulitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.5 (2.8 to 36.6)	-14.7 (-23.0 to -5.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.5 (8.0 to 45.9)	-14.7 (-29.9 to 2.1)
Pyoderma	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	59.4 (44.6 to 71.6)	22.5 (17.1 to 28.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.4 (36.8 to 82.6)	22.9 (8.1 to 38.8)
Scabies	1.8 (1.5 to 2.1)	2.2 (1.9 to 2.6)	23.0 (0.4 to 56.0)	-0.9 (-18.8 to 25.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	22.9 (-0.2 to 54.7)	-0.7 (-19.1 to 25.3)
Fungal skin diseases	9.9 (7.6 to 13.0)	14.5 (11.3 to 19.0)	46.9 (36.5 to 56.8)	0.1 (-0.0 to 0.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	46.8 (36.4 to 57.1)	0.4 (-0.5 to 1.3)
Viral skin diseases	3.1 (2.3 to 3.8)	3.4 (2.5 to 4.3)	9.9 (2.0 to 18.0)	0.1 (-2.2 to 2.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	10.1 (1.8 to 18.8)	0.5 (-3.1 to 4.5)
Acne vulgaris	10.0 (7.4 to 13.0)	12.0 (8.5 to 16.9)	18.7 (-23.9 to 87.8)	0.7 (-35.2 to 58.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	19.3 (-23.7 to 87.9)	1.5 (-35.2 to 58.7)
Alopecia areata	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	50.2 (34.1 to 70.1)	0.1 (-10.8 to 14.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.2 (27.6 to 75.4)	0.6 (-14.4 to 17.4)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.9 (20.1 to 93.0)	0.2 (-22.5 to 27.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.9 (20.0 to 93.9)	3.2 (-22.5 to 27.6)
Urticaria	1.5 (1.1 to 1.9)	2.2 (1.6 to 2.9)	46.2 (6.1 to 128.2)	-5.4 (-39.4 to 45.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	45.2 (-6.8 to 131.2)	-5.4 (-39.7 to 49.4)
Decubitus ulcer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.9 (0.1 to 99.3)	-20.6 (-46.3 to 10.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.2 (-3.4 to 104.5)	-21.0 (-47.6 to 15.2)
Other skin and subcutaneous diseases	8.0 (5.0 to 12.6)	13.0 (8.1 to 20.8)	63.6 (48.7 to 79.7)	-1.5 (-5.6 to 2.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	63.5 (48.2 to 79.8)	-1.1 (-5.7 to 3.3)
Sense organ diseases	-	-	-	-	1.0 (0.7 to 1.4)	1.5 (1.0 to 2.1)	50.2 (41.8 to 57.0)	-10.2 (-14.1 to -6.6)
Glaucoma	0.2 (0.2 to 0.2)	0.3 (0.2 to 0.3)	42.8 (24.0 to 66.3)	-21.4 (-31.3 to -8.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.0 (24.1 to 75.8)	-19.6 (-33.1 to -3.5)
Cataract	1.1 (0.8 to 1.3)	1.4 (1.1 to 1.7)	28.7 (16.4 to 45.1)	-28.7 (-35.1 to -20.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	32.9 (19.9 to 48.7)	-27.5 (-34.1 to -21.1)
Macular degeneration	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	108.3 (62.2 to 163.4)	12.4 (-10.8 to 40.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.8 (60.5 to 157.5)	10.6 (-12.6 to 37.4)
Uncorrected refractive error	12.8 (11.9 to 13.5)	20.4 (19.2 to 21.7)	59.3 (47.1 to 74.0)	4.8 (-12.0 to 31.1)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	47.2 (38.0 to 59.9)	-10.2 (-15.3 to -3.5)
Age-related and other hearing loss	19.3 (18.2 to 20.4)	30.5 (28.7 to 32.5)	58.0 (52.8 to 64.8)	-9.3 (-12.1 to -5.8)	0.6 (0.4 to 0.8)	0.9 (0.6 to 1.3)	57.4 (45.1 to 68.9)	-8.6 (-14.3 to -2.8)
Other vision loss	0.4 (0.4 to 0.5)	0.4 (0.4 to 0.5)	5.1 (-39.3 to -27.5)	-33.8 (-39.3 to -27.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.1 (1.0 to 27.9)	-31.6 (-38.0 to -24.2)
Other sense organ diseases	3.3 (3.2 to 3.5)	4.1 (3.9 to 4.3)	24.3 (16.7 to 33.2)	-0.6 (-6.8 to 6.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	23.7 (14.4 to 33.4)	0.0 (-7.2 to 7.7)
Oral disorders	-	-	-	-	0.4 (0.3 to 0.7)	0.7 (0.4 to 1.1)	61.4 (56.5 to 66.5)	-3.8 (-6.8 to -0.9)
Deciduous caries	11.7 (11.1 to 12.3)	9.5 (9.0 to 10.0)	-18.5 (-24.2 to -13.6)	-0.2 (-7.1 to 5.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.4 (-8.9 to 8.3)	-0.1 (-8.9 to 8.3)
Permanent caries	59.6 (57.0 to 62.2)	82.7 (79.6 to 86.0)	38.7 (30.8 to 47.0)	-0.1 (-5.7 to 5.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	38.8 (30.4 to 47.5)	0.3 (-5.4 to 6.2)
Periodontal diseases	13.1 (12.6 to 13.7)	23.3 (22.1 to 24.4)	77.1 (65.4 to 90.1)	-2.5 (-8.9 to 4.7)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	77.5 (65.7 to 90.7)	-2.2 (-7.7 to 5.2)

Appendix Table G.4 - Saint Lucia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	8.4 (8.1 to 8.7)	13.9 (13.4 to 14.3)	65.1 (58.0 to 72.5)	-6.4 (-10.4 to -2.2)	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	65.2 (57.9 to 73.2)	-6.2 (-10.4 to -1.8)
Other oral disorders	2.2 (2.1 to 2.3)	3.3 (3.1 to 3.5)	51.2 (39.3 to 64.3)	-0.3 (-8.2 to 7.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	51.3 (38.6 to 64.9)	0.1 (-8.1 to 8.7)
Injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.9 (0.6 to 1.2)	24.4 (12.5 to 38.4)	-26.4 (-33.4 to -18.4)
Transport injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	22.0 (7.2 to 39.0)	-28.6 (-37.2 to -18.9)
Road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	17.9 (3.1 to 34.5)	-31.0 (-39.5 to -21.4)
Pedestrian road injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	3.6 (-11.0 to 20.2)	-38.0 (-46.6 to -28.6)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.0 (16.0 to 44.2)	-23.9 (-31.8 to -15.0)
Motorcyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.0 (-2.9 to 28.6)	-35.6 (-44.1 to -26.2)
Motor vehicle road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	26.0 (9.2 to 45.4)	-26.8 (-36.2 to -15.7)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.5 (-6.8 to 21.4)	-38.5 (-45.9 to -30.0)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.6 (62.4 to 108.1)	5.1 (-6.4 to 19.5)
Unintentional injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	24.1 (13.3 to 34.7)	-26.3 (-32.4 to -19.9)
Falls	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	27.3 (12.2 to 43.8)	-28.4 (-36.9 to -19.2)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.6 (-16.1 to 13.2)	-40.4 (-48.3 to -31.3)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.2 (-21.2 to 2.4)	-43.7 (-49.9 to -35.8)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.6 (-18.3 to 14.9)	-34.0 (-44.1 to -22.7)
Exposure to mechanical forces	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	4.2 (-4.5 to 12.8)	-33.0 (-37.7 to -28.0)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.3 (61.6 to 112.3)	11.2 (-1.7 to 27.1)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.4 (38.0 to 80.2)	-1.5 (-12.9 to 11.1)
Other exposure to mechanical forces	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-1.8 (-9.8 to 6.2)	-36.6 (-41.0 to -31.9)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.3 (91.1 to 113.6)	20.4 (13.6 to 27.1)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.3 (67.8 to 105.3)	15.1 (4.8 to 26.1)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.2 (65.3 to 111.8)	18.3 (4.7 to 31.7)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.0 (64.1 to 104.6)	13.4 (2.9 to 24.9)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.7 (12.9 to 38.3)	-23.6 (-30.5 to -15.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.8 (-17.9 to 15.2)	-38.3 (-47.0 to -27.6)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.1 (18.3 to 51.9)	-9.2 (-19.2 to 3.1)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.3 (25.4 to 56.2)	-17.5 (-25.0 to -9.3)
Other unintentional injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	86.3 (70.8 to 101.2)	3.3 (-5.0 to 11.3)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	25.4 (16.6 to 43.5)	47.0 (-35.6 to -16.9)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.3 (-3.5 to 22.2)	-39.1 (-45.5 to -31.4)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.6 (13.1 to 49.9)	-24.0 (-33.5 to -12.8)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.5 (61.7 to 100.1)	3.9 (-6.1 to 15.5)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.3 (19.0 to 61.5)	-20.1 (-30.8 to -6.9)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.7 (-13.8 to 19.1)	-40.4 (-49.0 to -29.7)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	323.4 (136.3 to 829.5)	373.4 (163.5 to 946.7)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	323.4 (136.3 to 829.5)	373.4 (163.5 to 946.7)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Saint Vincent and the Grenadines prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	9.5 (7.0 to 12.5)	11.2 (8.4 to 14.5)	17.5 (14.1 to 20.6)	17.5 (2.3 to 2.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.5 (1.0 to 2.1)	1.2 (0.9 to 1.7)	-16.5 (-24.9 to -8.4)	-5.9 (-16.0 to 3.2)
HIV/AIDS and tuberculosis	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	85.2 (33.6 to 208.9)	48.2 (6.5 to 144.6)
Tuberculosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	10.1 (5.6 to 15.2)	-9.7 (-13.0 to -5.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.5 (-1.1 to 21.9)	-9.9 (-19.2 to -0.2)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	102.6 (49.0 to 666.5)	108.3 (15.8 to 525.9)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.3 (18.7 to 530.4)	57.4 (-13.7 to 379.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.3 (18.6 to 533.2)	57.4 (-13.8 to 383.2)
HIV/AIDS resulting in other diseases	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	136.1 (37.1 to 592.4)	96.7 (15.0 to 471.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	163.6 (48.5 to 724.5)	109.0 (15.3 to 585.5)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.3 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-23.4 (-28.5 to -16.8)	-12.4 (-17.8 to -5.7)
Diarrheal diseases	0.8 (0.7 to 0.8)	0.6 (0.6 to 0.6)	-20.8 (-28.1 to -12.0)	-0.4 (-9.1 to 10.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-21.6 (-29.3 to -12.1)	-4.9 (-10.1 to 10.7)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.4 (-86.0 to -22.9)	-35.7 (-84.5 to -14.8)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.5 (-49.0 to -25.3)	-32.1 (-43.2 to -17.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.5 (-49.0 to -25.3)	-32.1 (-43.3 to -17.6)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.9 (-50.8 to -22.8)	-31.4 (-44.1 to -13.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.9 (-50.8 to -22.8)	-31.4 (-44.2 to -13.9)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.6 (-99.3 to 138.2)	-43.9 (-99.3 to 160.4)
Lower respiratory infections	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-40.2 (-53.0 to -18.2)	-36.3 (-48.3 to -12.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.4 (-55.5 to -14.7)	-35.7 (-50.6 to -9.1)
Upper respiratory infections	5.6 (5.0 to 6.2)	5.2 (4.8 to 5.8)	-6.6 (-18.5 to 7.8)	-3.6 (-15.0 to 11.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-6.8 (-19.1 to 7.2)	-3.5 (-15.5 to 11.6)
Otitis media	1.3 (1.2 to 1.4)	1.0 (1.0 to 1.1)	-19.2 (-25.4 to -12.7)	-12.1 (-18.4 to -5.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.0 (-27.8 to -13.6)	-13.3 (-20.3 to -5.9)
Meningitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.6 (-76.0 to -62.8)	-70.3 (-75.3 to -62.6)
Pneumococcal meningitis	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-72.7 (-78.3 to -66.1)	-74.9 (-79.6 to -69.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-71.7 (-79.2 to -62.6)	-72.0 (-79.4 to -63.6)
H influenzae type B meningitis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-76.5 (-84.7 to -66.5)	-77.0 (-84.5 to -67.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-74.3 (-84.6 to -56.3)	-72.9 (-83.4 to -55.2)
Meningococcal meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-72.1 (-80.6 to -59.1)	-74.0 (-82.3 to -61.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.6 (-79.5 to -51.6)	-71.4 (-79.6 to -53.3)
Other meningitis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-69.8 (-76.3 to -57.8)	-71.2 (-76.9 to -58.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-64.8 (-74.3 to -46.6)	-64.4 (-73.7 to -46.3)
Encephalitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.3 (-38.5 to -6.8)	-22.4 (-46.4 to -18.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.8 (-33.2 to 3.8)	-26.3 (-40.5 to -9.8)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.8 (-96.2 to 554.3)	-40.5 (-95.4 to 590.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.8 (-96.2 to 562.4)	-40.5 (-95.4 to 606.0)
Whooping cough	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.8 (-13.2 to -10.3)	28.4 (26.4 to 30.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.9 (-41.5 to 35.7)	28.2 (-14.5 to 96.6)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.7 (-94.2 to -75.4)	-88.7 (-94.2 to -75.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-86.7 (-94.3 to -74.4)	-86.2 (-93.8 to -73.9)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to 0.0)	-100.0 (-100.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to nan)	-100.0 (-100.0 to nan)
Varicella and herpes zoster	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-11.1 (-22.3 to 5.1)	-2.4 (-17.5 to 19.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.3 (-11.2 to 68.7)	-4.5 (-29.4 to 39.3)
Neglected tropical diseases and malaria	-	-	-	-	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.2)	-28.9 (-57.2 to 16.4)	-19.3 (-55.0 to 31.5)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.8 (-58.9 to 85.0)	-6.5 (-56.3 to 93.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.8 (-58.9 to 80.7)	-6.4 (-56.2 to 88.4)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.4 (-53.9 to 99.7)	-7.3 (-56.7 to 91.8)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.6 (-63.8 to 76.8)	-10.8 (-53.0 to 100.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.6 (-64.0 to 76.9)	-10.8 (-53.3 to 102.0)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.2 (-52.4 to 118.7)	-8.6 (-56.4 to 103.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.6 (-55.7 to 117.8)	-7.3 (-58.7 to 106.7)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	80.4 (-62.8 to 378.7)	16.2 (-71.5 to 195.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.5 (-63.7 to 451.4)	22.4 (-71.8 to 237.0)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.5 (-37.3 to -16.8)	-42.5 (-51.2 to -36.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.4 (-44.0 to -4.3)	-42.6 (-55.7 to -26.6)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.3)	397.5 (395.2 to 400.2)	400.4 (398.1 to 403.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	394.6 (320.4 to 493.5)	399.6 (335.4 to 487.6)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.2 (-59.9 to -18.2)	-49.9 (-63.2 to -25.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.2 (-59.9 to -18.0)	-49.9 (-63.3 to -25.0)
Intestinal nematode infections	-	-	-	-	0.1 (0.1 to 0.3)	0.1 (0.0 to 0.1)	-45.9 (-73.1 to 15.8)	-40.7 (-72.7 to 24.7)
Ascariasis	24.9 (17.8 to 34.1)	12.2 (7.7 to 19.4)	-51.8 (-72.7 to -14.5)	-53.3 (-73.4 to -15.5)	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-93.0 (-98.2 to -83.7)	-93.7 (-97.8 to -79.5)
Trichuriasis	36.4 (27.0 to 49.8)	5.3 (3.2 to 8.5)	-85.9 (-92.1 to -74.8)	-86.7 (-92.6 to -75.8)	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-99.8 (-100.0 to -99.2)	-99.8 (-100.0 to -99.2)
Hookworm disease	0.9 (0.6 to 1.3)	16.0 (10.7 to 23.1)	1781.4 (993.8 to 3,132.3)	1,694.0 (887.5 to 3,105.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	4,551.4 (2,252.6 to 9,805.9)	4,536.6 (2,365.3 to 10,011.9)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	1.5 (1.1 to 1.9)	1.0 (1.0 to 1.1)	-32.0 (-45.2 to -10.7)	-12.8 (-28.6 to 11.4)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-36.3 (-44.0 to -5.4)	-11.9 (-22.0 to 30.5)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.8 (-41.7 to -13.8)	-31.7 (-43.7 to -17.8)
Maternal hemorrhage	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.0 (-2.1 to 31.8)	-4.0 (-16.2 to 12.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.5 (-10.5 to 29.7)	5.4 (-23.1 to 10.5)
Maternal sepsis and other maternal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.8 (-41.5 to -1.4)	-40.6 (-56.3 to -26.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.7 (-51.1 to -16.7)	-43.6 (-56.4 to -27.7)
Maternal hypertensive disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.5 (-38.0 to -25.9)	-34.3 (-39.4 to -28.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.3 (-51.1 to -9.7)	-34.2 (-52.5 to -11.8)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.0 (-62.1 to -3.7)	-37.7 (-60.5 to -4.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.0 (-62.2 to -3.3)	-37.7 (-60.6 to -4.6)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.6 (-70.5 to 42.1)	-36.5 (-71.1 to 26.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.6 (-70.7 to 42.5)	-36.5 (-71.1 to 26.3)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.4 (-54.0 to 14.3)	-29.1 (-56.1 to 10.4)
Neonatal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	82.6 (20.3 to 172.7)	94.3 (27.7 to 187.8)
Preterm birth complications	0.4 (0.2 to 0.8)	1.0 (0.5 to 1.8)	128.1 (64.5 to 208.2)	131.2 (69.7 to 212.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	118.6 (26.7 to 275.2)	128.9 (32.1 to 292.2)
Neonatal encephalopathy due to birth asphyxia and trauma	0.5 (0.2 to 1.4)	0.5 (0.2 to 1.2)	-12.7 (-35.4 to 36.4)	-11.2 (-35.0 to 41.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	8.3 (-33.8 to 152.5)	17.9 (-27.6 to 174.0)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	144.1 (80.3 to 202.9)	263.7 (168.5 to 351.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	143.7 (78.6 to 229.0)	263.0 (166.0 to 390.1)
Hemolytic disease and other neonatal jaundice	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	34.2 (-44.4 to 265.4)	40.7 (-41.4 to 287.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	31.6 (-44.3 to 263.6)	38.9 (-41.6 to 283.4)
Other neonatal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14,658.2 (33.7 to 32,523.7)	15,566.3 (40.8 to 34,553.8)
Nutritional deficiencies	-	-	-	-	0.8 (0.5 to 1.2)	0.6 (0.4 to 0.8)	-30.1 (-32.7 to -28.1)	-18.5 (-21.4 to -16.5)
Protein-energy malnutrition	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.1)	-53.5 (-78.1 to 7.9)	-35.7 (-68.6 to 44.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.6 (-78.5 to 11.0)	-35.3 (-69.2 to 45.1)
Iodine deficiency	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-29.2 (-53.4 to 1.6)	-39.0 (-59.0 to -11.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.3 (-53.9 to 2.2)	-38.6 (-60.1 to -10.8)
Vitamin A deficiency	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-59.7 (-67.4 to -51.9)	-53.8 (-61.7 to -44.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-60.5 (-68.4 to -51.8)	-55.8 (-63.7 to -45.9)

Appendix Table G.4 - Saint Vincent and the Grenadines prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	24.3 (23.9 to 24.7)	18.8 (18.6 to 19.0)	-22.6 (-24.1 to -21.1)	-16.8 (-18.3 to -15.2)	0.8 (0.5 to 1.2)	0.6 (0.4 to 0.8)	-29.5 (-31.9 to -27.9)	-18.0 (-20.6 to -15.5)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-74.6 to 793.0)	199.1 (62.9 to 1,084.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-16.1 (-23.3 to -3.6)	-8.6 (-15.4 to 0.8)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.1 (7.1 to 23.4)	-7.6 (-18.0 to 5.3)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.6 (3.3 to 49.3)	-14.5 (-27.4 to 1.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-12.6 to 73.5)	-34.0 (-38.2 to -20.8)
Chlamydial infection	2.9 (2.4 to 3.4)	2.9 (2.4 to 3.5)	-1.0 (-22.6 to 30.8)	-9.4 (-27.8 to 18.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.8 (-15.3 to 28.5)	-4.6 (-22.2 to 15.9)
Gonococcal infection	0.3 (0.3 to 0.4)	0.3 (0.2 to 0.4)	2.9 (-27.6 to 40.3)	-2.1 (-30.8 to 32.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.0 (-46.0 to 25.2)	-19.3 (-47.6 to 15.7)
Trichomoniasis	0.7 (0.4 to 1.0)	0.7 (0.5 to 1.0)	8.6 (-46.4 to 93.4)	-11.9 (-51.0 to 50.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.1 (-52.7 to 105.7)	-14.0 (-57.1 to 59.3)
Genital herpes	22.3 (21.2 to 23.3)	27.9 (2.2 to 3.4)	25.3 (16.9 to 34.1)	-6.2 (-12.3 to 0.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (8.7 to 31.3)	-4.0 (-13.2 to 1.5)
Other sexually transmitted diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-12.7 to 72.3)	20.4 (-28.6 to 34.2)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.0 (-33.0 to -7.5)	-29.3 (-40.2 to -13.3)
Hepatitis A	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-23.2 (-23.8 to -22.6)	-9.5 (-9.8 to -9.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.6 (-20.5 to 0.7)	-4.4 (-14.4 to 6.7)
Hepatitis B	5.0 (4.0 to 6.0)	2.8 (2.2 to 3.4)	-44.3 (-58.8 to -21.5)	-51.5 (-63.6 to -32.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.6 (-53.9 to -6.9)	-51.8 (-66.5 to -25.8)
Hepatitis C	1.6 (1.5 to 1.8)	1.5 (1.3 to 1.6)	-10.3 (-22.5 to 4.1)	-28.7 (-38.3 to -18.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.6 (-41.5 to 11.3)	-30.8 (-53.2 to -1.4)
Hepatitis E	-	-	-	-	-	-	-	-
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.5 (-55.3 to -37.2)	-59.2 (-65.4 to -52.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.7 (-54.1 to -32.6)	-56.4 (-64.9 to -48.8)
Other infectious diseases	1.1 (0.9 to 1.3)	0.8 (0.7 to 0.8)	-29.7 (-36.7 to -19.9)	-14.0 (-21.2 to -4.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-28.7 (-36.5 to -11.7)	-4.6 (-15.1 to 15.1)
Non-communicable diseases	-	-	-	-	7.5 (5.6 to 9.7)	9.4 (7.0 to 12.2)	25.8 (22.3 to 29.2)	3.1 (0.2 to 5.5)
Neoplasms	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	123.1 (89.3 to 163.3)	72.7 (45.8 to 103.3)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.0 (-10.0 to 69.6)	-9.7 (-34.1 to 23.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.9 (-13.1 to 63.6)	-13.1 (-36.9 to 19.4)
Stomach cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.5 (-28.7 to 20.5)	-32.0 (-46.9 to -10.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.7 (-35.6 to 11.0)	-37.5 (-52.2 to -17.7)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	255.6 (168.3 to 354.9)	164.4 (101.2 to 249.4)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	324.2 (106.7 to 721.5)	209.3 (51.1 to 521.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	310.1 (118.7 to 636.3)	198.0 (59.9 to 450.4)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,034.5 (490.8 to 2,094.2)	735.4 (344.3 to 1,506.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	961.7 (488.5 to 1,803.2)	677.8 (335.7 to 1,286.6)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.5 (7.0 to 210.3)	35.8 (-20.5 to 132.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.1 (14.8 to 165.1)	30.2 (-12.7 to 99.1)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.0 (-2.4 to 177.4)	17.7 (-29.0 to 109.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.9 (6.2 to 137.4)	33.9 (-22.9 to 78.5)
Larynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.0 (22.8 to 290.5)	21.0 (-16.0 to 173.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.7 (9.6 to 185.1)	15.6 (-22.9 to 102.2)
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.6 (8.1 to 81.0)	-1.0 (-22.9 to 29.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.9 (-3.5 to 71.5)	-8.3 (-31.1 to 23.0)
Breast cancer	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	39.2 (7.7 to 97.3)	-8.1 (-39.2 to 30.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.5 (7.7 to 102.0)	-0.3 (-28.1 to 35.9)
Cervical cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	15.0 (-1.9 to 25.7)	-2.2 (-60.5 to 44.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.2 (-41.8 to 24.9)	-42.2 (-59.9 to -15.3)
Uterine cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	138.3 (6.3 to 299.8)	64.9 (-26.8 to 171.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.9 (2.8 to 273.4)	61.0 (-28.6 to 158.4)
Prostate cancer	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.9)	294.5 (134.6 to 521.9)	211.7 (85.5 to 386.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	241.4 (106.7 to 411.8)	172.1 (65.6 to 310.4)
Colon and rectum cancer	0.2 (0.2 to 0.2)	0.6 (0.5 to 0.6)	198.4 (155.1 to 240.9)	129.7 (96.9 to 162.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	188.8 (146.2 to 230.8)	121.9 (89.2 to 154.8)
Lip and oral cavity cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.2 (0.1 to 87.6)	-2.4 (-23.2 to 33.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.4 (-3.2 to 78.2)	-4.8 (-31.1 to 27.8)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.8 (-25.4 to 48.6)	-28.1 (-48.0 to 2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.5 (-26.7 to 41.8)	-30.5 (-48.2 to -1.0)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.3 (9.0 to 119.2)	-6.4 (-39.3 to 43.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.8 (-8.7 to 106.2)	-9.2 (-39.0 to 36.0)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.4 (-73.2 to 18.1)	-68.7 (-79.7 to -10.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.5 (-73.3 to 11.6)	-68.9 (-80.1 to -15.9)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	553.2 (401.5 to 747.3)	387.2 (272.4 to 530.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	463.2 (333.0 to 614.2)	316.0 (218.1 to 429.6)
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.1 (-29.7 to 37.7)	-30.0 (-49.3 to 0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.0 (-32.9 to 39.8)	-33.9 (-50.7 to 1.1)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	178.8 (75.0 to 322.7)	103.1 (27.5 to 206.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	339.5 (77.3 to 660.3)	222.0 (30.2 to 477.5)
Ovarian cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	327.9 (204.1 to 488.1)	223.3 (130.7 to 340.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	296.7 (169.6 to 471.6)	200.5 (101.9 to 328.1)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	537.5 (25.8 to 1,151.5)	397.4 (6.2 to 847.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	489.1 (9.9 to 1,074.5)	347.2 (-15.5 to 798.8)
Kidney cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	562.3 (20.7 to 1,011.1)	18.1 (-7.6 to 53.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.8 (13.2 to 93.1)	9.8 (-14.7 to 45.6)
Bladder cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	697.4 (485.1 to 1,035.5)	517.4 (357.7 to 781.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	878.5 (595.2 to 1,341.8)	655.7 (441.7 to 1,016.4)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	257.1 (17.3 to 488.3)	265.3 (23.8 to 465.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	272.5 (29.0 to 473.6)	260.1 (21.2 to 410.5)
Thyroid cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	93.6 (35.1 to 167.1)	40.7 (-2.4 to 92.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.0 (30.0 to 165.6)	37.4 (-3.4 to 90.5)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	137.5 (82.1 to 203.6)	80.2 (38.1 to 131.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	142.9 (90.1 to 210.0)	85.9 (43.8 to 138.0)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	599.4 (6.1 to 1,074.0)	601.6 (4.3 to 1,027.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	613.2 (2.7 to 1,032.1)	594.4 (0.2 to 946.1)
Non-Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	90.5 (37.6 to 160.4)	44.7 (7.5 to 98.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.8 (32.3 to 142.6)	33.6 (0.4 to 81.1)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	116.8 (31.8 to 246.0)	52.6 (6.5 to 141.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.0 (23.4 to 222.5)	43.6 (-11.4 to 126.5)
Leukemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.6 (-31.9 to 96.4)	25.8 (-20.2 to 11.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.8 (-15.7 to 80.5)	19.3 (-13.7 to 60.6)
Other neoplasms	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	123.3 (45.8 to 232.3)	103.9 (51.5 to 195.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.5 (48.8 to 217.7)	91.6 (45.2 to 171.1)
Cardiovascular diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	64.9 (35.8 to 98.4)	24.2 (3.6 to 50.0)
Rheumatic heart disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.0 (11.8 to 51.2)	-4.2 (-17.7 to 12.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.6 (12.1 to 56.8)	-4.1 (-17.8 to 14.8)
Ischemic heart disease	0.6 (0.6 to 0.8)	1.5 (1.3 to 2.0)	140.5 (89.9 to 214.6)	79.1 (42.4 to 134.9)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	172.5 (106.9 to 287.2)	103.1 (50.8 to 191.1)
Cerebrovascular disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	35.4 (13.1 to 72.3)	1.2 (-16.0 to 29.7)
Ischemic stroke	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	32.0 (10.9 to 70.0)	0.3 (-16.5 to 29.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.2 (9.3 to 70.8)	-0.0 (-17.8 to 29.0)
Hemorrhagic stroke	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	46.9 (5.7 to 105.5)	6.8 (-24.0 to 53.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.1 (4.4 to 108.2)	6.5 (-25.2 to 54.9)
Hypertensive heart disease	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	18.9 (6.1 to 36.0)	-11.1 (-20.2 to 1.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.5 (4.0 to 39.3)	-11.2 (-22.4 to 3.7)
Cardiomyopathy and myocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.8 (32.9 to 105.7)	21.4 (-1.6 to 54.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.1 (27.6 to 112.1)	21.0 (-5.2 to 60.0)
Atrial fibrillation and flutter	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	22.1 (7.9 to 64.3)	-4.1 (-28.2 to 29.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.2 (-7.4 to 63.8)	-4.2 (-27.8 to 28.8)
Peripheral vascular disease	2.6 (2.1 to 3.2)	3.8 (3.0 to 4.7)	45.4 (16.2 to 81.5)	-1.1 (-20.5 to 23.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.0 (-39.8 to 106.4)	-16.0 (-51.1 to 67.2)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.1 (-62.9 to 0.7)	-43.7 (-69.5 to -14.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.8 (-64.8 to 13.1)	-4.2 (-71.8 to 6.5)
Other cardiovascular and circulatory diseases	0.3 (0.2 to 0.6)	0.4 (0.3 to 0.5)	31.2 (-28.1 to 154.8)	6.2 (-47.2 to 85.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.3 (-28.8 to 160.0)	5.6 (-47.5 to 85.3)
Chronic respiratory diseases	-	-	-	-	0.5 (0.4 to 0.7)	0.7 (0.5 to 0.9)	29.3 (12.8 to 50.0)	1.8 (-11.9 to 18.0)
Chronic obstructive pulmonary disease	3.9 (3.8 to 4.1)	5.5 (5.2 to 5.7)	38.9 (34.7 to 43.2)	0.3 (-2.6 to 3.4)	0.2 (0.2 to 0.3)	0.4 (0.2 to 0.5)	51.1 (21.2 to 76.3)	9.6 (-12.8 to 27.0)

Appendix Table G.4 - Saint Vincent and the Grenadines prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumonia	-	-	-	-	0.0	0.0	35.1	-2.0
Silicosis	0.0	0.0	26.0	-8.1	0.0	0.0	(29.5 to 40.6)	(5.7 to 2.1)
Asbestosis	-	-	0.0	0.0	-	-	26.1	-8.2
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	41.7	2.7	0.0	0.0	41.5	2.5
Asthma	5.5	6.9	24.1	10.4	0.2	0.3	23.9	10.4
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	43.8	10.3	0.0	0.0	45.4	11.0
Other chronic respiratory diseases	-	-	-	-	0.1	0.0	-42.0	-58.2
Cirrhosis	-	-	-	-	0.0	0.0	28.6	41.1
Cirrhosis due to hepatitis B	0.0	0.0	10.7	-19.0	0.0	0.0	12.2	-17.6
Cirrhosis due to hepatitis C	0.0	0.0	58.5	21.2	0.0	0.0	57.1	20.5
Cirrhosis due to alcohol use	0.0	0.0	16.5	-20.8	0.0	0.0	15.6	-21.2
Cirrhosis due to other causes	0.0	0.0	25.4	23.5	0.0	0.0	24.5	23.2
Digestive diseases	-	-	-	-	0.1	0.2	27.2	1.0
Peptic ulcer disease	0.9	0.5	-38.9	-53.6	0.0	0.0	-28.7	-47.6
Gastritis and duodenitis	2.0	2.4	17.6	-1.0	0.1	0.1	8.8	-4.6
Appendicitis	0.0	0.0	-7.0	-6.8	0.0	0.0	-5.6	-5.7
Paralytic ileus and intestinal obstruction	0.0	0.0	38.0	46.0	0.0	0.0	37.2	44.5
Inguinal, femoral, and abdominal hernia	0.3	0.2	-25.8	-43.4	0.0	0.0	-25.3	-43.0
Inflammatory bowel disease	0.1	0.2	78.6	31.0	0.0	0.0	78.3	31.1
Vascular intestinal disorders	0.0	0.0	12.8	-10.8	0.0	0.0	12.8	-10.8
Gallbladder and biliary diseases	0.1	0.1	-7.1	-33.9	0.0	0.0	-9.4	-34.2
Pancreatitis	0.0	0.0	103.9	51.2	0.0	0.0	100.8	49.1
Other digestive diseases	-	-	-	-	0.0	0.0	352.6	259.7
Neurological disorders	-	-	-	-	0.7	0.8	23.9	4.3
Alzheimer disease and other dementias	0.7	0.8	25.0	0.7	0.1	0.1	24.7	0.7
Parkinson disease	0.0	0.0	28.5	-0.8	0.0	0.0	28.4	-1.7
Epilepsy	0.3	0.3	24.6	19.6	0.1	0.1	28.1	24.2
Multiple sclerosis	0.0	0.0	164.5	82.9	0.0	0.0	154.0	76.7
Migraine	10.1	11.3	11.7	3.3	0.4	0.5	9.5	-5.1
Tension-type headache	16.9	23.8	40.8	18.4	0.1	0.0	17.9	0.2
Medication overuse headache	0.4	0.8	89.8	45.2	0.1	0.1	89.7	45.5
Other neurological disorders	0.0	0.0	13.2	2.6	0.0	0.0	-5.9	-24.8
Mental and substance use disorders	-	-	-	-	2.4	2.7	14.8	-0.2
Schizophrenia	0.2	0.3	39.0	-0.2	0.2	0.2	38.5	-0.1
Alcohol use disorders	0.6	0.8	35.2	9.0	0.1	0.1	35.4	9.2
Drug use disorders	-	-	-	-	0.1	0.2	18.3	2.2
Opioid use disorders	0.1	0.1	55.5	4.3	0.0	0.0	54.2	4.4
Cocaine use disorders	0.2	0.2	31.9	31.2	0.0	0.0	31.9	7.3
Amphetamine use disorders	0.2	0.2	-3.9	-3.0	0.0	0.0	-3.6	-2.6
Cannabis use disorders	0.2	0.2	-1.3	0.1	0.0	0.0	-1.5	0.1
Other drug use disorders	-	-	-	-	0.0	0.1	10.4	1.3
Depressive disorders	-	-	-	-	0.9	1.0	17.5	0.8
Major depressive disorder	3.8	4.4	16.0	-0.8	0.8	0.9	15.4	-0.8
Dysthymia	1.1	1.5	31.8	0.1	0.1	0.1	31.8	-0.9
Bipolar disorder	0.7	0.9	22.1	-0.5	0.1	0.2	21.4	-0.7
Anxiety disorders	5.9	6.7	14.6	4.9	0.5	0.6	14.2	-0.8
Eating disorders	-	-	-	-	0.3	0.4	3.4	0.8
Anorexia nervosa	0.0	0.0	-1.6	6.0	0.0	0.0	-1.4	6.1
Bulimia nervosa	0.1	0.1	-3.9	-0.1	0.0	0.0	-3.7	0.1
Autistic spectrum disorders	-	-	-	-	0.1	0.1	1.1	1.2
Autism	0.3	0.3	1.7	0.9	0.2	0.1	1.2	1.1
Asperger syndrome	0.5	0.5	1.3	1.2	0.0	0.0	1.3	1.3
Attention-deficit/hyperactivity disorder	1.0	0.7	-23.6	-0.1	0.0	0.0	-23.6	-0.1
Conduct disorder	1.3	1.1	-23.7	-0.2	0.0	0.0	-23.6	-0.1
Idiopathic intellectual disability	0.4	0.3	-20.9	-19.4	0.0	0.0	-21.7	-19.9
Other mental and substance use disorders	1.5	1.9	30.3	0.7	0.1	0.1	29.8	0.7
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	0.7	1.1	47.8	16.2
Diabetes mellitus	4.3	8.5	96.3	36.8	0.3	0.6	97.1	33.4
Acute glomerulonephritis	0.0	0.0	-7.8	9.8	0.0	0.0	-7.8	9.8
Chronic kidney disease	-	-	-	-	0.1	0.2	24.3	3.2
Chronic kidney disease due to diabetes mellitus	2.4	3.3	36.0	-0.1	0.0	0.0	40.5	4.0
Chronic kidney disease due to hypertension	1.6	1.9	22.1	10.5	0.0	0.1	18.9	-2.2
Chronic kidney disease due to glomerulonephritis	2.4	5.3	119.6	48.2	0.0	0.0	48.2	119.6
Chronic kidney disease due to other causes	3.5	4.0	14.5	-0.0	0.0	0.1	20.5	6.3
Urinary diseases and male infertility	-	-	-	-	0.0	0.0	39.4	9.4

Appendix Table G.4 - Saint Vincent and the Grenadines prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.0 (34.7 to 66.3)	31.6 (19.0 to 44.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.8 (20.5 to 85.3)	31.6 (7.5 to 59.2)
Urolithiasis	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.6)	58.7 (17.1 to 134.9)	15.6 (-15.8 to 64.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.5 (22.5 to 123.4)	15.0 (-12.9 to 60.3)
Benign prostatic hyperplasia	0.6 (0.5 to 0.6)	0.8 (0.7 to 0.8)	38.3 (24.6 to 52.8)	8.7 (-2.6 to 20.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.5 (24.3 to 53.9)	8.5 (-2.9 to 21.0)
Male infertility due to other causes	0.7 (0.6 to 0.9)	0.9 (0.7 to 1.1)	16.7 (8.1 to 52.0)	-0.8 (-22.2 to 29.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.7 (9.7 to 52.3)	-0.3 (-21.1 to 31.1)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.5 (5.8 to 144.3)	14.5 (22.7 to 77.2)
Gynecological diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	26.0 (10.2 to 42.5)	4.9 (-15.9 to 7.4)
Uterine fibroids	1.5 (1.3 to 1.6)	2.4 (2.2 to 2.6)	63.9 (60.9 to 67.5)	-3.0 (-3.0 to -2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	31.3 (15.3 to 44.4)	-13.7 (-23.5 to -6.3)
Polycystic ovarian syndrome	1.7 (1.5 to 1.9)	2.2 (2.0 to 2.5)	32.7 (11.9 to 59.2)	0.7 (-13.6 to 18.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.1 (11.6 to 58.6)	0.9 (-13.5 to 18.8)
Female infertility due to other causes	0.6 (0.3 to 0.9)	0.8 (0.5 to 1.2)	27.5 (-38.1 to 166.7)	-0.2 (-52.9 to 120.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.8 (-37.2 to 148.4)	0.7 (-51.1 to 104.6)
Endometriosis	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	39.5 (8.1 to 73.2)	4.0 (-17.6 to 29.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.0 (7.4 to 74.8)	4.3 (-19.0 to 30.4)
Genital prolapse	4.5 (3.7 to 5.6)	6.6 (5.3 to 7.7)	46.4 (7.9 to 84.3)	-1.2 (-23.9 to 21.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.0 (7.2 to 84.7)	-1.3 (-24.4 to 21.4)
Premenstrual syndrome	4.4 (3.5 to 5.3)	5.2 (3.8 to 6.5)	15.9 (-18.0 to 65.7)	-1.9 (-32.0 to 39.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	15.5 (-19.0 to 64.8)	-1.5 (-32.7 to 40.7)
Other gynecological diseases	0.3 (0.3 to 0.4)	0.3 (0.3 to 0.4)	-2.6 (-22.4 to 23.8)	-18.8 (-34.9 to 1.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.4 (-28.0 to 43.1)	-19.7 (-39.7 to 16.3)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-12.6 (-17.6 to -4.4)	2.2 (-7.5 to 6.2)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.4 (-28.0 to -13.5)	3.7 (-3.8 to 15.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.3 (-30.8 to -14.0)	4.1 (-5.4 to 16.6)
Thalassemia trait	1.4 (1.1 to 1.9)	1.5 (1.1 to 1.9)	3.5 (-1.3 to 8.8)	1.4 (-3.3 to 6.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.7 (-13.4 to 12.5)	4.8 (-8.1 to 19.6)
Sickle cell disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-5.6 (-14.0 to 12.8)	4.4 (-4.7 to 24.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.6 (-1.2 to 22.9)	7.8 (-7.2 to 24.7)
Sickle cell trait	8.1 (7.5 to 8.6)	8.3 (7.7 to 8.9)	3.3 (0.5 to 6.3)	-1.3 (-1.5 to 4.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-10.0 (-20.2 to 4.1)	2.3 (-9.4 to 19.2)
G6PD deficiency	6.1 (4.5 to 7.4)	6.5 (5.1 to 8.0)	7.0 (-25.4 to 58.4)	5.3 (-26.5 to 55.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.8 (-38.2 to 29.1)	-4.9 (-34.0 to 29.4)
G6PD trait	17.4 (16.2 to 18.4)	17.7 (16.4 to 18.9)	1.5 (-7.6 to 12.0)	-1.3 (-10.2 to 8.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.6 (-65.7 to 644.2)	64.7 (-58.4 to 581.5)
Other hemoglobinopathies and hemolytic anemias	1.0 (1.0 to 1.1)	0.8 (0.8 to 0.9)	20.7 (-27.6 to -12.9)	-18.4 (-25.8 to -10.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.0 (-43.9 to -21.0)	-20.2 (-33.0 to -4.9)
Endocrine, metabolic, blood, and immune disorders	1.1 (1.0 to 1.2)	0.9 (0.8 to 0.9)	-20.1 (-29.3 to -8.1)	12.7 (-22.6 to -1.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-25.9 (-37.0 to -5.7)	-10.6 (-24.4 to 11.8)
Musculoskeletal disorders	-	-	-	-	1.1 (0.8 to 1.5)	1.6 (1.2 to 2.1)	41.3 (32.7 to 52.0)	2.8 (-2.5 to 9.4)
Rheumatoid arthritis	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.4)	66.0 (55.4 to 76.9)	32.4 (23.6 to 41.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	64.3 (50.6 to 79.4)	31.2 (20.6 to 43.0)
Osteoarthritis	2.9 (2.8 to 3.1)	4.3 (4.1 to 4.4)	45.3 (38.2 to 53.1)	0.7 (-4.2 to 6.4)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	45.8 (37.8 to 53.9)	0.4 (-4.9 to 6.0)
Low back and neck pain	-	-	-	-	0.7 (0.5 to 1.0)	0.9 (0.7 to 1.3)	32.3 (20.3 to 50.1)	0.7 (-8.4 to 13.0)
Low back pain	3.9 (3.4 to 4.3)	5.2 (4.6 to 5.7)	32.8 (14.6 to 53.0)	1.8 (-11.4 to 15.9)	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.8)	32.5 (13.9 to 53.8)	1.8 (-11.7 to 16.3)
Neck pain	2.8 (2.4 to 3.2)	3.8 (3.3 to 4.3)	35.7 (18.7 to 61.5)	-1.0 (-13.2 to 16.5)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	35.1 (18.6 to 61.7)	-1.1 (-13.5 to 16.5)
Gout	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.2 (27.2 to 61.9)	-1.2 (-12.5 to 11.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.8 (15.1 to 79.8)	-1.9 (-21.0 to 23.2)
Other musculoskeletal disorders	2.3 (1.9 to 2.6)	3.6 (3.0 to 4.3)	58.8 (46.1 to 71.0)	5.9 (-2.4 to 13.4)	0.2 (0.1 to 0.3)	0.5 (0.2 to 0.5)	58.7 (45.9 to 71.3)	0.7 (-3.1 to 13.4)
Other non-communicable diseases	-	-	-	-	1.7 (1.1 to 2.4)	1.9 (1.3 to 2.8)	12.7 (8.5 to 17.1)	-5.2 (-8.5 to -2.0)
Congenital anomalies	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	23.8 (7.6 to 44.6)	22.0 (5.5 to 42.1)
Neural tube defects	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.8 (-13.7 to 27.5)	16.6 (-3.8 to 41.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.1 (-20.4 to 50.0)	22.6 (-10.0 to 67.7)
Congenital heart anomalies	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.6)	37.1 (4.2 to 75.3)	44.7 (9.8 to 85.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.9 (3.3 to 73.2)	44.1 (10.3 to 85.4)
Orofacial clefts	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	25.1 (-11.2 to 77.1)	40.6 (-0.4 to 98.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.7 (-30.4 to 73.2)	27.0 (-21.7 to 92.9)
Down syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	18.6 (-10.1 to 47.3)	16.3 (-12.0 to 44.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.6 (-2.1 to 62.8)	18.4 (-9.6 to 51.1)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.6 (-28.7 to 52.7)	4.9 (-28.0 to 55.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.3 (-29.1 to 64.5)	5.6 (-30.1 to 60.9)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.5 (-34.9 to 66.6)	2.1 (-35.0 to 66.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.7 (-28.4 to 85.4)	1.4 (-35.6 to 65.4)
Chromosomal unbalanced rearrangements	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.2)	13.9 (-15.4 to 56.9)	13.6 (-17.5 to 53.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.2 (-10.3 to 70.3)	14.2 (-15.9 to 57.1)
Other congenital anomalies	0.4 (0.4 to 0.5)	0.4 (0.3 to 0.5)	-7.1 (-16.2 to 0.9)	-12.0 (-20.3 to -4.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	23.4 (-0.3 to 56.1)	20.8 (-0.9 to 52.5)
Skin and subcutaneous diseases	-	-	-	-	0.5 (0.3 to 0.8)	0.6 (0.4 to 0.9)	4.4 (9.0 to 13.6)	-0.9 (-13.0 to 6.6)
Dermatitis	4.8 (3.9 to 5.7)	5.5 (4.4 to 6.6)	14.0 (8.7 to 18.7)	-0.1 (-0.2 to 0.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	8.0 (2.3 to 13.1)	-0.1 (-2.8 to 2.7)
Psoriasis	0.0 (0.7 to 0.9)	1.0 (0.8 to 1.1)	21.1 (17.8 to 25.6)	0.0 (-0.1 to 0.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	20.5 (12.6 to 28.7)	0.1 (-5.0 to 5.8)
Cellulitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.6 (-19.6 to 8.4)	-13.3 (-23.0 to -4.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.1 (-25.8 to 15.7)	-13.1 (-28.2 to 4.0)
Pyoderma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	26.1 (15.3 to 36.3)	23.3 (17.7 to 29.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.9 (6.9 to 46.9)	23.1 (7.5 to 41.6)
Scabies	1.4 (1.2 to 1.6)	1.3 (1.1 to 1.6)	-4.4 (-24.7 to 16.8)	-1.4 (-2.4 to 2.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-5.7 (-23.3 to 16.3)	-1.7 (-22.2 to 22.7)
Fungal skin diseases	7.6 (5.8 to 10.0)	8.6 (6.7 to 11.4)	13.2 (4.2 to 22.0)	13.2 (0.1 to 27.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	12.7 (4.0 to 21.7)	0.4 (-0.6 to 1.3)
Viral skin diseases	2.4 (1.8 to 3.0)	2.1 (1.5 to 2.7)	-13.7 (-18.4 to -8.0)	0.2 (-1.9 to 2.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-13.8 (-19.0 to -7.7)	3.2 (-3.3 to 3.5)
Acne vulgaris	8.7 (6.6 to 11.5)	7.3 (5.3 to 9.1)	-14.3 (-45.3 to 19.8)	-3.6 (-38.0 to 33.7)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-14.1 (-45.5 to 20.1)	-3.5 (-38.0 to 34.3)
Alopecia areata	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	15.6 (1.6 to 30.9)	-0.3 (-12.0 to 13.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.1 (-2.9 to 36.3)	-0.6 (-14.6 to 17.9)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.5 (0.2 to 66.8)	5.8 (-19.6 to 35.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.9 (0.2 to 67.4)	5.8 (-19.7 to 35.9)
Urticaria	1.0 (0.7 to 1.4)	1.2 (0.7 to 1.6)	20.0 (-38.9 to 86.9)	-0.2 (-47.6 to 49.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	19.7 (-39.6 to 87.2)	-0.1 (-48.7 to 50.7)
Decubitus ulcer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.5 (-19.7 to 28.7)	-24.5 (-39.0 to 2.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.0 (-24.1 to 34.0)	-23.9 (-42.4 to 5.8)
Other skin and subcutaneous diseases	5.7 (3.7 to 9.0)	7.4 (4.7 to 11.5)	28.6 (15.0 to 44.0)	-0.5 (-5.8 to 3.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	28.5 (14.6 to 44.2)	-0.5 (-5.8 to 4.0)
Sense organ diseases	-	-	-	-	0.7 (0.5 to 1.0)	0.8 (0.5 to 1.1)	11.9 (5.0 to 18.1)	-10.5 (-14.3 to -6.3)
Glaucoma	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	5.2 (-6.8 to 20.0)	-20.3 (-28.9 to -9.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.4 (-9.7 to 24.2)	-20.1 (-31.1 to -2.8)
Cataract	0.7 (0.6 to 0.9)	0.7 (0.5 to 0.8)	-9.2 (-17.7 to 1.7)	-28.9 (-35.6 to -21.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-8.5 (-17.2 to 0.1)	-28.5 (-34.9 to -21.1)
Macular degeneration	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	62.6 (27.2 to 115.1)	10.4 (-13.0 to 44.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.1 (24.8 to 105.7)	8.8 (-14.1 to 40.2)
Uncorrected refractive error	9.4 (8.8 to 9.9)	11.5 (10.7 to 12.2)	22.6 (11.9 to 34.0)	5.6 (-13.3 to 2.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	12.4 (4.7 to 21.9)	-11.1 (-16.3 to -4.3)
Age-related and other hearing loss	13.5 (12.7 to 14.3)	16.7 (15.7 to 17.9)	23.9 (19.5 to 29.8)	-8.8 (-11.6 to -5.2)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	16.8 (7.2 to 26.0)	-8.5 (-14.2 to -1.8)
Other vision loss	0.3 (0.3 to 0.4)	0.2 (0.2 to 0.3)	-20.1 (-28.9 to -10.4)	-32.8 (-38.1 to -26.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.3 (-25.1 to -1.3)	-31.8 (-38.4 to -22.5)
Other sense organ diseases	2.5 (2.4 to 2.7)	2.5 (2.3 to 2.6)	-2.7 (-9.1 to 5.6)	-1.2 (-7.7 to 6.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-3.1 (-10.9 to 5.6)	-1.0 (-8.5 to 7.0)
Oral disorders	-	-	-	-	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	24.8 (20.9 to 29.0)	-4.5 (-7.5 to -1.3)
Deciduous caries	9.6 (9.3 to 9.9)	6.4 (6.2 to 6.7)	-32.9 (-36.4 to -29.4)	-0.5 (-5.7 to 4.7)	0.0 (0.0 to 0			

Appendix Table G.4 - Saint Vincent and the Grenadines prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	5.7 (5.5 to 5.9)	7.2 (7.0 to 7.5)	27.5 (21.8 to 33.6)	-6.7 (-10.7 to -2.5)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	27.5 (21.7 to 34.0)	-7.0 (-11.3 to -2.5)
Other oral disorders	1.7 (1.6 to 1.8)	2.0 (1.8 to 2.1)	16.1 (7.1 to 25.1)	-0.9 (-8.1 to 6.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	15.6 (6.4 to 25.4)	-0.9 (-8.4 to 7.2)
Injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.5 (0.4 to 0.7)	-4.1 (-13.4 to 6.5)	-25.4 (-32.2 to -17.4)
Transport injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-1.1 (-13.6 to 13.2)	-24.7 (-33.8 to -14.3)
Road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	5.9 (-18.0 to 8.2)	28.1 (-37.0 to -18.0)
Pedestrian road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-22.0 (-32.8 to -9.3)	-38.3 (-46.4 to -28.9)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.5 (-13.5 to 8.9)	-24.1 (-32.6 to -15.7)
Motorcyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.8 (-26.9 to -2.1)	-36.8 (-45.7 to -27.8)
Motor vehicle road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	5.9 (-3.3 to 21.8)	-20.3 (-30.4 to -8.4)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.3 (-32.7 to -10.3)	-41.6 (-48.8 to -32.8)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.4 (49.3 to 89.4)	24.7 (10.9 to 40.5)
Unintentional injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-6.0 (-13.7 to 2.5)	-25.6 (-31.8 to -19.2)
Falls	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-7.7 (-18.3 to 5.2)	-29.4 (-37.5 to -19.8)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.8 (-32.2 to -8.8)	-37.2 (-45.3 to -27.6)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.1 (-39.4 to -21.6)	-42.8 (-49.3 to -35.5)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.9 (-37.1 to -6.4)	-33.1 (-43.5 to -20.3)
Exposure to mechanical forces	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-17.2 (-23.5 to -10.1)	-30.5 (-34.8 to -25.5)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.4 (24.0 to 64.2)	10.8 (-2.7 to 26.5)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.0 (4.9 to 34.4)	-3.8 (-14.1 to 8.6)
Other exposure to mechanical forces	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-21.7 (-27.4 to -14.9)	-33.8 (-38.0 to -29.0)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.4 (49.6 to 68.4)	24.7 (17.6 to 32.7)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.7 (38.2 to 67.9)	23.2 (12.9 to 35.1)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.3 (38.8 to 76.8)	27.6 (14.0 to 41.9)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.3 (33.9 to 65.6)	20.6 (9.6 to 33.7)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.8 (-12.5 to 7.9)	-21.0 (-28.3 to -13.3)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.2 (-33.2 to -6.1)	-32.3 (-41.8 to -20.3)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.4 (-8.3 to 19.9)	-9.5 (-19.9 to 2.6)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.4 (-3.9 to 18.5)	-17.1 (-24.6 to -8.8)
Other unintentional injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	46.5 (35.3 to 59.6)	3.9 (-3.9 to 13.4)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.1 (-12.2 to 14.7)	-25.5 (-34.6 to -14.7)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.7 (-22.3 to -1.3)	-37.1 (-43.8 to -29.2)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.0 (-10.4 to 19.7)	-22.6 (-32.7 to -10.8)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.1 (29.3 to 60.0)	6.2 (-4.0 to 17.7)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.0 (-6.0 to 28.3)	-18.6 (-29.5 to -4.7)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.3 (-32.4 to -6.4)	-39.4 (-48.4 to -28.8)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.8 (-35.5 to 52.1)	30.6 (-10.9 to 100.6)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.8 (-35.5 to 52.1)	30.6 (-10.9 to 100.6)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Samoa prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	11.9 (8.9 to 15.6)	15.0 (11.0 to 19.4)	26.0 (20.7 to 31.0)	-0.4 (-4.0 to 2.9)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.0 (1.4 to 2.7)	2.1 (1.4 to 2.9)	5.0 (6.2 to 22.9)	-9.2 (-23.4 to 8.2)
HIV/AIDS and tuberculosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	31.1 (15.1 to 55.4)	-0.2 (-11.1 to 16.8)
Tuberculosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	16.5 (10.4 to 23.3)	-11.4 (-15.6 to -6.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	16.4 (4.7 to 29.4)	-11.1 (-18.4 to -2.4)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	665.5 (177.3 to 1,338.0)	486.5 (111.1 to 1,056.3)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	502.7 (118.3 to 1,103.6)	348.0 (59.5 to 810.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	502.7 (118.1 to 1,104.2)	348.0 (59.4 to 810.9)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	499.6 (121.9 to 967.7)	390.9 (78.8 to 787.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	648.3 (175.5 to 1,362.9)	487.2 (109.1 to 1,114.0)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.5)	-10.5 (-17.7 to -2.7)	-18.0 (-24.3 to -11.4)
Diarrheal diseases	0.7 (0.7 to 0.8)	0.7 (0.6 to 0.7)	-10.6 (-24.3 to 5.6)	-11.1 (-22.9 to 2.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-10.7 (-25.7 to 5.2)	-11.4 (-23.7 to 2.6)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.4 (-33.1 to -3.4)	-25.7 (-38.5 to -10.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.8 (-36.7 to 4.1)	-24.7 (-40.1 to -6.9)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.9 (-47.9 to -17.6)	-40.0 (-52.7 to -25.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.6 (-49.4 to -12.9)	-39.7 (-53.7 to -22.3)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	688.1 (78.7 to 5,189.9)	624.4 (81.0 to 5,614.4)
Lower respiratory infections	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-32.0 (-48.4 to -2.7)	-37.2 (-50.5 to -7.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.3 (-50.3 to -5.3)	-37.4 (-51.7 to -7.3)
Upper respiratory infections	5.1 (4.8 to 5.4)	5.6 (5.3 to 5.9)	10.0 (0.9 to 19.6)	-1.3 (-8.8 to 6.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	9.7 (0.4 to 19.6)	-1.3 (-8.6 to 7.0)
Otitis media	2.4 (2.3 to 2.6)	2.4 (2.2 to 2.5)	-2.5 (-8.9 to 4.5)	-12.0 (-18.0 to -5.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-2.7 (-10.7 to 5.9)	-11.7 (-18.5 to -4.1)
Meningitis	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-29.4 (-43.2 to -13.5)	-35.9 (-46.9 to -21.6)
Pneumococcal meningitis	0.8 (0.5 to 1.2)	0.6 (0.3 to 0.9)	-27.9 (-41.9 to -12.8)	-37.3 (-47.5 to -24.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-27.6 (-50.0 to -1.6)	-34.4 (-52.3 to -13.3)
H influenzae type B meningitis	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.2)	-40.4 (-55.8 to -10.3)	-48.4 (-60.9 to -22.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.6 (-58.1 to 18.4)	-43.3 (-60.6 to 6.2)
Meningococcal meningitis	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-32.5 (-57.9 to -9.1)	-43.1 (-60.5 to -21.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.1 (-61.2 to 6.3)	-43.2 (-63.6 to -7.6)
Other meningitis	0.3 (0.1 to 0.5)	0.2 (0.1 to 0.4)	-32.0 (-46.1 to -2.0)	-39.6 (-58.8 to -11.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-32.0 (-50.9 to 18.1)	-37.4 (-53.5 to 6.2)
Encephalitis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	2.6 (-12.0 to 20.5)	15.6 (-26.4 to -2.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.7 (-11.3 to 29.1)	-11.3 (-24.3 to 6.5)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	158.1 (69.9 to 2,033.1)	122.8 (70.3 to 1,489.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	158.1 (70.3 to 2,038.3)	122.8 (70.4 to 1,522.5)
Whooping cough	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	67.7 (61.8 to 74.0)	77.0 (70.7 to 83.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.1 (55.2 to 80.7)	77.5 (63.9 to 90.5)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-62.4 (-84.9 to 12.7)	-66.7 (-86.0 to -3.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.7 (-81.6 to 31.9)	-55.9 (-81.7 to 6.4)
Measles	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	123.3 (15.0 to 47.4)	15.8 (-11.6 to 53.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.8 (-23.4 to 56.3)	16.9 (-20.5 to 62.4)
Varicella and herpes zoster	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	12.2 (0.4 to 26.0)	-0.3 (-14.2 to 14.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.8 (-0.1 to 54.1)	-0.8 (-20.6 to 23.6)
Neglected tropical diseases and malaria	-	-	-	-	0.3 (0.1 to 0.6)	0.2 (0.1 to 0.4)	-16.5 (-46.3 to 9.4)	-40.7 (-65.0 to -16.5)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.5 (-33.2 to 112.3)	8.8 (-38.5 to 97.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.7 (-34.0 to 106.4)	7.4 (-38.3 to 89.8)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,283.5 (1,644.4 to 3,071.4)	2,591.6 (1,919.4 to 3,390.9)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.6 (-30.7 to 152.5)	18.2 (-27.3 to 119.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.6 (-30.9 to 153.1)	18.2 (-27.4 to 120.4)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,510.7 (1,950.3 to 3,132.6)	2,816.6 (2,169.4 to 3,449.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,441.6 (1,778.3 to 3,290.8)	2,733.9 (2,028.3 to 3,623.7)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-88.6 (-97.0 to -63.9)	-91.3 (-97.2 to -76.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-88.0 (-96.9 to -60.1)	-91.0 (-97.2 to -74.2)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.7 (-27.5 to -15.0)	-39.9 (-42.6 to -34.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.4 (-39.1 to 3.3)	-38.8 (-51.3 to -24.0)
Lymphatic filariasis	4.0 (2.8 to 5.9)	1.4 (0.7 to 2.5)	-66.7 (-77.3 to -52.6)	-72.9 (-82.3 to -62.5)	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.3)	-32.7 (-65.3 to -3.3)	-51.4 (-75.7 to -25.9)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	433.6 (431.0 to 436.7)	368.3 (366.0 to 371.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	436.5 (324.3 to 605.6)	369.8 (285.1 to 497.1)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.4 (-50.0 to 71.8)	-32.1 (-58.8 to 32.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.4 (-50.1 to 72.3)	-32.1 (-58.8 to 32.8)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.4 (-19.9 to 54.7)	-0.4 (-31.5 to 43.1)
Ascariasis	-	-	25.1 (-47.9 to 215.9)	2.6 (-57.4 to 159.7)	-	-	-	-
Trichuriasis	2.6 (1.7 to 3.9)	3.1 (2.0 to 4.8)	18.0 (-35.1 to 119.0)	3.1 (-49.4 to 110.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.7 (-90.3 to 891.7)	-20.8 (-92.1 to 990.2)
Hookworm disease	3.2 (2.2 to 4.5)	3.7 (2.5 to 5.6)	17.9 (-31.2 to 106.7)	11.2 (-46.0 to 93.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.4 (-19.9 to 54.7)	-0.4 (-31.5 to 43.1)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	1.6 (1.2 to 2.1)	1.7 (1.5 to 1.9)	3.3 (-19.5 to 42.4)	-1.3 (-23.3 to 37.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	7.1 (-16.9 to 81.4)	2.0 (-21.2 to 77.6)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.2 (-36.6 to 6.4)	-25.0 (-47.0 to -10.0)
Maternal hemorrhage	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-4.1 (-31.9 to 18.0)	-18.3 (-41.4 to 0.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.5 (-46.1 to 20.5)	-19.8 (-54.4 to 2.6)
Maternal sepsis and other maternal infections	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-7.4 (-33.4 to 12.5)	-34.2 (-53.0 to -18.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.4 (-53.4 to 52.9)	-33.5 (-63.3 to 17.0)
Maternal hypertensive disorders	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-8.2 (-14.2 to 7.3)	-21.7 (-28.9 to -8.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.2 (-25.8 to 15.0)	-21.8 (-36.3 to -3.2)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.3 (-69.7 to 10.1)	-55.0 (-74.9 to -15.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.2 (-77.7 to 43.4)	-53.3 (-81.8 to 14.9)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.3 (-53.5 to 51.8)	-23.5 (-60.9 to 18.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.3 (-53.7 to 51.9)	-23.5 (-61.1 to 19.2)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.5 (-53.8 to 37.5)	-29.3 (-60.3 to 16.6)
Neonatal disorders	-	-	-	-	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.9)	42.0 (9.4 to 157.5)	30.7 (-16.1 to 135.0)
Preterm birth complications	0.9 (0.5 to 1.5)	1.7 (0.9 to 3.0)	93.1 (37.3 to 172.5)	69.2 (24.0 to 135.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	94.7 (18.9 to 241.0)	74.5 (9.9 to 201.7)
Neonatal encephalopathy due to birth asphyxia and trauma	0.4 (0.2 to 0.9)	0.3 (0.1 to 0.7)	-24.5 (-50.4 to 10.7)	-33.7 (-55.8 to -0.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-9.9 (-48.0 to 43.6)	-15.5 (-50.7 to 33.6)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.2 (24.2 to 52.1)	51.2 (35.0 to 65.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.8 (17.6 to 64.3)	54.0 (27.7 to 78.4)
Hemolytic disease and other neonatal jaundice	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	11.9 (-72.0 to 432.7)	2.2 (-74.8 to 372.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	8.7 (-71.5 to 367.2)	-0.4 (-73.6 to 324.4)
Other neonatal disorders	-	-	-	-	0.2 (0.0 to 0.4)	0.2 (0.1 to 0.6)	30.8 (-44.2 to 216.7)	19.5 (-48.8 to 191.9)
Nutritional deficiencies	-	-	-	-	0.8 (0.5 to 1.1)	0.8 (0.5 to 1.2)	5.6 (1.2 to 8.7)	-3.3 (-7.2 to -0.5)
Protein-energy malnutrition	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-30.3 (-60.0 to 26.8)	-38.2 (-60.9 to 8.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-60.8 to 31.5)	-36.9 (-61.6 to 10.7)
Iodine deficiency	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-25.7 (-41.0 to -1.6)	-38.0 (-51.9 to -14.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.7 (-43.0 to -2.4)	-37.5 (-52.9 to -15.2)
Vitamin A deficiency	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-38.0 (-50.3 to -25.3)	-43.9 (-54.2 to -33.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.5 (-50.6 to -26.7)	-46.0 (-54.9 to -35.6)

Appendix Table G.4 - Samoa prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	23.7 (23.1 to 24.2)	25.4 (25.0 to 25.8)	7.3 (4.5 to 10.4)	1.7 (-4.3 to 0.9)	0.7 (0.5 to 1.1)	0.8 (0.5 to 1.2)	7.1 (2.7 to 10.0)	1.8 (-0.8 to 3.8)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.2 (-62.9 to 115.4)	-23.8 (-64.1 to 94.2)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	6.0 (-4.9 to 18.4)	-7.7 (-17.4 to 2.8)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	9.6 (-0.8 to 21.0)	-2.4 (-10.7 to 6.3)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.5 (-22.4 to 14.8)	-35.2 (-45.5 to -22.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-33.1 to 29.6)	34.4 (-52.2 to -12.1)
Chlamydial infection	14.8 (12.0 to 17.6)	15.8 (13.1 to 18.7)	8.0 (-17.2 to 39.7)	-3.4 (-24.3 to 22.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	8.4 (-4.2 to 22.9)	-1.3 (-11.6 to 10.3)
Gonococcal infection	1.2 (0.9 to 1.6)	1.2 (0.8 to 1.5)	-5.9 (-35.6 to 52.0)	-11.5 (-37.8 to 34.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.6 (-19.0 to 62.0)	4.6 (-22.2 to 47.6)
Trichomoniasis	1.4 (0.9 to 2.3)	1.8 (1.2 to 2.4)	24.8 (-38.7 to 131.3)	-1.7 (-46.7 to 72.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.7 (-43.2 to 153.5)	-4.1 (-51.6 to 90.6)
Genital herpes	20.5 (20.0 to 21.1)	25.4 (24.8 to 26.1)	24.0 (19.3 to 28.3)	5.2 (-8.6 to -4.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.5 (9.8 to 28.5)	10.0 (-10.0 to -0.4)
Other sexually transmitted diseases	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-8.3 (-19.8 to 4.7)	-34.2 (-41.8 to -25.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-30.7 to 27.9)	-28.1 (-44.5 to -4.9)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-43.9 to -7.2)	-28.6 (-56.5 to -23.9)
Hepatitis A	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	-3.9 (-4.3 to -3.5)	-6.8 (-7.0 to -6.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-7.9 to 15.5)	-2.9 (-12.5 to 7.2)
Hepatitis B	30.8 (22.2 to 41.2)	14.7 (11.3 to 18.0)	-52.6 (-66.1 to -28.2)	-60.2 (-71.0 to -39.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.1 (-65.1 to -17.1)	-88.5 (-72.6 to -36.8)
Hepatitis C	5.1 (4.3 to 5.7)	4.6 (4.0 to 5.1)	-9.5 (-23.5 to 9.7)	-29.0 (-38.9 to -15.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.9 (-32.2 to 20.0)	27.5 (-46.2 to 0.6)
Hepatitis E	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	33.1 (13.0 to 59.1)	16.9 (0.5 to 43.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.6 (4.6 to 72.1)	16.8 (-7.4 to 52.1)
Leprosy	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	15.4 (-22.2 to 134.1)	-16.8 (-42.9 to 71.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.0 (-24.3 to 138.1)	-17.0 (-43.6 to 73.9)
Other infectious diseases	1.1 (0.9 to 1.4)	1.1 (1.0 to 1.3)	3.9 (-17.6 to 28.9)	-1.1 (-21.6 to 23.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	17.0 (-10.7 to 57.1)	12.5 (-13.5 to 59.1)
Non-communicable diseases	-	-	-	-	9.5 (7.1 to 12.4)	12.3 (9.1 to 15.9)	29.3 (23.5 to 34.9)	12.3 (-3.6 to 3.7)
Neoplasms	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.2 (-14.1 to 166.6)	0.6 (-42.4 to 75.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-12.6 to 145.2)	24.2 (-4.3 to 59.4)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.5 (-14.2 to 79.0)	-17.1 (-41.7 to 19.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-19.1 to 72.0)	-3.4 (-46.0 to 13.4)
Stomach cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-14.2 to 79.0)	-17.1 (-41.7 to 19.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-19.1 to 72.0)	-21.4 (-46.0 to 13.4)
Liver cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	161.2 (30.7 to 499.6)	74.3 (-11.5 to 316.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-22.8 to 394.5)	41.8 (-17.6 to 241.2)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	482.7 (179.9 to 1,171.7)	286.1 (89.1 to 717.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-154.0 to 891.6)	53.3 (-71.5 to 542.4)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.0 (-51.8 to 112.8)	-36.6 (-66.6 to 37.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-54.5 to 75.3)	-44.5 (-68.4 to 13.1)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-51.8 to 112.8)	-36.6 (-66.6 to 37.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-54.5 to 75.3)	-44.5 (-68.4 to 13.1)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	794.4 (383.1 to 1,596.6)	568.6 (235.6 to 1,131.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-39.2 to 162.7)	276.7 (125.0 to 622.5)
Larynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	19.3 (-17.4 to 76.3)	-21.5 (-45.2 to 14.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-23.0 to 74.4)	-24.2 (-48.4 to 13.3)
Tracheal, bronchus and lung cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	144.4 (49.1 to 293.7)	64.3 (2.4 to 157.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-38.0 to 258.4)	49.6 (-4.8 to 131.5)
Breast cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	35.7 (-22.5 to 134.1)	27.6 (-50.4 to 43.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-21.8 to 143.6)	-15.2 (-48.9 to 45.6)
Cervical cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	76.3 (-15.5 to 282.0)	19.0 (-41.2 to 154.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-18.1 to 286.1)	19.2 (-41.8 to 150.3)
Uterine cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	161.6 (46.7 to 344.3)	74.8 (0.3 to 189.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-37.2 to 300.0)	55.7 (-7.3 to 158.4)
Prostate cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	123.3 (61.5 to 194.6)	46.7 (8.0 to 93.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-53.5 to 178.0)	38.1 (-1.6 to 80.6)
Colon and rectum cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.9 (-34.8 to 104.9)	-24.3 (-55.8 to 35.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-33.4 to 98.1)	-25.1 (-54.8 to 31.1)
Lip and oral cavity cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.3 (-13.1 to 159.5)	1.1 (-38.9 to 81.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-14.8 to 147.8)	-1.5 (-39.8 to 67.8)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.3 (-27.6 to 171.9)	-9.4 (-52.2 to 71.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-27.0 to 146.9)	-12.5 (-52.3 to 61.4)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.4 (-6.0 to 180.7)	16.9 (-35.5 to 90.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-9.4 to 158.3)	10.2 (-37.5 to 73.9)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	153.4 (54.2 to 334.8)	62.0 (-2.4 to 166.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-45.9 to 292.6)	49.8 (-4.4 to 142.6)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	116.7 (30.4 to 279.4)	46.0 (-12.7 to 147.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-23.9 to 251.3)	34.5 (-18.2 to 132.5)
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.0 (54.2 to 196.3)	25.8 (-7.4 to 79.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-35.7 to 256.5)	29.9 (-22.2 to 116.8)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.2 (4.9 to 283.8)	38.1 (-28.2 to 156.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-1.8 to 288.2)	34.8 (-29.5 to 148.2)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.6 (1.1 to 277.8)	43.0 (-27.0 to 173.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-6.9 to 239.4)	30.1 (-30.6 to 144.9)
Kidney cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.7 (30.7 to 241.8)	45.9 (-1.7 to 147.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-27.9 to 234.0)	37.4 (-6.6 to 136.6)
Bladder cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.0 (-38.6 to 102.5)	-42.8 (-69.4 to 16.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-45.6 to 108.3)	-45.5 (-72.7 to 18.8)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.6 (-10.6 to 166.2)	32.1 (-17.5 to 104.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-3.5 to 152.5)	28.2 (-18.2 to 91.1)
Thyroid cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.0 (-1.9 to 174.6)	26.1 (-20.8 to 127.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-6.6 to 168.3)	21.4 (-24.4 to 98.6)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.8 (37.4 to 220.2)	49.5 (-0.7 to 128.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-6.3 to 208.2)	40.2 (-3.0 to 120.1)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	109.2 (12.1 to 287.4)	56.0 (-14.9 to 180.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-9.5 to 232.0)	40.2 (-21.2 to 139.6)
Non-Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	147.4 (39.4 to 339.7)	65.8 (-4.1 to 187.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-37.5 to 320.8)	58.5 (-7.6 to 173.1)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.8 (9.5 to 191.8)	18.2 (-26.1 to 88.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-2.4 to 177.7)	13.1 (-32.0 to 85.9)
Leukemia	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	104.6 (23.6 to 238.4)	57.9 (-6.2 to 136.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-27.2 to 189.9)	40.2 (-3.6 to 107.2)
Other neoplasms	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	267.7 (70.0 to 607.6)	217.4 (48.2 to 432.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-63.9 to 539.7)	190.3 (33.1 to 370.8)
Cardiovascular diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	93.4 (48.7 to 142.3)	27.9 (-1.0 to 57.7)
Rheumatic heart disease	0.3 (0.3 to 0.3)	0.3 (0.3 to 0.4)	20.1 (4.0 to 39.7)	-2.4 (-14.5 to 11.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-6.7 to 44.3)	-6.3 (-30.0 to 10.4)
Ischemic heart disease	0.7 (0.6 to 0.9)	1.1 (0.9 to 1.3)	59.4 (17.1 to 111.4)	-0.1 (-26.7 to 33.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	64.9 (24.3 to 109.3)	4.1 (-21.5 to 31.1)
Cerebrovascular disease	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	52.6 (26.0 to 90.8)	-1.4 (-19.7 to 22.7)
Ischemic stroke	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	56.8 (27.8 to 91.6)	-1.5 (-21.2 to 22.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-25.1 to 93.4)	-1.8 (-21.7 to 23.5)
Hemorrhagic stroke	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.2)	52.9 (23.8 to 91.5)	-1.0 (-19.7 to 24.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-21.2 to 91.9)	-1.3 (-21.0 to 25.8)
Hypertensive heart disease	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	85.5 (48.1 to 134.3)	16.2 (-7.1 to 46.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-46.9 to 133.3)	16.0 (-7.9 to 46.1)
Cardiomyopathy and myocarditis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	89.8 (62.5 to 124.0)	33.0 (12.8 to 59.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-57.3 to 129.8)	89.5 (10.5 to 63.2)
Atrial fibrillation and flutter	0.1 (0.1 to 0.1)	0.5 (0.4 to 0.6)	494.1 (324.9 to 722.7)	196.3 (105.4 to 329.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (-326.0 to 728.4)	496.3 (109.1 to 336.1)
Peripheral vascular disease	1.6 (1.3 to 2.1)	2.9 (2.2 to 3.7)	80.6 (17.7 to 160.2)	11.2 (-24.8 to 57.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-31.2 to 296.0)	-22.3 (-63.4 to 96.4)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.6 (12.9 to 99.2)	17.6 (-19.3 to 57.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-8.4 to 109.0)	55.0 (-21.2 to 68.6)
Other cardiovascular and circulatory diseases	1.0 (0.6 to 1.3)	2.1 (0.9 to 3.1)	117.7 (-0.9 to 301.7)	54.7 (-31.9 to 193.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	117.6 (-2.9 to 305.1)	55.1 (-31.8 to 193.1)
Chronic respiratory diseases	-	-	-	-	0.5 (0.3 to 0.7)	0.7 (0.4 to 0.9)	39.3 (19.8 to 60.9)	-3.2 (-17.5 to 11.9)
Chronic obstructive pulmonary disease	3.7 (3.5 to 3.9)	5.3 (5.0 to 5.6)	43.0 (38.9 to 47.2)	0.5 (-2.4 to 3.5)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	43.1 (20.5 to 65.7)	0.9 (-15.7 to 16.4)

Appendix Table G.4 - Samoa prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	140.4 (125.1 to 155.4)	140.4 (48.3 to 71.8)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.8 (26.6 to 39.1)	-14.9 (-19.1 to -10.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.5 (26.1 to 38.7)	-15.0 (-19.2 to -10.9)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	188.9 (175.1 to 204.6)	99.9 (91.1 to 109.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	184.2 (169.7 to 200.3)	96.5 (85.8 to 108.5)
Asthma	1.5 (1.1 to 1.9)	2.9 (2.3 to 3.5)	90.7 (49.4 to 177.4)	27.1 (4.0 to 73.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	91.9 (49.0 to 178.1)	27.9 (3.5 to 78.2)
Interstitial lung disease and pulmonary sarcoidosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.2 (10.3 to 108.5)	7.3 (-21.4 to 46.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.8 (10.0 to 108.7)	7.0 (-21.7 to 49.5)
Other chronic respiratory diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-10.5 (-32.8 to 24.1)	-36.0 (-52.0 to -11.9)
Cirrhosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.0 (-30.3 to -6.8)	-39.4 (-40.7 to -24.2)
Cirrhosis due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.6 (-27.9 to 15.2)	-23.7 (-40.3 to -7.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.5 (-32.8 to 21.6)	-23.6 (-42.7 to -1.9)
Cirrhosis due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.9 (-42.4 to 77.6)	-14.7 (-52.9 to 50.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-45.0 to 86.3)	-15.1 (-54.2 to 52.1)
Cirrhosis due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.7 (-67.5 to -27.9)	0.0 (-74.7 to -46.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.5 (-69.6 to -22.9)	-63.3 (-76.6 to -43.4)
Cirrhosis due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.5 (-51.9 to 4.0)	-31.9 (-53.2 to -4.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.1 (-59.4 to 15.9)	-32.5 (-57.8 to 6.1)
Digestive diseases	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	27.0 (1.8 to 46.9)	37.9 (-23.4 to 10.3)
Peptic ulcer disease	0.9 (0.8 to 0.9)	1.0 (1.0 to 1.0)	16.9 (10.9 to 23.5)	-23.3 (-27.2 to -18.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	16.1 (-0.5 to 29.8)	-22.9 (-32.4 to -13.4)
Gastritis and duodenitis	1.2 (1.2 to 1.3)	1.2 (1.1 to 1.3)	-0.1 (-7.3 to 5.0)	-22.0 (-27.1 to -17.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-6.8 (-18.2 to 3.0)	-23.3 (-30.3 to -17.5)
Appendicitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.7 (-34.4 to 29.2)	-25.0 (-43.9 to -0.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.4 (-43.5 to 48.1)	-23.2 (-50.9 to 15.8)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.8 (-32.7 to 48.3)	-11.7 (-28.4 to 3.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.3 (-34.2 to 64.1)	-11.3 (-36.1 to 19.5)
Inguinal, femoral, and abdominal hernia	0.5 (0.4 to 0.6)	0.8 (0.7 to 0.9)	42.6 (16.9 to 83.5)	-3.5 (-19.7 to 21.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.4 (-15.7 to 82.4)	-3.4 (-19.4 to 20.6)
Inflammatory bowel disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.7 (15.1 to 30.6)	-9.1 (-14.6 to -3.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.5 (2.4 to 46.3)	-9.5 (-22.7 to 7.2)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.6 (34.1 to 174.8)	59.3 (-18.8 to 190.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.2 (9.2 to 178.7)	47.1 (-25.4 to 174.0)
Gallbladder and biliary diseases	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	42.1 (23.4 to 62.0)	-9.0 (-18.5 to 6.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.5 (19.7 to 68.0)	-7.1 (-20.0 to 9.4)
Pancreatitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.3 (34.7 to 61.6)	4.9 (-3.6 to 14.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.2 (24.2 to 75.4)	5.1 (-10.1 to 23.7)
Other digestive diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	92.3 (-10.4 to 186.3)	47.4 (-33.1 to 125.7)
Neurological disorders	-	-	-	-	0.7 (0.5 to 1.0)	0.9 (0.6 to 1.3)	31.3 (8.4 to 54.4)	-0.5 (-16.0 to 15.3)
Alzheimer disease and other dementias	0.4 (0.4 to 0.5)	0.8 (0.7 to 0.9)	93.6 (62.1 to 125.5)	3.5 (-13.3 to 20.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	100.2 (67.7 to 134.0)	3.4 (-13.3 to 21.2)
Parkinson disease	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	62.8 (54.2 to 72.5)	-0.1 (-4.7 to 5.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.1 (45.2 to 80.5)	-0.1 (-9.2 to 10.1)
Epilepsy	0.5 (0.4 to 0.6)	0.5 (0.4 to 0.7)	12.4 (-23.5 to 64.3)	-1.1 (-31.4 to 44.2)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	10.3 (-27.1 to 62.2)	-2.4 (-34.7 to 43.1)
Multiple sclerosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	142.2 (115.8 to 172.9)	77.1 (58.0 to 98.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	142.2 (115.7 to 172.9)	77.1 (58.0 to 98.6)
Migraine	10.4 (7.8 to 12.5)	12.5 (9.6 to 15.8)	22.5 (-13.8 to 62.7)	7.7 (-26.8 to 33.0)	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.7)	21.9 (-15.0 to 40.6)	19.9 (-26.7 to 32.7)
Tension-type headache	20.2 (16.3 to 24.3)	23.7 (21.1 to 26.5)	17.8 (-8.1 to 48.6)	-4.2 (-22.9 to 16.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	17.4 (8.6 to 48.6)	-4.2 (-22.8 to 17.3)
Medication overuse headache	0.5 (0.3 to 0.6)	0.9 (0.6 to 1.2)	97.0 (69.0 to 146.6)	50.6 (29.1 to 87.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	96.2 (67.3 to 144.1)	51.0 (28.6 to 88.0)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.1 (-12.5 to 57.4)	3.0 (-21.4 to 36.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-18.0 (-52.1 to 37.6)	-56.5 (-74.9 to -26.9)
Mental and substance use disorders	-	-	-	-	2.5 (1.8 to 3.2)	3.0 (2.1 to 3.8)	19.6 (16.0 to 23.1)	-0.0 (-2.8 to 2.2)
Schizophrenia	0.4 (0.4 to 0.4)	0.5 (0.5 to 0.6)	29.7 (24.7 to 35.4)	-0.6 (-4.2 to 3.8)	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.4)	29.3 (21.6 to 37.8)	0.5 (-6.2 to 5.6)
Alcohol use disorders	1.0 (0.9 to 1.1)	1.5 (1.3 to 1.6)	48.6 (39.4 to 60.2)	30.8 (23.3 to 39.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	48.8 (37.3 to 63.5)	31.2 (21.8 to 42.6)
Drug use disorders	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-1.2 (-16.1 to 17.3)	-8.9 (-21.7 to 5.5)
Opioid use disorders	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	32.5 (19.2 to 51.3)	4.1 (-5.2 to 15.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	32.0 (15.8 to 55.3)	4.1 (-8.4 to 20.7)
Cocaine use disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	0.1 (-0.8 to 23.7)	0.1 (-10.3 to 10.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-12.3 to 37.2)	0.8 (-19.8 to 21.7)
Amphetamine use disorders	0.5 (0.4 to 0.6)	0.4 (0.3 to 0.4)	-19.7 (-34.4 to 3.2)	-20.9 (-34.6 to -1.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-19.5 (-36.4 to 3.9)	-20.9 (-36.1 to 0.3)
Cannabis use disorders	0.6 (0.5 to 0.7)	0.6 (0.6 to 0.7)	3.9 (-3.3 to 11.8)	-0.1 (-6.0 to 6.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.1 (8.6 to 19.2)	0.1 (-11.1 to 13.5)
Other drug use disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-13.7 (-39.1 to 24.5)	-16.7 (-41.1 to 18.4)
Depressive disorders	-	-	-	-	0.7 (0.5 to 1.1)	0.9 (0.6 to 1.3)	25.5 (17.6 to 33.0)	-0.6 (-6.5 to 4.8)
Major depressive disorder	2.8 (2.2 to 3.4)	3.5 (2.7 to 4.2)	24.3 (14.7 to 33.4)	-0.4 (-8.2 to 6.3)	0.6 (0.4 to 0.9)	0.7 (0.5 to 1.1)	23.6 (13.8 to 33.2)	-0.6 (-8.3 to 6.7)
Dysthymia	1.6 (1.4 to 1.8)	2.1 (1.9 to 2.4)	33.1 (29.2 to 37.5)	-0.5 (-0.8 to -0.3)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	32.5 (27.3 to 37.8)	-0.5 (-2.8 to 1.7)
Bipolar disorder	0.7 (0.6 to 0.9)	0.9 (0.8 to 1.1)	22.5 (14.1 to 34.4)	-1.0 (-6.9 to 4.9)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	22.0 (12.5 to 34.5)	-1.0 (-7.7 to 6.5)
Anxiety disorders	3.9 (3.2 to 4.6)	4.6 (3.9 to 5.4)	18.2 (15.1 to 22.1)	0.4 (-0.8 to -0.1)	0.4 (0.2 to 0.5)	0.4 (0.3 to 0.6)	19.6 (14.7 to 23.0)	-0.6 (-3.5 to 2.5)
Eating disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.2 (-14.9 to 13.9)	-5.0 (-17.7 to 8.8)
Anorexia nervosa	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-5.3 (-15.3 to 3.6)	-9.6 (-19.3 to -0.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.8 (-23.4 to 17.0)	-9.8 (-27.3 to 9.9)
Bulimia nervosa	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	4.1 (2.1 to 8.2)	0.8 (-0.4 to 1.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.7 (-14.5 to 29.0)	0.2 (-17.0 to 22.8)
Autistic spectrum disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	12.6 (8.6 to 17.1)	0.2 (-2.9 to 3.9)
Autism	0.5 (0.5 to 0.6)	0.6 (0.6 to 0.6)	13.1 (12.7 to 13.7)	0.2 (0.2 to 0.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	12.6 (7.4 to 18.7)	0.1 (-4.3 to 4.9)
Asperger syndrome	0.8 (0.7 to 0.8)	0.9 (0.8 to 0.9)	12.7 (12.1 to 13.3)	0.3 (0.2 to 0.3)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	12.5 (7.6 to 17.4)	0.4 (-3.5 to 4.2)
Attention-deficit/hyperactivity disorder	1.4 (1.3 to 1.4)	1.4 (1.3 to 1.5)	1.9 (1.8 to 2.0)	-1.4 (-1.5 to -1.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.8 (5.6 to 10.5)	-1.6 (-8.5 to 6.8)
Conduct disorder	1.4 (1.3 to 1.5)	1.1 (1.3 to 1.5)	1.2 (0.9 to 1.5)	-1.2 (-1.2 to -1.0)	0.2 (0.0 to 0.2)	0.2 (0.1 to 0.2)	1.2 (-3.6 to 6.7)	-1.1 (-5.9 to 4.2)
Idiopathic intellectual disability	0.7 (0.4 to 1.0)	0.7 (0.4 to 1.1)	4.7 (-26.9 to 51.2)	-3.4 (-32.8 to 39.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	4.1 (-27.2 to 52.5)	3.7 (-33.0 to 42.6)
Other mental and substance use disorders	2.1 (2.0 to 2.3)	2.7 (2.5 to 2.8)	27.0 (24.7 to 29.4)	0.5 (0.1 to 0.9)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	26.5 (20.8 to 32.5)	0.5 (-3.1 to 4.4)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	1.0 (0.7 to 1.4)	1.4 (1.0 to 2.0)	37.7 (24.0 to 51.6)	5.6 (-6.6 to 17.8)
Diabetes mellitus	7.0 (6.2 to 8.2)	11.0 (9.4 to 12.5)	57.1 (27.8 to 90.6)	12.9 (8.9 to 35.7)	0.5 (0.3 to 0.6)	0.7 (0.5 to 1.0)	61.7 (29.7 to 96.3)	12.7 (9.9 to 37.6)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.6 (22.0 to 39.0)	12.7 (7.4 to 19.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.6 (22.0 to 39.1)	12.7 (7.4 to 19.1)
Chronic kidney disease	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	3.1 (16.1 to 41.0)	0.2 (-6.9 to 12.7)
Chronic kidney disease due to diabetes mellitus	0.5 (0.3 to 0.7)	1.1 (0.8 to 1.5)	118.9 (55.7 to 235.9)	51.4 (3.5 to 133.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.7 (55.4 to 200.7)	52.9 (10.9 to 123.1)
Chronic kidney disease due to hypertension	1.1 (0.7 to 1.6)	0.6 (0.4 to 0.8)	46.9 (-59.2 to -28.0)	-53.5 (-65.5 to -39.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (-11.5 to 59.4)	-2.8 (-26.3 to 25.3)
Chronic kidney disease due to glomerulonephritis	1.2 (0.8 to 1.8)	1.4 (0.9 to 2.2)	15.1 (-21.8 to 53.8)	9.4 (-36.1 to 59.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.9 (-69.8 to -38.4)	60.7 (-73.5 to -41.6)
Chronic kidney disease due to other causes	2.8 (2.0 to 4.0)	3.9 (2.7 to 5.5)	42.8 (17.2 to 66.6)	7.2 (-10.5 to 25.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	49.2 (24.4 to 79.9)	14.4 (-6.2 to 36.8)
Urinary diseases and male infertility	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	39.7 (25.4 to 54.6)	-4.1 (-14.2 to 6.8)

Appendix Table G.4 - Samoa prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.7 (40.0 to 65.2)	26.2 (17.5 to 37.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.1 (19.1 to 91.9)	26.7 (3.8 to 52.9)
Urolithiasis	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	19.6 (-0.0 to 44.2)	-22.0 (-33.3 to -4.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (7.7 to 35.3)	-13.6 (-21.7 to -4.2)
Benign prostatic hyperplasia	1.0 (0.9 to 1.0)	1.5 (1.3 to 1.6)	53.5 (34.7 to 75.9)	-2.7 (-14.7 to 11.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.0 (34.1 to 76.6)	-2.3 (-14.8 to 12.4)
Male infertility due to other causes	1.2 (0.9 to 1.4)	1.4 (1.1 to 1.7)	19.7 (-11.8 to 63.5)	4.2 (-22.2 to 40.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-14.3 to 65.6)	3.7 (-23.6 to 42.6)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-31.1 to 31.9)	0.0 (-47.8 to 13.5)
Gynecological diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	16.6 (1.7 to 32.6)	-10.7 (-20.8 to -0.4)
Uterine fibroids	2.4 (2.2 to 2.6)	3.4 (3.1 to 3.7)	40.5 (39.2 to 41.9)	-7.5 (-7.7 to -7.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	30.4 (19.8 to 39.5)	-8.7 (-15.6 to -2.0)
Polycystic ovarian syndrome	1.9 (1.7 to 2.1)	2.3 (2.0 to 2.5)	21.7 (4.4 to 40.8)	-6.8 (-19.5 to 6.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.7 (5.0 to 42.0)	-6.7 (-19.3 to 6.9)
Female infertility due to other causes	1.2 (0.9 to 1.5)	1.5 (1.2 to 1.8)	25.7 (9.4 to 77.3)	-2.5 (-29.9 to 40.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.3 (-11.2 to 21.6)	-0.9 (-28.9 to 38.0)
Endometriosis	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.3)	24.7 (1.9 to 55.0)	-4.9 (-22.6 to 17.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.2 to 58.1)	5.5 (-23.8 to 19.7)
Genital prolapse	5.8 (5.0 to 6.6)	7.3 (6.4 to 8.2)	24.7 (2.4 to 52.7)	-8.8 (-23.7 to 9.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.6 (1.6 to 54.4)	-8.8 (-23.7 to 10.5)
Premenstrual syndrome	4.5 (3.2 to 6.1)	4.2 (2.4 to 6.2)	-6.3 (-44.0 to 45.8)	-22.9 (-54.3 to 17.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-45.1 to 47.4)	-7.1 (-54.5 to 20.3)
Other gynecological diseases	0.4 (0.3 to 0.5)	0.4 (0.4 to 0.5)	15.7 (-11.4 to 55.6)	-4.7 (-27.7 to 29.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.9 (-10.8 to 63.4)	-6.9 (-25.4 to 63.4)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	8.6 (0.9 to 20.6)	-0.2 (-9.0 to 12.1)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.6 (-23.5 to 7.5)	-6.9 (-25.0 to 5.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.6 (-34.7 to 27.3)	-10.8 (-35.0 to 21.7)
Thalassemia trait	4.9 (3.8 to 6.9)	5.6 (4.2 to 8.0)	14.5 (7.6 to 19.4)	0.3 (-5.1 to 4.6)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	10.0 (0.7 to 21.3)	0.6 (-8.7 to 13.2)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.1 (-77.3 to -32.3)	-64.1 (-77.9 to -34.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-68.3 (-81.6 to -28.6)	-69.2 (-82.4 to -30.1)
Sickle cell trait	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	44.1 (-55.7 to -24.6)	-51.3 (-61.5 to -31.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.7 (-67.9 to -16.7)	54.5 (-68.8 to -32.0)
G6PD deficiency	7.1 (4.8 to 9.6)	8.2 (4.8 to 11.0)	16.8 (-42.5 to 89.4)	2.4 (-49.6 to 66.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.7 (-61.8 to 58.6)	-29.1 (-64.5 to 25.6)
G6PD trait	32.7 (30.4 to 34.7)	37.8 (35.3 to 40.2)	15.9 (5.1 to 27.4)	-0.3 (-9.5 to 9.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.4 (-77.8 to 548.9)	0.8 (-72.4 to 329.0)
Other hemoglobinopathies and hemolytic anemias	0.7 (0.6 to 0.9)	0.8 (0.7 to 0.9)	9.2 (-17.1 to 35.8)	1.5 (-21.5 to 25.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.5 (-25.8 to 59.2)	1.5 (-28.8 to 48.9)
Endocrine, metabolic, blood, and immune disorders	1.6 (1.4 to 1.8)	1.8 (1.7 to 1.9)	14.8 (-0.1 to 34.1)	2.2 (-8.8 to 15.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	15.5 (2.0 to 47.5)	4.9 (-6.3 to 24.9)
Musculoskeletal disorders	-	-	-	-	1.7 (1.2 to 2.3)	2.4 (1.7 to 3.3)	40.4 (28.4 to 57.1)	1.3 (-7.2 to 11.4)
Rheumatoid arthritis	0.1 (0.1 to 0.1)	0.3 (0.3 to 0.3)	144.7 (129.5 to 159.2)	81.1 (69.0 to 91.9)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	142.3 (117.9 to 168.6)	80.6 (64.8 to 97.0)
Osteoarthritis	2.1 (2.0 to 2.1)	3.3 (3.2 to 3.5)	61.1 (51.7 to 70.6)	0.7 (-4.8 to 6.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	60.4 (50.7 to 70.2)	0.8 (-5.1 to 6.7)
Low back and neck pain	-	-	-	-	1.3 (0.8 to 1.7)	1.7 (1.2 to 2.4)	36.2 (20.2 to 58.7)	1.4 (-11.1 to 16.6)
Low back pain	7.3 (6.8 to 7.8)	9.6 (9.0 to 10.3)	32.9 (20.7 to 45.0)	-0.1 (-8.5 to 8.3)	0.8 (0.6 to 1.1)	1.1 (0.7 to 1.5)	32.2 (19.6 to 44.9)	-0.0 (-8.7 to 8.2)
Neck pain	4.6 (3.2 to 6.2)	6.6 (4.8 to 8.4)	43.3 (9.5 to 108.8)	3.5 (-24.3 to 45.2)	0.5 (0.3 to 0.7)	0.7 (0.4 to 1.0)	42.7 (9.3 to 109.7)	3.5 (-24.3 to 45.2)
Gout	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	64.0 (49.5 to 81.5)	7.8 (-1.5 to 19.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.7 (33.2 to 99.3)	6.9 (-11.7 to 30.7)
Other musculoskeletal disorders	3.2 (2.5 to 3.8)	4.5 (3.5 to 5.5)	40.8 (31.1 to 55.2)	-6.1 (-11.0 to 3.3)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	40.4 (30.2 to 54.7)	-5.2 (-11.4 to 40.0)
Other non-communicable diseases	-	-	-	-	2.6 (1.8 to 3.7)	3.2 (2.2 to 4.5)	20.4 (3.3 to 38.0)	-5.3 (-14.3 to 4.8)
Congenital anomalies	-	-	-	-	0.3 (0.2 to 0.8)	0.5 (0.3 to 0.8)	43.2 (-36.6 to 201.4)	33.9 (-39.1 to 176.6)
Neural tube defects	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	26.1 (3.4 to 53.1)	20.2 (-1.6 to 46.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.4 (-4.0 to 81.0)	25.5 (-6.7 to 69.5)
Congenital heart anomalies	0.6 (0.5 to 0.7)	1.0 (0.8 to 1.1)	62.0 (22.8 to 110.3)	53.0 (14.9 to 99.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.0 (30.4 to 119.3)	59.8 (22.5 to 108.8)
Orofacial clefts	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	53.5 (18.7 to 98.8)	54.4 (18.9 to 101.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.2 (-21.4 to 68.3)	17.2 (-18.3 to 63.8)
Down syndrome	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	33.0 (7.9 to 69.4)	22.5 (-0.1 to 55.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.7 (12.4 to 85.5)	28.8 (3.6 to 67.6)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.0 (-30.5 to 79.0)	6.3 (-37.4 to 61.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.0 (-30.2 to 84.0)	5.6 (-37.2 to 64.6)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.3 (-18.6 to 81.7)	10.7 (-26.7 to 63.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.3 (-24.1 to 112.2)	11.0 (-35.6 to 85.9)
Chromosomal unbalanced rearrangements	0.0 (0.2 to 0.3)	0.3 (0.3 to 0.4)	32.9 (3.8 to 74.3)	21.8 (-4.6 to 50.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	41.1 (9.6 to 88.8)	28.2 (-1.0 to 71.8)
Other congenital anomalies	0.6 (0.5 to 0.7)	0.6 (0.5 to 0.7)	-1.6 (-10.9 to 8.3)	-13.6 (-21.7 to -5.6)	0.3 (0.1 to 0.7)	0.3 (0.2 to 0.7)	41.8 (-50.1 to 288.8)	33.3 (-52.9 to 267.4)
Skin and subcutaneous diseases	-	-	-	-	1.1 (0.7 to 1.6)	1.2 (0.8 to 1.9)	12.9 (5.3 to 24.1)	-1.0 (-6.6 to 9.1)
Dermatitis	10.0 (7.9 to 11.7)	11.6 (9.4 to 13.5)	15.7 (13.2 to 18.8)	-0.0 (-0.2 to 0.1)	0.4 (0.2 to 0.6)	0.4 (0.3 to 0.7)	12.6 (8.4 to 16.8)	0.0 (-2.5 to 2.6)
Psoriasis	0.0 (0.8 to 1.1)	0.0 (1.1 to 1.4)	-11.9 (21.6 to 27.1)	-24.3 (-0.1 to 0.3)	0.0 (0.1 to 0.1)	0.0 (0.1 to 0.1)	-11.0 (14.7 to 32.2)	-22.9 (-5.7 to 5.8)
Cellulitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.0 (-23.5 to 7.3)	-51.8 (-34.2 to -8.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.0 (-35.3 to 23.5)	-52.0 (-41.4 to -1.2)
Pyoderma	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-52.0 (-59.1 to -42.1)	-51.8 (-59.0 to -42.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.0 (-60.6 to -41.6)	-52.0 (-60.1 to -42.5)
Scabies	3.5 (2.7 to 5.3)	3.5 (2.7 to 4.7)	3.0 (-41.4 to 47.0)	-11.3 (-42.7 to 31.1)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	2.7 (-4.4 to 46.9)	-11.2 (-42.7 to 31.3)
Fungal skin diseases	15.9 (14.0 to 19.8)	20.1 (16.9 to 23.7)	24.9 (16.7 to 21.8)	18.9 (-0.1 to 0.2)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	18.7 (16.3 to 21.8)	0.1 (-0.6 to 0.9)
Viral skin diseases	3.9 (3.0 to 4.7)	4.1 (3.3 to 5.0)	7.0 (3.5 to 11.1)	0.0 (-2.2 to 2.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	6.8 (2.3 to 12.1)	-0.0 (-3.4 to 3.6)
Acne vulgaris	12.8 (9.9 to 16.1)	13.3 (9.7 to 17.3)	2.8 (-31.7 to 56.4)	-0.4 (-30.7 to 51.5)	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.3)	2.5 (-32.2 to 57.6)	-0.3 (-31.0 to 51.5)
Alopecia areata	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.2)	29.8 (6.5 to 54.2)	2.7 (-17.5 to 24.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.2 (3.8 to 59.5)	3.2 (-16.7 to 27.2)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.0 (-0.0 to 57.7)	2.3 (-22.5 to 25.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.3 (-6.7 to 68.6)	-1.9 (-26.5 to 31.8)
Urticaria	1.3 (0.9 to 1.7)	1.7 (1.3 to 2.2)	28.9 (9.1 to 111.7)	2.8 (-26.8 to 64.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	28.8 (9.1 to 111.4)	3.5 (-27.5 to 63.8)
Decubitus ulcer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.9 (1.3 to 96.5)	-7.0 (-30.4 to 40.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.7 (-4.9 to 96.4)	-7.7 (-34.0 to 42.7)
Other skin and subcutaneous diseases	9.7 (6.6 to 13.8)	12.6 (8.5 to 18.5)	30.1 (19.9 to 39.7)	-2.0 (-5.0 to 0.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	29.5 (19.5 to 39.0)	-1.9 (-5.0 to 1.2)
Sense organ diseases	-	-	-	-	1.3 (0.7 to 1.5)	1.3 (0.9 to 1.8)	22.7 (16.8 to 27.9)	-12.2 (-14.9 to -9.1)
Glaucoma	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	27.0 (10.2 to 61.1)	-15.1 (-26.4 to 9.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.5 (-2.0 to 75.0)	-20.3 (-35.6 to 10.8)
Cataract	0.7 (0.5 to 1.0)	0.9 (0.6 to 1.2)	29.5 (1.9 to 82.5)	-29.5 (-42.5 to -3.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	30.3 (2.5 to 77.2)	-29.7 (-43.2 to -7.7)
Macular degeneration	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.8)	36.7 (-4.1 to 78.0)	-8.9 (-36.6 to 19.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.2 (3.6 to 83.0)	-9.2 (-32.5 to 18.1)
Uncorrected refractive error	9.9 (9.1 to 10.7)	12.7 (11.8 to 13.7)	28.0 (17.8 to 42.4)	6.0 (-13.5 to 23.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	17.3 (9.7 to 26.8)	-13.8 (-18.9 to -7.7)
Age-related and other hearing loss	18.5 (17.3 to 19.7)	24.2 (22.7 to 25.9)	31.0 (25.8 to 35.8)	-8.7 (-11.9 to -6.2)	0.6 (0.4 to 0.8)	0.7 (0.5 to 1.1)	18.7 (17.0 to 34.7)	-9.5 (-13.2 to -5.4)
Other vision loss	0.8 (0.7 to 1.0)	0.9 (0.7 to 1.1)	2.5 (-8.7 to 18.3)	-23.7 (-31.5 to -10.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	5.2 (-8.5 to 22.5)	-23.1 (-32.8 to -13.3)
Other sense organ diseases	3.9 (3.7 to 4.1)	4.5 (4.3 to 4.7)	15.8 (7.1 to 24.6)	0.4 (-6.4 to 6.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	15.3 (5.7 to 24.9)	0.3 (-7.1 to 7.4)
Oral disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	17.4 (12.5 to 23.2)	-13.5 (-18.1 to -8.8)
Deciduous caries	20.1 (19.7 to 20.5)	21.3 (20.9 to 21.7)	6.0 (3.5 to 8.7)	0.2 (-2.1 to 2.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.0 (-2.0 to 13.2)	0.2 (-5.7 to 6.8)
Permanent caries	51.2 (48.6 to 53.8)	61.5 (58.5 to 64.4)	19.9 (12.3 to 28.3)	2.4 (-3.7 to 8.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	19.6 (11.6 to 28.3)	2.4 (-4.0 to 8.2)
Periodontal diseases	1.2 (1.1 to 1.2)	1.7 (1.6 to 1.8)	48.0 (35.2 to 60.2)	1.9 (-6.4 to 10.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.0 (34.4 to 60.6)	1.9 (-6.6 to 10.1)

Appendix Table G.4 - Samoa prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	1.7 (1.6 to 1.8)	1.8 (1.7 to 1.9)	5.6 (2.5 to 14.5)	-33.8 (-38.6 to -28.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	5.1 (3.4 to 14.6)	-33.8 (-38.9 to -28.0)
Other oral disorders	2.4 (2.3 to 2.6)	3.0 (2.8 to 3.2)	22.6 (13.6 to 34.0)	-0.1 (-7.0 to 8.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	22.3 (12.2 to 34.5)	-0.0 (-7.4 to 9.3)
Injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	48.8 (34.2 to 61.1)	13.6 (5.7 to 21.3)
Transport injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	52.6 (46.7 to 59.5)	13.1 (9.3 to 17.7)
Road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	54.1 (47.3 to 62.1)	14.9 (10.6 to 20.1)
Pedestrian road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.4 (47.7 to 72.0)	20.9 (13.8 to 29.0)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.6 (34.1 to 53.4)	7.2 (0.2 to 13.9)
Motorcyclist road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	44.4 (35.3 to 55.4)	6.1 (-0.3 to 14.1)
Motor vehicle road injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	62.4 (50.1 to 74.6)	21.9 (13.8 to 30.1)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.0 (47.2 to 67.8)	13.4 (6.8 to 20.5)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.5 (33.3 to 51.9)	1.3 (-4.6 to 8.2)
Unintentional injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	51.2 (46.7 to 55.9)	14.0 (10.9 to 17.2)
Falls	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	53.6 (45.6 to 61.7)	11.3 (6.2 to 16.5)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.6 (12.9 to 34.7)	-3.6 (-10.3 to 4.5)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.2 (-3.5 to 15.9)	-16.3 (-22.9 to -9.4)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.5 (-30.1 to 0.2)	-30.6 (-40.8 to -19.1)
Exposure to mechanical forces	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	61.1 (52.1 to 69.3)	26.7 (21.1 to 32.7)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.4 (5.8 to 23.8)	-10.2 (-16.5 to -3.2)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.6 (32.2 to 60.2)	15.8 (5.4 to 26.4)
Other exposure to mechanical forces	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	65.2 (55.1 to 74.1)	30.0 (23.7 to 36.5)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.0 (28.9 to 45.2)	4.4 (-2.0 to 11.2)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.3 (31.5 to 49.6)	7.7 (1.8 to 13.6)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.6 (28.2 to 58.8)	10.5 (0.4 to 21.1)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.6 (28.8 to 47.2)	5.5 (0.2 to 11.2)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.7 (31.8 to 48.5)	7.3 (2.2 to 12.7)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.7 (21.7 to 55.7)	14.3 (3.7 to 24.5)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.0 (16.2 to 35.2)	1.5 (-4.4 to 8.6)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.2 (40.4 to 61.3)	6.3 (-0.5 to 14.4)
Other unintentional injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	63.8 (52.3 to 75.2)	24.3 (16.3 to 32.5)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.3 (22.4 to 33.2)	-4.0 (-7.4 to 0.1)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.7 (20.9 to 42.7)	-3.7 (-10.9 to 3.6)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.1 (20.4 to 32.8)	-4.1 (-8.1 to 0.5)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.7 (11.4 to 26.7)	-8.6 (-14.1 to -2.9)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.9 (20.2 to 37.8)	-1.7 (-8.6 to 4.8)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.2 (19.1 to 34.8)	-4.3 (-9.2 to 1.9)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	29.7 (-47.0 to 196.0)	30.5 (-45.7 to 188.3)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	29.7 (-47.0 to 196.0)	30.5 (-45.7 to 188.3)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Sao Tome and Principe prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	10.8 (7.8 to 14.2)	17.9 (13.1 to 23.7)	66.7 (61.1 to 73.1)	-1.1 (-4.6 to 2.3)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.9 (2.0 to 4.1)	4.7 (3.3 to 6.5)	58.0 (46.3 to 81.4)	-3.4 (-12.8 to 16.0)
HIV/AIDS and tuberculosis	-	-	-	-	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.8)	240.5 (137.1 to 1,269.7)	65.7 (17.8 to 554.8)
Tuberculosis	0.1 (0.1 to 0.2)	0.3 (0.3 to 0.3)	98.7 (83.3 to 117.9)	-0.9 (-8.3 to 8.4)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	100.9 (80.8 to 125.0)	-0.1 (-6.6 to 11.1)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.7)	20,744.5 (1,014.3 to 218,692.7)	11,055.5 (451.0 to 109,064.9)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	18,496.7 (687.0 to 144,281.1)	9,113.1 (277.0 to 70,426.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16,959.3 (628.8 to 145,386.5)	8,173.0 (250.1 to 69,898.5)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.1)	0.9 (0.2 to 3.8)	17,913.4 (979.2 to 139,250.6)	9,928.5 (487.1 to 78,512.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.7)	23,931.6 (1,064.6 to 443,121.9)	13,114.9 (477.2 to 258,869.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.2 (0.4 to 0.7)	0.3 (0.5 to 0.9)	31.2 (17.8 to 46.7)	-18.7 (-25.8 to -10.2)
Diarrheal diseases	1.5 (1.3 to 1.8)	2.2 (1.9 to 2.4)	42.5 (15.0 to 71.6)	-9.1 (-24.7 to 7.1)	0.2 (0.2 to 0.4)	0.3 (0.2 to 0.5)	42.8 (14.3 to 72.6)	-8.4 (-24.8 to 7.6)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.4 (-48.6 to 8.5)	-48.7 (-67.6 to -32.9)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.5 (-39.5 to -1.9)	-50.1 (-62.3 to -38.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.7 (-41.3 to 7.1)	-49.0 (-62.7 to -34.6)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.7 (-17.2 to 35.3)	-34.1 (-48.0 to -13.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.4 (-20.2 to 42.0)	-33.5 (-49.4 to -12.3)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-87.5 (-99.5 to -41.5)	-92.1 (-99.7 to 23.2)
Lower respiratory infections	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	71.0 (33.0 to 140.7)	14.4 (-8.2 to 45.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.6 (31.4 to 149.3)	14.7 (-9.2 to 50.4)
Upper respiratory infections	4.2 (4.0 to 4.4)	7.3 (6.7 to 7.9)	73.8 (57.3 to 92.4)	5.1 (-4.9 to 15.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	73.9 (57.2 to 93.9)	5.2 (-5.0 to 16.2)
Otitis media	2.6 (2.4 to 2.9)	3.9 (3.6 to 4.2)	47.4 (34.2 to 62.2)	-8.9 (-17.2 to 0.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	47.1 (32.3 to 63.6)	-8.5 (-17.6 to 1.9)
Meningitis	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	9.5 (26.8 to 7.4)	-43.7 (-53.7 to -32.6)
Pneumococcal meningitis	0.5 (0.3 to 0.8)	0.5 (0.2 to 0.7)	-14.3 (-33.4 to 14.7)	-46.9 (-57.3 to -29.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	56.7 (-35.5 to 20.0)	-42.9 (-58.4 to -28.0)
H influenzae type B meningitis	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-25.7 (-44.9 to 13.6)	-54.6 (-66.9 to -28.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.4 (-43.9 to 13.5)	-48.5 (-64.6 to -30.5)
Meningococcal meningitis	0.3 (0.1 to 0.6)	0.2 (0.1 to 0.5)	-20.3 (-40.6 to 19.6)	-50.4 (-62.7 to -25.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-11.9 (-40.2 to 29.7)	-45.7 (-61.3 to -20.1)
Other meningitis	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-7.3 (-31.1 to 16.6)	-37.6 (-55.6 to -20.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.2 (-21.7 to 32.9)	-33.3 (-48.8 to -12.5)
Encephalitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	50.6 (34.5 to 70.6)	5.6 (-17.3 to 1.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.7 (31.0 to 89.9)	-6.1 (-19.1 to 9.9)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-62.3 (-97.8 to 67.6)	-71.1 (-98.0 to 247.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-62.3 (-97.8 to 708.6)	-71.1 (-98.0 to 248.9)
Whooping cough	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-75.7 (-78.5 to -72.7)	-84.4 (-86.2 to -82.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-75.8 (-80.3 to -69.8)	-84.4 (-87.3 to -80.6)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-72.4 (-92.1 to -30.4)	-82.9 (-95.0 to -58.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.7 (-78.8 to 41.0)	-69.5 (-86.3 to -22.2)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-71.4 (-76.8 to -64.8)	-81.6 (-85.1 to -77.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.1 (-81.2 to -57.2)	-81.4 (-87.9 to -72.6)
Varicella and herpes zoster	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	79.0 (59.3 to 107.7)	7.0 (-12.2 to 34.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.6 (33.7 to 164.6)	10.0 (-22.8 to 60.9)
Neglected tropical diseases and malaria	-	-	-	-	0.9 (0.6 to 1.3)	1.3 (0.8 to 1.9)	46.3 (26.0 to 71.0)	-10.0 (-26.1 to 9.2)
Malaria	20.2 (17.9 to 22.8)	26.6 (23.0 to 30.3)	31.3 (16.7 to 47.0)	-20.8 (-30.1 to -11.1)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.4)	20.9 (6.6 to 36.0)	-23.4 (-32.4 to -14.3)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.9 (-60.9 to 187.8)	-22.6 (-70.7 to 75.4)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.6 (3.4 to 121.6)	-8.3 (-28.4 to 26.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.6 (3.3 to 122.2)	-8.3 (-28.5 to 26.5)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.9 (-62.3 to 155.3)	-23.1 (-72.5 to 66.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.7 (-61.6 to 188.8)	-22.7 (-71.0 to 76.1)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	4.6 (1.8 to 9.9)	7.9 (3.1 to 16.9)	71.0 (65.7 to 75.4)	0.0 (-2.7 to 2.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	70.8 (42.1 to 91.8)	0.9 (-14.4 to 14.1)
Cysticercosis	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.5)	42.8 (-54.9 to 327.5)	-27.2 (-75.7 to 83.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	54.9 (-51.3 to 380.5)	-22.0 (-75.0 to 104.6)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.8 (-14.6 to 23.5)	-36.8 (-41.2 to -12.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.7 (-21.6 to 26.0)	-35.1 (-44.9 to -11.3)
Lymphatic filariasis	7.9 (6.0 to 9.7)	12.3 (9.2 to 15.3)	52.7 (12.3 to 119.8)	-9.1 (-32.2 to 26.5)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.6)	55.1 (15.5 to 92.9)	-5.6 (-40.4 to 23.3)
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.3)	705.4 (697.4 to 714.7)	395.5 (390.6 to 401.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	705.3 (531.9 to 980.9)	395.5 (302.5 to 519.2)
Yellow fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.9 (-47.8 to -38.8)	-73.0 (-79.3 to -64.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-55.9 (-67.9 to -38.7)	-73.0 (-79.3 to -64.0)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.5 (-56.8 to 42.0)	-54.4 (-68.3 to -5.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.5 (-57.5 to 42.7)	-35.4 (-68.5 to -5.2)
Intestinal nematode infections	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	62.3 (13.3 to 143.1)	0.9 (-34.2 to 66.4)
Ascariasis	38.9 (27.8 to 52.6)	63.5 (45.3 to 87.6)	61.8 (3.0 to 152.1)	-1.8 (-42.9 to 72.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	63.6 (-20.2 to 253.0)	2.3 (-55.3 to 163.2)
Trichuriasis	31.8 (2.8 to 43.9)	52.2 (37.4 to 73.7)	62.3 (1.5 to 171.6)	-0.4 (-43.9 to 90.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	57.4 (-36.6 to 328.5)	-0.4 (-66.9 to 217.0)
Hookworm disease	18.4 (12.8 to 26.1)	31.4 (21.1 to 46.2)	68.7 (-4.5 to 190.5)	27.7 (-47.7 to 93.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	65.6 (3.0 to 168.4)	1.3 (-44.5 to 80.1)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	2.1 (1.6 to 2.6)	3.1 (2.9 to 3.3)	48.0 (17.7 to 94.7)	-4.2 (-21.4 to 20.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.5)	35.5 (-2.1 to 103.6)	-17.8 (-45.4 to 35.7)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	17.7 (37.4 to 90.3)	-17.7 (-28.8 to -3.0)
Maternal hemorrhage	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	99.1 (24.2 to 253.2)	-11.6 (-43.0 to 52.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.8 (-22.5 to 344.3)	-17.2 (-61.2 to 103.1)
Maternal sepsis and other maternal infections	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-5.5 (-36.9 to 11.9)	-59.0 (-72.5 to -52.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.6 (-59.0 to 48.1)	-59.6 (-77.0 to -33.1)
Maternal hypertensive disorders	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	42.5 (26.8 to 53.5)	-33.1 (-44.0 to -24.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.1 (10.3 to 71.4)	-33.4 (-47.2 to -18.1)
Obstructed labor	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	60.1 (42.6 to 78.9)	-16.3 (-25.7 to -7.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	60.0 (37.0 to 87.8)	-16.6 (-28.0 to -3.8)
Complications of abortion	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.3)	112.0 (34.4 to 503.5)	-10.0 (-16.3 to 283.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.0 (27.9 to 509.0)	-10.0 (-19.6 to 291.3)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	79.5 (60.6 to 773.1)	134.6 (-0.1 to 443.3)
Neonatal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.6)	299.0 (158.0 to 506.2)	148.5 (61.4 to 278.8)
Preterm birth complications	0.4 (0.2 to 0.8)	1.7 (1.0 to 2.7)	291.4 (198.2 to 479.3)	131.7 (78.0 to 236.2)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	440.8 (236.1 to 881.6)	228.3 (108.9 to 496.0)
Neonatal encephalopathy due to birth asphyxia and trauma	0.6 (0.1 to 1.7)	0.8 (0.2 to 2.1)	50.6 (-3.0 to 227.3)	-12.1 (-43.0 to 102.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	198.8 (61.5 to 449.6)	87.9 (-0.6 to 265.2)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	122.9 (113.8 to 148.6)	48.1 (42.1 to 65.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	126.8 (107.6 to 152.8)	50.8 (38.0 to 68.0)
Hemolytic disease and other neonatal jaundice	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	195.1 (34.4 to 503.5)	84.8 (-16.3 to 283.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	190.6 (27.9 to 509.0)	82.1 (-19.6 to 291.3)
Other neonatal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	276.1 (60.6 to 773.1)	134.6 (-0.1 to 443.3)
Nutritional deficiencies	-	-	-	-	1.3 (0.9 to 1.8)	1.9 (1.2 to 2.7)	47.2 (37.9 to 59.5)	-10.4 (-16.3 to -3.4)
Protein-energy malnutrition	0.6 (0.3 to 0.9)	1.2 (0.6 to 2.2)	115.3 (-4.6 to 383.0)	23.7 (-30.0 to 124.2)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	182.3 (-4.3 to 397.4)	25.3 (-31.9 to 132.1)
Iodine deficiency	4.2 (2.4 to 6.4)	3.8 (2.0 to 6.2)	-10.6 (-57.2 to 110.8)	-50.5 (-77.3 to 18.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-9.9 (-57.0 to 110.4)	-50.4 (-77.2 to 19.4)
Vitamin A deficiency	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-25.5 (-41.9 to -4.4)	-55.4 (-64.7 to -41.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.7 (-43.0 to -7.3)	-56.2 (-66.0 to -42.6)

Appendix Table G.4 - Sao Tome and Principe prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	30.6 (30.1 to 31.2)	47.2 (46.8 to 47.6)	54.4 (51.0 to 57.3)	-6.7 (-8.2 to -5.3)	1.1 (0.7 to 1.6)	1.6 (1.1 to 2.4)	47.9 (43.0 to 51.1)	47.9 (-10.5 to -5.8)
Other nutritional deficiencies	-	-	-	-	0.0	0.0	241.8 (7.7 to 890.2)	95.4 (-27.3 to 362.0)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	47.8 (33.4 to 71.9)	-12.9 (-21.1 to -2.1)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.0	0.0	81.3 (45.7 to 124.0)	-8.4 (-23.8 to 9.6)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.9 (-14.9 to 23.8)	-41.5 (-50.0 to -29.9)	0.0	0.0	2.8 (-54.7 to 24.1)	-41.6 (-54.7 to 24.1)
Chlamydial infection	1.6 (1.1 to 2.1)	3.0 (2.1 to 3.8)	93.9 (24.8 to 182.7)	-2.1 (35.1 to 42.5)	0.0	0.0	93.3 (21.8 to 210.1)	-1.7 (-36.4 to 56.8)
Gonococcal infection	0.5 (0.3 to 0.6)	0.8 (0.6 to 1.1)	77.7 (16.2 to 260.4)	-9.3 (-38.1 to 72.5)	0.0	0.0	68.7 (7.4 to 188.6)	-12.8 (-41.4 to 39.6)
Trichomoniasis	1.3 (0.7 to 2.0)	2.9 (1.5 to 4.3)	130.7 (-13.2 to 394.3)	11.2 (-52.5 to 108.5)	0.0	0.0	132.7 (-20.8 to 435.0)	12.9 (-56.5 to 119.4)
Genital herpes	16.6 (15.2 to 17.9)	30.8 (28.2 to 33.5)	85.3 (66.3 to 107.0)	2.0 (-11.7 to 10.3)	0.0	0.0	84.9 (63.6 to 109.6)	84.9 (-12.7 to 11.1)
Other sexually transmitted diseases	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	68.1 (38.5 to 98.3)	-27.7 (-40.1 to -15.0)	0.0	0.0	69.1 (9.8 to 170.6)	21.6 (-46.6 to 18.6)
Hepatitis	-	-	-	-	0.0	0.0	17.6 (-7.0 to 46.2)	-35.3 (-51.3 to -15.7)
Hepatitis A	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.3)	42.7 (41.5 to 44.0)	-4.9 (-5.0 to -4.7)	0.0	0.0	55.8 (38.0 to 74.7)	0.4 (-10.2 to 12.7)
Hepatitis B	23.1 (19.3 to 27.6)	21.4 (18.6 to 24.5)	-7.0 (-26.6 to 15.4)	-45.7 (-57.9 to -33.0)	0.0	0.0	2.8 (-33.5 to 48.3)	-44.1 (-65.2 to -17.4)
Hepatitis C	8.1 (7.1 to 9.0)	9.6 (8.4 to 10.9)	18.5 (0.7 to 40.4)	-29.0 (-39.2 to -13.7)	0.0	0.0	17.6 (-13.1 to 58.6)	-22.7 (-47.0 to 2.3)
Hepatitis E	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	13.4 (-21.4 to 93.0)	-39.5 (-56.7 to 3.8)	0.0	0.0	13.7 (-25.6 to 100.5)	-39.7 (-58.4 to 6.4)
Leprosy	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	0.0	-	-
Other infectious diseases	1.5 (1.1 to 1.8)	2.2 (1.9 to 2.5)	49.2 (27.4 to 80.9)	-5.2 (-17.9 to 11.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	44.3 (26.1 to 88.3)	-3.7 (-15.5 to 22.1)
Non-communicable diseases	-	-	-	-	7.5 (5.5 to 9.7)	12.9 (9.4 to 16.8)	72.5 (65.6 to 78.2)	0.9 (-2.9 to 4.0)
Neoplasms	-	-	-	-	0.0	0.1	85.6 (41.6 to 128.3)	26.8 (-0.2 to 54.3)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.6 (-7.7 to 140.3)	10.9 (-30.7 to 72.6)	0.0	0.0	50.6 (-7.2 to 130.6)	10.2 (-30.0 to 68.1)
Stomach cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.6 (-12.7 to 94.4)	-3.1 (-34.7 to 38.9)	0.0	0.0	34.5 (-11.4 to 92.8)	-2.4 (-34.2 to 37.5)
Liver cancer	-	-	-	-	0.0	0.0	0.0	0.0
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.9 (-41.4 to 251.9)	3.0 (-58.2 to 148.7)	0.0	0.0	40.8 (-37.0 to 239.3)	0.6 (-54.6 to 142.5)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	235.7 (52.9 to 570.5)	154.3 (14.1 to 397.0)	0.0	0.0	212.6 (51.0 to 494.0)	134.9 (16.9 to 330.8)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.2 (-68.4 to 52.7)	-4.9 (-75.1 to 17.7)	0.0	0.0	-27.9 (-65.6 to 42.0)	-44.8 (-72.5 to 6.1)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-103.3 (-57.0 to 83.2)	-37.9 (-69.6 to 28.6)	0.0	0.0	-33.7 (-53.6 to 60.7)	-39.6 (-67.1 to 11.4)
Larynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.7 (3.4 to 171.6)	25.2 (-22.4 to 95.8)	0.0	0.0	43.9 (-16.1 to 133.0)	5.8 (-36.6 to 71.7)
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.6 (-12.9 to 96.0)	2.5 (-33.2 to 43.1)	0.0	0.0	37.5 (-11.9 to 97.7)	1.7 (-33.1 to 43.7)
Breast cancer	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.5)	80.9 (45.7 to 126.6)	16.6 (-5.5 to 43.6)	0.0	0.0	97.7 (44.4 to 172.9)	26.0 (5.4 to 70.7)
Cervical cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	77.9 (-6.1 to 204.8)	0.2 (-41.6 to 69.7)	0.0	0.0	78.4 (-4.6 to 205.4)	1.3 (-41.2 to 68.7)
Uterine cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.8 (-13.5 to 181.1)	12.3 (-38.2 to 97.3)	0.0	0.0	60.9 (-15.1 to 194.0)	12.2 (-40.3 to 101.9)
Prostate cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	172.1 (76.1 to 313.6)	114.2 (37.1 to 224.9)	0.0	0.0	169.1 (69.5 to 319.3)	111.2 (34.3 to 227.9)
Colon and rectum cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	52.4 (33.4 to 70.5)	7.4 (-6.0 to 20.4)	0.0	0.0	52.3 (32.3 to 72.5)	6.9 (-7.3 to 21.0)
Lip and oral cavity cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.0)	59.1 (-8.6 to 164.1)	0.8 (-40.4 to 61.4)	0.0	0.0	56.0 (-7.4 to 155.0)	0.8 (-40.1 to 56.5)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.6 (-13.2 to 186.6)	-7.6 (-48.8 to 62.7)	0.0	0.0	58.7 (-12.2 to 169.2)	-8.6 (-48.3 to 62.5)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.4 (-25.6 to 173.2)	-4.4 (-52.4 to 68.5)	0.0	0.0	49.4 (-21.6 to 152.4)	-4.7 (-48.2 to 61.3)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.2 (-42.6 to 93.5)	-16.2 (-57.8 to 41.5)	0.0	0.0	10.5 (-40.8 to 83.2)	-18.0 (-57.3 to 35.8)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.0 (14.6 to 185.3)	23.6 (-19.8 to 79.1)	0.0	0.0	85.9 (20.1 to 168.3)	24.2 (-15.1 to 70.7)
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	132.4 (25.1 to 281.2)	30.4 (-25.2 to 104.1)	0.0	0.0	125.5 (19.3 to 268.2)	27.7 (-26.8 to 101.8)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	126.7 (23.1 to 265.4)	52.0 (-14.6 to 146.4)	0.0	0.0	153.5 (56.6 to 287.4)	68.0 (-3.1 to 168.2)
Ovarian cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	163.9 (39.8 to 346.7)	70.4 (-11.4 to 183.2)	0.0	0.0	159.2 (30.2 to 359.4)	66.0 (-16.2 to 192.3)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	157.9 (-4.3 to 439.4)	18.0 (-55.6 to 139.9)	0.0	0.0	150.8 (-2.4 to 423.4)	15.8 (-54.8 to 131.8)
Kidney cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.5 (11.0 to 272.6)	59.8 (-7.1 to 161.9)	0.0	0.0	113.1 (14.2 to 263.4)	55.3 (-9.1 to 158.0)
Bladder cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	20.0 (-4.0 to 49.2)	-14.0 (-32.0 to 9.3)	0.0	0.0	19.1 (-5.8 to 48.4)	-15.5 (-33.3 to 8.3)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.2 (5.3 to 220.2)	27.3 (-25.4 to 86.5)	0.0	0.0	102.2 (9.5 to 207.3)	24.7 (-26.5 to 82.3)
Thyroid cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	143.2 (20.8 to 311.9)	36.0 (-31.5 to 130.0)	0.0	0.0	131.2 (10.1 to 298.7)	30.7 (-35.5 to 129.4)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.1 (-16.4 to 112.2)	4.3 (-42.7 to 52.1)	0.0	0.0	37.9 (-16.7 to 116.2)	-3.7 (-42.3 to 56.2)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	126.2 (18.8 to 312.1)	46.1 (-20.1 to 154.7)	0.0	0.0	129.4 (25.0 to 307.4)	42.4 (-22.1 to 136.4)
Non-Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.5 (17.6 to 225.5)	36.3 (-20.3 to 113.3)	0.0	0.0	105.2 (14.1 to 217.2)	31.8 (-23.0 to 110.1)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.9 (-15.3 to 202.5)	24.3 (-33.1 to 134.1)	0.0	0.0	67.2 (-10.8 to 189.2)	17.5 (-32.5 to 109.1)
Leukemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.9 (-11.0 to 261.1)	26.7 (-31.7 to 123.3)	0.0	0.0	78.5 (-3.4 to 201.1)	19.0 (-34.3 to 106.1)
Other neoplasms	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	142.2 (32.4 to 301.1)	57.1 (5.8 to 137.0)	0.0	0.0	130.9 (30.7 to 268.7)	44.7 (-12.0 to 115.0)
Cardiovascular diseases	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.5)	48.5 (17.3 to 86.5)	-0.9 (-20.1 to 23.1)
Rheumatic heart disease	1.3 (0.9 to 1.7)	1.9 (1.4 to 2.5)	43.5 (-0.0 to 109.9)	-15.7 (-37.1 to 18.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	46.0 (2.5 to 108.9)	-11.6 (-33.5 to 22.0)
Ischemic heart disease	1.2 (0.9 to 1.4)	1.1 (0.9 to 1.3)	-6.3 (-28.2 to 23.7)	-26.7 (-43.0 to -4.7)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-21.2 (-48.4 to 18.4)	-96.6 (-57.9 to -6.6)
Cerebrovascular disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.5 (20.2 to 92.0)	0.5 (-22.5 to 24.5)
Ischemic stroke	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	51.9 (17.2 to 86.5)	1.4 (-23.7 to 23.7)	0.0	0.0	53.7 (17.3 to 92.5)	1.8 (-24.1 to 26.7)
Hemorrhagic stroke	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.7 (14.3 to 95.2)	-5.4 (-30.8 to 20.6)	0.0	0.0	56.0 (15.2 to 102.4)	-4.6 (-31.2 to 25.1)
Hypertensive heart disease	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.5)	33.8 (-11.9 to 115.3)	-1.3 (-36.3 to 57.1)	0.0	0.0	34.4 (-12.4 to 116.5)	-0.9 (-36.5 to 58.1)
Cardiomyopathy and myocarditis	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	36.7 (-14.3 to 143.8)	-5.4 (-44.9 to 82.5)	0.0	0.0	36.9 (-14.5 to 144.1)	-4.4 (-45.3 to 84.1)
Atrial fibrillation and flutter	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	290.3 (118.8 to 607.1)	189.4 (49.1 to 442.5)	0.0	0.0	302.7 (120.3 to 622.9)	195.3 (52.6 to 448.2)
Peripheral vascular disease	2.2 (1.7 to 2.9)	3.0 (1.8 to 4.3)	33.1 (-21.0 to 119.6)	-4.1 (-38.6 to 53.1)	0.0	0.0	4.7 (-51.6 to 85.5)	-28.0 (-63.6 to 45.0)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.6 (-31.2 to 78.9)	-24.1 (-62.6 to 37.1)	0.0	0.0	18.8 (-35.8 to 102.8)	-21.1 (-66.5 to 54.3)
Other cardiovascular and circulatory diseases	0.7 (0.4 to 1.1)	1.6 (0.8 to 2.4)	137.6 (13.5 to 374.7)	48.3 (-24.4 to 210.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	138.1 (16.1 to 383.2)	49.6 (-25.4 to 215.5)
Chronic respiratory diseases	-	-	-	-	0.5 (0.3 to 0.6)	0.8 (0.6 to 1.1)	82.3 (58.6 to 112.4)	5.3 (-7.7 to 23.5)
Chronic obstructive pulmonary disease	3.8 (3.7 to 4.1)	6.3 (6.0 to 6.6)	64.8 (59.2 to 70.8)	-1.2 (-4.8 to 2.0)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	68.5 (46.6 to 101.7)	0.4 (-12.2 to 20.3)

Appendix Table G.4 - Sao Tome and Principe prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumonia	0.0	0.0	-	-	0.0	0.0	50.2	-6.2
Silicosis	(0.0 to 0.0)	(0.0 to 0.0)	(27.9 to 44.5)	(-16.2 to -6.4)	(0.0 to 0.0)	(0.0 to 0.0)	(27.2 to 44.0)	(-16.4 to -6.5)
Asbestosis	-	-	0.0	0.0	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	95.2	0.2	0.0	0.0	65.0	0.2
Asthma	(1.7 to 2.7)	(4.4 to 6.4)	(79.5 to 226.9)	(5.1 to 81.4)	(0.1 to 0.2)	(0.2 to 0.3)	(80.6 to 230.9)	(5.0 to 82.7)
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	75.8	2.3	0.0	0.0	75.2	2.3
Other chronic respiratory diseases	-	-	-	-	0.0	0.1	47.8	-11.2
Cirrhosis	-	-	-	-	(0.0 to 0.1)	(0.0 to 0.1)	(8.1 to 98.2)	(-3.3 to 19.5)
Cirrhosis due to hepatitis B	0.0	0.0	-17.6	-48.0	(0.0 to 0.0)	(0.0 to 0.0)	(58.7 to 35.6)	(-70.8 to -19.3)
Cirrhosis due to hepatitis C	0.0	0.0	102.1	30.6	(0.0 to 0.0)	(0.0 to 0.0)	97.4	29.5
Cirrhosis due to alcohol use	0.0	0.0	30.0	-17.8	(0.0 to 0.0)	(0.0 to 0.0)	32.6	-16.9
Cirrhosis due to other causes	0.0	0.0	69.0	21.2	(0.0 to 0.0)	(0.0 to 0.0)	69.4	21.4
Digestive diseases	-	-	-	-	0.2	0.3	71.4	8.7
Peptic ulcer disease	0.7	0.8	17.6	-18.5	0.0	0.0	19.4	-19.2
Gastritis and duodenitis	1.5	2.2	48.3	0.5	(0.0 to 0.0)	(0.0 to 0.0)	(-0.4 to 43.3)	(-32.1 to -5.1)
Appendicitis	0.0	0.0	108.2	13.8	0.0	0.0	110.0	13.9
Paralytic ileus and intestinal obstruction	0.0	0.0	40.2 to 233.9	(-19.5 to 64.5)	(0.0 to 0.0)	(0.0 to 0.0)	(31.6 to 247.0)	(-24.5 to 76.9)
Inguinal, femoral, and abdominal hernia	0.4	0.4	10.2	-20.9	0.0	0.0	10.4	-20.9
Inflammatory bowel disease	0.1	0.2	126.9	26.2	(0.0 to 0.0)	(0.0 to 0.0)	(-17.1 to 39.2)	(-37.1 to 0.2)
Vascular intestinal disorders	0.0	0.0	86.0	2.9	(0.0 to 0.0)	(0.0 to 0.1)	(107.8 to 153.0)	(17.2 to 37.6)
Gallbladder and biliary diseases	0.0	0.0	63.8	6.4	(0.0 to 0.0)	(0.0 to 0.0)	(31.0 to 205.2)	(-37.4 to 79.6)
Pancreatitis	0.0	0.0	102.2	9.3	(0.0 to 0.0)	(0.0 to 0.0)	(42.3 to 93.7)	(-7.2 to 23.7)
Other digestive diseases	-	-	-	-	0.0	0.1	119.9	39.6
Neurological disorders	-	-	-	-	(0.0 to 0.0)	(0.0 to 0.1)	(68.3 to 189.9)	(7.1 to 81.9)
Alzheimer disease and other dementias	0.2	0.3	29.1	-2.7	(0.3 to 0.7)	(0.6 to 1.3)	(58.9 to 117.5)	(-5.0 to 25.0)
Parkinson disease	0.0	0.0	35.3	0.0	(0.0 to 0.0)	(0.0 to 0.1)	(6.7 to 58.3)	(-19.6 to 19.8)
Epilepsy	0.3	0.4	58.0	-2.3	0.1	0.1	36.8	1.0
Multiple sclerosis	0.0	0.0	121.6	13.6	(0.0 to 0.0)	(0.1 to 0.2)	(-22.4 to 274.5)	(-52.0 to 131.0)
Migraine	13.5	7.8	72.5	-3.9	(0.0 to 0.0)	(0.0 to 0.0)	(71.2 to 177.2)	(-43.3 to 42.6)
Tension-type headache	(7.2 to 8.5)	(12.4 to 14.8)	(53.6 to 94.8)	(-12.3 to 11.1)	(0.2 to 0.4)	(0.3 to 0.7)	(51.9 to 95.8)	(-12.5 to 10.9)
Medication overuse headache	0.5	1.3	190.4	59.9	0.1	0.2	190.8	60.3
Other neurological disorders	0.0	0.0	54.8	-6.6	(0.0 to 0.0)	(0.0 to 0.0)	25.5	-8.4
Mental and substance use disorders	-	-	-	-	2.3	4.2	78.4	0.8
Schizophrenia	0.2	0.4	101.8	0.1	(1.6 to 3.2)	(2.9 to 5.7)	(71.3 to 86.8)	(-2.7 to 5.0)
Alcohol use disorders	0.5	1.0	109.2	10.5	0.1	0.1	111.9	10.9
Drug use disorders	-	-	-	-	0.1	0.3	105.6	-0.7
Opioid use disorders	0.2	0.3	122.3	-0.9	0.1	0.1	123.3	-0.6
Cocaine use disorders	0.0	0.1	125.4	0.0	(0.0 to 0.0)	(0.1 to 0.2)	(93.2 to 153.8)	(-11.9 to 12.2)
Amphetamine use disorders	0.2	0.3	77.0	-3.3	0.0	0.0	75.7	-3.8
Cannabis use disorders	0.1	0.1	80.1	0.4	0.0	0.0	79.8	-0.1
Other drug use disorders	-	-	-	-	(0.0 to 0.0)	(0.0 to 0.1)	(40.0 to 157.4)	(-26.3 to 33.7)
Depressive disorders	-	-	-	-	1.0	1.9	83.6	2.7
Major depressive disorder	4.6	8.3	82.6	2.8	(0.6 to 1.6)	(1.1 to 3.0)	(70.5 to 101.5)	(-5.1 to 11.4)
Dysthymia	1.0	2.0	87.6	0.2	0.1	0.2	88.4	0.4
Bipolar disorder	0.6	1.1	94.8	-0.3	0.1	0.2	96.0	-0.0
Anxiety disorders	2.7	4.5	69.1	0.1	(0.1 to 0.2)	(0.1 to 0.4)	(82.0 to 111.1)	(-5.8 to 6.6)
Eating disorders	-	-	-	-	0.0	0.1	79.5	-1.2
Anorexia nervosa	0.0	0.0	79.9	3.0	(0.0 to 0.0)	(0.0 to 0.1)	(35.9 to 132.2)	(-20.3 to 33.4)
Bulimia nervosa	0.1	0.2	80.1	-1.9	0.0	0.0	79.7	-2.1
Autistic spectrum disorders	-	-	-	-	0.1	0.2	65.8	0.3
Autism	0.4	0.6	65.7	0.1	(0.1 to 0.1)	(0.1 to 0.2)	(57.9 to 75.3)	(-3.7 to 5.1)
Asperger syndrome	0.5	0.8	65.6	0.1	0.1	0.1	66.1	0.4
Attention-deficit/hyperactivity disorder	0.9	1.4	44.5	0.1	(0.0 to 0.1)	(0.1 to 0.1)	(57.9 to 73.7)	(-3.9 to 4.3)
Conduct disorder	1.4	2.1	40.8	0.2	(0.0 to 0.0)	(0.0 to 0.0)	(33.3 to 56.0)	(-7.2 to 7.8)
Idiopathic intellectual disability	(1.3 to 1.5)	(1.8 to 2.1)	(40.3 to 41.4)	(0.0 to 0.0)	(0.0 to 0.2)	(0.1 to 0.3)	(35.1 to 47.7)	(-4.0 to 4.9)
Other mental and substance use disorders	1.3	2.5	93.9	-0.0	0.1	0.2	94.8	0.1
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	0.7	1.3	85.7	13.2
Diabetes mellitus	1.5	4.4	195.2	67.6	(0.5 to 1.0)	(0.9 to 1.8)	(73.8 to 98.6)	(4.4 to 23.5)
Acute glomerulonephritis	0.0	0.0	34.9	-	(0.0 to 0.0)	(0.0 to 0.0)	(114.2 to 257.1)	(-26.1 to 113.0)
Chronic kidney disease	-	-	-	-	0.2	0.3	67.4	-0.4
Chronic kidney disease due to diabetes mellitus	1.1	1.8	62.8	5.8	(0.1 to 0.3)	(0.2 to 0.4)	(51.8 to 86.1)	(-9.9 to 8.7)
Chronic kidney disease due to hypertension	5.3	8.6	66.5	4.1	(0.0 to 0.0)	(0.0 to 0.0)	(4.5 to 118.3)	(-40.9 to 36.9)
Chronic kidney disease due to glomerulonephritis	3.0	5.3	77.0	-17.1	(0.0 to 0.1)	(0.1 to 0.2)	(34.6 to 104.1)	(-18.1 to 27.3)
Chronic kidney disease due to other causes	3.4	5.3	57.0	-4.6	(0.0 to 0.1)	(0.0 to 0.1)	(14.4 to 110.5)	(-30.3 to 29.7)
Urinary diseases and male infertility	-	-	-	-	0.0	0.1	38.2	-0.0
	-	-	-	-	(0.0 to 0.1)	(0.0 to 0.1)	(23.1 to 56.4)	(-10.8 to 12.2)

Appendix Table G.4 - SA Tome and Príncipe prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.2 (65.7 to 101.5)	0.0 (-0.6 to 16.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.6 (43.3 to 133.0)	7.3 (-12.1 to 29.7)
Urolithiasis	0.3 (0.3 to 0.4)	0.4 (0.3 to 0.5)	23.1 (7.5 to 43.5)	-14.6 (-24.1 to -2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.7 (48.0 to 97.3)	3.1 (-8.2 to 15.4)
Benign prostatic hyperplasia	1.0 (0.9 to 1.1)	1.2 (1.1 to 1.3)	23.5 (9.1 to 41.8)	-1.9 (-13.1 to 12.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	23.4 (8.5 to 41.9)	-1.9 (-13.4 to 12.6)
Male infertility due to other causes	0.4 (0.3 to 0.6)	1.1 (0.8 to 1.5)	169.8 (70.8 to 292.9)	16.0 (-26.6 to 74.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	170.1 (69.9 to 300.8)	15.8 (-25.8 to 76.2)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	151.1 (55.5 to 257.6)	51.6 (-7.2 to 136.2)
Gynecological diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	121.9 (87.7 to 159.2)	2.3 (-11.7 to 17.4)
Uterine fibroids	1.4 (1.3 to 1.5)	3.1 (2.8 to 3.4)	120.0 (118.6 to 121.3)	-1.5 (-1.8 to -1.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	109.5 (87.8 to 123.9)	-6.2 (-17.7 to -0.7)
Polycystic ovarian syndrome	1.4 (1.2 to 1.6)	3.2 (2.9 to 3.6)	134.5 (96.4 to 178.6)	2.6 (-11.7 to 20.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	130.6 (93.9 to 175.6)	1.7 (-12.2 to 19.5)
Female infertility due to other causes	0.3 (0.2 to 0.5)	0.8 (0.5 to 1.1)	137.1 (30.0 to 372.8)	-1.0 (-4.5 to 99.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	132.7 (26.9 to 360.1)	-2.4 (-45.5 to 97.9)
Endometriosis	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	105.7 (64.7 to 157.1)	-11.1 (-27.8 to 8.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.2 (62.7 to 162.4)	-11.0 (-29.3 to 11.9)
Genital prolapse	3.6 (3.2 to 4.0)	7.0 (6.2 to 8.0)	95.7 (65.4 to 132.0)	5.7 (-9.4 to 24.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.8 (65.1 to 134.1)	5.8 (-9.1 to 25.0)
Premenstrual syndrome	3.8 (2.8 to 5.0)	9.6 (6.0 to 12.4)	157.7 (53.4 to 282.0)	19.6 (-25.5 to 79.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	156.4 (48.4 to 281.6)	20.0 (-26.4 to 81.7)
Other gynecological diseases	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	85.0 (26.3 to 164.1)	-8.2 (-35.3 to 28.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.9 (-12.6 to 208.2)	-6.9 (-52.2 to 51.6)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	55.9 (44.8 to 71.1)	-2.5 (-9.2 to 8.4)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.3 (21.3 to 57.9)	-11.0 (-23.6 to 2.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.8 (13.8 to 49.0)	-14.5 (-27.8 to -3.8)
Thalassemia trait	1.4 (1.2 to 1.7)	2.3 (1.9 to 2.6)	60.3 (53.8 to 71.1)	-3.2 (-7.1 to 3.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	43.4 (18.3 to 69.8)	-9.3 (-25.0 to 7.7)
Sickle cell disorders	0.4 (0.3 to 0.4)	0.7 (0.6 to 0.8)	87.9 (69.9 to 109.9)	18.9 (7.8 to 33.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	91.7 (62.9 to 119.5)	18.9 (-1.8 to 34.8)
Sickle cell trait	20.4 (19.1 to 21.7)	34.1 (31.9 to 36.2)	67.4 (61.0 to 73.1)	-7.0 (-2.8 to 4.6)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	67.4 (31.5 to 74.0)	5.9 (-15.0 to 9.3)
G6PD deficiency	27.8 (18.2 to 36.0)	47.7 (36.3 to 59.9)	71.5 (15.7 to 170.0)	4.0 (-30.0 to 64.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.0 (-34.8 to 184.4)	-2.8 (-55.4 to 91.2)
G6PD trait	28.9 (27.7 to 29.6)	47.6 (44.7 to 48.9)	64.8 (54.3 to 73.7)	-0.0 (-6.4 to 5.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.9 (-64.7 to 560.3)	2.3 (-76.1 to 346.3)
Other hemoglobinopathies and hemolytic anemias	1.3 (1.1 to 1.5)	2.0 (1.8 to 2.2)	50.1 (26.5 to 76.8)	-8.5 (-19.9 to 3.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	44.5 (17.8 to 89.7)	-9.0 (-26.9 to 15.8)
Endocrine, metabolic, blood, and immune disorders	1.6 (1.4 to 1.9)	2.5 (2.0 to 2.8)	49.4 (16.4 to 92.0)	-7.0 (-23.2 to 12.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	48.6 (6.1 to 102.9)	4.9 (-27.7 to 24.5)
Musculoskeletal disorders	-	-	-	-	1.4 (1.0 to 1.8)	2.3 (1.7 to 3.1)	68.8 (47.8 to 97.2)	-2.9 (-14.6 to 9.9)
Rheumatoid arthritis	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	17.2 (10.5 to 25.1)	-31.4 (-35.2 to -26.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	18.4 (8.3 to 30.2)	-31.0 (-36.3 to -24.9)
Osteoarthritis	2.5 (2.4 to 2.6)	3.7 (3.6 to 3.9)	50.1 (42.1 to 58.5)	2.5 (-3.1 to 8.0)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	51.1 (42.4 to 60.2)	2.8 (-2.9 to 8.6)
Low back and neck pain	-	-	-	-	1.0 (0.7 to 1.4)	1.7 (1.2 to 2.4)	71.9 (44.1 to 112.6)	4.8 (-20.3 to 14.7)
Low back pain	6.0 (5.1 to 7.1)	9.8 (8.2 to 11.5)	63.6 (27.3 to 111.1)	-6.0 (-26.1 to 19.0)	0.7 (0.4 to 0.9)	1.1 (0.7 to 1.6)	64.8 (27.9 to 113.0)	-5.8 (-26.0 to 19.3)
Neck pain	3.5 (2.7 to 4.2)	6.5 (5.6 to 7.3)	86.2 (50.2 to 146.1)	-2.6 (-20.3 to 27.7)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	87.6 (51.0 to 149.9)	-2.3 (-20.3 to 27.9)
Gout	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.2 (31.6 to 85.1)	-3.3 (-17.5 to 13.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.7 (24.4 to 103.3)	-2.7 (-25.6 to 25.7)
Other musculoskeletal disorders	2.0 (1.6 to 2.5)	3.6 (2.8 to 4.4)	76.0 (61.9 to 93.3)	3.7 (-2.2 to 12.4)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	78.0 (63.4 to 95.9)	0.0 (-2.1 to 13.8)
Other non-communicable diseases	-	-	-	-	1.6 (1.1 to 2.4)	2.5 (1.7 to 3.8)	55.5 (45.4 to 66.2)	-6.5 (-10.4 to -1.5)
Congenital anomalies	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	108.7 (71.5 to 153.6)	32.0 (8.7 to 60.1)
Neural tube defects	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	255.8 (178.8 to 332.3)	130.0 (80.8 to 179.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	297.0 (177.1 to 459.8)	160.8 (85.0 to 253.7)
Congenital heart anomalies	0.2 (0.2 to 0.3)	0.8 (0.6 to 1.0)	292.0 (172.2 to 477.3)	151.0 (73.0 to 273.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	271.6 (166.5 to 445.7)	140.0 (68.3 to 253.0)
Orofacial clefts	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	444.7 (272.1 to 711.7)	271.4 (153.4 to 465.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	356.5 (186.3 to 644.8)	212.2 (97.2 to 406.1)
Down syndrome	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	119.5 (62.0 to 189.4)	39.4 (2.1 to 84.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	120.2 (57.6 to 190.5)	42.4 (2.9 to 89.5)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.9 (55.5 to 214.2)	26.8 (-7.3 to 87.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	118.6 (55.0 to 244.3)	27.2 (-9.9 to 98.8)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.3 (12.2 to 161.0)	-5.9 (-32.4 to 56.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.7 (30.3 to 203.1)	-3.3 (-30.7 to 61.6)
Chromosomal unbalanced rearrangements	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	118.3 (63.5 to 183.2)	8.4 (3.3 to 20.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.2 (59.5 to 187.2)	41.2 (4.6 to 85.8)
Other congenital anomalies	0.5 (0.4 to 0.7)	0.8 (0.6 to 1.1)	52.2 (29.5 to 78.1)	-7.5 (-20.0 to 8.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	60.1 (19.3 to 115.5)	2.1 (-23.6 to 37.8)
Skin and subcutaneous diseases	-	-	-	-	0.5 (0.3 to 0.8)	0.9 (0.6 to 1.5)	76.1 (56.0 to 94.8)	5.0 (-3.0 to 13.4)
Dermatitis	4.8 (3.8 to 5.9)	8.5 (6.6 to 10.7)	76.8 (70.5 to 83.1)	0.0 (-0.2 to 0.2)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	70.8 (62.8 to 78.6)	0.1 (-2.5 to 3.0)
Psoriasis	0.7 (0.6 to 0.9)	1.3 (1.0 to 1.6)	76.7 (70.5 to 82.2)	0.0 (-0.2 to 0.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	76.7 (64.7 to 90.3)	-0.1 (-4.9 to 5.0)
Cellulitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.1 (42.3 to 83.5)	-1.7 (-13.7 to 10.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.8 (24.3 to 112.8)	-2.1 (-22.1 to 23.6)
Pyoderma	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	46.0 (36.2 to 58.1)	-4.2 (-10.5 to 2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.4 (31.1 to 63.9)	-4.0 (-12.9 to 6.5)
Scabies	1.0 (0.9 to 1.2)	1.5 (1.3 to 1.7)	42.2 (16.5 to 72.3)	-12.6 (-28.5 to 5.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	42.5 (16.5 to 73.3)	-12.6 (-28.9 to 5.5)
Fungal skin diseases	14.1 (10.1 to 19.6)	23.3 (16.8 to 32.9)	65.2 (56.2 to 78.2)	0.2 (-0.0 to 0.3)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.1)	65.2 (56.3 to 78.5)	0.2 (-0.5 to 1.0)
Viral skin diseases	1.8 (1.4 to 2.2)	2.8 (2.1 to 3.5)	56.0 (44.2 to 66.4)	-0.7 (-5.8 to 4.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	55.9 (42.2 to 68.2)	-0.5 (-6.8 to 5.7)
Acne vulgaris	8.9 (6.5 to 11.9)	17.2 (11.5 to 24.9)	96.0 (13.1 to 205.2)	22.1 (-25.4 to 86.2)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	97.7 (13.2 to 206.0)	22.0 (-25.3 to 86.8)
Alopecia areata	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	67.6 (40.7 to 97.8)	-0.8 (-16.9 to 16.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.0 (34.1 to 106.3)	-0.6 (-19.5 to 19.6)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.0 (29.1 to 113.1)	-1.5 (-23.7 to 27.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.0 (29.0 to 113.1)	-1.5 (-23.8 to 27.7)
Urticaria	0.4 (0.3 to 0.6)	1.1 (0.8 to 1.5)	156.5 (60.3 to 427.2)	34.4 (-14.0 to 167.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	158.6 (58.1 to 442.1)	35.9 (-14.5 to 174.7)
Decubitus ulcer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.1 (37.8 to 120.0)	20.5 (-9.0 to 58.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.6 (36.1 to 127.2)	20.8 (-13.5 to 60.2)
Other skin and subcutaneous diseases	6.2 (4.1 to 9.2)	10.2 (6.9 to 14.7)	64.7 (48.0 to 84.9)	-0.1 (-2.4 to 2.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	65.5 (48.5 to 85.2)	0.1 (-2.6 to 2.8)
Sense organ diseases	-	-	-	-	0.9 (0.6 to 1.2)	1.2 (0.8 to 1.7)	35.4 (24.1 to 48.4)	-14.0 (-18.8 to -7.8)
Glaucoma	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	34.9 (0.2 to 99.7)	-8.0 (-40.2 to 19.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.6 (4.4 to 98.2)	-14.6 (-34.0 to 21.0)
Cataract	1.2 (0.9 to 1.5)	1.2 (0.8 to 1.5)	-4.9 (-24.5 to 21.7)	-27.8 (-41.9 to -10.9)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-0.0 (-19.4 to 23.0)	-24.8 (-38.7 to -9.4)
Macular degeneration	0.2 (0.1 to 0.4)	0.4 (0.3 to 0.6)	85.5 (17.9 to 175.3)	34.9 (-10.8 to 105.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.3 (16.8 to 167.1)	30.9 (-10.8 to 97.6)
Uncorrected refractive error	10.1 (7.9 to 12.2)	15.5 (11.5 to 19.5)	54.4 (4.5 to 110.6)	-3.1 (-30.2 to 32.8)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	37.8 (15.2 to 65.8)	-13.0 (-24.8 to 3.6)
Age-related and other hearing loss	14.9 (12.9 to 16.6)	22.4 (19.1 to 25.3)	49.8 (41.2 to 57.7)	-6.6 (-10.3 to -3.1)	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.9)	39.6 (20.2 to 61.0)	-12.1 (-19.4 to -4.5)
Other vision loss	0.5 (0.4 to 0.6)	0.5 (0.4 to 0.6)	2.8 (-13.7 to 25.0)	-35.6 (-46.8 to -22.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	2.6 (-16.0 to 26.7)	-32.7 (-45.9 to -18.0)
Other sense organ diseases	2.9 (2.7 to 3.0)	4.5 (4.3 to 4.7)	57.1 (46.4 to 68.6)	-0.3 (-6.5 to 5.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	57.1 (45.0 to 71.8)	-0.1 (-7.2 to 6.8)
Oral disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	68.4 (56.4 to 79.7)	-2.0 (-10.5 to 5.8)
Deciduous caries	12.3 (11.6 to 12.9)	17.9 (16.9 to 18.8)	45.4 (35.3 to 57.3)	0.6 (-6.1 to 8.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.1 (33.1 to 59.9)	0.4 (-8.0 to 10.7)
Permanent caries	29.5 (26.3 to 32.8)	50.8 (46.3 to 55.6)	72.7 (48.7 to 97.6)	0.5 (-12.2 to 14.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	73.1 (49.2 to 97.8)	0.6 (-12.4 to 14.3)
Periodontal diseases	6.7 (6.0 to 7.5)	11.1 (10.0 to 12.3)	68.0 (43.2 to 93.6)	-2.2 (-17.8 to 13.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	69.9 (44.3 to 94.5)	-2.1 (-17.6 to 13.6)

Appendix Table G.4 - Sao Tome and Principe prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	0.4 (0.4 to 0.5)	0.6 (0.5 to 0.6)	35.4 (22.3 to 51.9)	-7.8 (-16.2 to 3.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.9 (22.1 to 54.8)	-7.3 (-16.8 to 4.7)
Other oral disorders	1.7 (1.6 to 1.7)	2.9 (2.7 to 3.1)	75.2 (60.5 to 90.1)	-0.7 (-8.5 to 7.2)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	75.5 (59.8 to 92.1)	-0.5 (-8.6 to 8.2)
Injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	18.1 (6.9 to 30.5)	-27.3 (-34.4 to -19.6)
Transport injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	12.9 (1.1 to 29.5)	-29.4 (-37.8 to -19.6)
Road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	9.9 (4.5 to 26.4)	-30.7 (-39.2 to -20.9)
Pedestrian road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.8 (-18.7 to 12.5)	-36.1 (-44.8 to -25.8)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.4 (-9.2 to 13.7)	-31.8 (-38.7 to -24.0)
Motorcyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.3 (-8.7 to 23.8)	-37.4 (-46.1 to -27.5)
Motor vehicle road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	20.7 (3.5 to 41.1)	-25.2 (-35.2 to -13.2)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.4 (-31.6 to -8.9)	-52.0 (-58.0 to -44.7)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.0 (19.6 to 51.2)	-20.3 (-28.6 to -9.9)
Unintentional injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	20.7 (11.0 to 31.3)	-26.1 (-32.5 to -19.3)
Falls	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	17.5 (4.8 to 32.0)	-28.3 (-36.8 to -18.9)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.1 (-23.7 to 6.2)	-44.3 (-51.7 to -34.4)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.1 (-14.1 to 13.2)	-37.6 (-45.3 to -29.2)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.4 (-11.1 to 30.8)	-37.2 (-46.1 to -26.7)
Exposure to mechanical forces	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	25.7 (17.2 to 34.7)	-24.4 (-29.3 to -19.2)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.7 (2.1 to 30.5)	-34.2 (-41.5 to -25.3)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.4 (35.0 to 76.9)	-3.2 (-15.2 to 8.4)
Other exposure to mechanical forces	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	25.9 (17.4 to 34.9)	-24.1 (-29.0 to -19.1)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.7 (67.2 to 89.8)	13.8 (6.6 to 22.0)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.4 (10.2 to 35.1)	-24.8 (-31.5 to -17.2)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.2 (10.9 to 49.6)	-23.1 (-32.7 to -12.2)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.8 (3.9 to 30.5)	-26.2 (-33.4 to -17.6)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.6 (13.6 to 37.9)	-21.7 (-28.2 to -14.0)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.9 (-34.0 to -1.1)	-44.2 (-52.8 to -31.7)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.2 (45.0 to 83.3)	-8.3 (-17.2 to 2.0)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.4 (20.0 to 46.0)	-17.6 (-25.1 to -9.2)
Other unintentional injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.6 (20.9 to 43.3)	-17.5 (-23.7 to -10.3)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.4 (-0.3 to 30.3)	-33.9 (-41.9 to -24.2)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.2 (37.5 to 74.8)	-14.1 (-23.6 to -3.3)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.6 (6.0 to 25.2)	-37.6 (-45.5 to -27.2)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.7 (15.0 to 42.7)	-25.3 (-32.5 to -16.8)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.8 (23.3 to 63.4)	-21.3 (-30.8 to -8.1)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.4 (-18.9 to 11.3)	-45.1 (-53.0 to -35.4)
Forces of nature, war, and legal intervention	-	-	-	-	-	-	-	-
Exposure to forces of nature	-	-	-	-	-	-	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Saudi Arabia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,471.4 (1,068.2 to 1,927.4)	3,119.1 (2,300.1 to 4,033.7)	112.0 (104.9 to 119.7)	2.3 (-0.2 to 6.3)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	209.4 (145.8 to 290.0)	264.5 (186.7 to 364.6)	26.3 (18.4 to 36.4)	-16.7 (-21.3 to -10.2)
HIV/AIDS and tuberculosis	-	-	-	-	1.9 (1.3 to 2.6)	4.1 (2.8 to 5.9)	117.2 (82.6 to 168.1)	-0.9 (-13.6 to 20.9)
Tuberculosis	6.0 (5.5 to 6.4)	11.2 (10.5 to 11.9)	88.3 (78.6 to 100.1)	-12.2 (-15.7 to -7.7)	1.8 (1.2 to 2.5)	3.4 (2.3 to 4.7)	87.0 (62.6 to 114.4)	-12.7 (-27.0 to -3.1)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.2)	0.7 (0.3 to 1.7)	361.0 (304.0 to 12,901.4)	0.7 (0.0 to 1.7)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	808.5 (258.7 to 9,837.5)	294.4 (57.9 to 4,120.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	808.5 (256.7 to 10,293.6)	294.4 (57.8 to 4,241.9)
HIV/AIDS resulting in other diseases	0.7 (0.0 to 1.5)	5.3 (2.6 to 9.9)	735.7 (236.9 to 11,548.1)	298.1 (61.5 to 4,946.7)	0.1 (0.0 to 0.2)	0.7 (0.3 to 1.7)	940.0 (301.2 to 13,946.1)	376.0 (87.4 to 6,047.0)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	49.6 (34.2 to 67.3)	54.4 (38.3 to 74.0)	9.9 (0.7 to 19.3)	-19.3 (-25.6 to -13.3)
Diarrheal diseases	227.7 (212.1 to 243.9)	237.6 (220.1 to 255.0)	4.5 (-6.2 to 15.2)	-18.1 (-26.1 to -10.5)	37.1 (24.8 to 51.2)	38.5 (25.9 to 52.9)	3.9 (-7.0 to 14.9)	-18.2 (-26.4 to -10.0)
Intestinal infectious diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	52.2 (15.7 to 97.4)	0.3 (-21.5 to 28.4)
Typhoid fever	1.2 (1.0 to 1.4)	1.7 (1.4 to 2.0)	47.4 (14.5 to 86.6)	-2.2 (-21.8 to 22.2)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	47.8 (9.6 to 100.1)	-1.8 (-24.1 to 27.0)
Paratyphoid fever	0.6 (0.5 to 0.7)	0.9 (0.8 to 1.1)	52.9 (17.7 to 98.8)	3.1 (-20.3 to 34.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	52.9 (17.6 to 98.9)	3.1 (-20.3 to 34.4)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	124.3 (-11.0 to 489.7)	47.7 (-40.4 to 281.3)
Lower respiratory infections	12.1 (8.9 to 16.8)	10.3 (8.0 to 13.7)	-11.9 (-39.3 to 13.4)	-34.9 (-54.5 to -11.8)	1.3 (0.8 to 2.0)	1.1 (0.6 to 1.6)	-13.2 (-41.4 to 15.2)	-34.9 (-55.9 to -10.8)
Upper respiratory infections	336.7 (303.0 to 374.0)	547.1 (484.0 to 607.4)	62.2 (40.0 to 90.0)	-2.6 (-15.9 to 15.1)	4.0 (2.2 to 6.5)	6.4 (3.6 to 10.9)	61.4 (39.0 to 90.6)	-2.5 (-16.0 to 14.9)
Otitis media	202.1 (190.0 to 214.4)	291.4 (269.9 to 316.2)	44.3 (30.8 to 58.8)	-7.5 (-15.8 to 2.7)	3.7 (2.2 to 6.0)	5.3 (3.1 to 8.5)	42.5 (28.7 to 57.6)	-8.7 (-17.2 to 1.2)
Meningitis	-	-	-	-	1.6 (1.4 to 3.5)	1.6 (1.1 to 2.2)	-34.9 (-51.3 to -16.5)	-63.4 (-71.4 to -54.2)
Pneumococcal meningitis	8.9 (5.2 to 15.3)	5.6 (3.6 to 9.3)	-36.7 (-53.8 to -8.4)	-67.0 (-76.1 to -54.2)	0.9 (0.5 to 1.3)	0.6 (0.4 to 0.9)	-29.3 (-50.8 to 5.4)	-62.0 (-72.9 to -46.2)
H influenzae type B meningitis	6.0 (1.9 to 14.0)	2.4 (0.9 to 5.5)	-58.6 (-72.5 to -32.1)	-76.7 (-84.5 to -59.8)	0.8 (0.4 to 1.2)	0.4 (0.2 to 0.6)	-53.2 (-70.5 to -22.1)	-72.6 (-82.4 to -54.7)
Meningococcal meningitis	1.6 (0.6 to 4.1)	1.0 (0.4 to 2.2)	-38.9 (-57.2 to 0.7)	-66.7 (-75.8 to -42.5)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-33.2 (-57.6 to 20.0)	-63.2 (-74.6 to -36.0)
Other meningitis	4.1 (2.2 to 7.9)	2.9 (1.6 to 5.7)	-30.2 (-46.9 to 0.0)	-61.4 (-69.6 to -45.4)	0.6 (0.4 to 0.8)	0.6 (0.3 to 0.7)	-22.8 (-45.0 to 15.1)	-57.0 (-68.3 to -37.9)
Encephalitis	3.1 (1.3 to 8.4)	4.8 (2.1 to 13.4)	53.0 (26.4 to 90.8)	-30.0 (-31.5 to -0.7)	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.0)	57.3 (26.4 to 111.7)	-16.7 (-30.9 to 8.9)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-97.6 to 280.6)	0.0 (0.0 to 0.0)	-	-
Whooping cough	4.2 (3.3 to 5.3)	1.4 (1.0 to 1.8)	-67.8 (-70.1 to -65.3)	-69.3 (-71.5 to -66.9)	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.1)	-67.7 (-75.4 to -58.5)	-69.2 (-76.5 to -60.3)
Tetanus	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-87.2 (-92.7 to -74.1)	-92.0 (-95.4 to -83.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-84.4 (-92.2 to -57.9)	-89.6 (-94.6 to -72.9)
Measles	0.8 (0.6 to 1.0)	0.0 (0.0 to 0.0)	-98.1 (-98.8 to -96.9)	-98.2 (-98.9 to -97.1)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-98.0 (-98.8 to -96.5)	-98.1 (-98.9 to -96.8)
Varicella and herpes zoster	13.2 (12.4 to 14.2)	19.4 (16.8 to 21.7)	47.3 (26.2 to 70.4)	6.0 (-14.0 to 29.2)	0.2 (0.1 to 0.4)	0.5 (0.3 to 0.8)	126.9 (59.3 to 250.3)	10.1 (-25.1 to 63.4)
Neglected tropical diseases and malaria	-	-	-	-	10.6 (6.5 to 16.1)	12.5 (7.9 to 18.3)	16.4 (0.2 to 52.3)	-17.9 (-29.3 to 5.6)
Malaria	35.6 (22.1 to 54.2)	99.2 (61.3 to 163.9)	176.4 (80.0 to 322.6)	84.6 (20.5 to 184.9)	0.4 (0.2 to 0.6)	1.1 (0.6 to 1.7)	176.1 (57.7 to 517.3)	84.9 (2.3 to 288.5)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	27.8 (-0.8 to 62.6)	-21.1 (-37.9 to -4.5)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	30.3 (-1.8 to 68.8)	-7.2 (-28.6 to 17.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.3 (-1.9 to 68.9)	-7.2 (-28.6 to 17.7)
Cutaneous and mucocutaneous leishmaniasis	4.6 (3.5 to 6.2)	5.9 (4.5 to 7.9)	28.0 (8.6 to 52.6)	-21.7 (-33.3 to -7.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	27.6 (-2.1 to 65.2)	21.9 (-39.4 to 0.3)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	16.6 (6.4 to 37.9)	33.1 (12.7 to 74.6)	99.6 (94.7 to 107.4)	1.0 (-1.2 to 5.1)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.7)	103.4 (41.3 to 121.0)	3.4 (-26.6 to 13.1)
Cysticercosis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-77.9 (-91.9 to -28.4)	-90.0 (-95.5 to -72.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-75.6 (-91.2 to -22.2)	-89.1 (-95.2 to -69.7)
Cystic echinococcosis	0.4 (0.4 to 0.5)	1.1 (1.1 to 1.2)	159.1 (119.4 to 185.7)	25.7 (9.1 to 36.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	153.8 (108.0 to 210.9)	23.9 (-2.7 to 58.2)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.1 (0.0 to 0.5)	0.6 (0.1 to 2.1)	407.5 (364.1 to 462.2)	190.5 (165.6 to 221.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.4)	407.5 (363.7 to 462.2)	190.5 (165.4 to 221.8)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.0 (-72.0 to -18.4)	-65.7 (-83.9 to -52.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.0 (-72.1 to -18.2)	-65.7 (-83.9 to -52.7)
Intestinal nematode infections	-	-	-	-	2.1 (1.1 to 3.7)	2.4 (1.3 to 4.0)	13.6 (-30.8 to 66.9)	-30.8 (-56.3 to 2.7)
Ascariasis	495.0 (418.6 to 598.5)	1,279.9 (1,073.2 to 1,529.1)	158.5 (98.1 to 229.1)	40.1 (5.9 to 80.3)	0.8 (0.3 to 1.8)	0.2 (0.1 to 0.3)	-81.8 (-92.9 to -54.3)	-87.2 (-95.0 to -67.6)
Trichuriasis	90.3 (76.2 to 107.8)	261.8 (218.3 to 312.0)	190.1 (126.6 to 275.7)	55.2 (18.9 to 103.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	116.3 (-73.7 to 1,794.1)	18.7 (-87.6 to 997.2)
Hookworm disease	432.2 (366.0 to 481.9)	709.4 (613.0 to 828.9)	63.0 (38.0 to 108.6)	65.7 (27.5 to 13.6)	1.3 (0.7 to 2.0)	2.2 (1.2 to 3.7)	79.9 (9.5 to 158.2)	4.1 (-38.7 to 48.2)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	229.6 (181.0 to 278.8)	259.1 (225.9 to 296.2)	12.5 (-7.6 to 43.1)	-20.9 (-34.2 to -2.3)	7.8 (4.7 to 11.8)	8.4 (5.2 to 12.1)	5.4 (-16.1 to 51.9)	-21.3 (-37.6 to 12.2)
Maternal disorders	-	-	-	-	1.3 (0.8 to 2.1)	1.2 (0.7 to 1.9)	-8.8 (-29.9 to 13.2)	-57.5 (-66.7 to -48.0)
Maternal hemorrhage	3.7 (3.3 to 4.2)	5.3 (3.7 to 7.0)	45.9 (-2.6 to 101.3)	-34.0 (-56.7 to -8.3)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	28.2 (-35.3 to 119.6)	41.4 (-70.3 to -1.5)
Maternal sepsis and other maternal infections	10.6 (6.3 to 15.4)	5.5 (3.1 to 8.2)	-47.3 (-69.8 to -22.3)	-79.0 (-87.3 to -67.5)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-52.6 (-75.9 to -14.2)	-78.8 (-88.8 to -61.9)
Maternal hypertensive disorders	12.0 (6.6 to 19.0)	10.6 (5.0 to 17.2)	-11.5 (-29.2 to 2.0)	-58.2 (-63.0 to -53.5)	0.6 (0.3 to 1.0)	0.5 (0.2 to 0.9)	-12.2 (-30.7 to 5.2)	-58.4 (-64.7 to -51.8)
Obstructed labor	0.4 (0.2 to 0.6)	0.3 (0.2 to 0.5)	-17.4 (-46.4 to 46.2)	-61.3 (-74.7 to -33.2)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-14.7 (-63.7 to 87.3)	-59.3 (-82.6 to -17.0)
Complications of abortion	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	10.3 (-35.6 to 90.3)	-52.4 (-71.0 to -20.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.3 (-35.7 to 90.7)	-52.4 (-71.1 to -20.1)
Other maternal disorders	-	-	-	-	0.3 (0.2 to 0.6)	0.3 (0.2 to 0.6)	-1.5 (-36.7 to 49.2)	-54.1 (-70.1 to -30.8)
Neonatal disorders	-	-	-	-	15.6 (10.3 to 23.0)	35.6 (23.9 to 48.9)	133.7 (42.0 to 228.7)	43.8 (-11.1 to 102.8)
Preterm birth complications	43.9 (31.9 to 59.3)	137.6 (103.6 to 181.5)	212.7 (148.8 to 297.2)	83.0 (45.9 to 131.3)	5.4 (3.6 to 7.5)	17.3 (12.1 to 23.6)	221.2 (144.0 to 339.8)	92.7 (46.7 to 161.9)
Neonatal encephalopathy due to birth asphyxia and trauma	24.4 (13.3 to 44.4)	30.9 (17.9 to 53.2)	28.4 (-35.1 to 140.8)	-20.8 (-60.6 to 47.5)	6.6 (3.9 to 10.8)	9.9 (5.6 to 16.0)	49.2 (-16.3 to 168.2)	-5.7 (-46.4 to 70.0)
Neonatal sepsis and other neonatal infections	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	1.7 (-12.9 to 12.8)	4.1 (-10.9 to 15.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-13.8 to 18.1)	2.6 (-11.8 to 20.8)
Hemolytic disease and other neonatal jaundice	6.6 (2.2 to 15.2)	16.5 (4.3 to 37.7)	196.4 (-59.9 to 853.1)	80.1 (-75.7 to 472.3)	2.5 (0.8 to 5.6)	6.1 (1.6 to 12.6)	194.2 (-60.2 to 748.4)	77.0 (-76.0 to 397.4)
Other neonatal disorders	-	-	-	-	1.2 (0.6 to 2.1)	2.3 (1.4 to 3.5)	102.3 (-7.7 to 295.3)	25.0 (-42.8 to 141.0)
Nutritional deficiencies	-	-	-	-	120.9 (81.0 to 173.5)	143.5 (95.1 to 206.0)	18.4 (8.0 to 33.5)	-23.5 (-28.7 to -14.0)
Protein-energy malnutrition	50.0 (20.5 to 104.6)	82.9 (29.4 to 194.1)	60.8 (-54.3 to 459.6)	53.4 (-55.8 to 423.0)	5.4 (2.2 to 13.5)	6.2 (3.2 to 24.3)	10.4 (-54.5 to 459.4)	55.7 (-56.0 to 428.9)
Iodine deficiency	125.3 (80.7 to 171.3)	197.9 (140.8 to 267.3)	57.2 (-2.6 to 159.0)	-19.6 (51.0 to 32.8)	2.2 (1.2 to 3.9)	3.5 (2.0 to 5.8)	56.0 (-3.9 to 159.5)	-20.0 (-51.3 to 34.7)
Vitamin A deficiency	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-

Appendix Table G.4 - Saudi Arabia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	3,551.5 (3,489.8 to 3,615.0)	4,461.7 (4,413.8 to 4,510.5)	25.8 (22.8 to 28.6)	-25.1 (-27.0 to -23.2)	112.2 (74.8 to 163.4)	128.6 (85.1 to 187.1)	14.6 (10.7 to 18.3)	26.6 (-29.1 to -23.7)
Other nutritional deficiencies	-	-	-	-	0.3 (0.1 to 0.9)	1.0 (0.3 to 2.7)	282.5 (20.7 to 1,548.3)	282.5 (23.0 to 1,453.3)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	9.3 (5.8 to 14.3)	13.1 (8.2 to 20.4)	39.4 (12.8 to 80.3)	-15.5 (-31.8 to 6.0)
Sexually transmitted diseases excluding HIV	-	-	-	-	2.9 (1.6 to 5.1)	5.7 (3.0 to 10.1)	100.5 (31.2 to 210.1)	-2.9 (-33.7 to 47.8)
Syphilis	0.4 (0.3 to 0.4)	0.6 (0.5 to 0.7)	50.3 (21.8 to 96.1)	-39.8 (-48.7 to -28.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	57.7 (10.2 to 121.7)	38.1 (-54.9 to -13.5)
Chlamydial infection	262.4 (164.9 to 377.4)	568.7 (347.3 to 785.7)	116.7 (9.8 to 324.8)	9.8 (-43.4 to 108.6)	1.5 (0.7 to 2.8)	3.0 (1.2 to 5.7)	96.4 (-3.6 to 329.8)	-1.0 (-50.1 to 119.3)
Gonococcal infection	95.6 (66.4 to 124.4)	172.9 (130.6 to 215.2)	81.2 (27.3 to 169.6)	-4.7 (-32.4 to 38.2)	0.7 (0.4 to 1.2)	1.2 (0.7 to 2.0)	78.5 (24.1 to 166.9)	-6.8 (-34.1 to 35.4)
Trichomoniasis	73.8 (46.7 to 109.1)	148.1 (95.1 to 203.0)	100.6 (28.4 to 227.0)	-4.6 (-38.9 to 51.1)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.5)	99.6 (15.0 to 269.3)	-4.0 (-45.1 to 69.5)
Genital herpes	1,779.8 (1,674.2 to 1,884.3)	4,061.5 (3,844.7 to 4,284.8)	128.2 (111.7 to 147.4)	-3.0 (-10.0 to 5.3)	3.0 (2.2 to 4.1)	1.1 (0.3 to 2.6)	122.2 (98.9 to 144.1)	34.3 (-11.4 to 6.2)
Other sexually transmitted diseases	2.7 (1.9 to 3.7)	4.8 (3.3 to 6.5)	79.8 (44.6 to 122.6)	-25.1 (-39.2 to -5.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	121.0 (47.9 to 241.7)	0.6 (-30.2 to 52.0)
Hepatitis	-	-	-	-	1.0 (0.6 to 1.4)	1.6 (1.0 to 2.4)	67.4 (46.6 to 95.7)	-17.3 (-27.5 to 0.2)
Hepatitis A	19.0 (18.2 to 20.0)	31.0 (30.0 to 32.1)	63.2 (61.1 to 65.2)	4.4 (4.1 to 4.8)	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.2)	85.8 (66.6 to 111.9)	2.7 (-8.2 to 15.6)
Hepatitis B	784.6 (703.8 to 859.0)	934.1 (844.3 to 1,028.8)	18.5 (4.8 to 38.7)	-37.8 (-45.1 to -28.9)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.7)	42.4 (-0.4 to 115.5)	-39.0 (-55.7 to 0.8)
Hepatitis C	343.5 (316.4 to 371.0)	580.6 (537.8 to 621.5)	69.6 (50.6 to 89.4)	-23.0 (-30.9 to -14.7)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	51.5 (19.7 to 94.6)	-24.3 (-43.7 to 2.9)
Hepatitis E	6.0 (5.1 to 7.0)	9.9 (8.7 to 11.4)	66.2 (42.8 to 96.1)	-8.7 (-21.8 to 7.1)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	71.2 (30.0 to 119.3)	-10.2 (-31.4 to 16.6)
Leprosy	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.3)	22.9 (-23.0 to 181.0)	-44.5 (-62.5 to 24.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.0 (-23.4 to 212.7)	-41.9 (-65.2 to 39.6)
Other infectious diseases	167.3 (131.7 to 206.6)	193.2 (157.7 to 231.7)	15.3 (-8.5 to 48.0)	-23.1 (-38.5 to -4.1)	5.5 (3.1 to 8.2)	5.8 (3.4 to 8.6)	5.8 (-26.3 to 62.3)	-23.4 (-46.6 to 15.4)
Non-communicable diseases	-	-	-	-	1,193.2 (871.4 to 1,548.3)	2,770.8 (2,045.9 to 3,578.8)	132.2 (123.6 to 141.3)	8.0 (4.2 to 12.0)
Neoplasms	-	-	-	-	2.5 (1.6 to 3.6)	5.2 (3.7 to 7.0)	106.1 (50.3 to 173.4)	6.3 (-20.6 to 37.1)
Esophageal cancer	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	26.8 (-28.6 to 144.0)	-38.3 (-64.7 to 16.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	30.8 (-20.8 to 138.9)	-36.3 (-61.6 to 14.4)
Stomach cancer	1.1 (0.8 to 1.4)	1.6 (1.3 to 2.0)	55.4 (10.6 to 113.6)	-20.1 (-42.3 to 10.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	52.5 (8.8 to 117.5)	-22.4 (-45.0 to 11.9)
Liver cancer	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	104.6 (36.2 to 206.1)	7.8 (-28.6 to 64.2)
Liver cancer due to hepatitis B	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	77.7 (-32.2 to 317.4)	-10.9 (-65.8 to 117.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	92.7 (-22.1 to 317.7)	-2.8 (-60.9 to 124.6)
Liver cancer due to hepatitis C	0.1 (0.0 to 0.1)	0.4 (0.2 to 0.6)	509.1 (192.7 to 1,202.8)	222.1 (51.7 to 613.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	501.5 (218.2 to 1,093.7)	213.5 (61.8 to 540.7)
Liver cancer due to alcohol use	0.3 (0.1 to 0.4)	0.6 (0.2 to 0.6)	39.5 (-35.1 to 196.9)	-25.2 (-65.3 to 58.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	46.1 (-29.5 to 180.1)	-21.6 (-62.9 to 49.6)
Liver cancer due to other causes	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	54.8 (-35.7 to 234.9)	-15.8 (-67.5 to 86.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	57.8 (-31.2 to 219.8)	16.2 (-65.6 to 83.4)
Larynx cancer	0.5 (0.3 to 0.7)	0.7 (0.5 to 1.0)	60.2 (-0.5 to 159.3)	-32.3 (-58.4 to 8.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	62.4 (-0.0 to 164.1)	-31.3 (-58.2 to 10.8)
Tracheal, bronchus and lung cancer	0.6 (0.4 to 0.8)	1.3 (1.0 to 1.6)	114.5 (50.7 to 199.2)	3.1 (-27.7 to 43.8)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	119.3 (50.1 to 223.4)	4.1 (-28.9 to 56.7)
Breast cancer	4.3 (2.7 to 6.5)	10.1 (7.8 to 12.8)	138.5 (39.8 to 283.9)	10.9 (-32.1 to 70.9)	0.3 (0.2 to 0.5)	0.8 (0.5 to 1.1)	139.9 (47.4 to 288.3)	13.3 (-28.9 to 74.5)
Cervical cancer	1.0 (0.6 to 1.6)	3.1 (0.7 to 1.4)	110.4 (40.0 to 176.0)	-64.4 (-73.5 to -26.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	45.4 (-39.1 to 79.6)	84.4 (-73.3 to -25.8)
Uterine cancer	0.7 (0.3 to 1.1)	0.8 (0.5 to 1.4)	22.8 (-34.8 to 231.5)	-51.6 (-73.7 to 23.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	18.7 (-38.7 to 232.4)	-53.0 (-74.0 to 24.1)
Prostate cancer	1.0 (0.6 to 1.6)	4.6 (3.0 to 7.4)	349.8 (168.2 to 674.9)	101.4 (20.3 to 247.5)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.7)	268.0 (130.4 to 494.4)	68.9 (6.1 to 173.0)
Colon and rectum cancer	2.5 (1.8 to 3.3)	6.8 (5.7 to 8.2)	175.8 (94.2 to 274.9)	40.3 (0.1 to 87.2)	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.8)	175.7 (98.8 to 284.5)	40.5 (1.9 to 92.3)
Lip and oral cavity cancer	1.0 (0.6 to 1.4)	1.7 (1.2 to 2.2)	68.0 (5.0 to 198.0)	-18.1 (-48.7 to 28.8)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	67.9 (6.1 to 188.0)	-18.7 (-48.5 to 29.1)
Nasopharynx cancer	0.8 (0.4 to 1.2)	0.5 (0.3 to 0.7)	-46.1 (-68.6 to 33.9)	-73.3 (-84.5 to -39.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-43.1 (-65.9 to 45.4)	71.3 (-83.0 to -35.5)
Other pharynx cancer	0.3 (0.2 to 0.5)	0.7 (0.5 to 0.9)	105.1 (28.1 to 219.5)	-11.9 (-44.7 to 34.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	103.8 (30.8 to 216.4)	-11.1 (-44.1 to 37.8)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.3)	137.5 (35.2 to 263.9)	21.8 (-37.8 to 89.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	122.2 (27.2 to 233.5)	12.3 (-42.0 to 77.1)
Pancreatic cancer	0.1 (0.1 to 0.2)	0.3 (0.3 to 0.4)	175.6 (85.5 to 304.8)	38.4 (-5.6 to 103.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	171.4 (91.5 to 274.5)	33.9 (-7.0 to 88.6)
Malignant skin melanoma	0.2 (0.1 to 0.2)	0.5 (0.4 to 0.7)	202.7 (93.4 to 353.7)	30.9 (-15.4 to 91.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	189.5 (61.1 to 331.5)	26.7 (-20.5 to 90.5)
Non-melanoma skin cancer	1.1 (1.0 to 1.3)	3.3 (2.9 to 3.9)	198.6 (146.6 to 265.1)	34.3 (8.0 to 70.6)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	199.1 (115.3 to 335.6)	38.0 (-7.3 to 110.4)
Ovarian cancer	0.4 (0.3 to 0.7)	0.9 (0.5 to 0.9)	49.6 (-6.5 to 159.9)	-26.8 (-53.6 to 25.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	55.6 (-5.7 to 175.8)	-23.8 (-54.5 to 39.9)
Testicular cancer	0.5 (0.2 to 0.8)	1.3 (1.0 to 2.0)	168.7 (35.5 to 461.5)	18.4 (-38.3 to 128.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	162.2 (22.4 to 518.3)	16.5 (-43.2 to 141.0)
Kidney cancer	0.7 (0.5 to 1.0)	1.4 (1.1 to 1.8)	92.4 (28.1 to 178.4)	49.3 (-28.0 to 62.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	103.0 (34.4 to 203.9)	11.2 (-28.2 to 67.4)
Bladder cancer	1.3 (0.8 to 1.9)	1.5 (1.1 to 2.3)	10.8 (-28.6 to 147.6)	-46.9 (-65.2 to 6.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	13.1 (-27.1 to 145.0)	45.5 (-64.4 to 4.2)
Brain and nervous system cancer	1.3 (0.9 to 1.9)	2.4 (1.8 to 2.9)	81.3 (17.6 to 154.3)	34.4 (-7.5 to 80.8)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	102.5 (36.4 to 176.6)	36.0 (-7.1 to 86.1)
Thyroid cancer	3.0 (1.6 to 4.6)	4.2 (3.0 to 6.6)	34.6 (-24.9 to 245.2)	-37.3 (-62.6 to 44.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	34.0 (-25.2 to 234.9)	-36.3 (-62.4 to 37.1)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-37.9 to 36.7)	0.0 (-72.0 to -35.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-37.2 to 40.9)	0.0 (-71.3 to -33.4)
Hodgkin lymphoma	1.0 (0.4 to 1.5)	0.6 (0.4 to 1.2)	-50.2 (-69.8 to 168.8)	-68.9 (-81.3 to 181.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-48.1 (-68.7 to 181.2)	-67.8 (-80.2 to 46.8)
Non-Hodgkin lymphoma	1.9 (1.3 to 2.6)	4.8 (3.7 to 6.7)	150.7 (62.5 to 319.6)	37.6 (-7.5 to 118.9)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	151.3 (60.7 to 324.0)	34.1 (-11.0 to 120.8)
Multiple myeloma	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	132.5 (23.8 to 410.7)	2.0 (-43.3 to 107.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	127.1 (23.1 to 374.0)	1.0 (-45.2 to 88.3)
Leukemia	1.3 (1.0 to 1.7)	3.2 (2.6 to 3.8)	147.6 (72.8 to 229.0)	80.8 (27.2 to 145.7)	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.5)	158.9 (86.7 to 252.2)	84.3 (25.8 to 159.6)
Other neoplasms	2.3 (1.5 to 4.7)	5.1 (4.1 to 6.5)	143.1 (2.3 to 250.4)	57.1 (-10.1 to 126.7)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	142.3 (11.1 to 248.1)	44.8 (-11.3 to 111.2)
Cardiovascular diseases	-	-	-	-	21.7 (14.6 to 30.3)	50.5 (33.9 to 68.9)	135.7 (79.5 to 188.5)	3.4 (-18.8 to 23.2)
Rheumatic heart disease	50.3 (47.4 to 53.3)	99.8 (93.5 to 106.4)	98.8 (80.6 to 118.2)	0.4 (-8.3 to 10.1)	2.6 (1.7 to 3.8)	5.6 (3.6 to 7.9)	111.7 (82.2 to 150.2)	9.7 (-7.8 to 37.7)
Ischemic heart disease	101.2 (84.7 to 122.6)	185.1 (162.4 to 218.0)	82.3 (43.0 to 136.0)	-20.5 (-37.9 to 20.0)	5.8 (3.8 to 8.4)	11.2 (7.5 to 15.9)	91.6 (39.8 to 107.7)	-19.1 (-39.8 to 10.7)
Cerebrovascular disease	-	-	-	-	0.3 (0.2 to 0.4)	0.9 (0.6 to 1.3)	209.0 (120.4 to 312.6)	21.6 (-15.0 to 65.6)
Ischemic stroke	1.7 (1.4 to 2.1)	5.2 (4.3 to 6.3)	207.4 (124.0 to 306.2)	21.3 (-13.3 to 62.2)	0.3 (0.2 to 0.4)	0.8 (0.5 to 1.2)	206.4 (119.2 to 312.7)	20.8 (-15.4 to 65.8)
Hemorrhagic stroke	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.6)	220.7 (109.6 to 398.5)	35.8 (-15.3 to 99.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	219.6 (111.3 to 387.6)	34.8 (-14.8 to 96.4)
Hypertensive heart disease	9.8 (7.6 to 12.5)	34.3 (25.8 to 43.1)	253.3 (145.5 to 396.6)	52.0 (20.0 to 116.8)	1.1 (0.7 to 1.6)	3.7 (2.4 to 5.4)	249.2 (146.0 to 392.5)	49.8 (1.5 to 115.3)
Cardiomyopathy and myocarditis	10.1 (8.3 to 11.9)	33.9 (27.2 to 41.6)	236.2 (156.2 to 345.7)	41.2 (-1.3 to 99.8)	1.1 (0.7 to 1.6)	3.7 (2.4 to 5.5)	236.6 (149.3 to 351.6)	11.3 (-2.5 to 100.1)
Atrial fibrillation and flutter	5.3 (3.6 to 8.9)	33.4 (25.4 to 46.8)	552.1 (305.6 to 841.6)	178.3 (71.0 to 306.6)	0.4 (0.2 to 0.7)	2.6 (1.6 to 3.9)	557.0 (311.2 to 860.6)	178.2 (67.8 to 311.2)
Peripheral vascular disease	135.5 (97.2 to 168.6)	407.3 (284.9 to 543.1)	200.4 (94.2 to 358.6)	18.2 (-16.8 to 64.2)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	88.4 (13.5 to 238.8)	-5.7 (-43.8 to 74.2)
Endocarditis	0.4 (0.3 to 0.6)	1.1 (0.8 to 1.5)	177.3 (87.3 to 325.8)	15.9 (-20.5 to 75.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	180.6 (77.3 to 365.2)	17.2 (-27.7 to 100.0)
Other cardiovascular and circulatory diseases	145.9 (101.9 to 215.9)	327.7 (184.2 to 441.0)	125.4 (24.3 to 250.5)	12.4 (-4.7 to 50.3)	0.8 (0.1 to 1.6)	1.2 (1.1 to 34.2)	134.6 (22.5 to 248.8)	1.1 (-47.4 to 48.8)
Chronic respiratory diseases	-</							

Appendix Table G.4 - Saudi Arabia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.1	128.6	-6.4
Silicosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	109.1 (98.6 to 119.8)	-18.2 (-22.4 to -13.9)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	110.2 (99.1 to 121.0)	-18.0 (-22.6 to -13.5)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.1 (0.1 to 0.1)	0.3 (0.3 to 0.3)	217.4 (126.4 to 149.4)	-2.1 (-6.5 to 2.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	140.3 (128.3 to 153.0)	-0.7 (-5.5 to 3.7)
Asthma	870.1 (739.7 to 996.6)	2,106.9 (1,880.9 to 2,340.8)	140.7 (102.9 to 201.9)	15.2 (-0.9 to 40.5)	38.3 (24.0 to 55.9)	92.6 (60.0 to 135.8)	140.5 (101.8 to 200.5)	15.6 (-1.1 to 41.6)
Interstitial lung disease and pulmonary sarcoidosis	1.0 (0.8 to 1.3)	2.4 (1.9 to 2.9)	133.8 (61.0 to 227.2)	-2.5 (-30.2 to 34.7)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	137.1 (63.4 to 231.1)	-2.6 (-32.2 to 38.0)
Other chronic respiratory diseases	-	-	-	-	1.1 (0.6 to 1.7)	1.6 (1.0 to 2.4)	55.8 (9.2 to 118.7)	-35.5 (-54.9 to -10.3)
Cirrhosis	-	-	-	-	1.0 (0.7 to 1.3)	1.2 (0.8 to 1.7)	29.4 (9.7 to 51.1)	-30.4 (-39.3 to -20.2)
Cirrhosis due to hepatitis B	1.4 (1.0 to 1.8)	1.6 (1.0 to 2.5)	14.5 (-40.7 to 132.3)	-38.8 (66.8 to 21.3)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.4)	11.5 (-43.6 to 128.3)	-40.0 (67.9 to 22.3)
Cirrhosis due to hepatitis C	2.0 (1.5 to 2.4)	3.9 (2.8 to 4.8)	100.1 (33.0 to 190.5)	-3.4 (-40.1 to 39.8)	0.3 (0.2 to 0.5)	0.6 (0.4 to 1.0)	96.0 (24.8 to 198.7)	-4.7 (-42.3 to 41.2)
Cirrhosis due to alcohol use	0.7 (0.5 to 1.0)	0.5 (0.3 to 0.9)	-29.1 (-60.2 to 45.8)	0.1 (-80.2 to -32.6)	0.1 (0.1 to 0.2)	0.2 (0.0 to 0.2)	-28.3 (-64.1 to 56.7)	65.5 (-81.8 to -30.4)
Cirrhosis due to other causes	1.7 (1.4 to 2.0)	1.5 (1.1 to 1.9)	-12.4 (-35.3 to 19.8)	-36.7 (-54.0 to -12.8)	0.3 (0.2 to 0.4)	0.3 (0.1 to 0.4)	-13.4 (-44.3 to 38.7)	-37.9 (-59.7 to -3.0)
Digestive diseases	-	-	-	-	7.3 (5.1 to 9.7)	16.1 (11.5 to 21.5)	122.5 (95.5 to 150.4)	-0.9 (-10.9 to 9.3)
Peptic ulcer disease	25.4 (19.7 to 30.2)	39.0 (30.3 to 47.0)	54.0 (20.0 to 97.2)	-28.1 (-39.8 to -12.9)	0.9 (0.6 to 1.3)	1.4 (1.0 to 2.1)	64.0 (17.6 to 119.7)	-23.2 (-42.2 to -4.9)
Gastritis and duodenitis	40.8 (34.6 to 46.2)	39.4 (32.2 to 46.0)	-3.4 (-24.4 to 18.1)	47.0 (-57.6 to -35.3)	1.7 (1.1 to 2.6)	1.6 (1.0 to 2.5)	-8.3 (-32.6 to 32.9)	-45.1 (-79.9 to -25.3)
Appendicitis	1.1 (0.7 to 1.6)	2.0 (1.4 to 2.5)	87.9 (-2.3 to 181.8)	-7.1 (-49.7 to 35.7)	0.2 (0.2 to 0.6)	0.6 (0.3 to 1.0)	85.2 (-11.1 to 215.3)	-7.4 (-52.8 to 49.5)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	116.6 (79.9 to 156.2)	0.0 (-14.9 to 18.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	119.0 (78.3 to 165.1)	2.0 (-21.9 to 31.0)
Inguinal, femoral, and abdominal hernia	29.7 (25.3 to 34.5)	54.3 (45.4 to 64.4)	82.7 (47.9 to 134.8)	-14.0 (-33.2 to 12.9)	0.3 (0.1 to 0.6)	0.6 (0.3 to 1.1)	81.5 (45.8 to 137.1)	-14.2 (-34.1 to 14.6)
Inflammatory bowel disease	9.8 (8.9 to 10.6)	34.8 (31.8 to 37.6)	256.0 (217.2 to 302.7)	48.9 (32.5 to 67.2)	2.1 (1.4 to 2.9)	7.4 (5.0 to 10.1)	253.3 (203.0 to 314.1)	48.2 (29.7 to 71.8)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	112.6 (42.5 to 197.5)	-2.9 (-41.3 to 45.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	114.4 (41.5 to 215.3)	-1.9 (-43.4 to 63.2)
Gallbladder and biliary diseases	4.8 (4.2 to 5.8)	11.1 (9.3 to 12.9)	132.3 (81.8 to 177.1)	1.9 (-20.4 to 22.2)	0.5 (0.3 to 0.7)	1.1 (0.7 to 1.7)	129.7 (78.9 to 189.4)	1.8 (-22.1 to 22.3)
Pancreatitis	2.7 (2.5 to 2.9)	5.9 (5.3 to 6.3)	118.2 (95.6 to 143.9)	-9.0 (-17.4 to -1.4)	0.8 (0.5 to 1.1)	1.7 (1.1 to 2.4)	116.0 (74.2 to 172.1)	-9.6 (-24.3 to 8.4)
Other digestive diseases	-	-	-	-	0.6 (0.3 to 0.9)	1.6 (1.1 to 2.1)	187.0 (85.6 to 296.8)	27.9 (-15.5 to 76.9)
Neurological disorders	-	-	-	-	105.1 (71.1 to 145.8)	247.5 (161.4 to 349.5)	135.8 (96.6 to 178.2)	6.6 (-7.4 to 22.0)
Alzheimer disease and other dementias	53.7 (46.0 to 61.8)	113.8 (99.2 to 127.8)	112.6 (74.4 to 156.9)	2.4 (-16.1 to 24.1)	7.6 (5.3 to 10.1)	15.9 (11.4 to 20.6)	110.4 (72.5 to 156.4)	1.8 (-17.1 to 24.6)
Parkinson disease	2.6 (2.0 to 3.2)	6.2 (4.7 to 7.7)	138.9 (117.3 to 164.6)	5.3 (-1.3 to 16.2)	0.3 (0.2 to 0.4)	0.7 (0.4 to 1.0)	139.9 (105.0 to 179.0)	4.8 (-8.8 to 20.8)
Epilepsy	72.6 (57.5 to 84.9)	124.3 (98.9 to 147.3)	70.9 (27.6 to 130.6)	-4.0 (-28.1 to 28.4)	24.7 (16.1 to 34.2)	45.3 (29.7 to 61.9)	82.4 (32.3 to 153.9)	3.5 (-24.5 to 44.8)
Multiple sclerosis	1.7 (1.3 to 2.1)	5.8 (3.9 to 7.6)	242.7 (118.6 to 411.6)	35.4 (-11.9 to 101.1)	0.6 (0.4 to 0.8)	1.9 (1.1 to 2.8)	230.2 (104.7 to 425.4)	32.2 (-15.1 to 101.6)
Migraine	1,415.4 (1,010.3 to 2,000.0)	3,397.3 (2,516.2 to 4,495.3)	441.7 (71.4 to 244.9)	8.3 (-20.0 to 46.0)	48.1 (26.0 to 78.8)	115.2 (62.8 to 184.0)	140.6 (70.5 to 246.2)	8.1 (-20.3 to 46.8)
Tension-type headache	2,524.2 (2,318.4 to 2,714.8)	5,076.1 (3,771.0 to 6,414.4)	99.5 (48.4 to 160.7)	-4.4 (-23.1 to 22.2)	3.8 (1.9 to 6.7)	7.7 (3.3 to 13.9)	98.8 (40.0 to 160.5)	-4.6 (-23.9 to 21.4)
Medication overuse headache	106.8 (72.0 to 142.0)	373.5 (241.6 to 501.8)	249.5 (185.5 to 336.1)	50.8 (22.9 to 86.2)	16.8 (9.5 to 25.9)	58.3 (33.6 to 91.0)	248.1 (182.5 to 337.9)	50.7 (22.2 to 85.1)
Other neurological disorders	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	89.5 (12.4 to 204.8)	0.5 (-39.4 to 49.0)	3.2 (1.8 to 5.3)	2.5 (1.7 to 3.5)	-20.2 (-52.8 to 41.6)	-62.6 (-78.0 to -33.8)
Mental and substance use disorders	-	-	-	-	401.3 (278.7 to 554.1)	838.1 (584.9 to 1,146.3)	108.9 (98.0 to 121.2)	-0.1 (-3.0 to 3.3)
Schizophrenia	37.2 (33.6 to 40.6)	90.5 (82.6 to 97.9)	143.6 (132.1 to 156.6)	-0.1 (-4.3 to 4.2)	23.8 (17.6 to 29.0)	57.6 (42.7 to 69.8)	142.1 (124.8 to 160.9)	0.3 (-6.3 to 6.3)
Alcohol use disorders	60.8 (50.2 to 71.8)	167.8 (150.1 to 186.0)	176.7 (144.0 to 217.3)	26.8 (16.2 to 41.4)	6.0 (3.8 to 8.5)	16.5 (10.9 to 23.8)	178.2 (140.8 to 223.7)	27.7 (14.2 to 43.5)
Drug use disorders	-	-	-	-	78.9 (48.6 to 115.0)	178.3 (112.1 to 258.3)	125.3 (100.6 to 155.9)	-1.9 (-12.0 to 11.1)
Opioid use disorders	167.6 (108.4 to 237.1)	386.6 (251.2 to 535.5)	130.2 (104.5 to 162.4)	-2.3 (-12.6 to 10.9)	69.4 (40.8 to 103.1)	159.9 (96.8 to 235.9)	129.6 (103.1 to 164.2)	-2.3 (-13.1 to 12.6)
Cocaine use disorders	12.5 (9.5 to 15.8)	28.3 (22.6 to 34.3)	126.1 (66.9 to 219.6)	9.3 (-17.4 to 51.8)	3.7 (1.0 to 2.6)	9.7 (2.3 to 5.7)	177.9 (59.0 to 228.9)	11.0 (-21.7 to 56.1)
Amphetamine use disorders	20.5 (16.2 to 25.5)	35.6 (28.4 to 42.7)	75.3 (25.7 to 131.6)	-7.6 (-32.4 to 20.4)	2.7 (1.6 to 4.2)	4.6 (2.8 to 7.1)	73.7 (50.7 to 142.7)	-8.0 (-34.7 to 26.2)
Cannabis use disorders	25.2 (19.7 to 30.5)	46.8 (37.4 to 55.7)	85.9 (80.2 to 92.9)	-0.4 (-0.8 to -0.0)	0.7 (0.4 to 1.1)	1.3 (0.8 to 2.0)	85.3 (55.4 to 118.8)	-0.4 (-15.5 to 16.0)
Other drug use disorders	-	-	-	-	4.4 (2.7 to 6.6)	8.5 (5.4 to 12.7)	93.0 (35.1 to 179.0)	-1.2 (-30.4 to 42.5)
Depressive disorders	-	-	-	-	20.1 (73.6 to 207.9)	282.7 (152.2 to 448.1)	112.2 (84.0 to 142.6)	0.2 (-7.1 to 7.3)
Major depressive disorder	579.6 (348.9 to 827.8)	1,230.6 (656.5 to 1,792.7)	112.0 (77.7 to 144.9)	0.1 (-7.7 to 8.5)	119.4 (63.6 to 193.4)	251.7 (122.6 to 414.7)	110.2 (76.1 to 144.0)	-0.2 (-8.1 to 8.5)
Dysthymia	139.2 (110.7 to 167.3)	323.0 (257.1 to 389.1)	132.0 (122.7 to 144.6)	0.4 (0.1 to 0.6)	13.4 (8.5 to 19.8)	31.0 (19.6 to 45.8)	130.9 (119.4 to 145.8)	0.1 (-2.9 to 3.0)
Bipolar disorder	103.0 (87.8 to 117.7)	224.4 (196.7 to 251.8)	118.1 (105.2 to 132.9)	-0.7 (-5.5 to 4.3)	20.9 (12.7 to 31.6)	45.3 (28.2 to 67.5)	117.0 (100.6 to 133.6)	-0.9 (-7.2 to 5.3)
Anxiety disorders	596.0 (259.6 to 861.0)	1,198.2 (855.2 to 1,708.0)	102.5 (81.0 to 126.2)	0.6 (-0.2 to 1.6)	54.9 (21.9 to 91.2)	109.7 (47.1 to 175.8)	100.8 (80.1 to 125.9)	0.5 (-2.3 to 3.0)
Eating disorders	-	-	-	-	2.2 (1.3 to 3.4)	4.1 (2.4 to 6.5)	89.3 (66.9 to 114.2)	7.3 (-4.7 to 20.2)
Anorexia nervosa	2.5 (1.5 to 3.8)	5.3 (3.3 to 7.7)	107.5 (81.0 to 153.4)	18.8 (3.8 to 44.5)	0.5 (0.3 to 0.9)	1.1 (0.6 to 1.8)	109.4 (58.2 to 176.5)	20.1 (-9.8 to 57.3)
Bulimia nervosa	7.8 (5.3 to 11.2)	14.3 (9.7 to 20.5)	83.4 (77.1 to 92.7)	3.0 (0.6 to 6.0)	1.6 (0.9 to 2.7)	3.0 (1.7 to 4.9)	83.4 (59.6 to 110.2)	3.1 (-10.4 to 16.8)
Autistic spectrum disorders	-	-	-	-	20.1 (14.0 to 27.4)	35.8 (24.8 to 48.3)	78.4 (71.6 to 85.5)	0.2 (-3.6 to 3.5)
Autism	50.2 (47.5 to 53.0)	90.3 (85.6 to 95.4)	80.1 (78.7 to 81.6)	-0.1 (-0.1 to -0.1)	12.4 (8.4 to 17.0)	22.1 (15.1 to 30.4)	78.6 (69.2 to 88.8)	-0.2 (-5.0 to 4.9)
Asperger syndrome	76.5 (71.7 to 81.1)	137.0 (128.4 to 145.3)	79.2 (77.5 to 81.1)	-0.1 (-0.2 to -0.1)	7.7 (5.3 to 10.7)	13.6 (9.5 to 19.0)	78.2 (70.3 to 87.1)	-0.1 (-4.1 to 4.0)
Attention-deficit/hyperactivity disorder	109.6 (90.5 to 129.3)	159.6 (131.9 to 188.1)	45.7 (45.2 to 46.1)	2.0 (1.7 to 2.2)	1.3 (0.8 to 2.1)	1.9 (1.1 to 3.1)	46.3 (34.9 to 57.4)	2.3 (-5.1 to 9.9)
Conduct disorder	190.3 (158.3 to 220.4)	286.7 (236.1 to 330.5)	49.9 (47.6 to 51.4)	2.8 (2.4 to 3.4)	22.9 (14.1 to 34.4)	34.2 (21.0 to 51.5)	69.4 (42.9 to 95.6)	2.5 (-1.4 to 6.3)
Idiopathic intellectual disability	410.0 (349.6 to 485.9)	695.5 (593.8 to 837.1)	69.5 (56.4 to 84.7)	4.1 (-11.4 to 4.5)	20.1 (13.4 to 28.2)	33.9 (21.0 to 47.9)	68.3 (54.7 to 84.3)	-4.3 (-11.8 to 4.8)
Other mental and substance use disorders	233.0 (215.9 to 249.5)	513.4 (479.8 to 545.7)	120.7 (115.5 to 125.7)	-1.0 (-1.5 to -0.6)	17.4 (11.9 to 23.5)	38.2 (26.1 to 51.6)	119.4 (108.2 to 129.8)	-1.4 (-4.8 to 2.4)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	177.3 (122.1 to 243.2)	531.3 (369.4 to 719.4)	200.4 (162.3 to 241.6)	39.9 (18.8 to 62.7)
Diabetes mellitus	993.3 (839.2 to 1,148.5)	3,847.6 (3,414.2 to 4,303.4)	288.9 (224.0 to 372.2)	61.2 (29.6 to 97.3)	94.1 (61.9 to 131.7)	378.2 (257.1 to 520.6)	303.1 (228.8 to 399.7)	60.1 (27.0 to 97.6)
Acute glomerulonephritis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	10.4 (-17.5 to -3.8)	-33.7 (-38.0 to -29.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.4 (-17.5 to -3.8)	-33.7 (-38.0 to -29.7)
Chronic kidney disease	-	-	-	-	13.3 (9.3 to 18.2)	27.4 (19.2 to 38.0)	106.4 (82.4 to 131.4)	-1.5 (-11.5 to 6.8)
Chronic kidney disease due to diabetes mellitus	20.7 (14.0 to 31.2)	48.0 (32.2 to 73.1)	132.3 (76.0 to 204.8)	-5.0 (-32.0 to 24.8)	2.4 (1.5 to 3.4)	6.2 (4.3 to 9.0)	162.8 (96.4 to 238.4)	10.6 (-17.8 to 40.3)
Chronic kidney disease due to hypertension	22.1 (16.7 to 28.2)	35.1 (25.7 to 48.2)	58.5 (21.5 to 99.1)	-28.1 (-42.6 to -11.8)	3.8 (2.6 to 5.4)	6.9 (4.5 to 10.1)	80.9 (34.1 to 131.8)	-7.0 (-42.7 to -1.7)
Chronic kidney disease due to glomerulonephritis	25.7 (18.0 to 37.9)	40.6 (25.0 to 64.1)	52.5 (5.3 to 102.5)	2.3 (-53.4 to -34.9)	2.3 (1.4 to 3.5)	3.3 (2.1 to 4.9)	42.2 (-0.6 to 117.5)	-22.5 (-44.0 to 19.4)
Chronic kidney disease due to other causes	37.6 (27.6 to 52.3)	82.4 (62.0 to 111.3)	118.4 (72.5 to 179.5)	3.6 (-17.3 to 42.8)	4.7 (3.2 to 6.8)	10.9 (7.1 to 15.6)	130.0 (78.2 to 194.5)	15.9 (-4.2 to 58.9)
Urinary diseases and male infertility	-	-	-	-	5.9 (3.8 to 8.7)	15.3 (9.5 to 23.3)	157.8 (118.7 to 213.6)	9.0 (-3.8 to 26.6)

Appendix Table G.4 - Saudi Arabia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	2.9 (2.6 to 3.1)	5.8 (5.5 to 6.1)	103.5 (84.5 to 129.0)	2.5 (-1.8 to 15.8)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	102.0 (58.0 to 163.9)	10.0 (-13.1 to 30.2)
Urolithiasis	141.6 (82.3 to 231.4)	435.0 (202.3 to 863.2)	307.7 (105.8 to 509.1)	2.1 (-11.6 to 57.8)	1.1 (0.7 to 1.8)	3.9 (2.0 to 7.5)	231.7 (154.2 to 357.2)	42.2 (12.4 to 84.8)
Benign prostatic hyperplasia	95.9 (87.3 to 103.1)	217.6 (201.3 to 234.7)	126.8 (103.7 to 152.9)	-1.6 (-12.2 to 10.3)	3.4 (2.2 to 4.8)	7.7 (5.0 to 11.0)	128.1 (105.2 to 155.1)	-1.5 (-11.9 to 10.9)
Male infertility due to other causes	155.6 (101.4 to 218.9)	319.5 (207.7 to 440.0)	105.6 (20.8 to 242.1)	-3.6 (4.4 to 58.5)	1.1 (0.4 to 2.2)	2.1 (0.9 to 4.6)	103.6 (14.5 to 239.1)	-3.5 (-45.6 to 60.7)
Other urinary diseases	-	-	-	-	0.3 (0.1 to 0.4)	1.4 (0.5 to 2.8)	489.7 (206.4 to 807.4)	132.8 (33.4 to 260.7)
Gynecological diseases	-	-	-	-	17.1 (11.1 to 25.7)	38.6 (25.0 to 57.6)	126.7 (97.6 to 156.2)	0.4 (-11.6 to 12.7)
Uterine fibroids	187.0 (167.3 to 204.7)	515.5 (464.5 to 561.4)	175.8 (172.3 to 179.6)	-1.1 (-1.5 to -0.7)	3.2 (1.9 to 5.2)	7.2 (4.2 to 11.8)	122.9 (104.1 to 137.5)	-14.3 (-20.0 to -10.1)
Polycystic ovarian syndrome	257.8 (232.0 to 281.2)	579.7 (512.5 to 646.1)	126.1 (90.7 to 158.9)	0.5 (-13.3 to 13.8)	2.5 (1.2 to 4.7)	5.7 (2.6 to 10.6)	125.6 (89.0 to 158.3)	0.5 (-13.8 to 13.8)
Female infertility due to other causes	36.6 (14.6 to 72.8)	93.2 (27.4 to 171.5)	155.7 (-38.3 to 561.5)	15.7 (-74.4 to 273.6)	0.2 (0.1 to 0.5)	0.5 (0.1 to 1.4)	149.4 (-29.9 to 605.9)	15.0 (-69.0 to 256.4)
Endometriosis	21.2 (17.8 to 25.1)	52.9 (45.6 to 60.7)	150.8 (99.9 to 214.5)	7.8 (-12.8 to 32.1)	2.0 (1.2 to 2.7)	4.9 (3.2 to 6.8)	148.7 (94.8 to 216.7)	7.4 (-13.9 to 35.0)
Genital prolapse	552.3 (452.8 to 675.7)	1,407.3 (1,137.9 to 1,707.7)	156.0 (94.1 to 230.3)	3.3 (-19.2 to 28.4)	1.8 (0.8 to 3.5)	4.4 (2.1 to 8.7)	154.8 (94.1 to 231.1)	2.9 (-19.7 to 29.3)
Premenstrual syndrome	749.7 (588.4 to 935.6)	1,682.5 (1,192.6 to 2,190.5)	125.2 (59.2 to 204.0)	9.8 (-21.4 to 47.4)	6.3 (3.7 to 9.9)	14.1 (7.8 to 22.5)	124.2 (58.6 to 206.4)	9.6 (-21.4 to 48.0)
Other gynecological diseases	38.2 (28.7 to 47.8)	64.2 (59.5 to 70.2)	68.4 (30.0 to 127.3)	-22.9 (-40.0 to 3.6)	1.1 (0.6 to 1.6)	1.9 (1.2 to 2.7)	64.4 (30.9 to 166.3)	-24.9 (-40.0 to 21.0)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	40.1 (26.8 to 57.1)	62.9 (42.3 to 89.5)	57.1 (47.4 to 67.2)	1.2 (-7.2 to 7.6)
Thalassemias	5.4 (4.0 to 6.6)	6.6 (5.2 to 8.0)	22.2 (11.5 to 36.3)	-8.8 (-16.5 to 1.7)	0.4 (0.2 to 0.6)	0.4 (0.3 to 0.7)	20.9 (-21.5 to 95.7)	-11.3 (-41.9 to 41.5)
Thalassemia trait	878.8 (759.2 to 987.9)	1,476.8 (1,326.2 to 1,646.3)	68.2 (60.4 to 77.2)	-5.1 (-9.5 to 0.5)	17.0 (11.1 to 24.9)	26.9 (17.8 to 39.2)	60.7 (30.3 to 78.6)	5.6 (-18.4 to 17.3)
Sickle cell disorders	46.2 (40.4 to 50.3)	76.4 (71.0 to 81.3)	65.1 (48.7 to 89.9)	8.7 (-2.7 to 27.4)	4.9 (3.4 to 6.6)	8.8 (6.2 to 12.0)	81.1 (58.0 to 107.3)	13.0 (-2.3 to 28.6)
Sickle cell trait	2,733.6 (2,601.3 to 2,852.9)	4,673.3 (4,489.2 to 4,843.9)	71.1 (65.7 to 76.2)	-9.8 (-6.8 to -0.9)	13.0 (8.3 to 18.8)	29.9 (13.8 to 30.5)	60.3 (41.6 to 92.2)	6.1 (-5.7 to 31.1)
G6PD deficiency	1,524.9 (1,428.6 to 1,612.2)	2,724.3 (2,557.1 to 2,879.2)	78.5 (64.3 to 94.4)	-0.1 (-8.0 to 8.8)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.4)	35.1 (-9.1 to 98.1)	-21.4 (-44.8 to 13.2)
G6PD trait	3,024.8 (3,003.0 to 3,052.7)	5,195.0 (5,146.8 to 5,230.5)	71.9 (70.0 to 73.8)	0.6 (-0.6 to 1.7)	0.1 (0.0 to 0.2)	0.2 (0.0 to 0.3)	92.2 (85.0 to 3,206.9)	23.3 (-87.4 to 147.5)
Other hemoglobinopathies and hemolytic anemias	168.2 (141.5 to 193.9)	212.8 (186.2 to 240.0)	26.6 (7.5 to 50.9)	-29.6 (-39.0 to -18.7)	4.7 (3.0 to 6.9)	5.4 (3.4 to 7.9)	14.9 (-13.4 to 57.1)	-30.2 (-46.4 to -7.2)
Endocrine, metabolic, blood, and immune disorders	207.2 (178.7 to 232.8)	274.2 (243.4 to 301.0)	32.6 (16.0 to 54.1)	-20.1 (-29.2 to -9.7)	6.8 (4.5 to 9.8)	8.9 (5.9 to 12.6)	20.1 (4.4 to 67.2)	-17.0 (-31.4 to 2.8)
Musculoskeletal disorders	-	-	-	-	192.3 (135.1 to 259.1)	493.0 (342.2 to 667.4)	157.4 (117.8 to 198.2)	7.0 (-6.7 to 22.7)
Rheumatoid arthritis	12.0 (11.1 to 12.9)	16.5 (15.2 to 17.8)	38.4 (23.0 to 54.5)	-36.5 (-43.4 to -29.1)	2.8 (2.0 to 3.7)	3.9 (2.7 to 5.2)	37.6 (15.4 to 59.7)	-37.0 (-45.0 to -28.6)
Osteoarthritis	260.2 (248.1 to 272.4)	697.8 (662.1 to 736.0)	168.5 (150.2 to 188.7)	2.2 (-4.1 to 9.2)	15.7 (10.9 to 21.6)	42.2 (29.2 to 57.8)	168.5 (149.0 to 189.8)	1.5 (-5.2 to 8.5)
Low back and neck pain	-	-	-	-	155.2 (106.3 to 213.3)	394.6 (268.5 to 544.1)	154.7 (107.8 to 208.4)	10.2 (-10.0 to 31.1)
Low back pain	987.2 (823.1 to 1,192.0)	2,565.5 (2,156.9 to 2,998.7)	160.9 (99.0 to 241.1)	12.8 (-11.9 to 43.2)	110.0 (72.0 to 153.4)	284.2 (184.8 to 404.7)	160.0 (97.5 to 238.5)	12.6 (-12.3 to 43.0)
Neck pain	462.5 (400.2 to 536.2)	1,132.9 (949.3 to 1,302.1)	143.2 (103.6 to 202.0)	-0.1 (-15.4 to 22.8)	45.3 (30.5 to 64.6)	110.3 (72.8 to 156.3)	141.5 (103.1 to 199.8)	-0.6 (-16.3 to 22.6)
Gout	5.9 (4.9 to 7.0)	15.4 (12.6 to 18.0)	161.0 (101.0 to 234.4)	-2.1 (-25.6 to 22.9)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	162.2 (85.1 to 257.7)	-1.9 (-29.4 to 31.3)
Other musculoskeletal disorders	202.3 (153.8 to 245.4)	574.8 (438.6 to 754.0)	183.3 (149.6 to 225.2)	9.2 (0.5 to 19.9)	18.4 (11.6 to 26.5)	51.8 (32.1 to 76.6)	161.2 (147.4 to 213.1)	8.4 (-1.2 to 19.3)
Other non-communicable diseases	-	-	-	-	212.6 (139.9 to 314.9)	409.5 (270.7 to 594.0)	92.4 (83.1 to 103.6)	-5.8 (-9.9 to -1.7)
Congenital anomalies	-	-	-	-	16.2 (11.4 to 21.8)	45.6 (30.9 to 64.0)	179.7 (126.3 to 255.0)	62.7 (33.0 to 103.8)
Neural tube defects	3.3 (2.8 to 4.0)	6.5 (5.4 to 7.6)	95.2 (54.8 to 150.8)	21.2 (-3.8 to 55.9)	0.9 (0.6 to 1.3)	1.9 (1.3 to 2.7)	109.1 (53.6 to 183.3)	31.4 (-4.1 to 76.8)
Congenital heart anomalies	76.2 (61.1 to 101.3)	224.6 (189.6 to 284.1)	199.4 (107.9 to 294.4)	83.4 (27.1 to 144.4)	2.7 (1.3 to 4.7)	8.2 (5.4 to 11.0)	201.2 (117.6 to 305.9)	87.4 (36.3 to 153.0)
Orofacial clefts	15.6 (11.8 to 19.9)	44.3 (34.3 to 59.1)	181.5 (101.3 to 321.9)	84.8 (32.1 to 177.2)	0.4 (0.1 to 0.4)	0.4 (0.3 to 0.7)	80.7 (17.7 to 188.1)	17.3 (-22.5 to 88.6)
Down syndrome	24.8 (20.2 to 30.8)	57.4 (48.0 to 68.4)	133.9 (70.8 to 200.1)	37.8 (1.0 to 77.5)	2.9 (2.0 to 4.1)	7.3 (5.2 to 9.7)	148.8 (79.8 to 227.6)	42.8 (3.7 to 89.5)
Turner syndrome	0.5 (0.4 to 0.7)	1.0 (0.8 to 1.4)	103.7 (43.3 to 207.9)	21.3 (-14.7 to 81.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.2 (43.8 to 221.4)	21.9 (-17.5 to 83.1)
Klinefelter syndrome	0.6 (0.4 to 0.7)	1.0 (0.7 to 1.3)	79.0 (15.7 to 141.0)	-1.1 (-36.1 to 33.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.4 (26.7 to 165.2)	-3.2 (-37.3 to 30.9)
Chromosomal unbalanced rearrangements	21.3 (16.3 to 27.3)	47.1 (35.9 to 60.5)	121.2 (58.8 to 216.4)	2.5 (-6.3 to 87.1)	6.0 (1.7 to 3.4)	6.0 (4.0 to 8.2)	156.2 (66.7 to 238.2)	37.0 (-4.1 to 96.0)
Other congenital anomalies	40.9 (35.1 to 47.7)	73.2 (60.7 to 86.9)	78.1 (54.6 to 109.9)	-7.9 (-20.3 to 10.5)	6.8 (4.3 to 10.4)	21.7 (13.3 to 33.3)	216.2 (100.6 to 385.6)	83.2 (19.9 to 180.0)
Skin and subcutaneous diseases	-	-	-	-	90.0 (56.2 to 142.9)	164.6 (103.0 to 255.1)	82.8 (68.1 to 100.3)	0.3 (-6.4 to 9.1)
Dermatitis	857.1 (733.4 to 998.0)	1,702.7 (1,450.7 to 1,980.1)	98.6 (92.8 to 106.8)	-0.1 (-0.2 to 0.0)	26.2 (16.8 to 38.3)	48.8 (31.2 to 70.9)	86.7 (76.5 to 96.7)	-0.2 (-2.8 to 2.4)
Psoriasis	87.1 (70.1 to 107.7)	189.0 (149.4 to 240.0)	116.8 (108.3 to 125.9)	0.0 (-0.1 to 0.2)	0.0 (4.7 to 10.3)	7.1 (9.9 to 22.7)	115.3 (98.6 to 132.9)	-0.2 (-6.2 to 5.8)
Cellulitis	3.3 (2.7 to 4.1)	5.0 (4.0 to 6.3)	49.5 (29.1 to 71.6)	-14.7 (-22.6 to -4.1)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.6)	48.6 (12.5 to 94.0)	-14.5 (-31.4 to 6.1)
Pyoderma	13.5 (10.7 to 17.2)	18.3 (14.6 to 24.0)	34.9 (21.3 to 51.6)	-7.6 (-13.2 to -0.8)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	33.7 (14.2 to 56.4)	-8.0 (-19.0 to 3.5)
Scabies	52.6 (44.4 to 63.2)	87.7 (76.9 to 100.2)	68.6 (27.5 to 108.0)	-3.4 (-26.2 to 18.9)	1.4 (0.7 to 2.3)	2.3 (1.2 to 3.6)	67.8 (28.2 to 110.5)	-3.2 (-26.0 to 20.8)
Fungal skin diseases	885.9 (885.2 to 1,126.8)	1,889.8 (1,467.5 to 2,352.2)	110.8 (100.9 to 122.2)	-0.1 (-0.3 to 0.1)	6.0 (2.0 to 10.8)	10.1 (4.3 to 22.7)	110.1 (99.9 to 122.0)	-0.2 (-1.2 to 0.8)
Viral skin diseases	431.6 (370.7 to 493.6)	659.2 (549.1 to 763.6)	52.6 (46.0 to 60.0)	-0.1 (-2.1 to 2.0)	13.4 (8.3 to 19.9)	20.3 (12.5 to 30.4)	52.1 (44.1 to 60.4)	-0.1 (-3.5 to 3.2)
Acne vulgaris	2,243.9 (1,740.1 to 2,763.6)	3,838.9 (2,831.0 to 4,670.0)	71.7 (22.0 to 134.8)	4.3 (-26.6 to 43.0)	24.4 (10.7 to 48.4)	41.6 (18.3 to 75.5)	71.7 (21.4 to 135.4)	4.5 (-26.9 to 43.6)
Alopecia areata	25.1 (22.0 to 28.1)	51.1 (45.7 to 56.7)	103.8 (76.2 to 141.1)	2.1 (-11.8 to 18.3)	0.8 (0.5 to 1.3)	1.7 (1.1 to 2.6)	102.6 (69.3 to 144.5)	1.6 (-13.8 to 20.4)
Pruritus	3.4 (1.9 to 5.3)	7.7 (4.5 to 12.0)	124.9 (16.4 to 367.2)	6.9 (-52.0 to 111.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	119.9 (9.7 to 376.6)	5.6 (-52.0 to 116.5)
Urticaria	123.3 (85.5 to 161.5)	238.5 (165.8 to 310.0)	92.3 (25.4 to 195.6)	-0.1 (-35.3 to 44.2)	7.4 (4.2 to 11.9)	14.1 (8.1 to 22.2)	91.5 (23.8 to 196.1)	-1.5 (-36.7 to 42.6)
Decubitus ulcer	1.8 (1.5 to 2.1)	3.7 (3.0 to 4.2)	99.8 (59.4 to 143.9)	-5.5 (-28.1 to 22.8)	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.8)	98.1 (52.0 to 151.1)	-6.0 (-31.8 to 25.7)
Other skin and subcutaneous diseases	651.2 (452.9 to 911.8)	1,492.6 (1,020.6 to 2,095.9)	128.9 (107.5 to 153.2)	0.7 (-3.2 to 3.6)	0.7 (1.7 to 7.8)	8.7 (3.9 to 17.7)	128.3 (105.9 to 153.3)	0.4 (-3.5 to 3.6)
Sense organ diseases	-	-	-	-	80.9 (54.6 to 115.0)	144.3 (94.9 to 208.9)	47.2 (68.9 to 88.8)	-17.0 (-20.9 to -13.6)
Glaucoma	51.7 (37.8 to 66.6)	107.7 (79.2 to 145.2)	109.1 (48.0 to 191.8)	-13.9 (-37.3 to 22.6)	2.0 (1.2 to 3.1)	4.1 (2.5 to 6.3)	104.1 (59.3 to 179.9)	-16.1 (-37.2 to 17.0)
Cataract	123.6 (92.5 to 149.8)	182.7 (147.3 to 225.3)	48.7 (19.4 to 84.0)	-33.0 (-46.8 to -18.9)	5.2 (3.3 to 7.4)	7.7 (5.1 to 11.0)	47.0 (23.8 to 76.3)	-33.8 (-43.9 to -22.1)
Macular degeneration	39.8 (29.7 to 49.8)	82.5 (57.3 to 112.3)	105.2 (47.6 to 213.5)	-21.0 (-42.8 to 24.8)	1.6 (1.0 to 2.4)	3.1 (1.8 to 4.8)	94.1 (42.6 to 183.7)	-24.4 (-43.6 to 14.6)
Uncorrected refractive error	1,244.9 (1,097.4 to 1,397.7)	2,453.3 (2,042.0 to 2,893.9)	97.4 (56.9 to 142.1)	-9.3 (-21.0 to 10.1)	25.2 (15.8 to 38.7)	44.5 (26.8 to 68.9)	76.0 (55.6 to 99.6)	-18.2 (-27.4 to -7.6)
Age-related and other hearing loss	1,074.8 (998.0 to 1,169.3)	2,303.1 (2,121.5 to 2,518.5)	114.5 (102.8 to 127.1)	-9.9 (-13.2 to -6.7)	29.0 (19.5 to 40.9)	57.2 (37.1 to 82.0)	97.3 (82.0 to 115.0)	-12.0 (-17.3 to -6.5)
Other vision loss	170.2 (148.0 to 195.7)	253.7 (218.2 to 297.9)	48.9 (32.6 to 69.0)	-26.0 (-33.5 to -16.4)	8.0 (5.3 to 11.3)	11.7 (7.7 to 16.6)	46.2 (30.1 to 64.6)	-30.8 (-37.6 to -21.3)
Other sense organ diseases	370.4 (351.1 to 390.1)	607.9 (577.7 to 637.1)	64.5 (52.0 to 76.4)	0.2 (-6.3 to 6.6)	9.9 (6.0 to 14.7)	16.1 (9.9 to 23.9)	62.6 (48.9 to 76.3)	-0.2 (-7.7 to 7.1)
Oral disorders	-							

Appendix Table G.4 - Saudi Arabia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	337.3 (311.4 to 364.0)	772.1 (683.2 to 852.1)	130.2 (97.7 to 160.2)	-4.5 (-18.4 to 7.8)	9.2 (6.1 to 12.6)	21.0 (14.0 to 29.2)	130.4 (96.8 to 161.5)	-5.0 (-18.7 to 7.7)
Other oral disorders	236.4 (222.4 to 250.5)	491.7 (462.9 to 520.7)	107.8 (93.5 to 127.9)	-0.3 (-6.6 to 8.1)	6.9 (4.3 to 10.3)	14.4 (9.0 to 21.6)	106.7 (79.0 to 127.4)	-0.5 (-7.3 to 8.1)
Injuries	-	-	-	-	68.9 (52.5 to 88.0)	83.8 (60.7 to 112.0)	21.2 (7.9 to 37.2)	44.1 (-49.9 to -37.6)
Transport injuries	-	-	-	-	37.3 (27.9 to 48.0)	39.3 (27.9 to 53.2)	4.9 (8.5 to 21.8)	-11.1 (-56.8 to -44.0)
Road injuries	-	-	-	-	34.1 (25.5 to 43.8)	35.3 (25.1 to 47.7)	2.8 (-10.6 to 20.0)	-51.7 (-57.4 to -44.5)
Pedestrian road injuries	-	-	-	-	7.2 (5.4 to 9.3)	6.2 (4.4 to 8.4)	-1.3 (-27.1 to 20.0)	-57.1 (-62.6 to -50.1)
Cyclist road injuries	-	-	-	-	2.8 (2.1 to 3.6)	3.7 (2.6 to 4.9)	29.7 (15.0 to 45.9)	-41.0 (-47.7 to -33.8)
Motorcyclist road injuries	-	-	-	-	3.4 (2.5 to 4.4)	3.1 (2.2 to 4.3)	-0.1 (-21.7 to 6.1)	-59.2 (-64.3 to -53.2)
Motor vehicle road injuries	-	-	-	-	20.4 (15.3 to 26.3)	22.2 (16.0 to 30.1)	8.1 (7.8 to 27.5)	-49.8 (-56.3 to -41.9)
Other road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-0.4 (-52.1 to -35.3)	-74.2 (-77.3 to -70.3)
Other transport injuries	-	-	-	-	3.1 (2.4 to 4.1)	4.0 (2.8 to 5.5)	26.7 (11.4 to 44.5)	-45.7 (-51.7 to -38.5)
Unintentional injuries	-	-	-	-	30.9 (23.5 to 39.5)	43.1 (31.6 to 57.5)	39.0 (26.6 to 53.0)	-36.3 (-42.1 to -30.4)
Falls	-	-	-	-	12.0 (9.0 to 15.4)	17.5 (12.5 to 23.7)	46.2 (29.2 to 64.7)	-35.7 (-43.5 to -27.6)
Drowning	-	-	-	-	0.7 (0.5 to 0.9)	0.6 (0.4 to 0.9)	-13.8 (-26.7 to 3.3)	-58.2 (-63.8 to -50.9)
Fire, heat, and hot substances	-	-	-	-	2.1 (1.6 to 2.7)	1.6 (1.2 to 2.2)	-25.4 (-36.6 to -12.6)	-63.4 (-68.3 to -57.9)
Poisonings	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-0.4 (-20.0 to 23.9)	-49.5 (-58.9 to -38.6)
Exposure to mechanical forces	-	-	-	-	9.4 (7.1 to 12.2)	14.5 (10.6 to 19.6)	54.1 (40.2 to 69.0)	-27.5 (-33.0 to -21.4)
Unintentional firearm injuries	-	-	-	-	0.5 (0.3 to 0.6)	0.6 (0.4 to 0.8)	22.6 (5.8 to 42.3)	-46.5 (-53.5 to -38.7)
Unintentional suffocation	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	120.6 (86.8 to 154.7)	4.5 (9.0 to 17.2)
Other exposure to mechanical forces	-	-	-	-	8.9 (6.7 to 11.6)	13.8 (10.1 to 18.7)	55.2 (41.3 to 70.1)	-26.7 (-32.3 to -20.6)
Adverse effects of medical treatment	-	-	-	-	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	131.6 (116.2 to 147.9)	11.0 (3.6 to 18.5)
Animal contact	-	-	-	-	0.5 (0.4 to 0.7)	0.6 (0.5 to 0.8)	18.4 (5.4 to 33.2)	-43.4 (-49.2 to -37.3)
Venomous animal contact	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	22.0 (4.9 to 43.5)	-42.9 (-50.4 to -34.0)
Non-venomous animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	15.9 (1.2 to 32.2)	-43.8 (-50.0 to -36.8)
Foreign body	-	-	-	-	0.5 (0.4 to 0.7)	0.8 (0.6 to 1.1)	53.5 (39.6 to 69.9)	-26.5 (-32.6 to -19.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-15.9 (-31.9 to 4.6)	-51.0 (-59.0 to -40.6)
Foreign body in eyes	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	83.1 (62.4 to 104.4)	-9.7 (-18.6 to -0.5)
Foreign body in other body part	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.6)	69.1 (50.6 to 89.7)	-24.2 (-31.3 to -16.3)
Other unintentional injuries	-	-	-	-	5.2 (3.9 to 6.7)	6.6 (4.8 to 8.9)	28.0 (15.2 to 41.0)	-41.1 (-46.3 to -35.6)
Self-harm and interpersonal violence	-	-	-	-	0.5 (0.4 to 0.6)	1.3 (0.9 to 1.7)	167.1 (133.0 to 208.4)	33.4 (16.9 to 52.6)
Self-harm	-	-	-	-	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.6)	452.7 (379.0 to 536.5)	126.3 (98.4 to 159.4)
Interpersonal violence	-	-	-	-	0.4 (0.3 to 0.5)	0.9 (0.6 to 1.2)	115.4 (86.5 to 151.2)	10.2 (-4.2 to 26.7)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	154.6 (123.5 to 187.4)	27.8 (14.0 to 42.6)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	194.3 (149.5 to 249.6)	44.8 (23.7 to 70.3)
Assault by other means	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	80.6 (52.3 to 112.3)	5.8 (-19.6 to 10.0)
Forces of nature, war, and legal intervention	-	-	-	-	0.2 (0.1 to 0.6)	0.2 (0.1 to 0.3)	-19.7 (-56.5 to 35.4)	-62.1 (-80.0 to -33.2)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	978.3 (659.1 to 1,518.1)	363.1 (216.4 to 607.4)
Collective violence and legal intervention	-	-	-	-	0.2 (0.1 to 0.6)	0.1 (0.0 to 0.2)	-53.8 (-72.1 to -26.3)	-77.6 (-87.5 to -61.8)

Appendix Table G.4 - Senegal prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	703.4 (513.5 to 929.6)	1,314.0 (948.8 to 1,729.3)	86.8 (82.4 to 91.3)	86.8 (-3.6 to 1.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	232.0 (161.4 to 322.7)	378.3 (265.1 to 524.5)	63.0 (57.5 to 69.6)	-13.5 (-17.3 to -9.2)
HIV/AIDS and tuberculosis	-	-	-	-	5.7 (3.9 to 7.6)	17.2 (11.6 to 24.3)	201.2 (159.5 to 264.3)	42.0 (21.8 to 75.1)
Tuberculosis	16.0 (14.9 to 17.2)	29.5 (27.4 to 31.8)	83.8 (74.1 to 94.2)	-12.3 (-16.8 to -7.7)	4.9 (3.3 to 6.6)	9.0 (6.1 to 12.2)	84.3 (71.8 to 98.7)	-12.3 (-17.6 to -6.2)
HIV/AIDS	-	-	-	-	0.8 (0.5 to 1.2)	8.2 (4.9 to 12.8)	93.3 (597.1 to 1,406.2)	421.2 (256.3 to 673.3)
HIV/AIDS resulting in mycobacterial infection	0.1 (0.1 to 0.2)	0.7 (0.4 to 1.1)	477.5 (297.4 to 740.4)	181.9 (94.5 to 313.2)	0.0 (0.0 to 0.1)	0.3 (0.1 to 0.5)	461.1 (223.3 to 872.5)	172.3 (64.0 to 364.1)
HIV/AIDS resulting in other diseases	7.2 (4.9 to 9.6)	58.8 (46.9 to 70.8)	721.7 (500.3 to 1,056.3)	335.3 (218.1 to 503.6)	0.7 (0.4 to 1.1)	7.9 (4.8 to 12.4)	963.6 (611.2 to 1,469.9)	439.0 (262.3 to 716.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	52.6 (37.5 to 69.8)	65.1 (46.6 to 87.8)	23.9 (12.8 to 34.8)	-32.2 (-38.0 to -26.0)
Diarrheal diseases	166.0 (156.0 to 174.6)	206.6 (190.6 to 223.3)	23.9 (12.8 to 37.4)	-29.3 (-35.3 to -22.1)	26.8 (18.0 to 36.6)	33.2 (22.5 to 46.8)	23.7 (12.1 to 37.9)	-29.2 (-35.8 to -22.3)
Intestinal infectious diseases	-	-	-	-	0.4 (0.3 to 0.7)	0.3 (0.2 to 0.5)	0.3 (-4.2 to -3.9)	-25.0 (-68.3 to -47.8)
Typhoid fever	2.2 (1.9 to 2.6)	1.7 (1.4 to 2.1)	-22.3 (-38.4 to 0.4)	-58.1 (-66.7 to -46.4)	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-20.9 (-40.6 to 7.7)	-56.9 (-67.0 to -42.2)
Paratyphoid fever	1.5 (1.3 to 1.8)	1.5 (1.2 to 1.9)	0.7 (-23.7 to 29.3)	-45.5 (-60.8 to -29.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.8 (-26.7 to 38.2)	44.9 (-61.7 to -27.0)
Other intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-74.8 (-87.2 to -50.9)	-86.3 (-93.0 to -73.4)
Lower respiratory infections	4.2 (3.5 to 4.8)	7.9 (6.8 to 9.3)	89.4 (52.7 to 139.0)	8.6 (4.1 to 19.2)	8.5 (3.0 to 0.6)	8.8 (0.5 to 1.2)	8.8 (47.8 to 146.2)	8.4 (-10.3 to 32.7)
Upper respiratory infections	448.7 (416.5 to 482.8)	824.9 (763.5 to 886.7)	83.0 (66.2 to 102.6)	-2.4 (-11.1 to 7.7)	5.3 (2.9 to 8.8)	9.6 (5.4 to 16.1)	83.1 (65.8 to 103.2)	-2.4 (-11.1 to 8.1)
Otitis media	166.9 (151.9 to 185.5)	285.8 (261.5 to 312.9)	70.3 (52.2 to 90.4)	-9.1 (-19.9 to 2.7)	3.5 (2.0 to 5.6)	5.9 (3.5 to 9.5)	71.1 (51.3 to 91.5)	-8.6 (-19.2 to 3.3)
Meningitis	-	-	-	-	15.3 (10.3 to 21.1)	14.0 (9.5 to 19.1)	-8.0 (-25.6 to 13.9)	-50.7 (-59.3 to -40.2)
Pneumococcal meningitis	75.2 (46.8 to 111.8)	63.9 (39.5 to 93.8)	-15.2 (-32.1 to 6.8)	-54.2 (-63.1 to -42.8)	6.8 (4.4 to 10.1)	5.8 (3.9 to 7.9)	-13.7 (-40.2 to 15.5)	-64.3 (-67.5 to -41.6)
H influenzae type B meningitis	32.4 (12.3 to 61.5)	30.3 (13.7 to 53.9)	-6.4 (-28.8 to 36.3)	-51.0 (-62.6 to -29.2)	3.3 (2.0 to 5.1)	3.9 (2.2 to 6.1)	15.5 (-17.9 to 82.0)	-38.5 (-56.0 to -4.2)
Meningococcal meningitis	19.0 (7.3 to 40.6)	15.2 (5.5 to 31.2)	-9.7 (-49.3 to 17.3)	-55.7 (-71.6 to -36.6)	2.6 (1.4 to 4.4)	2.0 (1.1 to 3.1)	-21.3 (-53.2 to 15.1)	-55.5 (-73.5 to -37.9)
Other meningitis	21.9 (12.9 to 36.4)	19.7 (10.6 to 32.1)	-9.4 (-28.7 to 10.9)	-50.3 (-59.9 to -29.6)	2.6 (1.7 to 3.6)	2.4 (1.5 to 3.4)	-5.9 (-31.5 to 16.8)	-48.0 (-61.8 to -36.0)
Encephalitis	1.4 (0.7 to 3.0)	2.5 (1.2 to 5.3)	73.5 (56.8 to 99.6)	17.9 (-15.7 to 21.1)	0.3 (0.1 to 0.2)	0.3 (0.2 to 0.5)	79.3 (53.7 to 117.9)	-6.1 (-18.3 to 10.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.1 (-97.6 to 1,434.9)	-64.5 (-97.8 to 446.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.1 (-97.8 to 448.3)	-64.5 (-97.8 to 448.3)
Whooping cough	8.0 (6.2 to 10.2)	7.9 (6.2 to 10.1)	-0.6 (-3.8 to 2.7)	-42.2 (-44.1 to -40.3)	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.6)	-0.5 (-10.7 to 11.6)	-42.2 (-48.2 to -35.0)
Tetanus	1.9 (0.9 to 3.8)	0.9 (0.5 to 2.0)	-53.8 (-83.4 to 40.7)	-75.8 (-91.5 to -24.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-20.8 (-63.6 to 72.7)	-57.7 (-80.7 to -10.4)
Measles	2.4 (1.8 to 3.0)	2.0 (1.6 to 2.5)	-14.2 (-22.0 to -6.6)	-54.2 (-55.2 to -46.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-14.0 (-34.2 to 12.3)	-50.5 (-62.1 to -35.7)
Varicella and herpes zoster	4.6 (4.2 to 5.1)	9.1 (8.4 to 10.1)	97.3 (69.1 to 126.9)	3.0 (-17.8 to 29.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	93.1 (35.1 to 179.3)	2.5 (-30.6 to 52.2)
Neglected tropical diseases and malaria	-	-	-	-	43.7 (27.8 to 67.5)	56.1 (36.0 to 83.3)	28.6 (14.8 to 44.0)	-33.2 (-42.7 to -23.0)
Malaria	984.9 (922.7 to 1,050.5)	1,286.1 (1,192.5 to 1,376.8)	30.2 (22.4 to 38.0)	-31.2 (-36.0 to -26.8)	10.6 (7.0 to 15.4)	12.1 (8.2 to 17.4)	14.0 (-1.9 to 30.6)	-37.1 (-45.2 to -29.5)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.0 (23.9 to 159.4)	-7.1 (-38.1 to 39.7)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.1 (11.3 to 167.1)	-6.1 (-35.2 to 36.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.1 (11.3 to 167.4)	-6.1 (-35.3 to 36.6)
Cutaneous and mucocutaneous leishmaniasis	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	78.1 (32.6 to 137.0)	-6.9 (-32.0 to 25.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.9 (23.0 to 160.7)	-7.1 (-38.4 to 39.8)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Schistosomiasis	1,701.8 (1,360.9 to 2,085.6)	1,873.2 (1,440.0 to 2,406.1)	8.2 (-3.7 to 31.6)	-44.2 (-50.3 to -32.2)	16.1 (8.1 to 29.2)	17.6 (8.7 to 33.0)	8.1 (6.4 to 32.7)	-44.2 (-51.4 to -32.0)
Cysticercosis	0.5 (0.1 to 1.7)	1.1 (0.3 to 3.8)	73.1 (-70.9 to 2,756.6)	-23.1 (-83.5 to 708.1)	0.1 (0.0 to 0.4)	0.3 (0.1 to 1.1)	87.5 (-68.9 to 3,243.8)	-16.8 (-83.1 to 916.7)
Cystic echinococcosis	2.0 (1.6 to 2.2)	2.2 (1.8 to 2.9)	6.2 (-19.3 to 62.8)	-40.9 (-53.3 to -17.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	9.2 (-25.9 to 74.8)	-39.2 (-55.9 to -12.0)
Lymphatic filariasis	158.1 (115.8 to 209.6)	283.3 (222.6 to 370.2)	80.3 (27.0 to 155.4)	-8.8 (-31.3 to 22.0)	4.8 (2.2 to 8.5)	9.1 (4.4 to 16.1)	89.6 (28.1 to 158.0)	-3.3 (-35.9 to 40.2)
Onchocerciasis	10.1 (7.6 to 13.5)	-	100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.5 (0.3 to 0.8)	0.5 (0.3 to 0.8)	100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Trachoma	23.2 (11.9 to 36.9)	16.6 (8.4 to 28.1)	-28.6 (-59.9 to 30.5)	-61.2 (-79.0 to -33.2)	1.3 (0.7 to 2.3)	1.0 (0.4 to 1.8)	-27.6 (-61.6 to 24.3)	-61.2 (-79.7 to -32.3)
Dengue	0.8 (0.3 to 1.7)	7.1 (2.8 to 16.0)	818.1 (808.1 to 829.6)	387.8 (382.5 to 393.9)	0.1 (0.0 to 0.3)	1.2 (0.4 to 2.8)	822.4 (602.5 to 1,137.5)	387.4 (286.2 to 532.5)
Yellow fever	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-38.5 (-11.1 to -20.4)	-67.4 (-72.9 to -40.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.5 (-51.1 to -20.4)	-67.4 (-72.9 to -60.0)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-52.2 to 83.4)	9.9 (-65.0 to 7.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-52.2 to 83.5)	-22.8 (-65.1 to 7.3)
Intestinal nematode infections	-	-	-	-	0.8 (0.5 to 1.3)	1.6 (0.9 to 2.6)	89.2 (33.2 to 140.5)	-0.4 (-28.1 to 29.1)
Ascariasis	191.9 (138.4 to 263.3)	367.1 (259.3 to 513.1)	92.0 (16.7 to 199.6)	1.7 (-43.2 to 77.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	87.8 (1.5 to 261.1)	2.7 (-51.0 to 127.4)
Trichuriasis	505.1 (343.0 to 720.6)	947.9 (646.4 to 1,332.9)	90.7 (10.8 to 204.4)	1.3 (-49.4 to 81.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	91.1 (8.0 to 223.7)	1.7 (-48.0 to 87.4)
Hookworm disease	238.6 (189.1 to 352.2)	491.6 (358.3 to 674.3)	88.7 (19.2 to 203.1)	0.8 (-42.4 to 70.0)	0.8 (0.4 to 1.2)	1.4 (0.8 to 2.3)	89.3 (29.2 to 148.7)	0.2 (-31.1 to 35.2)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Other neglected tropical diseases	171.9 (124.1 to 220.8)	301.3 (280.2 to 333.6)	74.6 (35.4 to 145.0)	-4.1 (-24.2 to 28.9)	9.0 (5.2 to 13.8)	13.1 (8.7 to 18.8)	45.8 (18.5 to 104.2)	-28.7 (-46.9 to -11.1)
Maternal disorders	-	-	-	-	1.3 (0.9 to 1.9)	2.0 (1.3 to 3.0)	48.2 (24.3 to 74.9)	-28.2 (-38.9 to -15.9)
Maternal hemorrhage	1.9 (1.5 to 2.3)	3.5 (1.8 to 5.3)	86.4 (-14.5 to 203.7)	-17.8 (-60.0 to 32.3)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	77.6 (-22.8 to 196.1)	-19.5 (-64.2 to 29.3)
Maternal sepsis and other maternal infections	2.0 (1.3 to 2.8)	2.2 (1.4 to 3.3)	5.7 (-14.2 to 21.9)	-50.9 (-59.9 to -43.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.9 (-34.5 to 64.4)	-51.5 (-67.5 to -27.3)
Maternal hypertensive disorders	2.5 (1.0 to 4.5)	4.0 (1.5 to 7.3)	60.0 (44.1 to 68.3)	-26.8 (-34.4 to -23.2)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.4)	57.4 (30.8 to 85.5)	-27.8 (-39.7 to -15.0)
Obstructed labor	2.6 (1.9 to 3.2)	3.8 (2.7 to 4.7)	43.9 (28.7 to 60.1)	-28.6 (-36.7 to -20.0)	0.9 (0.5 to 1.3)	1.2 (0.7 to 1.9)	44.2 (19.3 to 71.0)	-28.9 (-40.0 to -15.5)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.6 (1.0 to 202.5)	-24.1 (-53.7 to 26.0)	0.1 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.6 (1.0 to 202.9)	-24.1 (-53.8 to 26.5)
Other maternal disorders	-	-	-	-	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.6)	54.0 (1.0 to 145.8)	-27.0 (-52.2 to 15.9)
Neonatal disorders	-	-	-	-	4.1 (2.4 to 6.9)	20.0 (13.3 to 27.2)	389.0 (214.4 to 697.5)	179.9 (70.9 to 368.5)
Preterm birth complications	15.4 (9.8 to 23.4)	65.6 (46.3 to 90.2)	327.8 (248.1 to 426.5)	122.1 (81.2 to 172.9)	1.1 (0.7 to 1.6)	7.1 (4.8 to 9.7)	555.0 (372.5 to 883.2)	258.3 (158.0 to 437.0)
Neonatal encephalopathy due to birth asphyxia and trauma	43.5 (4.6 to 135.6)	62.0 (14.8 to 177.5)	58.0 (3.4 to 289.2)	-19.6 (-46.8 to 108.8)	1.8 (0.7 to 4.0)	6.3 (3.5 to 10.2)	259.0 (81.8 to 712.1)	102.7 (-3.3 to 432.8)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.3)	0.3 (0.1 to 0.7)	121.0 (100.3 to 155.5)	0.0 (-22.4 to 56.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	122.2 (96.2 to 160.2)	35.8 (19.9 to 59.1)
Hemolytic disease and other neonatal jaundice	2.0 (0.8 to 3.8)	12.5 (7.2 to 20.2)	536.4 (155.4 to 1,422.2)	280.2 (51.9 to 845.0)	0.8 (0.3 to 1.6)	4.8 (2.5 to 8.5)	521.4 (147.8 to 1,461.4)	267.1 (45.5 to 826.7)
Other neonatal disorders	-	-	-	-	0.4 (0.2 to 0.8)	1.7 (0.7 to 3.3)	324.7 (97.7 to 880.9)	141.3 (8.5 to 477.0)
Nutritional deficiencies	-	-	-	-	117.2 (78.0 to 165.7)	205.9 (137.6 to 290.3)	75.6 (68.8 to 83.3)	-6.3 (-8.9 to -3.3)
Protein-energy malnutrition	42.2 (28.2 to 62.0)	97.4 (54.7 to 161.8)	125.0 (11.0 to 346.7)	25.2 (-32.3 to 129.9)	2.7 (2.9 to 8.7)	2.1 (5.5 to 22.1)	17.8 (11.8 to 35.7)	26.5 (-32.7 to 137.4)
Iodine deficiency	149.4 (120.6 to 177.3)	154.6 (126.5 to 185.5)	2.6 (-18.7 to 35.6)	-48.7 (-59.8 to -30.1)	2.7 (1.6 to 4.3)	2.8 (1.7 to 4.5)	2.5 (-18.6 to 35.0)	-48.5 (-59.7 to -30.3)
Vitamin A deficiency	18.0 (12.6 to 24.9)	16.1 (10.4 to 22.2)	-10.4 (-29.8 to 8.5)	-52.6 (-61.8 to -42.8)	0.8 (0.5 to 1.3)	0.7 (0.4 to 1.2)	-11.3 (-28.5 to 8.6)	-52.3 (-60.7 to -41.7)

Appendix Table G.4 - Senegal prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	2,723.0 (2,673.5 to 2,771.5)	4,938.8 (4,878.2 to 4,994.6)	80.7 (77.3 to 84.4)	-4.1 (-5.7 to -2.5)	108.5 (73.1 to 154.5)	190.3 (127.6 to 271.1)	75.6 (71.5 to 78.8)	75.6 (76 to 3.6)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	240.9 (27.9 to 853.0)	87.3 (-25.2 to 387.2)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	7.3 (4.8 to 10.7)	12.1 (8.0 to 17.6)	63.4 (51.3 to 95.5)	-16.3 (-24.0 to -5.8)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.2 (0.6 to 2.1)	2.0 (1.1 to 3.6)	75.2 (41.9 to 114.3)	-14.8 (-28.3 to -1.1)
Syphilis	0.7 (0.6 to 0.8)	0.8 (0.7 to 0.9)	7.7 (-11.1 to 29.7)	-43.2 (-51.3 to -34.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	8.1 (-20.6 to 44.1)	43.4 (-55.9 to -25.8)
Chlamydia infection	86.5 (65.5 to 107.5)	156.1 (119.2 to 201.7)	75.7 (29.4 to 173.9)	-14.0 (-34.7 to 30.3)	0.3 (0.1 to 0.5)	0.5 (0.3 to 0.9)	92.2 (18.4 to 229.3)	-6.3 (40.5 to 51.1)
Gonococcal infection	31.1 (24.0 to 38.9)	52.6 (37.5 to 70.7)	66.2 (14.1 to 144.6)	-19.3 (-43.3 to 11.8)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.6)	65.7 (3.3 to 213.3)	-19.8 (-46.2 to 43.3)
Trichomoniasis	109.1 (75.2 to 152.9)	192.6 (105.3 to 295.0)	78.7 (-16.4 to 215.5)	-13.0 (-55.8 to 46.6)	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.8)	70.9 (-26.6 to 226.3)	-16.3 (-60.2 to 51.9)
Genital herpes	1,092.3 (1,004.6 to 1,185.7)	2,174.4 (1,988.2 to 2,353.1)	98.2 (76.5 to 124.6)	-4.9 (-12.0 to 11.5)	0.3 (0.1 to 0.7)	0.6 (0.2 to 1.4)	88.5 (74.0 to 138.9)	-1.0 (-12.6 to 11.9)
Other sexually transmitted diseases	3.1 (2.1 to 4.2)	5.2 (3.6 to 7.0)	65.9 (46.6 to 106.7)	-22.7 (-31.9 to -2.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	74.0 (19.2 to 161.8)	-18.6 (-41.5 to 17.3)
Hepatitis	-	-	-	-	1.0 (0.7 to 1.6)	1.3 (0.8 to 1.9)	25.0 (5.8 to 52.7)	-39.7 (-58.7 to -20.3)
Hepatitis A	13.4 (12.7 to 14.2)	23.2 (22.1 to 24.4)	72.3 (71.3 to 73.4)	-2.6 (-2.7 to -2.4)	0.2 (0.2 to 0.4)	0.5 (0.3 to 0.7)	86.9 (65.2 to 111.5)	1.8 (-9.8 to 13.6)
Hepatitis B	1,501.2 (1,241.5 to 1,787.5)	1,623.2 (1,410.7 to 1,857.1)	8.0 (-14.2 to 36.1)	-45.4 (-55.6 to -32.7)	0.7 (0.4 to 1.0)	0.7 (0.4 to 1.0)	-1.6 (-35.0 to 43.5)	-51.4 (-72.1 to -25.8)
Hepatitis C	497.6 (434.9 to 557.8)	738.7 (646.9 to 828.4)	47.8 (23.9 to 73.7)	-23.1 (-34.3 to -10.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	41.7 (4.8 to 89.3)	-21.1 (-45.2 to 4.4)
Hepatitis E	2.2 (1.6 to 2.9)	3.1 (2.1 to 4.2)	40.6 (-8.4 to 109.0)	-29.9 (-53.5 to 3.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	39.2 (-17.6 to 127.7)	-30.2 (-55.8 to 11.6)
Leprosy	1.1 (0.7 to 1.5)	1.4 (1.2 to 1.7)	30.7 (3.5 to 76.6)	-27.2 (-40.3 to -4.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	31.6 (1.2 to 83.1)	-27.0 (-41.8 to -2.0)
Other infectious diseases	123.3 (93.8 to 155.8)	216.7 (202.0 to 234.5)	74.9 (61.4 to 96.5)	-5.2 (-13.1 to 7.1)	5.1 (3.2 to 7.3)	8.6 (5.8 to 12.4)	69.1 (55.0 to 121.9)	-7.2 (-16.7 to 21.7)
Non-communicable diseases	-	-	-	-	451.5 (332.7 to 589.0)	895.4 (650.4 to 1,162.9)	98.1 (92.2 to 105.2)	1.6 (-1.3 to 4.9)
Neoplasms	-	-	-	-	1.8 (1.3 to 2.4)	4.2 (2.9 to 5.9)	131.7 (88.0 to 186.1)	29.1 (4.2 to 61.9)
Esophageal cancer	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	64.5 (13.3 to 138.6)	-6.5 (-34.7 to 36.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	64.0 (16.2 to 134.7)	-6.6 (-35.2 to 34.1)
Stomach cancer	0.8 (0.7 to 1.0)	1.2 (0.9 to 1.5)	40.1 (3.6 to 86.3)	-18.6 (-39.1 to 8.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	39.7 (3.9 to 88.7)	-18.7 (-40.2 to 9.4)
Liver cancer	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.2 to 0.5)	55.0 (19.9 to 112.7)	-13.4 (-36.8 to 17.5)
Liver cancer due to hepatitis B	0.7 (0.4 to 1.0)	1.1 (0.7 to 1.7)	69.3 (-10.9 to 199.1)	-5.9 (-52.4 to 62.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	68.8 (12.9 to 171.0)	-8.3 (-49.6 to 47.3)
Liver cancer due to hepatitis C	0.1 (0.0 to 0.2)	0.4 (0.2 to 0.7)	375.7 (125.2 to 1,134.2)	165.3 (29.7 to 574.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	346.3 (134.4 to 993.3)	144.3 (33.8 to 480.5)
Liver cancer due to alcohol use	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.4)	-21.5 (-61.9 to 53.8)	-56.5 (-79.0 to -34.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-20.4 (-59.7 to 46.6)	-55.2 (-76.8 to -18.4)
Liver cancer due to other causes	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	27.9 (-36.0 to 120.8)	-35.1 (-65.0 to 22.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	16.3 (-35.3 to 88.1)	21.6 (-64.5 to 7.9)
Larynx cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	-8.7 (-37.3 to 109.3)	-46.2 (-62.5 to 19.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.9 (-37.2 to 106.9)	-45.3 (-62.9 to 20.4)
Tracheal, bronchus and lung cancer	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	46.4 (11.9 to 90.9)	-14.9 (-33.4 to 11.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	48.1 (12.5 to 97.3)	-13.8 (-34.1 to 15.3)
Breast cancer	2.4 (1.9 to 2.9)	7.9 (5.9 to 10.6)	233.6 (139.0 to 354.2)	73.0 (23.6 to 133.4)	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.9)	199.4 (112.2 to 314.1)	56.7 (11.5 to 116.7)
Cervical cancer	4.2 (3.1 to 5.6)	7.2 (4.6 to 10.5)	71.1 (6.9 to 169.8)	-1.8 (-37.3 to 52.0)	0.3 (0.2 to 0.5)	0.6 (0.3 to 0.9)	46.3 (9.6 to 169.6)	36.4 (-36.2 to 52.4)
Uterine cancer	0.8 (0.5 to 1.3)	2.1 (1.2 to 3.3)	155.9 (38.5 to 335.1)	44.5 (-19.1 to 144.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	152.0 (38.3 to 333.8)	41.6 (-21.3 to 139.5)
Prostate cancer	1.5 (0.9 to 2.5)	7.5 (4.9 to 12.7)	430.8 (161.5 to 834.6)	193.4 (43.1 to 414.3)	0.2 (0.1 to 0.3)	0.7 (0.4 to 1.2)	350.9 (131.3 to 702.5)	146.9 (27.3 to 338.8)
Colon and rectum cancer	0.8 (0.7 to 0.9)	2.3 (1.8 to 2.8)	181.7 (124.7 to 259.1)	47.9 (19.9 to 86.9)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	165.0 (110.7 to 240.8)	39.4 (10.7 to 81.2)
Lip and oral cavity cancer	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	90.6 (32.6 to 168.6)	5.8 (-27.8 to 50.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	90.2 (32.9 to 166.7)	5.3 (-25.1 to 51.6)
Nasopharynx cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	71.6 (9.0 to 161.7)	-12.1 (-42.9 to 32.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.6 (10.1 to 141.5)	-14.7 (-42.8 to 22.1)
Other pharynx cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	59.5 (0.8 to 158.6)	-12.5 (-46.0 to 43.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.8 (6.0 to 144.6)	-12.0 (-41.7 to 36.5)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	84.9 (24.7 to 167.2)	-4.1 (-35.4 to 42.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.5 (25.5 to 151.9)	-5.7 (-33.9 to 34.3)
Pancreatic cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	162.2 (89.2 to 258.0)	44.2 (5.8 to 96.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	161.0 (103.2 to 238.2)	42.6 (7.3 to 91.5)
Malignant skin melanoma	0.3 (0.2 to 0.4)	0.7 (0.5 to 1.0)	138.1 (69.8 to 230.2)	23.1 (-10.7 to 74.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	156.7 (60.7 to 230.8)	18.6 (-15.1 to 71.8)
Non-melanoma skin cancer	0.4 (0.3 to 0.6)	1.0 (0.7 to 1.4)	132.0 (43.3 to 279.1)	19.5 (-27.8 to 81.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	204.6 (103.4 to 334.8)	54.1 (-7.6 to 135.0)
Ovarian cancer	0.3 (0.2 to 0.4)	0.7 (0.5 to 0.9)	144.1 (61.2 to 266.9)	36.3 (-10.7 to 113.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	144.4 (55.4 to 285.9)	35.4 (-17.7 to 122.6)
Testicular cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.4)	171.3 (43.7 to 406.5)	28.7 (-28.3 to 131.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	157.7 (26.0 to 402.9)	22.8 (-35.7 to 118.9)
Kidney cancer	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	69.7 (6.9 to 168.7)	4.2 (-24.5 to 48.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	74.9 (9.1 to 179.2)	3.2 (-26.5 to 45.5)
Bladder cancer	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.9)	62.8 (17.2 to 137.7)	-13.0 (-38.5 to 26.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	61.3 (15.9 to 134.6)	-13.6 (-39.0 to 27.7)
Brain and nervous system cancer	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.8)	224.8 (98.1 to 365.3)	68.4 (18.0 to 126.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	225.5 (113.8 to 353.8)	59.5 (14.9 to 112.1)
Thyroid cancer	0.3 (0.2 to 0.4)	0.6 (0.4 to 1.0)	102.2 (20.8 to 249.8)	8.1 (-37.0 to 94.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	97.8 (20.0 to 252.9)	4.2 (-36.4 to 91.2)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.1 (35.5 to 181.1)	2.9 (-30.2 to 56.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	91.6 (33.9 to 180.5)	1.1 (-2.3 to 54.0)
Hodgkin lymphoma	0.3 (0.2 to 0.4)	0.8 (0.5 to 1.3)	153.5 (55.3 to 354.6)	52.7 (1.5 to 137.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	150.7 (57.3 to 315.8)	47.4 (-1.4 to 125.8)
Non-Hodgkin lymphoma	0.9 (0.7 to 1.2)	2.2 (1.6 to 3.0)	145.7 (71.9 to 237.2)	41.4 (2.8 to 98.5)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	144.9 (74.7 to 240.4)	36.1 (0.9 to 94.7)
Multiple myeloma	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	151.9 (58.4 to 300.4)	35.7 (-16.8 to 123.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	140.3 (48.2 to 276.9)	29.1 (-24.4 to 116.4)
Leukemia	0.3 (0.2 to 0.3)	0.7 (0.5 to 1.0)	186.2 (73.2 to 361.0)	36.5 (-2.4 to 97.8)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	156.7 (77.1 to 263.3)	18.6 (-15.8 to 65.3)
Other neoplasms	2.5 (1.8 to 3.9)	7.0 (4.4 to 9.7)	203.7 (36.7 to 359.8)	50.0 (5.2 to 130.0)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	185.5 (47.8 to 316.3)	38.4 (8.8 to 111.7)
Cardiovascular diseases	-	-	-	-	12.8 (8.6 to 17.9)	23.8 (15.4 to 34.7)	85.2 (39.2 to 147.2)	-1.3 (-24.2 to 24.0)
Rheumatic heart disease	83.6 (61.1 to 107.3)	141.8 (106.6 to 198.8)	58.9 (19.2 to 191.5)	-16.5 (-36.0 to 30.8)	4.2 (2.4 to 6.5)	7.2 (4.1 to 11.8)	63.0 (22.8 to 186.8)	-12.4 (-34.2 to 33.8)
Ischemic heart disease	59.5 (47.8 to 74.3)	75.7 (65.0 to 92.4)	26.9 (-3.4 to 71.6)	-25.5 (-41.7 to -2.5)	3.1 (2.0 to 4.8)	3.5 (2.2 to 5.2)	11.3 (51.0 to -3.4)	-33.0 (-51.0 to -3.4)
Cerebrovascular disease	-	-	-	-	0.6 (0.4 to 0.8)	1.1 (0.7 to 1.5)	83.9 (48.1 to 131.4)	-0.8 (-21.9 to 30.1)
Ischemic stroke	2.9 (2.5 to 3.3)	5.3 (4.5 to 6.3)	85.2 (47.6 to 134.0)	0.4 (-21.3 to 31.7)	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.1)	83.8 (46.4 to 137.5)	0.2 (-21.7 to 32.3)
Hemorrhagic stroke	0.8 (0.7 to 1.0)	1.5 (1.2 to 1.8)	82.4 (36.5 to 129.0)	-3.8 (-28.1 to 24.2)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	83.1 (36.4 to 132.7)	-3.9 (-29.4 to 26.8)
Hypertensive heart disease	9.2 (6.3 to 12.5)	18.3 (14.6 to 22.4)	99.3 (38.7 to 197.2)	1.2 (-29.0 to 49.7)	1.0 (0.6 to 1.5)	2.0 (1.3 to 2.8)	98.4 (39.1 to 197.8)	1.1 (-29.1 to 50.9)
Cardiomyopathy and myocarditis	1.0 (5.1 to 9.4)	5.0 (11.6 to 15.5)	425.4 (38.1 to 181.9)	142.9 (-28.2 to 64.1)	0.1 (0.5 to 1.1)	0.4 (1.0 to 2.2)	424.4 (40.1 to 182.6)	144.7 (-28.0 to 64.1)
Atrial fibrillation and flutter	106.5 (71.1 to 137.7)	160.3 (107.9 to 212.1)	46.2 (-11.6 to 179.9)	-21.1 (-50.3 to 35.0)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	24.6 (-36.1 to 257.1)	-33.1 (-63.0 to 53.8)
Endocarditis	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.8)	16.1 (-19.8 to 66.9)	-34.4 (-62.4 to 15.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	22.2 (-26.9 to 91.2)	-32.8 (-67.2 to 26.4)
Other cardiovascular and circulatory diseases	42.4 (23.4 to 70.8)	114.7 (41.5 to 180.9)	176.7 (-3.5 to 501.1)	37.6 (-52.1 to 198.1)	3.0 (1.5 to 5.1)	8.0 (2.6 to 13.7)	35.7 (4.4 to 49.3)	35.7 (-52.8 to 203.7)
Chronic respiratory diseases	-	-	-	-	28.9 (19.1 to 41.3)	56.5 (38.1 to 78.8)	93.8 (74.9 to 132.7)	-3.4 (-12.2 to 16.4)
Chronic obstructive pulmonary disease	231.2 (217.7 to 244.3)	436.7 (413.3 to 460.9)	88.3 (81.3 to 95.4)	-1.5 (-5.2 to 2.1)	19.1 (12.4 to 27.5)	35.9 (23.1 to 51.6)	85.6 (68.6	

Appendix Table G.4 - Senegal prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumonia	-	-	-	-	0.0	0.0	74.6	4.1
Silicosis	0.0	0.1	63.3	-13.3	0.0	0.0	(68.6 to 81.4)	(-11.5 to -5.1)
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	60.7	-14.0
Coal workers pneumoconiosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Other pneumoconiosis	0.0	0.1	90.3	-0.6	0.0	0.0	87.7	-1.5
Asthma	107.8	303.2	181.1	26.8	4.7	13.3	183.0	27.2
Interstitial lung disease and pulmonary sarcoidosis	0.2	0.3	105.3	4.1	0.0	0.0	104.2	3.7
Other chronic respiratory diseases	-	-	-	-	5.0	7.4	45.4	-24.2
Cirrhosis	-	-	-	-	0.2	0.8	47.8	20.1
Cirrhosis due to hepatitis B	1.6	1.7	7.2	-38.9	0.3	0.3	(28.5 to 70.0)	(-29.0 to -10.3)
Cirrhosis due to hepatitis C	0.3	0.9	198.3	57.4	0.1	0.2	194.6	57.2
Cirrhosis due to alcohol use	0.7	0.8	11.7	-37.3	0.1	0.1	11.5	-37.6
Cirrhosis due to other causes	0.8	1.1	97.6	19.4	0.1	0.3	95.6	19.2
Digestive diseases	0.1	0.2	79.0	-1.8	0.0	0.1	32.0	15.7
Peptic ulcer disease	37.8	55.2	46.0	-19.4	1.4	2.1	52.6	-18.6
Gastritis and duodenitis	83.7	160.7	91.7	4.7	3.7	6.6	79.4	0.4
Appendicitis	0.8	1.9	123.1	7.2	0.3	0.6	124.2	7.7
Paralytic ileus and intestinal obstruction	0.1	0.2	79.0	-1.8	0.0	0.1	77.7	-1.9
Inguinal, femoral, and abdominal hernia	29.7	46.2	54.2	-18.0	0.3	0.5	54.4	-17.9
Inflammatory bowel disease	6.6	16.3	147.5	26.0	1.4	3.5	146.7	25.5
Vascular intestinal disorders	0.0	0.0	0.0	9.4	0.0	0.0	180.4	12.1
Gallbladder and biliary diseases	2.1	4.4	109.7	0.2	0.5	0.5	110.6	1.9
Pancreatitis	1.1	2.4	115.7	8.0	0.3	0.7	115.8	8.4
Other digestive diseases	-	-	-	-	1.3	1.9	53.7	-20.0
Neurological disorders	-	-	-	-	30.6	65.1	112.4	5.5
Alzheimer disease and other dementias	8.9	19.4	104.8	0.8	1.2	2.5	109.5	0.5
Parkinson disease	0.4	0.8	86.0	0.2	0.1	0.1	85.7	0.2
Epilepsy	14.0	27.2	95.7	3.3	4.1	8.3	108.0	10.3
Multiple sclerosis	0.4	0.9	130.0	15.2	0.1	0.3	126.6	13.4
Migraine	505.3	988.2	95.2	0.3	37.2	73.7	96.4	-0.2
Tension-type headache	877.7	1,811.3	105.2	2.7	10.3	20.0	115.5	12.3
Medication overuse headache	32.3	96.3	200.4	48.5	5.1	15.1	201.9	49.4
Other neurological disorders	0.0	0.0	78.8	-9.1	1.5	2.3	59.0	-23.5
Mental and substance use disorders	-	-	-	-	145.4	297.5	104.3	3.8
Schizophrenia	14.3	29.1	103.3	-0.0	9.1	18.6	103.9	-0.1
Alcohol use disorders	34.4	77.6	124.8	11.3	3.3	7.5	127.6	12.0
Drug use disorders	-	-	-	-	8.6	17.6	104.9	-1.9
Opioid use disorders	11.0	23.2	108.2	-1.4	4.6	9.5	108.7	-1.5
Cocaine use disorders	2.7	6.2	129.3	18.2	0.7	1.0	118.7	2.8
Amphetamine use disorders	11.3	22.0	94.0	-4.8	1.5	2.9	93.7	-5.0
Cannabis use disorders	5.1	10.3	101.2	-0.3	0.1	0.3	100.7	-0.6
Other drug use disorders	-	-	-	-	1.9	3.9	98.3	-3.0
Depressive disorders	-	-	-	-	62.8	134.4	112.8	7.0
Major depressive disorder	273.4	590.4	113.7	7.7	56.2	121.2	114.0	7.8
Dysthymia	68.1	138.1	101.9	6.6	6.6	13.3	102.1	1.0
Bipolar disorder	38.5	80.0	106.5	0.7	7.8	16.3	107.1	0.7
Anxiety disorders	170.1	331.3	94.7	0.5	15.7	30.5	94.0	0.5
Eating disorders	-	-	-	-	1.8	3.7	105.1	1.2
Anorexia nervosa	1.3	2.6	108.9	5.4	0.3	0.6	109.8	6.0
Bulimia nervosa	7.2	14.8	104.7	0.5	1.5	3.1	104.5	0.4
Autistic spectrum disorders	-	-	-	-	9.0	16.9	86.6	-1.1
Autism	22.9	43.3	88.4	-1.1	5.7	10.7	88.8	-1.0
Asperger syndrome	33.0	62.1	87.7	-1.4	3.3	6.2	87.9	-1.3
Attention-deficit/hyperactivity disorder	57.1	104.1	81.7	0.1	0.7	1.3	82.0	0.2
Conduct disorder	84.2	152.0	80.0	0.1	10.1	18.2	80.3	0.3
Idiopathic intellectual disability	205.9	397.5	91.7	5.1	10.1	19.4	91.8	5.1
Other mental and substance use disorders	85.9	176.0	104.0	-1.0	6.4	13.1	104.5	-1.0
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	49.5	108.9	119.8	20.8
Diabetes mellitus	130.5	473.5	260.1	86.6	9.5	33.4	251.1	82.8
Acute glomerulonephritis	0.1	0.1	19.0	-33.5	0.0	0.0	19.0	-33.5
Chronic kidney disease	-	-	-	-	12.0	22.6	88.9	-1.0
Chronic kidney disease due to diabetes mellitus	59.9	128.6	114.6	15.9	1.0	2.2	115.6	15.5
Chronic kidney disease due to hypertension	328.2	614.5	85.6	4.0	1.9	7.6	87.9	-6.1
Chronic kidney disease due to glomerulonephritis	281.5	539.0	90.7	1.1	4.3	8.0	96.1	2.8
Chronic kidney disease due to other causes	213.5	404.0	87.2	-5.7	2.7	4.9	83.1	-9.8
Urinary diseases and male infertility	-	-	-	-	2.4	4.2	77.2	4.5

Appendix Table G.4 - Senegal prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.4 (1.3 to 1.5)	3.0 (2.8 to 3.2)	111.4 (93.4 to 132.4)	0.0 (-0.1 to 17.7)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	112.3 (65.5 to 167.2)	8.2 (-10.6 to 28.5)
Urolithiasis	15.3 (11.7 to 19.6)	25.0 (19.4 to 32.5)	63.3 (40.0 to 84.6)	-11.2 (-22.9 to -2.6)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	100.6 (76.3 to 131.9)	4.7 (-5.7 to 16.8)
Benign prostatic hyperplasia	44.5 (40.3 to 49.2)	76.7 (69.7 to 83.5)	72.2 (48.9 to 96.0)	-3.1 (-15.4 to 8.7)	1.6 (1.0 to 2.3)	2.7 (1.8 to 3.9)	70.9 (48.0 to 95.1)	-3.4 (-15.8 to 8.4)
Male infertility due to other causes	92.1 (73.3 to 112.2)	170.0 (139.2 to 202.2)	84.5 (36.5 to 147.4)	-16.3 (-37.9 to 13.4)	0.6 (0.2 to 1.2)	1.1 (0.4 to 2.3)	85.6 (38.9 to 148.4)	-15.6 (-36.9 to 12.5)
Other urinary diseases	-	-	-	-	0.0	0.0	0.0	-
Gynecological diseases	-	-	-	-	8.7 (5.7 to 13.1)	19.1 (12.6 to 28.3)	118.7 (96.7 to 148.6)	4.5 (-4.9 to 17.0)
Uterine fibroids	103.9 (94.1 to 113.1)	223.9 (201.9 to 244.3)	114.7 (113.6 to 115.7)	5.5 (5.3 to 5.8)	2.5 (1.6 to 3.7)	5.1 (3.2 to 7.7)	107.5 (86.4 to 118.8)	0.7 (-10.1 to 6.0)
Polycystic ovarian syndrome	97.0 (86.5 to 109.6)	223.5 (200.4 to 247.2)	130.2 (93.3 to 168.7)	8.1 (-7.3 to 24.5)	0.9 (0.4 to 1.8)	2.2 (1.0 to 4.2)	130.0 (93.2 to 170.1)	7.6 (-7.8 to 25.2)
Female infertility due to other causes	84.4 (65.3 to 103.2)	150.0 (117.1 to 194.3)	75.2 (25.1 to 150.4)	0.4 (-4.2 to 19.3)	0.8 (0.2 to 0.9)	0.8 (0.3 to 1.6)	74.2 (24.1 to 149.4)	-1.8 (-42.6 to 18.1)
Endometriosis	9.7 (8.0 to 11.2)	20.0 (17.0 to 23.2)	105.4 (65.8 to 162.7)	-3.7 (-21.9 to 20.8)	0.9 (0.6 to 1.2)	1.8 (1.2 to 2.6)	105.6 (61.3 to 165.2)	-3.6 (-23.1 to 22.1)
Genital prolapse	239.1 (208.2 to 272.5)	492.6 (425.8 to 554.3)	105.1 (68.1 to 151.2)	4.5 (-10.6 to 23.8)	0.8 (0.4 to 1.4)	1.6 (0.7 to 3.0)	106.0 (68.7 to 153.0)	4.6 (-10.8 to 25.0)
Premenstrual syndrome	237.4 (167.1 to 308.4)	625.3 (461.9 to 789.4)	159.2 (82.0 to 321.2)	24.1 (-14.8 to 111.2)	2.0 (1.1 to 3.2)	5.2 (3.0 to 8.0)	160.0 (80.1 to 320.0)	23.9 (-15.5 to 111.4)
Other gynecological diseases	33.8 (28.3 to 39.6)	69.5 (54.6 to 84.0)	105.5 (49.9 to 162.2)	0.6 (-25.9 to 28.2)	1.3 (0.7 to 1.9)	2.5 (1.6 to 3.7)	100.8 (41.0 to 165.7)	-2.1 (-29.8 to 30.5)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	11.7 (7.9 to 16.6)	20.7 (14.0 to 29.4)	75.9 (65.6 to 95.2)	-4.8 (-11.7 to 6.8)
Thalassemias	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	74.8 (61.0 to 91.1)	-3.6 (-11.2 to 5.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.7 (52.2 to 88.0)	-4.8 (-14.7 to 4.1)
Thalassemia trait	72.0 (64.7 to 78.5)	135.9 (125.1 to 146.9)	88.2 (80.5 to 97.5)	-0.2 (-4.3 to 4.7)	1.4 (0.9 to 2.0)	2.5 (1.7 to 3.6)	77.6 (54.6 to 105.5)	-2.8 (-14.9 to 13.9)
Sickle cell disorders	12.9 (11.3 to 14.3)	25.9 (22.9 to 28.3)	100.1 (75.2 to 133.0)	10.6 (-3.7 to 29.1)	1.4 (0.9 to 1.9)	2.7 (1.9 to 3.7)	102.9 (72.5 to 142.1)	10.6 (-5.0 to 29.9)
Sickle cell trait	995.0 (925.0 to 1,057.5)	1,847.9 (1,723.5 to 1,952.4)	84.8 (77.4 to 93.8)	-2.1 (-6.1 to 2.6)	4.7 (3.1 to 6.8)	8.3 (5.6 to 12.0)	75.4 (49.6 to 103.5)	4.0 (-14.1 to 12.7)
G6PD deficiency	870.3 (767.2 to 962.2)	1,761.8 (1,626.9 to 1,904.1)	101.9 (78.4 to 128.5)	7.0 (-5.4 to 21.1)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	87.7 (39.3 to 158.8)	0.9 (-18.5 to 26.2)
G6PD trait	1,759.2 (1,720.2 to 1,787.7)	3,404.2 (3,346.2 to 3,457.2)	93.0 (88.2 to 98.0)	3.5 (1.0 to 6.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	84.6 (-35.1 to 384.9)	-0.3 (-66.3 to 150.5)
Other hemoglobinopathies and hemolytic anemias	118.3 (104.8 to 131.8)	206.8 (189.5 to 225.3)	74.5 (53.9 to 100.8)	-8.1 (-20.8 to 6.3)	4.0 (2.6 to 5.8)	6.8 (4.5 to 9.8)	66.8 (47.1 to 108.8)	-10.8 (-25.5 to 8.9)
Endocrine, metabolic, blood, and immune disorders	134.3 (122.9 to 144.7)	286.8 (193.7 to 271.6)	75.9 (37.2 to 110.3)	-5.6 (-20.2 to 8.2)	5.2 (3.3 to 7.5)	9.0 (5.7 to 12.7)	72.2 (32.3 to 111.4)	-7.0 (-23.5 to 10.5)
Musculoskeletal disorders	-	-	-	-	76.5 (53.5 to 101.5)	146.4 (104.0 to 194.8)	90.1 (76.5 to 111.5)	-2.8 (-9.2 to 5.4)
Rheumatoid arthritis	9.4 (8.9 to 9.8)	12.8 (12.1 to 13.4)	36.6 (26.6 to 45.6)	-33.2 (-37.8 to -28.7)	2.2 (1.6 to 2.9)	3.0 (2.1 to 4.0)	37.5 (22.4 to 53.3)	-32.8 (-38.7 to -26.5)
Osteoarthritis	134.0 (128.7 to 139.4)	253.9 (244.2 to 264.0)	88.6 (78.8 to 99.7)	2.6 (-2.5 to 7.9)	6.7 (5.2 to 8.2)	15.5 (10.8 to 20.9)	88.5 (78.3 to 99.6)	2.7 (-2.7 to 8.1)
Low back and neck pain	-	-	-	-	53.5 (37.1 to 72.3)	106.3 (74.4 to 143.6)	97.4 (77.6 to 129.1)	-0.6 (-10.7 to 13.0)
Low back pain	285.8 (266.7 to 306.9)	552.4 (518.6 to 584.7)	92.4 (75.6 to 111.5)	-1.7 (-9.5 to 8.1)	31.9 (21.7 to 44.1)	61.5 (41.7 to 85.2)	92.6 (76.0 to 112.3)	-1.6 (-9.5 to 8.0)
Neck pain	220.2 (174.0 to 261.6)	456.5 (390.8 to 530.6)	103.2 (61.3 to 182.7)	1.0 (-21.1 to 34.8)	21.6 (13.9 to 31.5)	44.8 (29.6 to 63.6)	103.9 (60.0 to 184.1)	0.9 (-20.6 to 34.6)
Gout	0.6 (0.5 to 0.7)	1.1 (0.9 to 1.2)	82.2 (54.3 to 112.4)	-3.0 (-17.5 to 12.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	81.5 (43.6 to 131.6)	-3.7 (-24.3 to 24.2)
Other musculoskeletal disorders	138.8 (105.4 to 170.4)	238.2 (179.8 to 297.7)	70.5 (58.5 to 84.1)	-9.9 (-17.0 to -3.6)	12.6 (8.1 to 18.4)	21.5 (13.7 to 31.7)	91.9 (58.2 to 86.0)	-9.8 (-17.2 to -3.3)
Other non-communicable diseases	-	-	-	-	96.5 (62.8 to 141.5)	175.6 (117.0 to 257.1)	82.0 (72.3 to 92.1)	-5.8 (-9.3 to -1.5)
Congenital anomalies	-	-	-	-	5.0 (3.2 to 7.4)	12.7 (8.9 to 17.3)	158.6 (110.8 to 217.6)	42.7 (13.8 to 76.3)
Neural tube defects	0.7 (0.6 to 0.9)	4.2 (3.7 to 4.9)	468.8 (366.8 to 605.5)	245.0 (180.0 to 332.9)	0.2 (0.1 to 0.2)	1.2 (0.8 to 1.6)	586.0 (409.0 to 814.1)	330.5 (220.3 to 467.7)
Congenital heart anomalies	6.6 (4.4 to 8.7)	43.8 (36.6 to 51.0)	561.5 (364.6 to 902.2)	299.1 (174.2 to 522.8)	0.3 (0.1 to 0.4)	1.5 (0.6 to 2.2)	480.3 (292.9 to 758.1)	249.3 (137.3 to 422.0)
Orofacial clefts	0.7 (0.3 to 1.1)	6.7 (5.3 to 8.4)	865.2 (432.9 to 1,978.5)	548.5 (248.1 to 1,387.8)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	772.7 (359.1 to 1,789.7)	479.7 (204.1 to 1,245.5)
Down syndrome	3.8 (3.0 to 4.7)	12.0 (9.7 to 15.7)	214.3 (138.9 to 328.0)	82.1 (38.1 to 150.3)	0.4 (0.3 to 0.6)	1.4 (1.0 to 2.0)	218.2 (133.4 to 345.7)	88.8 (37.4 to 162.6)
Turner syndrome	0.2 (0.1 to 0.2)	0.5 (0.4 to 0.7)	167.8 (92.7 to 327.8)	48.0 (5.4 to 134.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	171.8 (93.7 to 341.6)	47.2 (3.8 to 137.8)
Klinefelter syndrome	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	82.9 (39.1 to 150.4)	-3.9 (-26.9 to 21.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.2 (48.6 to 146.2)	-3.7 (-26.9 to 21.4)
Chromosomal unbalanced rearrangements	6.1 (5.0 to 7.8)	19.2 (16.8 to 21.9)	214.7 (142.8 to 294.9)	82.9 (40.8 to 131.3)	0.7 (0.5 to 1.0)	2.2 (1.6 to 3.0)	217.6 (139.7 to 307.0)	88.8 (42.1 to 145.9)
Other congenital anomalies	34.6 (24.9 to 45.9)	59.6 (43.9 to 78.6)	72.2 (40.0 to 105.4)	-8.1 (-25.8 to 10.5)	3.4 (1.9 to 5.6)	6.3 (3.6 to 10.1)	87.4 (41.7 to 150.9)	1.2 (-25.4 to 36.0)
Skin and subcutaneous diseases	-	-	-	-	33.7 (20.7 to 55.0)	64.8 (40.1 to 105.2)	92.4 (71.1 to 110.4)	0.9 (-7.8 to 8.5)
Dermatitis	311.0 (245.8 to 388.0)	611.0 (476.6 to 767.4)	95.6 (92.9 to 98.6)	0.2 (0.0 to 0.4)	9.0 (5.6 to 13.1)	17.5 (10.8 to 25.3)	93.2 (86.2 to 99.9)	0.3 (-2.3 to 2.9)
Psoriasis	47.8 (38.0 to 57.2)	93.9 (73.9 to 113.4)	95.6 (92.7 to 98.3)	-4.1 (-0.3 to 0.1)	3.9 (2.5 to 5.7)	7.7 (5.0 to 11.1)	97.7 (84.1 to 111.2)	0.0 (-5.1 to 5.6)
Cellulitis	1.4 (1.1 to 1.7)	2.6 (2.0 to 3.2)	88.6 (60.9 to 121.0)	-2.2 (-14.0 to 15.4)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	87.5 (40.2 to 154.9)	-1.7 (-21.7 to 26.9)
Pyoderma	13.1 (9.6 to 16.9)	22.1 (16.6 to 28.3)	68.6 (58.2 to 82.3)	-4.4 (-10.7 to 2.7)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	68.8 (52.6 to 86.9)	-4.1 (-13.1 to 4.9)
Scabies	83.6 (73.3 to 95.9)	120.2 (104.2 to 141.3)	43.2 (18.8 to 75.0)	-22.3 (-36.0 to -5.6)	2.2 (1.2 to 3.5)	3.1 (1.7 to 5.2)	42.9 (18.5 to 75.1)	-22.4 (-36.3 to 5.0)
Fungal skin diseases	888.3 (638.8 to 1,242.0)	1,702.8 (1,229.5 to 2,386.8)	90.5 (86.6 to 96.5)	9.3 (-0.4 to 0.1)	5.0 (3.9 to 6.1)	9.6 (7.3 to 12.6)	90.8 (86.3 to 96.7)	-0.2 (-0.9 to 0.5)
Viral skin diseases	113.4 (88.6 to 139.6)	209.7 (161.8 to 262.9)	84.4 (71.0 to 95.1)	-0.6 (-5.8 to 3.8)	3.5 (2.1 to 5.5)	6.5 (3.8 to 10.3)	84.6 (69.1 to 97.8)	-0.6 (-7.1 to 5.2)
Acne vulgaris	529.6 (364.4 to 722.5)	1,023.1 (686.0 to 1,513.0)	98.3 (1.5 to 214.0)	6.4 (-42.1 to 63.2)	5.7 (2.5 to 11.4)	11.1 (4.7 to 23.7)	98.4 (1.4 to 213.9)	6.3 (-42.5 to 63.5)
Alopecia areata	6.4 (5.8 to 7.1)	12.6 (11.3 to 14.0)	94.5 (68.2 to 124.7)	0.1 (-13.6 to 15.1)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	95.1 (61.5 to 140.1)	0.1 (-16.6 to 19.6)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.0 (47.8 to 142.4)	3.4 (-25.9 to 23.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.0 (47.8 to 142.8)	-0.0 (-25.9 to 24.3)
Urticaria	27.6 (16.4 to 41.7)	73.0 (52.9 to 97.6)	157.6 (56.7 to 420.7)	22.1 (-25.8 to 112.7)	1.6 (0.8 to 2.8)	4.3 (2.5 to 6.6)	157.2 (55.8 to 433.8)	20.0 (-26.1 to 115.8)
Decubitus ulcer	0.5 (0.5 to 0.6)	1.2 (1.0 to 1.4)	120.4 (79.7 to 192.0)	10.8 (-14.1 to 63.4)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	120.2 (72.9 to 195.6)	11.2 (-17.4 to 72.4)
Other skin and subcutaneous diseases	389.7 (265.0 to 559.5)	724.2 (485.8 to 1,040.2)	85.0 (76.8 to 94.2)	-2.6 (-6.0 to 0.6)	2.3 (1.0 to 4.7)	4.3 (1.9 to 8.6)	85.3 (76.5 to 95.1)	-2.7 (-6.1 to 0.7)
Sense organ diseases	-	-	-	-	49.3 (32.3 to 71.6)	81.6 (53.8 to 120.0)	66.2 (54.7 to 76.8)	-11.2 (-15.4 to -7.5)
Glaucoma	10.0 (7.3 to 13.0)	18.2 (13.8 to 23.1)	82.3 (29.9 to 132.3)	2.4 (-25.2 to 26.4)	0.7 (0.4 to 1.0)	1.3 (0.8 to 2.0)	96.1 (46.1 to 149.9)	6.3 (-21.3 to 38.6)
Cataract	41.4 (29.6 to 56.1)	61.7 (42.3 to 82.4)	48.7 (9.3 to 100.9)	-16.9 (-36.7 to 10.4)	3.5 (2.2 to 5.4)	5.1 (3.1 to 7.7)	44.3 (8.5 to 87.0)	-20.3 (-35.4 to -0.5)
Macular degeneration	8.5 (5.5 to 13.0)	27.1 (19.1 to 36.2)	224.2 (102.7 to 376.5)	90.5 (20.9 to 179.5)	0.5 (0.3 to 0.8)	1.5 (0.9 to 2.2)	215.2 (103.6 to 345.7)	79.3 (20.9 to 145.9)
Uncorrected refractive error	60.3 (55.5 to 65.0)	1,093.4 (1,011.9 to 1,177.4)	80.8 (63.8 to 98.5)	-3.3 (-11.0 to 4.9)	12.6 (8.2 to 19.3)	20.8 (13.2 to 31.9)	64.7 (52.8 to 77.2)	-32.7 (-17.8 to -6.7)
Age-related and other hearing loss	887.9 (746.6 to 1,003.9)	1,550.6 (1,318.8 to 1,754.3)	74.3 (64.0 to 84.4)	-4.4 (-10.5 to -2.7)	25.0 (14.8 to 38.7)	41.0 (24.6 to 64.2)	61.2 (42.3 to 86.5)	-6.7 (-19.9 to -4.8)
Other vision loss	26.0 (20.6 to 33.3)	36.0 (28.4 to 45.3)	38.3 (17.9 to 61.5)	-22.4 (-32.1 to -8.9)	2.2 (1.4 to 3.4)	3.3 (2.1 to 4.8)	49.2 (24.4 to 75.6)	3.3 (-30.4 to 0.3)
Other sense organ diseases	179.6 (170.4 to 189.2)	331.9 (313.4 to 351.1)	83.8 (71.0 to 99.5)	-0.3 (-6.0 to 6.5)	4.8 (2.9 to 7.1)	8.8 (5.4 to 13.1)	84.3 (69.8 to 101.9)	-0.1 (-6.7 to 7.7)
Oral disorders	-	-	-	-	8.5 (4.6 to 14.1)	16.2 (8.8 to 27.1)	89.5 (77.9 to 103.9)	-2.1 (-9.3 to 5.6)
Deciduous caries	763.5 (724.4 to 803.3)	1,340.6 (1,274.2 to 1,408.7)	74.6 (63.9 to 88.7)	-0.3 (-6.5 to 7.6)	0.3 (0.1 to 0.6)	0.5 (0.2 to 1.0)	74.4 (58.9 to 92.8)	-0.4 (-9.4 to 10.0)
Permanent caries	1,902.4 (1,699.7 to 2,113.3)	3,649.1 (3,217.3 to 4,059.5)	92.1 (65.1 to 121.7)	-1.5 (-15.9 to 14.6)	1.9 (0.9 to 3.6)	3.6 (1.7 to 6.6)	91.9 (65.0 to 123.2)	-1.4 (-16.1 to 14.6)
Periodontal diseases	407.2 (365.3 to 452.3)	764.5 (685.5 to 850.7)	87.9 (60.7 to 117.7)	-2.3 (-18.8 to 14.4)	2.7 (1.1 to 5.5)	5.0 (1.9 to 10.3)	88.0 (60.8 to 117.8)	-2.3 (-18.5 to 14.8)

Appendix Table G.4 - Senegal prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.								
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Edentulism and severe tooth loss	21.8 (20.1 to 23.6)	39.1 (36.5 to 42.0)	77.9 (60.8 to 99.2)	-5.9 (-13.9 to 4.6)	0.6 (0.4 to 0.8)	1.1 (0.7 to 1.5)	77.9 (59.3 to 101.2)	-5.8 (-14.4 to 5.6)
Other oral disorders	106.0 (99.3 to 112.6)	206.9 (193.8 to 220.9)	94.3 (78.4 to 113.6)	-0.6 (-7.9 to 8.0)	3.1 (1.9 to 4.6)	6.0 (3.8 to 9.2)	94.3 (77.4 to 115.2)	-0.5 (-8.4 to 8.5)
Injuries	-	-	-	-	19.8 (15.4 to 25.0)	40.4 (30.5 to 52.4)	103.5 (92.3 to 113.9)	13.1 (7.3 to 18.2)
Transport injuries	-	-	-	-	7.6 (5.8 to 9.7)	14.7 (11.0 to 19.2)	93.7 (79.4 to 106.3)	9.5 (2.5 to 16.2)
Road injuries	-	-	-	-	7.0 (5.3 to 8.9)	7.4 (10.1 to 17.5)	92.7 (77.7 to 105.8)	8.4 (1.3 to 15.1)
Pedestrian road injuries	-	-	-	-	1.9 (1.5 to 2.5)	3.2 (2.4 to 4.2)	65.3 (48.9 to 79.9)	-4.6 (-12.1 to 2.3)
Cyclist road injuries	-	-	-	-	0.5 (0.4 to 0.7)	1.0 (0.7 to 1.3)	86.7 (72.2 to 100.6)	12.5 (4.5 to 20.2)
Motorcyclist road injuries	-	-	-	-	1.1 (0.9 to 1.5)	1.7 (1.2 to 2.2)	46.1 (33.1 to 59.6)	-21.0 (-27.4 to -14.1)
Motor vehicle road injuries	-	-	-	-	3.3 (2.5 to 4.1)	7.4 (5.6 to 9.7)	127.8 (104.5 to 152.6)	27.5 (16.0 to 41.1)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	43.8 (33.1 to 55.4)	-25.7 (-30.5 to -20.8)
Other transport injuries	-	-	-	-	0.6 (0.5 to 0.8)	1.3 (1.0 to 1.7)	103.7 (86.6 to 123.4)	19.2 (10.7 to 29.5)
Unintentional injuries	-	-	-	-	11.2 (8.7 to 14.3)	23.7 (18.0 to 30.9)	110.9 (99.8 to 121.1)	14.3 (8.9 to 19.1)
Falls	-	-	-	-	4.9 (3.7 to 6.2)	10.1 (7.6 to 13.2)	107.9 (96.0 to 119.8)	7.9 (2.0 to 14.0)
Drowning	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.6)	29.0 (14.5 to 43.6)	-29.6 (-36.2 to -23.1)
Fire, heat, and hot substances	-	-	-	-	0.8 (0.6 to 1.1)	1.2 (0.9 to 1.6)	49.9 (35.9 to 66.6)	-15.2 (-21.2 to -8.1)
Poisonings	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	39.7 (15.6 to 66.1)	-27.1 (-37.5 to -16.2)
Exposure to mechanical forces	-	-	-	-	3.2 (2.4 to 4.1)	7.1 (5.4 to 9.3)	126.0 (104.4 to 144.7)	30.4 (20.6 to 39.3)
Unintentional firearm injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	81.3 (65.3 to 97.0)	-2.5 (-10.9 to 5.5)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	264.1 (205.9 to 327.4)	112.3 (84.2 to 142.6)
Other exposure to mechanical forces	-	-	-	-	3.0 (2.3 to 3.9)	6.7 (5.1 to 8.9)	127.2 (104.6 to 147.5)	31.8 (21.2 to 41.3)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	107.6 (96.8 to 121.9)	14.8 (7.7 to 22.6)
Animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.6)	69.3 (56.3 to 83.6)	-7.1 (-12.7 to -0.7)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	68.1 (47.4 to 90.8)	-9.5 (-19.3 to 1.0)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	70.5 (59.0 to 83.2)	-5.1 (-10.1 to 0.7)
Foreign body	-	-	-	-	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.7)	124.6 (106.9 to 143.3)	30.1 (19.9 to 41.0)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	52.5 (34.8 to 73.2)	-11.4 (-19.1 to -2.6)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	110.4 (83.6 to 139.1)	12.5 (-0.3 to 25.6)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	183.5 (148.7 to 220.3)	57.4 (38.6 to 76.8)
Other unintentional injuries	-	-	-	-	1.4 (1.1 to 1.8)	3.6 (2.7 to 4.7)	152.6 (131.1 to 177.1)	40.5 (29.8 to 53.0)
Self-harm and interpersonal violence	-	-	-	-	0.5 (0.4 to 0.6)	0.9 (0.7 to 1.2)	86.4 (76.3 to 95.2)	-0.3 (-5.0 to 3.7)
Self-harm	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	82.7 (67.2 to 98.8)	-5.9 (-12.8 to 1.5)
Interpersonal violence	-	-	-	-	0.4 (0.3 to 0.5)	0.8 (0.6 to 1.0)	87.2 (76.1 to 97.7)	1.3 (-4.2 to 6.1)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	99.8 (83.1 to 116.0)	9.0 (0.8 to 17.1)
Assault by sharp object	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	110.2 (95.9 to 125.7)	10.4 (3.3 to 18.5)
Assault by other means	-	-	-	-	0.3 (0.2 to 0.3)	0.5 (0.4 to 0.6)	78.1 (63.5 to 91.4)	-3.3 (-10.2 to 2.7)
Forces of nature, war, and legal intervention	-	-	-	-	0.5 (0.2 to 1.1)	1.0 (0.4 to 2.6)	113.1 (35.5 to 213.5)	61.7 (6.5 to 131.6)
Exposure to forces of nature	-	-	-	-	-	0.1 (0.0 to 0.1)	-	-
Collective violence and legal intervention	-	-	-	-	0.5 (0.2 to 1.1)	1.0 (0.3 to 2.5)	101.6 (27.9 to 195.1)	54.4 (1.0 to 118.3)

Appendix Table G.4 - Serbia prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
All causes	-	-	-	-	1,076.0 (806.3 to 1,397.8)	1,145.7 (851.6 to 1,478.2)	6.4 (3.6 to 9.9)	-4.6 (-7.0 to -1.4)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	-	-	-	-
HIV/AIDS and tuberculosis	-	-	-	-	50.8 to 101.4	41.1 to 83.0	-17.9	-11.1 to 5.1
Tuberculosis	3.1 (2.9 to 3.2)	4.0 (3.7 to 4.2)	29.2 (23.3 to 36.7)	13.9 (9.2 to 20.0)	1.0 (0.6 to 1.3)	1.3 (0.8 to 1.6)	26.4 (12.0 to 49.0)	13.0 (0.9 to 32.0)
HIV/AIDS	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	1.2	1.2
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.2 (-81.0 to 52.9)	-44.0 (-82.7 to 40.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.2	-44.0
HIV/AIDS resulting in other diseases	0.8 (0.6 to 1.2)	1.6 (0.8 to 2.7)	104.2 (-14.3 to 271.0)	93.0 (-19.9 to 252.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	5.0	1.6
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	-	-	-	-
Diarrheal diseases	26.6 (24.7 to 28.5)	20.9 (19.6 to 22.2)	-21.8 (-28.5 to -13.6)	-9.7 (-18.3 to -0.4)	4.2 (2.9 to 5.9)	3.3 (2.3 to 4.5)	-22.8 (-30.7 to -13.3)	-9.2 (-19.0 to 1.2)
Intestinal infectious diseases	-	-	-	-	0.0	0.0	0.0	0.0
Typhoid fever	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-38.8 (-58.7 to -13.6)	-34.5 (-53.8 to -8.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.8	-34.5
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.8 (-58.4 to -14.6)	-32.0 (-52.5 to -6.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.8	-32.0
Other intestinal infectious diseases	-	-	-	-	0.0	0.0	-97.6	-97.4
Lower respiratory infections	4.2 (3.6 to 4.7)	2.9 (2.5 to 3.4)	-29.9 (-44.8 to -13.4)	-17.0 (-34.7 to 2.6)	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-30.9	-17.2
Upper respiratory infections	95.4 (91.6 to 98.9)	88.7 (84.6 to 92.9)	-7.0 (-12.8 to -1.3)	-1.1 (-7.2 to 5.3)	1.1 (0.6 to 1.9)	1.0 (0.6 to 1.7)	-7.5	-1.1
Otitis media	102.8 (95.6 to 108.8)	88.8 (83.2 to 95.2)	-13.7 (-19.4 to -6.7)	-5.9 (-12.0 to 1.0)	2.1 (1.3 to 3.3)	1.8 (1.0 to 2.8)	-16.1	-7.4
Meningitis	-	-	-	-	0.2	0.2	-49.4	-47.8
Pneumococcal meningitis	1.6 (1.0 to 2.7)	0.8 (0.5 to 1.3)	-50.4 (-61.8 to -35.7)	-52.8 (-63.4 to -39.4)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-66.8 to -25.4	(-65.5 to -20.4)
H influenzae type B meningitis	0.7 (0.2 to 1.6)	0.3 (0.1 to 0.7)	-52.5 (-68.9 to 14.8)	-50.9 (-67.6 to 28.7)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-49.3	-43.9
Meningococcal meningitis	0.5 (0.1 to 1.3)	0.2 (0.1 to 0.5)	-62.5 (-79.2 to -30.6)	-63.0 (-78.8 to -28.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.0)	-62.0	-60.9
Other meningitis	0.8 (0.3 to 1.7)	0.4 (0.2 to 0.8)	-52.2 (-64.3 to -18.9)	-52.2 (-64.5 to -14.6)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-51.2	-49.2
Encephalitis	1.5 (0.6 to 3.7)	1.3 (0.6 to 3.3)	-9.3 (-25.8 to 9.5)	-8.3 (-33.4 to -0.7)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-9.4	-17.0
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0	0.0	-86.5	-85.7
Whooping cough	4.2 (3.3 to 5.4)	0.7 (0.6 to 0.9)	-82.8 (-84.1 to -81.3)	-73.2 (-75.3 to -70.9)	0.2 (0.1 to 0.3)	0.0 (0.0 to 0.1)	-82.8	-73.2
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0	0.0	-88.6	-90.4
Measles	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -99.9)	-100.0 (-100.0 to -99.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0	-100.0
Varicella and herpes zoster	5.5 (5.1 to 5.9)	4.8 (4.3 to 5.3)	-13.0 (-23.0 to -1.3)	-1.7 (-10.8 to 7.8)	1.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	5.8	-2.1
Neglected tropical diseases and malaria	-	-	-	-	-	-	-	-
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.1 (-86.1 to 243.2)	20.7 (-84.9 to 277.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.9	23.8
Chagas disease	-	-	-	-	0.0	0.0	-	-
Leishmaniasis	-	-	-	-	0.0	0.0	-	-
Visceral leishmaniasis	-	-	-	-	0.0	0.0	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	-	-	0.0	0.0	-	-
African trypanosomiasis	-	-	-	-	0.0	0.0	-	-
Schistosomiasis	-	-	-	-	0.0	0.0	-	-
Cysticercosis	3.4 (1.7 to 6.7)	0.5 (0.2 to 1.0)	-84.6 (-95.3 to -54.7)	-86.5 (-95.8 to -61.0)	0.9 (0.4 to 1.8)	0.1 (0.1 to 0.3)	-83.5	-85.6
Cystic echinococcosis	3.0 (2.8 to 3.2)	2.0 (1.8 to 2.1)	-33.5 (-39.3 to -27.4)	-40.4 (-46.1 to -34.9)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-33.9	-40.2
Lymphatic filariasis	-	-	-	-	0.0	0.0	-	-
Onchocerciasis	-	-	-	-	0.0	0.0	-	-
Trachoma	-	-	-	-	0.0	0.0	-	-
Dengue	-	-	-	-	0.0	0.0	-	-
Yellow fever	-	-	-	-	0.0	0.0	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.3 (-66.0 to -25.1)	-40.2 (-66.8 to -24.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.3	-40.2
Intestinal nematode infections	-	-	-	-	0.0	0.0	-	-
Ascariasis	-	-	-	-	0.0	0.0	-	-
Trichuriasis	-	-	-	-	0.0	0.0	-	-
Hookworm disease	-	-	-	-	0.0	0.0	-	-
Food-borne trematodiasis	-	-	-	-	0.0	0.0	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.2	-70.0
Maternal disorders	-	-	-	-	0.1	0.1	-35.1	-34.5
Maternal hemorrhage	0.6 (0.5 to 0.8)	0.6 (0.4 to 0.7)	-12.6 (-47.4 to 33.6)	-11.3 (-47.6 to 39.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.1	-34.7
Maternal sepsis and other maternal infections	1.5 (0.9 to 2.5)	0.9 (0.5 to 1.3)	-42.2 (-61.2 to -7.1)	-40.4 (-60.7 to -7.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.0	-44.0
Maternal hypertensive disorders	1.2 (0.6 to 2.1)	0.8 (0.4 to 1.3)	-34.7 (-41.2 to -23.3)	-34.7 (-41.5 to -22.2)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-35.0	-34.8
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.2 (-68.7 to 122.1)	-23.7 (-68.2 to 128.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.2	-23.7
Complications of abortion	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-31.4 (-59.6 to 42.6)	-30.9 (-60.9 to 45.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.2	-28.0
Other maternal disorders	-	-	-	-	0.0	0.0	-65.3 to 70.8	(-66.8 to 79.0)
Neonatal disorders	-	-	-	-	14.1	12.1	-14.9	-8.0
Preterm birth complications	58.1 (35.3 to 94.3)	58.2 (35.8 to 95.0)	-0.3 (-28.0 to 36.1)	4.8 (-24.5 to 44.1)	7.4 (4.5 to 11.3)	8.2 (5.0 to 12.9)	9.2	17.7
Neonatal encephalopathy due to birth asphyxia and trauma	16.1 (8.5 to 31.5)	6.3 (3.2 to 13.8)	-61.7 (-79.1 to -33.2)	-58.4 (-77.3 to -27.7)	4.0 (2.2 to 7.2)	1.7 (0.9 to 2.7)	-58.2	-54.0
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-68.6 (-74.4 to -59.2)	-50.3 (-59.4 to -35.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-62.2	-49.6
Hemolytic disease and other neonatal jaundice	3.2 (0.9 to 8.4)	1.8 (0.4 to 3.4)	-46.2 (-84.9 to 222.9)	-42.1 (-83.6 to 251.0)	1.2 (0.3 to 3.3)	0.7 (0.2 to 1.4)	-42.5	-38.5
Other neonatal disorders	-	-	-	-	1.4	1.5	8.9	17.3
Nutritional deficiencies	-	-	-	-	43.7 (29.2 to 63.3)	35.7 (23.8 to 52.2)	-18.1	-1.4
Protein-energy malnutrition	11.8 (8.4 to 16.3)	7.4 (5.3 to 10.2)	-36.9 (-60.3 to 0.9)	-0.5 (-37.3 to 58.9)	1.5 (0.8 to 2.4)	0.9 (0.5 to 1.6)	-36.6	-0.0
Iodine deficiency	27.4 (9.8 to 58.6)	22.9 (8.5 to 46.1)	-20.0 (-76.3 to 228.2)	-20.4 (-76.2 to 215.5)	0.4 (0.2 to 1.2)	0.4 (0.1 to 0.9)	-20.0	-30.8
Vitamin A deficiency	-	-	-	-	0.0	0.0	-	-
Iron-deficiency anemia	1,478.0 (1,457.8 to 1,499.2)	1,354.7 (1,319.3 to 1,388.6)	-8.3 (-10.8 to -5.9)	2.3 (-0.2 to 4.8)	40.5 (26.9 to 59.2)	33.9 (22.5 to 49.8)	-16.2	3.1

Appendix Table G.4 - Serbia prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	1.3 (0.4 to 2.9)	0.5 (0.3 to 1.2)	-58.3 (83.3 to 14.5)	-34.3 (-73.7 to 80.4)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	3.9 (2.4 to 6.3)	3.3 (2.0 to 5.4)	-14.8 (-27.9 to -0.9)	-1.4 (-18.2 to 15.6)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.6 (0.8 to 3.0)	1.6 (0.8 to 3.0)	-2.1 (-12.3 to 9.6)	-3.2 (-13.3 to 9.0)
Syphilis	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.3)	17.7 (2.3 to 42.3)	-6.1 (-18.6 to 13.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	16.8 (-13.7 to 57.1)	-5.9 (-29.0 to 24.5)
Chlamydial infection	223.6 (194.1 to 251.2)	214.2 (189.8 to 238.9)	-4.1 (-19.7 to 15.6)	1.2 (-17.5 to 19.6)	0.7 (0.4 to 1.1)	0.6 (0.3 to 1.1)	-1.3 (-21.7 to 15.7)	-1.1 (-19.7 to 20.2)
Gonococcal infection	52.7 (40.5 to 62.7)	44.3 (35.0 to 53.8)	-15.9 (-37.2 to 13.9)	-1.1 (-32.9 to 22.3)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-20.7 (-43.4 to 13.5)	-15.7 (-43.0 to 22.0)
Trichomoniasis	105.1 (78.4 to 133.8)	117.4 (90.9 to 160.1)	10.7 (-18.9 to 67.8)	15.4 (-16.1 to 78.3)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	11.1 (-23.7 to 79.2)	15.3 (-21.7 to 93.1)
Genital herpes	1,706.2 (1,540.8 to 1,854.1)	1,812.9 (1,650.0 to 1,973.5)	6.0 (-5.7 to 21.6)	-5.7 (-16.0 to 8.2)	0.4 (0.1 to 1.1)	0.5 (0.1 to 1.1)	4.8 (-7.4 to 21.3)	-5.4 (-16.6 to 9.2)
Other sexually transmitted diseases	2.2 (1.6 to 2.8)	1.7 (1.2 to 2.2)	-25.3 (-38.9 to 4.3)	-24.2 (-37.8 to 5.5)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-47.1 (-71.0 to -23.2)	-15.4 (-47.2 to 29.8)
Hepatitis	-	-	-	-	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.5)	-28.9 (-28.9 to -6.5)	-16.9 (-26.6 to -4.3)
Hepatitis A	9.8 (9.5 to 10.0)	7.8 (7.6 to 8.0)	-20.5 (-20.7 to -20.3)	-9.1 (-9.6 to -8.5)	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-19.5 (-19.5 to -0.8)	-5.4 (-14.4 to 5.5)
Hepatitis B	236.6 (177.5 to 288.4)	167.3 (131.9 to 194.0)	-28.6 (-48.7 to -8.7)	-30.7 (-50.7 to -10.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-27.7 (-53.6 to -0.0)	-31.5 (-55.5 to -5.5)
Hepatitis C	162.4 (145.8 to 178.4)	135.4 (122.8 to 148.2)	-16.8 (-27.3 to -3.0)	-26.2 (-35.7 to -14.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.4 (-46.4 to 21.4)	-28.9 (-49.9 to 2.4)
Hepatitis E	-	-	-	-	-	-	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	61.7 (51.0 to 71.0)	50.9 (44.0 to 58.2)	-17.5 (-30.9 to 0.5)	2.0 (-17.8 to 27.1)	1.9 (1.2 to 2.8)	1.4 (0.9 to 2.1)	-24.8 (-47.4 to 3.4)	3.1 (-30.2 to 42.2)
Non-communicable diseases	-	-	-	-	887.4 (662.7 to 1,150.1)	1,018.5 (756.8 to 1,310.4)	14.7 (11.4 to 19.0)	1.5 (-1.3 to 5.4)
Neoplasms	-	-	-	-	101.6 (7.6 to 14.0)	142.7 (105.5 to 18.3)	41.7 (15.4 to 55.1)	84.7 (-9.8 to 20.9)
Esophageal cancer	0.5 (0.4 to 0.7)	0.6 (0.5 to 0.7)	11.5 (-18.8 to 52.2)	-12.3 (-35.3 to 18.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	11.9 (-18.8 to 57.9)	-12.4 (-35.0 to 20.6)
Stomach cancer	3.9 (3.1 to 4.8)	2.9 (2.5 to 3.3)	-26.7 (-40.4 to -6.5)	-44.8 (-55.0 to -29.9)	0.5 (0.3 to 0.6)	0.4 (0.3 to 0.5)	-24.1 (-40.6 to -1.4)	-42.8 (-54.9 to -26.5)
Liver cancer	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	11.0 (-17.3 to 60.5)	-18.6 (-39.4 to 16.3)
Liver cancer due to hepatitis B	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-10.7 (-62.0 to 97.4)	-31.9 (-70.9 to 48.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.1 (-60.0 to 85.9)	-33.9 (-69.4 to 37.6)
Liver cancer due to hepatitis C	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	83.4 (3.3 to 218.3)	33.8 (-24.4 to 130.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	81.4 (11.8 to 200.9)	31.3 (-17.9 to 112.9)
Liver cancer due to alcohol use	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	1.3 (-42.4 to 71.4)	-26.8 (-57.7 to 23.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	1.7 (-33.7 to 59.6)	-26.7 (-52.0 to 14.0)
Liver cancer due to other causes	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-45.1 (-71.0 to 5.8)	-58.7 (-77.8 to -20.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.6 (-88.2 to -4.3)	-60.1 (-76.0 to -28.1)
Larynx cancer	2.4 (1.6 to 3.5)	3.2 (2.5 to 4.0)	32.2 (-12.4 to 101.5)	32.2 (-29.5 to 59.8)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	10.7 (-21.3 to 60.1)	-11.9 (-36.3 to 25.7)
Tracheal, bronchus and lung cancer	7.2 (5.8 to 8.8)	7.7 (6.7 to 8.7)	7.6 (-15.1 to 38.0)	-15.6 (-32.7 to 7.3)	1.1 (0.8 to 1.5)	1.2 (0.9 to 1.6)	10.4 (-13.6 to 39.5)	-13.6 (-32.0 to 9.1)
Breast cancer	20.6 (16.4 to 25.3)	43.9 (39.9 to 48.1)	113.6 (70.9 to 167.1)	66.6 (33.4 to 107.4)	1.6 (1.1 to 2.2)	2.6 (1.8 to 3.6)	70.6 (30.8 to 116.3)	33.3 (2.7 to 68.5)
Cervical cancer	9.2 (6.8 to 12.4)	7.3 (5.8 to 8.7)	-20.6 (-42.9 to 10.1)	-30.5 (-50.1 to -3.5)	0.7 (0.4 to 1.0)	0.5 (0.4 to 0.8)	-20.7 (-42.4 to 12.5)	-30.9 (-50.2 to -2.5)
Uterine cancer	6.2 (3.9 to 8.8)	5.3 (4.0 to 6.9)	-13.6 (-43.4 to 37.5)	-30.0 (-53.9 to 8.1)	0.4 (0.2 to 0.7)	0.4 (0.2 to 0.5)	-31.0 (-43.8 to 15.1)	-31.0 (-55.4 to 7.8)
Prostate cancer	5.1 (5.1 to 9.0)	15.8 (12.8 to 18.8)	144.0 (74.3 to 224.7)	69.9 (21.6 to 126.7)	0.7 (0.4 to 1.0)	1.5 (1.0 to 2.1)	136.8 (60.6 to 224.0)	62.3 (11.0 to 118.3)
Colon and rectum cancer	15.7 (13.2 to 18.3)	24.5 (22.6 to 26.4)	56.3 (31.2 to 88.8)	17.8 (-0.9 to 41.6)	1.3 (0.9 to 1.8)	2.1 (1.5 to 2.7)	55.3 (28.4 to 88.4)	15.6 (-3.7 to 40.7)
Lip and oral cavity cancer	3.3 (2.4 to 4.3)	3.4 (2.7 to 4.2)	3.9 (-27.9 to 50.7)	-17.6 (-42.3 to 18.0)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	4.9 (-26.4 to 51.4)	-17.3 (-41.8 to 17.1)
Nasopharynx cancer	0.4 (0.3 to 0.7)	0.2 (0.2 to 0.3)	-45.0 (-67.2 to -5.4)	-52.8 (-70.9 to -20.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-45.1 (-65.0 to -9.7)	-53.7 (-70.5 to -24.1)
Other pharynx cancer	1.2 (0.7 to 1.8)	1.1 (0.7 to 1.6)	-9.9 (-47.5 to 60.2)	-22.8 (-56.8 to 30.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-21.1 (-40.7 to 61.9)	21.2 (-50.9 to 27.2)
Gallbladder and biliary tract cancer	0.3 (0.3 to 0.5)	0.4 (0.3 to 0.5)	4.5 (-32.0 to 45.7)	-23.9 (-50.6 to 5.6)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	4.9 (-32.7 to 47.5)	-22.6 (-50.5 to 7.9)
Pancreatic cancer	0.7 (0.6 to 0.9)	1.0 (0.9 to 1.2)	44.2 (13.2 to 86.9)	6.9 (-16.1 to 38.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	43.8 (12.8 to 86.4)	7.3 (-15.6 to 38.8)
Malignant skin melanoma	3.3 (2.3 to 4.9)	5.2 (3.6 to 7.2)	59.8 (20.0 to 106.3)	35.9 (2.4 to 74.4)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	53.5 (15.4 to 100.3)	29.3 (-1.3 to 67.8)
Non-melanoma skin cancer	6.1 (6.1 to 7.9)	14.4 (12.4 to 17.0)	106.3 (76.0 to 149.2)	49.7 (22.3 to 72.0)	0.5 (0.1 to 0.3)	0.5 (0.3 to 0.7)	106.6 (88.4 to 276.5)	71.1 (21.6 to 146.8)
Ovarian cancer	2.8 (2.0 to 3.7)	2.5 (2.1 to 2.9)	-9.5 (-34.6 to 27.5)	-24.8 (-45.0 to 6.3)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-7.8 (-36.2 to 33.3)	-23.8 (-47.5 to 10.5)
Testicular cancer	3.3 (2.0 to 5.6)	2.9 (1.7 to 4.3)	-10.0 (-53.1 to 71.9)	-12.2 (-53.8 to 70.9)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-10.3 (-54.2 to 71.9)	-12.8 (-55.3 to 68.3)
Kidney cancer	2.7 (2.2 to 3.5)	4.5 (3.8 to 5.2)	64.2 (29.4 to 112.1)	29.9 (2.7 to 64.7)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	63.6 (26.9 to 114.7)	28.2 (8.2 to 66.2)
Bladder cancer	5.9 (4.4 to 7.3)	5.7 (4.7 to 6.7)	-1.1 (-23.2 to 29.7)	-28.9 (-42.8 to -4.4)	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	0.9 (-21.9 to 35.1)	25.9 (-42.1 to 1.6)
Brain and nervous system cancer	2.5 (1.9 to 3.1)	3.2 (2.6 to 3.8)	28.2 (1.7 to 60.6)	15.5 (-9.3 to 46.4)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	27.3 (1.4 to 64.1)	12.7 (-9.8 to 43.7)
Thyroid cancer	2.2 (1.5 to 3.0)	2.6 (2.0 to 3.5)	14.8 (-21.0 to 95.1)	2.6 (-29.8 to 76.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	14.0 (-21.8 to 98.8)	-0.6 (-31.3 to 71.0)
Mesothelioma	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	40.7 (-11.8 to 99.5)	9.6 (-30.4 to 53.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.3 (-9.9 to 106.7)	13.3 (-28.9 to 58.9)
Hodgkin lymphoma	1.9 (1.2 to 2.6)	1.5 (1.1 to 2.0)	-19.1 (-45.8 to 17.2)	-22.3 (-48.1 to 13.2)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-23.0 (-46.4 to 9.2)	-27.0 (-49.9 to 4.0)
Non-Hodgkin lymphoma	2.9 (2.1 to 4.1)	3.4 (2.3 to 4.3)	17.0 (-23.8 to 53.1)	-2.8 (-34.9 to 26.9)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.4)	19.2 (-21.6 to 59.2)	-2.1 (-34.7 to 29.1)
Multiple myeloma	0.5 (0.3 to 0.7)	0.7 (0.5 to 1.1)	29.4 (-6.6 to 168.1)	29.4 (-25.5 to 105.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	58.5 (-13.8 to 166.0)	23.8 (-31.4 to 106.4)
Leukemia	2.7 (2.1 to 3.4)	3.1 (2.7 to 3.6)	18.0 (-12.9 to 55.3)	-2.2 (-28.6 to 28.5)	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	25.6 (-5.9 to 66.3)	0.4 (-24.1 to 31.6)
Other neoplasms	5.4 (4.1 to 7.6)	10.4 (8.0 to 12.5)	96.7 (24.6 to 176.7)	63.2 (3.9 to 127.6)	0.7 (0.3 to 0.6)	0.7 (0.5 to 1.0)	89.6 (23.3 to 156.9)	54.5 (0.4 to 117.2)
Cardiovascular diseases	-	-	-	-	17.5 (12.2 to 24.5)	27.4 (19.2 to 37.2)	57.7 (23.4 to 89.5)	15.1 (-10.1 to 38.4)
Rheumatic heart disease	1.4 (1.1 to 1.6)	1.7 (1.4 to 2.1)	24.3 (-5.4 to 74.1)	-1.9 (-23.6 to 33.8)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	23.7 (-11.9 to 78.1)	-1.9 (-28.3 to 37.9)
Ischemic heart disease	130.4 (114.6 to 151.0)	172.8 (151.9 to 197.1)	33.4 (9.9 to 59.3)	-3.2 (-19.4 to 15.6)	7.0 (4.7 to 10.0)	9.4 (6.3 to 13.0)	34.5 (8.7 to 68.8)	-4.7 (-21.6 to 18.9)
Cerebrovascular disease	-	-	-	-	2.1 (1.7 to 3.1)	3.1 (2.1 to 4.2)	48.8 (9.0 to 88.8)	6.4 (-12.6 to 33.5)
Ischemic stroke	12.6 (10.6 to 14.5)	16.9 (14.5 to 19.5)	34.0 (8.6 to 69.7)	4.4 (-14.5 to 31.9)	1.9 (1.3 to 2.6)	2.5 (1.7 to 3.5)	35.2 (7.8 to 71.0)	5.7 (-14.2 to 33.6)
Hemorrhagic stroke	2.7 (2.2 to 3.2)	3.5 (2.8 to 4.3)	33.5 (-0.8 to 72.3)	10.0 (-16.7 to 41.5)	0.4 (0.3 to 0.6)	0.6 (0.3 to 0.8)	31.7 (-4.0 to 74.7)	9.9 (-18.5 to 44.7)
Hypertensive heart disease	18.7 (16.4 to 21.3)	31.0 (27.9 to 34.3)	65.2 (39.4 to 95.5)	11.5 (-6.3 to 32.7)	2.0 (1.4 to 2.8)	3.4 (2.4 to 4.6)	65.9 (39.4 to 98.3)	12.7 (-4.7 to 34.6)
Cardiomyopathy and myocarditis	23.3 (20.3 to 26.2)	25.5 (23.0 to 27.8)	9.4 (-6.3 to 29.1)	-23.4 (-35.0 to -10.3)	2.5 (1.7 to 3.4)	2.7 (1.9 to 3.7)	9.7 (-7.2 to 29.8)	-22.9 (-35.0 to -8.6)
Atrial fibrillation and flutter	2.6 (1.9 to 3.4)	23.5 (18.7 to 30.1)	814.9 (546.2 to 1,254.9)	528.4 (339.4 to 832.2)	0.2 (0.1 to 0.3)	1.8 (1.2 to 2.7)	820.1 (530.7 to 1,267.3)	538.9 (336.8 to 850.2)
Peripheral vascular disease	297.0 (230.8 to 368.7)	398.2 (296.7 to 498.8)	35.7 (-15.7 to 93.1)	-1.3 (-39.8 to 36.4)	0.4 (0.1 to 0.8)	0.3 (0.1 to 0.7)	-10.6 (-60.4 to 67.0)	-45.2 (-74.9 to 2.0)
Endocarditis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	32.2 (-12.9 to 83.9)	17.5 (-22.6 to 64.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.7 (-13.1 to 95.0)	25.2 (-21.0 to 75.5)
Other cardiovascular and circulatory diseases	42.2 (18.2 to 92.9)	90.5 (44.2 to 134.9)	132.3 (-24.5 to 452.2)	80.9 (-42.0 to 344.4)	2.9 (1.2 to 6.1)	6.4 (2.7 to 10.6)	134.5 (-24.7 to 448.7)	83.1 (-42.2 to 342.5)
Chronic respiratory diseases	-	-	-	-	52.4 (36.0 to 72.0)	57.1 (38.9 to 77.9)	8.8 (-7.3 to 32.1)	6.9 (-22.0 to 12.7)
Chronic obstructive pulmonary disease	500.2 (476.5 to 523.1)	601.3 (573.5 to 627.2)	20.2 (16.6 to 23.7)	-0.8 (-3.7 to 2.1)	29.7 (19.6 to 42.7)	36.1 (23.5 to 50.8)	20.1 (-18.8 to 27.3)	-0.3 (-2.0 to 2.3)
Pneumoconiosis	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	2.7 (-4.0 to 9.3)	-14.7 (-24.2 to -14.7)

Appendix Table G.4 - Serbia prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Silicosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	23.2 (16.9 to 29.6)	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.6 (17.2 to 30.2)	-4.1 (-9.0 to 1.0)
Asbestosis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	22.8 (17.5 to 28.6)	-3.9 (-8.1 to 0.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.5 (18.0 to 29.6)	-3.5 (-7.8 to 1.0)
Coal workers pneumoconiosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	19.4 (13.6 to 26.3)	-4.3 (-9.0 to 0.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.0 (14.2 to 27.1)	-3.9 (-8.6 to 1.3)
Other pneumoconiosis	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-23.6 (-30.8 to -13.7)	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.1 (-30.7 to -13.2)	-39.0 (-45.6 to -32.5)
Asthma	496.0 (411.9 to 562.7)	468.9 (411.2 to 518.5)	-4.9 (-22.6 to 17.1)	-16.4 (-31.6 to 5.6)	21.7 (13.8 to 31.8)	20.2 (13.0 to 29.3)	7.9 (-23.9 to 16.6)	-16.6 (-32.8 to 5.7)
Interstitial lung disease and pulmonary sarcoidosis	1.2 (0.9 to 1.5)	1.4 (1.1 to 1.8)	15.9 (16.5 to 69.2)	-0.5 (-29.2 to 45.7)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	17.2 (16.4 to 69.7)	0.4 (-2.8 to 45.6)
Other chronic respiratory diseases	-	-	-	-	0.7 (0.4 to 1.2)	0.6 (0.4 to 1.0)	-10.1 (-40.4 to 38.0)	-26.0 (-50.8 to 13.5)
Cirrhosis	-	-	-	-	0.8 (0.5 to 1.1)	0.7 (0.5 to 0.9)	-15.2 (-28.2 to 0.6)	-22.3 (-33.6 to -9.1)
Cirrhosis due to hepatitis B	1.0 (0.7 to 1.3)	1.1 (0.8 to 1.5)	8.6 (-28.2 to 82.2)	-5.5 (-36.7 to 59.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	0.2 (-31.1 to 85.7)	-5.9 (-38.5 to 63.2)
Cirrhosis due to hepatitis C	1.4 (0.9 to 1.8)	1.1 (0.7 to 1.5)	-22.4 (-52.7 to 29.2)	-32.0 (-58.8 to 9.1)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	0.2 (-55.5 to 31.4)	-23.6 (-61.1 to 12.5)
Cirrhosis due to alcohol use	1.3 (0.9 to 1.7)	0.8 (0.5 to 1.1)	-37.8 (-60.9 to 2.6)	-48.2 (-67.4 to -14.7)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-36.9 (-62.3 to 10.4)	-47.0 (-68.1 to -7.5)
Cirrhosis due to other causes	1.1 (0.9 to 1.3)	1.0 (0.7 to 1.3)	-0.0 (-35.0 to 33.1)	-2.1 (-28.5 to 31.8)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-3.5 (-37.4 to 45.7)	-0.5 (-33.5 to 46.1)
Digestive diseases	-	-	-	-	10.7 (7.6 to 14.2)	13.5 (9.6 to 18.0)	26.3 (17.9 to 34.9)	2.8 (-4.9 to 10.2)
Peptic ulcer disease	76.4 (71.2 to 80.5)	58.9 (53.3 to 63.4)	-22.8 (-30.3 to -15.4)	-48.3 (-53.2 to -43.4)	2.7 (1.8 to 3.7)	2.3 (1.6 to 3.3)	-12.8 (-20.8 to -2.2)	-40.4 (-45.6 to -33.2)
Gastritis and duodenitis	9.1 (8.0 to 10.1)	18.1 (16.2 to 20.0)	99.7 (73.5 to 130.5)	58.2 (36.0 to 83.8)	0.5 (0.3 to 0.7)	0.9 (0.6 to 1.3)	80.5 (41.9 to 125.5)	46.5 (13.7 to 90.6)
Appendicitis	0.5 (0.4 to 0.6)	0.3 (0.3 to 0.4)	-31.8 (-53.9 to -5.7)	-26.1 (-50.8 to 4.1)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-32.2 (-57.9 to 9.3)	-26.7 (-52.1 to 22.2)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	19.5 (-8.5 to 51.1)	-0.1 (-26.8 to 45.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	14.8 (-2.1 to 61.2)	-1.1 (-34.6 to 50.5)
Inguinal, femoral, and abdominal hernia	59.6 (51.3 to 68.4)	66.5 (57.0 to 78.0)	11.2 (-8.6 to 35.8)	-16.2 (-30.9 to 0.8)	0.6 (0.3 to 1.2)	0.7 (0.3 to 1.3)	11.5 (-9.3 to 36.0)	-15.2 (-30.4 to 2.7)
Inflammatory bowel disease	14.2 (13.5 to 14.9)	22.6 (21.6 to 23.6)	58.7 (49.1 to 68.9)	38.9 (30.8 to 47.5)	3.0 (2.0 to 4.1)	4.8 (3.3 to 6.5)	58.9 (46.4 to 72.0)	39.8 (28.8 to 51.8)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	30.8 (-4.6 to 73.0)	-8.6 (-33.0 to 20.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.2 (-4.5 to 81.3)	-5.5 (-33.2 to 28.6)
Gallbladder and biliary diseases	24.5 (20.9 to 27.8)	25.2 (22.2 to 28.5)	3.0 (-14.0 to 27.6)	-16.7 (-30.1 to 3.0)	2.6 (1.7 to 3.5)	2.6 (1.8 to 3.7)	2.7 (-14.5 to 27.2)	-16.5 (-30.3 to 3.2)
Pancreatitis	2.9 (2.7 to 3.0)	4.5 (4.2 to 4.7)	54.3 (43.9 to 71.2)	3.3 (-23.6 to 46.5)	0.8 (0.6 to 1.1)	1.3 (0.9 to 1.7)	59.9 (34.0 to 81.4)	35.2 (15.6 to 57.0)
Other digestive diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.7 (0.5 to 1.0)	123.5 (68.0 to 230.1)	81.5 (37.4 to 166.9)
Neurological disorders	-	-	-	-	89.8 (61.0 to 123.8)	111.9 (77.3 to 152.8)	24.3 (12.9 to 38.2)	11.5 (1.7 to 24.0)
Alzheimer disease and other dementias	80.6 (71.7 to 90.2)	130.5 (114.7 to 147.4)	62.8 (34.9 to 91.8)	0.7 (-17.1 to 18.8)	11.5 (8.2 to 15.1)	19.2 (13.7 to 25.1)	67.6 (37.8 to 99.2)	2.1 (-16.5 to 21.7)
Parkinson disease	6.3 (4.2 to 8.2)	9.0 (6.0 to 11.9)	43.2 (28.6 to 54.7)	0.7 (-10.5 to 5.1)	0.7 (0.4 to 1.1)	1.1 (0.6 to 1.6)	43.7 (23.8 to 64.7)	-0.1 (-12.9 to 12.6)
Epilepsy	29.5 (20.1 to 42.1)	33.1 (22.3 to 45.0)	11.9 (-32.1 to 89.3)	14.0 (-31.3 to 94.0)	8.4 (4.8 to 13.5)	9.8 (5.5 to 15.1)	17.4 (-31.1 to 95.5)	21.0 (-29.8 to 101.2)
Multiple sclerosis	4.2 (3.7 to 4.6)	8.5 (7.7 to 9.4)	106.1 (76.3 to 136.0)	1.4 (-62.0 to 116.7)	1.4 (0.9 to 1.8)	2.8 (2.0 to 3.7)	106.4 (70.1 to 148.5)	90.4 (56.8 to 129.2)
Migraine	1,428.5 (1,326.8 to 1,553.0)	1,445.1 (1,318.7 to 1,569.7)	1.6 (-10.7 to 12.8)	-0.7 (-13.0 to 10.6)	48.7 (29.4 to 72.0)	49.1 (28.8 to 71.3)	1.2 (-11.3 to 13.3)	-0.5 (-13.4 to 11.3)
Tension-type headache	1,851.1 (1,695.0 to 2,000.8)	1,912.0 (1,754.2 to 2,070.7)	3.0 (-7.5 to 16.7)	0.2 (-10.0 to 13.5)	12.0 (1.4 to 4.9)	2.9 (1.4 to 5.1)	2.0 (-7.9 to 16.7)	0.5 (-10.3 to 14.2)
Medication overuse headache	94.9 (61.3 to 130.4)	161.2 (105.3 to 222.7)	67.7 (24.5 to 135.3)	56.2 (15.6 to 117.4)	14.9 (8.1 to 23.7)	25.2 (14.2 to 39.7)	68.2 (34.0 to 136.2)	57.4 (17.3 to 120.2)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.9 (-16.7 to 62.1)	7.4 (-21.0 to 48.0)	1.5 (1.0 to 2.2)	1.7 (1.2 to 2.3)	14.7 (-19.5 to 62.3)	-25.8 (-47.8 to 4.5)
Mental and substance use disorders	-	-	-	-	206.5 (150.7 to 269.5)	209.7 (152.0 to 272.5)	1.6 (-1.0 to 3.9)	-1.2 (-3.4 to 0.8)
Schizophrenia	31.8 (23.1 to 34.2)	33.6 (30.9 to 36.3)	5.5 (1.6 to 9.8)	-1.1 (-4.9 to 3.2)	20.4 (14.9 to 24.6)	21.5 (15.6 to 26.2)	5.6 (-0.3 to 12.1)	-0.6 (-6.0 to 5.7)
Alcohol use disorders	93.6 (83.7 to 103.1)	82.5 (73.9 to 90.9)	-11.9 (-18.1 to -5.9)	-17.2 (-23.0 to -11.7)	9.3 (6.2 to 13.3)	8.2 (5.3 to 11.7)	-11.6 (-18.3 to -4.5)	-16.7 (-22.9 to -10.2)
Drug use disorders	-	-	-	-	10.6 (6.7 to 15.2)	10.1 (6.5 to 14.3)	-4.4 (-18.3 to 11.4)	-4.3 (-19.2 to 12.1)
Opioid use disorders	10.5 (5.0 to 17.7)	10.5 (5.2 to 17.5)	0.2 (-9.2 to 10.3)	-0.3 (-9.1 to 9.2)	4.4 (2.0 to 7.9)	4.4 (2.0 to 7.7)	1.0 (-13.2 to 16.3)	0.4 (-12.9 to 15.1)
Cocaine use disorders	5.7 (4.3 to 6.9)	6.4 (5.3 to 7.6)	12.3 (-16.7 to 56.5)	14.4 (-16.5 to 61.3)	0.8 (0.5 to 1.2)	0.9 (0.6 to 1.3)	12.6 (-21.7 to 60.6)	15.0 (-20.7 to 65.6)
Amphetamine use disorders	15.1 (13.3 to 18.9)	13.4 (10.9 to 15.7)	-11.2 (-36.9 to 8.2)	-16.5 (-38.3 to 8.2)	2.1 (1.3 to 3.1)	2.1 (1.1 to 2.7)	-1.9 (-32.0 to 11.0)	-16.5 (-39.2 to 11.1)
Cannabis use disorders	15.0 (12.0 to 17.9)	14.2 (11.4 to 16.9)	-5.3 (-6.8 to -3.9)	0.0 (-0.0 to 0.0)	0.4 (0.3 to 0.7)	0.4 (0.3 to 0.6)	-4.6 (-17.7 to 11.5)	0.9 (-12.6 to 17.7)
Other drug use disorders	-	-	-	-	2.9 (1.8 to 4.5)	2.7 (1.6 to 3.9)	-7.9 (-35.4 to 29.3)	-8.1 (-35.6 to 29.5)
Depressive disorders	-	-	-	-	77.8 (53.4 to 107.8)	82.8 (56.3 to 114.7)	6.5 (11.1 to 11.5)	0.4 (-4.3 to 5.1)
Major depressive disorder	314.1 (270.5 to 353.7)	323.3 (285.6 to 377.1)	5.8 (-0.3 to 11.5)	0.0 (-5.7 to 4.8)	64.2 (43.1 to 89.0)	67.7 (44.9 to 94.8)	5.6 (-1.1 to 11.6)	0.5 (-5.3 to 6.0)
Dysthymia	142.3 (117.7 to 166.5)	157.6 (131.2 to 183.0)	10.8 (8.5 to 13.3)	-0.1 (-0.1 to -0.0)	13.7 (8.9 to 20.0)	15.1 (9.8 to 22.1)	10.5 (7.2 to 14.0)	0.2 (-2.0 to 2.7)
Bipolar disorder	70.3 (56.6 to 83.1)	74.8 (61.7 to 88.8)	6.4 (0.0 to 12.8)	-0.4 (-6.3 to 5.2)	14.2 (8.6 to 21.6)	15.1 (9.1 to 22.9)	6.5 (-1.2 to 14.2)	0.1 (-7.2 to 6.9)
Anxiety disorders	346.9 (291.7 to 401.4)	354.2 (296.9 to 407.2)	2.2 (-0.3 to 4.6)	-0.1 (-0.2 to -0.1)	31.8 (21.7 to 45.3)	32.3 (21.9 to 45.9)	1.6 (-1.9 to 5.2)	0.1 (-2.5 to 2.7)
Eating disorders	-	-	-	-	2.3 (1.4 to 3.6)	2.1 (1.3 to 3.3)	2.1 (-14.7 to 0.0)	0.5 (-7.8 to 7.4)
Anorexia nervosa	1.1 (0.9 to 1.4)	1.0 (0.8 to 1.2)	-15.5 (-24.7 to -6.5)	-6.5 (-16.6 to 3.2)	0.2 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-15.2 (-37.0 to 10.3)	-6.0 (-30.6 to 22.3)
Bulimia nervosa	9.7 (7.1 to 13.0)	9.0 (6.5 to 12.3)	-6.8 (-8.9 to -5.0)	-0.0 (-0.1 to 0.0)	2.1 (1.2 to 3.3)	1.9 (1.1 to 3.0)	-6.6 (-14.4 to 1.8)	0.3 (-7.7 to 8.7)
Autistic spectrum disorders	-	-	-	-	11.3 (7.9 to 15.4)	10.8 (7.5 to 14.7)	-4.4 (-7.5 to -1.3)	0.5 (-2.8 to 3.8)
Autism	29.2 (27.7 to 30.8)	28.1 (26.6 to 29.7)	-4.0 (-4.6 to -3.4)	0.1 (0.1 to 0.1)	7.2 (4.8 to 9.9)	6.9 (4.6 to 9.4)	-4.3 (-8.7 to 0.3)	-0.3 (-4.3 to 5.4)
Asperger syndrome	41.6 (39.0 to 44.2)	39.8 (37.1 to 42.5)	-4.4 (-5.2 to -3.6)	0.1 (0.1 to 0.2)	4.1 (2.9 to 5.8)	3.9 (2.8 to 5.5)	-4.7 (-8.5 to -1.0)	0.4 (-3.6 to 4.2)
Attention-deficit/hyperactivity disorder	47.6 (43.8 to 51.3)	36.2 (33.3 to 39.1)	-23.8 (-24.3 to -23.6)	0.1 (0.1 to 0.1)	0.6 (0.3 to 0.9)	0.4 (0.3 to 0.7)	0.4 (-28.8 to -18.6)	0.2 (-6.3 to 7.2)
Conduct disorder	70.3 (66.3 to 74.6)	52.6 (49.5 to 56.0)	-25.1 (-25.7 to -24.5)	0.1 (0.1 to 0.1)	8.5 (5.3 to 12.3)	6.4 (4.0 to 9.2)	-25.0 (-28.3 to -21.8)	0.3 (-4.1 to 4.6)
Idiopathic intellectual disability	148.7 (118.2 to 183.2)	126.0 (93.8 to 156.8)	-15.1 (-25.3 to -6.0)	-12.2 (-21.9 to -2.6)	7.2 (4.8 to 10.2)	6.1 (3.8 to 8.7)	-15.4 (-24.9 to -5.7)	-11.8 (-22.7 to 1.4)
Other mental and substance use disorders	170.1 (159.9 to 180.1)	187.7 (176.8 to 198.9)	10.4 (9.3 to 11.4)	0.0 (-0.1 to 0.1)	12.6 (8.5 to 17.0)	13.9 (9.5 to 18.5)	10.4 (6.4 to 14.6)	0.6 (-3.1 to 4.4)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	100.2 (71.1 to 135.1)	122.9 (88.0 to 165.3)	22.5 (10.3 to 39.8)	9.1 (-1.4 to 23.3)
Diabetes mellitus	541.0 (445.7 to 637.8)	713.3 (592.8 to 852.2)	31.9 (5.0 to 68.8)	17.7 (-5.0 to 49.0)	39.9 (26.2 to 57.2)	55.6 (36.4 to 79.5)	39.0 (9.1 to 84.9)	19.4 (-5.2 to 57.6)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.7 (-60.0 to -49.4)	-46.3 (-52.7 to -40.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.7 (-60.0 to -49.4)	-46.3 (-52.7 to -40.4)
Chronic kidney disease	-	-	-	-	29.0 (21.3 to 37.9)	34.1 (24.5 to 44.8)	18.0 (6.6 to 28.1)	3.7 (-5.0 to 11.7)
Chronic kidney disease due to diabetes mellitus	157.0 (109.0 to 229.1)	204.9 (151.3 to 301.9)	31.9 (-1.0 to 69.1)	6.9 (-16.1 to 36.4)	4.3 (3.0 to 5.8)	5.5 (3.9 to 7.6)	30.8 (-3.4 to 67.9)	8.8 (-17.9 to 38.4)
Chronic kidney disease due to hypertension	237.0 (167.7 to 334.0)	220.2 (157.7 to 313.3)	-7.6 (-25.0 to 22.9)	-12.9 (-29.6 to 10.4)	9.8 (7.0 to 13.1)	7.1 (5.0 to 9.3)	-28.1 (-40.4 to -15.0)	-37.0 (-48.2 to -25.8)
Chronic kidney disease due to glomerulonephritis	335.5 (217.1 to 479.5)	250.5 (178.4 to 365.4)	-25.0 (-39.9 to -9.6)	-33.5 (-45.1 to -20.7)	5.6 (3.8 to 7.7)	5.7 (4.0 to 7.7)	1.8 (-16.2 to 37.7)	-4.7 (-20.5 to 26.0)
Chronic kidney disease due to other causes	361.0 (252.1 to 516.3)	580.5 (419.2 to 788.0)	61.9 (33.6 to 92.0)	61.9 (23.5 to 66.4)	9.4 (6.6 to 12.7)	15.6 (11.3 to 21.0)	65.9 (43.9 to 101.4)	46.8 (27.1 to 73.4)
Urinary diseases and male infertility	-	-	-	-	6.4 (4.1 to 9.2)	9.5 (6.2 to 13.7)	47.3 (25.1 to 75.0)	8.6 (-7.8 to 29.9)
Interstitial nephritis and urinary tract infections	1.7 (1.5 to 2.0)	1.8 (1.6 to 2.1)	5.7 (-12.9 to 25.2)	4.3 (-14.9 to 23.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	4.9 (-21.6 to 39.7)	4.3 (-22.6 to 39.0)

Appendix Table G.4 - Serbia prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Urolithiasis	85.1 (52.4 to 134.2)	104.6 (73.1 to 154.1)	24.5 (4.3 to 48.1)	4.9 (-18.9 to 9.6)	0.7 (0.4 to 1.2)	0.9 (0.5 to 1.5)	24.3 (9.1 to 40.0)	0.3 (-11.0 to 12.0)
Benign prostatic hyperplasia	145.2 (125.0 to 163.9)	215.1 (183.8 to 241.5)	49.0 (18.6 to 82.3)	6.0 (-16.6 to 30.4)	5.2 (3.3 to 7.4)	7.7 (4.9 to 11.1)	50.2 (20.4 to 84.8)	7.3 (-14.9 to 32.1)
Male infertility due to other causes	35.9 (26.5 to 46.1)	35.5 (26.2 to 45.7)	-1.9 (-32.4 to 43.0)	2.2 (-29.0 to 49.3)	0.2 (0.1 to 0.5)	0.2 (0.1 to 0.5)	-2.7 (-33.3 to 41.8)	2.7 (-29.8 to 49.0)
Other urinary diseases	-	-	-	-	0.3 (0.1 to 0.5)	0.6 (0.2 to 1.1)	181.7 (1.9 to 284.9)	130.7 (-17.4 to 218.4)
Gynecological diseases	-	-	-	-	11.7 (7.6 to 18.0)	12.8 (7.6 to 18.1)	4.7 (-10.9 to 16.6)	4.8 (-12.6 to 15.2)
Uterine fibroids	220.5 (200.8 to 239.0)	232.6 (212.9 to 251.4)	5.5 (4.8 to 6.3)	0.5 (0.5 to 0.5)	2.5 (1.4 to 4.4)	2.7 (1.5 to 4.5)	5.7 (0.4 to 11.9)	2.0 (-3.2 to 8.2)
Polycystic ovarian syndrome	170.5 (150.0 to 190.1)	172.1 (152.9 to 190.3)	1.2 (-14.8 to 18.1)	2.6 (-13.9 to 19.8)	1.6 (0.7 to 3.1)	1.6 (0.8 to 3.1)	2.1 (-14.2 to 20.2)	3.3 (-12.9 to 22.0)
Female infertility due to other causes	22.6 (6.4 to 44.4)	25.6 (9.8 to 45.6)	12.4 (-57.0 to 303.1)	17.5 (-55.6 to 316.5)	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.3)	17.5 (-56.6 to 295.8)	17.5 (-55.0 to 304.9)
Endometriosis	18.4 (15.7 to 21.3)	19.3 (16.3 to 22.3)	5.3 (-16.6 to 32.2)	4.9 (-16.9 to 31.2)	1.7 (1.1 to 2.4)	1.8 (1.2 to 2.5)	4.7 (-18.8 to 34.1)	4.8 (-18.6 to 33.9)
Genital prolapse	538.2 (481.2 to 600.5)	587.7 (525.3 to 650.6)	9.1 (-6.9 to 27.5)	-0.1 (-15.3 to 17.1)	1.7 (0.8 to 3.2)	1.9 (0.9 to 3.5)	9.3 (-7.2 to 28.0)	0.2 (-15.4 to 17.5)
Premenstrual syndrome	385.2 (260.4 to 513.6)	362.9 (254.8 to 494.0)	-5.3 (-42.9 to 46.9)	-3.2 (-41.7 to 49.7)	3.2 (1.8 to 5.3)	3.1 (1.7 to 5.1)	-5.3 (-43.2 to 47.8)	-3.0 (-42.1 to 50.9)
Other gynecological diseases	29.6 (24.6 to 35.4)	30.5 (26.3 to 35.0)	3.6 (-16.6 to 26.1)	3.0 (-16.8 to 24.1)	0.8 (0.5 to 1.2)	0.8 (0.5 to 1.2)	5.7 (-23.7 to 46.3)	5.3 (-23.5 to 43.4)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	9.1 (6.0 to 13.0)	7.9 (5.2 to 11.6)	-13.8 (-20.8 to -3.1)	-4.1 (-11.3 to 11.8)
Thalassemias	0.4 (0.1 to 0.7)	0.3 (0.1 to 0.5)	-27.8 (-34.9 to -18.5)	-2.1 (-12.0 to 10.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Thalassemia trait	262.6 (200.5 to 339.0)	254.0 (186.3 to 330.8)	-3.1 (-11.5 to 4.1)	-0.8 (-8.6 to 6.2)	7.0 (4.6 to 10.2)	6.0 (3.9 to 8.7)	-14.5 (-23.6 to 2.5)	-6.0 (-14.7 to 10.2)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.1 (-37.2 to -15.2)	-5.8 (-23.5 to 4.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.2 (-40.0 to -9.3)	-7.7 (-29.1 to 4.7)
Sickle cell trait	36.6 (27.4 to 49.2)	33.4 (23.6 to 46.2)	-7.5 (-26.0 to 14.4)	-5.2 (-24.0 to 3.9)	0.3 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-31.3 (-51.1 to 2.6)	-19.9 (-51.3 to 22.6)
G6PD deficiency	97.5 (72.8 to 122.6)	67.9 (20.0 to 108.2)	-30.3 (-79.1 to 14.3)	-28.2 (-78.6 to 17.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.7 (-25.6 to -10.4)	0.1 (-18.2 to 3.0)
G6PD trait	1,299.0 (1,207.7 to 1,381.1)	1,274.5 (1,178.5 to 1,365.6)	-1.8 (-11.7 to 8.8)	-0.8 (-10.8 to 9.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-23.5 (-65.4 to 73.8)	-11.9 (-65.9 to 94.2)
Other hemoglobinopathies and hemolytic anemias	75.2 (68.3 to 83.5)	78.0 (71.1 to 85.2)	3.8 (-8.9 to 17.5)	4.6 (-8.7 to 18.8)	1.7 (1.0 to 2.5)	1.6 (1.0 to 2.4)	-5.6 (-26.1 to 25.9)	7.8 (-15.3 to 42.7)
Endocrine, metabolic, blood, and immune disorders	126.7 (119.5 to 134.7)	122.8 (117.3 to 128.1)	-3.2 (-9.5 to 3.9)	1.2 (-5.1 to 8.6)	4.0 (2.7 to 5.6)	3.7 (2.5 to 5.3)	-7.6 (-15.9 to 2.4)	1.1 (-7.0 to 11.7)
Musculoskeletal disorders	-	-	-	-	299.1 (169.2 to 316.4)	285.3 (203.6 to 377.1)	-4.6 (-10.8 to 2.8)	2.7 (-4.7 to 10.8)
Rheumatoid arthritis	14.3 (13.3 to 15.2)	25.0 (23.4 to 26.8)	75.4 (59.3 to 92.5)	41.1 (28.7 to 54.6)	3.3 (2.4 to 4.4)	5.8 (4.1 to 7.7)	73.8 (56.0 to 94.9)	41.6 (26.9 to 57.7)
Osteoarthritis	494.3 (473.5 to 513.8)	666.6 (640.9 to 690.0)	35.0 (27.1 to 42.3)	1.2 (-4.6 to 6.7)	30.1 (21.2 to 41.4)	40.6 (28.5 to 55.3)	34.7 (26.5 to 42.3)	1.7 (-4.3 to 7.3)
Low back and neck pain	-	-	-	-	180.7 (125.5 to 242.3)	207.1 (142.5 to 278.2)	1.3 (3.2 to 27.6)	1.3 (-8.8 to 12.6)
Low back pain	1,243.6 (1,152.8 to 1,339.4)	1,423.7 (1,287.0 to 1,554.5)	14.0 (2.0 to 30.6)	-0.4 (-10.8 to 14.1)	43.0 (92.8 to 192.1)	49.9 (106.9 to 219.0)	16.2 (1.6 to 30.1)	4.4 (-10.5 to 14.4)
Neck pain	440.1 (362.9 to 511.1)	510.1 (425.4 to 599.6)	16.1 (-6.2 to 45.0)	4.1 (-16.3 to 29.1)	4.1 (28.9 to 61.2)	4.9 (32.4 to 69.8)	16.2 (-6.0 to 45.2)	4.4 (-15.7 to 29.9)
Gout	5.0 (4.7 to 5.3)	6.3 (5.9 to 6.7)	25.6 (14.4 to 37.9)	0.7 (-8.0 to 10.1)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	25.2 (-3.0 to 58.8)	1.2 (-21.5 to 26.8)
Other musculoskeletal disorders	271.7 (211.1 to 331.5)	347.9 (275.9 to 429.5)	27.7 (17.6 to 39.8)	8.4 (0.6 to 17.8)	24.7 (16.0 to 36.0)	31.6 (20.6 to 46.3)	27.8 (17.6 to 40.1)	9.0 (1.0 to 19.1)
Other non-communicable diseases	-	-	-	-	159.9 (106.1 to 230.8)	175.8 (117.7 to 255.3)	10.0 (-5.9 to 14.2)	-5.1 (-9.2 to -2.0)
Congenital anomalies	-	-	-	-	11.0 (7.9 to 14.4)	12.4 (8.8 to 16.2)	12.5 (-1.9 to 29.6)	12.7 (-2.0 to 30.5)
Neural tube defects	2.8 (2.3 to 3.4)	2.2 (1.8 to 2.6)	-20.1 (-37.9 to 0.5)	-12.3 (-31.6 to 10.6)	0.9 (0.6 to 1.3)	0.7 (0.5 to 1.1)	-17.3 (-44.4 to 14.7)	-8.9 (-38.5 to 28.3)
Congenital heart anomalies	55.4 (45.3 to 68.6)	61.3 (51.3 to 71.5)	12.1 (-16.8 to 40.1)	17.3 (-12.7 to 46.2)	1.9 (0.7 to 3.2)	2.2 (0.9 to 3.8)	17.1 (-12.7 to 43.8)	24.0 (-6.8 to 52.6)
Crofacial clefts	9.8 (7.7 to 12.4)	11.8 (9.5 to 15.2)	22.5 (-12.5 to 62.8)	25.6 (-10.3 to 66.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-19.9 (-47.0 to 15.1)	-17.4 (-45.6 to 20.1)
Down syndrome	9.0 (6.8 to 11.6)	11.6 (9.4 to 14.3)	27.5 (-7.2 to 84.9)	24.0 (-9.9 to 79.1)	1.3 (0.8 to 1.8)	1.8 (1.3 to 2.4)	30.1 (3.3 to 105.0)	40.8 (-6.8 to 89.2)
Turner syndrome	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.5)	-0.5 (-37.7 to 55.1)	6.3 (-33.4 to 65.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.2 (-39.2 to 63.2)	7.1 (-35.1 to 72.4)
Klinefelter syndrome	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	1.8 (-34.0 to 45.1)	6.7 (-30.8 to 52.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.8 (-33.1 to 47.4)	6.2 (-31.4 to 51.4)
Chromosomal unbalanced rearrangements	16.6 (13.3 to 21.6)	19.2 (16.0 to 23.3)	17.2 (-11.4 to 53.0)	14.2 (-13.8 to 49.0)	2.3 (1.6 to 3.2)	2.9 (2.1 to 3.9)	29.9 (-2.4 to 72.8)	29.0 (-10.1 to 58.3)
Other congenital anomalies	33.1 (26.7 to 38.7)	30.1 (25.0 to 35.2)	-8.3 (-17.6 to 1.9)	-0.4 (-18.9 to 0.2)	4.5 (3.0 to 6.4)	4.6 (3.1 to 6.4)	1.9 (-16.7 to 35.0)	6.1 (-13.3 to 41.5)
Skin and subcutaneous diseases	-	-	-	-	47.2 (30.7 to 69.6)	43.7 (28.4 to 64.8)	-7.2 (-14.9 to -0.7)	-7.6 (-14.7 to -1.2)
Dermatitis	455.4 (382.8 to 539.3)	457.0 (384.7 to 536.8)	0.3 (-1.1 to 2.0)	-0.0 (-0.0 to 0.0)	11.9 (7.6 to 17.3)	11.7 (7.5 to 17.1)	-1.3 (-4.6 to 2.2)	0.4 (-2.5 to 3.1)
Psoriasis	83.8 (73.5 to 93.9)	89.8 (78.9 to 100.7)	7.1 (5.4 to 9.5)	0.0 (-0.0 to 0.0)	6.8 (4.6 to 9.5)	7.3 (4.9 to 10.2)	6.9 (0.9 to 13.4)	0.4 (-5.0 to 6.4)
Cellulitis	1.5 (1.2 to 2.0)	1.6 (1.2 to 2.0)	2.6 (-10.6 to 19.5)	0.7 (-10.8 to 15.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	1.9 (-18.5 to 28.0)	1.3 (-18.9 to 26.1)
Pyoderma	9.4 (7.5 to 11.9)	9.8 (7.7 to 12.4)	3.6 (-4.0 to 11.7)	5.3 (0.6 to 11.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	2.9 (-7.4 to 15.2)	5.7 (-3.0 to 15.7)
Scabies	19.9 (18.0 to 22.1)	15.1 (13.9 to 16.6)	-24.0 (-33.4 to -13.5)	-19.7 (-29.9 to -8.4)	0.5 (0.3 to 0.8)	0.4 (0.2 to 0.6)	-24.0 (-34.1 to -11.6)	-19.5 (-30.7 to -6.2)
Fungal skin diseases	785.2 (614.0 to 1,025.9)	819.5 (645.7 to 1,054.3)	4.4 (0.6 to 8.6)	0.0 (-0.0 to 0.1)	4.4 (1.8 to 9.6)	4.6 (1.8 to 9.8)	4.2 (0.2 to 8.6)	0.3 (-0.6 to 1.2)
Viral skin diseases	198.6 (154.3 to 243.7)	178.9 (132.6 to 221.0)	-12.4 (-15.7 to -8.6)	-9.0 (-1.8 to 9.5)	5.4 (3.6 to 9.5)	5.4 (3.2 to 8.4)	-22.4 (-24.7 to -8.2)	-1.3 (-2.9 to 3.4)
Acne vulgaris	226.9 (170.5 to 282.5)	224.1 (172.6 to 270.2)	-2.2 (-24.4 to 41.7)	-2.2 (-16.2 to 57.9)	2.5 (1.1 to 4.7)	2.4 (1.1 to 4.5)	-2.1 (-16.7 to 41.4)	5.7 (-16.3 to 57.9)
Alopecia areata	12.0 (10.6 to 13.4)	13.1 (11.5 to 14.9)	9.7 (-7.8 to 32.8)	1.2 (-14.8 to 21.9)	0.4 (0.2 to 0.6)	0.4 (0.3 to 0.7)	9.3 (-8.4 to 34.8)	1.7 (-15.1 to 24.5)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-15.5 to 38.3)	0.0 (-23.8 to 23.2)	0.0 (-15.7 to 38.4)	-
Urticaria	171.1 (127.0 to 214.4)	108.2 (72.5 to 146.5)	-35.8 (-59.0 to -13.4)	-37.1 (-58.7 to -14.6)	10.1 (6.1 to 15.7)	6.4 (3.6 to 10.1)	-35.9 (-59.1 to -13.1)	-36.6 (-59.3 to -13.3)
Decubitus ulcer	1.6 (1.3 to 1.9)	2.9 (2.1 to 3.6)	85.6 (26.6 to 138.8)	33.7 (-7.3 to 69.0)	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	0.2 (-22.4 to 144.6)	0.4 (-8.7 to 78.6)
Other skin and subcutaneous diseases	695.2 (417.7 to 1,149.9)	772.2 (438.0 to 1,353.3)	10.4 (0.5 to 20.5)	-4.9 (-8.7 to -1.5)	4.1 (1.6 to 8.8)	4.5 (1.8 to 10.2)	10.3 (0.3 to 20.6)	-4.5 (-8.5 to -0.9)
Sense organ diseases	-	-	-	-	77.8 (50.3 to 113.3)	90.5 (59.7 to 131.2)	16.4 (10.1 to 23.0)	-9.2 (-14.0 to -4.2)
Glaucoma	11.2 (9.3 to 13.5)	11.8 (9.7 to 14.5)	5.8 (-15.2 to 29.6)	-14.3 (-30.3 to 3.6)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.7)	10.5 (9.3 to 32.2)	-4.7 (-27.9 to 1.6)
Cataract	119.2 (93.7 to 146.4)	125.3 (99.2 to 153.9)	5.2 (-12.2 to 26.0)	-29.5 (-40.9 to -36.7)	4.1 (2.6 to 6.0)	4.7 (2.7 to 6.6)	8.4 (9.0 to 28.1)	0.7 (-39.3 to -15.6)
Macular degeneration	30.2 (22.5 to 38.0)	47.0 (34.3 to 62.2)	54.4 (18.1 to 110.8)	18.5 (-8.9 to 57.8)	1.0 (0.6 to 1.6)	1.6 (0.9 to 2.5)	55.6 (18.4 to 108.6)	17.9 (-8.9 to 54.0)
Uncorrected refractive error	938.5 (769.8 to 1,103.9)	1,122.9 (948.7 to 1,319.4)	20.1 (8.2 to 56.4)	-2.0 (-25.6 to 26.8)	14.2 (8.1 to 23.4)	15.8 (8.7 to 26.9)	10.4 (-7.1 to 33.6)	-8.6 (-23.5 to 10.3)
Age-related and other hearing loss	1,863.4 (1,649.8 to 2,056.4)	2,170.3 (1,934.3 to 2,371.8)	16.4 (11.4 to 21.6)	-8.2 (-11.6 to -4.1)	49.5 (32.4 to 71.7)	60.0 (40.2 to 85.8)	21.4 (13.5 to 30.6)	-8.6 (-14.0 to -2.1)
Other vision loss	61.1 (52.6 to 71.3)	49.4 (42.3 to 58.2)	-19.0 (-29.6 to -7.4)	-19.0 (-37.4 to -19.9)	2.5 (1.6 to 3.7)	2.2 (1.5 to 3.2)	-11.1 (-22.5 to 0.3)	-25.7 (-34.3 to -16.6)
Other sense organ diseases	229.8 (219.6 to 240.7)	230.5 (220.0 to 241.4)	0.3 (-6.1 to 7.2)	-0.3 (-6.7 to 6.0)	6.1 (3.8 to 8.9)	6.0 (3.7 to 8.9)	-0.4 (-7.7 to 7.1)	-0.2 (-7.1 to 7.4)
Oral disorders	-	-	-	-	24.0 (14.0 to 37.7)	29.2 (17.7 to 45.2)	22.4 (15.7 to 29.1)	1.9 (-2.5 to 6.6)
Deciduous caries	657.7 (635.8 to 682.0)	425.1 (409.1 to 442.1)	-35.3 (-38.9 to -31.6)	-0.1 (-5.6 to 5.7)	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.2)	-35.5 (-40.5 to -29.3)	-0.3 (-8.1 to 9.5)
Permanent caries	4,145.1 (3,781.9 to 4,510.3)	4,091.6 (3,542.7 to 4,505.1)	-1.2 (-15.2 to 11.2)	-2.8 (-15.9 to 11.5)	2.4 (1.1 to 4.7)	2.1 (1.0 to 4.6)	2.1 (-15.8 to 11.1)	2.1 (-16.2 to 11.6)
Periodontal diseases	1,096.1 (998.3 to 1,200.0)	1,279.4 (1,176.3 to 1,396.2)	16.2 (4.1 to 31.4)	-0.3 (-10.6 to 12.4)	7.1 (2.8 to 14.9)	8.3 (3.3 to 17.3)	16.5 (4	

Appendix Table G.4 - Serbia prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Other oral disorders	179.7 (169.4 to 189.9)	188.0 (178.8 to 198.6)	4.7 (-3.0 to 12.7)	-4.2 (-7.3 to 7.9)	5.2 (3.3 to 7.8)	5.5 (3.4 to 8.2)	4.5 (-3.3 to 13.3)	0.1 (-7.4 to 8.6)
Injuries	-	-	-	-	115.8 (88.1 to 149.6)	67.5 (48.5 to 91.1)	-42.0 (-49.0 to -33.2)	-51.6 (-57.4 to -44.4)
Transport injuries	-	-	-	-	18.4 (13.7 to 23.8)	5.2 (3.7 to 7.0)	-71.8 (-75.6 to -66.7)	-74.9 (-78.2 to -70.5)
Road injuries	-	-	-	-	15.0 (11.2 to 19.5)	4.2 (3.0 to 5.7)	-72.1 (-76.2 to -66.8)	-75.1 (-78.7 to -70.4)
Pedestrian road injuries	-	-	-	-	3.4 (2.5 to 4.5)	1.1 (0.8 to 1.5)	-69.0 (-74.4 to -62.6)	-73.0 (-77.6 to -67.5)
Cyclist road injuries	-	-	-	-	2.5 (1.8 to 3.3)	0.7 (0.5 to 0.9)	-73.7 (-77.2 to -69.6)	-76.5 (-79.7 to -72.8)
Motorcyclist road injuries	-	-	-	-	1.5 (1.1 to 1.9)	0.5 (0.3 to 0.7)	-67.0 (-72.2 to -60.2)	-70.3 (-74.9 to -64.2)
Motor vehicle road injuries	-	-	-	-	7.4 (5.5 to 9.6)	2.0 (1.4 to 2.6)	-73.8 (-77.7 to -68.7)	-76.3 (-79.8 to -71.6)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.0)	-81.8 (-84.5 to -78.5)	-84.0 (-86.3 to -81.2)
Other transport injuries	-	-	-	-	3.4 (2.5 to 4.4)	1.0 (0.7 to 1.3)	-70.7 (-74.6 to -65.6)	-74.1 (-77.5 to -69.7)
Unintentional injuries	-	-	-	-	95.8 (73.0 to 123.9)	61.1 (44.1 to 82.5)	-36.6 (-44.1 to -27.3)	-47.6 (-53.8 to -39.8)
Falls	-	-	-	-	76.9 (58.5 to 99.1)	53.9 (38.9 to 73.0)	-30.2 (-39.2 to -19.3)	-43.6 (-50.8 to -34.7)
Drowning	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.2)	-46.4 (-54.4 to -36.8)	-53.3 (-60.1 to -45.2)
Fire, heat, and hot substances	-	-	-	-	1.2 (0.9 to 1.5)	0.7 (0.5 to 1.0)	-41.8 (-51.9 to -28.7)	-46.0 (-55.4 to -33.8)
Poisonings	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-50.7 (-58.4 to -40.4)	-54.3 (-61.6 to -44.4)
Exposure to mechanical forces	-	-	-	-	12.2 (9.0 to 15.9)	4.2 (3.0 to 5.8)	-65.6 (-70.0 to -59.9)	-66.4 (-71.0 to -60.5)
Unintentional firearm injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.1)	-65.5 (-70.7 to -59.1)	-68.0 (-72.7 to -62.3)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-80.4 (-83.4 to -75.6)	-81.4 (-84.4 to -76.2)
Other exposure to mechanical forces	-	-	-	-	11.8 (8.7 to 15.4)	4.1 (3.0 to 5.7)	-65.4 (-69.9 to -59.7)	-66.2 (-70.9 to -60.3)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	23.3 (14.5 to 32.5)	2.0 (-5.1 to 9.7)
Animal contact	-	-	-	-	0.6 (0.4 to 0.8)	0.4 (0.3 to 0.6)	-26.0 (-33.0 to -16.7)	-30.9 (-37.4 to -22.6)
Venomous animal contact	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-19.8 (-30.4 to -5.9)	-24.2 (-34.9 to -10.8)
Non-venomous animal contact	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-29.1 (-37.2 to -18.9)	-34.2 (-41.2 to -25.4)
Foreign body	-	-	-	-	0.7 (0.5 to 0.9)	0.4 (0.3 to 0.5)	-45.5 (-53.1 to -36.0)	-49.1 (-56.2 to -40.5)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-39.9 (-50.8 to -26.3)	-45.3 (-54.9 to -33.1)
Foreign body in eyes	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-22.0 (-34.4 to -12.8)	-23.1 (-36.9 to -13.2)
Foreign body in other body part	-	-	-	-	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-58.3 (-65.3 to -48.0)	-61.6 (-68.2 to -52.8)
Other unintentional injuries	-	-	-	-	3.8 (2.8 to 4.9)	1.1 (0.8 to 1.4)	-71.8 (-76.7 to -65.9)	-74.1 (-78.7 to -68.1)
Self-harm and interpersonal violence	-	-	-	-	1.6 (1.2 to 2.1)	0.8 (0.6 to 1.2)	-47.7 (-53.8 to -39.8)	-55.4 (-60.5 to -49.1)
Self-harm	-	-	-	-	1.0 (0.7 to 1.3)	0.6 (0.4 to 0.8)	-42.7 (-49.4 to -34.6)	-52.1 (-57.6 to -45.5)
Interpersonal violence	-	-	-	-	0.6 (0.5 to 0.8)	0.3 (0.2 to 0.4)	-55.6 (-61.8 to -47.5)	-60.7 (-66.1 to -53.9)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-55.8 (-61.0 to -48.6)	-61.4 (-65.7 to -55.5)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-39.0 (-49.1 to -26.4)	-46.5 (-55.0 to -35.7)
Assault by other means	-	-	-	-	0.4 (0.3 to 0.5)	0.2 (0.1 to 0.2)	-58.6 (-64.4 to -50.9)	-63.2 (-68.3 to -56.7)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.3 (0.1 to 0.8)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	0.3 (0.1 to 0.8)	-	-

Appendix Table G.4 - Seychelles prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	5.8 (4.3 to 7.5)	9.0 (6.7 to 11.7)	56.2 (49.2 to 62.2)	56.2 (3.1 to 4.4)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.7 (0.5 to 1.0)	0.8 (0.6 to 1.1)	16.1 (11.1 to 32.3)	-3.5 (-16.3 to 9.5)
HIV/AIDS and tuberculosis	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	53.1 (37.7 to 78.0)	-11.0 (-19.8 to 1.9)
Tuberculosis	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	37.6 (29.0 to 49.1)	-19.0 (-24.4 to -12.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	37.1 (25.3 to 50.4)	-19.5 (-26.2 to -11.4)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	647.8 (288.1 to 9,601.7)	346.1 (139.5 to 5,401.9)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	514.7 (240.3 to 9,731.1)	230.9 (82.7 to 5,388.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	514.7 (238.4 to 9,844.4)	230.9 (82.5 to 4,03.9)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	370.6 (149.0 to 8,900.0)	193.6 (55.1 to 5,491.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	643.7 (281.9 to 18,295.0)	351.0 (138.7 to 11,127.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.0 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-3.7 (-19.2 to 12.4)	-22.9 (-34.6 to -9.8)
Diarrheal diseases	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-34.1 (-69.0 to 10.8)	-42.7 (-73.3 to -5.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-34.6 (-70.5 to 11.4)	-42.7 (-74.1 to -3.3)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.3 (53.8 to 27.0)	-36.0 (59.3 to 10.5)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.3 (-48.8 to 24.8)	-34.7 (-53.3 to 9.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.9 (-49.2 to 28.5)	-32.9 (54.5 to 12.1)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.5 (-60.7 to -3.0)	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.0 (-61.3 to -1.0)	-44.3 (-64.8 to -12.6)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	132.3 (94.7 to 1,667.3)	106.4 (95.5 to 1,497.5)
Lower respiratory infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.8 (24.6 to 82.2)	0.7 (-14.7 to 17.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.4 (18.9 to 90.7)	0.5 (-17.7 to 27.8)
Upper respiratory infections	2.4 (2.2 to 2.7)	3.1 (2.7 to 3.4)	27.4 (7.6 to 47.6)	1.4 (-14.4 to 17.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	26.7 (7.4 to 48.0)	1.4 (-13.8 to 18.1)
Otitis media	0.9 (0.8 to 1.0)	0.9 (0.9 to 1.0)	0.8 (-6.4 to 9.8)	-15.9 (-21.8 to -9.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.3 (7.4 to 12.1)	-14.7 (-21.8 to -6.1)
Meningitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.7 (-24.3 to 22.3)	-31.4 (-43.9 to -10.0)
Pneumococcal meningitis	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-11.9 (-33.8 to 14.3)	-41.4 (-55.4 to -23.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.8 (-41.7 to 13.2)	-41.1 (-57.4 to -21.2)
H influenzae type B meningitis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-15.7 (-43.4 to 62.1)	-38.0 (57.9 to 27.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.3 (-45.5 to 105.0)	-26.9 (57.7 to 58.7)
Meningococcal meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.8 (-35.7 to 71.7)	-36.1 (58.2 to 18.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.8 (-32.1 to 78.8)	-25.5 (54.4 to 23.2)
Other meningitis	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-8.2 (-31.0 to 40.6)	-35.0 (-50.5 to 4.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.6 (-28.9 to 71.9)	-25.5 (47.3 to 29.2)
Encephalitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	14.2 (-12.5 to 39.5)	-20.0 (-38.0 to -1.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.5 (7.4 to 52.1)	-15.0 (-33.1 to 6.3)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.4 (-90.7 to 562.2)	-31.0 (-93.1 to 381.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.4 (-90.8 to 562.5)	-31.0 (-93.1 to 381.6)
Whooping cough	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.9 (-13.6 to -12.3)	-9.3 (-10.1 to -8.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.4 (-42.1 to 30.7)	-8.8 (-39.6 to 35.0)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	865.4 (232.0 to 2,959.9)	629.7 (139.4 to 2,149.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	877.7 (269.7 to 2,572.5)	654.0 (189.7 to 1,830.9)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-60.3 (-65.8 to -53.8)	-58.4 (-64.1 to -51.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.4 (-78.2 to -30.7)	-59.5 (-76.7 to -27.8)
Varicella and herpes zoster	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	29.6 (13.8 to 51.3)	-1.0 (-13.6 to 15.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.1 (20.3 to 88.5)	-1.2 (-19.4 to 24.8)
Neglected tropical diseases and malaria	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	20.0 (-19.0 to 83.3)	-0.7 (-36.4 to 48.4)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.7 (-34.4 to 148.7)	5.0 (47.8 to 97.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.9 (-33.7 to 153.4)	6.1 (-47.7 to 103.0)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.6 (5.6 to 43.7)	-0.9 (-19.7 to 23.4)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.5 (-70.1 to 75.1)	-27.5 (-72.1 to 52.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.5 (-70.2 to 75.3)	-27.5 (-72.1 to 52.9)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.7 (-4.1 to 45.7)	0.5 (-18.8 to 25.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.7 (-4.3 to 45.8)	0.5 (-19.0 to 25.3)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-71.9 (-92.4 to -26.2)	-83.5 (-95.3 to -60.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.0 (-92.3 to -17.0)	-82.5 (-95.3 to -55.6)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.8 (16.7 to 91.3)	-8.7 (-18.4 to 26.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.8 (1.7 to 116.0)	-5.8 (-28.3 to 39.5)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	550.0 (545.4 to 555.3)	401.3 (397.8 to 405.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	544.6 (436.6 to 684.3)	398.7 (321.9 to 500.7)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.0 (-65.6 to 654.5)	-47.2 (-80.7 to 372.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.0 (-65.8 to 658.0)	-47.2 (-80.8 to 373.3)
Intestinal nematode infections	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	19.0 (24.3 to 97.5)	-2.4 (-40.1 to 62.0)
Ascariasis	12.5 (8.3 to 19.0)	16.1 (9.7 to 25.4)	27.7 (-33.7 to 141.2)	-3.3 (-51.0 to 86.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.6 (-60.1 to 292.7)	-4.4 (-68.6 to 233.5)
Trichuriasis	25.4 (18.0 to 36.2)	33.8 (22.0 to 49.6)	32.5 (-23.9 to 130.5)	0.8 (-44.1 to 72.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	24.1 (-56.6 to 249.9)	1.1 (-67.0 to 183.7)
Hookworm disease	12.9 (8.6 to 19.2)	17.6 (11.4 to 27.6)	36.3 (-25.0 to 159.0)	1.4 (-47.1 to 83.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	18.9 (-28.2 to 96.2)	-4.2 (-43.2 to 58.1)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	0.5 (0.4 to 0.6)	0.4 (0.3 to 0.6)	-10.5 (-36.0 to 35.0)	-5.5 (-32.6 to 46.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.5 (-44.2 to 83.2)	0.1 (-37.4 to 112.4)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-	-
Maternal hemorrhage	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	8.4 (-19.7 to 31.9)	-17.0 (-38.4 to 0.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Maternal sepsis and other maternal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.8 (-26.9 to 46.1)	-39.6 (-57.9 to -13.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.8 (-60.4 to 39.2)	-49.1 (-71.3 to -5.2)
Maternal hypertensive disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.4 (-9.5 to 24.0)	-23.2 (-29.1 to -10.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.1 (-22.0 to 36.5)	-22.5 (-40.3 to 2.7)
Obstructed labor	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	35.0 (26.2 to 44.7)	-14.5 (-19.6 to -8.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	34.5 (21.2 to 48.3)	-14.3 (-22.1 to -5.8)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.4 (-44.7 to 92.0)	-24.1 (-60.5 to 35.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.4 (-60.5 to 35.5)	-24.1 (-60.5 to 35.5)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.8 (-49.6 to 148.5)	-25.6 (-66.1 to 64.0)
Neonatal disorders	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	88.7 (35.7 to 174.6)	51.1 (8.9 to 119.3)
Preterm birth complications	0.3 (0.2 to 0.5)	0.8 (0.4 to 1.4)	147.0 (81.0 to 227.7)	88.6 (39.4 to 149.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	123.9 (46.2 to 254.6)	76.8 (16.0 to 178.0)
Neonatal encephalopathy due to birth asphyxia and trauma	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.4)	5.9 (-23.5 to 54.6)	-18.0 (-41.5 to 18.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.9 (-32.4 to 69.4)	-16.5 (-43.9 to 38.3)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.1 (81.1 to 97.9)	94.1 (91.1 to 111.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.7 (63.0 to 113.1)	97.9 (73.8 to 127.1)
Hemolytic disease and other neonatal jaundice	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	112.6 (-1.7 to 487.0)	69.5 (-22.1 to 371.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.6 (-6.6 to 513.9)	66.6 (-25.3 to 384.2)
Other neonatal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	107.0 (0.1 to 310.3)	65.7 (-19.9 to 227.9)
Nutritional deficiencies	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-12.9 (-29.6 to 0.9)	-11.5 (-29.3 to 2.1)
Protein-energy malnutrition	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-20.7 (-67.4 to 50.3)	-27.8 (-65.8 to 55.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-68.0 to 48.7)	-29.0 (-66.5 to 54.7)
Iodine deficiency	0.6 (0.1 to 1.3)	0.8 (0.4 to 1.2)	31.7 (-60.3 to 596.0)	-15.4 (-74.8 to 349.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.0 (-61.1 to 608.3)	-16.1 (-74.7 to 358.9)
Vitamin A deficiency	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-35.3 (-51.2 to -16.8)	-45.9 (-57.3 to -32.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.1 (-49.2 to -14.1)	-46.4 (-57.3 to -33.3)

Appendix Table G.4 - Seychelles prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	6.5 (6.2 to 6.8)	6.6 (5.9 to 7.0)	1.4 (-9.7 to 8.3)	6.7 (-17.4 to 0.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-7.8 (-26.9 to 2.2)	-3.9 (-24.1 to 6.5)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-	-
Sexually transmitted diseases excluding HIV	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.3 (-18.6 to 21.0)	-43.0 (-53.7 to -32.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Chlamydial infection	1.5 (1.3 to 1.8)	2.3 (1.9 to 2.7)	52.9 (22.1 to 91.6)	7.2 (-14.0 to 34.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Gonococcal infection	0.6 (0.4 to 0.7)	0.6 (0.4 to 0.8)	2.5 (-30.7 to 80.3)	-20.4 (-45.5 to 39.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trichomoniasis	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	49.3 (-10.3 to 224.6)	-12.3 (-47.1 to 73.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Genital herpes	6.6 (6.2 to 7.0)	10.5 (9.8 to 11.1)	59.6 (47.0 to 74.0)	7.6 (-14.8 to 0.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other sexually transmitted diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.3 (1.3 to 60.5)	-26.9 (-43.0 to -8.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hepatitis A	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	3.9 (3.3 to 4.4)	-8.7 (-9.2 to -8.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hepatitis B	7.4 (5.4 to 9.2)	6.5 (5.2 to 8.2)	-14.3 (-36.0 to 31.4)	-41.8 (-56.5 to -23.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hepatitis C	1.9 (1.7 to 2.1)	2.3 (2.0 to 2.5)	17.7 (2.3 to 38.0)	-26.5 (-35.1 to -14.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hepatitis E	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.1 (-13.2 to 51.4)	-18.0 (-37.6 to 7.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.5 (-24.8 to 1,472.0)	10.3 (-56.5 to 781.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other infectious diseases	0.3 (0.3 to 0.4)	0.3 (0.3 to 0.4)	-7.7 (-27.1 to 36.5)	-5.9 (-25.9 to 42.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Non-communicable diseases	-	-	-	-	3.6 (3.6 to 6.3)	5.9 (5.9 to 10.3)	63.8 (56.0 to 70.1)	3.0 (-1.4 to 6.6)
Neoplasms	0.0	0.0	0.0	0.1	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	158.6 (107.4 to 200.5)	54.7 (22.4 to 81.3)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.8 (-8.6 to 99.2)	-24.9 (-48.2 to 10.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Stomach cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.2 (-7.9 to 34.2)	-36.5 (-47.9 to -23.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	461.4 (162.8 to 961.4)	203.8 (42.0 to 489.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,129.2 (443.8 to 2,457.6)	595.9 (208.6 to 1,311.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	240.7 (85.2 to 556.7)	98.9 (9.5 to 283.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	147.0 (28.8 to 382.9)	38.0 (-29.5 to 175.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Larynx cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	287.8 (6.2 to 441.6)	121.0 (-40.9 to 209.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.2 (-12.0 to 46.8)	-37.4 (-47.8 to -13.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Breast cancer	0.1 (0.1 to 0.2)	0.6 (0.5 to 0.7)	390.5 (275.8 to 518.5)	163.2 (104.1 to 229.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-	-
Cervical cancer	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	14.5 (-35.6 to 34.6)	-5.5 (-66.1 to -29.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Uterine cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	18.5 (-18.5 to 109.9)	-34.4 (55.0 to 20.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Prostate cancer	0.1 (0.1 to 0.3)	0.8 (0.5 to 1.1)	522.7 (180.6 to 893.7)	301.8 (80.1 to 540.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	-	-
Colon and rectum cancer	0.2 (0.2 to 0.2)	0.4 (0.4 to 0.4)	81.6 (62.2 to 101.4)	8.7 (-3.0 to 20.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Lip and oral cavity cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	136.3 (11.4 to 240.4)	32.9 (-37.1 to 95.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.8 (-5.2 to 26.0)	-53.3 (-76.5 to -39.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	102.2 (19.9 to 223.6)	9.2 (-35.0 to 72.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	184.3 (-15.0 to 310.0)	71.8 (-49.0 to 147.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	195.9 (131.4 to 289.3)	78.7 (-39.8 to 136.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.4 (30.8 to 241.4)	6.1 (-29.7 to 83.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.2 (25.2 to 226.1)	13.8 (-25.8 to 96.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Ovarian cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	251.3 (158.0 to 387.8)	91.9 (42.1 to 166.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	438.7 (87.7 to 963.0)	196.3 (-4.3 to 470.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Kidney cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	808.6 (561.5 to 1,176.7)	408.3 (268.2 to 603.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Bladder cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	26.8 (1.3 to 143.1)	-24.6 (-39.8 to 41.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.1 (-26.6 to 150.6)	-42.1 (-58.8 to 43.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Thyroid cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	79.5 (30.7 to 178.6)	-2.3 (-23.8 to 56.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.3 (-29.2 to 35.9)	-38.8 (-57.0 to -15.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.9 (-72.7 to 148.1)	-75.9 (83.1 to 59.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Non-Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	740.3 (84.8 to 1,061.3)	410.1 (10.7 to 594.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.2 (8.8 to 250.4)	3.1 (-40.8 to 95.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leukemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	560.7 (386.1 to 756.7)	382.0 (240.1 to 496.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neoplasms	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	254.5 (148.8 to 361.9)	139.2 (69.5 to 207.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cardiovascular diseases	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	102.8 (65.4 to 144.3)	21.0 (-0.9 to 44.0)
Rheumatic heart disease	0.9 (0.7 to 1.1)	1.4 (1.1 to 1.6)	55.9 (14.3 to 102.8)	0.6 (-26.0 to 31.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-	-
Ischemic heart disease	0.5 (0.4 to 0.6)	0.9 (0.7 to 1.0)	80.1 (32.0 to 130.0)	9.9 (-20.4 to 42.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	-	-
Cerebrovascular disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-	-
Ischemic stroke	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	69.3 (37.9 to 103.2)	3.4 (-16.3 to 24.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hemorrhagic stroke	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	71.2 (38.5 to 105.4)	1.8 (-17.6 to 23.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hypertensive heart disease	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	70.9 (41.5 to 109.3)	0.5 (-18.0 to 22.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cardiomyopathy and myocarditis	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	86.9 (55.9 to 125.3)	7.6 (-11.2 to 31.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Atrial fibrillation and flutter	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	150.1 (88.4 to 227.3)	47.6 (11.3 to 94.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Peripheral vascular disease	2.2 (1.9 to 2.6)	4.0 (3.3 to 4.7)	80.0 (38.2 to 127.2)	-3.9 (-25.7 to 20.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.7 (-7.5 to 72.2)	-23.4 (-46.5 to 0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other cardiovascular and circulatory diseases	0.6 (0.4 to 0.8)	1.9 (0.9 to 2.5)	208.6 (45.1 to 410.0)	75.6 (-16.9 to 197.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	-	-
Chronic respiratory diseases	-	-	-	-	0.3 (0.2 to 0.5)	0.5 (0.4 to 0.7)	51.7 (35.7 to 70.4)	-10.5 (-19.3 to -0.2)
Chronic obstructive pulmonary disease	2.3 (2.2 to 2.5)	4.0 (3.7 to 4.3)	72.7 (65.7 to 80.3)	-0.8 (-4.4 to 3.3)	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	72.1 (48.2 to 93.9)	-1.2 (-15.3 to 11.2)

Appendix Table G.4 - Seychelles prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	154.0	60.0
Silicosis	0.0	0.0	54.4	-11.5	0.0	0.0	(163.7 to 205.8)	(48.0 to 73.3)
Asbestosis	-	-	0.0	0.0	-	-	53.7	-12.0
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	252.3	100.6	0.0	0.0	241.0	93.4
Asthma	2.1	2.3	10.6	-29.7	0.1	0.1	8.9	-30.4
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	78.5	4.4	0.0	0.0	78.8	3.9
Other chronic respiratory diseases	-	-	-	-	0.0	0.0	18.3	-31.7
Cirrhosis	-	-	-	-	0.0	0.0	72.6	-4.1
Cirrhosis due to hepatitis B	0.0	0.0	77.3	-4.4	0.0	0.0	49.3 to 97.2	(-16.5 to 8.9)
Cirrhosis due to hepatitis C	0.0	0.0	134.5	25.5	0.0	0.0	136.0	25.8
Cirrhosis due to alcohol use	0.0	0.0	35.4	-28.8	0.0	0.0	23.3 to 315.9	(-41.4 to 120.4)
Cirrhosis due to other causes	0.0	0.0	79.2	25.1	0.0	0.0	80.1	24.9
Digestive diseases	-	-	-	-	0.0	0.0	85.6 to 188.1	(-21.8 to 94.1)
Peptic ulcer disease	0.4	0.3	-8.6	-45.8	0.0	0.0	3.9 to 20.1	(-31.1 to -20.7)
Gastritis and duodenitis	0.8	0.8	3.7	-30.4	0.0	0.0	-5.9	-44.9
Appendicitis	0.0	0.0	12.8	-21.7	0.0	0.0	13.0	-20.3
Paralytic ileus and intestinal obstruction	0.0	0.0	75.5	19.6	0.0	0.0	75.4	19.7
Inguinal, femoral, and abdominal hernia	0.1	0.2	50.8	-5.2	0.0	0.0	50.4	-5.9
Inflammatory bowel disease	0.0	0.0	80.8	5.1	0.0	0.0	79.9	4.7
Vascular intestinal disorders	0.0	0.0	49.0	-6.0	0.0	0.0	50.4	-4.8
Gallbladder and biliary diseases	0.0	0.0	194.6	-25.2	0.0	0.0	180.0	-26.2
Pancreatitis	0.0	0.0	106.9	16.5	0.0	0.0	106.8	16.4
Other digestive diseases	-	-	-	-	0.0	0.0	29.7	-53.3
Neurological disorders	-	-	-	-	0.0	0.0	48.9 to 28.7	(-66.1 to -13.8)
Alzheimer disease and other dementias	0.5	0.7	53.3	-1.3	0.1	0.1	62.9	5.7
Parkinson disease	0.0	0.1	65.6	1.6	0.0	0.0	12.2	-1.8
Epilepsy	0.3	0.3	17.0	-10.8	0.1	0.1	64.8	0.5
Multiple sclerosis	0.0	0.0	234.0	78.8	0.0	0.0	234.0	78.8
Migraine	7.3	12.3	73.5	8.3	0.3	0.3	200.1 to 270.0	(61.3 to 97.7)
Tension-type headache	14.8	22.9	53.9	0.2	0.0	0.0	53.8	0.3
Medication overuse headache	0.2	0.6	158.3	48.8	0.0	0.1	156.7	48.6
Other neurological disorders	0.0	0.0	46.7	2.2	0.0	0.0	27.8	-18.1
Mental and substance use disorders	-	-	-	-	1.2	1.8	52.5	-1.3
Schizophrenia	0.2	0.4	79.4	0.6	0.1	0.2	45.6 to 59.8	(-4.6 to 2.1)
Alcohol use disorders	0.5	0.7	52.5	-6.2	0.0	0.1	52.3	-6.3
Drug use disorders	-	-	-	-	0.2	0.2	37.2	0.4
Opioid use disorders	0.1	0.1	72.9	2.4	0.0	0.1	10.6 to 68.7	(-18.1 to 21.9)
Cocaine use disorders	0.1	0.1	43.7	-5.9 to 12.3	0.0	0.0	50.5 to 103.3	(-10.4 to 16.4)
Amphetamine use disorders	0.4	0.5	25.2	-0.9	0.0	0.1	24.8	-1.0
Cannabis use disorders	0.2	0.3	30.8	2.9	0.0	0.0	30.2	2.6
Other drug use disorders	-	-	-	-	0.1	0.1	27.0	-0.6
Depressive disorders	-	-	-	-	0.4	0.6	63.1	2.0
Major depressive disorder	1.4	2.2	61.1	-2.2	0.3	0.4	60.1	-2.3
Dysthymia	0.8	1.4	73.8	-0.8	0.1	0.1	73.3	-1.0
Bipolar disorder	0.4	0.6	61.1	-0.8	0.1	0.1	60.6	-0.6
Anxiety disorders	1.8	2.7	56.5	-1.2	0.3	0.3	46.4 to 77.7	(-7.1 to 6.6)
Eating disorders	-	-	-	-	0.0	0.0	15.4	-2.6
Anorexia nervosa	0.0	0.0	11.6	-4.2	0.0	0.0	12.5	-3.3
Bulimia nervosa	0.0	0.0	17.1	-2.2	0.0	0.0	17.8	-1.8
Autistic spectrum disorders	-	-	-	-	0.1	0.1	32.5	1.2
Autism	0.2	0.3	33.5	1.1	0.1	0.1	28.0 to 37.5	(-2.1 to 4.7)
Asperger syndrome	0.3	0.4	33.5	1.5	0.0	0.0	32.7	1.4
Attention-deficit/hyperactivity disorder	0.5	0.5	-6.4	0.8	0.0	0.0	6.1	1.1
Conduct disorder	0.5	0.5	-6.4	0.8	0.0	0.0	12.8 to 0.6	(-6.0 to 8.1)
Idiopathic intellectual disability	0.4	0.4	21.2	-21.2	0.0	0.0	22.2	-37.7
Other mental and substance use disorders	1.0	1.7	69.5	1.2	0.1	0.1	69.0	1.1
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	0.6	1.2	106.0	30.4
Diabetes mellitus	3.7	10.9	195.4	67.1	0.2	0.7	194.4	65.4
Acute glomerulonephritis	0.0	0.0	17.6	-6.9	0.0	0.0	17.6	-6.9
Chronic kidney disease	-	-	-	-	0.1	0.1	49.4	-2.4
Chronic kidney disease due to diabetes mellitus	0.3	0.7	175.4	69.9	0.0	0.0	33.2 to 65.0	(-9.5 to 5.2)
Chronic kidney disease due to hypertension	0.5	0.3	-40.1	-54.5	0.0	0.0	60.2	0.2
Chronic kidney disease due to glomerulonephritis	0.6	0.8	26.4	-12.2	0.0	0.0	21.6 to 136.5	(-23.6 to 36.9)
Chronic kidney disease due to other causes	1.6	2.4	52.7	6.8	0.0	0.1	60.4	4.8
Urinary diseases and male infertility	-	-	-	-	0.0	0.1	79.5	10.8

Appendix Table G.4 - Seychelles prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.0 (69.4 to 96.4)	24.6 (15.8 to 34.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.4 (48.0 to 126.2)	24.3 (2.6 to 52.4)
Urolithiasis	0.4 (0.3 to 0.5)	0.8 (0.6 to 1.0)	0.8 (62.5 to 136.0)	17.3 (-6.4 to 35.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.6 (66.9 to 110.5)	7.8 (-4.0 to 21.0)
Benign prostatic hyperplasia	0.7 (0.7 to 0.8)	1.2 (1.1 to 1.3)	66.7 (47.3 to 93.2)	5.7 (-6.7 to 22.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	65.8 (46.4 to 92.7)	4.8 (-7.5 to 22.1)
Male infertility due to other causes	0.3 (0.2 to 0.5)	0.5 (0.4 to 0.7)	63.1 (-0.3 to 159.6)	4.3 (-35.3 to 66.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.7 (-2.7 to 158.4)	4.0 (-36.1 to 69.3)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	213.4 (36.1 to 402.6)	88.7 (-20.6 to 187.8)
Gynecological diseases	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	67.6 (42.3 to 95.9)	-5.3 (-18.5 to 10.8)
Uterine fibroids	1.1 (1.0 to 1.2)	2.5 (2.3 to 2.7)	126.6 (122.1 to 131.5)	-2.9 (-3.0 to -2.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.3 (91.2 to 151.3)	-4.3 (-13.2 to 12.4)
Polycystic ovarian syndrome	0.9 (0.8 to 1.1)	1.5 (1.3 to 1.7)	62.8 (29.1 to 104.2)	-7.6 (-26.0 to 14.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.4 (28.9 to 102.0)	-6.7 (-25.5 to 15.0)
Female infertility due to other causes	0.3 (0.1 to 0.5)	0.5 (0.1 to 0.8)	67.9 (-66.6 to 344.5)	8.8 (-75.8 to 100.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.8 (-63.6 to 334.0)	8.3 (-73.8 to 182.2)
Endometriosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	76.8 (43.8 to 121.3)	-3.2 (-21.1 to 20.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.4 (39.4 to 127.4)	-3.4 (-22.7 to 23.5)
Genital prolapse	2.8 (2.5 to 3.2)	5.0 (4.4 to 5.7)	77.2 (47.6 to 117.0)	-6.1 (-21.0 to 12.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.7 (47.1 to 118.8)	-6.2 (-21.0 to 12.7)
Premenstrual syndrome	2.7 (1.9 to 3.4)	3.9 (2.8 to 4.9)	43.0 (-10.3 to 125.0)	-7.1 (-40.3 to 50.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	42.9 (-9.8 to 122.6)	-7.1 (-40.1 to 48.1)
Other gynecological diseases	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	55.8 (2.6 to 95.6)	-9.2 (-38.6 to 13.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.8 (-11.4 to 145.5)	-22.5 (-53.3 to 29.5)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	2.3 (-6.5 to 10.6)	-7.8 (-16.4 to -0.5)
Thalassemias	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	4.0 (-3.5 to 19.0)	3.6 (-3.2 to 15.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.3 (-25.8 to 54.7)	3.0 (-26.4 to 53.9)
Thalassemia trait	5.1 (3.6 to 7.8)	6.7 (4.8 to 10.6)	32.0 (26.5 to 36.5)	-1.1 (-4.1 to 2.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	3.3 (5.7 to 11.1)	-8.0 (-16.3 to -1.9)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.4 (-4.7 to 76.1)	7.0 (-15.4 to 55.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.4 (-17.5 to 112.3)	7.3 (-28.5 to 83.7)
Sickle cell trait	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	34.0 (-9.5 to 88.2)	0.0 (-32.3 to 42.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.2 (-61.1 to 161.6)	-14.7 (-61.5 to 172.2)
G6PD deficiency	7.6 (5.1 to 10.0)	9.4 (6.3 to 12.9)	23.8 (-23.1 to 114.6)	-7.7 (-42.6 to 59.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.9 (-65.9 to 98.8)	-29.8 (-66.7 to 92.1)
G6PD trait	13.1 (11.5 to 14.4)	17.2 (15.0 to 19.0)	31.8 (11.8 to 55.4)	-2.1 (-17.0 to 15.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.3 (-62.2 to 472.5)	-8.9 (-65.9 to 293.3)
Other hemoglobinopathies and hemolytic anemias	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.4)	6.3 (-14.0 to 32.5)	-6.4 (-23.0 to 18.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.6 (-28.6 to 35.7)	-5.2 (-28.3 to 41.2)
Endocrine, metabolic, blood, and immune disorders	0.6 (0.5 to 0.6)	0.7 (0.7 to 0.8)	26.6 (10.0 to 44.3)	2.2 (-9.8 to 16.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.4 (10.4 to 57.9)	7.9 (-9.2 to 28.2)
Musculoskeletal disorders	-	-	-	-	0.8 (0.6 to 1.0)	1.4 (0.9 to 1.9)	74.8 (54.7 to 97.1)	-0.4 (-11.6 to 10.6)
Rheumatoid arthritis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	125.0 (94.0 to 158.3)	38.7 (19.0 to 59.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.4 (89.3 to 162.7)	37.8 (16.1 to 61.3)
Osteoarthritis	1.1 (1.0 to 1.2)	2.0 (1.9 to 2.2)	85.5 (71.1 to 102.5)	3.0 (-5.1 to 12.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	86.1 (70.8 to 103.3)	2.6 (-5.7 to 12.0)
Low back and neck pain	-	-	-	-	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.4)	72.9 (47.1 to 102.1)	-4.1 (-15.1 to 16.1)
Low back pain	3.6 (2.9 to 4.2)	6.3 (5.3 to 7.4)	76.9 (39.4 to 117.1)	2.5 (-17.5 to 24.7)	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.0)	76.6 (38.0 to 117.1)	2.3 (-18.1 to 24.5)
Neck pain	1.8 (1.5 to 2.1)	3.1 (2.3 to 3.8)	65.4 (21.8 to 132.5)	-5.7 (-29.4 to 34.0)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	64.8 (21.9 to 132.3)	-5.9 (-29.5 to 33.7)
Gout	0.0 (0.0 to 0.0)	0.0 (0.1 to 0.1)	107.5 (72.7 to 154.5)	9.4 (-8.9 to 34.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.6 (58.7 to 174.3)	9.2 (-14.1 to 44.2)
Other musculoskeletal disorders	1.4 (1.1 to 1.6)	2.4 (1.8 to 3.1)	72.6 (55.0 to 93.1)	8.1 (-16.2 to -0.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	71.1 (55.2 to 94.0)	-8.3 (-16.5 to -0.7)
Other non-communicable diseases	-	-	-	-	1.2 (0.8 to 1.7)	1.7 (1.1 to 2.3)	40.8 (33.0 to 48.7)	-6.5 (-10.4 to -2.0)
Congenital anomalies	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	68.3 (29.4 to 146.3)	31.9 (3.4 to 92.9)
Neural tube defects	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.5 (-5.0 to 33.8)	-6.0 (-21.5 to 10.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.0 (-14.6 to 48.2)	-5.5 (-28.7 to 24.7)
Congenital heart anomalies	0.3 (0.2 to 0.3)	0.5 (0.4 to 0.6)	57.7 (22.1 to 113.6)	23.9 (-4.0 to 67.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.1 (22.7 to 108.9)	26.3 (-1.3 to 66.6)
Orofacial clefts	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	49.4 (13.0 to 91.9)	19.8 (-9.2 to 54.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.2 (-12.8 to 80.2)	0.9 (-30.1 to 42.2)
Down syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	57.5 (21.0 to 112.1)	16.0 (-10.5 to 55.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.0 (30.2 to 134.4)	19.4 (-8.4 to 63.7)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.8 (-8.8 to 110.0)	5.8 (-29.3 to 64.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.4 (-9.8 to 120.1)	6.4 (-31.3 to 67.5)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.3 (0.4 to 104.3)	4.5 (-24.2 to 54.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.9 (-7.0 to 172.8)	3.1 (-36.3 to 83.5)
Chromosomal unbalanced rearrangements	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	50.2 (11.9 to 104.3)	6.6 (-17.6 to 50.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.7 (-19.9 to 123.2)	15.5 (-14.9 to 56.8)
Other congenital anomalies	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	9.3 (-8.3 to 24.7)	-17.6 (-30.5 to -4.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	78.0 (13.8 to 228.6)	44.6 (-7.3 to 161.8)
Skin and subcutaneous diseases	-	-	-	-	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.8)	37.3 (28.5 to 45.3)	0.1 (-6.0 to 4.9)
Dermatitis	3.3 (2.8 to 3.8)	4.8 (4.0 to 5.6)	45.7 (38.9 to 51.7)	-0.1 (-0.2 to 0.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	36.3 (27.9 to 43.6)	-0.2 (-3.0 to 2.6)
Psoriasis	0.5 (0.4 to 0.6)	0.8 (0.6 to 1.0)	57.8 (50.9 to 67.2)	0.0 (-0.2 to 0.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	56.9 (45.5 to 71.1)	-0.1 (-5.2 to 5.4)
Cellulitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.4 (32.4 to 66.5)	0.6 (-7.3 to 12.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.7 (14.0 to 88.1)	1.2 (-17.9 to 26.2)
Pyoderma	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-44.8 (-55.2 to -32.3)	-51.7 (-59.0 to -42.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.3 (-55.9 to -30.7)	-52.1 (-60.1 to -41.6)
Scabies	0.7 (0.7 to 0.8)	0.9 (0.8 to 1.0)	19.7 (3.1 to 43.7)	-11.7 (-23.6 to 4.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.3 (21.1 to 44.0)	-11.6 (-23.7 to 4.8)
Fungal skin diseases	9.0 (6.3 to 9.7)	11.4 (9.1 to 13.6)	42.3 (34.0 to 51.5)	0.4 (0.1 to 0.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	44.8 (34.5 to 51.2)	0.3 (-0.5 to 1.1)
Viral skin diseases	1.5 (1.2 to 1.9)	1.7 (1.2 to 2.2)	8.6 (1.0 to 15.8)	0.1 (-1.8 to 2.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	8.2 (0.1 to 16.3)	0.1 (-3.0 to 3.7)
Acne vulgaris	3.3 (2.4 to 4.3)	3.7 (2.7 to 4.9)	12.3 (-28.9 to 66.6)	0.6 (-36.7 to 48.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	12.3 (-29.1 to 65.6)	0.6 (-36.6 to 49.1)
Alopecia areata	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	56.5 (32.6 to 84.5)	2.0 (-13.4 to 21.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.7 (28.9 to 89.1)	1.9 (-15.7 to 24.0)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.2 (25.1 to 114.8)	1.6 (-21.7 to 34.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.6 (15.9 to 131.5)	0.9 (-27.0 to 42.2)
Urticaria	0.6 (0.4 to 0.8)	0.9 (0.7 to 1.2)	62.2 (13.1 to 148.2)	4.7 (-25.8 to 58.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	61.4 (11.3 to 145.4)	4.1 (-26.0 to 58.8)
Decubitus ulcer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.3 (2.2 to 95.4)	-5.5 (-35.6 to 27.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.3 (-0.1 to 98.8)	-7.5 (-37.4 to 29.8)
Other skin and subcutaneous diseases	4.6 (3.0 to 6.9)	7.6 (4.9 to 11.4)	64.8 (48.4 to 85.4)	-0.1 (-2.6 to 3.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	64.6 (47.6 to 84.8)	-0.3 (-3.1 to 3.4)
Sense organ diseases	-	-	-	-	0.9 (0.4 to 0.9)	0.9 (0.6 to 1.3)	30.8 (26.6 to 46.9)	-4.2 (-18.5 to -9.0)
Glaucoma	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	41.9 (-8.8 to 115.6)	-17.4 (-48.1 to 28.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.2 (0.0 to 103.5)	-14.2 (-41.5 to 21.8)
Cataract	0.8 (0.6 to 1.2)	1.0 (0.7 to 1.4)	17.9 (-1.1 to 52.0)	-26.1 (-37.9 to -7.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	19.8 (4.8 to 38.1)	-24.2 (-34.7 to -12.8)
Macular degeneration	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	118.3 (44.3 to 225.3)	22.5 (-18.0 to 85.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.8 (34.5 to 157.3)	8.4 (-21.5 to 57.9)
Uncorrected refractive error	5.3 (4.0 to 6.6)	8.2 (6.3 to 10.8)	52.0 (9.5 to 115.1)	4.3 (-30.9 to 39.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	35.8 (14.5 to 65.8)	-13.7 (-26.3 to 5.9)
Age-related and other hearing loss	11.0 (10.1 to 11.7)	17.3 (15.7 to 18.9)	57.4 (50.4 to 64.9)	-9.3 (-12.8 to -6.2)	0.4 (0.2 to 0.5)	0.5 (0.3 to 0.8)	41.7 (28.6 to 57.1)	-12.3 (-18.3 to -6.4)
Other vision loss	0.6 (0.5 to 0.8)	0.7 (0.5 to 0.9)	13.8 (8.4 to 36.9)	-27.5 (-42.8 to -14.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	15.6 (-3.6 to 37.5)	-28.5 (-40.1 to -14.5)
Other sense organ diseases	1.6 (1.6 to 1.7)	2.1 (2.0 to 2.2)	29.3 (21.3 to 38.2)	-0.1 (-6.7 to 6.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	28.3 (19.5 to 38.5)	-0.3 (-6.9 to 7.4)
Oral disorders	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	50.7 (43.3 to 61.0)	-4.4 (-10.5 to 2.7)
Deciduous caries	6.6 (6.2 to 7.0)	5.6 (5.3 to 5.9)	-14.8 (-22.7 to -7.7)	-6.6 (-9.6 to 7.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.9 (-23.7 to -6.0)	-9.7 (-11.2 to 9.7)
Permanent caries	19.6 (17.9 to 22.0)	28.4 (25.0 to 31.9)	44.7 (20.3 to 71.6)	1.9 (-15.7 to 21.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	44.3 (19.6 to 70.9)	1.8 (-15.4 to 20.9)
Periodontal diseases	2.0 (1.7 to 2.2)	3.8 (3.4 to 4.3)	92.4 (63.7 to 126.4)	1.9 (-13.4 to 20.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	92.3 (63.8 to 127.4)	1.4 (-14.1 to 20.1)

Appendix Table G.4 - Seychelles prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	0.6 (0.5 to 0.7)	0.8 (0.7 to 0.9)	32.0 (12.2 to 57.3)	-20.6 (-32.5 to -5.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.9 (12.0 to 57.1)	-20.8 (-32.9 to -5.6)
Other oral disorders	1.1 (1.1 to 1.2)	1.7 (1.6 to 1.8)	53.8 (42.5 to 66.4)	0.4 (-6.8 to 8.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	53.4 (41.1 to 66.4)	0.4 (-7.0 to 8.8)
Injuries	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	12.3 (1.9 to 24.9)	-33.0 (-39.0 to -26.0)
Transport injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	1.3 (-11.5 to 15.8)	-40.7 (-47.8 to -32.6)
Road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	46.2 (-11.0 to 17.6)	-40.2 (-47.8 to -31.6)
Pedestrian road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.2 (-10.2 to 22.6)	-36.2 (-45.0 to -26.5)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.4 (-7.8 to 21.0)	-36.5 (-44.7 to -27.8)
Motorcyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.5 (-17.5 to 14.1)	-44.7 (-52.4 to -35.2)
Motor vehicle road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.4 (-9.2 to 26.0)	-36.6 (-46.0 to -25.0)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.8 (-18.5 to 8.0)	-45.4 (-52.4 to -37.5)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.8 (-15.7 to 11.1)	-43.5 (-50.3 to -34.6)
Unintentional injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	25.9 (15.8 to 36.8)	-24.2 (-29.8 to -18.2)
Falls	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	55.2 (37.8 to 74.7)	-8.8 (-18.8 to 2.1)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.1 (-24.1 to 1.6)	-49.2 (-55.9 to -41.5)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.4 (-43.5 to -23.0)	-59.8 (-65.6 to -53.9)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.8 (-28.5 to 4.8)	-45.9 (-54.5 to -35.0)
Exposure to mechanical forces	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-10.7 (-19.1 to -1.6)	-45.5 (-49.7 to -40.8)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.8 (-44.0 to -28.2)	-62.4 (-66.3 to -57.6)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.2 (-4.9 to 21.5)	-30.0 (-37.3 to -21.1)
Other exposure to mechanical forces	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.3 (-17.8 to 0.3)	-44.6 (-49.0 to -39.5)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.5 (51.8 to 71.6)	2.1 (-3.6 to 9.1)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.8 (-29.4 to -7.8)	-48.5 (-54.1 to -41.4)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.0 (-29.4 to 1.6)	-46.3 (-55.0 to -36.1)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.0 (-34.7 to -12.8)	-50.6 (-56.6 to -43.9)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.1 (20.9 to 45.8)	-17.2 (-24.0 to -9.5)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.2 (-22.1 to 12.5)	-37.1 (-46.4 to -25.0)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.7 (33.6 to 52.9)	-8.1 (-14.6 to -1.4)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.4 (38.8 to 72.1)	-10.4 (-18.2 to -0.1)
Other unintentional injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	294.9 (249.5 to 342.3)	118.4 (94.8 to 144.7)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.3 (-34.9 to -15.2)	-97.4 (-62.1 to -51.3)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.8 (-24.9 to -5.4)	-54.0 (-58.8 to -48.4)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.7 (-36.6 to -16.3)	-57.9 (-62.7 to -51.4)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.2 (-27.4 to -9.6)	-51.8 (-56.3 to -46.5)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.3 (-30.4 to -5.9)	-54.0 (-59.8 to -46.0)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.2 (-40.2 to -19.8)	-59.9 (-64.9 to -53.7)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Sierra Leone prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.									
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013	
All causes	-	-	-	-	416.3 (303.3 to 551.9)	573.6 (416.6 to 748.9)	38.1 (28.3 to 46.8)	38.1 (-13.1 to -1.4)	
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	163.2 (111.6 to 228.3)	176.5 (122.6 to 238.7)	8.2 (8.5 to 28.8)	-30.0 (-42.1 to -13.6)	
HIV/AIDS and tuberculosis	-	-	-	-	4.8 (3.2 to 6.6)	18.2 (12.0 to 25.7)	273.3 (208.1 to 395.3)	122.6 (85.0 to 195.9)	
Tuberculosis	15.1 (14.0 to 16.3)	30.5 (28.8 to 32.4)	102.5 (88.9 to 116.3)	25.9 (17.9 to 34.0)	4.6 (3.1 to 6.2)	9.3 (6.3 to 12.6)	105.1 (89.7 to 120.8)	26.9 (17.8 to 35.9)	
HIV/AIDS	-	-	-	-	0.2 (0.1 to 0.2)	8.8 (5.0 to 14.5)	4,113.8 (1,242.8 to 11,221.5)	499.7 (701.8 to 7,163.1)	
HIV/AIDS resulting in mycobacterial infection	0.1 (0.0 to 0.2)	2.3 (1.2 to 3.8)	3,664.5 (1,087.6 to 11,228.5)	2,199.2 (617.9 to 6,846.7)	0.0 (0.0 to 0.1)	0.8 (0.4 to 1.5)	3,569.2 (1,076.2 to 11,255.1)	2,103.6 (613.6 to 7,773.1)	
HIV/AIDS resulting in other diseases	2.2 (0.7 to 5.5)	57.6 (39.3 to 83.2)	2,903.7 (903.4 to 8,034.7)	1,754.8 (532.1 to 4,951.8)	0.2 (0.1 to 0.6)	8.0 (4.3 to 13.6)	4,255.4 (1,152.3 to 14,363.7)	2,608.1 (640.6 to 9,348.0)	
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	26.0 (18.7 to 34.9)	22.3 (16.1 to 29.8)	-14.5 (-21.6 to -5.0)	-40.3 (-45.2 to -33.9)	
Diarrheal diseases	79.8 (72.1 to 86.9)	61.9 (56.8 to 66.9)	-22.5 (-31.5 to -12.0)	-46.0 (-51.5 to -39.4)	12.8 (8.7 to 17.9)	10.0 (6.8 to 13.9)	-27.0 (-31.5 to -11.6)	-45.7 (-51.5 to -39.2)	
Intestinal infectious diseases	-	-	-	-	0.4 (0.3 to 0.6)	0.2 (0.1 to 0.2)	0.2 (-71.9 to -49.4)	0.2 (-81.0 to -66.3)	
Typhoid fever	1.9 (1.6 to 2.2)	0.8 (0.7 to 1.0)	-57.5 (-65.8 to -46.3)	-71.5 (-77.5 to -63.9)	0.2 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-55.4 (-66.7 to -41.8)	-70.2 (-77.3 to -60.9)	
Paratyphoid fever	1.2 (1.0 to 1.5)	0.7 (0.5 to 0.8)	-45.6 (-61.7 to -29.1)	-64.1 (-74.2 to -53.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-44.5 (-62.6 to -24.3)	-63.1 (-74.3 to -49.9)	
Other intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-9.1 (-95.7 to -77.2)	-93.4 (-97.1 to -84.9)	
Lower respiratory infections	5.3 (4.3 to 6.8)	5.8 (4.6 to 6.9)	12.3 (-26.0 to 42.5)	-17.0 (-39.5 to 1.5)	0.6 (0.3 to 0.8)	0.5 (0.4 to 0.9)	12.6 (-27.5 to 46.0)	-16.8 (-46.0 to 3.4)	
Upper respiratory infections	147.0 (136.4 to 156.4)	217.0 (203.4 to 231.3)	47.6 (35.2 to 61.2)	-2.2 (-10.7 to 7.4)	1.7 (1.0 to 2.8)	2.5 (1.4 to 4.2)	48.3 (35.5 to 63.1)	-1.7 (-10.4 to 8.4)	
Otitis media	87.3 (79.6 to 94.8)	120.1 (109.0 to 132.4)	37.8 (23.5 to 51.7)	-9.5 (-19.8 to 1.1)	1.8 (1.1 to 2.8)	2.4 (1.5 to 3.9)	37.4 (22.3 to 53.9)	-9.3 (-19.9 to 2.6)	
Meningitis	-	-	-	-	8.1 (5.6 to 11.0)	6.1 (4.2 to 8.4)	-24.7 (-38.8 to -5.9)	-48.2 (-57.1 to -35.1)	
Pneumococcal meningitis	37.1 (22.3 to 56.9)	27.4 (17.2 to 41.3)	-26.3 (-42.9 to -2.6)	-49.4 (-60.1 to -33.4)	2.4 (2.1 to 4.6)	2.4 (1.7 to 3.3)	-25.3 (-45.9 to 7.0)	-49.0 (-61.8 to -30.6)	
H influenzae type B meningitis	15.3 (5.3 to 28.6)	10.2 (4.5 to 18.6)	-32.0 (-53.9 to -8.0)	-54.7 (-69.4 to -37.8)	1.5 (1.0 to 2.2)	1.1 (0.7 to 1.7)	-21.6 (-51.8 to 14.9)	-47.8 (-67.1 to -23.0)	
Meningococcal meningitis	19.1 (6.2 to 39.8)	13.8 (5.4 to 28.6)	-25.7 (-48.0 to -1.3)	-49.3 (-62.0 to -33.7)	2.2 (1.2 to 3.8)	1.6 (1.0 to 2.5)	-21.2 (-57.0 to 9.1)	-45.7 (-68.0 to -28.4)	
Other meningitis	10.2 (6.5 to 15.8)	7.6 (5.0 to 11.7)	-25.4 (-42.3 to -1.4)	-45.9 (-58.6 to -25.7)	1.2 (0.8 to 1.8)	0.9 (0.6 to 1.3)	-21.4 (-44.4 to 4.2)	-42.9 (-60.4 to -22.9)	
Encephalitis	0.8 (0.4 to 1.7)	1.2 (0.6 to 2.5)	50.2 (35.9 to 69.4)	0.1 (-8.3 to 9.3)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	54.0 (31.6 to 81.5)	21.3 (-12.5 to 15.9)	
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (97.0 to 1,774.3)	0.0 (0.0 to 0.0)	-	-	
Whooping cough	6.5 (5.0 to 8.3)	3.0 (2.4 to 3.9)	-53.2 (-66.3 to -40.1)	-66.1 (-83.3 to -48.9)	0.3 (0.2 to 0.5)	0.1 (0.1 to 0.2)	-53.0 (-58.7 to -47.5)	-66.0 (-70.1 to -61.9)	
Tetanus	0.8 (0.3 to 1.4)	0.2 (0.2 to 0.9)	-71.2 (-81.9 to -38.6)	-71.2 (-88.5 to -7.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-69.9 (-74.3 to -41.3)	-65.0 (-83.6 to -7.3)	
Measles	1.2 (1.0 to 1.6)	0.2 (0.1 to 0.2)	-87.2 (-90.5 to -84.5)	-91.3 (-93.2 to -89.0)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.0)	-87.8 (-93.5 to -80.0)	-91.3 (-95.3 to -85.8)	
Varicella and herpes zoster	2.5 (2.3 to 2.7)	3.9 (3.6 to 4.3)	59.0 (39.7 to 79.5)	5.1 (-15.8 to 25.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	58.6 (12.9 to 112.5)	6.6 (-26.6 to 44.3)	
Neglected tropical diseases and malaria	-	-	-	-	89.4 (57.0 to 136.7)	59.5 (36.2 to 90.2)	-34.9 (-52.8 to -0.1)	-56.1 (-68.9 to -31.0)	
Malaria	2,285.8 (2,099.8 to 2,480.5)	2,114.3 (1,993.2 to 2,331.5)	-7.3 (-14.8 to -1.1)	-42.4 (-47.4 to -38.0)	20.7 (13.6 to 29.7)	19.2 (12.8 to 27.4)	-7.0 (-16.8 to 1.4)	-39.6 (-45.5 to -34.2)	
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	142.5 (-10.3 to 377.5)	61.1 (-41.0 to 210.0)	
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.4 (-0.5 to 108.6)	-1.2 (-27.1 to 35.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.4 (-0.6 to 108.9)	-1.2 (-27.2 to 36.1)	
Cutaneous and mucocutaneous leishmaniasis	2.2 (1.1 to 3.6)	5.3 (2.5 to 9.1)	139.9 (-131.1 to 356.9)	60.9 (-41.5 to 204.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	142.5 (-10.3 to 378.1)	61.1 (-41.0 to 210.2)	
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	
Schistosomiasis	2,451.8 (881.0 to 4,047.4)	254.1 (16.2 to 1,407.3)	-95.5 (-98.4 to -42.5)	-97.2 (-99.0 to -66.7)	26.3 (9.2 to 57.7)	3.0 (0.3 to 14.1)	-94.2 (-97.5 to -42.0)	-96.1 (-98.3 to -64.2)	
Cysticercosis	2.5 (0.9 to 5.3)	2.4 (0.7 to 4.9)	-1.4 (-73.3 to 182.8)	-37.2 (-79.1 to 73.8)	0.7 (0.2 to 1.5)	0.7 (0.2 to 1.4)	4.5 (-73.4 to 204.3)	-33.2 (-78.9 to 88.1)	
Cystic echinococcosis	0.9 (0.8 to 1.0)	1.0 (0.9 to 1.1)	11.1 (-1.3 to 30.9)	8.6 (-0.8 to 19.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	11.8 (-11.4 to 46.5)	8.2 (-9.2 to 32.0)	
Lymphatic filariasis	137.6 (109.9 to 177.2)	45.9 (27.7 to 74.6)	-67.0 (-77.8 to -54.4)	-71.3 (-81.3 to -59.5)	5.1 (2.1 to 10.0)	3.7 (1.6 to 7.7)	-34.7 (-59.7 to 5.3)	-43.8 (-70.5 to -17.3)	
Onchocerciasis	458.3 (347.5 to 590.1)	279.2 (151.4 to 464.9)	-39.2 (-68.0 to 8.6)	-57.4 (-75.3 to -24.7)	23.8 (13.7 to 36.1)	21.2 (6.8 to 44.3)	-41.4 (-61.8 to 57.1)	-41.4 (-69.7 to 5.9)	
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	
Dengue	0.6 (0.2 to 1.3)	4.3 (1.7 to 9.4)	646.8 (640.1 to 654.5)	392.0 (387.6 to 397.1)	0.1 (0.0 to 0.2)	0.7 (0.2 to 1.7)	651.9 (499.1 to 849.7)	393.7 (305.7 to 507.7)	
Yellow fever	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.1)	-58.9 (-68.4 to -46.0)	-73.1 (-78.3 to -65.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.9 (-68.3 to -46.0)	-73.1 (-78.4 to -65.4)	
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-40.7 to 88.1)	0.0 (51.6 to 30.3)	0.0 (-40.8 to 88.3)	0.0 (-51.9 to 30.5)	
Intestinal nematode infections	-	-	-	-	8.5 (5.1 to 13.6)	6.9 (4.1 to 10.6)	-19.9 (-30.9 to -6.8)	-48.8 (-57.1 to -38.6)	
Ascariasis	1,263.7 (946.3 to 1,646.0)	879.1 (671.5 to 1,156.2)	-30.9 (-52.8 to 2.3)	-56.1 (-72.8 to -29.3)	0.8 (0.4 to 1.5)	0.6 (0.3 to 1.0)	-28.9 (-48.7 to -2.8)	-54.6 (-68.4 to -34.8)	
Trichuriasis	1,271.4 (955.1 to 1,685.2)	846.6 (636.4 to 1,140.3)	-33.3 (-55.3 to -1.8)	-57.1 (-74.4 to -32.1)	0.6 (0.3 to 1.1)	0.4 (0.2 to 0.7)	-31.8 (-56.5 to 5.4)	-55.9 (-74.8 to -25.3)	
Hookworm disease	1,576.4 (1,245.1 to 2,000.6)	1,386.1 (1,040.5 to 1,649.0)	-12.1 (-41.9 to 15.0)	-47.2 (-65.3 to -22.4)	5.9 (4.3 to 11.2)	5.9 (3.5 to 9.1)	-8.0 (-31.2 to -1.9)	-47.5 (-57.3 to -35.5)	
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	
Other neglected tropical diseases	58.6 (45.1 to 72.1)	101.4 (93.1 to 112.8)	72.6 (38.4 to 125.3)	19.7 (-1.6 to 49.5)	4.1 (2.1 to 7.3)	3.9 (2.6 to 5.5)	0.9 (-37.0 to 42.3)	-50.6 (-73.2 to -19.2)	
Maternal disorders	-	-	-	-	1.0 (0.6 to 1.5)	1.4 (0.8 to 2.2)	42.5 (21.9 to 71.3)	-13.4 (-25.7 to 3.3)	
Maternal hemorrhage	1.5 (0.9 to 2.1)	2.1 (1.2 to 2.9)	34.2 (-15.9 to 125.4)	22.2 (-49.8 to 28.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	23.6 (-44.2 to 231.2)	-28.2 (-68.0 to 88.1)	
Maternal sepsis and other maternal infections	1.6 (1.1 to 2.3)	2.1 (1.4 to 2.9)	31.0 (19.0 to 55.5)	-24.2 (-30.9 to -10.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.7 (-26.2 to 113.2)	-28.3 (-55.3 to 16.4)	
Maternal hypertensive disorders	1.3 (0.5 to 2.4)	1.7 (0.6 to 3.0)	26.7 (18.3 to 36.1)	-28.1 (-33.7 to -22.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	26.5 (6.8 to 52.1)	-28.0 (-39.4 to -14.3)	
Obstructed labor	2.1 (1.3 to 2.9)	3.0 (2.0 to 4.1)	43.2 (29.2 to 61.6)	-11.2 (-20.2 to -0.0)	0.7 (0.4 to 1.1)	0.7 (0.6 to 1.6)	44.4 (23.2 to 74.3)	-10.9 (-23.3 to 5.9)	
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	22.3 (3.4 to 41.7)	-31.6 (-63.4 to 25.8)	-	-	
Other maternal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.4)	49.1 (-5.6 to 127.9)	-11.1 (-46.6 to 34.7)	
Neonatal disorders	-	-	-	-	1.7 (0.9 to 3.4)	5.7 (3.4 to 8.9)	237.4 (96.8 to 503.2)	134.6 (27.8 to 341.0)	
Preterm birth complications	11.5 (5.2 to 22.6)	39.3 (21.1 to 71.1)	243.6 (190.0 to 369.7)	122.9 (88.4 to 195.3)	0.5 (0.3 to 0.9)	3.0 (1.7 to 5.0)	491.2 (241.8 to 963.2)	295.2 (132.7 to 612.9)	
Neonatal encephalopathy due to birth asphyxia and trauma	31.1 (2.0 to 99.5)	32.7 (3.4 to 102.7)	9.6 (-18.1 to 89.1)	-28.8 (-46.9 to 24.7)	0.9 (0.3 to 2.4)	1.4 (0.5 to 3.0)	56.7 (21.1 to 229.3)	5.6 (-32.9 to 152.6)	
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.2)	0.2 (0.0 to 0.3)	88.3 (82.6 to 96.1)	46.2 (41.8 to 52.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.5 (74.3 to 102.7)	46.4 (35.4 to 57.4)	
Hemolytic disease and other neonatal jaundice	0.4 (0.2 to 0.9)	2.1 (0.7 to 4.7)	336.5 (63.6 to 1,358.9)	239.1 (17.2 to 1,095.9)	0.2 (0.1 to 0.4)	0.8 (0.3 to 1.9)	350.5 (66.3 to 1,423.3)	247.3 (21.2 to 1,135.0)	
Other neonatal disorders	-	-	-	-	0.1 (0.1 to 0.3)	0.4 (0.2 to 0.8)	218.7 (37.7 to 692.2)	118.4 (-8.7 to 465.3)	
Nutritional deficiencies	-	-	-	-	37.2 (25.0 to 53.7)	65.0 (43.5 to 93.0)	74.2 (60.7 to 92.2)	20.5 (11.8 to 31.5)	
Protein-energy malnutrition	26.9 (18.6 to 37.3)	45.3 (22.3 to 81.4)	63.1 (-24.1 to 236.3)	16.2 (-39.1 to 121.3)	3.6 (1.8 to 5.3)	5.6 (2.4 to 11.0)	64.5 (-23.6 to 249.7)	37.6 (-39.4 to 129.1)	
Iodine deficiency	142.7 (92.7 to 216.6)	148.1 (74.7 to 237.8)	4.3 (-56.2 to 104.3)	-33.3 (-73.3 to 30.7)	2.6 (1.3 to 4.7)	2.7 (1.2 to 4.9)	5.3 (-55.6 to 104.0)	-32.8 (-72.7 to 33.5)	
Vitamin A deficiency	6.4 (4.7 to 8.3)	6.0 (4.3 to 8.1)	-6.0 (-27.1 to 20.8)	-32.0 (-48.2 to -11.0)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	-4.0 (-27.1 to 23.3)	-30.0 (-47.4 to -6.9)	

Appendix Table G.4 - Sierra Leone prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	847.6 (825.0 to 867.9)	1,603.4 (1,588.6 to 1,618.4)	89.1 (84.6 to 94.4)	29.9 (27.4 to 32.6)	31.1 (20.9 to 44.7)	56.4 (37.8 to 81.3)	81.6 (74.5 to 88.5)	27.6 (23.0 to 34.1)
Other nutritional deficiencies	-	-	-	-	0.0	0.0	0.0	42.9
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	3.1 (2.0 to 4.5)	4.5 (3.0 to 6.5)	45.7 (31.6 to 68.9)	-9.6 (-18.9 to 1.2)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.8 (0.4 to 1.3)	1.1 (0.6 to 1.9)	44.0 (15.2 to 76.6)	-13.4 (-28.1 to 3.6)
Syphilis	0.5 (0.4 to 0.5)	0.4 (0.3 to 0.4)	-18.1 (-31.2 to -1.0)	-44.8 (-51.9 to -36.1)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	44.7 (38.5 to 51.6)	47.2 (-5.2 to -30.5)
Chlamydial infection	58.1 (43.1 to 75.9)	88.6 (54.4 to 115.6)	54.6 (-8.6 to 140.3)	-8.8 (-43.1 to 41.2)	0.3 (0.1 to 0.5)	0.4 (0.2 to 0.7)	57.6 (51.1 to 155.6)	-6.1 (-40.8 to 52.1)
Gonococcal infection	19.8 (13.8 to 25.6)	30.2 (22.1 to 39.7)	51.1 (5.5 to 125.1)	-8.7 (-34.1 to 30.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	41.2 (-13.6 to 117.9)	-15.7 (-45.4 to 31.1)
Trichomoniasis	47.3 (27.5 to 74.9)	70.2 (31.4 to 130.9)	36.7 (-27.2 to 233.5)	-17.3 (-53.3 to 78.3)	0.1 (0.0 to 0.2)	0.3 (0.0 to 0.1)	34.1 (-39.0 to 258.7)	-17.7 (-60.4 to 90.4)
Genital herpes	694.0 (586.2 to 684.7)	998.7 (910.8 to 1,084.9)	57.0 (39.2 to 76.1)	-4.6 (-11.9 to 10.9)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.7)	48.9 (38.6 to 80.4)	13.2 (-12.3 to 12.8)
Other sexually transmitted diseases	1.6 (1.1 to 2.2)	2.2 (1.6 to 2.9)	40.6 (19.8 to 65.7)	-17.8 (-30.3 to -4.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.9 (-0.5 to 113.3)	-13.5 (-38.3 to 22.2)
Hepatitis	-	-	-	-	0.6 (0.3 to 0.9)	0.6 (0.4 to 0.9)	3.4 (-16.8 to 28.3)	-36.8 (-50.6 to -17.9)
Hepatitis A	7.2 (6.8 to 7.6)	10.2 (9.7 to 10.7)	41.1 (40.4 to 42.0)	-1.9 (-2.1 to -1.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	53.8 (36.1 to 73.5)	2.7 (-8.1 to 15.2)
Hepatitis B	925.8 (783.1 to 1,070.5)	733.9 (595.0 to 853.1)	-20.7 (-37.8 to -0.5)	-48.1 (-59.1 to -37.6)	0.4 (0.2 to 0.6)	0.3 (0.2 to 0.5)	-15.0 (-40.6 to 22.1)	-46.8 (-62.2 to 20.5)
Hepatitis C	297.7 (262.0 to 337.1)	319.0 (285.8 to 354.4)	7.1 (-9.7 to 26.4)	-29.6 (-39.2 to -17.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	9.4 (-18.5 to 49.3)	-24.9 (-42.2 to 0.8)
Hepatitis E	1.1 (0.9 to 1.4)	1.1 (0.8 to 1.6)	1.0 (-39.2 to 78.3)	-37.6 (-62.8 to 13.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 1.1)	2.1 (-42.4 to 91.4)	-36.8 (-64.7 to 16.7)
Leprosy	1.0 (0.7 to 1.4)	0.9 (0.8 to 1.1)	-9.9 (-24.2 to 30.2)	-28.3 (-42.0 to -9.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	1.5 (-24.2 to 41.9)	-26.6 (-42.2 to -2.4)
Other infectious diseases	43.0 (35.5 to 51.3)	74.7 (66.4 to 82.9)	74.2 (45.1 to 112.5)	19.7 (3.1 to 39.6)	1.7 (1.0 to 2.4)	2.7 (1.8 to 3.9)	62.7 (40.5 to 108.6)	11.4 (-3.2 to 40.7)
Non-communicable diseases	-	-	-	-	241.5 (175.5 to 311.2)	374.0 (273.1 to 485.4)	54.9 (48.3 to 60.5)	1.0 (-3.4 to 4.6)
Neoplasms	-	-	-	-	1.0 (0.7 to 1.4)	1.6 (1.2 to 2.2)	66.4 (35.6 to 108.2)	24.1 (0.1 to 55.8)
Esophageal cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	31.3 (-14.1 to 103.8)	-1.4 (-33.8 to 52.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	32.9 (-9.2 to 99.4)	0.5 (-30.8 to 49.5)
Stomach cancer	0.5 (0.4 to 0.6)	0.5 (0.4 to 0.7)	14.5 (-15.5 to 57.8)	-13.0 (-34.8 to 18.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	15.6 (-14.5 to 62.7)	-11.6 (-34.9 to 23.0)
Liver cancer	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	26.4 (-11.9 to 80.4)	-7.5 (-34.8 to 31.8)
Liver cancer due to hepatitis B	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.7)	46.9 (-28.2 to 191.1)	4.4 (-48.9 to 104.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	47.6 (-19.5 to 166.9)	3.9 (-44.9 to 87.9)
Liver cancer due to hepatitis C	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.4)	221.7 (52.4 to 552.0)	147.1 (23.9 to 396.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	198.1 (49.8 to 470.2)	126.3 (22.8 to 324.8)
Liver cancer due to alcohol use	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-39.3 (-75.1 to 29.5)	-53.7 (-79.6 to -5.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-38.4 (-71.0 to 21.7)	-52.6 (-76.3 to -9.2)
Liver cancer due to other causes	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-22.6 (-58.5 to 47.4)	-22.6 (-71.3 to -0.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-24.3 (-53.7 to 29.7)	-47.2 (-67.8 to -6.7)
Larynx cancer	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.2)	-27.2 (-53.3 to 75.5)	-42.6 (-61.8 to 29.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.9 (-51.9 to 77.0)	-40.9 (-61.8 to 36.7)
Tracheal, bronchus and lung cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	12.2 (-17.5 to 52.2)	-13.2 (-35.4 to 14.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.5 (-15.9 to 65.6)	-10.3 (-34.1 to 22.6)
Breast cancer	1.3 (1.0 to 1.8)	2.7 (2.0 to 3.8)	103.9 (37.3 to 210.7)	37.4 (-4.9 to 107.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	90.6 (26.7 to 183.9)	30.1 (-11.6 to 91.6)
Cervical cancer	2.3 (1.6 to 3.2)	3.3 (2.2 to 4.7)	39.2 (-11.9 to 121.7)	1.9 (-35.6 to 55.4)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	41.8 (8.0 to 125.3)	15.6 (-32.4 to 60.9)
Uterine cancer	0.4 (0.2 to 0.6)	0.6 (0.4 to 1.1)	72.6 (-3.7 to 222.0)	26.0 (-25.9 to 130.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	75.2 (-4.7 to 224.1)	28.1 (-26.8 to 130.7)
Prostate cancer	0.7 (0.4 to 1.4)	2.7 (1.6 to 4.7)	269.3 (120.1 to 499.6)	174.1 (74.8 to 313.3)	0.1 (0.0 to 0.1)	0.3 (0.1 to 0.4)	223.3 (98.5 to 406.0)	143.9 (57.6 to 263.3)
Colon and rectum cancer	0.4 (0.3 to 0.5)	0.7 (0.6 to 0.8)	67.0 (29.2 to 117.1)	18.1 (-7.2 to 51.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	66.2 (28.1 to 120.4)	19.2 (-9.7 to 56.3)
Lip and oral cavity cancer	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	43.2 (-1.9 to 113.8)	6.4 (-26.2 to 56.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.4 (0.9 to 111.1)	9.0 (-24.1 to 59.0)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	43.9 (-8.2 to 121.1)	-7.1 (-38.9 to 42.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.0 (-6.8 to 107.9)	-9.8 (-38.4 to 34.9)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	17.3 (-30.0 to 101.1)	-14.1 (-48.4 to 44.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.7 (-23.8 to 100.4)	-11.7 (-43.1 to 44.5)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.1 (-11.6 to 103.2)	-3.9 (-38.6 to 45.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.6 (-7.7 to 92.0)	-3.6 (-35.4 to 42.2)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	78.9 (26.0 to 148.3)	33.3 (-3.6 to 82.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.6 (37.9 to 141.0)	33.9 (2.4 to 79.8)
Malignant skin melanoma	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	76.7 (25.4 to 171.1)	17.6 (-15.2 to 85.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.7 (17.8 to 175.7)	17.3 (-17.8 to 89.2)
Non-melanoma skin cancer	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	69.0 (3.2 to 175.0)	18.0 (-24.8 to 95.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	100.0 (32.7 to 199.9)	40.7 (-12.6 to 128.4)
Ovarian cancer	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	42.7 (-9.9 to 122.6)	3.0 (-35.5 to 59.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	49.8 (-16.7 to 141.6)	8.1 (-40.9 to 75.1)
Testicular cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	95.8 (0.4 to 253.0)	14.1 (-37.3 to 104.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.2 (-5.9 to 263.3)	12.2 (-40.3 to 103.3)
Kidney cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	19.8 (-27.6 to 103.1)	-12.6 (-38.0 to 27.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.9 (-24.6 to 98.0)	-11.1 (-35.2 to 28.0)
Bladder cancer	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	16.7 (-17.8 to 88.0)	-12.6 (-41.4 to 36.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.6 (-15.5 to 86.2)	-10.2 (-38.6 to 43.6)
Brain and nervous system cancer	0.1 (0.1 to 0.1)	0.3 (0.1 to 0.3)	152.2 (56.1 to 273.9)	59.8 (14.4 to 117.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	148.7 (60.7 to 256.4)	52.6 (10.2 to 105.3)
Thyroid cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	22.9 (-32.0 to 134.7)	-14.1 (-52.9 to 61.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.4 (-29.3 to 133.1)	-12.3 (-51.4 to 59.8)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.2 (1.5 to 125.1)	17.5 (-31.2 to 56.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.0 (-1.5 to 125.0)	2.3 (-32.3 to 55.3)
Hodgkin lymphoma	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	132.8 (45.7 to 263.9)	67.3 (12.6 to 152.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	127.2 (47.8 to 251.0)	61.1 (9.4 to 141.3)
Non-Hodgkin lymphoma	0.5 (0.3 to 0.7)	1.0 (0.5 to 1.7)	51.9 (6.0 to 118.4)	7.2 (-21.1 to 49.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	56.1 (8.9 to 122.4)	9.8 (-18.5 to 54.4)
Multiple myeloma	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	72.7 (8.4 to 177.3)	22.6 (-25.7 to 98.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.0 (2.4 to 169.8)	17.2 (-31.4 to 98.0)
Leukemia	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	96.5 (7.9 to 242.7)	17.6 (-22.4 to 72.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.9 (19.6 to 162.8)	7.6 (-23.2 to 52.1)
Other neoplasms	1.3 (0.8 to 2.6)	2.5 (1.7 to 3.9)	106.6 (4.5 to 221.6)	22.8 (-20.1 to 82.9)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	98.1 (9.6 to 195.7)	15.9 (-21.7 to 74.7)
Cardiovascular diseases	-	-	-	-	6.7 (4.6 to 9.3)	9.4 (6.3 to 13.5)	40.0 (11.1 to 77.0)	-1.8 (-20.4 to 20.0)
Rheumatic heart disease	45.4 (33.6 to 54.2)	59.2 (40.8 to 73.5)	29.9 (-22.4 to 96.6)	-14.6 (-46.6 to 20.9)	2.2 (1.3 to 3.2)	2.9 (1.7 to 4.5)	32.4 (-19.2 to 98.9)	-11.6 (-43.4 to 24.8)
Ischemic heart disease	31.3 (24.6 to 40.2)	28.7 (24.1 to 34.8)	-8.3 (-32.3 to 27.8)	-26.5 (-43.4 to -1.9)	1.5 (0.9 to 2.4)	1.2 (0.8 to 1.8)	-22.8 (-48.3 to 26.2)	-96.3 (-55.3 to -4.3)
Cerebrovascular disease	-	-	-	-	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.6)	39.9 (6.1 to 74.2)	-3.0 (-27.1 to 23.8)
Ischemic stroke	1.7 (1.4 to 2.0)	2.4 (1.9 to 2.8)	39.0 (7.3 to 72.5)	-2.4 (-24.8 to 24.6)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	39.7 (6.1 to 80.3)	-2.0 (-25.7 to 28.1)
Hemorrhagic stroke	0.5 (0.4 to 0.6)	0.7 (0.5 to 0.8)	36.4 (-2.4 to 74.0)	-9.0 (-36.1 to 15.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	39.1 (-1.9 to 79.9)	-7.5 (-37.5 to 20.9)
Hypertensive heart disease	5.7 (4.1 to 7.5)	7.5 (5.4 to 9.7)	30.4 (-10.7 to 98.4)	-6.2 (-33.7 to 40.8)	0.6 (0.4 to 1.0)	0.8 (0.5 to 1.2)	31.6 (-10.7 to 101.1)	-4.9 (-33.3 to 44.0)
Cardiomyopathy and myocarditis	4.1 (3.2 to 5.3)	5.1 (3.8 to 6.6)	23.4 (-13.7 to 80.2)	-9.0 (-41.2 to 41.2)	0.4 (0.3 to 0.7)	0.6 (0.3 to 0.8)	24.7 (-16.5 to 81.5)	-7.9 (-41.6 to 43.4)
Atrial fibrillation and flutter	0.4 (0.3 to 0.5)	1.3 (0.9 to 1.7)	228.0 (125.8 to 361.3)	193.1 (43.8 to 358.5)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	220.1 (114.8 to 382.6)	193.7 (42.4 to 358.6)
Peripheral vascular disease	58.9 (39.9 to 80.2)	87.1 (52.4 to 123.4)	45.6 (-11.3 to 142.3)	0.2 (-33.1 to 58.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	37.6 (-48.6 to 202.2)	8.7 (-51.6 to 121.9)
Endocarditis	0.3 (0.2 to 0.6)	0.4 (0.2 to 0.5)	22.2 (-41.3 to 93.4)	-8.4 (-65.8 to 67.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-7.0 (-49.0 to 100.6)	-7.0 (-67.4 to 90.8)
Other cardiovascular and circulatory diseases	21.0 (12.9 to 31.9)	46.2 (23.5 to 71.4)	121.1 (9.9 to 303.9)	52.6 (-28.0 to 190.2)	1.5 (0.8 to 2.4)	3.2 (1.5 to 5.5)	53.8 (9.3 to 303.6)	25.8 (-28.2 to 195.5)
Chronic respiratory diseases	-	-	-	-	15.3 (10.2 to 21.6)	21.4 (14.2 to 30.2)	39.3 (19.7 to 60.1)	-4.6 (-17.8 to 10.7)
Chronic obstructive pulmonary disease	131.7 (123.8 to 138.7)	192.7 (181.3 to 202.7)	46.4 (41.2 to 51.3)	-1.3 (-4.6 to 1.7)	10.6 (7.1 to 14.9)	15.8 (1		

Appendix Table G.4 - Sierra Leone prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumonia	0.0	0.0	-	-	0.0	0.0	38.5	-6.2
Silicosis	(0.0 to 0.0)	(0.0 to 0.0)	(21.2 to 35.2)	(-15.8 to -7.0)	(0.0 to 0.0)	(0.0 to 0.0)	(33.7 to 43.7)	(-9.5 to -2.9)
Asbestosis	-	-	0.0	0.0	0.0	0.0	27.7	-11.9
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	49.3	0.3	0.0	0.0	49.0	0.2
Asthma	(5.2 to 68.1)	(38.8 to 84.6)	(26.9 to 71.5)	(-41.3 to 29.4)	(1.3 to 3.5)	(1.4 to 4.2)	(27.5 to 72.6)	(-41.6 to 29.3)
Interstitial lung disease and pulmonary sarcoidosis	0.1	0.1	58.5	2.2	0.0	0.0	56.9	1.7
Other chronic respiratory diseases	-	-	-	-	2.5	3.0	24.5	-16.3
Cirrhosis	-	-	-	-	(1.4 to 4.0)	(1.8 to 4.8)	(-12.4 to 71.3)	(-40.9 to 12.6)
Cirrhosis due to hepatitis B	0.9	0.8	-3.2	-33.1	(0.2 to 0.5)	(0.3 to 0.6)	(10.8 to 40.7)	(-23.5 to -7.0)
Cirrhosis due to hepatitis C	0.4	0.6	64.0	21.2	0.1	0.1	63.8	21.0
Cirrhosis due to alcohol use	0.5	0.5	2.2	-29.0	0.1	0.1	28.8	-
Cirrhosis due to other causes	0.5	0.7	63.2	16.6	0.1	0.1	62.6	17.4
Digestive diseases	(0.4 to 0.6)	(0.6 to 1.0)	(16.3 to 128.9)	(-19.9 to 69.2)	(0.1 to 0.1)	(0.1 to 0.2)	(8.3 to 152.7)	(-23.5 to 75.9)
Peptic ulcer disease	25.4	29.0	14.2	-13.0	0.9	1.1	14.9	-17.4
Gastritis and duodenitis	51.2	71.6	40.0	0.1	2.2	3.1	41.7	-0.4
Appendicitis	0.5	0.7	87.2	14.3	0.1	0.3	87.5	14.7
Paralytic ileus and intestinal obstruction	0.1	0.1	43.8	-0.4	0.0	0.0	43.7	0.4
Inguinal, femoral, and abdominal hernia	14.7	18.2	24.1	-12.8	0.2	0.2	24.7	-11.8
Inflammatory bowel disease	3.8	7.4	95.6	26.0	0.8	1.6	97.5	27.2
Vascular intestinal disorders	0.0	0.0	107.2	16.2	0.0	0.0	106.5	11.3
Gallbladder and biliary diseases	1.1	1.9	69.9	0.5	0.1	0.2	72.0	10.2
Pancreatitis	0.6	1.1	72.3	9.5	0.2	0.3	73.9	10.0
Other digestive diseases	-	-	-	-	0.8	1.2	46.9	-1.3
Neurological disorders	-	-	-	-	17.3	28.5	65.3	6.6
Alzheimer disease and other dementias	4.6	5.9	30.0	-1.5	(11.6 to 24.0)	(19.2 to 40.0)	(43.1 to 88.8)	(7.5 to 19.8)
Parkinson disease	0.2	0.3	34.6	0.5	0.0	0.0	36.1	1.5
Epilepsy	8.3	12.1	44.4	-5.0	2.4	3.7	52.6	0.5
Multiple sclerosis	0.2	0.4	81.4	14.5	0.1	0.1	80.0	13.4
Migraine	280.6	490.5	75.0	4.4	9.5	14.8	59.3	-1.5
Tension-type headache	490.2	813.7	66.4	3.5	5.6	10.2	36.8	-12.8
Medication overuse headache	18.7	41.8	124.3	45.4	2.9	6.6	125.7	45.8
Other neurological disorders	0.0	0.0	41.7	-7.9	0.9	1.3	35.5	0.7
Mental and substance use disorders	-	-	-	-	78.2	124.9	59.6	1.4
Schizophrenia	8.3	13.4	61.9	0.1	(54.0 to 106.9)	(86.5 to 170.9)	(54.7 to 65.5)	(-1.5 to 5.5)
Alcohol use disorders	19.4	36.1	86.0	1.9	5.2	8.6	63.7	0.7
Drug use disorders	-	-	-	-	4.8	8.1	68.3	1.0
Opioid use disorders	6.4	10.7	64.9	-1.0	2.6	4.4	67.1	0.1
Cocaine use disorders	(4.3 to 9.4)	(7.0 to 15.7)	(50.5 to 86.1)	(-8.4 to 8.8)	(1.6 to 4.0)	(2.6 to 6.9)	(44.2 to 90.2)	(-9.8 to 10.8)
Amphetamine use disorders	(1.6 to 2.2)	(2.8 to 3.8)	(43.2 to 119.8)	(-13.8 to 2.5)	(0.2 to 0.4)	(0.3 to 0.7)	(38.2 to 138.5)	(-19.4 to 35.1)
Cannabis use disorders	6.2	10.0	62.0	-1.3	0.8	1.3	64.5	0.3
Other drug use disorders	(5.7 to 6.6)	(9.1 to 10.8)	(45.5 to 80.9)	(-10.4 to 10.1)	(0.5 to 1.2)	(0.8 to 1.9)	(36.8 to 95.6)	(-15.6 to 18.0)
Depressive disorders	2.8	4.5	62.5	0.3	0.1	0.1	61.9	0.0
Major depressive disorder	(2.2 to 3.3)	(3.5 to 5.4)	(60.0 to 65.1)	(0.2 to 0.4)	(0.0 to 0.1)	(0.1 to 0.2)	(28.7 to 104.6)	(-19.1 to 23.3)
Dysthymia	-	-	-	-	1.0	1.8	68.3	1.5
Bipolar disorder	-	-	-	-	(0.6 to 1.6)	(1.1 to 2.6)	(22.5 to 127.6)	(-24.9 to 36.1)
Anxiety disorders	-	-	-	-	4.8	7.4	54.9	0.4
Eating disorders	-	-	-	-	(19.4 to 52.1)	(30.3 to 82.9)	(47.1 to 69.7)	(-4.4 to 9.0)
Anorexia nervosa	0.7	1.1	64.7	2.7	29.8	46.9	56.4	0.3
Bulimia nervosa	(0.5 to 0.9)	(0.8 to 1.4)	(46.5 to 86.8)	(-8.8 to 16.3)	(1.6 to 4.4)	(2.5 to 7.6)	(45.7 to 71.2)	(-5.4 to 11.0)
Autistic spectrum disorders	3.9	6.4	62.8	-1.2	3.7	6.0	60.0	1.1
Autism	(2.7 to 5.7)	(4.4 to 9.3)	(58.9 to 66.6)	(-1.4 to -1.0)	(2.4 to 5.4)	(3.8 to 8.7)	(54.1 to 65.7)	(-1.5 to 3.4)
Asperger syndrome	12.3	18.8	53.2	-0.1	4.4	7.2	65.0	0.7
Attention-deficit/hyperactivity disorder	(11.7 to 12.9)	(17.9 to 19.8)	(53.0 to 53.4)	(-0.1 to -0.0)	(2.0 to 4.1)	(3.1 to 6.4)	(46.2 to 62.6)	(-4.0 to 5.6)
Conduct disorder	17.7	27.0	53.0	-0.1	1.8	2.7	54.3	0.7
Idiopathic intellectual disability	(16.6 to 18.7)	(25.3 to 28.6)	(52.6 to 53.4)	(-0.1 to -0.0)	(1.2 to 2.5)	(1.9 to 3.8)	(47.1 to 61.9)	(-3.3 to 4.8)
Other mental and substance use disorders	29.4	43.8	49.0	0.6	0.4	0.5	49.7	1.2
Diabetes, urogenital, blood, and endocrine diseases	(27.2 to 31.8)	(40.4 to 47.3)	(48.7 to 49.2)	(0.6 to 0.6)	(0.2 to 0.5)	(0.3 to 0.8)	(39.1 to 61.3)	(-6.3 to 8.8)
Diabetes mellitus	43.4	64.4	48.5	0.5	5.2	7.7	50.0	1.5
Acute glomerulonephritis	(40.9 to 45.9)	(60.7 to 68.2)	(48.3 to 48.8)	(0.5 to 0.6)	(3.3 to 7.5)	(4.9 to 11.2)	(43.1 to 56.7)	(-2.9 to 6.1)
Chronic kidney disease	104.0	156.0	58.0	4.5	5.0	8.1	59.3	5.4
Chronic kidney disease due to diabetes mellitus	(48.3 to 148.8)	(100.4 to 221.6)	(31.6 to 139.2)	(-14.5 to 64.3)	(2.3 to 8.0)	(4.3 to 12.3)	(31.8 to 141.3)	(-14.1 to 65.8)
Chronic kidney disease due to hypertension	49.0	79.1	61.3	-0.2	3.6	5.9	63.3	0.7
Chronic kidney disease due to glomerulonephritis	(45.8 to 52.2)	(73.8 to 84.1)	(60.1 to 62.6)	(-0.4 to -0.1)	(2.5 to 4.9)	(4.0 to 8.0)	(56.7 to 70.6)	(-2.9 to 4.4)
Chronic kidney disease due to other causes	-	-	-	-	25.1	43.0	71.2	15.7
Urinary diseases and male infertility	-	-	-	-	(18.0 to 33.8)	(29.8 to 58.4)	(59.2 to 85.1)	(5.7 to 26.1)
Diabetes mellitus	50.8	128.2	151.7	65.3	3.7	8.9	143.2	62.8
Acute glomerulonephritis	(40.4 to 62.2)	(103.9 to 153.5)	(92.4 to 226.9)	(20.3 to 124.2)	(2.5 to 5.2)	(5.7 to 12.9)	(76.0 to 222.9)	(13.9 to 122.2)
Chronic kidney disease	0.0	0.0	-32.8	-2.2	0.0	0.0	-32.8	-32.8
Chronic kidney disease due to diabetes mellitus	(0.0 to 0.0)	(0.0 to 0.0)	(-12.1 to 7.0)	(-38.1 to -27.5)	(0.0 to 0.0)	(0.0 to 0.0)	(-12.1 to 7.1)	(-38.2 to -27.5)
Chronic kidney disease due to hypertension	39.3	54.4	41.6	-1.8	6.6	9.9	50.1	-0.2
Chronic kidney disease due to glomerulonephritis	(24.3 to 62.1)	(36.0 to 85.1)	(8.0 to 102.3)	(-30.7 to 43.2)	(4.7 to 8.8)	(6.9 to 13.2)	(33.4 to 67.5)	(-10.5 to 9.9)
Chronic kidney disease due to other causes	17.7	26.4	51.3	2.2	0.7	0.9	38.1	-2.8
Urinary diseases and male infertility	(10.6 to 295.0)	(152.9 to 439.7)	(24.5 to 98.4)	(-17.6 to 33.9)	(0.4 to 1.0)	(0.6 to 1.3)	(-4.5 to 111.2)	(-30.0 to 43.0)
Urinary diseases and male infertility	123.3	226.7	48.5	2.5	2.2	3.2	45.2	-5.5
Urinary diseases and male infertility	(106.6 to 225.1)	(152.5 to 346.1)	(16.3 to 88.6)	(-23.5 to 20.2)	(1.6 to 3.1)	(2.3 to 4.9)	(18.8 to 94.3)	(-20.8 to 31.0)
Urinary diseases and male infertility	116.8	184.8	59.5	3.5	1.5	2.3	55.8	1.5
Urinary diseases and male infertility	(71.5 to 198.7)	(111.7 to 320.1)	(18.1 to 107.6)	(-21.3 to 41.6)	(1.0 to 2.1)	(1.5 to 3.1)	(22.0 to 103.4)	(-19.7 to 34.1)
Urinary diseases and male infertility	-	-	-	-	2.0	2.0	45.8	1.4
Urinary diseases and male infertility	-	-	-	-	(0.9 to 1.4)	(1.2 to 3.0)	(29.1 to 65.4)	(8.7 to 13.1)

Appendix Table G.4 - Sierra Leone prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.8 (0.7 to 0.8)	1.3 (1.2 to 1.3)	66.5 (51.8 to 84.7)	7.5 (-1.4 to 17.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	67.3 (32.6 to 110.8)	8.0 (-11.5 to 29.2)
Urolithiasis	8.3 (6.2 to 11.4)	10.5 (7.7 to 13.6)	28.0 (5.9 to 49.1)	-8.7 (-25.5 to 5.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	54.7 (33.6 to 77.4)	2.7 (-8.6 to 15.5)
Benign prostatic hyperplasia	26.2 (23.9 to 28.5)	34.7 (31.5 to 38.0)	32.3 (17.0 to 52.1)	0.3 (-10.0 to 13.3)	0.9 (0.6 to 1.3)	1.2 (0.8 to 1.8)	33.1 (17.2 to 52.7)	1.1 (-9.6 to 14.4)
Male infertility due to other causes	50.6 (38.6 to 63.4)	91.6 (74.7 to 112.1)	80.4 (35.2 to 150.4)	2.3 (-24.8 to 43.2)	0.3 (0.1 to 0.7)	0.5 (0.2 to 1.2)	81.3 (36.2 to 149.2)	2.7 (-23.2 to 41.4)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (-20.2 to 137.2)	0.0 (-46.5 to 53.0)
Gynecological diseases	-	-	-	-	3.9 (2.4 to 6.0)	7.4 (4.6 to 11.2)	88.2 (62.9 to 121.6)	13.0 (-1.4 to 31.8)
Uterine fibroids	62.2 (56.4 to 67.6)	100.7 (90.8 to 109.9)	62.0 (60.8 to 63.0)	2.0 (1.8 to 2.3)	0.8 (0.4 to 1.3)	1.7 (1.0 to 2.7)	108.2 (87.4 to 175.5)	28.0 (15.7 to 68.1)
Polycystic ovarian syndrome	55.9 (50.2 to 61.8)	102.6 (92.7 to 113.7)	83.9 (59.3 to 112.0)	7.2 (-6.6 to 22.4)	0.5 (0.3 to 1.0)	1.0 (0.5 to 1.9)	85.7 (60.3 to 113.4)	8.2 (-6.4 to 23.2)
Female infertility due to other causes	58.2 (42.2 to 76.4)	93.4 (72.0 to 118.8)	60.3 (10.4 to 59.3)	-5.8 (-36.0 to 43.6)	0.3 (0.1 to 0.6)	0.5 (0.2 to 1.0)	60.6 (11.3 to 141.2)	-5.2 (-35.6 to 42.5)
Endometriosis	5.7 (4.8 to 6.5)	8.9 (7.6 to 10.4)	58.3 (26.8 to 93.8)	-6.7 (-25.4 to 14.0)	0.5 (0.3 to 0.7)	0.8 (0.5 to 1.2)	59.9 (27.0 to 101.6)	-6.1 (-25.6 to 18.7)
Genital prolapse	138.2 (119.4 to 156.5)	216.7 (189.4 to 249.2)	56.5 (31.2 to 86.0)	2.1 (-13.8 to 19.2)	0.4 (0.2 to 0.8)	0.7 (0.3 to 1.3)	57.3 (32.0 to 88.6)	2.7 (-13.7 to 20.9)
Premenstrual syndrome	138.2 (85.8 to 184.2)	261.2 (185.0 to 338.2)	88.3 (12.5 to 228.7)	12.2 (-34.9 to 102.6)	1.1 (0.6 to 1.9)	2.2 (1.2 to 3.6)	90.2 (14.7 to 229.6)	13.1 (-35.4 to 105.1)
Other gynecological diseases	6.1 (4.0 to 8.1)	17.6 (11.6 to 23.8)	187.8 (93.2 to 360.7)	72.6 (19.4 to 169.1)	0.2 (0.1 to 0.3)	0.5 (0.2 to 0.8)	185.9 (40.9 to 584.1)	68.4 (-7.5 to 275.3)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	7.8 (5.3 to 11.1)	12.0 (8.2 to 17.0)	54.5 (42.8 to 67.1)	5.1 (-3.6 to 14.2)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	31.5 (2.9 to 49.7)	-12.5 (-32.0 to 1.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.9 (1.0 to 42.1)	-16.9 (-33.3 to -5.6)
Thalassemia trait	30.2 (25.6 to 35.8)	46.8 (37.8 to 55.7)	54.8 (47.9 to 62.1)	2.0 (-2.6 to 6.8)	0.5 (0.3 to 0.8)	0.8 (0.5 to 1.2)	51.1 (23.6 to 79.9)	2.1 (-15.6 to 23.9)
Sickle cell disorders	18.7 (18.7 to 20.5)	30.2 (27.4 to 32.8)	61.2 (47.9 to 79.5)	7.8 (-1.3 to 21.6)	1.9 (1.3 to 2.5)	3.0 (2.1 to 4.1)	62.3 (40.7 to 85.7)	7.8 (-6.2 to 22.1)
Sickle cell trait	801.1 (779.7 to 827.7)	1,279.6 (1,195.4 to 1,362.8)	58.5 (48.1 to 56.3)	0.4 (-2.5 to 2.9)	5.8 (2.6 to 5.7)	9.8 (8.8 to 8.5)	46.3 (23.3 to 70.0)	-0.2 (-10.9 to 14.5)
G6PD deficiency	558.0 (410.3 to 724.5)	828.3 (604.6 to 1,058.6)	50.6 (0.8 to 121.6)	-0.8 (-33.7 to 45.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	51.5 (-6.2 to 128.6)	4.6 (-35.8 to 51.9)
G6PD trait	958.5 (890.7 to 1,002.7)	1,456.2 (1,349.7 to 1,523.1)	52.4 (38.0 to 65.3)	1.1 (-8.4 to 9.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	59.4 (-59.7 to 423.9)	11.3 (-70.2 to 277.2)
Other hemoglobinopathies and hemolytic anemias	43.9 (37.9 to 50.6)	78.4 (69.4 to 87.3)	78.7 (52.5 to 114.4)	1.3 (5.6 to 36.8)	2.2 (0.8 to 1.9)	2.2 (1.4 to 3.3)	68.0 (36.2 to 120.8)	16.9 (-8.5 to 43.5)
Endocrine, metabolic, blood, and immune disorders	49.6 (42.4 to 57.9)	83.8 (68.3 to 96.4)	69.4 (30.5 to 108.0)	15.3 (-4.3 to 36.0)	2.9 (1.1 to 2.6)	3.3 (1.8 to 4.2)	65.5 (5.9 to 142.6)	13.3 (-19.3 to 51.7)
Musculoskeletal disorders	-	-	-	-	47.6 (33.6 to 63.3)	71.7 (50.3 to 96.9)	51.6 (27.5 to 71.9)	-1.4 (-13.6 to 10.4)
Rheumatoid arthritis	5.2 (4.9 to 5.4)	5.7 (5.5 to 6.0)	10.4 (3.7 to 18.3)	-30.6 (-35.0 to -25.6)	1.2 (0.9 to 1.6)	1.4 (1.0 to 1.9)	12.3 (0.4 to 23.7)	-29.7 (-35.8 to -23.6)
Osteoarthritis	76.7 (73.5 to 79.7)	107.9 (102.9 to 112.6)	41.0 (32.0 to 49.6)	2.4 (-3.6 to 8.4)	4.7 (3.3 to 6.4)	6.0 (4.6 to 9.0)	41.9 (32.6 to 50.7)	3.1 (-3.2 to 9.1)
Low back and neck pain	-	-	-	-	34.8 (23.6 to 47.2)	54.7 (37.1 to 75.1)	58.8 (25.5 to 88.9)	1.2 (-16.0 to 19.0)
Low back pain	202.0 (166.2 to 235.4)	312.1 (258.6 to 373.4)	55.9 (19.5 to 98.0)	1.2 (-20.0 to 26.1)	22.3 (14.2 to 31.7)	34.8 (22.9 to 50.8)	57.7 (20.4 to 100.5)	2.4 (-19.8 to 27.9)
Neck pain	128.2 (101.7 to 153.5)	201.8 (169.0 to 234.4)	57.5 (21.5 to 106.7)	-1.5 (-21.4 to 27.0)	12.5 (8.0 to 18.0)	19.9 (13.3 to 28.2)	59.0 (22.1 to 108.9)	-0.7 (-21.1 to 28.3)
Gout	0.3 (0.3 to 0.4)	0.5 (0.4 to 0.5)	41.3 (18.2 to 67.2)	0.0 (-17.8 to 14.7)	-2.8 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.9 (11.7 to 83.5)	-1.4 (-24.2 to 27.5)
Other musculoskeletal disorders	76.5 (56.6 to 96.3)	98.8 (61.6 to 131.1)	98.8 (9.1 to 54.2)	32.7 (-39.0 to 3.8)	6.9 (4.3 to 10.2)	9.0 (5.0 to 14.1)	38.8 (8.8 to 55.9)	6.6 (-38.9 to 54.4)
Other non-communicable diseases	-	-	-	-	44.6 (28.6 to 67.0)	65.1 (41.6 to 99.0)	45.7 (38.4 to 52.9)	-4.1 (-8.7 to 0.1)
Congenital anomalies	-	-	-	-	1.4 (1.0 to 1.9)	2.8 (2.0 to 3.9)	104.1 (71.0 to 141.1)	31.3 (7.8 to 60.5)
Neural tube defects	0.1 (0.1 to 0.2)	0.6 (0.5 to 0.7)	372.2 (213.5 to 541.3)	258.1 (132.2 to 398.1)	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.2)	416.0 (221.8 to 689.9)	310.6 (155.5 to 530.5)
Congenital heart anomalies	1.1 (0.7 to 1.6)	5.3 (4.2 to 8.0)	442.9 (240.5 to 805.3)	317.5 (150.2 to 599.8)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.1)	295.1 (116.1 to 577.3)	203.5 (68.9 to 408.6)
Orofacial clefts	0.1 (0.1 to 0.2)	0.6 (0.4 to 0.9)	447.7 (206.9 to 907.6)	368.0 (150.1 to 793.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	495.9 (186.2 to 880.4)	349.2 (135.1 to 772.3)
Down syndrome	1.2 (0.9 to 1.5)	3.3 (2.6 to 4.2)	186.5 (106.9 to 318.2)	98.6 (41.7 to 191.1)	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.5)	185.9 (99.1 to 323.4)	97.6 (36.7 to 193.1)
Turner syndrome	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	134.6 (56.5 to 271.8)	55.6 (3.8 to 146.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	139.3 (59.6 to 277.1)	56.7 (4.3 to 147.4)
Klinefelter syndrome	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	47.1 (5.8 to 92.0)	-4.0 (-30.8 to 26.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.1 (13.4 to 106.1)	-3.2 (-30.2 to 27.3)
Chromosomal unbalanced rearrangements	1.8 (1.3 to 2.3)	5.5 (4.5 to 6.2)	189.9 (123.0 to 331.5)	186.4 (52.3 to 200.9)	0.6 (0.1 to 0.3)	0.2 (0.0 to 0.9)	197.9 (118.1 to 351.7)	105.6 (49.9 to 210.3)
Other congenital anomalies	12.0 (8.7 to 15.0)	16.9 (12.3 to 21.6)	41.3 (17.9 to 66.2)	-8.3 (-24.0 to 9.3)	1.0 (0.6 to 1.4)	1.4 (0.9 to 2.2)	48.1 (15.8 to 93.0)	-4.2 (-25.2 to 28.2)
Skin and subcutaneous diseases	-	-	-	-	18.1 (11.3 to 28.5)	27.8 (17.4 to 44.1)	54.2 (41.1 to 64.0)	0.8 (-6.7 to 7.3)
Dermatitis	171.5 (134.4 to 214.3)	269.4 (209.8 to 340.0)	56.8 (54.7 to 59.5)	-0.0 (-0.1 to 0.1)	4.9 (3.1 to 7.1)	7.7 (4.8 to 11.3)	56.3 (49.8 to 62.1)	0.7 (-2.4 to 3.5)
Psoriasis	26.8 (21.1 to 32.2)	41.8 (32.8 to 50.5)	56.0 (53.1 to 58.4)	-0.0 (-0.1 to 0.1)	2.2 (1.4 to 3.2)	3.4 (2.2 to 4.9)	57.4 (46.8 to 68.4)	0.8 (-4.4 to 6.2)
Cellulitis	0.7 (0.6 to 0.9)	1.1 (0.9 to 1.4)	53.3 (29.5 to 79.0)	-0.3 (-17.2 to 17.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	54.3 (14.3 to 104.9)	0.3 (-22.6 to 27.5)
Pyoderma	6.8 (5.0 to 8.8)	9.3 (7.0 to 11.9)	36.5 (28.0 to 47.6)	0.2 (-10.6 to 3.0)	-4.2 (0.0 to 1.1)	0.0 (0.0 to 0.1)	37.1 (23.4 to 53.3)	-3.7 (-12.8 to 6.6)
Scabies	62.6 (47.9 to 81.8)	53.9 (45.8 to 65.3)	-13.4 (-35.9 to 20.0)	-40.2 (-56.3 to -18.0)	1.6 (0.9 to 2.7)	1.4 (0.8 to 2.3)	97.6 (-35.6 to 21.3)	-40.0 (-55.9 to -17.0)
Fungal skin diseases	481.7 (351.2 to 669.8)	748.2 (538.6 to 1,045.7)	54.1 (15.0 to 58.6)	2.1 (-0.0 to 1.8)	4.2 (1.0 to 6.1)	4.2 (1.6 to 9.5)	55.0 (51.6 to 59.9)	0.5 (-0.3 to 1.5)
Viral skin diseases	59.5 (46.2 to 73.3)	88.8 (68.0 to 110.5)	49.2 (38.4 to 59.5)	-0.5 (-5.9 to 5.0)	1.8 (1.1 to 2.9)	2.7 (1.6 to 4.4)	50.4 (37.8 to 62.3)	0.9 (-6.2 to 6.9)
Acne vulgaris	220.6 (158.0 to 305.6)	381.3 (237.1 to 488.1)	73.2 (2.8 to 165.3)	12.0 (-32.0 to 69.1)	2.4 (1.1 to 4.7)	4.1 (1.8 to 8.0)	73.8 (2.9 to 168.4)	12.6 (-32.0 to 70.3)
Alopecia areata	3.6 (3.2 to 4.0)	5.4 (4.8 to 6.2)	52.9 (28.0 to 82.0)	0.0 (-14.4 to 18.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	53.5 (24.2 to 89.7)	0.7 (-16.1 to 22.2)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.5 (16.7 to 84.4)	-3.2 (-24.1 to 21.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.5 (16.7 to 84.7)	-3.2 (-24.1 to 21.4)
Urticaria	16.3 (11.8 to 22.6)	33.9 (22.9 to 45.5)	106.6 (18.5 to 233.8)	28.9 (-26.0 to 102.7)	1.0 (0.6 to 1.5)	2.0 (1.1 to 3.2)	109.6 (18.3 to 244.5)	29.8 (-26.2 to 105.8)
Decubitus ulcer	0.3 (0.3 to 0.3)	0.5 (0.4 to 0.5)	59.0 (31.6 to 93.6)	2.4 (-20.7 to 36.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	59.9 (30.3 to 103.9)	4.6 (-21.1 to 42.8)
Other skin and subcutaneous diseases	222.5 (150.9 to 320.9)	319.5 (216.7 to 463.2)	43.6 (35.0 to 52.9)	-4.6 (-9.3 to -1.0)	1.3 (0.6 to 2.7)	1.9 (0.8 to 3.9)	44.4 (35.8 to 53.9)	-4.0 (-8.8 to -0.3)
Sense organ diseases	-	-	-	-	20.2 (13.1 to 29.4)	27.3 (17.6 to 39.7)	75.0 (24.5 to 47.5)	-7.6 (-14.2 to -0.2)
Glaucoma	2.1 (1.5 to 2.9)	4.6 (3.6 to 6.1)	123.3 (53.3 to 210.7)	20.8 (-15.0 to 64.5)	0.2 (0.1 to 0.3)	0.2 (0.0 to 0.6)	123.6 (52.6 to 211.8)	27.6 (-11.8 to 80.4)
Cataract	11.7 (7.5 to 16.4)	13.9 (8.6 to 20.5)	18.3 (-28.3 to 101.8)	-15.2 (-42.1 to 25.2)	1.0 (0.6 to 1.6)	1.3 (0.8 to 2.1)	28.2 (-18.9 to 103.8)	-10.2 (-37.3 to 25.1)
Macular degeneration	2.2 (1.3 to 3.4)	4.8 (2.4 to 7.8)	112.5 (15.9 to 272.0)	49.3 (-16.9 to 154.6)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.4)	107.8 (19.0 to 245.2)	42.9 (-13.5 to 127.8)
Uncorrected refractive error	390.5 (264.3 to 414.2)	467.0 (354.8 to 586.1)	41.6 (-0.1 to 92.8)	-2.9 (-25.3 to 84.0)	6.6 (4.3 to 10.3)	8.7 (5.4 to 13.6)	30.1 (6.9 to 56.7)	-11.3 (-56.6 to 3.1)
Age-related and other hearing loss	462.4 (403.0 to 519.6)	619.0 (535.6 to 698.1)	33.8 (26.5 to 41.7)	6.5 (-10.4 to -2.7)	8.9 (5.6 to 13.9)	11.6 (7.0 to 18.0)	9.7 (16.6 to 46.3)	-9.1 (-16.1 to -3.6)
Other vision loss	7.3 (5.7 to 9.0)	11.8 (9.5 to 14.9)	62.4 (30.7 to 98.5)	4.5 (-17.5 to 30.6)	0.7 (0.4 to 1.1)	1.2 (0.8 to 1.8)	73.3 (34.7 to 118.9)	10.4 (-17.7 to 43.4)
Other sense organ diseases	95.7 (90.7 to 100.4)	141.1 (134.0 to 148.6)	47.4 (37.7 to 58.4)	-0.3 (-5.7 to 5.9)	2.5 (1.5 to 3.7)	3.8 (2.3 to 5.6)	48.0 (36.5 to 61.2)	0.5 (-5.9 to 7.4)
Oral disorders	-	-	-	-	5.0 (2.7 to 8.3)	7.		

Appendix Table G.4 - Sierra Leone prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	13.4 (12.3 to 14.4)	19.0 (17.4 to 20.5)	41.9 (25.6 to 57.7)	1.0 (-9.4 to 12.0)	0.4 (0.2 to 0.5)	0.5 (0.3 to 0.7)	43.1 (26.5 to 60.9)	1.8 (-9.3 to 13.1)
Other oral disorders	59.0 (55.3 to 62.4)	91.3 (85.9 to 96.6)	54.5 (42.8 to 68.9)	-0.9 (-8.1 to 7.4)	1.7 (1.1 to 2.5)	2.7 (1.7 to 4.1)	55.4 (43.0 to 71.0)	-0.2 (-7.8 to 8.5)
Injuries	-	-	-	-	11.6 (8.9 to 14.8)	23.1 (15.8 to 34.5)	90.7 (54.3 to 202.3)	37.0 (7.6 to 128.5)
Transport injuries	-	-	-	-	5.2 (4.0 to 6.7)	6.3 (4.8 to 8.1)	19.9 (13.6 to 26.9)	-17.4 (-21.5 to -13.0)
Road injuries	-	-	-	-	4.8 (3.7 to 6.1)	5.7 (4.3 to 7.4)	18.9 (12.2 to 25.9)	-18.3 (-22.5 to -13.9)
Pedestrian road injuries	-	-	-	-	1.2 (0.9 to 1.6)	1.4 (1.0 to 1.8)	9.0 (1.5 to 19.6)	-22.7 (-28.6 to -16.7)
Cyclist road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.3 to 0.4)	-2.2 (-8.6 to 4.0)	-28.4 (-32.5 to -24.0)
Motorcyclist road injuries	-	-	-	-	0.8 (0.6 to 1.1)	0.8 (0.6 to 1.1)	1.2 (-7.2 to 10.6)	-31.7 (-37.0 to -25.8)
Motor vehicle road injuries	-	-	-	-	2.3 (1.8 to 2.9)	3.1 (2.4 to 4.0)	35.1 (23.4 to 46.5)	-8.4 (-15.7 to -1.2)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	6.6 (13.6 to 0.3)	-39.0 (-43.2 to -34.9)
Other transport injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	32.3 (22.3 to 43.6)	-7.0 (-13.5 to -0.4)
Unintentional injuries	-	-	-	-	6.1 (4.7 to 7.7)	8.1 (6.2 to 10.5)	32.6 (27.7 to 37.7)	-10.7 (-14.4 to -7.3)
Falls	-	-	-	-	2.6 (2.0 to 3.4)	3.6 (2.7 to 4.7)	39.0 (30.8 to 47.4)	-9.1 (-14.6 to -3.6)
Drowning	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	4.8 (5.5 to 15.7)	-28.8 (-35.0 to -22.7)
Fire, heat, and hot substances	-	-	-	-	0.4 (0.3 to 0.6)	0.5 (0.4 to 0.6)	13.6 (2.8 to 25.9)	-21.4 (-27.9 to -14.3)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.2 (9.9 to 33.6)	-28.3 (-39.4 to -15.7)
Exposure to mechanical forces	-	-	-	-	1.7 (1.3 to 2.3)	2.2 (1.7 to 3.0)	30.0 (22.9 to 36.3)	-13.0 (-17.0 to -8.7)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	27.4 (16.7 to 38.8)	-16.4 (-23.1 to -9.4)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.1 (55.6 to 102.3)	18.4 (7.2 to 34.0)
Other exposure to mechanical forces	-	-	-	-	1.6 (1.2 to 2.1)	2.1 (1.6 to 2.8)	29.7 (22.5 to 36.4)	-13.1 (-17.1 to -8.8)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	63.1 (51.6 to 74.4)	15.2 (7.3 to 23.1)
Animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	30.4 (21.2 to 41.1)	-11.8 (-17.3 to -5.4)
Venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	33.1 (17.0 to 50.0)	-11.4 (-20.7 to -1.3)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	28.0 (20.2 to 38.3)	-12.3 (-16.7 to -6.1)
Foreign body	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	39.1 (30.3 to 47.4)	-5.4 (-9.6 to -0.6)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	22.2 (6.7 to 40.5)	-11.5 (-20.7 to -2.2)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	50.0 (33.6 to 69.6)	-3.8 (-12.7 to 6.9)
Foreign body in other body part	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	44.9 (36.3 to 54.3)	-3.0 (-8.2 to 3.4)
Other unintentional injuries	-	-	-	-	0.8 (0.6 to 1.0)	1.0 (0.8 to 1.3)	33.3 (24.7 to 44.1)	-7.7 (-13.7 to -0.3)
Self-harm and interpersonal violence	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	30.4 (24.1 to 37.4)	-13.8 (-18.0 to -9.5)
Self-harm	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	44.5 (32.5 to 57.3)	-5.3 (-11.8 to 1.5)
Interpersonal violence	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	27.5 (20.7 to 34.8)	-16.3 (-20.9 to -11.6)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	32.1 (21.6 to 43.9)	-12.8 (-19.2 to -5.2)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	54.2 (41.6 to 68.2)	-0.4 (-8.6 to 9.2)
Assault by other means	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	19.7 (11.2 to 28.2)	-21.7 (-27.1 to -16.3)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	8.4 (3.1 to 19.6)	35,905.0 (19,182.7 to 72,393.9)	28,617.2 (14,874.9 to 58,619.8)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	69.3 (42.6 to 104.7)	21.9 (5.7 to 42.5)
Collective violence and legal intervention	-	-	-	-	-	8.4 (3.1 to 19.6)	-	-

Appendix Table G.4 - Singapore prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	238.2 (176.1 to 311.7)	408.6 (300.3 to 531.3)	71.6 (65.6 to 76.9)	0.5 (-2.4 to 3.2)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	22.1 (15.1 to 31.0)	26.5 (17.9 to 37.6)	19.1 (10.5 to 32.6)	-6.1 (-12.6 to 3.5)
HIV/AIDS and tuberculosis	-	-	-	-	0.6 (0.4 to 0.8)	0.9 (0.6 to 1.2)	50.6 (34.5 to 71.1)	-15.6 (-24.5 to -3.7)
Tuberculosis	1.7 (1.6 to 1.9)	2.4 (2.3 to 2.6)	39.3 (31.9 to 48.1)	-23.4 (-27.4 to -18.9)	0.5 (0.4 to 0.7)	0.7 (0.5 to 1.0)	37.6 (23.8 to 54.4)	-23.4 (-30.8 to -14.7)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	139.3 (98.9 to 168.8)	139.3 (119.5 to 158.2)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.4 (-28.3 to 189.9)	-14.3 (59.1 to 70.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.4 (-28.3 to 190.3)	-14.3 (59.3 to 71.3)
HIV/AIDS resulting in other diseases	0.4 (0.2 to 0.7)	1.7 (0.8 to 2.9)	340.1 (188.2 to 606.1)	206.5 (94.5 to 399.4)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.3)	257.8 (99.1 to 581.6)	142.0 (32.3 to 361.3)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	1.8 (1.2 to 2.6)	2.2 (1.5 to 3.3)	26.6 (19.3 to 34.8)	-11.1 (-16.3 to -5.5)
Diarrheal diseases	0.9 (0.8 to 1.0)	1.2 (1.0 to 1.3)	33.7 (13.4 to 56.2)	-0.3 (-14.7 to 16.9)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	32.2 (8.3 to 63.4)	-0.0 (-17.7 to 24.4)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.0 (60.0 to 69.8)	27.7 (68.3 to 30.1)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.2 (-29.6 to 28.7)	-26.5 (-44.1 to -2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.2 (-29.7 to 28.8)	-26.5 (-44.1 to -2.9)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.6 (-25.3 to 50.0)	-13.5 (-39.6 to 15.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.6 (-25.7 to 50.4)	-13.5 (-39.7 to 15.4)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.0 (-99.0 to 4.005.2)	65.0 (-99.2 to 3.144.1)
Lower respiratory infections	1.3 (1.2 to 1.5)	1.6 (1.3 to 1.8)	16.4 (-2.9 to 34.8)	-45.0 (-53.0 to -37.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	11.8 (9.7 to 35.0)	-45.9 (-55.7 to -36.0)
Upper respiratory infections	53.2 (50.4 to 56.3)	68.7 (65.0 to 72.2)	29.2 (19.6 to 38.0)	-1.2 (-8.1 to 5.3)	0.6 (0.4 to 1.0)	0.8 (0.5 to 1.3)	28.7 (18.6 to 39.0)	-1.2 (-8.5 to 6.8)
Otitis media	28.2 (26.4 to 30.2)	35.9 (33.5 to 38.3)	27.3 (16.5 to 38.2)	-11.9 (-18.5 to -5.6)	0.5 (0.3 to 0.8)	0.7 (0.4 to 1.0)	26.2 (15.8 to 38.8)	-12.6 (-19.5 to -5.4)
Meningitis	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	15.1 (-16.3 to 65.3)	-17.3 (-39.5 to 21.5)
Pneumococcal meningitis	0.8 (0.5 to 1.3)	0.9 (0.6 to 1.6)	13.3 (-10.0 to 51.5)	-37.5 (-42.4 to -4.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	0.1 (-17.4 to 71.9)	21.6 (-43.6 to 17.0)
H influenzae type B meningitis	0.3 (0.1 to 0.8)	0.3 (0.1 to 0.8)	-7.9 (-50.4 to 110.8)	-33.1 (-62.6 to 63.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-2.5 (-49.5 to 150.5)	-24.3 (-61.2 to 91.6)
Meningococcal meningitis	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	66.6 (9.9 to 225.0)	-1.0 (-36.8 to 115.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	100.4 (25.5 to 264.5)	22.9 (-23.1 to 134.4)
Other meningitis	0.6 (0.2 to 1.2)	0.6 (0.3 to 1.4)	6.1 (-39.4 to 75.2)	-25.5 (-54.4 to 32.0)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	9.1 (-47.2 to 129.2)	-17.8 (-60.4 to 73.3)
Encephalitis	0.1 (0.1 to 0.4)	0.2 (0.1 to 0.6)	50.1 (2.6 to 103.8)	-47.8 (-37.1 to 25.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.6 (21.3 to 118.5)	2.7 (-24.8 to 35.3)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.3 (-94.7 to 227.0)	-69.3 (-96.3 to 129.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.3 (-94.7 to 245.6)	-69.3 (-96.3 to 132.8)
Whooping cough	0.4 (0.3 to 0.5)	0.2 (0.1 to 0.2)	-50.1 (-52.2 to -48.1)	-41.2 (-43.6 to -38.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.4 (-60.0 to -39.0)	-41.5 (-52.9 to -27.8)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.6 (-73.7 to -29.4)	-64.1 (-81.4 to -46.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-55.4 (-77.3 to -26.6)	-65.4 (-83.0 to -45.1)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.1 (-66.2 to -38.0)	-47.8 (-61.6 to -29.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.1 (-66.3 to -37.9)	-47.8 (-61.7 to -29.3)
Varicella and herpes zoster	2.0 (1.8 to 2.3)	2.9 (2.5 to 3.4)	41.1 (23.2 to 63.3)	-7.4 (-17.6 to 5.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	72.4 (39.0 to 115.7)	-3.8 (-21.8 to 19.3)
Neglected tropical diseases and malaria	-	-	-	-	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.6)	146.6 (42.1 to 238.1)	62.7 (-13.8 to 132.1)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.3 (-54.5 to 351.2)	5.8 (-63.9 to 256.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.0 (-40.7 to 384.0)	28.0 (-54.8 to 274.0)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.2 (-79.4 to 126.1)	-65.1 (-89.2 to 24.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.6 (-76.9 to 170.5)	-61.2 (-88.0 to 42.5)
Cystic echinococcosis	0.4 (0.3 to 0.4)	0.3 (0.3 to 0.3)	-10.6 (-17.7 to 6.6)	-51.2 (-54.7 to -40.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.3 (-29.8 to 21.4)	-49.5 (-59.8 to -32.9)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	0.2 (0.0 to 0.8)	0.9 (0.2 to 3.0)	307.3 (271.6 to 352.5)	190.3 (164.8 to 222.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.5)	293.8 (197.0 to 503.1)	183.9 (115.3 to 328.3)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.6 (-32.5 to 108.7)	-9.1 (-52.6 to 44.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.6 (-32.5 to 108.9)	-9.1 (-52.6 to 44.8)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	365.5 (218.7 to 568.3)	232.1 (127.2 to 378.1)
Maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-12.6 (-37.0 to 15.5)	-19.4 (-41.9 to 5.8)
Maternal hemorrhage	0.5 (0.4 to 0.6)	0.6 (0.4 to 0.8)	11.3 (-24.8 to 49.3)	4.8 (-29.9 to 40.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.5 (-55.0 to 53.8)	-12.5 (-57.6 to 41.4)
Maternal sepsis and other maternal infections	0.3 (0.1 to 0.5)	0.2 (0.1 to 0.4)	-16.3 (-44.8 to 40.2)	-37.8 (-59.5 to 6.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.1 (-48.0 to 3.2)	-37.6 (-56.3 to -13.6)
Maternal hypertensive disorders	0.4 (0.2 to 0.7)	0.4 (0.2 to 0.6)	-15.8 (-31.2 to 11.5)	-22.4 (-35.0 to 2.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.0 (-40.6 to 24.0)	-22.1 (-44.3 to 12.8)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.7 (-47.9 to 36.8)	-22.8 (-51.3 to 29.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.7 (-48.0 to 37.2)	-22.8 (-51.4 to 29.8)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.8 (-38.5 to 24.0)	-17.2 (-42.6 to 16.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.8 (-38.8 to 24.3)	-17.2 (-42.6 to 16.7)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.6 (-48.5 to 48.5)	-19.4 (-53.2 to 36.6)
Neonatal disorders	-	-	-	-	3.6 (2.2 to 5.2)	5.1 (2.9 to 8.3)	37.4 (-17.5 to 135.6)	4.4 (-37.5 to 77.9)
Preterm birth complications	17.3 (10.4 to 28.1)	27.2 (14.3 to 48.3)	55.5 (4.4 to 136.1)	14.8 (-21.7 to 73.7)	2.3 (1.4 to 3.4)	3.4 (2.0 to 5.1)	49.0 (-13.9 to 169.8)	12.4 (-35.2 to 103.1)
Neonatal encephalopathy due to birth asphyxia and trauma	3.8 (2.3 to 6.4)	2.2 (1.0 to 5.5)	-45.0 (-70.8 to 1.7)	-57.2 (-76.9 to -22.3)	0.7 (0.5 to 1.1)	0.5 (0.3 to 0.7)	-38.7 (-62.9 to 4.3)	-52.4 (-70.9 to -18.9)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.5 (16.4 to 129.2)	75.6 (55.5 to 206.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.1 (-75.3 to nan)	89.8 (-67.0 to nan)
Hemolytic disease and other neonatal jaundice	1.0 (0.3 to 2.0)	1.6 (0.5 to 7.0)	53.4 (-65.2 to 547.0)	20.4 (-73.0 to 388.6)	0.2 (0.1 to 0.6)	0.5 (0.2 to 1.8)	90.3 (-54.6 to 528.2)	43.7 (-65.7 to 368.1)
Other neonatal disorders	-	-	-	-	0.4 (0.2 to 0.6)	0.7 (0.3 to 1.4)	108.3 (-18.4 to 357.4)	58.1 (-38.5 to 243.5)
Nutritional deficiencies	-	-	-	-	14.7 (9.7 to 21.5)	16.6 (11.0 to 24.4)	12.8 (9.0 to 16.7)	-7.5 (-10.2 to -5.2)
Protein-energy malnutrition	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.8 (-81.9 to 30.5)	-89.5 (-94.2 to -84.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-66.0 (-86.4 to 36.9)	-88.8 (-95.3 to -51.3)
Iodine deficiency	16.9 (7.8 to 26.1)	14.9 (7.2 to 24.2)	-11.4 (-65.0 to 92.4)	-37.1 (-74.3 to 34.1)	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.5)	-12.0 (-65.0 to 94.4)	-37.7 (-74.7 to 36.1)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron-deficiency anemia	508.2 (501.7 to 514.7)	627.2 (617.0 to 637.3)	23.4 (21.0 to 25.9)	-5.6 (-7.4 to -3.8)	14.4 (9.5 to 21.1)	16.4 (10.8 to 24.0)	13.3 (9.6 to 16.7)	-7.0 (-9.7 to -4.7)

Appendix Table G.4 - Singapore prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.0	0.0	55.9	84.7
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.0	0.0	-79.4 to -14.0	-92.8 to -71.7
Sexually transmitted diseases excluding HIV	-	-	-	-	0.5	0.6	28.1	-3.6
Syphilis	0.1	0.3	118.5	8.0	0.0	0.0	114.5	7.7
Chlamydial infection	107.7	126.2	17.4	0.4	0.0	0.0	59.5 to 192.8	-18.9 to 43.8
Gonococcal infection	8.0	8.2	2.5	-2.2	0.0	0.0	-11.3 to 58.2	-27.8 to 29.9
Trichomoniasis	12.7	16.7	30.1	2.5	0.0	0.0	33.7	4.8
Genital herpes	329.4	500.3	52.0	-9.4	0.1	0.1	47.3	-9.4
Other sexually transmitted diseases	0.5	0.6	7.5	-17.8	0.0	0.0	21.8	-2.6
Hepatitis	0.4	0.4	-12.2 to 33.2	-32.6 to 3.4	0.1	0.2	8.9	-25.6
Hepatitis A	2.4	2.6	9.8	-14.3	0.1	0.1	19.5	-11.8
Hepatitis B	132.7	118.1	-11.0	-40.6	0.1	0.1	5.6 to 34.6	-21.5 to -0.4
Hepatitis C	25.6	36.3	42.6	-27.0	0.0	0.0	-27.7 to 40.6	-53.4 to -11.0
Hepatitis E	-	-	11.0 to 176.3	-17.1 to 106.2	0.0	0.0	38.9	-30.1
Leprosy	0.0	0.0	41.8	-33.3	0.0	0.0	53.6	-28.3
Other infectious diseases	20.2	22.5	11.8	-6.3	0.4	0.6	1.1	-8.1
Non-communicable diseases	-	-	-	-	201.0	363.6	80.9	4.3
Neoplasms	-	-	-	-	148.4 to 261.4	264.7 to 470.6	74.0 to 87.5	0.3 to 7.5
Esophageal cancer	0.2	0.2	26.2	-52.9	0.0	0.0	23.1	-53.7
Stomach cancer	1.2	1.9	60.6	-35.8	0.1	0.2	44.5	-42.2
Liver cancer	-	-	-	-	0.0	0.1	172.7	8.7
Liver cancer due to hepatitis B	0.1	0.4	376.9	15.5	0.0	0.1	83.9 to 262.7	-27.0 to 45.9
Liver cancer due to hepatitis C	0.0	0.4	1,028.7	330.1	0.0	0.0	117.2	1.8
Liver cancer due to alcohol use	0.1	0.1	47.8	-42.4	0.0	0.0	27.7	-50.2
Liver cancer due to other causes	0.0	0.0	-21.8	-67.6	0.0	0.0	-30.2	-86.5 to -31.2
Larynx cancer	0.3	0.4	40.4	-41.1	0.0	0.0	30.7	-46.6
Tracheal, bronchus and lung cancer	1.4	3.1	116.6	-13.8	0.2	0.4	92.1	-23.3
Breast cancer	6.7	21.4	220.2	31.1	0.4	1.1	186.7	22.3
Cervical cancer	1.7	1.8	49.7	-49.7	0.1	0.1	4.9	-50.2
Uterine cancer	1.3	2.0	56.6	-38.8	0.0	0.0	49.5	-41.1
Prostate cancer	1.1	5.3	378.3	83.9	0.0	0.4	339.7	67.3
Colon and rectum cancer	4.2	12.0	181.7	13.6	0.4	1.0	160.6	4.0
Lip and oral cavity cancer	0.9	1.5	71.2	-20.5	0.1	0.1	67.2	-23.2
Nasopharynx cancer	1.0	0.7	-23.7	-60.9	0.1	0.1	-23.8	-61.3
Other pharynx cancer	0.5	0.9	78.9	-22.8	0.0	0.1	73.5	-25.7
Gallbladder and biliary tract cancer	0.1	0.2	56.6	-38.8	0.0	0.0	49.5	-41.1
Pancreatic cancer	0.1	0.3	206.8	20.5	0.0	0.0	189.4	14.3
Malignant skin melanoma	0.2	0.5	118.1	4.9	0.0	0.0	109.9	-1.1
Non-melanoma skin cancer	5.7	13.4	131.6	-12.6	0.1	0.2	189.8	4.6
Ovarian cancer	0.5	1.2	132.6	10.7	0.1	0.1	122.4	5.1
Testicular cancer	0.1	0.1	-9.4	-37.4	0.0	0.0	-11.0	-40.4
Kidney cancer	0.4	1.5	238.5	44.7	0.0	0.1	209.5	30.7
Bladder cancer	0.7	1.9	168.9	9.8	0.1	0.1	156.2	4.6
Brain and nervous system cancer	0.3	0.4	44.3	-9.8	0.0	0.0	52.2	-9.7
Thyroid cancer	0.5	1.2	133.9	16.2	0.0	0.1	123.2	7.5
Mesothelioma	0.0	0.0	-17.6	97.9	0.0	0.0	93.3	-20.0
Hodgkin lymphoma	0.1	0.1	24.7	-18.5	0.0	0.0	19.6	-26.7
Non-Hodgkin lymphoma	0.9	2.5	169.7	30.3	0.0	0.2	153.3	21.5
Multiple myeloma	0.1	0.4	207.5	22.6	0.0	0.1	188.8	14.8
Leukemia	2.5	7.3	188.4	61.7	0.2	0.5	173.6	53.0
Other neoplasms	1.9	5.9	212.4 to 344.3	27.1 to 147.9	0.1	0.1	73.7	-4.8
Cardiovascular diseases	-	-	-	-	4.4 to 8.9	12.2 to 24.6	107.5 to 254.4	-15.9 to 42.0
Rheumatic heart disease	0.5	1.0	125.0	3.6	0.1	0.1	116.4	-0.2
Ischemic heart disease	31.0	79.6	157.2	2.2	0.5	5.6	157.8	-0.6
Cerebrovascular disease	-	-	-	-	1.4 to 3.2	3.7 to 7.9	95.1 to 238.8	-22.5 to 28.8
Ischemic stroke	9.4	22.5	138.5	-6.7	1.4	4.6	136.3	-4.1
Hemorrhagic stroke	3.6	8.8	143.0	4.1	0.5	1.3	139.6	4.7
Hypertensive heart disease	2.8	9.9	253.2	30.6	0.3	1.1	249.3	30.4
Cardiomyopathy and myocarditis	2.9	7.4	156.0	10.6	0.3	0.8	152.9	10.7
Atrial fibrillation and flutter	3.0	11.1	275.8	44.6	0.2	0.9	247.1	44.1
Peripheral vascular disease	37.7	84.5	121.0	-14.5	0.0	0.1	137.2	-17.6
Endocarditis	0.1	0.5	262.8	49.5	0.0	0.1	269.7	54.9
Other cardiovascular and circulatory diseases	19.8	67.0	259.7	53.6	1.4	4.8	259.1	53.1
Chronic respiratory diseases	-	-	-	-	6.6 to 12.8	10.6 to 20.5	44.0 to 82.2	-12.3 to 10.5
Chronic obstructive pulmonary disease	62.1	119.7	92.7	-4.6	3.8	7.0	83.3	-9.6
Pneumoconiosis	-	-	-	-	0.0	0.0	72.5	-20.9

Appendix Table G.4 - Singapore prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.9 (50.8 to 67.0)	-31.9 (-34.8 to -28.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.7 (55.8 to 74.1)	-28.9 (-32.8 to -25.0)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	71.6 (61.4 to 82.7)	-18.6 (-23.1 to -14.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.5 (66.4 to 88.4)	-16.3 (-20.7 to -11.5)
Asthma	122.7 (112.8 to 133.1)	180.3 (168.1 to 192.8)	46.8 (31.9 to 63.7)	5.5 (-7.0 to 15.7)	5.5 (3.6 to 7.8)	8.0 (5.2 to 11.4)	45.7 (30.9 to 62.4)	9.9 (7.1 to 15.7)
Interstitial lung disease and pulmonary sarcoidosis	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	77.3 (21.8 to 150.8)	-12.7 (-40.1 to 14.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.3 (30.9 to 154.4)	-11.4 (-38.9 to 26.8)
Other chronic respiratory diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	76.8 (23.1 to 180.9)	-12.6 (-39.6 to 36.4)
Cirrhosis	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	16.7 (6.1 to 45.5)	-42.8 (-53.3 to -29.6)
Cirrhosis due to hepatitis B	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	35.9 (-20.7 to 161.0)	-34.9 (-62.0 to 19.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	36.5 (-27.7 to 173.3)	-34.4 (-64.3 to 28.1)
Cirrhosis due to hepatitis C	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	20.2 (-69.8 to 225.6)	-40.8 (84.4 to 63.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	18.4 (-71.3 to 221.5)	-41.9 (-84.8 to 60.3)
Cirrhosis due to alcohol use	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-18.7 (-51.5 to 131.7)	-62.8 (-77.9 to -3.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-18.6 (-57.0 to 148.8)	-62.3 (-79.6 to 2.3)
Cirrhosis due to other causes	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	67.2 (-12.2 to 211.2)	-3.9 (-47.9 to 71.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.1 (-20.9 to 216.9)	-7.1 (-53.1 to 75.6)
Digestive diseases	-	-	-	-	1.6 (1.2 to 2.2)	2.4 (1.7 to 3.2)	47.0 (33.5 to 60.0)	-35.0 (-41.2 to -28.8)
Peptic ulcer disease	14.8 (12.9 to 16.6)	13.6 (11.9 to 15.2)	-7.8 (-15.8 to 0.1)	-68.1 (-70.8 to -65.3)	0.5 (0.4 to 0.7)	0.6 (0.4 to 0.8)	11.7 (2.1 to 28.6)	-60.7 (-64.6 to -55.0)
Gastritis and duodenitis	4.1 (3.6 to 4.7)	2.8 (2.5 to 3.2)	-31.6 (-42.4 to -20.1)	-66.5 (-72.0 to -60.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-22.7 (-38.8 to 4.2)	-61.7 (-68.7 to -46.8)
Appendicitis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-9.9 (-24.7 to 12.6)	-28.4 (-40.9 to -9.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.8 (-30.4 to 28.1)	-26.8 (-45.9 to 3.9)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	82.9 (45.4 to 115.3)	0.4 (-21.0 to 21.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.5 (28.3 to 131.7)	-0.3 (-28.7 to 31.3)
Inguinal, femoral, and abdominal hernia	4.5 (3.7 to 5.2)	9.3 (7.6 to 10.9)	107.7 (57.0 to 161.6)	-15.4 (-36.6 to 7.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	106.0 (53.5 to 160.6)	-55.6 (-36.5 to 7.1)
Inflammatory bowel disease	1.0 (0.9 to 1.2)	1.9 (1.7 to 2.2)	85.3 (49.0 to 141.9)	5.0 (-15.3 to 34.7)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	83.4 (42.8 to 143.7)	4.9 (-18.4 to 37.3)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	128.6 (69.5 to 243.7)	-3.0 (-28.3 to 39.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	122.5 (48.0 to 253.4)	-3.5 (-36.7 to 53.3)
Gallbladder and biliary diseases	2.7 (2.3 to 3.0)	4.5 (3.9 to 5.2)	66.5 (39.4 to 111.5)	-23.8 (-35.6 to -7.7)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	64.2 (34.9 to 111.3)	-24.0 (-37.1 to -4.4)
Pancreatitis	0.6 (0.6 to 0.6)	1.3 (1.2 to 1.4)	119.2 (106.3 to 133.7)	0.2 (-12.1 to 26.7)	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	116.6 (84.1 to 154.7)	19.1 (2.7 to 38.5)
Other digestive diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	79.8 (35.0 to 122.6)	-21.0 (-40.4 to -2.1)
Neurological disorders	-	-	-	-	10.0 (9.9 to 10.5)	21.0 (14.5 to 28.2)	111.2 (84.6 to 138.8)	6.4 (-7.7 to 20.1)
Alzheimer disease and other dementias	9.1 (7.6 to 10.6)	32.3 (26.8 to 37.9)	256.5 (183.3 to 355.6)	11.5 (-12.2 to 42.7)	1.3 (0.9 to 1.8)	4.9 (3.3 to 6.5)	266.1 (189.0 to 369.6)	11.9 (-12.9 to 44.0)
Parkinson disease	1.5 (1.3 to 1.8)	4.0 (3.5 to 4.5)	155.5 (142.9 to 168.8)	-1.7 (-6.0 to 3.0)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.6)	154.0 (125.6 to 181.0)	-1.2 (-11.2 to 8.7)
Epilepsy	1.8 (1.3 to 2.2)	1.8 (1.1 to 2.6)	0.3 (-40.4 to 65.9)	-30.9 (59.3 to 14.3)	0.7 (0.4 to 1.0)	0.8 (0.4 to 1.2)	8.7 (36.8 to 80.4)	-24.2 (-56.0 to 26.6)
Multiple sclerosis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	190.6 (143.4 to 256.1)	70.8 (43.8 to 104.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	190.6 (143.4 to 256.3)	70.8 (43.7 to 104.9)
Migraine	120.6 (102.6 to 134.1)	193.8 (171.5 to 216.4)	60.1 (36.6 to 99.8)	11.3 (-3.8 to 37.6)	4.2 (2.5 to 6.2)	6.6 (3.9 to 10.0)	58.8 (34.2 to 97.8)	11.4 (-4.7 to 38.9)
Tension-type headache	260.0 (239.6 to 280.5)	866.5 (740.8 to 953.0)	235.9 (180.9 to 273.3)	117.7 (90.0 to 149.9)	1.3 (0.2 to 0.7)	1.3 (0.6 to 2.3)	223.8 (99.0 to 273.8)	118.0 (88.2 to 150.7)
Medication overuse headache	10.1 (6.5 to 13.8)	25.7 (17.3 to 34.6)	153.0 (101.3 to 229.5)	53.0 (22.2 to 99.0)	1.6 (0.9 to 2.5)	4.1 (2.3 to 6.3)	150.8 (79.0 to 228.1)	52.5 (22.5 to 99.0)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.1 (32.9 to 158.7)	12.1 (-19.0 to 52.4)	1.5 (1.0 to 2.2)	2.8 (1.9 to 4.1)	83.8 (27.6 to 176.3)	-41.4 (-59.4 to -12.2)
Mental and substance use disorders	-	-	-	-	70.0 (48.9 to 94.3)	101.5 (70.9 to 136.7)	45.1 (31.8 to 57.6)	-0.4 (-8.3 to 5.4)
Schizophrenia	9.1 (8.4 to 9.7)	14.2 (13.1 to 15.3)	56.9 (49.5 to 65.4)	-1.7 (-5.9 to 2.8)	5.9 (4.3 to 7.2)	9.2 (6.7 to 11.2)	59.9 (45.5 to 67.0)	-1.7 (-7.8 to 4.5)
Alcohol use disorders	20.9 (18.5 to 23.4)	29.8 (26.5 to 33.3)	42.4 (32.1 to 54.1)	4.4 (-2.2 to 11.9)	2.1 (1.4 to 3.1)	3.0 (2.0 to 4.3)	4.4 (29.7 to 54.7)	4.4 (-4.0 to 13.3)
Drug use disorders	-	-	-	-	6.8 (4.7 to 9.3)	8.8 (6.0 to 11.7)	29.7 (15.0 to 49.4)	1.9 (-9.7 to 16.9)
Opioid use disorders	7.9 (6.1 to 10.0)	11.2 (9.1 to 13.5)	41.1 (29.0 to 60.8)	8.7 (0.8 to 21.8)	3.4 (2.2 to 4.8)	4.7 (3.2 to 6.5)	40.3 (25.9 to 61.1)	8.8 (-1.7 to 23.3)
Cocaine use disorders	5.0 (4.4 to 5.7)	6.3 (5.6 to 7.1)	25.6 (6.0 to 49.0)	-2.7 (-18.0 to 16.0)	0.7 (0.4 to 1.0)	0.9 (0.6 to 1.3)	24.3 (2.1 to 54.8)	-2.9 (-20.3 to 21.2)
Amphetamine use disorders	6.8 (5.5 to 8.1)	7.9 (7.0 to 8.9)	16.1 (-4.5 to 43.6)	6.4 (-23.2 to 15.3)	0.9 (0.6 to 1.3)	1.0 (0.6 to 1.5)	15.1 (4.6 to 48.1)	6.9 (-26.0 to 19.7)
Cannabis use disorders	6.2 (5.5 to 6.9)	7.3 (6.5 to 8.1)	16.9 (15.2 to 18.9)	-0.5 (-0.8 to -0.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	16.8 (1.1 to 33.1)	-0.6 (-14.1 to 13.2)
Other drug use disorders	-	-	-	-	1.6 (1.0 to 2.4)	1.9 (1.2 to 2.8)	18.1 (-13.5 to 69.2)	-6.2 (-31.2 to 35.2)
Depressive disorders	-	-	-	-	32.5 (20.9 to 48.2)	49.2 (30.8 to 74.1)	51.0 (23.6 to 74.2)	-0.8 (-16.7 to 11.3)
Major depressive disorder	135.0 (94.5 to 173.2)	206.2 (140.9 to 288.9)	52.7 (21.2 to 78.7)	-0.8 (-18.9 to 13.2)	28.1 (17.3 to 42.7)	42.4 (25.3 to 66.5)	51.1 (19.5 to 77.1)	0.7 (-18.9 to 12.9)
Dysthymia	45.6 (38.2 to 54.0)	70.1 (59.2 to 82.0)	53.3 (39.2 to 69.6)	-0.4 (-7.2 to 5.2)	4.5 (2.9 to 6.5)	6.8 (4.5 to 9.8)	52.0 (37.5 to 67.9)	-0.7 (-7.8 to 5.9)
Bipolar disorder	19.1 (15.6 to 22.8)	27.5 (22.8 to 32.8)	43.8 (33.6 to 53.9)	-0.6 (-6.9 to 5.1)	3.9 (2.4 to 5.9)	5.6 (3.5 to 8.5)	42.5 (30.9 to 55.8)	-0.7 (-8.3 to 7.0)
Anxiety disorders	80.4 (42.0 to 110.9)	116.4 (67.4 to 158.9)	45.8 (29.2 to 65.9)	0.7 (-0.5 to 1.0)	7.5 (3.4 to 11.7)	10.7 (5.6 to 16.6)	44.8 (27.8 to 65.0)	0.7 (-2.2 to 3.8)
Eating disorders	-	-	-	-	0.9 (0.5 to 1.4)	1.1 (0.7 to 1.6)	11.8 (10.6 to 35.1)	11.8 (1.7 to 22.9)
Anorexia nervosa	1.3 (1.0 to 1.6)	1.9 (1.5 to 2.5)	47.0 (26.9 to 69.9)	31.8 (13.0 to 51.1)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	46.6 (19.6 to 74.7)	31.5 (6.4 to 57.2)
Bulimia nervosa	2.9 (1.8 to 4.4)	3.1 (2.0 to 4.8)	10.1 (7.2 to 13.5)	2.0 (1.7 to 2.4)	0.6 (0.3 to 1.0)	0.7 (0.4 to 1.1)	10.4 (-0.6 to 22.9)	2.4 (-7.3 to 12.3)
Autistic spectrum disorders	-	-	-	-	3.4 (2.4 to 4.7)	4.6 (3.2 to 6.3)	35.1 (30.2 to 39.7)	-0.9 (-4.2 to 2.3)
Autism	8.8 (8.3 to 9.2)	11.9 (11.3 to 12.6)	36.4 (35.0 to 37.9)	-0.9 (-0.9 to -0.8)	2.2 (1.4 to 3.0)	2.9 (2.0 to 4.0)	35.2 (28.7 to 42.3)	-0.7 (-5.3 to 4.0)
Asperger syndrome	12.3 (11.5 to 13.1)	16.7 (15.5 to 17.8)	35.7 (33.9 to 37.6)	-1.1 (-1.2 to -1.1)	1.2 (0.9 to 1.7)	1.7 (1.1 to 2.3)	34.8 (29.0 to 40.5)	-1.2 (-4.9 to 2.8)
Attention-deficit/hyperactivity disorder	14.4 (13.2 to 15.5)	15.8 (14.5 to 17.1)	10.2 (10.0 to 10.4)	-0.7 (-0.8 to -0.7)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	10.2 (2.7 to 18.5)	-0.8 (-7.5 to 6.7)
Conduct disorder	19.1 (17.4 to 20.9)	21.8 (19.9 to 23.8)	14.0 (13.4 to 14.6)	-0.5 (-0.6 to -0.5)	2.3 (1.5 to 3.4)	2.6 (1.7 to 3.8)	13.9 (9.1 to 19.1)	-0.6 (-4.7 to 3.8)
Idiopathic intellectual disability	11.1 (6.7 to 15.2)	10.3 (5.7 to 15.3)	-7.2 (-28.6 to 11.3)	-33.2 (-47.9 to -20.3)	0.6 (0.4 to 1.0)	0.6 (0.3 to 1.0)	7.5 (-20.0 to 12.4)	-33.0 (-48.3 to -19.3)
Other mental and substance use disorders	49.6 (46.5 to 52.6)	77.6 (73.1 to 82.0)	56.5 (52.7 to 60.4)	0.6 (-0.7 to -0.4)	3.8 (2.5 to 5.1)	5.8 (3.9 to 7.8)	54.8 (47.7 to 62.2)	0.7 (-4.3 to 3.2)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	23.2 (15.8 to 32.9)	56.6 (38.3 to 78.0)	144.0 (120.0 to 170.8)	33.3 (20.6 to 47.1)
Diabetes mellitus	194.4 (170.0 to 224.4)	623.4 (553.7 to 688.9)	220.7 (171.2 to 278.3)	66.0 (40.2 to 92.4)	11.7 (7.6 to 17.0)	37.2 (24.6 to 52.2)	218.7 (168.3 to 279.2)	62.2 (37.3 to 89.7)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.1 (-3.7 to 14.6)	-19.1 (-24.6 to -12.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.1 (-3.7 to 14.7)	-19.1 (-24.6 to -12.3)
Chronic kidney disease	-	-	-	-	1.8 (1.3 to 2.4)	3.6 (2.5 to 4.8)	96.8 (72.7 to 133.9)	7.4 (-4.5 to 24.7)
Chronic kidney disease due to diabetes mellitus	28.4 (17.9 to 47.5)	65.6 (40.4 to 126.5)	131.3 (57.4 to 205.4)	6.8 (-31.5 to 38.1)	0.5 (0.3 to 0.6)	1.2 (0.8 to 1.8)	170.2 (98.4 to 255.1)	33.7 (1.5 to 74.9)
Chronic kidney disease due to hypertension	22.8 (15.7 to 33.4)	38.3 (24.9 to 62.5)	66.3 (19.8 to 135.0)	-6.8 (-32.5 to 28.0)	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.0)	77.0 (35.8 to 129.3)	-8.5 (-28.8 to 15.7)
Chronic kidney disease due to glomerulonephritis	25.2 (15.8 to 48.0)	39.0 (23.9 to 76.9)	54.2 (10.2 to 105.2)	-24.3 (-47.3 to -0.8)	0.4 (0.3 to 0.5)	0.7 (0.5 to 1.0)	80.1 (40.1 to 133.1)	10.6 (-12.4 to 40.4)
Chronic kidney disease due to other causes	29.6 (19.2 to 51.2)	46.0 (28.3 to 82.6)	55.8 (13.3 to 109.0)	66.7 (-36.0 to 90.0)	0.5 (0.3 to 0.7)	0.8 (0.6 to 1.2)	66.2 (27.0 to 140.8)	4.7 (-25.8 to 29.8)
Urinary diseases and male infertility	-	-	-	-	2.0 (1.3 to 2.8)	4.9 (3.2 to 6.9)	146.3 (116.2 to 185.8)	-0.4 (-13.1 to 15.5)
Interstitial nephritis and urinary tract infections	0.6 (0.5 to 0.6)	1.1 (1.0 to 1.3)	92.9 (65.5 to 129.8)	22.5 (5.1 to 44.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	92.4 (46.7 to 143.6)	23.3 (-4.7 to 55.6)

Appendix Table G.4 - Singapore prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Urolithiasis	10.7 (5.4 to 20.8)	33.2 (16.2 to 60.8)	205.4 (154.5 to 287.0)	2.2 (13.1 to 69.1)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.6)	131.9 (91.3 to 177.7)	11.1 (-4.3 to 32.4)
Benign prostatic hyperplasia	48.6 (41.8 to 53.4)	122.3 (110.4 to 134.1)	151.9 (117.4 to 196.3)	-1.5 (-16.0 to 16.0)	1.8 (1.1 to 2.5)	4.4 (2.9 to 6.3)	151.0 (116.2 to 195.3)	-1.7 (-16.2 to 16.0)
Male infertility due to other causes	8.2 (5.8 to 10.8)	9.4 (6.8 to 12.2)	16.4 (23.9 to 66.5)	2.9 (-32.4 to 47.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	16.2 (-23.6 to 78.2)	2.9 (-31.7 to 58.7)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	302.4 (3.6 to 527.5)	95.2 (-48.5 to 194.9)
Gynecological diseases	-	-	-	-	3.9 (2.5 to 5.8)	5.3 (3.4 to 8.1)	9.1 (16.6 to 55.6)	-9.1 (-15.8 to 11.1)
Uterine fibroids	83.3 (72.4 to 95.6)	143.4 (126.5 to 162.5)	72.2 (67.8 to 76.8)	2.6 (2.5 to 2.8)	1.1 (0.6 to 1.8)	1.7 (1.0 to 2.9)	55.1 (46.1 to 63.8)	0.1 (-5.1 to 4.2)
Polycystic ovarian syndrome	43.7 (40.1 to 47.5)	60.0 (54.8 to 65.7)	37.6 (21.4 to 53.5)	6.0 (-6.6 to 18.4)	0.4 (0.2 to 0.8)	0.6 (0.3 to 1.1)	36.8 (20.4 to 53.1)	5.8 (-7.3 to 18.0)
Female infertility due to other causes	2.0 (0.4 to 4.8)	3.1 (0.5 to 7.2)	74.0 (-79.8 to 999.2)	27.1 (-85.1 to 725.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.4 (-78.3 to 911.3)	24.2 (-84.1 to 663.2)
Endometriosis	9.5 (7.4 to 11.3)	11.7 (9.2 to 14.2)	24.5 (-5.4 to 61.9)	-4.1 (-26.7 to 22.9)	0.9 (0.5 to 1.3)	1.1 (0.7 to 1.6)	24.9 (7.1 to 65.2)	-3.7 (-28.5 to 25.8)
Genital prolapse	115.9 (90.7 to 135.5)	204.0 (169.7 to 239.1)	75.1 (37.6 to 136.7)	2.6 (-17.5 to 32.5)	0.4 (0.2 to 0.7)	0.7 (0.3 to 1.2)	74.4 (36.8 to 135.2)	2.7 (-17.6 to 33.0)
Premenstrual syndrome	95.8 (54.1 to 130.8)	100.9 (61.0 to 158.3)	2.4 (-39.1 to 92.8)	-17.2 (-52.9 to 58.4)	0.8 (0.4 to 1.4)	0.9 (0.4 to 1.5)	2.1 (-40.0 to 92.1)	-17.9 (-54.2 to 58.6)
Other gynecological diseases	10.7 (9.1 to 12.5)	14.2 (13.3 to 15.1)	32.6 (16.0 to 54.7)	0.4 (-13.8 to 16.7)	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	30.1 (12.1 to 77.3)	-1.2 (-15.1 to 33.0)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	2.6 (1.7 to 3.5)	3.8 (2.5 to 5.6)	46.0 (29.0 to 67.5)	7.9 (-3.5 to 22.6)
Thalassemias	0.3 (0.3 to 0.4)	0.4 (0.3 to 0.4)	11.1 (3.0 to 21.5)	5.4 (-2.0 to 14.6)	0.0 (0.0 to 0.0)	0.0 (-10.7 to 32.0)	8.2 (-10.7 to 32.0)	1.2 (-16.8 to 25.3)
Thalassemia trait	112.4 (106.1 to 120.5)	163.7 (155.6 to 172.9)	45.7 (39.4 to 52.4)	2.6 (-1.7 to 7.1)	2.0 (1.3 to 2.9)	3.0 (2.0 to 4.4)	54.2 (29.6 to 74.2)	13.3 (-3.2 to 27.2)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.0 (7.2 to 23.3)	-1.0 (-6.9 to 6.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.9 (7.8 to 30.8)	-0.8 (-8.4 to 10.0)
Sickle cell trait	1.3 (1.1 to 1.3)	1.3 (1.0 to 1.4)	5.8 (-1.3 to 9.1)	-25.2 (-30.2 to -22.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.9 (-16.0 to 1.9)	-34.1 (-37.4 to -22.3)
G6PD deficiency	38.7 (29.1 to 48.0)	55.1 (47.2 to 64.0)	42.0 (13.7 to 90.3)	0.5 (-19.6 to 35.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.5 (25.8 to 38.6)	-0.2 (-5.8 to 3.6)
G6PD trait	213.1 (204.0 to 223.8)	311.1 (297.4 to 324.7)	46.0 (37.1 to 54.8)	1.8 (-4.4 to 8.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.7 (-69.3 to 332.9)	11.7 (-72.1 to 292.6)
Other hemoglobinopathies and hemolytic anemias	23.6 (20.8 to 26.3)	33.3 (29.7 to 36.0)	40.4 (23.3 to 65.8)	-5.4 (-17.4 to 10.7)	0.6 (0.3 to 0.8)	0.7 (0.4 to 1.0)	23.5 (7.5 to 82.7)	-5.9 (-29.9 to 35.4)
Endocrine, metabolic, blood, and immune disorders	38.4 (35.7 to 41.6)	57.4 (54.5 to 60.5)	49.3 (37.4 to 63.8)	-0.3 (-7.9 to 8.7)	1.3 (0.9 to 1.8)	1.9 (1.3 to 2.6)	50.0 (36.8 to 72.8)	1.7 (-6.7 to 16.3)
Musculoskeletal disorders	-	-	-	-	39.8 (28.1 to 53.2)	81.2 (58.3 to 108.5)	104.3 (89.3 to 117.3)	9.5 (-1.8 to 15.8)
Rheumatoid arthritis	3.5 (3.3 to 3.6)	7.3 (6.9 to 7.7)	111.7 (95.1 to 126.9)	-4.7 (-12.5 to 2.5)	0.8 (0.6 to 1.1)	1.7 (1.2 to 2.3)	108.3 (88.1 to 131.1)	-4.8 (-13.7 to 5.1)
Osteoarthritis	107.4 (101.2 to 114.6)	257.9 (246.0 to 269.0)	140.2 (122.9 to 157.5)	-3.7 (-10.6 to 3.0)	3.8 (2.5 to 5.5)	9.0 (6.0 to 13.0)	138.7 (120.7 to 156.4)	-3.7 (-10.6 to 3.1)
Low back and neck pain	-	-	-	-	23.3 (16.1 to 31.8)	44.6 (30.9 to 60.8)	92.5 (69.2 to 111.4)	14.9 (-1.6 to 25.4)
Low back pain	99.0 (91.2 to 105.6)	172.8 (160.7 to 183.9)	74.8 (57.3 to 91.2)	2.0 (-8.0 to 11.4)	11.2 (7.6 to 15.6)	19.3 (13.0 to 27.1)	72.7 (55.5 to 89.9)	2.3 (-8.2 to 11.8)
Neck pain	121.1 (102.1 to 142.2)	255.3 (225.1 to 284.1)	113.3 (71.7 to 154.1)	12.1 (3.1 to 50.2)	12.1 (8.1 to 17.3)	25.3 (17.3 to 35.4)	111.6 (70.8 to 151.7)	27.4 (2.8 to 50.5)
Gout	3.2 (2.7 to 3.6)	7.8 (6.8 to 8.8)	145.0 (100.0 to 193.8)	9.8 (-10.3 to 30.9)	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	139.6 (82.2 to 209.7)	8.9 (-15.6 to 40.5)
Other musculoskeletal disorders	126.9 (103.3 to 148.9)	277.4 (229.4 to 326.0)	118.5 (103.7 to 134.8)	6.7 (0.9 to 12.1)	11.8 (7.7 to 17.0)	25.6 (17.0 to 36.5)	117.6 (101.9 to 135.0)	6.9 (-1.0 to 13.0)
Other non-communicable diseases	-	-	-	-	38.0 (26.0 to 54.0)	62.0 (42.4 to 86.3)	62.9 (56.2 to 70.4)	-8.7 (-12.6 to -4.8)
Congenital anomalies	-	-	-	-	3.0 (2.1 to 4.1)	4.2 (3.0 to 5.5)	37.6 (22.5 to 58.0)	-6.6 (-16.2 to 6.5)
Neural tube defects	1.2 (1.1 to 1.4)	1.3 (1.1 to 1.5)	5.8 (-13.0 to 30.5)	-18.5 (-33.1 to 0.5)	0.3 (0.3 to 0.5)	0.4 (0.3 to 0.6)	5.7 (-21.1 to 45.7)	-18.0 (-38.9 to 13.9)
Congenital heart anomalies	27.6 (23.3 to 32.9)	32.2 (27.2 to 39.0)	16.4 (-5.8 to 46.0)	-14.9 (-30.9 to 6.3)	1.0 (0.4 to 1.7)	1.2 (0.5 to 2.1)	18.5 (-1.4 to 43.6)	-11.6 (-26.3 to 6.8)
Orofacial clefts	5.8 (4.8 to 6.9)	7.1 (5.8 to 8.4)	22.1 (-4.9 to 55.1)	-11.6 (-31.4 to 12.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	21.0 (-1.2 to 64.8)	-12.0 (-37.7 to 19.4)
Down syndrome	2.3 (1.9 to 2.8)	3.8 (3.1 to 4.7)	65.9 (25.5 to 119.0)	5.2 (-20.6 to 38.8)	0.6 (0.2 to 0.4)	0.6 (0.4 to 0.8)	87.6 (40.7 to 152.7)	6.8 (-20.5 to 42.3)
Turner syndrome	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	43.4 (-6.6 to 113.9)	8.2 (-29.1 to 61.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.8 (-10.7 to 115.6)	8.1 (-31.2 to 64.1)
Klinefelter syndrome	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	77.5 (22.4 to 161.0)	28.3 (-11.4 to 88.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.8 (-3.0 to 179.7)	26.8 (-24.0 to 104.7)
Chromosomal unbalanced rearrangements	3.8 (3.2 to 4.8)	6.2 (5.1 to 7.5)	62.0 (38.0 to 116.1)	2.9 (-25.1 to 37.4)	0.5 (0.4 to 0.7)	0.9 (0.7 to 1.3)	83.1 (32.9 to 147.8)	4.5 (-24.5 to 39.9)
Other congenital anomalies	4.6 (3.4 to 5.5)	5.8 (3.9 to 7.1)	29.4 (-2.4 to 59.1)	-14.7 (-35.2 to 4.6)	0.7 (0.5 to 1.0)	0.9 (0.6 to 1.3)	29.8 (4.3 to 65.5)	-0.8 (-25.5 to 18.3)
Skin and subcutaneous diseases	-	-	-	-	16.3 (10.5 to 24.6)	23.2 (15.3 to 34.4)	42.1 (30.7 to 56.0)	-1.2 (-8.4 to 8.2)
Dermatitis	173.0 (139.8 to 206.8)	241.3 (197.2 to 283.7)	39.7 (34.5 to 45.0)	-0.1 (-0.2 to 0.1)	4.5 (2.9 to 6.6)	6.3 (4.0 to 9.0)	38.2 (32.7 to 44.3)	0.1 (-2.6 to 2.4)
Psoriasis	35.9 (31.3 to 40.5)	57.7 (50.3 to 64.6)	60.7 (53.1 to 68.6)	-0.1 (-0.2 to 0.1)	3.0 (2.0 to 4.1)	4.7 (3.2 to 6.7)	59.0 (49.0 to 70.0)	-0.3 (-4.3 to 4.6)
Cellulitis	1.2 (1.0 to 1.6)	2.1 (1.7 to 2.8)	71.8 (54.3 to 93.7)	-1.1 (-9.9 to 7.3)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	69.8 (39.0 to 107.0)	-0.8 (-16.8 to 17.7)
Pyoderma	1.9 (1.4 to 2.5)	2.4 (1.8 to 3.2)	26.8 (14.0 to 40.2)	-11.9 (-15.6 to -7.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.3 (8.0 to 44.5)	-11.9 (-21.0 to -1.9)
Scabies	1.7 (1.4 to 2.0)	1.8 (1.5 to 2.2)	7.8 (-17.2 to 40.8)	-21.5 (-38.4 to -0.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	6.4 (-20.2 to 44.5)	-21.4 (-40.0 to 2.8)
Fungal skin diseases	159.8 (127.9 to 195.1)	261.4 (214.2 to 306.8)	63.7 (54.8 to 74.0)	-0.4 (-0.7 to -0.1)	0.9 (0.4 to 1.5)	1.5 (0.6 to 3.1)	62.5 (55.5 to 72.9)	-0.4 (-1.4 to 0.6)
Viral skin diseases	62.9 (48.2 to 77.8)	77.5 (64.2 to 94.0)	23.0 (17.4 to 33.3)	-2.0 (-2.1 to 3.1)	2.0 (1.1 to 3.1)	2.4 (1.4 to 3.8)	22.5 (16.5 to 32.6)	-0.2 (-3.2 to 3.1)
Acne vulgaris	319.9 (239.3 to 407.9)	347.8 (277.1 to 448.9)	7.0 (-20.0 to 59.8)	-6.5 (-31.6 to 44.5)	3.5 (1.5 to 6.8)	3.8 (1.7 to 7.3)	6.7 (-20.4 to 60.0)	-6.5 (-31.5 to 45.7)
Alopecia areata	4.2 (3.9 to 4.5)	6.9 (6.4 to 7.4)	63.4 (46.0 to 81.9)	-0.4 (-9.8 to 10.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	62.2 (41.0 to 84.7)	0.0 (-12.4 to 13.6)
Pruritus	1.0 (0.8 to 1.2)	1.8 (1.5 to 2.2)	90.8 (35.9 to 145.5)	-0.8 (-28.3 to 29.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.1 (33.2 to 145.9)	-1.7 (-29.7 to 31.1)
Urticaria	19.0 (14.6 to 23.8)	33.3 (24.1 to 45.7)	74.6 (24.4 to 154.1)	2.0 (-28.5 to 46.9)	1.1 (0.7 to 1.7)	2.0 (1.1 to 3.1)	71.6 (22.4 to 152.0)	2.1 (-28.7 to 46.5)
Decubitus ulcer	1.0 (0.8 to 1.2)	2.3 (2.0 to 2.8)	141.5 (73.7 to 237.8)	-0.0 (-29.4 to 43.1)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	134.0 (67.2 to 229.5)	-1.5 (-30.6 to 45.0)
Other skin and subcutaneous diseases	155.1 (100.2 to 236.2)	305.5 (185.3 to 502.3)	95.7 (69.1 to 121.9)	-0.0 (-2.6 to 3.2)	0.9 (0.4 to 1.9)	1.8 (0.7 to 4.0)	94.8 (67.6 to 121.2)	-0.1 (-3.0 to 3.2)
Sense organ diseases	-	-	-	-	14.7 (10.0 to 20.7)	27.6 (19.0 to 38.2)	88.1 (79.5 to 98.3)	-15.4 (-18.7 to -11.9)
Glaucoma	9.6 (7.7 to 12.0)	14.9 (11.4 to 18.1)	54.3 (29.0 to 85.5)	-3.4 (-44.5 to 18.3)	0.8 (0.5 to 1.1)	1.3 (0.9 to 1.8)	64.6 (46.6 to 92.6)	-31.3 (-41.9 to -20.3)
Cataract	14.6 (10.2 to 18.9)	27.2 (18.9 to 35.9)	86.6 (43.9 to 148.5)	-36.0 (-50.4 to -34.8)	0.9 (0.6 to 1.4)	1.8 (1.1 to 2.6)	85.4 (48.9 to 139.6)	-36.8 (-49.0 to -18.5)
Macular degeneration	8.8 (6.1 to 11.9)	27.7 (20.0 to 36.3)	217.5 (136.4 to 311.1)	14.5 (-14.8 to 50.2)	0.5 (0.3 to 0.8)	1.7 (1.0 to 2.4)	204.9 (132.2 to 281.6)	4.9 (-19.6 to 31.4)
Uncorrected refractive error	124.5 (114.2 to 135.4)	217.3 (199.1 to 235.1)	74.9 (59.6 to 89.8)	-13.9 (-20.7 to -7.2)	3.6 (2.4 to 5.2)	5.7 (3.8 to 8.2)	57.3 (46.3 to 67.6)	-20.4 (-24.1 to -16.1)
Age-related and other hearing loss	258.5 (240.1 to 276.5)	551.5 (516.1 to 588.0)	113.6 (103.7 to 121.9)	-8.5 (-11.8 to -5.7)	5.4 (3.5 to 8.1)	12.1 (8.0 to 18.0)	127.8 (111.0 to 148.6)	-7.2 (-12.9 to -1.0)
Other vision loss	28.3 (23.7 to 33.7)	37.8 (30.3 to 45.4)	34.1 (15.2 to 52.6)	-31.4 (-40.6 to -20.9)	1.8 (1.2 to 2.5)	2.5 (1.6 to 3.5)	39.6 (23.6 to 56.1)	-30.9 (-38.0 to -22.1)
Other sense organ diseases	58.9 (54.9 to 63.1)	89.7 (85.7 to 93.8)	52.5 (41.3 to 65.3)	0.8 (-6.8 to 8.5)	1.6 (0.9 to 2.4)	2.4 (1.5 to 3.5)	50.7 (38.0 to 64.0)	0.9 (-7.7 to 9.5)
Oral disorders	-	-	-	-	4.0 (2.5 to 6.1)	7.1 (4.3 to 10.8)	77.4 (68.2 to 85.5)	-8.7 (-13.3 to -4.5)
Deciduous caries	155.1 (151.7 to 158.5)	149.2 (146.2 to 152.1)	-3.8 (-6.6 to -1.0)	-1.1 (-3.9 to 1.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-0.9 (-10.8 to 4.2)	-0.9 (-8.3 to 7.1)
Permanent caries	355.0 (350.8 to 381.5)	516.2 (495.7 to 536.5)	41.5 (33.4 to 49.4)	51.5 (-8.1 to 2.6)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.6)	40.7 (31.8 to 50.2)	-3.2 (-8.7 to 3.2)
Periodontal diseases	119.6 (112.0 to 127.0)	249.7 (235.2 to 265.0)	108.1 (91.9 to 129.8)	3.1 (-4.7 to 13.1)	0.8 (0.3 to 1.6)	1.6 (0.7 to 3.3)	106.8 (90.5 to 128.7)	3.0 (-4.8 to 13.0)
Edentulism and severe tooth loss	54.1							

Appendix Table G.4 - Singapore prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	50.0 (46.9 to 52.9)	77.0 (72.6 to 81.1)	53.9 (41.8 to 66.5)	0.4 (-6.8 to 8.3)	1.5 (0.9 to 2.2)	2.3 (1.4 to 3.4)	52.8 (40.4 to 66.8)	0.3 (-7.3 to 9.1)
Injuries	-	-	-	-	15.2 (11.5 to 19.6)	18.6 (13.3 to 25.1)	22.1 (10.3 to 35.9)	37.4 (-43.5 to -30.5)
Transport injuries	-	-	-	-	4.2 (3.2 to 5.4)	2.8 (2.0 to 3.7)	-34.5 (-41.6 to -25.9)	-63.2 (-66.9 to -58.9)
Road injuries	-	-	-	-	4.0 (3.0 to 5.1)	2.4 (1.8 to 3.2)	-39.0 (-45.6 to -31.1)	-65.7 (-69.1 to -61.8)
Pedestrian road injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.5 (0.4 to 0.7)	-56.0 (-34.1 to -17.2)	-41.7 (-65.7 to -57.8)
Cyclist road injuries	-	-	-	-	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.3)	-39.7 (-47.4 to -30.4)	-67.1 (-71.0 to -62.5)
Motorcyclist road injuries	-	-	-	-	1.2 (0.9 to 1.5)	0.6 (0.4 to 0.8)	-53.7 (-60.5 to -44.8)	-72.0 (-75.8 to -67.0)
Motor vehicle road injuries	-	-	-	-	1.6 (1.2 to 2.1)	1.1 (0.8 to 1.4)	-33.3 (-39.6 to -25.8)	-62.6 (-65.9 to -58.8)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.6 (-64.6 to -53.2)	-76.7 (-79.4 to -73.3)
Other transport injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	32.9 (17.0 to 48.9)	-28.5 (-37.1 to -19.8)
Unintentional injuries	-	-	-	-	10.5 (8.0 to 13.6)	15.4 (11.0 to 20.9)	46.6 (33.4 to 59.9)	-27.9 (-34.7 to -20.5)
Falls	-	-	-	-	6.5 (4.9 to 8.3)	10.9 (7.8 to 14.8)	68.3 (50.4 to 87.8)	-24.4 (-32.6 to -15.0)
Drowning	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	13.6 (0.2 to 27.7)	-38.2 (-45.0 to -30.8)
Fire, heat, and hot substances	-	-	-	-	0.4 (0.3 to 0.7)	0.6 (0.4 to 1.0)	35.4 (17.2 to 55.5)	-23.1 (-32.6 to -13.1)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.7 (-44.4 to -21.8)	-61.1 (-66.9 to -54.0)
Exposure to mechanical forces	-	-	-	-	3.0 (2.2 to 3.9)	2.8 (2.0 to 3.8)	-7.4 (-16.2 to 3.2)	-44.4 (-49.2 to -38.5)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.4 (-20.8 to 5.2)	-40.7 (-47.4 to -31.7)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.3 (15.9 to 52.3)	21.2 (-30.1 to -10.3)
Other exposure to mechanical forces	-	-	-	-	2.9 (2.2 to 3.8)	2.7 (1.9 to 3.7)	-7.6 (-16.4 to 3.1)	-44.5 (-49.4 to -38.7)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	88.9 (73.5 to 104.4)	2.1 (-6.5 to 10.5)
Animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	35.5 (24.0 to 48.1)	-16.2 (-22.4 to -9.1)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.2 (20.8 to 54.4)	-13.7 (-23.9 to -3.1)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	35.1 (22.3 to 49.2)	-17.0 (-23.5 to -8.7)
Foreign body	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	22.2 (12.4 to 32.3)	-21.4 (-29.6 to -14.4)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.3 (0.9 to 35.1)	-30.8 (-39.7 to -19.4)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	26.9 (13.4 to 43.1)	-12.8 (-23.9 to -1.6)
Foreign body in other body part	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	21.2 (8.8 to 32.6)	-22.9 (-32.3 to -15.4)
Other unintentional injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.5 (0.3 to 0.7)	253.6 (217.4 to 295.9)	56.5 (40.6 to 74.4)
Self-harm and interpersonal violence	-	-	-	-	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	-5.2 (-13.9 to 4.2)	47.0 (-51.4 to -42.2)
Self-harm	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	59.3 (41.3 to 79.0)	-15.8 (-24.6 to -6.3)
Interpersonal violence	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-34.6 (-41.5 to -27.0)	-61.7 (-65.4 to -57.4)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.8 (-48.9 to -34.2)	-66.7 (-70.5 to -62.6)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-16.4 (-23.1 to -8.6)	-51.6 (-55.0 to -47.3)
Assault by other means	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-37.5 (-44.4 to -29.0)	-63.1 (-67.1 to -58.6)
Forces of nature, war, and legal intervention	-	-	-	-	-	-	-	-
Exposure to forces of nature	-	-	-	-	-	-	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Slovakia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	590.9 (436.1 to 751.2)	674.7 (504.3 to 873.0)	16.1 (13.8 to 18.6)	16.1 (-5.1 to 1.1)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	36.9 (25.6 to 52.1)	30.1 (21.0 to 42.3)	-18.6 (-23.6 to -12.2)	-3.9 (-9.5 to 3.1)
HIV/AIDS and tuberculosis	-	-	-	-	0.5 (0.4 to 0.7)	0.5 (0.3 to 0.7)	-5.9 (-18.8 to 9.5)	-24.3 (-34.8 to -11.5)
Tuberculosis	1.8 (1.7 to 1.9)	1.6 (1.5 to 1.8)	-8.5 (-15.0 to -1.2)	-26.8 (-31.8 to -21.1)	0.5 (0.4 to 0.7)	0.5 (0.3 to 0.7)	-8.5 (-21.7 to 6.7)	-26.4 (-36.8 to -14.2)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	631.9 (371.8 to 1,561.1)	631.9 (284.7 to 1,266.6)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	312.7 (92.2 to 702.1)	228.3 (54.0 to 539.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	312.7 (91.7 to 703.6)	228.3 (51.8 to 540.6)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	1,075.2 (585.8 to 1,912.1)	868.9 (460.4 to 1,562.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	795.6 (372.4 to 1,569.8)	635.9 (285.1 to 1,274.7)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	4.0 (2.7 to 5.6)	3.7 (2.6 to 5.2)	-6.7 (-12.7 to -1.0)	-1.0 (-7.7 to 5.5)
Diarrheal diseases	11.7 (10.9 to 12.5)	11.2 (10.5 to 12.0)	-4.5 (-13.5 to 5.6)	4.1 (-6.2 to 15.8)	1.9 (1.3 to 2.7)	1.8 (1.2 to 2.5)	5.8 (-16.1 to 5.5)	4.0 (-7.7 to 16.7)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-74.8 to -0.7)	0.0 (-74.0 to 1.9)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.0 (-46.0 to -20.7)	-34.3 (-44.1 to -20.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.0 (-46.0 to -20.6)	-34.3 (-44.1 to -20.6)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.5 (-48.4 to -20.1)	-32.6 (-45.2 to -17.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.5 (-48.4 to -20.1)	-32.6 (-45.2 to -17.3)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-89.7 (-99.6 to 184.1)	-89.7 (-99.6 to 184.1)
Lower respiratory infections	0.6 (0.6 to 0.7)	0.5 (0.4 to 0.5)	-28.2 (-31.5 to -25.0)	-15.2 (-19.6 to -10.9)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-27.9 (-31.1 to -14.9)	-14.3 (-28.7 to 2.7)
Upper respiratory infections	51.9 (49.7 to 54.4)	51.4 (49.2 to 53.6)	-0.6 (-6.5 to 4.3)	-0.2 (-5.8 to 5.1)	0.6 (0.3 to 1.0)	0.6 (0.3 to 1.0)	-1.1 (-8.4 to 6.1)	-0.1 (-7.3 to 7.5)
Otitis media	56.2 (52.0 to 60.4)	51.3 (47.7 to 54.9)	-8.7 (-16.1 to 0.1)	-6.3 (-13.3 to 2.3)	1.1 (0.7 to 1.8)	1.0 (0.6 to 1.6)	-12.3 (-20.4 to -2.1)	-8.2 (-16.6 to 2.1)
Meningitis	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-9.0 (-29.9 to 17.0)	-11.0 (-33.0 to 14.4)
Pneumococcal meningitis	0.5 (0.3 to 0.8)	0.5 (0.3 to 0.8)	-3.6 (-24.6 to 27.7)	-14.8 (-33.6 to 11.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-1.2 (-25.0 to 45.3)	-7.2 (-29.8 to 34.6)
H influenzae type B meningitis	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	-21.4 (-60.5 to 21.6)	-23.7 (-60.2 to 25.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-14.5 (-63.8 to 47.6)	-11.0 (-62.0 to 55.4)
Meningococcal meningitis	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.2)	-18.4 (-47.3 to 30.8)	-24.7 (-50.8 to 33.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.5 (-49.9 to 54.8)	-12.2 (-51.3 to 55.5)
Other meningitis	0.3 (0.1 to 0.6)	0.2 (0.1 to 0.5)	-35.3 (-38.6 to 11.7)	-20.8 (-40.1 to 7.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-10.8 (-44.7 to 30.6)	-11.9 (-47.0 to 29.4)
Encephalitis	0.5 (0.2 to 1.3)	0.6 (0.3 to 1.6)	13.6 (-12.4 to 34.7)	-3.5 (-23.4 to 17.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	17.9 (5.0 to 44.2)	2.6 (-17.8 to 25.0)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.0 (-92.1 to 465.8)	-46.9 (-91.7 to 460.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.0 (-91.9 to 467.9)	-46.9 (-91.9 to 467.9)
Whooping cough	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-33.8 (-33.8 to -33.7)	-5.3 (-5.4 to -5.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.5 (-58.0 to -0.2)	-4.6 (-39.8 to 42.4)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.0 (-66.5 to -6.0)	-25.2 (-66.6 to -5.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.0 (-66.9 to -8.7)	-25.6 (-66.2 to -5.4)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -89.5)	-100.0 (-100.0 to -84.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -89.4)	-100.0 (-100.0 to -84.4)
Varicella and herpes zoster	3.0 (2.8 to 3.2)	2.6 (2.4 to 2.9)	-12.7 (-23.4 to -0.7)	-3.3 (-12.3 to 6.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	-11.1 (-15.1 to 41.0)	-2.8 (-24.7 to 22.3)
Neglected tropical diseases and malaria	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-31.5 (-59.2 to 11.8)	-44.7 (-66.5 to -10.0)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.1 (-72.2 to 326.6)	4.1 (-71.4 to 348.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.7 (-71.7 to 329.9)	6.1 (-71.0 to 350.3)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.2 (0.0 to 0.3)	0.0 (0.0 to 0.1)	-80.2 (-93.5 to -3.4)	-83.9 (-94.6 to -25.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-77.8 (-93.0 to 18.6)	-82.0 (-94.1 to -10.2)
Cystic echinococcosis	0.5 (0.4 to 0.5)	0.5 (0.5 to 0.6)	15.6 (0.3 to 31.3)	-7.9 (-19.7 to 2.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	13.8 (-13.2 to 47.6)	-8.6 (-29.9 to 16.5)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.6 (-38.8 to 23.7)	-9.7 (-42.0 to 21.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.6 (-38.8 to 23.8)	-9.7 (-42.1 to 21.5)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.8 (-39.5 to 45.5)	-10.6 (-42.5 to 43.7)
Maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-29.9 (-44.6 to -11.2)	-39.1 (-51.8 to -22.8)
Maternal hemorrhage	0.3 (0.2 to 0.4)	0.3 (0.3 to 0.3)	-6.0 (-24.6 to 23.4)	-18.5 (-35.2 to 9.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.9 (-62.0 to -7.8)	-50.2 (-64.4 to -9.6)
Maternal sepsis and other maternal infections	0.7 (0.4 to 1.1)	0.3 (0.2 to 0.5)	-49.6 (-66.0 to -30.6)	-55.8 (-70.0 to -38.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.6 (-66.7 to -32.7)	-57.0 (-70.8 to -39.6)
Maternal hypertensive disorders	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.7)	-21.9 (-32.0 to -7.6)	-33.6 (-41.9 to -21.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-22.8 (-42.9 to 4.3)	-34.1 (-51.0 to -11.7)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.4 (-33.8 to -11.4)	-33.1 (-43.2 to -23.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.4 (-33.9 to -11.4)	-33.1 (-43.2 to -23.3)
Complications of abortion	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-11.8 (-23.4 to 2.3)	-24.4 (-34.4 to -12.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.0 (-42.3 to 67.8)	-21.7 (-51.9 to 50.4)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.0 (-64.1 to 40.7)	-38.9 (-68.8 to 23.0)
Neonatal disorders	-	-	-	-	5.8 (3.7 to 8.2)	5.0 (3.4 to 6.8)	-14.0 (-39.9 to 27.1)	-12.9 (-39.2 to 29.4)
Preterm birth complications	20.5 (15.7 to 26.4)	24.6 (19.1 to 31.9)	20.0 (-0.3 to 40.6)	18.1 (-2.2 to 38.5)	2.4 (1.6 to 3.3)	3.2 (2.2 to 4.4)	31.9 (-6.7 to 76.8)	33.0 (-5.7 to 78.4)
Neonatal encephalopathy due to birth asphyxia and trauma	6.4 (3.3 to 12.3)	3.7 (2.0 to 8.1)	-40.0 (-68.6 to -4.8)	-38.7 (-68.3 to -2.7)	1.7 (0.9 to 2.8)	1.6 (0.6 to 1.6)	-39.4 (-72.2 to 9.8)	-36.4 (-71.0 to 14.7)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.0 (7.9 to 46.8)	61.2 (47.3 to 100.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.7 (-43.3 to 192.1)	70.2 (-23.3 to 298.9)
Hemolytic disease and other neonatal jaundice	1.5 (0.4 to 3.2)	0.6 (0.2 to 1.8)	-61.4 (-90.7 to 38.5)	-61.8 (-90.7 to 39.5)	0.6 (0.1 to 1.3)	0.3 (0.1 to 0.8)	-59.9 (-90.4 to 48.4)	-59.6 (-90.3 to 49.8)
Other neonatal disorders	-	-	-	-	1.1 (0.3 to 1.9)	0.6 (0.3 to 1.2)	-59.4 (-76.1 to 152.2)	-58.9 (-75.8 to 156.7)
Nutritional deficiencies	-	-	-	-	24.4 (16.2 to 35.4)	19.0 (12.6 to 27.9)	-22.0 (-25.5 to -17.9)	-1.5 (-5.2 to 3.1)
Protein-energy malnutrition	3.2 (2.3 to 4.4)	1.9 (1.4 to 2.7)	-39.5 (-60.7 to -2.0)	-13.6 (-43.9 to 40.0)	0.4 (0.2 to 0.6)	0.2 (0.1 to 0.4)	-39.5 (-60.9 to -0.3)	-13.7 (-44.2 to 41.9)
Iodine deficiency	43.1 (21.9 to 83.8)	32.8 (13.5 to 62.0)	-22.5 (-69.2 to 96.3)	-21.5 (-71.7 to 72.1)	0.8 (0.3 to 1.7)	0.6 (0.2 to 1.3)	-21.2 (-69.0 to 100.8)	-20.2 (-71.2 to 75.5)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron-deficiency anemia	829.3 (815.6 to 843.7)	765.0 (754.6 to 775.7)	-7.8 (-9.7 to -5.9)	0.1 (-2.2 to 2.5)	23.1 (15.3 to 33.6)	18.1 (12.0 to 26.7)	-21.6 (-24.7 to -18.4)	-0.4 (-3.5 to 3.8)

Appendix Table G.4 - Slovakia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.2)	-26.0 (-60.1 to 33.8)	-26.0 (-42.9 to 91.8)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.1 (1.3 to 3.4)	1.8 (1.0 to 2.9)	-15.0 (-25.0 to 1.6)	-2.9 (-16.9 to 14.5)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.8 (0.4 to 1.6)	0.9 (0.5 to 1.8)	10.3 (-1.6 to 23.7)	-2.2 (-12.8 to 10.1)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	27.1 (1.6 to 59.7)	-5.1 (-24.0 to 18.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-5.0 (-32.6 to 34.1)
Chlamydial infection	125.3 (111.3 to 138.7)	139.6 (114.9 to 144.2)	4.2 (-11.9 to 20.9)	3.4 (-18.4 to 12.3)	4.2 (0.2 to 0.6)	4.2 (0.2 to 0.7)	-1.4 (-11.4 to 28.5)	-1.4 (-17.7 to 19.3)
Gonococcal infection	29.3 (23.7 to 34.7)	27.9 (22.6 to 33.6)	-4.6 (-27.8 to 28.6)	-7.0 (-29.5 to 27.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-3.4 (-32.0 to 35.5)	-4.7 (-34.0 to 34.8)
Trichomoniasis	58.1 (39.0 to 80.4)	74.0 (54.8 to 97.8)	27.9 (-20.9 to 102.1)	16.3 (-29.5 to 84.3)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	30.0 (-22.4 to 121.3)	17.6 (-31.9 to 103.5)
Genital herpes	894.1 (799.5 to 979.9)	1,024.9 (933.5 to 1,113.7)	14.8 (0.1 to 32.0)	-9.1 (-20.8 to 4.5)	0.2 (0.1 to 0.6)	0.3 (0.1 to 0.6)	13.0 (-2.4 to 30.8)	-9.0 (-21.2 to 4.8)
Other sexually transmitted diseases	0.5 (0.4 to 0.7)	0.5 (0.4 to 0.7)	-0.8 (-18.0 to 19.4)	-12.4 (-27.6 to 5.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-22.2 to 62.2)	0.0 (-31.2 to 40.8)
Hepatitis	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-14.6 (-25.5 to -2.1)	-19.4 (-29.2 to -8.0)
Hepatitis A	5.1 (5.0 to 5.3)	4.2 (4.0 to 4.3)	-19.2 (-19.6 to -18.9)	-12.8 (-14.0 to -11.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-8.6 (-17.9 to 3.2)	-9.2 (-18.6 to 3.0)
Hepatitis B	131.4 (107.6 to 160.8)	97.7 (78.6 to 120.4)	-25.7 (-42.6 to -2.2)	-33.2 (-49.1 to -11.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-26.1 (-47.6 to 4.8)	-37.6 (-56.0 to -12.6)
Hepatitis C	86.5 (78.0 to 95.5)	75.4 (68.5 to 82.6)	-12.7 (-23.8 to -0.4)	-28.2 (-37.3 to -18.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.9 (-41.2 to 20.4)	-31.0 (-50.7 to -2.4)
Hepatitis E	-	-	-	-	7.6 (16.6 to 12.0)	-	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	34.6 (28.4 to 39.2)	27.6 (24.3 to 30.9)	-20.2 (-31.4 to -3.1)	0.6 (-17.4 to 23.6)	1.0 (0.6 to 1.5)	0.7 (0.4 to 1.0)	-34.3 (-49.9 to -7.3)	0.3 (-28.3 to 41.4)
Non-communicable diseases	-	-	-	-	475.9 (356.1 to 614.0)	583.8 (432.4 to 755.5)	22.6 (19.9 to 25.8)	1.0 (-1.3 to 3.5)
Neoplasms	-	-	-	-	6.8 (5.1 to 8.7)	9.9 (7.3 to 12.8)	45.0 (33.7 to 56.9)	6.5 (-1.9 to 15.3)
Esophageal cancer	0.5 (0.4 to 0.6)	0.6 (0.5 to 0.8)	30.3 (-5.9 to 76.2)	-8.5 (-33.3 to 23.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	25.6 (-9.9 to 73.3)	-11.7 (-36.7 to 21.5)
Stomach cancer	3.1 (2.7 to 3.6)	2.5 (2.1 to 2.9)	-19.0 (-30.6 to -4.3)	-41.6 (-49.9 to -30.8)	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-24.1 (-36.8 to -8.8)	-45.3 (-54.3 to -33.9)
Liver cancer	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	17.5 (-12.3 to 61.0)	-15.4 (-37.3 to 16.0)
Liver cancer due to hepatitis B	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.2)	-4.4 (-66.7 to 72.3)	-30.6 (-75.0 to 24.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.7 (-68.1 to 43.9)	-37.0 (-76.6 to 2.1)
Liver cancer due to hepatitis C	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.4)	145.8 (35.0 to 362.5)	76.6 (-3.6 to 232.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	119.3 (38.5 to 285.2)	57.9 (-0.1 to 172.4)
Liver cancer due to alcohol use	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	13.7 (-31.2 to 95.1)	-17.9 (-50.1 to 38.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	4.7 (-31.1 to 68.3)	-24.8 (-50.9 to 20.5)
Liver cancer due to other causes	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-34.7 (-66.2 to 25.8)	-51.9 (-74.8 to -7.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.5 (-65.2 to 14.3)	-55.5 (-74.0 to -16.9)
Larynx cancer	1.0 (0.7 to 1.4)	0.9 (0.6 to 1.2)	-8.1 (-39.6 to 29.0)	-28.1 (-56.5 to -8.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-16.4 (-39.8 to 15.3)	-40.9 (-57.2 to -18.5)
Tracheal, bronchus and lung cancer	4.1 (3.6 to 4.6)	4.2 (3.7 to 4.8)	4.4 (-14.3 to 25.8)	-25.1 (-38.5 to -9.9)	0.6 (0.5 to 0.8)	0.6 (0.5 to 0.8)	-1.5 (-18.3 to 16.5)	-29.2 (-41.2 to -16.9)
Breast cancer	9.0 (7.8 to 10.9)	20.7 (18.4 to 23.3)	131.9 (91.3 to 173.9)	68.6 (39.4 to 99.0)	0.7 (0.5 to 1.0)	1.3 (0.9 to 1.7)	70.1 (35.2 to 102.6)	23.7 (-1.1 to 47.0)
Cervical cancer	4.5 (3.8 to 5.6)	3.4 (2.4 to 4.3)	-22.3 (-48.1 to 3.6)	-39.6 (-59.6 to -20.0)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-22.2 (-48.5 to 21.4)	-39.3 (-60.0 to -17.0)
Uterine cancer	4.7 (4.1 to 5.4)	5.2 (3.8 to 7.2)	8.9 (-19.6 to 52.2)	-21.4 (-41.3 to 9.3)	0.8 (0.2 to 0.4)	0.8 (0.2 to 0.5)	2.6 (-22.5 to 51.7)	25.6 (-44.0 to 84.0)
Prostate cancer	6.1 (5.0 to 7.8)	13.1 (10.4 to 15.8)	114.2 (70.2 to 176.1)	56.0 (24.0 to 98.6)	0.6 (0.4 to 0.9)	1.2 (0.8 to 1.7)	99.7 (55.3 to 153.7)	77.7 (13.3 to 82.2)
Colon and rectum cancer	10.4 (9.9 to 11.1)	19.5 (17.7 to 21.6)	87.5 (67.4 to 110.0)	35.6 (21.6 to 51.9)	0.9 (0.7 to 1.2)	1.6 (1.2 to 2.1)	76.8 (56.8 to 99.2)	28.0 (13.2 to 43.5)
Lip and oral cavity cancer	2.2 (2.0 to 2.5)	3.4 (2.4 to 4.5)	53.7 (4.0 to 107.3)	8.4 (-25.4 to 44.6)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	47.7 (-1.0 to 99.4)	4.0 (-30.0 to 38.9)
Nasopharynx cancer	0.6 (0.3 to 0.9)	0.2 (0.1 to 0.4)	-66.2 (-80.7 to -17.0)	-75.7 (-86.1 to -39.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-65.4 (-78.1 to -14.6)	-75.0 (-84.2 to -37.9)
Other pharynx cancer	1.3 (0.8 to 1.8)	2.0 (1.2 to 3.1)	56.2 (-14.8 to 187.4)	9.9 (-39.7 to 100.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	48.8 (-13.3 to 152.2)	4.5 (-38.7 to 77.3)
Gallbladder and biliary tract cancer	0.5 (0.4 to 0.6)	0.4 (0.3 to 0.6)	-6.3 (-25.4 to 25.3)	-32.6 (-47.1 to -9.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-8.5 (-32.0 to 28.8)	-34.3 (-50.6 to -7.6)
Pancreatic cancer	0.6 (0.5 to 0.6)	0.8 (0.7 to 1.0)	50.2 (21.5 to 84.4)	8.6 (-12.4 to 32.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	43.2 (14.4 to 76.2)	3.4 (-16.5 to 26.3)
Malignant skin melanoma	2.3 (1.7 to 3.2)	4.0 (2.8 to 5.5)	75.0 (36.4 to 118.0)	31.8 (2.8 to 62.1)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	66.8 (29.4 to 106.7)	25.3 (-2.5 to 55.2)
Non-melanoma skin cancer	2.5 (2.5 to 2.5)	5.2 (3.8 to 6.8)	108.0 (-16.2 to 120.4)	42.5 (-16.2 to 57.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	72.8 (-13.4 to 169.4)	20.5 (-40.1 to 89.1)
Ovarian cancer	1.3 (1.1 to 1.5)	2.0 (1.7 to 2.4)	59.1 (23.6 to 100.8)	16.8 (-8.9 to 47.2)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	53.9 (15.3 to 101.5)	12.7 (-15.8 to 48.3)
Testicular cancer	1.3 (0.9 to 1.8)	1.8 (1.0 to 2.7)	34.4 (-29.2 to 129.9)	17.3 (-38.3 to 95.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	28.6 (-32.2 to 119.1)	11.3 (-40.9 to 90.4)
Kidney cancer	2.1 (1.8 to 2.5)	5.2 (4.3 to 6.2)	147.0 (99.4 to 200.9)	80.0 (45.8 to 120.0)	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	134.7 (85.5 to 195.4)	70.8 (34.9 to 114.0)
Bladder cancer	0.9 (2.8 to 3.8)	4.6 (3.8 to 5.5)	371.9 (15.0 to 70.3)	4.3 (-16.5 to 22.9)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	31.7 (7.6 to 65.9)	5.1 (-21.8 to 19.5)
Brain and nervous system cancer	1.0 (0.9 to 1.2)	1.4 (1.1 to 1.7)	35.5 (12.2 to 61.3)	13.0 (-6.2 to 35.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	33.4 (8.4 to 61.5)	8.7 (-11.3 to 31.1)
Thyroid cancer	1.5 (1.2 to 1.9)	2.3 (1.7 to 3.0)	48.3 (9.1 to 101.4)	13.8 (-16.5 to 54.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	41.5 (1.4 to 96.4)	7.6 (-22.6 to 48.1)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.6 (-23.9 to 68.3)	-5.9 (-44.4 to 23.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.5 (-25.0 to 69.9)	-5.1 (-44.6 to 24.0)
Hodgkin lymphoma	0.9 (0.6 to 1.1)	0.8 (0.6 to 1.2)	-9.0 (-29.7 to 32.9)	-7.2 (-38.3 to 16.5)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-18.8 (-32.2 to 26.3)	-23.6 (-41.5 to 9.4)
Non-Hodgkin lymphoma	2.1 (1.5 to 3.1)	4.2 (2.5 to 6.2)	111.8 (24.0 to 188.6)	59.2 (-4.7 to 116.3)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	100.0 (16.7 to 177.9)	50.4 (-10.8 to 107.9)
Multiple myeloma	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.0)	63.8 (6.5 to 164.6)	19.2 (-21.4 to 90.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	56.6 (-4.3 to 146.2)	13.8 (-29.4 to 78.6)
Leukemia	1.9 (1.7 to 2.1)	2.5 (2.1 to 3.0)	35.0 (7.6 to 63.9)	8.5 (-14.9 to 33.5)	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.4)	28.5 (0.3 to 55.9)	-0.0 (-21.3 to 21.1)
Other neoplasms	3.3 (2.9 to 3.9)	7.9 (6.5 to 9.5)	142.6 (91.5 to 194.0)	91.7 (51.3 to 131.8)	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.7)	122.1 (71.3 to 174.0)	74.0 (35.1 to 112.5)
Cardiovascular diseases	-	-	-	-	16.3 (6.9 to 13.7)	16.3 (11.5 to 22.0)	0.0 (-32.7 to 92.0)	0.0 (-4.3 to 39.4)
Rheumatic heart disease	1.0 (0.9 to 1.1)	1.4 (1.3 to 1.4)	36.2 (25.9 to 48.1)	2.2 (-5.4 to 10.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	0.2 (8.8 to 64.6)	0.9 (-18.4 to 22.6)
Ischemic heart disease	65.2 (56.4 to 77.5)	88.4 (78.8 to 99.0)	35.9 (12.9 to 62.6)	-2.3 (-18.3 to 16.5)	3.6 (2.4 to 5.1)	4.9 (3.3 to 6.8)	36.4 (13.1 to 70.0)	-2.5 (-18.6 to 20.7)
Cerebrovascular disease	-	-	-	-	1.1 (0.8 to 1.7)	1.7 (1.2 to 2.3)	55.4 (11.6 to 73.2)	5.1 (-1.2 to 27.9)
Ischemic stroke	6.8 (5.7 to 7.8)	9.3 (7.8 to 10.8)	36.1 (9.4 to 74.7)	-0.3 (-19.2 to 27.4)	1.0 (0.7 to 1.4)	1.4 (0.9 to 1.9)	36.5 (9.6 to 76.3)	0.7 (-19.2 to 29.0)
Hemorrhagic stroke	1.5 (1.2 to 1.8)	2.1 (1.7 to 2.5)	39.9 (4.5 to 90.9)	6.4 (-19.9 to 44.8)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.5)	39.5 (-0.3 to 93.5)	6.6 (-22.6 to 48.0)
Hypertensive heart disease	9.9 (9.0 to 10.9)	16.6 (15.4 to 17.9)	66.9 (49.4 to 89.2)	18.8 (6.4 to 35.1)	1.1 (0.7 to 1.4)	1.8 (1.3 to 2.4)	67.9 (49.0 to 92.6)	20.1 (6.5 to 37.3)
Cardiomyopathy and myocarditis	10.0 (8.9 to 11.1)	10.4 (9.6 to 11.1)	3.6 (-9.0 to 18.3)	-24.3 (-31.5 to -13.4)	1.1 (0.7 to 1.4)	1.1 (0.8 to 1.5)	0.0 (-9.7 to 20.3)	-23.1 (-33.8 to -11.8)
Atrial fibrillation and flutter	1.2 (0.9 to 1.5)	19.1 (15.8 to 23.1)	1,554.8 (1,111.8 to 2,207.9)	1,067.2 (760.8 to 1,546.5)	0.1 (0.1 to 0.1)	0.1 (1.0 to 2.1)	1.5 (1,104.7 to 2,284.0)	1,071.9 (753.3 to 1,593.7)
Peripheral vascular disease	158.3 (109.3 to 201.2)	222.8 (172.3 to 275.5)	42.7 (-1.3 to 97.1)	1.3 (-30.1 to 39.6)	0.3 (0.1 to 0.6)	0.2 (0.1 to 0.4)	-26.7 (-63.8 to 100.7)	-49.7 (-74.4 to 35.2)
Endocarditis	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.4)	168.5 (110.9 to 245.8)	99.6 (56.9 to 155.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (49.0 to 178.1)	49.8 (10.3 to 108.4)
Other cardiovascular and circulatory diseases	36.2 (23.9 to 62.1)	71.0 (46.1 to 95.2)	106.5 (-2.2 to 225.3)	52.8 (-27.6 to 141.6)	2.5 (1.4 to 4.3)	5.0 (2.8 to 7.4)	107.8 (-6.0 to 224.3)	53.7 (-26.7 to 142.5)
Chronic respiratory diseases	-	-	-	-	21.0 (14.5 to 28.6)	21.0 (19.8 to 37.9)	0.0 (-10.5 to 53.2)	0.0 (-8.2 to 21.5)
Chronic obstructive pulmonary disease	259.1 (247.7 to 271.2)	337.7 (322.7 to 351.8)	30.3 (26.5 to 34.2)	-0.3 (-3.2 to 2.6)	15.2 (10.0 to 21.1)	19.9 (13.0 to 27.6)	31.2 (10.5 to 55.4)	0.7 (-14.9 to 19.0)
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.7 (-10.2 to 3.8)	-27.8 (-32.5 to -22.5)

Appendix Table G.4 - Slovakia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	37.8 (30.7 to 45.2)	2.3 (-3.0 to 7.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.1 (31.0 to 45.6)	-
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-32.5 (-35.6 to -29.7)	-48.4 (-50.6 to -46.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.4 (-35.4 to -29.4)	-48.4 (-50.6 to -46.1)
Asthma	118.3 (95.9 to 145.2)	171.1 (149.2 to 197.5)	44.7 (12.8 to 84.5)	5.1 (-5.0 to 18.6)	7.4 (3.3 to 7.4)	24.7 (4.8 to 10.6)	23.7 (12.6 to 85.1)	24.7 (5.2 to 61.2)
Interstitial lung disease and pulmonary sarcoidosis	1.0 (0.7 to 1.3)	2.2 (2.0 to 2.3)	126.1 (62.8 to 214.0)	76.9 (27.7 to 145.0)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	116.3 (53.9 to 214.5)	69.3 (20.6 to 145.0)
Other chronic respiratory diseases	-	-	-	-	0.6 (0.3 to 0.8)	0.6 (0.4 to 0.9)	5.7 (-22.3 to 45.4)	-18.8 (-40.8 to 12.3)
Cirrhosis	-	-	-	-	0.9 (0.6 to 1.2)	0.9 (0.6 to 1.2)	3.8 (-6.3 to 14.9)	-18.2 (-25.9 to -9.8)
Cirrhosis due to hepatitis B	1.2 (0.9 to 1.5)	1.6 (1.0 to 2.1)	27.1 (-17.1 to 93.5)	-2.7 (-37.8 to 45.8)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.4)	27.9 (-20.5 to 98.0)	-2.7 (-38.6 to 51.3)
Cirrhosis due to hepatitis C	1.2 (0.8 to 1.7)	1.3 (0.7 to 1.8)	-1.7 (-43.4 to 99.5)	-26.2 (55.5 to 48.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-1.1 (-44.0 to 98.4)	-25.3 (-55.9 to 48.1)
Cirrhosis due to alcohol use	1.8 (1.4 to 2.4)	1.3 (0.9 to 1.9)	-25.6 (-55.7 to 11.2)	-45.2 (-67.3 to -18.1)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.4)	0.2 (-57.7 to 12.6)	-25.8 (-69.0 to -16.6)
Cirrhosis due to other causes	1.0 (0.8 to 1.3)	1.4 (1.1 to 1.7)	30.7 (-4.8 to 79.7)	15.4 (-14.0 to 55.7)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	30.5 (-11.0 to 88.4)	16.5 (-18.5 to 64.1)
Digestive diseases	-	-	-	-	6.9 (5.0 to 9.3)	8.8 (6.3 to 11.7)	26.6 (17.7 to 35.8)	-0.3 (-7.6 to 7.5)
Peptic ulcer disease	44.2 (38.4 to 49.9)	34.5 (28.5 to 40.4)	-21.8 (-33.2 to -9.8)	-45.4 (-53.4 to -37.2)	1.5 (1.0 to 2.1)	1.4 (1.0 to 2.0)	6.7 (-18.4 to 8.5)	-34.0 (-41.8 to -23.2)
Gastritis and duodenitis	8.9 (8.3 to 9.5)	10.7 (10.0 to 11.5)	20.7 (8.7 to 33.2)	16.7 (4.5 to 31.1)	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.8)	15.8 (0.3 to 38.2)	19.1 (1.3 to 48.5)
Appendicitis	0.4 (0.4 to 0.5)	0.3 (0.3 to 0.3)	-34.9 (-43.2 to -22.6)	-24.9 (-34.7 to -11.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-34.4 (-50.8 to -9.7)	-24.7 (-45.5 to 6.2)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.2)	40.2 (-6.6 to 88.7)	29.8 (-20.9 to 101.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	38.6 (-12.0 to 100.7)	29.6 (-24.5 to 113.7)
Inguinal, femoral, and abdominal hernia	17.0 (15.2 to 19.1)	18.6 (16.9 to 20.8)	9.1 (-4.9 to 26.7)	-17.4 (-27.8 to -4.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	9.7 (-4.8 to 28.5)	-16.5 (-37.4 to -3.3)
Inflammatory bowel disease	8.4 (8.1 to 8.8)	14.3 (13.7 to 15.0)	69.8 (60.7 to 80.4)	34.1 (26.7 to 42.0)	1.8 (1.2 to 2.4)	3.0 (2.1 to 4.1)	69.6 (57.5 to 84.4)	34.6 (25.0 to 46.3)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.1 to 98.0)	2.6 (-24.5 to 46.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.1 to 98.8)	2.6 (-30.5 to 47.1)
Gallbladder and biliary diseases	16.6 (14.5 to 18.6)	15.5 (13.3 to 17.4)	-6.9 (-22.6 to 10.9)	-30.4 (-41.7 to -17.2)	1.7 (1.2 to 2.4)	1.6 (1.1 to 2.3)	-6.7 (-23.3 to 12.4)	-30.1 (-42.2 to -16.1)
Pancreatitis	2.2 (2.1 to 2.3)	3.2 (3.1 to 3.4)	46.6 (37.8 to 55.5)	0.6 (7.7 to 21.3)	0.9 (0.4 to 0.9)	0.9 (0.6 to 1.3)	46.2 (29.1 to 66.5)	14.8 (1.1 to 30.1)
Other digestive diseases	-	-	-	-	0.4 (0.3 to 0.6)	0.9 (0.6 to 1.2)	11.0 (64.1 to 180.0)	64.8 (29.0 to 119.2)
Neurological disorders	-	-	-	-	51.5 (35.2 to 70.0)	63.5 (43.3 to 87.5)	23.3 (8.8 to 39.4)	4.2 (-8.1 to 17.8)
Alzheimer disease and other dementias	46.3 (40.3 to 52.3)	67.8 (59.0 to 78.1)	47.0 (20.5 to 76.9)	0.5 (-17.6 to 21.8)	6.6 (4.7 to 8.7)	9.8 (6.9 to 12.9)	49.6 (23.1 to 80.5)	1.3 (-16.6 to 22.7)
Parkinson disease	3.4 (2.3 to 4.5)	4.6 (3.2 to 6.2)	37.2 (28.3 to 46.6)	-1.3 (-7.5 to 5.3)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.8)	37.6 (22.0 to 56.3)	-0.7 (-11.7 to 10.0)
Epilepsy	24.9 (15.9 to 35.6)	21.4 (13.2 to 31.7)	-15.5 (-52.4 to 55.5)	-19.8 (-53.9 to 47.8)	7.8 (4.2 to 12.3)	6.9 (3.9 to 11.3)	-10.7 (-52.0 to 70.0)	-14.0 (-53.5 to 62.3)
Multiple sclerosis	2.6 (1.5 to 3.6)	4.8 (3.3 to 6.2)	85.1 (15.0 to 233.9)	46.3 (-9.3 to 163.4)	0.8 (0.5 to 1.3)	1.6 (0.9 to 2.3)	84.3 (10.9 to 243.0)	46.1 (-12.5 to 168.2)
Migraine	766.7 (694.0 to 831.7)	850.0 (781.2 to 921.9)	11.0 (-1.4 to 26.0)	-1.8 (-12.3 to 11.9)	26.1 (15.5 to 39.1)	1.7 (0.6 to 43.0)	10.4 (-2.3 to 26.1)	-1.7 (-12.6 to 12.7)
Tension-type headache	995.0 (909.9 to 1,080.4)	1,116.5 (1,023.5 to 1,217.9)	12.3 (-1.1 to 26.4)	0.5 (-1.4 to 12.3)	1.7 (0.7 to 2.6)	1.7 (0.8 to 3.0)	11.3 (-14.4 to 28.7)	1.3 (-12.4 to 13.0)
Medication overuse headache	49.4 (31.0 to 67.3)	84.8 (51.7 to 122.1)	69.9 (19.3 to 155.3)	39.5 (-4.8 to 107.8)	7.7 (4.3 to 12.1)	13.2 (7.0 to 21.6)	70.1 (14.7 to 155.7)	39.9 (5.1 to 107.8)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.6 (-10.9 to 74.3)	6.5 (-21.6 to 46.8)	0.6 (0.4 to 0.8)	0.9 (0.6 to 1.3)	57.7 (-3.5 to 132.3)	9.5 (-33.0 to 61.2)
Mental and substance use disorders	-	-	-	-	114.5 (83.3 to 148.6)	126.2 (92.2 to 164.4)	10.2 (7.5 to 13.2)	-2.0 (-4.3 to 0.3)
Schizophrenia	16.6 (15.2 to 17.9)	20.3 (18.7 to 21.9)	22.0 (17.1 to 27.1)	-1.3 (-5.2 to 2.6)	10.6 (7.9 to 12.8)	13.0 (9.6 to 15.7)	22.0 (15.4 to 29.3)	-0.9 (-6.2 to 5.0)
Alcohol use disorders	64.4 (58.9 to 69.8)	57.9 (52.7 to 63.3)	-10.0 (-15.3 to -4.4)	-10.0 (-28.7 to -19.7)	6.4 (4.3 to 9.1)	5.8 (3.9 to 8.2)	-10.0 (-16.2 to -3.4)	-24.2 (-29.3 to -18.6)
Drug use disorders	-	-	-	-	7.4 (5.0 to 9.9)	8.5 (5.9 to 11.2)	15.2 (1.7 to 29.7)	1.5 (-10.4 to 14.5)
Opioid use disorders	9.6 (7.1 to 12.4)	11.5 (8.7 to 14.5)	21.0 (6.8 to 36.9)	3.1 (-8.8 to 16.5)	4.0 (2.6 to 5.6)	4.8 (3.1 to 6.8)	21.2 (5.9 to 39.0)	3.3 (-9.7 to 18.6)
Cocaine use disorders	3.3 (2.6 to 3.9)	4.1 (3.4 to 4.7)	24.7 (2.5 to 64.7)	11.5 (-13.9 to 46.8)	0.4 (0.3 to 0.7)	0.6 (0.4 to 0.8)	25.1 (-7.4 to 75.7)	11.6 (-17.5 to 58.0)
Amphetamine use disorders	6.9 (6.9 to 9.6)	8.4 (7.4 to 9.3)	21.4 (-15.4 to 24.5)	2.4 (-22.6 to 14.1)	1.1 (0.7 to 1.6)	1.1 (0.7 to 1.6)	6.1 (-19.8 to 30.5)	-6.1 (-26.3 to 20.0)
Cannabis use disorders	11.7 (10.3 to 13.1)	11.9 (10.5 to 13.1)	1.4 (-4.7 to 7.3)	1.0 (-4.7 to 6.8)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	1.2 (-13.2 to 17.9)	1.2 (-13.2 to 17.2)
Other drug use disorders	-	-	-	-	1.5 (0.9 to 2.3)	1.7 (1.0 to 2.4)	8.9 (-21.3 to 50.9)	-1.0 (-29.0 to 37.9)
Depressive disorders	-	-	-	-	41.7 (28.5 to 57.7)	48.3 (32.7 to 66.5)	16.1 (9.7 to 22.9)	-0.3 (-5.2 to 5.2)
Major depressive disorder	168.7 (147.1 to 190.6)	194.1 (165.4 to 220.8)	15.0 (7.7 to 23.2)	-0.5 (-6.5 to 6.4)	34.4 (23.1 to 48.3)	39.5 (26.0 to 55.0)	14.6 (7.1 to 22.6)	-0.3 (-6.3 to 6.4)
Dysthymia	75.3 (62.8 to 88.1)	92.9 (77.3 to 108.4)	23.2 (20.7 to 25.9)	-0.3 (-0.4 to -0.2)	7.2 (4.7 to 10.6)	8.9 (5.8 to 13.0)	23.0 (19.2 to 27.4)	0.1 (-2.5 to 2.5)
Bipolar disorder	37.4 (30.3 to 43.9)	44.6 (36.6 to 53.2)	19.5 (12.8 to 26.8)	-0.3 (-5.9 to 5.9)	7.5 (4.5 to 11.5)	9.0 (5.5 to 13.8)	19.5 (10.9 to 27.8)	-0.1 (-7.1 to 7.4)
Anxiety disorders	187.8 (158.0 to 217.8)	205.7 (172.5 to 237.9)	9.6 (5.3 to 13.6)	17.2 (-0.5 to -0.3)	17.2 (11.7 to 24.6)	18.7 (12.7 to 26.7)	9.0 (3.8 to 13.9)	-0.2 (-2.8 to 2.2)
Eating disorders	-	-	-	-	1.3 (0.8 to 2.0)	1.3 (0.8 to 2.0)	2.1 (-7.7 to 10.2)	2.1 (-5.8 to 10.8)
Anorexia nervosa	0.7 (0.5 to 0.8)	0.8 (0.6 to 1.0)	17.9 (5.5 to 31.0)	24.0 (11.7 to 37.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	17.0 (-8.7 to 50.9)	23.2 (-4.0 to 59.8)
Bulimia nervosa	5.5 (4.0 to 7.4)	5.5 (3.9 to 7.5)	-0.6 (-4.8 to 2.7)	-0.5 (-0.6 to -0.5)	1.2 (0.7 to 1.8)	1.2 (0.7 to 1.8)	-0.9 (-9.8 to 8.5)	-0.4 (-8.4 to 8.3)
Autistic spectrum disorders	-	-	-	-	6.1 (4.2 to 8.3)	6.2 (4.3 to 8.5)	1.6 (-1.7 to 4.8)	0.8 (-2.3 to 4.1)
Autism	15.8 (15.0 to 16.7)	16.2 (15.3 to 17.1)	2.2 (1.5 to 3.0)	0.5 (0.4 to 0.5)	3.9 (2.6 to 5.3)	3.9 (2.6 to 5.4)	1.6 (-2.9 to 6.4)	0.8 (-3.7 to 5.5)
Asperger syndrome	22.5 (21.1 to 23.9)	22.9 (21.4 to 24.5)	2.0 (0.9 to 3.0)	0.6 (0.6 to 0.6)	2.2 (1.6 to 3.1)	2.3 (1.6 to 3.2)	1.5 (-2.7 to 5.9)	0.8 (-3.3 to 5.0)
Attention-deficit/hyperactivity disorder	27.5 (25.3 to 29.7)	18.8 (17.3 to 20.3)	-31.6 (-32.4 to -31.2)	0.2 (0.2 to 0.2)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-31.8 (-36.8 to -26.6)	0.2 (-7.0 to 7.8)
Conduct disorder	41.0 (38.6 to 43.5)	26.6 (24.9 to 28.3)	-35.2 (-36.1 to -34.2)	0.2 (0.2 to 0.2)	5.0 (3.1 to 7.3)	3.2 (2.0 to 4.7)	-35.3 (-38.4 to -32.0)	0.2 (-4.3 to 4.7)
Idiopathic intellectual disability	89.0 (74.9 to 107.1)	76.1 (63.4 to 92.3)	-14.4 (-21.7 to -6.8)	-16.6 (-23.6 to -9.3)	4.3 (2.9 to 6.1)	3.7 (2.4 to 5.3)	-14.8 (-23.7 to -6.7)	-16.4 (-24.2 to -8.9)
Other mental and substance use disorders	89.5 (84.3 to 94.6)	111.8 (105.0 to 118.2)	24.9 (23.6 to 26.1)	0.3 (0.2 to 0.5)	6.6 (4.5 to 8.9)	8.3 (5.7 to 11.1)	25.0 (-2.9 to 45.5)	0.8 (-2.9 to 4.5)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	51.2 (35.8 to 69.0)	67.6 (47.9 to 90.2)	31.7 (18.1 to 48.1)	8.3 (-2.7 to 20.7)
Diabetes mellitus	271.2 (223.8 to 316.6)	411.6 (342.4 to 484.2)	50.4 (22.4 to 91.0)	19.9 (-1.0 to 52.5)	20.0 (13.1 to 28.7)	31.0 (20.6 to 44.5)	54.2 (19.6 to 103.7)	19.9 (-6.4 to 56.0)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.7 (-54.8 to -48.3)	-42.9 (-46.5 to -39.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.7 (-54.8 to -48.3)	-42.9 (-46.5 to -39.2)
Chronic kidney disease	-	-	-	-	14.3 (10.3 to 18.5)	18.3 (13.3 to 23.7)	27.6 (18.1 to 39.2)	4.1 (-3.2 to 13.5)
Chronic kidney disease due to diabetes mellitus	141.5 (101.2 to 209.3)	230.3 (157.1 to 321.8)	63.1 (31.7 to 104.7)	26.1 (1.3 to 59.2)	3.5 (2.4 to 4.8)	6.0 (4.2 to 8.0)	74.3 (38.8 to 119.4)	32.7 (6.0 to 65.9)
Chronic kidney disease due to hypertension	116.2 (72.8 to 184.6)	85.2 (58.3 to 124.4)	-26.0 (-46.9 to -9.3)	-31.7 (-46.9 to -9.3)	3.0 (2.1 to 4.2)	1.3 (0.9 to 1.8)	-55.9 (-65.8 to -41.9)	-64.4 (-72.7 to -52.9)
Chronic kidney disease due to glomerulonephritis	123.3 (87.6 to 174.6)	56.7 (44.4 to 80.2)	-54.2 (-63.5 to -37.2)	-60.3 (-68.5 to -46.4)	2.8 (1.9 to 3.8)	2.3 (1.6 to 3.1)	-18.4 (-34.5 to 4.2)	-28.2 (-40.6 to -9.9)
Chronic kidney disease due to other causes	213.6 (151.7 to 310.5)	386.5 (247.3 to 474.4)	80.6 (25.3 to 93.6)	59.0 (11.7 to 62.2)	5.0 (3.6 to 6.5)	8.6 (6.2 to 11.2)	72.2 (44.3 to 108.0)	43.1 (20.6 to 70.5)
Urinary diseases and male infertility	-	-	-	-	3.1 (2.1 to 4.5)	4.1 (2.7 to 5.8)	29.4 (20.2 to 43.4)	-4.4 (-11.3 to 5.7)
Interstitial nephritis and urinary tract infections	1.2 (1.1 to 1.3)	1.5 (1.4 to 1.5)	20.9 (12.7 to 29.0)	17.7 (9.6 to 25.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	20.1 (0.4 to 47.5)	18.1 (-1.1 to 46.5)

Appendix Table G.4 - Slovakia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Urolithiasis	44.3 (32.1 to 64.8)	53.8 (38.8 to 75.6)	22.2 (7.7 to 34.4)	-2.2 (-1.9 to -1.9)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.7)	20.7 (7.0 to 31.1)	-9.9 (-20.4 to -2.1)
Benign prostatic hyperplasia	71.3 (63.9 to 77.9)	93.8 (89.3 to 98.1)	30.9 (20.3 to 46.6)	-4.9 (-12.8 to 6.3)	2.5 (1.6 to 3.6)	3.3 (2.2 to 4.7)	31.7 (20.6 to 47.9)	-4.3 (-12.3 to 7.4)
Male infertility due to other causes	19.9 (14.6 to 26.5)	23.2 (16.7 to 30.8)	16.8 (25.6 to 76.1)	4.9 (-33.9 to 57.5)	0.1 (0.0 to 0.3)	0.1 (0.1 to 0.3)	17.6 (-26.4 to 71.4)	5.5 (-34.7 to 54.4)
Other urinary diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	34.6 (-26.9 to 86.4)	3.6 (-44.3 to 43.0)
Gynecological diseases	-	-	-	-	6.5 (4.1 to 9.7)	7.5 (4.8 to 11.4)	16.6 (-0.3 to 33.7)	1.8 (-14.8 to 15.8)
Uterine fibroids	117.9 (107.3 to 127.9)	140.1 (127.9 to 151.3)	18.8 (17.9 to 19.6)	-2.6 (-2.7 to -2.5)	1.4 (0.8 to 2.4)	1.7 (1.0 to 2.9)	21.6 (13.9 to 30.6)	0.7 (-5.6 to 8.0)
Polycystic ovarian syndrome	94.7 (84.4 to 104.3)	107.5 (96.4 to 119.2)	13.6 (2.7 to 31.7)	1.6 (-13.2 to 17.5)	0.9 (0.4 to 1.7)	1.0 (0.5 to 1.9)	13.9 (-2.6 to 33.5)	1.8 (-12.8 to 18.9)
Female infertility due to other causes	10.1 (4.1 to 24.2)	11.8 (5.3 to 30.0)	17.1 (56.2 to 352.6)	15.5 (-61.7 to 292.9)	1.8 (0.0 to 0.2)	1.1 (0.0 to 0.2)	15.9 (-55.3 to 348.9)	1.8 (-60.8 to 293.5)
Endometriosis	284.4 (8.5 to 111.9)	352.2 (10.0 to 13.7)	23.9 (-6.5 to 46.9)	-3.0 (-17.3 to 28.5)	0.9 (0.6 to 1.3)	1.1 (0.7 to 1.6)	23.8 (9.0 to 51.0)	-3.0 (-19.6 to 31.6)
Genital prolapse	200.6 (253.9 to 315.8)	219.2 (316.6 to 392.2)	12.1 (5.6 to 43.8)	2.1 (-17.4 to 13.2)	1.7 (0.4 to 1.7)	1.8 (0.5 to 2.1)	12.4 (5.5 to 44.4)	2.1 (-17.5 to 14.1)
Premenstrual syndrome	20.2 (131.3 to 286.9)	22.6 (146.9 to 291.5)	12.1 (35.9 to 87.4)	-1.5 (-41.9 to 69.8)	0.6 (0.9 to 2.9)	0.6 (1.0 to 3.1)	8.5 (-36.4 to 88.8)	-4.6 (-42.7 to 70.4)
Other gynecological diseases	18.5 to 21.9	21.0 to 24.5	2.2 to 24.9	-10.2 to 9.5	0.4 to 0.8	0.4 to 0.9	8.8 to 30.6	-1.7 to 14.3
Hemoglobinopathies and hemolytic anemias	-	-	-	-	5.1 (3.4 to 7.4)	4.7 (3.1 to 6.8)	7.8 (-16.3 to 11.8)	-2.7 (-11.6 to 7.5)
Thalassemias	0.2 (0.1 to 0.4)	0.2 (0.0 to 0.3)	-29.5 (-36.5 to -18.8)	-1.1 (-10.7 to 13.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.4 (-46.5 to 28.3)	18.2 (-26.3 to 85.2)
Thalassemia trait	142.2 (110.0 to 182.9)	144.8 (107.9 to 190.5)	1.7 (6.0 to 7.8)	-2.2 (-9.1 to 3.5)	3.9 (2.6 to 5.8)	3.7 (2.5 to 5.4)	4.8 (-13.9 to 3.7)	-2.6 (-11.2 to 6.4)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.7 (-38.2 to -3.5)	-0.1 (-26.2 to 13.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.8 (-47.4 to 3.0)	-4.6 (-40.7 to 14.5)
Sickle cell trait	18.2 (9.6 to 26.2)	17.2 (8.6 to 26.3)	-0.9 (-31.8 to 4.2)	-4.0 (-34.5 to 1.0)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-31.5 (-47.6 to 15.9)	-22.2 (-46.4 to 28.6)
G6PD deficiency	674.8 (25.7 to 44.2)	699.2 (16.1 to 47.3)	3.7 (56.5 to 50.3)	-1.6 (58.0 to 45.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.9 (-29.4 to 6.0)	6.6 (-24.9 to 18.4)
G6PD trait	613.8 to 727.3	634.0 to 752.4	4.2 (8.5 to 16.7)	-1.6 (-13.2 to 10.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-26.9 (-71.1 to 99.2)	0.3 (-72.7 to 91.4)
Other hemoglobinopathies and hemolytic anemias	42.0 (37.7 to 46.7)	43.8 (40.0 to 47.1)	4.2 (7.6 to 17.3)	2.0 (-10.6 to 16.1)	1.0 (0.6 to 1.4)	0.8 (0.5 to 1.2)	-15.8 (-36.5 to 16.7)	0.3 (-23.6 to 38.1)
Endocrine, metabolic, blood, and immune disorders	69.5 (65.1 to 72.9)	68.3 (66.1 to 70.3)	-1.8 (-7.1 to 4.5)	-1.0 (-7.1 to 6.0)	2.2 (1.5 to 3.1)	2.0 (1.4 to 2.8)	-9.7 (-16.1 to 10.5)	-3.2 (-10.5 to 7.6)
Musculoskeletal disorders	-	-	-	-	88.8 (88.8 to 156.0)	156.9 (115.1 to 216.1)	77.2 (21.7 to 39.9)	1.8 (-4.4 to 9.0)
Rheumatoid arthritis	7.0 (6.1 to 8.0)	13.8 (12.8 to 15.1)	96.6 (68.0 to 133.4)	51.4 (29.5 to 79.4)	1.6 (1.1 to 2.2)	3.2 (2.2 to 4.2)	95.8 (66.1 to 131.8)	51.6 (28.7 to 79.8)
Osteoarthritis	260.0 (249.3 to 270.4)	369.1 (354.2 to 382.6)	42.1 (34.8 to 50.0)	1.9 (-3.3 to 7.5)	15.7 (11.1 to 21.3)	22.4 (15.7 to 30.5)	42.3 (34.8 to 50.2)	2.3 (-3.2 to 7.9)
Low back and neck pain	-	-	-	-	97.3 (66.2 to 132.0)	121.8 (83.1 to 166.2)	25.0 (15.8 to 36.7)	0.3 (-7.2 to 9.3)
Low back pain	693.6 (635.1 to 712.0)	836.5 (791.9 to 881.7)	24.2 (14.9 to 34.2)	-0.7 (-7.9 to 7.2)	74.4 (50.1 to 102.6)	92.3 (63.1 to 127.1)	24.1 (15.1 to 34.3)	-0.2 (-7.5 to 8.1)
Neck pain	234.2 (188.9 to 270.4)	302.1 (252.2 to 351.5)	27.6 (3.2 to 68.9)	1.3 (-17.4 to 33.4)	22.8 (15.3 to 32.0)	29.5 (19.0 to 43.0)	27.6 (3.2 to 71.0)	1.7 (-16.9 to 35.9)
Gout	2.5 (2.3 to 2.6)	3.4 (3.2 to 3.6)	38.6 (27.0 to 50.6)	1.8 (-6.7 to 10.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	38.3 (11.5 to 72.8)	1.6 (-17.5 to 27.3)
Other musculoskeletal disorders	120.3 (89.5 to 150.3)	169.9 (130.6 to 211.0)	41.4 (29.6 to 54.9)	6.2 (-2.7 to 15.5)	10.9 (7.0 to 16.1)	15.5 (9.9 to 22.5)	41.6 (29.2 to 56.0)	6.6 (-8.2 to 16.6)
Other non-communicable diseases	-	-	-	-	87.5 (58.4 to 126.4)	99.5 (66.3 to 144.7)	13.9 (9.3 to 17.6)	-3.9 (-9.3 to 2.7)
Congenital anomalies	-	-	-	-	6.6 (4.7 to 8.7)	8.1 (5.7 to 10.8)	23.1 (5.6 to 43.8)	15.4 (-1.0 to 35.8)
Neural tube defects	1.3 (1.1 to 1.5)	1.1 (0.9 to 1.3)	-17.1 (-32.4 to 0.9)	-13.9 (-30.2 to 4.9)	0.4 (0.3 to 0.6)	0.4 (0.2 to 0.5)	-15.8 (-39.9 to 15.9)	-12.1 (-36.8 to 21.0)
Congenital heart anomalies	33.8 (27.8 to 42.4)	36.0 (29.4 to 45.0)	7.7 (-19.3 to 36.2)	5.8 (-20.5 to 33.9)	1.2 (0.5 to 2.1)	1.2 (0.5 to 2.2)	8.4 (-17.9 to 35.6)	8.0 (-18.4 to 34.7)
Crofacial clefts	6.0 (5.2 to 7.2)	6.6 (5.3 to 8.2)	8.6 (-17.3 to 42.5)	5.7 (-19.3 to 38.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-10.0 (-36.1 to 23.0)	-11.6 (-38.0 to 23.0)
Down syndrome	4.6 (3.6 to 5.7)	5.6 (4.6 to 6.7)	20.3 (-7.0 to 65.9)	7.9 (-16.4 to 48.8)	0.6 (0.4 to 0.9)	0.8 (0.6 to 1.1)	11.9 (0.2 to 86.8)	12.9 (-15.4 to 56.4)
Turner syndrome	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	4.1 (-33.0 to 45.3)	3.3 (-33.4 to 43.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.5 (-34.4 to 49.4)	2.5 (-35.1 to 46.2)
Klinefelter syndrome	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	26.5 (-19.1 to 77.2)	24.3 (-20.6 to 73.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.7 (-14.8 to 95.2)	23.8 (-21.5 to 83.6)
Chromosomal unbalanced rearrangements	11.3 (9.0 to 13.7)	14.1 (11.3 to 17.7)	24.0 (9.4 to 72.4)	11.2 (-18.6 to 54.3)	1.5 (1.1 to 2.2)	2.1 (1.5 to 2.9)	36.5 (-1.8 to 90.6)	14.7 (-17.3 to 61.3)
Other congenital anomalies	17.8 (14.4 to 21.2)	17.5 (14.5 to 20.5)	-1.6 (-11.5 to 8.2)	-0.2 (-19.0 to -1.7)	2.9 (1.8 to 3.9)	3.5 (2.2 to 5.1)	24.9 (0.6 to 67.0)	22.9 (-0.8 to 64.1)
Skin and subcutaneous diseases	-	-	-	-	25.9 (17.1 to 38.1)	26.1 (17.1 to 38.7)	0.8 (-7.9 to 9.1)	-5.9 (-13.7 to 1.6)
Dermatitis	245.3 (206.4 to 290.9)	269.5 (225.9 to 318.8)	9.9 (7.5 to 12.1)	-0.0 (-0.1 to 0.1)	6.4 (4.1 to 9.3)	6.8 (4.4 to 10.0)	6.5 (2.0 to 10.7)	0.2 (-2.9 to 3.0)
Psoriasis	44.5 (39.2 to 49.8)	52.3 (45.7 to 58.8)	17.5 (15.6 to 19.6)	0.0 (-0.1 to 0.1)	3.6 (2.4 to 5.1)	4.2 (2.8 to 5.9)	17.2 (10.5 to 24.2)	0.3 (-5.2 to 5.9)
Cellulitis	1.4 (1.2 to 1.7)	1.5 (1.3 to 1.9)	10.3 (-2.9 to 27.5)	1.7 (-8.9 to 13.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	6.6 (-12.8 to 37.8)	1.2 (-18.6 to 24.3)
Pyoderma	7.1 (6.0 to 8.7)	7.7 (6.2 to 9.7)	7.1 (1.6 to 13.1)	-3.8 (-5.6 to -2.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	6.4 (-2.7 to 15.9)	-3.6 (-10.3 to 2.7)
Scabies	10.0 (9.2 to 11.0)	8.8 (8.1 to 9.7)	-11.9 (-23.0 to -0.3)	-0.3 (-23.0 to -0.4)	0.3 (0.1 to 0.4)	0.2 (0.1 to 0.4)	-12.1 (-25.0 to 1.4)	-12.0 (-24.3 to 1.0)
Fungal skin diseases	420.0 (328.0 to 550.3)	470.6 (368.0 to 612.8)	12.3 (5.4 to 18.3)	0.2 (0.1 to 0.3)	2.3 (0.9 to 5.2)	2.6 (1.1 to 5.7)	11.9 (4.9 to 18.1)	0.4 (-0.5 to 1.2)
Viral skin diseases	110.5 (85.3 to 135.3)	98.6 (73.2 to 126.1)	-9.8 (-16.6 to -5.8)	-1.0 (-1.8 to 2.0)	3.4 (2.0 to 5.3)	3.0 (1.8 to 4.7)	-14.4 (-17.6 to -5.8)	0.2 (-3.0 to 3.6)
Acne vulgaris	152.2 (117.5 to 187.3)	148.4 (117.8 to 178.8)	-2.9 (-31.8 to 39.8)	7.3 (-23.9 to 55.5)	1.6 (0.7 to 3.0)	1.6 (0.7 to 3.1)	-3.0 (-31.9 to 40.3)	7.6 (-24.0 to 56.0)
Alopecia areata	6.3 (5.4 to 7.2)	7.4 (6.5 to 8.4)	18.2 (0.7 to 43.9)	1.5 (-14.0 to 23.7)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.4)	18.2 (-3.5 to 46.3)	2.6 (-15.3 to 26.9)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.5 (-11.1 to 49.6)	-2.0 (-24.5 to 23.1)
Urticaria	95.0 (72.5 to 117.2)	74.2 (54.4 to 94.3)	-22.2 (-46.9 to 15.1)	-29.2 (-51.8 to 3.3)	4.4 (3.4 to 8.4)	4.4 (2.6 to 6.6)	-22.2 (-47.4 to 14.1)	-28.7 (-51.9 to 1.1)
Decubitus ulcer	1.0 (0.8 to 1.1)	1.5 (1.2 to 1.9)	54.8 (19.8 to 99.1)	15.0 (-11.1 to 47.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	53.0 (15.0 to 105.7)	14.6 (-12.5 to 53.4)
Other skin and subcutaneous diseases	365.4 (221.0 to 598.1)	445.5 (263.1 to 746.5)	21.3 (12.3 to 32.0)	-4.2 (-8.9 to 1.6)	2.1 (0.9 to 4.7)	2.6 (1.0 to 5.8)	21.3 (11.6 to 32.1)	-3.9 (-8.7 to 1.9)
Sense organ diseases	-	-	-	-	42.4 (27.9 to 61.8)	50.2 (32.9 to 72.9)	18.4 (13.4 to 23.5)	-9.4 (-13.0 to -5.3)
Glaucoma	6.4 (5.2 to 7.4)	6.9 (5.6 to 8.6)	8.3 (-11.9 to 36.4)	-18.5 (-33.7 to -2.8)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	11.2 (-7.6 to 35.8)	-17.2 (-31.1 to 0.9)
Cataract	62.7 (50.7 to 74.5)	65.2 (47.4 to 81.0)	5.1 (-4.1 to 27.3)	-26.3 (-41.7 to -11.2)	2.1 (1.4 to 3.2)	2.3 (1.4 to 3.5)	7.3 (-13.8 to 27.9)	-24.7 (-39.4 to -11.0)
Macular degeneration	17.2 (12.4 to 21.6)	26.6 (20.0 to 34.2)	53.9 (16.7 to 109.4)	8.7 (-17.3 to 46.5)	0.6 (0.3 to 0.9)	0.9 (0.5 to 1.4)	53.6 (16.7 to 106.3)	7.7 (-17.3 to 43.7)
Uncorrected refractive error	578.3 (525.1 to 626.9)	723.9 (658.8 to 788.6)	25.4 (11.2 to 40.3)	-2.5 (-13.5 to 9.0)	8.4 (4.7 to 14.1)	9.8 (5.5 to 16.4)	16.3 (6.2 to 26.3)	-7.8 (-15.6 to 0.2)
Age-related and other hearing loss	972.3 (868.4 to 1,068.0)	1,202.7 (1,065.3 to 1,318.7)	23.7 (18.3 to 29.0)	-8.1 (-15.1 to -4.2)	26.4 (17.6 to 37.6)	32.4 (21.3 to 46.6)	22.6 (15.3 to 30.4)	-9.0 (-14.0 to -3.0)
Other vision loss	34.6 (30.3 to 39.3)	28.9 (24.5 to 34.4)	-17.1 (-27.6 to -0.2)	-31.2 (-39.6 to -18.3)	1.4 (1.0 to 2.1)	1.3 (0.9 to 1.9)	7.7 (-19.3 to 3.4)	2.7 (-34.6 to 17.1)
Other sense organ diseases	124.2 (118.5 to 130.1)	129.4 (123.5 to 135.7)	4.1 (2.1 to 11.2)	-0.3 (-5.8 to 6.5)	3.3 (2.0 to 4.8)	3.4 (2.1 to 5.0)	3.2 (-3.6 to 10.8)	-0.1 (-6.5 to 7.4)
Oral disorders	-	-	-	-	12.6 (7.5 to 19.7)	15.0 (8.8 to 23.6)	18.8 (13.0 to 25.1)	-5.9 (-10.7 to -0.8)
Deciduous caries	368.5 (351.5 to 384.3)	217.4 (207.5 to 226.6)	-41.0 (-44.6 to -37.4)	-0.5 (-6.6 to 5.7)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-41.0 (-46.3 to -35.4)	-0.6 (-9.3 to 8.7)
Permanent caries	2,392.5 (1,959.4 to 2,431.9)	2,408.1 (2,166.5 to 2,614.0)	0.7 (5.0 to 27.6)	8.8 (-12.2 to 19.2)	1.4 (0.6 to 2.5)	1.4 (0.7 to 2.7)	1.4 (5.7 to 27.4)	1.6 (-12.2 to 19.1)
Periodontal diseases	567.9 (523.8 to 610.8)	753.5 (685.2 to 831.9)	32.5 (18.1 to 51.9)	0.5 (-10.2 to 15.0)	3.7 (1.5 to 7.5)	4.9 (1.9 to 10.0)	32.6 (18.0 to 51.5)	0.7 (-10.0 to 15.1)
Edentulism and severe tooth loss	174.3 (166.7 to 181.4)	200.1 (192.1 to 208.0)	14.7 (8.4 to 22.0)	-16.7 (-21.1 to -11.4)	4.7 (3.2 to 6.5)	5.4 (3.7 to 7.5)	14.9 (8.1 to 22.7)	-16.4 (-21.2 to -10.8)

Appendix Table G.4 - Slovakia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	96.0 (90.6 to 101.6)	109.8 (104.1 to 115.8)	14.5 (6.0 to 23.5)	-0.3 (-7.7 to 7.3)	2.8 (1.7 to 4.2)	3.2 (2.0 to 4.7)	14.1 (5.1 to 23.8)	-0.3 (-8.1 to 8.2)
Injuries	-	-	-	-	68.1 (51.3 to 88.6)	60.8 (42.8 to 81.9)	-11.1 (-19.7 to -1.5)	-31.8 (-38.5 to -24.4)
Transport injuries	-	-	-	-	7.8 (5.9 to 10.2)	3.0 (2.1 to 4.0)	-62.0 (-66.1 to -57.3)	-70.3 (-73.4 to -66.7)
Road injuries	-	-	-	-	5.3 (4.0 to 6.9)	1.6 (1.1 to 2.1)	-70.4 (-74.0 to -66.4)	-76.9 (-79.7 to -73.8)
Pedestrian road injuries	-	-	-	-	1.2 (0.9 to 1.6)	0.4 (0.3 to 0.5)	-68.7 (-73.0 to -64.0)	-75.7 (-79.0 to -72.0)
Cyclist road injuries	-	-	-	-	1.1 (0.8 to 1.5)	0.3 (0.2 to 0.4)	-71.8 (-74.7 to -68.5)	-78.1 (-80.4 to -75.6)
Motorcyclist road injuries	-	-	-	-	0.5 (0.4 to 0.6)	0.1 (0.1 to 0.2)	-77.2 (-80.3 to -73.8)	-82.0 (-84.4 to -79.3)
Motor vehicle road injuries	-	-	-	-	2.4 (1.8 to 3.1)	0.8 (0.5 to 1.0)	-68.6 (-72.7 to -63.3)	-75.4 (-78.6 to -71.2)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-92.4 (-93.3 to -91.3)	-94.1 (-94.8 to -93.2)
Other transport injuries	-	-	-	-	2.6 (1.9 to 3.4)	1.4 (1.0 to 1.9)	-44.5 (-50.6 to -37.5)	-56.5 (-61.0 to -51.1)
Unintentional injuries	-	-	-	-	59.4 (44.9 to 77.4)	57.2 (40.4 to 77.2)	-4.1 (-13.6 to 6.2)	-26.6 (-33.8 to -18.8)
Falls	-	-	-	-	47.1 (35.6 to 61.2)	47.0 (33.1 to 63.3)	-0.6 (-11.6 to 11.3)	-25.2 (-33.5 to -16.2)
Drowning	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-36.5 (-45.3 to -27.2)	-50.0 (-56.7 to -42.7)
Fire, heat, and hot substances	-	-	-	-	0.7 (0.5 to 0.9)	0.5 (0.4 to 0.7)	-20.6 (-31.1 to -9.0)	-33.6 (-42.2 to -24.1)
Poisonings	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-34.5 (-44.7 to -22.9)	-43.2 (-52.4 to -32.6)
Exposure to mechanical forces	-	-	-	-	8.1 (6.0 to 10.6)	6.6 (4.7 to 9.0)	-19.0 (-24.7 to -11.6)	-32.8 (-37.7 to -27.1)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-31.7 (-42.1 to -19.8)	-43.3 (-51.7 to -34.1)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-92.8 (-40.3 to -24.7)	-43.8 (-50.2 to -37.3)
Other exposure to mechanical forces	-	-	-	-	7.8 (5.9 to 10.3)	6.4 (4.6 to 8.8)	-18.6 (-24.4 to -11.2)	-32.5 (-37.3 to -26.8)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	33.4 (22.3 to 47.6)	6.6 (-1.8 to 17.7)
Animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-1.2 (-10.6 to 9.1)	-15.1 (-22.9 to -6.6)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-2.1 (-15.9 to 13.6)	-16.0 (-28.1 to -1.9)
Non-venomous animal contact	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-0.6 (-11.1 to 11.9)	-14.7 (-23.3 to -4.6)
Foreign body	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	-10.5 (-19.5 to -0.1)	-26.1 (-33.2 to -17.7)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-37.2 (-47.2 to -23.6)	-46.7 (-54.9 to -35.6)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	4.4 (-1.3 to 10.4)	6.8 (-15.7 to -3.3)
Foreign body in other body part	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	3.5 (-6.8 to 15.9)	-17.0 (-25.0 to -7.6)
Other unintentional injuries	-	-	-	-	2.5 (1.8 to 3.3)	2.2 (1.6 to 2.9)	-12.1 (-20.1 to -2.5)	-31.5 (-37.5 to -24.0)
Self-harm and interpersonal violence	-	-	-	-	0.8 (0.6 to 1.0)	0.6 (0.4 to 0.8)	-29.5 (-36.9 to -20.0)	-45.6 (-51.3 to -38.5)
Self-harm	-	-	-	-	0.5 (0.3 to 0.6)	0.3 (0.2 to 0.5)	-28.9 (-36.8 to -19.1)	-45.9 (-51.9 to -38.3)
Interpersonal violence	-	-	-	-	0.3 (0.3 to 0.4)	0.2 (0.2 to 0.3)	-30.2 (-38.8 to -19.8)	-45.3 (-51.7 to -37.5)
Assault by firearm	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-24.2 (-30.8 to -16.5)	-40.9 (-45.9 to -35.0)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-10.5 (-22.2 to 3.7)	-30.0 (-39.0 to -18.9)
Assault by other means	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-34.9 (-43.3 to -24.7)	-48.9 (-55.2 to -41.1)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Slovenia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	240.6 (180.4 to 309.5)	279.4 (209.6 to 359.9)	16.1 (13.0 to 19.0)	16.1 (-6.9 to -2.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	13.5 (9.3 to 18.8)	11.8 (8.2 to 16.4)	-12.3 (-17.5 to -7.2)	-2.2 (-8.0 to 3.0)
HIV/AIDS and tuberculosis	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-16.0 (-28.4 to -3.0)	-30.4 (-40.9 to -19.1)
Tuberculosis	0.8 (0.7 to 0.8)	0.6 (0.6 to 0.7)	-17.8 (-24.5 to -10.1)	-33.1 (-38.5 to -27.1)	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-18.9 (-30.7 to -6.1)	-33.0 (-43.3 to -22.0)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.1 (-79.4 to 90.0)	-32.4 (-82.7 to 66.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.1 (-79.5 to 91.0)	-32.4 (-82.7 to 66.5)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.3)	241.9 (23.3 to 564.0)	209.6 (5.8 to 504.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.0 (-45.4 to 313.4)	60.2 (-51.7 to 278.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	1.6 (1.1 to 2.2)	1.5 (1.0 to 2.0)	-5.3 (-10.9 to 1.2)	-5.9 (-11.6 to 0.8)
Diarrheal diseases	4.6 (4.2 to 4.9)	4.5 (4.2 to 4.8)	-2.1 (-11.9 to 8.4)	-5.4 (-15.4 to 5.1)	0.7 (0.5 to 1.0)	0.7 (0.5 to 1.0)	-5.7 (-14.4 to 7.8)	-5.4 (-16.3 to 6.4)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.3 (-17.1 to 33.1)	5.9 (-16.2 to 31.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.3 (-17.2 to 33.2)	5.9 (-16.3 to 31.4)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.8 (-16.9 to 44.1)	11.7 (-15.3 to 44.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.8 (-17.0 to 44.2)	11.7 (-15.3 to 44.6)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Lower respiratory infections	0.3 (0.3 to 0.3)	0.2 (0.2 to 0.2)	-18.0 (-22.8 to -12.9)	-22.1 (-27.6 to -16.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.0 (-31.2 to -4.4)	-21.6 (-34.7 to -5.5)
Upper respiratory infections	19.4 (18.6 to 20.2)	19.0 (18.3 to 19.9)	-1.9 (-6.7 to 4.2)	-0.9 (-5.7 to 4.6)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	-3.3 (-8.8 to 4.6)	-0.8 (-7.4 to 6.2)
Otitis media	20.8 (19.4 to 22.4)	18.8 (17.5 to 20.1)	-10.1 (-16.6 to -2.4)	-6.5 (-12.4 to 1.5)	0.4 (0.3 to 0.7)	0.4 (0.2 to 0.6)	-12.7 (-19.4 to -4.5)	-8.1 (-15.0 to 0.1)
Meningitis	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-	-
Pneumococcal meningitis	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-21.7 (-36.9 to 0.0)	-34.9 (-48.0 to -16.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.9 (-38.8 to -11.0)	-27.2 (-43.4 to -16.0)
H influenzae type B meningitis	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-42.2 (-69.9 to -2.6)	-44.5 (-68.7 to -3.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.3 (-71.0 to 12.0)	-42.6 (-70.0 to 23.5)
Meningococcal meningitis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-27.8 (-70.2 to 24.1)	-36.8 (-72.6 to 20.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.3 (-73.4 to 39.6)	-29.9 (-75.6 to 39.0)
Other meningitis	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-21.5 (-41.3 to 3.1)	-30.5 (-46.4 to -2.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.0 (-41.9 to 28.5)	-25.5 (-47.3 to 19.9)
Encephalitis	0.8 (0.3 to 2.0)	0.9 (0.3 to 2.5)	12.0 (-11.2 to 34.7)	12.0 (-11.2 to 34.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	13.5 (-11.9 to 50.0)	2.3 (-20.2 to 35.9)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-55.8 (-94.1 to 244.1)	-55.9 (-94.0 to 238.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-55.8 (-94.2 to 245.7)	-55.9 (-94.1 to 239.7)
Whooping cough	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	64.0 (57.1 to 71.3)	89.3 (81.4 to 97.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.2 (17.8 to 137.4)	91.8 (36.0 to 174.0)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-69.1 (-79.7 to -41.5)	-68.5 (-80.1 to -50.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-69.4 (-79.9 to -44.6)	-68.5 (-81.0 to -51.7)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-97.1 (-100.0 to -90.5)	-96.5 (-100.0 to -88.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-97.1 (-100.0 to -90.5)	-96.5 (-100.0 to -88.6)
Varicella and herpes zoster	1.0 (1.0 to 1.1)	1.0 (0.9 to 1.1)	-0.8 (-13.6 to 12.8)	-1.8 (-10.8 to 7.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	15.7 (-11.3 to 47.1)	-2.7 (-22.7 to 21.2)
Neglected tropical diseases and malaria	-	-	-	-	0.2 (0.1 to 0.3)	0.0 (0.0 to 0.1)	-77.0 (-89.9 to -42.1)	-80.2 (-90.8 to -52.6)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.8 (-53.2 to 354.1)	70.5 (-49.8 to 385.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.3 (-51.6 to 368.8)	73.9 (-49.3 to 406.4)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.8 (-50.7 to 57.1)	2.6 (-49.8 to 61.4)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.4 (-52.4 to 60.2)	3.1 (50.3 to 64.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.4 (-52.7 to 60.5)	3.1 (50.4 to 64.8)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.2 (-54.4 to 66.3)	-11.0 (-50.0 to 52.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.2 (-54.8 to 67.6)	-11.0 (-50.1 to 52.1)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.5 (0.2 to 0.9)	0.1 (0.0 to 0.2)	-82.2 (-93.5 to -46.1)	-84.8 (-94.3 to -56.4)	0.1 (0.0 to 0.3)	0.0 (0.0 to 0.1)	-80.4 (-93.6 to -37.0)	-83.3 (-94.0 to -49.6)
Cystic echinococcosis	0.2 (0.2 to 0.2)	0.1 (0.1 to 0.1)	-63.1 (-66.3 to -59.3)	-63.1 (-72.1 to -65.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-62.3 (-69.9 to -52.9)	-68.0 (-73.6 to -61.0)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.2 (-62.4 to 7.5)	-15.1 (-64.9 to 7.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.2 (-62.4 to 7.7)	-15.1 (-65.0 to 7.7)
Intestinal nematode infections	-	-	-	-	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.9 (-5.1 to 183.4)	88.6 (5.7 to 232.7)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-5.6 (-29.7 to 18.9)	-1.7 (-27.7 to 25.0)
Maternal hemorrhage	0.5 (0.3 to 0.6)	0.5 (0.3 to 0.6)	-0.5 (-28.8 to 32.8)	4.0 (-26.9 to 40.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.9 (-56.9 to 56.5)	-2.0 (-54.3 to 65.3)
Maternal sepsis and other maternal infections	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-20.7 (-52.4 to 12.5)	20.7 (-53.1 to 9.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.2 (-47.1 to 4.9)	-22.8 (-46.5 to 8.9)
Maternal hypertensive disorders	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-3.0 (-17.5 to 15.5)	0.3 (-14.1 to 18.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.7 (-26.9 to 29.9)	0.9 (-23.5 to 33.1)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.4 (-16.6 to 9.6)	-1.6 (-13.1 to 14.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.4 (-16.7 to 9.7)	-1.6 (-13.2 to 14.5)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.5 (-15.0 to 16.1)	1.2 (-12.7 to 19.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.5 (-15.1 to 16.3)	1.2 (-12.8 to 20.0)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.5 (-45.1 to 77.3)	5.9 (-42.6 to 85.5)
Neonatal disorders	-	-	-	-	2.1 (1.4 to 2.9)	2.3 (1.5 to 3.1)	9.5 (-18.3 to 39.5)	11.9 (-17.2 to 43.6)
Preterm birth complications	9.5 (7.4 to 12.5)	11.5 (9.0 to 15.0)	20.1 (3.3 to 39.8)	18.9 (2.2 to 39.1)	1.2 (0.8 to 1.6)	1.5 (1.0 to 2.0)	26.5 (-1.8 to 63.7)	29.1 (-0.3 to 68.0)
Neonatal encephalopathy due to birth asphyxia and trauma	2.1 (1.1 to 4.1)	1.1 (0.6 to 2.5)	-45.4 (-69.2 to -7.9)	-43.3 (-68.3 to -3.5)	0.6 (0.3 to 1.0)	0.3 (0.2 to 0.5)	-41.1 (-72.7 to 5.8)	-41.1 (-71.4 to 11.5)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-229.0 (80.0 to 223.3)	148.0 (94.9 to 250.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	146.6 (18.0 to 421.3)	167.9 (27.7 to 464.3)
Hemolytic disease and other neonatal jaundice	0.6 (0.1 to 2.0)	0.3 (0.2 to 0.6)	-35.5 (-86.9 to 99.1)	-34.0 (-86.6 to 105.1)	0.2 (0.1 to 0.8)	0.1 (0.1 to 0.3)	-32.6 (-86.4 to 117.1)	-31.1 (-86.3 to 119.0)
Other neonatal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.6)	307.6 (31.2 to 599.7)	318.6 (34.4 to 616.6)
Nutritional deficiencies	-	-	-	-	8.7 (5.7 to 12.6)	7.2 (4.7 to 10.4)	-17.6 (-21.5 to -12.7)	-3.0 (-7.9 to 2.3)
Protein-energy malnutrition	0.8 (0.6 to 1.1)	0.7 (0.5 to 0.9)	-17.6 (-48.6 to 28.9)	-5.7 (-41.0 to 47.6)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-18.1 (-49.9 to 30.1)	-6.2 (-42.7 to 49.0)
Iodine deficiency	20.3 (8.5 to 34.7)	10.4 (3.1 to 18.9)	-51.0 (-84.0 to 52.1)	-52.6 (-84.3 to 51.2)	0.4 (0.1 to 0.7)	0.2 (0.1 to 0.4)	-51.0 (-84.2 to 52.1)	-52.2 (-84.5 to 48.8)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-

Appendix Table G.4 - Slovenia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	300.1 (296.1 to 303.7)	285.4 (280.6 to 290.3)	-4.9 (-7.1 to -2.4)	-0.4 (-2.7 to 2.3)	8.0 (5.3 to 11.7)	6.7 (4.4 to 9.7)	-16.2 (-19.8 to -13.2)	-1.2 (-4.8 to 2.9)
Other nutritional deficiencies	-	-	-	-	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	-	2.2 (-51.5 to 114.3)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.8 (0.5 to 1.2)	0.7 (0.4 to 1.1)	-14.2 (-27.4 to -0.7)	-3.0 (22.5 to 14.2)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.3 (0.2 to 0.6)	0.3 (0.2 to 0.6)	-	-2.8 (-13.4 to 9.6)
Syphilis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	28.5 (9.7 to 52.8)	-9.0 (-22.8 to 8.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-10.3 (32.0 to 19.1)
Chlamydial infection	47.9 (42.8 to 53.2)	44.1 (39.2 to 48.8)	-7.6 (-21.7 to 7.6)	-0.4 (-1.6 to 1.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-4.9 (-22.4 to 18.0)	2.7 (-16.2 to 27.6)
Gonococcal infection	11.3 (9.2 to 14.0)	8.9 (7.2 to 10.6)	-21.3 (-41.5 to 3.5)	-9.0 (-32.6 to 23.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-21.8 (-42.7 to 8.4)	-10.0 (35.2 to 25.6)
Trichomoniasis	24.1 (15.9 to 32.5)	24.1 (18.2 to 30.6)	0.9 (-31.6 to 52.7)	3.7 (-32.7 to 57.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.6 (-38.5 to 68.4)	3.8 (-39.6 to 74.7)
Genital herpes	360.6 (327.0 to 393.1)	395.8 (358.9 to 432.9)	9.8 (-3.6 to 24.5)	9.3 (-20.2 to 3.7)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	1.3 (-6.9 to 23.2)	-9.1 (-20.9 to 4.7)
Other sexually transmitted diseases	0.3 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-6.6 (-23.9 to 7.3)	-11.0 (-24.4 to 5.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-2.8 (32.0 to 37.3)
Hepatitis	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-19.8 (-32.8 to -7.1)	-21.9 (-33.7 to -10.2)
Hepatitis A	1.7 (1.6 to 1.7)	1.4 (1.3 to 1.4)	-17.6 (-18.7 to -16.6)	-13.7 (-15.7 to -11.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-	-11.3 (-20.6 to 1.4)
Hepatitis B	52.4 (42.0 to 64.8)	26.9 (21.2 to 43.8)	-29.2 (-48.2 to -9.9)	-34.3 (-52.7 to -9.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-32.3 (-56.4 to -2.3)	-39.5 (-59.3 to -11.3)
Hepatitis C	38.8 (35.0 to 43.0)	31.6 (28.6 to 34.6)	-18.7 (-28.7 to -4.9)	-31.1 (-41.8 to -21.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.3 (-36.4 to 35.3)	-25.6 (-45.7 to 4.9)
Hepatitis E	-	-	-	-	-	-	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	12.0 (10.0 to 13.8)	10.4 (9.1 to 11.7)	-13.1 (-27.2 to 5.5)	-0.1 (-21.2 to 25.1)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-23.7 (-48.1 to 7.5)	0.7 (35.7 to 42.6)
Non-communicable diseases	-	-	-	-	189.7 (141.8 to 244.2)	231.5 (172.6 to 298.4)	22.0 (18.7 to 25.8)	0.9 (-2.5 to 3.2)
Neoplasms	-	-	-	-	2.5 (1.9 to 3.2)	4.1 (3.0 to 5.3)	62.1 (45.5 to 77.1)	8.6 (-2.7 to 18.9)
Esophageal cancer	0.2 (0.2 to 0.2)	0.2 (0.1 to 0.3)	4.9 (-23.8 to 42.8)	-29.1 (-48.3 to -3.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.0 (-24.4 to 42.4)	-29.1 (-49.1 to -3.5)
Stomach cancer	1.4 (1.2 to 1.6)	1.3 (1.1 to 1.6)	-4.2 (-19.9 to 14.7)	-39.5 (-49.4 to -27.8)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-10.4 (-26.5 to 8.1)	-43.3 (-53.3 to -31.6)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (-15.5 to 13.1)	0.0 (-27.2 to 46.8)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	25.1 (-45.3 to 131.3)	-16.0 (-63.4 to 57.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.6 (-47.7 to 96.8)	-24.9 (-65.2 to 31.0)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	293.7 (94.2 to 753.2)	151.2 (24.9 to 444.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	252.7 (88.2 to 569.2)	122.9 (20.3 to 315.2)
Liver cancer due to alcohol use	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	75.1 (-0.8 to 202.7)	9.5 (-38.3 to 90.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.3 (-4.0 to 154.7)	-2.7 (-40.7 to 58.4)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.2 (-55.2 to 77.7)	-2.8 (-71.1 to 8.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.2 (-55.8 to 52.7)	-46.4 (-72.3 to -5.3)
Larynx cancer	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.6)	32.6 (-14.7 to 88.5)	-6.1 (-39.2 to 32.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	1.9 (-27.3 to 43.7)	-28.2 (-48.0 to 0.8)
Tracheal, bronchus and lung cancer	1.5 (1.4 to 1.7)	2.2 (1.9 to 2.6)	47.3 (21.8 to 74.2)	-0.4 (-17.8 to 18.1)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	38.2 (16.1 to 64.4)	-6.1 (-21.3 to 11.4)
Breast cancer	4.8 (4.2 to 5.6)	10.6 (9.2 to 11.9)	124.4 (75.7 to 163.5)	52.6 (21.3 to 79.8)	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.9)	67.4 (23.2 to 100.2)	14.3 (-15.4 to 36.9)
Cervical cancer	1.4 (1.1 to 1.6)	0.9 (0.6 to 1.2)	-32.1 (-51.2 to -9.6)	-17.3 (-41.8 to -29.6)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-28.8 (-51.9 to -5.2)	-48.0 (-62.9 to -25.7)
Uterine cancer	2.0 (1.6 to 2.4)	1.9 (1.4 to 2.6)	-2.4 (-30.6 to 33.0)	-33.3 (-52.3 to -7.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-3.6 (-32.8 to 32.9)	-34.7 (-54.1 to -8.9)
Prostate cancer	2.5 (2.1 to 3.0)	7.0 (5.4 to 8.3)	181.6 (113.6 to 252.0)	78.2 (34.8 to 123.8)	0.2 (0.2 to 0.3)	0.6 (0.4 to 0.9)	162.0 (97.1 to 230.8)	63.6 (23.1 to 106.7)
Colon and rectum cancer	3.4 (3.2 to 3.7)	8.0 (7.2 to 8.9)	132.4 (106.2 to 160.6)	49.9 (32.3 to 68.2)	0.3 (0.2 to 0.4)	0.6 (0.5 to 0.8)	113.2 (85.6 to 141.9)	36.9 (18.4 to 55.0)
Lip and oral cavity cancer	0.8 (0.7 to 1.0)	1.0 (0.7 to 1.2)	34.2 (-13.9 to 52.5)	-18.9 (-38.7 to 8.6)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	9.4 (-20.6 to 44.2)	-22.2 (-43.4 to 2.8)
Nasopharynx cancer	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-51.2 (-68.6 to -24.6)	-62.8 (-76.2 to -42.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-64.7 (-76.5 to -48.1)
Other pharynx cancer	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.9)	53.0 (-7.6 to 175.2)	11.3 (-33.1 to 100.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	37.7 (-13.7 to 132.0)	-0.0 (-38.0 to 67.7)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	24.9 (-21.1 to 69.8)	-24.1 (-51.7 to 2.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.5 (-30.2 to 58.9)	-30.4 (-56.0 to -2.9)
Pancreatic cancer	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.4)	85.6 (46.7 to 132.7)	16.2 (-7.3 to 45.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	76.8 (41.0 to 122.8)	12.7 (-9.6 to 41.1)
Malignant skin melanoma	1.0 (0.7 to 1.4)	2.3 (1.6 to 3.1)	118.9 (88.1 to 170.0)	61.5 (25.7 to 98.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	100.4 (51.1 to 146.6)	48.0 (14.7 to 81.5)
Non-melanoma skin cancer	1.2 (0.8 to 1.6)	2.7 (1.9 to 3.6)	127.1 (86.5 to 209.6)	39.7 (-14.4 to 126.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	181.5 (66.3 to 452.5)	63.2 (-1.8 to 210.1)
Ovarian cancer	0.6 (0.5 to 0.7)	0.9 (0.7 to 1.0)	38.5 (5.3 to 71.7)	-2.4 (-25.3 to 21.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	33.9 (-2.2 to 73.8)	-5.9 (30.7 to 21.7)
Testicular cancer	0.6 (0.4 to 0.8)	0.4 (0.2 to 0.7)	-23.7 (-59.8 to 35.7)	-22.6 (-58.2 to 37.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-24.9 (-61.5 to 32.9)	-24.5 (-60.6 to 33.4)
Kidney cancer	0.7 (0.6 to 0.8)	1.7 (1.3 to 2.0)	135.7 (82.0 to 189.4)	60.3 (22.7 to 96.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	120.4 (71.6 to 176.1)	49.9 (15.9 to 86.2)
Bladder cancer	1.0 (0.8 to 1.1)	1.7 (1.2 to 2.1)	84.8 (27.5 to 131.3)	18.2 (-18.4 to 48.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	72.4 (17.4 to 118.7)	9.9 (-24.8 to 39.5)
Brain and nervous system cancer	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	44.5 (17.3 to 74.9)	12.4 (-9.1 to 38.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	39.7 (9.7 to 72.0)	8.5 (-13.9 to 32.3)
Thyroid cancer	0.6 (0.4 to 0.7)	0.7 (0.5 to 1.0)	6.6 (-21.5 to 107.5)	-18.5 (-39.4 to 56.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.8 (-28.8 to 98.9)	-24.6 (-45.8 to 48.3)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.6 (-28.6 to 62.5)	35.5 (-51.3 to 9.8)
Hodgkin lymphoma	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-30.8 (-49.9 to 3.9)	-38.2 (-55.9 to -5.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.8 (-50.5 to -6.6)	-42.0 (-58.0 to -12.0)
Non-Hodgkin lymphoma	0.9 (0.7 to 1.5)	2.0 (1.2 to 2.7)	128.5 (102.2 to 209.7)	53.3 (-24.3 to 108.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	115.2 (4.6 to 194.8)	44.6 (-29.0 to 97.9)
Multiple myeloma	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	76.9 (5.5 to 177.8)	15.7 (-29.3 to 82.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	70.8 (3.2 to 173.2)	11.4 (-32.9 to 78.6)
Leukemia	0.6 (0.5 to 0.6)	0.9 (0.8 to 1.1)	64.2 (29.9 to 309.7)	10.3 (-14.0 to 38.9)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	55.4 (22.4 to 96.1)	3.3 (-18.6 to 29.2)
Other neoplasms	1.0 (0.8 to 1.3)	2.1 (1.7 to 2.6)	112.8 (57.4 to 176.8)	48.9 (10.7 to 91.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	93.0 (41.8 to 154.8)	35.7 (-0.1 to 78.0)
Cardiovascular diseases	-	-	-	-	3.9 (2.8 to 5.3)	7.1 (5.0 to 9.6)	85.2 (47.6 to 121.7)	18.7 (-6.0 to 42.5)
Rheumatic heart disease	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	38.7 (25.0 to 53.5)	-2.8 (-12.1 to 7.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.1 (7.6 to 76.9)	-3.4 (-23.7 to 22.8)
Ischemic heart disease	27.9 (24.1 to 32.6)	45.7 (40.7 to 51.4)	64.0 (36.7 to 100.5)	4.9 (-12.8 to 28.6)	1.5 (1.0 to 2.1)	2.5 (1.7 to 3.4)	67.5 (30.4 to 107.6)	3.3 (-18.8 to 29.2)
Cerebrovascular disease	-	-	-	-	0.5 (0.4 to 0.7)	0.7 (0.5 to 1.0)	38.4 (6.6 to 79.9)	-1.7 (-23.3 to 26.6)
Ischemic stroke	3.0 (2.6 to 3.5)	4.1 (3.4 to 5.0)	38.7 (6.4 to 75.4)	-3.7 (-26.2 to 21.6)	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.8)	38.2 (4.7 to 76.7)	-3.3 (-25.7 to 23.9)
Hemorrhagic stroke	0.6 (0.5 to 0.8)	0.9 (0.7 to 1.2)	44.3 (2.4 to 109.6)	7.1 (-22.0 to 53.6)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	41.6 (-1.2 to 112.6)	6.6 (-24.4 to 58.6)
Hypertensive heart disease	4.1 (3.8 to 4.6)	8.2 (7.5 to 8.8)	97.2 (72.7 to 132.9)	18.2 (3.2 to 33.4)	0.4 (0.3 to 0.6)	0.9 (0.6 to 1.2)	97.2 (70.6 to 124.9)	19.2 (3.1 to 35.3)
Cardiomyopathy and myocarditis	0.6 (4.6 to 5.6)	0.9 (5.5 to 6.4)	27.7 (2.7 to 32.4)	-27.7 (-35.9 to -17.4)	0.1 (0.4 to 0.7)	0.6 (0.4 to 0.8)	27.5 (0.9 to 32.4)	15.8 (-36.7 to -16.8)
Atrial fibrillation and flutter	0.6 (0.4 to 0.7)	7.2 (5.6 to 9.7)	1174.6 (781.7 to 1759.7)	665.1 (431.6 to 1007.8)	0.0 (0.0 to 0.1)	0.5 (0.3 to 0.8)	1171.2 (754.6 to 1783.0)	670.5 (424.4 to 1035.4)
Peripheral vascular disease	68.3 (50.2 to 83.9)	103.0 (72.2 to 129.3)	52.1 (1.8 to 123.3)	-2.1 (-35.5 to 43.0)	0.2 (0.1 to 0.4)	0.2 (0.0 to 0.2)	-55.9 (-79.1 to 7.5)	-76.1 (-88.6 to -42.7)
Endocarditis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	258.2 (169.8 to 370.9)	174.1 (112.6 to 266.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (99.7 to 273.3)	111.5 (56.4 to 182.9)
Other cardiovascular and circulatory diseases	8.9 (3.9 to 19.7)	25.3 (13.8 to 36.8)	213.7 (5.5 to 586.3)	113.0 (-28.3 to 366.9)	0.5 (0.3 to 1.3)	1.8 (0.8 to 2.8)	213.3 (4.4 to 593.8)	114.2 (-28.7 to 375.2)
Chronic respiratory diseases	-	-	-	-	8.3 (5.7 to 11.4)	10.5 (7.1 to 14.8)	24.1 (5.9 to 57.6)	-4.8 (-19.9 to 20.7)
Chronic obstructive pulmonary disease	109.1 (104.2 to 113.8)	147.0 (140.2 to 153.4)	34.8 (30.6 to 38.4)	0.3 (-2.8 to 2.9)	6.3 (4.1 to 8.9)	8.3 (5.4 to 11.9)	29.6 (7.9 to 73.9)	-2.6 (-18.9 to 29.2)

Appendix Table G.4 - Slovenia prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	(45.1 to 19.5)	(-24.9 to -14.6)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.1 (38.1 to 53.2)	0.7 (-3.7 to 6.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	(39.8 to 55.1)	(-2.7 to 7.4)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.4 (-11.2 to 2.6)	-30.1 (-35.0 to -25.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.7 (-9.4 to 4.8)	-28.8 (-33.8 to -23.6)
Asthma	44.5 (36.8 to 56.2)	47.0 (39.3 to 55.0)	6.1 (-24.2 to 39.0)	-12.6 (-43.5 to 16.9)	1.9 (1.2 to 2.9)	2.0 (1.3 to 3.0)	4.8 (-25.8 to 38.8)	-12.9 (-44.5 to 18.6)
Interstitial lung disease and pulmonary sarcoidosis	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.4)	48.4 (14.4 to 91.4)	18.3 (-8.4 to 53.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	49.0 (14.3 to 92.8)	18.0 (-9.2 to 53.2)
Other chronic respiratory diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	74.7 (19.7 to 185.2)	29.7 (-11.0 to 109.3)
Cirrhosis	-	-	-	-	0.3 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-39.8 (-28.0 to -11.3)	-95.3 (-41.8 to -28.3)
Cirrhosis due to hepatitis B	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	-3.0 (-38.6 to 31.3)	-24.1 (-52.3 to 2.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-4.2 (-40.1 to 41.6)	-24.4 (-62.5 to 11.9)
Cirrhosis due to hepatitis C	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.5)	-14.6 (-52.9 to 34.2)	-34.2 (-61.8 to 3.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-15.9 (-55.4 to 40.1)	-34.6 (-68.8 to 8.1)
Cirrhosis due to alcohol use	0.5 (0.4 to 0.7)	0.3 (0.2 to 0.4)	-46.5 (-65.6 to -11.0)	0.1 (-74.3 to -33.2)	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-46.2 (-67.8 to -11.3)	-59.2 (-75.7 to -32.9)
Cirrhosis due to other causes	0.3 (0.2 to 0.3)	0.4 (0.2 to 0.4)	7.7 (-22.7 to 52.0)	-5.2 (-29.9 to 29.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	7.9 (-25.8 to 38.3)	-5.3 (-35.3 to 38.3)
Digestive diseases	-	-	-	-	2.5 (1.8 to 3.4)	3.0 (2.2 to 4.1)	19.5 (10.2 to 29.6)	-10.0 (-17.3 to -1.8)
Peptic ulcer disease	18.8 (17.9 to 19.5)	10.0 (8.8 to 11.0)	-46.4 (-52.5 to -41.4)	-69.5 (-72.9 to -66.6)	0.7 (0.4 to 0.9)	0.4 (0.3 to 0.6)	-34.2 (-39.9 to -26.2)	-61.9 (-65.3 to -57.0)
Gastritis and duodenitis	2.3 (2.0 to 2.5)	2.7 (2.5 to 2.9)	19.0 (3.1 to 35.8)	-5.7 (-19.0 to 10.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	19.1 (-10.8 to 48.5)	-2.2 (-24.8 to 23.9)
Appendicitis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	43.1 (-50.0 to -30.4)	-32.9 (-41.3 to -16.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-41.8 (-58.2 to -16.9)	-31.3 (-53.4 to 2.5)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.8 (10.8 to 66.7)	2.9 (-29.8 to 27.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.5 (2.3 to 85.3)	3.9 (-32.3 to 39.0)
Inguinal, femoral, and abdominal hernia	7.0 (6.3 to 7.8)	10.1 (9.1 to 11.3)	42.7 (23.6 to 68.7)	-2.7 (-15.1 to 14.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	42.6 (23.8 to 68.9)	-1.6 (-13.9 to 14.5)
Inflammatory bowel disease	3.0 (2.9 to 3.2)	5.4 (5.2 to 5.6)	79.7 (69.7 to 89.4)	0.6 (-37.1 to 52.6)	0.6 (0.4 to 0.9)	1.1 (0.8 to 1.5)	78.2 (65.0 to 94.4)	45.5 (34.4 to 58.6)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.1 (7.9 to 85.5)	-11.5 (-31.6 to 14.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.2 (-12.9 to 118.6)	-10.9 (-40.6 to 35.7)
Gallbladder and biliary diseases	6.8 (5.9 to 7.6)	6.6 (5.7 to 7.5)	-2.1 (-21.2 to 20.1)	-28.3 (-42.0 to -13.2)	0.7 (0.5 to 1.0)	0.7 (0.4 to 1.0)	2.3 (-21.9 to 20.2)	-27.9 (-42.1 to -11.5)
Pancreatitis	0.8 (0.7 to 0.8)	0.9 (0.9 to 0.9)	21.1 (13.0 to 28.8)	-5.3 (-11.6 to 6.2)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	20.6 (5.6 to 37.3)	-4.7 (-16.2 to 8.8)
Other digestive diseases	-	-	-	-	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	167.6 (97.7 to 231.7)	101.8 (48.6 to 151.0)
Neurological disorders	-	-	-	-	20.7 (14.3 to 28.2)	25.9 (18.1 to 35.3)	25.3 (12.4 to 41.2)	4.9 (-6.2 to 18.1)
Alzheimer disease and other dementias	20.2 (17.7 to 22.7)	36.2 (31.5 to 41.2)	80.1 (49.9 to 114.7)	-1.3 (-17.7 to 18.1)	2.8 (2.0 to 3.7)	5.2 (3.8 to 6.9)	84.4 (52.1 to 121.1)	-0.4 (-17.5 to 19.1)
Parkinson disease	1.4 (1.0 to 1.9)	2.3 (1.6 to 3.0)	65.4 (54.4 to 76.4)	2.3 (-4.7 to 10.4)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	64.5 (45.2 to 86.9)	2.8 (-9.4 to 15.7)
Epilepsy	9.3 (5.8 to 13.3)	7.9 (4.9 to 11.6)	-14.7 (-53.0 to 49.5)	-18.7 (-55.3 to 43.9)	2.9 (1.5 to 4.7)	2.6 (1.4 to 4.2)	11.8 (-52.7 to 59.9)	-14.7 (-54.7 to 55.9)
Multiple sclerosis	0.9 (0.5 to 1.4)	1.6 (1.2 to 2.1)	70.7 (34.2 to 265.7)	43.6 (-4.9 to 211.0)	0.3 (0.1 to 0.5)	0.5 (0.3 to 0.8)	69.5 (11.0 to 277.9)	44.3 (-5.7 to 219.3)
Migraine	301.2 (274.1 to 328.0)	314.6 (287.1 to 344.2)	4.2 (-7.2 to 20.1)	10.2 (-12.3 to 12.9)	1.5 (0.6 to 14.9)	2.7 (6.2 to 15.6)	10.7 (-8.0 to 20.0)	-4.1 (-12.4 to 14.0)
Tension-type headache	393.6 (360.1 to 427.9)	415.4 (380.8 to 451.5)	5.4 (-6.5 to 19.5)	-0.1 (-12.2 to 13.5)	0.0 (0.3 to 1.0)	0.0 (0.3 to 1.1)	4.9 (-7.6 to 19.6)	0.4 (-12.8 to 14.5)
Medication overuse headache	20.9 (13.1 to 28.5)	35.3 (22.8 to 49.4)	68.5 (22.1 to 133.7)	46.5 (4.9 to 100.9)	3.2 (1.8 to 5.0)	5.5 (3.1 to 8.7)	67.5 (21.6 to 132.6)	46.9 (4.3 to 103.1)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.7 (-12.5 to 75.5)	6.3 (-24.3 to 46.2)	0.4 (0.3 to 0.6)	0.7 (0.4 to 0.9)	52.3 (9.1 to 115.3)	-12.7 (-37.6 to 23.1)
Mental and substance use disorders	-	-	-	-	43.5 (31.8 to 56.5)	45.3 (33.0 to 59.2)	4.1 (-1.5 to 9.7)	-1.6 (-3.8 to 1.0)
Schizophrenia	6.8 (6.2 to 7.3)	7.6 (7.0 to 8.2)	11.1 (6.6 to 16.4)	-1.4 (-5.4 to 3.1)	4.3 (3.2 to 5.2)	4.8 (3.5 to 5.8)	11.0 (4.4 to 18.3)	0.7 (-6.8 to 5.9)
Alcohol use disorders	23.1 (21.1 to 25.3)	23.1 (21.1 to 25.1)	-0.4 (-6.5 to 6.3)	-9.5 (-14.8 to -3.3)	2.3 (1.5 to 3.2)	2.3 (1.5 to 3.2)	0.4 (-7.4 to 7.0)	-9.0 (-15.4 to -2.5)
Drug use disorders	-	-	-	-	1.8 (1.2 to 2.5)	1.6 (1.1 to 2.3)	-10.8 (-25.8 to 6.7)	-8.8 (-24.2 to 10.1)
Opioid use disorders	1.2 (0.7 to 1.9)	1.3 (0.8 to 1.9)	7.4 (-1.9 to 21.7)	3.4 (-5.2 to 15.7)	0.5 (0.3 to 0.8)	0.5 (0.3 to 0.9)	8.2 (-8.0 to 29.8)	4.6 (-10.7 to 24.3)
Cocaine use disorders	1.4 (1.1 to 1.7)	1.4 (1.2 to 1.6)	0.6 (-24.2 to 31.3)	-2.6 (-23.3 to 36.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	0.9 (-28.5 to 36.6)	1.9 (-26.4 to 42.8)
Amphetamine use disorders	3.2 (2.5 to 3.8)	2.3 (1.9 to 2.7)	-25.7 (-43.2 to -8.8)	-22.4 (-41.8 to 4.9)	0.4 (0.2 to 0.6)	0.3 (0.2 to 0.5)	-26.2 (-45.2 to 3.5)	-22.6 (-43.3 to 9.7)
Cannabis use disorders	4.7 (4.2 to 5.2)	4.1 (3.7 to 4.5)	-13.1 (-18.7 to -8.2)	0.4 (-6.0 to 6.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-13.3 (-24.0 to 0.1)	0.2 (-12.1 to 16.2)
Other drug use disorders	-	-	-	-	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.7)	-18.7 (-42.4 to 17.7)	-15.0 (-40.7 to 22.8)
Depressive disorders	-	-	-	-	16.6 (11.2 to 22.8)	18.2 (12.5 to 25.1)	9.5 (3.8 to 16.1)	0.4 (-5.7 to 4.9)
Major depressive disorder	67.3 (58.0 to 76.0)	73.6 (62.7 to 83.8)	9.1 (2.4 to 16.7)	-0.8 (-7.1 to 5.1)	13.6 (9.2 to 18.9)	14.8 (9.8 to 20.7)	8.3 (1.5 to 16.1)	-0.3 (-6.4 to 6.2)
Dysthymia	30.9 (25.7 to 36.0)	35.9 (30.0 to 41.6)	16.3 (12.5 to 20.6)	-1.3 (-1.6 to -1.0)	2.9 (1.9 to 4.3)	3.4 (2.2 to 4.9)	15.7 (10.9 to 20.8)	-0.9 (-3.4 to 1.5)
Bipolar disorder	15.2 (12.2 to 18.1)	16.7 (13.8 to 19.5)	9.6 (3.6 to 16.7)	-0.8 (-6.5 to 5.2)	3.1 (1.8 to 4.6)	3.3 (2.0 to 5.0)	9.2 (1.6 to 17.3)	-0.4 (-7.4 to 7.2)
Anxiety disorders	73.5 (61.6 to 85.0)	76.1 (64.1 to 87.7)	3.6 (-0.0 to 7.3)	3.6 (-1.9 to -1.2)	1.5 (4.6 to 9.5)	1.5 (4.7 to 9.8)	4.1 (-1.5 to 7.4)	1.1 (-3.5 to 1.5)
Eating disorders	-	-	-	-	0.5 (0.3 to 0.8)	0.4 (0.3 to 0.7)	-16.3 (-23.6 to -8.9)	0.6 (-7.4 to 9.1)
Anorexia nervosa	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.3)	-2.4 (-11.7 to 7.7)	18.5 (6.6 to 30.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-2.3 (-25.2 to 26.6)	18.7 (-8.6 to 53.7)
Bulimia nervosa	2.1 (1.5 to 2.8)	1.7 (1.2 to 2.4)	-18.1 (-21.1 to -15.3)	-2.0 (-2.5 to -1.7)	0.4 (0.3 to 0.7)	0.4 (0.2 to 0.6)	-18.1 (-25.7 to -10.7)	-1.9 (-9.7 to 6.7)
Autistic spectrum disorders	-	-	-	-	2.3 (1.5 to 3.1)	2.3 (1.6 to 3.1)	0.8 (-2.8 to 4.3)	2.0 (-1.7 to 5.5)
Autism	6.0 (5.7 to 6.3)	6.1 (5.7 to 6.4)	1.5 (0.7 to 2.5)	1.6 (1.5 to 1.7)	1.5 (1.0 to 2.0)	1.5 (1.0 to 2.0)	0.6 (-4.8 to 5.4)	1.8 (-3.5 to 6.9)
Asperger syndrome	8.5 (7.9 to 9.0)	8.6 (8.0 to 9.3)	1.9 (0.8 to 3.0)	2.1 (2.0 to 2.2)	0.8 (0.6 to 1.2)	0.8 (0.6 to 1.2)	1.1 (-3.1 to 5.4)	2.2 (-1.8 to 6.2)
Attention-deficit/hyperactivity disorder	9.2 (8.4 to 9.9)	6.3 (5.8 to 6.8)	-31.5 (-31.9 to -31.2)	0.5 (0.4 to 0.5)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-31.5 (-36.3 to -25.8)	0.7 (-6.8 to 8.7)
Conduct disorder	11.5 (12.7 to 14.3)	8.8 (8.3 to 9.4)	-23.5 (-35.1 to -34.3)	0.3 (0.3 to 0.4)	1.6 (1.0 to 2.4)	1.1 (0.7 to 1.6)	-34.6 (-37.6 to -31.5)	0.4 (-4.1 to 5.0)
Idiopathic intellectual disability	32.1 (26.7 to 38.5)	25.7 (21.8 to 32.4)	-17.1 (-24.6 to -9.4)	-17.5 (-24.7 to -10.0)	1.6 (1.0 to 2.2)	1.3 (0.9 to 1.8)	-17.5 (-25.2 to -9.4)	-17.2 (-24.9 to -9.0)
Other mental and substance use disorders	37.0 (34.8 to 39.1)	42.8 (40.2 to 45.2)	15.5 (13.8 to 17.3)	1.5 (1.2 to 1.9)	2.7 (1.9 to 3.7)	3.1 (2.1 to 4.2)	14.8 (10.7 to 19.3)	2.0 (-1.4 to 5.8)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	20.8 (14.8 to 27.7)	27.6 (19.8 to 36.8)	32.2 (18.7 to 51.8)	8.0 (-2.0 to 23.1)
Diabetes mellitus	115.2 (96.1 to 139.9)	171.8 (140.4 to 202.6)	49.0 (18.9 to 86.8)	21.7 (-1.8 to 51.1)	8.7 (5.6 to 12.5)	12.8 (8.4 to 18.3)	47.6 (14.0 to 98.7)	35.8 (-10.0 to 54.7)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.8 (-58.1 to -49.2)	-53.8 (-55.2 to -45.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.8 (-58.1 to -49.2)	-53.8 (-55.2 to -45.9)
Chronic kidney disease	-	-	-	-	6.2 (4.6 to 7.9)	8.1 (5.9 to 10.4)	31.5 (15.6 to 41.4)	5.2 (-7.4 to 12.4)
Chronic kidney disease due to diabetes mellitus	30.1 (19.1 to 43.0)	54.3 (38.5 to 74.9)	81.1 (34.3 to 143.0)	34.7 (-2.4 to 75.9)	0.8 (0.5 to 1.1)	1.5 (1.1 to 2.1)	96.6 (47.1 to 172.5)	47.1 (9.3 to 104.9)
Chronic kidney disease due to hypertension	50.6 (37.1 to 72.3)	52.1 (35.6 to 76.7)	1.8 (-26.0 to 50.7)	-12.7 (-34.5 to 27.5)	2.0 (1.4 to 2.6)	0.9 (0.6 to 1.2)	-53.1 (-62.1 to -41.4)	-62.6 (-69.8 to -53.0)
Chronic kidney disease due to glomerulonephritis	69.1 (49.6 to 98.9)	35.6 (27.6 to 49.2)	-48.4 (-58.6 to -32.7)	-47.1 (-65.0 to -45.8)	1.2 (0.9 to 1.6)	1.5 (1.1 to 2.1)	21.8 (-4.7 to 72.4)	8.5 (-16.1 to 47.7)
Chronic kidney disease due to other causes	88.5 (63.3 to 125.2)	150.7 (111.1 to 208.8)	70.4 (43.6 to 104.0)	32.4 (14.9 to 55.5)	2.3 (1.6 to 3.0)	4.1 (3.0 to 5.4)	83.8 (58.6 to 115.0)	43.8 (25.9 to 68.4)
Urinary diseases and male infertility	-	-	-	-	0.9 (0.6 to 1.3)	1.5 (1.0 to 2.2)	72.6 (47.4 to 95.5)	16.1 (-1.9 to 31.8)

Appendix Table G.4 - Slovenia prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.3 (0.3 to 0.3)	0.4 (0.4 to 0.4)	18.8 (10.5 to 27.7)	11.3 (3.3 to 20.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.8 (-1.1 to 45.2)	11.8 (-11.3 to 39.5)
Urolithiasis	18.1 (11.8 to 28.1)	23.5 (15.9 to 35.7)	30.7 (8.9 to 54.5)	-13.4 (-26.2 to -1.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	7.1 (14.3 to 53.4)	-7.1 (-18.9 to 4.7)
Benign prostatic hyperplasia	19.7 (18.3 to 21.2)	33.4 (31.7 to 35.8)	69.6 (54.2 to 87.9)	9.0 (-1.4 to 20.8)	0.7 (0.4 to 1.0)	1.2 (0.8 to 1.6)	9.5 (53.4 to 88.2)	9.5 (-1.2 to 21.3)
Male infertility due to other causes	5.3 (3.9 to 7.1)	5.4 (4.0 to 7.0)	1.4 (-31.0 to 45.3)	7.1 (-27.0 to 53.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	3.1 (-32.7 to 54.0)	9.2 (-29.1 to 64.5)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.3)	0.1 (-2.2 to 13.1)	88.0 (-30.6 to 923.7)
Gynecological diseases	-	-	-	-	2.4 (1.6 to 3.7)	2.6 (1.6 to 3.8)	4.3 (-9.2 to 26.7)	0.7 (-12.0 to 23.2)
Uterine fibroids	47.4 (43.2 to 51.3)	52.5 (48.1 to 56.6)	10.6 (9.6 to 11.8)	-2.0 (-2.1 to -2.0)	0.3 (0.3 to 1.0)	0.6 (0.3 to 1.0)	9.3 (3.1 to 15.9)	-0.2 (-5.3 to 5.9)
Polycystic ovarian syndrome	36.6 (32.3 to 40.4)	36.2 (32.5 to 40.1)	-1.0 (-14.6 to 15.6)	-0.7 (-14.5 to 16.0)	0.3 (0.2 to 0.6)	0.3 (0.2 to 0.6)	-0.9 (-14.2 to 15.5)	-0.2 (-13.8 to 16.4)
Female infertility due to other causes	2.5 (0.8 to 4.6)	2.5 (0.6 to 4.7)	-3.8 (-75.8 to 224.6)	-3.8 (-73.9 to 232.7)	0.0 (0.0 to 0.3)	0.0 (0.0 to 0.0)	0.0 (-74.8 to 231.0)	0.0 (-73.3 to 244.3)
Endometriosis	3.9 (3.3 to 4.6)	4.2 (3.6 to 4.7)	5.8 (-14.6 to 31.3)	4.0 (-15.8 to 29.0)	0.4 (0.2 to 0.5)	0.4 (0.3 to 0.5)	5.6 (-16.2 to 34.0)	4.6 (-16.8 to 31.0)
Genital prolapse	117.2 (103.7 to 132.0)	130.4 (117.5 to 143.8)	11.1 (-4.8 to 31.2)	-4.5 (-18.5 to 12.3)	0.4 (0.2 to 0.7)	0.4 (0.2 to 0.8)	11.0 (-5.5 to 30.5)	-4.1 (-18.6 to 12.5)
Premenstrual syndrome	73.5 (38.7 to 103.6)	75.5 (47.2 to 108.5)	-1.8 (-36.9 to 123.0)	3.3 (-32.9 to 131.2)	0.6 (0.3 to 1.1)	0.6 (0.3 to 1.1)	-1.6 (-37.6 to 123.1)	3.7 (-3.8 to 129.6)
Other gynecological diseases	6.5 (5.8 to 7.2)	6.2 (5.8 to 6.6)	-3.8 (-14.2 to 6.7)	-3.5 (-14.2 to 7.7)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-3.5 (-19.3 to 20.7)	-2.4 (-18.3 to 21.0)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	1.8 (1.2 to 2.6)	1.8 (1.2 to 2.6)	3.3 (-10.6 to 12.9)	-1.3 (-8.6 to 12.8)
Thalassemias	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-24.4 (-32.4 to -14.5)	0.4 (-10.2 to 13.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.8 (-48.6 to 5.0)	-4.9 (-33.7 to 43.3)
Thalassemia trait	54.1 (41.6 to 69.6)	55.7 (41.5 to 72.1)	3.0 (-6.6 to 11.6)	-0.6 (-9.5 to 7.3)	1.4 (0.9 to 2.0)	1.4 (0.9 to 2.0)	-1.3 (-11.1 to 14.6)	-0.9 (-10.4 to 13.2)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.3 (-66.5 to -3.1)	-8.0 (-46.5 to 12.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.6 (-73.9 to -7.5)	-26.7 (-68.5 to 5.6)
Sickle cell trait	8.7 (5.4 to 11.6)	7.2 (4.1 to 10.2)	-15.8 (-50.1 to 3.5)	-18.7 (-51.8 to 0.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-15.3 (-56.3 to -6.6)	-29.1 (-57.4 to 4.4)
G6PD deficiency	17.0 (12.7 to 20.6)	14.5 (9.4 to 21.0)	-16.0 (-47.1 to 38.1)	-18.4 (-48.8 to 34.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.0 (-14.5 to 4.9)	11.8 (-13.3 to 14.5)
G6PD trait	263.3 (243.5 to 283.6)	266.1 (237.3 to 288.0)	0.8 (-12.9 to 11.5)	-4.0 (-17.0 to 6.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.6 (-57.0 to 100.4)	-11.3 (-62.1 to 127.7)
Other hemoglobinopathies and hemolytic anemias	15.6 (14.0 to 17.1)	17.5 (16.0 to 18.8)	12.0 (-0.5 to 31.1)	3.3 (-10.4 to 22.6)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	-3.2 (-27.2 to 36.9)	4.0 (-21.2 to 48.5)
Endocrine, metabolic, blood, and immune disorders	25.5 (24.0 to 26.9)	26.7 (25.7 to 27.8)	7.2 (-1.2 to 11.7)	0.8 (-5.9 to 8.3)	5.1 (0.5 to 1.1)	0.8 (0.5 to 1.1)	9.9 (-8.3 to 8.6)	0.1 (-7.5 to 11.3)
Musculoskeletal disorders	-	-	-	-	52.5 (36.6 to 70.1)	66.7 (47.7 to 88.4)	27.0 (18.9 to 35.2)	1.2 (-5.7 to 7.7)
Rheumatoid arthritis	5.3 (4.9 to 5.6)	7.8 (7.4 to 8.4)	48.6 (36.3 to 63.1)	3.5 (-5.3 to 13.0)	1.2 (0.9 to 1.6)	1.8 (1.3 to 2.3)	47.0 (33.1 to 62.2)	4.1 (-5.6 to 14.5)
Osteoarthritis	111.1 (107.0 to 115.5)	167.5 (161.1 to 173.8)	50.7 (43.4 to 58.9)	-0.3 (-5.2 to 5.2)	6.7 (4.7 to 9.1)	10.0 (7.1 to 13.7)	50.1 (42.8 to 58.9)	0.1 (-4.8 to 6.0)
Low back and neck pain	-	-	-	-	41.3 (28.4 to 55.7)	50.2 (34.9 to 68.4)	21.1 (11.8 to 31.4)	0.5 (-8.0 to 8.6)
Low back pain	290.9 (272.7 to 309.5)	354.4 (331.9 to 374.9)	22.0 (11.6 to 32.2)	-0.7 (-8.8 to 7.3)	31.9 (21.2 to 43.9)	38.6 (26.5 to 53.5)	20.8 (11.0 to 31.3)	-0.4 (-8.6 to 7.9)
Neck pain	97.5 (82.4 to 114.4)	120.2 (99.4 to 140.7)	23.5 (-2.1 to 53.2)	3.1 (-18.9 to 27.8)	9.5 (6.3 to 13.5)	11.6 (7.7 to 16.2)	3.6 (-2.9 to 52.8)	3.6 (-19.0 to 28.3)
Gout	1.0 (1.0 to 1.1)	1.6 (1.5 to 1.7)	50.9 (38.3 to 64.2)	8.8 (-0.4 to 18.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (18.7 to 85.6)	0.0 (-13.7 to 35.4)
Other musculoskeletal disorders	36.7 (24.9 to 49.0)	52.8 (38.3 to 67.8)	44.1 (28.5 to 61.9)	9.7 (-0.7 to 22.9)	3.3 (2.0 to 5.1)	4.7 (3.0 to 7.1)	43.7 (27.4 to 62.5)	3.3 (-0.6 to 23.5)
Other non-communicable diseases	-	-	-	-	34.6 (23.2 to 49.6)	40.9 (27.7 to 58.8)	18.3 (14.5 to 22.4)	-6.7 (-9.9 to -3.6)
Congenital anomalies	-	-	-	-	2.7 (1.9 to 3.6)	2.9 (2.0 to 3.7)	4.1 (-10.1 to 19.7)	-2.3 (-15.5 to 12.2)
Neural tube defects	0.6 (0.5 to 0.7)	0.4 (0.3 to 0.5)	-29.2 (-46.2 to -8.3)	-25.5 (-43.5 to -3.9)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-27.7 (-51.3 to 2.4)	-23.7 (-48.2 to 9.4)
Congenital heart anomalies	15.1 (12.5 to 19.2)	13.7 (11.9 to 16.0)	-8.4 (-31.9 to 18.2)	-8.8 (-32.0 to 17.6)	0.5 (0.2 to 0.9)	0.5 (0.2 to 0.8)	-7.9 (-29.8 to 16.7)	-6.9 (-28.4 to 17.5)
Orofacial clefts	2.5 (1.8 to 3.3)	2.3 (1.9 to 2.9)	-7.7 (-34.9 to 30.3)	-9.2 (-35.9 to 28.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.0 (-43.1 to 31.1)	-14.0 (-45.0 to 29.6)
Down syndrome	2.2 (1.7 to 3.1)	2.5 (1.9 to 3.3)	18.4 (-28.4 to 68.6)	6.5 (-35.4 to 51.5)	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	28.5 (-22.5 to 84.4)	8.2 (-34.3 to 55.8)
Turner syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	0.9 (-32.0 to 53.1)	3.6 (-30.3 to 57.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.3 (-34.3 to 55.8)	3.3 (-31.2 to 59.3)
Klinefelter syndrome	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	34.5 (-13.6 to 143.7)	33.3 (-14.6 to 141.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.9 (-22.4 to 143.3)	30.8 (-21.4 to 145.1)
Chromosomal unbalanced rearrangements	37.4 (3.2 to 4.4)	45.5 (3.7 to 5.8)	20.3 (-5.9 to 62.8)	10.3 (-15.6 to 46.1)	0.5 (0.4 to 0.7)	0.7 (0.5 to 1.0)	12.1 (2.0 to 78.3)	31.2 (-14.1 to 49.3)
Other congenital anomalies	7.0 (5.6 to 8.2)	6.7 (5.5 to 7.9)	-3.6 (-13.8 to 6.5)	-10.1 (-19.7 to -0.2)	1.1 (0.8 to 1.6)	1.1 (0.7 to 1.6)	-3.5 (-18.6 to 18.9)	-4.2 (-19.6 to 19.1)
Skin and subcutaneous diseases	-	-	-	-	9.7 (6.5 to 14.2)	9.6 (6.3 to 14.1)	-1.3 (-8.4 to 6.9)	-5.3 (-11.9 to 2.0)
Dermatitis	95.9 (80.4 to 113.8)	99.9 (84.2 to 117.2)	4.2 (1.7 to 7.0)	-0.1 (-0.3 to 0.0)	2.5 (1.6 to 3.6)	2.5 (1.6 to 3.6)	2.3 (-1.8 to 6.5)	0.1 (-2.6 to 3.2)
Psoriasis	17.8 (15.6 to 20.0)	20.1 (17.6 to 22.6)	13.0 (10.3 to 16.4)	1.4 (-0.2 to 0.3)	0.1 (1.0 to 2.0)	1.6 (1.1 to 2.3)	12.1 (5.9 to 18.7)	0.3 (-4.8 to 5.8)
Cellulitis	0.3 (0.3 to 0.4)	0.4 (0.3 to 0.5)	13.5 (2.4 to 25.2)	4.2 (-4.5 to 13.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.0 (-9.0 to 36.1)	4.6 (-14.7 to 28.6)
Pyoderma	2.2 (1.8 to 2.6)	2.2 (1.9 to 2.7)	4.2 (-1.8 to 10.2)	-5.4 (-7.4 to -3.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.0 (-6.1 to 12.4)	-5.4 (-12.1 to 1.7)
Scabies	3.6 (3.3 to 4.0)	3.2 (2.9 to 3.4)	-13.2 (-23.6 to -1.3)	-10.8 (-21.2 to 1.1)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-13.7 (-16.3 to -10.8)	-10.8 (-22.6 to 2.4)
Fungal skin diseases	185.1 (129.0 to 215.9)	182.1 (143.3 to 232.4)	-1.6 (-4.6 to 16.9)	0.6 (-0.2 to 1.5)	1.0 (0.4 to 2.2)	1.0 (0.4 to 2.2)	0.5 (3.8 to 16.4)	0.5 (-1.4 to 2.8)
Viral skin diseases	39.6 (30.1 to 49.2)	35.4 (26.7 to 44.8)	-10.8 (-14.5 to -6.0)	0.2 (-1.4 to 2.0)	1.2 (0.7 to 1.9)	1.1 (0.6 to 1.7)	-11.3 (-15.8 to -6.9)	0.4 (-2.7 to 3.5)
Acne vulgaris	40.8 (30.5 to 51.6)	37.1 (29.6 to 44.6)	-9.4 (-33.3 to 28.8)	15.0 (-16.2 to 65.4)	0.4 (0.2 to 0.8)	0.4 (0.2 to 0.8)	-9.4 (-33.4 to 29.0)	15.2 (-16.5 to 66.8)
Alopecia areata	2.5 (2.2 to 2.8)	3.0 (2.6 to 3.4)	21.8 (0.3 to 44.6)	2.7 (-14.4 to 19.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	20.0 (-2.1 to 46.0)	2.5 (-15.7 to 22.9)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.3 (5.3 to 56.9)	0.0 (0.0 to 0.0)	22.1 (-5.3 to 56.9)	1.9 (-21.4 to 27.2)
Urticaria	36.7 (28.4 to 45.2)	28.2 (21.1 to 36.2)	-24.3 (-47.0 to 10.5)	-29.5 (-50.5 to 4.3)	2.1 (1.3 to 3.2)	1.6 (1.0 to 2.4)	-24.9 (-47.7 to 10.6)	-28.8 (-50.0 to 5.6)
Decubitus ulcer	0.3 (0.3 to 0.4)	0.8 (0.7 to 1.0)	140.4 (87.7 to 218.9)	49.9 (19.4 to 94.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	133.3 (76.1 to 218.0)	48.8 (15.6 to 100.7)
Other skin and subcutaneous diseases	148.6 (89.4 to 249.1)	183.3 (102.3 to 320.9)	22.0 (9.7 to 35.4)	-3.7 (-7.6 to 0.4)	0.9 (0.3 to 1.9)	1.1 (0.4 to 2.4)	21.5 (8.5 to 34.5)	-3.6 (-7.4 to 0.9)
Sense organ diseases	-	-	-	-	16.8 (11.1 to 24.3)	22.0 (14.9 to 31.5)	30.5 (24.5 to 36.9)	-9.1 (-13.0 to -5.0)
Glaucoma	2.6 (2.2 to 3.2)	2.9 (2.3 to 3.6)	11.3 (-6.8 to 37.1)	-18.9 (-30.9 to -1.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	15.5 (-1.9 to 41.4)	-19.3 (-30.6 to -3.5)
Cataract	27.7 (22.4 to 32.8)	32.9 (26.5 to 39.5)	18.9 (-0.7 to 36.6)	-29.8 (-40.7 to -19.4)	0.9 (0.6 to 1.4)	1.1 (0.7 to 1.7)	21.3 (2.2 to 38.6)	-28.7 (-38.7 to -18.8)
Macular degeneration	6.9 (5.3 to 8.6)	11.9 (8.6 to 15.6)	74.2 (31.2 to 122.1)	16.5 (-12.2 to 45.9)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.6)	73.0 (31.7 to 119.6)	13.9 (-13.2 to 42.4)
Uncorrected refractive error	197.2 (165.5 to 208.9)	252.9 (213.6 to 289.3)	35.2 (12.1 to 61.2)	-7.0 (-18.7 to 17.8)	2.9 (1.7 to 4.8)	3.6 (2.0 to 5.9)	23.1 (7.8 to 40.3)	-7.8 (-19.0 to 4.5)
Age-related and other hearing loss	406.8 (362.0 to 447.3)	531.8 (478.2 to 579.4)	30.7 (24.9 to 36.5)	-7.6 (-11.2 to -3.6)	10.9 (7.3 to 15.4)	15.9 (10.1 to 20.8)	36.3 (28.9 to 46.0)	-8.3 (-13.1 to -2.7)
Other vision loss	13.5 (11.8 to 15.6)	11.8 (9.8 to 14.2)	-13.2 (-23.1 to 1.2)	-30.8 (-37.1 to -21.3)	0.6 (0.4 to 0.8)	0.5 (0.4 to 0.8)	5.1 (-15.4 to 8.5)	-27.6 (-34.2 to -19.5)
Other sense organ diseases	46.8 (44.8 to 48.9)	51.5 (49.0 to 54.0)	9.9 (3.0 to 17.7)	-0.8 (-6.6 to 6.1)	1.2 (0.7 to 1.8)	1.3 (0.8 to 1.9)	8.6 (1.2 to 16.8)	-0.5 (-7.0 to 6.8)
Oral disorders	-	-	-	-	5.3 (3.0 to 8.4)	6.5 (3.7 to 10.4)	23.3 (15.5 to 28.5)	-4.7 (-8.7 to -0.7)
Deciduous caries	104.1 (100.8 to 107.4)	75.1 (72.4 to 77.6)	-27.7 (-31.2 to -24.4)	-0.9 (-5.7 to 3.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.9 (-34.0 to -21.6)	-1.2 (-6.6 to 7.6)
Permanent caries	786.8 (749.3 to 822.2)	791.4 (754.1 to 830.2)	0.8 (-6.1 to 6.8)	-2.4 (-8.9 to 4.0)	0.5 (0.2 to 0.9)	0.5 (0.2 to 0.9)	0.2 (-6.9 to 6.6)	2.4 (-8.9 to 4.3)
Periodontal diseases	291.3 (278.1 to 302.9)	383.7 (366.4 to 400.3)	31.7 (23.1 to 40.8)	1.9 (-4.4 to 9.3)	2.3 (0.8 to 3.9)	2.5 (1.0 to 5.1)	31.2 (22.5 to 40.3)	2.5 (-4.1 to 9.6)

Appendix Table G.4 - Slovenia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	66.4 (63.0 to 69.6)	87.3 (83.2 to 91.8)	31.9 (22.4 to 41.7)	-15.3 (-21.3 to -9.1)	1.8 (1.2 to 2.5)	2.3 (1.6 to 3.2)	31.4 (21.9 to 41.1)	31.4 (-21.1 to -8.6)
Other oral disorders	38.2 (36.2 to 40.3)	41.5 (39.2 to 44.0)	8.7 (1.2 to 18.0)	-0.6 (-7.7 to 7.6)	1.1 (0.7 to 1.7)	1.2 (0.7 to 1.8)	8.1 (0.2 to 17.4)	-0.5 (-8.0 to 8.2)
Injuries	-	-	-	-	37.4 (28.3 to 48.2)	36.1 (25.8 to 48.4)	-4.1 (-14.4 to 7.1)	-29.8 (-37.4 to -21.5)
Transport injuries	-	-	-	-	9.1 (6.8 to 11.8)	5.9 (4.1 to 8.0)	-36.0 (-44.1 to -26.6)	-49.3 (-55.7 to -41.8)
Road injuries	-	-	-	-	8.2 (6.2 to 10.6)	5.5 (3.9 to 7.4)	-33.7 (-42.3 to -23.6)	-47.3 (-54.1 to -39.4)
Pedestrian road injuries	-	-	-	-	0.9 (0.6 to 1.1)	0.5 (0.4 to 0.7)	-37.0 (-45.5 to -26.8)	-53.0 (-59.3 to -45.5)
Cyclist road injuries	-	-	-	-	1.8 (1.4 to 2.4)	1.3 (1.0 to 1.8)	-26.9 (-34.5 to -17.3)	-42.5 (-48.4 to -35.2)
Motorcyclist road injuries	-	-	-	-	1.0 (0.8 to 1.3)	0.8 (0.5 to 1.1)	-25.0 (-35.5 to -13.0)	-38.0 (-46.6 to -28.2)
Motor vehicle road injuries	-	-	-	-	4.4 (3.3 to 5.7)	2.8 (2.0 to 3.8)	-37.4 (-46.5 to -26.4)	-49.8 (-57.1 to -41.1)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-59.1 (-64.5 to -53.0)	-67.7 (-71.9 to -63.1)
Other transport injuries	-	-	-	-	0.9 (0.7 to 1.1)	0.4 (0.3 to 0.5)	-56.7 (-61.5 to -50.8)	-67.3 (-70.8 to -62.9)
Unintentional injuries	-	-	-	-	28.0 (21.3 to 36.0)	30.0 (21.5 to 40.1)	6.5 (-4.0 to 18.0)	-23.4 (-31.1 to -15.0)
Falls	-	-	-	-	20.6 (15.6 to 26.4)	22.2 (16.0 to 29.7)	7.3 (-4.9 to 20.6)	-26.3 (-34.9 to -16.8)
Drowning	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-33.4 (-42.3 to -22.7)	-47.4 (-54.2 to -38.9)
Fire, heat, and hot substances	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.3)	-12.9 (-24.1 to -0.5)	-28.1 (-37.3 to -17.5)
Poisonings	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-14.8 (-26.8 to -1.8)	-23.2 (-34.6 to -11.7)
Exposure to mechanical forces	-	-	-	-	5.3 (4.0 to 7.0)	5.6 (4.0 to 7.5)	4.4 (-3.2 to 12.8)	-14.1 (-19.5 to -7.9)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-82.2 (-83.3 to -81.1)	-47.6 (-56.1 to -37.0)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.8 (-30.3 to -12.5)	-36.1 (-43.0 to -28.7)
Other exposure to mechanical forces	-	-	-	-	5.2 (3.9 to 6.9)	5.5 (4.0 to 7.4)	5.1 (2.4 to 13.5)	-13.6 (-18.9 to -7.4)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.2 (23.2 to 40.9)	-0.4 (-6.6 to 6.2)
Animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	0.4 (-8.9 to 10.6)	-13.8 (-21.7 to -5.5)
Venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	5.1 (-8.6 to 18.6)	-7.1 (-19.7 to 5.3)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-2.3 (-12.0 to 9.4)	-17.3 (-25.4 to -8.0)
Foreign body	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-7.0 (-15.8 to 2.9)	-23.9 (-30.9 to -16.3)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-33.4 (-44.9 to -18.9)	-45.1 (-54.4 to -33.4)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.9 (-3.9 to 9.6)	-9.0 (-15.5 to -2.4)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	2.1 (-7.9 to 13.2)	-18.5 (-26.2 to -10.0)
Other unintentional injuries	-	-	-	-	1.3 (1.0 to 1.7)	1.5 (1.1 to 2.0)	15.3 (6.9 to 23.8)	-12.8 (-18.5 to -6.3)
Self-harm and interpersonal violence	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-25.5 (-32.9 to -15.5)	-41.2 (-46.9 to -33.5)
Self-harm	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-20.3 (-28.0 to -10.3)	-37.1 (-43.1 to -29.6)
Interpersonal violence	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-32.7 (-41.3 to -22.3)	-46.7 (-53.3 to -38.6)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.2 (-22.7 to -6.3)	-33.6 (-39.2 to -26.6)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.9 (-34.2 to -14.0)	-39.9 (-47.0 to -31.5)
Assault by other means	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-37.3 (-45.8 to -26.8)	-50.4 (-57.0 to -42.3)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Solomon Islands prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
All causes	-	-	-	-	23.1 (16.9 to 30.2)	43.0 (31.8 to 56.0)	85.6 (79.7 to 92.9)	85.6 (-4.3 to 2.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	5.5 (3.8 to 7.8)	8.4 (5.9 to 11.6)	50.5 (38.0 to 66.3)	-11.6 (-20.1 to -1.4)
HIV/AIDS and tuberculosis	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	101.9 (83.2 to 122.6)	-0.2 (-7.7 to 9.9)
Tuberculosis	0.4 (0.4 to 0.4)	0.8 (0.8 to 0.8)	88.0 (80.5 to 95.2)	-6.8 (-10.3 to -3.4)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	88.2 (73.5 to 102.4)	-6.6 (-12.5 to -0.7)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,499.9 (522.7 to 2,769.4)	694.9 (217.4 to 1,358.1)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,103.9 (375.6 to 2,138.1)	508.2 (141.1 to 1,018.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,103.9 (374.8 to 2,140.8)	508.2 (139.1 to 1,020.3)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	1,101.0 (374.9 to 2,124.9)	528.6 (154.8 to 1,078.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,473.0 (513.7 to 2,956.0)	704.6 (214.7 to 1,486.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	1.5 (0.8 to 1.5)	1.5 (1.1 to 2.0)	35.7 (27.6 to 44.0)	-17.9 (-22.4 to -13.0)
Diarrheal diseases	3.1 (2.9 to 3.2)	4.4 (4.2 to 4.6)	43.4 (33.0 to 54.2)	-7.5 (-14.1 to -0.6)	0.7 (0.3 to 0.7)	0.7 (0.5 to 1.0)	43.4 (31.8 to 54.9)	-7.4 (-14.6 to -0.0)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.7 (9.3 to 67.4)	-30.2 (-44.9 to -0.0)
Typhoid fever	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	11.7 (4.8 to 33.1)	-33.4 (-43.4 to -21.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.8 (-13.3 to 46.1)	-32.3 (-46.7 to -15.0)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.8 (-26.2 to 14.4)	-46.9 (-57.2 to -34.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.3 (-30.8 to 23.7)	47.1 (-58.7 to -30.7)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	332.2 (85.7 to 10,562.0)	158.1 (-91.6 to 5,212.7)
Lower respiratory infections	0.6 (0.5 to 0.7)	0.6 (0.5 to 0.8)	1.5 (-26.6 to 40.9)	-28.5 (-43.4 to -9.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-0.1 (-29.0 to 40.6)	-29.3 (-44.8 to -10.1)
Upper respiratory infections	9.8 (9.4 to 10.3)	16.9 (16.1 to 17.7)	72.2 (60.4 to 83.3)	-1.8 (-7.9 to 4.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	72.1 (59.2 to 84.8)	-1.6 (-8.1 to 5.1)
Otitis media	4.7 (4.3 to 5.0)	7.1 (6.7 to 7.5)	52.8 (42.0 to 63.0)	-11.8 (-18.1 to -5.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	52.2 (39.9 to 64.2)	-11.6 (-18.6 to -4.3)
Meningitis	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	12.2 (-2.0 to 34.1)	-35.1 (-42.6 to -23.0)
Pneumococcal meningitis	1.7 (1.0 to 2.5)	1.9 (1.1 to 2.8)	13.9 (-7.1 to 35.1)	-35.7 (-47.4 to -24.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	11.5 (-11.6 to 42.6)	-35.6 (-47.4 to -19.7)
H influenzae type B meningitis	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.6)	-0.2 (-19.8 to 30.1)	-44.3 (-54.4 to -28.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	3.4 (-31.6 to 55.6)	-40.8 (-60.2 to -11.2)
Meningococcal meningitis	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.5)	14.3 (-12.3 to 45.4)	-36.8 (-48.5 to -21.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.4 (-24.0 to 66.9)	-37.1 (-53.2 to -11.9)
Other meningitis	0.7 (0.3 to 1.2)	0.8 (0.4 to 1.3)	14.7 (-5.8 to 44.2)	-34.1 (-46.3 to -16.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	18.9 (-9.2 to 58.9)	-30.5 (-45.4 to -7.8)
Encephalitis	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	64.1 (46.3 to 92.5)	-11.1 (-19.1 to 1.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.1 (49.9 to 114.2)	-4.6 (-18.2 to 11.2)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.8 (-89.6 to 761.8)	-44.3 (-92.9 to 368.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.8 (-89.7 to 768.3)	-44.3 (-93.0 to 377.3)
Whooping cough	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-15.9 (-18.9 to -12.8)	-42.7 (-44.7 to -40.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.4 (-24.6 to -4.7)	-42.4 (-48.7 to -35.1)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.8 (-86.3 to -4.4)	-82.5 (-92.3 to -48.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-55.5 (-84.3 to 19.9)	-76.0 (-89.5 to -48.9)
Measles	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-43.6 (-52.6 to -33.5)	-42.3 (-68.3 to -55.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-44.0 (-59.1 to -19.0)	-42.5 (-72.7 to -45.9)
Varicella and herpes zoster	0.4 (0.3 to 0.4)	0.6 (0.6 to 0.7)	68.2 (52.7 to 87.6)	-0.3 (-12.2 to 15.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.7 (46.8 to 128.1)	-0.3 (-18.6 to 21.2)
Neglected tropical diseases and malaria	-	-	-	-	1.5 (0.9 to 2.2)	2.4 (1.6 to 3.7)	65.7 (33.8 to 105.6)	-6.7 (-29.1 to 21.9)
Malaria	71.4 (68.0 to 75.1)	103.9 (97.2 to 111.2)	45.6 (37.5 to 54.3)	-19.3 (-24.0 to -14.1)	0.6 (0.4 to 0.9)	1.0 (0.7 to 1.4)	57.6 (43.8 to 65.7)	-8.7 (-15.4 to -4.8)
Chagas disease	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,160.3 (881.7 to 1,462.8)	884.8 (683.8 to 1,126.7)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.8 (-16.5 to 283.2)	10.4 (-39.5 to 102.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.8 (-16.5 to 283.9)	10.4 (-39.7 to 102.4)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,249.7 (940.5 to 1,558.2)	939.6 (722.7 to 1,180.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,247.1 (943.5 to 1,563.5)	931.6 (715.8 to 1,188.5)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	10.3 (-43.0 to 140.6)	-41.6 (-66.6 to 9.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	16.8 (-41.3 to 158.9)	-38.4 (-65.8 to 17.3)
Cystic echinococcosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-47.7 (-18.4 to 32.2)	-47.7 (-58.4 to -40.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.5 (-23.1 to 46.7)	47.5 (-60.3 to -33.5)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-30.4 (-69.1 to 27.0)	-69.9 (-86.3 to -44.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.7 (-67.1 to 16.3)	-71.2 (-85.4 to -49.6)
Dengue	0.1 (0.0 to 0.1)	0.5 (0.2 to 1.0)	769.2 (762.7 to 776.7)	388.3 (384.7 to 392.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	770.9 (607.4 to 981.6)	388.1 (314.0 to 483.3)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.7 (-24.5 to 129.9)	-33.3 (-59.7 to 18.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.7 (-24.6 to 130.2)	33.3 (-59.7 to 18.6)
Intestinal nematode infections	-	-	-	-	0.6 (0.4 to 1.1)	1.1 (0.6 to 2.0)	75.2 (14.5 to 167.7)	-0.8 (-42.0 to 67.0)
Ascariasis	10.6 (6.7 to 17.7)	16.0 (10.7 to 23.0)	54.5 (-19.1 to 175.9)	-9.0 (-53.0 to 79.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-98.0 (-99.6 to -89.7)	-98.5 (-99.7 to -91.3)
Trichuriasis	69.1 (51.4 to 91.1)	121.7 (87.1 to 172.3)	77.7 (12.9 to 172.7)	-1.4 (-42.4 to 66.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	75.8 (-31.6 to 412.4)	1.3 (-68.8 to 245.8)
Hookworm disease	100.4 (78.5 to 128.6)	180.0 (140.8 to 223.6)	79.8 (30.5 to 155.6)	0.6 (-33.2 to 49.5)	1.0 (0.3 to 0.9)	1.0 (0.6 to 1.8)	85.4 (17.1 to 196.3)	2.9 (-42.3 to 77.9)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	3.4 (2.5 to 4.4)	4.7 (4.1 to 5.3)	35.8 (5.1 to 85.9)	-17.1 (-35.5 to 13.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	34.3 (11.3 to 109.7)	-16.1 (-31.0 to 34.1)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.2 (3.6 to 64.5)	-32.8 (-48.5 to -18.2)
Maternal hemorrhage	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	62.4 (17.8 to 306.2)	-18.5 (-40.4 to 4.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.4 (-3.2 to 92.3)	-25.7 (-51.4 to -2.8)
Maternal sepsis and other maternal infections	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	11.9 (-4.5 to 57.8)	-48.3 (-55.6 to -27.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.5 (-39.7 to 88.8)	-50.5 (-69.5 to -14.0)
Maternal hypertensive disorders	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	38.4 (26.6 to 61.5)	-32.3 (-36.4 to -20.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.6 (12.0 to 74.7)	-32.2 (-45.0 to -15.6)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.9 (-59.6 to 93.9)	-53.5 (-77.9 to -6.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.7 (-63.1 to 164.2)	-53.6 (-79.8 to 29.9)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.3 (-26.4 to 105.8)	-37.3 (-62.4 to -1.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.3 (-26.5 to 106.1)	-37.3 (-62.5 to -1.0)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.7 (-11.4 to 117.6)	-33.0 (-56.2 to 7.0)
Neonatal disorders	-	-	-	-	0.6 (0.3 to 1.0)	1.3 (0.8 to 2.0)	115.1 (21.0 to 328.3)	29.4 (-26.4 to 155.7)
Preterm birth complications	1.5 (0.8 to 2.8)	5.8 (3.0 to 10.6)	275.3 (170.0 to 435.2)	115.8 (60.1 to 200.8)	0.2 (0.1 to 0.3)	0.6 (0.4 to 1.0)	251.8 (121.3 to 561.0)	110.3 (32.6 to 279.5)
Neonatal encephalopathy due to birth asphyxia and trauma	1.1 (0.4 to 2.5)	1.5 (0.7 to 3.3)	37.9 (-2.2 to 103.9)	-23.4 (-46.1 to 13.7)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	68.4 (2.7 to 179.5)	0.5 (-37.5 to 68.4)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	168.7 (159.3 to 177.8)	93.4 (86.6 to 100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	169.9 (132.0 to 218.4)	94.3 (67.0 to 129.2)
Hemolytic disease and other neonatal jaundice	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.7)	67.4 (-33.5 to 703.9)	-2.8 (-61.0 to 359.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	37.6 (-32.8 to 509.8)	-3.3 (-60.2 to 264.7)
Other neonatal disorders	-	-	-	-	0.3 (0.1 to 0.8)	0.4 (0.1 to 0.8)	46.7 (-40.0 to 457.6)	-11.8 (-63.6 to 228.2)
Nutritional deficiencies	-	-	-	-	2.0 (1.3 to 2.9)	2.5 (1.7 to 3.7)	28.0 (28.5 to 34.9)	-23.8 (-28.0 to -20.4)
Protein-energy malnutrition	1.6 (1.2 to 2.1)	1.3 (0.9 to 1.9)	-18.1 (-47.8 to 37.2)	4.4 (-62.6 to -10.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	18.1 (-48.0 to 37.2)	49.3 (-63.0 to -9.4)
Iodine deficiency	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.2)	19.8 (-5.1 to 49.1)	-38.5 (-52.2 to -22.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.4 (-7.8 to 51.7)	-37.5 (-53.4 to -21.3)
Vitamin A deficiency	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-8.3 (-27.2 to 11.0)	-46.3 (-56.4 to -35.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.5 (-33.9 to 4.7)	-50.7 (-60.0 to -40.4)

Appendix Table G.4 - Solomon Islands prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
Iron-deficiency anemia	50.4 (49.5 to 51.4)	70.3 (69.3 to 71.3)	39.5 (35.7 to 42.9)	-0.1 (-22.5 to -17.9)	1.8 (1.2 to 2.5)	2.3 (1.6 to 3.4)	33.7 (28.1 to 38.0)	33.7 (-25.4 to -19.4)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.9 (55.5 to 126.6)	30.0 (68.9 to 47.4)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	44.8 (28.1 to 65.2)	-22.8 (-32.6 to -12.6)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	92.5 (63.0 to 125.3)	-2.8 (-15.6 to 11.5)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.8 (8.7 to 41.9)	39.3 (45.5 to -41.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	21.8 (-11.2 to 77.5)	-39.3 (-54.2 to -16.7)
Chlamydial infection	8.7 (7.0 to 10.8)	15.9 (12.1 to 19.3)	82.9 (29.6 to 146.0)	-5.4 (30.8 to 25.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	87.3 (47.5 to 136.0)	-2.9 (-22.2 to 19.8)
Gonococcal infection	1.9 (1.4 to 2.8)	3.4 (2.3 to 4.9)	82.0 (0.3 to 195.2)	-5.3 (-44.6 to 49.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.9 (27.9 to 185.6)	2.6 (-30.9 to 45.4)
Trichomoniasis	2.6 (1.5 to 3.8)	6.9 (4.4 to 9.0)	158.1 (64.4 to 411.6)	19.5 (-21.1 to 124.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	166.4 (61.6 to 541.8)	21.6 (-23.5 to 174.6)
Genital herpes	38.0 (36.9 to 38.9)	76.0 (74.1 to 77.9)	100.0 (92.6 to 107.4)	-2.5 (-5.9 to 0.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.7 (82.4 to 110.0)	-2.7 (-7.8 to 2.6)
Other sexually transmitted diseases	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	48.8 (32.6 to 74.8)	-31.3 (-38.7 to -19.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.6 (12.7 to 108.5)	-26.2 (-45.0 to -3.3)
Hepatitis	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-10.1 (-29.8 to 12.2)	-56.0 (-67.4 to -42.8)
Hepatitis A	0.5 (0.5 to 0.6)	0.9 (0.8 to 0.9)	59.8 (58.6 to 61.0)	-1.7 (-1.8 to -1.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.1 (53.7 to 94.6)	0.7 (-10.1 to 12.2)
Hepatitis B	125.5 (104.2 to 146.0)	73.8 (62.3 to 86.3)	-41.3 (-54.0 to -25.2)	-48.5 (-74.3 to -40.9)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-34.2 (-54.2 to -11.0)	-66.4 (-78.0 to -53.7)
Hepatitis C	3.0 (2.7 to 3.3)	4.2 (3.8 to 4.7)	42.1 (20.1 to 65.0)	-27.6 (-36.8 to -17.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.2 (16.5 to 83.2)	21.5 (-47.6 to 8.8)
Hepatitis E	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	113.3 (73.3 to 160.8)	10.4 (-9.8 to 36.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	116.9 (65.4 to 185.7)	10.8 (-14.7 to 45.0)
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	184.9 (13.2 to 896.9)	47.1 (-35.9 to 469.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	212.4 (9.7 to 2514.1)	57.5 (-38.4 to 1328.8)
Other infectious diseases	2.4 (1.9 to 3.0)	3.2 (2.8 to 3.6)	35.5 (10.9 to 63.5)	-18.5 (-33.7 to -1.3)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	50.1 (28.6 to 91.0)	-4.0 (-25.6 to 26.9)
Non-communicable diseases	-	-	-	-	16.9 (12.5 to 22.1)	35.5 (24.8 to 43.6)	97.4 (91.0 to 104.6)	0.9 (-2.2 to 4.2)
Neoplasms	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	225.2 (112.5 to 430.4)	53.2 (4.7 to 134.5)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	180.7 (35.9 to 502.4)	38.6 (-33.0 to 182.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	185.5 (37.9 to 468.7)	41.7 (-31.1 to 176.2)
Stomach cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	154.2 (68.5 to 306.4)	26.8 (-13.6 to 95.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	153.4 (66.0 to 311.5)	25.3 (-14.8 to 94.5)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	394.2 (166.6 to 858.3)	157.9 (42.3 to 390.6)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	489.4 (173.1 to 1,267.5)	208.6 (47.4 to 613.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	478.0 (198.2 to 1,087.7)	201.6 (57.8 to 501.6)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	977.9 (345.6 to 2,540.8)	450.3 (125.9 to 1,260.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	945.3 (385.0 to 2,348.3)	434.3 (148.4 to 1,135.7)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.6 (7.2 to 379.7)	11.1 (-53.4 to 140.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.4 (-3.5 to 343.7)	7.9 (-51.2 to 124.0)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	190.0 (11.2 to 712.0)	47.4 (-43.2 to 322.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	177.6 (20.2 to 616.6)	41.1 (-38.3 to 269.1)
Larynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	144.3 (26.8 to 405.4)	29.3 (-37.7 to 174.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	156.1 (31.7 to 403.6)	32.8 (-36.8 to 173.8)
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	114.7 (39.7 to 257.0)	4.9 (-29.0 to 62.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	116.0 (40.3 to 250.7)	5.6 (-28.5 to 61.4)
Breast cancer	0.4 (0.2 to 0.6)	2.1 (1.5 to 3.3)	469.9 (254.5 to 858.0)	199.5 (92.9 to 375.4)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	371.8 (192.4 to 713.9)	135.4 (51.7 to 291.2)
Cervical cancer	0.3 (0.2 to 0.5)	0.6 (0.3 to 1.1)	94.5 (10.8 to 257.3)	-9.3 (-46.3 to 62.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-10.2 (12.1 to 37.3)	-10.2 (-45.7 to 60.8)
Uterine cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	144.2 (29.0 to 374.2)	20.1 (-35.3 to 126.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	142.4 (25.5 to 371.7)	19.2 (-36.3 to 124.1)
Prostate cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.3)	292.1 (132.6 to 573.6)	89.4 (14.0 to 213.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	272.0 (121.3 to 557.9)	77.5 (8.4 to 200.9)
Colon and rectum cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	303.7 (169.2 to 541.8)	90.9 (33.3 to 189.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	282.8 (154.9 to 491.1)	80.1 (24.1 to 167.6)
Lip and oral cavity cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	97.4 (17.3 to 239.7)	-4.2 (-42.2 to 62.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.1 (20.3 to 239.6)	-4.8 (-40.8 to 51.9)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.3 (17.2 to 303.4)	3.2 (-41.8 to 86.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.7 (16.3 to 277.0)	0.3 (-42.4 to 75.9)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.0 (-10.5 to 213.7)	-18.3 (54.1 to 49.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.3 (-5.0 to 193.0)	-19.4 (-52.2 to 40.8)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.8 (10.1 to 280.6)	-2.9 (-46.9 to 75.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.7 (10.7 to 255.4)	-6.6 (-46.5 to 62.3)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	218.1 (99.3 to 452.7)	53.5 (0.7 to 143.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	221.9 (114.7 to 405.8)	55.6 (8.1 to 130.9)
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	356.6 (104.5 to 564.8)	69.6 (5.1 to 190.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	221.3 (97.8 to 521.5)	54.5 (-4.0 to 161.1)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	203.7 (111.9 to 370.8)	38.4 (-1.1 to 105.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	222.6 (92.6 to 453.0)	49.0 (-12.1 to 147.0)
Ovarian cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	172.0 (36.2 to 452.1)	29.0 (-34.7 to 149.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	169.3 (37.7 to 432.6)	28.4 (-33.0 to 140.2)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	162.0 (20.3 to 457.0)	23.1 (-37.1 to 142.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	159.2 (17.6 to 448.2)	18.0 (-35.7 to 127.0)
Kidney cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	142.6 (41.2 to 346.0)	16.1 (-31.0 to 106.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	138.4 (38.3 to 334.3)	11.8 (-32.1 to 102.3)
Bladder cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.3 (-84.3 to -17.1)	-87.5 (-94.3 to -57.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-72.6 (-87.9 to -19.7)	-89.1 (-95.2 to -58.1)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	168.2 (51.2 to 392.4)	39.7 (-12.6 to 137.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	166.2 (60.6 to 364.5)	32.8 (-17.8 to 124.4)
Thyroid cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	166.8 (48.9 to 390.6)	29.2 (-27.9 to 128.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	160.6 (38.5 to 398.9)	24.9 (-31.4 to 124.7)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	141.7 (47.9 to 317.7)	19.7 (-19.9 to 117.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	144.1 (51.3 to 314.1)	29.5 (-18.4 to 113.2)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	238.0 (78.9 to 572.5)	74.1 (-2.2 to 225.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	214.4 (76.8 to 515.1)	55.9 (-6.0 to 181.0)
Non-Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	363.7 (85.3 to 831.5)	135.8 (-7.2 to 357.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	355.4 (80.8 to 798.7)	128.9 (-8.4 to 342.2)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	225.4 (68.9 to 596.0)	54.0 (-20.4 to 231.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	217.6 (64.5 to 568.0)	49.5 (-22.6 to 218.8)
Leukemia	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	402.1 (153.4 to 827.2)	169.8 (59.9 to 342.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	378.8 (175.1 to 697.5)	135.2 (49.4 to 276.1)
Other neoplasms	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	477.7 (147.1 to 1,032.3)	214.4 (34.5 to 472.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	453.8 (137.8 to 988.6)	182.9 (20.7 to 403.9)
Cardiovascular diseases	-	-	-	-	0.9 (0.6 to 1.2)	2.3 (1.6 to 3.2)	165.4 (125.7 to 206.3)	28.5 (12.2 to 45.7)
Rheumatic heart disease	12.1 (10.2 to 14.1)	31.4 (27.8 to 34.7)	162.0 (112.7 to 212.7)	31.5 (9.5 to 55.4)	0.6 (0.4 to 0.9)	1.5 (1.0 to 2.2)	160.5 (111.7 to 210.3)	30.4 (9.1 to 53.6)
Ischemic heart disease	1.0 (0.8 to 1.3)	2.2 (1.8 to 2.6)	115.1 (65.0 to 195.6)	0.1 (-24.3 to 36.9)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	124.5 (76.3 to 191.0)	4.6 (-19.1 to 37.0)
Cerebrovascular disease	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	102.3 (62.9 to 142.7)	5.4 (-23.6 to 16.7)
Ischemic stroke	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.4)	104.4 (62.8 to 146.0)	-4.9 (-24.9 to 18.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	104.1 (60.2 to 150.2)	-4.7 (-25.6 to 19.1)
Hemorrhagic stroke	0.2 (0.2 to 0.2)	0.4 (0.4 to 0.5)	100.6 (65.4 to 146.9)	-5.2 (-22.5 to 18.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	100.2 (62.7 to 147.0)	-5.5 (-24.7 to 18.1)
Hypertensive heart disease	0.2 (0.2 to 0.2)	0.5 (0.4 to 0.5)	144.5 (100.6 to 203.6)	15.7 (-7.3 to 45.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	143.9 (98.0 to 204.5)	15.8 (-6.9 to 46.3)
Cardiomyopathy and myocarditis	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.4)	152.2 (115.0 to 199.4)	29.5 (6.6 to 57.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	153.8 (110.7 to 209.8)	30.2 (5.6 to 58.5)
Atrial fibrillation and flutter	0.1 (0.1 to 0.1)	0.5 (0.4 to 0.6)	466.7 (231.6 to 875.9)	143.4 (28.1 to 357.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	469.3 (235.8 to 872.3)	145.8 (30.0 to 356.0)
Peripheral vascular disease	2.4 (1.8 to 3.2)	5.9 (4.5 to 7.6)	140.3 (65.7 to 272.9)	9.6 (-24.0 to 55.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.6 (-21.0 to 174.1)	-32.9 (-63.4 to 29.5)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.3 (47.8 to 148.3)	7.6 (-17.7 to 40.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.5 (52.8 to 164.1)	11.9 (-18.4 to 56.3)
Other cardiovascular and circulatory diseases	0.5 (1.0 to 2.0)	5.1 (2.6 to 7.4)	249.7 (74.6 to 505.8)	65.7 (-17.7 to 206.3)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	246.6 (75.7 to 504.0)	67.9 (-17.8 to 208.8)
Chronic respiratory diseases	-	-	-	-	0.9 (0.6 to 1.2)	1.7 (1.1 to 2.3)	91.7 (66.6 to 123.4)	-6.7 (-19.4 to 8.0)
Chronic obstructive pulmonary disease	6.2 (5.9 to 6							

Appendix Table G.4 - Solomon Islands prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	236.2	53.7
Silicosis	0.0	0.0	76.9	-19.2	0.0	0.0	(213.5 to 256.5)	(41.2 to 65.9)
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	66.8 to 84.8	(-23.7 to -15.1)
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	300.5	97.3	0.0	0.0	300.8	92.0
Asthma	3.5	7.4	(293.2 to 328.4)	(89.0 to 105.3)	0.2	0.3	109.9	-1.2
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	109.9	1.3	0.0	0.0	111.0	1.3
Other chronic respiratory diseases	-	-	-	-	0.2	0.2	24.9	-38.7
Cirrhosis	-	-	-	-	0.0	0.0	(-13.5 to 73.2)	(-57.6 to -15.4)
Cirrhosis due to hepatitis B	0.1	0.1	40.5	-24.2	0.0	0.0	39.9	-24.7
Cirrhosis due to hepatitis C	0.0	0.0	48.5	-15.1	0.0	0.0	50.4	-14.4
Cirrhosis due to alcohol use	0.0	0.0	-59.2	-18.9	0.0	0.0	(-15.5 to 178.4)	(53.0 to 61.4)
Cirrhosis due to other causes	0.0	0.0	10.0	-30.3	0.0	0.0	(-52.9 to 30.4)	(-75.6 to -35.6)
Digestive diseases	-	-	-	-	0.3	0.4	57.2	-20.3
Peptic ulcer disease	2.3	3.2	35.3	-33.3	0.1	0.1	(39.9 to 76.3)	(-28.9 to -12.5)
Gastritis and duodenitis	2.1	2.9	41.4	-25.2	0.1	0.1	42.0	-21.3
Appendicitis	0.0	0.0	31.7	-31.0	0.0	0.0	30.6	-30.5
Paralytic ileus and intestinal obstruction	0.0	0.0	78.7	-3.7	0.0	0.0	(-16.3 to 125.4)	(53.3 to 13.6)
Inguinal, femoral, and abdominal hernia	1.0	1.7	75.8	-12.6	0.0	0.0	75.5	-12.5
Inflammatory bowel disease	0.0	0.1	85.0	-8.4	0.0	0.0	(42.0 to 122.9)	(-31.9 to 8.4)
Vascular intestinal disorders	0.0	0.0	142.7	71.2	0.0	0.0	(52.0 to 120.2)	(-23.2 to 8.0)
Gallbladder and biliary diseases	0.1	0.2	91.3	-9.1	0.0	0.0	91.8	-8.9
Pancreatitis	0.0	0.1	112.7	4.3	0.0	0.0	112.5	4.1
Other digestive diseases	-	-	-	-	0.1	0.1	92.7	-2.4
Neurological disorders	-	-	-	-	1.3	2.6	102.2	0.9
Alzheimer disease and other dementias	0.6	1.3	126.4	3.9	0.2	0.2	(64.8 to 147.0)	(-15.0 to 17.4)
Parkinson disease	0.1	0.2	113.2	-0.6	0.0	0.0	113.2	-0.5
Epilepsy	0.9	1.6	78.8	0.4	0.3	0.5	89.3	6.6
Multiple sclerosis	0.0	0.0	273.2	80.5	0.0	0.0	273.2	80.5
Migraine	18.7	35.7	90.2	0.2	0.6	1.2	(23.7 to 315.7)	(63.7 to 99.6)
Tension-type headache	35.9	69.2	93.9	-1.0	0.1	0.1	(32.3 to 109.8)	(-29.7 to 34.5)
Medication overuse headache	0.9	2.6	204.6	52.0	0.1	0.4	203.6	51.5
Other neurological disorders	0.0	0.0	83.8	3.4	0.1	0.1	(159.1 to 273.3)	(30.3 to 83.7)
Mental and substance use disorders	-	-	-	-	4.5	8.7	93.1	0.7
Schizophrenia	0.7	1.5	106.5	-0.3	0.5	1.0	(87.9 to 98.3)	(-1.7 to 3.0)
Alcohol use disorders	1.8	4.6	153.4	29.7	0.2	0.5	154.7	30.3
Drug use disorders	-	-	-	-	0.5	0.9	76.4	-6.6
Opioid use disorders	0.3	0.5	116.0	1.5	0.1	0.2	(50.6 to 109.5)	(-19.1 to 8.3)
Cocaine use disorders	0.2	0.4	91.3	-7.9	0.1	0.2	(87.9 to 150.6)	(-11.5 to 17.0)
Amphetamine use disorders	1.0	1.7	58.9	-12.5	0.1	0.2	58.3	-12.7
Cannabis use disorders	1.1	2.0	81.6	-0.3	0.0	0.1	81.2	-0.4
Other drug use disorders	-	-	-	-	0.2	0.3	63.4	-10.8
Depressive disorders	-	-	-	-	1.3	2.6	98.3	0.8
Major depressive disorder	5.0	9.8	97.0	1.1	2.0	4.0	(87.6 to 109.1)	(-3.7 to 5.9)
Dysthymia	2.8	5.8	105.4	0.7	0.3	0.6	105.2	0.7
Bipolar disorder	1.3	2.7	101.1	0.1	0.3	0.6	101.6	0.2
Anxiety disorders	7.1	13.4	89.5	0.6	1.3	2.6	(85.6 to 119.8)	(-6.8 to 7.9)
Eating disorders	-	-	-	-	0.0	0.1	74.8	-4.7
Anorexia nervosa	0.1	0.1	64.8	-9.6	0.0	0.0	64.6	-9.6
Bulimia nervosa	0.1	0.1	88.3	1.4	0.0	0.0	(31.0 to 105.8)	(-27.7 to 12.0)
Autistic spectrum disorders	-	-	-	-	0.4	0.7	77.8	-6.7
Autism	1.0	1.7	78.1	-0.8	0.2	0.4	(70.5 to 84.7)	(-4.0 to 2.6)
Asperger syndrome	1.4	2.5	77.2	-1.0	0.1	0.3	77.0	-0.8
Attention-deficit/hyperactivity disorder	2.6	4.2	64.2	-0.1	0.0	0.1	(69.1 to 85.4)	(-4.5 to 3.1)
Conduct disorder	2.6	4.3	62.7	0.3	0.0	0.5	(52.7 to 77.3)	(-7.2 to 7.9)
Idiopathic intellectual disability	1.2	1.8	50.6	-10.6	0.1	0.1	(54.2 to 71.5)	(-5.2 to 5.5)
Other mental and substance use disorders	3.7	7.5	103.4	-0.8	0.3	0.6	103.2	-0.8
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	1.7	3.6	111.8	10.8
Diabetes mellitus	10.3	25.4	149.6	23.5	0.6	1.6	(93.5 to 130.0)	(-0.6 to 22.2)
Acute glomerulonephritis	0.0	0.0	92.1	9.1	0.0	0.0	151.6	23.2
Chronic kidney disease	0.0	0.0	(79.7 to 103.8)	(3.0 to 14.6)	0.0	0.0	(10.2 to 200.4)	(0.3 to 47.9)
Chronic kidney disease due to diabetes mellitus	0.9	2.7	188.8	50.6	0.2	0.4	96.6	3.1
Chronic kidney disease due to hypertension	2.0	1.6	-39.0	-52.2	0.1	0.1	(78.7 to 118.7)	(-4.2 to 12.7)
Chronic kidney disease due to glomerulonephritis	2.3	4.0	76.1	6.1	0.0	0.0	182.7	45.7
Chronic kidney disease due to other causes	4.9	10.6	113.2	7.3	0.1	0.2	(113.8 to 287.0)	(3.0 to 109.1)
Urinary diseases and male infertility	-	-	-	-	0.1	0.2	127.4	11.7
	-	-	-	-	0.1	0.2	102.8	-5.1
	-	-	-	-	0.1	0.1	(80.3 to 125.7)	(-16.6 to 6.7)

Appendix Table G.4 - Solomon Islands prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.0 (0.0 to 0.1)	0.1 (0.1 to 1.1)	135.2 (116.3 to 158.6)	27.1 (18.2 to 38.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	135.5 (83.7 to 197.4)	27.8 (4.4 to 54.5)
Urolithiasis	0.6 (0.4 to 0.7)	1.1 (0.7 to 1.4)	91.2 (59.9 to 141.7)	-7.6 (-20.6 to 11.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.6 (64.6 to 111.7)	-8.5 (-17.5 to 1.3)
Benign prostatic hyperplasia	1.6 (1.4 to 1.8)	3.2 (2.9 to 4.2)	102.6 (72.4 to 133.2)	-6.7 (-20.4 to 7.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	102.5 (70.9 to 133.7)	-6.5 (-20.7 to 7.8)
Male infertility due to other causes	2.1 (1.7 to 2.5)	4.2 (3.4 to 5.1)	103.7 (55.6 to 166.6)	-2.7 (-25.1 to 27.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	102.0 (50.8 to 169.2)	-2.7 (-26.9 to 29.0)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	144.4 (60.5 to 196.2)	0.0 (-20.6 to 44.2)
Gynecological diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.8)	101.2 (73.1 to 127.2)	-4.6 (-16.9 to 7.4)
Uterine fibroids	4.6 (4.2 to 5.0)	9.8 (8.9 to 10.8)	114.0 (113.0 to 115.0)	-0.0 (-0.2 to 0.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	92.6 (79.0 to 103.9)	-9.9 (-16.2 to -4.7)
Polycystic ovarian syndrome	3.6 (3.1 to 4.0)	7.3 (6.5 to 8.1)	106.1 (69.2 to 143.5)	-2.1 (-18.7 to 14.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	106.3 (69.4 to 144.5)	-2.1 (-19.1 to 14.9)
Female infertility due to other causes	2.2 (1.7 to 2.8)	4.9 (3.8 to 6.1)	116.4 (61.7 to 201.2)	1.2 (-26.3 to 42.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	115.7 (63.1 to 203.4)	1.6 (-24.5 to 42.9)
Endometriosis	0.4 (0.4 to 0.5)	0.9 (0.8 to 1.1)	109.7 (69.5 to 156.4)	-0.2 (-18.6 to 22.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	109.1 (68.4 to 163.9)	-0.4 (-19.5 to 25.0)
Genital prolapse	10.4 (9.0 to 11.7)	21.1 (17.4 to 24.8)	103.3 (63.9 to 149.7)	-2.0 (-18.6 to 15.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	103.1 (63.8 to 152.0)	-1.9 (-19.0 to 16.7)
Premenstrual syndrome	7.1 (4.7 to 9.5)	14.9 (10.3 to 21.1)	116.4 (20.5 to 235.1)	0.2 (-43.9 to 59.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	116.6 (20.5 to 230.8)	1.6 (-43.6 to 58.8)
Other gynecological diseases	0.7 (0.5 to 0.9)	1.1 (0.9 to 1.4)	59.6 (14.3 to 122.4)	-18.8 (-41.6 to 15.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.0 (11.0 to 103.0)	-20.5 (-48.9 to 46.6)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.3 (0.2 to 0.5)	0.5 (0.4 to 0.9)	78.6 (62.0 to 102.9)	6.2 (-5.2 to 22.7)
Thalassemias	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	59.4 (42.0 to 96.3)	0.4 (-10.5 to 24.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.4 (-16.5 to 128.7)	-12.7 (-44.4 to 32.9)
Thalassemia trait	12.6 (8.3 to 18.4)	22.9 (16.2 to 32.7)	79.2 (68.2 to 101.0)	0.3 (-5.8 to 14.9)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.8)	93.4 (70.8 to 114.4)	14.5 (-1.2 to 29.9)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.4 (-36.9 to -5.1)	-52.6 (-60.8 to -41.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.7 (-34.1 to 17.5)	-48.5 (-60.8 to -28.3)
Sickle cell trait	0.4 (0.4 to 0.4)	0.4 (0.4 to 0.5)	6.9 (-6.8 to 25.9)	6.9 (-47.9 to 29.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.9 (-38.4 to 80.1)	42.2 (-62.7 to -10.3)
G6PD deficiency	51.8 (46.2 to 57.2)	84.8 (76.1 to 93.4)	64.0 (40.5 to 91.0)	-8.3 (-21.4 to 6.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.8 (-32.3 to 184.4)	-17.3 (-59.5 to 66.6)
G6PD trait	72.6 (71.6 to 73.5)	131.7 (129.4 to 134.0)	81.3 (77.6 to 85.3)	2.3 (0.2 to 4.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.1 (91.6 to 3,215.5)	-4.3 (-93.5 to 1,477.4)
Other hemoglobinopathies and hemolytic anemias	1.8 (1.3 to 2.2)	2.4 (1.9 to 2.7)	32.1 (1.1 to 76.8)	-25.1 (-42.2 to -2.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	27.8 (-12.5 to 103.2)	-25.0 (-49.2 to 23.8)
Endocrine, metabolic, blood, and immune disorders	3.2 (2.4 to 3.6)	5.9 (4.3 to 7.2)	55.1 (29.4 to 106.5)	5.3 (-20.9 to 11.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	54.5 (17.0 to 128.9)	4.3 (-25.4 to 22.1)
Musculoskeletal disorders	-	-	-	-	3.0 (2.1 to 4.2)	4.6 (4.3 to 8.5)	104.8 (85.8 to 129.4)	0.3 (-7.7 to 10.2)
Rheumatoid arthritis	0.2 (0.2 to 0.2)	0.8 (0.7 to 0.8)	251.2 (233.2 to 273.1)	75.2 (65.7 to 86.4)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	251.1 (215.1 to 291.7)	75.1 (62.0 to 91.6)
Osteoarthritis	3.2 (3.1 to 3.3)	6.9 (6.6 to 7.2)	115.1 (103.5 to 128.1)	2.2 (-3.0 to 7.9)	0.2 (0.1 to 0.3)	0.2 (0.3 to 0.6)	114.7 (102.8 to 128.6)	2.0 (-3.3 to 8.2)
Low back and neck pain	-	-	-	-	2.3 (1.6 to 3.2)	4.6 (3.2 to 6.4)	100.3 (77.0 to 131.4)	-0.9 (-11.8 to 12.4)
Low back pain	12.7 (11.9 to 13.6)	25.5 (23.8 to 27.1)	99.9 (82.8 to 117.7)	-0.9 (-7.7 to 6.2)	1.4 (1.0 to 2.0)	2.9 (1.9 to 4.0)	98.7 (82.3 to 118.1)	-1.0 (-8.2 to 6.4)
Neck pain	8.7 (6.6 to 10.4)	17.6 (13.1 to 23.1)	101.6 (48.2 to 187.6)	-1.2 (-25.7 to 35.9)	0.9 (0.5 to 1.3)	1.7 (1.1 to 2.6)	100.8 (48.2 to 190.0)	-1.3 (-26.0 to 35.2)
Gout	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.4)	121.0 (100.5 to 146.0)	3.2 (-6.7 to 14.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (79.3 to 170.2)	3.7 (-15.2 to 24.5)
Other musculoskeletal disorders	5.1 (4.0 to 6.3)	10.7 (8.4 to 13.2)	106.6 (92.6 to 127.9)	-2.7 (-9.3 to 5.6)	0.5 (0.3 to 0.7)	1.0 (0.6 to 1.4)	106.8 (90.7 to 128.6)	-2.6 (-9.9 to 6.1)
Other non-communicable diseases	-	-	-	-	4.3 (2.9 to 5.6)	7.7 (5.3 to 10.9)	77.7 (68.4 to 87.6)	-6.8 (-10.0 to -3.3)
Congenital anomalies	-	-	-	-	0.4 (0.3 to 0.7)	0.8 (0.5 to 1.2)	87.2 (24.9 to 168.3)	13.4 (-23.3 to 58.3)
Neural tube defects	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	117.8 (77.0 to 160.9)	34.0 (9.2 to 59.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	125.1 (55.9 to 217.0)	39.0 (-2.4 to 92.5)
Congenital heart anomalies	0.8 (0.6 to 0.9)	2.1 (1.8 to 2.6)	177.8 (111.2 to 266.5)	69.0 (28.1 to 125.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.0)	181.4 (115.7 to 274.4)	72.0 (32.3 to 129.8)
Orofacial clefts	0.2 (0.1 to 0.2)	0.4 (0.4 to 0.5)	156.4 (105.7 to 226.0)	63.5 (29.6 to 108.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	118.8 (54.5 to 223.1)	39.0 (0.6 to 100.9)
Down syndrome	0.3 (0.2 to 0.3)	0.5 (0.4 to 0.6)	109.8 (58.0 to 180.1)	27.3 (-4.2 to 70.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	115.2 (61.2 to 190.4)	32.7 (-0.4 to 80.1)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.3 (33.6 to 182.2)	10.8 (-22.6 to 63.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.1 (30.0 to 194.5)	10.7 (-26.4 to 67.2)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.1 (41.8 to 158.6)	7.6 (-20.0 to 45.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.8 (38.1 to 202.2)	6.9 (-27.5 to 59.5)
Chromosomal unbalanced rearrangements	0.4 (0.3 to 0.4)	0.7 (0.6 to 0.9)	101.1 (58.1 to 174.2)	21.6 (-4.6 to 65.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	107.4 (58.1 to 188.3)	27.3 (-3.3 to 75.2)
Other congenital anomalies	1.2 (1.0 to 1.3)	1.8 (1.5 to 2.0)	52.6 (37.5 to 68.0)	-13.8 (-21.4 to -6.0)	0.2 (0.2 to 0.6)	0.5 (0.3 to 0.8)	70.8 (-1.3 to 184.3)	2.3 (-40.0 to 66.4)
Skin and subcutaneous diseases	-	-	-	-	1.8 (1.1 to 2.7)	3.3 (2.1 to 5.0)	82.9 (70.3 to 95.7)	1.1 (-6.1 to 6.8)
Dermatitis	16.9 (13.7 to 20.7)	31.3 (25.3 to 38.1)	84.5 (81.2 to 87.8)	0.1 (0.0 to 0.2)	0.6 (0.4 to 0.9)	1.1 (0.7 to 1.7)	79.3 (71.4 to 86.3)	0.2 (-2.4 to 2.6)
Psoriasis	1.7 (1.5 to 2.0)	3.4 (2.9 to 3.9)	94.2 (92.1 to 96.0)	0.1 (-0.2 to 0.1)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	91.1 (80.3 to 108.4)	-0.2 (-5.5 to 6.2)
Cellulitis	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	43.5 (25.5 to 64.1)	-15.2 (-23.3 to -5.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.0 (30.0 to 94.3)	-15.0 (-31.9 to 3.2)
Pyoderma	0.5 (0.4 to 0.7)	0.4 (0.3 to 0.5)	-27.2 (-38.3 to -12.2)	-51.8 (-59.0 to -42.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.2 (-39.4 to -11.0)	-51.9 (-59.7 to -42.1)
Scabies	4.2 (3.9 to 4.5)	6.0 (5.5 to 6.4)	43.0 (29.8 to 59.3)	-19.2 (-26.5 to -10.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	42.8 (25.0 to 60.0)	-19.2 (-26.6 to -10.4)
Fungal skin diseases	30.8 (25.3 to 36.2)	57.5 (47.9 to 67.1)	87.6 (83.2 to 91.1)	0.3 (-0.3 to 0.1)	0.3 (0.1 to 0.4)	0.3 (0.1 to 0.7)	86.9 (82.9 to 91.4)	-0.2 (-0.9 to 0.5)
Viral skin diseases	7.5 (5.8 to 9.0)	12.6 (9.7 to 15.4)	68.9 (62.5 to 75.3)	0.2 (-1.8 to 2.2)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.6)	68.8 (60.7 to 77.0)	3.2 (-3.1 to 7.2)
Acne vulgaris	23.4 (16.8 to 30.2)	44.4 (30.4 to 59.7)	92.2 (21.8 to 189.6)	8.9 (-29.2 to 61.9)	0.3 (0.1 to 0.5)	0.5 (0.2 to 0.9)	92.3 (21.8 to 190.4)	8.8 (-29.2 to 62.5)
Alopecia areata	0.3 (0.3 to 0.4)	0.6 (0.5 to 0.7)	86.5 (47.3 to 136.1)	-1.1 (-20.2 to 24.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.9 (41.1 to 138.0)	-0.8 (-21.5 to 26.2)
Pruritus	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	90.6 (54.1 to 140.7)	-3.1 (-22.5 to 38.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.5 (38.8 to 157.0)	-2.8 (-27.7 to 32.2)
Urticaria	2.2 (1.4 to 2.9)	4.9 (3.5 to 6.2)	122.5 (36.3 to 283.8)	8.9 (30.5 to 79.7)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	121.7 (35.3 to 287.3)	9.5 (-31.1 to 81.7)
Decubitus ulcer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	84.2 (56.0 to 116.6)	0.8 (-13.5 to 20.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.5 (44.9 to 127.2)	0.2 (-19.2 to 26.8)
Other skin and subcutaneous diseases	15.9 (11.2 to 22.2)	31.3 (21.9 to 44.3)	96.1 (86.1 to 106.4)	-0.4 (-3.7 to 2.9)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	96.0 (85.1 to 106.8)	-0.3 (-3.9 to 3.1)
Sense organ diseases	-	-	-	-	1.8 (1.2 to 2.5)	3.0 (2.0 to 4.3)	70.6 (62.6 to 79.1)	-11.9 (-14.5 to -8.8)
Glaucoma	0.3 (0.2 to 0.3)	0.5 (0.4 to 0.6)	82.3 (46.2 to 134.2)	-10.6 (-26.7 to 20.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	88.5 (31.6 to 139.3)	-17.7 (-38.4 to 25.7)
Cataract	1.0 (0.7 to 1.2)	1.6 (1.2 to 2.1)	63.4 (24.8 to 101.1)	-22.8 (-39.2 to -5.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	60.4 (24.4 to 90.3)	-23.6 (-40.0 to -10.2)
Macular degeneration	0.6 (0.4 to 0.9)	1.1 (0.8 to 1.5)	85.3 (52.8 to 138.8)	-5.5 (-23.0 to 18.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	81.2 (51.5 to 128.8)	-8.2 (-23.1 to 12.7)
Uncorrected refractive error	17.1 (15.7 to 18.5)	30.9 (28.3 to 33.7)	80.9 (63.0 to 100.1)	-6.5 (-14.0 to 0.4)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	66.9 (55.5 to 81.6)	-14.0 (-18.6 to -7.9)
Age-related and other hearing loss	30.8 (28.5 to 33.1)	56.4 (52.3 to 61.0)	82.9 (75.1 to 89.8)	-9.1 (-12.3 to -6.5)	1.0 (0.7 to 1.4)	1.7 (1.2 to 2.5)	73.6 (62.2 to 86.1)	-9.8 (-13.7 to -5.7)
Other vision loss	1.4 (1.1 to 1.7)	2.1 (1.6 to 2.6)	47.3 (29.0 to 71.2)	-21.2 (-30.6 to -9.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	45.6 (27.0 to 65.3)	-23.2 (-32.0 to -14.0)
Other sense organ diseases	7.4 (7.1 to 7.8)	13.0 (12.4 to 13.7)	75.3 (63.7 to 88.5)	0.6 (-5.4 to 7.3)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	74.9 (61.8 to 90.8)	0.7 (-5.9 to 8.1)
Oral disorders	-	-	-	-	0.3 (0.2 to 0.5)	0.6 (0.3 to 0.9)	78.3 (70.6 to 86.6)	-14.0 (-18.3 to -9.5)
Deciduous caries	42.2 (41.5 to 42.8)	66.9 (65.7 to 68.1)	58.8 (54.3 to 62.9)	0.4 (-2.5 to 2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.7 (48.9 to 68.6)	0.3 (-5.4 to 6.6)
Permanent caries	94.3 (90.1 to 98.5)	176.2 (167.0 to 185.5)	86.9 (75.7 to 99.9)	0.5 (-5.3 to 6.7)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	86.6 (75.2 to 100.5)	0.4 (-5.5 to 6.8)
Periodontal diseases	2.0 (1.9 to 2.1)	4.2 (4.0 to 4.5)	111.5 (94.1 to 130.2)	0.6 (-7.2 to 8.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	111.2 (92.3 to 130.8)	0.7 (-7.9 to 9.0)

Appendix Table G.4 - Solomon Islands prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	2.6 (2.4 to 2.8)	3.7 (3.5 to 3.9)	41.7 (30.2 to 53.7)	-33.9 (-38.8 to -28.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	41.7 (29.6 to 54.6)	-33.9 (-39.0 to -28.3)
Other oral disorders	4.5 (4.2 to 4.7)	8.6 (8.1 to 9.1)	92.5 (76.8 to 107.9)	-0.2 (-7.5 to 7.4)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	92.3 (75.2 to 109.2)	-0.2 (-8.1 to 7.6)
Injuries	-	-	-	-	0.7 (0.5 to 0.9)	1.2 (0.9 to 1.5)	75.9 (59.7 to 88.1)	-9.4 (-16.4 to -3.8)
Transport injuries	-	-	-	-	0.3 (0.2 to 0.3)	0.5 (0.3 to 0.6)	86.8 (73.8 to 101.2)	-4.1 (-10.0 to 2.0)
Road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	82.4 (77.7 to 108.0)	-0.5 (-7.3 to 6.3)
Pedestrian road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	91.1 (73.4 to 111.0)	1.8 (-6.0 to 10.9)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.3 (67.2 to 103.4)	-2.7 (-12.7 to 6.8)
Motorcyclist road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	84.2 (66.6 to 102.7)	-6.1 (-13.8 to 2.4)
Motor vehicle road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	101.9 (83.2 to 120.5)	4.3 (-4.3 to 13.0)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.1 (74.3 to 107.7)	-4.3 (-11.0 to 3.4)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	61.7 (50.8 to 74.1)	-19.2 (-24.6 to -13.1)
Unintentional injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.7)	92.1 (83.1 to 101.6)	-1.5 (-5.6 to 3.0)
Falls	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	80.8 (68.4 to 93.7)	-7.8 (-13.2 to -1.6)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.0 (32.1 to 65.0)	-21.7 (-28.6 to -13.4)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.5 (12.7 to 37.1)	-33.2 (-38.3 to -27.4)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.8 (3.1 to 50.2)	-33.4 (-42.9 to -22.0)
Exposure to mechanical forces	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	116.1 (103.4 to 128.7)	10.8 (4.8 to 16.4)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.1 (28.3 to 50.0)	-29.4 (-34.6 to -24.2)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.6 (77.5 to 112.9)	1.4 (-6.3 to 10.6)
Other exposure to mechanical forces	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	122.6 (108.9 to 136.8)	14.2 (7.4 to 20.5)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.9 (94.5 to 117.8)	5.6 (-0.4 to 12.3)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.2 (65.5 to 92.2)	-9.1 (-14.6 to -3.4)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.1 (67.9 to 113.4)	-4.3 (-13.2 to 5.9)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.8 (59.0 to 83.1)	-13.2 (-18.3 to -7.4)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.7 (62.0 to 84.9)	-8.9 (-14.3 to -3.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.4 (23.0 to 64.3)	-15.9 (-25.4 to -6.9)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.4 (67.8 to 93.7)	-5.9 (-12.0 to 0.3)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.7 (72.9 to 104.3)	-7.4 (-14.2 to -0.2)
Other unintentional injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	126.6 (106.8 to 147.3)	16.4 (7.2 to 26.3)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	53.2 (42.4 to 66.1)	-22.7 (-27.9 to -16.7)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.9 (45.3 to 79.7)	-21.2 (-28.6 to -13.5)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.2 (38.5 to 63.2)	-23.3 (-28.5 to -17.0)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.6 (44.8 to 70.3)	-17.8 (-23.6 to -11.6)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.2 (46.7 to 77.2)	-19.5 (-26.0 to -10.9)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.5 (33.5 to 59.8)	-25.4 (-31.0 to -18.7)
Forces of nature, war, and legal intervention	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-12.6 (-28.4 to 25.3)	-51.7 (-58.2 to -38.2)
Exposure to forces of nature	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-12.6 (-28.4 to 25.3)	-51.7 (-58.2 to -38.2)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Somalia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	632.5 (460.7 to 832.5)	973.1 (712.6 to 1,276.6)	54.2 (46.7 to 59.1)	3.9 (-7.8 to 1.1)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	160.8 (107.7 to 235.5)	271.5 (182.9 to 392.3)	68.8 (58.0 to 80.9)	1.9 (-3.1 to 7.8)
HIV/AIDS and tuberculosis	-	-	-	-	6.9 (4.7 to 9.6)	14.5 (9.7 to 19.6)	110.1 (68.2 to 162.0)	30.7 (6.3 to 64.8)
Tuberculosis	21.2 (19.1 to 23.3)	32.4 (30.2 to 34.6)	53.6 (44.3 to 64.9)	-1.8 (-7.7 to 4.8)	6.4 (4.3 to 8.8)	9.9 (6.7 to 13.4)	54.6 (43.1 to 68.0)	-1.4 (-7.8 to 6.4)
HIV/AIDS	-	-	-	-	0.5 (0.0 to 0.6)	4.6 (2.6 to 7.4)	745.1 (445.5 to 1,192.6)	745.1 (54.5 to 1,217.9)
HIV/AIDS resulting in mycobacterial infection	0.1 (0.0 to 0.5)	0.9 (0.4 to 1.4)	881.4 (62.8 to 17,948.6)	560.1 (8.8 to 12,917.6)	0.0 (0.0 to 0.2)	0.3 (0.1 to 0.6)	857.3 (62.7 to 33,536.4)	541.5 (8.6 to 22,174.9)
HIV/AIDS resulting in other diseases	4.5 (0.2 to 14.0)	28.4 (19.7 to 39.0)	766.4 (65.8 to 13,243.4)	441.8 (4.5 to 8,495.9)	0.4 (0.0 to 1.5)	4.3 (2.4 to 7.1)	1,354.6 (130.0 to 28,056.6)	839.2 (39.2 to 19,165.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	28.9 (20.5 to 39.1)	38.1 (26.3 to 51.6)	31.5 (21.1 to 42.2)	-20.2 (-26.7 to -13.8)
Diarrheal diseases	69.7 (63.9 to 75.4)	108.8 (104.2 to 113.8)	56.5 (43.4 to 73.2)	0.8 (-7.0 to 9.4)	11.3 (7.6 to 15.8)	17.7 (12.0 to 24.2)	56.9 (41.9 to 75.0)	-46.5 (-8.0 to 9.8)
Intestinal infectious diseases	-	-	-	-	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	17.4 (-12.3 to 48.9)	-29.4 (-45.4 to -11.0)
Typhoid fever	2.1 (1.8 to 2.3)	2.7 (2.3 to 3.0)	28.4 (5.4 to 49.9)	-22.9 (-36.4 to -8.1)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	28.5 (-3.1 to 67.2)	-22.7 (-40.2 to -3.5)
Paratyphoid fever	0.8 (0.7 to 0.9)	1.2 (1.0 to 1.4)	54.7 (17.7 to 98.5)	-6.9 (-28.3 to 19.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	54.2 (12.9 to 114.6)	-6.9 (-30.1 to 23.1)
Other intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-33.4 (-62.4 to 24.3)	-59.8 (-77.2 to -25.2)
Lower respiratory infections	13.1 (9.1 to 16.6)	11.0 (7.5 to 14.0)	-16.9 (-50.6 to 45.2)	-43.5 (-58.5 to -24.9)	1.4 (0.8 to 2.1)	1.1 (0.6 to 1.7)	-16.4 (-51.6 to 46.5)	-43.9 (-59.7 to -23.1)
Upper respiratory infections	420.8 (376.5 to 464.1)	688.7 (620.1 to 751.0)	64.0 (48.9 to 83.3)	-0.4 (-10.5 to 10.3)	4.9 (2.7 to 8.2)	8.1 (4.5 to 13.7)	64.3 (48.9 to 83.3)	-0.2 (-10.1 to 10.3)
Otitis media	111.2 (101.6 to 121.2)	166.2 (153.3 to 180.8)	50.3 (35.9 to 64.6)	-11.7 (-20.1 to -4.1)	2.3 (1.4 to 3.6)	3.4 (2.0 to 5.5)	49.3 (32.5 to 67.9)	-12.1 (-21.9 to -2.0)
Meningitis	-	-	-	-	7.2 (4.8 to 10.1)	5.5 (3.8 to 7.5)	-24.2 (-38.7 to -8.0)	-52.2 (-60.5 to -42.8)
Pneumococcal meningitis	23.2 (14.9 to 34.8)	18.4 (11.7 to 25.2)	-19.4 (-37.3 to 1.6)	-47.5 (-59.2 to -34.6)	2.2 (1.4 to 3.0)	1.8 (1.2 to 2.8)	-15.2 (-39.3 to 19.3)	-46.5 (-59.9 to -25.3)
H influenzae type B meningitis	15.3 (7.5 to 26.6)	10.3 (5.0 to 17.5)	-33.0 (-49.1 to -7.1)	-58.2 (-67.8 to -42.1)	1.9 (1.1 to 2.9)	1.2 (0.8 to 1.8)	-34.7 (-60.1 to 1.6)	-60.1 (-75.3 to -38.3)
Meningococcal meningitis	3.9 (1.5 to 7.3)	2.9 (1.2 to 5.9)	-24.8 (-43.1 to 4.7)	-49.5 (-61.6 to -30.8)	0.5 (0.3 to 0.9)	0.4 (0.2 to 0.6)	-27.1 (-47.4 to 4.6)	-52.4 (-64.2 to -33.6)
Other meningitis	21.5 (11.4 to 35.8)	16.3 (8.9 to 25.9)	-23.9 (-34.6 to -8.2)	-50.9 (-58.2 to -40.5)	2.7 (1.6 to 3.9)	2.0 (1.3 to 2.8)	-23.7 (-38.9 to -2.0)	-51.6 (-61.4 to -39.4)
Encephalitis	1.1 (0.5 to 2.3)	1.9 (0.9 to 3.5)	54.0 (42.5 to 81.3)	1.3 (-10.3 to 10.2)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	61.4 (35.8 to 98.0)	-2.1 (-15.5 to 15.3)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-2.5 (-96.6 to 2,579.2)	-33.2 (-96.4 to 997.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.5 (-96.6 to 2,579.7)	-33.2 (-96.5 to 1,015.1)
Whooping cough	15.2 (11.6 to 19.7)	27.2 (20.8 to 35.4)	79.4 (77.5 to 81.4)	13.6 (12.4 to 14.9)	0.8 (0.4 to 1.2)	1.3 (0.8 to 2.2)	79.6 (69.4 to 90.8)	13.8 (7.1 to 21.0)
Tetanus	2.6 (0.7 to 8.1)	1.1 (0.6 to 2.1)	-46.5 (-87.3 to 92.7)	-67.5 (-92.6 to 24.8)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-26.6 (-71.4 to 39.9)	-51.9 (-83.5 to -7.2)
Measles	3.6 (2.6 to 4.8)	0.1 (0.1 to 0.2)	-96.9 (-97.9 to -95.4)	-98.0 (-98.7 to -97.1)	0.3 (0.2 to 0.5)	0.0 (0.0 to 0.0)	-96.8 (-97.9 to -95.0)	-96.0 (-98.7 to -96.9)
Varicella and herpes zoster	4.1 (3.7 to 4.5)	6.8 (6.2 to 7.5)	67.9 (48.4 to 90.1)	-1.2 (-18.1 to 24.3)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	49.0 (9.8 to 112.5)	-4.5 (-31.5 to 42.8)
Neglected tropical diseases and malaria	-	-	-	-	48.9 (27.7 to 85.5)	74.9 (42.0 to 132.0)	53.1 (40.5 to 63.6)	-9.3 (-17.0 to -3.8)
Malaria	529.7 (505.9 to 554.3)	627.2 (600.0 to 656.4)	18.9 (14.4 to 22.8)	-29.8 (-32.5 to -27.6)	6.2 (4.1 to 9.1)	6.8 (4.6 to 10.0)	10.8 (0.9 to 23.1)	-33.0 (-39.4 to -26.7)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	50.8 (8.0 to 102.1)	-8.2 (-30.5 to 17.1)
Visceral leishmaniasis	0.5 (0.3 to 0.7)	0.7 (0.4 to 1.0)	51.6 (6.6 to 111.2)	-7.5 (-30.1 to 22.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	52.0 (0.1 to 117.9)	-8.0 (-33.0 to 25.7)
Cutaneous and mucocutaneous leishmaniasis	1.1 (0.7 to 1.7)	1.6 (1.0 to 2.5)	44.9 (-3.2 to 135.3)	-10.4 (-40.3 to 39.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.7 (-8.8 to 147.4)	-9.8 (-42.2 to 43.3)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	2,965.1 (2,064.6 to 3,954.2)	4,675.6 (3,251.9 to 6,250.1)	58.1 (54.3 to 61.8)	-3.5 (-5.4 to -1.4)	28.5 (13.7 to 57.6)	44.8 (21.0 to 90.6)	57.2 (35.6 to 71.6)	-3.8 (-15.1 to 2.7)
Cysticercosis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	83.1 (-62.8 to 628.5)	2.2 (-70.6 to 253.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.5 (-62.1 to 633.6)	2.3 (-70.6 to 251.9)
Cystic echinococcosis	2.0 (1.7 to 2.3)	3.1 (2.8 to 3.5)	59.9 (22.9 to 89.9)	-6.4 (-25.2 to 11.7)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	55.3 (15.7 to 101.5)	-6.5 (-28.5 to 17.7)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	18.0 (8.5 to 31.4)	9.0 (4.1 to 17.4)	-50.3 (-74.9 to -3.6)	-68.4 (-82.2 to -37.5)	1.1 (0.5 to 2.0)	0.7 (0.3 to 1.3)	-41.9 (-66.0 to 5.3)	-63.0 (-77.4 to -30.6)
Dengue	0.2 (0.0 to 0.6)	1.5 (0.4 to 4.4)	705.6 (695.9 to 717.0)	384.0 (378.2 to 390.8)	0.0 (0.0 to 0.1)	0.3 (0.1 to 0.8)	660.7 (495.3 to 873.8)	351.5 (266.1 to 458.1)
Yellow fever	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-56.4 (-79.9 to -37.2)	-73.8 (-79.7 to -45.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.4 (-67.9 to -37.1)	-73.8 (-79.7 to -45.0)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Intestinal nematode infections	-	-	-	-	8.5 (5.1 to 13.2)	13.6 (8.1 to 20.9)	60.0 (40.6 to 80.9)	-2.4 (-16.0 to 11.8)
Ascariasis	415.2 (313.1 to 550.2)	677.5 (510.6 to 885.2)	63.5 (7.7 to 150.5)	-1.8 (-40.9 to 65.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	68.2 (21.7 to 131.1)	1.2 (-32.3 to 44.2)
Trichuriasis	1,529.8 (1,188.0 to 1,929.8)	2,518.6 (1,964.0 to 3,248.0)	65.8 (16.7 to 137.9)	0.7 (-36.6 to 54.5)	1.6 (0.9 to 2.7)	2.7 (1.4 to 4.5)	68.1 (38.9 to 104.0)	0.2 (-20.7 to 26.1)
Hookworm disease	1,318.0 (1,048.2 to 1,654.4)	2,157.9 (1,723.1 to 2,653.2)	64.0 (19.0 to 123.3)	64.0 (-31.0 to 47.0)	10.8 (4.1 to 10.5)	10.8 (6.5 to 16.6)	58.1 (37.2 to 83.4)	-2.0 (-18.1 to 14.4)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	97.1 (75.6 to 120.2)	189.1 (174.2 to 210.8)	95.0 (57.2 to 152.2)	22.9 (-0.6 to 56.9)	4.4 (2.6 to 6.8)	8.5 (5.4 to 12.7)	90.6 (60.2 to 157.4)	10.5 (-10.8 to 45.4)
Maternal disorders	-	-	-	-	2.4 (1.6 to 3.5)	3.1 (2.1 to 4.4)	29.0 (9.1 to 50.9)	-20.9 (-32.0 to -7.3)
Maternal hemorrhage	2.0 (1.7 to 2.3)	2.3 (1.7 to 2.9)	18.5 (-13.4 to 57.2)	-38.8 (-46.7 to -7.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	29.6 (-25.2 to 107.8)	-24.0 (-55.3 to 19.9)
Maternal sepsis and other maternal infections	3.7 (2.8 to 4.8)	3.8 (2.8 to 4.9)	2.0 (-13.2 to 22.7)	-34.8 (-45.7 to -38.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	4.2 (-28.5 to 54.2)	-35.8 (-54.5 to -9.2)
Maternal hypertensive disorders	3.1 (1.5 to 5.1)	4.2 (2.2 to 6.9)	37.7 (18.5 to 53.5)	-17.6 (-28.6 to -7.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	38.2 (14.1 to 64.1)	-17.4 (-31.5 to -1.7)
Obstructed labor	4.8 (3.8 to 5.8)	6.0 (4.9 to 7.3)	25.9 (14.3 to 39.1)	-21.8 (-28.9 to -13.0)	1.6 (1.0 to 2.3)	2.0 (1.3 to 2.9)	26.0 (9.0 to 45.3)	-21.6 (-31.5 to -9.7)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other maternal disorders	-	-	-	-	15.9 (10.0 to 21.9)	15.9 (10.0 to 21.9)	41.5 (-23.5 to 139.7)	-15.0 (-51.6 to 35.9)
Neonatal disorders	-	-	-	-	0.6 (0.3 to 0.9)	0.8 (0.5 to 1.2)	35.8 (-10.8 to 101.2)	-17.1 (-45.4 to 24.2)
Preterm birth complications	20.7 (9.3 to 41.8)	70.1 (35.0 to 131.4)	242.1 (186.1 to 354.6)	104.0 (71.0 to 157.3)	1.2 (0.6 to 1.9)	5.5 (3.0 to 9.1)	228.3 (111.9 to 448.5)	106.8 (24.4 to 255.8)
Neonatal encephalopathy due to birth asphyxia and trauma	44.5 (3.5 to 152.4)	53.8 (6.6 to 171.1)	29.7 (-1.3 to 125.8)	-22.8 (-42.0 to 30.6)	1.4 (0.5 to 3.4)	2.6 (1.1 to 5.3)	91.8 (17.4 to 329.5)	14.8 (-28.6 to 208.3)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	107.0 (87.2 to 132.8)	35.3 (22.4 to 52.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	109.0 (78.7 to 142.8)	0.0 (-16.8 to 58.7)
Hemolytic disease and other neonatal jaundice	1.3 (0.5 to 2.6)	4.7 (1.4 to 11.0)	269.7 (7.4 to 1,260.5)	153.7 (-24.5 to 875.9)	0.5 (0.2 to 1.0)	1.8 (0.5 to 4.4)	265.0 (8.3 to 1,265.4)	150.1 (-25.6 to 865.6)
Other neonatal disorders	-	-	-	-	1.0 (0.3 to 2.4)	3.2 (1.3 to 6.9)	231.0 (48.7 to 740.7)	105.8 (-11.8 to 432.3)
Nutritional deficiencies	-	-	-	-	64.3 (42.0 to 93.1)	118.9 (79.6 to 169.7)	85.4 (59.1 to 114.7)	15.2 (0.7 to 32.0)
Protein-energy malnutrition	87.0 (42.4 to 150.9)	125.1 (59.9 to 218.0)	44.8 (-40.9 to 244.6)	-6.7 (-57.8 to 103.2)	6.7 (4.6 to 20.2)	15.5 (6.5 to 31.1)	44.7 (-41.4 to 251.9)	6.9 (-58.6 to 107.6)
Iodine deficiency	294.4 (157.3 to 477.2)	307.0 (161.1 to 514.8)	3.8 (-52.4 to 156.1)	-35.5 (-76.2 to 69.7)	5.3 (2.3 to 10.2)	5.6 (2.3 to 10.4)	3.7 (-52.4 to 151.2)	-35.5 (-75.7 to 69.5)
Vitamin A deficiency	13.9 (8.5 to 23.9)	15.4 (8.5 to 27.6)	10.3 (-20.2 to 56.7)	-34.0 (-50.9 to -13.8)	0.7 (0.4 to 1.2)	0.8 (0.4 to 1.4)	7.9 (-19.6 to 33.7)	-34.4 (-49.6 to -20.0)

Appendix Table G.4 - Somalia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	1,327.3 (1,300.8 to 1,351.5)	2,650.3 (2,563.8 to 2,749.3)	100.5 (92.3 to 108.6)	29.5 (23.1 to 36.2)	47.5 (31.9 to 68.5)	104.5 (65.4 to 139.7)	104.5 (95.7 to 116.1)	28.6 (23.7 to 38.6)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	-	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	5.3 (3.3 to 8.2)	8.9 (5.7 to 13.5)	68.2 (47.4 to 93.3)	-3.6 (-15.4 to 9.9)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.7 (1.0 to 2.9)	2.8 (1.5 to 4.9)	60.6 (23.3 to 108.8)	-0.3 (-20.9 to 23.9)
Syphilis	0.8 (0.7 to 0.9)	0.8 (0.7 to 0.9)	-6.8 (-24.0 to 14.2)	-37.9 (-47.7 to -26.3)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	55.5 (-28.8 to 22.2)	2.3 (-50.7 to -21.6)
Chlamydial infection	114.3 (64.3 to 163.6)	205.6 (128.0 to 269.1)	73.1 (23.7 to 226.5)	7.0 (-21.2 to 92.4)	0.6 (0.3 to 1.2)	1.2 (0.5 to 2.4)	94.5 (51.1 to 244.6)	20.6 (-34.1 to 101.3)
Gonococcal infection	52.3 (34.0 to 72.7)	73.5 (48.2 to 104.5)	38.8 (-16.4 to 146.5)	-15.0 (-48.1 to 45.4)	0.3 (0.1 to 0.5)	0.4 (0.2 to 0.7)	39.0 (-14.3 to 135.2)	-15.2 (-45.8 to 34.3)
Trichomoniasis	106.3 (71.4 to 161.4)	173.4 (99.8 to 283.6)	66.7 (-21.4 to 227.6)	4.8 (-43.7 to 79.2)	0.2 (0.0 to 0.4)	0.3 (0.1 to 0.7)	60.7 (-24.1 to 272.1)	1.2 (-46.3 to 97.7)
Genital herpes	1,439.8 (1,231.8 to 1,627.0)	2,253.3 (1,893.8 to 2,608.5)	55.2 (17.1 to 92.5)	1.8 (-13.9 to 20.2)	0.4 (0.1 to 1.0)	0.6 (0.2 to 1.5)	38.4 (25.9 to 97.9)	5.1 (-15.5 to 24.3)
Other sexually transmitted diseases	2.5 (1.6 to 3.5)	3.3 (2.5 to 4.4)	32.8 (8.0 to 68.4)	-14.5 (-30.2 to 9.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	36.8 (5.8 to 102.6)	-13.6 (-39.0 to 22.9)
Hepatitis	-	-	-	-	0.8 (0.5 to 1.2)	0.7 (0.5 to 1.1)	-3.9 (-21.2 to 22.1)	-45.8 (-57.0 to -28.5)
Hepatitis A	12.0 (11.3 to 12.7)	20.4 (19.2 to 21.6)	71.2 (71.0 to 71.2)	0.7 (0.6 to 0.8)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	73.2 (51.3 to 95.7)	-0.8 (-12.1 to 10.7)
Hepatitis B	1,147.1 (677.8 to 1,413.4)	728.9 (611.4 to 848.2)	-36.8 (-50.9 to -9.6)	-40.7 (-68.9 to -47.9)	0.5 (0.3 to 0.9)	0.3 (0.2 to 0.5)	-37.5 (-54.4 to -8.7)	-9.1 (-69.9 to -38.7)
Hepatitis C	101.8 (90.5 to 114.3)	116.6 (100.0 to 132.5)	15.2 (-3.2 to 36.0)	-26.3 (-36.8 to -14.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.4 (-13.2 to 39.8)	-33.2 (-51.3 to -10.1)
Hepatitis E	1.5 (1.1 to 1.8)	2.0 (1.4 to 2.6)	36.2 (-4.6 to 106.4)	-17.8 (-41.6 to 20.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	34.6 (-15.2 to 113.9)	-17.8 (-45.9 to 28.0)
Leprosy	0.2 (0.1 to 0.3)	0.5 (0.5 to 0.6)	207.6 (134.2 to 315.9)	106.7 (63.0 to 170.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	214.9 (122.3 to 374.0)	112.8 (54.2 to 202.3)
Other infectious diseases	66.8 (51.1 to 81.8)	131.3 (113.1 to 144.1)	97.1 (73.3 to 133.8)	26.0 (11.5 to 48.1)	2.8 (1.7 to 4.4)	5.4 (3.5 to 8.1)	91.7 (54.9 to 137.7)	14.8 (-14.0 to 43.7)
Non-communicable diseases	-	-	-	-	-	-	-	-
Neoplasms	-	-	-	-	1.8 (0.0 to 3.5)	2.9 (469.9 to 838.7)	59.4 (51.8 to 62.8)	9.9 (-4.6 to 2.4)
Esophageal cancer	0.6 (0.3 to 1.0)	0.8 (0.4 to 1.3)	34.5 (-27.2 to 134.6)	-8.8 (-49.5 to 54.1)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	37.9 (-20.9 to 140.9)	-6.6 (-46.0 to 57.5)
Stomach cancer	0.4 (0.2 to 0.6)	0.6 (0.3 to 0.9)	48.8 (-10.0 to 146.6)	3.1 (-36.5 to 65.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	51.4 (-9.1 to 155.2)	4.6 (-36.7 to 70.9)
Liver cancer	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	36.5 (-22.3 to 136.2)	5.9 (-47.4 to 61.1)
Liver cancer due to hepatitis B	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	30.9 (-54.9 to 222.4)	-10.6 (-68.8 to 148.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.4 (-53.2 to 210.8)	-12.7 (-68.4 to 130.0)
Liver cancer due to hepatitis C	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	243.8 (42.5 to 836.0)	122.6 (7.4 to 470.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	229.5 (45.3 to 751.7)	114.5 (-4.3 to 424.3)
Liver cancer due to alcohol use	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-25.2 (-67.4 to 91.2)	-47.6 (-76.8 to 31.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.7 (-65.4 to 74.8)	-46.7 (-75.3 to 18.1)
Liver cancer due to other causes	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-7.9 (-56.4 to 92.4)	-38.2 (-71.3 to 37.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.8 (-53.8 to 72.6)	-40.6 (-69.7 to 20.8)
Larynx cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	28.9 (-25.1 to 117.8)	-11.8 (-48.0 to 50.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.0 (-23.8 to 128.0)	-9.8 (-46.8 to 57.8)
Tracheal, bronchus and lung cancer	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	43.5 (-16.1 to 138.4)	-0.5 (-40.3 to 59.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	48.5 (-16.0 to 153.0)	3.0 (-40.3 to 72.9)
Breast cancer	2.9 (1.6 to 5.1)	5.3 (3.0 to 8.8)	78.8 (7.0 to 210.8)	19.4 (-28.1 to 106.3)	0.3 (0.1 to 0.5)	0.5 (0.2 to 0.8)	67.4 (-0.6 to 197.1)	13.2 (-32.1 to 96.2)
Cervical cancer	4.1 (2.0 to 6.9)	5.0 (2.6 to 8.5)	21.8 (-31.3 to 133.4)	-5.9 (-53.5 to 60.9)	0.3 (0.2 to 0.6)	0.4 (0.2 to 0.8)	54.3 (-29.8 to 137.3)	-14.4 (-51.6 to 61.6)
Uterine cancer	0.6 (0.3 to 1.0)	0.7 (0.3 to 1.3)	19.8 (-40.9 to 149.6)	-17.7 (-58.9 to 66.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	22.3 (-9.6 to 159.7)	-16.1 (-67.5 to 75.6)
Prostate cancer	1.4 (0.7 to 2.6)	4.4 (2.2 to 7.6)	208.9 (71.5 to 489.3)	107.7 (18.7 to 281.9)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	175.8 (58.9 to 402.9)	87.8 (9.6 to 236.2)
Colon and rectum cancer	1.0 (0.6 to 1.6)	1.6 (1.0 to 2.6)	57.2 (-2.9 to 161.5)	6.2 (-33.5 to 70.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	57.1 (-4.7 to 160.9)	6.5 (-34.3 to 73.4)
Lip and oral cavity cancer	0.6 (0.3 to 1.0)	0.8 (0.4 to 1.4)	44.6 (-18.0 to 153.7)	-1.0 (-45.7 to 69.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	47.4 (-16.7 to 159.2)	0.9 (-42.7 to 71.2)
Nasopharynx cancer	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	5.6 (-44.3 to 112.4)	-30.8 (-63.7 to 39.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.1 (-43.5 to 106.2)	-30.7 (-62.5 to 38.1)
Other pharynx cancer	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	21.3 (-40.5 to 154.5)	-16.6 (-59.9 to 71.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.3 (-35.4 to 139.0)	-12.8 (-54.5 to 62.1)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	61.0 (-7.5 to 184.2)	8.0 (-38.7 to 89.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.0 (-5.3 to 172.1)	5.8 (-37.1 to 76.6)
Pancreatic cancer	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	37.5 (-19.2 to 136.9)	-7.9 (-45.7 to 54.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.9 (-16.0 to 129.3)	-6.1 (-43.4 to 51.2)
Malignant skin melanoma	0.4 (0.2 to 0.7)	0.7 (0.4 to 1.2)	78.1 (7.9 to 204.6)	16.5 (-30.6 to 95.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	75.6 (5.2 to 204.7)	14.1 (-32.6 to 93.6)
Non-melanoma skin cancer	0.4 (0.3 to 0.5)	0.7 (0.5 to 0.9)	73.5 (22.0 to 131.5)	17.2 (-18.1 to 60.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.0 (16.2 to 213.4)	28.6 (-27.0 to 120.7)
Ovarian cancer	0.3 (0.1 to 0.5)	0.3 (0.2 to 0.5)	4.7 (-40.3 to 86.3)	-28.3 (-59.0 to 25.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	5.3 (-42.4 to 87.4)	-28.0 (-62.2 to 27.9)
Testicular cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	75.7 (-7.2 to 242.8)	12.0 (-38.9 to 116.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.4 (-13.1 to 251.3)	10.0 (-42.3 to 113.1)
Kidney cancer	0.3 (0.3 to 0.9)	0.4 (0.3 to 0.9)	16.1 (-45.0 to 131.0)	6.6 (-41.5 to 47.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	24.7 (-38.9 to 131.1)	-0.4 (-35.8 to 56.8)
Bladder cancer	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	33.7 (-22.9 to 120.0)	-7.4 (-44.8 to 46.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	36.3 (-20.9 to 122.9)	-5.0 (-44.9 to 50.6)
Brain and nervous system cancer	0.2 (0.2 to 0.4)	0.5 (0.3 to 0.7)	104.5 (37.6 to 206.4)	23.7 (-15.4 to 90.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	96.4 (32.1 to 197.8)	18.4 (-20.1 to 89.9)
Thyroid cancer	0.3 (0.1 to 0.6)	0.4 (0.2 to 0.7)	26.1 (-39.3 to 144.1)	-16.3 (-59.9 to 65.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.6 (-39.4 to 143.4)	-16.6 (-59.6 to 62.3)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.2 (-19.5 to 151.7)	2.2 (-42.7 to 67.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.7 (-17.8 to 158.7)	0.0 (-41.4 to 72.1)
Hodgkin lymphoma	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.1)	94.8 (22.6 to 223.5)	33.3 (-20.1 to 134.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	88.2 (17.8 to 201.9)	26.1 (-24.3 to 122.6)
Non-Hodgkin lymphoma	1.1 (0.7 to 1.6)	1.3 (0.9 to 2.0)	19.6 (-26.4 to 86.3)	-15.6 (-46.3 to 33.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	22.8 (-20.5 to 89.7)	-12.1 (-43.4 to 41.9)
Multiple myeloma	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	54.8 (-17.2 to 196.7)	4.9 (-43.4 to 95.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	53.8 (-20.2 to 196.6)	4.9 (-47.3 to 104.7)
Leukemia	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	61.2 (-5.9 to 158.1)	2.2 (-33.0 to 53.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	55.1 (3.8 to 132.3)	0.7 (-35.0 to 55.5)
Other neoplasms	2.6 (1.6 to 4.7)	5.3 (3.4 to 8.2)	109.7 (17.6 to 229.0)	23.5 (-17.2 to 83.8)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.6)	101.9 (23.5 to 202.1)	18.5 (-22.3 to 74.4)
Cardiovascular diseases	-	-	-	-	11.2 (7.6 to 15.6)	16.2 (11.1 to 22.6)	44.7 (16.1 to 79.2)	-5.8 (-24.3 to 15.6)
Rheumatic heart disease	69.7 (54.5 to 84.1)	106.7 (85.4 to 124.8)	51.6 (15.8 to 112.9)	-5.5 (-26.5 to 27.4)	3.5 (2.1 to 5.3)	5.2 (3.1 to 7.8)	47.4 (13.2 to 105.2)	-10.8 (-30.0 to 19.8)
Ischemic heart disease	61.2 (49.0 to 79.2)	65.2 (53.4 to 80.8)	6.3 (-20.3 to 50.2)	-26.7 (-43.2 to 3.1)	3.2 (1.9 to 4.8)	3.2 (2.0 to 4.8)	3.8 (-31.9 to 57.1)	-31.1 (-51.2 to 10.5)
Cerebrovascular disease	-	-	-	-	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.8)	58.7 (26.7 to 105.6)	4.7 (-16.3 to 34.7)
Ischemic stroke	1.7 (1.4 to 2.0)	2.6 (2.2 to 3.1)	57.1 (26.0 to 99.0)	4.6 (-15.2 to 31.6)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	57.8 (24.9 to 101.1)	4.9 (-17.1 to 34.8)
Hemorrhagic stroke	0.5 (0.4 to 0.6)	0.8 (0.6 to 1.0)	62.4 (19.1 to 123.0)	4.0 (-21.3 to 44.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	62.3 (20.1 to 123.3)	3.6 (-22.0 to 44.2)
Hypertensive heart disease	8.6 (6.6 to 10.9)	14.9 (10.7 to 19.3)	73.2 (20.4 to 147.2)	15.9 (-19.2 to 67.6)	0.9 (0.9 to 1.3)	1.6 (1.0 to 2.4)	73.0 (18.1 to 149.7)	15.9 (-19.9 to 70.9)
Cardiomyopathy and myocarditis	6.3 (5.1 to 7.8)	10.7 (7.8 to 13.9)	69.3 (22.2 to 139.9)	10.8 (-26.6 to 69.3)	1.2 (0.4 to 1.0)	1.2 (0.7 to 1.7)	71.4 (20.1 to 142.9)	11.3 (-27.4 to 70.4)
Atrial fibrillation and flutter	2.7 (2.1 to 3.6)	6.9 (5.0 to 9.2)	153.8 (74.2 to 269.2)	81.0 (13.3 to 175.8)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.8)	151.8 (72.7 to 271.0)	80.6 (13.6 to 176.5)
Peripheral vascular disease	92.9 (62.9 to 127.3)	120.8 (77.8 to 179.6)	34.2 (-30.3 to 147.4)	-8.2 (-46.7 to 53.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	44.9 (-31.7 to 266.7)	-0.8 (-50.7 to 166.6)
Endocarditis	0.2 (0.2 to 0.4)	0.3 (0.2 to 0.5)	43.8 (-12.2 to 130.8)	2.4 (-47.5 to 85.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	48.2 (-19.6 to 153.5)	5.1 (-52.6 to 101.6)
Other cardiovascular and circulatory diseases	32.8 (16.8 to 55.2)	54.2 (27.4 to 81.0)	68.9 (-24.3 to 259.6)	2.3 (-54.6 to 148.7)	2.3 (1.0 to 4.4)	3.8 (1.7 to 6.2)	69.3 (-24.5 to 261.5)	4.5 (-54.5 to 154.7)
Chronic respiratory diseases	-	-	-	-	32.3 (20.9 to 47.5)	40.6 (26.9 to 57.3)	26.4 (5.0 to 54.9)	-16.3 (-33.0 to 2.5)
Chronic obstructive pulmonary disease	210.1 (199.7 to 219.4)	318.8 (304.3 to 332.7)	52.3 (46.9 to 56.9)	-				

Appendix Table G.4 - Somalia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	45.3	-4.9
Silicosis	0.0	0.0	36.2	-9.7	0.0	0.0	(40.7 to 50.3)	(-7.9 to -1.8)
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	36.1	-9.7
Coal workers pneumoconiosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Other pneumoconiosis	0.0	0.0	0.0	0.0	0.0	0.0	53.7	0.0
Asthma	109.9	126.9	18.7	-16.5	4.8	5.5	18.5	-16.9
Interstitial lung disease and pulmonary sarcoidosis	0.1	0.2	75.4	6.8	0.0	0.0	74.2	6.6
Other chronic respiratory diseases	-	-	-	-	10.1	8.5	-17.2	-45.5
Cirrhosis	-	-	-	-	0.7	0.7	50.0	-10.8
Cirrhosis due to hepatitis B	1.0	1.1	9.7	-20.3	0.2	0.2	(18.2 to 52.5)	(-19.8 to -1.4)
Cirrhosis due to hepatitis C	0.4	0.6	58.5	4.1	0.1	0.1	59.0	4.6
Cirrhosis due to alcohol use	0.7	0.8	11.1	-24.5	0.1	0.1	(-19.3 to 227.2)	(-39.5 to 95.0)
Cirrhosis due to other causes	0.9	1.5	72.3	22.4	0.1	0.3	(-28.9 to 52.3)	(-49.8 to 2.7)
Digestive diseases	-	-	-	-	7.9	13.2	65.5	12.8
Peptic ulcer disease	43.3	56.0	29.4	-10.2	1.4	2.1	49.9	4.9
Gastritis and duodenitis	76.8	118.1	54.3	2.4	3.4	5.2	55.2	6.7
Appendicitis	0.8	1.3	61.2	-1.1	0.2	0.4	61.0	-0.9
Paralytic ileus and intestinal obstruction	0.1	0.1	49.4	-4.1	0.0	0.0	49.6	-3.0
Inguinal, femoral, and abdominal hernia	21.6	57.2	168.2	0.2	0.6	0.6	166.0	161.2
Inflammatory bowel disease	5.9	11.4	94.7	25.4	1.2	2.4	95.5	25.7
Vascular intestinal disorders	0.0	0.0	33.1	-20.0	0.0	0.0	35.6	-14.9
Gallbladder and biliary diseases	2.0	3.4	71.9	0.2	0.4	0.4	72.9	14.7
Pancreatitis	1.0	1.7	65.1	4.2	0.3	0.5	66.9	4.8
Other digestive diseases	-	-	-	-	0.9	1.4	59.9	9.5
Neurological disorders	-	-	-	-	23.2	41.9	83.4	11.4
Alzheimer disease and other dementias	9.7	14.7	52.8	0.3	1.3	2.0	54.8	1.3
Parkinson disease	0.5	0.8	48.3	-0.5	0.1	0.1	48.9	0.0
Epilepsy	12.0	20.8	74.8	3.3	3.3	5.8	75.3	3.8
Multiple sclerosis	0.4	0.6	76.1	14.7	0.1	0.2	76.8	14.4
Migraine	386.0	588.4	72.1	5.2	14.4	19.5	52.4	1.4
Tension-type headache	726.9	1,277.3	76.7	5.4	6.1	1.9	77.4	5.8
Medication overuse headache	28.4	68.4	140.3	52.4	4.4	10.8	143.4	52.9
Other neurological disorders	0.0	0.0	50.8	-8.6	1.4	1.9	46.5	-4.3
Mental and substance use disorders	-	-	-	-	142.1	230.3	62.1	0.1
Schizophrenia	13.3	20.4	54.8	0.5	8.4	13.1	55.7	1.0
Alcohol use disorders	61.5	87.3	42.4	-10.4	6.0	8.6	42.6	-10.3
Drug use disorders	-	-	-	-	7.6	12.1	59.2	0.8
Opioid use disorders	10.0	15.2	53.3	-0.1	4.1	6.3	42.1	0.5
Cocaine use disorders	2.3	3.6	66.3	-14.8	0.6	0.7	65.4	-5.6
Amphetamine use disorders	9.6	15.7	63.8	-0.8	1.3	2.1	64.4	-0.4
Cannabis use disorders	7.8	13.1	67.5	0.1	0.2	0.4	68.5	0.5
Other drug use disorders	-	-	-	-	1.7	2.8	64.0	0.9
Depressive disorders	-	-	-	-	68.3	108.6	59.1	-0.9
Major depressive disorder	303.7	479.9	58.6	-1.3	62.3	99.3	59.4	-1.0
Dysthymia	62.3	96.7	55.8	-0.0	6.0	9.3	56.2	0.2
Bipolar disorder	34.3	54.1	57.9	0.1	6.9	11.0	59.0	0.6
Anxiety disorders	187.2	300.5	60.7	-0.1	37.2	27.6	61.1	0.1
Eating disorders	-	-	-	-	1.5	2.5	68.1	0.3
Anorexia nervosa	1.0	1.8	75.0	2.9	0.2	0.4	76.4	3.0
Bulimia nervosa	6.1	10.2	66.7	-0.3	1.3	2.2	67.1	-0.1
Autistic spectrum disorders	-	-	-	-	7.6	12.6	66.6	0.4
Autism	19.4	32.1	66.0	0.1	4.8	8.0	66.8	0.4
Asperger syndrome	27.9	46.2	65.9	0.2	2.8	4.6	66.5	0.4
Attention-deficit/hyperactivity disorder	44.7	79.7	78.7	0.2	1.0	1.0	78.8	0.2
Conduct disorder	64.8	117.0	81.6	0.2	7.8	7.8	81.3	0.3
Idiopathic intellectual disability	92.4	200.4	113.1	29.5	4.5	9.8	114.2	29.8
Other mental and substance use disorders	77.1	119.7	55.8	0.1	5.7	9.0	56.4	0.3
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	28.8	47.3	64.7	4.1
Diabetes mellitus	68.8	119.9	72.9	9.2	5.2	9.1	71.3	9.6
Acute glomerulonephritis	0.1	0.1	34.8	-1.4	0.0	0.0	34.8	-1.4
Chronic kidney disease	0.1	0.1	28.0	-17.2	0.0	0.0	(27.9 to 45.7)	(-17.2 to -8.8)
Chronic kidney disease due to diabetes mellitus	87.2	126.9	47.5	-6.2	1.3	2.0	47.8	-4.2
Chronic kidney disease due to hypertension	263.1	417.9	64.2	2.3	3.1	4.9	58.8	3.8
Chronic kidney disease due to glomerulonephritis	215.5	362.1	63.4	5.5	3.6	5.7	63.4	0.5
Chronic kidney disease due to other causes	169.9	278.1	62.2	-5.4	2.2	3.5	59.2	-5.3
Urinary diseases and male infertility	-	-	-	-	1.8	2.8	49.6	1.3

Appendix Table G.4 - Somalia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.2 (1.1 to 1.3)	2.1 (2.0 to 2.2)	72.9 (58.8 to 90.0)	0.0 (-0.5 to 16.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	73.6 (37.1 to 123.4)	7.7 (-11.1 to 31.4)
Urolithiasis	14.9 (11.1 to 19.3)	17.2 (12.6 to 22.3)	17.7 (-3.2 to 34.5)	-20.8 (-32.9 to -8.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	50.5 (30.2 to 73.0)	-2.8 (-14.4 to 8.9)
Benign prostatic hyperplasia	40.2 (36.8 to 43.8)	59.4 (54.0 to 64.6)	48.2 (31.2 to 68.5)	1.4 (-10.1 to 14.2)	1.4 (0.9 to 2.0)	2.2 (1.4 to 3.0)	49.4 (31.2 to 69.8)	2.2 (-9.7 to 15.1)
Male infertility due to other causes	34.8 (22.0 to 53.1)	53.4 (35.2 to 74.8)	52.8 (-2.9 to 166.5)	0.4 (-3.6 to 68.3)	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.7)	52.3 (-9.0 to 173.3)	-0.5 (-39.1 to 72.2)
Other urinary diseases	-	-	-	-	-	-	-	-
Gynecological diseases	-	-	-	-	-	-	-	-
Uterine fibroids	96.2 (87.1 to 104.8)	145.4 (131.5 to 158.3)	51.7 (51.4 to 52.0)	-0.3 (-0.3 to -0.3)	1.3 (0.8 to 2.2)	2.3 (1.3 to 3.7)	69.8 (54.5 to 90.6)	10.7 (0.2 to 24.4)
Polycystic ovarian syndrome	87.9 (79.2 to 96.2)	144.2 (128.1 to 161.4)	63.9 (41.5 to 90.5)	3.0 (-10.8 to 18.4)	0.8 (0.4 to 1.6)	1.4 (0.7 to 2.6)	65.1 (42.0 to 92.9)	3.2 (-10.8 to 19.4)
Female infertility due to other causes	42.9 (16.1 to 75.2)	49.8 (24.8 to 81.3)	20.0 (-54.1 to 241.6)	-21.0 (-72.3 to 125.2)	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.6)	19.9 (-52.1 to 234.9)	-21.9 (-71.4 to 117.8)
Endometriosis	9.1 (7.7 to 10.5)	12.9 (10.9 to 14.8)	43.3 (13.9 to 75.7)	-7.9 (-27.0 to 12.1)	0.8 (0.6 to 1.2)	1.2 (0.8 to 1.7)	42.7 (10.9 to 80.7)	8.0 (-28.1 to 15.3)
Genital prolapse	159.1 (135.3 to 182.4)	257.9 (216.2 to 299.9)	62.4 (29.4 to 99.7)	6.1 (-13.7 to 26.5)	0.5 (0.2 to 1.0)	0.8 (0.4 to 1.5)	63.0 (29.5 to 101.7)	6.1 (-13.3 to 27.4)
Premenstrual syndrome	218.8 (141.8 to 299.1)	304.8 (198.5 to 418.1)	39.5 (-13.3 to 139.1)	-9.0 (-45.3 to 50.9)	1.8 (1.0 to 3.1)	2.6 (1.3 to 4.2)	39.2 (-15.2 to 143.5)	-9.2 (-45.6 to 51.9)
Other gynecological diseases	13.8 (9.6 to 17.9)	27.6 (20.9 to 34.8)	98.9 (39.9 to 198.5)	23.2 (-13.2 to 81.1)	0.4 (0.2 to 0.6)	0.8 (0.4 to 1.2)	104.2 (19.8 to 338.1)	26.1 (-28.6 to 156.9)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	-	-	-	-
Thalassemias	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	67.1 (21.1 to 132.4)	-2.0 (-27.8 to 35.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.4 (18.9 to 134.2)	-4.0 (-28.6 to 35.9)
Thalassemia trait	35.7 (21.7 to 52.6)	58.9 (33.2 to 86.5)	64.5 (49.2 to 96.9)	-0.0 (-7.2 to 22.1)	0.7 (0.5 to 1.1)	1.1 (0.7 to 1.6)	48.4 (18.5 to 73.0)	-8.1 (-22.5 to 7.0)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.6 (59.4 to 89.4)	4.7 (-4.6 to 13.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.2 (51.4 to 90.9)	4.9 (-8.9 to 16.9)
Sickle cell trait	44.7 (40.3 to 50.1)	72.9 (67.4 to 79.3)	64.5 (50.7 to 77.2)	0.1 (-8.4 to 7.6)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.4)	43.7 (-19.0 to 172.1)	13.5 (-49.8 to 67.1)
G6PD deficiency	489.6 (341.2 to 636.9)	845.7 (499.3 to 1,208.6)	73.8 (-9.1 to 184.7)	5.8 (-44.5 to 73.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	76.5 (21.7 to 171.1)	16.1 (-17.6 to 61.7)
G6PD trait	1,383.4 (1,186.0 to 1,509.1)	2,291.4 (2,012.6 to 2,494.7)	65.5 (40.3 to 99.0)	0.7 (-14.6 to 21.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	67.2 (-68.3 to 629.6)	6.0 (-83.4 to 460.9)
Other hemoglobinopathies and hemolytic anemias	50.2 (40.9 to 57.4)	105.7 (93.4 to 117.6)	111.5 (81.8 to 161.6)	4.2 (-25.7 to 71.8)	1.7 (1.0 to 2.6)	3.5 (2.2 to 5.3)	106.4 (56.5 to 188.6)	33.9 (-3.0 to 82.7)
Endocrine, metabolic, blood, and immune disorders	74.4 (68.8 to 80.3)	139.2 (112.9 to 161.5)	87.7 (48.0 to 134.6)	18.3 (-0.7 to 39.9)	3.5 (-1.8 to 3.8)	5.1 (3.2 to 7.2)	88.5 (40.4 to 142.9)	33.8 (-11.3 to 37.4)
Musculoskeletal disorders	-	-	-	-	-	-	-	-
Rheumatoid arthritis	13.9 (13.3 to 14.4)	19.6 (18.9 to 20.4)	40.9 (33.8 to 49.7)	-11.5 (-16.1 to -6.2)	3.3 (2.3 to 4.3)	4.7 (3.3 to 6.2)	42.2 (31.5 to 55.2)	-11.0 (-17.1 to -4.0)
Osteoarthritis	119.4 (114.3 to 124.7)	180.2 (172.5 to 187.3)	51.6 (42.5 to 60.6)	1.6 (-4.2 to 7.1)	7.2 (5.1 to 9.8)	11.0 (7.7 to 15.0)	52.1 (42.8 to 61.4)	2.0 (-3.7 to 7.7)
Low back and neck pain	-	-	-	-	-	-	-	-
Low back pain	264.8 (242.4 to 288.5)	403.4 (369.5 to 436.7)	52.8 (37.2 to 71.7)	-1.1 (-10.6 to 9.5)	29.2 (19.7 to 40.0)	44.9 (30.2 to 61.9)	53.7 (37.8 to 73.9)	-0.6 (-10.0 to 10.6)
Neck pain	209.4 (165.2 to 255.8)	348.6 (293.3 to 410.8)	66.0 (28.1 to 130.9)	4.8 (-17.9 to 39.1)	20.4 (13.5 to 29.9)	34.3 (23.0 to 49.1)	67.3 (29.1 to 133.0)	5.2 (-17.6 to 40.6)
Gout	0.8 (0.7 to 0.9)	1.3 (1.1 to 1.4)	48.1 (28.1 to 80.8)	-2.2 (-15.2 to 19.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	49.9 (15.2 to 100.3)	0.0 (-24.2 to 31.5)
Other musculoskeletal disorders	81.6 (54.4 to 109.1)	165.4 (102.8 to 223.9)	103.6 (68.2 to 136.1)	35.9 (11.6 to 57.1)	7.3 (4.3 to 11.3)	15.0 (8.4 to 23.3)	104.1 (69.2 to 138.5)	36.2 (11.6 to 58.5)
Other non-communicable diseases	-	-	-	-	-	-	-	-
Congenital anomalies	-	-	-	-	-	-	-	-
Neural tube defects	0.4 (0.3 to 0.5)	1.4 (1.2 to 1.7)	278.9 (187.7 to 386.7)	150.8 (87.8 to 224.9)	0.1 (0.1 to 0.1)	0.4 (0.2 to 0.5)	329.3 (175.3 to 515.1)	194.0 (84.4 to 318.6)
Congenital heart anomalies	3.0 (2.0 to 4.4)	13.0 (9.4 to 17.5)	331.3 (165.5 to 611.4)	191.0 (72.4 to 410.8)	0.1 (0.1 to 0.2)	0.5 (0.2 to 0.8)	269.6 (133.1 to 528.5)	152.6 (59.0 to 334.1)
Orofacial clefts	0.3 (0.2 to 0.5)	1.5 (0.9 to 2.1)	351.7 (155.6 to 753.1)	0.0 (-75.6 to 563.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	345.1 (135.4 to 844.2)	223.4 (60.3 to 608.9)
Down syndrome	2.4 (1.8 to 3.0)	6.1 (4.9 to 7.5)	154.3 (88.7 to 245.3)	60.4 (17.6 to 123.9)	0.3 (0.2 to 0.4)	0.7 (0.5 to 1.0)	154.1 (81.2 to 263.1)	60.1 (13.3 to 130.4)
Turner syndrome	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	125.2 (43.2 to 255.6)	38.1 (-12.4 to 120.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	126.9 (43.7 to 258.0)	39.0 (-12.2 to 122.6)
Klinefelter syndrome	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.3)	58.2 (17.5 to 105.3)	-4.6 (-29.1 to 24.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.9 (15.0 to 101.5)	-3.9 (-28.6 to 25.0)
Chromosomal unbalanced rearrangements	8.0 (3.0 to 5.0)	10.2 (8.7 to 12.2)	60.6 (92.2 to 253.6)	159.7 (21.4 to 123.3)	0.2 (0.3 to 0.7)	0.2 (0.8 to 1.6)	65.4 (25.2 to 259.4)	65.4 (17.8 to 127.4)
Other congenital anomalies	46.1 (33.5 to 56.7)	66.6 (47.5 to 85.0)	44.6 (24.9 to 69.7)	-11.3 (-22.6 to 4.5)	4.5 (2.8 to 6.7)	6.7 (3.9 to 10.3)	48.4 (24.3 to 75.7)	-11.0 (-24.9 to 6.9)
Skin and subcutaneous diseases	-	-	-	-	-	-	-	-
Dermatitis	245.9 (190.3 to 316.0)	400.4 (308.9 to 513.9)	63.5 (61.8 to 65.0)	-0.0 (-0.0 to 0.0)	8.8 (5.5 to 13.0)	14.6 (9.0 to 21.2)	65.9 (60.0 to 73.1)	0.2 (-2.6 to 3.3)
Psoriasis	37.9 (32.8 to 43.3)	60.5 (52.4 to 69.2)	60.4 (59.2 to 61.5)	0.0 (-0.0 to 0.0)	3.1 (2.1 to 4.4)	5.0 (3.4 to 7.0)	61.2 (50.0 to 73.0)	0.4 (-5.0 to 6.3)
Cellulitis	1.3 (1.0 to 1.7)	2.1 (1.7 to 2.7)	64.8 (49.1 to 80.6)	2.5 (-6.6 to 13.3)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	63.1 (24.6 to 111.5)	1.9 (-16.7 to 25.7)
Pyoderma	11.2 (8.3 to 14.6)	17.2 (12.8 to 22.1)	53.2 (43.6 to 64.3)	-4.2 (-10.5 to 3.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	52.7 (37.7 to 70.4)	-4.2 (-13.0 to 6.1)
Scabies	113.1 (80.6 to 178.5)	171.3 (116.6 to 289.8)	46.8 (-13.0 to 189.5)	-15.7 (-50.0 to 72.8)	2.9 (1.5 to 5.3)	4.4 (2.1 to 8.4)	47.2 (-12.2 to 189.8)	-15.5 (-50.2 to 77.1)
Fungal skin diseases	695.9 (501.4 to 988.2)	1,161.7 (829.8 to 1,651.6)	67.4 (63.2 to 71.0)	3.9 (0.0 to 1.1)	6.6 (1.5 to 8.9)	6.6 (2.5 to 14.8)	68.0 (61.5 to 78.6)	0.3 (-0.4 to 1.0)
Viral skin diseases	152.4 (112.3 to 191.7)	257.0 (192.8 to 320.9)	69.3 (62.6 to 77.3)	-0.0 (-3.5 to 3.3)	4.7 (2.7 to 7.6)	8.0 (4.5 to 12.9)	69.6 (63.0 to 78.6)	4.3 (-2.9 to 6.9)
Acne vulgaris	246.3 (184.0 to 337.9)	387.9 (250.5 to 545.0)	54.7 (-4.0 to 146.1)	-10.4 (-40.0 to 38.3)	2.7 (1.2 to 5.3)	4.2 (1.9 to 8.7)	54.5 (-3.8 to 146.5)	-10.5 (-39.9 to 38.9)
Alopecia areata	5.6 (5.0 to 6.3)	9.2 (8.2 to 10.3)	62.8 (38.9 to 89.7)	-0.8 (-15.3 to 17.3)	0.2 (0.1 to 0.3)	0.5 (0.2 to 0.5)	63.6 (33.5 to 99.0)	-0.4 (-17.0 to 18.9)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.5 (26.5 to 95.5)	0.0 (-24.0 to 25.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.5 (26.2 to 95.6)	-2.5 (-24.0 to 25.2)
Urticaria	23.5 (14.9 to 32.0)	51.9 (36.5 to 71.5)	119.4 (48.8 to 271.3)	29.4 (-18.0 to 106.9)	1.4 (0.7 to 2.2)	3.1 (1.8 to 5.0)	121.5 (48.8 to 276.9)	29.9 (-17.3 to 108.0)
Decubitus ulcer	0.7 (0.6 to 0.8)	1.2 (1.0 to 1.4)	65.7 (34.2 to 111.4)	5.4 (-24.6 to 47.8)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	67.1 (33.8 to 116.1)	6.5 (-25.9 to 52.8)
Other skin and subcutaneous diseases	326.6 (219.3 to 459.4)	494.5 (334.3 to 701.6)	52.1 (42.2 to 61.2)	-4.4 (-10.6 to 2.2)	1.9 (0.8 to 3.9)	2.9 (1.3 to 5.9)	52.5 (42.3 to 61.7)	-4.0 (-10.1 to 2.7)
Sense organ diseases	-	-	-	-	-	-	-	-
Glaucoma	11.3 (8.0 to 15.3)	13.8 (9.5 to 17.6)	22.7 (-3.0 to 54.0)	-19.9 (-37.1 to 4.5)	1.1 (0.6 to 1.8)	1.3 (0.7 to 1.9)	14.9 (6.1 to 50.5)	24.0 (-4.0 to -0.6)
Cataract	38.8 (27.7 to 54.3)	54.2 (35.3 to 78.3)	36.4 (8.1 to 88.1)	-4.3 (-24.0 to 17.3)	3.0 (1.9 to 4.4)	4.0 (2.4 to 6.4)	34.7 (3.4 to 64.3)	-8.3 (-28.3 to 9.6)
Macular degeneration	6.7 (4.0 to 11.4)	12.9 (7.0 to 22.3)	89.7 (12.7 to 256.3)	33.2 (-21.5 to 154.3)	0.3 (0.2 to 0.6)	0.6 (0.3 to 1.1)	78.4 (11.6 to 252.6)	22.6 (-21.3 to 143.3)
Uncorrected refractive error	492.2 (373.5 to 608.4)	757.1 (596.7 to 918.8)	55.5 (13.9 to 88.1)	0.0 (-23.1 to 34.8)	10.1 (6.4 to 15.9)	14.2 (8.9 to 22.3)	40.4 (18.5 to 68.2)	-11.0 (-23.1 to 5.2)
Age-related and other hearing loss	854.5 (725.6 to 964.4)	1,161.7 (979.3 to 1,357.8)	39.1 (31.7 to 47.5)	-7.6 (-11.1 to -3.7)	36.4 (17.0 to 41.8)	36.4 (21.7 to 55.9)	36.4 (17.0 to 46.1)	-11.0 (-20.0 to -6.4)
Other vision loss	18.9 (14.4 to 24.8)	22.2 (16.6 to 29.3)	17.1 (2.6 to 39.0)	-23.9 (-32.5 to -12.2)	1.7 (1.0 to 2.6)	2.0 (1.2 to 3.2)	21.1 (1.0 to 40.9)	-21.5 (-34.2 to -6.3)
Other sense organ diseases	152.7 (144.5 to 160.4)	250.4 (237.5 to 266.4)	64.4 (53.0 to 78.6)	-0.1 (-5.9 to 7.0)	4.1 (2.5 to 6.0)	6.7 (4.1 to 10.1)	65.1 (51.0 to 80.7)	0.3 (-6.8 to 7.5)
Oral disorders	-	-	-	-	-	-	-	-
Deciduous caries	707.4 (675.1 to 745.6)	1,206.8 (1,152.6 to 1,269.6)	71.4 (58.3 to 84.3)	0.1 (-7.2 to 7.3)	0.1 (0.1 to 0.5)	0.5 (0.2 to 0.9)	71.1 (56.0 to 87.4)	0.0 (-8.7 to 9.5)
Permanent caries	1,899.0 (1,710.4 to 2,067.9)	3,185.3 (2,850.4 to 3,538.1)	68.8 (47.8 to 96.9)	2.3 (-8.6 to 14.2)	3.9 (0.8 to 3.6)	3.2 (1.4 to 6.2)	69.2 (47.2 to 97.4)	2.5 (-8.6 to 14.8)
Periodontal diseases	547.5 (531.1 to 563.4)	829.2 (802.6 to 857.9)	51.9 (45.3 to 58.3)	0.5 (-3.8 to 4.9)	3.6 (1.4 to 7.2)	5.4 (2.2 to 10.9)	52.4 (45.4 to 59.1)	0.8 (-3.7 to 5.2)

Appendix Table G.4 - Somalia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	109.8 (102.5 to 117.4)	151.3 (141.9 to 162.2)	38.1 (26.1 to 51.5)	-7.2 (-15.1 to 1.3)	3.0 (2.0 to 4.2)	4.2 (2.8 to 5.8)	38.6 (26.4 to 52.9)	-6.7 (-14.8 to 2.0)
Other oral disorders	91.1 (85.3 to 96.9)	145.9 (138.2 to 154.2)	60.6 (48.1 to 74.9)	-0.6 (-7.7 to 7.6)	2.7 (1.7 to 4.0)	4.3 (2.7 to 6.4)	61.2 (48.0 to 76.0)	-0.4 (-8.1 to 7.4)
Injuries	-	-	-	-	61.8 (34.5 to 123.4)	56.8 (31.1 to 117.6)	-9.1 (-22.2 to 7.4)	-33.9 (-43.9 to -18.3)
Transport injuries	-	-	-	-	8.9 (6.7 to 11.5)	7.3 (5.6 to 9.3)	-18.0 (-22.7 to -12.4)	-49.1 (-51.4 to -46.1)
Road injuries	-	-	-	-	7.8 (5.9 to 10.1)	6.5 (5.0 to 8.2)	-16.9 (-21.0 to -10.9)	-48.4 (-50.8 to -45.3)
Pedestrian road injuries	-	-	-	-	2.7 (2.0 to 3.5)	2.5 (1.8 to 3.2)	-8.6 (-16.9 to 0.8)	-42.0 (-45.9 to -37.7)
Cyclist road injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.4 (0.3 to 0.5)	-45.0 (-49.4 to -39.8)	-64.7 (-67.4 to -61.6)
Motorcyclist road injuries	-	-	-	-	0.9 (0.7 to 1.2)	0.7 (0.5 to 0.9)	-22.1 (-27.6 to -16.4)	-48.1 (-51.5 to -44.8)
Motor vehicle road injuries	-	-	-	-	3.4 (2.6 to 4.4)	2.9 (2.2 to 3.7)	-15.3 (-23.7 to -6.5)	-49.3 (-53.5 to -44.5)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-42.3 (-46.5 to -37.6)	-63.3 (-65.3 to -60.9)
Other transport injuries	-	-	-	-	1.1 (0.8 to 1.4)	0.8 (0.6 to 1.0)	-26.2 (-31.6 to -19.2)	-54.0 (-57.2 to -50.2)
Unintentional injuries	-	-	-	-	13.1 (10.1 to 16.9)	13.5 (10.5 to 17.0)	2.5 (-2.3 to 8.5)	-38.3 (-41.6 to -35.0)
Falls	-	-	-	-	5.4 (4.1 to 7.0)	6.8 (5.2 to 8.7)	24.9 (16.9 to 33.8)	-27.4 (-32.8 to -22.2)
Drowning	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.3 to 0.5)	18.9 (8.2 to 30.5)	-21.9 (-27.9 to -16.1)
Fire, heat, and hot substances	-	-	-	-	1.6 (1.2 to 2.0)	1.8 (1.4 to 2.3)	13.3 (2.7 to 25.1)	-31.7 (-36.8 to -25.9)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	12.2 (-3.9 to 33.3)	-29.3 (-37.2 to -19.3)
Exposure to mechanical forces	-	-	-	-	3.1 (2.4 to 4.1)	2.7 (2.1 to 3.6)	-13.4 (-21.5 to -1.6)	-50.0 (-54.1 to -44.2)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	30.9 (19.7 to 43.5)	-16.9 (-23.9 to -9.2)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.7 (-47.0 to -15.4)	-64.3 (-69.9 to -55.1)
Other exposure to mechanical forces	-	-	-	-	3.0 (2.3 to 3.9)	2.6 (1.9 to 3.4)	-14.8 (-23.0 to -2.9)	-51.3 (-55.5 to -45.2)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	65.2 (54.9 to 74.0)	9.5 (2.6 to 16.5)
Animal contact	-	-	-	-	0.7 (0.5 to 0.9)	0.7 (0.5 to 0.9)	-2.0 (-9.7 to 5.8)	-37.9 (-42.2 to -33.8)
Venomous animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	1.1 (-10.8 to 13.0)	-36.5 (-43.1 to -29.8)
Non-venomous animal contact	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	-4.7 (-13.4 to 7.1)	-39.2 (-43.8 to -33.4)
Foreign body	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.3)	4.8 (-2.2 to 18.1)	-40.4 (-46.8 to -33.0)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	46.4 (28.8 to 64.2)	-2.3 (-11.1 to 6.4)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	37.1 (14.1 to 59.1)	-20.4 (-33.7 to -7.6)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-22.2 (-35.4 to -7.0)	-55.4 (-63.2 to -46.5)
Other unintentional injuries	-	-	-	-	1.6 (1.2 to 2.1)	0.7 (0.5 to 0.9)	-59.3 (-66.5 to -48.3)	-77.8 (-81.3 to -72.5)
Self-harm and interpersonal violence	-	-	-	-	1.0 (0.8 to 1.3)	1.2 (0.9 to 1.6)	23.0 (15.6 to 31.5)	-20.2 (-24.5 to -15.2)
Self-harm	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	54.2 (43.0 to 66.1)	1.5 (-5.1 to 8.5)
Interpersonal violence	-	-	-	-	0.9 (0.7 to 1.1)	1.1 (0.8 to 1.3)	19.1 (11.1 to 28.5)	-23.8 (-28.5 to -18.0)
Assault by firearm	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	21.3 (10.4 to 32.6)	-22.8 (-29.0 to -16.5)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	56.6 (42.4 to 72.3)	0.4 (-8.2 to 11.1)
Assault by other means	-	-	-	-	0.6 (0.5 to 0.8)	0.7 (0.5 to 0.8)	9.9 (0.7 to 20.5)	-29.9 (-35.4 to -23.7)
Forces of nature, war, and legal intervention	-	-	-	-	38.8 (13.9 to 100.7)	34.8 (10.5 to 94.8)	-12.7 (-35.6 to 14.9)	-28.1 (-47.0 to -5.2)
Exposure to forces of nature	-	-	-	-	5.7 (2.3 to 13.2)	2.2 (0.9 to 4.9)	-61.8 (-66.4 to -57.2)	69.1 (-73.6 to -64.4)
Collective violence and legal intervention	-	-	-	-	33.1 (10.9 to 88.6)	32.6 (9.4 to 91.9)	-3.2 (-30.1 to 28.9)	-17.9 (-40.7 to 9.3)

Appendix Table G.4 - South Africa prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	3,674.0 (2,733.5 to 4,772.3)	6,486.7 (4,865.5 to 8,319.3)	76.7 (69.3 to 84.4)	76.7 (6.8 to 15.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	828.3 (584.8 to 1,160.8)	1,912.0 (1,423.9 to 2,488.7)	131.6 (98.4 to 170.5)	70.9 (45.3 to 100.5)
HIV/AIDS and tuberculosis	-	-	-	-	151.9 (103.6 to 205.8)	1,127.4 (809.9 to 1,486.1)	648.1 (525.0 to 767.2)	347.9 (273.0 to 422.8)
Tuberculosis	481.3 (453.1 to 510.4)	771.7 (737.8 to 808.9)	60.4 (52.4 to 68.5)	-4.6 (-9.1 to -0.2)	147.1 (100.2 to 199.4)	233.0 (160.9 to 313.2)	58.5 (50.1 to 67.4)	-5.5 (-10.2 to -0.5)
HIV/AIDS	-	-	-	-	4.1 (3.3 to 6.6)	894.1 (640.4 to 1,189.4)	16.2 (14,830.8 to 23,118.7)	2.2 (9,872.5 to 15,688.9)
HIV/AIDS resulting in mycobacterial infection	3.3 (1.9 to 5.0)	276.1 (208.3 to 333.2)	8,233.9 (6,509.1 to 11,260.2)	5,169.4 (4,083.5 to 7,024.0)	1.3 (0.6 to 2.1)	101.4 (64.5 to 143.7)	8,141.9 (6,095.1 to 11,883.6)	5,095.1 (3,831.5 to 7,360.2)
HIV/AIDS resulting in other diseases	49.3 (45.0 to 53.8)	6,030.4 (5,762.3 to 6,290.9)	12,192.3 (11,188.0 to 13,139.2)	8,087.7 (7,471.7 to 8,746.2)	3.6 (2.4 to 4.9)	793.1 (560.6 to 1,069.7)	22,148.3 (17,979.9 to 27,711.1)	15,200.8 (12,781.1 to 19,038.7)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	84.3 (59.6 to 114.7)	99.9 (70.2 to 135.4)	18.6 (11.2 to 26.4)	-6.1 (-11.5 to -0.3)
Diarrheal diseases	298.9 (277.0 to 318.6)	338.6 (315.2 to 360.7)	13.4 (3.3 to 25.3)	-4.1 (-12.2 to 5.4)	48.5 (32.9 to 67.9)	54.5 (36.9 to 75.3)	12.6 (1.8 to 24.6)	-14.2 (-35.3 to 5.6)
Intestinal infectious diseases	-	-	-	-	0.9 (0.6 to 1.3)	0.7 (0.5 to 1.1)	0.7 (-34.5 to 11.5)	-14.2 (-51.0 to -17.6)
Typhoid fever	5.1 (4.2 to 5.8)	4.3 (3.6 to 5.1)	-14.3 (-34.0 to 6.0)	-35.7 (-50.5 to -20.6)	0.7 (0.4 to 1.0)	0.6 (0.4 to 0.9)	-13.0 (-35.1 to 14.0)	-34.8 (-51.5 to -15.2)
Paratyphoid fever	2.4 (2.0 to 2.9)	2.5 (2.0 to 3.0)	5.4 (-20.7 to 37.3)	-20.9 (-40.2 to 2.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	0.1 (-23.0 to 45.0)	6.8 (-41.2 to 5.8)
Other intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-77.3 (-98.8 to -50.4)	-83.1 (-92.8 to -63.1)
Lower respiratory infections	9.8 (7.8 to 11.5)	10.8 (8.8 to 13.2)	12.4 (-18.0 to 42.3)	-18.7 (-38.2 to 1.1)	1.0 (0.7 to 1.5)	1.1 (0.7 to 1.6)	9.3 (-23.7 to 47.0)	-18.8 (-40.0 to 5.3)
Upper respiratory infections	960.5 (869.8 to 1,048.5)	1,301.2 (1,179.3 to 1,431.6)	35.5 (21.2 to 52.6)	-2.6 (-13.2 to 9.6)	11.3 (6.4 to 19.0)	15.2 (8.6 to 25.0)	34.6 (19.9 to 52.7)	-2.9 (-13.7 to 9.9)
Otitis media	674.5 (624.6 to 730.1)	874.1 (804.9 to 940.9)	29.3 (19.5 to 40.4)	-6.9 (-14.0 to 0.8)	12.0 (7.0 to 19.3)	15.6 (9.1 to 25.7)	29.6 (18.5 to 40.7)	-6.3 (-14.2 to 1.7)
Meningitis	-	-	-	-	7.3 (5.0 to 10.0)	8.6 (5.9 to 11.9)	19.5 (13.9 to 29.2)	-16.1 (-28.2 to -2.7)
Pneumococcal meningitis	15.9 (10.1 to 24.6)	20.5 (12.5 to 33.0)	28.8 (1.2 to 55.3)	-14.9 (-33.0 to 2.1)	1.6 (1.1 to 2.2)	2.0 (1.4 to 2.9)	28.3 (-2.6 to 54.8)	-14.2 (-32.8 to 4.5)
H influenzae type B meningitis	18.0 (6.8 to 37.1)	20.0 (7.5 to 43.5)	10.2 (-18.3 to 44.3)	-23.8 (-41.7 to 3.1)	2.3 (1.4 to 3.3)	2.6 (1.6 to 3.9)	15.5 (-24.7 to 67.3)	-15.7 (-44.7 to 20.8)
Meningococcal meningitis	10.6 (3.4 to 25.5)	12.9 (4.8 to 29.5)	21.4 (-9.3 to 69.2)	-19.4 (-37.6 to 15.9)	1.4 (0.8 to 2.2)	1.7 (1.1 to 2.7)	26.1 (-13.7 to 86.3)	-13.9 (-40.4 to 25.0)
Other meningitis	14.9 (8.1 to 28.1)	17.3 (9.3 to 32.7)	14.3 (-11.9 to 52.6)	-20.7 (-37.6 to 14.8)	2.0 (1.3 to 2.8)	2.3 (1.5 to 3.3)	15.2 (-13.8 to 60.8)	-18.7 (-38.7 to 11.7)
Encephalitis	5.1 (2.2 to 11.7)	8.2 (3.5 to 20.4)	61.2 (30.3 to 81.4)	-6.6 (-13.3 to 4.7)	0.7 (0.5 to 1.0)	1.1 (0.7 to 1.5)	69.8 (26.5 to 92.2)	4.8 (-15.6 to 24.2)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.5 (-92.0 to 1,171.0)	-24.6 (-92.9 to 720.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.5 (-92.0 to 1,189.6)	-24.6 (-93.0 to 724.1)
Whooping cough	25.6 (19.9 to 32.6)	38.0 (29.4 to 48.8)	48.5 (45.2 to 52.0)	41.2 (38.0 to 44.5)	1.3 (0.7 to 2.0)	1.9 (1.1 to 3.0)	49.3 (35.0 to 63.8)	41.9 (28.2 to 55.7)
Tetanus	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-81.3 (-99.8 to -61.4)	-86.6 (-92.7 to -72.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-75.3 (-85.9 to -55.8)	-81.7 (-88.9 to -68.1)
Measles	8.2 (6.4 to 10.5)	0.4 (0.3 to 0.7)	-94.7 (-96.5 to -91.9)	-95.0 (-96.7 to -92.3)	0.7 (0.4 to 1.2)	0.7 (0.0 to 1.1)	94.6 (-96.5 to -91.4)	94.9 (-96.7 to -91.9)
Varicella and herpes zoster	23.3 (21.3 to 25.6)	36.0 (32.1 to 40.3)	54.5 (33.7 to 81.9)	5.0 (-12.9 to 27.2)	0.6 (0.3 to 0.9)	1.0 (0.6 to 1.6)	75.4 (26.3 to 143.1)	5.6 (-24.5 to 48.9)
Neglected tropical diseases and malaria	-	-	-	-	150.8 (90.8 to 251.9)	229.0 (125.4 to 401.2)	49.6 (30.6 to 76.2)	4.9 (-8.7 to 24.0)
Malaria	623.2 (505.8 to 764.1)	536.4 (401.5 to 668.2)	-13.6 (-32.1 to 2.3)	-42.2 (-54.6 to -31.4)	5.3 (3.6 to 7.5)	4.9 (3.3 to 7.2)	-6.7 (-16.2 to 6.4)	-32.4 (-39.5 to -21.6)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	49.4 (-7.9 to 143.9)	15.3 (-27.3 to 83.6)
Visceral leishmaniasis	0.4 (0.3 to 0.6)	0.6 (0.4 to 1.0)	49.3 (-7.9 to 142.5)	15.2 (-27.3 to 83.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	49.3 (-8.0 to 143.8)	15.2 (-27.3 to 83.6)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	680.5 (474.5 to 933.0)	500.1 (347.7 to 700.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	680.5 (474.4 to 933.3)	500.1 (346.7 to 700.3)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	4,159.6 (1,767.8 to 7,887.5)	6,439.0 (2,798.6 to 12,125.0)	54.9 (50.7 to 60.2)	1.3 (-1.2 to 4.8)	34.9 (13.8 to 81.0)	54.0 (21.4 to 124.0)	55.2 (32.8 to 77.8)	3.3 (-10.6 to 18.0)
Cysticercosis	25.9 (13.4 to 47.8)	23.7 (9.4 to 51.4)	-7.4 (-71.4 to 150.7)	-49.9 (-83.2 to 46.8)	7.2 (3.3 to 14.5)	7.2 (2.6 to 14.9)	-5.5 (-70.8 to 160.3)	-48.4 (-82.8 to 53.5)
Cystic echinococcosis	11.1 (10.6 to 11.6)	8.6 (7.5 to 9.2)	-21.3 (-32.3 to -15.9)	-46.0 (-54.4 to -42.2)	1.0 (0.7 to 1.5)	0.8 (0.5 to 1.1)	-22.2 (-37.4 to -7.0)	47.0 (-57.4 to -36.6)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.3 (-63.8 to -25.3)	-59.7 (-69.9 to -41.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.3 (-64.0 to -25.3)	-59.7 (-69.9 to -41.1)
Intestinal nematode infections	-	-	-	-	76.5 (45.0 to 122.3)	110.4 (65.7 to 178.0)	44.3 (28.9 to 60.0)	1.6 (-10.0 to 13.5)
Ascariasis	5,919.5 (4,158.2 to 8,322.4)	8,511.8 (5,653.8 to 12,787.9)	43.2 (-15.2 to 146.0)	-0.3 (-44.3 to 74.8)	3.3 (1.7 to 5.6)	4.4 (2.3 to 7.6)	35.0 (6.7 to 75.2)	-1.0 (-23.1 to 31.2)
Trichuriasis	14,777.5 (11,329.1 to 19,090.2)	21,224.0 (16,120.8 to 27,984.5)	42.6 (-2.4 to 110.5)	-0.6 (-34.0 to 50.5)	31.9 (17.1 to 53.9)	44.4 (23.8 to 73.6)	38.8 (15.7 to 68.7)	-0.8 (-18.3 to 21.9)
Hookworm disease	8,616.1 (6,299.4 to 11,460.1)	12,894.6 (9,320.6 to 17,664.5)	48.3 (-3.2 to 137.1)	41.4 (-36.1 to 64.7)	61.6 (25.5 to 63.9)	61.6 (37.7 to 93.9)	49.3 (29.9 to 70.1)	3.4 (-10.5 to 18.5)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	516.6 (404.3 to 633.6)	527.3 (494.3 to 565.9)	2.2 (-17.2 to 30.0)	-15.2 (-30.5 to 5.9)	25.8 (15.0 to 43.0)	52.0 (22.5 to 117.0)	84.8 (14.1 to 236.6)	52.1 (-7.4 to 164.3)
Maternal disorders	-	-	-	-	13.4 (9.1 to 18.3)	13.9 (9.6 to 19.1)	4.3 (-8.0 to 16.7)	-33.3 (-41.0 to -25.6)
Maternal hemorrhage	13.9 (11.9 to 15.8)	24.4 (18.0 to 31.0)	75.9 (28.0 to 127.5)	5.9 (-21.6 to 36.4)	0.5 (0.3 to 0.7)	0.8 (0.4 to 1.2)	63.4 (-6.2 to 148.2)	1.6 (-43.6 to 49.8)
Maternal sepsis and other maternal infections	7.9 (5.1 to 12.1)	8.2 (5.4 to 12.0)	3.7 (-7.8 to 23.9)	-36.4 (-43.5 to -23.7)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	3.0 (-33.1 to 34.6)	-38.2 (-56.1 to -16.6)
Maternal hypertensive disorders	6.1 (2.9 to 10.1)	6.3 (3.0 to 10.7)	4.1 (-1.2 to 10.7)	-34.4 (-38.3 to -29.8)	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.6)	3.3 (-19.2 to 34.0)	-34.6 (-48.8 to -16.1)
Obstructed labor	33.3 (30.3 to 36.7)	34.8 (32.1 to 37.9)	4.5 (-2.1 to 11.6)	-33.1 (-37.2 to -28.9)	11.0 (7.3 to 15.1)	11.3 (7.6 to 15.6)	3.2 (-8.3 to 15.5)	-33.8 (-41.0 to -26.4)
Complications of abortion	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	63.1 (-13.8 to 224.5)	1.7 (-44.1 to 95.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.1 (-14.0 to 225.4)	1.7 (-44.1 to 95.5)
Other maternal disorders	-	-	-	-	1.5 (0.9 to 2.2)	1.5 (0.9 to 2.1)	-4.9 (-34.6 to 42.5)	-38.4 (-57.7 to -7.0)
Neonatal disorders	-	-	-	-	41.5 (24.0 to 65.0)	69.8 (43.9 to 99.2)	70.1 (1.2 to 174.7)	25.8 (-25.5 to 102.3)
Preterm birth complications	50.9 (35.7 to 74.8)	155.1 (114.1 to 212.5)	204.9 (152.8 to 274.1)	114.9 (78.1 to 163.0)	5.1 (3.3 to 7.4)	16.6 (11.0 to 22.9)	224.6 (127.7 to 364.7)	134.7 (65.4 to 233.1)
Neonatal encephalopathy due to birth asphyxia and trauma	136.2 (26.8 to 411.9)	154.5 (40.4 to 448.3)	17.3 (-9.7 to 81.6)	-17.3 (-36.7 to -29.9)	10.9 (5.4 to 18.6)	16.6 (9.6 to 24.8)	52.5 (-1.1 to 168.5)	13.2 (-26.8 to 105.4)
Neonatal sepsis and other neonatal infections	0.2 (0.1 to 0.4)	0.4 (0.1 to 0.8)	88.8 (82.3 to 104.0)	85.4 (79.0 to 100.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	91.9 (70.1 to 114.1)	88.4 (67.0 to 110.3)
Hemolytic disease and other neonatal jaundice	16.9 (7.3 to 33.1)	30.0 (12.1 to 58.9)	74.5 (-29.2 to 359.5)	28.7 (-47.3 to 238.2)	6.6 (2.6 to 13.5)	11.6 (4.4 to 23.3)	73.4 (-28.4 to 370.2)	26.5 (-47.0 to 245.3)
Other neonatal disorders	-	-	-	-	18.9 (8.4 to 34.6)	25.0 (12.7 to 42.8)	33.8 (-43.0 to 216.2)	-0.3 (-58.0 to 132.7)
Nutritional deficiencies	-	-	-	-	348.3 (228.0 to 506.0)	321.4 (215.1 to 464.7)	-7.6 (-16.9 to 1.6)	-30.0 (-37.3 to -22.3)
Protein-energy malnutrition	168.5 (74.5 to 350.9)	106.1 (34.1 to 249.9)	-40.1 (-82.4 to 105.2)	-4.6 (-82.4 to 93.3)	21.0 (8.0 to 44.4)	13.2 (4.1 to 32.1)	-40.1 (-82.2 to 106.8)	-42.6 (-82.6 to 93.4)
Iodine deficiency	3,460.8 (2,379.5 to 4,630.3)	2,150.5 (1,408.6 to 2,987.4)	-38.0 (-76.1 to -32.2)	-59.8 (-76.1 to -32.2)	62.1 (33.4 to 106.6)	38.4 (19.7 to 66.6)	-38.1 (-63.0 to 2.5)	-59.9 (-76.0 to -32.3)
Vitamin A deficiency	42.1 (32.6 to 52.4)	31.2 (23.7 to 40.3)	-26.2 (-36.2 to -15.2)	-45.8 (-53.6 to -36.8)	1.4 (0.8 to 2.2)	1.0 (0.6 to 1.6)	-28.4 (-40.2 to -16.1)	47.5 (-36.3 to 37.8)

Appendix Table G.4 - South Africa prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	8,100.6 (7,982.6 to 8,212.5)	8,653.5 (8,495.1 to 8,811.2)	6.8 (4.5 to 9.1)	-0.5 (-22.3 to -18.8)	263.6 (175.4 to 377.6)	268.6 (178.4 to 389.7)	1.9 (-0.8 to 5.6)	-0.6 (-22.7 to -17.5)
Other nutritional deficiencies	-	-	-	-	0.3 (0.1 to 0.7)	0.2 (0.1 to 0.7)	-12.9 (-78.6 to 264.8)	-16.3 (-79.1 to 243.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	38.0 (23.7 to 59.6)	50.5 (31.4 to 80.6)	32.2 (16.1 to 53.2)	-8.3 (-18.9 to 4.2)
Sexually transmitted diseases excluding HIV	-	-	-	-	22.9 (13.1 to 37.9)	34.1 (19.6 to 56.9)	49.3 (22.2 to 79.5)	-5.1 (-21.0 to 12.4)
Syphilis	3.9 (3.4 to 4.4)	4.7 (4.0 to 5.4)	19.7 (-3.5 to 45.7)	-32.4 (-43.6 to -19.7)	0.9 (0.5 to 1.2)	0.7 (0.5 to 1.2)	18.8 (-12.9 to 56.8)	32.9 (-49.0 to -13.4)
Chlamydial infection	2,149.5 (1,839.6 to 2,475.4)	3,389.6 (2,959.3 to 3,790.8)	58.1 (27.2 to 92.1)	1.4 (-17.5 to 21.5)	12.5 (6.8 to 20.9)	18.6 (10.1 to 30.2)	48.4 (6.7 to 102.3)	-5.0 (-30.5 to 26.3)
Gonococcal infection	699.6 (571.1 to 833.0)	984.7 (805.6 to 1,158.7)	41.8 (5.6 to 87.0)	-6.8 (-30.4 to 21.3)	3.7 (1.9 to 6.5)	5.6 (2.9 to 9.5)	49.6 (-3.3 to 149.8)	-1.5 (-34.9 to 60.4)
Trichomoniasis	1,878.3 (1,475.0 to 2,447.7)	2,855.4 (2,227.5 to 3,477.0)	52.6 (13.0 to 108.5)	-0.9 (-25.6 to 33.6)	3.2 (1.2 to 6.8)	4.9 (1.9 to 10.3)	50.9 (7.9 to 111.1)	-1.4 (-28.3 to 36.7)
Genital herpes	8,923.9 (8,467.4 to 9,375.0)	14,517.7 (13,639.8 to 15,353.9)	62.2 (50.9 to 75.9)	3.4 (-9.9 to 3.9)	2.4 (0.8 to 5.8)	3.9 (1.2 to 9.1)	59.4 (45.6 to 74.0)	-3.7 (-11.3 to 4.6)
Other sexually transmitted diseases	18.2 (12.8 to 24.1)	24.7 (17.4 to 34.3)	34.9 (16.6 to 62.0)	-18.0 (-28.8 to -0.9)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	37.3 (-1.9 to 90.1)	-14.6 (-37.9 to 15.1)
Hepatitis	-	-	-	-	2.4 (1.5 to 3.5)	2.9 (1.8 to 4.3)	23.2 (1.9 to 44.6)	-19.8 (-34.8 to -4.1)
Hepatitis A	47.5 (45.6 to 49.4)	58.4 (56.4 to 60.4)	23.0 (22.3 to 23.7)	-4.6 (-4.7 to -4.4)	1.1 (0.7 to 1.6)	1.5 (1.0 to 2.2)	37.7 (21.1 to 55.1)	-2.0 (-13.6 to 9.7)
Hepatitis B	2,134.4 (1,824.4 to 2,481.1)	2,077.4 (1,788.5 to 2,303.9)	-5.0 (-21.3 to 17.8)	-37.3 (-47.8 to -23.0)	1.0 (0.6 to 1.6)	1.1 (0.6 to 1.7)	5.4 (-31.1 to 48.3)	-35.1 (-57.8 to -6.9)
Hepatitis C	647.4 (576.8 to 712.5)	758.3 (697.3 to 838.7)	18.5 (3.6 to 39.0)	-17.8 (-36.8 to -17.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	14.7 (-11.6 to 50.1)	-28.1 (-47.4 to 0.1)
Hepatitis E	5.2 (4.6 to 5.9)	7.5 (6.7 to 8.2)	42.0 (20.9 to 68.2)	-8.8 (-23.0 to 7.0)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	44.4 (4.1 to 101.1)	-8.9 (-32.7 to 24.3)
Leprosy	2.0 (1.1 to 3.0)	1.7 (1.2 to 2.1)	-14.7 (-30.1 to 19.5)	-49.7 (-58.4 to -30.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-15.0 (-38.8 to 28.5)	-49.8 (-63.1 to -25.4)
Other infectious diseases	369.3 (291.2 to 448.6)	379.6 (338.6 to 419.1)	2.7 (-12.5 to 20.4)	-17.3 (-27.7 to -5.0)	12.7 (7.6 to 18.6)	13.4 (8.6 to 20.0)	4.8 (-11.1 to 40.1)	-10.8 (-24.5 to 16.3)
Non-communicable diseases	-	-	-	-	2,638.0 (1,955.6 to 3,404.0)	4,379.0 (3,248.5 to 5,618.8)	66.1 (62.4 to 69.9)	1.5 (-0.7 to 3.6)
Neoplasms	-	-	-	-	25.9 (18.1 to 34.2)	42.0 (29.7 to 57.5)	59.3 (31.1 to 117.6)	-5.2 (-22.0 to 29.6)
Esophageal cancer	7.6 (5.3 to 9.9)	9.5 (7.2 to 12.7)	22.8 (-19.6 to 105.6)	-28.9 (-52.2 to 13.5)	1.1 (0.7 to 1.6)	1.4 (0.9 to 2.0)	26.4 (-18.5 to 103.1)	-27.1 (-51.6 to 11.1)
Stomach cancer	6.5 (5.4 to 7.5)	5.3 (4.4 to 6.3)	-18.3 (-35.0 to 2.9)	-53.8 (-63.4 to -41.6)	0.7 (0.5 to 1.0)	0.6 (0.4 to 0.9)	-16.7 (-34.9 to 7.9)	-52.9 (-63.5 to -39.4)
Liver cancer	-	-	-	-	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	14.8 (-14.9 to 54.5)	-32.5 (-49.3 to -10.4)
Liver cancer due to hepatitis B	0.6 (0.4 to 1.0)	1.0 (0.6 to 1.4)	53.5 (-15.5 to 159.6)	-6.3 (-47.2 to 63.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	51.9 (-12.4 to 142.5)	-8.1 (-42.4 to 53.4)
Liver cancer due to hepatitis C	0.5 (0.3 to 0.7)	0.7 (0.4 to 1.7)	89.8 (-14.5 to 283.3)	11.3 (-48.0 to 123.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	90.3 (-5.9 to 263.5)	9.5 (-44.0 to 111.1)
Liver cancer due to alcohol use	1.1 (0.8 to 1.6)	0.9 (0.6 to 1.4)	-9.1 (-56.1 to 40.3)	-53.1 (-74.1 to -20.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-18.1 (-54.5 to 33.3)	-52.7 (-72.5 to -24.1)
Liver cancer due to other causes	0.5 (0.3 to 0.8)	0.4 (0.2 to 0.5)	-23.9 (-59.7 to 23.7)	-30.4 (-75.5 to -25.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-11.1 (-57.0 to 13.5)	-58.0 (-73.7 to -31.2)
Larynx cancer	5.6 (2.5 to 7.5)	4.5 (3.2 to 6.5)	-23.9 (-48.5 to 75.4)	-56.3 (-70.2 to -2.6)	0.5 (0.2 to 0.8)	0.4 (0.3 to 0.7)	-21.2 (-47.6 to 82.9)	-54.8 (-70.2 to 0.7)
Tracheal, bronchus and lung cancer	12.5 (10.6 to 14.7)	11.1 (9.1 to 14.1)	-11.7 (-30.6 to 16.5)	-48.9 (-59.5 to 30.0)	1.8 (1.3 to 2.4)	1.6 (1.1 to 2.3)	-10.0 (-30.1 to 19.2)	-47.9 (-59.4 to -31.5)
Breast cancer	46.4 (32.9 to 57.9)	67.7 (48.5 to 87.7)	44.3 (6.6 to 118.3)	-13.1 (-34.9 to 29.0)	3.8 (2.3 to 5.2)	5.6 (3.7 to 8.1)	47.0 (10.0 to 125.3)	-11.7 (-33.4 to 29.7)
Cervical cancer	26.1 (13.9 to 34.9)	21.5 (15.3 to 29.3)	-19.4 (-48.3 to 53.6)	-80.4 (-67.6 to -44.5)	1.8 (1.0 to 3.0)	1.8 (1.1 to 2.7)	-21.9 (-43.9 to 56.3)	-46.7 (-65.1 to -12.9)
Uterine cancer	5.7 (3.6 to 8.9)	11.1 (6.3 to 16.9)	91.8 (22.7 to 203.2)	8.9 (-30.5 to 72.7)	0.4 (0.2 to 0.6)	0.8 (0.4 to 1.3)	103.6 (29.5 to 229.5)	14.7 (-8.2 to 87.2)
Prostate cancer	33.8 (17.3 to 49.2)	130.9 (84.1 to 194.6)	274.3 (133.7 to 709.4)	96.8 (25.0 to 325.1)	3.6 (1.8 to 5.4)	12.6 (7.6 to 19.8)	237.9 (123.0 to 646.3)	76.1 (16.3 to 282.3)
Colon and rectum cancer	26.6 (22.9 to 30.2)	44.1 (37.6 to 50.7)	65.5 (36.2 to 99.6)	-8.6 (-25.0 to 9.9)	2.3 (1.7 to 3.0)	3.8 (2.7 to 5.0)	63.3 (34.1 to 99.7)	-10.7 (-27.1 to 8.4)
Lip and oral cavity cancer	11.0 (6.7 to 15.0)	14.3 (10.5 to 19.8)	26.7 (-12.3 to 111.2)	-27.5 (-49.5 to 21.2)	1.0 (0.5 to 1.4)	1.3 (0.8 to 1.9)	29.1 (-8.9 to 117.3)	-26.0 (-48.8 to 22.4)
Nasopharynx cancer	1.7 (1.0 to 2.3)	0.8 (0.6 to 1.1)	-53.9 (-71.0 to -7.0)	-72.0 (-82.3 to -44.4)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.1)	0.1 (-48.0 to -2.4)	-70.5 (-80.7 to -43.6)
Other pharynx cancer	3.1 (1.5 to 4.5)	3.5 (2.1 to 5.5)	11.5 (-37.9 to 118.7)	-36.4 (-64.7 to 21.9)	0.3 (0.1 to 0.4)	0.3 (0.2 to 0.5)	16.0 (-35.8 to 118.1)	-33.8 (-63.6 to 26.7)
Gallbladder and biliary tract cancer	0.8 (0.3 to 1.1)	0.4 (0.3 to 0.6)	-53.8 (-67.2 to 46.4)	-74.3 (-82.0 to -47.2)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-52.4 (-65.7 to 53.1)	-73.2 (-81.2 to -12.1)
Pancreatic cancer	1.6 (1.4 to 1.9)	2.3 (1.9 to 2.8)	41.0 (9.9 to 81.2)	-22.0 (-38.8 to 0.9)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	41.4 (9.0 to 83.3)	-21.5 (-38.8 to 2.3)
Malignant skin melanoma	10.0 (7.1 to 12.7)	12.3 (9.0 to 17.1)	23.0 (-10.3 to 77.4)	-21.5 (-46.6 to 5.2)	0.8 (0.4 to 0.9)	0.8 (0.5 to 1.2)	24.1 (-10.4 to 85.2)	-36.5 (-47.4 to 9.2)
Non-melanoma skin cancer	4.0 (3.0 to 5.4)	12.8 (9.4 to 17.1)	215.8 (133.9 to 330.9)	68.0 (24.7 to 131.9)	0.2 (0.1 to 0.3)	0.8 (0.4 to 1.1)	257.2 (138.0 to 421.2)	87.8 (21.8 to 182.5)
Ovarian cancer	4.0 (2.8 to 5.6)	5.4 (3.8 to 7.4)	33.6 (-3.7 to 90.1)	-20.0 (-42.3 to 13.4)	0.5 (0.3 to 0.8)	0.7 (0.5 to 1.1)	43.3 (0.5 to 113.5)	-14.3 (-40.6 to 27.2)
Testicular cancer	2.9 (1.5 to 4.6)	2.6 (1.6 to 4.1)	-8.3 (-47.4 to 65.6)	-40.7 (-65.1 to 1.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-2.4 (-43.5 to 81.5)	-35.8 (-61.1 to 11.5)
Kidney cancer	4.8 (3.8 to 5.9)	6.4 (5.0 to 8.5)	33.0 (-1.4 to 78.3)	-18.4 (-37.8 to 11.6)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.7)	38.2 (1.6 to 87.0)	-14.3 (-37.0 to 14.9)
Bladder cancer	7.4 (5.8 to 9.4)	7.3 (5.8 to 9.3)	-3.7 (-30.0 to 100.1)	-47.8 (-61.7 to 7.1)	0.6 (0.3 to 0.9)	0.6 (0.4 to 0.9)	-1.8 (-28.8 to 105.7)	-47.1 (-61.8 to 10.9)
Brain and nervous system cancer	3.5 (2.1 to 4.5)	2.7 (1.9 to 3.5)	-26.0 (-48.4 to 42.5)	-47.2 (-61.4 to 2.9)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-21.6 (-42.5 to 52.6)	-46.2 (-59.6 to 4.6)
Thyroid cancer	6.5 (3.6 to 8.9)	7.0 (4.6 to 10.1)	8.8 (-27.4 to 76.0)	-33.5 (-56.1 to 9.9)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.7)	17.5 (-21.7 to 91.0)	-28.8 (-53.0 to 18.2)
Mesothelioma	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	62.8 (17.4 to 126.2)	8.7 (-33.9 to 30.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	62.5 (14.1 to 129.6)	9.6 (-36.4 to 28.1)
Hodgkin lymphoma	2.6 (1.2 to 3.9)	2.6 (1.8 to 4.0)	-2.6 (-37.8 to 125.3)	-3.2 (-55.7 to 51.1)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.4)	1.9 (-35.4 to 131.9)	-30.6 (-54.9 to 52.8)
Non-Hodgkin lymphoma	10.1 (7.1 to 13.2)	16.5 (12.2 to 24.3)	59.1 (21.1 to 130.7)	1.8 (-21.5 to 45.5)	0.8 (0.5 to 1.1)	1.3 (0.9 to 2.1)	63.0 (23.4 to 144.5)	3.8 (-20.8 to 49.4)
Multiple myeloma	1.5 (0.9 to 2.0)	2.7 (1.9 to 3.6)	82.8 (17.7 to 183.7)	4.7 (-33.9 to 65.0)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	83.0 (13.4 to 196.6)	5.3 (-36.1 to 70.4)
Leukemia	8.3 (6.0 to 10.9)	7.2 (5.4 to 9.3)	-13.1 (-39.9 to 30.5)	-57.1 (-53.2 to -9.0)	0.9 (0.6 to 1.3)	0.9 (0.6 to 1.3)	-9.9 (-28.4 to 34.8)	-36.2 (-51.8 to -11.2)
Other neoplasms	27.3 (18.7 to 35.1)	47.5 (30.8 to 63.6)	74.8 (14.9 to 150.3)	27.0 (-12.2 to 83.9)	1.8 (1.1 to 2.7)	3.2 (1.9 to 4.7)	73.0 (17.1 to 150.1)	22.0 (-14.3 to 76.6)
Cardiovascular diseases	-	-	-	-	59.9 (41.5 to 82.7)	115.7 (78.3 to 160.2)	93.8 (53.7 to 135.8)	0.2 (-19.4 to 20.6)
Rheumatic heart disease	27.5 (25.9 to 28.9)	42.6 (40.1 to 45.5)	55.1 (43.7 to 69.4)	0.0 (-6.7 to 8.3)	1.9 (1.3 to 2.7)	2.9 (1.9 to 4.1)	54.2 (17.4 to 92.0)	-3.7 (-26.8 to 20.1)
Ischemic heart disease	382.3 (316.0 to 458.1)	559.4 (470.9 to 688.8)	46.5 (12.8 to 91.9)	-22.6 (-40.3 to 1.8)	23.5 (15.4 to 34.2)	32.4 (20.6 to 48.6)	37.6 (24.4 to 88.0)	-27.4 (-45.4 to 0.5)
Cerebrovascular disease	-	-	-	-	4.9 (3.4 to 6.6)	9.0 (6.1 to 12.1)	83.0 (46.7 to 130.8)	1.1 (-19.6 to 29.1)
Ischemic stroke	25.7 (22.1 to 29.1)	48.2 (41.7 to 56.6)	85.9 (51.0 to 139.0)	1.6 (-19.4 to 32.2)	3.8 (2.6 to 5.2)	7.1 (4.7 to 9.7)	84.5 (47.4 to 136.2)	1.2 (-20.4 to 32.2)
Hemorrhagic stroke	7.0 (5.8 to 8.1)	12.4 (10.2 to 14.8)	77.2 (38.4 to 127.2)	-0.1 (-22.9 to 29.2)	1.1 (0.7 to 1.5)	1.9 (1.3 to 2.7)	76.8 (34.8 to 131.5)	0.0 (-24.9 to 32.8)
Hypertensive heart disease	50.5 (40.4 to 61.5)	102.9 (85.3 to 124.2)	103.4 (58.1 to 169.9)	3.8 (-20.6 to 40.5)	5.5 (3.6 to 7.8)	11.0 (7.3 to 15.6)	102.1 (56.4 to 170.1)	3.4 (-21.1 to 40.2)
Cardiomyopathy and myocarditis	28.1 (23.0 to 33.4)	61.4 (52.8 to 72.3)	118.4 (78.9 to 167.6)	24.8 (-1.3 to 58.2)	3.0 (2.0 to 4.2)	6.6 (4.3 to 9.2)	116.4 (75.8 to 170.2)	20.6 (-2.7 to 58.8)
Atrial fibrillation and flutter	141.0 (113.1 to 167.1)	344.7 (283.6 to 416.3)	143.5 (92.2 to 216.3)	12.6 (-12.5 to 48.3)	10.6 (7.0 to 14.9)	25.9 (17.0 to 37.1)	143.5 (92.2 to 216.0)	13.1 (-12.0 to 48.4)
Peripheral vascular disease	1,266.1 (994.2 to 1,586.4)	2,426.9 (1,947.5 to 2,903.7)	95.0 (38.0 to 156.9)	1.8 (-26.1 to 33.8)	0.8 (0.3 to 1.5)	1.4 (0.6 to 2.9)	83.3 (-11.5 to 257.3)	-12.1 (-57.8 to 71.5)
Endocarditis	1.1 (0.8 to 1.4)	1.1 (0.8 to 1.3)	-0.0 (-25.6 to 33.6)	-36.4 (-51.2 to -44.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-5.2 (-33.3 to 36.2)	-38.8 (-56.6 to -11.3)
Other cardiovascular and circulatory diseases	138.4 (76.0 to 237.2)	376.9 (136.8 to 609.3)	177.3 (-8.7 to 493.0)	55.6 (-49.4 to 241.5)	9.7 (4.7 to 17.8)	9.7 (4.7 to 17.8)	9.7 (-10.0 to 492.9)	55.

Appendix Table G.4 - South Africa prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumonia	-	-	-	-	0.1	0.2	66.6	-
Silicosis	0.2	0.3	57.5	-15.2	0.0	0.1	56.6	-15.5
Asbestosis	0.1	0.2	70.4	-8.2	0.0	0.0	69.4	-8.6
Coal workers pneumoconiosis	0.2	0.3	69.8	-6.4	0.0	0.1	68.5	-7.0
Other pneumoconiosis	0.4	0.7	75.7	-2.6	0.0	0.1	73.3	-3.2
Asthma	1,881.4	2,863.7	53.1	-0.7	82.8	125.8	52.7	-6.2
Interstitial lung disease and pulmonary sarcoidosis	0.9	1.6	80.4	8.8	0.1	0.2	79.9	8.4
Other chronic respiratory diseases	-	-	-	-	10.4	12.4	18.3	-32.1
Cirrhosis	-	-	-	-	6.2	7.1	14.5	-5.7
Cirrhosis due to hepatitis B	2.6	4.4	67.8	0.8	0.4	0.7	64.6	-0.7
Cirrhosis due to hepatitis C	2.0	3.6	78.1	0.4	0.3	0.6	77.7	3.1
Cirrhosis due to alcohol use	5.4	7.0	28.5	-26.8	0.9	1.1	27.9	-26.7
Cirrhosis due to other causes	3.8	6.3	65.5	18.8	0.6	1.1	63.9	18.4
Digestive diseases	-	-	-	-	44.6	79.2	78.1	3.5
Peptic ulcer disease	226.3	274.6	21.2	-35.7	8.6	10.4	21.2	-36.2
Gastritis and duodenitis	417.0	708.0	69.8	6.0	18.1	28.8	59.3	1.3
Appendicitis	4.4	7.6	75.1	13.7	1.3	2.3	73.1	12.3
Paralytic ileus and intestinal obstruction	0.4	0.7	68.0	-2.2	0.1	0.2	61.5	-2.8
Inguinal, femoral, and abdominal hernia	89.9	122.0	35.8	-25.4	0.9	1.3	35.6	-25.2
Inflammatory bowel disease	39.7	84.5	112.2	24.9	8.4	17.7	110.3	24.5
Vascular intestinal disorders	0.1	0.1	61.4	-11.7	0.0	0.0	64.1	-9.0
Gallbladder and biliary diseases	13.0	29.6	127.5	0.4	1.4	3.0	124.5	19.5
Pancreatitis	7.2	13.1	81.5	4.6	2.1	3.8	80.4	4.6
Other digestive diseases	-	-	-	-	3.6	11.7	231.0	92.2
Neurological disorders	-	-	-	-	168.5	293.1	74.4	5.7
Alzheimer disease and other dementias	91.9	205.6	123.8	7.6	13.0	29.6	128.1	8.4
Parkinson disease	3.3	6.3	91.7	-0.9	0.4	0.8	90.9	-0.6
Epilepsy	48.4	71.5	50.4	3.4	15.0	22.6	53.1	5.9
Multiple sclerosis	3.6	6.9	93.9	13.2	1.2	2.3	91.9	12.2
Migraine	2,716.7	4,205.2	54.9	-0.4	92.6	141.5	50.0	-1.2
Tension-type headache	4,830.0	8,083.9	67.7	4.7	7.3	12.2	66.6	4.4
Medication overuse headache	194.4	481.6	146.5	51.3	30.4	74.4	144.5	50.6
Other neurological disorders	0.1	0.1	40.7	-7.4	8.6	9.7	12.7	-45.2
Mental and substance use disorders	-	-	-	-	873.9	1,363.2	56.2	0.5
Schizophrenia	86.9	144.6	66.4	-1.4	43.9	72.6	65.2	-1.9
Alcohol use disorders	388.2	1,005.9	159.6	58.9	38.3	99.6	160.8	59.8
Drug use disorders	-	-	-	-	52.2	83.3	59.8	-1.9
Opioid use disorders	70.2	115.6	63.4	-3.0	28.8	46.6	61.6	-3.9
Cocaine use disorders	20.2	34.3	69.1	2.7	6.6	11.1	66.9	1.2
Amphetamine use disorders	62.2	96.4	55.1	1.9	8.1	12.5	53.7	1.0
Cannabis use disorders	54.3	80.5	48.1	-0.0	1.6	2.3	48.5	0.1
Other drug use disorders	49.0	73.0	48.6	-0.1	1.0	1.7	57.8	1.5
Depressive disorders	-	-	-	-	11.0	17.2	57.3	1.5
Major depressive disorder	1,263.8	2,024.3	60.4	1.0	258.5	408.6	58.3	0.1
Dysthymia	416.4	704.0	69.1	0.9	40.0	66.9	67.6	0.2
Bipolar disorder	228.5	376.5	64.9	0.6	46.3	75.3	62.9	-0.2
Anxiety disorders	1,653.9	2,465.5	49.4	-2.0	152.1	224.5	49.7	-2.7
Eating disorders	-	-	-	-	9.5	13.9	46.6	-0.4
Anorexia nervosa	6.5	9.5	45.2	1.2	1.4	2.0	44.3	1.0
Bulimia nervosa	38.3	56.6	47.7	-0.3	8.1	11.9	46.7	-0.8
Autistic spectrum disorders	-	-	-	-	43.9	62.0	41.3	-1.2
Autism	112.8	161.0	42.7	-0.8	27.8	39.3	41.5	-1.2
Asperger syndrome	161.5	229.1	41.9	-1.1	16.1	22.7	41.1	-1.3
Attention-deficit/hyperactivity disorder	245.0	308.4	25.9	0.3	3.0	3.7	25.9	0.3
Conduct disorder	357.7	445.9	24.6	0.3	42.9	53.5	24.8	0.4
Idiopathic intellectual disability	1,575.0	2,292.9	46.5	-12.4	27.0	42.5	55.6	-12.5
Other mental and substance use disorders	520.5	870.1	67.2	-0.9	38.7	64.1	66.6	-1.6
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	231.8	392.7	69.8	2.9
Diabetes mellitus	1,218.0	2,378.5	95.3	13.2	83.5	162.0	91.1	10.0
Acute glomerulonephritis	0.2	0.2	10.0	-18.1	0.0	0.0	18.1	-18.1
Chronic kidney disease	-	-	-	-	66.8	109.9	64.6	0.8
Chronic kidney disease due to diabetes mellitus	585.1	1,031.6	76.9	0.3	8.8	15.3	75.2	-0.1
Chronic kidney disease due to hypertension	1,607.2	2,444.9	50.1	-2.8	21.4	37.2	74.8	2.6
Chronic kidney disease due to glomerulonephritis	1,492.0	2,513.0	68.3	-2.2	69.3	117.4	70.3	-1.9
Chronic kidney disease due to other causes	1,016.2	1,581.6	55.8	-0.6	13.7	22.1	59.5	-0.9
Urinary diseases and male infertility	-	-	-	-	13.1	23.5	79.9	-3.8

Appendix Table G.4 - South Africa prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013	
Interstitial nephritis and urinary tract infections	7.5 (7.0 to 8.0)	12.4 (11.7 to 13.3)	66.0 (51.3 to 81.8)	0.2 (-1.5 to 15.7)	0.2 (0.2 to 0.4)	0.4 (0.3 to 0.6)	65.3 (31.6 to 104.3)	7.0 (-1.8 to 28.3)	
Urolithiasis	86.2 (65.4 to 123.5)	142.6 (103.7 to 189.4)	68.1 (40.6 to 93.0)	-10.2 (-24.6 to 1.8)	1.0 (0.6 to 1.4)	1.7 (1.1 to 2.4)	78.7 (57.3 to 105.1)	0.7 (-10.1 to 14.5)	
Benign prostatic hyperplasia	278.8 (251.6 to 309.2)	494.4 (454.8 to 535.4)	77.5 (55.0 to 101.2)	-7.2 (-18.6 to 5.5)	9.9 (6.4 to 14.1)	17.6 (11.4 to 24.8)	77.6 (55.0 to 102.1)	-6.9 (-18.4 to 5.9)	
Male infertility due to other causes	134.3 (103.1 to 164.8)	207.5 (163.7 to 257.1)	54.5 (34.0 to 108.0)	-4.1 (-29.3 to 29.5)	0.9 (0.4 to 1.8)	1.3 (0.6 to 2.7)	52.8 (9.7 to 111.2)	-4.6 (-31.2 to 30.0)	
Other urinary diseases	-	-	-	-	-	1.1 (0.6 to 1.7)	2.4 (1.4 to 3.9)	26.6 (71.1 to 220.4)	-2.3 (-1.0 to 85.4)
Gynecological diseases	-	-	-	-	39.9 (25.3 to 59.8)	64.8 (41.3 to 96.5)	62.0 (38.5 to 89.3)	-1.0 (-13.5 to 14.9)	
Uterine fibroids	640.4 (579.6 to 697.3)	1,151.4 (1,046.0 to 1,248.7)	79.7 (78.5 to 81.1)	5.2 (5.0 to 5.4)	9.3 (5.3 to 15.3)	13.9 (7.8 to 23.4)	50.0 (31.9 to 64.1)	-10.4 (-20.8 to -1.9)	
Polycystic ovarian syndrome	585.3 (526.9 to 647.3)	987.5 (870.5 to 1,081.1)	69.6 (46.6 to 92.9)	4.3 (-8.9 to 17.8)	5.7 (2.7 to 10.3)	9.5 (4.4 to 18.1)	68.5 (45.6 to 92.3)	3.7 (-9.5 to 17.7)	
Female infertility due to other causes	179.2 (116.1 to 248.7)	291.0 (190.2 to 400.5)	62.4 (3.5 to 166.2)	-0.8 (-37.6 to 66.4)	0.9 (0.3 to 2.1)	1.5 (0.6 to 3.3)	58.9 (2.6 to 154.8)	-2.3 (-8.0 to 62.5)	
Endometriosis	59.0 (50.3 to 68.1)	90.5 (75.5 to 105.6)	53.7 (21.1 to 90.8)	-6.0 (-25.4 to 16.1)	5.4 (3.6 to 7.6)	8.2 (5.4 to 11.6)	51.8 (18.2 to 90.8)	-7.4 (-27.3 to 15.1)	
Genital prolapse	1,314.7 (1,135.8 to 1,493.8)	2,413.5 (2,006.9 to 2,795.8)	83.1 (48.6 to 127.2)	5.6 (-12.6 to 29.2)	4.2 (2.0 to 7.9)	7.6 (3.5 to 14.4)	82.1 (46.8 to 129.0)	5.1 (-13.2 to 29.3)	
Premenstrual syndrome	1,377.2 (955.6 to 1,850.2)	2,533.3 (1,759.0 to 3,555.8)	83.3 (14.3 to 179.1)	15.8 (-26.9 to 73.8)	11.5 (6.3 to 18.5)	21.0 (10.7 to 34.8)	82.1 (13.1 to 181.3)	14.7 (-23.4 to 73.2)	
Other gynecological diseases	106.9 (85.5 to 129.4)	128.7 (110.5 to 150.2)	20.4 (-5.3 to 55.1)	-23.4 (-39.4 to -2.2)	6.3 (1.6 to 14.2)	3.0 (1.7 to 4.5)	6.1 (-23.3 to 65.9)	-32.6 (-51.7 to 4.4)	
Hemoglobinopathies and hemolytic anemias	-	-	-	-	13.7 (8.9 to 19.9)	15.6 (9.9 to 22.3)	13.8 (-0.2 to 34.8)	-12.8 (-22.2 to 1.5)	
Thalassemias	1.0 (0.6 to 1.7)	0.2 (0.0 to 0.3)	-77.7 (-83.8 to -71.0)	-84.1 (-89.9 to -79.1)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.0)	-78.8 (-84.2 to -73.1)	-85.0 (-89.3 to -80.6)	
Thalassemia trait	165.1 (130.7 to 196.6)	231.9 (180.8 to 280.4)	43.9 (15.0 to 47.4)	0.0 (-19.7 to 2.4)	3.4 (2.2 to 4.9)	4.9 (3.3 to 7.3)	44.6 (23.1 to 67.0)	6.7 (-7.8 to 22.1)	
Sickle cell disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	31.1 (16.5 to 37.2)	1.0 (-10.6 to 5.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.4 (15.8 to 48.6)	4.4 (-14.0 to 11.5)	
Sickle cell trait	113.7 (103.6 to 120.2)	164.1 (150.6 to 174.3)	43.6 (38.7 to 53.7)	0.4 (-3.6 to 6.9)	0.4 (0.2 to 0.7)	0.6 (0.3 to 1.0)	43.6 (-27.3 to 201.8)	21.5 (-36.4 to 145.5)	
G6PD deficiency	621.2 (604.1 to 636.7)	919.1 (897.5 to 945.1)	47.8 (42.6 to 53.9)	2.7 (-0.9 to 6.9)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	57.3 (44.9 to 69.8)	16.8 (9.9 to 24.5)	
G6PD trait	4,157.3 (4,124.3 to 4,195.9)	5,968.0 (5,905.6 to 6,025.9)	43.6 (41.4 to 45.9)	-0.0 (-1.5 to 1.6)	0.2 (0.1 to 0.3)	0.2 (0.0 to 0.3)	-1.7 (-71.1 to 158.7)	-19.4 (-73.4 to 103.4)	
Other hemoglobinopathies and hemolytic anemias	344.1 (297.7 to 377.7)	361.9 (328.4 to 392.7)	5.0 (-5.3 to 21.6)	-25.5 (-31.7 to -16.2)	9.5 (5.9 to 14.1)	2.2 (6.2 to 14.2)	2.2 (-16.4 to 34.1)	-21.2 (-33.8 to -0.4)	
Endocrine, metabolic, blood, and immune disorders	442.7 (416.6 to 480.3)	504.9 (466.0 to 540.7)	14.2 (0.9 to 26.2)	-15.6 (-24.2 to -7.7)	14.8 (9.9 to 21.3)	17.0 (11.5 to 24.2)	14.5 (-2.3 to 33.5)	-11.4 (-23.0 to 2.6)	
Musculoskeletal disorders	-	-	-	-	545.5 (389.0 to 723.5)	1,002.2 (710.8 to 1,322.4)	84.0 (71.2 to 96.9)	5.9 (-0.3 to 12.3)	
Rheumatoid arthritis	92.5 (85.8 to 99.0)	189.4 (178.5 to 199.9)	105.3 (86.8 to 124.9)	15.3 (4.9 to 27.4)	21.7 (15.4 to 28.7)	43.9 (31.7 to 57.9)	102.7 (83.4 to 125.7)	15.0 (3.6 to 28.0)	
Osteoarthritis	897.5 (864.3 to 929.8)	1,748.9 (1,677.9 to 1,811.3)	95.0 (84.6 to 105.2)	3.2 (-2.3 to 8.3)	54.5 (37.7 to 73.9)	105.5 (74.1 to 143.7)	93.9 (82.9 to 104.3)	3.0 (-2.6 to 8.1)	
Low back and neck pain	-	-	-	-	412.6 (288.8 to 553.6)	727.3 (508.7 to 963.6)	76.3 (60.4 to 93.3)	2.8 (-5.4 to 11.7)	
Low back pain	2,210.3 (2,082.3 to 2,334.9)	3,799.8 (3,594.9 to 4,023.7)	72.2 (58.1 to 86.7)	0.3 (-7.6 to 8.1)	244.4 (166.8 to 340.5)	415.7 (283.1 to 573.7)	70.3 (56.5 to 85.4)	-0.2 (-8.4 to 8.1)	
Neck pain	1,719.9 (1,478.2 to 1,991.4)	3,211.1 (2,776.4 to 3,626.1)	87.1 (52.9 to 126.6)	8.2 (-9.6 to 30.8)	168.2 (114.4 to 233.8)	311.7 (209.9 to 435.9)	86.0 (50.7 to 125.5)	7.7 (-10.7 to 30.4)	
Gout	8.0 (7.2 to 8.8)	13.5 (12.3 to 14.8)	68.0 (45.8 to 95.2)	-7.8 (-19.2 to 6.9)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	68.4 (31.9 to 115.5)	-7.4 (-27.8 to 18.1)	
Other musculoskeletal disorders	623.9 (473.1 to 787.4)	1,398.2 (1,053.7 to 1,735.2)	123.6 (104.5 to 146.5)	26.5 (15.4 to 37.7)	56.4 (36.3 to 82.6)	125.4 (80.0 to 185.4)	120.9 (102.1 to 146.3)	25.4 (14.6 to 37.5)	
Other non-communicable diseases	-	-	-	-	451.3 (288.0 to 680.4)	701.0 (457.9 to 1,045.6)	55.4 (48.1 to 62.8)	-3.2 (-7.2 to 0.6)	
Congenital anomalies	-	-	-	-	25.3 (18.6 to 33.0)	47.3 (33.7 to 64.6)	85.5 (53.3 to 135.6)	28.1 (6.0 to 62.3)	
Neural tube defects	7.1 (5.9 to 8.7)	10.2 (9.2 to 11.3)	44.4 (16.9 to 75.9)	8.9 (-12.3 to 33.5)	2.0 (1.2 to 2.9)	3.0 (2.0 to 4.1)	51.7 (9.0 to 106.7)	16.0 (-16.0 to 55.4)	
Congenital heart anomalies	96.3 (72.1 to 125.5)	200.6 (161.6 to 242.8)	112.2 (52.4 to 180.1)	55.6 (10.7 to 105.8)	3.3 (1.6 to 5.9)	6.7 (2.8 to 12.2)	102.0 (44.9 to 165.8)	50.6 (7.7 to 98.2)	
Orofacial clefts	14.2 (10.4 to 18.1)	27.6 (22.1 to 35.1)	93.8 (40.4 to 197.1)	0.4 (7.2 to 128.5)	0.4 (0.1 to 0.4)	0.4 (0.2 to 0.6)	11.9 (7.6 to 18.2)	31.5 (-17.6 to 115.6)	
Down syndrome	27.3 (22.4 to 33.0)	41.6 (35.2 to 49.6)	52.6 (19.4 to 100.6)	6.2 (-17.1 to 39.7)	3.3 (2.3 to 4.4)	5.0 (3.5 to 6.7)	54.9 (17.0 to 103.4)	4.8 (-21.2 to 37.9)	
Turner syndrome	1.2 (0.9 to 1.5)	1.6 (1.3 to 2.1)	41.0 (-5.1 to 103.3)	-0.2 (-32.9 to 45.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.4 (-5.3 to 116.2)	-0.2 (-33.1 to 47.6)	
Klinefelter syndrome	1.1 (0.8 to 1.4)	1.5 (1.1 to 2.0)	36.9 (-2.0 to 94.5)	-4.6 (-31.8 to 35.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.3 (4.8 to 110.0)	-4.5 (-32.2 to 35.8)	
Chromosomal unbalanced rearrangements	47.8 (39.5 to 56.8)	70.6 (55.9 to 83.9)	48.3 (10.3 to 102.9)	0.2 (-22.9 to 42.9)	0.5 (4.0 to 8.0)	0.5 (5.9 to 11.5)	48.7 (8.6 to 105.9)	1.2 (-26.4 to 39.6)	
Other congenital anomalies	92.4 (71.5 to 108.5)	119.2 (99.4 to 138.4)	28.2 (17.1 to 54.3)	-14.7 (-22.3 to 3.8)	10.7 (7.3 to 15.0)	23.7 (15.5 to 35.3)	117.4 (64.1 to 218.3)	46.9 (12.2 to 114.5)	
Skin and subcutaneous diseases	-	-	-	-	182.6 (113.9 to 288.9)	273.9 (173.9 to 433.2)	50.9 (34.7 to 63.6)	1.8 (-8.1 to 9.5)	
Dermatitis	1,619.3 (1,337.2 to 1,917.3)	2,471.7 (2,023.5 to 2,940.4)	52.6 (49.8 to 55.3)	0.1 (-0.1 to 0.3)	47.4 (31.6 to 68.1)	69.9 (45.1 to 99.4)	47.4 (41.6 to 53.0)	-0.2 (-3.2 to 2.7)	
Psoriasis	261.0 (222.7 to 302.1)	418.1 (355.3 to 485.3)	60.1 (58.1 to 62.6)	0.0 (-0.2 to 0.2)	21.2 (14.3 to 30.4)	33.6 (22.6 to 48.1)	38.6 (48.7 to 68.5)	-0.8 (-6.0 to 4.5)	
Cellulitis	8.0 (6.3 to 10.2)	12.0 (9.6 to 15.2)	48.7 (36.6 to 73.8)	-2.1 (-10.6 to 8.7)	0.6 (0.3 to 0.9)	0.9 (0.5 to 1.3)	48.6 (19.7 to 85.9)	2.0 (-19.8 to 19.6)	
Pyoderma	56.8 (42.7 to 72.0)	69.0 (53.4 to 88.1)	21.6 (10.8 to 34.0)	-4.4 (-10.7 to 2.8)	0.4 (0.1 to 0.7)	0.4 (0.2 to 0.9)	21.0 (7.3 to 37.2)	-4.5 (-13.5 to 6.2)	
Scabies	359.6 (319.3 to 399.4)	447.7 (399.3 to 497.8)	24.6 (5.8 to 45.0)	-12.2 (-24.9 to 2.1)	9.3 (5.2 to 14.8)	11.5 (6.5 to 18.5)	24.5 (4.2 to 44.9)	-12.3 (-25.6 to 1.9)	
Fungal skin diseases	4,236.0 (3,237.8 to 5,566.7)	6,318.4 (4,933.9 to 8,337.5)	49.2 (44.5 to 55.2)	49.2 (-0.3 to 0.0)	49.2 (9.3 to 52.6)	35.6 (14.1 to 78.2)	48.4 (43.5 to 54.2)	-0.4 (-1.1 to 0.4)	
Viral skin diseases	682.1 (521.4 to 838.7)	903.5 (680.9 to 1,149.2)	32.3 (25.9 to 38.8)	-0.1 (-2.4 to 2.1)	21.1 (12.2 to 33.2)	27.8 (16.1 to 43.8)	31.7 (24.4 to 39.0)	0.3 (-4.0 to 3.2)	
Acne vulgaris	3,187.3 (2,336.6 to 4,084.6)	4,252.7 (2,965.8 to 5,555.4)	34.3 (-23.1 to 102.8)	-3.4 (-44.7 to 43.1)	34.6 (15.0 to 66.7)	45.8 (20.4 to 91.5)	34.4 (-23.8 to 102.3)	-3.4 (-44.9 to 43.6)	
Alopecia areata	34.7 (31.2 to 38.7)	53.8 (47.5 to 60.1)	55.5 (32.4 to 78.5)	-0.7 (-14.6 to 14.5)	1.2 (0.7 to 1.8)	1.8 (1.1 to 2.7)	54.2 (26.0 to 82.1)	-0.9 (-17.1 to 17.5)	
Pruritus	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	59.7 (25.2 to 109.0)	0.4 (-22.8 to 28.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.7 (25.1 to 103.3)	-0.4 (-23.1 to 28.7)	
Urticaria	171.7 (110.9 to 241.9)	425.0 (266.0 to 569.1)	150.9 (39.4 to 331.7)	40.7 (-18.8 to 129.0)	10.1 (5.4 to 16.9)	25.0 (13.5 to 38.8)	149.5 (37.1 to 336.4)	43.0 (-19.2 to 131.7)	
Decubitus ulcer	5.0 (4.2 to 6.0)	10.5 (8.6 to 12.5)	108.3 (61.1 to 174.4)	10.1 (-19.5 to 55.0)	0.7 (0.5 to 1.0)	1.5 (1.0 to 2.1)	105.0 (54.4 to 175.7)	10.1 (-20.8 to 58.5)	
Other skin and subcutaneous diseases	2,104.2 (1,421.1 to 3,020.0)	3,507.8 (2,320.0 to 5,161.5)	66.5 (57.0 to 75.8)	-0.1 (-3.1 to 2.8)	12.3 (5.4 to 25.4)	20.4 (8.9 to 42.8)	65.6 (55.8 to 74.9)	-0.3 (-3.5 to 2.8)	
Sense organ diseases	-	-	-	-	183.1 (115.8 to 276.2)	283.3 (178.7 to 427.9)	54.8 (47.9 to 61.1)	-8.2 (-12.1 to -4.2)	
Glaucoma	108.6 (89.2 to 131.5)	132.9 (108.4 to 158.8)	22.8 (1.7 to 42.8)	-31.8 (-44.7 to -39.1)	5.2 (3.4 to 7.4)	7.1 (4.5 to 10.2)	36.3 (15.2 to 58.0)	-24.5 (-36.5 to -11.4)	
Cataract	149.7 (113.4 to 189.4)	226.6 (182.0 to 282.1)	52.4 (22.0 to 82.9)	-22.7 (-37.0 to -7.7)	7.0 (4.3 to 10.1)	10.5 (6.8 to 15.2)	51.8 (24.4 to 78.1)	-23.6 (-37.1 to -10.3)	
Macular degeneration	54.2 (40.7 to 68.3)	97.3 (75.5 to 119.7)	80.3 (42.2 to 121.7)	-0.0 (-26.2 to 15.8)	2.0 (1.3 to 3.1)	3.7 (2.3 to 5.3)	80.9 (43.4 to 121.2)	-7.1 (-25.5 to 13.1)	
Uncorrected refractive error	4,256.7 (3,974.5 to 4,508.2)	6,878.8 (6,438.5 to 7,287.1)	61.5 (48.6 to 76.2)	3.4 (-10.5 to 14.9)	36.4 (31.0 to 95.1)	86.3 (46.3 to 146.3)	52.5 (42.5 to 64.8)	-8.0 (-13.6 to -2.9)	
Age-related and other hearing loss	4,686.1 (4,228.8 to 5,179.3)	7,644.6 (6,814.6 to 8,414.4)	62.9 (57.2 to 69.6)	-7.5 (-10.2 to -4.4)	84.0 (52.7 to 129.4)	136.7 (84.6 to 209.3)	69.6 (52.2 to 73.8)	52.6 (-11.6 to 27.1)	
Other vision loss	115.3 (98.3 to 136.4)	152.2 (125.7 to 181.2)	31.5 (19.4 to 45.9)	-20.8 (-28.8 to -12.5)	5.9 (3.9 to 8.6)	7.4 (4.8 to 10.7)	25.8 (12.5 to 40.8)	-4.1 (-31.5 to -15.8)	
Other sense organ diseases	852.9 (811.5 to 896.5)	1,199.2 (1,140.5 to 1,258.9)	40.5 (30.7 to 50.4)	0.2 (-6.3 to 7.0)	22.7 (13.9 to 33.5)	31.6 (19.6 to 46.9)	39.2 (28.9 to 51.4)	0.0 (-6.8 to 7.6)	
Oral disorders	-	-	-	-					

Appendix Table G.4 - South Africa prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	910.9 (861.2 to 964.0)	1,517.3 (1,426.0 to 1,628.1)	66.1 (52.3 to 82.3)	-10.7 (-18.1 to -2.5)	25.0 (16.7 to 34.6)	41.3 (27.9 to 57.1)	65.5 (51.9 to 81.7)	65.5 (-18.4 to -2.3)
Other oral disorders	586.3 (548.8 to 619.6)	918.2 (865.3 to 973.7)	56.1 (43.5 to 71.2)	-0.6 (-8.0 to 8.5)	17.1 (10.7 to 25.6)	26.7 (16.9 to 39.2)	55.3 (42.9 to 71.6)	-0.9 (-8.6 to 8.4)
Injuries	-	-	-	-	207.7 (156.1 to 271.8)	195.7 (146.4 to 256.9)	-5.2 (-19.0 to 7.1)	-43.7 (-51.3 to -36.9)
Transport injuries	-	-	-	-	49.7 (37.7 to 64.3)	37.8 (27.7 to 49.8)	-24.2 (-31.5 to -15.5)	-53.8 (-58.0 to -49.1)
Road injuries	-	-	-	-	45.8 (34.7 to 59.1)	32.9 (24.2 to 43.5)	-28.2 (-35.1 to -19.6)	-96.1 (-60.1 to -51.4)
Pedestrian road injuries	-	-	-	-	10.3 (7.8 to 13.3)	7.8 (5.6 to 10.3)	-24.7 (-33.3 to -14.3)	-52.5 (-57.3 to -46.4)
Cyclist road injuries	-	-	-	-	4.5 (3.4 to 5.9)	2.9 (2.1 to 3.8)	-36.7 (-42.1 to -30.5)	-61.8 (-65.0 to -58.0)
Motorcyclist road injuries	-	-	-	-	7.6 (5.7 to 9.9)	5.2 (3.7 to 7.0)	-32.1 (-40.0 to -22.3)	-59.4 (-63.9 to -54.2)
Motor vehicle road injuries	-	-	-	-	22.5 (17.1 to 29.1)	16.7 (12.4 to 21.8)	-26.1 (-34.8 to -16.8)	-95.1 (-59.8 to -49.7)
Other road injuries	-	-	-	-	0.8 (0.6 to 1.0)	0.4 (0.3 to 0.5)	-47.1 (-52.5 to -40.2)	-68.6 (-71.6 to -64.7)
Other transport injuries	-	-	-	-	4.0 (3.0 to 5.2)	4.8 (3.6 to 6.4)	21.8 (9.9 to 35.3)	-29.0 (-35.7 to -21.3)
Unintentional injuries	-	-	-	-	120.4 (91.7 to 154.9)	130.8 (97.4 to 172.8)	8.3 (0.3 to 19.0)	-38.0 (-42.6 to -31.9)
Falls	-	-	-	-	71.1 (53.9 to 91.8)	73.1 (53.3 to 97.4)	2.3 (-6.3 to 13.4)	-43.1 (-48.0 to -36.7)
Drowning	-	-	-	-	2.1 (1.5 to 2.7)	1.8 (1.3 to 2.4)	-14.8 (-25.4 to -2.5)	-44.3 (-50.8 to -37.1)
Fire, heat, and hot substances	-	-	-	-	8.3 (6.4 to 10.5)	11.4 (8.3 to 15.2)	36.1 (20.2 to 54.7)	-14.5 (-24.0 to -3.7)
Poisonings	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	8.9 (6.4 to 27.8)	-29.8 (-38.8 to -19.0)
Exposure to mechanical forces	-	-	-	-	21.6 (16.9 to 28.1)	27.4 (20.2 to 36.8)	26.3 (15.5 to 39.8)	-22.1 (-29.1 to -13.3)
Unintentional firearm injuries	-	-	-	-	0.9 (0.7 to 1.1)	1.9 (1.4 to 2.5)	115.8 (90.6 to 146.4)	30.6 (15.7 to 48.8)
Unintentional suffocation	-	-	-	-	0.3 (0.3 to 0.4)	0.5 (0.4 to 0.6)	46.1 (30.6 to 62.2)	-10.2 (-19.1 to -0.8)
Other exposure to mechanical forces	-	-	-	-	20.4 (15.5 to 26.6)	25.1 (18.4 to 34.0)	22.2 (11.3 to 35.3)	-24.6 (-31.6 to -16.0)
Adverse effects of medical treatment	-	-	-	-	0.7 (0.4 to 1.0)	1.5 (0.9 to 2.2)	119.5 (106.1 to 132.2)	30.4 (22.3 to 38.4)
Animal contact	-	-	-	-	2.5 (1.9 to 3.3)	2.7 (2.0 to 3.6)	7.1 (-1.7 to 18.4)	-32.1 (-37.4 to -25.9)
Venomous animal contact	-	-	-	-	1.1 (0.8 to 1.4)	1.2 (0.9 to 1.6)	12.6 (1.0 to 27.9)	-28.4 (-35.5 to -19.4)
Non-venomous animal contact	-	-	-	-	1.4 (1.1 to 1.9)	1.5 (1.1 to 2.0)	2.7 (-6.7 to 14.5)	-34.9 (-40.7 to -28.0)
Foreign body	-	-	-	-	2.0 (1.5 to 2.6)	1.9 (1.4 to 2.5)	-6.0 (-14.9 to 6.2)	-43.4 (-48.8 to -36.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.5 (0.4 to 0.7)	0.6 (0.4 to 0.7)	9.8 (5.1 to 27.2)	-27.1 (-35.9 to -16.6)
Foreign body in eyes	-	-	-	-	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	24.2 (8.2 to 43.2)	-21.1 (-32.8 to -9.4)
Foreign body in other body part	-	-	-	-	1.2 (0.9 to 1.5)	0.9 (0.7 to 1.2)	-21.1 (-30.0 to -8.7)	-54.4 (-59.5 to -47.1)
Other unintentional injuries	-	-	-	-	11.8 (8.9 to 15.4)	10.9 (8.2 to 14.2)	-8.1 (-15.2 to 0.1)	-46.0 (-50.2 to -41.3)
Self-harm and interpersonal violence	-	-	-	-	12.3 (9.4 to 15.7)	19.8 (14.7 to 26.4)	60.7 (43.9 to 83.7)	-1.7 (-11.5 to 12.2)
Self-harm	-	-	-	-	1.0 (0.7 to 1.3)	2.3 (1.7 to 3.1)	141.0 (117.7 to 170.2)	38.6 (25.4 to 53.6)
Interpersonal violence	-	-	-	-	11.3 (8.7 to 14.4)	17.5 (13.0 to 23.3)	53.9 (37.0 to 77.3)	-5.5 (-15.7 to 8.3)
Assault by firearm	-	-	-	-	1.7 (1.2 to 2.1)	2.7 (2.0 to 3.6)	61.8 (46.1 to 81.7)	-1.6 (-10.6 to 9.8)
Assault by sharp object	-	-	-	-	2.2 (1.7 to 2.9)	4.5 (3.1 to 6.3)	102.7 (75.6 to 140.7)	22.4 (5.7 to 45.4)
Assault by other means	-	-	-	-	7.5 (5.7 to 9.5)	10.4 (7.8 to 13.4)	37.6 (23.0 to 58.5)	15.1 (-23.6 to -2.4)
Forces of nature, war, and legal intervention	-	-	-	-	25.4 (9.1 to 61.8)	7.4 (2.8 to 16.2)	-70.4 (-77.8 to -61.2)	-78.6 (-83.7 to -71.9)
Exposure to forces of nature	-	-	-	-	-	0.1 (0.0 to 0.1)	-	-
Collective violence and legal intervention	-	-	-	-	25.4 (9.1 to 61.8)	7.3 (2.8 to 16.1)	-70.7 (-78.0 to -61.7)	-78.8 (-83.8 to -72.1)

Appendix Table G.4 - South Korea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	4,068.8 (3,007.8 to 5,256.6)	5,739.6 (4,224.5 to 7,439.6)	41.1 (37.1 to 45.1)	-2.2 (-4.6 to 0.4)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	431.2 (295.4 to 604.8)	415.9 (290.1 to 575.8)	-3.5 (-7.6 to 1.4)	-4.0 (-7.9 to 0.0)
HIV/AIDS and tuberculosis	-	-	-	-	27.2 (18.4 to 36.7)	32.4 (22.2 to 43.5)	19.1 (9.9 to 29.3)	-20.6 (-26.1 to -14.3)
Tuberculosis	88.5 (84.2 to 93.1)	105.0 (97.8 to 112.6)	18.6 (11.6 to 25.6)	-22.0 (-26.2 to -18.2)	27.1 (18.3 to 36.6)	31.7 (21.8 to 42.9)	17.2 (8.1 to 26.9)	-21.9 (-27.2 to -15.9)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.3)	0.7 (0.3 to 1.3)	371.3 (122.4 to 1,457.5)	251.8 (59.3 to 1,025.5)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	71.4 (-22.6 to 434.5)	17.1 (-48.2 to 269.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.4 (-22.7 to 436.7)	17.1 (-48.3 to 271.4)
HIV/AIDS resulting in other diseases	1.0 (0.3 to 1.5)	8.5 (4.6 to 13.5)	737.1 (408.6 to 2,256.0)	556.7 (296.6 to 1,783.1)	0.1 (0.0 to 0.3)	0.7 (0.3 to 1.2)	385.2 (123.0 to 1,666.7)	263.4 (59.1 to 2,489.9)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	30.4 (20.3 to 44.5)	26.8 (17.5 to 39.7)	-11.8 (-19.9 to -4.7)	-21.7 (-28.7 to -14.9)
Diarrheal diseases	13.4 (11.9 to 14.9)	15.0 (13.4 to 16.7)	11.6 (-3.5 to 31.5)	-0.2 (-14.0 to 17.3)	2.2 (1.4 to 3.1)	2.4 (1.6 to 3.4)	0.4 (-9.9 to 36.2)	0.4 (-17.0 to 23.9)
Intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-30.1 (-54.8 to -2.9)	-30.8 (-53.9 to -4.9)
Typhoid fever	0.3 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-25.7 (-44.2 to 0.6)	-26.7 (-43.9 to -2.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-25.7 (-44.2 to 0.7)	-26.7 (-44.0 to -2.5)
Paratyphoid fever	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-11.6 (-33.3 to 10.3)	-10.9 (-29.7 to 11.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.6 (-33.4 to 10.5)	-10.9 (-29.8 to 11.1)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-65.1 (-93.0 to 62.7)	-65.4 (-93.0 to 61.6)
Lower respiratory infections	19.2 (16.9 to 21.3)	14.9 (12.7 to 17.1)	-22.6 (-35.8 to -7.9)	-55.3 (-62.4 to -47.1)	2.0 (1.3 to 2.8)	1.5 (1.0 to 2.1)	-25.2 (-33.2 to -6.6)	-55.6 (-63.3 to -45.6)
Upper respiratory infections	856.0 (807.3 to 908.8)	865.7 (816.8 to 917.8)	1.0 (-6.6 to 10.1)	-1.5 (-9.2 to 7.0)	10.1 (5.7 to 16.9)	10.1 (5.7 to 17.0)	0.6 (-7.6 to 10.9)	-1.5 (-9.8 to 7.9)
Otitis media	445.8 (414.3 to 476.8)	451.3 (424.1 to 479.4)	1.2 (-6.3 to 9.3)	-11.5 (-17.7 to -4.9)	8.2 (4.8 to 13.5)	8.1 (4.7 to 13.0)	-0.3 (-8.9 to 9.2)	-12.4 (-19.7 to -5.0)
Meningitis	-	-	-	-	6.2 (4.1 to 8.7)	2.8 (1.7 to 4.2)	-55.1 (-70.0 to -36.9)	-59.8 (-73.2 to -43.5)
Pneumococcal meningitis	24.7 (15.3 to 39.0)	11.4 (7.0 to 19.5)	-54.2 (-64.1 to -42.3)	-64.4 (-72.3 to -55.6)	1.0 (1.5 to 3.3)	1.0 (0.7 to 1.4)	-57.2 (-66.7 to -42.2)	-63.2 (-70.8 to -50.7)
H influenzae type B meningitis	7.1 (2.7 to 14.5)	2.8 (0.9 to 6.3)	-63.4 (-82.4 to -22.1)	-67.1 (-83.2 to -22.7)	1.0 (0.5 to 1.7)	0.4 (0.2 to 0.8)	-62.5 (-81.9 to 4.1)	-62.8 (-82.1 to 4.3)
Meningococcal meningitis	3.8 (1.3 to 9.1)	2.4 (0.9 to 6.0)	-36.0 (-62.6 to 6.1)	-54.9 (-72.6 to -12.9)	0.5 (0.3 to 0.8)	0.4 (0.2 to 0.7)	-22.4 (-51.8 to 19.8)	-41.9 (-64.3 to -4.3)
Other meningitis	16.3 (7.3 to 32.4)	6.9 (2.5 to 15.3)	-58.0 (-80.2 to -33.7)	-64.2 (-81.4 to -38.6)	2.3 (1.3 to 3.8)	1.0 (0.5 to 1.8)	-56.6 (-80.9 to -17.9)	-59.8 (-81.9 to -24.6)
Encephalitis	2.3 (1.0 to 5.6)	2.7 (1.2 to 7.3)	19.6 (-17.2 to 48.3)	-15.3 (-39.4 to 7.5)	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	30.2 (9.9 to 64.3)	3.7 (-24.3 to 21.4)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-78.3 (-97.9 to 107.7)	-80.2 (-98.0 to 65.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-78.3 (-97.9 to 110.2)	-80.2 (-98.0 to 66.4)
Whooping cough	11.4 (8.9 to 14.5)	2.2 (1.7 to 2.8)	-80.5 (-82.0 to -78.9)	-72.2 (-74.4 to -70.0)	0.6 (0.3 to 0.9)	0.1 (0.1 to 0.2)	-80.5 (-84.4 to -76.7)	-72.1 (-77.7 to -66.7)
Tetanus	0.2 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-82.7 (-91.5 to -55.2)	-84.1 (-92.2 to -59.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-81.0 (-93.3 to -56.4)	-81.8 (-93.5 to -58.7)
Measles	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-96.5 (-97.2 to -96.0)	-96.0 (-95.9 to -94.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-96.5 (-97.2 to -96.0)	-95.0 (-95.9 to -94.1)
Varicella and herpes zoster	29.2 (26.8 to 31.6)	32.6 (29.0 to 36.9)	11.5 (-0.5 to 25.7)	-8.2 (-17.2 to 1.8)	0.9 (0.5 to 1.4)	1.3 (0.7 to 2.0)	44.2 (17.6 to 76.8)	-3.8 (-21.4 to 15.5)
Neglected tropical diseases and malaria	-	-	-	-	35.4 (23.9 to 48.8)	37.1 (24.6 to 51.5)	4.3 (-6.0 to 22.3)	-6.9 (-14.2 to 9.2)
Malaria	3.6 (2.9 to 4.4)	3.7 (2.9 to 4.6)	4.1 (-20.1 to 35.5)	4.5 (-18.3 to 35.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	3.2 (-9.4 to 0.1)	3.2 (-2.8 to 4.6)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-64.4 (-88.1 to 36.2)	-77.3 (-92.3 to -20.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-61.0 (-87.0 to 49.5)	-75.0 (-91.7 to -8.7)
Cystic echinococcosis	6.7 (6.2 to 7.2)	3.0 (2.8 to 3.2)	-56.4 (-60.7 to -49.3)	-69.8 (-73.0 to -65.4)	0.6 (0.4 to 0.9)	0.3 (0.2 to 0.4)	-55.9 (-65.6 to -40.8)	-69.2 (-75.7 to -60.2)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.9 (-80.5 to -22.5)	-50.5 (-83.3 to -34.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.9 (-80.5 to -22.5)	-50.5 (-83.3 to -34.2)
Intestinal nematode infections	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	23.3 (50.7 to 62.8)	-4.2 (-61.0 to 24.9)
Ascariasis	-	-	-32.2 (-62.2 to 29.1)	-42.0 (-67.0 to 5.4)	-	-	-	-
Trichuriasis	-	171.9 (90.8 to 297.6)	395.6 (150.1 to 906.0)	322.8 (123.2 to 720.9)	-	0.0 (0.0 to 0.0)	-	-
Hookworm disease	32.5 (23.9 to 43.8)	44.4 (24.9 to 72.2)	33.9 (-25.4 to 138.5)	7.2 (-43.0 to 61.8)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	23.3 (-50.7 to 62.8)	-4.2 (-61.0 to 24.9)
Food-borne trematodiasis	944.4 (857.6 to 1,020.3)	1,264.8 (1,088.7 to 1,400.4)	34.3 (21.0 to 43.4)	-7.9 (-16.6 to -1.5)	18.7 (12.2 to 26.2)	25.2 (16.5 to 35.6)	35.3 (19.3 to 47.8)	7.0 (-1.9 to 0.5)
Other neglected tropical diseases	480.1 (378.7 to 582.4)	390.2 (374.0 to 410.0)	-19.2 (-33.2 to 3.1)	-3.6 (-19.8 to 21.7)	15.7 (9.3 to 23.0)	11.3 (7.4 to 16.6)	-30.0 (-37.6 to 3.6)	-3.7 (-14.9 to 40.5)
Maternal disorders	-	-	-	-	0.8 (0.5 to 1.3)	0.7 (0.4 to 1.1)	-17.2 (-38.1 to 13.9)	-12.3 (-33.3 to 19.9)
Maternal hemorrhage	5.8 (5.1 to 6.7)	6.5 (4.7 to 8.1)	10.9 (-19.7 to 43.5)	16.9 (-14.9 to 51.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-0.6 (-4.8 to 66.2)	4.8 (-38.1 to 74.3)
Maternal sepsis and other maternal infections	1.8 (1.8 to 4.5)	4.0 (1.4 to 4.0)	-53.3 (-53.3 to 31.0)	-62.8 (-62.8 to -1.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-33.7 (-53.7 to -6.2)	-36.7 (-55.1 to -13.4)
Maternal hypertensive disorders	6.4 (2.9 to 10.6)	4.7 (2.3 to 7.9)	-27.6 (-51.2 to 21.8)	-23.3 (-44.8 to 25.4)	0.3 (0.1 to 0.6)	0.2 (0.1 to 0.4)	-27.9 (-55.3 to 33.5)	-22.5 (-50.2 to 36.7)
Obstructed labor	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-29.1 (-55.9 to 10.5)	-22.7 (-51.2 to 21.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-29.1 (-55.9 to 11.1)	-22.7 (-51.3 to 21.9)
Complications of abortion	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-14.4 (-35.4 to 22.3)	-9.0 (-31.5 to 30.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.4 (-35.4 to 22.4)	-9.0 (-31.5 to 30.9)
Other maternal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-12.7 (-42.8 to 45.1)	-7.3 (-38.4 to 51.7)
Neonatal disorders	-	-	-	-	39.0 (26.1 to 54.9)	54.9 (36.5 to 76.1)	41.3 (-0.8 to 93.9)	36.7 (-4.1 to 86.0)
Preterm birth complications	159.5 (113.1 to 220.7)	250.5 (176.3 to 363.0)	56.8 (23.4 to 99.6)	44.6 (14.1 to 84.5)	19.9 (13.1 to 28.6)	31.1 (20.7 to 43.5)	54.3 (15.1 to 120.3)	47.7 (10.5 to 110.4)
Neonatal encephalopathy due to birth asphyxia and trauma	48.6 (26.4 to 83.5)	34.1 (17.0 to 69.9)	-31.5 (-61.2 to 18.1)	-31.5 (-61.4 to 14.7)	9.5 (6.0 to 14.1)	7.3 (4.5 to 11.1)	-24.5 (-54.2 to 24.9)	-24.7 (-53.7 to 24.6)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	121.2 (106.0 to 135.7)	213.8 (192.2 to 234.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	118.9 (64.1 to 209.7)	216.5 (132.8 to 339.3)
Hemolytic disease and other neonatal jaundice	15.3 (5.3 to 42.5)	15.2 (4.1 to 34.8)	-2.6 (-75.9 to 359.2)	-4.7 (-76.0 to 342.6)	4.3 (1.6 to 11.0)	4.7 (1.3 to 10.5)	11.6 (-70.5 to 347.6)	6.3 (-71.0 to 332.3)
Other neonatal disorders	-	-	-	-	5.3 (2.4 to 8.9)	11.8 (6.8 to 18.1)	121.8 (18.3 to 372.2)	113.8 (14.2 to 352.2)
Nutritional deficiencies	-	-	-	-	275.7 (182.5 to 400.2)	243.8 (161.6 to 357.4)	-11.6 (-14.1 to -9.2)	-5.0 (-7.5 to -3.1)
Protein-energy malnutrition	0.7 (0.3 to 1.1)	0.4 (0.2 to 1.0)	-50.3 (-65.4 to 46.1)	-82.4 (-88.0 to -49.6)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-50.2 (-73.6 to 51.1)	-50.8 (-90.4 to -45.3)
Iodine deficiency	272.2 (125.5 to 461.8)	199.0 (119.2 to 293.8)	-24.9 (-65.0 to 77.6)	-36.8 (-70.2 to 46.9)	4.9 (2.0 to 9.7)	3.6 (1.7 to 6.4)	-24.9 (-65.2 to 76.8)	-36.4 (-70.1 to 45.9)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-

Appendix Table G.4 - South Korea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	9,133.3 (9,035.8 to 9,230.7)	9,167.3 (9,126.7 to 9,212.5)	0.3 (-0.9 to 1.6)	0.1 (-4.3 to -1.9)	270.6 (178.7 to 392.5)	240.1 (159.0 to 352.6)	-11.2 (-13.5 to -8.4)	-11.2 (-6.4 to -2.7)
Other nutritional deficiencies	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-39.9 (63.3 to 6.1)	-78.9 (-87.3 to -60.9)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	22.7 (14.4 to 35.7)	20.4 (12.4 to 33.0)	-10.9 (-19.0 to -0.8)	-5.9 (-13.3 to 2.8)
Sexually transmitted diseases excluding HIV	-	-	-	-	8.6 (4.7 to 16.3)	9.4 (4.9 to 17.5)	8.8 (-7.8 to 26.2)	-3.3 (-17.5 to 13.5)
Syphilis	1.6 (1.3 to 1.8)	3.3 (2.9 to 3.8)	107.2 (69.8 to 170.7)	11.5 (-6.9 to 40.9)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	106.6 (45.7 to 159.8)	12.3 (-19.3 to 60.4)
Chlamydial infection	2,040.1 (1,692.8 to 2,388.4)	1,996.3 (1,683.4 to 2,323.6)	-2.1 (-22.6 to 22.2)	-3.3 (-24.1 to 21.2)	5.6 (3.0 to 10.2)	5.5 (2.8 to 10.1)	-2.1 (-23.4 to 24.3)	-2.3 (-24.1 to 24.3)
Gonococcal infection	106.4 (81.5 to 142.3)	87.0 (68.5 to 113.9)	-18.5 (-42.8 to 19.5)	-10.7 (-37.5 to 31.0)	0.5 (0.3 to 0.9)	0.4 (0.2 to 0.7)	-14.8 (-43.0 to 23.2)	-7.6 (-38.7 to 33.3)
Trichomoniasis	162.4 (101.4 to 234.2)	212.0 (134.5 to 302.4)	31.0 (-25.4 to 128.6)	12.2 (-34.4 to 100.8)	0.2 (0.1 to 0.6)	0.3 (0.1 to 0.8)	32.4 (-30.7 to 171.4)	13.1 (-42.3 to 137.3)
Genital herpes	6,632.3 (6,280.0 to 6,946.3)	9,082.2 (8,498.1 to 9,668.1)	36.6 (25.8 to 47.6)	9.0 (-16.3 to -2.0)	1.8 (0.6 to 4.3)	2.3 (0.7 to 5.7)	21.3 (16.9 to 44.1)	-6.7 (-17.1 to -0.6)
Other sexually transmitted diseases	7.5 (5.3 to 9.8)	7.0 (5.1 to 9.0)	-5.6 (-26.4 to 14.6)	-22.1 (-38.2 to -6.1)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	0.2 (-32.6 to 52.9)	0.2 (-37.4 to 37.9)
Hepatitis	-	-	-	-	2.5 (1.6 to 3.7)	2.3 (1.5 to 3.5)	-7.9 (-21.0 to 9.2)	-24.3 (-34.3 to -11.1)
Hepatitis A	42.7 (41.1 to 44.4)	35.6 (34.0 to 37.2)	-16.7 (-17.3 to -16.2)	-14.2 (-15.9 to -12.5)	1.2 (0.8 to 1.8)	1.1 (0.7 to 1.6)	-7.4 (-17.0 to 4.6)	-10.8 (-20.2 to 0.2)
Hepatitis B	2,334.9 (2,378.3 to 2,695.9)	1,938.8 (1,806.5 to 2,072.3)	-23.5 (-30.4 to -16.4)	-37.8 (-43.0 to -32.4)	1.3 (0.8 to 1.9)	1.1 (0.7 to 1.7)	-10.2 (-30.2 to 22.7)	-35.2 (-52.3 to -12.0)
Hepatitis C	518.0 (482.0 to 554.4)	609.8 (561.2 to 653.5)	17.9 (6.1 to 30.1)	-31.5 (-38.3 to -24.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	23.4 (-15.3 to 73.1)	-28.5 (-50.6 to 2.7)
Hepatitis E	-	-	1.5 (-26.6 to 50.2)	-5.6 (-32.0 to 35.2)	-	-	-	-
Leprosy	0.6 (0.3 to 1.1)	1.4 (0.8 to 2.1)	115.0 (76.9 to 197.7)	12.2 (-11.5 to 57.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	110.0 (49.6 to 227.6)	10.5 (-23.2 to 74.3)
Other infectious diseases	363.8 (298.3 to 431.0)	315.0 (302.8 to 329.2)	-13.5 (-22.6 to -4.3)	-3.7 (-13.3 to 6.0)	11.5 (7.4 to 16.9)	8.5 (5.6 to 12.7)	-26.0 (-33.8 to -17.4)	-3.9 (-13.9 to 6.0)
Non-communicable diseases	-	-	-	-	29.3 (2,491.9 to 4,371.6)	71.2 (3,716.0 to 6,550.2)	145.1 (45.0 to 54.5)	17.1 (-1.6 to 4.1)
Neoplasms	-	-	-	-	29.3 (21.7 to 37.9)	71.2 (52.5 to 93.5)	145.1 (111.9 to 169.3)	17.1 (0.8 to 28.9)
Esophageal cancer	2.1 (1.5 to 2.8)	3.9 (2.7 to 5.4)	80.5 (18.8 to 189.6)	-20.0 (-46.2 to 23.6)	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.9)	72.7 (21.7 to 160.2)	-23.9 (-46.5 to 10.3)
Stomach cancer	40.5 (35.2 to 46.8)	58.7 (50.5 to 68.3)	44.9 (22.6 to 71.3)	-33.2 (-44.0 to -20.7)	4.9 (3.5 to 6.4)	6.3 (4.5 to 8.4)	30.2 (8.2 to 53.4)	-40.5 (-50.8 to -29.4)
Liver cancer	-	-	-	-	1.9 (1.2 to 2.6)	4.5 (2.9 to 6.7)	140.5 (56.6 to 252.3)	11.8 (-22.8 to 59.7)
Liver cancer due to hepatitis B	4.2 (2.6 to 6.3)	10.7 (6.5 to 15.9)	156.1 (35.2 to 345.4)	27.0 (-32.9 to 113.2)	0.6 (0.4 to 0.9)	1.3 (0.7 to 2.1)	115.6 (20.8 to 249.3)	6.7 (-38.8 to 70.8)
Liver cancer due to hepatitis C	1.7 (1.1 to 2.6)	16.4 (11.1 to 23.9)	848.5 (441.4 to 1,648.6)	314.6 (132.9 to 664.4)	0.3 (0.2 to 0.4)	2.0 (1.2 to 3.1)	659.3 (356.9 to 1,269.7)	232.6 (96.4 to 488.8)
Liver cancer due to alcohol use	6.2 (4.0 to 8.9)	8.8 (5.6 to 13.8)	42.9 (-27.0 to 163.1)	-35.9 (-65.9 to 15.3)	0.9 (0.5 to 1.4)	1.7 (0.6 to 1.7)	19.1 (-33.7 to 100.1)	-46.2 (-69.8 to -11.2)
Liver cancer due to other causes	0.5 (0.3 to 0.8)	0.4 (0.2 to 0.7)	-17.0 (-62.3 to 69.4)	-60.1 (-82.0 to -47.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-26.8 (-64.0 to 43.7)	64.7 (-8.2 to 31.3)
Larynx cancer	3.5 (2.4 to 4.5)	5.1 (3.8 to 7.6)	43.9 (4.2 to 122.3)	-33.8 (-51.9 to 0.8)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.8)	19.1 (-14.8 to 79.3)	-45.3 (-60.7 to -21.0)
Tracheal, bronchus and lung cancer	12.5 (11.1 to 14.6)	39.8 (34.3 to 45.5)	220.9 (152.3 to 280.9)	47.3 (11.4 to 75.5)	2.0 (1.4 to 2.7)	5.9 (4.2 to 7.6)	193.3 (131.7 to 247.1)	34.8 (3.8 to 59.5)
Breast cancer	56.0 (47.8 to 64.5)	178.1 (158.5 to 197.3)	219.2 (161.9 to 280.8)	35.4 (13.0 to 62.2)	2.8 (1.9 to 4.2)	8.0 (5.2 to 11.4)	189.1 (98.7 to 244.5)	32.8 (6.4 to 56.5)
Cervical cancer	25.6 (20.7 to 34.8)	21.4 (15.7 to 26.6)	-15.1 (-45.5 to 16.1)	-50.9 (-70.2 to -32.4)	1.9 (1.2 to 2.9)	1.6 (1.0 to 2.3)	-19.4 (-46.0 to 21.2)	-90.2 (-71.0 to -29.3)
Uterine cancer	16.5 (7.1 to 22.8)	14.0 (10.3 to 19.5)	-20.1 (-45.9 to 144.2)	-60.2 (-72.4 to 23.4)	1.1 (0.4 to 1.8)	0.9 (0.6 to 1.4)	-20.3 (-40.0 to 139.2)	-60.2 (-73.1 to 17.9)
Prostate cancer	8.0 (6.7 to 9.6)	42.8 (33.6 to 51.3)	438.5 (306.6 to 586.6)	105.5 (52.9 to 165.5)	0.7 (0.5 to 1.1)	4.1 (2.6 to 5.7)	462.2 (286.3 to 678.7)	111.7 (43.1 to 196.7)
Colon and rectum cancer	34.8 (32.6 to 37.5)	150.1 (136.2 to 164.8)	331.8 (276.9 to 385.0)	85.1 (61.3 to 107.7)	3.0 (2.2 to 4.0)	12.0 (8.6 to 15.8)	293.9 (243.7 to 346.9)	64.6 (43.0 to 88.9)
Lip and oral cavity cancer	5.2 (4.2 to 6.5)	10.0 (8.0 to 12.4)	93.2 (41.4 to 159.6)	-6.3 (-31.2 to 26.4)	0.5 (0.3 to 0.7)	0.9 (0.6 to 1.2)	83.7 (32.2 to 147.2)	-12.9 (-37.3 to 19.5)
Nasopharynx cancer	1.2 (0.8 to 2.3)	1.7 (1.0 to 2.4)	63.6 (-41.4 to 161.5)	-11.2 (-67.5 to 42.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	62.9 (-43.0 to 148.6)	-13.5 (-69.3 to 31.6)
Other pharynx cancer	2.4 (1.6 to 3.3)	5.1 (3.2 to 7.2)	112.9 (28.2 to 241.5)	4.1 (-37.7 to 67.3)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	102.5 (27.5 to 215.5)	-1.5 (-39.9 to 50.3)
Gallbladder and biliary tract cancer	3.1 (2.5 to 4.5)	6.3 (4.1 to 8.0)	115.9 (18.0 to 392.6)	-12.4 (-53.3 to 19.1)	0.7 (0.5 to 1.1)	1.4 (0.8 to 2.0)	96.5 (8.3 to 171.1)	-19.1 (-56.7 to 12.2)
Pancreatic cancer	2.1 (1.7 to 2.5)	5.5 (4.5 to 6.7)	159.3 (98.0 to 237.6)	6.5 (-19.6 to 37.9)	0.5 (0.3 to 0.6)	1.1 (0.8 to 1.5)	139.7 (90.6 to 196.2)	-0.6 (-21.4 to 24.5)
Malignant skin melanoma	1.4 (1.4 to 3.6)	4.8 (3.4 to 7.1)	250.0 (167.3 to 303.1)	292.4 (34.0 to 59.2)	0.7 (0.1 to 0.3)	0.3 (0.2 to 0.5)	86.3 (12.5 to 197.2)	4.9 (-38.3 to 50.9)
Non-melanoma skin cancer	81.0 (46.0 to 117.3)	195.1 (89.3 to 299.8)	140.3 (-1.0 to 376.2)	-4.1 (-61.6 to 90.2)	1.0 (0.4 to 1.8)	2.5 (1.1 to 4.6)	165.3 (12.6 to 385.0)	4.5 (-56.4 to 90.3)
Ovarian cancer	3.3 (2.8 to 4.3)	9.6 (7.5 to 11.4)	197.0 (89.5 to 274.8)	71.2 (3.2 to 113.8)	0.4 (0.3 to 0.6)	1.2 (0.8 to 1.6)	180.3 (79.1 to 297.2)	60.0 (2.5 to 126.0)
Testicular cancer	0.9 (0.5 to 1.5)	1.0 (0.5 to 1.4)	17.2 (-50.4 to 120.4)	-6.8 (-59.7 to 73.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	9.1 (-56.2 to 136.9)	-15.8 (-65.5 to 74.7)
Kidney cancer	8.8 (5.0 to 7.0)	28.4 (19.4 to 27.1)	224.1 (211.9 to 392.7)	32.4 (56.4 to 150.2)	0.7 (0.3 to 0.6)	2.1 (1.1 to 2.2)	191.2 (183.3 to 369.0)	17.1 (40.2 to 136.2)
Bladder cancer	7.2 (7.2 to 10.1)	23.1 (23.1 to 34.2)	160.9 (160.9 to 307.2)	6.1 (6.1 to 65.7)	0.6 (0.5 to 1.0)	2.9 (1.4 to 2.9)	272.8 (130.1 to 272.8)	-12.9 (-7.7 to 48.6)
Brain and nervous system cancer	5.3 (4.1 to 6.3)	7.3 (6.0 to 9.1)	35.8 (6.8 to 83.3)	-7.2 (-26.9 to 22.8)	0.6 (0.4 to 0.8)	0.8 (0.5 to 1.1)	35.4 (6.3 to 84.3)	-12.9 (-31.5 to 17.8)
Thyroid cancer	16.0 (10.6 to 32.0)	73.6 (31.4 to 102.9)	541.2 (199.9 to 792.0)	304.2 (-21.7 to 452.8)	0.9 (0.5 to 2.0)	4.1 (1.6 to 6.9)	510.5 (165.1 to 761.9)	271.4 (-26.1 to 416.1)
Mesothelioma	0.1 (0.1 to 1.6)	0.2 (0.1 to 0.3)	140.4 (84.4 to 228.1)	6.2 (-16.8 to 45.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	146.4 (94.6 to 243.4)	9.5 (-15.1 to 49.1)
Hodgkin lymphoma	0.8 (0.6 to 1.6)	1.4 (0.7 to 1.8)	89.5 (-36.6 to 179.6)	49.9 (-50.0 to 119.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	83.9 (-34.7 to 162.4)	37.3 (-51.3 to 95.3)
Non-Hodgkin lymphoma	10.0 (7.7 to 17.8)	31.4 (19.2 to 39.5)	245.9 (23.7 to 354.9)	101.7 (-29.6 to 162.5)	0.8 (0.5 to 1.4)	2.3 (1.3 to 3.3)	228.1 (12.8 to 332.9)	87.2 (-37.7 to 149.1)
Multiple myeloma	1.2 (0.8 to 1.9)	4.4 (2.6 to 6.4)	285.1 (104.2 to 520.3)	74.4 (-9.5 to 188.4)	0.3 (0.1 to 0.4)	0.9 (0.5 to 1.4)	255.0 (81.6 to 497.9)	58.5 (-19.0 to 172.9)
Leukemia	9.8 (6.3 to 9.8)	12.3 (10.3 to 14.3)	25.5 (15.0 to 300.4)	17.3 (-16.4 to 46.8)	1.0 (0.7 to 1.4)	1.5 (1.1 to 2.1)	56.3 (16.7 to 92.9)	4.9 (-22.3 to 29.0)
Other neoplasms	25.1 (17.2 to 31.8)	80.7 (66.7 to 102.7)	206.6 (131.6 to 419.3)	87.4 (43.4 to 199.5)	1.8 (1.1 to 2.7)	5.3 (3.6 to 7.4)	181.9 (114.6 to 375.6)	68.5 (29.3 to 169.1)
Cardiovascular diseases	-	-	-	-	92.1 (63.7 to 127.4)	249.5 (169.5 to 343.8)	173.2 (109.0 to 242.8)	16.2 (-10.6 to 46.1)
Rheumatic heart disease	6.6 (5.4 to 8.0)	13.4 (10.2 to 16.9)	104.3 (42.9 to 169.9)	2.5 (-26.6 to 36.0)	0.7 (0.5 to 1.1)	1.4 (0.9 to 2.2)	96.0 (25.7 to 180.3)	-1.1 (-35.2 to 39.2)
Ischemic heart disease	361.0 (278.4 to 484.4)	899.6 (738.0 to 1,086.4)	149.7 (71.7 to 249.2)	26.8 (-28.2 to 41.5)	1.7 (-2.2 to 41.5)	69.1 (45.7 to 97.9)	19.8 (84.2 to 348.8)	5.5 (-23.5 to 39.6)
Cerebrovascular disease	-	-	-	-	25.3 (17.5 to 34.0)	71.8 (50.0 to 97.2)	183.0 (135.2 to 250.9)	19.8 (-0.0 to 50.4)
Ischemic stroke	125.3 (107.2 to 144.2)	361.4 (320.6 to 405.0)	187.4 (136.2 to 260.4)	15.7 (-4.5 to 46.5)	18.4 (12.5 to 24.8)	52.5 (36.0 to 72.2)	183.7 (129.8 to 259.1)	16.0 (5.1 to 47.5)
Hemorrhagic stroke	45.5 (37.5 to 55.3)	130.9 (112.2 to 148.8)	191.2 (119.6 to 266.3)	33.7 (-2.4 to 69.9)	6.8 (4.5 to 9.6)	19.3 (12.6 to 26.6)	184.6 (114.6 to 261.8)	33.3 (-3.8 to 69.5)
Hypertensive heart disease	42.1 (35.7 to 48.1)	134.0 (117.3 to 149.9)	219.4 (162.5 to 277.5)	17.8 (-2.9 to 40.5)	4.6 (3.2 to 6.5)	14.6 (9.9 to 20.6)	215.8 (155.4 to 278.3)	18.3 (4.2 to 42.9)
Cardiomyopathy and myocarditis	32.2 (26.0 to 38.7)	90.1 (81.3 to 100.3)	180.7 (127.0 to 251.4)	180.7 (-1.9 to 60.5)	25.2 (2.3 to 5.0)	9.8 (6.7 to 13.7)	179.4 (121.1 to 256.2)	26.1 (-3.1 to 63.1)
Atrial fibrillation and flutter	69.7 (60.4 to 80.9)	161.1 (133.0 to 191.8)	132.4 (77.2 to 188.9)	-4.5 (-26.3 to 18.2)	5.6 (3.7 to 7.9)	12.7 (8.3 to 18.0)	128.9 (75.1 to 188.5)	-4.7 (-27.1 to 18.9)
Peripheral vascular disease	179.4 (123.7 to 266.8)	378.3 (225.5 to 565.5)	112.0 (25.8 to 418.7)	-15.3 (-47.2 to 41.4)	0.1 (0.0 to 0.2)	0.2 (0.0 to 0.5)	88.0 (-35.7 to 456.7)	-42.9 (-80.4 to 67.7)
Endocarditis	0.8 (0.6 to 1.2)	4.0 (2.4 to 5.3)	418.3 (172.8 to 670.6)	143.1 (27.2 to 259.3)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.7)	399.1 (154.8 to 691.4)	136.7 (20.7 to 287.0)
Other cardiovascular and circulatory diseases	38.9 (196.5 to 603.7)	974.3 (429.4 to 1,484.9)	179.2 (6.5 to 474.8)	179.2 (-50.2 to 179.2)	32.0 (12.1 to 45.9)			

Appendix Table G.4 - South Korea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumococcal	-	-	-	-	0.2	0.2	60.1	-18.9
Silicosis	0.2	0.4	59.1	-24.6	0.0	0.1	(52.0 to 67.0)	(-22.1 to -15.6)
Asbestosis	(0.2 to 0.3)	(0.4 to 0.4)	(51.2 to 67.4)	(-28.4 to -20.4)	0.0	0.0	(52.1 to 68.7)	(-28.3 to -20.2)
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.5	0.9	57.9	-56.5	0.1	0.2	60.0	-16.0
Asthma	(0.5 to 0.6)	(0.8 to 1.0)	(47.0 to 67.8)	(-20.8 to -11.9)	0.1	0.1	(48.8 to 69.7)	(-20.2 to -11.6)
Interstitial lung disease and pulmonary sarcoidosis	1.9	3.3	77.7	-2.7	0.3	0.5	80.2	-2.3
Other chronic respiratory diseases	(1.5 to 2.3)	(2.5 to 4.3)	(23.9 to 141.1)	(-32.6 to 31.3)	0.2	0.4	(25.3 to 144.2)	(-31.7 to 33.0)
Cirrhosis	-	-	-	-	2.7	1.4	-49.4	-71.3
Cirrhosis due to hepatitis B	8.6	8.9	4.2	-41.7	(1.7 to 4.2)	(0.8 to 2.2)	(-63.9 to -27.3)	(-79.9 to -59.0)
Cirrhosis due to hepatitis C	2.2	2.5	16.5	-32.3	(2.1 to 4.2)	(1.9 to 3.8)	(-21.9 to -10.0)	(-55.1 to -44.2)
Cirrhosis due to alcohol use	6.9	3.9	-44.3	-69.7	1.4	1.5	3.8	-41.5
Cirrhosis due to other causes	(5.8 to 7.9)	(2.9 to 4.8)	(-59.6 to -22.2)	(-77.7 to -58.3)	0.1	0.2	(-62.8 to -19.6)	(-79.3 to -56.7)
Digestive diseases	40.7	61.8	51.5	-26.8	4.3	6.4	48.7	-26.9
Peptic ulcer disease	290.5	187.3	-35.6	-77.0	9.7	8.3	-15.1	-69.0
Gastritis and duodenitis	65.9	35.0	-46.7	-71.1	3.0	1.9	-39.0	-65.9
Appendicitis	1.6	1.1	-33.1	-29.7	0.3	0.3	-31.0	-27.9
Paralytic ileus and intestinal obstruction	0.7	1.0	52.9	-0.5	0.2	0.3	48.5	-0.2
Inguinal, femoral, and abdominal hernia	76.7	167.8	117.2	-6.9	0.8	1.7	115.3	-6.5
Inflammatory bowel disease	(65.9 to 87.1)	(141.6 to 196.7)	(77.5 to 176.8)	(-25.7 to 21.5)	(0.4 to 1.5)	(0.8 to 3.2)	(75.5 to 176.6)	(-25.6 to 21.6)
Vascular intestinal disorders	0.2	0.5	149.8	10.8	0.1	0.2	139.0	9.1
Gallbladder and biliary diseases	40.7	61.8	51.5	-26.8	4.3	6.4	48.7	-26.9
Pancreatitis	8.4	16.9	100.6	21.4	2.9	5.0	97.8	21.5
Other digestive diseases	(8.0 to 8.8)	(16.1 to 17.7)	(87.8 to 114.2)	(13.9 to 29.3)	(1.7 to 3.5)	(3.4 to 6.8)	(60.3 to 134.5)	(8.5 to 42.2)
Neurological disorders	-	-	-	-	1.4	2.9	133.2	7.1
Alzheimer disease and other dementias	171.7	586.5	241.6	1.5	(249.3 to 541.4)	(351.5 to 722.2)	(21.3 to 55.5)	(-15.0 to 4.4)
Parkinson disease	15.7	40.9	159.8	-1.1	1.9	4.9	157.4	-0.6
Epilepsy	40.7	40.5	-1.1	-15.7	15.6	16.6	6.2	-7.8
Multiple sclerosis	2.4	6.1	155.0	66.7	0.9	2.1	143.9	60.0
Migraine	8,406.0	9,177.8	8.5	9.6	289.8	313.3	7.4	8.9
Tension-type headache	(7,400.5 to 9,297.9)	(8,258.7 to 10,100.1)	(-5.1 to 28.6)	(-20.7 to 5.1)	(170.2 to 433.4)	(191.2 to 462.7)	(-6.2 to 28.4)	(-20.6 to 6.9)
Medication overuse headache	5,731.4	13,718.8	139.4	92.9	8.7	20.7	137.4	92.4
Other neurological disorders	(5,360.0 to 6,161.3)	(12,058.0 to 15,161.0)	(107.8 to 170.6)	(67.9 to 116.9)	(4.2 to 15.3)	(10.1 to 36.4)	(105.9 to 167.9)	(68.0 to 116.7)
Mental and substance use disorders	151.5	310.0	104.4	41.9	23.9	48.5	103.4	42.4
Schizophrenia	130.9	183.3	39.9	-1.5	880.2	1,026.8	16.9	-1.9
Alcohol use disorders	874.0	844.6	-3.4	-15.8	(628.7 to 1,147.3)	(741.6 to 1,342.2)	(11.4 to 21.1)	(-5.3 to 1.0)
Drug use disorders	(805.8 to 942.1)	(768.5 to 914.7)	(-9.9 to 3.4)	(-21.6 to -10.1)	(58.8 to 128.0)	(56.1 to 120.6)	(-11.2 to 3.4)	(-22.3 to -9.6)
Opioid use disorders	106.8	136.4	27.9	9.3	66.9 to 132.6	76.8 to 145.9	(-2.1 to 27.7)	(-9.4 to 16.3)
Cocaine use disorders	(77.9 to 138.5)	(111.5 to 165.5)	(12.5 to 51.0)	(-1.0 to 24.7)	44.7	57.1	27.7	9.7
Amphetamine use disorders	114.5	105.2	-7.8	-7.2	(27.8 to 64.5)	(38.6 to 78.3)	(11.8 to 53.1)	(-1.7 to 26.7)
Cannabis use disorders	(96.4 to 135.1)	(91.8 to 117.7)	(-25.9 to 14.6)	(-25.6 to 14.8)	15.0	13.7	-8.5	-7.1
Other drug use disorders	104.2	94.4	-9.4	0.5	(0.9 to 4.5)	(1.8 to 4.0)	(-21.4 to 6.1)	(-12.3 to 17.0)
Depressive disorders	1,464.3	1,720.1	17.5	13.3	25.5	25.1	-0.9	-4.1
Major depressive disorder	819.4	1,036.6	26.9	-1.0	(15.9 to 38.5)	(16.0 to 36.7)	(-29.7 to 35.9)	(-31.3 to 31.4)
Dysthymia	660.7	889.6	34.4	-0.6	233.3	296.9	28.0	-0.9
Bipolar disorder	274.1	344.4	25.8	-0.2	(56.8 to 128.0)	(56.1 to 120.6)	(-11.2 to 3.4)	(-22.3 to -9.6)
Anxiety disorders	(218.2 to 332.2)	(281.5 to 410.2)	(16.0 to 37.0)	(-5.5 to 6.2)	98.3	109.7	11.8	2.5
Eating disorders	1,135.2 to 1,785.0	(1,379.3 to 2,083.9)	(8.9 to 27.8)	(-1.6 to -10.0)	(66.9 to 132.6)	(76.8 to 145.9)	(-2.1 to 27.7)	(-9.4 to 16.3)
Anorexia nervosa	15.5	18.7	21.0	38.9	13.4	12.5	-7.0	8.7
Bulimia nervosa	(11.8 to 19.6)	(14.8 to 22.9)	(6.9 to 38.2)	(23.6 to 55.8)	(8.1 to 20.5)	(7.5 to 18.6)	(-15.2 to 1.9)	(-0.1 to 18.3)
Autistic spectrum disorders	47.7	40.1	-15.9	-1.3	53.8	58.4	8.6	11.1
Autism	138.6	152.1	9.7	0.8	(37.6 to 73.3)	(40.3 to 79.6)	(4.7 to 12.5)	(-2.3 to 4.7)
Asperger syndrome	194.1	212.4	9.4	1.1	34.4	37.3	8.5	1.0
Attention-deficit/hyperactivity disorder	(181.9 to 206.3)	(198.5 to 226.7)	(7.6 to 11.3)	(1.1 to 1.2)	(22.9 to 47.6)	(24.9 to 51.0)	(3.2 to 14.0)	(-3.7 to 6.0)
Conduct disorder	274.2	195.7	-28.7	0.6	19.5	2.4	-28.6	0.8
Idiopathic intellectual disability	(254.5 to 291.4)	(181.3 to 208.1)	(-28.9 to -28.5)	(0.5 to 0.6)	(4.0 to 5.1)	(1.4 to 3.6)	(-33.3 to -23.1)	(-5.8 to 8.4)
Other mental and substance use disorders	734.3	997.8	35.9	0.9	25.5	25.1	-0.9	-4.1
Diabetes, urogenital, blood, and endocrine diseases	1,464.3	1,720.1	17.5	13.3	(15.9 to 38.5)	(16.0 to 36.7)	(-29.7 to 35.9)	(-31.3 to 31.4)
Diabetes mellitus	2,038.6	4,370.9	112.7	25.2	(86.6 to 200.0)	(99.8 to 230.8)	(7.9 to 27.1)	(-3.7 to 1.5)
Acute glomerulonephritis	(1,766.2 to 2,336.9)	(3,832.0 to 5,052.3)	(79.7 to 100.7)	(6.7 to 59.1)	(86.6 to 200.0)	(99.8 to 230.8)	(7.9 to 27.1)	(-3.7 to 1.5)
Chronic kidney disease	0.1	0.0	-23.1	-36.6	13.4	12.5	-7.0	8.7
Chronic kidney disease due to diabetes mellitus	307.0	649.6	116.5	11.8	(8.1 to 20.5)	(7.5 to 18.6)	(-15.2 to 1.9)	(-0.1 to 18.3)
Chronic kidney disease due to hypertension	331.5	375.9	16.9	-20.5	2.0	4.0	19.7	38.1
Chronic kidney disease due to glomerulonephritis	(213.7 to 545.2)	(268.5 to 520.9)	(-21.6 to 57.8)	(-51.9 to 7.1)	(2.0 to 5.0)	(2.5 to 5.9)	(1.0 to 46.5)	(17.8 to 68.3)
Chronic kidney disease due to other causes	(261.2 to 563.0)	(358.0 to 662.0)	(9.0 to 71.7)	(-0.7 to 1.2)	291.3	527.3	80.9	13.5
Urinary diseases and male infertility	-	-	-	-	20.8	51.6	147.2	9.2

Appendix Table G.4 - South Korea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	8.7 (7.7 to 9.6)	14.6 (13.0 to 16.1)	67.7 (47.3 to 94.2)	6.7 (4.0 to 10.4)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.7)	64.9 (31.2 to 110.2)	64.9 (-0.7 to 54.4)
Urolithiasis	123.0 (46.1 to 196.9)	291.4 (99.2 to 504.8)	129.5 (106.4 to 181.7)	7.7 (6.1 to 31.0)	1.3 (0.6 to 2.1)	2.7 (1.0 to 4.9)	107.7 (54.9 to 162.0)	8.2 (-13.4 to 32.0)
Benign prostatic hyperplasia	455.1 (396.9 to 510.2)	1,186.1 (1,033.9 to 1,328.9)	159.8 (121.1 to 214.4)	6.9 (8.9 to 28.2)	16.6 (10.7 to 24.0)	43.0 (27.0 to 61.7)	159.1 (120.4 to 213.5)	7.4 (8.4 to 29.2)
Male infertility due to other causes	115.2 (82.0 to 147.5)	123.5 (89.0 to 167.3)	6.6 (-27.6 to 66.7)	2.1 (-29.8 to 62.5)	0.8 (0.3 to 1.7)	0.8 (0.3 to 1.7)	1.1 (-30.8 to 74.0)	1.1 (-32.2 to 68.0)
Other urinary diseases	-	-	-	-	2.3 (0.9 to 3.1)	4.6 (1.3 to 8.8)	177.5 (115.5 to 234.0)	31.2 (-34.6 to 77.8)
Gynecological diseases	-	-	-	-	58.6 (38.5 to 86.5)	75.9 (49.0 to 113.1)	29.5 (13.4 to 48.7)	5.3 (-7.3 to 19.7)
Uterine fibroids	1,029.7 (937.6 to 1,129.6)	1,581.8 (1,440.3 to 1,729.8)	53.5 (50.8 to 56.8)	0.1 (0.0 to 0.2)	15.3 (9.0 to 25.4)	21.1 (12.1 to 35.6)	38.0 (29.0 to 44.8)	-2.4 (-8.1 to 1.3)
Polycystic ovarian syndrome	624.5 (578.1 to 677.5)	742.7 (688.9 to 801.4)	19.0 (4.9 to 33.3)	1.6 (-10.0 to 13.2)	5.9 (2.8 to 11.3)	6.9 (3.2 to 12.7)	18.2 (4.7 to 33.1)	1.0 (-9.8 to 13.3)
Female infertility due to other causes	32.7 (5.6 to 70.4)	0.4 (5.0 to 89.3)	0.4 (-85.6 to 455.6)	-36.9 (-89.4 to 300.9)	0.2 (0.0 to 0.5)	0.2 (0.0 to 0.6)	0.0 (-84.1 to 402.0)	-28.7 (-88.3 to 275.5)
Endometriosis	130.0 (105.6 to 156.1)	148.0 (121.1 to 177.3)	13.0 (-12.0 to 47.6)	-5.5 (-26.0 to 23.1)	12.1 (7.6 to 17.5)	13.7 (8.9 to 19.7)	12.9 (-13.6 to 50.6)	5.5 (-27.1 to 25.6)
Genital prolapse	1,741.5 (1,439.5 to 2,061.1)	2,637.4 (2,222.1 to 3,039.4)	52.0 (18.4 to 93.2)	-0.7 (-22.4 to 24.3)	5.6 (2.6 to 10.5)	8.4 (4.1 to 15.8)	51.6 (17.5 to 93.3)	-0.7 (-22.0 to 24.2)
Premenstrual syndrome	1,663.9 (1,173.9 to 2,200.6)	2,318.5 (1,724.7 to 2,917.5)	40.5 (-9.7 to 108.7)	34.9 (-13.4 to 93.6)	14.0 (7.7 to 22.3)	19.5 (11.3 to 31.5)	40.4 (-10.1 to 107.0)	34.8 (-13.3 to 93.9)
Other gynecological diseases	186.8 (166.7 to 209.0)	203.0 (194.1 to 211.5)	8.6 (-4.4 to 22.6)	-4.7 (-16.1 to 7.7)	21.8 (3.7 to 7.9)	22.8 (4.2 to 8.6)	4.7 (-4.6 to 40.2)	1.4 (-16.0 to 23.3)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	21.8 (14.2 to 31.9)	22.8 (15.1 to 33.4)	4.7 (-6.2 to 19.5)	1.4 (-8.6 to 15.6)
Thalassemias	1.6 (1.3 to 2.0)	2.0 (1.5 to 2.5)	19.3 (-1.5 to 48.5)	38.5 (16.1 to 66.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	13.5 (-13.1 to 46.5)	28.9 (-1.2 to 66.8)
Thalassemia trait	772.7 (667.9 to 879.5)	890.0 (770.1 to 1,022.0)	15.1 (10.6 to 19.4)	0.7 (-3.0 to 4.5)	10.7 (7.0 to 15.9)	11.2 (7.3 to 16.5)	5.1 (-6.1 to 16.4)	1.6 (-9.2 to 11.4)
Sickle cell disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-5.5 (-16.1 to 5.5)	7.5 (-4.1 to 20.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.5 (-24.7 to 4.9)	-0.6 (-16.3 to 15.7)
Sickle cell trait	9.2 (8.7 to 9.2)	10.1 (9.5 to 10.2)	10.0 (9.2 to 10.0)	-9.5 (-4.1 to 3.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	6.8 (6.8 to 8.0)	1.6 (-1.6 to -0.9)
G6PD deficiency	62.5 (45.2 to 81.4)	76.6 (57.8 to 98.9)	21.2 (-20.8 to 84.3)	6.2 (-30.5 to 61.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-48.0 to 100.1)	48.9 (31.1 to 69.6)
G6PD trait	2,253.9 (2,135.7 to 2,360.2)	2,636.4 (2,489.5 to 2,763.0)	17.0 (8.7 to 25.7)	-0.6 (-7.6 to 6.8)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	15.6 (-25.1 to 71.4)	1.3 (-33.3 to 51.7)
Other hemoglobinopathies and hemolytic anemias	422.1 (368.4 to 460.2)	511.8 (481.3 to 539.5)	21.2 (9.9 to 38.3)	0.9 (-8.5 to 14.2)	10.5 (6.5 to 15.8)	11.0 (7.1 to 16.2)	4.5 (-16.3 to 40.5)	0.9 (-18.7 to 34.9)
Endocrine, metabolic, blood, and immune disorders	640.7 (603.5 to 676.1)	795.3 (747.3 to 825.5)	22.4 (13.6 to 32.3)	21.1 (-6.3 to 9.9)	21.2 (14.4 to 29.9)	25.1 (17.1 to 34.3)	21.9 (6.5 to 34.9)	2.3 (-7.9 to 15.1)
Musculoskeletal disorders	-	-	-	-	981.3 (685.9 to 1,301.5)	1,660.6 (1,184.9 to 2,196.0)	69.2 (57.0 to 83.1)	6.1 (-0.7 to 13.8)
Rheumatoid arthritis	60.0 (57.5 to 62.4)	116.0 (111.0 to 121.2)	93.2 (82.1 to 105.6)	-5.4 (-10.7 to 1.0)	14.1 (10.0 to 18.5)	26.9 (19.2 to 35.2)	90.3 (75.0 to 107.9)	-4.9 (-12.3 to 3.5)
Osteoarthritis	1,454.3 (1,387.2 to 1,520.6)	3,252.0 (3,113.3 to 3,414.6)	123.4 (110.9 to 138.3)	-5.3 (-10.3 to 0.8)	51.0 (33.5 to 74.2)	113.0 (73.3 to 163.0)	121.7 (108.5 to 136.9)	-5.1 (-10.5 to 1.0)
Low back and neck pain	-	-	-	-	758.9 (520.9 to 1,020.9)	1,194.2 (822.2 to 1,626.6)	65.8 (43.6 to 75.2)	6.3 (-2.6 to 17.1)
Low back pain	5,201.5 (4,755.4 to 5,691.3)	7,800.7 (7,201.8 to 8,390.0)	50.2 (32.9 to 69.6)	-0.6 (-11.1 to 11.3)	586.1 (392.0 to 809.9)	868.3 (580.4 to 1,209.0)	48.5 (31.3 to 68.0)	-0.4 (-10.8 to 12.1)
Neck pain	1,742.8 (1,520.6 to 2,017.9)	3,314.6 (2,950.9 to 3,680.8)	90.8 (58.9 to 126.4)	29.2 (9.2 to 52.1)	172.7 (117.7 to 240.7)	325.9 (221.0 to 454.4)	89.4 (57.8 to 125.9)	29.5 (9.5 to 52.6)
Gout	30.0 (23.6 to 34.9)	67.4 (54.0 to 79.1)	123.9 (72.8 to 200.5)	11.7 (-12.9 to 45.3)	1.0 (0.6 to 1.4)	2.2 (1.4 to 3.1)	122.2 (61.2 to 206.5)	11.7 (-17.3 to 52.8)
Other musculoskeletal disorders	1,703.2 (1,369.6 to 2,025.4)	3,542.2 (2,937.9 to 4,163.5)	108.3 (94.9 to 125.0)	36.2 (3.3 to 16.7)	10.0 (100.2 to 236.6)	10.1 (214.9 to 462.2)	107.6 (93.2 to 124.8)	6.3 (-3.7 to 17.7)
Other non-communicable diseases	-	-	-	-	547.8 (364.4 to 796.6)	761.1 (514.8 to 1,089.8)	39.1 (32.6 to 45.7)	5.7 (-8.7 to -2.6)
Congenital anomalies	-	-	-	-	42.0 (29.2 to 56.5)	62.8 (43.9 to 84.9)	49.9 (29.0 to 73.9)	27.3 (9.2 to 48.0)
Neural tube defects	12.3 (10.7 to 14.1)	13.4 (11.3 to 16.5)	7.3 (-11.3 to 38.4)	7.4 (-11.2 to 38.4)	4.0 (2.6 to 5.6)	4.4 (2.9 to 6.4)	9.4 (-20.1 to 60.3)	10.6 (-20.1 to 62.3)
Congenital heart anomalies	440.4 (365.5 to 554.8)	396.1 (333.9 to 473.9)	-9.8 (-32.3 to 18.8)	-17.0 (-37.8 to 9.2)	16.0 (6.6 to 27.8)	14.4 (5.9 to 24.7)	-9.6 (-30.3 to 15.6)	-14.9 (-34.2 to 8.0)
Orofacial clefts	95.6 (80.9 to 118.5)	95.7 (75.9 to 118.7)	-0.2 (-26.9 to 33.7)	-0.7 (-33.9 to 20.8)	0.9 (0.6 to 1.3)	0.9 (0.5 to 1.3)	0.5 (-31.9 to 39.0)	-0.2 (-38.1 to 25.0)
Down syndrome	38.4 (32.3 to 45.3)	53.3 (42.3 to 64.1)	40.1 (4.0 to 81.1)	10.3 (-18.0 to 42.8)	5.1 (3.6 to 6.9)	8.1 (5.6 to 10.8)	60.3 (18.2 to 107.8)	12.5 (-17.1 to 45.5)
Turner syndrome	2.3 (1.7 to 3.3)	2.6 (1.8 to 3.3)	13.5 (-23.8 to 66.6)	8.1 (-27.6 to 58.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	12.7 (-27.2 to 68.3)	7.7 (-30.7 to 60.5)
Klinefelter syndrome	1.5 (1.2 to 2.0)	2.3 (1.9 to 3.2)	51.5 (9.7 to 119.3)	38.8 (0.4 to 100.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-4.4 to 151.8)	38.0 (-12.0 to 124.2)
Chromosomal unbalanced rearrangements	59.0 (48.9 to 70.1)	80.6 (68.5 to 92.0)	36.2 (9.1 to 76.5)	36.2 (-14.2 to 38.9)	0.7 (5.5 to 10.6)	0.7 (8.8 to 16.2)	12.2 (23.5 to 104.8)	10.1 (-12.6 to 45.4)
Other congenital anomalies	68.9 (49.0 to 83.2)	73.9 (50.2 to 90.9)	9.1 (-18.1 to 37.3)	-13.2 (-34.2 to 10.2)	8.2 (5.4 to 11.7)	22.8 (14.1 to 33.9)	176.3 (90.5 to 303.3)	146.0 (70.0 to 262.0)
Skin and subcutaneous diseases	-	-	-	-	264.8 (173.0 to 406.3)	291.8 (190.3 to 440.4)	10.6 (1.3 to 18.6)	-3.2 (-9.8 to 2.7)
Dermatitis	2,661.6 (2,178.6 to 3,133.3)	3,095.6 (2,535.1 to 3,633.5)	16.4 (10.8 to 21.6)	-0.1 (-4.2 to 0.0)	71.1 (44.9 to 102.3)	80.1 (51.4 to 115.0)	12.6 (7.1 to 18.2)	0.0 (-2.4 to 2.6)
Psoriasis	541.6 (472.6 to 608.4)	743.2 (649.7 to 831.2)	37.1 (30.6 to 44.5)	0.2 (-0.0 to 0.3)	37.1 (29.9 to 62.5)	60.2 (41.0 to 85.3)	35.8 (27.1 to 44.8)	0.2 (-4.0 to 4.7)
Cellulitis	18.3 (15.1 to 22.7)	27.2 (21.9 to 34.5)	47.3 (33.9 to 66.2)	-1.0 (-9.3 to 6.8)	1.3 (0.8 to 1.9)	1.9 (1.2 to 2.8)	45.0 (21.5 to 77.2)	-0.8 (-15.7 to 17.5)
Pyoderma	29.0 (22.1 to 38.9)	30.4 (22.5 to 40.9)	4.5 (-7.5 to 18.0)	-11.4 (-15.2 to -6.7)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	3.4 (-12.0 to 20.2)	-11.6 (-20.5 to -2.1)
Scabies	27.1 (22.8 to 32.4)	22.8 (19.7 to 27.1)	-16.6 (-34.6 to 9.2)	-23.6 (-39.5 to -0.2)	0.7 (0.4 to 1.1)	0.6 (0.3 to 0.9)	-16.5 (-37.3 to 10.6)	-0.6 (-41.3 to 1.7)
Fungal skin diseases	2,444.5 (1,947.6 to 2,980.6)	3,360.1 (2,749.6 to 3,952.6)	37.6 (28.0 to 48.1)	37.6 (10.5 to 64.1)	13.8 (5.6 to 28.9)	13.8 (7.7 to 39.9)	35.5 (26.6 to 46.8)	0.2 (-0.4 to 1.9)
Viral skin diseases	1,059.4 (833.8 to 1,290.6)	964.7 (767.9 to 1,172.2)	-9.2 (-13.6 to -2.2)	-0.5 (-2.6 to 1.7)	32.9 (19.2 to 51.8)	29.7 (17.3 to 47.0)	-9.7 (-14.5 to -2.8)	-0.4 (-3.8 to 3.0)
Acne vulgaris	5,789.0 (4,569.2 to 7,152.3)	4,220.6 (3,438.9 to 5,188.7)	-26.8 (-45.3 to -4.9)	-11.6 (-33.9 to 14.9)	63.0 (28.5 to 124.4)	45.8 (20.5 to 87.0)	-26.9 (-45.4 to -5.1)	-11.6 (-34.3 to 15.2)
Alopecia areata	63.1 (58.7 to 67.6)	86.7 (80.8 to 93.4)	37.1 (23.8 to 53.1)	-1.1 (-9.9 to 10.4)	2.1 (1.4 to 3.2)	2.9 (1.8 to 4.3)	35.8 (19.1 to 55.0)	-0.6 (-12.1 to 13.1)
Pruritus	13.4 (10.4 to 16.4)	22.9 (15.4 to 28.3)	69.1 (20.4 to 150.0)	0.5 (-30.0 to 48.3)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.5)	69.0 (13.9 to 157.4)	1.9 (-31.3 to 47.7)
Urticaria	37.1 (24.5 to 420.0)	404.9 (302.5 to 530.0)	23.9 (-21.6 to 77.8)	-10.5 (-39.3 to 27.3)	19.6 (11.6 to 29.6)	23.9 (14.3 to 36.5)	22.1 (-22.8 to 75.2)	-10.2 (-40.4 to 27.7)
Decubitus ulcer	13.6 (10.5 to 16.2)	30.5 (25.0 to 35.9)	122.6 (69.2 to 208.9)	-5.6 (-28.9 to 37.0)	2.0 (1.3 to 2.9)	4.4 (3.0 to 6.1)	116.4 (61.0 to 206.5)	-5.3 (-29.7 to 37.8)
Other skin and subcutaneous diseases	2,304.7 (1,537.4 to 3,414.2)	3,942.5 (2,347.3 to 6,516.3)	69.8 (40.4 to 99.0)	-0.4 (-2.7 to 1.9)	13.6 (6.0 to 28.3)	23.1 (9.4 to 51.4)	68.0 (40.0 to 97.5)	-0.3 (-2.9 to 2.4)
Sense organ diseases	-	-	-	-	167.9 (111.2 to 237.5)	493.4 (197.4 to 415.4)	17.9 (64.2 to 85.2)	-13.0 (-16.6 to -9.1)
Glaucoma	89.1 (67.8 to 115.0)	124.0 (90.1 to 172.6)	37.9 (7.9 to 83.5)	-39.8 (-49.6 to -23.6)	7.3 (4.8 to 10.6)	11.6 (7.0 to 17.3)	57.8 (23.9 to 94.8)	-33.5 (-43.4 to -21.9)
Cataract	71.0 (36.2 to 111.9)	162.9 (102.0 to 241.0)	127.5 (33.7 to 351.1)	-23.2 (-52.6 to 52.3)	4.5 (2.2 to 7.2)	10.4 (5.7 to 16.6)	128.6 (36.7 to 297.2)	-26.0 (-52.1 to 30.0)
Macular degeneration	74.3 (52.8 to 101.8)	196.2 (128.7 to 271.6)	167.7 (79.0 to 261.9)	6.6 (-31.1 to 43.5)	4.3 (2.6 to 6.6)	11.5 (6.9 to 18.1)	164.0 (93.7 to 251.3)	-2.7 (-30.0 to 25.3)
Uncorrected refractive error	1,582.0 (1,409.9 to 1,747.1)	2,482.7 (2,246.7 to 2,712.0)	57.4 (40.0 to 75.1)	-12.9 (-13.3 to -14.1)	12.1 (7.2 to 17.1)	15.9 (34.0 to 55.3)	39.5 (23.1 to 52.9)	-20.2 (-25.3 to -13.7)
Age-related and other hearing loss	3,577.7 (3,145.4 to 3,847.2)	7,255.0 (6,795.3 to 7,724.1)	102.8 (93.8 to 111.4)	-7.6 (-11.0 to -4.7)	72.1 (45.1 to 108.9)	72.1 (100.2 to 231.9)	116.7 (98.4 to 136.0)	-6.1 (-12.8 to 0.2)
Other vision loss	286.4 (221.4 to 355.0)	332.5 (245.3 to 419.1)	15.5 (-1.0 to 38.2)	-34.7 (-43.4 to -24.8)	17.8 (11.6 to 25.4)	22.0 (14.1 to 31.9)	24.3 (5.5 to 42.5)	-33.5 (-40.7 to -26.3)
Other sense organ diseases	926.3 (882.4 to 971.4)	1,146.8 (1,094.8 to 1,202.4)	23.7 (15.3 to 32.0)	0.2 (-6.4 to 6.6)	24.7 (15.1 to 36.4)	30.0 (18.6 to 44.3)	21.8 (12.9 to 30.9)	

Appendix Table G.4 - South Korea prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	926.0 (867.5 to 988.6)	1,733.6 (1,644.7 to 1,819.8)	87.1 (70.1 to 103.8)	-20.7 (-27.1 to -14.0)	25.7 (17.3 to 35.3)	47.6 (31.8 to 66.1)	85.6 (68.1 to 102.2)	-20.6 (-27.2 to -13.7)
Other oral disorders	767.6 (727.6 to 811.4)	985.7 (928.8 to 1,036.7)	28.4 (18.8 to 38.4)	-0.2 (-7.2 to 7.3)	22.6 (14.2 to 33.8)	28.8 (17.9 to 42.6)	27.7 (17.7 to 38.0)	0.0 (-7.4 to 7.9)
Injuries	-	-	-	-	251.6 (192.5 to 323.9)	255.5 (184.4 to 344.6)	1.2 (8.4 to 11.3)	-40.8 (-46.1 to -34.8)
Transport injuries	-	-	-	-	86.3 (65.5 to 111.2)	47.6 (34.5 to 63.4)	-38.7 (-50.5 to -26.9)	-66.0 (-68.9 to -62.6)
Road injuries	-	-	-	-	74.8 (56.6 to 96.0)	38.2 (27.8 to 50.7)	-49.0 (-54.3 to -43.4)	-48.1 (-71.0 to -64.9)
Pedestrian road injuries	-	-	-	-	12.4 (9.3 to 16.3)	8.2 (5.8 to 11.2)	-33.8 (-40.8 to -26.3)	-61.0 (-64.6 to -57.2)
Cyclist road injuries	-	-	-	-	10.6 (8.0 to 13.6)	4.2 (3.1 to 5.5)	-60.4 (-65.1 to -54.9)	-75.7 (-78.5 to -72.6)
Motorcyclist road injuries	-	-	-	-	18.0 (13.5 to 23.3)	7.0 (5.0 to 9.4)	-61.2 (-66.8 to -54.2)	-74.1 (-77.7 to -70.0)
Motor vehicle road injuries	-	-	-	-	33.3 (25.5 to 42.3)	18.6 (13.7 to 24.4)	-44.1 (-49.1 to -38.7)	-65.2 (-68.0 to -62.2)
Other road injuries	-	-	-	-	0.4 (0.3 to 0.6)	0.1 (0.1 to 0.2)	-69.6 (-73.3 to -64.9)	-80.4 (-82.6 to -77.7)
Other transport injuries	-	-	-	-	11.6 (8.7 to 15.3)	9.3 (6.7 to 12.6)	-19.7 (-26.3 to -11.7)	-52.7 (-56.5 to -48.0)
Unintentional injuries	-	-	-	-	158.5 (120.4 to 204.9)	201.8 (145.0 to 273.1)	27.1 (15.9 to 38.4)	-28.4 (-35.0 to -21.4)
Falls	-	-	-	-	86.2 (64.7 to 111.2)	136.6 (98.8 to 183.5)	58.2 (42.3 to 75.4)	-22.2 (-30.6 to -12.5)
Drowning	-	-	-	-	1.1 (0.8 to 1.4)	0.9 (0.7 to 1.2)	-16.4 (-27.8 to -5.8)	-45.2 (-52.1 to -39.1)
Fire, heat, and hot substances	-	-	-	-	7.5 (4.8 to 11.4)	8.5 (5.0 to 13.7)	12.2 (2.2 to 26.7)	-26.7 (-34.6 to -19.0)
Poisonings	-	-	-	-	0.6 (0.4 to 0.8)	0.2 (0.2 to 0.3)	-62.0 (-68.3 to -55.8)	-73.1 (-77.4 to -68.9)
Exposure to mechanical forces	-	-	-	-	55.7 (42.3 to 72.6)	41.8 (29.8 to 57.2)	-25.2 (-33.0 to -17.4)	-47.2 (-52.0 to -42.0)
Unintentional firearm injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.5 (0.3 to 0.6)	-8.8 (-21.9 to 5.0)	-29.7 (-38.6 to -20.3)
Unintentional suffocation	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.3)	10.4 (-4.9 to 25.9)	-20.7 (-30.4 to -10.4)
Other exposure to mechanical forces	-	-	-	-	55.0 (41.8 to 71.7)	41.0 (29.2 to 56.2)	-25.6 (-33.3 to -17.7)	-47.5 (-52.3 to -42.2)
Adverse effects of medical treatment	-	-	-	-	1.5 (1.0 to 2.2)	2.5 (1.6 to 3.7)	66.9 (54.6 to 81.5)	1.3 (-5.8 to 10.1)
Animal contact	-	-	-	-	1.9 (1.4 to 2.5)	2.4 (1.7 to 3.3)	25.5 (15.1 to 38.0)	-11.5 (-18.0 to -3.8)
Venomous animal contact	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	18.7 (5.5 to 33.7)	-12.7 (-21.9 to -2.8)
Non-venomous animal contact	-	-	-	-	1.5 (1.1 to 2.1)	2.0 (1.4 to 2.8)	27.1 (15.4 to 40.9)	-11.2 (-18.6 to -2.7)
Foreign body	-	-	-	-	1.9 (1.3 to 2.7)	2.0 (1.3 to 3.0)	5.8 (-2.6 to 14.6)	-19.1 (-27.3 to -11.5)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.3 to 0.4)	3.6 (9.0 to 20.9)	-26.8 (-35.3 to -14.7)
Foreign body in eyes	-	-	-	-	0.6 (0.3 to 0.9)	0.6 (0.4 to 1.0)	8.6 (-4.4 to 21.8)	-11.6 (-23.0 to 0.7)
Foreign body in other body part	-	-	-	-	1.0 (0.7 to 1.5)	1.1 (0.6 to 1.6)	4.7 (-5.7 to 14.4)	-20.8 (-30.1 to -13.1)
Other unintentional injuries	-	-	-	-	2.1 (1.5 to 2.8)	6.8 (4.7 to 9.5)	226.9 (189.6 to 267.9)	51.0 (34.3 to 69.6)
Self-harm and interpersonal violence	-	-	-	-	6.1 (4.6 to 7.9)	5.9 (4.2 to 8.0)	-3.5 (-12.6 to 7.8)	-37.5 (-42.8 to -31.1)
Self-harm	-	-	-	-	1.9 (1.4 to 2.6)	3.3 (2.3 to 4.5)	68.4 (49.4 to 87.5)	0.6 (-10.4 to 11.2)
Interpersonal violence	-	-	-	-	4.2 (3.2 to 5.3)	2.7 (1.9 to 3.6)	-36.5 (-42.9 to -28.9)	-56.2 (-60.2 to -51.5)
Assault by firearm	-	-	-	-	0.4 (0.3 to 0.5)	0.2 (0.1 to 0.3)	-45.8 (-52.6 to -39.0)	-62.6 (-66.8 to -58.3)
Assault by sharp object	-	-	-	-	0.6 (0.5 to 0.8)	0.5 (0.3 to 0.7)	-24.0 (-30.8 to -17.2)	-48.8 (-52.5 to -44.8)
Assault by other means	-	-	-	-	3.2 (2.4 to 4.1)	2.0 (1.4 to 2.7)	-37.9 (-44.9 to -29.8)	-56.9 (-61.4 to -51.7)
Forces of nature, war, and legal intervention	-	-	-	-	0.7 (0.3 to 1.4)	0.2 (0.1 to 0.5)	-68.4 (-77.3 to -57.7)	-82.7 (-88.4 to -75.1)
Exposure to forces of nature	-	-	-	-	0.7 (0.3 to 1.4)	0.2 (0.1 to 0.5)	-68.4 (-77.3 to -57.7)	-82.7 (-88.4 to -75.1)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - South Sudan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	642.6 (467.2 to 845.0)	1,173.8 (866.0 to 1,533.5)	83.9 (74.8 to 91.2)	83.9 (-11.8 to -4.1)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	240.9 (158.4 to 341.9)	381.3 (264.8 to 530.4)	58.9 (43.5 to 77.1)	-20.5 (-29.2 to -10.0)
HIV/AIDS and tuberculosis	-	-	-	-	5.5 (3.1 to 13.9)	36.3 (20.1 to 59.9)	643.4 (106.7 to 1,155.3)	260.1 (-1.1 to 525.8)
Tuberculosis	13.4 (12.3 to 14.7)	26.4 (24.5 to 28.5)	96.9 (84.2 to 109.3)	-3.8 (-9.8 to 2.2)	4.0 (2.7 to 5.5)	8.0 (5.5 to 10.8)	98.3 (82.3 to 114.8)	-2.6 (-10.2 to 5.0)
HIV/AIDS	-	-	-	-	1.5 (0.0 to 8.9)	28.4 (13.5 to 50.6)	633.5 (107.1 to 983.7)	267.8 (-1.1 to 516.07.7)
HIV/AIDS resulting in mycobacterial infection	0.2 (0.0 to 1.6)	3.3 (1.8 to 5.3)	4,760.5 (80.1 to 386,040.7)	2,398.8 (-11.7 to 209,421.1)	0.1 (0.0 to 0.6)	1.2 (0.0 to 2.1)	4,665.6 (79.1 to 1,138,222.3)	2,403.1 (-11.1 to 703,815.5)
HIV/AIDS resulting in other diseases	12.3 (0.1 to 62.8)	150.4 (93.9 to 221.0)	4,186.2 (101.9 to 165,376.1)	2,098.2 (-2.1 to 84,210.2)	1.4 (0.0 to 8.8)	27.2 (12.6 to 49.2)	8,024.2 (97.4 to 441,955.1)	4,220.6 (-5.4 to 256,843.6)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	27.7 (19.7 to 37.6)	38.3 (27.0 to 52.2)	37.7 (23.3 to 53.8)	-22.2 (-29.0 to -14.5)
Diarrheal diseases	77.3 (65.8 to 89.7)	110.3 (95.1 to 125.5)	42.1 (14.4 to 75.1)	-15.2 (-30.0 to 1.1)	12.4 (8.1 to 17.6)	17.7 (11.8 to 25.1)	42.5 (14.8 to 74.8)	-14.9 (-29.3 to 2.9)
Intestinal infectious diseases	-	-	-	-	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.4)	0.3 (-1.0 to 0.7)	0.3 (-5.1 to 4.5)
Typhoid fever	1.3 (1.1 to 1.4)	1.6 (1.4 to 1.8)	25.9 (3.3 to 50.3)	-33.2 (-44.6 to -18.8)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	28.1 (5.4 to 71.7)	-32.0 (-47.5 to -10.6)
Paratyphoid fever	0.5 (0.4 to 0.5)	0.7 (0.6 to 0.9)	54.4 (23.5 to 101.6)	-18.4 (-35.7 to 5.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	55.3 (15.8 to 113.0)	-17.9 (-37.5 to 8.2)
Other intestinal infectious diseases	-	-	-	-	0.0	0.0	-43.5	-70.1
Lower respiratory infections	5.0 (3.8 to 6.8)	7.1 (4.8 to 11.1)	33.8 (-15.3 to 162.6)	-10.6 (-38.2 to 48.5)	0.5 (0.3 to 0.8)	0.7 (0.4 to 1.4)	32.3 (-17.5 to 167.5)	29.9 (-38.7 to 52.1)
Upper respiratory infections	382.5 (344.5 to 422.9)	718.3 (649.3 to 781.5)	86.9 (67.9 to 110.5)	-2.1 (-12.0 to 9.7)	4.5 (2.5 to 7.4)	8.4 (4.7 to 14.3)	87.2 (67.7 to 112.6)	-1.7 (-13.9 to 10.2)
Otitis media	101.3 (92.5 to 110.5)	171.3 (156.9 to 185.7)	68.6 (50.9 to 88.0)	-12.7 (-22.2 to -1.7)	2.1 (1.2 to 3.3)	3.5 (2.1 to 5.5)	68.5 (47.1 to 90.9)	-12.2 (-23.3 to -0.5)
Meningitis	-	-	-	-	6.2 (4.2 to 8.6)	6.1 (4.1 to 8.3)	-2.4 (-15.3 to 15.2)	-47.4 (-54.5 to -38.9)
Pneumococcal meningitis	22.3 (13.6 to 34.3)	21.7 (13.9 to 32.0)	-2.0 (-24.0 to 22.5)	-48.0 (-59.6 to -36.1)	2.1 (1.4 to 3.0)	2.2 (1.5 to 3.0)	2.2 (-21.6 to 32.6)	-44.7 (-57.4 to -31.0)
H influenzae type B meningitis	12.6 (5.2 to 23.7)	11.1 (4.8 to 19.9)	-11.1 (-35.6 to 18.5)	-54.1 (-66.6 to -39.0)	1.5 (0.9 to 2.2)	1.3 (0.9 to 2.0)	-8.2 (-32.5 to 31.4)	-52.5 (-64.7 to -34.2)
Meningococcal meningitis	3.4 (1.1 to 7.0)	3.4 (1.2 to 6.7)	-2.8 (-27.7 to 59.8)	-45.0 (-59.1 to -13.9)	0.5 (0.2 to 0.8)	0.5 (0.3 to 0.8)	1.9 (-26.3 to 84.4)	-42.0 (-57.8 to -2.0)
Other meningitis	17.8 (8.6 to 31.8)	16.6 (8.2 to 29.9)	-5.6 (-26.6 to 17.3)	-48.6 (-59.9 to -35.4)	2.2 (1.4 to 3.2)	2.1 (1.3 to 3.0)	-5.3 (-28.2 to 27.1)	-48.3 (-60.8 to -31.3)
Encephalitis	0.9 (0.4 to 1.9)	1.7 (0.8 to 3.5)	88.4 (67.3 to 111.8)	0.1 (-12.4 to 6.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	92.0 (58.7 to 127.1)	-3.0 (-17.2 to 11.3)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.9 (-96.3 to 1,728.2)	-52.6 (-96.8 to 640.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.9 (-96.8 to 654.0)	-52.6 (-96.8 to 654.0)
Whooping cough	20.1 (15.2 to 26.3)	22.4 (17.2 to 29.2)	11.5 (9.6 to 13.4)	-29.8 (-30.9 to -28.6)	1.0 (0.6 to 1.6)	1.1 (0.6 to 1.8)	11.8 (5.2 to 18.9)	-29.6 (-33.8 to -25.0)
Tetanus	1.4 (0.8 to 2.3)	1.0 (0.5 to 1.7)	-35.4 (-73.1 to 77.9)	-64.3 (-85.7 to 1.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-31.9 (-68.0 to 24.0)	-59.4 (-77.7 to -28.7)
Measles	6.4 (4.3 to 9.3)	1.3 (1.0 to 1.8)	-79.1 (-82.8 to -74.4)	-97.1 (-89.4 to -84.2)	0.6 (0.3 to 1.0)	0.1 (0.1 to 0.2)	-29.0 (-84.4 to -71.8)	-47.0 (-90.3 to -82.5)
Varicella and herpes zoster	3.7 (3.3 to 4.1)	7.2 (6.4 to 8.1)	96.5 (65.5 to 126.8)	0.9 (-22.5 to 23.4)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	97.5 (27.1 to 179.5)	0.5 (-36.4 to 43.0)
Neglected tropical diseases and malaria	-	-	-	-	121.5 (71.0 to 186.9)	173.6 (108.8 to 257.6)	44.3 (26.6 to 62.1)	-32.5 (-40.4 to -24.2)
Malaria	841.5 (720.4 to 989.2)	941.5 (809.2 to 1,092.2)	11.1 (-3.1 to 29.6)	-41.6 (-49.9 to -31.2)	8.3 (5.4 to 12.2)	9.4 (6.3 to 13.7)	13.2 (2.6 to 31.1)	-40.4 (-46.0 to -32.6)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	0.0	-	-
Leishmaniasis	-	-	-	-	0.3 (0.1 to 0.4)	0.4 (0.2 to 0.7)	69.2 (11.8 to 121.1)	-11.1 (-37.6 to 9.7)
Visceral leishmaniasis	3.6 (2.5 to 5.0)	5.9 (3.8 to 9.0)	67.2 (14.4 to 110.1)	-12.5 (-37.3 to 5.2)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.7)	68.0 (7.7 to 123.2)	-12.0 (-39.3 to 11.3)
Cutaneous and mucocutaneous leishmaniasis	1.0 (0.6 to 1.5)	1.9 (1.1 to 3.1)	100.9 (30.1 to 232.9)	-1.3 (-37.2 to 57.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.7 (23.6 to 249.0)	-0.3 (-37.1 to 60.5)
African trypanosomiasis	0.5 (0.2 to 1.0)	0.8 (0.5 to 1.4)	89.0 (40.1 to 161.1)	-5.5 (-29.2 to 30.3)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.4)	84.3 (23.2 to 194.2)	-7.1 (-71.5 to 52.4)
Schistosomiasis	2,401.4 (1,803.8 to 3,016.3)	4,882.5 (3,684.2 to 6,129.3)	102.6 (98.3 to 106.3)	102.6 (-1.3 to 1.9)	22.1 (10.9 to 42.5)	45.3 (22.3 to 86.2)	104.8 (80.4 to 128.2)	52.4 (-9.0 to 8.9)
Cysticercosis	0.7 (0.4 to 1.0)	1.5 (0.8 to 2.5)	130.2 (-0.2 to 325.2)	5.5 (-50.8 to 86.8)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	140.9 (-3.1 to 372.5)	9.6 (-51.6 to 105.1)
Cystic echinococcosis	1.4 (1.3 to 1.6)	3.0 (2.7 to 3.4)	110.2 (87.4 to 154.2)	18.5 (6.5 to 43.9)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	110.5 (70.9 to 166.2)	21.2 (2.4 to 51.7)
Lymphatic filariasis	104.8 (82.7 to 130.0)	206.6 (155.4 to 257.3)	96.5 (41.4 to 173.2)	-2.4 (-25.2 to 28.9)	2.6 (1.3 to 4.4)	5.2 (2.8 to 8.9)	100.0 (40.7 to 173.7)	-0.5 (-30.8 to 36.5)
Onchocerciasis	1,233.8 (708.1 to 2,050.2)	1,577.4 (1,002.9 to 2,320.7)	25.6 (12.2 to 43.9)	-89.2 (-44.9 to -31.3)	77.9 (36.3 to 133.1)	88.2 (52.6 to 152.7)	27.9 (47.0 to 49.0)	-89.4 (-47.0 to -30.9)
Trachoma	48.0 (29.6 to 70.2)	43.5 (26.5 to 62.6)	-9.3 (-30.7 to 16.2)	-57.1 (-66.3 to -44.9)	3.6 (2.1 to 5.6)	3.7 (2.1 to 5.7)	2.0 (-16.1 to 26.8)	-53.5 (-67.1 to -41.3)
Dengue	0.1 (0.0 to 0.4)	1.3 (0.3 to 3.9)	850.3 (838.8 to 863.5)	384.7 (378.9 to 391.5)	0.0 (0.0 to 0.1)	0.2 (0.0 to 0.7)	794.3 (562.4 to 1,072.0)	348.8 (248.4 to 470.4)
Yellow fever	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-50.0 (-66.9 to -19.4)	-74.2 (-82.0 to -62.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.0 (-66.9 to -19.4)	-74.2 (-82.0 to -62.1)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-26.4 to 72.5)	0.0 (-52.0 to -8.4)
Intestinal nematode infections	-	-	-	-	2.0 (1.2 to 3.0)	3.9 (2.4 to 6.0)	99.3 (59.0 to 136.7)	-0.2 (-17.0 to 17.0)
Ascariasis	79.8 (51.7 to 116.6)	152.6 (100.8 to 233.0)	88.2 (4.8 to 252.3)	-2.8 (-51.5 to 99.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.4 (36.7 to 159.1)	-0.3 (-31.3 to 45.1)
Trichuriasis	155.3 (97.7 to 235.1)	307.9 (200.1 to 476.3)	95.9 (8.1 to 263.3)	1.4 (-49.6 to 109.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.3 (12.2 to 232.2)	0.2 (-46.3 to 80.2)
Hookworm disease	533.6 (375.5 to 746.6)	1,051.0 (723.0 to 1,497.5)	95.2 (81.1 to 227.0)	0.0 (-45.5 to 79.5)	2.0 (1.2 to 3.0)	3.9 (2.4 to 5.9)	99.3 (59.0 to 136.7)	-0.2 (-17.1 to 17.0)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0	-	-	-
Other neglected tropical diseases	107.4 (79.9 to 134.3)	164.5 (151.5 to 182.1)	52.8 (21.1 to 104.4)	-18.8 (-34.1 to 4.5)	4.4 (2.5 to 6.5)	6.6 (4.3 to 9.6)	48.2 (27.1 to 112.6)	-20.0 (-32.0 to 11.7)
Maternal disorders	-	-	-	-	2.3 (1.5 to 3.2)	3.4 (2.3 to 4.9)	50.7 (26.5 to 76.1)	-26.3 (-37.5 to -13.9)
Maternal hemorrhage	1.6 (1.3 to 1.9)	2.5 (1.7 to 3.3)	52.4 (3.3 to 115.9)	25.4 (-48.8 to 4.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	54.3 (-27.2 to 177.8)	-26.9 (-64.0 to 25.8)
Maternal sepsis and other maternal infections	3.3 (2.3 to 4.3)	3.0 (1.6 to 4.1)	-4.1 (-43.6 to 15.6)	-53.6 (-76.4 to -43.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-1.5 (-40.3 to 51.5)	-52.5 (-71.6 to -29.3)
Maternal hypertensive disorders	2.6 (1.3 to 4.4)	3.7 (1.9 to 6.2)	41.8 (29.5 to 55.3)	-31.5 (-38.3 to -25.2)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.4)	42.1 (21.8 to 66.6)	-31.4 (-41.3 to -19.4)
Obstructed labor	4.6 (3.7 to 5.6)	6.9 (5.6 to 8.3)	49.5 (34.0 to 65.7)	-26.3 (-34.9 to -18.0)	1.5 (1.0 to 2.1)	2.2 (1.5 to 3.2)	49.8 (28.9 to 72.8)	-26.2 (-36.9 to -15.4)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	71.9 (-15.3 to 172.0)	-20.2 (-57.6 to 21.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other maternal disorders	-	-	-	-	0.5 (0.3 to 0.8)	0.9 (0.5 to 1.3)	58.0 (47.7 to 135.6)	-23.2 (-48.7 to 14.4)
Neonatal disorders	-	-	-	-	3.4 (1.7 to 6.4)	11.7 (7.4 to 17.5)	259.9 (112.7 to 514.8)	97.7 (7.6 to 266.1)
Preterm birth complications	18.3 (8.2 to 36.2)	72.8 (36.8 to 132.9)	300.9 (234.2 to 404.0)	107.3 (71.3 to 156.4)	0.9 (0.5 to 1.7)	5.4 (3.2 to 8.5)	465.9 (247.6 to 984.2)	207.7 (91.3 to 490.5)
Neonatal encephalopathy due to birth asphyxia and trauma	42.9 (3.0 to 154.5)	55.4 (6.5 to 180.7)	38.4 (0.3 to 152.9)	-28.9 (-50.1 to 30.3)	1.2 (0.4 to 3.1)	2.6 (1.0 to 5.2)	109.4 (34.6 to 417.2)	14.8 (-29.7 to 225.8)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	118.0 (99.4 to 140.9)	42.0 (29.9 to 56.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	118.5 (93.9 to 147.1)	42.4 (26.3 to 61.0)
Hemolytic disease and other neonatal jaundice	0.5 (0.2 to 1.2)	2.9 (1.1 to 6.3)	439.4 (50.4 to 2,799.2)	234.9 (-8.8 to 1,806.7)	0.2 (0.1 to 0.5)	1.1 (0.4 to 2.7)	456.3 (48.9 to 2,968.0)	238.0 (-10.6 to 1,891.4)
Other neonatal disorders	-	-	-	-	1.0 (0.4 to 2.2)	2.6 (1.2 to 4.8)	170.5 (17.5 to 605.6)	48.8 (-39.0 to 293.8)
Nutritional deficiencies	-	-	-	-	74.9 (49.0 to 107.0)	108.9 (72.1 to 158.3)	45.7 (25.7 to 70.7)	-23.9 (-33.7 to -12.8)
Protein-energy malnutrition	92.2 (46.9 to 158.3)	146.1 (74.6 to 256.4)	56.7 (-34.4 to 295.2)	0.0 (-55.0 to 133.3)	0.0 (4.8 to 21.3)	0.0 (7.7 to 33.8)	0.0 (-33.8 to 297.1)	0.0 (-55.2 to 138.9)
Iodine deficiency	241.9 (124.2 to 414.0)	342.8 (163.9 to 566.7)	47.8 (-49.2 to 278.6)	-27.9 (-77.6 to 132.3)	4.3 (1.8 to 8.5)	6.1 (2.5 to 11.7)	48.0 (-49.0 to 271.8)	-27.6 (-77.6 to 129.2)
Vitamin A deficiency	25.2 (18.1 to 33.8)	28.8 (19.9 to 38.2)	13.7 (-6.0 to 36.8)	-38.1 (-49.1 to -25.2)	1.2 (0.7 to 1.9)	1.4 (0.8 to 2.2)	15.3 (-6.3 to 37.7)	-36.3 (-47.7 to -23.6)

Appendix Table G.4 - South Sudan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	1,595.0 (1,566.1 to 1,624.2)	2,368.6 (2,284.0 to 2,479.1)	48.1 (42.5 to 55.1)	-5.7 (-28.8 to -21.9)	57.9 (38.9 to 83.5)	83.3 (54.9 to 120.5)	44.0 (37.3 to 53.4)	44.0 (-30.1 to -20.8)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.2)	0.0 (0.0 to 0.2)	-	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	5.7 (3.6 to 8.7)	9.1 (5.8 to 13.4)	60.0 (38.1 to 88.5)	19.8 (-28.2 to -2.1)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.5 (0.8 to 2.7)	3.1 (1.7 to 5.2)	99.6 (50.2 to 184.2)	-3.0 (-24.1 to 28.2)
Syphilis	0.8 (0.7 to 0.9)	0.9 (0.8 to 1.1)	19.4 (-1.6 to 41.0)	-40.1 (-48.9 to -30.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	19.9 (7.1 to 56.3)	39.6 (-51.9 to -23.4)
Chlamydial infection	105.0 (74.3 to 134.3)	219.6 (158.3 to 283.3)	108.6 (56.1 to 178.4)	1.6 (-21.5 to 35.2)	0.5 (0.2 to 1.0)	1.3 (0.6 to 2.2)	140.2 (33.6 to 354.1)	17.6 (-34.7 to 131.5)
Gonococcal infection	52.4 (31.5 to 71.7)	104.9 (61.0 to 140.3)	101.7 (6.2 to 216.6)	-3.5 (-45.6 to 44.7)	0.3 (0.2 to 0.5)	0.6 (0.3 to 1.0)	92.6 (24.7 to 210.9)	-7.4 (-37.5 to 44.8)
Trichomoniasis	110.6 (52.4 to 161.7)	161.7 (109.0 to 243.7)	41.2 (-18.2 to 312.8)	-24.5 (-54.2 to 78.5)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.6)	34.4 (-32.4 to 381.9)	-26.8 (-60.0 to 104.2)
Genital herpes	1,208.3 (1,022.7 to 1,403.1)	2,603.0 (2,144.6 to 3,015.8)	116.2 (66.3 to 169.5)	4.7 (-15.2 to 26.3)	0.3 (0.1 to 0.8)	0.7 (0.2 to 1.7)	118.4 (64.8 to 176.9)	5.6 (-16.0 to 28.5)
Other sexually transmitted diseases	2.4 (1.6 to 3.3)	3.5 (2.1 to 4.9)	50.0 (1.4 to 94.5)	-27.5 (-54.7 to -3.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	65.9 (13.4 to 139.6)	-19.8 (-44.6 to 12.0)
Hepatitis	-	-	-	-	0.6 (0.4 to 0.9)	1.0 (0.6 to 1.4)	53.5 (12.3 to 104.7)	-26.2 (-48.4 to 9.1)
Hepatitis A	9.9 (9.4 to 10.5)	18.4 (17.5 to 19.2)	84.1 (83.0 to 85.1)	-0.3 (-0.3 to -0.2)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	101.4 (79.1 to 127.0)	0.8 (-9.7 to 13.0)
Hepatitis B	804.0 (645.8 to 974.7)	1,054.5 (811.4 to 1,298.1)	31.7 (-7.5 to 75.4)	-34.2 (-54.2 to -11.3)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.8)	28.8 (-26.2 to 106.3)	-35.3 (-63.8 to 16.5)
Hepatitis C	104.1 (94.1 to 116.0)	151.6 (133.4 to 169.8)	45.7 (22.9 to 68.9)	-25.9 (-36.7 to -15.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.3 (9.0 to 85.2)	-29.6 (-49.8 to 3.7)
Hepatitis E	1.5 (1.1 to 1.9)	2.9 (2.1 to 3.8)	91.8 (27.2 to 193.6)	-5.2 (-35.1 to 40.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	95.3 (21.3 to 216.0)	-4.4 (-37.8 to 47.6)
Leprosy	4.1 (3.2 to 5.2)	6.5 (5.7 to 7.2)	56.9 (33.5 to 88.2)	-21.4 (-31.5 to -9.0)	0.2 (0.2 to 0.4)	0.4 (0.3 to 0.5)	58.1 (31.3 to 94.2)	-20.2 (-31.4 to -5.7)
Other infectious diseases	76.0 (57.9 to 95.9)	114.8 (99.5 to 131.1)	50.5 (30.3 to 73.7)	-21.7 (-31.5 to -11.6)	3.3 (2.0 to 5.1)	4.7 (3.0 to 7.1)	44.8 (15.3 to 77.8)	-22.2 (-42.8 to -5.6)
Non-communicable diseases	-	-	-	-	380.1 (280.4 to 491.5)	752.1 (557.2 to 970.8)	98.1 (90.2 to 104.2)	2.1 (-5.8 to 0.9)
Neoplasms	-	-	-	-	1.5 (1.0 to 2.3)	4.3 (3.0 to 6.1)	184.3 (102.1 to 286.6)	46.0 (0.5 to 99.0)
Esophageal cancer	0.6 (0.4 to 0.9)	1.4 (0.9 to 2.1)	136.7 (37.2 to 287.3)	16.4 (-31.8 to 88.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	135.1 (40.9 to 260.8)	15.3 (-27.8 to 75.2)
Stomach cancer	0.3 (0.2 to 0.4)	0.8 (0.6 to 1.0)	152.1 (63.7 to 270.8)	21.3 (-19.3 to 76.2)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	146.9 (60.3 to 278.3)	19.6 (-22.2 to 79.9)
Liver cancer	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	89.1 (1.2 to 213.4)	4.1 (-47.4 to 52.5)
Liver cancer due to hepatitis B	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	134.4 (-39.7 to 912.7)	16.4 (-70.9 to 374.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	130.7 (-36.9 to 860.1)	15.1 (-70.6 to 360.3)
Liver cancer due to hepatitis C	0.1 (0.0 to 0.1)	0.3 (0.1 to 0.4)	354.4 (112.7 to 978.8)	119.5 (7.3 to 397.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	334.4 (117.1 to 881.0)	106.7 (8.6 to 333.9)
Liver cancer due to alcohol use	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-13.2 (-59.5 to 102.7)	-54.4 (-78.1 to 6.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.4 (-56.5 to 89.3)	-53.0 (-76.7 to -1.0)
Liver cancer due to other causes	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	145.5 (-44.5 to 138.3)	-40.8 (-72.2 to 27.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.5 (-42.4 to 112.2)	-42.6 (-71.1 to 12.7)
Larynx cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	135.1 (40.3 to 291.1)	14.8 (-31.6 to 87.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	134.3 (34.1 to 304.5)	14.3 (-34.0 to 95.2)
Tracheal, bronchus and lung cancer	0.2 (0.1 to 0.3)	0.5 (0.4 to 0.6)	141.9 (55.9 to 283.6)	20.3 (-21.8 to 85.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	136.0 (43.9 to 270.3)	17.6 (-26.6 to 81.8)
Breast cancer	2.5 (1.5 to 4.0)	7.7 (5.4 to 10.8)	212.0 (82.8 to 449.0)	57.4 (-5.9 to 169.8)	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.9)	193.0 (71.0 to 406.0)	48.0 (-12.2 to 147.2)
Cervical cancer	5.1 (3.1 to 4.0)	5.1 (3.0 to 7.5)	105.5 (12.2 to 287.5)	0.2 (-42.2 to 91.6)	0.4 (0.1 to 0.4)	0.4 (0.2 to 0.7)	189.7 (15.5 to 277.5)	5.4 (-41.5 to 87.4)
Uterine cancer	0.4 (0.2 to 0.8)	0.9 (0.5 to 1.5)	112.5 (3.1 to 328.2)	10.2 (-43.8 to 117.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	113.4 (1.6 to 320.6)	9.4 (-46.3 to 111.4)
Prostate cancer	1.5 (0.7 to 2.6)	8.4 (4.6 to 13.8)	467.0 (197.8 to 924.7)	158.8 (38.2 to 345.9)	0.2 (0.1 to 0.3)	0.8 (0.4 to 1.4)	422.9 (183.5 to 817.5)	137.8 (30.3 to 306.6)
Colon and rectum cancer	1.0 (0.7 to 1.4)	3.1 (2.5 to 3.8)	199.3 (105.9 to 333.9)	49.9 (4.2 to 111.6)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	187.3 (92.6 to 326.3)	43.6 (-1.3 to 106.6)
Lip and oral cavity cancer	0.5 (0.3 to 0.8)	1.2 (0.9 to 1.7)	130.2 (41.5 to 258.4)	16.8 (-21.2 to 84.2)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	131.8 (40.9 to 271.9)	18.3 (-27.2 to 87.1)
Nasopharynx cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	50.4 (-14.6 to 162.4)	-22.4 (-55.9 to 29.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.3 (-12.0 to 160.7)	22.6 (-55.1 to 28.9)
Other pharynx cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	100.6 (9.8 to 309.4)	1.6 (-44.7 to 96.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.2 (10.7 to 278.6)	3.7 (-44.3 to 88.8)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	176.1 (72.9 to 326.3)	33.1 (-16.3 to 98.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	156.0 (67.5 to 279.3)	23.1 (-18.5 to 79.6)
Pancreatic cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	134.5 (51.4 to 249.5)	13.9 (-25.9 to 65.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.2 (54.1 to 227.1)	10.5 (-25.6 to 54.4)
Malignant skin melanoma	0.2 (0.2 to 0.5)	0.6 (0.6 to 1.3)	156.1 (59.0 to 323.7)	25.7 (-20.5 to 105.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	156.6 (58.0 to 322.3)	23.4 (-21.2 to 104.1)
Non-melanoma skin cancer	0.3 (0.3 to 0.4)	1.2 (0.9 to 1.6)	240.0 (150.4 to 380.5)	58.7 (15.6 to 123.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	372.8 (210.0 to 611.8)	105.9 (28.6 to 216.9)
Ovarian cancer	0.2 (0.1 to 0.4)	0.5 (0.4 to 0.8)	142.8 (18.8 to 369.4)	18.9 (-40.9 to 128.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	139.6 (15.5 to 398.6)	18.3 (-41.8 to 141.9)
Testicular cancer	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.7)	242.4 (77.1 to 535.9)	66.4 (-12.6 to 201.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	229.0 (70.1 to 521.8)	57.8 (-16.0 to 190.9)
Kidney cancer	0.2 (0.3 to 1.3)	0.7 (0.8 to 2.0)	102.7 (-3.6 to 287.8)	47.3 (-9.8 to 127.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	115.7 (13.2 to 290.1)	48.9 (-4.9 to 134.5)
Bladder cancer	0.2 (0.2 to 0.4)	0.6 (0.4 to 0.8)	154.7 (57.6 to 309.4)	15.9 (-28.4 to 76.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	148.9 (48.9 to 296.8)	12.4 (-30.5 to 75.6)
Brain and nervous system cancer	0.2 (0.2 to 0.3)	0.6 (0.4 to 0.8)	160.7 (65.2 to 303.4)	32.6 (-8.9 to 93.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	158.0 (73.2 to 291.8)	27.3 (-12.2 to 85.7)
Thyroid cancer	0.3 (0.1 to 0.5)	0.7 (0.4 to 1.1)	149.9 (19.5 to 365.0)	25.9 (-38.6 to 133.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	145.6 (23.9 to 351.4)	22.7 (-36.5 to 120.1)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	136.3 (37.8 to 288.2)	48.0 (-31.7 to 93.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	142.1 (39.9 to 299.6)	19.5 (-31.3 to 96.1)
Hodgkin lymphoma	0.3 (0.2 to 0.5)	0.9 (0.6 to 1.4)	197.8 (82.3 to 387.0)	65.6 (6.8 to 160.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	186.6 (89.0 to 359.2)	52.0 (-3.3 to 136.6)
Non-Hodgkin lymphoma	1.2 (0.7 to 1.9)	2.9 (1.9 to 4.1)	139.7 (44.0 to 291.3)	41.7 (-7.6 to 124.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	137.7 (52.7 to 285.0)	36.2 (-12.6 to 117.5)
Multiple myeloma	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.4)	161.0 (53.0 to 331.4)	28.1 (-24.7 to 111.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	155.9 (50.1 to 328.1)	26.4 (-25.4 to 111.5)
Leukemia	0.2 (0.2 to 0.4)	0.6 (0.4 to 0.9)	163.8 (56.5 to 336.9)	48.0 (-1.6 to 121.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	159.6 (75.6 to 296.0)	36.4 (-5.1 to 99.4)
Other neoplasms	2.5 (1.5 to 5.1)	8.4 (5.8 to 12.5)	256.3 (80.4 to 473.1)	85.5 (22.8 to 168.1)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.8)	247.2 (92.7 to 434.8)	71.8 (15.8 to 148.4)
Cardiovascular diseases	-	-	-	-	9.5 (6.5 to 13.2)	18.8 (12.9 to 26.3)	97.0 (55.3 to 153.4)	-3.6 (-23.2 to 18.7)
Rheumatic heart disease	60.9 (48.3 to 75.1)	114.6 (88.1 to 141.5)	88.2 (34.4 to 160.4)	-5.3 (-30.5 to 25.6)	3.0 (1.9 to 4.5)	5.5 (3.4 to 8.4)	84.3 (35.0 to 150.3)	-9.3 (-30.6 to 21.4)
Ischemic heart disease	53.2 (40.5 to 69.0)	81.2 (65.6 to 101.6)	52.7 (2.9 to 120.0)	-26.2 (-47.5 to 2.0)	2.7 (1.6 to 4.1)	3.9 (2.4 to 5.9)	42.4 (-13.8 to 127.7)	-29.9 (-54.8 to 6.3)
Cerebrovascular disease	-	-	-	-	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	114.6 (63.9 to 188.9)	5.3 (-17.7 to 39.3)
Ischemic stroke	1.5 (1.2 to 1.9)	3.2 (2.6 to 3.8)	115.3 (61.5 to 191.3)	4.3 (-19.6 to 39.7)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	115.5 (62.7 to 194.1)	5.8 (-19.2 to 42.3)
Hemorrhagic stroke	0.4 (0.3 to 0.5)	0.9 (0.7 to 1.2)	113.3 (55.8 to 192.6)	3.0 (-22.6 to 38.1)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	112.8 (56.1 to 192.9)	3.3 (-23.2 to 39.1)
Hypertensive heart disease	7.3 (5.2 to 9.6)	17.9 (13.0 to 24.2)	143.1 (73.7 to 273.6)	6.2 (-25.1 to 61.9)	0.8 (0.5 to 1.2)	1.9 (1.2 to 2.8)	143.3 (73.8 to 279.1)	8.4 (-24.8 to 65.4)
Cardiomyopathy and myocarditis	2.2 (1.7 to 2.8)	9.4 (7.0 to 12.3)	326.5 (194.3 to 539.8)	75.2 (13.8 to 171.9)	0.2 (0.1 to 0.2)	0.7 (0.4 to 1.0)	326.5 (190.9 to 536.8)	79.9 (15.8 to 180.9)
Atrial fibrillation and flutter	81.9 (55.2 to 114.7)	159.8 (82.8 to 243.0)	102.6 (-22.4 to 204.2)	-9.1 (-55.6 to 24.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	95.8 (-15.3 to 361.9)	-17.9 (-64.9 to 92.0)
Endocarditis	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	121.7 (22.5 to 266.8)	37.5 (-38.0 to 123.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	137.4 (23.2 to 306.5)	40.4 (-40.8 to 147.9)
Other cardiovascular and circulatory diseases	28.5 (13.9 to 50.2)	67.4 (35.4 to 99.2)	142.1 (2.6 to 424.5)	14.2 (-54.1 to 178.6)	1.9 (0.9 to 3.6)	4.6 (2.2 to 7.7)	148.8 (5.7 to 431.8)	16.4 (-53.1 to 181.8)
Chronic respiratory diseases	-	-	-	-	29.7 (18.8 to 43.7)	49.3 (32.2 to 70.2)	65.9 (36.5 to 100.2)	-17.3 (-31.9 to -0.5)
Chronic obstructive pulmonary disease	192.3 (183.4 to 201.1)	388.0 (370.6 to 404.8)	101.0 (95.1 to 107.6)	-0.9 (-3.7 to 2.5)	15.6 (10.3 to 21.6)	32.8 (21.		

Appendix Table G.4 - South Sudan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	98.9	-4.5
Silicosis	0.0	0.0	90.1	-9.2	(0.0 to 0.0)	(0.0 to 0.0)	(92.1 to 105.2)	(-7.7 to -1.5)
Asbestosis	-	-	0.0	0.0	0.0	0.0	90.0	-9.2
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.1	106.5	0.5	0.0	0.0	106.6	0.6
Asthma	(0.0 to 0.0)	(0.1 to 0.1)	(98.3 to 116.3)	(-3.1 to 4.5)	(0.0 to 0.0)	(0.0 to 0.0)	(97.7 to 116.4)	(-3.6 to 4.8)
Interstitial lung disease and pulmonary sarcoidosis	89.0	160.9	83.1	-7.9	3.8	6.9	84.4	-7.2
Other chronic respiratory diseases	(55.7 to 127.9)	(119.9 to 211.3)	(19.2 to 169.2)	(-34.7 to 30.1)	(2.0 to 6.4)	(4.1 to 10.7)	(18.7 to 170.6)	(-35.0 to 31.4)
Cirrhosis	0.1	0.3	124.2	8.2	0.0	0.0	123.6	7.9
Cirrhosis due to hepatitis B	(0.1 to 0.1)	(0.2 to 0.3)	(58.1 to 229.1)	(-18.9 to 49.0)	(0.0 to 0.0)	(0.0 to 0.1)	(59.2 to 224.6)	(-18.8 to 47.8)
Cirrhosis due to hepatitis C	-	-	-	-	10.3	9.5	-7.0	-53.6
Cirrhosis due to alcohol use	-	-	-	-	(4.7 to 19.2)	(4.6 to 17.1)	(-45.8 to 52.4)	(-73.0 to -23.9)
Cirrhosis due to other causes	0.8	1.2	59.7	-12.8	0.1	0.2	59.7	-12.8
Digestive diseases	(0.5 to 1.0)	(0.9 to 1.6)	(2.2 to 147.8)	(47.1 to 32.0)	(0.1 to 0.2)	(0.1 to 0.3)	(-3.4 to 165.2)	(-48.9 to 38.4)
Peptic ulcer disease	0.4	1.0	156.3	26.9	0.1	0.2	157.8	27.6
Gastritis and duodenitis	(0.2 to 0.7)	(0.7 to 1.4)	(55.0 to 399.3)	(-27.5 to 138.6)	(0.0 to 0.1)	(0.1 to 0.3)	(49.7 to 402.1)	(-28.8 to 140.6)
Appendicitis	0.8	1.0	27.7	-34.5	0.1	0.2	28.4	-33.8
Paralytic ileus and intestinal obstruction	(0.6 to 0.9)	(0.7 to 1.2)	(7.2 to 75.1)	(-52.1 to -10.1)	(0.1 to 0.2)	(0.1 to 0.2)	(-10.8 to 89.4)	(-53.2 to -4.4)
Inguinal, femoral, and abdominal hernia	0.8	1.5	79.1	5.9	0.1	0.3	77.9	4.7
Inflammatory bowel disease	(0.7 to 1.0)	(1.2 to 1.8)	(39.6 to 130.2)	(-21.2 to 45.7)	(0.1 to 0.2)	(0.2 to 0.4)	(23.0 to 155.2)	(-27.5 to 54.6)
Vascular intestinal disorders	-	-	-	-	7.3	14.9	104.1	-1.0
Peptic ulcer disease	38.7	69.3	78.2	-17.4	1.3	2.4	80.0	-18.5
Gastritis and duodenitis	(34.2 to 42.3)	(63.1 to 74.9)	(58.9 to 202.9)	(-25.3 to -6.7)	(0.9 to 1.9)	(1.6 to 3.4)	(45.4 to 115.4)	(-29.2 to -6.2)
Appendicitis	68.2	128.1	87.2	-7.1	2.9	5.7	95.9	-3.4
Paralytic ileus and intestinal obstruction	(62.0 to 73.7)	(118.1 to 138.7)	(68.9 to 106.8)	(-15.3 to 1.5)	(1.9 to 4.1)	(3.8 to 8.0)	(71.7 to 122.5)	(-11.3 to 7.9)
Inguinal, femoral, and abdominal hernia	0.7	1.5	103.8	-0.6	0.2	0.4	102.7	-0.5
Inflammatory bowel disease	(0.5 to 0.9)	(1.1 to 1.9)	(49.0 to 205.5)	(-23.0 to 41.2)	(0.1 to 0.3)	(0.3 to 0.7)	(35.5 to 216.0)	(-28.8 to 51.2)
Vascular intestinal disorders	0.1	0.2	97.9	-1.4	0.0	0.1	99.3	8.9
Peptic ulcer disease	(0.1 to 0.1)	(0.1 to 0.2)	(36.1 to 218.4)	(-12.7 to 18.9)	(0.0 to 0.0)	(0.0 to 0.1)	(24.8 to 232.4)	(-21.1 to 33.2)
Gastritis and duodenitis	15.0	55.2	265.4	180.0	0.2	0.6	254.9	178.7
Appendicitis	(12.5 to 19.2)	(47.4 to 67.2)	(184.5 to 380.8)	(131.7 to 236.6)	(0.1 to 0.3)	(0.3 to 1.1)	(172.7 to 376.8)	(129.1 to 238.7)
Paralytic ileus and intestinal obstruction	5.3	13.7	154.8	25.7	1.1	2.9	157.0	27.3
Inflammatory bowel disease	(5.1 to 5.6)	(13.1 to 14.2)	(138.8 to 169.8)	(19.0 to 32.4)	(0.8 to 1.5)	(2.0 to 3.9)	(133.1 to 181.3)	(17.1 to 37.5)
Vascular intestinal disorders	0.0	0.0	89.8	-15.0	0.0	0.0	93.5	-9.6
Gastritis and duodenitis	(0.0 to 0.0)	(0.0 to 0.0)	(23.5 to 170.3)	(-49.3 to 29.2)	(0.0 to 0.0)	(0.0 to 0.0)	(24.9 to 178.5)	(-45.1 to 47.5)
Appendicitis	1.7	4.2	140.6	15.4	0.2	0.4	140.5	17.0
Paralytic ileus and intestinal obstruction	(1.5 to 1.9)	(3.8 to 4.6)	(105.3 to 182.2)	(-2.0 to 37.2)	(0.1 to 0.2)	(0.3 to 0.6)	(99.6 to 195.4)	(-1.6 to 41.1)
Inflammatory bowel disease	1.0	2.1	116.3	4.4	0.3	0.6	117.1	5.5
Vascular intestinal disorders	(0.9 to 1.0)	(2.0 to 2.2)	(98.5 to 136.4)	(-3.9 to 13.3)	(0.2 to 0.4)	(0.4 to 0.8)	(80.6 to 159.3)	(-10.1 to 23.9)
Other digestive diseases	-	-	-	-	1.1	1.8	75.9	-14.5
Neurological disorders	-	-	-	-	(0.6 to 1.8)	(1.1 to 2.8)	(22.5 to 145.6)	(-40.0 to 19.3)
Alzheimer disease and other dementias	-	-	-	-	21.3	48.3	127.7	5.3
Parkinson disease	-	-	-	-	(14.0 to 30.0)	(31.6 to 67.9)	(78.0 to 187.9)	(-16.4 to 23.7)
Epilepsy	7.3	19.0	157.9	1.1	0.9	2.5	169.0	4.2
Multiple sclerosis	(6.4 to 8.2)	(16.6 to 21.2)	(116.4 to 206.6)	(-14.8 to 18.4)	(0.7 to 1.2)	(1.8 to 3.3)	(124.8 to 218.5)	(-12.7 to 22.6)
Migraine	0.4	1.0	123.4	-1.5	0.1	0.1	123.3	0.6
Tension-type headache	(0.3 to 0.6)	(0.6 to 1.4)	(101.7 to 151.5)	(-9.4 to 11.3)	(0.0 to 0.1)	(0.1 to 0.2)	(83.2 to 173.7)	(-15.1 to 20.8)
Medication overuse headache	11.2	21.7	94.8	-0.6	3.1	6.2	99.9	2.3
Other neurological disorders	(6.1 to 17.9)	(11.9 to 35.0)	(-11.9 to 307.8)	(-54.0 to 109.7)	(1.5 to 5.5)	(3.1 to 10.5)	(-9.9 to 324.1)	(-53.7 to 114.5)
Schizophrenia	0.4	0.9	128.7	14.6	0.1	0.3	131.6	16.0
Alcohol use disorders	(0.3 to 0.4)	(0.8 to 1.0)	(97.4 to 166.1)	(-0.3 to 32.0)	(0.1 to 0.2)	(0.2 to 0.4)	(83.6 to 187.8)	(-8.2 to 42.8)
Drug use disorders	315.6	676.2	112.7	6.8	10.6	22.8	114.0	7.4
Opioid use disorders	(216.4 to 403.7)	(488.1 to 888.7)	(37.0 to 250.2)	(-28.6 to 59.9)	(5.8 to 16.7)	(12.4 to 37.1)	(36.0 to 256.8)	(-28.7 to 63.2)
Cocaine use disorders	67.1	1,464.7	116.5	3.4	1.0	2.2	118.2	4.1
Amphetamine use disorders	(61.9 to 722.2)	(1,339.1 to 1,575.6)	(95.4 to 142.3)	(-5.1 to 14.0)	(0.5 to 1.8)	(1.1 to 3.9)	(94.5 to 144.2)	(-4.6 to 15.6)
Other drug use disorders	27.0	78.8	190.6	42.2	4.2	12.2	193.1	43.8
Depressive disorders	(18.0 to 37.1)	(51.5 to 110.1)	(123.2 to 281.7)	(4.6 to 86.5)	(2.4 to 6.6)	(6.9 to 19.1)	(124.3 to 288.9)	(6.2 to 88.3)
Bipolar disorder	0.0	0.0	78.1	-9.1	1.3	2.0	59.3	-36.4
Anxiety disorders	(0.0 to 0.0)	(0.0 to 0.0)	(32.9 to 142.3)	(-33.8 to 23.7)	(0.7 to 3.1)	(1.2 to 3.4)	(-5.2 to 136.6)	(-62.5 to -3.9)
Eating disorders	-	-	-	-	125.3	251.6	101.0	-0.2
Anorexia nervosa	12.2	24.7	101.8	0.5	(87.8 to 167.9)	(176.2 to 339.2)	(91.2 to 109.4)	(-4.8 to 41.1)
Bulimia nervosa	(11.1 to 13.2)	(22.7 to 26.8)	(93.1 to 111.4)	(-3.3 to 4.9)	7.7	15.6	103.5	1.4
Autistic spectrum disorders	57.1	105.3	84.0	-9.2	5.5	10.2	84.7	-8.8
Depressive disorders	(52.5 to 62.1)	(97.3 to 113.9)	(74.6 to 93.6)	(-13.4 to -4.6)	(3.7 to 7.8)	(6.8 to 14.5)	(73.5 to 97.0)	(-14.2 to -3.3)
Bipolar disorder	-	-	-	-	6.9	14.5	109.2	2.8
Anxiety disorders	9.1	18.8	106.9	2.3	(4.6 to 9.5)	(9.4 to 20.1)	(85.8 to 134.8)	(-8.3 to 13.9)
Eating disorders	(6.0 to 13.1)	(12.4 to 27.6)	(80.0 to 133.1)	(-10.8 to 13.3)	3.7	7.6	108.2	2.9
Anorexia nervosa	(2.1 to 3.2)	(4.6 to 6.8)	(65.3 to 183.8)	(-15.3 to 34.5)	(0.2 to 0.6)	(0.5 to 1.2)	(74.7 to 205.8)	(-20.4 to 43.7)
Bulimia nervosa	9.0	18.7	106.8	0.4	1.2	2.4	108.0	1.1
Autistic spectrum disorders	(8.4 to 9.7)	(17.2 to 20.3)	(84.9 to 130.8)	(-9.3 to 11.3)	(0.7 to 1.7)	(1.5 to 3.6)	(75.4 to 143.1)	(-13.9 to 17.9)
Depressive disorders	7.3	15.1	106.2	0.1	0.2	0.4	107.0	0.7
Bipolar disorder	(5.4 to 8.9)	(11.2 to 18.4)	(105.7 to 106.6)	(0.1 to 0.2)	(0.1 to 0.3)	(0.2 to 0.7)	(75.0 to 149.8)	(-14.6 to 19.5)
Anxiety disorders	-	-	-	-	1.5	3.2	110.9	2.6
Eating disorders	-	-	-	-	(1.0 to 2.3)	(2.0 to 4.7)	(53.0 to 187.7)	(-24.8 to 40.2)
Anorexia nervosa	-	-	-	-	58.7	115.0	96.4	-2.0
Bulimia nervosa	-	-	-	-	(37.3 to 85.7)	(75.1 to 165.6)	(78.1 to 112.5)	(-10.9 to 6.7)
Autistic spectrum disorders	262.8	511.7	94.6	-3.0	53.3	104.0	95.7	-2.3
Depressive disorders	(202.3 to 326.2)	(409.8 to 626.5)	(75.7 to 112.2)	(-13.0 to 6.6)	(33.2 to 79.2)	(66.4 to 152.6)	(76.0 to 113.8)	(-12.2 to 7.4)
Bipolar disorder	57.2	116.1	102.2	-0.1	5.4	11.0	103.4	0.7
Anxiety disorders	(47.2 to 68.0)	(95.8 to 138.0)	(100.5 to 103.7)	(-0.2 to -0.1)	(3.5 to 7.9)	(7.2 to 16.1)	(97.5 to 109.8)	(-1.6 to 3.1)
Eating disorders	31.7	64.4	102.9	-0.4	6.3	12.9	104.3	0.3
Anorexia nervosa	(27.2 to 36.0)	(54.9 to 73.6)	(89.9 to 114.4)	(-5.8 to 4.3)	(3.9 to 9.6)	(8.0 to 19.4)	(88.5 to 120.0)	(-6.8 to 6.8)
Bulimia nervosa	17.1	39.1	102.6	0.2	15.6	31.9	103.8	0.5
Autistic spectrum disorders	(69.6 to 280.7)	(142.8 to 575.7)	(100.0 to 105.5)	(-0.3 to -0.1)	(5.9 to 27.9)	(11.9 to 57.4)	(97.0 to 110.9)	(-2.0 to 3.3)
Anorexia nervosa	-	-	-	-	1.4	2.9	108.0	0.5
Bulimia nervosa	1.0	2.0	110.4	2.1	0.2	0.4	112.7	2.8
Autistic spectrum disorders	(0.7 to 1.2)	(1.5 to 2.7)	(86.5 to 135.0)	(-8.7 to 13.5)	(0.1 to 0.3)	(0.3 to 0.7)	(60.3 to 170.9)	(-21.4 to 30.2)
Depressive disorders	5.7	11.7	105.9	-0.6	1.2	2.5	107.4	0.2
Bipolar disorder	(3.9 to 8.3)	(8.0 to 17.1)	(105.4 to 106.4)	(-0.7 to -0.5)	(0.7 to 1.9)	(1.4 to 4.0)	(86.7 to 128.4)	(-9.3 to 9.7)
Anxiety disorders	-	-	-	-	6.9	13.5	96.6	1.0
Eating disorders	17.7	34.8	96.0	0.3	(4.8 to 9.3)	(9.3 to 18.3)	(89.3 to 104.7)	(-2.3 to 4.5)
Anorexia nervosa	(16.8 to 18.6)	(33.0 to 36.6)	(95.6 to 96.4)	(0.3 to 0.3)	4.3	8.5	96.8	1.0
Bulimia nervosa	25.5	50.0	95.3	0.4	2.5	5.0	96.2	1.0
Autistic spectrum disorders	(23.9 to 27.0)	(46.8 to 52.9)	(94.8 to 95.9)	(0.4 to 0.4)	(1.8 to 3.5)	(3.4 to 6.9)	(87.3 to 105.0)	(-2.9 to 4.9)
Depressive disorders	41.2	83.2	101.4	0.3	10.5	20.2	102.2	0.7
Bipolar disorder	(38.0 to 44.5)	(76.8 to 89.9)	(101.2 to 101.4)	(0.3 to 0.4)	(0.3 to 0.8)	(0.6 to 1.5)	(87.2 to 118.9)	(-6.8 to 8.8)
Anxiety disorders	60.1	122.2	103.6	6.3	7.2	14.6	104.7	0.8
Eating disorders	(56.7 to 63.7)	(115.7 to 130.0)	(103.3 to 103.8)	(0.3 to 0.3)	(4.5 to 10.4)	(9.2 to 21.3)	(84.7 to 113.8)	(-3.7 to 5.4)
Anorexia nervosa	71.4	181.8	148.4	29.5	3.5	8.8	150.3	30.1
Bulimia nervosa	(18.9 to 109.9)	(94.4 to 254.2)	(98.9 to 427.2)	(1.9 to 166.4)	(0.9 to 5.9)	(4.2 to 13.8)	(97.9 to 425.8)	(1.9 to 169.6)
Autistic spectrum disorders	71.1	145.3	103.6	0.2	5.2	10.7	104.7	0.9
Anorexia nervosa	(66.3 to 75.5)	(135.4 to 154.6)	(102.8 to 104.4)	(0.1 to 0.2)	(3.5 to 7.0)	(7.3 to 14.4)	(96.4 to 113.3)	(-2.8 to 4.9)
Bulimia nervosa	-	-	-	-	29.2	56.6	94.5	0.4
Autistic spectrum disorders	75.0	172.8	129.0	15.7	(20.4 to 39.2)	(39.9 to 75.9)	(76.7 to 112.3)	(-9.7 to 10.1)
Depressive disorders	(59.8 to 91.2)	(142.0 to 206.1)	(74.1 to 200.5)	(-16.1 to 53.7)	5.6	12.9	130.5	17.7
Bipolar disorder	0.1	0.1	52.3	0.0	(3.6 to 7.9)	(8.3 to 18.1)	(69.7 to 204.8)	(-17.3 to 55.1)
Anxiety disorders	(0.1 to 0.1)	(0.1 to 0.1)	(39.0 to 67.3)	(-19.5 to -7.2)	-13.6			

Appendix Table G.4 - South Sudan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.1 (1.0 to 1.2)	2.3 (2.2 to 2.5)	112.2 (92.9 to 130.6)	0.0 (-1.2 to 15.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	112.3 (63.6 to 177.6)	7.5 (-12.4 to 31.0)
Urolithiasis	13.0 (9.8 to 16.6)	21.0 (16.2 to 27.1)	62.2 (38.6 to 78.8)	0.1 (-32.6 to -12.7)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	97.7 (74.0 to 131.5)	-3.3 (-13.6 to 9.5)
Benign prostatic hyperplasia	33.5 (30.5 to 36.4)	75.0 (68.3 to 81.7)	122.7 (97.7 to 154.7)	0.2 (-10.4 to 13.6)	1.2 (0.8 to 1.6)	2.6 (1.7 to 3.7)	124.6 (98.7 to 158.9)	2.0 (-9.2 to 16.0)
Male infertility due to other causes	33.4 (22.0 to 48.2)	60.7 (37.6 to 89.4)	76.2 (61.1 to 227.6)	-16.8 (49.8 to 55.6)	0.2 (0.1 to 0.4)	0.4 (0.1 to 0.9)	84.6 (7.2 to 230.4)	-12.6 (-47.9 to 56.9)
Other urinary diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	27.5 (8.1 to 134.7)	0.1 (-54.0 to 14.4)
Gynecological diseases	-	-	-	-	6.0 (3.9 to 8.9)	11.1 (7.0 to 16.6)	84.1 (54.4 to 117.7)	-9.9 (-23.1 to 4.3)
Uterine fibroids	90.2 (81.7 to 98.0)	176.6 (159.7 to 192.2)	95.3 (94.4 to 96.0)	-0.3 (-0.4 to -0.2)	1.5 (0.9 to 2.4)	2.5 (1.4 to 4.1)	60.9 (40.0 to 75.9)	-20.0 (-31.0 to -11.9)
Polycystic ovarian syndrome	80.9 (72.5 to 88.9)	171.6 (149.7 to 194.0)	110.4 (79.9 to 153.1)	2.4 (-11.7 to 20.8)	0.8 (0.4 to 1.4)	1.6 (0.8 to 3.1)	111.2 (81.2 to 153.0)	2.6 (-10.7 to 20.7)
Female infertility due to other causes	36.3 (11.4 to 65.5)	59.5 (17.9 to 112.5)	65.1 (-61.5 to 601.1)	0.2 (-85.2 to 257.5)	0.3 (0.0 to 0.5)	0.3 (0.1 to 0.8)	67.1 (-60.4 to 616.4)	-22.9 (-85.0 to 257.2)
Endometriosis	8.3 (7.0 to 9.6)	15.3 (12.7 to 17.9)	82.4 (40.6 to 127.9)	-9.9 (29.7 to 11.5)	0.8 (0.5 to 1.1)	1.4 (0.9 to 2.0)	83.8 (41.4 to 131.0)	-9.1 (-29.3 to 13.5)
Genital prolapse	149.7 (124.6 to 171.9)	309.8 (258.2 to 357.9)	106.3 (65.6 to 160.1)	3.2 (-15.9 to 26.0)	0.5 (0.2 to 0.9)	1.0 (0.5 to 1.8)	106.9 (65.1 to 165.9)	3.7 (-15.5 to 29.0)
Premenstrual syndrome	203.7 (152.9 to 273.0)	421.8 (275.9 to 573.2)	106.2 (22.6 to 216.3)	1.0 (-39.7 to 52.3)	1.7 (0.6 to 2.7)	3.5 (1.9 to 5.7)	107.0 (24.1 to 219.5)	1.0 (-59.2 to 54.4)
Other gynecological diseases	18.3 (13.5 to 23.2)	27.8 (19.5 to 36.5)	50.9 (6.3 to 111.7)	-26.1 (-46.1 to 3.2)	1.6 (0.3 to 0.9)	0.8 (0.3 to 1.2)	39.6 (-32.1 to 140.1)	-33.4 (-64.5 to 14.9)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	4.1 (2.6 to 6.0)	7.1 (4.7 to 10.2)	73.6 (50.4 to 107.7)	-10.5 (-21.6 to 6.5)
Thalassemias	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	69.7 (9.2 to 308.8)	-9.8 (-40.9 to 111.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.8 (8.2 to 297.7)	19.0 (-41.4 to 106.8)
Thalassemia trait	38.2 (16.5 to 83.7)	80.7 (43.3 to 162.3)	102.5 (91.7 to 231.9)	3.9 (-0.9 to 72.8)	0.7 (0.4 to 1.1)	1.6 (1.0 to 2.3)	140.4 (79.5 to 203.7)	25.6 (-7.5 to 54.6)
Sickle cell disorders	0.9 (0.4 to 1.5)	1.6 (0.6 to 2.7)	80.0 (25.6 to 321.8)	-3.4 (-31.2 to 17.6)	0.1 (0.0 to 0.2)	0.2 (0.0 to 0.4)	109.1 (30.0 to 193.7)	10.1 (-31.5 to 47.7)
Sickle cell trait	249.9 (134.4 to 380.4)	486.0 (251.4 to 748.4)	94.0 (54.3 to 109.7)	0.5 (-20.2 to 8.6)	1.1 (0.7 to 1.6)	2.3 (1.5 to 3.4)	102.7 (63.8 to 167.2)	5.9 (-15.2 to 51.2)
G6PD deficiency	325.0 (223.4 to 431.3)	599.6 (332.4 to 878.9)	85.7 (-5.9 to 208.8)	-4.0 (51.0 to 59.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	90.0 (57.1 to 126.1)	-1.6 (-11.6 to 9.6)
G6PD trait	1,222.1 (1,042.3 to 1,333.7)	2,351.4 (2,066.2 to 2,577.5)	90.9 (62.7 to 130.5)	-1.3 (-15.9 to 19.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	95.7 (-56.8 to 368.9)	4.7 (-75.2 to 159.0)
Other hemoglobinopathies and hemolytic anemias	66.8 (55.2 to 75.6)	92.8 (82.5 to 102.3)	38.7 (19.4 to 69.6)	-33.8 (-41.0 to -23.6)	2.1 (1.3 to 3.1)	2.9 (1.8 to 4.3)	35.9 (5.4 to 91.6)	-33.6 (-46.6 to -11.8)
Endocrine, metabolic, blood, and immune disorders	83.3 (74.3 to 93.3)	127.5 (106.8 to 146.6)	52.1 (21.4 to 90.1)	-21.8 (-34.5 to -6.7)	3.0 (1.9 to 4.4)	4.5 (2.9 to 6.5)	59.5 (10.5 to 109.8)	-19.8 (-37.8 to 5.4)
Musculoskeletal disorders	-	-	-	-	62.4 (44.8 to 82.0)	130.2 (92.3 to 173.0)	107.9 (90.5 to 129.9)	2.7 (-5.6 to 11.5)
Rheumatoid arthritis	12.5 (11.9 to 13.0)	23.6 (22.6 to 24.6)	88.9 (78.4 to 99.8)	-10.2 (-15.4 to -4.3)	2.9 (2.1 to 3.8)	5.5 (3.9 to 7.2)	90.7 (75.4 to 107.0)	-8.8 (-15.4 to -1.5)
Osteoarthritis	105.6 (101.4 to 109.8)	223.2 (214.1 to 232.3)	110.6 (99.3 to 122.8)	1.4 (-3.8 to 6.8)	6.3 (4.4 to 8.5)	13.3 (9.4 to 18.0)	111.5 (99.6 to 124.1)	3.0 (-2.5 to 8.7)
Low back and neck pain	-	-	-	-	45.1 (32.1 to 60.4)	94.3 (65.2 to 128.8)	108.3 (84.3 to 136.9)	2.8 (-8.9 to 15.2)
Low back pain	242.9 (219.3 to 262.6)	492.4 (449.8 to 540.6)	101.6 (79.4 to 129.0)	-0.2 (-11.7 to 11.4)	25.5 (17.7 to 36.7)	53.8 (36.4 to 76.1)	102.9 (80.5 to 130.4)	1.0 (-10.7 to 12.8)
Neck pain	192.8 (158.0 to 228.4)	415.9 (342.3 to 490.8)	116.0 (68.1 to 183.2)	4.8 (-16.5 to 33.0)	18.6 (12.5 to 26.3)	40.3 (26.0 to 56.9)	117.3 (68.9 to 186.3)	5.8 (-15.9 to 34.3)
Gout	0.8 (0.7 to 0.9)	1.5 (1.3 to 1.7)	101.2 (70.1 to 140.5)	-1.6 (-16.9 to 16.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	103.5 (55.1 to 170.4)	0.4 (-23.3 to 30.4)
Other musculoskeletal disorders	92.3 (69.2 to 118.7)	194.3 (148.1 to 243.2)	109.8 (91.6 to 128.4)	5.1 (-3.5 to 13.0)	8.2 (5.2 to 12.1)	17.5 (11.0 to 25.6)	111.8 (94.0 to 131.0)	8.3 (-2.3 to 14.8)
Other non-communicable diseases	-	-	-	-	93.3 (62.3 to 135.0)	177.3 (119.1 to 254.3)	89.9 (81.9 to 98.4)	-5.3 (-8.9 to -2.1)
Congenital anomalies	-	-	-	-	4.8 (3.1 to 7.1)	10.0 (6.5 to 14.2)	106.1 (80.0 to 140.9)	4.2 (-8.9 to 21.6)
Neural tube defects	0.3 (0.2 to 0.4)	1.4 (1.2 to 1.7)	374.4 (259.8 to 565.3)	180.6 (110.6 to 306.3)	0.1 (0.0 to 0.1)	0.4 (0.2 to 0.5)	443.7 (249.2 to 739.0)	237.0 (116.5 to 434.6)
Congenital heart anomalies	2.1 (1.3 to 3.4)	14.2 (10.0 to 18.4)	581.1 (277.0 to 1,078.0)	318.1 (118.4 to 665.2)	0.1 (0.0 to 0.2)	0.5 (0.2 to 0.9)	469.0 (198.5 to 882.5)	250.5 (79.4 to 537.7)
Orofacial clefts	0.2 (0.1 to 0.4)	1.6 (1.0 to 2.5)	588.8 (262.2 to 1,236.0)	375.2 (131.1 to 871.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	588.8 (235.4 to 1,300.4)	358.7 (117.2 to 902.7)
Down syndrome	1.9 (1.4 to 2.4)	6.6 (5.3 to 8.0)	253.9 (162.3 to 377.1)	92.7 (42.1 to 159.8)	0.2 (0.1 to 0.3)	0.8 (0.5 to 1.0)	251.5 (149.8 to 395.5)	90.8 (35.0 to 167.6)
Turner syndrome	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	182.1 (101.0 to 352.1)	47.7 (3.3 to 138.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	186.1 (96.9 to 366.8)	48.1 (1.3 to 144.0)
Klinefelter syndrome	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	87.9 (30.4 to 169.5)	-2.7 (-32.7 to 39.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.4 (34.3 to 178.9)	-2.5 (-32.5 to 40.0)
Chromosomal unbalanced rearrangements	5.2 (2.4 to 4.7)	10.9 (9.2 to 13.4)	341.9 (127.2 to 409.9)	0.4 (-23.3 to 39.5)	0.2 (0.2 to 0.6)	0.4 (0.0 to 1.7)	349.3 (126.1 to 424.3)	84.6 (20.4 to 187.2)
Other congenital anomalies	42.7 (29.8 to 52.7)	72.8 (51.8 to 92.4)	69.3 (47.1 to 98.8)	-13.3 (-24.9 to 0.9)	4.1 (2.4 to 6.2)	7.1 (4.2 to 10.8)	72.4 (45.7 to 107.5)	-12.2 (-24.9 to 6.2)
Skin and subcutaneous diseases	-	-	-	-	26.6 (17.0 to 41.9)	53.9 (34.2 to 85.5)	102.4 (91.0 to 117.3)	2.3 (-3.6 to 8.1)
Dermatitis	224.9 (173.8 to 288.9)	447.5 (344.1 to 578.7)	98.4 (95.7 to 100.0)	-0.0 (-0.1 to 0.0)	8.0 (4.9 to 11.7)	15.7 (9.7 to 23.2)	97.5 (89.1 to 105.4)	0.5 (-2.7 to 3.8)
Psoriasis	34.8 (30.1 to 39.8)	70.3 (60.8 to 80.6)	101.7 (100.2 to 102.8)	0.0 (-0.0 to 0.0)	2.8 (1.9 to 4.0)	5.7 (3.9 to 8.0)	103.2 (89.3 to 117.3)	1.0 (-4.6 to 6.7)
Cellulitis	1.2 (0.9 to 1.5)	2.4 (1.9 to 2.9)	101.1 (74.4 to 126.5)	4.4 (-8.0 to 17.4)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	101.0 (50.2 to 162.2)	5.7 (-17.0 to 31.1)
Pyoderma	10.1 (7.4 to 13.0)	17.1 (12.9 to 21.9)	69.7 (57.0 to 83.6)	-4.2 (-10.5 to 3.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	69.9 (52.8 to 89.2)	-3.6 (-12.6 to 6.0)
Scabies	92.8 (68.2 to 123.4)	150.5 (115.7 to 194.5)	60.8 (7.5 to 147.9)	-18.9 (-46.3 to 22.3)	2.4 (1.2 to 4.2)	3.9 (2.0 to 6.5)	61.0 (74.1 to 150.3)	-18.4 (-46.4 to 23.6)
Fungal skin diseases	638.8 (460.3 to 907.9)	1,289.1 (923.1 to 1,830.4)	101.3 (98.3 to 103.0)	0.1 (-0.1 to 0.2)	7.2 (4.1 to 8.1)	7.2 (2.8 to 16.2)	101.6 (98.5 to 104.3)	0.1 (-0.2 to 1.4)
Viral skin diseases	138.2 (100.8 to 175.4)	267.3 (198.8 to 337.3)	92.8 (84.5 to 102.2)	-0.1 (-3.0 to 3.3)	4.2 (2.4 to 6.2)	8.2 (4.7 to 13.2)	93.4 (83.0 to 104.1)	0.8 (-3.5 to 4.8)
Acne vulgaris	228.4 (155.2 to 309.9)	545.1 (377.9 to 781.3)	131.4 (42.7 to 324.9)	12.0 (-29.4 to 101.1)	2.5 (1.1 to 4.9)	5.9 (2.5 to 12.1)	131.8 (43.8 to 328.7)	12.0 (-29.6 to 101.2)
Alopecia areata	5.2 (4.6 to 5.9)	10.1 (9.1 to 11.3)	92.7 (67.1 to 125.4)	-2.0 (-14.9 to 12.8)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	93.8 (57.0 to 137.6)	-1.0 (-16.9 to 18.7)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.8 (51.8 to 138.4)	0.1 (-23.3 to 35.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.8 (51.5 to 138.6)	-0.1 (-23.4 to 25.6)
Urticaria	18.2 (10.9 to 28.4)	54.7 (37.9 to 75.1)	199.7 (86.2 to 406.2)	37.7 (-11.9 to 117.8)	1.1 (0.6 to 1.8)	3.2 (1.8 to 5.2)	203.2 (85.7 to 407.0)	39.7 (-10.2 to 125.8)
Decubitus ulcer	0.6 (0.5 to 0.7)	1.4 (1.2 to 1.6)	128.1 (81.1 to 176.9)	3.1 (-22.5 to 34.8)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	128.4 (73.5 to 184.8)	5.2 (-23.1 to 40.7)
Other skin and subcutaneous diseases	293.4 (198.9 to 418.8)	574.7 (385.4 to 819.9)	95.0 (86.5 to 103.3)	-2.9 (-7.3 to 0.2)	1.7 (0.8 to 3.4)	3.3 (1.5 to 6.8)	95.7 (87.2 to 104.5)	-2.0 (-6.4 to 1.2)
Sense organ diseases	-	-	-	-	51.7 (34.8 to 75.0)	92.9 (62.6 to 133.1)	95.5 (68.4 to 91.6)	-8.8 (-13.3 to -4.7)
Glaucoma	4.0 (2.6 to 5.5)	10.2 (7.5 to 13.1)	155.2 (105.8 to 238.5)	23.9 (-2.8 to 63.5)	0.4 (0.2 to 0.7)	1.0 (0.6 to 1.5)	137.4 (80.4 to 225.9)	14.8 (-15.3 to 58.1)
Cataract	58.5 (42.2 to 75.1)	139.8 (102.9 to 175.4)	140.0 (100.9 to 182.8)	5.9 (-10.0 to 25.1)	4.3 (2.8 to 6.2)	10.6 (6.8 to 14.7)	146.7 (110.8 to 189.3)	9.2 (-5.8 to 25.7)
Macular degeneration	2.2 (1.4 to 3.1)	8.1 (4.5 to 11.8)	278.0 (131.4 to 481.1)	91.8 (23.3 to 190.4)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	284.4 (141.6 to 468.2)	87.8 (26.2 to 173.2)
Uncorrected refractive error	582.3 (493.7 to 669.6)	1,061.3 (882.9 to 1,230.9)	81.4 (46.9 to 123.3)	9.7 (-24.1 to 6.4)	17.5 (12.0 to 24.8)	29.5 (19.6 to 42.7)	68.3 (56.8 to 84.3)	-16.0 (-20.9 to -9.9)
Age-related and other hearing loss	775.8 (662.4 to 876.6)	1,428.1 (1,185.1 to 1,632.9)	83.1 (73.3 to 94.4)	-7.5 (-10.8 to -3.6)	41.9 (15.1 to 37.5)	41.9 (25.2 to 63.8)	70.9 (50.9 to 92.7)	-12.8 (-20.2 to -5.3)
Other vision loss	15.1 (11.7 to 19.3)	27.2 (21.7 to 33.7)	78.8 (52.6 to 111.0)	-0.9 (-13.3 to 14.4)	1.3 (0.8 to 1.9)	2.4 (1.6 to 3.6)	93.2 (60.4 to 141.4)	6.2 (-9.7 to 28.4)
Other sense organ diseases	137.4 (130.4 to 144.7)	260.8 (248.3 to 275.2)	89.1 (75.9 to 104.0)	-0.1 (-6.3 to 6.2)	3.6 (2.2 to 5.4)	6.9 (4.2 to 10.3)	89.5 (74.6 to 106.3)	0.6 (-6.3 to 7.4)
Oral disorders	-	-	-	-	10.1 (5.8 to 16.2)	20.5 (11.7 to 33.2)	102.0 (93.8 to 111.0)	-1.4 (-5.2 to 2.8)
Deciduous caries	627.1 (596.6 to 658.1)	1,143.1 (1,088.4 to 1,198.4)	81.8 (69.6 to 94.2)	0.7 (-6.0 to 7.2)	0.7 (0.1 to 0.5)	0.7 (0.1 to 0.		

Appendix Table G.4 - South Sudan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	94.8 (87.1 to 101.9)	190.6 (178.4 to 204.0)	100.0 (81.5 to 124.1)	-7.2 (-14.4 to 2.8)	2.5 (1.7 to 3.5)	5.1 (3.5 to 7.1)	100.9 (81.7 to 125.8)	-5.6 (-13.6 to 4.4)
Other oral disorders	83.3 (78.2 to 87.8)	167.8 (157.6 to 176.8)	100.8 (85.6 to 116.8)	-0.4 (-8.1 to 6.8)	2.4 (1.5 to 3.6)	4.9 (3.1 to 7.2)	101.5 (85.2 to 118.8)	0.1 (-7.6 to 7.7)
Injuries	-	-	-	-	21.5 (16.5 to 27.4)	40.3 (30.8 to 51.8)	87.3 (81.3 to 95.6)	-4.5 (-7.2 to -0.7)
Transport injuries	-	-	-	-	8.8 (6.6 to 11.2)	15.6 (11.7 to 20.0)	77.0 (69.6 to 85.3)	-6.7 (-9.9 to -3.5)
Road injuries	-	-	-	-	7.3 (5.9 to 9.9)	13.8 (10.4 to 17.7)	76.5 (67.9 to 85.4)	-6.9 (-10.5 to -3.4)
Pedestrian road injuries	-	-	-	-	2.7 (2.0 to 3.4)	4.4 (3.3 to 5.7)	65.0 (51.6 to 80.4)	-11.6 (-17.1 to -5.9)
Cyclist road injuries	-	-	-	-	0.7 (0.5 to 0.9)	1.1 (0.8 to 1.4)	58.2 (47.6 to 70.1)	-14.4 (-20.1 to -7.9)
Motorcyclist road injuries	-	-	-	-	0.9 (0.7 to 1.1)	1.4 (1.0 to 1.8)	51.0 (40.7 to 62.8)	-20.2 (-24.7 to -14.6)
Motor vehicle road injuries	-	-	-	-	3.4 (2.6 to 4.4)	6.8 (5.1 to 8.6)	97.1 (84.0 to 114.3)	2.9 (-3.0 to 10.2)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	13.0 (6.2 to 20.3)	-42.3 (-45.4 to -39.0)
Other transport injuries	-	-	-	-	1.0 (0.7 to 1.3)	1.8 (1.3 to 2.3)	82.1 (71.8 to 92.9)	-4.5 (-10.7 to 1.6)
Unintentional injuries	-	-	-	-	11.8 (9.1 to 15.2)	22.1 (16.9 to 28.4)	86.9 (80.4 to 93.1)	-6.7 (-9.7 to -3.7)
Falls	-	-	-	-	4.9 (3.8 to 6.4)	10.4 (7.9 to 13.4)	110.8 (98.8 to 126.4)	-1.2 (-6.3 to 5.3)
Drowning	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	50.8 (35.0 to 67.1)	-21.3 (-27.9 to -14.6)
Fire, heat, and hot substances	-	-	-	-	1.4 (1.1 to 1.8)	2.3 (1.7 to 3.0)	61.3 (48.3 to 79.4)	-15.5 (-21.4 to -8.5)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	43.4 (23.1 to 68.2)	-26.3 (-35.1 to -15.8)
Exposure to mechanical forces	-	-	-	-	2.8 (2.2 to 3.7)	5.1 (3.9 to 6.6)	78.1 (69.2 to 86.5)	-8.2 (-12.4 to -4.3)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	117.1 (101.4 to 135.1)	9.9 (2.7 to 18.2)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	129.4 (111.3 to 152.4)	16.4 (8.7 to 25.9)
Other exposure to mechanical forces	-	-	-	-	2.7 (2.0 to 3.6)	4.8 (3.6 to 6.2)	75.9 (67.2 to 84.7)	-9.3 (-13.6 to -5.2)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	115.5 (101.9 to 128.6)	9.2 (2.4 to 17.1)
Animal contact	-	-	-	-	0.6 (0.5 to 0.8)	1.0 (0.7 to 1.2)	61.2 (49.2 to 73.3)	-17.8 (-22.6 to -12.6)
Venomous animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	61.1 (44.8 to 81.2)	-18.3 (-25.9 to -9.5)
Non-venomous animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	61.0 (47.4 to 75.6)	-17.5 (-22.5 to -11.3)
Foreign body	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	95.7 (85.5 to 106.6)	-1.1 (-5.5 to 4.0)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	86.9 (63.1 to 112.7)	0.2 (-8.5 to 10.0)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	95.7 (77.6 to 117.2)	-0.3 (-8.0 to 9.3)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	99.1 (87.1 to 111.4)	-1.5 (-7.4 to 5.1)
Other unintentional injuries	-	-	-	-	1.4 (1.1 to 1.8)	2.3 (1.7 to 2.9)	60.6 (47.1 to 76.3)	-17.3 (-23.8 to -10.6)
Self-harm and interpersonal violence	-	-	-	-	0.9 (0.7 to 1.1)	2.0 (1.6 to 2.6)	124.9 (113.8 to 136.9)	16.9 (11.7 to 22.2)
Self-harm	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	113.5 (98.5 to 129.1)	6.7 (0.1 to 13.4)
Interpersonal violence	-	-	-	-	0.8 (0.6 to 1.0)	1.8 (1.4 to 2.3)	126.5 (114.2 to 139.5)	18.6 (12.8 to 24.7)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	133.1 (114.0 to 149.6)	22.0 (12.6 to 30.4)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	157.4 (140.7 to 177.5)	32.5 (23.8 to 42.0)
Assault by other means	-	-	-	-	0.5 (0.4 to 0.7)	1.2 (0.9 to 1.5)	118.1 (101.7 to 133.8)	14.4 (6.8 to 21.7)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.7 (0.2 to 2.0)	-	-
Exposure to forces of nature	-	-	-	-	-	-	-	-
Collective violence and legal intervention	-	-	-	-	-	0.7 (0.2 to 2.0)	-	-

Appendix Table G.4 - Spain prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
All causes	-	-	-	-	4,878.4 (3,651.1 to 6,243.3)	6,506.9 (4,878.9 to 8,352.5)	33.4 (30.4 to 36.5)	1.6 (-3.8 to 0.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	-	-	-	-
HIV/AIDS and tuberculosis	-	-	-	-	15.2 (8.6 to 24.9)	10.4 (6.6 to 16.1)	-30.9 (-49.9 to -7.6)	-50.9 (-64.7 to -34.6)
Tuberculosis	10.1 (9.7 to 10.5)	11.3 (10.9 to 11.7)	11.8 (8.0 to 15.7)	-12.0 (-14.8 to -9.1)	3.1 (2.0 to 4.2)	3.4 (2.3 to 4.7)	12.0 (5.5 to 31.2)	-10.9 (-24.8 to 4.2)
HIV/AIDS	-	-	-	-	12.1 (6.0 to 21.2)	7.0 (3.7 to 12.1)	-41.5 (-62.0 to -14.2)	-81.6 (-75.0 to -43.6)
HIV/AIDS resulting in mycobacterial infection	0.2 (0.1 to 0.3)	0.0 (0.0 to 0.1)	-78.2 (-88.8 to -66.1)	-85.3 (-92.4 to -76.9)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-78.2 (-88.9 to -66.0)	-85.3 (-92.4 to -76.9)
HIV/AIDS resulting in other diseases	81.7 (53.1 to 119.1)	91.3 (54.8 to 142.1)	10.6 (-15.6 to 41.5)	-28.0 (-44.7 to -6.9)	12.0 (6.0 to 21.1)	6.9 (3.7 to 12.0)	-41.3 (-62.0 to -14.0)	-61.5 (-75.0 to -43.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	21.0 (13.3 to 32.1)	22.9 (14.3 to 35.1)	8.9 (1.2 to 17.6)	-3.4 (-16.5 to -3.8)
Diarrheal diseases	1.9 (1.6 to 2.1)	2.4 (2.1 to 2.6)	25.2 (7.0 to 48.6)	-3.1 (-16.5 to 14.4)	0.4 (0.2 to 0.4)	0.4 (0.3 to 0.6)	24.0 (3.9 to 49.0)	-2.3 (-17.6 to 16.7)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (43.4 to 32.6)	0.0 (50.6 to 14.1)
Typhoid fever	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-3.4 (-16.0 to 8.6)	-16.9 (-27.7 to -5.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.4 (-16.1 to 8.6)	-16.9 (-27.7 to -5.4)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.7 (-10.9 to 68.9)	7.9 (-23.1 to 51.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.7 (-11.2 to 68.9)	7.9 (-23.1 to 51.2)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (88.2 to 191.5)	-46.6 (-90.0 to 151.7)
Lower respiratory infections	3.9 (3.8 to 4.0)	4.6 (4.4 to 4.8)	18.0 (12.6 to 24.2)	-21.9 (-25.6 to -17.9)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	17.1 (1.6 to 37.3)	-21.1 (-32.2 to -6.1)
Upper respiratory infections	592.9 (569.3 to 618.5)	698.0 (662.5 to 728.8)	17.8 (9.6 to 25.1)	0.5 (-5.9 to 6.9)	6.9 (3.9 to 11.6)	8.1 (4.5 to 13.6)	17.4 (8.5 to 26.3)	0.4 (-6.7 to 8.3)
Otitis media	516.8 (458.3 to 576.1)	519.4 (463.1 to 581.3)	0.7 (-12.7 to 15.5)	-16.3 (-27.6 to -6.4)	9.4 (5.6 to 15.2)	9.4 (5.5 to 15.0)	-0.0 (-13.5 to 15.2)	-16.5 (-27.0 to -6.4)
Meningitis	-	-	-	-	2.0 (1.3 to 3.0)	2.2 (1.4 to 3.3)	10.9 (-23.5 to 50.8)	-9.5 (-38.4 to 25.0)
Pneumococcal meningitis	4.2 (2.4 to 6.9)	4.5 (2.8 to 7.8)	8.6 (-14.9 to 41.6)	-18.2 (-37.0 to 7.6)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.6)	4.1 (-35.1 to 53.9)	4.1 (-50.8 to 21.5)
H influenzae type B meningitis	2.2 (0.6 to 4.8)	2.4 (0.8 to 5.8)	10.4 (-35.1 to 118.7)	-10.9 (-46.9 to 87.7)	0.3 (0.2 to 0.6)	0.4 (0.2 to 0.6)	16.8 (-42.0 to 176.4)	-1.0 (-50.8 to 145.9)
Meningococcal meningitis	3.6 (1.1 to 9.4)	3.7 (1.1 to 10.5)	3.3 (-33.5 to 62.6)	-19.7 (-47.8 to 36.7)	0.5 (0.2 to 0.9)	0.5 (0.3 to 0.9)	5.4 (-33.3 to 87.1)	-15.6 (-47.0 to 60.3)
Other meningitis	5.0 (2.3 to 10.6)	5.5 (2.4 to 11.7)	8.9 (-23.9 to 53.5)	-14.1 (-38.8 to 28.0)	0.7 (0.4 to 1.1)	0.8 (0.5 to 1.4)	10.1 (-26.4 to 80.3)	-10.8 (-41.0 to 50.6)
Encephalitis	1.2 (0.5 to 3.1)	1.5 (0.7 to 4.0)	25.4 (3.5 to 54.8)	-9.9 (-19.1 to 22.9)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	33.3 (8.7 to 65.3)	4.1 (-14.7 to 30.0)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.4 (-93.7 to 376.5)	-59.6 (-95.7 to 279.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.4 (-93.8 to 378.7)	-59.6 (-95.8 to 299.9)
Whooping cough	4.5 (3.5 to 5.8)	1.3 (1.0 to 1.7)	-70.4 (-72.8 to -67.7)	-74.9 (-77.0 to -72.6)	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.1)	-70.3 (-77.1 to -62.5)	-74.9 (-80.6 to -68.2)
Tetanus	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	89.9 (-94.8 to -76.5)	-91.7 (-95.7 to -80.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-90.8 (-96.8 to -74.4)	-92.2 (-97.8 to -78.6)
Measles	0.6 (0.6 to 0.6)	0.0 (0.0 to 0.0)	-99.4 (-99.5 to -99.3)	-99.4 (-99.6 to -99.4)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.1 (-99.6 to -99.1)	-99.5 (-99.6 to -99.2)
Varicella and herpes zoster	36.2 (32.4 to 40.4)	46.7 (41.7 to 52.3)	29.2 (9.2 to 51.3)	1.0 (-11.7 to 14.4)	1.5 (0.9 to 2.3)	2.0 (1.2 to 3.1)	34.1 (6.4 to 68.2)	1.3 (-18.0 to 23.9)
Neglected tropical diseases and malaria	-	-	-	-	1.4 (0.7 to 2.6)	1.0 (0.6 to 1.9)	-24.4 (-64.6 to 48.3)	-46.1 (-75.2 to 5.9)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.1 (-64.7 to 439.9)	14.3 (-68.9 to 372.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-64.4 to 445.0)	0.0 (-68.9 to 377.5)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-11.2 to 21.5)	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.6 (-11.2 to 21.5)	-16.4 (-28.7 to -3.9)
Visceral leishmaniasis	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	16.8 (-4.1 to 37.6)	-10.5 (-26.4 to 6.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.8 (-4.1 to 37.7)	-10.5 (-26.4 to 6.8)
Cutaneous and mucocutaneous leishmaniasis	0.5 (0.4 to 0.7)	0.4 (0.3 to 0.6)	-15.2 (-34.9 to 10.4)	-27.0 (-42.0 to -6.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.2 (-34.9 to 10.4)	-27.0 (-42.0 to -6.4)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	1.4 (0.6 to 2.9)	0.6 (0.2 to 1.3)	-55.8 (-84.0 to 60.9)	-67.3 (-88.1 to 22.0)	0.5 (0.2 to 1.1)	0.3 (0.1 to 0.5)	-51.4 (-81.9 to 93.6)	-63.9 (-86.8 to 42.2)
Cystic echinococcosis	3.8 (3.5 to 4.2)	5.4 (4.9 to 6.3)	43.3 (34.0 to 52.6)	-3.1 (-10.5 to 4.0)	0.4 (0.2 to 0.5)	0.5 (0.3 to 0.7)	42.1 (11.4 to 82.0)	-3.2 (-24.2 to 24.8)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.8 (-60.2 to 30.9)	8.3 (-68.6 to 7.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.8 (-60.2 to 32.2)	8.3 (-68.6 to 7.6)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	24.5 (6.6 to 51.6)	12.2 (1.1 to 34.5)	-57.8 (-96.0 to 192.0)	-69.7 (-97.1 to 106.2)	0.5 (0.1 to 1.5)	0.2 (0.0 to 0.9)	-57.3 (-96.3 to 210.2)	-68.9 (-97.3 to 123.9)
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (32.1 to 188.8)	0.0 (2.7 to 118.0)
Maternal disorders	-	-	-	-	0.5 (0.3 to 0.8)	0.9 (0.5 to 1.3)	79.0 (14.4 to 142.6)	44.9 (-8.9 to 95.6)
Maternal hemorrhage	5.9 (2.9 to 8.9)	7.9 (3.8 to 11.7)	34.6 (-41.6 to 180.9)	11.5 (-53.8 to 131.6)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.5)	106.6 (-35.7 to 342.8)	71.0 (-49.4 to 259.3)
Maternal sepsis and other maternal infections	2.2 (1.1 to 3.4)	3.1 (1.2 to 5.0)	43.1 (-45.9 to 182.7)	-8.4 (-64.2 to 81.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	27.9 (-11.8 to 76.8)	-3.1 (-32.4 to 28.3)
Maternal hypertensive disorders	3.4 (2.2 to 4.9)	5.1 (3.3 to 7.7)	52.1 (30.0 to 75.9)	21.0 (8.4 to 37.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	50.7 (10.7 to 109.5)	20.7 (-10.5 to 65.5)
Obstructed labor	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	38.3 (25.5 to 49.0)	14.5 (3.9 to 23.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	38.3 (25.5 to 49.1)	14.5 (3.8 to 23.7)
Complications of abortion	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	52.3 (38.0 to 67.7)	23.7 (12.1 to 36.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.3 (37.9 to 67.7)	23.7 (12.6 to 36.2)
Other maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	156.2 (25.6 to 279.2)	83.2 (2.4 to 209.4)
Neonatal disorders	-	-	-	-	34.5 (23.7 to 47.2)	49.8 (34.1 to 66.5)	43.8 (9.6 to 95.3)	21.7 (-7.3 to 65.9)
Preterm birth complications	142.2 (107.6 to 190.7)	199.1 (152.0 to 259.9)	40.2 (18.9 to 62.7)	16.9 (-1.1 to 35.6)	18.7 (12.8 to 25.4)	28.2 (19.3 to 38.3)	51.2 (12.5 to 93.2)	27.8 (-5.1 to 63.6)
Neonatal encephalopathy due to birth asphyxia and trauma	32.8 (18.7 to 60.2)	23.0 (12.2 to 49.4)	-32.2 (-54.3 to 7.5)	-42.6 (-61.2 to -8.5)	8.3 (5.4 to 12.4)	6.2 (3.8 to 9.3)	-25.9 (-54.6 to 29.1)	-36.6 (-61.1 to 11.6)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	107.2 (81.9 to 175.4)	67.6 (47.1 to 122.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.3 (60.9 to 186.5)	72.6 (30.2 to 131.8)
Hemolytic disease and other neonatal jaundice	11.1 (3.6 to 28.3)	7.1 (2.3 to 13.9)	-33.0 (-85.1 to 225.8)	-44.1 (-87.5 to 174.0)	4.7 (1.4 to 11.8)	3.2 (1.0 to 6.5)	-29.3 (-85.2 to 242.3)	-40.8 (-87.6 to 191.7)
Other neonatal disorders	-	-	-	-	2.9 (1.5 to 6.1)	12.3 (6.4 to 18.2)	378.1 (72.1 to 685.6)	302.2 (46.5 to 568.2)
Nutritional deficiencies	-	-	-	-	150.4 (96.5 to 221.6)	157.5 (101.5 to 231.2)	4.8 (-3.9 to 14.4)	-0.6 (-7.8 to 7.0)
Protein-energy malnutrition	0.5 (0.2 to 0.9)	0.6 (0.3 to 1.1)	18.2 (-19.9 to 84.2)	-42.0 (-58.1 to -13.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	16.6 (-43.8 to 135.4)	41.7 (-69.2 to 9.9)
Iodine deficiency	700.6 (272.0 to 1,255.6)	688.7 (369.0 to 1,147.2)	-0.0 (-54.3 to 167.7)	-18.9 (-62.8 to 118.5)	12.5 (4.1 to 25.4)	12.2 (5.4 to 23.1)	-0.7 (-55.6 to 171.2)	-18.7 (-63.4 to 119.5)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-

Appendix Table G.4 - Spain prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	5,090.3 (4,913.6 to 5,197.2)	5,907.3 (5,756.9 to 6,026.4)	15.9 (12.5 to 20.1)	0.8 (-1.8 to 4.4)	137.8 (90.9 to 201.5)	145.3 (96.2 to 213.4)	5.3 (-0.2 to 12.0)	0.5 (-3.7 to 6.5)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	47.0 (-40.7 to 201.0)	-25.9 (-68.1 to 43.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	13.7 (8.2 to 23.0)	14.5 (8.8 to 23.8)	5.9 (-5.7 to 19.2)	-4.2 (-15.7 to 9.2)
Sexually transmitted diseases excluding HIV	-	-	-	-	6.9 (3.8 to 12.7)	8.2 (4.5 to 14.6)	18.8 (3.8 to 34.7)	0.8 (-11.8 to 15.1)
Syphilis	2.0 (1.7 to 2.4)	4.1 (3.6 to 4.8)	103.9 (68.9 to 144.4)	36.6 (11.6 to 65.7)	0.4 (0.2 to 0.6)	0.8 (0.5 to 1.1)	99.9 (49.4 to 172.8)	33.9 (-1.1 to 85.5)
Chlamydial infection	1,631.5 (1,356.2 to 1,915.8)	1,787.9 (1,558.4 to 2,027.9)	9.7 (-11.8 to 36.7)	-1.7 (-20.4 to 21.2)	4.4 (2.4 to 8.3)	5.0 (2.7 to 9.2)	13.6 (-6.2 to 36.7)	1.0 (-16.1 to 22.3)
Gonococcal infection	175.0 (123.6 to 237.6)	177.9 (142.6 to 220.0)	3.4 (-31.7 to 49.0)	13.1 (-25.6 to 66.8)	0.6 (0.3 to 1.2)	0.6 (0.3 to 1.2)	-2.2 (-31.2 to 30.7)	0.7 (-28.8 to 36.5)
Trichomoniasis	127.3 (84.5 to 175.4)	154.7 (121.3 to 198.3)	21.3 (-19.6 to 93.8)	-0.8 (-37.3 to 58.6)	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.6)	19.7 (-23.0 to 107.1)	-0.9 (-39.3 to 74.6)
Genital herpes	4,526.7 (4,208.1 to 4,826.0)	5,099.5 (5,216.9 to 6,120.1)	26.1 (12.3 to 39.4)	-10.2 (-20.4 to -0.6)	1.2 (0.4 to 2.9)	1.4 (0.5 to 3.5)	23.0 (7.9 to 37.4)	10.0 (-21.0 to 37.7)
Other sexually transmitted diseases	4.1 (3.0 to 5.2)	3.5 (2.4 to 4.7)	-14.2 (-39.3 to 16.9)	-39.3 (-56.4 to -17.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	7.3 (-24.5 to 50.5)	-1.7 (-38.8 to 22.2)
Hepatitis	-	-	-	-	1.1 (0.7 to 1.7)	1.2 (0.8 to 1.7)	4.8 (-7.1 to 18.0)	-11.4 (-21.1 to 0.2)
Hepatitis A	29.7 (28.2 to 31.2)	31.4 (29.8 to 33.1)	5.9 (-5.4 to 6.2)	-7.0 (-8.1 to -5.9)	0.9 (0.6 to 1.3)	1.0 (0.6 to 1.4)	8.8 (-4.6 to 22.7)	-5.7 (-17.5 to 7.0)
Hepatitis B	305.5 (268.9 to 350.0)	232.3 (201.4 to 258.9)	-24.0 (-36.1 to -10.1)	-40.1 (-48.7 to -29.9)	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.2)	-14.9 (-43.5 to 39.9)	-38.9 (-58.9 to -0.4)
Hepatitis C	673.3 (628.9 to 722.6)	669.3 (621.7 to 714.9)	-0.4 (-10.2 to 9.9)	-27.0 (-34.3 to -19.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	1.3 (-30.0 to 46.4)	-25.1 (-45.2 to 3.3)
Hepatitis E	-	-	-	-	14.5 (-20.1 to 56.0)	2.4 (-20.1 to 38.1)	-	-
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.8 (3.8 to 43.9)	-17.6 (-31.6 to -1.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.2 (4.3 to 45.0)	-17.4 (-31.0 to -0.3)
Other infectious diseases	205.8 (174.4 to 238.2)	216.2 (198.8 to 230.8)	5.3 (-10.5 to 23.4)	-0.9 (-16.3 to 17.8)	5.6 (3.8 to 8.8)	5.1 (3.3 to 7.7)	-9.2 (-27.0 to 15.4)	-8.2 (-25.7 to 18.4)
Non-communicable diseases	-	-	-	-	5,857.1 (3,136.4 to 5,425.6)	5,857.1 (4,370.5 to 7,515.9)	2.0 (35.1 to 42.3)	2.0 (-0.6 to 4.6)
Neoplasms	-	-	-	-	61.8 (46.4 to 79.4)	111.2 (82.5 to 142.6)	80.1 (68.4 to 92.9)	14.5 (7.1 to 22.4)
Esophageal cancer	3.2 (2.4 to 3.9)	3.9 (2.9 to 5.2)	21.5 (-15.1 to 82.3)	-20.1 (-44.5 to 22.3)	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.8)	16.4 (-14.8 to 70.7)	-23.0 (-44.7 to 15.6)
Stomach cancer	24.4 (21.4 to 27.8)	28.1 (23.8 to 33.4)	14.8 (-3.1 to 36.0)	-29.7 (-40.4 to -18.3)	2.7 (1.9 to 3.5)	2.9 (2.1 to 3.9)	8.3 (-10.5 to 31.2)	-33.5 (-44.4 to -20.8)
Liver cancer	-	-	-	-	0.8 (0.5 to 1.2)	1.4 (0.9 to 2.2)	66.0 (24.8 to 140.9)	7.4 (-18.3 to 57.2)
Liver cancer due to hepatitis B	0.8 (0.5 to 1.2)	2.0 (1.1 to 3.0)	141.7 (17.8 to 331.6)	65.9 (-17.8 to 197.7)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.4)	108.3 (9.1 to 246.4)	42.3 (-24.6 to 133.0)
Liver cancer due to hepatitis C	2.6 (1.8 to 3.6)	7.0 (4.6 to 10.4)	161.9 (64.0 to 346.6)	68.2 (6.8 to 195.6)	0.4 (0.2 to 0.6)	0.9 (0.5 to 1.4)	122.6 (50.4 to 249.8)	43.0 (-2.2 to 124.9)
Liver cancer due to alcohol use	1.8 (1.1 to 2.5)	0.9 (0.9 to 3.0)	-5.3 (-52.1 to 94.3)	-38.9 (-71.3 to 25.0)	1.7 (0.2 to 0.4)	0.2 (0.1 to 0.4)	-17.1 (-58.1 to 62.7)	-46.6 (-74.1 to 4.0)
Liver cancer due to other causes	0.3 (0.1 to 0.5)	0.2 (0.1 to 0.3)	-28.3 (-71.1 to 96.3)	-54.3 (-80.7 to 18.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-35.4 (-70.1 to 65.2)	-59.3 (-80.7 to 1.1)
Larynx cancer	17.0 (12.2 to 22.1)	16.0 (12.2 to 22.5)	-7.0 (-31.1 to 26.1)	-36.5 (-53.6 to -13.0)	1.8 (1.2 to 2.5)	1.5 (1.0 to 2.3)	-14.9 (-36.6 to 15.4)	-41.9 (-57.3 to -20.5)
Tracheal, bronchus and lung cancer	29.4 (26.8 to 32.1)	46.4 (39.6 to 52.4)	58.3 (32.0 to 83.6)	6.2 (-11.6 to 22.6)	4.2 (3.1 to 5.5)	6.3 (4.5 to 8.2)	50.0 (25.7 to 75.4)	0.7 (-15.6 to 18.2)
Breast cancer	171.1 (152.8 to 189.7)	333.0 (310.9 to 352.8)	94.6 (72.1 to 123.1)	22.9 (9.2 to 40.0)	9.4 (6.5 to 12.8)	16.1 (11.1 to 22.5)	70.8 (49.6 to 92.4)	7.3 (-6.3 to 20.5)
Cervical cancer	17.4 (13.3 to 20.6)	17.2 (12.8 to 21.1)	-1.5 (-21.1 to 26.8)	-44.9 (-48.1 to -16.9)	1.3 (0.8 to 1.8)	1.3 (0.8 to 1.8)	4.5 (-21.5 to 28.2)	-43.7 (-48.5 to -14.6)
Uterine cancer	38.2 (30.2 to 46.9)	55.9 (38.5 to 71.8)	46.3 (-7.4 to 97.6)	-2.8 (-29.8 to 34.2)	2.5 (1.6 to 3.6)	3.6 (2.1 to 5.3)	44.4 (21.8 to 99.7)	-4.2 (-31.8 to 30.6)
Prostate cancer	74.0 (60.4 to 88.1)	209.0 (174.7 to 257.5)	180.0 (121.4 to 261.4)	76.0 (40.3 to 125.8)	6.4 (4.5 to 8.5)	16.1 (11.4 to 22.5)	149.3 (95.6 to 229.0)	55.1 (23.0 to 103.5)
Colon and rectum cancer	87.2 (81.8 to 93.2)	208.2 (186.3 to 231.6)	138.6 (110.0 to 169.2)	49.3 (33.1 to 66.3)	7.3 (5.3 to 9.4)	16.5 (12.0 to 21.8)	127.7 (99.0 to 158.3)	41.2 (24.0 to 59.7)
Lip and oral cavity cancer	28.1 (22.9 to 33.7)	33.1 (26.6 to 41.7)	17.6 (-12.0 to 56.3)	-22.8 (-41.1 to 22.9)	2.3 (1.6 to 3.3)	2.6 (1.8 to 3.6)	14.9 (-13.6 to 50.5)	-24.7 (-42.6 to -14.4)
Nasopharynx cancer	2.4 (2.4 to 4.9)	3.5 (1.7 to 3.9)	32.9 (-57.9 to 21.6)	-55.0 (-72.0 to -38.6)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.4)	34.7 (56.1 to 11.1)	-67.7 (-70.5 to -24.7)
Other pharynx cancer	10.5 (7.5 to 14.0)	13.8 (9.8 to 19.5)	31.6 (-14.6 to 101.9)	-9.7 (-41.3 to 39.5)	0.8 (0.5 to 1.2)	1.1 (0.7 to 1.7)	28.9 (-14.6 to 93.6)	-11.8 (-41.9 to 35.4)
Gallbladder and biliary tract cancer	2.1 (1.6 to 2.7)	2.3 (1.8 to 3.3)	7.3 (-20.7 to 59.3)	-36.5 (-52.7 to -5.0)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.8)	4.5 (-27.8 to 61.6)	-36.6 (-55.1 to -5.2)
Pancreatic cancer	3.4 (2.9 to 4.0)	7.5 (6.3 to 8.9)	117.7 (74.5 to 175.1)	39.0 (11.6 to 74.4)	0.7 (0.5 to 0.9)	1.3 (0.9 to 1.8)	96.9 (58.0 to 144.1)	26.7 (3.3 to 55.1)
Malignant skin melanoma	21.1 (15.3 to 28.3)	41.4 (27.2 to 56.4)	96.2 (50.3 to 140.2)	29.8 (-1.0 to 57.9)	2.4 (0.8 to 1.9)	2.4 (1.4 to 3.6)	89.1 (45.8 to 134.4)	25.3 (-4.8 to 53.7)
Non-melanoma skin cancer	101.8 (75.7 to 129.6)	246.0 (209.1 to 288.9)	142.7 (74.0 to 239.3)	48.9 (8.1 to 104.8)	1.6 (0.9 to 2.6)	4.0 (2.4 to 6.3)	155.4 (77.9 to 263.5)	53.1 (9.0 to 112.6)
Ovarian cancer	10.3 (8.9 to 11.9)	19.1 (15.0 to 23.0)	84.8 (44.5 to 128.4)	20.6 (-2.9 to 48.2)	1.3 (0.9 to 1.7)	2.3 (1.5 to 3.1)	79.9 (35.4 to 131.7)	17.2 (-9.1 to 48.5)
Testicular cancer	3.9 (2.7 to 5.7)	5.5 (3.0 to 8.6)	39.3 (-25.1 to 152.9)	7.2 (-41.7 to 96.0)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.6)	35.7 (-28.5 to 155.3)	4.1 (-4.1 to 100.8)
Kidney cancer	17.2 (14.9 to 19.8)	39.9 (32.9 to 48.2)	99.9 (91.4 to 181.2)	52.0 (26.8 to 81.6)	1.2 (0.9 to 1.7)	2.7 (1.8 to 3.8)	139.7 (79.1 to 169.7)	44.5 (19.4 to 76.4)
Bladder cancer	60.4 (52.5 to 69.8)	107.3 (80.4 to 129.9)	78.3 (35.9 to 122.5)	13.5 (-11.9 to 39.3)	4.5 (3.2 to 6.0)	7.6 (4.9 to 10.3)	71.5 (31.3 to 112.4)	8.5 (-15.9 to 32.7)
Brain and nervous system cancer	10.0 (8.5 to 12.4)	16.9 (13.7 to 20.0)	69.3 (36.9 to 102.6)	18.7 (-1.4 to 40.5)	1.0 (0.7 to 1.4)	1.7 (1.1 to 2.3)	63.4 (27.4 to 101.8)	14.9 (-7.0 to 40.0)
Thyroid cancer	13.6 (10.4 to 16.4)	20.6 (16.0 to 27.1)	48.0 (14.4 to 120.4)	2.6 (-21.7 to 53.7)	0.8 (0.5 to 1.1)	1.2 (0.7 to 1.8)	45.2 (10.5 to 111.8)	0.2 (-25.1 to 49.9)
Mesothelioma	0.9 (0.5 to 1.0)	0.7 (0.6 to 1.1)	-21.1 (-36.4 to 68.2)	-48.2 (-58.0 to 10.2)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-16.9 (-33.5 to 73.5)	45.8 (-56.5 to 14.2)
Hodgkin lymphoma	7.4 (5.3 to 10.1)	7.6 (5.6 to 11.0)	2.9 (-28.3 to 50.3)	-20.0 (-44.8 to 18.4)	0.6 (0.4 to 0.9)	0.6 (0.4 to 0.9)	-0.4 (-29.8 to 41.6)	-23.7 (-46.3 to 11.1)
Non-Hodgkin lymphoma	23.8 (18.3 to 35.8)	48.0 (29.4 to 59.8)	111.5 (17.5 to 164.9)	37.3 (-20.9 to 69.7)	1.7 (1.1 to 2.7)	3.3 (2.0 to 4.8)	103.1 (10.6 to 159.4)	32.4 (-25.9 to 65.5)
Multiple myeloma	5.4 (3.6 to 8.1)	9.8 (6.4 to 14.1)	84.4 (21.3 to 163.5)	19.5 (-19.8 to 68.3)	1.1 (0.6 to 1.8)	1.9 (1.1 to 3.0)	74.9 (13.4 to 155.9)	13.3 (-25.9 to 60.5)
Leukemia	16.8 (14.8 to 18.9)	26.6 (22.2 to 30.9)	58.4 (29.1 to 89.8)	0.9 (-17.7 to 18.6)	2.1 (1.5 to 2.8)	3.3 (2.3 to 4.4)	55.6 (24.2 to 93.3)	-2.7 (-21.9 to 19.0)
Other neoplasms	38.5 (31.6 to 45.6)	116.5 (87.4 to 141.8)	205.2 (125.1 to 278.6)	93.9 (47.1 to 141.4)	2.7 (1.9 to 3.7)	7.6 (5.0 to 10.5)	181.7 (106.4 to 253.5)	80.3 (35.8 to 120.4)
Cardiovascular diseases	-	-	-	-	200.8 (142.3 to 270.4)	317.2 (221.8 to 420.2)	58.4 (35.0 to 82.8)	1.6 (-13.1 to 17.2)
Rheumatic heart disease	5.1 (4.7 to 5.4)	7.4 (7.0 to 7.9)	46.0 (33.4 to 60.3)	-0.2 (-8.7 to 8.8)	0.5 (0.3 to 0.8)	0.8 (0.5 to 1.1)	41.8 (6.8 to 120.1)	-4.1 (-29.8 to 50.4)
Ischemic heart disease	1,432.5 (1,195.6 to 1,740.7)	1,729.1 (1,522.1 to 1,981.7)	20.7 (-3.1 to 51.8)	-22.9 (-38.1 to -3.1)	85.3 (55.1 to 124.2)	95.6 (64.4 to 133.4)	12.6 (-12.0 to 45.4)	-28.4 (-44.2 to 7.8)
Cerebrovascular disease	-	-	-	-	45.0 (31.5 to 58.4)	65.8 (46.5 to 88.3)	45.6 (25.5 to 71.6)	-4.0 (-16.5 to 11.5)
Ischemic stroke	265.7 (239.3 to 294.0)	382.3 (328.8 to 433.3)	43.1 (22.8 to 71.3)	-7.1 (-20.0 to 10.1)	37.5 (26.0 to 49.5)	53.9 (36.7 to 74.3)	43.3 (21.4 to 71.5)	-6.2 (-19.9 to 11.0)
Hemorrhagic stroke	52.2 (39.2 to 64.8)	82.6 (64.4 to 101.5)	58.8 (14.6 to 117.1)	5.8 (-20.3 to 43.4)	7.5 (4.7 to 10.8)	11.9 (7.7 to 16.4)	58.2 (16.6 to 119.1)	6.8 (-19.9 to 44.9)
Hypertensive heart disease	49.8 (43.6 to 56.4)	89.6 (80.4 to 99.8)	80.3 (52.3 to 112.6)	10.5 (-6.5 to 30.0)	5.3 (3.6 to 7.2)	9.5 (6.6 to 12.9)	80.3 (49.3 to 115.0)	11.3 (-7.1 to 32.7)
Cardiomyopathy and myocarditis	48.8 (41.4 to 56.4)	62.6 (57.5 to 69.9)	28.2 (6.8 to 57.6)	-16.3 (-29.8 to 1.3)	5.2 (3.6 to 7.4)	6.7 (4.7 to 9.1)	28.4 (3.9 to 58.0)	15.6 (-31.0 to 9.4)
Atrial fibrillation and flutter	302.4 (226.6 to 380.6)	897.0 (798.2 to 987.8)	199.0 (128.9 to 295.3)	90.1 (45.6 to 154.9)	22.8 (14.2 to 33.6)	68.2 (46.7 to 93.8)	201.0 (130.2 to 301.5)	93.4 (48.7 to 161.4)
Peripheral vascular disease	1,075.5 (870.6 to 1,269.9)	2,035.4 (1,718.0 to 2,333.6)	90.3 (46.2 to 130.5)	17.8 (-9.4 to 44.4)	0.9 (0.4 to 1.7)	1.9 (0.9 to 3.5)	118.5 (41.8 to 261.9)	37.0 (-12.3 to 120.9)
Endocarditis	2.4 (1.6 to 2.9)	2.5 (1.9 to 3.6)	2.4 (-29.7 to 72.2)	-28.8 (-51.8 to 17.9)	0.3 (0.1 to 0.4)	0.3 (0.1 to 0.4)	3.8 (-4.4 to 89.4)	-3.8 (-57.6 to 31.9)
Other cardiovascular and circulatory diseases	510.0 (300.7 to 747.0)	978.6 (611.7 to 1,297.0)	90.9 (8.4 to 237.1)	21.5 (-30.8 to 115.0)	90.9 (8.3 to 56.7)	88.5 (38.0 to 101.7)	91.2 (7.7 to 240.3)	21.7 (-30.8 to 116.4)
Chronic respiratory diseases								

Appendix Table G.4 - Spain prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	24.1 (19.4 to 29.2)	24.1 (-20.3 to -14.0)
Silicosis	0.2 (0.2 to 0.2)	0.3 (0.2 to 0.3)	6.5 (0.6 to 10.6)	-29.3 (-33.2 to -26.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	7.0 (0.7 to 11.2)	-29.0 (-33.0 to -26.3)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	54.9 (47.9 to 61.4)	1.8 (-2.9 to 6.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	56.1 (48.8 to 62.7)	2.6 (-2.3 to 7.1)
Other pneumoconiosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	24.5 (16.7 to 32.8)	35.4 (-20.4 to 9.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.2 (18.5 to 35.0)	24.2 (-19.3 to -8.0)
Asthma	2,229.7 (2,229.7 to 2,480.8)	2,565.9 (2,565.9 to 2,814.8)	14.0 (6.5 to 22.5)	1.1 (-6.2 to 8.8)	103.5 (67.7 to 146.7)	117.2 (78.0 to 164.9)	13.2 (5.9 to 21.6)	13.2 (6.0 to 9.3)
Interstitial lung disease and pulmonary sarcoidosis	3.8 (2.8 to 4.8)	5.7 (4.3 to 6.9)	50.0 (3.0 to 111.0)	2.5 (-28.7 to 41.6)	0.5 (0.3 to 0.8)	0.8 (0.5 to 1.2)	49.0 (1.6 to 115.9)	2.1 (-29.8 to 43.7)
Other chronic respiratory diseases	-	-	-	-	23.2 (13.7 to 38.2)	2.2 (1.3 to 3.5)	-90.3 (-93.1 to -87.0)	-93.5 (-95.2 to -91.1)
Cirrhosis	-	-	-	-	3.8 (2.8 to 4.6)	3.4 (2.4 to 4.9)	11.3 (7.9 to 15.5)	27.6 (-35.6 to -18.6)
Cirrhosis due to hepatitis B	1.9 (1.2 to 2.8)	2.1 (1.3 to 3.0)	10.3 (-43.7 to 87.7)	-23.3 (60.8 to 31.4)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.6)	9.3 (47.4 to 91.2)	-23.6 (62.9 to 34.6)
Cirrhosis due to hepatitis C	7.3 (4.6 to 9.7)	10.1 (7.3 to 12.8)	40.0 (-12.2 to 129.8)	-3.7 (-39.3 to 62.6)	1.2 (0.7 to 1.8)	1.6 (1.0 to 2.5)	33.3 (-16.6 to 136.8)	33.5 (-41.9 to 66.5)
Cirrhosis due to alcohol use	9.5 (7.4 to 11.6)	6.3 (4.3 to 9.0)	-33.3 (-57.4 to -1.4)	1.5 (-71.6 to -31.8)	1.0 (1.0 to 2.2)	1.0 (0.6 to 1.6)	-33.5 (-59.3 to 5.4)	-33.5 (-72.5 to -27.0)
Cirrhosis due to other causes	1.9 (1.2 to 2.6)	2.7 (1.6 to 4.0)	40.2 (-29.3 to 159.4)	3.4 (45.3 to 79.4)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.7)	41.3 (-33.4 to 171.3)	4.1 (-46.9 to 84.0)
Digestive diseases	-	-	-	-	57.7 (41.0 to 76.4)	103.1 (72.9 to 137.6)	78.7 (65.5 to 91.8)	25.1 (15.1 to 34.6)
Peptic ulcer disease	227.6 (219.0 to 235.7)	196.9 (168.9 to 219.3)	-13.5 (-22.9 to -5.2)	-52.8 (-58.8 to -47.0)	7.7 (5.3 to 10.6)	7.8 (5.4 to 11.1)	1.4 (9.8 to 14.6)	-43.7 (-51.1 to -34.7)
Gastritis and duodenitis	15.5 (12.9 to 18.7)	14.3 (11.5 to 17.1)	-8.4 (-26.6 to 14.3)	-37.4 (-50.1 to -21.0)	0.9 (0.6 to 1.4)	0.9 (0.6 to 1.4)	-2.2 (-30.6 to 33.3)	-30.9 (-50.8 to -2.7)
Appendicitis	1.9 (1.7 to 2.2)	1.6 (1.5 to 1.7)	-17.2 (-28.8 to -6.6)	-16.9 (-28.8 to -3.3)	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.7)	-16.1 (-39.4 to 15.5)	-16.3 (-41.9 to 20.0)
Paralytic ileus and intestinal obstruction	0.7 (0.6 to 0.8)	0.9 (0.8 to 1.0)	35.0 (4.4 to 63.0)	0.2 (-41.4 to 24.8)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.4)	9.2 (5.7 to 80.4)	9.2 (-43.6 to 33.7)
Inguinal, femoral, and abdominal hernia	110.6 (95.9 to 126.9)	158.2 (135.8 to 185.3)	42.6 (16.4 to 78.6)	-11.6 (-27.3 to 8.6)	1.1 (0.5 to 2.1)	1.6 (0.8 to 3.0)	41.9 (15.3 to 77.3)	-10.9 (-27.0 to 8.7)
Inflammatory bowel disease	161.8 (151.9 to 172.6)	323.4 (304.2 to 341.0)	100.4 (82.2 to 115.6)	41.5 (28.5 to 52.8)	33.8 (23.2 to 45.7)	67.3 (46.4 to 91.7)	99.6 (80.3 to 117.4)	41.9 (28.0 to 54.6)
Vascular intestinal disorders	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	61.7 (24.4 to 110.8)	-1.6 (-22.6 to 26.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	58.4 (5.1 to 148.7)	-1.1 (-34.8 to 44.8)
Gallbladder and biliary diseases	60.9 (54.2 to 68.1)	96.4 (85.6 to 107.5)	58.0 (33.3 to 87.7)	-2.7 (-13.6 to 20.8)	4.3 (4.2 to 8.7)	9.9 (6.7 to 13.7)	57.1 (30.9 to 87.9)	57.1 (-14.5 to 21.6)
Pancreatitis	8.5 (8.2 to 8.9)	14.7 (14.1 to 15.3)	72.7 (62.0 to 83.3)	17.8 (10.5 to 25.0)	2.5 (1.7 to 3.4)	4.2 (2.8 to 5.7)	70.7 (40.9 to 101.6)	17.0 (0.4 to 38.9)
Other digestive diseases	-	-	-	-	4.5 (3.1 to 6.2)	10.4 (6.8 to 14.5)	132.3 (85.8 to 177.4)	62.1 (30.0 to 93.8)
Neurological disorders	-	-	-	-	432.3 (299.4 to 585.1)	608.5 (420.7 to 824.9)	40.8 (26.5 to 58.4)	40.8 (8.7 to 12.6)
Alzheimer disease and other dementias	575.7 (524.5 to 635.1)	912.4 (669.1 to 1,159.2)	58.2 (18.6 to 103.9)	-15.1 (-33.6 to 8.0)	83.2 (60.1 to 106.5)	134.7 (88.7 to 190.7)	62.0 (19.0 to 109.5)	62.0 (-34.5 to 8.9)
Parkinson disease	83.2 (74.5 to 91.9)	133.5 (119.6 to 147.3)	60.2 (51.8 to 70.5)	0.7 (-4.4 to 6.3)	9.6 (6.7 to 12.9)	15.3 (10.7 to 20.8)	59.5 (46.8 to 74.4)	1.2 (-6.8 to 10.0)
Epilepsy	135.5 (99.7 to 168.2)	156.5 (112.4 to 200.7)	15.1 (-21.3 to 73.7)	-7.4 (-36.8 to 25.0)	52.9 (34.5 to 74.9)	63.7 (39.0 to 92.8)	19.8 (-18.7 to 83.7)	-2.7 (-34.2 to 47.8)
Multiple sclerosis	18.6 (17.6 to 19.6)	46.8 (44.0 to 49.6)	151.8 (132.9 to 171.1)	75.6 (62.2 to 89.3)	6.1 (4.3 to 7.8)	15.2 (10.9 to 19.3)	150.2 (120.9 to 187.0)	75.0 (54.0 to 100.7)
Migraine	5,846.5 (5,171.8 to 6,507.9)	9,695.0 (6,057.1 to 7,362.0)	65.0 (-2.5 to 32.9)	-1.1 (-21.1 to 5.0)	198.5 (118.0 to 300.0)	225.8 (135.7 to 335.9)	14.0 (1.0 to 32.2)	-10.0 (-23.7 to 10.2)
Tension-type headache	9,472.7 (6,869.6 to 12,188.8)	12,338.8 (11,522.0 to 13,110.8)	31.0 (0.2 to 80.5)	4.0 (-19.9 to 43.7)	14.3 (6.6 to 26.4)	18.5 (9.2 to 32.3)	30.2 (-1.2 to 80.4)	4.0 (-20.5 to 44.6)
Medication overuse headache	340.6 (234.7 to 451.3)	747.8 (512.1 to 976.4)	119.5 (89.0 to 156.9)	63.8 (41.3 to 91.0)	52.9 (30.7 to 81.1)	115.9 (68.0 to 176.7)	119.2 (87.1 to 156.8)	64.4 (40.6 to 92.6)
Other neurological disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	30.0 (-7.3 to 71.1)	-0.1 (-27.5 to 31.5)	14.8 (10.0 to 20.5)	19.4 (12.3 to 27.9)	29.4 (-2.7 to 89.0)	27.1 (-44.8 to 5.1)
Mental and substance use disorders	-	-	-	-	985.1 (708.6 to 1,282.4)	1,181.9 (852.5 to 1,550.5)	20.2 (12.0 to 25.4)	-0.8 (-5.3 to 2.5)
Schizophrenia	106.8 (84.5 to 133.0)	147.5 (117.9 to 182.2)	37.9 (28.3 to 48.8)	-1.1 (-7.4 to 5.8)	67.9 (48.4 to 90.2)	94.0 (66.7 to 124.2)	38.2 (27.3 to 52.1)	8.0 (-8.9 to 8.6)
Alcohol use disorders	447.6 (406.5 to 493.5)	483.8 (434.8 to 532.9)	7.9 (0.4 to 15.4)	-11.1 (-17.1 to -5.4)	44.8 (29.2 to 62.6)	48.2 (31.8 to 68.1)	7.8 (-0.9 to 16.0)	-11.2 (-18.4 to -4.3)
Drug use disorders	-	-	-	-	112.3 (80.0 to 145.8)	134.3 (95.7 to 174.4)	19.5 (10.3 to 29.5)	1.0 (-6.5 to 9.4)
Opioid use disorders	159.2 (138.0 to 179.2)	207.6 (182.0 to 231.8)	30.2 (21.4 to 41.6)	1.5 (-4.4 to 8.9)	66.3 (47.0 to 86.8)	86.3 (61.7 to 112.2)	30.1 (20.3 to 43.1)	2.0 (-5.3 to 10.7)
Cocaine use disorders	92.8 (86.3 to 100.9)	102.2 (96.6 to 109.8)	10.2 (-1.3 to 23.1)	11.2 (-9.2 to 13.0)	27.1 (8.4 to 18.3)	27.1 (3.6 to 26.0)	2.2 (-11.0 to 17.0)	2.2 (-11.0 to 17.0)
Amphetamine use disorders	61.5 (55.6 to 67.4)	60.3 (54.7 to 65.5)	-1.7 (-13.4 to 10.5)	-4.4 (-16.0 to 7.9)	8.0 (4.9 to 11.7)	7.8 (4.9 to 11.0)	-3.0 (-17.9 to 16.2)	-4.9 (-17.9 to 14.5)
Cannabis use disorders	147.2 (134.8 to 158.8)	136.3 (126.6 to 147.0)	-7.5 (-12.7 to -2.0)	0.7 (-5.0 to 7.0)	4.3 (2.8 to 6.3)	3.9 (2.6 to 5.7)	-7.7 (-18.2 to 4.5)	0.7 (10.6 to 13.1)
Other drug use disorders	-	-	-	-	20.9 (13.3 to 30.0)	22.1 (14.2 to 31.8)	5.1 (-20.7 to 43.0)	-0.8 (-25.1 to 35.6)
Depressive disorders	-	-	-	-	350.6 (231.6 to 497.4)	441.1 (287.1 to 637.2)	26.4 (6.6 to 39.7)	-0.4 (-14.0 to 8.1)
Major depressive disorder	1,428.5 (1,118.4 to 1,708.2)	1,789.5 (1,342.5 to 2,287.8)	25.7 (2.1 to 42.0)	-0.8 (-16.4 to 9.2)	289.3 (186.6 to 415.0)	360.0 (227.1 to 538.5)	25.0 (1.7 to 41.2)	-0.5 (-17.0 to 9.7)
Dysthymia	640.4 (542.2 to 750.8)	852.0 (718.6 to 998.5)	33.0 (28.6 to 37.2)	-0.4 (-0.5 to -0.3)	61.3 (40.2 to 88.3)	81.2 (53.4 to 117.4)	32.5 (27.2 to 38.1)	-0.3 (-2.6 to 2.1)
Bipolar disorder	290.9 (241.4 to 340.2)	366.5 (307.8 to 423.9)	26.0 (18.8 to 34.7)	-0.9 (-6.3 to 5.3)	58.8 (36.0 to 89.5)	73.6 (45.5 to 110.8)	25.1 (17.0 to 35.7)	-0.9 (-7.5 to 6.7)
Anxiety disorders	1,448.1 (1,200.6 to 1,739.3)	1,713.5 (1,398.2 to 2,022.7)	18.4 (7.9 to 29.1)	18.4 (6.7 to 7.7)	350.6 (88.2 to 189.4)	441.1 (103.4 to 226.0)	26.4 (6.6 to 28.3)	-0.4 (-7.0 to 8.2)
Eating disorders	-	-	-	-	35.1 (21.2 to 51.6)	35.6 (21.2 to 52.7)	1.6 (6.1 to 10.3)	4.3 (0.3 to 9.8)
Anorexia nervosa	36.5 (29.2 to 44.1)	43.3 (32.9 to 54.5)	18.4 (1.9 to 34.5)	20.6 (6.2 to 33.0)	7.8 (4.9 to 11.2)	9.2 (5.7 to 13.5)	18.1 (0.1 to 37.0)	20.3 (3.8 to 36.7)
Bulimia nervosa	129.3 (89.9 to 173.6)	125.6 (84.1 to 173.1)	-3.0 (-12.5 to 5.9)	-0.4 (-0.5 to -0.2)	27.3 (15.9 to 42.2)	26.5 (14.9 to 41.5)	-3.2 (-13.4 to 7.0)	-0.3 (-5.2 to 4.5)
Autistic spectrum disorders	-	-	-	-	43.5 (30.4 to 58.9)	51.4 (35.8 to 70.1)	18.3 (14.1 to 22.5)	0.8 (-2.6 to 4.2)
Autism	112.8 (106.3 to 119.2)	134.1 (126.0 to 142.3)	18.8 (17.6 to 20.1)	0.5 (0.5 to 0.5)	27.5 (18.4 to 37.1)	32.5 (21.8 to 44.2)	18.3 (12.4 to 24.0)	18.3 (-4.1 to 5.5)
Asperger syndrome	161.5 (150.9 to 172.4)	192.2 (178.8 to 206.0)	18.9 (17.8 to 19.9)	0.7 (0.6 to 0.7)	16.0 (11.1 to 22.2)	18.9 (13.3 to 26.1)	18.4 (14.0 to 23.2)	0.8 (-3.1 to 4.8)
Attention-deficit/hyperactivity disorder	276.9 (235.5 to 312.7)	210.9 (179.4 to 238.5)	-23.9 (-24.2 to -23.7)	0.1 (0.1 to 0.1)	3.4 (2.0 to 5.2)	2.6 (1.5 to 4.0)	-23.7 (-28.3 to -18.5)	0.3 (-5.7 to 6.9)
Conduct disorder	348.1 (292.8 to 404.5)	246.5 (210.2 to 288.4)	-28.6 (-30.1 to -27.4)	0.1 (0.1 to 0.1)	41.9 (25.6 to 63.5)	29.9 (18.6 to 45.4)	-28.5 (-31.6 to -25.3)	0.1 (-3.8 to 4.2)
Idiopathic intellectual disability	715.1 (602.1 to 850.9)	758.2 (642.4 to 933.9)	7.2 (-2.4 to 18.3)	-9.5 (-17.5 to -0.5)	42.2 (28.5 to 58.8)	45.1 (30.5 to 63.0)	6.8 (3.1 to 18.1)	9.4 (-17.7 to 0.2)
Other mental and substance use disorders	714.0 (672.0 to 755.5)	968.6 (912.9 to 1,022.9)	35.6 (33.0 to 38.0)	0.4 (0.3 to 0.6)	52.7 (35.6 to 70.8)	71.0 (48.5 to 95.3)	34.9 (28.8 to 40.0)	0.6 (-2.6 to 4.2)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	587.6 (411.6 to 792.5)	947.2 (667.2 to 1,264.6)	61.9 (42.9 to 78.6)	11.7 (-1.1 to 23.1)
Diabetes mellitus	4,944.3 (4,250.7 to 5,582.8)	8,668.9 (7,371.3 to 9,934.5)	75.8 (43.2 to 108.4)	20.4 (-1.8 to 43.6)	322.0 (209.1 to 450.5)	588.0 (388.2 to 818.0)	83.5 (48.8 to 118.5)	24.6 (5.8 to 49.2)
Acute glomerulonephritis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-0.0 (-9.7 to 5.0)	-15.5 (-21.8 to -8.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.0 (-9.7 to 5.0)	-15.5 (-21.9 to -8.6)
Chronic kidney disease	-	-	-	-	151.1 (101.4 to 204.4)	206.2 (136.9 to 279.0)	36.5 (29.5 to 43.2)	36.5 (-7.0 to 1.0)
Chronic kidney disease due to diabetes mellitus	360.7 (250.7 to 514.7)	522.8 (424.1 to 633.0)	45.3 (6.3 to 116.0)	0.9 (-25.6 to 46.4)	22.3 (13.6 to 32.9)	31.5 (19.9 to 44.6)	40.2 (11.8 to 89.4)	-3.3 (-22.9 to 29.5)
Chronic kidney disease due to hypertension	450.3 (362.7 to 610.0)	402.6 (309.4 to 512.3)	-11.3 (-32.9 to 21.4)	-37.2 (-51.2 to -16.4)	43.6 (27.7 to 63.5)	17.3 (11.3 to 24.2)	-60.4 (-68.4 to -46.7)	-71.5 (-77.4 to -62.4)
Chronic kidney disease due to glomerulonephritis	638.2 (411.4 to 924.2)	363.7 (302.7 to 431.6)	-43.5 (-58.2 to -9.7)	-43.5 (-67.6 to -34.6)	15.6 (10.1 to 22.6)	15.6 (8.2 to 49.4)	15.6 (12.5 to 19.2)	128.8 (25.7 to 93.3)
Chronic kidney disease due to other causes	1,420.2 (1,103.0 to 1,749.3)	2,081.2 (1,895.2 to 2,603.0)	56.3 (30.2 to 88.0)	13.1 (-5.0 to 32.4)	69.5 (46.1 to 99.3)	122.0 (81.7 to 165.9)	76.2 (45.5 to 118.8)	25.4 (4.2 to 49.7)
Urinary diseases and male infertility	-	-	-	-	35.5 (23.1 to 50.9)	54.5 (35.0 to 77.1)	53.4 (38.6 to 70.0)	4.2 (5.6 to 15.3)

Appendix Table G.4 - Spain prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	6.7 (6.4 to 7.1)	11.7 (11.0 to 12.3)	75.0 (61.1 to 88.6)	23.7 to 45.5	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	72.7 (39.6 to 111.5)	342 (7.8 to 67.1)
Urolithiasis	500.1 (274.1 to 841.8)	935.2 (464.6 to 1,619.1)	86.0 (47.4 to 128.8)	19.9 (-7.4 to 46.2)	3.8 (1.9 to 7.0)	7.3 (3.2 to 14.4)	93.2 (54.0 to 133.9)	25.9 (-0.9 to 53.0)
Benign prostatic hyperplasia	843.3 (776.6 to 905.8)	1,261.1 (1,171.2 to 1,356.6)	49.6 (33.9 to 67.5)	1.1 (-10.0 to 13.3)	29.9 (19.2 to 42.4)	44.4 (29.1 to 62.5)	48.8 (32.6 to 66.6)	1.3 (-9.8 to 13.5)
Male infertility due to other causes	116.9 (79.6 to 152.8)	164.7 (115.7 to 220.4)	40.3 (-12.8 to 123.5)	3.9 (-33.8 to 64.2)	0.8 (0.3 to 1.7)	1.1 (0.5 to 2.4)	39.7 (-14.5 to 124.9)	4.3 (-34.4 to 67.1)
Other urinary diseases	-	-	-	-	0.9 (0.4 to 1.5)	1.2 (0.5 to 2.2)	38.4 (2.3 to 118.2)	8.7 (-33.7 to 42.8)
Gynecological diseases	-	-	-	-	44.3 (28.0 to 69.8)	60.4 (37.6 to 95.0)	35.8 (18.1 to 56.4)	-3.9 (-16.6 to 10.7)
Uterine fibroids	1,519.5 (1,329.8 to 1,687.8)	2,362.4 (2,069.4 to 2,630.5)	55.4 (54.2 to 56.6)	-1.7 (-1.7 to -1.6)	13.1 (6.6 to 24.2)	20.2 (10.3 to 36.6)	53.6 (42.8 to 69.1)	-1.1 (-7.7 to 9.1)
Polycystic ovarian syndrome	621.9 (540.1 to 707.2)	831.8 (704.9 to 937.2)	33.8 (8.8 to 62.7)	-1.7 (-20.6 to 20.0)	5.9 (2.8 to 11.2)	7.8 (3.7 to 14.7)	33.3 (8.6 to 61.2)	-2.3 (-20.7 to 18.3)
Female infertility due to other causes	16.8 (4.2 to 50.2)	18.7 (5.1 to 48.7)	10.7 (-82.3 to 55.5)	20.1 (-87.5 to 322.4)	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.3)	18.2 (-80.5 to 493.8)	-20.5 (-86.2 to 290.5)
Endometriosis	103.9 (75.0 to 137.8)	139.7 (99.2 to 179.9)	30.6 (8.6 to 119.4)	-7.0 (-35.2 to 54.8)	9.6 (5.8 to 14.3)	12.9 (7.7 to 19.8)	30.1 (-11.4 to 120.6)	-7.7 (-35.8 to 56.4)
Genital prolapse	2,417.1 (2,193.8 to 2,645.1)	3,266.5 (2,958.4 to 3,584.1)	34.8 (19.6 to 53.7)	-4.3 (-16.0 to 9.8)	7.7 (3.6 to 14.2)	10.3 (5.0 to 19.6)	34.8 (18.9 to 54.8)	-4.4 (-16.4 to 10.2)
Premenstrual syndrome	708.2 (493.3 to 908.9)	801.4 (647.6 to 1,014.3)	12.2 (-17.2 to 71.4)	-7.5 (-33.3 to 40.5)	6.0 (3.4 to 9.6)	7.7 (4.0 to 10.3)	12.7 (-19.2 to 72.4)	-6.9 (-34.9 to 24.8)
Other gynecological diseases	93.9 (76.2 to 185.9)	113.7 (91.9 to 178.2)	26.3 (-43.7 to 111.7)	-0.3 (-57.0 to 75.6)	0.3 (1.0 to 6.7)	2.4 (1.3 to 5.8)	35.8 (-70.3 to 287.2)	2.2 (-78.5 to 219.1)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	22.9 (15.2 to 33.6)	24.1 (15.8 to 35.0)	5.3 (-2.1 to 18.1)	-6.1 (-17.1 to 3.7)
Thalassemias	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-5.1 (-13.7 to 16.7)	-3.1 (-11.6 to 19.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.6 (-16.2 to 3.6)	-7.4 (-13.8 to 7.3)
Thalassemia trait	261.2 (235.1 to 290.7)	311.6 (280.5 to 345.2)	19.4 (8.7 to 29.6)	-1.9 (-10.5 to 6.1)	8.0 (5.5 to 11.6)	8.5 (5.8 to 12.2)	6.7 (8.3 to 19.7)	-5.6 (-18.4 to 5.3)
Sickle cell disorders	0.9 (0.8 to 1.0)	1.0 (0.9 to 1.1)	10.0 (-6.0 to 28.2)	2.7 (-11.9 to 21.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	15.5 (5.4 to 28.7)	9.4 (-1.2 to 22.0)
Sickle cell trait	510.5 (470.8 to 554.1)	612.5 (569.2 to 659.0)	19.8 (12.5 to 27.4)	-1.6 (-7.3 to 4.4)	8.8 (5.7 to 13.0)	9.0 (5.8 to 13.4)	2.5 (-20.1 to 28.1)	-6.3 (-25.7 to 13.3)
G6PD deficiency	232.0 (148.3 to 422.9)	399.4 (330.5 to 459.0)	87.3 (-13.5 to 175.0)	53.1 (-28.9 to 124.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	53.3 (-0.0 to 117.6)	14.9 (-20.0 to 58.0)
G6PD trait	2,817.7 (2,683.6 to 2,948.2)	3,524.2 (3,364.2 to 3,671.3)	25.1 (17.8 to 32.4)	1.9 (-4.1 to 7.9)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.6)	35.1 (-25.7 to 173.9)	21.8 (-37.4 to 182.8)
Other hemoglobinopathies and hemolytic anemias	271.2 (248.8 to 293.6)	337.2 (317.1 to 360.1)	24.3 (11.6 to 39.4)	-0.4 (-12.1 to 12.3)	5.6 (3.6 to 8.3)	6.0 (3.7 to 9.0)	5.6 (-15.0 to 35.7)	-8.9 (-28.4 to 15.7)
Endocrine, metabolic, blood, and immune disorders	401.4 (381.9 to 421.6)	498.8 (472.7 to 515.4)	23.4 (15.8 to 31.2)	-1.0 (-7.5 to 6.5)	11.8 (8.0 to 16.4)	14.0 (9.5 to 19.2)	18.5 (7.5 to 32.4)	3.9 (-14.7 to 5.3)
Musculoskeletal disorders	-	-	-	-	931.8 (664.4 to 1,233.4)	1,363.7 (973.6 to 1,792.1)	46.3 (36.8 to 56.6)	6.4 (-0.6 to 14.4)
Rheumatoid arthritis	108.2 (98.0 to 119.5)	191.8 (171.5 to 213.5)	77.1 (53.9 to 103.3)	19.0 (4.0 to 35.8)	24.7 (17.4 to 33.1)	43.4 (29.5 to 58.2)	75.4 (50.4 to 101.6)	19.0 (3.2 to 36.5)
Osteoarthritis	2,709.8 (2,579.8 to 2,838.1)	4,059.7 (3,869.4 to 4,267.0)	50.1 (39.9 to 59.7)	-3.0 (-9.7 to 3.4)	92.7 (61.9 to 133.8)	138.4 (92.0 to 198.4)	49.4 (39.6 to 59.8)	-2.7 (-9.4 to 4.0)
Low back and neck pain	-	-	-	-	697.7 (469.6 to 910.9)	953.6 (660.2 to 1,272.4)	40.7 (28.7 to 54.1)	4.7 (-4.7 to 14.2)
Low back pain	3,757.9 (3,587.7 to 3,989.7)	5,179.3 (4,939.6 to 5,480.5)	37.9 (27.9 to 47.0)	3.0 (-4.8 to 9.3)	416.0 (282.1 to 573.3)	570.0 (380.6 to 775.9)	37.2 (27.1 to 46.3)	3.4 (-4.8 to 9.5)
Neck pain	2,685.7 (2,346.6 to 3,012.1)	3,953.5 (3,453.3 to 4,475.0)	47.2 (22.9 to 72.9)	7.0 (-11.2 to 27.4)	261.7 (178.3 to 369.6)	383.6 (264.9 to 530.2)	46.9 (22.9 to 73.2)	7.1 (-10.8 to 28.0)
Gout	86.9 (78.6 to 95.8)	136.6 (123.0 to 149.9)	57.3 (35.4 to 81.8)	4.2 (-10.0 to 20.8)	2.7 (1.8 to 3.6)	4.2 (2.8 to 5.7)	57.2 (28.9 to 92.1)	5.2 (-14.5 to 29.3)
Other musculoskeletal disorders	1,476.7 (1,198.6 to 1,784.4)	2,471.1 (2,008.1 to 2,956.8)	67.2 (56.5 to 79.2)	20.1 (12.4 to 28.3)	134.0 (89.1 to 191.6)	224.1 (150.4 to 321.3)	67.2 (55.9 to 79.2)	3.2 (-12.2 to 29.2)
Other non-communicable diseases	-	-	-	-	697.0 (478.5 to 980.9)	894.4 (618.2 to 1,247.3)	28.6 (22.0 to 34.5)	-6.0 (-10.8 to -0.7)
Congenital anomalies	-	-	-	-	63.0 (44.4 to 84.0)	73.8 (51.1 to 98.5)	17.2 (1.8 to 34.2)	-4.9 (-17.3 to 9.0)
Neural tube defects	9.8 (8.7 to 11.3)	8.5 (7.4 to 10.1)	-13.1 (-29.2 to 8.1)	-25.3 (-39.3 to -7.0)	3.2 (2.2 to 4.4)	2.9 (1.9 to 4.1)	-11.0 (-34.5 to 22.4)	-23.0 (-42.8 to 5.6)
Congenital heart anomalies	348.3 (293.6 to 426.8)	375.7 (311.3 to 453.5)	8.0 (-18.5 to 41.2)	-9.8 (-31.7 to 17.8)	12.0 (4.7 to 22.0)	13.0 (5.0 to 22.7)	8.9 (-15.4 to 40.3)	-8.2 (-28.4 to 18.2)
Orofacial clefts	34.5 (29.4 to 40.7)	33.4 (27.9 to 39.1)	-3.7 (-23.4 to 20.0)	-20.2 (-36.6 to -0.6)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	5.5 (-29.1 to 25.5)	-21.8 (-41.4 to 4.0)
Down syndrome	55.2 (46.3 to 70.8)	66.9 (56.7 to 78.4)	23.6 (-13.3 to 49.3)	-1.4 (-30.6 to 18.5)	8.2 (5.9 to 11.5)	10.3 (7.3 to 13.4)	28.1 (-9.1 to 59.3)	-0.8 (-30.4 to 22.0)
Turner syndrome	1.7 (1.2 to 2.2)	2.1 (1.5 to 2.8)	23.7 (-12.8 to 80.0)	4.6 (-26.7 to 52.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	22.6 (-14.8 to 86.9)	3.4 (-27.2 to 57.5)
Klinefelter syndrome	1.2 (0.9 to 1.6)	1.7 (1.3 to 2.3)	50.1 (-3.4 to 127.0)	25.1 (-19.3 to 90.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.4 (-9.1 to 147.5)	24.1 (-25.1 to 97.1)
Chromosomal unbalanced rearrangements	87.4 (74.9 to 103.2)	106.6 (89.9 to 127.4)	20.9 (-1.6 to 54.6)	3.4 (-21.7 to 23.2)	12.9 (9.3 to 16.6)	16.3 (11.9 to 21.9)	25.3 (0.7 to 61.8)	2.4 (-22.0 to 25.9)
Other congenital anomalies	123.1 (80.9 to 170.7)	125.4 (76.3 to 178.3)	2.0 (-20.3 to 26.4)	-19.6 (-35.5 to 0.1)	26.4 (16.4 to 38.8)	30.9 (18.5 to 46.0)	16.5 (-4.9 to 44.0)	-2.9 (-20.4 to 20.7)
Skin and subcutaneous diseases	-	-	-	-	244.3 (154.3 to 378.3)	277.6 (179.5 to 422.2)	13.5 (3.3 to 28.9)	-2.7 (-11.6 to 12.8)
Dermatitis	2,197.6 (1,705.4 to 2,692.6)	2,796.2 (2,142.6 to 3,479.6)	27.2 (20.3 to 32.8)	-0.0 (-0.1 to 0.1)	50.5 (30.7 to 74.0)	62.6 (38.3 to 93.3)	24.0 (18.5 to 29.3)	0.0 (-2.4 to 2.6)
Psoriasis	589.0 (492.1 to 653.1)	745.2 (636.6 to 852.2)	26.5 (28.0 to 33.8)	0.1 (-0.0 to 0.2)	59.7 (31.3 to 63.6)	80.1 (40.5 to 83.6)	30.1 (24.6 to 36.6)	0.2 (-3.8 to 4.4)
Cellulitis	13.0 (10.9 to 16.5)	19.2 (16.2 to 24.1)	47.4 (33.0 to 66.6)	5.9 (-4.2 to 18.5)	0.9 (0.6 to 1.3)	1.3 (0.9 to 1.9)	45.3 (19.7 to 76.9)	5.0 (-12.9 to 28.1)
Pyoderma	9.7 (8.2 to 11.6)	11.4 (9.5 to 13.8)	16.8 (11.4 to 24.9)	-3.7 (-7.2 to 0.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	16.5 (0.5 to 36.2)	-3.6 (-16.9 to 12.9)
Scabies	26.5 (22.2 to 30.7)	23.3 (19.4 to 27.4)	-12.4 (-27.9 to 8.7)	-21.7 (-36.6 to -2.9)	0.7 (0.4 to 1.1)	0.6 (0.3 to 0.9)	-12.7 (-28.8 to 10.7)	-11.7 (-39.2 to 16.4)
Fungal skin diseases	2,855.1 (2,533.1 to 3,165.4)	3,730.2 (3,322.4 to 4,075.1)	30.5 (27.1 to 34.2)	8.4 (0.3 to 25.6)	15.9 (6.5 to 33.6)	20.7 (8.5 to 43.2)	30.0 (26.4 to 33.8)	2.4 (-0.4 to 1.5)
Viral skin diseases	832.5 (665.6 to 1,016.0)	880.9 (696.5 to 1,076.8)	5.8 (0.5 to 11.3)	0.7 (-2.0 to 2.9)	25.6 (15.1 to 39.7)	27.0 (15.7 to 42.1)	5.3 (-0.2 to 11.6)	0.7 (-2.7 to 4.1)
Acne vulgaris	6,292.1 (4,456.4 to 8,026.8)	5,015.0 (3,866.7 to 6,193.0)	-21.7 (-43.1 to 25.5)	-11.0 (-36.8 to 45.6)	68.2 (31.4 to 129.6)	54.3 (24.2 to 101.7)	-21.8 (-43.1 to 25.5)	-11.1 (-36.7 to 45.8)
Alopecia areata	65.9 (61.3 to 70.8)	90.4 (82.4 to 98.5)	37.1 (22.2 to 53.0)	-0.3 (-9.8 to 10.3)	2.2 (1.4 to 3.3)	3.0 (1.9 to 4.4)	36.4 (19.2 to 54.7)	0.1 (-11.9 to 13.7)
Pruritus	5.2 (3.2 to 7.2)	7.5 (5.4 to 9.8)	46.1 (-4.7 to 117.0)	3.8 (-32.0 to 52.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	63.7 (-9.5 to 133.4)	2.2 (-34.4 to 67.0)
Urticaria	239.9 (177.3 to 299.9)	333.7 (262.4 to 409.9)	40.0 (-3.2 to 98.2)	8.6 (-24.4 to 54.6)	14.0 (8.4 to 21.1)	19.4 (11.5 to 28.9)	38.7 (-4.9 to 99.2)	9.0 (-25.4 to 56.8)
Decubitus ulcer	23.1 (17.8 to 28.1)	36.9 (30.0 to 44.1)	59.4 (18.5 to 126.7)	-7.0 (-29.6 to 30.0)	3.2 (2.1 to 4.5)	5.1 (3.3 to 7.1)	5.7 (13.7 to 125.4)	-6.5 (-31.4 to 30.9)
Other skin and subcutaneous diseases	2,979.2 (1,688.0 to 5,128.3)	4,158.8 (2,303.9 to 7,260.3)	39.4 (29.4 to 46.1)	0.1 (-2.0 to 2.0)	17.3 (7.0 to 38.8)	24.0 (9.4 to 54.6)	38.9 (29.3 to 46.1)	0.3 (-2.2 to 2.5)
Sense organ diseases	-	-	-	-	283.9 (191.4 to 403.6)	411.0 (279.4 to 577.1)	44.3 (36.0 to 57.2)	-7.8 (-13.2 to -1.8)
Glaucoma	50.6 (34.9 to 65.2)	60.5 (45.4 to 81.2)	18.6 (-5.7 to 52.0)	-27.1 (-41.7 to -9.0)	4.8 (2.9 to 7.1)	5.7 (3.7 to 8.3)	21.1 (8.9 to 63.1)	-25.3 (-42.9 to -2.9)
Cataract	150.9 (102.3 to 220.8)	206.4 (135.7 to 293.9)	36.8 (8.1 to 72.1)	-25.6 (-41.5 to -6.2)	12.6 (7.6 to 18.9)	17.0 (10.4 to 26.6)	35.3 (10.7 to 64.9)	-26.5 (-39.4 to -10.7)
Macular degeneration	176.5 (128.9 to 240.1)	276.2 (198.4 to 373.0)	55.5 (30.0 to 85.9)	-4.7 (-19.7 to 14.0)	9.6 (6.1 to 14.1)	15.4 (9.6 to 22.4)	58.9 (33.7 to 89.7)	-7.0 (-20.4 to 10.5)
Uncorrected refractive error	3,023.3 (2,813.5 to 3,228.9)	4,215.3 (3,873.0 to 4,542.7)	39.2 (26.0 to 55.5)	-6.0 (-14.5 to 25.3)	47.2 (28.8 to 73.8)	61.8 (37.0 to 100.1)	30.5 (21.7 to 41.5)	-10.1 (-16.2 to -2.9)
Age-related and other hearing loss	6,093.6 (5,216.3 to 6,901.3)	8,650.4 (7,538.4 to 9,769.2)	42.0 (35.8 to 49.3)	-8.0 (-13.3 to -3.9)	176.1 (116.3 to 256.6)	270.5 (176.5 to 395.8)	5.7 (39.4 to 75.7)	5.7 (-13.8 to 4.6)
Other vision loss	145.3 (105.9 to 199.7)	138.2 (103.1 to 185.3)	-4.6 (-17.5 to 12.7)	-37.0 (-45.3 to -25.2)	9.5 (6.0 to 14.1)	10.2 (6.6 to 15.2)	6.8 (-9.1 to 26.2)	-28.2 (-38.6 to -15.5)
Other sense organ diseases	924.1 (879.9 to 967.1)	1,176.0 (1,115.9 to 1,229.2)	27.3 (19.6 to 35.6)	-0.3 (-6.1 to 6.2)	24.1 (14.8 to 35.7)	30.4 (18.7 to 45.1)	26.2 (17.4 to 35.5)	-0.1 (-6.9 to 7.4)
Oral disorders	-							

Appendix Table G.4 - Spain prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	2,501.8 (2,316.2 to 2,708.0)	3,089.9 (2,835.0 to 3,335.7)	23.3 (10.0 to 38.6)	-19.8 (-28.6 to -10.1)	67.7 (45.8 to 94.6)	83.1 (55.6 to 115.4)	22.9 (9.2 to 38.2)	22.9 (-28.7 to -9.9)
Other oral disorders	737.7 (693.8 to 777.0)	937.6 (890.1 to 989.5)	26.7 (18.3 to 37.5)	-0.5 (-7.4 to 7.8)	21.4 (13.6 to 31.8)	27.2 (17.1 to 40.5)	26.3 (17.0 to 37.7)	-0.6 (-7.9 to 8.3)
Injuries	-	-	-	-	419.1 (323.8 to 531.1)	392.7 (281.9 to 529.3)	-6.4 (-17.3 to 4.8)	-39.4 (-46.1 to -32.2)
Transport injuries	-	-	-	-	63.1 (47.7 to 81.3)	20.5 (14.8 to 27.3)	-67.6 (-71.0 to -63.5)	-77.9 (-80.1 to -75.0)
Road injuries	-	-	-	-	56.1 (42.8 to 72.3)	11.3 (8.2 to 14.9)	-80.0 (-81.9 to -77.7)	-86.2 (-87.5 to -84.5)
Pedestrian road injuries	-	-	-	-	8.5 (6.3 to 11.0)	1.9 (1.4 to 2.5)	-77.7 (-79.9 to -75.2)	-85.0 (-86.5 to -83.2)
Cyclist road injuries	-	-	-	-	2.9 (2.2 to 3.8)	0.7 (0.5 to 1.0)	-74.5 (-77.9 to -70.5)	-81.8 (-84.2 to -78.9)
Motorcyclist road injuries	-	-	-	-	12.0 (9.0 to 15.6)	2.1 (1.5 to 2.8)	-82.8 (-85.4 to -79.8)	-88.2 (-89.9 to -86.0)
Motor vehicle road injuries	-	-	-	-	32.3 (24.6 to 41.3)	6.5 (4.8 to 8.5)	-80.0 (-81.7 to -77.8)	-86.1 (-87.3 to -84.6)
Other road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.0 (0.0 to 0.1)	-90.1 (-91.3 to -88.6)	-93.1 (-93.9 to -92.0)
Other transport injuries	-	-	-	-	6.9 (5.2 to 9.1)	9.2 (6.6 to 12.4)	32.6 (18.9 to 47.8)	-9.0 (-18.2 to 1.2)
Unintentional injuries	-	-	-	-	351.4 (272.1 to 446.1)	368.1 (263.6 to 496.3)	4.7 (-8.2 to 17.3)	-32.0 (-39.5 to -24.1)
Falls	-	-	-	-	262.4 (201.3 to 324.2)	304.9 (218.6 to 409.2)	15.2 (-0.6 to 34.0)	-24.8 (-35.2 to -13.9)
Drowning	-	-	-	-	0.7 (0.5 to 0.9)	0.5 (0.4 to 0.7)	-22.5 (-31.8 to -12.9)	-46.5 (-53.1 to -39.9)
Fire, heat, and hot substances	-	-	-	-	7.1 (4.5 to 11.2)	4.8 (2.8 to 7.8)	-33.2 (-41.7 to -22.6)	-56.7 (-62.6 to -49.5)
Poisonings	-	-	-	-	0.5 (0.4 to 0.7)	0.3 (0.2 to 0.4)	-41.6 (-52.1 to -29.8)	-58.4 (-66.1 to -49.5)
Exposure to mechanical forces	-	-	-	-	44.8 (33.7 to 59.4)	31.7 (22.0 to 43.4)	-29.6 (-37.3 to -19.6)	-49.0 (-54.6 to -41.6)
Unintentional firearm injuries	-	-	-	-	0.8 (0.6 to 1.1)	0.3 (0.2 to 0.4)	-61.4 (-65.9 to -56.4)	-71.9 (-75.2 to -68.3)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	39.2 (17.8 to 60.6)	-3.9 (-18.5 to 10.8)
Other exposure to mechanical forces	-	-	-	-	43.8 (32.9 to 58.2)	31.2 (21.6 to 42.8)	-29.2 (-37.0 to -19.0)	-48.7 (-54.4 to -41.1)
Adverse effects of medical treatment	-	-	-	-	2.1 (1.3 to 3.2)	3.0 (1.9 to 4.4)	42.0 (27.9 to 56.3)	0.3 (-9.2 to 9.4)
Animal contact	-	-	-	-	1.9 (1.3 to 2.4)	2.3 (1.6 to 3.2)	28.3 (16.1 to 41.3)	-5.4 (-14.6 to 4.0)
Venomous animal contact	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	23.4 (4.5 to 45.2)	-5.2 (-20.4 to 11.5)
Non-venomous animal contact	-	-	-	-	1.6 (1.1 to 2.1)	2.0 (1.4 to 2.8)	29.1 (15.0 to 42.8)	-5.4 (-15.5 to 4.7)
Foreign body	-	-	-	-	2.2 (1.5 to 3.0)	2.3 (1.5 to 3.3)	4.0 (-8.7 to 17.2)	-21.3 (-32.2 to -10.8)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.6)	2.1 (-12.5 to 18.8)	-30.3 (-41.2 to -16.8)
Foreign body in eyes	-	-	-	-	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	10.3 (-1.3 to 23.9)	-12.1 (-23.1 to -0.8)
Foreign body in other body part	-	-	-	-	1.4 (1.0 to 2.1)	1.5 (0.9 to 2.3)	2.7 (-12.6 to 20.4)	-21.3 (-34.0 to -6.9)
Other unintentional injuries	-	-	-	-	29.7 (21.2 to 40.0)	18.3 (12.4 to 25.4)	-39.1 (-45.3 to -29.9)	-62.2 (-66.5 to -56.3)
Self-harm and interpersonal violence	-	-	-	-	4.6 (3.5 to 6.0)	4.1 (2.9 to 5.6)	-10.7 (-18.7 to -1.9)	-38.3 (-43.8 to -32.4)
Self-harm	-	-	-	-	1.4 (1.0 to 1.9)	1.7 (1.2 to 2.3)	22.1 (8.2 to 39.0)	-17.4 (-27.1 to -5.9)
Interpersonal violence	-	-	-	-	3.2 (2.4 to 4.1)	2.4 (1.7 to 3.3)	-25.0 (-32.8 to -17.0)	-47.0 (-52.6 to -41.3)
Assault by firearm	-	-	-	-	0.5 (0.3 to 0.6)	0.4 (0.3 to 0.5)	-17.9 (-26.0 to -9.0)	-43.9 (-49.4 to -37.7)
Assault by sharp object	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	3.6 (-4.6 to 13.0)	-28.1 (-34.0 to -21.5)
Assault by other means	-	-	-	-	2.4 (1.8 to 3.0)	1.7 (1.2 to 2.2)	-30.8 (-38.6 to -22.3)	-50.5 (-56.2 to -44.4)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.9 (-24.8 to 30.2)	-24.0 (-44.8 to -0.4)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.0 (-16.9 to 45.8)	-20.5 (-41.0 to 4.9)
Collective violence and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.2 (-44.0 to 30.2)	-27.5 (-54.8 to 12.6)

Appendix Table G.4 - Sri Lanka prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,577.4 (1,168.2 to 2,056.0)	2,060.1 (1,523.4 to 2,684.7)	30.5 (26.5 to 34.8)	-5.5 (-8.1 to -2.9)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	287.9 (198.4 to 405.1)	225.6 (156.4 to 317.6)	-21.8 (-26.9 to -15.2)	-32.4 (-36.9 to -26.6)
HIV/AIDS and tuberculosis	-	-	-	-	7.0 (4.8 to 9.5)	10.8 (7.4 to 14.6)	53.4 (41.1 to 67.9)	-0.8 (-9.2 to 8.7)
Tuberculosis	23.0 (21.4 to 24.8)	35.0 (32.6 to 37.7)	51.6 (42.1 to 62.2)	-2.7 (-9.6 to 4.6)	7.0 (4.8 to 9.5)	10.6 (7.2 to 14.4)	50.9 (38.4 to 65.2)	-2.3 (-10.8 to 6.9)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	1,681.4 (957.3 to 2,370.8)	1,180.6 (666.6 to 1,709.5)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,395.6 (776.0 to 2,057.2)	877.8 (472.2 to 1,309.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,395.6 (774.3 to 2,063.4)	877.8 (468.2 to 1,311.4)
HIV/AIDS resulting in other diseases	0.1 (0.1 to 0.2)	1.6 (1.2 to 2.0)	1,450.2 (779.1 to 2,098.5)	1,090.5 (573.0 to 1,599.7)	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	1,650.8 (947.8 to 2,393.2)	1,190.8 (661.0 to 1,741.9)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	24.3 (16.9 to 34.1)	20.2 (13.4 to 29.5)	-17.6 (-28.0 to -6.1)	-29.1 (-38.1 to -19.7)
Diarrheal diseases	31.3 (19.4 to 39.5)	17.3 (13.1 to 22.4)	-45.4 (-61.2 to -12.0)	-51.6 (-65.5 to -24.4)	5.1 (2.8 to 7.5)	2.8 (1.7 to 4.2)	-45.5 (-62.0 to -10.7)	-51.7 (-66.3 to -23.9)
Intestinal infectious diseases	-	-	-	-	0.9 (0.5 to 1.3)	0.5 (0.3 to 0.8)	-41.1 (-63.3 to -13.5)	-49.7 (-66.9 to -21.7)
Typhoid fever	5.0 (3.7 to 6.3)	2.9 (2.0 to 3.8)	-41.2 (-60.1 to -14.8)	-47.5 (-63.8 to -21.6)	0.7 (0.4 to 1.0)	0.4 (0.2 to 0.6)	-40.2 (-61.4 to -5.1)	-46.3 (-65.2 to -13.8)
Paratyphoid fever	3.0 (2.2 to 3.9)	1.5 (1.0 to 1.9)	-52.7 (-67.2 to -26.0)	-56.5 (-69.8 to -31.6)	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.1)	-51.9 (-68.0 to -24.2)	-56.1 (-73.0 to -30.5)
Other intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-69.6 (-90.4 to -23.6)	-72.4 (-91.1 to -33.3)
Lower respiratory infections	3.0 (2.1 to 4.0)	5.3 (3.6 to 6.9)	71.4 (29.4 to 148.9)	35.5 (1.5 to 95.0)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	69.6 (19.3 to 155.4)	35.0 (4.4 to 100.5)
Upper respiratory infections	588.5 (514.5 to 667.5)	698.2 (613.9 to 786.2)	18.3 (-1.6 to 40.8)	1.5 (-15.4 to 20.5)	6.9 (3.8 to 11.7)	8.2 (4.5 to 12.7)	18.3 (-1.8 to 41.5)	1.8 (-15.3 to 20.7)
Otitis media	223.6 (211.1 to 237.3)	215.2 (201.8 to 227.6)	-4.0 (-11.6 to 3.7)	-15.4 (-22.3 to -8.7)	4.5 (2.7 to 7.1)	4.3 (2.6 to 6.8)	-3.2 (-12.1 to 6.2)	-13.8 (-21.7 to -5.5)
Meningitis	-	-	-	-	5.0 (3.3 to 7.2)	2.1 (1.4 to 2.9)	-58.4 (-66.2 to -50.8)	-64.7 (-71.3 to -58.8)
Pneumococcal meningitis	26.3 (15.1 to 42.6)	11.7 (6.8 to 18.4)	-56.1 (-66.5 to -41.4)	-65.6 (-73.7 to -54.7)	2.3 (1.5 to 3.4)	1.0 (0.7 to 1.5)	-53.6 (-66.6 to -39.0)	-61.7 (-72.1 to -49.8)
H influenzae type B meningitis	13.4 (4.2 to 26.2)	3.5 (1.1 to 7.4)	-73.8 (-82.2 to -65.5)	-78.4 (-85.0 to -71.2)	1.4 (0.8 to 2.1)	0.4 (0.3 to 0.6)	-71.2 (-79.3 to -60.0)	-74.5 (-81.5 to -64.8)
Meningococcal meningitis	2.2 (0.7 to 5.1)	1.1 (0.4 to 2.7)	-50.9 (-66.2 to -33.2)	-63.2 (-74.0 to -52.4)	0.3 (0.1 to 0.4)	0.1 (0.1 to 0.2)	-46.3 (-61.2 to -27.2)	-58.5 (-69.2 to -44.1)
Other meningitis	9.4 (4.1 to 18.0)	4.2 (2.0 to 8.3)	-55.6 (-65.6 to -44.3)	-64.4 (-71.7 to -55.1)	1.2 (0.7 to 1.7)	0.5 (0.3 to 0.7)	-54.6 (-66.7 to -40.3)	-61.7 (-70.8 to -50.3)
Encephalitis	6.7 (3.0 to 14.5)	6.0 (2.6 to 13.6)	-10.6 (-29.5 to 3.0)	-33.8 (-47.0 to -23.4)	0.8 (0.6 to 1.1)	0.8 (0.5 to 1.1)	-4.1 (-22.1 to 14.6)	-26.6 (-39.3 to -12.5)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Whooping cough	1.2 (0.9 to 1.6)	0.6 (0.5 to 0.8)	-49.2 (-51.5 to -46.9)	-52.0 (-54.1 to -49.8)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-48.7 (-64.0 to -29.9)	-51.5 (-65.8 to -33.5)
Tetanus	0.3 (0.2 to 0.5)	0.0 (0.0 to 0.1)	-83.9 (-92.6 to -80.0)	-86.9 (-93.9 to -67.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-80.4 (-89.9 to -59.3)	-83.5 (-91.3 to -66.0)
Measles	0.7 (0.5 to 0.8)	0.1 (0.1 to 0.2)	-86.4 (-90.3 to -80.9)	-86.9 (-90.6 to -81.6)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-86.0 (-90.9 to -77.4)	-86.6 (-91.3 to -78.2)
Varicella and herpes zoster	13.8 (12.3 to 15.5)	19.0 (16.3 to 21.5)	37.1 (13.6 to 62.4)	0.0 (-17.1 to 17.8)	0.6 (0.4 to 1.0)	0.9 (0.5 to 1.4)	43.9 (12.8 to 78.2)	-0.4 (-21.0 to 22.4)
Neglected tropical diseases and malaria	-	-	-	-	53.9 (33.3 to 82.0)	26.5 (15.9 to 42.3)	-50.6 (-63.5 to -29.1)	-46.6 (-69.7 to -43.0)
Malaria	2.3 (1.9 to 2.7)	2.0 (1.8 to 2.2)	-12.5 (-30.2 to 3.7)	-29.7 (-44.5 to -15.4)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-34.5 (-46.5 to -20.9)	-45.9 (-56.3 to -34.3)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.4 (28.3 to 85.5)	27.8 (6.0 to 55.5)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.9 (-64.6 to 106.7)	-32.2 (-66.9 to 82.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.9 (-64.7 to 108.1)	-32.2 (-67.0 to 82.2)
Cutaneous and mucocutaneous leishmaniasis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	58.8 (30.9 to 91.0)	30.3 (7.1 to 58.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.8 (30.8 to 91.2)	30.3 (7.1 to 58.3)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	8.3 (4.7 to 13.4)	3.0 (0.9 to 7.2)	-67.3 (-86.9 to -6.6)	-77.2 (-91.0 to -29.0)	2.4 (1.2 to 4.2)	0.9 (0.3 to 2.3)	-65.9 (-86.4 to 7.4)	-76.0 (-90.9 to -20.5)
Cystic echinococcosis	3.4 (3.1 to 3.7)	2.2 (2.0 to 2.3)	-34.9 (-45.2 to -27.2)	-48.4 (-56.0 to -43.2)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-36.2 (-51.6 to -18.8)	-49.4 (-60.4 to -36.6)
Lymphatic filariasis	90.4 (39.6 to 193.9)	51.1 (16.8 to 126.5)	-44.0 (-67.2 to -23.5)	-62.8 (-78.3 to -49.9)	7.3 (1.3 to 21.1)	5.3 (1.3 to 15.1)	-18.9 (-62.1 to 19.9)	-48.9 (-76.3 to -22.6)
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	6.8 (2.4 to 15.5)	41.1 (14.6 to 93.2)	498.2 (497.7 to 498.8)	398.1 (397.7 to 398.6)	1.1 (0.4 to 2.9)	6.7 (2.1 to 17.2)	497.0 (425.1 to 578.4)	399.8 (346.4 to 463.7)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Intestinal nematode infections	-	-	-	-	34.1 (19.8 to 55.4)	6.8 (3.9 to 10.9)	-79.9 (-84.3 to -75.3)	-83.1 (-86.9 to -79.2)
Ascariasis	2,282.0 (1,682.3 to 3,177.6)	1,274.2 (837.9 to 1,862.9)	-45.8 (-66.9 to -7.4)	-55.0 (-73.2 to -22.1)	6.3 (3.0 to 11.9)	0.7 (0.3 to 1.2)	-89.6 (-93.3 to -82.9)	-89.9 (-93.5 to -83.6)
Trichuriasis	1,073.8 (724.7 to 1,553.2)	1,284.8 (858.5 to 1,917.4)	18.9 (-31.5 to 112.9)	-2.4 (-4.7 to 7.6)	0.7 (0.3 to 1.5)	0.5 (0.2 to 0.9)	-31.7 (-71.7 to 44.7)	-41.9 (-76.3 to 29.0)
Hookworm disease	5,032.1 (3,892.4 to 6,556.3)	5,032.1 (3,866.3 to 6,556.3)	0.0 (-84.1 to -58.5)	-29.6 (-47.2 to -6.6)	5.7 (1.6 to 43.6)	5.7 (3.3 to 9.1)	82.7 (-84.1 to -73.1)	82.7 (-87.2 to -78.1)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	243.9 (190.9 to 297.6)	194.5 (180.2 to 210.0)	-20.3 (-35.0 to 1.3)	-25.1 (-38.3 to -6.6)	8.5 (5.1 to 12.4)	6.5 (4.1 to 9.6)	-24.8 (-36.1 to 10.7)	-25.5 (-36.5 to 8.9)
Maternal disorders	-	-	-	-	0.7 (0.4 to 1.0)	0.6 (0.4 to 1.0)	-8.8 (-39.5 to 29.3)	-19.1 (-47.8 to 12.2)
Maternal hemorrhage	7.0 (6.3 to 7.9)	8.2 (5.1 to 11.1)	15.6 (-28.0 to 59.1)	0.2 (-37.4 to 38.2)	0.3 (0.2 to 0.5)	0.3 (0.1 to 0.5)	-5.5 (-58.1 to 53.8)	-16.0 (-64.4 to 34.8)
Maternal sepsis and other maternal infections	5.8 (3.6 to 8.3)	4.6 (2.8 to 6.8)	-19.3 (-40.1 to -5.5)	-39.1 (-53.9 to -28.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-30.1 (-62.8 to 26.0)	-42.1 (-67.9 to 5.8)
Maternal hypertensive disorders	2.2 (1.1 to 3.8)	2.5 (1.3 to 4.0)	10.1 (-2.8 to 32.8)	-3.1 (-10.5 to 13.4)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	10.6 (-17.2 to 50.1)	-2.7 (-25.8 to 29.5)
Obstructed labor	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.2)	-21.3 (-64.8 to 45.4)	-31.4 (-69.4 to 25.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-21.8 (-66.7 to 67.0)	-31.0 (-71.1 to 42.9)
Complications of abortion	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	43.2 (-27.8 to 177.2)	21.1 (-39.5 to 136.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.2 (-28.0 to 178.2)	21.1 (-39.8 to 136.8)
Other maternal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-15.3 (-52.9 to 44.1)	-26.6 (-58.9 to 24.3)
Neonatal disorders	-	-	-	-	22.5 (15.7 to 31.1)	29.7 (20.1 to 41.1)	32.6 (-6.9 to 94.2)	15.6 (-18.6 to 69.5)
Preterm birth complications	74.1 (54.5 to 101.7)	157.0 (109.4 to 232.0)	110.0 (61.6 to 178.1)	75.6 (35.3 to 132.5)	9.1 (6.2 to 12.5)	17.6 (11.8 to 24.6)	91.9 (40.2 to 181.2)	65.7 (21.2 to 143.3)
Neonatal encephalopathy due to birth asphyxia and trauma	51.3 (22.1 to 102.8)	30.5 (12.1 to 72.3)	-41.7 (-70.5 to -16.5)	-51.2 (-75.5 to -11.4)	5.5 (3.4 to 8.1)	3.9 (2.4 to 5.7)	-28.7 (-54.5 to 7.3)	-36.1 (-59.3 to -4.3)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	40.4 (27.5 to 53.4)	31.4 (19.4 to 43.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.5 (14.9 to 66.7)	31.5 (7.5 to 56.0)
Hemolytic disease and other neonatal jaundice	4.5 (1.8 to 8.1)	3.2 (1.3 to 6.7)	-31.6 (-68.1 to 59.4)	-40.3 (-72.7 to 37.8)	1.7 (0.7 to 3.3)	1.3 (0.5 to 2.7)	-29.6 (-67.6 to 60.4)	-38.7 (-71.7 to 39.4)
Other neonatal disorders	-	-	-	-	6.2 (3.0 to 10.3)	7.0 (3.1 to 13.6)	11.8 (-59.9 to 203.1)	-2.3 (-65.1 to 164.3)
Nutritional deficiencies	-	-	-	-	164.0 (109.0 to 235.3)	123.7 (82.3 to 178.0)	-24.5 (-29.6 to -19.8)	-37.7 (-37.0 to -28.5)
Protein-energy malnutrition	120.5 (78.8 to 174.2)	80.8 (48.1 to 125.4)	-33.3 (-65.2 to 21.9)	-37.2 (-67.1 to 14.4)	37.2 (8.2 to 25.0)	15.1 (5.2 to 16.9)	10.1 (-65.3 to 23.5)	37.0 (-67.3 to 15.9)
Iodine deficiency	303.3 (240.1 to 387.3)	181.8 (128.3 to 236.8)	-40.1 (-62.2 to -11.6)	-53.9 (-70.6 to -32.2)	5.4 (3.3 to 8.6)	3.3 (1.7 to 5.4)	-40.1 (-62.3 to -10.9)	-53.9 (-70.8 to -31.4)
Vitamin A deficiency	5.6 (3.6 to 7.6)	3.3 (2.2 to 4.5)	-40.5 (-56.2 to -21.5)	-47.4 (-61.5 to -30.3)	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.2)	-38.3 (-54.8 to -17.5)	-46.8 (-60.5 to -29.1)

Appendix Table G.4 - Sri Lanka prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	4,488.0 (4,435.3 to 4,539.2)	3,734.4 (3,698.9 to 3,774.4)	-17.1 (-18.3 to -15.8)	-29.9 (-30.9 to -28.8)	142.7 (95.3 to 206.1)	109.2 (72.4 to 159.1)	-23.4 (-25.6 to -21.9)	-31.8 (-33.6 to -30.6)
Other nutritional deficiencies	-	-	-	-	1.0 (0.2 to 1.3)	1.0 (0.3 to 1.9)	120.7 (55.4 to 477.8)	107.8 (57.9 to 444.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	15.5 (9.5 to 24.2)	14.1 (8.7 to 22.1)	-10.9 (-20.4 to 7.0)	-21.1 (-29.4 to -5.0)
Sexually transmitted diseases excluding HIV	-	-	-	-	6.5 (3.6 to 10.3)	7.6 (4.2 to 12.4)	16.2 (6.0 to 28.3)	-1.9 (-9.8 to 8.1)
Syphilis	0.7 (0.6 to 0.8)	0.6 (0.5 to 0.7)	-10.2 (-25.6 to 9.6)	-44.2 (-53.0 to -32.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-30.2 (-34.0 to -25.0)	-43.7 (-58.8 to -22.2)
Chlamydial infection	1,223.8 (1,078.2 to 1,375.9)	1,493.1 (1,325.3 to 1,691.0)	21.6 (4.3 to 43.2)	5.4 (-2.2 to 24.1)	5.3 (2.9 to 8.4)	6.1 (3.3 to 10.0)	15.6 (4.4 to 30.1)	0.3 (-9.3 to 12.4)
Gonococcal infection	61.5 (39.9 to 84.3)	71.2 (47.9 to 94.5)	14.9 (-31.2 to 91.9)	4.6 (-36.7 to 71.8)	0.4 (0.2 to 0.7)	0.5 (0.3 to 0.8)	10.6 (-25.2 to 84.5)	-0.8 (-32.6 to 63.6)
Trichomoniasis	70.5 (45.9 to 99.6)	91.1 (51.4 to 132.3)	24.9 (-31.0 to 130.5)	-1.1 (-44.7 to 79.3)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	33.2 (-34.8 to 163.7)	4.7 (-47.6 to 105.1)
Genital herpes	1,886.9 (1,811.1 to 1,956.5)	2,505.7 (2,381.6 to 2,633.8)	32.4 (23.9 to 41.0)	8.9 (-14.7 to -3.2)	0.5 (0.2 to 1.2)	0.7 (0.2 to 1.6)	28.9 (17.2 to 39.2)	48.2 (-15.5 to -2.1)
Other sexually transmitted diseases	2.7 (2.1 to 3.6)	2.6 (2.0 to 3.4)	-4.7 (-16.4 to 10.2)	-26.7 (-35.6 to -15.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	3.2 (-33.3 to 61.6)	-16.9 (-45.4 to 27.7)
Hepatitis	-	-	-	-	1.0 (0.6 to 1.4)	1.0 (0.6 to 1.5)	4.8 (8.3 to 20.6)	-12.3 (-24.0 to 2.1)
Hepatitis A	23.6 (22.8 to 24.4)	22.7 (22.1 to 23.3)	-4.1 (-4.7 to -3.4)	-8.1 (-8.2 to -7.8)	0.5 (0.3 to 0.8)	0.6 (0.4 to 0.9)	6.2 (5.0 to 18.6)	-0.1 (-10.7 to 11.6)
Hepatitis B	661.6 (576.5 to 769.5)	611.6 (533.4 to 690.6)	-8.1 (-23.4 to 12.8)	-28.6 (-40.2 to -13.0)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	5.7 (-28.0 to 60.3)	-26.1 (-48.9 to 11.8)
Hepatitis C	142.2 (127.5 to 156.9)	151.1 (133.8 to 167.8)	6.0 (-9.4 to 22.7)	26.7 (-36.8 to -14.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.8 (-16.3 to 37.8)	-25.7 (-43.2 to -3.7)
Hepatitis E	3.1 (2.6 to 3.7)	2.9 (2.4 to 3.4)	-7.5 (-30.7 to 19.9)	-22.1 (-41.7 to -0.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-5.6 (-37.8 to 36.4)	-21.4 (-48.6 to 11.5)
Leprosy	1.8 (1.4 to 2.3)	3.1 (2.7 to 3.5)	73.2 (42.9 to 109.0)	2.6 (-14.8 to 22.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	71.2 (32.8 to 124.9)	1.2 (-19.8 to 31.9)
Other infectious diseases	183.0 (149.2 to 221.0)	145.2 (129.8 to 161.6)	-21.0 (-34.7 to -6.0)	-28.1 (-40.1 to -15.0)	7.9 (4.6 to 12.6)	5.3 (3.4 to 7.9)	-36.6 (-47.7 to -7.0)	-40.4 (-50.4 to -12.0)
Non-communicable diseases	-	-	-	-	1,207.9 (893.6 to 1,556.7)	44.7 (1,298.3 to 2,266.2)	44.7 (40.1 to 50.3)	1.2 (-1.7 to 4.5)
Neoplasms	-	-	-	-	4.7 (3.3 to 6.2)	9.6 (6.7 to 13.0)	103.8 (71.2 to 159.6)	16.6 (-1.7 to 49.2)
Esophageal cancer	0.5 (0.3 to 0.6)	1.4 (0.8 to 2.0)	217.4 (47.8 to 421.4)	76.8 (-19.5 to 183.8)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	207.9 (33.8 to 362.0)	69.9 (-26.5 to 157.3)
Stomach cancer	1.0 (0.9 to 1.2)	1.9 (1.6 to 2.3)	86.6 (46.9 to 134.0)	-3.6 (-24.3 to 21.5)	0.1 (0.0 to 0.2)	0.2 (0.0 to 0.3)	71.7 (36.4 to 120.9)	-11.2 (-30.2 to 15.1)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	6,609.8 (5,052.4 to 8,652.5)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	7,370.3 (4,054.4 to 15,894.6)	5,193.4 (2,910.5 to 11,288.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7,312.6 (4,372.0 to 15,817.8)	5,089.4 (2,992.9 to 11,053.0)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	16,131.9 (5,515.5 to 31,739.6)	9,631.4 (3,343.7 to 19,023.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16,316.4 (5,387.7 to 28,886.7)	9,738.8 (3,272.4 to 17,173.1)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3,675.7 (1,402.2 to 10,157.5)	2,172.2 (800.0 to 6,249.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3,532.3 (1,412.5 to 9,469.4)	2,102.2 (826.6 to 5,704.3)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,112.7 (1,066.4 to 4,345.9)	1,629.8 (786.6 to 3,305.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.7 (1,202.6 to 4,151.8)	1.7 (883.5 to 3,159.8)
Larynx cancer	0.6 (0.4 to 0.8)	0.9 (0.6 to 1.2)	52.9 (10.8 to 113.7)	-12.8 (-37.0 to 21.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	57.3 (12.7 to 121.9)	-10.3 (-35.9 to 27.0)
Tracheal, bronchus and lung cancer	1.0 (0.9 to 1.1)	2.4 (2.0 to 2.9)	148.4 (101.9 to 203.2)	37.6 (11.8 to 66.5)	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.5)	132.1 (78.1 to 200.6)	28.8 (-2.2 to 65.0)
Breast cancer	8.9 (7.6 to 10.5)	40.7 (33.1 to 48.2)	359.5 (262.8 to 459.0)	176.9 (119.1 to 235.5)	0.7 (0.5 to 1.0)	2.6 (1.7 to 3.6)	271.6 (181.7 to 368.8)	123.4 (69.3 to 177.3)
Cervical cancer	2.1 (1.6 to 3.4)	3.2 (2.4 to 4.4)	52.9 (4.0 to 131.1)	62.9 (-43.5 to 31.0)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	63.0 (-2.8 to 135.3)	-6.1 (-43.4 to 34.0)
Uterine cancer	0.9 (0.6 to 1.6)	2.8 (1.4 to 4.3)	234.0 (40.0 to 467.8)	81.4 (-23.1 to 205.6)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	226.0 (37.4 to 476.6)	78.0 (-26.1 to 203.6)
Prostate cancer	1.5 (1.1 to 2.3)	7.7 (4.2 to 11.0)	440.8 (186.0 to 725.6)	191.5 (40.2 to 341.1)	0.1 (0.1 to 0.2)	0.7 (0.3 to 1.1)	466.9 (154.9 to 794.1)	210.2 (36.4 to 383.9)
Colon and rectum cancer	2.7 (2.4 to 3.1)	7.0 (6.0 to 8.3)	158.1 (116.6 to 210.8)	34.5 (13.5 to 62.1)	0.3 (0.2 to 0.3)	0.6 (0.4 to 0.8)	130.2 (88.2 to 183.1)	20.5 (-2.1 to 47.6)
Lip and oral cavity cancer	8.6 (6.1 to 10.7)	13.1 (9.1 to 19.4)	50.7 (-6.6 to 139.9)	-17.1 (-48.7 to 30.6)	0.8 (0.5 to 1.1)	1.1 (0.7 to 1.8)	49.6 (-4.3 to 131.7)	-16.7 (-47.0 to 28.4)
Nasopharynx cancer	1.4 (1.0 to 1.7)	0.5 (0.3 to 1.0)	-67.5 (-78.4 to -12.8)	-80.9 (-87.2 to -46.9)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	81.6 (-78.5 to -12.8)	-81.6 (-87.4 to -47.8)
Other pharynx cancer	1.6 (1.1 to 2.1)	2.3 (1.5 to 3.3)	39.2 (-16.0 to 121.5)	-24.9 (-53.5 to 20.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	35.5 (-12.8 to 107.9)	-26.6 (-52.0 to 12.5)
Gallbladder and biliary tract cancer	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	87.7 (8.0 to 180.1)	-1.8 (-42.7 to 48.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	73.1 (2.4 to 149.0)	-8.9 (-45.8 to 32.4)
Pancreatic cancer	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	53.1 (20.8 to 102.8)	-23.0 (-39.1 to 12.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	41.4 (16.2 to 74.2)	-28.9 (-41.5 to -11.2)
Malignant skin melanoma	0.8 (0.6 to 1.0)	0.9 (0.7 to 1.5)	9.1 (-22.3 to 67.7)	71.1 (-56.7 to -2.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	93.4 (-28.8 to 65.6)	-42.7 (-60.5 to -2.4)
Non-melanoma skin cancer	0.6 (0.4 to 0.8)	2.0 (1.5 to 2.8)	254.3 (159.5 to 375.2)	91.3 (37.6 to 163.7)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	263.3 (145.9 to 449.2)	97.5 (28.9 to 212.4)
Ovarian cancer	0.6 (0.5 to 0.7)	1.4 (1.0 to 2.0)	144.8 (77.0 to 246.3)	48.1 (8.5 to 109.9)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	127.5 (52.2 to 248.2)	38.6 (7.3 to 110.5)
Testicular cancer	0.2 (0.1 to 0.3)	0.5 (0.2 to 1.0)	270.4 (42.7 to 674.4)	169.8 (5.8 to 453.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	227.4 (24.2 to 598.9)	133.5 (-9.0 to 388.7)
Kidney cancer	1.4 (1.2 to 1.6)	4.1 (3.3 to 5.1)	196.2 (130.2 to 288.3)	92.6 (23.3 to 106.6)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	170.2 (107.6 to 249.8)	43.7 (10.1 to 85.7)
Bladder cancer	0.5 (0.4 to 0.6)	1.0 (0.8 to 1.3)	113.4 (62.5 to 187.1)	6.8 (-19.0 to 44.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	94.9 (46.4 to 166.7)	-2.6 (-28.0 to 37.3)
Brain and nervous system cancer	0.7 (0.6 to 1.0)	1.8 (1.3 to 2.2)	151.7 (67.6 to 223.2)	75.3 (19.1 to 123.7)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	146.6 (62.9 to 218.1)	67.4 (13.6 to 113.7)
Thyroid cancer	8.0 (4.6 to 10.5)	9.7 (5.6 to 19.4)	-8.8 (-38.7 to 214.9)	-42.5 (-62.6 to 92.4)	0.5 (0.2 to 0.7)	0.6 (0.3 to 1.2)	-7.1 (-39.6 to 208.8)	-44.0 (-63.5 to 85.0)
Mesothelioma	0.2 (0.2 to 0.2)	0.0 (0.0 to 0.0)	-90.4 (-90.4 to -92.4)	-85.9 (-95.3 to -91.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-85.9 (-90.5 to -81.1)	-93.4 (-100.7 to -90.2)
Hodgkin lymphoma	0.4 (0.3 to 0.7)	1.0 (0.7 to 1.3)	155.7 (16.9 to 295.4)	109.4 (-3.2 to 216.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	152.4 (-19.8 to 281.5)	100.7 (-7.8 to 197.1)
Non-Hodgkin lymphoma	3.1 (1.0 to 4.3)	3.2 (2.2 to 4.1)	-4.1 (-30.0 to 192.3)	-8.0 (-61.7 to 79.2)	0.2 (0.1 to 0.4)	0.2 (0.2 to 0.4)	-12.0 (-34.9 to 186.3)	-52.2 (-64.8 to 73.6)
Multiple myeloma	0.4 (0.1 to 0.8)	0.3 (0.2 to 0.5)	-7.8 (-72.9 to 220.1)	-54.2 (-86.7 to 69.9)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-7.7 (-72.1 to 255.4)	-54.0 (-86.4 to 90.6)
Leukemia	132.7 (0.6 to 1.0)	409.8 (2.1 to 3.8)	206.5 (166.8 to 424.6)	207.6 (115.3 to 315.8)	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.4)	238.4 (146.4 to 344.1)	147.1 (77.4 to 222.6)
Other neoplasms	5.4 (2.8 to 7.6)	9.1 (6.4 to 14.1)	33.5 (-5.8 to 335.2)	-18.2 (-43.1 to 176.9)	0.4 (0.2 to 0.7)	0.6 (0.4 to 1.1)	23.8 (-12.2 to 300.6)	27.1 (-47.9 to 149.5)
Cardiovascular diseases	-	-	-	-	40.4 (28.6 to 54.6)	82.1 (54.6 to 112.9)	102.9 (64.0 to 143.9)	18.8 (-3.3 to 41.2)
Rheumatic heart disease	228.6 (166.3 to 277.9)	306.7 (239.9 to 367.5)	33.5 (-0.9 to 92.5)	-2.5 (-27.4 to 37.0)	11.7 (7.1 to 17.3)	16.3 (10.3 to 23.9)	39.9 (5.9 to 96.7)	0.4 (-24.5 to 36.3)
Ischemic heart disease	112.2 (92.3 to 137.3)	224.2 (186.0 to 271.8)	99.2 (52.3 to 157.5)	7.8 (-19.2 to 33.8)	3.7 (5.2 to 11.4)	15.6 (10.5 to 22.7)	99.3 (52.4 to 156.2)	3.7 (-19.2 to 34.9)
Cerebrovascular disease	-	-	-	-	5.8 (4.0 to 7.7)	10.7 (7.2 to 14.2)	84.1 (53.3 to 122.4)	0.4 (-16.4 to 22.0)
Ischemic stroke	18.6 (15.8 to 21.6)	35.5 (29.1 to 41.4)	88.6 (56.2 to 130.6)	1.2 (-16.4 to 24.0)	2.8 (1.9 to 3.8)	5.2 (3.4 to 7.3)	88.0 (54.1 to 132.3)	1.2 (-17.1 to 25.2)
Hemorrhagic stroke	20.1 (17.8 to 23.1)	36.5 (31.3 to 42.2)	80.4 (48.1 to 115.2)	-1.0 (-18.2 to 18.7)	3.0 (2.0 to 4.1)	5.4 (3.6 to 7.4)	80.3 (46.9 to 118.7)	-0.3 (-18.7 to 21.0)
Hypertensive heart disease	28.5 (23.0 to 32.2)	54.0 (47.8 to 60.9)	89.3 (57.2 to 122.2)	0.7 (-17.4 to 16.6)	3.2 (2.2 to 4.4)	6.0 (4.2 to 8.3)	89.7 (55.7 to 122.0)	-0.2 (-18.2 to 16.4)
Cardiomyopathy and myocarditis	12.4 (10.3 to 14.8)	24.6 (21.9 to 26.9)	96.4 (62.4 to 145.8)	13.4 (-7.4 to 45.5)	1.4 (0.9 to 2.0)	2.7 (1.8 to 3.7)	95.6 (58.3 to 147.1)	15.3 (-9.5 to 45.8)
Atrial fibrillation and flutter	10.9 (8.8 to 13.1)	21.8 (16.4 to 27.8)	99.6 (40.7 to 171.7)	1.7 (-29.8 to 42.6)	0.9 (0.6 to 1.2)	2.0 (1.1 to 2.5)	101.6 (41.0 to 180.0)	2.0 (-29.3 to 46.6)
Peripheral vascular disease	494.4 (403.7 to 617.0)	918.6 (748.0 to 1,097.6)	86.6 (34.7 to 139.4)	-2.2 (-29.0 to 21.2)	0.2 (0.1 to 0.5)	0.4 (0.2 to 1.0)	73.0 (-37.7 to 495.4)	-14.3 (-67.8 to 191.7)
Endocarditis	0.5 (0.4 to 0.7)	1.0 (0.6 to 1.3)	92.1 (15.6 to 170.2)	24.7 (-25.2 to 75.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	95.0 (14.3 to 189.6)	27.4 (-27.0 to 88.8)
Other cardiovascular and circulatory diseases	132.7 (89.4 to 187.3)	409.8 (191.1 to 565.8)	206.5 (40.2 to 401.7)	207.6 (-16.9 to 207.0)				

Appendix Table G.4 - Sri Lanka prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	163.0 (144.3 to 181.8)	163.0 (39.3 to 64.3)
Silicosis	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.2)	44.9 (38.1 to 52.1)	-20.4 (-24.2 to -16.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	44.4 (37.2 to 51.7)	-20.8 (-24.6 to -16.5)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.3 (0.3 to 0.4)	1.1 (1.0 to 1.2)	224.5 (208.8 to 238.2)	94.7 (86.0 to 102.9)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	217.5 (198.3 to 237.4)	88.8 (76.1 to 103.1)
Asthma	927.9 (977.8 to 1,070.1)	1,263.9 (1,074.4 to 1,424.2)	35.4 (11.7 to 65.6)	3.4 (-14.8 to 24.4)	41.1 (26.3 to 59.1)	55.7 (35.3 to 78.9)	35.3 (11.5 to 67.0)	3.9 (-15.1 to 25.1)
Interstitial lung disease and pulmonary sarcoidosis	1.3 (1.0 to 1.6)	2.2 (1.7 to 2.8)	73.7 (30.9 to 134.6)	7.8 (-18.7 to 44.1)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	74.4 (29.1 to 135.5)	6.4 (-21.7 to 43.6)
Other chronic respiratory diseases	-	-	-	-	4.1 (2.5 to 6.4)	4.3 (2.6 to 6.7)	2.4 (-26.2 to 50.4)	-37.3 (-54.3 to -8.2)
Cirrhosis	-	-	-	-	1.1 (0.7 to 1.5)	1.5 (1.0 to 2.0)	7.2 (19.6 to 57.5)	-8.6 (-20.0 to 4.5)
Cirrhosis due to hepatitis B	2.3 (1.5 to 3.0)	3.3 (1.9 to 4.4)	41.8 (-16.5 to 147.0)	-5.8 (44.5 to 62.8)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.8)	40.8 (-21.4 to 151.4)	6.1 (-47.8 to 68.7)
Cirrhosis due to hepatitis C	1.1 (0.7 to 1.5)	2.0 (1.2 to 2.9)	83.5 (-5.4 to 222.6)	19.1 (-38.8 to 109.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	82.9 (-11.7 to 231.3)	19.6 (-41.4 to 119.5)
Cirrhosis due to alcohol use	2.1 (1.4 to 2.8)	2.2 (1.4 to 3.3)	-37.2 (-38.8 to 93.7)	0.3 (-62.0 to 18.0)	0.3 (0.2 to 0.6)	0.4 (0.2 to 0.6)	2.1 (-40.4 to 93.8)	-37.0 (-62.7 to 20.4)
Cirrhosis due to other causes	0.9 (0.7 to 1.1)	1.3 (0.9 to 1.9)	48.1 (0.5 to 117.8)	21.3 (-16.6 to 79.3)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.4)	47.2 (-9.4 to 137.3)	21.9 (-25.4 to 95.1)
Digestive diseases	-	-	-	-	15.3 (10.6 to 21.1)	20.4 (14.2 to 28.2)	33.6 (20.5 to 46.6)	-14.1 (-22.0 to -6.2)
Peptic ulcer disease	71.9 (57.7 to 85.7)	72.3 (61.5 to 84.6)	0.4 (-14.6 to 20.7)	-44.1 (-51.9 to -34.1)	2.4 (1.5 to 3.5)	2.6 (1.7 to 3.8)	11.4 (-16.3 to 36.9)	-37.5 (-51.0 to -23.9)
Gastritis and duodenitis	174.8 (164.4 to 186.0)	200.0 (187.6 to 211.0)	14.2 (5.0 to 23.1)	-26.7 (-31.8 to -21.6)	6.6 (4.4 to 9.3)	7.6 (5.1 to 10.9)	16.5 (1.3 to 28.3)	-20.7 (-28.3 to -13.1)
Appendicitis	1.4 (1.0 to 1.8)	1.2 (0.9 to 1.6)	-10.7 (-45.7 to 36.5)	-26.7 (-54.7 to 7.8)	0.4 (0.2 to 0.7)	0.4 (0.2 to 0.6)	-11.3 (-49.1 to 55.9)	-26.8 (-58.2 to 25.0)
Paralytic ileus and intestinal obstruction	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	33.0 (-6.0 to 108.1)	-8.4 (-32.0 to 36.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	39.8 (-0.0 to 112.9)	-7.9 (-35.7 to 45.9)
Inguinal, femoral, and abdominal hernia	31.6 (27.0 to 37.4)	46.7 (39.2 to 55.3)	47.6 (18.6 to 82.3)	-15.8 (-34.4 to 6.6)	0.3 (0.2 to 0.6)	0.5 (0.2 to 0.9)	46.8 (16.3 to 83.9)	-15.6 (-34.4 to 7.0)
Inflammatory bowel disease	2.1 (2.0 to 2.3)	3.2 (3.1 to 3.4)	50.5 (40.5 to 61.5)	-1.6 (-8.3 to 5.3)	0.5 (0.3 to 0.6)	0.7 (0.5 to 1.0)	50.7 (25.0 to 79.9)	-0.8 (-16.6 to 17.9)
Vascular intestinal disorders	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	99.4 (36.3 to 174.7)	17.1 (-25.1 to 73.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.9 (24.5 to 190.5)	12.6 (-34.1 to 87.0)
Gallbladder and biliary diseases	4.7 (4.2 to 5.3)	5.8 (5.1 to 6.5)	26.2 (3.6 to 48.8)	-26.2 (-36.9 to -14.6)	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.9)	21.1 (-3.1 to 48.1)	-26.8 (-40.1 to -12.1)
Pancreatitis	3.9 (3.7 to 4.2)	7.0 (6.6 to 7.3)	77.3 (63.3 to 91.0)	13.4 (4.9 to 22.2)	1.2 (0.8 to 1.6)	2.1 (1.4 to 2.8)	76.4 (52.4 to 105.9)	13.6 (-0.8 to 32.0)
Other digestive diseases	-	-	-	-	3.5 (2.3 to 5.0)	5.9 (3.8 to 8.5)	72.5 (32.1 to 106.0)	10.2 (-15.5 to 32.3)
Neurological disorders	-	-	-	-	125.1 (82.2 to 178.2)	184.5 (123.3 to 254.6)	48.1 (21.2 to 87.5)	7.9 (-8.8 to 33.9)
Alzheimer disease and other dementias	76.4 (64.8 to 88.3)	149.0 (124.1 to 173.5)	95.0 (56.7 to 143.7)	-0.9 (-19.7 to 25.9)	11.0 (7.6 to 14.8)	21.5 (14.9 to 28.7)	95.2 (57.3 to 147.9)	-0.5 (-20.1 to 28.0)
Parkinson disease	7.2 (6.3 to 8.1)	13.8 (12.0 to 15.6)	90.8 (82.7 to 101.1)	0.1 (-4.0 to 5.1)	0.9 (0.6 to 1.2)	1.7 (1.1 to 2.3)	91.6 (69.8 to 114.6)	0.8 (-10.1 to 12.1)
Epilepsy	80.5 (57.9 to 103.6)	101.8 (73.5 to 132.4)	26.9 (-18.8 to 87.2)	3.0 (-33.4 to 51.6)	26.1 (15.7 to 38.4)	34.4 (20.4 to 49.7)	32.0 (-16.4 to 99.1)	8.4 (-30.9 to 65.1)
Multiple sclerosis	0.1 (0.1 to 0.1)	0.3 (0.3 to 0.3)	174.8 (148.1 to 208.4)	82.9 (65.0 to 105.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	174.8 (147.9 to 208.5)	82.9 (65.0 to 105.6)
Migraine	2,021.1 (1,395.5 to 2,536.7)	69.9 (2,667.0 to 3,248.1)	2,780.8 (-1.0 to 105.4)	36.5 (-22.5 to 56.9)	5.2 (38.3 to 108.4)	95.5 (56.1 to 145.4)	21.1 (-1.2 to 105.9)	-26.8 (-22.3 to 58.4)
Tension-type headache	3,827.1 (3,407.9 to 4,223.4)	5,093.4 (4,695.3 to 5,425.9)	31.9 (17.1 to 54.7)	0.9 (-10.4 to 16.4)	5.8 (2.8 to 13.6)	7.7 (4.0 to 9.3)	31.8 (16.7 to 54.1)	1.1 (-16.9 to 16.9)
Medication overuse headache	61.2 (41.2 to 81.4)	136.2 (92.1 to 177.5)	122.0 (86.3 to 161.3)	54.8 (32.1 to 80.1)	9.7 (5.6 to 14.9)	21.5 (12.3 to 32.6)	121.4 (84.0 to 162.1)	55.3 (30.0 to 82.3)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.3 (0.5 to 81.4)	2.4 (-24.2 to 36.7)	1.6 (1.0 to 2.4)	2.0 (1.3 to 2.8)	25.5 (-18.5 to 80.7)	-36.1 (-57.9 to -7.9)
Mental and substance use disorders	-	-	-	-	310.5 (223.7 to 411.1)	399.5 (283.9 to 526.8)	28.8 (22.4 to 34.4)	-1.2 (-4.6 to 2.2)
Schizophrenia	57.4 (49.1 to 65.5)	81.6 (70.2 to 93.1)	41.7 (35.3 to 48.9)	0.2 (-3.9 to 4.5)	0.2 (26.3 to 47.1)	21.5 (37.6 to 66.4)	41.5 (32.7 to 51.0)	0.6 (-5.0 to 7.0)
Alcohol use disorders	124.8 (113.0 to 137.6)	146.0 (131.8 to 161.8)	16.6 (8.6 to 24.3)	-10.9 (-16.7 to -5.3)	12.5 (8.2 to 17.5)	14.5 (9.6 to 20.6)	16.1 (6.4 to 25.8)	-10.9 (-18.6 to -4.1)
Drug use disorders	-	-	-	-	39.2 (25.7 to 54.2)	42.1 (27.9 to 58.3)	8.1 (-13.2 to 34.3)	-5.0 (-23.4 to 17.3)
Opioid use disorders	20.5 (15.9 to 25.2)	25.7 (20.3 to 31.3)	25.4 (14.2 to 39.1)	-2.2 (-11.1 to 6.9)	8.6 (5.6 to 11.9)	10.8 (7.2 to 15.0)	25.4 (9.5 to 45.9)	-1.7 (-14.5 to 10.9)
Cocaine use disorders	14.3 (13.3 to 15.3)	16.6 (15.1 to 17.9)	15.8 (3.5 to 28.9)	1.0 (-11.5 to 10.0)	2.0 (1.3 to 2.9)	2.3 (1.5 to 3.3)	16.0 (4.8 to 37.9)	-0.5 (-18.4 to 17.7)
Amphetamine use disorders	95.5 (75.0 to 114.4)	95.8 (78.2 to 115.2)	-0.0 (-26.2 to 32.6)	-8.1 (-31.8 to 20.6)	12.6 (7.6 to 18.9)	12.6 (7.5 to 19.5)	-0.4 (-26.1 to 34.1)	-8.1 (-31.3 to 22.1)
Cannabis use disorders	40.3 (27.7 to 51.4)	44.1 (31.8 to 55.1)	8.8 (5.8 to 15.3)	-0.8 (-0.9 to -0.7)	1.2 (0.6 to 1.8)	1.3 (0.7 to 2.0)	9.5 (-4.6 to 25.9)	-0.3 (-13.2 to 12.7)
Other drug use disorders	-	-	-	-	14.8 (8.8 to 22.8)	15.1 (9.2 to 22.8)	1.9 (-29.4 to 48.9)	-7.2 (-35.7 to 35.5)
Depressive disorders	-	-	-	-	91.3 (57.4 to 133.6)	131.9 (82.4 to 192.3)	49.9 (33.6 to 58.0)	2.3 (-3.0 to 10.0)
Major depressive disorder	342.8 (228.9 to 449.2)	491.3 (321.2 to 659.2)	42.4 (29.7 to 60.7)	2.2 (-4.4 to 12.4)	70.9 (41.2 to 108.5)	101.0 (57.6 to 153.7)	42.0 (29.1 to 60.4)	2.6 (-4.3 to 13.1)
Dysthymia	210.6 (180.6 to 239.2)	319.3 (277.0 to 360.6)	51.0 (46.1 to 57.0)	1.1 (-0.9 to 1.4)	20.5 (13.3 to 29.7)	30.8 (20.1 to 44.7)	50.7 (44.3 to 57.2)	1.4 (-0.7 to 3.6)
Bipolar disorder	104.9 (86.0 to 122.2)	142.9 (121.8 to 164.5)	36.1 (26.0 to 45.9)	0.6 (-5.3 to 5.7)	21.6 (13.0 to 32.9)	29.2 (18.1 to 44.4)	35.6 (24.8 to 49.1)	0.9 (-5.8 to 8.0)
Anxiety disorders	456.8 (193.8 to 724.9)	608.6 (287.0 to 936.2)	33.4 (17.1 to 57.1)	1.3 (-1.0 to 2.0)	42.4 (16.5 to 74.3)	56.2 (25.6 to 97.9)	33.3 (17.0 to 57.5)	1.7 (-1.3 to 4.9)
Eating disorders	-	-	-	-	1.9 (1.2 to 2.9)	2.0 (1.3 to 3.0)	5.5 (9.0 to 21.4)	1.7 (-11.7 to 17.1)
Anorexia nervosa	4.7 (3.6 to 5.9)	4.9 (3.8 to 6.3)	4.2 (-5.7 to 15.5)	1.2 (-7.9 to 12.0)	1.0 (0.6 to 1.5)	1.1 (0.7 to 1.6)	4.2 (-14.7 to 27.4)	1.5 (-16.9 to 24.3)
Bulimia nervosa	4.3 (2.8 to 6.3)	4.6 (3.0 to 6.7)	5.6 (2.3 to 10.9)	1.2 (-1.1 to 1.4)	0.9 (0.5 to 1.5)	1.0 (0.5 to 1.6)	7.2 (-12.1 to 30.6)	2.2 (-14.9 to 23.2)
Autistic spectrum disorders	-	-	-	-	21.0 (14.3 to 28.6)	24.8 (17.1 to 33.7)	18.2 (14.1 to 22.3)	-1.0 (-4.8 to 2.5)
Autism	53.5 (50.7 to 56.3)	63.7 (60.4 to 67.2)	18.6 (17.8 to 19.4)	-1.3 (-1.3 to -1.2)	13.3 (8.9 to 18.1)	15.7 (10.6 to 21.6)	18.4 (12.4 to 24.3)	-0.8 (-5.6 to 3.9)
Asperger syndrome	76.5 (71.7 to 81.2)	90.6 (84.9 to 96.2)	18.0 (17.0 to 19.0)	-1.7 (-1.7 to -1.6)	7.7 (5.3 to 10.6)	9.1 (6.3 to 12.6)	17.9 (13.1 to 23.2)	-1.3 (-4.9 to 2.8)
Attention-deficit/hyperactivity disorder	115.9 (106.8 to 123.6)	108.2 (99.8 to 115.5)	-6.9 (-7.1 to -6.8)	-0.3 (-0.3 to -0.3)	1.4 (0.8 to 2.2)	1.3 (0.8 to 2.0)	6.7 (12.9 to 0.1)	0.0 (-6.5 to 7.2)
Conduct disorder	117.9 (111.0 to 124.8)	108.8 (102.4 to 115.1)	-8.1 (-8.2 to -8.0)	0.2 (-4.2 to 4.0)	14.2 (8.9 to 20.9)	13.2 (8.4 to 19.1)	7.6 (-12.4 to -2.6)	0.1 (-4.9 to 5.8)
Idiopathic intellectual disability	147.3 (85.6 to 207.7)	74.1 (40.1 to 115.0)	-50.9 (-74.2 to -25.7)	-57.5 (-74.2 to -25.7)	3.6 (3.8 to 11.6)	3.6 (1.9 to 6.3)	-50.9 (-70.3 to -15.0)	-57.3 (-73.9 to -24.5)
Other mental and substance use disorders	269.4 (252.4 to 285.6)	370.4 (349.0 to 391.6)	37.1 (34.7 to 39.4)	-1.2 (-1.5 to -1.0)	20.3 (13.8 to 27.4)	27.8 (18.8 to 37.6)	38.8 (31.2 to 42.8)	-0.9 (-4.5 to 3.0)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	119.8 (83.4 to 165.8)	211.6 (144.7 to 294.4)	76.6 (57.7 to 98.0)	18.8 (5.3 to 32.4)
Diabetes mellitus	597.4 (497.8 to 698.8)	1,487.3 (1,244.0 to 1,753.9)	148.1 (93.5 to 223.4)	51.9 (17.7 to 97.2)	42.2 (27.9 to 60.8)	102.3 (65.3 to 147.8)	143.1 (88.1 to 210.8)	44.2 (10.6 to 83.3)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.6 (-46.1 to -36.3)	0.0 (-48.3 to -39.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.6 (-46.1 to -36.3)	-41.6 (-48.4 to -39.4)
Chronic kidney disease	-	-	-	-	17.9 (12.1 to 24.6)	25.3 (17.2 to 35.2)	41.8 (25.9 to 56.0)	-1.8 (-10.3 to 5.5)
Chronic kidney disease due to diabetes mellitus	64.2 (40.0 to 90.7)	175.2 (119.6 to 256.5)	171.5 (90.7 to 292.1)	65.5 (21.9 to 136.6)	1.9 (1.1 to 2.8)	4.7 (2.7 to 7.4)	147.0 (72.6 to 270.1)	52.4 (6.7 to 122.7)
Chronic kidney disease due to hypertension	124.4 (75.5 to 204.0)	61.7 (45.0 to 86.1)	-49.3 (-64.8 to -29.5)	-58.6 (-69.8 to -45.0)	3.8 (2.3 to 5.5)	5.4 (3.3 to 7.8)	46.4 (-4.9 to 96.0)	0.5 (-33.0 to 31.6)
Chronic kidney disease due to glomerulonephritis	135.8 (90.8 to 192.3)	179.6 (108.7 to 284.9)	34.4 (-19.8 to 81.7)	1.3 (-38.7 to 30.4)	1.3 (1.9 to 4.3)	1.2 (0.7 to 1.8)	-0.9 (-72.0 to -41.4)	-68.9 (-76.9 to -54.5)
Chronic kidney disease due to other causes	388.3 (261.6 to 556.8)	572.4 (382.5 to 783.6)	46.8 (22.1 to 86.9)	6.7 (-12.0 to 30.4)	9.3 (6.2 to 13.2)	14.0 (9.4 to 19.8)	49.9 (27.2 to 81.6)	4.0 (-14.5 to 23.2)
Urinary diseases and male infertility	-	-	-	-	13.7 (8.8 to 19.6)	31.6 (19.6 to 48.2)	132.7 (74.8 to 192.7)	33.6 (2.7 to 68.3)

Appendix Table G.4 - Sri Lanka prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	3.0 (2.8 to 3.2)	5.2 (5.0 to 5.5)	72.8 (59.9 to 86.1)	72.8 (19.1 to 37.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	72.8 (39.2 to 114.3)	72.8 (6.3 to 56.9)
Urolithiasis	71.3 (55.1 to 101.7)	167.4 (124.3 to 216.2)	138.8 (94.1 to 171.9)	138.8 (8.7 to 53.4)	1.1 (0.7 to 1.6)	2.1 (1.4 to 2.9)	84.6 (62.4 to 109.7)	17.6 (4.3 to 32.9)
Benign prostatic hyperplasia	175.0 (157.0 to 191.4)	316.7 (290.3 to 340.7)	80.3 (59.9 to 105.3)	80.3 (-16.9 to 6.5)	6.3 (4.0 to 9.1)	11.4 (7.5 to 16.1)	80.2 (59.6 to 104.8)	-5.8 (-17.1 to 6.8)
Male infertility due to other causes	81.6 (55.7 to 109.1)	92.1 (60.8 to 131.1)	11.6 (-29.1 to 81.4)	11.6 (-38.8 to 55.9)	-4.0 (0.2 to 1.2)	0.6 (0.2 to 1.3)	9.4 (-31.1 to 86.4)	-5.0 (-40.4 to 60.0)
Other urinary diseases	-	-	-	-	-	-	-	-
Gynecological diseases	-	-	-	-	22.4 (14.6 to 33.3)	27.9 (18.1 to 42.7)	23.9 (8.7 to 43.1)	6.3 (-16.9 to 9.1)
Uterine fibroids	337.3 (307.3 to 369.8)	532.8 (488.6 to 580.4)	57.4 (55.6 to 59.5)	57.4 (3.1 to 3.1)	3.1 (3.6 to 9.7)	7.4 (4.2 to 12.3)	22.9 (11.3 to 32.7)	-15.5 (-22.8 to -9.7)
Polycystic ovarian syndrome	259.3 (218.1 to 300.9)	328.5 (280.5 to 379.5)	25.9 (2.4 to 59.4)	25.9 (-20.0 to 24.5)	2.6 (1.2 to 5.0)	3.2 (1.5 to 6.2)	26.1 (2.7 to 61.2)	-0.4 (-19.2 to 25.8)
Female infertility due to other causes	62.4 (38.5 to 87.0)	98.3 (55.2 to 140.1)	49.7 (-15.7 to 156.1)	49.7 (-30.9 to 109.1)	22.9 (0.1 to 0.8)	0.3 (0.2 to 1.1)	216.4 (79.9 to 360.6)	18.4 (17.4 to 193.7)
Endometriosis	31.4 (26.5 to 36.3)	42.2 (36.5 to 48.5)	33.5 (9.6 to 68.2)	33.5 (-15.8 to 28.5)	2.9 (1.9 to 4.2)	3.9 (2.7 to 5.4)	34.2 (8.9 to 71.3)	3.5 (-15.8 to 31.5)
Genital prolapse	777.3 (674.0 to 885.3)	1,195.0 (1,026.7 to 1,330.4)	54.0 (26.7 to 83.9)	54.0 (-14.5 to 21.9)	3.1 (1.2 to 4.7)	2.5 (1.8 to 7.1)	54.0 (26.5 to 85.1)	3.3 (-14.7 to 22.1)
Premenstrual syndrome	707.4 (511.5 to 891.3)	842.3 (581.6 to 1,187.9)	16.3 (-22.0 to 86.1)	16.3 (-34.4 to 55.5)	6.0 (3.4 to 9.6)	7.1 (4.0 to 11.9)	16.4 (-21.6 to 87.9)	-1.8 (-35.0 to 58.6)
Other gynecological diseases	68.9 (55.3 to 84.7)	65.2 (59.3 to 72.0)	-5.8 (-26.3 to 19.9)	-5.8 (-40.9 to -2.0)	2.1 (1.2 to 3.1)	1.9 (1.2 to 2.7)	-10.7 (-26.7 to 39.9)	-28.3 (-41.1 to 12.1)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	15.2 (10.0 to 22.0)	16.6 (11.0 to 24.1)	9.1 (-1.5 to 23.1)	-6.7 (-15.6 to 4.6)
Thalassemias	1.7 (1.5 to 1.9)	1.8 (1.5 to 2.0)	1.1 (-8.3 to 11.4)	1.1 (-10.2 to 8.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-11.5 (-30.0 to 13.6)	-13.7 (-31.7 to 10.7)
Thalassemia trait	609.5 (562.9 to 656.1)	739.1 (697.2 to 784.5)	20.8 (16.6 to 26.5)	20.8 (-4.9 to 3.2)	8.7 (5.8 to 12.7)	11.7 (7.7 to 17.1)	35.8 (17.4 to 55.7)	18.6 (8.8 to 35.0)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.9 (-43.0 to 26.1)	10.9 (-45.7 to 19.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.3 (-4.8 to 59.0)	14.7 (-46.1 to 47.7)
Sickle cell trait	27.3 (15.3 to 37.7)	29.9 (15.5 to 38.2)	21.4 (-40.2 to 54.1)	21.4 (-51.2 to 25.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-15.5 (-59.6 to 34.5)	27.5 (-64.4 to 12.0)
G6PD deficiency	1,970.1 (1,568.2 to 2,371.0)	2,434.6 (1,975.1 to 2,891.0)	23.3 (-6.9 to 63.2)	23.3 (-24.2 to 33.1)	0.5 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-28.6 (-61.5 to 3.5)	-40.4 (-68.3 to -13.8)
G6PD trait	3,867.7 (3,676.4 to 3,991.5)	4,875.1 (4,578.8 to 5,077.0)	25.7 (17.3 to 34.2)	25.7 (-4.5 to 9.3)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	8.8 (-71.2 to 4,321.8)	-3.5 (-76.7 to 2,874.7)
Other hemoglobinopathies and hemolytic anemias	213.7 (184.1 to 237.4)	169.1 (149.7 to 187.5)	-24.0 (-31.7 to -6.7)	-24.0 (-46.0 to -2.9)	5.8 (3.5 to 8.5)	4.2 (2.6 to 6.3)	-26.5 (-45.4 to 5.7)	-39.0 (-54.2 to -14.4)
Endocrine, metabolic, blood, and immune disorders	250.3 (217.1 to 275.7)	248.6 (233.7 to 263.9)	-1.2 (-11.2 to 13.5)	-1.2 (-28.6 to -9.9)	8.3 (5.5 to 11.9)	7.9 (4.6 to 11.3)	5.9 (-17.6 to 15.3)	-21.8 (-31.7 to -4.4)
Musculoskeletal disorders	-	-	-	-	203.3 (143.7 to 272.1)	307.6 (219.5 to 409.8)	51.7 (37.9 to 64.9)	-2.2 (-10.4 to 5.9)
Rheumatoid arthritis	9.8 (8.8 to 10.8)	30.4 (28.4 to 32.4)	209.2 (174.5 to 248.4)	209.2 (74.2 to 121.3)	2.4 (1.6 to 3.2)	7.2 (5.0 to 9.5)	205.7 (164.0 to 259.6)	95.0 (69.8 to 128.2)
Osteoarthritis	242.4 (228.4 to 256.4)	477.4 (450.3 to 506.7)	95.9 (80.4 to 115.2)	95.9 (-2.7 to 15.3)	5.5 (15.0 to 20.2)	29.5 (20.4 to 40.1)	96.1 (80.2 to 115.4)	5.7 (-2.7 to 15.6)
Low back and neck pain	-	-	-	-	155.4 (106.6 to 214.1)	225.1 (156.2 to 303.6)	46.6 (28.6 to 62.0)	-2.1 (-13.2 to 8.4)
Low back pain	953.7 (902.2 to 1,012.4)	1,418.6 (1,340.0 to 1,493.6)	48.4 (36.6 to 60.3)	48.4 (-9.3 to 5.3)	107.5 (73.0 to 149.8)	158.7 (106.2 to 217.4)	48.0 (35.6 to 59.9)	-1.5 (-9.4 to 5.9)
Neck pain	481.6 (374.4 to 584.1)	672.5 (523.0 to 828.2)	39.6 (-1.2 to 91.0)	39.6 (-32.1 to 29.3)	47.9 (30.5 to 70.9)	66.4 (42.6 to 97.7)	39.1 (-1.6 to 90.9)	-4.2 (-31.7 to 30.0)
Gout	10.2 (8.9 to 11.5)	17.8 (15.0 to 20.6)	74.1 (40.6 to 111.9)	74.1 (-20.2 to 18.1)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.8)	74.0 (29.3 to 132.7)	-1.0 (-26.0 to 29.9)
Other musculoskeletal disorders	327.6 (248.5 to 400.5)	492.2 (366.0 to 608.5)	49.3 (36.2 to 63.3)	49.3 (-22.5 to -6.3)	30.2 (19.9 to 43.4)	45.3 (28.8 to 66.0)	46.1 (35.8 to 64.5)	-1.3 (-22.4 to 5.7)
Other non-communicable diseases	-	-	-	-	288.8 (196.4 to 412.2)	383.1 (257.2 to 548.1)	32.7 (8.8 to 37.0)	-6.0 (-8.8 to -3.3)
Congenital anomalies	-	-	-	-	20.5 (14.6 to 27.2)	30.1 (22.2 to 39.6)	46.6 (25.5 to 78.1)	24.6 (6.5 to 50.6)
Neural tube defects	3.3 (2.8 to 3.8)	5.0 (4.4 to 5.7)	48.8 (24.1 to 91.7)	48.8 (12.7 to 74.5)	1.1 (0.7 to 1.5)	1.7 (1.1 to 2.3)	55.2 (15.7 to 129.4)	42.3 (6.6 to 110.0)
Congenital heart anomalies	49.8 (40.5 to 63.8)	113.4 (96.4 to 136.4)	129.0 (65.7 to 196.5)	129.0 (45.4 to 158.7)	1.7 (0.8 to 3.1)	4.3 (1.8 to 7.7)	143.9 (83.0 to 217.4)	114.1 (60.0 to 176.4)
Orofacial clefts	10.4 (8.1 to 14.2)	25.1 (21.4 to 30.8)	142.6 (69.7 to 235.0)	142.6 (54.1 to 207.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	44.8 (50.1 to 120.7)	32.6 (-12.7 to 99.3)
Down syndrome	15.8 (13.1 to 19.2)	26.9 (22.2 to 32.8)	69.1 (28.7 to 126.1)	69.1 (3.8 to 81.4)	2.0 (1.4 to 2.7)	3.9 (2.7 to 5.2)	91.7 (46.1 to 165.3)	44.6 (10.8 to 99.9)
Turner syndrome	0.5 (0.4 to 0.7)	0.7 (0.6 to 0.9)	32.0 (8.8 to 84.1)	32.0 (-21.2 to 59.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.9 (-13.6 to 96.1)	13.0 (-25.0 to 69.1)
Klinefelter syndrome	0.6 (0.4 to 0.7)	0.7 (0.5 to 0.9)	23.4 (-10.9 to 77.5)	23.4 (-26.5 to 46.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.4 (-45.5 to 105.4)	0.7 (-37.5 to 69.6)
Chromosomal unbalanced rearrangements	21.6 (17.6 to 26.0)	37.2 (30.7 to 46.5)	70.3 (30.8 to 132.7)	70.3 (5.2 to 86.3)	2.7 (1.9 to 3.7)	5.3 (3.8 to 7.1)	94.1 (45.6 to 165.7)	47.3 (10.0 to 100.0)
Other congenital anomalies	98.5 (76.5 to 119.8)	96.2 (76.8 to 115.0)	-2.7 (-14.4 to 11.5)	-2.7 (-28.4 to -7.0)	12.8 (8.2 to 18.2)	14.7 (9.8 to 20.9)	14.2 (-6.7 to 49.3)	0.6 (-17.6 to 31.9)
Skin and subcutaneous diseases	-	-	-	-	97.5 (61.4 to 151.3)	121.8 (78.0 to 187.0)	25.0 (18.2 to 32.3)	2.2 (-2.8 to 7.7)
Dermatitis	848.7 (718.3 to 1,001.5)	1,071.8 (913.8 to 1,246.4)	25.9 (22.3 to 30.1)	25.9 (0.0 to 0.3)	0.1 (16.1 to 36.3)	30.7 (19.6 to 44.5)	22.7 (16.8 to 28.4)	0.5 (-2.4 to 3.3)
Psoriasis	129.6 (106.1 to 159.5)	178.8 (145.8 to 222.7)	37.6 (31.5 to 44.1)	37.6 (-0.2 to 0.2)	0.7 (7.0 to 15.4)	1.6 (9.7 to 21.2)	37.1 (26.5 to 46.9)	0.1 (-5.2 to 5.8)
Cellulitis	4.0 (3.2 to 5.0)	5.6 (4.4 to 6.9)	41.7 (17.2 to 63.6)	41.7 (-14.7 to 17.0)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	40.3 (5.3 to 81.1)	1.7 (-21.5 to 28.7)
Pyoderma	24.3 (18.2 to 31.2)	13.3 (10.5 to 17.3)	-45.4 (-54.5 to -34.4)	-45.4 (-59.1 to -43.1)	0.1 (0.1 to 0.3)	0.1 (0.0 to 0.2)	-45.4 (-55.4 to -33.0)	-51.8 (-59.9 to -42.1)
Scabies	198.8 (180.3 to 219.1)	177.3 (162.2 to 194.3)	-11.1 (-22.2 to 2.1)	-11.1 (-35.8 to -16.3)	5.1 (2.9 to 8.3)	4.6 (2.5 to 7.3)	-11.0 (-21.8 to 19.6)	-26.6 (-35.2 to -16.2)
Fungal skin diseases	2,283.1 (1,970.7 to 2,570.7)	2,893.3 (2,514.8 to 3,199.8)	244.4 (21.1 to 285.1)	244.4 (-0.6 to 0.3)	13.0 (5.2 to 27.2)	16.3 (6.5 to 33.9)	34.2 (20.7 to 28.6)	-0.3 (-0.9 to 0.4)
Viral skin diseases	422.3 (340.9 to 510.3)	451.4 (357.9 to 548.5)	6.5 (2.7 to 10.5)	6.5 (-1.8 to 1.8)	0.0 (8.3 to 19.9)	13.1 (8.6 to 21.4)	6.5 (1.4 to 11.3)	0.3 (-2.9 to 3.5)
Acne vulgaris	1,218.1 (1,027.2 to 1,401.6)	1,352.1 (1,123.9 to 1,589.4)	10.1 (-12.1 to 42.9)	10.1 (-12.4 to 42.4)	9.6 (6.0 to 24.9)	13.2 (6.8 to 28.3)	10.4 (-11.9 to 43.2)	9.8 (-12.2 to 43.0)
Alopecia areata	22.7 (20.1 to 25.4)	32.6 (29.0 to 36.8)	43.1 (21.3 to 70.7)	43.1 (-12.4 to 21.8)	0.8 (0.5 to 1.1)	1.1 (0.7 to 1.6)	42.1 (18.3 to 74.0)	2.5 (-13.4 to 23.7)
Pruritus	5.7 (3.2 to 4.2)	5.4 (4.6 to 6.2)	44.8 (20.2 to 76.3)	44.8 (-18.2 to 18.4)	2.2 (0.0 to 0.1)	0.1 (0.0 to 0.1)	49.9 (13.9 to 85.4)	-2.6 (-21.5 to 23.8)
Urticaria	141.7 (107.2 to 178.3)	237.4 (172.4 to 309.2)	65.4 (14.8 to 148.0)	65.4 (-14.8 to 76.5)	21.3 (5.0 to 13.2)	8.5 (8.2 to 21.6)	14.1 (13.0 to 148.8)	21.5 (-14.9 to 77.8)
Decubitus ulcer	2.8 (2.3 to 3.3)	4.4 (3.7 to 5.2)	61.1 (26.4 to 97.3)	61.1 (-24.9 to 25.4)	-2.3 (0.3 to 0.6)	0.7 (0.4 to 0.9)	57.5 (22.0 to 98.7)	-2.8 (-27.6 to 28.0)
Other skin and subcutaneous diseases	1,210.9 (822.6 to 1,757.9)	1,848.4 (1,194.1 to 2,488.5)	51.6 (35.8 to 66.6)	51.6 (-2.1 to 3.4)	7.2 (3.2 to 14.9)	10.9 (4.8 to 22.6)	51.3 (35.1 to 66.7)	0.6 (-2.0 to 3.6)
Sense organ diseases	-	-	-	-	147.6 (101.8 to 205.1)	199.8 (134.2 to 279.7)	35.2 (27.9 to 42.1)	-12.6 (-16.0 to -9.6)
Glaucoma	14.1 (9.3 to 19.4)	18.0 (13.2 to 24.2)	30.9 (-11.4 to 77.4)	30.9 (-47.1 to 3.5)	-2.2 (0.5 to 1.3)	1.2 (0.8 to 1.9)	43.8 (28.0 to 90.9)	-17.1 (-40.6 to 8.6)
Cataract	81.7 (48.7 to 115.0)	121.5 (78.4 to 161.3)	45.9 (25.2 to 85.4)	45.9 (-34.4 to -6.4)	4.4 (2.5 to 6.8)	6.7 (3.9 to 9.9)	49.8 (31.9 to 82.1)	-22.3 (-31.0 to -7.7)
Macular degeneration	7.2 (4.8 to 10.9)	16.6 (11.0 to 24.6)	134.8 (52.8 to 250.6)	134.8 (-21.7 to 78.3)	0.4 (0.2 to 0.6)	0.9 (0.5 to 1.4)	118.8 (49.6 to 210.2)	10.4 (-23.1 to 55.9)
Uncorrected refractive error	1,368.8 (1,244.2 to 1,485.9)	2,043.9 (1,875.5 to 2,213.9)	48.6 (33.2 to 66.1)	48.6 (-17.6 to 11.1)	-8.7 (11.5 to 32.7)	20.1 (15.9 to 46.4)	39.7 (28.9 to 53.4)	-12.6 (-18.9 to 4.9)
Age-related and other hearing loss	2,824.0 (2,677.5 to 2,973.5)	4,240.2 (4,058.3 to 4,473.5)	49.8 (43.9 to 54.8)	49.8 (-12.7 to -7.2)	9.8 (7.4 to 14.6)	10.7 (9.8 to 20.8)	14.4 (26.1 to 43.6)	-12.5 (-16.8 to -8.6)
Other vision loss	85.8 (68.2 to 108.3)	89.2 (72.0 to 108.6)	4.3 (-12.4 to 20.3)	4.3 (-42.9 to -19.4)	2.7 (3.1 to 6.9)	5.2 (3.5 to 7.6)	10.3 (-1.9 to 24.5)	-29.9 (-38.8 to -21.2)
Other sense organ diseases	389.4 (371.0 to 408.2)	497.9 (476.5 to 519.6)	27.3 (19.3 to 36.5)	27.3 (-5.2 to 7.9)	0.8 (6.5 to 15.6)	10.4 (8.1 to 19.9)	26.9 (17.7 to 37.0)	1.2 (-5.9 to 9.0)
Oral disorders	-	-	-	-	23.2 (13.8 to 36.4)	31.4 (18.7 to 49.6)	35.2 (27.0 to 43.8)	-9.1 (-15.1 to -3.2)
Deciduous caries	1,718.2 (1,662.0 to 1,768.3)	1,695.8 (1,630.5 to 1,758.5)	-1.7 (-5.9 to 2.3)	-1.7				

Appendix Table G.4 - Sri Lanka prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	204.3 (185.6 to 223.0)	271.7 (246.4 to 298.2)	32.8 (16.8 to 51.3)	-28.7 (-37.3 to -18.8)	5.7 (3.7 to 8.0)	7.5 (5.1 to 10.7)	32.8 (15.6 to 51.5)	-28.5 (-37.6 to -18.8)
Other oral disorders	290.5 (274.4 to 306.7)	388.5 (368.1 to 408.8)	33.1 (23.1 to 44.1)	0.5 (-7.1 to 8.7)	8.6 (6.9 to 10.9.4)	11.4 (7.1 to 16.7)	33.1 (22.1 to 45.1)	0.9 (-7.4 to 9.5)
Injuries	-	-	-	-	81.6 (60.9 to 109.4)	85.1 (61.3 to 115.2)	5.4 (-16.1 to 20.2)	-27.6 (-40.5 to -18.3)
Transport injuries	-	-	-	-	19.1 (14.3 to 25.0)	27.6 (19.3 to 37.4)	43.5 (28.0 to 61.1)	-8.1 (-17.6 to 2.9)
Road injuries	-	-	-	-	8.4 (6.4 to 11.0)	7.9 (4.6 to 28.3)	144.0 (114.2 to 178.5)	30.8 (34.0 to 70.3)
Pedestrian road injuries	-	-	-	-	1.3 (1.0 to 1.8)	3.1 (2.2 to 4.2)	132.1 (99.4 to 166.4)	42.7 (23.8 to 62.0)
Cyclist road injuries	-	-	-	-	0.7 (0.5 to 0.9)	1.6 (1.2 to 2.2)	139.4 (111.5 to 172.6)	40.4 (22.7 to 60.2)
Motorcyclist road injuries	-	-	-	-	3.3 (2.5 to 4.3)	8.0 (5.6 to 11.0)	143.1 (110.8 to 182.4)	49.9 (31.4 to 72.6)
Motor vehicle road injuries	-	-	-	-	3.1 (2.3 to 4.0)	7.9 (5.6 to 10.6)	153.1 (120.3 to 196.0)	56.6 (40.0 to 84.0)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	101.5 (76.0 to 132.9)	18.9 (5.0 to 35.8)
Other transport injuries	-	-	-	-	10.7 (7.9 to 14.1)	6.8 (4.8 to 9.2)	-36.2 (-43.5 to -28.4)	-58.9 (-63.5 to -53.8)
Unintentional injuries	-	-	-	-	41.3 (31.3 to 53.6)	47.1 (34.2 to 63.6)	13.5 (4.5 to 22.5)	-22.9 (-28.6 to -17.1)
Falls	-	-	-	-	9.7 (7.3 to 12.6)	14.3 (10.0 to 19.4)	47.2 (30.0 to 67.1)	-11.5 (-21.9 to 0.7)
Drowning	-	-	-	-	0.2 (0.1 to 0.2)	0.5 (0.4 to 0.8)	184.4 (143.4 to 239.7)	92.3 (67.0 to 125.9)
Fire, heat, and hot substances	-	-	-	-	2.6 (2.0 to 3.3)	1.9 (1.3 to 2.6)	-29.0 (-38.3 to -17.0)	-50.7 (-56.9 to -42.9)
Poisonings	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-41.0 (-50.4 to -30.4)	-56.8 (-63.4 to -49.7)
Exposure to mechanical forces	-	-	-	-	22.2 (16.6 to 29.2)	19.4 (13.9 to 26.4)	-12.3 (-19.3 to -5.8)	-37.3 (-41.8 to -33.1)
Unintentional firearm injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	12.1 (0.2 to 25.5)	-17.5 (-25.7 to -8.3)
Unintentional suffocation	-	-	-	-	20.7 (15.6 to 27.3)	18.2 (13.0 to 24.6)	-12.3 (-19.1 to -5.8)	-37.3 (-41.7 to -33.2)
Adverse effects of medical treatment	-	-	-	-	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.7)	52.9 (44.4 to 63.1)	2.2 (-3.7 to 9.3)
Animal contact	-	-	-	-	1.0 (0.8 to 1.4)	1.0 (0.7 to 1.3)	-7.8 (-16.9 to 3.3)	-34.0 (-40.0 to -26.7)
Venomous animal contact	-	-	-	-	0.5 (0.4 to 0.7)	0.5 (0.3 to 0.6)	-6.9 (-17.4 to 5.4)	-32.9 (-40.0 to -24.3)
Non-venomous animal contact	-	-	-	-	0.5 (0.4 to 0.7)	0.5 (0.3 to 0.7)	-8.6 (-19.2 to 3.4)	-35.1 (-41.5 to -27.1)
Foreign body	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	16.1 (4.8 to 28.5)	-20.6 (-27.8 to -13.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-16.8 (-31.9 to 1.2)	-39.4 (-49.6 to -27.5)
Foreign body in eyes	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	23.3 (14.6 to 31.8)	-10.6 (-17.7 to -4.1)
Foreign body in other body part	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	32.2 (18.2 to 47.9)	-15.9 (-24.0 to -7.0)
Other unintentional injuries	-	-	-	-	4.8 (3.6 to 6.3)	8.9 (6.4 to 12.0)	85.6 (64.6 to 105.2)	22.4 (9.8 to 34.8)
Self-harm and interpersonal violence	-	-	-	-	6.5 (4.9 to 8.3)	2.8 (2.0 to 3.9)	-56.8 (-62.0 to -50.1)	-70.9 (-74.3 to -66.8)
Self-harm	-	-	-	-	0.9 (0.7 to 1.2)	0.5 (0.4 to 0.7)	-44.9 (-51.1 to -37.7)	-64.9 (-68.6 to -60.5)
Interpersonal violence	-	-	-	-	5.6 (4.3 to 7.1)	2.3 (1.7 to 3.2)	-58.7 (-64.2 to -52.1)	-71.9 (-75.5 to -67.8)
Assault by firearm	-	-	-	-	0.6 (0.4 to 0.8)	0.3 (0.2 to 0.4)	-52.6 (-57.3 to -47.7)	-67.5 (-70.5 to -64.5)
Assault by sharp object	-	-	-	-	1.2 (0.9 to 1.5)	0.6 (0.4 to 0.8)	-53.1 (-59.6 to -44.9)	-88.1 (-72.3 to -103.0)
Assault by other means	-	-	-	-	3.8 (2.9 to 4.9)	1.5 (1.1 to 2.0)	-61.3 (-66.8 to -54.3)	-73.7 (-77.3 to -69.3)
Forces of nature, war, and legal intervention	-	-	-	-	14.6 (6.0 to 33.6)	7.7 (3.6 to 16.7)	-46.6 (-73.7 to 12.3)	-57.5 (-79.3 to -12.1)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.1)	0.8 (0.5 to 1.6)	1,933.4 (1,071.2 to 4,074.8)	2,037.6 (1,140.3 to 4,232.4)
Collective violence and legal intervention	-	-	-	-	14.5 (5.9 to 33.5)	6.8 (2.9 to 15.3)	-52.2 (-77.3 to 1.6)	-62.2 (-81.9 to -21.4)

Appendix Table G.4 - Sudan prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
All causes	-	-	-	-	1,976.0 (1,436.2 to 2,594.2)	3,742.5 (2,721.6 to 4,882.9)	89.7 (82.7 to 96.0)	89.7 (-6.7 to -1.2)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	544.2 (371.8 to 781.3)	891.6 (602.9 to 1,256.5)	63.8 (50.7 to 79.7)	-12.9 (-18.1 to -6.6)
HIV/AIDS and tuberculosis	-	-	-	-	4.4 (2.7 to 6.6)	17.9 (11.6 to 25.7)	309.8 (168.5 to 510.3)	100.3 (29.9 to 204.9)
Tuberculosis	11.3 (10.8 to 11.7)	22.8 (22.1 to 23.5)	102.5 (95.7 to 110.4)	-2.5 (-5.8 to 0.9)	3.4 (2.3 to 4.6)	7.0 (4.7 to 9.5)	103.8 (81.8 to 128.8)	-1.7 (-10.7 to 7.5)
HIV/AIDS	-	-	-	-	1.0 (0.1 to 2.6)	10.3 (6.3 to 17.8)	1,183.4 (279.8 to 19,965.3)	529.9 (89.4 to 10,164.8)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.1)	0.4 (0.2 to 0.6)	1,063.9 (261.1 to 20,178.2)	472.8 (74.4 to 10,662.0)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.3)	1,063.9 (261.0 to 20,659.8)	472.8 (73.0 to 10,783.6)
HIV/AIDS resulting in other diseases	8.5 (0.6 to 21.1)	68.9 (54.4 to 91.0)	810.8 (191.4 to 12,854.5)	355.4 (43.8 to 6,479.4)	1.0 (0.0 to 2.6)	10.8 (6.2 to 17.6)	1,191.3 (276.2 to 28,365.7)	532.4 (87.9 to 15,499.7)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	64.8 (44.8 to 88.6)	109.4 (74.8 to 151.1)	68.9 (45.1 to 95.0)	-6.2 (-18.1 to 6.2)
Diarrheal diseases	256.6 (224.2 to 288.0)	497.4 (420.0 to 571.7)	94.4 (57.2 to 133.7)	13.1 (-7.3 to 32.9)	41.5 (27.1 to 59.6)	80.8 (53.5 to 115.4)	94.8 (57.2 to 134.3)	13.3 (-6.9 to 33.8)
Intestinal infectious diseases	-	-	-	-	0.7 (0.4 to 0.9)	0.8 (0.5 to 1.1)	17.4 (10.0 to 52.9)	35.3 (-48.8 to -17.9)
Typhoid fever	3.3 (2.9 to 3.8)	4.3 (3.6 to 5.0)	29.4 (4.1 to 59.8)	-28.7 (-43.1 to -12.1)	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.8)	30.6 (2.6 to 72.6)	-27.5 (-45.3 to -8.1)
Paratyphoid fever	1.7 (1.4 to 2.0)	2.3 (2.0 to 2.7)	35.5 (4.3 to 75.7)	-26.4 (-43.9 to -4.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	35.8 (-1.3 to 86.5)	-26.8 (-46.0 to -2.0)
Other intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-44.4 (-65.8 to -5.9)	-69.3 (-81.6 to -49.6)
Lower respiratory infections	23.4 (14.4 to 37.7)	19.3 (13.1 to 29.7)	-16.6 (-63.5 to 53.9)	-37.0 (-71.6 to 12.4)	2.4 (1.2 to 4.5)	2.2 (1.1 to 3.4)	-16.2 (-64.7 to 55.2)	-38.9 (-72.2 to 9.9)
Upper respiratory infections	426.3 (381.4 to 478.4)	786.8 (685.1 to 908.4)	84.7 (50.7 to 125.4)	-1.8 (-18.0 to 17.9)	5.0 (2.8 to 8.4)	9.3 (5.2 to 15.9)	85.2 (50.6 to 127.7)	-1.2 (-18.3 to 18.9)
Otitis media	258.9 (240.8 to 280.1)	434.0 (399.7 to 482.2)	66.6 (49.1 to 91.0)	-9.3 (-19.5 to 7.5)	4.7 (2.9 to 7.6)	7.9 (4.6 to 12.8)	66.3 (47.0 to 87.8)	-9.9 (-20.4 to 4.2)
Meningitis	-	-	-	-	7.8 (5.0 to 11.5)	6.4 (4.2 to 9.3)	-17.2 (-32.5 to -0.4)	-54.5 (-62.5 to -45.4)
Pneumococcal meningitis	28.5 (17.0 to 42.4)	23.3 (13.8 to 35.4)	-18.8 (-37.2 to 7.1)	-55.3 (-65.6 to -41.8)	2.5 (1.7 to 3.5)	2.2 (1.4 to 3.2)	-13.5 (-31.9 to 17.2)	-52.0 (-61.5 to -36.9)
H influenzae type B meningitis	17.5 (7.0 to 31.0)	12.7 (4.7 to 24.1)	-28.0 (-50.4 to 3.3)	-61.8 (-73.7 to -45.6)	1.9 (1.2 to 2.8)	1.5 (0.9 to 2.4)	-19.6 (-47.0 to 33.7)	-56.4 (-70.7 to -28.5)
Meningococcal meningitis	13.6 (4.0 to 26.5)	9.4 (2.8 to 19.7)	-32.0 (-55.7 to 4.7)	-63.2 (-76.0 to -42.0)	1.8 (0.9 to 3.3)	1.3 (0.6 to 2.3)	-31.9 (-56.2 to 19.4)	-63.1 (-75.5 to -38.9)
Other meningitis	13.2 (6.8 to 22.2)	11.6 (6.0 to 19.5)	-11.4 (-32.0 to 15.4)	-51.5 (-62.1 to -35.5)	1.6 (1.0 to 2.5)	1.4 (0.9 to 2.2)	-9.6 (-33.6 to 18.6)	-49.3 (-61.9 to -33.2)
Encephalitis	6.4 (2.8 to 13.1)	8.3 (3.6 to 18.2)	29.0 (10.2 to 46.9)	-31.2 (-42.3 to -23.1)	0.8 (0.5 to 1.1)	1.1 (0.7 to 1.5)	35.6 (17.1 to 57.9)	-26.7 (-35.5 to -15.0)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Whooping cough	19.3 (15.0 to 24.6)	9.6 (7.4 to 12.2)	-50.3 (-54.0 to -46.3)	-69.6 (-71.9 to -67.2)	1.0 (0.6 to 1.5)	0.5 (0.3 to 0.8)	-50.3 (-57.8 to -42.0)	-69.6 (-74.2 to -64.5)
Tetanus	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.2)	-48.6 (-79.9 to -6.3)	-71.9 (-89.2 to -46.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.7 (-53.5 to 49.3)	-52.1 (-72.7 to -14.4)
Measles	6.5 (4.9 to 8.3)	2.1 (1.6 to 2.7)	-68.2 (-72.8 to -62.9)	-81.0 (-83.7 to -77.8)	0.6 (0.3 to 0.9)	0.2 (0.1 to 0.3)	-68.4 (-79.4 to -55.1)	-41.1 (-87.5 to -73.3)
Varicella and herpes zoster	16.9 (15.8 to 18.3)	31.1 (28.8 to 33.8)	84.4 (63.0 to 104.0)	5.9 (-15.0 to 30.1)	0.3 (0.2 to 0.4)	0.6 (0.3 to 1.0)	116.0 (50.6 to 209.2)	10.6 (-26.8 to 66.1)
Neglected tropical diseases and malaria	-	-	-	-	155.5 (94.3 to 251.8)	229.8 (138.4 to 377.4)	47.3 (35.6 to 64.8)	-20.2 (-28.2 to -10.3)
Malaria	4,131.6 (3,477.9 to 5,032.4)	3,944.9 (3,073.7 to 4,913.7)	-4.5 (-19.4 to 12.5)	-51.2 (-59.2 to -42.8)	36.8 (24.3 to 53.4)	34.0 (22.5 to 49.5)	-7.5 (-20.8 to 3.2)	-51.8 (-58.3 to -46.4)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Leishmaniasis	-	-	-	-	0.7 (0.4 to 1.1)	6.8 (3.2 to 13.2)	888.3 (520.1 to 1,413.4)	728.8 (417.0 to 1,148.1)
Visceral leishmaniasis	6.4 (4.0 to 9.2)	11.3 (7.7 to 15.9)	76.2 (37.7 to 143.5)	-1.8 (-21.8 to 30.6)	0.4 (0.2 to 0.8)	0.8 (0.5 to 1.3)	77.2 (27.1 to 162.6)	-1.0 (-24.8 to 39.4)
Cutaneous and mucocutaneous leishmaniasis	20.9 (14.3 to 29.6)	562.9 (370.1 to 827.8)	2,636.1 (1,830.5 to 3,269.1)	2,008.6 (1,393.5 to 2,466.0)	0.2 (0.1 to 0.4)	6.0 (2.6 to 12.3)	2,605.6 (1,834.1 to 3,301.8)	1,978.8 (1,376.6 to 2,469.0)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	8,267.2 (6,320.4 to 10,475.3)	11,387.8 (8,468.5 to 15,154.5)	35.8 (25.2 to 62.9)	-31.2 (-36.6 to -17.4)	76.9 (37.0 to 146.7)	106.9 (50.4 to 206.5)	37.6 (20.3 to 62.8)	-30.1 (-38.2 to -17.6)
Cysticercosis	4.3 (2.1 to 7.2)	4.4 (1.7 to 9.1)	1.8 (-61.6 to 118.4)	-46.6 (-77.2 to 5.7)	1.2 (0.5 to 2.1)	1.2 (0.4 to 2.6)	1.3 (-60.8 to 134.8)	45.9 (-76.9 to 12.4)
Cystic echinococcosis	1.5 (1.2 to 1.9)	1.4 (1.1 to 1.9)	-6.5 (-17.8 to 7.9)	-53.4 (-59.2 to -43.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-5.1 (-28.6 to 22.9)	-52.2 (-64.9 to -36.2)
Lymphatic filariasis	388.5 (319.7 to 460.8)	1,223.3 (995.1 to 1,473.5)	215.0 (158.2 to 278.6)	57.3 (31.7 to 85.0)	12.1 (5.7 to 21.1)	39.0 (19.1 to 68.1)	220.8 (178.3 to 287.6)	60.5 (37.3 to 94.5)
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	58.8 (32.5 to 91.3)	32.3 (17.2 to 52.0)	-45.3 (-58.1 to -24.7)	-74.1 (-80.3 to -64.1)	4.9 (2.6 to 8.1)	2.7 (1.4 to 4.7)	-44.5 (-57.0 to -27.3)	-73.7 (-80.2 to -64.1)
Dengue	1.2 (0.4 to 2.9)	10.8 (3.7 to 26.0)	821.9 (810.7 to 834.8)	385.6 (379.7 to 392.4)	0.2 (0.1 to 0.5)	1.8 (0.5 to 4.6)	787.6 (600.1 to 1,000.9)	357.1 (285.2 to 445.7)
Yellow fever	0.5 (0.2 to 1.3)	0.3 (0.1 to 0.7)	-50.9 (-74.2 to -1.0)	-73.7 (-84.7 to -52.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-50.9 (-74.2 to 1.2)	-73.7 (-84.8 to -52.4)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Intestinal nematode infections	-	-	-	-	6.9 (4.2 to 10.5)	12.9 (7.6 to 20.0)	89.0 (40.1 to 141.2)	-2.0 (-25.9 to 22.6)
Ascariasis	277.3 (180.1 to 403.7)	522.3 (344.5 to 799.0)	85.9 (3.7 to 242.1)	-1.4 (-50.8 to 101.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.0 (34.4 to 156.2)	0.6 (-30.8 to 47.8)
Trichuriasis	539.9 (341.1 to 813.8)	1,039.6 (674.6 to 1,612.1)	90.4 (6.9 to 254.6)	1.4 (-49.6 to 109.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.7 (7.6 to 218.1)	0.1 (-47.1 to 79.9)
Hookworm disease	1,847.3 (1,306.8 to 2,567.1)	3,552.6 (2,438.8 to 5,066.7)	91.5 (15.7 to 220.3)	6.9 (-45.5 to 79.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.0 (40.0 to 141.5)	-2.1 (-26.0 to 22.6)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	401.8 (313.5 to 488.4)	640.3 (600.2 to 687.6)	59.9 (30.8 to 105.4)	-13.9 (-27.9 to 6.6)	15.8 (9.8 to 23.7)	24.4 (16.0 to 36.3)	52.9 (31.5 to 110.7)	-17.9 (-28.8 to 9.3)
Maternal disorders	-	-	-	-	10.3 (7.2 to 14.1)	15.5 (10.5 to 21.1)	50.1 (33.0 to 72.1)	-26.7 (-34.9 to -17.0)
Maternal hemorrhage	5.5 (4.6 to 6.5)	8.6 (5.4 to 11.5)	57.1 (-5.5 to 125.8)	-25.9 (-53.6 to 3.6)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	69.0 (-13.2 to 119.4)	-29.0 (-58.2 to 0.7)
Maternal sepsis and other maternal infections	17.7 (11.8 to 24.9)	20.8 (14.2 to 29.4)	17.6 (0.1 to 34.5)	-46.0 (-54.3 to -38.1)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	13.3 (-32.8 to 89.2)	46.5 (-66.5 to -14.5)
Maternal hypertensive disorders	16.8 (6.5 to 29.5)	24.0 (8.7 to 42.5)	42.6 (29.8 to 54.8)	-31.8 (-40.6 to -26.0)	0.8 (0.3 to 1.7)	1.2 (0.4 to 2.5)	41.7 (23.1 to 61.1)	-32.2 (-42.7 to -22.4)
Obstructed labor	23.3 (21.2 to 25.5)	35.1 (31.3 to 39.0)	50.6 (39.8 to 62.7)	-26.5 (-31.4 to -21.1)	7.6 (5.1 to 10.5)	11.5 (7.7 to 15.8)	51.1 (35.0 to 68.0)	-26.1 (-33.5 to -18.6)
Complications of abortion	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	59.4 (-23.7 to 179.4)	-29.1 (-64.1 to 19.7)	0.1 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.1 (-23.8 to 180.1)	-1.9 (-64.1 to 19.8)
Other maternal disorders	-	-	-	-	1.4 (0.7 to 2.3)	2.2 (1.3 to 3.4)	59.1 (-11.5 to 196.3)	-22.3 (-56.9 to 43.4)
Neonatal disorders	-	-	-	-	12.2 (7.3 to 18.2)	66.0 (40.5 to 100.5)	440.7 (235.3 to 745.4)	215.3 (96.4 to 392.2)
Preterm birth complications	42.8 (27.9 to 64.3)	194.9 (140.1 to 263.5)	358.7 (263.7 to 506.7)	136.2 (88.3 to 212.8)	3.6 (2.3 to 5.1)	22.6 (14.7 to 33.2)	524.6 (338.3 to 897.5)	236.7 (139.1 to 428.3)
Neonatal encephalopathy due to birth asphyxia and trauma	25.4 (9.4 to 65.6)	76.3 (40.0 to 140.8)	230.9 (48.8 to 617.4)	80.1 (-22.8 to 342.3)	3.8 (1.7 to 7.1)	16.8 (8.7 to 28.0)	361.7 (97.2 to 943.9)	190.6 (21.5 to 543.8)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	137.0 (239.7 to 346.5)	258.0 (125.2 to 196.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	265.4 (187.1 to 401.1)	142.3 (90.4 to 232.3)
Hemolytic disease and other neonatal jaundice	10.3 (4.0 to 22.0)	66.4 (28.3 to 135.0)	556.2 (78.4 to 2,245.3)	291.0 (3.6 to 1,323.1)	3.5 (1.4 to 7.1)	18.2 (7.9 to 34.5)	418.2 (72.4 to 1,601.6)	202.4 (-0.3 to 875.8)
Other neonatal disorders	-	-	-	-	1.3 (0.4 to 4.0)	8.5 (2.6 to 21.6)	573.5 (154.8 to 1,942.0)	293.0 (51.5 to 1,071.8)
Nutritional deficiencies	-	-	-	-	280.5 (191.1 to 402.6)	425.6 (275.3 to 624.9)	51.2 (30.9 to 78.0)	-20.5 (-27.5 to -10.2)
Protein-energy malnutrition	254.5 (143.4 to 409.0)	387.5 (152.6 to 871.5)	43.6 (-49.5 to 310.0)	-12.8 (-69.3 to 149.4)	31.6 (14.8 to 57.2)	48.4 (16.5 to 114.0)	44.1 (-49.4 to 320.2)	-22.4 (-69.3 to 156.0)
Iodine deficiency	249.9 (208.3 to 292.2)	307.3 (258.3 to 356.7)	22.9 (-1.4 to 55.1)	-38.3 (-51.3 to -20.7)	4.5 (2.7 to 7.1)	5.5 (3.4 to 8.5)	22.7 (-2.2 to 55.4)	-38.0 (-51.6 to -20.2)
Vitamin A deficiency	27.1 (18.4 to 35.4)	24.1 (16.3 to 32.1)	-10.6 (-27.1 to 5.2)	-51.6 (-60.1 to -43.4)	1.7 (1.0 to 2.6)	1.5 (0.9 to 2.4)	-13.9 (-33.1 to 6.0)	-53.4 (-63.4 to -43.4)

Appendix Table G.4 - Sudan prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	6,530.8 (6,424.5 to 6,671.5)	10,702.2 (10,438.9 to 10,957.7)	64.0 (59.8 to 68.2)	-5.1 (-17.4 to -12.6)	233.7 (156.7 to 334.6)	357.4 (238.4 to 515.5)	53.8 (47.9 to 58.8)	23.7 (-23.2 to -17.1)
Other nutritional deficiencies	-	-	-	-	8.8 (1.3 to 31.6)	9.7 (2.3 to 43.8)	12.7 (55.8 to 463.9)	49.7 (-73.1 to 241.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	16.5 (10.8 to 24.5)	27.3 (17.8 to 41.3)	64.6 (42.1 to 92.6)	-14.6 (-25.1 to -2.1)
Sexually transmitted diseases excluding HIV	-	-	-	-	3.2 (1.8 to 5.8)	6.8 (3.7 to 11.8)	112.3 (45.5 to 217.4)	2.7 (-26.7 to 45.2)
Syphilis	0.5 (0.4 to 0.5)	0.6 (0.6 to 0.7)	26.8 (8.6 to 47.3)	-39.8 (-47.1 to -31.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	39.3 (-2.0 to 74.3)	39.3 (-53.7 to -18.2)
Chlamydial infection	323.6 (216.2 to 442.3)	677.7 (469.4 to 896.1)	107.8 (31.3 to 250.7)	0.9 (-31.8 to 66.7)	1.5 (0.7 to 2.9)	3.5 (1.6 to 6.5)	130.5 (-0.8 to 407.2)	14.3 (-51.5 to 138.2)
Gonococcal infection	107.3 (77.7 to 145.1)	210.6 (156.2 to 272.4)	95.3 (31.8 to 211.0)	-2.3 (-30.5 to 49.8)	0.7 (0.4 to 1.2)	1.4 (0.7 to 2.2)	89.1 (27.0 to 210.7)	-6.1 (-34.4 to 47.9)
Trichomoniasis	104.3 (51.0 to 164.5)	270.1 (183.6 to 362.5)	162.7 (44.9 to 447.3)	20.2 (-23.2 to 122.3)	0.2 (0.0 to 0.4)	0.5 (0.2 to 1.1)	173.0 (38.2 to 588.7)	24.3 (-24.5 to 170.9)
Genital herpes	2,300.5 (2,166.5 to 2,434.3)	4,616.5 (4,364.4 to 4,879.7)	101.0 (84.7 to 118.1)	-4.0 (-11.9 to 4.4)	1.6 (0.2 to 1.5)	1.2 (0.4 to 2.9)	99.2 (80.6 to 119.3)	-3.8 (-12.6 to 5.6)
Other sexually transmitted diseases	3.7 (2.7 to 5.0)	5.9 (4.4 to 7.8)	58.1 (35.3 to 87.3)	-26.5 (-37.1 to -13.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	104.3 (39.1 to 213.1)	1.0 (-31.3 to 43.1)
Hepatitis	-	-	-	-	2.2 (1.4 to 3.2)	3.3 (2.1 to 4.9)	54.4 (28.7 to 88.9)	-25.2 (-39.2 to -4.7)
Hepatitis A	36.5 (34.5 to 38.5)	61.2 (58.3 to 64.1)	67.7 (66.5 to 69.0)	-3.0 (-3.2 to -2.8)	0.7 (0.4 to 1.0)	1.2 (0.8 to 1.8)	85.7 (64.8 to 110.2)	2.4 (-7.9 to 15.3)
Hepatitis B	3,086.3 (2,830.5 to 3,361.4)	3,704.9 (3,236.0 to 4,108.2)	20.4 (2.1 to 37.5)	-38.1 (-46.4 to -29.2)	1.2 (0.7 to 1.7)	1.5 (0.9 to 2.2)	24.1 (9.9 to 77.5)	-40.3 (-57.6 to -10.9)
Hepatitis C	790.9 (708.7 to 877.6)	1,202.8 (1,067.7 to 1,349.4)	52.3 (28.7 to 79.2)	-24.7 (-35.1 to -13.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	47.4 (10.4 to 99.7)	-23.3 (-41.7 to 3.5)
Hepatitis E	8.3 (5.7 to 10.9)	17.6 (10.2 to 24.5)	109.4 (6.6 to 260.0)	2.5 (-44.7 to 72.0)	0.2 (0.1 to 0.4)	0.5 (0.2 to 0.9)	109.9 (7.5 to 283.6)	2.5 (-44.5 to 80.1)
Leprosy	1.2 (0.8 to 1.6)	2.0 (1.7 to 2.2)	66.0 (32.6 to 114.8)	-18.5 (-32.7 to 3.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	67.3 (22.4 to 135.3)	-17.7 (-37.9 to 13.0)
Other infectious diseases	297.9 (240.7 to 351.7)	474.8 (406.4 to 552.8)	59.5 (33.2 to 91.6)	-15.6 (-28.3 to -0.6)	11.1 (7.0 to 16.3)	17.1 (11.0 to 25.1)	54.0 (22.2 to 88.8)	-18.5 (-36.6 to -2.6)
Non-communicable diseases	-	-	-	-	102.1 (1,008.5 to 1,762.8)	2,762.8 (2,021.4 to 3,587.0)	102.1 (94.2 to 108.4)	4.6 (-4.2 to 2.4)
Neoplasms	-	-	-	-	4.3 (2.8 to 6.0)	10.1 (6.8 to 14.5)	138.2 (92.6 to 193.3)	19.1 (-1.8 to 45.0)
Esophageal cancer	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.9)	74.5 (10.9 to 165.6)	-15.3 (-45.5 to 33.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	72.3 (15.2 to 154.7)	-16.2 (-44.8 to 24.7)
Stomach cancer	2.4 (1.8 to 3.1)	3.9 (2.8 to 5.1)	60.2 (22.6 to 120.0)	-21.5 (-40.2 to 7.5)	0.5 (0.2 to 0.5)	0.5 (0.3 to 0.7)	57.5 (17.6 to 114.0)	-23.4 (-42.6 to 5.0)
Liver cancer	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	182.6 (91.3 to 302.9)	42.2 (5.6 to 101.4)
Liver cancer due to hepatitis B	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	174.7 (23.1 to 478.4)	37.7 (-41.0 to 222.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	166.8 (91.5 to 437.6)	31.0 (-38.3 to 193.2)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.1)	0.3 (0.2 to 0.5)	711.5 (318.0 to 1,476.2)	305.5 (105.5 to 683.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	675.5 (334.1 to 1,288.3)	285.9 (109.7 to 608.7)
Liver cancer due to alcohol use	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.6)	148.7 (24.3 to 385.2)	23.2 (-37.5 to 132.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	135.6 (33.6 to 326.2)	16.0 (-33.9 to 103.4)
Liver cancer due to other causes	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	52.6 (-21.3 to 310.7)	-17.7 (-62.7 to 115.5)	0.0 (0.0 to 0.0)	0.2 (0.0 to 0.0)	54.5 (-16.7 to 262.1)	-0.3 (-60.3 to 87.3)
Larynx cancer	1.0 (0.6 to 1.6)	1.7 (1.1 to 2.9)	72.4 (20.5 to 144.4)	-14.6 (-40.2 to 19.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	66.3 (17.0 to 140.3)	-17.2 (-43.3 to 19.7)
Tracheal, bronchus and lung cancer	1.8 (1.0 to 2.3)	3.4 (2.0 to 4.4)	89.1 (44.3 to 151.9)	-7.4 (-27.9 to 22.6)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.8)	83.6 (37.0 to 146.3)	-9.9 (-31.7 to 20.1)
Breast cancer	7.9 (5.4 to 12.9)	24.5 (15.3 to 39.6)	207.6 (110.2 to 348.6)	46.4 (2.7 to 107.7)	0.7 (0.4 to 1.1)	2.0 (1.2 to 3.4)	185.0 (92.3 to 309.5)	36.7 (6.8 to 90.5)
Cervical cancer	3.1 (1.5 to 3.3)	4.2 (1.9 to 4.8)	41.4 (-12.2 to 116.3)	8.0 (-56.0 to 6.0)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	49.8 (-9.7 to 122.3)	-28.2 (-55.1 to 9.0)
Uterine cancer	1.3 (0.7 to 2.3)	2.6 (1.4 to 4.4)	101.6 (9.3 to 242.9)	-2.5 (-46.8 to 65.1)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	95.8 (9.2 to 229.1)	-5.1 (-46.7 to 58.1)
Prostate cancer	2.3 (1.1 to 3.6)	11.3 (6.4 to 18.1)	397.7 (204.1 to 889.0)	143.5 (50.8 to 370.0)	0.2 (0.1 to 0.4)	1.1 (0.6 to 1.7)	327.3 (164.6 to 712.9)	109.7 (30.0 to 305.0)
Colon and rectum cancer	2.7 (2.3 to 3.2)	8.8 (6.7 to 11.0)	221.2 (150.3 to 305.1)	53.2 (20.0 to 94.5)	0.3 (0.2 to 0.4)	0.8 (0.5 to 1.1)	190.8 (128.4 to 272.9)	38.6 (8.9 to 81.3)
Lip and oral cavity cancer	1.2 (0.6 to 1.7)	2.1 (1.3 to 3.1)	86.4 (32.5 to 164.9)	-7.7 (-34.0 to 30.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	84.4 (30.4 to 162.4)	-9.6 (-34.8 to 29.6)
Nasopharynx cancer	0.7 (0.5 to 1.0)	0.9 (0.6 to 1.3)	23.1 (-23.6 to 97.0)	-38.8 (-60.4 to -3.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	20.6 (-22.1 to 86.1)	39.7 (-60.5 to -9.1)
Other pharynx cancer	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.6)	47.2 (9.4 to 140.2)	-28.8 (-55.8 to 16.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	43.6 (-6.2 to 129.7)	-30.1 (-54.8 to 11.6)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	113.5 (46.4 to 214.5)	1.7 (-30.5 to 50.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	100.8 (43.3 to 184.4)	-2.7 (-31.6 to 37.4)
Pancreatic cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	148.6 (81.2 to 233.9)	18.9 (-11.8 to 59.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	137.7 (83.4 to 206.4)	12.3 (-14.7 to 44.8)
Malignant skin melanoma	0.9 (0.5 to 1.6)	1.7 (1.1 to 2.7)	89.0 (26.2 to 163.2)	1.7 (-36.0 to 28.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	89.0 (22.8 to 163.9)	-0.3 (-37.1 to 29.0)
Non-melanoma skin cancer	1.4 (1.0 to 2.0)	3.7 (2.5 to 5.2)	163.5 (44.8 to 289.3)	26.4 (-37.2 to 92.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	195.8 (101.7 to 321.8)	40.5 (-9.0 to 108.7)
Ovarian cancer	0.6 (0.4 to 0.9)	1.2 (0.7 to 1.9)	110.4 (36.2 to 222.8)	1.7 (-33.8 to 51.5)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	103.8 (26.5 to 215.0)	-0.0 (-40.2 to 54.6)
Testicular cancer	0.3 (0.2 to 0.5)	0.8 (0.5 to 1.4)	195.5 (45.9 to 469.8)	37.6 (-24.1 to 155.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	176.9 (31.1 to 475.2)	29.7 (-29.7 to 146.4)
Kidney cancer	0.9 (0.4 to 1.2)	1.7 (1.2 to 2.6)	89.0 (51.3 to 264.4)	8.0 (-1.6 to 85.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	89.0 (53.1 to 243.9)	38.0 (-7.0 to 75.0)
Bladder cancer	1.5 (1.1 to 2.0)	3.1 (2.2 to 4.2)	105.7 (44.4 to 191.3)	-2.6 (-31.3 to 34.3)	0.3 (0.1 to 0.2)	0.3 (0.2 to 0.4)	98.8 (41.8 to 176.7)	-6.0 (-32.4 to 30.5)
Brain and nervous system cancer	2.3 (1.2 to 6.7)	5.2 (3.3 to 10.1)	154.7 (29.3 to 252.3)	33.4 (-15.4 to 74.9)	0.2 (0.1 to 0.6)	0.2 (0.3 to 1.0)	147.4 (43.2 to 238.2)	25.0 (-13.1 to 66.1)
Thyroid cancer	1.7 (0.9 to 3.4)	4.1 (2.3 to 7.4)	150.3 (55.0 to 285.5)	17.8 (-24.2 to 81.5)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.5)	138.0 (46.6 to 279.3)	11.1 (-29.9 to 75.3)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.8 (-3.3 to 89.8)	-31.9 (-51.2 to -1.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.1 (-9.9 to 91.9)	29.7 (-50.8 to 1.0)
Hodgkin lymphoma	1.7 (0.4 to 3.1)	2.9 (1.2 to 5.2)	78.0 (-1.4 to 236.0)	-2.4 (-41.9 to 75.2)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.4)	74.4 (-3.1 to 217.8)	-6.6 (-43.4 to 55.4)
Non-Hodgkin lymphoma	1.6 (1.0 to 3.0)	4.2 (2.9 to 6.3)	174.6 (68.5 to 278.3)	39.9 (-8.5 to 93.4)	0.1 (0.1 to 0.3)	0.3 (0.2 to 0.6)	160.5 (65.0 to 255.9)	30.3 (-15.1 to 77.3)
Multiple myeloma	0.2 (0.1 to 0.3)	0.3 (0.3 to 0.7)	156.5 (71.8 to 294.5)	24.7 (-16.8 to 89.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	144.6 (65.1 to 267.5)	17.9 (-21.4 to 82.6)
Leukemia	2.8 (1.9 to 5.4)	6.5 (4.6 to 9.4)	140.4 (36.7 to 269.3)	34.1 (-5.9 to 88.9)	0.3 (0.2 to 0.5)	0.8 (0.5 to 1.1)	124.4 (52.7 to 212.0)	20.2 (-11.1 to 63.1)
Other neoplasms	4.1 (2.1 to 12.7)	13.7 (8.4 to 27.6)	275.8 (90.9 to 431.7)	81.2 (19.8 to 146.4)	0.3 (0.1 to 0.8)	0.9 (0.5 to 1.8)	243.1 (91.9 to 388.4)	59.4 (13.1 to 119.3)
Cardiovascular diseases	-	-	-	-	26.4 (17.6 to 37.3)	52.3 (35.0 to 73.5)	100.4 (51.1 to 148.9)	1.8 (-21.4 to 25.1)
Rheumatic heart disease	30.1 (26.6 to 33.7)	59.6 (50.4 to 69.0)	97.3 (62.6 to 138.4)	-0.1 (-16.8 to 17.2)	1.7 (1.1 to 2.5)	3.6 (2.3 to 5.2)	109.5 (66.7 to 168.6)	9.7 (-14.6 to 52.3)
Ischemic heart disease	114.4 (94.5 to 138.5)	195.5 (168.1 to 227.1)	72.2 (35.3 to 115.1)	-13.0 (-30.5 to 6.1)	6.3 (4.0 to 9.4)	10.5 (7.1 to 15.6)	72.5 (28.2 to 129.2)	-11.2 (-33.1 to 17.9)
Cerebrovascular disease	-	-	-	-	0.9 (0.6 to 1.2)	1.8 (1.2 to 2.5)	104.0 (63.1 to 166.8)	-2.7 (-23.0 to 28.8)
Ischemic stroke	4.9 (3.9 to 5.7)	10.0 (8.2 to 11.5)	102.3 (65.7 to 166.4)	-3.9 (-21.7 to 26.1)	0.7 (0.5 to 1.0)	1.5 (1.0 to 2.2)	102.9 (63.4 to 173.2)	-3.7 (-22.9 to 30.5)
Hemorrhagic stroke	0.8 (0.6 to 1.0)	1.6 (1.2 to 2.1)	109.5 (38.8 to 202.9)	0.3 (-34.0 to 45.0)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	109.2 (38.8 to 203.7)	0.1 (-33.7 to 44.4)
Hypertensive heart disease	5.9 (4.3 to 7.8)	15.4 (10.9 to 20.0)	158.8 (68.3 to 289.8)	33.8 (-14.8 to 104.8)	0.7 (0.4 to 1.0)	1.7 (1.0 to 2.7)	159.4 (65.6 to 292.5)	34.3 (-17.0 to 105.8)
Cardiomyopathy and myocarditis	13.4 (11.4 to 15.4)	44.9 (38.3 to 52.9)	232.7 (172.5 to 309.2)	78.9 (41.5 to 130.6)	1.5 (1.0 to 2.1)	4.9 (3.3 to 7.1)	235.9 (172.1 to 316.4)	80.2 (42.1 to 132.2)
Atrial fibrillation and flutter	9.0 (6.1 to 13.0)	25.4 (17.8 to 34.2)	191.9 (56.5 to 369.9)	40.1 (-24.1 to 138.0)	0.7 (0.4 to 1.1)	1.9 (1.2 to 2.9)	195.0 (57.4 to 364.5)	41.4 (-24.9 to 137.1)
Peripheral vascular disease	192.3 (145.1 to 239.2)	438.8 (317.6 to 593.2)	125.5 (54.1 to 270.1)	7.4 (-25.3 to 61.6)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	82.9 (5.9 to 253.4)	-16.1 (-65.3 to 66.3)
Endocarditis	0.4 (0.3 to 0.7)	0.9 (0.6 to 1.6)	107.9 (50.9 to 197.6)	19.7 (-15.0 to 85.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	130.7 (57.4 to 233.4)	24.5 (-16.3 to 102.4)
Other cardiovascular and circulatory diseases	208.9 (137.7 to 299.3)	397.8 (239.5 to 519.3)	89.2 (11.8 to 177.3)	-4.7 (-44.8 to 38.3)	14.6 (8.3 to 23.2)	27.1 (14.8 to 42.3)	89.0 (10.9 to 177.5)	4.7 (-44.8 to 39.7)

Appendix Table G.4 - Sudan prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumococcosis	-	-	-	-	0.0	0.1	95.3	-7.3
Silicosis	0.1	0.1	78.9	-14.8	0.0	0.0	77.7	-15.4
Asbestosis	0.1	0.1	0.0	0.0	0.0	0.0	-	-
Coal workers pneumococcosis	-	-	0.0	0.0	-	-	-	-
Other pneumococcosis	0.2	0.3	104.9	-2.2	0.0	0.1	104.9	-2.1
Asthma	249.2	895.4	254.3	32.8	10.7	39.2	261.0	35.6
Interstitial lung disease and pulmonary sarcoidosis	1.0	2.3	128.3	15.1	0.1	0.3	128.2	15.2
Other chronic respiratory diseases	-	-	-	-	2.9	4.3	52.0	-27.2
Cirrhosis	-	-	-	-	1.3	1.8	40.6	-19.6
Cirrhosis due to hepatitis B	2.6	3.1	19.5	-31.0	0.4	0.5	18.4	-31.8
Cirrhosis due to hepatitis C	2.6	4.8	88.9	5.5	0.8	0.8	86.7	5.3
Cirrhosis due to alcohol use	0.7	0.7	-50.7	0.1	0.1	0.1	-6.4	-50.5
Cirrhosis due to other causes	2.0	2.5	26.2	-20.2	0.3	0.4	27.1	-20.6
Digestive diseases	-	-	-	-	12.3	21.6	76.7	-14.8
Peptic ulcer disease	64.2	74.1	15.4	-39.6	2.6	3.1	23.4	-36.6
Gastritis and duodenitis	58.0	57.8	0.1	-46.5	2.6	2.6	-1.2	-44.6
Appendicitis	1.5	2.2	51.9	-22.9	0.4	0.7	53.9	-21.3
Paralytic ileus and intestinal obstruction	0.2	0.6	192.2	16.2	0.1	0.2	199.0	19.1
Inguinal, femoral, and abdominal hernia	75.4	109.5	48.9	-16.9	0.8	1.1	48.0	-17.4
Inflammatory bowel disease	12.6	39.0	209.7	48.4	2.7	8.3	212.0	49.1
Vascular intestinal disorders	0.0	0.1	93.9	-4.9	0.0	0.0	93.4	-4.8
Gallbladder and biliary diseases	5.4	11.0	102.6	0.6	1.1	1.9	103.9	-1.9
Pancreatitis	3.1	6.0	93.5	-7.9	0.9	1.8	92.9	-8.0
Other digestive diseases	-	-	-	-	1.7	2.7	65.9	-20.4
Neurological disorders	-	-	-	-	131.6	280.0	113.8	6.3
Alzheimer disease and other dementias	62.2	133.2	113.7	-0.8	8.4	18.5	115.7	0.3
Parkinson disease	6.0	12.7	113.1	0.6	0.7	1.5	113.6	1.4
Epilepsy	91.5	174.6	90.9	-0.0	27.4	53.9	97.0	3.2
Multiple sclerosis	1.3	4.8	268.1	73.3	0.5	1.6	256.3	66.5
Migraine	1,943.2	3,703.7	88.2	4.3	66.1	126.1	88.4	-4.1
Tension-type headache	3,014.7	6,074.6	103.0	3.6	4.6	9.2	102.9	4.1
Medication overuse headache	137.7	417.4	203.7	48.1	21.5	65.4	205.1	48.5
Other neurological disorders	0.0	0.1	99.0	3.6	2.5	4.0	66.7	-24.3
Mental and substance use disorders	-	-	-	-	437.4	860.0	96.6	-1.6
Schizophrenia	41.0	86.4	110.6	-0.2	26.1	55.1	111.7	0.2
Alcohol use disorders	93.0	181.6	95.1	-3.6	9.1	17.9	96.5	-3.3
Drug use disorders	-	-	-	-	40.2	77.4	92.1	-7.8
Opioid use disorders	68.1	131.9	92.6	-9.4	28.0	54.5	93.4	-9.0
Cocaine use disorders	11.9	23.5	97.9	-2.0	4.1	8.1	106.1	-2.0
Amphetamine use disorders	28.4	50.0	76.9	-9.3	3.7	6.5	77.4	-8.9
Cannabis use disorders	29.2	57.4	96.7	-0.0	0.8	1.7	97.2	0.4
Other drug use disorders	-	-	-	-	5.7	10.7	87.1	-5.9
Depressive disorders	-	-	-	-	152.6	311.9	106.6	0.3
Major depressive disorder	670.3	1,361.9	103.7	-0.1	136.5	278.2	104.1	0.3
Dysthymia	168.8	351.0	108.1	0.1	16.2	33.7	108.6	0.4
Bipolar disorder	115.1	233.6	103.2	-1.3	23.2	47.3	103.7	-0.9
Anxiety disorders	758.1	1,508.7	99.6	0.1	69.6	138.9	100.4	0.5
Eating disorders	-	-	-	-	2.5	5.2	106.5	5.1
Anorexia nervosa	2.0	5.0	152.3	30.8	0.4	1.1	153.1	31.0
Bulimia nervosa	10.1	19.8	96.4	-0.1	2.1	4.2	96.8	0.0
Autistic spectrum disorders	-	-	-	-	23.4	44.7	90.9	0.4
Autism	59.1	112.6	90.8	-0.0	14.5	27.8	91.2	0.3
Asperger syndrome	89.0	169.1	90.1	-0.1	8.9	16.9	90.9	0.4
Attention-deficit/hyperactivity disorder	149.6	271.5	81.6	0.1	1.8	3.3	82.3	0.5
Conduct disorder	276.2	501.9	81.8	0.1	1.0	1.9	82.2	-7.2
Idiopathic intellectual disability	777.9	1,243.7	60.1	-13.9	38.0	60.6	69.1	-13.7
Other mental and substance use disorders	239.3	497.1	107.8	-0.1	17.8	37.1	108.7	0.3
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	138.6	286.3	106.4	5.8
Diabetes mellitus	466.5	1,223.2	161.2	27.2	37.5	97.6	159.3	23.8
Acute glomerulonephritis	0.2	0.2	45.9	0.0	0.0	0.0	45.9	0.0
Chronic kidney disease	-	-	-	-	17.5	35.0	100.5	0.8
Chronic kidney disease due to diabetes mellitus	126.4	290.2	130.0	14.1	3.3	7.5	128.3	12.4
Chronic kidney disease due to hypertension	102.2	155.7	50.6	-21.6	5.0	8.6	75.6	-18.3
Chronic kidney disease due to glomerulonephritis	170.1	386.6	127.3	17.4	6.3	14.6	130.6	18.6
Chronic kidney disease due to other causes	226.9	527.1	133.5	17.4	6.3	14.6	130.6	18.6
Urinary diseases and male infertility	-	-	-	-	7.4	15.7	114.2	3.5

Appendix Table G.4 - Sudan prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	3.8 (3.5 to 4.1)	7.8 (7.4 to 8.3)	100.0 (86.7 to 129.5)	0.1 (-5.1 to 13.8)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	108.6 (54.5 to 171.3)	5.1 (-17.2 to 27.7)
Urolithiasis	141.3 (89.0 to 249.2)	307.7 (150.9 to 555.0)	126.1 (45.7 to 170.8)	7.8 (26.0 to 30.5)	1.0 (0.6 to 1.6)	2.3 (1.3 to 3.8)	137.1 (92.5 to 164.6)	15.1 (-8.2 to 29.0)
Benign prostatic hyperplasia	113.9 (103.8 to 123.7)	240.7 (224.6 to 257.2)	111.3 (91.2 to 137.9)	4.0 (-8.4 to 13.8)	4.0 (2.6 to 5.7)	8.5 (5.5 to 12.1)	112.2 (90.8 to 139.3)	1.8 (-8.3 to 14.5)
Male infertility due to other causes	226.4 (180.3 to 277.1)	448.1 (363.6 to 547.4)	97.1 (47.0 to 163.1)	-5.2 (-28.0 to 25.4)	1.5 (0.6 to 3.0)	2.9 (1.2 to 6.1)	97.5 (41.5 to 170.3)	-4.6 (-30.3 to 27.9)
Other urinary diseases	-	-	-	-	0.8 (0.3 to 1.7)	1.7 (0.9 to 3.0)	84.0 (29.5 to 138.5)	10.8 (-4.1 to 92.0)
Gynecological diseases	-	-	-	-	25.9 (16.5 to 39.9)	54.0 (33.9 to 79.1)	107.2 (79.7 to 151.4)	-1.6 (-12.5 to 15.2)
Uterine fibroids	283.6 (256.1 to 309.1)	621.3 (561.7 to 676.8)	119.2 (118.7 to 119.9)	0.9 (0.9 to 1.0)	5.8 (3.6 to 9.0)	11.5 (7.0 to 18.1)	98.3 (86.1 to 112.0)	-8.5 (-14.1 to -2.8)
Polycystic ovarian syndrome	356.4 (327.0 to 385.5)	737.1 (664.7 to 814.5)	106.9 (82.4 to 137.5)	-1.3 (-12.3 to 12.9)	3.5 (1.6 to 6.6)	7.2 (3.4 to 13.5)	107.0 (82.4 to 138.9)	-1.1 (-12.0 to 13.2)
Female infertility due to other causes	180.8 (135.7 to 240.6)	390.4 (238.9 to 445.9)	83.4 (21.7 to 164.1)	-6.3 (-45.6 to 19.7)	0.9 (0.4 to 2.1)	1.7 (0.6 to 3.7)	84.0 (20.1 to 165.5)	-15.7 (-45.0 to 19.9)
Endometriosis	29.1 (24.6 to 34.2)	64.6 (55.8 to 74.0)	121.9 (80.2 to 180.9)	3.9 (-15.9 to 31.4)	2.7 (1.7 to 3.8)	5.9 (4.1 to 8.3)	123.2 (75.6 to 184.3)	4.4 (-17.6 to 33.0)
Genital prolapse	810.7 (623.6 to 983.6)	1,646.3 (1,260.0 to 2,036.0)	102.7 (47.5 to 180.5)	-4.2 (-28.7 to 27.4)	2.6 (1.1 to 4.9)	5.2 (2.4 to 9.9)	102.7 (48.0 to 183.1)	-3.9 (-28.7 to 28.3)
Premenstrual syndrome	951.9 (506.8 to 1,324.1)	2,174.7 (1,509.6 to 3,001.4)	123.9 (47.9 to 330.4)	12.0 (-24.1 to 98.0)	8.0 (3.6 to 13.4)	12.0 (9.6 to 30.8)	124.0 (49.4 to 330.0)	12.2 (-24.2 to 98.0)
Other gynecological diseases	71.0 (45.2 to 96.9)	133.5 (106.1 to 160.7)	88.8 (36.6 to 192.1)	-7.9 (-32.7 to 40.1)	2.5 (1.2 to 3.6)	4.2 (2.6 to 6.1)	67.8 (17.2 to 225.8)	-18.1 (-42.8 to 54.3)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	37.9 (25.2 to 53.9)	64.8 (43.2 to 93.5)	70.3 (54.0 to 88.3)	-11.0 (-20.2 to -1.4)
Thalassemias	7.7 (5.6 to 9.9)	14.0 (10.9 to 17.1)	81.8 (56.4 to 117.4)	2.0 (-11.7 to 21.4)	0.5 (0.3 to 0.9)	0.9 (0.5 to 1.5)	73.8 (10.8 to 161.2)	-4.2 (-37.2 to 41.6)
Thalassemia trait	1,120.1 (937.7 to 1,298.9)	2,161.4 (1,894.4 to 2,414.7)	93.0 (78.3 to 111.4)	1.6 (-6.2 to 11.3)	21.2 (14.3 to 30.4)	38.5 (25.4 to 56.3)	82.8 (53.2 to 110.8)	-1.9 (-20.4 to 12.5)
Sickle cell disorders	5.7 (4.5 to 6.7)	12.2 (10.2 to 13.9)	114.3 (70.4 to 177.4)	20.1 (-4.0 to 55.0)	0.6 (0.4 to 0.9)	1.3 (0.9 to 1.9)	113.4 (65.9 to 174.4)	16.9 (-5.4 to 44.7)
Sickle cell trait	1,141.6 (1,035.3 to 1,242.4)	2,125.1 (1,932.7 to 2,301.9)	86.2 (77.1 to 94.7)	5.2 (-6.9 to 2.4)	9.2 (3.3 to 7.6)	9.2 (5.6 to 13.6)	76.6 (37.5 to 117.7)	-5.5 (-25.2 to 15.4)
G6PD deficiency	479.8 (415.8 to 544.0)	1,029.2 (855.9 to 1,215.6)	114.2 (67.8 to 163.2)	12.7 (-11.6 to 38.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	107.4 (99.4 to 120.6)	107.4 (9.8 to 16.9)
G6PD trait	1,847.3 (1,759.9 to 1,927.8)	3,506.4 (3,308.5 to 3,664.8)	90.3 (75.0 to 107.7)	0.1 (-8.0 to 6.6)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	97.7 (40.2 to 172.1)	5.1 (-19.3 to 37.6)
Other hemoglobinopathies and hemolytic anemias	327.9 (276.5 to 370.5)	516.6 (430.0 to 572.5)	57.7 (33.8 to 90.5)	10.2 (-29.3 to -6.5)	10.2 (6.2 to 15.3)	14.5 (8.6 to 22.2)	42.1 (1.6 to 102.2)	-28.4 (-46.4 to -3.5)
Endocrine, metabolic, blood, and immune disorders	349.6 (304.2 to 390.5)	567.5 (483.8 to 640.8)	62.9 (33.2 to 95.0)	-4.9 (-26.8 to -1.5)	12.4 (8.1 to 17.7)	19.2 (12.3 to 27.5)	54.6 (18.2 to 95.3)	-19.9 (-34.0 to 0.2)
Musculoskeletal disorders	-	-	-	-	270.6 (187.4 to 358.3)	571.7 (404.5 to 769.3)	111.2 (85.7 to 141.1)	0.8 (-9.6 to 12.8)
Rheumatoid arthritis	27.5 (25.1 to 29.6)	49.2 (46.1 to 52.3)	79.0 (62.8 to 99.8)	-11.8 (-19.7 to -0.2)	6.5 (4.5 to 8.6)	11.7 (8.3 to 15.5)	79.3 (58.1 to 103.9)	-11.6 (-20.5 to 1.1)
Osteoarthritis	331.7 (312.9 to 350.9)	707.2 (661.4 to 749.1)	113.5 (97.1 to 131.3)	0.3 (-6.6 to 8.0)	20.0 (13.9 to 27.7)	42.8 (30.3 to 58.2)	114.4 (97.9 to 132.1)	0.8 (-6.4 to 8.6)
Low back and neck pain	-	-	-	-	212.2 (142.8 to 286.1)	440.9 (303.9 to 601.4)	107.5 (76.7 to 146.6)	-0.9 (-14.7 to 15.0)
Low back pain	1,416.4 (1,211.6 to 1,628.2)	2,895.6 (2,506.4 to 3,275.8)	104.6 (64.6 to 156.0)	-2.7 (-20.1 to 19.4)	157.0 (103.2 to 217.6)	322.5 (212.1 to 454.9)	105.4 (65.3 to 157.7)	-2.1 (-20.0 to 20.8)
Neck pain	568.3 (487.4 to 659.8)	1,214.7 (1,031.2 to 1,402.6)	114.4 (71.4 to 162.4)	2.0 (-18.0 to 26.1)	55.2 (37.1 to 76.2)	118.4 (81.3 to 162.9)	114.7 (73.1 to 163.0)	2.4 (-17.5 to 26.2)
Gout	5.9 (5.0 to 6.9)	12.5 (10.5 to 14.4)	111.2 (65.3 to 172.3)	0.4 (-21.2 to 29.2)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	111.8 (55.3 to 188.0)	0.3 (-26.3 to 35.6)
Other musculoskeletal disorders	352.1 (259.8 to 436.8)	888.8 (626.3 to 1,036.8)	138.3 (122.3 to 158.8)	10.5 (3.6 to 19.2)	31.7 (20.2 to 46.5)	75.9 (49.0 to 110.5)	93.8 (121.8 to 151.5)	11.3 (-3.7 to 20.8)
Other non-communicable diseases	-	-	-	-	298.8 (204.0 to 419.9)	557.2 (379.9 to 784.4)	86.7 (77.6 to 94.3)	-8.2 (-10.7 to -5.3)
Congenital anomalies	-	-	-	-	10.5 (7.8 to 14.2)	32.0 (22.8 to 43.6)	203.0 (154.4 to 265.6)	63.2 (37.5 to 95.6)
Neural tube defects	2.7 (2.2 to 3.5)	10.8 (8.9 to 12.8)	298.3 (189.4 to 436.4)	137.0 (71.0 to 219.3)	0.7 (0.4 to 1.0)	3.1 (2.0 to 4.5)	367.8 (202.8 to 622.1)	182.5 (84.7 to 333.1)
Congenital heart anomalies	31.2 (22.5 to 41.3)	146.8 (122.7 to 186.4)	374.9 (232.0 to 595.4)	180.3 (94.7 to 316.9)	1.2 (0.5 to 2.0)	5.0 (2.2 to 8.9)	329.9 (195.0 to 520.8)	159.3 (80.4 to 281.8)
Orofacial clefts	4.2 (2.8 to 6.1)	26.4 (19.7 to 35.1)	302.8 (268.2 to 954.0)	0.1 (-13.1 to 580.1)	0.4 (0.0 to 0.1)	0.4 (0.2 to 0.7)	449.3 (205.6 to 858.3)	249.8 (93.2 to 504.2)
Down syndrome	18.4 (14.6 to 23.3)	52.8 (40.2 to 69.0)	184.0 (107.3 to 313.0)	61.3 (17.7 to 135.7)	2.1 (1.4 to 3.1)	6.3 (4.1 to 9.1)	191.9 (113.2 to 330.1)	67.0 (22.5 to 149.2)
Turner syndrome	0.5 (0.4 to 0.8)	1.3 (1.0 to 1.7)	140.9 (58.8 to 262.6)	31.5 (-13.6 to 97.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	142.8 (64.8 to 270.4)	30.0 (-11.4 to 101.9)
Klinefelter syndrome	0.6 (0.5 to 0.9)	1.1 (0.8 to 1.7)	86.3 (9.0 to 192.7)	-1.1 (-4.2 to 55.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.1 (14.6 to 211.1)	-1.3 (-42.3 to 55.5)
Chromosomal unbalanced rearrangements	17.4 (14.5 to 21.5)	47.2 (37.5 to 61.0)	169.0 (93.4 to 267.1)	2.0 (-9.6 to 11.0)	6.0 (1.4 to 2.8)	5.6 (4.0 to 7.9)	179.6 (96.6 to 284.1)	61.1 (13.0 to 123.5)
Other congenital anomalies	50.1 (41.0 to 60.3)	89.4 (73.5 to 109.0)	77.1 (44.0 to 124.5)	-10.0 (-25.4 to 15.9)	4.5 (3.0 to 6.8)	11.5 (7.2 to 18.7)	155.7 (85.7 to 249.1)	26.5 (-4.4 to 74.5)
Skin and subcutaneous diseases	-	-	-	-	107.6 (67.3 to 163.4)	202.3 (123.5 to 314.6)	88.7 (62.6 to 108.1)	-2.1 (-12.3 to 6.5)
Dermatitis	1,071.2 (847.2 to 1,307.7)	2,100.8 (1,655.9 to 2,559.5)	96.2 (94.0 to 98.6)	-0.0 (-0.0 to 0.0)	36.4 (21.4 to 53.7)	70.2 (41.0 to 105.2)	93.0 (85.5 to 99.5)	0.4 (-2.3 to 3.0)
Psoriasis	180.0 (79.7 to 124.0)	202.4 (159.9 to 251.8)	102.5 (100.5 to 104.6)	8.1 (-0.0 to 0.0)	6.1 (5.3 to 11.9)	16.5 (10.6 to 24.1)	102.7 (87.3 to 117.4)	0.3 (-5.4 to 6.0)
Cellulitis	4.1 (3.2 to 5.2)	6.6 (5.1 to 8.4)	62.4 (39.4 to 81.2)	-14.5 (-24.5 to -3.4)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.7)	62.8 (26.0 to 104.9)	-13.5 (-30.6 to 5.4)
Pyoderma	17.2 (13.5 to 21.9)	27.8 (22.2 to 35.2)	61.7 (52.6 to 73.4)	-7.6 (-13.1 to -1.1)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	61.8 (44.5 to 85.4)	-7.3 (-17.3 to 3.7)
Scabies	88.5 (66.2 to 115.4)	158.6 (124.9 to 227.8)	80.0 (21.9 to 161.5)	-4.9 (-35.1 to 31.6)	2.3 (1.2 to 3.8)	4.1 (2.2 to 7.0)	79.6 (62.0 to 165.0)	-4.6 (-35.5 to 34.0)
Fungal skin diseases	1,077.6 (804.9 to 1,361.9)	2,152.7 (1,620.5 to 2,702.8)	99.9 (96.6 to 103.9)	0.0 (-0.1 to 0.0)	6.0 (2.4 to 12.8)	12.1 (8.4 to 25.6)	100.2 (92.0 to 104.9)	0.3 (-0.4 to 1.2)
Viral skin diseases	480.0 (371.1 to 579.8)	879.7 (675.7 to 1,067.0)	83.4 (78.1 to 88.3)	-0.0 (-1.9 to 2.0)	14.8 (8.6 to 23.3)	27.3 (15.9 to 42.5)	83.8 (76.7 to 91.3)	0.7 (-2.8 to 3.7)
Acne vulgaris	2,268.1 (1,798.2 to 2,798.9)	4,202.3 (2,838.7 to 5,359.2)	88.4 (12.3 to 162.1)	0.4 (-38.5 to 36.6)	24.5 (11.0 to 45.9)	45.5 (19.6 to 87.4)	88.6 (11.9 to 163.0)	0.7 (-38.7 to 37.0)
Alopecia areata	25.1 (21.5 to 28.7)	48.9 (41.6 to 55.7)	93.7 (59.7 to 138.5)	-0.5 (-17.9 to 20.7)	0.8 (0.5 to 1.3)	1.6 (1.0 to 2.6)	94.4 (56.0 to 147.7)	-0.2 (-18.4 to 22.5)
Pruritus	3.4 (2.4 to 4.7)	8.1 (5.4 to 11.0)	144.2 (41.1 to 286.9)	21.4 (-34.3 to 129.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	144.5 (40.1 to 294.9)	22.6 (-36.1 to 132.1)
Urticaria	153.2 (106.9 to 210.6)	239.6 (157.0 to 338.8)	58.5 (-14.8 to 161.3)	-18.0 (-48.7 to 30.0)	9.1 (5.1 to 14.8)	14.2 (7.6 to 24.0)	58.3 (-17.0 to 161.0)	-17.9 (-49.6 to 30.8)
Decubitus ulcer	2.2 (1.7 to 2.7)	3.7 (3.1 to 4.5)	75.8 (25.0 to 133.5)	-16.4 (-47.8 to 26.8)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.8)	76.1 (23.2 to 136.3)	-15.7 (-47.7 to 29.6)
Other skin and subcutaneous diseases	807.6 (555.3 to 1,140.1)	1,623.0 (1,115.3 to 2,322.4)	100.9 (93.3 to 109.5)	-0.8 (-4.2 to 2.2)	4.7 (2.1 to 9.5)	9.5 (4.2 to 19.3)	101.3 (92.8 to 110.1)	-0.5 (-4.2 to 2.8)
Sense organ diseases	-	-	-	-	147.9 (102.8 to 202.7)	257.1 (177.3 to 355.5)	74.2 (67.3 to 84.1)	-13.4 (-16.8 to -9.7)
Glaucoma	50.6 (40.4 to 62.3)	94.2 (74.3 to 117.1)	84.9 (51.5 to 139.1)	-10.5 (-29.1 to 13.0)	4.3 (2.8 to 6.2)	7.8 (5.2 to 11.1)	83.9 (50.2 to 130.1)	-10.6 (-29.0 to 11.0)
Cataract	305.3 (218.7 to 379.2)	567.6 (400.8 to 727.1)	86.6 (65.2 to 106.2)	-13.3 (-21.2 to -5.5)	28.0 (18.0 to 39.7)	51.5 (32.7 to 73.6)	84.1 (67.3 to 102.5)	-13.0 (-20.8 to -6.0)
Macular degeneration	20.2 (11.5 to 31.1)	32.7 (20.8 to 45.9)	62.1 (11.1 to 175.3)	-18.7 (-43.9 to 31.2)	1.2 (0.7 to 2.0)	2.0 (1.2 to 3.1)	66.6 (17.0 to 162.0)	-17.3 (-40.7 to 19.6)
Uncorrected refractive error	1,820.3 (1,562.3 to 2,087.2)	3,318.4 (2,869.4 to 3,785.5)	82.6 (51.8 to 115.6)	-9.2 (-23.0 to 5.2)	52.2 (35.3 to 75.2)	87.4 (57.8 to 127.7)	66.7 (55.5 to 82.8)	-16.7 (-23.1 to -9.1)
Age-related and other hearing loss	1,289.8 (1,196.3 to 1,395.1)	2,397.4 (2,202.6 to 2,584.0)	85.4 (74.2 to 96.1)	-9.7 (-13.4 to -6.4)	33.8 (22.2 to 48.4)	60.6 (40.0 to 86.4)	79.6 (63.1 to 94.5)	-10.6 (-16.0 to -5.4)
Other vision loss	178.2 (146.6 to 215.1)	285.2 (231.5 to 343.5)	59.8 (46.4 to 77.9)	-18.0 (-25.8 to -8.1)	15.2 (10.2 to 21.3)	24.0 (16.1 to 33.6)	57.7 (43.6 to 76.8)	-19.7 (-27.0 to -9.4)
Other sense organ diseases	475.9 (450.6 to 502.7)	890.6 (843.9 to 933.2)	87.2 (73.7 to 100.8)	0.2 (-5.5 to 7.0)	12.7 (7.8 to 18.8)	23.7 (14.4 to 35.4)	87.3 (71.7 to 103.4)	

Appendix Table G.4 - Sudan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	581.4 (529.8 to 627.8)	1,127.6 (1,031.2 to 1,210.9)	93.5 (73.3 to 120.8)	-7.7 (-16.4 to 4.6)	15.8 (10.6 to 21.9)	30.8 (20.5 to 42.8)	94.1 (73.2 to 122.5)	-7.3 (-16.2 to 5.2)
Other oral disorders	287.4 (271.0 to 304.5)	572.8 (539.2 to 604.8)	99.8 (83.4 to 116.5)	-0.3 (-7.8 to 7.4)	8.4 (5.2 to 12.5)	16.8 (10.4 to 24.9)	100.2 (82.9 to 118.6)	0.0 (-7.8 to 8.3)
Injuries	-	-	-	-	63.2 (41.3 to 101.8)	88.1 (61.5 to 126.7)	41.2 (19.4 to 61.6)	-22.3 (-32.6 to -12.6)
Transport injuries	-	-	-	-	13.8 (10.4 to 17.9)	27.6 (20.8 to 35.6)	99.4 (90.9 to 107.9)	1.2 (-2.4 to 4.7)
Road injuries	-	-	-	-	10.8 (8.1 to 13.9)	20.6 (15.4 to 26.7)	98.0 (81.3 to 100.8)	-2.0 (-6.7 to 1.3)
Pedestrian road injuries	-	-	-	-	2.5 (1.9 to 3.2)	4.4 (3.3 to 5.7)	76.5 (62.4 to 90.4)	-6.9 (-12.6 to -1.5)
Cyclist road injuries	-	-	-	-	1.1 (0.8 to 1.4)	2.3 (1.7 to 3.0)	112.6 (96.1 to 128.6)	7.7 (0.4 to 15.6)
Motorcyclist road injuries	-	-	-	-	1.4 (1.1 to 1.8)	2.3 (1.7 to 3.0)	58.5 (49.1 to 69.1)	-19.8 (-23.9 to -14.8)
Motor vehicle road injuries	-	-	-	-	5.7 (4.3 to 7.3)	11.5 (8.6 to 14.9)	102.6 (86.6 to 117.7)	-2.0 (-4.6 to 0.4)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	12.0 (4.9 to 19.7)	-44.8 (-47.6 to -41.7)
Other transport injuries	-	-	-	-	3.1 (2.3 to 4.0)	7.0 (5.2 to 9.1)	128.8 (116.3 to 145.8)	15.3 (8.8 to 22.8)
Unintentional injuries	-	-	-	-	16.8 (12.8 to 21.5)	30.1 (22.8 to 38.5)	79.4 (73.3 to 85.4)	-8.8 (-11.7 to -5.8)
Falls	-	-	-	-	7.6 (5.8 to 9.8)	14.8 (11.2 to 19.3)	95.7 (85.6 to 107.3)	-1.7 (-7.0 to 4.0)
Drowning	-	-	-	-	0.6 (0.5 to 0.8)	0.8 (0.6 to 1.0)	22.9 (12.0 to 36.0)	-35.8 (-40.7 to -30.0)
Fire, heat, and hot substances	-	-	-	-	2.0 (1.5 to 2.5)	2.6 (2.0 to 3.3)	30.9 (19.0 to 43.2)	-33.4 (-38.0 to -28.3)
Poisonings	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	41.1 (12.7 to 75.3)	-27.8 (-40.2 to -13.4)
Exposure to mechanical forces	-	-	-	-	3.5 (2.8 to 4.6)	6.3 (4.8 to 8.2)	79.6 (69.7 to 89.9)	-10.6 (-14.5 to -5.9)
Unintentional firearm injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	62.8 (50.9 to 76.6)	21.6 (-26.7 to -15.4)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	131.1 (109.8 to 153.9)	17.1 (8.2 to 27.7)
Other exposure to mechanical forces	-	-	-	-	3.3 (2.5 to 4.3)	5.9 (4.5 to 7.8)	79.9 (69.7 to 91.1)	-10.3 (-14.4 to -5.2)
Adverse effects of medical treatment	-	-	-	-	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	116.4 (102.1 to 132.5)	11.4 (4.0 to 20.5)
Animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.7 (0.5 to 0.9)	105.1 (89.9 to 121.8)	4.0 (-2.3 to 10.6)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	103.1 (77.3 to 132.6)	2.4 (-8.5 to 15.3)
Non-venomous animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	106.9 (92.7 to 121.9)	5.4 (-0.3 to 11.3)
Foreign body	-	-	-	-	0.6 (0.4 to 0.8)	1.1 (0.8 to 1.4)	89.7 (79.7 to 100.8)	-3.7 (-8.6 to 0.6)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	56.1 (34.7 to 81.4)	-14.5 (-23.5 to -5.3)
Foreign body in eyes	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	98.6 (76.3 to 121.7)	-0.0 (-9.1 to 9.0)
Foreign body in other body part	-	-	-	-	0.3 (0.2 to 0.4)	0.6 (0.5 to 0.8)	100.7 (87.1 to 115.1)	-1.4 (-7.6 to 5.1)
Other unintentional injuries	-	-	-	-	1.7 (1.3 to 2.1)	2.9 (2.2 to 3.8)	74.3 (63.3 to 87.2)	-15.0 (-20.0 to -9.2)
Self-harm and interpersonal violence	-	-	-	-	0.6 (0.4 to 0.7)	1.8 (1.4 to 2.3)	228.1 (209.8 to 246.3)	69.0 (61.6 to 77.0)
Self-harm	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	159.3 (136.2 to 185.3)	23.7 (13.7 to 34.6)
Interpersonal violence	-	-	-	-	0.5 (0.4 to 0.7)	1.7 (1.3 to 2.2)	234.1 (214.4 to 253.7)	73.6 (65.6 to 82.4)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	235.2 (209.1 to 261.8)	78.7 (66.3 to 91.7)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.5)	275.1 (246.6 to 307.7)	91.0 (77.5 to 106.7)
Assault by other means	-	-	-	-	0.3 (0.3 to 0.4)	1.1 (0.8 to 1.4)	221.4 (198.8 to 249.1)	66.8 (57.6 to 78.3)
Forces of nature, war, and legal intervention	-	-	-	-	32.1 (14.2 to 68.0)	28.6 (12.2 to 62.8)	-11.7 (-28.2 to 11.2)	-45.1 (-54.9 to -29.9)
Exposure to forces of nature	-	-	-	-	15.4 (6.1 to 33.7)	9.4 (3.8 to 21.1)	-38.8 (-42.7 to -34.8)	-60.2 (-64.2 to -55.2)
Collective violence and legal intervention	-	-	-	-	16.7 (6.3 to 38.3)	19.2 (7.7 to 46.4)	-29.7 (-19.3 to 61.3)	-29.7 (-49.1 to -1.7)

Appendix Table G.4 - Suriname prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	39.6 (28.9 to 51.8)	54.3 (40.3 to 70.8)	38.7 (23.1 to 45.1)	7.4 (-20.1 to -2.1)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	5.7 (4.0 to 8.0)	6.8 (4.8 to 9.5)	19.3 (11.5 to 27.7)	-2.2 (-8.7 to 4.8)
HIV/AIDS and tuberculosis	-	-	-	-	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.8)	259.9 (159.8 to 428.4)	138.5 (73.7 to 249.2)
Tuberculosis	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.4)	49.2 (43.0 to 55.9)	-0.6 (-4.6 to 3.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	49.1 (35.0 to 65.4)	0.4 (-8.9 to 10.9)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.6)	593.1 (264.7 to 1,652.6)	369.4 (131.5 to 1,138.5)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	560.4 (240.5 to 1,584.4)	321.0 (114.3 to 979.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	531.1 (195.7 to 1,607.8)	301.9 (89.3 to 994.8)
HIV/AIDS resulting in other diseases	0.5 (0.2 to 1.1)	3.3 (2.5 to 4.3)	635.6 (252.7 to 1,644.0)	427.3 (150.5 to 1,156.1)	0.0 (0.0 to 0.1)	0.3 (0.2 to 0.6)	593.2 (262.6 to 1,667.0)	370.1 (130.4 to 1,159.3)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	1.0 (0.7 to 1.3)	1.0 (0.7 to 1.4)	3.2 (-4.0 to 11.3)	-13.1 (-18.8 to -6.7)
Diarrheal diseases	2.7 (2.6 to 2.9)	2.9 (2.8 to 3.1)	7.2 (0.2 to 16.1)	-3.9 (-10.2 to 3.8)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	6.5 (-2.2 to 15.7)	-11.2 (-3.9 to 4.8)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-78.8 to -15.0)	-48.7 (-82.4 to -29.5)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.2 (-36.8 to -10.7)	-37.7 (-47.7 to -26.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.2 (-37.0 to -10.5)	-37.7 (-47.7 to -26.8)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.7 (-39.2 to -2.3)	-35.2 (-48.7 to -19.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.7 (-39.2 to -2.0)	-35.2 (-48.8 to -19.9)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-96.8 (-99.8 to 55.3)	-97.4 (-99.8 to 55.3)
Lower respiratory infections	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	19.1 (-4.6 to 56.4)	-0.2 (-18.1 to 28.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.7 (-2.8 to 31.9)	0.7 (-20.2 to 31.9)
Upper respiratory infections	21.3 (19.0 to 23.5)	26.5 (24.0 to 29.1)	24.6 (5.9 to 43.5)	-2.1 (-16.6 to 12.9)	0.3 (0.1 to 0.4)	0.3 (0.2 to 0.5)	24.5 (5.6 to 43.9)	-1.8 (-16.3 to 13.2)
Otitis media	4.8 (4.5 to 5.0)	5.2 (4.9 to 5.5)	8.8 (2.3 to 16.9)	-11.7 (-17.0 to -5.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	6.7 (-1.3 to 16.7)	-13.2 (-19.3 to -5.2)
Meningitis	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-54.7 (-67.6 to -37.0)	-64.7 (-74.3 to -51.3)
Pneumococcal meningitis	0.6 (0.4 to 1.0)	0.3 (0.2 to 0.4)	-58.6 (-69.8 to -45.4)	-69.7 (-77.6 to -60.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-56.2 (-72.0 to -30.8)	-65.9 (-77.9 to -48.4)
H influenzae type B meningitis	0.3 (0.1 to 0.6)	0.1 (0.0 to 0.2)	-61.1 (-72.6 to -38.8)	-70.4 (-78.3 to -52.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.4 (-74.6 to -24.7)	-66.8 (-79.7 to -40.4)
Meningococcal meningitis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-58.6 (-74.1 to -39.6)	-69.6 (-80.2 to -53.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.6 (-78.6 to -32.3)	-67.5 (-83.2 to -47.7)
Other meningitis	0.3 (0.1 to 0.6)	0.1 (0.1 to 0.2)	-53.5 (-65.6 to -36.0)	-65.0 (-74.2 to -51.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-50.5 (-68.5 to -21.2)	-61.3 (-74.8 to -40.2)
Encephalitis	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	9.6 (-6.5 to 28.2)	-24.4 (-34.1 to -10.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.9 (-9.9 to 37.7)	-3.9 (-34.4 to -3.9)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.8 (-93.7 to 843.9)	-32.9 (-94.2 to 605.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.8 (-93.7 to 859.9)	-32.9 (-94.3 to 607.6)
Whooping cough	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-59.7 (-61.9 to -57.5)	-59.7 (-61.9 to -57.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-59.6 (-68.2 to -49.2)	-59.6 (-68.1 to -49.2)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-76.1 (-89.2 to -60.2)	-81.5 (-91.8 to -69.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-75.5 (-87.6 to -56.3)	-80.3 (-89.7 to -65.0)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	0.3 (0.3 to 0.3)	0.4 (0.3 to 0.4)	22.5 (3.6 to 44.7)	-0.6 (-18.3 to 20.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (8.9 to 119.7)	-0.6 (-29.5 to 43.6)
Neglected tropical diseases and malaria	-	-	-	-	0.4 (0.2 to 0.6)	0.6 (0.4 to 0.9)	41.4 (13.6 to 91.7)	16.8 (-7.4 to 57.2)
Malaria	1.7 (1.4 to 2.2)	1.8 (1.4 to 2.2)	2.0 (-20.2 to 34.7)	-17.6 (-35.8 to 8.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.2 (-31.9 to 50.4)	-21.0 (-43.6 to 19.3)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.4 (23.5 to 83.6)	10.4 (-9.2 to 34.2)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.6 (-44.7 to 103.3)	-12.5 (50.6 to 85.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.6 (-44.8 to 105.5)	-12.5 (50.8 to 85.8)
Cutaneous and mucocutaneous leishmaniasis	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	50.8 (28.4 to 76.7)	10.9 (-7.7 to 30.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.3 (23.8 to 85.0)	11.0 (-9.2 to 34.5)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	3.8 (1.4 to 8.2)	5.4 (2.0 to 11.4)	39.5 (35.9 to 42.9)	0.2 (-2.1 to 2.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	38.7 (15.9 to 59.9)	1.7 (-12.8 to 17.0)
Cysticercosis	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-44.5 (-80.6 to 51.6)	-60.5 (-85.4 to 2.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-42.4 (-81.5 to 57.4)	-58.9 (-85.7 to 10.7)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.3 (32.6 to 58.1)	-5.5 (-14.9 to 0.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.8 (12.7 to 86.3)	-5.5 (-26.8 to 18.5)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.1 (0.0 to 0.3)	0.8 (0.3 to 1.9)	545.0 (543.5 to 546.8)	393.3 (392.1 to 394.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.3)	542.2 (464.4 to 650.1)	394.1 (336.6 to 467.3)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.0 (-44.8 to -2.4)	-39.9 (-59.2 to 24.0)
Intestinal nematode infections	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	60.1 (5.3 to 154.1)	24.0 (-28.7 to 103.3)
Ascariasis	8.7 (6.6 to 11.6)	10.0 (7.8 to 12.9)	15.3 (-21.8 to 63.8)	-14.3 (-41.2 to 24.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.0 (-99.8 to -95.7)	-99.1 (-99.8 to -96.2)
Trichuriasis	6.0 (4.6 to 7.7)	2.6 (2.0 to 3.4)	-57.1 (-69.4 to -36.4)	-68.5 (-77.6 to -52.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.2 (-99.9 to -90.7)	-99.4 (-99.9 to -92.7)
Hookworm disease	19.8 (16.2 to 23.9)	37.1 (30.4 to 45.4)	86.5 (42.5 to 149.0)	85.0 (3.8 to 87.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	91.0 (17.7 to 218.7)	46.1 (-13.5 to 148.5)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	5.8 (4.6 to 7.1)	6.0 (5.7 to 6.4)	3.4 (-15.8 to 30.7)	-10.7 (-26.2 to 11.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	0.5 (-12.1 to 42.7)	-11.8 (-23.7 to 23.5)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.2 (-16.2 to 28.4)	-14.1 (-30.4 to 4.2)
Maternal hemorrhage	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.5 (11.5 to 40.8)	-2.4 (-13.1 to 9.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.4 (4.9 to 45.1)	-3.2 (-18.0 to 12.5)
Maternal sepsis and other maternal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.8 (-16.8 to 22.5)	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.5 (-28.0 to 17.1)	-32.1 (-47.1 to -13.3)
Maternal hypertensive disorders	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-14.5 (-5.3 to 13.9)	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.2 (-24.4 to 39.7)	-14.7 (-37.0 to 13.4)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.7 (-40.6 to 56.0)	-16.2 (-49.4 to 33.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.7 (-40.6 to 58.5)	-16.2 (-49.5 to 34.4)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.6 (-44.4 to 140.6)	-2.9 (-53.6 to 81.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.6 (-46.9 to 141.0)	-2.9 (-53.7 to 82.6)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.5 (-39.9 to 63.0)	-13.4 (-51.2 to 33.9)
Neonatal disorders	-	-	-	-	0.5 (0.4 to 0.8)	1.0 (0.6 to 1.4)	86.3 (15.2 to 168.6)	50.5 (-6.5 to 116.9)
Preterm birth complications	1.8 (1.0 to 3.3)	4.8 (2.6 to 8.9)	166.5 (93.0 to 257.0)	106.3 (51.6 to 174.4)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.8)	155.5 (32.6 to 335.1)	102.7 (-5.7 to 247.5)
Neonatal encephalopathy due to birth asphyxia and trauma	2.7 (0.7 to 7.3)	3.3 (1.0 to 8.4)	22.2 (-3.6 to 61.0)	5.9 (-24.7 to 26.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	33.1 (-20.9 to 115.7)	8.9 (-34.5 to 77.5)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	109.2 (97.3 to 120.0)	109.2 (95.9 to 118.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.4 (91.8 to 130.5)	109.9 (90.4 to 128.9)
Hemolytic disease and other neonatal jaundice	0.3 (0.1 to 0.7)	0.4 (0.2 to 0.7)	47.9 (-45.9 to 312.0)	18.4 (-56.1 to 229.4)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.3)	47.7 (-43.0 to 317.4)	18.2 (-53.9 to 233.6)
Other neonatal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	105.3 (20.2 to 266.8)	66.0 (-2.7 to 196.8)
Nutritional deficiencies	-	-	-	-	3.4 (2.3 to 5.0)	3.5 (2.4 to 5.1)	3.1 (-2.0 to 7.0)	-15.2 (-19.8 to -12.0)
Protein-energy malnutrition	1.3 (0.7 to 2.4)	0.9 (0.5 to 1.6)	-22.2 (-69.8 to 56.4)	-32.7 (-69.4 to 51.3)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	0.1 (-70.0 to 58.4)	-32.6 (-69.6 to 54.2)
Iodine deficiency	0.5 (0.4 to 0.7)	0.5 (0.4 to 0.6)	-13.6 (-42.4 to 22.2)	-37.8 (-58.3 to -11.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.1 (-42.2 to 23.4)	-37.5 (-58.1 to -11.2)
Vitamin A deficiency	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-43.2 (-53.8 to -32.0)	-52.3 (-60.0 to -42.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.2 (-53.6 to -30.7)	-53.3 (-61.3 to -42.7)

Appendix Table G.4 - Suriname prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	101.6 (100.3 to 102.9)	111.4 (110.4 to 112.3)	9.7 (7.9 to 11.5)	-3.1 (-14.4 to -11.7)	3.2 (2.2 to 4.7)	3.4 (2.3 to 4.9)	5.1 (2.4 to 6.9)	-14.2 (-16.2 to -12.6)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	-	-
Sexually transmitted diseases excluding HIV	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-	-
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.7 (24.5 to 82.3)	-13.4 (-27.4 to 1.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Chlamydial infection	11.3 (9.5 to 13.1)	13.7 (11.5 to 16.1)	22.9 (-6.4 to 53.4)	-5.1 (-27.0 to 17.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-	-
Gonococcal infection	1.3 (1.0 to 1.7)	1.6 (1.2 to 2.0)	20.6 (-13.6 to 68.3)	-4.3 (-31.3 to 30.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trichomoniasis	3.0 (1.9 to 4.2)	3.7 (2.6 to 4.9)	26.7 (-20.0 to 124.8)	-7.0 (-39.5 to 58.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Genital herpes	91.3 (86.3 to 96.3)	135.3 (128.6 to 142.4)	48.2 (37.7 to 59.9)	-4.7 (-11.3 to 2.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-	-
Other sexually transmitted diseases	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	28.4 (10.6 to 54.1)	-16.7 (-28.4 to -0.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hepatitis A	0.5 (0.5 to 0.5)	0.5 (0.5 to 0.6)	5.7 (5.5 to 5.9)	-9.7 (-10.2 to -9.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hepatitis B	20.0 (14.6 to 25.1)	14.8 (12.4 to 17.6)	25.1 (-43.8 to -1.6)	-47.7 (-62.2 to -32.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hepatitis C	6.7 (5.9 to 7.4)	7.6 (6.8 to 8.3)	13.7 (-1.2 to 33.5)	-26.1 (-35.3 to -14.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hepatitis E	-	-	24.5 (12.8 to 40.8)	-1.0 (-10.4 to 12.3)	-	-	-	-
Leprosy	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	15.4 (-19.9 to 104.0)	-31.9 (-52.3 to 19.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other infectious diseases	4.3 (3.5 to 5.2)	4.5 (4.3 to 4.8)	4.6 (-4.5 to 12.2)	-11.9 (-18.9 to -5.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-	-
Non-communicable diseases	-	-	-	-	28.8 (21.4 to 37.3)	44.8 (33.5 to 58.2)	55.4 (50.4 to 59.9)	23.8 (-0.4 to 5.9)
Neoplasms	-	-	-	-	0.3 (0.2 to 0.4)	0.7 (0.5 to 0.9)	132.1 (86.4 to 194.2)	38.0 (10.2 to 73.9)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.1 (15.5 to 133.0)	-11.5 (-36.5 to 25.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Stomach cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	9.1 (-17.2 to 44.4)	-39.6 (-53.9 to -21.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	616.1 (256.9 to 1,233.1)	315.3 (111.0 to 670.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,992.2 (983.1 to 3,643.4)	1,034.7 (498.4 to 1,917.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	210.4 (61.3 to 494.2)	73.0 (-10.8 to 230.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	194.2 (54.3 to 414.4)	69.3 (-13.0 to 195.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Larynx cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	65.2 (16.5 to 137.1)	-8.0 (-34.4 to 31.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Tracheal, bronchus and lung cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	72.0 (30.6 to 127.3)	-3.4 (-25.7 to 25.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Breast cancer	0.6 (0.5 to 0.7)	1.1 (0.8 to 1.5)	95.7 (36.4 to 173.3)	11.7 (-21.7 to 53.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	-	-
Cervical cancer	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	11.6 (-25.9 to 69.9)	-44.3 (-56.0 to -1.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-	-
Uterine cancer	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.5)	161.4 (19.3 to 343.7)	44.3 (-32.9 to 142.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Prostate cancer	0.4 (0.3 to 0.6)	2.0 (1.2 to 3.0)	343.0 (184.6 to 577.8)	137.5 (52.1 to 265.8)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	-	-
Colon and rectum cancer	0.3 (0.2 to 0.3)	0.7 (0.5 to 0.9)	157.1 (101.6 to 226.8)	42.4 (12.4 to 79.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	-	-
Lip and oral cavity cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	69.0 (22.5 to 130.4)	-5.3 (-31.6 to 29.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.2 (-9.7 to 100.4)	-20.6 (-47.1 to 15.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	58.0 (0.1 to 147.8)	-14.0 (-45.3 to 33.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.6 (-61.6 to 81.5)	-66.0 (-79.1 to -0.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	735.2 (531.2 to 1,001.3)	357.7 (245.4 to 505.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Malignant skin melanoma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	28.9 (-6.5 to 91.4)	-23.0 (-43.1 to 13.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Non-melanoma skin cancer	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	217.9 (143.8 to 313.9)	73.2 (30.7 to 125.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Ovarian cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	452.6 (278.7 to 709.1)	242.0 (135.3 to 390.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	588.2 (16.2 to 1,423.8)	345.3 (-23.8 to 887.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Kidney cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	43.0 (9.4 to 87.3)	-14.1 (-34.4 to 12.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Bladder cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	14.9 (-18.6 to 99.1)	-38.5 (-56.3 to 4.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	461.4 (59.3 to 681.5)	345.2 (25.3 to 501.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Thyroid cancer	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	116.7 (46.8 to 211.4)	36.9 (-8.2 to 96.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	362.9 (178.1 to 364.2)	102.0 (54.1 to 155.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	1,051.4 (46.9 to 1,674.5)	805.5 (12.6 to 1,250.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Non-Hodgkin lymphoma	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	93.5 (35.0 to 165.3)	22.4 (-15.1 to 68.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	159.3 (54.3 to 336.0)	42.6 (-15.2 to 139.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leukemia	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	43.0 (16.9 to 111.3)	-14.1 (-6.0 to 62.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neoplasms	0.4 (0.4 to 0.6)	1.1 (0.9 to 1.4)	146.3 (86.5 to 230.0)	79.5 (38.0 to 135.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-	-
Cardiovascular diseases	-	-	-	-	0.4 (0.3 to 0.5)	0.9 (0.6 to 1.2)	140.9 (94.1 to 192.9)	34.1 (10.5 to 60.4)
Rheumatic heart disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.2 (28.6 to 80.6)	-6.5 (-21.5 to 9.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Ischemic heart disease	2.1 (1.8 to 2.5)	6.9 (5.7 to 8.5)	217.9 (151.4 to 323.4)	70.0 (34.9 to 124.6)	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.5)	-	-
Cerebrovascular disease	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	82.6 (47.0 to 128.1)	0.5 (-1.9 to 27.6)
Ischemic stroke	0.6 (0.5 to 0.7)	1.1 (0.9 to 1.3)	80.0 (44.7 to 130.0)	-1.9 (-22.1 to 27.8)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	-	-
Hemorrhagic stroke	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.4)	81.7 (28.5 to 139.3)	-0.5 (-31.0 to 36.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	-	-
Hypertensive heart disease	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.4)	56.7 (37.3 to 76.2)	-15.4 (-26.2 to -4.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cardiomyopathy and myocarditis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	81.2 (53.6 to 109.3)	5.4 (-12.2 to 24.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Atrial fibrillation and flutter	0.6 (0.5 to 0.7)	1.8 (1.4 to 2.3)	209.7 (141.6 to 338.2)	62.9 (22.1 to 132.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	-	-
Peripheral vascular disease	9.7 (7.5 to 12.3)	17.4 (14.0 to 20.7)	81.5 (23.5 to 144.9)	-2.8 (-32.1 to 26.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.2 (-12.9 to 55.2)	-27.4 (-45.1 to 0.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other cardiovascular and circulatory diseases	1.2 (0.6 to 2.2)	1.9 (1.6 to 2.4)	61.2 (-14.3 to 227.5)	-7.4 (-50.0 to 92.8)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	-	-
Chronic respiratory diseases	-	-	-	-	2.2 (1.5 to 3.0)	3.2 (2.2 to 4.3)	45.0 (20.8 to 70.3)	-7.8 (-22.4 to 7.4)
Chronic obstructive pulmonary disease	15.5 (14.7 to 16.2)	26.1 (24.8 to 27.3)	68.7 (64.1 to 73.8)	-0.4 (-2.9 to 2.6)	1.0 (0.6 to 1.3)	1.8 (1.1 to 2.5)	81.8 (51.9 to 121.4)	7.7 (-8.8 to 32.3)

Appendix Table G.4 - Suriname prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	64.2	-5.3
Silicosis	0.0	0.0	52.5	-12.3	0.0	0.0	51.9	-12.7
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	74.5	0.9	0.0	0.0	73.6	0.3
Asthma	21.1	27.2	28.4	-10.5	0.9	1.2	27.8	-10.3
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	81.0	3.4	0.0	0.0	81.8	3.6
Other chronic respiratory diseases	-	-	-	-	0.3	0.2	-27.1	-56.5
Cirrhosis	-	-	-	-	0.0	0.0	61.9	3.3
Cirrhosis due to hepatitis B	0.0	0.0	45.4	-9.2	0.0	0.0	47.3	-7.6
Cirrhosis due to hepatitis C	0.0	0.0	90.5	17.2	0.0	0.0	87.7	16.4
Cirrhosis due to alcohol use	0.0	0.0	43.2	-16.7	0.0	0.0	44.7	-15.9
Cirrhosis due to other causes	0.0	0.0	67.0	25.9	0.0	0.0	62.9	22.8
Digestive diseases	-	-	-	-	0.5	0.9	74.2	5.3
Peptic ulcer disease	2.7	2.7	0.2	-43.6	0.1	0.1	13.2	-36.9
Gastritis and duodenitis	7.2	11.3	58.2	-3.5	0.2	0.3	53.7	-1.8
Appendicitis	0.0	0.0	18.4	-8.3	0.0	0.0	20.9	-6.8
Paralytic ileus and intestinal obstruction	0.0	0.0	39.4	11.0	0.0	0.0	37.4	8.9
Inguinal, femoral, and abdominal hernia	1.2	1.4	8.4	-40.6	0.0	0.0	9.7	-39.4
Inflammatory bowel disease	0.4	0.8	106.4	27.4	0.1	0.2	107.2	28.8
Vascular intestinal disorders	0.0	0.0	71.2	-0.5	0.0	0.0	71.2	-0.5
Gallbladder and biliary diseases	0.2	0.3	16.4	-1.4	0.0	0.0	16.5	-31.4
Pancreatitis	0.0	0.1	140.7	50.7	0.0	0.0	142.1	52.9
Other digestive diseases	-	-	-	-	0.0	0.1	640.6	349.6
Neurological disorders	-	-	-	-	2.5	3.8	54.4	2.9
Alzheimer disease and other dementias	2.0	3.7	87.5	0.4	0.3	0.5	91.2	2.0
Parkinson disease	0.0	0.1	82.5	-1.5	0.0	0.0	85.6	0.3
Epilepsy	0.9	1.6	67.4	24.8	0.3	0.5	71.6	28.4
Multiple sclerosis	0.0	0.1	201.5	85.8	0.0	0.0	188.9	78.5
Migraine	40.9	54.5	34.2	1.8	0.4	0.5	41.5	2.0
Tension-type headache	80.1	118.4	48.7	2.5	0.1	0.2	49.0	3.2
Medication overuse headache	1.8	3.6	101.0	29.5	0.3	0.6	101.7	30.3
Other neurological disorders	0.0	0.0	40.0	-1.0	0.1	0.1	38.5	-26.2
Mental and substance use disorders	-	-	-	-	9.4	13.2	41.2	0.8
Schizophrenia	1.0	1.6	56.0	-0.6	0.7	1.0	56.6	0.4
Alcohol use disorders	2.4	3.9	58.4	9.2	0.4	0.4	59.2	10.1
Drug use disorders	-	-	-	-	0.5	0.7	36.3	1.5
Opioid use disorders	0.3	0.4	64.3	0.9	0.1	0.2	66.1	1.7
Cocaine use disorders	0.7	1.0	45.9	1.5	0.1	0.1	47.3	5.9
Amphetamine use disorders	0.8	0.9	13.8	-3.7	0.1	0.1	14.2	-3.1
Cannabis use disorders	0.7	0.8	20.0	-0.3	0.0	0.0	20.2	-0.2
Other drug use disorders	-	-	-	-	0.2	0.3	28.9	1.1
Depressive disorders	-	-	-	-	3.5	5.0	44.1	0.5
Major depressive disorder	14.8	21.1	42.5	-0.3	3.0	4.3	42.4	0.5
Dysthymia	4.6	7.2	56.2	0.2	0.4	0.7	56.4	0.7
Bipolar disorder	2.9	4.2	43.7	-0.3	0.6	0.9	43.4	0.4
Anxiety disorders	23.3	32.8	40.9	0.3	2.1	3.0	40.6	0.7
Eating disorders	-	-	-	-	0.1	0.2	19.7	1.9
Anorexia nervosa	0.1	0.1	26.2	6.4	0.0	0.0	25.6	5.8
Bulimia nervosa	0.5	0.6	18.0	1.0	0.1	0.1	18.7	1.3
Autistic spectrum disorders	-	-	-	-	0.5	0.6	29.9	-0.1
Autism	1.2	1.6	30.4	-0.4	0.3	0.4	30.1	0.1
Asperger syndrome	1.8	2.4	29.7	-0.2	0.2	0.2	29.4	-0.2
Attention-deficit/hyperactivity disorder	3.4	3.7	11.7	-0.6	0.0	0.0	11.8	-0.5
Conduct disorder	4.4	3.4	-22.7	0.6	0.0	0.0	4.4	-0.1
Idiopathic intellectual disability	1.0	1.2	17.8	-8.9	0.1	0.1	17.2	-8.9
Other mental and substance use disorders	6.2	9.1	47.1	-0.5	0.5	0.7	47.2	0.3
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	3.0	5.3	72.5	10.8
Diabetes mellitus	19.8	41.1	104.6	23.7	1.4	2.9	110.2	22.9
Acute glomerulonephritis	0.0	0.0	30.5	10.4	0.0	0.0	30.5	10.4
Chronic kidney disease	-	-	-	-	0.5	0.8	53.7	1.7
Chronic kidney disease due to diabetes mellitus	9.2	16.2	72.5	4.1	0.1	0.2	74.0	6.1
Chronic kidney disease due to hypertension	6.0	9.0	48.4	6.1	0.2	0.2	51.0	-3.1
Chronic kidney disease due to glomerulonephritis	13.4	20.2	51.5	2.2	0.1	0.1	50.9	8.7
Chronic kidney disease due to other causes	13.2	18.6	40.7	-2.9	0.2	0.2	42.8	-0.2
Urinary diseases and male infertility	-	-	-	-	0.1	0.2	68.8	-1.3

Appendix Table G.4 - Suriname prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	88.2 (68.4 to 113.4)	0.0 (20.7 to 48.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.2 (49.2 to 135.2)	33.6 (9.4 to 62.4)
Urolithiasis	2.4 (1.7 to 3.2)	4.8 (3.3 to 7.6)	100.0 (60.3 to 180.1)	7.8 (-7.7 to 59.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	92.4 (64.4 to 166.1)	14.3 (-2.1 to 59.0)
Benign prostatic hyperplasia	2.0 (1.8 to 2.2)	3.4 (3.1 to 3.7)	69.6 (49.7 to 95.2)	-6.7 (-18.3 to 8.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	72.2 (51.6 to 97.8)	-5.3 (-17.3 to 10.0)
Male infertility due to other causes	3.1 (2.5 to 3.9)	4.3 (3.5 to 5.3)	37.2 (4.0 to 88.9)	1.0 (-29.1 to 39.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	35.3 (5.0 to 90.5)	1.2 (-29.0 to 42.2)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (22.9 to 180.6)	0.0 (52.9 to 70.2)
Gynecological diseases	-	-	-	-	0.5 (0.3 to 0.8)	0.8 (0.5 to 1.2)	46.4 (28.0 to 64.8)	-2.6 (-14.1 to 9.7)
Uterine fibroids	6.9 (6.2 to 7.5)	12.4 (11.3 to 13.4)	78.3 (75.8 to 81.1)	-1.7 (-1.8 to -1.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	51.7 (36.9 to 63.6)	-9.7 (-18.2 to -3.1)
Polycystic ovarian syndrome	7.4 (6.5 to 8.4)	11.1 (10.0 to 12.3)	51.1 (27.3 to 78.0)	0.9 (-13.7 to 17.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	50.9 (27.8 to 78.8)	1.3 (-13.2 to 18.0)
Female infertility due to other causes	2.8 (1.7 to 4.5)	4.1 (2.3 to 6.1)	51.5 (-25.3 to 173.6)	4.7 (-50.2 to 94.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-24.8 to 162.1)	0.0 (-49.6 to 92.2)
Endometriosis	0.7 (0.6 to 0.8)	1.1 (0.9 to 1.3)	54.9 (21.0 to 90.5)	2.1 (-20.0 to 24.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	54.5 (18.7 to 93.6)	2.3 (-21.7 to 27.7)
Genital prolapse	19.4 (15.7 to 22.6)	32.0 (25.8 to 37.0)	63.9 (26.7 to 119.4)	0.6 (-20.8 to 30.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	63.8 (25.6 to 118.3)	0.9 (-21.4 to 30.8)
Premenstrual syndrome	18.4 (14.0 to 23.3)	24.9 (17.7 to 31.7)	36.4 (-10.7 to 99.5)	-0.1 (-34.9 to 48.7)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	36.6 (-11.8 to 100.4)	0.2 (-31.0 to 51.0)
Other gynecological diseases	1.5 (1.3 to 1.8)	1.9 (1.7 to 2.1)	24.0 (-6.2 to 61.4)	-11.3 (-33.1 to 16.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	18.4 (-5.0 to 91.4)	-14.3 (-31.8 to 38.1)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.4 (0.2 to 0.5)	0.4 (0.3 to 0.6)	18.9 (10.7 to 30.8)	-4.9 (-11.6 to 4.2)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.0 (-8.8 to 12.0)	-4.5 (-15.4 to 3.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.7 (1.5 to 12.8)	-1.1 (-5.8 to 4.4)
Thalassemia trait	4.0 (2.3 to 5.4)	5.1 (3.0 to 6.9)	28.3 (20.1 to 33.6)	-3.0 (-9.2 to 0.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	29.2 (10.2 to 49.2)	0.3 (-14.4 to 15.5)
Sickle cell disorders	0.3 (0.3 to 0.3)	0.4 (0.3 to 0.4)	26.1 (15.6 to 44.9)	2.4 (-6.4 to 16.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	33.9 (16.6 to 52.4)	4.4 (-7.9 to 18.2)
Sickle cell trait	27.1 (24.6 to 29.4)	36.5 (33.1 to 39.7)	34.3 (30.2 to 38.0)	1.5 (-1.5 to 4.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	28.7 (9.3 to 56.4)	3.5 (-11.8 to 29.9)
G6PD deficiency	37.9 (32.1 to 43.4)	46.4 (39.7 to 52.6)	22.6 (-1.6 to 54.7)	-7.1 (-25.4 to 17.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.4 (-16.7 to 131.5)	6.3 (-37.1 to 78.3)
G6PD trait	72.3 (67.7 to 76.4)	98.2 (92.4 to 104.3)	35.9 (25.1 to 48.3)	2.3 (-5.8 to 11.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.8 (62.5 to 1,095.9)	68.1 (-6.4 to 726.3)
Other hemoglobinopathies and hemolytic anemias	4.6 (4.2 to 5.0)	5.0 (4.7 to 5.3)	8.6 (-1.4 to 19.6)	-16.8 (-23.5 to -9.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-1.5 (-15.2 to 18.2)	-19.5 (-31.0 to -4.7)
Endocrine, metabolic, blood, and immune disorders	1.5 (1.0 to 4.9)	12.6 (4.6 to 5.3)	74.5 (-1.0 to 29.5)	12.6 (-20.9 to 1.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	9.7 (-4.4 to 35.5)	-12.6 (-24.4 to 9.5)
Musculoskeletal disorders	-	-	-	-	4.4 (3.1 to 5.8)	7.8 (5.5 to 10.2)	78.4 (62.2 to 99.1)	9.4 (0.6 to 21.5)
Rheumatoid arthritis	0.8 (0.8 to 0.9)	1.8 (1.7 to 1.9)	118.7 (104.4 to 133.6)	40.6 (30.9 to 50.4)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	117.1 (98.9 to 139.1)	40.9 (29.2 to 53.9)
Osteoarthritis	10.7 (10.3 to 11.1)	20.2 (19.5 to 21.0)	89.6 (79.6 to 99.6)	2.5 (-2.9 to 7.8)	0.6 (0.4 to 0.9)	1.2 (0.9 to 1.7)	91.3 (80.9 to 102.7)	3.6 (-2.0 to 9.5)
Low back and neck pain	-	-	-	-	2.9 (2.0 to 3.9)	4.6 (3.2 to 6.2)	59.1 (39.0 to 83.2)	1.4 (-9.9 to 15.3)
Low back pain	15.9 (14.3 to 17.7)	24.9 (22.4 to 27.5)	57.1 (31.7 to 79.7)	0.2 (-14.8 to 13.5)	1.8 (1.2 to 2.5)	2.8 (1.8 to 3.9)	57.3 (31.6 to 80.9)	1.0 (-14.4 to 15.2)
Neck pain	11.4 (9.7 to 13.4)	18.6 (16.1 to 21.1)	61.5 (32.1 to 110.5)	1.0 (-15.7 to 29.1)	1.1 (0.7 to 1.6)	1.8 (1.2 to 2.5)	61.9 (32.3 to 110.5)	1.7 (-14.8 to 30.3)
Gout	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	70.0 (48.2 to 91.4)	-5.4 (-16.6 to 5.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.7 (33.5 to 117.9)	-4.6 (-25.1 to 21.3)
Other musculoskeletal disorders	6.8 (3.8 to 9.4)	16.6 (13.4 to 20.0)	138.5 (98.3 to 266.2)	37.2 (13.2 to 105.6)	1.5 (0.3 to 1.0)	1.5 (1.0 to 2.2)	139.3 (98.0 to 278.1)	38.4 (12.9 to 111.9)
Other non-communicable diseases	-	-	-	-	6.2 (4.2 to 9.0)	9.0 (6.0 to 13.2)	45.3 (40.6 to 50.6)	-4.5 (-7.9 to -1.5)
Congenital anomalies	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.7)	50.0 (31.5 to 71.7)	13.8 (0.0 to 30.0)
Neural tube defects	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	22.2 (-4.4 to 55.4)	2.4 (-19.6 to 30.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.1 (-15.3 to 78.5)	5.3 (-28.3 to 49.5)
Congenital heart anomalies	1.2 (0.9 to 1.5)	1.9 (1.6 to 2.2)	60.0 (22.2 to 119.5)	29.3 (-1.4 to 77.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	55.7 (21.1 to 111.4)	26.7 (-1.9 to 72.0)
Orofacial clefts	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	46.2 (5.1 to 113.0)	24.3 (-10.6 to 81.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.0 (-15.8 to 126.3)	17.5 (-28.7 to 89.7)
Down syndrome	0.3 (0.3 to 0.4)	0.5 (0.4 to 0.6)	47.1 (21.6 to 83.1)	12.7 (-6.9 to 40.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	54.7 (25.2 to 97.3)	14.4 (-7.3 to 44.9)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.3 (-14.8 to 100.3)	5.6 (-33.2 to 57.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.6 (-17.0 to 109.9)	5.4 (-35.2 to 63.4)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.8 (-14.1 to 99.3)	4.8 (-34.2 to 52.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	42.1 (-11.1 to 106.8)	5.1 (-34.1 to 53.3)
Chromosomal unbalanced rearrangements	0.6 (0.5 to 0.7)	0.8 (0.7 to 1.0)	41.8 (8.5 to 87.6)	0.1 (-17.3 to 43.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	48.3 (13.1 to 96.4)	9.2 (-16.7 to 45.2)
Other congenital anomalies	1.7 (1.4 to 2.0)	2.0 (1.7 to 2.3)	19.1 (9.4 to 31.5)	-12.1 (-19.0 to -3.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	51.8 (24.7 to 86.5)	14.0 (-5.7 to 38.8)
Skin and subcutaneous diseases	-	-	-	-	2.0 (1.3 to 3.2)	2.8 (1.8 to 4.3)	36.5 (25.1 to 46.8)	1.1 (-6.5 to 7.8)
Dermatitis	19.1 (15.5 to 22.8)	26.8 (21.8 to 32.1)	40.9 (35.6 to 45.0)	0.0 (-0.0 to 0.1)	0.5 (0.3 to 0.7)	0.7 (0.4 to 1.0)	36.9 (31.5 to 42.4)	0.5 (-2.2 to 3.5)
Psoriasis	2.2 (2.8 to 3.6)	4.7 (4.1 to 5.3)	47.6 (44.4 to 51.7)	0.0 (-0.1 to 0.1)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	47.6 (38.4 to 57.0)	0.7 (-4.7 to 6.4)
Cellulitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.4 (7.3 to 44.2)	-13.0 (-23.7 to -2.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.8 (-1.4 to 52.5)	-12.0 (-27.8 to 5.3)
Pyoderma	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	63.9 (52.0 to 73.6)	22.3 (16.8 to 27.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.3 (41.4 to 89.0)	22.0 (8.4 to 39.7)
Scabies	5.3 (4.5 to 6.1)	6.7 (5.8 to 7.9)	28.3 (2.9 to 58.2)	1.1 (-18.7 to 22.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	28.0 (23.0 to 38.6)	1.0 (-18.9 to 25.0)
Fungal skin diseases	29.4 (22.4 to 38.9)	41.9 (32.5 to 55.3)	42.6 (35.9 to 49.9)	0.2 (-0.3 to 0.1)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.5)	42.5 (35.5 to 50.1)	0.2 (-0.7 to 1.3)
Viral skin diseases	8.7 (6.5 to 11.1)	10.4 (7.7 to 13.1)	18.6 (14.1 to 25.7)	0.1 (-2.0 to 2.2)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	18.4 (12.7 to 26.2)	0.3 (-3.3 to 3.9)
Acne vulgaris	31.5 (23.7 to 40.3)	33.9 (21.5 to 45.5)	7.7 (-34.3 to 66.9)	-8.2 (-43.6 to 41.4)	0.3 (0.2 to 0.7)	0.4 (0.2 to 0.8)	7.7 (-34.3 to 67.9)	-8.1 (-43.9 to 41.7)
Alopecia areata	0.4 (0.3 to 0.4)	0.5 (0.5 to 0.6)	44.9 (27.4 to 65.4)	-0.7 (-12.3 to 13.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.0 (21.5 to 71.5)	0.3 (-14.5 to 17.0)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.6 (22.9 to 96.5)	0.2 (-20.1 to 28.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.6 (22.5 to 96.7)	0.2 (-20.3 to 28.1)
Urticaria	3.6 (2.6 to 4.9)	6.2 (4.5 to 7.6)	73.5 (14.2 to 148.5)	11.8 (-22.2 to 54.1)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	73.4 (13.2 to 152.0)	12.8 (-21.5 to 57.0)
Decubitus ulcer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	37.7 (8.1 to 78.0)	-21.7 (-40.7 to 6.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.3 (1.5 to 89.8)	-19.8 (-44.6 to 14.2)
Other skin and subcutaneous diseases	22.2 (14.9 to 33.3)	35.4 (23.0 to 55.3)	59.3 (46.3 to 72.7)	-0.8 (-4.7 to 3.0)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.4)	59.5 (45.8 to 72.9)	-0.2 (-4.1 to 3.9)
Sense organ diseases	-	-	-	-	2.6 (1.8 to 3.7)	3.8 (2.5 to 5.3)	65.9 (38.8 to 94.0)	-9.8 (-13.8 to -5.3)
Glaucoma	0.5 (0.4 to 0.6)	0.7 (0.6 to 0.9)	36.0 (18.0 to 56.2)	-18.5 (-29.7 to -6.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	44.1 (21.6 to 68.4)	-16.9 (-31.3 to -2.2)
Cataract	2.3 (1.7 to 2.9)	3.1 (2.4 to 3.8)	34.2 (20.9 to 50.4)	-27.9 (-34.5 to -19.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	38.3 (25.0 to 51.5)	-26.0 (-32.6 to -18.9)
Macular degeneration	0.6 (0.4 to 0.7)	1.1 (0.8 to 1.4)	101.5 (47.8 to 145.3)	10.3 (-20.5 to 35.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	101.7 (51.8 to 147.1)	10.2 (-17.9 to 36.3)
Uncorrected refractive error	35.0 (32.7 to 37.3)	54.4 (51.2 to 57.9)	55.5 (43.2 to 70.3)	4.7 (-11.2 to 3.6)	0.5 (0.3 to 0.9)	0.8 (0.4 to 1.2)	45.1 (36.2 to 56.8)	-9.6 (-14.7 to -3.0)
Age-related and other hearing loss	51.3 (47.8 to 55.0)	79.0 (73.9 to 84.9)	53.8 (48.2 to 61.7)	-9.4 (-12.1 to -6.7)	1.6 (1.1 to 2.2)	2.3 (1.6 to 3.3)	50.0 (39.8 to 62.7)	-8.7 (-13.8 to -1.3)
Other vision loss	1.2 (1.0 to 1.3)	1.2 (1.0 to 1.4)	3.0 (-8.6 to 12.8)	-32.0 (-38.2 to -26.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	12.4 (-3.7 to 27.5)	-30.0 (-38.1 to -22.4)
Other sense organ diseases	9.2 (8.8 to 9.6)	12.1 (11.6 to 12.7)	31.4 (23.5 to 40.7)	-0.6 (-6.1 to 6.2)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	31.1 (22.0 to 41.2)	0.1 (-6.2 to 7.2)
Oral disorders	-	-	-	-	1.2 (0.7 to 1.8)	1.9 (1.2 to 2.9)	58.3 (55.0 to 64.5)	-3.4 (-6.7 to 0.1)
Deciduous caries	33.2 (31.9 to 34.3)	34.3 (33.1 to 35.6)	3.2 (-1.9 to 9.7)	0.0 (-5.0 to 6.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.4 (-3.3 to 13.0)	0.3 (-7.3 to 9.7)
Permanent caries	182.1 (173.8 to 190.9)	244.3 (235.7 to 254.2)	34.0 (25.8 to 42.8)	-0.4 (-6.2 to 5.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.5)	34.0 (25.3 to 42.8)	-0.2 (-6.1 to 5.7)
Periodontal diseases	40.5 (38.5 to 42.6)	65.2 (62.1 to 68.4)	61.0 (50.3 to 72.6)	-2.4 (-9.0 to 4.7)	0.3 (0.1 to 0.5)	0.4 (0.2 to 0.9)	61.4 (50.2 to 73.2)	-2.0 (-8.6 to 5.1)

Appendix Table G.4 - Suriname prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes								
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	20.0 (19.4 to 20.8)	34.1 (32.9 to 35.5)	70.1 (62.2 to 79.1)	-6.3 (-10.5 to -1.5)	0.5 (0.4 to 0.8)	0.9 (0.6 to 1.3)	71.4 (62.5 to 81.4)	5.4 (-10.0 to -0.3)
Other oral disorders	6.7 (6.3 to 7.1)	9.5 (9.0 to 10.1)	43.1 (31.9 to 54.1)	0.0 (-7.6 to 7.7)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	42.9 (31.6 to 54.8)	0.4 (-7.7 to 8.4)
Injuries	-	-	-	-	5.1 (2.6 to 10.5)	2.8 (2.0 to 3.9)	-40.6 (-69.0 to -7.1)	-64.8 (-81.6 to -42.9)
Transport injuries	-	-	-	-	0.8 (0.6 to 1.0)	0.9 (0.6 to 1.2)	15.3 (0.9 to 32.6)	-25.8 (-34.6 to -15.6)
Road injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.8 (0.6 to 1.1)	9.6 (4.5 to 26.9)	24.4 (-37.8 to -19.0)
Pedestrian road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-4.2 (-17.8 to 13.5)	-37.4 (-45.5 to -27.0)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	21.3 (7.9 to 35.6)	-23.0 (-31.2 to -14.1)
Motorcyclist road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	0.0 (-13.2 to 16.5)	-36.3 (-44.4 to -26.4)
Motor vehicle road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	17.9 (14.4 to 37.7)	-23.9 (-33.8 to -12.1)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.2 (-16.9 to 10.2)	-40.1 (-47.5 to -32.0)
Other transport injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	90.0 (68.9 to 113.2)	18.3 (5.3 to 32.9)
Unintentional injuries	-	-	-	-	1.2 (0.9 to 1.6)	1.4 (1.0 to 1.9)	15.5 (6.4 to 25.3)	-27.0 (-32.8 to -20.9)
Falls	-	-	-	-	0.5 (0.3 to 0.6)	0.6 (0.4 to 0.7)	17.3 (3.9 to 31.9)	-30.7 (-38.9 to -21.7)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.4 (-20.9 to 7.6)	-39.1 (-47.0 to -29.4)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-13.5 (-24.6 to -1.2)	-41.7 (-48.3 to -33.9)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.8 (-22.4 to 11.4)	-33.8 (-44.7 to -22.5)
Exposure to mechanical forces	-	-	-	-	0.5 (0.4 to 0.7)	0.5 (0.4 to 0.7)	-2.1 (-8.9 to 5.6)	-32.6 (-36.9 to -27.8)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	65.3 (45.6 to 90.1)	9.6 (-3.1 to 24.5)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.9 (34.7 to 73.5)	3.4 (-7.7 to 16.3)
Other exposure to mechanical forces	-	-	-	-	0.5 (0.4 to 0.6)	0.4 (0.3 to 0.6)	-7.2 (-13.5 to 0.0)	-36.0 (-40.1 to -31.5)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.5 (87.1 to 109.2)	23.9 (17.3 to 31.3)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.8 (70.5 to 107.9)	22.6 (11.5 to 33.5)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.8 (69.3 to 114.6)	27.4 (13.7 to 41.0)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.5 (66.3 to 107.4)	19.4 (7.5 to 31.9)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.1 (9.7 to 35.6)	-21.3 (-28.1 to -12.6)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.3 (-21.6 to 10.9)	-36.9 (-45.9 to -25.6)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.7 (15.3 to 52.2)	-10.1 (-20.8 to 2.8)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.2 (24.5 to 54.0)	-13.6 (-21.0 to -4.5)
Other unintentional injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	81.2 (65.7 to 98.1)	4.0 (-4.1 to 13.4)
Self-harm and interpersonal violence	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	12.4 (0.4 to 29.0)	-28.8 (-36.6 to -18.8)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.2 (5.0 to 21.1)	-34.4 (-41.4 to -26.1)
Interpersonal violence	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	13.8 (0.4 to 32.0)	-27.3 (-35.9 to -16.5)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.5 (39.9 to 74.0)	-2.2 (-11.3 to 8.9)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.1 (3.0 to 38.4)	-24.1 (-34.1 to -12.4)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-10.0 (-23.0 to 6.8)	-41.8 (-49.8 to -31.6)
Forces of nature, war, and legal intervention	-	-	-	-	3.0 (0.7 to 8.4)	0.4 (0.1 to 0.9)	-86.9 (-91.9 to -79.0)	-91.6 (-94.8 to -86.2)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	3.0 (0.7 to 8.4)	0.4 (0.1 to 0.9)	-87.0 (-91.9 to -79.1)	-91.6 (-94.8 to -86.2)

Appendix Table G.4 - Swaziland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	79.4 (57.5 to 104.5)	138.1 (102.0 to 180.9)	74.5 (61.1 to 83.6)	74.5 (4.8 to 18.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	23.7 (15.6 to 36.0)	50.3 (35.6 to 68.4)	115.4 (65.9 to 158.5)	73.4 (23.4 to 118.5)
HIV/AIDS and tuberculosis	-	-	-	-	2.0 (1.4 to 2.6)	24.1 (16.7 to 32.1)	1,120.4 (913.7 to 1,360.9)	610.6 (482.7 to 766.9)
Tuberculosis	5.8 (5.3 to 6.2)	14.4 (13.7 to 15.1)	149.6 (135.3 to 166.2)	38.2 (30.7 to 46.7)	1.8 (1.2 to 2.4)	4.3 (3.0 to 5.8)	147.3 (131.3 to 165.7)	36.7 (28.4 to 45.5)
HIV/AIDS	-	-	-	-	1.7 (0.2 to 0.3)	1.7 (13.5 to 26.5)	8.723.6 (6,913.8 to 10,977.5)	5,133.5 (4,738.3 to 7,825.6)
HIV/AIDS resulting in mycobacterial infection	0.1 (0.1 to 0.2)	6.2 (4.7 to 7.3)	4,896.5 (3,586.4 to 7,247.1)	2,970.8 (2,179.1 to 4,414.0)	0.0 (0.0 to 0.1)	2.3 (1.4 to 3.1)	4,811.5 (3,418.4 to 7,326.7)	2,915.6 (2,075.7 to 4,437.4)
HIV/AIDS resulting in other diseases	2.5 (2.0 to 2.9)	154.1 (141.4 to 164.9)	6,041.5 (5,286.2 to 7,500.7)	4,181.1 (3,616.2 to 5,130.6)	0.2 (0.1 to 0.2)	17.5 (11.8 to 23.7)	9,755.7 (7,630.7 to 12,507.3)	7,143.1 (5,457.0 to 9,235.7)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	2.9 (2.0 to 3.9)	3.1 (2.2 to 4.1)	8.8 (0.9 to 16.5)	-13.7 (-19.2 to -8.0)
Diarrheal diseases	10.1 (9.4 to 10.9)	10.2 (9.5 to 10.8)	0.6 (-9.0 to 10.7)	-11.7 (-19.3 to -3.8)	1.7 (1.1 to 2.3)	1.7 (1.1 to 2.3)	0.1 (-9.7 to 11.1)	-12.3 (-20.2 to -3.6)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Typhoid fever	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-14.3 (-33.7 to 7.4)	-37.2 (-51.0 to -22.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.8 (-35.5 to 16.1)	-36.7 (-51.7 to -16.7)
Paratyphoid fever	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	9.8 (-16.4 to 43.0)	-17.6 (-37.3 to 7.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.8 (-19.3 to 49.9)	-16.9 (-38.3 to 9.3)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Lower respiratory infections	1.1 (0.9 to 1.4)	1.2 (1.0 to 1.3)	1.4 (-20.6 to 35.2)	-13.4 (-30.2 to 10.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	1.1 (-23.4 to 37.3)	-13.7 (-31.4 to 12.3)
Upper respiratory infections	13.2 (12.5 to 13.8)	18.7 (17.8 to 19.5)	42.3 (32.4 to 53.2)	0.4 (-6.0 to 7.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	41.6 (29.7 to 54.5)	-0.2 (-7.6 to 8.3)
Otitis media	16.3 (14.8 to 18.0)	21.6 (19.7 to 23.8)	32.8 (21.7 to 45.2)	-6.7 (-14.0 to 1.6)	0.2 (0.2 to 0.5)	0.4 (0.2 to 0.6)	32.6 (20.3 to 46.7)	-6.4 (-14.2 to 3.5)
Meningitis	-	-	-	-	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.9)	12.2 (-3.7 to 36.1)	-24.1 (-33.1 to -8.9)
Pneumococcal meningitis	1.3 (0.8 to 2.0)	1.5 (0.9 to 2.4)	16.0 (-7.2 to 53.7)	-22.0 (-37.4 to 2.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	0.1 (-18.0 to 58.6)	24.4 (-42.0 to 1.8)
H influenzae type B meningitis	1.4 (0.5 to 2.8)	1.6 (0.6 to 3.1)	9.7 (-17.1 to 47.6)	-27.3 (-43.6 to -1.2)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	19.9 (-26.0 to 76.0)	-18.2 (-49.0 to 19.1)
Meningococcal meningitis	0.9 (0.3 to 2.0)	1.0 (0.3 to 2.3)	8.6 (-18.6 to 38.9)	-28.9 (-45.2 to -9.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	7.4 (-23.7 to 47.9)	-29.2 (-48.5 to -6.3)
Other meningitis	1.3 (0.7 to 2.4)	1.6 (0.9 to 2.7)	16.8 (-10.5 to 48.8)	-20.3 (-38.8 to 11.7)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	16.3 (-20.4 to 63.8)	-20.5 (-43.9 to 9.3)
Encephalitis	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.4)	60.3 (34.5 to 83.7)	-5.9 (-10.4 to 1.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.4 (30.5 to 100.3)	5.7 (-11.3 to 25.7)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	127.5 (83.4 to 4,005.7)	108.7 (-79.3 to 2,490.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	127.5 (83.5 to 4,084.0)	108.7 (-79.5 to 2,495.0)
Whooping cough	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.8)	50.3 (46.8 to 53.9)	44.9 (41.5 to 48.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.4 (31.3 to 71.9)	44.9 (26.6 to 66.3)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-68.8 (-86.7 to -26.1)	-78.7 (-90.8 to -49.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-74.1 (-87.1 to -50.5)	-81.6 (-89.5 to -67.0)
Measles	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	74.9 (-78.2 to -71.0)	-76.2 (-79.3 to -72.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.3 (-81.9 to -60.6)	-75.7 (-82.8 to -63.0)
Varicella and herpes zoster	0.5 (0.5 to 0.6)	0.8 (0.7 to 0.9)	53.9 (30.7 to 75.8)	2.5 (-20.8 to 32.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.5 (7.0 to 140.2)	0.6 (-34.9 to 56.5)
Neglected tropical diseases and malaria	-	-	-	-	9.1 (4.5 to 18.1)	11.6 (5.8 to 22.5)	32.8 (-14.7 to 64.2)	-12.8 (-47.5 to 10.7)
Malaria	1.5 (0.9 to 2.1)	1.0 (0.7 to 1.4)	-29.8 (-33.6 to -21.6)	-39.2 (-42.3 to -31.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-20.3 (-33.1 to -6.6)	-34.6 (-44.5 to -20.1)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.5 (-14.1 to 154.0)	12.8 (-28.0 to 72.1)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.5 (-13.7 to 153.4)	12.8 (-27.8 to 71.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.5 (-14.1 to 154.0)	12.8 (-28.0 to 72.1)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.5 (-7.9 to 96.6)	2.5 (-28.7 to 34.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.5 (-7.9 to 97.0)	2.5 (-28.8 to 35.3)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	227.5 (105.2 to 390.8)	290.1 (135.0 to 501.4)	26.8 (21.0 to 38.8)	-20.1 (-23.7 to -12.7)	2.1 (0.9 to 4.7)	2.7 (1.1 to 5.9)	25.8 (6.1 to 41.9)	-20.2 (-30.1 to -11.2)
Cysticercosis	0.8 (0.3 to 1.5)	0.7 (0.3 to 1.2)	-19.9 (-67.7 to 146.9)	-61.6 (-80.7 to -1.2)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	0.2 (-67.0 to 169.1)	-59.0 (-79.7 to 6.5)
Cystic echinococcosis	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.4)	70.1 (48.9 to 103.3)	-27.2 (-39.1 to -19.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.3 (33.6 to 127.0)	-27.0 (-42.4 to -11.0)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.8 (-39.5 to 68.8)	-23.3 (-52.8 to 24.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.8 (-39.6 to 69.4)	-23.3 (-52.9 to 24.4)
Intestinal nematode infections	-	-	-	-	3.3 (2.0 to 5.3)	4.7 (2.8 to 7.6)	45.2 (35.5 to 54.8)	-0.7 (-8.6 to 7.1)
Ascariasis	181.9 (128.2 to 256.6)	265.7 (182.2 to 382.8)	45.6 (-11.2 to 141.1)	0.5 (-45.8 to 81.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	36.6 (19.0 to 58.7)	-0.8 (-16.9 to 19.1)
Trichuriasis	395.9 (304.3 to 515.1)	578.1 (418.2 to 790.1)	45.6 (-3.5 to 118.1)	0.2 (-39.8 to 62.8)	1.1 (0.6 to 1.8)	1.5 (0.8 to 2.6)	41.4 (25.2 to 60.1)	-0.6 (-14.6 to 16.4)
Hookworm disease	344.6 (277.1 to 428.5)	521.4 (409.8 to 658.5)	51.6 (8.5 to 109.6)	2.0 (-32.8 to 46.6)	3.0 (1.3 to 3.2)	3.0 (1.8 to 4.7)	49.7 (35.9 to 61.0)	-0.9 (-9.7 to 8.8)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	13.2 (10.2 to 16.3)	14.7 (13.6 to 16.1)	11.3 (-10.5 to 44.0)	-7.9 (-24.4 to 16.2)	3.5 (1.1 to 8.9)	3.9 (1.4 to 9.7)	29.7 (-57.1 to 140.0)	-12.5 (-73.9 to 68.6)
Maternal disorders	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	3.3 (-8.7 to 17.5)	-40.8 (-47.6 to -33.5)
Maternal hemorrhage	0.7 (0.6 to 0.8)	1.1 (0.7 to 1.4)	55.2 (3.9 to 103.4)	-24.3 (-48.3 to -0.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	41.4 (-31.8 to 134.3)	-33.5 (-66.9 to 7.8)
Maternal sepsis and other maternal infections	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-20.9 (-31.8 to -4.8)	-53.0 (-60.4 to -44.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.1 (-51.3 to 46.2)	-53.3 (-70.2 to -24.9)
Maternal hypertensive disorders	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-4.3 (-14.3 to 5.5)	-49.6 (-53.1 to -45.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.9 (-25.7 to 18.4)	-49.9 (-59.3 to -38.3)
Obstructed labor	0.7 (0.7 to 0.8)	0.8 (0.7 to 0.8)	0.9 (-5.6 to 7.6)	-40.1 (-43.9 to -36.5)	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-0.1 (-11.9 to 13.9)	-40.9 (-47.1 to -33.6)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.0 (-43.5 to 55.1)	-50.5 (-67.8 to -22.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.4 (-33.9 to 65.0)	-42.6 (-62.5 to -6.9)
Neonatal disorders	-	-	-	-	1.4 (0.8 to 2.4)	2.0 (1.1 to 3.3)	45.0 (-9.6 to 163.3)	-1.0 (-38.5 to 75.6)
Preterm birth complications	3.4 (1.8 to 6.1)	8.8 (4.8 to 15.6)	154.6 (90.3 to 259.7)	76.4 (34.0 to 136.0)	0.4 (0.2 to 0.6)	0.9 (0.5 to 1.5)	110.2 (14.1 to 347.8)	41.1 (-22.7 to 190.6)
Neonatal encephalopathy due to birth asphyxia and trauma	3.3 (0.6 to 9.7)	4.4 (0.7 to 13.7)	31.6 (-18.5 to 58.0)	7.7 (-38.9 to 77.9)	0.3 (0.1 to 0.5)	0.3 (0.1 to 0.5)	0.5 (-51.6 to 108.8)	-28.2 (-65.8 to 43.6)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	177.0 (151.5 to 196.5)	177.0 (148.1 to 192.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	177.0 (144.7 to 224.9)	177.0 (141.4 to 220.6)
Hemolytic disease and other neonatal jaundice	0.4 (0.2 to 0.8)	0.6 (0.3 to 1.1)	40.3 (-55.5 to 248.8)	-8.8 (-71.6 to 128.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	40.7 (-54.2 to 260.2)	-7.9 (-70.5 to 131.2)
Other neonatal disorders	-	-	-	-	0.5 (0.2 to 1.4)	0.7 (0.2 to 1.4)	24.9 (-46.9 to 194.7)	-15.5 (-63.6 to 102.6)
Nutritional deficiencies	-	-	-	-	7.3 (4.9 to 10.7)	8.0 (5.3 to 11.7)	9.3 (0.4 to 20.8)	-20.0 (-29.4 to -7.7)
Protein-energy malnutrition	1.2 (0.4 to 3.1)	1.1 (0.4 to 2.3)	8.0 (-73.4 to 259.2)	-10.5 (-70.8 to 186.5)	0.1 (0.0 to 0.4)	0.1 (0.0 to 0.3)	0.1 (-74.2 to 275.9)	-11.1 (-71.0 to 197.5)
Iodine deficiency	45.7 (18.6 to 71.6)	45.0 (25.3 to 67.8)	-4.6 (-53.0 to 172.8)	-42.3 (-73.3 to 73.6)	0.8 (0.3 to 1.5)	0.8 (0.4 to 1.4)	-4.9 (-53.1 to 168.9)	-42.6 (-73.3 to 73.8)
Vitamin A deficiency	1.0 (0.8 to 1.2)	0.8 (0.6 to 1.0)	-20.9 (-31.5 to -9.1)	-42.9 (-50.6 to -33.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-23.6 (-35.5 to -9.1)	-45.5 (-53.6 to -34.9)

Appendix Table G.4 - Swaziland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	186.9 (183.2 to 190.5)	219.8 (212.6 to 227.5)	17.6 (13.3 to 22.1)	-13.9 (-17.4 to -10.1)	6.3 (4.2 to 9.2)	7.1 (4.7 to 10.2)	11.6 (7.6 to 18.4)	35.4 (-18.7 to -9.3)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-69.2 to 557.0)	28.6 (-65.6 to 436.8)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.7 (0.4 to 1.1)	1.0 (0.6 to 1.6)	39.5 (9.5 to 73.4)	-6.1 (-26.8 to 17.5)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.3 (0.1 to 0.5)	0.5 (0.2 to 0.8)	76.7 (3.7 to 185.6)	-3.8 (-38.0 to 46.7)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	19.7 (0.7 to 43.7)	-39.8 (-38.6 to -41.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-9.7 to 59.6)	-90.1 (-45.2 to -10.5)
Chlamydial infection	29.0 (21.9 to 39.0)	50.7 (36.2 to 67.9)	80.9 (2.7 to 173.6)	-0.7 (-40.0 to 50.4)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	107.9 (-48.8 to 411.3)	12.4 (-70.4 to 187.2)
Gonococcal infection	9.3 (6.0 to 13.1)	18.1 (12.5 to 23.9)	95.5 (13.5 to 245.7)	7.8 (-33.5 to 84.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	93.4 (2.6 to 260.8)	8.0 (-39.9 to 88.9)
Trichomoniasis	19.4 (10.4 to 32.7)	32.9 (17.8 to 58.1)	71.6 (-17.2 to 249.5)	-6.1 (-44.0 to 81.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	68.1 (-27.4 to 267.9)	-8.8 (-49.6 to 86.3)
Genital herpes	178.2 (167.3 to 187.5)	285.4 (269.4 to 304.0)	59.8 (46.9 to 76.1)	-5.7 (-12.8 to 2.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	99.4 (45.0 to 177.9)	-6.2 (-13.7 to 3.3)
Other sexually transmitted diseases	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	13.6 (-3.3 to 34.9)	-31.2 (-41.1 to -18.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.6 (-15.6 to 93.0)	-0.7 (-47.8 to 3.0)
Hepatitis	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	18.7 (5.0 to 45.5)	-26.2 (-44.3 to -7.1)
Hepatitis A	1.5 (1.4 to 1.5)	1.7 (1.7 to 1.8)	19.7 (18.3 to 21.2)	-5.3 (-5.4 to -5.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	44.1 (27.6 to 62.8)	-1.1 (-11.6 to 11.2)
Hepatitis B	103.9 (82.5 to 126.5)	100.6 (75.7 to 124.8)	-4.5 (-26.1 to 29.9)	-38.1 (-50.9 to -18.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	3.1 (-31.7 to 48.4)	-35.6 (-59.0 to -6.4)
Hepatitis C	20.3 (17.9 to 22.5)	24.7 (22.0 to 27.5)	22.4 (4.7 to 43.9)	-24.3 (-34.5 to -13.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.0 (-15.4 to 45.5)	-22.5 (-44.0 to 5.0)
Hepatitis E	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.2)	28.4 (7.1 to 55.7)	-24.6 (-35.7 to -7.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.0 (-8.8 to 80.3)	-24.5 (-45.7 to 3.4)
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.7 (21.5 to 105.6)	-7.8 (-26.0 to 20.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.7 (21.5 to 107.8)	-7.9 (-26.0 to 21.3)
Other infectious diseases	9.2 (7.2 to 11.2)	10.4 (9.4 to 11.5)	13.2 (0.4 to 30.3)	-8.8 (-18.2 to 2.7)	0.4 (0.2 to 0.6)	0.4 (0.3 to 0.7)	18.0 (-4.9 to 47.4)	-1.6 (-27.4 to 21.4)
Non-communicable diseases	-	-	-	-	52.3 (38.6 to 67.9)	83.5 (61.7 to 108.3)	59.1 (54.9 to 64.9)	2.4 (-4.8 to 1.0)
Neoplasms	-	-	-	-	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	112.1 (70.6 to 182.6)	20.7 (-3.4 to 55.9)
Esophageal cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	73.0 (14.0 to 156.7)	-0.2 (-33.3 to 45.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.2 (18.8 to 158.5)	0.8 (-31.6 to 47.6)
Stomach cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	101.1 (49.6 to 171.7)	8.9 (-20.6 to 48.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.1 (45.4 to 174.2)	6.7 (-23.3 to 48.4)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.3 (21.4 to 196.7)	2.7 (-29.1 to 60.9)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	192.7 (28.9 to 836.8)	81.4 (-20.3 to 485.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	175.1 (32.4 to 757.5)	71.8 (-17.9 to 432.2)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	284.7 (73.1 to 819.1)	116.1 (5.8 to 381.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	254.0 (80.8 to 706.7)	96.3 (7.0 to 313.6)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.2 (-39.1 to 108.5)	-33.6 (-62.9 to 19.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.6 (-34.6 to 85.0)	-36.2 (-61.0 to 10.3)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.4 (-43.0 to 99.4)	5.4 (-66.3 to 19.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.3 (-39.7 to 70.5)	-42.6 (-66.1 to 2.4)
Larynx cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	85.8 (-0.7 to 189.3)	6.9 (-39.8 to 64.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.9 (13.9 to 203.5)	9.1 (-32.5 to 69.9)
Tracheal, bronchus and lung cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	90.8 (32.7 to 158.2)	8.2 (-20.5 to 44.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.1 (32.8 to 159.7)	6.6 (-21.1 to 43.8)
Breast cancer	0.4 (0.2 to 0.5)	0.8 (0.5 to 1.2)	96.0 (34.9 to 388.8)	22.6 (-16.2 to 162.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	93.3 (29.6 to 364.9)	20.0 (-18.6 to 148.3)
Cervical cancer	0.6 (0.2 to 0.8)	0.6 (0.4 to 0.8)	127.4 (44.4 to 252.1)	19.6 (-24.0 to 90.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	124.4 (41.2 to 255.3)	17.0 (-27.4 to 85.4)
Uterine cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	83.9 (-13.7 to 237.7)	6.4 (-46.5 to 88.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.6 (-12.7 to 244.7)	8.3 (-46.2 to 88.3)
Prostate cancer	0.3 (0.2 to 0.5)	1.5 (0.9 to 2.3)	343.8 (164.8 to 738.2)	149.5 (52.8 to 353.4)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	334.2 (166.2 to 670.0)	142.1 (50.1 to 313.1)
Colon and rectum cancer	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.5)	105.3 (61.1 to 165.5)	22.2 (-4.2 to 58.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	105.1 (59.7 to 169.9)	21.1 (-5.3 to 61.7)
Lip and oral cavity cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	93.9 (13.0 to 196.8)	11.8 (-30.6 to 68.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.4 (18.1 to 209.7)	35.9 (-28.4 to 73.6)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.3 (-7.3 to 133.2)	-18.1 (-47.5 to 29.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-3.5 to 133.3)	-17.0 (-44.0 to 28.3)
Other pharynx cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	52.0 (-27.2 to 218.8)	-8.8 (-56.0 to 87.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.9 (-21.7 to 243.0)	-5.7 (-52.3 to 101.1)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.2 (-26.0 to 134.0)	-18.5 (-56.8 to 39.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.8 (-27.1 to 114.5)	-21.2 (-57.5 to 32.1)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.5 (18.5 to 129.5)	-2.9 (-29.2 to 35.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.2 (19.8 to 121.1)	-5.0 (-31.4 to 31.6)
Malignant skin melanoma	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	90.7 (32.6 to 230.4)	9.6 (-21.1 to 69.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.4 (35.5 to 230.2)	11.9 (-20.1 to 69.8)
Non-melanoma skin cancer	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.4)	346.0 (160.1 to 569.5)	121.2 (40.1 to 214.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	424.6 (180.0 to 767.3)	152.7 (43.0 to 295.7)
Ovarian cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	132.2 (9.5 to 531.0)	33.3 (-36.1 to 215.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	138.8 (10.0 to 578.6)	34.5 (-37.0 to 236.2)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	125.3 (29.4 to 289.9)	24.8 (-26.8 to 99.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	143.6 (34.1 to 334.5)	34.0 (-21.8 to 120.0)
Kidney cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	120.6 (21.2 to 277.3)	41.3 (-14.5 to 131.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	127.7 (24.6 to 280.8)	36.1 (-16.0 to 123.3)
Bladder cancer	0.4 (0.3 to 0.5)	0.1 (0.1 to 0.1)	-73.7 (-82.6 to -63.2)	-86.9 (-91.7 to -81.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-79.9 (-87.2 to -70.9)	-89.6 (-93.7 to -85.1)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	66.5 (10.2 to 166.6)	11.8 (-17.3 to 70.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.5 (16.7 to 165.9)	7.6 (-20.1 to 61.3)
Thyroid cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	96.9 (8.7 to 385.2)	10.0 (-37.4 to 123.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.8 (16.0 to 398.2)	17.1 (-33.3 to 121.8)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.5 (-1.0 to 136.9)	-11.8 (-42.7 to 35.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.7 (2.8 to 145.7)	-9.0 (-41.7 to 41.4)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	247.4 (6.7 to 300.2)	124.2 (6.7 to 300.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	242.4 (64.7 to 520.4)	110.3 (6.0 to 255.9)
Non-Hodgkin lymphoma	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.3)	139.6 (50.6 to 520.5)	44.1 (-7.0 to 254.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	136.1 (51.7 to 501.3)	40.0 (8.3 to 238.5)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	73.9 (9.8 to 197.1)	4.6 (-31.9 to 67.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.8 (6.9 to 191.6)	6.2 (-35.8 to 69.3)
Leukemia	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	76.5 (7.6 to 230.3)	23.4 (-13.7 to 116.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.0 (20.2 to 221.7)	34.8 (-17.7 to 107.1)
Other neoplasms	0.3 (0.2 to 0.4)	0.9 (0.6 to 1.5)	191.8 (93.8 to 417.1)	96.0 (41.2 to 236.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	178.8 (87.3 to 402.1)	78.2 (27.5 to 211.0)
Cardiovascular diseases	-	-	-	-	0.9 (0.6 to 1.3)	1.6 (1.1 to 2.2)	72.4 (31.2 to 115.0)	-2.4 (-22.8 to 19.8)
Rheumatic heart disease	0.6 (0.6 to 0.6)	0.9 (0.8 to 1.0)	53.9 (40.8 to 68.2)	-1.4 (-8.8 to 5.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	46.2 (14.0 to 81.0)	-7.4 (-28.2 to 15.6)
Ischemic heart disease	6.6 (5.4 to 8.1)	8.6 (6.9 to 10.4)	33.6 (-3.7 to 71.7)	-21.5 (-41.6 to -1.9)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.8)	33.5 (4.4 to 77.3)	-21.3 (-44.4 to 2.3)
Cerebrovascular disease	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	63.5 (23.5 to 105.3)	3.4 (-28.1 to 23.9)
Ischemic stroke	0.4 (0.4 to 0.5)	0.7 (0.6 to 0.8)	66.7 (24.5 to 110.9)	-2.2 (-28.0 to 26.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	64.6 (23.3 to 112.4)	-2.7 (-28.3 to 27.5)
Hemorrhagic stroke	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	60.5 (23.4 to 106.7)	-4.2 (-28.0 to 23.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.0 (20.9 to 109.5)	-4.0 (-29.6 to 26.2)
Hypertensive heart disease	0.5 (0.4 to 0.7)	1.0 (0.7 to 1.3)	90.9 (28.0 to 182.2)	8.2 (-28.3 to 62.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	88.8 (27.1 to 181.9)	7.5 (-28.4 to 62.8)
Cardiomyopathy and myocarditis	0.6 (0.5 to 0.8)	0.9 (0.7 to 1.1)	45.1 (2.2 to 104.6)	6.4 (-39.2 to 39.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	41.2 (-2.0 to 104.3)	8.4 (-39.6 to 37.2)
Atrial fibrillation and flutter	1.2 (0.9 to 1.5)	2.8 (2.2 to 3.5)	133.8 (76.2 to 226.9)	13.5 (-18.5 to 67.2)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	131.9 (75.6 to 222.8)	13.7 (-18.0 to 67.5)
Peripheral vascular disease	17.0 (12.7 to 20.7)	33.5 (25.6 to 41.4)	98.0 (44.9 to 170.4)	10.3 (-18.4 to 48.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.7 (-26.5 to 441.5)	-4.5 (-64.6 to 133.8)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.3 (-33.3 to 25.9)	-40.1 (-55.5 to -12.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.9 (-36.9 to 35.2)	-40.5 (-58.4 to -3.5)
Other cardiovascular and circulatory diseases	2.8 (1.5 to 4.6)	6.7 (2.7 to 10.3)	148.7 (6.3 to 415.9)	22.8 (-50.0 to 199.6)	0.2 (0.1 to 0.3)	0.5 (0.1 to 0.9)	147.8 (-7.8 to 409.7)	33.4 (-51.6 to 197.5)
Chronic respiratory diseases	-	-	-	-	3.9 (2.6 to 5.3)	5.4 (3.7 to 7.5)	39.4 (17.7 to 71.3)	-11.5 (-23.2 to 6.6)
Chronic obstructive pulmonary disease	28.1 (26.9 to 29.4)	45.9 (44.1 to 48.0)	63.3 (58.2 to 68.5)	-0.8 (-3.8 to 2.3)	2.5 (1.6 to 3.4)			

Appendix Table G.4 - Swaziland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	65.3	-3.9
Silicosis	0.0	0.0	59.3	-8.5	0.0	0.0	(60.2 to 71.2)	(-6.7 to -0.8)
Asbestosis	-	-	0.0	0.0	-	-	59.5	-8.4
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	69.5	0.5	0.0	0.0	70.4	0.9
Asthma	29.4	29.7	0.7	-33.3	1.3	1.3	4.7	-34.3
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	88.6	13.1	0.0	0.0	86.5	12.5
Other chronic respiratory diseases	-	-	-	-	0.1	0.2	43.3	-11.5
Cirrhosis	-	-	-	-	0.1	0.1	62.6	0.7
Cirrhosis due to hepatitis B	0.1	0.1	83.2	13.3	0.0	0.0	77.3	11.1
Cirrhosis due to hepatitis C	0.0	0.1	82.7	2.7	0.0	0.0	(-12.6 to 200.8)	(-45.6 to 85.1)
Cirrhosis due to alcohol use	0.1	0.1	44.7	-14.6	0.0	0.0	42.0	-15.8
Cirrhosis due to other causes	0.1	0.2	73.2	32.6	0.0	0.0	71.5	30.9
Digestive diseases	-	-	-	-	0.1	1.5	76.1	8.0
Peptic ulcer disease	4.1	5.5	33.1	-28.9	0.1	0.2	47.3	-21.8
Gastritis and duodenitis	8.4	14.1	67.6	11.6	0.4	0.6	61.0	14.8
Appendicitis	0.1	0.2	81.7	7.8	0.0	0.0	78.5	6.4
Paralytic ileus and intestinal obstruction	0.0	0.0	46.9	2.0	0.0	0.0	46.0	0.9
Inguinal, femoral, and abdominal hernia	1.7	2.4	38.4	-19.0	0.0	0.0	37.5	-19.1
Inflammatory bowel disease	0.7	1.5	110.8	26.1	0.2	0.2	108.2	24.6
Vascular intestinal disorders	0.0	0.0	42.3	-13.7	0.0	0.0	43.6	-11.1
Gallbladder and biliary diseases	0.2	0.5	121.6	21.0	0.0	0.0	121.2	21.3
Pancreatitis	0.1	0.2	81.0	6.8	0.0	0.1	80.3	7.7
Other digestive diseases	-	-	-	-	0.1	0.2	119.7	35.3
Neurological disorders	-	-	-	-	3.4	5.7	67.8	1.1
Alzheimer disease and other dementias	1.2	2.3	95.9	3.2	0.2	0.3	97.4	3.3
Parkinson disease	0.0	0.1	79.2	-0.0	0.0	0.0	77.8	0.0
Epilepsy	1.2	1.8	58.2	6.1	0.4	0.6	63.9	10.4
Multiple sclerosis	0.1	0.1	80.5	8.9	0.0	0.0	79.5	7.7
Migraine	90.2	97.4	8.2	-2.6	2.1	3.0	4.8	-2.3
Tension-type headache	98.8	172.8	75.0	3.7	0.1	0.3	74.0	2.8
Medication overuse headache	3.9	8.3	112.7	33.5	0.6	1.3	110.1	31.5
Other neurological disorders	0.0	0.0	40.6	-6.7	0.1	0.2	27.0	-33.0
Mental and substance use disorders	-	-	-	-	19.4	31.0	60.2	-2.1
Schizophrenia	1.6	2.7	68.7	-1.2	1.0	1.7	54.4	5.0
Alcohol use disorders	8.8	25.7	189.5	0.9	2.5	2.5	190.8	58.1
Drug use disorders	-	-	-	-	1.0	1.7	77.2	1.2
Opioid use disorders	1.2	2.0	69.1	1.7	0.5	0.8	65.5	-0.5
Cocaine use disorders	0.4	0.7	80.9	0.1	0.1	0.1	89.7	6.7
Amphetamine use disorders	1.3	2.5	93.6	4.2	0.2	0.3	92.6	3.5
Cannabis use disorders	1.1	2.1	82.1	4.0	0.0	0.1	81.1	3.3
Other drug use disorders	-	-	-	-	0.2	0.4	89.7	3.4
Depressive disorders	-	-	-	-	7.2	10.5	51.1	7.0
Major depressive disorder	31.5	47.4	51.4	-6.4	6.5	9.6	49.4	-7.6
Dysthymia	7.9	13.2	67.2	-1.3	0.8	1.3	65.6	-2.3
Bipolar disorder	4.4	7.7	75.7	-0.5	0.9	1.5	73.8	-1.9
Anxiety disorders	32.6	52.5	60.8	3.0	4.8	59.4	3.5	0.0
Eating disorders	-	-	-	-	0.2	0.4	65.6	-7.4
Anorexia nervosa	0.2	0.2	59.9	-6.7	0.0	0.1	60.2	-6.6
Bulimia nervosa	0.9	1.5	67.6	-6.9	0.2	0.3	66.6	-7.6
Autistic spectrum disorders	-	-	-	-	1.0	1.5	60.1	2.1
Autism	2.6	3.9	50.3	2.6	0.6	0.9	48.8	1.7
Asperger syndrome	3.7	5.5	50.2	3.4	0.4	0.5	49.2	2.6
Attention-deficit/hyperactivity disorder	6.5	9.3	42.2	1.5	0.1	0.1	42.0	1.3
Conduct disorder	9.6	13.6	42.4	1.1	1.1	1.6	42.4	6.0
Idiopathic intellectual disability	46.3	61.5	32.8	-13.3	2.3	3.0	32.6	-13.3
Other mental and substance use disorders	9.4	17.3	83.9	2.3	0.7	1.3	82.5	1.2
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	4.4	6.7	53.5	-1.5
Diabetes mellitus	20.0	34.0	71.0	4.8	1.3	2.2	68.0	2.3
Acute glomerulonephritis	0.0	0.0	9.9	9.1	0.0	0.0	9.9	9.1
Chronic kidney disease	-	-	-	-	1.4	2.1	51.3	-1.3
Chronic kidney disease due to diabetes mellitus	11.0	18.1	63.5	4.8	0.2	0.3	64.4	5.8
Chronic kidney disease due to hypertension	34.5	50.4	48.1	1.0	0.4	0.6	48.5	-2.9
Chronic kidney disease due to glomerulonephritis	29.4	46.4	57.7	4.5	0.5	0.7	49.5	0.0
Chronic kidney disease due to other causes	22.7	32.4	41.5	-6.9	0.3	0.4	44.2	-5.1
Urinary diseases and male infertility	-	-	-	-	0.2	0.4	88.6	5.2

Appendix Table G.4 - Swaziland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	61.5 (44.4 to 79.2)	0.0 (-5.5 to 13.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.8 (23.2 to 106.8)	2.9 (-15.5 to 26.4)
Urolithiasis	1.4 (1.1 to 1.9)	2.2 (1.7 to 2.9)	55.0 (39.3 to 79.0)	-11.3 (-19.9 to 1.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.1 (51.3 to 99.9)	2.6 (-7.9 to 14.6)
Benign prostatic hyperplasia	4.3 (3.9 to 4.6)	7.7 (6.9 to 8.4)	79.6 (58.3 to 105.2)	0.8 (-11.0 to 13.9)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	78.0 (56.9 to 103.5)	0.4 (-11.4 to 13.7)
Male infertility due to other causes	1.4 (1.0 to 1.9)	3.2 (2.3 to 4.3)	124.2 (45.9 to 245.4)	26.1 (-17.5 to 85.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	122.6 (38.6 to 254.9)	23.7 (-21.4 to 86.8)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	73.0 (76.1 to 373.1)	73.0 (7.6 to 185.5)
Gynecological diseases	-	-	-	-	0.8 (0.5 to 1.2)	1.2 (0.8 to 1.8)	56.2 (22.8 to 89.9)	-10.5 (-26.3 to 6.6)
Uterine fibroids	13.1 (11.8 to 14.2)	18.5 (16.7 to 20.2)	41.9 (40.5 to 43.1)	-6.9 (-7.4 to -6.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	30.7 (14.1 to 41.5)	-19.6 (-30.2 to -12.8)
Polycystic ovarian syndrome	12.7 (11.3 to 13.9)	19.8 (17.2 to 22.3)	55.5 (32.7 to 84.2)	-10.9 (-21.9 to 4.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	58.8 (32.9 to 85.3)	-11.0 (-21.5 to 3.9)
Female infertility due to other causes	1.6 (0.7 to 2.6)	2.8 (1.4 to 4.6)	80.5 (-21.7 to 326.9)	7.6 (-54.6 to 164.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.2 (-21.8 to 314.2)	6.2 (-53.7 to 157.3)
Endometriosis	1.3 (1.1 to 1.5)	1.7 (1.5 to 2.0)	36.3 (11.9 to 68.8)	-20.3 (-34.9 to -1.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	35.3 (8.4 to 71.6)	-21.1 (-37.0 to -1.2)
Genital prolapse	25.8 (22.2 to 29.7)	40.5 (33.0 to 47.6)	56.8 (23.6 to 97.8)	-3.8 (-21.8 to 17.3)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	56.0 (22.3 to 98.8)	-4.5 (-22.5 to 17.4)
Premenstrual syndrome	25.9 (15.1 to 37.3)	51.6 (30.3 to 71.6)	100.7 (-11.6 to 277.1)	7.7 (-44.5 to 129.7)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.7)	98.3 (-14.0 to 281.5)	7.1 (-45.7 to 129.2)
Other gynecological diseases	2.1 (1.5 to 2.5)	2.7 (2.0 to 3.4)	27.6 (-3.8 to 72.5)	-27.4 (-42.6 to -9.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	18.9 (-35.1 to 118.9)	-36.4 (-60.1 to 13.2)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	19.5 (3.1 to 46.9)	-8.1 (-19.4 to 10.1)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-62.5 (-80.8 to -43.8)	-75.8 (-89.5 to -62.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.7 (-81.7 to -46.5)	-77.1 (-90.0 to -64.6)
Thalassemia trait	4.0 (3.2 to 4.8)	5.5 (4.2 to 6.6)	44.7 (4.6 to 45.9)	-0.3 (-27.9 to 0.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	31.1 (10.6 to 51.8)	-0.1 (-14.1 to 13.4)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.6 (23.4 to 40.5)	-4.6 (-10.2 to 1.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.4 (30.4 to 55.3)	0.2 (-7.9 to 9.0)
Sickle cell trait	6.1 (5.3 to 6.9)	9.3 (7.8 to 10.8)	52.0 (41.5 to 67.6)	4.8 (-2.8 to 15.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	38.6 (-16.7 to 152.6)	6.5 (-30.7 to 91.0)
G6PD deficiency	17.1 (16.7 to 17.5)	26.4 (25.6 to 26.9)	54.4 (49.1 to 59.5)	7.1 (3.4 to 10.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.0 (27.0 to 59.3)	11.3 (1.9 to 21.2)
G6PD trait	104.5 (103.2 to 105.7)	142.6 (140.9 to 143.9)	36.4 (33.9 to 39.0)	-6.6 (-8.3 to -4.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.0 (-70.0 to 242.2)	-17.5 (-74.1 to 114.8)
Other hemoglobinopathies and hemolytic anemias	7.4 (6.0 to 8.6)	9.1 (8.0 to 10.1)	23.8 (6.0 to 51.1)	-10.5 (-21.9 to 3.3)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	13.4 (8.7 to 59.4)	-12.5 (-29.1 to 18.5)
Endocrine, metabolic, blood, and immune disorders	10.4 (9.4 to 11.5)	12.4 (10.9 to 13.6)	19.5 (2.7 to 36.7)	-0.4 (-19.7 to 0.4)	0.4 (0.2 to 0.5)	0.4 (0.3 to 0.6)	15.9 (-6.3 to 41.4)	9.6 (-22.6 to 6.7)
Musculoskeletal disorders	-	-	-	-	8.9 (6.4 to 11.8)	15.5 (11.0 to 20.4)	73.7 (58.1 to 95.0)	2.2 (-5.2 to 10.7)
Rheumatoid arthritis	2.4 (2.2 to 2.5)	4.5 (4.3 to 4.8)	90.9 (76.2 to 108.7)	2.0 (-5.7 to 10.9)	0.6 (0.4 to 0.7)	1.1 (0.8 to 1.4)	89.9 (72.6 to 111.7)	1.9 (-6.4 to 11.6)
Osteoarthritis	14.4 (13.8 to 15.0)	24.6 (23.6 to 25.6)	70.8 (60.6 to 81.0)	1.7 (-3.8 to 7.7)	0.6 (0.6 to 1.2)	2.0 (1.0 to 2.0)	69.0 (58.9 to 79.0)	1.2 (-4.4 to 7.1)
Low back and neck pain	-	-	-	-	6.4 (4.5 to 8.7)	11.3 (7.9 to 15.1)	75.5 (53.7 to 105.9)	3.2 (-7.3 to 15.8)
Low back pain	29.4 (27.5 to 31.2)	49.8 (46.9 to 53.0)	68.8 (55.7 to 86.2)	0.7 (-7.1 to 10.4)	3.3 (2.2 to 4.5)	5.5 (3.7 to 7.6)	66.9 (53.3 to 84.1)	-0.4 (-8.1 to 9.4)
Neck pain	32.0 (25.8 to 37.0)	59.7 (49.7 to 70.2)	85.5 (47.9 to 150.5)	8.1 (-13.6 to 34.9)	3.1 (2.1 to 4.6)	5.8 (3.9 to 8.2)	83.8 (45.8 to 150.0)	7.0 (-14.5 to 34.1)
Gout	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	59.6 (38.4 to 83.1)	-5.0 (-17.0 to 8.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.8 (26.1 to 101.0)	-4.8 (-25.1 to 19.9)
Other musculoskeletal disorders	11.6 (8.9 to 14.6)	18.7 (14.7 to 22.5)	61.4 (46.5 to 75.6)	1.1 (-7.6 to 8.8)	1.7 (0.7 to 1.5)	1.7 (1.1 to 2.4)	59.0 (41.7 to 73.9)	4.9 (-9.3 to 7.8)
Other non-communicable diseases	-	-	-	-	10.2 (6.6 to 15.2)	15.0 (9.7 to 22.5)	47.5 (40.8 to 54.9)	-7.2 (-10.2 to -4.2)
Congenital anomalies	-	-	-	-	0.7 (0.5 to 0.9)	0.8 (0.6 to 1.1)	20.3 (0.7 to 38.9)	-23.3 (-34.4 to -12.1)
Neural tube defects	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	9.6 (-12.8 to 40.2)	-27.9 (-42.5 to -7.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	7.4 (-30.1 to 55.4)	-27.9 (-52.6 to 3.4)
Congenital heart anomalies	2.2 (1.8 to 2.8)	2.6 (2.0 to 3.3)	14.4 (-15.9 to 56.8)	-27.2 (-45.5 to 0.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	13.7 (-16.8 to 55.6)	-25.9 (-45.0 to 1.8)
Orofacial clefts	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	20.7 (-18.0 to 82.5)	-17.5 (-44.1 to 24.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.5 (-20.9 to 89.7)	-18.7 (-46.2 to 28.6)
Down syndrome	0.6 (0.5 to 0.7)	0.7 (0.6 to 0.9)	20.5 (-9.7 to 51.0)	-27.8 (-45.6 to -8.6)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	16.2 (-15.1 to 51.4)	-33.6 (-51.0 to -13.7)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.9 (-29.5 to 64.8)	-31.7 (-58.5 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.5 (-31.9 to 73.3)	-32.6 (-61.1 to 0.6)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.1 (11.7 to 93.6)	-5.0 (-24.5 to 12.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.1 (29.1 to 128.1)	-0.1 (-20.5 to 39.3)
Chromosomal unbalanced rearrangements	1.1 (0.9 to 1.4)	1.3 (1.0 to 1.7)	17.7 (-15.0 to 52.9)	-29.7 (-48.6 to -7.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	17.0 (-19.4 to 50.7)	35.4 (-53.9 to -12.6)
Other congenital anomalies	2.2 (1.7 to 2.8)	3.0 (2.3 to 3.7)	32.9 (17.1 to 58.8)	-12.9 (-22.4 to 6.3)	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	27.2 (-1.4 to 62.3)	-15.2 (-31.9 to 4.4)
Skin and subcutaneous diseases	-	-	-	-	4.1 (2.5 to 6.5)	6.3 (4.0 to 10.1)	54.5 (41.3 to 68.4)	-0.5 (-7.7 to 6.9)
Dermatitis	34.5 (28.9 to 40.6)	53.9 (44.4 to 63.9)	56.2 (52.4 to 59.0)	-0.3 (-0.7 to 0.2)	1.1 (0.7 to 1.5)	1.6 (1.0 to 2.3)	51.0 (44.3 to 57.1)	-1.1 (-4.0 to 1.7)
Psoriasis	5.2 (4.5 to 6.0)	8.5 (7.3 to 9.8)	63.7 (61.2 to 66.3)	0.1 (-0.3 to 0.5)	0.4 (0.3 to 0.6)	0.7 (0.5 to 1.0)	62.1 (51.5 to 74.9)	-1.0 (-6.1 to 4.9)
Cellulitis	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	50.0 (29.8 to 70.4)	1.1 (-12.0 to 16.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.8 (13.7 to 92.1)	0.9 (-19.3 to 26.9)
Pyoderma	1.5 (1.1 to 2.0)	1.8 (1.4 to 2.3)	18.3 (8.3 to 30.8)	-4.0 (-10.4 to 3.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.7 (4.4 to 32.8)	-4.3 (-13.4 to 5.7)
Scabies	8.6 (7.5 to 9.7)	11.0 (9.8 to 12.2)	28.4 (8.7 to 52.3)	-13.7 (-26.5 to 9.9)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	27.8 (8.1 to 51.8)	-13.8 (-27.1 to 1.3)
Fungal skin diseases	92.6 (69.4 to 121.7)	145.2 (109.0 to 192.0)	56.3 (51.6 to 63.1)	0.8 (0.8 to 0.9)	1.2 (0.2 to 1.1)	0.8 (0.3 to 1.8)	56.7 (50.8 to 62.6)	0.7 (0.0 to 1.5)
Viral skin diseases	17.4 (13.4 to 21.2)	24.2 (18.2 to 30.2)	39.2 (29.9 to 49.2)	0.2 (-2.2 to 3.0)	0.5 (0.3 to 0.8)	0.7 (0.4 to 1.2)	38.8 (28.0 to 49.5)	0.0 (-3.7 to 4.0)
Acne vulgaris	77.2 (56.3 to 101.3)	120.4 (89.7 to 153.8)	52.3 (4.2 to 135.1)	-7.8 (-33.5 to 39.7)	0.8 (0.4 to 1.6)	1.3 (0.6 to 2.5)	52.4 (3.9 to 135.0)	-7.9 (-33.8 to 39.9)
Alopecia areata	0.7 (0.6 to 0.8)	1.1 (1.0 to 1.3)	55.6 (33.7 to 84.4)	1.9 (-12.2 to 20.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	54.6 (27.0 to 94.4)	1.0 (-15.3 to 23.8)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.1 (26.6 to 101.2)	4.7 (-17.4 to 30.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.1 (26.6 to 101.3)	4.7 (-17.5 to 30.8)
Urticaria	3.6 (2.5 to 4.8)	7.5 (4.7 to 11.1)	108.7 (5.7 to 287.4)	18.5 (-42.8 to 97.0)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.7)	107.1 (5.5 to 291.8)	17.5 (-43.6 to 94.6)
Decubitus ulcer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	73.3 (42.6 to 118.3)	-1.2 (-23.2 to 37.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.3 (38.3 to 120.9)	-1.2 (-24.9 to 38.1)
Other skin and subcutaneous diseases	40.3 (28.0 to 57.1)	65.4 (44.4 to 93.9)	62.2 (51.9 to 72.6)	0.5 (-3.3 to 3.2)	0.2 (0.1 to 0.5)	0.4 (0.2 to 0.8)	61.3 (51.1 to 71.8)	-0.0 (-3.9 to 3.1)
Sense organ diseases	-	-	-	-	4.1 (2.6 to 5.9)	5.8 (3.8 to 8.7)	42.2 (35.6 to 49.9)	-9.7 (-13.1 to -6.1)
Glaucoma	2.1 (1.7 to 2.5)	2.5 (2.1 to 3.0)	19.9 (-0.6 to 37.1)	-29.2 (-41.2 to -18.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	37.6 (3.2 to 66.7)	-19.6 (-39.1 to -0.6)
Cataract	2.9 (2.3 to 3.6)	3.9 (2.8 to 5.1)	34.7 (6.6 to 67.0)	-25.6 (-38.8 to -12.8)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	31.2 (-1.9 to 89.1)	-27.3 (-42.5 to -4.3)
Macular degeneration	1.0 (0.7 to 1.2)	1.5 (1.2 to 1.9)	59.0 (24.9 to 106.4)	-6.1 (-27.2 to 21.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	56.2 (23.0 to 97.7)	-9.5 (-29.1 to 11.0)
Uncorrected refractive error	90.9 (84.7 to 97.2)	139.1 (129.6 to 148.3)	53.1 (38.8 to 67.5)	-3.3 (-10.6 to 4.5)	1.3 (0.8 to 2.2)	1.9 (1.1 to 2.4)	42.4 (31.6 to 53.7)	-10.3 (-16.0 to -4.1)
Age-related and other hearing loss	80.4 (71.0 to 90.1)	122.9 (107.4 to 137.1)	52.9 (46.4 to 59.2)	-6.7 (-9.5 to -3.4)	1.6 (1.0 to 2.4)	2.4 (1.5 to 3.7)	50.2 (37.2 to 61.6)	-4.5 (-10.8 to 1.8)
Other vision loss	2.6 (2.2 to 3.1)	3.3 (2.8 to 3.9)	28.5 (13.9 to 42.5)	-20.0 (-30.5 to -12.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	26.6 (-3.0 to 51.6)	-21.3 (-40.0 to -7.3)
Other sense organ diseases	20.8 (19.6 to 21.9)	28.1 (26.5 to 29.6)	35.1 (25.7 to 46.7)	-0.2 (-6.6 to 6.1)	0.6 (0.3 to 0.8)	0.7 (0.5 to 1.1)	34.0 (23.9 to 46.6)	0.7 (-7.6 to 7.0)
Oral disorders	-	-	-	-	1.3 (0.8 to 2.0)	2.0 (1.3 to 3.2)	55.1 (48.0 to 61.3)	-7.1 (-12.0 to -3.8)
Deciduous caries	85.5 (82.0 to 89.0)	94.8 (91.2 to 98.4)	10.9 (5.1 to 17.5)	-0.8 (-5.9 to 5.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	11.0 (2.1 to 20.2)	0.7 (-8.6 to 7.9)
Permanent caries	356.8 (343.9 to 371.7)	575.4 (552.2 to 597.4)	61.3 (52.4 to 70.6)	1.2 (-3.2 to 6.3)	0.4 (0.2 to 0.7)	0.6 (0.3 to 1.1)	60.6 (51.8 to 70.2)	0.7 (-4.0 to 6.0)
Periodontal diseases	15.1 (14.3 to 15.9)	25.7 (24.4 to 27.0)	70.4 (58.2 to 84.5)	0.9 (-6.2 to 8.8)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	69.2 (56.9 to 84.0)	0.2 (-7.2 to 8.4)

Appendix Table G.4 - Swaziland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	17.6 (16.6 to 18.7)	26.4 (25.0 to 27.9)	50.2 (38.0 to 62.1)	-12.0 (-18.8 to -5.6)	0.5 (0.3 to 0.7)	0.7 (0.5 to 1.0)	48.9 (36.1 to 61.1)	-22.4 (-19.4 to -5.6)
Other oral disorders	12.1 (11.4 to 12.8)	19.3 (18.0 to 20.6)	59.4 (43.6 to 73.8)	-1.5 (-9.8 to 6.4)	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.8)	58.0 (42.2 to 73.9)	-2.1 (-11.2 to 6.3)
Injuries	-	-	-	-	3.4 (2.6 to 4.3)	4.5 (3.3 to 6.1)	33.8 (20.0 to 48.8)	-18.3 (-26.2 to -9.3)
Transport injuries	-	-	-	-	0.9 (0.7 to 1.1)	1.4 (1.0 to 1.8)	54.9 (35.4 to 77.6)	3.1 (-8.7 to 16.6)
Road injuries	-	-	-	-	1.2 (0.6 to 1.0)	1.2 (0.8 to 1.6)	50.1 (30.7 to 72.6)	0.3 (-11.4 to 14.0)
Pedestrian road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	21.6 (3.1 to 43.7)	-15.5 (-26.7 to -3.2)
Cyclist road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	53.4 (37.6 to 71.1)	2.5 (-8.0 to 13.8)
Motorcyclist road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	51.5 (30.3 to 74.5)	-0.4 (-13.6 to 14.0)
Motor vehicle road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	65.9 (42.2 to 95.4)	10.2 (-4.1 to 27.6)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.9 (-14.8 to 14.0)	-38.8 (-46.3 to -29.7)
Other transport injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	91.2 (69.6 to 116.3)	21.5 (8.1 to 38.1)
Unintentional injuries	-	-	-	-	2.2 (1.7 to 2.8)	2.8 (2.0 to 3.7)	24.5 (13.9 to 36.7)	-26.9 (-33.4 to -19.5)
Falls	-	-	-	-	1.2 (0.9 to 1.6)	1.3 (0.9 to 1.7)	3.0 (-7.6 to 15.6)	-40.3 (-46.6 to -32.6)
Drowning	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-20.8 (-32.4 to -5.6)	-45.4 (-52.8 to -36.4)
Fire, heat, and hot substances	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	28.5 (11.8 to 50.0)	-12.7 (-23.2 to 0.2)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.2 (-0.6 to 40.1)	-22.7 (-32.3 to -12.5)
Exposure to mechanical forces	-	-	-	-	0.5 (0.3 to 0.6)	0.8 (0.6 to 1.1)	74.8 (63.3 to 88.1)	12.9 (5.6 to 21.1)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.0 (87.6 to 146.5)	35.0 (18.2 to 54.8)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.7 (51.6 to 91.4)	11.4 (-0.5 to 22.9)
Other exposure to mechanical forces	-	-	-	-	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.0)	73.2 (62.1 to 86.4)	11.8 (4.7 to 20.0)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.5 (92.4 to 115.4)	28.2 (21.1 to 36.0)
Animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	20.1 (9.1 to 32.7)	-21.5 (-28.1 to -14.4)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.4 (12.1 to 46.8)	-16.2 (-25.6 to -6.8)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.4 (2.5 to 27.6)	-25.3 (-32.1 to -16.5)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	22.3 (10.5 to 35.0)	-19.2 (-26.2 to -11.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.6 (-27.2 to 6.4)	-35.1 (-44.6 to -23.0)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.7 (26.7 to 62.3)	-9.0 (-18.3 to 1.3)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.9 (21.6 to 49.7)	-15.1 (-22.9 to -5.8)
Other unintentional injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	42.5 (31.0 to 54.5)	-12.1 (-19.1 to -4.9)
Self-harm and interpersonal violence	-	-	-	-	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.6)	53.3 (33.3 to 77.1)	-0.9 (-13.1 to 13.8)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	123.9 (98.4 to 152.5)	31.3 (17.3 to 47.7)
Interpersonal violence	-	-	-	-	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	48.1 (28.6 to 71.8)	-3.8 (-16.3 to 10.9)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	71.6 (54.7 to 92.3)	10.6 (-0.0 to 22.5)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	79.9 (56.4 to 109.7)	11.9 (-2.9 to 31.1)
Assault by other means	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	33.9 (15.4 to 58.7)	-12.1 (-24.3 to 3.6)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-72.9 (-81.5 to -63.2)	-75.6 (-83.4 to -67.2)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-59.9 (-66.1 to -54.1)	-65.3 (-71.0 to -59.8)
Collective violence and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-81.1 (-88.1 to -71.9)	-82.8 (-89.2 to -72.9)

Appendix Table G.4 - Sweden prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,199.1 (902.8 to 1,529.3)	1,365.6 (1,020.1 to 1,741.6)	14.0 (11.3 to 16.0)	14.0 (-4.0 to 0.0)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	42.1 (29.2 to 59.7)	47.8 (32.7 to 67.1)	13.7 (4.6 to 23.1)	3.5 (-4.6 to 11.1)
HIV/AIDS and tuberculosis	-	-	-	-	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.5)	5.5 (-14.5 to 27.7)	-6.7 (-24.4 to 13.5)
Tuberculosis	1.3 (1.2 to 1.4)	1.3 (1.2 to 1.3)	-1.5 (-5.7 to 3.0)	-10.3 (-14.0 to -6.2)	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	-1.2 (-20.7 to 20.7)	-10.2 (-28.4 to 11.4)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	27.2 (-21.8 to 98.2)	4.1 (-35.9 to 64.8)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.0 (-65.2 to -5.2)	-43.5 (-68.3 to -12.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.0 (-65.3 to -5.1)	-43.5 (-68.5 to -12.1)
HIV/AIDS resulting in other diseases	0.9 (0.5 to 1.4)	1.8 (0.8 to 3.0)	100.0 (21.1 to 184.6)	57.5 (5.4 to 126.6)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	27.4 (-21.7 to 98.7)	4.2 (-35.9 to 65.0)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	4.7 (3.0 to 7.1)	4.9 (3.0 to 7.4)	3.0 (-4.2 to 10.6)	-8.8 (-14.6 to -2.1)
Diarrheal diseases	3.1 (2.8 to 3.5)	3.0 (2.7 to 3.4)	-3.1 (-17.5 to 14.8)	-15.1 (-30.4 to 5.7)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.7)	2.9 (-19.9 to 18.8)	-15.4 (-32.1 to 8.1)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-68.4 to 3.7)	-39.5 (-71.5 to -7.2)
Typhoid fever	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-38.2 (-59.3 to -0.1)	-44.7 (-63.9 to -10.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.2 (-59.3 to 0.3)	-44.7 (-64.0 to -10.2)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.3 (-51.5 to 38.3)	-19.8 (-56.3 to 27.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.3 (-51.6 to 38.4)	-19.8 (-56.3 to 28.2)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-75.5 (-99.3 to 692.1)	-78.4 (-99.4 to 608.3)
Lower respiratory infections	1.2 (1.1 to 1.3)	0.9 (0.8 to 1.0)	-24.3 (-31.5 to -14.4)	-29.6 (-38.1 to -21.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-22.1 (-35.3 to -4.9)	-27.7 (-40.1 to -13.8)
Upper respiratory infections	128.5 (123.3 to 134.5)	142.1 (135.5 to 147.7)	10.4 (3.6 to 18.1)	-0.0 (-6.7 to 6.7)	1.5 (0.9 to 2.5)	1.7 (0.9 to 2.8)	10.5 (2.9 to 19.2)	0.1 (-7.1 to 7.8)
Otitis media	106.8 (95.6 to 119.5)	106.2 (94.8 to 119.3)	-0.1 (-16.0 to 14.1)	-12.0 (-23.8 to -1.0)	1.9 (1.2 to 3.1)	1.9 (1.1 to 3.2)	-1.1 (-15.6 to 13.0)	-13.2 (-24.3 to -1.7)
Meningitis	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-20.1 (-35.8 to 1.4)	-30.0 (-44.0 to -9.1)
Pneumococcal meningitis	0.7 (0.4 to 1.2)	0.6 (0.3 to 0.9)	-22.1 (-41.0 to 5.0)	-33.9 (-52.1 to -11.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-17.3 (-51.8 to 7.0)	-29.8 (-60.1 to -8.0)
H influenzae type B meningitis	0.4 (0.1 to 0.9)	0.2 (0.1 to 0.6)	-35.4 (-64.5 to 6.3)	-42.6 (-68.0 to -2.1)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-30.6 (-63.8 to 31.4)	-37.7 (-68.3 to 22.4)
Meningococcal meningitis	0.3 (0.1 to 0.8)	0.2 (0.1 to 0.6)	-23.3 (-54.4 to 37.4)	-32.5 (-60.5 to 28.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-15.4 (-55.0 to 73.3)	-25.4 (-60.8 to 62.3)
Other meningitis	0.6 (0.3 to 1.3)	0.5 (0.2 to 1.0)	-8.5 (-40.2 to 7.1)	-27.5 (-46.8 to -1.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-10.1 (-42.7 to 28.3)	-19.9 (-49.4 to 18.0)
Encephalitis	0.8 (0.3 to 2.4)	0.9 (0.4 to 2.6)	13.5 (-4.3 to 51.0)	17.7 (-16.9 to 32.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	23.3 (-1.6 to 61.1)	7.7 (-13.0 to 43.0)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.3 (-92.1 to 513.4)	-43.7 (-92.6 to 413.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.3 (-92.1 to 517.7)	-43.7 (-92.7 to 417.3)
Whooping cough	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	150.2 (136.9 to 164.6)	144.7 (131.7 to 158.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	152.5 (85.3 to 252.0)	147.0 (80.7 to 246.2)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.5 (-67.3 to 22.7)	-36.7 (-70.5 to 10.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.0 (-62.7 to 16.4)	-34.5 (-67.1 to 5.9)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.5 (10.4 to 188.4)	68.8 (6.6 to 178.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.9 (10.3 to 188.8)	68.8 (6.5 to 178.8)
Varicella and herpes zoster	7.5 (6.5 to 8.7)	8.8 (7.5 to 10.4)	16.6 (-6.1 to 43.1)	1.1 (-15.2 to 20.8)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	20.4 (-10.8 to 60.6)	1.5 (-23.9 to 33.0)
Neglected tropical diseases and malaria	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-9.0 (-35.6 to 27.5)	-25.7 (-48.9 to 5.8)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.8 (-72.5 to 450.6)	5.5 (-75.1 to 396.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.4 (-72.2 to 470.7)	6.1 (-74.9 to 415.7)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-83.1 (-93.7 to -35.5)	-84.6 (-94.9 to -45.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-82.5 (-93.4 to -32.6)	-84.1 (-94.7 to -43.0)
Cystic echinococcosis	0.9 (0.9 to 1.0)	1.1 (1.0 to 1.3)	14.5 (-4.0 to 48.7)	-9.0 (-24.0 to 20.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	12.5 (-14.0 to 54.4)	-9.0 (-32.2 to 26.5)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.9 (-52.8 to 17.3)	-50.8 (-60.2 to 3.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.9 (-52.9 to 17.3)	-10.8 (-60.2 to 3.8)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.9 (-15.3 to 150.0)	71.2 (-32.5 to 119.2)
Maternal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-11.3 (-35.9 to 33.5)	-15.0 (-39.0 to 27.8)
Maternal hemorrhage	2.0 (1.1 to 3.0)	1.9 (0.9 to 3.0)	-5.0 (-57.9 to 83.0)	-9.2 (-60.0 to 76.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-20.6 (-59.6 to 93.2)	-23.6 (-61.8 to 85.3)
Maternal sepsis and other maternal infections	2.3 (1.0 to 4.0)	1.8 (0.5 to 3.1)	-20.5 (-72.7 to 77.9)	-21.2 (-72.4 to 79.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-13.7 (-54.5 to 57.6)	-16.6 (-55.0 to 51.7)
Maternal hypertensive disorders	1.0 (0.6 to 1.6)	1.0 (0.6 to 1.5)	-4.7 (-16.8 to 19.8)	-9.9 (-21.7 to 13.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-3.7 (-28.6 to 31.9)	-9.1 (-32.6 to 23.3)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.1 (-11.2 to 4.9)	-7.7 (-15.3 to 0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.1 (-11.2 to 4.9)	-7.7 (-15.3 to 0.2)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.2 (-12.4 to 12.5)	-5.2 (-16.7 to 6.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.2 (-12.4 to 12.6)	-5.2 (-16.7 to 6.8)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	1.2 (-45.8 to 96.3)	-5.4 (-48.2 to 87.5)
Neonatal disorders	-	-	-	-	7.8 (5.4 to 10.7)	11.3 (7.9 to 15.2)	47.4 (5.7 to 88.5)	30.8 (-6.3 to 67.6)
Preterm birth complications	43.8 (31.4 to 63.2)	62.7 (43.9 to 92.1)	43.3 (18.2 to 71.6)	27.7 (4.9 to 52.7)	6.6 (3.2 to 6.1)	6.6 (4.6 to 8.9)	46.4 (4.5 to 90.5)	30.8 (-6.9 to 70.0)
Neonatal encephalopathy due to birth asphyxia and trauma	8.8 (4.3 to 19.0)	5.4 (2.2 to 15.6)	-41.3 (-62.1 to -6.7)	-47.4 (-65.9 to -17.2)	1.1 (1.1 to 2.5)	1.1 (0.7 to 1.6)	-36.4 (-61.4 to 1.1)	-43.1 (-65.9 to -9.6)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.1 (50.8 to 152.2)	79.5 (52.9 to 155.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.1 (20.5 to 206.4)	90.6 (22.1 to 210.6)
Hemolytic disease and other neonatal jaundice	1.7 (0.6 to 4.1)	1.7 (0.7 to 3.4)	-1.2 (-67.7 to 195.9)	-12.3 (-71.3 to 164.1)	0.7 (0.2 to 1.7)	0.7 (0.3 to 1.5)	1.9 (-65.6 to 207.9)	9.6 (-69.7 to 175.0)
Other neonatal disorders	-	-	-	-	0.9 (0.5 to 1.7)	2.9 (1.7 to 4.7)	266.3 (59.5 to 491.7)	226.2 (42.3 to 427.7)
Nutritional deficiencies	-	-	-	-	26.3 (17.4 to 39.0)	28.1 (18.3 to 41.4)	7.0 (-6.5 to 19.1)	-0.7 (-14.0 to 9.8)
Protein-energy malnutrition	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	25.4 (-22.2 to 102.3)	-6.2 (-40.8 to 46.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.5 (-38.5 to 142.7)	-4.9 (-51.5 to 73.7)
Iodine deficiency	138.4 (75.5 to 228.2)	90.8 (32.2 to 177.3)	-38.2 (-77.5 to 65.8)	-28.2 (-78.7 to 47.5)	2.5 (1.1 to 4.8)	1.6 (0.5 to 3.5)	1.6 (-77.4 to 67.2)	-44.7 (-78.3 to 49.5)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron-deficiency anemia	954.8 (918.9 to 973.5)	1,105.7 (1,045.5 to 1,137.5)	16.0 (8.5 to 21.4)	3.7 (-3.7 to 9.6)	23.9 (15.8 to 34.8)	26.5 (17.2 to 39.1)	11.6 (-3.2 to 23.1)	2.6 (-11.2 to 13.9)

Appendix Table G.4 - Sweden prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-65 (-48.2 to 122.4)	-65 (-58.5 to 59.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.4 (1.4 to 4.7)	2.7 (1.5 to 4.9)	11.8 (-40.8 to 95.9)	2.5 (-52.4 to 111.6)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.1 (0.6 to 2.1)	1.2 (0.6 to 2.3)	11.8 (-2.3 to 29.8)	0.7 (-12.5 to 19.2)
Syphilis	0.4 (0.3 to 0.4)	0.7 (0.6 to 0.8)	82.0 (45.7 to 152.8)	52.5 (19.9 to 122.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	81.1 (23.9 to 184.1)	52.5 (0.6 to 147.9)
Chlamydial infection	159.6 (130.0 to 187.0)	179 (146.2 to 223.1)	12.1 (-11.9 to 47.5)	5.6 (-17.6 to 39.7)	12.1 (3.3 to 0.9)	0.5 (0.3 to 0.9)	3.8 (-16.7 to 42.6)	6.9 (-22.7 to 35.9)
Gonococcal infection	29.7 (19.7 to 41.2)	29.9 (19.4 to 41.3)	2.0 (-45.1 to 64.1)	-3.2 (-49.0 to 59.9)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-3.7 (-36.8 to 49.0)	-6.3 (-40.5 to 43.7)
Trichomoniasis	22.7 (14.6 to 31.5)	26.5 (19.5 to 35.1)	15.4 (-25.4 to 102.4)	11.2 (-29.6 to 100.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	15.2 (-28.8 to 126.7)	10.4 (-34.9 to 128.8)
Genital herpes	1,422.3 (1,331.5 to 1,507.0)	1,556.0 (1,441.1 to 1,670.7)	9.1 (-0.2 to 20.8)	-5.8 (-14.2 to 5.0)	0.4 (0.1 to 0.9)	0.4 (0.1 to 1.0)	8.5 (-1.7 to 21.6)	-5.6 (-14.9 to 6.3)
Other sexually transmitted diseases	0.7 (0.5 to 1.0)	0.4 (0.3 to 0.5)	-42.2 (-52.3 to -26.0)	-44.1 (-53.4 to -29.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-41.6 to 15.2)	-23.8 (-47.0 to 10.0)
Hepatitis	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	0.2 (-12.2 to 12.1)	-10.4 (-21.5 to 0.3)
Hepatitis A	6.1 (5.8 to 6.4)	6.2 (5.8 to 6.6)	0.9 (-0.5 to 2.2)	-9.1 (-10.6 to -7.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	2.9 (-9.5 to 15.5)	-7.6 (-19.0 to 4.7)
Hepatitis B	48.7 (42.2 to 55.9)	40.5 (36.0 to 45.2)	-17.0 (-29.9 to 0.9)	-27.0 (-38.1 to -11.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.7 (-47.5 to 34.4)	-24.8 (-53.2 to 17.8)
Hepatitis C	203.3 (184.2 to 224.8)	174.7 (152.9 to 198.4)	-14.1 (-27.1 to 1.3)	-27.7 (-39.3 to -14.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.1 (-44.5 to 46.6)	-21.2 (-48.5 to 14.3)
Hepatitis E	-	-	-	-	32.1 (-8.1 to 87.0)	-	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	41.4 (33.1 to 80.0)	45.2 (37.5 to 80.6)	10.5 (-45.5 to 105.6)	0.9 (-54.0 to 110.6)	1.1 (0.6 to 3.2)	1.3 (0.7 to 3.1)	15.6 (-63.6 to 202.3)	6.3 (-68.4 to 216.6)
Non-communicable diseases	-	-	-	-	1,024.7 (765.7 to 1,305.3)	1,213.8 (908.0 to 1,550.0)	18.6 (15.9 to 21.1)	1.7 (-0.7 to 3.8)
Neoplasms	-	-	-	-	18.4 (13.7 to 23.6)	26.2 (19.4 to 33.8)	42.5 (32.0 to 51.9)	13.5 (5.9 to 21.0)
Esophageal cancer	0.7 (0.6 to 0.8)	0.8 (0.6 to 1.0)	21.8 (-6.9 to 56.2)	-4.4 (-26.6 to 23.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	24.6 (-6.1 to 60.6)	-2.1 (-24.9 to 24.2)
Stomach cancer	4.4 (3.9 to 5.1)	3.6 (3.0 to 4.3)	-19.5 (-31.7 to -6.6)	-35.9 (-44.9 to -26.3)	0.5 (0.3 to 0.6)	0.4 (0.3 to 0.5)	-21.6 (-36.7 to -3.9)	-37.2 (-48.2 to -24.2)
Liver cancer	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	0.2 (-2.6 to 4.8)	-17.6 (-35.6 to 17.2)
Liver cancer due to hepatitis B	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	1.3 (-54.7 to 117.0)	-18.5 (-63.6 to 71.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	11.3 (-48.7 to 136.1)	-10.3 (-87.0 to 87.2)
Liver cancer due to hepatitis C	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	68.1 (-7.5 to 224.8)	36.6 (-26.2 to 165.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	76.4 (5.5 to 222.0)	43.7 (-14.3 to 168.5)
Liver cancer due to alcohol use	0.4 (0.3 to 0.6)	0.2 (0.1 to 0.4)	-48.3 (-72.7 to 19.1)	-59.6 (-78.1 to -11.2)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-40.9 (-67.5 to 25.0)	-53.6 (-74.1 to -3.8)
Liver cancer due to other causes	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-57.5 (-82.6 to -3.5)	-66.5 (-85.7 to -26.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-55.2 (-80.5 to -3.2)	-64.5 (-83.6 to -25.1)
Larynx cancer	0.9 (0.7 to 1.1)	0.8 (0.6 to 1.0)	-11.1 (-30.4 to 10.7)	-21.8 (-46.6 to -15.8)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-12.0 (-34.1 to 14.9)	-31.7 (-47.8 to -12.3)
Tracheal, bronchus and lung cancer	5.4 (5.0 to 6.1)	7.6 (6.1 to 8.7)	45.5 (7.9 to 66.1)	12.0 (-16.1 to 27.9)	0.7 (0.5 to 1.0)	1.0 (0.7 to 1.4)	41.6 (5.5 to 67.8)	9.5 (-16.7 to 30.0)
Breast cancer	73.2 (68.0 to 78.3)	106.3 (101.0 to 112.2)	45.3 (33.4 to 58.1)	14.8 (5.5 to 25.1)	3.6 (2.5 to 5.1)	4.8 (3.2 to 6.8)	32.9 (18.2 to 47.4)	5.1 (-6.8 to 17.4)
Cervical cancer	3.9 (3.4 to 4.9)	3.0 (2.1 to 3.8)	-21.4 (-45.7 to 2.9)	-34.5 (-56.5 to -13.4)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	0.2 (-4.6 to 3.9)	-33.7 (-56.6 to -9.9)
Uterine cancer	8.6 (5.8 to 9.9)	11.9 (7.8 to 15.0)	38.4 (5.5 to 78.7)	27.8 (-19.9 to 35.3)	0.8 (0.3 to 0.8)	0.8 (0.5 to 1.1)	3.6 (2.0 to 7.7)	3.1 (-2.4 to 36.9)
Prostate cancer	50.6 (43.3 to 59.0)	100.3 (86.3 to 119.4)	98.0 (67.6 to 133.4)	66.5 (41.5 to 96.7)	4.0 (2.9 to 5.4)	7.2 (5.2 to 9.8)	79.5 (53.7 to 112.4)	51.4 (30.1 to 80.5)
Colon and rectum cancer	26.9 (25.7 to 28.3)	46.9 (42.7 to 52.1)	73.9 (56.9 to 94.5)	37.7 (24.8 to 52.4)	2.2 (1.6 to 2.8)	3.7 (2.7 to 4.7)	66.6 (49.6 to 89.4)	32.3 (19.0 to 49.3)
Lip and oral cavity cancer	4.0 (3.5 to 4.5)	5.7 (4.5 to 6.9)	42.9 (9.2 to 77.6)	12.5 (-14.5 to 38.7)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	36.5 (0.8 to 73.5)	7.4 (-19.3 to 36.3)
Nasopharynx cancer	0.3 (0.3 to 0.5)	0.2 (0.2 to 0.3)	-37.4 (-55.8 to -12.7)	-48.7 (-61.7 to -29.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.1 (-56.7 to -16.3)	-49.8 (-64.0 to -31.7)
Other pharynx cancer	1.3 (1.1 to 1.6)	1.4 (1.0 to 1.9)	10.8 (-23.0 to 49.5)	-10.7 (-37.5 to 21.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	10.9 (-24.9 to 51.2)	-10.4 (-39.2 to 21.2)
Gallbladder and biliary tract cancer	0.6 (0.5 to 0.7)	0.4 (0.3 to 0.5)	-37.7 (-52.3 to -13.2)	-50.0 (-61.0 to -31.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	0.1 (-5.1 to 0.7)	-51.1 (-60.2 to -23.0)
Pancreatic cancer	1.2 (1.1 to 1.3)	1.3 (1.1 to 1.6)	6.7 (-13.4 to 31.6)	-14.2 (-29.9 to 5.2)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	11.1 (-13.6 to 39.7)	-10.7 (-29.6 to 10.6)
Malignant skin melanoma	15.6 (11.5 to 22.1)	19.9 (13.7 to 27.4)	27.9 (4.8 to 52.0)	2.7 (-15.0 to 21.5)	0.9 (0.6 to 1.4)	1.1 (0.7 to 1.8)	7.1 (1.4 to 31.0)	1.3 (-17.0 to 21.6)
Non-melanoma skin cancer	3.2 (3.2 to 4.7)	4.7 (6.6 to 9.8)	47.5 (60.6 to 159.9)	57.7 (28.4 to 99.8)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	11.5 (50.5 to 207.4)	10.9 (23.9 to 135.9)
Ovarian cancer	4.1 (3.7 to 4.5)	4.1 (3.3 to 4.9)	-0.6 (-19.5 to 21.1)	-23.1 (-37.4 to -6.9)	0.5 (0.4 to 0.7)	0.5 (0.3 to 0.7)	0.6 (-20.2 to 28.4)	-21.8 (-38.2 to 0.1)
Testicular cancer	1.6 (1.2 to 2.2)	1.5 (1.0 to 2.2)	-7.0 (-49.0 to 56.4)	-13.4 (-53.8 to 46.2)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-8.4 (-50.6 to 56.0)	-14.4 (-54.8 to 45.9)
Kidney cancer	6.3 (5.5 to 7.0)	7.5 (6.3 to 8.7)	19.5 (-0.4 to 42.5)	-4.9 (-21.9 to 12.8)	0.5 (0.3 to 0.6)	0.7 (0.4 to 0.7)	16.9 (-5.8 to 41.2)	-6.7 (-24.2 to 13.0)
Bladder cancer	11.4 (10.2 to 13.1)	14.1 (10.3 to 16.8)	26.2 (-6.3 to 49.0)	21.4 (-25.5 to 16.1)	0.8 (0.6 to 1.1)	1.0 (0.7 to 1.4)	21.4 (-10.3 to 46.0)	4.7 (-12.9 to 14.2)
Brain and nervous system cancer	2.4 (2.1 to 2.9)	4.0 (3.3 to 4.7)	63.7 (38.2 to 92.1)	27.9 (9.5 to 50.2)	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	27.9 (24.7 to 86.8)	22.3 (1.7 to 46.6)
Thyroid cancer	2.5 (1.9 to 2.9)	2.5 (2.0 to 3.2)	-14.9 (-19.2 to 32.6)	-19.9 (-33.1 to 12.7)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-0.8 (-24.2 to 30.9)	-17.2 (-36.8 to 9.4)
Mesothelioma	0.3 (0.2 to 0.3)	0.2 (0.2 to 0.4)	-11.7 (-32.2 to 61.7)	-29.1 (-45.3 to 28.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-8.7 (-37.5 to 68.7)	-26.6 (-48.8 to 30.0)
Hodgkin lymphoma	1.0 (0.8 to 1.3)	1.1 (0.8 to 1.5)	3.4 (-23.6 to 42.7)	-22.0 (-35.9 to 23.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	0.1 (-27.9 to 35.8)	-1.3 (-39.0 to 17.2)
Non-Hodgkin lymphoma	8.1 (6.0 to 11.6)	10.5 (6.8 to 13.4)	33.1 (-25.6 to 70.0)	4.9 (-41.4 to 36.7)	0.6 (0.4 to 0.9)	0.7 (0.4 to 1.1)	28.3 (-30.8 to 64.7)	2.0 (-45.5 to 33.1)
Multiple myeloma	2.2 (1.5 to 3.2)	2.3 (1.5 to 3.4)	7.2 (-22.0 to 40.5)	-12.6 (-36.5 to 14.6)	0.4 (0.3 to 0.7)	0.5 (0.3 to 0.7)	6.4 (-25.4 to 45.0)	-13.0 (-38.5 to 18.9)
Leukemia	4.7 (4.3 to 5.2)	6.8 (5.7 to 7.8)	45.8 (20.7 to 69.3)	10.1 (-10.9 to 29.3)	0.6 (0.4 to 0.8)	0.8 (0.6 to 1.1)	66.7 (12.9 to 71.0)	8.8 (-12.4 to 31.7)
Other neoplasms	3.6 (2.9 to 4.5)	8.5 (6.3 to 10.8)	140.2 (67.8 to 212.4)	101.7 (47.8 to 154.2)	0.6 (0.2 to 0.4)	0.6 (0.4 to 0.9)	108.1 (45.7 to 176.3)	78.6 (32.0 to 125.3)
Cardiovascular diseases	-	-	-	-	66.7 (35.9 to 65.9)	66.7 (47.1 to 86.9)	8.8 (14.6 to 55.0)	8.8 (-7.4 to 26.0)
Rheumatic heart disease	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	11.2 (7.1 to 30.7)	-7.3 (-21.1 to 7.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.9 (-12.0 to 43.9)	-6.8 (-25.4 to 16.4)
Ischemic heart disease	239.7 (207.4 to 277.1)	312.9 (270.4 to 359.8)	31.2 (4.4 to 57.8)	1.1 (-19.5 to 22.2)	13.1 (9.0 to 18.6)	16.5 (11.0 to 22.8)	26.7 (-0.8 to 54.1)	-3.1 (-25.4 to 19.4)
Cerebrovascular disease	-	-	-	-	12.9 (8.7 to 17.6)	14.4 (10.0 to 19.1)	11.3 (-12.9 to 32.5)	-5.7 (-25.4 to 9.0)
Ischemic stroke	70.8 (60.7 to 84.4)	78.4 (66.0 to 90.5)	12.0 (-16.1 to 34.1)	-6.7 (-28.1 to 9.5)	6.6 (6.6 to 14.0)	7.3 (7.3 to 15.3)	12.2 (-15.0 to 34.5)	-5.7 (-27.5 to 10.0)
Hemorrhagic stroke	20.4 (16.3 to 25.4)	22.6 (18.1 to 28.0)	11.7 (-20.6 to 53.0)	-5.9 (-31.0 to 26.5)	2.9 (1.9 to 4.2)	3.2 (2.1 to 4.5)	11.7 (-20.4 to 53.1)	-5.3 (-31.3 to 27.4)
Hypertensive heart disease	14.7 (12.5 to 17.1)	19.9 (17.5 to 22.5)	36.2 (11.3 to 66.8)	11.6 (-8.3 to 35.0)	1.6 (1.0 to 2.2)	2.1 (1.5 to 2.9)	37.0 (11.5 to 66.5)	12.6 (-9.1 to 36.6)
Cardiomyopathy and myocarditis	14.3 (12.0 to 17.6)	16.0 (14.4 to 17.9)	11.7 (-10.8 to 40.5)	-7.6 (-25.2 to 13.7)	1.5 (1.0 to 2.2)	1.7 (1.2 to 2.3)	12.2 (-1.1 to 40.9)	-7.5 (-26.6 to 14.6)
Atrial fibrillation and flutter	99.9 (83.8 to 120.8)	196.1 (180.4 to 208.9)	97.7 (57.8 to 139.3)	77.7 (33.4 to 100.6)	7.5 (4.9 to 10.8)	15.0 (10.4 to 20.4)	100.3 (59.3 to 142.3)	70.5 (35.4 to 104.2)
Peripheral vascular disease	511.9 (400.1 to 593.1)	557.3 (454.9 to 650.3)	9.2 (-15.4 to 43.4)	-12.6 (-33.7 to 16.1)	2.1 (0.9 to 3.7)	2.2 (1.0 to 3.9)	4.4 (-26.6 to 57.3)	-14.7 (-40.1 to 31.4)
Endocarditis	0.7 (0.5 to 0.8)	1.2 (1.1 to 1.5)	82.2 (42.8 to 164.0)	68.4 (32.4 to 138.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	49.9 (3.0 to 139.0)	36.5 (-3.4 to 113.6)
Other cardiovascular and circulatory diseases	158.2 (97.3 to 223.3)	211.5 (136.1 to 274.5)	33.9 (-24.0 to 131.7)	8.8 (-38.1 to 92.2)	11.0 (6.0 to 17.3)	14.8 (8.2 to 21.6)	34.4 (-24.0 to 136.4)	9.1 (-38.6 to 92.9)
Chronic respiratory diseases	-	-	-	-	66.7 (49.0 to 95.3)	66.7 (60.9 to 118.2)	8.8 (6.3 to 43.2)	8.8 (-6.6 to 20.4)
Chronic obstructive pulmonary disease	735.1 (691.6 to 776.5)	873.5 (820.8 to 927.5)	18.8 (13.6 to 24.6)	-1.9 (-6.3 to 2.9)	39.7 (26.0 to 55.3)	51.9 (41.4 to 74.1)	30.7 (-1.3 to 69.0)	9.3 (-17.6 to 38.8)
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.6 (-14.4 to -2.0)	-24.5 (-29.8 to -19.0)

Appendix Table G.4 - Sweden prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-21.9 (-26.9 to -16.8)	-62.4 (-40.1 to -32.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.0 (-27.0 to -16.8)	-36.4 (-40.3 to -32.5)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-1.3 (-10.7 to 9.2)	-18.4 (-26.4 to -9.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.4 (-9.5 to 11.2)	-17.6 (-25.6 to -7.8)
Asthma	665.7 (653.6 to 718.0)	808.9 (780.5 to 837.4)	21.2 (11.1 to 25.0)	1.3 (-0.2 to 13.3)	29.9 (19.3 to 43.1)	35.4 (23.0 to 50.0)	18.0 (16.9 to 25.5)	6.9 (0.4 to 13.8)
Interstitial lung disease and pulmonary sarcoidosis	0.6 (0.5 to 0.8)	1.1 (1.0 to 1.3)	74.6 (30.9 to 138.0)	41.2 (8.2 to 91.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	71.9 (20.9 to 132.9)	39.2 (4.8 to 87.4)
Other chronic respiratory diseases	-	-	-	-	0.9 (0.5 to 1.4)	0.5 (0.3 to 0.7)	-46.0 (-61.1 to -26.2)	-54.7 (-67.7 to -38.5)
Cirrhosis	-	-	-	-	0.5 (0.3 to 0.6)	0.4 (0.3 to 0.6)	-4.8 (-17.8 to 10.0)	-23.2 (-33.5 to -10.6)
Cirrhosis due to hepatitis B	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-13.8 (-52.6 to 37.1)	-30.1 (-61.3 to 11.2)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-14.2 (-54.8 to 55.7)	-30.7 (-63.6 to 25.7)
Cirrhosis due to hepatitis C	1.1 (0.6 to 1.6)	1.4 (1.1 to 1.6)	25.7 (-14.2 to 157.7)	-1.2 (-32.6 to 93.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	25.0 (-18.7 to 159.3)	-1.9 (-35.8 to 92.6)
Cirrhosis due to alcohol use	1.1 (0.7 to 1.5)	0.7 (0.5 to 1.0)	-37.2 (-61.7 to 11.4)	-49.9 (-69.1 to -7.7)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-36.5 (-63.0 to 17.2)	-49.5 (-70.5 to -2.8)
Cirrhosis due to other causes	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	3.8 (-48.9 to 94.7)	-13.2 (-55.0 to 54.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	3.0 (-49.8 to 102.6)	-12.7 (-55.7 to 62.7)
Digestive diseases	-	-	-	-	18.7 (13.4 to 24.8)	22.6 (16.1 to 30.2)	20.7 (10.3 to 30.4)	5.0 (-4.3 to 13.6)
Peptic ulcer disease	107.4 (104.2 to 110.8)	51.4 (47.5 to 55.0)	-52.1 (-55.1 to -49.2)	-63.8 (-66.3 to -61.4)	3.2 (2.2 to 4.5)	1.8 (1.2 to 2.5)	-45.5 (-49.5 to -39.9)	-58.7 (-62.0 to -53.3)
Gastritis and duodenitis	15.7 (13.2 to 18.2)	12.7 (10.7 to 14.9)	-19.2 (-32.1 to -4.2)	-32.2 (-43.8 to -18.4)	0.5 (0.4 to 0.8)	0.6 (0.4 to 0.8)	3.4 (-16.6 to 26.7)	-16.4 (-34.9 to 6.6)
Appendicitis	0.5 (0.4 to 0.6)	0.4 (0.4 to 0.4)	-29.5 (-29.8 to -7.4)	-29.5 (-38.7 to -17.6)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-18.9 (-40.3 to 12.3)	-29.3 (-49.7 to 2.7)
Paralytic ileus and intestinal obstruction	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.4)	44.6 (34.2 to 58.5)	21.9 (11.0 to 39.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	43.8 (10.1 to 88.9)	21.7 (-2.3 to 53.7)
Inguinal, femoral, and abdominal hernia	10.7 (9.3 to 12.5)	12.1 (10.1 to 14.6)	12.6 (-9.6 to 46.4)	7.7 (-23.7 to 14.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	22.8 (-10.4 to 45.5)	7.9 (-24.6 to 15.6)
Inflammatory bowel disease	49.4 (46.3 to 52.4)	67.0 (62.2 to 71.3)	35.8 (24.0 to 48.2)	15.1 (4.7 to 25.8)	10.2 (7.0 to 13.9)	13.9 (9.5 to 18.8)	35.8 (22.5 to 49.4)	15.4 (3.8 to 27.2)
Vascular intestinal disorders	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	4.4 (-24.7 to 63.2)	-15.6 (-37.8 to 28.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.8 (-36.9 to 89.0)	-12.1 (-43.6 to 40.5)
Gallbladder and biliary diseases	14.3 (13.1 to 15.6)	16.0 (14.1 to 17.6)	11.6 (4.5 to 28.4)	-6.3 (-19.0 to 7.3)	1.5 (1.0 to 2.0)	1.6 (1.1 to 2.3)	12.1 (-5.9 to 30.8)	-5.6 (-20.7 to 10.3)
Pancreatitis	2.1 (2.0 to 2.2)	2.7 (2.6 to 2.8)	26.9 (19.9 to 34.7)	0.6 (1.9 to 14.0)	2.7 (1.9 to 4.0)	0.8 (0.5 to 1.0)	27.3 (7.4 to 48.5)	6.5 (-9.5 to 27.8)
Other digestive diseases	-	-	-	-	2.3 (1.6 to 3.2)	3.6 (2.4 to 5.0)	57.5 (19.0 to 88.1)	37.2 (2.6 to 64.0)
Neurological disorders	-	-	-	-	91.7 (64.7 to 120.9)	112.0 (78.4 to 147.6)	22.5 (9.4 to 35.9)	3.2 (-7.8 to 13.8)
Alzheimer disease and other dementias	151.6 (138.4 to 168.3)	197.5 (155.1 to 236.2)	31.8 (-0.2 to 60.1)	2.9 (-21.2 to 24.2)	22.1 (16.3 to 28.4)	29.2 (19.6 to 39.5)	33.3 (-0.2 to 62.5)	3.8 (-21.3 to 25.8)
Parkinson disease	8.2 (6.3 to 10.3)	10.0 (7.6 to 12.6)	22.5 (10.9 to 32.5)	0.8 (-8.4 to 8.0)	0.9 (0.6 to 1.3)	1.2 (0.7 to 1.7)	23.3 (6.7 to 40.5)	1.3 (-11.9 to 15.2)
Epilepsy	25.2 (18.4 to 31.7)	24.3 (16.3 to 32.5)	-4.1 (-38.6 to 45.5)	-15.6 (-45.7 to 27.2)	10.2 (6.3 to 14.2)	10.1 (6.0 to 14.9)	-1.3 (-38.3 to 53.3)	-12.8 (-45.3 to 35.3)
Multiple sclerosis	8.8 (8.1 to 9.5)	17.3 (15.5 to 19.1)	96.2 (71.2 to 122.9)	7.1 (47.3 to 91.0)	2.9 (2.0 to 3.7)	5.6 (4.0 to 7.2)	95.6 (67.6 to 127.0)	68.1 (44.8 to 95.0)
Migraine	1,188.6 (1,088.9 to 1,294.4)	1,268.5 (1,118.8 to 1,406.5)	7.1 (-9.6 to 22.6)	-5.3 (-20.4 to 8.0)	40.1 (24.0 to 59.8)	42.6 (25.2 to 62.4)	6.5 (-10.6 to 22.2)	-5.3 (-20.8 to 8.0)
Tension-type headache	1,499.3 (1,465.5 to 1,822.4)	1,941.7 (1,548.3 to 2,339.7)	29.6 (-9.1 to 50.3)	17.6 (-18.8 to 34.6)	5.2 (1.2 to 4.3)	2.9 (1.4 to 5.2)	5.3 (-9.7 to 50.3)	5.3 (-19.3 to 34.1)
Medication overuse headache	50.2 (34.0 to 66.2)	87.4 (60.1 to 113.7)	74.4 (46.6 to 104.8)	49.0 (25.8 to 74.8)	7.8 (4.5 to 12.0)	13.5 (7.7 to 21.0)	74.7 (47.1 to 104.6)	49.9 (26.1 to 74.4)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.4 (-8.2 to 53.9)	-1.7 (-22.6 to 31.6)	5.3 (3.7 to 7.3)	6.9 (4.5 to 9.9)	31.2 (-7.3 to 76.6)	7.8 (-22.0 to 43.2)
Mental and substance use disorders	-	-	-	-	225.1 (157.7 to 295.5)	249.2 (175.7 to 333.1)	10.6 (4.2 to 16.9)	-1.2 (-6.0 to 3.4)
Schizophrenia	30.9 (25.5 to 34.9)	33.3 (28.6 to 38.3)	8.2 (-3.1 to 15.4)	-5.1 (-16.0 to 1.3)	19.5 (14.8 to 24.3)	21.0 (15.2 to 26.3)	8.0 (-4.1 to 17.0)	-5.1 (-16.0 to 3.4)
Alcohol use disorders	150.2 (140.4 to 159.5)	152.1 (151.0 to 172.8)	7.9 (1.9 to 14.1)	-2.7 (-8.8 to 3.0)	14.9 (9.9 to 20.9)	16.1 (10.7 to 22.7)	7.9 (0.9 to 14.7)	2.7 (-9.3 to 3.6)
Drug use disorders	-	-	-	-	18.3 (12.4 to 25.4)	20.0 (13.5 to 27.3)	9.0 (-2.2 to 24.2)	0.3 (-10.2 to 14.5)
Opioid use disorders	20.8 (12.9 to 30.9)	23.2 (14.6 to 31.7)	12.0 (-3.2 to 28.8)	3.4 (-9.6 to 20.5)	8.5 (4.8 to 13.6)	9.5 (5.4 to 14.5)	12.0 (-4.0 to 32.5)	3.3 (-1.7 to 23.2)
Cocaine use disorders	11.8 (9.5 to 14.5)	12.8 (10.2 to 15.0)	9.2 (-17.5 to 41.6)	1.5 (-25.1 to 32.9)	1.6 (1.0 to 2.4)	1.7 (1.1 to 2.6)	8.4 (-19.3 to 46.3)	1.1 (-26.0 to 37.9)
Amphetamine use disorders	24.0 (22.2 to 26.2)	25.4 (23.4 to 27.4)	6.3 (-5.0 to 17.2)	3.0 (-13.5 to 7.6)	3.1 (2.0 to 4.6)	3.2 (2.0 to 4.7)	3.2 (-7.2 to 21.1)	3.2 (-15.5 to 11.1)
Cannabis use disorders	12.7 (11.7 to 13.6)	13.3 (12.4 to 14.3)	5.2 (-0.5 to 10.4)	0.1 (-5.8 to 5.1)	0.1 (0.2 to 0.5)	0.4 (0.3 to 0.6)	5.5 (-10.0 to 22.9)	0.4 (-15.2 to 17.2)
Other drug use disorders	-	-	-	-	4.7 (3.1 to 7.0)	5.1 (3.1 to 7.4)	7.5 (-19.7 to 42.0)	-1.4 (-26.8 to 31.2)
Depressive disorders	-	-	-	-	82.9 (49.8 to 124.0)	93.2 (55.5 to 148.2)	11.8 (-4.8 to 29.1)	-2.5 (-16.0 to 10.0)
Major depressive disorder	344.4 (229.2 to 498.2)	388.3 (244.2 to 609.0)	11.8 (-8.9 to 33.0)	-2.9 (-20.0 to 12.2)	69.3 (39.2 to 107.9)	77.7 (43.7 to 129.7)	11.3 (-6.6 to 32.1)	9.0 (-19.8 to 11.7)
Dysthymia	143.6 (122.0 to 166.3)	163.1 (137.9 to 189.5)	13.6 (11.8 to 15.3)	-0.2 (-0.3 to -0.1)	13.6 (9.0 to 20.1)	15.5 (10.3 to 22.9)	13.6 (10.5 to 16.5)	-0.0 (-2.2 to 2.3)
Bipolar disorder	64.9 (54.3 to 74.4)	71.8 (60.6 to 82.1)	10.6 (4.1 to 16.8)	-0.7 (-6.7 to 5.4)	13.0 (8.1 to 19.6)	14.4 (8.9 to 21.6)	10.7 (3.2 to 18.8)	-0.4 (-7.8 to 7.3)
Anxiety disorders	440.5 (255.7 to 621.4)	489.7 (295.4 to 687.6)	11.2 (8.0 to 16.5)	-0.2 (-0.5 to -0.1)	39.8 (20.1 to 63.0)	44.2 (23.1 to 69.8)	11.2 (7.1 to 16.4)	-0.1 (-2.3 to 2.2)
Eating disorders	-	-	-	-	6.3 (3.5 to 10.0)	7.0 (4.0 to 10.7)	6.4 (4.4 to 20.6)	6.4 (0.1 to 15.5)
Anorexia nervosa	7.3 (4.6 to 10.6)	9.5 (5.8 to 13.9)	28.8 (15.0 to 57.9)	23.8 (10.8 to 51.4)	1.5 (0.8 to 2.5)	2.0 (1.1 to 3.3)	29.2 (12.2 to 61.1)	24.5 (8.4 to 54.0)
Bulimia nervosa	22.7 (13.3 to 33.9)	23.8 (14.0 to 35.4)	4.8 (2.8 to 6.4)	-0.0 (-0.1 to 0.1)	4.8 (2.4 to 7.9)	5.0 (2.5 to 8.4)	4.8 (-0.9 to 10.3)	0.1 (-5.3 to 4.9)
Autistic spectrum disorders	-	-	-	-	9.4 (6.6 to 12.8)	10.5 (7.4 to 14.2)	11.5 (8.0 to 15.2)	0.5 (-2.9 to 3.8)
Autism	24.9 (23.3 to 26.5)	27.7 (25.9 to 29.6)	11.5 (11.1 to 12.0)	0.3 (0.3 to 0.3)	6.0 (4.0 to 8.3)	6.7 (4.5 to 9.2)	11.4 (6.4 to 16.5)	0.6 (-4.4 to 5.1)
Asperger syndrome	34.4 (32.0 to 36.7)	38.5 (35.6 to 41.0)	11.7 (11.3 to 12.1)	0.4 (0.4 to 0.4)	3.4 (2.3 to 4.7)	3.8 (2.6 to 5.2)	11.5 (7.1 to 16.0)	0.5 (-3.3 to 4.7)
Attention-deficit/hyperactivity disorder	47.4 (40.6 to 54.3)	49.1 (42.0 to 56.2)	3.5 (3.4 to 3.5)	0.1 (0.1 to 0.2)	0.6 (0.3 to 0.9)	0.6 (0.3 to 0.9)	3.5 (-2.5 to 10.3)	0.2 (-5.7 to 7.0)
Conduct disorder	58.9 (49.6 to 68.8)	59.7 (50.2 to 69.9)	1.4 (0.6 to 2.1)	0.1 (0.1 to 0.2)	7.1 (4.3 to 10.6)	7.2 (4.4 to 10.9)	1.6 (-2.4 to 6.0)	0.3 (-3.5 to 4.5)
Idiopathic intellectual disability	20.4 (11.9 to 29.5)	19.6 (11.5 to 29.0)	-4.0 (-33.6 to 37.6)	-1.4 (-40.8 to 23.6)	1.1 (0.6 to 1.9)	1.2 (0.6 to 1.9)	-2.2 (-34.9 to 39.5)	-14.6 (-41.8 to 24.2)
Other mental and substance use disorders	165.1 (155.4 to 174.3)	189.9 (178.5 to 200.9)	15.0 (14.2 to 15.9)	0.3 (0.2 to 0.4)	12.1 (8.2 to 16.3)	13.9 (9.4 to 18.8)	15.0 (10.9 to 19.4)	0.4 (-3.3 to 4.3)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	82.2 (59.5 to 106.5)	104.0 (74.0 to 136.6)	26.6 (19.9 to 33.2)	6.7 (1.5 to 12.3)
Diabetes mellitus	180.6 (140.3 to 215.8)	301.7 (226.8 to 372.3)	67.0 (34.0 to 108.5)	39.4 (13.4 to 73.5)	14.0 (9.4 to 19.4)	23.6 (15.2 to 33.7)	69.1 (38.6 to 104.2)	40.4 (16.8 to 72.3)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.3 (-54.3 to -43.0)	-45.9 (-51.3 to -40.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.3 (-54.3 to -43.0)	-45.9 (-51.3 to -40.8)
Chronic kidney disease	-	-	-	-	37.2 (25.1 to 50.0)	43.5 (29.0 to 58.7)	17.0 (10.5 to 23.8)	-1.5 (-6.6 to 3.1)
Chronic kidney disease due to diabetes mellitus	113.6 (69.9 to 191.9)	159.8 (104.5 to 237.5)	42.7 (-1.9 to 95.8)	10.5 (-18.6 to 49.6)	6.5 (4.0 to 9.7)	8.2 (5.0 to 12.5)	24.1 (-2.2 to 75.5)	-1.0 (-23.0 to 39.1)
Chronic kidney disease due to hypertension	104.8 (75.3 to 148.9)	122.1 (79.4 to 179.0)	14.2 (-13.4 to 64.0)	-5.6 (-31.1 to 24.5)	10.9 (6.5 to 16.1)	3.9 (2.5 to 5.7)	-64.5 (-72.9 to -48.4)	-69.3 (-76.9 to -57.7)
Chronic kidney disease due to glomerulonephritis	178.0 (110.9 to 298.9)	100.7 (73.8 to 131.7)	-42.3 (-59.6 to -18.7)	-46.2 (-61.9 to -28.4)	3.8 (2.4 to 5.6)	8.3 (5.3 to 11.6)	117.6 (63.7 to 192.5)	77.0 (33.6 to 133.6)
Chronic kidney disease due to other causes	346.7 (242.2 to 452.2)	490.4 (345.5 to 684.2)	40.3 (16.8 to 78.5)	40.3 (9.9 to 44.7)	17.4 (10.8 to 22.3)	23.4 (15.7 to 31.1)	49.6 (21.7 to 82.0)	20.4 (2.9 to 51.2)
Urinary diseases and male infertility	-	-	-	-	11.0 (7.2 to 15.6)	15.0 (9.7 to 21.5)	36.2 (24.7 to 48.4)	11.3 (2.1 to 21.7)
Interstitial nephritis and urinary tract infections	1.4 (1.3 to 1.5)	2.0 (1.9 to 2.1)	38.5 (26.9 to 49.6)	22.1 (11.2 to 33.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	37.7 (11.6 to 70.6)	21.7 (-1.6 to 52.8)

Appendix Table G.4 - Sweden prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Urolithiasis	108.5 (53.9 to 197.6)	252.3 (177.4 to 390.6)	81.1 (78.6 to 280.9)	119.6 (45.2 to 220.2)	0.9 (0.4 to 1.9)	2.1 (1.1 to 3.8)	114.8 (76.6 to 251.4)	76.4 (44.8 to 188.4)
Benign prostatic hyperplasia	275.2 (256.1 to 293.3)	350.8 (327.5 to 376.6)	27.6 (14.9 to 40.4)	3.0 (-6.9 to 13.5)	9.7 (6.4 to 13.6)	12.4 (8.2 to 17.8)	27.8 (15.0 to 40.9)	3.1 (-6.7 to 13.7)
Male infertility due to other causes	37.7 (28.2 to 50.4)	38.2 (27.4 to 49.7)	0.6 (-34.1 to 53.6)	-1.6 (-36.0 to 49.3)	0.3 (0.1 to 0.5)	0.3 (0.1 to 0.5)	0.6 (-35.2 to 55.6)	-0.9 (-37.0 to 51.6)
Other urinary diseases	-	-	-	-	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	91.5 (39.2 to 224.0)	55.2 (13.5 to 162.4)
Gynecological diseases	-	-	-	-	10.4 (6.7 to 16.0)	11.2 (7.1 to 17.2)	4.9 (7.6 to 24.6)	-1.1 (-13.9 to 17.1)
Uterine fibroids	272.7 (246.4 to 299.5)	299.0 (270.5 to 327.2)	9.6 (9.1 to 10.1)	0.3 (0.3 to 0.4)	2.3 (1.1 to 4.4)	2.6 (1.3 to 4.7)	10.9 (4.4 to 27.2)	1.9 (-12.2 to 17.6)
Polycystic ovarian syndrome	122.9 (107.2 to 138.3)	146.9 (124.7 to 172.5)	19.3 (2.6 to 49.8)	12.6 (-8.5 to 42.2)	1.2 (0.6 to 2.2)	1.4 (0.6 to 2.6)	18.0 (-3.9 to 47.1)	11.9 (-9.4 to 39.8)
Female infertility due to other causes	13.0 (1.8 to 34.8)	13.4 (2.3 to 28.3)	2.3 (-77.5 to 607.5)	2.5 (-76.8 to 619.4)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	9.2 (-78.4 to 621.1)	9.0 (-78.1 to 615.9)
Endometriosis	24.4 (18.3 to 30.6)	23.5 (16.7 to 30.1)	-4.5 (-38.9 to 48.1)	-8.0 (-41.0 to 39.8)	2.2 (1.4 to 3.4)	2.2 (1.3 to 3.2)	1.2 (-38.8 to 48.4)	-8.1 (-41.4 to 40.6)
Genital prolapse	556.2 (502.5 to 604.6)	621.9 (565.0 to 681.1)	11.7 (-1.1 to 26.5)	-3.2 (-15.5 to 10.3)	1.8 (0.8 to 3.4)	2.0 (0.9 to 3.6)	11.7 (-1.3 to 27.4)	-3.3 (-15.3 to 10.7)
Premenstrual syndrome	288.9 (231.9 to 350.5)	310.6 (249.3 to 365.1)	7.5 (-17.8 to 38.2)	3.3 (-21.3 to 31.5)	2.4 (1.5 to 3.8)	2.6 (1.5 to 4.1)	7.4 (-18.2 to 38.3)	3.5 (-21.7 to 32.7)
Other gynecological diseases	20.0 (15.7 to 39.1)	19.7 (15.6 to 40.0)	3.2 (-49.5 to 60.4)	-3.4 (-49.0 to 50.6)	0.4 (0.2 to 1.4)	0.4 (0.2 to 1.4)	0.4 (-76.2 to 165.6)	-7.1 (-75.3 to 149.1)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	6.8 (4.5 to 9.7)	7.5 (5.0 to 10.9)	10.2 (2.0 to 22.3)	-1.6 (-10.1 to 8.4)
Thalassemias	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	7.4 (-4.3 to 18.7)	3.3 (-7.7 to 14.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.2 to 0.4)	2.3 (-24.7 to 42.8)
Thalassemia trait	132.8 (120.0 to 147.1)	153.3 (141.3 to 167.2)	15.5 (7.0 to 24.5)	3.0 (-4.3 to 10.2)	3.8 (2.6 to 5.5)	4.4 (2.9 to 6.3)	14.2 (0.4 to 29.0)	1.8 (-7.9 to 13.3)
Sickle cell disorders	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	4.1 (-11.1 to 22.2)	-3.3 (-18.2 to 13.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.4 (-2.6 to 18.3)	-1.0 (-10.5 to 9.6)
Sickle cell trait	138.6 (128.9 to 149.6)	149.2 (139.3 to 158.6)	7.6 (2.6 to 13.0)	-3.9 (-8.4 to 1.0)	1.8 (1.1 to 2.6)	2.6 (1.1 to 2.6)	0.4 (-20.8 to 20.9)	-8.2 (-27.3 to 10.1)
G6PD deficiency	30.6 (18.6 to 48.3)	41.4 (24.6 to 56.4)	37.2 (-26.4 to 142.4)	22.4 (-34.6 to 116.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.0 (-39.3 to 113.6)	14.5 (-51.7 to 107.4)
G6PD trait	983.6 (881.4 to 1,086.8)	1,075.1 (950.8 to 1,204.9)	9.2 (-4.3 to 27.0)	-2.4 (-14.5 to 13.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-2.8 (-44.9 to 70.1)	-11.5 (-54.1 to 72.2)
Other hemoglobinopathies and hemolytic anemias	51.9 (47.3 to 56.4)	64.5 (58.3 to 71.7)	24.3 (7.1 to 43.6)	4.3 (-9.6 to 19.6)	1.0 (0.7 to 1.6)	1.2 (0.7 to 1.8)	14.3 (-20.4 to 59.9)	-0.1 (-24.5 to 26.5)
Endocrine, metabolic, blood, and immune disorders	92.5 (88.1 to 97.3)	107.1 (100.3 to 131.2)	14.6 (5.5 to 42.7)	-1.0 (-9.4 to 35.6)	2.7 (1.9 to 3.7)	3.1 (2.1 to 4.6)	13.9 (1.1 to 64.3)	-0.4 (-10.7 to 64.6)
Musculoskeletal disorders	-	-	-	-	209.8 (206.1 to 385.0)	345.3 (246.7 to 457.0)	19.2 (13.5 to 25.0)	2.6 (-2.6 to 7.5)
Rheumatoid arthritis	49.0 (45.3 to 52.5)	66.8 (62.7 to 71.3)	36.2 (23.7 to 50.6)	14.9 (5.2 to 26.4)	11.0 (7.9 to 14.5)	15.1 (10.8 to 19.9)	37.2 (24.2 to 52.0)	15.9 (5.4 to 28.0)
Osteoarthritis	478.8 (453.4 to 505.2)	585.4 (555.1 to 615.7)	22.3 (13.1 to 30.8)	-1.0 (-8.3 to 5.8)	16.3 (10.6 to 23.3)	19.9 (13.0 to 28.6)	22.6 (13.4 to 31.1)	-0.7 (-8.3 to 6.3)
Low back and neck pain	-	-	-	-	234.4 (162.6 to 318.4)	272.1 (189.2 to 373.7)	16.2 (9.5 to 23.1)	1.0 (-5.3 to 6.9)
Low back pain	1,631.7 (1,562.0 to 1,704.5)	1,919.6 (1,824.7 to 2,026.3)	17.6 (10.3 to 26.3)	1.9 (-4.7 to 9.5)	179.0 (121.9 to 247.7)	210.6 (143.6 to 288.8)	17.7 (10.4 to 26.2)	2.3 (-4.6 to 9.7)
Neck pain	572.3 (530.2 to 616.5)	635.2 (580.9 to 685.2)	10.9 (-0.5 to 23.7)	-3.7 (-13.8 to 7.1)	55.4 (38.5 to 75.9)	61.5 (42.8 to 85.4)	11.1 (-0.6 to 24.0)	-3.5 (-13.7 to 7.5)
Gout	19.3 (17.4 to 21.1)	24.7 (22.2 to 27.4)	28.2 (10.7 to 46.9)	4.1 (-9.5 to 19.9)	0.6 (0.4 to 0.8)	0.8 (0.5 to 1.0)	29.2 (6.2 to 54.1)	5.1 (-13.9 to 26.4)
Other musculoskeletal disorders	306.6 (242.4 to 367.2)	415.1 (325.2 to 508.3)	35.1 (23.7 to 46.6)	13.8 (5.1 to 23.6)	27.7 (18.1 to 39.4)	37.5 (24.6 to 54.4)	35.5 (23.1 to 47.9)	14.1 (4.8 to 24.4)
Other non-communicable diseases	-	-	-	-	177.8 (120.4 to 251.6)	199.5 (137.2 to 279.8)	12.2 (6.9 to 18.4)	-3.3 (-9.4 to 2.3)
Congenital anomalies	-	-	-	-	15.2 (10.9 to 20.2)	17.9 (12.9 to 23.6)	18.4 (0.5 to 35.8)	3.1 (-12.7 to 19.6)
Neural tube defects	3.0 (2.6 to 3.4)	3.0 (2.6 to 3.6)	0.5 (-16.7 to 25.3)	-10.0 (-25.3 to 12.3)	1.0 (0.7 to 1.4)	1.0 (0.7 to 1.4)	-0.3 (-24.4 to 36.9)	-10.5 (-31.7 to 23.4)
Congenital heart anomalies	81.0 (67.1 to 104.2)	75.9 (64.0 to 92.1)	-6.0 (-28.3 to 23.4)	-16.0 (-35.6 to 9.9)	2.8 (1.1 to 4.9)	2.6 (1.1 to 4.6)	-4.9 (-26.9 to 21.8)	-14.7 (-34.0 to 9.1)
Crofacial clefts	13.5 (11.2 to 16.5)	13.3 (10.7 to 16.6)	-2.5 (-23.8 to 31.4)	-13.1 (-31.9 to 17.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-2.3 (-30.2 to 39.8)	-13.0 (-38.7 to 26.4)
Down syndrome	14.8 (12.1 to 17.9)	18.3 (15.4 to 21.8)	22.1 (-3.4 to 59.7)	4.4 (-17.6 to 36.4)	2.2 (1.6 to 3.0)	2.9 (2.0 to 3.8)	5.4 (-0.5 to 66.0)	27.0 (-17.0 to 38.3)
Turner syndrome	0.5 (0.4 to 0.7)	0.5 (0.4 to 0.7)	7.4 (-29.7 to 55.2)	0.0 (-36.5 to 39.1)	-3.5 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.2 (-32.2 to 59.5)	-3.4 (-38.7 to 43.7)
Klinefelter syndrome	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	23.1 (-12.5 to 92.4)	9.6 (-22.3 to 71.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.8 (-24.5 to 97.2)	8.3 (-30.6 to 82.6)
Chromosomal unbalanced rearrangements	21.2 (17.3 to 25.9)	25.5 (19.3 to 31.4)	20.2 (-11.6 to 61.6)	2.7 (-24.7 to 38.5)	3.2 (2.3 to 4.3)	4.0 (2.8 to 5.5)	24.3 (6.6 to 68.3)	3.2 (-24.3 to 40.7)
Other congenital anomalies	20.6 (15.2 to 24.3)	19.3 (13.8 to 24.2)	-4.2 (-29.3 to 10.7)	-25.9 (-37.1 to -2.1)	5.9 (3.8 to 8.3)	7.3 (4.6 to 10.8)	24.7 (-1.9 to 57.7)	12.2 (-12.4 to 42.3)
Skin and subcutaneous diseases	-	-	-	-	59.2 (38.9 to 88.8)	65.1 (42.6 to 97.3)	10.3 (0.5 to 21.9)	-1.1 (-11.4 to 11.7)
Dermatitis	586.6 (474.2 to 703.0)	643.6 (522.9 to 767.7)	9.7 (8.8 to 10.9)	-0.0 (-0.1 to -0.0)	17.2 (11.3 to 25.0)	18.9 (12.3 to 27.3)	10.2 (7.4 to 12.9)	0.1 (-2.4 to 2.5)
Psoriasis	118.6 (102.3 to 135.1)	135.8 (117.0 to 155.2)	14.5 (13.3 to 15.8)	0.0 (-0.1 to 0.1)	9.5 (6.4 to 13.3)	10.8 (7.4 to 15.5)	14.5 (9.4 to 19.3)	0.3 (-4.4 to 4.5)
Cellulitis	0.7 (0.6 to 0.9)	0.8 (0.7 to 1.0)	14.1 (4.1 to 26.2)	0.0 (-10.1 to 7.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	14.7 (-3.4 to 37.6)	-1.6 (-12.9 to 13.2)
Pyoderma	6.0 (4.9 to 7.3)	8.5 (6.9 to 10.6)	41.3 (33.8 to 49.6)	20.4 (14.0 to 26.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	41.0 (27.2 to 54.6)	20.3 (8.4 to 31.4)
Scabies	5.7 (4.5 to 6.5)	4.6 (3.8 to 5.4)	-18.2 (-36.5 to 4.5)	-24.0 (-41.0 to -4.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-18.2 (-37.5 to 5.6)	-24.0 (-42.0 to -3.3)
Fungal skin diseases	651.8 (578.9 to 715.6)	754.5 (667.9 to 826.4)	15.7 (14.8 to 16.7)	0.2 (0.2 to 0.3)	3.6 (1.5 to 7.6)	4.2 (1.7 to 8.7)	15.7 (14.3 to 17.1)	0.3 (-0.6 to 1.3)
Viral skin diseases	170.0 (135.1 to 206.4)	186.2 (148.1 to 227.1)	9.5 (6.7 to 12.3)	9.5 (-1.9 to 30.0)	0.4 (0.0 to 1.0)	0.5 (0.3 to 0.9)	5.7 (5.5 to 13.4)	0.5 (-3.1 to 4.2)
Acne vulgaris	1,231.4 (768.3 to 1,998.9)	1,217.5 (965.7 to 1,557.4)	-2.0 (-31.6 to 63.2)	-5.5 (-36.0 to 60.8)	13.3 (5.7 to 26.3)	13.1 (6.1 to 25.7)	-2.1 (-31.9 to 64.4)	-6.5 (-36.3 to 60.6)
Alopecia areata	15.5 (14.3 to 16.7)	18.1 (16.7 to 19.5)	16.9 (4.8 to 30.5)	0.4 (-9.3 to 11.9)	0.5 (0.3 to 0.8)	0.6 (0.4 to 0.9)	16.8 (2.4 to 32.9)	0.5 (-11.7 to 14.4)
Pruritus	0.8 (0.8 to 1.8)	1.5 (1.0 to 2.2)	14.6 (22.3 to 90.1)	-4.0 (-31.9 to 47.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.6 (-25.0 to 97.9)	-4.4 (-35.9 to 50.5)
Urticaria	75.0 (55.2 to 99.2)	91.4 (67.7 to 115.4)	24.8 (-22.3 to 78.5)	7.5 (-31.8 to 52.8)	4.4 (2.6 to 6.8)	5.3 (3.2 to 8.1)	24.5 (-2.2 to 77.6)	7.7 (-31.5 to 54.3)
Decubitus ulcer	6.5 (5.2 to 8.0)	6.8 (5.2 to 8.6)	3.7 (-23.6 to 48.1)	-16.3 (-37.8 to 16.0)	0.9 (0.6 to 1.3)	0.9 (0.6 to 1.4)	3.9 (-25.3 to 48.1)	-15.7 (-38.5 to 17.2)
Other skin and subcutaneous diseases	761.3 (418.4 to 1,357.9)	916.7 (493.7 to 1,658.1)	20.2 (14.0 to 24.9)	0.4 (-3.0 to 3.2)	4.4 (1.7 to 10.0)	5.3 (2.0 to 12.4)	20.2 (13.7 to 25.2)	0.6 (-3.0 to 3.5)
Sense organ diseases	-	-	-	-	69.6 (47.0 to 98.2)	80.4 (54.7 to 113.2)	15.5 (7.9 to 25.3)	-6.6 (-12.0 to 1.9)
Glaucoma	3.3 (2.4 to 4.7)	3.2 (2.2 to 4.7)	-5.4 (-30.2 to 36.5)	-24.2 (-41.5 to 7.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	7.8 (-3.8 to 28.0)	24.4 (-4.2 to 2.4)
Cataract	10.9 (6.7 to 18.3)	8.6 (4.8 to 14.1)	-21.4 (-49.5 to 25.7)	-36.2 (-58.2 to -2.2)	0.5 (0.3 to 0.9)	0.4 (0.2 to 0.7)	-18.0 (-46.1 to 26.8)	-33.4 (-55.5 to -1.8)
Macular degeneration	13.7 (8.9 to 19.7)	18.4 (12.4 to 27.2)	33.2 (3.6 to 76.3)	3.9 (-15.0 to 33.1)	0.7 (0.4 to 1.0)	0.8 (0.5 to 1.4)	28.2 (0.9 to 64.8)	0.6 (-18.7 to 26.5)
Uncorrected refractive error	1,086.9 (862.6 to 1,337.0)	1,233.0 (1,029.1 to 1,437.6)	13.2 (9.7 to 50.4)	-6.1 (-27.2 to 29.6)	11.8 (5.9 to 21.8)	13.2 (6.3 to 23.9)	12.3 (9.3 to 46.1)	-6.6 (-26.0 to 25.1)
Age-related and other hearing loss	1,665.7 (1,610.1 to 1,723.0)	1,869.0 (1,802.5 to 1,940.3)	12.3 (8.7 to 15.9)	-9.9 (-13.1 to -6.4)	50.5 (34.4 to 69.6)	59.1 (40.5 to 80.5)	17.2 (7.6 to 28.7)	-6.9 (-13.0 to 1.7)
Other vision loss	10.2 (7.3 to 14.0)	7.9 (5.5 to 11.8)	-24.4 (-35.9 to 5.9)	24.4 (-46.5 to -17.1)	0.4 (0.3 to 0.8)	0.5 (0.3 to 0.6)	0.4 (-30.7 to 4.6)	-16.5 (-42.0 to -14.5)
Other sense organ diseases	211.7 (202.1 to 221.6)	242.3 (231.1 to 252.5)	14.5 (7.7 to 22.0)	-0.2 (-5.8 to 5.5)	5.5 (3.5 to 8.1)	6.3 (3.9 to 9.3)</		

Appendix Table G.4 - Sweden prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Other oral disorders	163.0 (154.8 to 172.2)	185.5 (176.3 to 194.4)	13.9 (7.0 to 20.3)	0.3 (-6.0 to 6.3)	4.7 (3.0 to 7.1)	5.4 (3.3 to 8.0)	13.8 (6.3 to 20.5)	0.3 (-6.4 to 6.7)
Injuries	-	-	-	-	132.3 (100.5 to 170.0)	104.0 (75.5 to 140.5)	-21.5 (-30.2 to -12.6)	-35.6 (-42.4 to -28.7)
Transport injuries	-	-	-	-	24.3 (18.3 to 31.3)	13.6 (9.9 to 18.1)	-44.0 (-49.4 to -37.7)	-54.6 (-59.1 to -49.1)
Road injuries	-	-	-	-	21.4 (16.1 to 27.4)	12.2 (8.9 to 16.2)	-43.0 (-48.7 to -36.1)	-53.8 (-58.6 to -48.0)
Pedestrian road injuries	-	-	-	-	1.7 (1.3 to 2.2)	1.2 (0.8 to 1.6)	-31.1 (-39.8 to -25.4)	-47.9 (-52.6 to -40.6)
Cyclist road injuries	-	-	-	-	1.7 (1.3 to 2.2)	1.0 (0.7 to 1.3)	-41.4 (-49.6 to -32.1)	-51.5 (-58.4 to -43.5)
Motorcyclist road injuries	-	-	-	-	3.5 (2.6 to 4.6)	2.1 (1.5 to 2.9)	-40.5 (-49.3 to -28.9)	-51.7 (-59.0 to -41.7)
Motor vehicle road injuries	-	-	-	-	14.2 (10.7 to 18.3)	7.9 (5.8 to 10.5)	-44.6 (-49.6 to -38.9)	-55.2 (-59.4 to -50.4)
Other road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.1)	-66.6 (-70.8 to -61.6)	-72.5 (-76.1 to -68.3)
Other transport injuries	-	-	-	-	2.9 (2.1 to 3.7)	1.4 (1.0 to 1.9)	-51.9 (-56.6 to -46.6)	-60.3 (-63.8 to -56.1)
Unintentional injuries	-	-	-	-	106.6 (81.3 to 137.0)	89.4 (65.0 to 120.9)	-16.4 (-25.7 to -6.8)	-30.4 (-37.6 to -23.2)
Falls	-	-	-	-	82.7 (63.3 to 105.7)	70.1 (51.0 to 94.3)	-15.4 (-26.1 to -3.9)	-29.1 (-37.4 to -20.4)
Drowning	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-54.3 (-59.0 to -48.0)	-62.5 (-66.8 to -57.6)
Fire, heat, and hot substances	-	-	-	-	2.1 (1.4 to 3.3)	2.2 (1.3 to 3.6)	0.7 (-12.0 to 12.9)	-15.2 (-26.5 to -4.3)
Poisonings	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-42.4 (-51.5 to -32.1)	-51.5 (-59.7 to -42.0)
Exposure to mechanical forces	-	-	-	-	10.3 (7.6 to 13.4)	6.0 (4.3 to 8.1)	-42.1 (-47.3 to -36.2)	-50.8 (-55.4 to -45.9)
Unintentional firearm injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-77.4 (-80.0 to -74.4)	-80.4 (-82.7 to -77.8)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	28.6 (13.2 to 44.2)	5.4 (-7.8 to 19.1)
Other exposure to mechanical forces	-	-	-	-	10.1 (7.5 to 13.3)	5.9 (4.2 to 8.0)	-42.2 (-47.4 to -36.3)	-50.8 (-55.4 to -45.9)
Adverse effects of medical treatment	-	-	-	-	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.9)	19.7 (10.3 to 30.1)	1.5 (-5.6 to 9.4)
Animal contact	-	-	-	-	0.3 (0.3 to 0.5)	0.5 (0.3 to 0.6)	30.1 (20.0 to 41.5)	9.0 (0.5 to 18.8)
Venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	28.9 (14.5 to 45.7)	10.4 (-2.3 to 25.8)
Non-venomous animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	30.5 (19.7 to 42.2)	8.8 (-0.3 to 18.9)
Foreign body	-	-	-	-	0.6 (0.4 to 0.8)	0.5 (0.4 to 0.8)	-8.2 (-17.7 to 0.3)	-20.1 (-29.4 to -12.3)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-10.0 (-20.8 to 1.6)	-22.7 (-33.0 to -10.2)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-1.4 (-11.8 to 9.7)	-11.9 (-21.8 to -1.0)
Foreign body in other body part	-	-	-	-	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	-9.1 (-20.6 to 1.0)	-21.3 (-31.9 to -12.3)
Other unintentional injuries	-	-	-	-	9.9 (7.2 to 13.3)	9.5 (6.7 to 13.2)	-4.3 (-11.4 to 4.0)	-22.2 (-27.8 to -15.1)
Self-harm and interpersonal violence	-	-	-	-	1.4 (1.1 to 1.8)	1.0 (0.7 to 1.4)	-29.2 (-35.2 to -22.2)	-41.0 (-46.1 to -35.0)
Self-harm	-	-	-	-	0.6 (0.4 to 0.8)	0.5 (0.4 to 0.7)	-17.1 (-26.6 to -6.3)	-30.1 (-38.3 to -20.9)
Interpersonal violence	-	-	-	-	0.8 (0.6 to 1.1)	0.5 (0.4 to 0.7)	-38.3 (-44.2 to -31.2)	-48.8 (-53.9 to -42.8)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-47.9 (-53.2 to -41.6)	-57.3 (-61.6 to -52.1)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-26.9 (-32.2 to -20.8)	-39.2 (-43.7 to -34.0)
Assault by other means	-	-	-	-	0.6 (0.5 to 0.8)	0.4 (0.3 to 0.5)	-38.6 (-45.2 to -30.4)	-49.0 (-54.9 to -41.9)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	246.3 (112.5 to 457.6)	232.0 (87.1 to 455.7)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	246.3 (112.5 to 457.6)	232.0 (87.1 to 455.7)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Switzerland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	958.3 (719.3 to 1,218.2)	1,190.8 (892.6 to 1,521.1)	24.2 (20.6 to 27.6)	3.3 (-6.1 to 0.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	32.4 (22.4 to 45.5)	37.5 (26.2 to 52.1)	15.9 (4.3 to 27.2)	1.0 (-8.9 to 9.2)
HIV/AIDS and tuberculosis	-	-	-	-	1.4 (0.9 to 2.1)	1.3 (0.8 to 1.9)	-11.2 (-38.6 to 21.8)	-31.0 (-51.6 to -5.3)
Tuberculosis	1.3 (1.3 to 1.4)	1.5 (1.4 to 1.5)	10.1 (5.8 to 15.1)	-8.3 (-11.9 to -4.3)	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	10.8 (8.2 to 32.9)	-7.6 (-23.5 to 12.1)
HIV/AIDS	-	-	-	-	1.1 (0.6 to 1.6)	0.8 (0.4 to 1.4)	-41.2 (-53.8 to 24.2)	-41.2 (-64.9 to -5.9)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-68.2 (-84.3 to -43.0)	-74.4 (-87.4 to -53.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-68.2 (-84.3 to -43.0)	-74.4 (-87.4 to -53.1)
HIV/AIDS resulting in other diseases	7.5 (5.8 to 9.8)	10.7 (6.7 to 16.5)	39.8 (7.6 to 105.9)	0.9 (-34.6 to 51.4)	1.0 (0.6 to 1.6)	0.8 (0.4 to 1.4)	-20.1 (-53.8 to 24.5)	-41.1 (-66.9 to -5.7)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	3.7 (2.4 to 5.6)	4.1 (2.6 to 6.2)	10.7 (2.5 to 19.3)	-8.7 (-14.8 to -2.3)
Diarrheal diseases	2.5 (2.2 to 2.9)	2.6 (2.3 to 2.9)	3.1 (-13.3 to 23.7)	-16.1 (-32.4 to 5.1)	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	1.6 (-16.4 to 26.2)	-19.0 (-34.0 to 8.8)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-63.2 to 52.7)	-12.0 (-68.1 to 32.3)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.6 (-21.3 to 7.1)	-21.8 (-32.5 to -9.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.6 (-21.4 to 7.2)	-21.8 (-32.5 to -9.9)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.3 (-6.9 to 70.3)	16.3 (-15.7 to 50.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.3 (-7.3 to 70.4)	16.3 (-15.9 to 50.8)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-65.9 (-99.0 to 1,911.8)	-70.6 (-99.2 to 1,568.6)
Lower respiratory infections	0.4 (0.4 to 0.4)	0.4 (0.4 to 0.4)	8.2 (2.7 to 13.7)	-11.0 (-15.9 to -6.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	9.8 (-12.2 to 36.7)	8.9 (-27.7 to 14.3)
Upper respiratory infections	101.0 (95.8 to 105.8)	119.5 (113.7 to 125.5)	18.3 (11.3 to 27.1)	0.6 (-5.4 to 8.0)	1.2 (0.7 to 1.9)	1.4 (0.8 to 2.3)	18.2 (10.1 to 27.5)	1.0 (-5.7 to 8.6)
Otitis media	82.5 (71.5 to 92.3)	88.9 (77.9 to 102.7)	7.9 (7.5 to 24.2)	-11.0 (-22.1 to -0.1)	1.5 (0.9 to 2.4)	1.6 (0.9 to 2.6)	7.3 (7.3 to 23.3)	-12.0 (-22.3 to -0.0)
Meningitis	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-0.2 (-21.5 to 28.5)	-17.3 (-35.7 to 7.3)
Pneumococcal meningitis	0.6 (0.4 to 1.0)	0.6 (0.4 to 1.0)	1.4 (-22.2 to 30.2)	-21.4 (-39.3 to 1.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.1 (-33.0 to 31.7)	-2.6 (-48.8 to 8.2)
H influenzae type B meningitis	0.3 (0.1 to 0.8)	0.2 (0.1 to 0.6)	-16.0 (-59.8 to 59.0)	-30.7 (-66.7 to 35.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-16.7 (-67.2 to 91.7)	-29.2 (-72.6 to 63.7)
Meningococcal meningitis	0.3 (0.1 to 0.7)	0.3 (0.1 to 0.7)	-3.2 (-42.1 to 68.4)	-21.6 (-53.2 to 40.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-46.9 to 81.4)	-0.3 (-56.5 to 52.1)
Other meningitis	0.5 (0.3 to 1.0)	0.5 (0.3 to 1.1)	7.3 (-29.9 to 86.7)	-10.7 (-40.9 to 56.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	10.4 (-36.9 to 128.1)	-5.6 (-46.4 to 93.1)
Encephalitis	0.7 (0.3 to 2.0)	0.8 (0.0 to 2.3)	15.8 (0.5 to 54.5)	9.6 (-22.7 to 22.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	24.9 (0.5 to 64.2)	2.6 (-22.4 to 30.2)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.1 (-93.5 to 348.4)	-58.7 (-94.5 to 273.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.1 (-93.5 to 353.9)	-58.7 (-94.5 to 274.4)
Whooping cough	0.9 (0.7 to 1.1)	0.3 (0.2 to 0.4)	-63.0 (-65.4 to -60.6)	-64.4 (-66.6 to -62.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-62.7 (-70.5 to -54.9)	-64.0 (-71.7 to -56.4)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.3 (-54.0 to 118.7)	-0.3 (-61.8 to 47.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.5 (-54.1 to 133.9)	9.4 (-61.4 to 62.0)
Measles	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-91.2 (-92.6 to -89.9)	-91.5 (-92.8 to -90.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-91.0 (-94.3 to -84.3)	-91.3 (-94.5 to -84.6)
Varicella and herpes zoster	5.6 (4.7 to 6.3)	7.0 (6.0 to 8.2)	25.0 (2.1 to 58.5)	0.5 (-14.1 to 20.9)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	32.6 (0.5 to 84.5)	1.6 (-22.8 to 36.7)
Neglected tropical diseases and malaria	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-26.6 (-45.2 to -4.4)	-43.1 (-57.0 to -25.9)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.1 (-65.1 to 469.8)	5.3 (-70.5 to 388.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.4 (-64.7 to 487.1)	5.7 (-70.3 to 404.0)
Chagas disease	-	-	0.0 (0.0 to 0.0)	-	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-50.3 (-83.7 to 29.3)	-59.6 (-86.7 to 1.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.2 (-83.9 to 38.5)	-58.3 (-86.2 to 5.7)
Cystic echinococcosis	0.4 (0.4 to 0.5)	0.3 (0.3 to 0.4)	-23.2 (-30.2 to -18.7)	-42.0 (-47.3 to -38.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-21.0 (-37.2 to 2.3)	-39.8 (-51.5 to -23.2)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.6 (-52.1 to 32.2)	-13.2 (-62.2 to 10.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.6 (-52.1 to 32.4)	-13.2 (-62.2 to 10.1)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.3 (-46.2 to 23.8)	-32.7 (-57.6 to 0.6)
Maternal disorders	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	11.4 (-34.0 to 63.1)	4.3 (-38.5 to 53.7)
Maternal hemorrhage	2.4 (1.8 to 3.0)	2.7 (1.0 to 4.3)	11.9 (-55.8 to 80.7)	5.0 (-58.4 to 71.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	9.4 (-59.4 to 82.2)	2.8 (-62.2 to 72.6)
Maternal sepsis and other maternal infections	0.6 (0.2 to 1.2)	0.7 (0.3 to 1.2)	14.0 (-56.4 to 365.7)	2.7 (-59.4 to 314.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.4 (-36.7 to 82.8)	-2.4 (-40.5 to 64.3)
Maternal hypertensive disorders	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.8)	13.1 (2.2 to 26.2)	5.2 (-4.8 to 17.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.8 (-16.6 to 51.7)	4.9 (-22.4 to 41.0)
Obstructed labor	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	8.3 (0.9 to 16.6)	1.8 (-5.0 to 9.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.6 (-56.1 to 176.4)	0.8 (-59.1 to 151.8)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.2 (43.0 to 71.2)	45.5 (33.2 to 59.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.2 (42.9 to 71.2)	45.5 (33.1 to 59.4)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	9.0 (-44.9 to 150.9)	9.0 (-49.0 to 135.0)
Neonatal disorders	-	-	-	-	5.8 (4.0 to 8.3)	8.6 (6.1 to 11.4)	51.3 (5.5 to 99.7)	26.7 (-20.5 to 68.1)
Preterm birth complications	26.2 (19.3 to 37.2)	46.7 (33.5 to 66.7)	78.0 (39.6 to 122.5)	49.4 (16.6 to 87.1)	3.2 (2.2 to 4.4)	5.9 (4.1 to 8.1)	84.7 (36.6 to 147.3)	55.0 (14.5 to 108.3)
Neonatal encephalopathy due to birth asphyxia and trauma	5.8 (3.1 to 12.1)	4.9 (2.5 to 11.5)	-18.1 (-41.5 to 24.6)	-31.4 (-50.6 to 4.1)	1.3 (0.9 to 1.9)	1.1 (0.8 to 1.6)	-15.7 (-43.3 to 36.7)	-29.1 (-52.5 to 15.2)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.0 (84.2 to 102.4)	80.4 (76.7 to 94.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.0 (96.4 to 270.0)	85.2 (51.1 to 255.0)
Hemolytic disease and other neonatal jaundice	1.9 (0.5 to 5.3)	1.1 (0.2 to 2.2)	-31.6 (-91.2 to 254.7)	-43.3 (-92.6 to 201.9)	0.8 (0.2 to 2.3)	0.5 (0.1 to 1.0)	-27.2 (-90.5 to 275.9)	-39.7 (-92.1 to 219.5)
Other neonatal disorders	-	-	-	-	0.5 (0.2 to 0.9)	1.1 (0.5 to 1.9)	138.9 (4.1 to 452.1)	100.2 (-12.6 to 364.9)
Nutritional deficiencies	-	-	-	-	19.0 (12.4 to 27.7)	21.0 (13.9 to 30.8)	11.0 (-1.5 to 20.7)	-0.7 (-12.3 to 6.3)
Protein-energy malnutrition	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	288.0 (3.2 to 571.1)	134.0 (-37.7 to 276.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	259.7 (-20.2 to 736.7)	115.5 (-46.8 to 332.2)
Iodine deficiency	28.9 (18.3 to 43.1)	18.5 (12.8 to 26.6)	-35.1 (-64.9 to 18.8)	-45.8 (-69.8 to -2.3)	0.5 (0.3 to 0.9)	0.3 (0.2 to 0.6)	-34.9 (-65.5 to 17.9)	-45.7 (-70.2 to -2.6)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron-deficiency anemia	750.9 (729.8 to 770.5)	895.6 (854.3 to 925.4)	19.4 (13.3 to 24.6)	1.4 (-4.9 to 5.7)	18.5 (12.1 to 26.9)	20.6 (13.7 to 30.3)	12.4 (-0.5 to 22.0)	0.2 (-11.4 to 7.2)

Appendix Table G.4 - Switzerland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.9 (-36.3 to 394.5)	39.2 (-54.1 to 160.0)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.3 (1.3 to 4.0)	2.3 (1.3 to 4.0)	0.1 (-23.7 to 55.8)	-10.5 (-34.3 to 52.2)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.9 (0.4 to 1.6)	1.0 (0.5 to 1.7)	13.9 (-3.6 to 34.9)	-3.2 (-18.7 to 17.5)
Syphilis	0.3 (0.3 to 0.4)	0.6 (0.5 to 0.7)	86.5 (46.5 to 124.8)	37.9 (6.8 to 69.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	84.5 (32.8 to 156.2)	37.5 (-3.1 to 92.5)
Chlamydial infection	129.3 (91.4 to 160.3)	114.3 (64.3 to 164.5)	-11.3 (-53.3 to 33.9)	-8.4 (-57.2 to 24.4)	0.4 (0.2 to 0.7)	0.4 (0.2 to 0.7)	-9.5 (-26.9 to 49.5)	-4.5 (-33.8 to 40.6)
Gonococcal infection	25.5 (18.0 to 34.7)	21.1 (12.8 to 30.1)	-15.5 (-54.7 to 32.5)	-19.5 (-58.8 to 28.8)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-14.3 (-43.2 to 26.9)	-19.1 (-47.7 to 26.9)
Trichomoniasis	20.1 (13.8 to 28.7)	24.6 (17.1 to 34.9)	20.0 (-20.0 to 101.8)	7.7 (-29.5 to 82.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	21.2 (-26.1 to 126.1)	9.8 (-34.6 to 109.1)
Genital herpes	1,013.2 (956.0 to 1,074.2)	1,235.7 (1,151.3 to 1,314.8)	22.2 (12.0 to 32.5)	-4.8 (-12.7 to 3.3)	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.8)	20.6 (9.1 to 32.2)	-4.6 (-13.7 to 4.5)
Other sexually transmitted diseases	1.4 (0.9 to 2.0)	0.9 (0.7 to 1.2)	-36.0 (-52.8 to -4.2)	-42.3 (-57.2 to -14.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.4 (-35.3 to 29.3)	-19.8 (-43.3 to 15.8)
Hepatitis	-	-	-	-	0.2 (0.2 to 0.4)	0.2 (0.1 to 0.3)	3.7 (-17.1 to 11.2)	-19.1 (-30.0 to -7.6)
Hepatitis A	4.5 (4.3 to 4.8)	5.1 (4.8 to 5.4)	11.8 (11.6 to 12.0)	-3.7 (-4.4 to -3.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	14.4 (1.3 to 29.1)	-2.9 (-13.5 to 10.1)
Hepatitis B	138.7 (114.9 to 163.3)	87.9 (72.6 to 104.9)	-36.8 (-52.4 to -17.2)	-49.0 (-61.7 to -32.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-34.1 (-62.1 to -3.6)	47.8 (-69.5 to -24.2)
Hepatitis C	154.1 (136.7 to 171.6)	150.9 (136.4 to 166.7)	-2.0 (-15.7 to 14.8)	-25.0 (-35.7 to -11.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.0 (-33.1 to 56.9)	-24.9 (-45.5 to 11.4)
Hepatitis E	-	-	-	-	6.5 (4.4 to 28.3)	-	-	-
Leprosy	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other infectious diseases	30.5 (26.3 to 38.3)	37.7 (29.7 to 53.7)	16.7 (-10.8 to 81.8)	2.9 (-25.0 to 75.0)	1.2 (0.6 to 2.1)	1.1 (0.6 to 2.3)	-8.3 (-45.0 to 108.8)	-12.5 (-47.2 to 104.4)
Non-communicable diseases	-	-	-	-	756.8 (563.7 to 962.1)	991.1 (740.8 to 1,263.1)	31.0 (26.5 to 34.9)	1.9 (-1.7 to 5.3)
Neoplasms	-	-	-	-	14.4 (10.7 to 18.5)	20.5 (15.5 to 26.8)	45.4 (33.9 to 58.6)	0.1 (-7.8 to 8.7)
Esophageal cancer	1.0 (0.8 to 1.1)	1.2 (1.0 to 1.6)	28.7 (-2.3 to 75.9)	-11.9 (-33.5 to 20.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	23.2 (-7.7 to 66.8)	-15.6 (-37.4 to 15.3)
Stomach cancer	3.6 (3.1 to 4.2)	2.8 (2.4 to 3.4)	-19.9 (-35.1 to -3.7)	-46.0 (-55.6 to -35.7)	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-23.0 (-38.6 to -5.6)	47.7 (-57.7 to -36.7)
Liver cancer	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	69.8 (26.1 to 139.8)	17.3 (-13.7 to 63.5)
Liver cancer due to hepatitis B	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	87.5 (-22.0 to 311.3)	30.3 (-44.8 to 188.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	78.7 (-22.3 to 289.3)	24.7 (-46.7 to 167.4)
Liver cancer due to hepatitis C	0.2 (0.1 to 0.3)	0.9 (0.5 to 1.2)	352.5 (145.2 to 1,012.4)	211.7 (67.7 to 674.7)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	309.8 (130.0 to 911.8)	185.0 (60.2 to 602.4)
Liver cancer due to alcohol use	0.5 (0.3 to 0.7)	0.4 (0.2 to 0.6)	-24.4 (-58.4 to 41.7)	-48.1 (-71.6 to -2.5)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-24.0 (-56.9 to 42.0)	-48.2 (-70.9 to -3.2)
Liver cancer due to other causes	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-4.9 (-62.2 to 142.7)	-35.7 (-73.3 to 54.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.4 (-61.4 to 138.7)	-36.8 (-72.9 to 53.9)
Larynx cancer	1.6 (1.1 to 2.0)	1.4 (1.1 to 1.8)	-11.1 (-36.9 to 17.9)	-41.1 (-57.0 to -19.5)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-20.4 (-42.4 to 10.3)	45.5 (-60.7 to -24.3)
Tracheal, bronchus and lung cancer	6.6 (6.0 to 7.3)	9.0 (7.3 to 10.2)	38.7 (3.5 to 60.8)	-5.6 (-29.4 to 9.6)	0.9 (0.6 to 1.1)	1.1 (0.8 to 1.5)	30.4 (-1.6 to 52.3)	-10.8 (-32.4 to 4.4)
Breast cancer	59.1 (54.7 to 63.3)	88.6 (83.4 to 93.6)	49.8 (37.1 to 64.2)	2.3 (-6.5 to 11.7)	3.1 (2.2 to 4.2)	4.1 (2.8 to 5.6)	30.8 (15.7 to 47.0)	-10.1 (-20.5 to 0.9)
Cervical cancer	3.8 (2.9 to 4.5)	3.4 (2.5 to 4.4)	-10.4 (-28.8 to 17.1)	-35.2 (-49.3 to -15.4)	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.4)	-10.7 (-32.5 to 19.8)	-35.6 (-51.3 to -12.9)
Uterine cancer	1.8 (1.4 to 2.3)	4.3 (2.0 to 5.7)	144.6 (22.1 to 245.2)	44.9 (-14.5 to 130.6)	0.3 (0.1 to 0.2)	0.3 (0.1 to 0.4)	58.3 (17.3 to 247.2)	36.3 (-19.7 to 133.6)
Prostate cancer	32.8 (27.8 to 38.4)	78.1 (67.4 to 94.4)	137.3 (98.2 to 188.9)	62.4 (35.4 to 98.7)	2.6 (1.8 to 3.4)	5.3 (3.7 to 7.4)	103.2 (64.6 to 171.2)	38.9 (12.3 to 83.7)
Colon and rectum cancer	21.4 (19.9 to 23.0)	29.3 (26.1 to 32.6)	37.7 (18.8 to 57.2)	-5.2 (-18.1 to 8.0)	1.7 (1.3 to 2.2)	2.2 (1.6 to 2.9)	30.5 (12.0 to 50.9)	-9.8 (-22.3 to 3.5)
Lip and oral cavity cancer	3.6 (3.0 to 4.4)	5.8 (4.7 to 7.2)	63.2 (8.1 to 114.5)	12.3 (-25.5 to 48.2)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.6)	57.8 (2.5 to 107.0)	9.0 (-29.1 to 42.8)
Nasopharynx cancer	0.8 (0.5 to 1.1)	0.3 (0.2 to 0.5)	-67.3 (-95.5 to -17.1)	-76.3 (-85.1 to -41.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-68.0 (-79.1 to -48.4)	-76.9 (-85.1 to -41.1)
Other pharynx cancer	1.7 (1.2 to 2.3)	1.8 (1.3 to 2.5)	3.0 (-32.7 to 60.4)	-28.4 (-53.0 to 12.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	27.9 (-31.6 to 64.6)	3.3 (-52.4 to 14.9)
Gallbladder and biliary tract cancer	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.7)	40.1 (-16.8 to 91.5)	-6.2 (-44.1 to 26.6)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	32.6 (-21.5 to 89.9)	-10.8 (-45.4 to 24.5)
Pancreatic cancer	1.0 (0.9 to 1.2)	1.7 (1.4 to 1.9)	63.9 (31.5 to 105.0)	12.0 (-10.0 to 39.8)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.4)	57.0 (24.4 to 97.4)	7.5 (-14.3 to 33.8)
Malignant skin melanoma	14.0 (9.3 to 18.0)	20.8 (14.8 to 30.4)	47.0 (14.6 to 99.0)	6.0 (-17.9 to 43.2)	0.8 (0.5 to 1.2)	1.2 (0.7 to 1.8)	41.9 (9.5 to 91.9)	2.9 (-20.9 to 39.2)
Non-melanoma skin cancer	4.7 (3.4 to 6.2)	6.6 (4.8 to 9.2)	42.0 (8.2 to 110.7)	2.2 (-36.0 to 40.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	10.2 (4.9 to 126.9)	10.2 (-23.6 to 55.6)
Ovarian cancer	2.4 (2.0 to 2.8)	3.4 (2.8 to 4.0)	41.4 (11.1 to 78.2)	-3.0 (-23.2 to 21.6)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	39.9 (5.7 to 83.5)	-3.7 (-26.8 to 26.0)
Testicular cancer	3.2 (1.9 to 4.7)	1.7 (1.1 to 2.8)	-47.4 (-71.1 to 22.3)	-51.8 (-72.9 to 10.6)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-47.7 (-71.5 to 21.8)	-52.0 (-74.0 to 10.7)
Kidney cancer	3.9 (3.3 to 4.5)	9.1 (7.5 to 10.8)	135.4 (83.9 to 204.5)	64.6 (28.5 to 109.5)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	123.8 (70.9 to 196.0)	56.5 (-19.5 to 103.7)
Bladder cancer	4.7 (6.9 to 9.7)	6.4 (7.5 to 10.7)	42.0 (-12.9 to 31.2)	-28.7 (-41.5 to -12.5)	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.9)	21.5 (-17.7 to 25.5)	31.0 (-44.5 to -15.4)
Brain and nervous system cancer	1.5 (1.3 to 1.8)	2.3 (1.9 to 2.7)	51.0 (24.0 to 81.3)	11.3 (-7.8 to 32.4)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	44.9 (15.5 to 79.5)	6.4 (-13.3 to 30.0)
Thyroid cancer	3.8 (3.2 to 5.0)	5.8 (4.1 to 7.4)	56.8 (1.6 to 116.7)	17.6 (-23.9 to 62.1)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	50.9 (-1.6 to 108.1)	13.2 (-26.4 to 56.2)
Mesothelioma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	59.9 (4.4 to 140.6)	11.8 (-27.0 to 68.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (3.9 to 147.7)	14.5 (-26.8 to 73.4)
Hodgkin lymphoma	1.4 (0.7 to 1.9)	0.6 (0.4 to 1.2)	-66.3 (-76.3 to 20.5)	-70.6 (-79.9 to -1.5)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-68.3 (-77.9 to 15.0)	-72.5 (-81.3 to 5.5)
Non-Hodgkin lymphoma	7.5 (5.5 to 11.1)	12.0 (7.7 to 15.4)	64.7 (3.6 to 105.4)	13.9 (-28.4 to 41.9)	0.5 (0.3 to 0.8)	0.8 (0.5 to 1.2)	59.8 (-0.1 to 96.6)	10.3 (-30.8 to 36.2)
Multiple myeloma	1.3 (0.9 to 1.9)	2.2 (1.5 to 3.3)	61.1 (4.4 to 174.4)	11.2 (-29.6 to 89.5)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.7)	53.6 (1.5 to 165.1)	6.0 (-30.1 to 83.7)
Leukemia	3.8 (3.3 to 4.3)	5.1 (4.4 to 5.9)	36.3 (11.0 to 65.9)	-5.2 (-24.2 to 15.4)	0.5 (0.3 to 0.6)	0.6 (0.4 to 0.8)	29.5 (4.6 to 60.1)	-9.8 (-27.7 to 11.5)
Other neoplasms	3.1 (2.5 to 3.8)	7.0 (5.7 to 9.1)	126.3 (69.4 to 205.6)	59.2 (22.8 to 108.8)	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.7)	106.0 (55.2 to 182.1)	46.6 (13.0 to 92.8)
Cardiovascular diseases	-	-	-	-	22.4 (15.5 to 30.3)	31.7 (22.7 to 41.9)	41.4 (16.4 to 70.2)	-3.0 (-20.3 to 17.3)
Rheumatic heart disease	0.6 (0.6 to 0.6)	0.8 (0.8 to 0.9)	34.1 (22.7 to 46.7)	-4.0 (-11.8 to 4.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	31.6 (-9.2 to 125.0)	-7.1 (-36.9 to 61.1)
Ischemic heart disease	175.0 (140.6 to 213.0)	234.8 (206.6 to 270.1)	34.5 (4.0 to 74.0)	-10.4 (-31.4 to 17.3)	9.3 (5.9 to 13.6)	11.9 (8.1 to 16.7)	28.3 (-5.7 to 74.0)	-15.6 (-39.0 to 17.4)
Cerebrovascular disease	-	-	-	-	6.4 (5.4 to 10.6)	11.6 (8.1 to 15.5)	46.4 (15.5 to 78.7)	3.4 (-16.8 to 24.3)
Ischemic stroke	48.4 (40.0 to 57.5)	69.5 (59.6 to 81.0)	45.7 (11.8 to 81.8)	2.5 (-20.1 to 25.1)	6.6 (4.4 to 9.0)	9.6 (6.6 to 13.0)	47.4 (13.6 to 81.0)	3.8 (-19.6 to 25.8)
Hemorrhagic stroke	9.5 (6.9 to 12.6)	13.9 (8.9 to 19.3)	43.1 (-8.2 to 138.4)	1.2 (-33.4 to 65.2)	1.3 (0.8 to 2.0)	2.0 (1.2 to 3.0)	44.2 (-8.4 to 136.6)	2.6 (-33.6 to 63.2)
Hypertensive heart disease	2.8 (1.9 to 3.8)	3.3 (1.9 to 5.5)	10.9 (-34.3 to 110.3)	-23.7 (-54.7 to 46.4)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.6)	13.0 (-35.4 to 120.1)	-22.1 (-55.2 to 54.3)
Cardiomyopathy and myocarditis	2.0 (1.4 to 2.8)	2.4 (1.8 to 3.3)	22.9 (-18.9 to 88.6)	-12.8 (-46.1 to 31.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	21.8 (-2.9 to 99.2)	-13.1 (-43.2 to 40.5)
Atrial fibrillation and flutter	7.9 (4.7 to 11.1)	12.5 (8.7 to 16.2)	57.6 (7.2 to 148.9)	8.8 (-25.4 to 67.2)	0.6 (0.3 to 0.9)	0.9 (0.6 to 1.4)	59.3 (7.2 to 152.2)	10.3 (-26.0 to 70.2)
Peripheral vascular disease	257.8 (206.3 to 317.0)	389.1 (280.5 to 518.6)	48.9 (2.6 to 127.7)	3.1 (-30.6 to 57.5)	0.3 (0.1 to 0.7)	0.4 (0.2 to 0.9)	30.8 (-32.9 to 239.1)	-10.6 (-54.3 to 126.4)
Endocarditis	0.1 (0.1 to 0.1)	0.6 (0.5 to 0.7)	544.8 (357.2 to 839.2)	402.3 (250.2 to 643.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (195.0 to 537.7)	224.9 (129.8 to 390.9)
Other cardiovascular and circulatory diseases	53.3 (32.2 to 77.0)	89.6 (55.5 to 120.1)	70.1 (-1.6 to 206.2)	18.6 (-30.4 to 112.0)	3.6 (2.0 to 5.8)	6.1 (3.4 to 9.2)	70.9 (-2.0 to 207.3)	19.4 (-30.9 to 114.3)
Chronic respiratory diseases	-	-	-	-	50.7 (34.3 to 69.7)	68.0 (45.2 to 92.5)	33.5 (15.3 to 65.5)	0.6 (-13.0 to 20.7)
Chronic obstructive pulmonary disease	919.3 (821.5 to 1,009.3)	1,254.5 (1,121.8 to 1,374.8)	36.4 (28.2 to 46.0)	-1.3 (-7.6 to 5.7)	40.0 (25.8 to 56.4)	53.1 (37.7 to 75.0)	30.2 (10.2 to 70.3)	-4.7 (-19.4 to 21.8)
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.6 (-5.2 to 3.8)	-25.4 (-31.8 to -2.5)

Appendix Table G.4 - Switzerland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.2 (5.4 to 17.2)	-21.3 (-25.4 to -17.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.4 (5.5 to 17.7)	11.4 (-25.4 to -16.8)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-10.4 (-15.0 to -5.0)	-34.4 (-37.9 to -30.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.1 (-13.8 to -3.3)	-33.5 (-37.0 to -29.4)
Asthma	219.8 (192.4 to 246.3)	331.5 (282.7 to 377.3)	50.8 (23.8 to 82.8)	9.5 (-1.1 to 17.4)	14.2 (6.1 to 13.5)	14.2 (9.3 to 20.5)	59.8 (22.2 to 83.3)	41.8 (3.5 to 48.2)
Interstitial lung disease and pulmonary sarcoidosis	0.6 (0.5 to 0.8)	0.9 (0.8 to 1.0)	43.9 (14.5 to 84.3)	2.5 (-17.9 to 31.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	44.3 (14.5 to 87.1)	3.1 (-18.2 to 33.3)
Other chronic respiratory diseases	-	-	-	-	1.1 (0.7 to 1.8)	0.6 (0.4 to 0.9)	-45.0 (-59.1 to -23.8)	-59.9 (-70.1 to -44.5)
Cirrhosis	-	-	-	-	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.5)	12.2 (2.0 to 28.8)	-18.6 (-29.1 to -6.8)
Cirrhosis due to hepatitis B	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	21.4 (-30.3 to 140.2)	-12.4 (-48.6 to 73.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	20.5 (-36.1 to 154.0)	-12.9 (-52.0 to 85.0)
Cirrhosis due to hepatitis C	0.6 (0.3 to 1.0)	1.2 (0.8 to 1.5)	92.0 (12.7 to 233.6)	35.8 (-17.6 to 135.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	88.6 (7.2 to 247.4)	34.6 (-21.9 to 147.1)
Cirrhosis due to alcohol use	1.1 (0.8 to 1.3)	0.6 (0.5 to 0.9)	-39.3 (-59.5 to -11.6)	-57.2 (-71.4 to -37.6)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-39.3 (-62.5 to -4.4)	-57.2 (-73.7 to -32.2)
Cirrhosis due to other causes	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	26.8 (-24.7 to 178.9)	-4.7 (-39.6 to 100.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	26.9 (-31.2 to 186.4)	-4.3 (-44.3 to 102.9)
Digestive diseases	-	-	-	-	10.8 (7.6 to 14.7)	15.9 (11.1 to 21.5)	45.6 (21.7 to 85.1)	11.2 (-8.1 to 43.8)
Peptic ulcer disease	48.1 (42.9 to 53.3)	22.2 (19.8 to 24.2)	-53.6 (-60.9 to -47.2)	-70.0 (-74.7 to -65.4)	1.6 (1.1 to 2.2)	0.9 (0.6 to 1.3)	-43.0 (-52.0 to -29.9)	-62.8 (-69.4 to -53.2)
Gastritis and duodenitis	3.3 (2.8 to 3.9)	3.6 (2.9 to 4.3)	6.6 (-16.0 to 37.7)	-22.2 (-39.4 to 0.7)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	20.5 (-17.9 to 65.4)	-11.7 (-40.0 to 22.1)
Appendicitis	0.4 (0.4 to 0.5)	0.4 (0.4 to 0.4)	0.2 (-11.6 to 16.2)	-12.1 (-22.6 to 3.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	2.4 (-25.0 to 41.1)	-10.7 (-37.8 to 28.5)
Paralytic ileus and intestinal obstruction	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.3)	65.7 (50.9 to 88.3)	20.3 (5.1 to 53.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	65.5 (24.8 to 116.6)	21.8 (-7.7 to 68.7)
Inguinal, femoral, and abdominal hernia	46.7 (41.1 to 52.6)	60.0 (52.3 to 68.9)	28.2 (8.3 to 53.7)	-10.0 (-23.3 to 6.9)	0.6 (0.2 to 0.9)	0.6 (0.3 to 1.1)	28.2 (8.8 to 55.3)	9.1 (-22.8 to 8.6)
Inflammatory bowel disease	27.2 (21.6 to 33.1)	44.3 (37.9 to 52.7)	61.2 (23.3 to 126.8)	22.2 (-7.2 to 73.9)	5.6 (3.6 to 8.0)	9.1 (6.1 to 12.6)	61.1 (22.1 to 129.3)	11.7 (-8.1 to 75.5)
Vascular intestinal disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	51.2 (8.0 to 112.4)	4.9 (-23.3 to 42.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.2 (-9.3 to 163.0)	5.4 (-30.7 to 70.0)
Gallbladder and biliary diseases	9.8 (8.3 to 11.5)	14.9 (13.1 to 17.1)	51.1 (24.3 to 91.3)	13.4 (-8.3 to 42.3)	1.0 (0.7 to 1.4)	1.5 (1.0 to 2.1)	52.5 (22.6 to 94.2)	14.8 (-9.1 to 46.0)
Pancreatitis	1.5 (1.4 to 1.5)	2.3 (2.2 to 2.4)	56.3 (47.8 to 65.5)	2.3 (11.1 to 24.4)	0.6 (0.3 to 0.6)	0.6 (0.4 to 0.9)	55.9 (33.1 to 85.8)	37.9 (-0.1 to 40.0)
Other digestive diseases	-	-	-	-	1.4 (0.9 to 2.1)	2.7 (1.7 to 4.0)	90.5 (29.5 to 197.7)	45.2 (-0.9 to 128.9)
Neurological disorders	-	-	-	-	74.9 (52.5 to 103.7)	100.8 (70.0 to 135.4)	33.7 (16.7 to 60.5)	4.6 (-9.9 to 27.8)
Alzheimer disease and other dementias	108.6 (85.9 to 135.8)	159.4 (127.5 to 197.7)	46.9 (6.7 to 96.8)	-2.7 (-28.3 to 29.4)	15.3 (10.6 to 21.1)	23.0 (15.8 to 31.7)	50.7 (8.7 to 103.9)	-0.9 (-27.1 to 32.1)
Parkinson disease	6.5 (5.5 to 12.0)	12.5 (8.2 to 17.3)	46.2 (33.9 to 55.7)	1.0 (-7.2 to 6.7)	1.4 (0.5 to 1.5)	1.4 (0.8 to 2.1)	47.3 (30.3 to 65.6)	1.9 (-10.3 to 14.3)
Epilepsy	20.3 (14.1 to 26.9)	22.9 (14.8 to 30.9)	12.9 (-30.9 to 78.4)	-7.3 (-43.5 to 46.3)	8.1 (4.9 to 11.9)	9.5 (5.5 to 14.3)	17.2 (-29.6 to 85.0)	-3.2 (-42.3 to 55.6)
Multiple sclerosis	9.0 (7.7 to 10.3)	16.0 (14.2 to 17.8)	79.1 (48.0 to 114.2)	38.9 (13.9 to 66.6)	2.9 (2.0 to 3.8)	5.1 (3.6 to 6.6)	78.7 (45.0 to 117.8)	39.4 (12.3 to 68.5)
Migraine	1,054.1 (847.9 to 1,276.8)	1,211.0 (967.4 to 1,522.0)	14.1 (-19.4 to 60.1)	-4.7 (-33.3 to 36.5)	35.2 (20.3 to 55.1)	40.5 (23.2 to 62.2)	14.4 (-19.6 to 60.8)	-4.3 (-33.0 to 37.9)
Tension-type headache	1,423.7 (1,063.7 to 1,973.6)	1,225.6 (1,191.1 to 2,539.5)	-13.9 (18.2 to 114.0)	57.6 (0.6 to 78.5)	2.1 (1.0 to 3.9)	3.3 (1.6 to 5.9)	25.7 (17.4 to 115.1)	1.7 (-0.2 to 30.0)
Medication overuse headache	47.2 (30.5 to 65.8)	92.6 (58.7 to 127.9)	94.4 (50.4 to 169.4)	54.1 (21.1 to 112.9)	7.3 (4.1 to 11.6)	14.2 (9.9 to 21.8)	94.6 (50.9 to 172.6)	54.3 (21.4 to 114.4)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.2 (-14.4 to 99.7)	5.8 (-30.9 to 55.7)	3.1 (2.0 to 4.4)	3.7 (2.4 to 5.3)	19.1 (-16.1 to 70.8)	-17.6 (-41.3 to 17.0)
Mental and substance use disorders	-	-	-	-	160.9 (114.4 to 214.3)	194.2 (137.3 to 259.3)	21.0 (15.1 to 25.4)	1.1 (-3.3 to 4.1)
Schizophrenia	20.1 (15.7 to 24.4)	25.0 (19.3 to 30.0)	24.6 (15.4 to 33.3)	-0.9 (-8.3 to 6.6)	12.6 (8.6 to 16.7)	15.7 (10.7 to 20.5)	24.7 (14.7 to 36.0)	-0.3 (-8.6 to 8.8)
Alcohol use disorders	93.6 (84.8 to 102.5)	107.7 (97.8 to 118.4)	15.1 (9.6 to 21.7)	-1.1 (-6.2 to 4.8)	9.3 (6.2 to 13.3)	10.7 (7.0 to 15.3)	15.1 (8.2 to 22.6)	0.8 (-6.9 to 5.7)
Drug use disorders	-	-	-	-	13.1 (8.6 to 19.0)	17.8 (12.0 to 25.1)	36.3 (18.1 to 55.4)	20.6 (4.7 to 37.9)
Opioid use disorders	15.9 (9.0 to 26.4)	23.1 (14.6 to 34.0)	47.7 (21.1 to 83.8)	28.0 (5.2 to 60.9)	6.5 (3.3 to 11.1)	9.4 (5.4 to 15.0)	48.6 (20.1 to 87.2)	29.2 (5.0 to 63.2)
Cocaine use disorders	10.5 (8.0 to 13.0)	12.3 (10.0 to 15.4)	18.1 (-14.3 to 59.8)	6.2 (-25.1 to 43.3)	1.4 (0.9 to 2.1)	1.7 (1.1 to 2.5)	18.8 (-15.4 to 64.7)	6.4 (-26.0 to 48.6)
Amphetamine use disorders	12.6 (10.6 to 14.7)	17.2 (15.0 to 19.1)	35.9 (12.3 to 67.2)	22.4 (0.0 to 51.9)	1.5 (1.0 to 2.4)	2.2 (1.3 to 3.3)	22.7 (10.3 to 71.9)	2.7 (-1.9 to 56.2)
Cannabis use disorders	19.8 (17.3 to 22.4)	21.2 (18.5 to 23.9)	7.1 (6.2 to 8.2)	0.1 (0.0 to 0.1)	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.9)	7.3 (-4.1 to 19.6)	0.3 (-10.6 to 11.6)
Other drug use disorders	-	-	-	-	3.1 (1.9 to 4.6)	3.9 (2.5 to 5.7)	27.5 (7.7 to 74.4)	15.3 (-17.2 to 57.2)
Depressive disorders	-	-	-	-	54.2 (33.3 to 82.3)	65.8 (39.6 to 100.7)	21.7 (6.3 to 32.9)	-0.8 (-14.6 to 7.6)
Major depressive disorder	217.9 (141.4 to 304.3)	263.0 (169.6 to 382.6)	21.2 (3.0 to 35.0)	-1.8 (-18.4 to 8.1)	43.4 (25.2 to 69.1)	52.1 (29.5 to 84.4)	21.2 (2.1 to 35.4)	1.1 (-18.5 to 9.5)
Dysthymia	114.7 (96.6 to 133.0)	142.4 (120.5 to 165.3)	24.2 (21.5 to 26.9)	-0.3 (-0.5 to -0.2)	10.8 (7.2 to 16.0)	13.5 (8.9 to 19.9)	24.1 (20.3 to 28.2)	0.0 (-2.4 to 2.4)
Bipolar disorder	51.9 (43.3 to 60.5)	62.1 (52.0 to 72.6)	19.6 (13.3 to 26.4)	-0.4 (-5.8 to 5.0)	10.3 (6.4 to 15.5)	12.4 (7.6 to 18.5)	19.5 (11.9 to 29.2)	0.0 (-6.5 to 7.6)
Anxiety disorders	356.2 (199.6 to 500.1)	425.8 (251.0 to 599.0)	20.0 (12.9 to 28.9)	-0.4 (-0.7 to -0.2)	32.0 (15.6 to 50.4)	38.3 (19.9 to 60.4)	19.8 (12.2 to 29.1)	-0.0 (-2.2 to 2.3)
Eating disorders	-	-	-	-	4.3 (2.6 to 6.8)	4.6 (2.7 to 7.1)	4.1 (-2.5 to 14.2)	1.1 (-5.8 to 9.4)
Anorexia nervosa	7.2 (4.0 to 10.7)	7.8 (4.4 to 11.4)	7.8 (9.0 to 24.7)	2.7 (-12.9 to 18.5)	1.5 (0.7 to 2.6)	1.6 (0.8 to 2.7)	8.5 (-11.1 to 28.4)	3.3 (-14.1 to 22.6)
Bulimia nervosa	13.4 (8.0 to 20.2)	13.9 (8.4 to 20.8)	3.4 (1.0 to 5.5)	-0.2 (-0.4 to 0.0)	2.8 (1.4 to 4.7)	2.9 (1.5 to 4.9)	3.5 (-3.2 to 11.0)	0.2 (-6.0 to 7.1)
Autistic spectrum disorders	-	-	-	-	7.3 (5.2 to 9.9)	8.7 (6.0 to 11.8)	19.2 (15.4 to 22.8)	0.8 (-2.3 to 4.1)
Autism	19.2 (18.1 to 20.3)	22.9 (21.6 to 24.3)	19.3 (18.5 to 20.1)	0.5 (0.4 to 0.5)	4.6 (3.2 to 6.3)	5.5 (3.7 to 7.5)	19.0 (13.8 to 24.5)	0.8 (-3.7 to 5.6)
Asperger syndrome	27.5 (25.7 to 29.4)	32.9 (30.6 to 35.3)	19.5 (18.8 to 20.3)	0.6 (0.5 to 0.7)	2.7 (1.9 to 3.7)	3.2 (2.2 to 4.4)	19.2 (14.2 to 24.2)	0.7 (-3.4 to 4.9)
Attention-deficit/hyperactivity disorder	32.1 (27.7 to 36.1)	33.4 (28.8 to 37.6)	4.0 (3.9 to 4.0)	0.0 (0.0 to 0.0)	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.6)	0.2 (-2.4 to 11.2)	0.2 (-6.3 to 6.9)
Conduct disorder	45.2 (38.0 to 52.9)	47.3 (39.8 to 55.3)	4.8 (4.4 to 5.1)	0.0 (-0.0 to 0.0)	5.4 (3.3 to 8.1)	5.7 (3.5 to 8.6)	4.9 (0.7 to 9.1)	0.1 (-3.8 to 4.1)
Idiopathic intellectual disability	39.9 (25.0 to 56.9)	38.0 (22.8 to 56.2)	-4.1 (-43.2 to 47.0)	-20.3 (-5.2 to 23.3)	2.1 (1.2 to 3.7)	2.2 (1.1 to 3.7)	1.9 (-43.4 to 47.8)	-20.2 (-52.7 to 24.7)
Other mental and substance use disorders	131.8 (124.1 to 139.2)	164.8 (155.1 to 173.8)	25.1 (23.9 to 26.4)	0.5 (0.4 to 0.7)	9.6 (6.5 to 12.8)	12.0 (8.2 to 16.1)	25.0 (2.6 to 48.8)	0.9 (-2.6 to 4.8)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	66.8 (47.6 to 87.1)	98.8 (70.3 to 132.6)	47.8 (35.3 to 61.8)	10.3 (1.5 to 20.1)
Diabetes mellitus	261.0 (201.7 to 320.4)	513.4 (394.9 to 663.3)	96.8 (42.8 to 167.2)	42.8 (3.5 to 89.2)	16.3 (10.4 to 23.2)	31.4 (19.8 to 47.0)	93.1 (41.6 to 155.8)	39.2 (2.8 to 83.9)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.2 (-5.0 to 8.9)	-11.0 (-17.6 to -4.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.2 (-5.0 to 8.9)	-11.0 (-17.6 to -4.8)
Chronic kidney disease	-	-	-	-	25.8 (17.3 to 35.3)	34.6 (23.1 to 46.5)	34.1 (26.4 to 41.7)	0.8 (-3.3 to 5.2)
Chronic kidney disease due to diabetes mellitus	94.8 (58.8 to 146.5)	158.5 (106.5 to 249.2)	67.4 (16.7 to 145.3)	19.0 (-13.6 to 66.7)	4.4 (2.7 to 6.6)	7.4 (4.5 to 10.6)	67.7 (25.3 to 121.6)	20.3 (-9.5 to 56.8)
Chronic kidney disease due to hypertension	80.2 (62.1 to 106.1)	98.6 (67.4 to 137.9)	22.8 (-8.7 to 57.5)	-7.5 (-30.3 to 17.3)	6.9 (4.4 to 9.9)	3.6 (2.2 to 5.7)	-49.3 (-62.6 to -22.9)	-60.9 (-71.2 to -42.1)
Chronic kidney disease due to glomerulonephritis	132.3 (77.1 to 215.4)	91.2 (70.4 to 124.0)	-29.3 (-56.8 to 10.1)	-43.5 (-64.7 to -15.2)	2.6 (1.6 to 3.8)	6.1 (3.8 to 8.8)	137.0 (78.5 to 210.7)	77.9 (35.4 to 127.1)
Chronic kidney disease due to other causes	309.6 (222.9 to 446.0)	405.6 (299.0 to 571.9)	31.0 (5.9 to 60.1)	11.9 (-19.3 to 20.3)	11.9 (7.8 to 17.0)	17.5 (12.0 to 23.7)	46.4 (21.5 to 79.1)	9.9 (-8.5 to 32.1)
Urinary diseases and male infertility	-	-	-	-	7.5 (5.0 to 10.6)	13.1 (8.6 to 18.4)	75.6 (62.8 to 88.4)	8.2 (4.8 to 33.8)
Interstitial nephritis and urinary tract infections	0.7 (0.6 to 0.7)	1.1 (1.0 to 1.1)	57.2 (46.0 to 69.5)	29.3 (19.2 to 39.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	57.3 (23.9 to 103.6)	29.6 (1.0 to 71.1)

Appendix Table G.4 - Switzerland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Urolithiasis	96.6 (65.0 to 145.1)	172.6 (116.1 to 275.1)	80.9 (35.2 to 119.8)	21.7 (-4.4 to 52.7)	0.8 (0.5 to 1.3)	1.4 (0.8 to 2.5)	79.5 (37.2 to 115.3)	25.6 (-3.0 to 50.5)
Benign prostatic hyperplasia	177.9 (165.3 to 189.9)	310.0 (302.1 to 316.9)	74.2 (62.6 to 88.2)	22.6 (14.1 to 31.9)	6.2 (4.1 to 8.6)	10.8 (7.2 to 15.1)	75.6 (61.1 to 89.3)	23.7 (14.7 to 33.4)
Male infertility due to other causes	30.8 (22.8 to 40.1)	34.2 (25.2 to 44.2)	10.5 (-24.4 to 66.4)	3.0 (-29.9 to 55.2)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.5)	10.3 (-26.1 to 70.4)	2.8 (-31.3 to 60.1)
Other urinary diseases	-	-	-	-	0.3 (0.1 to 0.5)	0.6 (0.2 to 1.2)	114.2 (17.7 to 232.7)	49.8 (-17.2 to 132.9)
Gynecological diseases	-	-	-	-	9.2 (5.9 to 14.1)	10.7 (6.7 to 16.6)	15.8 (2.4 to 28.6)	-2.9 (-13.8 to 8.5)
Uterine fibroids	281.5 (239.9 to 326.0)	360.7 (309.7 to 417.4)	28.1 (27.0 to 29.3)	0.1 (0.1 to 0.2)	2.4 (1.2 to 4.4)	2.9 (1.4 to 5.5)	22.1 (8.2 to 36.9)	-3.3 (-14.5 to 8.0)
Polycystic ovarian syndrome	115.3 (96.5 to 133.1)	140.3 (119.8 to 161.6)	21.4 (-0.5 to 51.0)	5.9 (-12.9 to 32.8)	1.1 (0.5 to 2.1)	1.3 (0.6 to 2.5)	21.6 (-1.7 to 49.6)	6.7 (-13.5 to 32.9)
Female infertility due to other causes	8.5 (0.9 to 24.2)	11.1 (2.0 to 23.8)	55.2 (-84.0 to 979.0)	47.2 (-85.4 to 924.8)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	46.4 (-85.8 to 987.2)	36.8 (-86.8 to 915.8)
Endometriosis	21.4 (16.1 to 26.7)	22.8 (16.6 to 28.5)	6.6 (-30.1 to 52.1)	7.2 (-38.9 to 31.6)	2.0 (1.2 to 2.9)	2.1 (1.3 to 3.2)	4.5 (-29.2 to 52.6)	-7.2 (-37.8 to 32.8)
Genital prolapse	444.5 (399.1 to 488.8)	546.2 (494.9 to 600.2)	22.6 (6.4 to 42.6)	-4.5 (-18.1 to 11.6)	1.4 (0.7 to 2.6)	1.7 (0.8 to 3.2)	22.8 (5.5 to 42.7)	-4.2 (-18.3 to 11.9)
Premenstrual syndrome	219.3 (182.0 to 259.6)	246.9 (219.6 to 276.2)	12.9 (-8.7 to 37.7)	1.0 (-19.1 to 25.4)	1.8 (1.1 to 2.8)	2.1 (1.3 to 3.1)	13.0 (-8.2 to 40.4)	1.3 (-19.1 to 26.4)
Other gynecological diseases	19.1 (15.1 to 33.9)	19.7 (16.9 to 32.8)	10.8 (-45.2 to 77.7)	-4.4 (-50.8 to 53.3)	0.5 (0.3 to 1.3)	0.5 (0.3 to 1.1)	1.9 (-65.8 to 129.2)	-13.9 (-68.8 to 100.8)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	5.5 (3.7 to 8.0)	6.7 (4.5 to 9.8)	20.3 (4.0 to 37.4)	-0.1 (-10.9 to 11.8)
Thalassemias	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	11.4 (2.4 to 21.0)	7.5 (-1.1 to 16.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.5 (-14.9 to 48.5)	13.5 (-16.8 to 40.9)
Thalassemia trait	105.3 (95.2 to 117.4)	132.4 (121.2 to 144.4)	25.9 (12.1 to 37.8)	3.9 (-5.5 to 11.5)	3.1 (2.1 to 4.5)	3.9 (2.6 to 5.7)	25.7 (2.5 to 44.9)	2.9 (-10.8 to 13.9)
Sickle cell disorders	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.3)	6.4 (-7.8 to 24.0)	-4.4 (-18.0 to 11.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	18.1 (5.1 to 29.4)	5.6 (-6.6 to 17.5)
Sickle cell trait	129.0 (119.1 to 139.0)	144.7 (134.1 to 154.5)	12.2 (6.3 to 17.3)	-6.8 (-11.5 to -2.7)	1.6 (0.9 to 2.4)	1.8 (1.1 to 2.7)	13.1 (-1.7 to 35.7)	-3.8 (-23.8 to 13.2)
G6PD deficiency	81.9 (50.8 to 114.3)	114.3 (64.2 to 166.7)	39.8 (-25.1 to 166.1)	16.0 (-38.0 to 116.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.1 (-13.6 to 110.1)	3.8 (-31.0 to 78.6)
G6PD trait	938.8 (846.3 to 1,025.7)	1,092.9 (982.4 to 1,174.3)	16.6 (1.4 to 33.2)	-3.4 (-16.0 to 10.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-0.9 (-45.0 to 76.3)	-19.6 (-58.9 to 72.3)
Other hemoglobinopathies and hemolytic anemias	40.2 (37.1 to 43.6)	52.9 (48.3 to 58.5)	30.9 (15.1 to 51.2)	2.6 (-12.1 to 19.3)	0.7 (0.5 to 1.1)	0.9 (0.5 to 1.5)	16.8 (-8.3 to 55.9)	-2.1 (-25.2 to 38.5)
Endocrine, metabolic, blood, and immune disorders	80.1 (76.3 to 83.9)	83.8 (77.2 to 99.9)	21.2 (-6.0 to 25.1)	-17.9 (-27.2 to 13.9)	2.4 (1.6 to 3.3)	2.4 (1.5 to 3.8)	-5.0 (-15.3 to 36.0)	-22.3 (-32.2 to 34.6)
Musculoskeletal disorders	-	-	-	-	217.5 (154.5 to 287.3)	288.6 (206.2 to 381.9)	32.6 (24.0 to 42.0)	3.4 (-3.8 to 10.8)
Rheumatoid arthritis	25.6 (22.8 to 28.9)	38.7 (34.7 to 43.0)	51.4 (27.3 to 74.1)	9.4 (-7.7 to 24.6)	5.7 (4.0 to 7.6)	8.7 (6.1 to 11.5)	52.0 (27.9 to 77.4)	10.4 (-7.1 to 27.2)
Osteoarthritis	398.1 (340.0 to 457.8)	553.9 (471.7 to 655.0)	38.8 (8.2 to 81.8)	-4.4 (-25.3 to 26.9)	13.3 (8.5 to 19.2)	18.6 (11.8 to 27.0)	39.5 (8.5 to 82.9)	-3.8 (-24.8 to 27.9)
Low back and neck pain	-	-	-	-	183.3 (127.5 to 246.0)	239.6 (166.8 to 323.6)	30.8 (20.2 to 41.1)	3.4 (-5.2 to 11.5)
Low back pain	1,189.0 (1,127.0 to 1,254.7)	1,588.7 (1,494.6 to 1,693.4)	33.3 (25.1 to 44.6)	5.6 (-1.2 to 14.6)	56.6 (87.5 to 177.6)	73.3 (119.3 to 240.4)	33.3 (25.2 to 45.0)	6.1 (-0.7 to 15.6)
Neck pain	557.6 (481.1 to 629.1)	689.8 (554.4 to 834.3)	23.8 (-1.1 to 53.0)	-4.6 (-25.1 to 19.1)	53.7 (36.4 to 75.0)	66.3 (43.8 to 95.9)	23.5 (-1.6 to 53.6)	4.3 (-25.7 to 20.1)
Gout	15.3 (13.9 to 17.1)	22.1 (19.8 to 24.6)	43.5 (24.5 to 68.3)	1.7 (-12.0 to 19.1)	0.5 (0.3 to 0.6)	0.7 (0.5 to 0.9)	44.3 (18.5 to 76.2)	2.3 (-16.1 to 25.7)
Other musculoskeletal disorders	164.9 (127.0 to 202.8)	235.5 (181.3 to 289.0)	42.8 (30.9 to 55.7)	7.3 (-1.5 to 16.8)	14.7 (9.5 to 21.4)	21.1 (13.6 to 30.5)	43.7 (30.9 to 57.0)	8.3 (-1.3 to 18.0)
Other non-communicable diseases	-	-	-	-	138.1 (95.6 to 195.6)	171.9 (117.7 to 240.9)	42.5 (18.5 to 80.6)	4.2 (-9.3 to 0.5)
Congenital anomalies	-	-	-	-	11.9 (8.2 to 16.1)	15.3 (10.6 to 21.1)	28.3 (11.4 to 50.9)	3.4 (-10.7 to 23.7)
Neural tube defects	1.4 (1.2 to 1.7)	1.4 (1.2 to 1.7)	-0.3 (-22.5 to 29.5)	-15.7 (-34.6 to 9.3)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.7)	1.1 (-28.2 to 46.5)	-14.6 (-39.4 to 24.4)
Congenital heart anomalies	92.8 (80.4 to 113.8)	99.7 (85.4 to 117.3)	7.4 (-14.5 to 32.9)	-10.3 (-28.4 to 10.6)	3.2 (1.3 to 5.5)	3.4 (1.4 to 5.9)	8.6 (-12.1 to 32.3)	-8.6 (-26.0 to 10.9)
Crofacial clefts	8.8 (7.2 to 10.7)	9.3 (7.6 to 11.6)	6.2 (-19.7 to 37.7)	-11.6 (-33.2 to 14.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	4.7 (-21.0 to 49.8)	-12.3 (-39.4 to 26.2)
Down syndrome	7.4 (6.2 to 8.9)	9.4 (7.6 to 11.1)	27.6 (-0.1 to 61.1)	0.4 (-21.3 to 26.1)	1.1 (0.8 to 1.4)	1.4 (1.0 to 1.9)	1.7 (0.9 to 72.9)	34.1 (-23.4 to 31.0)
Turner syndrome	0.4 (0.4 to 0.6)	0.5 (0.4 to 0.7)	19.9 (-17.9 to 73.6)	0.0 (-30.4 to 46.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.6 (-22.4 to 77.3)	1.3 (-32.9 to 50.5)
Klinefelter syndrome	0.3 (0.3 to 0.5)	0.5 (0.4 to 0.6)	54.1 (9.7 to 112.5)	28.4 (-8.3 to 76.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.9 (-6.0 to 124.2)	26.4 (-17.9 to 92.2)
Chromosomal unbalanced rearrangements	20.6 (17.6 to 24.3)	26.9 (23.0 to 31.8)	30.4 (4.5 to 62.3)	2.6 (-18.0 to 27.9)	3.0 (2.2 to 3.9)	4.1 (3.0 to 5.5)	37.0 (9.1 to 73.1)	3.5 (-17.4 to 29.9)
Other congenital anomalies	21.0 (12.9 to 28.8)	21.7 (13.4 to 29.7)	3.4 (-18.5 to 32.4)	3.4 (-34.2 to 6.8)	4.0 (2.5 to 5.9)	5.7 (3.3 to 8.8)	28.7 (5.0 to 100.4)	15.8 (-13.3 to 69.2)
Skin and subcutaneous diseases	-	-	-	-	48.7 (31.3 to 73.9)	56.5 (36.6 to 85.2)	16.4 (5.9 to 27.4)	-2.2 (-10.9 to 8.9)
Dermatitis	493.6 (365.7 to 611.6)	580.0 (431.6 to 716.8)	17.5 (15.3 to 19.8)	-0.1 (-0.1 to -0.0)	15.0 (8.7 to 22.5)	17.4 (10.1 to 26.1)	16.2 (12.3 to 19.9)	0.1 (-2.3 to 2.5)
Psoriasis	101.5 (87.6 to 117.4)	127.4 (109.1 to 147.1)	25.5 (23.2 to 28.1)	0.1 (-0.1 to 0.2)	8.0 (5.5 to 11.2)	10.1 (6.9 to 14.1)	25.7 (20.5 to 31.5)	0.6 (-3.4 to 5.0)
Cellulitis	4.3 (1.1 to 1.7)	1.5 (1.2 to 1.8)	9.6 (-0.2 to 24.9)	9.6 (-15.5 to 4.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	11.6 (-9.5 to 41.5)	-5.2 (-22.6 to 18.3)
Pyoderma	7.8 (6.3 to 9.8)	9.7 (7.8 to 12.1)	25.2 (20.5 to 29.9)	0.5 (-1.0 to 2.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	24.8 (14.8 to 35.1)	1.0 (-6.8 to 8.5)
Scabies	4.4 (3.7 to 5.0)	4.1 (3.4 to 4.9)	-1.9 (-25.5 to 18.1)	-18.9 (-36.7 to 2.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-5.9 (-28.3 to 20.3)	-18.4 (-37.4 to 4.3)
Fungal skin diseases	503.3 (445.7 to 554.1)	640.4 (567.6 to 700.7)	27.2 (25.4 to 29.0)	0.4 (0.2 to 0.5)	2.8 (1.1 to 5.8)	3.5 (1.4 to 7.3)	27.1 (24.8 to 29.2)	0.6 (-0.3 to 1.5)
Viral skin diseases	133.6 (104.1 to 164.7)	152.2 (120.7 to 185.0)	14.0 (9.8 to 18.1)	0.5 (-1.8 to 2.7)	4.6 (2.4 to 10.5)	4.6 (2.7 to 7.2)	13.8 (9.1 to 19.0)	0.6 (-2.7 to 4.0)
Acne vulgaris	1,016.6 (761.6 to 1,346.7)	979.4 (762.9 to 1,288.6)	-4.8 (-32.5 to 44.4)	-10.1 (-35.9 to 37.4)	11.0 (4.8 to 20.9)	10.6 (4.7 to 19.7)	-9.9 (-32.7 to 44.8)	-9.9 (-36.1 to 38.0)
Alopecia areata	11.8 (10.9 to 12.7)	15.3 (14.1 to 16.5)	29.1 (18.3 to 40.5)	-0.1 (-7.7 to 8.3)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.7)	28.6 (14.2 to 42.6)	0.1 (-10.4 to 11.9)
Pruritus	0.9 (0.6 to 1.2)	1.2 (0.7 to 1.7)	33.5 (-24.7 to 131.0)	-2.7 (-41.3 to 64.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.5 (-26.5 to 143.9)	-2.8 (-43.5 to 75.8)
Urticaria	59.1 (40.5 to 80.9)	75.4 (50.4 to 103.5)	29.7 (-25.2 to 103.5)	4.3 (-41.3 to 50.3)	3.4 (1.9 to 5.4)	4.3 (2.4 to 6.8)	28.4 (-26.0 to 104.0)	-1.1 (-41.5 to 50.7)
Decubitus ulcer	3.8 (2.7 to 5.1)	5.6 (4.3 to 7.1)	45.5 (7.1 to 130.7)	-0.5 (-26.5 to 55.1)	0.5 (0.3 to 0.8)	0.8 (0.5 to 1.1)	46.3 (5.9 to 132.3)	0.5 (-26.6 to 58.2)
Other skin and subcutaneous diseases	577.6 (335.9 to 989.7)	779.4 (434.1 to 1,370.1)	34.5 (26.7 to 41.5)	0.7 (-2.6 to 3.5)	3.3 (1.4 to 7.2)	4.5 (1.8 to 10.2)	34.6 (26.2 to 41.7)	0.9 (-2.7 to 4.0)
Sense organ diseases	-	-	-	-	53.3 (35.8 to 76.1)	69.4 (46.9 to 98.1)	30.3 (20.7 to 40.8)	-8.3 (-15.0 to -1.1)
Glaucoma	9.7 (6.9 to 13.2)	9.6 (7.2 to 12.5)	-1.0 (-19.3 to 25.0)	30.5 (-42.7 to 13.4)	0.5 (0.5 to 1.3)	0.9 (0.5 to 1.3)	0.9 (-20.0 to 27.3)	-28.6 (-47.6 to -9.9)
Cataract	26.3 (16.0 to 36.9)	25.4 (14.8 to 36.4)	-4.1 (-30.7 to 29.3)	36.7 (-54.4 to 14.8)	1.6 (0.9 to 2.5)	1.6 (0.9 to 2.6)	-1.3 (-25.9 to 30.5)	-34.5 (-51.3 to -16.0)
Macular degeneration	32.5 (22.3 to 44.8)	47.3 (33.5 to 68.2)	44.4 (17.2 to 91.3)	-2.6 (-19.4 to 25.8)	2.0 (1.2 to 3.0)	2.9 (1.7 to 4.5)	41.8 (16.0 to 74.8)	-5.4 (-21.1 to 14.9)
Uncorrected refractive error	823.4 (689.6 to 991.5)	1,036.8 (862.3 to 1,224.2)	26.7 (-4.7 to 64.6)	-8.8 (-31.3 to 20.5)	10.9 (6.3 to 18.9)	13.2 (7.3 to 22.6)	21.7 (-1.3 to 48.9)	-11.2 (-27.8 to 10.5)
Age-related and other hearing loss	1,122.1 (974.9 to 1,263.7)	1,475.1 (1,265.7 to 1,683.9)	31.8 (24.7 to 36.5)	-8.2 (-13.9 to -4.4)	32.1 (21.2 to 47.4)	44.1 (29.1 to 63.7)	38.1 (23.4 to 51.5)	-5.7 (-15.9 to 3.4)
Other vision loss	24.2 (18.5 to 31.3)	21.3 (14.3 to 28.6)	-11.1 (-29.0 to 5.1)	36.4 (-47.3 to 25.4)	2.2 (1.0 to 2.3)	1.6 (0.9 to 2.3)	2.6 (-16.1 to 14.2)	-2.7 (-38.0 to -16.3)
Other sense organ diseases	160.5 (153.2 to 167.7)	199.2 (190.5 to 208.6)	24.2 (17.1 to 31.4)	-0.3 (-5.4 to 4.9)	4.1 (2.6 to 6.1)			

Appendix Table G.4 - Switzerland prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	129.7 (122.8 to 137.3)	160.0 (151.6 to 167.7)	23.4 (14.1 to 31.8)	0.0 (-7.3 to 7.0)	3.7 (2.4 to 5.6)	4.6 (2.9 to 6.9)	23.3 (13.8 to 31.9)	0.2 (-7.6 to 7.9)
Injuries	-	-	-	-	169.1 (129.4 to 215.9)	162.2 (118.1 to 216.4)	-4.6 (-14.7 to 6.6)	-30.1 (-37.1 to -22.0)
Transport injuries	-	-	-	-	33.9 (25.7 to 43.2)	23.2 (16.9 to 30.8)	-31.9 (-38.9 to -24.0)	-50.0 (-55.1 to -44.1)
Road injuries	-	-	-	-	32.3 (24.4 to 41.2)	21.1 (15.4 to 27.9)	-35.0 (-41.8 to -27.5)	-52.1 (-57.1 to -46.5)
Pedestrian road injuries	-	-	-	-	3.1 (2.3 to 4.1)	2.4 (1.7 to 3.2)	-23.5 (-30.5 to -15.7)	-44.7 (-49.9 to -38.5)
Cyclist road injuries	-	-	-	-	6.9 (5.2 to 8.9)	4.6 (3.4 to 6.1)	-33.3 (-41.2 to -24.2)	-49.7 (-55.6 to -42.8)
Motorcyclist road injuries	-	-	-	-	8.4 (6.3 to 10.7)	5.4 (3.8 to 7.3)	-35.7 (-44.4 to -25.3)	-52.1 (-58.7 to -44.2)
Motor vehicle road injuries	-	-	-	-	13.5 (10.2 to 17.1)	8.5 (6.3 to 11.2)	-37.3 (-42.6 to -31.2)	-54.4 (-58.2 to -49.8)
Other road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.2 (0.1 to 0.2)	-54.9 (-60.0 to -49.0)	-66.2 (-70.0 to -61.6)
Other transport injuries	-	-	-	-	1.6 (1.2 to 2.1)	2.1 (1.5 to 2.9)	30.6 (18.6 to 44.4)	6.5 (-14.6 to 2.4)
Unintentional injuries	-	-	-	-	134.0 (102.8 to 170.3)	138.0 (100.3 to 184.5)	2.5 (-8.3 to 14.3)	-24.3 (-32.0 to -16.1)
Falls	-	-	-	-	103.4 (78.8 to 130.7)	107.0 (78.2 to 141.7)	3.1 (-9.1 to 17.3)	-24.6 (-33.2 to -14.7)
Drowning	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-26.5 (-33.9 to -18.6)	-45.4 (-51.1 to -39.3)
Fire, heat, and hot substances	-	-	-	-	1.5 (0.9 to 2.2)	1.7 (1.0 to 2.8)	18.5 (4.3 to 34.7)	8.4 (-19.6 to 4.2)
Poisonings	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-36.0 (-44.3 to -25.9)	-51.1 (-58.1 to -42.6)
Exposure to mechanical forces	-	-	-	-	20.3 (15.2 to 26.5)	18.2 (13.0 to 24.8)	-10.7 (-17.9 to -1.4)	-30.4 (-35.9 to -23.1)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-38.6 (-47.0 to -29.5)	-51.5 (-57.9 to -44.0)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-10.2 (-21.1 to 1.9)	-30.5 (-39.1 to -20.7)
Other exposure to mechanical forces	-	-	-	-	20.1 (15.1 to 26.3)	18.1 (13.0 to 24.6)	-10.5 (-17.8 to -1.3)	-30.3 (-35.8 to -23.1)
Adverse effects of medical treatment	-	-	-	-	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.8)	41.5 (31.7 to 52.7)	5.4 (-1.3 to 12.9)
Animal contact	-	-	-	-	0.6 (0.4 to 0.8)	0.7 (0.5 to 1.0)	24.1 (14.9 to 34.4)	-5.9 (-12.9 to 2.3)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	17.4 (4.3 to 31.4)	-7.1 (-18.0 to 5.3)
Non-venomous animal contact	-	-	-	-	0.5 (0.4 to 0.7)	0.6 (0.4 to 0.9)	25.3 (15.8 to 36.5)	-5.7 (-12.8 to 2.9)
Foreign body	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	1.1 (-8.6 to 9.9)	-19.0 (-28.0 to -11.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-5.8 (-16.6 to 5.9)	-27.6 (-36.6 to -17.6)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	6.0 (-4.7 to 17.1)	-11.8 (-22.2 to -1.6)
Foreign body in other body part	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	1.6 (-9.7 to 11.7)	-18.6 (-28.9 to -10.0)
Other unintentional injuries	-	-	-	-	7.4 (5.3 to 9.9)	9.2 (6.5 to 12.7)	25.0 (16.0 to 36.2)	-9.4 (-16.0 to -1.8)
Self-harm and interpersonal violence	-	-	-	-	1.2 (0.9 to 1.5)	1.0 (0.7 to 1.4)	-14.7 (-21.6 to -7.1)	-36.2 (-41.3 to -30.4)
Self-harm	-	-	-	-	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.8)	6.3 (-3.1 to 17.1)	-20.1 (-27.5 to -11.4)
Interpersonal violence	-	-	-	-	0.6 (0.5 to 0.8)	0.4 (0.3 to 0.5)	-34.3 (-40.6 to -27.0)	-50.4 (-55.1 to -44.8)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-32.7 (-39.5 to -26.0)	-50.3 (-55.1 to -45.4)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-12.4 (-18.8 to -4.3)	-33.9 (-38.7 to -27.8)
Assault by other means	-	-	-	-	0.5 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-38.4 (-45.1 to -30.9)	-53.3 (-58.2 to -47.4)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	162.5 (69.8 to 277.3)	162.9 (50.0 to 296.3)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	162.5 (69.8 to 277.3)	162.9 (50.0 to 296.3)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Syria prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,244.5 (897.5 to 1,662.5)	2,355.5 (1,733.2 to 3,060.4)	90.7 (63.3 to 114.3)	-11.7 (-29.8 to 3.4)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	203.9 (139.3 to 287.1)	292.0 (203.1 to 397.2)	43.3 (26.4 to 64.8)	-7.2 (-17.6 to 6.7)
HIV/AIDS and tuberculosis	-	-	-	-	1.4 (0.9 to 1.9)	2.3 (1.5 to 3.2)	65.0 (42.9 to 91.4)	-19.6 (-28.8 to -8.4)
Tuberculosis	4.6 (4.4 to 4.8)	7.5 (7.1 to 8.0)	63.6 (55.9 to 71.1)	-21.4 (-24.9 to -17.9)	1.4 (0.9 to 1.9)	2.3 (1.5 to 3.2)	64.9 (42.9 to 91.3)	-19.7 (-28.8 to -8.4)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7,355.3 (2,503.0 to 167,590.2)	4,431.0 (1,184.4 to 85,651.6)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5,307.1 (1,724.8 to 146,340.1)	2,367.8 (735.7 to 71,155.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5,307.1 (1,724.1 to 148,554.6)	2,367.8 (733.4 to 71,985.8)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5,822.2 (1,826.1 to 143,012.9)	2,779.5 (860.2 to 73,117.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7,375.1 (2,494.6 to 196,591.7)	3,458.3 (1,114.5 to 102,246.9)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	35.1 (24.6 to 47.9)	41.2 (29.0 to 55.8)	17.3 (8.6 to 26.7)	-20.3 (-25.6 to -14.5)
Diarrheal diseases	141.3 (131.9 to 150.7)	168.7 (157.4 to 178.9)	19.0 (8.7 to 29.8)	-14.3 (-21.0 to -7.2)	23.1 (15.4 to 31.8)	27.4 (18.7 to 37.3)	18.9 (7.4 to 30.7)	-33.7 (-21.3 to 5.6)
Intestinal infectious diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	3.0 (2.0 to 3.1)	33.9 (-48.2 to -17.9)
Typhoid fever	1.1 (1.0 to 1.3)	1.3 (1.1 to 1.5)	11.1 (-12.5 to 35.2)	-28.6 (-43.3 to -13.4)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	11.3 (-16.4 to 44.4)	-28.4 (-44.8 to -10.9)
Paratyphoid fever	0.6 (0.5 to 0.7)	0.7 (0.6 to 0.8)	13.8 (-11.2 to 46.9)	-26.6 (-43.1 to -4.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	14.1 (-12.7 to 50.2)	26.6 (-43.6 to -2.6)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-78.3 (-90.9 to -51.8)	-86.1 (-94.0 to -69.2)
Lower respiratory infections	10.7 (8.9 to 12.8)	8.0 (6.4 to 9.9)	-25.1 (-43.4 to -2.8)	-43.2 (-55.3 to -27.7)	1.1 (0.7 to 1.6)	0.8 (0.5 to 1.3)	-25.0 (-45.7 to -0.1)	-42.4 (-56.2 to -26.3)
Upper respiratory infections	262.2 (230.4 to 296.9)	428.4 (385.7 to 475.6)	61.8 (40.7 to 91.8)	-3.0 (-14.9 to 14.4)	3.1 (1.7 to 5.2)	5.0 (2.8 to 8.6)	61.9 (40.4 to 93.0)	-2.1 (-14.5 to 15.2)
Otitis media	162.3 (150.5 to 177.5)	234.1 (217.0 to 251.5)	43.6 (31.9 to 56.1)	-10.1 (-18.0 to -1.6)	3.0 (1.8 to 4.9)	4.2 (2.5 to 6.9)	42.1 (30.1 to 55.6)	-10.7 (-18.4 to -1.7)
Meningitis	-	-	-	-	3.6 (2.4 to 5.1)	2.1 (1.4 to 3.0)	-40.8 (-53.1 to -20.9)	-64.2 (-70.3 to -53.6)
Pneumococcal meningitis	13.9 (8.6 to 22.1)	8.4 (5.1 to 13.5)	-40.3 (-56.5 to -19.2)	-66.1 (-74.7 to -53.8)	1.3 (0.8 to 1.8)	0.8 (0.5 to 1.1)	-37.1 (-58.7 to -14.6)	-62.6 (-74.0 to -49.9)
H influenzae type B meningitis	8.8 (3.0 to 17.3)	4.1 (1.5 to 8.3)	-53.0 (-67.7 to -27.1)	-73.3 (-81.0 to -58.2)	0.9 (0.6 to 1.6)	0.5 (0.3 to 0.9)	47.0 (-70.8 to -3.8)	-67.6 (-81.5 to -42.0)
Meningococcal meningitis	4.9 (1.5 to 10.7)	2.7 (0.8 to 6.2)	-44.9 (-58.0 to -24.9)	-69.3 (-76.0 to -58.8)	0.6 (0.3 to 1.1)	0.3 (0.2 to 0.6)	69.3 (-60.6 to -18.8)	-67.9 (-75.9 to -54.6)
Other meningitis	6.0 (3.2 to 10.1)	4.2 (2.1 to 7.4)	-31.5 (-47.3 to -10.1)	-58.3 (-68.4 to -47.0)	0.8 (0.5 to 1.2)	0.5 (0.3 to 0.8)	58.3 (-53.0 to -5.3)	-58.7 (-69.3 to -43.2)
Encephalitis	9.5 (1.5 to 7.9)	4.8 (2.0 to 10.9)	-49.5 (-12.8 to 53.6)	-59.0 (-38.4 to -83.3)	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.9)	38.1 (14.0 to 72.0)	-28.8 (-37.1 to -7.8)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.5 (-95.9 to 888.9)	-59.0 (-96.1 to 372.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.5 (-96.0 to 919.8)	-59.0 (-96.2 to 379.7)
Whooping cough	4.8 (3.8 to 6.2)	5.3 (4.2 to 6.8)	10.2 (9.6 to 10.8)	-10.2 (-10.7 to -9.7)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.4)	9.6 (5.3 to 28.1)	-10.6 (-22.8 to 4.3)
Tetanus	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-81.4 (-90.6 to -63.8)	-89.9 (-94.3 to -77.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-72.4 (-87.5 to -38.0)	-81.8 (-91.6 to -60.3)
Measles	1.8 (1.4 to 2.2)	0.7 (0.6 to 0.9)	-60.3 (-66.1 to -54.4)	-69.3 (-72.6 to -63.2)	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.1)	69.7 (-74.1 to -40.7)	-68.3 (-79.1 to -52.2)
Varicella and herpes zoster	10.4 (9.7 to 11.2)	15.9 (14.4 to 17.7)	51.4 (33.2 to 72.4)	1.7 (-15.5 to 22.1)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	120.4 (58.6 to 204.2)	7.0 (-23.8 to 47.3)
Neglected tropical diseases and malaria	-	-	-	-	15.9 (9.0 to 27.6)	16.0 (9.7 to 25.5)	2.6 (-28.7 to 44.6)	-28.2 (-50.6 to 5.9)
Malaria	0.2 (0.1 to 0.2)	0.0 (0.0 to 0.0)	-84.1 (-92.5 to -67.8)	-93.4 (-96.9 to -86.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.1 (-34.5 to 160.6)	-35.7 (-69.4 to 22.2)
Chagas disease	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Leishmaniasis	-	-	-	-	0.8 (0.4 to 1.6)	1.8 (0.8 to 3.4)	125.3 (89.4 to 171.3)	18.1 (0.9 to 40.0)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.8 (-0.5 to 76.4)	-8.2 (-28.7 to 15.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.8 (-0.7 to 76.6)	-8.2 (-28.7 to 15.9)
Cutaneous and mucocutaneous leishmaniasis	73.4 (55.2 to 97.0)	165.8 (126.9 to 215.8)	125.2 (89.9 to 169.1)	16.6 (-0.5 to 38.3)	0.8 (0.4 to 1.6)	1.8 (0.8 to 3.4)	125.4 (89.5 to 171.6)	18.1 (0.9 to 40.0)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	6.3 (2.5 to 15.2)	12.4 (4.8 to 29.4)	94.4 (91.0 to 99.4)	0.8 (-0.9 to 3.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	100.0 (65.9 to 113.7)	5.4 (-13.8 to 12.1)
Cysticercosis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-70.3 (-92.2 to 4.6)	-85.3 (-95.8 to -50.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.0 (-91.8 to 16.7)	-83.8 (-95.6 to -44.3)
Cystic echinococcosis	1.1 (0.9 to 1.3)	1.6 (1.5 to 1.8)	42.1 (29.0 to 73.2)	-37.4 (-43.9 to -27.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	47.6 (12.0 to 101.8)	-35.5 (-50.1 to -15.7)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Dengue	0.3 (0.1 to 1.0)	3.0 (0.7 to 8.5)	756.4 (746.1 to 768.4)	391.6 (385.7 to 398.5)	0.1 (0.0 to 0.2)	0.5 (0.1 to 1.4)	700.8 (525.1 to 915.6)	356.7 (269.2 to 463.2)
Yellow fever	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-70.9 (-70.9 to -17.9)	-57.9 (-80.8 to -57.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-47.8 (-70.9 to -17.8)	-71.1 (-80.9 to -57.8)
Intestinal nematode infections	-	-	-	-	7.8 (3.2 to 16.4)	4.8 (2.0 to 10.3)	-39.5 (-71.1 to 42.9)	-54.2 (-79.0 to 14.1)
Ascariasis	2,460.4 (1,976.3 to 3,042.5)	4,210.4 (3,241.9 to 5,339.7)	70.6 (17.4 to 133.8)	-4.9 (-35.1 to 36.2)	7.1 (2.8 to 15.4)	3.7 (1.2 to 9.1)	51.7 (-80.4 to 38.0)	-62.2 (-85.6 to 12.1)
Trichuriasis	651.9 (511.1 to 815.0)	1,220.6 (944.4 to 1,558.1)	85.6 (31.6 to 170.6)	1.2 (-31.9 to 55.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	97.7 (-67.0 to 1,205.0)	6.9 (-85.4 to 783.5)
Hookworm disease	198.9 (161.7 to 241.7)	365.2 (291.4 to 461.6)	83.3 (33.9 to 148.2)	0.6 (-29.5 to 40.3)	1.1 (0.3 to 1.0)	1.1 (0.5 to 2.0)	85.7 (-10.4 to 239.5)	8.0 (-46.1 to 103.9)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	197.6 (150.8 to 244.6)	252.1 (217.3 to 290.1)	27.1 (2.4 to 66.2)	-13.8 (-28.5 to 8.4)	7.1 (4.3 to 10.6)	8.7 (5.5 to 12.6)	21.2 (-2.9 to 78.0)	-14.2 (-31.4 to 23.9)
Maternal disorders	-	-	-	-	0.9 (0.5 to 1.5)	1.0 (0.5 to 1.7)	10.5 (-11.8 to 31.2)	-47.6 (-57.9 to -37.7)
Maternal hemorrhage	2.9 (2.4 to 3.4)	4.6 (3.4 to 5.8)	61.7 (15.6 to 120.8)	-35.5 (-47.0 to 2.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	37.8 (-20.9 to 129.2)	-36.5 (-61.6 to 6.7)
Maternal sepsis and other maternal infections	7.3 (4.8 to 10.4)	7.4 (4.8 to 11.1)	1.5 (-31.8 to 38.8)	-57.1 (-70.6 to -41.7)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.2)	-12.9 (-50.9 to 47.9)	-59.0 (-75.2 to -34.6)
Maternal hypertensive disorders	8.1 (3.0 to 14.6)	9.0 (3.1 to 16.5)	10.3 (-0.7 to 20.8)	-47.1 (-55.7 to -43.1)	0.4 (0.1 to 0.8)	0.4 (0.1 to 0.9)	9.7 (-7.4 to 28.8)	-47.7 (-57.0 to -39.2)
Obstructed labor	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.6)	-2.8 (-34.4 to 48.4)	-54.3 (-68.2 to -31.4)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.2)	-1.8 (-58.4 to 93.4)	-53.4 (-79.2 to -10.1)
Complications of abortion	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	24.4 (-26.9 to 105.7)	-45.3 (-67.1 to -12.3)	0.1 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.4 (-27.0 to 105.8)	-45.3 (-67.2 to -12.1)
Other maternal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	11.5 (-32.4 to 98.8)	-47.1 (-68.4 to -5.2)
Neonatal disorders	-	-	-	-	18.7 (10.9 to 33.1)	64.1 (38.7 to 95.0)	247.9 (112.7 to 448.4)	119.9 (37.2 to 242.8)
Preterm birth complications	58.5 (33.1 to 100.5)	227.9 (147.3 to 344.1)	293.9 (168.3 to 480.6)	129.3 (59.0 to 246.2)	7.1 (4.1 to 11.1)	31.1 (19.6 to 45.6)	342.7 (158.2 to 608.8)	169.0 (60.5 to 330.2)
Neonatal encephalopathy due to birth asphyxia and trauma	22.9 (10.5 to 48.4)	49.4 (28.3 to 74.4)	120.8 (4.9 to 418.9)	43.5 (-31.2 to 224.6)	5.5 (2.6 to 11.2)	11.8 (7.0 to 18.4)	122.5 (11.3 to 394.2)	47.4 (-26.6 to 226.6)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	25.9 (4.3 to 39.3)	0.0 (-13.2 to 16.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.6 (0.2 to 46.8)	6.3 (-16.6 to 22.3)
Hemolytic disease and other neonatal jaundice	11.5 (4.5 to 28.1)	48.0 (16.8 to 100.9)	312.4 (32.4 to 1,733.9)	166.8 (-15.1 to 1,098.3)	3.5 (1.4 to 7.7)	12.4 (4.8 to 24.9)	248.3 (27.1 to 1,321.4)	119.2 (-19.3 to 800.7)
Other neonatal disorders	-	-	-	-	2.6 (0.9 to 5.9)	8.8 (2.3 to 17.6)	230.1 (34.8 to 752.7)	107.4 (-13.5 to 443.8)
Nutritional deficiencies	-	-	-	-	124.5 (81.0 to 181.6)	156.3 (103.1 to 227.3)	26.4 (8.1 to 46.2)	-19.9 (-29.2 to -8.9)
Protein-energy malnutrition	94.2 (40.7 to 183.7)	102.5 (44.8 to 211.3)	8.7 (-62.9 to 241.7)	-10.0 (-69.1 to 183.0)	11.9 (4.5 to 26.3)	12.9 (4.7 to 27.6)	8.5 (-63.1 to 255.6)	-10.3 (-69.2 to 193.4)
Iodine deficiency	453.6 (212.3 to 747.7)	487.9 (282.8 to 758.3)	8.3 (-45.2 to 134.7)	-45.0 (-73.4 to 26.6)	8.2 (3.3 to 16.2)	8.8 (4.3 to 16.1)	8.5 (-45.5 to 135.6)	-44.7 (-73.2 to 27.9)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-

Appendix Table G.4 - Syria prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	2,996.7 (2,947.4 to 3,043.3)	4,235.2 (4,173.2 to 4,302.7)	40.8 (37.7 to 43.6)	-16.7 (-18.9 to -14.8)	99.9 (66.6 to 144.8)	131.8 (87.8 to 191.2)	33.1 (27.7 to 35.1)	33.1 (-20.2 to -14.6)
Other nutritional deficiencies	-	-	-	-	4.5 (1.0 to 12.6)	2.8 (0.8 to 8.2)	-38.1 (-88.3 to 271.6)	-48.6 (-90.2 to 206.4)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	7.4 (4.7 to 11.1)	11.1 (7.0 to 16.7)	50.5 (23.5 to 91.0)	-6.9 (-23.0 to 13.9)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.8 (0.9 to 3.2)	3.7 (2.0 to 6.4)	110.0 (39.2 to 217.4)	0.6 (-30.1 to 45.0)
Syphilis	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.4)	37.9 (15.5 to 69.1)	-43.0 (-51.2 to -32.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	45.7 (7.8 to 94.8)	-38.8 (-55.4 to -17.3)
Chlamydial infection	196.4 (126.1 to 279.9)	393.5 (299.4 to 544.9)	101.7 (20.9 to 248.6)	3.0 (-38.4 to 68.6)	0.8 (0.3 to 1.8)	1.9 (0.9 to 3.6)	156.0 (0.0 to 410.2)	17.8 (-48.5 to 144.8)
Gonococcal infection	62.6 (47.6 to 77.8)	98.2 (72.3 to 125.1)	57.4 (3.9 to 122.7)	-19.7 (-46.7 to 10.7)	0.4 (0.2 to 0.7)	0.8 (0.4 to 1.3)	81.9 (12.7 to 165.5)	-8.2 (-41.4 to 31.0)
Trichomoniasis	54.5 (31.8 to 95.6)	114.5 (81.9 to 157.7)	118.8 (11.0 to 321.5)	-1.9 (-41.8 to 73.2)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	128.6 (-2.1 to 381.4)	0.9 (-46.7 to 97.2)
Genital herpes	1,222.4 (1,159.5 to 1,298.0)	2,610.6 (2,484.6 to 2,758.6)	112.2 (97.9 to 131.2)	-7.4 (-14.1 to 0.4)	0.3 (0.1 to 0.8)	0.7 (0.2 to 1.7)	188.9 (87.1 to 331.5)	-6.2 (-14.5 to 3.1)
Other sexually transmitted diseases	2.0 (1.5 to 2.6)	3.4 (2.6 to 4.5)	67.7 (45.4 to 103.7)	-27.7 (-38.8 to -12.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	106.5 (39.5 to 206.9)	5.8 (-33.7 to 34.5)
Hepatitis	-	-	-	-	0.7 (0.4 to 1.0)	1.4 (0.9 to 2.1)	100.3 (69.6 to 146.6)	6.6 (-10.3 to 36.3)
Hepatitis A	19.7 (18.7 to 20.7)	28.3 (27.2 to 29.4)	43.2 (41.6 to 44.9)	-4.0 (-4.0 to -3.9)	0.4 (0.3 to 0.6)	0.7 (0.4 to 1.0)	67.3 (48.0 to 87.2)	0.0 (-10.3 to 11.1)
Hepatitis B	627.6 (573.0 to 707.4)	1,381.2 (1,146.5 to 1,649.3)	116.8 (75.1 to 183.3)	15.9 (-6.4 to 48.7)	0.2 (0.1 to 0.4)	0.6 (0.3 to 0.9)	144.5 (59.5 to 325.8)	10.4 (-25.4 to 97.3)
Hepatitis C	147.6 (132.9 to 161.3)	231.3 (202.7 to 258.3)	56.7 (31.5 to 81.8)	-25.9 (-36.7 to -15.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.2 (17.3 to 88.8)	-23.3 (-43.4 to 6.2)
Hepatitis E	1.5 (0.9 to 2.2)	4.4 (3.4 to 5.8)	194.4 (66.3 to 432.3)	50.3 (-12.2 to 177.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	199.1 (61.6 to 479.3)	48.6 (-16.7 to 180.4)
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	174.9 (-9.8 to 1,840.1)	22.4 (-57.2 to 782.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	185.5 (-9.2 to 2,616.5)	25.5 (-57.2 to 1,134.0)
Other infectious diseases	139.9 (109.3 to 171.6)	182.6 (147.2 to 219.2)	29.7 (4.0 to 66.4)	-15.4 (-30.5 to 4.7)	4.9 (3.0 to 7.3)	6.0 (3.7 to 8.8)	21.9 (-16.7 to 72.8)	-15.6 (-41.6 to 18.1)
Non-communicable diseases	-	-	-	-	836.8 (613.9 to 1,084.1)	1,361.5 (1,368.6 to 2,423.7)	122.5 (111.4 to 135.1)	72.2 (2.0 to 13.2)
Neoplasms	-	-	-	-	1.6 (1.1 to 2.2)	4.4 (3.0 to 6.0)	180.5 (110.7 to 267.7)	25.2 (-8.1 to 62.6)
Esophageal cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	78.6 (13.9 to 187.7)	-24.5 (-51.5 to 21.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	84.9 (26.8 to 177.2)	-21.9 (-47.5 to 19.6)
Stomach cancer	1.1 (0.8 to 1.4)	1.7 (1.3 to 2.1)	51.0 (6.3 to 110.8)	-34.8 (-54.0 to -9.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	59.2 (11.0 to 121.4)	-30.7 (-51.0 to -2.7)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	199.2 (109.5 to 328.2)	31.5 (-10.5 to 87.3)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	137.1 (-2.2 to 434.3)	0.6 (-59.9 to 137.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	133.6 (0.2 to 385.5)	0.5 (-58.0 to 118.6)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	568.3 (214.6 to 1,533.3)	188.1 (34.9 to 595.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	555.2 (232.2 to 1,439.9)	180.0 (41.5 to 568.9)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	64.9 (-28.2 to 281.9)	-26.3 (-68.1 to 57.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.3 (-21.5 to 253.4)	-26.4 (-66.4 to 48.4)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	54.9 (-39.3 to 271.3)	-36.0 (-74.4 to 72.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.2 (-34.8 to 243.8)	27.4 (-72.4 to 58.7)
Larynx cancer	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.5)	140.7 (20.9 to 301.2)	2.5 (-49.4 to 68.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	151.0 (23.0 to 324.3)	6.9 (-49.5 to 78.9)
Tracheal, bronchus and lung cancer	0.5 (0.4 to 0.6)	1.0 (0.8 to 1.3)	97.6 (38.8 to 182.1)	-16.7 (-39.6 to 18.6)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	106.7 (40.2 to 198.5)	-11.8 (-38.5 to 25.8)
Breast cancer	2.0 (1.4 to 2.7)	4.5 (3.1 to 6.0)	127.0 (36.5 to 263.4)	-8.0 (-44.2 to 47.2)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	118.2 (31.5 to 260.0)	-10.3 (-46.0 to 44.6)
Cervical cancer	1.4 (0.9 to 1.1)	1.6 (1.1 to 2.4)	49.1 (-26.7 to 90.0)	-19.9 (-68.4 to -20.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	46.2 (-25.9 to 102.2)	-46.2 (-67.7 to -13.6)
Uterine cancer	0.5 (0.3 to 1.0)	1.4 (0.7 to 2.3)	206.1 (12.1 to 535.9)	23.5 (-54.6 to 153.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	206.8 (19.9 to 553.3)	24.0 (-54.0 to 156.3)
Prostate cancer	1.1 (0.6 to 1.8)	5.9 (3.6 to 9.4)	428.0 (173.7 to 910.2)	111.0 (6.6 to 295.7)	0.1 (0.1 to 0.2)	0.6 (0.3 to 1.0)	397.1 (164.1 to 843.4)	95.4 (4.4 to 273.6)
Colon and rectum cancer	1.1 (0.9 to 1.4)	3.6 (2.8 to 4.5)	230.1 (136.7 to 353.6)	34.3 (-3.2 to 81.2)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.5)	219.2 (127.9 to 337.3)	29.7 (-6.8 to 77.9)
Lip and oral cavity cancer	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.9)	81.2 (7.0 to 194.4)	-22.7 (-53.0 to 22.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	83.9 (16.2 to 198.9)	-20.6 (-50.1 to 27.2)
Nasopharynx cancer	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	33.7 (-17.5 to 124.3)	-41.3 (-63.5 to -2.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	35.4 (-15.9 to 122.7)	-40.6 (-62.7 to -2.6)
Other pharynx cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	53.2 (-13.1 to 173.5)	-36.1 (-63.1 to 13.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.9 (-9.8 to 162.7)	-35.7 (-61.7 to 7.6)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	104.2 (22.0 to 223.0)	-14.5 (-49.4 to 35.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.6 (18.4 to 197.8)	-18.7 (-50.4 to 23.3)
Pancreatic cancer	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	354.1 (219.9 to 547.2)	93.3 (37.7 to 172.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	362.3 (233.2 to 518.1)	96.1 (-19.0 to 161.7)
Malignant skin melanoma	0.6 (0.2 to 0.5)	0.3 (0.2 to 0.5)	69.8 (-48.0 to 69.7)	-49.8 (-77.2 to -24.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.4 (-46.8 to 83.1)	62.6 (-76.5 to -15.8)
Non-melanoma skin cancer	1.0 (0.7 to 1.4)	3.1 (2.2 to 4.1)	202.9 (96.0 to 376.6)	19.4 (-21.5 to 97.9)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	247.2 (139.8 to 414.1)	45.0 (-2.7 to 124.4)
Ovarian cancer	0.3 (0.2 to 0.4)	0.7 (0.4 to 1.1)	138.1 (39.2 to 323.4)	0.1 (-40.5 to 74.6)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	135.4 (35.4 to 334.9)	-0.5 (-43.0 to 84.0)
Testicular cancer	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.8)	215.6 (57.5 to 526.6)	41.7 (-27.6 to 175.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	215.6 (39.1 to 603.1)	41.5 (-33.7 to 200.5)
Kidney cancer	0.4 (0.3 to 0.6)	1.0 (0.7 to 1.3)	127.9 (51.9 to 257.2)	15.1 (-18.8 to 70.7)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	137.9 (57.2 to 263.2)	14.0 (-21.8 to 68.0)
Bladder cancer	0.2 (0.1 to 0.3)	0.5 (0.4 to 0.7)	172.3 (56.3 to 310.2)	15.7 (-35.2 to 74.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	172.6 (60.6 to 305.5)	15.1 (-32.8 to 75.3)
Brain and nervous system cancer	0.4 (0.3 to 0.8)	2.2 (1.3 to 2.8)	503.1 (106.6 to 821.3)	231.1 (11.0 to 369.3)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	525.6 (116.4 to 823.0)	214.9 (5.7 to 360.2)
Thyroid cancer	0.9 (0.6 to 1.3)	2.2 (1.0 to 4.1)	149.0 (22.1 to 321.5)	3.4 (-47.3 to 75.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	145.3 (23.3 to 317.2)	1.9 (-46.6 to 68.0)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.0 (10.3 to 153.4)	-82.2 (-53.7 to -24.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.1 (46.8 to 83.1)	154.5 (-76.5 to -15.8)
Hodgkin lymphoma	1.1 (0.7 to 1.6)	1.8 (1.2 to 3.0)	62.1 (-7.3 to 213.8)	-5.5 (-44.0 to 63.3)	0.0 (0.1 to 0.1)	0.2 (0.1 to 0.3)	64.9 (-6.6 to 203.9)	-7.8 (-43.0 to 56.9)
Non-Hodgkin lymphoma	1.2 (0.8 to 1.7)	3.4 (2.6 to 4.5)	182.1 (85.9 to 314.1)	34.3 (-10.5 to 96.9)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	181.2 (87.4 to 305.8)	32.4 (-13.0 to 96.1)
Multiple myeloma	0.1 (0.0 to 0.1)	0.2 (0.2 to 0.3)	262.3 (88.7 to 540.8)	0.2 (-21.5 to 186.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	251.2 (87.0 to 512.4)	50.8 (-21.0 to 177.0)
Leukemia	0.6 (0.4 to 0.9)	2.1 (1.6 to 2.7)	278.4 (112.2 to 531.0)	153.6 (66.7 to 277.9)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.4)	344.8 (179.9 to 557.1)	154.5 (66.7 to 266.4)
Other neoplasms	1.8 (1.2 to 3.0)	8.6 (4.8 to 11.9)	444.8 (75.9 to 756.3)	216.0 (-7.2 to 398.3)	0.1 (0.1 to 0.2)	0.6 (0.3 to 1.0)	476.8 (84.2 to 793.7)	211.4 (-11.2 to 384.8)
Cardiovascular diseases	-	-	-	-	17.6 (11.9 to 24.5)	34.4 (23.3 to 48.3)	95.9 (48.9 to 162.0)	-4.0 (-24.4 to 23.8)
Rheumatic heart disease	30.6 (21.8 to 39.0)	61.9 (40.5 to 78.4)	97.0 (35.8 to 243.9)	-4.7 (-33.7 to 54.2)	1.6 (0.9 to 2.4)	3.6 (2.1 to 5.3)	117.4 (53.5 to 258.0)	9.7 (-22.5 to 72.5)
Ischemic heart disease	73.3 (57.6 to 90.7)	145.6 (126.3 to 169.8)	99.4 (54.3 to 151.0)	-14.9 (-32.5 to 6.0)	3.5 (2.5 to 5.7)	8.4 (5.5 to 12.1)	114.3 (62.7 to 188.0)	-6.1 (-29.3 to 23.4)
Cerebrovascular disease	-	-	-	-	0.5 (0.3 to 0.7)	1.2 (0.8 to 1.7)	147.9 (93.5 to 208.4)	2.9 (-20.0 to 27.8)
Ischemic stroke	2.9 (2.4 to 3.4)	6.9 (5.9 to 7.8)	141.9 (89.1 to 195.0)	-1.1 (-22.4 to 22.0)	0.4 (0.3 to 0.6)	1.1 (0.7 to 1.4)	151.1 (93.6 to 213.7)	3.8 (-20.8 to 30.2)
Hemorrhagic stroke	0.5 (0.4 to 0.6)	1.1 (0.8 to 1.4)	128.9 (55.9 to 243.2)	-2.5 (-34.9 to 50.8)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	130.7 (58.1 to 241.4)	-1.6 (-33.8 to 49.8)
Hypertensive heart disease	7.1 (5.1 to 9.1)	25.3 (18.2 to 32.3)	254.8 (150.9 to 415.2)	53.4 (4.4 to 127.5)	0.8 (0.5 to 1.1)	2.8 (1.7 to 4.2)	267.4 (161.1 to 427.2)	58.9 (10.0 to 134.2)
Cardiomyopathy and myocarditis	7.4 (6.3 to 8.8)	21.1 (21.8 to 34.3)	261.9 (166.8 to 386.1)	69.1 (19.9 to 135.1)	3.0 (1.9 to 4.3)	3.0 (1.9 to 4.3)	271.2 (169.7 to 410.4)	75.6 (21.6 to 150.3)
Atrial fibrillation and flutter	9.2 (6.3 to 12.6)	25.1 (18.4 to 31.7)	173.5 (62.7 to 359.4)	4.3 (-38.8 to 67.7)	0.6 (0.4 to 1.0)	1.9 (1.2 to 2.8)	196.4 (79.9 to 400.3)	13.2 (-31.6 to 82.8)
Peripheral vascular disease	115.1 (85.5 to 151.2)	317.3 (231.0 to 410.8)	182.8 (70.7 to 319.4)	10.2 (-27.9 to 58.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	99.2 (-6.6 to 293.9)	-19.3 (-61.1 to 58.0)
Endocarditis	0.4 (0.3 to 0.7)	1.5 (1.0 to 1.9)	280.7 (84.2 to 501.2)	106.8 (7.5 to 227.7)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	294.3 (85.0 to 548.5)	108.5 (0.8 to 250.4)
Other cardiovascular and circulatory diseases	12.0 (9.3 to 183.6)	189.5 (84.1 to 282.1)	41.9 (-34.5 to 154.6)	-27.2 (-66.6 to 24.9)	9.2 (5.6 to 13.9)	13.2 (6.1 to 21.4)	42.9 (-34.0 to 157.0)	36.9 (-66.2 to 26.8)

Appendix Table G.4 - Syria prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	120.8 (113.2 to 128.8)	-7.9 (-11.1 to -4.5)
Silicosis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	104.0 (95.0 to 115.3)	-17.0 (-21.1 to -12.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.9 (94.1 to 116.7)	-17.0 (-21.4 to -11.6)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	29.4 (120.0 to 138.9)	-2.3 (-6.1 to 1.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	130.4 (120.5 to 140.7)	-1.6 (-5.3 to 2.8)
Asthma	550.0 (452.2 to 641.1)	960.9 (845.8 to 1,060.2)	74.2 (43.7 to 113.9)	-5.5 (-18.5 to 8.7)	24.4 (15.3 to 35.9)	42.6 (27.8 to 62.3)	74.9 (43.0 to 115.0)	-4.3 (-17.6 to 10.7)
Interstitial lung disease and pulmonary sarcoidosis	0.7 (0.5 to 0.8)	1.6 (1.3 to 2.0)	139.4 (75.7 to 209.3)	3.9 (-25.0 to 35.2)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	142.9 (79.2 to 212.6)	4.9 (-23.9 to 36.7)
Other chronic respiratory diseases	-	-	-	-	1.9 (1.0 to 3.2)	4.1 (2.3 to 6.9)	115.8 (21.3 to 248.2)	-7.0 (-45.6 to 50.2)
Cirrhosis	-	-	-	-	0.9 (0.5 to 1.0)	0.9 (0.6 to 1.2)	28.3 (9.5 to 48.7)	31.4 (-39.8 to -22.0)
Cirrhosis due to hepatitis B	1.5 (1.0 to 1.9)	1.4 (0.6 to 2.2)	-0.8 (-60.4 to 89.7)	-50.3 (-78.4 to -13.4)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	0.7 (-60.9 to 105.9)	-49.1 (-78.0 to -7.6)
Cirrhosis due to hepatitis C	1.3 (0.9 to 1.7)	2.4 (1.6 to 3.2)	94.8 (10.4 to 205.1)	4.1 (-46.4 to 58.9)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	96.1 (3.5 to 238.9)	6.3 (-46.7 to 71.6)
Cirrhosis due to alcohol use	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.5)	-11.7 (-55.1 to 66.8)	-0.1 (-79.5 to -26.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-6.0 (-54.8 to 80.2)	-58.5 (-79.4 to -19.2)
Cirrhosis due to other causes	1.2 (0.9 to 1.5)	1.2 (0.9 to 1.6)	6.1 (-28.1 to 57.4)	-28.3 (-50.9 to 8.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	6.1 (-36.9 to 63.8)	-28.2 (-56.6 to 18.8)
Digestive diseases	-	-	-	-	6.0 (4.2 to 8.0)	12.4 (8.8 to 16.5)	106.5 (81.5 to 131.7)	-1.1 (-11.8 to 9.9)
Peptic ulcer disease	15.5 (12.8 to 18.0)	21.9 (18.4 to 25.3)	39.7 (14.4 to 76.3)	-41.2 (-53.1 to -24.4)	0.6 (0.4 to 0.9)	1.0 (0.7 to 1.4)	59.1 (20.4 to 99.3)	-31.9 (-47.8 to -15.2)
Gastritis and duodenitis	36.0 (31.8 to 40.1)	34.8 (30.9 to 38.8)	-3.6 (-17.8 to 12.2)	-46.4 (-54.5 to -37.1)	1.6 (1.1 to 2.4)	1.7 (1.1 to 2.5)	0.5 (-22.2 to 35.2)	-38.4 (-49.4 to -21.6)
Appendicitis	0.9 (0.6 to 1.1)	1.3 (0.8 to 1.8)	57.4 (0.5 to 127.7)	-20.1 (-47.6 to 10.2)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.7)	55.4 (-10.9 to 156.4)	-18.9 (-49.0 to 31.1)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	101.2 (52.5 to 154.9)	0.1 (-12.5 to 21.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	100.5 (37.0 to 203.6)	0.1 (-20.8 to 42.8)
Inguinal, femoral, and abdominal hernia	39.9 (29.9 to 54.6)	65.8 (55.9 to 79.5)	67.1 (10.8 to 145.2)	-12.9 (-35.5 to 22.8)	0.4 (0.2 to 0.8)	0.7 (0.3 to 1.3)	69.2 (10.7 to 152.5)	-9.3 (-33.6 to 31.4)
Inflammatory bowel disease	7.6 (7.0 to 8.2)	25.0 (22.9 to 27.1)	229.0 (193.7 to 263.6)	44.6 (29.7 to 60.0)	1.6 (1.1 to 2.2)	5.3 (3.6 to 7.2)	233.9 (189.2 to 281.7)	49.0 (30.0 to 68.2)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	118.3 (57.5 to 214.1)	-0.5 (-35.1 to 56.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	119.8 (59.5 to 216.0)	2.7 (-34.6 to 64.5)
Gallbladder and biliary diseases	3.2 (2.8 to 3.6)	7.1 (6.1 to 8.4)	123.0 (82.7 to 172.2)	0.3 (-21.0 to 16.9)	0.3 (0.2 to 0.5)	0.7 (0.5 to 1.0)	125.2 (79.3 to 186.5)	4.1 (-20.1 to 24.0)
Pancreatitis	1.9 (1.7 to 2.0)	3.9 (3.6 to 4.2)	108.1 (90.8 to 127.3)	-8.7 (-15.6 to -0.5)	0.5 (0.4 to 0.7)	1.1 (0.8 to 1.6)	111.8 (72.3 to 156.3)	-5.6 (-20.4 to 12.3)
Other digestive diseases	-	-	-	-	0.6 (0.3 to 0.8)	1.4 (0.8 to 2.1)	143.8 (74.3 to 247.5)	16.2 (-16.4 to 64.7)
Neurological disorders	-	-	-	-	107.0 (70.8 to 149.9)	246.4 (163.4 to 345.1)	129.8 (105.5 to 164.6)	9.8 (-1.6 to 24.8)
Alzheimer disease and other dementias	38.8 (32.8 to 44.5)	99.3 (85.7 to 114.4)	155.8 (110.1 to 211.0)	0.9 (-18.4 to 25.4)	5.0 (3.6 to 6.6)	13.7 (9.7 to 17.8)	172.8 (121.1 to 241.0)	7.0 (-15.5 to 36.6)
Parkinson disease	3.7 (2.0 to 5.3)	9.4 (5.2 to 13.3)	151.8 (130.4 to 186.1)	2.1 (-6.5 to 15.0)	0.4 (0.2 to 0.6)	1.1 (0.5 to 1.7)	168.1 (134.3 to 210.3)	9.2 (-3.7 to 25.7)
Epilepsy	59.0 (49.4 to 68.4)	105.6 (88.0 to 122.6)	77.7 (42.9 to 125.1)	1.4 (-18.8 to 27.4)	17.7 (11.6 to 24.4)	34.7 (23.6 to 47.5)	97.3 (51.4 to 153.6)	14.1 (-11.7 to 46.6)
Multiple sclerosis	1.7 (1.0 to 2.3)	7.0 (4.4 to 10.0)	304.3 (135.0 to 762.1)	70.4 (-0.1 to 238.9)	0.6 (0.3 to 0.8)	2.3 (1.3 to 3.5)	302.4 (128.0 to 754.0)	69.4 (-0.9 to 239.2)
Migraine	1,927.6 (1,674.6 to 2,163.6)	4,215.4 (3,790.1 to 4,712.9)	118.2 (83.2 to 161.8)	1.8 (-11.8 to 24.1)	65.9 (37.2 to 98.1)	144.3 (86.3 to 213.8)	119.1 (79.3 to 186.4)	6.9 (-11.2 to 26.5)
Tension-type headache	1,997.1 (1,834.1 to 2,161.5)	4,080.3 (3,823.9 to 4,318.6)	103.8 (82.5 to 125.5)	-1.2 (-9.6 to 8.5)	3.0 (1.5 to 3.0)	6.2 (3.0 to 10.8)	104.9 (83.3 to 126.7)	0.1 (-8.8 to 10.2)
Medication overuse headache	79.6 (52.0 to 107.4)	265.4 (176.4 to 354.8)	231.8 (163.6 to 322.7)	48.9 (23.2 to 84.0)	12.5 (7.2 to 19.3)	41.7 (23.1 to 64.5)	233.7 (161.9 to 328.8)	51.3 (23.7 to 89.3)
Other neurological disorders	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	83.5 (24.1 to 187.7)	0.2 (-31.9 to 48.9)	1.9 (1.1 to 3.0)	2.3 (1.4 to 3.7)	19.8 (-33.1 to 118.2)	-54.4 (-74.2 to -15.9)
Mental and substance use disorders	-	-	-	-	268.6 (185.0 to 369.1)	573.0 (398.0 to 775.5)	113.0 (101.8 to 128.2)	6.7 (-6.2 to 22.3)
Schizophrenia	23.9 (21.6 to 26.2)	55.8 (51.0 to 60.2)	132.8 (121.4 to 144.6)	-0.4 (-4.3 to 4.1)	15.1 (11.1 to 18.4)	35.6 (26.2 to 43.2)	136.4 (118.6 to 153.9)	2.2 (-4.7 to 9.7)
Alcohol use disorders	54.7 (49.7 to 60.2)	103.5 (93.2 to 114.0)	88.2 (77.7 to 100.2)	-9.2 (-14.1 to -4.0)	5.4 (3.6 to 7.7)	10.2 (6.8 to 14.9)	89.6 (74.6 to 107.0)	-8.2 (-15.0 to -0.6)
Drug use disorders	-	-	-	-	30.9 (17.5 to 50.0)	89.9 (53.4 to 133.0)	186.7 (137.4 to 292.2)	28.4 (7.0 to 76.3)
Opioid use disorders	56.7 (29.2 to 95.6)	183.5 (110.7 to 266.3)	218.8 (144.7 to 397.8)	34.0 (5.6 to 104.0)	23.4 (11.2 to 41.4)	76.3 (42.5 to 116.4)	222.6 (148.5 to 404.0)	36.3 (8.4 to 107.8)
Cocaine use disorders	8.3 (7.4 to 11.4)	19.6 (16.1 to 24.6)	110.2 (60.2 to 179.7)	0.7 (-21.0 to 31.4)	2.7 (0.8 to 1.9)	2.7 (1.6 to 4.0)	111.0 (53.5 to 192.6)	2.5 (-22.8 to 36.7)
Amphetamine use disorders	16.8 (13.2 to 20.2)	27.2 (22.3 to 32.6)	61.2 (22.8 to 113.5)	-15.1 (-34.1 to 9.1)	2.2 (1.3 to 3.4)	3.6 (2.2 to 5.5)	62.5 (17.3 to 121.4)	-14.0 (-36.7 to 15.3)
Cannabis use disorders	18.3 (13.8 to 22.5)	35.0 (27.1 to 42.3)	90.6 (85.3 to 97.7)	0.2 (-0.2 to 0.3)	0.5 (0.3 to 0.8)	1.0 (0.6 to 1.6)	90.9 (61.7 to 127.2)	0.8 (-13.6 to 18.1)
Other drug use disorders	-	-	-	-	3.5 (2.2 to 5.1)	6.3 (4.0 to 9.5)	80.1 (28.2 to 153.2)	-8.2 (-33.7 to 28.7)
Depressive disorders	-	-	-	-	90.2 (51.8 to 144.0)	202.7 (116.5 to 321.4)	123.8 (96.5 to 151.7)	8.9 (-1.8 to 17.3)
Major depressive disorder	393.1 (246.2 to 559.7)	880.2 (533.8 to 1,238.0)	122.6 (93.6 to 150.8)	8.0 (-3.8 to 17.3)	80.6 (43.9 to 133.6)	181.0 (99.4 to 292.6)	123.5 (93.4 to 154.6)	10.2 (-2.2 to 20.1)
Dysthymia	99.9 (81.1 to 118.8)	225.8 (183.3 to 267.7)	124.9 (119.1 to 132.5)	0.1 (-0.0 to 0.1)	9.6 (6.1 to 13.9)	21.7 (13.9 to 31.7)	126.8 (117.3 to 137.3)	1.7 (-1.0 to 5.8)
Bipolar disorder	70.3 (59.7 to 80.3)	152.6 (131.6 to 171.4)	116.1 (103.7 to 132.8)	-0.8 (-5.0 to 4.7)	14.2 (8.7 to 21.3)	31.0 (19.0 to 46.4)	117.5 (100.9 to 139.1)	1.1 (-5.4 to 9.1)
Anxiety disorders	465.1 (198.6 to 684.4)	919.1 (435.7 to 1,303.1)	97.6 (81.6 to 117.8)	-0.1 (-0.3 to 0.1)	42.9 (16.7 to 71.3)	84.7 (35.6 to 135.8)	123.8 (81.2 to 122.1)	1.3 (-1.5 to 5.2)
Eating disorders	-	-	-	-	1.7 (1.0 to 2.7)	3.3 (2.0 to 5.0)	94.8 (71.1 to 120.5)	4.0 (-7.8 to 17.2)
Anorexia nervosa	1.7 (1.1 to 2.5)	3.8 (2.5 to 5.4)	116.3 (89.3 to 152.4)	20.2 (4.7 to 38.4)	0.4 (0.2 to 0.6)	0.8 (0.5 to 1.3)	115.4 (63.9 to 188.9)	20.1 (8.0 to 59.5)
Bulimia nervosa	6.3 (4.3 to 8.9)	11.9 (8.1 to 16.9)	87.4 (81.1 to 93.9)	-0.9 (-1.1 to -0.6)	1.3 (0.8 to 2.2)	2.5 (1.4 to 4.0)	88.4 (63.5 to 113.7)	-0.5 (-12.6 to 12.7)
Autistic spectrum disorders	-	-	-	-	14.7 (10.3 to 20.1)	25.9 (18.1 to 35.2)	76.5 (68.4 to 83.7)	1.6 (-2.3 to 5.7)
Autism	36.8 (34.8 to 38.9)	65.4 (62.0 to 69.1)	76.7 (75.7 to 77.9)	0.1 (0.1 to 0.1)	9.1 (6.1 to 12.6)	16.1 (10.9 to 22.2)	76.8 (67.1 to 87.0)	1.7 (-3.7 to 6.9)
Asperger syndrome	55.5 (52.0 to 58.8)	97.8 (91.7 to 103.7)	75.6 (74.2 to 77.1)	0.1 (0.1 to 0.1)	5.6 (3.9 to 7.7)	9.8 (6.8 to 13.6)	75.8 (68.0 to 83.8)	1.4 (-2.7 to 5.8)
Attention-deficit/hyperactivity disorder	97.8 (80.6 to 115.3)	148.2 (122.3 to 174.6)	51.0 (50.3 to 51.4)	0.4 (0.4 to 0.5)	1.2 (0.7 to 1.9)	1.8 (1.0 to 2.8)	51.2 (40.4 to 62.8)	0.7 (-6.7 to 8.5)
Conduct disorder	18.2 (150.6 to 210.0)	275.9 (228.1 to 320.0)	51.6 (49.9 to 53.4)	0.4 (0.4 to 0.5)	21.9 (13.8 to 33.2)	33.2 (20.3 to 50.4)	52.0 (45.2 to 58.7)	0.1 (-3.5 to 4.9)
Idiopathic intellectual disability	494.2 (341.3 to 483.3)	626.2 (524.1 to 755.5)	54.4 (40.8 to 67.6)	-9.9 (-17.9 to -2.1)	9.8 (13.2 to 27.7)	30.6 (20.2 to 42.8)	54.6 (40.7 to 65.5)	-9.0 (-17.3 to -0.6)
Other mental and substance use disorders	142.5 (132.7 to 152.0)	322.4 (301.4 to 342.3)	125.2 (122.9 to 127.7)	0.0 (-0.1 to 0.1)	10.6 (7.2 to 14.2)	24.1 (16.4 to 32.4)	127.2 (117.4 to 139.9)	2.2 (-1.9 to 8.3)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	100.9 (70.0 to 141.2)	245.0 (163.4 to 339.3)	141.1 (114.2 to 181.8)	17.3 (0.7 to 41.0)
Diabetes mellitus	555.5 (448.9 to 651.1)	1,630.6 (1,384.0 to 1,876.3)	191.9 (134.8 to 266.9)	24.1 (-2.2 to 57.9)	43.3 (28.7 to 61.6)	134.0 (86.7 to 191.9)	208.2 (141.1 to 304.4)	27.6 (-1.5 to 69.7)
Acute glomerulonephritis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	16.0 (8.9 to 22.8)	-24.3 (-28.1 to -20.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.0 (8.9 to 22.8)	-24.3 (-28.1 to -20.6)
Chronic kidney disease	-	-	-	-	10.3 (7.4 to 13.7)	20.8 (14.6 to 28.2)	102.0 (84.4 to 122.2)	0.9 (-6.1 to 9.3)
Chronic kidney disease due to diabetes mellitus	72.2 (48.5 to 102.3)	179.8 (121.9 to 259.6)	147.3 (86.8 to 230.7)	6.4 (-19.7 to 38.8)	1.8 (1.2 to 2.5)	4.6 (3.1 to 6.5)	156.6 (103.4 to 248.9)	13.4 (-13.1 to 48.5)
Chronic kidney disease due to hypertension	64.2 (42.8 to 98.0)	89.6 (62.7 to 127.0)	40.2 (-0.9 to 95.0)	-24.2 (-43.5 to -2.8)	2.9 (2.0 to 4.2)	5.3 (3.5 to 7.4)	77.5 (39.5 to 135.4)	-18.9 (-37.3 to 5.8)
Chronic kidney disease due to glomerulonephritis	194.2 (72.4 to 149.6)	175.1 (114.6 to 247.1)	66.9 (24.6 to 126.2)	-1.8 (-46.5 to 45.5)	1.9 (1.2 to 2.6)	2.4 (1.5 to 3.2)	31.6 (3.0 to 94.9)	-30.1 (-43.1 to 9.9)
Chronic kidney disease due to other causes	139.7 (99.4 to 205.7)	313.1 (216.4 to 422.2)	124.6 (64.8 to 190.7)	12.1 (-14.9 to 38.3)	3.8 (2.2 to 5.1)	8.5 (5.8 to 11.7)	126.4 (78.1 to 186.4)	18.5 (-7.5 to 45.4)
Urinary diseases and male infertility	-	-	-	-	5.0 (3.2 to 7.4)	16.0 (9.0 to 27.7)	206.3 (138.7 to 340.9)	31.5 (3.3 to 81.9)

Appendix Table G.4 - Syria prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	2.3 (2.1 to 2.5)	4.7 (4.4 to 5.0)	104.1 (84.9 to 125.1)	0.1 (-3.5 to 12.8)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	104.6 (59.8 to 163.1)	104.6 (12.6 to 29.4)
Urolithiasis	74.3 (52.6 to 122.3)	240.9 (147.1 to 470.6)	208.7 (165.8 to 305.4)	0.5 (-0.1 to 0.6)	1.7 (0.3 to 0.8)	1.7 (0.9 to 3.1)	220.8 (171.0 to 331.4)	46.7 (23.6 to 87.0)
Benign prostatic hyperplasia	74.7 (68.1 to 81.5)	181.0 (164.3 to 195.0)	241.5 (115.6 to 168.6)	-0.0 (-10.7 to 10.6)	2.5 (1.6 to 3.5)	6.4 (4.2 to 9.3)	159.8 (123.9 to 204.8)	7.4 (-7.4 to 25.7)
Male infertility due to other causes	67.0 (47.7 to 92.3)	139.7 (91.0 to 196.7)	106.2 (39.6 to 205.1)	-2.3 (-34.0 to 43.3)	0.5 (0.2 to 1.0)	1.0 (0.4 to 2.0)	105.3 (36.0 to 209.6)	-2.3 (-35.0 to 43.8)
Other urinary diseases	-	-	-	-	1.5 (0.8 to 2.6)	6.8 (2.5 to 15.8)	305.6 (123.1 to 653.6)	91.2 (2.5 to 237.3)
Gynecological diseases	-	-	-	-	13.8 (8.6 to 20.7)	29.8 (19.1 to 44.9)	116.0 (72.2 to 169.3)	-2.1 (-18.8 to 17.2)
Uterine fibroids	150.4 (134.8 to 164.6)	390.9 (353.5 to 425.3)	158.7 (155.7 to 162.0)	1.3 (1.1 to 1.4)	2.6 (1.6 to 4.2)	5.9 (3.4 to 9.7)	121.7 (108.3 to 135.8)	-9.5 (-14.8 to -4.7)
Polycystic ovarian syndrome	209.2 (187.6 to 229.6)	450.7 (406.8 to 500.2)	114.1 (85.2 to 149.0)	-3.0 (-14.8 to 11.7)	2.0 (0.9 to 3.8)	4.4 (2.1 to 8.3)	114.3 (86.2 to 150.1)	-2.2 (-14.4 to 12.4)
Female infertility due to other causes	21.7 (10.4 to 39.3)	63.5 (24.8 to 108.7)	185.5 (9.0 to 694.2)	35.9 (-51.9 to 293.6)	0.1 (0.0 to 0.3)	0.4 (0.1 to 0.8)	110.8 (14.5 to 586.0)	30.1 (-50.0 to 265.8)
Endometriosis	16.7 (14.0 to 19.7)	40.3 (34.7 to 46.3)	140.5 (94.5 to 200.7)	4.8 (15.1 to 29.1)	1.5 (1.0 to 2.2)	3.7 (2.5 to 5.3)	141.3 (87.1 to 207.8)	5.3 (-16.5 to 31.5)
Genital prolapse	450.1 (337.6 to 535.7)	1,072.4 (863.2 to 1,306.3)	135.4 (79.9 to 202.7)	-0.3 (-22.0 to 29.9)	1.4 (0.6 to 2.7)	3.4 (1.5 to 6.3)	135.4 (81.1 to 222.8)	0.2 (-22.0 to 30.2)
Premenstrual syndrome	592.5 (357.3 to 850.1)	1,219.9 (767.5 to 1,782.0)	103.2 (14.5 to 274.0)	0.9 (-41.4 to 78.8)	5.0 (2.6 to 8.3)	10.2 (5.1 to 18.0)	103.4 (13.3 to 273.4)	0.8 (-42.1 to 81.1)
Other gynecological diseases	34.5 (25.5 to 43.2)	61.9 (56.9 to 66.8)	79.2 (41.8 to 138.9)	-15.3 (-32.4 to 12.2)	1.0 (0.6 to 1.5)	1.8 (1.2 to 2.6)	75.9 (45.0 to 206.7)	-16.5 (-31.2 to 41.3)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	22.6 (14.9 to 32.6)	36.3 (24.5 to 52.4)	60.3 (47.0 to 77.0)	1.1 (-9.6 to 13.6)
Thalassemias	5.6 (4.6 to 6.5)	8.7 (7.3 to 10.1)	52.6 (39.4 to 72.2)	4.8 (-4.3 to 17.8)	0.4 (0.2 to 0.6)	0.6 (0.4 to 0.9)	58.2 (5.1 to 135.5)	7.4 (-28.2 to 56.9)
Thalassemia trait	748.8 (681.6 to 809.4)	1,322.0 (1,225.9 to 1,418.0)	75.5 (67.8 to 84.4)	-0.1 (-4.5 to 5.0)	15.9 (10.6 to 23.1)	27.0 (18.0 to 39.6)	69.6 (49.1 to 88.0)	8.4 (-8.9 to 23.1)
Sickle cell disorders	1.5 (1.2 to 1.7)	2.3 (2.0 to 2.7)	52.2 (28.1 to 85.7)	0.2 (-14.8 to 19.7)	0.2 (0.0 to 0.2)	0.3 (0.2 to 0.4)	68.8 (36.7 to 107.8)	3.7 (-12.4 to 24.3)
Sickle cell trait	440.6 (402.7 to 474.7)	704.4 (644.9 to 759.9)	59.3 (52.7 to 66.6)	2.3 (-13.2 to -5.3)	3.4 (1.4 to 3.3)	3.4 (2.1 to 4.9)	48.5 (15.7 to 86.9)	6.3 (-22.8 to 17.5)
G6PD deficiency	309.2 (229.9 to 390.8)	556.8 (474.5 to 656.5)	79.0 (33.7 to 149.8)	1.8 (-24.1 to 42.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	66.9 (54.4 to 80.2)	4.5 (-0.9 to 10.5)
G6PD trait	1,623.6 (1,173.1 to 2,061.1)	3,147.4 (2,262.6 to 3,720.1)	94.5 (25.1 to 191.8)	10.8 (-28.7 to 66.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.3)	87.6 (-55.0 to 473.0)	25.5 (-72.1 to 267.6)
Other hemoglobinopathies and hemolytic anemias	130.2 (105.8 to 146.4)	186.0 (159.2 to 206.0)	42.1 (18.2 to 79.2)	-3.7 (-31.2 to -3.5)	3.7 (2.1 to 5.7)	4.8 (3.0 to 7.2)	28.9 (-11.4 to 102.9)	-23.0 (-44.4 to 18.3)
Endocrine, metabolic, blood, and immune disorders	170.1 (143.9 to 192.9)	246.1 (221.4 to 266.4)	43.4 (25.7 to 71.5)	-4.5 (-23.4 to -2.3)	8.1 (3.8 to 8.6)	8.1 (5.3 to 11.6)	141.2 (13.4 to 79.2)	-12.8 (-23.9 to 9.4)
Musculoskeletal disorders	-	-	-	-	126.8 (84.5 to 176.6)	313.0 (213.5 to 429.3)	149.9 (94.7 to 210.7)	8.4 (-10.5 to 30.2)
Rheumatoid arthritis	16.7 (15.6 to 17.8)	29.2 (27.2 to 31.4)	74.3 (59.2 to 92.6)	-20.5 (-27.3 to -12.2)	3.9 (2.8 to 5.2)	6.9 (4.8 to 9.2)	76.3 (56.4 to 99.6)	-18.1 (-26.3 to -7.8)
Osteoarthritis	192.3 (181.5 to 203.1)	493.6 (465.0 to 524.0)	155.3 (136.6 to 177.7)	0.5 (-6.6 to 8.8)	11.3 (8.0 to 15.4)	30.0 (20.9 to 40.6)	163.5 (141.0 to 191.5)	4.3 (-4.4 to 14.8)
Low back and neck pain	-	-	-	-	103.6 (68.5 to 147.3)	245.9 (161.0 to 347.2)	141.2 (75.4 to 216.9)	6.6 (-18.2 to 33.1)
Low back pain	651.0 (478.3 to 840.9)	1,511.1 (1,178.4 to 2,010.8)	137.5 (51.2 to 235.8)	4.1 (-28.0 to 42.3)	71.3 (43.6 to 104.7)	167.6 (101.2 to 255.3)	141.1 (52.1 to 242.3)	7.1 (-26.0 to 46.6)
Neck pain	333.4 (288.3 to 387.0)	800.3 (681.8 to 923.1)	139.2 (92.9 to 184.3)	2.5 (-16.3 to 23.8)	32.3 (21.8 to 45.6)	78.2 (53.6 to 110.0)	142.3 (94.7 to 189.9)	4.8 (-14.7 to 27.2)
Gout	3.6 (3.1 to 4.2)	9.4 (7.9 to 10.8)	163.2 (107.2 to 220.1)	5.8 (-17.6 to 27.1)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	171.8 (96.5 to 257.5)	9.9 (-19.5 to 43.7)
Other musculoskeletal disorders	88.1 (49.9 to 150.4)	330.3 (162.2 to 500.0)	288.5 (90.1 to 458.5)	7.9 (-21.3 to 118.0)	58.9 (3.8 to 14.9)	30.1 (13.6 to 51.7)	391.2 (94.5 to 480.8)	64.7 (-20.2 to 127.5)
Other non-communicable diseases	-	-	-	-	159.4 (107.5 to 230.5)	323.5 (222.4 to 455.0)	101.9 (82.2 to 125.9)	-1.2 (-7.0 to 8.8)
Congenital anomalies	-	-	-	-	13.9 (9.5 to 20.5)	47.7 (27.3 to 85.8)	222.7 (138.3 to 519.5)	92.1 (43.6 to 256.1)
Neural tube defects	3.7 (3.0 to 4.6)	7.0 (5.8 to 8.3)	87.0 (37.9 to 151.7)	19.7 (-11.4 to 60.7)	1.1 (0.7 to 1.6)	2.1 (1.4 to 3.1)	97.0 (30.6 to 192.6)	27.3 (-14.7 to 87.3)
Congenital heart anomalies	59.8 (49.1 to 72.5)	162.9 (137.9 to 205.8)	170.3 (114.4 to 251.8)	68.7 (33.1 to 119.8)	2.0 (0.0 to 3.6)	5.8 (2.3 to 10.2)	182.0 (123.3 to 266.9)	78.5 (41.8 to 131.6)
Orofacial clefts	12.0 (8.9 to 17.4)	30.2 (23.3 to 39.2)	151.7 (64.4 to 261.6)	69.7 (10.0 to 143.7)	0.3 (0.1 to 0.3)	0.3 (0.2 to 0.6)	88.1 (20.5 to 199.5)	25.7 (-19.3 to 96.0)
Down syndrome	17.9 (13.7 to 22.3)	41.3 (32.2 to 52.6)	129.2 (60.5 to 235.6)	39.3 (-2.7 to 102.3)	2.1 (1.4 to 3.0)	5.3 (3.7 to 7.3)	146.9 (71.6 to 262.8)	49.5 (3.5 to 120.2)
Turner syndrome	0.4 (0.3 to 0.6)	0.9 (0.8 to 1.0)	98.1 (51.9 to 159.9)	17.2 (-9.7 to 54.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.2 (52.4 to 180.1)	16.6 (-12.8 to 59.9)
Klinefelter syndrome	0.4 (0.3 to 0.6)	0.7 (0.5 to 0.9)	75.8 (12.5 to 165.2)	0.9 (-35.2 to 52.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.7 (10.7 to 244.1)	0.0 (-43.2 to 74.2)
Chromosomal unbalanced rearrangements	15.9 (13.8 to 21.0)	36.2 (29.0 to 47.0)	122.6 (51.0 to 194.2)	29.0 (-8.3 to 79.3)	4.6 (1.4 to 2.8)	4.6 (3.1 to 6.5)	139.7 (60.0 to 226.0)	38.6 (-3.4 to 96.6)
Other congenital anomalies	31.5 (26.0 to 38.0)	53.6 (45.1 to 64.5)	69.2 (48.6 to 99.0)	-10.6 (-23.0 to 4.6)	6.5 (3.8 to 11.5)	29.6 (13.5 to 65.9)	313.1 (148.5 to 946.7)	143.7 (48.5 to 513.4)
Skin and subcutaneous diseases	-	-	-	-	62.2 (38.5 to 96.0)	112.0 (69.6 to 173.6)	79.8 (64.4 to 99.8)	-0.2 (-7.5 to 8.8)
Dermatitis	541.7 (456.0 to 615.2)	1,061.1 (889.1 to 1,211.0)	94.9 (90.3 to 100.5)	0.0 (-0.0 to 0.1)	15.4 (10.0 to 22.2)	29.0 (18.5 to 42.0)	88.1 (79.0 to 97.5)	1.1 (-1.9 to 4.6)
Psoriasis	60.5 (48.4 to 74.9)	127.1 (99.8 to 158.4)	108.9 (103.2 to 115.9)	-0.0 (-0.1 to 0.0)	4.9 (3.2 to 7.2)	10.4 (6.7 to 15.4)	110.9 (93.7 to 130.0)	2.3 (-4.3 to 9.5)
Cellulitis	2.5 (2.0 to 3.1)	3.7 (3.0 to 4.7)	45.9 (28.0 to 65.3)	-17.8 (-27.9 to -6.2)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	47.8 (14.9 to 89.9)	-15.7 (-32.9 to 6.4)
Pyoderma	10.6 (8.4 to 13.5)	14.8 (11.9 to 19.0)	38.5 (27.3 to 51.3)	-7.6 (-13.1 to -1.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	37.7 (19.6 to 59.4)	-7.0 (-17.4 to 4.7)
Scabies	49.1 (38.5 to 63.6)	82.2 (67.5 to 104.0)	67.0 (14.5 to 134.3)	-2.4 (-31.3 to 34.2)	1.3 (0.7 to 2.1)	2.1 (1.1 to 3.5)	66.6 (14.0 to 136.6)	-1.4 (-31.6 to 36.6)
Fungal skin diseases	602.2 (489.9 to 837.6)	1,339.3 (1,022.2 to 1,667.3)	102.0 (92.9 to 113.7)	0.1 (-0.0 to 0.1)	7.5 (1.5 to 7.9)	17.5 (8.0 to 36.0)	103.2 (93.1 to 115.7)	1.6 (-0.0 to 4.5)
Viral skin diseases	304.7 (235.5 to 366.7)	479.1 (365.3 to 588.5)	56.3 (48.8 to 65.0)	0.1 (-1.5 to 1.5)	9.5 (5.5 to 14.7)	14.9 (8.5 to 23.4)	56.6 (46.6 to 66.6)	0.8 (-2.8 to 4.0)
Acne vulgaris	1,696.0 (1,289.8 to 2,141.9)	2,846.5 (2,248.3 to 3,531.3)	67.3 (21.2 to 128.0)	-0.8 (-27.7 to 37.9)	8.2 (18.2 to 35.2)	30.9 (14.3 to 57.9)	67.2 (20.6 to 128.6)	-0.6 (-27.5 to 38.4)
Alopecia areata	15.3 (13.2 to 17.8)	29.3 (25.0 to 33.1)	91.0 (53.8 to 131.8)	-1.5 (-18.0 to 21.6)	0.5 (0.3 to 0.8)	1.0 (0.6 to 1.5)	91.4 (49.8 to 137.5)	0.1 (-19.1 to 24.5)
Pruritus	2.1 (1.3 to 3.0)	5.3 (3.2 to 7.8)	154.4 (29.5 to 385.1)	19.2 (-44.3 to 149.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	160.1 (32.3 to 394.6)	24.5 (-43.6 to 164.9)
Urticaria	88.4 (60.1 to 121.5)	158.5 (116.1 to 206.1)	80.8 (14.4 to 185.8)	-4.4 (-37.1 to 38.0)	5.2 (2.9 to 8.3)	9.4 (5.5 to 14.7)	80.5 (13.7 to 194.0)	-4.8 (-36.6 to 41.4)
Decubitus ulcer	1.3 (1.1 to 1.6)	2.6 (2.1 to 3.3)	93.3 (39.4 to 154.7)	-16.8 (-46.7 to 24.9)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	98.8 (42.4 to 164.9)	-11.8 (-44.7 to 33.1)
Other skin and subcutaneous diseases	474.4 (324.4 to 675.5)	1,035.0 (699.1 to 1,506.8)	117.2 (98.9 to 134.7)	-0.3 (-3.5 to 2.9)	2.8 (1.2 to 5.7)	6.1 (2.7 to 12.5)	119.8 (100.1 to 140.0)	2.0 (-2.2 to 8.0)
Sense organ diseases	-	-	-	-	62.7 (43.0 to 87.9)	118.6 (80.8 to 165.7)	89.1 (78.5 to 101.0)	-11.9 (-17.4 to -5.5)
Glaucoma	26.9 (19.1 to 40.2)	51.8 (33.3 to 73.5)	91.0 (39.9 to 157.4)	-19.1 (-43.8 to 8.4)	2.0 (1.3 to 3.1)	4.1 (2.3 to 6.3)	101.7 (49.1 to 162.2)	-13.7 (-38.9 to 15.6)
Cataract	85.9 (62.3 to 114.8)	178.1 (123.1 to 235.0)	106.6 (66.4 to 161.7)	-19.0 (-32.4 to 1.0)	6.3 (3.7 to 9.7)	13.4 (7.8 to 19.8)	108.4 (66.5 to 189.5)	-16.4 (-31.3 to 9.2)
Macular degeneration	18.0 (9.2 to 30.9)	29.3 (17.8 to 45.1)	60.3 (15.9 to 166.7)	-37.2 (-53.3 to 0.6)	1.1 (0.5 to 1.9)	1.9 (1.0 to 3.2)	73.4 (28.1 to 173.3)	-31.1 (-48.7 to 1.8)
Uncorrected refractive error	775.1 (718.0 to 840.2)	1,562.1 (1,449.1 to 1,675.6)	100.8 (87.8 to 115.0)	-7.2 (-13.0 to -1.5)	19.8 (13.0 to 29.2)	36.0 (23.5 to 52.9)	81.5 (67.8 to 97.2)	-12.8 (-19.1 to -6.4)
Age-related and other hearing loss	768.3 (711.9 to 826.4)	1,639.9 (1,525.4 to 1,767.3)	112.7 (103.4 to 121.4)	-9.7 (-12.6 to -6.7)	4.7 (12.7 to 27.8)	7.5 (26.6 to 59.0)	103.2 (95.7 to 127.3)	1.6 (-12.4 to 0.7)
Other vision loss	84.4 (62.7 to 112.2)	122.1 (93.6 to 157.9)	44.8 (18.9 to 73.1)	-29.6 (-42.1 to -11.5)	6.2 (3.9 to 9.2)	9.3 (5.6 to 13.8)	48.1 (24.1 to 81.9)	-26.7 (-40.1 to -9.4)
Other sense organ diseases	294.7 (279.2 to 313.4)	492.4 (467.7 to 517.2)	66.5 (54.3 to 79.3)	-0.1 (-6.1 to 6.5)	7.9 (4.9 to 11.6)	13.1 (8.0 to 19.4)	66.4 (52.4 to 81.8)	1.4 (-5.9 to 9.5)
Oral disorders	-	-	-	-	20.7 (12.7 to 30.9)	45.3 (27.9 to 69.2)	118.8 (105.2 to 134.7)	-1.9 (-8.8 to 6.2)</

Appendix Table G.4 - Syria prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.								
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	332.2 (307.1 to 356.5)	757.2 (693.8 to 826.2)	126.8 (104.0 to 154.2)	-7.7 (-16.7 to 2.9)	8.8 (5.9 to 12.3)	20.7 (13.8 to 29.6)	135.6 (110.1 to 167.0)	-3.8 (-13.8 to 8.9)
Other oral disorders	175.1 (165.5 to 185.0)	352.7 (332.0 to 374.2)	100.4 (84.4 to 118.8)	-0.8 (-8.7 to 6.8)	5.1 (3.2 to 7.6)	10.3 (6.5 to 15.4)	101.2 (83.7 to 121.3)	0.6 (-7.7 to 8.9)
Injuries	-	-	-	-	203.9 (63.1 to 485.7)	202.0 (99.6 to 459.6)	-2.6 (-45.8 to 174.6)	-67.4 (-79.7 to -7.7)
Transport injuries	-	-	-	-	4.6 (3.5 to 6.0)	4.6 (3.3 to 6.3)	-0.4 (-10.4 to 11.5)	-53.8 (-58.3 to -48.7)
Road injuries	-	-	-	-	4.1 (3.1 to 5.2)	4.0 (2.8 to 5.4)	-0.5 (-13.6 to 8.7)	-55.3 (-59.7 to -50.4)
Pedestrian road injuries	-	-	-	-	0.9 (0.7 to 1.2)	0.7 (0.5 to 1.0)	-15.6 (-26.2 to -8.8)	-58.6 (-63.2 to -53.0)
Cyclist road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.6)	21.9 (9.1 to 36.5)	-45.2 (-50.9 to -38.7)
Motorcyclist road injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.5 (0.3 to 0.6)	-12.2 (-23.8 to 1.2)	-60.4 (-65.2 to -54.8)
Motor vehicle road injuries	-	-	-	-	2.3 (1.7 to 2.9)	2.3 (1.6 to 3.1)	-0.3 (-12.5 to 13.5)	-54.3 (-59.6 to -48.5)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.0 (-55.1 to -41.8)	-76.8 (-79.4 to -73.8)
Other transport injuries	-	-	-	-	0.6 (0.4 to 0.7)	0.7 (0.5 to 0.9)	21.9 (8.9 to 36.8)	-43.7 (-49.4 to -37.0)
Unintentional injuries	-	-	-	-	17.0 (13.0 to 22.0)	22.7 (16.8 to 30.3)	33.2 (22.5 to 44.8)	-36.3 (-41.0 to -31.0)
Falls	-	-	-	-	8.2 (6.2 to 10.6)	14.7 (10.6 to 19.9)	79.3 (61.8 to 98.6)	-20.7 (-28.8 to -12.4)
Drowning	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	2.7 (-11.9 to 19.6)	-48.6 (-55.1 to -41.5)
Fire, heat, and hot substances	-	-	-	-	1.3 (1.0 to 1.6)	1.3 (0.9 to 1.7)	-0.1 (-13.7 to 16.3)	-49.9 (-55.5 to -43.1)
Poisonings	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	26.7 (1.2 to 59.0)	-32.7 (-44.1 to -18.2)
Exposure to mechanical forces	-	-	-	-	5.4 (4.1 to 7.1)	1.3 (1.0 to 1.8)	-75.5 (-78.4 to -72.3)	-88.9 (-90.0 to -87.7)
Unintentional firearm injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.0 (0.0 to 0.1)	-83.0 (-85.1 to -80.6)	-92.7 (-93.5 to -91.7)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-63.7 (-68.0 to -58.6)	-83.8 (-85.6 to -81.9)
Other exposure to mechanical forces	-	-	-	-	5.1 (3.9 to 6.8)	1.3 (0.9 to 1.7)	-75.2 (-78.2 to -71.9)	-88.8 (-89.9 to -87.5)
Adverse effects of medical treatment	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	131.1 (116.3 to 146.9)	13.8 (5.8 to 22.0)
Animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	62.0 (39.5 to 88.7)	-18.5 (-27.4 to -8.4)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	65.9 (36.1 to 108.6)	-18.0 (-31.1 to -0.8)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	58.0 (33.7 to 83.5)	-18.9 (-28.0 to -9.5)
Foreign body	-	-	-	-	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.7)	57.6 (43.7 to 73.8)	-20.3 (-26.2 to -13.7)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-11.0 (-25.6 to 7.9)	-47.0 (-54.5 to -37.8)
Foreign body in eyes	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	83.4 (60.3 to 105.5)	-6.7 (-16.6 to 2.7)
Foreign body in other body part	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	76.7 (59.8 to 96.3)	-16.3 (-23.6 to -8.3)
Other unintentional injuries	-	-	-	-	1.0 (0.8 to 1.4)	3.7 (2.8 to 5.0)	256.1 (221.3 to 297.4)	26.2 (13.9 to 40.8)
Self-harm and interpersonal violence	-	-	-	-	0.8 (0.6 to 1.0)	1.1 (0.8 to 1.4)	37.0 (21.3 to 56.1)	-32.3 (-39.4 to -23.5)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.7 (14.3 to 50.7)	-45.6 (-51.9 to -37.6)
Interpersonal violence	-	-	-	-	0.8 (0.6 to 1.0)	1.0 (0.8 to 1.4)	37.2 (21.4 to 56.6)	-31.7 (-38.9 to -22.8)
Assault by firearm	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	54.4 (38.3 to 74.1)	-21.5 (-29.4 to -12.9)
Assault by sharp object	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	57.0 (37.7 to 81.7)	-24.5 (-32.9 to -13.5)
Assault by other means	-	-	-	-	0.5 (0.3 to 0.6)	0.6 (0.4 to 0.8)	24.6 (7.9 to 44.0)	-37.7 (-45.5 to -28.3)
Forces of nature, war, and legal intervention	-	-	-	-	181.4 (39.6 to 464.1)	173.6 (73.8 to 429.6)	-7.4 (-50.1 to 241.8)	-70.1 (-81.9 to 1.7)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	181.4 (39.6 to 464.1)	173.5 (73.8 to 429.6)	-7.4 (-50.1 to 241.8)	-70.1 (-81.9 to 1.7)

Appendix Table G.4 - Taiwan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,858.9 (1,365.0 to 2,436.1)	2,598.3 (1,932.4 to 3,374.3)	40.0 (31.2 to 48.6)	3.4 (-8.5 to 1.3)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	277.3 (177.8 to 427.4)	163.0 (112.6 to 228.5)	-40.3 (-53.8 to -25.5)	-37.0 (-51.5 to -22.5)
HIV/AIDS and tuberculosis	-	-	-	-	4.6 (3.1 to 6.3)	9.3 (6.4 to 12.6)	103.1 (82.6 to 125.1)	18.2 (7.1 to 30.8)
Tuberculosis	15.1 (14.0 to 16.3)	28.7 (26.8 to 31.0)	91.1 (77.3 to 105.4)	9.8 (2.1 to 17.3)	4.6 (3.1 to 6.3)	8.6 (5.9 to 11.9)	89.2 (71.1 to 109.1)	10.2 (0.1 to 20.9)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.6 (0.3 to 1.2)	8,081.3 (2,695.3 to 70,390.6)	5,770.4 (1,888.9 to 48,369.4)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	10,127.9 (3,225.8 to 77,330.5)	6,078.4 (1,939.5 to 48,573.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10,127.9 (3,224.9 to 80,505.6)	6,078.4 (1,938.3 to 49,694.6)
HIV/AIDS resulting in other diseases	0.1 (0.0 to 0.2)	4.4 (2.4 to 8.0)	6,279.0 (2,117.4 to 58,168.8)	4,751.9 (1,590.1 to 45,016.7)	0.0 (0.0 to 0.0)	0.6 (0.3 to 1.2)	8,038.0 (2,632.8 to 81,267.7)	5,773.8 (1,840.0 to 59,578.3)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	29.1 (20.0 to 40.0)	15.1 (10.3 to 21.4)	-48.2 (-54.9 to -40.4)	-40.9 (-47.5 to -34.0)
Diarrheal diseases	104.7 (94.1 to 116.2)	24.0 (21.0 to 27.4)	-76.9 (-80.4 to -72.9)	-57.9 (-64.5 to -50.6)	17.0 (11.2 to 23.9)	4.0 (2.7 to 5.6)	-78.6 (-80.4 to -72.3)	-57.1 (-64.2 to -49.7)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (-69.0 to 8.6)	0.0 (-63.2 to 10.8)
Typhoid fever	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-41.6 (-70.4 to -5.6)	-39.2 (-66.2 to -5.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.6 (-70.5 to -5.3)	-39.2 (-66.3 to -4.6)
Paratyphoid fever	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-40.6 (-65.7 to 0.9)	-33.7 (-60.9 to 8.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.6 (-65.7 to 1.2)	-33.7 (-61.0 to 9.0)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.9 (-90.0 to 86.2)	7.9 (-89.1 to 508.1)
Lower respiratory infections	12.6 (11.7 to 13.6)	12.5 (11.8 to 13.1)	-0.0 (-9.1 to 8.4)	-20.4 (-27.6 to -13.6)	1.3 (0.9 to 1.9)	1.3 (0.8 to 1.8)	-4.3 (-16.5 to 9.9)	-21.7 (-31.7 to -10.1)
Upper respiratory infections	251.6 (240.3 to 263.1)	267.9 (255.0 to 283.1)	7.1 (-0.8 to 14.6)	-0.9 (-7.8 to 5.9)	3.0 (1.7 to 4.9)	3.1 (1.8 to 5.3)	6.7 (-2.2 to 15.9)	-0.5 (-8.6 to 7.5)
Otitis media	242.8 (229.0 to 258.0)	210.7 (198.0 to 224.3)	-12.9 (-19.0 to -6.0)	-14.6 (-20.4 to -8.7)	4.8 (2.8 to 7.5)	4.2 (2.4 to 6.6)	-12.6 (-19.8 to -4.9)	-13.1 (-20.0 to -6.5)
Meningitis	-	-	-	-	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.8)	-19.2 (-41.2 to 8.2)	-31.3 (-48.1 to -8.9)
Pneumococcal meningitis	2.1 (1.2 to 3.4)	2.0 (1.2 to 3.5)	-1.7 (-24.6 to 43.0)	-31.7 (-47.0 to -1.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-9.9 (-22.6 to 26.8)	-27.7 (-39.4 to -2.3)
H influenzae type B meningitis	0.6 (0.2 to 1.4)	0.4 (0.1 to 1.0)	-39.3 (-64.3 to -2.2)	-46.9 (-66.8 to -9.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-30.4 (-62.4 to 5.8)	-30.5 (-61.1 to 5.7)
Meningococcal meningitis	0.4 (0.1 to 1.0)	0.3 (0.1 to 0.8)	-23.2 (-55.5 to 17.9)	-43.2 (-65.1 to 1.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-11.9 (-53.1 to 28.1)	-30.8 (-60.7 to 9.7)
Other meningitis	2.4 (1.0 to 5.2)	1.7 (0.7 to 4.1)	-30.9 (-54.2 to 0.3)	-44.2 (-60.2 to -15.1)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.4)	-26.7 (-55.6 to 16.4)	-34.7 (-60.1 to 3.0)
Encephalitis	6.1 (2.5 to 15.9)	5.0 (2.2 to 13.9)	-17.9 (-41.6 to 6.9)	-88.9 (-55.5 to -16.8)	0.8 (0.5 to 1.1)	0.7 (0.5 to 1.0)	-9.4 (-27.1 to 21.5)	-27.7 (-43.1 to -5.9)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.7 (-94.4 to 285.3)	-52.7 (-95.1 to 330.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.7 (-94.4 to 286.1)	-52.7 (-95.1 to 331.3)
Whooping cough	15.3 (11.8 to 19.8)	2.0 (1.6 to 2.6)	-86.8 (-88.0 to -85.5)	-73.9 (-76.2 to -71.3)	0.8 (0.4 to 1.2)	0.1 (0.1 to 0.2)	-86.8 (-88.5 to -84.6)	-73.9 (-77.3 to -69.5)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-79.2 (-87.6 to -68.8)	-82.9 (-89.9 to -71.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-78.2 (-88.2 to -63.3)	-81.9 (-90.0 to -69.3)
Measles	0.5 (0.4 to 0.6)	0.1 (0.1 to 0.1)	-81.9 (-85.1 to -78.0)	-85.9 (-71.9 to -58.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-81.4 (-87.6 to -72.7)	-64.9 (-77.2 to -47.5)
Varicella and herpes zoster	20.9 (19.0 to 22.9)	24.7 (21.8 to 27.9)	19.4 (1.6 to 38.4)	-0.3 (-12.3 to 13.1)	0.8 (0.5 to 1.2)	1.2 (0.7 to 1.8)	45.3 (17.4 to 76.8)	-0.4 (-18.2 to 20.4)
Neglected tropical diseases and malaria	-	-	-	-	131.4 (68.2 to 238.8)	28.1 (16.5 to 47.0)	-78.2 (-86.7 to -64.9)	-77.7 (-86.6 to -65.4)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.2 (-88.5 to 137.1)	-7.4 (-88.8 to 137.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.4 (-88.1 to 150.6)	-3.3 (-88.2 to 148.1)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.3 (-36.4 to 47.5)	1.3 (-37.0 to 56.7)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.1 (-48.4 to 65.5)	1.0 (-47.1 to 86.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.1 (-48.4 to 65.8)	1.0 (-47.4 to 87.0)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	12.5 (-12.0 to 41.8)	1.2 (-19.1 to 26.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.5 (-12.0 to 41.8)	1.2 (-19.1 to 26.2)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	1.7 (0.5 to 4.3)	0.2 (0.1 to 0.5)	-86.1 (-95.3 to -34.9)	-89.4 (-96.5 to -49.3)	0.5 (0.1 to 1.4)	0.1 (0.0 to 0.2)	-83.2 (-94.6 to -17.6)	-87.3 (-95.9 to -36.2)
Cystic echinococcosis	4.2 (3.9 to 4.6)	1.8 (1.5 to 2.2)	-56.5 (-64.2 to -50.2)	-70.1 (-75.5 to -63.1)	0.4 (0.3 to 0.5)	0.2 (0.1 to 0.3)	-57.0 (-68.6 to -43.9)	-69.7 (-77.8 to -59.8)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	1.9 (0.7 to 4.3)	10.8 (4.1 to 24.3)	464.3 (458.0 to 471.6)	400.5 (395.0 to 407.0)	0.3 (0.1 to 0.8)	1.7 (0.6 to 4.4)	452.8 (336.4 to 626.1)	397.4 (294.0 to 540.9)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.2 (-70.5 to -42.6)	-62.8 (-73.2 to -49.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.2 (-70.6 to -42.6)	-62.8 (-73.2 to -49.1)
Intestinal nematode infections	-	-	-	-	125.3 (63.1 to 230.7)	23.1 (13.1 to 40.9)	-81.4 (-89.2 to -68.5)	-82.1 (-89.6 to -70.9)
Ascariasis	14,445.1 (13,288.8 to 15,611.0)	2,488.7 (1,790.2 to 3,425.8)	-83.1 (-87.7 to -76.2)	-85.9 (-89.4 to -80.8)	99.2 (45.9 to 191.3)	0.8 (0.2 to 2.4)	-93.3 (-99.7 to -97.4)	-94.4 (-99.8 to -97.9)
Trichuriasis	5,459.7 (4,354.6 to 6,811.3)	998.8 (682.4 to 1,421.3)	-81.7 (-88.0 to -71.6)	-84.9 (-89.7 to -77.2)	6.4 (1.8 to 18.2)	0.0 (0.0 to 0.1)	-99.6 (-99.9 to -97.3)	-97.9 (-99.8 to -97.9)
Hookworm disease	3,020.5 (2,416.8 to 3,822.5)	3,657.1 (2,837.8 to 4,638.5)	21.9 (-12.9 to 68.1)	19.7 (-27.0 to 38.0)	19.7 (11.3 to 32.9)	22.2 (12.5 to 39.8)	11.5 (-31.0 to 80.0)	11.5 (-33.6 to 69.6)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	148.2 (120.4 to 183.4)	99.2 (80.8 to 131.8)	-33.3 (-47.0 to -6.7)	-4.8 (-24.8 to 34.7)	4.9 (3.0 to 7.1)	3.1 (1.8 to 5.0)	-37.6 (-55.5 to 1.4)	-1.4 (-29.3 to 58.5)
Maternal disorders	-	-	-	-	0.8 (0.5 to 1.2)	0.5 (0.3 to 0.8)	-37.4 (-59.4 to -15.0)	-35.4 (-57.6 to -14.1)
Maternal hemorrhage	12.2 (11.0 to 13.5)	10.9 (8.0 to 13.7)	-10.7 (-32.9 to 15.8)	-9.8 (-33.2 to 15.4)	0.5 (0.3 to 0.7)	0.3 (0.1 to 0.5)	-35.9 (-64.5 to -3.3)	-35.5 (-64.5 to -3.4)
Maternal sepsis and other maternal infections	4.1 (2.3 to 6.3)	3.5 (2.1 to 5.3)	-13.6 (-37.5 to 8.4)	-34.5 (-52.6 to -15.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-29.2 (-63.5 to 30.1)	-34.1 (-66.8 to 27.7)
Maternal hypertensive disorders	1.3 (0.7 to 2.1)	0.9 (0.5 to 1.4)	-29.1 (-36.7 to -17.7)	-21.8 (-30.6 to -10.9)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-28.4 (-54.1 to 15.7)	-21.1 (-49.0 to 21.6)
Obstructed labor	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.1)	-60.2 (-82.5 to -1.9)	-58.0 (-80.8 to 2.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-57.3 (-84.2 to 35.0)	-55.3 (-82.8 to 39.2)
Complications of abortion	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-15.3 (-49.3 to 45.5)	-10.7 (-46.7 to 52.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.3 (-49.3 to 45.6)	-10.7 (-46.8 to 52.0)
Other maternal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.2)	-41.9 (-70.2 to 2.9)	-39.8 (-69.5 to 5.7)
Neonatal disorders	-	-	-	-	18.3 (11.4 to 27.4)	39.2 (24.3 to 58.7)	119.2 (30.8 to 223.5)	107.3 (23.8 to 210.6)
Preterm birth complications	64.1 (37.1 to 111.2)	148.3 (78.8 to 272.3)	129.5 (71.4 to 219.5)	107.8 (57.8 to 189.4)	8.4 (4.8 to 12.3)	18.3 (11.1 to 29.1)	114.6 (36.7 to 291.8)	101.7 (28.4 to 265.5)
Neonatal encephalopathy due to birth asphyxia and trauma	24.2 (9.0 to 57.7)	26.2 (9.4 to 63.8)	8.3 (-22.7 to 41.1)	1.2 (-27.3 to 29.9)	3.2 (2.1 to 4.9)	3.4 (2.0 to 5.2)	4.4 (-35.9 to 72.0)	1.5 (-37.1 to 67.6)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	450.5 (78.9 to 176.5)	421.9 (343.8 to 585.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	450.5 (45.8 to 302.6)	421.9 (261.5 to 898.5)
Hemolytic disease and other neonatal jaundice	4.6 (2.3 to 8.7)	4.5 (1.2 to 12.9)	-21.0 (-73.8 to 189.5)	-25.7 (-75.3 to 170.7)	1.8 (0.9 to 3.6)	1.8 (0.5 to 5.5)	-16.0 (-72.3 to 193.6)	-21.8 (-73.9 to 177.3)
Other neonatal disorders	-	-	-	-	4.9 (2.1 to 10.4)	15.8 (8.7 to 26.3)	240.5 (46.4 to 618.8)	221.7 (40.2 to 580.9)
Nutritional deficiencies	-	-	-	-	84.7 (54.6 to 127.1)	63.5 (40.9 to 94.1)	-24.9 (-38.3 to -10.7)	-9.0 (-23.9 to 4.5)
Protein-energy malnutrition	9.5 (3.9 to 19.1)	3.7 (1.7 to 7.3)	-61.3 (-86.8 to 15.4)	-31.5 (-77.3 to 113.6)	1.2 (0.4 to 2.5)	0.5 (0.2 to 1.0)	-91.4 (-86.7 to 19.9)	-30.5 (-77.1 to 122.8)
Iodine deficiency	827.5 (311.1 to 1,503.4)	706.8 (375.1 to 1,237.4)	-10.2 (-64.4 to 133.7)	-27.9 (-71.4 to 84.6)	14.8 (4.8 to 30.4)	12.7 (5.5 to 24.7)	-10.7 (-64.1 to 134.4)	-28.5 (-71.3 to 86.9)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-

Appendix Table G.4 - Taiwan prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	2,387.2 (2,336.2 to 2,438.5)	2,004.7 (1,820.2 to 2,113.8)	-15.5 (-23.2 to -11.8)	-6.1 (-13.3 to -1.2)	68.5 (45.4 to 100.0)	50.3 (32.5 to 73.7)	-26.3 (-39.9 to -20.0)	-26.3 (-18.8 to 2.1)
Other nutritional deficiencies	-	-	-	-	0.2 (0.0 to 0.4)	0.0 (0.0 to 0.1)	-0.2 (-0.1 to -0.3)	-0.2 (-0.1 to -0.3)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	8.4 (5.3 to 12.9)	7.3 (4.5 to 11.5)	-1.1 (-2.4 to 2.1)	-1.1 (-2.2 to 6.5)
Sexually transmitted diseases excluding HIV	-	-	-	-	3.0 (1.7 to 5.3)	3.3 (1.8 to 5.9)	0.3 (-0.7 to 3.0)	0.3 (-0.7 to 3.0)
Syphilis	0.7 (0.6 to 0.8)	0.7 (0.6 to 0.8)	-0.8 (-1.6 to 21.7)	-46.3 (-54.2 to -45.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-0.9 (-1.0 to -0.8)	-0.9 (-0.9 to -0.9)
Chlamydial infection	313.5 (248.1 to 370.0)	291.5 (237.0 to 361.0)	-6.3 (-28.9 to 17.4)	-12.7 (-34.1 to 8.3)	1.3 (0.7 to 2.1)	1.3 (0.7 to 2.2)	0.0 (-0.6 to 0.6)	0.0 (-0.6 to 0.6)
Gonococcal infection	99.9 (78.4 to 124.3)	95.3 (72.9 to 116.6)	-3.7 (-31.7 to 33.1)	-2.4 (-30.9 to 33.8)	0.6 (0.3 to 0.9)	0.5 (0.3 to 0.9)	-0.1 (-0.3 to 0.1)	-0.1 (-0.3 to 0.1)
Trichomoniasis	144.6 (102.3 to 191.3)	203.9 (141.7 to 268.1)	43.9 (-13.9 to 110.3)	21.0 (-26.7 to 75.3)	0.2 (0.1 to 0.5)	0.4 (0.1 to 0.8)	0.2 (-0.2 to 0.6)	0.2 (-0.2 to 0.6)
Genital herpes	2,669.3 (2,456.4 to 2,842.4)	3,382.4 (3,109.0 to 3,640.2)	27.1 (15.2 to 42.2)	34.8 (-22.9 to 4.5)	0.7 (0.2 to 1.7)	0.9 (0.3 to 2.2)	0.2 (-0.1 to 0.5)	0.2 (-0.1 to 0.5)
Other sexually transmitted diseases	5.0 (3.5 to 6.8)	4.7 (3.6 to 6.2)	-5.5 (-20.4 to 11.9)	-26.5 (-38.0 to -13.3)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	0.0 (-0.1 to 0.1)	0.0 (-0.1 to 0.1)
Hepatitis	-	-	-	-	1.9 (1.2 to 2.8)	1.8 (1.1 to 2.6)	-0.1 (-0.3 to 0.1)	-0.1 (-0.3 to 0.1)
Hepatitis A	21.9 (21.2 to 22.6)	17.4 (16.8 to 18.0)	-20.3 (-20.7 to -20.0)	-17.2 (-18.8 to -15.7)	0.6 (0.4 to 0.9)	0.6 (0.4 to 0.8)	-0.1 (-0.2 to 0.0)	-0.1 (-0.2 to 0.0)
Hepatitis B	2,220.5 (1,986.2 to 2,449.7)	1,729.6 (1,542.6 to 1,903.1)	-21.3 (-34.1 to -9.3)	-37.7 (-47.7 to -28.7)	1.1 (0.7 to 1.7)	1.0 (0.6 to 1.5)	-0.1 (-0.2 to 0.1)	-0.1 (-0.2 to 0.1)
Hepatitis C	622.0 (571.1 to 669.7)	690.3 (640.3 to 740.2)	11.7 (-0.7 to 23.8)	-25.4 (-33.2 to -17.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.0 (-0.1 to 0.1)	0.0 (-0.1 to 0.1)
Hepatitis E	5.2 (4.6 to 5.9)	5.7 (4.1 to 7.0)	10.8 (-24.3 to 41.6)	7.1 (-22.4 to 34.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	0.1 (-0.1 to 0.2)	0.1 (-0.1 to 0.2)
Leprosy	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other infectious diseases	106.1 (85.4 to 128.4)	76.6 (66.1 to 97.9)	-28.3 (-40.0 to -5.4)	-4.2 (-20.4 to 27.2)	3.5 (2.1 to 5.2)	2.2 (1.3 to 3.5)	-1.3 (-2.8 to 0.2)	-1.3 (-2.8 to 0.2)
Non-communicable diseases	-	-	-	-	11,152.2 to 13,939.2	17,744.3 to 23,056.0	59.1 to 65.1	59.1 to 65.1
Neoplasms	-	-	-	-	14.1 (10.3 to 18.6)	42.3 (30.3 to 56.6)	207.9 (152.1 to 235.9)	207.9 (152.1 to 235.9)
Esophageal cancer	1.7 (1.2 to 2.6)	3.4 (2.0 to 4.8)	131.2 (5.3 to 249.6)	9.7 (-48.7 to 61.3)	0.2 (0.2 to 0.4)	0.5 (0.3 to 0.7)	117.6 (1.6 to 231.7)	117.6 (51.2 to 53.8)
Stomach cancer	8.5 (7.7 to 9.4)	15.0 (13.4 to 16.7)	77.9 (54.4 to 104.9)	1.5 (-24.5 to 0.8)	0.9 (0.7 to 1.2)	1.5 (1.1 to 2.1)	68.0 (40.6 to 100.6)	68.0 (31.4 to -3.1)
Liver cancer	-	-	-	-	1.0 (0.7 to 1.3)	2.7 (1.9 to 3.6)	169.9 (126.5 to 235.9)	169.9 (126.5 to 235.9)
Liver cancer due to hepatitis B	3.4 (2.6 to 4.3)	8.7 (5.5 to 12.2)	157.6 (52.0 to 294.2)	37.3 (-18.3 to 111.3)	0.4 (0.3 to 0.6)	1.0 (0.6 to 1.5)	127.8 (38.4 to 247.5)	127.8 (25.8 to 83.7)
Liver cancer due to hepatitis C	1.1 (0.7 to 1.5)	9.7 (6.0 to 13.6)	816.4 (431.0 to 1,528.3)	367.4 (171.9 to 722.4)	0.1 (0.1 to 0.2)	1.1 (0.6 to 1.7)	671.9 (361.6 to 1,253.1)	671.9 (134.4 to 572.6)
Liver cancer due to alcohol use	1.8 (1.2 to 2.4)	3.0 (1.7 to 4.6)	65.8 (-6.1 to 195.8)	-15.5 (-52.5 to 50.4)	0.2 (0.2 to 0.3)	0.6 (0.2 to 0.6)	51.9 (-11.4 to 173.1)	51.9 (-55.2 to 34.8)
Liver cancer due to other causes	1.3 (0.9 to 1.8)	1.8 (1.2 to 2.7)	35.5 (-14.3 to 139.0)	-26.0 (-53.1 to 33.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	25.6 (-17.7 to 108.9)	25.6 (-55.1 to 14.1)
Larynx cancer	2.4 (1.9 to 3.6)	3.8 (2.2 to 4.7)	72.8 (-6.5 to 114.6)	-15.1 (-53.4 to 6.1)	0.3 (0.1 to 0.3)	0.3 (0.2 to 0.5)	73.4 (-9.3 to 134.0)	73.4 (-56.3 to 12.3)
Tracheal, bronchus and lung cancer	7.6 (6.9 to 8.3)	23.6 (21.4 to 26.6)	210.8 (175.5 to 261.4)	53.7 (35.8 to 79.0)	1.0 (0.8 to 1.3)	3.1 (2.3 to 4.0)	197.8 (155.4 to 252.3)	197.8 (26.6 to 73.0)
Breast cancer	16.9 (15.1 to 19.2)	112.0 (90.6 to 123.1)	574.9 (363.1 to 670.5)	6.5 (-149.9 to 318.3)	1.2 (0.8 to 1.6)	6.5 (4.3 to 9.0)	450.6 (241.8 to 559.3)	450.6 (85.0 to 256.4)
Cervical cancer	17.7 (12.9 to 20.8)	10.9 (8.9 to 16.9)	-40.4 (-51.7 to -0.1)	-37.7 (-73.8 to -46.6)	1.3 (0.8 to 1.8)	0.8 (0.6 to 1.3)	-9.2 (-52.9 to 0.2)	-9.2 (-74.2 to -46.8)
Uterine cancer	3.9 (2.8 to 7.2)	14.0 (4.3 to 21.3)	339.7 (3.5 to 563.1)	125.6 (-46.5 to 231.0)	0.9 (0.1 to 0.5)	0.9 (0.2 to 1.5)	32.5 (-4.3 to 548.3)	32.5 (-50.5 to 223.5)
Prostate cancer	6.2 (4.6 to 9.8)	41.0 (18.8 to 58.4)	660.8 (215.0 to 1,007.4)	244.0 (43.7 to 401.4)	0.5 (0.4 to 0.9)	3.5 (1.5 to 5.6)	647.6 (199.8 to 985.8)	647.6 (29.9 to 370.7)
Colon and rectum cancer	21.3 (19.7 to 23.0)	92.1 (84.8 to 99.7)	335.8 (286.9 to 389.3)	120.8 (95.8 to 148.4)	1.7 (1.2 to 2.3)	7.2 (5.2 to 9.3)	318.6 (266.8 to 376.7)	318.6 (82.7 to 139.1)
Lip and oral cavity cancer	8.3 (6.4 to 12.6)	21.2 (9.5 to 30.3)	185.7 (6.1 to 313.6)	50.7 (-44.1 to 115.3)	0.7 (0.4 to 1.1)	1.7 (0.7 to 2.8)	181.9 (29.9 to 108.3)	181.9 (-45.5 to 108.3)
Nasopharynx cancer	8.7 (6.8 to 11.0)	7.4 (5.7 to 9.8)	-15.0 (-37.6 to 19.0)	-51.2 (-64.3 to -31.7)	0.7 (0.5 to 1.2)	0.7 (0.4 to 1.0)	-1.7 (-38.4 to 17.3)	-1.7 (-64.4 to -34.2)
Other pharynx cancer	2.2 (1.6 to 3.5)	9.8 (3.8 to 13.5)	389.4 (36.1 to 620.9)	143.0 (-31.8 to 256.2)	0.2 (0.1 to 0.3)	0.8 (0.3 to 1.2)	345.1 (24.5 to 564.3)	345.1 (-38.5 to 225.1)
Gallbladder and biliary tract cancer	0.3 (0.2 to 0.4)	0.9 (0.4 to 1.2)	226.0 (4.6 to 323.7)	55.5 (-51.0 to 102.7)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	189.4 (-8.6 to 271.5)	189.4 (-57.6 to 77.9)
Pancreatic cancer	0.7 (0.6 to 0.7)	2.4 (2.0 to 2.7)	261.6 (200.7 to 336.9)	77.2 (47.5 to 113.1)	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.6)	238.5 (185.3 to 309.6)	238.5 (38.1 to 99.3)
Malignant skin melanoma	0.8 (0.6 to 1.2)	2.3 (1.5 to 3.0)	204.1 (86.4 to 307.0)	58.9 (-21.0 to 112.5)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	180.9 (74.1 to 299.5)	180.9 (-10.6 to 103.7)
Non-melanoma skin cancer	2.6 (2.1 to 3.2)	10.2 (8.7 to 12.3)	288.2 (213.1 to 383.6)	64.5 (28.0 to 108.3)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	201.0 (97.7 to 365.2)	201.0 (-29.8 to 81.9)
Ovarian cancer	2.3 (1.9 to 2.6)	5.2 (4.4 to 6.2)	130.5 (86.5 to 188.1)	31.7 (7.6 to 63.2)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	125.4 (65.6 to 206.8)	125.4 (-6.3 to 74.4)
Testicular cancer	0.7 (0.5 to 1.1)	1.5 (0.8 to 2.4)	122.9 (1.8 to 229.9)	82.1 (-13.7 to 235.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	119.9 (-2.1 to 343.8)	119.9 (-19.3 to 252.3)
Kidney cancer	8.8 (3.4 to 4.3)	15.0 (13.0 to 17.1)	69.5 (227.3 to 366.6)	19.5 (71.4 to 145.9)	0.3 (0.2 to 0.4)	1.0 (0.7 to 1.4)	276.9 (207.9 to 361.1)	276.9 (158.7 to 139.0)
Bladder cancer	6.5 (5.5 to 7.7)	22.4 (14.5 to 27.1)	256.3 (116.2 to 354.8)	72.7 (1.9 to 119.0)	0.5 (0.3 to 0.7)	1.7 (1.0 to 2.3)	245.4 (102.9 to 348.6)	245.4 (-5.4 to 111.3)
Brain and nervous system cancer	2.3 (1.8 to 2.9)	3.5 (2.8 to 4.2)	53.5 (20.4 to 85.6)	30.0 (0.9 to 61.9)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	55.6 (22.5 to 85.6)	55.6 (-6.1 to 46.9)
Thyroid cancer	7.5 (5.9 to 9.4)	15.4 (10.4 to 19.4)	107.2 (49.7 to 173.0)	30.3 (-6.3 to 70.1)	0.4 (0.3 to 0.6)	0.9 (0.5 to 1.3)	106.0 (69.9 to 175.2)	106.0 (-11.0 to 67.2)
Mesothelioma	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	97.2 (57.8 to 153.9)	0.0 (-26.4 to 19.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	186.6 (46.9 to 161.0)	186.6 (-25.2 to 21.2)
Hodgkin lymphoma	0.7 (0.5 to 0.9)	0.9 (0.7 to 1.2)	32.7 (-4.2 to 96.3)	2.5 (25.0 to 50.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	27.0 (-7.2 to 91.5)	27.0 (-31.3 to 37.8)
Non-Hodgkin lymphoma	6.0 (5.1 to 8.1)	28.1 (11.6 to 37.8)	480.6 (80.3 to 597.2)	229.0 (2.5 to 293.5)	0.4 (0.3 to 0.6)	2.0 (0.7 to 3.2)	457.8 (69.4 to 590.0)	457.8 (-4.9 to 282.8)
Multiple myeloma	0.6 (0.4 to 0.8)	1.5 (0.9 to 2.1)	169.5 (56.7 to 328.8)	33.3 (-23.5 to 114.2)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	160.0 (45.7 to 316.8)	160.0 (-29.8 to 106.1)
Leukemia	4.1 (3.5 to 5.0)	10.0 (8.7 to 11.3)	144.0 (93.4 to 195.9)	88.4 (47.8 to 133.0)	0.5 (0.3 to 0.6)	1.2 (0.8 to 1.6)	159.7 (104.0 to 216.5)	159.7 (42.5 to 117.5)
Other neoplasms	11.1 (8.3 to 17.6)	39.6 (32.4 to 45.9)	271.1 (119.4 to 404.4)	133.9 (43.6 to 214.5)	0.8 (0.5 to 1.3)	2.6 (1.8 to 3.6)	245.2 (104.9 to 380.5)	245.2 (27.0 to 186.2)
Cardiovascular diseases	-	-	-	-	48.0 (34.0 to 66.1)	102.2 (70.4 to 142.7)	113.2 (65.5 to 166.6)	113.2 (-13.9 to 35.7)
Rheumatic heart disease	57.1 (54.1 to 60.0)	76.6 (72.0 to 81.4)	34.8 (24.8 to 45.8)	0.4 (-6.8 to 8.1)	4.0 (2.7 to 5.6)	5.1 (3.2 to 7.3)	29.5 (-6.2 to 64.1)	29.5 (-35.9 to 10.0)
Ischemic heart disease	127.9 (103.1 to 161.0)	279.1 (239.0 to 324.3)	123.1 (59.5 to 177.8)	-0.7 (-28.1 to 23.1)	9.6 (6.4 to 14.3)	22.1 (15.2 to 30.9)	134.9 (70.0 to 188.6)	134.9 (-22.6 to 29.2)
Cerebrovascular disease	-	-	-	-	12.3 (8.6 to 16.2)	23.2 (16.1 to 31.1)	89.6 (56.0 to 120.5)	89.6 (-17.0 to 2.0)
Ischemic stroke	41.8 (34.1 to 50.2)	78.2 (62.1 to 95.5)	87.5 (35.0 to 150.5)	-15.5 (-39.7 to 11.3)	6.2 (4.1 to 8.7)	11.5 (7.5 to 16.1)	85.3 (33.2 to 150.7)	85.3 (-38.9 to 11.8)
Hemorrhagic stroke	41.0 (34.9 to 47.9)	79.1 (65.6 to 93.3)	93.9 (53.3 to 144.5)	-8.9 (-28.9 to 14.2)	6.1 (4.2 to 8.4)	11.7 (7.8 to 16.4)	91.5 (51.9 to 143.0)	91.5 (-28.8 to 15.1)
Hypertensive heart disease	26.5 (21.3 to 32.1)	77.6 (66.2 to 89.6)	194.1 (127.5 to 267.2)	34.4 (4.2 to 74.8)	3.0 (1.9 to 4.3)	8.6 (5.9 to 12.2)	192.1 (127.7 to 267.2)	192.1 (45.1 to 76.1)
Cardiomyopathy and myocarditis	22.1 (18.2 to 26.9)	46.1 (40.5 to 51.8)	110.8 (69.6 to 163.9)	20.4 (-4.1 to 48.9)	2.5 (1.6 to 3.6)	5.1 (3.5 to 7.1)	107.9 (62.3 to 164.4)	107.9 (-7.1 to 51.1)
Atrial fibrillation and flutter	3.7 (3.2 to 4.3)	35.7 (33.0 to 38.7)	859.9 (704.4 to 1,054.4)	229.7 (170.9 to 302.0)	0.3 (0.2 to 0.4)	2.8 (1.9 to 3.8)	855.9 (682.4 to 1,103.0)	855.9 (168.5 to 324.5)
Peripheral vascular disease	257.1 (193.3 to 332.1)	512.2 (337.2 to 672.9)	105.1 (32.5 to 190.4)	-8.0 (-39.7 to 29.1)	0.2 (0.1 to 0.5)	0.6 (0.2 to 1.1)	195.9 (32.5 to 595.5)	195.9 (-45.9 to 166.8)
Endocarditis	1.5 (1.0 to 2.3)	4.0 (2.8 to 5.0)	184.6 (65.2 to 317.6)	59.4 (-8.3 to 134.5)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.7)	175.3 (54.4 to 327.0)	175.3 (-12.7 to 142.5)
Other cardiovascular and circulatory diseases	22.0 (13.7 to 34.0)	47.7 (22.8 to 71.4)	117.9 (-7.4 to 306.5)	-9.9 (-45.6 to 139.4)	2.9 (8.7 to 26.4)	16.1 (15.3 to 58.6)	28.1 (-8.2 to 315.0)	28.1 (-45.4 to 145.4)
Chronic respiratory diseases	-	-	-	-	97.9 (66.8 to 132			

Appendix Table G.4 - Taiwan prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.5)	153.1 (172.9 to 215.4)	52.4 (41.4 to 64.4)
Silicosis	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.4)	71.8 (62.4 to 80.8)	-18.6 (-22.6 to -14.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (61.6 to 80.6)	-18.8 (-22.9 to -14.3)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.4 (0.4 to 0.5)	1.6 (1.5 to 1.7)	299.2 (241.8 to 278.4)	95.0 (85.9 to 105.0)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	250.0 (226.9 to 277.0)	90.1 (78.1 to 103.3)
Asthma	1,132.7 (1,021.0 to 1,249.5)	1,347.5 (1,214.3 to 1,483.0)	19.6 (2.9 to 37.5)	-1.6 (-15.4 to 13.2)	50.0 (31.8 to 71.8)	59.3 (39.0 to 84.9)	18.7 (20.2 to 36.1)	-1.4 (-15.3 to 14.0)
Interstitial lung disease and pulmonary sarcoidosis	1.7 (1.3 to 2.1)	3.2 (2.5 to 3.8)	86.1 (38.6 to 164.0)	2.1 (-22.4 to 39.7)	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.7)	84.5 (36.8 to 161.7)	2.2 (23.9 to 41.1)
Other chronic respiratory diseases	-	-	-	-	3.4 (2.0 to 5.5)	7.0 (4.2 to 10.9)	105.3 (47.3 to 184.3)	13.1 (-18.2 to 55.7)
Cirrhosis	-	-	-	-	1.7 (1.2 to 2.4)	1.9 (1.3 to 2.7)	9.8 (1.8 to 25.2)	-2.7 (-36.5 to -20.6)
Cirrhosis due to hepatitis B	5.2 (4.5 to 5.8)	5.1 (3.7 to 6.4)	0.0 (-29.5 to 26.8)	-38.0 (-56.6 to -21.7)	0.9 (0.6 to 1.2)	0.8 (0.5 to 1.3)	-8.8 (-31.6 to 31.0)	-38.4 (-56.9 to -18.9)
Cirrhosis due to hepatitis C	1.6 (1.1 to 2.2)	2.9 (1.8 to 4.0)	76.7 (9.7 to 217.8)	0.3 (-37.1 to 76.6)	0.5 (0.1 to 0.4)	0.5 (0.3 to 0.8)	76.0 (3.1 to 225.2)	1.4 (-39.2 to 85.7)
Cirrhosis due to alcohol use	2.4 (1.7 to 3.0)	2.6 (1.2 to 3.7)	8.3 (-33.5 to 73.8)	-38.7 (-62.1 to -1.6)	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.7)	7.2 (-37.2 to 85.4)	-38.8 (-64.4 to 3.5)
Cirrhosis due to other causes	1.0 (0.8 to 1.3)	1.7 (0.8 to 1.6)	14.0 (-23.9 to 81.7)	-8.8 (-36.4 to 43.2)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	13.7 (-31.4 to 98.2)	-8.3 (-41.8 to 55.2)
Digestive diseases	-	-	-	-	23.9 (16.6 to 33.1)	30.8 (21.4 to 41.7)	28.4 (20.6 to 39.3)	-25.1 (-30.3 to -20.0)
Peptic ulcer disease	159.1 (151.0 to 167.6)	213.6 (193.8 to 233.5)	34.4 (25.5 to 47.0)	-41.7 (-45.7 to -36.7)	5.0 (3.3 to 7.0)	7.1 (4.9 to 9.9)	42.8 (26.7 to 66.3)	-36.9 (-43.5 to -26.6)
Gastritis and duodenitis	305.4 (298.2 to 312.0)	427.6 (412.8 to 447.4)	40.4 (35.4 to 46.9)	-20.6 (-23.7 to -17.2)	11.4 (7.8 to 16.2)	13.4 (9.2 to 19.1)	16.9 (9.0 to 30.1)	-24.0 (-28.5 to -14.0)
Appendicitis	1.6 (1.3 to 2.0)	1.4 (1.1 to 1.7)	-15.0 (-35.8 to 18.8)	-26.8 (-45.2 to 0.1)	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.7)	-13.3 (-42.5 to 30.9)	-25.2 (50.4 to 12.4)
Paralytic ileus and intestinal obstruction	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.4)	101.0 (73.7 to 126.4)	10.6 (-3.1 to 25.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	93.8 (56.0 to 138.9)	10.7 (-11.9 to 41.0)
Inguinal, femoral, and abdominal hernia	34.2 (30.1 to 39.4)	46.2 (36.6 to 55.2)	37.0 (0.4 to 67.7)	-32.9 (-50.1 to -16.8)	0.4 (0.2 to 0.6)	0.5 (0.2 to 0.9)	36.2 (-0.6 to 68.0)	-32.8 (-50.2 to -16.2)
Inflammatory bowel disease	3.6 (3.4 to 3.7)	5.4 (5.1 to 5.7)	53.3 (42.5 to 63.6)	-5.7 (-12.4 to 0.4)	0.8 (0.5 to 1.1)	1.2 (0.8 to 1.6)	52.9 (26.2 to 81.6)	-4.9 (-20.8 to 11.3)
Vascular intestinal disorders	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	97.7 (39.3 to 203.7)	-6.6 (-35.7 to 44.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (30.9 to 204.3)	-3.6 (-38.9 to 55.2)
Gallbladder and biliary diseases	8.7 (8.0 to 9.5)	14.9 (13.6 to 16.3)	71.4 (53.2 to 92.2)	-3.1 (-21.3 to -3.1)	1.6 (0.6 to 1.2)	1.6 (1.1 to 2.1)	69.9 (45.7 to 98.6)	-12.7 (-24.0 to 0.7)
Pancreatitis	5.9 (5.6 to 6.2)	9.0 (8.7 to 9.4)	53.8 (44.1 to 63.3)	-8.0 (-13.8 to -2.5)	1.7 (1.2 to 2.4)	2.7 (1.8 to 3.6)	51.7 (31.6 to 75.3)	-8.0 (-19.7 to 5.3)
Other digestive diseases	-	-	-	-	3.2 (2.0 to 4.6)	3.8 (2.5 to 5.4)	19.9 (5.1 to 60.0)	-30.8 (-45.3 to -8.2)
Neurological disorders	-	-	-	-	103.0 (69.9 to 143.2)	165.7 (112.4 to 225.9)	61.4 (40.9 to 81.6)	5.9 (-6.9 to 18.0)
Alzheimer disease and other dementias	61.9 (52.4 to 70.5)	195.6 (159.5 to 233.6)	216.0 (152.3 to 293.5)	6.6 (-14.2 to 34.0)	8.9 (6.2 to 11.7)	29.3 (19.9 to 38.8)	229.3 (161.6 to 314.5)	5.7 (-14.8 to 33.8)
Parkinson disease	21.7 (17.4 to 26.0)	52.6 (44.3 to 61.8)	142.9 (123.5 to 169.1)	8.7 (1.2 to 19.4)	2.6 (1.7 to 3.7)	6.3 (4.3 to 8.8)	140.2 (115.4 to 171.5)	8.7 (-2.0 to 21.5)
Epilepsy	39.5 (28.2 to 51.9)	35.0 (22.5 to 49.9)	-10.7 (-46.5 to 42.7)	-22.7 (-53.6 to 22.5)	13.4 (7.7 to 20.2)	13.0 (7.5 to 20.0)	-7.7 (-42.3 to 55.2)	-14.6 (-49.5 to 37.2)
Multiple sclerosis	0.2 (0.2 to 0.3)	0.8 (0.6 to 0.9)	233.2 (167.4 to 314.8)	0.1 (-72.9 to 168.8)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	233.2 (166.8 to 314.8)	115.3 (72.2 to 168.9)
Migraine	1,430.2 (1,462.2 to 1,816.5)	2,128.3 (1,761.3 to 2,439.9)	71.4 (5.7 to 55.7)	1.7 (-17.8 to 20.4)	55.9 (33.0 to 82.8)	72.8 (42.1 to 109.2)	30.8 (4.7 to 55.3)	2.4 (-17.6 to 21.2)
Tension-type headache	3,145.8 (2,351.1 to 4,354.4)	3,807.2 (3,068.4 to 4,627.0)	24.8 (-22.3 to 75.5)	-10.4 (-41.2 to 24.7)	4.8 (2.1 to 8.8)	5.8 (2.7 to 10.7)	25.0 (-22.2 to 76.3)	-10.1 (-24.2 to 24.6)
Medication overuse headache	92.6 (63.1 to 123.1)	212.8 (144.6 to 282.2)	130.6 (88.2 to 186.5)	57.0 (29.3 to 92.7)	14.6 (8.4 to 22.6)	33.5 (19.1 to 52.1)	129.0 (85.7 to 189.9)	57.4 (29.5 to 97.7)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	54.0 (6.3 to 120.5)	12.8 (-18.3 to 57.6)	2.8 (1.9 to 4.0)	4.9 (3.2 to 6.8)	72.7 (29.2 to 143.6)	-39.0 (-54.8 to -13.8)
Mental and substance use disorders	-	-	-	-	362.3 (260.0 to 476.1)	461.1 (330.0 to 602.4)	27.3 (21.3 to 33.5)	0.4 (-2.6 to 3.7)
Schizophrenia	68.4 (62.2 to 75.1)	95.9 (88.1 to 105.0)	40.7 (34.4 to 48.0)	0.0 (-4.3 to 4.6)	0.0 (33.0 to 54.4)	0.0 (46.4 to 75.7)	0.0 (31.2 to 49.8)	0.4 (-5.5 to 6.9)
Alcohol use disorders	188.0 (167.4 to 210.8)	231.6 (210.1 to 252.4)	23.9 (14.0 to 34.5)	-4.4 (-10.7 to 1.9)	18.8 (12.3 to 26.9)	23.2 (15.1 to 33.2)	23.9 (12.7 to 36.3)	-4.0 (-11.5 to 4.1)
Drug use disorders	-	-	-	-	32.1 (22.3 to 42.7)	35.2 (24.5 to 45.8)	10.0 (-1.5 to 22.1)	-1.2 (-11.1 to 9.5)
Opioid use disorders	31.5 (26.7 to 36.1)	38.4 (32.9 to 43.4)	22.6 (12.4 to 33.6)	-1.4 (-9.2 to 6.8)	13.2 (9.2 to 17.5)	16.2 (11.3 to 21.4)	23.1 (8.5 to 37.9)	-0.7 (-11.7 to 10.7)
Cocaine use disorders	18.1 (16.8 to 19.4)	19.6 (18.1 to 21.1)	8.9 (-1.4 to 20.9)	8.9 (-10.1 to 9.8)	2.5 (1.6 to 3.6)	2.7 (1.7 to 3.9)	9.3 (9.1 to 32.8)	-0.4 (-16.8 to 20.8)
Amphetamine use disorders	46.7 (43.3 to 49.7)	45.3 (42.7 to 48.4)	-2.4 (-11.3 to 6.9)	-2.2 (-10.9 to 7.1)	6.1 (3.8 to 9.2)	6.0 (3.7 to 8.6)	-2.2 (-15.4 to 12.0)	-1.6 (-14.7 to 13.1)
Cannabis use disorders	54.1 (46.7 to 61.7)	53.7 (47.0 to 60.2)	-0.3 (-2.8 to 2.1)	-0.1 (-0.2 to -0.1)	1.6 (1.0 to 2.3)	1.6 (1.0 to 2.3)	-0.3 (-12.4 to 12.6)	-0.0 (12.0 to 12.8)
Other drug use disorders	-	-	-	-	8.7 (5.4 to 13.0)	8.7 (5.4 to 12.8)	0.7 (-24.1 to 35.6)	-1.7 (-25.0 to 33.3)
Depressive disorders	-	-	-	-	43.1 (43.1 to 93.0)	65.5 (65.5 to 145.1)	52.7 (42.2 to 69.8)	5.1 (-1.9 to 13.5)
Major depressive disorder	198.2 (146.0 to 256.1)	303.9 (203.7 to 414.2)	53.5 (30.2 to 75.3)	7.1 (-3.0 to 20.8)	40.6 (25.1 to 61.3)	61.8 (36.2 to 95.1)	51.9 (29.4 to 74.2)	7.5 (-3.7 to 20.7)
Dysthymia	258.9 (223.2 to 293.4)	418.7 (363.5 to 469.2)	62.5 (55.5 to 70.0)	1.3 (0.9 to 1.7)	24.9 (16.3 to 35.6)	40.3 (26.4 to 57.8)	61.5 (53.8 to 70.0)	1.6 (-1.0 to 3.9)
Bipolar disorder	109.9 (86.6 to 132.5)	146.7 (118.4 to 176.7)	34.4 (24.2 to 44.0)	-0.5 (-6.0 to 4.7)	22.4 (13.4 to 34.7)	29.9 (18.2 to 45.5)	33.7 (21.8 to 45.3)	-0.1 (-7.2 to 7.3)
Anxiety disorders	1,171.7 (888.1 to 1,482.5)	1,403.6 (1,062.1 to 1,794.2)	20.2 (7.7 to 35.7)	108.2 (-8.4 to 8.2)	65.5 (67.2 to 160.3)	102.1 (82.1 to 190.3)	55.7 (71.1 to 34.7)	5.1 (8.6 to 9.4)
Eating disorders	-	-	-	-	2.2 (1.2 to 3.7)	2.5 (1.4 to 3.9)	10.7 (6.8 to 31.0)	10.7 (3.7 to 43.5)
Anorexia nervosa	5.5 (3.6 to 8.1)	6.9 (4.6 to 9.9)	25.9 (6.8 to 45.0)	38.9 (18.9 to 60.4)	1.2 (0.6 to 1.9)	1.5 (0.8 to 2.4)	26.2 (-0.1 to 59.8)	39.6 (11.2 to 76.8)
Bulimia nervosa	5.1 (2.6 to 9.6)	4.7 (2.4 to 8.7)	-8.9 (-13.0 to 0.7)	0.5 (0.2 to 1.2)	1.1 (0.5 to 2.1)	1.0 (0.5 to 2.0)	-7.9 (-24.4 to 13.4)	1.4 (-15.8 to 22.6)
Autistic spectrum disorders	-	-	-	-	24.8 (17.1 to 33.8)	27.2 (18.7 to 37.0)	9.6 (6.0 to 13.7)	-0.8 (-3.9 to 2.7)
Autism	63.6 (60.3 to 67.1)	70.2 (66.4 to 74.2)	10.7 (9.4 to 12.1)	-1.1 (-1.2 to -1.1)	15.7 (10.6 to 21.5)	17.3 (11.6 to 23.6)	10.0 (4.8 to 15.4)	-0.6 (-5.0 to 4.1)
Asperger syndrome	91.0 (85.2 to 96.7)	99.5 (92.8 to 106.6)	9.8 (8.1 to 11.4)	-1.5 (-1.6 to -1.4)	9.1 (6.3 to 12.7)	9.9 (6.9 to 13.8)	9.3 (4.7 to 13.9)	-1.1 (-4.9 to 2.8)
Attention-deficit/hyperactivity disorder	127.8 (105.3 to 149.3)	93.7 (77.3 to 109.4)	-26.4 (-26.8 to -26.2)	0.4 (0.4 to 0.5)	1.6 (0.9 to 2.5)	1.1 (0.7 to 1.8)	-26.2 (-31.0 to -20.4)	0.8 (-5.7 to 7.9)
Conduct disorder	103.3 (91.3 to 119.7)	79.5 (68.3 to 91.3)	-24.1 (-25.5 to -23.0)	0.4 (0.4 to 0.5)	12.6 (7.6 to 18.6)	9.6 (5.8 to 14.3)	-21.6 (-28.1 to -18.9)	1.2 (-4.6 to 7.3)
Idiopathic intellectual disability	73.3 (47.0 to 97.5)	57.7 (31.0 to 87.6)	-21.4 (-44.0 to -0.5)	29.8 (-49.4 to -11.8)	3.6 (2.0 to 5.4)	2.8 (1.4 to 4.6)	-21.2 (-45.9 to 0.9)	-2.9 (-49.9 to -9.3)
Other mental and substance use disorders	346.3 (324.5 to 367.7)	479.2 (450.7 to 505.7)	39.0 (35.4 to 42.6)	-1.2 (-1.6 to -0.8)	26.0 (17.7 to 35.1)	35.9 (24.4 to 48.6)	38.1 (32.1 to 44.5)	0.8 (-4.5 to 3.0)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	148.8 (105.9 to 202.3)	274.5 (195.5 to 373.2)	84.4 (65.4 to 104.4)	18.8 (7.2 to 31.1)
Diabetes mellitus	905.7 (767.0 to 1,045.1)	2,036.1 (1,722.8 to 2,339.9)	125.4 (85.3 to 173.2)	36.5 (11.6 to 66.8)	61.8 (41.1 to 86.2)	142.5 (96.4 to 201.8)	129.7 (87.4 to 180.5)	31.7 (8.8 to 61.1)
Acute glomerulonephritis	6.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-49.3 (-54.2 to -44.2)	97.5 (-42.6 to -32.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-54.3 to -44.1)	-49.3 (-42.7 to -32.2)
Chronic kidney disease	-	-	-	-	30.7 (22.3 to 39.3)	52.3 (37.2 to 68.1)	69.2 (44.2 to 100.5)	11.6 (-4.7 to 31.1)
Chronic kidney disease due to diabetes mellitus	113.3 (69.2 to 182.5)	299.5 (185.3 to 458.8)	164.5 (88.7 to 281.6)	42.6 (-0.8 to 104.6)	3.1 (2.0 to 4.4)	11.5 (7.6 to 16.7)	271.2 (121.9 to 466.5)	102.4 (21.4 to 213.6)
Chronic kidney disease due to hypertension	329.3 (202.4 to 516.3)	188.7 (131.7 to 273.3)	-42.0 (-56.9 to -19.2)	-54.6 (-66.2 to -35.9)	6.7 (4.7 to 9.2)	11.3 (7.2 to 16.5)	70.6 (12.3 to 128.5)	7.6 (-27.2 to 43.0)
Chronic kidney disease due to glomerulonephritis	274.0 (183.1 to 470.8)	389.0 (184.5 to 508.4)	5.6 (-26.8 to 41.0)	5.6 (-51.3 to 9.6)	8.9 (6.2 to 11.9)	5.3 (3.4 to 7.4)	41.2 (-56.9 to 15.0)	54.1 (-65.9 to -36.5)
Chronic kidney disease due to other causes	478.9 (299.9 to 768.7)	689.2 (487.6 to 941.2)	48.2 (13.3 to 95.7)	4.0 (-24.5 to 38.9)	12.0 (8.5 to 16.0)	24.2 (16.7 to 31.8)	102.8 (58.0 to 155.0)	36.2 (-9.5 to 68.1)
Urinary diseases and male infertility	-	-	-	-	12.7 (7.9 to 18.6)	29.1 (17.2 to 43.2)	130.2 (95.1 to 164.6)	16.9 (0.0 to 34.3)

Appendix Table G.4 - Taiwan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	2.9 (2.7 to 3.1)	5.5 (5.0 to 5.9)	91.1 (70.8 to 111.7)	26.9 (14.5 to 37.9)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	89.0 (51.4 to 137.9)	26.6 (3.4 to 55.6)
Urolithiasis	122.6 (48.3 to 193.4)	376.8 (185.8 to 535.7)	213.0 (150.4 to 311.2)	44.3 (17.1 to 83.8)	1.3 (0.7 to 2.0)	3.2 (1.6 to 5.1)	146.6 (102.4 to 192.0)	32.3 (15.0 to 53.9)
Benign prostatic hyperplasia	173.7 (160.0 to 188.7)	382.9 (348.0 to 417.4)	121.5 (97.5 to 149.6)	1.6 (-9.6 to 14.2)	6.3 (4.1 to 9.1)	13.9 (9.0 to 19.6)	120.4 (95.8 to 148.7)	1.9 (-10.1 to 14.5)
Male infertility due to other causes	94.7 (71.4 to 119.5)	104.0 (79.8 to 132.5)	11.2 (-22.2 to 57.5)	11.2 (-29.2 to 42.9)	0.6 (0.2 to 1.3)	0.6 (0.3 to 1.3)	9.1 (-25.3 to 55.8)	1.1 (-30.6 to 44.2)
Other urinary diseases	-	-	-	-	4.4 (2.0 to 7.3)	11.3 (4.8 to 18.7)	25.7 (64.8 to 258.8)	39.7 (7.5 to 94.7)
Gynecological diseases	-	-	-	-	21.4 (13.6 to 32.0)	28.4 (17.6 to 43.2)	32.9 (11.6 to 55.5)	1.8 (-13.1 to 19.0)
Uterine fibroids	414.7 (371.2 to 452.5)	689.4 (627.2 to 746.4)	66.9 (63.6 to 70.7)	2.9 (2.9 to 3.0)	4.4 (2.3 to 7.6)	6.7 (3.4 to 12.1)	49.4 (25.2 to 113.3)	-0.2 (-16.6 to 45.4)
Polycystic ovarian syndrome	273.5 (237.9 to 305.7)	369.9 (331.3 to 411.9)	35.7 (15.5 to 62.0)	9.7 (-6.3 to 29.9)	2.7 (1.2 to 4.9)	3.6 (1.7 to 6.7)	35.2 (15.9 to 61.3)	10.2 (-5.2 to 30.6)
Female infertility due to other causes	121.6 (82.3 to 163.8)	156.8 (97.4 to 221.0)	30.2 (-28.1 to 115.9)	25.7 (-41.8 to 74.0)	0.6 (0.2 to 1.4)	0.8 (0.3 to 1.7)	10.0 (-27.4 to 114.3)	5.5 (-41.0 to 76.0)
Endometriosis	39.2 (33.2 to 45.3)	50.7 (43.3 to 58.0)	29.7 (5.1 to 62.1)	2.1 (-17.3 to 26.5)	3.6 (2.4 to 5.2)	4.7 (3.1 to 6.6)	29.8 (3.2 to 62.6)	2.4 (-17.9 to 27.7)
Genital prolapse	964.1 (838.1 to 1,085.2)	1,508.6 (1,325.5 to 1,702.0)	57.3 (30.7 to 89.4)	2.4 (-14.8 to 23.1)	3.1 (1.5 to 5.8)	4.8 (2.3 to 9.2)	57.2 (29.1 to 90.2)	2.7 (-15.0 to 23.8)
Premenstrual syndrome	738.7 (513.5 to 1,059.3)	830.4 (583.1 to 1,133.5)	13.5 (-32.9 to 78.4)	-0.5 (-40.4 to 36.9)	6.2 (3.4 to 10.3)	7.0 (3.9 to 11.8)	13.6 (-34.1 to 80.0)	-0.4 (-40.6 to 58.9)
Other gynecological diseases	39.7 (32.6 to 48.2)	41.4 (34.0 to 49.2)	4.3 (-20.4 to 35.6)	-13.8 (-34.4 to 9.1)	0.8 (0.4 to 1.2)	0.7 (0.4 to 1.1)	-10.1 (-44.0 to 75.2)	-24.5 (-54.0 to 38.6)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	15.3 (10.8 to 23.2)	15.4 (10.2 to 22.5)	5.4 (-14.4 to 4.8)	1.4 (-8.1 to 12.1)
Thalassemias	1.9 (1.0 to 2.8)	1.1 (0.6 to 1.8)	-42.8 (-58.5 to -28.9)	-25.0 (-46.7 to -4.8)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-45.1 (-62.5 to -22.3)	-31.3 (-53.6 to 0.8)
Thalassemia trait	542.9 (375.3 to 786.8)	619.1 (413.7 to 892.4)	14.7 (8.7 to 19.3)	-0.4 (-4.0 to 3.6)	13.2 (8.8 to 18.8)	13.0 (8.7 to 18.8)	-0.7 (-11.5 to 7.0)	4.2 (-7.5 to 10.7)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.0 (-10.4 to -7.6)	6.8 (5.8 to 7.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.7 (-7.4 to -2.4)	7.2 (5.8 to 8.4)
Sickle cell trait	3.7 (3.3 to 3.8)	4.2 (3.9 to 4.3)	15.7 (12.5 to 18.1)	0.0 (-2.6 to 3.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-4.2 (-58.0 to -13.7)	44.9 (-56.7 to -21.0)
G6PD deficiency	469.3 (448.8 to 488.6)	532.5 (507.9 to 558.2)	14.0 (6.9 to 20.8)	-1.2 (-7.4 to 4.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-20.9 (-37.5 to 1.6)	-25.2 (-38.4 to -3.8)
G6PD trait	2,357.4 (2,319.7 to 2,389.9)	2,820.3 (2,772.1 to 2,862.7)	20.2 (17.5 to 22.5)	2.8 (0.5 to 4.8)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	0.2 (-59.3 to 486.0)	16.9 (-61.8 to 484.2)
Other hemoglobinopathies and hemolytic anemias	97.9 (86.9 to 114.2)	93.0 (84.0 to 106.1)	-4.5 (-21.5 to 15.8)	-2.9 (-20.2 to 22.7)	2.6 (1.6 to 3.8)	2.0 (1.2 to 3.1)	-8.0 (-38.2 to 38.1)	-23.9 (-25.4 to 47.6)
Endocrine, metabolic, blood, and immune disorders	175.5 (158.7 to 193.9)	199.0 (183.4 to 218.0)	13.0 (1.0 to 27.9)	2.1 (-10.4 to 17.0)	6.0 (4.0 to 8.3)	6.8 (4.6 to 9.6)	3.9 (-2.8 to 14.2)	3.9 (1.6 to 23.7)
Musculoskeletal disorders	-	-	-	-	376.1 (259.3 to 514.7)	676.9 (470.6 to 920.0)	80.8 (50.8 to 114.1)	7.4 (-10.0 to 26.5)
Rheumatoid arthritis	11.4 (10.9 to 11.9)	30.1 (28.6 to 31.5)	165.2 (147.9 to 183.5)	42.3 (32.9 to 51.3)	2.7 (1.9 to 3.6)	7.0 (4.9 to 9.4)	160.6 (131.3 to 194.9)	42.3 (27.2 to 59.6)
Osteoarthritis	431.4 (402.3 to 458.2)	944.0 (892.6 to 993.2)	119.6 (103.8 to 139.1)	0.8 (-6.3 to 9.6)	26.6 (18.6 to 35.8)	58.2 (41.2 to 78.1)	118.4 (103.1 to 139.1)	1.1 (-5.8 to 10.2)
Low back and neck pain	-	-	-	-	294.7 (195.2 to 406.4)	507.7 (337.1 to 705.5)	73.3 (35.9 to 115.1)	7.1 (-15.9 to 33.0)
Low back pain	1,552.4 (1,151.7 to 2,026.0)	2,846.1 (2,157.2 to 3,412.6)	90.0 (24.8 to 146.5)	10.1 (-26.3 to 41.0)	172.9 (104.6 to 261.3)	316.3 (195.6 to 461.8)	88.9 (24.7 to 144.6)	11.2 (-25.9 to 41.6)
Neck pain	1,231.9 (971.7 to 1,472.0)	1,933.5 (1,570.1 to 2,439.2)	55.5 (20.9 to 110.5)	4.0 (-18.5 to 37.1)	121.8 (80.4 to 174.5)	191.4 (124.1 to 278.3)	55.0 (20.1 to 110.8)	4.2 (-19.3 to 37.7)
Gout	29.3 (27.2 to 31.4)	56.6 (53.2 to 60.3)	93.8 (77.0 to 113.9)	-0.9 (-9.6 to 9.3)	0.9 (0.6 to 1.3)	1.8 (1.2 to 2.5)	92.5 (60.6 to 129.3)	-0.6 (-16.1 to 16.9)
Other musculoskeletal disorders	557.0 (451.6 to 668.5)	1,110.9 (891.0 to 1,341.3)	100.7 (85.5 to 113.6)	10.0 (3.0 to 16.7)	51.1 (32.9 to 73.5)	102.2 (66.4 to 146.0)	100.5 (84.4 to 115.5)	18.5 (2.6 to 18.1)
Other non-communicable diseases	-	-	-	-	328.7 (209.9 to 490.4)	445.0 (287.6 to 659.4)	35.4 (29.5 to 42.0)	-5.3 (-8.6 to -2.0)
Congenital anomalies	-	-	-	-	21.3 (15.5 to 27.9)	27.2 (20.0 to 35.5)	27.2 (11.5 to 48.1)	6.6 (-6.0 to 23.8)
Neural tube defects	3.1 (2.6 to 3.7)	3.2 (2.6 to 4.2)	1.9 (-21.9 to 38.5)	0.1 (-23.6 to 36.0)	1.0 (0.7 to 1.5)	1.1 (0.7 to 1.6)	-0.4 (-30.9 to 57.4)	-1.5 (-32.4 to 57.5)
Congenital heart anomalies	103.3 (80.1 to 129.5)	111.1 (91.1 to 134.3)	7.8 (-19.7 to 48.4)	-2.2 (-27.0 to 34.4)	4.1 (1.9 to 6.9)	4.2 (1.8 to 7.4)	-1.0 (-24.4 to 33.9)	-8.0 (-29.1 to 23.6)
Orofacial clefts	20.6 (16.0 to 25.9)	19.5 (15.1 to 25.7)	-5.4 (-33.3 to 31.9)	-5.8 (-40.7 to 17.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	0.2 (-37.0 to 40.3)	-15.1 (-42.7 to 24.2)
Down syndrome	23.8 (20.1 to 29.5)	32.2 (26.0 to 39.3)	35.8 (3.9 to 77.8)	6.1 (-18.5 to 38.8)	3.2 (2.3 to 4.3)	4.9 (3.6 to 6.5)	53.7 (14.9 to 101.1)	7.7 (-19.5 to 42.4)
Turner syndrome	0.7 (0.6 to 0.9)	0.8 (0.6 to 1.1)	18.8 (-12.1 to 66.0)	10.2 (-18.9 to 54.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.5 (-15.5 to 74.8)	11.1 (-21.3 to 61.7)
Klinefelter syndrome	0.5 (0.4 to 0.8)	0.8 (0.6 to 1.2)	57.1 (1.6 to 137.8)	39.8 (-9.5 to 111.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.4 (-8.0 to 161.1)	38.0 (-18.7 to 127.0)
Chromosomal unbalanced rearrangements	32.6 (27.6 to 37.7)	44.9 (36.1 to 57.3)	37.6 (5.5 to 83.6)	4.4 (-17.7 to 43.6)	6.8 (3.2 to 8.6)	6.8 (4.7 to 9.5)	55.5 (17.5 to 109.9)	9.2 (-17.5 to 47.0)
Other congenital anomalies	65.1 (54.2 to 76.9)	69.1 (58.7 to 80.9)	6.5 (-3.7 to 18.9)	-10.1 (-18.5 to -0.4)	8.4 (5.4 to 12.0)	10.0 (6.6 to 14.1)	19.3 (-7.7 to 56.9)	13.2 (-11.5 to 46.5)
Skin and subcutaneous diseases	-	-	-	-	145.0 (85.0 to 237.5)	160.9 (95.4 to 262.1)	10.9 (1.6 to 21.0)	1.8 (-5.8 to 9.9)
Dermatitis	967.6 (826.9 to 1,116.7)	1,186.7 (1,008.2 to 1,365.8)	23.0 (18.2 to 29.5)	0.2 (0.0 to 0.3)	26.4 (16.9 to 38.1)	31.4 (20.0 to 45.1)	18.7 (13.1 to 25.8)	0.5 (-2.1 to 3.2)
Psoriasis	64.0 (56.4 to 71.3)	88.8 (79.0 to 98.5)	39.4 (34.4 to 44.4)	4.3 (-0.6 to 4.0)	5.2 (3.5 to 7.5)	7.2 (4.9 to 10.3)	0.1 (-26.0 to 52.6)	0.1 (-8.3 to 9.1)
Cellulitis	4.3 (3.3 to 5.4)	1.6 (1.3 to 1.9)	-63.3 (-68.2 to -57.1)	-69.7 (-75.7 to -64.6)	0.3 (0.2 to 0.5)	0.1 (0.1 to 0.2)	-42.0 (-69.1 to -52.7)	-68.6 (-76.1 to -58.7)
Pyoderma	26.1 (19.8 to 33.4)	12.9 (10.0 to 17.7)	-51.9 (-60.5 to -38.2)	-51.9 (-59.1 to -43.0)	0.1 (0.1 to 0.3)	0.1 (0.0 to 0.2)	-51.0 (-61.9 to -37.6)	-52.1 (-60.0 to -43.2)
Scabies	173.0 (162.7 to 184.9)	195.2 (183.9 to 209.5)	13.2 (4.0 to 24.0)	-2.0 (-9.6 to 7.7)	4.4 (2.5 to 7.0)	5.0 (2.8 to 8.0)	12.9 (2.6 to 24.8)	-1.6 (-10.2 to 8.7)
Fungal skin diseases	3.3 (1,947.7 to 2,645.6)	4.9 (2,519.9 to 3,284.5)	49.0 (20.7 to 32.3)	26.3 (-4.0 to 40.0)	0.0 (5.2 to 27.3)	0.0 (6.7 to 33.9)	0.0 (20.2 to 32.0)	0.0 (-0.6 to 0.6)
Viral skin diseases	407.2 (312.5 to 494.4)	369.5 (272.7 to 458.2)	-9.2 (-14.9 to -2.2)	0.2 (-1.7 to 2.0)	12.5 (7.7 to 18.8)	11.4 (6.7 to 17.3)	-9.4 (-16.1 to -2.4)	0.8 (-2.9 to 3.9)
Acne vulgaris	5,657.5 (4,970.6 to 6,222.0)	5,087.2 (4,411.8 to 5,727.0)	-10.0 (-23.4 to 8.1)	2.7 (-12.9 to 23.2)	61.2 (29.0 to 114.0)	55.4 (25.9 to 102.4)	-9.8 (-23.2 to 8.4)	3.1 (-12.6 to 23.8)
Alopecia areata	20.7 (17.8 to 23.6)	29.3 (25.4 to 33.4)	42.6 (16.2 to 72.1)	-0.1 (-18.5 to 20.4)	0.7 (0.4 to 1.1)	1.0 (0.6 to 1.5)	40.8 (12.8 to 74.0)	0.0 (-19.5 to 22.8)
Pruritus	3.3 (2.8 to 3.9)	4.9 (3.9 to 5.8)	47.6 (15.5 to 82.6)	3.7 (-23.5 to 19.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	49.8 (8.7 to 93.5)	-3.5 (-21.2 to 26.2)
Urticaria	208.7 (163.5 to 260.8)	313.9 (240.1 to 383.3)	50.6 (6.3 to 110.3)	7.5 (-22.1 to 48.8)	12.4 (7.7 to 18.5)	18.7 (11.4 to 28.9)	49.7 (5.4 to 111.0)	8.3 (-21.6 to 51.2)
Decubitus ulcer	3.1 (2.4 to 3.7)	7.4 (5.5 to 8.9)	148.2 (64.8 to 227.1)	6.6 (-33.0 to 46.9)	0.5 (0.3 to 0.7)	1.1 (0.7 to 1.5)	136.0 (56.5 to 214.2)	5.0 (-34.0 to 48.2)
Other skin and subcutaneous diseases	1,389.4 (926.6 to 2,085.3)	2,234.3 (1,403.7 to 3,506.8)	60.5 (39.5 to 79.7)	-0.8 (-3.5 to 1.9)	8.2 (3.5 to 16.9)	13.1 (5.6 to 28.5)	60.1 (39.8 to 79.9)	-0.5 (-3.4 to 2.3)
Sense organ diseases	-	-	-	-	128.7 (83.6 to 182.7)	212.3 (140.8 to 300.0)	65.2 (56.1 to 72.6)	-10.3 (-13.8 to -6.7)
Glaucoma	8.0 (6.0 to 10.3)	12.6 (9.0 to 16.9)	54.1 (26.1 to 110.4)	-30.0 (-41.8 to -4.4)	0.7 (0.4 to 1.0)	1.0 (0.6 to 1.5)	48.8 (17.1 to 120.3)	-36.1 (-49.7 to -5.9)
Cataract	35.0 (22.8 to 49.8)	84.7 (60.9 to 115.1)	147.1 (75.7 to 265.3)	-16.6 (-35.0 to 19.9)	1.9 (1.1 to 2.9)	4.7 (2.9 to 7.2)	152.5 (79.5 to 239.2)	-14.5 (-34.4 to 11.7)
Macular degeneration	60.1 (41.0 to 84.1)	104.6 (77.8 to 133.8)	77.7 (35.5 to 121.9)	-19.1 (-38.3 to 0.9)	2.7 (1.6 to 4.4)	4.8 (3.0 to 7.2)	77.8 (38.5 to 121.3)	1.7 (-37.9 to 19.7)
Uncorrected refractive error	1,082.9 (995.3 to 1,167.0)	1,749.1 (1,636.7 to 1,868.9)	62.4 (45.3 to 79.0)	-10.0 (-18.5 to -1.6)	17.6 (10.7 to 28.1)	27.1 (16.0 to 43.6)	53.7 (42.6 to 65.5)	-12.5 (-18.1 to -6.6)
Age-related and other hearing loss	3,266.6 (3,071.6 to 3,450.7)	5,589.8 (5,288.0 to 5,887.0)	71.6 (65.1 to 78.2)	-9.4 (-11.9 to -6.5)	89.9 (59.4 to 127.7)	154.2 (102.3 to		

Appendix Table G.4 - Taiwan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	393.3 (352.9 to 437.2)	523.9 (479.4 to 572.1)	33.0 (16.3 to 54.1)	-38.7 (-46.6 to -30.0)	10.9 (7.2 to 15.1)	14.5 (9.6 to 20.4)	33.4 (15.6 to 53.0)	-38.5 (-46.4 to -29.9)
Other oral disorders	357.1 (335.3 to 377.4)	470.6 (445.1 to 495.8)	32.3 (22.1 to 43.8)	0.6 (-6.6 to 8.8)	10.5 (6.5 to 15.5)	13.8 (8.7 to 20.5)	31.8 (20.9 to 43.8)	0.7 (-6.5 to 9.5)
Injuries	-	-	-	-	77.1 (57.9 to 100.3)	84.3 (59.8 to 114.7)	8.8 (-3.3 to 23.1)	-34.8 (-41.6 to -26.6)
Transport injuries	-	-	-	-	32.0 (23.9 to 41.5)	29.8 (21.1 to 40.7)	-7.3 (-19.1 to 8.0)	-42.2 (-49.1 to -33.3)
Road injuries	-	-	-	-	27.8 (20.8 to 36.0)	26.0 (18.5 to 35.6)	-6.9 (-19.3 to 9.1)	-42.0 (-49.1 to -32.6)
Pedestrian road injuries	-	-	-	-	4.9 (3.6 to 6.3)	4.6 (3.3 to 6.2)	-6.4 (-20.8 to 11.2)	-43.2 (-51.2 to -33.5)
Cyclist road injuries	-	-	-	-	2.4 (1.8 to 3.1)	2.5 (1.7 to 3.3)	1.7 (-9.6 to 15.2)	-42.0 (-48.0 to -34.7)
Motorcyclist road injuries	-	-	-	-	8.3 (6.2 to 10.8)	8.1 (5.7 to 11.2)	-3.6 (-18.3 to 15.0)	-38.4 (-47.1 to -27.5)
Motor vehicle road injuries	-	-	-	-	12.1 (9.0 to 15.5)	10.8 (7.7 to 14.8)	-11.2 (-24.4 to 5.3)	-43.6 (-51.4 to -34.0)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	5.2 (-9.0 to 21.9)	-38.0 (-45.8 to -29.1)
Other transport injuries	-	-	-	-	4.2 (3.1 to 5.4)	3.8 (2.7 to 5.2)	-9.1 (-19.6 to 4.0)	-43.8 (-50.2 to -35.8)
Unintentional injuries	-	-	-	-	38.2 (28.9 to 49.4)	50.8 (36.2 to 69.3)	32.7 (19.8 to 47.5)	-23.7 (-30.9 to -15.2)
Falls	-	-	-	-	28.2 (21.2 to 36.6)	39.4 (27.8 to 53.9)	38.8 (23.8 to 56.4)	-22.9 (-31.4 to -13.1)
Drowning	-	-	-	-	0.8 (0.6 to 1.1)	0.5 (0.3 to 0.6)	-43.1 (-51.9 to -32.7)	-64.0 (-69.0 to -58.0)
Fire, heat, and hot substances	-	-	-	-	1.0 (0.8 to 1.3)	0.8 (0.5 to 1.0)	-24.1 (-35.9 to -11.5)	-51.8 (-58.6 to -44.3)
Poisonings	-	-	-	-	0.4 (0.2 to 0.5)	0.2 (0.2 to 0.3)	-29.8 (-40.5 to -15.8)	-50.5 (-57.6 to -40.8)
Exposure to mechanical forces	-	-	-	-	4.8 (3.6 to 6.4)	6.1 (4.4 to 8.3)	26.4 (15.7 to 38.2)	-16.9 (-23.2 to -10.0)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-58.6 (-64.9 to -51.6)	-70.8 (-74.9 to -65.9)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-1.2 (-12.8 to 11.8)	-37.1 (-43.9 to -30.0)
Other exposure to mechanical forces	-	-	-	-	4.6 (3.4 to 6.1)	6.0 (4.3 to 8.1)	29.3 (18.4 to 41.2)	-15.1 (-21.5 to -8.1)
Adverse effects of medical treatment	-	-	-	-	0.4 (0.3 to 0.6)	0.7 (0.4 to 1.0)	65.1 (53.2 to 78.1)	4.0 (-3.5 to 12.0)
Animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	8.4 (5.6 to 22.8)	-27.9 (-36.6 to -19.4)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	12.7 (-3.1 to 29.6)	-24.8 (-35.2 to -13.9)
Non-venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	3.2 (-13.0 to 20.9)	-31.8 (-41.0 to -21.5)
Foreign body	-	-	-	-	0.6 (0.5 to 0.8)	0.7 (0.5 to 1.0)	16.3 (3.6 to 31.3)	-28.5 (-36.1 to -20.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.3)	-9.1 (-23.9 to 13.3)	-45.0 (-53.8 to -33.9)
Foreign body in eyes	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	26.3 (10.8 to 42.1)	-10.6 (-20.0 to 0.6)
Foreign body in other body part	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	29.1 (12.3 to 48.4)	-23.1 (-32.0 to -13.0)
Other unintentional injuries	-	-	-	-	1.7 (1.3 to 2.3)	2.3 (1.6 to 3.1)	31.6 (18.1 to 47.1)	-19.4 (-27.2 to -10.7)
Self-harm and interpersonal violence	-	-	-	-	7.0 (5.3 to 9.0)	3.7 (2.6 to 5.0)	-47.9 (-54.1 to -40.0)	-47.2 (-70.8 to -42.8)
Self-harm	-	-	-	-	2.2 (1.6 to 2.9)	1.7 (1.2 to 2.3)	-23.0 (-32.1 to -12.6)	-55.6 (-60.7 to -50.0)
Interpersonal violence	-	-	-	-	4.8 (3.6 to 6.1)	1.9 (1.4 to 2.7)	-59.5 (-64.9 to -52.9)	-73.1 (-76.4 to -69.0)
Assault by firearm	-	-	-	-	0.6 (0.4 to 0.7)	0.3 (0.2 to 0.4)	-54.0 (-59.0 to -47.7)	-69.6 (-72.7 to -65.9)
Assault by sharp object	-	-	-	-	0.6 (0.4 to 0.8)	0.3 (0.2 to 0.5)	-47.1 (-54.3 to -36.8)	-65.5 (-70.0 to -59.1)
Assault by other means	-	-	-	-	3.6 (2.7 to 4.6)	1.4 (1.0 to 1.9)	-62.3 (-67.8 to -55.8)	-74.8 (-78.2 to -70.8)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93,406.6 (4,795.6 to 589,708.6)	110,480.4 (5,161.7 to 576,456.9)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93,406.6 (4,795.6 to 589,708.6)	110,480.4 (5,161.7 to 576,456.9)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Tajikistan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	413.2 (303.8 to 540.2)	686.4 (508.0 to 893.3)	66.0 (61.3 to 71.5)	66.0 (-0.9 to 5.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	61.5 (42.2 to 86.4)	95.0 (65.9 to 129.9)	54.3 (40.3 to 72.5)	5.2 (-4.6 to 17.8)
HIV/AIDS and tuberculosis	-	-	-	-	2.4 (1.6 to 3.2)	5.4 (3.5 to 7.5)	121.7 (91.4 to 175.8)	25.8 (9.3 to 57.9)
Tuberculosis	7.4 (6.9 to 7.8)	14.9 (14.2 to 15.6)	101.6 (91.6 to 112.6)	14.9 (9.4 to 20.3)	2.3 (1.6 to 3.1)	4.6 (3.1 to 6.2)	101.5 (87.2 to 119.1)	14.5 (7.4 to 23.2)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.3)	0.7 (0.1 to 2.0)	748.8 (1.8 to 47,405.1)	377.9 (-43.1 to 27,615.7)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	682.9 (-40.3 to 79,904.0)	327.3 (-68.1 to 46,782.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	682.9 (-41.5 to 80,524.0)	327.3 (-68.9 to 47,074.8)
HIV/AIDS resulting in other diseases	0.9 (0.0 to 2.2)	6.5 (1.5 to 14.4)	707.9 (31.5 to 68,156.5)	367.3 (-22.0 to 40,773.1)	0.1 (0.0 to 0.3)	0.7 (0.1 to 2.0)	756.1 (-6.0 to 291,428.3)	388.2 (-48.9 to 157,389.4)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	10.1 (7.1 to 13.7)	12.4 (8.6 to 16.9)	23.0 (11.8 to 32.9)	-16.2 (-23.7 to -9.5)
Diarrheal diseases	28.4 (26.6 to 30.2)	37.4 (35.2 to 40.2)	31.8 (21.2 to 43.6)	-5.6 (-12.7 to 2.8)	4.6 (3.1 to 6.5)	6.1 (4.1 to 8.6)	11.6 (19.6 to 45.4)	-5.7 (-13.7 to 3.4)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.0 (-21.2 to 12.9)	-35.2 (-46.0 to -22.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.0 (-21.2 to 13.0)	-35.2 (-46.0 to -22.7)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.8 (-18.4 to 19.2)	-32.1 (-44.1 to -18.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.8 (-18.5 to 19.2)	-32.1 (-44.1 to -18.0)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Lower respiratory infections	2.3 (2.1 to 2.6)	1.2 (1.0 to 1.5)	-48.8 (-58.9 to -31.1)	-53.3 (-60.9 to -40.8)	0.2 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-48.7 (-73.0 to -28.0)	-53.7 (-63.5 to -38.8)
Upper respiratory infections	71.3 (65.8 to 77.8)	100.9 (93.4 to 107.7)	41.9 (26.9 to 58.0)	-6.4 (-16.9 to 3.8)	0.8 (0.5 to 1.4)	1.2 (0.7 to 2.0)	41.2 (26.5 to 59.0)	-6.7 (-17.0 to 4.6)
Otitis media	69.4 (63.0 to 75.8)	97.0 (88.6 to 106.1)	39.9 (28.3 to 51.9)	-10.0 (-17.4 to -2.1)	1.5 (0.9 to 2.3)	2.0 (1.2 to 3.2)	37.6 (25.2 to 49.9)	-10.0 (-17.7 to -1.6)
Meningitis	-	-	-	-	2.0 (1.2 to 3.1)	1.7 (1.2 to 2.3)	-16.3 (-38.2 to 16.4)	-45.6 (-58.5 to -26.2)
Pneumococcal meningitis	6.8 (4.0 to 10.3)	6.2 (3.9 to 9.1)	-8.5 (-25.6 to 14.1)	-4.4 (-52.4 to -30.2)	0.6 (0.4 to 1.1)	0.6 (0.4 to 0.9)	-16.3 (-38.2 to 16.4)	-45.6 (-58.7 to -12.7)
H influenzae type B meningitis	5.5 (2.2 to 10.5)	4.2 (1.8 to 7.3)	-19.7 (-53.6 to 19.6)	-48.9 (-67.9 to -24.9)	0.8 (0.4 to 1.5)	0.6 (0.3 to 0.9)	-17.8 (-66.1 to 45.5)	-46.5 (-76.9 to -7.5)
Meningococcal meningitis	1.5 (0.6 to 3.1)	1.3 (0.5 to 2.7)	-13.1 (-34.6 to 13.9)	-44.8 (-56.9 to -26.7)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-17.9 (-45.3 to 18.2)	-47.1 (-63.2 to -25.9)
Other meningitis	2.6 (1.6 to 4.2)	2.6 (1.7 to 4.1)	-0.3 (-21.3 to 25.2)	-35.6 (-48.4 to -17.1)	0.4 (0.2 to 0.6)	0.3 (0.2 to 0.5)	-2.9 (-37.7 to 34.6)	-36.1 (-55.2 to -12.3)
Encephalitis	1.8 (0.9 to 3.9)	2.8 (1.3 to 5.9)	57.4 (39.3 to 84.1)	-2.3 (-11.6 to 18.2)	0.2 (0.2 to 0.3)	0.4 (0.2 to 0.5)	55.4 (31.1 to 82.9)	-1.7 (-16.2 to 15.8)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.0 (-95.0 to 1,909.7)	-29.2 (-94.6 to 814.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.0 (-95.0 to 1,914.1)	-29.2 (-94.6 to 817.9)
Whooping cough	10.7 (8.2 to 13.9)	15.8 (12.1 to 20.6)	47.3 (45.8 to 48.8)	12.9 (11.8 to 14.1)	0.5 (0.3 to 0.9)	0.8 (0.5 to 1.3)	47.1 (38.2 to 57.6)	12.8 (5.8 to 20.9)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.5 (-60.7 to 28.4)	-59.1 (-74.2 to -15.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.5 (-45.1 to 56.7)	-48.6 (-64.0 to 4.4)
Measles	0.2 (0.2 to 0.2)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	4.1 (3.9 to 4.3)	5.5 (5.3 to 5.8)	36.1 (27.4 to 45.4)	-0.7 (-9.2 to 8.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	52.1 (22.6 to 87.2)	-0.6 (-20.0 to 22.6)
Neglected tropical diseases and malaria	-	-	-	-	3.8 (2.3 to 6.1)	3.8 (2.5 to 5.5)	0.3 (-25.5 to 34.6)	-24.7 (-44.5 to 0.0)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.8 (-48.2 to 4.3)	-52.5 (-68.6 to -30.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-58.6 (-70.4 to -38.6)	-73.9 (-81.9 to -61.2)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	394.2 (191.1 to 732.2)	355.7 (162.8 to 649.8)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.3 (2.2 to 92.4)	-3.2 (-25.7 to 30.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.3 (2.1 to 92.8)	-3.2 (-25.8 to 30.3)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.4 (0.3 to 0.6)	2,452.3 (1,812.4 to 3,386.9)	2,030.9 (1,521.3 to 2,845.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,386.6 (1,629.3 to 3,500.2)	1,960.3 (1,362.8 to 2,901.6)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.6 (-82.0 to 51.5)	-74.8 (-89.4 to -22.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-55.4 (-81.4 to 61.0)	-73.9 (-89.7 to -19.5)
Cystic echinococcosis	3.1 (2.6 to 3.5)	5.4 (5.1 to 5.8)	68.7 (48.0 to 107.4)	21.6 (10.3 to 42.2)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	69.8 (37.7 to 114.8)	22.8 (3.8 to 47.7)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.2 (0.0 to 0.5)	1.3 (0.4 to 3.8)	660.9 (651.7 to 671.6)	390.8 (384.8 to 397.7)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.6)	628.0 (489.5 to 781.9)	364.4 (284.5 to 454.5)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-33.2 to 54.0)	0.0 (-49.2 to -1.0)	4.1 (-33.3 to 54.1)	27.0 (-49.2 to -0.9)
Intestinal nematode infections	-	-	-	-	1.4 (0.6 to 2.8)	0.2 (0.1 to 0.4)	85.2 (-91.4 to -74.1)	88.0 (-93.3 to -78.5)
Ascariasis	540.6 (392.2 to 750.0)	773.7 (503.8 to 1,153.8)	42.7 (-15.5 to 138.1)	-5.7 (-49.1 to 68.6)	1.4 (0.6 to 2.8)	0.2 (0.1 to 0.3)	85.2 (-92.7 to -76.3)	88.0 (-94.5 to -80.5)
Trichuriasis	35.6 (23.3 to 53.7)	38.4 (24.1 to 61.1)	6.4 (-41.9 to 98.3)	-31.6 (-66.1 to 43.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.4 (-79.4 to 423.9)	-36.8 (-86.9 to 282.5)
Hookworm disease	3.3 (1.8 to 5.6)	5.8 (3.2 to 9.7)	74.8 (-26.7 to 284.0)	0.7 (-58.5 to 118.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.7 (40.2 to 127.0)	3.1 (-21.9 to 34.1)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	60.8 (45.2 to 78.0)	82.5 (68.2 to 97.9)	35.0 (4.9 to 81.4)	0.9 (-21.8 to 36.1)	2.1 (1.2 to 3.2)	2.9 (1.8 to 4.2)	32.7 (13.3 to 110.3)	0.8 (-24.0 to 63.3)
Maternal disorders	-	-	-	-	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.4)	10.2 (-16.3 to 46.5)	-38.4 (-52.5 to -20.0)
Maternal hemorrhage	1.4 (1.1 to 1.6)	1.8 (1.3 to 2.3)	31.5 (-3.9 to 71.6)	-25.7 (-45.9 to -1.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	28.2 (-16.6 to 84.5)	-27.4 (-53.1 to 3.1)
Maternal sepsis and other maternal infections	5.4 (3.3 to 7.9)	5.5 (3.2 to 8.3)	2.3 (-16.0 to 14.1)	-45.9 (-56.4 to -38.1)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-12.6 (-44.1 to 32.8)	-11.4 (-67.1 to -28.8)
Maternal hypertensive disorders	0.6 (0.3 to 1.0)	0.8 (0.4 to 1.4)	33.2 (9.5 to 51.8)	-25.2 (-37.5 to -15.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	30.0 (-7.1 to 78.5)	-26.9 (-47.3 to -0.7)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.6 (-8.5 to 82.4)	-28.2 (-47.6 to 1.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.6 (-8.7 to 83.3)	-28.2 (-47.6 to 1.0)
Complications of abortion	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	33.3 (14.7 to 60.6)	-25.0 (-35.3 to -10.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.2 (-36.1 to 182.5)	-24.0 (-61.1 to 54.9)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	17.5 (-41.2 to 135.9)	-34.7 (-66.5 to 31.5)
Neonatal disorders	-	-	-	-	3.9 (2.2 to 6.0)	16.2 (10.3 to 23.3)	307.8 (182.1 to 616.5)	177.7 (91.6 to 395.8)
Preterm birth complications	13.9 (7.6 to 25.1)	53.0 (32.5 to 84.9)	286.5 (187.3 to 450.5)	148.8 (87.6 to 252.9)	1.4 (0.8 to 2.1)	7.3 (4.2 to 11.1)	429.9 (191.9 to 800.2)	251.4 (96.9 to 488.3)
Neonatal encephalopathy due to birth asphyxia and trauma	8.9 (2.4 to 27.8)	13.9 (6.3 to 32.4)	70.8 (0.3 to 301.2)	11.0 (-36.4 to 173.2)	1.0 (0.4 to 1.9)	2.9 (1.6 to 4.7)	199.6 (40.2 to 553.9)	112.4 (0.6 to 375.1)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.2 (68.6 to 105.1)	0.0 (30.9 to 59.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.2 (48.6 to 148.9)	44.3 (15.4 to 93.3)
Hemolytic disease and other neonatal jaundice	2.5 (1.1 to 4.8)	7.8 (3.6 to 14.8)	217.0 (16.9 to 675.4)	117.4 (-21.3 to 426.0)	1.0 (0.4 to 1.9)	2.9 (1.3 to 5.4)	216.7 (17.7 to 668.9)	116.3 (-21.7 to 419.6)
Other neonatal disorders	-	-	-	-	0.5 (0.2 to 1.0)	3.0 (1.3 to 5.8)	456.2 (141.2 to 1,226.3)	278.3 (64.3 to 809.8)
Nutritional deficiencies	-	-	-	-	38.0 (25.2 to 55.3)	52.5 (34.8 to 76.6)	38.2 (15.7 to 59.0)	-5.6 (-18.0 to 7.6)
Protein-energy malnutrition	26.4 (9.8 to 53.6)	33.7 (13.0 to 74.0)	24.1 (-58.3 to 374.2)	-4.7 (-68.0 to 264.5)	4.2 (1.1 to 7.0)	4.2 (1.5 to 9.8)	24.2 (-58.8 to 388.1)	-4.7 (-68.3 to 274.4)
Iodine deficiency	192.1 (96.4 to 315.8)	204.4 (97.2 to 350.3)	7.2 (-61.4 to 203.2)	-38.9 (-77.5 to 79.1)	3.5 (1.5 to 6.7)	3.7 (1.4 to 7.1)	6.8 (-61.1 to 198.8)	-38.7 (-77.4 to 76.8)
Vitamin A deficiency	6.0 (4.9 to 7.3)	4.5 (3.6 to 5.6)	-25.1 (-32.6 to -15.2)	-49.5 (-54.2 to -43.5)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-26.1 (-37.1 to -14.3)	-50.2 (-57.2 to -42.8)

Appendix Table G.4 - Tajikistan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	936.8 (904.7 to 952.1)	1,369.0 (1,339.1 to 1,398.3)	47.8 (42.3 to 53.0)	-3.9 (-9.9 to 4.4)	30.6 (20.4 to 44.6)	43.8 (29.1 to 63.7)	43.3 (36.0 to 49.0)	43.3 (6.3 to 47.2)
Other nutritional deficiencies	-	-	-	-	0.4 (0.1 to 1.2)	0.6 (0.1 to 1.9)	51.5 (-61.6 to 516.9)	16.3 (-70.5 to 373.6)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	3.1 (2.0 to 4.7)	4.6 (2.9 to 7.1)	46.1 (22.6 to 71.4)	-7.2 (-19.7 to 4.0)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.2 (0.7 to 2.1)	2.0 (1.2 to 3.4)	64.7 (42.4 to 91.6)	-7.0 (-18.2 to 5.5)
Syphilis	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	0.9 (-14.8 to 18.0)	-36.9 (-45.5 to -28.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.4 (-23.0 to 39.9)	-35.4 (-53.4 to -13.7)
Chlamydial infection	152.9 (133.6 to 173.2)	275.6 (239.9 to 314.4)	80.5 (49.5 to 117.3)	1.4 (-15.0 to 20.1)	0.7 (0.4 to 1.1)	1.2 (0.7 to 2.0)	78.0 (40.6 to 120.7)	-0.7 (-19.9 to 19.8)
Gonococcal infection	35.5 (28.3 to 43.6)	53.8 (42.7 to 66.0)	51.1 (10.4 to 100.2)	-14.1 (-36.3 to 12.4)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	58.9 (15.1 to 127.2)	-9.8 (-34.3 to 26.3)
Trichomoniasis	73.4 (49.1 to 100.5)	81.8 (64.0 to 103.3)	11.8 (-26.5 to 75.3)	-31.3 (-51.8 to 3.1)	0.1 (0.0 to 0.3)	0.1 (0.1 to 0.3)	4.4 (-36.0 to 72.4)	-34.4 (-57.1 to 2.9)
Genital herpes	611.4 (588.9 to 635.5)	1,088.7 (1,028.4 to 1,106.2)	78.5 (66.1 to 83.5)	-1.7 (-6.0 to 2.4)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.7)	74.4 (61.3 to 85.8)	-1.9 (-7.7 to 4.0)
Other sexually transmitted diseases	1.3 (0.9 to 1.6)	2.0 (1.5 to 2.6)	60.7 (38.8 to 83.9)	-15.9 (-27.9 to -4.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	67.9 (23.0 to 131.9)	-7.5 (-31.1 to 22.7)
Hepatitis	-	-	-	-	0.4 (0.3 to 0.7)	0.6 (0.4 to 0.9)	35.0 (14.8 to 69.2)	-22.5 (-35.8 to 4.7)
Hepatitis A	8.3 (7.9 to 8.8)	12.2 (11.7 to 12.7)	46.7 (45.6 to 47.7)	1.2 (1.2 to 1.3)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	57.0 (39.2 to 79.6)	-0.2 (-10.8 to 12.5)
Hepatitis B	508.8 (438.0 to 578.3)	575.0 (488.3 to 666.0)	13.0 (-8.9 to 42.4)	-30.2 (-43.1 to -13.0)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	21.0 (-16.7 to 62.1)	-33.4 (-53.3 to 11.1)
Hepatitis C	339.5 (306.3 to 375.5)	420.6 (373.6 to 471.3)	23.4 (6.6 to 44.4)	-26.0 (-35.3 to -14.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	16.8 (-13.3 to 55.2)	-25.0 (-45.9 to 4.1)
Hepatitis E	0.6 (0.5 to 0.7)	1.0 (0.9 to 1.2)	63.9 (33.5 to 105.9)	-4.9 (-23.2 to 16.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.6 (13.7 to 147.6)	-5.8 (-33.8 to 38.2)
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	42.1 (31.6 to 53.5)	57.5 (44.2 to 72.4)	37.0 (1.0 to 84.1)	0.8 (-24.4 to 34.1)	1.5 (0.9 to 2.2)	1.9 (1.1 to 2.9)	33.8 (-17.9 to 102.6)	0.4 (-37.9 to 55.7)
Non-communicable diseases	-	-	-	-	2.1 (235.0 to 415.4)	2.1 (393.6 to 692.2)	34.2 (63.2 to 72.4)	-16.1 (-2.4 to 3.0)
Neoplasms	-	-	-	-	1.6 (1.1 to 2.0)	1.6 (1.5 to 2.8)	34.2 (15.0 to 59.9)	-16.1 (-27.6 to -0.5)
Esophageal cancer	0.5 (0.4 to 0.7)	0.6 (0.4 to 0.8)	8.5 (-28.6 to 59.1)	-26.0 (-51.8 to 9.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	10.5 (-25.2 to 58.6)	-25.3 (-49.2 to 7.2)
Stomach cancer	1.4 (1.2 to 1.6)	1.2 (1.0 to 1.4)	-15.3 (-33.7 to 5.5)	-42.7 (-55.3 to -27.9)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	4.7 (-3.5 to 6.4)	-42.7 (-54.6 to -28.5)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	71.0 (26.1 to 135.0)	17.7 (-13.5 to 61.7)
Liver cancer due to hepatitis B	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	57.2 (-5.0 to 166.3)	4.8 (-36.6 to 73.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.0 (-7.7 to 118.7)	1.9 (-29.8 to 45.4)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	333.9 (161.6 to 650.5)	197.6 (78.3 to 415.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	317.4 (177.7 to 532.6)	186.4 (91.2 to 333.8)
Liver cancer due to alcohol use	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	47.4 (-12.5 to 150.5)	4.8 (-36.9 to 76.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.9 (-7.3 to 124.8)	2.1 (-32.8 to 56.5)
Liver cancer due to other causes	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-103.2 (-54.7 to 62.6)	-42.7 (-71.5 to 9.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.7 (-51.7 to 38.0)	-45.1 (-69.6 to -8.3)
Larynx cancer	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-6.9 (-35.5 to 36.0)	-41.7 (-60.2 to -34.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.2 (-32.8 to 33.5)	-42.3 (-58.1 to -15.3)
Tracheal, bronchus and lung cancer	0.5 (0.5 to 0.6)	0.3 (0.3 to 0.4)	-38.6 (-51.5 to -17.6)	-60.2 (-68.2 to -45.3)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-35.5 (-50.8 to -12.5)	-58.4 (-67.9 to -42.5)
Breast cancer	1.2 (1.0 to 1.5)	4.4 (3.7 to 5.0)	251.1 (171.8 to 338.9)	124.9 (72.8 to 182.4)	0.3 (0.1 to 0.2)	0.3 (0.2 to 0.4)	128.8 (68.7 to 204.4)	31.6 (-2.1 to 78.6)
Cervical cancer	1.1 (0.7 to 1.4)	0.8 (0.6 to 1.4)	-30.3 (-50.0 to 54.3)	-62.0 (-72.4 to -9.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	48.5 (-6.8 to 60.4)	-40.7 (-71.3 to 5.4)
Uterine cancer	0.6 (0.4 to 1.0)	0.9 (0.6 to 1.4)	53.2 (-7.3 to 140.4)	-14.0 (-47.6 to 31.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	52.1 (-6.3 to 137.7)	-14.8 (-47.4 to 31.5)
Prostate cancer	0.5 (0.4 to 0.7)	1.0 (0.8 to 1.4)	92.4 (40.1 to 178.6)	40.2 (0.7 to 101.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	81.5 (24.0 to 181.4)	29.5 (-9.2 to 103.8)
Colon and rectum cancer	1.2 (1.1 to 1.3)	1.3 (1.1 to 1.5)	8.3 (-10.6 to 35.0)	-35.3 (-46.7 to -21.6)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	8.1 (-12.4 to 33.8)	-35.6 (-47.3 to -20.3)
Lip and oral cavity cancer	0.5 (0.4 to 0.8)	0.7 (0.5 to 0.9)	26.9 (-14.3 to 79.3)	-17.7 (-45.1 to 17.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	27.0 (-12.5 to 81.5)	-17.5 (-43.4 to 17.5)
Nasopharynx cancer	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	41.1 (-35.5 to 61.8)	-42.2 (-64.5 to -9.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.2 (-35.3 to 56.0)	-43.6 (-63.3 to -14.8)
Other pharynx cancer	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	8.6 (-45.3 to 122.0)	-30.2 (-63.8 to 42.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.4 (-37.4 to 95.1)	-28.8 (-58.1 to 27.9)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-8.2 (-44.8 to 46.2)	-36.9 (-62.1 to 3.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.5 (-41.4 to 43.7)	-35.4 (-59.5 to 1.6)
Pancreatic cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	96.9 (47.0 to 170.0)	34.6 (1.4 to 83.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.1 (61.0 to 150.2)	38.8 (11.4 to 72.1)
Malignant skin melanoma	0.6 (0.5 to 0.8)	1.3 (0.9 to 1.7)	113.4 (45.7 to 184.4)	98.4 (-12.3 to 68.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	98.4 (34.0 to 174.2)	12.4 (-18.4 to 63.4)
Non-melanoma skin cancer	1.4 (1.1 to 1.8)	2.3 (1.8 to 2.7)	66.4 (19.7 to 128.2)	12.6 (-21.6 to 54.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	81.5 (33.4 to 144.3)	19.3 (-12.9 to 60.9)
Ovarian cancer	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	92.0 (25.5 to 186.8)	14.5 (-26.8 to 69.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	92.6 (22.5 to 199.7)	13.3 (-29.0 to 76.7)
Testicular cancer	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	87.2 (7.2 to 216.8)	-9.9 (-40.7 to 63.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.9 (-1.4 to 218.2)	-2.0 (-44.7 to 62.7)
Kidney cancer	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	59.2 (-4.3 to 140.3)	18.8 (-17.7 to 60.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	69.5 (7.1 to 146.7)	20.4 (-14.1 to 68.4)
Bladder cancer	0.4 (0.3 to 0.4)	0.5 (0.3 to 0.5)	199.6 (-25.9 to 40.5)	99.2 (-46.2 to 4.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	204.9 (-23.1 to 42.4)	96.3 (-44.3 to 7.2)
Brain and nervous system cancer	0.4 (0.3 to 0.7)	1.0 (0.8 to 1.3)	199.6 (33.0 to 328.7)	99.2 (-2.2 to 172.3)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	204.9 (42.6 to 328.1)	96.3 (0.1 to 162.4)
Thyroid cancer	0.6 (0.4 to 0.9)	0.9 (0.5 to 1.4)	54.2 (4.8 to 131.2)	-14.1 (-40.4 to 26.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	52.5 (4.0 to 134.6)	-13.9 (-40.2 to 28.0)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-3.8 to 46.3)	-
Hodgkin lymphoma	0.5 (0.3 to 0.9)	0.6 (0.6 to 1.2)	56.1 (-12.7 to 171.9)	3.1 (-40.3 to 75.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	54.3 (-11.9 to 166.3)	-0.2 (-38.9 to 63.5)
Non-Hodgkin lymphoma	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.8)	45.6 (-2.9 to 125.5)	1.0 (-32.2 to 47.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	55.0 (4.5 to 129.2)	4.2 (-28.7 to 52.9)
Multiple myeloma	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	64.9 (0.6 to 180.9)	-1.5 (-39.3 to 71.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.1 (1.5 to 157.0)	-3.9 (-37.7 to 57.1)
Leukemia	1.7 (1.3 to 2.1)	1.5 (1.2 to 2.1)	-15.3 (-34.4 to 28.6)	-36.4 (-51.5 to -15.6)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-2.2 (-27.0 to 29.5)	-96.1 (-49.1 to -15.1)
Other neoplasms	1.9 (1.2 to 3.3)	3.2 (2.5 to 4.0)	77.0 (-4.1 to 167.4)	11.4 (-25.1 to 58.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	72.2 (2.7 to 155.6)	5.7 (-25.0 to 50.8)
Cardiovascular diseases	-	-	-	-	3.6 (2.4 to 5.0)	4.7 (3.2 to 6.5)	30.2 (1.3 to 69.7)	-8.8 (-27.1 to 15.9)
Rheumatic heart disease	0.5 (0.4 to 0.5)	0.7 (0.6 to 0.8)	40.9 (22.2 to 68.9)	-8.7 (-22.3 to 11.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	46.2 (16.1 to 96.3)	-6.9 (-26.4 to 23.1)
Ischemic heart disease	31.2 (26.3 to 38.2)	41.3 (36.8 to 49.3)	32.5 (5.0 to 70.2)	-2.7 (-20.8 to 24.1)	1.6 (1.0 to 2.3)	1.9 (1.3 to 2.7)	18.8 (9.9 to 66.3)	-7.9 (-29.4 to 24.1)
Cerebrovascular disease	-	-	-	-	0.4 (0.3 to 0.6)	0.6 (0.5 to 0.9)	59.7 (18.4 to 100.8)	0.0 (-27.2 to 25.2)
Ischemic stroke	1.4 (1.2 to 1.7)	2.2 (1.8 to 2.6)	57.2 (16.9 to 96.4)	2.1 (-24.9 to 28.0)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	57.7 (16.6 to 101.9)	1.2 (-25.9 to 30.1)
Hemorrhagic stroke	1.2 (1.0 to 1.4)	2.0 (1.6 to 2.3)	61.6 (18.7 to 108.1)	-0.7 (-30.1 to 26.6)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	62.8 (15.1 to 114.8)	-1.2 (-33.5 to 29.9)
Hypertensive heart disease	3.8 (3.3 to 4.2)	5.3 (4.7 to 5.8)	40.0 (19.2 to 64.1)	0.7 (-15.7 to 16.4)	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.8)	40.3 (18.4 to 65.5)	-0.8 (-16.5 to 17.7)
Cardiomyopathy and myocarditis	2.3 (2.0 to 2.7)	3.8 (3.4 to 4.2)	62.5 (39.3 to 93.2)	12.9 (-4.2 to 37.7)	0.4 (0.2 to 0.3)	0.4 (0.3 to 0.5)	63.1 (38.4 to 97.4)	13.6 (-5.7 to 40.3)
Atrial fibrillation and flutter	0.1 (0.1 to 0.1)	0.6 (0.4 to 0.8)	386.0 (227.9 to 669.6)	172.3 (88.6 to 321.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	376.9 (190.3 to 742.4)	164.6 (64.4 to 338.4)
Peripheral vascular disease	64.3 (44.4 to 83.9)	101.8 (76.2 to 128.2)	58.3 (5.1 to 140.1)	6.1 (-29.4 to 61.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	14.7 (-50.7 to 109.1)	-12.2 (-61.2 to 61.6)
Endocarditis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	31.8 (1.5 to 69.1)	-8.4 (-29.9 to 21.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.1 (-6.7 to 90.7)	-8.3 (-37.4 to 33.4)
Other cardiovascular and circulatory diseases	11.6 (5.4 to 21.2)	13.4 (5.5 to 23.9)	10.1 (-59.8 to 210.9)	-20.1 (-75.5 to 98.9)	0.8 (0.4 to 1.5)	0.9 (0.3 to 1.8)	9.5 (-59.8 to 207.6)	-30.4 (-75.6 to 100.2)
Chronic respiratory diseases	-	-	-	-	11.4 (7.8 to 15.8)	18.6 (12.6 to 25.7)	62.5 (42.7 to 90.9)	-4.0 (-14.8 to 13.4)
Chronic obstructive pulmonary disease	128.9 (122.9 to 134.9)	216.1 (205.4 to 226.6)	67.6 (63.0 to 73.0)	0.0 (-2.8 to 3.1)	8.2 (5.5 to 11.5)	13.3 (8.7 to 18.8)	61.7 (39.2 to 90.9)	-2.9 (-17.2 to 15.3)

Appendix Table G.4 - Tajikistan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumococcal	-	-	-	-	0.0	0.0	-	-
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.4 (48.1 to 61.1)	-1.2 (-5.2 to 3.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	36.5 (31.1 to 42.8)	-37.0 (-20.3 to -13.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.4 (31.1 to 43.0)	-16.8 (-20.2 to -13.2)
Asthma	60.5 (45.2 to 76.3)	96.8 (66.9 to 128.6)	57.5 (7.4 to 145.8)	-10.5 (-34.7 to 27.2)	2.6 (1.6 to 4.1)	4.2 (2.4 to 6.5)	57.7 (6.7 to 145.7)	-10.5 (-35.1 to 27.9)
Interstitial lung disease and pulmonary sarcoidosis	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.7)	60.3 (3.6 to 136.3)	-6.7 (-40.4 to 37.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	60.3 (4.4 to 135.1)	-6.2 (-39.3 to 36.4)
Other chronic respiratory diseases	-	-	-	-	0.5 (0.3 to 0.9)	0.9 (0.5 to 1.5)	82.8 (6.1 to 162.8)	9.6 (-36.5 to 58.2)
Cirrhosis	-	-	-	-	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.4)	70.5 (51.8 to 90.5)	7.4 (-2.2 to 18.5)
Cirrhosis due to hepatitis B	1.5 (1.3 to 1.7)	2.4 (1.7 to 2.9)	63.4 (10.9 to 111.0)	4.4 (-25.0 to 33.2)	0.2 (0.2 to 0.4)	0.4 (0.2 to 0.6)	62.9 (9.2 to 121.3)	4.4 (-28.1 to 36.9)
Cirrhosis due to hepatitis C	0.8 (0.6 to 1.0)	1.3 (1.0 to 1.8)	73.6 (15.8 to 158.3)	3.2 (-31.0 to 52.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	73.4 (10.7 to 168.7)	3.2 (-31.8 to 59.0)
Cirrhosis due to alcohol use	0.5 (0.3 to 0.6)	0.8 (0.5 to 1.2)	74.7 (-7.8 to 169.7)	5.8 (-37.1 to 60.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	75.8 (-13.3 to 179.1)	5.2 (-41.9 to 63.4)
Cirrhosis due to other causes	0.8 (0.6 to 0.9)	1.4 (1.0 to 1.9)	81.3 (29.1 to 158.1)	28.6 (-9.6 to 89.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	80.9 (18.9 to 174.2)	28.8 (-15.4 to 93.8)
Digestive diseases	-	-	-	-	3.4 (2.4 to 4.6)	5.8 (4.1 to 7.6)	69.0 (51.8 to 84.7)	1.5 (-7.3 to 9.4)
Peptic ulcer disease	25.5 (22.8 to 27.7)	25.5 (22.1 to 29.1)	0.1 (-12.3 to 16.6)	-33.9 (-40.3 to -26.0)	0.8 (0.5 to 1.2)	0.8 (0.6 to 1.2)	8.3 (-14.0 to 32.5)	-30.3 (-42.3 to -19.9)
Gastritis and duodenitis	7.1 (6.4 to 7.8)	9.5 (8.5 to 10.7)	35.4 (16.4 to 55.1)	-2.0 (-15.2 to 12.1)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.8)	32.3 (2.4 to 74.7)	-1.6 (-19.6 to 23.3)
Appendicitis	0.5 (0.4 to 0.6)	0.8 (0.7 to 1.0)	61.6 (19.2 to 118.0)	3.5 (-21.4 to 33.8)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	61.6 (3.4 to 155.5)	3.2 (-30.1 to 54.0)
Paralytic ileus and intestinal obstruction	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	43.1 (-15.8 to 101.7)	5.8 (-19.2 to 31.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.1 (-22.9 to 134.6)	7.8 (-27.0 to 45.1)
Inguinal, femoral, and abdominal hernia	25.7 (20.3 to 34.5)	31.7 (27.6 to 37.5)	24.9 (-8.9 to 61.0)	-15.3 (-31.8 to 7.2)	0.3 (0.1 to 0.5)	0.3 (0.2 to 0.6)	25.4 (-9.3 to 60.8)	-15.1 (-31.2 to 7.4)
Inflammatory bowel disease	4.6 (4.4 to 4.8)	10.9 (10.5 to 11.3)	137.3 (124.0 to 150.1)	35.4 (28.2 to 43.4)	1.0 (0.7 to 1.3)	2.3 (1.6 to 3.2)	137.9 (118.2 to 159.7)	35.3 (24.7 to 46.8)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.7 (19.9 to 140.1)	22.6 (-21.0 to 95.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.8 (12.7 to 144.5)	18.5 (-28.5 to 97.4)
Gallbladder and biliary diseases	9.6 (8.2 to 4.1)	4.4 (3.7 to 5.0)	21.9 (0.7 to 50.5)	-39.2 (-32.7 to 2.8)	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.6)	20.5 (-0.8 to 52.8)	29.5 (-33.4 to 3.5)
Pancreatitis	0.9 (0.9 to 0.9)	2.4 (2.2 to 2.5)	161.9 (144.4 to 179.5)	47.4 (37.7 to 57.6)	0.3 (0.2 to 0.4)	0.7 (0.5 to 1.0)	161.6 (124.9 to 201.8)	47.4 (28.5 to 68.1)
Other digestive diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	71.8 (11.6 to 167.9)	2.6 (-31.0 to 58.0)
Neurological disorders	-	-	-	-	37.9 (25.3 to 53.0)	92.0 (43.9 to 62.0)	77.1 (53.8 to 104.0)	5.8 (-7.9 to 20.2)
Alzheimer disease and other dementias	18.1 (16.1 to 20.3)	24.2 (21.5 to 27.3)	33.5 (12.0 to 58.4)	0.7 (-16.0 to 20.1)	2.9 (1.9 to 3.5)	3.5 (2.5 to 4.6)	32.3 (10.7 to 57.3)	0.0 (-16.6 to 20.1)
Parkinson disease	1.2 (1.0 to 1.4)	1.7 (1.4 to 2.0)	41.6 (34.6 to 49.3)	0.6 (-3.8 to 5.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	41.1 (24.6 to 59.9)	-0.3 (-11.1 to 11.1)
Epilepsy	20.9 (14.8 to 27.8)	35.0 (24.3 to 46.2)	66.7 (5.4 to 162.6)	6.3 (-33.2 to 67.2)	3.3 (3.7 to 9.5)	10.8 (6.3 to 16.3)	71.0 (6.2 to 177.9)	9.6 (-31.9 to 76.1)
Multiple sclerosis	0.7 (0.6 to 0.8)	1.6 (1.5 to 1.8)	131.1 (104.4 to 162.8)	24.8 (10.6 to 41.6)	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.7)	130.9 (85.9 to 185.6)	24.8 (1.2 to 53.9)
Migraine	663.4 (583.3 to 741.5)	1,127.6 (994.7 to 1,243.8)	69.9 (44.2 to 100.5)	0.6 (-14.9 to 16.3)	23.0 (13.8 to 34.6)	38.5 (22.6 to 58.1)	70.0 (43.3 to 99.9)	0.0 (-15.0 to 16.5)
Tension-type headache	998.8 (918.6 to 1,088.7)	1,770.8 (1,491.6 to 2,008.6)	77.5 (49.4 to 106.7)	1.7 (-12.0 to 17.0)	1.5 (0.7 to 2.7)	2.7 (1.3 to 4.8)	77.7 (48.9 to 108.0)	2.0 (-12.7 to 18.1)
Medication overuse headache	24.3 (16.1 to 32.5)	62.5 (42.6 to 85.2)	158.0 (107.2 to 213.5)	42.5 (15.8 to 73.0)	3.8 (2.2 to 5.9)	9.9 (5.5 to 15.5)	157.4 (105.9 to 216.8)	42.9 (15.2 to 73.8)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.3 (20.7 to 118.7)	5.0 (-21.6 to 40.6)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	80.4 (25.4 to 149.0)	30.0 (-10.9 to 79.4)
Mental and substance use disorders	-	-	-	-	95.7 (68.7 to 128.8)	162.7 (116.6 to 213.9)	70.0 (66.0 to 74.4)	-0.5 (-2.7 to 1.9)
Schizophrenia	11.3 (10.3 to 12.2)	20.8 (18.9 to 22.5)	83.7 (75.5 to 92.6)	-0.6 (-4.5 to 3.5)	7.3 (5.4 to 8.9)	13.5 (10.0 to 16.4)	83.7 (72.0 to 96.5)	-0.7 (-6.7 to 5.7)
Alcohol use disorders	43.0 (37.5 to 48.5)	86.4 (75.3 to 98.7)	101.0 (87.3 to 114.9)	10.0 (3.2 to 17.3)	4.3 (2.8 to 6.2)	8.7 (5.6 to 12.5)	101.4 (86.4 to 116.6)	10.1 (2.0 to 18.3)
Drug use disorders	-	-	-	-	6.1 (4.1 to 8.1)	10.7 (7.4 to 14.5)	76.9 (55.9 to 101.9)	-1.0 (-11.7 to 11.6)
Opioid use disorders	5.1 (3.8 to 6.5)	9.5 (7.2 to 12.3)	89.0 (71.5 to 107.7)	0.8 (-7.9 to 9.7)	2.1 (1.4 to 3.0)	4.0 (2.6 to 5.6)	88.7 (65.2 to 112.7)	1.0 (-10.7 to 12.9)
Cocaine use disorders	3.1 (3.1 to 4.0)	6.0 (5.2 to 6.9)	65.8 (36.9 to 104.8)	6.5 (-21.0 to 12.2)	0.5 (0.3 to 0.7)	0.8 (0.5 to 1.2)	64.1 (28.3 to 112.8)	6.8 (-26.1 to 17.5)
Amphetamine use disorders	9.9 (9.1 to 10.8)	17.2 (15.8 to 18.6)	73.2 (54.7 to 96.5)	-0.4 (-10.4 to 12.0)	1.3 (0.8 to 1.9)	2.3 (1.4 to 3.4)	73.2 (47.1 to 106.4)	-0.4 (-14.8 to 16.7)
Cannabis use disorders	9.5 (8.7 to 10.3)	16.3 (15.0 to 17.7)	72.1 (71.3 to 72.9)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	72.1 (48.9 to 100.2)	0.4 (-12.5 to 16.3)
Other drug use disorders	-	-	-	-	1.8 (1.1 to 2.7)	3.1 (1.9 to 4.7)	71.1 (24.6 to 134.1)	-2.0 (-28.4 to 33.0)
Depressive disorders	-	-	-	-	6.4 (23.7 to 50.3)	10.0 (40.9 to 87.2)	72.2 (64.6 to 81.1)	0.3 (-4.8 to 4.6)
Major depressive disorder	147.0 (118.4 to 172.4)	251.9 (205.3 to 294.4)	71.3 (63.1 to 80.9)	-0.4 (-5.1 to 5.7)	30.5 (19.6 to 44.0)	52.3 (33.7 to 74.9)	71.3 (62.4 to 81.7)	-0.3 (-5.5 to 5.8)
Dysthymia	54.1 (44.0 to 63.5)	95.8 (77.6 to 112.4)	77.0 (72.2 to 81.5)	-0.4 (-0.7 to -0.2)	5.3 (3.4 to 7.6)	9.3 (5.9 to 13.4)	77.3 (70.9 to 83.8)	-0.5 (-2.8 to 1.7)
Bipolar disorder	28.3 (24.0 to 32.3)	50.3 (43.0 to 57.3)	78.0 (66.6 to 88.7)	-0.1 (-5.0 to 4.5)	5.8 (3.5 to 8.8)	10.3 (6.4 to 15.6)	78.1 (64.1 to 91.7)	-0.3 (-6.7 to 6.1)
Anxiety disorders	138.7 (112.7 to 167.1)	231.4 (186.9 to 278.2)	66.8 (61.9 to 71.7)	0.5 (-0.8 to -0.3)	12.9 (8.5 to 18.7)	21.5 (14.4 to 31.4)	68.8 (60.2 to 73.3)	0.5 (-3.2 to 2.1)
Eating disorders	-	-	-	-	1.3 (0.8 to 2.1)	2.3 (1.4 to 3.5)	69.4 (57.1 to 83.4)	-0.4 (-7.9 to 7.7)
Anorexia nervosa	0.4 (0.3 to 0.6)	0.8 (0.6 to 1.0)	81.7 (68.4 to 100.3)	8.6 (0.9 to 18.7)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	80.8 (32.6 to 150.6)	8.8 (-19.2 to 47.8)
Bulimia nervosa	5.9 (4.2 to 7.9)	9.9 (7.1 to 13.4)	69.1 (66.3 to 71.4)	-0.8 (-1.1 to -0.5)	1.2 (0.7 to 2.0)	2.1 (1.3 to 3.3)	68.4 (55.0 to 83.0)	-1.1 (-9.1 to 7.5)
Autistic spectrum disorders	-	-	-	-	6.4 (4.4 to 8.7)	10.0 (7.0 to 13.5)	57.5 (51.6 to 63.6)	0.0 (-2.8 to 4.0)
Autism	16.1 (15.3 to 16.9)	25.4 (24.1 to 26.7)	57.8 (57.3 to 58.3)	0.6 (0.6 to 0.6)	4.0 (2.7 to 5.6)	6.3 (4.2 to 8.7)	57.6 (49.2 to 65.8)	0.6 (-4.2 to 4.9)
Asperger syndrome	23.2 (21.7 to 24.5)	36.5 (34.2 to 38.7)	57.5 (56.7 to 58.3)	0.8 (0.7 to 0.8)	2.3 (1.6 to 3.3)	3.7 (2.5 to 5.2)	57.3 (50.4 to 64.8)	0.7 (-3.1 to 4.9)
Attention-deficit/hyperactivity disorder	37.2 (34.3 to 40.2)	54.3 (50.0 to 58.6)	45.9 (45.3 to 46.2)	0.6 (0.6 to 0.6)	0.5 (0.3 to 0.7)	0.7 (0.4 to 1.0)	46.2 (35.8 to 57.6)	1.0 (-6.1 to 8.6)
Conduct disorder	53.7 (50.0 to 56.9)	78 (74.0 to 83.5)	46.4 (45.5 to 47.5)	6.5 (0.5 to 16.3)	6.5 (4.1 to 9.5)	9.5 (6.0 to 13.9)	86.6 (46.6 to 53.1)	0.7 (-3.5 to 5.1)
Idiopathic intellectual disability	78.2 (59.0 to 97.2)	95.5 (65.7 to 120.9)	22.3 (-0.3 to 41.6)	-20.5 (-35.0 to -7.9)	3.9 (2.4 to 5.6)	4.7 (2.8 to 6.8)	22.2 (64.1 to 114.5)	-20.5 (-35.6 to -7.4)
Other mental and substance use disorders	66.1 (61.6 to 70.3)	120.8 (112.7 to 128.5)	82.9 (81.3 to 84.4)	0.4 (0.0 to 0.7)	5.0 (3.4 to 6.7)	9.1 (6.2 to 12.3)	83.3 (75.9 to 90.9)	0.4 (-3.1 to 3.9)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	42.1 (29.3 to 57.2)	74.8 (51.8 to 101.8)	77.8 (63.9 to 92.6)	10.0 (0.5 to 20.0)
Diabetes mellitus	177.5 (149.7 to 214.5)	403.8 (341.4 to 470.0)	128.6 (84.8 to 175.0)	27.6 (2.2 to 54.5)	13.7 (8.9 to 19.4)	30.5 (20.4 to 43.5)	125.3 (81.3 to 174.7)	26.1 (1.4 to 51.8)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.0 (-23.2 to -14.7)	-0.0 (-45.3 to -40.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.0 (-23.2 to -14.7)	-0.0 (-45.3 to -40.2)
Chronic kidney disease	-	-	-	-	8.9 (6.3 to 11.9)	14.3 (10.3 to 18.8)	60.5 (46.7 to 75.0)	-1.6 (-8.7 to 5.4)
Chronic kidney disease due to diabetes mellitus	39.7 (24.3 to 61.2)	69.3 (42.7 to 104.9)	70.9 (18.9 to 169.4)	1.3 (-26.7 to 51.1)	1.3 (0.9 to 1.9)	2.4 (1.6 to 3.5)	73.0 (23.8 to 187.3)	1.3 (-28.3 to 61.2)
Chronic kidney disease due to hypertension	94.9 (47.7 to 172.7)	163.6 (82.3 to 302.7)	71.0 (23.0 to 122.5)	9.3 (-20.3 to 36.6)	2.3 (1.6 to 3.2)	1.7 (1.1 to 2.5)	-26.1 (-45.1 to -3.2)	-56.1 (-67.6 to -42.9)
Chronic kidney disease due to glomerulonephritis	85.3 (56.8 to 129.9)	71.5 (53.2 to 96.2)	-15.1 (-37.1 to 9.2)	-15.1 (-58.5 to -35.9)	2.3 (1.5 to 3.2)	4.2 (2.9 to 5.7)	88.8 (47.9 to 133.4)	14.1 (-11.3 to 47.2)
Chronic kidney disease due to other causes	126.7 (77.9 to 217.1)	230.9 (141.8 to 372.0)	81.4 (51.0 to 135.4)	30.1 (8.2 to 59.8)	2.9 (2.0 to 4.0)	5.9 (4.2 to 8.0)	101.1 (65.1 to 159.0)	34.3 (9.6 to 70.9)
Urinary diseases and male infertility	-	-	-	-	2.1 (1.4 to 3.0)	3.2 (2.0 to 4.6)	53.6 (39.9 to 66.2)	11.0 (0.6 to 21.0)

Appendix Table G.4 - Tajikistan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.4 (1.3 to 1.5)	2.8 (2.5 to 3.1)	97.5 (72.4 to 124.7)	25.5 (11.5 to 40.4)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	97.1 (56.5 to 153.5)	97.1 (2.4 to 57.4)
Urolithiasis	25.3 (19.7 to 32.6)	41.6 (31.7 to 54.3)	62.7 (41.4 to 92.1)	3.9 (5.7 to 20.4)	0.2 (0.2 to 0.3)	0.4 (0.2 to 0.5)	58.1 (41.3 to 77.3)	-2.7 (-11.5 to 7.2)
Benign prostatic hyperplasia	45.1 (41.9 to 48.6)	67.1 (62.2 to 72.1)	48.6 (33.6 to 64.9)	1.6 (1.7 to 25.3)	2.4 (1.1 to 2.3)	2.4 (1.5 to 3.4)	48.3 (32.7 to 65.0)	12.8 (0.9 to 25.3)
Male infertility due to other causes	24.2 (18.9 to 30.6)	45.0 (34.5 to 55.4)	91.9 (24.3 to 148.1)	4.4 (-31.1 to 36.7)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.6)	92.9 (24.8 to 152.7)	5.4 (-30.1 to 38.0)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-17.2 to 73.4)	0.0 (-48.8 to 6.3)
Gynecological diseases	-	-	-	-	4.9 (3.1 to 7.4)	9.7 (6.2 to 14.4)	99.2 (69.0 to 133.2)	3.2 (-10.5 to 19.3)
Uterine fibroids	69.0 (61.9 to 75.4)	152.5 (138.3 to 165.7)	121.0 (117.6 to 124.6)	3.4 (3.1 to 3.6)	1.1 (0.7 to 1.9)	2.3 (1.3 to 3.8)	101.8 (91.4 to 110.7)	0.3 (-4.2 to 4.0)
Polycystic ovarian syndrome	72.1 (63.9 to 80.2)	141.6 (126.1 to 158.0)	96.4 (66.1 to 132.5)	1.4 (-12.7 to 17.0)	0.7 (0.3 to 1.3)	1.4 (0.6 to 2.6)	95.9 (65.6 to 131.5)	1.6 (-12.7 to 17.3)
Female infertility due to other causes	12.9 (7.2 to 19.1)	26.0 (17.4 to 35.3)	104.6 (23.8 to 205.0)	19.9 (-29.0 to 123.4)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	97.9 (19.4 to 256.8)	25.9 (-30.2 to 117.8)
Endometriosis	7.4 (6.1 to 8.8)	15.5 (13.2 to 17.7)	109.6 (67.8 to 160.2)	6.8 (-12.5 to 30.8)	0.7 (0.4 to 1.0)	1.4 (0.9 to 2.0)	108.6 (66.0 to 165.9)	6.7 (-13.1 to 32.9)
Genital prolapse	188.7 (164.6 to 214.1)	337.1 (284.7 to 391.0)	77.9 (45.0 to 119.9)	-1.4 (-16.8 to 16.8)	0.6 (0.3 to 1.1)	1.1 (0.5 to 2.0)	78.4 (44.5 to 121.1)	-1.6 (-17.3 to 16.4)
Premenstrual syndrome	142.9 (90.3 to 199.7)	294.4 (164.5 to 430.9)	108.3 (12.8 to 275.0)	8.6 (-39.6 to 90.0)	1.2 (0.6 to 2.0)	2.5 (1.1 to 4.4)	106.7 (10.6 to 275.9)	8.0 (-40.7 to 90.0)
Other gynecological diseases	15.6 (12.7 to 18.5)	28.9 (27.1 to 30.7)	85.5 (55.7 to 124.6)	-0.2 (-16.1 to 19.0)	0.5 (0.3 to 0.7)	0.9 (0.6 to 1.3)	85.4 (59.0 to 162.3)	-0.6 (-15.3 to 36.6)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	9.9 (6.6 to 14.5)	13.5 (9.0 to 19.6)	35.7 (23.3 to 54.7)	-3.8 (-15.2 to 12.3)
Thalassemias	2.3 (1.9 to 2.8)	3.2 (2.7 to 3.7)	37.7 (25.2 to 51.3)	-0.6 (-9.4 to 9.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	29.4 (-11.4 to 89.4)	-4.6 (-34.4 to 40.2)
Thalassemia trait	341.2 (315.3 to 368.7)	539.4 (500.6 to 577.7)	58.3 (52.0 to 64.4)	1.7 (-2.6 to 5.7)	8.7 (5.8 to 12.7)	11.8 (7.8 to 17.3)	36.0 (21.8 to 53.1)	-3.9 (-16.6 to 10.1)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.7 (2.2 to 32.4)	-21.3 (-30.2 to -9.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.6 (3.0 to 48.4)	-17.7 (-30.8 to 0.9)
Sickle cell trait	11.4 (7.4 to 8.9)	21.3 (9.4 to 12.6)	85.7 (18.9 to 56.3)	0.0 (-23.8 to 0.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	51.7 (-21.4 to 366.2)	6.8 (-47.4 to 189.5)
G6PD deficiency	11.4 (10.7 to 12.2)	21.3 (20.2 to 22.3)	85.7 (69.9 to 102.7)	0.0 (8.9 to 29.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.7 (49.3 to 60.2)	6.8 (4.1 to 15.0)
G6PD trait	593.8 (587.7 to 600.2)	924.3 (913.4 to 934.7)	55.7 (53.3 to 58.0)	-0.8 (-2.3 to 0.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	38.4 (-52.5 to 256.9)	-6.8 (-70.4 to 129.0)
Other hemoglobinopathies and hemolytic anemias	33.4 (24.6 to 39.1)	47.9 (40.3 to 54.0)	43.6 (13.4 to 98.3)	1.3 (-18.6 to 37.9)	1.0 (0.5 to 1.6)	1.4 (0.8 to 2.1)	35.3 (-15.5 to 148.3)	-3.0 (-39.0 to 85.5)
Endocrine, metabolic, blood, and immune disorders	74.4 (65.1 to 82.4)	100.7 (92.9 to 107.6)	35.0 (21.3 to 52.2)	2.7 (-15.9 to 1.7)	3.5 (1.8 to 3.7)	3.5 (2.4 to 4.9)	9.8 (15.9 to 59.6)	-9.8 (-18.3 to 5.2)
Musculoskeletal disorders	-	-	-	-	58.6 (41.4 to 77.9)	100.4 (70.5 to 134.0)	71.4 (55.1 to 90.9)	0.3 (-9.5 to 9.2)
Rheumatoid arthritis	6.6 (6.4 to 6.9)	12.7 (12.2 to 13.3)	91.2 (80.6 to 104.0)	16.6 (9.4 to 23.9)	1.6 (1.1 to 2.1)	3.1 (2.2 to 4.1)	91.4 (74.2 to 111.3)	15.8 (6.5 to 26.6)
Osteoarthritis	121.8 (117.2 to 126.6)	192.8 (184.8 to 200.8)	58.4 (49.4 to 67.5)	0.5 (-4.8 to 6.1)	7.5 (5.2 to 10.3)	11.9 (8.3 to 16.4)	58.8 (49.8 to 68.8)	0.2 (-5.2 to 6.1)
Low back and neck pain	-	-	-	-	42.9 (29.4 to 59.1)	74.3 (50.1 to 100.1)	42.7 (51.2 to 99.5)	-0.7 (-13.5 to 12.9)
Low back pain	248.1 (207.8 to 281.2)	419.9 (355.9 to 478.2)	68.6 (43.7 to 104.1)	-0.6 (-15.4 to 16.7)	27.8 (18.2 to 39.9)	47.2 (30.9 to 66.3)	69.1 (43.6 to 105.0)	-0.8 (-15.4 to 17.1)
Neck pain	152.7 (124.6 to 178.7)	271.5 (217.2 to 317.3)	78.0 (38.9 to 126.2)	-0.6 (-21.5 to 25.0)	15.1 (9.9 to 21.1)	26.9 (17.2 to 37.9)	78.6 (38.2 to 127.5)	-0.6 (-21.8 to 24.5)
Gout	2.2 (2.0 to 2.3)	3.7 (3.5 to 3.9)	71.9 (59.3 to 86.3)	4.7 (-2.9 to 12.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	73.9 (41.2 to 110.6)	4.6 (-13.6 to 26.3)
Other musculoskeletal disorders	70.7 (54.1 to 87.4)	122.7 (91.8 to 154.3)	74.5 (48.9 to 94.3)	0.5 (-16.5 to 10.0)	6.5 (4.2 to 9.5)	11.5 (7.2 to 16.7)	6.4 (50.7 to 97.4)	-0.6 (-16.6 to 10.8)
Other non-communicable diseases	-	-	-	-	63.2 (42.0 to 91.6)	96.4 (64.6 to 139.1)	52.5 (44.7 to 59.2)	-4.8 (-8.8 to -1.3)
Congenital anomalies	-	-	-	-	3.8 (2.7 to 5.1)	7.3 (5.3 to 9.5)	94.5 (66.1 to 133.5)	29.5 (10.8 to 55.1)
Neural tube defects	0.6 (0.5 to 0.8)	2.0 (1.7 to 2.5)	217.0 (137.3 to 335.1)	123.4 (68.3 to 205.3)	0.2 (0.1 to 0.3)	0.7 (0.4 to 0.9)	237.3 (122.1 to 444.7)	142.2 (59.5 to 293.0)
Congenital heart anomalies	9.1 (6.8 to 11.4)	35.2 (30.9 to 40.4)	289.1 (197.0 to 431.8)	168.6 (104.0 to 272.8)	0.3 (0.1 to 0.5)	1.2 (0.5 to 2.1)	265.7 (176.2 to 396.4)	156.4 (93.3 to 249.3)
Orofacial clefts	1.2 (0.8 to 1.8)	5.2 (4.3 to 6.5)	335.4 (175.6 to 555.1)	0.0 (-99.2 to 382.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	218.1 (114.4 to 496.9)	169.6 (55.6 to 336.2)
Down syndrome	3.8 (3.1 to 4.7)	7.6 (6.3 to 9.1)	101.4 (57.1 to 160.7)	35.6 (5.8 to 76.1)	0.5 (0.3 to 0.7)	0.9 (0.7 to 1.3)	103.7 (56.1 to 170.2)	39.2 (5.6 to 83.3)
Turner syndrome	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	94.2 (29.3 to 199.0)	25.1 (-16.1 to 88.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	100.5 (28.0 to 221.0)	25.5 (-19.5 to 79.3)
Klinefelter syndrome	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	68.0 (11.3 to 172.3)	8.5 (-24.4 to 75.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.8 (22.6 to 204.0)	7.3 (-29.0 to 74.8)
Chromosomal unbalanced rearrangements	5.7 (4.8 to 6.8)	12.0 (10.0 to 14.6)	106.3 (66.0 to 181.4)	28.9 (11.6 to 90.5)	0.7 (0.5 to 1.0)	1.5 (1.0 to 2.0)	118.4 (67.2 to 189.4)	43.0 (14.2 to 96.4)
Other congenital anomalies	17.2 (14.2 to 19.9)	23.2 (19.4 to 27.1)	34.3 (18.3 to 52.7)	-15.3 (-25.5 to -3.4)	2.1 (1.3 to 3.0)	3.0 (1.9 to 4.3)	43.7 (15.4 to 84.5)	-5.7 (-25.4 to 21.7)
Skin and subcutaneous diseases	-	-	-	-	20.8 (13.2 to 31.2)	33.2 (21.7 to 49.3)	60.5 (43.4 to 75.0)	-1.5 (-12.0 to 7.5)
Dermatitis	184.2 (151.0 to 220.1)	312.5 (252.2 to 377.8)	69.6 (65.9 to 73.2)	-0.1 (-0.2 to 0.0)	4.6 (2.8 to 6.7)	7.6 (4.6 to 11.2)	66.3 (59.4 to 72.1)	-0.1 (-2.0 to 2.6)
Psoriasis	34.2 (30.3 to 38.1)	58.0 (51.2 to 65.2)	69.7 (66.9 to 72.3)	0.0 (-0.2 to 0.3)	2.8 (1.9 to 4.0)	4.8 (3.2 to 6.7)	69.6 (59.4 to 80.9)	-0.1 (-5.0 to 5.2)
Cellulitis	2.0 (1.6 to 2.4)	2.6 (2.0 to 3.5)	32.7 (18.3 to 56.0)	-7.5 (-16.6 to 4.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	33.4 (22.2 to 72.9)	-7.1 (-25.4 to 14.9)
Pyoderma	5.6 (4.7 to 6.7)	8.7 (7.3 to 10.5)	9.1 (46.3 to 65.1)	0.0 (4.6 to 13.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	54.2 (38.3 to 71.8)	8.8 (-0.0 to 18.6)
Scabies	15.7 (13.1 to 18.6)	23.1 (19.6 to 27.0)	47.4 (18.4 to 81.3)	-5.6 (-24.1 to 15.6)	0.4 (0.2 to 0.7)	0.6 (0.3 to 1.0)	47.1 (17.0 to 82.7)	-5.7 (-25.1 to 17.8)
Fungal skin diseases	346.6 (262.2 to 456.8)	570.3 (431.5 to 759.7)	64.4 (59.6 to 70.0)	0.2 (0.0 to 0.4)	3.2 (0.8 to 4.3)	3.2 (1.3 to 7.2)	64.4 (59.4 to 70.2)	0.2 (-0.7 to 1.1)
Viral skin diseases	134.5 (104.4 to 161.7)	200.0 (152.4 to 243.8)	48.6 (41.8 to 54.0)	0.1 (-1.9 to 2.1)	4.2 (2.4 to 6.2)	6.2 (3.5 to 9.8)	48.6 (41.0 to 55.7)	0.1 (-3.0 to 3.5)
Acne vulgaris	133.2 (97.4 to 164.6)	225.0 (172.1 to 284.9)	67.6 (16.5 to 147.7)	2.1 (-28.3 to 44.5)	1.4 (0.6 to 2.8)	2.4 (1.1 to 4.5)	67.8 (16.3 to 148.1)	2.1 (-28.4 to 44.7)
Alopecia areata	5.1 (4.4 to 5.8)	8.3 (7.3 to 9.4)	62.0 (34.2 to 95.5)	-0.7 (-18.2 to 19.8)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	61.9 (31.3 to 98.8)	-0.5 (-19.2 to 21.9)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.3 (28.4 to 101.8)	0.5 (-23.5 to 31.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.3 (28.1 to 102.3)	0.5 (-23.5 to 31.2)
Urticaria	62.2 (44.4 to 87.0)	94.8 (62.9 to 125.9)	56.7 (-12.9 to 138.4)	-5.9 (-42.6 to 40.8)	3.7 (2.1 to 5.9)	5.7 (3.1 to 8.6)	56.0 (-13.3 to 138.4)	-6.4 (-43.7 to 40.8)
Decubitus ulcer	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.4)	49.6 (20.1 to 90.0)	-13.0 (-35.0 to 22.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	54.6 (20.5 to 100.8)	-10.2 (-34.9 to 29.7)
Other skin and subcutaneous diseases	220.9 (147.7 to 332.7)	358.4 (246.5 to 510.7)	62.9 (47.2 to 79.6)	-0.4 (-5.4 to 4.0)	1.3 (0.6 to 2.7)	2.1 (0.9 to 4.4)	62.9 (47.1 to 80.0)	-0.6 (-5.8 to 3.8)
Sense organ diseases	-	-	-	-	29.0 (19.3 to 41.2)	40.5 (26.6 to 58.0)	39.2 (31.8 to 47.0)	-9.6 (-13.2 to -5.7)
Glaucoma	5.0 (4.2 to 5.8)	6.8 (5.7 to 8.1)	36.3 (17.7 to 57.5)	-16.2 (-27.3 to -1.6)	0.4 (0.2 to 0.5)	0.5 (0.3 to 0.7)	33.2 (9.7 to 56.0)	-13.9 (-26.7 to 0.3)
Cataract	29.1 (22.2 to 35.2)	27.3 (20.9 to 34.3)	-5.0 (-27.9 to 17.8)	32.1 (-46.3 to -16.4)	1.0 (0.6 to 1.5)	0.9 (0.6 to 1.4)	-4.2 (-24.9 to 19.2)	-31.2 (-44.2 to -15.4)
Macular degeneration	8.0 (5.8 to 10.9)	14.2 (10.8 to 18.3)	78.5 (28.9 to 136.0)	16.7 (-15.3 to 54.9)	0.3 (0.1 to 0.4)	0.4 (0.3 to 0.7)	73.8 (26.3 to 125.8)	13.6 (-16.4 to 47.4)
Uncorrected refractive error	399.9 (324.6 to 392.9)	560.4 (505.5 to 616.4)	56.0 (36.7 to 79.6)	0.2 (-12.0 to 14.8)	5.8 (3.4 to 9.5)	8.5 (4.9 to 14.4)	45.2 (32.9 to 61.1)	-6.9 (-14.9 to 3.2)
Age-related and other hearing loss	514.6 (450.3 to 573.3)	761.8 (659.0 to 856.6)	47.7 (40.7 to 57.1)	-7.5 (-11.1 to -3.7)	17.0 (11.2 to 23.8)	23.8 (15.5 to 34.1)	40.1 (29.5 to 52.2)	-8.7 (-13.6 to -3.5)
Other vision loss	26.1 (23.2 to 29.4)	28.9 (25.2 to 32.7)	10.8 (0.2 to 21.3)	30.3 (-38.5 to -20.8)	1.2 (0.8 to 1.8)	1.3 (0.9 to 1.9)	6.5 (9.1 to 19.7)	3.0 (-40.3 to -22.5)
Other sense organ diseases	126.6 (119.6 to 133.0)	186.9 (177.2 to 196.1)	47.5 (37.2 to 59.2)	-0.2 (-6.4 to 6.4)	3.4 (2.1 to 5.2)	5.0 (3.0 to 7.5)	47.3 (36.1 to 60.6)	-0.2 (-7.0 to 7.2)
Oral disorders	-	-	-	-	9.6 (5.6 to 15.2)	15.3 (8.9 to 24.7)	59.4 (50.3 to 65.8)	-2.8 (-5.9 to 0.4)
Deciduous caries	680.4 (666.6 to 694.8)	868.5 (850.0 to 886.4)	27.6 (24.2 to 31.6)	0.6 (-2.0 to 3.7)	0.3 (0.1 to 0.5)	0.3 (0.1 to 0.7)	27.6 (23.0 to 35.4)	0.6 (-1.1 to 6.5)
Permanent caries	2,616.9 (2,523.6 to 2,706.5)	4,326.4 (4,184.3 to 4,455.4)	65.6 (56.4 to 73.4)	-0.2 (-4.4 to 3.7)	2.6 (1.2 to 5.0)	4.3 (2.0 to 8.3)	65.5 (56.9	

Appendix Table G.4 - Tajikistan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	103.2 (99.0 to 107.6)	144.4 (138.4 to 150.4)	39.8 (32.0 to 49.0)	-6.4 (-11.1 to -0.8)	2.8 (1.9 to 3.9)	4.0 (2.7 to 5.5)	40.1 (31.8 to 49.9)	-6.6 (-11.7 to -0.8)
Other oral disorders	77.0 (72.1 to 81.6)	129.1 (121.4 to 137.3)	67.9 (53.0 to 82.9)	-1.0 (-8.9 to 7.0)	2.3 (1.4 to 3.4)	3.8 (2.4 to 5.7)	67.7 (52.6 to 83.3)	-1.0 (-9.2 to 7.4)
Injuries	-	-	-	-	33.7 (25.5 to 43.7)	58.1 (41.7 to 78.6)	68.9 (50.1 to 115.8)	9.4 (-5.9 to 47.5)
Transport injuries	-	-	-	-	5.9 (4.4 to 7.5)	5.0 (3.7 to 6.5)	-15.2 (-20.2 to -10.1)	-49.2 (-52.0 to -46.4)
Road injuries	-	-	-	-	5.3 (3.7 to 6.4)	3.9 (2.9 to 5.0)	-21.1 (-27.2 to -17.6)	-53.3 (-56.1 to -50.7)
Pedestrian road injuries	-	-	-	-	1.1 (0.8 to 1.4)	0.8 (0.6 to 1.1)	-25.6 (-33.0 to -18.4)	-53.3 (-57.4 to -49.7)
Cyclist road injuries	-	-	-	-	0.6 (0.5 to 0.8)	0.5 (0.3 to 0.6)	-25.3 (-30.7 to -18.9)	-54.2 (-57.6 to -50.4)
Motorcyclist road injuries	-	-	-	-	0.5 (0.4 to 0.6)	0.4 (0.3 to 0.5)	-24.1 (-30.3 to -17.6)	-55.9 (-59.5 to -52.2)
Motor vehicle road injuries	-	-	-	-	2.8 (2.1 to 3.6)	2.2 (1.7 to 2.9)	-19.7 (-26.3 to -12.8)	-52.8 (-56.5 to -48.9)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-32.4 (-37.1 to -27.2)	-59.9 (-62.5 to -57.0)
Other transport injuries	-	-	-	-	0.9 (0.7 to 1.2)	1.1 (0.8 to 1.5)	23.0 (14.9 to 33.4)	-26.5 (-31.5 to -20.6)
Unintentional injuries	-	-	-	-	27.3 (20.6 to 35.4)	39.5 (29.5 to 51.6)	44.5 (38.6 to 51.1)	-12.7 (-16.3 to -8.8)
Falls	-	-	-	-	18.1 (13.6 to 23.7)	27.1 (20.1 to 35.4)	48.9 (40.7 to 57.7)	-11.3 (-15.6 to -6.2)
Drowning	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-13.7 (-21.7 to -6.2)	-46.9 (-51.2 to -42.3)
Fire, heat, and hot substances	-	-	-	-	0.9 (0.7 to 1.2)	1.1 (0.8 to 1.4)	18.3 (9.6 to 27.3)	-29.1 (-34.1 to -24.0)
Poisonings	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	6.2 (9.7 to 24.5)	-36.4 (-44.6 to -27.1)
Exposure to mechanical forces	-	-	-	-	5.0 (3.8 to 6.5)	6.8 (5.1 to 9.0)	34.7 (28.2 to 40.9)	-17.1 (-20.9 to -13.5)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	32.7 (19.5 to 45.2)	-19.7 (-27.5 to -12.4)
Unintentional suffocation	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	55.5 (42.8 to 70.7)	-3.6 (-11.0 to 4.5)
Other exposure to mechanical forces	-	-	-	-	4.9 (3.7 to 6.4)	6.5 (4.9 to 8.7)	34.5 (27.7 to 40.9)	-17.2 (-21.1 to -13.5)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	61.9 (52.9 to 73.8)	2.1 (-4.2 to 9.1)
Animal contact	-	-	-	-	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	61.1 (50.2 to 72.5)	1.1 (-5.1 to 6.8)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	59.5 (40.0 to 81.4)	-1.7 (-12.1 to 9.7)
Non-venomous animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	61.5 (51.5 to 73.2)	2.4 (-3.3 to 8.6)
Foreign body	-	-	-	-	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	46.2 (38.6 to 54.0)	-8.9 (-13.2 to -4.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	34.7 (21.6 to 51.7)	-14.3 (-21.6 to -5.8)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	59.4 (49.9 to 68.6)	-2.6 (-7.6 to 3.0)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	49.9 (39.0 to 61.4)	-7.7 (-14.1 to -0.7)
Other unintentional injuries	-	-	-	-	2.2 (1.6 to 2.8)	3.2 (2.4 to 4.2)	51.1 (41.3 to 61.1)	-7.7 (-13.4 to -1.3)
Self-harm and interpersonal violence	-	-	-	-	0.5 (0.4 to 0.7)	0.7 (0.5 to 0.9)	33.5 (26.7 to 40.0)	-24.1 (-27.8 to -20.4)
Self-harm	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	48.3 (37.8 to 60.6)	-15.8 (-21.4 to -9.4)
Interpersonal violence	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	22.9 (16.3 to 29.3)	-30.1 (-33.9 to -26.4)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	24.2 (16.3 to 34.1)	-27.6 (-32.0 to -22.3)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	27.9 (18.4 to 39.0)	-27.4 (-32.9 to -21.2)
Assault by other means	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.3)	21.7 (13.6 to 29.5)	-31.1 (-35.5 to -26.9)
Forces of nature, war, and legal intervention	-	-	-	-	-	-	-	-
Exposure to forces of nature	-	-	-	-	-	12.9 (5.4 to 27.1)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	12.9 (5.4 to 27.1)	-

Appendix Table G.4 - Tanzania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	2,438.6 (1,764.4 to 3,221.0)	4,519.2 (3,283.1 to 5,862.8)	85.3 (80.2 to 91.5)	85.3 (-7.1 to -1.2)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	817.3 (571.0 to 1,148.0)	1,334.8 (940.2 to 1,836.0)	63.4 (53.5 to 77.2)	-13.9 (-20.9 to -3.2)
HIV/AIDS and tuberculosis	-	-	-	-	80.1 (55.9 to 107.8)	232.9 (148.1 to 350.7)	187.2 (134.6 to 255.7)	56.4 (23.6 to 103.3)
Tuberculosis	39.4 (37.3 to 41.5)	69.3 (65.8 to 72.9)	75.7 (68.7 to 82.6)	-9.1 (-12.1 to -5.7)	12.0 (8.1 to 16.1)	21.1 (14.5 to 28.5)	76.0 (63.5 to 89.1)	-8.9 (-14.1 to -2.4)
HIV/AIDS	-	-	-	-	68.1 (47.0 to 92.7)	211.8 (130.7 to 324.4)	207.0 (145.0 to 285.9)	88.3 (30.5 to 123.8)
HIV/AIDS resulting in mycobacterial infection	6.6 (4.3 to 8.6)	13.5 (8.8 to 17.9)	104.8 (78.4 to 135.2)	9.5 (5.2 to 13.6)	2.4 (1.4 to 3.6)	5.0 (2.9 to 7.5)	105.0 (68.4 to 148.1)	10.1 (9.3 to 33.6)
HIV/AIDS resulting in other diseases	580.4 (500.6 to 653.1)	1,302.2 (1,146.2 to 1,490.9)	123.0 (101.9 to 148.8)	25.0 (11.5 to 39.7)	65.7 (45.3 to 90.1)	206.8 (125.9 to 317.7)	210.5 (147.1 to 292.0)	70.8 (31.5 to 127.5)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	106.7 (75.8 to 145.9)	170.5 (119.9 to 230.3)	59.9 (48.4 to 70.9)	-16.3 (-22.2 to -11.4)
Diarrheal diseases	279.9 (258.0 to 301.2)	499.5 (465.5 to 536.1)	78.3 (60.3 to 98.1)	-3.1 (-11.7 to 6.5)	45.3 (30.7 to 63.2)	81.0 (54.3 to 113.1)	78.7 (60.3 to 99.0)	31.0 (-11.8 to 6.2)
Intestinal infectious diseases	-	-	-	-	1.0 (0.6 to 1.5)	1.3 (0.9 to 1.9)	31.0 (0.2 to 67.7)	61.7 (-46.1 to -15.0)
Typhoid fever	5.6 (4.8 to 6.3)	7.5 (6.4 to 8.7)	35.7 (11.3 to 64.8)	-29.8 (-42.2 to -15.2)	0.7 (0.5 to 1.1)	1.0 (0.7 to 1.5)	37.8 (2.2 to 81.0)	-28.6 (-44.4 to -9.5)
Paratyphoid fever	2.1 (1.8 to 2.4)	3.4 (2.8 to 4.1)	60.8 (28.5 to 115.3)	-16.5 (-33.1 to 11.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	62.5 (18.9 to 130.5)	-16.0 (-36.4 to 14.3)
Other intestinal infectious diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.3)	-19.3 (-49.4 to 33.2)	-58.4 (-73.5 to -32.1)
Lower respiratory infections	20.8 (17.4 to 24.1)	27.8 (21.6 to 33.3)	34.4 (-1.3 to 75.1)	-24.3 (-38.0 to -9.8)	2.2 (1.4 to 3.2)	2.9 (1.7 to 4.4)	34.3 (6.5 to 77.7)	-24.1 (-40.6 to -5.5)
Upper respiratory infections	1,918.5 (1,816.7 to 2,017.0)	3,606.0 (3,445.5 to 3,789.5)	87.5 (73.0 to 102.8)	-1.8 (-8.7 to 6.2)	22.5 (12.7 to 37.1)	42.3 (23.4 to 71.0)	87.8 (73.0 to 104.4)	-1.6 (-8.7 to 6.2)
Otitis media	438.2 (401.7 to 479.0)	750.6 (686.6 to 821.3)	71.3 (55.3 to 89.9)	-12.8 (-20.7 to -2.5)	8.5 (5.2 to 13.6)	14.3 (8.4 to 23.0)	66.7 (48.7 to 87.3)	-14.3 (-22.7 to -3.9)
Meningitis	-	-	-	-	24.9 (17.2 to 34.9)	25.9 (18.5 to 35.1)	4.0 (-12.4 to 24.0)	-45.1 (-52.9 to -35.7)
Pneumococcal meningitis	97.3 (59.0 to 140.4)	91.7 (56.6 to 135.7)	-6.2 (-24.4 to 21.5)	-49.1 (-58.5 to -35.1)	8.9 (5.9 to 13.3)	8.8 (6.0 to 12.4)	2.7 (-33.1 to 34.4)	45.7 (-62.3 to -31.1)
H influenzae type B meningitis	58.2 (23.8 to 105.3)	51.5 (24.6 to 95.1)	-11.5 (-33.8 to 20.8)	-54.4 (-65.5 to -38.4)	6.4 (3.6 to 11.2)	3.5 (4.0 to 9.7)	3.5 (-39.0 to 61.4)	-46.2 (-67.8 to -18.4)
Meningococcal meningitis	13.4 (5.2 to 27.1)	12.5 (4.7 to 26.4)	-6.8 (-36.8 to 39.8)	-50.1 (-64.8 to -26.9)	1.7 (1.0 to 2.9)	1.6 (1.0 to 2.6)	-4.1 (-40.7 to 60.6)	49.0 (-65.2 to -23.3)
Other meningitis	71.9 (36.1 to 126.8)	69.2 (37.4 to 115.5)	-3.3 (-20.2 to 20.1)	-48.8 (-57.3 to -36.5)	7.9 (5.3 to 11.1)	9.0 (5.8 to 12.6)	13.8 (-19.8 to 48.6)	-39.8 (-55.1 to -23.2)
Encephalitis	4.5 (2.2 to 9.3)	7.5 (3.4 to 15.9)	65.3 (41.7 to 87.4)	-39.9 (-26.1 to -4.8)	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.4)	79.9 (41.0 to 104.3)	-12.8 (-25.5 to 1.6)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.5 (-96.3 to 1,936.9)	-54.9 (-96.7 to 596.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.5 (-96.4 to 1,952.4)	-54.9 (-96.7 to 614.7)
Whooping cough	16.0 (12.5 to 20.4)	20.7 (16.2 to 26.6)	29.7 (26.9 to 32.4)	-29.0 (-30.4 to 27.5)	0.8 (0.5 to 1.3)	1.0 (0.6 to 1.7)	29.8 (14.3 to 49.4)	-28.9 (-37.6 to -17.9)
Tetanus	0.9 (0.5 to 1.4)	0.8 (0.3 to 2.4)	-23.3 (-67.3 to 186.7)	-59.0 (-82.9 to 52.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-14.5 (-49.6 to 127.5)	-52.7 (-71.0 to 13.4)
Measles	6.2 (4.9 to 7.7)	1.8 (1.3 to 2.4)	-71.5 (-78.5 to -61.8)	-84.6 (-88.4 to -79.4)	0.6 (0.3 to 0.9)	0.2 (0.1 to 0.3)	21.4 (-84.0 to -53.7)	-86.6 (-91.4 to -75.1)
Varicella and herpes zoster	15.8 (14.3 to 17.3)	32.5 (30.0 to 35.2)	104.2 (80.7 to 134.5)	2.0 (-14.6 to 30.8)	0.3 (0.2 to 0.6)	0.7 (0.4 to 1.1)	101.0 (47.1 to 192.4)	1.3 (-26.3 to 59.9)
Neglected tropical diseases and malaria	-	-	-	-	335.1 (220.6 to 497.4)	412.5 (272.3 to 605.3)	22.9 (12.3 to 36.6)	-36.8 (-43.5 to -28.7)
Malaria	10,321.5 (9,883.9 to 10,781.1)	10,343.3 (9,891.4 to 10,822.4)	0.0 (-2.6 to 3.2)	-47.9 (-49.2 to -46.0)	97.9 (64.9 to 140.6)	101.4 (67.9 to 144.8)	3.6 (-4.8 to 13.8)	47.1 (-51.2 to -42.7)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Leishmaniasis	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	185.5 (19.6 to 442.4)	73.0 (-20.4 to 189.5)
Visceral leishmaniasis	1.0 (0.6 to 1.7)	2.1 (1.1 to 3.1)	108.6 (-16.1 to 313.0)	6.0 (-53.6 to 85.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	108.3 (-18.6 to 315.6)	6.2 (-54.3 to 85.7)
Cutaneous and mucocutaneous leishmaniasis	0.2 (0.1 to 0.3)	5.5 (3.4 to 8.3)	2,612.9 (1,652.4 to 4,143.5)	1,868.6 (1,177.9 to 2,966.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	2,534.8 (1,493.1 to 4,145.2)	1,085.9 (1,082.2 to 2,852.8)
African trypanosomiasis	2.3 (0.9 to 4.7)	0.1 (0.0 to 0.0)	-98.9 (-99.1 to -98.8)	-99.5 (-99.0 to -99.4)	0.6 (0.2 to 1.3)	0.0 (0.0 to 0.0)	-98.9 (-99.1 to -98.6)	-99.4 (-99.5 to -99.2)
Schistosomiasis	9,775.1 (7,769.5 to 11,833.8)	9,135.9 (6,693.2 to 12,359.3)	-6.6 (-22.5 to 26.5)	-53.8 (-60.5 to -35.2)	90.8 (46.6 to 165.3)	88.1 (45.0 to 167.2)	8.5 (-18.7 to 31.7)	52.0 (-58.3 to -33.2)
Cysticercosis	5.9 (3.4 to 9.1)	11.9 (5.9 to 19.8)	99.4 (10.6 to 275.2)	-10.7 (-47.5 to 58.5)	1.6 (0.9 to 2.7)	3.3 (1.5 to 6.0)	103.6 (7.2 to 287.7)	-9.0 (-47.8 to 65.8)
Cystic echinococcosis	4.8 (4.3 to 5.3)	18.6 (17.2 to 19.9)	287.9 (227.7 to 346.9)	91.3 (76.3 to 120.0)	0.4 (0.3 to 0.6)	1.7 (1.2 to 2.4)	289.4 (210.3 to 394.3)	95.4 (64.3 to 136.8)
Lymphatic filariasis	2,668.4 (2,318.7 to 3,050.4)	2,279.6 (1,812.9 to 2,870.9)	-14.8 (-31.1 to 3.6)	-54.3 (-64.8 to -45.6)	67.2 (37.4 to 112.5)	105.6 (57.6 to 176.7)	59.4 (15.8 to 95.3)	-18.5 (-39.4 to -1.6)
Onchocerciasis	429.9 (254.6 to 748.1)	349.1 (152.6 to 383.1)	-18.8 (-59.4 to -10.5)	-42.9 (-73.3 to -55.2)	27.0 (14.2 to 43.6)	9.8 (8.0 to 36.3)	28.6 (54.2 to 8.9)	-64.4 (-76.1 to -45.1)
Trachoma	16.9 (8.6 to 28.2)	30.6 (17.0 to 47.8)	83.5 (-3.1 to 236.2)	-27.5 (-61.7 to 30.3)	1.8 (0.9 to 3.2)	2.2 (1.2 to 3.6)	22.8 (-37.8 to 103.4)	-49.1 (-73.7 to -17.6)
Dengue	1.1 (0.3 to 3.0)	10.7 (3.3 to 27.9)	888.7 (827.3 to 852.0)	385.4 (379.5 to 392.3)	0.2 (0.1 to 0.5)	1.7 (0.5 to 4.9)	787.2 (639.1 to 971.7)	352.7 (283.4 to 425.6)
Yellow fever	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.2)	-48.8 (-61.9 to -25.9)	-73.3 (-79.3 to -63.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.8 (-61.1 to -25.8)	-73.3 (-79.3 to -63.7)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-7.5 to 101.3)	0.0 (-45.6 to -7.3)	0.0 (-7.6 to 101.7)	0.0 (-45.6 to -7.2)
Intestinal nematode infections	-	-	-	-	32.1 (19.7 to 49.5)	63.1 (38.5 to 98.6)	97.0 (77.4 to 117.0)	-0.2 (-10.3 to 9.7)
Ascariasis	1,105.9 (762.4 to 1,566.2)	2,127.4 (1,445.7 to 3,060.7)	89.2 (19.1 to 231.4)	-3.0 (-45.3 to 88.8)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.6)	90.4 (49.3 to 143.4)	-0.6 (-23.6 to 31.4)
Trichuriasis	2,130.6 (1,507.2 to 3,018.8)	4,082.3 (2,923.6 to 5,642.1)	93.0 (17.4 to 210.7)	0.2 (-44.6 to 75.2)	1.3 (0.7 to 2.2)	2.6 (1.3 to 4.4)	92.7 (55.8 to 141.4)	0.4 (-24.5 to 33.6)
Hookworm disease	4,296.6 (4,818.8 to 8,177.8)	12,110.3 (9,485.1 to 15,500.0)	184.2 (34.4 to 175.7)	94.2 (-36.3 to 54.2)	30.6 (18.9 to 46.9)	60.2 (36.8 to 93.8)	97.1 (75.8 to 118.0)	30.5 (-10.8 to 10.2)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	364.2 (269.0 to 459.7)	642.2 (596.1 to 697.2)	76.5 (38.6 to 137.4)	-10.7 (-28.6 to 17.7)	15.3 (9.2 to 22.9)	25.4 (16.9 to 36.5)	62.2 (40.1 to 134.5)	-18.7 (-32.1 to 16.7)
Maternal disorders	-	-	-	-	12.9 (8.7 to 17.6)	20.3 (13.7 to 28.3)	57.1 (35.9 to 81.9)	-20.4 (-30.7 to -9.0)
Maternal hemorrhage	4.7 (3.8 to 6.1)	9.4 (6.2 to 12.6)	100.4 (22.6 to 197.4)	-9.3 (-42.7 to 31.1)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	73.8 (-7.9 to 211.2)	-20.8 (-56.6 to 41.1)
Maternal sepsis and other maternal infections	13.5 (9.0 to 18.1)	15.4 (10.1 to 22.9)	16.1 (-19.9 to 35.4)	-41.8 (-59.2 to -32.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	16.4 (-26.5 to 77.6)	-42.1 (-61.1 to -15.7)
Maternal hypertensive disorders	11.7 (6.5 to 18.9)	18.8 (10.8 to 29.9)	60.3 (42.6 to 80.0)	-22.0 (-30.3 to -12.9)	0.6 (0.3 to 1.1)	1.0 (0.5 to 1.7)	60.4 (37.0 to 93.1)	-22.1 (-33.5 to -7.0)
Obstructed labor	26.9 (23.3 to 30.5)	42.1 (37.3 to 47.3)	56.9 (44.1 to 69.2)	-20.1 (-26.7 to -14.2)	8.8 (5.8 to 12.1)	13.8 (9.2 to 19.5)	57.0 (39.0 to 76.1)	-7.0 (-28.9 to -11.3)
Complications of abortion	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	76.4 (-9.5 to 217.7)	-19.9 (-55.2 to 39.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.4 (-9.8 to 217.8)	-19.9 (-55.3 to 40.3)
Other maternal disorders	-	-	-	-	3.1 (1.9 to 4.6)	4.9 (2.9 to 7.7)	58.7 (1.6 to 131.6)	-20.1 (-49.0 to 15.7)
Neonatal disorders	-	-	-	-	15.4 (9.2 to 26.1)	66.9 (44.6 to 94.0)	344.2 (182.4 to 594.6)	140.3 (46.4 to 275.9)
Preterm birth complications	73.8 (47.9 to 108.4)	314.6 (228.4 to 426.4)	329.0 (257.4 to 426.4)	115.7 (80.3 to 163.3)	4.5 (2.9 to 6.8)	29.8 (20.1 to 42.6)	568.5 (320.0 to 885.3)	246.0 (124.6 to 403.9)
Neonatal encephalopathy due to birth asphyxia and trauma	137.1 (12.5 to 451.6)	204.7 (37.0 to 620.9)	60.5 (16.7 to 238.3)	-19.5 (-41.2 to 71.8)	5.1 (2.6 to 11.8)	15.4 (7.6 to 27.3)	215.9 (68.2 to 566.5)	88.4 (-12.5 to 208.0)
Neonatal sepsis and other neonatal infections	0.3 (0.1 to 0.6)	0.9 (0.3 to 1.8)	183.0 (168.1 to 229.4)	64.7 (56.0 to 91.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.3)	67.0 (155.1 to 235.3)	17.0 (48.5 to 95.1)
Hemolytic disease and other neonatal jaundice	5.5 (2.2 to 10.7)	21.8 (10.2 to 38.1)	300.4 (56.4 to 1,022.4)	126.2 (-15.9 to 542.8)	2.2 (0.8 to 4.5)	8.4 (5.5 to 15.2)	293.9 (52.9 to 1,040.0)	118.8 (-18.5 to 555.2)
Other neonatal disorders	-	-	-	-	3.6 (1.5 to 7.4)	13.1 (6.3 to 23.7)	277.8 (50.8 to 804.7)	101.5 (-20.8 to 384.8)
Nutritional deficiencies	-	-	-	-	247.4 (165.0 to 357.8)	396.1 (264.3 to 573.5)	60.0 (48.1 to 71.9)	-18.1 (-23.8 to -11.7)
Protein-energy malnutrition	145.4 (79.9 to 244.0)	156.6 (81.8 to 254.3)	8.6 (-53.3 to 145.7)	37.2 (-68.5 to 22.3)	17.9 (8.2 to 34.3)	19.2 (8.2 to 36.3)	8.8 (-54.2 to 150.9)	-36.9 (-69.3 to 25.7)
Iodine deficiency	909.0 (521.6 to 1,326.8)	1,582.2 (987.8 to 2,316.2)	76.2 (5.5 to 197.5)	-7.1 (-45.6 to 61.8)	16.4 (8.0 to 28.9)	28.5 (14.5 to 50.2)	76.2 (5.1 to 197.2)	-7.0 (-45.8 to 59.5)
Vitamin A deficiency	39.6 (28.9 to 48.5)	45.0 (31.6 to 57.2)	13.8 (-7.5 to 33.1)	-41.7 (-51.9 to -31.7)	1.8 (1.1 to 2.8)	2.0 (1.2 to 3.1)	9.7 (-12.1 to	

Appendix Table G.4 - Tanzania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	5,559.4 (5,393.2 to 5,722.5)	9,536.2 (9,365.7 to 9,731.6)	71.1 (65.3 to 76.4)	-5.3 (-18.5 to -12.3)	211.2 (141.4 to 303.6)	346.2 (229.1 to 498.1)	63.9 (55.1 to 72.4)	63.9 (-21.6 to -13.1)
Other nutritional deficiencies	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-	-19.5 (-71.4 to 96.6)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	19.7 (12.4 to 30.2)	35.6 (22.4 to 54.1)	79.4 (62.6 to 109.6)	-7.2 (-15.5 to 5.2)
Sexually transmitted diseases excluding HIV	-	-	-	-	7.4 (4.2 to 12.7)	14.8 (8.4 to 25.5)	97.8 (68.5 to 157.2)	-1.9 (-15.0 to 20.6)
Syphilis	3.2 (2.8 to 3.6)	3.7 (3.2 to 4.2)	15.7 (-3.9 to 38.6)	-40.7 (-48.4 to -30.9)	0.7 (0.4 to 0.8)	0.7 (0.4 to 1.0)	17.1 (-12.9 to 51.8)	40.3 (-53.3 to -25.1)
Chlamydial infection	416.9 (324.7 to 494.7)	891.1 (670.5 to 1,124.6)	109.5 (56.7 to 215.5)	6.2 (-18.6 to 51.5)	2.3 (1.2 to 3.8)	5.5 (2.9 to 9.4)	137.5 (57.9 to 354.0)	19.1 (-19.1 to 112.9)
Gonococcal infection	189.3 (151.6 to 227.0)	382.4 (299.9 to 465.8)	100.9 (53.0 to 170.1)	0.4 (-23.0 to 31.2)	1.3 (0.7 to 2.2)	2.7 (1.5 to 4.5)	99.2 (38.4 to 228.1)	-1.3 (-29.3 to 57.3)
Trichomoniasis	575.1 (378.0 to 758.3)	1,017.9 (688.7 to 1,395.2)	76.8 (10.0 to 196.5)	-8.1 (-39.4 to 44.1)	1.0 (0.3 to 2.2)	1.8 (0.6 to 3.9)	79.5 (3.8 to 231.1)	-6.5 (-41.7 to 58.3)
Genital herpes	7,444.8 (6,961.8 to 7,891.7)	14,010.9 (12,934.5 to 15,124.0)	87.4 (69.1 to 108.8)	-3.3 (-11.2 to 6.1)	3.3 (0.7 to 5.1)	4.0 (1.4 to 9.5)	89.8 (66.8 to 113.0)	-2.6 (-12.1 to 8.6)
Other sexually transmitted diseases	11.0 (7.9 to 14.9)	17.3 (12.1 to 23.6)	56.4 (38.8 to 75.9)	-21.9 (-30.8 to -11.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	71.1 (18.1 to 149.7)	-15.4 (-38.8 to 17.7)
Hepatitis	-	-	-	-	1.9 (1.2 to 2.8)	3.1 (2.0 to 4.6)	68.6 (43.0 to 98.5)	-14.4 (-30.9 to 4.2)
Hepatitis A	47.2 (44.5 to 49.8)	85.8 (81.3 to 90.3)	81.5 (81.0 to 82.2)	-1.9 (-2.1 to -1.7)	0.8 (0.5 to 1.2)	1.6 (1.0 to 2.4)	92.0 (70.4 to 116.9)	2.1 (-8.3 to 14.3)
Hepatitis B	2,910.1 (1,958.8 to 2,609.9)	3,119.4 (2,538.6 to 3,669.3)	36.6 (7.5 to 67.1)	-29.4 (-42.9 to -13.9)	0.9 (0.6 to 1.4)	1.3 (0.8 to 2.0)	45.4 (5.5 to 100.9)	-24.3 (-48.0 to 5.2)
Hepatitis C	199.3 (179.2 to 222.0)	298.8 (265.8 to 334.8)	50.0 (26.7 to 76.0)	-23.4 (-33.4 to -11.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	41.1 (7.5 to 77.7)	-27.8 (-50.3 to -2.4)
Hepatitis E	3.2 (2.5 to 4.1)	5.9 (4.0 to 8.1)	84.1 (29.0 to 162.9)	-4.6 (-34.9 to 35.5)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	83.0 (13.5 to 194.4)	-5.1 (-41.1 to 48.6)
Leprosy	4.4 (3.3 to 5.6)	8.3 (7.3 to 9.3)	91.2 (60.7 to 138.2)	-3.2 (-16.9 to 16.2)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	92.0 (56.5 to 149.1)	-2.4 (-18.5 to 21.9)
Other infectious diseases	254.7 (192.3 to 320.1)	442.9 (387.5 to 499.6)	73.3 (51.1 to 98.5)	-13.5 (-25.2 to -0.8)	16.2 (6.5 to 15.0)	17.2 (11.1 to 25.2)	67.9 (45.0 to 100.3)	-13.1 (-26.7 to 4.4)
Non-communicable diseases	-	-	-	-	1,123.0 (1,123.0 to 1,971.4)	3,045.1 (2,238.6 to 3,924.0)	98.2 (92.0 to 105.6)	-0.5 (-3.4 to 2.8)
Neoplasms	-	-	-	-	6.1 (4.3 to 8.1)	14.9 (10.3 to 20.4)	144.0 (99.9 to 196.7)	20.0 (0.1 to 46.6)
Esophageal cancer	1.5 (1.0 to 2.2)	2.3 (1.5 to 3.3)	48.4 (-9.8 to 139.8)	-25.5 (-53.9 to 20.1)	0.2 (0.2 to 0.4)	0.4 (0.2 to 0.5)	47.0 (-3.1 to 122.3)	-25.7 (50.1 to 12.8)
Stomach cancer	1.2 (1.0 to 1.4)	2.1 (1.7 to 2.6)	79.2 (34.4 to 138.1)	-9.4 (-32.6 to 22.4)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	81.3 (33.6 to 142.4)	-8.5 (-34.0 to 24.9)
Liver cancer	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.8)	77.0 (28.2 to 137.8)	-10.2 (-34.7 to 25.9)
Liver cancer due to hepatitis B	0.3 (0.2 to 0.5)	0.6 (0.3 to 1.1)	105.6 (0.9 to 335.4)	7.4 (-51.0 to 160.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	97.5 (7.9 to 304.5)	5.7 (-48.6 to 141.1)
Liver cancer due to hepatitis C	0.3 (0.1 to 0.6)	1.2 (0.5 to 2.2)	309.2 (97.9 to 1,002.9)	94.5 (-6.2 to 434.4)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	283.5 (110.9 to 904.7)	80.5 (-0.9 to 363.4)
Liver cancer due to alcohol use	0.5 (0.3 to 0.8)	0.4 (0.2 to 0.7)	-12.2 (-51.6 to 53.5)	-53.8 (-75.2 to -17.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-11.2 (-48.2 to 45.6)	-52.9 (-72.5 to -20.1)
Liver cancer due to other causes	0.5 (0.2 to 0.7)	0.5 (0.3 to 1.0)	13.2 (-41.5 to 140.9)	-22.1 (-72.1 to 32.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	10.3 (-35.5 to 110.1)	-44.3 (-69.6 to 17.3)
Larynx cancer	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	110.7 (46.4 to 194.3)	4.4 (-27.3 to 47.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	110.4 (47.2 to 197.5)	3.2 (-30.1 to 54.0)
Tracheal, bronchus and lung cancer	0.6 (0.5 to 0.7)	1.3 (1.0 to 1.6)	104.5 (55.1 to 166.8)	1.5 (-23.1 to 31.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	103.5 (48.6 to 175.4)	0.1 (-25.6 to 36.5)
Breast cancer	12.3 (7.0 to 15.8)	31.6 (19.9 to 41.9)	157.3 (78.4 to 263.2)	31.0 (-5.7 to 82.1)	1.1 (0.6 to 1.6)	2.6 (1.6 to 3.8)	135.7 (67.9 to 227.1)	20.8 (-11.8 to 65.7)
Cervical cancer	12.4 (8.4 to 16.5)	18.3 (12.5 to 25.3)	46.8 (-5.1 to 117.2)	-25.2 (-50.3 to 10.5)	1.0 (0.6 to 1.5)	1.5 (0.2 to 3.2)	49.3 (-5.0 to 126.2)	-25.1 (-51.2 to 12.0)
Uterine cancer	1.7 (0.9 to 2.7)	2.6 (1.4 to 4.2)	55.4 (-9.4 to 167.8)	-18.5 (-51.6 to 41.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	57.6 (-6.9 to 168.9)	-17.6 (-51.0 to 41.5)
Prostate cancer	4.8 (2.8 to 7.3)	26.3 (16.6 to 40.5)	440.3 (230.7 to 838.0)	158.3 (62.0 to 343.7)	0.5 (0.3 to 0.7)	2.3 (1.3 to 3.7)	385.5 (203.1 to 697.8)	132.9 (47.4 to 275.0)
Colon and rectum cancer	4.5 (3.9 to 5.1)	12.0 (9.8 to 14.4)	167.1 (112.7 to 240.0)	32.5 (7.8 to 69.3)	0.4 (0.3 to 0.6)	1.1 (0.8 to 1.5)	152.4 (99.8 to 225.5)	26.3 (-0.0 to 64.2)
Lip and oral cavity cancer	1.8 (1.3 to 2.5)	3.7 (2.6 to 5.1)	104.0 (42.8 to 187.6)	2.8 (-30.9 to 49.9)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	106.0 (43.7 to 189.5)	3.7 (-31.3 to 48.8)
Nasopharynx cancer	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	78.1 (7.0 to 207.9)	-12.4 (-45.4 to 46.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	78.9 (9.6 to 187.5)	-13.0 (-43.7 to 37.7)
Other pharynx cancer	0.3 (0.2 to 0.5)	0.6 (0.4 to 1.0)	101.6 (18.1 to 251.1)	0.1 (-42.0 to 77.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	104.1 (29.4 to 225.3)	2.0 (-37.2 to 61.8)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	101.1 (39.3 to 185.1)	-1.2 (-31.6 to 41.3)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	90.5 (38.0 to 159.9)	-6.3 (-33.1 to 30.3)
Pancreatic cancer	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	92.5 (45.7 to 159.4)	-3.5 (-26.7 to 28.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	90.3 (49.7 to 141.5)	-5.6 (-25.1 to 19.3)
Malignant skin melanoma	1.5 (1.1 to 1.9)	3.4 (2.3 to 4.5)	131.7 (67.4 to 212.9)	15.7 (-15.3 to 59.1)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	127.5 (18.8 to 58.7)	13.0 (-18.8 to 58.7)
Non-melanoma skin cancer	1.3 (1.0 to 1.7)	3.7 (2.9 to 4.6)	179.9 (112.3 to 277.3)	35.1 (-1.3 to 81.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	245.2 (134.3 to 390.8)	57.6 (-5.4 to 142.5)
Ovarian cancer	0.6 (0.3 to 0.9)	1.2 (0.8 to 1.9)	119.7 (40.5 to 248.8)	4.7 (-29.8 to 58.1)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	120.3 (38.2 to 254.7)	4.4 (-32.8 to 73.4)
Testicular cancer	0.6 (0.4 to 1.0)	1.7 (1.0 to 2.6)	172.3 (94.5 to 372.8)	32.2 (-22.8 to 127.3)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.2)	160.9 (44.7 to 377.4)	28.6 (-26.5 to 125.9)
Kidney cancer	0.4 (1.0 to 2.4)	1.0 (2.2 to 5.4)	117.5 (13.2 to 308.4)	5.9 (-20.3 to 62.6)	0.0 (0.1 to 0.2)	0.0 (0.1 to 0.4)	116.5 (26.3 to 279.1)	6.5 (-19.8 to 57.1)
Bladder cancer	1.7 (0.3 to 0.6)	4.6 (0.7 to 1.3)	167.1 (56.2 to 201.0)	26.0 (-24.8 to 52.4)	0.2 (0.0 to 0.1)	0.4 (0.1 to 0.1)	147.1 (58.0 to 202.1)	17.7 (-25.6 to 53.9)
Brain and nervous system cancer	0.7 (1.2 to 2.4)	1.5 (2.9 to 7.1)	121.3 (68.8 to 326.1)	10.0 (-8.0 to 76.4)	0.0 (0.1 to 0.2)	0.1 (0.2 to 0.6)	116.6 (67.2 to 267.2)	7.6 (-12.4 to 55.7)
Thyroid cancer	0.0 (0.4 to 1.1)	0.1 (0.8 to 2.5)	110.9 (21.9 to 292.0)	6.2 (-41.3 to 98.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	113.7 (24.1 to 284.8)	6.4 (-38.4 to 92.1)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	363.1 (36.3 to 221.7)	31.4 (-33.1 to 60.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.6)	113.7 (36.1 to 228.1)	6.4 (-33.3 to 64.3)
Hodgkin lymphoma	1.6 (1.0 to 2.6)	4.2 (2.5 to 7.2)	156.8 (47.2 to 360.8)	39.9 (-6.7 to 111.9)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	143.0 (51.6 to 286.9)	31.3 (-10.4 to 86.7)
Non-Hodgkin lymphoma	2.4 (1.6 to 3.2)	6.0 (3.9 to 8.5)	150.4 (72.0 to 273.6)	20.0 (-9.8 to 65.4)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	139.7 (72.2 to 238.8)	15.8 (-13.4 to 58.2)
Multiple myeloma	0.3 (0.2 to 0.4)	0.5 (0.5 to 0.9)	126.9 (48.9 to 246.0)	11.9 (-26.9 to 72.7)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	120.9 (50.3 to 216.8)	9.8 (-28.5 to 64.0)
Leukemia	0.8 (0.5 to 1.2)	2.4 (1.4 to 3.8)	183.9 (53.8 to 416.8)	31.4 (-13.5 to 102.6)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	140.8 (59.8 to 272.2)	13.6 (-19.8 to 57.2)
Other neoplasms	9.7 (6.4 to 14.2)	40.0 (23.0 to 62.3)	308.5 (114.1 to 628.0)	66.0 (12.9 to 137.8)	0.7 (0.4 to 1.0)	2.4 (1.3 to 4.1)	271.8 (113.0 to 521.6)	46.1 (6.4 to 100.1)
Cardiovascular diseases	-	-	-	-	43.0 (28.7 to 59.3)	81.1 (54.9 to 113.5)	88.4 (52.3 to 134.2)	-8.3 (-25.5 to 11.8)
Rheumatic heart disease	263.6 (209.0 to 322.1)	473.5 (347.7 to 628.0)	80.9 (26.2 to 131.5)	-7.2 (-28.7 to 15.9)	13.1 (8.2 to 19.8)	23.1 (13.4 to 35.5)	77.1 (22.6 to 123.6)	-11.7 (-32.4 to 9.6)
Ischemic heart disease	223.9 (172.4 to 295.1)	399.5 (274.4 to 423.7)	53.0 (7.9 to 107.7)	-25.7 (-45.9 to -3.2)	11.9 (7.3 to 18.3)	16.5 (10.9 to 25.1)	43.6 (5.2 to 112.4)	-29.6 (-52.5 to 0.2)
Cerebrovascular disease	-	-	-	-	1.7 (1.1 to 2.4)	3.1 (2.1 to 4.4)	85.7 (43.7 to 145.8)	-13.3 (-34.7 to 14.6)
Ischemic stroke	8.2 (6.8 to 10.2)	15.2 (11.9 to 19.0)	85.5 (39.5 to 143.7)	-14.2 (-36.6 to 13.8)	1.3 (0.8 to 1.8)	2.4 (1.5 to 3.4)	86.9 (39.9 to 147.6)	-13.1 (-36.4 to 14.8)
Hemorrhagic stroke	2.6 (2.1 to 3.2)	4.8 (3.7 to 5.9)	82.7 (35.2 to 147.5)	-17.1 (-37.0 to 16.0)	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.1)	85.1 (36.4 to 154.2)	-14.7 (-35.4 to 21.7)
Hypertensive heart disease	32.0 (21.6 to 40.2)	81.5 (64.5 to 102.5)	154.1 (88.8 to 261.9)	17.2 (-14.2 to 63.6)	3.5 (2.1 to 5.1)	8.8 (5.8 to 12.5)	154.6 (88.7 to 261.1)	18.4 (-13.5 to 68.0)
Cardiomyopathy and myocarditis	23.2 (19.6 to 26.9)	67.3 (45.2 to 88.8)	195.9 (86.2 to 288.4)	46.5 (-14.7 to 103.3)	2.5 (1.7 to 3.7)	7.3 (4.3 to 11.0)	196.7 (85.9 to 290.6)	17.7 (-14.5 to 104.6)
Atrial fibrillation and flutter	10.8 (8.5 to 14.0)	34.6 (25.2 to 44.6)	224.2 (106.9 to 344.3)	49.5 (-17.1 to 110.2)	0.8 (0.5 to 1.2)	2.6 (1.6 to 3.9)	220.2 (103.4 to 342.5)	50.4 (-15.5 to 109.4)
Peripheral vascular disease	340.6 (203.8 to 485.9)	632.0 (432.9 to 845.6)	81.4 (5.1 to 287.0)	-15.0 (-48.5 to 59.0)	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.6)	70.7 (-46.9 to 605.3)	-24.5 (-71.7 to 176.0)
Endocarditis	0.9 (0.6 to 1.2)	1.4 (0.8 to 2.2)	56.9 (-5.4 to 217.2)	-26.6 (-66.2 to 98.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	65.3 (-10.3 to 278.4)	-24.2 (-68.3 to 119.4)
Other cardiovascular and circulatory diseases	122.4 (68.6 to 224.0)	367.9 (144.6 to 417.3)	104.0 (-9.0 to 346.4)	-8.5 (-61.0 to 111.7)	9.2 (4.5 to 16.4)	18.8 (8.9 to 32.8)	106.6 (-9.6 to 344.4)	-8.2 (-60.8 to 113.4)</

Appendix Table G.4 - Tanzania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.1	95.6	-
Silicosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	88.1 (80.4 to 96.7)	-8.0 (-12.0 to -3.6)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	88.0 (80.4 to 96.7)	-8.0 (-12.1 to -3.6)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	102.8 (94.7 to 110.7)	0.9 (-3.1 to 4.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	102.3 (94.2 to 110.4)	0.6 (-3.4 to 4.2)
Asthma	361.3 (243.0 to 486.5)	557.3 (343.3 to 819.3)	51.8 (31.1 to 148.8)	-15.3 (-37.4 to 24.4)	15.6 (8.4 to 25.1)	24.1 (13.1 to 39.7)	51.1 (25.1 to 152.3)	-15.4 (-37.4 to 25.0)
Interstitial lung disease and pulmonary sarcoidosis	0.5 (0.4 to 0.6)	1.1 (0.8 to 1.4)	111.2 (53.1 to 208.8)	6.9 (-18.8 to 46.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	111.7 (54.5 to 207.6)	7.1 (-18.6 to 44.7)
Other chronic respiratory diseases	-	-	-	-	25.8 (13.2 to 42.7)	44.6 (25.1 to 75.3)	74.2 (7.3 to 179.5)	-11.8 (-45.9 to 40.1)
Cirrhosis	-	-	-	-	2.0 (1.3 to 2.7)	3.2 (2.2 to 4.5)	64.8 (41.9 to 88.5)	-12.3 (-22.8 to -1.7)
Cirrhosis due to hepatitis B	3.5 (2.2 to 4.6)	5.0 (3.1 to 6.8)	43.5 (8.4 to 144.1)	-21.1 (51.8 to 40.5)	0.6 (0.3 to 0.9)	0.8 (0.4 to 1.3)	43.8 (-17.1 to 142.6)	-20.9 (-56.7 to 37.1)
Cirrhosis due to hepatitis C	1.4 (0.9 to 2.2)	4.1 (2.5 to 5.8)	211.1 (47.3 to 497.8)	52.0 (-26.3 to 164.4)	0.2 (0.1 to 0.4)	0.7 (0.4 to 1.1)	206.2 (45.6 to 546.5)	49.9 (-31.3 to 179.8)
Cirrhosis due to alcohol use	3.1 (2.6 to 3.8)	3.9 (3.0 to 5.0)	24.4 (8.4 to 71.1)	-35.8 (-51.9 to -12.6)	0.5 (0.3 to 0.7)	0.6 (0.4 to 1.0)	24.4 (-13.3 to 80.4)	36.0 (-54.0 to -10.2)
Cirrhosis due to other causes	3.8 (3.1 to 4.5)	6.4 (5.3 to 7.6)	65.0 (31.0 to 114.2)	-3.1 (-26.7 to 30.0)	0.6 (0.4 to 1.0)	1.1 (0.7 to 1.6)	65.9 (14.6 to 148.1)	-2.2 (-31.6 to 41.6)
Digestive diseases	-	-	-	-	30.6 (21.4 to 41.6)	61.6 (43.5 to 84.3)	102.3 (84.0 to 121.9)	0.2 (-9.3 to 8.0)
Peptic ulcer disease	157.7 (134.2 to 176.2)	230.4 (213.7 to 246.3)	45.8 (27.7 to 72.2)	-28.3 (-37.1 to -16.1)	5.6 (3.8 to 8.1)	8.8 (6.0 to 12.5)	60.0 (23.3 to 90.5)	-23.0 (-37.9 to -12.8)
Gastritis and duodenitis	307.4 (273.0 to 337.4)	581.5 (520.9 to 635.9)	88.6 (66.9 to 115.1)	-3.8 (-15.9 to 10.5)	12.8 (8.5 to 18.3)	25.5 (17.1 to 36.6)	99.4 (71.5 to 135.5)	1.7 (-11.4 to 17.7)
Appendicitis	2.9 (2.2 to 3.8)	6.4 (4.5 to 8.3)	116.8 (52.2 to 245.1)	7.4 (-21.3 to 64.9)	0.9 (0.5 to 1.4)	2.0 (1.1 to 3.0)	119.7 (41.4 to 267.2)	8.9 (-26.9 to 73.7)
Paralytic ileus and intestinal obstruction	0.5 (0.3 to 0.8)	0.8 (0.6 to 1.1)	79.3 (8.7 to 163.9)	0.1 (-27.2 to 10.4)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.4)	79.9 (-16.3 to 182.1)	6.1 (-32.4 to 25.3)
Inguinal, femoral, and abdominal hernia	41.8 (34.9 to 51.6)	144.9 (127.0 to 167.8)	248.4 (176.9 to 330.5)	197.4 (146.7 to 264.9)	0.4 (0.2 to 0.9)	1.5 (0.7 to 2.9)	238.9 (167.6 to 324.0)	194.4 (144.5 to 263.4)
Inflammatory bowel disease	22.6 (21.5 to 23.5)	56.0 (53.4 to 58.5)	147.6 (132.8 to 164.7)	25.3 (18.2 to 33.2)	4.8 (3.3 to 6.6)	11.9 (8.1 to 16.3)	148.2 (124.6 to 173.2)	25.8 (16.0 to 37.2)
Vascular intestinal disorders	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	92.4 (28.1 to 177.4)	-7.1 (-38.3 to 37.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.0 (29.2 to 181.1)	-4.2 (-37.6 to 43.8)
Gallbladder and biliary diseases	7.3 (6.5 to 8.2)	17.2 (15.5 to 18.9)	135.1 (104.1 to 169.6)	15.9 (-0.7 to 34.7)	1.8 (0.5 to 1.1)	1.8 (1.2 to 2.5)	134.7 (95.2 to 181.1)	16.5 (-2.2 to 37.3)
Pancreatitis	4.0 (3.7 to 4.2)	8.6 (8.1 to 9.1)	115.9 (100.5 to 132.7)	5.0 (-2.6 to 12.8)	1.2 (0.8 to 1.6)	2.5 (1.7 to 3.5)	117.3 (82.7 to 157.9)	5.7 (-8.2 to 22.5)
Other digestive diseases	-	-	-	-	4.0 (2.4 to 6.2)	7.6 (4.9 to 11.4)	91.5 (40.1 to 151.7)	-5.2 (-30.8 to 24.3)
Neurological disorders	-	-	-	-	87.2 (58.6 to 120.0)	111.9 (124.7 to 256.7)	111.9 (79.8 to 146.7)	3.1 (-10.8 to 18.4)
Alzheimer disease and other dementias	34.1 (29.7 to 37.9)	80.3 (71.4 to 89.5)	135.1 (100.0 to 178.5)	0.0 (-14.7 to 19.4)	4.7 (3.3 to 6.1)	11.2 (7.9 to 14.5)	139.2 (104.7 to 185.1)	0.7 (-13.9 to 22.1)
Parkinson disease	3.1 (2.4 to 3.7)	6.4 (5.2 to 7.8)	110.4 (94.9 to 127.4)	-1.2 (-7.5 to 6.5)	0.4 (0.2 to 0.5)	0.8 (0.5 to 1.1)	111.4 (79.4 to 147.9)	-0.2 (-14.3 to 16.4)
Epilepsy	37.8 (21.4 to 59.3)	71.0 (42.3 to 112.4)	86.2 (-4.7 to 282.9)	-4.3 (-51.5 to 96.1)	11.5 (5.6 to 19.3)	21.8 (11.3 to 37.4)	89.8 (-8.0 to 290.1)	-2.6 (-52.5 to 97.5)
Multiple sclerosis	1.2 (1.1 to 1.4)	2.7 (2.4 to 3.0)	122.2 (89.4 to 158.8)	13.1 (-1.7 to 30.5)	0.4 (0.3 to 0.6)	0.9 (0.7 to 1.3)	120.4 (79.2 to 171.4)	12.1 (-8.7 to 37.9)
Migraine	1,252.4 (1,120.5 to 1,381.1)	2,392.9 (2,125.8 to 2,692.2)	90.2 (63.1 to 124.7)	-2.2 (-15.2 to 11.0)	42.6 (25.4 to 64.0)	81.6 (48.1 to 119.5)	91.1 (61.2 to 126.0)	-1.6 (-15.7 to 11.9)
Tension-type headache	2,866.3 (2,684.8 to 3,041.0)	5,869.3 (5,341.3 to 6,426.1)	104.3 (82.5 to 130.3)	-0.3 (-8.9 to 8.6)	4.3 (2.1 to 7.5)	8.9 (4.3 to 15.6)	105.8 (81.2 to 133.5)	0.5 (-9.3 to 10.6)
Medication overuse headache	117.3 (76.5 to 160.6)	323.6 (212.9 to 452.4)	173.5 (103.7 to 273.6)	40.7 (5.7 to 81.6)	18.3 (10.2 to 28.7)	50.7 (29.0 to 79.4)	174.0 (101.7 to 277.7)	41.3 (6.6 to 83.4)
Other neurological disorders	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	88.9 (38.5 to 154.7)	-2.9 (-28.2 to 29.0)	5.0 (3.0 to 8.9)	8.7 (5.4 to 13.5)	79.4 (7.1 to 176.6)	-23.2 (-54.0 to 20.3)
Mental and substance use disorders	-	-	-	-	573.7 (398.2 to 775.4)	1,123.5 (778.7 to 1,518.1)	95.6 (91.1 to 101.8)	-0.1 (-2.4 to 2.8)
Schizophrenia	51.1 (47.0 to 55.5)	101.7 (93.3 to 110.3)	98.7 (90.0 to 106.9)	0.8 (-3.5 to 4.7)	0.8 (24.2 to 39.2)	0.8 (47.3 to 78.6)	98.7 (86.4 to 112.9)	1.2 (-4.7 to 7.3)
Alcohol use disorders	257.7 (239.2 to 277.7)	456.0 (423.9 to 491.0)	76.9 (68.1 to 85.8)	-10.1 (-14.3 to -5.7)	25.3 (16.7 to 36.0)	44.8 (29.9 to 62.3)	77.5 (65.3 to 88.9)	-9.7 (-15.6 to -4.4)
Drug use disorders	-	-	-	-	30.6 (20.3 to 42.2)	61.7 (40.9 to 85.3)	101.8 (81.3 to 124.0)	2.5 (-7.2 to 12.5)
Opioid use disorders	38.2 (24.4 to 55.3)	78.8 (51.0 to 113.6)	104.3 (88.0 to 138.9)	3.2 (-5.3 to 17.5)	15.6 (8.9 to 23.9)	32.3 (19.1 to 50.1)	106.3 (84.8 to 140.0)	4.0 (-6.6 to 19.5)
Cocaine use disorders	11.2 (10.2 to 14.2)	24.0 (19.6 to 27.8)	97.2 (57.6 to 145.1)	0.1 (-17.6 to 21.5)	1.6 (1.0 to 2.4)	3.3 (1.9 to 4.8)	97.3 (66.1 to 160.8)	0.5 (-23.6 to 28.6)
Amphetamine use disorders	40.6 (37.6 to 43.9)	78.8 (72.6 to 84.7)	94.1 (76.4 to 110.5)	-1.3 (-9.8 to 6.2)	5.3 (3.2 to 7.9)	10.3 (6.3 to 15.0)	95.1 (68.7 to 127.1)	-0.8 (-13.5 to 14.2)
Cannabis use disorders	38.2 (30.2 to 45.8)	74.9 (59.5 to 89.7)	95.9 (94.7 to 97.4)	0.2 (0.1 to 0.2)	1.1 (0.7 to 1.6)	2.2 (1.3 to 3.3)	96.5 (67.8 to 131.6)	0.5 (-13.8 to 17.3)
Other drug use disorders	-	-	-	-	7.0 (4.4 to 10.5)	13.7 (8.4 to 20.1)	95.1 (43.9 to 165.8)	-0.7 (-26.7 to 34.6)
Depressive disorders	-	-	-	-	30.4 (176.0 to 403.7)	59.3 (345.9 to 783.4)	95.1 (87.1 to 107.1)	1.2 (-4.8 to 5.1)
Major depressive disorder	1,225.0 (929.6 to 1,533.7)	2,380.1 (1,799.1 to 2,943.9)	93.1 (85.5 to 106.3)	-1.4 (-5.8 to 5.0)	251.7 (159.6 to 375.7)	490.7 (311.5 to 726.2)	94.2 (85.8 to 107.9)	-0.8 (-5.4 to 5.8)
Dysthymia	242.4 (200.1 to 289.4)	478.4 (393.0 to 571.6)	97.1 (95.6 to 98.4)	-0.5 (-0.6 to -0.4)	23.2 (15.0 to 33.9)	46.0 (29.8 to 67.0)	97.0 (91.8 to 104.1)	0.0 (-2.4 to 2.4)
Bipolar disorder	135.4 (114.9 to 153.5)	269.7 (229.5 to 308.8)	99.5 (87.0 to 110.4)	0.0 (-5.1 to 4.2)	27.4 (16.4 to 41.8)	54.8 (33.7 to 82.2)	100.3 (84.6 to 115.3)	0.4 (-5.9 to 6.7)
Anxiety disorders	717.8 (297.8 to 1,242.7)	1,466.3 (591.9 to 2,441.2)	96.1 (92.8 to 98.5)	0.6 (-0.8 to -0.4)	68.5 (25.2 to 123.4)	134.8 (49.1 to 244.6)	98.8 (90.5 to 103.8)	0.2 (-2.8 to 2.5)
Eating disorders	-	-	-	-	6.2 (3.7 to 9.8)	12.3 (7.3 to 19.3)	98.0 (80.5 to 115.7)	1.2 (-8.2 to 9.0)
Anorexia nervosa	4.2 (3.2 to 5.5)	8.6 (6.4 to 11.2)	103.0 (83.9 to 120.9)	3.3 (-6.0 to 13.2)	0.9 (0.5 to 1.4)	1.8 (1.1 to 2.8)	104.2 (60.9 to 158.7)	3.9 (-17.9 to 32.8)
Bulimia nervosa	25.2 (17.2 to 36.8)	49.6 (33.9 to 72.6)	96.3 (94.1 to 98.3)	-0.7 (-0.9 to -0.5)	5.3 (3.0 to 8.6)	10.4 (6.0 to 17.0)	97.1 (78.9 to 116.4)	-0.1 (-9.4 to 8.9)
Autistic spectrum disorders	-	-	-	-	30.4 (20.9 to 41.2)	59.3 (40.9 to 80.0)	95.1 (87.9 to 103.3)	1.2 (-2.0 to 4.9)
Autism	77.8 (73.8 to 81.9)	151.3 (143.5 to 159.2)	94.1 (94.0 to 94.3)	0.6 (0.6 to 0.7)	19.2 (12.9 to 26.4)	37.5 (25.3 to 51.6)	95.3 (84.6 to 106.7)	1.2 (-3.6 to 6.3)
Asperger syndrome	111.9 (104.9 to 118.6)	217.6 (203.9 to 231.6)	94.2 (94.0 to 94.4)	0.8 (0.8 to 0.8)	11.2 (7.6 to 15.6)	21.8 (15.1 to 30.4)	95.0 (86.1 to 104.6)	1.3 (-2.6 to 5.2)
Attention-deficit/hyperactivity disorder	189.8 (175.2 to 205.1)	361.8 (333.9 to 391.1)	90.5 (90.3 to 90.5)	0.2 (0.2 to 0.2)	2.3 (1.4 to 3.5)	4.4 (2.6 to 6.6)	91.3 (76.7 to 104.8)	0.6 (-6.8 to 7.5)
Conduct disorder	278.0 (261.1 to 294.6)	525.9 (495.7 to 557.2)	88.5 (88.8 to 89.1)	0.2 (0.2 to 0.2)	33.4 (20.9 to 48.7)	63.3 (39.6 to 91.4)	90.8 (81.9 to 98.1)	0.8 (-4.0 to 5.0)
Idiopathic intellectual disability	407.2 (173.9 to 565.4)	852.3 (522.0 to 1,113.5)	106.8 (75.6 to 210.7)	9.0 (-8.3 to 74.4)	19.9 (7.9 to 31.2)	41.7 (24.1 to 61.9)	107.7 (81.9 to 217.3)	9.4 (-8.1 to 76.9)
Other mental and substance use disorders	300.8 (280.1 to 319.9)	602.1 (561.2 to 640.8)	99.9 (99.3 to 100.5)	0.6 (0.4 to 0.7)	22.3 (15.1 to 30.1)	44.9 (30.4 to 60.5)	101.0 (92.0 to 110.2)	1.2 (-2.8 to 5.0)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	105.7 (74.8 to 142.8)	219.4 (154.0 to 298.1)	107.9 (94.7 to 120.5)	3.2 (-3.2 to 8.7)
Diabetes mellitus	103.4 (83.8 to 123.9)	249.8 (198.2 to 314.3)	140.5 (82.3 to 210.4)	22.3 (-9.6 to 57.7)	8.0 (5.2 to 11.3)	19.7 (12.7 to 28.9)	143.5 (84.3 to 222.0)	24.4 (-8.0 to 65.9)
Acute glomerulonephritis	0.3 (0.2 to 0.3)	0.4 (0.4 to 0.5)	61.7 (51.6 to 73.9)	-12.1 (-17.2 to -6.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.7 (51.5 to 73.9)	-12.1 (-17.3 to -6.7)
Chronic kidney disease	-	-	-	-	39.0 (28.0 to 51.2)	77.1 (54.9 to 101.9)	98.6 (78.2 to 116.1)	-0.7 (-10.5 to 8.5)
Chronic kidney disease due to diabetes mellitus	313.6 (186.3 to 496.5)	616.9 (382.5 to 926.0)	98.1 (37.1 to 190.1)	0.3 (-30.9 to 44.7)	4.7 (2.9 to 7.0)	9.3 (6.2 to 13.2)	96.7 (41.8 to 186.4)	-0.6 (-26.9 to 43.8)
Chronic kidney disease due to hypertension	1,034.3 (613.1 to 1,735.9)	2,011.7 (1,227.4 to 3,256.0)	94.8 (60.0 to 155.1)	0.6 (-22.5 to 23.3)	11.8 (8.2 to 16.3)	23.7 (16.6 to 32.0)	100.4 (64.5 to 145.7)	-0.3 (-17.0 to 22.7)
Chronic kidney disease due to glomerulonephritis	843.0 (573.1 to 1,176.8)	1,466.3 (1,169.0 to 2,444.4)	96.1 (65.8 to 159.3)	0.6 (-21.2 to 30.5)	6.5 (2.1 to 30.5)	13.8 (19.6 to 36.4)	97.9 (65.4 to 137.1)	2.8 (-18.5 to 22.9)
Chronic kidney disease due to other causes	666.6 (438.9 to 1,127.0)	1,292.0 (831.7 to 2,325.2)	93.9 (50.1 to 154.7)	-6.0 (-25.2 to 25.9)	8.6 (6.0 to 11.7)	16.7 (10.9 to 23.3)	93.6 (51.1 to 155.6)	-5.6 (-26.3 to 27.4)
Urinary diseases and male infertility	-	-	-	-	6.3 (4.2 to 9.0)	13.4 (8.7 to 19.2)	112.3 (96.8 to 126.8)	2.2 (-4.1 to 8.2)

Appendix Table G.4 - Tanzania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	4.8 (4.5 to 5.1)	10.0 (9.2 to 10.7)	108.2 (91.2 to 126.8)	0.2 (-2.5 to 14.8)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	109.2 (62.8 to 166.7)	6.3 (-11.5 to 28.4)
Urolithiasis	54.9 (41.8 to 71.3)	87.4 (68.6 to 110.6)	58.6 (43.0 to 84.3)	-21.2 (-28.6 to -10.1)	0.5 (0.4 to 0.8)	1.1 (0.7 to 1.5)	91.5 (67.8 to 121.3)	-6.0 (-15.4 to 6.3)
Benign prostatic hyperplasia	135.3 (122.4 to 146.5)	299.1 (269.3 to 322.0)	121.5 (106.2 to 134.4)	3.3 (-3.4 to 9.4)	4.8 (3.1 to 6.9)	10.7 (6.8 to 15.1)	122.8 (106.0 to 136.5)	4.4 (-2.9 to 10.8)
Male infertility due to other causes	81.3 (60.6 to 109.4)	141.3 (96.8 to 192.5)	72.2 (6.2 to 173.8)	-14.2 (47.9 to 37.3)	0.5 (0.2 to 1.1)	0.9 (0.3 to 1.8)	73.6 (6.6 to 172.3)	-14.1 (-46.8 to 34.8)
Other urinary diseases	-	-	-	-	0.3 (0.2 to 0.6)	0.5 (0.3 to 0.9)	64.4 (3.1 to 130.9)	-22.6 (-49.0 to 13.6)
Gynecological diseases	-	-	-	-	27.2 (17.5 to 40.2)	49.3 (31.5 to 74.7)	81.2 (56.5 to 108.0)	-9.5 (-20.6 to 2.8)
Uterine fibroids	374.4 (338.5 to 407.5)	691.5 (621.8 to 754.6)	84.5 (83.3 to 85.6)	-3.6 (-3.7 to -3.5)	6.7 (4.1 to 10.7)	11.4 (6.7 to 18.1)	68.1 (50.4 to 85.0)	-14.9 (-24.6 to -6.8)
Polycystic ovarian syndrome	349.1 (315.8 to 383.0)	692.0 (614.5 to 778.0)	97.0 (71.8 to 131.3)	-1.8 (-13.6 to 14.2)	3.4 (1.6 to 6.4)	6.8 (3.2 to 12.8)	98.5 (71.8 to 134.2)	-1.5 (-13.5 to 15.3)
Female infertility due to other causes	304.3 (254.4 to 360.0)	595.5 (451.5 to 680.5)	83.3 (38.8 to 136.2)	-8.7 (-32.4 to 17.1)	1.6 (0.6 to 3.2)	2.9 (1.1 to 6.0)	89.9 (40.1 to 136.8)	-8.2 (-31.5 to 18.2)
Endometriosis	36.0 (30.8 to 41.1)	62.7 (51.8 to 73.3)	73.0 (35.5 to 120.0)	-13.0 (-30.7 to 9.6)	3.3 (2.2 to 4.6)	5.8 (3.7 to 8.3)	73.9 (34.3 to 125.2)	-12.4 (-32.2 to 11.9)
Genital prolapse	626.0 (535.6 to 714.8)	1,277.0 (1,093.8 to 1,471.1)	103.8 (66.7 to 152.6)	1.8 (-15.1 to 22.0)	2.0 (0.9 to 3.7)	4.0 (2.0 to 7.5)	105.1 (66.5 to 154.5)	2.2 (-15.4 to 22.6)
Premenstrual syndrome	924.5 (661.9 to 1,236.5)	1,716.1 (1,274.6 to 2,396.5)	86.9 (20.6 to 180.8)	-7.3 (-39.8 to 35.8)	7.7 (4.2 to 12.6)	14.3 (8.3 to 23.0)	87.4 (19.5 to 182.1)	-7.5 (-40.3 to 36.7)
Other gynecological diseases	77.9 (52.6 to 104.2)	137.0 (96.3 to 179.1)	75.6 (22.6 to 165.6)	-11.6 (-38.3 to 34.6)	2.5 (1.3 to 3.8)	4.2 (2.1 to 6.2)	63.5 (-14.1 to 214.4)	-19.0 (-57.2 to 57.8)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	13.9 (8.8 to 20.2)	41.2 (27.6 to 59.0)	197.3 (151.0 to 264.5)	52.7 (32.2 to 88.1)
Thalassemias	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	80.9 (40.8 to 123.0)	-5.2 (-25.9 to 17.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.2 (57.1 to 94.6)	-6.0 (-17.9 to 2.2)
Thalassemia trait	211.6 (144.4 to 279.9)	411.2 (280.2 to 529.3)	93.2 (72.9 to 123.8)	0.1 (-10.4 to 16.2)	4.0 (2.6 to 5.7)	8.0 (5.2 to 11.7)	102.6 (69.2 to 140.6)	4.5 (-14.1 to 21.3)
Sickle cell disorders	1.0 (0.7 to 1.4)	22.1 (15.3 to 28.2)	2,085.4 (1,317.7 to 2,993.6)	1,024.3 (661.8 to 1,480.2)	0.2 (0.1 to 0.3)	2.7 (1.6 to 4.1)	1,547.3 (908.3 to 2,476.0)	804.2 (455.2 to 1,324.2)
Sickle cell trait	583.9 (392.6 to 823.4)	3,774.4 (3,134.2 to 4,323.6)	541.9 (370.0 to 739.9)	231.9 (143.1 to 335.3)	2.4 (1.3 to 3.7)	18.8 (12.1 to 27.4)	671.9 (507.2 to 1,130.7)	303.6 (229.8 to 607.9)
G6PD deficiency	2,729.7 (2,449.4 to 3,000.3)	5,188.2 (4,392.7 to 5,948.0)	89.5 (56.4 to 126.7)	-1.5 (-18.7 to 17.6)	0.2 (0.1 to 0.4)	0.5 (0.3 to 0.7)	94.0 (13.7 to 215.2)	3.2 (-33.3 to 49.2)
G6PD trait	5,473.0 (5,369.1 to 5,567.5)	10,405.5 (10,115.5 to 10,636.5)	89.9 (83.9 to 96.0)	-2.1 (-5.2 to 1.0)	0.2 (0.1 to 0.3)	0.4 (0.1 to 0.6)	86.0 (-36.6 to 297.6)	-5.3 (-67.4 to 102.8)
Other hemoglobinopathies and hemolytic anemias	206.9 (158.2 to 243.0)	326.8 (284.3 to 364.1)	58.0 (32.3 to 100.8)	-24.8 (-36.4 to -9.3)	6.8 (4.0 to 10.4)	10.8 (6.6 to 16.2)	59.2 (15.2 to 136.8)	-24.2 (-43.5 to 7.3)
Endocrine, metabolic, blood, and immune disorders	295.4 (252.4 to 334.9)	509.8 (401.4 to 601.8)	71.4 (31.0 to 136.9)	65.1 (-31.8 to 8.9)	11.2 (6.7 to 16.3)	65.1 (11.0 to 27.7)	65.1 (84.5 to 140.1)	-16.9 (-39.6 to 9.5)
Musculoskeletal disorders	-	-	-	-	269.1 (189.7 to 358.8)	548.6 (391.6 to 732.5)	103.7 (84.8 to 125.1)	1.9 (-4.9 to 9.8)
Rheumatoid arthritis	53.6 (51.3 to 55.9)	96.5 (92.7 to 100.4)	79.5 (69.4 to 92.1)	-11.9 (-17.1 to -6.3)	12.7 (9.0 to 16.8)	22.9 (16.2 to 30.6)	79.9 (66.8 to 97.4)	-11.3 (-17.3 to -4.1)
Osteoarthritis	433.1 (414.3 to 450.8)	896.7 (863.8 to 931.7)	106.8 (95.9 to 119.6)	1.5 (-3.6 to 7.2)	26.4 (18.7 to 35.9)	54.6 (37.9 to 74.2)	107.1 (95.6 to 120.5)	2.1 (-3.3 to 8.1)
Low back and neck pain	-	-	-	-	194.5 (134.2 to 263.6)	394.9 (273.9 to 532.8)	103.1 (76.3 to 131.5)	1.2 (-9.1 to 12.7)
Low back pain	1,019.1 (963.2 to 1,074.3)	1,992.6 (1,882.6 to 2,104.3)	95.0 (80.7 to 111.2)	-1.3 (-8.1 to 6.5)	112.9 (76.5 to 156.6)	221.3 (147.0 to 307.5)	95.7 (81.1 to 112.0)	-0.6 (-7.6 to 7.2)
Neck pain	836.0 (645.6 to 1,045.9)	1,768.4 (1,369.4 to 2,133.9)	111.3 (58.0 to 177.9)	3.6 (-17.6 to 30.6)	81.6 (51.6 to 118.3)	173.5 (111.0 to 246.1)	112.7 (58.0 to 181.2)	4.0 (-17.9 to 31.2)
Gout	3.1 (2.7 to 3.5)	6.3 (5.5 to 6.9)	103.1 (70.2 to 141.4)	0.2 (-14.9 to 17.9)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	103.1 (57.3 to 161.8)	0.0 (-22.5 to 30.1)
Other musculoskeletal disorders	392.3 (295.1 to 495.8)	114.3 (64.4 to 1,040.4)	114.3 (97.5 to 131.2)	7.9 (-0.3 to 15.9)	84.6 (25.5 to 52.5)	76.0 (48.7 to 111.8)	114.3 (97.2 to 132.9)	4.4 (-0.5 to 16.8)
Other non-communicable diseases	-	-	-	-	312.4 (201.2 to 458.5)	602.7 (384.3 to 899.2)	92.9 (84.0 to 100.9)	-4.4 (-8.3 to -0.9)
Congenital anomalies	-	-	-	-	14.0 (9.9 to 18.7)	34.4 (25.2 to 45.2)	146.0 (113.1 to 189.5)	24.7 (8.8 to 45.5)
Neural tube defects	2.5 (2.0 to 3.0)	11.8 (10.1 to 14.0)	380.7 (270.9 to 544.3)	169.9 (108.4 to 262.1)	0.6 (0.4 to 0.8)	3.2 (2.1 to 4.5)	454.2 (289.9 to 701.1)	216.0 (125.0 to 361.7)
Congenital heart anomalies	20.5 (15.2 to 26.8)	112.5 (88.0 to 142.8)	443.1 (290.5 to 722.0)	207.7 (120.1 to 368.6)	0.8 (0.4 to 1.3)	3.8 (1.6 to 6.9)	379.7 (239.3 to 632.5)	174.9 (94.1 to 328.8)
Orofacial clefts	2.2 (1.2 to 3.4)	16.1 (11.8 to 23.3)	319.9 (311.9 to 1,299.6)	344.0 (146.1 to 791.5)	0.0 (0.0 to 0.1)	0.3 (0.2 to 0.5)	577.9 (256.0 to 1,316.1)	312.9 (116.3 to 788.6)
Down syndrome	12.6 (10.4 to 14.9)	36.9 (30.1 to 45.0)	191.0 (128.1 to 275.2)	58.7 (23.7 to 104.2)	1.4 (1.0 to 2.0)	4.3 (2.9 to 5.9)	194.3 (123.0 to 300.4)	60.6 (22.4 to 113.7)
Turner syndrome	0.5 (0.4 to 0.7)	1.4 (1.1 to 1.9)	166.9 (74.5 to 304.4)	39.4 (-9.1 to 113.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	168.3 (71.5 to 312.6)	39.4 (-11.3 to 114.7)
Klinefelter syndrome	0.7 (0.6 to 0.9)	1.4 (1.0 to 2.0)	93.0 (29.4 to 193.7)	0.7 (-3.2 to 53.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.8 (32.1 to 201.5)	1.4 (-32.2 to 54.5)
Chromosomal unbalanced rearrangements	21.4 (16.9 to 27.2)	60.2 (48.6 to 75.9)	181.4 (99.5 to 294.5)	2.5 (8.6 to 119.3)	7.0 (1.6 to 3.5)	7.0 (4.8 to 9.7)	184.0 (102.0 to 302.3)	56.6 (10.4 to 125.0)
Other congenital anomalies	90.5 (67.2 to 111.8)	155.9 (115.3 to 194.6)	71.8 (49.2 to 100.1)	-11.2 (-22.0 to 3.6)	8.7 (5.4 to 12.5)	15.8 (10.2 to 22.6)	81.3 (52.4 to 118.9)	-8.1 (-21.8 to 10.2)
Skin and subcutaneous diseases	-	-	-	-	126.1 (78.8 to 193.8)	255.4 (156.9 to 401.4)	102.2 (88.0 to 117.3)	3.5 (-3.9 to 11.8)
Dermatitis	985.4 (776.9 to 1,215.0)	1,924.0 (1,514.8 to 2,367.1)	94.9 (94.0 to 96.0)	-0.0 (-0.2 to 0.1)	31.6 (20.4 to 46.6)	61.5 (39.6 to 90.8)	94.6 (86.9 to 101.8)	0.3 (-2.7 to 3.1)
Psoriasis	149.7 (129.3 to 171.5)	294.4 (254.2 to 337.7)	96.4 (95.4 to 97.3)	0.0 (-0.1 to 0.1)	12.2 (8.3 to 17.1)	24.0 (16.3 to 33.7)	97.3 (83.4 to 112.1)	0.5 (-5.1 to 6.7)
Cellulitis	5.0 (4.0 to 6.4)	10.4 (8.2 to 12.7)	104.9 (75.9 to 144.4)	5.3 (-9.5 to 27.8)	0.4 (0.2 to 0.6)	0.7 (0.5 to 1.1)	105.4 (51.6 to 173.7)	5.5 (-16.8 to 36.1)
Pyoderma	44.0 (32.5 to 56.8)	78.2 (58.6 to 100.2)	77.4 (66.8 to 91.0)	-4.2 (-10.5 to 3.0)	0.3 (0.1 to 0.6)	0.4 (0.2 to 1.0)	78.1 (58.7 to 97.0)	-3.8 (-13.8 to 5.3)
Scabies	678.1 (544.2 to 850.9)	904.7 (700.4 to 1,135.6)	34.2 (-2.2 to 77.3)	-30.4 (-50.3 to -2.3)	17.5 (9.6 to 29.1)	23.4 (12.6 to 40.0)	34.2 (-2.8 to 78.4)	-30.2 (-50.1 to -12.2)
Fungal skin diseases	2,962.5 (2,339.4 to 3,635.6)	5,743.0 (4,532.0 to 7,044.5)	93.6 (92.1 to 95.1)	16.8 (0.1 to 33.3)	16.8 (6.8 to 36.3)	35.1 (13.1 to 70.1)	94.1 (91.8 to 96.2)	0.2 (-0.2 to 1.3)
Viral skin diseases	573.5 (478.3 to 678.7)	1,108.1 (919.1 to 1,305.7)	92.7 (85.9 to 101.5)	-0.3 (-3.1 to 3.4)	17.7 (11.0 to 26.6)	34.2 (20.9 to 51.7)	93.7 (84.1 to 103.0)	0.2 (-3.9 to 4.1)
Acne vulgaris	1,481.5 (1,192.6 to 1,781.5)	4,354.7 (3,662.7 to 5,095.5)	192.4 (135.8 to 269.6)	51.7 (23.7 to 91.6)	16.0 (7.5 to 29.1)	47.2 (21.9 to 87.0)	192.9 (136.9 to 272.0)	51.8 (23.7 to 92.7)
Alopecia areata	22.5 (20.1 to 25.3)	44.4 (38.8 to 49.6)	96.4 (66.1 to 131.7)	0.5 (-15.2 to 18.2)	0.8 (0.5 to 1.2)	1.5 (0.9 to 2.3)	97.6 (62.7 to 142.2)	0.8 (-16.0 to 22.8)
Pruritus	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	97.3 (54.1 to 146.5)	0.9 (-20.5 to 27.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.2 (54.0 to 146.7)	0.9 (-20.7 to 28.0)
Urticaria	86.7 (40.3 to 125.7)	246.6 (107.9 to 359.7)	176.5 (47.8 to 508.6)	31.2 (-30.7 to 160.2)	5.1 (2.3 to 8.5)	14.6 (6.2 to 24.0)	179.7 (45.9 to 520.1)	32.9 (-29.0 to 161.2)
Decubitus ulcer	2.7 (2.3 to 3.1)	5.9 (5.0 to 7.0)	117.4 (78.0 to 176.1)	0.4 (-22.1 to 36.9)	0.4 (0.3 to 0.6)	0.9 (0.6 to 1.3)	118.3 (72.7 to 183.3)	1.2 (-23.6 to 40.7)
Other skin and subcutaneous diseases	1,273.3 (841.2 to 1,757.9)	2,427.0 (1,580.1 to 3,403.9)	90.1 (82.1 to 99.8)	-3.6 (-8.8 to 1.6)	7.5 (3.3 to 15.4)	14.3 (6.3 to 29.2)	90.7 (81.9 to 100.1)	-3.1 (-8.2 to 2.2)
Sense organ diseases	-	-	-	-	129.4 (86.6 to 183.4)	228.0 (151.8 to 325.0)	111.2 (65.5 to 188.2)	-11.2 (-15.7 to -6.2)
Glaucoma	30.7 (25.1 to 37.7)	59.6 (47.6 to 76.3)	95.4 (52.9 to 145.3)	-0.8 (-22.1 to 23.2)	2.8 (1.9 to 4.1)	5.7 (3.8 to 8.3)	101.9 (56.5 to 154.5)	3.5 (-21.1 to 32.3)
Cataract	107.0 (82.8 to 134.6)	170.8 (136.4 to 215.0)	58.8 (33.6 to 92.9)	-25.4 (-36.0 to -9.3)	6.7 (4.4 to 9.7)	11.1 (7.4 to 15.9)	66.6 (38.7 to 116.8)	-22.7 (-35.0 to -0.1)
Macular degeneration	26.3 (16.7 to 36.0)	56.3 (40.8 to 76.0)	112.0 (56.9 to 213.8)	9.4 (-17.7 to 57.3)	1.3 (0.8 to 2.0)	2.9 (1.8 to 4.4)	117.0 (63.5 to 218.1)	9.6 (-14.7 to 53.1)
Uncorrected refractive error	1,864.3 (1,476.3 to 2,252.9)	3,522.4 (2,925.6 to 4,249.2)	88.7 (43.5 to 149.7)	4.1 (-25.2 to 19.9)	34.8 (23.8 to 53.3)	60.6 (37.8 to 95.6)	72.9 (49.0 to 105.1)	-12.6 (-23.8 to 1.6)
Age-related and other hearing loss	2,657.7 (2,396.6 to 2,910.3)	4,865.5 (4,343.5 to 5,368.1)	82.7 (74.3 to 93.8)	6.6 (-9.5 to 2.9)	4.6 (-9.5 to 2.9)	10.3 (38.1 to 87.7)	10.9 (66.4 to 157.7)	-0.9 (-16.8 to 4.9)
Other vision loss	75.8 (64.9 to 89.1)	113.2 (93.5 to 133.4)	49.2 (31.8 to 65.7)	-20.4 (-29.8 to -11.3)	8.0 (5.4 to 11.4)	12.2 (8.4 to 17.2)	53.1 (34.7 to 75.0)	-16.6 (-26.9 to -5.2)
Other sense organ diseases	602.6 (567.4 to 635.3)	1,163.7 (1,104.5 to 1,228.5)	92.6 (78.6 to 108.0)	-0.5 (-6.5 to 6.6)	16.1 (9.8 to 23.8)	31.1 (18.8 to 46.5)</		

Appendix Table G.4 - Tanzania prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.								
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	394.9 (367.4 to 423.0)	770.1 (714.8 to 821.8)	95.0 (76.4 to 114.7)	-6.7 (-15.1 to 1.5)	10.8 (7.3 to 14.9)	21.1 (14.1 to 29.1)	95.2 (76.3 to 116.0)	-6.1 (-14.5 to 2.7)
Other oral disorders	364.4 (341.4 to 387.5)	705.4 (663.9 to 750.8)	93.1 (78.1 to 112.5)	-1.3 (-8.5 to 8.2)	10.7 (6.2 to 16.0)	20.7 (12.8 to 31.4)	93.7 (77.0 to 113.8)	-1.1 (-8.8 to 8.7)
Injuries	-	-	-	-	85.8 (65.2 to 110.1)	139.3 (105.2 to 181.0)	62.3 (56.6 to 68.2)	-14.3 (-17.1 to -11.3)
Transport injuries	-	-	-	-	28.7 (21.7 to 37.1)	40.9 (30.9 to 53.1)	42.4 (35.0 to 50.2)	-21.6 (-24.9 to -17.8)
Road injuries	-	-	-	-	11.1 (9.0 to 13.5)	35.5 (27.0 to 46.5)	42.5 (34.6 to 51.1)	-21.9 (-25.4 to -17.7)
Pedestrian road injuries	-	-	-	-	8.7 (6.5 to 11.3)	11.5 (8.5 to 14.9)	31.4 (20.3 to 44.1)	-26.0 (-31.1 to -20.1)
Cyclist road injuries	-	-	-	-	2.2 (1.7 to 2.9)	2.9 (2.1 to 3.8)	30.0 (21.8 to 39.9)	-27.2 (-31.6 to -21.5)
Motorcyclist road injuries	-	-	-	-	2.8 (2.1 to 3.7)	3.6 (2.7 to 4.7)	29.3 (18.6 to 39.3)	-30.1 (-35.3 to -25.0)
Motor vehicle road injuries	-	-	-	-	11.1 (8.4 to 14.3)	17.5 (13.2 to 22.5)	58.9 (46.6 to 72.0)	-13.9 (-19.4 to -7.8)
Other road injuries	-	-	-	-	0.3 (0.3 to 0.4)	0.3 (0.2 to 0.4)	-10.6 (-16.8 to -4.7)	-52.5 (-55.5 to -49.6)
Other transport injuries	-	-	-	-	3.6 (2.7 to 4.7)	5.0 (3.8 to 6.6)	41.2 (31.0 to 51.4)	-21.0 (-25.8 to -15.3)
Unintentional injuries	-	-	-	-	51.7 (39.2 to 66.4)	89.7 (67.9 to 117.1)	73.6 (67.3 to 80.5)	-10.6 (-13.8 to -7.0)
Falls	-	-	-	-	21.6 (16.3 to 28.0)	41.8 (31.2 to 54.9)	92.7 (81.4 to 106.1)	-5.7 (-11.0 to 0.2)
Drowning	-	-	-	-	1.1 (0.8 to 1.5)	1.5 (1.1 to 2.0)	36.1 (22.6 to 49.5)	-26.3 (-32.4 to -20.5)
Fire, heat, and hot substances	-	-	-	-	5.8 (4.4 to 7.4)	8.9 (6.9 to 11.5)	54.1 (39.3 to 67.4)	-18.8 (-24.9 to -12.9)
Poisonings	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	37.9 (16.9 to 61.6)	-27.5 (-36.3 to -18.0)
Exposure to mechanical forces	-	-	-	-	12.4 (9.4 to 16.1)	20.9 (15.8 to 27.4)	69.3 (61.3 to 77.3)	-10.0 (-13.9 to -6.0)
Unintentional firearm injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.9 (0.6 to 1.1)	101.5 (86.0 to 117.5)	5.3 (-2.6 to 13.3)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	117.6 (98.8 to 140.0)	14.0 (6.3 to 23.8)
Other exposure to mechanical forces	-	-	-	-	11.8 (8.9 to 15.4)	19.8 (14.9 to 26.0)	67.6 (59.6 to 76.0)	-11.0 (-15.0 to -6.8)
Adverse effects of medical treatment	-	-	-	-	0.4 (0.2 to 0.5)	0.8 (0.5 to 1.1)	111.0 (98.9 to 123.3)	8.4 (1.6 to 15.3)
Animal contact	-	-	-	-	2.6 (2.0 to 3.5)	3.6 (2.7 to 4.8)	37.3 (27.7 to 48.4)	-27.5 (-31.5 to -22.9)
Venomous animal contact	-	-	-	-	1.2 (0.8 to 1.6)	1.6 (1.2 to 2.2)	38.6 (22.7 to 56.7)	-27.1 (-34.3 to -19.4)
Non-venomous animal contact	-	-	-	-	1.5 (1.1 to 2.0)	2.0 (1.4 to 2.7)	36.3 (26.0 to 47.7)	-27.6 (-31.4 to -23.0)
Foreign body	-	-	-	-	0.9 (0.7 to 1.2)	1.7 (1.3 to 2.2)	86.4 (76.6 to 96.9)	-4.1 (-8.8 to 0.8)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.3 to 0.4)	69.7 (49.3 to 90.1)	-6.5 (-15.0 to 1.3)
Foreign body in eyes	-	-	-	-	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	93.3 (74.1 to 117.7)	-1.2 (-10.0 to 8.1)
Foreign body in other body part	-	-	-	-	0.5 (0.4 to 0.7)	1.0 (0.8 to 1.3)	89.9 (77.7 to 104.0)	-4.1 (-10.6 to 2.7)
Other unintentional injuries	-	-	-	-	6.7 (5.0 to 8.7)	10.2 (7.7 to 13.5)	52.9 (39.2 to 67.6)	-20.0 (-26.6 to -13.1)
Self-harm and interpersonal violence	-	-	-	-	4.8 (3.6 to 6.1)	8.5 (6.4 to 11.0)	77.5 (68.6 to 86.5)	-4.3 (-9.0 to 0.1)
Self-harm	-	-	-	-	0.5 (0.3 to 0.6)	0.9 (0.7 to 1.1)	87.2 (71.1 to 101.9)	-4.5 (-11.7 to 2.1)
Interpersonal violence	-	-	-	-	4.3 (3.3 to 5.5)	7.6 (5.7 to 9.8)	76.6 (67.1 to 85.8)	-4.6 (-9.1 to 0.2)
Assault by firearm	-	-	-	-	0.8 (0.6 to 1.0)	1.5 (1.1 to 1.9)	86.5 (75.1 to 99.4)	0.7 (-5.7 to 7.3)
Assault by sharp object	-	-	-	-	0.6 (0.5 to 0.8)	1.3 (1.0 to 1.7)	103.9 (91.7 to 119.7)	7.5 (1.2 to 15.6)
Assault by other means	-	-	-	-	2.9 (2.2 to 3.7)	4.8 (3.7 to 6.2)	67.7 (56.8 to 78.7)	-8.8 (-14.5 to -3.4)
Forces of nature, war, and legal intervention	-	-	-	-	0.6 (0.3 to 1.1)	0.1 (0.0 to 0.2)	-82.4 (-92.3 to -58.8)	-87.2 (-94.4 to -70.4)
Exposure to forces of nature	-	-	-	-	0.6 (0.3 to 1.1)	0.1 (0.0 to 0.1)	-90.1 (-95.7 to -78.6)	-92.6 (-96.7 to -84.2)
Collective violence and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.1)	-	-

Appendix Table G.4 - Thailand prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	4,846.7 (3,548.7 to 6,333.8)	6,756.0 (5,005.2 to 8,785.7)	39.4 (34.8 to 44.0)	4.3 (-6.9 to 1.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	798.0 (552.1 to 1,125.8)	669.8 (446.8 to 930.1)	-16.2 (-25.6 to -4.2)	-26.8 (-33.4 to -18.8)
HIV/AIDS and tuberculosis	-	-	-	-	51.4 (35.0 to 69.4)	95.9 (64.5 to 137.8)	86.7 (59.7 to 115.3)	12.7 (-2.8 to 30.5)
Tuberculosis	109.0 (103.4 to 115.2)	207.7 (195.5 to 221.1)	90.2 (81.1 to 100.7)	6.6 (1.7 to 12.2)	33.4 (22.9 to 44.8)	62.9 (42.6 to 84.7)	88.5 (75.3 to 101.4)	6.5 (-0.5 to 13.2)
HIV/AIDS	-	-	-	-	17.9 (11.2 to 27.8)	32.5 (17.3 to 62.5)	83.5 (11.7 to 153.2)	28.1 (22.5 to 75.5)
HIV/AIDS resulting in mycobacterial infection	1.7 (0.9 to 2.7)	3.0 (0.9 to 6.7)	76.0 (-30.6 to 189.1)	3.1 (-60.0 to 67.0)	0.7 (0.3 to 1.2)	1.1 (0.3 to 2.7)	71.9 (-37.4 to 213.3)	1.5 (-64.5 to 77.2)
HIV/AIDS resulting in other diseases	217.8 (160.7 to 306.4)	341.5 (245.7 to 452.8)	57.9 (15.3 to 102.1)	12.8 (-18.7 to 44.0)	17.3 (10.7 to 26.9)	31.8 (16.3 to 60.9)	83.3 (8.9 to 156.1)	29.0 (23.6 to 78.7)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	74.8 (52.1 to 102.7)	70.1 (48.7 to 96.5)	-6.2 (-13.4 to 1.6)	-9.9 (-16.8 to -2.6)
Diarrheal diseases	189.0 (172.0 to 205.7)	163.6 (143.8 to 183.9)	-13.4 (-26.2 to 0.9)	-8.1 (-21.2 to 6.5)	30.7 (20.6 to 43.0)	26.3 (17.9 to 36.4)	-14.2 (-27.4 to 0.3)	-7.6 (-22.0 to 7.6)
Intestinal infectious diseases	-	-	-	-	2.2 (1.3 to 3.4)	1.3 (0.8 to 2.0)	-39.4 (-59.3 to -2.3)	-37.6 (-57.6 to 0.1)
Typhoid fever	12.6 (8.6 to 17.5)	8.2 (6.3 to 10.4)	-35.1 (-57.1 to 3.8)	-34.0 (-54.7 to 5.8)	1.7 (1.0 to 2.6)	1.1 (0.7 to 1.7)	-34.7 (-56.9 to 9.7)	-33.3 (-56.0 to 9.0)
Paratyphoid fever	7.8 (5.2 to 10.4)	3.9 (3.2 to 5.1)	-49.6 (-65.1 to -20.9)	0.4 (-63.0 to -15.1)	0.2 (0.2 to 0.7)	0.2 (0.1 to 0.3)	-49.2 (-66.6 to -17.4)	-45.3 (-64.2 to -12.3)
Other intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.3)	0.0 (0.0 to 0.1)	-76.6 (-91.6 to -39.3)	-76.0 (-91.4 to -38.5)
Lower respiratory infections	22.5 (12.3 to 34.5)	38.7 (29.3 to 48.8)	71.6 (2.5 to 182.8)	23.5 (23.2 to 96.2)	2.4 (1.1 to 4.1)	3.9 (2.4 to 5.7)	67.4 (-1.7 to 187.1)	22.2 (-2.2 to 96.5)
Upper respiratory infections	1,210.4 (1,153.2 to 1,267.6)	1,342.7 (1,273.5 to 1,414.1)	10.9 (2.7 to 19.0)	-0.1 (-7.8 to 6.7)	14.3 (8.0 to 23.9)	15.8 (8.9 to 26.2)	10.4 (1.9 to 19.4)	-0.2 (-8.2 to 7.7)
Otitis media	728.3 (683.3 to 777.6)	640.1 (596.0 to 681.5)	-12.0 (-19.5 to -3.8)	-14.6 (-21.7 to -7.4)	14.5 (8.6 to 23.4)	12.7 (7.6 to 20.2)	-12.2 (-21.4 to -3.4)	-13.3 (-22.0 to -5.2)
Meningitis	-	-	-	-	4.6 (3.2 to 6.4)	4.5 (3.0 to 6.2)	-3.5 (-18.2 to 15.8)	-18.3 (-29.9 to -1.9)
Pneumococcal meningitis	15.8 (9.5 to 23.9)	17.9 (10.3 to 28.6)	12.1 (-10.4 to 46.3)	-18.6 (-34.5 to 5.6)	1.6 (1.1 to 2.1)	1.7 (1.2 to 2.5)	9.6 (-11.7 to 45.2)	11.8 (-29.1 to 16.3)
H influenzae type B meningitis	11.7 (4.2 to 23.1)	8.0 (2.6 to 17.6)	-32.2 (-56.8 to -10.3)	-43.9 (-61.2 to -24.9)	1.4 (0.8 to 2.0)	0.9 (0.6 to 1.5)	-30.6 (-55.1 to 9.9)	-35.2 (-57.4 to 2.2)
Meningococcal meningitis	1.3 (0.4 to 2.8)	1.7 (0.6 to 4.0)	28.9 (-20.3 to 89.5)	-12.8 (-44.4 to 30.8)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	35.5 (-0.1 to 88.2)	-4.3 (-28.3 to 38.5)
Other meningitis	12.5 (6.2 to 23.3)	12.6 (6.1 to 24.8)	-0.8 (-19.2 to 24.4)	-21.4 (-34.1 to 1.0)	1.6 (1.0 to 2.2)	1.6 (1.0 to 2.3)	0.2 (-17.0 to 46.1)	-14.9 (-28.7 to 23.2)
Encephalitis	18.2 (7.8 to 41.0)	18.0 (7.9 to 45.0)	-1.3 (-24.9 to 14.5)	-29.0 (-45.1 to -15.2)	2.3 (1.6 to 3.4)	2.4 (1.6 to 3.4)	5.6 (-11.6 to 27.4)	-20.1 (-32.8 to -3.8)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-50.4 (-94.1 to 514.6)	-52.9 (-94.3 to 417.7)	0.0 (0.0 to 0.0)	-50.4 (-94.3 to 531.6)	-52.9 (-94.3 to 420.4)
Whooping cough	13.4 (10.5 to 17.2)	0.6 (0.4 to 0.8)	-95.5 (-96.2 to -94.6)	-93.2 (-94.3 to -92.0)	0.7 (0.4 to 1.1)	0.0 (0.0 to 0.1)	-95.5 (-97.1 to -93.4)	-93.3 (-95.8 to -90.1)
Tetanus	2.4 (1.5 to 3.8)	0.1 (0.1 to 0.3)	-94.1 (-97.0 to -86.5)	-95.0 (-97.4 to -88.5)	0.3 (0.1 to 0.4)	0.0 (0.0 to 0.0)	-93.0 (-96.9 to -81.9)	-93.9 (-97.4 to -83.4)
Measles	7.9 (6.1 to 9.9)	0.4 (0.2 to 0.5)	-95.6 (-97.2 to -93.0)	-95.5 (-95.8 to -89.7)	0.7 (0.4 to 1.1)	0.0 (0.0 to 0.1)	-95.5 (-97.2 to -92.4)	-94.4 (-95.9 to -88.8)
Varicella and herpes zoster	56.8 (51.8 to 62.4)	70.8 (62.8 to 80.1)	24.5 (5.9 to 47.5)	-0.7 (-14.9 to 17.2)	2.1 (1.2 to 3.1)	3.1 (1.9 to 4.8)	49.7 (18.5 to 91.1)	-0.7 (-20.8 to 25.2)
Neglected tropical diseases and malaria	-	-	-	-	237.7 (147.0 to 360.1)	245.9 (135.2 to 391.2)	2.0 (-21.4 to 34.8)	-24.9 (-38.9 to -6.1)
Malaria	1,036.1 (968.7 to 1,104.3)	1,126.8 (1,043.9 to 1,221.3)	8.7 (2.4 to 17.4)	-6.2 (-11.3 to 0.9)	10.2 (6.6 to 15.0)	11.2 (7.2 to 16.6)	9.9 (-5.5 to 29.6)	10.7 (-3.7 to 30.5)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.3 (-7.9 to 37.4)	1.6 (-19.2 to 23.2)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.1 (-63.1 to 10.0)	-24.7 (-54.3 to 44.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.1 (-63.3 to 10.1)	-24.7 (-54.4 to 45.6)
Cutaneous and mucocutaneous leishmaniasis	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	0.0 (-7.4 to 37.7)	14.7 (-19.1 to 23.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.7 (-7.6 to 37.9)	1.7 (-19.2 to 23.7)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	53.9 (33.4 to 82.5)	7.5 (3.4 to 14.8)	-86.7 (-94.0 to -69.6)	-91.1 (-95.9 to -79.9)	15.6 (8.3 to 24.7)	2.4 (1.0 to 5.1)	-85.8 (-93.8 to -65.4)	-90.3 (-95.8 to -76.8)
Cystic echinococcosis	11.7 (10.3 to 13.4)	11.8 (10.7 to 13.7)	1.6 (-16.5 to 32.8)	-24.2 (-37.8 to -0.3)	1.1 (0.7 to 1.6)	1.1 (0.7 to 1.6)	-0.2 (-25.0 to 41.1)	-25.0 (-43.1 to 5.0)
Lymphatic filariasis	3.0 (2.0 to 4.7)	0.3 (0.2 to 0.6)	-89.9 (-94.6 to -84.7)	-93.8 (-96.7 to -90.8)	0.2 (0.0 to 0.4)	0.0 (0.0 to 0.1)	-77.4 (-91.1 to -61.3)	-87.6 (-95.1 to -78.8)
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	17.4 (6.5 to 39.1)	100.6 (37.7 to 226.0)	477.5 (476.0 to 479.3)	402.4 (401.1 to 404.0)	2.8 (0.9 to 6.9)	16.3 (5.4 to 40.4)	473.6 (390.5 to 572.0)	404.6 (338.8 to 482.7)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-93.0 (-94.6 to -64.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-93.0 (-94.6 to -64.0)	94.7 (-95.9 to -72.9)
Intestinal nematode infections	-	-	-	-	107.4 (61.4 to 173.7)	56.9 (31.0 to 101.6)	-47.9 (-65.3 to -20.6)	-53.2 (-68.6 to -31.2)
Ascariasis	3,739.7 (2,661.9 to 5,231.5)	3,362.5 (2,140.0 to 5,095.7)	-11.5 (-47.8 to 52.2)	-26.2 (-56.0 to 25.9)	7.4 (3.5 to 14.2)	0.6 (0.2 to 1.3)	-92.0 (-95.8 to -84.1)	91.6 (95.4 to -83.9)
Trichuriasis	5,819.5 (4,010.8 to 8,319.5)	2,080.8 (1,276.7 to 3,250.3)	-64.4 (-80.2 to -37.2)	-70.7 (-83.4 to -48.7)	3.7 (1.8 to 6.7)	0.1 (0.0 to 0.3)	-97.5 (-98.9 to -94.0)	-98.0 (-99.1 to -95.3)
Hookworm disease	16,531.5 (12,918.2 to 20,823.9)	11,262.0 (8,231.4 to 15,120.6)	-32.3 (-52.7 to -0.3)	-36.4 (-61.0 to -9.5)	96.2 (55.7 to 151.1)	36.2 (30.5 to 100.5)	-62.8 (-82.4 to -10.5)	-49.0 (-66.3 to -23.8)
Food-borne trematodiasis	3,506.7 (2,730.3 to 4,394.8)	5,743.7 (4,393.2 to 7,295.4)	64.0 (28.8 to 106.9)	1.5 (-19.9 to 27.8)	84.6 (19.9 to 149.1)	149.7 (67.5 to 260.9)	77.3 (62.1 to 135.2)	1.8 (-20.0 to 28.7)
Other neglected tropical diseases	488.3 (403.1 to 598.1)	272.7 (222.4 to 401.6)	-45.2 (-58.7 to -18.7)	-33.7 (-49.3 to 0.2)	15.9 (9.8 to 23.4)	8.2 (4.8 to 14.5)	-49.4 (-64.7 to -3.1)	-33.7 (-54.0 to 25.7)
Maternal disorders	-	-	-	-	3.1 (2.1 to 4.5)	2.6 (1.5 to 3.8)	-16.3 (-43.7 to 4.4)	-15.1 (-41.7 to 5.8)
Maternal hemorrhage	59.5 (55.8 to 63.7)	63.6 (47.0 to 79.6)	6.9 (-20.6 to 30.7)	8.4 (-19.3 to 32.8)	2.2 (1.5 to 3.2)	1.9 (1.1 to 2.8)	-13.0 (-47.2 to 11.8)	-10.6 (-44.6 to 14.0)
Maternal sepsis and other maternal infections	18.4 (12.0 to 26.2)	11.5 (7.1 to 18.8)	-38.1 (-55.4 to -22.5)	-54.7 (-67.4 to -42.4)	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.2)	-50.1 (-70.7 to -21.8)	-55.7 (-73.9 to -31.9)
Maternal hypertensive disorders	6.3 (2.8 to 11.1)	4.3 (2.1 to 7.2)	-32.0 (-39.1 to -15.4)	-30.9 (-36.2 to -19.5)	0.3 (0.1 to 0.6)	0.2 (0.1 to 0.4)	-31.5 (-50.3 to 0.8)	-30.4 (-49.3 to -3.6)
Obstructed labor	0.4 (0.2 to 0.7)	0.2 (0.1 to 0.3)	-58.4 (-82.7 to 1.5)	-58.9 (-83.1 to 0.2)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-58.4 (-82.7 to 1.8)	-58.9 (-83.2 to 0.7)
Complications of abortion	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-	-18.7 (-51.9 to 38.6)	-20.8 (-51.9 to 38.6)	0.0 (0.0 to 0.0)	-18.7 (-51.2 to 47.1)	-20.8 (-51.9 to 39.4)
Other maternal disorders	-	-	-	-	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.5)	32.4 (-48.1 to 161.3)	34.4 (-45.8 to 170.6)
Neonatal disorders	-	-	-	-	66.8 (45.6 to 94.4)	81.2 (56.9 to 109.2)	24.0 (9.3 to 54.6)	18.1 (-13.2 to 46.6)
Preterm birth complications	223.3 (166.9 to 301.5)	416.8 (314.3 to 548.8)	87.1 (52.0 to 124.6)	67.0 (35.3 to 101.5)	28.4 (18.8 to 39.9)	50.6 (35.2 to 68.3)	79.0 (33.5 to 133.8)	67.3 (24.3 to 118.2)
Neonatal encephalopathy due to birth asphyxia and trauma	17.6 (8.0 to 329.6)	94.3 (43.9 to 190.4)	47.2 (-66.8 to -17.2)	-52.1 (-70.1 to -34.8)	21.7 (14.0 to 31.2)	13.8 (9.3 to 19.3)	-36.0 (-55.8 to -9.6)	-36.2 (-55.5 to -7.3)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	45.9 (21.4 to 95.5)	129.0 (90.5 to 150.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.5 (22.5 to 74.0)	46.3 (92.2 to 173.0)
Hemolytic disease and other neonatal jaundice	26.6 (10.7 to 69.5)	23.3 (10.0 to 48.0)	-12.8 (-73.4 to 113.8)	-3.3 (-75.2 to 98.4)	9.3 (3.6 to 24.8)	9.2 (3.9 to 19.2)	11.2 (-67.4 to 142.1)	4.2 (-69.5 to 123.3)
Other neonatal disorders	-	-	-	-	7.4 (4.3 to 12.0)	7.6 (4.4 to 13.3)	-3.3 (-38.1 to 95.1)	-6.6 (-41.2 to 86.5)
Nutritional deficiencies	-	-	-	-	328.9 (215.0 to 490.9)	140.4 (89.7 to 202.0)	-57.0 (-65.6 to -49.1)	-51.4 (-60.7 to -41.4)
Protein-energy malnutrition	148.1 (100.3 to 210.9)	63.5 (34.8 to 104.3)	-57.8 (-79.0 to -21.2)	-36.2 (-68.2 to 19.1)	18.7 (10.4 to 30.8)	8.0 (3.7 to 14.5)	-57.5 (-79.3 to -20.1)	-35.7 (-68.7 to 20.8)
Iodine deficiency	1,399.6 (1,111.1 to 1,827.6)	1,025.6 (767.1 to 1,321.1)	-26.1 (-51.4 to 2.8)	-42.8 (-62.8 to -20.6)	25.3 (14.5 to 43.6)	18.4 (10.5 to 30.3)	-26.6 (-51.9 to 2.9)	-42.9 (-63.0 to -20.1)
Vitamin A deficiency	7.2 (4.6 to 9.9)	4.8 (3.1 to 6.7)	-34.4 (-46.6 to -15.6)	-40.8 (-52.3 to -25.8)	0.4 (0.2 to 0.7)	0.3 (0.2 to 0.5)	-31.4 (-47.0 to -10.0)	-31.0 (-59.9 to -31.2)

Appendix Table G.4 - Thailand prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	8 223.7 (7,859.4 to 8,471.0)	4 502.5 (4,017.8 to 4,793.8)	-45.2 (-51.5 to -40.9)	-53.9 (-51.0 to -39.6)	240.4 (160.2 to 353.8)	110.0 (67.9 to 161.6)	54.1 (-5.2 to -48.2)	51.1 (-59.5 to -39.0)
Other nutritional deficiencies	-	-	-	-	44.2 (10.3 to 94.3)	3.7 (1.2 to 11.6)	-93.5 (-97.5 to -48.1)	-90.2 (-96.3 to -22.0)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	35.3 (21.8 to 54.5)	33.7 (20.3 to 52.6)	-5.2 (-15.0 to 10.4)	-11.7 (-20.8 to 6.2)
Sexually transmitted diseases excluding HIV	-	-	-	-	19.7 (11.0 to 31.9)	22.6 (12.5 to 36.5)	14.4 (3.2 to 26.7)	0.0 (-9.4 to 10.2)
Syphilis	2.5 (2.2 to 2.8)	2.5 (2.1 to 2.8)	0.6 (-15.5 to 16.1)	-44.9 (-53.6 to -37.0)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.7)	44.7 (-59.3 to 38.2)	46.6 (-59.3 to -25.1)
Chlamydial infection	3 144.1 (2,701.4 to 3,621.7)	3 911.3 (3,069.9 to 4,622.4)	24.5 (-3.2 to 55.2)	14.2 (-12.1 to 44.7)	15.0 (8.2 to 24.7)	17.1 (9.4 to 27.9)	13.6 (1.9 to 27.5)	4.1 (-6.5 to 17.2)
Gonococcal infection	284.1 (172.4 to 405.8)	261.1 (193.8 to 335.0)	-8.8 (-43.7 to 55.7)	-8.0 (-43.2 to 54.8)	1.7 (0.9 to 2.9)	1.7 (0.9 to 2.9)	-1.4 (-33.2 to 63.4)	-3.3 (-34.7 to 57.5)
Trichomoniasis	242.3 (160.4 to 335.5)	295.9 (191.5 to 398.7)	25.8 (-31.2 to 100.6)	-3.6 (-47.6 to 55.0)	0.4 (0.1 to 0.9)	0.5 (0.2 to 1.1)	30.6 (-42.4 to 141.3)	0.5 (-56.6 to 87.1)
Genital herpes	7 042.3 (6,829.0 to 7,232.8)	10 947.3 (9,666.5 to 10,410.7)	42.8 (35.5 to 49.7)	8.6 (-13.1 to -4.1)	1.9 (0.6 to 4.6)	2.6 (0.8 to 6.3)	37.0 (22.2 to 47.3)	8.6 (-14.2 to -2.6)
Other sexually transmitted diseases	11.6 (8.4 to 15.8)	10.0 (7.8 to 13.2)	-13.4 (-27.3 to 1.6)	-37.7 (-47.7 to -26.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	5.5 (-29.7 to 66.4)	1.9 (-44.3 to 28.2)
Hepatitis	-	-	-	-	4.1 (2.6 to 6.0)	4.2 (2.6 to 6.2)	1.1 (-12.9 to 23.8)	-18.4 (-29.9 to -0.5)
Hepatitis A	72.9 (70.5 to 75.2)	59.9 (58.6 to 61.1)	-17.9 (-18.8 to -16.9)	-11.0 (-11.3 to -10.6)	1.8 (1.2 to 2.7)	1.8 (1.1 to 2.6)	-3.0 (-12.9 to 8.8)	-3.6 (-13.1 to 8.4)
Hepatitis B	4 064.4 (3,765.2 to 4,405.0)	3 394.8 (3,060.0 to 3,778.9)	-16.5 (-27.2 to -4.9)	-34.4 (-43.6 to -25.0)	1.7 (1.1 to 2.6)	2.0 (1.2 to 3.2)	10.3 (-18.0 to 67.9)	25.7 (-44.8 to 11.9)
Hepatitis C	1 930.0 (1,779.5 to 2,086.7)	2 102.0 (1,936.3 to 2,268.6)	8.8 (-2.0 to 21.8)	-27.9 (-34.9 to -19.4)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	14.7 (-11.0 to 58.4)	23.7 (-45.6 to 4.9)
Hepatitis E	10.5 (8.7 to 12.2)	6.5 (5.5 to 7.6)	-37.8 (-51.2 to -21.8)	-44.3 (-55.9 to -30.8)	0.3 (0.2 to 0.5)	0.3 (0.1 to 0.3)	-37.7 (-57.2 to -10.0)	-45.2 (-62.2 to -22.6)
Leprosy	2.7 (2.0 to 3.5)	3.3 (2.8 to 3.9)	25.4 (10.4 to 45.1)	-35.2 (-42.8 to -25.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	26.9 (5.1 to 73.6)	-34.7 (-50.1 to -13.1)
Other infectious diseases	361.5 (300.0 to 435.1)	206.2 (173.1 to 294.4)	-44.1 (-54.0 to -17.2)	-35.9 (-48.2 to -1.9)	11.3 (7.0 to 16.6)	6.8 (4.2 to 11.5)	-41.3 (-57.1 to 3.3)	-28.6 (-48.8 to 30.5)
Non-communicable diseases	-	-	-	-	3 894.4 (2,882.0 to 5,019.3)	5 902.4 (4,383.6 to 7,647.8)	51.6 (46.0 to 57.2)	0.6 (-2.2 to 3.7)
Neoplasms	-	-	-	-	26.2 (19.1 to 34.8)	72.3 (51.3 to 97.6)	175.1 (133.4 to 220.1)	34.3 (15.2 to 56.5)
Esophageal cancer	1.2 (0.9 to 1.7)	3.9 (2.6 to 5.4)	223.6 (96.8 to 414.0)	29.6 (-16.9 to 102.1)	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.9)	204.0 (91.1 to 376.7)	22.6 (-20.6 to 87.6)
Stomach cancer	5.5 (4.9 to 6.2)	17.1 (13.8 to 20.7)	207.0 (143.9 to 287.5)	33.7 (7.3 to 68.2)	0.7 (0.5 to 0.9)	2.0 (1.3 to 2.7)	177.1 (114.9 to 254.1)	20.1 (-6.3 to 54.1)
Liver cancer	-	-	-	-	2.0 (1.4 to 2.7)	5.4 (3.6 to 7.6)	163.0 (95.9 to 253.2)	38.0 (-11.9 to 56.9)
Liver cancer due to hepatitis B	5.5 (4.0 to 7.3)	18.9 (11.4 to 28.0)	235.9 (101.5 to 459.1)	54.2 (7.3 to 154.1)	0.9 (0.6 to 1.3)	2.6 (1.4 to 4.0)	181.8 (81.8 to 349.2)	29.6 (-16.3 to 106.7)
Liver cancer due to hepatitis C	1.8 (1.3 to 2.5)	12.1 (6.4 to 20.1)	549.4 (233.1 to 1,182.8)	177.1 (43.0 to 445.9)	0.3 (0.2 to 0.4)	1.7 (0.9 to 2.9)	425.5 (190.3 to 904.2)	124.7 (21.8 to 324.5)
Liver cancer due to alcohol use	2.6 (1.7 to 3.7)	4.4 (2.3 to 7.9)	67.6 (-17.1 to 239.9)	-28.0 (-63.6 to 40.7)	0.4 (0.3 to 0.6)	0.6 (0.3 to 1.2)	42.6 (-25.4 to 181.5)	-38.3 (-67.3 to 20.4)
Liver cancer due to other causes	2.4 (1.6 to 3.5)	3.7 (2.2 to 5.7)	48.7 (-17.5 to 166.1)	-31.3 (-63.0 to 24.3)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.9)	30.4 (-23.4 to 119.8)	40.0 (-65.2 to 2.0)
Larynx cancer	4.6 (3.1 to 5.5)	10.0 (6.6 to 13.3)	114.3 (56.5 to 185.3)	-1.3 (-27.4 to 30.4)	0.4 (0.3 to 0.6)	0.9 (0.5 to 1.4)	116.0 (55.4 to 194.8)	-0.4 (-30.5 to 34.0)
Tracheal, bronchus and lung cancer	16.7 (14.8 to 18.7)	41.6 (33.8 to 51.5)	147.9 (98.2 to 217.0)	13.1 (-9.4 to 45.5)	2.6 (1.8 to 3.4)	6.1 (4.2 to 8.3)	134.6 (85.1 to 200.2)	7.6 (-14.3 to 37.1)
Breast cancer	51.5 (41.8 to 59.2)	195.7 (159.3 to 230.0)	281.4 (207.0 to 384.6)	101.0 (62.7 to 151.8)	3.9 (2.6 to 5.3)	11.8 (7.6 to 16.8)	203.3 (129.7 to 289.2)	56.9 (20.4 to 100.9)
Cervical cancer	20.9 (15.1 to 39.9)	55.8 (36.8 to 74.8)	189.9 (18.9 to 308.3)	1.6 (-38.8 to 109.6)	1.6 (1.0 to 3.1)	4.2 (2.5 to 6.3)	19.7 (9.0 to 32.1)	51.6 (-38.4 to 114.8)
Uterine cancer	16.9 (5.6 to 24.6)	21.0 (12.3 to 30.0)	20.2 (-28.9 to 207.6)	45.3 (66.4 to 46.1)	1.1 (0.3 to 1.9)	1.4 (0.7 to 2.3)	19.4 (-20.1 to 218.3)	45.8 (-67.4 to 50.1)
Prostate cancer	9.8 (6.3 to 12.4)	61.1 (31.9 to 87.2)	517.0 (311.3 to 748.3)	142.6 (63.4 to 234.8)	0.9 (0.5 to 1.2)	5.4 (2.6 to 8.5)	522.7 (322.7 to 753.0)	140.9 (63.6 to 232.3)
Colon and rectum cancer	31.4 (28.6 to 34.3)	92.4 (77.8 to 109.1)	192.7 (143.2 to 257.8)	32.5 (10.3 to 61.2)	2.8 (2.0 to 3.6)	7.6 (5.3 to 10.3)	172.8 (124.0 to 234.3)	22.7 (0.8 to 50.9)
Lip and oral cavity cancer	12.4 (9.8 to 15.8)	35.6 (24.9 to 48.0)	186.9 (101.9 to 305.3)	28.4 (-10.5 to 86.2)	1.1 (0.8 to 1.5)	3.1 (1.9 to 4.6)	18.6 (95.1 to 297.8)	25.7 (-13.3 to 79.3)
Nasopharynx cancer	3.2 (2.5 to 4.2)	7.7 (5.3 to 10.9)	134.4 (54.1 to 256.8)	27.6 (-16.4 to 92.3)	0.7 (0.2 to 0.5)	0.6 (0.5 to 1.1)	13.3 (56.9 to 246.3)	24.6 (-14.9 to 85.0)
Other pharynx cancer	3.9 (2.8 to 5.2)	8.3 (5.6 to 11.9)	110.8 (31.0 to 227.7)	-0.2 (-37.6 to 54.2)	0.4 (0.2 to 0.5)	0.7 (0.5 to 1.2)	104.0 (32.6 to 209.3)	-4.6 (-38.7 to 44.7)
Gallbladder and biliary tract cancer	1.6 (1.3 to 2.2)	4.7 (3.1 to 6.5)	204.0 (70.1 to 347.1)	31.2 (-25.1 to 93.5)	0.4 (0.3 to 0.6)	1.1 (0.6 to 1.8)	172.4 (51.5 to 316.2)	18.8 (-32.6 to 78.9)
Pancreatic cancer	1.3 (1.1 to 1.5)	3.5 (2.7 to 4.3)	164.8 (106.8 to 244.2)	15.4 (-10.8 to 49.6)	0.3 (0.2 to 0.4)	0.7 (0.4 to 0.9)	145.5 (97.6 to 207.9)	7.0 (-14.6 to 35.1)
Malignant skin melanoma	5.2 (5.2 to 9.4)	9.4 (6.4 to 12.4)	80.4 (-13.1 to 83.1)	19.8 (-49.7 to 5.4)	0.6 (0.3 to 0.9)	0.6 (0.3 to 0.9)	17.8 (-16.7 to 88.7)	32.6 (-51.8 to 6.8)
Non-melanoma skin cancer	5.1 (3.3 to 7.7)	29.6 (20.6 to 39.6)	506.4 (234.8 to 896.1)	161.1 (37.9 to 327.8)	0.2 (0.1 to 0.4)	1.5 (0.8 to 2.4)	718.2 (244.5 to 1,455.1)	240.3 (39.9 to 564.0)
Ovarian cancer	5.8 (4.8 to 7.0)	14.9 (10.3 to 20.4)	154.8 (78.2 to 265.0)	38.6 (-1.9 to 97.7)	0.7 (0.5 to 1.0)	2.9 (1.1 to 2.8)	151.5 (65.6 to 274.0)	36.4 (9.3 to 106.1)
Testicular cancer	2.2 (1.4 to 3.1)	4.8 (2.7 to 8.4)	110.0 (8.4 to 304.9)	40.9 (-29.2 to 174.2)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.6)	103.4 (-6.0 to 314.2)	34.4 (-33.8 to 169.5)
Kidney cancer	5.4 (5.3 to 7.3)	17.6 (10.8 to 17.9)	223.4 (63.3 to 195.7)	34.0 (-14.7 to 52.2)	0.5 (0.3 to 0.7)	1.0 (0.7 to 1.5)	112.7 (59.7 to 191.6)	9.1 (-17.9 to 48.6)
Bladder cancer	5.4 (4.2 to 6.5)	17.6 (13.2 to 23.2)	223.4 (135.8 to 358.9)	34.0 (-3.3 to 92.6)	0.5 (0.3 to 0.6)	1.4 (0.9 to 2.1)	197.0 (115.9 to 329.2)	22.9 (-11.4 to 81.0)
Brain and nervous system cancer	5.4 (4.0 to 6.4)	11.9 (8.6 to 14.8)	118.9 (74.8 to 172.9)	36.1 (9.3 to 71.5)	0.6 (0.4 to 0.8)	1.3 (0.8 to 1.8)	111.8 (68.0 to 166.1)	26.9 (0.1 to 63.4)
Thyroid cancer	12.3 (8.2 to 15.4)	31.4 (20.4 to 42.4)	155.1 (81.3 to 257.7)	44.8 (2.2 to 100.8)	0.7 (0.4 to 1.1)	1.9 (1.1 to 2.9)	155.4 (80.7 to 254.8)	41.5 (0.9 to 93.3)
Mesothelioma	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-44.0 (-35.0 to 15.7)	60.2 (-70.0 to -47.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.0 (-34.5 to 16.7)	59.9 (-69.7 to -46.4)
Hodgkin lymphoma	2.6 (1.5 to 3.4)	3.7 (2.6 to 5.1)	39.2 (-4.8 to 146.2)	3.3 (-29.9 to 80.7)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	40.3 (-3.9 to 136.0)	-0.8 (-31.2 to 65.7)
Non-Hodgkin lymphoma	13.4 (9.0 to 16.1)	33.9 (25.1 to 44.2)	152.7 (88.6 to 255.9)	40.4 (6.1 to 95.5)	1.0 (0.6 to 1.5)	2.5 (1.6 to 3.6)	143.3 (78.1 to 249.3)	32.5 (-1.2 to 86.7)
Multiple myeloma	0.5 (0.4 to 0.7)	1.5 (1.1 to 2.0)	180.6 (101.5 to 306.8)	37.5 (0.0 to 98.4)	0.1 (0.1 to 0.2)	0.5 (0.2 to 0.5)	172.5 (99.6 to 277.0)	31.8 (-2.7 to 82.4)
Leukemia	9.3 (7.1 to 11.4)	28.2 (19.5 to 39.2)	161.7 (97.3 to 243.6)	88.1 (29.0 to 117.0)	1.2 (0.8 to 1.6)	3.0 (2.0 to 4.1)	153.4 (96.9 to 224.6)	44.8 (11.6 to 86.2)
Other neoplasms	15.5 (12.5 to 19.4)	65.0 (48.9 to 85.1)	314.7 (219.4 to 446.4)	145.9 (87.7 to 226.1)	1.2 (0.8 to 1.6)	4.5 (2.9 to 6.6)	286.1 (196.0 to 404.5)	117.8 (66.6 to 185.7)
Cardiovascular diseases	-	-	-	-	130.2 (90.3 to 175.4)	299.9 (205.7 to 413.0)	131.1 (86.7 to 178.0)	14.5 (-5.2 to 36.4)
Rheumatic heart disease	745.5 (599.5 to 952.2)	1 113.7 (877.4 to 1 326.3)	48.9 (7.6 to 103.8)	1.2 (-25.6 to 34.4)	38.2 (23.5 to 57.1)	59.4 (37.6 to 88.5)	54.7 (12.9 to 109.1)	1.9 (-23.8 to 33.7)
Ischemic heart disease	422.8 (346.4 to 508.1)	786.1 (639.8 to 979.6)	83.8 (44.6 to 144.8)	-25.0 (-40.8 to -0.7)	29.6 (19.1 to 41.8)	55.3 (37.7 to 79.3)	85.2 (49.1 to 144.0)	23.6 (-38.9 to 0.5)
Cerebrovascular disease	-	-	-	-	16.4 (11.5 to 21.5)	37.8 (26.6 to 50.0)	131.1 (89.5 to 176.1)	2.5 (-16.2 to 23.3)
Ischemic stroke	50.9 (44.0 to 57.4)	124.6 (105.6 to 145.5)	145.8 (96.3 to 196.8)	3.6 (-17.2 to 26.7)	7.7 (5.3 to 10.4)	18.5 (12.7 to 25.6)	143.1 (91.6 to 198.3)	3.5 (-18.2 to 27.6)
Hemorrhagic stroke	57.7 (50.0 to 65.7)	128.8 (111.1 to 145.9)	123.8 (83.8 to 169.1)	1.9 (-16.2 to 24.1)	8.7 (5.9 to 12.0)	19.3 (13.2 to 26.4)	120.2 (81.1 to 166.9)	1.2 (-16.6 to 23.2)
Hypertensive heart disease	80.9 (70.9 to 92.7)	193.2 (165.3 to 220.6)	138.6 (97.1 to 192.2)	0.6 (-1.2 to 24.0)	9.1 (6.4 to 12.7)	21.7 (14.4 to 30.8)	137.7 (95.4 to 194.8)	0.6 (-17.4 to 24.5)
Cardiomyopathy and myocarditis	12.0 (7.2 to 21.3)	38.0 (24.9 to 57.9)	230.5 (85.3 to 484.4)	51.1 (-25.5 to 179.9)	1.0 (0.5 to 1.9)	3.0 (1.6 to 5.1)	218.2 (76.1 to 496.1)	47.4 (-26.4 to 182.8)
Peripheral vascular disease	1 469.7 (1,175.3 to 1,757.8)	3 417.1 (2,818.3 to 4,037.6)	131.7 (80.3 to 211.8)	-1.7 (-22.6 to 28.7)	0.7 (0.3 to 1.4)	1.8 (0.7 to 3.7)	132.8 (24.7 to 428.5)	-14.0 (-54.6 to 91.9)
Endocarditis	2.1 (1.0 to 4.1)	11.1 (4.9 to 17.1)	512.9 (38.8 to 1 538.4)	249.8 (-25.1 to 814.6)	0.2 (0.1 to 0.5)	1.2 (0.5 to 2.4)	537.2 (32.5 to 1 868.4)	260.5 (-30.1 to 1 014.1)
Other cardiovascular and circulatory diseases	418.3 (262.7 to 619.5)	1 549.7 (819.6 to 2 172.9)	279.2 (82.4 to 545.3)	102.0 (-1.7 to 256.9)	30.0 (16.4 to 50.2)	111.1 (52.2 to 174.9)	280.1 (82.6 to 540.9)	

Appendix Table G.4 - Thailand prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.4 (0.3 to 0.5)	1.0 (0.7 to 1.4)	180.3 (160.0 to 199.8)	39.7 (28.4 to 50.2)
Silicosis	0.4 (0.4 to 0.5)	0.8 (0.8 to 0.9)	91.5 (80.8 to 103.0)	-12.7 (-17.6 to -7.5)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	89.1 (74.7 to 100.8)	-14.3 (-20.6 to -8.6)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	0.5 (0.5 to 0.5)	0.9 (0.8 to 0.9)	67.4 (61.3 to 72.7)	-16.0 (-18.8 to -13.4)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	67.9 (59.6 to 74.7)	-15.9 (-19.7 to -12.7)
Other pneumoconiosis	1.1 (1.0 to 1.1)	4.1 (3.8 to 4.3)	278.7 (261.2 to 298.0)	0.2 (0.1 to 0.3)	0.7 (0.5 to 0.9)	0.7 (0.5 to 1.1)	271.1 (250.4 to 297.2)	34.0 (32.0 to 107.8)
Asthma	4,275.0 (3,840.3 to 4,736.5)	4,385.9 (3,886.5 to 4,903.5)	2.2 (-13.1 to 19.4)	-19.9 (-31.5 to -6.7)	190.7 (122.0 to 276.7)	193.2 (124.9 to 284.4)	0.8 (-14.4 to 18.2)	-20.3 (-31.2 to -6.8)
Interstitial lung disease and pulmonary sarcoidosis	4.2 (3.3 to 5.1)	8.0 (5.9 to 9.9)	91.2 (36.8 to 171.8)	3.4 (-27.7 to 43.7)	0.6 (0.3 to 0.8)	1.1 (0.6 to 1.7)	92.1 (36.6 to 169.9)	2.8 (-28.7 to 44.0)
Other chronic respiratory diseases	-	-	-	-	25.0 (14.3 to 39.5)	8.2 (5.0 to 13.1)	-67.0 (-76.0 to -53.6)	-82.5 (-87.2 to -75.8)
Cirrhosis	-	-	-	-	4.8 (3.3 to 6.7)	5.5 (3.8 to 7.7)	13.9 (1.0 to 30.0)	-32.2 (-40.3 to -24.8)
Cirrhosis due to hepatitis B	9.4 (7.9 to 11.1)	9.9 (7.3 to 12.8)	6.5 (-27.1 to 38.7)	-38.7 (-57.2 to -20.0)	1.6 (1.0 to 2.3)	1.6 (1.0 to 2.5)	4.9 (-30.8 to 48.3)	-38.9 (-59.4 to -15.4)
Cirrhosis due to hepatitis C	4.6 (3.2 to 6.4)	7.6 (4.8 to 10.2)	68.2 (-0.5 to 161.2)	-4.4 (-45.9 to 48.1)	0.8 (0.4 to 1.2)	1.3 (0.7 to 2.0)	65.4 (-5.8 to 172.8)	-5.3 (-48.3 to 54.0)
Cirrhosis due to alcohol use	10.7 (8.7 to 12.6)	10.9 (7.8 to 14.3)	-46.7 (-26.7 to 38.8)	1.8 (-61.5 to -26.2)	1.8 (1.1 to 2.6)	1.8 (1.1 to 2.8)	0.8 (-30.6 to 42.4)	46.6 (-63.1 to -24.2)
Cirrhosis due to other causes	4.1 (3.2 to 4.8)	4.6 (3.5 to 6.0)	12.5 (-17.2 to 57.8)	-9.4 (-32.2 to 26.4)	0.7 (0.4 to 1.1)	0.8 (0.5 to 1.2)	11.8 (-27.2 to 73.3)	-9.6 (-39.5 to 36.8)
Digestive diseases	-	-	-	-	56.6 (39.3 to 78.1)	85.4 (58.9 to 118.2)	52.0 (33.4 to 67.9)	-17.5 (-27.1 to -9.3)
Peptic ulcer disease	327.6 (288.2 to 365.4)	384.4 (336.0 to 428.7)	17.4 (4.1 to 32.1)	-50.4 (-55.6 to -45.2)	10.6 (7.1 to 15.1)	13.5 (9.0 to 19.5)	28.4 (8.2 to 49.7)	-45.4 (-52.1 to -36.9)
Gastritis and duodenitis	541.1 (507.4 to 572.2)	670.4 (611.3 to 730.6)	24.0 (13.5 to 34.4)	-33.3 (-38.6 to -28.0)	20.6 (13.8 to 29.5)	24.2 (16.2 to 34.4)	17.3 (3.3 to 32.7)	-28.6 (-35.6 to -19.3)
Appendicitis	4.5 (3.5 to 5.9)	4.0 (3.3 to 4.8)	-9.1 (-34.5 to 20.6)	-24.6 (-43.6 to -0.8)	1.4 (0.8 to 2.1)	1.3 (0.8 to 1.9)	-8.9 (-40.8 to 40.0)	-22.8 (-48.9 to 17.7)
Paralytic ileus and intestinal obstruction	0.8 (0.5 to 1.2)	0.8 (0.7 to 1.1)	18.2 (-37.3 to 72.3)	-12.7 (-51.5 to 22.7)	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.4)	15.7 (-41.6 to 80.5)	-12.7 (-54.8 to 33.3)
Inguinal, femoral, and abdominal hernia	114.3 (98.7 to 133.5)	209.0 (172.7 to 248.6)	82.7 (47.2 to 125.3)	-10.8 (-29.3 to 11.2)	1.2 (0.6 to 2.3)	2.2 (1.0 to 4.1)	81.0 (44.6 to 122.5)	-11.2 (-29.8 to 11.0)
Inflammatory bowel disease	10.6 (10.1 to 11.1)	14.7 (13.9 to 15.5)	38.1 (28.6 to 48.9)	-18.0 (-23.4 to -11.6)	2.3 (1.5 to 3.2)	3.1 (2.1 to 4.3)	36.6 (14.3 to 61.1)	-18.1 (-30.2 to -4.6)
Vascular intestinal disorders	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	102.2 (31.5 to 200.3)	-7.5 (-41.5 to 47.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	99.0 (24.4 to 212.8)	-7.0 (-46.1 to 60.4)
Gallbladder and biliary diseases	17.1 (15.3 to 19.2)	26.9 (24.3 to 29.5)	57.8 (35.0 to 82.4)	-17.7 (-31.9 to -12.1)	2.8 (1.2 to 2.6)	2.8 (1.9 to 3.9)	25.3 (70.5 to 84.4)	-22.2 (-33.9 to -10.1)
Pancreatitis	12.6 (11.9 to 13.3)	25.2 (24.0 to 26.5)	100.5 (86.1 to 116.9)	15.4 (6.9 to 24.9)	3.8 (2.5 to 5.2)	7.5 (5.1 to 10.3)	98.4 (70.0 to 131.2)	15.4 (0.5 to 32.7)
Other digestive diseases	-	-	-	-	14.6 (9.5 to 21.8)	30.4 (19.9 to 43.7)	117.0 (50.7 to 168.7)	17.8 (-12.1 to 44.9)
Neurological disorders	-	-	-	-	531.8 (351.6 to 747.8)	787.0 (516.6 to 1,103.5)	48.1 (25.7 to 74.9)	1.6 (-12.3 to 19.7)
Alzheimer disease and other dementias	209.7 (171.7 to 249.7)	612.6 (527.1 to 714.4)	192.4 (123.7 to 279.9)	9.6 (-17.3 to 44.9)	30.4 (20.7 to 41.1)	90.5 (62.6 to 121.6)	197.6 (125.6 to 291.1)	30.0 (-17.7 to 46.7)
Parkinson disease	21.0 (18.8 to 23.4)	53.5 (47.8 to 59.1)	154.7 (141.8 to 167.7)	4.2 (-1.1 to 9.4)	2.6 (1.7 to 3.6)	6.5 (4.4 to 8.9)	152.5 (125.5 to 183.1)	3.9 (-6.2 to 15.6)
Epilepsy	258.1 (185.5 to 332.0)	303.8 (215.5 to 392.4)	17.8 (-21.5 to 71.9)	-0.2 (-33.5 to 45.9)	82.0 (49.0 to 119.8)	104.0 (60.9 to 152.8)	27.0 (-18.8 to 90.0)	8.9 (-30.3 to 62.6)
Multiple sclerosis	0.4 (0.4 to 0.4)	1.1 (1.1 to 1.2)	193.5 (160.8 to 228.5)	80.5 (62.2 to 102.5)	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.5)	193.5 (160.8 to 228.5)	80.5 (62.2 to 102.6)
Migraine	10,211.4 (8,489.1 to 11,704.3)	13,875.2 (11,659.7 to 16,460.0)	38.7 (10.5 to 69.9)	-11.0 (-17.0 to 28.2)	347.6 (206.4 to 526.2)	477.5 (284.2 to 736.6)	37.6 (19.8 to 69.6)	9.1 (-16.2 to 27.7)
Tension-type headache	13,011.7 (11,740.2 to 14,225.5)	17,403.4 (16,378.4 to 18,555.4)	33.9 (19.9 to 50.3)	0.3 (-9.6 to 12.3)	19.9 (9.7 to 34.7)	26.5 (18.0 to 46.6)	33.3 (18.8 to 50.5)	0.5 (-10.2 to 12.7)
Medication overuse headache	200.9 (137.1 to 264.8)	467.5 (315.8 to 617.7)	132.9 (101.1 to 165.4)	51.6 (32.1 to 71.8)	32.0 (18.2 to 49.7)	74.0 (41.8 to 113.2)	132.0 (97.7 to 165.6)	51.7 (30.6 to 73.6)
Other neurological disorders	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	40.5 (6.9 to 95.7)	3.5 (-22.0 to 39.8)	17.1 (9.7 to 25.3)	7.7 (5.1 to 11.2)	-56.1 (-70.2 to -15.5)	-83.4 (-88.9 to -68.4)
Mental and substance use disorders	-	-	-	-	1,084.1 (776.2 to 1,422.5)	1,999.4 (1,002.4 to 3,046.4)	29.4 (22.0 to 35.6)	-1.6 (-5.2 to 1.8)
Schizophrenia	199.9 (172.2 to 230.7)	300.0 (261.5 to 349.2)	50.1 (41.5 to 57.6)	0.6 (-5.2 to 5.9)	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.8)	49.3 (33.3 to 59.8)	0.8 (-5.9 to 7.6)
Alcohol use disorders	356.3 (318.9 to 395.6)	520.9 (476.1 to 570.4)	46.2 (36.3 to 57.9)	8.5 (1.8 to 15.1)	35.7 (23.6 to 51.5)	52.1 (34.9 to 75.4)	45.7 (33.7 to 60.4)	8.6 (0.3 to 17.4)
Drug use disorders	-	-	-	-	139.7 (92.3 to 196.1)	142.5 (95.8 to 195.7)	2.1 (-14.5 to 20.8)	-2.5 (-18.0 to 15.4)
Opioid use disorders	70.5 (58.8 to 83.2)	91.8 (75.6 to 107.2)	29.9 (19.4 to 43.4)	0.5 (-7.8 to 9.8)	29.8 (20.2 to 39.9)	38.7 (26.3 to 51.2)	30.0 (15.2 to 47.1)	0.8 (-10.5 to 13.2)
Cocaine use disorders	49.4 (45.4 to 53.0)	54.4 (50.7 to 58.1)	9.5 (-0.7 to 23.0)	6.9 (-10.3 to 11.0)	6.9 (4.4 to 9.7)	7.6 (4.9 to 11.0)	0.0 (-8.3 to 32.6)	-0.0 (-17.7 to 19.8)
Amphetamine use disorders	344.2 (303.1 to 389.1)	317.3 (270.6 to 366.1)	-7.5 (-24.1 to 10.1)	-4.0 (-22.0 to 14.1)	45.7 (28.4 to 67.1)	42.1 (25.5 to 62.2)	-8.0 (-25.3 to 12.6)	-4.0 (-22.5 to 17.2)
Cannabis use disorders	138.9 (94.7 to 177.9)	138.6 (102.5 to 171.4)	-0.5 (-5.5 to 10.3)	0.1 (-0.0 to 0.2)	4.1 (2.2 to 6.4)	4.0 (2.4 to 6.2)	-0.2 (-13.3 to 18.3)	0.4 (-12.5 to 13.8)
Other drug use disorders	-	-	-	-	53.2 (31.5 to 81.4)	50.1 (30.7 to 75.9)	-6.6 (-32.2 to 30.5)	-3.7 (-30.7 to 33.9)
Depressive disorders	-	-	-	-	68.6 (194.4 to 456.3)	77.7 (282.2 to 672.6)	13.4 (33.6 to 61.6)	0.4 (-8.0 to 7.7)
Major depressive disorder	1,167.8 (766.8 to 1,538.3)	1,682.2 (1,079.6 to 2,265.6)	43.9 (27.6 to 63.9)	-1.7 (-10.3 to 9.1)	242.3 (138.7 to 368.8)	346.0 (195.0 to 536.4)	42.6 (26.2 to 62.4)	-1.4 (-10.2 to 10.3)
Dysthymia	698.8 (599.1 to 796.1)	1,134.7 (987.1 to 1,281.4)	62.2 (54.4 to 71.5)	-0.1 (-0.2 to 0.0)	68.1 (44.5 to 98.4)	109.7 (72.0 to 157.1)	61.1 (52.4 to 71.1)	-0.1 (-2.4 to 2.3)
Bipolar disorder	354.0 (293.0 to 410.4)	489.3 (421.2 to 560.6)	38.2 (28.7 to 49.0)	-0.9 (-5.6 to 4.1)	73.1 (43.9 to 110.7)	100.3 (61.2 to 149.6)	37.3 (26.4 to 50.1)	-0.7 (-7.0 to 5.8)
Anxiety disorders	1,546.4 (648.9 to 2,461.9)	2,062.5 (1,015.5 to 3,147.1)	34.3 (10.2 to 68.7)	34.3 (-0.3 to 0.0)	310.4 (54.6 to 254.3)	455.8 (88.4 to 331.7)	46.5 (9.6 to 68.9)	1.1 (-3.0 to 3.0)
Eating disorders	-	-	-	-	6.7 (4.3 to 9.9)	61.1 (3.8 to 9.3)	-10.2 (-21.8 to 5.7)	-0.7 (-13.4 to 14.6)
Anorexia nervosa	16.5 (12.7 to 20.9)	14.5 (11.2 to 18.5)	-12.4 (-22.0 to -2.0)	-2.2 (-11.5 to 8.0)	3.5 (2.2 to 5.3)	3.1 (1.9 to 4.7)	-12.1 (-29.4 to 10.6)	-1.9 (-19.8 to 21.8)
Bulimia nervosa	15.1 (9.8 to 21.9)	13.9 (9.0 to 20.2)	-8.6 (-13.4 to -4.4)	-0.2 (-0.6 to 0.0)	3.2 (1.8 to 5.3)	3.0 (1.7 to 5.2)	-8.1 (-24.7 to 13.2)	0.1 (-17.3 to 21.3)
Autistic spectrum disorders	-	-	-	-	68.6 (47.9 to 92.0)	77.7 (53.7 to 105.8)	13.4 (9.4 to 17.3)	0.4 (-2.8 to 3.7)
Autism	174.7 (165.5 to 183.9)	199.6 (189.0 to 210.7)	14.2 (13.0 to 15.6)	0.2 (0.2 to 0.2)	43.5 (29.1 to 60.2)	49.4 (32.9 to 68.1)	13.4 (7.7 to 19.0)	0.4 (-4.2 to 5.1)
Asperger syndrome	248.9 (233.3 to 264.0)	283.0 (264.6 to 301.9)	13.7 (12.0 to 15.4)	0.2 (0.2 to 0.2)	25.1 (17.3 to 35.2)	28.3 (19.6 to 39.4)	13.1 (8.3 to 18.2)	0.5 (-3.3 to 4.3)
Attention-deficit/hyperactivity disorder	384.4 (354.0 to 410.1)	489.3 (262.3 to 305.2)	26.7 (-25.9 to 25.5)	-26.7 (-40.0 to -0.0)	47.9 (2.8 to 7.2)	35.3 (2.1 to 5.3)	-26.2 (-31.1 to -19.7)	0.1 (-7.3 to 8.1)
Conduct disorder	396.8 (373.7 to 420.4)	291.0 (273.8 to 308.5)	-26.7 (-26.8 to -26.5)	26.7 (-4.1 to -0.1)	47.9 (30.1 to 69.8)	35.3 (22.0 to 51.1)	-26.2 (-30.0 to -22.1)	0.1 (-4.6 to 6.2)
Idiopathic intellectual disability	1,108.8 (825.9 to 1,438.1)	865.3 (630.4 to 1,111.2)	-21.6 (-42.1 to 3.0)	-29.7 (-47.8 to -7.9)	42.4 (33.9 to 80.2)	42.4 (26.6 to 62.7)	-22.0 (-42.5 to 3.2)	-29.8 (-47.7 to -7.0)
Other mental and substance use disorders	896.2 (838.4 to 950.4)	1,298.3 (1,223.9 to 1,370.8)	44.9 (41.1 to 48.5)	0.0 (-0.1 to 0.1)	67.9 (45.7 to 90.8)	97.6 (65.6 to 131.4)	43.8 (37.2 to 50.8)	0.2 (-3.7 to 3.7)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	407.6 (282.9 to 560.8)	775.7 (536.9 to 1,057.0)	90.3 (72.8 to 109.6)	28.2 (17.5 to 39.8)
Diabetes mellitus	1,731.5 (1,537.8 to 1,913.9)	5,731.0 (4,898.3 to 6,742.9)	229.8 (179.2 to 299.1)	85.5 (56.5 to 122.9)	109.1 (73.8 to 154.3)	377.4 (245.5 to 535.2)	244.8 (184.8 to 319.6)	87.1 (55.1 to 125.2)
Acute glomerulonephritis	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-40.7 (-44.3 to -36.8)	-35.9 (-40.1 to -31.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.7 (-44.3 to -36.8)	-35.9 (-40.1 to -31.6)
Chronic kidney disease	-	-	-	-	71.7 (50.3 to 92.6)	111.7 (79.9 to 143.8)	56.0 (37.7 to 77.3)	-3.0 (-10.1 to 13.7)
Chronic kidney disease due to diabetes mellitus	263.2 (179.9 to 358.1)	803.1 (581.8 to 1,290.2)	206.6 (105.1 to 350.5)	62.6 (14.7 to 128.5)	6.8 (4.4 to 9.5)	19.7 (13.9 to 26.3)	191.0 (120.7 to 290.3)	55.1 (-19.7 to 111.2)
Chronic kidney disease due to hypertension	534.0 (327.8 to 811.3)	248.2 (203.2 to 300.8)	-52.2 (-69.6 to -26.7)	-60.4 (-72.2 to -45.3)	16.6 (11.3 to 22.1)	19.8 (14.2 to 26.7)	18.4 (-3.9 to 55.1)	-23.7 (-38.0 to -11.1)
Chronic kidney disease due to glomerulonephritis	742.1 (448.0 to 1,067.5)	745.1 (517.8 to 1,137.8)	-1.2 (-32.2 to 69.6)	-1.2 (-49.1 to 13.7)	9.2 (6.1 to 13.1)	9.2 (6.2 to 13.3)	3.8 (-68.9 to -40.3)	-68.2 (-76.2 to -55.5)
Chronic kidney disease due to other causes	1,891.5 (1,284.4 to 2,577.1)	2,985.4 (2,137.2 to 4,188.6)	57.8 (20.3 to 112.2)	15.2				

Appendix Table G.4 - Thailand prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	9.9 (9.4 to 10.5)	17.5 (16.6 to 18.5)	75.7 (63.4 to 90.6)	17.4 to 36.1	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	74.1 (39.9 to 124.6)	74.1 (3.0 to 55.7)
Urolithiasis	227.4 (123.6 to 320.1)	549.4 (380.2 to 759.0)	137.5 (91.0 to 265.1)	13.2 (8.3 to 66.5)	3.5 (2.3 to 5.0)	7.0 (4.4 to 9.9)	95.4 (71.6 to 128.7)	11.8 (-0.2 to 28.9)
Benign prostatic hyperplasia	463.7 (418.8 to 504.5)	1,181.7 (1,078.3 to 1,278.5)	155.4 (125.4 to 190.5)	4.7 (8.5 to 19.0)	16.9 (11.0 to 24.4)	43.0 (27.6 to 61.9)	154.3 (124.3 to 189.2)	4.6 (-8.3 to 18.9)
Male infertility due to other causes	346.5 (257.6 to 443.4)	376.1 (265.4 to 510.5)	7.6 (-28.3 to 69.7)	-1.1 (-35.2 to 50.5)	2.4 (1.0 to 5.2)	2.6 (1.0 to 7.2)	6.8 (-29.5 to 68.2)	-3.4 (-36.3 to 51.7)
Other urinary diseases	-	-	-	-	1.5 (0.7 to 3.1)	9.2 (4.5 to 14.7)	686.4 (127.8 to 1,066.1)	364.6 (36.6 to 578.5)
Gynecological diseases	-	-	-	-	67.7 (42.9 to 103.4)	83.9 (52.8 to 127.3)	23.3 (9.0 to 41.3)	-8.0 (-19.0 to 4.4)
Uterine fibroids	1,161.7 (1,057.1 to 1,274.4)	1,988.4 (1,825.6 to 2,160.5)	71.2 (68.2 to 74.4)	-0.9 (-1.0 to -0.9)	14.3 (8.1 to 24.1)	16.4 (8.2 to 30.2)	13.4 (7.2 to 29.8)	-30.0 (-41.4 to -20.9)
Polycystic ovarian syndrome	940.8 (823.4 to 1,071.9)	1,127.6 (959.6 to 1,276.5)	19.7 (-2.8 to 45.4)	-8.8 (-26.0 to 10.3)	9.3 (4.3 to 17.4)	11.2 (5.0 to 20.5)	20.2 (-21.1 to 46.3)	-8.2 (-25.4 to 11.0)
Female infertility due to other causes	207.7 (135.4 to 293.8)	279.3 (165.1 to 408.6)	32.2 (-24.4 to 136.7)	9.8 (-36.8 to 92.8)	1.2 (0.5 to 2.8)	1.6 (0.6 to 3.5)	27.6 (-30.0 to 129.6)	8.8 (-38.6 to 94.8)
Endometriosis	108.6 (91.4 to 125.2)	149.5 (129.7 to 169.5)	37.9 (13.1 to 69.5)	0.7 (-17.2 to 22.4)	10.1 (6.6 to 14.2)	14.0 (9.2 to 19.8)	37.5 (9.5 to 73.5)	1.1 (-19.8 to 25.6)
Genital prolapse	2,640.0 (2,311.8 to 2,953.6)	4,228.5 (3,740.4 to 4,791.7)	60.3 (33.1 to 90.3)	-0.7 (-16.8 to 17.4)	8.5 (4.1 to 15.8)	13.5 (6.4 to 25.3)	60.0 (31.9 to 92.6)	-0.6 (-17.6 to 18.0)
Premenstrual syndrome	2,503.2 (1,800.5 to 3,261.0)	3,046.9 (2,317.1 to 3,699.4)	21.3 (-14.9 to 79.9)	8.0 (-24.0 to 57.1)	21.2 (12.0 to 33.8)	25.8 (15.0 to 40.8)	21.3 (-15.2 to 80.0)	8.6 (-24.8 to 58.7)
Other gynecological diseases	115.4 (83.7 to 147.0)	75.5 (59.8 to 94.6)	-34.8 (-54.2 to -3.3)	-49.4 (-64.4 to -23.2)	3.0 (1.5 to 4.7)	1.3 (0.8 to 2.1)	-56.8 (-73.3 to -40.0)	-67.3 (-79.4 to -29.0)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	116.5 (77.2 to 168.9)	122.8 (81.4 to 178.3)	5.8 (-13.2 to 14.5)	-7.1 (-13.0 to 14.9)
Thalassemias	88.6 (81.0 to 96.8)	72.5 (66.7 to 78.7)	-18.0 (-22.8 to -13.2)	2.3 (-3.7 to 8.1)	5.9 (3.8 to 8.6)	5.1 (3.4 to 7.4)	-13.1 (-27.4 to 8.3)	8.9 (-7.4 to 35.1)
Thalassemia trait	6,312.3 (6,010.9 to 6,644.8)	7,377.3 (7,042.8 to 7,744.1)	16.9 (12.3 to 20.7)	-1.0 (-4.8 to 2.0)	99.1 (65.6 to 142.8)	111.4 (74.1 to 162.2)	13.1 (9.4 to 22.8)	12.9 (10.5 to 20.8)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.3 (-15.9 to 4.4)	9.3 (-7.4 to 14.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.8 (-13.9 to 16.7)	15.6 (-7.3 to 22.7)
Sickle cell trait	102.8 (84.7 to 113.3)	113.8 (100.1 to 133.9)	11.8 (-1.6 to 18.5)	0.5 (-16.5 to 0.3)	0.5 (0.2 to 0.9)	0.5 (0.2 to 0.9)	3.3 (-7.2 to 18.2)	-1.2 (-71.0 to 175.6)
G6PD deficiency	4,308.4 (4,097.8 to 4,544.1)	5,115.2 (4,797.6 to 5,399.9)	18.8 (9.4 to 28.2)	0.9 (-7.1 to 8.8)	0.5 (0.3 to 0.7)	0.1 (0.0 to 0.3)	-70.5 (-88.4 to -46.0)	-67.7 (-88.2 to -40.5)
G6PD trait	10,971.3 (10,809.0 to 11,135.3)	13,225.9 (13,048.2 to 13,449.3)	20.5 (18.2 to 23.4)	0.4 (-1.5 to 2.9)	0.4 (0.0 to 0.7)	0.5 (0.2 to 0.9)	27.5 (-58.9 to 1,283.6)	31.5 (-65.2 to 1,207.2)
Other hemoglobinopathies and hemolytic anemias	396.9 (374.5 to 451.6)	244.0 (219.3 to 275.3)	-38.5 (-48.0 to -28.2)	-53.8 to -32.5	10.1 (6.5 to 14.9)	5.0 (3.1 to 7.9)	-50.6 (-61.6 to -28.8)	-46.6 (-59.8 to -21.0)
Endocrine, metabolic, blood, and immune disorders	554.8 (500.5 to 618.5)	525.5 (481.6 to 580.6)	-5.4 (-16.3 to 7.3)	-5.4 (-29.1 to -7.9)	17.8 (12.0 to 25.1)	17.7 (11.8 to 24.7)	-5.4 (-15.8 to 20.0)	-3.7 (-0.2 to 4.2)
Musculoskeletal disorders	-	-	-	-	491.2 (344.2 to 646.9)	878.4 (608.9 to 1,156.9)	79.5 (63.2 to 93.5)	27.8 (-7.6 to 7.4)
Rheumatoid arthritis	55.2 (52.1 to 58.3)	137.7 (130.3 to 145.8)	150.4 (129.8 to 169.8)	44.3 (31.9 to 56.4)	13.3 (9.3 to 17.9)	32.8 (22.8 to 43.8)	145.9 (119.1 to 174.0)	43.7 (29.0 to 59.3)
Osteoarthritis	762.0 (717.0 to 807.6)	1,780.7 (1,663.6 to 1,889.2)	133.7 (111.0 to 153.9)	2.1 (-7.4 to 10.5)	47.5 (33.2 to 64.1)	110.5 (76.5 to 148.4)	132.9 (108.9 to 153.5)	2.1 (-7.6 to 11.1)
Low back and neck pain	-	-	-	-	299.9 (205.4 to 405.9)	459.8 (316.1 to 625.4)	54.1 (31.1 to 76.4)	-3.7 (-17.1 to 8.6)
Low back pain	1,407.7 (1,278.6 to 1,546.4)	2,205.5 (1,982.4 to 2,392.9)	57.7 (33.8 to 78.4)	-5.0 (-18.5 to 6.2)	159.3 (107.0 to 220.0)	247.2 (168.0 to 343.8)	55.9 (32.7 to 76.5)	-5.1 (-18.3 to 6.6)
Neck pain	1,406.8 (1,161.8 to 1,674.5)	2,144.6 (1,657.5 to 2,560.9)	54.1 (9.7 to 95.5)	-1.3 (-28.6 to 24.3)	140.6 (91.6 to 202.7)	212.6 (135.1 to 306.1)	53.4 (9.0 to 94.6)	-1.3 (-28.7 to 25.1)
Gout	39.4 (35.4 to 43.5)	88.6 (79.7 to 98.6)	124.8 (93.1 to 161.4)	9.3 (-6.4 to 26.0)	2.9 (0.8 to 1.8)	2.9 (1.9 to 4.0)	123.3 (76.3 to 184.6)	9.3 (-12.9 to 37.9)
Other musculoskeletal disorders	1,393.2 (1,036.1 to 1,762.6)	2,952.5 (2,208.5 to 3,693.2)	112.6 (92.3 to 135.0)	4.6 (-4.0 to 12.4)	128.1 (81.6 to 189.1)	472.4 (172.5 to 393.2)	111.5 (90.6 to 133.6)	8.8 (-6.6 to 11.5)
Other non-communicable diseases	-	-	-	-	830.6 (559.3 to 1,178.7)	1,174.1 (787.1 to 1,676.9)	41.5 (34.2 to 48.6)	-6.4 (-10.3 to -1.7)
Congenital anomalies	-	-	-	-	58.8 (41.5 to 78.2)	77.7 (55.9 to 100.7)	32.1 (12.6 to 58.5)	19.0 (0.8 to 42.1)
Neural tube defects	11.7 (10.0 to 14.0)	13.8 (11.6 to 16.5)	17.0 (8.5 to 49.3)	19.5 (-7.1 to 52.3)	3.7 (2.3 to 5.4)	4.6 (2.9 to 6.5)	21.6 (-16.7 to 76.5)	25.7 (-14.7 to 82.8)
Congenital heart anomalies	160.3 (132.3 to 186.3)	315.3 (253.3 to 388.9)	95.7 (52.9 to 149.9)	82.7 (43.0 to 134.1)	5.6 (2.8 to 9.5)	11.5 (4.8 to 19.8)	103.6 (62.3 to 159.3)	92.0 (53.4 to 143.5)
Orofacial clefts	35.7 (29.3 to 43.9)	68.1 (55.8 to 81.9)	92.0 (40.6 to 149.9)	87.5 (36.3 to 144.0)	0.6 (0.3 to 0.9)	0.7 (0.4 to 1.1)	20.0 (-12.3 to 86.0)	27.0 (-13.1 to 80.1)
Down syndrome	50.9 (41.9 to 60.5)	82.3 (65.1 to 112.2)	59.0 (24.7 to 131.5)	30.7 (3.0 to 91.1)	6.4 (4.5 to 8.5)	12.1 (8.4 to 16.8)	85.8 (42.8 to 168.5)	38.7 (7.6 to 101.6)
Turner syndrome	1.7 (1.3 to 2.2)	2.2 (1.7 to 2.9)	22.9 (-6.2 to 78.4)	14.1 (-13.6 to 66.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	24.6 (-11.1 to 95.2)	14.5 (-18.2 to 77.2)
Klinefelter syndrome	1.8 (1.5 to 2.1)	2.2 (1.7 to 3.2)	17.4 (-8.1 to 80.6)	2.7 (-19.6 to 58.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.8 (-20.3 to 108.2)	3.1 (-32.6 to 74.4)
Chromosomal unbalanced rearrangements	73.1 (61.0 to 86.9)	112.5 (91.0 to 136.3)	52.9 (21.1 to 98.7)	9.2 (-0.1 to 63.3)	9.2 (6.4 to 12.5)	16.4 (11.5 to 22.0)	78.5 (37.6 to 134.0)	38.5 (3.8 to 72.8)
Other congenital anomalies	257.6 (192.9 to 317.6)	239.2 (181.8 to 289.1)	-7.3 (-16.6 to 5.1)	-18.5 (-26.6 to -8.2)	33.3 (20.5 to 47.7)	32.4 (21.3 to 44.9)	-2.7 (-22.1 to 24.1)	-4.2 (-22.3 to 21.4)
Skin and subcutaneous diseases	-	-	-	-	295.4 (191.9 to 454.4)	370.6 (238.6 to 563.1)	25.7 (16.2 to 34.7)	2.6 (-4.5 to 8.8)
Dermatitis	2,828.9 (2,415.0 to 3,255.6)	3,541.5 (3,015.3 to 4,056.1)	25.0 (19.8 to 31.8)	-0.0 (-0.0 to 0.0)	84.6 (56.0 to 122.3)	101.0 (65.6 to 145.6)	19.2 (12.3 to 26.7)	0.3 (-2.6 to 3.1)
Psoriasis	441.4 (346.8 to 541.1)	635.6 (487.8 to 785.4)	43.3 (35.5 to 55.0)	-0.0 (-0.0 to 0.0)	43.0 (23.4 to 53.6)	52.0 (33.5 to 77.1)	42.8 (30.7 to 55.9)	0.1 (-5.0 to 5.7)
Cellulitis	12.9 (10.2 to 16.2)	18.9 (15.1 to 24.3)	45.2 (27.8 to 68.8)	1.6 (-9.3 to 13.4)	0.9 (0.6 to 1.4)	1.3 (0.8 to 2.0)	43.6 (11.3 to 79.8)	0.9 (-17.0 to 26.5)
Pyoderma	76.7 (57.7 to 98.2)	38.4 (30.1 to 51.4)	-49.9 (-59.7 to -38.2)	-51.8 (-59.0 to -43.0)	0.4 (0.2 to 1.0)	0.2 (0.1 to 0.5)	-51.9 (-61.1 to -37.4)	-51.9 (-60.1 to -42.4)
Scabies	647.6 (586.5 to 719.5)	632.6 (555.2 to 734.7)	-3.0 (-17.3 to 18.5)	-16.6 (-28.1 to 0.4)	16.8 (9.3 to 27.4)	16.3 (9.3 to 25.8)	-3.3 (-17.7 to 17.7)	-16.3 (-28.1 to 1.4)
Fungal skin diseases	6,699.6 (5,249.7 to 8,132.6)	8,363.9 (6,756.4 to 9,886.3)	24.3 (16.8 to 34.5)	24.3 (0.0 to 47.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	24.4 (16.1 to 34.0)	9.2 (-0.5 to 0.9)
Viral skin diseases	1,198.4 (889.8 to 1,512.2)	1,107.1 (805.5 to 1,429.0)	-8.0 (-14.9 to 0.4)	0.1 (-1.9 to 1.9)	37.3 (21.4 to 58.6)	34.4 (19.1 to 55.7)	-8.3 (-15.2 to 0.6)	3.9 (-3.2 to 9.5)
Acne vulgaris	2,409.8 (1,760.3 to 3,106.2)	2,548.6 (1,873.0 to 3,283.8)	6.3 (-31.9 to 63.4)	24.3 (-20.0 to 93.8)	26.3 (11.4 to 53.6)	27.7 (12.3 to 55.1)	6.1 (-32.1 to 64.4)	24.7 (-20.5 to 94.4)
Alopecia areata	71.5 (63.0 to 79.8)	108.2 (94.8 to 121.5)	51.5 (27.9 to 79.0)	3.1 (-12.0 to 20.0)	2.4 (1.5 to 3.7)	3.6 (2.3 to 5.6)	50.3 (24.3 to 82.9)	3.3 (-13.8 to 24.4)
Pruritus	10.1 (8.5 to 11.8)	16.0 (13.4 to 18.7)	59.9 (26.4 to 95.5)	0.8 (-19.6 to 23.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	59.8 (18.7 to 107.9)	1.0 (-14.2 to 30.4)
Urticaria	482.9 (331.3 to 668.4)	798.3 (590.6 to 1,039.8)	69.2 (-4.0 to 173.7)	14.8 (-32.2 to 77.2)	29.0 (16.2 to 45.0)	47.7 (27.6 to 75.0)	67.0 (-5.9 to 175.0)	14.4 (-32.2 to 78.1)
Decubitus ulcer	8.2 (6.8 to 9.7)	17.7 (14.1 to 21.7)	114.5 (64.3 to 181.2)	2.0 (-24.1 to 38.9)	1.3 (0.8 to 1.8)	2.6 (1.7 to 3.8)	108.2 (55.5 to 178.6)	1.4 (-27.2 to 40.0)
Other skin and subcutaneous diseases	3,690.7 (2,510.4 to 5,325.4)	6,167.2 (3,853.0 to 9,493.7)	65.8 (41.8 to 92.1)	0.6 (-2.5 to 2.9)	21.9 (9.8 to 44.4)	21.9 (15.7 to 77.0)	64.9 (40.6 to 89.7)	0.6 (-2.8 to 3.3)
Sense organ diseases	-	-	-	-	401.3 (272.2 to 558.6)	615.6 (413.2 to 862.1)	53.4 (41.7 to 66.6)	-13.1 (-17.6 to -7.2)
Glaucoma	9.6 (7.6 to 12.0)	17.5 (13.7 to 22.1)	82.4 (47.6 to 136.1)	-0.1 (-35.5 to 2.2)	1.1 (0.7 to 1.6)	2.0 (1.3 to 2.9)	84.3 (42.7 to 144.5)	21.6 (-39.8 to 3.0)
Cataract	93.6 (72.7 to 113.5)	213.8 (164.4 to 270.6)	131.6 (82.1 to 172.9)	-14.2 (-32.2 to 0.3)	9.3 (6.1 to 13.0)	20.5 (13.6 to 29.0)	122.1 (79.9 to 158.9)	-17.4 (-32.4 to -4.4)
Macular degeneration	16.6 (11.5 to 22.2)	42.2 (30.7 to 55.8)	156.7 (66.2 to 268.7)	6.0 (-30.9 to 55.4)	1.2 (0.7 to 1.7)	2.8 (1.9 to 4.2)	144.0 (68.5 to 227.7)	-5.5 (-34.2 to 27.0)
Uncorrected refractive error	3,512.9 (2,190.5 to 4,691.6)	5,961.6 (4,274.1 to 7,780.1)	69.0 (10.2 to 223.1)	-10.1 (-36.6 to 15.2)	50.8 (28.7 to 87.5)	82.0 (46.2 to 121.0)	58.0 (20.2 to 149.1)	-12.6 (-31.7 to 36.0)
Age-related and other hearing loss	8,426.2 (7,957.4 to 8,936.2)	14,607.5 (13,904.4 to 15,431.5)	73.5 (66.2 to 79.9)	-10.1 (-13.3 to -7.4)	75.1 (196.0 to 396.8)	440.7 (294.2 to 621.3)	53.1 (39.6 to 65.4)	-13.3 (-18.5 to -8.5)
Other vision loss	214.5 (184.2 to 250.5)	43.9 (25.3 to 365.0)	43.9 (28.8 to 58.6)	-24.8 (-34.0 to -18.1)	17.8 (12.4 to 24.9)	26.3 (17.9 to 37.4)	48.0 (32.4 to 65.1)	-28.4 (-36.7 to -20.3)
Other sense organ diseases	1,244.4 (1,184.2 to 1,311.1)	1,530.0 (1,460.5 to 1,603.0)	23.1 (15.					

Appendix Table G.4 - Thailand prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	490.3 (440.4 to 548.9)	845.5 (753.6 to 937.3)	72.9 (46.8 to 99.2)	-26.5 (-37.0 to -14.7)	13.7 (9.2 to 19.1)	23.5 (15.6 to 33.4)	71.7 (45.1 to 98.7)	-26.7 (-37.5 to -14.9)
Other oral disorders	964.5 (906.6 to 1,017.8)	1,308.0 (1,230.1 to 1,377.1)	35.5 (25.3 to 47.7)	-0.1 (-7.6 to 8.4)	28.5 (17.7 to 43.1)	38.4 (24.1 to 57.7)	34.7 (23.7 to 47.6)	0.0 (-7.8 to 9.1)
Injuries	-	-	-	-	154.3 (116.3 to 199.0)	183.8 (130.6 to 250.9)	18.7 (4.7 to 34.4)	-28.0 (-36.2 to -19.3)
Transport injuries	-	-	-	-	86.4 (64.7 to 111.5)	99.6 (70.1 to 136.4)	14.8 (-0.7 to 32.2)	-30.4 (-39.0 to -20.7)
Road injuries	-	-	-	-	77.0 (57.6 to 99.3)	85.2 (60.0 to 116.9)	10.2 (5.1 to 27.6)	-32.8 (-41.3 to -23.3)
Pedestrian road injuries	-	-	-	-	10.0 (7.4 to 12.9)	11.5 (8.2 to 15.5)	14.5 (2.6 to 32.9)	-30.3 (-39.4 to -20.3)
Cyclist road injuries	-	-	-	-	4.4 (3.2 to 5.8)	5.3 (3.7 to 7.2)	19.7 (6.0 to 34.7)	-31.6 (-39.1 to -23.4)
Motorcyclist road injuries	-	-	-	-	36.3 (27.2 to 47.4)	36.1 (25.1 to 50.5)	-1.0 (-15.5 to 15.9)	-39.8 (-47.8 to -30.7)
Motor vehicle road injuries	-	-	-	-	25.9 (19.1 to 33.1)	32.0 (22.7 to 43.6)	23.1 (4.7 to 47.2)	-23.9 (-34.6 to -10.3)
Other road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	-13.2 (-24.7 to 0.4)	-50.2 (-56.2 to -43.1)
Other transport injuries	-	-	-	-	9.5 (7.1 to 12.4)	14.4 (10.2 to 19.9)	51.5 (33.8 to 73.6)	-12.5 (-22.4 to 0.3)
Unintentional injuries	-	-	-	-	57.1 (43.2 to 74.0)	76.0 (54.9 to 102.7)	32.5 (20.8 to 46.1)	-19.7 (-26.4 to -12.4)
Falls	-	-	-	-	21.6 (16.0 to 27.9)	32.1 (22.5 to 43.6)	48.2 (31.8 to 68.1)	-20.5 (-29.6 to -10.1)
Drowning	-	-	-	-	2.5 (1.9 to 3.3)	1.9 (1.4 to 2.6)	-24.4 (-35.6 to -9.6)	-50.1 (-57.0 to -41.4)
Fire, heat, and hot substances	-	-	-	-	4.0 (3.0 to 5.2)	3.2 (2.3 to 4.4)	-19.3 (-31.3 to -6.6)	-46.3 (-53.8 to -38.6)
Poisonings	-	-	-	-	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.6)	-1.5 (-18.7 to 16.4)	-31.8 (-43.2 to -20.0)
Exposure to mechanical forces	-	-	-	-	19.2 (14.6 to 25.2)	24.4 (17.6 to 33.4)	27.0 (16.6 to 38.2)	-14.7 (-20.5 to -8.5)
Unintentional firearm injuries	-	-	-	-	1.1 (0.9 to 1.5)	1.3 (0.9 to 1.8)	16.4 (2.5 to 32.4)	24.0 (-32.2 to -14.6)
Unintentional suffocation	-	-	-	-	0.5 (0.4 to 0.7)	0.7 (0.5 to 0.9)	33.5 (17.4 to 50.6)	-8.2 (-18.4 to 2.4)
Other exposure to mechanical forces	-	-	-	-	17.6 (13.3 to 23.2)	22.4 (16.2 to 30.7)	27.5 (16.8 to 38.8)	-14.3 (-20.2 to -8.1)
Adverse effects of medical treatment	-	-	-	-	1.0 (0.7 to 1.5)	1.8 (1.1 to 2.6)	69.5 (58.9 to 79.8)	3.2 (-3.2 to 9.7)
Animal contact	-	-	-	-	1.7 (1.3 to 2.3)	1.8 (1.3 to 2.4)	4.2 (7.3 to 16.6)	-31.1 (-38.0 to -24.3)
Venomous animal contact	-	-	-	-	0.8 (0.6 to 1.1)	0.9 (0.6 to 1.2)	5.3 (8.5 to 20.4)	-28.7 (-37.4 to -19.5)
Non-venomous animal contact	-	-	-	-	0.9 (0.7 to 1.2)	0.9 (0.7 to 1.3)	3.3 (9.3 to 17.6)	-33.3 (-40.2 to -25.9)
Foreign body	-	-	-	-	1.1 (0.8 to 1.5)	1.5 (1.1 to 2.0)	34.4 (20.8 to 49.5)	-15.7 (-23.1 to -7.5)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-10.9 (-27.3 to 8.9)	-40.2 (-50.0 to -28.3)
Foreign body in eyes	-	-	-	-	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	29.2 (20.2 to 39.5)	-9.0 (-15.6 to -2.4)
Foreign body in other body part	-	-	-	-	0.5 (0.4 to 0.6)	0.8 (0.6 to 1.1)	69.9 (51.6 to 89.9)	-4.1 (-13.3 to 6.1)
Other unintentional injuries	-	-	-	-	5.5 (4.1 to 7.1)	8.8 (6.4 to 11.8)	60.8 (46.6 to 75.6)	-1.1 (-8.8 to 7.2)
Self-harm and interpersonal violence	-	-	-	-	7.6 (5.7 to 9.8)	5.6 (3.9 to 7.6)	-27.4 (-36.2 to -16.6)	-96.3 (-61.3 to -50.5)
Self-harm	-	-	-	-	1.8 (1.3 to 2.4)	1.5 (1.0 to 2.0)	-20.2 (-29.9 to -9.4)	-54.1 (-59.4 to -48.2)
Interpersonal violence	-	-	-	-	5.8 (4.4 to 7.3)	4.1 (2.9 to 5.6)	-29.6 (-38.7 to -17.9)	-57.1 (-62.3 to -50.7)
Assault by firearm	-	-	-	-	0.6 (0.5 to 0.8)	0.5 (0.4 to 0.7)	-15.3 (-24.5 to -4.6)	-48.9 (-54.0 to -43.1)
Assault by sharp object	-	-	-	-	1.2 (0.9 to 1.6)	1.0 (0.7 to 1.4)	-21.0 (-31.6 to -7.5)	-51.4 (-57.8 to -43.7)
Assault by other means	-	-	-	-	3.9 (3.0 to 5.0)	2.6 (1.8 to 3.5)	-34.5 (-43.6 to -22.6)	-60.1 (-65.4 to -53.6)
Forces of nature, war, and legal intervention	-	-	-	-	3.1 (1.2 to 7.2)	2.6 (1.2 to 5.4)	-15.3 (-53.7 to 57.9)	-53.0 (-74.6 to -11.0)
Exposure to forces of nature	-	-	-	-	0.4 (0.2 to 0.7)	1.7 (0.7 to 3.7)	349.3 (227.2 to 676.1)	162.5 (95.6 to 358.1)
Collective violence and legal intervention	-	-	-	-	2.7 (1.0 to 6.2)	0.9 (0.4 to 1.8)	-66.0 (-78.2 to -47.4)	-81.2 (-88.5 to -70.3)

Appendix Table G.4 - The Bahamas prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	22.9 (17.0 to 29.9)	40.9 (30.6 to 53.0)	78.1 (74.1 to 82.6)	1.3 (0.7 to 3.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.9 (2.1 to 4.0)	3.9 (2.7 to 5.3)	32.7 (22.6 to 43.7)	4.7 (-3.6 to 12.7)
HIV/AIDS and tuberculosis	-	-	-	-	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	95.2 (30.1 to 147.6)	10.7 (26.8 to 40.7)
Tuberculosis	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.2)	44.4 (36.0 to 53.1)	-21.6 (-25.8 to -16.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	43.1 (26.5 to 61.3)	-21.4 (-30.2 to -12.3)
HIV/AIDS	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	111.0 (27.0 to 194.1)	20.4 (28.9 to 65.1)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.5 (-13.0 to 90.0)	-22.7 (-53.8 to 2.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.8 (-24.1 to 151.6)	-22.6 (59.7 to 32.9)
HIV/AIDS resulting in other diseases	1.3 (0.9 to 2.0)	3.3 (2.5 to 4.4)	152.9 (71.9 to 218.9)	54.9 (4.4 to 94.6)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	111.9 (27.2 to 186.2)	21.0 (28.9 to 66.7)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.5 (0.4 to 0.7)	0.6 (0.4 to 0.9)	16.6 (8.0 to 25.7)	-7.4 (-13.8 to -0.7)
Diarrheal diseases	1.6 (1.5 to 1.7)	1.9 (1.8 to 2.1)	19.3 (8.7 to 32.2)	2.6 (-6.1 to 12.9)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	17.8 (6.3 to 31.2)	2.3 (-7.3 to 14.0)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-36.1 to 30.7)	-22.2 (-50.7 to -0.0)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.5 (-15.4 to 23.0)	-20.8 (-34.3 to -6.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.5 (-15.4 to 23.0)	-20.8 (-34.4 to -5.7)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.4 (-20.3 to 26.8)	-20.4 (-37.1 to -1.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.4 (-20.9 to 26.9)	-20.4 (-37.2 to -1.1)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-97.6 to 826.2)	-56.2 (-98.1 to 595.2)
Lower respiratory infections	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	34.3 (-6.3 to 94.5)	-16.4 (-43.5 to 11.3)	0.0 (0.0 to 0.0)	0.0 (-10.9 to 98.3)	33.2 (-44.2 to 17.9)	-15.7 (-42.2 to 17.9)
Upper respiratory infections	13.3 (12.2 to 14.7)	17.7 (16.0 to 19.3)	32.9 (15.8 to 51.3)	-3.8 (-15.9 to 9.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	32.0 (15.6 to 50.3)	-3.9 (-15.7 to 10.0)
Otitis media	3.0 (2.8 to 3.2)	3.5 (3.3 to 3.7)	16.4 (8.2 to 24.9)	-11.4 (-17.4 to -5.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	14.2 (4.1 to 24.3)	-12.5 (-20.0 to -4.6)
Meningitis	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-42.8 (-55.6 to -27.1)	-60.3 (-69.1 to -49.2)
Pneumococcal meningitis	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.2)	-46.4 (-56.0 to -29.2)	-66.7 (-72.5 to -56.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.3 (-57.1 to -22.4)	-62.0 (-70.5 to -49.0)
H influenzae type B meningitis	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-49.5 (-74.1 to 10.3)	-65.0 (-80.6 to -18.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.2 (-76.8 to 19.4)	-57.9 (-82.4 to -11.9)
Meningococcal meningitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.5 (-68.8 to 4.3)	-63.5 (-78.3 to -30.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.0 (-70.3 to 20.7)	-59.8 (-79.2 to -20.0)
Other meningitis	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-46.1 (-58.0 to -25.8)	-64.5 (-72.9 to -48.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.6 (-57.4 to -8.3)	-59.9 (-70.4 to -37.7)
Encephalitis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	29.4 (4.5 to 69.7)	-33.4 (-34.7 to 3.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.3 (2.9 to 84.4)	-18.3 (35.6 to 11.7)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.2 (-93.5 to 348.5)	-55.8 (-95.3 to 222.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.2 (-93.7 to 352.0)	-55.8 (-95.4 to 229.2)
Whooping cough	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-76.8 (-78.8 to -74.6)	-75.8 (-77.8 to -73.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-76.5 (-82.3 to -69.6)	-75.5 (-81.5 to -68.2)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-73.2 (-89.5 to -44.7)	-81.3 (-92.5 to -62.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.8 (-82.5 to -39.1)	-76.5 (-86.7 to -55.9)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.3)	32.9 (11.2 to 66.6)	-2.5 (-19.3 to 23.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.7 (30.1 to 165.9)	-5.4 (-32.4 to 41.4)
Neglected tropical diseases and malaria	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	5.7 (-17.1 to 50.3)	-6.0 (25.9 to 30.9)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.3 (-1.3 to 245.5)	21.6 (-25.0 to 163.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.9 (-0.5 to 249.6)	22.5 (-24.1 to 166.5)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.0 (-17.9 to 151.6)	-2.4 (-43.6 to 75.6)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.4 (-43.6 to 85.7)	-11.3 (51.2 to 54.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.4 (-43.6 to 86.0)	-11.3 (51.2 to 54.8)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	52.2 (-15.8 to 160.5)	-0.2 (-43.5 to 85.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.8 (-18.5 to 167.3)	-1.4 (-44.9 to 83.2)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-30.7 (-79.8 to 69.3)	-58.8 (-87.2 to -5.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.6 (-79.6 to 81.6)	-58.4 (-86.7 to 5.3)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.6 (-4.2 to 17.9)	-42.2 (-46.8 to -35.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.4 (-12.2 to 35.0)	40.2 (-51.4 to -25.6)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.4)	319.7 (284.5 to 363.9)	192.0 (167.5 to 222.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	308.7 (212.1 to 507.1)	187.4 (120.9 to 324.0)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.9 (-43.0 to 21.7)	41.9 (-59.4 to -15.0)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.6 (25.9 to 115.3)	-0.1 (-26.3 to 26.7)
Ascariasis	-	-	70.6 (2.7 to 187.4)	-0.4 (-40.0 to 68.0)	-	-	-	-
Trichuriasis	-	-	68.3 (-1.0 to 191.2)	-1.7 (-42.2 to 70.2)	-	-	-	-
Hookworm disease	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	68.8 (11.9 to 160.2)	1.4 (-34.6 to 52.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.6 (25.9 to 115.3)	-0.1 (-26.3 to 26.7)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	2.7 (2.1 to 3.4)	2.9 (2.7 to 3.1)	7.4 (-13.1 to 36.9)	-0.3 (-18.6 to 25.9)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-0.6 (-13.5 to 44.2)	0.0 (-12.8 to 45.1)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Maternal hemorrhage	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.5 (-18.4 to 61.7)	-30.8 (44.7 to 12.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.5 (-34.0 to 51.5)	-29.0 (55.4 to 4.5)
Maternal sepsis and other maternal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.8 (-38.5 to 17.3)	-45.7 (-62.7 to -30.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.5 (-37.4 to 7.9)	-44.4 (-58.0 to -28.0)
Maternal hypertensive disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.7 (-10.4 to 14.3)	-25.8 (-34.1 to -18.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.7 (-25.4 to 44.6)	-25.7 (-45.3 to 3.3)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.4 (-38.6 to 36.0)	-33.2 (-54.0 to -0.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.4 (-38.7 to 36.1)	-33.2 (-54.1 to -0.2)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.2 (-28.4 to 124.8)	-14.3 (47.9 to 54.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.2 (-28.6 to 124.9)	-14.3 (47.9 to 55.8)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Neonatal disorders	-	-	-	-	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.1)	93.8 (32.5 to 168.0)	46.8 (1.3 to 103.0)
Preterm birth complications	1.3 (0.8 to 2.3)	3.8 (2.1 to 6.7)	183.6 (107.0 to 275.3)	102.7 (47.7 to 167.5)	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.6)	151.3 (46.9 to 306.9)	87.1 (10.1 to 202.1)
Neonatal encephalopathy due to birth asphyxia and trauma	1.9 (0.5 to 4.9)	1.7 (0.6 to 4.2)	-8.5 (-40.3 to 52.4)	-34.6 (58.1 to 11.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	10.9 (-34.2 to 76.4)	-13.6 (-48.6 to 38.6)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.9 (12.7 to 34.0)	25.9 (19.3 to 41.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.2 (9.8 to 37.8)	26.2 (16.3 to 45.9)
Hemolytic disease and other neonatal jaundice	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	86.0 (-21.6 to 386.4)	39.7 (-40.4 to 263.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	88.7 (-18.4 to 376.4)	41.2 (-38.6 to 257.9)
Other neonatal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.2)	201.3 (37.2 to 538.2)	128.5 (4.1 to 381.0)
Nutritional deficiencies	-	-	-	-	1.4 (1.0 to 2.1)	1.7 (1.1 to 2.4)	15.6 (11.4 to 19.0)	-1.8 (-5.1 to 0.7)
Protein-energy malnutrition	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-9.8 (-56.4 to 88.3)	-21.9 (-58.7 to 46.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.7 (-57.4 to 88.8)	21.9 (-59.6 to 53.0)
Iodine deficiency	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.3)	2.0 (-30.8 to 42.8)	-36.0 (-56.6 to -9.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.7 (-33.0 to 44.5)	-35.7 (-57.7 to -7.9)
Vitamin A deficiency	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-41.2 (-51.7 to -29.6)	-52.0 (-59.9 to -42.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.5 (-53.3 to -30.0)	-54.3 (-62.4 to -44.8)

Appendix Table G.4 - The Bahamas prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	45.5 (44.8 to 46.1)	57.5 (56.7 to 58.3)	26.5 (24.3 to 28.6)	-0.9 (-2.7 to 0.7)	1.4 (0.9 to 2.1)	1.6 (1.1 to 2.4)	16.2 (12.1 to 19.6)	16.2 (4.5 to 1.2)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	25.6 (12.9 to 44.5)	-3.7 (-12.7 to 9.0)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	44.9 (26.8 to 61.8)	-7.2 (-17.6 to 3.1)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.0 (53.0 to 113.3)	-17.4 (-28.7 to -4.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.2 (26.7 to 150.8)	37.5 (-39.7 to 13.7)
Chlamydial infection	7.7 (6.4 to 9.0)	10.1 (8.3 to 11.8)	31.9 (5.0 to 67.7)	-8.5 (-27.2 to 14.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	37.5 (11.4 to 65.8)	-5.8 (-23.2 to 13.3)
Gonococcal infection	1.1 (0.9 to 1.3)	1.4 (1.1 to 1.6)	27.8 (5.7 to 77.2)	-8.8 (-32.3 to 25.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.0 (-22.5 to 70.3)	-18.9 (-44.8 to 19.5)
Trichomoniasis	1.8 (1.3 to 2.7)	2.7 (1.6 to 3.7)	46.4 (-15.9 to 128.2)	-4.7 (-43.0 to 48.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.5 (-24.9 to 144.1)	-5.9 (-48.9 to 59.3)
Genital herpes	57.2 (53.9 to 60.0)	101.4 (95.8 to 107.3)	76.5 (64.1 to 92.4)	-5.2 (-12.1 to 2.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	78.3 (54.1 to 87.4)	5.5 (-12.5 to 3.6)
Other sexually transmitted diseases	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	32.0 (7.1 to 66.2)	-11.1 (-35.9 to 0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.8 (15.7 to 127.1)	1.0 (-26.2 to 39.8)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.6 (-7.6 to 38.8)	-29.7 (-41.7 to -13.1)
Hepatitis A	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.3)	27.5 (26.2 to 28.6)	-0.6 (-0.7 to -0.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.5 (24.3 to 59.3)	-0.3 (-1.5 to 11.7)
Hepatitis B	12.1 (8.8 to 14.9)	9.9 (8.2 to 11.9)	-19.2 (-39.3 to 24.8)	-50.9 (-63.0 to -25.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.3 (-43.3 to 28.7)	-52.9 (-68.0 to -27.3)
Hepatitis C	4.2 (3.7 to 4.7)	6.1 (5.5 to 6.7)	45.6 (26.1 to 69.3)	22.1 (-32.0 to -10.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.7 (4.2 to 81.2)	-24.8 (-44.8 to 3.1)
Hepatitis E	-	-	37.7 (24.6 to 53.6)	-2.9 (-13.4 to 7.7)	-	-	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	2.0 (1.6 to 2.4)	2.2 (2.0 to 2.4)	11.9 (5.2 to 34.0)	-0.5 (-15.0 to 18.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	13.1 (5.5 to 53.4)	7.5 (-10.2 to 44.0)
Non-communicable diseases	-	-	-	-	18.8 (13.9 to 24.3)	35.2 (26.3 to 45.5)	87.7 (82.6 to 93.7)	3.0 (0.6 to 6.0)
Neoplasms	-	-	-	-	0.3 (0.2 to 0.3)	0.7 (0.5 to 1.0)	185.2 (119.2 to 252.7)	24.1 (-4.7 to 53.4)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.0 (38.9 to 178.1)	-20.0 (-44.6 to 9.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	100.0 (39.8 to 174.4)	-20.9 (-44.4 to 7.9)
Stomach cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	51.1 (14.8 to 92.2)	-39.3 (-53.9 to -22.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.1 (9.4 to 88.4)	-41.4 (-56.5 to -25.1)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	421.1 (273.4 to 607.0)	118.8 (55.8 to 197.4)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	462.9 (199.5 to 1,058.5)	150.0 (30.2 to 422.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	437.3 (204.8 to 945.0)	137.7 (33.1 to 367.5)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,762.3 (887.1 to 3,877.6)	649.1 (297.2 to 1,412.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,635.0 (869.2 to 3,324.7)	586.9 (293.9 to 1,197.4)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	156.3 (36.4 to 402.1)	5.4 (-43.5 to 96.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	143.0 (40.2 to 363.5)	-0.8 (-42.9 to 78.8)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	156.3 (36.5 to 344.7)	10.7 (-41.0 to 98.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	145.6 (38.1 to 295.0)	5.3 (-41.3 to 70.3)
Larynx cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	81.3 (20.9 to 165.3)	-26.2 (-50.1 to 7.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.0 (18.5 to 173.2)	-25.2 (-51.9 to 11.3)
Tracheal, bronchus and lung cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	99.9 (48.1 to 163.9)	-18.4 (-39.7 to 6.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.0 (41.7 to 159.8)	-20.9 (-41.7 to 4.4)
Breast cancer	0.6 (0.5 to 0.7)	1.5 (1.0 to 2.0)	134.3 (59.6 to 239.8)	1.7 (-31.1 to 43.7)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.2)	138.7 (65.3 to 237.4)	3.2 (-28.3 to 43.6)
Cervical cancer	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.5)	27.0 (-17.7 to 90.2)	-2.4 (-62.6 to 46.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.2 (-17.3 to 91.4)	7.5 (-6.1 to 14.9)
Uterine cancer	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	229.5 (55.2 to 459.8)	31.3 (-37.9 to 120.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	224.0 (52.1 to 443.3)	28.8 (-39.8 to 113.9)
Prostate cancer	0.5 (0.4 to 0.8)	2.8 (1.7 to 4.2)	446.6 (207.9 to 772.4)	111.0 (21.2 to 237.3)	0.1 (0.0 to 0.1)	0.3 (0.1 to 0.4)	386.9 (176.1 to 661.4)	88.9 (7.9 to 194.9)
Colon and rectum cancer	0.3 (0.3 to 0.3)	0.8 (0.6 to 1.0)	188.5 (119.3 to 256.3)	17.1 (-10.3 to 45.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	177.7 (110.9 to 248.3)	12.8 (-13.0 to 41.8)
Lip and oral cavity cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	95.5 (34.7 to 170.4)	-19.0 (-44.3 to 11.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.8 (31.9 to 167.2)	-21.1 (-45.0 to 10.0)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.8 (8.4 to 108.4)	-36.7 (-56.8 to -3.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.3 (8.4 to 100.1)	-38.2 (-57.5 to -8.5)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	74.6 (16.6 to 177.4)	-29.4 (-52.2 to 9.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.1 (15.7 to 175.8)	-30.0 (-53.1 to 9.3)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-66.6 (-50.1 to 131.3)	0.0 (-80.6 to -7.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.8 (-50.4 to 134.3)	66.8 (-80.3 to -8.0)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	696.9 (478.7 to 965.3)	220.7 (133.7 to 229.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	644.0 (444.5 to 887.9)	195.1 (114.2 to 295.4)
Malignant skin melanoma	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	44.2 (1.8 to 133.8)	-22.8 (-52.4 to 5.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.0 (-2.2 to 133.6)	34.1 (53.9 to 6.9)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	267.7 (182.7 to 388.6)	50.4 (14.9 to 101.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	322.9 (200.2 to 512.2)	72.0 (14.8 to 160.4)
Ovarian cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	503.3 (295.6 to 768.2)	173.9 (81.4 to 286.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	492.8 (276.9 to 784.1)	167.3 (69.5 to 295.5)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	389.6 (25.0 to 987.9)	191.5 (-25.1 to 523.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	354.0 (20.2 to 1,054.1)	168.8 (-30.1 to 554.7)
Kidney cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	85.4 (39.4 to 143.1)	-19.3 (-39.0 to 5.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.0 (33.6 to 143.8)	21.2 (-42.3 to 6.4)
Bladder cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	57.1 (15.9 to 141.7)	-35.5 (-52.8 to -0.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.4 (11.1 to 144.6)	-37.0 (-55.1 to -0.8)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	387.4 (71.9 to 637.8)	203.1 (5.2 to 348.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	410.6 (79.8 to 634.6)	196.4 (-1.2 to 312.8)
Thyroid cancer	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.7)	150.5 (69.7 to 260.6)	25.7 (-13.9 to 78.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	145.7 (69.5 to 261.2)	21.4 (-15.3 to 74.3)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	238.3 (150.4 to 340.8)	37.9 (-2.3 to 80.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	256.2 (164.7 to 364.2)	44.2 (6.1 to 88.6)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	785.4 (43.1 to 1,333.0)	487.2 (6.0 to 825.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	791.1 (38.5 to 1,304.0)	472.4 (-11.8 to 773.6)
Non-Hodgkin lymphoma	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	144.3 (78.0 to 223.8)	20.3 (-12.3 to 55.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	136.7 (71.8 to 210.8)	15.3 (-16.1 to 51.3)
Multiple myeloma	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	233.5 (111.9 to 405.2)	33.9 (-15.0 to 102.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	221.1 (102.9 to 394.7)	28.6 (-17.8 to 97.3)
Leukemia	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	84.4 (24.8 to 157.6)	9.3 (-20.3 to 46.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.0 (37.7 to 154.5)	3.9 (-21.2 to 38.4)
Other neoplasms	0.3 (0.3 to 0.4)	0.9 (0.7 to 1.2)	191.1 (110.2 to 300.1)	55.4 (14.7 to 107.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	186.1 (105.6 to 289.7)	49.1 (8.9 to 97.1)
Cardiovascular diseases	-	-	-	-	0.2 (0.2 to 0.3)	0.8 (0.5 to 1.0)	235.4 (172.1 to 305.4)	35.9 (12.8 to 60.0)
Rheumatic heart disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.7 (72.0 to 134.8)	-4.9 (-18.2 to 10.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.6 (72.5 to 143.5)	-4.6 (-18.2 to 12.7)
Ischemic heart disease	1.2 (1.0 to 1.3)	5.8 (4.9 to 7.0)	402.6 (294.7 to 530.2)	87.9 (47.3 to 134.6)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.4)	485.1 (322.3 to 705.2)	118.4 (57.3 to 194.1)
Cerebrovascular disease	-	-	-	-	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	150.7 (109.1 to 204.1)	1.8 (-16.6 to 23.7)
Ischemic stroke	0.3 (0.3 to 0.4)	0.9 (0.7 to 1.0)	156.5 (108.7 to 209.9)	1.5 (-18.5 to 23.7)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	153.9 (106.3 to 207.6)	0.8 (-19.0 to 22.6)
Hemorrhagic stroke	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	150.7 (70.5 to 248.1)	5.2 (-31.8 to 53.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	147.1 (69.1 to 242.5)	5.5 (-31.1 to 52.1)
Hypertensive heart disease	0.1 (0.1 to 0.1)	0.3 (0.3 to 0.3)	131.4 (103.7 to 160.7)	-10.7 (-21.9 to 1.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	130.2 (98.4 to 163.5)	-10.7 (-23.1 to 2.1)
Cardiomyopathy and myocarditis	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	149.4 (101.4 to 195.5)	8.9 (-13.3 to 33.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	144.4 (98.5 to 201.6)	8.0 (-14.7 to 35.8)
Atrial fibrillation and flutter	0.4 (0.4 to 0.5)	1.5 (1.3 to 1.8)	256.1 (171.7 to 367.0)	32.9 (-0.3 to 80.5)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	254.3 (170.2 to 361.5)	32.7 (-0.7 to 78.1)
Peripheral vascular disease	5.5 (4.3 to 6.8)	14.6 (12.0 to 17.3)	165.6 (91.9 to 260.1)	0.8 (-22.5 to 28.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	156.2 (23.4 to 416.8)	-6.4 (-57.1 to 83.0)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.0 (30.7 to 166.5)	-4.8 (-40.6 to 24.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	112.9 (40.9 to 192.1)	0.3 (-35.1 to 38.8)
Other cardiovascular and circulatory diseases	0.7 (0.3 to 1.3)	1.5 (1.3 to 1.9)	127.9 (15.9 to 373.9)	4.7 (-45.5 to 117.3)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	128.0 (14.2 to 368.9)	5.2 (-45.6 to 119.3)
Chronic respiratory diseases	-	-	-	-	1.3 (0.9 to 1.7)	2.5 (1.7 to 3.4)	95.6 (73.3 to 125.3)	2.0 (-8.9 to 17.4)
Chronic obstructive pulmonary disease	9.7 (9.2 to 10.1)	20.8 (19.7 to 21.8)	114.5 (107.8 to 121.3)	-0.1 (-3.2 to 2.8)	0.6 (0.4 to 0.9)	1.4 (0.9 to 2.0)	130.9 (97.3 to 165.8)	8.9 (-7.8 to 26.0)

Appendix Table G.4 - The Bahamas prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	115.6	-4.3
Silicosis	0.0	0.0	101.6	-11.2	0.0	0.0	101.0	-11.5
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Coal workers pneumoconiosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Other pneumoconiosis	0.0	0.0	427.2	1.5	0.0	0.0	126.2	1.0
Asthma	13.3	22.9	73.0	2.7	0.6	1.0	71.4	2.6
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	148.9	6.5	0.0	0.0	149.3	6.7
Other chronic respiratory diseases	0.0	0.0	0.0	0.0	0.1	0.1	23.0	-42.1
Cirrhosis	0.0	0.0	0.0	0.0	0.0	0.0	85.6	-6.4
Cirrhosis due to hepatitis B	0.0	0.0	60.1	-23.5	0.0	0.0	59.4	-17.8
Cirrhosis due to hepatitis C	0.0	0.0	126.5	10.8	0.0	0.0	121.0	10.3
Cirrhosis due to alcohol use	0.0	0.0	61.3	-28.1	0.0	0.0	60.3	-28.2
Cirrhosis due to other causes	0.0	0.0	83.9	19.7	0.0	0.0	81.0	19.5
Digestive diseases	0.0	0.0	98.2	36.4	0.3	0.7	108.3	2.1
Peptic ulcer disease	1.6	1.9	18.8	-50.2	0.1	0.1	34.2	-43.4
Gastritis and duodenitis	4.2	8.5	103.7	0.6	0.2	0.3	78.1	-5.6
Appendicitis	0.0	0.0	29.3	-7.4	0.0	0.0	30.5	-6.7
Paralytic ileus and intestinal obstruction	0.0	0.0	45.0	-30.6	0.0	0.0	45.0	-30.6
Inguinal, femoral, and abdominal hernia	0.6	0.8	33.1	-47.5	0.0	0.0	33.1	-47.0
Inflammatory bowel disease	0.3	0.8	136.6	21.0	0.1	0.2	134.7	20.9
Vascular intestinal disorders	0.0	0.0	123.8	-6.3	0.0	0.0	123.8	-6.3
Gallbladder and biliary diseases	0.1	0.2	47.9	-33.7	0.0	0.0	46.3	-34.4
Pancreatitis	0.0	0.0	191.4	51.9	0.0	0.0	187.3	51.3
Other digestive diseases	0.0	0.0	0.0	0.0	0.0	0.1	714.6	300.2
Neurological disorders	1.1	3.0	170.4	0.1	1.5	2.9	84.6	3.3
Alzheimer disease and other dementias	0.0	0.1	156.2	-1.6	0.0	0.0	154.2	-2.2
Parkinson disease	0.4	0.8	82.5	21.1	0.2	0.3	87.3	26.7
Epilepsy	0.0	0.1	256.0	85.8	0.0	0.0	243.6	80.2
Multiple sclerosis	0.0	0.1	219.8	67.2	0.0	0.0	183.3	49.7
Migraine	26.5	41.8	58.1	1.4	1.4	3.4	96.3	-3.1
Tension-type headache	50.7	86.1	69.1	3.8	0.1	0.1	68.1	3.7
Medication overuse headache	1.1	2.9	159.1	39.0	0.2	0.5	157.1	38.4
Other neurological disorders	0.0	0.0	61.7	-1.8	0.0	0.1	77.4	-34.2
Mental and substance use disorders	0.7	1.2	83.2	-0.5	6.1	9.8	61.0	0.0
Schizophrenia	1.6	2.8	72.5	1.8	0.2	0.3	71.7	1.6
Alcohol use disorders	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Drug use disorders	0.2	0.3	93.4	4.0	0.1	0.1	91.3	3.9
Opioid use disorders	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cocaine use disorders	0.5	0.8	58.0	0.1	0.1	0.1	57.0	2.0
Amphetamine use disorders	0.5	0.7	34.1	-1.4	0.1	0.1	33.6	-1.6
Cannabis use disorders	0.6	1.0	35.1	-0.2	0.0	0.0	35.2	-0.3
Other drug use disorders	0.0	0.0	0.0	0.0	0.1	0.2	46.5	1.4
Depressive disorders	9.5	15.9	66.7	0.2	2.0	3.3	65.0	0.1
Major depressive disorder	3.0	5.6	86.9	0.3	0.5	0.5	85.4	-0.2
Dysthymia	1.9	3.2	67.6	-0.3	0.4	0.6	66.2	-0.2
Bipolar disorder	1.5	2.4	61.3	0.1	1.4	2.2	59.6	-0.2
Anxiety disorders	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Eating disorders	0.1	0.1	35.0	5.4	0.0	0.0	34.2	4.9
Anorexia nervosa	0.0	0.0	184.4	-7.0	0.0	0.0	184.4	-7.0
Bulimia nervosa	0.3	0.4	31.2	0.5	0.1	0.1	31.5	0.7
Autistic spectrum disorders	0.8	1.1	43.6	0.1	0.2	0.3	42.3	0.1
Autism	1.1	1.6	42.5	0.1	0.1	0.2	41.4	0.1
Asperger syndrome	2.1	2.2	8.3	-0.2	0.0	0.0	8.1	-0.3
Attention-deficit/hyperactivity disorder	2.7	3.1	8.9	0.3	0.3	0.6	9.0	-0.1
Conduct disorder	0.5	0.7	34.2	-5.6	0.0	0.0	33.3	-5.8
Idiopathic intellectual disability	3.9	6.9	77.1	-0.0	0.3	0.5	75.5	-0.1
Other mental and substance use disorders	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Diabetes, urogenital, blood, and endocrine diseases	15.6	42.8	173.3	29.3	1.1	3.0	180.6	26.4
Diabetes mellitus	0.0	0.0	33.2	1.5	0.0	0.0	33.2	1.5
Acute glomerulonephritis	0.0	0.0	23.1	4.3	0.0	0.0	23.0	4.3
Chronic kidney disease	6.3	13.6	115.0	-0.5	0.1	0.2	100.9	-3.8
Chronic kidney disease due to diabetes mellitus	4.6	8.0	73.4	7.9	0.1	0.2	69.7	-5.1
Chronic kidney disease due to hypertension	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Chronic kidney disease due to glomerulonephritis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Chronic kidney disease due to other causes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Urinary diseases and male infertility	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Appendix Table G.4 - The Bahamas prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	119.1 (93.5 to 141.7)	0.0 (19.9 to 45.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	116.3 (76.7 to 173.0)	32.8 (10.5 to 63.9)
Urolithiasis	1.4 (0.9 to 1.9)	4.0 (2.5 to 6.7)	177.0 (107.2 to 278.6)	16.4 (-12.8 to 60.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	155.8 (101.8 to 248.9)	15.9 (-9.3 to 55.8)
Benign prostatic hyperplasia	1.1 (1.0 to 1.1)	2.8 (2.6 to 3.0)	163.6 (141.3 to 187.7)	-0.2 (-9.6 to 9.5)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	163.6 (139.4 to 188.3)	-0.2 (-9.8 to 9.3)
Male infertility due to other causes	2.0 (1.6 to 2.5)	3.0 (2.3 to 3.7)	49.1 (10.7 to 102.2)	0.4 (-25.9 to 35.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.4 (8.9 to 103.6)	0.0 (-26.7 to 38.2)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.9 (15.0 to 186.2)	-21.8 (-46.5 to 33.4)
Gynecological diseases	-	-	-	-	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	72.1 (51.6 to 94.3)	4.2 (-8.7 to 17.9)
Uterine fibroids	4.9 (4.4 to 5.3)	9.7 (8.9 to 10.5)	99.6 (96.5 to 103.2)	-1.2 (-1.2 to -1.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	84.3 (69.2 to 103.3)	0.6 (-7.1 to 11.3)
Polycystic ovarian syndrome	5.1 (4.4 to 5.8)	8.6 (7.7 to 9.4)	66.8 (41.6 to 100.8)	2.0 (-12.6 to 20.6)	0.1 (0.0 to 0.1)	0.2 (0.0 to 0.2)	66.5 (41.2 to 100.7)	2.2 (-12.2 to 21.7)
Female infertility due to other causes	1.9 (1.0 to 2.9)	3.2 (1.6 to 4.8)	70.5 (-23.7 to 234.9)	6.8 (-52.7 to 115.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.4 (-22.8 to 226.8)	7.9 (-51.5 to 115.3)
Endometriosis	0.5 (0.4 to 0.6)	0.9 (0.7 to 1.0)	79.3 (43.6 to 120.0)	8.1 (-13.3 to 32.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	78.2 (42.1 to 122.3)	7.8 (-13.8 to 33.1)
Genital prolapse	13.2 (10.1 to 16.1)	26.3 (22.4 to 30.4)	98.7 (56.1 to 179.4)	1.1 (-18.7 to 31.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	97.8 (54.2 to 178.5)	0.8 (-19.3 to 31.5)
Premenstrual syndrome	12.9 (10.0 to 16.0)	20.5 (14.8 to 26.1)	59.2 (10.7 to 119.8)	7.2 (-25.9 to 49.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	59.1 (9.9 to 120.8)	7.4 (-26.8 to 48.9)
Other gynecological diseases	0.7 (0.6 to 0.9)	1.1 (1.0 to 1.2)	51.6 (21.2 to 87.1)	-2.8 (-21.5 to 18.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.8 (16.2 to 140.0)	1.9 (-21.9 to 51.9)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.7)	29.1 (21.7 to 39.6)	2.0 (-3.7 to 9.8)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.5 (-8.6 to 12.1)	-4.9 (-12.4 to 7.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.4 (-16.8 to 2.4)	-9.7 (-18.6 to 0.0)
Thalassemia trait	3.3 (2.8 to 4.0)	4.7 (3.8 to 5.8)	42.0 (35.1 to 50.1)	-3.2 (-7.5 to 2.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	27.6 (7.2 to 43.5)	-5.5 (-19.9 to 6.4)
Sickle cell disorders	0.7 (0.6 to 0.8)	1.0 (0.9 to 1.1)	41.7 (31.3 to 56.2)	9.7 (2.4 to 19.7)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	48.0 (31.5 to 66.6)	8.7 (-8.8 to 20.7)
Sickle cell trait	33.8 (31.0 to 36.2)	51.7 (48.1 to 55.0)	53.1 (46.4 to 59.7)	0.2 (-0.0 to 0.0)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	24.2 (10.3 to 46.4)	3.1 (-7.8 to 19.3)
G6PD deficiency	6.1 (5.0 to 7.3)	9.0 (7.0 to 11.2)	46.9 (8.6 to 97.0)	1.1 (-25.2 to 35.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.1 (4.8 to 48.1)	-2.0 (-17.1 to 12.4)
G6PD trait	36.9 (33.9 to 39.6)	56.3 (52.1 to 60.4)	52.2 (36.2 to 71.1)	2.1 (-8.6 to 14.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.8 (-77.8 to 208.7)	-34.8 (-80.1 to 106.4)
Other hemoglobinopathies and hemolytic anemias	1.8 (1.5 to 2.1)	2.5 (2.2 to 2.7)	34.8 (14.2 to 61.7)	0.3 (-15.0 to 18.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	19.1 (9.4 to 64.9)	0.7 (-24.2 to 36.8)
Endocrine, metabolic, blood, and immune disorders	2.0 (1.7 to 2.3)	2.7 (2.5 to 2.9)	31.9 (15.3 to 56.8)	1.5 (-10.7 to 17.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	19.5 (-1.4 to 63.3)	4.7 (-18.8 to 31.1)
Musculoskeletal disorders	-	-	-	-	2.9 (2.1 to 3.9)	3.5 (4.4 to 8.2)	111.8 (95.3 to 130.1)	3.7 (-3.3 to 11.8)
Rheumatoid arthritis	0.6 (0.6 to 0.6)	1.5 (1.4 to 1.5)	143.7 (128.5 to 157.8)	24.9 (17.1 to 32.5)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	138.1 (119.2 to 157.2)	23.5 (14.5 to 33.2)
Osteoarthritis	6.4 (6.1 to 6.7)	16.6 (15.9 to 17.2)	158.7 (144.0 to 174.5)	2.0 (-3.7 to 8.0)	0.4 (0.3 to 0.5)	1.0 (0.7 to 1.4)	157.2 (141.7 to 179.9)	1.7 (-4.2 to 7.8)
Low back and neck pain	-	-	-	-	1.9 (1.3 to 2.5)	3.5 (2.4 to 4.7)	89.5 (64.3 to 117.3)	0.5 (-1.3 to 15.1)
Low back pain	10.0 (8.9 to 11.2)	19.1 (16.9 to 21.2)	91.3 (63.4 to 126.1)	0.6 (-13.0 to 18.0)	1.1 (0.7 to 1.6)	2.1 (1.4 to 3.0)	89.5 (60.9 to 124.5)	0.8 (-13.7 to 18.3)
Neck pain	7.5 (6.0 to 9.2)	14.2 (12.2 to 16.2)	89.5 (48.1 to 149.2)	0.3 (-20.7 to 30.1)	0.7 (0.5 to 1.1)	1.4 (0.9 to 1.9)	88.1 (46.6 to 148.2)	0.2 (-21.0 to 29.6)
Gout	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	126.3 (100.7 to 158.0)	-4.0 (-14.6 to 8.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	123.6 (74.5 to 186.0)	-4.4 (-24.8 to 21.6)
Other musculoskeletal disorders	5.8 (4.7 to 6.9)	14.5 (12.0 to 17.5)	150.2 (127.4 to 176.0)	11.0 (1.5 to 20.6)	0.5 (0.3 to 0.8)	1.3 (0.9 to 1.9)	184.4 (124.9 to 173.5)	31.1 (9.9 to 20.5)
Other non-communicable diseases	-	-	-	-	3.9 (2.6 to 5.6)	6.8 (4.5 to 9.9)	74.9 (68.8 to 84.0)	-5.2 (-8.3 to -1.3)
Congenital anomalies	-	-	-	-	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.6)	95.0 (66.8 to 133.2)	35.2 (15.0 to 62.2)
Neural tube defects	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	49.1 (20.0 to 93.1)	19.6 (-3.4 to 54.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.7 (3.4 to 133.3)	23.2 (-16.1 to 90.0)
Congenital heart anomalies	0.9 (0.7 to 1.1)	2.0 (1.6 to 2.4)	124.9 (59.4 to 217.4)	70.9 (21.7 to 140.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	124.2 (60.0 to 214.4)	71.3 (23.0 to 140.7)
Orofacial clefts	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	98.3 (37.0 to 177.0)	62.0 (11.0 to 124.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.1 (3.8 to 147.0)	29.6 (-16.2 to 96.8)
Down syndrome	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.4)	83.9 (42.6 to 137.7)	27.1 (-1.5 to 64.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	103.2 (55.7 to 167.9)	31.1 (0.4 to 72.8)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.3 (3.3 to 118.5)	10.5 (-24.6 to 58.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.2 (3.4 to 126.4)	9.6 (-25.2 to 63.5)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.8 (-4.0 to 107.2)	-2.2 (-32.3 to 46.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.1 (1.6 to 119.2)	-2.4 (-32.5 to 46.6)
Chromosomal unbalanced rearrangements	0.4 (0.3 to 0.5)	0.7 (0.6 to 0.9)	82.3 (34.2 to 137.4)	65.3 (-7.1 to 54.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	82.3 (50.2 to 168.9)	31.1 (-3.4 to 73.1)
Other congenital anomalies	1.1 (0.9 to 1.2)	1.4 (1.2 to 1.7)	34.1 (21.2 to 47.5)	-11.3 (-19.8 to -3.1)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	90.9 (51.4 to 154.2)	31.4 (4.2 to 75.0)
Skin and subcutaneous diseases	-	-	-	-	1.3 (0.8 to 2.0)	2.0 (1.2 to 3.0)	47.5 (36.7 to 66.5)	-3.0 (-9.7 to 8.4)
Dermatitis	12.3 (9.9 to 14.7)	19.4 (15.7 to 23.2)	58.2 (52.1 to 64.1)	-0.0 (-0.0 to 0.0)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.7)	51.8 (45.0 to 58.5)	-0.1 (-2.7 to 2.8)
Psoriasis	2.0 (1.8 to 2.3)	3.5 (3.0 to 4.0)	73.5 (68.0 to 80.2)	0.0 (-0.0 to 0.0)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	71.8 (61.7 to 83.3)	-0.0 (-4.8 to 5.2)
Cellulitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.6 (27.7 to 69.2)	-14.5 (-22.6 to -5.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.4 (18.5 to 78.9)	-14.3 (-28.9 to 1.5)
Pyoderma	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	87.5 (71.0 to 101.7)	22.6 (17.0 to 28.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.1 (59.8 to 114.2)	22.6 (8.4 to 38.9)
Scabies	3.4 (2.9 to 3.9)	4.5 (3.9 to 5.3)	32.9 (6.9 to 64.5)	-2.6 (-20.9 to 19.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	32.3 (5.7 to 62.7)	-2.8 (-21.2 to 19.1)
Fungal skin diseases	18.5 (14.1 to 24.7)	30.3 (23.8 to 40.0)	63.6 (52.1 to 76.9)	0.1 (-0.0 to 0.1)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	62.5 (51.3 to 75.9)	-0.1 (-0.9 to 0.8)
Viral skin diseases	5.5 (4.0 to 6.9)	6.8 (4.9 to 8.7)	23.6 (17.0 to 32.1)	-0.1 (-2.3 to 1.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	22.8 (15.6 to 32.0)	0.1 (-3.7 to 3.2)
Acne vulgaris	20.0 (14.6 to 26.2)	24.2 (17.1 to 32.1)	20.0 (-18.7 to 93.5)	-4.2 (-35.5 to 52.4)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.5)	19.9 (-18.8 to 94.9)	-4.2 (-35.6 to 52.7)
Alopecia areata	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.4)	66.4 (47.1 to 90.9)	-1.8 (-13.1 to 12.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.2 (39.4 to 98.7)	-1.6 (-16.1 to 15.3)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.6 (51.3 to 133.7)	0.4 (-18.2 to 26.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.6 (51.1 to 134.0)	0.4 (-18.4 to 26.8)
Urticaria	2.5 (1.7 to 3.5)	4.1 (2.7 to 5.9)	57.8 (1.7 to 190.9)	-10.9 (-42.1 to 52.4)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.4)	55.9 (0.8 to 186.3)	-11.5 (-42.1 to 54.2)
Decubitus ulcer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	73.7 (41.7 to 108.6)	-23.5 (-40.2 to -6.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.7 (32.2 to 120.8)	-23.0 (-42.4 to -0.8)
Other skin and subcutaneous diseases	13.7 (9.2 to 20.1)	27.2 (17.3 to 42.7)	97.4 (73.1 to 122.9)	-1.6 (-5.8 to 2.4)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	96.0 (71.3 to 121.8)	-1.7 (-6.0 to 2.5)
Sense organ diseases	-	-	-	-	1.6 (1.1 to 2.2)	2.9 (2.0 to 4.1)	81.1 (73.5 to 94.1)	-11.1 (-15.0 to -6.8)
Glaucoma	0.3 (0.3 to 0.4)	0.6 (0.5 to 0.7)	74.1 (49.6 to 102.7)	-19.7 (-30.8 to -7.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	85.7 (56.1 to 114.4)	-19.3 (-32.0 to -5.4)
Cataract	1.3 (1.0 to 1.7)	2.5 (1.9 to 3.0)	83.8 (64.0 to 109.7)	-29.8 (-36.4 to -20.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	86.1 (67.6 to 107.7)	-29.4 (-35.7 to -21.5)
Macular degeneration	0.3 (0.2 to 0.4)	0.9 (0.7 to 1.2)	191.8 (141.4 to 272.9)	12.6 (-7.6 to 43.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	186.6 (137.7 to 263.2)	10.1 (-9.4 to 39.3)
Uncorrected refractive error	19.9 (18.3 to 21.6)	39.3 (36.4 to 42.3)	98.4 (75.2 to 120.9)	-3.5 (-13.6 to 6.4)	0.3 (0.0 to 0.5)	0.6 (0.3 to 0.9)	81.2 (65.0 to 99.4)	-10.0 (-16.7 to -2.4)
Age-related and other hearing loss	31.1 (28.8 to 33.6)	62.7 (58.8 to 66.9)	101.2 (92.9 to 111.2)	-9.4 (-12.1 to -5.8)	1.0 (0.6 to 1.3)	1.8 (1.2 to 2.5)	90.0 (75.6 to 107.6)	-9.9 (-15.3 to -3.0)
Other vision loss	0.7 (0.6 to 0.8)	0.9 (0.7 to 1.0)	24.4 (8.9 to 38.4)	-32.6 (-38.9 to -27.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	38.8 (20.2 to 59.2)	-31.8 (-38.8 to -24.0)
Other sense organ diseases	5.7 (5.4 to 6.0)	8.4 (8.0 to 8.8)	47.4 (38.2 to 56.5)	-0.3 (-6.6 to 6.0)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	45.6 (35.0 to 56.5)	-0.2 (-7.4 to 6.7)
Oral disorders	-	-	-	-	0.7 (0.4 to 1.2)	1.5 (0.9 to 2.3)	99.4 (91.3 to 108.6)	-4.2 (-7.2 to -1.3)
Deciduous caries	19.0 (18.1 to 20.0)	17.4 (16.7 to 18.2)	-8.2 (-14.5 to -1.6)	-0.4 (-7.2 to 6.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.4 (-16.0 to -0.1)	0.5 (-8.2 to 8.4)
Permanent caries	115.4 (110.5 to 120.3)	173.5 (167.1 to 179.0)	50.5 (41.5 to 60.0)	0.4 (-5.0 to 6.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	49.8 (40.8 to 59.5)	6.4 (-5.3 to 6.4)
Periodontal diseases	25.5 (24.2 to 26.9)	50.8 (48.1 to 53.5)	98.9 (84.4 to 114.7)	-2.4 (-9.4 to 5.0)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.7)	97.9 (83.4 to 113.4)	-2.5 (-9.6 to 4.9)

Appendix Table G.4 - The Bahamas prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	11.9 (11.4 to 12.3)	27.8 (26.8 to 28.7)	133.6 (122.6 to 145.7)	-4.2 (-10.5 to -1.7)	0.3 (0.2 to 0.5)	0.8 (0.5 to 1.0)	132.2 (120.8 to 144.8)	-6.5 (-11.0 to -1.6)
Other oral disorders	4.3 (4.0 to 4.5)	7.1 (6.7 to 7.4)	65.7 (53.0 to 79.8)	-0.1 (-7.5 to 7.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	64.6 (51.0 to 79.3)	-0.2 (-8.2 to 8.1)
Injuries	-	-	-	-	1.3 (1.0 to 1.6)	1.8 (1.3 to 2.4)	39.7 (26.4 to 55.0)	-27.6 (-34.0 to -20.2)
Transport injuries	-	-	-	-	0.5 (0.4 to 0.6)	0.6 (0.5 to 0.9)	35.8 (18.1 to 55.6)	-28.6 (-37.1 to -19.3)
Road injuries	-	-	-	-	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.8)	30.4 (13.2 to 50.4)	-31.1 (-39.2 to -22.0)
Pedestrian road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	15.2 (-1.8 to 33.7)	-39.0 (-47.1 to -30.3)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	48.5 (31.9 to 67.6)	-24.3 (-32.0 to -15.2)
Motorcyclist road injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	18.1 (2.4 to 36.5)	-37.3 (-44.8 to -28.6)
Motor vehicle road injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	39.2 (19.5 to 62.9)	-26.2 (-35.6 to -15.1)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.6 (7.0 to 40.0)	-38.0 (-45.2 to -30.1)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	98.1 (76.4 to 124.5)	1.0 (-9.5 to 13.6)
Unintentional injuries	-	-	-	-	0.7 (0.6 to 0.9)	1.0 (0.8 to 1.4)	42.0 (30.9 to 54.5)	-27.1 (-32.8 to -20.8)
Falls	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	54.8 (37.7 to 73.3)	-29.3 (-37.5 to -20.5)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.8 (5.8 to 29.9)	-39.9 (-48.1 to -30.5)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.5 (-13.3 to 16.9)	-43.7 (-50.6 to -35.6)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.3 (8.9 to 26.6)	-35.1 (-44.0 to -23.5)
Exposure to mechanical forces	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	13.0 (4.1 to 23.0)	-33.5 (-37.9 to -28.6)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.6 (69.7 to 122.9)	8.9 (-4.3 to 22.7)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.9 (51.9 to 96.2)	-2.1 (-12.8 to 9.2)
Other exposure to mechanical forces	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	6.6 (-1.5 to 16.0)	-36.8 (-41.1 to -31.9)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	144.7 (131.4 to 157.1)	21.5 (15.0 to 28.2)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.9 (85.3 to 127.7)	9.8 (0.6 to 19.7)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.8 (78.8 to 129.1)	12.9 (0.9 to 25.8)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.0 (85.6 to 130.6)	8.0 (-2.1 to 18.8)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.3 (34.0 to 64.5)	-22.0 (-28.7 to -14.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.9 (-3.9 to 35.6)	-36.9 (-46.1 to -25.9)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.5 (32.6 to 76.8)	-9.6 (-20.8 to 3.2)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.0 (52.0 to 85.4)	-15.3 (-22.5 to -7.0)
Other unintentional injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	120.0 (102.2 to 139.5)	0.6 (-7.0 to 9.2)
Self-harm and interpersonal violence	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	38.1 (21.4 to 59.8)	-27.5 (-35.7 to -17.3)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.9 (8.6 to 40.0)	-38.4 (-45.3 to -30.5)
Interpersonal violence	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	41.8 (23.6 to 64.8)	-24.9 (-34.0 to -13.6)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.6 (76.9 to 119.2)	2.2 (-7.2 to 12.5)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.2 (28.5 to 77.1)	-21.2 (-31.0 to -7.5)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.6 (-6.9 to 30.2)	-41.2 (-49.7 to -30.9)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - The Gambia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	86.8 (62.8 to 114.5)	166.5 (121.3 to 220.1)	91.9 -4.4	91.9 (-7.5 to -1.9)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	27.5 (19.0 to 38.5)	47.3 (33.2 to 65.5)	72.5 (63.1 to 82.4)	-13.6 (-17.9 to -9.0)
HIV/AIDS and tuberculosis	-	-	-	-	0.9 (0.6 to 1.2)	3.2 (2.2 to 4.3)	246.7 (202.4 to 303.5)	58.1 (39.2 to 85.5)
Tuberculosis	2.9 (2.7 to 3.0)	6.0 (5.7 to 6.4)	112.0 (102.9 to 121.9)	2.7 (1.0 to 6.9)	0.9 (0.6 to 1.2)	1.9 (1.3 to 2.5)	112.7 (100.7 to 125.8)	3.2 (-1.9 to 8.8)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.1)	3.4 (2.8 to 4.0)	2,355.2 (1,559.5 to 4,776.0)	1,133.3 (671.3 to 2,269.3)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.4)	1,594.9 (981.5 to 3,244.4)	709.8 (409.8 to 1,515.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	1,545.3 (832.4 to 3,558.7)	682.1 (351.4 to 1,677.6)
HIV/AIDS resulting in other diseases	0.5 (0.3 to 0.7)	12.1 (9.5 to 13.8)	2,565.0 (1,733.7 to 4,466.9)	1,282.6 (842.6 to 2,339.8)	0.0 (0.0 to 0.1)	1.3 (0.8 to 1.8)	2,622.9 (1,565.2 to 5,523.5)	1,205.8 (665.2 to 2,729.6)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	6.4 (4.5 to 8.6)	8.1 (5.8 to 10.9)	27.7 (18.3 to 37.6)	-34.8 (-39.9 to -29.8)
Diarrheal diseases	23.9 (22.4 to 25.3)	26.8 (25.6 to 28.1)	12.3 (3.9 to 21.8)	-43.9 (-48.2 to -39.7)	3.8 (2.6 to 5.3)	4.3 (3.0 to 6.0)	12.7 (3.9 to 22.5)	43.8 (-48.4 to -39.5)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-	-
Typhoid fever	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.2)	-15.9 (-35.8 to 8.4)	-58.4 (-68.5 to -45.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.2 (-39.7 to 20.7)	-56.9 (-69.1 to -42.4)
Paratyphoid fever	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	7.6 (-18.0 to 37.0)	-46.8 (-58.4 to -31.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.1 (-21.7 to 49.7)	46.0 (-59.7 to -28.1)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-84.1 (-98.1 to -47.7)	-92.1 (-99.1 to -53.1)
Lower respiratory infections	0.6 (0.5 to 0.6)	0.9 (0.8 to 1.0)	52.4 (25.9 to 90.9)	-16.3 (-27.3 to -2.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	54.5 (20.4 to 103.1)	-15.6 (-29.7 to 2.6)
Upper respiratory infections	52.7 (46.4 to 58.6)	108.5 (97.5 to 119.7)	105.3 (74.4 to 140.9)	1.0 (-13.3 to 18.1)	0.6 (0.4 to 1.1)	1.3 (0.7 to 2.1)	105.6 (75.3 to 142.1)	1.2 (-13.4 to 18.2)
Otitis media	20.1 (18.1 to 22.0)	38.1 (34.1 to 42.3)	89.3 (71.3 to 109.5)	-7.1 (-16.5 to 2.8)	0.4 (0.2 to 0.7)	0.8 (0.5 to 1.3)	89.7 (70.2 to 112.7)	-7.0 (-16.9 to 4.1)
Meningitis	-	-	-	-	1.3 (0.9 to 1.8)	1.5 (1.0 to 2.0)	14.3 (5.8 to 40.9)	-41.8 (-51.9 to -29.3)
Pneumococcal meningitis	6.2 (3.7 to 9.3)	6.4 (4.0 to 9.8)	1.7 (-18.8 to 39.1)	-48.2 (-58.8 to -29.4)	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.9)	7.9 (-18.7 to 50.2)	45.5 (-58.2 to -25.3)
H influenzae type B meningitis	2.6 (0.9 to 4.8)	2.5 (1.1 to 4.8)	2.2 (-36.9 to 46.4)	-49.0 (-67.7 to -29.0)	0.3 (0.1 to 0.5)	0.3 (0.2 to 0.5)	16.5 (-36.6 to 83.2)	-41.8 (-67.7 to -10.4)
Meningococcal meningitis	2.6 (0.9 to 5.8)	2.9 (1.2 to 6.1)	14.3 (-12.1 to 64.4)	-42.0 (-55.3 to -17.3)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	29.3 (-11.6 to 99.3)	-34.3 (-53.1 to -0.4)
Other meningitis	1.6 (1.0 to 2.4)	1.7 (1.1 to 2.5)	4.9 (-18.7 to 30.2)	-45.3 (-58.0 to -30.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	10.4 (-18.9 to 43.5)	-42.9 (-58.4 to -24.6)
Encephalitis	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.7)	91.9 (73.8 to 114.5)	-2.2 (-12.8 to 13.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	92.2 (69.8 to 132.3)	-3.7 (-16.0 to 9.9)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.8 (-95.4 to 2,242.6)	-49.9 (-96.2 to 699.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.8 (-95.4 to 2,253.8)	-49.9 (-96.3 to 700.9)
Whooping cough	0.5 (0.4 to 0.6)	0.4 (0.3 to 0.5)	-17.1 (-21.5 to -12.5)	-57.9 (-60.1 to -55.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.0 (-31.5 to -0.8)	-57.8 (-65.3 to -49.4)
Tetanus	0.2 (0.1 to 0.5)	0.1 (0.0 to 0.1)	-75.3 (-94.3 to 4.9)	-87.8 (-97.5 to -47.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-69.4 (-88.7 to 8.5)	-83.5 (-94.3 to -44.4)
Measles	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-27.1 (-37.2 to -15.2)	-45.5 (-68.6 to -57.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.3 (-54.8 to 12.9)	-42.6 (-77.2 to -43.7)
Varicella and herpes zoster	0.6 (0.5 to 0.6)	1.2 (1.1 to 1.3)	113.3 (86.3 to 141.8)	1.7 (-18.3 to 24.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.3 (48.7 to 186.6)	2.4 (-30.3 to 42.6)
Neglected tropical diseases and malaria	-	-	-	-	5.6 (3.4 to 8.7)	9.8 (6.1 to 15.2)	75.2 (59.1 to 91.3)	-15.2 (-25.6 to -2.8)
Malaria	142.7 (133.1 to 152.5)	219.0 (201.9 to 236.8)	53.2 (44.0 to 62.9)	-26.2 (-31.3 to -19.9)	1.6 (1.1 to 2.4)	2.4 (1.6 to 3.4)	45.3 (28.5 to 63.8)	-28.2 (-37.0 to -19.4)
Chagas disease	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,460.8 (586.0 to 4,424.1)	1,049.2 (429.3 to 2,945.8)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.0 (3.9 to 204.8)	-3.6 (-42.2 to 44.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.0 (3.8 to 205.2)	-3.6 (-42.3 to 44.3)
Cutaneous and mucocutaneous leishmaniasis	0.1 (0.0 to 0.1)	0.9 (0.4 to 1.7)	1,432.2 (646.7 to 4,361.5)	1,064.4 (449.3 to 2,672.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,470.5 (588.3 to 4,487.4)	1,056.6 (431.0 to 2,987.9)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	166.7 (78.1 to 297.8)	340.2 (161.5 to 608.9)	104.1 (99.4 to 108.6)	0.2 (-1.7 to 2.1)	1.6 (0.6 to 3.5)	3.2 (1.3 to 7.1)	105.6 (80.5 to 120.2)	0.5 (-10.0 to 7.2)
Cysticercosis	0.1 (0.0 to 0.3)	0.0 (0.0 to 0.1)	-78.3 (-95.8 to 55.1)	-89.6 (-97.4 to -32.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-74.9 (-95.8 to 87.2)	-88.1 (-97.3 to -23.5)
Cystic echinococcosis	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.3)	39.7 (25.9 to 55.0)	-2.9 (-12.5 to 9.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.1 (13.0 to 75.4)	-2.5 (-19.6 to 15.7)
Lymphatic filariasis	39.4 (28.2 to 51.2)	70.2 (52.7 to 88.3)	76.6 (37.7 to 140.8)	-14.4 (-29.8 to 6.7)	1.2 (0.6 to 2.2)	2.2 (1.0 to 3.8)	79.0 (26.9 to 152.1)	-15.9 (-37.4 to 18.1)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	0.5 (0.3 to 0.7)	0.2 (0.1 to 0.4)	-52.6 (-65.6 to -34.8)	-74.3 (-81.7 to -63.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.5 (-64.9 to -35.1)	-73.8 (-81.2 to -63.5)
Dengue	0.1 (0.1 to 0.3)	1.3 (0.5 to 2.8)	891.3 (882.4 to 901.5)	389.2 (384.8 to 394.3)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.5)	896.1 (685.0 to 1,157.7)	388.5 (301.9 to 494.7)
Yellow fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.7 (-68.4 to -4.0)	-73.9 (-83.2 to -57.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.7 (-65.5 to -3.6)	-73.9 (-83.2 to -57.5)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Intestinal nematode infections	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	100.0 (45.1 to 169.8)	-3.4 (-30.2 to 34.3)
Ascariasis	8.0 (5.0 to 12.5)	16.3 (10.2 to 24.9)	104.6 (9.9 to 291.4)	1.1 (-53.7 to 121.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	100.1 (-4.4 to 337.3)	-1.4 (-56.6 to 129.1)
Trichuriasis	23.6 (14.8 to 37.3)	47.8 (29.8 to 75.7)	100.8 (7.6 to 294.7)	-1.9 (-55.3 to 127.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.7 (-6.0 to 340.8)	1.7 (-62.8 to 145.4)
Hookworm disease	45.4 (28.6 to 68.7)	91.6 (61.3 to 138.7)	104.0 (13.2 to 269.0)	0.1 (-51.5 to 109.0)	0.3 (0.1 to 0.2)	0.3 (0.2 to 0.4)	100.0 (45.0 to 169.7)	-3.4 (-30.3 to 34.3)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	18.6 (13.8 to 23.5)	33.9 (31.6 to 37.4)	82.8 (43.1 to 147.1)	-14.0 (-30.5 to 10.6)	0.9 (0.6 to 1.5)	1.5 (1.0 to 2.2)	58.2 (29.7 to 123.6)	-31.1 (-48.8 to -9.9)
Maternal disorders	-	-	-	-	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.8)	75.8 (48.6 to 101.1)	-11.4 (-24.2 to 0.7)
Maternal hemorrhage	1.0 (0.7 to 1.3)	2.5 (1.8 to 3.1)	145.1 (70.5 to 247.3)	30.0 (-7.8 to 79.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	132.2 (46.3 to 252.5)	21.6 (-23.4 to 87.1)
Maternal sepsis and other maternal infections	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	22.7 (7.4 to 57.2)	-38.7 (-47.5 to -22.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.1 (-41.5 to 115.0)	-40.4 (-66.4 to 2.0)
Maternal hypertensive disorders	0.3 (0.1 to 0.6)	0.6 (0.2 to 1.1)	89.8 (49.0 to 114.7)	-0.1 (-19.6 to 12.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	87.3 (45.2 to 126.0)	-1.5 (-23.1 to 17.3)
Obstructed labor	0.7 (0.5 to 0.9)	1.1 (0.8 to 1.4)	62.6 (45.4 to 81.6)	-18.3 (-26.9 to -9.0)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	62.7 (39.5 to 88.6)	-18.2 (-29.6 to -6.3)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.3 (13.2 to 263.9)	-7.3 (-38.8 to 66.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.3 (13.1 to 264.4)	-7.3 (-38.9 to 66.7)
Other maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	78.7 (6.6 to 175.4)	9.1 (-45.3 to 40.1)
Neonatal disorders	-	-	-	-	0.6 (0.3 to 1.0)	3.0 (1.9 to 4.4)	423.7 (216.8 to 811.6)	175.8 (60.7 to 401.0)
Preterm birth complications	3.0 (1.5 to 5.8)	14.4 (8.7 to 24.2)	376.2 (263.3 to 598.5)	132.3 (83.0 to 230.9)	0.2 (0.1 to 0.4)	1.6 (1.0 to 2.8)	625.8 (260.2 to 1,280.7)	275.7 (92.2 to 615.8)
Neonatal encephalopathy due to birth asphyxia and trauma	5.6 (0.6 to 17.7)	8.5 (1.6 to 24.9)	60.9 (14.5 to 261.7)	-23.3 (-45.7 to 72.0)	0.2 (0.1 to 0.5)	0.7 (0.3 to 1.1)	207.9 (67.3 to 631.7)	58.5 (-16.9 to 351.9)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	241.3 (238.2 to 307.6)	84.7 (83.1 to 120.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	248.5 (213.8 to 307.4)	88.7 (69.9 to 120.5)
Hemolytic disease and other neonatal jaundice	0.2 (0.1 to 0.4)	1.1 (0.5 to 2.0)	246.8 (191.1 to 318.9)	0.4 (-57.6 to 75.4)	0.1 (0.0 to 0.2)	0.4 (0.2 to 0.8)	518.7 (192.4 to 1,368.3)	244.0 (57.9 to 764.0)
Other neonatal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.5)	385.3 (115.8 to 1,073.3)	155.0 (13.7 to 534.3)
Nutritional deficiencies	-	-	-	-	12.8 (8.5 to 18.1)	21.2 (14.0 to 30.6)	65.7 (47.9 to 82.8)	-20.6 (-27.7 to -14.0)
Protein-energy malnutrition	10.1 (4.8 to 19.2)	13.2 (6.0 to 25.0)	29.0 (-52.9 to 270.5)	31.2 (-70.8 to 76.8)	1.6 (0.5 to 2.5)	1.6 (0.6 to 3.5)	29.0 (-4.9 to 274.3)	31.1 (-71.8 to 78.4)
Iodine deficiency	39.5 (21.7 to 64.4)	45.1 (25.9 to 71.4)	12.9 (-38.5 to 128.1)	-42.4 (-70.6 to 21.5)	0.7 (0.3 to 1.4)	0.8 (0.4 to 1.6)	13.0 (-39.4 to 127.1)	-42.4 (-70.8 to 21.3)
Vitamin A deficiency	0.7 (0.5 to 1.0)	0.7 (0.4 to 0.9)	-8.8 (-24.1 to 11.4)	-55.9 (-63.3 to -44.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.1 (-32.2 to 8.9)	-57.8 (-66.2 to -46.6)

Appendix Table G.4 - The Gambia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	283.9 (278.9 to 288.9)	503.4 (495.8 to 511.0)	77.2 (73.9 to 80.8)	-16.5 (-18.0 to -14.7)	10.8 (7.2 to 15.4)	18.7 (12.6 to 26.9)	73.0 (68.4 to 77.3)	-18.0 (-20.2 to -15.5)
Other nutritional deficiencies	-	-	-	-	0.0	0.0	0.0	-6.2
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.9 (0.6 to 1.3)	1.4 (0.9 to 2.1)	56.5 to 561.3 (52.6 to 86.0)	(-75.1 to 219.6) (-29.1 to -13.4)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.6)	65.6 (26.7 to 114.5)	-16.8 (-34.0 to 0.8)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	6.9 (-10.9 to 28.4)	-46.0 (-53.6 to -37.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.5 (-18.9 to -41.6)	45.8 (-57.6 to -31.7)
Chlamydial infection	13.4 (7.8 to 17.5)	28.1 (19.0 to 36.5)	111.9 (29.5 to 220.8)	6.5 (-32.4 to 63.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	86.8 (4.4 to 227.9)	-5.8 (-4.9 to 56.6)
Gonococcal infection	5.0 (3.6 to 6.6)	8.8 (5.3 to 11.8)	80.3 (12.3 to 155.0)	-9.8 (-38.2 to 25.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	56.8 (-12.2 to 157.0)	-20.8 (53.1 to 26.1)
Trichomoniasis	21.1 (14.6 to 27.7)	28.5 (12.9 to 47.4)	30.6 (-40.1 to 175.9)	-28.2 (-63.4 to 28.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	25.2 (-46.9 to 180.5)	-30.4 (-66.8 to 34.3)
Genital herpes	130.3 (120.8 to 138.6)	269.3 (250.8 to 285.7)	106.9 (88.1 to 126.9)	1.5 (-7.5 to 11.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	105.8 (82.8 to 128.5)	1.5 (-9.0 to 12.2)
Other sexually transmitted diseases	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	81.3 (50.7 to 116.6)	-11.5 (-27.3 to 6.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.7 (24.2 to 174.1)	8.0 (-35.7 to 30.3)
Hepatitis	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	29.6 (5.6 to 60.5)	-40.2 (-52.7 to -20.1)
Hepatitis A	1.6 (1.5 to 1.7)	3.1 (2.9 to 3.2)	88.5 (88.0 to 89.2)	-3.3 (-3.4 to -3.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	100.4 (75.9 to 126.3)	2.0 (-9.6 to 13.8)
Hepatitis B	180.5 (150.0 to 214.2)	210.7 (179.4 to 240.8)	17.2 (-6.4 to 46.9)	-48.1 (-54.6 to -32.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	3.5 (-26.3 to 45.4)	-50.1 (-64.6 to -25.6)
Hepatitis C	14.0 (12.3 to 15.6)	20.9 (18.8 to 23.2)	49.5 (28.0 to 78.7)	-26.4 (-36.3 to -15.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.7 (19.1 to 95.5)	-23.2 (-45.3 to 10.4)
Hepatitis E	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	24.5 (-4.8 to 87.2)	-35.3 (-49.7 to -9.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.8 (-11.6 to 98.4)	-34.7 (-52.3 to -3.6)
Leprosy	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.2)	18.8 (-27.4 to 127.2)	-35.0 (-57.9 to 24.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.4 (-28.0 to 153.8)	-33.0 (-58.7 to 35.1)
Other infectious diseases	13.3 (10.1 to 16.7)	23.9 (22.2 to 25.4)	79.9 (62.7 to 98.5)	-16.3 (-25.3 to -9.0)	0.5 (0.3 to 0.8)	0.9 (0.6 to 1.3)	75.9 (59.8 to 103.9)	-16.6 (-25.2 to -3.1)
Non-communicable diseases	-	-	-	-	55.3 (40.6 to 71.4)	114.2 (84.1 to 147.4)	106.4 (100.0 to 113.9)	1.0 (-2.0 to 5.0)
Neoplasms	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.9)	98.9 (41.2 to 197.9)	-6.9 (-31.0 to 31.3)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	134.0 (28.6 to 321.7)	15.4 (-34.9 to 103.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	132.1 (35.7 to 302.2)	15.4 (-31.9 to 93.8)
Stomach cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	78.7 (8.1 to 203.1)	-9.5 (-44.7 to 48.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.4 (4.6 to 194.9)	-9.4 (-45.2 to 45.9)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	114.2 (24.2 to 275.0)	7.2 (-36.3 to 77.4)
Liver cancer due to hepatitis B	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.5)	133.1 (15.2 to 385.4)	12.9 (-46.1 to 137.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	128.7 (14.1 to 347.9)	11.7 (-45.8 to 121.5)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	477.7 (144.4 to 1,287.8)	185.7 (23.1 to 534.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	431.8 (135.1 to 1,118.9)	158.3 (15.3 to 442.8)
Liver cancer due to alcohol use	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	11.6 (-49.5 to 154.7)	-42.0 (-71.4 to 23.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.2 (-45.7 to 132.3)	-42.0 (-70.5 to 16.5)
Liver cancer due to other causes	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	41.9 (-32.8 to 181.8)	-22.9 (-66.7 to 34.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.2 (-32.3 to 165.6)	33.9 (-65.7 to 24.9)
Larynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	139.9 (23.7 to 332.2)	33.4 (-34.7 to 150.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.3 (13.1 to 267.9)	8.1 (-41.4 to 90.4)
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	102.7 (20.1 to 226.6)	7.0 (-33.5 to 62.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	100.5 (19.1 to 240.8)	6.4 (-33.2 to 72.1)
Breast cancer	0.9 (0.7 to 1.0)	0.5 (0.3 to 0.9)	-23.3 (-65.6 to 0.1)	-79.6 (-87.2 to -65.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	13.2 (-35.6 to 102.2)	-56.3 (-74.5 to -22.8)
Cervical cancer	0.5 (0.2 to 0.8)	1.1 (0.5 to 1.9)	126.9 (26.1 to 350.6)	10.0 (-37.2 to 116.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	127.4 (26.6 to 339.4)	12.4 (-36.2 to 108.6)
Uterine cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.3)	111.0 (2.3 to 335.8)	0.7 (-48.7 to 103.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.6 (1.2 to 331.4)	0.6 (-1.2 to 102.5)
Prostate cancer	0.1 (0.1 to 0.2)	0.5 (0.3 to 0.7)	329.0 (196.9 to 523.4)	136.1 (61.5 to 231.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	316.4 (175.5 to 500.5)	129.7 (52.9 to 229.3)
Colon and rectum cancer	0.4 (0.4 to 0.4)	0.9 (0.8 to 1.0)	108.0 (87.2 to 133.7)	2.2 (-6.8 to 11.6)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	108.4 (84.0 to 138.9)	2.5 (-7.0 to 14.0)
Lip and oral cavity cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	122.9 (22.6 to 315.2)	7.4 (-36.7 to 93.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	121.2 (25.7 to 290.2)	8.7 (-33.8 to 88.8)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.6 (5.7 to 296.7)	-1.3 (-46.6 to 86.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.3 (5.6 to 274.5)	2.7 (-45.1 to 75.7)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.6 (-1.3 to 303.2)	-4.0 (-51.1 to 89.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.3 (6.6 to 277.4)	-5.5 (-48.1 to 79.4)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.8 (2.5 to 262.5)	-6.7 (-49.8 to 67.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.4 (1.2 to 238.1)	-10.1 (-50.5 to 58.2)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	188.5 (67.1 to 428.5)	41.8 (-14.1 to 145.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	189.5 (74.6 to 401.4)	43.5 (-12.3 to 142.6)
Malignant skin melanoma	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	179.1 (60.3 to 410.6)	37.7 (-19.3 to 132.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	178.8 (57.6 to 394.7)	35.0 (-20.3 to 130.4)
Non-melanoma skin cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	152.6 (86.0 to 245.9)	28.4 (-4.1 to 80.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	200.0 (115.4 to 333.8)	52.3 (4.4 to 134.0)
Ovarian cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	194.9 (61.0 to 471.7)	42.8 (-21.1 to 162.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	186.0 (46.9 to 501.0)	39.5 (-30.3 to 179.7)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	140.1 (14.0 to 389.5)	11.7 (-42.4 to 116.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.0 (13.5 to 370.1)	6.9 (-42.3 to 104.5)
Kidney cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	102.1 (13.7 to 288.1)	22.8 (-24.8 to 116.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	114.4 (19.7 to 292.7)	23.8 (-24.6 to 112.9)
Bladder cancer	0.2 (0.2 to 0.2)	0.1 (0.0 to 0.1)	-41.3 (-76.4 to -38.6)	-84.1 (-89.7 to -75.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.1 (-81.3 to -49.9)	-86.9 (-91.6 to -79.9)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	272.3 (113.4 to 512.8)	88.4 (14.0 to 202.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	256.4 (108.2 to 490.7)	76.6 (7.8 to 179.7)
Thyroid cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	154.8 (46.3 to 393.5)	27.6 (-26.9 to 146.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	148.9 (38.9 to 393.3)	24.7 (-29.2 to 133.2)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	134.3 (43.4 to 301.2)	17.0 (-28.9 to 99.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	133.7 (42.7 to 290.9)	16.4 (-28.7 to 98.6)
Hodgkin lymphoma	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.2)	174.8 (55.9 to 380.5)	53.3 (-12.8 to 163.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	168.1 (47.9 to 358.0)	47.0 (-16.0 to 149.9)
Non-Hodgkin lymphoma	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	136.6 (37.7 to 292.3)	23.1 (-24.5 to 108.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	136.4 (41.3 to 298.9)	21.0 (-25.1 to 109.4)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	177.7 (53.3 to 432.8)	35.4 (-24.2 to 158.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	169.7 (47.3 to 439.3)	33.1 (-28.0 to 158.6)
Leukemia	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	218.2 (91.6 to 433.4)	61.5 (-3.2 to 161.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	190.7 (80.7 to 362.9)	43.3 (-13.2 to 128.8)
Other neoplasms	0.3 (0.2 to 0.4)	0.8 (0.5 to 1.2)	205.6 (43.3 to 440.6)	38.1 (-19.1 to 135.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	191.7 (50.5 to 396.2)	27.9 (-24.3 to 118.4)
Cardiovascular diseases	-	-	-	-	1.4 (1.0 to 1.9)	2.8 (1.8 to 4.0)	91.4 (53.8 to 137.0)	-2.0 (-20.2 to 19.7)
Rheumatic heart disease	10.1 (7.7 to 13.1)	15.1 (11.7 to 19.0)	50.7 (8.3 to 115.1)	-22.6 (-38.5 to 5.9)	0.5 (0.3 to 0.8)	0.8 (0.5 to 1.1)	54.5 (10.5 to 119.6)	-18.1 (-36.1 to 13.5)
Ischemic heart disease	5.8 (4.7 to 7.6)	8.3 (6.6 to 10.3)	42.1 (1.5 to 99.0)	-23.1 (-44.1 to 2.6)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	31.6 (-23.3 to 98.5)	-31.6 (-56.6 to 4.7)
Cerebrovascular disease	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	101.4 (63.6 to 142.9)	0.5 (-1.9 to 20.7)
Ischemic stroke	0.3 (0.3 to 0.4)	0.7 (0.6 to 0.7)	103.9 (61.8 to 141.5)	1.1 (-20.3 to 20.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	104.3 (61.4 to 147.4)	1.1 (-20.9 to 23.6)
Hemorrhagic stroke	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	92.9 (53.0 to 147.6)	-6.8 (-24.3 to 21.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.0 (51.1 to 152.7)	-6.0 (-25.8 to 24.9)
Hypertensive heart disease	1.2 (0.9 to 1.5)	2.2 (1.4 to 2.9)	93.1 (2.0 to 333.9)	-7.7 (-50.3 to 46.3)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	94.3 (1.5 to 195.7)	-2.3 (-49.8 to 49.4)
Cardiomyopathy and myocarditis	0.8 (0.6 to 1.0)	1.6 (1.2 to 2.0)	96.2 (40.1 to 173.7)	-0.0 (-34.7 to 53.8)	0.0 (0.1 to 0.1)	0.2 (0.1 to 0.3)	96.1 (38.4 to 177.9)	0.0 (-34.9 to 55.1)
Atrial fibrillation and flutter	0.1 (0.1 to 0.1)	0.6 (0.5 to 0.8)	482.0 (299.9 to 832.4)	172.2 (58.0 to 376.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	480.8 (292.0 to 845.1)	174.2 (58.8 to 386.5)
Peripheral vascular disease	11.5 (8.4 to 14.8)	21.6 (15.8 to 29.2)	86.8 (29.0 to 186.9)	-7.9 (-34.4 to 38.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.4 (-46.7 to 139.9)	-40.7 (-69.0 to 19.2)
Endocarditis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	33.2 (-17.4 to 112.0)	-25.1 (-58.8 to 40.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.3 (-18.9 to 149.3)	-23.3 (-61.5 to 56.7)
Other cardiovascular and circulatory diseases	5.1 (3.4 to 7.2)	14.6 (7.7 to 21.7)	184.8 (45.5 to 399.8)	34.6 (-30.7 to 148.3)	0.4 (0.2 to 0.5)	1.0 (0.5 to 1.7)	185.0 (72.2 to 409.1)	35.4 (-31.6 to 155.0)
Chronic respiratory diseases	-	-	-	-	3.3 (2.2 to 4.5)	7.1 (4.9 to 9.8)	118.9 (78.0 to 157.1)	-1.2 (-18.4 to 15.1)
Chronic obstructive pulmonary disease	26.4 (25.0 to 27.7)	53.3 (50.4 to 56.3)	102.2 (95.					

Appendix Table G.4 - The Gambia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumococcal	-	-	-	-	0.0	0.0	87.3	-
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.4 (64.9 to 82.5)	-13.9 (-18.3 to -9.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.5 to 95.1	(-11.5 to -4.8)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	73.0	(-18.7 to -9.0)
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.7 (92.9 to 110.6)	-4.8 (-4.3 to 2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.2	(-4.9 to 3.2)
Asthma	11.5 (6.9 to 17.3)	45.1 (34.1 to 57.7)	296.4 (134.8 to 574.6)	53.6 (4.4 to 124.3)	0.5 (0.3 to 0.9)	2.0 (1.2 to 3.1)	297.9	(5.2 to 128.2)
Interstitial lung disease and pulmonary sarcoidosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.3 (54.8 to 172.5)	3.7 (-19.5 to 30.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.4	4.5
Other chronic respiratory diseases	-	-	-	-	0.6 (0.3 to 0.9)	0.9 (0.5 to 1.4)	50.3	(-26.7 to 5.9)
Cirrhosis	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	61.4	(-28.4 to -10.1)
Cirrhosis due to hepatitis B	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	16.4 (-38.9 to 90.6)	-35.5 (-68.4 to 0.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	17.6	(-39.7 to 102.7)
Cirrhosis due to hepatitis C	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	154.6 (53.3 to 322.0)	14.5 (-34.1 to 77.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	153.3	(-36.1 to 86.0)
Cirrhosis due to alcohol use	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	42.3 (-9.4 to 136.5)	-27.5 (-55.0 to 22.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.9	(-12.2 to 151.2)
Cirrhosis due to other causes	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	89.4 (41.4 to 149.7)	2.5 (-26.2 to 47.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	88.4	(5.6 to 17.1)
Digestive diseases	-	-	-	-	1.0 (0.7 to 1.4)	2.1 (1.5 to 2.9)	105.6	(-11.1 to 9.3)
Peptic ulcer disease	4.4 (3.7 to 5.0)	6.2 (5.5 to 7.0)	40.1 (20.5 to 67.5)	-25.8 (-33.2 to -13.4)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	45.3	(-41.7 to -14.3)
Gastritis and duodenitis	10.7 (9.3 to 11.8)	20.4 (18.4 to 22.3)	90.7 (64.4 to 123.0)	-1.0 (-13.2 to 13.6)	0.4 (0.3 to 0.6)	0.9 (0.6 to 1.3)	99.4	(13.4 to 20.2)
Appendicitis	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	146.6 (67.2 to 347.4)	13.3 (-18.1 to 98.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	149.5	(-24.0 to 111.5)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.2 (15.3 to 188.1)	-3.0 (-16.3 to 11.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.7	(-25.6 to 30.0)
Inguinal, femoral, and abdominal hernia	2.4 (2.0 to 2.8)	3.8 (3.2 to 5.0)	60.2 (23.5 to 113.2)	-17.7 (-36.7 to 7.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	61.1	(-36.6 to 7.4)
Inflammatory bowel disease	0.8 (0.7 to 0.8)	2.0 (1.9 to 2.1)	158.7 (142.9 to 175.6)	25.3 (18.5 to 33.1)	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.6)	159.9	(16.6 to 36.3)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	208.9 (128.8 to 338.8)	25.7 (-9.4 to 86.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	204.3	(-25.7 to 107.9)
Gallbladder and biliary diseases	0.2 (0.2 to 0.3)	0.5 (0.5 to 0.6)	126.8 (95.5 to 163.6)	0.0 (-8.7 to 24.1)	0.1 (0.0 to 0.0)	0.1 (0.0 to 0.1)	128.0	(9.9 to 29.1)
Pancreatitis	0.1 (0.1 to 0.1)	0.3 (0.3 to 0.3)	122.2 (104.7 to 142.3)	6.9 (-1.4 to 15.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	122.4	(-8.5 to 24.8)
Other digestive diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	115.8	(-26.8 to 57.8)
Neurological disorders	-	-	-	-	3.5 (2.3 to 4.8)	7.7 (5.1 to 10.9)	121.9	(-3.3 to 20.7)
Alzheimer disease and other dementias	1.0 (0.8 to 1.1)	1.9 (1.7 to 2.1)	99.5 (66.2 to 144.5)	2.1 (-15.4 to 24.0)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	102.8	(-14.9 to 25.5)
Parkinson disease	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	93.1 (82.7 to 103.8)	0.2 (-4.3 to 6.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.8	(-15.8 to 19.9)
Epilepsy	0.9 (0.5 to 1.5)	1.8 (1.0 to 2.8)	91.0 (-4.0 to 291.2)	-5.9 (-53.0 to 94.2)	0.3 (0.1 to 0.5)	0.6 (0.3 to 1.0)	97.0	(-51.7 to 105.0)
Multiple sclerosis	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	143.0 (105.7 to 190.6)	17.1 (1.1 to 37.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	139.2	(-5.9 to 47.8)
Migraine	61.5 (56.0 to 67.1)	125.0 (115.2 to 135.4)	102.8 (79.2 to 131.1)	2.1 (-10.8 to 13.3)	2.1 (1.3 to 3.1)	4.3 (2.6 to 6.4)	109.9	(-11.0 to 14.0)
Tension-type headache	107.3 (98.5 to 117.0)	228.4 (206.6 to 248.4)	113.4 (87.2 to 141.4)	3.9 (-6.6 to 14.8)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.6)	113.5	(-7.1 to 15.6)
Medication overuse headache	3.8 (2.5 to 5.2)	11.8 (7.6 to 16.4)	210.6 (108.7 to 340.5)	48.4 (8.1 to 103.5)	0.6 (0.3 to 0.9)	1.9 (1.0 to 3.0)	211.9	(7.9 to 104.4)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.5 (40.7 to 165.1)	-6.6 (-33.7 to 27.2)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	92.5	(-37.6 to 45.8)
Mental and substance use disorders	-	-	-	-	20.6 (14.5 to 27.1)	42.8 (29.8 to 57.0)	107.8	(-1.0 to 7.7)
Schizophrenia	1.8 (1.6 to 1.9)	3.6 (3.3 to 4.0)	105.5 (96.9 to 116.3)	-0.4 (-4.0 to 4.2)	1.1 (0.8 to 1.4)	2.3 (1.7 to 2.9)	106.3	(-5.4 to 6.3)
Alcohol use disorders	4.3 (4.0 to 4.7)	9.8 (9.1 to 10.5)	126.3 (114.8 to 137.9)	11.2 (6.2 to 16.5)	0.4 (0.3 to 0.6)	0.9 (0.6 to 1.3)	128.4	(4.8 to 20.4)
Drug use disorders	-	-	-	-	1.1 (0.7 to 1.5)	2.2 (1.5 to 3.1)	99.5	(-11.2 to 7.4)
Opioid use disorders	1.4 (0.9 to 2.1)	2.9 (1.9 to 4.2)	102.3 (83.3 to 133.8)	-4.9 (-13.4 to 7.9)	0.6 (0.3 to 0.9)	1.2 (0.7 to 1.9)	103.4	(-14.2 to 10.3)
Cocaine use disorders	0.4 (0.4 to 0.5)	0.9 (0.7 to 1.0)	98.6 (59.3 to 152.7)	1.3 (-17.9 to 20.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	100.0	(-22.9 to 28.4)
Amphetamine use disorders	1.5 (1.4 to 1.6)	2.8 (2.6 to 3.0)	91.2 (73.2 to 115.2)	-2.3 (-10.8 to 8.8)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	92.6	(-15.2 to 16.2)
Cannabis use disorders	0.7 (0.5 to 0.8)	1.3 (1.0 to 1.6)	100.0 (98.0 to 101.8)	-0.5 (-0.7 to -0.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	97.8	(-19.5 to 22.0)
Other drug use disorders	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	95.9	(-28.6 to 33.7)
Depressive disorders	-	-	-	-	10.2 (6.7 to 14.5)	21.5 (14.1 to 31.4)	113.1	(-1.2 to 13.6)
Major depressive disorder	45.9 (37.0 to 56.8)	97.9 (77.8 to 120.7)	113.3 (97.3 to 130.1)	5.5 (-1.9 to 14.5)	9.4 (6.1 to 13.6)	20.2 (13.0 to 29.3)	113.6	(-1.6 to 14.9)
Dysthymia	8.3 (6.6 to 10.1)	17.0 (13.7 to 20.7)	106.2 (102.9 to 110.4)	1.5 (1.1 to 2.1)	0.8 (0.5 to 1.2)	1.8 (1.1 to 2.4)	106.7	(-0.7 to 4.4)
Bipolar disorder	4.9 (4.2 to 5.6)	10.0 (8.6 to 11.4)	102.1 (88.9 to 115.0)	0.7 (-4.6 to 5.9)	1.0 (0.6 to 1.5)	2.0 (1.2 to 3.1)	102.7	(-5.9 to 7.7)
Anxiety disorders	20.7 (17.1 to 24.8)	42.3 (35.0 to 50.4)	104.5 (102.0 to 106.8)	4.7 (0.4 to 1.1)	10.2 (1.3 to 2.7)	21.5 (2.6 to 5.6)	113.1	(-2.2 to 4.3)
Eating disorders	-	-	-	-	0.2 (0.1 to 0.4)	0.5 (0.3 to 0.7)	100.8	(-6.3 to 10.8)
Anorexia nervosa	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.4)	109.7 (86.1 to 142.5)	5.2 (-6.4 to 21.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	110.8	(-18.8 to 36.4)
Bulimia nervosa	1.0 (0.6 to 1.4)	1.9 (1.3 to 2.8)	98.3 (92.3 to 104.2)	0.7 (-0.0 to 1.8)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	99.0	(-7.6 to 11.0)
Autistic spectrum disorders	-	-	-	-	1.1 (0.8 to 1.5)	2.2 (1.5 to 3.0)	102.4	(-4.6 to 1.8)
Autism	2.8 (2.7 to 3.0)	5.7 (5.4 to 6.0)	101.7 (101.6 to 101.8)	-1.6 (-1.7 to -1.6)	0.7 (0.5 to 1.0)	1.4 (0.9 to 1.9)	102.6	(-6.2 to 3.5)
Asperger syndrome	4.1 (3.8 to 4.3)	8.2 (7.6 to 8.6)	101.2 (101.0 to 101.3)	-2.1 (-2.3 to -2.0)	0.4 (0.3 to 0.6)	0.8 (0.6 to 1.1)	101.9	(-5.4 to 2.1)
Attention-deficit/hyperactivity disorder	6.7 (6.2 to 7.2)	13.7 (12.7 to 14.9)	106.0 (105.9 to 106.4)	0.2 (0.2 to 0.2)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	106.7	(-7.1 to 8.2)
Conduct disorder	0.6 (0.0 to 10.1)	20.0 (18.9 to 21.2)	109.7 (109.1 to 110.2)	0.1 (0.1 to 0.1)	1.1 (0.7 to 1.7)	2.4 (1.5 to 3.5)	113.3	(-3.8 to 5.1)
Idiopathic intellectual disability	27.4 (17.2 to 36.6)	51.6 (36.4 to 66.4)	88.0 (60.8 to 134.5)	6.1 (-20.3 to 20.4)	1.3 (0.7 to 2.0)	2.5 (1.5 to 3.7)	88.8	(-20.7 to 21.1)
Other mental and substance use disorders	11.2 (10.4 to 11.9)	21.9 (20.4 to 23.3)	96.3 (95.2 to 97.6)	-1.5 (-2.0 to -1.0)	0.8 (0.6 to 1.1)	1.6 (1.1 to 2.2)	97.0	(-4.5 to 2.7)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	5.2 (3.7 to 7.0)	10.9 (7.7 to 14.9)	110.2	(-0.7 to 14.9)
Diabetes mellitus	8.0 (6.5 to 9.6)	24.1 (19.8 to 29.0)	202.1 (138.7 to 277.4)	48.2 (11.8 to 88.7)	0.5 (0.5 to 0.8)	1.7 (1.1 to 2.4)	212.5	(-15.3 to 101.7)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.2 (24.8 to 44.8)	-31.9 (-35.8 to -28.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.2	(-35.8 to -28.0)
Chronic kidney disease	-	-	-	-	1.4 (1.0 to 1.9)	2.8 (2.0 to 3.8)	102.7	(-9.9 to 8.4)
Chronic kidney disease due to diabetes mellitus	7.2 (4.8 to 11.0)	15.1 (8.5 to 25.0)	104.9 (47.9 to 182.7)	3.7 (-24.4 to 41.1)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	105.7	(-23.0 to 42.9)
Chronic kidney disease due to hypertension	37.7 (22.5 to 69.7)	80.9 (49.4 to 140.6)	115.7 (70.7 to 171.6)	6.8 (-14.4 to 29.7)	0.5 (0.3 to 0.7)	0.9 (0.6 to 1.3)	95.5	(-17.3 to 10.6)
Chronic kidney disease due to glomerulonephritis	33.3 (22.2 to 48.9)	67.4 (43.7 to 100.2)	101.4 (63.9 to 154.3)	0.5 (-16.5 to 21.6)	1.0 (0.3 to 2.0)	1.0 (0.7 to 1.4)	106.6	(-14.3 to 30.3)
Chronic kidney disease due to other causes	25.8 (15.0 to 47.9)	54.9 (33.4 to 96.5)	111.3 (60.7 to 202.2)	-0.1 (-21.1 to 36.3)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	100.2	(-23.5 to 26.8)
Urinary diseases and male infertility	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.8)	87.8	(-11.1 to 8.7)

Appendix Table G.4 - The Gambia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.2 (0.2 to 0.2)	0.4 (0.3 to 0.4)	121.3 (102.6 to 145.9)	0.0 (0.9 to 17.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	122.4 (76.7 to 189.4)	122.4 (-10.1 to 33.0)
Urolithiasis	1.8 (1.3 to 2.3)	2.9 (2.2 to 3.8)	63.3 (39.0 to 120.9)	-15.7 (-24.6 to 7.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	103.0 (76.2 to 137.0)	-0.1 (-10.3 to 14.4)
Benign prostatic hyperplasia	5.4 (4.9 to 5.8)	9.9 (9.1 to 10.7)	83.2 (64.0 to 107.6)	-2.4 (-12.3 to 9.6)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	84.4 (64.4 to 108.1)	-1.7 (-12.1 to 10.0)
Male infertility due to other causes	9.6 (7.5 to 12.3)	18.6 (14.2 to 23.1)	93.2 (35.9 to 166.2)	-5.3 (-33.8 to 31.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	90.5 (34.4 to 161.2)	-6.0 (-33.2 to 30.9)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.8 (3.2 to 185.0)	-16.9 (-47.8 to 35.9)
Gynecological diseases	-	-	-	-	1.0 (0.6 to 1.4)	2.1 (1.4 to 3.2)	118.9 (82.3 to 155.4)	7.5 (-8.8 to 24.6)
Uterine fibroids	11.5 (10.2 to 12.6)	27.6 (24.9 to 30.1)	141.2 (138.3 to 144.2)	13.1 (12.6 to 13.5)	0.2 (0.1 to 0.2)	0.5 (0.3 to 0.8)	109.0 (90.8 to 122.1)	-0.2 (-9.0 to 5.6)
Polycystic ovarian syndrome	12.5 (10.8 to 14.2)	28.2 (25.0 to 31.6)	124.8 (86.9 to 172.7)	11.1 (-4.8 to 30.7)	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.5)	123.6 (85.2 to 172.8)	10.6 (-5.7 to 31.5)
Female infertility due to other causes	7.5 (4.7 to 11.5)	17.3 (9.7 to 27.5)	129.8 (17.0 to 350.2)	13.3 (-46.9 to 133.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	125.5 (10.8 to 348.9)	11.5 (-47.2 to 132.8)
Endometriosis	1.2 (1.0 to 1.4)	2.5 (2.2 to 2.9)	109.1 (69.6 to 163.1)	3.3 (-14.8 to 28.2)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	108.9 (67.1 to 171.1)	4.0 (-16.0 to 31.0)
Genital prolapse	26.5 (22.9 to 30.8)	59.0 (50.4 to 68.0)	122.4 (80.5 to 175.3)	9.3 (-5.9 to 29.8)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	122.6 (79.9 to 175.4)	9.5 (-6.2 to 30.3)
Premenstrual syndrome	32.2 (20.9 to 42.5)	79.2 (51.5 to 102.3)	146.7 (43.1 to 314.4)	24.4 (-28.1 to 111.7)	0.3 (0.1 to 0.4)	0.7 (0.4 to 1.1)	147.5 (40.6 to 311.4)	25.3 (-29.2 to 110.9)
Other gynecological diseases	3.3 (2.4 to 4.3)	6.1 (4.4 to 7.9)	82.4 (27.3 to 159.7)	-8.4 (-36.4 to 30.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	67.7 (-7.7 to 194.7)	-16.3 (-53.3 to 47.9)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	1.5 (1.0 to 2.1)	2.8 (1.9 to 3.9)	91.4 (79.4 to 109.7)	-7.9 (-13.1 to 1.8)
Thalassemias	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	86.3 (68.0 to 101.5)	-8.8 (-18.1 to -0.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.1 (52.7 to 117.6)	-9.7 (-23.5 to 3.6)
Thalassemia trait	15.8 (13.2 to 18.3)	31.6 (26.3 to 37.4)	99.8 (89.4 to 105.8)	-1.6 (-6.7 to 1.5)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	100.1 (77.0 to 128.8)	-0.3 (-14.5 to 15.6)
Sickle cell disorders	1.7 (1.4 to 1.8)	3.6 (3.2 to 3.9)	112.3 (89.0 to 145.9)	6.6 (-5.2 to 25.0)	0.2 (0.1 to 0.2)	0.5 (0.3 to 0.5)	113.5 (79.8 to 150.4)	8.3 (-7.5 to 25.2)
Sickle cell trait	120.0 (112.0 to 127.6)	241.0 (226.3 to 255.5)	100.4 (94.3 to 107.6)	-1.4 (-4.4 to 2.2)	0.6 (0.4 to 0.8)	1.1 (0.7 to 1.6)	99.5 (66.6 to 129.0)	-2.9 (-14.8 to 16.4)
G6PD deficiency	67.0 (61.4 to 72.3)	140.1 (127.6 to 154.2)	108.8 (84.7 to 138.9)	2.6 (-9.1 to 17.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.3 (68.3 to 167.5)	2.4 (-10.1 to 17.3)
G6PD trait	199.6 (175.5 to 183.5)	368.4 (359.3 to 377.8)	105.0 (98.3 to 112.7)	3.3 (-0.1 to 7.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.4 (-20.2 to 381.5)	-4.9 (-61.4 to 169.2)
Other hemoglobinopathies and hemolytic anemias	12.2 (10.6 to 13.6)	20.1 (18.3 to 21.7)	65.4 (46.5 to 96.3)	-24.1 (-32.8 to -12.6)	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.9)	62.9 (40.2 to 108.1)	-27.3 (-39.3 to -7.7)
Endocrine, metabolic, blood, and immune disorders	14.5 (13.3 to 17.8)	25.6 (20.9 to 29.5)	77.5 (36.3 to 125.2)	-15.6 (-31.1 to -2.4)	0.5 (0.3 to 0.8)	1.0 (0.6 to 1.4)	77.6 (25.6 to 122.3)	-15.0 (-34.7 to 3.1)
Musculoskeletal disorders	-	-	-	-	9.3 (6.4 to 12.5)	19.5 (13.3 to 26.4)	109.9 (81.5 to 143.6)	2.1 (-11.0 to 15.0)
Rheumatoid arthritis	1.0 (1.0 to 1.1)	1.6 (1.5 to 1.6)	53.5 (43.7 to 63.8)	-29.6 (-34.5 to -24.9)	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	54.8 (38.9 to 73.7)	-29.1 (-35.2 to -22.6)
Osteoarthritis	13.6 (13.1 to 14.2)	28.6 (27.4 to 29.8)	110.4 (98.1 to 121.5)	2.9 (-2.4 to 8.1)	0.8 (0.6 to 1.1)	1.8 (1.2 to 2.4)	111.5 (98.7 to 123.7)	3.4 (-2.0 to 9.0)
Low back and neck pain	-	-	-	-	7.2 (4.9 to 9.9)	15.0 (10.1 to 20.7)	107.5 (72.1 to 150.9)	0.3 (-16.3 to 18.5)
Low back pain	41.9 (33.8 to 49.0)	84.4 (65.8 to 102.1)	100.9 (49.8 to 174.6)	-2.2 (-24.6 to 25.1)	4.7 (3.0 to 6.7)	9.4 (6.1 to 13.8)	101.7 (50.3 to 177.8)	-1.7 (-24.5 to 26.3)
Neck pain	25.8 (21.7 to 30.3)	56.0 (47.4 to 64.0)	116.6 (71.9 to 175.1)	2.5 (-16.8 to 25.4)	2.5 (1.7 to 3.6)	5.5 (3.7 to 7.8)	117.5 (72.4 to 176.6)	3.0 (-16.3 to 26.9)
Gout	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	93.3 (64.2 to 128.9)	-5.5 (-19.3 to 13.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.9 (53.2 to 150.6)	-4.6 (-27.8 to 26.2)
Other musculoskeletal disorders	10.8 (8.1 to 14.0)	26.3 (19.7 to 33.5)	140.4 (117.8 to 188.4)	15.6 (4.8 to 32.9)	1.0 (0.6 to 1.5)	2.4 (1.5 to 3.6)	121.1 (117.7 to 130.7)	16.3 (5.1 to 33.9)
Other non-communicable diseases	-	-	-	-	10.7 (6.8 to 16.3)	20.7 (13.2 to 31.7)	93.1 (81.4 to 105.1)	-5.1 (-9.6 to -0.8)
Congenital anomalies	-	-	-	-	0.6 (0.4 to 0.8)	1.5 (1.0 to 2.1)	175.0 (125.2 to 239.1)	38.2 (11.7 to 70.4)
Neural tube defects	0.1 (0.1 to 0.1)	0.4 (0.4 to 0.5)	515.5 (390.8 to 680.3)	242.3 (169.2 to 336.6)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	631.9 (426.3 to 898.7)	320.5 (204.5 to 475.9)
Congenital heart anomalies	0.6 (0.5 to 0.8)	4.4 (3.4 to 5.8)	507.5 (369.9 to 926.5)	294.7 (153.8 to 495.6)	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	486.0 (286.7 to 783.7)	226.6 (109.3 to 403.7)
Orofacial clefts	0.1 (0.0 to 0.1)	0.6 (0.4 to 0.8)	839.0 (454.1 to 1,544.5)	480.9 (229.1 to 998.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	796.2 (376.0 to 1,593.0)	452.3 (188.6 to 1,008.0)
Down syndrome	0.4 (0.3 to 0.5)	1.4 (1.2 to 1.8)	259.5 (173.2 to 359.6)	90.3 (44.5 to 144.7)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	92.9 (166.9 to 381.8)	263.7 (43.1 to 156.3)
Turner syndrome	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	205.7 (126.7 to 322.9)	57.9 (15.8 to 118.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	208.0 (118.5 to 336.8)	58.8 (13.1 to 125.0)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	99.1 (35.1 to 183.5)	-3.7 (-34.4 to 36.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.7 (32.7 to 178.8)	-4.5 (-35.5 to 36.0)
Chromosomal unbalanced rearrangements	0.0 (0.5 to 0.8)	0.0 (2.0 to 2.8)	88.1 (166.8 to 376.4)	0.1 (-42.0 to 155.9)	0.0 (0.0 to 0.1)	0.0 (0.2 to 0.4)	94.0 (167.4 to 339.3)	94.0 (43.5 to 169.0)
Other congenital anomalies	4.1 (3.0 to 5.5)	7.7 (5.7 to 10.5)	87.1 (61.9 to 124.4)	-5.7 (-20.0 to 11.6)	0.4 (0.2 to 0.7)	0.8 (0.5 to 1.3)	101.7 (57.8 to 169.0)	0.2 (-22.8 to 35.7)
Skin and subcutaneous diseases	-	-	-	-	4.6 (2.8 to 7.3)	9.9 (5.4 to 14.3)	93.4 (73.7 to 118.3)	-2.7 (-11.5 to 7.0)
Dermatitis	38.2 (29.9 to 47.9)	78.2 (61.3 to 98.1)	104.5 (103.3 to 105.6)	0.3 (-0.1 to 0.6)	1.1 (0.7 to 1.6)	2.3 (1.4 to 3.3)	104.4 (96.6 to 111.9)	0.5 (-2.4 to 3.2)
Psoriasis	5.8 (4.6 to 7.0)	11.8 (9.4 to 14.2)	103.3 (101.8 to 105.2)	0.1 (-0.5 to 0.2)	0.5 (0.3 to 0.7)	1.0 (0.6 to 1.4)	104.2 (89.9 to 118.1)	0.3 (-4.6 to 5.9)
Cellulitis	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.4)	100.3 (71.8 to 134.9)	-2.8 (-17.2 to 15.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	100.0 (52.0 to 164.7)	-3.0 (-23.4 to 24.7)
Pyoderma	1.6 (1.2 to 2.1)	3.0 (2.2 to 3.9)	87.8 (77.0 to 101.7)	-4.3 (-10.6 to 2.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.6 (69.5 to 109.4)	-4.1 (-13.0 to 6.1)
Scabies	9.4 (8.1 to 10.8)	14.7 (12.4 to 17.5)	56.9 (25.2 to 97.3)	-21.7 (-36.6 to -1.1)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.6)	57.4 (25.3 to 98.4)	-21.3 (-36.8 to -0.6)
Fungal skin diseases	107.5 (77.0 to 151.7)	219.9 (156.8 to 308.4)	103.6 (102.7 to 104.6)	0.4 (-0.6 to 0.2)	1.2 (0.4 to 1.4)	2.4 (0.5 to 2.8)	103.9 (102.0 to 106.1)	-0.1 (-1.0 to 0.6)
Viral skin diseases	13.8 (10.3 to 17.4)	27.8 (21.5 to 34.3)	101.2 (91.1 to 115.2)	-0.9 (-5.1 to 4.2)	0.4 (0.2 to 0.7)	0.9 (0.5 to 1.4)	102.1 (89.0 to 118.8)	6.2 (-6.3 to 6.5)
Acne vulgaris	109.9 (79.8 to 139.5)	182.2 (127.9 to 253.7)	59.3 (8.1 to 177.4)	-19.5 (-43.6 to 37.3)	1.2 (0.5 to 2.3)	2.0 (0.9 to 3.9)	59.5 (8.4 to 178.8)	-19.3 (-43.6 to 37.2)
Alopecia areata	0.8 (0.7 to 0.9)	1.6 (1.4 to 1.9)	102.7 (70.0 to 143.9)	-0.4 (-15.6 to 15.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	104.2 (60.5 to 153.9)	0.0 (-17.9 to 18.9)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.5 (57.7 to 157.8)	2.8 (-24.5 to 28.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.5 (57.3 to 157.9)	-2.8 (-24.5 to 28.7)
Urticaria	3.5 (1.9 to 5.5)	9.0 (5.8 to 13.8)	153.9 (7.6 to 474.6)	23.9 (-40.4 to 118.9)	0.2 (0.1 to 0.4)	0.5 (0.3 to 0.9)	163.6 (7.5 to 473.1)	24.9 (-41.3 to 122.6)
Decubitus ulcer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	126.1 (81.7 to 170.3)	8.6 (-17.6 to 52.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	125.9 (79.3 to 181.4)	10.6 (-18.3 to 60.3)
Other skin and subcutaneous diseases	45.6 (30.8 to 65.1)	90.7 (61.6 to 128.0)	99.3 (90.3 to 107.6)	-2.1 (-5.5 to 0.6)	0.3 (0.1 to 0.5)	0.5 (0.2 to 1.1)	99.6 (90.5 to 108.5)	-1.8 (-5.4 to 1.2)
Sense organ diseases	-	-	-	-	4.5 (2.8 to 6.7)	8.1 (5.0 to 12.3)	79.5 (62.9 to 97.9)	-10.7 (-17.3 to -4.1)
Glaucoma	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	71.9 (20.5 to 126.4)	1.3 (-26.7 to 30.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.5 (7.1 to 112.4)	-7.8 (-35.1 to 22.3)
Cataract	1.1 (0.7 to 1.5)	1.6 (1.1 to 2.0)	38.2 (15.9 to 63.7)	-26.8 (-40.1 to -16.6)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	44.9 (27.0 to 66.4)	-24.3 (-33.7 to -14.4)
Macular degeneration	0.3 (0.2 to 0.4)	1.2 (0.9 to 1.5)	273.5 (183.8 to 371.5)	93.6 (43.7 to 152.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	263.9 (178.1 to 365.5)	86.1 (43.1 to 143.1)
Uncorrected refractive error	62.2 (46.2 to 79.8)	117.9 (85.9 to 149.5)	90.7 (27.9 to 177.8)	4.4 (-31.4 to 30.7)	0.8 (0.4 to 1.5)	1.5 (0.7 to 2.6)	85.4 (34.2 to 150.6)	-7.3 (-29.3 to 19.4)
Age-related and other hearing loss	102.0 (85.7 to 115.7)	188.1 (157.7 to 214.4)	84.3 (74.4 to 94.6)	-7.2 (-10.6 to -3.8)	3.0 (1.7 to 4.6)	5.2 (3.1 to 7.9)	122.2 (55.1 to 97.1)	-12.2 (-19.2 to -5.5)
Other vision loss	0.8 (0.7 to 1.0)	1.1 (0.8 to 1.4)	34.7 (11.0 to 60.4)	-24.0 (-34.8 to -6.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	20.3 (-6.4 to 52.3)	-26.6 (-40.7 to -8.2)
Other sense organ diseases	21.5 (20.2 to 22.7)	43.6 (41.1 to 46.2)	102.8 (87.4 to 119.5)	0.1 (-6.3 to 6.6)	0.6 (0.4 to 0.8)	1.2 (0.7 to 1.7)	103.5 (85.9 to 122.8)	0.6 (-6.7 to 9.9)
Oral disorders	-	-	-	-	1.1 (0.6 to 1.9)	2.2 (1.2 to 3.8)	100.9 (87.9 to 113.4)	1.1 (-8.4 to 5.9)
Deciduous caries	92.1 (87.3 to 96.4)	187.0 (177.9 to 196.8)	103.1 (88.6 to 117.4)	0.3 (-6.8 to 7.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	183.6 (84.9 to 124.7)	0.6 (-8.6 to 10.5)
Permanent caries	231.2 (202.5 to 255.2)	456.2 (410.7 to 502.8)	96.5 (71.1 to 146.9)	-4.3 (-17.6 to 22.8)	0.2 (0.1 to 0.4)	0.5 (0.2 to 0.9)	96.7 (70.6 to 145.7)	-4.1 (-17.4 to 2

Appendix Table G.4 - The Gambia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	2.3 (2.1 to 2.5)	4.5 (4.2 to 4.9)	98.0 (77.7 to 124.4)	-1.4 (-10.5 to 9.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	99.1 (76.4 to 128.0)	-0.6 (-10.3 to 11.6)
Other oral disorders	12.9 (12.1 to 13.7)	26.0 (24.3 to 27.6)	101.8 (83.0 to 119.0)	-0.4 (-8.2 to 7.4)	0.4 (0.2 to 0.6)	0.8 (0.5 to 1.1)	101.9 (83.1 to 120.7)	-0.3 (-8.2 to 8.2)
Injuries	-	-	-	-	4.1 (2.8 to 6.0)	4.9 (3.7 to 6.4)	23.5 (9.3 to 44.8)	-35.3 (-51.5 to -24.9)
Transport injuries	-	-	-	-	1.2 (0.9 to 1.5)	1.7 (1.3 to 2.3)	45.3 (35.0 to 57.6)	-22.4 (-27.3 to -16.5)
Road injuries	-	-	-	-	1.1 (0.8 to 1.4)	1.6 (1.2 to 2.1)	48.8 (34.0 to 57.5)	-25.5 (-27.6 to -15.6)
Pedestrian road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	31.6 (19.2 to 47.6)	-27.4 (-33.2 to -20.0)
Cyclist road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	30.7 (20.6 to 41.6)	-27.3 (-32.8 to -20.8)
Motorcyclist road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	25.0 (12.8 to 39.4)	-34.7 (-40.5 to -28.2)
Motor vehicle road injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.9 (0.7 to 1.1)	61.1 (45.2 to 79.6)	-14.7 (-22.2 to -6.3)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.2 (6.0 to 27.5)	-42.5 (-47.1 to -37.4)
Other transport injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	51.0 (39.5 to 64.4)	-20.5 (-26.1 to -13.2)
Unintentional injuries	-	-	-	-	1.7 (1.3 to 2.1)	2.7 (2.0 to 3.6)	62.4 (54.7 to 70.6)	-18.8 (-23.0 to -14.5)
Falls	-	-	-	-	0.6 (0.5 to 0.8)	1.1 (0.8 to 1.4)	69.1 (57.4 to 81.0)	-19.3 (-25.2 to -13.3)
Drowning	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	18.0 (5.8 to 33.1)	-37.6 (-43.2 to -30.6)
Fire, heat, and hot substances	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	39.2 (25.1 to 55.1)	-27.1 (-33.3 to -20.3)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.9 (15.2 to 70.9)	-30.7 (-40.3 to -19.7)
Exposure to mechanical forces	-	-	-	-	0.5 (0.4 to 0.7)	0.9 (0.6 to 1.2)	58.5 (49.8 to 68.4)	-19.2 (-23.6 to -14.4)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.8 (34.4 to 63.6)	-25.0 (-31.8 to -17.2)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.9 (83.3 to 127.3)	4.5 (-4.5 to 15.2)
Other exposure to mechanical forces	-	-	-	-	0.5 (0.4 to 0.7)	0.8 (0.6 to 1.1)	58.5 (49.6 to 68.6)	-19.2 (-23.7 to -14.4)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.1 (99.6 to 129.1)	13.9 (6.8 to 21.9)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	56.5 (44.6 to 68.7)	-18.1 (-23.6 to -12.2)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.8 (39.8 to 81.5)	-17.4 (-25.9 to -7.6)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.1 (42.6 to 66.6)	-18.7 (-23.7 to -12.8)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	69.3 (58.0 to 81.8)	-12.5 (-17.5 to -6.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.1 (15.4 to 54.6)	-25.1 (-33.4 to -16.1)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.4 (73.8 to 121.4)	-4.8 (-13.4 to 4.8)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.4 (63.4 to 89.2)	-10.8 (-17.1 to -3.5)
Other unintentional injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	68.2 (56.6 to 82.2)	-12.9 (-18.7 to -6.9)
Self-harm and interpersonal violence	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	46.6 (34.9 to 56.7)	-24.3 (-29.6 to -18.7)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.5 (55.1 to 90.0)	-15.7 (-22.6 to -7.7)
Interpersonal violence	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	40.7 (29.6 to 52.4)	-26.7 (-32.4 to -20.7)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.6 (38.6 to 65.7)	-20.2 (-26.3 to -14.2)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.2 (58.6 to 89.4)	-11.9 (-19.1 to -3.6)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	29.6 (18.7 to 42.7)	-32.4 (-38.0 to -26.0)
Forces of nature, war, and legal intervention	-	-	-	-	1.2 (0.4 to 2.9)	0.4 (0.1 to 0.9)	-67.4 (-73.7 to -58.3)	-76.8 (-81.1 to -70.5)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-	-
Collective violence and legal intervention	-	-	-	-	1.2 (0.4 to 2.9)	0.3 (0.1 to 0.8)	-70.2 (-75.2 to -63.4)	-78.1 (-81.8 to -72.9)

Appendix Table G.4 - Timor-Leste prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	63.1 (45.9 to 82.9)	86.0 (62.7 to 113.0)	36.4 (21.5 to 41.7)	36.4 (-9.0 to 32.1)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	19.2 (13.3 to 26.4)	23.3 (16.4 to 32.2)	21.5 (9.9 to 33.0)	-20.0 (-26.0 to -13.2)
HIV/AIDS and tuberculosis	-	-	-	-	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.4)	87.0 (71.7 to 104.4)	45.1 (34.4 to 57.0)
Tuberculosis	1.8 (1.7 to 2.0)	3.4 (3.2 to 3.6)	85.6 (72.6 to 99.1)	42.4 (33.2 to 52.2)	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.4)	84.2 (69.1 to 100.2)	43.3 (32.6 to 55.2)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8,252.6 (1,742.6 to 768,292.9)	8,252.6 (1,597.1 to 370,971.6)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11,054.0 (2,329.5 to 0.0)	9,639.4 (1,990.2 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11,054.0 (2,319.3 to nan)	9,639.4 (1,954.4 to nan)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.4)	6,598.3 (1,464.8 to 0.0)	6,105.7 (1,348.2 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8,190.2 (1,507.9 to nan)	7,505.5 (1,375.4 to nan)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	3.1 (2.1 to 4.2)	2.9 (2.1 to 4.0)	-5.4 (-17.0 to 8.9)	-35.6 (-42.7 to -27.3)
Diarrheal diseases	10.6 (8.8 to 12.4)	10.5 (9.1 to 12.0)	-1.8 (-20.5 to 24.6)	-34.5 (-45.8 to -18.8)	1.7 (1.1 to 2.5)	1.7 (1.2 to 2.4)	1.3 (-19.7 to 26.8)	-34.1 (-45.6 to -17.7)
Intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-30.7 (55.5 to 24.1)	-54.1 (-70.4 to -20.1)
Typhoid fever	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-30.5 (-51.1 to 20.9)	-53.9 (-67.8 to -22.5)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-28.8 (-53.4 to 28.3)	-52.9 (-69.2 to -20.5)
Paratyphoid fever	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.2)	-40.7 (-62.3 to -1.3)	-62.3 (-75.8 to -38.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.1 (-63.4 to 2.3)	-61.5 (-76.0 to -37.1)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.5 (-91.0 to 348.2)	-50.6 (-94.2 to 202.3)
Lower respiratory infections	0.3 (0.3 to 0.4)	0.3 (0.3 to 0.4)	4.6 (-25.9 to 36.1)	4.3 (-22.7 to 28.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.2 (-28.7 to 40.8)	3.2 (-23.8 to 31.6)
Upper respiratory infections	22.5 (20.8 to 24.2)	31.1 (28.9 to 33.6)	37.8 (24.5 to 53.9)	-8.3 (-17.3 to 2.3)	0.3 (0.1 to 0.4)	0.4 (0.2 to 0.6)	38.3 (24.3 to 56.1)	-8.0 (-16.9 to 3.1)
Otitis media	10.4 (9.6 to 11.1)	13.6 (12.7 to 14.6)	31.1 (21.6 to 42.0)	-15.1 (-20.9 to -7.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	34.1 (21.4 to 49.0)	-13.5 (-20.7 to -4.5)
Meningitis	-	-	-	-	0.5 (0.4 to 0.8)	0.3 (0.2 to 0.5)	-35.8 (-46.1 to -17.9)	-54.8 (-61.5 to -43.5)
Pneumococcal meningitis	2.5 (1.5 to 3.8)	1.4 (0.9 to 2.2)	-44.0 (-54.8 to -22.5)	-58.6 (-66.6 to -45.4)	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-37.9 (-57.9 to -5.5)	-55.8 (-68.5 to -35.5)
H influenzae type B meningitis	1.3 (0.5 to 2.3)	0.7 (0.3 to 1.3)	-42.7 (-56.8 to -25.2)	-61.0 (-70.4 to -49.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-31.0 (-54.8 to 1.2)	-53.0 (-68.5 to -31.4)
Meningococcal meningitis	0.2 (0.1 to 0.5)	0.1 (0.0 to 0.2)	-49.7 (-66.3 to -25.1)	-64.3 (-75.8 to -48.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.3 (-63.5 to -13.8)	-63.9 (-73.0 to -43.4)
Other meningitis	1.3 (0.6 to 2.2)	0.7 (0.4 to 1.3)	-42.3 (-53.4 to -23.3)	-57.9 (-65.5 to -45.2)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-35.8 (-57.1 to -4.8)	-53.3 (-67.8 to -32.7)
Encephalitis	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.6)	9.9 (-4.9 to 28.3)	-23.4 (-33.9 to -13.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	21.9 (-0.7 to 50.3)	26.3 (-29.9 to -0.6)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.9 (-99.6 to 190.8)	-22.2 (-99.6 to 36.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-88.9 (-99.7 to 202.5)	-92.2 (-99.5 to 41.1)
Whooping cough	2.0 (1.5 to 2.6)	0.8 (0.6 to 1.0)	-59.3 (-62.4 to -56.0)	-71.1 (-73.3 to -68.7)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-59.1 (-63.6 to -54.1)	-70.9 (-74.2 to -67.4)
Tetanus	0.3 (0.1 to 0.7)	0.0 (0.0 to 0.0)	-95.7 (-98.6 to -90.6)	-97.1 (-99.1 to -95.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-92.8 (-97.0 to -87.1)	-94.7 (-97.8 to -91.3)
Measles	0.6 (0.4 to 0.9)	0.0 (0.0 to 0.0)	-96.9 (-97.5 to -95.3)	-97.9 (-98.6 to -96.8)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	96.8 (-98.0 to -95.1)	97.8 (-98.6 to -95.6)
Varicella and herpes zoster	0.8 (0.7 to 0.8)	1.2 (1.1 to 1.3)	55.8 (38.5 to 76.6)	-0.1 (-12.3 to 14.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 1.1)	54.8 (24.8 to 91.9)	0.8 (-18.1 to 21.6)
Neglected tropical diseases and malaria	-	-	-	-	3.1 (2.0 to 4.8)	3.9 (2.5 to 5.9)	24.6 (7.2 to 42.8)	-20.2 (-35.6 to -4.6)
Malaria	115.5 (102.0 to 128.3)	132.6 (119.2 to 149.5)	15.6 (-1.0 to 26.5)	-22.5 (-35.7 to -14.8)	1.0 (0.7 to 1.5)	1.6 (1.0 to 2.2)	-7.1 (38.6 to 62.5)	-7.1 (-13.4 to 1.3)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.0 (-15.3 to 88.5)	-15.3 (-39.7 to 20.2)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.4 (-52.6 to 170.4)	-10.6 (58.0 to 73.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.4 (-52.9 to 170.9)	-10.6 (-58.0 to 74.1)
Cutaneous and mucocutaneous leishmaniasis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	24.6 (-4.6 to 64.2)	-16.1 (-33.4 to 6.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.1 (-15.4 to 88.4)	-15.3 (-39.7 to 20.3)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.6 (0.4 to 0.9)	0.3 (0.1 to 0.5)	-57.7 (-86.1 to -10.7)	-71.9 (-90.3 to -40.3)	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.1)	-54.5 (-85.2 to -1.9)	-69.0 (-89.6 to -34.4)
Cystic echinococcosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-37.2 (-45.0 to -31.6)	-55.5 (-59.5 to -51.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.3 (-53.4 to -15.3)	-55.0 (-64.9 to -42.6)
Lymphatic filariasis	19.2 (10.1 to 28.5)	17.4 (9.7 to 28.9)	-8.6 (-49.1 to 46.5)	-34.9 (-59.9 to -2.4)	0.9 (0.3 to 1.9)	1.0 (0.3 to 2.4)	17.2 (-32.5 to 117.1)	-17.5 (-54.0 to 52.8)
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.1 (0.0 to 0.2)	0.6 (0.2 to 1.3)	626.6 (618.9 to 635.6)	374.0 (369.0 to 379.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	631.5 (463.7 to 897.0)	377.7 (287.0 to 519.8)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-79.4 to 34.2)	0.0 (0.0 to 0.0)	-56.3 (-79.4 to 34.2)	-72.4 (-83.4 to -17.9)
Intestinal nematode infections	-	-	-	-	0.4 (0.2 to 0.9)	0.4 (0.2 to 0.7)	-3.7 (-47.5 to 70.9)	-34.9 (-65.3 to 23.1)
Ascariasis	102.9 (70.4 to 151.0)	140.8 (91.5 to 210.0)	35.4 (-21.6 to 141.9)	-8.7 (-51.7 to 84.9)	0.2 (0.1 to 0.6)	0.1 (0.0 to 0.1)	-74.4 (-92.0 to -37.0)	-81.0 (-94.4 to -30.9)
Trichuriasis	89.0 (59.8 to 131.6)	131.7 (88.9 to 196.7)	48.6 (-16.0 to 155.6)	-1.4 (-49.3 to 90.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	46.7 (-68.8 to 688.7)	-2.1 (-82.1 to 523.6)
Hookworm disease	49.1 (33.9 to 69.8)	71.2 (51.0 to 98.4)	45.3 (-9.8 to 136.8)	0.2 (-42.9 to 71.0)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	79.9 (8.3 to 181.1)	8.4 (-44.0 to 92.5)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	16.1 (13.6 to 18.7)	20.4 (18.4 to 22.8)	26.4 (7.9 to 53.2)	-21.6 (-31.8 to -7.5)	0.6 (0.4 to 0.9)	0.7 (0.5 to 1.1)	20.9 (14.1 to 58.6)	-29.4 (-40.1 to -10.6)
Maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	14.6 (-22.7 to 59.5)	3.6 (-29.1 to 37.8)
Maternal hemorrhage	0.5 (0.4 to 0.5)	0.8 (0.6 to 1.1)	80.4 (22.2 to 144.1)	63.2 (10.3 to 118.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.1 (-28.3 to 154.5)	29.6 (-31.0 to 113.3)
Maternal sepsis and other maternal infections	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-31.8 (-40.8 to -14.6)	-34.1 (-43.5 to -16.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.6 (-56.5 to 24.8)	-37.7 (-59.5 to -2.1)
Maternal hypertensive disorders	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.4)	11.3 (-2.5 to 30.9)	-4.2 (-11.8 to 8.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.7 (-9.1 to 37.5)	-4.6 (-19.4 to 14.8)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.2 (-54.1 to 53.1)	-24.0 (-56.2 to 32.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.6 (-65.2 to 119.9)	-25.3 (-67.1 to 90.7)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.8 (-19.5 to 122.4)	11.9 (-29.4 to 75.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.8 (-28.5 to 154.7)	9.9 (-39.4 to 109.2)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.3 (-48.4 to 77.9)	-12.3 (-53.5 to 54.7)
Neonatal disorders	-	-	-	-	0.4 (0.3 to 0.8)	2.5 (1.5 to 4.0)	459.1 (216.8 to 880.3)	298.3 (124.8 to 606.0)
Preterm birth complications	2.5 (1.1 to 5.1)	11.0 (6.0 to 20.1)	349.6 (207.1 to 578.7)	190.0 (96.9 to 339.1)	0.1 (0.1 to 0.2)	1.2 (0.7 to 1.9)	766.2 (402.7 to 1,403.8)	502.5 (252.5 to 937.7)
Neonatal encephalopathy due to birth asphyxia and trauma	3.8 (0.8 to 9.4)	3.7 (1.4 to 8.2)	4.7 (-43.5 to 127.5)	-34.0 (-63.3 to -11.4)	0.1 (0.0 to 0.2)	0.4 (0.2 to 0.5)	238.6 (75.1 to 612.9)	133.9 (11.8 to 455.9)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.3 (68.1 to 149.3)	59.1 (34.2 to 99.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.3 (58.9 to 181.2)	105.0 (26.8 to 124.5)
Hemolytic disease and other neonatal jaundice	0.1 (0.0 to 0.3)	0.7 (0.3 to 1.6)	375.7 (0.1 to 1,817.8)	272.5 (-22.3 to 1,381.9)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.6)	378.0 (7.8 to 1,741.6)	267.9 (-21.6 to 1,307.2)
Other neonatal disorders	-	-	-	-	0.1 (0.0 to 0.4)	0.7 (0.1 to 1.8)	363.4 (62.9 to 1,108.4)	227.2 (16.6 to 759.1)
Nutritional deficiencies	-	-	-	-	11.2 (7.4 to 16.0)	11.2 (8.0 to 17.2)	7.4 (-8.8 to 21.7)	-34.5 (-41.4 to -28.7)
Protein-energy malnutrition	10.8 (6.1 to 17.4)	13.3 (8.1 to 20.3)	24.1 (-39.3 to 157.4)	-12.6 (-57.2 to 82.1)	1.3 (0.7 to 2.4)	1.7 (0.9 to 2.8)	24.7 (-8.1 to 162.1)	-12.0 (-57.7 to 85.3)
Iodine deficiency	6.6 (1.9 to 11.5)	5.7 (2.7 to 9.4)	-13.9 (-62.7 to 114.8)	-35.3 (-72.0 to 58.6)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-13.1 (-63.3 to 112.5)	-35.2 (-72.2 to 58.0)
Vitamin A deficiency	0.9 (0.6 to 1.2)	0.8 (0.5 to 1.0)	-11.3 (-28.4 to 16.4)	-42.3 (-53.2 to -20.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-19.3 (-35.3 to 6.5)	-46.5 (-56.7 to -28.3)

Appendix Table G.4 - Timor-Leste prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	260.6 (257.3 to 264.0)	297.0 (292.9 to 301.3)	14.0 (12.0 to 16.0)	-26.5 (-27.9 to -25.1)	9.2 (6.1 to 13.1)	9.7 (6.5 to 14.1)	6.4 (2.8 to 9.1)	-36.3 (-38.9 to -33.8)
Other nutritional deficiencies	-	-	-	-	0.6 (0.1 to 1.9)	0.5 (0.2 to 1.2)	0.4 (-74.9 to 256.3)	0.4 (-82.3 to 150.5)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.7 (0.5 to 1.0)	0.9 (0.6 to 1.3)	18.5 (3.5 to 37.7)	-22.7 (-30.2 to -11.3)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	30.5 (9.7 to 55.4)	-2.5 (-15.7 to 13.1)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.5 (-41.2 to -18.7)	-44.9 (-52.1 to -36.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-49.5 to -3.8)	44.0 (-58.0 to -25.5)
Chlamydial infection	22.8 (16.1 to 33.6)	31.5 (23.9 to 42.4)	44.1 (-22.9 to 133.8)	7.1 (-38.5 to 65.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	34.9 (3.5 to 71.8)	2.3 (-18.6 to 25.0)
Gonococcal infection	3.4 (2.2 to 4.8)	4.8 (3.1 to 6.7)	37.7 (-11.9 to 131.9)	0.2 (-34.2 to 56.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.0 (-3.7 to 113.2)	4.1 (-25.3 to 46.8)
Trichomoniasis	2.6 (1.5 to 3.6)	2.3 (1.3 to 3.4)	-10.3 (-52.6 to 59.6)	-19.0 (-53.0 to 50.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.6 (-59.2 to 85.5)	-20.9 (-59.2 to 77.2)
Genital herpes	68.3 (65.5 to 71.1)	82.2 (78.7 to 85.3)	20.3 (13.2 to 28.4)	-7.2 (-12.9 to -1.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	22.4 (12.7 to 34.5)	6.9 (-13.6 to 0.1)
Other sexually transmitted diseases	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-35.0 (-47.3 to -20.3)	-39.9 (-49.9 to -24.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.3 (-41.0 to 53.7)	19.4 (-48.5 to 21.3)
Hepatitis	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	3.3 (-13.5 to 29.1)	-31.8 (-45.1 to -7.8)
Hepatitis A	1.3 (1.2 to 1.3)	1.9 (1.8 to 1.9)	44.8 (44.8 to 45.1)	-4.0 (-4.1 to -3.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	56.0 (38.9 to 77.9)	2.3 (-8.2 to 14.6)
Hepatitis B	75.6 (59.1 to 93.0)	67.0 (53.9 to 85.6)	-12.5 (-32.6 to 24.3)	-40.8 (-54.0 to -16.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-29.5 (-50.5 to 13.8)	-45.8 (-62.8 to -8.9)
Hepatitis C	18.1 (16.0 to 20.3)	19.7 (17.3 to 22.2)	8.8 (-7.9 to 31.6)	-25.7 (-35.1 to -12.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.2 (-13.9 to 45.2)	-25.0 (-46.2 to 2.6)
Hepatitis E	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	4.5 (-18.2 to 38.7)	-25.1 (-41.5 to -4.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.6 (-27.8 to 47.9)	-25.6 (-46.8 to 4.6)
Leprosy	0.4 (0.3 to 0.6)	0.5 (0.4 to 0.5)	20.6 (7.5 to 62.7)	-16.1 (-33.9 to 11.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.7 (7.5 to 67.0)	-14.8 (-33.7 to 14.0)
Other infectious diseases	12.5 (10.9 to 14.1)	15.2 (13.8 to 16.8)	22.2 (2.2 to 41.8)	-22.6 (-33.7 to -12.7)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.8)	16.9 (-5.5 to 45.0)	-30.5 (-41.9 to -12.2)
Non-communicable diseases	-	-	-	-	41.7 (30.5 to 54.0)	41.7 (44.0 to 78.6)	41.1 (38.8 to 50.1)	2.2 (-5.1 to 1.1)
Neoplasms	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	74.7 (37.5 to 111.4)	-2.5 (-15.7 to 13.2)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	89.9 (30.2 to 173.9)	3.4 (-28.7 to 52.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.3 (39.0 to 155.8)	2.4 (-24.3 to 39.9)
Stomach cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	42.1 (8.0 to 88.1)	-14.6 (-35.2 to 12.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.0 (6.7 to 90.7)	-15.0 (-36.9 to 13.1)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	240.4 (126.2 to 400.0)	109.3 (43.3 to 196.5)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	272.9 (63.8 to 708.6)	145.6 (2.9 to 444.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	271.9 (69.3 to 599.4)	140.7 (64.4 to 363.4)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	604.1 (188.0 to 1,550.6)	296.7 (69.3 to 843.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	584.1 (194.3 to 1,393.9)	275.3 (62.6 to 766.0)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.0 (-46.4 to 163.9)	-29.8 (-6.2 to 43.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.0 (-42.3 to 153.2)	-30.5 (-65.0 to 34.5)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.3 (-10.2 to 313.2)	24.1 (-37.5 to 176.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.2 (-3.7 to 257.3)	19.6 (-35.1 to 140.5)
Larynx cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	30.4 (2.4 to 68.6)	-37.1 (-51.8 to -13.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (6.9 to 73.2)	-31.7 (-47.6 to -8.9)
Tracheal, bronchus and lung cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	82.2 (37.1 to 150.4)	5.6 (-19.4 to 37.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.9 (35.7 to 149.6)	4.8 (-19.6 to 39.5)
Breast cancer	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	84.2 (-10.7 to 170.4)	34.6 (-28.0 to 96.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	87.4 (-8.3 to 180.6)	35.2 (-26.5 to 97.5)
Cervical cancer	0.4 (0.2 to 0.5)	0.3 (0.2 to 0.5)	-8.7 (-40.2 to 40.1)	-27.4 (-51.5 to 10.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.8 (-40.6 to 41.5)	-27.2 (-51.9 to 11.3)
Uterine cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	47.0 (-20.5 to 180.9)	-1.7 (-45.2 to 78.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.5 (-24.6 to 187.4)	-3.3 (-48.3 to 82.3)
Prostate cancer	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	414.8 (215.5 to 730.3)	119.6 (41.0 to 255.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	363.6 (198.3 to 661.9)	99.0 (27.3 to 227.8)
Colon and rectum cancer	0.7 (0.6 to 0.7)	1.3 (1.2 to 1.4)	89.3 (73.7 to 107.8)	-7.2 (-15.4 to 1.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	88.0 (69.2 to 108.4)	-6.7 (-15.7 to 2.9)
Lip and oral cavity cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	71.8 (18.9 to 156.2)	3.2 (-28.0 to 48.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.5 (18.7 to 150.1)	2.5 (-28.1 to 48.2)
Nasopharynx cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	19.8 (-23.3 to 98.3)	-14.5 (-44.6 to 39.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.8 (-22.6 to 86.2)	-16.8 (-45.0 to 29.3)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	32.1 (-24.9 to 133.7)	-21.0 (-53.3 to 36.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.4 (-20.6 to 125.4)	-21.1 (-51.5 to 29.4)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.1 (25.5 to 176.1)	-2.9 (-33.2 to 43.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.5 (23.0 to 164.1)	-4.6 (-34.3 to 44.3)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.9 (46.3 to 175.1)	12.5 (-19.2 to 48.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.0 (53.1 to 157.6)	10.1 (-16.8 to 41.9)
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	110.0 (22.5 to 196.1)	37.9 (-11.7 to 90.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.0 (20.2 to 189.5)	30.5 (-13.7 to 87.9)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	116.0 (32.3 to 205.7)	21.3 (-31.4 to 76.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	144.9 (70.5 to 244.8)	32.3 (-12.1 to 95.1)
Ovarian cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.3 (-39.8 to 138.7)	-12.3 (-53.1 to 67.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.1 (-44.0 to 148.8)	-12.3 (-56.9 to 72.1)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.2 (-2.4 to 235.7)	54.7 (-15.6 to 156.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.5 (-16.2 to 266.7)	44.3 (-27.5 to 171.4)
Kidney cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.6 (-32.4 to 171.4)	8.3 (-41.0 to 52.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.2 (-27.6 to 159.1)	-8.7 (-39.6 to 46.4)
Bladder cancer	0.2 (0.2 to 0.2)	0.3 (0.2 to 0.3)	46.9 (30.0 to 67.7)	-38.4 (-46.1 to -29.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.5 (26.8 to 68.9)	-38.0 (-46.5 to -28.3)
Brain and nervous system cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	119.7 (-20.2 to 250.5)	39.2 (-28.4 to 100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	106.9 (-10.5 to 206.7)	30.6 (-23.9 to 83.8)
Thyroid cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	52.8 (-24.2 to 177.8)	9.1 (-38.6 to 96.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.6 (-23.1 to 179.1)	4.2 (-39.7 to 83.2)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	122.2 (26.4 to 50.7)	31.6 (-54.4 to -1.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.0 (-23.1 to 61.4)	-31.3 (-53.1 to -3.5)
Hodgkin lymphoma	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	46.9 (-18.5 to 190.9)	9.1 (-32.1 to 77.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.7 (-16.9 to 157.7)	4.7 (-31.1 to 59.4)
Non-Hodgkin lymphoma	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	83.3 (-21.2 to 217.1)	24.6 (-32.3 to 92.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.6 (-18.5 to 201.0)	19.3 (-32.2 to 79.6)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	116.0 (38.0 to 239.9)	22.5 (-20.9 to 88.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.4 (44.0 to 216.5)	18.3 (-18.3 to 72.6)
Leukemia	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	159.9 (-25.3 to 367.9)	61.7 (-37.8 to 141.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	151.1 (-13.8 to 257.7)	48.6 (-29.1 to 99.1)
Other neoplasms	0.2 (0.1 to 0.5)	0.4 (0.3 to 0.7)	255.8 (5.3 to 462.3)	87.4 (7.6 to 176.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	220.2 (11.2 to 398.5)	67.1 (9.7 to 140.1)
Cardiovascular diseases	-	-	-	-	1.1 (0.7 to 1.5)	2.2 (1.5 to 3.0)	102.8 (63.0 to 153.4)	23.9 (0.7 to 46.8)
Rheumatic heart disease	8.7 (6.6 to 10.8)	12.1 (9.7 to 14.6)	39.0 (6.6 to 92.9)	-0.9 (-23.6 to 25.4)	0.4 (0.3 to 0.7)	0.6 (0.4 to 0.9)	40.9 (8.2 to 89.0)	0.6 (-2.6 to 26.5)
Ischemic heart disease	2.1 (1.7 to 2.6)	4.9 (3.7 to 6.5)	131.7 (74.1 to 236.9)	6.5 (-18.8 to 47.0)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	128.2 (73.9 to 231.5)	9.5 (-15.6 to 52.3)
Cerebrovascular disease	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	90.7 (56.3 to 138.3)	2.5 (-1.6 to 31.5)
Ischemic stroke	0.4 (0.3 to 0.4)	0.8 (0.6 to 0.9)	107.2 (68.5 to 166.7)	3.4 (-16.3 to 34.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	106.1 (64.7 to 164.6)	4.2 (-15.6 to 35.4)
Hemorrhagic stroke	0.5 (0.4 to 0.5)	0.8 (0.7 to 1.0)	81.5 (46.7 to 127.6)	0.0 (-17.8 to 30.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	79.4 (43.1 to 128.0)	1.0 (-18.6 to 32.7)
Hypertensive heart disease	0.6 (0.5 to 0.6)	1.1 (1.0 to 1.3)	97.2 (61.6 to 139.9)	2.9 (-15.8 to 26.9)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	96.7 (60.3 to 140.4)	3.1 (-15.3 to 29.2)
Cardiomyopathy and myocarditis	0.3 (0.3 to 0.4)	0.6 (0.5 to 0.6)	76.7 (48.2 to 114.3)	12.0 (-8.3 to 39.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	76.4 (45.1 to 115.7)	24.4 (-9.9 to 41.3)
Atrial fibrillation and flutter	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	74.7 (22.5 to 191.0)	-11.8 (-40.0 to 50.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.5 (17.2 to 194.4)	-11.5 (-41.6 to 52.4)
Peripheral vascular disease	12.0 (9.6 to 14.9)	19.9 (16.0 to 23.3)	67.5 (17.4 to 115.0)	-5.6 (-28.7 to 18.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.2 (-36.1 to 425.8)	-30.3 (-71.5 to 59.9)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	60.6 (10.9 to 122.0)	8.9 (-29.6 to 46.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.9 (11.3 to 150.3)	12.2 (-32.7 to 69.1)
Other cardiovascular and circulatory diseases	0.6 (2.1 to 5.7)	11.0 (5.9 to 15.5)	213.3 (51.8 to 456.6)	190.5 (-1.9 to 277.8)	0.3 (0.1 to 0.4)	0.8 (0.4 to 1.2)	215.5 (47.9 to 466.4)	102.5 (-3.4 to 280.0)
Chronic respiratory diseases	-	-	-	-	2.5 (1.7 to 3.6)	3.4 (2.3 to 4.7)	35.9 (13.2 to 64.3)	-8.9 (-23.7 to 8.1)
Chronic obstructive pulmonary disease	16.2 (14.9 to 17.6)	24.6 (22.7 to 26.7)	51.7 (45.5 to 57.6)	1.1 (-2.8 to 4.5)	1.6 (1.1 to 2.3)	2.4 (1.6 to		

Appendix Table G.4 - Timor-Leste prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	150.0	51.1
Silicosis	0.0	0.0	41.4	-21.2	(0.0 to 0.0)	(0.0 to 0.0)	(134.6 to 164.9)	(38.9 to 64.1)
Asbestosis	(0.0 to 0.0)	(0.0 to 0.0)	(34.7 to 48.1)	(-24.8 to -17.2)	0.0	0.0	40.5	-21.5
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	98.2	0.0	0.0	0.0	190.5	89.2
Asthma	(0.0 to 0.0)	(0.0 to 0.0)	(183.3 to 213.1)	(86.5 to 103.8)	(0.0 to 0.0)	(0.0 to 0.0)	(173.8 to 207.3)	(76.0 to 103.8)
Interstitial lung disease and pulmonary sarcoidosis	9.1	15.1	61.6	9.7	0.4	0.7	61.5	10.4
Other chronic respiratory diseases	(7.0 to 11.9)	(10.9 to 21.4)	(16.9 to 166.0)	(-19.3 to 53.2)	(0.2 to 0.6)	(0.4 to 1.1)	(16.7 to 170.1)	(-18.7 to 54.6)
Cirrhosis	0.0	0.1	61.0	7.0	0.0	0.0	62.2	6.6
Cirrhosis due to hepatitis B	(0.0 to 0.0)	(0.0 to 0.1)	(12.7 to 129.6)	(-25.5 to 49.7)	(0.0 to 0.0)	(0.0 to 0.0)	(12.8 to 129.2)	(-25.5 to 51.2)
Cirrhosis due to hepatitis C	-	-	-	-	0.5	0.3	-38.9	-59.5
Cirrhosis due to alcohol use	0.0	0.0	-	-	(0.2 to 1.0)	(0.2 to 0.5)	(-65.2 to 3.5)	(-76.6 to -30.1)
Cirrhosis due to other causes	0.1	0.1	-7.4	-27.3	0.0	0.0	-7.0	-27.0
Digestive diseases	(0.1 to 0.1)	(0.1 to 0.1)	(-35.1 to 55.2)	(46.8 to 19.1)	(0.0 to 0.0)	(0.0 to 0.0)	(-38.5 to 65.8)	(-49.2 to 24.7)
Peptic ulcer disease	0.1	0.1	35.7	-0.6	0.0	0.0	32.3	-1.4
Gastritis and duodenitis	(0.0 to 0.1)	(0.0 to 0.1)	(-29.0 to 136.6)	(-45.3 to 79.5)	(0.0 to 0.0)	(0.0 to 0.0)	(-30.2 to 141.1)	(-48.7 to 85.7)
Appendicitis	0.1	0.0	-36.3	-52.6	0.0	0.0	-35.9	-52.3
Paralytic ileus and intestinal obstruction	(0.0 to 0.1)	(0.0 to 0.1)	(-62.3 to 28.5)	(-70.6 to -10.2)	(0.0 to 0.0)	(0.0 to 0.0)	(-64.8 to 31.3)	(-72.3 to -7.3)
Inguinal, femoral, and abdominal hernia	0.0	0.0	43.1	-1.0	0.0	0.0	45.5	2.0
Inflammatory bowel disease	3.2	5.1	56.9	-17.4	0.0	0.1	57.4	-16.6
Vascular intestinal disorders	(2.9 to 3.6)	(4.3 to 6.2)	(32.9 to 92.1)	(-31.8 to 1.8)	(0.0 to 0.1)	(0.0 to 0.1)	(31.8 to 90.9)	(-31.0 to 2.8)
Gallbladder and biliary diseases	0.1	0.1	38.3	-2.0	0.0	0.0	38.6	-1.4
Pancreatitis	(0.1 to 0.1)	(0.2 to 0.2)	(48.1 to 74.8)	(5.8 to 22.6)	(0.0 to 0.1)	(0.0 to 0.1)	(33.7 to 93.2)	(-1.4 to 32.9)
Other digestive diseases	-	-	-	-	0.1	0.1	-2.1	-43.9
Neurological disorders	-	-	-	-	(0.0 to 0.2)	(0.1 to 0.2)	(-36.3 to 62.6)	(-63.5 to -4.6)
Alzheimer disease and other dementias	1.1	2.9	154.0	3.6	(2.7 to 6.1)	(4.7 to 10.6)	(29.4 to 116.1)	(-7.4 to 34.0)
Parkinson disease	0.1	0.3	111.4	0.4	0.2	0.4	159.6	4.7
Epilepsy	(0.1 to 0.2)	(0.3 to 0.3)	(101.0 to 124.7)	(-3.8 to 5.2)	(0.0 to 0.0)	(0.0 to 0.0)	(82.9 to 137.8)	(-9.2 to 12.0)
Multiple sclerosis	3.3	5.4	63.0	5.7	0.9	1.6	81.9	18.0
Migraine	(2.3 to 4.3)	(3.8 to 6.8)	(2.5 to 157.3)	(-31.4 to 64.4)	(0.6 to 1.4)	(1.0 to 2.4)	(12.4 to 189.2)	(-23.7 to 85.5)
Tension-type headache	0.0	0.0	83.1	0.0	0.0	0.0	131.4	83.1
Medication overuse headache	7.4	113.5	60.2	13.1	(0.0 to 0.0)	(0.0 to 0.0)	(105.4 to 158.5)	(65.4 to 103.1)
Other neurological disorders	(5.2 to 90.7)	(83.0 to 142.2)	(4.0 to 133.3)	(-18.7 to 57.8)	(1.3 to 3.9)	(2.2 to 6.1)	(2.7 to 136.5)	(-19.0 to 60.6)
Mental and substance use disorders	149.2	208.0	39.3	1.5	0.2	0.3	39.5	1.6
Schizophrenia	(131.3 to 165.6)	(190.3 to 223.7)	(21.5 to 61.8)	(-9.3 to 14.7)	(0.1 to 0.4)	(0.2 to 0.6)	(20.6 to 63.2)	(-9.4 to 15.9)
Alcohol use disorders	2.3	4.6	101.8	51.8	0.4	0.7	101.9	52.0
Drug use disorders	(1.5 to 3.0)	(3.1 to 6.0)	(70.7 to 132.2)	(28.0 to 71.9)	(0.2 to 0.6)	(0.4 to 1.1)	(68.9 to 134.4)	(27.9 to 74.6)
Opioid use disorders	0.0	0.0	52.1	4.1	0.1	0.1	78.6	-26.9
Cocaine use disorders	(0.0 to 0.0)	(0.0 to 0.0)	(9.2 to 110.9)	(-23.0 to 44.7)	(0.0 to 0.2)	(0.1 to 0.2)	(-10.5 to 170.1)	(-64.0 to 9.2)
Amphetamine use disorders	11.6	15.9	36.2	0.1	11.6	15.9	36.2	0.1
Cannabis use disorders	(8.2 to 15.6)	(11.2 to 21.2)	(30.7 to 43.6)	(-2.8 to 4.0)	1.3	1.6	22.2	1.3
Other drug use disorders	2.1	2.5	21.6	0.8	0.8	0.8	20.6	-5.7
Depressive disorders	5.2	6.2	20.6	-5.8	0.5	0.6	20.6	-5.7
Major depressive disorder	(4.6 to 5.9)	(5.5 to 7.1)	(13.7 to 28.4)	(-10.8 to -0.5)	(0.3 to 0.7)	(0.4 to 0.9)	(12.6 to 31.0)	(-11.5 to 1.7)
Dysthymia	-	-	-	-	1.7	2.2	26.0	-3.1
Bipolar disorder	0.8	0.9	10.5	1.5	0.3	0.4	11.3	2.1
Anxiety disorders	(0.6 to 1.0)	(0.7 to 1.2)	(0.9 to 20.6)	(-5.7 to 8.5)	(0.2 to 0.5)	(0.2 to 0.5)	(-2.4 to 26.7)	(-8.8 to 13.2)
Eating disorders	0.6	0.8	31.0	0.1	0.1	0.1	31.0	0.0
Anorexia nervosa	(0.6 to 0.7)	(0.8 to 0.9)	(18.3 to 46.1)	(-9.9 to 9.6)	(0.1 to 0.1)	(0.1 to 0.2)	(7.1 to 60.3)	(-17.7 to 19.6)
Bulimia nervosa	4.3	5.5	27.2	-6.6	0.6	0.7	27.1	-6.5
Autistic spectrum disorders	(3.3 to 5.4)	(4.4 to 6.7)	(5.3 to 70.9)	(-27.9 to 21.0)	(0.3 to 0.9)	(0.4 to 1.1)	(-4.1 to 74.8)	(-28.2 to 23.7)
Autism	1.8	2.5	41.8	0.1	0.1	0.1	41.7	0.7
Asperger syndrome	(1.2 to 2.3)	(1.6 to 3.4)	(29.2 to 48.5)	(-0.3 to 0.7)	(0.0 to 0.1)	(0.0 to 0.1)	(20.2 to 68.0)	(-12.0 to 15.8)
Attention-deficit/hyperactivity disorder	-	-	-	-	0.7	0.9	29.5	-4.8
Conduct disorder	0.0	0.0	52.1	4.1	0.1	0.1	78.6	-26.9
Idiopathic intellectual disability	(0.0 to 0.0)	(0.0 to 0.0)	(9.2 to 110.9)	(-23.0 to 44.7)	(0.0 to 0.2)	(0.1 to 0.2)	(-10.5 to 170.1)	(-64.0 to 9.2)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	11.6	15.9	36.2	0.1
Diabetes mellitus	10.7	14.8	39.0	1.4	2.2	3.1	39.1	1.8
Acute glomerulonephritis	(7.5 to 14.4)	(10.4 to 19.5)	(28.7 to 54.2)	(-6.3 to 11.8)	(1.3 to 3.4)	(1.8 to 4.7)	(28.2 to 56.8)	(-5.5 to 12.9)
Chronic kidney disease	7.4	9.9	34.8	0.7	1.0	1.1	34.9	1.1
Chronic kidney disease due to diabetes mellitus	(6.2 to 8.5)	(8.5 to 11.3)	(30.3 to 39.5)	(0.4 to 0.9)	(0.5 to 1.0)	(0.6 to 1.4)	(29.0 to 41.4)	(-1.2 to 3.5)
Chronic kidney disease due to hypertension	3.9	5.1	30.6	1.2	0.8	1.0	31.0	1.7
Chronic kidney disease due to glomerulonephritis	(3.1 to 4.7)	(4.1 to 6.0)	(21.5 to 39.3)	(-4.6 to 5.9)	(0.5 to 1.2)	(0.6 to 1.6)	(18.6 to 42.4)	(-5.7 to 8.6)
Chronic kidney disease due to other causes	17.8	24.2	34.7	2.9	4.0	4.0	37.9	1.6
Urinary diseases and male infertility	(6.6 to 29.5)	(9.4 to 40.5)	(26.8 to 48.9)	(-0.3 to 1.4)	(0.6 to 3.0)	(0.8 to 4.2)	(25.9 to 50.3)	(-2.3 to 3.9)
Diabetes mellitus	0.2	0.3	53.4	-0.3	0.1	0.1	47.1	-0.5
Bulimia nervosa	(0.2 to 0.3)	(0.2 to 0.4)	(36.2 to 71.8)	(-10.4 to 10.9)	(0.0 to 0.1)	(0.0 to 0.1)	(23.1 to 89.9)	(-18.4 to 22.4)
Autistic spectrum disorders	0.2	0.3	40.1	-1.0	0.0	0.1	40.6	-0.7
Autism	(0.1 to 0.3)	(0.2 to 0.4)	(30.9 to 49.9)	(-1.6 to -0.3)	(0.0 to 0.1)	(0.0 to 0.1)	(14.6 to 72.5)	(-17.3 to 19.1)
Asperger syndrome	2.4	3.5	49.9	-0.7	0.9	1.4	50.8	-0.0
Attention-deficit/hyperactivity disorder	(2.2 to 2.5)	(3.4 to 3.7)	(49.5 to 50.3)	(-0.7 to -0.6)	(0.4 to 0.8)	(0.6 to 1.2)	(42.9 to 59.5)	(-4.5 to 4.4)
Conduct disorder	3.4	5.1	49.6	-0.8	0.3	0.5	50.2	-0.4
Idiopathic intellectual disability	(3.2 to 3.6)	(4.8 to 5.4)	(49.0 to 50.1)	(-0.9 to -0.8)	(0.2 to 0.5)	(0.4 to 0.7)	(43.4 to 58.2)	(-4.4 to 3.9)
Other mental and substance use disorders	5.6	9.9	77.9	-1.0	0.1	0.1	78.4	-0.8
Diabetes, urogenital, blood, and endocrine diseases	(5.1 to 5.9)	(9.1 to 10.6)	(77.4 to 78.7)	(-1.1 to -1.0)	(0.0 to 0.1)	(0.1 to 0.2)	(65.8 to 92.6)	(-7.3 to 7.3)
Diabetes mellitus	8.0	16.1	99.8	40.5	0.5	1.1	98.2	35.5
Acute glomerulonephritis	(6.6 to 9.4)	(13.3 to 18.7)	(63.6 to 150.1)	(11.6 to 19.5)	(0.3 to 0.8)	(0.7 to 1.5)	(60.4 to 151.9)	(7.3 to 71.7)
Chronic kidney disease	0.0	0.0	2.3	-38.1	0.0	0.0	2.3	-38.1
Chronic kidney disease due to diabetes mellitus	(0.0 to 0.0)	(0.0 to 0.0)	(-4.3 to 8.1)	(-41.3 to -34.9)	(0.0 to 0.0)	(0.0 to 0.0)	(-4.3 to 8.1)	(-41.3 to -34.9)
Chronic kidney disease due to hypertension	1.9	5.2	176.1	75.2	0.1	0.1	146.0	63.0
Chronic kidney disease due to glomerulonephritis	(1.2 to 3.0)	(3.6 to 7.5)	(102.7 to 296.9)	(32.2 to 142.4)	(0.0 to 0.1)	(0.1 to 0.2)	(79.0 to 236.8)	(20.2 to 121.0)
Chronic kidney disease due to other causes	5.8	3.2	-41.1	-57.1	0.1	0.2	43.7	2.8
Urinary diseases and male infertility	(3.1 to 11.4)	(2.2 to 5.0)	(-45.2 to -13.6)	(-70.1 to -42.2)	(0.1 to 0.2)	(0.1 to 0.3)	(7.6 to 88.1)	(-20.4 to 29.4)
Diabetes, urogenital, blood, and endocrine diseases	5.3	7.7	41.8	1.0	0.1	0.1	41.8	0.1
Diabetes mellitus	(3.4 to 8.3)	(4.5 to 12.4)	(5.2 to 100.8)	(-22.2 to 26.4)	(0.1 to 0.4)	(0.0 to 0.1)	(-70.0 to -37.0)	(-78.3 to -56.2)
Acute glomerulonephritis	14.7	26.9	83.2	4.2	0.3	0.6	67.1	-0.2
Chronic kidney disease	(9.1 to 23.4)	(16.6 to 44.4)	(55.6 to 118.6)	(-7.3 to 20.9)	(0.2 to 0.5)	(0.4 to 0.8)	(41.7 to 95.2)	(-18.7 to 14.6)
Urinary diseases and male infertility	-	-	-	-	0.2	0.4	75.3	-6.0
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	(0.1 to 0.3)	(0.2 to 0.5)	(52.8 to 99.8)	(-15.7 to 4.3)

Appendix Table G.4 - Timor-Leste prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	87.0 (70.2 to 105.1)	28.2 (18.1 to 37.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.9 (43.1 to 141.5)	87.9 (5.5 to 55.5)
Urolithiasis	2.4 (1.7 to 3.2)	3.9 (2.9 to 5.1)	63.7 (36.2 to 116.7)	-1.1 (-14.4 to 36.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	35.4 (18.5 to 54.6)	2.0 (-8.7 to 14.1)
Benign prostatic hyperplasia	3.3 (3.0 to 3.6)	6.9 (6.4 to 7.5)	110.4 (85.1 to 139.7)	-8.5 (-18.9 to 3.6)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	110.7 (84.8 to 141.5)	-7.9 (-18.5 to 4.3)
Male infertility due to other causes	3.4 (2.3 to 4.6)	3.9 (2.5 to 5.3)	16.1 (-33.4 to 97.3)	8.5 (-38.7 to 80.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	16.2 (-33.9 to 104.6)	7.3 (-39.9 to 85.1)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	27.9 (-31.9 to 126.2)	4.9 (-50.3 to 67.7)
Gynecological diseases	-	-	-	-	0.8 (0.5 to 1.2)	0.8 (0.5 to 1.3)	4.0 (-12.1 to 23.1)	-12.0 (-23.4 to 2.2)
Uterine fibroids	12.5 (11.3 to 13.7)	13.5 (12.4 to 14.8)	8.5 (7.1 to 9.8)	0.2 (-0.2 to 0.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-15.2 (-23.1 to -6.0)	-24.4 (-32.6 to -15.7)
Polycystic ovarian syndrome	10.5 (9.1 to 11.9)	11.5 (9.6 to 13.6)	9.8 (-13.4 to 38.0)	-5.1 (-23.8 to 15.4)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	10.5 (-12.5 to 38.2)	-4.4 (-22.7 to 16.7)
Female infertility due to other causes	2.6 (1.5 to 4.0)	2.8 (1.6 to 4.1)	9.6 (-41.9 to 102.4)	12.0 (-40.2 to 114.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.8 (-44.6 to 98.7)	10.0 (-41.4 to 108.3)
Endometriosis	1.2 (1.1 to 1.4)	1.3 (1.2 to 1.5)	7.6 (-12.9 to 31.8)	-1.8 (-20.3 to 19.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	7.8 (-13.9 to 36.5)	1.7 (-20.6 to 22.4)
Genital prolapse	27.3 (23.4 to 31.3)	33.8 (28.7 to 38.6)	24.4 (0.2 to 50.8)	0.1 (-15.4 to 15.6)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	24.2 (0.3 to 51.4)	0.3 (-15.6 to 16.3)
Premenstrual syndrome	26.6 (17.4 to 34.5)	31.4 (21.1 to 42.5)	17.7 (-28.5 to 96.8)	-6.1 (-41.2 to 62.3)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	17.8 (-28.5 to 98.5)	-6.2 (-41.4 to 62.8)
Other gynecological diseases	2.1 (1.5 to 2.7)	1.6 (1.2 to 1.9)	25.2 (-44.7 to 3.8)	-39.3 (-54.5 to -16.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-36.3 (-64.0 to -8.4)	47.9 (-68.5 to -5.1)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	1.4 (0.9 to 2.1)	2.1 (1.4 to 3.1)	49.1 (37.8 to 68.2)	-9.4 (-17.4 to 5.5)
Thalassemias	0.4 (0.2 to 0.8)	0.6 (0.3 to 1.2)	57.1 (47.4 to 68.9)	0.5 (-6.2 to 9.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	47.2 (4.4 to 121.5)	-5.1 (-30.2 to 33.1)
Thalassemia trait	54.8 (37.1 to 74.8)	84.0 (59.7 to 113.1)	53.1 (48.2 to 61.7)	2.4 (-0.7 to 8.7)	0.9 (0.6 to 1.3)	1.5 (1.0 to 2.2)	79.4 (61.3 to 99.1)	12.4 (-0.3 to 30.2)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.3 (-27.4 to 36.9)	-20.9 (-51.3 to -9.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.3 (-18.4 to 88.9)	10.3 (-45.4 to 31.5)
Sickle cell trait	0.7 (0.4 to 1.0)	1.0 (0.7 to 1.3)	49.6 (-9.9 to 83.5)	0.0 (-39.8 to 22.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.8 (-30.1 to 80.2)	-30.0 (-53.7 to -0.1)
G6PD deficiency	64.7 (36.4 to 88.5)	92.2 (63.3 to 125.3)	41.1 (-16.7 to 160.4)	-5.8 (-44.5 to 73.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.5 (-19.0 to 67.9)	-25.2 (-44.1 to -1.0)
G6PD trait	133.6 (112.1 to 146.9)	197.9 (161.7 to 222.8)	47.7 (19.0 to 83.6)	-0.4 (-19.7 to 23.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.9 (-70.1 to 440.0)	-12.4 (-81.6 to 294.2)
Other hemoglobinopathies and hemolytic anemias	15.2 (13.7 to 16.5)	17.2 (15.8 to 19.0)	12.7 (0.0 to 30.5)	-25.1 (-33.6 to -17.2)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.8)	0.0 (-20.7 to 29.3)	-38.9 (-50.7 to -25.3)
Endocrine, metabolic, blood, and immune disorders	14.3 (12.9 to 15.4)	18.0 (15.2 to 20.6)	26.4 (9.2 to 45.5)	18.1 (-27.6 to 8.8)	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.9)	26.3 (5.6 to 43.9)	26.3 (-37.8 to -12.1)
Musculoskeletal disorders	-	-	-	-	6.6 (4.6 to 9.1)	9.0 (6.1 to 12.1)	35.2 (13.5 to 60.7)	-1.7 (-15.6 to 15.0)
Rheumatoid arthritis	0.5 (0.5 to 0.6)	1.0 (0.9 to 1.1)	90.9 (74.8 to 108.2)	29.1 (19.1 to 41.8)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	90.1 (68.4 to 118.6)	29.6 (16.9 to 45.7)
Osteoarthritis	5.8 (5.4 to 6.2)	10.4 (9.8 to 11.0)	79.1 (64.7 to 94.1)	5.3 (-2.2 to 13.9)	0.4 (0.2 to 0.5)	0.6 (0.5 to 0.9)	78.4 (62.9 to 93.9)	5.9 (-1.8 to 14.7)
Low back and neck pain	-	-	-	-	5.3 (3.6 to 7.3)	5.8 (4.5 to 9.4)	28.5 (1.5 to 59.6)	-4.2 (-23.8 to 18.1)
Low back pain	31.5 (26.7 to 36.5)	42.4 (34.0 to 50.5)	35.2 (-3.4 to 77.6)	-2.8 (-27.9 to 19.9)	3.6 (2.3 to 5.1)	4.8 (3.1 to 6.8)	34.8 (-4.3 to 77.4)	-2.2 (-27.7 to 21.7)
Neck pain	17.1 (13.9 to 20.1)	19.9 (15.4 to 25.6)	17.4 (-14.8 to 52.2)	-9.2 (-33.7 to 19.8)	1.7 (1.1 to 2.5)	2.0 (1.2 to 2.9)	17.5 (-15.0 to 52.5)	-8.7 (-33.5 to 20.8)
Gout	0.3 (0.2 to 0.3)	0.4 (0.4 to 0.5)	56.5 (30.2 to 92.5)	1.8 (-15.2 to 23.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.5 (18.9 to 105.5)	3.6 (-20.7 to 33.3)
Other musculoskeletal disorders	9.6 (6.9 to 12.5)	14.2 (10.5 to 18.1)	48.6 (31.9 to 65.9)	1.8 (-5.4 to 9.0)	0.9 (0.6 to 1.3)	1.3 (0.8 to 1.9)	47.9 (30.7 to 65.5)	47.9 (5.7 to 9.9)
Other non-communicable diseases	-	-	-	-	10.6 (7.1 to 15.4)	15.4 (10.3 to 22.3)	45.4 (38.7 to 51.5)	-8.9 (-11.9 to -6.2)
Congenital anomalies	-	-	-	-	0.6 (0.4 to 1.0)	1.2 (0.8 to 1.7)	93.6 (59.1 to 139.5)	31.2 (6.7 to 61.7)
Neural tube defects	0.0 (0.0 to 0.0)	0.2 (0.2 to 0.3)	602.6 (454.9 to 776.4)	444.8 (329.0 to 581.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	789.9 (524.3 to 1,150.2)	610.1 (404.6 to 869.6)
Congenital heart anomalies	0.4 (0.3 to 0.5)	3.5 (2.9 to 4.3)	846.0 (561.4 to 1,257.8)	635.4 (405.2 to 966.1)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	640.1 (339.2 to 1,042.5)	457.3 (241.7 to 770.4)
Orofacial clefts	0.1 (0.0 to 0.1)	0.8 (0.6 to 1.0)	1,273.9 (696.6 to 2,255.0)	1,074.5 (555.6 to 2,016.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,012.0 (530.3 to 1,899.3)	842.5 (421.2 to 1,652.9)
Down syndrome	0.4 (0.3 to 0.4)	1.1 (0.9 to 1.3)	189.9 (134.1 to 266.6)	117.7 (74.7 to 175.7)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	203.7 (139.8 to 295.7)	130.7 (83.3 to 200.9)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	146.2 (76.6 to 261.9)	76.5 (26.3 to 159.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	142.2 (67.7 to 266.2)	76.4 (21.7 to 167.8)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.3 (9.7 to 139.4)	6.5 (-26.1 to 61.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.8 (-10.4 to 113.9)	7.1 (-32.2 to 63.8)
Chromosomal unbalanced rearrangements	0.5 (0.4 to 0.6)	1.5 (1.2 to 1.8)	181.4 (128.7 to 302.5)	118.9 (69.6 to 201.4)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	206.0 (134.0 to 322.1)	133.5 (78.7 to 219.8)
Other congenital anomalies	3.8 (2.7 to 5.1)	4.8 (3.4 to 6.4)	26.8 (8.3 to 47.7)	-16.5 (-28.0 to -4.1)	0.5 (0.3 to 0.8)	0.7 (0.4 to 1.1)	38.2 (12.3 to 69.8)	-13.4 (-28.4 to 7.1)
Skin and subcutaneous diseases	-	-	-	-	3.6 (2.3 to 5.5)	5.5 (3.5 to 8.3)	50.3 (42.6 to 58.7)	0.1 (-4.9 to 5.0)
Dermatitis	34.8 (29.3 to 40.9)	49.9 (42.3 to 58.6)	43.2 (39.2 to 47.1)	0.1 (-0.0 to 0.2)	1.1 (0.7 to 1.5)	1.6 (1.0 to 2.3)	48.8 (42.6 to 55.7)	0.5 (-2.4 to 3.2)
Psoriasis	5.0 (4.0 to 6.2)	7.1 (5.7 to 8.6)	42.2 (37.2 to 47.3)	0.0 (-0.2 to 0.3)	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.9)	42.6 (32.8 to 54.0)	0.5 (-4.4 to 6.2)
Cellulitis	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	46.5 (25.6 to 70.8)	-5.6 (-16.6 to 12.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.9 (9.1 to 92.1)	-4.9 (-23.1 to 17.9)
Pyoderma	1.3 (0.9 to 1.6)	0.8 (0.7 to 1.1)	-33.2 (-41.7 to -20.2)	-51.9 (-59.1 to -43.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.1 (-44.2 to -19.7)	-31.1 (-60.1 to -43.1)
Scabies	12.2 (10.0 to 15.2)	12.4 (10.3 to 15.0)	2.2 (-24.4 to 33.5)	-33.0 (-49.9 to -13.0)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	2.3 (-23.7 to 35.0)	-2.3 (-50.0 to -12.1)
Fungal skin diseases	82.6 (63.8 to 102.2)	122.0 (94.8 to 153.4)	48.5 (42.3 to 55.0)	48.5 (-0.1 to 0.2)	0.5 (0.2 to 0.9)	0.7 (0.3 to 1.5)	49.3 (42.4 to 55.4)	0.4 (-0.4 to 1.1)
Viral skin diseases	17.7 (13.2 to 22.1)	28.9 (22.2 to 35.3)	63.2 (56.9 to 71.7)	0.1 (-2.0 to 2.1)	0.2 (0.3 to 0.9)	0.2 (0.5 to 1.4)	64.0 (55.0 to 73.6)	0.3 (-2.7 to 3.9)
Acne vulgaris	18.0 (11.9 to 23.8)	38.6 (27.7 to 57.5)	113.8 (41.9 to 247.2)	31.9 (-7.2 to 118.9)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.8)	114.3 (41.7 to 248.5)	32.1 (-7.1 to 120.4)
Alopecia areata	0.8 (0.7 to 0.9)	1.3 (1.1 to 1.4)	50.8 (25.6 to 79.8)	2.2 (-13.3 to 19.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	50.9 (21.6 to 83.3)	2.8 (-14.8 to 21.8)
Pruritus	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	47.8 (15.3 to 83.0)	0.7 (-21.9 to 27.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.3 (7.1 to 94.7)	1.9 (-24.2 to 32.6)
Urticaria	5.6 (3.9 to 7.4)	8.8 (6.3 to 12.1)	56.4 (-1.2 to 128.5)	10.7 (-24.6 to 47.6)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.8)	56.8 (-1.9 to 132.1)	12.3 (-24.0 to 48.6)
Decubitus ulcer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	43.6 (10.8 to 85.2)	-3.9 (-32.4 to 43.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.7 (5.6 to 83.3)	-3.6 (-34.7 to 46.1)
Other skin and subcutaneous diseases	38.2 (26.9 to 52.5)	56.9 (39.5 to 81.4)	49.0 (33.3 to 67.5)	-0.5 (-3.0 to 2.4)	0.2 (0.1 to 0.5)	0.3 (0.2 to 0.7)	48.9 (33.0 to 67.0)	-0.1 (-3.0 to 2.8)
Sense organ diseases	-	-	-	-	5.6 (3.6 to 8.1)	7.6 (5.1 to 11.2)	96.7 (27.8 to 45.8)	-14.2 (-18.0 to -10.9)
Glaucoma	1.1 (0.8 to 1.4)	1.5 (1.0 to 2.1)	29.7 (-5.9 to 103.0)	-7.2 (-31.1 to 40.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	33.9 (43.0 to 97.0)	8.5 (-29.9 to 24.2)
Cataract	4.7 (3.4 to 6.1)	7.2 (4.7 to 9.7)	57.1 (5.4 to 92.6)	-28.1 (-47.6 to -17.0)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.7)	67.6 (30.1 to 100.1)	-25.2 (-38.6 to -15.2)
Macular degeneration	0.4 (0.3 to 0.6)	1.2 (0.7 to 1.9)	179.5 (79.5 to 390.7)	51.6 (1.7 to 154.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	163.3 (75.1 to 353.0)	28.7 (-4.7 to 100.5)
Uncorrected refractive error	95.0 (86.6 to 102.9)	136.1 (124.7 to 147.5)	43.5 (26.0 to 60.7)	-8.8 (-17.2 to -0.1)	1.6 (0.9 to 2.5)	2.1 (1.3 to 3.4)	37.8 (25.5 to 50.1)	-33.5 (-18.9 to -7.1)
Age-related and other hearing loss	77.2 (67.0 to 85.6)	106.5 (95.0 to 118.1)	38.0 (30.4 to 46.1)	-9.7 (-13.0 to -6.9)	2.7 (1.6 to 4.1)	3.7 (2.2 to 5.7)	34.8 (17.8 to 52.6)	-11.9 (-17.8 to -6.0)
Other vision loss	8.3 (7.2 to 9.8)	9.1 (7.5 to 11.3)	8.5 (-34.7 to -0.1)	24.9 (-3.7 to 40.1)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.7)	3.8 (-9.5 to 20.3)	3.8 (-38.2 to -12.3)
Other sense organ diseases	17.1 (16.2 to 18.0)	26.8 (25.3 to 28.3)	56.5 (45.2 to 69.0)	0.7 (-5.6 to 7.5)	0.5 (0.3 to 0.7)	0.7 (0.4 to 1.1)	56.6 (43.8 to 71.9)	1.1 (-6.1 to 9.0)
Oral disorders	-	-	-	-	0.8 (0.4 to 1.2)	1.1 (0.6 to 1.8)	44.6 (35.8 to 54.8)	-7.5 (-13.6 to -0.7)
Deciduous caries	85.5 (80.0 to 92.2)	138.7 (129.9 to 148.1)	62.5 (47.0 to 77.5)	0.1 (-9.3 to 9.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	62.8 (44.6 to 80.9)	0.3 (-10.7 to 11.0)
Permanent caries	198.1 (180.3 to 222.9)	299.9 (271.5 to 341.4)	50.8 (31.5 to 82.0)	0.9 (-11.6 to 22.3)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.6)	50.9 (31.0 to 81.9)	1.2 (-11.5 to 22.6)
Periodontal diseases	15.9 (14.3 to 17.7)	22.5 (19.7 to 25.6)	42.5 (16.5 to 65.7)	0.9 (-19.0 to 18.4)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)</		

Appendix Table G.4 - Timor-Leste prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	3.8 (3.4 to 4.2)	5.3 (4.7 to 5.9)	38.7 (18.2 to 63.9)	-27.0 (-36.9 to -14.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	38.0 (17.2 to 63.2)	-26.6 (-37.1 to -13.8)
Other oral disorders	11.3 (10.6 to 12.0)	16.0 (15.0 to 16.9)	41.9 (29.6 to 53.7)	0.0 (-7.4 to 7.6)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.7)	42.2 (28.9 to 55.6)	0.4 (-7.6 to 8.2)
Injuries	-	-	-	-	2.1 (1.6 to 2.8)	2.6 (2.0 to 3.3)	20.2 (15.8 to 24.8)	-8.7 (-11.4 to -5.9)
Transport injuries	-	-	-	-	0.8 (0.6 to 1.1)	1.0 (0.7 to 1.3)	17.0 (9.7 to 23.5)	-5.8 (-10.4 to -1.4)
Road injuries	-	-	-	-	0.3 (0.6 to 0.9)	0.9 (0.7 to 1.1)	18.1 (10.8 to 26.6)	-25.5 (-8.2 to 2.1)
Pedestrian road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	18.7 (6.3 to 35.0)	-3.5 (-11.2 to 6.2)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	7.0 (-1.7 to 15.3)	-14.1 (-20.3 to -7.5)
Motorcyclist road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	5.6 (-3.4 to 17.0)	-11.7 (-17.8 to -3.1)
Motor vehicle road injuries	-	-	-	-	0.3 (0.2 to 0.3)	0.3 (0.3 to 0.5)	38.3 (24.2 to 52.4)	10.6 (0.7 to 20.2)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.5 (6.4 to 23.0)	-16.0 (-20.2 to -10.1)
Other transport injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	2.7 (-3.7 to 10.1)	-21.9 (-26.1 to -16.2)
Unintentional injuries	-	-	-	-	1.2 (0.9 to 1.5)	1.5 (1.1 to 1.9)	27.5 (22.5 to 33.2)	-7.5 (-10.4 to -3.9)
Falls	-	-	-	-	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.6)	63.6 (54.4 to 73.3)	12.1 (6.5 to 18.6)
Drowning	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-32.9 (-41.3 to -25.3)	-47.8 (-53.1 to -43.1)
Fire, heat, and hot substances	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-23.3 (-30.3 to -14.6)	-44.9 (-48.9 to -40.0)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.7 (-32.1 to 0.4)	-39.9 (-49.0 to -29.5)
Exposure to mechanical forces	-	-	-	-	0.5 (0.4 to 0.7)	0.6 (0.5 to 0.8)	16.8 (9.7 to 26.9)	-17.4 (-22.0 to -11.9)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.4 (-14.1 to 0.2)	-31.7 (-36.3 to -27.2)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.9 (15.8 to 45.2)	-4.3 (-14.2 to 3.5)
Other exposure to mechanical forces	-	-	-	-	0.5 (0.4 to 0.6)	0.6 (0.4 to 0.8)	18.2 (10.7 to 29.0)	-16.7 (-21.6 to -10.7)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	51.7 (42.2 to 61.7)	2.8 (-3.4 to 10.2)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.7 (2.1 to 22.8)	-19.7 (-25.5 to -13.9)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.3 (-4.5 to 28.8)	-19.0 (-28.6 to -8.0)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.0 (3.0 to 24.0)	-20.2 (-25.6 to -14.9)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.3 (40.9 to 55.9)	5.2 (1.2 to 9.4)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.4 (33.1 to 72.7)	8.5 (-2.2 to 17.9)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	40.4 (30.7 to 49.1)	-0.5 (-6.1 to 4.8)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.4 (40.9 to 60.0)	6.6 (-0.1 to 13.8)
Other unintentional injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	79.5 (64.3 to 96.1)	25.7 (15.0 to 37.2)
Self-harm and interpersonal violence	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-23.2 (-27.2 to -19.4)	-40.5 (-43.2 to -37.9)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.4 (-31.6 to -18.5)	-44.6 (-48.4 to -40.3)
Interpersonal violence	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-22.9 (-27.5 to -18.7)	-39.7 (-42.8 to -36.6)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.7 (-30.2 to -19.3)	-41.2 (-45.1 to -37.0)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.2 (-23.1 to -9.0)	-35.5 (-40.7 to -30.4)
Assault by other means	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-24.6 (-29.8 to -19.1)	-40.8 (-44.5 to -36.6)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Togo prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	362.4 (263.7 to 480.2)	638.6 (463.8 to 836.5)	76.6 (67.3 to 84.0)	76.6 (8.2 to 0.1)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	121.7 (84.3 to 172.6)	181.8 (128.5 to 245.7)	50.1 (32.1 to 67.6)	-19.7 (-30.9 to -7.9)
HIV/AIDS and tuberculosis	-	-	-	-	3.1 (2.0 to 4.4)	22.2 (13.9 to 32.9)	613.0 (417.8 to 876.1)	264.5 (160.0 to 411.3)
Tuberculosis	5.1 (4.7 to 5.5)	10.1 (9.4 to 10.9)	98.5 (87.9 to 109.3)	1.4 (-3.7 to 6.9)	1.6 (1.1 to 2.1)	3.1 (2.1 to 4.2)	100.1 (83.9 to 117.3)	2.1 (-5.3 to 10.3)
HIV/AIDS	-	-	-	-	1.6 (0.8 to 2.5)	19.5 (11.5 to 29.2)	1,122.5 (694.4 to 2,008.9)	586.3 (304.1 to 1,067.2)
HIV/AIDS resulting in mycobacterial infection	0.2 (0.1 to 0.3)	1.3 (0.8 to 1.9)	674.6 (441.2 to 1,213.7)	302.8 (177.3 to 597.1)	0.1 (0.0 to 0.1)	0.5 (0.3 to 0.8)	661.0 (402.2 to 1,323.4)	295.6 (161.3 to 649.1)
HIV/AIDS resulting in other diseases	14.4 (9.4 to 19.4)	113.4 (99.3 to 131.4)	690.0 (515.3 to 1,092.6)	335.4 (227.7 to 565.1)	1.5 (0.8 to 2.4)	18.6 (11.2 to 28.5)	1,141.7 (693.8 to 2,128.8)	568.5 (303.2 to 1,136.6)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	24.0 (17.2 to 31.8)	35.1 (25.1 to 46.8)	46.2 (35.0 to 58.1)	-13.8 (-19.9 to -7.1)
Diarrheal diseases	78.5 (72.7 to 83.7)	124.7 (113.7 to 134.4)	59.0 (41.6 to 77.3)	-2.1 (-11.9 to 8.2)	12.7 (8.6 to 17.5)	20.1 (13.8 to 27.6)	58.9 (41.1 to 78.5)	-2.1 (-12.0 to 8.7)
Intestinal infectious diseases	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	0.2 (-6.7 to 57.9)	21.6 (-46.2 to -11.9)
Typhoid fever	0.8 (0.7 to 0.9)	1.0 (0.8 to 1.1)	23.2 (-6.3 to 55.5)	-30.1 (-46.7 to -13.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	24.2 (-10.3 to 68.9)	-29.3 (-47.5 to -7.2)
Paratyphoid fever	0.5 (0.4 to 0.6)	0.8 (0.6 to 0.9)	46.7 (17.4 to 81.8)	-15.5 (-33.7 to 6.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	46.3 (7.1 to 94.2)	-15.1 (-37.2 to 11.0)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.6 (-71.0 to 56.5)	-61.7 (-83.2 to -11.9)
Lower respiratory infections	6.0 (4.7 to 7.4)	9.0 (7.4 to 10.6)	47.6 (15.5 to 109.9)	-3.8 (-23.0 to 32.4)	0.6 (0.4 to 0.9)	0.9 (0.6 to 1.4)	48.1 (13.9 to 114.1)	-3.9 (-23.1 to 33.5)
Upper respiratory infections	196.9 (177.6 to 217.6)	288.9 (269.4 to 308.3)	46.7 (29.8 to 67.3)	-15.9 (-25.7 to -5.0)	2.3 (1.3 to 3.9)	3.4 (1.9 to 5.6)	47.0 (29.6 to 68.0)	-15.7 (-25.7 to -4.5)
Otitis media	82.9 (74.5 to 90.5)	133.9 (122.2 to 146.8)	61.4 (44.3 to 82.9)	-10.2 (-19.4 to 3.4)	1.7 (1.0 to 2.8)	2.8 (1.7 to 4.5)	62.1 (45.3 to 83.8)	-9.1 (-18.8 to 4.0)
Meningitis	-	-	-	-	6.1 (4.1 to 8.5)	7.1 (5.0 to 9.7)	17.8 (0.1 to 38.7)	-30.9 (-40.4 to -19.3)
Pneumococcal meningitis	19.3 (11.9 to 28.6)	24.9 (15.2 to 37.8)	30.5 (-6.5 to 71.4)	-35.1 (-48.0 to -3.3)	1.7 (1.2 to 2.4)	2.3 (1.6 to 3.3)	34.2 (0.5 to 83.7)	23.3 (-42.2 to 3.7)
H influenzae type B meningitis	9.8 (4.0 to 18.0)	9.2 (4.2 to 16.3)	-6.4 (-28.8 to 37.3)	-46.7 (-59.4 to -23.0)	1.1 (0.6 to 1.8)	1.1 (0.7 to 1.7)	-0.2 (-32.4 to 56.5)	-43.0 (-61.1 to -12.7)
Meningococcal meningitis	18.8 (6.9 to 39.4)	21.8 (8.1 to 46.5)	15.7 (-5.6 to 42.9)	-31.6 (-43.9 to -17.2)	2.2 (1.3 to 3.3)	2.5 (1.6 to 3.8)	16.4 (-10.0 to 53.6)	-30.2 (-44.0 to -10.0)
Other meningitis	8.5 (5.4 to 13.5)	9.8 (6.5 to 15.0)	14.7 (-13.6 to 53.3)	-29.8 (-46.5 to -6.9)	1.1 (0.7 to 1.7)	1.2 (0.8 to 1.7)	10.7 (-2.9 to 60.0)	-10.7 (-52.9 to -4.4)
Encephalitis	0.7 (0.3 to 1.6)	1.3 (0.6 to 2.6)	77.1 (58.9 to 99.4)	-9.8 (-10.1 to 8.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	41.6 (52.4 to 117.4)	-9.9 (-13.8 to 14.6)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.5 (-98.1 to 1,318.6)	-65.8 (-98.3 to 519.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.5 (-98.3 to 521.5)	-65.8 (-98.3 to 521.5)
Whooping cough	3.6 (2.8 to 4.6)	4.9 (3.9 to 6.3)	36.4 (35.1 to 37.6)	-14.6 (-15.4 to -13.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	36.3 (24.5 to 49.8)	-14.7 (-22.2 to -6.1)
Tetanus	0.5 (0.2 to 1.9)	0.2 (0.1 to 0.4)	-64.1 (-94.4 to 0.5)	-80.0 (-97.0 to -41.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-55.1 (-89.2 to -10.0)	-75.5 (-94.4 to -46.4)
Measles	1.4 (1.1 to 1.8)	0.4 (0.3 to 0.5)	-73.6 (-78.9 to -66.6)	-86.3 (-86.9 to -79.3)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	24.1 (-83.2 to -61.1)	-43.9 (-89.5 to -75.9)
Varicella and herpes zoster	2.4 (2.2 to 2.6)	4.3 (4.0 to 4.8)	86.3 (58.9 to 109.3)	2.0 (-17.2 to 20.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	83.2 (28.2 to 147.0)	0.7 (-30.4 to 36.8)
Neglected tropical diseases and malaria	-	-	-	-	56.7 (36.3 to 87.4)	38.6 (25.6 to 57.7)	-32.4 (-44.4 to -14.0)	-68.4 (-74.3 to -58.7)
Malaria	2,863.6 (2,559.8 to 3,186.9)	3,057.9 (2,636.4 to 3,525.1)	7.0 (-5.4 to 19.1)	-41.3 (-48.6 to -34.3)	24.7 (16.5 to 35.3)	25.9 (17.5 to 37.4)	5.2 (-3.4 to 12.5)	-38.8 (-43.4 to -35.1)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	208.6 (57.6 to 781.4)	69.6 (-18.4 to 310.3)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.1 (11.7 to 133.8)	-2.8 (-29.2 to 29.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.1 (11.6 to 134.0)	-2.8 (-29.2 to 29.0)
Cutaneous and mucocutaneous leishmaniasis	1.9 (0.7 to 3.2)	5.8 (3.2 to 9.1)	208.1 (58.1 to 755.9)	70.6 (-19.0 to 298.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	208.7 (57.6 to 782.8)	69.6 (-18.4 to 310.5)
African trypanosomiasis	0.0 (0.0 to 0.0)	-	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Schistosomiasis	1,593.8 (855.1 to 2,389.3)	257.7 (48.8 to 1,169.4)	-83.9 (-95.9 to -35.0)	-95.2 (-97.9 to -68.5)	16.3 (6.9 to 34.4)	2.9 (0.6 to 11.7)	-94.2 (-94.3 to -24.8)	-94.2 (-96.9 to -62.1)
Cysticercosis	3.0 (0.6 to 5.2)	7.8 (3.4 to 12.5)	151.8 (1.5 to 910.8)	16.3 (-50.8 to 359.0)	0.8 (0.2 to 1.5)	2.2 (0.9 to 3.9)	168.4 (6.2 to 1,023.9)	24.5 (-48.4 to 401.4)
Cystic echinococcosis	0.9 (0.9 to 1.0)	0.9 (0.8 to 1.0)	-0.9 (-12.9 to 1.9)	-42.0 (-46.6 to -33.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-6.1 (-27.3 to 19.5)	-41.6 (-52.7 to -27.9)
Lymphatic filariasis	82.6 (61.0 to 104.3)	12.3 (7.5 to 18.1)	-85.4 (-90.8 to -78.2)	-89.9 (-93.8 to -85.1)	2.4 (1.2 to 4.2)	1.0 (0.5 to 1.8)	-73.4 (-79.0 to -37.7)	-76.4 (-88.8 to -65.0)
Onchocerciasis	153.2 (115.2 to 206.0)	3.1 (1.5 to 5.2)	-98.0 (-99.1 to -96.5)	-98.3 (-99.2 to -97.0)	0.3 (4.7 to 12.3)	0.3 (0.1 to 0.5)	96.8 (-98.9 to -94.6)	97.7 (-98.9 to -95.9)
Trachoma	7.7 (4.4 to 12.0)	5.8 (3.4 to 8.9)	-24.1 (-46.5 to 11.2)	-58.9 (-73.1 to -41.6)	0.5 (0.2 to 0.8)	0.3 (0.2 to 0.6)	-27.0 (-48.9 to 6.1)	-59.9 (-73.6 to -42.8)
Dengue	0.4 (0.2 to 1.0)	3.7 (1.5 to 8.7)	777.7 (768.5 to 788.3)	388.2 (383.1 to 394.2)	0.1 (0.0 to 0.2)	0.6 (0.2 to 1.5)	778.1 (574.1 to 1,038.0)	387.5 (295.7 to 505.2)
Yellow fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.1 (-67.1 to -26.8)	-73.4 (-80.4 to -62.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.1 (-67.2 to -26.7)	-73.4 (-80.4 to -62.3)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-4.1 to 4.9)	0.0 (0.0 to 0.0)	-	-
Intestinal nematode infections	-	-	-	-	0.6 (0.4 to 1.0)	1.1 (0.6 to 1.8)	72.1 (26.2 to 122.7)	-3.8 (-28.0 to 22.3)
Ascariasis	159.9 (129.0 to 202.7)	287.6 (225.7 to 363.1)	80.8 (28.0 to 146.5)	0.4 (-33.8 to 46.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	79.2 (5.1 to 207.5)	1.6 (-43.6 to 99.9)
Trichuriasis	72.0 (55.4 to 92.1)	129.2 (98.9 to 166.4)	78.5 (25.5 to 159.9)	-1.2 (-34.8 to 58.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.7 (-2.4 to 196.2)	-2.4 (-50.5 to 90.0)
Hookworm disease	192.5 (153.2 to 240.2)	349.1 (277.6 to 428.7)	81.8 (30.9 to 150.9)	81.8 (-32.7 to 44.5)	0.6 (0.4 to 1.0)	1.1 (0.6 to 1.7)	71.9 (25.1 to 124.3)	4.1 (-28.3 to 22.4)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	47.4 (35.9 to 59.7)	104.5 (96.8 to 114.0)	121.3 (74.0 to 194.8)	32.0 (7.0 to 68.4)	3.2 (1.8 to 5.5)	4.2 (2.7 to 6.0)	33.4 (-11.2 to 88.0)	-43.7 (-68.0 to -12.7)
Maternal disorders	-	-	-	-	1.2 (0.7 to 1.9)	1.7 (1.0 to 2.6)	40.0 (20.0 to 63.6)	-29.3 (-39.1 to -17.9)
Maternal hemorrhage	1.4 (0.8 to 1.8)	2.8 (1.8 to 3.8)	101.2 (28.4 to 251.4)	-4.4 (-38.0 to 64.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	80.9 (-14.2 to 350.0)	-14.4 (-59.2 to 118.2)
Maternal sepsis and other maternal infections	1.8 (1.2 to 2.6)	1.3 (0.9 to 1.8)	-29.9 (-40.3 to -17.5)	-66.4 (-71.3 to -60.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-34.0 (-64.5 to 26.9)	-67.8 (-81.6 to -43.1)
Maternal hypertensive disorders	1.2 (0.5 to 2.2)	1.8 (0.7 to 3.4)	54.0 (40.3 to 68.0)	-26.9 (-32.9 to -20.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	52.6 (25.7 to 85.0)	-27.0 (-39.5 to -12.4)
Obstructed labor	2.7 (1.7 to 3.6)	3.6 (2.4 to 4.9)	37.3 (21.3 to 51.6)	-29.7 (-37.6 to -22.1)	0.9 (0.5 to 1.4)	1.2 (0.7 to 1.9)	37.5 (17.5 to 61.7)	-29.6 (-39.4 to -17.8)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.3 (-8.9 to 266.1)	-20.9 (-56.3 to 51.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other maternal disorders	-	-	-	-	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	39.0 (-9.8 to 135.9)	-30.5 (-54.6 to 17.3)
Neonatal disorders	-	-	-	-	2.4 (1.5 to 3.8)	9.6 (6.2 to 13.8)	309.5 (154.7 to 512.1)	137.4 (46.1 to 266.1)
Preterm birth complications	12.8 (6.7 to 23.6)	52.2 (29.6 to 88.9)	311.1 (234.8 to 431.6)	127.7 (88.0 to 190.7)	0.9 (0.6 to 1.5)	5.3 (3.0 to 8.3)	460.9 (238.1 to 847.4)	224.6 (96.1 to 438.5)
Neonatal encephalopathy due to birth asphyxia and trauma	21.8 (2.1 to 68.6)	33.5 (5.2 to 101.1)	60.1 (29.0 to 186.9)	-12.7 (-29.2 to 57.3)	0.9 (0.3 to 2.0)	2.2 (1.1 to 4.1)	162.9 (41.8 to 412.3)	51.9 (-18.9 to 220.1)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.3)	155.7 (141.1 to 181.6)	155.7 (55.8 to 82.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.3 (129.2 to 189.6)	65.0 (48.2 to 87.2)
Hemolytic disease and other neonatal jaundice	1.0 (0.5 to 2.0)	3.4 (1.4 to 6.6)	260.1 (11.9 to 891.2)	112.8 (-36.7 to 485.4)	0.4 (0.2 to 0.8)	1.3 (0.5 to 2.7)	257.8 (11.6 to 920.4)	114.9 (-35.5 to 519.4)
Other neonatal disorders	-	-	-	-	0.2 (0.1 to 0.5)	0.8 (0.4 to 1.4)	252.5 (63.0 to 602.4)	105.3 (-4.0 to 317.4)
Nutritional deficiencies	-	-	-	-	31.6 (21.5 to 45.1)	69.9 (47.2 to 99.8)	120.3 (106.3 to 141.9)	27.2 (20.8 to 37.3)
Protein-energy malnutrition	19.2 (11.9 to 31.1)	41.3 (20.7 to 77.0)	110.1 (-3.7 to 361.9)	24.0 (-38.6 to 152.7)	2.3 (1.2 to 4.2)	5.1 (2.2 to 9.7)	110.5 (-5.7 to 371.3)	25.8 (-39.1 to 165.2)
Iodine deficiency	101.3 (86.1 to 118.0)	136.2 (105.7 to 166.4)	34.3 (1.8 to 70.6)	-30.2 (-48.2 to -10.6)	1.8 (1.1 to 2.9)	2.5 (1.4 to 4.0)	34.8 (0.9 to 72.2)	-30.1 (-48.0 to -9.3)
Vitamin A deficiency	7.8 (5.3 to 10.9)	8.8 (5.7 to 12.7)	12.6 (-12.4 to 52.2)	-28.0 (-42.3 to -4.8)	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.7)	11.8 (-12.6 to 44.4)	-28.5 (-42.6 to -9.3)

Appendix Table G.4 - Togo prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	726.7 (706.5 to 745.6)	1,694.9 (1,672.1 to 1,713.7)	133.1 (126.2 to 140.1)	31.1 (27.7 to 36.9)	27.1 (18.2 to 38.6)	62.0 (41.5 to 88.8)	128.6 (118.2 to 140.6)	33.7 (27.2 to 40.7)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	165.4 (5.2 to 688.2)	55.4 (-40.7 to 338.3)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.6 (1.6 to 3.9)	4.8 (3.1 to 7.2)	82.3 (62.7 to 115.8)	-6.0 (-16.8 to 6.8)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.7 (0.4 to 1.2)	1.2 (0.7 to 2.2)	72.6 (30.3 to 122.5)	-14.3 (-32.4 to 6.5)
Syphilis	0.4 (0.3 to 0.5)	0.4 (0.4 to 0.5)	3.1 (-15.2 to 26.2)	-44.3 (-52.3 to -34.2)	0.1 (0.0 to 0.1)	0.4 (0.0 to 0.1)	44.1 (-25.1 to 39.6)	44.1 (-5.7 to 29.5)
Chlamydial infection	51.1 (33.4 to 67.3)	98.6 (65.4 to 132.3)	83.5 (26.8 to 215.6)	-7.7 (36.3 to 56.4)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.8)	76.9 (-0.9 to 217.6)	-10.6 (-48.2 to 53.2)
Gonococcal infection	18.5 (14.0 to 24.0)	29.6 (18.3 to 39.1)	58.9 (2.0 to 140.7)	-19.6 (-47.5 to 17.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	68.3 (-9.5 to 161.5)	-15.7 (-53.2 to 29.3)
Trichomoniasis	37.1 (22.4 to 54.6)	73.4 (47.3 to 103.3)	101.0 (6.0 to 262.2)	0.3 (-42.9 to 65.8)	0.1 (0.0 to 0.2)	0.3 (0.0 to 0.3)	101.9 (-2.0 to 294.1)	0.5 (-46.1 to 79.1)
Genital herpes	572.2 (526.5 to 618.7)	1,102.4 (1,013.6 to 1,182.9)	92.4 (71.7 to 114.8)	-1.9 (-12.1 to 9.3)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.7)	88.1 (69.1 to 117.8)	-1.7 (-13.2 to 10.7)
Other sexually transmitted diseases	1.5 (1.0 to 2.0)	2.2 (1.6 to 3.0)	53.5 (29.3 to 79.0)	-25.4 (-37.1 to -13.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	64.1 (11.2 to 136.2)	19.5 (-43.9 to 13.4)
Hepatitis	-	-	-	-	0.5 (0.3 to 0.8)	0.7 (0.4 to 1.0)	31.6 (11.1 to 67.3)	-32.5 (-45.4 to -12.7)
Hepatitis A	6.7 (6.3 to 7.1)	11.5 (10.9 to 12.1)	71.9 (70.9 to 72.8)	0.3 (0.3 to 0.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	80.1 (58.7 to 106.7)	-0.0 (-11.1 to 13.5)
Hepatitis B	742.1 (578.5 to 880.7)	806.4 (707.1 to 904.8)	7.3 (-13.9 to 48.0)	-42.7 (-51.2 to -34.5)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.5)	8.3 (-15.5 to 64.9)	-43.3 (-58.4 to -13.8)
Hepatitis C	311.7 (275.9 to 354.3)	408.7 (356.1 to 465.5)	31.6 (10.2 to 55.7)	-29.4 (-39.1 to -18.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	31.5 (-0.5 to 74.0)	-26.0 (-42.7 to -2.5)
Hepatitis E	1.3 (0.8 to 1.9)	2.3 (1.7 to 2.9)	69.3 (22.0 to 166.3)	-9.9 (-36.5 to 37.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	69.9 (14.6 to 186.1)	-10.1 (-39.7 to 42.4)
Leprosy	0.8 (0.6 to 1.2)	1.0 (0.8 to 1.1)	18.3 (-5.0 to 54.5)	-30.4 (-42.5 to -13.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	19.7 (6.7 to 63.1)	-29.8 (-43.6 to -8.0)
Other infectious diseases	34.1 (26.3 to 43.1)	76.1 (67.3 to 84.8)	120.7 (88.5 to 187.7)	30.9 (10.8 to 60.6)	1.3 (0.8 to 2.0)	2.8 (1.8 to 4.1)	109.1 (77.9 to 191.3)	23.7 (4.2 to 70.9)
Non-communicable diseases	-	-	-	-	227.9 (166.5 to 296.6)	437.0 (316.5 to 566.6)	91.8 (85.4 to 98.1)	2.6 (-1.3 to 6.1)
Neoplasms	-	-	-	-	0.9 (0.6 to 1.1)	1.5 (1.0 to 2.1)	72.3 (43.3 to 119.0)	-0.3 (-16.2 to 26.4)
Esophageal cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	55.1 (4.0 to 119.6)	-7.4 (-37.6 to 30.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.3 (9.6 to 116.0)	-6.5 (-34.5 to 28.8)
Stomach cancer	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	9.0 (-17.8 to 48.7)	-35.1 (-50.6 to -11.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	10.3 (-16.9 to 52.9)	-33.5 (-50.1 to -9.9)
Liver cancer	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	27.4 (7.6 to 79.0)	26.6 (-46.6 to 0.8)
Liver cancer due to hepatitis B	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.6)	61.5 (-25.7 to 355.2)	-12.2 (-59.1 to 140.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	57.9 (-16.7 to 344.2)	-13.2 (-54.7 to 128.8)
Liver cancer due to hepatitis C	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	206.4 (48.4 to 604.7)	82.9 (8.8 to 326.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	190.5 (45.9 to 530.9)	70.7 (-11.1 to 279.3)
Liver cancer due to alcohol use	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.2)	-45.4 (-77.0 to 22.0)	-64.7 (-83.5 to -26.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-4.0 (-7.5 to 13.7)	-64.1 (-82.2 to -32.3)
Liver cancer due to other causes	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-23.2 (-60.7 to 59.0)	-58.2 (-78.2 to -33.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.4 (-58.0 to 44.7)	-58.6 (-75.6 to -18.2)
Larynx cancer	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-20.5 (-47.3 to 87.0)	-51.9 (-68.1 to 9.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.2 (-47.7 to 89.0)	-49.0 (-67.8 to 11.3)
Tracheal, bronchus and lung cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	16.0 (-11.2 to 55.0)	-29.3 (-45.3 to -8.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.7 (-10.5 to 65.9)	-27.3 (-46.2 to -0.6)
Breast cancer	1.2 (0.9 to 1.5)	2.7 (2.0 to 3.6)	122.7 (61.6 to 228.7)	15.4 (-13.4 to 68.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	103.3 (46.2 to 208.2)	6.2 (-22.1 to 55.8)
Cervical cancer	2.0 (1.3 to 2.7)	2.6 (1.5 to 3.7)	23.4 (-21.0 to 95.8)	-44.4 (-56.8 to 12.2)	0.2 (0.1 to 0.2)	0.3 (0.1 to 0.3)	33.9 (-15.5 to 92.7)	-33.9 (-56.6 to 0.3)
Uterine cancer	0.4 (0.2 to 0.6)	0.6 (0.3 to 0.9)	55.5 (-15.0 to 168.3)	-14.3 (-52.1 to 45.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	56.3 (-14.4 to 174.4)	-13.9 (-51.9 to 48.8)
Prostate cancer	0.6 (0.4 to 1.0)	2.6 (1.5 to 4.3)	345.6 (126.3 to 666.9)	166.0 (41.5 to 345.0)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	277.8 (99.4 to 531.9)	132.3 (-26.0 to 277.6)
Colon and rectum cancer	0.4 (0.3 to 0.4)	0.7 (0.6 to 0.9)	90.0 (54.4 to 143.0)	7.6 (-11.9 to 35.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	85.3 (51.4 to 138.9)	5.7 (-14.2 to 34.9)
Lip and oral cavity cancer	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	51.0 (4.5 to 112.9)	-13.4 (-40.0 to 22.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.7 (7.2 to 109.1)	-13.1 (-39.3 to 24.1)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	41.2 (8.2 to 128.6)	-27.8 (-51.8 to 11.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.2 (-7.2 to 111.3)	-29.6 (-51.5 to 5.1)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.0 (-24.2 to 96.0)	-30.5 (-56.8 to 16.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.2 (-16.5 to 90.8)	-27.5 (-51.6 to 11.5)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.6 (-5.8 to 116.8)	-21.5 (-48.5 to 18.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.4 (-0.0 to 107.6)	21.0 (-44.8 to 18.4)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	107.3 (48.9 to 186.0)	21.0 (-11.9 to 61.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.3 (65.5 to 177.5)	22.0 (-7.7 to 63.0)
Malignant skin melanoma	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	83.8 (35.1 to 152.1)	3.4 (-28.9 to 32.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.8 (26.0 to 146.2)	-5.1 (-32.0 to 30.1)
Non-melanoma skin cancer	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.5)	84.2 (6.6 to 233.5)	5.7 (-33.1 to 72.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	110.6 (38.8 to 218.9)	19.8 (-25.0 to 88.0)
Ovarian cancer	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	83.1 (14.6 to 188.1)	-0.3 (-36.4 to 56.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	85.2 (12.1 to 203.4)	0.7 (-40.3 to 69.0)
Testicular cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	98.7 (1.2 to 295.3)	-3.3 (-48.0 to 80.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.3 (-7.6 to 295.8)	-4.3 (-50.6 to 76.5)
Kidney cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	39.4 (-17.7 to 151.5)	-18.8 (-42.9 to 16.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.1 (-20.0 to 149.8)	-17.9 (-42.7 to 16.8)
Bladder cancer	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	18.5 (-14.4 to 71.5)	-29.3 (-48.5 to 8.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.6 (-12.9 to 75.4)	-27.2 (-47.9 to 10.8)
Brain and nervous system cancer	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	149.5 (63.6 to 267.7)	34.1 (0.1 to 82.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	149.6 (71.5 to 256.1)	27.9 (-3.7 to 71.6)
Thyroid cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	38.6 (-20.2 to 140.9)	-27.1 (-57.7 to 27.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.8 (-23.6 to 152.6)	-27.8 (-58.8 to 26.5)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.7 (4.7 to 118.0)	0.0 (-43.9 to 27.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.5 (3.3 to 117.2)	-17.7 (-44.7 to 28.6)
Hodgkin lymphoma	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.5)	133.2 (47.3 to 270.9)	36.8 (-11.6 to 106.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	128.7 (43.9 to 260.2)	29.9 (-13.4 to 95.4)
Non-Hodgkin lymphoma	0.4 (0.3 to 0.6)	1.0 (0.5 to 1.7)	74.8 (18.7 to 173.3)	3.5 (-28.1 to 63.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	81.3 (23.0 to 183.5)	4.2 (-26.2 to 68.4)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	86.7 (14.7 to 185.1)	4.6 (-38.6 to 60.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.2 (16.7 to 180.6)	1.6 (-39.3 to 61.2)
Leukemia	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	87.0 (14.3 to 242.7)	3.3 (-33.8 to 49.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.8 (23.0 to 163.9)	-11.7 (-35.7 to 23.5)
Other neoplasms	1.2 (0.8 to 2.0)	2.3 (1.6 to 3.4)	98.9 (10.3 to 212.1)	3.7 (-34.0 to 54.1)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	93.3 (12.1 to 188.0)	-3.9 (-36.2 to 44.6)
Cardiovascular diseases	-	-	-	-	6.1 (4.1 to 8.4)	11.4 (7.5 to 16.3)	87.7 (47.1 to 131.4)	3.4 (-18.8 to 27.8)
Rheumatic heart disease	38.9 (30.8 to 49.6)	72.3 (48.8 to 91.7)	92.7 (13.2 to 156.1)	-3.4 (-33.4 to 27.0)	1.9 (1.2 to 3.0)	3.6 (2.1 to 5.5)	94.2 (19.4 to 155.0)	-0.3 (-28.9 to 28.6)
Ischemic heart disease	27.0 (21.2 to 36.7)	33.8 (28.2 to 41.7)	26.9 (-7.2 to 65.8)	-22.0 (-42.6 to 1.6)	1.4 (0.8 to 2.1)	1.7 (0.8 to 2.2)	33.3 (-30.7 to 57.9)	-33.3 (-57.1 to -3.5)
Cerebrovascular disease	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	83.2 (38.8 to 135.7)	0.3 (-26.1 to 29.4)
Ischemic stroke	1.4 (1.2 to 1.7)	2.6 (2.2 to 3.0)	82.8 (38.1 to 136.0)	0.6 (-26.8 to 30.9)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	84.5 (36.9 to 141.1)	1.5 (-26.3 to 33.9)
Hemorrhagic stroke	0.4 (0.3 to 0.5)	0.7 (0.6 to 0.9)	77.0 (32.8 to 135.2)	-6.0 (-31.3 to 24.1)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	77.7 (34.6 to 140.8)	-5.6 (-31.2 to 27.8)
Hypertensive heart disease	5.2 (3.6 to 6.9)	9.7 (7.2 to 12.8)	87.3 (20.5 to 180.9)	9.4 (-29.2 to 64.1)	0.6 (0.3 to 0.9)	1.1 (0.7 to 1.6)	89.5 (20.5 to 181.5)	10.7 (-29.0 to 66.2)
Cardiomyopathy and myocarditis	0.4 (2.7 to 4.7)	2.0 (4.5 to 8.4)	360.6 (13.7 to 163.1)	148.6 (-38.4 to 67.7)	0.0 (0.2 to 0.6)	0.2 (0.4 to 1.1)	360.5 (12.0 to 169.9)	152.7 (-39.1 to 68.9)
Atrial fibrillation and flutter	0.3 (0.3 to 0.6)	0.6 (1.5 to 2.6)	228.0 (19.5 to 183.8)	148.6 (-31.0 to 47.1)	0.0 (0.0 to 0.1)	0.2 (0.0 to 0.1)	360.5 (-30.9 to 374.8)	9.1 (-57.4 to 159.6)
Peripheral vascular disease	53.0 (34.0 to 66.3)	97.8 (65.0 to 136.6)	81.1 (19.5 to 183.8)	-1.1 (-31.0 to 47.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	86.4 (-30.9 to 374.8)	9.1 (-57.4 to 159.6)
Endocarditis	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	46.2 (-6.0 to 114.6)	-7.6 (-49.7 to 71.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	52.3 (-7.7 to 143.3)	-6.1 (-51.8 to 91.7)
Other cardiovascular and circulatory diseases	21.6 (13.1 to 32.4)	54.8 (28.1 to 82.6)	151.9 (23.8 to 367.5)	28.2 (-33.9 to 174.3)	1.5 (0.8 to 2.5)	3.9 (1.7 to 6.5)	156.6 (24.1 to 368.7)	40.0 (-34.2 to 178.4)
Chronic respiratory diseases	-	-	-	-	16.0 (10.8 to 21.5)	31.9 (21.6 to 43.6)	100.1 (77.2 to 125.8)	6.3 (-5.4 to 19.7)
Chronic obstructive pulmonary disease	115.9 (109.9 to 122.6)	214.3 (201.9 to 225.0)						

Appendix Table G.4 - Togo prevalence and VIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VIDs 1990 (thousands)	VIDs 2013 (thousands)	% change VIDs, 1990 to 2013	% change age-standardized VIDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.3 (70.9 to 83.3)	-4.3 (-7.3 to -1.1)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.9 (58.0 to 73.7)	-9.1 (-13.1 to -4.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.5 (57.7 to 73.2)	-9.2 (-13.3 to -4.9)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.3 (80.4 to 96.5)	1.1 (-2.8 to 4.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.2 (79.6 to 96.5)	1.0 (-3.4 to 5.3)
Asthma	100.9 (79.1 to 126.4)	245.9 (207.5 to 289.3)	143.0 (86.4 to 237.6)	35.3 (5.9 to 78.5)	4.4 (2.7 to 6.7)	10.8 (6.8 to 16.3)	143.6 (85.7 to 243.8)	35.5 (6.6 to 79.1)
Interstitial lung disease and pulmonary sarcoidosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	92.4 (39.8 to 169.7)	-0.0 (-24.5 to 36.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.6 (39.2 to 166.3)	-0.5 (-24.5 to 34.8)
Other chronic respiratory diseases	-	-	-	-	2.1 (1.2 to 3.4)	3.4 (2.0 to 5.2)	62.7 (18.3 to 124.5)	-13.2 (-36.3 to 20.3)
Cirrhosis	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.6)	50.1 (31.9 to 70.3)	47.8 (-26.6 to 82.2)
Cirrhosis due to hepatitis B	0.7 (0.5 to 0.9)	0.8 (0.6 to 1.1)	23.9 (-24.5 to 81.6)	-30.7 (55.2 to 10.3)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	24.8 (-30.4 to 89.5)	-29.8 (57.0 to 11.8)
Cirrhosis due to hepatitis C	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	84.5 (7.9 to 492.4)	5.4 (-40.6 to 186.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	83.7 (7.2 to 491.0)	3.8 (-40.5 to 183.8)
Cirrhosis due to alcohol use	0.4 (0.3 to 0.5)	0.5 (0.3 to 0.7)	17.1 (-26.0 to 89.2)	-37.4 (-58.8 to 3.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	17.9 (-28.4 to 95.8)	-37.5 (-60.0 to 7.0)
Cirrhosis due to other causes	0.4 (0.4 to 0.5)	0.8 (0.7 to 1.0)	88.0 (40.9 to 151.0)	10.6 (-20.1 to 53.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	88.8 (25.9 to 191.4)	11.6 (-24.2 to 71.4)
Digestive diseases	-	-	-	-	4.5 (3.1 to 6.2)	8.5 (5.9 to 11.5)	87.8 (68.1 to 114.1)	2.7 (-6.3 to 14.9)
Peptic ulcer disease	19.3 (16.2 to 22.2)	28.6 (22.2 to 33.4)	47.7 (17.5 to 86.1)	-18.2 (-31.6 to -0.6)	0.7 (0.5 to 1.0)	1.1 (0.7 to 1.6)	56.8 (20.0 to 107.7)	-12.8 (-29.1 to 7.3)
Gastritis and duodenitis	44.3 (38.7 to 48.7)	81.1 (69.8 to 89.9)	83.3 (54.6 to 115.0)	2.5 (-12.2 to 21.5)	1.9 (1.3 to 2.7)	3.3 (2.2 to 4.7)	75.1 (42.1 to 109.0)	2.2 (-13.9 to 18.4)
Appendicitis	0.4 (0.3 to 0.6)	1.0 (0.7 to 1.2)	114.7 (43.9 to 234.3)	10.5 (-23.5 to 53.8)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	117.3 (34.2 to 249.8)	11.6 (-25.7 to 63.2)
Paralytic ileus and intestinal obstruction	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	742.9 (33.7 to 164.6)	0.9 (-9.4 to 17.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	780.0 (19.1 to 187.3)	2.0 (-21.4 to 34.9)
Inguinal, femoral, and abdominal hernia	13.9 (11.5 to 18.8)	20.1 (17.7 to 22.9)	48.2 (3.4 to 88.3)	-13.4 (-31.3 to 9.5)	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.4)	48.2 (2.0 to 89.5)	-12.5 (-31.3 to 10.7)
Inflammatory bowel disease	3.4 (3.2 to 3.5)	8.1 (7.8 to 8.5)	142.2 (127.1 to 158.8)	26.2 (19.4 to 33.6)	0.7 (0.5 to 1.0)	1.7 (1.2 to 2.4)	143.8 (120.3 to 168.9)	26.9 (17.2 to 37.7)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	170.1 (77.4 to 325.5)	17.2 (-27.3 to 94.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	173.3 (76.7 to 328.9)	17.5 (-35.3 to 114.0)
Gallbladder and biliary diseases	1.1 (0.9 to 1.2)	2.2 (2.0 to 2.5)	109.7 (76.8 to 144.9)	7.6 (-9.0 to 28.2)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	113.3 (72.5 to 157.5)	9.1 (8.8 to 32.6)
Pancreatitis	0.6 (0.5 to 0.6)	1.2 (1.1 to 1.3)	112.4 (96.2 to 131.6)	9.2 (1.1 to 18.7)	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.5)	112.5 (77.9 to 158.2)	9.9 (-5.9 to 30.7)
Other digestive diseases	-	-	-	-	0.7 (0.4 to 1.0)	1.3 (0.8 to 2.0)	90.9 (41.1 to 185.5)	4.7 (-21.8 to 54.3)
Neurological disorders	-	-	-	-	15.0 (10.0 to 21.0)	30.4 (20.5 to 42.4)	103.3 (77.2 to 130.6)	7.2 (-5.9 to 21.1)
Alzheimer disease and other dementias	4.7 (4.1 to 5.3)	7.5 (6.4 to 8.6)	60.1 (30.5 to 96.4)	-3.8 (-21.2 to 18.6)	0.6 (0.4 to 0.8)	1.0 (0.7 to 1.4)	61.8 (30.9 to 99.5)	-4.4 (-20.8 to 20.2)
Parkinson disease	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	72.1 (62.2 to 83.1)	0.3 (-4.8 to 6.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	72.8 (42.2 to 112.5)	0.7 (-16.9 to 21.3)
Epilepsy	4.9 (2.8 to 7.7)	10.4 (5.8 to 16.5)	111.6 (6.5 to 331.1)	28.8 (-35.0 to 159.9)	1.4 (0.7 to 2.4)	3.2 (1.6 to 5.4)	125.6 (12.0 to 364.3)	37.2 (-32.2 to 177.7)
Multiple sclerosis	0.2 (0.2 to 0.2)	0.5 (0.4 to 0.5)	123.3 (91.3 to 163.4)	13.6 (-1.5 to 33.7)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	120.1 (79.5 to 173.2)	11.9 (8.6 to 39.4)
Migraine	478.3 (235.5 to 279.8)	257.7 (434.2 to 913.5)	46.7 (63.1 to 108.4)	8.4 (-13.3 to 10.1)	2.4 (5.2 to 13.1)	16.3 (7.7 to 23.9)	8.8 (61.1 to 109.5)	-1.9 (-13.2 to 10.6)
Tension-type headache	444.1 (402.0 to 482.8)	902.8 (831.8 to 974.5)	102.5 (81.3 to 132.4)	3.7 (-5.7 to 15.9)	1.7 (0.3 to 1.2)	1.4 (0.6 to 2.4)	103.5 (81.0 to 134.1)	4.5 (-5.6 to 17.0)
Medication overuse headache	16.5 (10.5 to 22.6)	45.0 (28.4 to 61.8)	172.2 (102.0 to 264.3)	39.2 (10.2 to 88.1)	2.6 (1.4 to 4.0)	7.1 (3.8 to 11.2)	172.9 (101.3 to 267.2)	39.6 (10.5 to 88.5)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.8 (23.1 to 126.2)	-6.4 (-30.1 to 23.1)	0.8 (0.5 to 1.3)	1.2 (0.8 to 1.8)	58.7 (5.3 to 124.3)	-5.8 (-38.6 to 36.3)
Mental and substance use disorders	-	-	-	-	74.6 (51.5 to 102.3)	143.2 (98.5 to 196.6)	92.0 (85.0 to 99.2)	1.3 (-2.0 to 4.7)
Schizophrenia	7.4 (6.7 to 8.0)	14.6 (13.3 to 16.0)	98.8 (90.4 to 108.0)	-0.5 (-4.3 to 3.6)	4.7 (3.4 to 5.7)	9.4 (6.9 to 11.5)	103.3 (87.8 to 114.0)	0.0 (-5.8 to 6.4)
Alcohol use disorders	18.7 (17.5 to 20.0)	41.7 (39.1 to 44.5)	122.7 (112.9 to 132.9)	14.0 (9.1 to 19.1)	1.8 (1.2 to 2.6)	4.1 (2.7 to 5.7)	126.1 (110.4 to 143.0)	15.2 (7.9 to 23.2)
Drug use disorders	-	-	-	-	4.4 (2.9 to 6.2)	8.8 (5.8 to 12.4)	100.1 (78.6 to 122.0)	-1.0 (-10.4 to 9.2)
Opioid use disorders	5.8 (3.9 to 8.4)	11.6 (7.7 to 17.0)	100.3 (81.9 to 118.0)	-2.1 (-10.3 to 5.4)	2.4 (1.4 to 3.7)	4.8 (2.9 to 7.6)	100.9 (79.3 to 123.5)	-1.9 (-11.8 to 8.2)
Cocaine use disorders	1.8 (1.4 to 2.1)	3.7 (3.2 to 4.3)	111.8 (64.7 to 175.2)	2.2 (-16.7 to 20.6)	0.2 (0.1 to 0.4)	0.5 (0.3 to 0.8)	113.1 (59.6 to 194.6)	2.7 (-20.1 to 37.8)
Amphetamine use disorders	5.7 (5.4 to 6.1)	11.1 (10.2 to 11.9)	95.7 (75.2 to 112.9)	-0.0 (-10.2 to 8.4)	0.7 (0.5 to 1.1)	1.5 (0.9 to 2.1)	95.9 (66.2 to 127.9)	0.0 (-14.9 to 15.9)
Cannabis use disorders	2.2 (1.7 to 2.7)	3.5 (2.5 to 4.5)	60.8 (26.9 to 86.1)	-13.8 (-29.2 to -2.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	58.9 (12.4 to 112.2)	-14.8 (-36.7 to 10.7)
Other drug use disorders	-	-	-	-	1.0 (0.6 to 1.5)	2.0 (1.2 to 2.9)	100.0 (45.4 to 171.8)	1.0 (-26.5 to 37.2)
Depressive disorders	-	-	-	-	32.0 (18.9 to 50.4)	63.3 (36.4 to 98.6)	97.5 (83.3 to 113.0)	3.1 (-3.8 to 9.5)
Major depressive disorder	139.4 (88.3 to 194.1)	274.9 (170.3 to 376.9)	96.6 (81.1 to 114.7)	2.7 (-4.3 to 10.1)	28.6 (16.4 to 46.3)	56.7 (30.8 to 91.2)	97.6 (81.5 to 115.2)	3.4 (-4.4 to 10.8)
Dysthymia	35.0 (28.3 to 42.2)	68.5 (55.0 to 83.1)	95.5 (92.7 to 97.9)	0.2 (0.1 to 0.3)	3.4 (2.2 to 4.9)	6.6 (4.2 to 9.6)	96.7 (90.3 to 102.7)	0.7 (-1.8 to 3.0)
Bipolar disorder	20.0 (17.0 to 22.7)	39.6 (33.5 to 45.1)	98.7 (86.7 to 109.1)	-0.2 (-5.1 to 4.2)	4.1 (2.5 to 6.1)	8.1 (4.9 to 12.2)	99.8 (84.9 to 114.9)	0.3 (-6.3 to 6.7)
Anxiety disorders	86.4 (71.8 to 103.0)	160.9 (133.3 to 191.6)	86.1 (81.9 to 90.3)	8.0 (-0.1 to 0.1)	14.9 (5.2 to 11.4)	14.9 (9.8 to 21.3)	86.7 (77.7 to 94.5)	0.4 (-2.6 to 3.5)
Eating disorders	-	-	-	-	0.9 (0.5 to 1.4)	1.8 (1.1 to 2.8)	94.3 (78.7 to 111.6)	0.5 (-7.5 to 9.0)
Anorexia nervosa	0.6 (0.5 to 0.8)	1.3 (0.9 to 1.6)	96.5 (76.1 to 118.0)	3.5 (-6.3 to 15.3)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	96.5 (52.7 to 150.6)	4.3 (-17.9 to 32.3)
Bulimia nervosa	3.7 (2.5 to 5.4)	7.2 (4.9 to 10.2)	94.0 (88.8 to 98.2)	-0.3 (-0.5 to -0.1)	0.8 (0.4 to 1.3)	1.5 (0.9 to 2.5)	94.1 (76.1 to 113.4)	-0.1 (-9.2 to 9.3)
Autistic spectrum disorders	-	-	-	-	4.5 (3.1 to 6.1)	8.2 (5.6 to 11.1)	81.8 (74.9 to 89.0)	1.5 (-2.6 to 3.9)
Autism	11.5 (10.9 to 12.1)	20.9 (19.8 to 22.0)	81.1 (80.7 to 81.4)	-0.1 (-0.1 to -0.1)	2.8 (1.9 to 3.9)	5.2 (3.5 to 7.1)	82.1 (71.9 to 92.6)	0.5 (-3.9 to 5.4)
Asperger syndrome	16.6 (15.6 to 17.6)	30.0 (28.1 to 31.7)	80.6 (80.1 to 81.2)	-0.1 (-0.2 to -0.1)	1.7 (1.1 to 2.3)	3.0 (2.1 to 4.2)	81.4 (73.2 to 90.1)	0.3 (-3.4 to 4.3)
Attention-deficit/hyperactivity disorder	28.3 (26.2 to 30.6)	48.8 (45.0 to 52.7)	72.4 (71.9 to 72.6)	0.3 (0.3 to 0.3)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	72.5 (60.0 to 87.2)	0.5 (-6.8 to 9.0)
Conduct disorder	41.6 (39.2 to 44.1)	71.7 (67.1 to 75.5)	71.3 (70.8 to 71.8)	0.3 (0.3 to 0.3)	5.0 (3.1 to 7.3)	8.6 (5.4 to 12.5)	81.8 (62.8 to 90.0)	0.8 (-3.2 to 5.2)
Idiopathic intellectual disability	114.5 (70.2 to 152.6)	182.0 (116.9 to 238.3)	59.4 (33.4 to 91.8)	-11.4 (-26.7 to 7.8)	5.6 (3.1 to 8.4)	8.9 (5.0 to 13.4)	59.7 (35.2 to 85.2)	-11.0 (-26.9 to 8.3)
Other mental and substance use disorders	44.3 (41.3 to 47.1)	88.1 (82.1 to 93.8)	98.9 (98.0 to 99.7)	-0.1 (-0.3 to 0.0)	3.3 (2.3 to 4.5)	6.6 (4.5 to 8.9)	99.9 (91.7 to 108.8)	0.3 (-3.1 to 4.2)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	22.7 (16.0 to 30.8)	47.4 (33.4 to 63.7)	109.0 (96.4 to 123.0)	17.4 (8.7 to 27.4)
Diabetes mellitus	36.8 (28.3 to 44.4)	124.0 (101.9 to 145.0)	238.0 (156.8 to 341.8)	79.5 (34.2 to 139.0)	2.6 (1.7 to 3.6)	8.8 (5.8 to 12.5)	234.4 (147.9 to 335.1)	79.8 (15.9 to 139.1)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.7 (12.3 to 32.0)	-0.0 (-32.2 to -23.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.7 (12.3 to 32.0)	-0.0 (-32.2 to -23.1)
Chronic kidney disease	-	-	-	-	6.0 (4.3 to 7.9)	10.9 (7.7 to 14.6)	82.4 (66.3 to 100.4)	-1.0 (-9.0 to 9.8)
Chronic kidney disease due to diabetes mellitus	34.1 (21.3 to 52.3)	63.7 (42.2 to 100.2)	82.8 (44.2 to 164.3)	-0.0 (-21.3 to 49.8)	0.6 (0.4 to 0.8)	1.1 (0.7 to 1.6)	84.4 (47.2 to 143.6)	-0.1 (-2.6 to 36.8)
Chronic kidney disease due to hypertension	163.0 (100.9 to 287.7)	291.8 (189.3 to 491.9)	80.3 (44.4 to 124.9)	2.3 (-16.3 to 26.4)	1.9 (1.3 to 2.6)	3.6 (2.5 to 4.9)	90.7 (56.3 to 124.7)	0.6 (-16.2 to 18.4)
Chronic kidney disease due to glomerulonephritis	135.6 (88.1 to 209.9)	357.9 (163.5 to 402.3)	88.8 (55.9 to 121.1)	8.5 (-17.2 to 17.7)	2.1 (1.5 to 2.9)	3.8 (2.6 to 5.2)	90.3 (51.1 to 117.1)	1.2 (-14.1 to 21.8)
Chronic kidney disease due to other causes	113.1 (69.7 to 198.7)	191.5 (106.3 to 314.2)	70.1 (28.7 to 119.9)	-5.2 (-29.0 to 22.6)	1.4 (1.0 to 1.9)	2.4 (1.6 to 3.3)	71.1 (29.9 to 122.1)	-7.3 (-31.3 to 24.2)
Urinary diseases and male infertility	-	-	-	-	1.1 (0.7 to 1.5)	1.9 (1.2 to 2.8)	83.4 (64.3 to 106.9)	5.0 (-5.7 to 18.3)

Appendix Table G.4 - Togo prevalence and VIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VIDs 1990 (thousands)	VIDs 2013 (thousands)	% change VIDs, 1990 to 2013	% change age-standardized VIDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.7 (0.7 to 0.8)	1.4 (1.3 to 1.5)	100.6 (82.8 to 123.2)	0.0 (-1.1 to 16.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	101.1 (57.0 to 158.4)	101.1 (-11.3 to 31.9)
Urolithiasis	7.6 (5.8 to 9.9)	11.3 (8.7 to 14.7)	49.7 (31.9 to 77.8)	-13.7 (-23.2 to -0.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	92.8 (68.3 to 122.0)	92.8 (-6.7 to 16.5)
Benign prostatic hyperplasia	21.3 (19.3 to 23.0)	37.5 (34.5 to 40.4)	75.8 (55.2 to 100.0)	5.1 (-6.7 to 18.7)	0.8 (0.5 to 1.1)	1.4 (0.9 to 1.9)	77.3 (56.3 to 101.8)	77.3 (-6.2 to 20.2)
Male infertility due to other causes	30.1 (23.0 to 37.9)	60.1 (46.1 to 74.0)	101.4 (41.2 to 177.3)	-3.8 (-33.1 to 32.2)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.8)	101.6 (40.7 to 183.2)	101.6 (-32.8 to 33.5)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	96.4 (18.1 to 212.0)	96.4 (-35.6 to 64.7)
Gynecological diseases	-	-	-	-	3.6 (2.3 to 5.3)	8.4 (5.6 to 12.6)	134.6 (105.0 to 178.4)	134.6 (1.5 to 34.2)
Uterine fibroids	54.6 (49.4 to 59.4)	111.4 (100.5 to 121.5)	104.1 (103.4 to 104.8)	2.6 (2.5 to 2.8)	0.9 (0.5 to 1.4)	2.0 (1.2 to 3.1)	128.4 (109.5 to 151.8)	128.4 (4.8 to 26.0)
Polycystic ovarian syndrome	51.1 (45.4 to 56.4)	108.5 (97.4 to 120.2)	112.1 (85.5 to 143.2)	3.5 (-9.2 to 17.5)	0.5 (0.2 to 0.9)	1.0 (0.5 to 1.9)	112.4 (85.8 to 143.7)	112.4 (-8.6 to 17.7)
Female infertility due to other causes	22.6 (16.5 to 29.4)	47.6 (34.0 to 64.5)	107.7 (38.4 to 233.9)	0.7 (-32.6 to 64.9)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.5)	106.9 (38.1 to 230.3)	106.9 (-32.2 to 65.2)
Endometriosis	5.1 (4.3 to 5.9)	9.9 (8.4 to 11.4)	95.3 (56.1 to 142.2)	-5.4 (-23.6 to 16.4)	0.5 (0.3 to 0.6)	0.9 (0.6 to 1.3)	95.2 (55.5 to 148.3)	95.2 (-24.3 to 19.9)
Genital prolapse	121.2 (105.1 to 136.9)	246.4 (214.0 to 279.9)	102.4 (67.9 to 144.4)	3.2 (-11.5 to 20.9)	0.4 (0.2 to 0.7)	0.8 (0.4 to 1.5)	103.6 (68.4 to 145.9)	103.6 (-11.1 to 22.0)
Premenstrual syndrome	115.4 (77.2 to 159.6)	322.7 (239.7 to 426.7)	178.6 (77.6 to 332.3)	1.0 (-12.4 to 119.4)	2.7 (0.5 to 1.6)	3.4 (1.6 to 4.3)	179.5 (79.2 to 336.3)	179.5 (-12.7 to 122.5)
Other gynecological diseases	8.2 (5.4 to 11.2)	22.2 (15.2 to 30.5)	169.6 (73.1 to 319.8)	34.7 (-13.0 to 110.6)	0.3 (0.1 to 0.4)	0.7 (0.3 to 1.1)	159.9 (11.1 to 399.9)	159.9 (-45.0 to 155.1)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	7.9 (5.4 to 11.0)	14.2 (9.7 to 19.6)	78.9 (65.4 to 94.3)	78.9 (-3.5 to 11.7)
Thalassemias	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	52.4 (39.2 to 67.4)	-10.4 (-18.1 to -1.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.5 (30.2 to 61.3)	46.5 (-22.6 to -4.7)
Thalassemia trait	55.2 (45.7 to 64.2)	94.8 (79.2 to 110.1)	71.3 (65.4 to 79.3)	-4.9 (-8.3 to -0.6)	1.1 (0.7 to 1.6)	1.7 (1.2 to 2.4)	60.0 (36.8 to 83.3)	60.0 (-20.8 to 7.3)
Sickle cell disorders	21.3 (19.7 to 22.8)	38.9 (36.0 to 41.6)	83.0 (69.4 to 98.8)	5.0 (-3.3 to 14.7)	2.1 (1.5 to 2.8)	3.9 (2.7 to 5.2)	86.2 (65.4 to 110.5)	86.2 (-5.9 to 17.7)
Sickle cell trait	769.9 (715.4 to 802.3)	1,368.1 (1,284.9 to 1,439.5)	80.1 (73.2 to 86.3)	0.0 (-3.9 to 3.4)	3.6 (2.4 to 5.3)	6.2 (4.1 to 8.9)	69.2 (43.6 to 99.5)	69.2 (-12.0 to 14.9)
G6PD deficiency	522.7 (376.6 to 671.3)	947.3 (750.1 to 1,160.3)	82.4 (27.0 to 155.3)	1.2 (-29.6 to 42.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	78.5 (7.5 to 205.4)	78.5 (-34.5 to 73.1)
G6PD trait	905.0 (840.4 to 944.1)	1,633.2 (1,518.9 to 1,718.1)	80.5 (64.9 to 97.6)	0.4 (-8.3 to 9.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	67.8 (-49.1 to 293.6)	67.8 (-69.8 to 126.2)
Other hemoglobinopathies and hemolytic anemias	33.0 (27.7 to 38.3)	75.6 (67.4 to 84.0)	130.1 (93.3 to 178.8)	2.2 (13.0 to 50.5)	1.0 (0.6 to 1.4)	2.0 (1.4 to 3.1)	118.1 (76.5 to 201.1)	118.1 (3.2 to 65.6)
Endocrine, metabolic, blood, and immune disorders	41.5 (32.8 to 48.6)	88.1 (70.5 to 101.3)	111.6 (67.2 to 187.9)	1.5 (0.7 to 50.5)	3.2 (0.9 to 2.2)	3.2 (1.9 to 4.6)	113.6 (39.4 to 233.0)	113.6 (-12.0 to 69.8)
Musculoskeletal disorders	-	-	-	-	40.8 (28.3 to 54.9)	79.5 (55.1 to 107.5)	94.9 (64.9 to 122.0)	94.9 (-12.8 to 13.6)
Rheumatoid arthritis	4.8 (4.5 to 5.0)	6.4 (6.1 to 6.7)	33.0 (24.5 to 43.4)	-33.8 (-38.4 to -28.5)	1.1 (0.8 to 1.5)	1.5 (1.1 to 2.0)	34.8 (20.7 to 49.9)	34.8 (-39.0 to -26.5)
Osteoarthritis	67.2 (64.3 to 69.8)	122.3 (117.1 to 127.5)	81.7 (72.2 to 93.6)	1.5 (-3.5 to 7.7)	4.1 (2.8 to 5.6)	7.5 (5.2 to 10.3)	82.9 (72.5 to 95.4)	82.9 (-3.2 to 8.2)
Low back and neck pain	-	-	-	-	30.4 (20.2 to 42.2)	59.9 (40.5 to 83.5)	97.7 (58.3 to 135.8)	97.7 (-18.4 to 19.4)
Low back pain	173.9 (138.6 to 222.1)	336.1 (269.0 to 400.7)	96.8 (41.3 to 150.6)	1.0 (-24.9 to 26.7)	19.3 (12.1 to 28.7)	37.6 (24.6 to 55.2)	98.2 (42.2 to 152.9)	98.2 (-24.1 to 27.5)
Neck pain	113.4 (91.5 to 134.2)	226.1 (192.1 to 261.6)	100.3 (54.8 to 158.9)	0.7 (-19.5 to 26.7)	11.1 (7.2 to 15.9)	22.3 (14.9 to 31.1)	100.7 (55.7 to 162.3)	100.7 (-19.3 to 27.4)
Gout	0.3 (0.3 to 0.3)	0.5 (0.5 to 0.6)	78.9 (51.3 to 115.3)	-2.5 (-17.0 to 15.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.9 (41.5 to 126.6)	79.9 (-23.8 to 25.7)
Other musculoskeletal disorders	57.6 (43.6 to 72.9)	115.8 (86.8 to 145.8)	100.7 (84.2 to 118.1)	7.5 (-1.6 to 15.3)	5.2 (3.3 to 7.7)	10.5 (6.7 to 15.6)	102.0 (85.9 to 122.2)	102.0 (-1.5 to 16.6)
Other non-communicable diseases	-	-	-	-	47.1 (30.8 to 69.4)	82.7 (54.0 to 123.5)	76.0 (64.4 to 85.3)	76.0 (-8.9 to 0.8)
Congenital anomalies	-	-	-	-	2.5 (1.6 to 3.7)	4.8 (3.3 to 6.9)	97.7 (61.2 to 139.8)	97.7 (-6.7 to 37.9)
Neural tube defects	0.4 (0.3 to 0.4)	1.2 (1.0 to 1.4)	218.7 (158.6 to 301.0)	92.1 (55.9 to 142.5)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	243.5 (144.0 to 394.2)	243.5 (52.4 to 201.5)
Congenital heart anomalies	3.3 (2.4 to 4.5)	12.1 (9.4 to 15.6)	263.8 (146.8 to 437.5)	118.1 (47.0 to 224.9)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.7)	225.6 (120.1 to 392.2)	225.6 (34.1 to 197.0)
Orofacial clefts	0.3 (0.2 to 0.5)	1.5 (1.0 to 2.0)	332.9 (165.5 to 602.2)	0.0 (66.5 to 369.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	308.5 (151.7 to 621.4)	308.5 (59.9 to 372.4)
Down syndrome	1.9 (1.6 to 2.3)	4.8 (3.9 to 6.0)	146.7 (88.1 to 245.9)	42.8 (7.5 to 102.4)	0.2 (0.2 to 0.3)	0.6 (0.4 to 0.8)	147.1 (82.2 to 259.8)	147.1 (7.4 to 111.5)
Turner syndrome	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	119.1 (63.3 to 242.4)	23.2 (-9.1 to 91.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	122.0 (61.6 to 248.3)	122.0 (-11.4 to 92.4)
Klinefelter syndrome	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	72.1 (36.8 to 101.1)	-4.6 (-23.6 to 11.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.8 (46.9 to 115.1)	83.8 (-24.2 to 11.2)
Chromosomal unbalanced rearrangements	0.0 (2.6 to 4.0)	0.0 (6.3 to 10.2)	83.3 (78.8 to 230.1)	0.0 (3.7 to 93.6)	0.4 (0.2 to 0.5)	0.9 (0.6 to 1.3)	146.6 (77.2 to 241.7)	146.6 (3.9 to 101.0)
Other congenital anomalies	17.1 (12.9 to 22.2)	27.8 (20.5 to 35.9)	62.1 (37.1 to 95.0)	-10.6 (-23.7 to 9.3)	1.7 (0.9 to 2.7)	2.6 (1.5 to 4.4)	61.5 (18.2 to 110.4)	61.5 (-31.4 to 22.9)
Skin and subcutaneous diseases	-	-	-	-	16.2 (10.1 to 25.4)	30.1 (19.0 to 47.8)	85.7 (69.6 to 105.2)	85.7 (-6.4 to 11.8)
Dermatitis	158.7 (125.0 to 198.1)	298.5 (232.5 to 376.3)	88.0 (85.2 to 90.9)	0.0 (-0.1 to 0.1)	4.6 (2.9 to 6.6)	8.5 (5.3 to 12.4)	85.6 (78.6 to 92.2)	85.6 (-2.3 to 3.2)
Psoriasis	24.4 (19.3 to 29.2)	46.3 (36.3 to 56.0)	90.0 (87.5 to 92.2)	0.0 (-0.1 to 0.1)	2.0 (1.3 to 2.9)	3.8 (2.4 to 5.6)	91.0 (79.1 to 103.3)	91.0 (-4.7 to 5.9)
Cellulitis	0.7 (0.5 to 0.9)	1.2 (0.9 to 1.5)	78.7 (55.7 to 101.3)	-1.9 (-16.9 to 10.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	78.7 (35.6 to 132.8)	78.7 (-23.3 to 22.1)
Pyoderma	6.5 (4.8 to 8.4)	10.4 (7.8 to 13.3)	58.9 (48.6 to 72.1)	-4.3 (-10.5 to 3.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	59.5 (43.2 to 76.2)	59.5 (-12.8 to 5.4)
Scabies	35.8 (31.3 to 40.5)	59.4 (48.7 to 70.9)	66.9 (29.8 to 106.7)	-6.3 (-24.4 to 16.3)	0.9 (0.5 to 1.5)	1.5 (0.9 to 2.5)	67.2 (31.0 to 108.2)	67.2 (-25.8 to 17.2)
Fungal skin diseases	448.9 (323.7 to 627.4)	825.3 (596.4 to 1,160.1)	83.3 (79.1 to 90.0)	2.5 (-0.1 to 0.0)	4.7 (1.0 to 5.7)	4.7 (1.8 to 10.6)	83.8 (79.4 to 90.8)	83.8 (-0.4 to 1.1)
Viral skin diseases	56.9 (43.8 to 70.3)	98.9 (76.0 to 123.2)	73.6 (63.2 to 86.0)	-0.9 (-5.7 to 4.2)	1.8 (1.0 to 2.8)	3.1 (1.8 to 4.8)	74.3 (62.5 to 88.9)	74.3 (-5.9 to 5.5)
Acne vulgaris	197.7 (131.3 to 261.7)	358.2 (220.7 to 508.6)	83.3 (-2.8 to 188.2)	1.0 (-46.4 to 55.5)	2.1 (0.9 to 4.2)	3.9 (1.7 to 7.5)	83.9 (-2.1 to 188.7)	83.9 (-46.7 to 55.9)
Alopecia areata	3.3 (2.9 to 3.7)	6.0 (5.3 to 6.8)	82.7 (57.7 to 116.3)	0.1 (-14.8 to 15.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	83.0 (51.9 to 124.7)	83.0 (-16.2 to 19.3)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.5 (40.1 to 124.5)	-1.7 (-24.2 to 23.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.5 (39.4 to 134.7)	83.5 (-24.2 to 23.4)
Urticaria	15.9 (11.0 to 23.2)	36.6 (21.5 to 54.4)	122.2 (37.2 to 383.4)	13.1 (-30.3 to 124.7)	0.9 (0.5 to 1.6)	2.2 (1.1 to 3.7)	124.5 (35.2 to 393.2)	124.5 (-30.2 to 127.4)
Decubitus ulcer	0.3 (0.2 to 0.4)	0.6 (0.5 to 0.7)	89.8 (44.1 to 146.1)	5.0 (-22.2 to 49.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	92.8 (42.4 to 156.9)	92.8 (-24.1 to 56.0)
Other skin and subcutaneous diseases	191.9 (130.6 to 274.7)	352.4 (239.7 to 503.7)	83.5 (76.7 to 92.1)	-0.7 (-3.2 to 2.6)	1.1 (0.5 to 2.3)	2.1 (0.9 to 4.3)	84.1 (77.0 to 93.4)	84.1 (-3.0 to 3.2)
Sense organ diseases	-	-	-	-	24.7 (15.5 to 35.1)	39.5 (25.7 to 57.8)	64.5 (51.4 to 78.3)	64.5 (-12.5 to -0.4)
Glaucoma	2.8 (1.9 to 3.8)	8.1 (6.1 to 10.6)	185.8 (120.5 to 322.9)	50.0 (11.3 to 121.7)	0.2 (0.1 to 0.2)	0.6 (0.4 to 0.9)	179.8 (116.0 to 293.6)	179.8 (64.2 to 110.4)
Cataract	15.2 (11.1 to 19.6)	27.4 (19.6 to 36.2)	81.7 (41.1 to 130.0)	-0.5 (-18.4 to 24.4)	1.3 (0.8 to 1.9)	2.2 (1.4 to 3.3)	74.0 (32.0 to 131.3)	74.0 (-22.5 to 21.8)
Macular degeneration	2.5 (1.7 to 3.9)	13.4 (8.5 to 20.5)	439.5 (231.1 to 766.4)	190.3 (84.4 to 379.4)	0.1 (0.1 to 0.2)	0.7 (0.4 to 1.2)	394.5 (216.7 to 662.2)	394.5 (73.9 to 300.2)
Uncorrected refractive error	315.9 (254.3 to 382.2)	541.4 (407.1 to 688.2)	72.8 (18.1 to 141.2)	-5.6 (-35.3 to 31.7)	6.5 (4.2 to 10.2)	10.2 (6.1 to 15.9)	57.3 (29.9 to 92.9)	57.3 (-8.7 to 5.4)
Age-related and other hearing loss	452.3 (378.8 to 512.2)	756.6 (645.8 to 872.6)	69.1 (61.6 to 78.4)	-6.8 (-10.0 to -3.0)	12.8 (7.5 to 19.6)	21.1 (12.0 to 31.5)	57.2 (39.9 to 76.5)	57.2 (-18.5 to 4.8)
Other vision loss	8.4 (6.8 to 10.4)	16.7 (13.0 to 21.0)	99.4 (67.9 to 138.3)	19.3 (1.9 to 45.1)	0.7 (0.5 to 1.1)	1.4 (0.9 to 2.1)	96.0 (59.9 to 142.2)	96.0 (-6.4 to 43.4)
Other sense organ diseases	89.9 (85.2 to 94.9)	156.9 (149.0 to 165.1)	74.3 (62.6 to 87.4)	-0.4 (-6.3 to 				

Appendix Table G.4 - Togo prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	12.2 (11.3 to 13.1)	22.1 (20.4 to 23.9)	80.7 (62.1 to 104.3)	0.8 (-8.8 to 13.1)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	82.0 (61.1 to 106.6)	15 (-8.7 to 14.9)
Other oral disorders	54.0 (51.0 to 57.1)	101.6 (95.6 to 107.7)	88.0 (74.0 to 106.0)	-0.5 (-7.2 to 7.8)	1.6 (1.0 to 2.4)	3.0 (1.9 to 4.4)	88.5 (74.1 to 107.4)	-0.1 (-7.2 to 8.4)
Injuries	-	-	-	-	12.9 (9.8 to 16.6)	19.8 (14.8 to 25.6)	53.2 (46.7 to 60.5)	-15.1 (-18.4 to -11.2)
Transport injuries	-	-	-	-	5.3 (4.0 to 6.8)	7.7 (5.7 to 10.0)	44.8 (35.8 to 53.5)	-19.6 (-24.0 to -14.9)
Road injuries	-	-	-	-	4.9 (3.7 to 6.2)	7.0 (5.2 to 9.0)	45.5 (33.9 to 52.6)	-20.9 (-25.8 to -15.9)
Pedestrian road injuries	-	-	-	-	1.2 (0.9 to 1.6)	1.6 (1.2 to 2.1)	29.2 (17.3 to 41.8)	-26.8 (-32.4 to -21.0)
Cyclist road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.6)	18.6 (9.6 to 28.4)	-30.5 (-35.6 to -24.9)
Motorcyclist road injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.9 (0.7 to 1.2)	25.5 (14.1 to 37.6)	-31.7 (-37.6 to -26.0)
Motor vehicle road injuries	-	-	-	-	2.4 (1.8 to 3.1)	3.9 (2.9 to 5.0)	61.5 (46.9 to 75.5)	-11.9 (-18.9 to -4.9)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	9.9 (0.8 to 18.9)	-42.9 (-47.0 to -38.8)
Other transport injuries	-	-	-	-	0.5 (0.3 to 0.6)	0.7 (0.5 to 1.0)	59.3 (49.2 to 71.0)	-7.4 (-13.0 to -1.0)
Unintentional injuries	-	-	-	-	7.2 (5.5 to 9.3)	11.2 (8.4 to 14.7)	55.7 (50.6 to 61.8)	-14.1 (-17.2 to -10.9)
Falls	-	-	-	-	2.8 (2.1 to 3.6)	4.6 (3.4 to 6.1)	63.8 (54.9 to 73.0)	-13.1 (-18.1 to -8.6)
Drowning	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	19.8 (8.2 to 32.2)	-31.8 (-37.5 to -25.6)
Fire, heat, and hot substances	-	-	-	-	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.8)	33.2 (19.1 to 46.2)	-23.3 (-29.0 to -17.4)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.8 (10.9 to 59.6)	-28.0 (-37.5 to -16.0)
Exposure to mechanical forces	-	-	-	-	2.3 (1.7 to 3.0)	3.5 (2.6 to 4.6)	51.9 (44.5 to 59.8)	-15.4 (-19.3 to -11.3)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	49.8 (36.1 to 63.8)	-18.5 (-25.2 to -10.8)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	96.8 (76.7 to 118.3)	9.5 (-0.6 to 19.4)
Other exposure to mechanical forces	-	-	-	-	2.2 (1.6 to 2.9)	3.3 (2.5 to 4.3)	51.6 (43.9 to 59.8)	-15.5 (-19.6 to -11.2)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	99.8 (87.2 to 113.7)	15.5 (7.7 to 24.0)
Animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	52.2 (41.1 to 62.9)	-14.1 (-19.5 to -9.0)
Venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	55.8 (36.8 to 76.1)	-13.8 (-22.8 to -4.5)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	49.0 (39.7 to 59.5)	-14.4 (-19.3 to -9.4)
Foreign body	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	64.5 (55.2 to 75.4)	-7.1 (-12.2 to -1.6)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	32.0 (13.0 to 49.9)	-18.3 (-27.2 to -10.0)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	80.4 (64.1 to 100.5)	-3.3 (-11.1 to 5.8)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	73.4 (61.4 to 87.3)	-4.7 (-11.4 to 2.8)
Other unintentional injuries	-	-	-	-	1.1 (0.8 to 1.4)	1.7 (1.3 to 2.3)	56.6 (45.9 to 68.2)	-11.9 (-17.5 to -5.2)
Self-harm and interpersonal violence	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.6)	51.1 (43.5 to 61.5)	-47.0 (-21.6 to -11.9)
Self-harm	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	75.8 (61.4 to 91.8)	-6.9 (-13.3 to 1.0)
Interpersonal violence	-	-	-	-	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	48.0 (39.2 to 58.0)	-19.4 (-24.1 to -14.0)
Assault by firearm	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	57.5 (46.3 to 69.7)	-14.1 (-19.5 to -7.8)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	82.2 (68.5 to 95.5)	-3.3 (-10.2 to 5.0)
Assault by other means	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	37.8 (27.7 to 48.6)	-24.9 (-30.2 to -19.4)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.1)	0.3 (0.1 to 0.8)	811.7 (626.8 to 1,092.0)	445.8 (344.2 to 605.9)
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	0.0 (0.0 to 0.1)	0.3 (0.1 to 0.8)	787.4 (611.9 to 1,046.6)	432.7 (333.6 to 581.1)

Appendix Table G.4 - Tonga prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	7.4 (5.4 to 9.6)	8.5 (6.3 to 11.0)	15.2 (11.2 to 18.6)	-2.3 (-5.2 to 0.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.4 (0.9 to 1.8)	1.3 (0.9 to 1.8)	-1.4 (-12.0 to 11.2)	-11.8 (-23.0 to 0.2)
HIV/AIDS and tuberculosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-11.3 to 14.7)	-14.2 (-23.8 to -2.3)
Tuberculosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-11.5 (-15.5 to -6.7)	-24.3 (-27.6 to -20.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.8 (-19.8 to -2.2)	-24.2 (-30.5 to -17.4)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	788.4 (291.8 to 1,520.8)	695.1 (233.7 to 1,361.5)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	432.1 (133.8 to 883.2)	352.0 (97.4 to 796.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	432.1 (131.2 to 885.1)	352.0 (97.2 to 798.1)
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	540.6 (210.5 to 1,088.1)	491.6 (191.2 to 1,004.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	794.5 (291.8 to 1,589.0)	702.9 (235.1 to 1,444.6)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.3 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-15.4 (-22.8 to -7.0)	-19.0 (-25.8 to -11.6)
Diarrheal diseases	0.5 (0.4 to 0.5)	0.5 (0.4 to 0.5)	1.8 (-12.2 to 17.5)	3.4 (-8.5 to 17.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	1.4 (-12.7 to 18.7)	3.5 (-9.7 to 17.8)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.0 (-41.7 to 16.8)	-26.2 (-42.5 to 11.2)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.4 (-34.9 to -9.7)	-25.2 (-36.7 to -13.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.6 (-39.4 to -2.8)	-24.6 (-39.4 to -8.7)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.9 (-47.9 to -20.7)	-40.3 (-50.9 to -25.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.5 (-49.6 to -17.1)	-40.2 (-52.0 to -23.6)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	296.8 (91.8 to 9,491.7)	280.9 (91.9 to 9,052.1)
Lower respiratory infections	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-16.7 (-38.3 to 3.1)	-19.9 (-36.8 to -5.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.3 (-40.9 to 3.4)	-20.8 (-38.4 to -4.1)
Upper respiratory infections	2.9 (2.8 to 3.1)	3.1 (3.0 to 3.2)	6.0 (-0.3 to 13.2)	-1.1 (-6.6 to 5.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	5.8 (-1.4 to 13.8)	-1.0 (-7.5 to 6.0)
Otitis media	1.4 (1.3 to 1.5)	1.3 (1.2 to 1.4)	-6.0 (-12.8 to 0.5)	-11.6 (-18.4 to -5.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.2 (-14.0 to 1.8)	-11.4 (-18.9 to -3.9)
Meningitis	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-37.6 (-47.9 to -23.9)	-40.3 (-49.6 to -27.8)
Pneumococcal meningitis	0.5 (0.3 to 0.8)	0.3 (0.2 to 0.6)	-32.9 (-45.4 to -18.3)	-38.0 (-47.9 to -26.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-37.8 (-56.5 to -10.5)	-40.5 (-56.8 to -15.3)
H influenzae type B meningitis	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-39.8 (-61.2 to -2.8)	-44.6 (-63.4 to -11.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.7 (-66.5 to 33.0)	-39.7 (-68.2 to 23.2)
Meningococcal meningitis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-38.6 (-63.6 to -19.7)	-43.4 (-64.7 to -27.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.1 (-67.9 to -16.2)	-47.5 (-68.3 to -24.0)
Other meningitis	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.2)	-33.4 (-49.4 to -13.1)	-37.3 (-51.7 to -18.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.1 (-57.1 to -7.5)	-38.0 (-57.8 to -11.0)
Encephalitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.2 (-13.1 to 18.7)	-12.1 (-23.4 to 3.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.0 (-14.8 to 32.0)	-5.7 (-22.5 to 14.3)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.1 (-93.9 to 85.7)	-15.7 (-93.2 to 581.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.1 (-94.0 to 862.0)	-15.7 (-93.4 to 597.5)
Whooping cough	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-68.9 (-71.0 to -66.7)	-66.5 (-68.8 to -64.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-68.7 (-77.7 to -57.7)	-66.3 (-75.9 to -54.6)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.1 (-92.1 to -47.9)	-82.4 (-92.8 to -54.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-74.4 (-89.6 to -35.8)	-76.8 (-89.4 to -47.5)
Measles	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	83.6 (-87.6 to -78.0)	-82.5 (-86.8 to -76.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-83.5 (-89.2 to -75.9)	-82.4 (-88.5 to -74.3)
Varicella and herpes zoster	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	6.2 (-5.3 to 19.7)	-0.8 (-14.1 to 15.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.0 (-5.8 to 43.3)	-1.5 (-19.5 to 24.3)
Neglected tropical diseases and malaria	-	-	-	-	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-18.1 (-40.9 to 10.8)	-36.9 (-57.8 to -9.6)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.5 (-41.6 to 107.0)	-4.3 (-44.5 to 94.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.6 (-41.7 to 104.3)	-5.1 (-44.5 to 93.4)
Chagas disease	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.7 (-13.4 to 31.9)	1.3 (-16.9 to 22.8)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.6 (-54.2 to 76.8)	-4.0 (-47.4 to 71.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.6 (-54.2 to 77.7)	-4.0 (-47.5 to 71.7)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.3 (-12.9 to 35.1)	1.7 (-17.2 to 25.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.3 (-13.1 to 35.4)	1.7 (-17.2 to 25.2)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.4 (-78.4 to 12.6)	-60.5 (-82.3 to -5.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.4 (-79.2 to 27.0)	-57.7 (-82.5 to 2.0)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.8 (-26.6 to -17.4)	-37.0 (-40.6 to -31.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.8 (-37.5 to -3.8)	-36.2 (-47.5 to -23.6)
Lymphatic filariasis	4.4 (3.1 to 6.0)	1.2 (0.7 to 1.8)	-73.7 (-83.1 to -60.3)	-76.9 (-85.4 to -67.1)	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.2)	-37.1 (-65.5 to -3.3)	-51.0 (-72.4 to -22.1)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	375.7 (363.1 to 390.6)	335.4 (323.8 to 349.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	373.4 (311.0 to 462.2)	334.6 (285.8 to 410.8)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.0 (-67.3 to -18.3)	-56.1 (-71.4 to -33.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-48.0 (-67.3 to -18.1)	-56.1 (-71.4 to -33.4)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-0.0 (-40.1 to 36.6)	-14.6 (-47.1 to 37.5)
Ascariasis	2.0 (1.2 to 3.5)	1.8 (1.2 to 2.7)	-6.6 (-54.5 to 75.5)	-12.2 (-57.2 to 73.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.5 (-99.9 to -96.3)	-17.8 (-99.9 to -95.9)
Trichuriasis	5.0 (3.3 to 7.5)	5.4 (3.6 to 8.2)	6.3 (-38.5 to 92.3)	-3.2 (-47.1 to 93.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.5 (-82.6 to 455.5)	-10.4 (-86.1 to 486.5)
Hookworm disease	5.6 (3.8 to 8.1)	10.1 (4.2 to 8.9)	80.1 (-34.1 to 84.4)	10.1 (-43.8 to 79.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	6.4 (-24.4 to 52.7)	2.2 (-38.0 to 48.7)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	1.0 (0.7 to 1.3)	1.0 (0.9 to 1.1)	0.2 (-24.0 to 46.1)	-1.8 (-25.9 to 44.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.7 (-13.1 to 80.1)	-2.1 (-15.9 to 81.5)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.3 (-35.5 to 7.0)	-23.4 (-43.4 to -5.0)
Maternal hemorrhage	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-8.2 (-36.8 to 21.2)	-17.3 (-43.3 to 10.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.5 (-45.5 to 21.0)	-17.8 (-51.8 to 9.4)
Maternal sepsis and other maternal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.2 (-22.3 to 22.6)	-28.0 (-39.6 to -6.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.1 (-56.9 to 35.3)	-33.0 (-61.4 to 8.4)
Maternal hypertensive disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.5 (-21.5 to 3.3)	-22.7 (-28.0 to -10.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.5 (-29.6 to 9.6)	-23.4 (-36.7 to -4.4)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.4 (-63.3 to 12.1)	-46.1 (-68.1 to -3.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.6 (-72.2 to 60.9)	-45.8 (-76.4 to 46.8)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.2 (-53.3 to 38.9)	-25.2 (-58.8 to 18.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.6 (-55.4 to 58.4)	-22.9 (-61.8 to 42.4)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.4 (-44.3 to 40.1)	-24.4 (-50.4 to 24.4)
Neonatal disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	29.5 (-26.4 to 156.7)	23.8 (-29.3 to 143.0)
Preterm birth complications	0.5 (0.3 to 0.9)	1.1 (0.6 to 2.0)	111.5 (48.5 to 214.1)	96.1 (40.0 to 188.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	87.0 (9.9 to 290.3)	77.4 (4.1 to 265.1)
Neonatal encephalopathy due to birth asphyxia and trauma	0.3 (0.1 to 0.7)	0.3 (0.1 to 0.7)	3.9 (-18.3 to 34.0)	4.9 (-24.1 to 23.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.6 (-32.2 to 66.2)	4.1 (-34.1 to 60.2)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.1 (96.6 to 115.2)	103.1 (116.2 to 136.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	103.1 (80.3 to 130.0)	103.2 (98.3 to 153.0)
Hemolytic disease and other neonatal jaundice	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	1.8 (-78.5 to 374.0)	-4.2 (-79.5 to 343.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.8 (-77.5 to 317.4)	-3.5 (-78.7 to 300.4)
Other neonatal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-7.8 (-64.2 to 207.7)	-12.1 (-65.3 to 191.3)
Nutritional deficiencies	-	-	-	-	0.6 (0.4 to 0.9)	0.6 (0.4 to 0.9)	2.9 (-4.4 to 5.0)	-2.8 (-6.1 to -1.0)
Protein-energy malnutrition	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-22.5 (-55.6 to 40.8)	-22.2 (-52.1 to 31.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.0 (-56.9 to 39.1)	-21.8 (-53.2 to 32.5)
Iodine deficiency	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-32.6 (-51.7 to -14.2)	-40.2 (-59.2 to -23.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.8 (-52.7 to -11.2)	-39.1 (-59.7 to -20.4)
Vitamin A deficiency	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.1 (-53.9 to -31.6)	-46.9 (-56.3 to -36.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.7 (-58.2 to -31.4)	-49.5 (-59.4 to -37.4)

Appendix Table G.4 - Tonga prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	16.9 (16.5 to 17.2)	17.6 (17.4 to 17.8)	4.4 (2.2 to 6.5)	-1.3 (-3.2 to 0.7)	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.9)	3.5 (0.2 to 5.6)	-2.3 (-5.8 to -0.5)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.1 (-73.9 to 60.7)	-36.5 (-72.1 to 56.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-1.5 (-11.0 to 10.0)	-10.5 (-19.0 to 0.2)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	7.4 (-4.1 to 21.4)	-0.6 (-9.5 to 10.6)
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.9 (-32.2 to -4.1)	-37.8 (-47.2 to -28.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.7 (-40.9 to -10.7)	49.7 (-54.0 to -15.1)
Chlamydial infection	4.7 (3.7 to 6.2)	5.8 (4.8 to 7.1)	26.8 (9.7 to 60.8)	18.7 (-13.3 to 49.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.4 (-8.1 to 22.5)	1.0 (-10.9 to 14.7)
Gonococcal infection	0.8 (0.5 to 1.0)	0.8 (0.5 to 1.1)	4.6 (-36.3 to 91.7)	0.8 (-36.5 to 79.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.5 (-24.8 to 65.7)	5.4 (-25.4 to 54.8)
Trichomoniasis	0.9 (0.6 to 1.3)	1.1 (0.6 to 1.7)	30.5 (-41.1 to 116.3)	6.9 (-47.1 to 104.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.6 (-45.9 to 150.4)	8.2 (-51.8 to 134.9)
Genital herpes	12.2 (11.8 to 12.4)	13.9 (13.6 to 14.3)	14.5 (10.5 to 19.7)	4.8 (-7.9 to -0.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.1 (-3.0 to 19.4)	-4.8 (-9.8 to 0.4)
Other sexually transmitted diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.9 (-15.8 to 10.8)	-26.9 (-35.5 to -14.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.5 (-29.4 to 27.2)	-24.5 (-41.5 to 2.4)
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.5 (-50.8 to -17.7)	-47.3 (-60.8 to -28.7)
Hepatitis A	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-1.6 (-2.0 to -1.2)	-3.1 (-3.2 to -3.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.6 (-7.8 to 18.2)	-0.7 (-11.8 to 10.8)
Hepatitis B	19.0 (13.9 to 24.0)	8.0 (6.4 to 9.7)	-58.6 (-69.2 to -36.3)	-43.5 (-72.8 to -47.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-56.9 (-73.2 to -39.9)	-63.7 (-76.6 to -42.0)
Hepatitis C	3.1 (2.7 to 3.5)	2.7 (2.4 to 3.0)	-12.9 (-25.9 to 1.4)	-27.0 (-37.0 to -16.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.8 (-33.9 to 18.8)	-23.8 (-34.7 to 8.5)
Hepatitis E	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.1 (3.0 to 53.0)	14.1 (-3.2 to 39.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.4 (-2.4 to 61.9)	14.2 (-9.0 to 48.2)
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.9 (-52.6 to 55.4)	-19.0 (-60.3 to 50.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.3 (-55.6 to 754.1)	-18.4 (-62.2 to 614.1)
Other infectious diseases	0.7 (0.6 to 0.9)	0.7 (0.6 to 0.8)	0.5 (-15.8 to 16.6)	-1.9 (-17.1 to 14.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.9 (-13.8 to 24.3)	2.0 (-16.0 to 25.2)
Non-communicable diseases	-	-	-	-	4.0 (4.3 to 7.5)	5.9 (5.2 to 9.0)	19.6 (14.8 to 23.2)	40.0 (-3.4 to 2.9)
Neoplasms	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	56.1 (13.4 to 107.4)	11.2 (-17.6 to 46.8)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.7 (9.1 to 285.1)	36.7 (-32.3 to 183.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.6 (-7.9 to 272.4)	38.9 (-33.4 to 175.8)
Stomach cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.8 (-11.5 to 80.5)	-6.1 (-33.9 to 32.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.5 (-14.2 to 78.2)	-7.5 (-36.5 to 29.5)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.8 (3.2 to 258.9)	35.8 (-27.1 to 166.2)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	149.9 (20.3 to 436.7)	86.5 (-12.6 to 310.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	129.2 (16.7 to 359.2)	70.1 (-15.1 to 254.0)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	311.3 (61.4 to 923.7)	187.9 (9.6 to 647.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	272.6 (57.7 to 780.5)	156.0 (8.0 to 544.3)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.9 (-58.7 to 96.6)	-37.7 (-71.2 to 41.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.5 (-58.8 to 79.3)	-40.7 (-72.0 to 28.3)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.1 (-51.5 to 171.1)	-18.6 (-65.5 to 102.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.1 (-52.1 to 144.2)	24.0 (-65.3 to 81.3)
Larynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.2 (-95.0 to -20.2)	-91.9 (-96.5 to -44.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-77.8 (-90.0 to -11.0)	-84.4 (-93.2 to -38.0)
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	38.7 (-3.1 to 97.5)	2.0 (-27.3 to 42.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.5 (-3.0 to 93.1)	-0.2 (-28.3 to 39.1)
Breast cancer	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	112.6 (30.8 to 226.1)	63.3 (2.5 to 146.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	87.4 (13.2 to 197.4)	41.6 (-12.8 to 119.8)
Cervical cancer	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-4.0 (-46.9 to 69.6)	-28.2 (-59.1 to 22.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.3 (-44.3 to 67.0)	-28.0 (-57.9 to 20.0)
Uterine cancer	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	12.8 (-39.9 to 118.1)	-9.2 (-51.0 to 70.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.7 (-39.9 to 108.8)	-10.1 (-51.3 to 63.3)
Prostate cancer	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.4)	165.9 (43.7 to 393.5)	97.0 (6.2 to 271.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	165.4 (47.4 to 405.2)	89.2 (4.5 to 254.6)
Colon and rectum cancer	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-52.7 (-66.3 to -26.1)	-70.8 (-79.2 to -53.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.8 (-65.9 to -24.6)	-70.1 (-78.0 to -51.8)
Lip and oral cavity cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.0)	34.7 (-21.3 to 110.6)	2.9 (-39.9 to 63.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.8 (-18.2 to 108.5)	1.0 (-38.6 to 62.1)
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.5 (-28.0 to 120.8)	2.0 (-43.0 to 73.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.0 (-29.9 to 108.7)	0.0 (-43.7 to 63.5)
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.5 (-30.4 to 138.4)	-9.1 (-48.9 to 73.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.6 (-29.4 to 126.8)	-9.9 (-48.0 to 66.8)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.2 (-39.0 to 123.1)	-5.5 (-52.7 to 76.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.0 (-40.2 to 105.3)	-10.4 (-53.0 to 61.2)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.8 (27.1 to 261.0)	43.6 (-5.5 to 104.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.7 (23.7 to 172.3)	37.8 (-9.0 to 97.3)
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.0 (32.1 to 266.0)	57.0 (-3.5 to 160.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.2 (27.1 to 244.3)	46.0 (-10.4 to 143.3)
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	154.3 (65.7 to 284.0)	73.2 (15.1 to 158.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	167.6 (59.8 to 338.8)	81.8 (7.2 to 202.7)
Ovarian cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.8 (-29.6 to 142.8)	1.6 (-45.0 to 82.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.9 (-29.2 to 137.6)	0.6 (-44.3 to 74.7)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.5 (-27.6 to 212.1)	34.6 (-33.8 to 169.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.5 (-27.4 to 220.9)	28.8 (-36.4 to 159.5)
Kidney cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.9 (-2.2 to 167.1)	25.2 (-24.1 to 107.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.5 (-4.9 to 154.1)	20.1 (-25.7 to 100.6)
Bladder cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-31.3 (-63.2 to 33.0)	-58.5 (-77.3 to -20.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.4 (-65.2 to 33.2)	-58.7 (-78.2 to -20.8)
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.8 (-6.2 to 174.9)	28.9 (-23.0 to 111.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	52.4 (-9.9 to 155.3)	22.0 (-30.6 to 100.9)
Thyroid cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.0 (-15.9 to 157.9)	20.3 (-31.0 to 108.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.6 (-18.8 to 151.4)	16.2 (-33.4 to 100.9)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.8 (2.4 to 137.9)	28.6 (-19.9 to 93.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.2 (4.2 to 137.8)	28.7 (-18.6 to 94.6)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.9 (12.8 to 265.5)	70.2 (2.6 to 176.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.8 (8.1 to 232.5)	52.0 (-11.0 to 156.0)
Non-Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	97.5 (7.6 to 223.9)	46.6 (-19.1 to 134.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.6 (5.8 to 215.3)	39.7 (-22.2 to 125.6)
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.6 (-4.1 to 167.0)	19.5 (-26.7 to 100.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	53.1 (-8.2 to 158.7)	15.7 (-30.6 to 97.5)
Leukemia	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	96.3 (13.1 to 251.3)	70.6 (8.4 to 188.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.2 (20.8 to 180.4)	51.9 (-2.9 to 128.9)
Other neoplasms	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	237.7 (84.3 to 520.7)	193.6 (61.0 to 376.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	221.9 (78.3 to 459.0)	154.6 (44.0 to 321.4)
Cardiovascular diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	43.6 (21.7 to 67.7)	15.5 (-2.0 to 34.0)
Rheumatic heart disease	2.7 (2.3 to 3.0)	3.1 (2.7 to 3.4)	13.8 (-3.8 to 37.9)	-2.2 (-17.8 to 17.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	13.3 (-3.6 to 36.6)	-2.8 (-18.2 to 16.4)
Ischemic heart disease	0.5 (0.4 to 0.6)	0.7 (0.5 to 0.8)	39.3 (8.2 to 88.1)	4.7 (-22.4 to 34.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	43.4 (13.4 to 97.3)	3.2 (-17.7 to 36.4)
Cerebrovascular disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.0 (24.0 to 71.8)	5.8 (-8.9 to 28.6)
Ischemic stroke	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	50.0 (24.7 to 86.2)	6.6 (-10.8 to 34.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.4 (22.4 to 86.2)	6.7 (-11.7 to 36.4)
Hemorrhagic stroke	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	44.2 (22.6 to 70.3)	5.9 (-10.2 to 26.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.2 (20.2 to 69.6)	5.8 (-10.9 to 26.6)
Hypertensive heart disease	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	60.4 (29.5 to 100.2)	15.6 (-7.2 to 45.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.2 (27.6 to 98.9)	15.3 (-7.8 to 45.0)
Cardiomyopathy and myocarditis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	65.4 (40.2 to 93.6)	29.4 (9.3 to 53.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.9 (38.9 to 95.8)	30.5 (8.3 to 55.0)
Atrial fibrillation and flutter	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.3)	288.4 (167.2 to 465.8)	121.6 (50.2 to 224.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	288.4 (166.9 to 469.1)	124.9 (51.2 to 231.2)
Peripheral vascular disease	1.1 (0.8 to 1.4)	1.6 (1.1 to 2.1)	48.1 (-3.3 to 124.2)	6.4 (-26.9 to 56.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.3 (-44.9 to 140.3)	-25.6 (-65.5 to 36.0)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.4 (-2.1 to 66.8)	8.9 (-23.4 to 40.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.4 (-8.7 to 77.1)	8.8 (-28.3 to 51.8)
Other cardiovascular and circulatory diseases	0.6 (0.4 to 0.8)	1.2 (0.6 to 1.8)	94.5 (8.0 to 254.4)	55.0 (-28.1 to 183.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	95.4 (-9.3 to 255.1)	55.4 (-2.8 to 189.3)
Chronic respiratory diseases	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	12.1 (-2.5 to 31.2)	-8.5 (-20.1 to 6.0)
Chronic obstructive pulmonary disease	2.3 (2.2 to 2.4)	2.9 (2.8 to 3.1)	28.2 (24.6 to 32.0)	-0.1 (-3.0 to 3.0)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.4)	22.9 (7.4 to 48.0)	-3.7 (-16.5 to 16.4)

Appendix Table G.4 - Tonga prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	111.7	57.5
Silicosis	0.0	0.0	13.9	-18.0	0.0	0.0	(96.9 to 126.1)	(45.2 to 68.9)
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	13.5	-18.2
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.0	0.0	158.0	97.9	0.0	0.0	152.8	94.0
Asthma	3.0	3.3	11.6	-0.9	0.1	0.1	10.6	-1.4
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	29.5	0.4	0.0	0.0	28.8	-0.0
Other chronic respiratory diseases	-	-	-	-	0.1	0.1	-18.4	-35.7
Cirrhosis	-	-	-	-	0.0	0.0	-17.6	-26.7
Cirrhosis due to hepatitis B	0.0	0.0	8.3	-18.5	0.0	0.0	(-28.0 to -4.9)	(-34.8 to -17.9)
Cirrhosis due to hepatitis C	0.0	0.0	1.6	-11.6	0.0	0.0	0.0	-10.5
Cirrhosis due to alcohol use	0.0	0.0	-48.4	-56.9	0.0	0.0	(-56.5 to 77.6)	(63.4 to 53.2)
Cirrhosis due to other causes	0.0	0.0	23.8	-23.0	0.0	0.0	(-66.3 to -19.5)	(-71.4 to -35.9)
Digestive diseases	-	-	-	-	0.1	0.1	17.7	-16.0
Peptic ulcer disease	0.7	0.6	-17.0	-40.1	0.0	0.0	(-4.9 to 22.1)	(-26.9 to -5.8)
Gastritis and duodenitis	0.8	0.8	-2.5	-20.6	0.0	0.0	-4.9	-32.8
Appendicitis	0.0	0.0	24.6	-33.0	0.0	0.0	(-21.9 to 7.3)	(-43.7 to -24.9)
Paralytic ileus and intestinal obstruction	0.0	0.0	26.5	-2.6	0.0	0.0	25.1	-1.2
Inguinal, femoral, and abdominal hernia	0.2	0.2	19.5	-11.8	0.0	0.0	(-9.7 to 77.2)	(-25.6 to 33.0)
Inflammatory bowel disease	0.0	0.0	13.4	-8.4	0.0	0.0	12.8	-8.5
Vascular intestinal disorders	0.0	0.0	113.7	107.4	0.0	0.0	(-4.7 to 33.3)	(-21.7 to 7.3)
Gallbladder and biliary diseases	0.0	0.0	30.4	30.0	0.0	0.0	30.0	5.2
Pancreatitis	0.0	0.0	35.4	5.6	0.0	0.0	(10.6 to 52.9)	(-19.1 to 10.3)
Other digestive diseases	-	-	-	-	0.0	0.0	47.7	5.0
Neurological disorders	-	-	-	-	0.4	0.4	28.5	15.7
Alzheimer disease and other dementias	0.3	0.5	74.4	5.0	0.0	0.1	(5.5 to 53.9)	(-14.5 to 22.2)
Parkinson disease	0.0	0.1	42.8	-0.7	0.0	0.0	42.1	-0.5
Epilepsy	0.3	0.3	7.2	-2.1	0.1	0.1	13.7	4.6
Multiple sclerosis	0.0	0.0	121.6	77.5	0.0	0.0	(-24.7 to 65.4)	(-30.4 to 52.6)
Migraine	7.1	6.0	-15.3	-2.2	0.2	0.2	18.7	3.1
Tension-type headache	11.7	13.7	17.9	3.0	0.0	0.0	(-21.2 to 67.0)	(-32.5 to 44.1)
Medication overuse headache	0.3	0.5	81.1	50.2	0.0	0.1	80.2	49.8
Other neurological disorders	0.0	0.0	13.6	3.5	0.0	0.0	(-15.7 to 33.3)	(-30.3 to 57.1)
Mental and substance use disorders	-	-	-	-	1.4	1.7	14.1	0.7
Schizophrenia	0.2	0.3	19.7	-0.8	0.2	0.2	(11.5 to 17.4)	(-1.4 to 3.4)
Alcohol use disorders	0.6	0.8	34.1	34.1	0.1	0.1	43.9	34.8
Drug use disorders	-	-	-	-	0.1	0.1	0.1	-5.3
Opioid use disorders	0.1	0.1	22.6	-0.1	0.0	0.0	(-14.8 to 16.7)	(-18.3 to 9.1)
Cocaine use disorders	0.1	0.1	6.7	5.8	0.0	0.0	(6.7 to 41.2)	(-11.9 to 13.9)
Amphetamine use disorders	0.3	0.2	-12.0	-11.3	0.0	0.0	(-12.5 to 31.0)	(-16.3 to 21.5)
Cannabis use disorders	0.4	0.4	2.0	-0.2	0.0	0.0	-12.8	-11.8
Other drug use disorders	-	-	-	-	0.0	0.0	(-32.3 to 8.8)	(-30.1 to 9.2)
Depressive disorders	-	-	-	-	0.4	0.5	18.2	0.3
Major depressive disorder	1.7	2.0	17.2	0.1	0.4	0.4	(12.0 to 24.8)	(-4.3 to 5.8)
Dysthymia	1.0	1.2	22.9	0.3	0.1	0.1	16.9	0.3
Bipolar disorder	0.4	0.5	15.8	-0.0	0.1	0.1	22.5	0.3
Anxiety disorders	2.3	2.6	13.3	0.2	0.2	0.2	(18.3 to 27.2)	(-2.0 to 2.5)
Eating disorders	-	-	-	-	0.0	0.0	15.3	-0.1
Anorexia nervosa	0.0	0.0	8.3	-11.3	0.0	0.0	(6.7 to 24.9)	(-6.4 to 6.2)
Bulimia nervosa	0.0	0.0	0.6	0.9	0.0	0.0	(8.4 to 17.7)	(-2.8 to 3.2)
Autistic spectrum disorders	-	-	-	-	0.1	0.1	-4.0	-5.5
Autism	0.3	0.3	8.6	-0.2	0.1	0.1	(-18.5 to 11.3)	(-19.1 to 9.1)
Asperger syndrome	0.4	0.5	8.3	-0.3	0.0	0.0	-7.7	-10.6
Attention-deficit/hyperactivity disorder	0.7	0.8	3.6	0.1	0.0	0.0	(-26.6 to 13.1)	(-28.3 to 9.0)
Conduct disorder	0.7	0.8	6.8	0.2	0.1	0.1	8.3	-0.2
Idiopathic intellectual disability	0.3	0.3	2.7	-3.6	0.0	0.0	(4.4 to 12.2)	(-3.3 to 2.8)
Other mental and substance use disorders	1.3	1.5	12.2	-0.5	0.1	0.1	2.9	0.1
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	0.6	0.8	27.8	6.7
Diabetes mellitus	4.1	5.9	42.2	14.1	0.3	0.4	(13.5 to 41.6)	(-6.7 to 21.7)
Acute glomerulonephritis	0.0	0.0	16.1	4.1	0.0	0.0	46.3	14.6
Chronic kidney disease	-	-	-	-	0.1	0.1	(13.6 to 81.4)	(-10.5 to 45.2)
Chronic kidney disease due to diabetes mellitus	0.3	0.7	91.7	46.7	0.0	0.0	16.1	4.1
Chronic kidney disease due to hypertension	0.6	0.3	-45.6	-52.9	0.0	0.0	(-37.0 to 176.2)	(-4.8 to 130.9)
Chronic kidney disease due to glomerulonephritis	0.8	0.8	2.5	-12.2	0.0	0.0	(-4.7 to 51.3)	(-21.2 to 24.8)
Chronic kidney disease due to other causes	1.6	2.2	34.6	9.7	0.0	0.1	(-71.1 to -40.5)	(-74.3 to -44.2)
Urinary diseases and male infertility	-	-	-	-	0.0	0.0	34.9	10.2
	-	-	-	-	0.0	0.0	26.7	-3.1
	-	-	-	-	0.0	0.1	(12.2 to 42.8)	(-14.6 to 9.8)

Appendix Table G.4 - Tonga prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.6 (32.9 to 56.4)	0.0 (17.3 to 36.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.1 (14.9 to 79.6)	26.0 (4.7 to 53.0)
Urolithiasis	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	0.3 (10.6 to 57.6)	-8.9 (-21.9 to 11.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.0 (7.6 to 37.5)	-4.7 (-14.0 to 7.2)
Benign prostatic hyperplasia	0.6 (0.6 to 0.7)	0.8 (0.7 to 0.9)	31.1 (12.0 to 52.5)	-4.9 (-19.1 to 10.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.0 (11.8 to 52.7)	-4.6 (-18.8 to 11.5)
Male infertility due to other causes	0.7 (0.6 to 0.9)	0.7 (0.6 to 0.9)	6.9 (-20.7 to 42.9)	-1.3 (-24.9 to 28.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.8 (-22.8 to 42.7)	-0.9 (-25.7 to 32.0)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-3.0 to 91.7)	0.0 (-21.5 to 52.6)
Gynecological diseases	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	17.6 (-2.5 to 33.8)	-4.1 (-18.1 to 7.6)
Uterine fibroids	1.4 (1.3 to 1.6)	1.9 (1.8 to 2.1)	35.5 (34.5 to 36.8)	-1.3 (-1.4 to -1.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	29.3 (20.6 to 35.7)	-2.3 (-8.5 to 2.1)
Polycystic ovarian syndrome	1.1 (1.0 to 1.3)	1.3 (1.2 to 1.5)	18.0 (0.8 to 38.9)	-3.2 (-17.0 to 11.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.9 (0.4 to 39.4)	-3.1 (-16.8 to 12.9)
Female infertility due to other causes	0.7 (0.6 to 0.9)	0.9 (0.7 to 1.1)	24.5 (8.1 to 58.1)	4.5 (-24.0 to 42.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.3 (-6.6 to 64.8)	4.5 (-22.3 to 42.5)
Endometriosis	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	21.1 (-4.5 to 54.6)	-1.4 (-20.8 to 25.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.7 (-6.1 to 55.9)	-1.5 (-22.8 to 26.5)
Genital prolapse	3.6 (3.1 to 4.0)	4.3 (3.6 to 4.9)	19.6 (-1.8 to 42.5)	-3.6 (-19.3 to 14.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.6 (-2.5 to 43.0)	-3.6 (-19.3 to 13.7)
Premenstrual syndrome	2.5 (1.6 to 3.6)	2.5 (1.3 to 3.4)	0.8 (-59.4 to 81.0)	-13.3 (-65.1 to 51.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.9 (-59.4 to 81.0)	0.0 (-64.7 to 51.1)
Other gynecological diseases	0.3 (0.2 to 0.4)	0.3 (0.3 to 0.4)	11.6 (-12.1 to 44.8)	-2.2 (-24.2 to 30.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.0 (-6.3 to 79.3)	-1.1 (-17.5 to 59.9)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	3.2 (-5.4 to 18.7)	-2.0 (-10.5 to 12.9)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.7 (-16.9 to 3.5)	-6.9 (-16.9 to 3.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.1 (-32.1 to 18.7)	-10.7 (-30.5 to 17.7)
Thalassemia trait	2.9 (2.5 to 3.4)	3.1 (2.6 to 3.8)	7.8 (3.4 to 13.1)	-1.1 (-4.7 to 3.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	4.1 (-5.8 to 21.1)	-1.7 (-11.9 to 11.5)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.2 (-15.2 to -1.1)	-12.3 (-17.6 to -3.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.2 (-21.8 to -5.0)	-17.3 (-25.5 to -8.6)
Sickle cell trait	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-15.8 (-21.9 to -8.7)	-23.4 (-28.8 to -17.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.2 (-58.8 to 9.7)	-36.7 (-58.7 to -10.0)
G6PD deficiency	2.5 (1.8 to 3.4)	2.9 (2.1 to 3.7)	15.9 (-28.2 to 71.3)	6.1 (-34.2 to 57.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.0 (-47.7 to 103.2)	1.2 (-42.0 to 71.6)
G6PD trait	18.5 (17.1 to 19.6)	20.3 (18.7 to 21.7)	9.4 (-0.1 to 21.9)	-0.4 (-9.0 to 11.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.4 (-95.1 to 3,118.9)	-14.6 (-93.7 to 1,831.7)
Other hemoglobinopathies and hemolytic anemias	0.5 (0.4 to 0.7)	0.6 (0.4 to 0.6)	6.1 (-21.9 to 53.3)	2.3 (-22.6 to 42.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.9 (-38.0 to 93.6)	0.6 (-37.8 to 85.2)
Endocrine, metabolic, blood, and immune disorders	1.0 (0.9 to 1.2)	1.1 (1.0 to 1.2)	9.5 (-2.9 to 26.7)	9.5 (-8.8 to 16.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	9.4 (-5.6 to 32.4)	2.4 (-10.7 to 21.7)
Musculoskeletal disorders	-	-	-	-	1.1 (0.8 to 1.4)	1.4 (1.0 to 1.8)	26.7 (16.0 to 43.9)	1.0 (-7.4 to 12.8)
Rheumatoid arthritis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	129.3 (114.8 to 144.4)	83.9 (72.9 to 96.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	126.7 (106.4 to 152.4)	83.5 (68.6 to 101.5)
Osteoarthritis	1.4 (1.3 to 1.4)	1.9 (1.9 to 2.0)	42.3 (34.2 to 50.5)	1.6 (-3.9 to 7.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	41.7 (33.2 to 50.4)	1.7 (-4.0 to 7.7)
Low back and neck pain	-	-	-	-	0.8 (0.5 to 1.1)	1.0 (0.7 to 1.3)	23.0 (9.2 to 45.8)	4.1 (-11.8 to 17.5)
Low back pain	4.4 (4.1 to 4.7)	5.4 (5.1 to 5.6)	22.0 (12.0 to 33.6)	-0.1 (-7.4 to 8.1)	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.8)	21.5 (11.2 to 33.0)	-0.1 (-7.2 to 8.6)
Neck pain	2.9 (2.1 to 3.6)	3.7 (2.9 to 4.7)	26.4 (-8.0 to 100.3)	0.5 (-26.5 to 53.6)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	25.4 (-8.6 to 101.2)	0.6 (-27.0 to 53.6)
Gout	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	39.5 (26.8 to 51.9)	4.2 (-5.2 to 13.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.0 (14.3 to 67.9)	4.5 (-14.2 to 25.3)
Other musculoskeletal disorders	2.0 (1.6 to 2.4)	2.6 (2.0 to 3.1)	25.1 (17.3 to 36.9)	-9.9 (-10.1 to 3.7)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	25.1 (16.6 to 37.2)	-3.9 (-10.4 to 4.2)
Other non-communicable diseases	-	-	-	-	1.4 (0.9 to 2.0)	1.5 (1.1 to 2.2)	9.7 (-1.8 to 19.4)	-6.6 (-13.5 to -0.2)
Congenital anomalies	-	-	-	-	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-0.2 (-48.4 to 66.3)	-4.1 (-49.2 to 57.3)
Neural tube defects	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.1 (-15.2 to 29.6)	0.4 (-18.0 to 25.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.0 (-24.0 to 42.6)	0.4 (-25.5 to 37.2)
Congenital heart anomalies	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	24.3 (-2.6 to 64.7)	18.7 (-7.1 to 58.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.0 (-2.9 to 64.3)	19.8 (-6.7 to 59.4)
Orofacial clefts	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	14.5 (-12.7 to 47.0)	11.8 (-15.4 to 43.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.0 (-28.4 to 57.0)	5.8 (-27.5 to 51.4)
Down syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	14.9 (-12.3 to 55.1)	8.0 (-17.8 to 45.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.6 (-10.6 to 61.6)	10.1 (-16.9 to 50.2)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.4 (-30.3 to 55.8)	-0.1 (-34.7 to 46.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.4 (-30.7 to 59.9)	0.4 (-35.6 to 49.3)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.1 (-20.2 to 61.4)	3.8 (-26.1 to 50.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.2 (-28.1 to 92.0)	2.6 (-34.6 to 76.1)
Chromosomal unbalanced rearrangements	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	121.7 (-13.4 to 38.4)	5.7 (-19.7 to 30.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.4 (-10.5 to 44.8)	7.9 (-17.4 to 35.2)
Other congenital anomalies	0.3 (0.3 to 0.4)	0.3 (0.3 to 0.4)	-5.1 (-14.9 to 5.6)	-13.4 (-21.7 to -4.3)	0.1 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-6.1 (-57.7 to 90.2)	-10.2 (-59.4 to 82.2)
Skin and subcutaneous diseases	-	-	-	-	0.6 (0.4 to 0.9)	0.6 (0.4 to 1.0)	9.2 (-0.6 to 18.5)	-0.3 (-8.0 to 7.5)
Dermatitis	5.3 (4.3 to 6.2)	5.9 (4.9 to 6.8)	11.4 (9.5 to 14.0)	0.0 (-0.0 to 0.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	9.3 (5.3 to 13.1)	0.2 (-2.4 to 2.7)
Psoriasis	0.6 (0.5 to 0.7)	0.7 (0.6 to 0.8)	16.1 (14.5 to 18.1)	0.0 (-0.1 to 0.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	15.8 (8.4 to 24.0)	0.0 (-5.2 to 6.4)
Cellulitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.5 (-21.3 to -5.8)	-25.9 (-33.5 to -17.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.9 (-35.1 to 12.1)	-24.6 (-40.0 to -7.3)
Pyoderma	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-53.5 (-60.5 to -44.2)	-51.9 (-59.0 to -42.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-53.7 (-61.6 to -42.9)	-52.1 (-60.1 to -42.2)
Scabies	2.1 (1.5 to 3.2)	1.8 (1.4 to 2.5)	-14.4 (-49.2 to 42.5)	-23.2 (-54.6 to 30.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-14.3 (-49.0 to 15.4)	-23.0 (-54.0 to 31.3)
Fungal skin diseases	8.2 (7.2 to 11.5)	9.8 (9.4 to 12.9)	134.4 (118.8 to 152.4)	13.4 (-0.1 to 40.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	13.3 (11.5 to 15.2)	0.0 (-0.8 to 0.6)
Viral skin diseases	2.2 (1.7 to 2.7)	2.3 (1.8 to 2.8)	4.1 (0.7 to 8.4)	-0.1 (-2.1 to 2.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	4.1 (-0.4 to 9.9)	0.0 (-3.2 to 3.8)
Acne vulgaris	7.4 (5.3 to 9.3)	7.7 (5.9 to 9.7)	2.2 (-29.6 to 58.5)	2.4 (-28.6 to 52.4)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	2.1 (-29.7 to 59.5)	2.1 (-28.8 to 52.8)
Alopecia areata	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	20.6 (1.5 to 45.0)	2.0 (-13.2 to 21.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.4 (-1.8 to 48.1)	2.5 (-15.2 to 24.3)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.8 (9.1 to 41.6)	-4.2 (-24.3 to 21.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.3 (-13.9 to 54.2)	-3.5 (-26.1 to 27.2)
Urticaria	0.8 (0.5 to 1.0)	1.0 (0.8 to 1.3)	35.6 (-4.9 to 110.1)	16.8 (-20.1 to 76.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	35.2 (-5.4 to 110.7)	17.1 (-20.6 to 78.8)
Decubitus ulcer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.6 (-16.5 to 69.0)	-13.0 (-38.4 to 33.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.2 (-22.7 to 67.4)	-14.5 (-41.8 to 37.2)
Other skin and subcutaneous diseases	5.8 (3.9 to 8.4)	6.9 (4.6 to 10.0)	18.8 (10.6 to 25.5)	-2.3 (-7.3 to 1.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	18.7 (10.2 to 25.5)	-2.3 (-7.1 to 1.8)
Sense organ diseases	-	-	-	-	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.9)	14.5 (9.6 to 19.6)	-9.6 (-12.7 to -6.7)
Glaucoma	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	18.6 (-7.7 to 40.4)	-14.5 (-32.7 to 5.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.8 (-23.5 to 35.4)	-26.9 (-47.1 to -6.3)
Cataract	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	10.7 (-10.0 to 46.2)	-29.3 (-43.8 to -11.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.6 (-6.8 to 45.3)	-26.2 (-39.7 to -10.0)
Macular degeneration	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	25.2 (0.3 to 71.7)	-7.1 (-24.6 to 24.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.8 (5.3 to 64.4)	-9.6 (-27.3 to 12.5)
Uncorrected refractive error	5.2 (4.7 to 5.6)	6.2 (5.8 to 6.7)	20.6 (8.2 to 34.1)	3.8 (-12.3 to 5.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	14.3 (4.3 to 24.6)	-7.8 (-15.4 to -0.6)
Age-related and other hearing loss	11.6 (10.8 to 12.3)	13.5 (12.7 to 14.4)	17.1 (12.8 to 20.8)	-9.1 (-12.1 to -6.5)	0.4 (0.2 to 0.5)	0.4 (0.3 to 0.6)	15.7 (9.1 to 22.7)	-9.9 (-13.5 to -6.0)
Other vision loss	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-3.0 (-16.6 to 12.6)	-20.5 (-33.1 to -6.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.9 (-19.0 to 11.9)	-23.4 (-35.3 to -10.9)
Other sense organ diseases	2.3 (2.2 to 2.4)	2.5 (2.4 to 2.6)	10.5 (2.4 to 18.0)	0.5 (-5.8 to 7.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	10.1 (1.6 to 19.0)	0.6 (-6.3 to 8.1)
Oral disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	7.6 (3.2 to 13.4)	-14.1 (-18.5 to -8.9)
Deciduous caries	11.6 (11.3 to 11.8)	11.6 (11.3 to 11.8)	-0.1 (-2.6 to 2.9)	0.1 (-2.4 to 3.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.1 (-5.8 to 6.2)	0.2 (-5.7 to 6.3)
Permanent caries	29.9 (28.6 to 31.3)	34.1 (31.8 to 36.2)	13.9 (4.5 to 22.3)	1.7 (-5.7 to 8.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	13.8 (4.2 to 22.4)	1.8 (-5.9 to 8.9)
Periodontal diseases	0.7 (0.7 to 0.8)	0.9 (0.9 to 1.0)	31.2 (21.0 to 42.8)	1.8 (-5.9 to 9.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.1 (20.1 to 43.2)	1.8 (-6.3 to 10.2)

Appendix Table G.4 - Tonga prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	1.2 (1.1 to 1.2)	1.1 (1.0 to 1.1)	-8.0 (-14.6 to -0.5)	-34.3 (-38.9 to -28.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.5 (-15.2 to -0.6)	-34.3 (-39.1 to -28.7)
Other oral disorders	1.5 (1.4 to 1.5)	1.7 (1.6 to 1.8)	14.2 (5.7 to 24.3)	-0.4 (-7.4 to 7.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	14.0 (5.4 to 24.8)	-0.4 (-7.1 to 8.5)
Injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	2.2 (7.5 to 13.5)	-16.7 (-24.4 to -7.8)
Transport injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	3.0 (9.8 to 18.5)	-15.7 (-25.3 to -3.8)
Road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	4.6 (9.0 to 21.0)	-14.1 (-24.5 to -1.8)
Pedestrian road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.0 (8.4 to 26.6)	-10.7 (-22.3 to 3.2)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.9 (1.0 to 27.6)	-9.2 (-19.5 to 3.1)
Motorcyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.3 (-11.9 to 16.7)	-17.8 (-28.0 to -5.9)
Motor vehicle road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.8 (9.7 to 23.8)	-12.4 (-24.3 to 1.5)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.8 (-10.1 to 19.8)	-16.6 (-27.6 to -5.5)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.4 (-16.2 to 6.4)	-23.5 (-32.0 to -14.1)
Unintentional injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	6.2 (2.6 to 15.3)	-14.2 (-21.2 to -7.1)
Falls	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	1.3 (-10.0 to 12.5)	-21.3 (-29.9 to -12.4)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.8 (-33.1 to -9.7)	-34.0 (-42.2 to -23.7)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.3 (-41.6 to -22.8)	-43.8 (-50.4 to -35.7)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.0 (-34.3 to -6.6)	-31.0 (-40.9 to -19.8)
Exposure to mechanical forces	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.3 (10.4 to 28.1)	0.5 (-6.5 to 7.9)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.2 (-35.8 to -19.6)	-39.7 (-45.6 to -32.7)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.3 (-5.6 to 16.0)	-11.0 (-19.5 to -2.1)
Other exposure to mechanical forces	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.5 (14.2 to 32.7)	4.1 (-3.1 to 11.8)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.8 (19.8 to 35.6)	5.0 (-1.7 to 11.2)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.7 (-7.9 to 12.2)	-16.4 (-23.5 to -8.8)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.9 (-5.1 to 22.7)	-10.1 (-19.9 to 0.2)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.3 (-13.0 to 8.1)	-21.1 (-28.5 to -12.3)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-6.8 (-15.1 to 3.1)	-21.8 (-28.5 to -14.3)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.5 (-41.8 to -14.0)	-37.2 (-47.1 to -25.0)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.7 (-2.7 to 13.2)	-10.2 (-17.0 to -2.8)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.5 (-6.3 to 14.9)	-18.1 (-25.4 to -10.1)
Other unintentional injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.9 (11.4 to 34.3)	-1.2 (-8.7 to 9.3)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.7 (-35.7 to -17.9)	-40.1 (-46.6 to -32.4)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.0 (-21.9 to 0.4)	-28.6 (-36.8 to -20.1)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.2 (-41.4 to -22.6)	-44.3 (-51.1 to -35.9)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.6 (-30.2 to -13.8)	-34.8 (-40.8 to -27.8)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.5 (-34.4 to -14.2)	-38.2 (-45.8 to -29.1)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.2 (-45.8 to -26.6)	-47.6 (-54.5 to -39.2)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.1 (-63.2 to -9.5)	-42.2 (-63.6 to -21.3)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.1 (-63.2 to -9.5)	-42.2 (-63.6 to -21.3)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Trinidad and Tobago prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	110.0 (81.4 to 143.1)	145.6 (108.7 to 189.9)	33.4 (29.2 to 35.5)	33.4 (-1.0 to 3.3)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	14.5 (10.2 to 19.9)	13.4 (9.4 to 18.4)	-1.0 (-14.0 to -0.5)	0.4 (-6.1 to 7.8)
HIV/AIDS and tuberculosis	-	-	-	-	0.5 (0.3 to 0.8)	1.0 (0.5 to 1.9)	103.8 (22.6 to 208.7)	49.6 (9.9 to 127.7)
Tuberculosis	0.6 (0.6 to 0.6)	0.7 (0.6 to 0.7)	16.7 (10.8 to 22.5)	-15.5 (-19.4 to -11.3)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	15.9 (3.1 to 31.4)	-15.3 (-24.0 to -5.6)
HIV/AIDS	-	-	-	-	0.3 (0.1 to 0.6)	0.8 (0.3 to 1.6)	34.5 (25.7 to 350.0)	34.5 (7.3 to 237.9)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.8 (-43.2 to 182.6)	6.7 (-59.9 to 104.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.8 (-43.3 to 185.4)	6.7 (-60.0 to 106.7)
HIV/AIDS resulting in other diseases	2.5 (1.4 to 4.1)	8.5 (5.2 to 12.9)	252.8 (112.6 to 415.3)	174.2 (64.7 to 301.7)	0.3 (0.1 to 0.6)	0.8 (0.3 to 1.6)	162.9 (25.6 to 350.9)	95.5 (7.1 to 240.7)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	2.2 (1.5 to 3.0)	1.8 (1.2 to 2.6)	-15.2 (-21.7 to -8.2)	-11.6 (-17.9 to -4.7)
Diarrheal diseases	4.8 (4.4 to 5.1)	4.0 (3.7 to 4.2)	-16.4 (-23.7 to -7.3)	-4.2 (-12.1 to 4.8)	0.8 (0.5 to 1.1)	0.6 (0.4 to 0.9)	-17.6 (-25.6 to -7.4)	-4.6 (-13.4 to 5.8)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-67.5 (-67.5 to -18.0)	-66.0 (-66.0 to -14.3)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.0 (-45.0 to -19.0)	-29.9 (-42.5 to -16.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.0 (-45.0 to -19.0)	-29.9 (-42.5 to -16.3)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.7 (-45.8 to -15.3)	-26.8 (-42.0 to -10.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.7 (-45.8 to -15.3)	-26.9 (-42.1 to -9.9)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.4 (-99.7 to 367.7)	-9.2 (-99.7 to 369.1)
Lower respiratory infections	0.7 (0.6 to 0.9)	0.5 (0.3 to 0.6)	-34.2 (-60.8 to -6.4)	-34.7 (-59.0 to -10.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-35.8 (-62.7 to -7.5)	-34.8 (-60.0 to -9.1)
Upper respiratory infections	62.8 (56.6 to 69.1)	62.9 (57.2 to 69.4)	0.2 (-12.8 to 14.5)	-2.0 (-14.4 to 12.1)	0.7 (0.4 to 1.2)	0.7 (0.4 to 1.2)	-0.6 (-13.2 to 13.9)	-2.2 (-14.4 to 11.9)
Otitis media	14.4 (13.5 to 15.3)	12.3 (11.6 to 13.0)	-14.6 (-20.5 to -7.4)	-11.4 (-17.3 to -4.6)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.4)	-16.2 (-23.4 to -8.0)	-12.6 (-20.0 to -4.6)
Meningitis	-	-	-	-	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-49.9 (-61.6 to -33.0)	-53.1 (-63.8 to -37.1)
Pneumococcal meningitis	1.2 (0.7 to 1.9)	0.5 (0.2 to 0.9)	-56.9 (-65.3 to -46.6)	-63.9 (-70.9 to -55.1)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-51.1 (-68.8 to -32.1)	-59.2 (-70.7 to -35.6)
H influenzae type B meningitis	0.4 (0.1 to 1.0)	0.2 (0.1 to 0.4)	-57.4 (-73.5 to -30.3)	-60.7 (-74.6 to 2.6)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-47.8 (-71.9 to 19.3)	-47.3 (-71.3 to 20.0)
Meningococcal meningitis	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-57.3 (-74.0 to -32.3)	-64.6 (-76.8 to -39.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.6 (-71.7 to -21.7)	-59.9 (-74.3 to -30.4)
Other meningitis	0.5 (0.2 to 1.0)	0.2 (0.1 to 0.5)	-50.5 (-62.5 to -31.3)	-57.0 (-67.3 to -35.9)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-43.4 (-59.0 to -15.5)	-47.8 (-62.3 to -21.8)
Encephalitis	0.1 (0.1 to 0.4)	0.1 (0.1 to 0.3)	-14.7 (-38.2 to 2.7)	-23.6 (-50.1 to -16.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.3 (-32.8 to 11.0)	-27.2 (-44.0 to -8.9)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.5 (-92.7 to 442.0)	-30.2 (-92.3 to 480.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.5 (-92.7 to 445.8)	-30.2 (-92.3 to 483.0)
Whooping cough	0.5 (0.4 to 0.6)	0.2 (0.2 to 0.4)	-34.2 (-34.3 to -34.0)	-9.3 (-9.6 to -9.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.9 (-42.3 to -26.5)	-9.1 (-20.2 to 1.2)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-73.1 (-85.1 to -51.0)	-75.2 (-86.4 to -54.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-74.7 (-88.5 to -48.3)	-75.4 (-88.6 to -50.7)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Varicella and herpes zoster	0.9 (0.8 to 1.0)	0.9 (0.8 to 1.1)	2.0 (-13.4 to 23.7)	-0.1 (-15.8 to 22.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	42.8 (4.2 to 107.9)	-0.9 (-27.7 to 44.1)
Neglected tropical diseases and malaria	-	-	-	-	0.7 (0.4 to 1.0)	0.5 (0.3 to 0.8)	-31.5 (-45.4 to 0.3)	-14.8 (-32.2 to 18.5)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.7 (-50.2 to 82.7)	4.3 (-48.3 to 92.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.7 (-49.3 to 91.0)	8.5 (-47.5 to 99.6)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.2 (-69.2 to 102.5)	-17.7 (-63.9 to 100.4)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.3 (-69.2 to 100.4)	-17.6 (-64.0 to 100.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.3 (-69.4 to 104.2)	-17.6 (-64.1 to 101.5)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.4 (-59.7 to 40.2)	-31.4 (-62.6 to 23.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.4 (-60.2 to 40.7)	-31.4 (-62.9 to 23.2)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.3 (0.1 to 0.5)	0.0 (0.0 to 0.1)	-85.9 (-95.5 to -35.5)	-89.7 (-96.3 to -54.4)	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-84.0 (-95.0 to -23.0)	-88.2 (-95.9 to -46.5)
Cystic echinococcosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-4.5 (-12.6 to 3.4)	-36.4 (-41.4 to -29.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.9 (-25.8 to 19.9)	-34.9 (-49.9 to -17.9)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.2 (0.0 to 0.6)	0.5 (0.1 to 1.8)	213.2 (187.6 to 245.2)	193.5 (169.6 to 223.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.3)	207.2 (139.0 to 334.9)	189.9 (128.6 to 305.0)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.7 (-56.0 to -4.9)	-42.0 (-58.7 to -14.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-36.7 (-56.0 to -4.8)	-42.0 (-58.7 to -14.3)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-	-
Ascariasis	10.3 (7.1 to 17.3)	10.1 (7.5 to 13.9)	0.0 (-45.2 to 61.1)	-10.5 (-46.1 to 42.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-99.9 (-100.0 to -98.5)	-99.9 (-100.0 to -98.4)
Trichuriasis	31.9 (24.3 to 42.5)	36.2 (26.1 to 49.6)	13.4 (-26.0 to 67.5)	-0.3 (-35.2 to 50.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.2 (-90.7 to 1,190.1)	-3.4 (-92.0 to 1,091.8)
Hookworm disease	11.1 (8.7 to 14.1)	12.4 (9.6 to 16.0)	12.7 (-21.6 to 58.5)	12.7 (-32.1 to 40.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-43.0 to 104.0)	0.0 (-43.2 to 96.0)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	14.9 (11.6 to 18.3)	11.0 (10.4 to 11.6)	-26.1 (-39.6 to -5.6)	-5.4 (-22.0 to 19.1)	0.5 (0.3 to 0.8)	0.4 (0.2 to 0.5)	-32.4 (-40.0 to -2.7)	-4.9 (-15.6 to 36.2)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Maternal hemorrhage	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.5 (24.4 to 55.0)	18.2 (7.9 to 34.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-27.1 (11.5 to 69.7)	17.0 (-2.7 to 47.5)
Maternal sepsis and other maternal infections	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-15.6 (-34.8 to 11.4)	-32.1 (-46.9 to -10.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.3 (-41.1 to -0.7)	-33.8 (-47.8 to -14.5)
Maternal hypertensive disorders	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-19.7 (-22.1 to -6.5)	-19.7 (-26.9 to -12.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.5 (-39.5 to 16.8)	-20.5 (-43.5 to 9.8)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.2 (-51.1 to 39.2)	-14.5 (-53.4 to 31.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.2 (-51.1 to 39.3)	-14.5 (-53.5 to 31.7)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.4 (-51.2 to 46.4)	-16.9 (-54.9 to 35.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.4 (-51.4 to 46.5)	-16.9 (-54.9 to 35.8)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Neonatal disorders	-	-	-	-	2.2 (1.5 to 3.0)	2.9 (2.0 to 4.0)	33.7 (-1.7 to 81.1)	36.0 (0.1 to 83.0)
Preterm birth complications	5.9 (3.2 to 10.5)	13.0 (7.0 to 24.6)	120.1 (64.6 to 193.3)	111.1 (60.0 to 182.2)	0.7 (0.4 to 1.1)	1.4 (0.9 to 2.0)	91.0 (19.3 to 224.4)	89.9 (19.0 to 224.8)
Neonatal encephalopathy due to birth asphyxia and trauma	7.4 (2.6 to 18.3)	6.9 (2.2 to 17.4)	-6.4 (-30.2 to 16.8)	-10.0 (-29.8 to 12.7)	0.8 (0.5 to 1.1)	0.6 (0.4 to 0.9)	-20.3 (-52.1 to 23.1)	-16.6 (-49.3 to 29.0)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	130.3 (85.4 to 195.5)	130.3 (141.5 to 285.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	128.8 (78.0 to 195.2)	198.3 (131.9 to 284.7)
Hemolytic disease and other neonatal jaundice	1.2 (0.6 to 2.7)	1.1 (0.5 to 2.1)	-4.6 (-70.9 to 148.7)	-3.6 (-70.4 to 151.2)	0.5 (0.2 to 0.9)	0.4 (0.2 to 0.8)	-0.5 (-69.8 to 153.2)	0.7 (-69.6 to 156.3)
Other neonatal disorders	-	-	-	-	0.2 (0.1 to 0.4)	0.5 (0.3 to 0.8)	106.8 (0.9 to 288.4)	110.8 (2.9 to 296.0)
Nutritional deficiencies	-	-	-	-	8.2 (5.5 to 11.9)	6.5 (4.3 to 9.4)	-20.9 (-24.3 to -18.3)	-8.1 (-11.5 to -5.0)
Protein-energy malnutrition	2.3 (1.3 to 3.7)	1.3 (0.7 to 2.2)	-41.7 (-73.3 to 24.5)	-24.2 (-64.2 to 58.0)	0.3 (0.1 to 0.5)	0.2 (0.1 to 0.3)	-41.6 (-73.6 to 24.5)	-23.9 (-64.7 to 63.2)
Iodine deficiency	1.3 (0.9 to 1.6)	1.0 (0.7 to 1.4)	-20.9 (-45.6 to 18.4)	-35.2 (-55.5 to -3.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.5 (-46.9 to 21.0)	-34.8 (-60.0 to -1.1)
Vitamin A deficiency	0.6 (0.4 to 0.7)	0.2 (0.2 to 0.3)	-58.3 (-65.5 to -48.2)	-53.4 (-61.4 to -42.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.8 (-66.1 to -48.5)	-54.6 (-63.3 to -44.1)

Appendix Table G.4 - Trinidad and Tobago prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	246.8 (243.4 to 249.8)	218.2 (215.2 to 221.1)	-11.6 (-13.0 to -10.1)	-6.9 (-8.2 to -5.6)	7.9 (5.3 to 11.4)	6.3 (4.2 to 9.2)	-20.0 (-22.6 to -18.3)	-7.2 (-9.6 to -5.6)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.7 (0.5 to 1.1)	0.7 (0.4 to 1.1)	-9.1 (-17.5 to 2.5)	-5.0 (-12.7 to 3.9)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	12.3 (-39.6 to 141.2)	-7.0 (-15.8 to 5.1)
Syphilis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	40.8 (18.6 to 67.8)	-13.3 (-25.8 to 2.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Chlamydial infection	34.2 (28.5 to 40.0)	35.1 (30.1 to 40.1)	2.6 (-18.3 to 29.6)	-7.7 (26.9 to 16.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	6.1 (-10.6 to 30.0)	-5.2 (-20.3 to 15.3)
Gonococcal infection	4.3 (3.3 to 5.4)	4.5 (3.6 to 5.6)	4.8 (-21.2 to 38.1)	-2.1 (-26.6 to 28.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.8 (-38.0 to 20.8)	-18.4 (-41.6 to 12.1)
Trichomoniasis	8.2 (5.4 to 12.0)	10.2 (6.7 to 15.2)	23.9 (-35.5 to 121.0)	3.1 (-44.2 to 90.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.2 (-39.6 to 141.2)	4.9 (-47.8 to 100.2)
Genital herpes	28.1 (26.7 to 293.9)	39.4 (35.4 to 396.9)	38.8 (23.3 to 44.2)	-6.5 (-13.4 to 1.4)	0.1 (0.0 to 0.2)	0.2 (0.0 to 0.2)	28.6 (16.2 to 41.2)	4.7 (-14.0 to 2.0)
Other sexually transmitted diseases	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-4.3 (-15.7 to 6.9)	-4.3 (-32.7 to -15.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.0 (7.9 to 63.9)	1.2 (-23.9 to 31.6)
Hepatitis	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-18.5 (-31.0 to 1.5)	-29.8 (-41.5 to -12.5)
Hepatitis A	1.4 (1.4 to 1.5)	1.1 (1.1 to 1.2)	-18.2 (-18.3 to -18.1)	-11.2 (-12.1 to -10.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-5.4 (-16.0 to 6.6)	-7.4 (-17.5 to 4.3)
Hepatitis B	59.7 (44.2 to 71.6)	35.4 (27.8 to 44.2)	-40.5 (-57.0 to -16.9)	-51.7 (-64.3 to -33.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-34.7 (-54.5 to -7.2)	-51.3 (-65.6 to -20.1)
Hepatitis C	20.0 (17.8 to 22.1)	20.3 (18.3 to 22.4)	1.2 (-13.3 to 16.2)	-27.3 (-37.6 to -16.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.5 (-24.1 to 46.1)	-24.0 (-45.3 to 8.9)
Hepatitis E	-	-	-	-	1.0 (-9.9 to 12.2)	-	-	-
Leprosy	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	57.2 (-25.0 to 448.8)	-2.0 (-53.4 to 261.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.7 (-31.0 to 647.3)	-0.4 (-57.0 to 399.6)
Other infectious diseases	10.7 (8.7 to 13.1)	8.3 (7.6 to 9.0)	-22.7 (-30.5 to -15.5)	-6.0 (-14.8 to 2.5)	0.4 (-0.2 to 0.5)	0.3 (0.2 to 0.4)	-22.7 (-33.4 to -7.8)	2.7 (-10.8 to 19.7)
Non-communicable diseases	-	-	-	-	89.3 (66.5 to 116.0)	41.6 (94.8 to 164.0)	46.4 (37.6 to 45.2)	41.1 (1.5 to 6.6)
Neoplasms	-	-	-	-	1.0 (0.7 to 1.3)	2.5 (1.8 to 3.3)	153.9 (119.0 to 204.4)	54.4 (31.9 to 83.4)
Esophageal cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	69.9 (27.6 to 125.9)	-5.5 (-29.3 to 25.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.8 (24.1 to 119.6)	-7.4 (-30.8 to 21.7)
Stomach cancer	0.4 (0.3 to 0.4)	0.4 (0.3 to 0.5)	9.7 (9.8 to 33.7)	-37.3 (-48.5 to -21.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	3.9 (-16.6 to 29.2)	-40.5 (-52.4 to -24.8)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-250.9 to 491.9)	0.0 (102.3 to 246.8)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	476.1 (147.6 to 961.8)	240.1 (44.3 to 540.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	407.2 (134.5 to 771.2)	199.2 (35.8 to 420.8)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,590.4 (811.9 to 3,174.3)	846.7 (411.0 to 1,762.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,400.2 (775.4 to 2,634.3)	740.4 (394.5 to 1,441.4)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	141.4 (40.9 to 298.9)	38.3 (-17.5 to 125.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.6 (35.2 to 213.5)	22.0 (-20.6 to 78.7)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.0 (29.2 to 262.3)	28.2 (-24.6 to 120.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	94.8 (22.5 to 196.7)	15.9 (-26.6 to 81.7)
Larynx cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	83.2 (36.5 to 141.5)	1.8 (-24.0 to 34.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.8 (36.0 to 150.4)	3.0 (-23.8 to 40.2)
Tracheal, bronchus and lung cancer	0.2 (0.2 to 0.2)	0.4 (0.4 to 0.5)	92.5 (56.9 to 132.5)	8.3 (-11.4 to 29.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	78.8 (40.7 to 120.2)	0.9 (-19.6 to 24.9)
Breast cancer	1.4 (1.2 to 1.6)	2.9 (2.3 to 3.6)	113.9 (68.9 to 175.5)	27.7 (1.0 to 64.7)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	98.7 (58.0 to 154.6)	19.2 (5.4 to 52.7)
Cervical cancer	0.8 (0.6 to 1.0)	0.9 (0.7 to 1.2)	12.3 (-17.2 to 58.0)	-93.3 (-51.1 to -6.0)	0.1 (-18.4 to 54.9)	0.1 (0.0 to 0.1)	34.6 (-15.4 to 54.9)	-24.6 (-51.4 to -9.1)
Uterine cancer	0.5 (0.3 to 0.8)	0.3 (0.7 to 1.9)	186.2 (44.4 to 365.2)	58.8 (-19.6 to 152.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	178.0 (37.1 to 350.5)	53.9 (-23.5 to 145.5)
Prostate cancer	2.2 (1.4 to 3.0)	10.0 (6.5 to 14.5)	359.8 (220.8 to 562.1)	160.5 (81.1 to 266.7)	0.2 (0.1 to 0.4)	1.0 (0.6 to 1.5)	307.8 (190.6 to 462.9)	135.3 (66.5 to 221.4)
Colon and rectum cancer	1.0 (1.0 to 1.1)	2.7 (2.3 to 3.1)	159.6 (122.0 to 206.0)	46.4 (24.4 to 72.6)	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	142.3 (104.1 to 186.0)	37.0 (14.9 to 61.6)
Lip and oral cavity cancer	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	59.6 (15.4 to 136.5)	-10.1 (-34.5 to 34.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	57.5 (11.4 to 127.5)	-11.5 (-36.8 to 28.9)
Nasopharynx cancer	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	13.0 (-23.1 to 69.2)	-29.0 (-51.1 to 4.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.0 (-22.3 to 60.8)	31.6 (-51.6 to -1.0)
Other pharynx cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	66.6 (10.1 to 161.3)	-8.8 (-39.9 to 39.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.8 (5.1 to 153.0)	-11.2 (-42.1 to 38.5)
Gallbladder and biliary tract cancer	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-38.7 (-62.6 to 73.6)	-65.7 (-79.0 to -1.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-40.3 (-63.1 to 75.6)	66.7 (-79.3 to 1.2)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	630.6 (480.5 to 818.1)	317.8 (229.3 to 428.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	564.0 (430.6 to 720.9)	274.0 (197.7 to 370.1)
Malignant skin melanoma	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	-6.6 (-29.5 to 66.9)	-60.8 (-55.3 to 6.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.1 (-31.7 to 72.1)	41.4 (-56.9 to 9.8)
Non-melanoma skin cancer	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.5)	175.6 (115.4 to 261.6)	61.3 (23.2 to 115.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	218.6 (125.4 to 345.2)	85.5 (28.1 to 170.9)
Ovarian cancer	0.1 (0.1 to 0.1)	0.3 (0.3 to 0.4)	423.6 (288.1 to 611.0)	223.3 (139.2 to 331.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	396.1 (248.9 to 608.8)	206.2 (121.1 to 343.5)
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	490.4 (45.6 to 1,126.3)	356.6 (15.5 to 853.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	463.9 (33.0 to 1,234.1)	335.5 (2.9 to 887.0)
Kidney cancer	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.5)	39.2 (9.6 to 84.1)	-17.0 (-35.0 to 8.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.9 (3.9 to 78.6)	19.6 (-37.8 to 6.6)
Bladder cancer	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	83.3 (41.3 to 189.3)	1.9 (-21.8 to 60.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.9 (28.8 to 167.7)	-5.6 (-29.1 to 48.4)
Brain and nervous system cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	354.7 (82.3 to 542.4)	271.2 (51.6 to 430.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	367.6 (84.4 to 526.4)	254.0 (39.9 to 375.6)
Thyroid cancer	0.6 (0.4 to 0.7)	1.1 (0.8 to 1.4)	89.0 (40.1 to 178.2)	29.0 (-4.5 to 89.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	88.2 (36.7 to 178.6)	26.7 (-6.5 to 88.9)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	207.4 (128.1 to 311.8)	75.9 (-29.3 to 142.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	222.5 (136.9 to 344.5)	86.3 (34.4 to 161.9)
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	976.1 (56.2 to 1,625.2)	817.6 (29.0 to 1,351.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	974.8 (44.3 to 1,525.1)	779.1 (15.3 to 1,202.4)
Non-Hodgkin lymphoma	0.5 (0.3 to 0.6)	1.0 (0.8 to 1.2)	103.6 (58.7 to 195.0)	33.0 (3.5 to 91.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	93.9 (48.1 to 180.3)	25.5 (-2.7 to 77.7)
Multiple myeloma	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	183.9 (88.1 to 339.6)	57.7 (3.7 to 146.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	168.5 (72.0 to 323.6)	49.7 (-4.7 to 138.8)
Leukemia	0.3 (0.2 to 0.4)	0.4 (0.4 to 0.6)	27.6 (18.2 to 119.5)	27.6 (-2.3 to 78.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	65.5 (28.4 to 113.9)	20.2 (-4.7 to 58.5)
Other neoplasms	1.1 (0.9 to 1.4)	3.5 (2.8 to 4.5)	206.0 (140.0 to 294.0)	124.4 (79.6 to 187.5)	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	197.1 (135.6 to 279.6)	112.7 (70.5 to 166.8)
Cardiovascular diseases	-	-	-	-	1.3 (0.9 to 1.8)	3.0 (2.1 to 4.1)	127.4 (83.3 to 181.5)	31.7 (9.8 to 60.4)
Rheumatic heart disease	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.6 (21.9 to 66.8)	-6.2 (-20.7 to 8.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.0 (22.5 to 70.7)	-6.2 (-20.2 to 9.9)
Ischemic heart disease	7.1 (6.1 to 8.3)	23.6 (18.6 to 31.1)	230.8 (153.6 to 361.6)	80.4 (38.6 to 146.4)	0.3 (0.2 to 0.5)	1.3 (0.8 to 1.9)	280.5 (178.4 to 463.2)	186.8 (48.9 to 201.2)
Cerebrovascular disease	-	-	-	-	0.4 (0.3 to 0.5)	0.7 (0.5 to 0.9)	70.9 (38.0 to 107.8)	1.1 (-2.0 to 21.8)
Ischemic stroke	2.0 (1.7 to 2.4)	3.5 (3.0 to 4.1)	75.3 (36.3 to 110.7)	0.1 (-24.0 to 23.0)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	74.1 (35.2 to 110.9)	-0.3 (-24.0 to 22.2)
Hemorrhagic stroke	0.7 (0.6 to 0.8)	1.2 (0.9 to 1.5)	65.8 (22.5 to 131.5)	-2.1 (-28.1 to 35.6)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	65.8 (19.7 to 134.3)	-1.6 (-29.7 to 38.1)
Hypertensive heart disease	0.8 (0.7 to 0.8)	1.2 (1.1 to 1.3)	53.3 (34.0 to 77.6)	-13.1 (-24.4 to 0.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	53.3 (33.0 to 79.2)	-13.3 (-25.4 to 1.2)
Cardiomyopathy and myocarditis	0.4 (0.3 to 0.4)	0.6 (0.6 to 0.7)	73.6 (48.6 to 104.6)	6.4 (-10.1 to 26.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	73.3 (41.4 to 108.1)	6.5 (-13.2 to 29.6)
Atrial fibrillation and flutter	2.6 (2.1 to 3.1)	6.0 (5.1 to 7.2)	132.5 (81.6 to 206.6)	33.9 (3.1 to 78.3)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	132.1 (82.5 to 206.8)	33.7 (3.6 to 77.5)
Peripheral vascular disease	29.4 (23.2 to 37.8)	56.8 (44.5 to 70.5)	95.1 (36.2 to 163.5)	6.4 (-23.6 to 40.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	59.7 (-42.8 to 219.0)	-7.0 (-66.0 to 91.9)
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.4 (8.4 to 52.9)	-15.9 (-38.6 to 3.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.7 (-1.2 to 53.6)	-15.8 (-41.0 to 3.6)
Other cardiovascular and circulatory diseases	3.7 (1.7 to 6.9)	5.6 (4.7 to 7.1)	57.2 (-20.2 to 234.9)	57.2 (-47.4 to 111.7)	0.3 (0.1 to 0.5)	0.4 (0.3 to 0.6)	57.8 (-20.6 to 245.8)	2.2 (-48.0 to 119.6)
Chronic respiratory diseases	-	-	-	-	4.7 (3.2 to 6.4)	8.1 (5.4 to 11.2)	71.4 (46.4 to 96.9)	18.6 (2.0 to 34.3)
Chronic obstructive pulmonary disease	49.9 (47.5 to 52.3)	78.3 (74.6 to 82.1)	56.9 (51.9 to 62.7)	-0.2 (-3.3 to 3.4)	3.0 (2.0 to 4.2)	5.3 (3.4 to 7.4)	76.2 (51.3 to 104.7)	13.0 (-3.4 to 30.9)

Appendix Table G.4 - Trinidad and Tobago prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	56.8	-4.1
Silicosis	0.0	0.0	46.4	-10.9	0.0	0.0	45.9	-11.1
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Coal workers pneumoconiosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Other pneumoconiosis	0.0	0.0	65.6	-	0.0	0.0	64.8	1.1
Asthma	30.9	53.2	71.9	44.8	1.4	2.3	70.9	45.4
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	72.9	5.0	0.0	0.0	72.8	4.9
Other chronic respiratory diseases	0.0	0.0	24.2	-	0.2	0.4	18.7	-24.0
Cirrhosis	0.0	0.0	21.2	-21.3	0.0	0.0	21.6	-18.3
Cirrhosis due to hepatitis B	0.0	0.0	47.6	65.2	0.0	0.0	48.9	66.1
Cirrhosis due to hepatitis C	0.1	0.1	81.0	18.0	0.0	0.0	79.6	18.0
Cirrhosis due to alcohol use	0.1	0.1	31.0	-21.4	0.0	0.0	30.9	-21.3
Cirrhosis due to other causes	0.1	0.1	52.0	31.4	0.0	0.0	48.0	29.5
Digestive diseases	0.0	0.0	27.3	17.5	1.6	2.5	51.8	1.2
Peptic ulcer disease	9.7	8.2	-15.3	-49.6	0.4	0.3	-9.6	-46.8
Gastritis and duodenitis	22.6	33.5	47.9	-0.5	0.8	1.1	34.9	-3.1
Appendicitis	0.0	0.0	-2.8	-7.4	0.0	0.0	-0.6	-6.2
Paralytic ileus and intestinal obstruction	0.0	0.0	27.3	-29.9	0.0	0.0	24.4	16.2
Inguinal, femoral, and abdominal hernia	3.8	3.5	-7.4	-46.3	0.0	0.0	-7.0	-45.8
Inflammatory bowel disease	1.3	2.4	86.8	27.3	0.3	0.5	85.6	27.2
Vascular intestinal disorders	0.0	0.0	50.7	-8.2	0.0	0.0	50.7	-8.2
Gallbladder and biliary diseases	0.8	0.8	11.6	-32.7	0.1	0.1	10.5	-33.3
Pancreatitis	0.1	0.2	119.7	50.5	0.0	0.1	118.9	51.4
Other digestive diseases	0.1	0.1	105.7	19.9	0.1	0.4	566.9	344.4
Neurological disorders	6.9	12.2	76.9	1.2	7.6	10.6	38.7	5.5
Alzheimer disease and other dementias	0.1	0.2	74.8	-1.1	0.0	0.0	75.0	-1.3
Parkinson disease	2.7	3.2	18.9	6.2	0.9	1.2	28.6	15.9
Epilepsy	0.1	0.2	170.2	86.6	0.0	0.1	160.7	80.8
Multiple sclerosis	0.1	0.2	144.8	69.1	0.0	0.0	113.6	48.2
Migraine	123.8	149.4	19.6	3.1	3.3	5.1	18.7	-9.1
Tension-type headache	243.2	305.3	25.1	1.4	0.4	0.5	24.5	1.3
Medication overuse headache	5.2	10.8	108.5	50.7	0.8	1.7	106.4	50.3
Other neurological disorders	0.0	0.0	25.2	2.6	0.2	0.3	41.5	-19.1
Mental and substance use disorders	3.2	4.5	40.3	-0.5	2.1	2.9	39.3	2.9
Schizophrenia	7.1	10.1	42.0	8.5	0.7	1.0	42.2	8.9
Alcohol use disorders	0.8	1.2	42.9	1.9	0.3	0.5	42.0	1.6
Drug use disorders	0.4	0.6	50.0	1.9	0.3	0.5	42.0	1.6
Opioid use disorders	0.4	0.6	50.0	1.9	0.3	0.5	42.0	1.6
Cocaine use disorders	2.3	2.3	0.0	-2.8	0.2	0.3	1.4	-3.1
Amphetamine use disorders	2.4	2.5	4.2	0.1	0.1	0.1	2.0	0.1
Cannabis use disorders	1.9	2.0	2.9	0.0	0.1	0.1	2.0	0.1
Other drug use disorders	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Depressive disorders	45.4	56.4	24.4	-0.9	9.4	11.5	23.3	-0.9
Major depressive disorder	14.4	20.4	41.6	0.0	1.4	2.0	40.7	-0.0
Dysthymia	8.9	11.5	29.0	-0.6	1.8	2.3	28.2	-0.8
Bipolar disorder	70.5	86.1	21.3	0.0	6.2	7.9	21.2	-0.1
Anxiety disorders	0.3	0.3	-0.9	4.0	0.1	0.1	-0.5	4.3
Eating disorders	0.3	0.3	-0.9	4.0	0.1	0.1	-0.5	4.3
Anorexia nervosa	1.5	1.5	0.6	-0.1	0.2	0.3	0.3	-0.2
Bulimia nervosa	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Autistic spectrum disorders	3.7	3.9	7.3	0.0	0.9	1.0	6.3	0.2
Autism	5.4	5.7	6.6	0.1	0.5	0.6	5.7	0.1
Asperger syndrome	9.7	7.2	-26.1	0.0	0.1	0.1	-26.1	0.1
Attention-deficit/hyperactivity disorder	12.8	6.5	-49.2	-27.6	0.0	0.0	-27.6	-49.2
Conduct disorder	3.4	2.6	-23.5	-21.6	0.2	0.1	-22.4	-26.3
Idiopathic intellectual disability	18.4	25.2	36.9	0.0	1.4	1.9	36.3	0.1
Other mental and substance use disorders	70.5	86.1	21.3	0.0	6.2	7.9	21.2	-0.1
Diabetes, urogenital, blood, and endocrine diseases	70.7	141.4	100.8	28.5	10.2	16.4	61.8	13.9
Diabetes mellitus	58.9	116.6	97.9	28.5	5.0	10.2	105.4	26.5
Acute glomerulonephritis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Chronic kidney disease	30.5	46.8	53.8	-3.6	1.6	2.2	33.9	-0.4
Chronic kidney disease due to diabetes mellitus	13.7	18.7	36.8	11.5	0.5	0.7	40.9	4.7
Chronic kidney disease due to hypertension	16.8	28.1	66.7	-15.1	1.1	1.5	43.0	-1.1
Chronic kidney disease due to glomerulonephritis	4.9	5.6	12.2	0.0	0.0	0.0	0.0	0.0
Chronic kidney disease due to other causes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Urinary diseases and male infertility	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Appendix Table G.4 - Trinidad and Tobago prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.3 (0.3 to 0.3)	0.4 (0.4 to 0.5)	61.7 (45.9 to 80.8)	30.5 (17.7 to 44.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.6 (32.9 to 97.3)	61.6 (9.1 to 58.4)
Urolithiasis	7.2 (5.2 to 10.1)	13.1 (5.8 to 25.2)	81.1 (-3.1 to 205.0)	-0.3 (-42.9 to 72.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	64.6 (7.9 to 180.6)	5.2 (-33.3 to 68.7)
Benign prostatic hyperplasia	6.6 (6.0 to 7.2)	11.6 (10.6 to 12.7)	73.9 (58.3 to 99.3)	-4.1 (-13.2 to 10.9)	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	74.4 (58.2 to 100.5)	-4.1 (-13.4 to 11.0)
Male infertility due to other causes	11.4 (9.4 to 13.5)	13.2 (11.2 to 15.7)	15.8 (9.7 to 52.3)	-0.8 (-22.7 to 30.7)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	15.9 (-10.3 to 53.9)	-0.4 (-22.5 to 32.5)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (-1.4 to 100.7)	0.0 (-37.2 to 25.0)
Gynecological diseases	-	-	-	-	1.6 (1.0 to 2.5)	2.0 (1.3 to 3.1)	23.5 (10.3 to 41.2)	-1.9 (-11.9 to 12.9)
Uterine fibroids	22.9 (20.6 to 24.9)	33.4 (30.4 to 36.1)	46.1 (44.4 to 48.3)	0.6 (0.6 to 0.7)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.7)	30.2 (14.8 to 43.3)	-4.8 (-15.3 to 4.6)
Polycystic ovarian syndrome	23.6 (20.5 to 26.3)	29.9 (26.5 to 33.1)	27.1 (7.4 to 51.9)	3.2 (-12.3 to 22.0)	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.6)	27.0 (7.1 to 52.7)	3.2 (-12.2 to 22.9)
Female infertility due to other causes	10.6 (8.3 to 13.0)	13.2 (9.8 to 17.4)	23.5 (-13.3 to 78.7)	1.7 (-29.4 to 46.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	23.8 (-13.3 to 77.4)	2.0 (-28.1 to 46.0)
Endometriosis	2.2 (1.9 to 2.6)	2.9 (2.5 to 3.4)	33.0 (6.6 to 63.0)	6.4 (-13.8 to 29.9)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	33.1 (4.2 to 63.1)	6.8 (-15.8 to 30.7)
Genital prolapse	63.1 (52.5 to 75.2)	94.7 (80.5 to 109.2)	50.5 (15.3 to 91.0)	2.2 (-20.2 to 29.3)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.6)	50.1 (14.9 to 91.0)	2.1 (-20.3 to 29.7)
Premenstrual syndrome	61.3 (47.2 to 73.9)	67.4 (48.1 to 88.0)	7.9 (-24.3 to 71.8)	-6.4 (-34.0 to 49.6)	0.5 (0.3 to 0.8)	0.6 (0.3 to 0.9)	7.3 (-25.6 to 69.4)	-6.6 (-35.3 to 50.5)
Other gynecological diseases	3.8 (3.1 to 4.5)	4.2 (3.8 to 4.6)	9.4 (-12.3 to 38.9)	-7.6 (-25.3 to 15.2)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.2)	1.9 (-18.6 to 61.6)	-11.2 (-29.6 to 37.5)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	1.2 (0.8 to 1.7)	1.1 (0.7 to 1.5)	7.3 (-13.1 to 0.4)	0.4 (-5.4 to 8.3)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.6 (-31.0 to -16.2)	0.0 (-8.0 to 11.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.5 (-36.8 to -20.0)	-3.3 (-14.5 to 7.8)
Thalassemia trait	12.7 (10.7 to 15.1)	13.7 (11.5 to 16.3)	8.0 (3.4 to 13.6)	-1.2 (-5.5 to 4.0)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	1.7 (-11.0 to 13.8)	2.7 (-10.1 to 15.4)
Sickle cell disorders	1.1 (0.9 to 1.2)	1.0 (0.9 to 1.1)	-2.8 (-12.1 to 9.7)	2.0 (-8.2 to 14.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	6.7 (-6.5 to 21.7)	4.0 (-8.5 to 18.1)
Sickle cell trait	93.2 (85.8 to 99.9)	104.4 (96.1 to 111.9)	11.9 (8.2 to 16.6)	2.3 (-1.1 to 6.6)	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.6)	27.7 (-17.9 to 11.4)	3.4 (-8.2 to 25.8)
G6PD deficiency	70.1 (58.5 to 83.1)	83.8 (66.9 to 99.8)	19.9 (-10.1 to 52.1)	10.2 (-17.3 to 40.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3.6 (-44.2 to 59.6)	4.7 (-43.5 to 60.7)
G6PD trait	204.5 (189.8 to 215.6)	227.7 (213.7 to 241.9)	11.1 (2.0 to 21.6)	0.7 (-7.5 to 10.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.3 (-76.3 to 556.2)	12.9 (-72.1 to 503.1)
Other hemoglobinopathies and hemolytic anemias	10.3 (9.4 to 11.2)	9.5 (8.9 to 10.2)	-7.0 (-17.5 to 3.6)	-8.3 (-17.5 to 1.3)	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-9.1 (-35.0 to -8.0)	-9.1 (-23.0 to 7.8)
Endocrine, metabolic, blood, and immune disorders	11.1 (10.0 to 11.9)	10.2 (9.6 to 10.9)	-7.5 (-15.9 to 3.5)	4.2 (-13.5 to 6.6)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-5.8 (-28.4 to 0.4)	-5.2 (-20.2 to 14.1)
Musculoskeletal disorders	-	-	-	-	14.6 (10.4 to 19.3)	23.4 (16.8 to 30.9)	60.3 (47.6 to 72.7)	5.6 (-1.9 to 12.6)
Rheumatoid arthritis	2.7 (2.6 to 2.8)	5.4 (5.2 to 5.6)	99.3 (87.2 to 114.0)	37.4 (28.7 to 47.9)	0.6 (0.5 to 0.9)	1.3 (0.9 to 1.7)	96.2 (80.7 to 114.8)	36.3 (26.1 to 49.2)
Osteoarthritis	35.5 (34.0 to 36.9)	64.4 (61.8 to 66.7)	81.5 (71.0 to 92.7)	2.1 (-3.8 to 8.1)	2.2 (1.5 to 2.9)	2.9 (2.8 to 5.3)	81.2 (70.4 to 92.1)	2.0 (-4.0 to 7.9)
Low back and neck pain	-	-	-	-	9.1 (6.3 to 12.4)	12.7 (8.7 to 17.2)	39.7 (20.3 to 58.0)	2.3 (-14.4 to 9.5)
Low back pain	49.5 (44.5 to 54.6)	68.6 (60.0 to 75.8)	38.5 (19.5 to 63.5)	-3.2 (-14.9 to 13.1)	5.5 (3.7 to 7.8)	7.6 (5.0 to 10.7)	36.9 (18.0 to 63.3)	-3.3 (-15.7 to 13.5)
Neck pain	36.0 (30.3 to 42.6)	51.7 (43.5 to 59.4)	44.9 (11.4 to 75.8)	-0.1 (-22.2 to 19.1)	3.6 (2.4 to 5.1)	5.1 (3.4 to 7.2)	44.0 (10.1 to 75.4)	-0.0 (-22.5 to 19.1)
Gout	0.4 (0.3 to 0.4)	0.6 (0.5 to 0.6)	62.1 (42.4 to 83.8)	-5.0 (-16.2 to 7.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.2 (26.2 to 104.6)	-5.2 (-25.7 to 21.0)
Other musculoskeletal disorders	29.1 (24.2 to 34.4)	60.2 (50.8 to 70.8)	106.8 (93.3 to 123.5)	26.6 (18.3 to 35.0)	2.7 (1.8 to 3.8)	5.5 (3.6 to 7.7)	105.4 (90.7 to 121.8)	25.9 (17.4 to 34.8)
Other non-communicable diseases	-	-	-	-	19.7 (13.2 to 28.6)	25.3 (17.0 to 36.8)	28.5 (24.3 to 32.5)	-5.8 (-8.3 to -3.2)
Congenital anomalies	-	-	-	-	1.3 (0.9 to 1.7)	1.5 (1.1 to 1.9)	16.8 (3.7 to 32.8)	7.8 (-4.7 to 23.1)
Neural tube defects	0.3 (0.3 to 0.4)	0.3 (0.2 to 0.3)	-17.6 (-32.2 to 2.3)	-11.8 (-27.3 to 9.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-19.4 (-40.4 to 10.9)	-12.7 (-35.3 to 21.0)
Congenital heart anomalies	5.4 (4.4 to 6.8)	5.8 (4.5 to 7.0)	7.7 (-29.9 to 46.2)	8.5 (-29.1 to 47.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	7.7 (-28.6 to 43.4)	9.9 (-26.5 to 46.1)
Orofacial clefts	0.9 (0.8 to 1.1)	0.9 (0.8 to 1.2)	-0.6 (-26.8 to 33.4)	6.9 (-21.1 to 44.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.4 (-36.6 to 40.2)	1.1 (-31.7 to 50.2)
Down syndrome	1.0 (0.9 to 1.3)	1.2 (1.0 to 1.5)	13.7 (-13.9 to 49.2)	2.6 (-22.0 to 34.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	2.6 (-7.0 to 66.0)	3.6 (-22.0 to 37.3)
Turner syndrome	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	4.6 (-30.4 to 63.5)	2.5 (-32.1 to 60.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.0 (-33.3 to 70.5)	2.1 (-35.2 to 64.8)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.6 (-21.6 to 48.2)	1.7 (-26.5 to 38.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.9 (-17.9 to 58.4)	1.3 (-27.7 to 38.1)
Chromosomal unbalanced rearrangements	2.0 (1.7 to 2.4)	2.3 (1.9 to 2.8)	14.3 (-10.3 to 48.1)	2.5 (-19.0 to 34.4)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.5)	24.5 (12.1 to 63.4)	4.6 (-18.7 to 35.2)
Other congenital anomalies	5.1 (4.3 to 5.9)	5.1 (4.3 to 6.0)	-0.4 (-10.2 to 10.3)	-11.9 (-20.0 to -2.3)	0.6 (0.4 to 0.8)	0.7 (0.5 to 1.0)	22.0 (-0.1 to 55.2)	13.4 (-6.4 to 44.2)
Skin and subcutaneous diseases	-	-	-	-	6.2 (4.0 to 9.6)	7.1 (4.5 to 10.5)	13.1 (5.4 to 21.1)	-0.6 (-6.5 to 5.6)
Dermatitis	58.0 (47.2 to 69.8)	69.0 (55.6 to 82.5)	18.8 (14.6 to 23.0)	-0.0 (-4.0 to -0.0)	1.6 (1.0 to 2.3)	1.8 (1.1 to 2.6)	13.7 (8.3 to 18.9)	0.0 (-2.6 to 2.5)
Psoriasis	0.7 (8.5 to 11.0)	12.8 (11.0 to 14.5)	31.1 (27.5 to 35.7)	0.0 (-0.0 to 0.0)	1.0 (0.5 to 1.1)	1.0 (0.7 to 1.5)	30.1 (22.4 to 38.6)	0.0 (-4.4 to 5.1)
Cellulitis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	10.4 (-6.3 to 27.8)	-13.0 (-22.7 to -3.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.6 (-13.9 to 36.5)	-12.7 (-28.6 to 5.5)
Pyoderma	0.4 (0.4 to 0.5)	0.6 (0.5 to 0.7)	39.9 (27.5 to 51.2)	22.5 (17.0 to 28.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.5 (18.9 to 61.6)	22.7 (8.0 to 39.8)
Scabies	15.8 (13.3 to 18.4)	15.7 (13.1 to 18.6)	-0.6 (-20.0 to 22.4)	-2.4 (-20.4 to 20.1)	0.4 (0.2 to 0.7)	0.4 (0.2 to 0.7)	-1.3 (-20.8 to 22.4)	-2.4 (-20.9 to 20.7)
Fungal skin diseases	89.3 (68.0 to 118.0)	109.0 (84.7 to 143.2)	22.4 (12.7 to 32.2)	0.0 (-0.0 to 0.0)	0.6 (0.2 to 1.1)	0.6 (0.2 to 1.3)	21.8 (12.1 to 31.4)	0.0 (-0.9 to 0.9)
Viral skin diseases	25.9 (19.3 to 32.4)	23.4 (16.7 to 30.3)	-9.9 (-15.8 to -3.3)	0.1 (-1.9 to 2.1)	0.8 (0.5 to 1.3)	0.7 (0.4 to 1.1)	-10.3 (-16.7 to -3.4)	0.0 (-3.4 to 3.3)
Acne vulgaris	87.7 (65.9 to 109.9)	75.9 (58.1 to 94.6)	-13.0 (-41.8 to 28.8)	-4.3 (-36.3 to 40.0)	1.0 (0.4 to 1.8)	0.8 (0.4 to 1.5)	-12.9 (-41.8 to 28.2)	-4.2 (-36.8 to 39.9)
Alopecia areata	1.1 (1.0 to 1.2)	1.4 (1.3 to 1.5)	22.9 (8.4 to 40.8)	-2.9 (-14.5 to 10.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-2.8 to 46.9)	-3.4 (-17.2 to 15.9)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.5 (10.1 to 76.9)	1.9 (-20.7 to 28.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.5 (9.7 to 76.9)	1.9 (-20.8 to 28.8)
Urticaria	12.4 (9.6 to 15.6)	17.0 (11.3 to 21.8)	38.6 (-11.2 to 95.1)	4.1 (-30.9 to 39.1)	0.7 (0.4 to 1.2)	1.0 (0.6 to 1.6)	38.7 (-12.1 to 96.6)	4.7 (-31.5 to 40.8)
Decubitus ulcer	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.2)	34.6 (-0.7 to 77.5)	-14.7 (-39.2 to 18.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.7 (-4.4 to 81.1)	-15.3 (-40.7 to 22.0)
Other skin and subcutaneous diseases	69.9 (45.9 to 106.9)	102.8 (63.3 to 166.1)	46.5 (30.3 to 61.7)	-1.7 (-5.9 to 2.2)	0.4 (0.2 to 0.9)	0.6 (0.3 to 1.3)	45.8 (29.6 to 61.3)	-1.7 (-6.2 to 2.3)
Sense organ diseases	-	-	-	-	8.3 (5.7 to 11.8)	11.5 (7.5 to 15.7)	33.6 (25.8 to 39.9)	-10.7 (-14.7 to -7.0)
Glaucoma	1.7 (1.4 to 2.0)	2.1 (1.7 to 2.6)	26.0 (11.1 to 44.8)	-20.0 (-29.8 to -7.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	33.9 (16.1 to 54.8)	-17.8 (-29.2 to -4.5)
Cataract	8.1 (6.2 to 9.9)	10.2 (8.0 to 12.4)	25.7 (12.9 to 40.1)	-28.5 (-35.6 to -20.6)	0.4 (0.3 to 0.6)	0.5 (0.4 to 0.8)	26.9 (13.7 to 41.0)	-27.8 (-35.6 to -20.1)
Macular degeneration	1.7 (1.3 to 2.2)	3.5 (2.7 to 4.5)	104.8 (62.6 to 151.4)	11.5 (-11.5 to 38.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	102.0 (62.2 to 143.9)	10.0 (-11.2 to 34.0)
Uncorrected refractive error	107.7 (101.2 to 114.6)	150.8 (140.0 to 161.6)	39.7 (27.3 to 53.8)	7.3 (-15.2 to 11.0)	1.6 (1.0 to 2.6)	2.1 (1.3 to 3.0)	29.5 (20.9 to 40.0)	-12.3 (-17.7 to -5.5)
Age-related and other hearing loss	165.1 (153.9 to 177.0)	242.7 (228.2 to 258.0)	46.9 (41.5 to 53.5)	-9.4 (-12.2 to -5.8)	5.1 (3.4 to 7.1)	7.0 (4.8 to 9.8)	39.7 (27.7 to 50.2)	8.6 (-14.8 to -2.7)
Other vision loss	3.6 (3.0 to 4.2)	3.3 (2.7 to 3.9)	-7.3 (-17.5 to 3.6)	-32.5 (-38.2 to -26.2)	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.4)	4.6 (-7.4 to 17.4)	-30.5 (-37.7 to -23.8)
Other sense organ diseases	28.3 (26.9 to 29.7)	30.7 (29.2 to 32.0)	8.6 (1.2 to 15.9)	-0.4 (-6.7 to 5.9)	0.8 (0.5 to 1.1)	0.8 (0.5 to 1.2)	7.5 (-0.9 to 15.4)	-0.3 (-7.3 to 6.9)
Oral disorders	-	-	-	-	3.8 (2.3 to 5.9)	5.6 (3.5 to 8.6)	46.6 (41.2 to 52.2)	-4.1 (-7.3 to 1.8)
Deciduous caries	95.0 (90.9 to 98.9)	62.4 (59.3 to 65.4)	-34.4 (-38.5 to -29.4)	-0.1 (-6.3 to 7.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-24.2 (-39.6 to -28.4)	0.1 (-8.1 to 8.8)
Permanent caries	538.9 (516.4 to 561.0)	608.9 (587.1 to 633.2)	13.0 (7.1 to 18.6)	0.7 (-4.1 to 5.6)	0.5 (0.2 to 1.0)	0.6 (0.3 to 1.2)	12.5 (6.8 to 18.1)	0.7 (-4.2 to 5.8)
Periodontal diseases	125.8 (120.4 to 131.8)	188.9 (180.0 to 198.0)	50.1 (40.8 to 60.5)	-2.7 (-8.5 to 4.3)	0.8 (0.3 to 1.7)	1.2 (0.5 to 2.5)	49.5 (40.3 to 60.1)	-2.7 (-8.7 to 4.2)

Appendix Table G.4 - Trinidad and Tobago prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	67.1 (64.9 to 69.3)	109.8 (106.0 to 113.3)	63.7 (55.5 to 71.1)	-6.3 (-10.8 to -2.3)	1.9 (1.3 to 2.6)	3.0 (2.1 to 4.2)	63.5 (54.9 to 71.1)	64 (-11.1 to -2.3)
Other oral disorders	20.2 (19.1 to 21.3)	25.3 (23.8 to 26.7)	25.4 (15.0 to 34.8)	-0.0 (-7.8 to 7.1)	6.2 (4.7 to 8.0)	5.9 (4.2 to 7.9)	-6.0 (-15.6 to 5.2)	-36.0 (-8.1 to 7.3)
Injuries	-	-	-	-	2.2 (1.6 to 2.8)	2.2 (1.6 to 3.0)	1.7 (-11.3 to 18.0)	-30.7 (-38.9 to -20.5)
Transport injuries	-	-	-	-	2.1 (1.5 to 2.7)	2.0 (1.4 to 2.7)	5.8 (-15.4 to 13.3)	-33.5 (-41.5 to -23.4)
Road injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.5 (0.3 to 0.6)	-14.9 (-26.9 to 1.1)	-41.7 (-49.2 to -31.5)
Pedestrian road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	5.1 (-6.7 to 18.9)	-30.1 (-37.3 to -21.5)
Cyclist road injuries	-	-	-	-	0.3 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-5.8 (-18.9 to 8.8)	-35.3 (-43.7 to -26.0)
Motorcyclist road injuries	-	-	-	-	1.1 (0.8 to 1.4)	1.1 (0.8 to 1.5)	9.8 (-11.1 to 21.9)	-29.0 (-38.4 to -17.3)
Motor vehicle road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-13.9 (-25.0 to 0.0)	-42.9 (-49.8 to -34.2)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	66.2 (48.1 to 89.5)	9.7 (-1.7 to 24.4)
Other transport injuries	-	-	-	-	3.7 (2.8 to 4.8)	3.3 (2.4 to 4.4)	-10.6 (-18.3 to -1.9)	-39.4 (-44.7 to -33.2)
Unintentional injuries	-	-	-	-	1.5 (1.2 to 2.0)	1.4 (1.0 to 1.9)	-8.6 (-18.9 to -4.6)	-43.3 (-49.9 to -35.1)
Falls	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.2 (-28.2 to -1.6)	-40.2 (-48.2 to -30.5)
Drowning	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-34.0 (-43.3 to -23.2)	-51.0 (-57.4 to -43.5)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.0 (-31.3 to -3.3)	-33.9 (-44.0 to -22.2)
Poisonings	-	-	-	-	1.5 (1.1 to 1.9)	1.2 (0.8 to 1.6)	-21.0 (-27.7 to -14.0)	-39.0 (-43.7 to -34.5)
Exposure to mechanical forces	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	39.1 (21.3 to 62.0)	1.2 (-11.2 to 15.5)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.4 (3.0 to 31.6)	-14.1 (-23.3 to -4.1)
Unintentional suffocation	-	-	-	-	1.4 (1.0 to 1.8)	1.0 (0.7 to 1.4)	-25.5 (-31.8 to -18.6)	-42.1 (-46.5 to -37.5)
Other exposure to mechanical forces	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.8 (72.4 to 94.5)	22.5 (15.6 to 30.5)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.3 (41.9 to 74.4)	12.9 (3.0 to 24.0)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	59.5 (40.8 to 79.7)	17.7 (4.5 to 31.6)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	55.6 (39.5 to 75.4)	9.7 (-1.6 to 23.1)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-2.0 (-11.9 to 10.9)	-30.5 (-37.2 to -22.3)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.1 (-28.5 to 2.7)	-37.0 (-46.2 to -25.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.3 (-10.7 to 19.7)	-19.3 (-31.1 to -5.5)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.2 (-5.6 to 18.5)	-28.8 (-35.6 to -20.5)
Foreign body in other body part	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	20.2 (9.0 to 33.3)	-26.6 (-33.4 to -19.0)
Other unintentional injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	2.8 (-10.2 to 18.4)	-49.4 (-37.6 to -19.5)
Self-harm and interpersonal violence	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-7.9 (-18.2 to 3.9)	-38.7 (-45.3 to -31.3)
Self-harm	-	-	-	-	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.4)	5.5 (-8.3 to 23.3)	-26.9 (-35.9 to -15.8)
Interpersonal violence	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	49.5 (32.9 to 69.3)	2.2 (-8.5 to 14.9)
Assault by firearm	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	12.2 (-2.5 to 31.8)	-22.0 (-31.5 to -9.4)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-21.1 (-32.6 to -6.3)	-44.8 (-52.5 to -35.1)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-93.3 (-97.0 to -83.9)	-92.8 (-96.8 to -82.7)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	165.5 (7.3 to 319.3)	183.5 (12.7 to 360.8)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-94.9 (-97.6 to -88.6)	-94.7 (-97.5 to -88.2)
Collective violence and legal intervention	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-94.9 (-97.6 to -88.6)	-94.7 (-97.5 to -88.2)

Appendix Table G.4 - Tunisia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	718.3 (522.3 to 938.9)	1,149.4 (846.4 to 1,500.5)	59.9 (55.4 to 65.6)	-11 (-3.4 to 1.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	103.3 (71.5 to 144.4)	105.7 (74.2 to 145.2)	2.2 (5.6 to 11.2)	-8.9 (-15.4 to -1.0)
HIV/AIDS and tuberculosis	-	-	-	-	1.0 (0.7 to 1.5)	1.7 (1.1 to 2.7)	0.7 (30.8 to 126.5)	-9.1 (-21.3 to 33.8)
Tuberculosis	3.3 (3.1 to 3.5)	4.8 (4.5 to 5.0)	43.5 (36.6 to 51.2)	-15.4 (-19.2 to -11.1)	1.0 (0.7 to 1.4)	1.5 (1.0 to 2.0)	42.8 (25.2 to 63.6)	-15.0 (-24.8 to -3.8)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.2 (0.0 to 0.2)	0.2 (1.8 to 4.4)	99.8 (6.5 to 40,487.2)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,146.9 (4.6 to 80,725.4)	590.0 (50.1 to 44,780.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,146.9 (8.0 to 81,027.0)	590.0 (50.9 to 46,413.0)
HIV/AIDS resulting in other diseases	0.2 (0.0 to 1.3)	2.0 (0.4 to 8.6)	2,266.2 (178.7 to 94,579.5)	1,300.2 (65.5 to 56,403.4)	0.0 (0.0 to 0.2)	0.2 (0.0 to 1.2)	1,935.9 (71.0 to 111,518.8)	1,075.6 (-6.8 to 65,424.3)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	23.3 (16.4 to 31.5)	20.5 (14.3 to 28.1)	-11.8 (-17.7 to -5.8)	-19.2 (-24.4 to -14.2)
Diarrheal diseases	103.7 (98.9 to 108.7)	89.8 (84.6 to 94.7)	-13.3 (-19.8 to -6.9)	-17.0 (-23.1 to -10.9)	16.9 (11.5 to 23.1)	14.6 (9.7 to 20.0)	-14.5 (-20.9 to -7.0)	-16.7 (-23.2 to -10.1)
Intestinal infectious diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	0.1 (33.6 to 9.1)	-0.1 (-41.7 to -6.7)
Typhoid fever	0.6 (0.5 to 0.7)	0.5 (0.5 to 0.6)	-10.1 (-29.0 to 13.2)	-22.7 (-38.4 to -2.8)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-9.5 (-31.0 to 15.8)	-22.5 (-39.7 to -1.6)
Paratyphoid fever	0.3 (0.3 to 0.4)	0.3 (0.2 to 0.3)	-10.2 (-32.6 to 16.1)	-20.6 (-40.3 to 0.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.2 (-32.6 to 16.3)	-20.6 (-40.3 to 0.3)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-77.6 (-57.7 to 11.7)	-80.6 (-96.3 to -12.5)
Lower respiratory infections	3.0 (2.5 to 3.5)	2.1 (1.5 to 2.1)	-40.4 (-50.7 to -26.9)	-44.4 (-53.9 to -34.2)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-40.4 (-54.8 to -23.9)	-44.0 (-56.9 to -30.3)
Upper respiratory infections	166.0 (146.6 to 184.6)	199.0 (178.7 to 219.3)	19.8 (3.8 to 38.6)	-3.9 (-16.0 to 11.4)	2.0 (1.1 to 3.2)	2.3 (1.3 to 3.9)	19.3 (2.9 to 37.9)	-3.7 (-16.9 to 11.8)
Otitis media	98.9 (91.0 to 108.4)	106.9 (99.2 to 116.8)	8.6 (5.6 to 24.3)	-7.5 (-19.9 to 5.5)	1.8 (1.1 to 3.0)	1.9 (1.1 to 3.1)	6.6 (6.6 to 21.8)	-9.0 (-20.4 to 3.8)
Meningitis	-	-	-	-	1.6 (1.1 to 2.4)	0.8 (0.5 to 1.1)	-50.6 (-62.2 to -41.4)	-62.8 (-70.7 to -55.9)
Pneumococcal meningitis	6.9 (4.0 to 11.3)	3.7 (2.2 to 5.9)	-46.6 (-59.9 to -25.0)	-64.0 (-72.8 to -49.6)	0.6 (0.4 to 0.9)	0.3 (0.2 to 0.5)	-45.4 (-59.4 to -21.2)	-60.5 (-70.5 to -43.7)
H influenzae type B meningitis	3.9 (1.2 to 8.1)	1.4 (0.5 to 3.1)	-63.4 (-77.0 to -47.9)	-73.1 (-81.8 to -60.3)	0.4 (0.2 to 0.8)	0.2 (0.1 to 0.3)	-62.3 (-79.4 to -36.5)	-69.4 (-83.0 to -49.6)
Meningococcal meningitis	2.6 (0.7 to 5.9)	1.1 (0.3 to 2.7)	-57.9 (-71.8 to -32.4)	-71.1 (-79.5 to -50.3)	0.3 (0.2 to 0.5)	0.1 (0.1 to 0.2)	-56.9 (-70.3 to -17.8)	-68.6 (-77.4 to -40.3)
Other meningitis	2.3 (1.2 to 4.2)	1.3 (0.7 to 2.6)	-44.7 (-59.3 to -20.1)	-59.1 (-69.5 to -41.8)	0.2 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-42.3 (-57.7 to -15.1)	-55.5 (-67.5 to -35.8)
Encephalitis	2.1 (0.9 to 4.9)	2.3 (1.0 to 5.8)	11.3 (-10.6 to 28.7)	-28.2 (-40.8 to -17.0)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	14.9 (-4.9 to 39.2)	-23.4 (-35.4 to -8.4)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.3 (-98.0 to 515.9)	-66.2 (-98.0 to 372.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.3 (-98.0 to 515.6)	-66.2 (-98.0 to 373.5)
Whooping cough	0.9 (0.7 to 1.1)	0.1 (0.1 to 0.2)	-86.2 (-87.7 to -84.5)	-84.1 (-85.8 to -82.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-86.4 (-92.1 to -78.1)	-84.4 (-90.8 to -74.8)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.7 (-97.0 to -88.9)	-95.1 (-97.6 to -91.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-91.9 (-96.1 to -82.7)	-93.2 (-96.7 to -85.8)
Measles	0.8 (0.6 to 1.0)	0.1 (0.1 to 0.2)	-87.6 (-85.7 to -76.3)	-81.6 (-83.3 to -72.4)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-81.7 (-90.1 to -69.2)	-78.7 (-88.4 to -64.3)
Varicella and herpes zoster	6.1 (5.6 to 6.6)	7.8 (6.4 to 9.3)	27.9 (3.9 to 53.0)	7.4 (-13.8 to 30.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	98.8 (34.5 to 180.3)	12.9 (-23.8 to 62.3)
Neglected tropical diseases and malaria	-	-	-	-	4.7 (2.6 to 7.8)	3.1 (1.9 to 4.6)	-32.2 (-54.5 to -1.8)	-25.2 (-50.0 to 6.0)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.8 (-20.7 to 266.0)	44.3 (-35.1 to 188.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.4 (-16.7 to 201.2)	34.5 (-33.0 to 136.6)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	8.9 (-12.8 to 35.0)	-9.5 (-27.8 to 12.8)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.6 (-24.9 to 29.6)	-8.2 (-28.5 to 19.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.6 (-24.9 to 30.0)	-8.2 (-28.5 to 20.0)
Cutaneous and mucocutaneous leishmaniasis	6.1 (4.5 to 8.1)	6.7 (5.0 to 8.9)	10.4 (9.7 to 32.1)	-9.2 (-25.6 to 8.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	9.3 (-13.1 to 36.2)	-9.5 (-28.4 to 13.0)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-79.6 (-93.6 to -42.2)	-88.1 (-96.0 to -46.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-76.8 (-93.1 to -31.6)	-86.6 (-95.7 to -60.8)
Cystic echinococcosis	0.6 (0.6 to 0.7)	0.9 (0.9 to 1.0)	47.9 (30.4 to 60.8)	-18.4 (-25.3 to -12.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	46.6 (16.1 to 82.3)	-18.3 (-34.7 to -0.3)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.6 (-71.9 to -35.0)	-66.3 (-77.0 to -50.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.6 (-71.9 to -34.8)	-66.3 (-77.0 to -50.8)
Intestinal nematode infections	-	-	-	-	1.1 (0.3 to 3.3)	0.2 (0.1 to 0.5)	-83.7 (-95.4 to -42.2)	-84.0 (-95.3 to -45.9)
Ascariasis	561.1 (459.2 to 725.1)	734.7 (604.7 to 891.1)	32.4 (-3.8 to 74.6)	-5.2 (-28.1 to 25.9)	1.1 (0.3 to 3.3)	0.1 (0.0 to 0.4)	-88.9 (-97.4 to -51.9)	-88.9 (-97.2 to -52.1)
Trichuriasis	231.7 (197.7 to 271.0)	327.1 (264.8 to 396.1)	41.3 (8.6 to 81.1)	-0.1 (-23.2 to 29.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.0 (88.5 to 1,359.7)	-15.9 (-92.4 to 1,036.5)
Hookworm disease	5.1 (4.1 to 6.3)	8.5 (7.0 to 10.3)	66.3 (25.4 to 119.4)	0.6 (-25.0 to 31.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	86.6 (40.8 to 116.8)	11.6 (-15.5 to 29.6)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	99.3 (75.5 to 124.1)	86.4 (72.6 to 100.6)	-12.9 (-30.8 to 14.9)	-10.2 (-27.6 to 15.4)	3.4 (2.0 to 4.9)	2.7 (1.7 to 4.0)	-20.8 (-42.1 to 21.2)	-9.7 (-34.7 to 37.2)
Maternal disorders	-	-	-	-	0.4 (0.2 to 0.7)	0.4 (0.2 to 0.6)	-11.8 (-32.2 to 11.1)	-43.3 (-56.2 to -28.9)
Maternal hemorrhage	1.6 (1.3 to 1.8)	2.0 (1.4 to 2.7)	29.5 (-15.4 to 78.4)	-18.0 (-45.7 to 10.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	7.8 (-48.9 to 92.8)	-30.4 (-66.7 to 20.6)
Maternal sepsis and other maternal infections	4.5 (2.9 to 6.4)	2.6 (1.6 to 4.1)	-40.6 (-61.3 to -22.8)	-68.3 (-79.1 to -58.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-45.9 (-72.4 to -2.0)	-67.2 (-82.6 to -41.9)
Maternal hypertensive disorders	3.6 (1.3 to 6.5)	3.3 (1.2 to 6.1)	-9.8 (-26.7 to 13.0)	-40.6 (-49.5 to -30.2)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-9.8 (-30.7 to 16.1)	-40.6 (-53.0 to -26.7)
Obstructed labor	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-19.4 (-43.0 to 31.4)	-47.1 (-62.6 to -15.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-18.9 (-67.8 to 95.0)	-46.8 (-78.5 to 26.0)
Complications of abortion	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	11.9 (-28.6 to 93.6)	-31.9 (-55.6 to 17.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.9 (-28.6 to 94.0)	-31.9 (-55.7 to 17.9)
Other maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	4.3 (-53.8 to 111.0)	-38.2 (-70.4 to 35.5)
Neonatal disorders	-	-	-	-	10.4 (6.2 to 16.4)	21.4 (13.0 to 32.3)	109.7 (26.3 to 212.6)	72.6 (3.3 to 157.9)
Preterm birth complications	24.6 (17.5 to 33.4)	62.7 (46.8 to 83.4)	155.7 (96.2 to 233.9)	98.2 (53.6 to 158.2)	3.0 (2.0 to 4.3)	7.9 (5.4 to 11.0)	167.2 (90.5 to 285.0)	114.3 (54.3 to 209.4)
Neonatal encephalopathy due to birth asphyxia and trauma	15.7 (7.2 to 28.1)	20.6 (11.2 to 35.7)	31.6 (-35.4 to 187.6)	9.9 (-46.7 to 140.8)	3.6 (1.6 to 6.1)	5.0 (2.7 to 8.6)	40.4 (-27.1 to 159.2)	19.3 (-37.4 to 155.5)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.4 (29.1 to 64.1)	73.0 (48.5 to 88.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (15.3 to 93.6)	0.0 (32.7 to 122.7)
Hemolytic disease and other neonatal jaundice	9.9 (3.2 to 24.5)	23.1 (8.0 to 44.5)	151.6 (-45.3 to 547.6)	107.2 (-55.4 to 430.9)	2.8 (1.0 to 6.4)	6.1 (2.3 to 11.8)	133.1 (-45.4 to 404.5)	88.9 (-55.8 to 312.4)
Other neonatal disorders	-	-	-	-	1.1 (0.5 to 2.0)	2.4 (1.1 to 4.5)	129.4 (-4.7 to 399.7)	88.3 (-20.9 to 311.3)
Nutritional deficiencies	-	-	-	-	58.9 (39.3 to 84.5)	53.8 (35.8 to 78.9)	-8.6 (-15.8 to -2.1)	-17.2 (-23.2 to -11.3)
Protein-energy malnutrition	22.8 (11.7 to 39.0)	12.2 (4.5 to 27.3)	-50.3 (-83.7 to 51.9)	-42.5 (-81.1 to 75.7)	2.9 (1.3 to 5.4)	1.5 (0.5 to 3.8)	-49.9 (-83.9 to 52.5)	-42.0 (-81.3 to 75.9)
Iodine deficiency	204.9 (134.0 to 288.8)	190.1 (140.2 to 245.6)	-8.2 (-40.8 to 58.8)	-38.5 (-60.5 to 8.2)	3.7 (1.9 to 6.6)	3.4 (2.0 to 5.6)	-8.4 (-40.3 to 58.5)	-38.3 (-61.0 to 8.6)
Vitamin A deficiency	2.8 (1.8 to 3.9)	1.7 (1.2 to 2.3)	-38.6 (-47.9 to -24.5)	-47.5 (-55.9 to -37.9)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-36.2 (-48.5 to -17.7)	-50.1 (-59.1 to -37.4)

Appendix Table G.4 - Tunisia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	1,619.0 (1,593.1 to 1,656.0)	1,716.1 (1,676.3 to 1,755.5)	6.1 (2.8 to 9.1)	-2.8 (-15.5 to -10.4)	51.4 (34.2 to 74.6)	48.4 (32.0 to 70.9)	-5.7 (-10.7 to -3.0)	-13.8 (-18.0 to -11.6)
Other nutritional deficiencies	-	-	-	-	0.8 (0.2 to 1.9)	0.4 (0.1 to 1.0)	-	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	4.6 (2.9 to 7.0)	4.9 (3.0 to 7.8)	6.3 (-13.1 to 28.7)	-11.6 (-26.8 to 4.1)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.5 (0.9 to 2.7)	2.2 (1.2 to 4.1)	43.3 (-2.2 to 97.4)	-6.8 (-33.9 to 26.6)
Syphilis	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.3)	23.9 (3.7 to 47.1)	-41.5 (-50.5 to -30.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	26.4 (-6.1 to 69.9)	40.1 (-55.5 to -19.2)
Chlamydial infection	135.0 (98.3 to 181.9)	190.0 (139.2 to 257.7)	39.9 (-10.8 to 112.3)	-4.8 (-37.9 to 42.1)	0.7 (0.3 to 1.7)	0.9 (0.4 to 1.8)	34.9 (-41.1 to 180.2)	-7.1 (-59.8 to 94.0)
Gonococcal infection	69.1 (57.6 to 81.9)	89.5 (73.8 to 105.3)	29.1 (1.0 to 67.0)	-7.2 (-26.9 to 18.2)	0.4 (0.2 to 0.7)	0.5 (0.3 to 0.9)	31.9 (-1.7 to 76.6)	-6.2 (-29.3 to 23.3)
Trichomoniasis	54.9 (37.9 to 73.9)	92.1 (66.9 to 115.7)	70.5 (14.1 to 150.2)	11.3 (-23.9 to 53.8)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	72.7 (10.2 to 170.4)	14.8 (-25.5 to 67.5)
Genital herpes	1,089.2 (1,028.8 to 1,154.3)	1,927.7 (1,807.1 to 2,045.0)	77.2 (62.1 to 92.7)	3.2 (-11.6 to 5.1)	0.0 (0.1 to 0.7)	0.5 (0.2 to 1.2)	71.1 (50.9 to 88.2)	3.4 (-12.5 to 5.7)
Other sexually transmitted diseases	1.7 (1.2 to 2.3)	2.3 (1.8 to 3.2)	38.7 (14.7 to 63.1)	-23.0 (-38.2 to -9.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (8.6 to 150.0)	-1.9 (-34.1 to 46.9)
Hepatitis	-	-	-	-	0.6 (0.4 to 0.9)	0.7 (0.4 to 1.1)	11.8 (-14.4 to 45.9)	-26.4 (-46.4 to -1.1)
Hepatitis A	10.9 (10.5 to 11.3)	11.3 (10.9 to 11.6)	3.3 (2.0 to 4.6)	-5.3 (-5.4 to -5.1)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	20.6 (7.0 to 37.7)	-2.3 (-13.0 to 11.0)
Hepatitis B	647.1 (512.4 to 797.3)	648.8 (476.5 to 799.3)	0.9 (-29.2 to 38.0)	-33.9 (-53.3 to -10.0)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	5.8 (-36.8 to 79.4)	-39.2 (-64.3 to 3.8)
Hepatitis C	55.8 (50.1 to 62.0)	73.8 (67.1 to 81.4)	32.3 (14.0 to 52.6)	-24.3 (-34.7 to -14.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.8 (-3.3 to 67.9)	23.3 (-44.4 to 6.5)
Hepatitis E	1.2 (0.9 to 1.6)	1.1 (1.0 to 1.3)	-6.7 (-29.1 to 28.7)	34.4 (-50.0 to -10.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-7.0 (-36.8 to 47.1)	-36.1 (-57.6 to -2.4)
Leprosy	0.1 (0.0 to 0.4)	0.1 (0.0 to 0.2)	5.2 (-40.4 to 581.6)	-47.1 (-69.6 to 260.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.4 (-43.6 to 700.3)	-45.8 (-71.6 to 340.6)
Other infectious diseases	71.5 (56.1 to 87.6)	65.5 (53.6 to 78.8)	-8.8 (-28.2 to 17.5)	-11.5 (-29.5 to 11.7)	2.4 (1.4 to 3.6)	2.0 (1.2 to 3.0)	-17.5 (-45.1 to 18.9)	-10.1 (-39.6 to 28.0)
Non-communicable diseases	-	-	-	-	579.9 (420.8 to 754.2)	1,008.5 (742.8 to 1,310.8)	73.8 (68.2 to 80.9)	27.7 (-0.5 to 5.8)
Neoplasms	-	-	-	-	2.7 (1.9 to 3.6)	6.1 (4.2 to 8.5)	127.0 (82.2 to 185.3)	9.3 (-11.6 to 36.6)
Esophageal cancer	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	98.0 (32.5 to 196.8)	-6.8 (-37.8 to 39.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.9 (41.0 to 173.4)	-7.8 (-33.9 to 27.7)
Stomach cancer	0.7 (0.6 to 0.9)	1.5 (1.2 to 1.9)	102.3 (49.9 to 177.3)	-7.4 (-31.2 to 26.7)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	91.4 (39.9 to 166.8)	-12.5 (-36.4 to 21.5)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	117.1 (52.3 to 209.0)	1.5 (-27.6 to 45.0)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	98.2 (8.5 to 261.2)	-4.2 (-46.9 to 71.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.3 (11.1 to 209.3)	-9.2 (-44.8 to 46.5)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	463.4 (211.2 to 916.4)	158.3 (40.5 to 367.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	430.3 (222.1 to 767.4)	140.1 (47.3 to 291.0)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.6 (-61.0 to 64.0)	-65.3 (-82.7 to -29.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.9 (-57.2 to 38.6)	-66.4 (-81.5 to -40.4)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	45.4 (-27.6 to 187.5)	-24.8 (-62.9 to 54.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.6 (-23.6 to 147.2)	-30.4 (-60.2 to 27.8)
Larynx cancer	0.8 (0.6 to 1.2)	1.8 (1.1 to 2.6)	109.5 (29.7 to 233.2)	-5.8 (-41.1 to 47.3)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	105.1 (25.4 to 237.5)	-8.1 (-42.9 to 46.8)
Tracheal, bronchus and lung cancer	1.4 (1.1 to 1.7)	2.8 (2.0 to 3.9)	102.6 (42.2 to 195.8)	-9.1 (-35.6 to 32.5)	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.7)	93.8 (32.8 to 176.8)	-13.0 (-39.7 to 23.1)
Breast cancer	4.7 (3.7 to 5.8)	13.8 (9.2 to 19.2)	192.0 (91.0 to 340.9)	37.7 (-9.0 to 105.1)	0.4 (0.3 to 0.6)	1.1 (0.7 to 1.7)	169.5 (79.5 to 299.6)	26.5 (-13.1 to 86.2)
Cervical cancer	1.6 (1.1 to 2.1)	2.0 (1.3 to 2.9)	23.2 (-23.0 to 88.2)	-41.8 (-62.9 to -12.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	41.1 (-2.1 to 95.7)	-41.1 (-62.9 to -8.4)
Uterine cancer	1.0 (0.6 to 1.5)	1.9 (1.0 to 3.0)	92.1 (10.2 to 224.2)	-10.1 (-47.0 to 51.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	90.0 (9.8 to 234.2)	-11.4 (-48.1 to 52.0)
Prostate cancer	1.3 (0.7 to 1.9)	6.2 (3.7 to 10.0)	387.9 (170.6 to 733.8)	90.6 (5.6 to 222.5)	0.2 (0.1 to 0.3)	0.6 (0.3 to 1.1)	285.4 (125.4 to 522.9)	47.8 (-14.9 to 140.6)
Colon and rectum cancer	2.5 (2.2 to 2.9)	7.4 (5.8 to 9.2)	191.9 (127.2 to 281.5)	32.5 (3.8 to 71.7)	0.2 (0.2 to 0.3)	0.6 (0.4 to 0.9)	169.9 (108.5 to 250.0)	21.1 (-5.4 to 56.8)
Lip and oral cavity cancer	0.8 (0.6 to 1.1)	1.6 (1.1 to 2.2)	94.6 (36.9 to 183.3)	-8.9 (-35.9 to 31.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	95.1 (34.6 to 180.5)	-9.3 (-37.9 to 31.1)
Nasopharynx cancer	1.2 (0.9 to 1.6)	1.7 (1.1 to 2.5)	42.0 (-10.5 to 124.7)	-23.8 (-52.3 to 16.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	39.8 (-9.8 to 115.0)	-25.9 (-52.2 to 14.0)
Other pharynx cancer	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	118.6 (29.8 to 258.5)	1.4 (-37.8 to 66.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	109.9 (27.8 to 230.7)	-3.1 (-39.5 to 50.2)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	73.9 (1.2 to 186.1)	-21.9 (-55.3 to 28.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	62.7 (-4.5 to 164.2)	-25.7 (-56.9 to 21.8)
Pancreatic cancer	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	158.0 (85.6 to 264.8)	15.0 (-17.1 to 60.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	151.2 (89.1 to 235.6)	11.9 (-17.5 to 49.8)
Malignant skin melanoma	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.8)	177.8 (96.4 to 293.7)	0.6 (-6.2 to 91.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	166.9 (12.8 to 298.4)	25.7 (-12.8 to 86.4)
Non-melanoma skin cancer	0.9 (0.6 to 1.2)	2.5 (1.6 to 3.5)	194.7 (52.2 to 332.0)	28.5 (-33.1 to 87.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	253.3 (133.6 to 408.7)	48.9 (-6.7 to 126.4)
Ovarian cancer	0.4 (0.3 to 0.5)	1.1 (0.7 to 1.6)	193.4 (88.5 to 359.0)	38.2 (-10.9 to 111.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	183.3 (71.7 to 357.1)	33.9 (-19.8 to 113.8)
Testicular cancer	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.8)	162.2 (44.3 to 389.7)	49.5 (-14.8 to 174.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	158.7 (30.9 to 429.6)	43.8 (-24.7 to 171.8)
Kidney cancer	1.1 (0.6 to 1.0)	1.5 (1.1 to 2.1)	105.5 (36.3 to 204.7)	10.1 (-16.8 to 71.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	106.6 (40.0 to 205.3)	12.3 (-21.0 to 64.3)
Bladder cancer	1.9 (1.3 to 2.4)	3.9 (2.6 to 5.4)	103.8 (34.5 to 204.2)	-10.4 (-41.4 to 31.6)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	102.4 (38.1 to 187.9)	-12.1 (-40.2 to 25.6)
Brain and nervous system cancer	0.8 (0.5 to 1.2)	1.2 (0.9 to 1.6)	53.0 (-10.5 to 126.3)	3.9 (-33.8 to 46.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	61.0 (0.2 to 131.7)	1.0 (-33.1 to 44.0)
Thyroid cancer	1.2 (0.8 to 1.6)	2.9 (1.9 to 4.0)	139.7 (53.5 to 282.5)	22.1 (-20.2 to 88.5)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	132.7 (48.2 to 261.0)	16.6 (-24.5 to 75.8)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.4 (9.5 to 140.8)	-35.6 (-41.8 to 30.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.9 (13.5 to 150.9)	-14.4 (-41.5 to 33.4)
Hodgkin lymphoma	1.3 (0.7 to 1.9)	1.8 (1.2 to 2.6)	47.4 (-10.8 to 140.6)	4.3 (-34.5 to 61.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	45.9 (-7.3 to 132.2)	-0.7 (-35.1 to 52.9)
Non-Hodgkin lymphoma	1.5 (1.1 to 1.9)	3.9 (2.9 to 5.2)	166.6 (88.3 to 278.4)	47.4 (4.1 to 109.2)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	155.9 (78.6 to 270.9)	37.3 (-3.4 to 98.7)
Multiple myeloma	0.2 (0.2 to 0.3)	0.6 (0.4 to 0.8)	152.0 (62.0 to 293.6)	15.8 (-25.8 to 78.5)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	139.8 (50.1 to 281.2)	9.2 (-31.7 to 74.8)
Leukemia	1.1 (0.8 to 1.5)	2.0 (1.5 to 2.5)	74.5 (18.4 to 147.0)	22.7 (-11.8 to 67.0)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	78.8 (27.8 to 157.5)	11.9 (-17.2 to 49.7)
Other neoplasms	1.2 (0.9 to 1.8)	3.1 (2.2 to 4.3)	160.3 (38.7 to 266.5)	54.5 (5.1 to 113.8)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	150.3 (47.1 to 249.8)	38.6 (-8.1 to 94.3)
Cardiovascular diseases	-	-	-	-	14.8 (10.1 to 20.4)	28.3 (18.9 to 39.7)	92.5 (54.6 to 133.5)	-2.7 (-20.5 to 17.1)
Rheumatic heart disease	21.6 (16.3 to 27.3)	38.4 (28.4 to 47.0)	83.5 (15.5 to 149.3)	6.9 (-28.9 to 39.4)	1.2 (0.7 to 1.8)	2.3 (1.4 to 3.4)	98.5 (30.1 to 183.5)	14.4 (-19.9 to 60.5)
Ischemic heart disease	72.7 (57.2 to 91.4)	124.0 (107.7 to 142.9)	70.3 (34.1 to 124.3)	-21.1 (-36.6 to 0.9)	4.2 (2.6 to 6.2)	6.8 (4.4 to 9.7)	62.1 (24.6 to 125.9)	-22.7 (-39.3 to 4.7)
Cerebrovascular disease	-	-	-	-	0.6 (0.4 to 0.7)	1.0 (0.7 to 1.4)	77.5 (42.8 to 122.4)	-17.7 (-33.6 to 2.8)
Ischemic stroke	3.1 (2.7 to 3.5)	5.5 (4.7 to 6.4)	76.6 (42.8 to 117.6)	-19.3 (-34.3 to -1.8)	0.5 (0.3 to 0.6)	0.8 (0.6 to 1.2)	77.6 (40.2 to 125.1)	-18.5 (-34.7 to 3.0)
Hemorrhagic stroke	0.5 (0.4 to 0.6)	0.8 (0.7 to 1.1)	76.8 (29.8 to 147.0)	-14.6 (-37.0 to 19.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	79.6 (31.0 to 148.8)	-13.0 (-36.4 to 22.1)
Hypertensive heart disease	6.9 (4.9 to 8.8)	20.5 (15.2 to 26.0)	195.2 (110.5 to 338.0)	40.0 (0.0 to 108.1)	0.8 (0.5 to 1.1)	2.3 (1.4 to 3.3)	190.2 (106.0 to 334.8)	38.9 (-1.9 to 106.6)
Cardiomyopathy and myocarditis	11.3 (4.9 to 7.1)	29.0 (11.7 to 20.1)	157.5 (84.1 to 245.8)	-1.2 (-7.7 to 85.1)	0.9 (0.4 to 0.9)	2.2 (1.0 to 2.6)	157.2 (84.4 to 252.9)	-1.0 (-8.6 to 86.6)
Atrial fibrillation and flutter	117.2 (8.8 to 157.0)	282.4 (202.6 to 357.5)	137.9 (71.9 to 252.5)	3.6 (-24.4 to 41.3)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	129.4 (38.0 to 277.8)	-20.0 (-53.4 to 37.0)
Endocarditis	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	120.7 (49.0 to 216.0)	16.9 (-19.9 to 66.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	120.0 (43.0 to 235.1)	17.8 (-23.3 to 77.0)
Other cardiovascular and circulatory diseases	91.4 (68.1 to 127.2)	167.3 (108.0 to 225.3)	84.2 (12.0 to 169.2)	5.3 (-38.3 to 49.0)	2.3 (4.0 to 10.0)	11.9 (6.7 to 17.7)	94.9 (12.6 to 170.2)	2.3 (-38.1 to 49.6)
Chronic respiratory diseases	-	-	-	-	33.9 (22.9 to 46.6)	52.5 (35.3 to 74.2)	54.0 (28.9 to 89.3)	-11.1 (-26.6 to 8.9)
Chronic obstructive pulmonary disease	293.8 (277.1 to 310.0)	576.6 (543.2 to 610.3)	96.1 (89.7 to 103.5)	-0.3 (-3.7 to 3.1)	19.7 (12.8 to 28.6)	38.5 (25.6 to 55.2)	94.4 (51.8 to 149.0)	-0.1 (-23.8 to 24.1)

Appendix Table G.4 - Tunisia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	86.6	-0.1
Silicosis	0.0	0.1	73.3	-20.1	0.0	0.0	(80.3 to 93.9)	(-13.5 to -6.5)
Asbestosis	(0.0 to 0.1)	(0.1 to 0.1)	(64.9 to 83.8)	(-24.1 to -15.5)	0.0	0.0	(64.5 to 83.3)	(-24.3 to -15.4)
Coal workers pneumoconiosis	-	-	0.0	0.0	-	-	-	-
Other pneumoconiosis	0.1	0.2	94.3	-	0.0	0.0	95.4	-2.8
Asthma	(0.1 to 0.1)	(0.1 to 0.2)	(86.5 to 103.9)	(-7.0 to 1.4)	(0.0 to 0.0)	(0.0 to 0.0)	(86.7 to 105.1)	(-6.7 to 1.8)
Interstitia lung disease and pulmonary sarcoidosis	285.9	289.0	0.8	-26.6	12.7	12.6	-1.1	27.4
Other chronic respiratory diseases	(255.5 to 322.4)	(228.9 to 375.1)	(-24.6 to 34.8)	(-43.2 to -3.2)	(8.2 to 18.9)	(7.6 to 19.7)	(-26.6 to 33.8)	(-44.3 to -3.2)
Cirrhosis	0.6	1.2	105.7	4.8	0.1	0.2	105.6	4.2
Cirrhosis due to hepatitis B	(0.5 to 0.7)	(1.0 to 1.5)	(54.0 to 190.2)	(-21.6 to 50.0)	(0.0 to 0.1)	(0.1 to 0.2)	(53.2 to 194.1)	(-22.2 to 51.7)
Cirrhosis due to hepatitis C	-	-	-	-	1.4	1.2	-17.5	-57.6
Cirrhosis due to alcohol use	-	-	-	-	0.5	0.6	38.2	(-72.0 to -34.9)
Cirrhosis due to other causes	0.9	1.3	36.0	-22.9	(0.3 to 0.7)	(0.4 to 0.9)	(14.8 to 56.0)	(-28.3 to -4.7)
Digestive diseases	0.9	1.8	104.0	15.8	0.2	0.2	35.5	-24.0
Peptic ulcer disease	(0.7 to 1.2)	(0.9 to 1.8)	(-4.2 to 117.2)	(45.5 to 19.5)	(0.1 to 0.2)	(0.1 to 0.3)	(-11.2 to 120.4)	(-48.5 to 24.0)
Gastritis and duodenitis	0.9	1.8	104.0	15.8	0.2	0.3	100.7	14.9
Appendicitis	(0.7 to 1.2)	(1.1 to 2.3)	(13.9 to 178.1)	(-34.9 to 58.2)	(0.1 to 0.3)	(0.2 to 0.4)	(5.5 to 197.2)	(-39.0 to 66.2)
Paralytic ileus and intestinal obstruction	0.3	0.3	-56.6	-13.3	0.1	0.1	-15.1	-57.2
Inguinal, femoral, and abdominal hernia	(0.2 to 0.5)	(0.2 to 0.4)	(-55.5 to 51.4)	(-77.3 to -26.8)	(0.0 to 0.1)	(0.0 to 0.1)	(-60.2 to 61.4)	(-79.9 to -20.6)
Inflammatory bowel disease	0.7	0.6	-24.9	-34.3	0.1	0.1	-24.4	-33.5
Vascular intestinal disorders	(0.6 to 0.9)	(0.4 to 0.8)	(-45.8 to 19.7)	(-54.4 to 4.8)	(0.1 to 0.2)	(0.1 to 0.2)	(-51.6 to 24.6)	(-58.8 to 9.7)
Peptic ulcer disease	20.7	23.0	10.7	-52.1	0.8	1.0	29.1	-44.7
Gastritis and duodenitis	(16.6 to 24.0)	(18.4 to 26.9)	(-12.8 to 41.0)	(-62.5 to -40.8)	(0.5 to 1.2)	(0.7 to 1.5)	(-1.0 to 58.1)	(-54.3 to -32.9)
Appendicitis	25.4	20.5	-19.2	-49.8	1.2	1.0	-13.6	-42.7
Paralytic ileus and intestinal obstruction	(22.2 to 28.8)	(18.1 to 22.8)	(-31.3 to -5.2)	(-57.0 to -41.4)	(0.8 to 1.7)	(0.7 to 1.5)	(-31.9 to 16.6)	(-52.6 to -25.2)
Inguinal, femoral, and abdominal hernia	0.6	0.7	16.8	-21.3	0.2	0.2	18.0	-19.8
Inflammatory bowel disease	(0.4 to 0.8)	(0.5 to 0.8)	(-34.9 to 91.0)	(-55.7 to 25.0)	(0.1 to 0.3)	(0.1 to 0.3)	(-36.3 to 101.1)	(-56.4 to 32.4)
Vascular intestinal disorders	0.1	0.1	53.1	-2.6	0.0	0.0	50.0	-0.9
Peptic ulcer disease	(0.1 to 0.2)	(0.1 to 0.2)	(-22.8 to 218.2)	(-39.0 to 74.0)	(0.0 to 0.1)	(0.0 to 0.1)	(-29.9 to 221.2)	(-42.7 to 81.5)
Gastritis and duodenitis	20.6	36.1	74.9	-11.9	0.2	0.4	73.6	-11.7
Appendicitis	(17.6 to 23.9)	(29.6 to 42.0)	(39.2 to 119.5)	(-31.5 to 12.3)	(0.1 to 0.4)	(0.2 to 0.7)	(38.9 to 119.6)	(-31.2 to 12.7)
Paralytic ileus and intestinal obstruction	6.2	16.5	165.8	43.6	1.3	3.5	164.2	43.7
Inguinal, femoral, and abdominal hernia	(5.7 to 6.7)	(15.2 to 18.0)	(137.3 to 200.0)	(28.7 to 62.1)	(0.9 to 1.8)	(2.4 to 4.8)	(132.5 to 204.9)	(26.9 to 64.9)
Inflammatory bowel disease	0.0	0.0	100.9	-0.5	0.0	0.0	99.2	0.3
Vascular intestinal disorders	(0.0 to 0.0)	(0.0 to 0.1)	(35.7 to 203.6)	(-40.4 to 53.8)	(0.0 to 0.0)	(0.0 to 0.0)	(32.4 to 210.6)	(-41.7 to 68.0)
Gallbladder and biliary diseases	2.3	4.4	87.2	-7.3	0.2	0.5	85.0	-7.5
Pancreatitis	(2.1 to 2.6)	(3.8 to 4.9)	(56.3 to 121.2)	(-21.4 to 11.2)	(0.2 to 0.3)	(0.3 to 0.6)	(50.8 to 125.4)	(-23.6 to 13.1)
Other digestive diseases	1.5	2.5	70.1	-8.4	0.4	0.7	68.9	-8.4
Neurological disorders	(1.4 to 1.6)	(2.4 to 2.7)	(51.1 to 86.5)	(-17.9 to -0.0)	(0.3 to 0.6)	(0.5 to 1.0)	(39.8 to 101.5)	(-22.5 to 7.9)
Alzheimer disease and other dementias	-	-	-	-	0.5	0.9	64.5	-14.1
Parkinson disease	-	-	-	-	(0.3 to 0.8)	(0.5 to 1.3)	(26.8 to 112.1)	(-33.9 to 10.7)
Epilepsy	-	-	-	-	40.8	83.4	104.2	14.2
Multiple sclerosis	-	-	-	-	(27.8 to 55.6)	(56.7 to 113.7)	(83.2 to 129.5)	(1.9 to 28.8)
Migraine	35.6	96.6	370.1	0.2	5.0	14.0	178.2	0.3
Tension-type headache	(30.5 to 40.4)	(82.6 to 109.9)	(119.6 to 239.0)	(-20.7 to 27.0)	(3.5 to 6.6)	(9.8 to 18.5)	(124.8 to 249.9)	(-21.6 to 28.4)
Medication overuse headache	3.0	7.0	131.4	1.2	0.4	0.8	130.2	1.0
Other neurological disorders	(2.3 to 3.7)	(5.6 to 8.4)	(111.2 to 153.1)	(-8.6 to 9.4)	(0.2 to 0.5)	(0.5 to 1.2)	(100.1 to 163.6)	(-12.1 to 14.2)
Schizophrenia	30.2	39.2	30.1	-2.3	9.3	13.5	44.0	9.2
Alcohol use disorders	(25.0 to 34.2)	(32.8 to 45.1)	(5.0 to 59.6)	(-21.0 to 20.3)	(6.2 to 12.9)	(8.8 to 18.4)	(12.5 to 84.5)	(-14.0 to 39.9)
Drug use disorders	1.3	4.9	269.9	94.0	0.4	1.6	265.3	93.7
Opioid use disorders	(0.8 to 1.7)	(3.1 to 6.8)	(120.4 to 571.2)	(19.0 to 232.2)	(0.2 to 0.7)	(0.9 to 2.5)	(113.3 to 591.4)	(15.0 to 248.9)
Cocaine use disorders	362.8	677.6	86.1	17.4	12.5	23.1	84.8	17.4
Amphetamine use disorders	(309.2 to 410.3)	(546.2 to 819.3)	(54.7 to 126.8)	(-14.0 to 42.5)	(14.2 to 42.5)	(13.3 to 35.0)	(53.4 to 126.3)	(-2.4 to 43.0)
Cannabis use disorders	1,370.1	2,112.3	56.0	-0.6	2.1	3.2	55.4	-0.5
Other drug use disorders	(1,275.0 to 1,461.6)	(1,365.2 to 2,683.4)	(-1.5 to 96.6)	(-35.9 to 24.8)	(1.0 to 3.6)	(1.3 to 6.0)	(-2.1 to 96.3)	(-35.9 to 25.1)
Medication overuse headache	63.5	166.7	162.9	50.6	10.0	26.2	161.7	50.3
Other neurological disorders	(42.8 to 85.9)	(109.2 to 227.2)	(108.3 to 230.5)	(18.9 to 86.3)	(5.7 to 15.6)	(14.7 to 40.3)	(107.1 to 229.4)	(18.6 to 87.5)
Mental and substance use disorders	0.0	0.0	51.8	2.3	1.0	0.9	-14.7	-68.7
Schizophrenia	(0.0 to 0.0)	(0.0 to 0.0)	(-2.5 to 126.3)	(-32.4 to 50.7)	(0.6 to 1.6)	(0.6 to 1.3)	(-47.6 to 31.4)	(-81.1 to -51.0)
Alcohol use disorders	19.3	35.5	83.6	-0.1	206.8	317.6	53.9	-0.5
Drug use disorders	(17.6 to 21.0)	(32.4 to 38.3)	(75.0 to 93.1)	(-4.7 to 4.6)	(142.9 to 284.1)	(221.9 to 426.9)	(45.1 to 64.1)	(-4.3 to 31.0)
Opioid use disorders	36.6	55.5	51.5	-5.0	12.5	22.8	82.9	-0.1
Cocaine use disorders	(32.2 to 41.8)	(49.4 to 61.9)	(42.0 to 62.2)	(-10.5 to 0.9)	(2.4 to 5.2)	(3.6 to 7.8)	(39.0 to 65.5)	(-12.3 to 2.7)
Amphetamine use disorders	-	-	-	-	31.3	50.9	62.4	-4.2
Cannabis use disorders	62.9	105.2	67.0	-4.2	(18.4 to 47.1)	(31.1 to 75.1)	(43.9 to 87.8)	(-14.4 to 10.8)
Other drug use disorders	(36.5 to 92.5)	(68.0 to 153.8)	(46.7 to 101.4)	(-15.5 to 13.3)	26.3	44.0	67.3	-4.0
Schizophrenia	6.5	10.2	57.2	0.9	(14.5 to 40.8)	(25.1 to 67.2)	(45.2 to 104.3)	(-15.9 to 14.3)
Cocaine use disorders	(5.2 to 8.3)	(8.3 to 11.9)	(9.3 to 110.9)	(-25.9 to 35.1)	(0.5 to 1.4)	(0.9 to 2.1)	(4.5 to 120.2)	(-28.8 to 40.0)
Amphetamine use disorders	11.0	13.9	25.7	-10.6	1.4	1.8	25.4	-10.5
Cannabis use disorders	(8.0 to 13.5)	(10.7 to 16.7)	(8.4 to 83.2)	(-34.4 to 25.8)	(0.8 to 2.2)	(1.1 to 2.8)	(-11.3 to 83.5)	(-36.6 to 27.7)
Other drug use disorders	12.6	17.1	35.7	-0.0	0.4	0.5	35.6	0.1
Depressive disorders	(9.7 to 15.2)	(13.6 to 20.3)	(30.6 to 42.1)	(-0.1 to 0.1)	(0.2 to 0.6)	(0.3 to 0.8)	(15.3 to 62.5)	(-14.2 to 17.7)
Major depressive disorder	-	-	-	-	2.4	3.2	37.1	-5.3
Dysthymia	-	-	-	-	(1.4 to 3.5)	(2.0 to 4.8)	(5.2 to 96.0)	(-34.2 to 34.5)
Bipolar disorder	62.9	105.2	67.0	-4.2	117.7	117.7	63.8	2.2
Anxiety disorders	(156.7 to 477.0)	(266.9 to 708.8)	(32.1 to 74.8)	(0.3 to 0.8)	(41.2 to 115.2)	(65.4 to 183.3)	(44.4 to 83.0)	(-6.8 to 11.3)
Eating disorders	311.0	504.1	62.8	2.4	64.4	103.7	61.9	2.4
Anorexia nervosa	(186.1 to 441.3)	(290.5 to 716.9)	(41.8 to 83.8)	(-8.1 to 13.6)	(34.5 to 105.8)	(55.5 to 167.8)	(40.0 to 83.7)	(-7.7 to 14.3)
Bulimia nervosa	80.0	144.5	80.5	0.6	7.8	13.9	79.7	0.7
Autistic spectrum disorders	(65.0 to 94.8)	(118.0 to 171.3)	(73.9 to 89.0)	(0.4 to 0.7)	(4.9 to 11.3)	(8.8 to 20.5)	(71.6 to 89.5)	(-1.9 to 3.2)
Autism	54.8	91.5	66.6	-0.8	11.2	18.6	65.9	-0.8
Asperger syndrome	(47.3 to 62.1)	(80.9 to 102.8)	(58.3 to 79.1)	(-5.4 to 4.5)	(7.0 to 17.0)	(11.5 to 28.0)	(55.5 to 80.1)	(-6.4 to 5.7)
Attention-deficit/hyperactivity disorder	333.4	500.4	50.5	0.5	30.9	46.3	49.7	0.5
Conduct disorder	(156.7 to 477.0)	(266.9 to 708.8)	(32.1 to 74.8)	(0.3 to 0.8)	(13.0 to 50.2)	(22.5 to 72.7)	(31.2 to 74.7)	(-1.6 to 3.1)
Idiopathic intellectual disability	-	-	-	-	1.2	1.6	36.4	5.1
Other mental and substance use disorders	24.1	32.0	32.5	-0.5	(0.7 to 1.9)	(1.0 to 2.6)	(21.5 to 53.9)	(-6.1 to 17.6)
Diabetes, urogenital, blood, and endocrine diseases	1.3	1.9	51.4	22.0	0.3	0.4	51.4	21.9
Diabetes mellitus	(0.8 to 1.9)	(1.3 to 2.8)	(31.4 to 72.6)	(7.1 to 38.8)	(0.1 to 0.5)	(0.2 to 0.7)	(15.8 to 100.5)	(-6.4 to 59.8)
Acute glomerulonephritis	4.4	5.8	31.9	0.1	0.9	1.2	31.8	0.5
Chronic kidney disease	(3.0 to 6.2)	(3.9 to 8.3)	(25.9 to 39.1)	(-0.3 to 0.6)	(0.5 to 1.5)	(0.7 to 2.0)	(15.5 to 50.2)	(-11.9 to 14.1)
Diabetes mellitus	-	-	-	-	9.6	12.6	31.3	-0.2
Acute glomerulonephritis	-	-	-	-	(6.6 to 13.0)	(8.7 to 17.0)	(26.8 to 35.4)	(-3.6 to 3.4)
Chronic kidney disease	24.1	32.0	32.5	-0.5	6.0	7.9	31.7	-0.1
Diabetes mellitus	(22.9 to 25.5)	(30.3 to 33.7)	(31.3 to 33.8)	(-0.5 to -0.4)	(4.0 to 8.2)	(5.3 to 10.7)	(25.0 to 38.8)	(-4.9 to 4.8)
Acute glomerulonephritis	36.1	47.5	31.5	-0.6	3.6	4.7	30.8	-0.4
Chronic kidney disease	(33.9 to 38.2)	(44.5 to 50.4)	(29.9 to 33.0)	(-0.7 to -0.6)	(2.5 to 5.1)	(3.3 to 6.6)	(25.5 to 36.4)	(-4.1 to 3.6)
Diabetes, urogenital, blood, and endocrine diseases	56.6	53.2	-5.9	0.4	0.7	0.7	-5.6	0.8
Diabetes mellitus	(46.7 to 66.7)	(43.9 to 62.8)	(-6.7 to -5.5)	(0.3 to 0.4)	(0.4 to 1.1)	(0.4 to 1.0)	(-12.8 to 2.4)	(-7.3 to 9.2)
Acute glomerulonephritis	104.3	96	-7.9	0.4	12.6	11.6	-7.7	0.6
Chronic kidney disease	(86.3 to 121.0)	(79.7 to 112.5)	(-9.6 to -5.6)	(0.4 to 0.5)	(7.8 to 19.1)	(7.2 to 17.8)	(-12.0 to -32.1)	(-33.3 to 4.7)
Idiopathic intellectual disability	252.0	296.0	17.5	-10.6	12.4	14.5	16.8	-10.6
Other mental and substance use disorders	(212.7 to 301.0)	(251.7 to 349.1)	(9.1 to 28.0)	(-17.0 to -2.8)	(8.3 to 17.6)	(9.6 to 20.3)	(0.8 to 27.1)	(-17.3 to -2.6)
Diabetes, urogenital, blood, and endocrine diseases	113.7	200.1	76.0	-0.4	8.5	15.0	75.5	-0.1
Diabetes mellitus	(106.1 to 121.0)	(188.2 to 211.8)	(73.1 to 78.8)	(-0.7 to -0.2)	(5.7 to 11.5)	(10.2 to 20.2)	(68.1 to 82.8)	(-3.8 to 3.4)
Acute glomerulonephritis	-	-	-	-	60.4	124.8	106.4	23.6
Chronic kidney disease								

Appendix Table G.4 - Tunisia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.6 (1.5 to 1.8)	2.7 (2.6 to 2.9)	66.1 (50.6 to 81.8)	-0.1 (-2.3 to 15.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	64.6 (33.2 to 104.7)	64.6 (11.9 to 28.3)
Urolithiasis	67.5 (39.2 to 121.8)	227.2 (153.5 to 387.2)	228.5 (177.5 to 377.6)	0.5 (31.5 to 106.1)	1.7 (0.3 to 0.8)	1.7 (1.0 to 2.9)	248.2 (200.3 to 342.6)	72.1 (53.1 to 112.9)
Benign prostatic hyperplasia	71.0 (64.6 to 77.2)	151.1 (138.7 to 161.0)	112.4 (90.6 to 140.7)	-7.0 (-16.6 to 4.6)	2.6 (1.7 to 3.7)	5.4 (3.5 to 7.8)	112.3 (89.8 to 140.6)	-6.7 (-16.4 to 5.9)
Male infertility due to other causes	60.1 (41.7 to 82.0)	88.7 (59.1 to 126.1)	46.6 (9.0 to 149.1)	-4.9 (-40.9 to 57.3)	0.4 (0.2 to 0.9)	0.6 (0.2 to 1.4)	46.1 (-12.2 to 159.4)	-4.3 (-42.6 to 65.4)
Other urinary diseases	-	-	-	-	0.3 (0.1 to 0.5)	1.6 (0.8 to 3.0)	33.5 (293.9 to 848.2)	217.8 (95.3 to 375.7)
Gynecological diseases	-	-	-	-	11.3 (7.2 to 16.9)	18.5 (11.8 to 28.2)	63.9 (35.3 to 97.0)	-2.8 (-18.3 to 17.5)
Uterine fibroids	129.3 (116.5 to 140.9)	271.3 (247.0 to 294.0)	109.9 (106.8 to 113.1)	1.7 (1.5 to 1.8)	2.0 (1.2 to 3.3)	3.7 (2.1 to 6.1)	81.1 (68.7 to 91.8)	-6.5 (-12.1 to -1.5)
Polycystic ovarian syndrome	164.1 (148.1 to 182.3)	272.0 (244.0 to 299.4)	66.9 (40.3 to 92.7)	-0.9 (-14.5 to 13.2)	1.6 (0.7 to 3.1)	2.7 (1.2 to 5.2)	66.1 (40.4 to 91.0)	-0.6 (-15.0 to 13.4)
Female infertility due to other causes	18.3 (10.8 to 29.6)	39.1 (21.4 to 60.1)	99.5 (7.8 to 278.4)	0.1 (-32.7 to 149.3)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.5)	18.7 (-1.2 to 252.3)	18.7 (-34.7 to 129.5)
Endometriosis	13.2 (10.9 to 15.4)	24.8 (21.4 to 28.7)	88.5 (51.5 to 137.6)	7.0 (-13.3 to 33.7)	1.2 (0.8 to 1.7)	2.3 (1.5 to 3.3)	88.5 (48.4 to 140.3)	6.8 (-15.6 to 36.0)
Genital prolapse	375.3 (276.4 to 462.8)	732.8 (617.5 to 894.0)	93.8 (48.6 to 173.3)	1.6 (-21.7 to 36.9)	2.3 (0.6 to 2.3)	3.1 (1.1 to 4.4)	93.2 (48.0 to 173.2)	1.4 (-21.4 to 37.8)
Premenstrual syndrome	525.0 (360.5 to 693.9)	761.4 (504.5 to 1,069.4)	43.8 (-11.1 to 122.9)	-4.6 (-43.7 to 52.3)	4.4 (2.4 to 7.3)	6.4 (3.4 to 10.9)	43.9 (-11.8 to 122.0)	-4.6 (-42.8 to 52.0)
Other gynecological diseases	22.5 (18.0 to 27.3)	31.5 (29.3 to 33.7)	40.3 (15.3 to 71.9)	-13.0 (-28.1 to 6.1)	0.7 (0.4 to 1.0)	0.9 (0.6 to 1.3)	33.8 (9.0 to 101.9)	-17.3 (-32.7 to 23.5)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	13.9 (9.3 to 20.2)	16.6 (11.1 to 24.2)	20.4 (11.0 to 37.4)	5.5 (-3.7 to 19.6)
Thalassemias	2.5 (2.0 to 3.0)	2.6 (2.1 to 3.0)	1.7 (7.3 to 18.0)	3.6 (-6.1 to 19.8)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	1.2 (-32.0 to 57.6)	1.6 (-31.7 to 57.1)
Thalassemia trait	431.4 (384.9 to 478.8)	596.1 (552.2 to 646.5)	37.7 (30.7 to 47.2)	2.2 (-3.0 to 9.5)	9.5 (6.4 to 13.9)	12.1 (8.1 to 17.5)	27.4 (8.3 to 47.3)	10.7 (-8.1 to 26.6)
Sickle cell disorders	1.7 (1.3 to 1.9)	2.0 (1.7 to 2.2)	16.8 (-1.0 to 53.1)	6.6 (-10.5 to 37.7)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	36.8 (10.8 to 61.8)	14.2 (-5.8 to 35.6)
Sickle cell trait	382.6 (354.0 to 411.5)	495.8 (457.5 to 530.5)	29.2 (23.8 to 35.2)	-2.1 (-8.2 to 0.2)	2.1 (1.2 to 3.0)	2.3 (1.4 to 3.4)	14.3 (-20.6 to 44.7)	2.9 (-29.3 to 27.4)
G6PD deficiency	170.5 (129.5 to 214.0)	184.0 (133.0 to 234.8)	8.0 (-24.3 to 56.9)	-20.0 (-43.9 to 16.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.5 (-2.3 to 13.1)	-10.3 (-14.5 to -7.4)
G6PD trait	1,183.3 (892.1 to 1,413.2)	1,671.0 (1,308.4 to 1,965.7)	42.0 (-1.4 to 98.6)	4.8 (-27.2 to 46.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	14.0 (-86.7 to 887.3)	19.1 (-86.7 to 669.9)
Other hemoglobinopathies and hemolytic anemias	69.7 (58.0 to 78.2)	78.8 (69.2 to 86.3)	12.8 (-4.3 to 41.8)	-14.9 (-26.8 to 2.6)	1.9 (1.0 to 2.9)	1.7 (1.1 to 2.6)	-6.3 (-34.8 to 72.9)	-16.3 (-40.8 to 44.1)
Endocrine, metabolic, blood, and immune disorders	95.9 (89.5 to 107.1)	108.9 (100.8 to 113.7)	12.8 (0.9 to 23.5)	-11.2 (-19.5 to -3.4)	3.3 (2.1 to 4.5)	3.3 (2.2 to 4.6)	14.7 (9.8 to 21.0)	-10.4 (-22.6 to 4.0)
Musculoskeletal disorders	-	-	-	-	108.6 (76.2 to 143.9)	211.0 (148.2 to 282.6)	94.0 (79.8 to 110.7)	19.1 (-4.6 to 10.9)
Rheumatoid arthritis	12.0 (11.2 to 12.9)	19.7 (18.4 to 21.0)	64.7 (48.6 to 80.6)	-11.4 (-19.9 to -2.5)	2.9 (2.0 to 3.9)	4.7 (3.3 to 6.1)	62.4 (44.5 to 81.5)	-11.5 (-20.6 to -1.2)
Osteoarthritis	177.8 (167.2 to 188.5)	410.6 (386.7 to 432.9)	131.0 (111.4 to 150.9)	1.7 (-6.3 to 10.2)	11.0 (7.6 to 15.1)	25.2 (17.5 to 34.6)	130.1 (110.8 to 150.3)	1.9 (-6.2 to 10.1)
Low back and neck pain	-	-	-	-	82.1 (56.4 to 110.2)	150.3 (102.9 to 203.7)	82.9 (64.8 to 104.2)	0.5 (-9.7 to 11.9)
Low back pain	487.3 (454.4 to 522.8)	881.1 (827.5 to 941.7)	81.4 (63.3 to 99.2)	0.7 (-8.7 to 9.8)	54.9 (36.5 to 77.2)	98.5 (67.0 to 137.1)	80.3 (61.6 to 98.2)	0.9 (-8.4 to 10.5)
Neck pain	276.5 (234.2 to 320.2)	527.6 (439.2 to 613.3)	92.0 (47.0 to 138.3)	1.1 (-22.4 to 25.7)	27.2 (18.4 to 38.8)	51.7 (34.8 to 73.7)	90.9 (46.1 to 137.6)	0.9 (-22.6 to 25.6)
Gout	3.5 (3.0 to 4.0)	7.2 (6.1 to 8.2)	105.6 (65.3 to 155.0)	-4.7 (-22.8 to 17.3)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	103.5 (52.7 to 171.7)	-4.8 (-28.0 to 24.1)
Other musculoskeletal disorders	137.1 (107.6 to 164.1)	335.0 (270.6 to 411.1)	145.1 (122.7 to 165.8)	20.5 (11.2 to 28.9)	12.6 (8.1 to 18.0)	30.6 (20.3 to 44.3)	43.8 (120.7 to 65.4)	20.9 (-12.0 to 28.8)
Other non-communicable diseases	-	-	-	-	106.4 (70.4 to 154.4)	175.9 (112.7 to 255.0)	65.3 (57.4 to 74.6)	-2.5 (-6.5 to 2.1)
Congenital anomalies	-	-	-	-	6.8 (5.0 to 8.9)	16.0 (10.9 to 21.8)	130.6 (89.4 to 197.3)	71.9 (40.2 to 122.0)
Neural tube defects	2.0 (1.6 to 2.4)	3.1 (2.4 to 3.9)	56.5 (16.5 to 103.3)	30.3 (-3.1 to 69.5)	0.6 (0.4 to 0.8)	0.9 (0.6 to 1.4)	67.9 (9.8 to 151.0)	42.1 (-6.9 to 109.5)
Congenital heart anomalies	32.7 (27.7 to 40.0)	79.5 (65.6 to 96.7)	142.8 (89.7 to 221.2)	95.7 (51.9 to 158.0)	1.1 (0.5 to 2.0)	2.8 (1.2 to 4.9)	144.5 (91.4 to 217.0)	101.3 (57.7 to 159.0)
Orofacial clefts	6.1 (4.4 to 8.4)	12.8 (9.7 to 16.9)	114.2 (36.1 to 214.2)	82.2 (15.2 to 166.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	46.0 (-13.6 to 129.7)	23.9 (-25.8 to 92.8)
Down syndrome	11.1 (8.6 to 14.4)	20.6 (15.8 to 26.6)	86.5 (22.9 to 162.8)	37.9 (-8.8 to 95.2)	1.4 (0.9 to 1.9)	2.9 (1.9 to 4.0)	106.7 (35.5 to 194.9)	44.6 (-5.2 to 105.4)
Turner syndrome	0.3 (0.2 to 0.4)	0.4 (0.4 to 0.5)	52.7 (-4.5 to 107.9)	17.2 (-27.0 to 60.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.2 (-2.1 to 126.6)	16.3 (-27.1 to 71.6)
Klinefelter syndrome	0.3 (0.2 to 0.4)	0.3 (0.3 to 0.4)	30.2 (-14.2 to 89.6)	-2.0 (-35.4 to 42.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	46.2 (-4.8 to 112.2)	-2.3 (-35.8 to 42.5)
Chromosomal unbalanced rearrangements	10.4 (8.4 to 12.8)	17.3 (14.4 to 20.6)	67.9 (26.6 to 111.3)	24.5 (-5.8 to 56.7)	2.3 (0.9 to 1.8)	2.4 (1.7 to 3.2)	30.9 (48.5 to 137.0)	30.9 (-2.9 to 65.5)
Other congenital anomalies	21.5 (18.1 to 25.7)	28.9 (24.1 to 34.3)	35.8 (11.1 to 61.4)	-6.6 (-23.9 to 10.1)	2.3 (1.7 to 3.3)	6.8 (3.9 to 10.6)	184.7 (94.9 to 363.1)	114.3 (47.4 to 247.1)
Skin and subcutaneous diseases	-	-	-	-	42.8 (26.6 to 65.9)	59.8 (37.4 to 93.1)	39.6 (25.4 to 54.1)	2.2 (-7.9 to 12.0)
Dermatitis	414.0 (354.5 to 469.8)	610.4 (516.9 to 693.4)	47.3 (42.0 to 53.2)	0.0 (-0.1 to 0.1)	12.6 (8.4 to 18.1)	17.5 (11.5 to 25.1)	39.0 (31.1 to 47.3)	0.2 (-2.3 to 2.9)
Psoriasis	45.6 (36.1 to 56.6)	75.4 (58.6 to 94.1)	64.8 (58.7 to 73.2)	-0.0 (-0.2 to 0.1)	6.1 (2.4 to 5.5)	6.1 (3.9 to 9.1)	64.0 (51.2 to 77.9)	0.1 (-5.7 to 6.5)
Cellulitis	1.7 (1.4 to 2.1)	2.1 (1.7 to 2.6)	22.4 (7.0 to 39.7)	-16.9 (-24.3 to -6.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	22.1 (-5.6 to 52.0)	-16.2 (-30.8 to 3.2)
Pyoderma	6.3 (5.0 to 8.0)	6.8 (5.4 to 8.9)	7.1 (-4.6 to 20.4)	-7.7 (-13.2 to -1.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	5.9 (-8.9 to 24.7)	-8.1 (-18.4 to 3.6)
Scabies	30.3 (24.8 to 38.0)	38.7 (32.6 to 48.1)	28.6 (-5.3 to 68.8)	-3.8 (-28.5 to 24.9)	0.8 (0.4 to 1.3)	1.0 (0.5 to 1.6)	27.6 (-6.7 to 68.8)	-3.5 (-28.6 to 25.1)
Fungal skin diseases	483.1 (367.9 to 602.4)	769.8 (601.9 to 943.7)	59.1 (49.2 to 71.7)	2.7 (-0.4 to 4.1)	4.3 (1.1 to 5.7)	4.3 (3.2 to 6.3)	58.5 (48.5 to 71.5)	-0.2 (-1.1 to 0.8)
Viral skin diseases	183.6 (141.2 to 224.7)	201.9 (148.9 to 256.7)	9.7 (2.0 to 16.9)	0.1 (-1.5 to 1.7)	5.7 (3.3 to 9.0)	6.2 (3.5 to 9.9)	9.4 (0.6 to 17.0)	3.1 (-3.2 to 3.4)
Acne vulgaris	972.1 (681.5 to 1,217.0)	1,231.7 (903.9 to 1,531.4)	25.9 (-15.1 to 100.6)	11.7 (-24.4 to 76.8)	10.6 (4.7 to 20.0)	13.4 (5.9 to 25.8)	25.6 (-15.4 to 101.9)	11.9 (-24.2 to 77.1)
Alopecia areata	10.6 (9.1 to 12.0)	16.6 (14.4 to 18.8)	56.9 (27.1 to 93.1)	-0.2 (-19.1 to 23.9)	0.4 (0.2 to 0.6)	0.6 (0.3 to 0.8)	55.7 (22.1 to 96.7)	-0.4 (-19.9 to 26.1)
Pruritus	1.6 (1.1 to 2.5)	3.6 (2.2 to 5.6)	117.0 (28.1 to 315.2)	25.1 (-23.3 to 158.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	153.3 (24.0 to 328.5)	25.2 (-24.7 to 160.9)
Urticaria	62.7 (41.7 to 83.9)	100.2 (72.0 to 139.9)	58.7 (-1.3 to 182.1)	-2.6 (-40.2 to 73.6)	3.7 (2.0 to 5.9)	5.9 (3.4 to 9.6)	57.2 (-1.7 to 179.8)	-2.5 (-40.3 to 75.2)
Decubitus ulcer	1.2 (0.9 to 1.4)	2.1 (1.7 to 2.6)	78.8 (43.5 to 144.8)	-20.6 (-37.6 to 14.2)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	76.7 (37.1 to 144.4)	-19.6 (-39.1 to 16.6)
Other skin and subcutaneous diseases	382.2 (255.8 to 567.2)	702.5 (452.2 to 1,099.1)	83.4 (64.0 to 100.7)	0.4 (-3.4 to 4.1)	2.3 (1.0 to 6.6)	4.1 (1.8 to 8.7)	82.5 (63.5 to 100.0)	0.4 (-3.6 to 4.3)
Sense organ diseases	-	-	-	-	39.6 (26.7 to 55.7)	68.8 (46.7 to 96.4)	3.3 (66.3 to 82.5)	-12.4 (-15.7 to -8.7)
Glaucoma	10.6 (7.7 to 13.6)	17.4 (13.6 to 20.9)	62.9 (36.9 to 110.0)	-21.5 (-35.8 to -8.8)	0.9 (0.6 to 1.4)	1.6 (1.0 to 2.3)	67.9 (35.9 to 115.6)	-21.3 (-36.1 to 0.5)
Cataract	35.7 (20.9 to 48.6)	74.7 (53.3 to 97.4)	112.1 (65.3 to 189.3)	-16.7 (-31.7 to 2.4)	3.0 (1.6 to 4.4)	6.4 (3.8 to 9.7)	118.8 (66.7 to 172.4)	-16.0 (-33.8 to -2.2)
Macular degeneration	6.6 (4.2 to 9.6)	11.3 (7.7 to 16.0)	74.8 (13.1 to 163.1)	-24.2 (-49.3 to 12.0)	0.4 (0.2 to 0.6)	0.8 (0.4 to 1.1)	92.9 (27.2 to 173.8)	-21.5 (-44.7 to 9.7)
Uncorrected refractive error	602.8 (562.9 to 640.8)	1,083.8 (1,016.1 to 1,145.7)	80.0 (66.9 to 92.1)	5.8 (-12.1 to 30.5)	10.4 (6.5 to 15.9)	17.3 (10.6 to 27.2)	66.4 (57.0 to 78.3)	-11.1 (-15.6 to -5.5)
Age-related and other hearing loss	671.0 (623.7 to 721.9)	1,252.6 (1,170.7 to 1,341.4)	86.7 (78.0 to 95.5)	-10.2 (-14.0 to -6.8)	17.6 (11.7 to 25.3)	33.2 (21.7 to 47.2)	88.2 (75.8 to 101.6)	-11.4 (-16.6 to -7.1)
Other vision loss	27.3 (22.4 to 32.5)	34.5 (27.9 to 42.4)	26.3 (10.0 to 44.8)	-28.0 (-38.0 to -16.1)	2.3 (1.6 to 3.4)	3.1 (2.0 to 4.5)	31.5 (15.0 to 49.3)	-28.8 (-39.4 to -18.6)
Other sense organ diseases	188.4 (179.8 to 197.8)	247.6 (236.6 to 258.0)	31.4 (23.6 to 40.0)	0.2 (-5.5 to 6.2)	5.0 (3.1 to 7.5)	6.6 (4.0 to 9.7)	30.1 (21.4 to 39.7)	0.3 (-6.2 to 7.4)
Oral disorders	-	-	-	-	17.2 (10.7 to 26.4)	31.4 (19.5 to 47.1)	82.8 (75.0 to 95.7)	-5.1 (-10.6 to 1.4)
Deciduous caries	810.6 (769.5 to 847.0)	664.9 (634.5 to 700.6)	-18.0 (-23.0 to -12.7)	0.4 (-5.7 to 6.8)	0.4 (0.1 to 0.6)	0.3 (0.1 to 0.5)	47.8 (26.0 to 10.3)	0.5 (-8.2 to 9.8)

Appendix Table G.4 - Tunisia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	301.5 (278.9 to 321.8)	609.5 (561.6 to 661.3)	101.4 (84.6 to 124.5)	-9.7 (-17.3 to 0.2)	8.4 (5.6 to 11.6)	16.8 (11.2 to 23.2)	100.7 (83.0 to 123.9)	-9.7 (-17.3 to 0.5)
Other oral disorders	128.6 (121.6 to 136.3)	201.8 (190.2 to 213.9)	56.9 (44.3 to 69.5)	-0.3 (-7.8 to 7.5)	3.8 (2.3 to 5.7)	5.9 (3.7 to 8.8)	56.0 (42.9 to 69.6)	-0.3 (-8.2 to 8.1)
Injuries	-	-	-	-	35.2 (26.8 to 45.3)	35.2 (25.2 to 47.8)	-0.5 (-13.0 to 14.0)	-44.1 (-50.7 to -36.5)
Transport injuries	-	-	-	-	21.2 (15.9 to 27.3)	18.2 (12.8 to 24.8)	-14.6 (-26.9 to 0.4)	-51.6 (-58.1 to -43.9)
Road injuries	-	-	-	-	20.0 (15.1 to 25.8)	16.6 (11.7 to 22.6)	-17.7 (-29.9 to -3.1)	-53.2 (-59.5 to -45.8)
Pedestrian road injuries	-	-	-	-	4.8 (3.5 to 6.2)	3.3 (2.3 to 4.6)	-30.5 (-41.4 to -15.9)	-58.8 (-64.7 to -50.9)
Cyclist road injuries	-	-	-	-	1.8 (1.3 to 2.3)	1.9 (1.4 to 2.6)	9.7 (-2.1 to 23.6)	-40.1 (-46.3 to -32.6)
Motorcyclist road injuries	-	-	-	-	2.6 (2.0 to 3.4)	1.9 (1.3 to 2.6)	-27.8 (-38.9 to -15.4)	-60.0 (-65.8 to -53.6)
Motor vehicle road injuries	-	-	-	-	10.7 (8.0 to 13.7)	9.3 (6.7 to 12.7)	-13.3 (-27.3 to 4.2)	-51.1 (-58.6 to -41.8)
Other road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-55.7 (-62.2 to 47.9)	-75.0 (-78.4 to -71.0)
Other transport injuries	-	-	-	-	1.2 (0.9 to 1.5)	1.6 (1.1 to 2.2)	39.5 (22.9 to 61.1)	-24.6 (-33.5 to -13.5)
Unintentional injuries	-	-	-	-	12.5 (9.6 to 16.2)	16.2 (11.8 to 21.8)	28.7 (17.4 to 40.8)	-29.2 (-35.1 to -22.6)
Falls	-	-	-	-	4.7 (3.6 to 6.1)	7.1 (5.1 to 9.6)	50.3 (32.5 to 71.5)	-24.8 (-33.8 to -14.2)
Drowning	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-29.2 (-39.1 to -17.2)	-57.3 (-62.9 to -50.7)
Fire, heat, and hot substances	-	-	-	-	1.1 (0.9 to 1.4)	0.9 (0.6 to 1.2)	-22.9 (-34.6 to -9.8)	-54.4 (-60.6 to -47.2)
Poisonings	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-23.5 (-40.2 to -3.9)	-50.0 (-59.8 to -37.8)
Exposure to mechanical forces	-	-	-	-	3.7 (2.8 to 4.9)	4.3 (3.1 to 5.8)	15.2 (4.0 to 26.3)	-30.6 (-36.2 to -24.6)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-9.2 (-19.7 to 8.2)	-47.9 (-54.5 to -40.1)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	58.1 (37.4 to 81.8)	-4.6 (-16.2 to 8.3)
Other exposure to mechanical forces	-	-	-	-	3.6 (2.7 to 4.6)	4.1 (3.0 to 5.6)	15.9 (4.7 to 27.1)	-30.1 (-35.8 to -23.9)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	101.0 (87.4 to 117.6)	13.1 (5.1 to 22.5)
Animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	27.6 (13.1 to 44.6)	-22.1 (-29.8 to -13.2)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	28.4 (8.8 to 51.8)	-21.5 (-32.8 to -8.3)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	26.7 (10.1 to 44.5)	-22.9 (-31.0 to -13.5)
Foreign body	-	-	-	-	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.5)	25.8 (14.3 to 39.7)	-25.8 (-32.2 to -18.8)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-29.5 (-42.8 to -13.2)	-53.1 (-61.1 to -43.5)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	42.3 (24.6 to 60.1)	-10.1 (-20.3 to 1.0)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	40.3 (26.7 to 57.8)	-22.4 (-29.3 to -14.5)
Other unintentional injuries	-	-	-	-	2.0 (1.5 to 2.7)	2.9 (2.1 to 3.8)	40.4 (27.0 to 53.4)	-24.0 (-31.0 to -17.0)
Self-harm and interpersonal violence	-	-	-	-	0.6 (0.4 to 0.8)	0.6 (0.5 to 0.9)	9.6 (-4.8 to 26.0)	-36.3 (-44.2 to -27.3)
Self-harm	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	96.4 (70.6 to 123.5)	-0.0 (-12.7 to 12.9)
Interpersonal violence	-	-	-	-	0.5 (0.4 to 0.6)	0.4 (0.3 to 0.6)	-12.3 (-24.6 to 2.4)	-47.4 (-54.3 to -39.1)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	1.0 (-12.1 to 14.3)	-39.3 (-46.6 to -32.3)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	4.1 (-1.2 to 24.8)	-39.2 (-47.7 to -28.3)
Assault by other means	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-22.4 (-33.9 to -8.3)	-52.9 (-60.0 to -44.5)
Forces of nature, war, and legal intervention	-	-	-	-	0.9 (0.3 to 2.1)	0.2 (0.1 to 0.4)	-79.1 (-86.6 to -68.0)	-88.7 (-93.1 to -82.1)
Exposure to forces of nature	-	-	-	-	0.3 (0.1 to 0.5)	0.1 (0.0 to 0.1)	-75.1 (-87.4 to -56.7)	-85.4 (-92.5 to -75.3)
Collective violence and legal intervention	-	-	-	-	0.6 (0.1 to 1.8)	0.1 (0.0 to 0.3)	-80.3 (-87.8 to -68.9)	-89.7 (-93.9 to -82.8)

Appendix Table G.4 - Turkey prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	5,229.8 (3,868.7 to 6,803.2)	8,265.3 (6,132.1 to 10,764.6)	58.0 (53.8 to 62.9)	-11.1 (-2.8 to 2.3)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	744.5 (517.1 to 1,042.9)	800.4 (561.8 to 1,092.5)	7.2 (0.6 to 17.4)	-11.1 (-17.2 to -2.7)
HIV/AIDS and tuberculosis	-	-	-	-	7.7 (5.2 to 10.4)	10.3 (7.0 to 14.0)	33.4 (18.0 to 50.4)	-17.8 (-26.1 to -8.6)
Tuberculosis	25.1 (23.9 to 26.3)	31.7 (30.2 to 33.2)	26.1 (21.0 to 31.6)	-22.4 (-25.5 to -19.3)	7.7 (5.2 to 10.4)	9.7 (6.4 to 13.1)	25.0 (10.7 to 41.1)	-22.7 (-30.6 to -13.9)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.0)	0.6 (0.3 to 1.1)	5,170.3 (2,791.3 to nan)	0.75 (1,618.0 to nan)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3,099.1 (1,588.6 to 0.0)	1,768.8 (860.7 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	3,099.1 (1,567.1 to nan)	1,768.8 (853.4 to nan)
HIV/AIDS resulting in other diseases	0.1 (0.0 to 0.2)	6.6 (3.7 to 10.4)	5,829.8 (3,402.0 to 0.0)	3,601.3 (2,073.7 to 0.0)	0.0 (0.0 to 0.0)	0.6 (0.3 to 1.1)	5,185.2 (2,783.7 to nan)	3,081.3 (1,609.1 to nan)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	168.8 (119.4 to 230.4)	145.8 (103.3 to 197.3)	-13.7 (-19.5 to -7.0)	-24.4 (-29.4 to -19.2)
Diarrheal diseases	669.8 (626.8 to 711.3)	604.8 (564.3 to 642.7)	-9.7 (-17.4 to -1.3)	-18.7 (-25.6 to -11.6)	109.0 (74.3 to 151.5)	97.8 (66.5 to 135.2)	-10.2 (-18.5 to -1.5)	-18.6 (-25.7 to -11.0)
Intestinal infectious diseases	-	-	-	-	0.7 (0.4 to 1.0)	0.6 (0.4 to 0.8)	-15.9 (-35.1 to 6.9)	-32.2 (-46.4 to -14.9)
Typhoid fever	3.8 (3.2 to 4.5)	3.4 (2.9 to 3.9)	-11.8 (-29.7 to 9.8)	-28.8 (-42.4 to -12.7)	0.5 (0.3 to 0.8)	0.5 (0.3 to 0.7)	-11.4 (-33.8 to 14.8)	-28.8 (-45.2 to -9.1)
Paratyphoid fever	2.0 (1.6 to 2.3)	1.7 (1.5 to 2.1)	-12.1 (-32.0 to 10.7)	-27.6 (-43.1 to -8.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-12.1 (-32.0 to 11.0)	-27.6 (-43.2 to -8.5)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-89.5 (-96.2 to -75.2)	-91.5 (-96.9 to -80.0)
Lower respiratory infections	190.0 (174.0 to 206.9)	120.1 (111.0 to 130.5)	-36.7 (-44.6 to -29.1)	-42.0 (-49.1 to -35.4)	20.0 (13.5 to 28.1)	12.4 (8.4 to 17.2)	-37.8 (-46.2 to -28.8)	-42.4 (-50.3 to -34.4)
Upper respiratory infections	769.1 (722.2 to 815.5)	1,022.7 (950.1 to 1,099.6)	33.1 (20.3 to 46.3)	0.9 (-8.9 to 10.4)	9.1 (5.1 to 15.3)	12.0 (6.7 to 20.3)	32.7 (19.1 to 47.2)	1.0 (-9.4 to 11.6)
Otitis media	668.3 (632.2 to 709.8)	728.5 (686.9 to 780.1)	8.7 (0.1 to 18.6)	-13.1 (-20.0 to -4.9)	12.2 (7.3 to 19.9)	13.2 (7.7 to 21.3)	8.1 (1.2 to 18.5)	-13.5 (-20.7 to -5.7)
Meningitis	-	-	-	-	13.1 (8.4 to 18.8)	5.7 (4.0 to 8.0)	-56.0 (-65.9 to -44.5)	-65.6 (-73.1 to -56.4)
Pneumococcal meningitis	46.4 (24.9 to 74.2)	21.8 (12.4 to 36.2)	-53.0 (-65.1 to -37.0)	-66.6 (-74.8 to -55.4)	4.0 (2.3 to 6.2)	2.0 (1.3 to 2.9)	-48.6 (-66.8 to -19.0)	-61.0 (-74.4 to -40.5)
H influenzae type B meningitis	33.7 (9.4 to 76.0)	11.1 (3.6 to 26.7)	-65.6 (-81.8 to -43.4)	-74.9 (-86.4 to -56.1)	3.5 (2.0 to 6.2)	1.3 (0.8 to 2.2)	-61.9 (-81.5 to -29.1)	-69.9 (-85.5 to -45.2)
Meningococcal meningitis	25.5 (8.2 to 62.4)	9.1 (2.8 to 24.4)	-65.9 (-76.7 to -48.1)	-74.9 (-82.0 to -61.2)	2.9 (1.6 to 4.6)	1.1 (0.6 to 1.9)	-63.3 (-76.9 to -38.9)	-71.5 (-81.0 to -53.0)
Other meningitis	21.1 (11.4 to 39.3)	9.9 (4.6 to 20.3)	-54.9 (-66.8 to -33.0)	-63.9 (-73.2 to -48.6)	2.7 (1.7 to 3.9)	1.3 (0.8 to 2.0)	-52.7 (-67.6 to -28.3)	-61.0 (-73.0 to -41.9)
Encephalitis	13.6 (5.9 to 32.8)	14.6 (6.4 to 38.0)	6.8 (-15.5 to 25.5)	-29.1 (-42.9 to -15.3)	1.8 (1.2 to 2.4)	2.0 (1.4 to 2.7)	12.7 (7.7 to 37.5)	-23.3 (-36.5 to -7.3)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-81.2 (-98.3 to 125.0)	-84.3 (-98.4 to 91.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-81.2 (-98.4 to 129.0)	-81.2 (-98.4 to 92.7)
Whooping cough	23.3 (18.2 to 29.7)	2.8 (2.1 to 3.6)	-88.1 (-89.5 to -86.5)	-87.3 (-88.8 to -85.5)	1.2 (0.7 to 1.9)	0.1 (0.1 to 0.2)	-88.0 (-91.0 to -84.3)	-87.2 (-90.4 to -83.3)
Tetanus	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.0)	-90.2 (-94.9 to -79.9)	-92.8 (-96.2 to -85.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-82.6 (-91.4 to -66.4)	-86.9 (-93.3 to -75.1)
Measles	10.7 (8.3 to 13.5)	3.7 (2.9 to 4.5)	-65.3 (-70.3 to -59.2)	-65.3 (-68.4 to -56.6)	1.0 (0.6 to 1.5)	0.3 (0.2 to 0.5)	-65.2 (-74.5 to -32.1)	-63.0 (-73.0 to -49.0)
Varicella and herpes zoster	39.6 (35.9 to 43.8)	52.9 (46.8 to 59.9)	32.7 (15.4 to 57.9)	32.7 (-12.3 to 30.0)	4.9 (0.5 to 1.4)	1.6 (1.0 to 2.6)	83.7 (37.1 to 160.8)	7.6 (-21.3 to 55.0)
Neglected tropical diseases and malaria	-	-	-	-	31.6 (18.5 to 49.0)	23.9 (15.8 to 34.7)	-24.5 (-39.6 to 8.4)	-27.8 (-41.8 to 2.1)
Malaria	23.2 (13.6 to 42.3)	51.7 (29.2 to 115.2)	124.6 (34.0 to 211.9)	83.5 (7.9 to 156.3)	0.4 (0.3 to 0.6)	0.7 (0.3 to 1.1)	61.6 (-7.5 to 140.2)	38.2 (-19.2 to 101.1)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	1.1 (-29.8 to 44.5)	-22.7 (-44.6 to 6.5)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.8 (-32.7 to 0.7)	-26.6 (-39.9 to -11.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-16.8 (-32.7 to 0.7)	-26.6 (-39.9 to -11.5)
Cutaneous and mucocutaneous leishmaniasis	2.6 (2.0 to 3.5)	2.7 (2.1 to 3.6)	2.4 (-12.7 to 17.9)	-22.1 (-33.4 to -10.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	1.8 (-30.2 to 47.8)	-22.5 (-45.2 to 8.5)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.1 (0.0 to 0.3)	0.0 (0.0 to 0.1)	-57.8 (-89.6 to 22.0)	-73.8 (-93.2 to -24.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-52.1 (-88.3 to 38.9)	-69.8 (-92.4 to -11.0)
Cystic echinococcosis	7.5 (6.9 to 8.3)	4.7 (3.8 to 6.0)	-40.3 (-46.2 to -24.2)	-64.7 (-68.2 to -54.9)	0.7 (0.5 to 1.0)	0.4 (0.3 to 0.7)	-38.1 (-53.2 to -16.7)	-63.1 (-71.9 to -50.4)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.1 (-76.3 to -31.5)	-69.0 (-81.4 to -53.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-57.1 (-76.3 to -31.5)	-69.0 (-81.5 to -53.7)
Intestinal nematode infections	-	-	-	-	6.1 (2.2 to 14.1)	0.6 (0.4 to 1.0)	89.2 (-95.2 to -76.5)	-89.6 (-95.3 to -78.6)
Ascariasis	2,910.4 (2,163.2 to 3,833.0)	2,973.4 (2,117.8 to 4,085.5)	0.7 (-33.6 to 57.9)	-27.3 (-53.0 to 17.8)	5.9 (2.1 to 13.9)	0.2 (0.1 to 0.5)	96.2 (-98.5 to -90.0)	-96.2 (-98.5 to -90.2)
Trichuriasis	965.0 (728.1 to 1,269.6)	1,850.7 (1,316.7 to 2,617.2)	89.4 (21.3 to 202.0)	34.4 (-15.9 to 121.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.3)	826.5 (147.9 to 3,228.8)	620.9 (73.3 to 2,619.2)
Hookworm disease	36.0 (23.7 to 50.9)	58.6 (39.6 to 83.1)	61.7 (-4.9 to 177.5)	0.2 (-4.1 to 72.0)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	12.0 (14.8 to 111.7)	12.0 (-27.9 to 30.6)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	713.3 (537.2 to 897.7)	675.0 (622.6 to 731.8)	-5.7 (-24.1 to 25.2)	-13.8 (-29.4 to 11.0)	24.4 (13.8 to 36.3)	22.1 (14.6 to 32.1)	-11.1 (-23.8 to 38.6)	-13.5 (-25.8 to 32.8)
Maternal disorders	-	-	-	-	3.3 (1.9 to 5.3)	2.9 (1.6 to 4.7)	-12.4 (-29.1 to 6.9)	-37.9 (-49.2 to -25.5)
Maternal hemorrhage	11.7 (10.0 to 13.6)	13.3 (9.8 to 16.8)	12.5 (-19.3 to 52.2)	21.0 (-43.4 to 7.0)	0.5 (0.3 to 0.7)	0.4 (0.2 to 0.7)	-4.6 (-47.2 to 58.9)	-31.5 (-61.9 to 12.5)
Maternal sepsis and other maternal infections	28.5 (17.4 to 38.4)	21.8 (13.6 to 32.0)	-23.4 (-42.1 to -2.7)	-55.8 (-65.9 to -44.2)	0.4 (0.2 to 0.7)	0.2 (0.1 to 0.4)	-35.2 (-65.6 to 16.2)	-57.3 (-76.4 to -25.6)
Maternal hypertensive disorders	35.8 (17.4 to 59.5)	31.5 (16.3 to 51.4)	-12.5 (-24.8 to 5.0)	-37.4 (-43.3 to -25.5)	1.8 (0.7 to 3.2)	1.5 (0.7 to 2.8)	-12.7 (-26.9 to 6.6)	-37.3 (-46.7 to -24.2)
Obstructed labor	1.1 (0.6 to 1.7)	0.7 (0.3 to 1.4)	-33.1 (-60.8 to 18.9)	-52.5 (-71.7 to -16.4)	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.5)	-32.9 (-77.8 to 59.9)	-52.3 (-84.1 to 14.6)
Complications of abortion	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	19.3 (-34.0 to 114.3)	-20.5 (-55.2 to 42.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.3 (-34.3 to 114.6)	-20.5 (-55.2 to 42.7)
Other maternal disorders	-	-	-	-	0.4 (0.2 to 0.7)	0.4 (0.2 to 0.8)	20.0 (-34.1 to 127.1)	15.2 (-52.9 to 58.0)
Neonatal disorders	-	-	-	-	46.3 (29.2 to 68.5)	163.5 (107.8 to 239.2)	249.1 (141.9 to 473.6)	175.8 (91.7 to 351.5)
Preterm birth complications	214.6 (153.4 to 294.5)	614.7 (457.1 to 794.9)	185.9 (125.8 to 278.3)	112.6 (67.9 to 180.1)	22.3 (14.3 to 31.9)	75.8 (51.4 to 104.5)	234.6 (149.4 to 423.0)	159.5 (94.5 to 307.2)
Neonatal encephalopathy due to birth asphyxia and trauma	69.0 (28.8 to 157.9)	111.4 (63.7 to 191.4)	69.3 (-23.1 to 315.5)	33.9 (-40.8 to 239.3)	13.9 (6.6 to 24.4)	31.2 (18.1 to 48.4)	126.7 (15.8 to 400.5)	86.7 (-4.6 to 310.2)
Neonatal sepsis and other neonatal infections	0.5 (0.2 to 1.1)	0.3 (0.1 to 0.6)	-40.6 (-45.5 to -34.0)	-34.1 (-39.5 to -26.8)	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-40.3 (-47.6 to -28.4)	-33.8 (-41.8 to -20.6)
Hemolytic disease and other neonatal jaundice	17.8 (4.3 to 51.4)	57.3 (18.9 to 197.0)	209.1 (-4.4 to 1,977.6)	142.9 (-23.0 to 1,547.6)	6.4 (1.4 to 18.8)	18.2 (6.6 to 52.5)	179.4 (-4.1 to 1,379.6)	118.1 (-24.8 to 1,079.1)
Other neonatal disorders	-	-	-	-	3.7 (1.1 to 10.2)	38.2 (16.5 to 66.7)	1,374.3 (144.9 to 3,523.3)	1,058.3 (94.8 to 2,748.8)
Nutritional deficiencies	-	-	-	-	456.0 (307.0 to 661.1)	419.1 (277.1 to 613.7)	-7.9 (-14.3 to -2.3)	-24.5 (-29.9 to -19.5)
Protein-energy malnutrition	118.8 (50.5 to 243.4)	34.5 (14.0 to 71.0)	-71.2 (-90.8 to -10.9)	-68.6 (-89.9 to -3.9)	14.8 (5.8 to 32.1)	4.3 (1.4 to 9.7)	-71.4 (-91.2 to -9.0)	-68.9 (-90.3 to -1.4)
Iodine deficiency	2,803.4 (2,065.4 to 3,648.2)	1,897.0 (1,333.1 to 2,606.3)	-32.9 (-56.9 to 8.5)	-55.5 (-71.9 to -26.8)	50.4 (28.4 to 83.5)	34.0 (18.6 to 57.5)	-33.1 (-56.9 to 8.8)	-55.3 (-71.7 to -26.6)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-

Appendix Table G.4 - Turkey prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	12,078.3 (11,893.2 to 12,265.2)	12,956.5 (12,816.7 to 13,103.2)	7.2 (4.9 to 9.8)	-16.3 (-18.0 to -14.5)	384.0 (256.5 to 555.5)	379.6 (252.0 to 553.3)	-1.1 (-4.5 to 1.2)	-1.1 (-20.4 to -15.4)
Other nutritional deficiencies	-	-	-	-	6.8 (1.9 to 18.2)	1.2 (0.4 to 2.8)	-82.3 (-96.0 to -31.1)	-80.8 (-95.6 to -25.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	30.7 (19.4 to 47.5)	34.9 (22.0 to 55.1)	14.2 (7.3 to 35.0)	-8.8 (-25.5 to 7.3)
Sexually transmitted diseases excluding HIV	-	-	-	-	10.3 (5.4 to 19.1)	14.6 (7.3 to 26.5)	43.0 (-15.3 to 112.2)	-6.6 (-42.4 to 36.1)
Syphilis	1.7 (1.6 to 1.9)	1.8 (1.6 to 2.1)	7.7 (8.3 to 24.2)	-44.1 (-52.1 to -36.4)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.7)	8.7 (-18.6 to 44.9)	43.1 (-57.8 to -23.9)
Chlamydial infection	1,079.6 (720.7 to 1,398.3)	1,325.8 (841.3 to 1,742.3)	22.2 (-33.5 to 101.3)	-16.3 (53.8 to 37.9)	5.1 (2.2 to 9.8)	7.1 (2.6 to 13.6)	42.4 (-51.5 to 185.6)	-1.6 (-66.3 to 95.2)
Gonococcal infection	314.3 (218.9 to 419.3)	406.2 (306.4 to 497.0)	30.1 (9.5 to 97.3)	-8.4 (-35.8 to 34.2)	2.0 (1.0 to 3.5)	2.8 (1.5 to 4.6)	35.8 (-7.1 to 140.4)	-4.9 (-34.2 to 68.7)
Trichomoniasis	205.5 (124.9 to 288.5)	237.2 (179.3 to 315.0)	16.3 (-27.1 to 98.2)	-24.8 (-50.7 to 20.9)	0.4 (0.1 to 0.8)	0.4 (0.1 to 0.8)	9.6 (-35.2 to 114.0)	-28.3 (-56.0 to 31.3)
Genital herpes	8,610.7 (8,320.1 to 8,946.3)	13,889.4 (13,386.6 to 14,475.6)	61.1 (53.2 to 69.5)	-7.4 (-11.9 to -2.6)	2.3 (0.7 to 5.6)	3.6 (1.2 to 8.7)	56.9 (45.5 to 67.9)	-7.5 (-13.0 to -1.4)
Other sexually transmitted diseases	11.4 (8.3 to 15.2)	14.1 (10.8 to 19.2)	25.5 (-0.8 to 46.1)	-27.0 (-42.0 to -15.0)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	51.2 (2.0 to 133.5)	-7.0 (-36.2 to 40.5)
Hepatitis	-	-	-	-	3.3 (2.1 to 4.8)	4.4 (2.8 to 6.5)	34.4 (17.5 to 53.2)	-8.9 (-20.6 to 5.9)
Hepatitis A	67.4 (64.8 to 70.0)	71.4 (68.8 to 74.0)	5.9 (5.6 to 6.1)	-10.9 (-11.6 to -10.3)	1.6 (1.0 to 2.4)	2.0 (1.3 to 2.9)	22.9 (9.2 to 37.6)	-6.1 (-16.1 to 5.0)
Hepatitis B	2,926.4 (2,705.9 to 3,123.5)	2,757.3 (2,577.1 to 2,931.7)	-6.0 (-14.2 to 4.1)	-35.5 (-40.7 to -28.6)	1.3 (0.8 to 1.9)	1.3 (0.8 to 1.9)	1.7 (-20.6 to 41.8)	-39.5 (-52.3 to -14.0)
Hepatitis C	552.3 (514.5 to 595.1)	679.2 (628.6 to 731.3)	22.7 (10.1 to 35.6)	-26.8 (-34.2 to -18.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	21.4 (5.5 to 54.6)	-25.8 (-45.0 to -2.3)
Hepatitis E	13.8 (11.9 to 15.8)	40.0 (33.7 to 46.2)	189.7 (133.7 to 264.3)	120.7 (76.9 to 180.5)	0.3 (0.2 to 0.5)	1.0 (0.6 to 1.6)	206.9 (123.9 to 330.6)	120.3 (61.7 to 212.9)
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.3 (31.6 to 187.7)	-10.4 (-27.2 to 53.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.3 (30.7 to 186.3)	-10.6 (-27.5 to 52.9)
Other infectious diseases	517.9 (412.8 to 634.4)	499.6 (434.9 to 569.4)	-3.5 (-21.1 to 18.0)	-15.5 (-30.1 to 2.4)	17.1 (10.5 to 25.4)	15.9 (10.9 to 23.4)	-6.8 (-26.4 to 16.0)	-11.4 (-29.5 to 10.0)
Non-communicable diseases	-	-	-	-	4,292.9 (3,166.8 to 5,546.8)	7,265.5 (5,417.2 to 9,460.3)	69.2 (64.6 to 74.3)	2.5 (-0.2 to 5.7)
Neoplasms	-	-	-	-	34.0 (24.9 to 43.9)	66.4 (47.3 to 88.1)	95.5 (65.9 to 129.7)	3.7 (-11.6 to 20.8)
Esophageal cancer	1.3 (1.0 to 1.7)	1.8 (1.3 to 2.3)	33.7 (2.5 to 83.7)	-31.4 (-50.1 to -6.2)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	34.3 (-0.2 to 72.5)	-31.2 (-49.7 to -9.9)
Stomach cancer	17.2 (15.1 to 19.6)	29.6 (24.7 to 35.4)	70.9 (39.9 to 112.7)	-16.3 (-31.1 to 4.0)	2.0 (1.4 to 2.6)	3.3 (2.3 to 4.5)	62.4 (31.7 to 102.7)	-20.7 (-35.5 to -0.9)
Liver cancer	-	-	-	-	0.3 (0.2 to 0.5)	0.8 (0.5 to 1.1)	185.5 (29.5 to 225.8)	23.6 (11.1 to 68.1)
Liver cancer due to hepatitis B	0.8 (0.5 to 1.1)	1.8 (1.2 to 2.5)	124.5 (22.2 to 296.1)	17.6 (-35.7 to 107.6)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	114.1 (67.3 to 241.8)	11.3 (-32.8 to 73.7)
Liver cancer due to hepatitis C	0.4 (0.3 to 0.6)	2.1 (1.4 to 2.9)	422.2 (200.3 to 813.5)	164.2 (55.6 to 358.2)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.5)	386.9 (206.1 to 686.5)	143.5 (54.2 to 305.6)
Liver cancer due to alcohol use	0.3 (0.2 to 0.4)	0.6 (0.2 to 0.6)	28.3 (-37.3 to 158.1)	-35.2 (-67.9 to 29.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	22.2 (-35.1 to 134.5)	-37.9 (-67.7 to 18.9)
Liver cancer due to other causes	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.7)	15.6 (-43.0 to 121.9)	-36.9 (-70.0 to 24.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	9.5 (-44.1 to 97.4)	40.6 (-70.9 to 10.3)
Larynx cancer	12.7 (9.0 to 16.0)	13.3 (9.7 to 18.0)	3.9 (-24.1 to 46.4)	-45.6 (-60.7 to -23.7)	1.2 (0.7 to 1.8)	1.3 (0.8 to 1.8)	1.0 (-28.3 to 41.6)	-47.3 (-62.3 to -27.1)
Tracheal, bronchus and lung cancer	22.9 (19.8 to 26.1)	43.9 (35.7 to 54.2)	90.6 (50.3 to 151.6)	-5.5 (-25.1 to 23.7)	3.9 (2.8 to 5.0)	7.0 (4.8 to 9.5)	80.7 (44.2 to 132.3)	-10.4 (-28.3 to 15.0)
Breast cancer	46.4 (37.9 to 56.3)	100.4 (78.4 to 125.8)	115.3 (60.2 to 185.6)	13.0 (-14.3 to 47.8)	4.0 (2.8 to 5.4)	8.1 (5.5 to 11.1)	100.0 (49.9 to 167.1)	4.5 (-20.1 to 38.1)
Cervical cancer	16.8 (12.8 to 23.5)	2.5 (1.3 to 21.3)	-2.5 (-36.5 to 42.1)	-84.4 (-66.1 to -26.7)	1.2 (0.8 to 1.9)	1.2 (0.8 to 1.8)	48.1 (-34.8 to 46.7)	8.8 (-65.7 to -25.9)
Uterine cancer	23.0 (14.6 to 35.7)	30.2 (18.0 to 44.7)	29.1 (-18.5 to 130.3)	-32.7 (-56.7 to 15.5)	1.5 (0.8 to 2.6)	1.9 (1.0 to 3.1)	27.4 (-22.1 to 126.6)	-34.4 (-51.9 to 11.9)
Prostate cancer	20.8 (13.0 to 29.4)	87.4 (55.3 to 136.7)	318.8 (184.4 to 542.6)	98.7 (37.5 to 198.7)	2.5 (1.5 to 3.7)	8.5 (5.0 to 13.5)	232.6 (142.3 to 384.2)	56.6 (13.6 to 122.9)
Colon and rectum cancer	25.0 (22.2 to 27.9)	80.7 (68.6 to 94.8)	222.7 (167.5 to 292.3)	62.9 (35.9 to 98.2)	2.2 (1.6 to 2.9)	6.7 (4.6 to 8.9)	196.8 (142.5 to 262.0)	48.5 (22.4 to 80.5)
Lip and oral cavity cancer	7.9 (5.8 to 10.4)	10.9 (8.2 to 14.1)	36.7 (-2.0 to 103.0)	-27.9 (-48.1 to 5.2)	0.7 (0.4 to 1.0)	0.9 (0.6 to 1.3)	33.9 (-3.9 to 94.2)	-30.2 (-49.4 to 10.1)
Nasopharynx cancer	3.4 (2.4 to 4.6)	4.5 (3.3 to 6.2)	34.2 (-10.3 to 108.5)	-24.4 (-49.7 to 16.4)	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	3.2 (-11.3 to 97.4)	-26.1 (-49.3 to 11.5)
Other pharynx cancer	1.4 (1.0 to 2.1)	2.4 (1.7 to 3.3)	73.6 (1.7 to 175.7)	-5.7 (-45.6 to 48.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	67.9 (1.3 to 171.7)	-10.0 (-46.1 to 43.2)
Gallbladder and biliary tract cancer	0.9 (0.7 to 1.2)	1.5 (1.1 to 1.9)	69.9 (11.8 to 147.5)	-18.4 (-46.6 to 20.3)	0.2 (0.2 to 0.3)	0.4 (0.2 to 0.6)	63.9 (6.8 to 137.6)	20.5 (-48.9 to 17.9)
Pancreatic cancer	1.7 (1.4 to 2.0)	5.3 (4.3 to 6.5)	209.9 (134.3 to 306.6)	52.5 (15.3 to 98.8)	0.4 (0.2 to 0.5)	1.0 (0.7 to 1.4)	194.2 (125.7 to 280.5)	44.1 (10.8 to 89.1)
Malignant skin melanoma	6.4 (4.7 to 7.9)	10.1 (7.4 to 13.7)	58.6 (12.6 to 116.4)	10.5 (-43.2 to 10.8)	0.4 (0.3 to 0.6)	0.7 (0.4 to 1.0)	36.3 (6.4 to 109.2)	26.6 (-47.8 to 5.2)
Non-melanoma skin cancer	23.2 (18.0 to 29.2)	69.7 (59.7 to 81.4)	202.6 (124.3 to 298.6)	47.2 (6.7 to 97.6)	0.6 (0.3 to 0.9)	2.0 (1.2 to 3.0)	275.9 (112.8 to 505.7)	94.5 (1.2 to 232.1)
Ovarian cancer	6.3 (4.8 to 7.9)	11.7 (8.8 to 15.5)	85.6 (30.2 to 172.2)	-2.5 (-29.9 to 40.3)	0.8 (0.6 to 1.2)	1.5 (1.0 to 2.2)	79.7 (19.0 to 174.0)	-6.1 (-35.8 to 38.1)
Testicular cancer	7.1 (4.2 to 13.1)	23.6 (10.8 to 38.2)	237.0 (30.8 to 233.5)	112.9 (-15.5 to 347.4)	0.4 (0.2 to 0.8)	1.4 (0.6 to 2.6)	223.5 (27.2 to 628.4)	102.5 (-19.6 to 340.3)
Kidney cancer	6.4 (6.8 to 10.9)	15.0 (11.8 to 18.8)	73.6 (23.2 to 143.4)	0.7 (-32.9 to 29.4)	0.7 (0.5 to 1.0)	1.2 (0.8 to 1.6)	68.9 (20.0 to 131.1)	32.3 (-35.7 to 21.9)
Bladder cancer	20.8 (15.7 to 25.9)	21.0 (15.6 to 34.1)	-4.7 (-31.6 to 95.5)	-52.1 (-65.5 to -4.5)	1.9 (1.3 to 2.6)	1.8 (1.1 to 3.0)	-8.6 (-32.7 to 82.4)	-54.4 (-66.5 to -11.1)
Brain and nervous system cancer	9.9 (7.7 to 14.4)	22.9 (16.9 to 27.9)	139.9 (49.6 to 214.9)	45.8 (-3.7 to 87.7)	1.1 (0.7 to 1.6)	2.4 (1.5 to 3.3)	128.2 (43.0 to 200.1)	34.6 (-11.5 to 76.0)
Thyroid cancer	24.2 (16.5 to 36.2)	33.6 (24.0 to 52.9)	38.4 (-20.9 to 154.5)	-20.9 (-53.6 to 41.9)	1.4 (0.8 to 2.4)	1.9 (1.1 to 3.3)	36.9 (-22.4 to 149.0)	-22.1 (-54.2 to 35.2)
Mesothelioma	0.6 (0.4 to 0.7)	0.9 (0.7 to 1.3)	58.0 (16.3 to 116.4)	16.2 (-37.8 to 15.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	62.3 (21.4 to 121.4)	-14.0 (-31.5 to 17.7)
Hodgkin lymphoma	8.5 (5.6 to 12.2)	9.7 (7.2 to 13.5)	14.2 (-28.8 to 84.0)	-20.4 (-48.7 to 23.2)	0.7 (0.4 to 1.1)	0.8 (0.5 to 1.2)	11.4 (-29.5 to 74.3)	-24.8 (-50.3 to 12.9)
Non-Hodgkin lymphoma	16.0 (12.2 to 23.9)	40.4 (28.7 to 49.4)	164.5 (51.3 to 263.9)	52.5 (-14.0 to 105.1)	1.2 (0.8 to 2.0)	2.9 (1.9 to 4.1)	156.3 (46.4 to 253.8)	44.1 (-18.1 to 96.8)
Multiple myeloma	2.6 (1.8 to 4.1)	6.8 (4.7 to 9.1)	166.3 (40.3 to 338.2)	36.5 (-27.6 to 119.4)	0.5 (0.3 to 0.9)	1.4 (0.8 to 2.0)	153.6 (31.6 to 323.9)	27.7 (-32.3 to 112.5)
Leukemia	29.0 (23.0 to 36.2)	39.8 (32.8 to 48.1)	37.7 (21.1 to 79.3)	10.5 (-15.2 to 39.0)	2.8 (2.0 to 3.8)	4.6 (3.1 to 6.2)	61.1 (21.4 to 103.2)	15.8 (-9.8 to 43.6)
Other neoplasms	3.7 (3.0 to 5.2)	22.5 (6.9 to 34.3)	624.7 (37.0 to 891.6)	358.6 (9.0 to 524.3)	0.3 (0.2 to 0.4)	1.6 (0.5 to 2.8)	579.7 (30.1 to 823.5)	305.5 (-17.1 to 451.1)
Cardiovascular diseases	-	-	-	-	116.2 (80.3 to 161.1)	224.3 (152.9 to 307.9)	93.9 (57.5 to 133.4)	4.0 (-14.4 to 23.1)
Rheumatic heart disease	51.5 (44.7 to 58.1)	89.1 (75.5 to 102.2)	73.3 (39.8 to 107.1)	11.2 (-9.9 to 33.0)	3.4 (2.0 to 4.9)	6.8 (4.4 to 9.7)	98.3 (51.4 to 188.7)	21.9 (-6.2 to 87.4)
Ischemic heart disease	594.9 (489.5 to 734.6)	1,007.0 (894.3 to 1,146.8)	69.5 (33.3 to 111.7)	-13.9 (-31.3 to 6.6)	34.4 (22.9 to 50.3)	58.2 (39.3 to 80.1)	70.1 (29.7 to 121.0)	-10.8 (-31.6 to 14.2)
Cerebrovascular disease	-	-	-	-	3.4 (2.3 to 4.7)	6.3 (4.3 to 8.6)	87.4 (51.9 to 130.6)	-4.1 (-22.3 to 18.4)
Ischemic stroke	18.2 (15.3 to 21.3)	34.9 (29.8 to 40.5)	91.8 (53.3 to 137.8)	-3.1 (-22.3 to 18.9)	2.8 (1.8 to 4.0)	5.4 (3.6 to 7.4)	91.0 (51.1 to 140.7)	-2.9 (-23.1 to 22.7)
Hemorrhagic stroke	3.4 (2.6 to 4.2)	5.8 (4.3 to 7.4)	67.6 (20.6 to 147.0)	-11.2 (-34.9 to 31.3)	0.6 (0.4 to 0.8)	1.0 (0.6 to 1.4)	69.6 (22.5 to 145.1)	-10.2 (-34.5 to 30.3)
Hypertensive heart disease	53.4 (41.1 to 64.7)	158.7 (134.1 to 183.9)	197.7 (131.1 to 291.1)	55.9 (21.7 to 107.0)	6.0 (4.0 to 8.6)	17.5 (11.7 to 24.2)	193.2 (128.6 to 285.9)	54.0 (19.7 to 105.7)
Cardiomyopathy and myocarditis	39.7 (33.4 to 47.8)	87.0 (77.0 to 99.1)	120.7 (75.1 to 169.0)	29.0 (2.1 to 59.4)	4.4 (2.8 to 6.4)	9.6 (6.4 to 13.5)	24.2 (70.9 to 174.0)	28.2 (0.1 to 61.1)
Atrial fibrillation and flutter	186.2 (160.5 to 212.9)	386.5 (322.4 to 455.0)	107.0 (63.7 to 156.5)	-8.2 (-27.7 to 14.5)	14.4 (9.9 to 20.0)	29.7 (19.8 to 41.9)	105.6 (62.0 to 154.7)	-8.8 (-29.0 to 14.2)
Peripheral vascular disease	807.4 (620.3 to 1,020.6)	1,834.8 (1,392.3 to 2,279.4)	126.7 (65.7 to 222.8)	8.3 (-20.0 to 48.2)	0.5 (0.2 to 1.0)	0.9 (0.4 to 1.9)	76.0 (-10.6 to 448.0)	-27.0 (-63.8 to 120.6)
Endocarditis	1.5 (1.0 to 2.2)	3.9 (3.0 to 5.0)	159.7 (76.0 to 298.7)	57.3 (6.6 to 149.6)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.7)	150.7 (67.3 to 286.9)	51.3 (-1.8 to 135.4)
Other cardiovascular and circulatory diseases	702.8 (525.3 to 971.6)	1,345.6 (902.7 to 1,690.6)	94.5 (25.9 to 1					

Appendix Table G.4 - Turkey prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumonia	-	-	-	-	0.2	0.4	74.8	-
Silicosis	0.3 (0.3 to 0.4)	0.5 (0.5 to 0.6)	62.8 (54.7 to 71.1)	-17.4 (-21.4 to -12.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	60.2 (51.8 to 69.6)	-18.8 (-22.8 to -13.7)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	0.2 (0.2 to 0.2)	0.4 (0.4 to 0.4)	83.5 (76.7 to 90.1)	-4.8 (-8.0 to -1.4)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	82.1 (75.0 to 89.2)	-5.3 (-8.8 to -1.8)
Other pneumoconiosis	0.6 (0.5 to 0.6)	1.0 (0.9 to 1.1)	82.3 (75.0 to 90.0)	-2.3 (-6.3 to 1.8)	0.2 (0.1 to 0.1)	0.2 (0.1 to 0.3)	80.9 (71.1 to 89.0)	-2.2 (-6.8 to 1.4)
Asthma	2,245.1 (2,081.5 to 2,391.0)	2,984.9 (2,762.1 to 3,194.7)	32.9 (19.4 to 47.7)	-1.5 (-11.3 to 8.2)	99.6 (64.7 to 141.2)	131.7 (85.3 to 188.9)	32.5 (18.4 to 47.3)	-1.5 (-11.3 to 8.6)
Interstitial lung disease and pulmonary sarcoidosis	4.3 (3.3 to 5.3)	8.1 (6.4 to 9.7)	88.5 (42.2 to 153.1)	1.5 (-22.1 to 35.4)	0.6 (0.3 to 0.9)	1.1 (0.7 to 1.7)	89.2 (43.1 to 155.4)	2.5 (-23.3 to 38.5)
Other chronic respiratory diseases	-	-	-	-	20.1 (11.4 to 32.2)	10.9 (6.7 to 16.7)	-44.8 (-64.8 to -22.6)	-69.9 (-80.8 to -57.4)
Cirrhosis	-	-	-	-	3.4 (2.3 to 4.7)	3.7 (2.6 to 5.1)	11.1 (-3.7 to 28.1)	-29.2 (-38.4 to -19.3)
Cirrhosis due to hepatitis B	8.0 (5.9 to 10.4)	13.1 (10.7 to 15.1)	63.8 (17.1 to 138.5)	-0.4 (-30.0 to 44.3)	1.3 (0.8 to 2.0)	2.1 (1.4 to 3.0)	61.0 (9.8 to 145.6)	-1.7 (-33.4 to 47.8)
Cirrhosis due to hepatitis C	6.2 (3.6 to 8.3)	4.4 (2.8 to 6.7)	-33.0 (-59.2 to 54.5)	-59.4 (-76.7 to -6.3)	1.0 (0.6 to 1.7)	0.7 (0.4 to 1.2)	-32.3 (-61.5 to 55.5)	-58.9 (-77.1 to -5.3)
Cirrhosis due to alcohol use	2.0 (1.3 to 2.9)	1.7 (1.3 to 2.5)	-12.2 (-45.0 to 47.5)	-52.6 (-70.6 to -20.5)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	-11.1 (-51.3 to 57.2)	-52.2 (-73.5 to -16.4)
Cirrhosis due to other causes	4.1 (3.3 to 5.0)	3.3 (2.7 to 4.4)	-13.0 (-35.1 to 13.4)	-28.0 (-46.4 to -5.0)	0.7 (0.4 to 1.1)	0.6 (0.4 to 0.9)	-14.4 (-42.5 to 29.7)	-28.6 (-52.4 to 6.5)
Digestive diseases	-	-	-	-	41.5 (29.1 to 55.8)	55.2 (39.4 to 74.2)	33.2 (20.0 to 48.0)	29.4 (-3.6 to 21.6)
Peptic ulcer disease	348.0 (290.6 to 402.4)	216.9 (190.0 to 242.4)	-37.9 (-46.9 to -27.2)	-69.1 (-73.3 to -63.8)	13.3 (8.8 to 18.6)	10.0 (6.8 to 13.9)	-24.6 (-37.3 to -13.1)	-62.6 (-68.1 to -57.6)
Gastritis and duodenitis	171.8 (156.5 to 185.7)	141.9 (129.6 to 155.3)	-17.4 (-27.2 to -7.3)	-49.8 (-54.9 to -44.2)	8.4 (5.5 to 12.2)	7.0 (4.6 to 10.2)	-16.8 (-31.1 to 4.8)	-48.6 (-55.2 to -37.0)
Appendicitis	4.2 (2.8 to 5.4)	6.7 (3.4 to 10.0)	11.7 (-28.8 to 96.9)	-24.3 (-49.4 to 25.5)	1.3 (0.7 to 2.0)	1.4 (0.8 to 2.2)	14.0 (-34.9 to 102.9)	-22.5 (-54.8 to 30.6)
Paralytic ileus and intestinal obstruction	0.9 (0.4 to 1.6)	1.3 (0.8 to 1.8)	59.4 (-38.1 to 273.3)	12.1 (-46.3 to 110.8)	0.3 (0.1 to 0.5)	0.4 (0.2 to 0.7)	56.8 (-39.9 to 285.4)	15.7 (-47.8 to 122.5)
Inguinal, femoral, and abdominal hernia	193.3 (162.8 to 228.8)	307.3 (258.4 to 362.2)	59.3 (23.8 to 104.3)	-14.9 (-34.3 to 10.4)	2.0 (1.0 to 3.9)	3.2 (1.5 to 6.1)	58.2 (23.1 to 103.2)	-14.7 (-34.6 to 10.4)
Inflammatory bowel disease	35.6 (32.7 to 38.7)	95.8 (88.2 to 104.0)	168.5 (139.6 to 202.2)	54.8 (38.7 to 74.0)	7.6 (5.1 to 10.5)	20.3 (13.8 to 28.2)	167.5 (134.9 to 209.7)	55.0 (36.4 to 79.3)
Vascular disorders	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	83.8 (22.3 to 189.9)	-5.1 (-36.2 to 58.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	83.8 (22.1 to 190.3)	-5.1 (-36.3 to 58.5)
Gallbladder and biliary diseases	20.4 (17.0 to 23.8)	38.1 (32.2 to 45.3)	87.0 (46.5 to 142.2)	-0.7 (-21.7 to 25.9)	2.1 (1.4 to 3.1)	4.0 (2.6 to 5.6)	84.9 (42.2 to 142.6)	-1.3 (-23.4 to 28.8)
Pancreatitis	10.5 (9.8 to 11.1)	17.1 (15.9 to 18.2)	62.3 (49.1 to 78.7)	-7.9 (-14.7 to 1.2)	3.1 (2.0 to 4.2)	5.0 (3.3 to 6.9)	61.7 (34.7 to 92.4)	-7.7 (-21.8 to 8.6)
Other digestive diseases	-	-	-	-	3.3 (2.0 to 4.8)	3.8 (2.5 to 5.4)	13.6 (-16.2 to 61.9)	-40.4 (-55.8 to -13.4)
Neurological disorders	-	-	-	-	523.5 (352.3 to 719.4)	922.6 (628.5 to 1,260.0)	76.1 (61.7 to 92.8)	6.4 (-2.3 to 16.1)
Alzheimer disease and other dementias	346.4 (303.4 to 389.1)	805.0 (704.2 to 914.5)	133.4 (91.8 to 176.8)	0.8 (-17.8 to 20.2)	49.3 (34.8 to 65.5)	116.0 (81.6 to 155.0)	136.7 (92.8 to 180.5)	0.8 (-17.9 to 21.0)
Parkinson disease	25.4 (14.4 to 36.7)	55.2 (30.6 to 76.7)	118.1 (98.9 to 136.7)	1.8 (-7.2 to 11.7)	3.0 (1.5 to 4.8)	6.5 (3.2 to 10.1)	116.5 (90.2 to 146.3)	1.7 (-10.5 to 15.5)
Epilepsy	304.5 (256.3 to 343.5)	407.4 (336.7 to 465.9)	33.4 (6.1 to 68.2)	-3.6 (-23.1 to 21.3)	92.2 (61.8 to 124.5)	139.1 (91.8 to 192.6)	50.6 (17.0 to 92.4)	9.8 (-14.4 to 40.5)
Multiple sclerosis	9.3 (7.6 to 10.9)	38.6 (31.7 to 45.2)	310.5 (226.9 to 431.3)	3.1 (-87.8 to 199.2)	3.1 (2.1 to 4.3)	12.7 (8.7 to 17.1)	308.1 (205.6 to 444.5)	133.3 (75.9 to 209.9)
Migraine	8,511.2 (7,669.0 to 9,330.3)	13,721.1 (12,502.7 to 14,913.5)	61.3 (40.3 to 84.8)	3.8 (-9.1 to 19.7)	291.5 (175.6 to 431.8)	467.8 (274.0 to 685.2)	60.7 (35.1 to 85.3)	6.7 (-9.3 to 20.5)
Tension-type headache	5,370.0 (4,734.1 to 6,108.4)	7,165.5 (6,639.2 to 7,737.0)	33.2 (13.7 to 55.9)	-14.2 (-26.2 to -0.7)	8.1 (4.0 to 14.2)	10.8 (5.3 to 19.0)	32.9 (12.7 to 55.6)	-14.2 (-26.0 to -0.3)
Medication overuse headache	357.8 (240.5 to 477.9)	909.4 (612.4 to 1,177.8)	153.1 (112.0 to 211.3)	51.2 (27.7 to 86.2)	56.3 (32.2 to 87.2)	142.3 (82.6 to 218.2)	152.4 (110.3 to 212.7)	51.0 (27.0 to 85.5)
Other neurological disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	79.5 (25.1 to 163.8)	22.6 (-15.1 to 73.7)	20.1 (12.5 to 31.6)	27.4 (18.3 to 37.4)	40.7 (-7.6 to 94.7)	-39.6 (-60.3 to -15.5)
Mental and substance use disorders	-	-	-	-	1,160.7 (825.6 to 1,502.9)	1,806.0 (1,289.2 to 2,327.7)	55.2 (49.7 to 63.8)	2.0 (-1.0 to 7.6)
Schizophrenia	135.0 (123.4 to 146.7)	232.1 (212.9 to 250.1)	71.7 (65.2 to 80.0)	-0.7 (-4.3 to 3.7)	86.7 (63.2 to 105.7)	148.7 (109.5 to 180.1)	71.6 (60.4 to 84.0)	0.4 (-6.3 to 6.0)
Alcohol use disorders	285.9 (254.7 to 317.1)	359.7 (324.1 to 397.8)	26.0 (14.5 to 37.6)	-19.1 (-25.7 to -12.4)	28.4 (18.7 to 41.1)	35.5 (24.1 to 50.9)	24.8 (12.4 to 39.5)	-19.8 (-27.1 to -11.1)
Drug use disorders	-	-	-	-	158.9 (88.8 to 262.2)	314.0 (186.2 to 473.7)	95.9 (63.5 to 169.6)	21.2 (1.1 to 68.5)
Opioid use disorders	261.3 (119.8 to 471.4)	597.4 (356.2 to 916.3)	125.9 (74.6 to 269.8)	31.6 (3.7 to 112.8)	108.7 (46.6 to 208.3)	248.3 (134.2 to 401.5)	126.1 (73.9 to 273.1)	32.4 (3.7 to 113.2)
Cocaine use disorders	59.4 (51.3 to 67.6)	90.4 (81.4 to 100.1)	51.8 (29.1 to 80.5)	-8.9 (-12.2 to 21.9)	12.5 (5.3 to 11.9)	12.7 (8.2 to 17.8)	8.6 (7.0 to 12.7)	3.6 (-15.4 to 28.4)
Amphetamine use disorders	117.5 (104.2 to 133.4)	140.5 (125.3 to 155.5)	19.6 (1.1 to 41.2)	-13.6 (-26.7 to 1.2)	15.5 (9.3 to 23.2)	18.4 (11.7 to 26.9)	18.8 (-3.3 to 45.3)	-13.9 (-29.8 to 4.7)
Cannabis use disorders	93.5 (76.7 to 110.6)	128.8 (107.6 to 150.5)	37.8 (34.4 to 41.6)	0.5 (0.4 to 0.6)	2.7 (1.7 to 4.1)	3.7 (2.3 to 5.6)	37.8 (19.6 to 61.5)	0.6 (-12.9 to 17.0)
Other drug use disorders	-	-	-	-	23.8 (14.6 to 35.4)	31.1 (19.8 to 46.0)	31.7 (-5.7 to 78.6)	-7.0 (-33.0 to 26.1)
Depressive disorders	-	-	-	-	354.5 (243.5 to 494.2)	573.7 (397.7 to 782.3)	61.8 (53.7 to 71.6)	1.9 (-2.9 to 7.6)
Major depressive disorder	1,465.9 (1,327.0 to 1,630.8)	2,367.8 (2,133.1 to 2,641.5)	61.2 (52.4 to 72.4)	2.2 (-3.5 to 9.0)	300.8 (202.2 to 419.4)	482.0 (325.2 to 659.1)	60.1 (51.1 to 71.7)	2.2 (-3.4 to 9.2)
Dysthymia	557.3 (455.6 to 659.8)	955.3 (780.2 to 1,130.2)	71.2 (66.8 to 76.8)	0.1 (-0.1 to 0.3)	53.7 (34.1 to 78.2)	91.7 (57.8 to 134.8)	70.7 (64.2 to 78.6)	0.2 (-2.2 to 2.8)
Bipolar disorder	371.0 (323.7 to 419.0)	600.6 (528.9 to 671.1)	61.6 (53.0 to 73.0)	-0.6 (-5.6 to 5.6)	75.5 (47.0 to 113.8)	121.7 (75.1 to 181.7)	61.1 (50.0 to 73.4)	-0.5 (-7.0 to 6.5)
Anxiety disorders	1,804.2 (1,490.3 to 2,107.9)	2,599.1 (2,069.1 to 3,148.8)	43.9 (24.8 to 61.8)	0.9 (-13.8 to 9.4)	166.4 (109.8 to 236.3)	238.6 (155.9 to 345.0)	61.8 (25.5 to 61.7)	1.9 (-13.7 to 10.3)
Eating disorders	-	-	-	-	8.1 (4.9 to 12.6)	11.3 (6.9 to 17.3)	39.5 (24.5 to 57.6)	4.2 (-6.2 to 16.7)
Anorexia nervosa	9.3 (5.8 to 13.2)	15.0 (9.4 to 23.1)	59.8 (38.9 to 91.2)	2.2 (-1.7 to 42.6)	2.0 (1.0 to 3.4)	3.2 (1.7 to 5.9)	59.3 (23.4 to 105.9)	21.6 (-4.5 to 55.0)
Bulimia nervosa	28.9 (19.7 to 40.7)	38.5 (26.3 to 54.7)	33.0 (28.7 to 38.5)	-1.5 (-1.7 to -1.3)	6.1 (3.5 to 9.9)	8.1 (4.8 to 13.0)	33.1 (18.0 to 51.6)	-1.5 (-12.4 to 11.2)
Autistic spectrum disorders	-	-	-	-	62.9 (43.6 to 85.4)	85.8 (58.9 to 115.7)	36.2 (31.6 to 41.1)	0.4 (-2.7 to 3.6)
Autism	158.6 (150.3 to 167.5)	217.6 (206.2 to 229.4)	37.1 (36.2 to 38.1)	0.2 (0.1 to 0.2)	39.2 (26.3 to 53.7)	53.5 (35.8 to 73.7)	36.5 (29.8 to 43.5)	0.3 (-4.3 to 5.1)
Asperger syndrome	236.6 (221.7 to 250.7)	322.8 (302.4 to 342.5)	36.4 (35.2 to 37.6)	0.2 (0.2 to 0.2)	23.7 (16.5 to 33.2)	32.3 (22.2 to 44.8)	35.9 (30.4 to 41.7)	0.4 (-3.3 to 4.3)
Attention-deficit/hyperactivity disorder	363.2 (299.7 to 428.1)	395.1 (326.3 to 465.8)	8.7 (8.2 to 9.1)	0.7 (0.6 to 0.8)	4.4 (2.5 to 9.6)	4.8 (2.8 to 7.6)	8.7 (0.6 to 16.7)	0.8 (-6.9 to 8.1)
Conduct disorder	679.5 (559.5 to 794.2)	732.2 (605.0 to 852.8)	8.1 (7.1 to 9.3)	0.6 (0.6 to 0.7)	81.4 (49.5 to 123.2)	86.2 (54.2 to 133.9)	8.3 (4.0 to 13.0)	0.3 (-3.1 to 5.1)
Idiopathic intellectual disability	1,550.5 (1,301.4 to 1,873.1)	1,794.3 (1,528.1 to 2,136.1)	15.6 (6.2 to 26.9)	-94.2 (-21.3 to -5.9)	75.8 (50.1 to 105.6)	87.4 (58.7 to 126.1)	15.1 (5.1 to 26.6)	-14.3 (-21.7 to -5.5)
Other mental and substance use disorders	770.2 (720.5 to 817.1)	1,291.3 (1,215.5 to 1,365.6)	67.5 (65.6 to 69.4)	-0.1 (-0.4 to 0.2)	57.7 (38.9 to 77.6)	96.3 (65.7 to 128.4)	67.1 (60.0 to 74.1)	0.1 (-3.6 to 3.9)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	461.6 (323.3 to 635.5)	872.3 (585.7 to 1,212.8)	89.0 (60.1 to 120.6)	13.3 (-5.0 to 33.2)
Diabetes mellitus	2,401.4 (2,022.1 to 2,835.4)	5,103.3 (4,048.9 to 6,077.5)	111.6 (75.2 to 162.1)	17.8 (-3.7 to 45.1)	202.5 (135.0 to 288.3)	438.5 (280.3 to 624.7)	118.9 (67.1 to 172.8)	17.2 (-11.4 to 47.5)
Acute glomerulonephritis	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.2)	-6.5 (-14.0 to 1.2)	-18.0 (-23.9 to -11.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-14.2 to 1.2)	-0.0 (-24.0 to -11.4)
Chronic kidney disease	-	-	-	-	51.6 (37.3 to 67.3)	85.9 (62.1 to 111.3)	66.1 (53.6 to 84.6)	-0.8 (-7.1 to 9.6)
Chronic kidney disease due to diabetes mellitus	825.1 (542.3 to 1,341.7)	1,252.3 (982.1 to 1,590.5)	56.0 (6.8 to 116.7)	-18.6 (-44.0 to 17.7)	12.1 (8.2 to 16.5)	22.0 (15.0 to 29.3)	81.7 (48.9 to 123.0)	-0.9 (-20.5 to 23.0)
Chronic kidney disease due to hypertension	466.6 (299.0 to 815.0)	506.0 (396.1 to 665.1)	13.9 (-27.7 to 50.5)	-27.8 (-51.1 to -7.0)	15.3 (10.7 to 20.8)	19.2 (13.6 to 25.6)	24.8 (3.3 to 55.2)	-28.7 (-41.4 to -13.3)
Chronic kidney disease due to glomerulonephritis	1,001.6 (584.8 to 1,704.6)	1,097.5 (803.1 to 1,366.7)	10.9 (-32.5 to 54.2)	-89.6 (-65.8 to -16.3)	63.9 (4.6 to 9.7)	8.9 (6.2 to 12.3)	28.3 (-0.4 to 73.1)	9.2 (-30.0 to 20.5)
Chronic kidney disease due to other causes	1,156.6 (704.7 to 1,929.4)	2,063.5 (1,527.4 to 2,833.5)	87.5 (18.2 to 138.4)	10.6 (-32.1 to 45.1)	17.3 (12.5 to 23.0)	35.9		

Appendix Table G.4 - Turkey prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	11.3 (10.5 to 12.1)	18.5 (17.4 to 19.6)	64.2 (50.3 to 81.2)	(-3.2 to 15.4)	0.4 (0.2 to 0.6)	0.6 (0.4 to 0.9)	63.2 (32.0 to 105.5)	5.6 (13.0 to 29.6)
Urolithiasis	2,329.4 (1,775.6 to 3,155.9)	3,254.7 (1,963.1 to 4,876.3)	41.3 (-12.9 to 97.4)	-15.7 (45.9 to 12.2)	10.1 (6.1 to 16.0)	17.0 (8.8 to 28.4)	71.0 (9.2 to 135.9)	1.9 (33.0 to 35.0)
Benign prostatic hyperplasia	459.1 (419.8 to 500.9)	945.4 (873.6 to 1,019.6)	105.9 (81.7 to 130.6)	-1.0 (-12.9 to 11.2)	16.6 (10.6 to 23.7)	34.2 (22.1 to 49.2)	106.0 (80.9 to 131.0)	-0.9 (13.0 to 12.1)
Male infertility due to other causes	350.2 (220.8 to 499.2)	510.3 (334.1 to 763.1)	44.3 (-16.6 to 153.5)	-5.7 (44.4 to 63.1)	2.5 (0.9 to 5.6)	3.5 (1.3 to 8.2)	42.9 (-19.8 to 158.7)	-6.2 (46.5 to 67.6)
Other urinary diseases	-	-	-	-	3.9 (0.6 to 12.3)	47.3 (8.1 to 109.5)	5374.2 (29.3 to 9,312.3)	-4.2 (-19.0 to 5,341.2)
Gynecological diseases	-	-	-	-	93.9 (61.6 to 134.9)	145.6 (93.6 to 212.2)	55.4 (38.0 to 72.4)	-2.2 (-12.7 to 9.1)
Uterine fibroids	955.7 (863.7 to 1,040.0)	1,771.7 (1,612.5 to 1,921.2)	85.2 (83.2 to 87.2)	0.1 (-0.1 to 0.3)	15.5 (9.3 to 25.3)	24.7 (14.4 to 41.5)	59.0 (47.8 to 68.6)	-10.4 (-16.4 to -5.7)
Polycystic ovarian syndrome	1,131.1 (1,020.8 to 1,234.9)	1,732.9 (1,559.7 to 1,907.8)	53.6 (33.0 to 73.7)	-6.0 (-18.3 to 6.3)	11.1 (5.2 to 20.1)	16.9 (7.8 to 31.7)	53.1 (33.2 to 73.1)	-6.0 (-17.9 to 5.8)
Female infertility due to other causes	119.1 (62.0 to 191.1)	182.1 (99.4 to 282.6)	50.7 (-21.4 to 218.5)	-2.8 (-51.1 to 111.1)	0.8 (0.3 to 1.7)	1.1 (0.4 to 2.4)	43.6 (-28.1 to 185.3)	-4.2 (52.4 to 91.4)
Endometriosis	92.3 (77.7 to 107.6)	158.8 (135.8 to 184.0)	72.9 (40.2 to 111.0)	2.2 (-16.0 to 24.7)	8.5 (5.6 to 12.2)	14.6 (9.7 to 20.9)	73.5 (37.5 to 112.3)	2.8 (-18.0 to 25.9)
Genital prolapse	2,712.0 (2,180.6 to 3,204.1)	4,805.8 (3,962.6 to 5,744.9)	77.3 (36.4 to 128.6)	0.9 (-21.9 to 28.9)	8.6 (4.0 to 16.1)	15.2 (7.3 to 29.1)	77.2 (36.1 to 129.8)	1.0 (22.4 to 29.4)
Premenstrual syndrome	5,268.2 (4,730.9 to 5,870.2)	7,922.3 (6,390.2 to 9,541.9)	50.5 (17.6 to 87.4)	2.8 (-19.7 to 28.6)	44.4 (23.9 to 65.3)	66.6 (40.2 to 103.3)	50.3 (17.3 to 87.0)	2.9 (-19.2 to 29.4)
Other gynecological diseases	176.9 (133.9 to 216.4)	228.2 (209.6 to 247.5)	29.1 (8.4 to 69.2)	-17.0 (-31.2 to 8.0)	5.1 (2.9 to 7.5)	6.5 (4.3 to 9.4)	25.7 (5.5 to 115.1)	-19.0 (-32.2 to 37.0)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	57.8 (38.8 to 83.2)	74.4 (49.0 to 107.8)	28.5 (17.8 to 42.3)	3.7 (-5.6 to 14.3)
Thalassemias	7.6 (6.1 to 9.0)	7.9 (6.9 to 9.2)	0.7 (-13.3 to 35.7)	-10.6 (-23.9 to 21.3)	0.7 (0.4 to 1.1)	0.7 (0.4 to 1.1)	-0.1 (-29.0 to 56.7)	-13.7 (38.9 to 34.5)
Thalassemia trait	1,676.8 (1,572.3 to 1,785.1)	2,333.2 (2,249.4 to 2,448.6)	38.9 (32.3 to 47.1)	0.5 (-4.3 to 6.3)	35.5 (23.3 to 52.1)	50.7 (33.7 to 73.6)	43.2 (27.1 to 65.2)	13.6 (0.2 to 30.7)
Sickle cell disorders	3.4 (3.0 to 3.8)	4.3 (3.8 to 4.7)	24.3 (10.1 to 44.0)	5.9 (-5.9 to 21.7)	0.5 (0.3 to 0.7)	0.6 (0.5 to 0.9)	31.1 (17.5 to 47.5)	6.1 (4.0 to 18.2)
Sickle cell trait	1,357.1 (1,256.8 to 1,459.8)	1,721.1 (1,592.3 to 1,830.1)	26.8 (21.9 to 32.4)	-8.9 (-11.9 to -4.2)	6.5 (3.9 to 9.8)	7.8 (4.5 to 11.7)	20.3 (5.7 to 51.0)	0.2 (-21.5 to 27.8)
G6PD deficiency	1,573.2 (1,429.9 to 1,719.8)	2,142.5 (1,918.7 to 2,370.2)	35.9 (19.3 to 55.9)	-1.6 (-13.7 to 13.0)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	32.5 (14.3 to 51.5)	4.1 (-7.2 to 15.9)
G6PD trait	7,985.1 (7,788.4 to 8,173.0)	11,190.4 (10,925.2 to 11,408.0)	40.1 (35.4 to 45.0)	0.6 (-2.8 to 4.1)	0.3 (0.1 to 0.5)	0.3 (0.1 to 0.5)	10.9 (-79.4 to 434.5)	4.9 (80.2 to 322.5)
Other hemoglobinopathies and hemolytic anemias	524.0 (435.6 to 581.9)	583.0 (504.1 to 642.3)	11.2 (-29.5 to -2.8)	14.2 (8.3 to 21.3)	14.2 (8.3 to 21.3)	14.0 (8.5 to 20.6)	-1.5 (-32.0 to 49.7)	-18.5 (42.1 to 21.2)
Endocrine, metabolic, blood, and immune disorders	686.4 (600.5 to 758.1)	797.1 (740.3 to 828.9)	14.8 (2.3 to 31.6)	-13.1 (-21.1 to -2.7)	22.3 (14.9 to 31.7)	24.6 (16.7 to 34.6)	9.9 (4.4 to 36.8)	-11.5 (-22.6 to 7.3)
Musculoskeletal disorders	-	-	-	-	1,010.5 (714.1 to 1,361.8)	1,808.1 (1,285.1 to 2,412.5)	79.3 (60.8 to 90.2)	1.5 (-4.6 to 7.3)
Rheumatoid arthritis	74.2 (70.5 to 78.3)	133.4 (126.6 to 140.5)	79.9 (67.5 to 93.1)	-0.6 (-7.4 to 6.8)	17.5 (12.3 to 23.4)	31.0 (21.9 to 41.7)	77.6 (61.8 to 95.6)	-1.0 (-9.6 to 8.3)
Osteoarthritis	1,062.1 (985.9 to 1,127.9)	2,194.7 (2,063.0 to 2,312.1)	106.5 (89.2 to 124.6)	0.1 (-8.0 to 9.0)	64.9 (44.9 to 89.9)	133.6 (92.0 to 184.0)	106.5 (88.3 to 124.7)	0.3 (-8.3 to 9.2)
Low back and neck pain	-	-	-	-	815.9 (560.0 to 1,110.9)	1,413.2 (973.4 to 1,931.3)	74.0 (60.7 to 87.1)	1.0 (-6.6 to 8.6)
Low back pain	5,574.2 (5,255.9 to 5,892.1)	9,667.7 (9,147.5 to 10,171.8)	73.4 (60.2 to 86.7)	0.9 (-6.6 to 8.6)	623.5 (420.8 to 871.8)	1,075.2 (730.9 to 1,502.7)	72.6 (58.7 to 86.1)	1.0 (-6.5 to 8.7)
Neck pain	1,940.0 (1,667.0 to 2,224.2)	3,466.4 (2,808.7 to 4,052.8)	80.3 (33.5 to 123.5)	1.3 (-23.4 to 25.5)	190.4 (126.1 to 267.3)	338.0 (225.0 to 483.3)	79.7 (33.5 to 122.9)	1.4 (-23.4 to 25.3)
Gout	22.2 (18.8 to 25.0)	43.4 (38.5 to 48.7)	94.7 (65.0 to 138.7)	0.3 (-14.9 to 21.9)	0.7 (0.5 to 1.0)	1.4 (0.9 to 2.0)	93.7 (49.9 to 158.8)	0.2 (-22.0 to 30.7)
Other musculoskeletal disorders	1,250.2 (962.8 to 1,537.9)	2,528.1 (1,989.2 to 3,099.1)	101.6 (87.7 to 119.5)	6.0 (-0.7 to 14.5)	113.6 (73.1 to 165.5)	228.6 (148.8 to 333.6)	81.2 (57.0 to 119.6)	0.2 (-0.4 to 14.9)
Other non-communicable diseases	-	-	-	-	676.0 (437.0 to 1,002.9)	1,082.0 (705.6 to 1,583.8)	60.2 (53.4 to 66.9)	-1.1 (-4.6 to 2.6)
Congenital anomalies	-	-	-	-	39.6 (28.0 to 55.1)	90.6 (64.7 to 121.4)	130.5 (78.2 to 188.1)	72.2 (35.9 to 114.9)
Neural tube defects	7.4 (5.6 to 9.7)	23.1 (18.5 to 29.3)	215.1 (121.6 to 354.0)	158.6 (82.2 to 272.9)	2.1 (1.3 to 3.1)	6.7 (4.4 to 9.6)	229.4 (113.8 to 397.3)	174.1 (78.4 to 313.7)
Congenital heart anomalies	131.6 (92.6 to 178.9)	479.5 (407.7 to 566.2)	266.8 (150.4 to 429.1)	193.9 (100.0 to 324.4)	4.7 (2.1 to 8.4)	16.7 (6.7 to 29.3)	250.1 (134.6 to 392.2)	187.1 (94.2 to 304.8)
Orofacial clefts	23.2 (14.2 to 31.7)	93.9 (72.5 to 130.4)	297.9 (167.1 to 619.9)	0.4 (-125.6 to 507.8)	1.1 (0.2 to 0.7)	1.1 (0.7 to 1.8)	130.4 (71.2 to 408.8)	130.4 (44.6 to 324.5)
Down syndrome	61.4 (48.6 to 79.8)	123.4 (93.8 to 161.8)	102.3 (37.2 to 185.9)	52.7 (3.4 to 113.8)	7.6 (5.1 to 10.7)	16.7 (11.3 to 24.1)	124.1 (49.0 to 219.3)	64.3 (9.0 to 133.0)
Turner syndrome	1.7 (1.3 to 2.2)	2.9 (2.1 to 3.8)	67.9 (6.4 to 163.8)	27.2 (-19.5 to 98.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	71.4 (4.5 to 172.5)	26.4 (-21.6 to 101.5)
Klinefelter syndrome	1.6 (1.3 to 2.1)	2.2 (1.7 to 2.7)	36.2 (0.9 to 74.9)	0.4 (-25.7 to 28.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.4 (10.4 to 94.5)	1.3 (-25.1 to 30.3)
Chromosomal unbalanced rearrangements	45.4 to 69.8 (45.4 to 69.8)	91.6 to 135.5 (91.6 to 135.5)	101.6 (54.4 to 169.3)	112.2 (16.3 to 103.0)	6.0 (4.7 to 9.7)	6.0 (4.7 to 9.7)	228.6 (148.8 to 333.6)	15.0 (22.6 to 121.2)
Other congenital anomalies	152.9 (129.8 to 176.6)	194.7 (163.0 to 229.2)	26.8 (14.3 to 42.0)	-13.7 (-22.4 to -3.5)	18.0 (11.4 to 30.6)	34.0 (22.1 to 49.8)	93.0 (60.2 to 188.7)	42.9 (-7.4 to 111.6)
Skin and subcutaneous diseases	-	-	-	-	291.9 (179.7 to 450.5)	414.2 (258.6 to 652.2)	41.8 (31.3 to 52.6)	1.4 (-5.8 to 9.2)
Dermatitis	2,631.1 (2,261.8 to 2,976.8)	3,939.2 (3,349.0 to 4,483.9)	49.5 (45.7 to 53.4)	0.1 (0.1 to 0.2)	74.6 (48.3 to 106.1)	107.6 (69.6 to 153.2)	44.1 (38.6 to 50.0)	0.2 (-2.5 to 2.8)
Psoriasis	309.2 (261.7 to 364.4)	498.8 (417.8 to 589.0)	61.0 (57.1 to 65.9)	61.0 (-0.5 to 0.3)	40.1 (16.9 to 36.2)	60.5 (27.2 to 58.7)	60.5 (49.3 to 71.7)	0.1 (-5.4 to 6.5)
Cellulitis	11.3 (9.3 to 13.6)	14.3 (11.2 to 18.1)	25.4 (9.5 to 48.5)	-14.4 (-23.5 to -1.2)	0.8 (0.5 to 1.2)	1.0 (0.6 to 1.5)	25.5 (-1.3 to 60.4)	-13.4 (-30.4 to 9.4)
Pyoderma	41.1 (32.9 to 52.0)	46.5 (37.3 to 61.1)	13.0 (2.5 to 24.7)	-7.6 (-13.1 to -1.2)	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.6)	12.4 (-3.4 to 29.1)	-7.7 (-18.5 to 3.6)
Scabies	202.9 (165.1 to 262.0)	252.6 (211.5 to 307.6)	25.3 (9.2 to 71.4)	-8.2 (-31.6 to 26.1)	5.2 (2.8 to 8.7)	6.5 (3.6 to 10.3)	24.6 (-9.8 to 70.3)	-7.9 (-32.0 to 16.2)
Fungal skin diseases	3,275.9 (2,516.8 to 4,054.3)	5,156.4 (4,040.4 to 6,324.3)	57.2 (50.2 to 66.2)	57.2 (-0.1 to 10.3)	18.7 (7.4 to 38.8)	28.9 (15.5 to 61.7)	86.9 (49.4 to 65.6)	0.2 (-0.6 to 1.1)
Viral skin diseases	1,190.4 (924.3 to 1,449.0)	1,419.9 (1,066.1 to 1,770.9)	19.1 (12.9 to 24.7)	0.1 (-2.0 to 1.9)	36.9 (21.6 to 57.5)	43.9 (25.1 to 69.1)	18.9 (11.6 to 25.1)	0.1 (-3.1 to 3.5)
Acne vulgaris	7,720.4 (6,573.3 to 9,018.6)	10,524.9 (9,238.7 to 11,932.3)	36.2 (14.8 to 68.2)	11.6 (-6.2 to 38.4)	83.8 (39.6 to 158.9)	114.3 (53.7 to 210.8)	36.3 (14.4 to 68.4)	11.7 (-6.5 to 38.5)
Alopecia areata	73.1 (64.0 to 83.1)	111.7 (96.8 to 127.2)	52.1 (25.7 to 84.8)	-0.5 (-17.2 to 20.5)	2.5 (1.6 to 3.8)	3.7 (2.3 to 5.6)	51.7 (23.0 to 89.0)	-0.3 (-18.9 to 23.6)
Pruritus	30.3 (23.8 to 36.1)	54.8 (45.9 to 65.4)	81.6 (37.0 to 141.1)	4.0 (-21.9 to 37.3)	0.3 (0.2 to 0.6)	0.6 (0.3 to 1.1)	80.5 (34.9 to 144.7)	4.1 (-22.4 to 40.4)
Urticaria	451.7 (304.6 to 607.3)	636.5 (442.7 to 822.8)	40.0 (-18.0 to 131.8)	-9.8 (47.9 to 54.6)	26.9 (15.0 to 42.1)	37.7 (21.9 to 57.3)	9.7 (-19.8 to 130.4)	-40.4 (-48.2 to 53.2)
Decubitus ulcer	8.9 (6.9 to 10.9)	14.1 (11.2 to 18.0)	57.6 (13.3 to 120.4)	-24.6 (-47.5 to 11.6)	1.3 (0.8 to 1.9)	2.1 (1.3 to 2.9)	57.6 (11.9 to 121.0)	-23.4 (-48.1 to 14.0)
Other skin and subcutaneous diseases	2,648.6 (1,767.1 to 3,936.5)	4,636.7 (2,969.4 to 7,278.2)	74.0 (60.5 to 88.3)	0.3 (-3.4 to 4.4)	15.6 (7.0 to 32.4)	27.2 (11.6 to 57.5)	73.4 (59.3 to 88.4)	0.4 (-3.4 to 4.7)
Sense organ diseases	-	-	-	-	222 (144.7 to 323.0)	370.2 (240.2 to 544.5)	66.3 (59.5 to 73.1)	-9.0 (-12.2 to -5.5)
Glaucoma	27.8 (18.7 to 37.8)	47.8 (33.2 to 70.5)	73.2 (16.2 to 147.3)	-6.9 (-36.6 to 32.7)	1.9 (1.1 to 3.0)	3.1 (1.9 to 4.9)	66.5 (15.8 to 130.0)	-11.6 (-37.8 to 23.3)
Cataract	104.5 (73.0 to 142.7)	158.1 (105.4 to 217.9)	49.1 (23.6 to 90.3)	-29.4 (-39.7 to -13.6)	7.0 (4.1 to 11.0)	11.2 (6.6 to 17.3)	59.4 (31.2 to 101.3)	-25.4 (-37.2 to -7.9)
Macular degeneration	18.1 (11.3 to 26.7)	35.1 (24.0 to 46.8)	100.5 (26.0 to 171.5)	-2.2 (-37.4 to 37.0)	1.0 (0.6 to 1.6)	2.0 (1.2 to 3.1)	106.1 (33.6 to 181.2)	-1.9 (-36.0 to 35.6)
Uncorrected refractive error	4,166.6 (3,802.0 to 4,439.4)	7,327.5 (6,845.2 to 7,790.7)	75.8 (59.9 to 92.2)	2.1 (-10.8 to 5.3)	52.8 (28.9 to 89.6)	88.7 (46.7 to 152.4)	88.7 (54.7 to 128.6)	-5.1 (-12.2 to 2.1)
Age-related and other hearing loss	4,758.8 (4,441.0 to 5,106.9)	8,291.2 (7,764.5 to 8,881.3)	74.3 (67.0 to 80.2)	-9.5 (-12.7 to -6.8)	122.2 (80.6 to 175.3)	215.0 (142.5 to 308.1)	76.0 (65.8 to 86.2)	-10.1 (-14.3 to -5.7)
Other vision loss	69.1 (55.7 to 84.2)	86.1 (67.8 to 108.6)	24.8 (2.0 to 48.3)	-21.8 (-35.5 to -7.0)	4.6 (3.0 to 6.6)	5.3 (3.4 to 7.8)	15.7 (5.0 to 39.1)	-29.8 (-43.0 to -15.4)
Other sense organ diseases	1,247.7 (1,184.4 to 1,306.9)							

Appendix Table G.4 - Turkey prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	2,110.0 (1,944.7 to 2,260.5)	3,880.2 (3,590.7 to 4,182.2)	83.5 (67.4 to 104.7)	-10.8 (-18.4 to -0.8)	58.3 (39.4 to 81.9)	106.8 (71.4 to 149.8)	82.8 (66.5 to 105.2)	82.8 (-18.8 to -0.4)
Other oral disorders	868.1 (817.0 to 918.9)	1,347.2 (1,267.3 to 1,417.3)	55.2 (41.6 to 67.7)	-0.0 (-8.3 to 7.5)	25.5 (15.9 to 37.8)	39.4 (25.0 to 59.2)	55.0 (40.2 to 68.2)	0.1 (-8.9 to 8.0)
Injuries	-	-	-	-	192.4 (144.9 to 248.1)	199.4 (143.3 to 267.5)	3.1 (-7.0 to 15.4)	-38.5 (-44.2 to -31.6)
Transport injuries	-	-	-	-	82.1 (61.5 to 106.5)	61.7 (43.7 to 84.3)	-25.2 (-35.0 to -13.6)	-55.0 (-60.5 to -48.6)
Road injuries	-	-	-	-	72.9 (54.8 to 94.5)	51.7 (36.8 to 70.8)	-29.4 (-39.2 to -17.6)	-97.2 (-62.8 to -50.8)
Pedestrian road injuries	-	-	-	-	17.0 (12.8 to 22.1)	10.7 (7.5 to 14.7)	-37.8 (-47.2 to -25.9)	-60.8 (-66.2 to -54.0)
Cyclist road injuries	-	-	-	-	6.9 (5.2 to 8.9)	6.4 (4.5 to 8.8)	-8.1 (-17.7 to 2.9)	-46.3 (-51.8 to -40.4)
Motorcyclist road injuries	-	-	-	-	8.8 (6.5 to 11.5)	5.5 (3.8 to 7.5)	-38.2 (-47.0 to -28.1)	-63.5 (-68.4 to -58.0)
Motor vehicle road injuries	-	-	-	-	39.5 (29.2 to 51.4)	29.0 (20.6 to 39.6)	-26.9 (-38.6 to -13.5)	-96.0 (-62.5 to -43.4)
Other road injuries	-	-	-	-	0.6 (0.5 to 0.8)	0.2 (0.2 to 0.3)	-63.7 (-68.8 to -57.5)	-78.6 (-81.3 to -75.3)
Other transport injuries	-	-	-	-	9.2 (6.9 to 11.9)	9.9 (7.0 to 13.3)	7.8 (-4.2 to 22.3)	-38.6 (-45.3 to -30.5)
Unintentional injuries	-	-	-	-	97.6 (73.8 to 126.0)	122.1 (89.3 to 162.4)	24.7 (14.3 to 35.9)	-26.7 (-32.7 to -20.3)
Falls	-	-	-	-	31.3 (23.7 to 40.3)	46.5 (33.1 to 63.0)	48.3 (31.8 to 65.6)	-18.7 (-27.9 to -9.1)
Drowning	-	-	-	-	1.8 (1.3 to 2.4)	1.2 (0.9 to 1.7)	-31.9 (-41.5 to -19.7)	57.4 (-63.0 to -50.6)
Fire, heat, and hot substances	-	-	-	-	7.1 (5.3 to 9.0)	3.7 (2.6 to 5.0)	-47.9 (-55.9 to -39.3)	-66.8 (-71.4 to -62.1)
Poisonings	-	-	-	-	1.0 (0.7 to 1.3)	0.6 (0.4 to 0.8)	-39.2 (-50.2 to -26.0)	-59.8 (-66.5 to -51.5)
Exposure to mechanical forces	-	-	-	-	19.3 (14.3 to 25.3)	43.5 (31.6 to 59.4)	125.9 (104.8 to 148.5)	38.8 (27.7 to 51.0)
Unintentional firearm injuries	-	-	-	-	0.9 (0.7 to 1.2)	2.0 (1.4 to 2.7)	110.7 (84.0 to 141.2)	22.5 (7.9 to 39.0)
Unintentional suffocation	-	-	-	-	0.2 (0.1 to 0.2)	0.6 (0.4 to 0.7)	229.6 (189.6 to 268.9)	97.9 (76.2 to 120.1)
Other exposure to mechanical forces	-	-	-	-	18.1 (13.5 to 23.9)	41.0 (29.7 to 55.9)	125.7 (104.6 to 149.2)	39.0 (27.6 to 51.8)
Adverse effects of medical treatment	-	-	-	-	0.8 (0.5 to 1.2)	1.6 (1.0 to 2.3)	94.9 (82.1 to 107.6)	18.7 (10.0 to 28.1)
Animal contact	-	-	-	-	1.5 (1.1 to 1.9)	1.7 (1.3 to 2.4)	17.2 (5.0 to 31.4)	-26.4 (-33.4 to -18.6)
Venomous animal contact	-	-	-	-	0.7 (0.5 to 0.9)	0.8 (0.6 to 1.1)	20.9 (4.1 to 42.3)	-23.6 (-33.4 to -11.1)
Non-venomous animal contact	-	-	-	-	0.8 (0.6 to 1.1)	0.9 (0.7 to 1.3)	13.7 (0.1 to 29.6)	-29.0 (-36.2 to -20.4)
Foreign body	-	-	-	-	1.9 (1.4 to 2.4)	2.3 (1.7 to 3.0)	22.6 (11.7 to 35.4)	-24.7 (-30.8 to -17.2)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-21.7 (-37.1 to -5.0)	46.9 (-56.2 to -36.9)
Foreign body in eyes	-	-	-	-	0.5 (0.3 to 0.7)	0.6 (0.4 to 1.0)	40.3 (27.2 to 56.4)	-9.4 (-17.5 to 0.4)
Foreign body in other body part	-	-	-	-	1.0 (0.8 to 1.3)	1.4 (1.0 to 1.8)	32.8 (18.4 to 49.1)	-22.5 (-29.8 to -14.0)
Other unintentional injuries	-	-	-	-	33.1 (24.7 to 42.8)	21.0 (15.4 to 28.1)	-36.7 (-42.1 to -30.6)	-61.7 (-64.8 to -58.3)
Self-harm and interpersonal violence	-	-	-	-	10.0 (7.6 to 12.7)	8.9 (6.3 to 12.1)	-11.5 (-22.3 to 11.4)	47.3 (-53.8 to -40.2)
Self-harm	-	-	-	-	1.2 (0.9 to 1.6)	2.6 (1.8 to 3.6)	116.7 (86.6 to 153.4)	22.1 (6.1 to 41.7)
Interpersonal violence	-	-	-	-	8.8 (6.7 to 11.2)	6.3 (4.5 to 8.6)	-29.0 (-38.4 to -17.6)	-57.4 (-62.8 to -51.1)
Assault by firearm	-	-	-	-	1.8 (1.4 to 2.4)	1.7 (1.2 to 2.3)	-9.1 (-19.3 to 1.4)	-45.5 (-51.3 to -39.8)
Assault by sharp object	-	-	-	-	1.9 (1.4 to 2.5)	1.7 (1.2 to 2.4)	-11.5 (-21.1 to 4.5)	-47.4 (-54.8 to -38.4)
Assault by other means	-	-	-	-	5.1 (3.9 to 6.5)	2.9 (2.1 to 4.0)	-42.5 (-50.8 to -32.4)	-65.3 (-70.1 to -59.6)
Forces of nature, war, and legal intervention	-	-	-	-	2.7 (1.2 to 5.6)	6.7 (3.1 to 13.3)	149.1 (83.4 to 230.5)	46.7 (10.2 to 96.7)
Exposure to forces of nature	-	-	-	-	1.6 (0.7 to 3.5)	3.3 (1.4 to 7.1)	107.9 (69.9 to 154.2)	17.3 (-3.5 to 41.8)
Collective violence and legal intervention	-	-	-	-	1.1 (0.5 to 2.5)	3.4 (1.5 to 6.8)	213.7 (76.4 to 424.4)	98.9 (14.7 to 228.4)

Appendix Table G.4 - Turkmenistan prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
All causes	-	-	-	-	299.5 (213.9 to 377.3)	458.4 (340.9 to 597.5)	53.3 (54.2 to 63.1)	-2.6 (-4.9 to -0.1)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	40.9 (28.0 to 58.1)	50.2 (35.4 to 69.5)	23.0 (11.1 to 35.4)	-3.6 (-13.3 to 5.6)
HIV/AIDS and tuberculosis	-	-	-	-	1.8 (1.2 to 2.5)	2.9 (1.9 to 4.1)	55.4 (36.4 to 92.9)	-8.1 (-18.4 to 13.6)
Tuberculosis	5.7 (5.4 to 6.0)	7.9 (7.4 to 8.4)	38.0 (30.9 to 46.0)	-18.1 (-22.1 to -13.8)	1.8 (1.2 to 2.4)	2.4 (1.6 to 3.3)	38.0 (26.1 to 51.1)	-11.3 (-24.3 to -11.3)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.4 (0.1 to 1.2)	1,090.4 (109.9 to 27,073.7)	900.3 (20.3 to 15,327.7)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	797.4 (55.8 to 118,795.6)	413.0 (-11.2 to 73,178.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	797.4 (54.5 to 122,985.0)	413.0 (-12.6 to 74,048.1)
HIV/AIDS resulting in other diseases	0.4 (0.0 to 1.6)	3.8 (1.1 to 10.5)	1,003.9 (95.7 to 93,755.1)	569.8 (23.4 to 57,971.1)	0.0 (0.0 to 0.2)	0.4 (0.1 to 1.2)	1,129.6 (110.7 to 260,099.9)	622.7 (17.8 to 168,849.0)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	6.5 (4.6 to 8.8)	6.5 (4.6 to 9.1)	0.6 (-7.8 to 8.9)	-19.2 (-25.5 to -12.8)
Diarrheal diseases	16.7 (15.7 to 17.8)	17.4 (16.3 to 18.6)	4.1 (-4.8 to 13.9)	-7.2 (-15.1 to 1.3)	2.7 (1.8 to 3.8)	2.8 (1.9 to 3.9)	1.1 (-6.3 to 15.0)	-6.2 (-15.5 to 2.7)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (66.5 to 36.7)	-
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.6 (-25.1 to 11.4)	-30.2 (-43.0 to -16.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-7.6 (-25.1 to 11.4)	-30.2 (-43.0 to -16.1)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.4 (-23.7 to 16.9)	-26.5 (-40.5 to -8.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.4 (-23.7 to 16.9)	-26.5 (-40.6 to -8.6)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-77.5 (-99.4 to 205.4)	-83.1 (-99.5 to 134.3)
Lower respiratory infections	1.9 (1.6 to 2.3)	1.0 (0.8 to 1.2)	-48.0 (-63.3 to -34.4)	-4.8 (-6.0 to -3.2)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-48.2 (-64.6 to -31.1)	-45.6 (-61.6 to -29.2)
Upper respiratory infections	67.6 (59.4 to 75.9)	89.0 (78.6 to 99.0)	32.1 (11.3 to 53.9)	-3.4 (-17.5 to 12.6)	0.8 (0.5 to 1.4)	1.1 (0.6 to 1.7)	31.7 (11.8 to 54.5)	-3.4 (-17.9 to 13.8)
Otitis media	47.7 (43.6 to 52.4)	60.2 (55.3 to 65.4)	26.5 (16.1 to 35.7)	-9.8 (-17.3 to -2.7)	1.0 (0.6 to 1.6)	1.2 (0.7 to 2.0)	23.5 (12.4 to 33.6)	-9.8 (-17.6 to -2.3)
Meningitis	-	-	-	-	1.4 (0.9 to 1.9)	1.0 (0.6 to 1.4)	-26.7 (-45.2 to -4.9)	-48.6 (-60.8 to -33.2)
Pneumococcal meningitis	4.7 (2.9 to 7.2)	3.6 (2.2 to 5.6)	-24.4 (-38.5 to -10.3)	-5.5 (-9.0 to -41.8)	0.5 (0.3 to 0.8)	0.4 (0.2 to 0.5)	-30.4 (-53.2 to -5.9)	-52.2 (-67.3 to -35.1)
H influenzae type B meningitis	3.3 (1.4 to 6.5)	2.4 (1.0 to 4.7)	-26.9 (-55.6 to 10.2)	-50.3 (-68.6 to -22.0)	0.5 (0.3 to 0.7)	0.4 (0.2 to 0.6)	-22.9 (-62.5 to 36.2)	-44.1 (-72.7 to -2.1)
Meningococcal meningitis	1.0 (0.4 to 2.2)	0.7 (0.3 to 1.6)	-31.2 (-53.5 to -0.7)	-53.4 (-66.5 to -31.9)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-35.8 (-60.2 to 13.0)	-53.9 (-70.7 to -20.0)
Other meningitis	1.6 (0.9 to 2.7)	1.3 (0.8 to 2.3)	-15.3 (-36.9 to 7.2)	-42.8 (-55.6 to -25.6)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-16.9 (-50.1 to 16.5)	-41.4 (-63.6 to -18.7)
Encephalitis	1.1 (0.5 to 2.5)	1.4 (0.7 to 3.4)	33.2 (12.5 to 56.9)	-13.8 (-26.2 to 0.8)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	36.7 (12.4 to 70.8)	-10.3 (-25.4 to 9.8)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.8 (-97.3 to 322.0)	-71.1 (-97.3 to 180.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-66.8 (-97.3 to 333.9)	-71.1 (-97.3 to 182.2)
Whooping cough	4.1 (3.2 to 5.2)	0.9 (0.7 to 1.1)	-78.7 (-80.6 to -76.6)	-77.3 (-79.4 to -75.1)	0.2 (0.1 to 0.3)	0.0 (0.0 to 0.1)	-78.7 (-81.9 to -74.8)	-77.3 (-80.7 to -73.2)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.7 (-71.8 to 5.3)	-60.8 (-79.8 to -28.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.6 (-54.9 to 23.6)	-46.7 (-68.4 to -20.0)
Measles	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -98.6)	-100.0 (-100.0 to -98.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -98.4)	-100.0 (-100.0 to -98.3)
Varicella and herpes zoster	2.7 (2.5 to 2.8)	3.1 (3.0 to 3.3)	18.1 (9.3 to 27.6)	-0.4 (-10.3 to 10.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	47.9 (17.8 to 89.0)	-0.4 (-23.4 to 26.5)
Neglected tropical diseases and malaria	-	-	-	-	2.0 (1.2 to 3.2)	1.8 (1.2 to 2.7)	-8.8 (-35.1 to 34.3)	-14.0 (-41.3 to 21.9)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-93.9 (-97.6 to -86.2)	-96.3 (-98.6 to -91.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.4 (-67.6 to 96.8)	-43.2 (-79.2 to 27.6)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-41.2 (-57.2 to -23.1)	-55.7 (-67.9 to -42.2)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.5 (-53.3 to 147.8)	-14.1 (-62.0 to 93.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.5 (-53.9 to 148.1)	-14.1 (-62.0 to 94.5)
Cutaneous and mucocutaneous leishmaniasis	2.4 (1.7 to 3.5)	1.3 (0.9 to 2.1)	-44.1 (-59.6 to -28.3)	-58.3 (-69.9 to -46.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-44.5 (-61.3 to -26.6)	-58.6 (-70.9 to -44.9)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.7 (-91.3 to 72.0)	-78.8 (-94.2 to -6.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-60.4 (-90.7 to 86.8)	-76.5 (-93.7 to 2.5)
Cystic echinococcosis	1.3 (1.1 to 1.5)	1.4 (1.3 to 1.5)	7.8 (-11.0 to 28.3)	-17.2 (-26.0 to -7.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	5.8 (-17.7 to 38.0)	-17.4 (-31.5 to 0.2)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	0.2 (0.1 to 0.5)	1.3 (0.4 to 3.1)	597.2 (588.7 to 607.1)	390.0 (384.1 to 397.0)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.6)	563.4 (460.7 to 674.6)	362.4 (295.9 to 434.2)
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.5 (-52.7 to -11.2)	-52.3 (-67.1 to -35.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-35.5 (-52.9 to -10.8)	-52.3 (-67.1 to -35.0)
Intestinal nematode infections	-	-	-	-	0.3 (0.1 to 1.2)	0.0 (0.0 to 0.0)	-90.9 (-98.2 to -60.8)	-91.5 (-98.4 to -64.8)
Ascariasis	119.5 (71.6 to 205.1)	156.1 (95.2 to 241.3)	32.1 (-38.0 to 159.9)	-8.8 (-56.8 to 91.2)	0.3 (0.0 to 1.2)	0.0 (0.0 to 0.0)	-98.1 (-99.7 to -86.9)	-98.2 (-99.7 to -87.6)
Trichuriasis	-	-	-	-	78.6 (-30.6 to 335.9)	4.4 (-59.5 to 155.1)	-	-
Hookworm disease	2.4 (1.3 to 4.1)	4.0 (2.2 to 7.0)	67.3 (-24.5 to 287.7)	-2.1 (-55.9 to 126.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.8 (-50.7 to 176.8)	-2.6 (-73.6 to 87.3)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	41.8 (30.7 to 53.3)	42.0 (38.6 to 46.3)	1.0 (-21.9 to 35.2)	-7.0 (-27.9 to 24.0)	1.5 (0.9 to 2.2)	1.4 (0.9 to 2.1)	-2.1 (-15.8 to 56.0)	-7.7 (-20.9 to 49.6)
Maternal disorders	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-	-
Maternal hemorrhage	0.9 (0.8 to 1.0)	1.0 (0.7 to 1.4)	11.0 (-27.3 to 55.1)	31.9 (-55.1 to -4.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	6.7 (-47.2 to 45.1)	-39.1 (-67.2 to -8.7)
Maternal sepsis and other maternal infections	3.8 (2.4 to 5.8)	2.6 (1.6 to 3.8)	-32.9 (-46.6 to -10.2)	-53.8 (-71.8 to -48.4)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-41.1 (-62.0 to -9.5)	-45.4 (-77.0 to -48.1)
Maternal hypertensive disorders	0.4 (0.2 to 0.6)	0.3 (0.1 to 0.5)	-11.1 (-23.3 to 8.6)	-45.2 (-52.8 to -33.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.8 (-38.6 to 22.5)	-45.5 (-61.8 to -24.3)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.4 (-38.4 to 20.3)	-46.6 (-61.8 to -26.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.4 (-38.5 to 20.4)	-46.6 (-61.9 to -26.9)
Complications of abortion	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-12.0 (-25.2 to 4.7)	-46.1 (-53.9 to -36.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.0 (-62.6 to 116.0)	-46.1 (-74.9 to 24.3)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.6 (-57.5 to 36.3)	-52.1 (-74.3 to -18.1)
Neonatal disorders	-	-	-	-	2.7 (1.8 to 3.9)	8.7 (5.6 to 12.4)	224.3 (102.1 to 366.7)	148.3 (55.0 to 259.5)
Preterm birth complications	9.9 (5.4 to 17.7)	30.9 (18.6 to 51.4)	213.5 (144.5 to 329.2)	124.5 (78.1 to 205.7)	1.0 (0.6 to 1.6)	3.9 (2.4 to 5.9)	284.5 (121.0 to 534.0)	184.4 (67.5 to 364.8)
Neonatal encephalopathy due to birth asphyxia and trauma	7.0 (1.8 to 21.9)	9.5 (3.7 to 23.9)	43.7 (-14.0 to 219.5)	5.4 (-38.3 to 144.6)	0.8 (0.3 to 1.6)	1.9 (0.9 to 3.4)	139.1 (-11.3 to 510.0)	93.0 (-29.1 to 406.0)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	106.4 (76.4 to 113.8)	138.0 (103.3 to 146.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.4 (66.1 to 144.1)	129.8 (91.5 to 181.4)
Hemolytic disease and other neonatal jaundice	1.7 (0.8 to 2.8)	4.3 (2.0 to 7.1)	154.2 (17.5 to 542.6)	90.8 (-10.1 to 392.9)	0.6 (0.3 to 1.1)	1.7 (0.7 to 2.9)	159.9 (20.0 to 548.2)	94.4 (-10.4 to 398.9)
Other neonatal disorders	-	-	-	-	0.3 (0.1 to 0.5)	1.2 (0.4 to 2.6)	343.9 (92.1 to 1,091.2)	240.7 (48.0 to 812.8)
Nutritional deficiencies	-	-	-	-	25.5 (16.7 to 37.2)	7.5 (18.2 to 40.0)	-	-
Protein-energy malnutrition	14.3 (5.9 to 29.3)	11.3 (4.3 to 24.2)	-21.6 (-73.8 to 156.7)	-15.9 (-71.9 to 175.8)	1.9 (0.6 to 4.1)	1.4 (0.5 to 3.1)	-21.9 (-54.9 to 162.4)	-15.7 (-73.1 to 181.1)
Iodine deficiency	113.0 (48.7 to 217.5)	100.4 (32.0 to 209.9)	-13.3 (-81.0 to 196.9)	-46.2 (-88.5 to 92.2)	2.1 (0.8 to 4.3)	1.8 (0.5 to 4.0)	-13.9 (-80.8 to 192.2)	-46.0 (-88.4 to 89.0)
Vitamin A deficiency	4.2 (3.4 to 5.0)	2.8 (2.3 to 3.4)	-33.1 (-41.0 to -25.6)	-49.2 (-54.7 to -43.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-33.8 (-43.7 to -23.5)	-49.5 (-56.8 to -42.1)

Appendix Table G.4 - Turkmenistan prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	646.6 (635.6 to 656.7)	751.7 (752.4 to 771.1)	17.8 (15.2 to 20.6)	9.4 (-11.3 to -7.3)	21.4 (14.2 to 31.2)	23.9 (15.8 to 34.6)	13.0 (8.0 to 14.3)	-0.0 (-13.2 to 8.2)
Other nutritional deficiencies	-	-	-	-	0.2 (0.1 to 0.6)	0.2 (0.1 to 0.6)	16.6 (-69.2 to 331.9)	24.4 (-67.1 to 360.8)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.2 (1.4 to 3.3)	2.8 (1.7 to 4.3)	25.7 (13.9 to 39.9)	-9.6 (-17.7 to -0.4)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.9 (0.5 to 1.5)	1.4 (0.8 to 2.4)	54.7 (36.1 to 80.2)	-6.3 (-16.3 to 7.5)
Syphilis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	5.2 (-9.9 to 22.1)	-37.7 (-45.7 to -29.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.5 (-17.9 to 47.5)	-35.2 (-52.6 to -12.5)
Chlamydial infection	113.7 (97.8 to 129.6)	189.4 (166.0 to 211.8)	66.8 (35.9 to 102.6)	1.7 (-16.0 to 22.1)	0.5 (0.3 to 0.8)	0.8 (0.4 to 1.3)	62.4 (32.1 to 101.2)	-1.1 (-18.5 to 20.7)
Gonococcal infection	28.3 (22.1 to 35.4)	42.7 (33.6 to 51.0)	51.2 (9.9 to 109.4)	-5.0 (-30.3 to 29.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	43.2 (0.2 to 109.9)	-9.4 (-36.0 to 30.0)
Trichomoniasis	53.3 (35.5 to 78.5)	63.2 (49.6 to 79.0)	802.3 (-26.4 to 100.5)	-1.7 (-51.6 to 16.9)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	13.7 (-34.6 to 96.3)	-29.0 (-56.5 to 15.7)
Genital herpes	451.0 (432.4 to 467.7)	802.3 (775.6 to 829.5)	77.7 (69.5 to 87.0)	-1.7 (-5.9 to 2.9)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.5)	4.9 (61.6 to 87.5)	-1.6 (-6.8 to 4.6)
Other sexually transmitted diseases	1.0 (0.7 to 1.2)	1.6 (1.1 to 2.1)	63.5 (39.6 to 92.4)	-10.8 (-23.7 to 4.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	61.9 (16.8 to 124.9)	5.5 (-28.9 to 28.9)
Hepatitis	-	-	-	-	0.3 (0.2 to 0.5)	0.4 (0.3 to 0.6)	28.6 (1.0 to 54.1)	-21.4 (-39.4 to -1.5)
Hepatitis A	4.8 (4.6 to 5.0)	5.6 (5.4 to 5.8)	17.8 (17.1 to 18.5)	-6.3 (-6.6 to -5.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	37.5 (22.4 to 55.0)	-3.3 (-13.8 to 7.6)
Hepatitis B	355.0 (305.6 to 412.6)	386.0 (327.5 to 452.5)	10.0 (-13.4 to 31.7)	-29.3 (-42.0 to -15.7)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	22.3 (-21.4 to 73.9)	-30.3 (-56.0 to 3.9)
Hepatitis C	252.2 (226.1 to 285.0)	295.6 (264.5 to 327.3)	17.7 (-1.1 to 36.7)	-30.0 (-39.7 to -19.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.2 (-15.6 to 51.3)	-26.2 (-43.9 to -3.7)
Hepatitis E	0.4 (0.3 to 0.4)	0.6 (0.5 to 0.6)	58.8 (40.6 to 81.6)	-1.6 (-13.5 to 13.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.1 (15.0 to 125.1)	-0.7 (-27.1 to 32.5)
Leprosy	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-
Other infectious diseases	28.6 (22.7 to 35.7)	29.4 (25.3 to 33.8)	2.8 (-14.3 to 20.9)	-7.9 (-22.1 to 7.6)	1.0 (0.6 to 1.5)	1.0 (0.6 to 1.4)	-0.5 (-19.6 to 15.0)	-7.7 (-25.3 to 6.7)
Non-communicable diseases	-	-	-	-	224.5 (166.3 to 291.9)	380.4 (283.2 to 491.1)	69.5 (64.4 to 74.7)	1.2 (-1.4 to 4.3)
Neoplasms	-	-	-	-	1.4 (1.0 to 1.8)	2.7 (1.9 to 3.7)	91.1 (57.2 to 134.6)	8.6 (-9.6 to 33.1)
Esophageal cancer	1.0 (0.8 to 1.2)	1.3 (0.9 to 2.0)	25.2 (-20.1 to 95.6)	-29.5 (-54.2 to 10.7)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	22.2 (-17.3 to 91.4)	-30.6 (-52.6 to 7.6)
Stomach cancer	0.7 (0.6 to 0.8)	0.9 (0.7 to 1.2)	24.8 (-4.0 to 67.0)	-30.4 (-45.4 to -6.9)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	24.8 (-6.0 to 63.3)	-30.3 (-48.2 to -9.7)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	106.9 (49.1 to 190.3)	21.4 (-11.9 to 69.3)
Liver cancer due to hepatitis B	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	91.2 (5.9 to 222.5)	8.9 (-39.7 to 82.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.4 (18.4 to 173.9)	5.3 (-32.6 to 56.1)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	429.2 (203.4 to 806.6)	207.7 (73.0 to 431.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	407.2 (226.7 to 689.7)	192.8 (91.0 to 355.9)
Liver cancer due to alcohol use	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	90.6 (15.0 to 227.1)	13.7 (-30.8 to 90.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.5 (27.6 to 173.1)	8.6 (-24.4 to 60.8)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-1.1 (-46.5 to 80.6)	-43.7 (-69.9 to 8.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.0 (-42.5 to 58.4)	45.5 (-67.5 to -4.1)
Larynx cancer	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	44.7 (-11.6 to 141.0)	-20.9 (-51.4 to 28.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	41.0 (-8.5 to 131.1)	-23.5 (-50.5 to 21.2)
Tracheal, bronchus and lung cancer	0.4 (0.3 to 0.5)	0.6 (0.5 to 0.8)	57.0 (15.2 to 119.5)	-15.5 (-36.9 to 16.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	55.8 (13.2 to 116.7)	-16.5 (-38.2 to 12.4)
Breast cancer	1.7 (1.3 to 2.1)	6.9 (5.7 to 8.3)	317.8 (221.9 to 450.5)	140.9 (86.0 to 224.1)	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.6)	212.0 (126.6 to 326.8)	69.6 (28.0 to 124.4)
Cervical cancer	1.4 (1.1 to 1.7)	1.7 (1.1 to 2.5)	16.2 (-26.1 to 75.5)	-99.4 (-59.9 to -7.6)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	16.7 (-27.2 to 61.9)	-99.2 (-60.5 to -5.9)
Uterine cancer	0.5 (0.3 to 0.7)	0.6 (0.3 to 1.3)	16.0 (-32.9 to 153.4)	-40.2 (-64.2 to 30.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	17.9 (-33.2 to 150.7)	-39.2 (-63.0 to 29.9)
Prostate cancer	0.3 (0.2 to 0.4)	0.8 (0.6 to 1.3)	169.6 (93.2 to 347.9)	53.6 (14.1 to 149.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	187.0 (86.3 to 430.3)	64.2 (12.1 to 198.6)
Colon and rectum cancer	0.9 (0.8 to 1.0)	2.1 (2.1 to 2.7)	133.6 (82.2 to 201.0)	26.1 (0.1 to 62.2)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	123.3 (68.6 to 190.7)	20.8 (-6.6 to 57.0)
Lip and oral cavity cancer	0.5 (0.3 to 0.6)	0.8 (0.6 to 1.1)	79.3 (17.4 to 161.7)	9.9 (-33.9 to 42.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	78.0 (18.8 to 160.6)	-0.9 (-33.8 to 43.4)
Nasopharynx cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	65.0 (2.1 to 168.8)	-12.6 (-45.1 to 40.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.1 (5.6 to 155.7)	-14.1 (-43.4 to 32.9)
Other pharynx cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	86.8 (1.3 to 254.8)	0.3 (-46.0 to 87.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.2 (8.8 to 207.2)	-0.8 (-40.9 to 62.6)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	40.0 (-23.4 to 125.5)	-20.4 (-56.6 to 27.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.1 (-25.2 to 116.3)	-23.1 (-58.1 to 21.3)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	202.3 (121.3 to 327.1)	73.4 (-28.7 to 140.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	188.8 (122.3 to 280.4)	64.6 (-24.8 to 112.8)
Malignant skin melanoma	0.5 (0.4 to 0.7)	1.2 (0.9 to 1.8)	133.3 (56.7 to 290.7)	27.8 (-10.1 to 96.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	234.5 (56.3 to 250.3)	24.2 (-13.8 to 92.9)
Non-melanoma skin cancer	1.0 (0.8 to 1.2)	2.3 (1.8 to 2.8)	127.3 (72.9 to 208.3)	30.6 (-2.6 to 75.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	181.6 (111.1 to 287.8)	56.1 (-15.7 to 117.7)
Ovarian cancer	0.3 (0.3 to 0.4)	0.8 (0.5 to 1.2)	145.1 (51.8 to 270.9)	33.5 (-16.4 to 101.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	139.1 (46.2 to 272.8)	30.2 (-19.2 to 108.8)
Testicular cancer	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.2)	138.8 (26.4 to 338.1)	30.1 (-28.8 to 134.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	133.6 (22.0 to 323.8)	26.5 (-28.9 to 124.8)
Kidney cancer	0.4 (0.3 to 0.5)	1.0 (0.7 to 1.3)	172.4 (86.2 to 289.4)	82.6 (26.9 to 157.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	175.6 (87.8 to 296.0)	75.5 (-19.2 to 149.1)
Bladder cancer	0.3 (0.3 to 0.4)	0.7 (0.5 to 0.9)	96.4 (40.5 to 176.5)	12.0 (-19.1 to 55.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	89.8 (35.8 to 171.9)	8.5 (-20.3 to 53.6)
Brain and nervous system cancer	0.3 (0.2 to 0.6)	0.7 (0.5 to 1.0)	189.0 (52.6 to 318.8)	0.1 (-14.3 to 173.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	199.8 (66.2 to 324.2)	95.9 (12.9 to 168.1)
Thyroid cancer	0.5 (0.4 to 0.6)	1.1 (0.7 to 1.6)	115.0 (42.4 to 236.7)	20.2 (-18.5 to 83.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	109.8 (37.5 to 237.9)	16.7 (-20.9 to 83.6)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-24.3 to 60.2)	0.0 (-59.3 to 42.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-24.2 to 61.0)	0.0 (-8.6 to -10.3)
Hodgkin lymphoma	0.4 (0.2 to 0.7)	0.6 (0.3 to 1.0)	57.8 (-7.5 to 160.9)	11.5 (-30.9 to 80.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	60.2 (-6.3 to 160.3)	8.6 (-32.2 to 67.4)
Non-Hodgkin lymphoma	0.4 (0.3 to 0.5)	0.8 (0.6 to 1.1)	108.2 (44.4 to 203.5)	33.1 (-6.9 to 102.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	108.3 (44.9 to 213.1)	30.0 (-8.6 to 105.1)
Multiple myeloma	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	118.7 (33.5 to 240.0)	16.0 (-28.5 to 77.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.6 (36.1 to 210.4)	11.6 (-27.8 to 63.5)
Leukemia	1.5 (1.2 to 1.9)	1.8 (1.4 to 2.4)	21.2 (-10.7 to 64.4)	21.2 (-22.3 to 37.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	30.9 (-3.4 to 78.1)	1.4 (-2.8 to 35.6)
Other neoplasms	1.6 (1.3 to 2.0)	4.5 (3.2 to 6.0)	174.3 (91.5 to 280.8)	71.4 (25.6 to 132.0)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	157.3 (88.5 to 261.7)	54.3 (-16.2 to 114.8)
Cardiovascular diseases	-	-	-	-	2.4 (1.6 to 3.4)	3.7 (2.5 to 5.1)	51.6 (18.6 to 99.4)	-10.6 (-29.5 to 15.6)
Rheumatic heart disease	0.3 (0.3 to 0.4)	0.5 (0.5 to 0.6)	56.2 (28.8 to 86.1)	-10.0 (-26.6 to 8.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	61.9 (22.8 to 112.7)	-7.4 (-30.4 to 19.4)
Ischemic heart disease	20.7 (17.2 to 26.0)	31.9 (28.3 to 36.8)	55.2 (15.9 to 93.5)	-6.3 (-29.2 to 16.3)	1.0 (0.7 to 1.5)	1.5 (1.0 to 2.1)	45.0 (0.6 to 98.8)	-10.4 (-35.7 to 21.1)
Cerebrovascular disease	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	73.4 (38.7 to 116.1)	-3.9 (-25.0 to 20.8)
Ischemic stroke	0.8 (0.7 to 1.0)	1.4 (1.1 to 1.7)	72.1 (32.2 to 116.3)	-3.9 (-27.4 to 22.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	74.8 (31.7 to 127.6)	-2.9 (-28.1 to 25.4)
Hemorrhagic stroke	1.0 (0.8 to 1.1)	1.7 (1.4 to 2.0)	71.1 (40.3 to 118.9)	-5.3 (-24.7 to 22.7)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	72.5 (34.3 to 124.0)	-4.4 (-26.1 to 23.8)
Hypertensive heart disease	2.5 (2.2 to 2.8)	4.2 (3.8 to 4.7)	69.8 (45.0 to 99.9)	0.2 (-15.4 to 18.7)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	70.5 (45.2 to 102.1)	0.6 (-14.9 to 20.0)
Cardiomyopathy and myocarditis	1.6 (1.4 to 1.9)	3.1 (2.9 to 3.4)	94.2 (63.4 to 125.5)	15.4 (-4.3 to 36.6)	0.3 (0.1 to 0.2)	0.7 (0.2 to 0.4)	98.1 (62.8 to 134.6)	17.2 (-3.9 to 40.7)
Atrial fibrillation and flutter	0.1 (0.1 to 0.1)	0.6 (0.5 to 0.8)	573.4 (386.7 to 916.9)	228.1 (142.0 to 387.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	562.8 (333.1 to 975.3)	219.6 (116.6 to 405.1)
Peripheral vascular disease	44.5 (33.0 to 54.7)	82.9 (62.7 to 109.1)	81.9 (37.7 to 205.4)	5.2 (-23.6 to 68.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	10.6 (-58.0 to 127.4)	-30.4 (-73.8 to 40.1)
Endocarditis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	42.5 (7.4 to 87.4)	-15.6 (-37.5 to 13.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.2 (-3.3 to 110.8)	-16.0 (-43.7 to 27.2)
Other cardiovascular and circulatory diseases	8.0 (3.8 to 14.6)	10.5 (4.4 to 18.8)	25.3 (-53.5 to 233.9)	25.3 (-75.8 to 89.0)	0.5 (0.3 to 1.1)	0.7 (0.3 to 1.4)	25.7 (-53.2 to 237.3)	-30.4 (-75.6 to 88.4)
Chronic respiratory diseases	-	-	-	-	8.5 (5.5 to 11.8)	14.0 (9.5 to 19.4)	65.2 (40.5 to 96.6)	-6.9 (-20.5 to 9.4)
Chronic obstructive pulmonary disease	93.1 (88.7 to 97.6)	164.9 (157.0 to 172.7)	77.2 (71.7 to 82.5)	-0.8 (-4.0 to 1.9)	5.9 (3.8 to 8.4)	10.1 (6.7 to 14.1)	73.4 (46.7 to 101	

Appendix Table G.4 - Turkmenistan prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	54.0	54.0
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.7 (64.2 to 78.9)	-2.3 (-6.1 to 2.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.8 (64.4 to 79.1)	-2.4 (-6.3 to 2.2)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	45.3 (0.0 to 0.1)	45.3 (38.8 to 52.5)	-17.6 (-21.1 to -14.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.6 (39.1 to 52.7)	-17.5 (-21.0 to -14.1)
Asthma	43.0 (28.7 to 56.9)	69.1 (50.5 to 85.6)	61.8 (5.9 to 147.9)	-10.1 (-38.2 to 32.6)	1.9 (1.1 to 2.9)	3.0 (1.8 to 4.5)	61.6 (5.5 to 151.2)	-9.8 (-38.2 to 33.9)
Interstitial lung disease and pulmonary sarcoidosis	0.3 (0.2 to 0.3)	0.5 (0.3 to 0.6)	68.6 (17.6 to 144.8)	-3.5 (-31.2 to 38.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	68.8 (17.9 to 144.0)	-3.1 (-31.3 to 38.2)
Other chronic respiratory diseases	-	-	-	-	0.7 (0.3 to 1.2)	0.8 (0.4 to 1.3)	11.5 (-17.5 to 53.4)	-37.3 (-53.6 to -13.8)
Cirrhosis	-	-	-	-	0.5 (0.3 to 0.7)	0.8 (0.5 to 1.1)	64.0 (47.9 to 82.9)	2.6 (-6.0 to 12.6)
Cirrhosis due to hepatitis B	1.2 (1.0 to 1.4)	2.0 (1.4 to 2.6)	69.3 (21.8 to 122.8)	4.7 (-21.7 to 38.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	68.1 (16.7 to 128.2)	4.8 (-24.4 to 39.3)
Cirrhosis due to hepatitis C	0.6 (0.4 to 0.8)	0.8 (0.4 to 1.4)	36.9 (-24.9 to 137.2)	-20.2 (-53.8 to 27.8)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	36.5 (-30.5 to 151.1)	-20.1 (-55.3 to 34.5)
Cirrhosis due to alcohol use	0.4 (0.3 to 0.5)	0.8 (0.5 to 1.1)	91.8 (2.7 to 188.8)	7.4 (-39.4 to 63.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	89.1 (3.2 to 194.1)	6.5 (-40.7 to 65.1)
Cirrhosis due to other causes	0.6 (0.5 to 0.7)	1.0 (0.7 to 1.3)	65.3 (4.8 to 119.2)	26.9 (-19.8 to 67.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	63.7 (-0.5 to 132.4)	26.4 (-23.1 to 77.7)
Digestive diseases	-	-	-	-	2.2 (1.5 to 2.9)	4.0 (2.8 to 5.3)	83.5 (65.3 to 98.8)	6.8 (-1.7 to 14.8)
Peptic ulcer disease	15.4 (14.2 to 16.6)	17.0 (15.4 to 18.2)	10.7 (-2.8 to 22.3)	-35.3 (-42.0 to -29.0)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	20.4 (-9.1 to 42.2)	-27.9 (-43.6 to -17.4)
Gastritis and duodenitis	5.0 (4.4 to 5.7)	6.6 (5.6 to 7.5)	31.4 (6.1 to 57.3)	0.0 (-15.1 to 15.3)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	29.1 (-7.3 to 80.0)	0.7 (-22.7 to 32.5)
Appendicitis	0.4 (0.3 to 0.4)	0.5 (0.4 to 0.6)	37.9 (1.2 to 81.1)	-1.4 (-24.7 to 25.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	37.7 (-9.5 to 106.7)	-1.7 (-33.3 to 42.0)
Paralytic ileus and intestinal obstruction	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	41.3 (-41.3 to 165.9)	20.7 (-32.9 to 98.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.5 (-38.9 to 195.2)	20.8 (-32.7 to 113.0)
Inguinal, femoral, and abdominal hernia	9.0 (7.9 to 10.3)	13.0 (11.5 to 15.1)	44.8 (20.9 to 70.4)	-9.7 (-24.8 to 8.7)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	45.3 (21.1 to 72.4)	-8.8 (-24.3 to 9.9)
Inflammatory bowel disease	3.3 (3.2 to 3.5)	8.1 (7.8 to 8.5)	143.8 (130.4 to 157.5)	35.4 (28.1 to 42.8)	0.7 (0.5 to 1.0)	1.7 (1.2 to 2.4)	143.8 (122.8 to 167.7)	35.7 (24.8 to 46.7)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.6 (30.2 to 151.0)	20.8 (-18.6 to 66.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.6 (23.2 to 154.4)	18.2 (-25.9 to 78.8)
Gallbladder and biliary diseases	2.5 (2.3 to 2.8)	3.5 (3.1 to 4.0)	40.4 (14.8 to 69.9)	-17.7 (-33.7 to -0.2)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	46.6 (13.4 to 74.6)	-17.7 (-33.5 to 1.2)
Pancreatitis	0.7 (0.6 to 0.7)	1.8 (1.7 to 1.9)	171.2 (153.7 to 190.0)	47.2 (37.9 to 56.8)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	170.9 (132.9 to 220.0)	47.3 (28.4 to 69.4)
Other digestive diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	126.7 (80.4 to 183.1)	31.8 (6.0 to 63.3)
Neurological disorders	-	-	-	-	27.3 (18.2 to 37.7)	47.1 (31.4 to 65.5)	72.4 (50.9 to 95.3)	5.2 (-5.9 to 17.8)
Alzheimer disease and other dementias	11.9 (10.4 to 13.4)	19.5 (17.3 to 21.9)	64.1 (35.8 to 97.5)	-1.2 (-19.3 to 20.5)	1.7 (1.2 to 2.3)	2.8 (2.1 to 3.8)	65.3 (35.5 to 99.2)	-0.7 (-19.6 to 21.4)
Parkinson disease	0.8 (0.7 to 0.9)	1.4 (1.2 to 1.6)	70.5 (62.1 to 79.9)	0.5 (-3.9 to 6.2)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	72.5 (52.0 to 96.4)	1.4 (-10.2 to 14.9)
Epilepsy	13.9 (9.4 to 18.6)	19.8 (12.9 to 26.6)	43.0 (-12.8 to 129.3)	-1.7 (-40.5 to 56.9)	4.5 (2.7 to 6.8)	5.0 (4.1 to 10.6)	7.0 (-7.8 to 148.2)	7.0 (-35.6 to 70.7)
Multiple sclerosis	0.5 (0.5 to 0.6)	1.3 (1.2 to 1.4)	136.4 (107.7 to 173.2)	25.9 (11.4 to 44.7)	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.6)	135.6 (89.5 to 192.3)	26.3 (2.4 to 55.1)
Migraine	483.7 (430.8 to 536.8)	790.5 (701.2 to 887.4)	63.7 (39.3 to 90.8)	17.7 (-15.1 to 14.5)	16.7 (9.1 to 24.5)	27.5 (16.3 to 40.6)	64.4 (37.6 to 91.0)	-0.7 (-15.2 to 15.7)
Tension-type headache	720.2 (658.5 to 785.0)	1,204.7 (1,048.4 to 1,355.1)	67.3 (40.8 to 94.1)	1.0 (-13.8 to 14.7)	1.1 (0.5 to 1.9)	1.8 (0.9 to 3.2)	67.7 (40.4 to 95.1)	1.2 (-14.0 to 15.6)
Medication overuse headache	18.1 (12.0 to 24.1)	46.2 (30.7 to 62.0)	156.0 (105.2 to 220.9)	42.1 (14.6 to 80.1)	2.9 (1.6 to 4.4)	7.3 (4.3 to 11.7)	155.9 (103.0 to 220.9)	42.3 (15.0 to 80.0)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.9 (15.5 to 122.0)	5.0 (-23.2 to 46.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	58.6 (16.5 to 117.0)	-7.1 (-32.3 to 29.5)
Mental and substance use disorders	-	-	-	-	69.7 (50.0 to 91.3)	113.4 (81.6 to 148.7)	62.6 (58.0 to 67.6)	-0.1 (-2.6 to 2.4)
Schizophrenia	8.4 (7.7 to 9.1)	15.5 (14.1 to 16.7)	83.6 (75.7 to 93.7)	-0.2 (-4.0 to 4.3)	5.5 (4.0 to 6.6)	10.1 (7.3 to 12.3)	83.9 (72.8 to 97.0)	0.1 (-5.4 to 6.3)
Alcohol use disorders	35.6 (31.5 to 40.4)	65.7 (57.4 to 75.3)	84.9 (73.0 to 97.6)	6.9 (0.2 to 14.1)	3.6 (2.3 to 5.1)	6.6 (4.3 to 9.5)	85.0 (71.4 to 99.7)	7.0 (-0.5 to 15.8)
Drug use disorders	-	-	-	-	4.5 (3.1 to 6.1)	7.5 (5.0 to 10.1)	65.0 (45.3 to 87.9)	-0.0 (-11.2 to 12.7)
Opioid use disorders	3.8 (2.7 to 5.0)	6.9 (5.1 to 8.5)	79.3 (63.2 to 103.0)	1.0 (-6.9 to 10.9)	1.6 (1.0 to 2.3)	2.9 (1.9 to 4.1)	79.8 (58.9 to 109.8)	1.5 (-8.9 to 15.2)
Cocaine use disorders	2.7 (2.4 to 3.1)	4.3 (3.7 to 5.0)	56.5 (30.6 to 91.0)	4.3 (-19.9 to 13.5)	0.4 (0.2 to 0.6)	0.6 (0.4 to 0.9)	57.1 (21.3 to 91.0)	4.4 (-25.2 to 20.6)
Amphetamine use disorders	7.4 (6.8 to 8.1)	11.7 (10.7 to 12.6)	58.0 (40.4 to 77.6)	0.4 (-10.4 to 12.4)	1.0 (0.6 to 1.4)	1.5 (0.9 to 2.3)	58.6 (32.8 to 85.6)	1.0 (-14.8 to 17.1)
Cannabis use disorders	6.8 (6.3 to 7.4)	10.5 (9.7 to 11.4)	53.4 (52.2 to 54.7)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	53.0 (32.8 to 78.2)	-0.3 (-13.1 to 15.7)
Other drug use disorders	-	-	-	-	1.4 (0.9 to 2.0)	2.2 (1.3 to 3.1)	57.3 (14.1 to 114.9)	-1.2 (-27.8 to 34.0)
Depressive disorders	-	-	-	-	26.0 (17.1 to 36.5)	43.6 (28.8 to 61.2)	67.6 (58.6 to 78.2)	0.2 (-5.4 to 5.7)
Major depressive disorder	106.5 (85.5 to 124.9)	176.9 (143.3 to 209.2)	66.0 (55.6 to 77.7)	0.1 (-6.6 to 6.6)	22.1 (14.0 to 31.9)	36.7 (23.7 to 52.2)	65.7 (54.9 to 78.3)	0.3 (-6.5 to 7.0)
Dysthymia	39.9 (32.2 to 46.9)	70.8 (57.9 to 82.8)	77.4 (72.8 to 83.4)	-0.2 (-0.4 to -0.1)	3.9 (2.5 to 5.7)	6.9 (4.4 to 10.1)	77.6 (71.0 to 84.9)	0.0 (-2.2 to 2.4)
Bipolar disorder	20.8 (17.7 to 23.8)	36.3 (31.3 to 41.2)	74.2 (64.2 to 86.5)	0.1 (-4.5 to 5.7)	4.3 (2.6 to 6.5)	7.5 (4.6 to 11.2)	74.5 (61.4 to 89.9)	0.6 (-6.2 to 8.2)
Anxiety disorders	102.2 (81.6 to 121.1)	158.8 (127.8 to 190.7)	58.4 (52.3 to 65.4)	9.3 (-0.4 to -0.1)	14.7 (6.2 to 13.4)	14.7 (9.9 to 21.3)	58.3 (50.7 to 66.4)	-0.1 (-2.6 to 2.8)
Eating disorders	-	-	-	-	1.0 (0.6 to 1.5)	1.5 (0.9 to 2.3)	52.2 (39.1 to 66.4)	0.2 (-8.0 to 9.5)
Anorexia nervosa	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.6)	61.3 (45.2 to 78.2)	8.8 (-2.2 to 19.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	60.4 (16.7 to 122.1)	8.1 (-20.1 to 47.9)
Bulimia nervosa	4.3 (3.1 to 5.8)	6.5 (4.6 to 8.8)	51.9 (48.2 to 55.2)	-0.3 (-0.3 to -0.2)	0.9 (0.5 to 1.4)	1.4 (0.8 to 2.2)	51.5 (38.1 to 66.5)	-0.3 (-8.8 to 9.0)
Autistic spectrum disorders	-	-	-	-	4.4 (3.1 to 6.0)	6.3 (4.4 to 8.6)	45.5 (38.9 to 48.4)	0.7 (-2.1 to 3.7)
Autism	11.2 (10.6 to 11.8)	16.1 (15.3 to 17.0)	44.1 (43.3 to 45.0)	0.3 (0.3 to 0.3)	2.8 (1.9 to 3.8)	4.0 (2.7 to 5.5)	43.8 (37.3 to 50.9)	0.6 (-3.7 to 5.2)
Asperger syndrome	16.0 (15.0 to 17.0)	23.0 (21.5 to 24.3)	43.2 (42.1 to 44.5)	0.4 (0.3 to 0.4)	1.6 (1.1 to 2.3)	2.3 (1.6 to 3.2)	43.0 (37.1 to 48.8)	0.6 (-3.3 to 4.4)
Attention-deficit/hyperactivity disorder	25.5 (23.5 to 27.5)	31.2 (28.7 to 33.7)	22.4 (21.7 to 22.8)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	22.4 (14.1 to 31.2)	0.2 (-6.4 to 7.2)
Conduct disorder	37.1 (35.0 to 39.3)	45.1 (42.4 to 47.9)	21.5 (20.6 to 22.6)	4.5 (0.1 to 8.2)	4.5 (2.8 to 6.6)	5.5 (3.4 to 8.0)	21.6 (16.8 to 27.2)	7.8 (-3.6 to 4.8)
Idiopathic intellectual disability	54.7 (40.5 to 68.7)	63.4 (44.0 to 80.2)	16.3 (-3.7 to 35.4)	-18.7 (-33.3 to -5.2)	2.7 (1.6 to 3.9)	3.1 (1.9 to 4.6)	16.2 (-4.9 to 37.3)	-18.6 (-33.9 to -3.7)
Other mental and substance use disorders	48.5 (45.2 to 51.7)	87.7 (82.0 to 93.0)	80.9 (79.0 to 82.8)	0.2 (-0.0 to 0.5)	3.7 (2.5 to 4.9)	6.6 (4.5 to 9.0)	81.0 (73.1 to 89.0)	0.4 (-3.4 to 4.3)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	27.0 (18.9 to 36.4)	50.6 (34.9 to 68.9)	87.5 (70.0 to 105.7)	12.4 (0.6 to 24.4)
Diabetes mellitus	144.5 (117.2 to 166.9)	326.6 (282.9 to 377.6)	126.1 (83.1 to 184.9)	24.7 (-1.8 to 59.3)	11.0 (7.2 to 15.6)	25.0 (16.8 to 35.5)	126.9 (83.2 to 185.0)	24.4 (-1.2 to 56.9)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.1 (-37.7 to -26.6)	-46.5 (-50.2 to -42.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.1 (-37.7 to -26.6)	-46.5 (-50.2 to -42.8)
Chronic kidney disease	-	-	-	-	6.4 (4.5 to 8.6)	10.7 (7.5 to 14.3)	67.5 (50.9 to 85.6)	2.9 (-7.4 to 14.1)
Chronic kidney disease due to diabetes mellitus	26.1 (17.3 to 40.6)	52.9 (27.8 to 82.5)	106.4 (20.0 to 182.6)	15.1 (-27.2 to 61.6)	0.9 (0.6 to 1.3)	1.9 (1.1 to 2.8)	114.3 (29.6 to 228.5)	15.8 (-25.9 to 80.8)
Chronic kidney disease due to hypertension	63.6 (35.9 to 120.9)	93.0 (44.9 to 167.1)	44.4 (4.9 to 92.9)	0.2 (-26.3 to 29.5)	1.7 (1.2 to 2.2)	1.3 (0.9 to 1.8)	-23.7 (-42.0 to -0.9)	0.6 (-66.6 to 43.1)
Chronic kidney disease due to glomerulonephritis	59.5 (38.3 to 86.3)	52.0 (35.4 to 72.2)	-11.9 (-31.8 to 12.9)	-44.1 (-56.8 to -28.5)	1.7 (1.1 to 2.4)	3.0 (2.1 to 4.3)	76.3 (40.5 to 137.1)	16.7 (-6.3 to 60.9)
Chronic kidney disease due to other causes	85.9 (51.0 to 148.5)	185.0 (100.8 to 228.6)	77.9 (31.3 to 153.3)	27.1 (1.7 to 62.6)	2.1 (1.5 to 3.0)	4.5 (3.0 to 6.2)	110.0 (63.0 to 169.1)	36.3 (3.8 to 74.2)
Urinary diseases and male infertility	-	-	-	-	1.4 (0.9 to 2.0)	2.5 (1.6 to 3.6)	82.0 (68.5 to 97.0)	13.0 (3.8 to 23.2)

Appendix Table G.4 - Turkmenistan prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.0 (0.9 to 1.0)	1.8 (1.6 to 1.9)	81.1 (59.7 to 105.8)	26.2 (12.4 to 41.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	81.8 (46.3 to 121.3)	81.8 (3.8 to 52.5)
Urolithiasis	19.2 (15.2 to 25.3)	33.8 (26.7 to 43.7)	78.9 (51.4 to 104.3)	4.4 (-13.2 to 19.1)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	82.4 (61.6 to 104.6)	7.2 (-5.4 to 19.6)
Benign prostatic hyperplasia	27.8 (25.8 to 29.8)	50.7 (47.2 to 54.1)	82.0 (64.1 to 101.8)	13.7 (2.3 to 26.6)	1.0 (0.7 to 1.4)	1.8 (1.2 to 2.6)	82.9 (65.0 to 102.5)	14.4 (2.6 to 26.9)
Male infertility due to other causes	17.8 (13.3 to 22.8)	30.8 (23.8 to 39.6)	71.4 (25.2 to 167.0)	0.7 (-27.0 to 59.0)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.4)	73.2 (23.8 to 168.1)	1.9 (-26.1 to 59.1)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	70.8 (25.9 to 160.7)	3.3 (-23.8 to 55.9)
Gynecological diseases	-	-	-	-	3.8 (2.4 to 5.7)	7.1 (4.5 to 10.7)	86.1 (59.7 to 119.0)	0.9 (-12.4 to 17.5)
Uterine fibroids	53.6 (48.0 to 58.5)	117.1 (106.4 to 127.0)	118.4 (114.4 to 122.8)	1.5 (1.4 to 1.7)	0.9 (0.5 to 1.4)	1.6 (0.9 to 2.7)	87.8 (76.4 to 98.5)	-6.0 (-11.1 to -1.5)
Polycystic ovarian syndrome	55.2 (47.7 to 62.7)	100.4 (88.8 to 112.3)	82.0 (50.2 to 121.7)	-0.6 (-16.2 to 18.5)	0.5 (0.2 to 1.0)	1.0 (0.5 to 1.9)	81.8 (49.2 to 120.7)	-0.1 (-16.2 to 18.6)
Female infertility due to other causes	10.9 (2.6 to 21.8)	19.3 (6.0 to 35.2)	75.3 (-50.0 to 762.5)	7.7 (-70.1 to 445.1)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	71.2 (-50.7 to 671.4)	5.3 (-70.1 to 385.5)
Endometriosis	5.6 (4.6 to 6.6)	11.0 (9.3 to 12.6)	95.6 (57.0 to 144.0)	4.8 (-15.7 to 28.3)	0.5 (0.3 to 0.8)	1.0 (0.7 to 1.5)	95.1 (53.3 to 148.8)	4.9 (-17.0 to 31.2)
Genital prolapse	140.0 (118.9 to 159.3)	249.7 (214.6 to 286.5)	78.9 (44.6 to 121.3)	-2.5 (-18.3 to 17.2)	0.4 (0.2 to 0.9)	0.8 (0.4 to 1.5)	78.2 (44.1 to 120.7)	-2.5 (-18.0 to 18.3)
Premenstrual syndrome	119.2 (77.8 to 165.1)	234.0 (156.2 to 332.3)	95.4 (14.4 to 225.7)	10.4 (-35.4 to 85.2)	1.0 (0.5 to 1.7)	2.0 (1.0 to 3.4)	95.3 (13.1 to 225.6)	11.4 (-34.9 to 86.0)
Other gynecological diseases	11.8 (10.0 to 13.7)	19.6 (18.1 to 21.2)	66.0 (40.9 to 95.9)	-5.9 (-20.0 to 9.8)	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.8)	64.1 (36.2 to 119.7)	-7.3 (-23.7 to 21.4)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	2.6 (1.7 to 3.8)	3.3 (2.2 to 4.8)	25.1 (12.8 to 54.5)	2.0 (-8.2 to 26.4)
Thalassemias	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	16.8 (6.9 to 27.7)	1.8 (-6.5 to 11.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.6 (-18.5 to 62.9)	-2.1 (-30.0 to 35.2)
Thalassemia trait	65.6 (58.9 to 77.1)	98.7 (88.1 to 114.9)	50.2 (43.7 to 59.7)	4.9 (0.9 to 11.1)	1.9 (1.3 to 2.7)	2.6 (1.7 to 3.7)	35.6 (22.8 to 55.8)	7.9 (-2.5 to 24.1)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.7 (11.3 to 22.6)	-5.7 (-13.2 to -4.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.7 (11.2 to 28.1)	-3.1 (-14.4 to -0.9)
Sickle cell trait	3.8 (3.7 to 4.2)	5.1 (4.7 to 5.3)	33.8 (22.2 to 36.1)	6.9 (-14.9 to -5.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.4 (-58.1 to 110.3)	22.1 (-64.6 to 69.6)
G6PD deficiency	7.5 (7.0 to 8.1)	12.7 (12.2 to 13.4)	69.1 (54.5 to 82.9)	17.8 (7.7 to 27.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	62.3 (58.1 to 68.9)	29.6 (24.2 to 35.7)
G6PD trait	414.6 (409.7 to 418.1)	600.3 (592.9 to 607.1)	44.7 (42.0 to 46.7)	-0.2 (-2.1 to 1.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.7 (-75.1 to 272.4)	-1.7 (-76.4 to 207.4)
Other hemoglobinopathies and hemolytic anemias	22.3 (16.6 to 25.4)	24.7 (21.4 to 27.6)	10.5 (-10.2 to 53.2)	-12.7 (-28.4 to 19.1)	0.7 (0.4 to 1.0)	0.7 (0.4 to 1.0)	2.5 (-31.3 to 87.7)	-13.0 (-40.4 to 68.0)
Endocrine, metabolic, blood, and immune disorders	51.0 (46.3 to 55.4)	58.7 (55.3 to 61.8)	15.3 (4.9 to 27.9)	12.9 (-19.5 to -4.6)	1.9 (1.2 to 2.6)	2.0 (1.4 to 2.8)	11.1 (6.5 to 28.8)	13.8 (-21.2 to -2.3)
Musculoskeletal disorders	-	-	-	-	41.8 (29.5 to 56.5)	78.1 (55.5 to 104.9)	87.8 (63.0 to 112.6)	3.6 (-7.8 to 15.8)
Rheumatoid arthritis	4.8 (4.6 to 5.0)	9.5 (9.1 to 9.9)	98.0 (86.1 to 111.3)	19.2 (12.3 to 26.9)	1.2 (0.8 to 1.5)	2.3 (1.6 to 3.1)	98.3 (78.9 to 117.9)	19.3 (9.3 to 29.8)
Osteoarthritis	85.5 (81.7 to 89.3)	159.6 (152.6 to 166.6)	86.8 (75.5 to 98.2)	1.0 (-4.3 to 7.1)	5.3 (3.7 to 7.3)	9.9 (6.9 to 13.6)	87.8 (76.1 to 99.9)	1.4 (-4.4 to 7.4)
Low back and neck pain	-	-	-	-	30.5 (21.0 to 42.1)	56.1 (38.8 to 77.6)	84.6 (52.9 to 119.2)	3.0 (-13.2 to 20.9)
Low back pain	173.0 (145.7 to 195.5)	317.2 (276.8 to 360.5)	82.6 (49.9 to 133.8)	2.6 (-14.1 to 26.7)	19.4 (12.9 to 27.6)	35.7 (24.1 to 50.6)	82.8 (49.0 to 134.4)	3.1 (-13.9 to 27.1)
Neck pain	112.1 (93.2 to 130.3)	206.2 (166.8 to 242.2)	83.4 (41.7 to 137.3)	1.3 (-22.2 to 30.4)	11.1 (7.2 to 15.8)	20.4 (13.2 to 29.4)	83.2 (41.6 to 138.7)	1.1 (-22.2 to 31.0)
Gout	1.5 (1.4 to 1.6)	2.8 (2.7 to 3.0)	91.3 (77.1 to 109.0)	3.0 (-4.5 to 12.0)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	91.9 (55.0 to 135.8)	3.5 (-15.2 to 25.0)
Other musculoskeletal disorders	52.0 (39.3 to 64.4)	105.2 (81.0 to 131.4)	103.0 (86.8 to 119.5)	4.8 (-0.7 to 14.9)	4.8 (3.1 to 7.0)	9.7 (6.3 to 14.4)	4.8 (86.8 to 122.1)	4.8 (-0.9 to 15.8)
Other non-communicable diseases	-	-	-	-	43.6 (28.5 to 64.5)	66.0 (43.5 to 96.8)	51.5 (44.5 to 57.4)	-5.9 (-9.0 to -2.8)
Congenital anomalies	-	-	-	-	2.3 (1.7 to 3.2)	3.9 (2.9 to 5.2)	68.5 (44.2 to 104.5)	21.8 (4.5 to 46.8)
Neural tube defects	0.4 (0.3 to 0.5)	0.9 (0.8 to 1.1)	140.3 (81.0 to 227.6)	92.1 (44.1 to 162.5)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	159.9 (73.6 to 343.7)	112.4 (42.8 to 263.3)
Congenital heart anomalies	5.1 (3.7 to 6.7)	17.4 (13.0 to 21.6)	241.6 (126.7 to 398.6)	161.3 (73.1 to 281.9)	0.2 (0.1 to 0.3)	0.6 (0.3 to 1.0)	211.7 (110.7 to 346.4)	137.6 (61.7 to 241.7)
Orofacial clefts	0.7 (0.5 to 1.0)	2.2 (1.5 to 2.9)	208.1 (87.9 to 401.9)	155.8 (56.2 to 320.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	179.8 (68.0 to 373.6)	132.3 (39.7 to 298.0)
Down syndrome	2.4 (1.9 to 2.9)	4.5 (3.8 to 5.8)	86.4 (40.7 to 159.9)	35.2 (2.0 to 88.5)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	94.6 (43.8 to 173.8)	38.4 (1.8 to 93.8)
Turner syndrome	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	63.7 (12.2 to 141.2)	16.9 (-20.0 to 71.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.4 (16.4 to 158.3)	17.5 (-20.1 to 77.7)
Klinefelter syndrome	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	54.6 (11.0 to 123.1)	9.3 (-21.3 to 57.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.9 (25.4 to 152.4)	8.9 (-21.9 to 57.7)
Chromosomal unbalanced rearrangements	0.0 (2.8 to 4.3)	0.0 (5.8 to 8.6)	60.0 (50.8 to 159.6)	-9.9 (10.2 to 90.6)	0.0 (0.3 to 0.6)	0.0 (0.6 to 1.2)	182.2 (10.6 to 98.2)	44.9 (-10.6 to 98.2)
Other congenital anomalies	12.1 (10.0 to 14.0)	15.4 (13.1 to 17.7)	28.1 (11.8 to 43.9)	-14.2 (-24.5 to -3.2)	1.3 (0.8 to 1.9)	1.6 (1.1 to 2.3)	21.9 (-2.4 to 55.0)	-11.4 (-29.2 to 11.5)
Skin and subcutaneous diseases	-	-	-	-	15.2 (9.7 to 22.7)	22.3 (14.6 to 33.5)	46.8 (34.5 to 61.6)	-5.0 (-12.9 to 5.0)
Dermatitis	132.9 (108.3 to 159.7)	214.7 (172.3 to 260.7)	61.4 (56.5 to 66.3)	-0.0 (-0.1 to 0.0)	3.3 (2.0 to 4.8)	5.1 (3.1 to 7.7)	57.2 (51.2 to 63.1)	0.1 (-2.4 to 2.6)
Psoriasis	24.7 (21.8 to 27.7)	41.0 (36.0 to 46.1)	65.9 (62.8 to 69.7)	0.0 (-0.1 to 0.2)	2.0 (1.4 to 2.9)	3.4 (2.3 to 4.7)	65.7 (55.6 to 76.3)	0.2 (-4.8 to 5.7)
Cellulitis	1.3 (1.1 to 1.6)	1.7 (1.3 to 2.2)	25.8 (9.3 to 50.5)	-5.9 (-16.4 to 8.4)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	25.4 (-3.7 to 63.8)	-5.8 (-25.3 to 18.6)
Pyoderma	3.8 (3.1 to 4.5)	5.3 (4.4 to 6.5)	41.1 (31.4 to 52.1)	9.0 (4.5 to 13.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	40.8 (25.2 to 58.0)	9.1 (-0.2 to 19.3)
Scabies	11.1 (9.3 to 12.9)	14.5 (12.4 to 17.1)	30.7 (4.1 to 67.9)	-7.3 (-24.9 to 16.5)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	30.4 (4.2 to 69.5)	-7.2 (-24.8 to 17.7)
Fungal skin diseases	217.4 (186.5 to 237.5)	390.7 (298.3 to 522.1)	58.3 (49.8 to 65.9)	0.1 (-0.0 to 0.2)	2.2 (0.5 to 3.1)	2.2 (0.9 to 5.0)	58.0 (49.7 to 66.0)	0.2 (-0.1 to 1.1)
Viral skin diseases	91.6 (70.4 to 110.1)	119.5 (90.7 to 149.2)	30.5 (23.4 to 37.6)	0.1 (-1.5 to 2.0)	2.9 (1.6 to 4.5)	3.7 (2.1 to 5.9)	30.2 (22.3 to 38.4)	0.1 (-2.8 to 3.3)
Acne vulgaris	101.6 (78.2 to 127.6)	149.4 (118.3 to 182.1)	48.4 (4.3 to 107.4)	3.3 (-26.1 to 43.5)	1.1 (0.5 to 2.2)	1.6 (0.8 to 3.1)	48.4 (4.3 to 107.9)	3.4 (-26.2 to 44.4)
Alopecia areata	3.6 (3.2 to 4.1)	5.7 (5.1 to 6.4)	58.6 (34.5 to 90.7)	0.9 (-14.9 to 19.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	57.7 (29.5 to 93.6)	1.0 (-15.7 to 21.5)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.0 (26.3 to 103.5)	-9.9 (-21.9 to 25.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.0 (26.1 to 103.6)	-0.9 (-22.0 to 25.9)
Urticaria	49.9 (38.1 to 63.5)	64.4 (48.1 to 82.4)	29.5 (-13.1 to 95.0)	-22.0 (-45.9 to 19.3)	3.0 (1.8 to 4.6)	3.9 (2.3 to 6.0)	29.7 (-13.2 to 95.7)	22.0 (-46.3 to 19.6)
Decubitus ulcer	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	61.2 (28.4 to 98.4)	-1.3 (-25.1 to 27.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	63.3 (27.0 to 104.5)	0.3 (-26.5 to 33.1)
Other skin and subcutaneous diseases	159.4 (107.7 to 238.3)	266.5 (180.8 to 390.9)	66.8 (53.1 to 83.3)	-2.8 (-7.1 to 2.7)	0.9 (0.4 to 1.9)	1.6 (0.7 to 3.2)	66.9 (52.9 to 83.5)	-2.7 (-7.1 to 3.2)
Sense organ diseases	-	-	-	-	19.3 (12.7 to 27.9)	28.5 (18.8 to 40.9)	68.1 (39.5 to 96.0)	-9.5 (-13.1 to -5.9)
Glaucoma	2.9 (2.4 to 3.4)	4.1 (3.4 to 4.9)	41.9 (23.4 to 66.5)	-19.5 (-30.7 to -4.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	33.9 (13.3 to 56.9)	-20.3 (-31.7 to -6.5)
Cataract	18.5 (13.3 to 23.4)	22.5 (16.2 to 29.0)	20.5 (2.7 to 50.3)	-29.3 (-38.8 to -15.8)	0.6 (0.3 to 0.9)	0.7 (0.4 to 1.1)	20.7 (3.6 to 49.7)	-29.0 (-37.9 to -15.7)
Macular degeneration	5.7 (4.0 to 7.9)	11.3 (8.3 to 14.2)	101.0 (54.9 to 148.2)	8.6 (-16.0 to 35.4)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.6)	98.8 (53.2 to 145.8)	8.1 (-16.7 to 34.0)
Uncorrected refractive error	296.0 (212.2 to 261.9)	367.2 (330.8 to 401.2)	55.6 (36.4 to 78.2)	5.5 (-16.1 to 38.1)	3.1 (2.1 to 6.1)	5.3 (3.0 to 9.1)	44.2 (31.3 to 59.9)	-10.2 (-18.1 to -0.7)
Age-related and other hearing loss	364.8 (317.6 to 408.1)	597.0 (516.8 to 671.6)	63.4 (55.1 to 74.8)	-7.7 (-10.9 to -3.7)	11.9 (7.8 to 16.9)	18.3 (12.0 to 26.1)	54.9 (42.4 to 66.4)	8.4 (-13.1 to -4.0)
Other vision loss	17.0 (14.7 to 19.5)	18.3 (15.8 to 21.4)	8.0 (-1.7 to 17.9)	-32.5 (-39.6 to -25.5)	0.6 (0.4 to 0.9)	0.6 (0.4 to 0.9)	2.3 (-9.0 to 13.1)	0.6 (-41.6 to -28.5)
Other sense organ diseases	85.5 (81.0 to 90.1)	116.0 (110.7 to 121.5)	35.9 (26.3 to 45.5)	0.0 (-6.0 to 6.6)	2.3 (1.4 to 3.4)	3.1 (1.9 to 4.5)	35.4 (24.9 to 45.8)	0.3 (-6.5 to 7.7)
Oral disorders	-	-	-	-	6.8 (4.0 to 10.9)	11.2 (6.5 to 17.9)	64.9 (58.9 to 70.6)	-2.3 (-5.4 to 0.8)
Deciduous caries	430.4 (421.1 to 439.3)	439.0 (430.5 to 448.6)	2.0 (-1.0 to 5.0)	0.6 (-2.2 to 3.6)	0.6 (0.1 to 0.3)	0.2 (0.1 to 0.3)	0.2 (-3.2 to 7.3)	0.6 (-4.3 to 5.9)
Permanent caries	1,873.9 (1,815.4 to 1,929.6)	2,914.1 (2,827.4 to 2,998.1)	55.5 (49.1 to 63.1)	-0.3 (-3.8 to 4.0)	1.9 (0.8 to 3.6)	2.9 (1.3 to 5.6)	55.3 (48.8 to 63.4)	-0.9 (-3.9 to 4.2)
Periodontal diseases	177.3 (168.4 to							

Appendix Table G.4 - Turkmenistan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	72.0 (68.9 to 74.8)	118.6 (113.3 to 123.4)	64.4 (55.5 to 75.8)	-6.2 (-10.8 to -0.4)	2.0 (1.4 to 2.8)	3.3 (2.2 to 4.6)	65.1 (55.1 to 77.0)	65.1 (11.0 to 0.1)
Other oral disorders	55.4 (52.0 to 58.6)	90.4 (84.8 to 95.8)	62.8 (50.8 to 76.7)	-0.7 (-7.6 to 7.2)	1.6 (1.0 to 2.5)	2.7 (1.6 to 4.0)	62.6 (50.2 to 77.6)	-0.4 (-7.6 to 7.5)
Injuries	-	-	-	-	24.1 (18.2 to 31.1)	27.8 (20.0 to 37.7)	15.2 (3.8 to 27.8)	-32.8 (-39.4 to -25.5)
Transport injuries	-	-	-	-	4.8 (3.6 to 6.3)	3.7 (2.7 to 5.0)	-23.7 (-33.0 to -12.9)	-54.2 (-59.5 to -48.2)
Road injuries	-	-	-	-	4.3 (3.0 to 5.2)	2.8 (2.0 to 3.8)	-30.2 (-39.4 to -19.6)	-57.8 (-63.0 to -52.0)
Pedestrian road injuries	-	-	-	-	0.8 (0.6 to 1.1)	0.5 (0.4 to 0.7)	-33.9 (-43.1 to -22.3)	-57.6 (-63.0 to -51.1)
Cyclist road injuries	-	-	-	-	0.5 (0.4 to 0.6)	0.4 (0.3 to 0.5)	-23.2 (-31.7 to -13.4)	-53.7 (-58.8 to -48.0)
Motorcyclist road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-28.0 (-38.6 to -17.3)	-58.4 (-64.1 to -52.7)
Motor vehicle road injuries	-	-	-	-	2.3 (1.7 to 3.0)	1.6 (1.1 to 2.2)	-30.5 (-40.4 to -18.7)	-58.5 (-64.0 to -52.0)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.7 (-46.9 to -28.7)	-63.6 (-68.0 to -58.2)
Other transport injuries	-	-	-	-	0.8 (0.6 to 1.0)	0.9 (0.6 to 1.2)	9.7 (2.1 to 23.0)	-36.3 (-42.9 to -28.7)
Unintentional injuries	-	-	-	-	18.9 (14.3 to 24.3)	23.6 (17.0 to 32.1)	25.3 (13.7 to 37.9)	-27.7 (-34.7 to -20.4)
Falls	-	-	-	-	12.6 (9.4 to 16.3)	16.1 (11.3 to 22.0)	27.3 (13.0 to 43.2)	-28.6 (-36.6 to -19.9)
Drowning	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-35.4 (-45.7 to -23.7)	-58.6 (-64.8 to -51.9)
Fire, heat, and hot substances	-	-	-	-	0.7 (0.5 to 0.9)	0.6 (0.5 to 0.9)	-7.0 (-18.4 to 6.5)	-43.2 (-50.0 to -35.5)
Poisonings	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-1.0 (-15.5 to 14.3)	-38.1 (-46.1 to -29.6)
Exposure to mechanical forces	-	-	-	-	3.7 (2.8 to 4.8)	4.4 (3.2 to 5.9)	19.5 (11.1 to 28.5)	-25.9 (-30.7 to -21.1)
Unintentional firearm injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-3.4 (-18.3 to 13.3)	-41.6 (-50.4 to -31.5)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	29.8 (15.9 to 45.4)	-18.2 (-25.9 to -8.9)
Other exposure to mechanical forces	-	-	-	-	3.6 (2.7 to 4.7)	4.3 (3.1 to 5.8)	19.8 (11.4 to 28.7)	-25.7 (-30.5 to -21.0)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	62.5 (52.5 to 73.7)	1.7 (-5.1 to 9.8)
Animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	32.6 (20.2 to 46.4)	-14.3 (-21.1 to -6.6)
Venomous animal contact	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	38.4 (21.9 to 58.8)	-12.2 (-22.2 to -1.2)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	29.2 (16.3 to 44.8)	-15.4 (-23.0 to -6.3)
Foreign body	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	15.7 (4.4 to 28.5)	-26.1 (-32.8 to -18.8)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-13.6 (-27.6 to 4.6)	-42.4 (-51.2 to -31.2)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	43.7 (34.1 to 53.9)	-8.8 (-15.7 to -2.4)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	27.3 (14.4 to 42.5)	-21.1 (-27.9 to -13.1)
Other unintentional injuries	-	-	-	-	1.2 (0.9 to 1.5)	1.8 (1.3 to 2.4)	52.6 (39.4 to 65.7)	-12.3 (-19.5 to -5.3)
Self-harm and interpersonal violence	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	9.5 (1.8 to 23.3)	-39.0 (-45.3 to -31.5)
Self-harm	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	28.1 (14.3 to 44.0)	-29.7 (-37.0 to -21.5)
Interpersonal violence	-	-	-	-	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.3)	-4.9 (-16.5 to 9.8)	-46.4 (-52.8 to -38.6)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.4 (-2.2 to 20.6)	-38.1 (-43.8 to -31.7)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	6.3 (-7.4 to 23.8)	-40.7 (-48.1 to -31.4)
Assault by other means	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	9.4 (-21.3 to 6.1)	-48.9 (-55.4 to -40.7)
Forces of nature, war, and legal intervention	-	-	-	-	0.0	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	0.0	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	0.0	-	-	-

Appendix Table G.4 - Uganda prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	2,036.7 (1,440.2 to 2,832.9)	3,455.1 (2,533.5 to 4,540.6)	71.4 (47.9 to 87.5)	71.4 (-24.7 to -8.8)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	599.4 (427.7 to 818.2)	963.3 (689.5 to 1,313.4)	60.5 (51.1 to 71.1)	-27.2 (-33.0 to -19.0)
HIV/AIDS and tuberculosis	-	-	-	-	113.7 (76.9 to 159.8)	203.0 (135.0 to 282.6)	77.8 (42.9 to 119.6)	-10.1 (-27.9 to 18.4)
Tuberculosis	52.1 (48.2 to 56.4)	89.9 (83.7 to 96.6)	72.8 (65.1 to 83.2)	-15.5 (-19.4 to -10.6)	15.5 (10.6 to 20.8)	27.4 (18.7 to 36.6)	77.0 (65.2 to 90.1)	-13.7 (-19.0 to -8.0)
HIV/AIDS	-	-	-	-	98.3 (65.8 to 141.1)	175.6 (114.1 to 249.2)	78.3 (58.0 to 116.5)	-33.4 (-29.7 to 24.0)
HIV/AIDS resulting in mycobacterial infection	15.7 (11.4 to 19.8)	21.0 (13.7 to 28.1)	33.7 (12.0 to 56.7)	-32.7 (-44.3 to -18.9)	5.7 (3.5 to 8.2)	7.8 (4.6 to 11.6)	36.0 (12.7 to 63.1)	-41.8 (-14.6 to -16.4)
HIV/AIDS resulting in other diseases	889.8 (791.4 to 1,009.2)	1,277.1 (1,136.5 to 1,425.5)	44.9 (18.8 to 60.5)	-25.0 (-37.7 to -15.9)	92.6 (61.3 to 135.1)	167.8 (108.3 to 239.2)	80.9 (38.2 to 132.9)	-7.7 (-29.7 to 28.4)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	110.8 (78.9 to 148.8)	161.2 (113.8 to 219.1)	45.6 (33.5 to 58.3)	-28.2 (-33.6 to -22.3)
Diarrheal diseases	402.5 (378.5 to 424.5)	538.2 (496.6 to 580.9)	33.8 (21.3 to 48.7)	-33.7 (-33.2 to -26.9)	64.9 (44.0 to 89.9)	87.5 (59.6 to 121.2)	34.4 (21.7 to 50.9)	-33.4 (-39.0 to -25.2)
Intestinal infectious diseases	-	-	-	-	1.6 (1.0 to 2.4)	0.8 (0.5 to 1.1)	0.8 (-61.8 to -33.0)	-47.7 (-81.7 to -68.9)
Typhoid fever	7.4 (6.5 to 8.4)	4.6 (4.1 to 5.2)	-37.5 (-47.2 to -26.5)	-70.9 (-75.5 to -65.7)	1.0 (0.6 to 1.4)	0.6 (0.4 to 0.9)	0.6 (-49.8 to -18.4)	-69.3 (-75.9 to -62.5)
Paratyphoid fever	2.8 (2.3 to 3.2)	2.1 (1.8 to 2.5)	-22.5 (-37.6 to -4.8)	-64.4 (-72.6 to -55.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-21.2 (-40.2 to 3.2)	-63.7 (-73.2 to -54.1)
Other intestinal infectious diseases	-	-	-	-	0.4 (0.2 to 0.9)	0.1 (0.0 to 0.1)	-85.5 (-91.6 to -74.9)	-92.6 (-96.0 to -88.2)
Lower respiratory infections	29.0 (23.7 to 35.5)	48.2 (38.7 to 57.2)	65.5 (25.9 to 120.9)	-20.9 (-36.0 to 1.1)	3.0 (1.9 to 4.4)	5.1 (3.3 to 7.5)	66.0 (23.5 to 129.7)	-20.5 (-36.8 to 3.8)
Upper respiratory infections	1,405.9 (1,335.8 to 1,473.8)	2,992.7 (2,854.5 to 3,131.2)	113.5 (99.4 to 128.0)	-0.0 (-6.2 to 6.9)	16.4 (9.3 to 27.0)	35.2 (20.0 to 58.8)	115.1 (100.7 to 130.1)	0.9 (-5.7 to 7.7)
Otitis media	306.8 (281.3 to 335.0)	608.2 (558.9 to 665.1)	98.4 (81.4 to 120.0)	-9.4 (-17.9 to 0.7)	6.3 (3.7 to 10.0)	12.5 (7.4 to 20.3)	98.9 (78.6 to 126.0)	-18.9 (-18.9 to 2.9)
Meningitis	-	-	-	-	16.5 (11.3 to 22.7)	17.3 (11.9 to 22.9)	4.2 (-15.4 to 28.2)	-48.1 (-57.1 to -38.4)
Pneumococcal meningitis	62.3 (38.3 to 91.7)	61.7 (38.7 to 91.1)	-0.2 (-18.3 to 20.8)	-49.6 (-58.5 to -39.1)	6.0 (3.9 to 7.9)	6.0 (4.2 to 8.3)	7.2 (-16.2 to 38.9)	-46.5 (-57.2 to -33.0)
H influenzae type B meningitis	36.3 (15.7 to 62.6)	33.5 (14.7 to 58.2)	-8.1 (-29.4 to 19.2)	-56.8 (-67.1 to -44.9)	3.8 (2.4 to 5.5)	4.2 (2.6 to 6.3)	11.1 (-22.7 to 66.5)	-48.6 (-63.0 to -24.8)
Meningococcal meningitis	9.1 (3.6 to 18.7)	8.2 (3.2 to 17.2)	-8.1 (-37.0 to 27.8)	-49.2 (-64.8 to -30.5)	1.2 (0.6 to 2.1)	1.1 (0.7 to 1.6)	-2.7 (-39.9 to 29.2)	-46.7 (-66.0 to -31.3)
Other meningitis	52.6 (28.0 to 89.5)	48.6 (25.9 to 83.3)	-7.6 (-24.5 to 13.5)	-53.3 (-62.4 to -44.0)	6.0 (3.9 to 8.6)	6.0 (4.0 to 8.2)	0.4 (-27.6 to 42.9)	-49.3 (-62.5 to -31.1)
Encephalitis	2.2 (1.5 to 6.5)	5.5 (2.6 to 11.2)	151.4 (48.5 to 97.0)	-73.3 (-29.7 to -60.0)	0.4 (0.3 to 0.5)	0.7 (0.5 to 1.0)	68.7 (15.6 to 122.8)	-12.4 (-24.4 to 1.0)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (-95.7 to 4,091.8)	-45.0 (-96.6 to 944.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (95.7 to 4,105.1)	0.0 (-96.7 to 958.3)
Whooping cough	19.6 (15.3 to 25.1)	29.7 (23.3 to 37.9)	51.9 (49.2 to 54.6)	-24.7 (-26.0 to -23.4)	1.0 (0.6 to 1.6)	1.5 (0.9 to 2.4)	52.4 (39.3 to 69.6)	-24.5 (-31.3 to -15.8)
Tetanus	1.6 (0.8 to 2.7)	0.2 (0.2 to 0.7)	-73.8 (-88.6 to -48.5)	-87.3 (-94.5 to -72.4)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (-83.1 to -47.2)	-82.7 (-91.3 to -73.4)
Measles	6.9 (5.2 to 9.0)	2.5 (1.9 to 3.3)	-63.5 (-69.8 to -56.0)	-63.5 (-85.4 to -78.7)	0.6 (0.4 to 1.0)	0.2 (0.1 to 0.4)	65.3 (-75.5 to -46.2)	-42.2 (-88.1 to -74.1)
Varicella and herpes zoster	10.9 (10.0 to 11.9)	24.8 (22.9 to 27.0)	128.5 (99.0 to 159.0)	5.9 (-17.6 to 28.8)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.8)	120.7 (55.4 to 206.5)	7.0 (-29.4 to 52.9)
Neglected tropical diseases and malaria	-	-	-	-	237.3 (155.2 to 347.3)	308.7 (204.0 to 456.3)	30.7 (19.3 to 44.0)	47.7 (-52.9 to -40.1)
Malaria	10,124.7 (9,692.9 to 10,563.8)	15,043.4 (14,382.4 to 15,740.8)	49.0 (44.3 to 54.1)	-33.6 (-36.1 to -31.4)	97.2 (64.8 to 140.9)	173.1 (116.4 to 248.3)	77.8 (70.4 to 93.8)	-22.9 (-26.4 to -18.0)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	488.1 (301.0 to 770.2)	253.5 (138.2 to 405.0)
Visceral leishmaniasis	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	113.6 (46.0 to 201.0)	0.8 (-23.4 to 30.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.6 (45.7 to 201.7)	0.8 (-23.4 to 30.9)
Cutaneous and mucocutaneous leishmaniasis	0.4 (0.2 to 0.6)	3.6 (2.3 to 5.5)	886.2 (560.7 to 1,363.5)	410.8 (245.0 to 655.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	856.9 (513.3 to 1,392.3)	395.4 (213.3 to 653.5)
African trypanosomiasis	18.1 (8.1 to 33.9)	1.0 (0.4 to 2.0)	-94.7 (-95.3 to -94.0)	-97.5 (-97.1 to -97.1)	4.9 (1.9 to 9.7)	0.3 (0.1 to 0.7)	-94.0 (-94.8 to -93.1)	-97.1 (-97.5 to -96.6)
Schistosomiasis	4,815.9 (2,916.8 to 7,144.0)	4,736.4 (2,747.1 to 7,453.2)	-1.8 (-18.8 to 37.8)	-4.8 (-62.5 to -36.1)	45.9 (19.7 to 86.6)	45.9 (21.2 to 92.0)	3.2 (-13.5 to 47.2)	53.2 (-60.1 to -32.6)
Cysticercosis	3.4 (1.8 to 6.1)	5.1 (2.0 to 8.6)	45.1 (-36.9 to 251.8)	-37.0 (-70.5 to 31.5)	0.9 (0.4 to 1.6)	1.4 (0.5 to 2.5)	58.0 (-32.1 to 287.1)	-32.0 (-68.2 to 37.7)
Cystic echinococcosis	10.2 (8.8 to 11.4)	8.9 (8.2 to 9.8)	-14.0 (-17.6 to -4.1)	-55.1 (-57.9 to -49.1)	0.9 (0.6 to 1.3)	0.8 (0.5 to 1.2)	-13.0 (-25.9 to 3.8)	-54.1 (-59.6 to -46.6)
Lymphatic filariasis	634.3 (522.0 to 753.7)	285.1 (203.4 to 381.8)	-55.2 (-66.5 to -41.6)	-75.5 (-81.9 to -68.0)	17.6 (8.9 to 29.5)	18.8 (9.8 to 32.0)	7.6 (-29.6 to 46.8)	-46.4 (-65.0 to -22.3)
Onchocerciasis	689.8 (413.1 to 1,196.5)	319.7 (204.9 to 459.2)	-53.6 (-71.4 to -22.3)	-52.6 (-85.1 to -61.1)	43.0 (22.1 to 69.4)	36.0 (11.1 to 47.4)	69.8 (-61.4 to -7.0)	-69.8 (-80.1 to -52.0)
Trachoma	11.4 (4.1 to 18.7)	7.9 (4.0 to 14.2)	-34.6 (-62.2 to 56.1)	-66.2 (-80.2 to -26.7)	0.8 (0.3 to 1.3)	0.6 (0.3 to 1.0)	-31.2 (-56.6 to 33.4)	-64.5 (-78.3 to -35.2)
Dengue	1.3 (0.4 to 2.9)	13.2 (4.7 to 29.8)	943.4 (931.0 to 957.7)	383.2 (377.5 to 389.8)	0.2 (0.1 to 0.6)	2.2 (0.6 to 5.3)	928.1 (683.9 to 1,288.6)	370.2 (279.0 to 489.4)
Yellow fever	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-43.7 (-63.3 to -12.6)	-73.7 (-81.3 to -62.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-43.7 (-63.5 to -11.7)	-73.7 (-81.3 to -62.8)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-33.4 to 106.0)	-37.0 (-63.4 to -13.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.7 (-33.7 to 106.2)	37.0 (-63.5 to -13.1)
Intestinal nematode infections	-	-	-	-	19.2 (12.0 to 29.3)	24.4 (15.2 to 37.2)	27.6 (10.5 to 39.4)	-44.2 (-50.3 to -38.0)
Ascariasis	907.1 (601.4 to 1,351.1)	893.8 (610.4 to 1,308.2)	-2.3 (-45.0 to 74.4)	-56.2 (-78.2 to -9.4)	0.5 (0.3 to 1.0)	0.5 (0.3 to 0.9)	0.8 (-32.9 to 50.7)	-54.9 (-72.7 to -27.7)
Trichuriasis	1,099.9 (689.2 to 1,690.1)	995.5 (656.1 to 1,464.4)	-8.2 (-49.9 to 63.6)	-58.6 (-80.2 to -12.7)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	0.2 (-38.0 to 47.5)	-5.7 (-74.9 to -27.1)
Hookworm disease	4,453.0 (3,207.0 to 6,236.8)	5,256.0 (3,737.7 to 7,316.2)	18.4 (-25.3 to 89.4)	-46.4 (-69.4 to -4.5)	18.4 (11.5 to 27.9)	18.4 (14.8 to 36.1)	28.7 (10.7 to 41.2)	-43.8 (-50.2 to -37.5)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	185.3 (141.7 to 233.9)	368.1 (330.3 to 407.6)	99.6 (56.7 to 161.7)	-8.0 (-27.1 to 18.2)	9.1 (5.4 to 14.3)	15.3 (9.8 to 22.4)	66.5 (38.1 to 127.3)	-30.9 (-48.1 to -8.5)
Maternal disorders	-	-	-	-	6.2 (4.3 to 8.5)	10.5 (7.3 to 14.5)	70.5 (44.1 to 96.8)	-22.2 (-33.0 to -10.5)
Maternal hemorrhage	4.4 (3.6 to 5.2)	7.0 (4.6 to 9.3)	51.6 (2.6 to 123.1)	-36.0 (-51.9 to 2.3)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.4)	59.3 (-19.9 to 170.8)	-28.2 (-64.4 to 20.7)
Maternal sepsis and other maternal infections	10.5 (6.9 to 15.2)	13.0 (8.4 to 17.3)	24.1 (0.9 to 52.5)	-42.0 (-52.4 to -29.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	22.1 (-23.1 to 94.3)	-43.6 (-62.0 to -16.2)
Maternal hypertensive disorders	8.5 (4.2 to 14.1)	14.5 (7.7 to 23.8)	69.3 (51.1 to 98.4)	-24.6 (-32.4 to -11.4)	0.4 (0.2 to 0.8)	0.7 (0.3 to 1.3)	73.5 (45.1 to 111.9)	-22.8 (-35.2 to -5.8)
Obstructed labor	12.8 (11.1 to 14.5)	20.9 (17.9 to 23.9)	64.5 (49.0 to 79.9)	-24.6 (-31.2 to -17.6)	4.0 (2.7 to 5.7)	6.8 (4.6 to 9.5)	68.6 (44.3 to 94.4)	-22.5 (-32.3 to -11.6)
Complications of abortion	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	116.9 (16.1 to 359.4)	6.3 (-46.8 to 79.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	116.9 (15.6 to 359.9)	-6.3 (-46.8 to 79.7)
Other maternal disorders	-	-	-	-	1.4 (0.9 to 2.1)	2.5 (1.6 to 3.8)	80.0 (15.9 to 161.8)	-18.2 (-44.9 to 18.7)
Neonatal disorders	-	-	-	-	8.7 (5.3 to 15.4)	46.5 (29.7 to 70.3)	449.1 (239.5 to 708.6)	169.4 (53.7 to 320.5)
Preterm birth complications	45.9 (29.7 to 69.0)	219.6 (152.9 to 309.2)	383.5 (303.1 to 486.4)	118.7 (83.3 to 164.0)	2.6 (1.7 to 3.6)	20.2 (13.0 to 28.7)	687.5 (450.9 to 1,010.2)	272.4 (163.7 to 426.8)
Neonatal encephalopathy due to birth asphyxia and trauma	102.9 (10.0 to 335.3)	168.3 (31.6 to 507.1)	77.3 (27.5 to 276.3)	-21.0 (-43.1 to 74.4)	3.7 (1.9 to 8.5)	12.7 (6.1 to 23.2)	263.2 (93.2 to 677.2)	74.4 (-12.5 to 335.5)
Neonatal sepsis and other neonatal infections	0.2 (0.1 to 0.5)	0.9 (0.3 to 1.8)	358.0 (253.4 to 286.8)	95.8 (89.1 to 107.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.3)	25.7 (237.3 to 303.7)	37.0 (80.5 to 116.1)
Hemolytic disease and other neonatal jaundice	3.0 (1.2 to 6.5)	19.1 (9.0 to 41.1)	539.1 (165.6 to 1,461.5)	260.5 (39.8 to 801.2)	1.2 (0.4 to 2.6)	7.3 (3.3 to 15.9)	544.6 (162.4 to 1,499.7)	250.1 (35.4 to 802.5)
Other neonatal disorders	-	-	-	-	1.3 (0.5 to 2.6)	6.1 (2.2 to 12.3)	383.3 (113.1 to 930.1)	136.4 (0.8 to 399.2)
Nutritional deficiencies	-	-	-	-	109.4 (72.2 to 157.5)	208.2 (155.4 to 298.7)	90.6 (71.6 to 108.5)	-11.4 (-21.6 to -1.6)
Protein-energy malnutrition	65.2 (42.2 to 97.5)	146.1 (86.1 to 225.9)	123.4 (21.9 to 327.7)	3.6 (-36.5 to 75.9)	4.2 (4.2 to 13.4)	7.9 (9.0 to 31.4)	18.0 (21.0 to 340.9)	5.3 (-36.0 to 82.4)
Iodine deficiency	470.0 (260.9 to 733.0)	742.1 (447.5 to 1,110.8)	63.8 (-16.4 to 209.0)	-23.5 (-62.9 to 52.1)	8.4 (4.0 to 16.6)	13.3 (6.6 to 23.9)	64.1 (-17.1 to 206.5)	-22.8 (-61.9 to 52.4)
Vitamin A deficiency	20.0 (14.8 to 25.9)	25.6 (18.0 to 34.9)	28.8 (7.5 to 51.0)	-39.6 (-49.7 to -28.0)	1.0 (0.6 to 1.5)	1.2 (0.7 to 1.9)	21.2 (2.1 to 52.5)	-39.0 (-50.9 to -23.2)

Appendix Table G.4 - Uganda prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	2,458.4 (2,379.5 to 2,556.3)	4,951.3 (4,837.7 to 5,071.6)	102.2 (89.7 to 110.5)	6.5 (-12.5 to -1.8)	92.2 (61.5 to 133.5)	175.7 (116.1 to 253.0)	91.2 (67.5 to 102.4)	91.2 (-19.8 to -3.3)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-17.2 to 44.2)	8.1 (-58.3 to 133.3)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	13.3 (8.1 to 20.8)	25.1 (15.5 to 39.8)	88.5 (68.6 to 112.9)	-13.4 (-22.5 to -1.9)
Sexually transmitted diseases excluding HIV	-	-	-	-	6.0 (3.3 to 10.4)	12.3 (6.7 to 21.9)	105.0 (61.7 to 157.0)	-7.6 (-23.2 to 11.0)
Syphilis	2.1 (1.8 to 2.4)	2.4 (2.0 to 2.8)	12.8 (8.9 to 43.1)	-42.7 (-52.3 to -31.0)	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	42.1 (-15.7 to 55.6)	42.1 (-55.0 to -25.9)
Chlamydial infection	443.4 (351.5 to 543.6)	1,001.6 (771.4 to 1,219.7)	128.7 (61.2 to 210.1)	1.7 (-23.9 to 38.1)	2.1 (1.1 to 3.8)	5.0 (2.6 to 8.6)	135.1 (46.4 to 323.4)	8.3 (-31.3 to 88.8)
Gonococcal infection	168.8 (125.5 to 209.9)	385.8 (283.9 to 486.9)	126.9 (56.8 to 229.7)	1.4 (-28.0 to 42.9)	0.9 (0.5 to 1.5)	2.0 (1.0 to 3.5)	123.1 (47.7 to 257.8)	0.4 (-30.6 to 58.7)
Trichomoniasis	333.3 (219.3 to 453.9)	694.8 (345.2 to 1,014.1)	104.1 (14.0 to 252.4)	-6.2 (-42.3 to 52.0)	0.6 (0.2 to 1.3)	1.2 (0.4 to 2.8)	103.7 (-1.9 to 262.9)	-6.0 (-49.1 to 59.5)
Genital herpes	6,286.1 (5,948.9 to 6,584.6)	11,328.9 (10,288.9 to 12,293.4)	80.3 (62.6 to 99.2)	-2.3 (-19.0 to -6.0)	1.9 (0.7 to 4.4)	3.5 (1.2 to 8.2)	78.5 (53.1 to 102.0)	34.5 (-25.1 to -6.2)
Other sexually transmitted diseases	6.7 (4.8 to 9.3)	11.2 (7.7 to 14.9)	65.7 (41.6 to 95.9)	-22.7 (-33.7 to -8.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	74.8 (17.2 to 163.6)	-18.8 (-42.6 to 14.5)
Hepatitis	-	-	-	-	1.5 (1.0 to 2.3)	2.7 (1.7 to 4.1)	75.9 (56.6 to 111.0)	-20.4 (-30.4 to -0.1)
Hepatitis A	35.4 (33.2 to 37.5)	68.2 (64.4 to 72.1)	93.4 (92.7 to 94.6)	-4.2 (-4.5 to -3.7)	0.6 (0.4 to 0.8)	1.3 (0.8 to 1.9)	121.6 (95.4 to 154.5)	7.1 (-4.5 to 21.8)
Hepatitis B	2,202.4 (1,978.7 to 2,432.5)	3,076.3 (2,804.0 to 3,346.2)	40.3 (21.7 to 60.2)	-33.8 (-41.8 to -24.8)	0.8 (0.5 to 1.2)	1.2 (0.7 to 1.8)	40.6 (11.7 to 94.9)	-32.2 (-45.3 to -6.1)
Hepatitis C	412.4 (370.2 to 454.7)	622.2 (558.7 to 697.9)	50.4 (30.7 to 76.8)	-26.8 (-36.1 to -36.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	53.6 (22.1 to 96.4)	-23.8 (-44.8 to 7.9)
Hepatitis E	3.4 (2.4 to 4.3)	7.5 (5.6 to 9.6)	119.4 (55.6 to 229.5)	2.5 (-25.1 to 48.2)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	124.5 (45.3 to 256.2)	4.8 (-30.0 to 58.8)
Leprosy	1.6 (1.1 to 2.3)	2.0 (1.7 to 2.4)	23.8 (0.5 to 63.0)	-31.6 (-42.8 to -12.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	27.1 (3.1 to 78.0)	-30.0 (-44.6 to -6.0)
Other infectious diseases	126.8 (95.4 to 157.5)	250.9 (224.0 to 272.7)	98.2 (76.1 to 121.9)	-9.1 (-20.8 to 2.2)	5.7 (3.4 to 8.7)	10.0 (6.3 to 14.8)	78.9 (42.1 to 110.3)	-18.9 (-42.9 to -1.6)
Non-communicable diseases	-	-	-	-	1,047.8 (776.9 to 1,351.7)	2,223.1 (1,646.0 to 2,854.0)	112.0 (105.1 to 119.3)	0.6 (-2.7 to 4.0)
Neoplasms	-	-	-	-	4.9 (3.5 to 6.5)	13.3 (9.3 to 17.9)	170.3 (120.8 to 232.7)	44.5 (17.4 to 84.9)
Esophageal cancer	1.6 (1.2 to 2.2)	3.1 (2.2 to 4.1)	86.9 (25.9 to 172.5)	3.9 (-29.0 to 50.4)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	84.2 (32.5 to 165.2)	1.7 (-26.5 to 42.0)
Stomach cancer	1.0 (0.8 to 1.2)	1.7 (1.4 to 2.1)	72.8 (27.8 to 132.9)	-4.2 (-29.3 to 31.2)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	71.7 (31.4 to 129.2)	-5.6 (-28.6 to 26.7)
Liver cancer	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.5)	108.5 (53.3 to 181.3)	11.5 (-18.4 to 52.6)
Liver cancer due to hepatitis B	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	124.6 (-6.9 to 376.5)	26.0 (-49.4 to 178.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	120.2 (25.3 to 331.5)	21.4 (-46.5 to 147.7)
Liver cancer due to hepatitis C	0.2 (0.1 to 0.3)	0.8 (0.5 to 1.2)	449.4 (159.5 to 1,066.8)	171.4 (34.5 to 473.6)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	416.0 (184.3 to 921.4)	153.0 (42.1 to 386.5)
Liver cancer due to alcohol use	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.6)	6.3 (-44.5 to 121.4)	-39.3 (-68.2 to 19.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	6.5 (-38.3 to 105.2)	-39.1 (-64.9 to 7.3)
Liver cancer due to other causes	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	32.8 (-27.3 to 152.8)	-29.7 (-63.5 to 33.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	29.3 (-25.3 to 119.6)	32.0 (-62.0 to 18.2)
Larynx cancer	0.4 (0.3 to 0.6)	0.9 (0.6 to 1.2)	104.9 (45.7 to 186.8)	9.1 (-22.8 to 54.3)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	96.5 (40.3 to 171.4)	3.6 (-27.3 to 45.5)
Tracheal, bronchus and lung cancer	0.5 (0.4 to 0.6)	1.1 (0.9 to 1.4)	116.1 (63.9 to 182.1)	19.1 (-8.4 to 56.2)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	111.0 (57.7 to 187.0)	15.8 (-14.5 to 56.4)
Breast cancer	6.4 (4.8 to 8.1)	19.3 (14.5 to 24.9)	203.7 (119.2 to 312.6)	60.9 (17.3 to 119.9)	0.6 (0.4 to 0.8)	1.6 (1.1 to 2.3)	170.5 (97.2 to 269.8)	42.1 (6.1 to 91.8)
Cervical cancer	11.2 (8.2 to 15.4)	19.4 (13.2 to 26.4)	75.9 (2.8 to 172.9)	6.5 (-45.9 to 47.0)	0.9 (0.6 to 1.4)	1.6 (1.0 to 2.3)	64.4 (6.2 to 169.8)	22.5 (-45.7 to 42.9)
Uterine cancer	1.6 (0.9 to 2.5)	2.8 (1.6 to 4.2)	77.4 (6.4 to 187.5)	-1.7 (-40.8 to 59.6)	0.2 (0.1 to 0.2)	0.3 (0.1 to 0.3)	76.0 (6.1 to 186.8)	-4.2 (-31.0 to 57.9)
Prostate cancer	5.1 (3.0 to 7.7)	31.2 (19.9 to 50.6)	503.9 (273.0 to 1,021.0)	212.7 (102.6 to 483.3)	0.6 (0.3 to 0.9)	3.0 (1.8 to 5.1)	412.1 (221.4 to 842.1)	166.3 (69.5 to 387.5)
Colon and rectum cancer	2.3 (2.0 to 2.7)	7.1 (6.0 to 8.6)	209.0 (148.3 to 283.3)	61.5 (28.8 to 100.0)	0.2 (0.2 to 0.3)	0.7 (0.5 to 0.9)	181.8 (122.3 to 256.5)	46.3 (15.9 to 86.1)
Lip and oral cavity cancer	1.2 (0.9 to 1.6)	2.5 (1.8 to 3.5)	105.9 (44.7 to 191.2)	12.2 (-21.7 to 58.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	104.4 (40.5 to 173.3)	8.9 (-25.0 to 49.8)
Nasopharynx cancer	0.9 (0.7 to 1.3)	1.9 (1.3 to 2.6)	108.0 (34.5 to 212.4)	1.1 (-32.6 to 48.9)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	101.9 (35.1 to 196.6)	2.7 (-34.5 to 38.3)
Other pharynx cancer	0.5 (0.3 to 0.7)	1.0 (0.7 to 1.4)	97.9 (20.6 to 240.2)	6.2 (-35.4 to 81.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	95.3 (24.0 to 213.1)	4.1 (-32.4 to 67.0)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	109.2 (41.0 to 212.7)	10.6 (-27.2 to 68.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.2 (40.9 to 178.5)	3.7 (-27.3 to 49.0)
Pancreatic cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	119.2 (60.5 to 204.5)	18.4 (-14.1 to 64.9)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	112.4 (65.1 to 172.1)	12.5 (-12.9 to 46.2)
Malignant skin melanoma	0.9 (0.7 to 1.3)	2.3 (1.6 to 3.2)	149.0 (72.8 to 234.5)	20.7 (-6.9 to 83.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	184.6 (68.3 to 228.0)	25.3 (-11.5 to 76.8)
Non-melanoma skin cancer	0.8 (0.7 to 1.0)	2.2 (1.8 to 2.8)	172.1 (112.6 to 239.0)	36.3 (2.2 to 76.5)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	234.4 (129.2 to 377.9)	62.7 (-1.1 to 160.0)
Ovarian cancer	1.3 (0.9 to 1.7)	2.8 (2.0 to 3.8)	120.7 (54.3 to 219.4)	14.3 (-20.7 to 63.8)	0.2 (0.1 to 0.3)	0.6 (0.3 to 0.6)	116.8 (48.3 to 223.8)	11.2 (-25.7 to 65.3)
Testicular cancer	0.1 (0.1 to 0.2)	0.5 (0.2 to 0.8)	225.8 (71.6 to 527.1)	51.9 (-17.6 to 215.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	189.7 (66.4 to 446.4)	36.6 (-22.7 to 167.8)
Kidney cancer	1.1 (0.7 to 1.9)	2.5 (1.4 to 4.5)	113.2 (5.4 to 386.7)	18.4 (-21.8 to 90.3)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	118.8 (9.3 to 371.0)	15.4 (-17.5 to 70.7)
Bladder cancer	0.7 (0.6 to 0.9)	1.4 (1.1 to 1.8)	97.5 (45.0 to 174.1)	6.9 (-21.7 to 49.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	97.8 (44.8 to 166.7)	6.5 (-21.9 to 48.5)
Brain and nervous system cancer	0.4 (0.3 to 0.5)	1.0 (0.7 to 1.4)	162.5 (83.9 to 270.6)	31.0 (-0.7 to 71.5)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	151.0 (84.2 to 239.6)	24.3 (-7.3 to 69.7)
Thyroid cancer	1.4 (0.9 to 1.9)	3.7 (2.5 to 5.4)	168.9 (85.2 to 304.7)	32.9 (-11.8 to 105.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	150.0 (71.2 to 278.3)	22.6 (-18.7 to 87.6)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	783.1 (27.5 to 144.9)	107.0 (35.7 to 28.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.0 (32.4 to 150.9)	9.1 (-35.1 to 31.9)
Hodgkin lymphoma	0.8 (0.6 to 1.1)	2.5 (1.7 to 3.5)	209.8 (99.1 to 399.0)	63.7 (8.9 to 156.0)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	173.5 (84.9 to 323.5)	40.3 (-5.5 to 107.0)
Non-Hodgkin lymphoma	4.5 (3.3 to 6.3)	13.7 (9.3 to 20.1)	204.7 (92.8 to 374.5)	49.9 (8.2 to 103.4)	0.3 (0.2 to 0.5)	1.0 (0.6 to 1.6)	188.0 (92.6 to 328.1)	38.8 (4.9 to 84.4)
Multiple myeloma	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	149.9 (48.7 to 290.9)	36.5 (-17.6 to 115.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	132.7 (45.8 to 275.8)	28.1 (-21.4 to 105.2)
Leukemia	0.0 (0.4 to 0.9)	1.9 (1.3 to 2.6)	201.5 (91.4 to 363.0)	78.1 (4.3 to 104.9)	0.0 (0.1 to 0.1)	0.2 (0.1 to 0.3)	182.6 (87.7 to 275.0)	22.5 (-6.9 to 63.6)
Other neoplasms	5.4 (2.1 to 10.3)	22.1 (11.8 to 33.9)	336.7 (107.0 to 626.1)	73.9 (14.9 to 155.4)	0.4 (0.1 to 0.7)	1.4 (0.7 to 2.2)	301.3 (113.2 to 530.2)	54.5 (8.1 to 119.0)
Cardiovascular diseases	-	-	-	-	31.0 (21.3 to 43.6)	59.5 (39.9 to 83.1)	92.6 (51.2 to 137.1)	-5.6 (-26.1 to 18.5)
Rheumatic heart disease	233.7 (192.2 to 268.9)	450.9 (377.9 to 514.1)	93.6 (63.4 to 132.4)	-11.9 (-23.2 to 3.4)	11.4 (7.3 to 16.6)	22.0 (14.1 to 32.2)	92.5 (61.4 to 130.8)	-13.5 (-26.2 to 3.7)
Ischemic heart disease	152.2 (115.7 to 196.9)	199.1 (164.5 to 244.1)	29.4 (5.2 to 84.8)	-29.0 (-46.7 to 1.1)	7.2 (4.7 to 12.1)	9.4 (6.1 to 14.1)	7.3 (-22.8 to 86.8)	-34.6 (-55.3 to 4.8)
Cerebrovascular disease	-	-	-	-	0.0 (0.6 to 1.2)	0.0 (1.2 to 2.4)	10.7 (-2.0 to 31.9)	3.1 (-20.0 to 31.9)
Ischemic stroke	4.2 (3.4 to 5.0)	8.3 (6.8 to 10.0)	101.0 (52.7 to 158.8)	3.0 (-20.8 to 31.8)	0.6 (0.4 to 0.9)	1.3 (0.8 to 1.8)	100.9 (53.6 to 160.2)	3.3 (-20.6 to 33.9)
Hemorrhagic stroke	1.3 (1.0 to 1.6)	2.7 (2.2 to 3.4)	108.6 (52.9 to 185.0)	1.5 (-22.2 to 40.5)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	108.3 (51.2 to 184.8)	1.2 (-22.6 to 40.0)
Hypertensive heart disease	20.7 (15.5 to 25.6)	51.3 (38.9 to 62.8)	148.6 (77.1 to 255.5)	22.3 (-13.9 to 77.4)	2.2 (1.4 to 3.1)	5.5 (3.5 to 7.9)	148.1 (75.2 to 254.1)	23.1 (-14.7 to 78.6)
Cardiomyopathy and myocarditis	12.2 (9.8 to 15.1)	32.7 (26.8 to 40.2)	167.9 (96.9 to 262.7)	41.1 (-0.3 to 103.4)	1.3 (0.8 to 1.9)	3.5 (2.4 to 5.0)	171.6 (96.8 to 269.1)	42.4 (-1.3 to 105.5)
Atrial fibrillation and flutter	4.6 (3.0 to 6.0)	18.9 (12.6 to 27.4)	310.1 (156.6 to 558.0)	106.9 (23.3 to 244.4)	0.3 (0.2 to 0.5)	1.4 (0.8 to 2.2)	306.2 (152.4 to 551.2)	106.2 (21.6 to 246.6)
Peripheral vascular disease	223.5 (148.3 to 291.2)	423.8 (318.7 to 542.6)	86.4 (23.9 to 224.5)	-2.7 (-35.5 to 61.6)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.4)	91.6 (-56.8 to 268.4)	-6.7 (-77.5 to 73.2)
Endocarditis	0.6 (0.4 to 1.0)	0.7 (0.6 to 1.0)	17.3 (-28.3 to 91.9)	-48.9 (-71.4 to -1.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	15.7 (-35.5 to 97.9)	-8.0 (-73.6 to 74.4)
Other cardiovascular and circulatory diseases	99.1 (51.0 to 171.5)	224.6 (100.5 to 337.1)	134.2 (-4.9 to 376.5)	12.2 (-59.2 to 136.9)	2.8 (3.1 to 12.2)	15.7 (6.4 to 26.2)	8.7 (-4.9 to 38.5)	8.7 (-59.0 to 140.4)

Appendix Table G.4 - Uganda prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.1	93.1	-3.5
Silicosis	0.1	0.1	80.8	-7.5	0.0	0.0	80.7	-7.6
Asbestosis	-	-	0.0	0.0	0.0	0.0	-	-
Coal workers pneumoconiosis	-	-	0.0	0.0	0.0	0.0	-	-
Other pneumoconiosis	0.1	0.2	104.2	0.7	0.0	0.0	104.0	0.8
Asthma	165.8	386.6	233.2	9.9	7.0	16.7	136.4	11.2
Interstitial lung disease and pulmonary sarcoidosis	0.3	0.8	138.3	13.4	0.0	0.1	139.6	14.1
Other chronic respiratory diseases	-	-	-	-	30.2	42.0	39.8	-30.7
Cirrhosis	-	-	-	-	1.4	2.4	68.9	14.1
Cirrhosis due to hepatitis B	2.5	3.7	47.4	-21.5	0.4	0.6	49.1	-20.6
Cirrhosis due to hepatitis C	1.3	2.4	97.4	-1.7	0.2	0.4	94.6	-1.9
Cirrhosis due to alcohol use	2.2	2.9	33.5	-29.5	0.3	0.5	34.8	-28.8
Cirrhosis due to other causes	2.7	5.4	99.9	9.3	0.2	0.9	103.3	10.8
Digestive diseases	107.7	136.3	26.9	-33.7	3.7	5.0	35.1	-30.6
Peptic ulcer disease	96.3 to 118.0	126.2 to 145.5	13.2 to 42.7	-40.8 to -25.8	2.5 to 5.3	3.4 to 7.2	13.5 to 56.4	-40.6 to -21.2
Gastritis and duodenitis	205.7	400.1	94.9	-2.7	9.2	18.8	105.0	-0.7
Appendicitis	2.0	4.8	139.3	6.6	0.6	1.5	143.8	8.2
Paralytic ileus and intestinal obstruction	0.3	0.6	98.1	-3.0	0.1	0.2	96.2	-2.7
Inguinal, femoral, and abdominal hernia	38.0	118.1	218.7	0.4	1.2	21.2	166.7	2.3
Inflammatory bowel disease	14.9	38.3	158.5	3.1	8.1	16.2	162.6	27.3
Vascular intestinal disorders	0.0	0.0	104.0	-2.4	0.0	0.0	108.8	5.6
Gallbladder and biliary diseases	5.0	11.3	127.2	1.2	1.2	2.5	129.2	16.1
Pancreatitis	2.6	5.8	121.9	5.1	0.8	1.7	125.9	6.4
Other digestive diseases	-	-	-	-	2.3	4.6	101.6	-3.3
Neurological disorders	-	-	-	-	61.3	148.5	142.5	12.9
Alzheimer disease and other dementias	22.2	47.6	114.4	1.5	3.0	6.5	119.4	1.8
Parkinson disease	1.2	2.4	95.0	0.2	0.1	0.3	94.6	1.0
Epilepsy	40.0	83.5	110.0	-2.4	11.6	25.7	120.6	2.6
Multiple sclerosis	0.7	1.6	132.1	12.9	0.2	0.6	132.8	12.6
Migraine	901.8	2,023.5	128.2	-2.7	29.8	69.0	133.8	6.4
Tension-type headache	1,947.4	4,514.4	133.3	4.4	2.9	6.9	136.2	5.9
Medication overuse headache	73.2	219.7	198.7	45.9	11.2	34.4	204.2	48.1
Other neurological disorders	0.0	0.0	100.3	-7.4	2.5	5.2	116.0	1.1
Mental and substance use disorders	-	-	-	-	390.9	853.1	118.2	1.8
Schizophrenia	33.6	70.0	109.1	0.8	20.7	44.5	115.2	3.4
Alcohol use disorders	177.9	337.9	90.6	-10.9	17.2	33.2	92.9	-9.9
Drug use disorders	-	-	-	-	19.6	43.5	121.1	3.9
Opioid use disorders	24.3	52.6	118.3	4.3	9.6	21.5	123.3	6.5
Cocaine use disorders	8.1	17.6	117.3	1.1	2.4	5.5	124.4	4.3
Amphetamine use disorders	27.8	59.7	114.9	-2.4	3.6	7.9	119.5	-0.5
Cannabis use disorders	21.7	48.0	121.9	0.1	0.6	1.4	124.6	1.5
Other drug use disorders	-	-	-	-	4.7	10.3	118.7	-0.1
Depressive disorders	-	-	-	-	2.9 to 6.8	6.6 to 15.5	63.4 to 201.5	25.5 to 38.3
Major depressive disorder	911.9	1,942.3	113.9	0.2	183.7	400.3	118.1	2.0
Dysthymia	159.6	330.5	107.7	-0.4	15.0	31.7	111.3	0.9
Bipolar disorder	89.8	189.6	112.0	-0.5	17.7	38.5	117.3	1.7
Anxiety disorders	421.7	927.9	116.7	0.1	37.9	84.5	117.5	1.8
Eating disorders	-	-	-	-	4.1	9.4	127.9	1.9
Anorexia nervosa	2.9	6.7	132.0	3.2	0.6	1.4	137.8	5.4
Bulimia nervosa	17.0	37.8	122.5	-0.4	3.5	8.0	125.9	1.4
Autistic spectrum disorders	-	-	-	-	20.8	45.5	119.0	1.8
Autism	53.6	115.7	116.4	0.5	13.1	28.7	119.5	1.9
Asperger syndrome	77.3	166.7	116.3	0.7	7.7	16.8	118.2	1.7
Attention-deficit/hyperactivity disorder	131.6	294.0	124.2	0.1	1.6	3.6	125.3	0.5
Conduct disorder	191.8	490.3	125.3	0.0	2.9	5.0	127.3	0.5
Idiopathic intellectual disability	315.4	712.9	124.5	8.0	15.3	35.0	126.4	8.8
Other mental and substance use disorders	199.4	421.4	112.0	0.4	14.5	31.4	116.3	2.1
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	70.8	158.7	124.0	11.1
Diabetes mellitus	153.4	474.3	211.1	56.0	11.6	34.0	193.1	49.0
Acute glomerulonephritis	0.2	0.3	50.0	-27.1	0.0	0.0	50.0	-27.1
Chronic kidney disease	-	-	-	-	25.7	55.8	116.5	2.2
Chronic kidney disease due to diabetes mellitus	206.9	381.5	85.4	-6.0	3.0	5.8	94.8	-4.4
Chronic kidney disease due to hypertension	67.2	1,453.9	116.7	2.9	7.7	17.3	124.6	5.2
Chronic kidney disease due to glomerulonephritis	519.9	1,260.6	121.6	-1.3	9.0	20.0	121.1	5.6
Chronic kidney disease due to other causes	485.2	974.4	103.4	-5.9	6.1	12.6	108.0	-3.1
Urinary diseases and male infertility	-	-	-	-	4.5	8.9	97.6	3.8

Appendix Table G.4 - Uganda prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	3.2 (3.0 to 3.5)	7.3 (6.8 to 7.9)	128.1 (106.5 to 148.3)	0.1 (-2.3 to 16.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	130.2 (78.9 to 196.5)	7.9 (-11.3 to 30.5)
Urolithiasis	36.1 (27.7 to 45.5)	55.8 (42.8 to 70.9)	56.9 (33.8 to 72.6)	-18.3 (-29.8 to -11.3)	0.3 (0.2 to 0.5)	0.7 (0.4 to 1.0)	102.1 (77.1 to 129.2)	-0.7 (-10.1 to 10.0)
Benign prostatic hyperplasia	93.4 (85.4 to 101.9)	182.4 (165.9 to 197.6)	95.4 (72.2 to 122.0)	4.2 (-7.7 to 17.6)	3.3 (2.1 to 4.6)	6.5 (4.2 to 9.1)	97.4 (73.6 to 125.4)	5.4 (-6.8 to 19.7)
Male infertility due to other causes	91.4 (60.4 to 129.1)	173.5 (117.7 to 250.8)	89.1 (14.0 to 231.0)	-14.2 (46.8 to 50.0)	0.6 (0.2 to 1.2)	1.1 (0.4 to 2.4)	98.3 (13.1 to 251.0)	-9.4 (-46.6 to 55.2)
Other urinary diseases	-	-	-	-	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.7)	80.7 (18.3 to 162.8)	-12.4 (-41.5 to 25.6)
Gynecological diseases	-	-	-	-	14.5 (9.2 to 21.3)	29.6 (18.9 to 45.0)	102.2 (73.1 to 139.4)	-5.5 (-17.5 to 10.6)
Uterine fibroids	236.1 (212.9 to 257.6)	473.3 (425.1 to 517.6)	101.1 (100.1 to 102.0)	-2.2 (-2.3 to -2.2)	2.8 (1.6 to 4.7)	5.8 (3.2 to 9.8)	107.9 (75.2 to 138.2)	-1.3 (-16.2 to 11.5)
Polycystic ovarian syndrome	234.9 (207.4 to 260.9)	510.2 (453.8 to 569.9)	117.6 (83.4 to 156.2)	0.6 (-13.4 to 16.2)	2.2 (1.0 to 4.2)	5.0 (2.3 to 9.3)	121.6 (86.9 to 162.4)	2.3 (-12.2 to 19.7)
Female infertility due to other causes	85.5 (54.2 to 120.8)	133.5 (84.5 to 188.7)	56.2 (-14.6 to 56.2)	0.4 (-6.2 to 22.6)	0.7 (0.2 to 1.0)	0.7 (0.3 to 1.6)	59.8 (-12.5 to 177.2)	-26.4 (-60.9 to 26.9)
Endometriosis	23.6 (19.9 to 27.5)	44.0 (37.3 to 50.7)	87.0 (48.5 to 132.0)	-12.6 (-29.0 to 6.7)	2.1 (1.4 to 2.9)	4.0 (2.6 to 5.7)	91.2 (49.0 to 142.0)	-10.4 (-29.2 to 11.7)
Genital prolapse	402.7 (347.9 to 461.7)	827.8 (698.0 to 971.0)	105.0 (66.2 to 157.9)	0.1 (-17.2 to 36.0)	1.2 (0.6 to 2.3)	2.6 (1.3 to 5.2)	108.4 (67.7 to 162.5)	1.3 (-16.2 to 25.4)
Premenstrual syndrome	619.2 (475.1 to 781.6)	1,194.1 (833.6 to 1,631.1)	92.1 (31.5 to 193.3)	-12.8 (-39.7 to 36.0)	5.1 (3.0 to 8.1)	10.0 (5.4 to 16.5)	96.1 (33.3 to 197.4)	-11.1 (-38.8 to 38.9)
Other gynecological diseases	24.3 (16.2 to 32.5)	55.7 (39.6 to 73.2)	129.4 (58.9 to 253.8)	3.8 (-25.6 to 51.6)	0.7 (0.3 to 1.0)	1.5 (0.7 to 2.3)	118.6 (8.4 to 442.6)	-2.7 (-43.6 to 120.2)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	8.6 (5.6 to 12.4)	19.3 (12.4 to 28.0)	124.0 (103.7 to 163.9)	4.2 (-5.8 to 23.3)
Thalassemias	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	128.3 (113.1 to 198.9)	6.3 (-0.7 to 39.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	133.1 (113.8 to 187.2)	9.4 (1.5 to 34.7)
Thalassemia trait	102.4 (76.0 to 125.7)	221.8 (173.7 to 268.5)	114.4 (107.6 to 147.6)	0.0 (-3.1 to 16.2)	2.1 (1.4 to 3.2)	5.2 (3.4 to 7.6)	142.3 (112.9 to 176.2)	12.4 (-0.1 to 28.1)
Sickle cell disorders	1.3 (1.1 to 1.5)	3.3 (2.7 to 3.8)	150.0 (100.3 to 219.4)	0.2 (-4.7 to 45.2)	0.2 (0.0 to 0.2)	0.6 (0.3 to 0.6)	153.0 (96.3 to 220.1)	18.5 (-2.8 to 42.0)
Sickle cell trait	583.6 (545.3 to 617.3)	1,279.5 (1,204.4 to 1,337.2)	119.1 (112.0 to 127.0)	2.2 (-1.1 to 5.9)	7.3 (1.7 to 4.2)	15.9 (4.4 to 10.5)	156.9 (102.6 to 267.3)	15.4 (-15.4 to 78.8)
G6PD deficiency	2,419.4 (2,166.7 to 2,679.1)	5,611.6 (5,101.8 to 6,175.8)	132.7 (113.6 to 156.2)	8.4 (-0.4 to 19.3)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	130.8 (6.0 to 318.4)	0.8 (-51.0 to 80.6)
G6PD trait	4,240.5 (4,192.5 to 4,283.9)	9,007.4 (8,906.1 to 9,115.9)	113.1 (109.3 to 116.8)	-1.0 (-2.8 to 0.7)	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.5)	127.2 (-64.1 to 1,099.7)	3.3 (-82.6 to 511.9)
Other hemoglobinopathies and hemolytic anemias	91.4 (70.9 to 110.9)	172.6 (152.2 to 191.8)	89.9 (54.5 to 136.3)	-15.5 (-28.8 to -1.3)	3.1 (1.9 to 4.6)	5.7 (3.5 to 8.3)	83.1 (49.5 to 161.8)	-15.6 (-32.0 to 15.1)
Endocrine, metabolic, blood, and immune disorders	154.5 (129.7 to 175.2)	309.8 (246.0 to 363.7)	96.3 (55.9 to 146.6)	5.8 (-23.1 to 9.0)	5.8 (3.6 to 8.4)	11.1 (6.8 to 16.3)	92.5 (30.5 to 171.9)	4.8 (-31.4 to 16.9)
Musculoskeletal disorders	-	-	-	-	161.1 (114.2 to 213.5)	342.0 (240.4 to 456.4)	111.5 (88.4 to 143.3)	2.9 (-5.1 to 13.2)
Rheumatoid arthritis	36.2 (34.6 to 37.7)	65.5 (62.7 to 68.4)	81.4 (71.1 to 93.1)	-13.9 (-18.8 to -8.4)	8.4 (6.0 to 11.0)	15.5 (10.8 to 20.6)	85.4 (70.1 to 102.0)	-12.5 (-19.0 to -5.5)
Osteoarthritis	282.3 (271.2 to 293.8)	545.9 (522.3 to 567.4)	94.1 (83.2 to 104.2)	1.1 (-4.3 to 6.4)	16.8 (11.6 to 22.9)	32.8 (23.0 to 44.2)	95.6 (84.3 to 106.2)	1.8 (-3.6 to 7.2)
Low back and neck pain	-	-	-	-	259.4 (87.3 to 169.3)	269.4 (187.4 to 362.1)	114.2 (88.4 to 143.3)	3.2 (-7.8 to 15.7)
Low back pain	666.1 (603.5 to 720.6)	1,370.9 (1,253.6 to 1,510.2)	106.0 (84.3 to 132.4)	0.7 (-9.4 to 13.3)	72.3 (49.0 to 99.8)	152.0 (103.5 to 214.7)	110.0 (86.1 to 138.2)	2.1 (-8.5 to 14.8)
Neck pain	556.1 (435.0 to 683.7)	1,199.3 (989.6 to 1,433.8)	116.7 (69.8 to 181.0)	2.7 (-18.0 to 30.2)	53.2 (35.2 to 76.2)	117.4 (76.1 to 165.9)	121.1 (71.5 to 188.2)	4.6 (-16.4 to 32.4)
Gout	2.0 (1.8 to 2.2)	4.0 (3.5 to 4.4)	101.0 (69.4 to 136.7)	2.6 (-14.1 to 20.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	103.0 (58.9 to 160.0)	3.7 (-20.3 to 34.1)
Other musculoskeletal disorders	118.7 (85.0 to 212.6)	268.1 (171.4 to 487.3)	116.4 (83.1 to 200.2)	8.0 (-10.2 to 44.8)	10.4 (6.2 to 19.2)	24.4 (13.1 to 46.4)	121.6 (85.5 to 207.3)	10.0 (-9.3 to 48.5)
Other non-communicable diseases	-	-	-	-	225.7 (147.4 to 330.6)	456.4 (300.6 to 673.5)	102.1 (91.7 to 114.3)	-5.0 (-9.4 to -0.4)
Congenital anomalies	-	-	-	-	15.3 (10.1 to 22.1)	38.0 (25.6 to 53.4)	148.2 (115.5 to 189.0)	13.4 (-1.4 to 32.5)
Neural tube defects	1.4 (1.2 to 1.8)	8.3 (7.0 to 9.6)	474.0 (341.9 to 639.9)	197.8 (129.2 to 283.8)	0.3 (0.2 to 0.5)	2.2 (1.4 to 3.2)	567.9 (339.9 to 920.1)	256.2 (138.8 to 445.8)
Congenital heart anomalies	11.3 (8.3 to 15.4)	79.5 (60.7 to 103.5)	612.6 (380.4 to 1,014.1)	279.2 (149.1 to 515.5)	0.4 (0.2 to 0.8)	2.7 (1.1 to 4.8)	507.2 (284.3 to 868.5)	227.9 (107.6 to 440.5)
Orofacial clefts	1.3 (0.8 to 1.8)	12.5 (9.2 to 16.1)	892.6 (514.1 to 1,540.5)	0.2 (-239.5 to 898.3)	0.2 (0.0 to 0.0)	0.2 (0.1 to 0.4)	431.7 (436.0 to 1,613.4)	431.7 (198.3 to 893.4)
Down syndrome	7.5 (6.3 to 8.8)	26.8 (21.8 to 33.6)	255.0 (171.7 to 355.8)	81.1 (38.4 to 132.2)	0.8 (0.6 to 1.2)	3.1 (2.1 to 4.3)	257.0 (167.3 to 385.9)	86.7 (40.5 to 152.1)
Turner syndrome	0.3 (0.2 to 0.5)	1.1 (0.8 to 1.4)	223.5 (120.6 to 374.5)	55.4 (6.0 to 129.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	224.7 (120.6 to 382.4)	55.0 (5.4 to 129.2)
Klinefelter syndrome	0.5 (0.4 to 0.7)	1.1 (0.9 to 1.4)	114.8 (50.2 to 196.9)	1.6 (-28.7 to 40.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	116.8 (15.6 to 200.2)	1.7 (-28.8 to 41.1)
Chromosomal unbalanced rearrangements	12.4 (9.7 to 15.6)	45.5 (36.7 to 56.6)	368.8 (164.7 to 405.0)	1.4 (-33.9 to 158.7)	0.2 (0.9 to 2.0)	5.2 (3.4 to 7.3)	275.4 (61.4 to 422.2)	96.7 (37.4 to 169.4)
Other congenital anomalies	125.7 (90.2 to 156.3)	240.8 (165.7 to 309.8)	89.9 (63.7 to 129.9)	-10.0 (-21.9 to 8.6)	12.3 (7.4 to 18.5)	24.6 (14.3 to 38.0)	98.4 (68.8 to 141.5)	-8.4 (-22.0 to 12.4)
Skin and subcutaneous diseases	-	-	-	-	79.1 (50.3 to 122.9)	175.3 (111.6 to 276.8)	121.3 (104.5 to 140.4)	2.2 (-6.0 to 10.0)
Dermatitis	666.3 (514.9 to 855.0)	1,428.2 (1,099.2 to 1,836.5)	115.0 (113.4 to 116.3)	-0.1 (-0.2 to 0.0)	23.9 (14.9 to 35.1)	52.4 (32.4 to 77.5)	118.4 (110.0 to 127.8)	1.0 (-1.0 to 4.3)
Psoriasis	102.2 (86.6 to 114.6)	211.5 (182.7 to 242.8)	111.9 (109.5 to 113.4)	0.0 (-0.1 to 0.1)	8.0 (5.5 to 11.3)	17.5 (11.8 to 24.5)	115.9 (99.7 to 132.2)	1.7 (-4.0 to 7.5)
Cellulitis	3.5 (2.7 to 4.4)	7.6 (5.9 to 9.7)	119.0 (82.5 to 157.1)	3.7 (-16.3 to 23.7)	0.3 (0.1 to 0.4)	0.6 (0.3 to 0.8)	120.7 (60.9 to 195.4)	4.3 (-20.9 to 36.0)
Pyoderma	31.4 (23.0 to 40.6)	61.9 (46.2 to 79.7)	97.7 (86.0 to 112.4)	-4.1 (-10.5 to 3.0)	0.2 (0.1 to 0.4)	0.4 (0.1 to 0.8)	98.6 (78.9 to 121.0)	-3.7 (-12.5 to 6.8)
Scabies	294.4 (216.2 to 414.5)	504.7 (399.0 to 684.1)	72.6 (11.6 to 187.5)	-20.0 (-48.3 to 28.0)	7.6 (3.9 to 13.4)	13.1 (6.7 to 22.6)	74.7 (12.6 to 189.5)	-19.5 (-47.9 to 19.4)
Fungal skin diseases	1,923.9 (1,372.3 to 2,740.9)	4,171.1 (2,930.0 to 5,938.1)	117.5 (114.8 to 119.7)	0.2 (-0.1 to 0.3)	10.8 (4.1 to 24.2)	23.6 (8.9 to 53.0)	118.9 (115.3 to 122.2)	0.9 (-0.9 to 2.9)
Viral skin diseases	430.4 (321.5 to 540.1)	937.4 (694.6 to 1,185.1)	118.6 (109.7 to 126.2)	-0.0 (-2.9 to 2.7)	13.2 (7.5 to 21.3)	29.1 (16.4 to 46.9)	120.1 (109.1 to 131.3)	0.7 (-3.5 to 4.9)
Acne vulgaris	512.4 (308.6 to 720.2)	1,618.1 (952.0 to 2,359.9)	195.4 (69.3 to 556.4)	28.3 (-22.4 to 172.7)	5.5 (2.3 to 11.1)	17.5 (7.4 to 36.0)	197.0 (69.5 to 565.8)	29.5 (-22.0 to 177.0)
Alopecia areata	15.2 (13.6 to 16.9)	32.6 (28.8 to 36.5)	114.2 (83.6 to 149.6)	0.5 (-14.3 to 16.7)	0.5 (0.3 to 0.8)	1.1 (0.7 to 1.7)	115.3 (78.5 to 164.4)	0.9 (-15.1 to 21.8)
Pruritus	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	113.1 (66.1 to 166.8)	2.3 (-20.6 to 31.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.1 (65.9 to 167.4)	2.3 (-20.7 to 31.2)
Urticaria	68.7 (37.8 to 97.8)	157.8 (112.4 to 223.6)	156.0 (29.1 to 350.3)	16.9 (-42.4 to 89.7)	4.0 (2.0 to 6.7)	10.0 (5.5 to 15.6)	158.6 (30.7 to 354.6)	19.1 (-41.5 to 93.9)
Decubitus ulcer	1.8 (1.5 to 2.1)	3.9 (3.5 to 4.4)	119.5 (78.1 to 175.7)	4.7 (-19.7 to 42.2)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	120.8 (77.2 to 180.5)	4.5 (-22.1 to 44.3)
Other skin and subcutaneous diseases	842.5 (567.9 to 1,206.0)	1,670.3 (1,127.9 to 2,387.9)	98.9 (86.1 to 110.9)	-4.5 (-11.1 to 0.2)	4.9 (2.2 to 10.0)	9.8 (4.4 to 20.2)	101.0 (88.2 to 112.6)	-3.7 (-10.2 to 0.9)
Sense organ diseases	-	-	-	-	102.7 (64.4 to 151.6)	184.6 (117.4 to 276.7)	90.8 (64.5 to 96.8)	-10.7 (-17.0 to -4.9)
Glaucoma	7.9 (6.2 to 9.8)	21.7 (16.3 to 26.6)	176.9 (126.2 to 228.9)	40.9 (10.9 to 67.2)	0.7 (0.4 to 1.0)	1.9 (1.2 to 2.8)	177.2 (111.7 to 239.8)	41.3 (5.1 to 76.7)
Cataract	21.6 (16.5 to 27.3)	41.2 (29.1 to 56.6)	90.2 (35.3 to 176.3)	-2.5 (-30.3 to 34.1)	1.4 (0.9 to 2.1)	2.6 (1.7 to 3.9)	88.3 (34.8 to 152.8)	-6.3 (-32.1 to 20.9)
Macular degeneration	5.5 (3.8 to 7.3)	15.8 (11.2 to 20.7)	188.1 (106.2 to 285.0)	55.6 (13.4 to 106.8)	0.3 (0.2 to 0.4)	0.8 (0.5 to 1.3)	196.9 (112.1 to 288.7)	55.3 (13.9 to 103.2)
Uncorrected refractive error	1,187.3 (907.4 to 1,431.3)	2,213.9 (1,696.6 to 2,778.6)	88.4 (35.3 to 166.6)	-7.2 (-3.1 to 25.0)	17.7 (10.4 to 28.9)	32.2 (18.3 to 55.0)	81.2 (45.0 to 129.5)	-11.3 (-28.6 to 9.2)
Age-related and other hearing loss	2,149.8 (1,826.4 to 2,436.8)	3,871.8 (3,177.9 to 4,552.3)	80.2 (69.8 to 92.6)	-7.7 (-11.1 to -3.7)	69.8 (43.4 to 104.1)	80.2 (71.3 to 184.9)	72.0 (51.2 to 94.8)	-13.1 (-20.7 to 6.2)
Other vision loss	23.4 (19.3 to 28.5)	40.0 (33.4 to 47.2)	72.3 (52.1 to 91.3)	-8.4 (-18.7 to 0.6)	1.7 (1.1 to 2.4)	3.0 (2.0 to 4.2)	78.2 (54.4 to 107.4)	0.4 (-11.9 to 14.6)
Other sense organ diseases	420.6 (398.1 to 443.7)	894.1 (827.3 to 959.6)	113.3 (94.2 to 133.0)	-0.4 (-7.3 to 6.8)	11.1 (6.8 to 16.6)	23.9 (14.7 to 36.1)	114.9 (93.8 to 136.4)	0.4 (-6.8 to 8.3)
Oral disorders	-	-	-					

Appendix Table G.4 - Uganda prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Edentulism and severe tooth loss	262.3 (243.5 to 281.7)	468.6 (439.1 to 500.2)	79.2 (62.9 to 97.8)	-7.6 (-15.2 to 0.9)	7.0 (4.8 to 9.8)	12.7 (8.6 to 17.5)	80.5 (64.0 to 99.0)	-7.0 (-14.9 to 2.0)
Other oral disorders	242.8 (229.1 to 256.5)	512.4 (479.7 to 540.9)	111.9 (97.0 to 126.7)	-0.6 (-7.2 to 5.6)	7.0 (4.4 to 10.4)	15.0 (9.4 to 22.4)	114.2 (98.0 to 130.3)	0.4 (-6.7 to 7.1)
Injuries	-	-	-	-	389.4 (119.0 to 908.8)	268.8 (129.5 to 532.7)	-28.7 (-43.2 to 9.2)	-49.7 (-57.1 to -36.8)
Transport injuries	-	-	-	-	24.0 (18.2 to 30.8)	38.0 (28.7 to 49.2)	58.5 (51.1 to 65.7)	-16.2 (-19.5 to -13.0)
Road injuries	-	-	-	-	21.1 (15.9 to 27.1)	34.5 (25.8 to 44.2)	61.7 (54.0 to 69.8)	-14.7 (-18.1 to -11.2)
Pedestrian road injuries	-	-	-	-	6.9 (5.2 to 8.8)	10.4 (7.9 to 13.6)	50.6 (38.8 to 63.4)	-19.0 (-23.9 to -14.0)
Cyclist road injuries	-	-	-	-	2.0 (1.5 to 2.6)	3.0 (2.2 to 3.9)	44.8 (35.2 to 54.2)	-20.5 (-27.4 to -15.2)
Motorcyclist road injuries	-	-	-	-	2.4 (1.8 to 3.1)	3.3 (2.4 to 4.4)	37.8 (27.9 to 47.3)	-27.0 (-31.5 to -22.3)
Motor vehicle road injuries	-	-	-	-	9.4 (7.1 to 12.1)	17.1 (13.0 to 22.1)	81.6 (68.6 to 93.7)	-5.9 (-11.1 to -0.9)
Other road injuries	-	-	-	-	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.3)	-1.5 (-8.1 to 5.0)	-50.1 (-52.9 to -47.1)
Other transport injuries	-	-	-	-	2.9 (2.2 to 3.7)	3.8 (2.9 to 5.0)	33.7 (25.7 to 42.5)	-27.3 (-31.7 to -22.3)
Unintentional injuries	-	-	-	-	29.2 (22.4 to 37.7)	51.7 (39.2 to 67.0)	76.9 (70.6 to 83.3)	-15.5 (-18.7 to -12.5)
Falls	-	-	-	-	13.3 (10.1 to 17.3)	26.2 (19.6 to 34.2)	96.6 (85.6 to 108.3)	-10.5 (-15.4 to -5.5)
Drowning	-	-	-	-	0.7 (0.5 to 0.9)	1.0 (0.8 to 1.4)	45.1 (31.0 to 63.1)	-25.9 (-31.9 to -18.3)
Fire, heat, and hot substances	-	-	-	-	3.8 (2.9 to 4.9)	6.3 (4.7 to 8.1)	65.3 (50.3 to 82.6)	-19.3 (-24.7 to -13.1)
Poisonings	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	48.9 (28.6 to 76.4)	-27.4 (-35.5 to -17.6)
Exposure to mechanical forces	-	-	-	-	6.7 (5.0 to 8.8)	11.5 (8.6 to 15.1)	71.8 (62.8 to 80.7)	-19.0 (-22.9 to -15.1)
Unintentional firearm injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	87.3 (72.4 to 105.2)	-10.3 (-17.7 to -2.5)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	127.1 (106.2 to 150.9)	7.6 (-0.9 to 17.3)
Other exposure to mechanical forces	-	-	-	-	6.4 (4.8 to 8.4)	10.9 (8.1 to 14.3)	70.5 (61.5 to 79.6)	-19.6 (-23.8 to -15.6)
Adverse effects of medical treatment	-	-	-	-	0.2 (0.2 to 0.4)	0.5 (0.3 to 0.8)	115.7 (101.3 to 128.5)	8.7 (1.2 to 15.5)
Animal contact	-	-	-	-	2.7 (2.0 to 3.5)	3.7 (2.7 to 4.8)	38.0 (28.8 to 47.1)	-31.3 (-35.1 to -27.7)
Venomous animal contact	-	-	-	-	1.2 (0.8 to 1.6)	1.7 (1.2 to 2.2)	40.8 (26.5 to 56.9)	-30.8 (-37.1 to -24.1)
Non-venomous animal contact	-	-	-	-	1.5 (1.1 to 2.0)	2.0 (1.4 to 2.7)	35.8 (26.6 to 44.6)	-31.6 (-35.4 to -28.2)
Foreign body	-	-	-	-	0.6 (0.5 to 0.8)	1.2 (0.9 to 1.5)	91.9 (80.4 to 102.9)	-5.4 (-10.4 to -0.3)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	77.4 (54.6 to 102.2)	-6.9 (-15.5 to 2.1)
Foreign body in eyes	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	111.9 (89.5 to 140.7)	0.3 (-8.7 to 9.3)
Foreign body in other body part	-	-	-	-	0.3 (0.3 to 0.4)	0.7 (0.5 to 0.9)	89.6 (78.2 to 101.8)	-6.3 (-12.5 to 0.3)
Other unintentional injuries	-	-	-	-	1.1 (0.8 to 1.5)	1.2 (0.9 to 1.6)	7.9 (8.5 to 26.1)	-35.8 (-44.0 to -25.7)
Self-harm and interpersonal violence	-	-	-	-	3.0 (2.3 to 3.8)	5.4 (4.1 to 7.0)	81.2 (72.4 to 90.7)	-5.4 (-9.6 to -0.7)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.9 (72.6 to 100.0)	-8.5 (-16.8 to -1.0)
Interpersonal violence	-	-	-	-	3.0 (2.3 to 3.8)	5.4 (4.1 to 6.9)	81.2 (72.3 to 90.6)	-5.4 (-9.6 to -0.7)
Assault by firearm	-	-	-	-	0.6 (0.4 to 0.7)	1.1 (0.8 to 1.4)	90.8 (79.0 to 105.8)	-0.6 (-6.3 to 6.4)
Assault by sharp object	-	-	-	-	0.5 (0.3 to 0.6)	1.0 (0.7 to 1.3)	105.8 (94.1 to 122.5)	5.4 (-1.4 to 13.8)
Assault by other means	-	-	-	-	1.9 (1.5 to 2.5)	3.4 (2.5 to 4.3)	72.3 (61.6 to 83.5)	-9.5 (-14.7 to -4.3)
Forces of nature, war, and legal intervention	-	-	-	-	333.2 (65.1 to 846.9)	173.7 (35.4 to 435.6)	-47.4 (-52.6 to -41.1)	-57.9 (-63.4 to -52.8)
Exposure to forces of nature	-	-	-	-	-	0.7 (0.1 to 0.5)	-	-
Collective violence and legal intervention	-	-	-	-	333.2 (65.1 to 846.9)	173.0 (35.2 to 435.3)	-47.5 (-52.6 to -41.5)	-57.9 (-63.4 to -53.0)

Appendix Table G.4 - Ukraine prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	5,966.4 (4,453.0 to 7,749.9)	5,910.5 (4,358.1 to 7,636.3)	-1.3 (-3.5 to 1.3)	-1.3 (-2.8 to 2.1)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	320.3 (225.6 to 442.2)	293.8 (214.3 to 400.5)	-8.5 (-19.8 to 7.1)	12.2 (-0.5 to 29.8)
HIV/AIDS and tuberculosis	-	-	-	-	18.9 (12.6 to 26.1)	47.4 (29.2 to 81.4)	140.3 (78.0 to 290.9)	147.1 (83.0 to 295.8)
Tuberculosis	55.6 (52.8 to 58.4)	58.6 (55.7 to 61.6)	5.4 (1.0 to 10.0)	7.3 (2.8 to 12.2)	16.9 (11.4 to 22.8)	17.8 (12.1 to 24.0)	6.0 (2.8 to 14.1)	8.4 (1.2 to 17.0)
HIV/AIDS	-	-	-	-	2.0 (0.0 to 5.2)	29.5 (15.0 to 60.8)	1,399.1 (460.0 to 8,533.8)	1,424.5 (476.6 to 8,061.8)
HIV/AIDS resulting in mycobacterial infection	0.2 (0.0 to 0.4)	2.1 (0.9 to 4.1)	1,236.2 (417.2 to 2,142,188.0)	1,299.8 (436.7 to 2,201,430.0)	0.3 (0.0 to 0.2)	0.8 (0.3 to 1.6)	1,178.7 (353.0 to 2,067,801.1)	1,230.4 (371.3 to 2,150,694.1)
HIV/AIDS resulting in other diseases	15.0 (0.0 to 29.9)	188.3 (125.7 to 276.5)	1,100.2 (450.6 to 900,432.2)	1,116.9 (460.1 to 901,779.6)	2.0 (0.0 to 5.1)	28.7 (14.4 to 59.8)	1,408.1 (444.5 to 8,136,296.9)	1,429.7 (459.2 to 8,033,796.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	56.1 (37.8 to 81.4)	45.0 (29.7 to 65.2)	-19.8 (-24.7 to -14.4)	-5.2 (-10.9 to 1.0)
Diarrheal diseases	82.1 (75.2 to 88.9)	70.4 (65.5 to 75.7)	-14.1 (-22.8 to -3.9)	0.3 (-10.6 to 12.2)	13.2 (8.8 to 18.3)	11.1 (7.6 to 15.2)	-19.8 (-25.0 to -3.8)	0.2 (-12.1 to 14.0)
Intestinal infectious diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-36.7 (-56.9 to -14.4)	25.9 (-47.5 to 0.9)
Typhoid fever	0.5 (0.4 to 0.7)	0.4 (0.3 to 0.5)	-33.3 (-54.0 to -10.8)	-22.4 (-43.6 to 4.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-33.4 (-54.1 to -10.8)	-22.4 (-43.6 to 4.4)
Paratyphoid fever	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-33.5 (-58.5 to -6.5)	-19.9 (-47.5 to 11.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.5 (-58.5 to -6.2)	-19.9 (-47.6 to 11.9)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-72.4 (-93.8 to -5.0)	67.5 (-92.7 to 23.8)
Lower respiratory infections	1.7 (1.4 to 2.2)	2.1 (1.8 to 2.4)	29.3 (-2.2 to 52.8)	66.8 (21.5 to 104.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	27.9 (-7.8 to 66.3)	63.7 (11.9 to 124.8)
Upper respiratory infections	1,715.1 (1,528.4 to 1,898.3)	1,421.8 (1,270.9 to 1,566.2)	-16.8 (-27.3 to -5.6)	-2.1 (-14.1 to 11.7)	20.1 (14.4 to 33.7)	16.6 (9.4 to 27.5)	-17.3 (-27.7 to -5.5)	-2.0 (-11.7 to 11.5)
Otitis media	691.4 (645.3 to 740.4)	530.4 (492.6 to 569.8)	-23.2 (-29.5 to -17.0)	-10.5 (-17.1 to -4.0)	13.9 (8.3 to 22.3)	10.3 (6.1 to 16.5)	-25.5 (-32.3 to -19.0)	-11.6 (-19.8 to -4.8)
Meningitis	-	-	-	-	4.5 (2.9 to 6.3)	2.2 (1.4 to 3.0)	-52.4 (-60.7 to -42.5)	-46.7 (-56.3 to -34.7)
Pneumococcal meningitis	19.2 (11.7 to 31.0)	10.8 (6.1 to 17.5)	-43.5 (-55.0 to -33.4)	-4.7 (-52.7 to -31.0)	1.7 (1.1 to 2.4)	0.9 (0.6 to 1.2)	-47.0 (-62.3 to -27.9)	-42.2 (-58.9 to -21.2)
H influenzae type B meningitis	12.1 (3.5 to 26.8)	5.4 (1.5 to 11.7)	-55.8 (-66.6 to -34.1)	-51.0 (-62.4 to -23.1)	1.3 (0.7 to 2.0)	0.6 (0.3 to 1.0)	-84.4 (-73.2 to -25.5)	-50.4 (-68.3 to -9.3)
Meningococcal meningitis	4.6 (1.3 to 11.6)	2.3 (0.6 to 5.7)	-50.7 (-64.7 to -34.3)	-48.2 (-62.1 to -27.2)	0.5 (0.3 to 0.9)	0.2 (0.1 to 0.4)	-56.2 (-69.7 to -33.3)	-52.1 (-66.5 to -23.4)
Other meningitis	8.6 (3.6 to 18.1)	4.8 (2.0 to 9.9)	-43.3 (-55.4 to -31.9)	-40.3 (-52.8 to -26.0)	1.0 (0.6 to 1.6)	0.5 (0.3 to 0.8)	-50.5 (-65.5 to -32.4)	-45.4 (-62.2 to -23.8)
Encephalitis	21.3 (8.9 to 51.9)	21.2 (8.7 to 51.2)	-0.4 (-15.7 to 16.8)	-2.7 (-14.4 to 19.0)	2.6 (1.8 to 3.7)	2.5 (1.7 to 3.5)	-5.4 (-24.7 to 24.3)	0.5 (-20.4 to 28.5)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-76.9 to 1,267.6)	51.8 (-73.7 to 1,342.6)	69.2 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-76.9 to 1,272.3)	69.2 (-74.4 to 1,348.4)
Whooping cough	12.6 (9.9 to 16.1)	21.9 (16.9 to 28.3)	73.8 (63.6 to 84.8)	151.4 (136.6 to 167.3)	0.6 (0.4 to 1.0)	1.1 (0.6 to 1.8)	73.7 (54.8 to 94.6)	151.1 (123.9 to 181.6)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-71.2 to 57.4)	-56.1 (-65.7 to -57.4)	-0.0 (0.0 to 0.0)	-0.0 (0.0 to 0.0)	-56.2 (-71.1 to 68.0)	-49.8 (-65.5 to 58.6)
Measles	0.2 (0.2 to 0.2)	0.1 (0.1 to 0.1)	-51.6 (-53.6 to -49.6)	-27.7 (-30.6 to -24.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-51.6 (-53.6 to -49.6)	-27.7 (-30.6 to -24.6)
Varicella and herpes zoster	29.3 (27.1 to 32.2)	24.4 (22.2 to 27.3)	-16.5 (-27.4 to -4.7)	-0.2 (-10.0 to 10.2)	0.9 (0.5 to 1.4)	0.9 (0.5 to 1.4)	-1.7 (-23.9 to 27.5)	0.9 (-20.2 to 27.7)
Neglected tropical diseases and malaria	-	-	-	-	8.4 (4.7 to 14.0)	6.8 (3.1 to 11.8)	-21.0 (-46.5 to 21.5)	-23.3 (-47.2 to 15.4)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.4 (-77.3 to 310.5)	-13.6 (-72.2 to 408.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-33.7 (-77.7 to 294.0)	-20.5 (-72.8 to 380.0)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	4.5 (2.1 to 7.6)	0.4 (0.2 to 0.8)	-90.6 (-95.8 to -74.7)	-91.6 (-96.2 to -76.9)	1.2 (0.5 to 2.3)	0.1 (0.1 to 0.2)	-89.9 (-96.0 to -71.3)	-91.0 (-96.4 to -73.7)
Cystic echinococcosis	16.1 (13.6 to 18.6)	9.3 (8.5 to 11.1)	-40.5 (-51.1 to -32.8)	-40.7 (-51.2 to -32.7)	1.5 (0.9 to 2.1)	0.8 (0.6 to 1.2)	-42.7 (-55.8 to -26.8)	-42.4 (-55.9 to -26.8)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-21.8 to 25.1)	13.7 (-14.1 to 43.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.4 (-21.9 to 25.1)	13.7 (-14.2 to 43.4)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	225.7 (151.8 to 316.3)	226.3 (146.0 to 335.2)	-0.2 (-34.3 to 59.2)	-1.9 (-34.6 to 56.4)	5.7 (2.4 to 10.7)	5.8 (2.3 to 10.9)	0.5 (-35.1 to 62.9)	-1.9 (-35.3 to 58.7)
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.1 (-20.6 to 64.8)	30.9 (-11.0 to 89.0)
Maternal disorders	-	-	-	-	1.9 (1.1 to 3.0)	1.3 (0.8 to 2.1)	-31.1 (-50.6 to -3.3)	-31.8 (-50.3 to -4.6)
Maternal hemorrhage	30.8 (22.4 to 39.8)	26.1 (20.6 to 31.9)	-15.5 (-37.7 to 18.5)	-17.0 (-38.1 to 17.2)	0.8 (0.4 to 1.3)	0.6 (0.3 to 0.9)	-27.5 (-62.7 to 50.6)	-29.9 (-62.5 to 48.7)
Maternal sepsis and other maternal infections	26.6 (16.4 to 41.9)	13.8 (8.9 to 20.9)	-47.6 (-59.7 to -35.1)	-44.7 (-57.4 to -31.8)	0.3 (0.2 to 0.6)	0.2 (0.1 to 0.3)	-51.1 (-68.1 to -30.4)	-51.5 (-68.3 to -30.4)
Maternal hypertensive disorders	7.9 (4.8 to 11.8)	6.2 (3.9 to 9.2)	-21.3 (-30.7 to -7.1)	-22.0 (-31.8 to -7.7)	0.4 (0.2 to 0.7)	0.3 (0.1 to 0.5)	-21.2 (-39.7 to 1.4)	-21.8 (-39.7 to 0.2)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.5 (-50.0 to 45.6)	-14.9 (-50.6 to 46.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.5 (-50.1 to 46.1)	-14.9 (-50.6 to 46.5)
Complications of abortion	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-17.4 (-40.6 to 13.7)	-17.9 (-41.8 to 13.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-13.0 (-51.4 to 54.9)	-13.3 (-52.9 to 59.3)
Other maternal disorders	-	-	-	-	0.3 (0.2 to 0.6)	0.2 (0.1 to 0.4)	-30.1 (-58.5 to 21.3)	-30.6 (-58.6 to 20.4)
Neonatal disorders	-	-	-	-	75.6 (49.2 to 112.9)	86.6 (55.2 to 132.4)	12.4 (-24.5 to 76.8)	34.1 (-10.4 to 112.1)
Preterm birth complications	270.6 (163.6 to 440.5)	339.2 (208.2 to 534.4)	25.2 (-1.4 to 63.8)	45.3 (13.2 to 95.0)	33.2 (20.4 to 52.4)	44.3 (27.4 to 69.0)	33.4 (-11.4 to 100.9)	57.9 (4.6 to 141.0)
Neonatal encephalopathy due to birth asphyxia and trauma	73.4 (33.9 to 157.0)	43.5 (21.1 to 94.9)	-39.9 (-71.7 to 24.1)	-27.4 (-66.6 to 57.3)	16.8 (9.2 to 31.7)	10.3 (5.5 to 20.0)	-38.4 (-73.5 to 35.4)	-23.5 (-67.1 to 66.5)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	22.4 (14.3 to 44.1)	67.4 (56.3 to 97.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.9 (-2.9 to 58.5)	69.5 (32.9 to 116.8)
Hemolytic disease and other neonatal jaundice	37.3 (20.5 to 74.9)	38.7 (17.8 to 72.1)	3.8 (-58.6 to 159.1)	5.8 (-50.8 to 213.7)	13.4 (7.3 to 25.7)	28.7 (6.2 to 22.8)	13.2 (-57.6 to 115.2)	22.2 (-48.7 to 160.6)
Other neonatal disorders	-	-	-	-	12.2 (5.7 to 22.5)	18.9 (9.5 to 38.1)	52.7 (-36.4 to 291.6)	81.2 (-23.8 to 374.4)
Nutritional deficiencies	-	-	-	-	141.7 (93.4 to 210.9)	92.4 (59.8 to 136.8)	-34.8 (-42.0 to -27.6)	-5.0 (-14.2 to 3.2)
Protein-energy malnutrition	33.5 (13.3 to 66.9)	12.1 (5.4 to 24.0)	-64.2 (-87.8 to 12.3)	-48.9 (-82.8 to 61.1)	4.2 (1.6 to 9.1)	1.5 (0.6 to 3.2)	-64.2 (-87.6 to 14.0)	-48.7 (-82.5 to 64.0)
Iodine deficiency	1,086.1 (619.7 to 1,644.4)	711.2 (383.5 to 1,068.4)	-33.3 (-68.6 to 23.9)	-33.3 (-65.5 to 31.9)	28.7 (9.3 to 35.2)	12.7 (5.8 to 23.4)	-53.6 (-68.3 to 25.1)	-29.1 (-65.7 to 33.3)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron-deficiency anemia	4,186.5 (4,105.3 to 4,273.5)	3,101.1 (3,003.5 to 3,183.4)	-25.9 (-28.5 to -23.3)	0.2 (-3.4 to 3.5)	117.2 (77.5 to 171.7)	77.6 (50.7 to 115.7)	-33.6 (-37.7 to -30.0)	0.2 (-4.5 to 5.4)

Appendix Table G.4 - Ukraine prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.8 (0.3 to 2.1)	0.5 (0.2 to 1.3)	-34.9 (-83.0 to 129.0)	-6.8 (-75.9 to 231.9)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	17.6 (10.5 to 29.6)	14.3 (8.3 to 24.9)	-19.0 (-27.9 to -7.9)	-0.1 (-15.5 to 15.4)
Sexually transmitted diseases excluding HIV	-	-	-	-	8.6 (4.3 to 16.6)	8.2 (4.1 to 16.3)	-5.0 (-14.9 to 4.9)	0.1 (-11.7 to 11.2)
Syphilis	1.6 (1.5 to 1.8)	1.4 (1.2 to 1.5)	-15.3 (-27.9 to -2.0)	-24.2 (-35.9 to -11.9)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-17.1 (-39.2 to 13.5)	-24.5 (-43.0 to 0.4)
Chlamydial infection	1,224.5 (1,058.9 to 1,383.2)	1,141.3 (989.7 to 1,294.3)	-6.7 (-23.3 to 15.2)	-4.7 (-17.5 to 25.4)	3.4 (1.8 to 6.1)	3.1 (1.6 to 5.4)	-8.4 (-23.5 to 11.6)	-0.9 (-17.4 to 21.2)
Gonococcal infection	278.2 (231.8 to 331.5)	215.6 (174.0 to 253.8)	-22.3 (-41.9 to 1.1)	-13.9 (-36.1 to 14.2)	1.1 (0.5 to 1.9)	0.8 (0.4 to 1.5)	-23.3 (-42.9 to 5.0)	-15.4 (-37.5 to 18.0)
Trichomoniasis	616.2 (465.0 to 859.2)	651.4 (509.1 to 822.1)	5.8 (-25.0 to 51.0)	16.3 (-20.5 to 70.4)	1.1 (0.4 to 2.3)	1.1 (0.4 to 2.5)	7.1 (-29.0 to 59.9)	17.2 (-25.0 to 81.6)
Genital herpes	9,636.6 (9,381.4 to 9,881.9)	10,222.6 (9,973.4 to 10,509.4)	6.0 (2.3 to 10.5)	4.3 (0.5 to 8.7)	2.5 (0.8 to 6.0)	2.6 (0.8 to 6.4)	5.3 (-0.2 to 11.1)	4.5 (-0.8 to 10.4)
Other sexually transmitted diseases	15.6 (11.8 to 20.3)	12.3 (9.4 to 15.9)	-21.2 (-30.6 to -9.5)	-17.3 (-27.0 to -4.8)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-11.6 (-34.1 to 19.8)	-6.9 (-30.8 to 29.0)
Hepatitis	-	-	-	-	2.4 (1.5 to 3.6)	1.8 (1.2 to 2.7)	-25.0 (-33.7 to -14.0)	-15.8 (-25.4 to -3.9)
Hepatitis A	46.8 (45.5 to 48.0)	36.4 (35.6 to 37.1)	-22.2 (-22.7 to -21.8)	-3.6 (-3.9 to -3.4)	1.3 (0.8 to 1.9)	1.1 (0.7 to 1.6)	-15.7 (-24.5 to -6.1)	-2.0 (-12.5 to 9.6)
Hepatitis B	2,002.6 (1,860.2 to 2,141.2)	1,135.1 (1,063.2 to 1,204.0)	-43.3 (-48.6 to -38.1)	-38.6 (-44.8 to -32.8)	1.0 (0.6 to 1.5)	0.6 (0.4 to 0.9)	-37.6 (-54.2 to -13.3)	-35.1 (-52.2 to -10.3)
Hepatitis C	1,310.7 (1,200.4 to 1,414.8)	939.8 (857.6 to 1,019.6)	-28.2 (-36.4 to -18.9)	-28.0 (-36.4 to -18.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-21.0 (-48.3 to 14.3)	-21.2 (-44.9 to 7.0)
Hepatitis E	-	-	-	-	8.1 (37.1 to 51.6)	16.7 (31.6 to 59.0)	-	-
Leprosy	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other infectious diseases	178.2 (139.2 to 215.4)	114.2 (84.9 to 141.0)	-36.1 (-51.1 to -16.4)	0.9 (-26.5 to 33.0)	6.5 (4.0 to 10.3)	4.3 (2.5 to 6.7)	-34.5 (-54.5 to -4.2)	5.3 (-32.1 to 50.0)
Non-communicable diseases	-	-	-	-	5,230.4 (3,863.5 to 6,778.7)	5,316.4 (3,914.7 to 6,879.7)	1.6 (-0.9 to 4.4)	1.3 (-1.0 to 4.1)
Neoplasms	-	-	-	-	60.0 (43.9 to 77.7)	63.0 (46.9 to 81.5)	5.0 (-2.9 to 13.3)	2.6 (-10.0 to 5.0)
Esophageal cancer	4.3 (3.4 to 5.3)	3.4 (2.6 to 4.5)	-21.9 (-41.3 to 9.6)	-26.8 (-44.9 to 2.0)	0.7 (0.4 to 0.9)	0.5 (0.3 to 0.7)	-21.6 (-42.9 to 10.0)	-26.9 (-45.8 to -0.4)
Stomach cancer	38.6 (33.3 to 45.1)	21.3 (18.1 to 25.1)	-44.6 (-54.1 to -34.1)	-49.3 (-58.3 to -40.2)	4.8 (3.4 to 6.3)	2.7 (1.9 to 3.6)	-42.7 (-53.1 to -31.2)	-47.8 (-57.0 to -37.8)
Liver cancer	-	-	-	-	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	-0.4 (-2.1 to 3.8)	-9.9 (-32.5 to 24.9)
Liver cancer due to hepatitis B	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.5)	2.8 (-53.0 to 97.2)	-3.5 (-54.5 to 84.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	2.1 (-49.0 to 82.5)	-7.5 (-50.5 to 62.0)
Liver cancer due to hepatitis C	0.4 (0.3 to 0.7)	0.9 (0.6 to 1.3)	112.5 (21.3 to 288.8)	93.6 (11.0 to 247.4)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	102.2 (31.2 to 238.7)	82.8 (19.4 to 204.4)
Liver cancer due to alcohol use	1.0 (0.7 to 1.5)	0.9 (0.6 to 1.3)	-13.7 (-50.8 to 50.0)	-22.6 (-55.8 to 33.4)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-16.3 (-46.5 to 26.6)	-25.2 (-51.7 to 12.3)
Liver cancer due to other causes	0.5 (0.3 to 0.7)	0.2 (0.1 to 0.3)	-54.0 (-74.1 to -12.0)	-57.1 (-75.9 to -19.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-56.1 (-72.2 to -27.1)	-59.4 (-73.9 to -33.6)
Larynx cancer	9.0 (5.4 to 12.4)	6.1 (4.3 to 8.5)	-32.2 (-58.8 to 10.6)	-36.4 (-61.7 to 7.4)	1.3 (0.7 to 1.9)	0.9 (0.5 to 1.3)	-35.2 (-55.9 to 12.1)	-39.4 (-57.9 to 6.9)
Tracheal, bronchus and lung cancer	37.7 (33.1 to 42.5)	24.1 (20.6 to 28.0)	-36.3 (-47.8 to -23.3)	-40.9 (-51.4 to -29.1)	6.1 (4.4 to 7.9)	4.1 (2.8 to 5.4)	-33.5 (-44.4 to -20.4)	-34.4 (-48.0 to -27.0)
Breast cancer	70.6 (54.4 to 87.0)	176.5 (153.8 to 196.9)	151.5 (100.9 to 216.0)	120.0 (75.9 to 177.5)	7.4 (4.8 to 9.9)	11.0 (7.5 to 15.0)	47.4 (19.3 to 85.3)	32.8 (7.0 to 67.9)
Cervical cancer	45.7 (30.0 to 55.7)	32.6 (24.1 to 41.4)	-28.8 (-45.3 to -2.0)	-30.2 (-45.9 to -5.0)	3.5 (2.0 to 5.1)	2.5 (1.6 to 3.6)	-29.5 (-47.6 to -10.1)	-31.2 (-48.6 to -3.0)
Uterine cancer	32.6 (24.8 to 41.9)	20.0 (14.5 to 29.5)	-38.8 (-58.7 to -2.8)	-42.4 (-60.8 to -7.4)	2.4 (1.4 to 3.3)	1.4 (0.8 to 2.3)	-39.7 (-58.5 to -17.7)	-42.8 (-60.9 to -7.2)
Prostate cancer	34.9 (28.3 to 44.1)	67.3 (51.9 to 81.9)	92.4 (43.1 to 160.9)	71.7 (27.5 to 128.6)	3.3 (2.2 to 4.7)	6.7 (4.2 to 9.2)	103.8 (45.2 to 176.6)	81.1 (10.4 to 143.3)
Colon and rectum cancer	84.0 (77.5 to 90.4)	93.8 (85.5 to 103.8)	11.3 (-0.8 to 27.3)	-0.0 (-10.0 to 14.0)	7.6 (5.5 to 9.9)	8.4 (6.2 to 11.0)	10.4 (2.1 to 26.6)	-1.5 (-12.5 to 13.4)
Lip and oral cavity cancer	22.7 (16.9 to 29.8)	26.1 (18.7 to 33.8)	15.3 (-20.3 to 67.8)	9.0 (-23.8 to 55.7)	2.1 (1.4 to 3.1)	2.4 (1.6 to 3.5)	15.5 (-19.5 to 62.2)	8.8 (-23.6 to 50.0)
Nasopharynx cancer	2.4 (1.4 to 3.8)	1.7 (1.1 to 2.4)	-27.6 (-59.1 to 21.6)	-28.4 (-57.9 to 30.0)	0.3 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-29.3 (-57.5 to 13.2)	-29.9 (-56.4 to 12.6)
Other pharynx cancer	6.0 (3.3 to 10.0)	5.6 (3.2 to 8.7)	-5.4 (-50.2 to 78.2)	-8.1 (-49.9 to 70.8)	0.6 (0.3 to 1.0)	0.6 (0.3 to 0.9)	0.6 (-45.3 to 78.2)	5.7 (-45.3 to 73.7)
Gallbladder and biliary tract cancer	1.4 (0.9 to 2.3)	1.4 (1.0 to 1.8)	11.5 (-45.6 to 60.0)	-0.8 (-51.5 to 40.7)	0.4 (0.2 to 0.7)	0.4 (0.2 to 0.6)	12.6 (-44.7 to 55.3)	0.0 (-50.0 to 34.9)
Pancreatic cancer	4.8 (4.0 to 5.5)	5.2 (4.4 to 6.1)	9.0 (-13.2 to 35.0)	-2.2 (-22.5 to 21.0)	1.0 (0.7 to 1.3)	1.0 (0.7 to 1.5)	9.1 (-13.1 to 36.0)	-1.2 (-20.9 to 21.7)
Malignant skin melanoma	16.2 (11.7 to 23.3)	28.3 (18.0 to 37.7)	76.7 (22.9 to 133.1)	76.0 (18.3 to 131.8)	1.1 (0.7 to 1.7)	1.8 (1.1 to 2.7)	70.6 (17.6 to 122.5)	66.2 (13.6 to 117.1)
Non-melanoma skin cancer	39.6 (31.0 to 48.9)	62.9 (54.4 to 74.2)	58.9 (22.0 to 111.1)	58.9 (4.8 to 79.3)	1.0 (0.6 to 1.5)	2.0 (1.2 to 3.0)	99.7 (32.7 to 191.6)	66.5 (12.3 to 145.1)
Ovarian cancer	20.8 (16.0 to 25.1)	17.2 (14.1 to 20.6)	-17.4 (-35.3 to 9.0)	-19.9 (-37.8 to 5.7)	2.7 (1.8 to 3.7)	2.3 (1.5 to 3.1)	-16.3 (-37.3 to 12.7)	-18.8 (-39.1 to 6.8)
Testicular cancer	3.8 (2.2 to 6.5)	3.5 (1.9 to 5.5)	-6.8 (-45.9 to 59.3)	-3.0 (-43.7 to 66.8)	0.3 (0.1 to 0.5)	0.2 (0.1 to 0.4)	-9.7 (-46.6 to 60.6)	-5.9 (-46.2 to 68.8)
Kidney cancer	26.1 (18.8 to 33.4)	34.4 (28.6 to 41.1)	32.0 (2.5 to 78.0)	28.3 (-0.9 to 68.4)	2.8 (1.2 to 2.8)	2.6 (1.7 to 3.6)	31.8 (33.0 to 76.2)	26.9 (-0.9 to 68.0)
Bladder cancer	28.0 (21.6 to 35.0)	21.7 (17.7 to 27.3)	-21.8 (-39.9 to 1.2)	-21.8 (-45.4 to -8.6)	2.3 (1.5 to 3.2)	2.1 (1.3 to 2.5)	-9.9 (-39.0 to 5.2)	-28.9 (-45.0 to -6.2)
Brain and nervous system cancer	10.2 (8.5 to 12.3)	11.0 (9.1 to 13.2)	7.9 (-9.9 to 30.7)	17.8 (-2.6 to 45.5)	1.1 (0.8 to 1.6)	1.2 (0.8 to 1.7)	5.1 (-13.2 to 28.4)	11.5 (-6.6 to 37.7)
Thyroid cancer	24.8 (17.3 to 33.0)	27.4 (19.9 to 35.0)	10.9 (-20.2 to 53.4)	12.6 (-17.7 to 54.3)	1.5 (0.9 to 2.3)	1.6 (1.0 to 2.5)	9.9 (-21.8 to 53.1)	10.7 (-21.5 to 53.4)
Mesothelioma	0.2 (0.1 to 0.4)	0.6 (0.3 to 0.8)	231.2 (-18.7 to 363.7)	201.7 (-24.4 to 311.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	222.9 (-17.5 to 356.9)	192.2 (-24.7 to 302.9)
Hodgkin lymphoma	5.6 (3.2 to 10.5)	5.2 (3.5 to 7.9)	-6.7 (-49.0 to 52.6)	-6.7 (-46.3 to 59.5)	0.5 (0.2 to 0.9)	0.4 (0.2 to 0.7)	-26.8 (-50.0 to 45.2)	-21.0 (-46.6 to 50.9)
Non-Hodgkin lymphoma	13.6 (8.7 to 20.9)	16.5 (10.3 to 21.0)	28.7 (-25.7 to 89.7)	23.8 (-28.0 to 81.3)	1.1 (0.6 to 1.8)	1.2 (0.8 to 2.0)	29.8 (-26.4 to 94.4)	24.2 (-27.9 to 84.6)
Multiple myeloma	1.3 (0.8 to 2.1)	2.0 (1.2 to 3.0)	55.8 (-23.9 to 194.0)	45.4 (-28.4 to 180.2)	0.3 (0.2 to 0.5)	0.5 (0.2 to 0.7)	44.5 (-27.3 to 169.0)	34.2 (-31.7 to 149.1)
Leukemia	29.1 (24.4 to 34.2)	18.4 (15.4 to 21.7)	-36.8 (-48.4 to -22.5)	-40.6 (-52.4 to -26.4)	3.3 (2.3 to 4.4)	3.2 (1.7 to 3.2)	-27.5 (-41.2 to -10.1)	-33.2 (-44.8 to -17.5)
Other neoplasms	14.7 (11.9 to 17.9)	21.7 (17.6 to 25.9)	47.5 (16.6 to 86.8)	58.6 (23.1 to 102.3)	1.1 (0.7 to 1.5)	1.5 (1.0 to 2.1)	42.7 (13.8 to 78.8)	50.1 (19.5 to 90.2)
Cardiovascular diseases	-	-	-	-	100.2 (71.1 to 138.1)	102.8 (72.2 to 139.3)	2.4 (-16.0 to 24.6)	-9.1 (-25.6 to 11.4)
Rheumatic heart disease	15.8 (13.9 to 17.8)	15.9 (14.2 to 17.6)	1.1 (-14.1 to 19.1)	-3.6 (-17.7 to 12.4)	1.5 (1.0 to 2.2)	1.6 (1.1 to 2.3)	5.0 (-19.0 to 47.1)	0.1 (-23.7 to 39.3)
Ischemic heart disease	873.9 (730.7 to 1,041.6)	861.1 (761.3 to 984.3)	-1.3 (-21.6 to 21.8)	-13.0 (-30.2 to 6.8)	44.8 (28.5 to 65.5)	41.6 (26.0 to 59.7)	-7.2 (-32.3 to 21.6)	-19.7 (-40.8 to 4.2)
Cerebrovascular disease	-	-	-	-	23.8 (16.2 to 32.1)	26.7 (18.4 to 36.1)	11.8 (-7.4 to 38.9)	4.1 (-13.1 to 28.4)
Ischemic stroke	148.2 (125.3 to 171.3)	168.0 (149.4 to 187.8)	13.2 (-5.5 to 39.7)	4.7 (-12.3 to 28.3)	4.7 (15.1 to 30.4)	4.2 (17.5 to 34.2)	12.7 (-6.7 to 39.9)	5.3 (-12.7 to 29.5)
Hemorrhagic stroke	8.5 (6.0 to 11.8)	8.5 (6.0 to 11.3)	1.4 (-42.6 to 64.3)	-2.4 (-43.5 to 53.6)	1.4 (0.8 to 2.2)	1.4 (0.8 to 2.1)	1.2 (-42.7 to 61.8)	-2.3 (-43.8 to 51.7)
Hypertensive heart disease	64.7 (50.3 to 81.7)	82.0 (62.7 to 106.4)	24.9 (-5.2 to 79.0)	3.7 (-20.9 to 47.8)	7.1 (4.6 to 10.6)	8.9 (5.6 to 13.4)	25.0 (-6.2 to 81.4)	4.2 (-21.4 to 48.7)
Cardiomyopathy and myocarditis	52.4 (41.3 to 68.9)	68.3 (53.5 to 84.5)	31.2 (-7.1 to 74.2)	16.3 (-14.6 to 53.1)	5.4 (3.4 to 7.8)	7.1 (4.5 to 10.2)	32.8 (-5.7 to 79.5)	17.1 (-14.9 to 56.9)
Atrial fibrillation and flutter	11.5 (8.0 to 17.0)	48.4 (36.6 to 63.3)	399.5 (162.3 to 580.2)	292.5 (132.3 to 488.2)	0.9 (0.5 to 1.5)	3.8 (2.4 to 5.8)	332.1 (149.1 to 592.8)	283.9 (125.6 to 507.2)
Peripheral vascular disease	1,857.4 (1,404.4 to 2,289.2)	2,408.4 (1,882.7 to 3,037.8)	28.4 (-11.1 to 101.0)	12.4 (-21.8 to 78.2)	3.3 (1.4 to 6.2)	2.4 (0.7 to 4.7)	-24.9 (-75.5 to 48.0)	-43.6 (-81.4 to 12.9)
Endocarditis	1.2 (0.8 to 2.0)	1.2 (0.7 to 1.7)	3.8 (-50.1 to 68.1)	-5.6 (-54.3 to 54.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	2.5 (-54.9 to 93.9)	-3.5 (-56.7 to 70.0)
Other cardiovascular and circulatory diseases	188.6 (78.1 to 363.2)	150.2 (37.9 to 348.3)	-27.4 (-82.6 to 166.6)	-31.1 (-83.6 to 154.9)	13.4 (4.9 to 27.6)	10.6 (2.4 to 26.1)	-27.4 (-81.9 to 162.7)	-31.3 (-83.6 to 151.2)
Chronic respiratory diseases	-	-	-	-	241.4 (168.6 to 325.8)	245.0 (161.4 to 321.1)	1.2 (-13.9 to 9.6)	-1.2 (-12.0 to 10.1)
Chronic obstructive pulmonary disease	2,040.8 (1,938.2 to 2,140.0)	2,120.9 (2,018.2 to 2,220.6)	3.9 (1.1 to 6.9)	-1.5 (-4.0 to 1.1)	124.2 (82.2 to 176.9)	134.7 (87.1 to 194.2)	8.9 (-11.5 to 29.4)	3.3 (-11.5 to 22.2)
Pneumoconiosis	-	-</						

Appendix Table G.4 - Ukraine prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.5 (0.4 to 0.5)	0.5 (0.4 to 0.5)	2.9 (-2.7 to 9.0)	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	3.5 (-2.1 to 9.8)	-
Asbestosis	-	-	-	-	-	-	-	-
Coal workers pneumoconiosis	0.3 (0.3 to 0.4)	0.4 (0.3 to 0.4)	3.3 (-0.0 to 7.2)	-4.1 (-7.3 to -0.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	3.9 (0.3 to 7.7)	-3.6 (-6.8 to -0.2)
Other pneumoconiosis	1.3 (1.2 to 1.4)	0.8 (0.7 to 0.9)	-40.1 (-43.1 to -36.0)	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-39.8 (-42.8 to -36.0)	-43.7 (-46.3 to -40.2)
Asthma	2,612.7 (2,452.5 to 2,774.6)	2,237.9 (2,056.3 to 2,422.8)	-14.3 (-23.4 to -4.7)	5.2 (-16.6 to 6.2)	114.8 (75.9 to 162.9)	97.5 (63.1 to 142.3)	-5.2 (-24.0 to -5.0)	-5.2 (-16.6 to 6.3)
Interstitial lung disease and pulmonary sarcoidosis	4.3 (3.2 to 5.5)	4.2 (2.9 to 5.6)	-2.7 (-41.4 to 51.7)	-1.3 (-40.3 to 52.2)	0.6 (0.3 to 0.9)	0.6 (0.3 to 0.9)	-2.2 (-41.1 to 50.5)	-1.2 (-40.0 to 50.2)
Other chronic respiratory diseases	-	-	-	-	1.5 (1.0 to 2.3)	2.0 (1.1 to 3.1)	27.1 (-10.7 to 76.7)	20.4 (-14.0 to 66.2)
Cirrhosis	-	-	-	-	5.3 (3.6 to 7.3)	7.9 (5.5 to 10.9)	48.7 (33.5 to 63.7)	52.6 (36.9 to 68.8)
Cirrhosis due to hepatitis B	6.8 (5.2 to 8.3)	8.5 (5.6 to 11.7)	21.3 (-16.7 to 105.6)	23.9 (-13.6 to 104.0)	1.1 (0.7 to 1.7)	1.4 (0.8 to 2.2)	26.2 (-22.5 to 104.6)	26.2 (-19.9 to 107.3)
Cirrhosis due to hepatitis C	6.1 (4.3 to 8.3)	17.2 (11.6 to 22.2)	186.1 (72.9 to 345.9)	186.1 (76.7 to 352.3)	1.0 (0.6 to 1.6)	2.8 (1.7 to 4.3)	179.5 (62.0 to 371.3)	185.4 (67.9 to 378.4)
Cirrhosis due to alcohol use	13.5 (11.4 to 15.3)	14.9 (10.0 to 19.0)	10.3 (-26.8 to 49.0)	10.5 (-28.6 to 50.1)	2.2 (1.4 to 3.2)	2.4 (1.4 to 3.7)	11.4 (-30.0 to 56.0)	11.6 (-29.2 to 55.8)
Cirrhosis due to other causes	5.9 (4.9 to 7.0)	7.4 (5.6 to 9.5)	24.4 (-10.8 to 72.4)	37.0 (0.7 to 83.9)	1.0 (0.6 to 1.5)	1.2 (0.8 to 1.9)	24.4 (-16.5 to 88.7)	36.5 (-5.5 to 102.1)
Digestive diseases	-	-	-	-	62.7 (44.9 to 82.0)	64.5 (46.0 to 85.5)	2.8 (-2.2 to 8.4)	1.9 (-3.5 to 7.7)
Peptic ulcer disease	378.0 (362.8 to 392.5)	333.9 (324.6 to 344.2)	-11.8 (-16.0 to -6.8)	-19.6 (-23.4 to -15.2)	11.5 (7.7 to 16.5)	10.2 (7.0 to 14.4)	-11.7 (-19.7 to -3.5)	-20.8 (-27.7 to -13.5)
Gastritis and duodenitis	83.8 (74.5 to 93.5)	83.6 (72.7 to 94.3)	0.1 (-13.3 to 11.3)	0.1 (-2.5 to 23.5)	5.1 (3.5 to 7.1)	4.1 (2.8 to 5.8)	-19.5 (-29.5 to -4.0)	1.3 (-12.6 to 25.1)
Appendicitis	3.7 (3.2 to 4.3)	2.9 (2.4 to 3.2)	-22.9 (-38.6 to -6.9)	-4.5 (-25.9 to 16.1)	1.2 (0.7 to 1.7)	0.9 (0.6 to 1.3)	-22.1 (-45.2 to 10.6)	-3.4 (-33.2 to 39.2)
Paralytic ileus and intestinal obstruction	0.7 (0.6 to 0.8)	0.7 (0.6 to 0.8)	5.8 (-11.0 to 28.7)	3.9 (-14.6 to 26.2)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	5.2 (-18.1 to 35.9)	4.2 (-20.5 to 34.6)
Inguinal, femoral, and abdominal hernia	161.7 (134.6 to 190.3)	169.7 (138.0 to 204.6)	4.5 (-16.8 to 34.1)	4.5 (-23.6 to 19.6)	1.7 (0.8 to 3.1)	1.7 (0.8 to 3.5)	0.0 (-16.7 to 35.4)	4.3 (-23.4 to 21.9)
Inflammatory bowel disease	109.7 (104.8 to 114.4)	134.3 (128.8 to 139.6)	22.5 (15.5 to 29.7)	21.1 (14.1 to 28.1)	23.1 (15.8 to 31.3)	28.2 (19.4 to 38.3)	22.5 (13.4 to 31.7)	21.4 (12.4 to 30.9)
Vascular intestinal disorders	0.5 (0.4 to 0.6)	0.6 (0.4 to 0.8)	16.8 (-14.5 to 64.5)	0.8 (-24.1 to 39.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	0.2 (-26.6 to 97.4)	2.7 (-34.5 to 66.1)
Gallbladder and biliary diseases	93.2 (84.5 to 102.5)	73.8 (63.4 to 85.7)	-20.4 (-33.3 to -7.2)	-25.3 (-38.0 to -12.7)	9.8 (6.6 to 13.5)	7.7 (5.0 to 10.9)	-20.8 (-34.5 to -7.4)	-20.8 (-38.2 to -12.6)
Pancreatitis	28.4 (26.9 to 29.7)	27.7 (26.0 to 29.1)	-2.7 (-9.7 to 5.3)	-2.7 (-12.1 to 2.0)	8.3 (5.5 to 11.2)	8.1 (5.6 to 11.0)	-2.8 (-12.7 to 10.2)	4.9 (-15.4 to 8.0)
Other digestive diseases	-	-	-	-	1.8 (1.2 to 2.6)	1.1 (2.0 to 4.5)	38.1 (33.4 to 119.8)	72.1 (31.8 to 119.5)
Neurological disorders	-	-	-	-	583.4 (391.1 to 804.9)	649.5 (440.9 to 884.0)	11.2 (0.3 to 22.3)	11.3 (0.2 to 23.0)
Alzheimer disease and other dementias	555.8 (472.2 to 636.0)	722.7 (631.1 to 815.1)	29.9 (6.9 to 57.4)	0.9 (-17.6 to 22.4)	81.5 (56.8 to 108.0)	108.7 (77.6 to 144.3)	32.9 (8.8 to 63.1)	1.1 (-17.6 to 24.1)
Parkinson disease	32.1 (27.6 to 36.2)	37.7 (32.3 to 42.5)	17.4 (11.1 to 24.7)	0.4 (-5.1 to 5.6)	3.9 (2.6 to 5.2)	4.5 (3.0 to 6.2)	17.4 (3.1 to 35.4)	0.9 (-11.0 to 14.4)
Epilepsy	108.3 (73.2 to 145.6)	97.9 (66.7 to 130.7)	-9.6 (-43.5 to 43.9)	0.4 (-36.7 to 59.9)	32.2 (18.0 to 50.8)	27.6 (16.3 to 42.4)	-14.4 (-49.2 to 43.9)	-14.4 (-43.2 to 61.8)
Multiple sclerosis	34.9 (31.4 to 38.6)	45.2 (40.8 to 49.4)	29.5 (12.3 to 48.3)	31.3 (13.3 to 50.9)	11.4 (8.1 to 14.8)	14.8 (10.5 to 19.3)	29.4 (6.9 to 54.8)	31.3 (9.0 to 57.2)
Migraine	8,812.6 (8,102.1 to 9,577.9)	8,254.7 (7,589.1 to 8,986.6)	-6.2 (-16.5 to 5.1)	-0.0 (-11.1 to 12.1)	298.2 (175.9 to 437.2)	278.2 (166.5 to 404.6)	-6.6 (-17.1 to 5.1)	0.2 (-11.7 to 12.9)
Tension-type headache	15,337.7 (14,401.2 to 16,341.7)	14,152.9 (12,620.1 to 15,647.8)	-7.7 (-18.9 to 4.4)	-1.1 (-13.2 to 12.4)	7.1 (11.2 to 40.5)	7.1 (10.5 to 38.0)	-0.8 (-18.6 to 14.4)	0.8 (-13.9 to 13.2)
Medication overuse headache	786.4 (512.8 to 1,088.1)	1,189.1 (762.7 to 1,618.5)	52.8 (13.4 to 91.2)	55.0 (15.7 to 93.5)	122.6 (68.8 to 193.6)	185.3 (103.0 to 291.0)	53.0 (13.8 to 91.6)	56.1 (14.8 to 93.8)
Other neurological disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	3.3 (-27.2 to 43.5)	6.3 (-23.5 to 46.1)	10.6 (6.9 to 15.4)	9.1 (6.2 to 12.6)	-13.6 (-36.3 to 16.4)	-30.7 (-49.1 to -6.3)
Mental and substance use disorders	-	-	-	-	1,264.4 (905.5 to 1,654.5)	1,198.0 (861.3 to 1,567.6)	-5.2 (-7.9 to -2.5)	0.2 (-2.4 to 3.0)
Schizophrenia	172.2 (150.2 to 185.4)	167.4 (153.2 to 180.5)	-2.7 (-6.6 to 1.4)	-0.5 (-4.6 to 3.8)	109.8 (80.2 to 132.4)	106.7 (78.2 to 128.5)	-2.8 (-8.8 to 3.2)	-0.4 (-6.7 to 6.3)
Alcohol use disorders	1,254.1 (1,160.1 to 1,360.6)	1,278.6 (1,186.8 to 1,378.4)	2.0 (-3.2 to 7.7)	1.8 (-0.4 to 11.0)	128.7 (83.9 to 177.5)	127.4 (84.8 to 180.9)	1.1 (-3.7 to 8.2)	4.9 (-0.8 to 11.4)
Drug use disorders	-	-	-	-	68.4 (46.8 to 90.1)	67.8 (47.2 to 91.6)	-0.6 (-12.8 to 13.0)	5.5 (-7.1 to 21.6)
Opioid use disorders	88.7 (76.5 to 101.3)	84.8 (72.6 to 96.6)	-4.3 (-10.8 to 1.7)	0.5 (-6.4 to 6.8)	36.9 (25.6 to 49.0)	35.3 (24.7 to 46.6)	-4.1 (-13.4 to 5.1)	0.6 (-9.3 to 10.6)
Cocaine use disorders	37.8 (29.9 to 46.0)	36.1 (29.9 to 41.9)	-4.0 (-25.8 to 22.8)	4.2 (-20.4 to 34.9)	5.2 (3.1 to 7.9)	5.0 (3.1 to 7.4)	-2.6 (-24.4 to 30.5)	5.5 (-23.8 to 43.9)
Amphetamine use disorders	73.6 (59.0 to 88.2)	79.6 (65.6 to 95.1)	8.1 (-18.3 to 45.6)	15.1 (-13.1 to 57.5)	7.3 (5.6 to 14.9)	10.4 (6.1 to 16.2)	15.6 (-19.7 to 48.3)	15.6 (-13.9 to 59.9)
Cannabis use disorders	62.7 (52.7 to 72.1)	54.8 (46.6 to 62.8)	-12.6 (-14.4 to -10.6)	0.4 (0.3 to 0.5)	1.8 (1.2 to 2.8)	1.6 (1.0 to 2.3)	-12.3 (-25.5 to 2.9)	0.9 (-13.9 to 18.2)
Other drug use disorders	-	-	-	-	14.9 (8.9 to 22.7)	15.5 (9.4 to 24.1)	3.9 (-28.4 to 52.2)	11.9 (-23.3 to 64.1)
Depressive disorders	-	-	-	-	540.5 (355.9 to 762.4)	523.3 (348.5 to 730.9)	-3.1 (-8.9 to 2.7)	-0.2 (-5.7 to 5.9)
Major depressive disorder	2,240.1 (1,805.0 to 2,712.6)	2,165.6 (1,742.3 to 2,606.9)	-3.3 (-10.1 to 3.7)	-0.2 (-6.9 to 6.7)	454.5 (289.6 to 660.4)	437.4 (281.7 to 624.2)	-3.7 (-10.4 to 3.3)	-0.1 (-6.7 to 7.0)
Dysthymia	899.4 (759.3 to 1,064.0)	900.1 (759.3 to 1,062.8)	0.1 (-0.9 to 1.2)	-0.4 (-0.5 to -0.3)	86.0 (56.9 to 126.4)	85.0 (57.1 to 125.4)	-0.2 (-2.7 to 2.4)	0.3 (-2.8 to 2.1)
Bipolar disorder	384.8 (337.3 to 429.9)	375.7 (331.6 to 422.6)	-2.4 (-7.4 to 2.7)	-0.8 (-5.7 to 4.6)	77.6 (48.1 to 115.1)	75.7 (47.2 to 113.2)	-2.5 (-8.8 to 4.1)	-0.6 (-7.0 to 6.4)
Anxiety disorders	1,382.4 (1,242.4 to 1,529.9)	1,271.1 (1,132.4 to 1,411.7)	-8.1 (-9.8 to -6.3)	-0.5 (-0.6 to -0.4)	126.0 (86.9 to 175.5)	115.3 (79.5 to 161.8)	-8.5 (-11.9 to -5.0)	-0.2 (-3.1 to 2.7)
Eating disorders	-	-	-	-	11.6 (7.1 to 17.8)	10.2 (6.1 to 15.8)	-12.2 (-19.9 to -2.7)	-0.4 (-7.4 to 8.9)
Anorexia nervosa	5.4 (4.3 to 6.8)	4.9 (3.8 to 6.2)	-9.5 (-18.7 to 2.2)	7.1 (-3.0 to 19.4)	1.2 (0.7 to 1.8)	1.0 (0.6 to 1.6)	-9.1 (-31.2 to 18.4)	7.2 (-17.0 to 40.4)
Bulimia nervosa	49.2 (35.5 to 65.4)	43.3 (30.3 to 58.9)	-12.2 (-16.2 to -8.1)	-0.9 (-1.1 to -0.8)	10.4 (6.3 to 16.3)	9.2 (5.4 to 14.5)	-12.4 (-20.6 to -3.3)	-1.2 (-8.9 to 8.2)
Autistic spectrum disorders	-	-	-	-	57.6 (40.1 to 77.9)	50.4 (35.1 to 68.2)	-12.4 (-15.3 to -9.6)	0.9 (-2.5 to 4.2)
Autism	149.5 (141.6 to 157.9)	131.5 (124.4 to 139.1)	-12.1 (-12.5 to -11.5)	0.6 (0.6 to 0.6)	36.6 (24.7 to 50.4)	32.0 (21.6 to 44.1)	-12.4 (-16.5 to -8.3)	0.9 (-0.1 to 5.7)
Asperger syndrome	211.0 (197.8 to 224.5)	185.2 (172.8 to 198.1)	-12.2 (-12.9 to -11.6)	0.8 (0.7 to 0.8)	21.0 (14.6 to 29.3)	21.0 (12.7 to 25.5)	-0.1 (-1.6 to 1.0)	0.9 (-3.0 to 5.0)
Attention-deficit/hyperactivity disorder	226.5 (208.4 to 244.5)	143.4 (131.9 to 154.8)	-36.6 (-37.5 to -36.2)	0.5 (0.4 to 0.5)	2.8 (1.6 to 4.3)	1.8 (1.0 to 2.7)	-36.8 (-41.3 to -31.7)	0.4 (-7.0 to 8.7)
Conduct disorder	331.5 (312.6 to 351.6)	195.0 (182.5 to 207.9)	-41.2 (-42.0 to -40.2)	0.4 (0.4 to 0.4)	40.2 (25.1 to 58.4)	23.6 (14.8 to 34.4)	-41.2 (-43.9 to -38.2)	0.5 (-4.2 to 5.2)
Idiopathic intellectual disability	761.8 (603.2 to 927.4)	537.6 (405.6 to 664.5)	-29.2 (-38.4 to -20.8)	-17.7 (-27.8 to -8.4)	37.0 (23.9 to 52.7)	26.1 (16.4 to 38.2)	-29.4 (-38.7 to -20.9)	-17.6 (-27.8 to -7.8)
Other mental and substance use disorders	1,215.6 (866.1 to 1,977.4)	1,616.6 (887.0 to 1,991.1)	33.4 (0.9 to 3.8)	0.6 (0.4 to 0.8)	115.6 (46.5 to 91.5)	102.2 (47.5 to 93.8)	-11.2 (-17.7 to 6.6)	-0.4 (-2.9 to 4.6)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	488.6 (345.5 to 659.4)	509.3 (356.2 to 675.4)	4.5 (-6.5 to 14.9)	4.4 (-5.5 to 13.5)
Diabetes mellitus	2,187.6 (1,671.6 to 2,743.8)	2,590.4 (2,037.5 to 3,169.7)	19.9 (-10.7 to 51.9)	18.0 (-11.9 to 47.0)	179.9 (115.5 to 261.6)	216.1 (140.7 to 304.7)	21.3 (8.0 to 54.1)	17.8 (-10.7 to 47.2)
Acute glomerulonephritis	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-25.2 (-32.1 to -17.2)	-12.6 (-19.7 to -4.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-25.2 (-32.1 to -17.2)	-12.6 (-19.9 to -4.5)
Chronic kidney disease	-	-	-	-	143.1 (102.5 to 187.4)	133.3 (94.9 to 171.6)	-7.0 (-16.3 to 2.0)	5.1 (-14.6 to 3.0)
Chronic kidney disease due to diabetes mellitus	825.5 (559.7 to 1,121.4)	653.2 (448.4 to 942.3)	-21.9 (-42.8 to 15.9)	-27.6 (-46.7 to 4.8)	27.0 (18.4 to 37.8)	19.9 (13.3 to 28.6)	-26.4 (-43.5 to -3.4)	-29.5 (-44.9 to -8.6)
Chronic kidney disease due to hypertension	1,036.7 (882.5 to 1,528.4)	1,265.8 (839.5 to 1,903.9)	22.1 (-7.2 to 63.2)	20.3 (-7.9 to 53.5)	27.0 (17.7 to 37.6)	6.8 (4.1 to 10.2)	-75.0 (-83.9 to -62.6)	-75.7 (-84.5 to -64.6)
Chronic kidney disease due to glomerulonephritis	947.7 (662.7 to 1,311.9)	591.4 (505.6 to 677.2)	-36.5 (-52.2 to -18.5)	-30.9 (-47.6 to -12.4)	42.6 (29.4 to 58.0)	54.3 (37.9 to 72.0)	-27.1 (-21.0 to 38.0)	31.7 (8.1 to 61.0)
Chronic kidney disease due to other causes	1,377.5 (938.2 to 1,923.2)	1,616.8 (1,189.9 to 2,100.0)	17.6 (-3.2 to 49.5)	17.6 (-7.7 to 38.5)	17.6 (31.9 to 63.2)	12.9 (37.3 to 70.2)	12.9 (-11.0 to 42.6)	11.3 (-10.3 to 39.4)
Urinary diseases and male infertility	-	-	-	-	48.7 (31.7 to 69.6)	59.6 (38.9 to 84.0)	22.6 (10.8 to 35.9)	8.9 (-1.2 to 20.4)
Interstitial nephritis and urinary tract infections	18.4 (17.2 to 19.5)	18.1 (17.0 to 19.2						

Appendix Table G.4 - Ukraine prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Urolithiasis	342.8 (245.3 to 494.6)	435.0 (312.2 to 620.6)	27.7 (1.8 to 52.1)	4.1 (-11.1 to 39.7)	4.1 (2.7 to 6.0)	4.6 (3.0 to 6.8)	12.8 (-9.9 to 27.7)	5.1 (-8.3 to 20.2)
Benign prostatic hyperplasia	1,162.4 (1,075.3 to 1,244.1)	1,446.8 (1,328.6 to 1,571.9)	24.8 (10.9 to 39.9)	41.6 (-3.1 to 22.1)	51.9 (26.7 to 58.7)	51.9 (34.1 to 73.5)	25.1 (11.1 to 40.4)	9.7 (-2.7 to 22.8)
Male infertility due to other causes	302.5 (244.4 to 375.1)	290.8 (230.3 to 363.8)	-2.9 (-31.0 to 29.1)	2.2 (-27.1 to 36.4)	2.1 (0.8 to 4.2)	2.0 (0.8 to 4.2)	-2.7 (-31.9 to 31.4)	2.3 (-28.6 to 38.1)
Other urinary diseases	-	-	-	-	0.3 (0.1 to 0.5)	0.4 (0.2 to 0.7)	100.7 (-16.9 to 206.4)	90.2 (-21.2 to 191.2)
Gynecological diseases	-	-	-	-	58.9 (37.8 to 89.4)	58.6 (37.3 to 88.8)	0.2 (-15.2 to 15.2)	3.9 (-12.7 to 19.8)
Uterine fibroids	1,226.5 (1,121.4 to 1,325.2)	1,200.2 (1,099.1 to 1,298.1)	-2.1 (-2.6 to -1.7)	-0.2 (-0.3 to -0.2)	11.5 (6.0 to 20.4)	11.3 (5.9 to 20.6)	-2.1 (-8.6 to 6.5)	-0.1 (-6.5 to 8.7)
Polycystic ovarian syndrome	884.3 (788.2 to 981.6)	856.4 (770.4 to 945.3)	-3.3 (-15.8 to 10.9)	0.8 (-12.1 to 16.1)	8.7 (4.0 to 16.6)	8.4 (3.9 to 16.3)	-3.5 (-15.5 to 11.2)	1.2 (-11.8 to 16.4)
Female infertility due to other causes	124.1 (72.8 to 188.9)	124.2 (73.6 to 178.6)	0.8 (-43.2 to 74.2)	6.8 (-39.6 to 87.1)	0.7 (0.3 to 1.6)	0.7 (0.3 to 1.6)	0.1 (-44.2 to 72.0)	5.2 (-40.3 to 82.7)
Endometriosis	95.0 (79.9 to 110.9)	28.9 (82.3 to 112.0)	-2.0 (-18.0 to 26.1)	2.0 (-15.6 to 29.6)	8.8 (5.8 to 12.5)	8.8 (5.9 to 12.5)	8.8 (-20.8 to 29.1)	5.5 (-1.2 to 31.4)
Genital prolapse	3,156.0 (2,810.0 to 3,498.5)	3,135.2 (2,795.6 to 3,474.9)	-0.7 (-14.3 to 14.9)	-0.2 (-14.8 to 16.1)	10.0 (4.7 to 19.0)	10.0 (4.7 to 19.3)	0.7 (-14.7 to 15.3)	0.7 (-14.9 to 16.7)
Premenstrual syndrome	1,971.8 (1,358.7 to 2,662.1)	2,020.4 (1,336.1 to 2,712.6)	4.6 (-40.9 to 61.6)	10.9 (-38.5 to 69.0)	16.6 (8.9 to 27.8)	17.0 (9.1 to 28.2)	4.8 (-40.7 to 61.4)	10.9 (-38.5 to 69.1)
Other gynecological diseases	112.7 (98.8 to 124.4)	101.0 (87.4 to 113.9)	-10.4 (-25.0 to 6.7)	-4.7 (-19.7 to 12.9)	2.5 (1.6 to 3.6)	2.3 (1.5 to 3.4)	-2.3 (-32.2 to 30.2)	-2.4 (-28.7 to 36.8)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	33.4 (22.5 to 48.1)	25.3 (16.7 to 36.6)	-24.4 (-30.1 to -18.7)	-1.1 (-8.4 to 6.0)
Thalassemias	1.0 (0.9 to 1.2)	0.7 (0.6 to 0.8)	-32.6 (-41.0 to -22.0)	1.7 (-10.8 to 17.9)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-31.7 (-47.2 to -9.0)	-0.4 (-23.3 to 36.5)
Thalassemia trait	871.4 (832.0 to 928.9)	797.4 (755.1 to 850.9)	-8.6 (-12.0 to -4.6)	2.4 (-1.3 to 6.4)	28.6 (19.4 to 41.1)	21.9 (14.6 to 31.5)	-23.3 (-28.9 to -17.7)	-1.6 (-9.3 to 6.0)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.2 (-32.7 to -4.5)	-1.1 (-13.1 to 19.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.6 (-26.8 to -11.8)	-1.6 (-6.2 to 35.1)
Sickle cell trait	23.5 (21.1 to 26.3)	21.0 (18.3 to 23.4)	-10.5 (-15.6 to -7.2)	0.0 (-6.5 to 7.5)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-32.5 (-57.4 to 29.3)	-10.3 (-47.7 to 81.1)
G6PD deficiency	86.5 (77.3 to 95.4)	78.3 (73.3 to 83.4)	-9.4 (-19.4 to 3.6)	1.7 (-9.7 to 16.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-27.3 (-43.5 to 4.5)	4.3 (-23.5 to 23.1)
G6PD trait	5,557.8 (5,508.6 to 5,622.0)	4,994.3 (4,927.0 to 5,060.6)	-10.1 (-11.5 to -8.8)	-1.5 (-3.1 to -0.1)	0.4 (0.1 to 0.6)	0.3 (0.1 to 0.4)	-6.9 (-58.4 to 129.6)	-31.1 (-57.5 to 256.0)
Other hemoglobinopathies and hemolytic anemias	154.8 (134.1 to 179.4)	118.9 (101.4 to 136.3)	-23.5 (-36.9 to -6.2)	-0.5 (-20.1 to 24.1)	4.1 (2.5 to 6.2)	2.8 (1.6 to 4.4)	2.4 (-50.7 to -2.0)	2.4 (-25.6 to 47.0)
Endocrine, metabolic, blood, and immune disorders	697.2 (659.0 to 735.0)	470.7 (444.7 to 497.3)	-32.5 (-37.4 to -27.0)	-20.6 (-27.6 to -12.0)	24.7 (16.8 to 34.5)	16.3 (11.2 to 22.4)	-33.8 (-40.3 to -26.9)	-21.2 (-30.4 to -12.7)
Musculoskeletal disorders	-	-	-	-	1,486.1 (1,056.0 to 1,950.5)	1,372.8 (1,121.3 to 2,060.5)	6.7 (0.5 to 12.1)	2.2 (-8.8 to 9.5)
Rheumatoid arthritis	260.1 (247.8 to 271.9)	279.7 (266.7 to 292.2)	7.6 (0.4 to 14.3)	0.3 (-5.9 to 6.1)	60.4 (43.2 to 79.9)	64.7 (46.3 to 85.9)	7.2 (-1.2 to 15.0)	2.8 (-7.1 to 7.7)
Osteoarthritis	3,208.3 (3,076.5 to 3,319.9)	3,616.8 (3,484.1 to 3,757.8)	12.6 (7.0 to 19.7)	0.1 (-4.8 to 6.6)	195.7 (137.0 to 267.0)	220.2 (154.4 to 299.3)	12.3 (6.8 to 19.6)	0.4 (-4.6 to 7.1)
Low back and neck pain	-	-	-	-	1,059.5 (724.7 to 1,429.2)	1,097.2 (763.8 to 1,474.6)	3.4 (-3.6 to 12.4)	1.9 (-11.9 to 11.2)
Low back pain	7,383.4 (6,990.0 to 7,770.9)	7,631.3 (7,230.0 to 8,009.9)	3.3 (-4.4 to 11.9)	1.0 (-6.3 to 9.8)	814.0 (548.3 to 1,115.8)	837.8 (577.6 to 1,154.9)	3.1 (-4.7 to 11.7)	1.3 (-6.3 to 10.0)
Neck pain	2,520.3 (2,110.7 to 2,920.1)	2,662.1 (2,270.3 to 3,059.4)	5.3 (-14.8 to 31.5)	5.1 (-15.7 to 32.1)	245.5 (160.9 to 343.2)	259.4 (174.3 to 369.3)	5.3 (-15.4 to 32.0)	5.4 (-16.0 to 33.4)
Gout	37.1 (34.9 to 39.6)	40.1 (37.4 to 42.7)	8.1 (-1.9 to 18.6)	0.7 (-8.5 to 10.2)	1.2 (0.8 to 1.6)	1.3 (0.8 to 1.7)	0.7 (-12.9 to 34.3)	0.7 (-18.7 to 25.1)
Other musculoskeletal disorders	1,871.4 (1,492.8 to 2,257.7)	2,098.6 (1,710.8 to 2,526.0)	12.2 (5.0 to 20.4)	6.8 (0.6 to 14.1)	169.3 (111.4 to 243.4)	189.4 (126.0 to 273.9)	11.9 (3.9 to 20.4)	6.8 (0.2 to 14.4)
Other non-communicable diseases	-	-	-	-	998.2 (630.9 to 1,333.4)	913.3 (618.8 to 1,299.8)	-8.6 (-6.5 to 0.6)	-4.6 (-8.4 to -1.6)
Congenital anomalies	-	-	-	-	65.1 (47.9 to 84.1)	65.1 (47.8 to 84.4)	0.0 (-11.1 to 12.8)	10.0 (-2.2 to 24.1)
Neural tube defects	16.2 (13.9 to 19.5)	12.9 (11.2 to 15.0)	-20.3 (-34.3 to -3.3)	-2.8 (-19.7 to 17.9)	5.2 (3.3 to 7.4)	4.1 (2.7 to 5.7)	-20.4 (-41.2 to 6.1)	-2.4 (-28.1 to 30.2)
Congenital heart anomalies	263.5 (232.6 to 298.7)	297.6 (256.9 to 354.2)	12.7 (-6.2 to 41.0)	27.7 (6.9 to 59.3)	9.2 (4.0 to 15.6)	10.6 (4.4 to 18.6)	13.7 (6.1 to 39.7)	31.1 (9.1 to 59.6)
Crofacial clefts	41.3 (33.0 to 49.7)	49.7 (41.0 to 61.0)	20.3 (-12.3 to 60.8)	31.1 (-4.1 to 75.4)	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.7)	-11.8 (-41.7 to 26.6)	-3.7 (-36.7 to 31.1)
Down syndrome	65.4 (54.2 to 81.9)	72.4 (61.6 to 87.4)	11.9 (-14.9 to 40.4)	19.7 (-8.4 to 49.1)	9.2 (6.5 to 12.5)	11.1 (8.0 to 14.6)	21.2 (9.3 to 57.2)	24.6 (-6.2 to 59.9)
Turner syndrome	1.8 (1.3 to 2.6)	1.5 (1.3 to 1.8)	-17.6 (-43.1 to 23.2)	-3.4 (-33.1 to 43.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-16.9 (-44.3 to 28.1)	-4.1 (-36.3 to 47.9)
Klinefelter syndrome	1.2 (0.9 to 1.7)	1.2 (0.9 to 1.7)	2.3 (-37.2 to 46.4)	18.5 (-27.0 to 69.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.3 (-32.2 to 56.9)	18.2 (-27.3 to 69.2)
Chromosomal unbalanced rearrangements	87.4 (72.0 to 109.4)	95.7 (80.4 to 113.8)	10.4 (-15.9 to 40.2)	18.1 (-9.5 to 50.3)	12.2 (8.5 to 16.4)	14.6 (10.3 to 19.5)	20.6 (-10.0 to 57.1)	23.6 (-7.1 to 60.1)
Other congenital anomalies	245.2 (199.0 to 285.7)	192.2 (159.1 to 225.9)	-22.1 (-29.1 to -12.4)	-16.0 (-23.9 to -5.7)	28.8 (20.1 to 40.1)	24.5 (16.5 to 33.6)	-16.0 (-29.0 to 2.6)	-4.0 (-19.4 to 18.3)
Skin and subcutaneous diseases	-	-	-	-	250.3 (163.8 to 367.3)	224.2 (147.3 to 329.7)	-10.6 (-17.8 to -1.7)	-1.5 (-9.4 to 7.6)
Dermatitis	2,293.1 (1,883.6 to 2,710.8)	2,122.9 (1,738.9 to 2,506.0)	-7.5 (-8.8 to -5.8)	-0.0 (-0.1 to 0.0)	59.0 (37.6 to 85.3)	53.7 (33.8 to 77.4)	-9.0 (-12.1 to -5.8)	0.0 (-2.7 to 2.8)
Psoriasis	462.3 (408.1 to 514.9)	448.2 (394.3 to 499.9)	-3.1 (-4.1 to -1.8)	0.0 (-0.1 to 0.1)	37.3 (25.0 to 52.6)	36.0 (24.3 to 50.8)	-3.4 (-4.8 to 1.8)	0.6 (-5.1 to 5.6)
Cellulitis	27.6 (23.4 to 33.1)	24.0 (20.2 to 29.4)	-13.5 (-20.2 to -3.2)	-1.7 (-8.5 to 8.2)	1.7 (1.3 to 2.8)	1.7 (1.1 to 2.5)	-0.0 (-2.7 to 3.2)	0.0 (-1.6 to 20.0)
Pyoderma	41.7 (34.5 to 50.5)	45.8 (37.5 to 56.8)	9.9 (3.3 to 16.1)	20.6 (16.0 to 26.2)	0.2 (0.1 to 0.5)	0.3 (0.1 to 0.6)	9.3 (-0.6 to 20.7)	20.8 (10.2 to 32.5)
Scabies	151.5 (129.8 to 176.4)	134.1 (112.5 to 161.7)	-11.9 (-29.2 to 10.1)	3.5 (-17.4 to 28.8)	3.9 (2.1 to 6.4)	3.4 (1.9 to 5.6)	-12.1 (-29.6 to 10.2)	3.5 (-17.6 to 30.4)
Fungal skin diseases	4,231.1 (3,331.1 to 5,483.4)	3,971.2 (3,111.2 to 5,116.0)	-6.0 (-9.9 to -2.9)	0.2 (0.1 to 0.3)	23.7 (9.5 to 51.3)	22.2 (8.8 to 48.0)	-6.3 (-10.0 to -2.9)	0.3 (-0.6 to 1.3)
Viral skin diseases	1,012.6 (776.2 to 1,250.4)	814.4 (595.4 to 1,046.4)	-19.7 (-24.2 to -15.5)	-1.7 (-1.6 to 1.8)	13.5 (17.8 to 48.8)	11.7 (14.1 to 39.7)	-1.7 (-24.7 to -15.5)	0.2 (-2.7 to 3.2)
Acne vulgaris	1,413.9 (1,087.7 to 1,700.9)	1,156.7 (969.3 to 1,397.7)	-17.9 (-36.7 to 9.5)	-4.2 (-20.8 to 41.6)	15.3 (7.1 to 30.0)	12.6 (5.8 to 23.7)	-17.9 (-36.9 to 10.1)	4.5 (-21.2 to 42.6)
Alopecia areata	65.6 (56.5 to 73.9)	64.7 (56.0 to 73.5)	-1.5 (-17.4 to 19.4)	0.5 (-14.5 to 20.0)	2.2 (1.3 to 3.3)	2.1 (1.3 to 3.3)	-1.9 (-19.1 to 21.6)	0.8 (-17.1 to 23.1)
Pruritus	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	0.7 (-23.7 to 23.2)	0.5 (-21.7 to 24.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.7 (-23.8 to 23.2)	0.5 (-21.9 to 24.4)
Urticaria	870.1 (648.2 to 1,074.8)	718.1 (522.0 to 931.1)	-18.5 (-44.9 to 27.5)	-11.3 (-39.0 to 38.7)	51.1 (30.2 to 76.6)	42.2 (25.0 to 64.1)	-18.2 (-45.0 to 27.7)	-10.6 (-38.6 to 41.6)
Decubitus ulcer	7.7 (6.2 to 10.0)	12.1 (9.0 to 16.0)	59.8 (8.0 to 119.8)	38.6 (-3.5 to 84.1)	1.1 (0.7 to 1.7)	1.8 (1.1 to 2.6)	55.1 (3.9 to 122.3)	36.5 (-5.4 to 87.5)
Other skin and subcutaneous diseases	4,012.1 (2,341.2 to 6,916.6)	3,984.2 (2,223.8 to 6,965.0)	-1.2 (-7.8 to 5.7)	-2.6 (-7.0 to 1.8)	23.4 (9.2 to 52.5)	23.2 (9.0 to 53.6)	-1.3 (-8.2 to 5.7)	-2.5 (-6.8 to 2.1)
Sense organ diseases	-	-	-	-	497.0 (330.6 to 718.7)	495.9 (337.9 to 710.9)	-0.1 (-5.3 to 5.1)	-9.5 (-14.1 to -5.5)
Glaucoma	76.9 (60.7 to 95.4)	74.5 (60.6 to 89.0)	-3.3 (-19.4 to 18.6)	-13.5 (-37.0 to 5.1)	4.6 (2.9 to 6.7)	4.8 (3.1 to 6.9)	5.2 (-14.8 to 27.7)	-10.6 (-25.9 to 7.9)
Cataract	761.0 (586.2 to 936.8)	679.9 (498.1 to 865.6)	-10.2 (-26.0 to 3.0)	-25.9 (-38.8 to -15.5)	29.1 (18.0 to 43.5)	26.3 (15.8 to 40.3)	-8.8 (-23.9 to 3.6)	-26.2 (-37.7 to -16.2)
Macular degeneration	192.6 (144.7 to 257.4)	238.7 (176.3 to 309.9)	24.7 (-8.6 to 58.6)	11.2 (-16.8 to 41.4)	7.0 (4.2 to 10.7)	8.7 (5.2 to 13.3)	24.7 (-6.6 to 58.4)	9.7 (-18.1 to 38.2)
Uncorrected refractive error	5,369.3 (4,873.0 to 5,789.3)	5,615.4 (5,119.5 to 6,114.8)	4.5 (-6.1 to 17.1)	-1.5 (-11.5 to 10.3)	85.2 (49.4 to 138.1)	82.9 (48.0 to 138.1)	-3.0 (-10.6 to 6.3)	-7.6 (-14.6 to 0.5)
Age-related and other hearing loss	10,963.2 (9,706.6 to 12,025.2)	11,051.4 (9,885.6 to 12,061.4)	0.7 (-3.0 to 4.9)	-7.6 (-11.0 to -3.6)	322.8 (216.3 to 459.7)	331.9 (225.7 to 470.5)	3.0 (-4.6 to 10.6)	-9.1 (-15.5 to -3.0)
Other vision loss	338.0 (280.3 to 407.8)	242.9 (198.3 to 288.9)	-27.6 (-38.6 to -17.1)	-27.6 (-38.7 to -19.0)	15.2 (9.9 to 22.5)	11.4 (7.4 to 16.6)	-24.8 (-35.7 to -14.0)	-28.9 (-38.8 to -19.2)
Other sense organ diseases	1,262.1 (1,206.2 to 1,318.6)	1,150.6 (1,093.9 to 1,204.4)	-8.8 (-14.9 to -2.6)	-0.0 (-6.8 to 6.3)	33.1 (20.7 to 49.0)	30.0 (18.6 to 44.6)	-9.5 (-15.8 to -2.2)	-0.1 (-7.0 to 7.8)
Oral disorders	-	-	-	-	125.7 (77.3 to 190.4)	128.5 (80.3 to 194.6)	2.2 (-1.3 to 6.4)	-2.3 (-5.5 to 1.6)
Deciduous caries	2,717.9 (2,582.6 to 2,841.0)	1,567.8 (1,493.9 to 1,646.8)	-					

Appendix Table G.4 - Ukraine prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.								
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Other oral disorders	980.1 (927.2 to 1,039.8)	931.3 (876.9 to 978.1)	-4.9 (-12.6 to 2.5)	-4.1 (-8.1 to 7.8)	28.6 (18.1 to 42.6)	27.1 (16.9 to 40.7)	-5.1 (-13.4 to 3.0)	-8.1 (-8.2 to 8.6)
Injuries	-	-	-	-	435.8 (325.3 to 563.9)	300.3 (219.8 to 398.7)	-31.2 (-35.3 to -26.8)	-35.0 (-38.7 to -30.7)
Transport injuries	-	-	-	-	144.5 (108.0 to 188.0)	68.0 (49.0 to 90.2)	-53.1 (-56.7 to -49.0)	-54.9 (-58.4 to -51.0)
Road injuries	-	-	-	-	119.2 (89.2 to 154.3)	53.0 (38.2 to 70.9)	-55.6 (-59.3 to -51.6)	-57.4 (-60.9 to -53.5)
Pedestrian road injuries	-	-	-	-	25.6 (19.1 to 33.3)	11.9 (8.5 to 16.0)	-53.4 (-58.0 to -48.2)	-56.4 (-60.9 to -51.5)
Cyclist road injuries	-	-	-	-	18.5 (13.5 to 24.2)	8.3 (5.9 to 11.1)	-55.0 (-58.9 to -50.7)	-56.5 (-60.2 to -52.4)
Motorcyclist road injuries	-	-	-	-	11.5 (8.5 to 15.2)	4.4 (3.1 to 5.9)	-62.2 (-66.2 to -57.9)	-63.1 (-67.1 to -58.9)
Motor vehicle road injuries	-	-	-	-	62.1 (46.2 to 79.7)	27.9 (20.3 to 37.5)	-55.1 (-59.5 to -50.0)	-56.7 (-61.0 to -51.7)
Other road injuries	-	-	-	-	1.5 (1.1 to 2.0)	0.5 (0.3 to 0.6)	-69.0 (-72.0 to -65.7)	-70.0 (-72.8 to -66.8)
Other transport injuries	-	-	-	-	25.3 (18.6 to 33.2)	15.0 (10.8 to 19.9)	-41.0 (-45.8 to -35.3)	-42.7 (-47.3 to -37.3)
Unintentional injuries	-	-	-	-	278.9 (207.6 to 362.6)	223.8 (164.8 to 296.9)	-19.9 (-24.0 to -15.6)	-24.6 (-28.3 to -20.6)
Falls	-	-	-	-	121.3 (90.6 to 157.9)	103.7 (75.9 to 138.1)	-14.6 (-20.5 to -8.2)	-22.2 (-27.5 to -16.0)
Drowning	-	-	-	-	4.6 (3.4 to 6.1)	2.3 (1.6 to 3.0)	-51.5 (-56.1 to -45.4)	-52.5 (-56.9 to -46.6)
Fire, heat, and hot substances	-	-	-	-	12.2 (9.2 to 15.7)	9.4 (6.8 to 12.8)	-23.3 (-30.9 to -15.4)	-23.8 (-31.2 to -16.0)
Poisonings	-	-	-	-	1.6 (1.2 to 2.2)	0.9 (0.6 to 1.2)	-46.3 (-53.1 to -38.4)	-43.2 (-50.7 to -34.0)
Exposure to mechanical forces	-	-	-	-	73.2 (54.9 to 95.5)	50.8 (36.9 to 68.0)	-30.7 (-34.7 to -26.6)	-31.3 (-35.0 to -27.6)
Unintentional firearm injuries	-	-	-	-	1.3 (1.0 to 1.6)	0.6 (0.5 to 0.8)	-49.2 (-55.1 to -42.0)	-48.0 (-53.9 to -40.7)
Unintentional suffocation	-	-	-	-	0.7 (0.5 to 0.9)	0.5 (0.4 to 0.7)	-30.4 (-36.3 to -22.8)	-30.9 (-36.7 to -23.1)
Other exposure to mechanical forces	-	-	-	-	71.2 (53.3 to 92.9)	49.6 (36.0 to 66.5)	-30.3 (-34.3 to -26.3)	-31.0 (-34.8 to -27.2)
Adverse effects of medical treatment	-	-	-	-	0.8 (0.5 to 1.1)	0.8 (0.5 to 1.2)	5.6 (-1.2 to 13.1)	2.0 (-4.4 to 9.1)
Animal contact	-	-	-	-	3.6 (2.7 to 4.7)	3.2 (2.3 to 4.2)	-12.9 (-18.6 to -6.9)	-11.5 (-17.4 to -5.6)
Venomous animal contact	-	-	-	-	1.2 (0.8 to 1.5)	1.0 (0.7 to 1.4)	-11.1 (-19.7 to -1.2)	-8.2 (-17.6 to 2.5)
Non-venomous animal contact	-	-	-	-	2.5 (1.8 to 3.3)	2.1 (1.5 to 2.9)	-13.8 (-19.9 to -7.2)	-13.3 (-19.2 to -7.0)
Foreign body	-	-	-	-	3.8 (2.9 to 4.8)	3.1 (2.3 to 4.0)	-19.5 (-25.3 to -13.8)	-19.7 (-25.4 to -14.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	1.6 (1.2 to 2.0)	1.1 (0.8 to 1.5)	-29.6 (-36.8 to -20.4)	-30.1 (-37.5 to -21.6)
Foreign body in eyes	-	-	-	-	0.7 (0.4 to 1.0)	0.6 (0.4 to 0.9)	-9.5 (-15.0 to -4.1)	-5.7 (-11.9 to 0.0)
Foreign body in other body part	-	-	-	-	1.6 (1.2 to 2.0)	1.4 (1.0 to 1.8)	-13.6 (-20.6 to -6.6)	-15.4 (-22.0 to -8.6)
Other unintentional injuries	-	-	-	-	57.7 (42.5 to 75.1)	49.7 (36.3 to 66.4)	-14.0 (-19.6 to -7.7)	-19.5 (-24.7 to -13.7)
Self-harm and interpersonal violence	-	-	-	-	12.4 (9.3 to 15.9)	8.5 (6.1 to 11.2)	-31.8 (-36.7 to -26.3)	-33.6 (-38.4 to -28.1)
Self-harm	-	-	-	-	5.7 (4.2 to 7.4)	4.5 (3.2 to 6.0)	-21.5 (-28.1 to -14.5)	-23.0 (-29.6 to -16.2)
Interpersonal violence	-	-	-	-	6.7 (5.1 to 8.6)	4.0 (2.9 to 5.3)	-40.5 (-45.6 to -34.8)	-42.4 (-47.3 to -37.0)
Assault by firearm	-	-	-	-	0.6 (0.4 to 0.7)	0.3 (0.2 to 0.4)	-44.5 (-48.5 to -39.8)	-46.0 (-49.9 to -41.3)
Assault by sharp object	-	-	-	-	1.1 (0.8 to 1.4)	0.7 (0.5 to 1.0)	-35.8 (-41.2 to -28.8)	-38.0 (-43.2 to -31.3)
Assault by other means	-	-	-	-	5.1 (3.9 to 6.5)	3.0 (2.2 to 3.9)	-41.2 (-46.5 to -35.3)	-43.0 (-48.1 to -37.3)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - United Arab Emirates prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	166.3 (122.8 to 216.7)	896.7 (664.9 to 1,160.1)	439.4 (416.9 to 462.1)	-0.4 (-3.7 to 3.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	21.9 (14.8 to 30.8)	73.5 (50.7 to 101.9)	237.5 (185.8 to 289.9)	-13.6 (-25.8 to 21.3)
HIV/AIDS and tuberculosis	-	-	-	-	0.2 (0.1 to 0.2)	0.6 (0.3 to 1.7)	204.7 (92.6 to 976.4)	-32.4 (-49.0 to 3,349.1)
Tuberculosis	0.5 (0.4 to 0.5)	0.5 (0.5 to 0.6)	13.2 (4.8 to 31.4)	-53.8 (-59.0 to -47.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	15.7 (8.7 to 52.6)	-55.0 (-62.5 to -45.6)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.1 to 1.5)	2,854.1 (1,013.0 to 48,025.6)	396.1 (95.3 to 143,422.4)
HIV/AIDS resulting in mycobacterial infection	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
HIV/AIDS resulting in other diseases	0.1 (0.0 to 0.2)	2.9 (1.6 to 5.7)	2,850.5 (1,127.1 to 25,395.7)	369.1 (101.5 to 56,924.2)	0.0 (0.0 to 0.0)	0.5 (0.1 to 1.5)	2,854.1 (1,013.0 to 48,025.6)	396.1 (95.3 to 143,422.4)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	2.8 (2.8 to 5.6)	14.3 (9.9 to 19.6)	249.3 (215.9 to 285.3)	-13.6 (-20.5 to -6.6)
Diarrheal diseases	17.1 (15.6 to 18.6)	58.0 (52.8 to 63.2)	239.3 (201.5 to 284.2)	-9.4 (-19.1 to 0.5)	4.1 (1.9 to 3.9)	9.4 (6.3 to 13.1)	238.0 (198.8 to 286.7)	-8.2 (-18.9 to 1.1)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	192.3 (88.5 to 343.1)	-33.5 (-56.0 to -7.7)
Typhoid fever	0.1 (0.1 to 0.2)	0.5 (0.4 to 0.6)	226.1 (133.9 to 360.8)	-26.3 (-42.7 to -2.7)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	229.1 (129.9 to 374.1)	-25.9 (-44.7 to 0.6)
Paratyphoid fever	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.3)	236.7 (140.3 to 389.1)	-23.7 (-39.3 to 4.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	238.1 (138.2 to 391.4)	-23.4 (-40.6 to 5.5)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.4 (-76.4 to 484.8)	-77.0 (-94.8 to 26.6)
Lower respiratory infections	0.4 (0.3 to 0.5)	1.1 (0.8 to 1.4)	201.1 (119.3 to 290.4)	-5.1 (-29.7 to 16.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	204.8 (114.7 to 330.3)	5.7 (-32.7 to 22.8)
Upper respiratory infections	36.2 (32.4 to 40.4)	175.5 (153.2 to 201.1)	384.4 (312.3 to 477.6)	-2.2 (-16.1 to 15.1)	0.4 (0.2 to 0.7)	2.1 (1.1 to 3.7)	384.9 (309.7 to 476.1)	-2.0 (-16.7 to 14.1)
Otitis media	20.7 (19.1 to 22.4)	86.1 (77.4 to 94.8)	316.3 (271.7 to 368.5)	-8.6 (-16.8 to 0.5)	0.4 (0.2 to 0.6)	1.6 (0.9 to 2.6)	311.8 (266.7 to 365.7)	-9.6 (-17.6 to -0.4)
Meningitis	-	-	-	-	0.3 (0.2 to 0.5)	0.6 (0.4 to 1.0)	101.8 (56.7 to 180.8)	-62.0 (-69.2 to -47.7)
Pneumococcal meningitis	0.9 (0.5 to 1.6)	1.8 (1.1 to 3.2)	102.3 (50.6 to 184.0)	-62.2 (-70.6 to -48.6)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	126.6 (65.5 to 206.2)	-67.6 (-67.9 to -45.0)
H influenzae type B meningitis	0.5 (0.2 to 1.2)	0.9 (0.3 to 2.0)	83.5 (-2.8 to 285.1)	-66.0 (-80.8 to -34.2)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	95.2 (-4.9 to 361.6)	-63.2 (-80.9 to -22.6)
Meningococcal meningitis	0.3 (0.1 to 0.8)	0.5 (0.2 to 1.4)	71.7 (-24.4 to 298.9)	-66.1 (-82.6 to -26.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	66.2 (-24.8 to 294.6)	-67.0 (-82.4 to -28.3)
Other meningitis	0.6 (0.3 to 1.3)	1.3 (0.7 to 2.8)	122.3 (42.1 to 220.8)	-57.8 (-73.9 to -44.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	123.3 (30.8 to 236.5)	-58.2 (-75.5 to -41.4)
Encephalitis	0.3 (0.1 to 0.9)	1.3 (0.6 to 3.6)	339.2 (278.0 to 434.3)	-33.9 (-25.1 to 25.5)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	354.0 (276.1 to 457.4)	-11.1 (-24.1 to 5.3)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.1 (-88.9 to 1,117.5)	-71.8 (-96.4 to 196.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.1 (-89.0 to 1,123.1)	-71.8 (-96.6 to 198.0)
Whooping cough	0.5 (0.4 to 0.7)	0.8 (0.6 to 1.1)	56.5 (50.8 to 62.3)	-45.2 (-47.2 to -43.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	57.0 (33.6 to 88.4)	-45.0 (-53.3 to -33.8)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-32.9 (-80.0 to 25.4)	-85.0 (-95.4 to -74.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-28.0 (-78.2 to 39.0)	-83.7 (-94.4 to -71.4)
Measles	0.3 (0.2 to 0.3)	0.2 (0.1 to 0.2)	35.2 (-49.0 to -17.1)	-71.1 (-82.0 to -70.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.7 (-6.1 to -0.6)	-77.2 (-86.2 to -64.8)
Varicella and herpes zoster	1.2 (1.1 to 1.3)	4.4 (3.6 to 5.3)	277.9 (205.3 to 369.1)	3.5 (-15.4 to 26.9)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	427.6 (230.7 to 732.2)	4.8 (-27.0 to 51.8)
Neglected tropical diseases and malaria	-	-	-	-	0.7 (0.4 to 1.0)	1.8 (1.1 to 2.7)	156.8 (97.6 to 265.8)	-13.6 (-33.7 to 22.8)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.3 (-67.3 to 82.0)	-86.3 (-94.8 to -70.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	782.9 (256.6 to 1,855.4)	57.9 (-37.2 to 246.2)
Chagas disease	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	373.3 (175.7 to 701.6)	-0.9 (-35.1 to 44.6)
Visceral leishmaniasis	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	260.6 (35.8 to 756.9)	-19.6 (-62.5 to 78.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	259.1 (34.5 to 753.5)	-19.7 (-62.8 to 79.7)
Cutaneous and mucocutaneous leishmaniasis	0.8 (0.6 to 1.2)	4.4 (2.4 to 6.9)	446.4 (142.8 to 815.1)	8.9 (-41.8 to 68.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	442.3 (143.4 to 835.1)	8.4 (-43.8 to 72.0)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-62.3 (-91.3 to 26.2)	-92.0 (-97.8 to -78.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-61.5 (-91.2 to 26.7)	-91.8 (-97.7 to -77.1)
Cystic echinococcosis	0.1 (0.1 to 0.1)	0.3 (0.3 to 0.3)	316.6 (246.3 to 495.9)	-4.2 (-21.7 to 21.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	323.0 (226.3 to 515.3)	-4.8 (-30.9 to 34.9)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.7 (-31.7 to 165.5)	-86.4 (-86.4 to -50.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.7 (-31.7 to 166.0)	-73.4 (-86.4 to -50.2)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	523.7 (357.6 to 689.8)	1.4 (-22.5 to 25.7)
Ascariasis	1.3 (0.9 to 1.8)	-	537.8 (280.8 to 945.7)	0.5 (-40.0 to 64.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)
Trichuriasis	-	-	518.7 (258.9 to 963.1)	-2.5 (-43.5 to 67.5)	-	-	-	-
Hookworm disease	1.3 (1.0 to 1.7)	8.1 (5.9 to 10.9)	532.4 (302.5 to 861.9)	-0.4 (-36.6 to 51.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	533.7 (357.6 to 689.8)	1.4 (-22.5 to 25.7)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	21.1 (16.9 to 25.2)	63.4 (55.9 to 70.5)	200.7 (152.3 to 272.7)	-14.2 (-28.4 to 5.8)	0.7 (0.4 to 1.0)	1.7 (1.0 to 2.5)	150.4 (89.3 to 264.3)	-13.3 (-34.4 to 26.0)
Maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	144.7 (76.7 to 230.8)	-66.4 (-75.4 to -55.1)
Maternal hemorrhage	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	227.2 (192.2 to 249.5)	56.3 (-59.9 to -33.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	222.3 (180.5 to 257.6)	-97.0 (-62.4 to -52.4)
Maternal sepsis and other maternal infections	0.9 (0.6 to 1.3)	1.7 (1.1 to 2.4)	85.1 (25.8 to 209.5)	-70.1 (-78.4 to -54.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.6 (-1.9 to 232.7)	-73.4 (-84.5 to -52.1)
Maternal hypertensive disorders	0.7 (0.3 to 1.4)	2.0 (0.6 to 3.7)	161.2 (97.0 to 244.8)	-64.6 (-73.3 to -52.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	162.3 (88.4 to 262.9)	-64.4 (-74.7 to -51.1)
Obstructed labor	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	112.6 (28.4 to 269.0)	-71.6 (-82.6 to -49.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.4 (-27.7 to 413.0)	-71.2 (-89.4 to -34.3)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	142.7 (39.0 to 317.6)	-67.1 (-80.7 to -42.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	142.7 (38.9 to 320.6)	-67.1 (-80.8 to -41.5)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	154.4 (13.0 to 438.4)	-65.0 (-84.4 to -27.0)
Neonatal disorders	-	-	-	-	2.3 (1.5 to 3.3)	11.4 (7.9 to 16.3)	407.5 (251.0 to 630.5)	0.7 (-29.4 to 43.7)
Preterm birth complications	7.2 (5.1 to 9.8)	42.3 (31.4 to 57.5)	492.4 (374.2 to 648.9)	13.9 (-8.4 to 45.3)	0.9 (0.6 to 1.3)	6.1 (4.2 to 8.5)	549.9 (381.9 to 826.1)	26.3 (-5.3 to 75.9)
Neonatal encephalopathy due to birth asphyxia and trauma	2.3 (1.2 to 4.2)	6.9 (4.3 to 11.9)	195.9 (50.2 to 467.9)	-40.6 (-69.6 to -11.2)	0.8 (0.4 to 1.4)	2.5 (1.5 to 3.9)	216.6 (51.9 to 562.2)	-35.1 (-69.2 to 33.9)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.4 (3.7 to 170.4)	-41.0 (-43.2 to -4.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.5 (5.9 to 186.3)	-39.2 (-62.4 to 1.6)
Hemolytic disease and other neonatal jaundice	0.4 (0.2 to 0.7)	1.3 (0.5 to 2.8)	249.1 (12.1 to 815.0)	-30.7 (-76.4 to 81.9)	0.2 (0.1 to 0.3)	0.6 (0.2 to 1.3)	253.2 (12.2 to 840.9)	-30.4 (-76.4 to 84.4)
Other neonatal disorders	-	-	-	-	0.4 (0.1 to 0.8)	2.3 (1.0 to 5.5)	514.9 (136.3 to 1,405.9)	25.6 (-52.8 to 204.3)
Nutritional deficiencies	-	-	-	-	13.5 (8.6 to 20.0)	40.1 (25.9 to 58.9)	199.9 (130.8 to 276.0)	-18.7 (-34.6 to 0.9)
Protein-energy malnutrition	13.3 (4.5 to 28.4)	30.1 (10.6 to 65.0)	122.1 (-35.4 to 735.8)	-21.5 (-77.1 to 195.8)	1.7 (0.5 to 3.8)	3.8 (1.2 to 8.8)	122.5 (-36.7 to 747.2)	21.4 (-77.6 to 199.9)
Iodine deficiency	45.5 (22.3 to 75.7)	179.9 (83.2 to 304.3)	285.0 (82.4 to 838.6)	-37.4 (-69.5 to 47.6)	0.8 (0.4 to 1.6)	3.2 (1.3 to 6.3)	286.6 (81.4 to 851.3)	-37.5 (-69.7 to 49.0)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-

Appendix Table G.4 - United Arab Emirates prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	346.9 (336.7 to 356.7)	1,264.4 (1,241.8 to 1,287.5)	264.4 (254.2 to 276.8)	-16.3 (-19.0 to -13.2)	10.0 (6.6 to 14.5)	20.9 (20.4 to 45.1)	207.9 (192.3 to 227.4)	207.9 (-20.9 to -10.9)
Other nutritional deficiencies	-	-	-	-	1.0 (0.2 to 2.8)	2.3 (0.5 to 6.5)	127.5 (43.7 to 850.8)	127.5 (80.0 to 236.4)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.1 (0.7 to 1.7)	5.0 (3.0 to 8.0)	342.0 (235.6 to 488.6)	-14.5 (-31.8 to 4.8)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.5 (0.3 to 0.8)	2.9 (1.4 to 5.2)	518.7 (259.3 to 893.9)	-11.4 (-45.7 to 31.9)
Syphilis	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	211.2 (128.1 to 393.9)	-40.3 (-50.3 to -22.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	225.5 (114.7 to 466.9)	225.5 (55.6 to -7.1)
Chlamydial infection	41.5 (26.9 to 58.7)	266.7 (162.1 to 377.3)	536.9 (271.4 to 1,020.3)	-4.5 (-4.2 to 6.2)	0.3 (0.1 to 0.5)	1.7 (0.7 to 3.5)	510.5 (135.4 to 1,151.5)	-13.4 (-64.6 to 69.2)
Gonococcal infection	12.9 (8.8 to 16.8)	75.8 (58.6 to 92.9)	484.5 (297.1 to 770.2)	-13.5 (-43.3 to 30.1)	0.1 (0.0 to 0.2)	0.7 (0.4 to 1.1)	610.9 (362.8 to 939.1)	0.4 (-33.6 to 47.4)
Trichomoniasis	7.7 (4.0 to 10.3)	41.7 (26.9 to 61.8)	443.2 (196.8 to 1,104.6)	-25.4 (-57.3 to 60.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	419.3 (81.4 to 1,194.0)	-28.9 (-71.6 to 81.3)
Genital herpes	243.6 (223.3 to 259.5)	1,483.6 (1,387.5 to 1,589.4)	509.2 (456.4 to 574.4)	-3.3 (-11.5 to 6.4)	0.1 (0.0 to 0.2)	0.4 (0.1 to 1.0)	312.5 (44.1 to 587.1)	-3.4 (-13.1 to 6.8)
Other sexually transmitted diseases	0.3 (0.2 to 0.4)	1.5 (1.1 to 1.9)	418.0 (332.2 to 569.2)	-14.1 (-29.6 to 10.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	559.9 (329.3 to 951.6)	4.7 (-27.6 to 50.9)
Hepatitis	-	-	-	-	0.2 (0.1 to 0.3)	0.7 (0.5 to 1.1)	354.9 (239.6 to 535.5)	-24.1 (-41.4 to 2.3)
Hepatitis A	1.9 (1.8 to 2.0)	8.9 (8.6 to 9.2)	374.4 (370.4 to 377.9)	-0.4 (-0.5 to -0.4)	0.0 (0.0 to 0.1)	0.3 (0.2 to 0.4)	461.4 (378.1 to 552.3)	0.1 (-11.9 to 13.4)
Hepatitis B	158.5 (122.7 to 206.1)	608.4 (410.4 to 814.9)	278.5 (154.1 to 407.2)	-34.4 (-54.5 to -0.2)	0.1 (0.0 to 0.2)	0.4 (0.2 to 0.6)	268.7 (115.3 to 604.1)	-41.3 (-63.0 to 4.9)
Hepatitis C	84.1 (71.5 to 96.0)	341.1 (296.3 to 393.6)	303.8 (230.4 to 396.1)	-26.0 (-36.3 to -13.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	242.2 (117.5 to 437.9)	-26.1 (-67.3 to 4.4)
Hepatitis E	0.3 (0.2 to 0.4)	2.4 (1.7 to 3.5)	803.6 (454.6 to 1,515.2)	40.8 (-10.7 to 138.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	836.5 (429.5 to 1,675.1)	42.6 (-14.5 to 154.6)
Leprosy	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	188.3 (-8.7 to 951.1)	-24.7 (-65.6 to 188.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	224.1 (-8.6 to 2,184.1)	-16.0 (-65.3 to 495.7)
Other infectious diseases	16.1 (13.3 to 19.0)	52.0 (44.9 to 59.8)	223.1 (171.3 to 290.3)	-16.1 (-30.5 to 1.5)	0.5 (0.3 to 0.7)	1.4 (0.8 to 2.1)	173.0 (93.2 to 270.0)	-14.6 (-38.7 to 15.0)
Non-communicable diseases	-	-	-	-	137.8 (102.0 to 179.0)	802.3 (595.2 to 1,031.6)	482.6 (458.0 to 507.8)	2.9 (-0.6 to 6.3)
Neoplasms	-	-	-	-	0.6 (0.4 to 0.8)	2.5 (1.6 to 3.5)	318.7 (196.8 to 509.0)	0.4 (-26.0 to 35.0)
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	155.9 (49.4 to 348.4)	-20.8 (-53.8 to 37.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	153.0 (52.6 to 336.2)	-19.5 (-49.6 to 35.6)
Stomach cancer	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	137.4 (53.5 to 267.9)	-26.6 (-50.8 to 3.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	138.0 (47.6 to 273.7)	-26.8 (-53.4 to 5.2)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	381.6 (193.9 to 695.8)	57.1 (-0.3 to 137.7)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	649.5 (202.1 to 1,666.5)	111.3 (-17.9 to 428.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	599.3 (193.4 to 1,472.1)	95.6 (-19.8 to 357.8)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	1,285.5 (362.3 to 3,588.9)	366.9 (88.3 to 868.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,172.0 (337.0 to 3,230.0)	312.8 (80.8 to 766.9)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.0 (-62.5 to 264.9)	-39.8 (-78.8 to 42.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.5 (-62.8 to 215.1)	-43.5 (-79.3 to 28.8)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	234.3 (32.3 to 736.0)	-27.7 (-65.2 to 134.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	211.1 (25.6 to 679.4)	-15.4 (-67.7 to 116.5)
Larynx cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	85.7 (2.8 to 235.2)	-30.5 (-60.5 to 18.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.9 (2.2 to 246.2)	-30.3 (-61.4 to 21.0)
Tracheal, bronchus and lung cancer	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	153.6 (56.7 to 338.4)	-11.8 (-42.9 to 35.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	155.3 (51.7 to 337.9)	-12.0 (-45.3 to 37.0)
Breast cancer	1.0 (0.6 to 1.6)	5.3 (3.2 to 8.4)	433.6 (206.3 to 908.8)	12.5 (-32.2 to 92.9)	0.1 (0.0 to 0.1)	0.4 (0.2 to 0.7)	414.6 (195.6 to 868.2)	6.3 (-36.5 to 82.6)
Cervical cancer	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.8)	127.6 (24.7 to 357.7)	-12.8 (-72.8 to -16.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	41.1 (18.5 to 363.0)	-51.1 (-71.4 to -13.3)
Uterine cancer	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.9)	155.9 (33.6 to 493.2)	-34.2 (-66.1 to 30.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	157.9 (26.6 to 497.3)	-36.0 (-68.6 to 25.5)
Prostate cancer	0.3 (0.1 to 0.6)	1.5 (0.7 to 3.1)	487.5 (214.2 to 965.0)	147.0 (38.7 to 308.9)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.3)	373.5 (164.5 to 710.4)	109.2 (24.0 to 227.7)
Colon and rectum cancer	1.1 (0.9 to 1.3)	3.6 (2.7 to 4.7)	232.8 (144.0 to 372.4)	-31.4 (-46.0 to -12.3)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	221.2 (129.8 to 356.5)	-33.7 (-48.5 to -14.7)
Lip and oral cavity cancer	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.6)	203.8 (74.7 to 447.4)	-16.0 (-50.2 to 39.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	202.1 (72.5 to 449.5)	-16.4 (-50.4 to 37.7)
Nasopharynx cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	179.9 (38.1 to 463.2)	-39.4 (-67.6 to 15.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	174.7 (35.2 to 447.5)	-40.5 (-67.7 to 15.3)
Other pharynx cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	136.6 (19.2 to 377.7)	-37.6 (-67.1 to 18.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	134.0 (21.6 to 377.7)	-38.4 (-66.8 to 16.5)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	168.5 (64.2 to 436.1)	-21.5 (-52.2 to 41.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	159.7 (58.3 to 410.6)	-24.0 (-54.0 to 41.1)
Pancreatic cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	243.0 (108.3 to 455.1)	3.7 (-33.9 to 53.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	243.5 (126.4 to 439.0)	2.0 (-33.6 to 47.5)
Malignant skin melanoma	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	357.6 (166.7 to 696.9)	6.1 (-39.8 to 49.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	336.6 (159.8 to 665.6)	9.9 (-42.5 to 42.3)
Non-melanoma skin cancer	0.1 (0.1 to 0.2)	0.6 (0.4 to 0.9)	464.4 (236.4 to 903.9)	32.4 (-16.9 to 151.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	576.3 (321.1 to 1,070.5)	49.4 (-6.5 to 140.2)
Ovarian cancer	0.1 (0.1 to 0.1)	0.4 (0.2 to 0.6)	315.3 (128.8 to 697.7)	-17.2 (-52.4 to 46.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	308.2 (113.9 to 688.3)	-20.8 (-55.3 to 43.5)
Testicular cancer	0.2 (0.1 to 0.3)	1.7 (0.9 to 3.1)	760.7 (322.6 to 1,762.3)	29.7 (-30.4 to 158.0)	0.0 (0.0 to 0.0)	0.2 (0.0 to 0.2)	744.9 (274.6 to 1,750.2)	29.3 (-33.7 to 152.8)
Kidney cancer	0.5 (0.1 to 0.2)	1.0 (0.5 to 1.1)	119.6 (161.4 to 650.4)	-25.1 (-28.4 to 93.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	106.2 (148.8 to 640.3)	-30.9 (-32.4 to 86.8)
Bladder cancer	0.3 (0.3 to 0.7)	1.0 (0.7 to 1.5)	376.4 (28.2 to 279.9)	9.5 (-54.4 to 13.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	391.8 (20.0 to 247.1)	8.4 (-57.5 to 2.0)
Brain and nervous system cancer	0.2 (0.1 to 0.4)	1.7 (0.6 to 2.7)	580.7 (197.0 to 630.4)	73.7 (-27.3 to 59.9)	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.2)	567.9 (204.0 to 688.5)	62.0 (-30.6 to 62.2)
Thyroid cancer	0.5 (0.3 to 0.8)	2.5 (1.6 to 3.8)	460.7 (166.1 to 984.6)	2.0 (-47.0 to 86.4)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.2)	440.1 (162.5 to 985.6)	-0.7 (-48.9 to 82.2)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	278.5 (66.1 to 359.4)	-29.7 (-58.1 to 11.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	180.4 (63.3 to 361.3)	-27.9 (-57.6 to 15.8)
Hodgkin lymphoma	0.1 (0.1 to 0.2)	0.7 (0.4 to 1.1)	390.7 (152.4 to 911.6)	-7.7 (-48.1 to 76.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	368.2 (119.5 to 899.2)	-11.8 (-49.2 to 71.2)
Non-Hodgkin lymphoma	0.6 (0.4 to 0.9)	3.8 (2.5 to 5.5)	520.9 (270.2 to 917.9)	39.9 (-15.9 to 116.5)	0.0 (0.0 to 0.1)	0.3 (0.2 to 0.4)	510.0 (262.5 to 922.0)	35.0 (-18.0 to 109.7)
Multiple myeloma	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	310.2 (122.2 to 652.9)	15.7 (-32.8 to 95.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	297.9 (113.8 to 624.5)	11.6 (-39.9 to 89.6)
Leukemia	0.5 (0.3 to 0.6)	1.9 (1.4 to 2.7)	423.8 (183.9 to 540.7)	6.1 (-25.5 to 50.7)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	356.1 (203.4 to 608.6)	6.5 (-26.8 to 56.2)
Other neoplasms	0.5 (0.4 to 0.9)	3.6 (2.3 to 5.5)	580.7 (281.1 to 1,039.1)	73.7 (2.2 to 162.1)	0.2 (0.0 to 0.1)	0.2 (0.1 to 0.4)	567.9 (265.5 to 1,035.9)	62.0 (-3.0 to 147.7)
Cardiovascular diseases	-	-	-	-	2.3 (1.5 to 3.3)	11.2 (7.3 to 16.2)	387.4 (259.3 to 537.4)	4.4 (-16.4 to 27.8)
Rheumatic heart disease	4.6 (3.4 to 6.0)	25.0 (18.7 to 31.2)	452.4 (292.2 to 700.4)	-1.7 (-31.5 to 32.7)	0.2 (0.1 to 0.4)	1.3 (0.8 to 2.0)	450.6 (295.6 to 730.8)	8.6 (-19.9 to 58.1)
Ischemic heart disease	5.5 (4.5 to 7.0)	13.4 (12.0 to 15.6)	147.9 (90.2 to 211.4)	-9.1 (-29.2 to 16.2)	0.3 (0.2 to 0.5)	2.0 (0.6 to 1.4)	127.7 (101.1 to 277.6)	-5.9 (-33.3 to 30.0)
Cerebrovascular disease	-	-	-	-	0.1 (0.1 to 0.1)	0.4 (0.2 to 0.5)	391.0 (270.7 to 583.5)	4.1 (-19.0 to 33.3)
Ischemic stroke	0.4 (0.3 to 0.5)	1.9 (1.5 to 2.4)	370.8 (264.1 to 565.4)	4.3 (-17.1 to 31.0)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.4)	381.8 (264.3 to 597.7)	3.8 (-19.5 to 32.4)
Hemorrhagic stroke	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.6)	431.3 (231.9 to 687.7)	6.5 (-29.5 to 52.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	430.3 (232.9 to 685.5)	6.4 (-29.2 to 52.7)
Hypertensive heart disease	0.9 (0.7 to 1.1)	3.5 (2.8 to 4.3)	285.0 (181.8 to 431.0)	35.1 (-4.4 to 88.2)	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.6)	286.3 (172.8 to 444.1)	33.0 (-7.7 to 87.2)
Cardiomyopathy and myocarditis	0.7 (1.1 to 1.6)	2.7 (5.7 to 9.9)	271.1 (315.0 to 688.0)	10.7 (-11.5 to 95.2)	0.2 (0.1 to 0.2)	0.2 (0.5 to 1.3)	284.2 (299.9 to 746.9)	11.0 (-12.2 to 95.7)
Atrial fibrillation and flutter	0.7 (0.6 to 1.0)	2.7 (1.7 to 3.7)	271.1 (105.7 to 454.7)	10.7 (-40.0 to 75.4)	0.2 (0.0 to 0.1)	0.2 (0.1 to 0.3)	284.2 (105.7 to 498.9)	11.0 (-40.7 to 77.1)
Peripheral vascular disease	11.3 (7.4 to 15.6)	37.6 (21.3 to 54.0)	246.3 (78.1 to 410.2)	12.5 (-15.2 to 36.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.5 (-32.6 to 161.1)	29.5 (-61.0 to 52.8)
Endocarditis	0.0 (0.0 to 0.1)	0.3 (0.2 to 0.4)	513.5 (317.2 to 824.3)	28.1 (-11.0 to 83.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	524.4 (316.6 to 896.5)	0.0 (-19.3 to 98.3)
Other cardiovascular and circulatory diseases	18.7 (13.2 to 26.6)	98.5 (59.1 to 141.0)	429.9 (208.8 to 739.8)	5.9 (-35.9 to 58.7)	1.3 (0.8 to 2.1)	7.0 (3.8 to 11.0)	438.8 (206.5 to 7	

Appendix Table G.4 - United Arab Emirates prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	353.8	-3.7
Silicosis	0.0	0.0	305.9	-9.6	0.0	0.0	(354.7 to 415.1)	(-7.1 to -0.0)
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	306.0	-9.7
Coal workers pneumoconiosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Other pneumoconiosis	0.0	0.1	433.8	0.5	0.0	0.0	434.2	1.3
Asthma	57.4	272.9	(396.1 to 469.7)	(-4.4 to 5.7)	12.1	12.1	(397.4 to 471.7)	(-3.7 to 6.9)
Interstitial lung disease and pulmonary sarcoidosis	0.1	0.7	398.8	-4.8	0.0	0.1	403.2	-3.2
Other chronic respiratory diseases	-	-	-	-	0.3	2.7	657.4	44.9
Cirrhosis	0.2	0.7	267.4	-8.6	0.1	0.3	(401.4 to 1,133.5)	(-2.1 to 139.1)
Cirrhosis due to hepatitis B	0.2	0.7	267.4	-8.6	0.1	0.3	210.6	-19.8
Cirrhosis due to hepatitis C	0.2	0.1	201.7	-20.5	0.0	0.1	(145.7 to 289.2)	(-30.8 to -7.6)
Cirrhosis due to alcohol use	0.1	0.1	72.9	-44.8	0.0	0.0	273.2	-9.1
Cirrhosis due to other causes	0.1	0.4	205.4	-14.2	0.0	0.1	(58.2 to 728.1)	(-50.7 to 56.7)
Digestive diseases	2.7	4.8	81.2	-38.4	0.1	0.2	(30.7 to 503.3)	(-65.5 to 51.6)
Peptic ulcer disease	1.8	3.4	(25.2 to 160.9)	(-53.7 to -19.2)	0.1	0.2	75.8	44.9
Gastritis and duodenitis	3.6	7.3	104.0	-49.5	0.0	0.3	(-33.4 to 266.2)	(-79.4 to 19.8)
Appendicitis	0.1	0.8	421.4	-17.1	0.0	0.2	212.5	-14.5
Paralytic ileus and intestinal obstruction	0.0	0.1	345.9	5.7	0.0	0.0	14.5	-9.2
Inguinal, femoral, and abdominal hernia	2.5	9.1	267.8	-7.2	0.0	0.1	(167.5 to 744.2)	(-26.6 to 66.7)
Inflammatory bowel disease	1.5	13.6	789.5	48.0	0.3	2.9	272.1	-7.3
Vascular intestinal disorders	0.0	0.0	310.3	-15.3	0.0	0.0	(197.4 to 368.0)	(-31.5 to 21.2)
Gallbladder and biliary diseases	0.4	1.7	324.0	-7.1	0.0	0.2	(642.6 to 970.9)	(-28.6 to 72.4)
Pancreatitis	0.4	2.3	506.2	-8.3	0.1	0.7	315.6	-11.6
Other digestive diseases	-	-	-	-	0.1	0.6	(177.5 to 518.0)	(-42.5 to 48.1)
Neurological disorders	2.5	5.0	102.6	-4.0	0.3	0.7	(210.8 to 505.7)	(-27.3 to 18.7)
Alzheimer disease and other dementias	0.3	1.0	206.0	2.1	0.0	0.1	505.0	-8.7
Parkinson disease	0.2	0.4	(168.3 to 255.9)	(-4.2 to 9.4)	0.0	0.1	(385.1 to 715.7)	(-24.5 to 8.2)
Epilepsy	5.3	31.6	488.4	13.5	2.2	13.0	463.5	-10.1
Multiple sclerosis	0.3	3.8	1,366.0	146.8	0.1	1.3	(312.3 to 669.9)	(-32.4 to 21.8)
Migraine	155.5	776.0	(994.3 to 1,915.4)	(-90.2 to 234.4)	0.1	0.1	508.2	8.1
Tension-type headache	316.8	2,040.3	(245.0 to 557.3)	(-37.7 to -2.5)	0.3	0.9	(403.1 to 639.4)	(-4.8 to 24.4)
Medication overuse headache	13.8	124.3	801.2	50.6	2.2	19.8	98.0	-4.0
Other neurological disorders	0.0	0.0	448.9	6.1	0.2	1.4	(65.5 to 134.3)	(-19.3 to 15.5)
Mental and substance use disorders	5.7	36.5	534.0	-0.4	49.7	315.9	216.2	2.4
Schizophrenia	5.2	32.5	495.9	-4.9	3.7	23.8	(157.9 to 296.3)	(-8.9 to 15.7)
Alcohol use disorders	11.8	75.5	540.4	-6.8	1.2	7.6	498.8	15.4
Drug use disorders	25.7	193.7	665.3	3.5	10.7	81.4	(250.6 to 957.7)	(-31.6 to 100.4)
Opioid use disorders	15.4	113.7	(523.8 to 799.9)	(-11.7 to 20.6)	5.8	17.0	(905.5 to 2,014.4)	(-79.9 to 237.6)
Cocaine use disorders	1.5	10.5	(400.6 to 902.9)	(-26.0 to 39.9)	0.2	0.4	498.8	15.4
Amphetamine use disorders	2.9	17.8	504.7	-13.5	0.4	2.3	546.6	4.5
Cannabis use disorders	3.2	21.7	574.0	0.6	0.1	0.6	(342.3 to 777.3)	(-17.5 to 33.2)
Other drug use disorders	5.7	36.5	534.0	-0.4	49.7	315.9	804.8	51.0
Depressive disorders	68.9	417.2	501.8	2.5	14.3	86.9	(569.4 to 1,087.4)	(-20.7 to 93.2)
Major depressive disorder	18.1	111.7	519.0	-0.2	1.8	10.9	536.2	0.5
Dysthymia	13.9	22.2	(478.7 to 549.5)	(-1.1 to 0.7)	1.1	2.6	(492.8 to 573.9)	(-4.4 to 5.1)
Bipolar disorder	14.0	91.5	554.6	-1.0	2.9	18.9	540.2	0.4
Anxiety disorders	5.7	38.5	473.1	4.0	5.3	30.7	(486.0 to 602.2)	(-7.0 to 6.6)
Eating disorders	0.3	2.1	621.9	17.0	0.1	0.5	543.7	-6.9
Anorexia nervosa	0.2	1.4	520.7	(2.2 to 35.7)	0.0	0.1	652.6	1.6
Bulimia nervosa	0.8	5.4	571.7	-3.9	0.2	1.2	(526.0 to 780.2)	(-12.4 to 17.4)
Autistic spectrum disorders	6.1	33.2	446.6	0.2	1.5	8.2	669.0	3.8
Autism	5.7	31.4	(443.2 to 450.6)	(0.2 to 0.2)	1.0	2.4	(527.6 to 810.8)	(-11.1 to 21.6)
Asperger syndrome	9.4	51.4	447.4	0.3	0.9	5.2	631.8	5.5
Attention-deficit/hyperactivity disorder	8.7	27.5	(264.9 to 283.4)	(0.9 to 1.1)	0.1	0.2	(388.1 to 952.7)	(-28.0 to 47.2)
Conduct disorder	7.3	22.8	(337.5 to 723.7)	(-36.3 to 17.1)	0.2	0.6	500.7	-13.8
Idiopathic intellectual disability	41.2	219.5	432.3	0.3	2.0	10.8	(318.7 to 776.9)	(-38.7 to 22.9)
Other mental and substance use disorders	33.5	223.3	566.5	-0.0	2.5	17.0	572.8	0.6
Diabetes, urogenital, blood, and endocrine diseases	124.2	708.0	473.8	13.5	9.2	51.6	(446.3 to 736.9)	(-14.8 to 19.5)
Diabetes mellitus	100.5	600.0	(345.5 to 614.5)	(-8.5 to 40.5)	6.0	13.2	549.8	-6.9
Acute glomerulonephritis	0.0	0.0	153.9	-35.0	0.0	0.0	(330.2 to 627.3)	(-8.3 to 44.7)
Chronic kidney disease	9.9	50.1	411.5	12.7	0.3	1.6	153.9	35.0
Chronic kidney disease due to diabetes mellitus	6.9	32.1	(225.7 to 637.5)	(-15.3 to 44.4)	0.2	0.4	(128.6 to 177.3)	(-39.0 to -30.9)
Chronic kidney disease due to hypertension	9.3	39.5	323.7	-20.1	0.5	2.7	431.8	0.6
Chronic kidney disease due to glomerulonephritis	15.8	82.2	412.7	4.0	0.3	1.2	(360.6 to 516.9)	(-7.4 to 11.2)
Chronic kidney disease due to other causes	18.4	107.1	470.6	10.5	0.5	3.3	433.6	13.4
Urinary diseases and male infertility	-	-	-	-	1.7	8.8	419.0	-16.4

Appendix Table G.4 - United Arab Emirates prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.3 (0.3 to 0.3)	1.7 (1.6 to 1.8)	469.1 (412.5 to 534.3)	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	467.4 (314.0 to 572.9)	1.9 (-16.1 to 25.6)
Urolithiasis	11.7 (6.9 to 23.1)	79.6 (40.3 to 147.9)	586.1 (343.7 to 856.8)	50.4 (28.5 to 88.8)	0.1 (0.1 to 0.2)	1.0 (0.6 to 1.8)	620.1 (455.4 to 795.6)	59.8 (38.9 to 90.4)
Benign prostatic hyperplasia	6.3 (5.8 to 6.7)	17.9 (16.4 to 19.1)	186.5 (152.3 to 217.9)	20.4 (5.0 to 35.0)	0.2 (0.1 to 0.3)	0.6 (0.4 to 0.9)	188.2 (155.7 to 222.0)	20.8 (5.6 to 35.6)
Male infertility due to other causes	27.7 (20.3 to 38.3)	210.1 (135.9 to 296.9)	652.9 (366.0 to 1,078.4)	-0.9 (-37.9 to 57.1)	0.2 (0.1 to 0.4)	1.9 (0.6 to 3.1)	653.7 (359.6 to 1,142.8)	-1.6 (-39.0 to 62.0)
Other urinary diseases	-	-	-	-	0.1 (0.1 to 0.5)	1.3 (0.6 to 2.7)	95.5 (324.1 to 1,668.1)	14.4 (9.5 to 282.8)
Gynecological diseases	-	-	-	-	1.6 (1.0 to 2.4)	10.5 (6.6 to 15.8)	558.3 (443.8 to 659.5)	9.7 (-4.9 to 23.4)
Uterine fibroids	20.5 (18.2 to 22.5)	125.6 (110.6 to 139.1)	513.2 (503.6 to 521.7)	36.2 (33.7 to 39.0)	0.3 (0.2 to 0.6)	2.0 (1.2 to 3.2)	474.5 (440.7 to 513.5)	13.4 (5.4 to 21.5)
Polycystic ovarian syndrome	27.2 (24.1 to 30.0)	174.2 (153.5 to 193.3)	541.7 (441.8 to 654.2)	7.6 (-6.6 to 23.7)	0.3 (0.1 to 0.5)	1.7 (0.8 to 3.3)	548.4 (448.4 to 662.8)	7.8 (-6.8 to 23.3)
Female infertility due to other causes	4.0 (1.0 to 8.2)	31.2 (8.0 to 63.2)	700.0 (140.1 to 2,676.6)	-	0.0 (0.0 to 0.1)	0.2 (0.0 to 0.4)	697.8 (171.6 to 2,456.4)	14.7 (-58.3 to 239.6)
Endometriosis	2.3 (1.9 to 2.7)	16.2 (13.6 to 19.0)	602.3 (462.9 to 829.4)	16.2 (-4.5 to 50.6)	0.2 (0.1 to 0.3)	1.5 (1.0 to 2.2)	605.0 (452.6 to 847.3)	16.1 (-6.7 to 51.7)
Genital prolapse	54.8 (43.4 to 65.1)	339.4 (246.5 to 418.8)	523.2 (311.7 to 744.8)	7.6 (-21.6 to 33.1)	0.2 (0.1 to 0.3)	1.1 (0.5 to 2.1)	524.4 (313.4 to 762.5)	8.0 (-20.9 to 33.8)
Premenstrual syndrome	55.4 (42.4 to 69.1)	406.6 (261.5 to 538.7)	656.2 (339.1 to 981.7)	12.2 (-28.6 to 56.9)	0.5 (0.3 to 0.7)	3.4 (1.8 to 5.6)	649.6 (336.7 to 983.3)	10.9 (-27.9 to 55.3)
Other gynecological diseases	3.7 (2.7 to 4.6)	19.2 (17.7 to 20.9)	423.8 (319.2 to 606.8)	-8.3 (-26.7 to 23.3)	0.1 (0.1 to 0.2)	0.6 (0.4 to 0.8)	417.4 (319.9 to 788.6)	-10.3 (-26.0 to 54.3)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	3.2 (2.1 to 4.8)	12.5 (8.3 to 18.3)	289.9 (227.5 to 334.4)	0.4 (-16.1 to 10.3)
Thalassemias	1.1 (0.8 to 1.4)	4.6 (3.6 to 5.6)	302.8 (256.7 to 383.2)	0.4 (-9.8 to 18.4)	0.1 (0.0 to 0.1)	0.3 (0.2 to 0.4)	268.3 (176.3 to 396.9)	0.4 (-23.8 to 34.3)
Thalassemia trait	151.4 (127.8 to 173.0)	782.5 (699.4 to 868.0)	414.7 (385.2 to 461.9)	-0.3 (-6.3 to 9.1)	2.4 (1.6 to 3.5)	9.4 (6.2 to 13.7)	301.1 (213.6 to 351.6)	5.4 (-18.3 to 16.8)
Sickle cell disorders	0.3 (0.2 to 0.3)	1.5 (1.1 to 1.7)	469.3 (327.8 to 647.0)	12.8 (-8.0 to 47.2)	0.0 (0.0 to 0.0)	0.2 (0.2 to 0.3)	552.5 (493.8 to 709.5)	14.4 (-4.6 to 39.9)
Sickle cell trait	73.2 (67.6 to 78.1)	385.4 (358.5 to 410.9)	427.2 (398.7 to 447.8)	0.3 (-4.3 to 4.8)	0.3 (0.2 to 0.4)	1.1 (0.7 to 1.6)	293.3 (239.5 to 503.6)	4.9 (-10.8 to 63.3)
G6PD deficiency	153.9 (137.9 to 170.4)	674.4 (595.0 to 772.7)	337.0 (269.9 to 421.1)	-18.2 (-31.0 to -2.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	255.4 (198.8 to 347.0)	-17.5 (-33.9 to 5.7)
G6PD trait	228.4 (222.1 to 234.1)	1,045.5 (1,014.5 to 1,070.5)	357.4 (340.6 to 374.5)	0.7 (-3.0 to 4.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	275.6 (75.0 to 6,246.4)	5.2 (-93.7 to 1,307.9)
Other hemoglobinopathies and hemolytic anemias	18.5 (15.5 to 20.0)	71.0 (65.8 to 76.4)	283.7 (240.8 to 335.6)	-20.6 (-29.6 to -9.3)	0.4 (0.3 to 0.6)	1.3 (0.8 to 2.1)	209.9 (125.0 to 329.6)	-26.1 (-44.9 to 0.6)
Endocrine, metabolic, blood, and immune disorders	20.3 (17.8 to 22.3)	73.6 (69.2 to 77.2)	362.9 (227.7 to 313.4)	-5.3 (-23.5 to -5.3)	0.6 (0.4 to 0.9)	2.0 (1.4 to 2.9)	230.2 (180.2 to 314.5)	-3.5 (-26.3 to 6.6)
Musculoskeletal disorders	-	-	-	-	25.0 (17.5 to 33.8)	150.5 (102.4 to 205.2)	500.9 (426.7 to 576.7)	3.3 (-5.9 to 12.8)
Rheumatoid arthritis	1.9 (1.7 to 2.1)	8.2 (7.4 to 9.2)	333.5 (276.8 to 393.7)	-22.6 (-31.6 to -12.7)	0.5 (0.3 to 0.6)	2.0 (1.4 to 2.8)	337.6 (264.2 to 426.4)	-22.2 (-32.5 to -11.5)
Osteoarthritis	23.5 (21.9 to 25.0)	90.8 (84.1 to 97.7)	287.9 (250.0 to 325.8)	-2.2 (-9.1 to 5.6)	1.5 (1.0 to 2.0)	7.9 (3.9 to 7.9)	291.3 (251.2 to 334.4)	-2.1 (-9.2 to 6.0)
Low back and neck pain	-	-	-	-	20.8 (14.2 to 28.5)	126.8 (85.3 to 175.5)	522.2 (425.4 to 605.1)	1.9 (-9.7 to 15.2)
Low back pain	128.7 (112.0 to 146.7)	791.2 (700.3 to 880.0)	513.7 (411.2 to 640.3)	2.5 (-10.8 to 18.2)	14.6 (9.5 to 20.7)	90.4 (58.9 to 129.8)	517.6 (413.9 to 646.2)	2.5 (-11.0 to 18.7)
Neck pain	62.0 (53.6 to 71.4)	365.0 (280.5 to 431.0)	494.9 (334.0 to 635.9)	0.9 (-18.6 to 19.7)	6.2 (4.1 to 8.7)	36.5 (23.5 to 52.4)	501.1 (336.8 to 642.4)	1.2 (-19.1 to 20.0)
Gout	0.8 (0.6 to 1.0)	3.8 (2.9 to 4.6)	384.3 (242.6 to 548.9)	6.3 (-15.6 to 31.3)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	389.1 (204.6 to 640.5)	5.3 (-24.0 to 40.8)
Other musculoskeletal disorders	25.4 (16.8 to 35.0)	169.2 (113.1 to 233.0)	366.6 (461.4 to 688.6)	21.1 (11.4 to 33.1)	2.3 (1.4 to 3.7)	15.8 (9.1 to 24.9)	216.6 (464.3 to 693.8)	21.6 (11.0 to 34.6)
Other non-communicable diseases	-	-	-	-	24.2 (16.4 to 35.1)	121.4 (81.3 to 176.7)	401.5 (367.2 to 441.5)	-4.4 (-8.5 to 0.4)
Congenital anomalies	-	-	-	-	2.1 (1.5 to 2.9)	14.5 (9.6 to 22.8)	558.9 (441.9 to 840.5)	36.1 (14.5 to 88.0)
Neural tube defects	0.7 (0.6 to 0.9)	3.7 (3.3 to 4.3)	422.2 (321.5 to 532.3)	5.5 (-15.0 to 28.2)	0.2 (0.1 to 0.3)	1.2 (0.8 to 1.6)	438.6 (285.6 to 624.5)	9.5 (-20.4 to 42.3)
Congenital heart anomalies	11.8 (10.0 to 14.2)	78.1 (66.3 to 91.8)	555.8 (426.3 to 743.1)	34.6 (8.2 to 72.8)	0.4 (0.2 to 0.7)	2.9 (1.2 to 5.1)	584.7 (453.5 to 768.3)	41.5 (14.1 to 77.8)
Orofacial clefts	1.5 (1.2 to 2.1)	8.8 (6.7 to 12.0)	485.6 (285.0 to 707.3)	25.7 (-17.2 to 74.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	301.1 (125.3 to 553.3)	-10.6 (-46.3 to 34.2)
Down syndrome	3.3 (2.7 to 4.0)	17.6 (14.3 to 21.0)	436.3 (301.1 to 603.0)	16.8 (-13.1 to 52.2)	0.4 (0.3 to 0.5)	2.0 (1.4 to 2.8)	423.0 (284.8 to 599.2)	21.9 (-9.0 to 60.2)
Turner syndrome	0.0 (0.0 to 0.1)	0.3 (0.2 to 0.4)	399.4 (247.3 to 708.1)	10.1 (-23.2 to 79.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	431.7 (257.1 to 779.9)	11.2 (-24.8 to 79.9)
Klinefelter syndrome	0.1 (0.1 to 0.1)	0.4 (0.3 to 0.5)	439.7 (269.0 to 747.6)	-2.0 (-32.9 to 53.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	537.3 (339.7 to 899.2)	-3.5 (-34.0 to 52.4)
Chromosomal unbalanced rearrangements	2.7 (2.3 to 3.2)	15.1 (11.7 to 20.7)	463.9 (315.4 to 707.7)	47.0 (-11.9 to 71.7)	0.3 (0.2 to 0.4)	1.7 (1.2 to 2.6)	420.6 (298.1 to 684.0)	22.4 (-7.1 to 81.2)
Other congenital anomalies	5.2 (4.3 to 6.1)	26.6 (21.9 to 31.0)	412.9 (343.8 to 512.8)	-8.3 (-19.1 to 7.3)	0.8 (0.5 to 1.2)	6.6 (3.6 to 13.6)	711.5 (418.5 to 1,417.0)	58.0 (4.0 to 195.4)
Skin and subcutaneous diseases	-	-	-	-	10.1 (6.3 to 15.7)	54.8 (34.1 to 85.3)	447.3 (384.4 to 511.5)	1.9 (-7.9 to 11.7)
Dermatitis	112.8 (86.9 to 139.3)	652.9 (483.5 to 812.9)	478.2 (447.0 to 506.9)	-0.2 (-0.5 to 0.1)	3.5 (2.0 to 5.2)	19.1 (10.5 to 29.8)	447.4 (390.8 to 493.5)	-0.0 (-2.8 to 2.8)
Psoriasis	10.9 (8.3 to 14.0)	65.1 (48.4 to 85.6)	495.8 (467.2 to 525.5)	0.1 (-0.5 to 0.6)	0.9 (0.6 to 1.3)	5.4 (3.4 to 8.2)	498.5 (434.5 to 561.5)	0.1 (-5.9 to 6.7)
Cellulitis	0.4 (0.3 to 0.5)	1.5 (1.1 to 2.1)	308.1 (232.4 to 419.6)	-15.1 (-26.7 to -3.5)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	319.0 (179.0 to 508.9)	-14.3 (-33.5 to 7.9)
Pyoderma	1.3 (1.0 to 1.7)	5.1 (3.8 to 7.1)	288.6 (226.1 to 351.4)	-7.4 (-13.3 to 0.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	286.6 (211.2 to 375.6)	-7.4 (-17.8 to 4.3)
Scabies	6.7 (5.4 to 8.7)	35.4 (26.2 to 50.0)	423.6 (233.6 to 753.3)	0.9 (-30.3 to 44.6)	0.2 (0.1 to 0.3)	0.9 (0.4 to 1.6)	422.7 (234.9 to 759.0)	0.7 (-31.0 to 42.7)
Fungal skin diseases	117.1 (86.3 to 149.9)	668.0 (475.3 to 890.3)	488.4 (428.8 to 508.0)	0.1 (-0.1 to 0.4)	0.7 (0.3 to 1.5)	3.8 (1.5 to 8.0)	470.5 (429.4 to 512.0)	0.2 (-0.8 to 1.2)
Viral skin diseases	35.9 (25.7 to 46.0)	160.9 (97.2 to 235.9)	344.2 (257.8 to 421.4)	-0.2 (-2.2 to 2.2)	1.1 (0.6 to 1.8)	5.0 (2.4 to 8.8)	344.0 (257.0 to 423.3)	0.3 (-3.3 to 3.6)
Acne vulgaris	209.8 (156.6 to 266.8)	1,146.1 (785.5 to 1,589.6)	445.8 (219.7 to 795.8)	2.8 (-34.1 to 69.0)	2.3 (1.0 to 4.4)	12.4 (5.2 to 23.7)	445.8 (219.1 to 798.8)	2.8 (-34.0 to 69.6)
Alopecia areata	2.5 (2.0 to 2.9)	13.6 (10.6 to 16.6)	451.1 (310.0 to 597.9)	0.8 (-18.3 to 22.8)	0.1 (0.1 to 0.1)	0.5 (0.3 to 0.7)	452.9 (300.1 to 626.3)	0.7 (-18.5 to 24.5)
Pruritus	0.4 (0.2 to 0.6)	2.8 (1.6 to 5.1)	344.7 (208.3 to 402.4)	37.6 (8.8 to 131.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	649.1 (204.1 to 1,457.7)	37.6 (9.8 to 137.7)
Urticaria	13.7 (6.0 to 22.6)	82.1 (54.5 to 121.7)	527.1 (170.7 to 1,449.9)	13.5 (-33.2 to 95.0)	0.8 (0.3 to 1.5)	5.0 (2.7 to 8.6)	529.9 (170.2 to 1,476.9)	12.6 (-34.7 to 96.7)
Decubitus ulcer	0.2 (0.1 to 0.2)	0.7 (0.5 to 0.9)	349.0 (241.1 to 469.0)	-5.3 (-37.7 to 46.5)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	364.1 (245.1 to 498.9)	-4.7 (-40.9 to 47.9)
Other skin and subcutaneous diseases	80.6 (54.7 to 113.0)	429.9 (268.6 to 658.9)	428.7 (337.8 to 528.3)	1.6 (-2.3 to 5.3)	0.5 (0.2 to 1.0)	2.6 (1.1 to 5.3)	432.0 (340.4 to 531.5)	1.7 (-2.4 to 5.5)
Sense organ diseases	-	-	-	-	9.2 (6.2 to 13.3)	37.0 (24.4 to 54.1)	361.0 (269.8 to 336.4)	-13.3 (-18.2 to -9.6)
Glaucoma	4.6 (2.9 to 6.5)	20.7 (14.0 to 28.5)	355.1 (256.5 to 512.7)	-27.2 (-46.3 to 2.1)	0.5 (0.2 to 0.5)	1.5 (0.8 to 2.3)	348.2 (252.0 to 515.6)	-24.4 (-43.2 to 5.1)
Cataract	7.0 (4.4 to 10.5)	16.2 (10.4 to 22.6)	125.2 (62.1 to 250.0)	-19.5 (-34.2 to -5.2)	0.5 (0.3 to 0.9)	1.2 (0.7 to 1.9)	125.9 (64.7 to 242.1)	-18.9 (-32.2 to -0.7)
Macular degeneration	1.6 (0.8 to 2.5)	3.0 (1.8 to 4.6)	82.1 (25.2 to 221.6)	-22.8 (-45.4 to 8.1)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	80.4 (23.9 to 201.4)	-21.8 (-42.9 to 3.9)
Uncorrected refractive error	137.8 (120.0 to 156.6)	655.4 (543.3 to 725.6)	361.6 (279.8 to 452.2)	-1.7 (-12.1 to 12.1)	3.1 (2.0 to 4.7)	13.3 (8.2 to 20.6)	323.2 (273.6 to 384.6)	-12.9 (-20.3 to -4.4)
Age-related and other hearing loss	126.0 (113.1 to 139.7)	537.3 (468.5 to 616.1)	326.2 (294.0 to 360.6)	-9.4 (-12.8 to -6.2)	3.1 (2.0 to 4.5)	12.0 (7.5 to 18.2)	288.6 (235.3 to 336.3)	-10.0 (-15.0 to 4.6)
Other vision loss	13.7 (10.1 to 18.7)	58.9 (43.0 to 76.5)	330.8 (248.9 to 425.4)	-24.6 (-37.8 to -8.7)	1.1 (0.6 to 1.7)	4.5 (2.7 to 7.0)	324.2 (253.2 to 433.6)	-24.3 (-36.6 to -7.0)
Other sense organ diseases	36.4 (34.6 to 38.3)	160.7 (151.0 to 170.5)	342.1 (307.8 to 376.5)	0.1 (-6.3 to 5.6)	1.0 (0.6 to 1.4)	4.3 (2.6 to 6.3)	341.2 (303.4 to 380.9)	0.3 (-7.3 to 6.8)
Oral disorders	-	-	-	-	2.8 (1.6 to 4.5)	15.1 (8.6 to 24.5)	434.6 (392.0 to 482.0)	0.1 (-7.7 to 9.5)
Deciduous caries	157.9 (152.7 to 162.5)	397.9 (385.7 to 410.6)	152.2 (140.9 to 164.6)	0.1 (-4.2 to 4.7)	0.1 (0.0 to 0.1			

Appendix Table G.4 - United Arab Emirates prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	25.1 (22.0 to 28.1)	98.3 (87.5 to 110.8)	293.6 (225.3 to 362.0)	-2.2 (-14.1 to 15.0)	0.7 (0.5 to 1.0)	2.8 (1.8 to 4.0)	298.6 (223.9 to 371.6)	-2.1 (-13.7 to 15.6)
Other oral disorders	29.2 (27.1 to 31.2)	171.4 (157.5 to 185.0)	486.8 (438.9 to 541.1)	-0.2 (-6.5 to 6.7)	0.9 (0.5 to 1.3)	5.1 (3.1 to 7.7)	487.9 (435.7 to 544.3)	0.1 (-7.0 to 7.7)
Injuries	-	-	-	-	6.6 (5.0 to 8.6)	20.9 (15.1 to 28.3)	213.9 (179.4 to 253.4)	-39.7 (-45.8 to -33.0)
Transport injuries	-	-	-	-	3.4 (2.6 to 4.4)	8.8 (6.2 to 11.9)	155.6 (121.9 to 198.0)	-49.9 (-55.7 to -43.0)
Road injuries	-	-	-	-	3.1 (2.3 to 3.9)	7.4 (5.2 to 10.0)	140.8 (108.1 to 182.8)	-52.5 (-58.1 to -45.8)
Pedestrian road injuries	-	-	-	-	0.7 (0.5 to 0.8)	1.4 (1.0 to 1.9)	114.6 (79.2 to 159.5)	-55.8 (-61.8 to -48.7)
Cyclist road injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.8 (0.6 to 1.1)	201.8 (165.2 to 243.8)	-42.0 (-47.8 to -35.6)
Motorcyclist road injuries	-	-	-	-	0.4 (0.3 to 0.5)	0.8 (0.6 to 1.2)	119.7 (84.7 to 156.8)	-58.3 (-64.0 to -52.4)
Motor vehicle road injuries	-	-	-	-	1.7 (1.3 to 2.2)	4.3 (3.1 to 5.8)	147.6 (110.5 to 194.1)	-51.5 (-57.7 to -43.8)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	37.9 (17.9 to 62.9)	-74.9 (-78.0 to -71.1)
Other transport injuries	-	-	-	-	0.4 (0.3 to 0.5)	1.4 (1.0 to 1.9)	284.1 (235.4 to 345.2)	-26.8 (-35.3 to -15.7)
Unintentional injuries	-	-	-	-	3.1 (2.3 to 4.0)	11.7 (8.5 to 15.8)	281.3 (248.2 to 317.3)	-28.5 (-34.5 to -22.0)
Falls	-	-	-	-	1.0 (0.8 to 1.4)	4.0 (2.8 to 5.4)	277.1 (230.9 to 330.4)	-25.4 (-34.0 to -15.3)
Drowning	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	150.3 (108.1 to 198.9)	-53.5 (-60.6 to -45.6)
Fire, heat, and hot substances	-	-	-	-	0.3 (0.2 to 0.3)	0.5 (0.4 to 0.7)	96.0 (65.3 to 136.7)	-59.8 (-65.0 to -53.4)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	174.8 (111.9 to 262.5)	-50.7 (-60.0 to -39.3)
Exposure to mechanical forces	-	-	-	-	1.0 (0.8 to 1.3)	4.3 (3.1 to 5.9)	326.1 (284.2 to 369.0)	-25.4 (-31.6 to -19.4)
Unintentional firearm injuries	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	236.9 (190.0 to 289.2)	-43.3 (-50.5 to -35.3)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	483.5 (397.2 to 577.1)	5.6 (-7.8 to 19.1)
Other exposure to mechanical forces	-	-	-	-	1.0 (0.7 to 1.3)	4.1 (3.0 to 5.6)	329.8 (288.4 to 374.2)	-24.6 (-31.0 to -18.5)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	461.9 (403.5 to 526.4)	16.0 (7.7 to 25.1)
Animal contact	-	-	-	-	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.2)	317.2 (259.9 to 378.3)	-21.9 (-30.3 to -12.7)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	333.6 (241.0 to 438.0)	-21.5 (-34.3 to -7.4)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	302.2 (247.8 to 360.5)	-22.2 (-30.8 to -13.1)
Foreign body	-	-	-	-	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	303.6 (260.8 to 351.4)	-23.9 (-30.5 to -16.1)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	115.8 (72.6 to 173.1)	-51.4 (-60.1 to -40.9)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	420.2 (342.5 to 503.0)	-9.1 (-18.6 to 2.0)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.2)	322.8 (279.3 to 380.7)	-19.4 (-27.3 to -11.0)
Other unintentional injuries	-	-	-	-	0.5 (0.4 to 0.7)	2.1 (1.5 to 2.9)	304.7 (256.7 to 358.3)	-26.0 (-33.2 to -19.2)
Self-harm and interpersonal violence	-	-	-	-	0.2 (0.1 to 0.2)	0.5 (0.3 to 0.6)	166.2 (131.4 to 206.5)	-49.4 (-55.5 to -42.2)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.2)	390.4 (318.4 to 477.6)	-11.4 (-22.1 to 2.1)
Interpersonal violence	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	106.1 (76.6 to 141.4)	-61.6 (-66.6 to -55.8)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	147.4 (116.1 to 181.3)	-53.7 (-58.8 to -48.2)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	143.9 (103.7 to 192.0)	-56.0 (-62.8 to -47.7)
Assault by other means	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	76.7 (48.8 to 111.0)	-66.4 (-71.4 to -60.7)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - United Kingdom prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	7,425.7 (5,555.5 to 9,505.6)	8,581.7 (6,417.0 to 11,007.1)	15.5 (14.1 to 17.1)	-1.4 (-2.7 to -0.2)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	297.5 (206.4 to 412.2)	336.2 (236.3 to 464.9)	13.4 (6.7 to 18.2)	4.9 (-0.9 to 9.1)
HIV/AIDS and tuberculosis	-	-	-	-	4.6 (3.1 to 6.5)	5.8 (4.0 to 7.9)	25.2 (5.5 to 50.1)	10.8 (6.1 to 31.5)
Tuberculosis	10.5 (10.0 to 10.9)	12.8 (12.4 to 13.2)	21.9 (19.3 to 25.0)	10.3 (8.1 to 12.9)	3.2 (2.2 to 4.3)	3.9 (2.7 to 5.2)	21.7 (14.8 to 30.0)	10.6 (3.7 to 18.3)
HIV/AIDS	-	-	-	-	1.4 (0.6 to 2.5)	1.9 (1.0 to 3.2)	32.3 (21.1 to 144.4)	10.7 (-33.2 to 103.7)
HIV/AIDS resulting in mycobacterial infection	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.2)	-23.0 (-58.0 to 31.0)	-31.9 (-63.0 to 14.8)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-23.0 (-58.1 to 31.1)	-31.9 (-63.1 to 14.9)
HIV/AIDS resulting in other diseases	8.3 (4.6 to 12.2)	23.5 (13.4 to 36.9)	180.4 (95.3 to 318.0)	128.0 (57.8 to 242.6)	1.4 (0.5 to 2.5)	1.8 (0.9 to 3.1)	34.6 (-20.2 to 164.4)	12.5 (-33.3 to 117.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	34.4 (22.0 to 50.7)	35.1 (22.6 to 52.0)	2.2 (-0.3 to 4.6)	-8.7 (-11.0 to -6.5)
Diarrheal diseases	19.4 (18.7 to 20.1)	19.9 (19.1 to 20.6)	2.6 (-2.9 to 8.4)	-7.8 (-13.7 to -1.2)	3.1 (2.1 to 4.2)	3.1 (2.2 to 4.3)	2.2 (-4.6 to 9.4)	-7.5 (-14.6 to 0.3)
Intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-47.4 to -18.5)	-30.9 (-51.0 to -24.1)
Typhoid fever	0.3 (0.3 to 0.4)	0.3 (0.2 to 0.3)	-27.3 (-36.1 to -18.3)	-32.8 (-41.1 to -24.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (-36.1 to -18.3)	-32.8 (-41.2 to -24.1)
Paratyphoid fever	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	2.7 (-8.3 to 16.8)	-2.7 (-12.4 to 10.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-8.3 to 16.9)	-2.7 (-12.4 to 10.6)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-92.5 to 45.5)	-70.4 (-93.0 to -3.8)
Lower respiratory infections	17.4 (16.1 to 19.3)	16.9 (15.8 to 18.4)	-2.6 (-11.7 to 6.4)	-23.6 (-30.0 to -17.0)	1.6 (1.1 to 2.3)	1.5 (1.1 to 2.2)	-2.1 (-12.2 to 8.2)	-22.8 (-29.8 to -15.3)
Upper respiratory infections	863.5 (853.4 to 874.1)	950.9 (938.4 to 962.9)	10.2 (8.0 to 12.1)	0.9 (-1.3 to 2.7)	10.1 (5.7 to 16.6)	11.1 (6.2 to 18.3)	10.0 (7.7 to 12.3)	1.0 (-1.4 to 3.1)
Otitis media	727.5 (682.9 to 767.4)	713.9 (664.8 to 756.0)	-1.5 (-8.1 to 3.4)	-12.2 (-17.9 to -7.9)	13.2 (7.7 to 21.2)	12.9 (7.5 to 20.4)	-2.4 (-8.5 to 2.5)	-3.1 (-13.1 to -9.1)
Meningitis	-	-	-	-	3.5 (2.8 to 4.5)	3.3 (2.8 to 4.7)	-4.3 (-11.8 to 4.3)	-14.4 (-21.7 to -5.7)
Pneumococcal meningitis	9.6 (6.1 to 15.6)	9.2 (6.0 to 15.0)	-4.5 (-12.0 to 4.7)	-18.3 (-25.1 to -10.5)	0.9 (0.6 to 1.3)	0.9 (0.6 to 1.2)	0.9 (-1.4 to 4.6)	-4.7 (-26.1 to -8.3)
H influenzae type B meningitis	5.2 (2.2 to 11.3)	4.9 (2.3 to 10.6)	-5.5 (-22.4 to 25.8)	-15.1 (-30.1 to 15.7)	0.7 (0.5 to 1.1)	0.8 (0.5 to 1.1)	2.8 (-18.9 to 33.5)	-5.9 (-26.5 to 23.2)
Meningococcal meningitis	4.6 (1.8 to 11.5)	4.1 (1.8 to 10.7)	-9.7 (-26.0 to 11.5)	-21.7 (-34.3 to -1.3)	0.7 (0.4 to 1.1)	0.6 (0.4 to 1.0)	-6.7 (-23.0 to 15.2)	-17.6 (-32.9 to 1.6)
Other meningitis	8.1 (4.1 to 17.1)	7.4 (3.9 to 16.2)	-8.7 (-20.8 to 2.3)	-18.5 (-28.5 to -6.7)	1.1 (0.7 to 1.6)	1.0 (0.7 to 1.5)	-1.0 (-18.7 to 5.7)	-15.9 (-26.9 to -3.7)
Encephalitis	2.7 (1.2 to 7.2)	3.5 (1.7 to 9.4)	30.1 (14.0 to 45.4)	11.7 (-2.1 to 26.2)	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	37.0 (23.9 to 48.3)	16.5 (6.6 to 29.2)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Whooping cough	8.0 (6.3 to 10.3)	4.4 (3.4 to 5.6)	-45.3 (-47.4 to -43.2)	-45.3 (-47.4 to -43.2)	0.4 (0.2 to 0.7)	0.2 (0.1 to 0.4)	-45.3 (-48.9 to -41.4)	-45.3 (-48.9 to -41.3)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Measles	0.8 (0.8 to 0.8)	0.1 (0.0 to 0.1)	-89.3 (-93.6 to -93.0)	-93.3 (-93.6 to -93.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-93.2 (-94.0 to -92.2)	-93.2 (-94.0 to -92.2)
Varicella and herpes zoster	49.6 (47.3 to 51.9)	56.4 (53.9 to 59.0)	13.8 (7.1 to 20.6)	0.4 (-4.8 to 5.2)	1.9 (1.2 to 3.0)	2.3 (1.4 to 3.5)	18.9 (9.0 to 29.3)	0.8 (-7.3 to 9.2)
Neglected tropical diseases and malaria	-	-	-	-	0.6 (0.4 to 0.8)	0.4 (0.3 to 0.6)	0.4 (-38.1 to -26.2)	-31.9 (-48.3 to -39.1)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.8 (-20.1 to 83.1)	10.8 (-26.3 to 69.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-17.5 to 86.8)	12.4 (-24.4 to 72.8)
Chagas disease	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Visceral leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Schistosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Cysticercosis	0.3 (0.2 to 0.3)	0.1 (0.1 to 0.1)	-68.8 (-78.4 to -57.2)	-73.6 (-81.8 to -63.5)	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-67.0 (-77.6 to -54.0)	-72.1 (-81.2 to -61.0)
Cystic echinococcosis	5.5 (5.3 to 5.6)	4.0 (3.9 to 4.1)	-26.0 (-28.4 to -24.1)	-39.3 (-40.8 to -38.0)	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.5)	-25.8 (-31.1 to -20.4)	-38.8 (-42.8 to -34.5)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Dengue	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Yellow fever	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.1 (-50.3 to 10.5)	-34.5 (-56.5 to -2.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.1 (-50.3 to 10.6)	-14.5 (-56.6 to -1.6)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Ascariasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Trichuriasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Hookworm disease	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	302.7 (60.1 to 401.7)	256.9 (42.2 to 346.2)
Maternal disorders	-	-	-	-	4.6 (3.0 to 6.7)	4.6 (3.0 to 6.7)	1.0 (-8.8 to 9.3)	1.7 (-8.0 to 10.0)
Maternal hemorrhage	59.7 (55.6 to 63.6)	61.9 (56.0 to 67.7)	3.8 (-7.3 to 15.5)	4.1 (-7.1 to 16.0)	2.6 (1.7 to 3.7)	2.5 (1.7 to 3.6)	-2.5 (-14.6 to 7.6)	-1.4 (-13.7 to 8.9)
Maternal sepsis and other maternal infections	3.0 (2.1 to 3.9)	3.0 (1.9 to 4.6)	-2.3 (-31.6 to 52.2)	-9.1 (-36.1 to 41.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-2.3 (-16.2 to 18.4)	-4.5 (-17.8 to 14.5)
Maternal hypertensive disorders	20.5 (13.6 to 29.7)	21.6 (14.5 to 31.1)	5.1 (-10.2 to 22.2)	5.1 (-0.5 to 11.5)	1.0 (0.5 to 1.6)	1.0 (0.6 to 1.8)	5.1 (-2.6 to 13.2)	5.0 (-2.2 to 12.8)
Obstructed labor	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	6.2 (-1.4 to 20.4)	6.2 (-1.0 to 21.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	6.2 (-1.4 to 20.5)	6.6 (-1.1 to 21.2)
Complications of abortion	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	14.0 (8.1 to 20.8)	13.7 (7.7 to 20.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.0 (8.1 to 20.8)	13.7 (7.7 to 20.6)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	1.0 (0.6 to 1.5)	6.1 (-12.7 to 22.8)	6.1 (-11.9 to 23.8)
Neonatal disorders	-	-	-	-	63.1 (46.1 to 81.6)	91.4 (67.2 to 118.4)	46.5 (19.8 to 63.9)	32.6 (8.2 to 48.8)
Preterm birth complications	313.1 (236.2 to 418.3)	545.8 (410.0 to 747.1)	74.5 (47.8 to 102.1)	57.4 (32.8 to 81.8)	41.3 (29.6 to 54.1)	69.4 (50.1 to 89.6)	68.6 (36.2 to 96.4)	53.0 (23.5 to 78.5)
Neonatal encephalopathy due to birth asphyxia and trauma	55.2 (33.5 to 108.5)	46.2 (25.6 to 105.5)	-20.1 (-35.0 to 9.3)	-27.4 (-40.7 to -2.5)	12.5 (9.3 to 15.7)	10.2 (7.6 to 13.1)	-18.6 (-30.3 to -5.9)	-18.6 (-36.4 to -14.3)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	68.7 (38.2 to 148.6)	70.1 (39.4 to 150.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.6 (32.4 to 148.5)	73.0 (33.5 to 150.5)
Hemolytic disease and other neonatal jaundice	14.5 (9.8 to 25.3)	11.8 (8.3 to 16.7)	-18.6 (-62.5 to 27.0)	-21.6 (-67.0 to 16.1)	5.9 (3.5 to 9.5)	5.0 (3.2 to 7.3)	-12.1 (-54.6 to 25.7)	-20.4 (-59.7 to 13.7)
Other neonatal disorders	-	-	-	-	3.3 (2.2 to 5.1)	6.8 (4.4 to 9.7)	107.1 (37.2 to 180.5)	87.2 (24.3 to 154.7)
Nutritional deficiencies	-	-	-	-	175.0 (115.0 to 255.4)	182.3 (118.6 to 267.9)	4.4 (-0.6 to 8.7)	-1.3 (-5.8 to 2.0)
Protein-energy malnutrition	0.4 (0.2 to 0.7)	0.3 (0.1 to 0.5)	-15.5 (-49.8 to 14.6)	-39.4 (-62.9 to -18.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-16.5 (-50.9 to 21.8)	-39.6 (-62.4 to -15.0)
Iodine deficiency	1,077.6 (871.7 to 1,336.3)	724.6 (576.0 to 895.9)	-32.5 (-50.4 to -6.1)	-28.9 (-54.8 to -15.0)	19.1 (11.3 to 30.6)	12.9 (7.3 to 21.0)	-32.6 (-50.4 to -6.9)	-38.9 (-55.0 to -15.4)
Vitamin A deficiency	-	-	-	-	0.0 (0.0 to 0.0)	-	-	-
Iron-deficiency anemia	6,195.7 (6,130.4 to 6,250.6)	7,024.1 (6,886.6 to 7,114.0)	13.5 (11.0 to 15.2)	2.9 (0.5 to 4.4)	155.8 (102.7 to 229.7)	169.3 (111.2 to 249.4)	9.0 (4.2 to 11.9)	2.4 (-1.7 to 4.9)

Appendix Table G.4 - United Kingdom prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-57.9 (-78.9 to -20.1)	-76.8 (-84.2 to -44.9)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	15.2 (9.4 to 24.5)	16.6 (10.1 to 27.2)	8.0 (-2.8 to 26.7)	1.4 (-10.8 to 22.8)
Sexually transmitted diseases excluding HIV	-	-	-	-	6.8 (3.6 to 12.6)	7.5 (4.1 to 13.8)	10.3 (4.5 to 18.1)	1.3 (-4.0 to 9.0)
Syphilis	2.4 (2.2 to 2.6)	4.2 (4.0 to 4.4)	72.4 (58.8 to 88.7)	40.6 (28.0 to 55.7)	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.1)	70.0 (53.1 to 93.4)	39.0 (23.9 to 60.0)
Chlamydial infection	1,097.0 (1,010.5 to 1,197.8)	1,123.3 (1,044.2 to 1,228.3)	2.7 (-11.2 to 16.2)	3.2 (-14.5 to 12.2)	3.2 (1.7 to 5.7)	3.4 (1.8 to 5.9)	4.5 (-4.8 to 18.5)	2.1 (-8.5 to 14.6)
Gonococcal infection	194.0 (168.3 to 220.3)	195.7 (173.2 to 221.6)	0.1 (-11.7 to 17.2)	0.5 (-11.4 to 18.6)	0.7 (0.4 to 1.3)	0.7 (0.4 to 1.3)	-3.3 (-12.5 to 9.2)	-3.6 (-13.4 to 9.1)
Trichomoniasis	170.2 (152.6 to 194.7)	185.9 (167.0 to 202.7)	9.4 (-6.0 to 24.5)	3.9 (-11.4 to 18.3)	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.7)	10.2 (-9.3 to 28.1)	4.9 (-14.2 to 22.7)
Genital herpes	7,357.4 (7,059.4 to 7,671.0)	8,226.7 (7,915.4 to 8,563.3)	11.7 (5.9 to 18.3)	-4.9 (-9.8 to 0.7)	1.9 (0.6 to 4.6)	2.1 (0.6 to 5.1)	10.5 (4.3 to 17.2)	-5.0 (-10.2 to 1.1)
Other sexually transmitted diseases	11.0 (8.1 to 13.7)	11.4 (8.5 to 14.4)	3.6 (-11.5 to 19.7)	3.1 (-16.8 to 12.1)	0.2 (0.2 to 0.4)	0.3 (0.2 to 0.4)	7.8 (-3.2 to 20.5)	2.1 (-8.7 to 14.8)
Hepatitis	-	-	-	-	1.8 (1.2 to 2.7)	1.7 (1.1 to 2.5)	-5.3 (-9.6 to -1.2)	-14.6 (-18.4 to -10.9)
Hepatitis A	42.0 (39.9 to 44.2)	42.0 (39.4 to 44.6)	-0.1 (-1.2 to 0.9)	-8.2 (-9.5 to -6.9)	1.3 (0.8 to 1.8)	1.3 (0.8 to 1.9)	2.3 (-1.6 to 6.3)	-6.9 (-10.6 to -3.1)
Hepatitis B	769.0 (711.1 to 827.6)	569.3 (531.1 to 618.7)	-26.1 (-34.2 to -16.8)	-35.6 (-42.8 to -26.7)	0.5 (0.3 to 0.7)	0.4 (0.2 to 0.5)	-23.5 (-34.1 to -12.0)	-33.9 (-43.0 to -24.5)
Hepatitis C	1,158.2 (1,122.8 to 1,193.6)	982.7 (950.5 to 1,014.4)	-15.1 (-19.0 to -11.4)	-28.2 (-31.3 to -25.0)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-13.4 (-23.1 to -2.5)	-27.0 (-34.1 to -19.1)
Hepatitis E	-	-	-	-	20.2 (14.7 to 50.3)	-	-	-
Leprosy	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-
Other infectious diseases	264.7 (250.7 to 289.6)	291.7 (273.6 to 333.2)	9.1 (-2.4 to 27.9)	2.4 (-9.6 to 23.2)	6.6 (4.2 to 10.1)	7.4 (4.6 to 11.6)	9.1 (-12.3 to 49.2)	4.6 (-17.1 to 46.3)
Non-communicable diseases	-	-	-	-	6,467.3 (4,807.3 to 8,273.9)	7,715.0 (5,763.0 to 9,912.4)	19.3 (17.6 to 21.0)	1.3 (-0.1 to 2.7)
Neoplasms	-	-	-	-	111.6 (83.8 to 141.5)	153.9 (115.2 to 197.1)	38.1 (28.4 to 46.3)	7.7 (0.5 to 14.1)
Esophageal cancer	11.0 (8.8 to 13.3)	16.0 (12.3 to 20.6)	44.5 (8.0 to 100.6)	12.6 (-15.7 to 53.8)	2.2 (1.2 to 2.1)	2.2 (1.6 to 3.1)	36.7 (12.2 to 73.0)	6.9 (-12.1 to 34.0)
Stomach cancer	34.1 (29.9 to 39.3)	28.5 (24.1 to 34.0)	-16.8 (-28.3 to -2.6)	-36.3 (-45.0 to -26.3)	3.8 (2.8 to 5.0)	2.9 (2.1 to 3.8)	-23.7 (-33.3 to -12.0)	-41.1 (-48.1 to -33.0)
Liver cancer	-	-	-	-	0.4 (0.3 to 0.6)	1.0 (0.6 to 1.4)	126.1 (49.7 to 196.4)	76.9 (19.8 to 130.6)
Liver cancer due to hepatitis B	0.6 (0.4 to 0.8)	1.4 (1.0 to 1.9)	148.3 (54.4 to 280.7)	96.6 (24.6 to 199.3)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	125.6 (45.5 to 223.2)	78.0 (18.1 to 151.8)
Liver cancer due to hepatitis C	0.8 (0.5 to 1.1)	3.6 (2.5 to 4.8)	376.1 (193.3 to 640.4)	274.0 (135.1 to 478.2)	0.1 (0.1 to 0.2)	0.5 (0.3 to 0.7)	318.7 (177.6 to 504.1)	229.2 (121.6 to 370.2)
Liver cancer due to alcohol use	1.2 (0.9 to 1.7)	1.8 (1.1 to 2.4)	47.7 (-13.4 to 132.2)	13.9 (-32.3 to 80.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	32.4 (-20.6 to 89.4)	2.2 (-38.0 to 46.2)
Liver cancer due to other causes	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	0.0 (-40.5 to 71.7)	-19.7 (-51.8 to 31.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-3.1 (-41.2 to 42.2)	-2.7 (-24.6 to 7.6)
Larynx cancer	10.8 (8.5 to 13.2)	11.1 (8.6 to 14.1)	3.1 (-17.0 to 25.2)	-20.9 (-36.4 to -4.7)	1.1 (0.7 to 1.5)	1.1 (0.7 to 1.5)	3.7 (-3.0 to 16.9)	25.0 (-9.9 to 10.1)
Tracheal, bronchus and lung cancer	74.8 (68.7 to 82.4)	81.4 (70.6 to 91.7)	9.0 (-8.7 to 26.4)	-15.3 (-28.5 to -2.0)	10.9 (8.1 to 13.9)	10.8 (8.0 to 13.7)	-0.7 (-14.6 to 12.1)	-22.6 (-32.8 to -12.5)
Breast cancer	365.0 (345.7 to 380.2)	555.1 (537.2 to 572.4)	52.2 (45.3 to 58.5)	17.1 (12.0 to 22.2)	21.9 (15.7 to 29.7)	27.5 (19.2 to 37.7)	25.7 (14.1 to 37.9)	-3.3 (-12.4 to 6.1)
Cervical cancer	30.3 (23.3 to 35.3)	19.9 (16.0 to 24.4)	-34.4 (-47.4 to -18.0)	-44.7 (-55.6 to -30.1)	2.2 (1.5 to 3.1)	1.5 (1.0 to 2.1)	-34.2 (-46.8 to -18.2)	-44.4 (-55.3 to -29.7)
Uterine cancer	3.7 (2.1 to 43.7)	52.8 (38.6 to 67.4)	1382.7 (73.0 to 112.1)	23.5 (-16.0 to 69.3)	2.3 (1.5 to 3.2)	3.5 (2.2 to 4.9)	39.6 (4.6 to 103.8)	19.6 (-17.2 to 62.2)
Prostate cancer	163.3 (144.9 to 188.6)	397.6 (342.6 to 465.4)	145.6 (100.6 to 179.7)	93.6 (57.1 to 119.7)	14.6 (10.6 to 19.6)	29.3 (20.4 to 39.8)	104.0 (45.9 to 142.7)	60.9 (14.4 to 90.4)
Colon and rectum cancer	175.3 (165.1 to 187.7)	233.7 (215.1 to 254.0)	33.4 (19.9 to 47.0)	3.7 (-6.6 to 14.5)	15.3 (11.4 to 19.7)	18.7 (13.7 to 24.4)	22.3 (10.2 to 34.7)	-4.9 (-14.1 to 4.9)
Lip and oral cavity cancer	17.2 (14.3 to 20.6)	22.0 (17.3 to 27.1)	27.6 (-5.8 to 67.5)	1.0 (-25.1 to 32.0)	1.6 (1.1 to 2.1)	1.9 (1.3 to 2.6)	19.9 (-9.3 to 52.6)	-4.1 (-26.8 to 21.7)
Nasopharynx cancer	2.1 (1.5 to 2.9)	1.5 (1.1 to 2.2)	-31.4 (-50.6 to -3.8)	-44.5 (-59.1 to -21.9)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-33.5 (-53.0 to -8.7)	-46.1 (-59.0 to -27.0)
Other pharynx cancer	8.8 (6.6 to 11.5)	11.9 (8.1 to 15.8)	35.8 (-13.6 to 105.6)	7.4 (-31.3 to 61.5)	0.7 (0.5 to 1.1)	1.0 (0.6 to 1.4)	30.7 (-16.9 to 91.7)	3.7 (-33.9 to 51.3)
Gallbladder and biliary tract cancer	1.8 (1.4 to 2.3)	1.7 (1.2 to 2.2)	-0.8 (-31.1 to 24.4)	-31.7 (-46.5 to -6.4)	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	-12.0 (-29.7 to 18.0)	-32.4 (-45.1 to -10.0)
Pancreatic cancer	7.9 (6.7 to 9.1)	11.0 (9.3 to 12.8)	39.7 (12.2 to 71.9)	9.2 (-12.4 to 33.6)	1.5 (1.1 to 1.9)	1.5 (1.4 to 2.5)	28.4 (11.7 to 46.8)	0.6 (-12.1 to 14.5)
Malignant skin melanoma	48.1 (35.7 to 66.7)	82.5 (57.4 to 112.0)	72.7 (30.4 to 109.3)	38.0 (3.7 to 67.4)	2.9 (1.9 to 4.5)	4.8 (2.9 to 7.3)	65.3 (28.8 to 99.2)	32.7 (1.1 to 59.7)
Non-melanoma skin cancer	64.1 (55.9 to 74.8)	102.7 (88.0 to 119.2)	59.2 (27.1 to 95.0)	61.4 (0.2 to 52.7)	2.9 (0.8 to 4.8)	2.2 (1.4 to 3.5)	90.0 (48.1 to 150.8)	48.1 (17.2 to 90.2)
Ovarian cancer	28.4 (24.5 to 33.5)	33.2 (27.8 to 39.4)	17.3 (-5.1 to 45.4)	-9.0 (-25.8 to 12.3)	3.7 (2.6 to 4.7)	4.1 (2.9 to 5.4)	12.7 (-7.5 to 35.8)	-12.2 (-27.6 to 6.0)
Testicular cancer	12.5 (8.4 to 16.4)	13.8 (9.9 to 19.5)	8.6 (-22.9 to 68.4)	0.1 (-29.4 to 53.9)	0.8 (0.4 to 1.2)	0.8 (0.5 to 1.3)	6.0 (-24.8 to 62.6)	-2.6 (-31.0 to 49.5)
Kidney cancer	33.9 (30.0 to 38.8)	56.6 (49.0 to 64.6)	66.8 (40.6 to 95.3)	29.5 (9.2 to 51.4)	2.5 (1.8 to 3.4)	3.9 (2.8 to 5.3)	56.9 (32.2 to 82.0)	31.8 (8.8 to 42.0)
Bladder cancer	77.2 (64.3 to 89.5)	98.1 (74.3 to 103.6)	26.9 (-3.9 to 35.9)	25.9 (-25.9 to 3.1)	6.0 (4.2 to 7.9)	6.3 (4.5 to 8.6)	6.5 (-9.7 to 25.1)	-18.2 (-30.3 to -4.4)
Brain and nervous system cancer	14.3 (12.0 to 16.9)	21.3 (17.6 to 25.4)	49.0 (26.2 to 74.3)	19.8 (2.4 to 40.9)	1.5 (1.1 to 2.0)	2.1 (1.5 to 2.8)	40.3 (20.5 to 63.3)	13.6 (-0.9 to 31.1)
Thyroid cancer	13.3 (10.9 to 15.7)	16.6 (13.0 to 20.3)	24.8 (-0.8 to 56.5)	5.5 (-17.0 to 31.5)	0.8 (0.5 to 1.2)	0.8 (0.6 to 1.4)	18.9 (-4.9 to 48.6)	1.0 (-20.5 to 24.5)
Mesothelioma	1.0 (0.8 to 1.8)	3.2 (1.7 to 3.9)	269.3 (36.1 to 331.3)	178.1 (73.3 to 224.8)	0.2 (0.1 to 0.4)	0.7 (0.3 to 0.9)	253.4 (26.7 to 308.2)	168.2 (0.7 to 209.6)
Hodgkin lymphoma	10.3 (7.5 to 13.5)	10.7 (7.9 to 14.2)	3.3 (-24.1 to 43.8)	3.3 (-32.6 to 30.4)	0.9 (0.6 to 1.2)	0.8 (0.5 to 1.2)	2.7 (-25.7 to 33.8)	-13.0 (-34.5 to 21.3)
Non-Hodgkin lymphoma	43.9 (35.7 to 60.2)	74.1 (50.6 to 92.5)	74.7 (-11.6 to 113.7)	35.8 (-23.0 to 66.1)	3.3 (2.2 to 4.9)	5.3 (3.2 to 7.4)	65.0 (-9.1 to 98.7)	28.6 (-27.4 to 55.2)
Multiple myeloma	9.5 (6.4 to 13.7)	15.1 (10.5 to 21.7)	58.8 (8.3 to 129.5)	24.0 (-15.3 to 77.6)	2.0 (1.2 to 3.1)	3.0 (1.9 to 4.5)	48.3 (7.0 to 102.5)	16.7 (-16.2 to 56.8)
Leukemia	26.2 (23.1 to 29.5)	42.8 (36.2 to 49.6)	63.9 (34.0 to 95.8)	24.6 (1.8 to 47.9)	3.4 (2.5 to 4.4)	5.3 (3.7 to 6.9)	52.6 (27.4 to 81.7)	17.4 (-1.8 to 37.9)
Other neoplasms	51.5 (44.2 to 62.3)	147.8 (115.1 to 179.9)	189.0 (117.7 to 271.4)	121.4 (72.6 to 174.6)	3.6 (2.6 to 4.9)	9.6 (6.5 to 13.3)	155.8 (101.5 to 238.9)	105.2 (59.9 to 153.2)
Cardiovascular diseases	-	-	-	-	-	-	-	-
Rheumatic heart disease	5.5 (5.0 to 5.9)	6.7 (6.1 to 7.3)	21.9 (9.4 to 36.8)	-1.1 (-10.5 to 10.2)	0.6 (0.4 to 0.8)	0.7 (0.5 to 1.0)	19.8 (-4.2 to 66.3)	-3.7 (-25.0 to 36.6)
Ischemic heart disease	1,334.4 (1,243.6 to 1,426.1)	1,557.5 (1,501.5 to 1,612.4)	16.9 (8.5 to 25.5)	-10.5 (-17.3 to -3.4)	87.8 (59.9 to 119.2)	102.1 (71.8 to 138.3)	16.7 (6.3 to 26.8)	-10.9 (-19.1 to -2.9)
Cerebrovascular disease	-	-	-	-	71.3 (50.5 to 93.0)	101.5 (72.3 to 130.8)	42.6 (34.2 to 50.0)	13.8 (7.7 to 19.8)
Ischemic stroke	414.2 (391.1 to 439.2)	594.1 (566.4 to 620.0)	43.5 (34.9 to 53.1)	14.0 (7.1 to 21.9)	58.7 (41.0 to 78.2)	83.8 (59.0 to 110.0)	42.8 (33.9 to 51.8)	13.9 (6.9 to 21.3)
Hemorrhagic stroke	87.3 (80.1 to 97.7)	123.8 (112.0 to 135.8)	41.3 (26.4 to 62.1)	13.4 (2.1 to 29.0)	12.6 (8.7 to 16.7)	17.7 (12.3 to 23.6)	40.2 (25.6 to 61.6)	12.9 (1.6 to 29.3)
Hypertensive heart disease	113.0 (99.0 to 128.6)	148.6 (130.3 to 168.1)	31.4 (12.2 to 53.7)	3.2 (-11.8 to 21.2)	12.0 (8.2 to 16.5)	15.8 (10.7 to 21.9)	31.7 (12.3 to 54.7)	3.8 (-11.7 to 22.5)
Cardiomyopathy and myocarditis	107.6 (98.7 to 117.1)	106.9 (99.2 to 115.2)	-0.4 (-11.4 to 10.5)	-19.5 (-28.0 to -11.4)	11.5 (7.9 to 15.5)	11.3 (8.0 to 15.3)	-0.8 (-12.4 to 10.6)	-19.6 (-28.4 to -11.2)
Atrial fibrillation and flutter	185.7 (171.5 to 202.7)	196.2 (170.5 to 217.0)	5.8 (-9.1 to 20.8)	-16.4 (-27.7 to -4.7)	5.8 (9.9 to 19.2)	14.1 (10.2 to 20.6)	14.5 (-9.6 to 20.7)	-16.5 (-27.7 to -4.4)
Peripheral vascular disease	2,299.8 (2,142.7 to 2,457.5)	3,068.0 (2,883.3 to 3,251.3)	33.4 (21.4 to 47.9)	3.8 (-5.3 to 15.3)	2.9 (1.3 to 5.2)	3.3 (1.6 to 5.7)	14.1 (-10.2 to 66.2)	-11.8 (-31.3 to 29.2)
Endocarditis	2.8 (2.0 to 3.4)	4.1 (3.3 to 5.6)	40.5 (22.8 to 125.1)	0.3 (0.9 to 79.6)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.7)	41.7 (19.8 to 134.1)	16.6 (-0.9 to 87.8)
Other cardiovascular and circulatory diseases	1,117.2 (973.5 to 1,574.2)	1,664.3 (1,085.7 to 2,113.3)	47.9 (-11.7 to 157.0)	18.1 (-28.8 to 105.6)	78.3 (42.1 to 124.2)	88.0 (66.2 to 171.1)	117.0 (-12.0 to 157.8)	48.0 (-29.0 to 106.8)
Chronic respiratory diseases	-	-	-	-	-	-	-	-
Chronic obstructive pulmonary disease	4,319.5 (3,578.4 to 5,071.2)	5,352.2 (4,425.3 to 6,267.9)	24.0 (18.7 to 29.2)	0.5 (-3.6 to 5.2)	199.0 (132.9 to 280.3)	243.2 (161.0 to 343.2)	22.2 (9.9 to 35.2)	-0.5 (-10.8 to 9.6)
Pneumoconiosis	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-15.4 (-21	

Appendix Table G.4 - United Kingdom prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	0.3 (0.3 to 0.4)	0.3 (0.3 to 0.3)	-15.7 (-19.4 to -12.3)	-2.6 (-35.4 to -30.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-16.1 (-19.7 to -12.7)	-32.8 (-35.6 to -30.2)
Asbestosis	-	-	-	-	-	-	-	-
Coal workers pneumoconiosis	-	-	-	-	-	-	-	-
Other pneumoconiosis	0.8 (0.5 to 1.1)	0.7 (0.4 to 1.0)	-14.9 (-24.3 to -5.5)	-32.4 (-40.0 to -25.6)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-15.1 (-24.4 to -6.0)	-32.5 (-40.2 to -25.7)
Asthma	3,090.8 (2,908.0 to 3,265.0)	3,411.7 (3,205.0 to 3,615.9)	9.9 (3.4 to 19.7)	13.0 (11.1 to 0.9)	131.0 (87.9 to 188.5)	146.2 (95.5 to 206.7)	11.5 (2.7 to 19.3)	8.1 (-14.1 to 0.8)
Interstitial lung disease and pulmonary sarcoidosis	7.0 (6.4 to 7.6)	8.8 (8.0 to 9.5)	25.7 (9.4 to 41.3)	1.9 (-1.0 to 14.2)	0.9 (0.6 to 1.4)	1.2 (0.7 to 1.7)	25.5 (9.2 to 42.2)	2.3 (-10.9 to 15.4)
Other chronic respiratory diseases	-	-	-	-	13.5 (8.2 to 21.0)	1.8 (1.1 to 2.6)	-86.8 (-88.9 to -84.5)	-89.2 (-90.9 to -87.4)
Cirrhosis	-	-	-	-	3.5 (2.5 to 4.8)	5.5 (3.8 to 7.6)	58.1 (51.5 to 64.8)	30.6 (25.3 to 36.2)
Cirrhosis due to hepatitis B	2.1 (1.9 to 2.4)	3.6 (3.0 to 4.0)	71.5 (39.3 to 103.3)	37.8 (13.2 to 66.7)	0.6 (0.2 to 0.5)	0.6 (0.4 to 0.8)	66.0 (34.3 to 104.7)	36.7 (9.7 to 69.1)
Cirrhosis due to hepatitis C	7.8 (7.1 to 8.5)	15.8 (14.6 to 17.4)	103.3 (78.8 to 131.6)	66.4 (45.9 to 89.8)	1.3 (0.9 to 1.8)	2.6 (1.7 to 3.5)	102.5 (76.2 to 134.7)	66.0 (43.8 to 92.3)
Cirrhosis due to alcohol use	9.1 (8.4 to 9.8)	9.6 (8.5 to 10.7)	5.0 (-9.1 to 21.5)	-15.0 (-26.7 to -1.0)	1.5 (1.0 to 2.0)	1.5 (1.0 to 2.2)	5.1 (-10.1 to 24.0)	-15.1 (-27.7 to 1.3)
Cirrhosis due to other causes	2.3 (2.0 to 2.5)	4.8 (4.3 to 5.4)	108.9 (83.9 to 145.8)	74.5 (54.3 to 102.2)	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.1)	102.1 (73.0 to 141.2)	70.0 (46.6 to 99.3)
Digestive diseases	-	-	-	-	113.6 (81.6 to 150.6)	139.2 (100.1 to 184.9)	22.4 (14.2 to 31.1)	4.1 (-3.1 to 11.8)
Peptic ulcer disease	692.1 (684.2 to 700.4)	263.0 (253.2 to 272.6)	-62.0 (-63.5 to -60.6)	-71.2 (-72.3 to -70.2)	21.2 (14.6 to 29.4)	10.3 (7.2 to 14.3)	-51.4 (-53.2 to -49.0)	-63.0 (-64.4 to -61.1)
Gastritis and duodenitis	142.2 (138.3 to 146.6)	214.3 (208.9 to 220.0)	50.7 (45.1 to 56.3)	22.3 (17.8 to 26.7)	6.1 (4.2 to 8.6)	9.3 (6.4 to 13.0)	52.4 (44.7 to 59.1)	23.9 (17.1 to 30.4)
Appendicitis	1.7 (1.7 to 1.8)	1.8 (1.7 to 1.9)	3.5 (-3.4 to 10.4)	-2.8 (-9.7 to 4.1)	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.8)	4.1 (-7.1 to 15.0)	-2.2 (-13.9 to 9.6)
Paralytic ileus and intestinal obstruction	0.7 (0.7 to 0.7)	1.1 (1.1 to 1.1)	60.3 (52.9 to 68.3)	31.0 (24.9 to 37.9)	0.3 (0.1 to 0.3)	0.4 (0.2 to 0.4)	57.8 (43.3 to 73.8)	30.5 (20.5 to 41.1)
Inguinal, femoral, and abdominal hernia	474.3 (453.3 to 496.8)	542.5 (520.3 to 566.8)	14.2 (7.6 to 22.2)	4.8 (-13.8 to -2.9)	5.4 (2.4 to 8.9)	5.4 (2.7 to 10.0)	14.4 (7.9 to 22.3)	4.5 (-13.3 to 2.5)
Inflammatory bowel disease	236.9 (223.6 to 250.4)	340.0 (320.5 to 358.2)	43.7 (32.3 to 53.7)	20.1 (10.2 to 28.7)	49.4 (34.3 to 66.9)	70.7 (48.9 to 95.9)	43.6 (31.6 to 53.5)	20.3 (10.0 to 28.9)
Vascular intestinal disorders	0.6 (0.5 to 0.6)	0.7 (0.7 to 0.8)	32.4 (18.5 to 49.5)	4.4 (-5.5 to 16.4)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	30.8 (11.5 to 55.8)	4.3 (-9.1 to 20.9)
Gallbladder and biliary diseases	68.2 (65.5 to 73.9)	106.5 (99.2 to 114.8)	57.2 (38.4 to 68.5)	26.0 (11.1 to 35.1)	7.0 (4.8 to 9.5)	10.9 (7.5 to 14.6)	56.8 (37.8 to 68.7)	25.8 (11.1 to 36.0)
Pancreatitis	14.2 (14.0 to 14.3)	20.2 (19.9 to 20.5)	42.6 (40.1 to 45.1)	20.2 (17.1 to 21.4)	4.1 (3.7 to 4.5)	5.8 (4.1 to 7.8)	42.3 (36.1 to 48.7)	19.3 (14.1 to 24.9)
Other digestive diseases	-	-	-	-	20.2 (13.9 to 27.7)	25.6 (17.3 to 34.8)	24.7 (7.2 to 54.2)	6.0 (-8.9 to 31.2)
Neurological disorders	-	-	-	-	645.9 (447.4 to 868.1)	804.1 (570.0 to 1,072.7)	24.4 (16.9 to 33.4)	5.3 (-1.7 to 13.2)
Alzheimer disease and other dementias	961.9 (900.9 to 1,022.5)	1,295.4 (1,202.7 to 1,389.0)	35.0 (21.5 to 47.3)	-0.1 (-9.9 to 8.8)	140.4 (104.3 to 179.4)	191.7 (141.6 to 245.8)	36.9 (23.0 to 49.3)	0.4 (-9.4 to 9.2)
Parkinson disease	75.3 (54.1 to 95.9)	95.3 (68.6 to 119.6)	26.4 (22.6 to 31.5)	0.3 (-3.1 to 3.6)	8.7 (5.4 to 12.5)	10.5 (6.9 to 15.5)	26.3 (20.8 to 32.8)	0.4 (-4.1 to 5.2)
Epilepsy	191.5 (140.1 to 239.0)	187.4 (131.7 to 238.7)	-2.6 (-33.5 to 43.8)	-13.5 (-40.9 to 27.9)	75.6 (47.5 to 107.8)	77.1 (46.8 to 109.9)	1.8 (-31.4 to 52.1)	-8.9 (-38.7 to 35.2)
Multiple sclerosis	54.9 (49.4 to 59.1)	100.9 (91.2 to 108.4)	83.7 (60.7 to 104.6)	53.3 (34.5 to 71.0)	18.0 (12.9 to 22.7)	32.8 (23.7 to 41.8)	82.6 (59.4 to 105.1)	52.7 (33.4 to 71.6)
Migraine	8,525.9 (7,933.8 to 9,042.8)	9,357.0 (8,746.5 to 10,095.0)	9.4 (0.2 to 20.1)	-2.0 (-10.3 to 7.6)	288.7 (173.3 to 427.3)	316.0 (192.3 to 461.0)	9.2 (-0.2 to 20.0)	-1.8 (-10.4 to 7.6)
Tension-type headache	12,341.6 (10,891.0 to 13,704.6)	17,211.4 (16,093.3 to 18,274.2)	39.7 (25.6 to 61.3)	24.2 (12.6 to 44.5)	38.6 (9.1 to 32.7)	45.7 (12.7 to 44.7)	28.3 (5.1 to 60.7)	24.3 (12.6 to 44.6)
Medication overuse headache	419.5 (283.9 to 542.2)	730.3 (496.1 to 947.5)	74.1 (59.4 to 91.6)	50.4 (37.0 to 65.0)	65.1 (38.7 to 97.8)	113.2 (65.9 to 173.5)	73.8 (58.9 to 91.4)	50.6 (36.9 to 64.9)
Other neurological disorders	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	13.8 (3.5 to 27.3)	-1.6 (-10.0 to 9.9)	31.0 (22.7 to 40.1)	36.5 (26.8 to 47.2)	17.5 (5.4 to 34.7)	-10.0 (-19.1 to 3.3)
Mental and substance use disorders	-	-	-	-	1,389.6 (990.4 to 1,857.8)	1,512.9 (1,078.0 to 2,014.4)	8.9 (7.1 to 10.7)	-1.7 (-2.9 to -0.4)
Schizophrenia	163.2 (143.2 to 182.8)	186.9 (165.6 to 208.9)	14.5 (12.3 to 17.5)	-1.1 (-3.1 to 1.3)	103.8 (74.7 to 128.1)	118.8 (85.5 to 145.7)	14.4 (11.5 to 17.8)	-1.0 (-3.6 to 2.0)
Alcohol use disorders	707.2 (644.1 to 778.0)	891.7 (820.2 to 973.1)	26.1 (22.3 to 29.7)	16.8 (13.7 to 20.1)	70.8 (46.5 to 101.0)	82.7 (58.9 to 126.2)	17.0 (22.1 to 30.2)	2.0 (13.7 to 20.5)
Drug use disorders	-	-	-	-	147.9 (102.7 to 196.4)	148.6 (103.1 to 196.1)	0.4 (-4.3 to 5.5)	-5.3 (-9.8 to -0.5)
Opioid use disorders	141.1 (98.8 to 198.2)	136.9 (98.6 to 191.3)	-3.1 (-9.9 to 6.9)	-13.0 (-19.0 to -5.2)	58.4 (36.9 to 87.2)	56.6 (36.2 to 83.8)	-3.3 (-10.6 to 7.0)	-12.8 (-19.3 to -4.7)
Cocaine use disorders	148.8 (145.5 to 151.8)	160.8 (157.2 to 164.6)	8.1 (4.5 to 11.7)	4.1 (0.6 to 7.7)	20.4 (13.4 to 28.6)	22.0 (14.6 to 31.0)	8.1 (3.8 to 12.9)	4.3 (-0.0 to 9.4)
Amphetamine use disorders	163.0 (158.1 to 166.0)	159.5 (155.7 to 163.3)	-1.5 (-5.0 to 1.9)	4.7 (-8.0 to 1.2)	21.1 (13.4 to 30.7)	20.7 (13.0 to 29.9)	4.6 (-6.3 to 2.5)	4.6 (-9.1 to -0.5)
Cannabis use disorders	214.5 (200.7 to 227.3)	210.0 (195.1 to 226.2)	-2.3 (-5.3 to 1.5)	-3.8 (-7.2 to 0.3)	6.2 (4.2 to 8.8)	6.1 (4.1 to 8.8)	-2.0 (-6.7 to 2.9)	-3.4 (-8.4 to 1.8)
Other drug use disorders	-	-	-	-	41.9 (27.8 to 57.4)	43.2 (28.8 to 59.0)	3.1 (-6.2 to 13.3)	-0.2 (-9.4 to 9.7)
Depressive disorders	-	-	-	-	455.9 (279.1 to 692.4)	492.8 (304.9 to 750.1)	8.2 (4.4 to 12.7)	-5.1 (-7.7 to -2.1)
Major depressive disorder	1,805.3 (1,228.6 to 2,571.0)	1,933.8 (1,311.7 to 2,746.5)	7.0 (2.4 to 12.8)	-4.4 (-9.3 to -2.6)	364.9 (211.5 to 590.3)	389.2 (226.9 to 630.7)	6.7 (1.9 to 12.3)	4.3 (-0.4 to -2.5)
Dysthymia	951.8 (827.0 to 1,084.6)	1,085.8 (939.9 to 1,232.8)	14.1 (12.4 to 15.7)	-0.3 (-0.7 to -0.0)	91.0 (60.0 to 132.0)	103.6 (68.1 to 151.8)	13.8 (11.9 to 15.7)	-0.2 (-1.0 to 0.6)
Bipolar disorder	429.6 (360.3 to 498.9)	475.1 (401.2 to 545.6)	10.6 (7.7 to 13.4)	-0.7 (-3.0 to 1.5)	86.5 (53.6 to 130.0)	95.5 (59.1 to 142.1)	10.4 (7.1 to 13.7)	10.4 (-3.0 to 2.1)
Anxiety disorders	2,950.6 (1,793.7 to 4,018.2)	3,265.6 (2,037.6 to 4,471.1)	11.2 (5.3 to 15.4)	-0.2 (-1.4 to 0.5)	268.2 (143.2 to 414.3)	296.3 (162.9 to 457.6)	11.0 (5.2 to 15.4)	-0.1 (-1.4 to 0.9)
Eating disorders	-	-	-	-	40.4 (23.8 to 62.2)	42.3 (25.3 to 65.3)	5.7 (1.9 to 9.1)	5.7 (2.4 to 9.3)
Anorexia nervosa	44.1 (28.0 to 65.8)	53.8 (33.6 to 79.4)	22.0 (15.0 to 31.3)	21.5 (15.0 to 30.2)	9.4 (5.1 to 15.6)	11.4 (6.3 to 19.0)	22.0 (13.9 to 31.7)	21.5 (14.3 to 30.9)
Bulimia nervosa	147.0 (96.8 to 222.9)	146.1 (96.8 to 218.9)	-0.6 (-2.4 to 1.9)	0.5 (-0.9 to 2.2)	31.0 (17.4 to 50.9)	30.8 (17.5 to 49.9)	-0.5 (-2.9 to 2.8)	0.6 (-1.5 to 3.4)
Autistic spectrum disorders	-	-	-	-	63.0 (44.0 to 85.7)	69.5 (48.7 to 94.5)	10.4 (9.2 to 11.6)	0.5 (-0.6 to 1.6)
Autism	163.6 (154.0 to 172.8)	181.0 (170.1 to 191.7)	10.6 (10.1 to 11.2)	0.4 (0.3 to 0.4)	39.8 (26.5 to 54.3)	43.9 (29.5 to 59.4)	10.3 (8.5 to 12.0)	0.4 (-1.1 to 2.0)
Asperger syndrome	233.7 (218.2 to 249.5)	250.1 (241.4 to 277.3)	10.9 (10.3 to 11.4)	0.5 (0.4 to 0.5)	23.1 (16.0 to 32.0)	25.6 (17.8 to 35.2)	10.5 (9.1 to 12.1)	0.5 (-0.7 to 1.9)
Attention-deficit/hyperactivity disorder	277.2 (233.5 to 322.5)	277.9 (233.6 to 422.0)	0.2 (-0.1 to 0.5)	0.7 (0.4 to 1.0)	3.4 (1.9 to 5.3)	3.4 (1.9 to 5.3)	0.3 (-1.8 to 2.4)	0.8 (-1.4 to 2.9)
Conduct disorder	412.9 (347.6 to 482.6)	413.3 (348.2 to 482.0)	0.1 (-0.2 to 0.4)	0.1 (0.1 to 0.1)	49.7 (30.5 to 75.0)	49.7 (30.4 to 75.0)	0.2 (-1.0 to 1.6)	0.2 (-1.0 to 1.6)
Idiopathic intellectual disability	343.9 (263.7 to 434.5)	255.5 (166.9 to 342.9)	-25.6 (-42.0 to -9.8)	-28.8 (-41.0 to -18.8)	20.3 (12.9 to 29.0)	15.1 (8.9 to 23.0)	-25.8 (-42.4 to -10.2)	-32.8 (-47.8 to -18.6)
Other mental and substance use disorders	1,081.7 (1,017.5 to 1,143.0)	1,247.6 (1,174.1 to 1,319.0)	15.3 (14.2 to 16.5)	0.4 (0.2 to 0.7)	79.7 (54.1 to 107.0)	91.6 (62.3 to 122.6)	15.0 (13.3 to 16.7)	0.6 (-0.6 to 1.9)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	617.7 (447.8 to 808.3)	906.5 (654.7 to 1,186.2)	46.6 (41.4 to 52.6)	20.0 (16.0 to 24.4)
Diabetes mellitus	2,390.0 (2,105.4 to 2,693.0)	5,343.3 (4,883.1 to 5,802.4)	124.1 (102.8 to 145.4)	80.6 (65.1 to 97.9)	164.8 (111.8 to 228.3)	363.0 (249.1 to 499.0)	120.4 (101.0 to 141.7)	77.4 (62.8 to 94.1)
Acute glomerulonephritis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-19.5 (-22.8 to -16.4)	-27.7 (-25.7 to -19.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.5 (-22.8 to -16.4)	-27.7 (-25.7 to -19.9)
Chronic kidney disease	-	-	-	-	232.9 (153.6 to 314.4)	280.6 (185.0 to 380.7)	20.7 (17.1 to 23.0)	0.0 (-1.5 to 1.6)
Chronic kidney disease due to diabetes mellitus	677.4 (473.8 to 943.2)	1,070.2 (718.1 to 1,441.4)	58.6 (37.4 to 79.2)	24.9 (8.3 to 39.8)	38.9 (24.7 to 54.1)	57.4 (36.4 to 79.3)	47.7 (30.3 to 67.4)	16.9 (3.6 to 31.7)
Chronic kidney disease due to hypertension	629.4 (479.5 to 818.0)	713.5 (487.4 to 974.8)	12.5 (-2.4 to 39.0)	-8.6 (-20.1 to 6.6)	62.1 (39.8 to 86.3)	25.5 (16.8 to 35.2)	-58.9 (-62.6 to -54.1)	-65.4 (-68.5 to -61.4)
Chronic kidney disease due to glomerulonephritis	1,016.4 (671.0 to 1,434.1)	616.0 (455.9 to 789.4)	-39.0 (-47.5 to -29.4)	-45.4 (-53.3 to -36.8)	24.3 (16.4 to 33.0)	49.5 (32.3 to 68.3)	103.8 (84.7 to 123.6)	67.8 (52.1 to 85.5)
Chronic kidney disease due to other causes	2,335.5 (1,676.7 to 3,085.9)	3,091.5 (2,188.1 to 4,153.6)	32.4 (23.4 to 40.0)	32.4 (3.2 to 16.9)	107.5 (72.7 to 144.5)	146.1 (98.4 to 203.2)	37.6 (25.8 to 47.2)	34.2 (5.1 to 21.8)
Urinary diseases and male infertility	-	-	-	-	58.9 (38.5 to 83.6)	80.6 (52.3 to 114.2)	36.7 (31.7 to 42.2)	15.6 (6.2 to 10.5)
Interstitial nephritis and urinary tract infections	6.4 (5.9 to 7.0)	10.2 (9.5 to 10.8)	58.4 (41.8 to 79.8)	3				

Appendix Table G.4 - United Kingdom prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
Urolithiasis	713.9 (408.7 to 1,134.1)	1,478.0 (871.0 to 2,457.5)	110.6 (83.6 to 127.3)	5.2 (46.3 to 80.1)	5.2 (2.6 to 9.4)	10.5 (5.2 to 20.2)	102.7 (81.5 to 122.2)	19.7 (44.7 to 77.6)
Benign prostatic hyperplasia	1,428.3 (1,391.1 to 1,463.6)	1,882.9 (1,859.6 to 1,905.7)	31.9 (28.2 to 35.5)	5.7 (2.8 to 8.6)	50.8 (33.4 to 71.3)	66.7 (43.7 to 93.1)	31.5 (27.6 to 35.2)	5.6 (2.5 to 8.6)
Male infertility due to other causes	241.7 (217.5 to 265.5)	246.9 (224.4 to 272.4)	2.5 (-10.7 to 15.9)	0.3 (-12.7 to 13.3)	1.7 (0.7 to 3.4)	1.7 (0.8 to 3.5)	0.4 (-11.0 to 16.7)	0.4 (-12.8 to 14.3)
Other urinary diseases	-	-	-	-	1.1 (0.4 to 2.1)	1.4 (0.5 to 2.7)	20.0 (7.9 to 119.2)	-5.3 (-27.5 to 72.4)
Gynecological diseases	-	-	-	-	70.9 (45.9 to 109.7)	80.6 (51.7 to 124.7)	13.7 (8.1 to 19.2)	1.9 (-3.6 to 6.7)
Uterine fibroids	2,242.3 (1,954.0 to 2,538.1)	2,727.3 (2,400.1 to 3,070.7)	21.7 (20.4 to 22.9)	1.3 (0.8 to 1.9)	18.7 (9.3 to 34.2)	22.7 (11.0 to 42.0)	21.1 (13.7 to 31.1)	2.0 (-4.3 to 10.1)
Polycystic ovarian syndrome	957.4 (911.3 to 1,005.7)	1,073.3 (1,025.4 to 1,119.6)	12.1 (5.7 to 18.9)	2.8 (-3.2 to 9.2)	9.1 (4.3 to 17.5)	10.2 (4.8 to 19.0)	11.7 (4.7 to 18.7)	2.8 (-3.5 to 9.3)
Female infertility due to other causes	61.8 (34.2 to 90.5)	72.2 (36.5 to 109.6)	14.5 (-41.4 to 161.8)	9.9 (-42.8 to 151.2)	0.4 (0.1 to 0.8)	0.5 (0.2 to 1.0)	14.6 (-40.8 to 164.0)	10.9 (-42.5 to 154.8)
Endometriosis	161.6 (146.6 to 174.8)	175.0 (158.4 to 191.5)	8.2 (-4.6 to 22.3)	0.9 (-13.0 to 12.2)	14.9 (10.0 to 20.9)	16.2 (10.6 to 22.6)	8.2 (-5.1 to 22.2)	1.3 (-12.9 to 12.0)
Genital prolapse	3,616.8 (3,516.2 to 3,724.1)	4,152.8 (4,030.5 to 4,264.8)	14.8 (10.2 to 19.4)	-2.3 (-6.4 to 1.8)	11.5 (5.6 to 21.5)	13.1 (6.4 to 24.5)	14.7 (10.2 to 19.4)	1.3 (-6.4 to 1.9)
Premenstrual syndrome	1,447.5 (1,260.8 to 1,615.7)	1,550.3 (1,393.5 to 1,697.1)	6.9 (-8.8 to 26.4)	1.5 (-13.9 to 19.7)	12.1 (7.5 to 18.2)	13.0 (8.1 to 19.6)	6.9 (-0.0 to 26.6)	1.3 (-13.9 to 19.9)
Other gynecological diseases	166.2 (160.3 to 173.7)	188.0 (177.0 to 216.7)	11.9 (5.4 to 30.3)	4.2 (-4.4 to 18.2)	4.2 (2.9 to 5.7)	5.0 (3.3 to 7.7)	16.4 (5.2 to 54.8)	4.8 (-5.4 to 41.3)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	61.7 (41.3 to 82.4)	62.6 (42.0 to 90.1)	1.5 (-1.6 to 5.0)	-6.4 (-9.2 to -3.3)
Thalassemias	1.7 (0.7 to 6.0)	1.7 (0.7 to 5.8)	0.5 (-6.3 to 4.5)	0.6 (-6.1 to 4.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	1.3 (-11.4 to 17.3)	-
Thalassemia trait	1,283.7 (1,001.8 to 2,249.2)	1,438.3 (1,126.6 to 2,501.1)	12.3 (8.7 to 14.7)	0.6 (-2.5 to 2.8)	34.4 (23.3 to 49.1)	36.0 (24.3 to 51.0)	4.9 (1.5 to 8.1)	-4.1 (-6.8 to -1.3)
Sickle cell disorders	4.7 (3.6 to 5.9)	4.8 (3.8 to 5.9)	2.4 (-4.0 to 10.9)	-1.9 (-8.1 to 5.8)	0.7 (0.4 to 1.0)	0.7 (0.4 to 1.1)	8.1 (0.2 to 17.4)	2.2 (-5.4 to 11.5)
Sickle cell trait	1,567.5 (1,321.1 to 1,864.9)	1,615.6 (1,350.5 to 1,961.9)	3.0 (0.4 to 5.7)	-6.6 (-4.8 to -4.5)	19.0 (12.4 to 27.8)	17.3 (11.3 to 25.0)	-9.0 (-13.3 to -2.4)	-13.4 (-19.5 to -7.6)
G6PD deficiency	421.6 (363.8 to 475.0)	530.5 (478.4 to 582.4)	25.8 (6.0 to 50.4)	25.8 (-5.2 to 35.1)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	15.7 (-32.5 to 4.1)	36.5 (-42.7 to -7.8)
G6PD trait	7,397.7 (7,190.9 to 7,630.0)	7,944.5 (7,687.8 to 8,190.3)	7.3 (2.9 to 11.9)	-3.4 (-7.4 to 0.6)	0.6 (0.4 to 1.0)	0.6 (0.4 to 1.0)	-0.3 (-18.2 to 20.0)	-5.2 (-23.9 to 14.7)
Other hemoglobinopathies and hemolytic anemias	335.9 (328.9 to 344.3)	415.1 (399.1 to 437.9)	23.3 (17.4 to 30.8)	5.8 (0.3 to 13.8)	6.8 (4.5 to 9.9)	7.7 (5.0 to 11.5)	13.2 (2.0 to 32.6)	0.9 (-8.7 to 19.4)
Endocrine, metabolic, blood, and immune disorders	874.9 (861.3 to 889.9)	1,177.5 (1,160.9 to 1,198.4)	34.6 (31.9 to 37.6)	16.4 (13.8 to 19.7)	28.6 (19.5 to 38.8)	39.1 (26.9 to 52.6)	36.7 (32.4 to 41.3)	19.0 (15.2 to 23.6)
Musculoskeletal disorders	-	-	-	-	1,776.8 (1,279.3 to 2,331.1)	2,111.5 (1,513.7 to 2,787.8)	18.8 (0.5 to 36.6)	0.6 (-2.3 to 3.6)
Rheumatoid arthritis	369.0 (360.9 to 378.7)	385.4 (375.7 to 395.6)	4.4 (0.9 to 8.2)	-14.1 (-16.9 to -11.1)	83.4 (60.3 to 108.6)	87.3 (63.3 to 114.9)	4.6 (0.9 to 8.5)	-13.6 (-16.6 to -10.4)
Osteoarthritis	3,786.3 (3,655.0 to 3,915.6)	4,702.5 (4,521.3 to 4,859.0)	24.7 (17.7 to 29.6)	-1.7 (-7.6 to 2.6)	129.1 (85.2 to 185.7)	160.2 (106.8 to 228.6)	24.7 (17.5 to 29.9)	-1.5 (-7.6 to 3.0)
Low back and neck pain	-	-	-	-	1,343.2 (941.4 to 1,806.9)	1,578.3 (1,102.6 to 2,138.0)	17.5 (13.4 to 22.1)	0.5 (-3.4 to 4.5)
Low back pain	8,107.6 (7,863.2 to 8,338.0)	9,700.3 (9,320.2 to 10,134.2)	19.5 (14.1 to 26.0)	1.7 (-3.3 to 7.6)	1.7 (614.7 to 1,227.2)	1.7 (724.9 to 1,469.1)	1.8 (13.8 to 25.8)	1.8 (-3.3 to 7.8)
Neck pain	4,634.9 (4,443.8 to 4,811.2)	5,296.6 (4,891.9 to 5,607.2)	14.9 (4.0 to 20.5)	-2.1 (-11.6 to 2.7)	451.3 (315.9 to 624.2)	514.5 (360.4 to 711.8)	14.6 (3.5 to 20.4)	2.1 (-11.9 to 2.7)
Gout	126.6 (122.4 to 130.7)	158.6 (153.6 to 163.7)	25.3 (19.5 to 30.9)	-0.4 (-5.1 to 4.2)	3.9 (2.7 to 5.2)	4.9 (3.4 to 6.5)	24.8 (16.8 to 33.3)	0.5 (-6.9 to 6.5)
Other musculoskeletal disorders	2,396.8 (1,921.0 to 2,845.7)	3,097.4 (2,498.7 to 3,693.9)	29.2 (24.4 to 33.6)	7.9 (4.5 to 11.1)	217.2 (143.2 to 309.0)	280.8 (186.6 to 402.0)	29.3 (24.6 to 33.8)	8.0 (4.7 to 11.5)
Other non-communicable diseases	-	-	-	-	1,188.3 (796.4 to 1,707.0)	1,321.8 (893.5 to 1,853.3)	11.8 (9.5 to 14.3)	-8.1 (-7.1 to -3.2)
Congenital anomalies	-	-	-	-	95.9 (69.3 to 124.6)	114.7 (83.4 to 149.3)	19.6 (13.2 to 26.0)	5.1 (-0.6 to 10.9)
Neural tube defects	18.1 (17.1 to 19.2)	19.1 (18.1 to 20.1)	5.7 (-2.4 to 13.3)	-3.7 (-11.1 to 3.2)	6.0 (4.2 to 7.8)	6.4 (4.4 to 8.4)	7.3 (-3.3 to 18.5)	-1.9 (-11.7 to 8.3)
Congenital heart anomalies	508.1 (481.0 to 537.3)	531.4 (495.3 to 569.5)	4.5 (-4.3 to 14.7)	-5.9 (-13.7 to 3.2)	18.1 (7.7 to 31.4)	19.1 (8.1 to 32.7)	5.6 (-2.1 to 14.9)	-4.2 (-11.2 to 4.4)
Crofacial clefts	79.9 (74.6 to 85.5)	82.6 (76.1 to 89.4)	3.3 (-5.9 to 13.5)	-7.8 (-16.0 to 1.2)	0.8 (0.5 to 1.1)	0.8 (0.5 to 1.1)	-2.3 (-15.2 to 9.2)	-12.6 (-22.0 to -1.8)
Down syndrome	81.2 (75.2 to 87.7)	99.9 (89.4 to 112.5)	23.2 (9.1 to 38.5)	6.2 (-6.0 to 19.5)	12.0 (9.2 to 15.2)	15.4 (11.6 to 19.4)	15.4 (13.5 to 44.1)	28.2 (-4.5 to 21.2)
Turner syndrome	2.9 (2.6 to 3.2)	3.3 (3.0 to 3.6)	13.3 (1.8 to 30.8)	2.8 (-7.5 to 18.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	11.9 (-0.3 to 30.6)	2.4 (-8.5 to 19.4)
Klinefelter syndrome	2.3 (2.1 to 2.6)	3.1 (2.8 to 3.4)	32.3 (15.9 to 50.4)	18.9 (4.2 to 35.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.2 (8.6 to 49.0)	18.1 (0.3 to 37.2)
Chromosomal unbalanced rearrangements	160.6 (148.9 to 171.0)	196.7 (181.1 to 216.1)	22.0 (11.6 to 37.1)	5.3 (-3.8 to 18.7)	23.7 (17.8 to 30.0)	30.3 (23.0 to 38.5)	27.0 (16.2 to 43.8)	6.6 (-2.3 to 20.7)
Other congenital anomalies	167.4 (122.3 to 214.6)	163.3 (113.8 to 215.6)	-2.7 (-15.5 to 8.7)	-2.7 (-25.3 to -4.6)	42.7 (23.3 to 49.5)	42.7 (27.8 to 59.9)	29.9 (7.9 to 36.3)	9.6 (-2.7 to 23.7)
Skin and subcutaneous diseases	-	-	-	-	422.6 (273.7 to 648.4)	446.3 (293.6 to 677.4)	5.9 (1.4 to 9.4)	-3.8 (-7.6 to -0.9)
Dermatitis	4,039.1 (3,177.8 to 4,897.7)	4,434.1 (3,484.1 to 5,353.2)	9.8 (8.2 to 11.5)	-0.2 (-0.4 to -0.1)	123.2 (78.1 to 180.3)	133.9 (84.8 to 197.0)	8.7 (6.9 to 10.3)	0.4 (-1.1 to 0.4)
Psoriasis	846.5 (730.2 to 972.9)	973.0 (836.5 to 1,118.7)	14.9 (13.2 to 16.7)	0.0 (-0.1 to 0.2)	68.0 (46.4 to 95.0)	78.0 (53.2 to 109.5)	14.7 (12.3 to 17.1)	1.6 (-1.2 to 1.6)
Cellulitis	32.6 (27.4 to 39.7)	42.4 (35.3 to 52.6)	30.0 (20.1 to 41.2)	2.2 (-2.7 to 10.9)	2.9 (1.5 to 3.2)	2.9 (1.9 to 4.2)	28.5 (17.3 to 41.6)	3.2 (-4.1 to 12.4)
Pyoderma	64.0 (54.1 to 76.3)	76.0 (64.2 to 90.7)	18.6 (14.9 to 22.8)	5.5 (2.6 to 8.3)	0.4 (0.1 to 0.8)	0.4 (0.2 to 0.9)	18.1 (13.4 to 22.9)	5.5 (1.8 to 9.1)
Scabies	38.3 (36.4 to 40.4)	32.3 (30.5 to 34.3)	-15.6 (-21.4 to -8.7)	-1.0 (-27.0 to -15.2)	1.0 (0.6 to 1.6)	0.8 (0.5 to 1.3)	-11.7 (-22.3 to -8.0)	-21.7 (-27.6 to -14.5)
Fungal skin diseases	4,241.7 (3,752.2 to 4,675.6)	4,926.1 (4,362.3 to 5,398.5)	16.1 (14.9 to 17.4)	0.3 (0.2 to 0.4)	23.6 (9.6 to 49.5)	27.3 (11.1 to 56.9)	15.9 (14.6 to 17.2)	0.4 (0.1 to 0.7)
Viral skin diseases	1,173.7 (925.1 to 1,439.8)	1,251.5 (995.2 to 1,519.5)	6.6 (4.5 to 9.5)	6.6 (-0.2 to 1.2)	36.1 (21.3 to 56.7)	36.4 (22.5 to 59.7)	18.4 (4.2 to 9.4)	0.5 (-0.4 to 1.6)
Acne vulgaris	9,583.2 (8,676.8 to 10,371.0)	8,020.7 (7,429.2 to 8,685.9)	-16.4 (-25.3 to -4.5)	-16.3 (-25.2 to -5.0)	103.9 (49.7 to 191.9)	86.9 (41.3 to 161.5)	-16.4 (-25.4 to -4.2)	-16.2 (-25.2 to -4.9)
Alopecia areata	100.0 (97.8 to 102.4)	118.0 (115.0 to 121.0)	18.0 (14.1 to 21.5)	0.2 (-3.0 to 3.0)	3.3 (2.1 to 4.9)	3.9 (2.5 to 5.7)	17.5 (12.9 to 21.7)	0.2 (-3.4 to 4.0)
Pruritus	7.9 (7.2 to 8.7)	8.9 (7.8 to 9.8)	12.0 (-3.9 to 28.2)	-7.7 (-20.4 to 6.2)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	11.3 (-5.3 to 30.3)	-7.8 (-21.5 to 8.0)
Urticaria	475.3 (437.1 to 512.5)	595.5 (529.5 to 663.7)	25.3 (10.3 to 43.2)	8.1 (-4.1 to 34.1)	27.8 (18.2 to 39.5)	34.7 (22.3 to 50.2)	25.0 (10.0 to 42.8)	8.2 (-4.0 to 24.4)
Decubitus ulcer	32.0 (29.7 to 34.2)	32.8 (30.0 to 35.2)	2.7 (-9.2 to 14.1)	2.7 (-28.5 to -11.7)	4.5 (3.2 to 5.9)	4.6 (3.2 to 6.2)	2.4 (-10.2 to 14.1)	-19.4 (-28.4 to -10.8)
Other skin and subcutaneous diseases	4,943.4 (2,758.6 to 8,647.2)	5,956.0 (3,287.1 to 10,540.9)	20.3 (15.5 to 23.8)	0.0 (-1.2 to 1.1)	28.7 (11.4 to 64.3)	28.7 (13.4 to 78.5)	20.1 (15.1 to 23.7)	0.1 (-1.2 to 1.1)
Sense organ diseases	-	-	-	-	456.7 (308.0 to 645.8)	532.2 (358.8 to 751.6)	16.6 (12.2 to 20.9)	-7.8 (-11.6 to -4.9)
Glaucoma	76.0 (59.9 to 92.1)	68.0 (52.3 to 85.6)	-10.8 (-18.8 to 1.7)	-39.9 (-36.4 to -22.1)	6.9 (4.5 to 9.8)	6.1 (3.8 to 8.6)	-12.2 (-20.1 to 11.1)	-90.5 (-37.2 to -21.0)
Cataract	203.1 (151.4 to 268.8)	180.1 (129.8 to 246.9)	-11.3 (-21.2 to -1.1)	-33.9 (-40.3 to -26.5)	12.3 (7.9 to 17.8)	11.3 (7.9 to 16.6)	-7.9 (-17.6 to 1.6)	-31.4 (-37.9 to -23.0)
Macular degeneration	272.2 (205.3 to 340.3)	339.6 (256.8 to 427.5)	24.7 (14.5 to 38.3)	-4.9 (-12.3 to 3.5)	17.1 (10.9 to 24.5)	20.6 (13.3 to 29.6)	20.2 (11.4 to 33.6)	-9.5 (-15.5 to -2.5)
Uncorrected refractive error	7,171.9 (6,754.6 to 7,526.2)	8,412.4 (7,852.8 to 8,897.8)	17.1 (7.5 to 27.2)	-5.0 (-13.1 to 3.0)	94.4 (53.6 to 157.3)	105.7 (59.8 to 177.9)	11.8 (4.4 to 19.8)	-8.6 (-14.9 to -2.3)
Age-related and other hearing loss	9,868.8 (8,789.9 to 10,885.0)	11,440.6 (10,120.8 to 12,794.0)	16.0 (11.7 to 19.8)	-8.2 (-12.0 to -4.5)	87.7 (183.9 to 396.4)	336.5 (234.3 to 480.6)	21.6 (15.5 to 28.8)	-

Appendix Table G.4 - United Kingdom prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	1,083.1 (1,065.7 to 1,100.4)	1,228.9 (1,205.8 to 1,252.0)	13.4 (10.8 to 16.3)	0.0 (-2.4 to 2.5)	31.5 (19.9 to 46.4)	35.6 (22.5 to 52.9)	13.3 (10.6 to 16.1)	0.1 (-2.3 to 2.7)
Injuries	-	-	-	-	660.9 (506.3 to 844.8)	530.5 (382.9 to 711.8)	-20.0 (-28.2 to -11.2)	-35.1 (-41.5 to -28.1)
Transport injuries	-	-	-	-	96.6 (72.7 to 123.9)	49.2 (35.7 to 65.4)	-49.3 (-54.3 to -43.5)	-58.9 (-63.0 to -54.1)
Road injuries	-	-	-	-	89.5 (67.4 to 114.5)	38.9 (28.2 to 51.6)	-56.7 (-60.9 to -51.8)	-64.7 (-68.2 to -60.6)
Pedestrian road injuries	-	-	-	-	18.3 (13.8 to 23.8)	7.0 (5.0 to 9.5)	-62.0 (-65.8 to -57.9)	-49.9 (-72.1 to -45.4)
Cyclist road injuries	-	-	-	-	8.5 (6.5 to 11.0)	3.2 (2.3 to 4.2)	-63.2 (-67.6 to -57.7)	-69.1 (-72.8 to -64.4)
Motorcyclist road injuries	-	-	-	-	16.3 (12.2 to 20.9)	6.7 (4.8 to 9.1)	-59.1 (-64.5 to -52.3)	-66.8 (-71.2 to -61.1)
Motor vehicle road injuries	-	-	-	-	45.7 (34.7 to 58.3)	21.9 (16.0 to 28.7)	-52.3 (-56.5 to -47.7)	-61.2 (-64.6 to -57.3)
Other road injuries	-	-	-	-	0.6 (0.5 to 0.8)	0.2 (0.1 to 0.2)	-68.9 (-72.5 to -64.6)	-74.5 (-77.5 to -70.8)
Other transport injuries	-	-	-	-	7.1 (5.3 to 9.3)	10.3 (7.4 to 13.9)	44.9 (34.6 to 55.2)	18.5 (10.5 to 26.7)
Unintentional injuries	-	-	-	-	556.9 (428.2 to 710.9)	476.1 (343.3 to 639.2)	-14.8 (-23.5 to -5.5)	-30.2 (-36.9 to -22.9)
Falls	-	-	-	-	451.7 (346.4 to 574.5)	386.5 (279.1 to 516.5)	-14.7 (-24.5 to -4.0)	-30.3 (-37.9 to -22.0)
Drowning	-	-	-	-	0.6 (0.4 to 0.7)	0.5 (0.3 to 0.6)	-22.2 (-26.0 to -18.3)	-36.5 (-39.7 to -33.4)
Fire, heat, and hot substances	-	-	-	-	11.6 (7.4 to 18.1)	9.0 (5.3 to 14.6)	-23.4 (-30.0 to -18.1)	-37.1 (-42.6 to -32.0)
Poisonings	-	-	-	-	0.7 (0.5 to 0.9)	0.4 (0.3 to 0.5)	-41.0 (-44.7 to -37.2)	-50.6 (-53.9 to -47.4)
Exposure to mechanical forces	-	-	-	-	54.3 (40.7 to 71.8)	48.0 (34.2 to 65.4)	-11.9 (-18.5 to -5.6)	-25.7 (-31.1 to -20.2)
Unintentional firearm injuries	-	-	-	-	0.6 (0.4 to 0.7)	0.4 (0.3 to 0.5)	-35.2 (-41.2 to -28.4)	-44.1 (-49.3 to -38.3)
Unintentional suffocation	-	-	-	-	0.5 (0.4 to 0.6)	1.0 (0.7 to 1.3)	98.2 (80.1 to 115.9)	62.9 (47.9 to 77.5)
Other exposure to mechanical forces	-	-	-	-	53.3 (39.8 to 70.5)	46.6 (33.2 to 63.6)	-12.7 (-19.2 to -6.4)	-26.3 (-31.7 to -20.9)
Adverse effects of medical treatment	-	-	-	-	3.3 (2.1 to 4.8)	3.9 (2.5 to 5.8)	19.5 (15.7 to 23.5)	-0.1 (-3.0 to 2.8)
Animal contact	-	-	-	-	2.2 (1.6 to 3.0)	2.9 (2.1 to 4.1)	30.8 (23.1 to 39.2)	8.7 (2.2 to 15.6)
Venomous animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	24.3 (16.7 to 32.6)	7.2 (0.3 to 13.9)
Non-venomous animal contact	-	-	-	-	1.9 (1.4 to 2.6)	2.5 (1.7 to 3.6)	32.0 (23.5 to 40.5)	8.9 (1.9 to 16.3)
Foreign body	-	-	-	-	3.2 (2.3 to 4.4)	3.1 (2.0 to 4.3)	-4.9 (-13.0 to 2.8)	-18.3 (-26.6 to -10.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.6 (0.4 to 0.7)	0.5 (0.4 to 0.6)	-7.5 (-14.5 to 0.7)	-24.7 (-30.7 to -18.0)
Foreign body in eyes	-	-	-	-	0.5 (0.3 to 0.7)	0.4 (0.3 to 0.7)	-2.3 (-10.1 to 3.7)	-12.6 (-20.8 to -5.7)
Foreign body in other body part	-	-	-	-	2.2 (1.5 to 3.1)	2.1 (1.3 to 3.1)	-8.8 (-14.9 to 4.0)	-18.0 (-27.5 to -9.5)
Other unintentional injuries	-	-	-	-	29.2 (20.8 to 39.5)	21.9 (15.3 to 30.3)	-25.2 (-29.4 to -20.9)	-42.4 (-45.8 to -39.1)
Self-harm and interpersonal violence	-	-	-	-	7.2 (5.4 to 9.3)	5.1 (3.7 to 6.8)	-29.6 (-34.6 to -24.2)	-42.4 (-46.5 to -37.8)
Self-harm	-	-	-	-	2.8 (2.1 to 3.7)	2.4 (1.7 to 3.2)	-15.3 (-19.5 to -11.2)	-30.9 (-34.2 to -27.5)
Interpersonal violence	-	-	-	-	4.4 (3.4 to 5.7)	2.7 (2.0 to 3.7)	-38.6 (-44.2 to -32.0)	-49.2 (-53.9 to -43.5)
Assault by firearm	-	-	-	-	0.5 (0.4 to 0.6)	0.3 (0.2 to 0.4)	-42.0 (-46.0 to -37.4)	-52.4 (-55.7 to -48.6)
Assault by sharp object	-	-	-	-	0.4 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-24.1 (-28.9 to -19.4)	-37.1 (-41.0 to -33.1)
Assault by other means	-	-	-	-	3.5 (2.7 to 4.5)	2.1 (1.5 to 2.9)	-39.8 (-45.8 to -32.7)	-50.2 (-55.1 to -44.1)
Forces of nature, war, and legal intervention	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-42.2 (-61.0 to -18.7)	51.2 (-67.1 to -31.2)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-83.9 (-92.8 to -61.4)	-86.4 (-94.0 to -66.7)
Collective violence and legal intervention	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-34.2 (-56.7 to -5.0)	43.6 (-63.2 to -18.7)

Appendix Table G.4 - United States prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	31,220.4 (23,431.4 to 39,869.5)	43,350.6 (32,492.9 to 55,328.9)	38.9 (36.5 to 41.2)	38.9 (0.4 to 3.9)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1,529.5 (1,083.8 to 2,092.1)	2,011.9 (1,437.0 to 2,758.4)	31.5 (21.5 to 43.0)	7.3 (-0.6 to 16.3)
HIV/AIDS and tuberculosis	-	-	-	-	81.3 (51.5 to 125.9)	56.0 (32.1 to 88.3)	-32.1 (-51.0 to -2.2)	-48.4 (-63.1 to -24.4)
Tuberculosis	45.8 (43.7 to 48.0)	34.3 (32.5 to 36.3)	-25.2 (-28.2 to -21.6)	-41.9 (-44.1 to -39.4)	14.0 (9.2 to 19.0)	10.3 (6.9 to 14.2)	-25.9 (-40.5 to -10.6)	-42.1 (-53.7 to -29.0)
HIV/AIDS	-	-	-	-	67.4 (40.7 to 106.3)	45.7 (23.3 to 77.7)	-49.8 (-56.1 to -2.9)	-49.8 (-67.0 to -20.3)
HIV/AIDS resulting in mycobacterial infection	0.7 (0.4 to 1.0)	0.1 (0.1 to 0.3)	-78.2 (-87.4 to -65.8)	-82.9 (-90.1 to -72.8)	0.3 (0.1 to 0.5)	0.1 (0.0 to 0.1)	-78.2 (-87.5 to -65.8)	-83.0 (-90.1 to -72.8)
HIV/AIDS resulting in other diseases	471.1 (370.7 to 592.1)	545.1 (330.2 to 876.5)	12.0 (-20.5 to 68.0)	-15.9 (-40.7 to 31.3)	67.1 (40.4 to 106.0)	45.6 (23.3 to 77.7)	-33.3 (-56.1 to 3.1)	-49.7 (-66.9 to -20.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	188.6 (114.7 to 297.9)	236.0 (143.7 to 371.8)	25.2 (19.8 to 30.9)	0.4 (-3.9 to 4.9)
Diarrheal diseases	80.3 (71.0 to 88.9)	100.1 (89.0 to 111.7)	24.7 (6.5 to 45.7)	0.5 (-14.5 to 18.2)	12.8 (8.5 to 18.3)	15.8 (10.5 to 22.0)	22.3 (13.1 to 51.9)	1.0 (-17.6 to 22.8)
Intestinal infectious diseases	-	-	-	-	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.4)	-24.6 (-36.9 to -7.9)	-40.2 (-50.1 to -27.7)
Typhoid fever	1.7 (1.6 to 1.9)	1.2 (1.1 to 1.4)	-29.0 (-38.9 to -16.3)	-43.8 (-50.9 to -34.7)	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-29.0 (-39.0 to -16.3)	-43.9 (-51.0 to -34.8)
Paratyphoid fever	0.7 (0.6 to 0.9)	0.7 (0.6 to 0.8)	-5.1 (-27.1 to 21.1)	-23.4 (-39.7 to -4.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-5.1 (-27.2 to 21.0)	-23.5 (-39.9 to -4.0)
Other intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-22.1 (-60.2 to 48.3)	-38.3 (-68.3 to 18.4)
Lower respiratory infections	16.2 (15.6 to 16.8)	21.0 (20.2 to 21.8)	29.5 (23.7 to 35.7)	-3.6 (-7.8 to 1.0)	1.7 (1.1 to 2.3)	2.2 (1.5 to 3.1)	29.4 (9.7 to 53.8)	3.1 (-18.3 to 16.8)
Upper respiratory infections	9,222.8 (8,799.9 to 9,661.4)	12,124.6 (11,786.1 to 12,436.9)	31.2 (25.5 to 39.3)	7.1 (2.2 to 13.4)	107.8 (59.9 to 178.4)	141.2 (79.0 to 232.8)	30.8 (24.1 to 39.4)	6.8 (1.3 to 13.6)
Otitis media	2,843.3 (2,700.6 to 3,002.6)	3,161.2 (2,994.7 to 3,337.3)	11.1 (3.6 to 19.5)	-12.9 (-18.6 to -6.8)	50.4 (29.2 to 81.3)	56.2 (33.0 to 91.2)	11.5 (3.0 to 20.8)	-12.9 (-19.2 to -6.3)
Meningitis	-	-	-	-	6.5 (4.5 to 9.2)	8.2 (5.5 to 11.8)	27.6 (-1.1 to 59.2)	3.3 (-22.4 to 29.7)
Pneumococcal meningitis	37.3 (23.4 to 62.3)	48.1 (31.1 to 78.2)	29.4 (0.5 to 61.6)	-0.5 (-23.6 to 28.9)	3.6 (2.4 to 5.2)	4.9 (3.2 to 7.5)	36.9 (-11.1 to 98.2)	9.0 (-30.0 to 61.6)
H influenzae type B meningitis	4.4 (1.5 to 10.3)	5.0 (1.8 to 11.4)	12.6 (-34.2 to 122.7)	-9.2 (-45.0 to 89.4)	0.7 (0.4 to 1.1)	0.8 (0.5 to 1.3)	21.2 (-36.8 to 144.7)	1.4 (-47.5 to 108.0)
Meningococcal meningitis	4.0 (1.6 to 9.7)	4.6 (1.8 to 11.5)	13.5 (-28.6 to 82.6)	-10.8 (-43.3 to 51.6)	0.7 (0.4 to 1.2)	0.7 (0.4 to 1.5)	13.8 (-30.9 to 101.7)	-8.6 (-44.7 to 65.8)
Other meningitis	10.9 (6.5 to 21.4)	11.8 (6.9 to 23.1)	7.7 (-17.7 to 40.7)	-13.0 (-33.2 to 17.1)	1.6 (1.0 to 2.3)	1.7 (1.1 to 2.7)	9.7 (-24.5 to 62.8)	-9.4 (-37.9 to 37.2)
Encephalitis	10.9 (4.8 to 30.4)	14.4 (6.3 to 41.3)	32.5 (6.7 to 58.4)	-19.9 (-19.9 to 20.5)	1.6 (1.1 to 2.2)	2.2 (1.4 to 3.0)	37.2 (4.7 to 70.8)	2.8 (-22.1 to 28.7)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.6 (-88.7 to 515.6)	-38.0 (-91.4 to 364.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.6 (-88.7 to 524.7)	-38.3 (-91.5 to 367.3)
Whooping cough	14.6 (11.2 to 18.7)	14.9 (11.4 to 19.1)	2.1 (1.6 to 2.5)	-5.3 (-5.8 to -4.9)	0.7 (0.4 to 1.2)	0.7 (0.4 to 1.2)	0.9 (-21.6 to 32.4)	-6.6 (-27.4 to 22.6)
Tetanus	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	56.7 (-71.3 to -33.5)	-64.7 (-76.7 to -45.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-54.4 (-71.4 to -18.7)	-62.6 (-77.6 to -32.6)
Measles	0.8 (0.8 to 0.8)	0.0 (0.0 to 0.0)	-98.7 (-98.8 to -98.5)	-98.8 (-98.9 to -98.6)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-98.7 (-98.8 to -98.5)	-98.8 (-98.9 to -98.6)
Varicella and herpes zoster	188.8 (170.2 to 208.1)	246.3 (224.2 to 274.8)	30.6 (13.3 to 50.8)	-0.2 (-12.0 to 12.8)	6.6 (4.1 to 10.1)	9.3 (5.5 to 14.1)	41.1 (10.5 to 75.2)	0.6 (-20.4 to 24.2)
Neglected tropical diseases and malaria	-	-	-	-	3.6 (2.1 to 6.5)	2.4 (1.4 to 4.7)	-31.4 (-66.3 to 26.3)	-47.8 (-74.6 to 1.7)
Malaria	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	12.2 (-69.9 to 275.6)	-7.1 (-75.1 to 211.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	13.1 (-69.5 to 275.1)	-5.7 (-74.9 to 207.0)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Visceral leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cutaneous and mucocutaneous leishmaniasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	4.2 (1.8 to 10.4)	1.4 (0.6 to 2.8)	-64.9 (-90.7 to -4.5)	-73.4 (-93.0 to -24.4)	1.7 (0.7 to 4.5)	0.6 (0.2 to 1.4)	-62.6 (-89.4 to 7.9)	-71.5 (-92.1 to -15.2)
Cystic echinococcosis	17.6 (16.5 to 19.2)	11.7 (10.1 to 13.2)	-35.5 (-42.6 to -24.9)	-52.0 (-57.5 to -46.4)	1.7 (1.1 to 2.4)	1.1 (0.7 to 1.7)	-31.6 (-45.5 to -13.6)	-49.9 (-59.4 to -37.8)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	0.9 (0.1 to 3.4)	3.0 (0.3 to 11.5)	263.0 (235.8 to 296.9)	187.3 (165.7 to 214.1)	0.1 (0.0 to 0.6)	0.5 (0.1 to 2.0)	262.8 (235.4 to 296.7)	186.7 (165.1 to 213.5)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.7 (-30.2 to 24.2)	-15.0 (-46.1 to -2.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	7.6 (-30.3 to 24.2)	-15.2 (-46.1 to -2.1)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.5)	1,176.5 (573.0 to 1,667.8)	910.3 (432.9 to 1,298.9)
Maternal disorders	-	-	-	-	2.3 (1.4 to 3.6)	2.4 (1.4 to 3.6)	0.4 (-24.2 to 28.0)	-7.3 (-29.9 to 18.4)
Maternal hemorrhage	26.6 (20.2 to 32.9)	24.5 (17.8 to 31.7)	-8.5 (-36.5 to 28.0)	-14.8 (-41.5 to 19.2)	0.7 (0.4 to 1.1)	0.6 (0.2 to 0.9)	-20.7 (-68.9 to 53.2)	-27.2 (-71.4 to 39.8)
Maternal sepsis and other maternal infections	33.9 (20.2 to 52.9)	34.0 (21.1 to 51.0)	-1.0 (-31.0 to 57.1)	-7.4 (-35.3 to 45.7)	0.4 (0.2 to 0.7)	0.4 (0.2 to 0.7)	-9.2 (-35.5 to 25.4)	2.8 (-41.8 to 15.1)
Maternal hypertensive disorders	13.4 (8.9 to 19.0)	14.5 (9.7 to 20.5)	7.7 (-0.6 to 19.0)	0.1 (-7.9 to 10.7)	0.7 (0.3 to 1.1)	0.7 (0.4 to 1.2)	7.6 (-28.2 to 55.7)	0.3 (-33.0 to 46.3)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	5.9 (-6.7 to 20.0)	-2.1 (-13.7 to 11.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.3 (-6.5 to 20.5)	-1.8 (-13.5 to 11.5)
Complications of abortion	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	-2.3 (-9.0 to 6.4)	-8.8 (-15.0 to -0.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-2.0 (-8.8 to 6.7)	-8.6 (-14.8 to -0.5)
Other maternal disorders	-	-	-	-	0.5 (0.3 to 0.8)	0.7 (0.4 to 1.0)	39.5 (5.4 to 71.3)	19.4 (-12.4 to 58.4)
Neonatal disorders	-	-	-	-	398.7 (286.2 to 528.9)	683.0 (487.8 to 910.4)	72.0 (32.9 to 111.2)	39.3 (7.6 to 71.3)
Preterm birth complications	1,891.6 (1,449.6 to 2,443.8)	3,796.6 (2,701.1 to 5,331.2)	99.3 (67.6 to 139.1)	59.6 (34.3 to 91.5)	232.3 (163.2 to 313.3)	462.6 (329.9 to 613.6)	99.6 (58.4 to 149.3)	61.5 (28.2 to 102.5)
Neonatal encephalopathy due to birth asphyxia and trauma	251.4 (150.5 to 448.1)	249.0 (129.9 to 537.9)	-5.0 (-33.4 to 36.5)	-22.8 (-45.5 to 9.8)	61.2 (41.0 to 86.0)	56.3 (37.1 to 80.7)	-6.9 (-39.0 to 33.5)	-23.4 (-49.4 to 10.0)
Neonatal sepsis and other neonatal infections	0.2 (0.1 to 0.4)	0.4 (0.1 to 0.8)	102.4 (82.5 to 150.9)	92.9 (73.9 to 139.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	103.7 (59.5 to 163.3)	94.1 (52.0 to 151.0)
Hemolytic disease and other neonatal jaundice	86.1 (28.1 to 198.4)	51.3 (13.2 to 129.0)	-39.5 (-89.2 to 210.2)	-39.5 (-91.4 to 151.7)	36.2 (11.4 to 84.7)	22.4 (5.7 to 56.9)	-36.6 (-88.5 to 204.0)	-48.9 (-90.7 to 145.7)
Other neonatal disorders	-	-	-	-	68.9 (42.1 to 101.4)	141.7 (85.5 to 213.1)	105.4 (34.4 to 210.1)	66.3 (9.0 to 150.8)
Nutritional deficiencies	-	-	-	-	769.4 (511.1 to 1,130.5)	929.2 (613.6 to 1,363.4)	20.8 (17.1 to 24.7)	-0.0 (-2.9 to 3.0)
Protein-energy malnutrition	8.7 (4.7 to 13.7)	10.6 (5.6 to 17.3)	20.6 (-9.9 to 67.2)	-24.1 (-42.0 to 2.7)	0.9 (0.4 to 1.7)	1.2 (0.5 to 2.1)	22.1 (-20.5 to 83.4)	-23.2 (-48.8 to 13.2)
Iodine deficiency	1,548.7 (929.9 to 2,248.7)	1,360.7 (864.3 to 2,062.0)	-11.9 (-51.0 to 57.9)	-29.5 (-61.0 to 27.0)	21.9 (13.5 to 50.2)	24.3 (12.2 to 43.1)	-12.2 (-51.2 to 60.9)	-29.7 (-60.6 to 27.6)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Iron deficiency anemia	27,993.2 (27,585.4 to 28,380.3)	35,318.8 (35,022.7 to 35,663.2)	26.2 (24.1 to 28.4)	1.7 (-0.2 to 3.5)	740.7 (489.8 to 1,088.6)	903.7 (596.0 to 1,330.5)	22.0 (18.8 to 25.4)	1.0 (-1.5 to 3.7)

Appendix Table G.4 - United States prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other nutritional deficiencies	-	-	-	-	0.1 (0.1 to 0.3)	0.2 (0.1 to 0.3)	37.5 (-15.3 to 112.3)	37.5 (-45.4 to 30.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	85.6 (51.4 to 143.1)	103.0 (62.0 to 172.8)	20.2 (8.5 to 33.7)	-1.5 (-12.2 to 11.5)
Sexually transmitted diseases excluding HIV	-	-	-	-	36.3 (18.5 to 71.2)	44.0 (22.3 to 87.6)	21.5 (9.5 to 34.3)	-2.4 (-11.7 to 8.6)
Syphilis	20.1 (18.6 to 21.6)	28.3 (22.8 to 32.7)	40.6 (16.2 to 68.6)	-2.8 (-21.3 to 17.4)	3.7 (2.4 to 5.3)	5.1 (3.3 to 7.5)	39.6 (5.2 to 88.1)	-3.6 (-28.1 to 33.3)
Chlamydial infection	4,187.0 (3,691.6 to 4,653.1)	4,966.1 (4,525.6 to 5,449.3)	18.4 (1.8 to 38.2)	2.9 (-11.8 to 20.3)	10.6 (5.5 to 19.5)	12.0 (6.9 to 23.8)	6.9 (-2.5 to 52.0)	21.0 (-15.7 to 32.7)
Gonococcal infection	586.8 (451.4 to 698.9)	588.9 (485.4 to 705.7)	0.4 (-26.7 to 37.4)	0.0 (-34.6 to 24.7)	2.7 (1.4 to 4.9)	2.5 (1.2 to 4.5)	-7.0 (-39.4 to 34.2)	-15.7 (-45.4 to 23.4)
Trichomoniasis	2,068.2 (1,486.1 to 2,652.7)	2,270.1 (1,731.8 to 2,949.7)	8.6 (-25.0 to 75.9)	-3.4 (-34.2 to 61.7)	3.4 (1.2 to 7.7)	3.8 (1.4 to 8.7)	9.7 (-33.2 to 94.2)	-2.0 (-41.5 to 78.9)
Genital herpes	57,434.6 (56,119.7 to 58,594.4)	73,923.8 (72,207.0 to 75,513.5)	28.7 (24.8 to 32.4)	-5.0 (-7.9 to -2.2)	14.9 (4.9 to 36.3)	18.9 (5.8 to 45.8)	26.5 (19.2 to 32.1)	-5.4 (-10.1 to -0.9)
Other sexually transmitted diseases	47.4 (34.5 to 59.9)	38.4 (28.4 to 48.9)	-19.0 (-34.1 to -2.2)	-25.0 (-38.7 to -8.9)	0.9 (0.6 to 1.4)	0.9 (0.6 to 1.4)	2.3 (-3.5 to 41.1)	-12.2 (-40.8 to 27.7)
Hepatitis	-	-	-	-	7.1 (4.5 to 10.4)	7.9 (5.0 to 11.7)	11.3 (1.0 to 25.2)	11.3 (-20.7 to 0.4)
Hepatitis A	193.9 (183.7 to 204.5)	216.0 (202.2 to 230.4)	11.4 (10.0 to 12.6)	-8.9 (-10.4 to -7.4)	5.6 (3.6 to 8.4)	6.5 (4.1 to 9.7)	14.5 (1.7 to 28.9)	-8.0 (-18.2 to 3.5)
Hepatitis B	1,922.6 (1,730.9 to 2,131.4)	1,861.1 (1,670.6 to 2,046.8)	-3.7 (-14.7 to 11.1)	-26.0 (-34.6 to -14.0)	1.1 (0.6 to 1.7)	1.0 (0.6 to 1.6)	-6.5 (-35.7 to 51.0)	-27.6 (-49.9 to 16.5)
Hepatitis C	3,105.9 (2,872.6 to 3,334.2)	3,228.7 (2,995.2 to 3,458.4)	3.9 (-5.7 to 15.6)	-24.8 (-31.6 to -16.1)	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.6)	10.5 (-12.6 to 40.0)	-19.6 (-35.0 to -0.2)
Hepatitis E	-	-	-	-	-	-	-	-
Leprosy	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	47.6 (-17.2 to 176.0)	0.5 (-44.8 to 90.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.1 (-26.7 to 386.1)	-3.9 (-51.9 to 230.4)
Other infectious diseases	1,191.7 (1,013.9 to 1,385.6)	1,464.2 (1,322.7 to 1,633.0)	22.8 (4.5 to 45.1)	1.3 (-14.3 to 21.2)	42.3 (25.8 to 63.5)	51.1 (32.3 to 77.6)	20.7 (0.4 to 51.2)	0.5 (-17.2 to 27.9)
Non-communicable diseases	-	-	-	-	27,500.7 (20,437.8 to 35,193.2)	38,807.4 (28,926.4 to 49,703.9)	41.2 (38.5 to 43.7)	3.6 (1.9 to 5.5)
Neoplasms	-	-	-	-	566.5 (420.9 to 729.1)	941.3 (692.4 to 1,235.1)	65.2 (51.7 to 83.4)	8.7 (0.0 to 20.9)
Esophageal cancer	22.3 (18.6 to 26.6)	35.4 (28.4 to 44.2)	57.4 (23.6 to 108.1)	-0.0 (-21.4 to 31.6)	3.1 (2.2 to 4.3)	4.9 (3.3 to 6.9)	55.9 (18.4 to 102.3)	-1.3 (-24.8 to 27.6)
Stomach cancer	74.9 (65.8 to 86.3)	93.4 (80.6 to 108.5)	24.1 (7.3 to 43.6)	-18.7 (-29.5 to -6.5)	7.8 (5.6 to 10.2)	9.3 (6.6 to 12.5)	19.8 (0.6 to 44.6)	-21.7 (-34.6 to -6.4)
Liver cancer	-	-	-	-	2.5 (1.7 to 3.7)	6.5 (3.8 to 9.8)	167.2 (69.6 to 279.7)	71.8 (9.9 to 143.7)
Liver cancer due to hepatitis B	1.8 (1.3 to 2.7)	6.3 (3.9 to 9.4)	249.0 (92.2 to 508.1)	133.2 (23.1 to 287.2)	0.3 (0.2 to 0.4)	0.8 (0.4 to 1.2)	201.0 (175.1 to 405.7)	93.0 (13.5 to 223.4)
Liver cancer due to hepatitis C	3.5 (2.6 to 4.9)	25.1 (16.3 to 35.2)	628.6 (336.3 to 1,068.3)	368.3 (179.6 to 655.6)	0.5 (0.3 to 0.7)	3.0 (1.7 to 4.6)	523.4 (284.6 to 855.7)	301.9 (148.1 to 513.5)
Liver cancer due to alcohol use	8.3 (6.0 to 12.0)	14.8 (9.0 to 21.9)	75.8 (1.5 to 197.5)	13.3 (-34.7 to 90.8)	1.1 (0.7 to 1.7)	1.8 (1.0 to 2.9)	54.7 (-6.9 to 150.9)	-1.0 (-40.5 to 59.0)
Liver cancer due to other causes	4.5 (3.3 to 6.0)	7.7 (4.9 to 11.0)	70.3 (1.9 to 176.8)	10.2 (-33.3 to 79.7)	0.6 (0.4 to 0.9)	0.7 (0.5 to 1.5)	49.5 (-9.5 to 132.3)	-2.9 (-41.1 to 49.2)
Larynx cancer	56.8 (45.9 to 70.5)	70.3 (54.4 to 89.5)	23.4 (-1.2 to 52.9)	-23.1 (-38.7 to -5.8)	5.6 (3.8 to 7.7)	6.3 (4.2 to 9.0)	12.4 (-12.0 to 45.2)	29.6 (-44.9 to -9.2)
Tracheal, bronchus and lung cancer	358.9 (332.1 to 386.1)	488.9 (430.0 to 546.1)	35.9 (19.1 to 54.3)	-13.0 (-23.2 to -1.5)	45.6 (33.7 to 58.5)	59.8 (44.0 to 76.7)	31.0 (14.7 to 49.4)	11.0 (-26.6 to -4.4)
Breast cancer	1,823.5 (1,614.3 to 1,971.4)	3,179.4 (2,942.7 to 3,405.9)	73.8 (56.3 to 98.1)	10.3 (-0.6 to 26.7)	104.1 (72.6 to 142.8)	153.3 (103.5 to 214.5)	46.2 (28.1 to 72.7)	-6.7 (-18.3 to 10.5)
Cervical cancer	107.1 (88.6 to 126.5)	99.4 (74.9 to 125.1)	-7.1 (-28.2 to 18.6)	-32.9 (-48.5 to -14.0)	7.8 (5.4 to 10.9)	7.5 (4.8 to 9.9)	-4.6 (-27.8 to 25.3)	-30.8 (-47.7 to -10.0)
Uterine cancer	264.3 (214.4 to 312.9)	426.7 (325.5 to 576.8)	60.3 (21.7 to 120.7)	17.3 (-22.8 to 38.9)	21.1 (14.4 to 23.9)	27.1 (17.7 to 41.1)	55.2 (16.6 to 119.0)	31.2 (-29.6 to 37.2)
Prostate cancer	1,446.2 (1,195.7 to 1,652.9)	3,102.3 (2,618.9 to 3,973.5)	112.0 (68.4 to 180.3)	41.9 (13.2 to 87.8)	107.7 (72.0 to 145.7)	216.4 (148.9 to 322.0)	93.5 (47.8 to 180.4)	29.3 (0.0 to 89.9)
Colon and rectum cancer	827.2 (780.9 to 872.9)	1,163.5 (1,051.2 to 1,280.8)	40.3 (25.7 to 57.7)	-8.0 (-17.2 to 3.0)	66.1 (48.8 to 84.5)	88.8 (64.2 to 117.1)	34.1 (18.5 to 52.7)	-12.0 (-22.1 to -0.3)
Lip and oral cavity cancer	138.1 (119.1 to 158.4)	203.8 (165.6 to 245.4)	47.8 (13.5 to 85.9)	-6.2 (-27.7 to 18.7)	11.2 (7.7 to 15.2)	15.8 (10.7 to 21.6)	42.1 (6.4 to 83.1)	-9.4 (-31.5 to 15.2)
Nasopharynx cancer	12.1 (8.9 to 15.8)	13.2 (9.8 to 19.5)	9.0 (-23.0 to 64.7)	-28.4 (-49.5 to 7.6)	1.1 (0.7 to 1.7)	1.2 (0.8 to 1.9)	3.9 (-28.5 to 52.9)	-31.8 (-51.6 to -0.7)
Other pharynx cancer	46.6 (36.0 to 57.4)	79.0 (59.5 to 105.7)	67.2 (21.9 to 141.1)	2.9 (-24.8 to 48.5)	2.9 (2.5 to 5.2)	6.1 (3.8 to 9.1)	60.3 (13.4 to 135.9)	-1.2 (-29.6 to 44.7)
Gallbladder and biliary tract cancer	7.4 (5.6 to 9.3)	11.3 (8.7 to 14.9)	52.6 (16.2 to 104.7)	-0.1 (-23.2 to 32.0)	1.7 (1.1 to 2.3)	2.4 (1.5 to 3.6)	41.6 (2.5 to 102.5)	-7.0 (-31.5 to 28.8)
Pancreatic cancer	32.2 (28.1 to 36.0)	54.6 (46.7 to 63.3)	69.5 (39.1 to 107.9)	10.0 (-9.4 to 34.4)	5.6 (3.9 to 7.4)	9.3 (6.6 to 12.3)	67.5 (34.3 to 107.5)	8.3 (-12.8 to 34.3)
Malignant skin melanoma	347.4 (237.4 to 478.4)	760.8 (513.4 to 1,135.2)	116.4 (79.5 to 173.3)	44.9 (20.5 to 84.7)	20.2 (12.4 to 31.3)	42.8 (25.3 to 69.5)	109.5 (69.7 to 167.8)	40.2 (14.0 to 81.1)
Non-melanoma skin cancer	724.5 (627.0 to 856.9)	1,410.3 (1,107.0 to 1,738.5)	91.2 (46.4 to 149.4)	21.1 (-4.9 to 62.3)	21.1 (5.4 to 16.2)	21.1 (11.5 to 34.8)	112.4 (67.7 to 167.7)	37.8 (9.5 to 72.5)
Ovarian cancer	96.3 (85.9 to 108.7)	125.3 (104.3 to 148.6)	29.9 (5.3 to 59.0)	-16.2 (-31.6 to 2.2)	12.0 (8.3 to 16.1)	15.4 (10.8 to 20.8)	28.5 (0.6 to 63.7)	-16.6 (-35.1 to 5.7)
Testicular cancer	65.2 (46.2 to 97.8)	78.7 (53.6 to 112.9)	20.4 (-23.4 to 84.9)	6.1 (-31.6 to 61.8)	3.9 (2.3 to 6.4)	4.6 (2.6 to 7.3)	18.9 (-25.0 to 82.7)	4.5 (-33.9 to 62.5)
Kidney cancer	192.5 (170.9 to 216.3)	431.9 (372.0 to 507.6)	123.8 (87.3 to 170.6)	43.7 (20.0 to 72.2)	13.3 (9.4 to 18.1)	28.5 (19.4 to 39.6)	113.6 (75.1 to 164.2)	37.2 (12.9 to 69.1)
Bladder cancer	324.3 (283.5 to 389.9)	504.9 (393.5 to 591.3)	54.8 (23.2 to 85.5)	21.3 (-19.8 to 21.0)	21.6 (16.8 to 32.5)	21.6 (24.6 to 48.7)	51.7 (18.3 to 82.9)	2.3 (-23.1 to 18.6)
Brain and nervous system cancer	62.4 (52.2 to 72.7)	95.4 (80.2 to 116.2)	52.4 (29.8 to 81.2)	8.8 (-7.1 to 28.3)	6.4 (4.5 to 8.6)	9.4 (6.6 to 13.0)	47.1 (22.9 to 77.2)	3.7 (-13.2 to 23.8)
Thyroid cancer	117.4 (99.9 to 150.4)	266.4 (191.8 to 327.6)	132.5 (56.1 to 199.4)	6.9 (8.3 to 107.3)	6.9 (4.5 to 10.1)	15.1 (9.1 to 22.6)	122.8 (49.5 to 193.6)	53.6 (4.5 to 101.9)
Mesothelioma	2.6 (2.2 to 4.0)	4.9 (3.4 to 6.5)	91.5 (19.8 to 146.4)	24.4 (-19.7 to 59.7)	0.6 (0.4 to 1.0)	1.1 (0.7 to 1.6)	84.1 (12.5 to 145.2)	20.5 (-24.5 to 58.5)
Hodgkin lymphoma	58.0 (41.0 to 74.9)	77.9 (58.6 to 127.0)	34.3 (-5.5 to 133.4)	29.6 (-25.4 to 88.1)	21.1 (2.9 to 6.0)	21.1 (3.7 to 9.8)	51.7 (8.8 to 126.2)	21.7 (-28.5 to 81.3)
Non-Hodgkin lymphoma	274.5 (195.2 to 380.6)	535.3 (352.8 to 716.5)	93.6 (40.1 to 169.4)	27.7 (-7.0 to 80.2)	19.7 (12.7 to 28.5)	36.5 (22.1 to 54.6)	84.4 (30.3 to 155.7)	21.8 (-13.5 to 71.5)
Multiple myeloma	55.8 (37.8 to 81.5)	109.0 (76.5 to 165.1)	93.9 (32.6 to 196.0)	26.1 (-12.6 to 92.1)	10.9 (6.7 to 17.1)	20.1 (12.1 to 30.4)	84.8 (23.3 to 178.3)	20.1 (-19.9 to 79.5)
Leukemia	152.1 (136.7 to 168.0)	234.3 (202.7 to 270.2)	53.9 (31.8 to 81.4)	5.1 (-10.2 to 22.2)	18.9 (13.6 to 24.3)	27.9 (20.2 to 36.4)	47.4 (22.4 to 77.4)	-0.6 (-16.8 to 18.3)
Other neoplasms	373.0 (323.3 to 451.4)	986.7 (795.8 to 1,176.3)	164.8 (106.3 to 227.0)	79.8 (42.4 to 118.8)	24.8 (17.3 to 33.9)	63.0 (42.4 to 87.3)	156.1 (94.5 to 218.2)	73.1 (34.1 to 112.0)
Cardiovascular diseases	-	-	-	-	996.8 (96.8 to 1,872.0)	1,548.8 (1,548.8 to 2,893.8)	56.0 (31.2 to 83.0)	4.3 (-12.6 to 23.0)
Rheumatic heart disease	32.6 (31.1 to 34.2)	45.2 (42.2 to 48.0)	38.6 (27.9 to 50.8)	-7.2 (-14.0 to 0.7)	3.6 (2.3 to 4.9)	4.9 (3.4 to 6.9)	37.0 (11.4 to 71.3)	-8.0 (-24.8 to 15.3)
Ischemic heart disease	7,466.7 (6,509.4 to 8,636.8)	10,551.0 (9,886.3 to 11,302.7)	41.3 (20.8 to 65.1)	-9.3 (-23.3 to 6.0)	522.8 (355.5 to 723.3)	706.4 (490.0 to 955.8)	35.6 (17.5 to 55.8)	-13.0 (-24.9 to -0.1)
Cerebrovascular disease	-	-	-	-	386.1 (262.6 to 521.4)	857.0 (611.5 to 1,123.4)	121.5 (90.8 to 159.1)	51.8 (30.8 to 76.8)
Ischemic stroke	2,350.6 (2,068.0 to 2,698.0)	5,076.5 (4,784.3 to 5,398.0)	115.3 (85.6 to 151.2)	46.4 (25.8 to 69.7)	46.4 (22.9 to 453.6)	46.4 (511.4 to 965.1)	175.5 (86.0 to 153.6)	51.8 (24.6 to 71.6)
Hemorrhagic stroke	384.8 (319.1 to 451.2)	949.6 (849.4 to 1,046.8)	147.6 (102.3 to 207.8)	74.2 (42.7 to 114.8)	55.3 (37.6 to 78.9)	137.0 (96.1 to 184.8)	148.0 (99.0 to 210.7)	75.0 (40.7 to 118.7)
Hypertensive heart disease	188.4 (174.0 to 204.3)	302.7 (281.8 to 325.7)	60.9 (43.8 to 80.0)	3.7 (-7.1 to 15.1)	20.3 (14.2 to 28.2)	32.6 (23.3 to 44.4)	60.1 (39.6 to 84.6)	3.2 (-10.0 to 18.8)
Cardiomyopathy and myocarditis	599.7 (52.2 to 596.2)	897.2 (835.1 to 968.1)	59.9 (46.5 to 76.3)	7.7 (-0.9 to 18.3)	60.6 (41.6 to 82.9)	97.1 (66.7 to 133.7)	60.7 (43.9 to 79.0)	8.0 (-2.8 to 19.9)
Atrial fibrillation and flutter	1,752.3 (1,568.3 to 1,915.4)	1,145.1 (801.5 to 1,525.0)	-34.8 (-54.3 to -12.6)	57.5 (-70.6 to -43.3)	57.5 (91.2 to 182.7)	132.3 (52.0 to 128.3)	85.7 (-55.3 to -13.7)	57.8 (-71.4 to -43.8)
Peripheral vascular disease	7,117.8 (6,125.4 to 8,077.4)	10,715.1 (9,050.6 to 12,525.6)	50.6 (22.0 to 83.5)	-4.9 (-24.2 to 17.4)	7.8 (3.7 to 14.2)	11.4 (5.5 to 22.4)	44.3 (7.1 to 102.1)	-8.5 (-33.5 to 27.3)
Endocarditis	36.7 (28.9 to 42.6)	35.7 (28.5 to 45.7)	-3.7 (-22.7 to 27.5)	-34.2 (-47.3 to -13.9)	3.5 (2.2 to 5.0)	3.6 (2.3 to 5.3)	0.4 (-23.9 to 42.2)	-31.3 (-47.7 to -3.4)
Other cardiovascular and circulatory diseases	3,764.5 (1,713.1 to 6,							

Appendix Table G.4 - United States prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Silicosis	1.1 (1.0 to 1.2)	1.3 (1.2 to 1.4)	17.1 (12.0 to 22.2)	2.2 (-25.3 to -18.8)	0.2 (0.1 to 0.3)	0.2 (0.2 to 0.3)	17.9 (12.7 to 23.0)	17.9 (-25.1 to -18.5)
Asbestosis	1.3 (1.2 to 1.4)	2.1 (2.0 to 2.2)	59.4 (53.1 to 66.0)	7.2 (3.1 to 11.7)	0.2 (0.2 to 0.4)	0.4 (0.3 to 0.6)	60.4 (53.9 to 67.2)	7.6 (3.4 to 12.1)
Coal workers pneumoconiosis	1.4 (1.3 to 1.4)	1.8 (1.7 to 1.9)	34.5 (28.7 to 39.9)	-7.7 (-11.9 to -4.0)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	36.8 (30.6 to 43.1)	-6.5 (-10.9 to -2.0)
Other pneumoconiosis	3.0 (2.6 to 3.4)	3.4 (3.0 to 3.9)	13.2 (6.3 to 20.5)	-22.3 (-27.1 to -17.4)	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.9)	15.2 (8.3 to 22.8)	-21.1 (-25.9 to -16.1)
Asthma	16,498.2 (15,656.3 to 17,272.3)	22,248.8 (21,420.8 to 23,065.9)	35.7 (26.8 to 43.8)	5.5 (-0.1 to 13.3)	723.8 (476.0 to 1,014.5)	773.5 (639.0 to 385.0)	6.1 (26.0 to 43.4)	6.1 (-0.6 to 13.5)
Interstitial lung disease and pulmonary sarcoidosis	31.5 (29.9 to 33.1)	38.3 (34.5 to 42.2)	21.1 (7.7 to 36.9)	-18.3 (-27.4 to -7.8)	4.3 (2.7 to 6.3)	5.1 (3.2 to 7.5)	19.8 (23.0 to 39.6)	-19.1 (-29.7 to -6.0)
Other chronic respiratory diseases	-	-	-	-	28.3 (18.2 to 42.3)	38.3 (24.9 to 56.7)	35.1 (11.0 to 65.9)	-7.3 (23.6 to 14.3)
Cirrhosis	-	-	-	-	14.2 (9.7 to 19.8)	20.5 (14.2 to 28.6)	44.4 (26.3 to 65.8)	-4.2 (-16.2 to 9.9)
Cirrhosis due to hepatitis B	6.2 (4.6 to 8.0)	11.1 (6.8 to 15.6)	78.7 (-0.4 to 165.3)	19.5 (-33.2 to 76.6)	1.0 (0.6 to 1.6)	1.8 (0.9 to 3.1)	78.6 (-6.3 to 195.0)	18.5 (35.5 to 94.1)
Cirrhosis due to hepatitis C	31.6 (23.7 to 38.2)	69.1 (53.2 to 83.3)	119.7 (55.2 to 202.7)	45.4 (3.1 to 100.9)	5.1 (3.1 to 7.7)	11.1 (7.1 to 16.2)	111.7 (45.7 to 212.5)	44.3 (-2.9 to 108.5)
Cirrhosis due to alcohol use	40.9 (35.1 to 47.7)	38.0 (27.1 to 50.7)	-8.5 (-33.9 to 33.4)	-40.5 (-57.0 to -12.7)	6.6 (4.3 to 9.7)	6.1 (3.4 to 9.9)	-8.6 (-38.0 to 42.2)	-40.4 (-59.6 to -7.6)
Cirrhosis due to other causes	8.5 (6.3 to 11.0)	8.0 (5.5 to 10.8)	-5.6 (-44.5 to 45.5)	-31.4 (-58.5 to 3.8)	1.4 (0.8 to 2.2)	1.4 (0.8 to 2.3)	-1.7 (-43.5 to 59.9)	-28.3 (-57.7 to 14.2)
Digestive diseases	-	-	-	-	399.5 (284.2 to 532.8)	510.5 (357.3 to 679.9)	27.7 (21.1 to 35.6)	-8.8 (-14.2 to -2.5)
Peptic ulcer disease	524.2 (485.0 to 563.8)	379.6 (287.1 to 460.9)	-27.3 (-43.3 to -12.5)	-51.8 (-62.0 to -42.5)	21.4 (14.5 to 30.7)	16.8 (11.1 to 24.1)	-21.8 (-35.1 to -8.3)	-48.3 (-57.3 to -38.3)
Gastritis and duodenitis	255.2 (223.2 to 286.3)	170.8 (149.3 to 191.3)	-33.1 (-44.5 to -21.2)	-53.3 (-61.8 to -44.4)	12.6 (8.5 to 18.1)	9.1 (5.9 to 13.4)	-27.6 (-44.7 to -4.3)	-50.1 (-62.8 to -29.8)
Appendicitis	8.7 (8.1 to 9.3)	10.4 (9.6 to 11.2)	19.6 (8.6 to 31.1)	-3.6 (-12.5 to 6.3)	2.8 (1.7 to 4.1)	3.3 (2.1 to 4.7)	20.5 (8.6 to 62.5)	-3.3 (-27.8 to 33.7)
Paralytic ileus and intestinal obstruction	8.2 (7.4 to 9.8)	13.8 (12.6 to 15.5)	68.1 (39.2 to 103.5)	22.5 (-3.8 to 56.0)	2.4 (1.6 to 3.5)	4.0 (2.6 to 5.8)	65.1 (23.7 to 118.8)	20.8 (-11.9 to 65.8)
Inguinal, femoral, and abdominal hernia	289.9 (258.1 to 326.0)	312.3 (273.9 to 365.9)	7.6 (-11.1 to 32.5)	-28.1 (-39.8 to -13.1)	2.9 (1.5 to 5.3)	3.1 (1.5 to 5.9)	7.0 (-11.5 to 32.8)	-28.3 (-39.9 to -12.9)
Inflammatory bowel disease	985.4 (938.6 to 1,032.8)	1,312.0 (1,253.4 to 1,370.3)	33.0 (25.0 to 41.9)	-5.1 (-10.8 to 0.9)	206.4 (142.9 to 280.8)	272.1 (185.8 to 370.8)	31.9 (22.4 to 43.0)	-5.6 (-12.4 to 2.3)
Vascular intestinal disorders	2.7 (2.1 to 3.5)	4.7 (3.4 to 6.8)	73.7 (23.5 to 163.5)	16.2 (-15.0 to 70.3)	0.8 (0.5 to 1.2)	1.4 (0.8 to 2.2)	71.6 (10.6 to 181.9)	14.7 (-22.4 to 76.3)
Gallbladder and biliary diseases	512.9 (468.1 to 563.3)	685.1 (626.2 to 750.0)	34.0 (16.3 to 51.4)	-4.6 (-17.4 to 8.3)	53.4 (36.7 to 73.8)	71.1 (48.9 to 97.6)	34.1 (15.0 to 52.5)	-4.3 (-18.8 to 10.7)
Pancreatitis	83.0 (79.6 to 86.2)	127.7 (118.8 to 128.3)	48.8 (41.2 to 57.4)	24.1 (1.1 to 12.5)	6.5 (1.6 to 32.7)	24.1 (24.6 to 48.0)	28.3 (29.2 to 68.4)	6.5 (-0.7 to 21.5)
Other digestive diseases	-	-	-	-	72.7 (49.6 to 101.1)	93.9 (62.2 to 132.4)	28.6 (11.0 to 49.5)	-7.9 (-20.6 to 7.1)
Neurological disorders	-	-	-	-	2,272.6 (1,601.6 to 3,007.9)	3,239.1 (2,289.8 to 4,240.8)	42.5 (30.9 to 57.0)	3.5 (-5.4 to 13.5)
Alzheimer disease and other dementias	3,773.1 (3,425.5 to 4,239.9)	6,179.9 (5,423.5 to 6,894.2)	63.8 (41.2 to 89.6)	3.8 (-10.2 to 19.8)	554.4 (403.6 to 722.8)	914.3 (652.9 to 1,217.3)	64.9 (41.8 to 90.9)	3.5 (-10.7 to 19.6)
Parkinson disease	322.2 (283.7 to 365.4)	580.0 (518.8 to 643.6)	80.3 (65.5 to 95.0)	20.1 (10.5 to 29.9)	37.1 (25.8 to 50.5)	65.5 (47.2 to 89.5)	79.9 (59.7 to 100.6)	37.3 (-5.9 to 33.1)
Epilepsy	762.5 (548.7 to 973.7)	827.8 (554.5 to 1,124.6)	8.2 (-32.8 to 68.8)	-15.7 (-47.6 to 31.3)	313.3 (194.8 to 448.8)	349.7 (209.2 to 538.0)	10.9 (-31.5 to 74.6)	10.9 (-46.6 to 36.8)
Multiple sclerosis	187.9 (177.0 to 198.9)	458.4 (429.3 to 487.4)	143.5 (124.7 to 165.1)	76.3 (62.6 to 92.2)	61.3 (44.3 to 77.8)	148.4 (106.6 to 190.7)	142.5 (114.4 to 172.3)	76.4 (55.4 to 97.5)
Migraine	26,333.5 (24,416.5 to 27,937.9)	30,732.7 (28,266.3 to 33,013.6)	16.7 (5.1 to 28.0)	-7.8 (-16.8 to 1.6)	888.3 (528.9 to 1,319.4)	1,027.9 (616.1 to 1,518.0)	15.9 (4.2 to 27.9)	-8.1 (-17.5 to 1.5)
Tension-type headache	75,727.0 (68,185.0 to 79,007.4)	101,057.7 (92,798.0 to 108,471.2)	33.7 (23.5 to 52.0)	11.1 (-3.5 to 10.0)	111.3 (53.6 to 195.0)	151.3 (72.7 to 266.9)	6.9 (22.7 to 52.0)	6.9 (-3.9 to 19.3)
Medication overuse headache	1,313.7 (90.9 to 1,843.8)	2,828.3 (1,855.1 to 3,906.9)	111.3 (62.3 to 206.4)	56.7 (20.5 to 125.7)	204.3 (109.4 to 332.0)	435.2 (243.3 to 666.8)	109.5 (59.4 to 205.8)	56.2 (19.0 to 126.6)
Other neurological disorders	0.6 (0.5 to 0.8)	0.8 (0.6 to 1.0)	26.5 (0.5 to 58.9)	-7.7 (-25.7 to 15.0)	102.9 (70.1 to 140.8)	145.5 (100.6 to 198.3)	40.7 (13.5 to 81.7)	-8.6 (-26.4 to 17.2)
Mental and substance use disorders	-	-	-	-	7,223.8 (5,231.7 to 9,326.2)	9,175.1 (6,642.3 to 11,815.6)	27.0 (23.8 to 30.4)	1.2 (-1.4 to 3.8)
Schizophrenia	1,011.1 (951.0 to 1,074.7)	1,292.4 (1,219.3 to 1,373.8)	27.6 (22.2 to 33.3)	-2.3 (-6.6 to 2.2)	643.6 (481.2 to 723.0)	814.7 (610.1 to 971.3)	26.5 (19.6 to 34.2)	-2.7 (-8.8 to 3.5)
Alcohol use disorders	3,962.5 (3,727.3 to 4,252.4)	5,122.2 (4,782.2 to 5,463.3)	29.2 (23.4 to 35.6)	5.5 (0.7 to 10.8)	395.2 (261.1 to 567.3)	507.6 (334.5 to 728.0)	28.3 (21.7 to 35.7)	5.3 (0.2 to 11.1)
Drug use disorders	-	-	-	-	604.6 (429.3 to 794.3)	711.3 (506.7 to 925.9)	17.8 (6.9 to 28.7)	1.1 (-8.3 to 10.7)
Opioid use disorders	588.9 (537.9 to 652.5)	728.9 (668.1 to 791.1)	23.5 (15.3 to 32.0)	5.7 (-1.1 to 12.9)	243.9 (175.1 to 313.3)	299.8 (214.6 to 386.6)	23.1 (11.8 to 34.3)	5.7 (-3.6 to 15.1)
Cocaine use disorders	756.1 (716.4 to 799.7)	846.3 (804.5 to 890.7)	11.9 (3.4 to 20.6)	-4.2 (-11.6 to 3.1)	103.7 (67.7 to 149.0)	115.1 (74.7 to 162.9)	11.0 (-0.7 to 23.5)	-4.9 (-14.8 to 5.5)
Amphetamine use disorders	445.9 (415.3 to 476.1)	536.3 (508.4 to 563.8)	19.9 (10.2 to 30.8)	18.9 (5.5 to 12.6)	58.0 (35.8 to 84.7)	69.5 (43.0 to 101.2)	19.9 (4.3 to 37.3)	3.2 (-10.2 to 18.4)
Cannabis use disorders	1,228.2 (1,150.9 to 1,308.9)	1,410.4 (1,326.0 to 1,496.0)	14.7 (9.8 to 19.6)	-0.8 (-5.1 to 3.8)	35.5 (23.6 to 50.4)	40.6 (27.2 to 58.2)	14.5 (3.3 to 25.2)	-0.9 (-10.3 to 8.3)
Other drug use disorders	-	-	-	-	163.5 (101.5 to 237.1)	186.3 (118.4 to 275.0)	14.8 (-15.3 to 50.6)	-1.5 (-26.9 to 29.1)
Depressive disorders	-	-	-	-	2,488.1 (1,722.2 to 3,253.2)	3,340.3 (2,300.2 to 4,999.3)	34.1 (27.4 to 42.4)	5.2 (-0.9 to 11.7)
Major depressive disorder	10,074.3 (9,141.5 to 11,065.0)	13,775.5 (12,708.6 to 14,908.4)	36.4 (28.9 to 46.0)	6.7 (0.7 to 14.7)	182.0 (1,408.1 to 2,785.0)	231.4 (1,907.2 to 3,748.3)	27.2 (27.7 to 45.5)	2.1 (0.6 to 14.5)
Dysthymia	4,625.9 (3,917.8 to 5,318.1)	5,920.0 (5,072.0 to 6,847.9)	27.7 (19.1 to 37.5)	-1.6 (-8.3 to 4.5)	443.7 (293.1 to 635.8)	563.5 (374.6 to 811.8)	27.0 (17.8 to 37.3)	-1.9 (-8.7 to 4.5)
Bipolar disorder	1,980.4 (1,783.8 to 2,184.9)	2,471.8 (2,242.6 to 2,702.8)	24.7 (19.0 to 30.9)	0.8 (-3.7 to 5.3)	400.8 (253.5 to 590.7)	496.4 (314.8 to 729.8)	23.9 (16.5 to 31.1)	0.8 (-5.3 to 6.3)
Anxiety disorders	17,860.2 (16,172.0 to 19,594.9)	22,560.2 (20,013.6 to 24,913.6)	26.2 (18.5 to 34.8)	-0.7 (-6.9 to 5.8)	1,626.5 (1,117.1 to 2,282.0)	2,040.9 (1,402.7 to 2,889.8)	25.4 (17.4 to 30.4)	-1.0 (-7.1 to 6.0)
Eating disorders	-	-	-	-	165.4 (107.9 to 242.8)	186.4 (122.5 to 271.4)	3.2 (7.0 to 20.0)	3.2 (-2.0 to 9.6)
Anorexia nervosa	192.2 (156.2 to 228.5)	241.9 (197.8 to 289.9)	25.2 (14.1 to 38.6)	13.9 (3.7 to 25.6)	40.7 (25.3 to 58.7)	51.1 (32.4 to 74.2)	25.4 (10.2 to 43.6)	14.1 (0.1 to 29.7)
Bulimia nervosa	594.9 (416.4 to 732.0)	645.5 (459.8 to 790.5)	8.4 (6.9 to 10.1)	-0.3 (-0.4 to -0.2)	124.7 (75.1 to 185.3)	135.3 (83.3 to 203.0)	8.4 (2.5 to 15.1)	0.3 (-5.6 to 5.5)
Autistic spectrum disorders	-	-	-	-	283.4 (195.5 to 386.9)	358.2 (250.7 to 483.7)	26.4 (21.6 to 31.6)	1.5 (-2.4 to 5.6)
Autism	744.6 (702.0 to 783.6)	955.7 (900.2 to 1,007.3)	28.2 (23.9 to 33.3)	2.5 (-1.0 to 6.4)	182.0 (120.4 to 249.0)	231.4 (157.6 to 311.6)	27.2 (20.2 to 34.7)	2.1 (-3.4 to 8.1)
Asperger syndrome	1,020.6 (955.1 to 1,088.9)	1,286.3 (1,203.8 to 1,374.0)	26.0 (25.2 to 26.8)	0.9 (0.8 to 0.9)	101.4 (70.1 to 140.3)	126.8 (87.3 to 176.2)	25.0 (20.8 to 30.1)	0.8 (-3.1 to 4.5)
Attention-deficit/hyperactivity disorder	1,423.2 (1,210.9 to 1,611.3)	1,661.8 (1,404.3 to 1,865.7)	17.1 (5.8 to 27.8)	-0.1 (-9.6 to 8.8)	17.3 (10.1 to 27.0)	20.3 (11.7 to 31.7)	16.9 (4.8 to 29.8)	-0.5 (-10.9 to 10.5)
Conduct disorder	1,256.1 (1,107.5 to 1,417.3)	1,485.1 (1,283.2 to 1,703.9)	18.3 (13.2 to 23.6)	-0.5 (-4.7 to 3.9)	151.0 (91.6 to 222.9)	178.5 (109.0 to 266.2)	18.1 (10.1 to 26.0)	-0.9 (-7.5 to 5.7)
Idiopathic intellectual disability	1,895.8 (1,422.4 to 2,438.7)	1,337.1 (691.2 to 1,987.2)	-4.0 (-55.5 to -10.5)	4.0 (-64.4 to -29.1)	4.4 (71.7 to 161.7)	78.6 (38.2 to 124.5)	-29.4 (-55.0 to -10.2)	-44.2 (-64.1 to -24.8)
Other mental and substance use disorders	4,537.0 (4,277.2 to 4,789.1)	6,028.9 (5,676.7 to 6,376.0)	32.6 (30.6 to 34.6)	0.6 (0.5 to 0.8)	335.4 (227.3 to 452.0)	441.9 (300.9 to 594.9)	31.8 (2.8 to 36.8)	0.5 (-2.8 to 4.2)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	2,144.0 (1,554.9 to 2,880.0)	3,788.2 (2,682.8 to 5,046.1)	77.0 (63.6 to 90.6)	24.8 (15.9 to 34.1)
Diabetes mellitus	10,375.0 (8,895.8 to 12,210.0)	26,430.2 (23,152.5 to 29,933.7)	154.2 (114.3 to 205.1)	70.4 (44.5 to 102.8)	753.5 (509.6 to 1,032.7)	1,854.9 (1,265.4 to 2,532.8)	146.0 (108.9 to 191.3)	63.8 (40.8 to 93.2)
Acute glomerulonephritis	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.2)	8.4 (2.1 to 14.2)	-14.0 (-18.8 to -9.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.3 (2.0 to 14.1)	-14.2 (-19.0 to -9.8)
Chronic kidney disease	-	-	-	-	465.4 (336.4 to 607.4)	761.2 (543.5 to 972.8)	64.0 (48.5 to 78.8)	14.2 (4.4 to 25.2)
Chronic kidney disease due to diabetes mellitus	2,116.6 (1,744.1 to 2,529.8)	3,990.9 (3,021.2 to 5,258.4)	87.5 (57.8 to 126.3)	25.7 (4.8 to 50.6)	120.8 (83.0 to 159.8)	242.4 (166.6 to 318.8)	99.6 (71.6 to 136.8)	31.4 (12.2 to 58.2)
Chronic kidney disease due to hypertension	2,145.7 (1,686.6 to 3,029.6)	2,261.2 (1,841.5 to 2,915.6)	6.5 (-13.4 to 26.5)	-22.6 (-36.9 to -6.7)	102.7 (71			

Appendix Table G.4 - United States prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.								
	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Urolithiasis	7,633.1 (6,436.2 to 8,917.5)	17,730.0 (13,806.5 to 21,249.5)	132.1 (103.9 to 153.9)	-	50.4 (31.7 to 75.4)	116.9 (72.1 to 176.4)	131.9 (103.3 to 154.4)	131.9 (93.2 to 176.5)
Benign prostatic hyperplasia	5,472.5 (5,069.4 to 5,829.0)	7,343.7 (6,667.6 to 7,977.0)	34.0 (18.0 to 49.8)	-12.3 (-23.4 to -1.7)	193.9 (125.9 to 270.5)	259.0 (167.8 to 369.4)	33.6 (17.5 to 50.1)	-12.9 (-23.9 to -1.9)
Male infertility due to other causes	914.2 (717.3 to 1,100.1)	982.6 (753.3 to 1,222.6)	7.7 (-24.5 to 52.6)	4.5 (-26.2 to 48.6)	6.4 (2.8 to 12.8)	6.5 (2.8 to 14.6)	3.5 (-26.9 to 53.9)	3.5 (-29.1 to 49.1)
Other urinary diseases	-	-	-	-	9.3 (5.3 to 16.7)	24.3 (10.8 to 41.4)	181.8 (41.2 to 275.1)	93.9 (-3.8 to 156.4)
Gynecological diseases	-	-	-	-	389.9 (252.8 to 554.8)	426.2 (284.3 to 612.3)	11.2 (-2.0 to 27.0)	4.2 (-1.5 to 9.6)
Uterine fibroids	4,760.3 (4,233.1 to 5,283.5)	6,288.1 (5,577.4 to 6,977.2)	31.9 (29.9 to 34.1)	-0.8 (-0.9 to -0.8)	49.5 (26.7 to 86.5)	63.7 (34.6 to 112.3)	28.5 (19.5 to 38.6)	0.0 (-6.7 to 8.2)
Polycystic ovarian syndrome	4,152.7 (3,732.2 to 4,599.6)	4,405.4 (4,020.3 to 4,825.0)	5.9 (-7.4 to 21.3)	-6.1 (-17.9 to 7.7)	39.5 (18.6 to 77.5)	41.9 (19.6 to 80.8)	5.9 (-7.3 to 21.5)	-5.8 (-17.3 to 8.1)
Female infertility due to other causes	70.4 (38.7 to 148.5)	113.7 (41.2 to 239.9)	56.9 (-47.5 to 330.0)	45.8 (-50.4 to 302.5)	0.4 (0.1 to 1.1)	0.6 (0.2 to 1.8)	50.8 (-48.3 to 293.0)	41.6 (-51.5 to 264.4)
Endometriosis	692.5 (611.8 to 778.9)	794.7 (709.6 to 883.2)	15.0 (-4.9 to 35.0)	2.5 (-15.1 to 19.6)	63.7 (42.4 to 89.6)	73.0 (48.7 to 100.7)	15.1 (-5.4 to 38.5)	7.6 (-15.7 to 22.9)
Genital prolapse	8,124.1 (7,317.8 to 9,040.9)	10,820.7 (9,619.8 to 12,093.0)	33.5 (13.8 to 54.5)	-3.7 (-19.1 to 12.1)	25.7 (12.4 to 48.7)	34.1 (16.0 to 65.3)	34.1 (12.8 to 55.1)	34.1 (-18.6 to 12.6)
Premenstrual syndrome	22,046.7 (18,225.4 to 25,972.3)	22,044.3 (17,849.6 to 26,175.7)	0.1 (-23.4 to 31.9)	-10.2 (-30.7 to 18.8)	184.3 (107.8 to 289.6)	183.8 (111.7 to 275.1)	0.0 (-24.4 to 32.1)	-10.2 (-31.3 to 18.5)
Other gynecological diseases	722.0 (661.8 to 786.9)	980.5 (925.5 to 1,034.4)	35.9 (21.9 to 49.9)	15.8 (4.6 to 26.9)	20.7 (13.8 to 29.5)	29.2 (19.8 to 40.6)	40.6 (21.1 to 70.4)	20.8 (4.1 to 45.2)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	205.2 (138.0 to 296.9)	242.1 (160.0 to 350.0)	18.0 (6.0 to 25.0)	-3.2 (-12.6 to 3.1)
Thalassemias	5.2 (4.9 to 5.5)	6.3 (5.9 to 6.9)	22.5 (16.8 to 30.4)	7.7 (2.5 to 14.4)	0.5 (0.3 to 0.7)	0.7 (0.5 to 1.0)	37.7 (19.2 to 58.5)	37.7 (4.0 to 41.1)
Thalassemia trait	2,841.3 (2,776.0 to 2,926.3)	3,542.4 (3,454.0 to 3,639.5)	24.6 (21.7 to 28.0)	-1.9 (-4.1 to 0.7)	78.7 (52.5 to 112.3)	95.0 (63.4 to 137.2)	20.6 (12.4 to 30.0)	-9.8 (-9.3 to 4.4)
Sickle cell disorders	25.0 (19.8 to 27.7)	26.8 (23.3 to 29.5)	7.5 (9.9 to 36.8)	-7.1 (-21.9 to 18.7)	3.3 (2.3 to 4.4)	3.8 (2.7 to 5.0)	13.9 (-0.5 to 28.0)	-2.1 (-14.9 to 10.7)
Sickle cell trait	7,367.5 (7,133.3 to 7,610.2)	8,937.1 (8,677.4 to 9,213.4)	21.3 (18.9 to 23.8)	-4.4 (-6.2 to -2.4)	84.7 (55.2 to 123.7)	97.9 (62.7 to 143.2)	15.5 (-5.7 to 29.5)	-2.8 (-18.3 to 8.6)
G6PD deficiency	8,711.6 (8,524.6 to 8,929.7)	10,402.1 (10,178.6 to 10,611.5)	19.2 (15.9 to 23.1)	0.9 (-8.5 to 2.8)	1.0 (0.5 to 1.3)	1.0 (0.6 to 1.5)	6.3 (-17.2 to 64.7)	-6.3 (-35.8 to 39.4)
G6PD trait	38,502.1 (38,116.2 to 38,912.2)	48,622.1 (48,123.6 to 49,953.8)	26.1 (24.7 to 27.8)	-1.0 (-2.1 to 0.3)	3.3 (1.6 to 5.2)	3.7 (1.9 to 5.9)	7.1 (-41.7 to 129.4)	-7.1 (-56.2 to 88.5)
Other hemoglobinopathies and hemolytic anemias	1,484.8 (1,390.8 to 1,585.7)	2,008.4 (1,846.9 to 2,160.6)	35.3 (21.7 to 50.4)	2.8 (-8.2 to 15.6)	33.9 (22.0 to 50.4)	40.2 (25.2 to 59.6)	18.8 (-4.8 to 48.2)	-5.0 (-23.7 to 21.3)
Endocrine, metabolic, blood, and immune disorders	2,240.1 (2,079.3 to 2,425.3)	2,818.5 (2,699.2 to 2,938.8)	26.0 (15.5 to 36.0)	-3.2 (-11.4 to 5.6)	72.8 (49.5 to 102.3)	91.6 (63.0 to 126.3)	25.9 (12.7 to 41.3)	-3.8 (-13.7 to 9.4)
Musculoskeletal disorders	-	-	-	-	5,945.5 (4,959.8 to 9,069.0)	10,155.9 (7,290.2 to 13,234.5)	46.3 (8.9 to 51.7)	5.3 (1.8 to 9.5)
Rheumatoid arthritis	655.2 (624.5 to 684.3)	1,309.1 (1,249.6 to 1,365.7)	99.9 (87.3 to 112.8)	33.9 (25.5 to 42.2)	148.0 (106.3 to 192.7)	295.2 (210.6 to 382.9)	99.7 (40.4 to 115.7)	33.7 (24.1 to 44.5)
Osteoarthritis	12,749.1 (12,347.0 to 13,169.3)	20,360.2 (19,740.4 to 20,987.5)	59.6 (53.2 to 66.6)	2.6 (-1.5 to 7.0)	435.3 (290.3 to 621.8)	693.9 (462.1 to 988.8)	59.4 (52.5 to 66.5)	2.3 (-2.1 to 6.9)
Low back and neck pain	-	-	-	-	4,563.7 (3,164.8 to 6,147.0)	6,357.4 (4,419.9 to 8,632.7)	39.4 (32.1 to 45.8)	9.1 (-1.0 to 9.1)
Low back pain	29,270.6 (27,719.6 to 30,792.6)	42,004.0 (40,370.7 to 43,685.3)	43.5 (33.2 to 52.1)	6.7 (-0.9 to 13.5)	6.7 (2,189.3 to 4,487.5)	6.5 (3,157.8 to 6,346.7)	6.5 (32.6 to 51.3)	6.5 (-0.8 to 13.4)
Neck pain	13,593.1 (13,192.3 to 13,959.7)	18,003.4 (17,582.7 to 18,395.7)	32.3 (27.9 to 37.1)	-1.5 (-4.8 to 2.2)	1,328.0 (917.3 to 1,816.2)	1,746.4 (1,222.6 to 2,397.7)	31.5 (26.8 to 36.7)	31.5 (-5.2 to 2.2)
Gout	515.8 (493.7 to 539.4)	777.7 (742.9 to 814.4)	50.7 (42.1 to 60.0)	-1.2 (-6.8 to 5.0)	15.9 (11.0 to 21.5)	23.9 (16.7 to 32.8)	49.8 (30.6 to 73.3)	-1.8 (-14.5 to 14.3)
Other musculoskeletal disorders	19,710.7 (17,983.4 to 21,465.4)	30,897.6 (27,847.3 to 33,773.5)	56.9 (45.5 to 68.9)	8.4 (1.3 to 16.2)	1,780.5 (1,209.4 to 2,452.5)	2,786.5 (1,894.2 to 3,858.3)	8.2 (44.6 to 68.8)	8.2 (1.0 to 16.9)
Other non-communicable diseases	-	-	-	-	3,019.9 (3,019.9 to 6,158.4)	5,797.4 (3,973.0 to 8,182.8)	8.2 (28.2 to 37.0)	8.2 (-7.1 to 0.0)
Congenital anomalies	-	-	-	-	396.3 (281.0 to 524.1)	565.3 (404.2 to 744.8)	42.6 (26.7 to 62.9)	9.6 (-3.6 to 26.3)
Neural tube defects	88.5 (75.2 to 104.1)	100.6 (88.7 to 117.1)	13.1 (6.3 to 42.6)	-6.6 (-22.5 to 17.9)	28.9 (19.1 to 39.8)	33.1 (22.2 to 46.8)	14.7 (-16.1 to 56.5)	-5.0 (-30.0 to 29.6)
Congenital heart anomalies	2,279.5 (1,961.0 to 2,668.0)	2,823.5 (2,423.2 to 3,397.6)	23.2 (-0.5 to 56.4)	-1.9 (-20.5 to 24.6)	81.6 (34.5 to 142.6)	101.7 (43.5 to 177.4)	23.5 (2.3 to 55.3)	-0.6 (-17.7 to 24.6)
Crofacial clefts	308.8 (254.0 to 369.1)	392.7 (342.6 to 452.4)	26.5 (1.5 to 60.0)	0.2 (-20.1 to 31.0)	3.2 (2.0 to 4.8)	3.6 (2.2 to 5.5)	13.9 (-11.1 to 57.7)	-10.0 (-35.1 to 25.0)
Down syndrome	319.3 (267.0 to 388.6)	470.2 (399.3 to 551.0)	48.2 (13.9 to 85.8)	45.2 (-16.6 to 36.4)	70.9 (32.2 to 60.3)	70.9 (50.9 to 91.0)	58.8 (20.2 to 101.9)	10.2 (-16.7 to 40.2)
Turner syndrome	13.2 (10.9 to 16.4)	16.7 (13.9 to 21.1)	26.2 (-2.7 to 66.2)	3.2 (-20.6 to 35.6)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.5)	23.9 (-7.9 to 68.4)	2.5 (-23.1 to 39.8)
Klinefelter syndrome	9.3 (6.9 to 12.0)	12.8 (9.6 to 16.5)	38.4 (-5.5 to 94.2)	10.0 (-24.9 to 54.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	29.7 (-21.5 to 103.9)	10.0 (-32.5 to 72.3)
Chromosomal unbalanced rearrangements	524.5 (433.1 to 633.4)	745.4 (609.2 to 879.8)	43.6 (11.0 to 76.6)	5.4 (-18.1 to 30.2)	73.7 (51.5 to 98.3)	112.2 (80.4 to 149.0)	53.1 (17.2 to 90.6)	6.5 (-18.4 to 32.9)
Other congenital anomalies	594.4 (407.1 to 708.6)	627.7 (439.1 to 779.2)	6.7 (-22.5 to 41.5)	8.7 (-40.3 to 8.7)	165.3 (109.6 to 223.8)	165.3 (160.5 to 348.2)	19.3 (10.5 to 28.5)	19.3 (-3.5 to 10.5)
Skin and subcutaneous diseases	-	-	-	-	1,526.3 (1,003.3 to 2,253.2)	1,929.8 (1,273.3 to 2,879.8)	26.5 (17.7 to 35.6)	0.3 (-6.3 to 7.6)
Dermatitis	17,226.7 (14,258.0 to 19,908.2)	21,266.9 (17,757.2 to 24,378.4)	23.5 (21.0 to 25.7)	0.1 (0.1 to 0.2)	516.7 (338.4 to 736.9)	637.9 (423.3 to 909.4)	23.5 (20.0 to 26.9)	2.1 (-2.5 to 2.2)
Psoriasis	2,209.3 (1,987.6 to 2,397.3)	3,072.7 (2,782.7 to 3,328.3)	39.0 (32.5 to 45.1)	3.3 (-1.2 to 7.8)	177.2 (121.8 to 245.0)	244.4 (168.8 to 336.5)	38.1 (28.6 to 47.8)	3.0 (-3.8 to 10.4)
Cellulitis	148.3 (123.9 to 180.8)	241.3 (197.4 to 297.7)	62.3 (48.0 to 79.0)	18.6 (8.7 to 28.1)	10.3 (6.6 to 14.7)	16.5 (10.6 to 23.9)	61.2 (37.5 to 89.6)	19.3 (1.6 to 39.1)
Pyoderma	49.1 (43.0 to 56.5)	49.4 (43.1 to 57.1)	0.6 (-2.6 to 3.6)	-18.3 (-20.3 to -16.5)	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.6)	0.3 (-15.1 to 18.7)	-18.5 (-31.2 to -3.6)
Scabies	69.7 (57.6 to 87.0)	83.7 (69.8 to 102.9)	20.3 (-12.9 to 63.6)	4.8 (-30.3 to 28.7)	1.8 (1.0 to 3.0)	2.1 (1.1 to 3.5)	4.1 (-16.9 to 64.3)	-4.1 (-33.2 to 31.4)
Fungal skin diseases	13,812.2 (12,193.8 to 15,480.2)	18,600.3 (16,980.7 to 20,332.9)	34.4 (25.8 to 45.9)	0.3 (-5.0 to 8.4)	76.9 (31.1 to 158.7)	103.1 (41.7 to 213.9)	33.7 (25.2 to 46.0)	0.1 (-5.4 to 8.6)
Viral skin diseases	5,221.9 (4,037.3 to 6,419.7)	6,289.2 (4,946.7 to 7,625.4)	20.2 (17.0 to 25.5)	20.2 (-2.2 to 15.5)	169.8 (92.4 to 252.6)	169.8 (111.9 to 300.8)	49.8 (15.4 to 25.9)	0.6 (-3.9 to 2.5)
Acne vulgaris	29,324.3 (22,881.8 to 35,490.1)	33,424.7 (25,735.8 to 40,568.8)	13.0 (-14.7 to 53.9)	-1.0 (-26.1 to 33.3)	317.3 (146.5 to 584.9)	361.9 (169.1 to 714.9)	13.0 (-14.9 to 53.9)	-1.3 (-26.3 to 33.0)
Alopecia areata	553.1 (526.8 to 577.5)	748.3 (713.6 to 782.8)	35.1 (27.0 to 44.0)	0.6 (-5.2 to 6.7)	18.3 (11.6 to 27.1)	24.6 (15.7 to 36.5)	34.5 (22.1 to 46.4)	0.4 (-8.7 to 9.3)
Pruritus	71.2 (67.4 to 75.1)	104.8 (99.3 to 110.9)	47.2 (36.5 to 58.9)	3.2 (-3.9 to 11.1)	0.7 (0.4 to 1.4)	1.1 (0.5 to 2.0)	46.4 (25.1 to 71.6)	2.9 (-11.9 to 20.7)
Urticaria	1,942.1 (1,397.1 to 2,577.5)	2,850.9 (2,010.3 to 3,670.3)	45.1 (5.4 to 108.9)	8.3 (-1.9 to 55.6)	113.6 (64.9 to 176.2)	166.0 (95.4 to 258.2)	45.1 (4.0 to 110.4)	8.2 (-22.8 to 56.7)
Decubitus ulcer	255.5 (220.7 to 284.5)	285.8 (249.9 to 330.6)	10.7 (-6.5 to 37.8)	-24.5 (-35.8 to -7.1)	10.7 (24.5 to 50.3)	40.3 (27.5 to 55.2)	10.9 (9.7 to 40.1)	-23.9 (-37.8 to -4.0)
Other skin and subcutaneous diseases	16,627.4 (9,672.9 to 28,428.3)	24,082.2 (13,871.9 to 41,633.0)	44.5 (33.6 to 56.4)	-0.2 (-4.9 to 3.9)	96.4 (39.4 to 207.4)	139.0 (55.2 to 311.4)	44.0 (32.8 to 55.6)	-0.4 (-5.2 to 4.0)
Sense organ diseases	-	-	-	-	1,689.2 (1,133.8 to 2,380.2)	2,319.5 (1,561.8 to 3,269.8)	37.4 (31.9 to 42.3)	-7.4 (-11.0 to -3.8)
Glaucoma	438.6 (371.4 to 512.4)	488.8 (407.8 to 576.0)	11.1 (-1.8 to 36.4)	-36.5 (-35.2 to -37.1)	35.2 (3.8 to 48.5)	48.8 (29.9 to 61.4)	23.8 (7.0 to 45.4)	-19.5 (-30.2 to -6.0)
Cataract	562.5 (436.7 to 710.2)	631.8 (487.2 to 802.5)	12.9 (-15.5 to 45.5)	-26.9 (-45.4 to -4.4)	35.5 (24.0 to 50.6)	44.0 (29.8 to 61.1)	24.7 (-0.1 to 53.9)	-20.5 (-45.2 to -1.0)
Macular degeneration	531.1 (435.1 to 649.7)	965.6 (764.1 to 1,163.7)	83.4 (38.4 to 122.1)	16.3 (-9.7 to 39.7)	31.4 (22.0 to 43.3)	51.3 (35.3 to 71.3)	63.6 (34.0 to 92.9)	2.7 (-14.6 to 21.0)
Uncorrected refractive error	19,549.9 (17,402.0 to 21,646.2)	27,592.4 (24,733.0 to 30,407.5)	41.0 (20.7 to 65.3)	-4.1 (-17.7 to 13.6)	272.0 (157.0 to 446.8)	361.5 (204.6 to 604.0)	32.4 (18.5 to 50.4)	-8.7 (-18.2 to 4.4)
Age-related and other hearing loss	40,954.3 (39,628.7 to 42,299.9)	58,987.9 (57,573.0 to 60,643.8)	43.8 (39.2 to 49.3)	-6.6 (-8.9 to -4.8)	1,104.6 (749.8 to 1,549.1)	1,565.0 (1,067.0 to 2,198.3)	41.9 (34.6 to 48.6)	-6.1 (-10.8 to -1.5)
Other vision loss	1,031.6 (886.9 to 1,198.5)	945.6 (780.4 to 1,134.0)	-8.5					

Appendix Table G.4 - United States prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Other oral disorders	4,640.7 (4,395.4 to 4,900.3)	5,784.4 (5,529.4 to 6,032.1)	24.6 (16.4 to 33.5)	-4.8 (-11.2 to 2.0)	135.1 (83.9 to 203.8)	167.2 (105.6 to 250.7)	23.8 (15.3 to 33.0)	-5.2 (-11.8 to 1.9)
Injuries	-	-	-	-	2,190.1 (1,673.2 to 2,819.2)	2,531.3 (1,828.1 to 3,407.7)	15.1 (4.8 to 26.9)	-20.8 (-27.7 to -12.9)
Transport injuries	-	-	-	-	538.7 (406.6 to 689.2)	518.2 (376.9 to 689.0)	-4.1 (-13.8 to 6.7)	-33.0 (-39.7 to -25.5)
Road injuries	-	-	-	-	459.1 (345.0 to 586.5)	420.4 (305.3 to 559.0)	-8.6 (-18.1 to 2.2)	-35.3 (-41.9 to -27.7)
Pedestrian road injuries	-	-	-	-	54.4 (40.5 to 70.9)	59.5 (42.2 to 81.4)	9.8 (1.5 to 22.3)	-34.8 (-31.1 to -14.4)
Cyclist road injuries	-	-	-	-	36.8 (27.6 to 47.4)	34.3 (24.7 to 45.8)	-7.2 (-19.2 to 6.9)	-33.0 (-41.7 to -22.8)
Motorcyclist road injuries	-	-	-	-	54.7 (40.8 to 70.3)	49.9 (35.6 to 67.0)	-9.1 (-24.1 to 9.1)	-35.3 (-46.0 to -22.3)
Motor vehicle road injuries	-	-	-	-	306.5 (231.9 to 390.0)	270.0 (196.7 to 355.0)	-12.1 (-20.4 to -2.7)	-37.9 (-43.5 to -31.1)
Other road injuries	-	-	-	-	6.7 (5.0 to 8.6)	6.2 (4.5 to 8.2)	-7.1 (-18.6 to 6.4)	-24.8 (-42.9 to -25.2)
Other transport injuries	-	-	-	-	79.6 (60.5 to 103.3)	97.8 (69.7 to 130.1)	22.7 (11.0 to 34.8)	-18.7 (-26.1 to -11.0)
Unintentional injuries	-	-	-	-	1,529.8 (1,161.1 to 1,969.3)	1,882.6 (1,359.4 to 2,554.6)	22.5 (11.7 to 34.8)	-16.1 (-23.2 to -8.1)
Falls	-	-	-	-	864.6 (658.4 to 1,099.0)	1,039.1 (751.7 to 1,393.0)	19.4 (6.1 to 36.4)	-19.2 (-28.0 to -8.3)
Drowning	-	-	-	-	6.9 (5.1 to 8.8)	7.3 (5.3 to 9.5)	5.3 (-4.9 to 15.6)	-25.1 (-31.9 to -17.3)
Fire, heat, and hot substances	-	-	-	-	53.2 (33.7 to 81.9)	64.5 (38.7 to 105.2)	20.0 (6.3 to 37.3)	-14.9 (-24.7 to -3.0)
Poisonings	-	-	-	-	16.8 (12.0 to 22.4)	15.7 (11.3 to 20.8)	-6.7 (-16.7 to 3.4)	-31.1 (-38.6 to -23.1)
Exposure to mechanical forces	-	-	-	-	276.5 (208.6 to 362.9)	263.2 (189.8 to 357.0)	-5.1 (-13.0 to 4.3)	-31.7 (-37.0 to -25.1)
Unintentional firearm injuries	-	-	-	-	19.7 (14.8 to 25.4)	15.7 (11.2 to 21.3)	-20.7 (-27.9 to -12.4)	-41.6 (-46.7 to -35.6)
Unintentional suffocation	-	-	-	-	1.3 (0.9 to 1.7)	2.4 (1.7 to 3.3)	86.1 (64.3 to 109.3)	33.3 (17.6 to 49.5)
Other exposure to mechanical forces	-	-	-	-	255.5 (192.8 to 335.6)	245.1 (176.4 to 332.9)	-4.3 (-12.5 to 5.2)	-31.3 (-36.9 to -24.4)
Adverse effects of medical treatment	-	-	-	-	31.1 (19.5 to 45.9)	41.0 (25.8 to 61.0)	31.9 (24.8 to 39.5)	-4.9 (-9.9 to 0.2)
Animal contact	-	-	-	-	24.4 (18.0 to 32.7)	32.8 (23.1 to 45.8)	33.8 (24.2 to 45.3)	-3.7 (-10.7 to 4.3)
Venomous animal contact	-	-	-	-	3.7 (2.8 to 4.8)	4.7 (3.4 to 6.1)	25.4 (14.1 to 37.5)	-6.7 (-15.3 to 2.6)
Non-venomous animal contact	-	-	-	-	20.7 (15.1 to 28.2)	28.2 (19.6 to 40.0)	35.5 (25.2 to 47.7)	-3.2 (-10.4 to 5.6)
Foreign body	-	-	-	-	15.4 (10.3 to 21.8)	16.1 (10.0 to 24.0)	4.5 (-5.3 to 12.6)	-20.1 (-28.7 to -13.4)
Pulmonary aspiration and foreign body in airway	-	-	-	-	2.0 (1.5 to 2.4)	1.8 (1.3 to 2.2)	-9.8 (-21.1 to 2.3)	-33.9 (-42.6 to -24.5)
Foreign body in eyes	-	-	-	-	7.4 (4.4 to 11.1)	7.7 (4.3 to 12.0)	4.2 (-5.1 to 12.3)	-18.2 (-27.1 to -11.1)
Foreign body in other body part	-	-	-	-	6.1 (4.1 to 8.6)	6.7 (4.1 to 10.0)	9.4 (-3.6 to 20.4)	-18.0 (-28.5 to -9.4)
Other unintentional injuries	-	-	-	-	240.7 (173.4 to 325.2)	402.8 (282.1 to 556.6)	66.8 (56.3 to 81.4)	12.1 (5.3 to 21.6)
Self-harm and interpersonal violence	-	-	-	-	121.3 (91.4 to 155.7)	123.0 (88.6 to 164.1)	0.9 (-8.0 to 11.8)	-27.1 (-33.3 to -19.5)
Self-harm	-	-	-	-	22.0 (15.7 to 28.9)	29.6 (21.0 to 40.2)	34.5 (22.6 to 49.5)	-3.1 (-11.8 to 7.9)
Interpersonal violence	-	-	-	-	99.4 (75.1 to 126.3)	93.3 (67.0 to 125.5)	-6.6 (-15.8 to 4.5)	-32.2 (-38.7 to -24.5)
Assault by firearm	-	-	-	-	18.8 (14.1 to 24.4)	18.5 (13.3 to 24.2)	-2.2 (-12.8 to 9.1)	-29.0 (-36.7 to -21.0)
Assault by sharp object	-	-	-	-	9.0 (6.6 to 12.1)	9.5 (6.7 to 13.1)	5.0 (-3.6 to 15.5)	-23.9 (-29.8 to -16.6)
Assault by other means	-	-	-	-	71.5 (53.7 to 91.1)	65.3 (46.8 to 88.1)	-9.1 (-19.1 to 3.9)	-34.1 (-41.3 to -24.8)
Forces of nature, war, and legal intervention	-	-	-	-	0.3 (0.2 to 0.5)	7.5 (3.3 to 17.1)	2,181.2 (868.5 to 5,401.4)	1,161.7 (469.7 to 2,899.6)
Exposure to forces of nature	-	-	-	-	0.3 (0.2 to 0.5)	3.2 (1.5 to 6.5)	868.7 (352.7 to 1,968.0)	453.6 (165.1 to 1,060.6)
Collective violence and legal intervention	-	-	-	-	-	4.4 (1.7 to 10.7)	-	-

Appendix Table G.4 - Uruguay prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	330.7 (247.9 to 425.1)	385.2 (289.2 to 496.7)	16.4 (13.9 to 19.2)	16.4 (-2.8 to 1.7)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	19.3 (13.6 to 27.1)	21.1 (15.0 to 29.0)	8.8 (3.5 to 16.3)	3.8 (-1.3 to 10.8)
HIV/AIDS and tuberculosis	-	-	-	-	0.5 (0.3 to 0.8)	1.0 (0.6 to 1.6)	86.4 (42.1 to 184.1)	63.9 (24.3 to 148.5)
Tuberculosis	1.4 (1.3 to 1.4)	1.3 (1.3 to 1.4)	-2.2 (-6.3 to 2.4)	-14.8 (-18.4 to -10.8)	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	-2.2 (-13.9 to 11.6)	-14.5 (-24.8 to -2.3)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.3)	0.5 (0.3 to 1.1)	737.7 (133.6 to 4,071.2)	621.7 (99.8 to 3,521.1)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	348.8 (24.5 to 1,648.5)	290.0 (8.9 to 1,422.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	348.8 (23.2 to 1,651.3)	290.0 (7.5 to 1,425.7)
HIV/AIDS resulting in other diseases	0.8 (0.1 to 2.6)	6.6 (4.1 to 9.8)	937.2 (206.7 to 4,739.8)	781.8 (160.4 to 4,045.9)	0.1 (0.0 to 0.3)	0.5 (0.3 to 1.1)	749.5 (133.8 to 4,378.0)	626.1 (100.0 to 3,788.9)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	2.7 (1.8 to 3.8)	2.5 (1.7 to 3.5)	-7.6 (-12.0 to -2.9)	-16.8 (-20.9 to -12.3)
Diarrheal diseases	0.6 (0.5 to 0.6)	0.6 (0.6 to 0.7)	5.9 (-8.2 to 21.2)	-4.1 (-17.3 to 9.9)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	5.0 (-14.9 to 29.4)	-4.0 (-22.3 to 18.8)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (-55.0 to 156.9)	0.0 (-57.9 to 140.6)
Typhoid fever	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-26.6 (-54.8 to 7.8)	-30.4 (-57.7 to 1.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-26.6 (-54.9 to 7.9)	-30.4 (-57.9 to 1.7)
Paratyphoid fever	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	16.5 (-28.0 to 71.3)	10.5 (-32.2 to 63.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.5 (-28.2 to 71.4)	10.5 (-32.3 to 63.2)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	105.9 (95.7 to 19,838.4)	93.7 (95.4 to 18,234.0)
Lower respiratory infections	8.5 (8.2 to 8.9)	8.4 (7.9 to 8.9)	-1.5 (-8.4 to 5.1)	-17.6 (-23.1 to -12.0)	0.9 (0.6 to 1.2)	0.8 (0.6 to 1.2)	-3.0 (-11.1 to 5.1)	-17.7 (-24.7 to -10.8)
Upper respiratory infections	49.5 (47.4 to 51.7)	52.0 (49.6 to 54.5)	4.9 (-1.3 to 12.0)	-2.1 (-8.0 to 4.7)	0.6 (0.3 to 1.0)	0.6 (0.3 to 1.0)	4.8 (-2.6 to 12.9)	-1.9 (-9.0 to 5.8)
Otitis media	36.4 (34.2 to 38.7)	32.9 (31.1 to 35.1)	-9.4 (-16.3 to -2.1)	-14.7 (-21.1 to -8.0)	0.7 (0.4 to 1.1)	0.6 (0.3 to 1.0)	-9.1 (-16.4 to -1.3)	-14.5 (-21.4 to -7.0)
Meningitis	-	-	-	-	0.3 (0.2 to 0.4)	0.1 (0.1 to 0.2)	-51.3 (-60.9 to -41.0)	-55.9 (-64.9 to -46.2)
Pneumococcal meningitis	1.2 (0.7 to 1.8)	0.6 (0.3 to 0.9)	-51.2 (-62.0 to -41.0)	-57.1 (-66.6 to -47.7)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	0.1 (-66.5 to -34.7)	0.1 (-69.7 to -40.8)
H influenzae type B meningitis	0.4 (0.1 to 0.9)	0.2 (0.1 to 0.4)	-59.5 (-75.7 to -43.2)	-63.0 (-77.3 to -47.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (-76.3 to -33.4)	0.0 (-78.0 to -37.1)
Meningococcal meningitis	0.5 (0.2 to 1.2)	0.2 (0.1 to 0.6)	-53.2 (-71.8 to -33.0)	-58.9 (-74.6 to -38.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.1 (-72.5 to -15.0)	0.1 (-75.3 to -21.8)
Other meningitis	0.6 (0.3 to 1.1)	0.3 (0.1 to 0.6)	-52.6 (-65.3 to -33.0)	-57.6 (-68.9 to -40.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.1 (-63.9 to -16.3)	0.1 (-67.7 to -23.7)
Encephalitis	0.3 (0.1 to 0.8)	0.3 (0.1 to 0.8)	-8.1 (-29.0 to 9.2)	-20.0 (-37.6 to -2.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-25.8 to 24.0)	0.0 (-34.8 to 11.2)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.5 (-94.5 to 309.9)	-55.4 (-94.5 to 293.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-94.6 to 310.8)	0.0 (-94.8 to 299.6)
Whooping cough	0.4 (0.3 to 0.5)	0.2 (0.2 to 0.3)	-45.3 (-47.1 to -43.5)	-39.4 (-41.4 to -37.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.2 (-55.3 to -32.8)	-39.4 (-50.5 to -25.5)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.9 (-93.0 to -73.5)	-88.2 (-93.7 to -75.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-85.5 (-93.0 to -70.9)	-86.7 (-93.6 to -73.5)
Measles	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -94.4)	-100.0 (-100.0 to -93.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-100.0 to -94.4)	0.0 (-100.0 to -93.9)
Varicella and herpes zoster	2.7 (2.4 to 2.9)	2.9 (2.6 to 3.3)	9.0 (-4.3 to 26.5)	1.3 (-10.4 to 15.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	17.4 (-4.7 to 49.4)	1.6 (-17.2 to 28.4)
Neglected tropical diseases and malaria	-	-	-	-	0.7 (0.5 to 1.0)	0.5 (0.3 to 0.7)	-30.6 (-37.3 to -21.6)	-44.9 (-50.3 to -37.4)
Malaria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-23.2 (-83.0 to 205.3)	-27.5 (-83.9 to 192.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-22.4 (-82.8 to 216.0)	-26.7 (-83.8 to 197.8)
Chagas disease	37.0 (34.9 to 39.0)	23.8 (22.3 to 25.4)	-35.8 (-40.6 to -30.6)	-46.2 (-50.1 to -41.9)	0.4 (0.3 to 0.6)	0.4 (0.2 to 0.5)	-18.4 (-27.6 to -8.0)	-35.7 (-42.9 to -27.5)
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.8 (-12.9 to 40.3)	-1.2 (-21.3 to 25.1)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.7 (-33.5 to 95.7)	9.4 (-36.3 to 88.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.7 (-33.8 to 96.5)	9.4 (-36.8 to 88.7)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	9.5 (-13.8 to 40.9)	-1.5 (-21.8 to 24.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.5 (-13.9 to 41.2)	-1.5 (-21.9 to 25.2)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-38.9 (-72.6 to 44.4)	-46.9 (-77.2 to 32.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-34.2 (-70.6 to 66.8)	-42.9 (-76.0 to 50.3)
Cystic echinococcosis	2.5 (2.2 to 2.9)	1.2 (1.0 to 1.4)	-52.7 (-58.0 to -45.4)	-62.3 (-66.3 to -56.4)	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-53.5 (-60.9 to -43.6)	-62.6 (-68.6 to -54.7)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-38.4 (-51.1 to -1.6)	-26.1 (-55.5 to -9.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.4 (-51.1 to -1.5)	-26.1 (-55.5 to -9.1)
Intestinal nematode infections	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Ascariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trichuriasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Hookworm disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-86.9 (-96.2 to -71.8)	-86.3 (-96.1 to -70.8)
Maternal disorders	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	1.4 (-27.0 to 26.0)	-8.1 (-34.0 to 14.0)
Maternal hemorrhage	0.6 (0.5 to 0.7)	0.9 (0.6 to 1.2)	46.8 (0.9 to 106.7)	32.9 (-8.4 to 86.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.9 (-44.9 to 101.9)	9.3 (-49.6 to 83.4)
Maternal sepsis and other maternal infections	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.5)	-30.4 (-70.5 to 151.0)	-22.6 (-74.7 to 115.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-13.7 (-53.5 to 45.9)	-27.6 (-57.7 to 32.5)
Maternal hypertensive disorders	0.6 (0.2 to 1.0)	0.5 (0.2 to 0.9)	-10.3 (-16.9 to 1.1)	-19.2 (-25.9 to -10.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-10.1 (-28.4 to 14.3)	-19.2 (-35.5 to 1.6)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.9 (-48.9 to 77.8)	-13.9 (-53.5 to 61.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.9 (-48.9 to 78.2)	-13.9 (-53.6 to 61.5)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.2 (-32.7 to 40.4)	-11.9 (-38.6 to 27.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-3.2 (-32.9 to 40.5)	-11.9 (-38.9 to 27.5)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.4 (-33.7 to 70.0)	3.7 (-40.2 to 53.9)
Neonatal disorders	-	-	-	-	3.4 (2.4 to 4.6)	5.3 (3.7 to 7.2)	56.8 (28.4 to 96.8)	46.9 (20.3 to 85.0)
Preterm birth complications	16.1 (11.9 to 21.8)	31.4 (23.2 to 43.0)	94.7 (61.3 to 141.6)	80.1 (48.6 to 122.5)	1.8 (1.2 to 2.4)	3.3 (2.3 to 4.5)	85.6 (52.3 to 133.2)	73.8 (41.7 to 118.8)
Neonatal encephalopathy due to birth asphyxia and trauma	4.9 (2.7 to 9.1)	3.7 (1.9 to 8.2)	-26.9 (-51.7 to 14.9)	-31.6 (-54.6 to 6.5)	1.0 (0.6 to 1.3)	0.7 (0.5 to 1.0)	0.7 (-49.3 to 10.9)	-25.2 (-52.0 to 5.3)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	45.6 (21.4 to 74.0)	67.5 (39.7 to 100.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.1 (12.4 to 82.2)	69.3 (29.3 to 109.6)
Hemolytic disease and other neonatal jaundice	0.7 (0.2 to 1.4)	1.1 (0.2 to 2.5)	32.2 (-49.7 to 400.4)	23.7 (-52.8 to 369.5)	0.3 (0.1 to 0.6)	0.4 (0.1 to 1.0)	27.8 (-51.6 to 388.9)	19.6 (-54.5 to 357.6)
Other neonatal disorders	-	-	-	-	0.4 (0.2 to 0.6)	0.9 (0.5 to 1.4)	145.9 (56.8 to 279.8)	130.6 (47.2 to 255.0)
Nutritional deficiencies	-	-	-	-	10.8 (7.2 to 15.8)	10.7 (7.0 to 15.5)	-1.4 (-5.7 to 1.6)	-2.8 (-6.8 to 0.8)
Protein-energy malnutrition	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-32.1 (-49.9 to -4.7)	-53.3 (-64.5 to -35.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	0.0 (-54.6 to -6.0)	-35.3 (-67.2 to -3.4)
Iodine deficiency	8.0 (6.5 to 9.7)	5.9 (4.6 to 7.3)	-26.3 (-44.3 to -2.8)	-34.6 (-50.4 to -13.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-26.3 (-44.2 to -1.8)	-34.4 (-50.4 to -13.0)
Vitamin A deficiency	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-

Appendix Table G.4 - Uruguay prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	359.5 (353.8 to 364.6)	367.4 (359.7 to 373.2)	2.2 (-0.2 to 4.4)	2.1 (-4.4 to 0.1)	10.7 (7.1 to 15.5)	10.5 (7.0 to 15.3)	-1.0 (-5.4 to 2.0)	-1.0 (-6.2 to 0.7)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	167.8 (-1.4 to 335.7)	84.1 (-23.7 to 182.8)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1.2 (0.7 to 1.9)	1.1 (0.7 to 1.7)	-6.5 (-24.2 to 17.9)	-11.4 (-29.2 to 12.6)
Sexually transmitted diseases excluding HIV	-	-	-	-	0.5 (0.3 to 0.9)	0.6 (0.3 to 1.0)	15.0 (-7.3 to 46.1)	1.4 (-18.9 to 29.7)
Syphilis	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.4)	29.4 (9.3 to 53.4)	4.0 (13.0 to 25.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	29.2 (-3.8 to 73.7)	4.2 (-23.7 to 41.6)
Chlamydial infection	57.4 (44.2 to 68.9)	65.3 (54.7 to 76.1)	13.3 (-10.9 to 51.1)	2.0 (-19.8 to 36.1)	0.3 (0.1 to 0.4)	0.3 (0.2 to 0.5)	20.5 (-20.6 to 96.6)	8.9 (-28.3 to 77.6)
Gonococcal infection	7.8 (5.8 to 10.2)	7.3 (5.5 to 9.5)	-6.0 (-35.9 to 35.6)	-14.2 (-41.3 to 23.5)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-1.5 (-29.0 to 39.5)	-10.4 (-35.4 to 27.0)
Trichomoniasis	18.0 (12.4 to 25.2)	17.1 (13.2 to 22.5)	-3.1 (-41.1 to 54.1)	-14.5 (-47.6 to 35.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-8.8 (-48.1 to 57.8)	-19.5 (-54.2 to 38.4)
Genital herpes	400.1 (419.3 to 460.8)	509.4 (476.0 to 524.2)	24.7 (6.5 to 21.6)	14.1 (-10.3 to 21.9)	0.1 (0.0 to 0.3)	0.1 (0.0 to 0.3)	13.2 (4.1 to 22.2)	3.8 (-11.4 to 4.3)
Other sexually transmitted diseases	0.6 (0.4 to 0.9)	0.5 (0.3 to 0.7)	-19.4 (-46.5 to 18.1)	-30.5 (-53.9 to 1.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-32.9 to 42.6)	0.0 (-41.2 to 25.7)
Hepatitis	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-1.0 (-11.1 to 10.9)	-9.2 (-18.6 to 1.5)
Hepatitis A	2.9 (2.8 to 3.0)	2.8 (2.7 to 2.9)	-2.1 (-2.4 to -1.7)	-6.3 (-7.0 to -5.6)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	3.5 (-7.5 to 16.5)	-4.6 (-14.5 to 7.8)
Hepatitis B	19.8 (18.5 to 21.1)	12.2 (11.3 to 13.2)	-38.2 (-44.5 to -32.0)	-45.1 (-50.8 to -39.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.8 (-55.5 to -4.8)	-41.2 (-61.3 to -9.4)
Hepatitis C	21.4 (19.4 to 23.7)	17.7 (16.2 to 19.2)	-17.2 (-27.4 to -6.7)	-29.8 (-38.4 to -20.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.8 (-34.8 to 11.0)	-25.2 (-42.6 to -4.5)
Hepatitis E	-	-	9.3 (-27.7 to 70.2)	-2.3 (-35.7 to 52.9)	-	-	-	-
Leprosy	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-19.4 (-51.8 to 137.8)	-37.2 (-63.6 to 91.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-19.7 (-55.5 to 157.0)	-36.7 (-65.5 to 102.2)
Other infectious diseases	13.9 (10.5 to 16.9)	13.2 (9.7 to 16.3)	-5.0 (-32.3 to 26.1)	-2.2 (-31.5 to 29.8)	0.6 (0.3 to 0.9)	0.4 (0.2 to 0.6)	-26.2 (-58.5 to 6.2)	-23.0 (-57.3 to 11.3)
Non-communicable diseases	-	-	-	-	283.4 (212.1 to 365.9)	289.8 (255.0 to 438.9)	2.9 (18.0 to 24.3)	2.9 (0.3 to 5.6)
Neoplasms	-	-	-	-	5.5 (4.1 to 7.2)	8.0 (5.8 to 10.4)	43.9 (29.7 to 60.7)	12.0 (0.7 to 24.7)
Esophageal cancer	0.5 (0.4 to 0.6)	0.5 (0.4 to 0.7)	-4.5 (-32.1 to 38.4)	-26.8 (-48.2 to 5.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-5.2 (-29.9 to 29.3)	-27.3 (-46.4 to -1.3)
Stomach cancer	1.5 (1.3 to 1.7)	1.6 (1.4 to 1.9)	8.5 (-11.5 to 33.3)	-17.3 (-33.0 to 0.4)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	2.8 (-1.9 to 25.8)	-22.2 (-37.4 to -5.3)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	231.7 (226.4 to 467.4)	230.9 (154.3 to 335.8)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	463.0 (159.9 to 1,079.1)	358.0 (112.0 to 853.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	415.5 (162.5 to 941.6)	319.9 (108.4 to 728.0)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	1,125.8 (606.1 to 1,934.6)	837.1 (443.0 to 1,465.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,010.3 (613.3 to 1,535.8)	742.0 (441.1 to 1,142.8)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	100.5 (50.3 to 344.5)	100.5 (15.9 to 248.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	135.2 (55.6 to 261.4)	80.5 (17.9 to 177.9)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.2 (-7.2 to 274.3)	95.2 (-25.6 to 179.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.7 (8.6 to 219.0)	40.7 (-26.5 to 137.6)
Larynx cancer	0.9 (0.6 to 1.2)	1.0 (0.7 to 1.3)	8.8 (-29.0 to 65.9)	-8.8 (-40.8 to 39.6)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-10.9 (-36.9 to 26.8)	-26.0 (-47.7 to 6.1)
Tracheal, bronchus and lung cancer	2.6 (2.4 to 2.9)	2.7 (2.3 to 3.2)	3.2 (-13.9 to 24.8)	-16.6 (-30.7 to 1.2)	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	-2.6 (-18.9 to 16.6)	-21.3 (-34.5 to -5.4)
Breast cancer	17.8 (15.9 to 19.6)	32.4 (29.6 to 35.3)	82.4 (59.8 to 108.1)	37.1 (19.8 to 56.9)	1.3 (0.9 to 1.7)	1.7 (1.2 to 2.4)	35.4 (12.7 to 65.6)	3.1 (-14.2 to 25.6)
Cervical cancer	3.7 (3.0 to 4.4)	2.6 (1.9 to 3.4)	-29.0 (-46.7 to -7.3)	-41.5 (-56.4 to -23.1)	0.1 (0.2 to 0.4)	0.2 (0.1 to 0.3)	-28.3 (-46.8 to -6.9)	-41.2 (-56.5 to -22.5)
Uterine cancer	3.4 (2.5 to 5.0)	3.6 (2.3 to 5.4)	4.4 (-25.1 to 43.0)	-16.0 (-40.3 to 17.0)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	2.9 (-27.1 to 43.8)	-17.8 (-42.1 to 16.2)
Prostate cancer	6.0 (4.6 to 7.6)	12.5 (9.2 to 16.7)	109.1 (61.9 to 186.8)	65.6 (27.8 to 125.0)	0.7 (0.4 to 1.0)	1.4 (0.9 to 2.1)	110.9 (67.3 to 175.5)	62.0 (28.8 to 111.0)
Colon and rectum cancer	8.0 (7.4 to 8.6)	12.5 (10.9 to 14.4)	54.9 (32.2 to 82.7)	18.2 (1.9 to 38.5)	0.7 (0.5 to 0.9)	1.1 (0.8 to 1.4)	47.5 (25.0 to 74.9)	11.5 (-4.6 to 31.8)
Lip and oral cavity cancer	1.2 (0.9 to 1.4)	1.3 (1.0 to 1.7)	12.8 (-14.7 to 47.8)	-9.1 (-31.0 to 18.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	8.9 (-18.3 to 47.0)	-12.6 (-33.9 to 19.1)
Nasopharynx cancer	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-23.3 (-48.9 to 14.4)	-35.7 (-57.6 to -4.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-49.0 to 5.5)	-38.2 (-57.8 to -12.3)
Other pharynx cancer	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.9)	-2.0 (-36.9 to 52.7)	-17.1 (-47.0 to 29.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-2.5 (-37.8 to 52.3)	-18.2 (-48.2 to 28.7)
Gallbladder and biliary tract cancer	0.3 (0.3 to 0.4)	0.3 (0.2 to 0.4)	-14.0 (-39.2 to 20.3)	-35.7 (-54.0 to -12.8)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-17.8 (-43.7 to 20.8)	-38.0 (-57.3 to -10.8)
Pancreatic cancer	0.1 (0.1 to 0.1)	0.5 (0.4 to 0.6)	273.3 (183.2 to 389.4)	184.2 (116.2 to 271.5)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	240.3 (169.0 to 337.8)	161.6 (108.3 to 232.3)
Malignant skin melanoma	1.2 (1.0 to 1.5)	1.5 (1.2 to 2.1)	21.8 (-11.8 to 76.3)	14.4 (-29.0 to 43.3)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	0.1 (-15.7 to 78.4)	0.1 (-32.1 to 43.1)
Non-melanoma skin cancer	2.3 (1.9 to 2.7)	3.8 (3.4 to 4.4)	65.5 (31.7 to 116.8)	22.2 (-2.6 to 59.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	62.7 (25.4 to 117.4)	15.3 (-10.1 to 51.7)
Ovarian cancer	0.4 (0.3 to 0.4)	0.9 (0.7 to 1.2)	166.3 (105.6 to 255.0)	112.4 (64.4 to 187.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	156.5 (80.5 to 267.4)	104.5 (42.5 to 192.8)
Testicular cancer	0.2 (0.1 to 0.4)	0.2 (0.2 to 1.3)	324.8 (-3.9 to 785.6)	268.9 (-17.1 to 674.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	316.6 (-6.7 to 827.4)	260.0 (-19.0 to 715.1)
Kidney cancer	1.9 (1.7 to 2.1)	3.4 (2.8 to 4.1)	79.6 (44.4 to 125.9)	49.3 (18.5 to 85.7)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	78.4 (38.1 to 122.0)	41.4 (12.7 to 79.6)
Bladder cancer	2.8 (2.3 to 3.3)	3.4 (2.7 to 4.2)	19.4 (-4.9 to 60.0)	-7.2 (-25.9 to 24.2)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	14.7 (-7.9 to 52.5)	-11.4 (-28.7 to 18.2)
Brain and nervous system cancer	0.2 (0.2 to 0.3)	0.6 (0.3 to 0.8)	230.6 (33.2 to 307.9)	182.6 (13.9 to 251.3)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	209.9 (24.7 to 292.9)	164.5 (6.4 to 232.0)
Thyroid cancer	1.4 (1.1 to 1.7)	1.8 (1.3 to 2.6)	28.1 (-7.8 to 86.5)	6.8 (-23.7 to 57.3)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	25.0 (-8.9 to 82.9)	3.3 (-24.8 to 52.2)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	245.9 (-42.7 to -1.2)	-40.0 (-53.6 to -20.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-24.6 (-42.3 to -4.8)	-39.6 (-53.3 to -20.4)
Hodgkin lymphoma	0.1 (0.0 to 0.1)	0.5 (0.1 to 0.7)	823.1 (16.7 to 1,243.4)	709.3 (3.5 to 1,100.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	816.0 (5.2 to 1,218.9)	699.3 (-7.1 to 1,064.6)
Non-Hodgkin lymphoma	2.2 (1.9 to 2.7)	3.5 (2.6 to 4.2)	58.3 (22.6 to 91.6)	28.7 (1.4 to 55.5)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	53.7 (17.3 to 89.0)	24.3 (-3.9 to 52.1)
Multiple myeloma	0.3 (0.3 to 0.4)	0.5 (0.4 to 0.7)	64.3 (19.5 to 132.9)	31.0 (-5.3 to 84.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	58.5 (8.2 to 136.3)	25.7 (-13.7 to 83.9)
Leukemia	0.7 (0.6 to 0.9)	0.9 (0.7 to 1.1)	24.9 (-12.6 to 56.4)	19.0 (-28.6 to 27.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	20.1 (-6.9 to 52.8)	-4.9 (-26.2 to 19.8)
Other neoplasms	4.0 (3.5 to 4.7)	9.7 (7.4 to 11.7)	143.5 (86.3 to 189.5)	95.5 (51.1 to 132.5)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	132.5 (74.7 to 185.1)	85.8 (40.0 to 125.1)
Cardiovascular diseases	-	-	-	-	8.4 (5.7 to 11.8)	13.1 (8.7 to 18.2)	57.3 (15.9 to 107.8)	20.3 (-11.9 to 59.1)
Rheumatic heart disease	0.8 (0.7 to 1.0)	1.0 (0.8 to 1.2)	22.6 (-5.5 to 56.2)	-3.0 (-25.0 to 23.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	19.6 (-14.6 to 60.5)	-5.2 (-32.7 to 27.0)
Ischemic heart disease	49.6 (41.8 to 59.0)	69.4 (59.7 to 82.9)	39.7 (8.7 to 85.5)	6.6 (-17.5 to 41.4)	3.2 (1.0 to 4.5)	4.4 (3.0 to 6.1)	36.0 (5.7 to 81.8)	2.5 (-20.9 to 37.6)
Cerebrovascular disease	-	-	-	-	1.2 (0.8 to 1.6)	1.4 (0.9 to 1.8)	18.4 (-6.0 to 44.4)	-3.8 (-23.1 to 17.0)
Ischemic stroke	6.0 (5.2 to 7.3)	6.9 (5.8 to 8.1)	13.8 (-10.7 to 40.9)	-8.6 (-27.6 to 12.7)	0.9 (0.6 to 1.2)	1.0 (0.7 to 1.4)	13.7 (-10.5 to 42.5)	-8.0 (-27.4 to 14.4)
Hemorrhagic stroke	1.8 (1.5 to 2.2)	2.4 (2.0 to 2.8)	32.4 (3.5 to 67.1)	9.1 (-12.9 to 36.4)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	32.3 (1.8 to 66.4)	9.3 (-15.0 to 37.1)
Hypertensive heart disease	8.4 (7.3 to 9.6)	12.7 (11.0 to 14.8)	50.5 (24.5 to 87.2)	7.4 (-10.5 to 33.4)	0.9 (0.5 to 1.3)	1.4 (0.9 to 1.9)	50.1 (23.9 to 86.3)	8.0 (-10.5 to 34.3)
Cardiomyopathy and myocarditis	5.5 (4.5 to 6.5)	6.9 (6.2 to 7.8)	25.7 (4.0 to 61.3)	25.7 (-19.5 to 23.6)	0.6 (0.4 to 0.8)	0.8 (0.5 to 1.0)	25.8 (2.2 to 61.8)	-2.3 (-20.0 to 25.0)
Atrial fibrillation and flutter	3.9 (2.8 to 5.3)	9.6 (7.6 to 11.9)	143.8 (72.2 to 253.0)	79.9 (28.4 to 156.9)	0.3 (0.2 to 0.5)	0.7 (0.5 to 1.1)	146.0 (72.0 to 258.3)	84.2 (28.5 to 163.1)
Peripheral vascular disease	74.5 (58.5 to 93.8)	95.2 (62.0 to 120.9)	28.3 (-17.7 to 89.1)	-2.2 (-39.8 to 46.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	67.0 (-21.9 to 236.0)	9.5 (-49.8 to 122.8)
Endocarditis	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.3)	30.1 (-13.7 to 78.8)	4.6 (-29.4 to 42.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.9 (-17.4 to 95.9)	6.9 (-31.3 to 58.4)
Other cardiovascular and circulatory diseases	29.1 (12.0 to 56.1)	60.1 (26.1 to 94.3)	113.2 (-27.3 to 454.9)	65.6 (-42.8 to 330.5)	2.1 (0.8 to 4.2)	4.3 (1.7 to 7.3)	114.7 (-4.2 to 460.7)	66.9 (-43.2 to 331.8)
Chronic respiratory diseases	-	-	-	-	24.7 (17.1 to 32.9)	28.7 (20.0 to 38.9)	15.7 (4.1 to 31.3)	-0.5 (-10.1 to 12.4)
Chronic obstructive pulmonary disease	231.8 (218.3 to 244.6)	287.1 (270.7 to 301.1)	23.9 (19.5 to 27.9)	1.2 (-2.3 to 4.5)	13.1 (8.7 to 18.1)	17.0 (11.3 to 23.7)	28.0 (10.4 to 57.3)	5.3 (-9.0 to 28.8)</

Appendix Table G.4 - Uruguay prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-1.9 (18.0 to 27.7)	-1.9 (-5.7 to 1.9)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.3 (13.7 to 26.4)	-4.2 (-9.2 to 0.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.9 (13.5 to 26.1)	23.9 (-9.6 to 0.2)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.5 (20.9 to 35.4)	2.5 (-2.7 to 8.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.5 (19.3 to 34.2)	26.5 (-4.1 to 7.4)
Asthma	232.2 (216.0 to 247.7)	252.5 (238.6 to 266.6)	8.9 (-0.4 to 18.7)	0.1 (-8.5 to 9.3)	10.2 (6.6 to 14.6)	11.1 (7.2 to 15.7)	8.6 (-1.0 to 18.4)	0.3 (-8.9 to 9.5)
Interstitial lung disease and pulmonary sarcoidosis	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	26.9 (-12.6 to 74.4)	2.3 (-28.5 to 40.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	26.2 (-12.9 to 75.6)	2.2 (-28.4 to 41.3)
Other chronic respiratory diseases	-	-	-	-	1.3 (0.8 to 1.9)	0.4 (0.3 to 0.7)	-65.1 (-74.1 to -49.5)	-71.7 (-79.0 to -59.1)
Cirrhosis	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	12.8 (-1.6 to 31.6)	-4.7 (-17.3 to 10.5)
Cirrhosis due to hepatitis B	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-5.2 (-50.2 to 72.8)	-21.8 (-59.5 to 42.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.2 (-53.2 to 83.1)	21.8 (-61.4 to 49.8)
Cirrhosis due to hepatitis C	0.3 (0.2 to 0.5)	0.5 (0.4 to 0.6)	54.0 (7.5 to 120.7)	30.0 (-9.6 to 87.3)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	55.1 (0.7 to 132.6)	30.0 (-14.9 to 97.0)
Cirrhosis due to alcohol use	0.4 (0.4 to 0.5)	0.4 (0.3 to 0.5)	-17.7 (-42.5 to 12.8)	-32.0 (-52.6 to -6.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-18.1 (-46.2 to 18.8)	-32.1 (-56.1 to 17.6)
Cirrhosis due to other causes	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	36.2 (-8.2 to 97.4)	19.8 (-17.4 to 73.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.4 (-15.4 to 100.8)	32.4 (-24.6 to 75.3)
Digestive diseases	-	-	-	-	4.1 (2.9 to 5.4)	4.9 (3.5 to 6.5)	19.7 (11.5 to 29.3)	-1.2 (-8.6 to 7.1)
Peptic ulcer disease	22.2 (21.6 to 22.8)	17.1 (16.4 to 17.9)	-23.1 (-26.8 to -18.9)	-44.4 (-46.9 to -41.6)	0.7 (0.5 to 1.0)	0.5 (0.4 to 0.7)	-21.7 (-31.7 to -15.0)	-44.3 (-51.4 to -39.4)
Gastritis and duodenitis	12.3 (12.0 to 12.6)	9.2 (8.5 to 9.9)	-25.3 (-31.6 to -19.5)	-39.2 (-44.7 to -33.6)	0.5 (0.3 to 0.6)	0.3 (0.2 to 0.5)	-24.1 (-31.5 to -13.2)	-36.6 (-42.9 to -26.6)
Appendicitis	0.2 (0.2 to 0.2)	0.2 (0.1 to 0.2)	-14.5 (-32.8 to 5.9)	-19.5 (-36.7 to -0.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-14.9 (-41.5 to 26.0)	-20.1 (-45.3 to 18.7)
Paralytic ileus and intestinal obstruction	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	70.3 (34.3 to 113.7)	39.2 (9.3 to 86.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.1 (17.2 to 136.9)	39.6 (-1.1 to 101.4)
Inguinal, femoral, and abdominal hernia	19.3 (17.3 to 21.5)	12.8 (11.0 to 15.1)	-33.5 (-44.9 to -19.3)	-50.1 (-58.4 to -39.6)	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.2)	-33.2 (-44.6 to -18.3)	-49.4 (-58.0 to -38.3)
Inflammatory bowel disease	7.6 (7.0 to 8.2)	10.5 (9.8 to 11.3)	39.3 (24.5 to 55.9)	16.6 (3.7 to 30.8)	1.6 (1.1 to 2.2)	2.2 (1.5 to 3.0)	38.5 (23.9 to 56.7)	16.6 (3.8 to 32.2)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.3 (0.9 to 91.7)	0.6 (-25.9 to 36.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.6 (-17.2 to 116.5)	0.9 (-35.6 to 52.8)
Gallbladder and biliary diseases	6.3 (5.6 to 7.0)	7.7 (6.8 to 8.6)	23.3 (2.2 to 40.7)	0.7 (-15.9 to 15.4)	0.7 (0.4 to 0.9)	0.8 (0.5 to 1.1)	22.2 (1.5 to 41.5)	0.9 (-16.9 to 16.6)
Pancreatitis	0.9 (0.9 to 1.0)	1.2 (1.2 to 1.3)	34.4 (26.3 to 43.1)	11.6 (4.9 to 18.5)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	34.1 (16.8 to 54.2)	12.0 (-2.8 to 29.2)
Other digestive diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.6)	192.2 (109.4 to 260.4)	140.3 (70.3 to 197.5)
Neurological disorders	-	-	-	-	22.2 (15.0 to 29.5)	29.3 (20.4 to 39.2)	31.5 (13.3 to 61.9)	9.1 (-6.7 to 35.3)
Alzheimer disease and other dementias	25.2 (21.6 to 28.5)	39.3 (32.8 to 44.9)	55.6 (25.8 to 94.6)	-1.8 (-19.6 to 22.1)	3.7 (2.6 to 5.0)	6.0 (4.0 to 7.9)	59.2 (28.0 to 99.5)	-1.2 (-19.9 to 23.3)
Parkinson disease	2.3 (1.9 to 2.8)	3.1 (2.6 to 3.7)	33.1 (23.7 to 43.4)	0.4 (-5.7 to 7.2)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	31.9 (16.6 to 50.5)	0.3 (-11.0 to 14.0)
Epilepsy	19.5 (14.9 to 23.5)	19.3 (14.8 to 23.9)	-0.9 (-29.5 to 39.1)	-8.8 (-35.3 to 27.3)	7.6 (4.8 to 10.6)	7.8 (5.0 to 11.0)	3.0 (-28.0 to 46.4)	-5.9 (-34.2 to 34.9)
Multiple sclerosis	0.9 (0.9 to 1.0)	1.8 (1.7 to 1.9)	88.8 (67.9 to 114.6)	61.1 (43.1 to 83.7)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	88.3 (57.4 to 127.3)	60.8 (34.0 to 94.4)
Migraine	184.1 (120.3 to 250.7)	246.8 (184.3 to 337.4)	32.9 (-14.0 to 155.2)	16.7 (-25.3 to 126.8)	3.7 (3.2 to 10.2)	6.0 (4.6 to 13.4)	61.2 (-13.9 to 156.2)	37.0 (-25.0 to 127.8)
Tension-type headache	578.5 (542.9 to 617.7)	669.0 (577.3 to 771.2)	15.6 (-2.3 to 34.7)	1.6 (-14.1 to 19.2)	1.0 (0.4 to 1.5)	1.0 (0.5 to 1.8)	15.4 (-35.2 to 35.2)	1.5 (-14.5 to 19.4)
Medication overuse headache	16.2 (9.9 to 22.5)	29.5 (19.7 to 40.0)	82.1 (32.6 to 162.9)	56.4 (14.5 to 124.7)	2.5 (1.3 to 4.0)	4.6 (2.6 to 7.3)	81.3 (32.5 to 162.8)	56.8 (14.7 to 125.6)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.5 (-14.2 to 47.7)	-1.3 (-24.1 to 30.5)	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.8)	-3.9 (-28.3 to 37.0)	-6.7 (-52.9 to -11.1)
Mental and substance use disorders	-	-	-	-	76.3 (54.8 to 99.5)	85.1 (61.5 to 110.7)	11.5 (8.9 to 14.3)	-0.7 (-3.1 to 1.7)
Schizophrenia	9.2 (8.2 to 10.1)	10.4 (9.4 to 11.4)	13.7 (8.5 to 19.1)	-1.7 (-6.2 to 3.1)	5.9 (4.3 to 7.2)	6.7 (4.9 to 8.2)	14.0 (7.1 to 21.3)	-1.4 (-7.5 to 5.0)
Alcohol use disorders	31.0 (28.1 to 34.1)	36.8 (33.1 to 40.8)	18.6 (11.2 to 27.1)	4.9 (-1.9 to 12.6)	3.1 (2.1 to 4.4)	3.7 (2.5 to 5.3)	18.8 (10.7 to 28.6)	5.3 (-2.2 to 14.0)
Drug use disorders	-	-	-	-	6.8 (4.6 to 9.1)	7.5 (5.1 to 10.1)	10.3 (-1.6 to 22.8)	-1.2 (-12.0 to 10.1)
Opioid use disorders	6.8 (5.4 to 8.6)	7.6 (5.9 to 9.6)	13.1 (1.0 to 24.6)	-1.1 (-12.7 to 9.0)	2.8 (1.9 to 3.9)	3.2 (2.1 to 4.5)	13.6 (-0.8 to 27.3)	-0.6 (-13.9 to 11.5)
Cocaine use disorders	2.3 (2.3 to 3.2)	2.8 (3.0 to 4.0)	25.6 (4.4 to 58.7)	2.7 (-6.3 to 42.5)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.7)	26.1 (0.2 to 68.8)	13.7 (-10.3 to 51.5)
Amphetamine use disorders	11.5 (10.7 to 12.3)	11.9 (11.1 to 12.6)	3.3 (-7.1 to 13.1)	-5.8 (-15.3 to 3.3)	1.5 (0.9 to 2.2)	1.6 (1.0 to 2.2)	3.7 (-8.6 to 16.8)	-5.2 (-16.8 to 6.8)
Cannabis use disorders	7.0 (5.9 to 8.0)	7.5 (6.4 to 8.5)	7.9 (7.3 to 8.7)	0.3 (0.3 to 0.4)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	7.8 (-4.6 to 22.8)	0.2 (-11.3 to 14.5)
Other drug use disorders	-	-	-	-	1.9 (1.2 to 2.9)	2.1 (1.3 to 3.1)	7.9 (-20.7 to 46.0)	-1.9 (-27.6 to 32.9)
Depressive disorders	-	-	-	-	25.0 (15.6 to 37.3)	28.2 (17.9 to 41.7)	13.3 (5.9 to 19.9)	0.9 (-7.1 to 4.9)
Major depressive disorder	98.8 (68.3 to 129.5)	111.4 (77.3 to 146.6)	13.0 (4.4 to 21.2)	-1.1 (-8.5 to 6.1)	20.2 (12.1 to 31.3)	22.7 (13.7 to 34.8)	12.6 (3.7 to 21.0)	-1.1 (-8.8 to 6.2)
Dysthymia	49.1 (41.6 to 56.4)	57.1 (48.5 to 65.5)	16.4 (15.3 to 17.6)	4.7 (-0.3 to -0.1)	5.5 (3.1 to 6.9)	5.5 (3.6 to 8.0)	16.2 (13.6 to 18.9)	-0.1 (-2.2 to 2.1)
Bipolar disorder	24.0 (21.1 to 26.9)	27.4 (24.3 to 30.7)	14.1 (9.2 to 20.5)	-0.0 (-4.6 to 5.7)	4.9 (3.0 to 7.2)	5.6 (3.5 to 8.2)	14.1 (7.7 to 21.7)	0.1 (-5.7 to 6.7)
Anxiety disorders	190.2 (167.6 to 211.0)	211.6 (186.5 to 234.5)	11.2 (10.2 to 12.2)	0.3 (-0.4 to -0.3)	17.5 (11.9 to 24.3)	19.4 (13.2 to 27.1)	11.0 (8.6 to 13.5)	4.3 (2.1 to 8.1)
Eating disorders	-	-	-	-	1.7 (1.0 to 2.6)	1.9 (1.1 to 2.9)	11.3 (5.3 to 18.5)	4.0 (-1.8 to 11.0)
Anorexia nervosa	1.2 (0.9 to 1.5)	1.7 (1.3 to 2.1)	40.8 (26.6 to 60.9)	31.9 (18.9 to 51.1)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	40.6 (17.1 to 69.9)	32.0 (9.8 to 58.3)
Bulimia nervosa	6.7 (4.4 to 9.7)	7.1 (4.6 to 10.3)	6.4 (4.6 to 7.6)	-1.0 (-1.2 to -0.8)	1.4 (0.8 to 2.3)	1.5 (0.9 to 2.4)	6.2 (0.1 to 12.5)	-1.1 (-6.1 to 4.8)
Autistic spectrum disorders	-	-	-	-	3.6 (2.5 to 4.9)	5.4 (2.7 to 5.4)	8.7 (5.4 to 12.0)	0.6 (-2.5 to 3.9)
Autism	9.5 (8.9 to 10.0)	10.3 (9.7 to 10.9)	8.8 (8.5 to 9.1)	0.3 (0.3 to 0.3)	2.3 (1.6 to 3.2)	2.5 (1.7 to 3.5)	8.7 (3.9 to 13.6)	0.6 (-3.9 to 5.1)
Asperger syndrome	13.0 (12.1 to 13.8)	14.1 (13.2 to 15.0)	8.7 (8.3 to 9.1)	0.4 (0.4 to 0.4)	1.3 (0.9 to 1.8)	1.4 (1.0 to 2.0)	8.6 (4.4 to 12.9)	0.6 (-3.2 to 4.7)
Attention-deficit/hyperactivity disorder	19.9 (18.3 to 21.4)	19.5 (18.0 to 21.0)	-2.0 (-2.3 to -1.8)	0.2 (0.2 to 0.2)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	-2.1 (-8.2 to 4.4)	0.2 (-6.0 to 5.7)
Conduct disorder	23.8 (21.8 to 25.9)	23.1 (21.1 to 25.2)	-3.1 (-3.6 to -2.5)	0.1 (0.1 to 0.2)	2.1 (1.8 to 4.2)	2.8 (1.8 to 4.0)	3.2 (-7.2 to 1.3)	0.2 (-4.0 to 4.7)
Idiopathic intellectual disability	15.6 (11.4 to 20.2)	11.0 (6.1 to 15.9)	-29.1 (-51.7 to -11.4)	-34.8 (-55.5 to -18.7)	0.9 (0.6 to 1.4)	0.7 (0.3 to 1.0)	-29.5 (-54.2 to -10.3)	-35.1 (-64.4 to -17.5)
Other mental and substance use disorders	52.1 (49.1 to 55.1)	61.8 (58.2 to 65.3)	18.6 (17.8 to 19.4)	0.3 (0.2 to 0.4)	3.9 (2.6 to 5.2)	4.6 (3.1 to 6.2)	18.6 (14.3 to 23.1)	0.6 (-3.0 to 4.4)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	24.7 (17.7 to 32.4)	31.4 (22.3 to 41.5)	27.1 (17.3 to 36.6)	7.4 (-0.4 to 15.4)
Diabetes mellitus	101.7 (80.3 to 121.8)	147.4 (119.3 to 178.3)	44.8 (13.7 to 83.6)	21.1 (-5.6 to 53.2)	7.1 (4.6 to 10.1)	10.3 (6.7 to 14.8)	43.7 (14.6 to 84.3)	18.7 (-4.6 to 52.2)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.8 (-27.0 to -16.4)	-26.5 (-30.9 to -21.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-21.8 (-27.0 to -16.4)	-21.8 (-30.9 to -21.1)
Chronic kidney disease	-	-	-	-	8.1 (5.8 to 10.9)	10.1 (7.4 to 13.3)	24.8 (15.6 to 37.4)	4.7 (-2.2 to 14.5)
Chronic kidney disease due to diabetes mellitus	14.8 (10.8 to 21.7)	38.4 (25.4 to 60.4)	161.0 (84.3 to 237.8)	109.2 (49.9 to 172.4)	0.8 (0.6 to 1.1)	2.3 (1.6 to 3.3)	179.9 (100.7 to 257.6)	130.3 (64.9 to 192.9)
Chronic kidney disease due to hypertension	30.9 (21.9 to 43.2)	28.5 (21.3 to 37.0)	-7.1 (-28.8 to 20.5)	-22.6 (-39.2 to -0.7)	1.4 (0.9 to 1.8)	2.1 (1.4 to 3.1)	52.7 (22.0 to 111.3)	23.7 (-1.6 to 70.0)
Chronic kidney disease due to glomerulonephritis	28.2 (22.3 to 36.0)	36.2 (25.2 to 50.6)	27.8 (-2.4 to 62.0)	11.2 (-18.9 to 26.8)	2.0 (1.4 to 2.7)	1.7 (1.1 to 2.4)	14.6 (-37.4 to 11.7)	25.1 (-44.2 to -2.0)
Chronic kidney disease due to other causes	76.3 (57.4 to 100.7)	73.1 (49.9 to 100.2)	-4.6 (-19.7 to 15.6)	-21.9 (-34.4 to -7.4)	3.9 (2.8 to 5.2)	4.0 (2.8 to 5.2)	2.6 (-14.1 to 17.7)	-13.0 (-26.9 to -1.3)
Urinary diseases and male infertility	-	-	-	-	2.5 (1.6 to 3.7)	3.2 (2.1 to 4.6)	27.2 (9.8 to 44.5)	1.0 (-12.8 to 15.1)

Appendix Table G.4 - Uruguay prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.7 (0.6 to 0.8)	1.1 (1.0 to 1.2)	51.1 (34.2 to 83.9)	51.1 (15.4 to 57.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	51.1 (23.1 to 90.3)	51.1 (5.7 to 65.9)
Urolithiasis	25.7 (14.1 to 45.6)	40.4 (21.2 to 71.7)	55.9 (15.9 to 85.8)	26.4 (9.7 to 45.6)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.6)	61.7 (23.4 to 87.8)	30.5 (-2.2 to 49.6)
Benign prostatic hyperplasia	62.5 (55.0 to 69.4)	78.2 (67.8 to 87.0)	25.3 (5.6 to 45.5)	-1.7 (-17.7 to 15.0)	2.2 (1.4 to 3.2)	2.8 (1.8 to 4.0)	25.4 (5.0 to 46.2)	-1.0 (-17.7 to 15.9)
Male infertility due to other causes	7.6 (5.7 to 10.1)	8.6 (6.3 to 11.3)	12.4 (-24.2 to 71.3)	-0.9 (-33.7 to 50.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	14.1 (-24.0 to 80.2)	0.2 (-33.2 to 59.5)
Other urinary diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	22.2 (-53.0 to 62.4)	45.0 (-61.6 to 33.1)
Gynecological diseases	-	-	-	-	3.6 (2.4 to 5.3)	4.0 (2.6 to 6.2)	10.3 (-3.8 to 27.8)	4.6 (-16.6 to 10.8)
Uterine fibroids	80.3 (71.7 to 89.9)	95.0 (84.7 to 106.3)	18.2 (17.8 to 18.6)	-1.1 (-1.2 to -1.1)	0.9 (0.5 to 1.6)	1.1 (0.6 to 1.8)	13.3 (5.5 to 19.8)	-3.9 (-10.3 to 1.7)
Polycystic ovarian syndrome	46.0 (40.9 to 50.9)	52.5 (47.6 to 56.9)	14.4 (-2.3 to 31.8)	-0.5 (-15.1 to 14.5)	0.4 (0.2 to 0.8)	0.5 (0.2 to 0.9)	14.6 (-1.6 to 31.8)	-0.3 (-14.6 to 14.6)
Female infertility due to other causes	0.6 (0.3 to 2.0)	0.6 (0.3 to 2.0)	12.8 (-72.1 to 345.8)	-2.2 (-75.8 to 286.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.9 (-68.7 to 306.1)	-1.8 (-73.0 to 252.3)
Endometriosis	8.2 (6.6 to 9.7)	8.9 (7.3 to 10.7)	8.2 (-16.9 to 42.4)	-6.3 (-28.3 to 23.7)	0.8 (0.5 to 1.1)	0.8 (0.5 to 1.2)	8.3 (-17.5 to 44.3)	-6.3 (-28.5 to 24.9)
Genital prolapse	136.7 (116.9 to 157.4)	153.2 (126.5 to 178.4)	11.8 (-8.9 to 37.8)	-4.4 (-22.5 to 18.6)	0.5 (0.2 to 0.8)	0.5 (0.2 to 0.9)	11.8 (-9.3 to 38.4)	-4.5 (-23.0 to 19.0)
Premenstrual syndrome	96.6 (56.1 to 134.4)	106.2 (62.9 to 144.9)	8.2 (-37.3 to 93.6)	-4.3 (-45.1 to 68.6)	0.8 (0.4 to 1.4)	0.9 (0.4 to 1.5)	7.9 (-38.4 to 92.4)	-4.9 (-45.9 to 69.1)
Other gynecological diseases	9.4 (8.2 to 10.9)	10.3 (9.7 to 10.9)	10.1 (-6.0 to 26.7)	-3.4 (-17.6 to 11.0)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	4.4 (-1.5 to 36.1)	-8.2 (-23.0 to 20.1)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	2.3 (1.5 to 3.4)	2.5 (1.7 to 3.6)	9.5 (0.9 to 20.8)	6.1 (-2.0 to 15.9)
Thalassemias	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	8.9 (-1.7 to 22.6)	9.7 (-0.9 to 23.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.7 (-20.3 to 59.8)	8.2 (-21.3 to 58.7)
Thalassemia trait	48.5 (46.0 to 52.3)	53.2 (49.2 to 58.1)	9.4 (4.6 to 14.2)	-0.2 (-4.3 to 4.0)	1.7 (1.2 to 2.5)	1.9 (1.3 to 2.8)	11.5 (3.3 to 19.4)	7.8 (0.0 to 15.1)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.3 (-15.2 to 12.3)	-2.9 (-17.9 to 9.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.3 (-18.3 to 14.0)	-4.0 (-21.2 to 10.2)
Sickle cell trait	9.6 (8.4 to 10.8)	10.5 (9.7 to 11.4)	9.7 (-6.2 to 21.4)	0.4 (-14.1 to 11.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	12.5 (-12.1 to 77.9)	13.9 (-11.7 to 81.7)
G6PD deficiency	55.0 (49.3 to 60.5)	63.2 (57.2 to 68.9)	14.6 (-0.5 to 34.0)	4.9 (-8.9 to 22.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	22.2 (-16.8 to 93.2)	18.2 (-21.6 to 89.8)
G6PD trait	388.2 (377.4 to 397.9)	414.1 (399.2 to 426.1)	6.7 (2.0 to 10.8)	-3.6 (-7.8 to 0.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.8 (-53.3 to 137.2)	10.8 (-55.4 to 137.6)
Other hemoglobinopathies and hemolytic anemias	13.1 (10.1 to 16.0)	14.3 (12.4 to 16.8)	9.1 (-14.6 to 46.7)	0.4 (-21.5 to 36.1)	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.6)	-1.5 (-25.9 to 67.0)	-4.9 (-27.5 to 58.7)
Endocrine, metabolic, blood, and immune disorders	29.4 (26.2 to 32.9)	36.1 (34.1 to 38.4)	22.5 (9.2 to 39.3)	1.0 (-0.4 to 28.5)	1.2 (0.7 to 1.4)	1.2 (0.8 to 1.7)	19.8 (8.4 to 47.5)	10.3 (-0.2 to 31.8)
Musculoskeletal disorders	-	-	-	-	59.6 (42.1 to 78.3)	75.1 (53.5 to 97.9)	26.3 (17.9 to 35.4)	6.8 (-0.7 to 14.5)
Rheumatoid arthritis	13.0 (12.3 to 13.6)	16.2 (15.4 to 16.9)	24.9 (17.2 to 34.1)	1.2 (-4.9 to 8.6)	3.0 (2.2 to 4.0)	3.8 (2.7 to 5.0)	23.9 (15.0 to 34.7)	1.0 (-6.2 to 9.8)
Osteoarthritis	153.0 (146.1 to 160.3)	199.3 (191.3 to 207.9)	30.2 (22.9 to 38.3)	0.4 (-5.4 to 6.6)	5.3 (3.5 to 7.6)	6.9 (4.5 to 9.9)	29.8 (21.9 to 37.9)	6.7 (-5.5 to 6.7)
Low back and neck pain	-	-	-	-	38.6 (26.7 to 52.4)	46.0 (31.6 to 61.8)	19.7 (7.7 to 32.4)	2.6 (-7.8 to 13.4)
Low back pain	186.7 (175.9 to 197.6)	216.7 (204.6 to 229.4)	16.2 (7.0 to 25.0)	-1.0 (-9.3 to 6.8)	20.7 (13.9 to 28.8)	24.1 (16.2 to 33.4)	16.3 (6.7 to 25.2)	-0.6 (-8.9 to 7.4)
Neck pain	182.2 (145.4 to 213.2)	224.0 (201.2 to 247.2)	22.5 (1.8 to 53.6)	5.1 (-12.6 to 32.1)	17.9 (11.7 to 25.4)	22.0 (15.1 to 30.8)	22.8 (2.0 to 54.0)	5.3 (-12.5 to 32.2)
Gout	6.4 (5.5 to 7.3)	8.2 (7.2 to 9.3)	29.2 (6.3 to 53.5)	4.3 (-14.3 to 24.0)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	29.3 (3.0 to 60.8)	5.1 (-15.9 to 30.6)
Other musculoskeletal disorders	135.8 (121.0 to 151.4)	198.8 (173.6 to 223.8)	46.5 (37.8 to 56.4)	24.8 (17.4 to 32.1)	12.4 (8.4 to 17.5)	18.4 (12.2 to 25.3)	46.4 (37.0 to 55.8)	25.0 (16.6 to 32.5)
Other non-communicable diseases	-	-	-	-	57.7 (38.4 to 83.3)	66.9 (44.6 to 97.2)	16.0 (11.4 to 20.2)	2.8 (-6.9 to 1.0)
Congenital anomalies	-	-	-	-	4.1 (3.0 to 5.3)	5.6 (4.0 to 7.4)	36.4 (18.1 to 59.1)	24.0 (6.9 to 44.8)
Neural tube defects	0.8 (0.7 to 1.0)	0.9 (0.7 to 1.1)	5.4 (-20.8 to 42.4)	-0.7 (-25.1 to 34.2)	0.2 (0.2 to 0.4)	0.3 (0.2 to 0.4)	2.7 (-30.9 to 61.8)	-2.6 (-34.3 to 52.7)
Congenital heart anomalies	20.7 (17.5 to 24.7)	29.2 (26.2 to 33.0)	40.7 (16.2 to 73.9)	29.6 (7.1 to 60.3)	0.7 (0.3 to 1.2)	1.1 (0.5 to 1.8)	46.4 (21.1 to 80.3)	36.2 (12.5 to 67.5)
Orofacial clefts	3.0 (2.3 to 3.5)	4.1 (3.4 to 5.1)	37.0 (5.4 to 80.8)	25.0 (-4.2 to 64.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-2.8 (-33.3 to 39.3)	-11.3 (-39.0 to 27.2)
Down syndrome	3.9 (3.2 to 4.7)	5.1 (4.1 to 6.2)	30.8 (-3.5 to 73.7)	17.4 (-13.1 to 55.7)	0.5 (0.4 to 0.7)	0.7 (0.5 to 1.0)	40.0 (-0.3 to 88.0)	23.1 (-12.2 to 65.2)
Turner syndrome	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	16.2 (-26.3 to 72.2)	7.8 (-31.6 to 60.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.5 (-28.8 to 77.4)	6.6 (-34.3 to 63.6)
Klinefelter syndrome	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	11.9 (-3.5 to 23.1)	3.7 (-10.6 to 14.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.1 (-11.2 to 58.6)	2.4 (-25.0 to 42.5)
Chromosomal unbalanced rearrangements	7.2 (6.1 to 8.6)	9.7 (7.9 to 12.0)	34.5 (6.0 to 84.4)	1.0 (-4.6 to 56.0)	1.4 (0.7 to 1.3)	1.4 (1.0 to 2.0)	24.7 (17.2 to 32.2)	26.8 (-1.3 to 71.6)
Other congenital anomalies	7.3 (5.6 to 8.8)	6.7 (4.6 to 8.7)	-7.7 (-27.6 to 5.0)	-17.8 (-34.9 to -6.3)	1.6 (1.0 to 2.2)	2.1 (1.3 to 3.0)	31.7 (3.6 to 71.7)	22.0 (-4.3 to 59.6)
Skin and subcutaneous diseases	-	-	-	-	18.5 (12.1 to 28.3)	20.6 (13.4 to 31.5)	11.6 (1.5 to 22.1)	0.9 (-8.4 to 11.0)
Dermatitis	177.1 (147.4 to 206.5)	197.5 (163.6 to 230.5)	11.5 (10.3 to 12.7)	0.0 (-0.0 to 0.1)	4.7 (3.0 to 6.8)	5.2 (3.3 to 7.5)	9.9 (6.5 to 13.2)	0.1 (-2.4 to 2.7)
Psoriasis	40.9 (36.0 to 45.6)	46.9 (41.2 to 52.3)	14.5 (13.9 to 15.2)	0.0 (-0.1 to 0.1)	3.3 (2.3 to 4.7)	3.8 (2.6 to 5.3)	14.4 (9.4 to 19.3)	0.2 (-4.2 to 4.5)
Cellulitis	1.6 (1.3 to 2.0)	2.0 (1.6 to 2.5)	21.4 (11.2 to 34.9)	2.7 (-5.2 to 12.7)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	20.7 (2.5 to 44.1)	2.7 (-13.1 to 22.2)
Pyoderma	3.5 (2.8 to 4.4)	3.3 (2.6 to 4.2)	-4.2 (-20.5 to -7.7)	-5.4 (-20.5 to -7.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.9 (-16.1 to 5.0)	-14.3 (-22.7 to -4.8)
Scabies	1.9 (1.6 to 2.2)	1.6 (1.4 to 1.9)	-13.5 (-30.4 to 6.9)	-20.5 (-35.3 to -10.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-31.1 to 10.7)	-13.6 (-37.3 to 2.6)
Fungal skin diseases	191.0 (156.6 to 226.2)	218.4 (179.8 to 256.6)	14.4 (12.5 to 15.9)	1.1 (-0.0 to 1.0)	1.2 (0.4 to 2.2)	1.2 (0.5 to 2.3)	14.2 (12.1 to 16.1)	0.3 (-0.7 to 1.2)
Viral skin diseases	71.2 (57.1 to 84.8)	73.8 (59.3 to 88.6)	3.7 (1.1 to 6.2)	0.1 (-2.2 to 2.2)	2.2 (1.3 to 3.4)	2.6 (1.3 to 3.6)	3.6 (0.0 to 7.1)	0.2 (-3.0 to 3.5)
Acne vulgaris	354.3 (235.7 to 444.1)	387.0 (298.1 to 500.0)	9.0 (-23.9 to 65.0)	4.6 (-27.0 to 59.1)	3.8 (1.7 to 7.5)	4.2 (1.9 to 8.2)	9.1 (-23.8 to 66.8)	4.7 (-27.0 to 60.3)
Alopecia areata	5.0 (4.6 to 5.3)	5.8 (5.4 to 6.3)	16.3 (5.0 to 30.0)	-0.7 (-10.1 to 11.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	15.8 (2.3 to 32.6)	-0.8 (-12.2 to 14.2)
Pruritus	1.3 (1.0 to 1.7)	1.5 (1.1 to 1.9)	14.7 (-21.4 to 58.8)	-2.8 (-32.8 to 34.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.3 (-23.6 to 61.2)	-2.1 (-34.1 to 36.9)
Urticaria	24.7 (18.9 to 33.6)	28.6 (20.2 to 37.9)	17.6 (-28.2 to 75.4)	-1.3 (-40.6 to 49.8)	1.5 (0.9 to 2.2)	1.7 (1.0 to 2.6)	16.7 (-28.8 to 74.9)	-1.2 (-41.9 to 50.5)
Decubitus ulcer	1.9 (1.4 to 2.4)	2.6 (1.9 to 3.1)	32.5 (-8.1 to 95.9)	-4.9 (-32.5 to 38.4)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.5)	31.7 (-10.9 to 94.5)	-4.6 (-33.8 to 38.7)
Other skin and subcutaneous diseases	215.5 (125.2 to 365.4)	257.0 (144.7 to 442.7)	18.9 (14.3 to 23.9)	0.4 (-2.1 to 3.7)	1.3 (0.5 to 2.9)	1.5 (0.6 to 3.5)	18.7 (14.2 to 23.8)	0.6 (-2.3 to 4.2)
Sense organ diseases	-	-	-	-	20.5 (13.7 to 29.1)	24.0 (16.1 to 34.1)	16.9 (11.5 to 24.0)	-10.6 (-14.5 to -6.6)
Glaucoma	7.4 (6.0 to 8.7)	7.6 (6.3 to 9.3)	3.1 (-15.1 to 24.5)	-26.7 (-39.3 to -13.2)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	13.1 (-1.5 to 36.0)	-21.1 (-33.6 to -5.7)
Cataract	9.8 (6.9 to 12.9)	10.3 (7.2 to 13.4)	3.2 (-20.8 to 48.9)	32.1 (-48.2 to -0.9)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.7)	4.4 (-18.5 to 37.3)	-31.9 (-46.4 to -10.7)
Macular degeneration	10.7 (8.3 to 13.1)	17.3 (13.4 to 20.7)	61.3 (33.2 to 99.9)	16.1 (-2.8 to 41.5)	0.5 (0.3 to 0.7)	0.8 (0.5 to 1.1)	59.5 (37.1 to 91.6)	8.7 (-5.3 to 30.1)
Uncorrected refractive error	289.7 (274.7 to 307.1)	341.1 (321.6 to 361.1)	17.8 (8.3 to 27.3)	4.6 (-12.1 to 3.2)	4.1 (2.4 to 6.8)	4.6 (2.6 to 7.7)	13.0 (6.0 to 20.3)	-8.7 (-14.4 to -2.4)
Age-related and other hearing loss	458.6 (433.1 to 483.2)	536.3 (508.5 to 564.8)	17.1 (13.4 to 20.2)	-8.7 (-11.8 to -6.0)	11.1 (8.1 to 17.3)	14.6 (9.8 to 20.8)	20.2 (11.5 to 32.2)	11.0 (-17.0 to -4.0)
Other vision loss	20.9 (17.4 to 24.4)	17.6 (14.7 to 21.1)	-15.6 (-24.3 to -2.3)	-35.3 (-41.2 to -26.0)	0.9 (0.6 to 1.3)	0.8 (0.5 to 1.1)	-13.0 (-22.8 to 0.3)	-33.9 (-40.4 to -25.3)
Other sense organ diseases	75.0 (71.7 to 78.3)	83.2 (79.5 to 87.2)	10.8 (4.1 to 17.9)	0.1 (-6.0 to 6.4)	2.0 (1.2 to 2.9)	2.2 (1.3 to 3.2)	10.3 (3.4 to 18.1)	0.1 (-6.2 to 7.1)
Oral disorders	-	-	-	-	14.6 (9.9 to 22.4)	16.7 (10.1 to 25.5)	14.3 (9.2 to 19.1)	-5.3 (-9.8 to -1.4)
Deciduous caries	170.8 (164.1 to 177.5)							

Appendix Table G.4 - Uruguay prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
Edentulism and severe tooth loss	283.8 (266.7 to 301.0)	317.8 (296.0 to 338.1)	11.8 (2.5 to 21.9)	-12.3 (-19.9 to -4.5)	7.8 (5.3 to 11.0)	8.7 (5.9 to 12.2)	11.5 (2.0 to 21.5)	11.5 (-19.7 to -4.3)
Other oral disorders	55.8 (52.8 to 58.7)	63.3 (59.8 to 66.9)	13.4 (5.2 to 22.4)	-0.1 (-7.4 to 7.9)	21.4 (1.0 to 2.4)	21.4 (1.2 to 2.7)	-23.7 (4.6 to 22.3)	-39.1 (-7.7 to 8.2)
Injuries	-	-	-	-	27.9 (21.3 to 35.9)	21.4 (15.4 to 28.9)	-23.7 (-31.0 to -16.3)	-39.1 (-45.0 to -33.2)
Transport injuries	-	-	-	-	6.9 (5.2 to 8.9)	3.6 (2.6 to 4.8)	-47.4 (-52.0 to -41.7)	-57.0 (-60.7 to -52.2)
Road injuries	-	-	-	-	6.4 (4.8 to 8.2)	3.0 (2.2 to 3.9)	-53.6 (-57.8 to -48.5)	-42.2 (-65.6 to -58.0)
Pedestrian road injuries	-	-	-	-	1.1 (0.9 to 1.5)	0.6 (0.4 to 0.8)	-47.5 (-51.8 to -41.9)	-58.1 (-61.6 to -53.5)
Cyclist road injuries	-	-	-	-	0.8 (0.6 to 1.1)	0.4 (0.3 to 0.5)	-58.2 (-63.1 to -52.1)	-65.5 (-69.6 to -60.4)
Motorcyclist road injuries	-	-	-	-	1.1 (0.8 to 1.5)	0.4 (0.3 to 0.6)	-63.6 (-69.0 to -57.5)	-69.7 (-74.3 to -64.5)
Motor vehicle road injuries	-	-	-	-	3.2 (2.4 to 4.0)	1.6 (1.1 to 2.1)	-50.6 (-54.6 to -46.8)	-59.7 (-63.0 to -55.7)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-70.3 (-73.8 to -66.2)	-75.8 (-78.8 to -72.4)
Other transport injuries	-	-	-	-	0.5 (0.4 to 0.7)	0.7 (0.5 to 0.9)	31.4 (20.2 to 44.2)	9.7 (0.5 to 20.4)
Unintentional injuries	-	-	-	-	20.0 (15.3 to 25.9)	17.0 (12.2 to 23.0)	-15.5 (-23.5 to -7.7)	-33.1 (-39.4 to -26.9)
Falls	-	-	-	-	11.0 (8.3 to 14.1)	9.9 (7.1 to 13.3)	-10.3 (-20.7 to 0.5)	-31.6 (-39.5 to -23.5)
Drowning	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-32.0 (-40.5 to -22.3)	-43.1 (-50.2 to -34.2)
Fire, heat, and hot substances	-	-	-	-	0.7 (0.4 to 1.0)	0.6 (0.4 to 1.1)	-5.7 (-16.4 to 6.7)	-21.6 (-30.5 to -11.0)
Poisonings	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-35.1 (-45.5 to -22.7)	44.5 (-33.5 to -33.4)
Exposure to mechanical forces	-	-	-	-	7.4 (5.6 to 9.7)	4.6 (3.3 to 6.2)	-38.6 (-43.9 to -32.5)	47.9 (-52.4 to -42.8)
Unintentional firearm injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	11.1 (7.7 to 15.5)	13.8 (-22.9 to -3.7)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-8.2 (-19.9 to 2.8)	-25.5 (-35.0 to -16.5)
Other exposure to mechanical forces	-	-	-	-	7.2 (5.5 to 9.4)	4.4 (3.1 to 5.9)	-39.8 (-45.1 to -33.7)	48.9 (-53.4 to -43.8)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	21.1 (11.5 to 29.9)	-0.6 (-7.7 to 6.4)
Animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	20.3 (12.1 to 30.3)	0.1 (6.5 to 8.2)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.3 (-1.7 to 22.9)	-6.0 (-16.4 to 5.0)
Non-venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	22.5 (14.1 to 33.4)	1.5 (-5.5 to 10.5)
Foreign body	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-8.5 (-17.6 to -0.9)	-20.2 (-28.8 to -12.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.4 (-25.3 to -1.6)	-27.9 (-37.5 to -16.0)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-15.5 (-13.1 to 10.6)	-12.1 (-23.6 to -0.5)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-10.7 (-21.0 to -1.8)	-22.3 (-31.8 to -14.1)
Other unintentional injuries	-	-	-	-	0.3 (0.2 to 0.4)	1.2 (0.9 to 1.7)	303.9 (265.2 to 361.6)	234.5 (202.9 to 280.5)
Self-harm and interpersonal violence	-	-	-	-	1.0 (0.8 to 1.3)	0.8 (0.6 to 1.1)	-23.9 (-30.0 to -17.0)	-35.5 (-40.8 to -29.8)
Self-harm	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	3.3 (-6.7 to 14.5)	-13.1 (-21.7 to -3.2)
Interpersonal violence	-	-	-	-	0.8 (0.6 to 1.1)	0.6 (0.4 to 0.8)	-30.3 (-36.3 to -23.1)	-40.9 (-46.0 to -34.6)
Assault by firearm	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.2 to 0.3)	-29.3 (-35.7 to -21.9)	40.0 (-45.5 to -33.8)
Assault by sharp object	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-7.3 (-15.5 to 1.6)	-21.1 (-28.0 to -13.2)
Assault by other means	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.3)	-38.4 (-45.6 to -30.1)	47.9 (-54.0 to -40.7)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.4 (-48.4 to 195.4)	-9.1 (-55.8 to 130.3)
Exposure to forces of nature	-	-	-	-	-	-	-	-
Collective violence and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-63.0 (-76.0 to -47.4)	-66.2 (-78.1 to -51.9)

Appendix Table G.4 - Uzbekistan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,748.8 (1,272.0 to 2,271.4)	2,505.4 (1,919.5 to 3,353.1)	49.3 (33.7 to 57.6)	49.3 (8.7 to 0.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	337.9 (205.4 to 553.9)	314.1 (211.5 to 454.4)	-4.1 (-39.8 to 33.3)	-18.2 (-43.8 to 9.1)
HIV/AIDS and tuberculosis	-	-	-	-	8.8 (5.9 to 11.8)	16.2 (11.0 to 21.9)	84.7 (68.4 to 104.6)	9.8 (0.9 to 20.0)
Tuberculosis	27.9 (26.0 to 29.7)	49.8 (47.3 to 52.6)	78.0 (68.2 to 90.6)	5.7 (0.4 to 12.1)	8.7 (5.8 to 11.7)	77.5 (10.5 to 21.0)	77.5 (62.1 to 95.9)	5.6 (-2.7 to 15.0)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.2)	0.7 (0.4 to 1.6)	1,139.6 (288.7 to 4,428.2)	651.6 (132.4 to 2,698.1)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	757.2 (154.1 to 3,224.0)	402.9 (47.2 to 1873.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	757.2 (153.3 to 3,280.7)	402.9 (47.0 to 1,885.3)
HIV/AIDS resulting in other diseases	0.7 (0.1 to 2.1)	8.4 (5.5 to 12.4)	1,274.9 (364.9 to 5,296.7)	769.8 (195.7 to 3,296.2)	0.1 (0.0 to 0.2)	0.7 (0.3 to 1.5)	1,138.0 (280.8 to 5,115.9)	660.1 (131.2 to 1,118.1)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	34.2 (24.3 to 46.0)	32.5 (23.0 to 43.9)	-5.0 (-12.4 to 2.4)	-23.2 (-29.4 to -17.8)
Diarrheal diseases	76.4 (71.7 to 81.1)	78.9 (74.3 to 83.7)	3.1 (-5.3 to 12.5)	-5.1 (-12.3 to 3.2)	12.5 (8.6 to 17.4)	12.9 (8.8 to 18.2)	-0.9 (-6.1 to 4.1)	-4.9 (-12.8 to 5.1)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-59.4 to -10.4	-68.0 to -29.0
Typhoid fever	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-11.4 (-27.3 to 4.7)	-31.4 (-42.8 to -18.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.4 (-27.3 to 4.7)	-31.5 (-42.9 to -18.5)
Paratyphoid fever	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-10.1 (-24.5 to 7.8)	-27.7 (-39.0 to -13.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.1 (-24.5 to 7.9)	-27.7 (-39.1 to -13.3)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-66.0 (-97.2 to -34.8)	-73.3 (-89.9 to -35.6)
Lower respiratory infections	10.8 (8.9 to 13.2)	4.0 (3.0 to 4.8)	-62.9 (-72.0 to -52.6)	-60.2 (-68.6 to -49.5)	1.1 (0.7 to 1.8)	0.4 (0.3 to 0.7)	-62.5 (-72.2 to -50.5)	-59.8 (-69.3 to -47.8)
Upper respiratory infections	319.1 (280.4 to 358.5)	425.1 (387.2 to 465.0)	33.4 (14.7 to 54.4)	-1.2 (-14.9 to 14.1)	3.8 (2.1 to 6.6)	5.0 (2.8 to 8.3)	32.7 (14.9 to 55.8)	-1.2 (-14.7 to 14.5)
Otitis media	266.6 (243.5 to 288.1)	333.7 (302.9 to 362.3)	25.0 (14.9 to 35.5)	-9.0 (-16.2 to -2.0)	5.6 (3.3 to 9.1)	6.8 (4.1 to 10.9)	21.6 (10.7 to 33.2)	-9.5 (-17.4 to -1.3)
Meningitis	-	-	-	-	8.6 (5.9 to 12.0)	5.0 (3.4 to 6.9)	-42.3 (-53.6 to -28.6)	-58.4 (-66.4 to -49.5)
Pneumococcal meningitis	29.9 (18.6 to 43.4)	21.4 (13.1 to 32.6)	-28.5 (-43.5 to -11.7)	-52.2 (-61.8 to -41.9)	3.2 (2.0 to 4.6)	2.1 (1.4 to 3.0)	-34.5 (-54.2 to -9.4)	-54.2 (-67.2 to -37.8)
H influenzae type B meningitis	22.7 (9.5 to 40.0)	12.3 (4.4 to 23.0)	-45.9 (-65.1 to -27.7)	-62.2 (-74.7 to -50.4)	3.0 (1.7 to 4.7)	1.5 (0.9 to 2.5)	-48.5 (-69.3 to -34.0)	-62.3 (-77.2 to -37.9)
Meningococcal meningitis	6.9 (2.7 to 14.1)	4.2 (1.5 to 9.6)	-39.1 (-58.4 to -22.3)	-58.2 (-70.1 to -48.4)	1.0 (0.5 to 1.6)	0.5 (0.3 to 0.8)	-46.2 (-65.2 to -24.1)	-61.3 (-74.0 to -47.7)
Other meningitis	10.6 (6.5 to 16.7)	7.1 (4.2 to 11.7)	-32.8 (-48.3 to -17.7)	-53.3 (-63.6 to -42.4)	1.5 (0.9 to 2.3)	0.9 (0.6 to 1.2)	-41.0 (-60.6 to -20.3)	-57.5 (-71.3 to -42.9)
Encephalitis	8.4 (3.9 to 18.3)	11.4 (5.2 to 24.6)	34.5 (17.8 to 49.0)	-31.1 (-42.8 to -3.7)	1.1 (0.8 to 1.5)	1.5 (1.0 to 2.0)	37.6 (13.9 to 64.6)	-6.9 (-24.3 to 8.8)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.6 (-95.9 to 550.9)	-53.1 (-95.7 to 326.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.6 (-95.8 to 560.6)	-53.1 (-95.8 to 331.4)
Whooping cough	21.3 (16.5 to 27.3)	8.0 (6.3 to 10.3)	-62.5 (-64.6 to -60.2)	-59.5 (-61.8 to -57.1)	1.1 (0.6 to 1.7)	0.4 (0.2 to 0.7)	-62.5 (-66.8 to -57.3)	-59.5 (-64.2 to -53.9)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.6 (-66.9 to -4.1)	-59.8 (-77.6 to -45.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-17.3 (-54.0 to 7.2)	-53.8 (-69.7 to -40.0)
Measles	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-99.3 (-100.0 to -94.4)	-99.9 (-100.0 to -94.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-99.9 (-100.0 to -94.4)	-99.9 (-100.0 to -94.0)
Varicella and herpes zoster	15.0 (14.3 to 15.8)	17.3 (16.4 to 18.4)	14.8 (6.6 to 23.3)	-1.4 (-11.0 to 9.6)	0.3 (0.2 to 0.4)	0.4 (0.2 to 0.6)	43.8 (13.7 to 85.1)	-0.7 (-23.6 to 26.7)
Neglected tropical diseases and malaria	-	-	-	-	9.0 (5.2 to 13.4)	8.6 (5.2 to 12.3)	-8.6 (-30.9 to 42.0)	-14.5 (-35.2 to 32.9)
Malaria	2.2 (1.8 to 2.6)	3.2 (2.6 to 3.9)	46.3 (22.1 to 79.2)	8.5 (-9.9 to 33.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	80.5 (47.0 to 105.2)	44.6 (17.9 to 64.1)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.3 (-12.8 to 64.8)	-6.5 (-31.0 to 27.1)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.0 (6.2 to 117.3)	28.8 (-7.4 to 70.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.0 (6.1 to 117.5)	28.8 (-7.4 to 70.9)
Cutaneous and mucocutaneous leishmaniasis	0.7 (0.5 to 1.0)	0.8 (0.6 to 1.2)	15.4 (-3.9 to 37.9)	-8.4 (-24.9 to 11.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	16.6 (-15.8 to 65.1)	-7.9 (-32.9 to 27.3)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-39.1 (-86.3 to 103.1)	-66.0 (-90.4 to 24.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-37.1 (-85.5 to 112.5)	-65.0 (-90.0 to 30.8)
Cystic echinococcosis	4.0 (3.4 to 4.9)	3.7 (3.0 to 5.2)	-10.4 (-18.9 to 9.1)	-41.4 (-45.5 to -30.9)	0.4 (0.2 to 0.6)	0.3 (0.2 to 0.6)	-9.2 (-30.0 to 19.6)	-40.5 (-51.9 to -25.0)
Lymphatic filariasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Dengue	0.4 (0.1 to 1.2)	2.5 (0.5 to 8.2)	587.5 (579.3 to 596.9)	391.5 (385.7 to 398.2)	0.1 (0.0 to 0.2)	0.4 (0.1 to 1.3)	557.3 (382.7 to 766.7)	366.1 (250.2 to 500.3)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.2 (-51.8 to 0.9)	-47.8 (-64.9 to -27.7)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-29.2 (-51.8 to 1.4)	-47.8 (-64.9 to -27.7)
Intestinal nematode infections	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	70.4 (-44.5 to 131.0)	0.6 (-71.1 to 41.0)
Ascariasis	-	-	69.5 (-31.5 to 302.8)	-0.3 (-59.7 to 137.2)	-	-	-	-
Trichuriasis	-	-	69.9 (-28.3 to 339.6)	-0.0 (-57.9 to 159.5)	-	-	-	-
Hookworm disease	13.2 (7.2 to 22.5)	22.1 (12.7 to 36.3)	68.6 (-24.5 to 262.6)	69.8 (-55.6 to 113.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	70.4 (-44.5 to 131.0)	0.6 (-71.1 to 41.0)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	240.1 (176.1 to 310.0)	214.5 (180.3 to 248.8)	-10.4 (-31.8 to 22.4)	-15.8 (-36.0 to 15.4)	8.4 (4.8 to 12.6)	7.4 (4.6 to 10.8)	-13.2 (-36.4 to 38.7)	-16.5 (-38.9 to 36.9)
Maternal disorders	-	-	-	-	0.9 (0.6 to 1.4)	0.7 (0.4 to 1.1)	-53.9 (-45.1 to 1.5)	-39.1 (-66.3 to -9.1)
Maternal hemorrhage	4.4 (3.7 to 5.1)	5.9 (4.3 to 7.4)	32.7 (-5.6 to 79.3)	-18.9 (-42.0 to 9.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	9.8 (-37.9 to 66.6)	-33.1 (-61.8 to 2.2)
Maternal sepsis and other maternal infections	23.9 (14.1 to 32.6)	15.1 (10.3 to 21.7)	-33.0 (-44.8 to -10.7)	-62.3 (-69.2 to -48.8)	0.4 (0.2 to 0.7)	0.2 (0.1 to 0.4)	-44.1 (-66.1 to -8.8)	-61.1 (-78.2 to -45.1)
Maternal hypertensive disorders	1.9 (1.0 to 3.2)	1.8 (0.8 to 3.1)	-5.6 (-18.3 to 5.8)	-42.2 (-49.5 to -35.5)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-7.7 (-37.2 to 26.3)	-43.2 (-61.0 to -22.6)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.6 (-40.1 to 26.5)	-46.4 (-62.1 to -29.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.6 (-40.2 to 26.9)	-46.4 (-62.2 to -23.8)
Complications of abortion	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	-11.6 (-23.9 to 6.7)	-46.0 (-53.3 to -35.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-9.7 (-61.3 to 89.6)	-45.0 (-74.5 to 8.6)
Other maternal disorders	-	-	-	-	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.3)	-27.1 (-57.5 to 23.9)	-55.7 (-74.2 to -24.8)
Neonatal disorders	-	-	-	-	22.0 (13.9 to 33.0)	45.5 (29.9 to 64.6)	107.1 (33.8 to 219.9)	57.7 (1.6 to 143.3)
Preterm birth complications	49.1 (34.5 to 68.7)	141.5 (106.3 to 189.4)	187.9 (141.4 to 245.6)	108.6 (75.8 to 151.2)	5.7 (3.8 to 8.1)	17.9 (11.9 to 25.0)	214.9 (128.4 to 336.8)	133.4 (69.5 to 224.2)
Neonatal encephalopathy due to birth asphyxia and trauma	37.6 (15.2 to 96.7)	50.8 (23.5 to 110.7)	38.8 (-16.8 to 160.4)	1.4 (-35.8 to 82.6)	7.1 (3.7 to 11.9)	11.7 (6.4 to 19.8)	68.8 (-27.1 to 225.6)	32.7 (-42.4 to 153.3)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	91.6 (73.5 to 99.9)	116.3 (95.9 to 125.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.6 (49.9 to 142.1)	118.8 (69.3 to 173.3)
Hemolytic disease and other neonatal jaundice	16.6 (7.9 to 32.0)	25.6 (13.1 to 50.3)	45.1 (-40.1 to 445.9)	9.6 (-54.8 to 313.8)	6.5 (2.8 to 13.0)	10.0 (4.9 to 20.6)	44.9 (-38.7 to 437.9)	9.3 (-54.1 to 302.2)
Other neonatal disorders	-	-	-	-	2.7 (1.2 to 5.3)	5.8 (3.0 to 10.5)	123.2 (-13.0 to 396.6)	69.5 (-32.3 to 282.8)
Nutritional deficiencies	-	-	-	-	250.7 (137.0 to 451.9)	196.2 (117.1 to 306.2)	-19.4 (-56.7 to 34.2)	-28.5 (-57.6 to 12.6)
Protein-energy malnutrition	161.9 (62.6 to 318.1)	71.1 (27.8 to 153.9)	-56.5 (-86.3 to 39.3)	52.7 (-85.1 to 51.5)	20.3 (7.4 to 42.9)	8.9 (3.1 to 20.5)	-54.6 (-86.2 to 40.5)	-52.6 (-85.0 to 52.8)
Iodine deficiency	737.1 (349.0 to 1,246.9)	636.5 (226.9 to 1,277.7)	-19.1 (-63.0 to 113.0)	-50.7 (-77.1 to 33.8)	13.3 (5.3 to 25.1)	11.5 (3.7 to 26.2)	-19.3 (-63.1 to 111.7)	-50.8 (-77.0 to 33.7)
Vitamin A deficiency	22.9 (18.5 to 27.5)	14.9 (11.9 to 18.3)	-35.1 (-42.9 to -25.2)	-49.4 (-55.0 to -43.1)	0.7 (0.4 to 1.1)	0.5 (0.3 to 0.7)	-34.9 (-44.7 to -22.9)	-49.3 (-56.6 to -41.4)

Appendix Table G.4 - Uzbekistan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	3,734.9 (3,668.9 to 3,796.7)	3,839.3 (3,757.6 to 3,922.6)	2.6 (-0.6 to 5.8)	-20.4 (-23.0 to -17.8)	123.6 (82.5 to 178.7)	118.3 (78.6 to 171.7)	-4.1 (-9.0 to -1.7)	-21.8 (-26.1 to -20.0)
Other nutritional deficiencies	-	-	-	-	92.7 (21.6 to 267.1)	57.0 (14.9 to 143.4)	-38.9 (-85.3 to 170.7)	-31.5 (-84.1 to 194.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	12.4 (7.9 to 18.7)	14.8 (9.2 to 23.0)	19.0 (3.0 to 36.5)	-13.1 (-24.3 to -3.4)
Sexually transmitted diseases excluding HIV	-	-	-	-	4.9 (2.8 to 8.2)	7.7 (4.3 to 13.0)	59.2 (36.5 to 80.9)	-4.1 (-16.1 to 7.8)
Syphilis	0.5 (0.5 to 0.6)	0.5 (0.5 to 0.6)	4.3 (-11.7 to 21.9)	-36.8 (-45.7 to -26.8)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	7.1 (-0.1 to 0.2)	-35.5 (-52.4 to -13.5)
Chlamydial infection	618.3 (535.3 to 701.6)	1,031.7 (901.5 to 1,158.8)	66.9 (40.1 to 100.2)	1.3 (-14.7 to 19.8)	2.7 (1.5 to 4.4)	4.4 (2.5 to 7.4)	64.8 (33.0 to 98.4)	-0.2 (-18.3 to 18.7)
Gonococcal infection	126.6 (100.3 to 156.4)	189.0 (151.2 to 231.1)	50.4 (7.8 to 101.9)	-6.5 (-31.3 to 21.9)	0.8 (0.4 to 1.3)	1.2 (0.6 to 2.0)	52.1 (6.2 to 122.5)	-5.8 (-33.2 to 38.0)
Trichomoniasis	277.1 (165.4 to 407.1)	377.9 (269.1 to 581.4)	37.9 (-16.9 to 116.2)	-15.5 (-44.7 to 23.9)	0.7 (0.2 to 1.0)	1.2 (0.2 to 1.5)	70.8 (-25.4 to 127.0)	-2.2 (-49.4 to 29.8)
Genital herpes	2,513.0 (2,422.0 to 2,607.4)	4,357.1 (4,205.7 to 4,502.8)	73.0 (65.1 to 81.8)	2.2 (-6.4 to 2.1)	0.7 (0.2 to 1.6)	1.2 (0.4 to 2.8)	70.8 (56.8 to 83.4)	-2.2 (-8.0 to 3.9)
Other sexually transmitted diseases	5.1 (3.7 to 6.3)	7.8 (5.8 to 10.3)	53.1 (30.9 to 77.8)	-15.1 (-28.0 to -1.7)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	60.1 (14.4 to 119.8)	-6.6 (-31.8 to 24.2)
Hepatitis	-	-	-	-	1.7 (1.1 to 2.5)	2.1 (1.3 to 3.1)	22.0 (3.5 to 41.6)	-23.6 (-37.6 to -7.6)
Hepatitis A	30.8 (29.4 to 32.2)	35.5 (34.3 to 36.6)	15.1 (13.5 to 16.6)	-3.7 (-3.7 to -3.5)	0.7 (0.4 to 1.0)	0.9 (0.6 to 1.3)	36.7 (21.4 to 53.7)	-0.3 (-10.6 to 12.0)
Hepatitis B	1,912.0 (1,676.5 to 2,105.0)	1,919.5 (1,624.2 to 2,180.4)	-0.5 (-17.9 to 22.5)	-34.0 (-44.9 to -21.1)	0.9 (0.6 to 1.3)	1.0 (0.6 to 1.5)	10.7 (-18.6 to 48.2)	-36.0 (-54.9 to -10.2)
Hepatitis C	1,091.2 (985.8 to 1,196.1)	1,289.7 (1,179.1 to 1,407.5)	17.8 (2.1 to 34.5)	-28.0 (-37.0 to -18.5)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	4.3 (-23.7 to 36.0)	-31.4 (-50.4 to -7.8)
Hepatitis E	2.0 (1.8 to 2.3)	3.2 (3.0 to 3.5)	58.8 (39.7 to 81.0)	-1.3 (-13.8 to 13.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	62.3 (15.2 to 125.2)	-0.3 (-29.1 to 34.7)
Leprosy	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-
Other infectious diseases	166.5 (131.2 to 206.9)	150.3 (116.1 to 185.0)	-9.7 (-31.1 to 17.1)	-17.8 (-37.2 to 6.6)	5.8 (3.6 to 8.5)	5.0 (2.9 to 7.3)	-13.7 (-44.4 to 9.0)	-18.5 (-46.8 to 6.5)
Non-communicable diseases	-	-	-	-	1,297.0 (958.2 to 1,694.6)	2,113.8 (1,556.6 to 2,735.7)	62.9 (57.9 to 68.6)	-0.3 (-3.1 to 3.3)
Neoplasms	-	-	-	-	5.7 (4.2 to 7.4)	10.0 (6.9 to 13.7)	74.6 (45.6 to 109.7)	0.4 (-15.3 to 21.0)
Esophageal cancer	2.9 (2.1 to 3.7)	2.6 (1.7 to 4.2)	-15.7 (-47.7 to 62.1)	-49.7 (-68.5 to -2.9)	0.5 (0.3 to 0.6)	0.4 (0.2 to 0.7)	-16.0 (-45.8 to 63.6)	-50.0 (-67.9 to -2.1)
Stomach cancer	4.2 (3.7 to 4.8)	3.8 (2.9 to 4.9)	-10.8 (-32.1 to 21.6)	-48.4 (-60.6 to -30.5)	0.6 (0.4 to 0.8)	0.5 (0.3 to 0.7)	-9.9 (-30.7 to 22.2)	-47.8 (-59.8 to -29.4)
Liver cancer	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	78.4 (20.5 to 142.6)	-0.3 (-29.6 to 44.4)
Liver cancer due to hepatitis B	0.2 (0.2 to 0.4)	0.4 (0.2 to 0.6)	52.1 (-13.4 to 157.1)	-13.4 (-49.5 to 49.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	47.2 (-3.7 to 124.1)	-15.3 (-45.0 to 27.8)
Liver cancer due to hepatitis C	0.1 (0.1 to 0.1)	0.3 (0.3 to 0.5)	355.1 (163.7 to 677.5)	165.2 (55.3 to 365.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	333.0 (173.5 to 568.0)	154.7 (62.4 to 291.9)
Liver cancer due to alcohol use	0.2 (0.2 to 0.3)	0.2 (0.2 to 0.5)	58.9 (-5.2 to 167.6)	-5.9 (-43.2 to 61.7)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	52.6 (1.6 to 133.3)	-9.6 (-37.4 to 39.7)
Liver cancer due to other causes	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	8.5 (-54.4 to 68.9)	-48.3 (-74.9 to -0.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-14.0 (-51.9 to 47.3)	-51.2 (-74.3 to -14.2)
Larynx cancer	0.7 (0.5 to 0.9)	1.1 (0.7 to 1.6)	64.1 (6.1 to 145.7)	-5.2 (-39.5 to 39.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	57.1 (4.5 to 130.8)	-10.2 (-39.9 to 33.3)
Tracheal, bronchus and lung cancer	2.2 (1.9 to 2.5)	2.3 (1.8 to 2.9)	2.7 (-21.0 to 39.1)	-41.9 (-55.1 to -21.0)	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.6)	2.8 (-23.6 to 41.6)	-42.0 (-56.0 to -21.3)
Breast cancer	5.6 (4.7 to 6.6)	29.3 (24.9 to 34.6)	416.2 (316.5 to 560.3)	207.3 (151.9 to 293.0)	0.6 (0.4 to 0.8)	2.0 (1.3 to 2.8)	217.3 (129.2 to 337.9)	76.1 (28.0 to 139.6)
Cervical cancer	6.3 (5.1 to 7.6)	10.4 (6.9 to 14.9)	64.7 (9.4 to 144.9)	46.2 (-43.7 to 22.9)	0.8 (0.3 to 0.7)	0.8 (0.4 to 1.3)	60.6 (4.8 to 142.4)	-17.4 (-44.4 to 22.9)
Uterine cancer	2.6 (1.6 to 3.6)	4.1 (2.5 to 6.1)	57.8 (-2.5 to 161.9)	-18.9 (-49.7 to 34.6)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.5)	57.2 (5.1 to 161.0)	-18.3 (-51.0 to 31.9)
Prostate cancer	1.5 (1.1 to 1.9)	4.1 (3.0 to 6.1)	160.0 (85.4 to 344.0)	62.9 (16.9 to 184.2)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.7)	168.5 (74.3 to 444.1)	68.7 (12.4 to 251.5)
Colon and rectum cancer	3.8 (3.4 to 4.1)	6.5 (5.3 to 7.9)	71.7 (37.0 to 115.0)	-3.8 (-22.5 to 19.0)	0.4 (0.3 to 0.5)	0.6 (0.4 to 0.8)	62.9 (25.9 to 107.2)	-8.8 (-29.1 to 15.3)
Lip and oral cavity cancer	2.1 (1.6 to 2.8)	3.5 (2.5 to 4.9)	67.5 (13.8 to 141.4)	-3.7 (-33.0 to 39.3)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	67.6 (16.4 to 137.4)	-3.9 (-32.9 to 38.7)
Nasopharynx cancer	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	54.5 (-2.4 to 144.8)	-14.7 (-45.7 to 35.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (-0.1 to 130.5)	-16.3 (-43.5 to 28.0)
Other pharynx cancer	0.3 (0.2 to 0.5)	0.6 (0.3 to 0.9)	63.9 (-9.0 to 212.0)	-7.5 (-49.0 to 72.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	62.1 (0.4 to 180.6)	-7.1 (-42.6 to 56.1)
Gallbladder and biliary tract cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	19.2 (-28.1 to 89.7)	-29.6 (-57.5 to 14.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	15.6 (-27.1 to 77.7)	-31.9 (-56.8 to 5.7)
Pancreatic cancer	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	98.9 (43.0 to 176.3)	16.2 (-15.3 to 60.7)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	96.9 (49.9 to 153.1)	15.2 (-11.7 to 48.3)
Malignant skin melanoma	1.1 (0.8 to 1.5)	2.5 (1.7 to 3.6)	127.3 (57.0 to 232.4)	31.6 (-9.3 to 86.7)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	116.5 (46.9 to 222.2)	26.2 (-13.8 to 86.7)
Non-melanoma skin cancer	5.8 (4.5 to 7.0)	12.1 (9.4 to 14.8)	106.4 (52.8 to 176.9)	22.4 (-10.0 to 67.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	147.8 (84.0 to 235.5)	45.6 (8.4 to 104.6)
Ovarian cancer	0.5 (0.3 to 0.7)	1.2 (0.8 to 1.7)	149.8 (43.6 to 317.0)	35.6 (-21.4 to 130.0)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	140.6 (39.0 to 302.0)	27.8 (-24.9 to 117.6)
Testicular cancer	0.7 (0.4 to 1.1)	1.7 (0.8 to 2.8)	123.6 (18.4 to 334.5)	26.3 (-32.2 to 142.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	116.8 (5.1 to 326.9)	21.9 (-37.3 to 137.6)
Kidney cancer	1.1 (0.7 to 1.2)	1.9 (1.5 to 2.5)	118.7 (48.9 to 212.5)	41.1 (-2.5 to 99.6)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	117.0 (48.8 to 222.0)	36.3 (-4.6 to 97.1)
Bladder cancer	0.6 (0.5 to 0.7)	1.1 (0.8 to 1.4)	85.2 (32.6 to 156.4)	6.9 (-22.5 to 48.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	80.6 (29.1 to 148.7)	5.4 (-23.3 to 45.0)
Brain and nervous system cancer	2.9 (2.2 to 3.8)	5.7 (4.3 to 7.2)	94.5 (43.5 to 161.3)	34.9 (3.9 to 75.9)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	97.2 (47.2 to 162.3)	30.2 (-0.7 to 67.0)
Thyroid cancer	0.6 (0.5 to 0.9)	1.3 (0.9 to 1.9)	106.7 (37.3 to 219.3)	17.5 (-20.8 to 78.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	100.2 (25.3 to 221.4)	13.0 (-26.9 to 78.3)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.9 (13.2 to 141.6)	-11.9 (-38.8 to 31.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.7 (14.7 to 147.2)	-10.3 (-38.1 to 35.9)
Hodgkin lymphoma	1.7 (1.1 to 2.7)	3.1 (2.1 to 4.6)	86.9 (5.3 to 207.5)	34.4 (-17.7 to 111.4)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	82.7 (6.6 to 196.7)	28.2 (-20.7 to 97.1)
Non-Hodgkin lymphoma	1.5 (1.0 to 2.0)	3.1 (2.2 to 4.1)	112.6 (47.0 to 225.9)	35.3 (-5.2 to 112.0)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	111.6 (46.8 to 225.9)	31.7 (8.8 to 105.9)
Multiple myeloma	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	100.3 (24.6 to 218.1)	11.2 (-30.8 to 73.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	92.9 (26.4 to 188.6)	7.3 (-28.6 to 58.5)
Leukemia	5.3 (4.2 to 6.6)	7.8 (6.1 to 9.9)	46.6 (12.8 to 95.3)	16.4 (-9.5 to 53.4)	0.5 (0.4 to 0.7)	0.8 (0.5 to 1.1)	49.9 (15.8 to 89.9)	5.9 (-17.3 to 35.9)
Other neoplasms	4.2 (3.3 to 5.5)	9.5 (7.2 to 12.2)	126.6 (57.5 to 218.1)	50.0 (10.9 to 101.6)	0.3 (0.2 to 0.4)	0.7 (0.4 to 1.0)	119.2 (57.4 to 201.0)	37.1 (3.2 to 81.7)
Cardiovascular diseases	-	-	-	-	14.4 (9.9 to 19.9)	22.3 (15.2 to 30.5)	55.8 (22.2 to 95.2)	-4.9 (-24.6 to 16.8)
Rheumatic heart disease	2.0 (1.7 to 2.2)	3.0 (2.7 to 3.4)	52.9 (31.2 to 87.4)	-8.8 (-23.0 to 14.6)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	59.0 (22.4 to 109.4)	-6.7 (-28.1 to 24.7)
Ischemic heart disease	123.6 (106.1 to 147.1)	183.0 (162.9 to 206.3)	49.4 (21.4 to 79.4)	-6.2 (-24.1 to 12.0)	6.2 (4.1 to 9.0)	8.6 (5.7 to 12.0)	30.7 (6.6 to 77.8)	-10.9 (-30.7 to 13.6)
Cerebrovascular disease	-	-	-	-	1.6 (1.1 to 2.2)	2.8 (1.9 to 3.8)	73.5 (32.9 to 110.7)	-0.0 (-24.8 to 24.2)
Ischemic stroke	5.7 (4.7 to 6.8)	9.7 (7.8 to 11.7)	71.2 (24.8 to 111.9)	-0.6 (-29.2 to 23.2)	0.9 (0.6 to 1.2)	1.5 (1.0 to 2.2)	71.4 (26.7 to 117.6)	-0.9 (-28.1 to 26.3)
Hemorrhagic stroke	4.7 (3.9 to 5.5)	8.2 (6.8 to 9.7)	74.5 (34.8 to 119.5)	0.4 (-23.9 to 29.7)	0.7 (0.5 to 1.0)	1.3 (0.8 to 1.8)	73.4 (31.3 to 122.3)	-0.0 (-25.3 to 30.5)
Hypertensive heart disease	15.4 (13.7 to 17.2)	25.0 (22.4 to 27.6)	62.8 (36.4 to 89.1)	0.8 (-16.2 to 17.5)	1.7 (1.1 to 2.4)	2.7 (1.9 to 3.8)	63.7 (35.5 to 90.4)	0.7 (-16.5 to 18.2)
Cardiomyopathy and myocarditis	0.6 (0.5 to 0.8)	3.1 (2.5 to 4.2)	398.7 (246.0 to 667.1)	0.1 (-87.2 to 274.6)	0.2 (0.0 to 0.1)	0.2 (0.1 to 0.4)	388.9 (210.1 to 728.7)	153.1 (66.7 to 297.7)
Atrial fibrillation and flutter	258.9 (204.4 to 324.3)	474.5 (343.9 to 660.8)	81.9 (26.6 to 170.6)	9.6 (-21.5 to 53.2)	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.7)	4.7 (-50.1 to 146.4)	-29.4 (-66.9 to 64.9)
Endocarditis	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	26.1 (-10.6 to 71.1)	-21.5 (-46.4 to 9.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	28.1 (-13.8 to 91.3)	-2.1 (-49.7 to 19.6)
Other cardiovascular and circulatory diseases	47.5 (22.9 to 85.0)	80.6 (42.6 to 128.0)	68.7 (-26.9 to 299.5)	2.4 (-58.4 to 130.3)	3.4 (1.5 to 6.4)	5.7 (2.6 to 10.0)	69.0 (-26.3 to 308.0)	-2.9 (-58.1 to 135.5)
Chronic respiratory diseases	-	-	-	-	53.5 (36.5 to 73.7)	73.9 (49.9 to 102.6)	38.6 (13.0 to 62.2)	-12.2 (-27.5 to 2.6)
Chronic obstructive pulmonary disease	521.0 (497.5 to 545.2)	899.3 (855.8 to 943.2)	72.2 (67.3 to 77.2)	-0.4 (-3.2 to 2.4)	32.9 (21.4 to 46.3)	54.6 (34.5 to 77.6)	67.7 (32.7 to 100.1)	-1.4 (-23.1 to 17.6)

Appendix Table G.4 - Uzbekistan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumonia	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	56.9 (52.4 to 62.2)	56.9 (-0.9 to -5.3)
Silicosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	67.2 (60.4 to 74.3)	-0.8 (-4.9 to 3.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.5 (60.4 to 74.8)	-0.7 (-4.9 to 4.0)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	81.7 (75.5 to 89.8)	2.7 (-0.6 to 1.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.0 (75.8 to 90.1)	2.9 (-0.5 to 7.3)
Other pneumoconiosis	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.3)	41.7 (35.4 to 48.1)	0.0 (-0.5 to -1.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	46.9 (35.7 to 48.2)	16.9 (-20.4 to -12.9)
Asthma	397.9 (321.1 to 484.1)	338.5 (264.7 to 417.9)	-14.7 (-40.0 to 14.6)	-38.2 (-53.3 to -21.6)	17.7 (10.9 to 26.2)	14.8 (9.0 to 22.6)	-15.8 (-40.9 to 13.4)	-39.0 (-54.2 to -21.8)
Interstitial lung disease and pulmonary sarcoidosis	1.4 (1.0 to 1.7)	2.4 (1.6 to 3.1)	77.1 (5.9 to 167.0)	3.0 (-35.6 to 51.3)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	78.1 (8.8 to 165.2)	3.5 (-34.2 to 52.2)
Other chronic respiratory diseases	-	-	-	-	2.7 (1.7 to 4.0)	4.1 (2.5 to 6.4)	53.9 (11.9 to 100.2)	-9.2 (-33.6 to 17.0)
Cirrhosis	-	-	-	-	2.6 (1.8 to 3.7)	4.6 (3.2 to 6.4)	76.2 (59.2 to 94.8)	11.7 (1.5 to 22.5)
Cirrhosis due to hepatitis B	6.7 (5.5 to 8.0)	11.5 (8.8 to 14.4)	69.0 (28.1 to 143.8)	6.3 (-21.9 to 49.3)	1.1 (0.7 to 1.7)	1.9 (1.2 to 2.9)	69.3 (22.7 to 145.7)	6.9 (-21.8 to 49.7)
Cirrhosis due to hepatitis C	3.0 (1.9 to 4.2)	5.7 (3.7 to 8.0)	83.0 (3.2 to 294.4)	8.1 (-41.6 to 141.0)	0.5 (0.3 to 0.8)	0.5 (0.5 to 1.6)	84.2 (-1.4 to 309.1)	9.0 (-42.9 to 146.1)
Cirrhosis due to alcohol use	2.4 (1.8 to 3.2)	4.4 (2.5 to 6.2)	80.5 (0.2 to 218.6)	6.1 (-36.3 to 79.4)	0.4 (0.2 to 0.6)	0.7 (0.4 to 1.2)	80.5 (-5.3 to 235.0)	6.1 (-39.5 to 84.2)
Cirrhosis due to other causes	3.5 (2.9 to 4.1)	6.0 (4.5 to 7.6)	73.3 (22.4 to 127.7)	34.4 (-7.5 to 77.8)	0.6 (0.4 to 0.9)	1.0 (0.6 to 1.6)	71.8 (15.5 to 143.5)	33.3 (-11.7 to 89.1)
Digestive diseases	-	-	-	-	13.0 (9.3 to 17.2)	24.4 (17.4 to 32.4)	88.7 (72.4 to 103.2)	12.8 (3.7 to 20.3)
Peptic ulcer disease	90.2 (79.6 to 98.5)	123.3 (116.0 to 130.6)	36.0 (23.0 to 55.6)	-22.9 (-29.9 to -12.8)	2.6 (1.7 to 3.7)	3.7 (2.5 to 5.3)	46.2 (11.3 to 66.8)	-13.0 (-31.2 to -1.9)
Gastritis and duodenitis	26.1 (23.1 to 29.3)	34.9 (30.3 to 40.3)	33.3 (13.5 to 58.7)	5.1 (-9.9 to 23.9)	1.4 (0.9 to 2.2)	2.0 (1.3 to 3.1)	37.7 (2.8 to 95.7)	12.7 (-10.8 to 52.1)
Appendicitis	2.1 (1.7 to 2.6)	2.7 (2.1 to 3.3)	29.2 (-3.4 to 59.4)	-6.4 (-28.3 to 12.3)	0.7 (0.4 to 1.0)	0.8 (0.5 to 1.3)	26.6 (-17.9 to 88.2)	-7.5 (-37.8 to 32.0)
Paralytic ileus and intestinal obstruction	0.3 (0.2 to 0.6)	0.4 (0.3 to 0.8)	32.0 (-44.9 to 209.0)	14.5 (-36.5 to 126.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	32.1 (-45.7 to 210.9)	13.8 (-39.5 to 126.2)
Inguinal, femoral, and abdominal hernia	40.5 (35.0 to 47.8)	55.4 (48.0 to 63.4)	37.7 (9.0 to 63.1)	-11.7 (-31.7 to 8.7)	0.4 (0.2 to 0.8)	0.6 (0.3 to 1.1)	37.3 (8.0 to 64.2)	-11.5 (-32.0 to 9.1)
Inflammatory bowel disease	18.7 (17.9 to 19.5)	44.5 (42.8 to 46.2)	137.2 (125.8 to 150.4)	35.1 (28.4 to 42.9)	4.0 (2.8 to 5.5)	9.6 (6.6 to 13.2)	138.1 (116.1 to 160.2)	35.4 (24.5 to 46.8)
Vascular intestinal disorders	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	78.6 (11.9 to 155.3)	19.7 (-28.2 to 75.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	71.7 (1.0 to 163.8)	14.9 (-37.6 to 90.8)
Gallbladder and biliary diseases	14.3 (12.8 to 16.2)	19.4 (16.6 to 22.1)	34.9 (10.5 to 62.4)	18.6 (-34.0 to -1.4)	1.5 (1.0 to 2.1)	2.0 (1.4 to 2.9)	34.9 (10.1 to 66.5)	18.7 (-34.9 to 0.2)
Pancreatitis	3.7 (3.5 to 3.8)	9.7 (9.3 to 10.3)	164.7 (148.8 to 184.0)	48.5 (39.7 to 59.0)	1.1 (0.7 to 1.5)	2.9 (1.9 to 3.9)	164.3 (126.7 to 207.5)	48.0 (29.3 to 70.5)
Other digestive diseases	-	-	-	-	1.1 (0.7 to 1.6)	2.6 (1.7 to 3.7)	135.7 (69.4 to 194.6)	41.1 (2.7 to 75.8)
Neurological disorders	-	-	-	-	157.6 (105.2 to 217.9)	264.2 (175.3 to 370.3)	67.1 (47.9 to 91.7)	4.8 (-5.9 to 18.1)
Alzheimer disease and other dementias	77.3 (67.0 to 87.9)	118.4 (104.6 to 133.3)	53.0 (27.6 to 82.7)	0.4 (-16.8 to 19.9)	11.4 (8.1 to 15.1)	17.4 (12.3 to 22.6)	53.2 (27.5 to 83.7)	0.9 (-16.8 to 21.2)
Parkinson disease	4.9 (4.1 to 5.6)	7.9 (6.8 to 9.0)	63.3 (55.4 to 70.5)	0.4 (-4.8 to 4.7)	0.6 (0.4 to 0.8)	1.0 (0.6 to 1.3)	64.0 (45.1 to 87.5)	0.4 (-10.4 to 14.2)
Epilepsy	83.5 (57.8 to 109.7)	122.4 (84.2 to 161.6)	46.3 (-5.5 to 128.2)	2.4 (-33.5 to 59.8)	27.7 (16.5 to 40.6)	42.0 (24.9 to 63.5)	50.9 (-3.4 to 141.1)	6.0 (-32.0 to 68.4)
Multiple sclerosis	3.2 (2.8 to 3.5)	7.3 (6.7 to 7.9)	131.0 (99.8 to 163.2)	25.6 (8.9 to 43.4)	1.1 (0.7 to 1.4)	2.4 (1.7 to 3.3)	130.0 (86.1 to 181.8)	20.0 (1.2 to 52.9)
Migraine	2,659.7 (2,334.1 to 2,992.7)	4,285.5 (3,641.0 to 4,746.6)	59.6 (36.2 to 87.2)	1.5 (-15.0 to 14.9)	47.2 (53.9 to 139.3)	417.2 (86.5 to 221.6)	59.4 (35.6 to 88.6)	-1.2 (-15.7 to 15.2)
Tension-type headache	4,019.3 (3,688.9 to 4,332.8)	6,709.4 (5,948.4 to 7,480.5)	66.5 (43.1 to 91.2)	0.7 (-12.4 to 14.4)	6.1 (3.0 to 11.0)	10.2 (4.9 to 18.2)	65.9 (42.5 to 91.7)	0.9 (-12.7 to 15.0)
Medication overuse headache	97.7 (66.6 to 131.4)	251.9 (167.8 to 342.1)	156.7 (106.8 to 225.9)	48.1 (21.5 to 84.7)	15.5 (9.0 to 23.9)	39.9 (22.8 to 60.9)	156.6 (107.6 to 229.1)	48.5 (21.3 to 85.0)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	56.1 (11.1 to 119.6)	6.7 (-21.8 to 47.1)	3.0 (2.0 to 4.2)	4.0 (2.7 to 5.7)	34.3 (-2.2 to 97.2)	-14.1 (-38.2 to 26.5)
Mental and substance use disorders	-	-	-	-	387.3 (279.2 to 507.4)	625.2 (449.4 to 814.8)	61.4 (57.3 to 65.9)	0.3 (-1.9 to 2.4)
Schizophrenia	46.5 (42.2 to 50.4)	84.0 (76.6 to 90.6)	80.4 (71.4 to 89.7)	-0.3 (-4.9 to 4.3)	30.3 (21.9 to 37.1)	54.6 (40.2 to 66.2)	80.4 (68.5 to 94.7)	-0.1 (-6.1 to 7.2)
Alcohol use disorders	179.8 (158.0 to 205.7)	361.7 (317.8 to 412.8)	100.5 (86.8 to 115.6)	15.9 (8.5 to 23.9)	18.2 (11.7 to 26.1)	36.5 (24.0 to 51.7)	100.7 (84.8 to 118.3)	16.1 (7.2 to 25.6)
Drug use disorders	-	-	-	-	24.6 (16.9 to 33.0)	41.0 (27.9 to 55.4)	67.5 (47.1 to 89.9)	0.5 (-11.2 to 13.0)
Opioid use disorders	21.1 (14.9 to 27.3)	37.5 (28.3 to 47.0)	78.0 (54.7 to 106.1)	1.2 (-10.3 to 12.7)	8.9 (5.4 to 12.8)	15.8 (10.3 to 22.3)	78.0 (53.4 to 108.5)	1.2 (-11.2 to 15.1)
Cocaine use disorders	14.6 (12.5 to 16.4)	23.7 (20.4 to 27.3)	60.5 (33.8 to 96.1)	6.0 (-18.6 to 15.0)	2.0 (1.3 to 2.9)	3.3 (2.0 to 4.6)	61.4 (22.9 to 107.8)	3.4 (-24.9 to 21.5)
Amphetamine use disorders	39.4 (36.4 to 42.7)	63.3 (57.9 to 68.1)	60.1 (42.4 to 79.5)	0.1 (-10.5 to 11.6)	5.2 (3.3 to 7.7)	8.4 (5.1 to 12.3)	60.5 (36.7 to 88.9)	0.4 (-14.0 to 17.2)
Cannabis use disorders	37.7 (34.6 to 41.0)	59.2 (54.5 to 64.1)	56.4 (55.3 to 57.6)	0.2 (0.2 to 0.3)	1.1 (0.7 to 1.6)	1.7 (1.1 to 2.6)	56.7 (33.9 to 82.0)	0.6 (-13.6 to 16.3)
Other drug use disorders	-	-	-	-	7.3 (4.6 to 10.8)	11.8 (7.3 to 17.7)	62.2 (19.0 to 115.6)	0.1 (-26.6 to 33.1)
Depressive disorders	-	-	-	-	24.8 (17.1 to 33.5)	36.9 (23.9 to 47.5)	64.9 (36.3 to 96.6)	0.2 (-2.5 to 4.0)
Major depressive disorder	599.6 (486.0 to 703.2)	979.9 (783.1 to 1,142.0)	63.3 (51.6 to 72.1)	-0.3 (-6.2 to 4.0)	124.8 (82.1 to 178.3)	203.4 (129.0 to 290.8)	63.2 (51.6 to 72.7)	-0.1 (-6.1 to 4.7)
Dysthymia	221.2 (179.8 to 259.9)	385.8 (315.5 to 450.5)	74.0 (69.8 to 78.9)	-0.5 (-0.8 to -0.3)	21.5 (13.8 to 31.3)	37.6 (24.0 to 54.9)	74.3 (68.1 to 81.1)	-0.3 (-2.7 to 2.0)
Bipolar disorder	115.2 (98.2 to 131.5)	198.5 (170.4 to 225.4)	72.0 (62.1 to 81.2)	-0.2 (-5.1 to 4.4)	23.7 (14.5 to 36.1)	40.8 (25.1 to 61.3)	71.9 (59.5 to 85.1)	-0.1 (-6.6 to 6.6)
Anxiety disorders	556.8 (453.7 to 671.0)	871.5 (701.2 to 1,046.2)	56.1 (50.0 to 62.9)	0.6 (-0.8 to -0.4)	51.9 (34.1 to 74.4)	81.0 (54.3 to 117.8)	64.9 (48.2 to 82.0)	0.4 (-3.2 to 2.5)
Eating disorders	-	-	-	-	5.4 (3.3 to 8.3)	8.3 (5.1 to 12.8)	53.8 (40.3 to 67.4)	0.3 (-7.6 to 8.6)
Anorexia nervosa	1.7 (1.3 to 2.2)	2.8 (2.1 to 3.6)	61.3 (46.9 to 82.7)	7.9 (-1.5 to 19.9)	0.4 (0.2 to 0.6)	0.6 (0.3 to 1.0)	61.9 (19.7 to 127.6)	8.8 (-18.9 to 49.6)
Bulimia nervosa	23.4 (17.0 to 31.7)	35.9 (25.7 to 48.8)	53.0 (49.2 to 56.1)	-0.6 (-0.9 to -0.4)	5.0 (3.0 to 7.7)	7.7 (4.6 to 12.1)	53.3 (39.8 to 68.2)	-0.4 (-8.8 to 8.2)
Autistic spectrum disorders	-	-	-	-	24.8 (17.1 to 33.5)	36.9 (23.9 to 47.5)	64.9 (36.3 to 96.6)	0.2 (-2.5 to 4.0)
Autism	62.6 (59.4 to 65.9)	89.3 (84.6 to 93.9)	42.2 (41.4 to 43.1)	0.7 (0.6 to 0.7)	15.7 (10.6 to 21.6)	22.2 (14.9 to 30.8)	41.6 (34.5 to 49.1)	0.7 (-3.7 to 5.4)
Asperger syndrome	89.8 (84.1 to 95.1)	127.4 (119.4 to 135.1)	41.5 (40.4 to 42.7)	0.8 (0.8 to 0.9)	9.1 (6.3 to 12.7)	12.8 (8.9 to 17.9)	40.9 (34.8 to 46.9)	0.8 (-3.1 to 4.7)
Attention-deficit/hyperactivity disorder	143.6 (132.4 to 155.1)	175.3 (161.3 to 189.2)	21.9 (21.1 to 22.3)	0.4 (0.4 to 0.4)	1.8 (1.0 to 2.8)	2.1 (1.3 to 3.3)	21.7 (12.6 to 31.8)	0.4 (-7.2 to 8.7)
Conduct disorder	209.5 (197.6 to 222.0)	254.6 (239.3 to 270.9)	21.7 (20.3 to 22.6)	0.3 (0.3 to 0.4)	25.5 (16.2 to 36.8)	30.5 (19.6 to 45.0)	21.4 (16.2 to 35.9)	0.5 (-3.6 to 4.9)
Idiopathic intellectual disability	296.8 (233.6 to 364.1)	359.0 (283.8 to 443.5)	20.5 (6.6 to 37.2)	-13.9 (-24.0 to -1.3)	14.6 (9.4 to 21.2)	17.6 (11.4 to 25.8)	20.4 (6.2 to 38.5)	-1.7 (-23.9 to 10.4)
Other mental and substance use disorders	268.3 (250.3 to 285.6)	482.0 (450.8 to 511.4)	79.3 (77.6 to 81.0)	0.6 (0.3 to 1.0)	20.3 (13.7 to 27.4)	36.4 (24.6 to 49.3)	79.4 (72.0 to 86.5)	0.7 (-2.8 to 4.4)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	161.5 (111.3 to 220.6)	280.5 (195.8 to 378.8)	74.0 (57.1 to 90.7)	7.1 (-3.4 to 18.6)
Diabetes mellitus	843.3 (712.9 to 974.8)	1,691.8 (1,388.5 to 1,953.3)	100.4 (62.3 to 146.3)	12.6 (-9.9 to 41.4)	65.0 (43.0 to 93.2)	130.3 (85.7 to 184.6)	101.4 (60.2 to 148.9)	12.4 (-10.6 to 39.9)
Acute glomerulonephritis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	22.5 (-26.2 to -18.3)	-0.5 (-4.2 to 3.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-0.5 (-26.3 to -18.2)	-0.5 (-4.2 to -3.7)
Chronic kidney disease	-	-	-	-	35.9 (25.8 to 47.1)	59.5 (42.1 to 79.3)	65.5 (50.8 to 81.2)	3.5 (-6.5 to 11.6)
Chronic kidney disease due to diabetes mellitus	156.5 (104.2 to 226.7)	297.6 (189.0 to 443.7)	88.2 (29.7 to 166.5)	8.0 (-22.9 to 62.2)	5.4 (3.4 to 7.9)	10.3 (6.8 to 14.6)	94.9 (33.2 to 169.7)	9.0 (-24.8 to 52.1)
Chronic kidney disease due to hypertension	367.0 (198.1 to 656.9)	512.4 (274.5 to 884.0)	37.0 (3.2 to 124.8)	-2.8 (-23.7 to 57.5)	9.6 (6.8 to 12.9)	9.6 (4.4 to 9.6)	-29.8 (-46.4 to -9.0)	0.8 (-67.4 to -46.9)
Chronic kidney disease due to glomerulonephritis	333.5 (228.7 to 487.6)	399.8 (217.9 to 382.9)	19.5 (-33.8 to 16.8)	-0.6 (-54.8 to 24.8)	9.2 (6.3 to 15.5)	9.2 (11.7 to 24.2)	85.6 (43.8 to 173.6)	21.2 (-4.5 to 86.6)
Chronic kidney disease due to other causes	474.4 (282.3 to 775.1)	865.6 (536.3 to 1,375.5)	82.0 (44.6 to 136.7)	35.3 (14.2 to 63.6)	11.8 (8.2 to 15.9)	25.3 (17.6 to 34.0)	115.0 (72.0 to 159.0)	40.8 (16.4 to 69.8)
Urinary diseases and male infertility	-	-	-	-	7.9 (5.2 to 11.2)	14.2 (9.3 to 20.3)	80.0 (65.8 to 97.1)	16.0 (6.7 to 27.2)

Appendix Table G.4 - Uzbekistan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	5.4 (4.9 to 5.9)	9.7 (8.6 to 10.7)	77.7 (53.9 to 105.0)	25.4 (10.8 to 42.3)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	76.8 (41.3 to 128.1)	25.5 (1.9 to 56.1)
Urolithiasis	91.6 (72.0 to 115.5)	168.1 (125.3 to 223.8)	85.0 (49.5 to 108.6)	10.1 (-10.4 to 21.2)	1.0 (0.7 to 1.4)	1.8 (1.2 to 2.6)	80.8 (54.3 to 103.0)	8.6 (-6.0 to 19.5)
Benign prostatic hyperplasia	167.2 (155.9 to 178.6)	304.4 (279.7 to 323.9)	81.6 (64.5 to 101.2)	18.0 (6.6 to 30.6)	6.1 (3.9 to 8.6)	11.0 (7.1 to 15.5)	81.6 (63.9 to 101.1)	17.8 (6.4 to 30.6)
Male infertility due to other causes	85.7 (64.6 to 109.4)	144.0 (107.0 to 188.9)	68.5 (9.1 to 147.3)	-0.1 (-35.5 to 46.2)	0.6 (0.2 to 1.1)	0.9 (0.4 to 2.0)	68.6 (9.6 to 145.5)	0.4 (-34.4 to 45.9)
Other urinary diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	9.3 (33.3 to 61.4)	0.5 (-17.6 to 56.5)
Gynecological diseases	-	-	-	-	20.9 (13.4 to 31.6)	38.1 (24.4 to 57.6)	83.1 (57.2 to 108.1)	0.6 (-12.6 to 12.3)
Uterine fibroids	292.7 (262.6 to 319.4)	623.1 (565.7 to 676.0)	112.3 (108.8 to 116.2)	1.5 (1.4 to 1.6)	4.8 (2.9 to 7.9)	8.3 (4.7 to 14.0)	70.7 (57.2 to 83.4)	-12.8 (-19.1 to -7.6)
Polycystic ovarian syndrome	300.4 (262.1 to 337.1)	545.7 (486.6 to 605.6)	81.3 (52.8 to 115.3)	-0.1 (-14.4 to 15.9)	2.9 (1.4 to 5.6)	5.3 (2.5 to 9.8)	79.9 (50.7 to 114.6)	-0.3 (-14.7 to 15.9)
Female infertility due to other causes	28.5 (10.6 to 53.5)	67.0 (33.2 to 107.0)	142.2 (2.2 to 546.1)	54.8 (-33.9 to 307.8)	0.2 (0.0 to 0.4)	0.4 (0.1 to 0.8)	129.6 (54.1 to 498.4)	46.1 (-38.6 to 284.9)
Endometriosis	30.6 (25.0 to 36.0)	60.8 (52.5 to 69.9)	97.9 (59.5 to 149.2)	6.8 (-12.7 to 33.5)	2.9 (1.8 to 4.0)	5.7 (3.7 to 8.2)	98.3 (58.5 to 153.1)	7.3 (-14.0 to 35.6)
Genital prolapse	763.9 (669.8 to 868.0)	1,398.7 (1,202.4 to 1,600.7)	83.1 (50.6 to 120.4)	0.0 (-15.8 to 17.7)	2.4 (1.2 to 4.5)	4.5 (2.1 to 8.5)	83.5 (49.5 to 120.9)	0.4 (-15.8 to 19.1)
Premenstrual syndrome	662.4 (459.9 to 902.1)	1,309.4 (941.5 to 1,717.1)	100.8 (21.3 to 210.1)	18.8 (-31.0 to 75.0)	5.6 (3.0 to 9.6)	11.1 (6.2 to 17.8)	100.9 (20.3 to 215.3)	18.6 (-31.4 to 77.9)
Other gynecological diseases	66.6 (53.0 to 78.8)	101.7 (93.8 to 109.5)	52.2 (30.3 to 89.5)	-13.0 (-25.8 to 7.2)	2.0 (1.3 to 2.9)	3.0 (2.0 to 4.3)	46.4 (23.9 to 117.2)	-16.9 (-29.9 to 20.8)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	21.3 (14.2 to 31.1)	27.6 (18.3 to 40.0)	29.0 (17.6 to 54.6)	5.7 (-4.1 to 28.3)
Thalassemias	1.9 (1.7 to 2.2)	2.1 (1.9 to 2.4)	11.1 (3.2 to 18.3)	-1.3 (-8.2 to 4.9)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	19.0 (-21.7 to 74.4)	3.0 (32.2 to 49.5)
Thalassemia trait	623.6 (588.9 to 666.5)	884.8 (841.2 to 949.0)	41.4 (36.4 to 52.0)	0.4 (-3.3 to 7.8)	16.8 (11.1 to 24.7)	23.7 (15.9 to 34.3)	40.8 (27.5 to 64.8)	15.5 (3.2 to 36.3)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.2 (23.2 to 35.2)	-1.8 (-3.6 to 4.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.7 (23.9 to 42.8)	-2.1 (-4.4 to 10.1)
Sickle cell trait	40.1 (8.4 to 10.3)	67.0 (11.6 to 13.6)	66.1 (30.9 to 41.6)	0.0 (-7.3 to 0.3)	0.0 (0.1 to 0.2)	0.0 (0.1 to 0.2)	125.2 (-14.0 to 45.0)	74.5 (-30.5 to 10.0)
G6PD deficiency	2,315.8 (2,289.5 to 2,333.4)	3,277.1 (3,248.2 to 3,300.1)	41.1 (39.7 to 43.3)	-1.1 (-2.1 to 0.4)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	-2.3 (-80.5 to 184.2)	-12.8 (-81.7 to 136.7)
Other hemoglobinopathies and hemolytic anemias	132.6 (98.2 to 156.4)	121.5 (102.7 to 137.1)	-9.0 (-25.1 to 25.1)	-27.9 (-39.8 to -4.0)	4.1 (2.3 to 6.3)	3.4 (2.1 to 5.2)	-16.5 (-4.3 to 49.7)	-31.0 (-48.1 to 24.4)
Endocrine, metabolic, blood, and immune disorders	291.5 (257.4 to 322.0)	309.7 (290.7 to 327.2)	6.0 (-4.2 to 20.1)	18.1 (-25.3 to -8.7)	6.0 (7.1 to 15.0)	10.8 (7.3 to 14.8)	19.3 (4.4 to 22.8)	19.3 (-26.4 to -5.5)
Musculoskeletal disorders	-	-	-	-	245.4 (172.4 to 330.9)	428.6 (302.9 to 577.1)	74.6 (55.1 to 100.6)	-0.5 (-10.0 to 12.2)
Rheumatoid arthritis	29.7 (28.5 to 30.8)	58.3 (56.0 to 60.6)	95.9 (85.4 to 107.5)	20.3 (14.1 to 27.5)	7.2 (5.1 to 9.6)	14.1 (10.0 to 18.7)	95.3 (78.5 to 113.5)	20.2 (11.2 to 29.9)
Osteoarthritis	498.3 (478.0 to 517.6)	877.2 (839.9 to 914.1)	75.8 (66.0 to 86.2)	0.1 (-5.4 to 5.6)	30.7 (21.5 to 41.6)	54.2 (38.2 to 74.9)	76.7 (66.8 to 87.9)	0.2 (-5.2 to 6.3)
Low back and neck pain	-	-	-	-	189.3 (123.5 to 248.5)	308.4 (210.4 to 420.3)	78.8 (44.9 to 106.1)	-2.2 (-15.5 to 17.2)
Low back pain	1,021.6 (861.3 to 1,176.5)	1,768.4 (1,539.1 to 2,019.8)	73.1 (40.0 to 112.5)	0.0 (-17.0 to 20.7)	115.1 (76.6 to 166.0)	199.0 (131.4 to 276.3)	73.2 (39.9 to 114.1)	0.2 (-17.2 to 21.1)
Neck pain	656.2 (527.1 to 774.8)	1,104.3 (922.3 to 1,290.9)	67.4 (29.9 to 122.0)	-5.8 (-25.8 to 24.8)	65.2 (42.5 to 93.1)	109.5 (72.6 to 155.8)	67.8 (29.6 to 123.0)	-5.8 (-25.7 to 25.5)
Gout	8.6 (8.1 to 9.1)	15.9 (15.0 to 16.8)	85.2 (71.3 to 100.7)	4.2 (-3.2 to 13.0)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	85.8 (52.8 to 131.8)	4.0 (-13.5 to 27.4)
Other musculoskeletal disorders	293.2 (221.7 to 372.1)	558.4 (434.9 to 695.0)	90.2 (74.2 to 108.6)	3.2 (-4.7 to 12.5)	26.9 (17.3 to 39.9)	51.4 (33.3 to 75.8)	91.4 (74.5 to 111.1)	9.6 (-4.9 to 13.2)
Other non-communicable diseases	-	-	-	-	256.1 (170.9 to 368.9)	380.1 (253.3 to 551.8)	48.5 (42.6 to 53.6)	-5.5 (-8.1 to -2.8)
Congenital anomalies	-	-	-	-	18.0 (12.8 to 23.7)	26.6 (19.4 to 34.4)	47.8 (27.5 to 71.6)	8.7 (-5.9 to 25.5)
Neural tube defects	4.4 (3.5 to 5.2)	7.0 (6.1 to 8.0)	57.3 (25.9 to 101.7)	22.8 (-1.8 to 57.0)	1.4 (0.9 to 2.0)	2.3 (1.5 to 3.2)	63.5 (13.2 to 136.7)	28.8 (-10.0 to 83.9)
Congenital heart anomalies	67.7 (52.6 to 89.1)	128.7 (104.7 to 157.3)	90.9 (33.0 to 162.1)	43.9 (0.5 to 98.5)	2.3 (1.0 to 4.2)	4.3 (1.8 to 7.6)	88.8 (30.9 to 154.1)	43.6 (-0.3 to 94.2)
Orofacial clefts	9.7 (6.1 to 12.9)	17.9 (14.7 to 21.0)	82.6 (23.0 to 215.7)	44.8 (-2.2 to 152.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	68.9 (0.2 to 206.4)	33.6 (-21.0 to 139.9)
Down syndrome	17.0 (14.4 to 19.6)	26.9 (22.3 to 32.5)	57.5 (23.0 to 102.2)	13.6 (-11.6 to 46.8)	2.1 (1.5 to 2.8)	3.4 (2.4 to 4.6)	62.4 (22.1 to 115.0)	14.5 (-13.9 to 52.3)
Turner syndrome	0.7 (0.5 to 1.0)	1.1 (0.8 to 1.3)	45.9 (-6.2 to 120.5)	4.6 (-32.9 to 57.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	50.1 (-3.6 to 134.0)	4.6 (-33.8 to 61.3)
Klinefelter syndrome	0.5 (0.4 to 0.7)	0.8 (0.6 to 0.9)	45.3 (0.5 to 89.0)	4.6 (-27.8 to 36.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.2 (12.9 to 117.0)	3.7 (-28.5 to 35.3)
Chromosomal unbalanced rearrangements	25.8 (23.1 to 34.8)	41.7 (35.6 to 50.5)	60.5 (18.5 to 97.1)	56.5 (-15.1 to 41.8)	3.2 (2.3 to 4.5)	5.2 (3.8 to 7.1)	14.7 (15.9 to 105.9)	14.7 (-15.9 to 46.1)
Other congenital anomalies	67.2 (55.9 to 78.7)	84.4 (71.6 to 99.1)	25.6 (10.6 to 43.3)	-14.4 (-23.8 to -2.4)	8.8 (5.7 to 12.4)	11.0 (7.4 to 15.5)	25.6 (1.5 to 61.0)	-6.4 (-24.3 to 18.4)
Skin and subcutaneous diseases	-	-	-	-	82.5 (53.6 to 124.6)	124.0 (79.8 to 185.9)	50.1 (38.8 to 63.2)	-1.4 (-8.9 to 6.6)
Dermatitis	738.7 (602.8 to 885.9)	1,177.2 (945.0 to 1,428.5)	59.0 (54.4 to 63.4)	-0.1 (-4.0 to -0.0)	18.2 (11.1 to 27.1)	28.2 (17.1 to 42.2)	54.9 (48.3 to 60.9)	0.0 (-2.7 to 2.8)
Psoriasis	137.4 (121.7 to 153.7)	224.9 (198.1 to 253.0)	63.3 (60.5 to 66.5)	0.0 (-0.2 to 0.2)	6.0 (7.8 to 15.9)	11.3 (12.5 to 26.2)	18.5 (52.8 to 74.6)	0.2 (-5.4 to 6.1)
Cellulitis	7.5 (6.0 to 9.2)	9.4 (7.3 to 12.0)	27.3 (5.9 to 43.6)	-3.3 (-16.2 to 7.9)	0.5 (0.3 to 0.8)	0.7 (0.4 to 1.0)	0.7 (-4.6 to 59.9)	-3.7 (-23.1 to 18.6)
Pyoderma	21.2 (17.7 to 25.1)	29.4 (24.4 to 35.8)	38.3 (28.5 to 49.2)	9.2 (4.7 to 13.9)	0.1 (0.0 to 0.3)	0.2 (0.1 to 0.4)	38.0 (23.0 to 55.0)	9.2 (-0.0 to 19.0)
Scabies	61.0 (52.1 to 72.0)	81.2 (69.7 to 94.6)	32.8 (8.3 to 63.4)	-5.5 (-22.8 to 15.1)	1.6 (0.9 to 2.6)	2.1 (1.2 to 3.4)	32.8 (6.9 to 65.1)	-5.3 (-23.5 to 16.2)
Fungal skin diseases	1,384.5 (1,047.2 to 1,827.3)	2,193.5 (1,651.7 to 2,872.5)	56.4 (47.5 to 62.7)	7.9 (0.0 to 0.5)	54.2 (3.1 to 17.3)	73.9 (4.9 to 27.4)	12.2 (47.3 to 62.7)	0.3 (-0.5 to 1.2)
Viral skin diseases	514.7 (397.9 to 618.5)	663.4 (506.0 to 823.3)	28.7 (21.0 to 36.1)	0.1 (-1.6 to 1.7)	16.1 (9.2 to 25.1)	20.6 (11.6 to 32.5)	28.2 (19.8 to 36.2)	0.3 (-3.0 to 3.1)
Acne vulgaris	542.9 (394.1 to 686.2)	809.3 (643.6 to 1,018.0)	49.6 (1.7 to 113.9)	2.5 (-29.5 to 44.3)	5.9 (2.6 to 11.5)	8.8 (4.0 to 16.7)	49.3 (1.5 to 115.1)	2.6 (-30.0 to 45.3)
Alopecia areata	20.3 (17.5 to 22.9)	31.4 (26.9 to 35.7)	54.3 (25.4 to 90.9)	0.2 (-17.8 to 24.1)	0.7 (0.4 to 1.1)	1.1 (0.7 to 1.6)	54.4 (23.2 to 97.3)	0.3 (-19.6 to 27.5)
Pruritus	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	56.4 (18.8 to 109.6)	0.0 (-24.2 to 34.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.4 (18.5 to 109.6)	0.0 (-24.3 to 34.5)
Urticaria	245.8 (174.2 to 315.6)	379.2 (291.9 to 459.1)	55.0 (6.2 to 132.9)	-5.8 (-33.4 to 29.9)	14.8 (8.5 to 24.0)	22.7 (13.4 to 33.8)	55.1 (5.3 to 134.1)	-5.9 (-33.8 to 31.0)
Decubitus ulcer	1.0 (0.8 to 1.1)	1.5 (1.2 to 1.8)	50.6 (25.3 to 102.8)	-7.7 (-25.9 to 32.3)	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	53.3 (24.1 to 109.4)	-5.7 (-28.2 to 38.1)
Other skin and subcutaneous diseases	889.1 (597.5 to 1,335.9)	1,472.8 (994.3 to 2,132.9)	65.3 (52.1 to 79.9)	-0.8 (-5.3 to 2.7)	5.3 (2.3 to 10.9)	8.7 (3.8 to 17.9)	65.3 (51.7 to 80.4)	-0.7 (-5.4 to 3.1)
Sense organ diseases	-	-	-	-	117.1 (77.9 to 165.8)	167.4 (110.5 to 239.8)	61.1 (35.0 to 50.1)	-9.6 (-13.3 to -6.1)
Glaucoma	20.3 (17.3 to 24.1)	30.0 (25.3 to 35.1)	47.3 (30.6 to 68.1)	-13.9 (-23.6 to -0.0)	1.4 (0.9 to 2.0)	2.2 (1.4 to 3.0)	50.7 (30.4 to 76.1)	-10.6 (-23.0 to 4.4)
Cataract	118.2 (94.3 to 141.6)	131.9 (101.4 to 160.1)	11.7 (-3.7 to 26.8)	-30.3 (-39.8 to -21.2)	4.0 (2.6 to 6.1)	4.6 (2.9 to 6.9)	13.2 (-2.3 to 27.4)	-29.0 (-38.8 to -20.9)
Macular degeneration	33.3 (24.7 to 45.8)	63.2 (48.9 to 77.2)	89.5 (52.7 to 139.3)	8.1 (-14.1 to 38.6)	1.1 (0.6 to 1.7)	2.0 (1.2 to 3.1)	85.5 (49.8 to 131.8)	5.9 (-15.1 to 34.6)
Uncorrected refractive error	1,478.4 (1,350.1 to 1,596.3)	2,236.5 (2,015.7 to 2,443.1)	50.8 (32.6 to 70.4)	3.5 (-15.1 to 37.5)	23.6 (14.0 to 38.2)	33.3 (19.5 to 55.6)	40.8 (28.4 to 54.9)	-10.2 (-17.6 to -1.1)
Age-related and other hearing loss	2,080.6 (1,820.6 to 2,323.9)	3,300.7 (2,864.7 to 3,699.5)	58.1 (50.1 to 67.9)	-7.3 (-10.9 to -3.4)	69.1 (45.9 to 97.1)	102.9 (68.0 to 145.5)	49.1 (37.2 to 59.7)	8.3 (-13.3 to -3.4)
Other vision loss	103.6 (91.6 to 117.3)	113.7 (98.5 to 129.2)	9.3 (0.4 to 20.4)	-30.1 (-36.1 to -23.2)	4.8 (3.2 to 6.8)	5.4 (3.5 to 7.7)	13.3 (0.7 to 27.4)	-2.0 (-34.7 to -20.5)
Other sense organ diseases	483.0 (457.8 to 507.0)	639.0 (608.1 to 669.2)	31.9 (23.1 to 42.4)	-0.2 (-6.2 to 6.3)	13.0 (8.0 to 19.7)	17.1 (10.5 to 25.3)	31.5 (21.6 to 42.7)	-0.2 (-6.9 to 7.3)
Oral disorders	-	-	-	-	38.6 (22.6 to 61.4)	62.0 (36.0 to 98.5)	60.8 (55.7 to 66.3)	-2.3 (-5.2 to 0.7)
Deciduous caries	2,448.3 (2,395.2 to 2,500.8)	2,408.2 (2,362.8 to 2,453.8)	-1.8 (-4.8 to 0.9)	0.6 (-2.5 to 3.3)	0.9 (0.4 to 1.8)	0.9 (0.4 to 1.8)	-0.9 (-7.4 to 4.7)	0.5 (-5.2 to 7.2)
Permanent caries	10,375.9 (10,025.0 to 10,743.1)	16,031.3 (15,575.7 to 16,481.8)	54.					

Appendix Table G.4 - Uzbekistan prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	419.8 (403.4 to 436.5)	662.9 (634.8 to 690.3)	57.6 (48.6 to 67.3)	-6.1 (-11.2 to -0.9)	11.6 (7.8 to 16.1)	18.4 (12.4 to 25.4)	58.1 (48.7 to 67.9)	-6.2 (-11.2 to -1.0)
Other oral disorders	308.8 (292.0 to 326.3)	497.3 (466.6 to 531.5)	60.5 (48.7 to 75.5)	-0.8 (-7.2 to 7.4)	9.1 (5.7 to 14.0)	14.7 (9.0 to 21.9)	60.5 (47.8 to 75.6)	-0.6 (-7.4 to 8.1)
Injuries	-	-	-	-	109.9 (83.5 to 140.7)	157.6 (113.0 to 213.6)	43.1 (27.2 to 60.1)	-13.3 (-22.6 to -3.3)
Transport injuries	-	-	-	-	19.0 (14.4 to 24.3)	20.7 (14.7 to 28.2)	8.8 (6.5 to 27.1)	-32.4 (-41.4 to -22.0)
Road injuries	-	-	-	-	17.1 (13.0 to 21.9)	17.1 (12.1 to 23.1)	0.8 (-15.0 to 16.8)	-37.8 (-46.3 to -27.8)
Pedestrian road injuries	-	-	-	-	4.2 (3.2 to 5.6)	3.6 (2.5 to 4.9)	-15.4 (-28.9 to 0.2)	-44.9 (-52.8 to -36.0)
Cyclist road injuries	-	-	-	-	1.8 (1.3 to 2.3)	2.3 (1.6 to 3.0)	27.1 (11.3 to 43.4)	-20.2 (-29.4 to -10.6)
Motorcyclist road injuries	-	-	-	-	1.8 (1.4 to 2.4)	1.7 (1.2 to 2.3)	-8.2 (-22.0 to 6.8)	-45.5 (-53.4 to -37.4)
Motor vehicle road injuries	-	-	-	-	9.1 (6.9 to 11.6)	9.4 (6.7 to 12.8)	2.4 (-13.9 to 23.2)	-36.1 (-46.2 to -23.9)
Other road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-20.7 (-32.6 to -5.4)	-51.8 (-58.7 to -43.2)
Other transport injuries	-	-	-	-	1.9 (1.4 to 2.4)	3.7 (2.7 to 5.0)	97.8 (70.9 to 127.9)	16.3 (0.7 to 34.5)
Unintentional injuries	-	-	-	-	89.0 (67.7 to 114.3)	134.4 (96.5 to 181.6)	50.6 (34.8 to 67.3)	-9.3 (-18.6 to 0.7)
Falls	-	-	-	-	63.4 (47.8 to 81.5)	90.0 (63.2 to 122.6)	41.4 (24.4 to 60.6)	-16.7 (-26.4 to -5.6)
Drowning	-	-	-	-	1.3 (0.9 to 1.7)	0.8 (0.6 to 1.2)	-35.1 (-44.3 to -24.0)	-58.0 (-63.5 to -51.3)
Fire, heat, and hot substances	-	-	-	-	3.2 (2.5 to 4.1)	3.4 (2.5 to 4.6)	3.2 (-10.7 to 18.9)	-34.6 (-42.9 to -25.2)
Poisonings	-	-	-	-	0.4 (0.3 to 0.6)	0.4 (0.3 to 0.6)	-1.0 (-15.7 to 16.0)	-36.7 (-45.0 to -26.7)
Exposure to mechanical forces	-	-	-	-	13.0 (9.9 to 17.0)	24.0 (17.5 to 32.3)	83.9 (62.1 to 104.5)	24.0 (12.5 to 34.9)
Unintentional firearm injuries	-	-	-	-	0.3 (0.3 to 0.4)	0.4 (0.3 to 0.5)	8.7 (7.2 to 30.1)	-31.4 (-41.6 to -18.5)
Unintentional suffocation	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	93.7 (66.4 to 123.9)	25.9 (9.6 to 42.7)
Other exposure to mechanical forces	-	-	-	-	12.6 (9.5 to 16.5)	23.3 (17.1 to 31.4)	85.8 (63.4 to 106.8)	25.6 (13.7 to 37.0)
Adverse effects of medical treatment	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	61.0 (52.3 to 71.7)	2.1 (-3.9 to 8.7)
Animal contact	-	-	-	-	0.9 (0.7 to 1.2)	1.3 (0.9 to 1.7)	39.2 (26.4 to 52.9)	-7.3 (-14.7 to 0.4)
Venomous animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	42.1 (22.9 to 63.4)	-7.9 (-19.0 to 4.1)
Non-venomous animal contact	-	-	-	-	0.6 (0.4 to 0.8)	0.8 (0.6 to 1.1)	37.5 (22.9 to 53.4)	-7.0 (-15.4 to 1.6)
Foreign body	-	-	-	-	0.9 (0.7 to 1.1)	1.2 (0.9 to 1.5)	34.3 (19.8 to 51.0)	-8.9 (-17.7 to 0.6)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.4 (0.3 to 0.5)	0.3 (0.2 to 0.4)	-18.1 (-33.0 to -0.0)	-43.3 (-52.6 to -31.8)
Foreign body in eyes	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	57.9 (45.7 to 71.0)	5.0 (-1.8 to 12.2)
Foreign body in other body part	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	89.9 (62.3 to 119.1)	26.3 (11.3 to 42.5)
Other unintentional injuries	-	-	-	-	5.6 (4.3 to 7.1)	12.9 (9.5 to 17.3)	132.8 (107.1 to 159.8)	45.7 (31.0 to 60.5)
Self-harm and interpersonal violence	-	-	-	-	1.9 (1.4 to 2.4)	2.3 (1.7 to 3.1)	24.6 (11.8 to 39.3)	-28.4 (-35.7 to -20.3)
Self-harm	-	-	-	-	0.9 (0.7 to 1.2)	1.2 (0.9 to 1.6)	28.7 (15.5 to 43.5)	-27.6 (-34.8 to -19.3)
Interpersonal violence	-	-	-	-	0.9 (0.7 to 1.2)	1.1 (0.8 to 1.5)	20.9 (6.3 to 37.6)	-29.4 (-37.7 to -20.2)
Assault by firearm	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	45.0 (30.3 to 60.3)	-13.4 (-21.0 to -5.2)
Assault by sharp object	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	26.3 (11.1 to 43.8)	-27.1 (-35.3 to -17.7)
Assault by other means	-	-	-	-	0.7 (0.5 to 0.8)	0.8 (0.5 to 1.0)	15.5 (0.2 to 33.1)	-32.5 (-41.2 to -22.5)
Forces of nature, war, and legal intervention	-	-	-	-	-	0.1 (0.0 to 0.2)	-	-
Exposure to forces of nature	-	-	-	-	-	0.0 (0.0 to 0.0)	-	-
Collective violence and legal intervention	-	-	-	-	-	0.1 (0.0 to 0.2)	-	-

Appendix Table G.4 - Vanuatu prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
All causes	-	-	-	-	11.2 (8.2 to 14.6)	19.9 (14.6 to 25.9)	78.4 (71.1 to 85.2)	78.4 (5.8 to 1.1)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	2.3 (1.6 to 3.2)	3.7 (2.5 to 5.1)	57.8 (35.8 to 79.8)	-6.2 (-20.7 to 10.2)
HIV/AIDS and tuberculosis	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	85.2 (65.8 to 114.0)	-7.9 (-16.6 to 4.9)
Tuberculosis	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.3)	66.2 (58.9 to 74.0)	-17.3 (-20.7 to -13.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.3 (51.7 to 82.2)	-17.2 (-23.2 to -10.6)
HIV/AIDS	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,246.6 (439.9 to 2,565.7)	641.4 (189.3 to 1,360.2)
HIV/AIDS resulting in mycobacterial infection	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
HIV/AIDS resulting in other diseases	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.2)	946.6 (388.1 to 1,963.0)	488.3 (175.6 to 1,030.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,246.6 (439.9 to 2,565.7)	641.4 (189.3 to 1,360.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	0.2 (0.3 to 0.6)	0.2 (0.4 to 0.7)	24.8 (14.7 to 33.4)	-19.5 (-25.9 to -14.4)
Diarrheal diseases	1.0 (0.9 to 1.1)	1.2 (1.1 to 1.3)	23.0 (9.6 to 38.4)	-34.0 (-22.1 to -4.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	22.7 (8.9 to 39.2)	-14.0 (-22.5 to -3.5)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.8 (-11.9 to 65.7)	-29.6 (-43.4 to 4.0)
Typhoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.9 (7.9 to 31.4)	-29.3 (-41.9 to -17.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	12.6 (-12.5 to 42.6)	-28.5 (-43.0 to -11.7)
Paratyphoid fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.8 (-26.8 to 11.0)	-44.2 (-54.4 to -31.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-9.5 (-30.9 to 18.6)	-44.0 (-56.0 to -28.5)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	162.3 (90.9 to 24,931.2)	65.6 (94.4 to 15,643.5)
Lower respiratory infections	0.3 (0.2 to 0.3)	0.3 (0.2 to 0.3)	-1.2 (-21.3 to 20.7)	-26.5 (-40.3 to -11.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-2.4 (-24.4 to 20.5)	-27.0 (-41.7 to -11.2)
Upper respiratory infections	4.5 (4.3 to 4.7)	7.5 (7.0 to 7.9)	65.0 (54.4 to 76.7)	-1.1 (-7.0 to 5.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	65.2 (53.2 to 78.4)	-1.0 (-7.6 to 6.7)
Otitis media	2.1 (2.0 to 2.3)	3.1 (2.9 to 3.2)	43.9 (34.2 to 54.7)	-12.3 (-18.4 to -5.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	43.3 (31.7 to 56.5)	-12.1 (-19.0 to -4.6)
Meningitis	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	18.3 (7.0 to 41.9)	-29.9 (-43.4 to -17.7)
Pneumococcal meningitis	0.7 (0.5 to 1.2)	0.8 (0.5 to 1.3)	13.1 (-4.2 to 35.5)	-34.9 (-43.7 to -23.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	13.6 (-10.2 to 48.5)	-32.8 (-45.4 to -14.8)
H influenzae type B meningitis	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	1.4 (-24.4 to 55.3)	-41.9 (-55.2 to -12.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.3 (-31.6 to 109.0)	-34.4 (-58.3 to 19.4)
Meningococcal meningitis	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.2)	12.0 (-17.8 to 46.8)	-37.3 (-51.4 to -17.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	11.6 (-28.5 to 63.3)	-36.4 (-55.9 to -10.8)
Other meningitis	0.3 (0.1 to 0.5)	0.3 (0.2 to 0.6)	24.2 (-3.6 to 53.6)	-26.9 (-41.9 to -7.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-15.8 to 80.0)	-21.4 (-46.8 to 8.7)
Encephalitis	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	60.0 (37.1 to 89.0)	-11.0 (-21.7 to 3.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.2 (30.0 to 106.1)	-6.5 (-23.4 to 13.3)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.5 (-89.1 to 720.0)	-42.2 (-94.3 to 362.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	4.5 (-89.2 to 728.8)	-42.2 (-94.4 to 369.2)
Whooping cough	0.2 (0.2 to 0.3)	0.1 (0.1 to 0.2)	-29.7 (-32.4 to -26.9)	-46.1 (-48.2 to -44.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.8 (-36.7 to -21.9)	-46.2 (-51.5 to -40.1)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	81.0 (-92.9 to -59.0)	-88.6 (-95.5 to -75.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-82.2 (-93.3 to -64.4)	-88.8 (-95.3 to -79.6)
Measles	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.0)	-55.2 (-70.7 to -58.7)	-37.7 (-77.9 to -68.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.6 (-73.9 to -54.0)	-74.0 (-80.3 to -65.3)
Varicella and herpes zoster	0.2 (0.2 to 0.2)	0.3 (0.2 to 0.3)	56.8 (39.8 to 73.6)	-1.1 (-14.5 to 13.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	77.7 (44.0 to 118.6)	-1.8 (-20.2 to 20.5)
Neglected tropical diseases and malaria	-	-	-	-	0.6 (0.4 to 0.9)	1.4 (0.9 to 2.0)	141.3 (87.1 to 227.6)	15.8 (-15.5 to 67.5)
Malaria	19.4 (18.3 to 20.6)	30.9 (29.1 to 32.9)	59.1 (49.5 to 67.7)	-6.3 (-12.0 to -1.1)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	58.5 (47.1 to 81.8)	-0.4 (-7.0 to 9.8)
Chagas disease	-	-	0.0 (0.0 to 0.0)	-	0.0 (0.0 to 0.0)	-	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	808.0 (642.8 to 1,095.4)	603.3 (478.6 to 829.6)
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.5 (-18.5 to 204.7)	13.2 (-33.7 to 97.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	56.5 (-18.6 to 205.0)	13.2 (-33.8 to 98.3)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	865.9 (681.0 to 1,198.0)	637.0 (502.5 to 879.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	865.9 (679.5 to 1,198.1)	637.0 (502.4 to 891.3)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Cysticercosis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-20.7 (-63.8 to 68.0)	-60.7 (-80.6 to -13.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.6 (-63.8 to 84.2)	-58.2 (-79.8 to -6.5)
Cystic echinococcosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	13.2 (-1.8 to 34.6)	-40.2 (-46.1 to -30.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	15.1 (-9.3 to 52.0)	-38.3 (-51.1 to -22.3)
Lymphatic filariasis	10.4 (8.7 to 12.3)	4.5 (3.1 to 6.3)	-56.4 (-69.1 to -43.1)	-75.3 (-82.7 to -68.2)	0.3 (0.2 to 0.5)	0.3 (0.2 to 0.6)	12.0 (-29.3 to 53.3)	-45.0 (-66.0 to -22.8)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-41.7 (-66.1 to 6.9)	-71.3 (-82.4 to -43.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.0 (-64.9 to -5.1)	-72.1 (-81.7 to -50.5)
Dengue	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	727.8 (719.6 to 737.3)	387.2 (382.3 to 392.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	727.9 (547.6 to 968.6)	386.1 (293.4 to 498.1)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.1 (-27.9 to 120.6)	-35.6 (-60.0 to 14.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.1 (-28.0 to 121.8)	35.6 (-60.4 to 14.7)
Intestinal nematode infections	-	-	-	-	0.0 (0.0 to 0.0)	0.7 (0.4 to 1.1)	733,722.6 (482,357.6 to 1,153,356.3)	485,832.0 (311,934.1 to 799,030.9)
Ascariasis	-	85.6 (57.9 to 123.8)	529,660.8 (325,887.0 to 914,246.5)	319,421.0 (173,564.6 to 582,024.8)	-	0.1 (0.1 to 0.3)	-	-
Trichuriasis	-	55.1 (38.0 to 76.8)	341,781.7 (198,096.9 to 612,228.9)	203,782.9 (107,606.3 to 399,119.9)	-	0.0 (0.0 to 0.1)	-	-
Hookworm disease	0.0 (0.0 to 0.0)	80.6 (62.3 to 103.6)	499,386.5 (331,899.5 to 761,948.6)	305,860.4 (184,660.8 to 504,386.8)	0.5 (0.0 to 0.0)	0.5 (0.3 to 0.8)	520,482.5 (361,709.2 to 830,144.0)	345,348.6 (230,260.0 to 580,629.6)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	1.4 (1.0 to 1.8)	1.5 (1.3 to 2.0)	11.9 (-16.6 to 57.4)	-24.0 (-43.0 to 6.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	7.2 (-27.8 to 78.3)	-26.4 (-50.2 to 24.3)
Maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	19.6 (-13.3 to 49.6)	-36.9 (-53.5 to -21.7)
Maternal hemorrhage	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	38.9 (1.0 to 78.6)	-26.1 (-46.4 to -5.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	28.2 (-25.1 to 73.5)	-32.0 (-59.4 to -8.8)
Maternal sepsis and other maternal infections	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-9.0 (-20.4 to 4.5)	-53.6 (-58.9 to -46.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.0 (-51.1 to 47.8)	-56.1 (-73.8 to -26.9)
Maternal hypertensive disorders	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	23.6 (15.8 to 45.8)	-34.0 (-37.9 to -22.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	24.4 (1.9 to 56.0)	-33.6 (-45.5 to -17.7)
Obstructed labor	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.5 (-68.2 to 66.4)	-54.0 (-82.5 to -14.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-8.6 (-68.5 to 151.5)	-52.4 (-84.2 to 25.6)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.3 (-16.2 to 130.6)	-32.1 (-55.3 to 13.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.3 (-16.5 to 130.8)	-32.1 (-55.3 to 13.7)
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.8 (-27.7 to 88.3)	-37.3 (-61.7 to -0.8)
Neonatal disorders	-	-	-	-	0.4 (0.2 to 0.7)	0.6 (0.4 to 1.0)	82.0 (-9.9 to 222.9)	13.9 (-43.5 to 102.1)
Preterm birth complications	0.7 (0.4 to 1.3)	2.6 (1.4 to 4.9)	258.8 (146.0 to 368.8)	117.2 (53.4 to 181.6)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	227.3 (74.1 to 403.4)	104.0 (10.1 to 208.9)
Neonatal encephalopathy due to birth asphyxia and trauma	0.5 (0.2 to 1.1)	0.9 (0.3 to 2.0)	81.0 (37.5 to 133.4)	7.7 (-14.8 to 38.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	82.4 (6.4 to 207.6)	15.5 (-30.6 to 90.3)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	264.0 (241.0 to 277.1)	187.0 (168.8 to 197.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	187.0 (209.5 to 320.7)	269.9 (144.0 to 231.6)
Hemolytic disease and other neonatal jaundice	0.2 (0.0 to 0.5)	0.2 (0.1 to 0.4)	47.5 (-82.8 to 486.0)	-8.4 (-89.3 to 251.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	41.5 (-79.1 to 436.9)	-12.1 (-87.0 to 227.8)
Other neonatal disorders	-	-	-	-	0.2 (0.0 to 0.4)	0.2 (0.1 to 0.4)	26.8 (-55.2 to 294.0)	-20.0 (-71.7 to 145.5)
Nutritional deficiencies	-	-	-	-	0.8 (0.5 to 1.2)	0.9 (0.6 to 1.3)	8.4 (-1.5 to 16.6)	-30.1 (-36.8 to -25.1)
Protein-energy malnutrition	0.7 (0.5 to 1.1)	0.7 (0.5 to 1.0)	-2.5 (-45.3 to 73.0)	-26.6 (-57.0 to 23.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.1 (-45.5 to 74.8)	-26.3 (-57.1 to 24.8)
Iodine deficiency	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	25.0 (-0.4 to 56.9)	-33.8 (-47.1 to -15.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.8 (-3.2 to 62.6)	-32.1 (-48.5 to -12.4)
Vitamin A deficiency	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-13.2 (-29.2 to 5.1)	-45.9 (-56.0 to -36.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-18.1 (-34.8 to -0.5)	-49.8 (-59.7 to -40.2)

Appendix Table G.4 - Vanuatu prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013	
Iron-deficiency anemia	20.6 (20.0 to 21.3)	24.0 (22.9 to 25.4)	16.4 (9.6 to 24.1)	-28.3 (-33.1 to -23.0)	0.7 (0.5 to 1.0)	0.8 (0.5 to 1.1)	10.3 (0.6 to 16.6)	30.1 (-37.4 to -25.4)	
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-20.8 (-66.9 to 93.2)	-39.7 (-74.0 to 38.9)	
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	49.1 (29.6 to 72.4)	-15.3 (-26.5 to -2.5)	
Sexually transmitted diseases excluding HIV	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	84.7 (63.9 to 107.5)	-2.6 (-12.1 to 8.8)	
Syphilis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.8 (-0.9 to 35.4)	-39.3 (-47.1 to -30.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	14.9 (-18.5 to 61.6)	-39.7 (-55.1 to -18.1)	
Chlamydial infection	8.6 (7.2 to 10.1)	15.1 (12.6 to 17.8)	76.6 (34.2 to 125.8)	-5.3 (-27.0 to 19.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	81.1 (54.3 to 110.7)	-3.6 (-16.2 to 11.1)	
Gonococcal infection	1.7 (1.3 to 2.2)	3.0 (2.3 to 3.7)	71.4 (18.1 to 160.3)	-6.6 (-33.9 to 38.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.6 (45.2 to 156.9)	4.4 (-19.8 to 35.7)	
Trichomoniasis	1.3 (0.8 to 1.8)	3.2 (2.1 to 4.3)	153.5 (41.2 to 322.6)	0.0 (-25.3 to 113.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	164.2 (35.7 to 437.2)	32.3 (-28.9 to 157.4)	
Genital herpes	18.0 (17.5 to 18.4)	34.3 (33.5 to 35.0)	90.5 (84.3 to 97.2)	9.9 (-6.9 to -0.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	88.3 (76.1 to 98.4)	4.0 (-0.1 to 0.8)	
Other sexually transmitted diseases	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	43.7 (29.4 to 72.6)	-26.7 (-33.9 to -11.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.1 (10.6 to 95.0)	23.1 (-40.7 to -0.4)	
Hepatitis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.0 (-23.4 to 32.3)	-48.7 (-62.1 to -29.7)	
Hepatitis A	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.3)	48.5 (47.4 to 49.7)	-3.1 (-3.2 to -3.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.6 (47.2 to 87.3)	-0.4 (-11.3 to 11.1)	
Hepatitis B	25.5 (17.0 to 32.9)	19.3 (15.3 to 23.4)	-25.3 (-45.0 to 19.7)	-40.8 (-71.5 to -40.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-30.6 (-57.7 to 5.8)	-64.4 (-78.4 to -44.2)	
Hepatitis C	4.0 (3.5 to 4.5)	5.6 (5.0 to 6.2)	40.1 (19.9 to 65.3)	-26.5 (-36.2 to -14.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	36.4 (4.8 to 79.3)	-23.0 (-44.1 to 5.8)	
Hepatitis E	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	114.5 (78.1 to 160.8)	16.0 (-3.9 to 40.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	116.6 (67.4 to 186.8)	15.5 (-8.8 to 50.1)	
Leprosy	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	89.8 (-32.4 to 1,038.4)	0.4 (-61.0 to 547.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	96.3 (-33.1 to 1,843.5)	2.4 (-61.8 to 925.1)	
Other infectious diseases	0.9 (0.7 to 1.2)	1.1 (0.7 to 1.4)	11.9 (-20.1 to 55.5)	-25.4 (-45.9 to 2.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	30.2 (-7.6 to 92.6)	-8.0 (-33.1 to 35.4)	
Non-communicable diseases	-	-	-	-	8.5 (6.2 to 11.1)	15.7 (11.5 to 20.3)	81.1 (77.0 to 91.5)	5.2 (-4.6 to 2.3)	
Neoplasms	0.0	0.0	0.0	0.0	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.3)	0.2 (149.0 to 497.8)	270.6 (33.0 to 191.7)	
Esophageal cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	134.9 (12.6 to 454.3)	16.9 (-42.6 to 183.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	130.7 (15.9 to 431.1)	14.6 (-41.8 to 167.9)	
Stomach cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	162.2 (69.1 to 332.2)	31.0 (-11.9 to 111.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	156.3 (63.4 to 316.9)	29.1 (-15.2 to 100.5)	
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	382.6 (166.3 to 813.0)	152.4 (41.0 to 369.3)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	465.2 (169.8 to 1,169.5)	194.0 (39.3 to 548.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	440.5 (173.9 to 1,010.9)	178.0 (42.4 to 466.6)	
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,072.5 (415.2 to 2,988.5)	500.0 (152.6 to 1,408.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,007.1 (424.4 to 2,705.0)	470.0 (159.9 to 1,242.1)	
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	104.9 (-0.5 to 374.5)	7.2 (-49.2 to 147.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.1 (0.5 to 314.6)	2.7 (-48.5 to 120.1)	
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	188.3 (33.7 to 557.4)	49.9 (-31.7 to 239.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	172.3 (41.7 to 450.4)	41.5 (-28.2 to 182.0)	
Larynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2,515.8 (507.2 to 5,841.0)	1,521.1 (227.5 to 3,429.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,350.9 (265.2 to 3,411.3)	763.3 (90.7 to 1,981.1)	
Tracheal, bronchus and lung cancer	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	116.9 (37.7 to 254.2)	7.7 (-29.0 to 67.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	111.9 (32.7 to 241.1)	5.5 (-30.7 to 63.8)	
Breast cancer	0.2 (0.1 to 0.4)	1.2 (0.9 to 1.8)	524.8 (282.5 to 933.6)	231.0 (109.1 to 429.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	398.9 (211.3 to 749.4)	154.2 (62.3 to 315.9)	
Cervical cancer	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.5)	95.3 (9.2 to 274.8)	4.7 (-43.9 to 77.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	95.6 (10.0 to 272.1)	-4.4 (-43.0 to 77.9)	
Uterine cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	29.1 (50.1 to 442.3)	0.0 (-27.1 to 156.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	168.8 (41.9 to 419.4)	28.1 (-28.9 to 140.7)	
Prostate cancer	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	280.8 (124.5 to 546.3)	87.5 (14.2 to 210.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	260.3 (113.9 to 496.5)	81.0 (12.3 to 192.7)	
Colon and rectum cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	280.0 (150.8 to 504.3)	87.8 (29.3 to 178.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	257.4 (134.7 to 458.9)	77.8 (21.5 to 162.3)	
Lip and oral cavity cancer	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.0)	92.7 (11.8 to 237.3)	-6.7 (-45.9 to 59.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.3 (14.0 to 225.3)	-7.1 (-43.3 to 56.0)	
Nasopharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	113.8 (17.0 to 325.2)	4.6 (-41.3 to 103.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	108.3 (14.8 to 302.8)	2.2 (-41.8 to 93.5)	
Other pharynx cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.8 (-13.7 to 234.6)	-20.1 (56.5 to 53.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.2 (-11.5 to 207.4)	-21.3 (55.8 to 45.5)	
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.8 (5.1 to 254.4)	-1.9 (-48.4 to 73.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	91.9 (4.5 to 231.0)	-6.0 (-48.4 to 60.8)	
Pancreatic cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	179.9 (80.5 to 346.9)	44.1 (-4.5 to 117.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	178.2 (84.4 to 325.6)	44.8 (-1.0 to 107.9)	
Malignant skin melanoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	342.1 (98.3 to 512.7)	70.8 (5.4 to 189.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	210.7 (84.6 to 447.9)	56.7 (-4.8 to 158.3)	
Non-melanoma skin cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	217.8 (115.2 to 382.3)	55.3 (8.5 to 126.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	246.3 (105.1 to 500.4)	72.0 (3.5 to 190.7)	
Ovarian cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	139.5 (32.8 to 386.2)	20.0 (-30.7 to 134.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	137.2 (32.0 to 355.3)	20.3 (-29.4 to 121.5)	
Testicular cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	170.1 (33.8 to 431.5)	37.0 (-28.5 to 158.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	158.5 (27.2 to 430.1)	31.4 (-33.3 to 150.6)	
Kidney cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	161.6 (56.2 to 344.1)	22.1 (-25.6 to 100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	150.3 (46.9 to 325.2)	17.1 (-30.6 to 94.9)	
Bladder cancer	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	1,066.8 (196.3 to 3,457.8)	477.9 (53.6 to 2,046.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,138.9 (202.1 to 4,460.3)	505.0 (52.8 to 2,590.6)	
Brain and nervous system cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	180.3 (66.6 to 384.4)	48.0 (-7.8 to 142.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	169.4 (63.1 to 352.3)	37.3 (-14.0 to 133.2)	
Thyroid cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	193.1 (61.3 to 460.2)	47.0 (-16.2 to 177.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	187.9 (57.7 to 462.4)	42.3 (-16.8 to 166.7)	
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	140.3 (41.5 to 320.3)	27.2 (-23.3 to 116.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	138.1 (42.0 to 310.5)	26.4 (-22.4 to 111.7)	
Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	275.2 (112.2 to 646.1)	95.3 (17.7 to 266.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	235.2 (98.3 to 550.0)	71.2 (7.1 to 212.7)	
Non-Hodgkin lymphoma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	377.8 (126.9 to 812.8)	152.0 (17.5 to 366.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	359.2 (115.8 to 769.8)	139.6 (8.8 to 334.6)	
Multiple myeloma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	241.9 (77.7 to 576.7)	64.8 (-12.4 to 229.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	226.6 (72.6 to 562.7)	57.7 (-18.0 to 220.1)	
Leukemia	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	426.9 (193.2 to 851.8)	191.6 (82.6 to 377.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	385.3 (201.6 to 715.6)	148.9 (64.2 to 303.0)	
Other neoplasms	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	563.3 (227.3 to 1,102.8)	272.6 (78.2 to 554.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	521.5 (199.2 to 1,028.4)	233.4 (57.7 to 474.6)	
Cardiovascular diseases	-	-	-	-	0.4 (0.2 to 0.5)	0.8 (0.5 to 1.1)	104.4 (64.6 to 155.8)	8.4 (-10.2 to 30.6)	
Rheumatic heart disease	4.4 (3.0 to 5.7)	7.4 (5.3 to 9.2)	68.0 (19.7 to 143.6)	-7.8 (-30.8 to 34.4)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	67.3 (20.0 to 142.1)	-8.4 (-31.1 to 32.0)	
Ischemic heart disease	0.6 (0.5 to 0.8)	1.1 (0.9 to 1.3)	83.1 (30.5 to 135.2)	-9.0 (-34.1 to 15.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	96.9 (47.0 to 148.3)	-4.4 (-26.8 to 19.8)	
Cerebrovascular disease	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	106.6 (16.6 to 142.4)	0.3 (-16.6 to 21.8)	
Ischemic stroke	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	95.8 (61.3 to 144.1)	-1.0 (-18.7 to 22.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.4 (61.3 to 149.4)	-0.5 (-18.2 to 24.6)	
Hemorrhagic stroke	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	100.7 (68.1 to 139.3)	0.2 (-15.9 to 22.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	102.7 (64.7 to 147.4)	0.9 (-17.5 to 24.1)	
Hypertensive heart disease	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.3)	141.7 (98.7 to 186.7)	17.3 (-9.9 to 42.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	142.8 (96.7 to 196.7)	17.4 (-4.5 to 43.4)	
Cardiomyopathy and myocarditis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	150.4 (112.9 to 194.9)	27.4 (6.8 to 53.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	151.1 (110.0 to 202.1)	27.4 (5.5 to 55.7)	
Atrial fibrillation and flutter	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.2)	246.8 (119.4 to 460.3)	100.4 (24.8 to 228.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	251.0 (118.5 to 471.1)	100.6 (24.8 to 227.5)	
Peripheral vascular disease	1.3 (0.9 to 1.8)	3.0 (2.2 to 4.0)	128.7 (47.5 to 271.0)	13.2 (-24.8 to 73.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.6 (-26.2 to 154.8)	-22.4 (56.0 to 58.2)	
Endocarditis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	98.8 (49.3 to 158.9)	12.4 (-18.9 to 51.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.6 (48.4 to 176.0)	13.0 (-20.3 to 61.8)	
Other cardiovascular and circulatory diseases	0.8 (0.5 to 1.1)	2.6 (1.3 to 3.8)	237.8 (66.4 to 504.0)	65.4 (-18.7 to 202.2)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	237.2 (70.4 to 506.4)	65.2 (-18.6 to 205.0)	
Chronic respiratory diseases	-	-	-	-	0.5 (0.3 to 0.7)	0.8 (0.5 to 1.1)	69.0 (40.8 to 111.3)	-13.8 (

Appendix Table G.4 - Vanuatu prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.0	215.0	50.3
Silicosis	0.0	0.0	59.9	-22.2	0.0	0.0	(192.3 to 234.9)	(38.0 to 62.2)
Asbestosis	0.0	0.0	0.0	0.0	0.0	0.0	59.3	-22.3
Coal workers pneumoconiosis	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Other pneumoconiosis	0.0	0.0	291.8	94.4	0.0	0.0	283.2	89.9
Asthma	2.5	3.8	(275.0 to 309.8)	(86.5 to 103.7)	0.1	0.2	50.5	-19.8
Interstitial lung disease and pulmonary sarcoidosis	0.0	0.0	102.1	2.1	0.0	0.0	102.8	1.4
Other chronic respiratory diseases	0.0	0.0	0.0	0.0	0.1	0.1	8.5	-45.6
Cirrhosis	0.0	0.0	39.6	-24.0	0.0	0.0	21.1	-39.0
Cirrhosis due to hepatitis B	0.0	0.0	105.5 to 78.0	(-38.8 to -4.3)	0.0	0.0	(6.9 to 38.5)	(-40.8 to -24.9)
Cirrhosis due to hepatitis C	0.0	0.0	42.9	-21.2	0.0	0.0	2.8 to 88.3	(-42.1 to -0.8)
Cirrhosis due to alcohol use	0.0	0.0	(-8.8 to 138.3)	(-47.0 to 22.7)	0.0	0.0	(-12.3 to 148.1)	(-48.7 to 29.9)
Cirrhosis due to other causes	0.0	0.0	-61.4	-23.6	0.0	0.0	-23.2	-61.1
Digestive diseases	0.0	0.0	(-45.6 to 7.2)	(-71.8 to -46.6)	0.0	0.0	(-48.4 to 12.8)	(-73.4 to -43.5)
Peptic ulcer disease	1.0	1.2	2.4	-32.4	0.0	0.0	3.5	-32.1
Gastritis and duodenitis	1.0	1.4	(-25.0 to 49.1)	(-49.7 to -2.2)	0.1	0.2	(-37.9 to 68.6)	(-57.2 to 7.5)
Appendicitis	0.0	0.0	25.0	-30.8	0.0	0.0	42.5	-23.5
Paralytic ileus and intestinal obstruction	0.0	0.0	(5.2 to 78.1)	(-48.2 to -4.9)	0.0	0.0	(-17.6 to 97.6)	(-53.4 to 6.4)
Inguinal, femoral, and abdominal hernia	0.5	0.8	55.9	-17.5	0.0	0.0	56.3	-17.2
Inflammatory bowel disease	0.0	0.0	(36.6 to 75.0)	(-25.8 to -6.1)	0.0	0.0	(35.5 to 75.8)	(-26.0 to -5.6)
Vascular intestinal disorders	0.0	0.0	79.9	-8.4	0.0	0.0	78.3	-8.9
Gallbladder and biliary diseases	0.0	0.0	(68.8 to 91.9)	(-13.7 to -2.3)	0.0	0.0	(49.2 to 114.5)	(-22.3 to 8.5)
Pancreatitis	0.0	0.0	123.5	60.3	0.0	0.0	117.8	54.0
Other digestive diseases	0.0	0.0	(37.1 to 236.9)	(-17.3 to 144.0)	0.0	0.0	(33.5 to 227.2)	(-24.2 to 148.2)
Neurological disorders	0.1	0.1	79.0	9.3	0.0	0.0	79.1	9.1
Alzheimer disease and other dementias	0.4	0.7	(56.3 to 119.5)	(-11.8 to 23.6)	0.0	0.1	(52.3 to 115.6)	(-12.4 to 24.2)
Parkinson disease	0.1	0.1	96.3	-0.7	0.0	0.0	98.1	-0.1
Epilepsy	0.4	0.7	(86.3 to 109.1)	(-4.9 to 4.9)	0.0	0.0	(79.2 to 119.6)	(-8.9 to 9.9)
Multiple sclerosis	0.0	0.0	68.2	-0.8	0.1	0.2	82.0	7.2
Migraine	0.0	0.0	(16.8 to 148.7)	(-32.0 to 47.4)	0.0	0.0	(23.1 to 169.5)	(-27.7 to 59.1)
Tension-type headache	17.2	33.1	263.3	81.6	0.0	0.0	263.3	81.6
Medication overuse headache	0.4	1.2	(216.1 to 310.4)	(60.1 to 104.0)	0.0	0.0	(215.9 to 310.5)	(60.1 to 104.1)
Other neurological disorders	0.0	0.0	90.8	2.6	0.0	0.6	89.7	2.1
Mental and substance use disorders	0.4	0.7	(24.3 to 154.6)	(-30.5 to 39.8)	0.0	0.3	(23.7 to 155.4)	(-31.4 to 39.3)
Schizophrenia	0.4	0.7	93.6	2.1	0.0	0.1	93.7	2.2
Alcohol use disorders	0.3 to 0.5	(0.8 to 1.6)	(56.6 to 133.5)	(-17.2 to 17.1)	0.0	0.0	(55.2 to 134.0)	(-17.5 to 23.7)
Drug use disorders	0.0	0.0	203.7	55.7	0.1	0.2	202.5	54.7
Opioid use disorders	0.0	0.0	(153.3 to 262.5)	(32.1 to 84.9)	0.0	0.1	(152.8 to 268.0)	(31.6 to 85.6)
Cocaine use disorders	0.0	0.0	75.3	2.0	0.0	0.0	42.6	-19.4
Amphetamine use disorders	0.0	0.0	(31.5 to 140.6)	(-23.0 to 38.2)	0.0	0.0	(-10.4 to 133.1)	(-49.3 to 30.1)
Cannabis use disorders	0.0	0.0	0.0	0.0	2.2	4.0	86.8	0.5
Other drug use disorders	0.0	0.0	0.0	0.0	(1.6 to 2.8)	(2.9 to 5.2)	(81.7 to 92.2)	(-1.9 to 2.8)
Depressive disorders	0.4	0.7	97.5	-0.4	0.2	0.5	97.3	-0.4
Major depressive disorder	0.3 to 0.4	(0.7 to 0.8)	(88.6 to 105.3)	(-4.8 to 3.6)	0.2 to 0.3	(0.3 to 0.6)	(85.3 to 110.5)	(-6.2 to 5.7)
Dysthymia	0.9	2.1	151.9	31.4	0.1	0.2	152.6	31.8
Bipolar disorder	0.0	0.0	(136.6 to 167.8)	(23.7 to 39.2)	0.1 to 0.1	(0.1 to 0.3)	(133.9 to 174.4)	(22.6 to 42.0)
Anxiety disorders	0.0	0.0	0.0	0.0	0.2	0.4	75.4	-5.6
Eating disorders	0.1	0.3	98.8	1.5	0.1	0.1	98.5	1.4
Anorexia nervosa	0.1 to 0.2	(0.2 to 0.3)	(79.8 to 126.9)	(-8.3 to 14.6)	0.0 to 0.1	(0.1 to 0.2)	(74.0 to 131.6)	(-11.2 to 17.0)
Bulimia nervosa	0.1	0.2	87.1	0.0	0.0	0.0	87.8	-0.1
Autistic spectrum disorders	0.1 to 0.1	(0.2 to 0.2)	(71.5 to 107.0)	(-8.9 to 9.6)	0.0 to 0.0	(0.0 to 0.0)	(60.0 to 127.5)	(-15.8 to 19.0)
Autism	0.5	0.8	61.3	-11.4	0.1	0.1	60.2	-11.8
Asperger syndrome	0.4 to 0.5	(0.6 to 0.9)	(29.0 to 102.0)	(-28.0 to 9.4)	0.0 to 0.1	(0.1 to 0.2)	(26.2 to 105.9)	(-29.4 to 11.8)
Attention-deficit/hyperactivity disorder	0.5	0.9	81.9	-0.0	0.0	0.0	82.1	0.1
Conduct disorder	0.4 to 0.5	(0.8 to 1.0)	(81.0 to 83.0)	(-0.1 to 0.1)	0.0 to 0.0	(0.0 to 0.0)	(61.9 to 104.2)	(-10.8 to 11.5)
Idiopathic intellectual disability	0.0	0.0	0.0	0.0	0.1	0.1	66.4	-9.0
Other mental and substance use disorders	0.0	0.0	0.0	0.0	(0.0 to 0.1)	(0.1 to 0.2)	(22.3 to 135.5)	(-32.8 to 27.5)
Diabetes, urogenital, blood, and endocrine diseases	0.0	0.0	0.0	0.0	0.6	1.2	91.7	0.8
Diabetes mellitus	2.4	4.6	90.2	0.7	0.4 to 0.9	(0.8 to 1.7)	(80.5 to 101.6)	(-4.6 to 5.4)
Acute glomerulonephritis	1.4	2.8	99.7	1.2	0.5	1.0	89.6	0.6
Chronic kidney disease	0.0	0.1	57.2	-11.2	0.0	0.0	56.5	-11.7
Chronic kidney disease due to diabetes mellitus	0.0 to 0.1	(0.0 to 0.1)	(39.7 to 78.6)	(-21.7 to 0.5)	0.0 to 0.0	(0.0 to 0.0)	(25.4 to 96.2)	(-29.3 to 9.8)
Chronic kidney disease due to hypertension	0.0	0.0	80.5	-0.7	0.0	0.0	79.4	-1.2
Chronic kidney disease due to glomerulonephritis	0.0 to 0.0	(0.0 to 0.1)	(77.5 to 82.5)	(-1.2 to -0.4)	0.0 to 0.0	(0.0 to 0.0)	(49.2 to 118.2)	(-18.2 to 19.6)
Chronic kidney disease due to other causes	0.0	0.0	0.0	0.0	0.2	0.3	69.5	-1.1
Urinary diseases and male infertility	0.5	0.8	70.2	-1.0	0.1 to 0.2	(0.2 to 0.4)	(63.3 to 76.1)	(-4.2 to 2.4)
Diabetes mellitus	0.7	1.1	69.3	-1.4	0.1	0.1	69.1	-1.2
Acute glomerulonephritis	0.6 to 0.7	(1.0 to 1.2)	(68.5 to 70.1)	(-1.5 to -1.3)	0.0 to 0.1	(0.1 to 0.2)	(61.7 to 76.4)	(-5.1 to 2.6)
Chronic kidney disease	1.1	1.8	57.7	-0.1	0.0	0.0	57.7	-0.0
Chronic kidney disease due to diabetes mellitus	1.1 to 1.2	(1.6 to 1.9)	(57.3 to 58.0)	(-0.1 to -0.0)	0.0 to 0.0	(0.0 to 0.0)	(46.2 to 69.7)	(-7.3 to 7.8)
Chronic kidney disease due to hypertension	0.5	0.7	23.2	-34.1	0.0	0.0	23.4	-24.1
Chronic kidney disease due to glomerulonephritis	0.3 to 0.9	(0.4 to 1.2)	(-12.7 to 75.4)	(-45.3 to 6.7)	0.0 to 0.0	(0.0 to 0.1)	(-13.5 to 78.3)	(-45.8 to 7.8)
Chronic kidney disease due to other causes	1.8	3.6	95.0	-1.4	0.1	0.3	95.1	-1.3
Diabetes, urogenital, blood, and endocrine diseases	1.7 to 2.0	(3.4 to 3.8)	(93.9 to 96.1)	(-1.8 to -1.0)	0.1 to 0.2	(0.2 to 0.4)	(87.1 to 102.8)	(-4.9 to 2.2)
Diabetes mellitus	4.5	9.7	116.6	9.0	1.0	2.6	84.6	3.5
Acute glomerulonephritis	0.0	0.0	0.0	0.0	(0.7 to 1.4)	(1.3 to 2.6)	(68.4 to 99.4)	(-7.6 to 12.7)
Chronic kidney disease	0.0	0.0	(70.1 to 177.6)	(-16.1 to 37.5)	0.3	0.6	121.8	10.9
Chronic kidney disease due to diabetes mellitus	0.0	0.0	81.8	8.7	0.0 to 0.4	(0.4 to 0.9)	(71.6 to 176.4)	(-16.1 to 36.6)
Chronic kidney disease due to hypertension	0.0	0.0	0.0	0.0	0.0	0.0	81.8	8.7
Chronic kidney disease due to glomerulonephritis	0.0 to 0.0	(0.0 to 0.0)	(69.8 to 94.6)	(3.0 to 14.2)	0.0 to 0.0	(0.0 to 0.0)	(69.7 to 94.6)	(2.9 to 14.2)
Chronic kidney disease due to other causes	0.5	1.4	197.2	58.5	0.1	0.2	83.4	1.5
Urinary diseases and male infertility	0.3 to 0.7	(1.0 to 1.9)	(97.4 to 318.2)	(6.3 to 122.6)	0.0 to 0.0	(0.0 to 0.0)	(65.2 to 102.1)	(-6.7 to 12.0)
Diabetes mellitus	1.0	0.7	-28.9	-56.0	0.0	0.0	76.6	-4.3
Acute glomerulonephritis	0.6 to 1.6	(0.5 to 0.9)	(53.4 to 0.5)	(-66.6 to -40.8)	0.0 to 0.0	(0.0 to 0.1)	(31.7 to 136.0)	(-27.1 to 28.8)
Chronic kidney disease	1.1	1.8	59.3	8.2	0.0	0.0	59.3	8.2
Chronic kidney disease due to diabetes mellitus	0.8 to 1.6	(1.1 to 2.8)	(12.6 to 117.9)	(-35.0 to 27.7)	0.0 to 0.0	(0.0 to 0.0)	(-52.5 to -7.2)	(-70.3 to -39.4)
Chronic kidney disease due to hypertension	2.4	4.9	104.2	8.6	0.0	0.1	113.3	10.2
Chronic kidney disease due to glomerulonephritis	1.6 to 3.5	(3.4 to 7.0)	(68.5 to 165.8)	(-8.5 to 34.7)	0.0 to 0.1	(0.1 to 0.1)	(79.1 to 177.4)	(-7.5 to 45.1)
Chronic kidney disease due to other causes	0.0	0.0	0.0	0.0	0.1	0.1	82.9	-8.8
Urinary diseases and male infertility	0.0	0.0	0.0	0.0	(0.0 to 0.1)	(0.1 to 0.1)	(64.2 to 104.9)	(-1.8 to 3.4)

Appendix Table G.4 - Vanuatu prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	125.3 (107.3 to 146.2)	28.4 (19.0 to 38.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	134.8 (75.1 to 182.0)	28.3 (3.2 to 56.5)
Urolithiasis	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.6)	68.5 (53.7 to 83.0)	-11.8 (-20.0 to -2.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.1 (59.5 to 100.3)	-8.8 (-17.0 to 0.2)
Benign prostatic hyperplasia	1.0 (0.9 to 1.0)	1.7 (1.5 to 1.9)	77.3 (54.6 to 105.6)	-11.3 (-22.9 to 3.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	78.5 (55.9 to 107.6)	-11.0 (-22.2 to 4.2)
Male infertility due to other causes	1.0 (0.8 to 1.2)	2.0 (1.5 to 2.4)	94.0 (38.8 to 152.3)	2.6 (-26.9 to 33.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	93.1 (38.7 to 156.3)	1.9 (-27.1 to 35.0)
Other urinary diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1.3 (0.7 to 2.0)	2.3 (0.0 to 4.6)
Gynecological diseases	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	82.1 (60.2 to 108.8)	-6.9 (-17.8 to 5.4)
Uterine fibroids	2.2 (2.0 to 2.4)	4.7 (4.3 to 5.2)	112.6 (110.9 to 114.5)	5.0 (4.6 to 5.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	71.4 (55.9 to 88.5)	-14.3 (-22.1 to -6.0)
Polycystic ovarian syndrome	1.8 (1.6 to 2.0)	3.4 (3.0 to 3.8)	90.9 (62.0 to 121.8)	-1.5 (-15.4 to 13.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	90.9 (61.9 to 122.2)	-1.3 (-14.9 to 13.8)
Female infertility due to other causes	1.2 (0.9 to 1.4)	2.3 (1.9 to 2.8)	102.5 (49.9 to 178.1)	8.1 (-21.5 to 49.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.0 (49.3 to 175.2)	6.7 (-21.0 to 46.4)
Endometriosis	0.2 (0.2 to 0.3)	0.4 (0.4 to 0.5)	92.8 (55.7 to 142.6)	-0.2 (-18.9 to 25.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	92.6 (49.9 to 147.7)	-0.3 (-21.6 to 28.3)
Genital prolapse	5.1 (4.4 to 5.8)	10.3 (8.6 to 11.7)	103.2 (64.8 to 145.1)	2.0 (-15.3 to 19.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	102.3 (64.7 to 144.1)	1.9 (-16.2 to 19.9)
Premenstrual syndrome	3.7 (2.4 to 5.1)	6.9 (4.9 to 9.7)	83.2 (20.7 to 221.2)	-5.7 (-39.9 to 57.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	83.8 (19.1 to 227.5)	-6.3 (-40.4 to 63.3)
Other gynecological diseases	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	36.5 (0.3 to 88.8)	-27.8 (-47.1 to 1.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	18.0 (-30.7 to 114.4)	-38.2 (-62.8 to 15.4)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	0.4 (0.2 to 0.5)	0.5 (0.4 to 0.9)	62.6 (47.4 to 84.4)	4.2 (-5.4 to 19.6)
Thalassemias	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.2)	47.1 (37.6 to 60.4)	-0.2 (-6.7 to 9.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	48.0 (13.0 to 96.1)	1.5 (-22.8 to 35.3)
Thalassemia trait	14.1 (13.0 to 15.3)	23.9 (22.0 to 26.0)	68.6 (63.2 to 76.3)	-1.1 (-4.4 to 3.4)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.8)	67.4 (50.4 to 91.0)	6.8 (-4.0 to 23.4)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-5.8 (-17.8 to 0.5)	-39.1 (-46.8 to -35.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.7 (-15.2 to 13.1)	-34.9 (-46.4 to -28.5)
Sickle cell trait	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	19.2 (8.1 to 25.5)	-0.3 (-36.8 to 26.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.1 (1.1 to 16.3)	34.3 (-37.3 to -30.4)
G6PD deficiency	8.8 (7.6 to 10.0)	15.4 (13.2 to 17.7)	75.7 (41.8 to 113.4)	2.9 (-16.8 to 25.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.7 (21.1 to 193.5)	8.4 (-23.8 to 60.4)
G6PD trait	33.6 (32.7 to 34.3)	58.1 (56.4 to 59.7)	72.6 (66.1 to 79.2)	2.8 (-1.0 to 6.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.2 (90.5 to 3,536.7)	10.3 (-92.1 to 1,377.2)
Other hemoglobinopathies and hemolytic anemias	0.7 (0.5 to 0.9)	0.8 (0.6 to 0.9)	11.0 (-16.1 to 54.1)	-30.9 (-46.9 to -7.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.6 (-28.6 to 83.5)	-28.7 (-53.4 to 25.8)
Endocrine, metabolic, blood, and immune disorders	1.4 (1.1 to 1.6)	2.0 (1.6 to 2.3)	41.1 (14.6 to 72.6)	0.0 (-23.0 to 6.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	29.6 (12.4 to 80.6)	4.8 (-22.7 to 13.9)
Musculoskeletal disorders	-	-	-	-	1.5 (1.0 to 2.0)	3.0 (2.1 to 4.1)	105.5 (82.7 to 132.4)	2.8 (-6.9 to 14.0)
Rheumatoid arthritis	0.1 (0.1 to 0.1)	0.4 (0.4 to 0.4)	245.8 (228.5 to 263.7)	77.1 (66.9 to 86.7)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	244.4 (214.1 to 282.5)	76.8 (62.7 to 93.3)
Osteoarthritis	1.7 (1.6 to 1.8)	3.6 (3.4 to 3.7)	110.5 (98.3 to 124.3)	3.4 (-2.4 to 9.4)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.3)	111.2 (98.1 to 125.4)	3.3 (-3.0 to 9.6)
Low back and neck pain	-	-	-	-	1.1 (0.7 to 1.5)	2.2 (1.5 to 3.1)	101.7 (72.9 to 137.9)	1.8 (-11.3 to 18.1)
Low back pain	6.3 (5.8 to 6.7)	12.4 (11.6 to 13.2)	96.9 (79.3 to 117.6)	0.3 (-7.5 to 9.9)	0.7 (0.5 to 1.0)	1.4 (0.9 to 2.0)	96.9 (79.1 to 118.1)	0.5 (-7.8 to 9.9)
Neck pain	3.9 (2.2 to 5.2)	8.2 (6.0 to 11.5)	111.3 (37.4 to 231.6)	5.1 (-29.3 to 48.3)	0.4 (0.2 to 0.6)	0.8 (0.5 to 1.3)	110.6 (37.7 to 235.3)	5.2 (-29.4 to 48.5)
Gout	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	108.7 (89.6 to 131.9)	0.1 (-9.2 to 10.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	110.5 (71.8 to 157.5)	0.9 (-17.4 to 22.1)
Other musculoskeletal disorders	2.7 (2.1 to 3.2)	5.4 (4.3 to 6.6)	103.4 (87.7 to 122.8)	-2.0 (-8.3 to 6.1)	0.2 (0.2 to 0.4)	0.5 (0.3 to 0.7)	103.4 (86.8 to 123.6)	-2.1 (-9.0 to 7.2)
Other non-communicable diseases	-	-	-	-	2.2 (1.5 to 3.2)	3.6 (2.4 to 5.2)	62.8 (50.9 to 71.0)	-9.7 (-13.9 to -6.3)
Congenital anomalies	-	-	-	-	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	45.3 (9.8 to 85.7)	-9.3 (-42.9 to 14.6)
Neural tube defects	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.2 (30.1 to 96.3)	-1.7 (-17.3 to 24.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.9 (13.8 to 121.5)	-0.8 (-26.1 to 41.5)
Congenital heart anomalies	0.4 (0.3 to 0.5)	0.7 (0.6 to 0.8)	73.4 (22.8 to 125.7)	8.3 (-23.3 to 41.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.7 (21.6 to 122.0)	7.8 (-23.2 to 41.9)
Orofacial clefts	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	64.0 (26.2 to 115.2)	5.0 (-19.6 to 38.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	63.3 (8.0 to 147.0)	2.6 (-30.3 to 55.3)
Down syndrome	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	73.8 (37.7 to 109.3)	4.7 (-16.6 to 26.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.4 (38.0 to 124.6)	6.2 (-16.7 to 32.7)
Turner syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.0 (19.5 to 136.8)	4.0 (-27.4 to 43.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.6 (17.0 to 146.1)	3.5 (-30.7 to 47.5)
Klinefelter syndrome	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.0 (20.0 to 158.3)	4.9 (-29.8 to 51.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	90.4 (12.7 to 215.4)	4.9 (-37.8 to 72.1)
Chromosomal unbalanced rearrangements	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.3)	61.2 (38.7 to 113.0)	4.7 (-15.6 to 29.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.3 (42.0 to 121.8)	6.3 (-15.8 to 33.2)
Other congenital anomalies	0.5 (0.4 to 0.6)	0.8 (0.7 to 0.9)	47.2 (31.7 to 62.1)	-13.8 (-22.3 to -5.0)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.4)	34.4 (-24.3 to 88.3)	-15.8 (-52.4 to 17.2)
Skin and subcutaneous diseases	-	-	-	-	1.0 (0.6 to 1.5)	1.6 (1.0 to 2.5)	65.6 (51.8 to 77.7)	-5.5 (-12.6 to 0.8)
Dermatitis	8.0 (6.5 to 9.7)	14.1 (11.4 to 17.1)	76.5 (73.0 to 79.5)	0.2 (0.0 to 0.3)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	70.6 (62.9 to 77.4)	0.2 (-2.6 to 2.9)
Psoriasis	0.8 (0.7 to 1.0)	1.6 (1.4 to 1.8)	88.4 (86.5 to 90.8)	0.1 (-0.4 to 0.2)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	88.1 (75.8 to 101.2)	0.0 (-5.5 to 5.5)
Cellulitis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.7 (20.8 to 51.4)	-16.0 (-23.1 to -7.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	35.5 (0.2 to 82.8)	-15.4 (-31.7 to 5.5)
Pyoderma	0.2 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-31.4 (-42.3 to -17.2)	-51.9 (-59.1 to -43.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-31.3 (-43.7 to -15.6)	-52.1 (-59.9 to -42.4)
Scabies	7.0 (5.4 to 8.3)	9.2 (7.1 to 11.6)	32.0 (4.9 to 74.3)	-25.5 (-45.9 to -3.0)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	31.8 (4.9 to 75.1)	-25.5 (-46.1 to -2.6)
Fungal skin diseases	14.6 (12.1 to 17.1)	26.5 (22.2 to 30.7)	81.5 (77.6 to 85.7)	0.1 (-0.3 to 0.2)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	81.3 (47.9 to 85.8)	-0.1 (-0.8 to 0.6)
Viral skin diseases	3.4 (2.6 to 4.1)	5.4 (4.2 to 6.7)	59.8 (52.7 to 66.7)	0.1 (-2.0 to 2.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	59.8 (50.8 to 68.8)	0.1 (-3.2 to 3.6)
Acne vulgaris	10.4 (7.7 to 13.4)	18.7 (14.1 to 23.9)	79.7 (22.8 to 152.5)	4.1 (-29.4 to 44.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	79.3 (22.6 to 152.0)	4.1 (-29.3 to 45.2)
Alopecia areata	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	86.1 (47.6 to 124.0)	4.2 (-16.5 to 26.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.0 (43.5 to 131.9)	4.0 (-16.6 to 26.5)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	80.2 (36.9 to 134.2)	4.8 (-28.5 to 25.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.0 (32.0 to 151.1)	-5.7 (-31.1 to 31.7)
Urticaria	1.3 (1.0 to 1.7)	2.2 (1.7 to 2.8)	73.4 (9.9 to 144.8)	-4.8 (-37.1 to 29.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	73.0 (9.9 to 147.7)	-5.0 (-37.4 to 30.2)
Decubitus ulcer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	33.3 (8.8 to 94.7)	-18.1 (-44.7 to 22.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	31.5 (-12.0 to 102.5)	-18.3 (-47.5 to 29.0)
Other skin and subcutaneous diseases	8.9 (6.2 to 12.6)	15.9 (11.0 to 22.6)	78.7 (69.2 to 89.2)	-6.8 (-11.2 to -2.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	78.8 (69.0 to 90.1)	-6.7 (-11.1 to -2.4)
Sense organ diseases	-	-	-	-	0.8 (0.6 to 1.2)	1.3 (0.9 to 1.9)	63.6 (56.1 to 71.4)	-11.6 (-14.5 to -8.8)
Glaucoma	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	79.7 (48.0 to 116.8)	-3.9 (-23.7 to 19.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	87.8 (45.4 to 131.7)	2.2 (-21.9 to 28.3)
Cataract	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	29.0 (4.3 to 85.0)	-29.9 (-43.2 to -3.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.4 (6.5 to 68.1)	-29.1 (-40.3 to -9.6)
Macular degeneration	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	75.2 (33.1 to 142.1)	-14.9 (-36.0 to 19.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.8 (31.6 to 129.5)	-15.4 (-35.4 to 14.1)
Uncorrected refractive error	7.9 (7.2 to 8.5)	14.1 (13.0 to 15.2)	78.5 (61.3 to 97.6)	6.0 (-14.3 to 2.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	68.0 (51.0 to 77.9)	-33.7 (-19.5 to -68.8)
Age-related and other hearing loss	15.9 (14.8 to 17.1)	28.5 (26.6 to 30.7)	79.1 (71.6 to 85.4)	-9.4 (-12.5 to -6.9)	0.1 (0.3 to 0.7)	0.9 (0.6 to 1.2)	66.2 (55.7 to 77.5)	-10.2 (-14.0 to -6.3)
Other vision loss	0.5 (0.4 to 0.6)	0.7 (0.5 to 0.8)	38.0 (19.8 to 54.5)	0.7 (-35.5 to -14.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	34.1 (15.4 to 51.2)	-27.9 (-36.8 to -17.9)
Other sense organ diseases	3.5 (3.3 to 3.7)	5.7 (5.4 to 6.0)	65.2 (53.4 to 77.5)	0.9 (-5.3 to 7.5)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	64.8 (51.7 to 78.8)	1.0 (-6.0 to 8.5)
Oral disorders	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	71.4 (61.7 to 81.4)	-13.4 (-18.7 to -8.5)
Deciduous caries	19.2 (18.9 to 19.5)	27.1 (26.6 to 27.7)	41.5 (37.4 to 45.3)	0.2 (-2.7 to 2.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.5 (33.4 to 50.0)	0.2 (-5.5 to 6.2)
Permanent caries	44.4 (42.1 to 46.6)	82.0 (78.5 to 85.8)	84.6 (72.9 to 97.5)	1.9 (-3.4 to 8.4)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	84.4 (72.8 to 97.9)	1.8 (-3.7 to 8.7)
Periodontal diseases	1.0 (1.0 to 1.1)	2.1 (2.0 to 2.3)	107.0 (87.3 to 125.3)	0.4 (-9.0 to 8.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.3 (87.0 to 125.4)	0.4 (-8.8 to 8.5)

Appendix Table G.4 - Vanuatu prevalence and YIDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YIDs 1990 (thousands)	YIDs 2013 (thousands)	% change YIDs, 1990 to 2013	% change age-standardized YIDs, 1990 to 2013
Edentulism and severe tooth loss	1.4 (1.4 to 1.5)	1.9 (1.8 to 2.0)	34.2 (23.5 to 45.0)	-33.5 (-38.7 to -28.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	35.1 (23.7 to 46.0)	-33.4 (-38.9 to -28.1)
Other oral disorders	2.2 (2.0 to 2.3)	4.0 (3.8 to 4.2)	86.2 (69.8 to 107.1)	-0.3 (-8.3 to 10.0)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	85.8 (68.4 to 106.8)	-0.2 (-8.4 to 10.3)
Injuries	-	-	-	-	0.3 (0.2 to 0.4)	0.5 (0.4 to 0.7)	73.3 (62.4 to 86.0)	-7.7 (-12.9 to -1.5)
Transport injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	74.8 (60.9 to 92.0)	-7.8 (-14.2 to 0.0)
Road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	76.8 (62.2 to 94.9)	-6.0 (-12.9 to 2.1)
Pedestrian road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.4 (56.8 to 96.6)	-3.7 (-12.5 to 6.3)
Cyclist road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.9 (59.8 to 93.0)	-6.2 (-13.6 to 3.6)
Motorcyclist road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	69.6 (53.8 to 88.8)	-11.3 (-19.0 to -2.3)
Motor vehicle road injuries	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	83.8 (64.7 to 106.6)	-2.0 (-11.2 to 8.4)
Other road injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	75.9 (59.9 to 94.7)	8.7 (-16.3 to 0.1)
Other transport injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	65.3 (51.7 to 82.2)	-15.6 (-22.2 to -7.3)
Unintentional injuries	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	80.7 (70.3 to 91.9)	-4.4 (-9.4 to 0.8)
Falls	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	65.5 (52.4 to 80.2)	-11.8 (-18.0 to -5.2)
Drowning	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.0 (23.3 to 54.8)	-24.4 (-31.6 to -16.6)
Fire, heat, and hot substances	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	17.6 (5.4 to 30.6)	-35.2 (-41.4 to -29.2)
Poisonings	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	20.4 (0.5 to 44.0)	-32.9 (-43.0 to -21.8)
Exposure to mechanical forces	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	107.1 (95.1 to 122.2)	8.8 (2.7 to 15.9)
Unintentional firearm injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.1 (18.8 to 41.5)	-32.4 (-37.5 to -26.5)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	82.2 (65.2 to 99.2)	-1.7 (-9.6 to 6.9)
Other exposure to mechanical forces	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	113.8 (101.1 to 129.7)	12.2 (5.8 to 19.7)
Adverse effects of medical treatment	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	97.3 (86.1 to 110.5)	5.4 (-0.8 to 12.8)
Animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	68.0 (56.1 to 82.3)	-11.8 (-17.3 to -5.5)
Venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	79.1 (59.3 to 101.5)	-6.5 (-15.5 to 3.4)
Non-venomous animal contact	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	58.8 (45.7 to 72.0)	-15.7 (-22.1 to -9.8)
Foreign body	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.7 (46.3 to 69.7)	-13.7 (-19.5 to -7.9)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.4 (6.9 to 44.4)	-23.5 (-32.5 to -13.5)
Foreign body in eyes	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.6 (58.5 to 80.5)	-7.8 (-14.0 to -2.0)
Foreign body in other body part	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	70.3 (55.3 to 87.2)	-11.9 (-19.1 to -3.6)
Other unintentional injuries	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	118.7 (99.8 to 136.6)	14.8 (5.5 to 23.4)
Self-harm and interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	39.3 (28.4 to 52.3)	-27.9 (-33.2 to -21.7)
Self-harm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	49.5 (33.6 to 67.4)	-25.0 (-32.5 to -17.2)
Interpersonal violence	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	34.8 (23.4 to 49.6)	-29.2 (-34.8 to -22.5)
Assault by firearm	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.2 (32.3 to 58.4)	-22.9 (-28.5 to -16.0)
Assault by sharp object	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	47.6 (32.2 to 65.4)	-24.0 (-31.1 to -15.5)
Assault by other means	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	23.3 (16.9 to 44.4)	-31.9 (-38.0 to -24.6)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	39.3 (20.5 to 64.2)	-14.2 (-26.4 to 0.5)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	39.3 (20.5 to 64.2)	-14.2 (-26.4 to 0.5)
Collective violence and legal intervention	-	-	-	-	-	-	-	-

Appendix Table G.4 - Venezuela prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,695.0 (1,241.8 to 2,197.6)	2,985.8 (2,225.2 to 3,874.6)	75.9 (70.1 to 83.3)	-0.3 (-3.2 to 3.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	196.9 (139.3 to 275.0)	260.0 (182.6 to 364.7)	31.5 (21.5 to 45.3)	-5.5 (-13.0 to 4.6)
HIV/AIDS and tuberculosis	-	-	-	-	3.9 (2.5 to 5.7)	8.2 (5.4 to 11.7)	113.3 (50.0 to 224.4)	16.1 (-17.1 to 74.2)
Tuberculosis	9.0 (8.5 to 9.5)	14.6 (14.0 to 15.2)	62.4 (55.4 to 71.1)	-12.1 (-15.9 to -8.1)	2.8 (1.9 to 3.8)	4.4 (3.0 to 6.0)	61.5 (42.2 to 83.3)	-11.8 (-21.3 to -1.4)
HIV/AIDS	-	-	-	-	1.1 (0.2 to 2.6)	3.8 (2.1 to 6.2)	268.3 (40.1 to 1,781.1)	103.2 (-21.4 to 982.9)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	56.9 (-53.4 to 906.9)	-17.8 (-75.9 to 465.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	56.9 (-53.5 to 953.7)	-17.8 (-75.9 to 478.5)
HIV/AIDS resulting in other diseases	8.4 (2.6 to 16.5)	47.0 (34.2 to 64.8)	473.1 (172.2 to 2,092.4)	246.4 (63.1 to 1,232.2)	1.1 (0.2 to 2.6)	3.8 (2.1 to 6.2)	266.3 (40.3 to 1,890.2)	104.7 (-21.2 to 1,062.0)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	46.6 (32.3 to 64.5)	54.0 (37.1 to 76.1)	15.3 (7.4 to 25.5)	-12.0 (-17.7 to -5.5)
Diarrheal diseases	136.2 (127.9 to 144.1)	150.7 (141.5 to 159.8)	10.5 (1.8 to 20.3)	-6.4 (-13.4 to 1.2)	22.1 (15.1 to 31.3)	24.5 (16.5 to 33.9)	9.3 (-0.5 to 20.6)	-7.1 (-15.0 to 2.0)
Intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-43.6 to -9.0)	-26.3 (-60.1 to -35.8)
Typhoid fever	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	-7.7 (-23.9 to 11.9)	-34.9 (-45.8 to -20.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-24.0 to 11.9)	-7.7 (-45.8 to -20.8)
Paratyphoid fever	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-5.6 (-24.3 to 15.6)	-31.7 (-45.2 to -16.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-24.3 to 15.8)	-31.7 (-45.2 to -16.1)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-91.7 (-91.7 to -91.7)	-94.1 (-98.0 to -43.8)
Lower respiratory infections	23.8 (17.0 to 29.5)	26.0 (22.4 to 29.8)	9.6 (-13.7 to 50.9)	-22.3 (-36.3 to 2.0)	2.5 (1.5 to 3.8)	2.7 (1.8 to 3.9)	8.7 (-15.4 to 52.8)	21.9 (-36.8 to 3.5)
Upper respiratory infections	958.1 (854.9 to 1,070.7)	1,405.0 (1,254.0 to 1,546.4)	47.1 (23.3 to 70.2)	0.2 (-15.8 to 15.2)	11.3 (6.3 to 18.9)	16.5 (9.2 to 27.9)	47.1 (22.8 to 70.9)	0.4 (-15.8 to 15.9)
Otitis media	260.6 (243.9 to 275.3)	329.3 (313.8 to 348.0)	26.1 (18.3 to 35.4)	-12.5 (-18.0 to -6.4)	5.0 (2.9 to 8.1)	6.2 (3.6 to 9.9)	23.6 (13.5 to 34.1)	-13.7 (-20.1 to -6.9)
Meningitis	-	-	-	-	3.7 (2.4 to 5.4)	2.4 (1.6 to 3.3)	-35.8 (-48.6 to -22.4)	-55.9 (-64.0 to -46.2)
Pneumococcal meningitis	18.1 (10.9 to 28.9)	12.6 (7.7 to 20.5)	-30.8 (-42.7 to -15.4)	-56.1 (-63.4 to -47.5)	1.7 (1.1 to 2.5)	1.1 (0.8 to 1.6)	-22.2 (-49.1 to -6.1)	-54.1 (-65.1 to -38.7)
H influenzae type B meningitis	7.7 (2.4 to 16.7)	4.3 (1.4 to 9.3)	-43.7 (-61.2 to -9.6)	-63.3 (-73.5 to -36.6)	0.9 (0.5 to 1.6)	0.6 (0.3 to 0.9)	-41.5 (-65.6 to 9.1)	-59.2 (-75.9 to -24.0)
Meningococcal meningitis	1.4 (0.5 to 3.2)	0.9 (0.3 to 2.3)	-35.0 (-58.0 to -1.3)	-58.0 (-69.9 to -36.8)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.2)	-41.3 (-62.2 to -0.7)	-60.5 (-73.3 to -34.8)
Other meningitis	7.0 (3.1 to 14.3)	4.2 (2.0 to 8.5)	-39.3 (-52.6 to -21.7)	-59.4 (-67.7 to -45.1)	0.9 (0.5 to 1.4)	0.6 (0.3 to 0.8)	-36.9 (-56.1 to -13.7)	-55.5 (-68.4 to -39.4)
Encephalitis	1.6 (0.7 to 3.9)	2.8 (1.2 to 6.9)	75.3 (42.9 to 106.4)	4.5 (-10.6 to 27.6)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.5)	81.5 (39.5 to 122.9)	11.5 (-11.4 to 35.7)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-95.5 to 470.9)	0.0 (0.0 to 0.0)	-	-
Whooping cough	22.9 (17.6 to 29.4)	13.8 (10.8 to 17.7)	-39.5 (-41.8 to -37.2)	-44.9 (-46.9 to -42.8)	1.1 (0.7 to 1.9)	0.7 (0.4 to 1.1)	-39.3 (-45.0 to -33.3)	-44.7 (-49.9 to -39.2)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-82.0 to -48.0)	0.0 (-88.3 to -66.0)	-	-
Measles	0.3 (0.3 to 0.3)	0.0 (0.0 to 0.0)	-100.0 (-100.0 to -100.0)	-100.0 (-100.0 to -100.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Varicella and herpes zoster	15.2 (14.0 to 16.7)	20.7 (18.1 to 23.7)	35.4 (19.4 to 58.2)	-3.4 (-18.9 to 18.5)	0.3 (0.2 to 0.5)	0.5 (0.3 to 0.9)	78.5 (28.4 to 164.7)	-5.8 (-35.3 to 42.6)
Neglected tropical diseases and malaria	-	-	-	-	50.8 (32.5 to 78.9)	65.8 (40.7 to 102.7)	28.7 (3.7 to 65.1)	-16.6 (-32.7 to 6.3)
Malaria	169.1 (108.5 to 286.0)	332.8 (157.1 to 729.0)	89.4 (9.5 to 232.3)	33.3 (-22.5 to 133.5)	3.0 (1.4 to 5.5)	6.8 (2.8 to 12.5)	129.3 (36.2 to 231.0)	79.5 (6.0 to 159.1)
Chagas disease	684.3 (662.8 to 707.3)	886.8 (821.9 to 950.8)	29.6 (18.9 to 40.1)	-30.4 (-36.2 to -24.8)	6.3 (4.3 to 8.9)	7.9 (5.2 to 11.4)	46.7 (12.5 to 88.2)	11.5 (-46.4 to 34.4)
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.1)	0.7 (0.3 to 1.4)	1,300.6 (1,117.5 to 1,525.1)	857.8 (746.2 to 987.7)
Visceral leishmaniasis	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-4.6 (-34.0 to 35.2)	-26.9 (-48.6 to 1.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-4.6 (-34.0 to 35.2)	-26.9 (-48.8 to 2.3)
Cutaneous and mucocutaneous leishmaniasis	4.2 (3.3 to 5.4)	64.7 (51.8 to 83.7)	1,447.0 (1,359.4 to 1,531.3)	932.8 (878.6 to 983.5)	0.0 (0.0 to 0.1)	0.7 (0.3 to 1.4)	1,431.8 (1,219.7 to 1,683.3)	926.1 (802.8 to 1,074.5)
African trypanosomiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Schistosomiasis	22.8 (10.4 to 48.0)	35.8 (15.8 to 76.7)	56.7 (47.5 to 62.9)	-3.3 (-6.9 to -0.2)	0.2 (0.1 to 0.4)	0.3 (0.1 to 0.6)	48.9 (12.5 to 74.7)	5.1 (-22.7 to 9.8)
Cysticercosis	12.6 (4.5 to 28.5)	10.6 (2.7 to 29.5)	-16.2 (-83.4 to 252.5)	-49.0 (-89.0 to 74.3)	3.6 (1.2 to 8.5)	3.2 (0.8 to 9.4)	-12.4 (-82.8 to 290.6)	-46.3 (-88.7 to 90.8)
Cystic echinococcosis	0.8 (0.6 to 0.9)	1.3 (1.1 to 1.6)	74.6 (54.3 to 87.5)	-15.4 (-25.5 to -10.6)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	72.2 (37.2 to 120.6)	-16.6 (-35.1 to 7.9)
Lymphatic filariasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Onchocerciasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Trachoma	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Dengue	3.9 (1.6 to 8.7)	29.6 (12.0 to 64.8)	651.1 (646.4 to 656.6)	392.2 (389.1 to 395.8)	0.6 (0.2 to 1.6)	4.8 (1.7 to 11.6)	645.5 (519.8 to 804.2)	391.5 (318.0 to 484.1)
Yellow fever	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-9.2 to 44.5)	0.0 (0.0 to 0.0)	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-30.5 to 4.3)	0.0 (-54.4 to -32.9)	-	-
Intestinal nematode infections	-	-	-	-	33.1 (18.6 to 56.8)	37.4 (19.1 to 67.0)	10.5 (-19.0 to 59.8)	-23.5 (-44.5 to 11.6)
Ascariasis	4,875.2 (4,174.5 to 5,660.4)	8,567.4 (5,561.6 to 12,734.3)	71.9 (11.0 to 186.4)	8.8 (-30.7 to 72.6)	13.1 (6.7 to 23.6)	11.0 (4.8 to 20.6)	-19.4 (-49.2 to 43.6)	-39.8 (-62.6 to 8.4)
Trichuriasis	6,111.5 (5,241.0 to 7,107.0)	10,556.7 (7,066.9 to 14,538.5)	71.0 (19.8 to 145.8)	7.4 (-2.4 to 58.0)	11.8 (6.4 to 21.2)	18.9 (7.9 to 37.0)	52.6 (-13.5 to 176.3)	-6.9 (-48.2 to 70.7)
Hookworm disease	1,131.7 (951.0 to 1,369.7)	1,527.8 (1,031.0 to 2,307.6)	31.7 (-13.3 to 114.2)	-17.1 (-45.9 to 37.0)	8.1 (4.8 to 12.3)	7.5 (4.4 to 12.2)	31.2 (-27.7 to 22.3)	-32.2 (-47.4 to -8.6)
Food-borne trematodiasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	126.0 (105.3 to 148.5)	150.3 (134.2 to 167.2)	19.3 (-4.6 to 50.9)	-2.9 (-21.8 to 21.4)	3.8 (2.4 to 5.7)	4.7 (3.0 to 6.9)	22.4 (-6.6 to 70.0)	1.7 (-21.9 to 40.3)
Maternal disorders	-	-	-	-	0.3 (0.1 to 0.5)	0.3 (0.1 to 0.5)	5.7 (-16.0 to 37.9)	-31.2 (-45.7 to -10.5)
Maternal hemorrhage	1.0 (0.9 to 1.0)	1.1 (1.0 to 1.2)	14.8 (4.9 to 25.1)	-27.2 (-33.4 to -20.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	25.2 (-31.9 to 29.2)	-22.3 (-56.3 to 44.3)
Maternal sepsis and other maternal infections	1.4 (0.8 to 2.4)	1.7 (0.9 to 2.7)	25.3 (-8.6 to 56.7)	-27.5 (-47.7 to -8.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	10.0 (-34.2 to 69.3)	-31.8 (-59.9 to 4.7)
Maternal hypertensive disorders	2.9 (1.0 to 5.3)	3.2 (1.1 to 6.0)	11.7 (0.3 to 16.9)	-27.1 (-36.4 to -23.0)	0.1 (0.0 to 0.3)	0.2 (0.0 to 0.3)	11.6 (-16.4 to 47.8)	-7.1 (-46.1 to -3.7)
Obstructed labor	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-24.0 (-74.9 to 221.7)	-48.7 (-83.2 to 108.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Complications of abortion	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	5.6 (-30.3 to 71.5)	-30.9 (-53.5 to 9.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (-47.2 to 112.6)	-
Other maternal disorders	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-12.0 (-43.4 to 48.3)	-43.0 (-63.1 to -3.6)
Neonatal disorders	-	-	-	-	25.8 (17.3 to 35.8)	50.6 (33.4 to 71.3)	95.3 (43.9 to 183.3)	35.5 (-0.3 to 97.7)
Preterm birth complications	75.2 (45.5 to 121.9)	206.2 (128.7 to 335.9)	176.9 (97.9 to 260.8)	85.2 (34.0 to 142.7)	10.6 (5.8 to 17.3)	29.4 (18.9 to 42.3)	183.8 (65.0 to 351.0)	93.9 (13.8 to 207.3)
Neonatal encephalopathy due to birth asphyxia and trauma	63.8 (27.6 to 131.7)	56.6 (24.0 to 116.7)	-12.8 (-41.4 to 35.5)	-11.2 (-60.3 to -9.1)	8.5 (5.3 to 12.8)	8.7 (5.1 to 14.4)	-1.1 (-41.3 to 95.3)	-30.2 (-58.3 to 37.9)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	10.0 (31.6 to 51.9)	37.7 (23.4 to 42.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-25.6 to 61.5)	36.3 (17.7 to 51.4)
Hemolytic disease and other neonatal jaundice	13.3 (6.5 to 22.6)	23.4 (12.3 to 51.1)	76.9 (-24.5 to 295.3)	21.5 (-48.4 to 174.9)	5.1 (2.3 to 9.3)	9.1 (4.3 to 21.2)	79.7 (-23.9 to 311.1)	24.4 (-47.6 to 185.1)
Other neonatal disorders	-	-	-	-	1.7 (1.0 to 2.6)	3.3 (1.9 to 5.4)	90.8 (20.4 to 240.7)	32.5 (-15.9 to 136.5)
Nutritional deficiencies	-	-	-	-	61.9 (41.0 to 90.1)	70.3 (46.8 to 102.9)	13.5 (4.6 to 23.6)	-10.7 (-17.8 to -2.4)
Protein-energy malnutrition	44.5 (32.3 to 57.1)	42.9 (21.3 to 76.6)	-8.2 (-53.5 to 83.9)	-20.4 (-58.3 to 8.7)	5.5 (3.4 to 8.7)	5.3 (2.3 to 10.1)	5.5 (-53.9 to 84.3)	-19.9 (-58.4 to 59.7)
Iodine deficiency	204.0 (103.2 to 338.1)	204.4 (102.6 to 317.3)	0.5 (-51.7 to 107.9)	-38.9 (-1.7 to 74.8)	3.7 (1.6 to 7.0)	3.7 (1.7 to 7.4)	-1.1 (-52.2 to 103.9)	-39.1 (-70.6 to 24.0)
Vitamin A deficiency	3.8 (2.7 to 4.9)	2.4 (1.8 to 3.1)	-36.4 (-44.9 to -25.6)	-52.8 (-59.8 to -45.6)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-36.5 (-49.9 to -19.1)	-54.4 (-63.4 to -43.6)

Appendix Table G.4 - Venezuela prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	1,632.5 (1,581.8 to 1,686.3)	2,048.0 (1,997.7 to 2,097.8)	25.3 (21.0 to 29.5)	5.7 (-8.8 to 2.7)	52.1 (34.7 to 75.5)	61.0 (40.7 to 89.9)	17.0 (11.7 to 22.2)	17.0 (-11.3 to -2.6)
Other nutritional deficiencies	-	-	-	-	0.4 (0.1 to 0.7)	0.4 (0.1 to 0.6)	-43.2 (-80.2 to 118.0)	-50.8 (-82.4 to 83.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	7.6 (4.8 to 11.9)	10.8 (6.8 to 17.2)	41.4 (24.2 to 60.5)	-6.1 (-15.9 to 4.7)
Sexually transmitted diseases excluding HIV	-	-	-	-	3.9 (2.3 to 6.6)	6.0 (3.4 to 10.6)	56.1 (34.0 to 79.0)	-6.6 (-18.5 to 5.5)
Syphilis	0.8 (0.6 to 0.9)	0.9 (0.7 to 1.0)	14.0 (9.7 to 40.7)	-45.8 (56.2 to -34.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.2)	15.0 (-21.3 to 67.1)	44.9 (-6.1 to -23.1)
Chlamydial infection	506.5 (351.8 to 675.9)	691.2 (476.2 to 994.0)	37.5 (-20.7 to 134.8)	-13.2 (48.9 to 44.3)	2.2 (1.3 to 3.7)	3.2 (1.9 to 5.1)	50.8 (18.6 to 87.5)	5.3 (-25.1 to 16.4)
Gonococcal infection	76.2 (55.1 to 99.2)	100.3 (74.2 to 134.4)	30.9 (7.5 to 95.0)	-15.0 (-39.6 to 27.0)	0.5 (0.3 to 0.8)	0.6 (0.3 to 1.1)	26.3 (-13.4 to 78.8)	-19.0 (-43.9 to 14.0)
Trichomoniasis	96.0 (57.8 to 133.0)	215.6 (135.6 to 315.1)	121.3 (30.5 to 395.5)	28.9 (-22.3 to 170.9)	0.2 (0.1 to 0.4)	0.4 (0.1 to 0.8)	125.9 (24.3 to 476.5)	30.9 (-24.8 to 213.7)
Genital herpes	3,136.9 (2,991.1 to 3,269.3)	5,895.0 (5,525.4 to 6,269.5)	87.4 (73.8 to 102.3)	-0.9 (-8.2 to 7.0)	13.9 (8.3 to 2.0)	1.6 (0.5 to 3.8)	83.2 (65.7 to 100.2)	43.9 (-9.2 to 8.3)
Other sexually transmitted diseases	2.7 (1.9 to 3.8)	3.8 (2.9 to 5.1)	42.2 (19.9 to 72.0)	-18.5 (-30.7 to -1.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	73.5 (18.1 to 165.7)	2.0 (-28.9 to 50.9)
Hepatitis	-	-	-	-	1.0 (0.6 to 1.5)	1.3 (0.8 to 2.0)	33.2 (13.4 to 59.1)	-17.3 (-30.3 to 0.5)
Hepatitis A	25.0 (24.0 to 26.0)	31.8 (30.7 to 32.9)	27.1 (26.4 to 27.8)	-5.6 (-5.9 to -5.3)	0.6 (0.4 to 0.9)	0.8 (0.5 to 1.2)	42.3 (26.3 to 59.0)	-2.8 (-13.2 to 7.9)
Hepatitis B	694.3 (506.3 to 890.1)	669.2 (495.0 to 875.7)	-4.6 (-35.6 to 45.2)	-42.2 (-61.1 to -11.2)	0.4 (0.2 to 0.6)	0.4 (0.2 to 0.7)	18.8 (-26.7 to 90.5)	-33.3 (-58.5 to 7.0)
Hepatitis C	414.4 (367.3 to 463.0)	587.0 (523.2 to 650.9)	40.8 (23.2 to 66.9)	-24.4 (-33.9 to -11.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	32.8 (0.7 to 85.2)	25.7 (-47.1 to 11.1)
Hepatitis E	-	-	-46.7 (-63.7 to -18.0)	-66.9 (-77.0 to -49.6)	-	-	-	-
Leprosy	0.5 (0.3 to 0.6)	1.0 (0.9 to 1.1)	104.3 (66.5 to 159.3)	-5.4 (-22.1 to 18.8)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	103.4 (45.7 to 198.1)	-5.3 (-33.3 to 39.3)
Other infectious diseases	88.2 (74.0 to 102.6)	107.2 (95.3 to 119.8)	21.7 (2.3 to 52.8)	-3.1 (-21.1 to 19.6)	2.7 (1.7 to 4.2)	3.4 (2.1 to 5.1)	22.6 (-3.9 to 67.5)	-0.6 (-21.4 to 33.2)
Non-communicable diseases	-	-	-	-	1,399.0 (1,011.7 to 1,826.0)	2,612.8 (1,942.5 to 3,392.0)	86.4 (79.2 to 95.6)	3.2 (-0.3 to 7.6)
Neoplasms	-	-	-	-	11.0 (8.1 to 14.5)	30.7 (22.0 to 41.0)	178.7 (142.0 to 216.9)	27.8 (9.5 to 47.4)
Esophageal cancer	0.4 (0.3 to 0.5)	1.0 (0.8 to 1.3)	133.1 (77.1 to 206.7)	-6.3 (-29.2 to 24.2)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	131.0 (79.2 to 199.8)	-7.3 (-29.5 to 21.9)
Stomach cancer	6.3 (5.7 to 6.9)	10.5 (9.2 to 12.0)	66.8 (41.8 to 97.9)	-32.5 (-42.4 to -19.7)	0.7 (0.5 to 0.9)	1.1 (0.8 to 1.5)	65.0 (37.0 to 97.2)	-33.3 (-44.4 to -20.0)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.1)	0.2 (0.0 to 0.1)	545.9 (410.6 to 697.0)	166.0 (108.2 to 231.3)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.3 (0.2 to 0.5)	1,091.7 (441.9 to 2,346.6)	418.8 (142.8 to 1,045.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	1,078.3 (486.4 to 2,086.6)	406.3 (158.2 to 925.2)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.1)	0.7 (0.4 to 0.9)	1,572.7 (823.8 to 3,424.9)	564.4 (271.7 to 1,346.7)	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	1,419.8 (829.5 to 2,850.2)	492.7 (269.0 to 1,097.7)
Liver cancer due to alcohol use	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.5)	207.5 (59.4 to 480.7)	28.3 (-32.1 to 142.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	193.4 (74.2 to 381.3)	23.0 (-28.7 to 97.9)
Liver cancer due to other causes	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	489.0 (43.3 to 424.7)	29.6 (-39.6 to 132.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	176.7 (52.7 to 356.9)	18.9 (-35.8 to 95.9)
Larynx cancer	2.3 (1.8 to 3.2)	5.1 (3.6 to 6.5)	115.6 (62.5 to 180.2)	-11.0 (-32.7 to 16.4)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	120.1 (64.6 to 187.2)	-9.5 (-32.8 to 19.2)
Tracheal, bronchus and lung cancer	3.2 (2.9 to 3.5)	7.5 (6.4 to 8.7)	131.8 (95.6 to 174.3)	-1.1 (-16.4 to 17.4)	0.5 (0.4 to 0.6)	1.1 (0.8 to 1.5)	128.5 (90.1 to 174.1)	-2.4 (-18.5 to 18.0)
Breast cancer	19.5 (17.1 to 22.0)	52.3 (42.9 to 63.2)	166.2 (115.2 to 236.7)	19.5 (-3.3 to 51.4)	1.5 (1.1 to 2.1)	3.9 (2.7 to 5.4)	151.3 (103.3 to 220.2)	12.2 (8.8 to 41.6)
Cervical cancer	20.8 (17.4 to 24.7)	30.7 (23.1 to 39.1)	47.0 (13.7 to 87.2)	-29.6 (-44.5 to -11.1)	1.5 (1.0 to 2.2)	2.3 (1.5 to 3.3)	66.6 (35.5 to 89.8)	-9.0 (-45.1 to -11.3)
Uterine cancer	6.9 (4.1 to 9.4)	10.3 (7.2 to 17.2)	43.4 (-2.1 to 160.3)	-39.2 (-58.1 to -7.5)	0.2 (0.2 to 0.7)	0.7 (0.4 to 1.2)	42.5 (3.6 to 155.7)	-40.5 (-59.3 to 4.6)
Prostate cancer	15.4 (10.3 to 22.9)	98.9 (63.1 to 137.3)	554.4 (265.7 to 911.2)	162.3 (45.6 to 302.6)	1.5 (0.9 to 2.3)	8.1 (4.7 to 12.3)	455.5 (215.1 to 731.1)	122.2 (26.5 to 234.8)
Colon and rectum cancer	8.1 (7.5 to 8.7)	24.1 (21.4 to 27.1)	196.3 (160.1 to 240.0)	23.3 (7.4 to 42.5)	0.7 (0.5 to 0.9)	1.9 (1.4 to 2.5)	183.8 (143.5 to 231.9)	17.5 (0.6 to 37.4)
Lip and oral cavity cancer	2.1 (1.7 to 2.8)	5.1 (4.0 to 6.5)	139.2 (85.8 to 204.7)	-1.3 (-21.1 to 27.6)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	136.6 (84.9 to 209.3)	-3.4 (-24.9 to 27.4)
Nasopharynx cancer	0.3 (0.3 to 0.4)	0.5 (0.4 to 0.7)	34.9 (2.6 to 103.0)	-38.8 (-56.1 to -9.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	30.5 (-3.3 to 92.7)	-41.2 (-56.6 to -13.1)
Other pharynx cancer	0.7 (0.5 to 0.9)	1.3 (1.0 to 1.8)	95.1 (38.4 to 179.3)	-18.1 (-42.0 to 15.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	94.4 (40.7 to 175.3)	-18.9 (-41.5 to 14.9)
Gallbladder and biliary tract cancer	0.6 (0.3 to 0.8)	0.5 (0.4 to 0.8)	-27.3 (-44.8 to 100.7)	-71.6 (-78.5 to -20.0)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-25.8 (-44.4 to 107.5)	-70.7 (-78.3 to -14.3)
Pancreatic cancer	0.1 (0.1 to 0.2)	1.4 (1.2 to 1.6)	913.2 (729.9 to 1,152.0)	315.4 (238.7 to 415.5)	0.0 (0.0 to 0.0)	0.3 (0.2 to 0.3)	833.2 (689.0 to 1,009.5)	275.7 (213.4 to 352.2)
Malignant skin melanoma	2.0 (1.6 to 2.5)	4.2 (3.3 to 6.1)	100.7 (51.4 to 231.2)	4.5 (-28.6 to 58.1)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	98.5 (30.6 to 57.6)	-6.3 (-30.6 to 57.6)
Non-melanoma skin cancer	4.8 (3.6 to 6.0)	16.2 (12.3 to 21.2)	237.2 (150.4 to 351.1)	34.3 (-4.6 to 84.6)	0.2 (0.1 to 0.3)	0.8 (0.5 to 1.3)	284.7 (173.1 to 443.0)	51.1 (-2.6 to 122.8)
Ovarian cancer	0.7 (0.6 to 0.8)	4.3 (3.5 to 5.3)	470.2 (350.8 to 641.6)	172.2 (115.5 to 251.5)	0.1 (0.1 to 0.1)	0.5 (0.4 to 0.8)	447.8 (308.6 to 640.7)	159.6 (90.5 to 250.1)
Testicular cancer	0.4 (0.2 to 0.8)	2.4 (0.8 to 4.4)	1,037.6 (47.1 to 2,150.0)	564.7 (-12.5 to 1,128.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.3)	872.8 (31.8 to 2,371.6)	473.5 (-20.0 to 1,211.4)
Kidney cancer	3.0 (2.7 to 3.3)	7.7 (6.4 to 9.1)	156.3 (111.2 to 220.6)	15.5 (-7.2 to 42.5)	0.2 (0.2 to 0.3)	0.6 (0.4 to 0.8)	153.3 (106.1 to 217.7)	11.0 (-10.7 to 40.4)
Bladder cancer	0.9 (0.7 to 1.1)	1.8 (1.4 to 2.2)	85.5 (49.1 to 150.1)	-25.4 (-40.9 to 1.2)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	83.1 (45.6 to 145.7)	-26.6 (-43.0 to 1.5)
Brain and nervous system cancer	0.4 (0.3 to 0.8)	3.0 (1.6 to 3.7)	724.8 (126.2 to 926.3)	412.2 (36.2 to 521.2)	0.0 (0.0 to 0.1)	0.3 (0.1 to 0.4)	754.4 (133.0 to 962.1)	393.9 (28.2 to 498.9)
Thyroid cancer	5.3 (4.3 to 7.4)	17.0 (11.0 to 22.0)	235.7 (104.7 to 350.7)	64.9 (-0.8 to 119.6)	0.3 (0.2 to 0.5)	1.0 (0.6 to 1.4)	229.7 (98.0 to 348.3)	59.4 (-4.5 to 115.4)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-4.9 to 38.1)	0.0 (-60.7 to -42.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-3.5 to 36.4)	0.0 (-60.0 to -43.8)
Hodgkin lymphoma	0.2 (0.1 to 0.5)	2.7 (0.9 to 3.9)	1,826.8 (97.9 to 2,643.2)	1,143.2 (22.9 to 1,614.3)	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.4)	1,857.5 (88.1 to 2,596.2)	1,103.4 (11.7 to 1,510.1)
Non-Hodgkin lymphoma	5.4 (4.1 to 6.3)	11.8 (9.5 to 15.9)	111.0 (66.2 to 205.5)	9.3 (-13.6 to 52.2)	0.4 (0.3 to 0.6)	0.9 (0.6 to 1.3)	110.4 (67.7 to 207.0)	6.8 (-14.8 to 49.3)
Multiple myeloma	0.5 (0.4 to 0.7)	1.6 (1.1 to 2.1)	195.2 (107.8 to 319.2)	22.3 (-14.1 to 72.3)	0.1 (0.1 to 0.2)	0.5 (0.2 to 0.5)	182.0 (91.4 to 305.1)	16.9 (-20.8 to 68.2)
Leukemia	6.8 (5.7 to 8.2)	10.4 (8.8 to 12.3)	52.2 (23.0 to 84.0)	4.9 (-12.4 to 25.5)	0.7 (0.5 to 0.9)	1.1 (0.8 to 1.5)	66.1 (34.9 to 100.4)	3.3 (-14.0 to 24.6)
Other neoplasms	15.8 (13.2 to 19.7)	53.9 (44.4 to 63.1)	243.0 (167.8 to 324.7)	99.7 (55.6 to 144.3)	1.0 (0.7 to 1.5)	3.5 (2.3 to 4.8)	236.5 (167.0 to 319.6)	88.2 (48.8 to 133.0)
Cardiovascular diseases	-	-	-	-	10.7 (7.2 to 14.6)	46.9 (31.7 to 65.1)	338.8 (241.8 to 474.0)	74.5 (37.8 to 125.6)
Rheumatic heart disease	0.4 (0.3 to 0.4)	0.8 (0.7 to 0.8)	112.3 (96.1 to 131.4)	0.3 (-7.9 to 9.6)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	128.7 (80.8 to 196.0)	5.4 (-18.5 to 37.6)
Ischemic heart disease	105.8 (86.0 to 130.7)	496.5 (367.0 to 628.9)	367.3 (228.9 to 559.1)	77.5 (28.0 to 150.7)	4.9 (3.0 to 7.3)	28.0 (17.8 to 41.9)	475.5 (272.7 to 791.4)	113.5 (42.6 to 229.5)
Cerebrovascular disease	-	-	-	-	2.3 (1.6 to 3.1)	5.3 (3.6 to 7.2)	131.8 (88.7 to 191.4)	0.6 (-18.1 to 26.1)
Ischemic stroke	4.0 (3.3 to 4.6)	9.6 (7.4 to 11.5)	142.2 (81.5 to 219.0)	-1.2 (-26.7 to 30.4)	0.6 (0.4 to 0.8)	1.5 (0.9 to 2.1)	140.9 (77.8 to 221.5)	-0.9 (-27.3 to 31.1)
Hemorrhagic stroke	11.1 (9.4 to 12.8)	25.8 (22.0 to 29.9)	131.7 (87.8 to 198.3)	0.7 (-18.3 to 31.9)	1.7 (1.1 to 2.3)	3.9 (2.6 to 5.4)	129.9 (83.0 to 195.8)	0.9 (-19.2 to 30.3)
Hypertensive heart disease	6.1 (4.6 to 7.8)	22.1 (18.6 to 25.2)	260.8 (194.7 to 350.0)	38.3 (14.8 to 67.4)	0.7 (0.4 to 1.0)	2.4 (1.6 to 3.4)	253.3 (193.6 to 357.5)	38.2 (13.8 to 70.4)
Cardiomyopathy and myocarditis	2.9 (2.0 to 3.8)	10.1 (8.2 to 11.9)	255.6 (184.2 to 354.8)	0.3 (-22.2 to 97.3)	0.3 (0.2 to 0.5)	1.1 (0.7 to 1.6)	254.5 (176.2 to 370.4)	56.6 (20.4 to 109.3)
Atrial fibrillation and flutter	8.7 (6.9 to 11.2)	26.9 (20.0 to 37.0)	209.2 (106.5 to 345.0)	15.9 (-25.4 to 73.2)	0.6 (0.4 to 1.0)	2.0 (1.3 to 3.1)	223.3 (115.0 to 376.9)	21.8 (-22.4 to 87.5)
Peripheral vascular disease	325.6 (238.7 to 435.4)	832.1 (673.7 to 1,004.5)	158.3 (71.9 to 275.7)	6.0 (-23.5 to 50.4)	0.1 (0.0 to 0.3)	0.4 (0.1 to 0.7)	146.0 (18.6 to 687.6)	-9.9 (-56.8 to 186.6)
Endocarditis	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	173.6 (77.2 to 244.6)	46.4 (-7.3 to 85.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	186.1 (74.4 to 270.9)	58.5 (-5.9 to 105.9)
Other cardiovascular and circulatory diseases	24.2 (11.8 to 45.4)	107.3 (61.8 to 158.7)	361.9 (105.7 to 782.2)	1.7 (-7.6 to 31.2)	7.6 (0.7 to 3.3)	7.6 (3.8 to 12.3)	357.9 (104.5 to 785.4)	104.8 (-8.0 to 302.7)
Chronic respiratory diseases	-	-	-	-				

Appendix Table G.4 - Venezuela prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.7 (76.5 to 91.2)	-14.6 (-17.3 to -11.6)
Silicosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.6 (93.9 to 110.4)	-8.6 (-11.9 to -5.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	107.3 (98.8 to 116.8)	-7.1 (-10.6 to -3.1)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	61.3 (54.2 to 68.8)	-22.2 (-24.9 to -18.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.1 (58.3 to 73.9)	-20.8 (-23.8 to -17.2)
Asthma	1,377.1 (1,212.0 to 1,549.4)	1,971.9 (1,749.9 to 2,212.7)	43.2 (23.8 to 66.8)	-11.4 (-22.6 to 2.4)	61.2 (39.2 to 89.1)	87.2 (56.1 to 126.5)	42.3 (22.4 to 67.3)	-11.2 (-22.8 to 2.9)
Interstitial lung disease and pulmonary sarcoidosis	0.3 (0.3 to 0.4)	0.7 (0.5 to 0.8)	107.3 (52.1 to 189.0)	-5.0 (-31.0 to 35.1)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	111.0 (55.2 to 193.6)	-4.1 (-30.1 to 36.3)
Other chronic respiratory diseases	-	-	-	-	2.6 (1.6 to 3.8)	2.5 (1.6 to 3.9)	-0.9 (-24.2 to 30.5)	-51.5 (-63.3 to -35.8)
Cirrhosis	-	-	-	-	0.2 (0.6 to 1.2)	1.5 (1.0 to 2.1)	78.9 (51.2 to 114.2)	9.9 (-23.3 to 6.6)
Cirrhosis due to hepatitis B	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.4)	115.3 (-19.3 to 325.2)	4.0 (-57.4 to 103.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (-19.3 to 325.3)	4.0 (-57.5 to 103.3)
Cirrhosis due to hepatitis C	1.6 (1.2 to 2.1)	3.0 (2.2 to 3.8)	87.8 (23.3 to 172.6)	-6.5 (-37.3 to 35.2)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	85.2 (14.9 to 185.6)	-7.4 (-40.9 to 43.3)
Cirrhosis due to alcohol use	2.2 (1.7 to 2.8)	3.8 (3.0 to 4.7)	65.8 (27.9 to 145.7)	-22.5 (-39.3 to 10.3)	0.4 (0.2 to 0.5)	0.6 (0.4 to 0.9)	67.5 (19.0 to 156.8)	-22.1 (-42.5 to 15.2)
Cirrhosis due to other causes	1.0 (0.8 to 1.3)	1.9 (1.4 to 2.4)	88.4 (28.1 to 182.8)	20.6 (-20.6 to 85.2)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	86.3 (18.8 to 210.1)	19.9 (-24.1 to 94.3)
Digestive diseases	-	-	-	-	11.5 (8.1 to 15.5)	23.6 (17.1 to 31.5)	106.3 (91.3 to 122.1)	-0.1 (-7.0 to 6.9)
Peptic ulcer disease	82.1 (77.4 to 86.8)	114.9 (107.1 to 123.0)	39.8 (27.8 to 52.3)	-40.2 (-45.0 to -35.2)	2.5 (1.7 to 3.5)	3.5 (2.4 to 5.0)	41.7 (26.9 to 61.0)	-38.1 (-44.2 to -29.8)
Gastritis and duodenitis	40.9 (36.2 to 45.4)	64.1 (59.1 to 69.5)	56.1 (40.2 to 77.2)	-22.0 (-30.8 to -9.4)	2.0 (1.3 to 2.8)	2.9 (2.0 to 4.2)	50.9 (26.1 to 76.6)	-18.7 (-28.5 to -5.5)
Appendicitis	0.8 (0.7 to 0.9)	1.0 (0.9 to 1.1)	24.9 (1.6 to 53.0)	-15.7 (-31.2 to 1.6)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	25.8 (-13.1 to 81.2)	-15.2 (-39.7 to 17.1)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	147.4 (82.3 to 267.5)	0.1 (-36.3 to 115.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	143.5 (57.5 to 279.8)	58.7 (16.6 to 120.3)
Inguinal, femoral, and abdominal hernia	59.9 (52.6 to 70.3)	99.0 (88.5 to 109.1)	66.0 (36.0 to 97.9)	-23.8 (-34.0 to -11.6)	0.6 (0.3 to 1.2)	1.0 (0.5 to 1.9)	65.0 (34.3 to 99.3)	-23.3 (-34.3 to -10.7)
Inflammatory bowel disease	20.5 (19.7 to 21.4)	49.6 (47.8 to 51.6)	141.3 (128.5 to 155.6)	23.9 (17.5 to 31.1)	4.4 (3.0 to 6.0)	10.5 (7.3 to 14.5)	139.8 (120.1 to 163.6)	23.8 (14.3 to 34.8)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	139.3 (85.9 to 216.7)	3.9 (-18.8 to 40.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (67.8 to 218.2)	-2.3 (-31.4 to 44.0)
Gallbladder and biliary diseases	10.1 (8.8 to 11.7)	19.7 (17.6 to 22.0)	96.3 (58.1 to 129.3)	-6.2 (-22.5 to 8.7)	2.1 (0.7 to 1.5)	2.1 (1.4 to 2.9)	94.9 (55.8 to 133.6)	5.9 (-23.5 to 10.6)
Pancreatitis	0.9 (0.8 to 0.9)	2.1 (2.0 to 2.2)	141.8 (122.7 to 159.1)	26.7 (17.6 to 35.7)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	138.6 (74.1 to 230.2)	26.3 (-4.3 to 69.1)
Other digestive diseases	-	-	-	-	0.4 (0.2 to 0.6)	2.4 (1.7 to 3.5)	618.9 (324.2 to 764.1)	248.7 (105.5 to 320.2)
Neurological disorders	-	-	-	-	118.6 (80.0 to 161.2)	232.3 (156.0 to 317.2)	95.6 (62.9 to 135.3)	6.0 (-10.4 to 24.4)
Alzheimer disease and other dementias	82.1 (71.4 to 93.0)	232.2 (204.4 to 261.0)	182.5 (133.5 to 236.7)	5.5 (-13.6 to 26.8)	11.6 (8.2 to 15.3)	33.1 (23.7 to 43.8)	186.5 (135.0 to 242.8)	5.9 (-13.8 to 27.8)
Parkinson disease	1.2 (1.0 to 1.5)	3.1 (2.6 to 3.7)	157.0 (141.5 to 173.4)	2.1 (-3.3 to 8.7)	0.1 (0.1 to 0.2)	0.1 (0.3 to 0.5)	156.3 (117.8 to 201.2)	2.4 (-13.4 to 20.2)
Epilepsy	102.2 (66.2 to 140.3)	152.9 (96.9 to 210.5)	50.0 (-13.4 to 159.4)	-4.4 (-44.7 to 65.8)	32.5 (18.2 to 49.5)	50.9 (28.5 to 77.8)	57.0 (-11.2 to 170.4)	1.4 (-42.6 to 75.3)
Multiple sclerosis	0.5 (0.5 to 0.6)	1.9 (1.8 to 2.1)	260.2 (229.3 to 298.0)	90.2 (73.7 to 109.9)	0.2 (0.1 to 0.2)	0.7 (0.5 to 0.9)	253.8 (207.0 to 309.0)	87.0 (62.3 to 116.0)
Migraine	1,515.4 (1,292.5 to 1,826.9)	2,885.5 (2,129.1 to 3,414.0)	90.2 (44.1 to 138.2)	-9.2 (-16.8 to 39.1)	52.1 (30.6 to 77.6)	98.1 (55.2 to 152.1)	89.6 (43.3 to 140.1)	9.4 (-16.6 to 39.5)
Tension-type headache	3,517.5 (2,706.7 to 4,153.3)	5,559.2 (6,101.6 to 7,034.3)	85.3 (54.7 to 137.8)	5.3 (-10.3 to 30.2)	5.4 (2.5 to 9.6)	10.0 (4.9 to 17.6)	85.2 (53.3 to 138.9)	5.6 (-10.7 to 30.9)
Medication overuse headache	79.7 (51.4 to 107.8)	204.5 (132.4 to 287.0)	158.5 (72.9 to 240.2)	39.9 (-9.3 to 81.9)	12.6 (7.0 to 19.9)	32.2 (17.6 to 52.4)	156.0 (68.9 to 250.9)	39.0 (-8.9 to 82.7)
Other neurological disorders	0.0 (0.0 to 0.0)	0.1 (0.0 to 1.1)	57.9 (10.5 to 125.1)	-5.6 (-33.3 to 32.7)	4.1 (2.6 to 5.8)	6.9 (4.7 to 9.4)	67.1 (16.6 to 127.8)	-37.8 (-57.5 to -15.2)
Mental and substance use disorders	-	-	-	-	464.3 (323.5 to 634.1)	754.8 (527.5 to 1,020.8)	62.6 (55.8 to 70.0)	-2.4 (-6.1 to 0.7)
Schizophrenia	46.9 (43.1 to 50.5)	86.7 (80.0 to 93.5)	84.9 (76.2 to 92.6)	-0.7 (-5.0 to 2.9)	30.3 (22.2 to 36.7)	55.6 (41.2 to 67.8)	84.2 (72.1 to 95.9)	0.5 (-6.7 to 5.1)
Alcohol use disorders	197.3 (170.1 to 226.9)	331.2 (293.8 to 373.0)	67.8 (52.3 to 85.8)	-3.3 (-11.8 to 6.0)	19.6 (12.8 to 28.1)	33.0 (21.6 to 47.2)	68.4 (51.2 to 87.3)	-2.8 (-12.0 to 7.0)
Drug use disorders	-	-	-	-	24.0 (15.7 to 34.5)	41.6 (27.3 to 56.9)	73.3 (45.6 to 108.2)	5.3 (-10.7 to 25.1)
Opioid use disorders	12.6 (6.1 to 22.2)	23.9 (11.4 to 39.7)	92.2 (58.0 to 113.3)	2.6 (-12.2 to 12.2)	5.2 (2.3 to 9.7)	9.9 (4.2 to 17.5)	91.8 (58.3 to 123.6)	2.9 (-13.4 to 18.2)
Cocaine use disorders	20.9 (21.0 to 40.1)	58.8 (47.7 to 69.7)	88.4 (38.6 to 190.1)	-2.2 (-15.7 to 65.1)	4.2 (2.5 to 6.5)	8.1 (5.0 to 12.1)	89.9 (38.3 to 198.7)	13.1 (-15.6 to 69.4)
Amphetamine use disorders	36.9 (34.2 to 39.8)	55.4 (51.5 to 59.7)	50.2 (34.9 to 66.9)	-1.6 (-11.3 to 8.8)	4.9 (3.0 to 7.1)	7.3 (4.5 to 10.8)	50.6 (29.2 to 75.9)	-1.0 (-14.5 to 15.4)
Cannabis use disorders	16.4 (12.6 to 20.5)	25.0 (19.4 to 30.9)	52.5 (49.7 to 55.7)	-0.1 (-0.1 to -0.0)	0.5 (0.3 to 0.7)	0.7 (0.4 to 1.1)	53.5 (25.8 to 86.8)	0.7 (-16.6 to 21.1)
Other drug use disorders	-	-	-	-	9.2 (5.6 to 13.9)	15.6 (9.9 to 22.8)	70.1 (23.3 to 132.8)	6.9 (-22.6 to 46.2)
Depressive disorders	-	-	-	-	188.8 (109.8 to 298.4)	305.9 (172.3 to 482.6)	62.1 (44.7 to 78.1)	4.4 (-12.4 to 2.1)
Major depressive disorder	814.8 (501.4 to 1,137.7)	1,307.6 (779.0 to 1,850.1)	60.2 (40.6 to 78.6)	-5.0 (-13.9 to 2.1)	169.3 (93.2 to 273.6)	269.6 (141.8 to 436.8)	58.2 (39.0 to 76.9)	-5.0 (-14.3 to 2.4)
Dysthymia	200.2 (161.2 to 237.7)	377.1 (310.2 to 445.5)	88.1 (81.4 to 96.6)	0.0 (-0.0 to 0.1)	19.4 (12.5 to 28.5)	36.4 (23.4 to 53.1)	87.2 (78.6 to 97.8)	0.1 (-2.5 to 2.6)
Bipolar disorder	145.4 (116.7 to 174.3)	252.1 (205.6 to 293.4)	73.4 (61.8 to 84.7)	-1.2 (-6.0 to 4.0)	29.8 (17.9 to 46.3)	51.4 (31.4 to 78.6)	73.0 (60.4 to 86.3)	-0.9 (-7.0 to 5.3)
Anxiety disorders	809.5 (526.8 to 1,060.7)	1,353.7 (894.8 to 1,748.2)	67.2 (57.8 to 77.3)	0.0 (-0.0 to 0.1)	75.0 (43.7 to 115.4)	124.9 (74.9 to 188.4)	66.7 (56.5 to 77.5)	0.2 (-1.2 to 2.4)
Eating disorders	-	-	-	-	6.2 (3.6 to 9.7)	9.2 (5.4 to 14.4)	50.0 (38.3 to 63.0)	1.1 (-6.4 to 10.0)
Anorexia nervosa	4.6 (3.5 to 5.9)	7.1 (5.4 to 9.2)	52.7 (35.6 to 71.8)	5.3 (-6.3 to 18.0)	1.0 (0.6 to 1.5)	1.5 (0.9 to 2.3)	53.8 (22.6 to 89.7)	6.1 (-15.5 to 30.3)
Bulimia nervosa	24.3 (15.9 to 35.8)	36.3 (23.8 to 53.3)	48.9 (45.9 to 52.8)	0.1 (0.1 to 0.2)	5.2 (2.9 to 8.4)	7.7 (4.4 to 12.5)	49.5 (37.4 to 62.5)	0.4 (-7.8 to 9.3)
Autistic spectrum disorders	-	-	-	-	23.4 (16.4 to 32.0)	35.6 (25.1 to 48.5)	51.1 (46.8 to 57.5)	0.4 (-3.0 to 3.6)
Autism	58.8 (55.7 to 62.6)	90.0 (85.2 to 95.5)	52.8 (51.9 to 53.7)	-0.0 (-0.0 to -0.0)	14.6 (9.9 to 20.1)	22.3 (15.1 to 30.4)	52.3 (44.9 to 60.0)	0.3 (-4.2 to 5.0)
Asperger syndrome	87.5 (82.0 to 92.6)	133.0 (124.5 to 141.2)	51.9 (50.7 to 53.1)	0.0 (-0.1 to -0.0)	8.8 (6.1 to 12.3)	13.3 (9.2 to 18.6)	51.7 (45.4 to 57.8)	0.3 (-3.6 to 4.1)
Attention-deficit/hyperactivity disorder	168.1 (154.0 to 179.3)	216.7 (198.5 to 231.2)	28.8 (28.4 to 29.0)	0.1 (0.1 to 0.1)	2.1 (1.2 to 3.1)	2.7 (1.6 to 4.0)	29.4 (20.4 to 38.7)	0.6 (-6.3 to 7.8)
Conduct disorder	22.2 (20.8 to 237.0)	286.5 (266.3 to 307.7)	29.4 (28.7 to 30.0)	0.0 (0.1 to 0.1)	26.7 (16.6 to 37.0)	34.7 (21.8 to 50.4)	29.9 (24.6 to 35.2)	0.2 (-3.6 to 4.6)
Idiopathic intellectual disability	358.1 (279.4 to 444.3)	455.9 (351.0 to 568.9)	27.3 (7.4 to 47.9)	-16.5 (-29.6 to -2.7)	17.6 (11.6 to 25.4)	22.3 (14.6 to 32.4)	27.0 (16.7 to 48.2)	0.3 (-29.7 to -2.2)
Other mental and substance use disorders	277.8 (259.0 to 295.1)	504.3 (473.9 to 533.6)	81.3 (79.0 to 83.7)	-0.0 (-0.1 to 0.0)	20.9 (14.2 to 28.1)	37.7 (25.6 to 50.9)	80.6 (67.0 to 87.9)	0.1 (-3.1 to 3.6)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	127.0 (88.5 to 179.4)	265.8 (182.6 to 365.5)	109.6 (91.7 to 128.6)	18.5 (7.6 to 29.5)
Diabetes mellitus	693.7 (583.1 to 796.8)	2,006.4 (1,723.8 to 2,325.0)	189.3 (144.0 to 239.5)	46.1 (21.3 to 74.8)	48.8 (32.8 to 70.4)	142.6 (95.5 to 198.8)	192.3 (145.6 to 244.6)	41.1 (17.2 to 67.8)
Acute glomerulonephritis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	9.8 (2.4 to 17.8)	-22.8 (-26.6 to -18.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	9.8 (2.3 to 17.8)	-22.8 (-26.6 to -18.7)
Chronic kidney disease	-	-	-	-	27.6 (19.8 to 36.7)	45.6 (32.8 to 60.2)	66.0 (47.9 to 83.8)	-0.6 (-11.4 to 9.0)
Chronic kidney disease due to diabetes mellitus	294.2 (206.0 to 453.8)	670.8 (438.6 to 1,007.2)	126.6 (71.4 to 194.7)	9.2 (-13.4 to 42.7)	4.4 (3.1 to 6.0)	9.6 (6.5 to 13.1)	117.8 (70.8 to 169.0)	8.2 (-3.5 to 35.2)
Chronic kidney disease due to hypertension	314.0 (192.4 to 500.3)	562.0 (377.9 to 854.0)	78.4 (39.5 to 146.0)	7.5 (-13.9 to 38.6)	7.2 (5.0 to 9.7)	11.8 (8.1 to 15.7)	62.5 (34.4 to 102.3)	-6.9 (-23.2 to 11.3)
Chronic kidney disease due to glomerulonephritis	436.6 (289.5 to 635.3)	789.2 (549.6 to 1,155.6)	81.5 (34.4 to 135.0)	6.3 (-24.5 to 25.9)	6.3 (4.3 to 9.7)	10.5 (7.1 to 14.2)	67.8 (33.4 to 111.6)	9.0 (-13.7 to 37.9)
Chronic kidney disease due to other causes	522.9 (342.2 to 776.4)	838.6 (574.4 to 1,265.1)	60.8 (27.4 to 98.3)	-5.0 (-23.1 to 20.4)	9.7 (6.7 to 13.1)	13.7 (9.6 to 18.4)	41.0 (16.5 to 77.2)	-9.0 (-26.5 to 17.3)
Urinary diseases and male infertility	-	-	-	-	4.4 (2.9 to 6.6)	10.4 (6.6 to 15.5)	134.7 (109.5 to 163.4)	0.6 (-11.4 to 16.4)

Appendix Table G.4 - Venezuela prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	4.3 (3.8 to 4.8)	7.7 (6.4 to 8.8)	76.9 (47.2 to 115.7)	0.1 (-9.1 to 24.7)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	75.7 (34.2 to 129.1)	5.4 (-16.2 to 33.3)
Urolithiasis	108.3 (73.5 to 170.4)	288.9 (179.1 to 473.0)	169.4 (111.5 to 205.8)	14.2 (-10.3 to 33.7)	0.6 (0.4 to 1.1)	1.7 (0.9 to 3.2)	168.2 (121.1 to 212.7)	21.7 (-0.2 to 42.1)
Benign prostatic hyperplasia	81.0 (70.2 to 91.6)	196.3 (174.5 to 222.7)	142.8 (107.4 to 190.1)	-3.9 (-19.4 to 17.9)	2.9 (1.9 to 4.2)	7.0 (4.5 to 10.1)	143.8 (107.7 to 193.1)	-3.4 (-19.1 to 17.6)
Male infertility due to other causes	87.8 (67.3 to 113.5)	139.2 (109.2 to 178.1)	58.4 (16.5 to 117.0)	-2.4 (-28.3 to 33.4)	0.6 (0.2 to 1.2)	0.9 (0.4 to 1.8)	59.3 (13.2 to 124.1)	-1.2 (-29.3 to 37.5)
Other urinary diseases	-	-	-	-	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.8)	146.3 (75.4 to 263.0)	16.6 (-19.8 to 71.6)
Gynecological diseases	-	-	-	-	20.2 (12.8 to 30.4)	36.1 (22.6 to 54.9)	77.6 (53.6 to 112.4)	1.5 (-11.1 to 20.8)
Uterine fibroids	334.4 (300.2 to 364.3)	657.1 (595.3 to 711.9)	96.3 (94.3 to 98.8)	1.0 (0.9 to 1.0)	2.7 (1.3 to 5.1)	5.2 (2.6 to 9.6)	91.0 (64.2 to 118.5)	-0.9 (-14.6 to 12.9)
Polycystic ovarian syndrome	311.0 (268.4 to 351.9)	526.0 (453.7 to 603.4)	69.6 (38.6 to 101.9)	-0.5 (-17.2 to 17.3)	3.0 (1.4 to 5.7)	5.1 (2.3 to 9.7)	69.3 (38.7 to 102.5)	-0.2 (-17.2 to 17.7)
Female infertility due to other causes	68.8 (42.4 to 95.9)	109.1 (61.6 to 160.4)	55.3 (-18.7 to 203.1)	-10.3 (-53.3 to 76.5)	0.4 (0.1 to 0.8)	0.6 (0.2 to 1.3)	55.9 (-18.0 to 204.0)	-9.9 (-53.3 to 77.0)
Endometriosis	33.9 (28.6 to 38.7)	61.4 (53.0 to 70.8)	80.2 (46.8 to 125.8)	4.6 (-14.5 to 30.0)	3.2 (2.1 to 4.4)	5.7 (3.8 to 8.2)	79.9 (43.8 to 127.8)	4.1 (-16.2 to 30.8)
Genital prolapse	1,092.6 (922.5 to 1,243.4)	2,057.7 (1,746.4 to 2,333.0)	88.8 (48.6 to 131.5)	-2.5 (-20.4 to 16.7)	3.5 (1.7 to 6.4)	6.6 (3.1 to 12.5)	88.1 (44.7 to 132.7)	-2.5 (-21.2 to 17.6)
Premenstrual syndrome	852.5 (638.2 to 1,058.7)	1,490.6 (1,116.0 to 1,899.1)	72.2 (23.3 to 163.8)	6.1 (-24.4 to 62.6)	7.2 (4.2 to 11.6)	7.2 (7.0 to 9.7)	72.4 (22.1 to 162.3)	5.4 (-0.7 to 63.4)
Other gynecological diseases	12.4 (10.1 to 15.0)	19.5 (16.1 to 23.9)	56.9 (16.9 to 113.8)	-8.4 (-33.3 to 25.4)	0.2 (0.1 to 0.4)	0.4 (0.3 to 0.7)	83.2 (5.9 to 251.7)	25.7 (-48.9 to 96.8)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	23.3 (15.5 to 33.5)	27.1 (17.9 to 38.8)	16.5 (5.9 to 25.2)	-9.9 (-17.7 to -3.8)
Thalassemias	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.2)	25.2 (14.1 to 43.8)	2.1 (-7.0 to 17.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	21.6 (9.5 to 77.2)	0.4 (-25.2 to 43.5)
Thalassemia trait	193.6 (179.5 to 211.6)	297.2 (277.7 to 319.8)	53.4 (46.5 to 60.7)	-0.4 (-4.9 to 4.9)	6.9 (4.5 to 10.0)	9.0 (6.0 to 13.0)	30.4 (19.4 to 42.4)	-3.9 (-12.3 to 4.8)
Sickle cell disorders	5.7 (5.0 to 6.2)	7.9 (7.2 to 8.5)	38.2 (23.8 to 59.4)	-1.7 (-11.1 to 11.8)	0.8 (0.5 to 1.0)	1.1 (0.8 to 1.5)	46.4 (28.4 to 69.3)	-0.5 (-11.8 to 13.3)
Sickle cell trait	955.1 (906.0 to 1,004.5)	1,420.6 (1,336.8 to 1,498.5)	48.5 (42.9 to 53.8)	-8.5 (-7.0 to 4.0)	14.4 (9.0 to 19.9)	14.4 (9.3 to 21.1)	44.7 (8.8 to 22.0)	24.5 (-27.3 to -2.0)
G6PD deficiency	605.9 (489.5 to 725.9)	983.4 (729.1 to 1,250.2)	62.6 (16.0 to 121.4)	5.7 (-24.6 to 43.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-15.0 (-55.3 to 144.1)	-34.2 (-64.3 to 83.2)
G6PD trait	2,525.9 (2,301.2 to 2,718.3)	3,933.3 (3,622.8 to 4,217.1)	55.5 (39.5 to 75.9)	0.3 (-10.1 to 13.4)	0.2 (0.0 to 0.3)	0.2 (0.1 to 0.3)	-2.5 (-67.1 to 264.0)	-21.3 (-72.8 to 168.8)
Other hemoglobinopathies and hemolytic anemias	73.7 (64.4 to 83.2)	98.8 (90.1 to 107.3)	33.8 (17.9 to 53.6)	-4.4 (-14.4 to 6.6)	1.8 (1.1 to 2.6)	2.3 (1.5 to 3.3)	30.5 (3.8 to 57.2)	-0.7 (-19.2 to 17.8)
Endocrine, metabolic, blood, and immune disorders	91.4 (80.7 to 101.4)	132.3 (116.9 to 146.5)	44.8 (27.8 to 63.6)	5.2 (-5.6 to 17.0)	2.6 (1.7 to 3.8)	3.9 (2.5 to 5.5)	49.9 (21.8 to 81.0)	9.9 (-9.1 to 29.6)
Musculoskeletal disorders	-	-	-	-	271.9 (188.4 to 365.2)	569.6 (391.4 to 760.8)	108.5 (74.9 to 155.4)	4.6 (-9.1 to 23.6)
Rheumatoid arthritis	54.4 (51.2 to 58.3)	120.2 (112.6 to 127.1)	121.2 (101.3 to 141.3)	4.0 (-5.2 to 13.2)	12.9 (9.1 to 17.1)	28.1 (19.9 to 37.2)	118.4 (97.8 to 138.8)	3.6 (-5.7 to 13.3)
Osteoarthritis	430.0 (414.2 to 447.7)	1,052.3 (1,014.0 to 1,093.4)	144.3 (131.8 to 158.2)	1.2 (-3.9 to 6.5)	26.4 (18.3 to 35.7)	64.2 (44.7 to 87.1)	143.3 (129.8 to 157.6)	1.1 (-1.1 to 6.8)
Low back and neck pain	-	-	-	-	195.5 (130.0 to 277.3)	369.2 (244.9 to 515.5)	69.1 (47.3 to 154.0)	-1.6 (-20.2 to 28.5)
Low back pain	1,277.9 (1,022.4 to 1,640.0)	2,447.9 (1,973.2 to 3,038.6)	91.0 (38.3 to 173.1)	0.5 (-25.0 to 36.6)	143.6 (90.4 to 211.2)	273.0 (175.1 to 397.4)	90.2 (36.8 to 172.5)	0.3 (-25.3 to 36.9)
Neck pain	524.7 (424.6 to 654.8)	977.8 (711.9 to 1,209.9)	87.0 (22.9 to 160.9)	-1.6 (-33.9 to 31.5)	51.9 (33.7 to 76.0)	96.2 (59.6 to 142.4)	85.7 (22.7 to 159.3)	-2.0 (-34.4 to 32.0)
Gout	6.7 (5.7 to 7.9)	15.6 (13.0 to 18.1)	131.2 (84.1 to 196.7)	2.3 (-17.3 to 28.1)	0.2 (0.0 to 0.3)	0.5 (0.3 to 0.7)	129.8 (72.6 to 217.2)	2.1 (-22.3 to 38.7)
Other musculoskeletal disorders	401.7 (333.8 to 474.8)	1,182.0 (943.3 to 1,427.3)	194.1 (167.5 to 218.9)	35.5 (-24.3 to 52.4)	36.9 (24.3 to 52.4)	107.6 (69.4 to 154.8)	192.3 (164.9 to 216.6)	15.3 (-23.2 to 45.3)
Other non-communicable diseases	-	-	-	-	280.5 (190.4 to 401.1)	501.6 (346.0 to 715.4)	78.8 (72.7 to 85.0)	-3.5 (-6.0 to -0.7)
Congenital anomalies	-	-	-	-	25.6 (18.7 to 33.2)	46.8 (34.0 to 61.9)	82.1 (59.8 to 111.8)	19.7 (4.9 to 39.0)
Neural tube defects	6.6 (5.4 to 8.4)	10.0 (7.9 to 12.6)	50.7 (13.2 to 105.4)	7.3 (-19.3 to 46.2)	2.2 (1.4 to 3.2)	3.2 (2.0 to 4.7)	50.1 (4.4 to 130.3)	8.0 (-27.9 to 66.4)
Congenital heart anomalies	95.0 (76.7 to 115.0)	208.7 (178.6 to 254.7)	120.2 (70.8 to 187.1)	53.6 (-19.4 to 101.1)	3.3 (1.4 to 5.8)	7.6 (3.3 to 13.3)	17.7 (77.0 to 194.2)	61.0 (-26.2 to 107.1)
Orofacial clefts	20.5 (15.3 to 27.0)	38.5 (31.2 to 48.1)	85.6 (36.6 to 171.5)	0.3 (-0.1 to 0.9)	0.4 (0.2 to 0.5)	0.4 (0.2 to 0.6)	35.3 (9.0 to 111.7)	-1.3 (-33.3 to 53.2)
Down syndrome	25.8 (20.9 to 31.6)	48.2 (41.0 to 58.5)	86.6 (43.9 to 146.3)	21.8 (-5.8 to 61.7)	3.2 (2.2 to 4.3)	6.5 (4.8 to 9.0)	104.9 (54.5 to 175.8)	27.7 (-3.5 to 72.1)
Turner syndrome	0.7 (0.6 to 1.0)	1.2 (0.9 to 1.4)	58.9 (12.0 to 119.0)	7.3 (-24.4 to 48.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.2 (10.6 to 129.5)	6.6 (-26.1 to 54.0)
Klinefelter syndrome	0.6 (0.4 to 0.8)	0.9 (0.7 to 1.2)	53.9 (-1.6 to 121.9)	1.2 (-35.2 to 45.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.6 (3.3 to 130.9)	0.8 (-35.5 to 45.4)
Chromosomal unbalanced rearrangements	33.6 (26.5 to 41.6)	60.7 (54.5 to 69.4)	81.4 (37.1 to 139.3)	4.1 (-10.5 to 57.4)	8.2 (2.9 to 5.7)	8.2 (5.9 to 10.9)	24.1 (43.5 to 165.7)	24.1 (-7.7 to 67.2)
Other congenital anomalies	90.6 (76.1 to 105.0)	127.0 (107.2 to 148.0)	40.2 (27.8 to 52.4)	-13.0 (-20.3 to -4.8)	12.5 (8.4 to 17.3)	20.9 (14.1 to 29.0)	66.4 (37.6 to 107.2)	8.3 (-9.7 to 35.2)
Skin and subcutaneous diseases	-	-	-	-	93.0 (59.7 to 139.2)	154.6 (100.1 to 234.2)	66.2 (54.9 to 81.0)	3.6 (-2.4 to 13.1)
Dermatitis	1,006.6 (803.1 to 1,236.0)	1,630.2 (1,309.5 to 1,981.7)	62.0 (57.5 to 65.7)	-0.0 (-0.0 to 0.0)	31.1 (19.1 to 46.2)	48.1 (29.5 to 70.4)	54.9 (47.4 to 61.6)	0.1 (-2.6 to 2.7)
Psoriasis	145.7 (127.9 to 165.0)	258.3 (225.3 to 291.8)	77.0 (73.3 to 81.7)	0.0 (-0.0 to 0.0)	12.0 (8.0 to 16.8)	21.0 (14.2 to 29.8)	75.3 (65.8 to 87.1)	0.1 (-4.9 to 4.9)
Cellulitis	0.9 (0.7 to 1.0)	1.5 (1.3 to 1.8)	71.2 (56.2 to 91.8)	1.0 (-5.8 to 9.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	70.5 (54.3 to 93.3)	1.5 (-8.5 to 13.9)
Pyoderma	6.3 (4.7 to 8.5)	8.3 (6.0 to 11.1)	32.2 (15.5 to 50.6)	-13.4 (-22.7 to -1.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	31.9 (7.5 to 63.2)	-13.4 (-27.7 to 5.0)
Scabies	213.0 (188.9 to 240.3)	303.1 (272.1 to 334.9)	42.6 (20.5 to 68.0)	-2.9 (-17.7 to 13.8)	5.5 (3.1 to 8.9)	7.8 (4.4 to 12.6)	42.1 (19.9 to 67.0)	-2.8 (-17.9 to 14.1)
Fungal skin diseases	1,372.7 (1,036.1 to 1,818.5)	2,315.3 (1,787.4 to 3,060.6)	68.8 (60.1 to 78.6)	7.8 (-0.0 to 0.0)	13.0 (11.5 to 17.2)	13.0 (5.3 to 29.1)	91.1 (59.6 to 78.2)	0.1 (-0.8 to 1.0)
Viral skin diseases	369.6 (285.2 to 447.2)	505.2 (387.9 to 626.1)	36.6 (29.5 to 42.8)	0.1 (-2.2 to 2.5)	1.1 (6.7 to 18.2)	15.7 (9.1 to 25.0)	36.5 (28.3 to 43.8)	0.3 (-3.5 to 4.3)
Acne vulgaris	985.4 (632.8 to 1,372.1)	1,699.7 (1,153.6 to 2,375.7)	79.1 (5.2 to 166.0)	25.7 (-25.9 to 84.3)	10.7 (4.3 to 22.4)	18.5 (7.8 to 36.6)	79.0 (4.6 to 165.9)	25.8 (-26.0 to 85.5)
Alopecia areata	16.8 (15.2 to 18.4)	28.4 (25.9 to 31.0)	68.2 (47.8 to 92.7)	-2.1 (-12.8 to 13.2)	0.6 (0.4 to 0.9)	1.0 (0.6 to 1.5)	68.0 (41.7 to 98.5)	-1.5 (-15.9 to 15.5)
Pruritus	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	85.9 (41.3 to 130.7)	0.0 (-23.7 to 24.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	85.9 (41.1 to 130.7)	-0.1 (-23.7 to 25.0)
Urticaria	132.4 (67.4 to 186.8)	297.8 (206.2 to 408.6)	113.6 (43.8 to 405.1)	15.3 (-22.0 to 120.1)	7.9 (3.4 to 12.9)	17.6 (10.0 to 27.9)	113.4 (42.9 to 414.1)	15.5 (-22.0 to 126.9)
Decubitus ulcer	2.1 (1.7 to 2.4)	4.5 (3.5 to 5.5)	121.6 (62.3 to 188.3)	-5.5 (-35.2 to 29.9)	0.3 (0.2 to 0.4)	0.7 (0.4 to 0.9)	117.2 (58.5 to 188.3)	-4.9 (-35.4 to 32.4)
Other skin and subcutaneous diseases	939.5 (639.8 to 1,373.9)	1,874.3 (1,214.3 to 2,909.1)	98.9 (79.0 to 119.0)	0.7 (-2.9 to 5.0)	5.5 (2.5 to 11.3)	11.0 (4.8 to 23.0)	98.1 (78.4 to 117.6)	0.7 (-2.9 to 5.2)
Sense organ diseases	-	-	-	-	116.7 (80.1 to 163.7)	210.7 (144.4 to 295.1)	80.4 (71.1 to 91.1)	-1.0 (-14.2 to -7.6)
Glaucoma	22.9 (19.6 to 26.4)	39.3 (33.3 to 46.2)	71.0 (50.3 to 99.2)	-21.4 (-30.9 to -6.6)	1.7 (1.2 to 2.3)	3.0 (2.1 to 4.3)	82.4 (50.5 to 116.3)	-18.6 (-33.7 to -0.4)
Cataract	76.8 (63.2 to 89.4)	141.5 (115.1 to 167.2)	83.8 (63.4 to 104.2)	-28.9 (-36.4 to -21.5)	5.3 (3.6 to 7.3)	10.1 (6.9 to 13.9)	91.3 (62.4 to 113.6)	-26.9 (-37.7 to -17.0)
Macular degeneration	28.2 (22.7 to 34.2)	73.4 (58.8 to 88.1)	160.5 (117.9 to 206.8)	5.3 (-12.7 to 25.4)	1.3 (0.9 to 1.9)	3.4 (2.2 to 4.8)	159.6 (114.4 to 208.8)	3.9 (-14.5 to 25.2)
Uncorrected refractive error	1,500.1 (1,307.1 to 1,708.5)	3,016.1 (2,641.9 to 3,368.1)	101.7 (67.0 to 137.9)	0.9 (-14.2 to 16.9)	23.9 (14.6 to 37.4)	43.7 (25.9 to 70.9)	82.0 (60.2 to 107.6)	-8.1 (-17.2 to 3.8)
Age-related and other hearing loss	2,140.4 (1,975.7 to 2,310.3)	4,167.3 (3,897.1 to 4,468.4)	94.5 (86.5 to 104.3)	-9.3 (-12.2 to -5.6)	68.0 (46.3 to 95.1)	83.0 (85.5 to 174.1)	126.2 (71.8 to 100.3)	10.1 (-14.2 to -5.6)
Other vision loss	58.1 (51.8 to 66.0)	73.4 (63.4 to 84.7)	25.4 (15.1 to 39.7)	-33.1 (-37.8 to -26.4)	4.5 (3.0 to 6.2)	6.1 (4.2 to 8.5)	37.9 (20.8 to 54	

Appendix Table G.4 - Venezuela prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	567.6 (555.3 to 582.1)	1,312.1 (1,277.8 to 1,346.5)	131.0 (123.0 to 139.1)	-3.0 (-6.3 to 0.3)	15.7 (10.6 to 21.7)	36.2 (24.5 to 49.9)	129.9 (121.9 to 138.4)	-3.1 (-6.4 to 0.3)
Other oral disorders	309.1 (290.0 to 327.4)	524.7 (495.1 to 552.6)	69.8 (56.1 to 83.5)	-1.0 (-8.7 to 6.8)	9.1 (5.8 to 13.6)	15.4 (9.7 to 22.9)	69.1 (54.7 to 84.6)	-1.0 (-8.7 to 7.4)
Injuries	-	-	-	-	99.1 (75.1 to 128.1)	113.1 (86.6 to 145.9)	14.1 (9.3 to 19.3)	-9.9 (-42.3 to -37.2)
Transport injuries	-	-	-	-	39.5 (29.7 to 51.3)	44.3 (33.2 to 56.6)	12.1 (5.6 to 20.0)	-4.8 (-45.6 to -39.2)
Road injuries	-	-	-	-	36.6 (27.5 to 47.4)	40.5 (30.4 to 51.7)	10.8 (4.2 to 19.4)	-4.4 (-46.5 to -39.6)
Pedestrian road injuries	-	-	-	-	12.2 (9.1 to 15.7)	13.4 (9.9 to 17.3)	9.6 (0.3 to 20.8)	-4.6 (-47.7 to -38.7)
Cyclist road injuries	-	-	-	-	2.1 (1.6 to 2.8)	1.9 (1.4 to 2.4)	-11.9 (-19.1 to -3.6)	-5.5 (-61.0 to -53.8)
Motorcyclist road injuries	-	-	-	-	3.1 (2.3 to 4.0)	3.5 (2.6 to 4.7)	15.1 (3.8 to 27.5)	-0.9 (-46.3 to -35.4)
Motor vehicle road injuries	-	-	-	-	18.2 (13.6 to 23.6)	21.2 (15.9 to 27.2)	16.2 (6.5 to 25.7)	-6.6 (-45.0 to -34.2)
Other road injuries	-	-	-	-	1.0 (0.7 to 1.2)	0.6 (0.4 to 0.8)	-40.3 (-45.5 to -34.4)	-6.9 (-71.4 to -65.9)
Other transport injuries	-	-	-	-	2.9 (2.2 to 3.9)	3.7 (2.8 to 4.8)	27.2 (16.6 to 38.8)	-34.4 (-39.3 to -28.9)
Unintentional injuries	-	-	-	-	48.2 (36.5 to 62.5)	49.5 (37.7 to 64.1)	2.6 (-1.3 to 6.8)	43.9 (-46.4 to -41.5)
Falls	-	-	-	-	14.3 (10.7 to 18.4)	23.1 (17.5 to 30.1)	61.8 (51.6 to 71.1)	-26.5 (-31.2 to -21.8)
Drowning	-	-	-	-	0.8 (0.6 to 1.1)	0.8 (0.6 to 1.1)	-2.8 (-13.2 to 8.1)	-46.1 (-51.3 to -40.5)
Fire, heat, and hot substances	-	-	-	-	2.2 (1.7 to 2.8)	2.0 (1.5 to 2.6)	-7.5 (-16.8 to 2.9)	-47.8 (-52.3 to -42.8)
Poisonings	-	-	-	-	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.2)	-21.1 (-35.4 to -4.3)	-53.0 (-60.6 to -43.6)
Exposure to mechanical forces	-	-	-	-	28.3 (21.3 to 36.9)	18.5 (13.9 to 24.4)	-34.5 (-38.6 to -29.8)	-62.8 (-65.4 to -59.6)
Unintentional firearm injuries	-	-	-	-	1.9 (1.5 to 2.5)	2.8 (2.1 to 3.7)	47.1 (33.6 to 62.7)	-18.6 (-25.9 to -10.5)
Unintentional suffocation	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	33.5 (16.5 to 50.3)	-26.2 (-34.7 to -17.5)
Other exposure to mechanical forces	-	-	-	-	26.1 (19.5 to 34.1)	15.3 (11.4 to 20.2)	-41.4 (-45.5 to -36.6)	-66.7 (-69.3 to -63.5)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	72.8 (61.6 to 84.8)	-13.4 (-19.0 to -7.5)
Animal contact	-	-	-	-	0.4 (0.3 to 0.5)	0.8 (0.6 to 1.1)	115.9 (96.2 to 134.9)	22.2 (12.6 to 32.6)
Venomous animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	101.9 (75.3 to 130.1)	15.8 (1.6 to 29.5)
Non-venomous animal contact	-	-	-	-	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.7)	125.2 (106.1 to 153.3)	26.4 (16.4 to 40.3)
Foreign body	-	-	-	-	0.8 (0.6 to 1.0)	1.0 (0.8 to 1.3)	22.9 (12.8 to 34.7)	-33.7 (-38.6 to -27.6)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.6)	36.3 (18.4 to 55.5)	-22.7 (-30.8 to -12.7)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	45.7 (28.9 to 64.4)	-17.4 (-27.0 to -6.2)
Foreign body in other body part	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	5.2 (-6.2 to 18.6)	-46.5 (-52.4 to -39.2)
Other unintentional injuries	-	-	-	-	1.1 (0.8 to 1.5)	2.8 (2.2 to 3.6)	149.5 (125.5 to 181.1)	18.0 (7.1 to 32.3)
Self-harm and interpersonal violence	-	-	-	-	11.3 (8.6 to 14.4)	18.9 (14.3 to 24.4)	66.3 (51.5 to 82.7)	-12.6 (-19.3 to -4.4)
Self-harm	-	-	-	-	0.6 (0.5 to 0.8)	1.1 (0.8 to 1.5)	80.7 (66.0 to 96.0)	-11.1 (-17.6 to -4.4)
Interpersonal violence	-	-	-	-	10.7 (8.2 to 13.6)	17.8 (13.5 to 22.9)	65.3 (51.1 to 82.9)	-12.6 (-19.8 to -4.1)
Assault by firearm	-	-	-	-	3.5 (2.6 to 4.5)	7.8 (5.8 to 10.3)	124.2 (104.7 to 148.0)	16.0 (6.7 to 28.1)
Assault by sharp object	-	-	-	-	2.3 (1.7 to 3.0)	4.1 (3.1 to 5.5)	77.2 (56.6 to 102.4)	-6.3 (-16.5 to 6.6)
Assault by other means	-	-	-	-	4.9 (3.7 to 6.3)	5.9 (4.5 to 7.5)	19.4 (7.1 to 30.6)	-36.2 (-42.1 to -30.7)
Forces of nature, war, and legal intervention	-	-	-	-	0.0 (0.0 to 0.1)	0.4 (0.3 to 0.7)	1,197.7 (556.9 to 2,720.6)	1,022.3 (470.7 to 2,354.2)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.1)	0.4 (0.2 to 0.7)	1,525.6 (729.2 to 3,440.9)	1,323.7 (627.9 to 3,006.5)
Collective violence and legal intervention	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	118.5 (19.3 to 227.9)	80.4 (1.6 to 169.1)

Appendix Table G.4 - Vietnam prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013	
All causes	-	-	-	-	8,513.8 (5,885.5 to 11,729.5)	9,232.7 (6,736.1 to 11,879.0)	10.4 (-9.1 to 23.2)	10.4 (-43.7 to -19.8)	
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	1,734.5 (1,189.5 to 2,443.8)	1,337.6 (943.2 to 1,825.4)	-22.9 (-28.4 to -15.9)	-35.0 (-39.7 to -28.8)	
HIV/AIDS and tuberculosis	-	-	-	-	27.6 (19.1 to 37.3)	85.7 (59.0 to 117.6)	207.5 (173.4 to 269.1)	70.9 (53.2 to 102.7)	
Tuberculosis	93.0 (88.1 to 97.3)	212.0 (204.2 to 219.3)	128.0 (117.8 to 138.6)	30.1 (24.2 to 36.1)	27.2 (18.8 to 36.7)	63.8 (44.3 to 84.6)	134.5 (117.8 to 153.1)	34.2 (25.3 to 44.2)	
HIV/AIDS	-	-	-	-	0.1 (0.1 to 0.0)	6,723.5 (1,890.4 to 16,756.7)	6,723.5 (2,149.8 to 17,922.6)	6,723.5 (1,890.6 to 9,520.6)	6,723.5 (1,161.4 to 9,644.6)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.1)	2.6 (1.1 to 5.0)	7,879.9 (2,493.6 to 18,646.5)	4,196.4 (1,323.1 to 10,060.6)	0.0 (0.0 to 0.0)	1.0 (0.3 to 2.0)	7,286.6 (2,149.8 to 17,922.6)	3,828.3 (1,161.4 to 9,644.6)	
HIV/AIDS resulting in other diseases	3.4 (1.2 to 11.4)	196.1 (137.9 to 274.6)	6,800.4 (1,605.0 to 15,747.0)	4,152.6 (956.3 to 9,703.1)	0.4 (0.1 to 0.4)	21.0 (10.9 to 38.5)	6,723.7 (1,831.0 to 18,874.1)	3,860.7 (1,036.2 to 10,970.8)	
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	237.9 (166.8 to 325.0)	160.3 (112.7 to 220.7)	-32.8 (-39.2 to -24.4)	-35.6 (-41.2 to -28.8)	
Diarrheal diseases	961.8 (877.8 to 1,058.2)	549.3 (499.3 to 597.7)	-42.9 (-50.3 to -34.7)	-40.6 (-48.0 to -32.6)	155.0 (104.4 to 216.8)	88.4 (58.4 to 122.2)	-43.0 (-50.3 to -34.2)	-46.2 (-47.7 to -31.3)	
Intestinal infectious diseases	-	-	-	-	1.9 (1.2 to 2.7)	1.2 (0.7 to 1.7)	-1.2 (-53.2 to -20.2)	-1.2 (-56.4 to -28.8)	
Typhoid fever	10.4 (8.5 to 12.2)	7.0 (5.7 to 8.1)	-32.3 (-47.2 to -16.3)	-38.5 (-51.5 to -24.8)	1.4 (0.9 to 2.1)	1.0 (0.6 to 1.4)	-31.2 (-49.1 to -10.4)	-37.9 (-53.2 to -19.9)	
Paratyphoid fever	6.6 (5.5 to 7.9)	3.5 (2.8 to 4.2)	-47.3 (-61.2 to -32.7)	-50.3 (-62.7 to -37.7)	0.3 (0.2 to 0.5)	0.2 (0.1 to 0.3)	-47.0 (-62.5 to -28.5)	-50.0 (-63.7 to -34.3)	
Other intestinal infectious diseases	-	-	-	-	0.1 (0.1 to 0.3)	0.0 (0.0 to 0.1)	-71.1 (-88.6 to -34.6)	-77.2 (-89.4 to -41.1)	
Lower respiratory infections	41.5 (35.4 to 48.8)	60.2 (51.4 to 67.9)	46.1 (15.5 to 78.3)	39.2 (10.1 to 67.0)	4.3 (2.7 to 6.2)	6.1 (4.1 to 8.7)	44.1 (11.0 to 81.9)	39.9 (8.9 to 73.4)	
Upper respiratory infections	1,973.0 (1,817.0 to 2,151.4)	2,591.4 (2,358.7 to 2,840.7)	30.7 (16.7 to 50.6)	3.6 (-7.4 to 19.1)	23.0 (12.8 to 38.3)	30.4 (17.1 to 49.8)	31.5 (16.3 to 52.3)	5.3 (-6.6 to 21.1)	
Otitis media	906.4 (850.2 to 971.8)	890.6 (831.6 to 945.0)	-1.7 (-9.7 to 6.4)	-16.5 (-22.7 to -9.6)	17.7 (10.5 to 28.0)	17.6 (10.6 to 28.2)	-0.6 (-9.8 to 8.7)	-14.5 (-21.7 to -6.4)	
Meningitis	-	-	-	-	27.1 (18.0 to 38.1)	8.7 (5.9 to 12.3)	-67.7 (-73.5 to -60.3)	-74.4 (-78.9 to -68.8)	
Pneumococcal meningitis	158.4 (87.5 to 244.9)	55.7 (32.4 to 88.5)	-65.3 (-73.7 to -51.1)	-75.2 (-81.3 to -64.8)	12.0 (8.1 to 16.8)	4.5 (3.0 to 6.3)	-45.0 (-71.0 to -50.6)	-71.3 (-77.4 to -62.0)	
H influenzae type B meningitis	70.6 (26.3 to 133.7)	16.4 (5.5 to 32.6)	-76.7 (-84.6 to -67.6)	-82.7 (-88.4 to -75.8)	6.5 (3.8 to 10.2)	1.7 (1.1 to 2.6)	-74.1 (-83.1 to -57.9)	-78.7 (-85.9 to -65.7)	
Meningococcal meningitis	10.5 (3.7 to 22.4)	3.5 (1.1 to 7.7)	-67.4 (-80.3 to -54.1)	-77.6 (-86.0 to -68.4)	1.2 (0.7 to 2.0)	0.4 (0.2 to 0.6)	-67.7 (-79.7 to -55.7)	-76.4 (-84.8 to -68.0)	
Other meningitis	67.0 (31.3 to 120.4)	19.0 (8.8 to 36.5)	-72.0 (-79.1 to -63.2)	-78.8 (-83.9 to -72.1)	7.3 (4.5 to 11.3)	2.2 (1.4 to 3.2)	-70.7 (-78.8 to -58.9)	-76.2 (-82.6 to -66.8)	
Encephalitis	27.7 (12.6 to 57.7)	27.4 (12.1 to 60.3)	-0.3 (-24.5 to 13.4)	-29.9 (-48.9 to -23.3)	3.2 (2.2 to 4.4)	3.3 (2.2 to 4.5)	-0.9 (-14.1 to 21.7)	-28.6 (-39.5 to -15.7)	
Diphtheria	0.0 (0.0 to 0.2)	0.0 (0.0 to 0.0)	-	-	0.0 (-97.6 to 254.4)	0.0 (0.0 to 0.0)	-	-	
Whooping cough	38.8 (30.4 to 49.4)	15.8 (12.3 to 20.2)	-59.5 (-61.1 to -57.8)	-47.2 (-49.4 to -45.1)	1.9 (1.1 to 3.1)	0.8 (0.4 to 1.3)	-59.2 (-64.6 to -53.3)	-47.0 (-53.9 to -39.2)	
Tetanus	11.0 (5.3 to 19.3)	0.9 (0.6 to 1.4)	-91.3 (-96.0 to -82.8)	-93.2 (-96.9 to -86.9)	0.6 (0.3 to 1.0)	0.1 (0.0 to 0.1)	-88.4 (-94.5 to -73.8)	-90.4 (-95.3 to -79.3)	
Measles	9.0 (7.2 to 11.2)	1.0 (0.8 to 1.4)	-88.5 (-90.6 to -85.9)	-85.3 (-88.0 to -81.9)	0.8 (0.5 to 1.3)	0.1 (0.0 to 0.2)	-88.5 (-93.7 to -81.2)	-85.4 (-92.0 to -76.0)	
Varicella and herpes zoster	71.3 (66.3 to 77.4)	93.6 (84.1 to 103.9)	31.0 (14.7 to 49.6)	0.9 (-13.0 to 16.6)	2.4 (1.4 to 3.7)	3.7 (2.2 to 5.9)	55.5 (26.4 to 94.6)	3.3 (-16.5 to 27.7)	
Neglected tropical diseases and malaria	-	-	-	-	382.9 (234.3 to 604.2)	276.0 (171.0 to 435.2)	-28.0 (-35.0 to -16.9)	-46.4 (-51.9 to -38.2)	
Malaria	307.5 (285.2 to 330.0)	392.2 (365.6 to 419.4)	27.7 (21.5 to 33.2)	-3.7 (-8.6 to 0.5)	2.2 (1.4 to 3.3)	3.0 (1.9 to 4.5)	39.8 (6.7 to 97.5)	15.8 (-15.6 to 64.4)	
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	
Leishmaniasis	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-61.2 (-71.3 to -46.2)	-73.5 (-80.2 to -63.7)	
Visceral leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.7 (-65.3 to 50.2)	-24.3 (-61.5 to 52.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-29.7 (-65.4 to 50.6)	-24.3 (-61.5 to 52.9)	
Cutaneous and mucocutaneous leishmaniasis	5.2 (3.7 to 6.8)	1.9 (1.4 to 2.6)	-62.6 (-70.2 to -53.5)	-74.9 (-79.8 to -69.0)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-61.3 (-71.4 to -46.3)	-73.6 (-80.3 to -63.8)	
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	
Schistosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	
Cysticercosis	24.1 (14.3 to 36.8)	8.8 (3.6 to 17.2)	-65.4 (-83.8 to -23.7)	-79.3 (-89.8 to -55.9)	6.2 (3.3 to 10.5)	2.6 (0.9 to 5.5)	-61.0 (-84.0 to -5.0)	-76.6 (-89.7 to -43.8)	
Cystic echinococcosis	10.2 (8.7 to 12.5)	11.4 (10.8 to 12.8)	19.7 (-10.6 to 40.6)	-18.5 (-36.3 to -3.4)	0.9 (0.6 to 1.4)	1.1 (0.7 to 1.5)	17.1 (-18.4 to 63.0)	-18.9 (-40.6 to 7.5)	
Lymphatic filariasis	17.2 (10.6 to 25.6)	7.8 (4.6 to 13.2)	-54.4 (-74.3 to -29.4)	-73.5 (-84.2 to -59.8)	0.7 (0.2 to 1.5)	0.6 (0.2 to 1.4)	-7.4 (-45.5 to 55.0)	-50.0 (-70.7 to -15.6)	
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	
Trachoma	59.3 (34.0 to 87.6)	27.4 (16.8 to 40.3)	-54.2 (-69.8 to -30.2)	-74.7 (-83.6 to -60.2)	3.3 (1.9 to 5.1)	1.6 (0.9 to 2.6)	-50.3 (-66.6 to -28.0)	-72.6 (-81.5 to -59.5)	
Dengue	20.8 (7.8 to 46.8)	135.0 (50.9 to 303.3)	548.3 (546.5 to 550.4)	398.3 (396.9 to 399.9)	3.4 (1.1 to 8.4)	21.9 (7.5 to 54.1)	551.3 (455.3 to 683.3)	407.2 (340.4 to 499.1)	
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	
Intestinal nematode infections	-	-	-	-	314.7 (183.6 to 518.1)	213.6 (123.2 to 344.6)	-32.2 (-39.0 to -25.3)	-51.4 (-56.3 to -46.2)	
Ascariasis	28,367.3 (25,203.7 to 31,998.2)	20,313.3 (14,238.4 to 29,002.5)	-30.0 (-50.4 to -3.2)	-50.5 (-64.8 to -26.5)	147.5 (80.4 to 254.5)	66.4 (35.4 to 111.6)	-54.9 (-62.0 to -46.5)	-67.1 (-72.4 to -60.7)	
Trichuriasis	14,309.1 (11,847.5 to 17,209.4)	10,655.8 (6,474.2 to 17,413.5)	-27.0 (-56.0 to 25.3)	-48.5 (-68.7 to -10.5)	44.2 (24.2 to 74.0)	22.7 (12.1 to 38.8)	-48.6 (-62.9 to -30.3)	-64.1 (-74.8 to -51.4)	
Hookworm disease	20,450.8 (18,065.4 to 23,279.4)	23,801.5 (15,886.2 to 31,464.8)	11.4 (-25.3 to 61.6)	-12.9 (-47.7 to 12.9)	122.9 (73.6 to 195.4)	124.5 (72.9 to 199.8)	-0.6 (-11.4 to 10.1)	-28.5 (-37.8 to -18.7)	
Food-borne trematodiasis	150.1 (114.5 to 185.3)	236.6 (178.3 to 294.7)	57.7 (43.6 to 70.8)	-4.3 (-9.3 to 0.3)	2.9 (1.8 to 4.3)	4.9 (3.0 to 7.3)	67.6 (44.0 to 94.1)	-2.5 (-14.0 to 11.6)	
Other neglected tropical diseases	1,341.9 (1,055.8 to 1,639.6)	838.9 (744.0 to 947.8)	-37.8 (-49.2 to -19.9)	-39.3 (-49.2 to -24.6)	48.6 (30.6 to 71.0)	26.7 (16.9 to 38.7)	-45.8 (-55.1 to -23.5)	-42.2 (-52.3 to -20.6)	
Maternal disorders	-	-	-	-	2.6 (1.7 to 4.0)	2.1 (1.3 to 3.1)	-19.6 (-41.7 to 5.1)	-46.8 (-61.5 to -31.3)	
Maternal hemorrhage	20.5 (17.4 to 23.2)	23.9 (15.6 to 31.0)	16.8 (-22.7 to 52.3)	-22.0 (-48.2 to 3.4)	0.9 (0.6 to 1.4)	0.9 (0.5 to 1.4)	-4.5 (-45.7 to 41.8)	-35.5 (-63.4 to -5.0)	
Maternal sepsis and other maternal infections	20.3 (11.5 to 33.1)	15.6 (9.5 to 24.3)	-22.6 (-44.5 to 8.7)	-57.9 (-71.0 to -40.2)	0.2 (0.1 to 0.6)	0.2 (0.1 to 0.3)	-37.3 (-66.8 to 21.4)	-61.1 (-77.8 to -29.1)	
Maternal hypertensive disorders	12.2 (6.0 to 20.9)	8.9 (4.4 to 15.1)	-28.0 (-34.1 to -14.7)	-51.8 (-57.9 to -42.4)	0.6 (0.3 to 1.2)	0.4 (0.2 to 0.9)	-27.7 (-46.3 to -8.8)	-52.0 (-64.6 to -33.8)	
Obstructed labor	0.7 (0.3 to 1.1)	0.4 (0.2 to 0.6)	-48.4 (-68.5 to 2.6)	-66.1 (-79.2 to -34.9)	0.2 (0.1 to 0.4)	0.1 (0.1 to 0.2)	-43.9 (-72.0 to 74.9)	-63.1 (-80.9 to 5.9)	
Complications of abortion	0.4 (0.2 to 0.6)	0.3 (0.2 to 0.5)	-17.7 (-59.1 to 49.9)	-47.1 (-73.0 to -8.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-	-	
Other maternal disorders	-	-	-	-	0.5 (0.2 to 0.9)	0.4 (0.2 to 0.7)	-18.6 (-58.4 to 88.3)	-46.4 (-72.7 to 24.1)	
Neonatal disorders	-	-	-	-	97.3 (64.5 to 141.8)	234.2 (158.6 to 328.4)	140.7 (69.6 to 244.5)	97.3 (37.6 to 179.7)	
Preterm birth complications	618.1 (399.6 to 987.6)	1,885.9 (1,267.2 to 2,865.0)	205.5 (133.7 to 301.6)	136.4 (80.5 to 210.9)	55.4 (36.4 to 84.0)	171.4 (115.9 to 242.5)	210.3 (113.4 to 352.9)	150.7 (72.9 to 266.0)	
Neonatal encephalopathy due to birth asphyxia and trauma	326.3 (114.7 to 705.0)	397.1 (152.5 to 679.1)	6.1 (-34.9 to 81.6)	-17.9 (-50.2 to 43.3)	23.1 (13.9 to 37.1)	33.3 (20.8 to 49.2)	45.1 (-9.3 to 146.8)	22.1 (-22.8 to 107.4)	
Neonatal sepsis and other neonatal infections	0.2 (0.0 to 0.3)	0.2 (0.1 to 0.4)	14.6 (-4.9 to 22.0)	58.8 (31.9 to 69.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	10.2 (-9.0 to 30.3)	52.8 (26.1 to 94.4)	
Hemolytic disease and other neonatal jaundice	23.9 (11.2 to 46.0)	51.0 (18.8 to 111.7)	105.3 (-35.7 to 627.1)	64.0 (-48.9 to 478.5)	7.0 (3.3 to 12.8)	14.0 (5.2 to 30.5)	86.5 (-32.4 to 530.5)	51.3 (-45.4 to 427.4)	
Other neonatal disorders	-	-	-	-	11.7 (3.9 to 31.7)	15.5 (7.1 to 28.1)	48.3 (-62.4 to 318.8)	19.6 (-69.3 to 238.9)	
Nutritional deficiencies	-	-	-	-	934.4 (633.7 to 1,335.6)	537.1 (356.7 to 783.2)	-42.6 (-48.4 to -36.1)	-48.7 (-53.3 to -42.9)	
Protein-energy malnutrition	340.2 (246.5 to 455.1)	234.8 (138.1 to 370.4)	-32.6 (-62.4 to 17.8)	-11.5 (-50.5 to 54.9)	42.1 (25.1 to 65.7)	29.3 (14.3 to 49.7)	-29.0 (-61.8 to 20.8)	-10.6 (-49.7 to 58.8)	
Iodine deficiency	643.7 (303.8 to 1,094.3)	630.2 (315.0 to 981.3)	-0.5 (-55.2 to 115.9)	-37.7 (-72.3 to 36.8)	11.4 (4.7 to 22.4)	11.3 (4.7 to 21.1)	0.4 (-55.4 to 123.9)	-36.7 (-71.8 to 40.6)	
Vitamin A deficiency	25.5 (18.7 to 32.4)	13.7 (9.7 to 18.4)	-46.3 (-55.9 to -35.8)	-52.6 (-60.1 to -45.8)	1.1 (0.6 to 1.7)	0.6 (0.3 to 0.9)	-47.8 (-59.1 to -34.9)	-56.3 (-65.2 to -47.2)	

Appendix Table G.4 - Vietnam prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	23,864.5 (23,600.5 to 24,114.0)	15,936.8 (15,663.8 to 16,227.9)	-33.3 (-34.7 to -31.7)	-47.4 (-48.6 to -46.2)	807.6 (540.4 to 1,160.4)	449.7 (298.5 to 661.4)	-44.4 (-46.6 to -42.2)	-44.4 (-54.2 to -50.8)
Other nutritional deficiencies	-	-	-	-	72.1 (26.2 to 163.0)	46.2 (18.6 to 93.6)	-33.3 (-73.7 to 58.0)	-12.5 (-65.5 to 107.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	51.9 (32.8 to 75.8)	42.2 (26.7 to 63.7)	-19.0 (-29.4 to -5.2)	-31.9 (-40.8 to -22.6)
Sexually transmitted diseases excluding HIV	-	-	-	-	10.2 (5.7 to 16.6)	15.5 (8.3 to 25.5)	51.5 (26.6 to 88.6)	-2.9 (-17.9 to 18.4)
Syphilis	2.4 (2.1 to 2.7)	2.5 (2.2 to 2.8)	2.5 (-14.3 to 26.8)	-43.7 (-52.1 to -32.2)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	25.0 (-21.3 to 45.3)	41.0 (-57.3 to -19.6)
Chlamydial infection	1,300.2 (904.1 to 1,730.7)	1,911.5 (1,556.7 to 2,282.3)	49.1 (-2.1 to 111.6)	-1.2 (-33.9 to 35.9)	5.9 (3.0 to 9.9)	9.1 (4.8 to 15.2)	54.9 (17.3 to 120.4)	3.3 (-21.0 to 44.7)
Gonococcal infection	219.1 (152.3 to 287.2)	303.9 (242.1 to 378.4)	37.3 (-4.0 to 122.3)	-2.9 (-31.6 to 54.5)	1.5 (0.8 to 2.6)	2.2 (1.2 to 3.6)	43.2 (-6.7 to 122.6)	0.1 (-34.0 to 53.7)
Trichomoniasis	189.3 (68.8 to 288.8)	308.4 (194.3 to 443.5)	63.5 (-19.1 to 330.0)	-7.7 (-52.0 to 147.8)	0.3 (0.1 to 0.7)	0.5 (0.2 to 1.2)	69.1 (-28.8 to 489.1)	-5.4 (-57.7 to 230.8)
Genital herpes	6,945.0 (6,663.7 to 7,290.7)	11,144.0 (10,600.8 to 11,730.3)	60.2 (49.0 to 72.5)	9.4 (-15.8 to -2.8)	1.8 (0.6 to 4.3)	2.9 (0.9 to 7.0)	58.5 (43.1 to 72.4)	7.7 (-15.5 to 0.1)
Other sexually transmitted diseases	7.5 (5.7 to 9.9)	9.1 (7.0 to 11.8)	21.6 (-0.1 to 46.2)	-31.7 (-44.4 to -17.3)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	39.3 (-12.1 to 124.1)	14.1 (-43.2 to 34.8)
Hepatitis	-	-	-	-	5.5 (3.5 to 8.0)	6.5 (4.1 to 9.5)	19.5 (2.9 to 36.9)	-18.7 (-30.7 to -6.4)
Hepatitis A	108.0 (103.3 to 112.6)	99.1 (96.6 to 101.5)	-8.3 (-9.9 to -6.6)	-9.8 (-10.1 to -9.4)	2.2 (1.4 to 3.2)	2.6 (1.7 to 3.9)	20.6 (7.1 to 34.5)	3.2 (-7.9 to 15.4)
Hepatitis B	6,163.3 (5,528.7 to 6,871.4)	5,892.4 (5,260.2 to 6,580.0)	-4.2 (-19.4 to 10.9)	-33.2 (-43.3 to -23.1)	2.6 (1.6 to 3.8)	3.1 (1.9 to 4.7)	22.4 (9.1 to 59.1)	-29.1 (-47.6 to -8.0)
Hepatitis C	2,477.3 (2,265.6 to 2,702.5)	2,896.6 (2,625.7 to 3,145.9)	16.9 (2.6 to 31.7)	-28.0 (-36.1 to -19.3)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	4.2 (-21.0 to 36.7)	-29.3 (-47.1 to -7.0)
Hepatitis E	14.7 (12.2 to 17.3)	15.2 (11.6 to 18.5)	3.4 (-24.3 to 34.5)	-30.1 (-47.4 to -3.3)	0.4 (0.3 to 0.6)	0.7 (0.3 to 0.7)	5.8 (-30.0 to 57.8)	-28.4 (-52.8 to 9.6)
Leprosy	9.7 (7.6 to 12.1)	9.6 (8.2 to 11.2)	-0.7 (-9.1 to 10.7)	-44.5 (-49.0 to -38.6)	0.6 (0.4 to 0.9)	0.6 (0.4 to 0.9)	1.8 (-15.7 to 25.4)	-43.0 (-51.8 to -31.0)
Other infectious diseases	1,017.4 (825.4 to 1,212.0)	640.4 (547.0 to 743.1)	-37.1 (-47.1 to -25.1)	-42.8 (-51.6 to -31.6)	35.7 (22.0 to 51.9)	19.6 (11.6 to 29.0)	-44.9 (-57.7 to -35.4)	-44.4 (-57.4 to -35.5)
Non-communicable diseases	-	-	-	-	6,075.1 (3,004.5 to 5,222.7)	6,707.3 (4,944.7 to 8,654.0)	10.8 (57.9 to 71.8)	2.0 (-1.9 to 6.8)
Neoplasms	-	-	-	-	32.9 (23.7 to 43.2)	55.6 (39.1 to 75.3)	67.6 (32.7 to 118.7)	-12.0 (-30.6 to 14.0)
Esophageal cancer	2.9 (1.9 to 4.3)	8.1 (4.6 to 12.1)	186.8 (34.5 to 429.3)	44.5 (-32.4 to 169.9)	0.5 (0.3 to 0.7)	1.2 (0.7 to 2.0)	177.1 (42.1 to 400.7)	38.7 (-28.6 to 151.9)
Stomach cancer	31.0 (24.7 to 38.0)	39.2 (28.8 to 54.3)	24.3 (-13.9 to 88.1)	-38.6 (-57.8 to -5.9)	3.9 (2.7 to 5.2)	4.9 (3.3 to 7.3)	26.3 (8.7 to 80.1)	-37.6 (-55.2 to -11.0)
Liver cancer	-	-	-	-	2.1 (1.4 to 2.9)	5.1 (3.3 to 7.3)	136.3 (61.6 to 245.4)	25.7 (-15.2 to 83.3)
Liver cancer due to hepatitis B	4.8 (2.7 to 7.5)	12.2 (6.8 to 18.9)	153.3 (27.5 to 383.0)	33.9 (-31.3 to 156.6)	0.8 (0.4 to 1.2)	2.0 (1.1 to 3.1)	143.8 (37.5 to 322.9)	29.3 (-25.8 to 130.0)
Liver cancer due to hepatitis C	3.1 (1.6 to 5.1)	13.3 (7.4 to 20.8)	331.0 (95.9 to 820.3)	120.4 (-1.8 to 370.2)	0.5 (0.3 to 0.8)	2.1 (1.2 to 3.4)	323.5 (117.7 to 678.8)	116.5 (13.1 to 300.9)
Liver cancer due to alcohol use	2.1 (1.2 to 3.5)	2.9 (1.5 to 5.0)	39.6 (-38.1 to 216.4)	-27.2 (-67.8 to 68.3)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.8)	37.4 (-35.1 to 181.7)	-27.5 (-66.6 to 51.3)
Liver cancer due to other causes	2.9 (1.7 to 4.5)	3.2 (1.8 to 5.5)	10.2 (-46.3 to 141.5)	-40.9 (-71.6 to 36.2)	0.5 (0.3 to 0.7)	0.5 (0.3 to 0.9)	9.9 (-41.7 to 112.6)	-39.8 (-69.1 to 23.0)
Larynx cancer	3.6 (2.5 to 6.9)	13.3 (6.6 to 19.7)	301.4 (49.7 to 571.3)	112.6 (-24.1 to 260.4)	0.4 (0.2 to 0.7)	1.2 (0.6 to 2.0)	257.3 (41.1 to 498.9)	88.8 (-27.0 to 224.3)
Tracheal, bronchus and lung cancer	20.8 (17.1 to 24.9)	33.0 (25.3 to 42.7)	58.0 (13.0 to 123.7)	-15.2 (-39.4 to 19.4)	3.4 (2.4 to 4.5)	5.2 (3.5 to 7.4)	48.1 (9.3 to 110.2)	-20.3 (-40.9 to 13.1)
Breast cancer	37.7 (28.2 to 47.4)	81.2 (61.0 to 108.2)	113.2 (48.8 to 232.0)	4.0 (-27.4 to 61.5)	3.2 (2.1 to 4.4)	5.4 (3.3 to 8.2)	67.1 (8.0 to 192.7)	-19.8 (-48.3 to 39.0)
Cervical cancer	33.5 (23.3 to 45.1)	30.2 (20.2 to 43.3)	-11.1 (-42.5 to 42.8)	-46.5 (-71.7 to -28.3)	2.1 (1.6 to 3.9)	2.4 (1.4 to 3.6)	11.4 (-43.6 to 45.2)	-96.7 (-72.6 to -27.4)
Uterine cancer	21.0 (8.4 to 33.2)	28.3 (13.3 to 47.3)	32.3 (-26.5 to 195.4)	-34.3 (-62.6 to 43.2)	1.4 (0.5 to 2.5)	1.9 (0.8 to 3.2)	28.9 (-29.9 to 194.6)	-35.7 (-64.0 to 40.8)
Prostate cancer	5.4 (3.5 to 8.1)	26.3 (14.8 to 53.4)	342.8 (148.3 to 1,019.1)	143.6 (36.1 to 482.1)	0.7 (0.4 to 1.1)	2.8 (1.4 to 6.1)	279.6 (105.7 to 1,028.7)	101.1 (11.1 to 468.8)
Colon and rectum cancer	27.4 (22.7 to 33.0)	48.0 (37.7 to 61.0)	73.5 (28.1 to 135.4)	-11.2 (-35.7 to 20.5)	2.7 (1.9 to 3.5)	4.1 (2.8 to 5.8)	53.7 (12.5 to 111.0)	-21.4 (-43.4 to 7.8)
Lip and oral cavity cancer	12.6 (9.2 to 18.7)	35.1 (17.6 to 52.6)	190.3 (28.4 to 379.5)	58.6 (-33.2 to 163.3)	1.1 (0.7 to 1.8)	3.1 (1.5 to 5.0)	184.0 (27.6 to 362.4)	54.1 (-33.7 to 151.7)
Nasopharynx cancer	14.3 (7.9 to 20.5)	3.2 (1.4 to 9.6)	-78.2 (-91.3 to 10.7)	91.8 (-95.2 to -36.2)	1.4 (0.7 to 2.1)	0.3 (0.1 to 1.0)	84.4 (-90.7 to 22.5)	-91.3 (-94.8 to -30.5)
Other pharynx cancer	10.0 (5.8 to 14.6)	9.9 (5.9 to 16.2)	-0.9 (-48.1 to 101.4)	-51.3 (-74.3 to 0.5)	1.0 (0.6 to 1.5)	0.9 (0.5 to 1.6)	-9.9 (-49.0 to 96.4)	-55.1 (-74.5 to -2.2)
Gallbladder and biliary tract cancer	0.4 (0.3 to 0.6)	0.8 (0.5 to 1.1)	86.7 (7.6 to 214.4)	-9.3 (-48.6 to 57.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.3)	78.5 (3.4 to 209.4)	-10.5 (-49.4 to 54.8)
Pancreatic cancer	1.0 (0.8 to 1.2)	1.6 (1.2 to 2.1)	62.5 (12.6 to 130.8)	-15.4 (-41.9 to 20.2)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	58.3 (14.7 to 110.3)	-16.6 (-60.1 to 12.8)
Malignant skin melanoma	1.7 (1.2 to 2.5)	2.8 (1.7 to 3.9)	59.1 (-7.7 to 155.1)	-22.2 (-55.7 to 25.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	29.6 (-18.6 to 127.7)	-31.4 (-42.2 to 13.4)
Non-melanoma skin cancer	6.2 (5.3 to 7.5)	16.0 (12.6 to 21.0)	153.6 (102.3 to 242.4)	37.7 (9.5 to 84.1)	0.2 (0.1 to 0.3)	0.7 (0.4 to 1.1)	215.0 (94.3 to 410.3)	72.9 (8.1 to 183.0)
Ovarian cancer	5.5 (4.2 to 7.2)	4.0 (2.6 to 6.1)	-28.2 (-56.9 to 21.2)	-65.6 (-79.4 to -43.0)	0.7 (0.5 to 1.0)	0.5 (0.3 to 0.9)	-28.5 (-57.7 to 22.0)	-65.4 (-79.5 to -42.4)
Testicular cancer	1.5 (0.8 to 2.4)	4.6 (2.3 to 7.6)	210.8 (68.9 to 437.6)	64.3 (-9.0 to 175.8)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.6)	178.8 (49.0 to 402.1)	45.9 (-19.5 to 167.0)
Kidney cancer	6.1 (0.8 to 1.5)	6.2 (2.8 to 5.2)	1.1 (123.0 to 430.1)	350.7 (18.4 to 187.6)	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.5)	211.2 (104.4 to 402.6)	72.0 (5.2 to 164.5)
Bladder cancer	6.1 (4.1 to 8.1)	5.2 (4.0 to 11.1)	-4.6 (-43.0 to 135.9)	-52.2 (-72.0 to 16.5)	0.6 (0.4 to 0.8)	0.5 (0.3 to 1.0)	-8.8 (-45.8 to 129.6)	-53.7 (-72.8 to 13.9)
Brain and nervous system cancer	6.2 (4.5 to 8.3)	18.1 (9.5 to 25.2)	198.2 (51.0 to 350.7)	76.5 (-1.9 to 160.3)	0.7 (0.4 to 1.0)	1.9 (0.9 to 3.0)	184.2 (52.0 to 318.5)	62.2 (6.6 to 136.5)
Thyroid cancer	14.6 (8.9 to 20.4)	22.6 (12.8 to 45.3)	32.5 (-23.9 to 290.8)	-31.5 (-61.6 to 91.9)	1.0 (0.6 to 1.5)	1.4 (0.7 to 3.0)	20.6 (-32.1 to 276.4)	-38.2 (-65.9 to 84.9)
Mesothelioma	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	0.1 (-23.2 to 94.8)	24.1 (55.6 to 13.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.7 (-20.6 to 103.0)	31.4 (-54.6 to 16.5)
Hodgkin lymphoma	4.1 (2.0 to 6.1)	2.4 (1.3 to 5.4)	-59.2 (-76.0 to 141.4)	-76.6 (-86.4 to 50.0)	0.4 (0.2 to 0.7)	0.2 (0.1 to 0.6)	-67.7 (-80.3 to 144.8)	-81.4 (-89.5 to 50.4)
Non-Hodgkin lymphoma	13.1 (9.5 to 17.0)	40.8 (27.7 to 55.3)	209.8 (102.5 to 372.8)	89.8 (18.5 to 180.3)	1.0 (0.7 to 1.5)	3.1 (1.9 to 4.7)	192.7 (85.4 to 336.8)	73.9 (8.2 to 155.6)
Multiple myeloma	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	137.5 (42.9 to 276.2)	21.2 (-27.0 to 91.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	123.7 (40.8 to 240.2)	14.7 (-27.7 to 73.6)
Leukemia	11.0 (6.2 to 17.2)	20.5 (15.2 to 27.3)	90.1 (9.5 to 262.2)	39.6 (-11.7 to 132.0)	1.4 (0.9 to 2.1)	2.4 (1.6 to 3.5)	71.2 (16.7 to 160.3)	9.8 (-24.3 to 62.4)
Other neoplasms	21.9 (15.2 to 33.9)	64.8 (45.6 to 86.0)	206.7 (66.5 to 361.8)	81.2 (5.4 to 170.7)	1.7 (1.0 to 2.8)	4.6 (2.8 to 6.8)	151.0 (59.3 to 311.8)	59.7 (3.5 to 138.3)
Cardiovascular diseases	-	-	-	-	144.5 (100.2 to 194.5)	314.2 (215.5 to 434.2)	117.9 (75.6 to 162.1)	23.9 (0.8 to 28.9)
Rheumatic heart disease	902.1 (699.6 to 1,105.2)	1,370.4 (1,138.0 to 1,647.7)	51.1 (14.6 to 106.7)	-4.4 (-26.2 to 30.4)	44.9 (27.0 to 67.2)	71.2 (45.0 to 105.1)	58.2 (20.5 to 112.6)	0.2 (-22.6 to 33.7)
Ischemic heart disease	400.2 (334.0 to 495.3)	720.0 (604.1 to 871.8)	79.1 (38.4 to 140.2)	0.0 (-22.3 to 35.1)	26.1 (17.8 to 37.6)	50.1 (33.2 to 70.6)	90.5 (48.0 to 154.1)	5.5 (-17.6 to 41.7)
Cerebrovascular disease	-	-	-	-	21.8 (15.5 to 28.2)	36.0 (25.4 to 48.9)	65.1 (37.6 to 97.4)	-7.4 (-23.2 to 10.9)
Ischemic stroke	76.5 (67.6 to 85.0)	121.3 (102.6 to 142.1)	58.0 (31.3 to 90.9)	-10.9 (-26.9 to 7.8)	10.4 (7.1 to 14.2)	17.5 (12.0 to 24.3)	66.7 (36.2 to 107.0)	-5.5 (-23.5 to 16.9)
Hemorrhagic stroke	81.7 (73.2 to 91.5)	127.2 (110.3 to 147.5)	55.8 (29.0 to 83.7)	-13.4 (-28.8 to 2.3)	11.3 (7.8 to 15.1)	18.5 (12.7 to 25.3)	63.7 (34.4 to 97.7)	-8.7 (-25.8 to 9.8)
Hypertensive heart disease	99.4 (86.6 to 114.1)	194.5 (166.1 to 222.1)	96.3 (57.2 to 133.7)	6.8 (-15.2 to 27.9)	10.3 (7.9 to 14.5)	21.2 (14.4 to 29.4)	105.7 (64.0 to 147.2)	11.9 (-11.1 to 35.0)
Cardiomyopathy and myocarditis	42.1 (35.9 to 49.6)	87.5 (77.7 to 96.3)	107.2 (72.5 to 151.1)	10.2 (-4.7 to 43.6)	4.4 (3.0 to 6.1)	9.4 (6.3 to 13.0)	22.4 (73.8 to 167.5)	20.4 (-4.0 to 51.4)
Atrial fibrillation and flutter	31.9 (24.9 to 39.5)	90.1 (68.8 to 116.1)	182.2 (93.5 to 302.7)	50.5 (1.0 to 115.7)	2.3 (1.5 to 3.4)	6.9 (4.4 to 10.3)	197.1 (103.2 to 339.2)	58.6 (6.5 to 134.5)
Peripheral vascular disease	1,745.5 (1,446.6 to 2,126.4)	3,454.9 (2,789.3 to 4,142.1)	98.8 (49.1 to 167.4)	-0.4 (-26.6 to 30.8)	1.1 (0.5 to 2.0)	2.2 (0.8 to 4.8)	112.6 (-12.7 to 273.8)	14.2 (-53.1 to 99.9)
Endocarditis	3.4 (2.2 to 4.5)	6.6 (4.0 to 9.0)	94.8 (27.0 to 178.2)	7.2 (-30.2 to 55.8)	0.4 (0.2 to 0.6)	0.7 (0.4 to 1.2)	104.2 (23.3 to 214.7)	12.9 (-31.9 to 76.7)
Other cardiovascular and circulatory diseases								

Appendix Table G.4 - Vietnam prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.3 (0.2 to 0.4)	0.9 (0.6 to 1.4)	198.2 (177.1 to 220.9)	61.4 (49.9 to 74.2)
Silicosis	0.5 (0.4 to 0.5)	0.8 (0.7 to 0.8)	61.2 (53.4 to 69.4)	-12.5 (-16.4 to -8.2)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	60.5 (52.4 to 68.7)	-12.8 (-17.0 to -8.4)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	1.2 (1.1 to 1.3)	4.4 (4.1 to 4.7)	263.2 (246.1 to 282.1)	99.2 (90.4 to 108.3)	0.2 (0.1 to 0.3)	0.8 (0.5 to 1.2)	253.0 (223.5 to 281.1)	93.5 (81.1 to 105.5)
Asthma	3,375.8 (3,066.2 to 3,779.2)	3,582.8 (3,201.1 to 3,919.7)	6.3 (-8.4 to 21.0)	-18.3 (-28.9 to -7.7)	148.1 (96.7 to 213.6)	157.9 (100.0 to 227.9)	6.7 (-8.8 to 22.5)	-17.0 (-28.4 to -5.7)
Interstitial lung disease and pulmonary sarcoidosis	4.5 (3.5 to 5.4)	8.4 (6.7 to 10.3)	87.1 (39.8 to 152.1)	8.1 (-20.0 to 46.1)	0.6 (0.4 to 0.9)	1.1 (0.7 to 1.8)	86.5 (38.2 to 152.9)	7.2 (-22.3 to 45.1)
Other chronic respiratory diseases	-	-	-	-	57.7 (27.0 to 109.8)	42.8 (26.4 to 66.8)	-23.5 (-55.6 to 34.3)	-57.5 (-75.4 to -23.9)
Cirrhosis	-	-	-	-	4.5 (3.1 to 6.1)	5.9 (4.1 to 8.2)	30.6 (15.5 to 48.8)	25.0 (-33.1 to -15.7)
Cirrhosis due to hepatitis B	9.1 (5.6 to 11.9)	11.2 (6.0 to 16.3)	23.9 (-39.3 to 151.8)	-29.6 (-65.5 to 35.1)	1.5 (0.8 to 2.3)	1.8 (0.9 to 3.2)	26.3 (-40.2 to 165.9)	-28.2 (-66.1 to 40.7)
Cirrhosis due to hepatitis C	6.3 (4.5 to 8.5)	10.1 (5.9 to 14.4)	63.8 (-10.9 to 175.8)	-8.5 (-49.1 to 54.8)	1.0 (0.6 to 1.6)	1.7 (0.8 to 2.7)	64.4 (-12.6 to 198.9)	-7.7 (-50.3 to 69.2)
Cirrhosis due to alcohol use	8.3 (5.8 to 11.2)	9.2 (5.4 to 12.9)	14.2 (-35.4 to 78.6)	-39.5 (-65.2 to -6.5)	1.3 (0.8 to 2.1)	1.5 (0.8 to 2.5)	16.1 (-34.9 to 89.6)	-38.2 (-65.2 to 0.3)
Cirrhosis due to other causes	4.3 (3.3 to 5.4)	5.2 (4.1 to 6.6)	21.8 (-15.2 to 68.1)	-8.7 (-36.6 to 26.7)	0.7 (0.4 to 1.1)	0.9 (0.5 to 1.4)	22.8 (-23.5 to 100.2)	-7.9 (-41.8 to 46.8)
Digestive diseases	-	-	-	-	63.5 (44.9 to 86.6)	75.6 (52.3 to 105.5)	19.2 (4.3 to 33.1)	-29.3 (-38.3 to -21.5)
Peptic ulcer disease	461.7 (377.7 to 520.8)	481.9 (409.5 to 545.4)	4.3 (-11.7 to 25.3)	-45.2 (-53.7 to -33.8)	15.8 (10.9 to 23.0)	14.9 (10.0 to 21.7)	-6.0 (-28.7 to 17.7)	-51.0 (-62.3 to -39.1)
Gastritis and duodenitis	698.0 (627.2 to 754.4)	753.9 (684.4 to 816.8)	7.9 (-2.1 to 21.0)	-31.1 (-37.2 to -23.3)	26.2 (18.0 to 36.7)	27.4 (18.2 to 39.7)	5.2 (-9.7 to 19.3)	-30.4 (-38.7 to -22.0)
Appendicitis	4.7 (3.5 to 5.9)	5.8 (4.5 to 7.4)	24.5 (-11.1 to 72.2)	-16.6 (-39.3 to 17.7)	1.4 (0.8 to 1.1)	1.8 (1.0 to 2.8)	27.7 (-20.4 to 106.5)	-12.5 (-44.9 to 39.2)
Paralytic ileus and intestinal obstruction	0.5 (0.5 to 0.6)	0.9 (0.8 to 1.0)	84.3 (33.3 to 99.3)	7.0 (-13.6 to 29.6)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	63.8 (22.8 to 109.7)	9.2 (-19.6 to 44.6)
Inguinal, femoral, and abdominal hernia	252.7 (220.0 to 284.7)	385.3 (330.6 to 446.2)	52.0 (25.1 to 84.7)	-9.0 (-25.7 to 12.0)	2.5 (1.2 to 4.7)	4.0 (1.9 to 7.6)	55.8 (27.6 to 90.2)	-5.9 (-23.4 to 16.8)
Inflammatory bowel disease	10.3 (9.9 to 10.9)	17.8 (16.9 to 18.7)	71.9 (61.0 to 83.8)	-2.6 (-8.9 to 3.8)	2.1 (1.4 to 2.9)	3.8 (2.5 to 5.4)	76.4 (47.3 to 114.5)	1.0 (-14.8 to 20.2)
Vascular intestinal disorders	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	55.8 (34.3 to 130.3)	-10.3 (-34.9 to 35.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	57.1 (20.3 to 149.5)	-7.4 (-41.4 to 49.0)
Gallbladder and biliary diseases	19.2 (17.5 to 21.2)	25.2 (22.8 to 27.7)	30.7 (14.8 to 50.1)	-2.0 (-32.1 to -10.9)	1.9 (1.3 to 2.7)	2.6 (1.8 to 3.6)	35.8 (10.3 to 58.3)	19.2 (-33.2 to -4.9)
Pancreatitis	13.9 (13.1 to 14.6)	28.8 (27.5 to 30.2)	107.6 (91.9 to 123.0)	15.0 (6.1 to 23.8)	3.9 (2.7 to 5.3)	5.7 (5.7 to 11.7)	114.7 (83.4 to 152.2)	19.7 (4.1 to 39.4)
Other digestive diseases	-	-	-	-	9.3 (5.7 to 15.1)	12.3 (7.7 to 18.2)	34.5 (-11.5 to 95.4)	-20.0 (-46.9 to 15.5)
Neurological disorders	-	-	-	-	373.0 (243.0 to 532.6)	729.5 (472.1 to 1,019.3)	98.8 (52.7 to 152.9)	20.6 (4.2 to 51.6)
Alzheimer disease and other dementias	354.8 (294.3 to 418.9)	702.4 (583.8 to 828.5)	97.6 (56.0 to 152.4)	4.1 (-17.8 to 33.2)	46.1 (33.3 to 61.5)	101.9 (70.6 to 137.4)	120.5 (71.3 to 183.3)	14.2 (-11.3 to 47.6)
Parkinson disease	28.0 (24.2 to 31.7)	50.1 (44.1 to 56.2)	78.9 (70.1 to 88.7)	1.4 (-3.1 to 6.5)	3.1 (2.2 to 4.2)	5.9 (4.1 to 8.0)	88.9 (66.7 to 114.2)	7.5 (-4.8 to 22.3)
Epilepsy	140.9 (105.8 to 173.5)	197.0 (142.7 to 251.8)	40.2 (-5.6 to 103.5)	5.8 (-29.2 to 53.6)	4.4 (2.5 to 5.8)	6.8 (3.8 to 9.2)	58.5 (6.7 to 130.3)	21.4 (-18.2 to 77.1)
Multiple sclerosis	0.4 (0.4 to 0.4)	1.4 (1.2 to 1.5)	238.5 (203.7 to 276.4)	81.1 (63.1 to 101.3)	0.1 (0.1 to 0.2)	0.5 (0.3 to 0.6)	238.5 (203.5 to 276.8)	81.1 (63.1 to 101.5)
Migraine	6,610.5 (4,675.7 to 8,955.4)	12,302.4 (8,696.3 to 15,580.9)	90.5 (23.5 to 185.2)	20.9 (-22.2 to 72.3)	220.9 (117.6 to 357.0)	420.9 (235.2 to 645.7)	59.9 (26.1 to 196.7)	21.9 (-19.5 to 81.4)
Tension-type headache	14,197.9 (12,822.1 to 15,745.5)	22,570.8 (21,039.6 to 24,141.9)	59.5 (41.5 to 78.1)	2.0 (-8.5 to 12.8)	21.3 (10.1 to 37.4)	34.2 (16.4 to 60.1)	61.3 (42.2 to 83.5)	3.7 (-7.5 to 15.7)
Medication overuse headache	219.5 (145.8 to 283.8)	575.0 (385.8 to 765.1)	162.1 (121.2 to 213.3)	49.4 (27.0 to 79.6)	33.6 (19.1 to 52.0)	90.3 (52.0 to 138.9)	167.8 (125.2 to 223.1)	54.1 (30.2 to 86.7)
Other neurological disorders	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	46.0 (7.6 to 98.4)	2.6 (-23.1 to 35.9)	7.4 (4.2 to 11.8)	12.0 (7.7 to 16.8)	63.3 (-0.1 to 185.9)	-13.9 (-47.9 to 50.6)
Mental and substance use disorders	-	-	-	-	1,058.8 (766.5 to 1,366.6)	1,687.9 (1,210.6 to 2,182.9)	59.3 (52.1 to 66.6)	1.2 (-2.9 to 36.5)
Schizophrenia	206.8 (181.3 to 235.4)	368.4 (324.1 to 421.5)	78.4 (68.1 to 89.3)	-0.6 (-6.2 to 4.8)	129.2 (95.1 to 161.9)	238.6 (176.7 to 297.6)	84.6 (71.6 to 101.0)	3.7 (-3.5 to 12.4)
Alcohol use disorders	403.7 (356.8 to 454.7)	564.4 (504.0 to 633.8)	39.9 (27.7 to 51.1)	-15.7 (-22.5 to -9.5)	39.4 (25.8 to 56.3)	56.1 (37.5 to 80.8)	42.3 (29.3 to 56.8)	-14.0 (-21.8 to -6.0)
Drug use disorders	-	-	-	-	140.8 (88.9 to 200.6)	193.4 (127.9 to 266.4)	37.5 (8.8 to 78.3)	-5.9 (-24.6 to 17.8)
Opioid use disorders	71.5 (54.8 to 89.5)	123.7 (97.1 to 152.0)	72.6 (59.6 to 92.8)	0.7 (-5.9 to 11.7)	29.1 (18.9 to 41.3)	52.0 (34.8 to 72.5)	78.0 (56.6 to 106.8)	4.5 (-7.1 to 20.2)
Cocaine use disorders	54.1 (50.1 to 58.2)	81.3 (74.9 to 88.0)	49.8 (35.9 to 67.3)	7.3 (-10.1 to 10.1)	16.7 (4.7 to 10.4)	11.5 (7.3 to 16.3)	21.9 (26.6 to 37.7)	2.2 (-15.4 to 25.2)
Amphetamine use disorders	360.1 (259.4 to 459.9)	429.9 (332.9 to 524.6)	19.1 (-12.4 to 72.1)	-13.7 (-35.8 to 20.3)	46.5 (27.1 to 71.0)	56.7 (33.5 to 85.3)	22.1 (-11.0 to 78.1)	-11.4 (-34.5 to 25.7)
Cannabis use disorders	119.5 (98.0 to 139.5)	164.5 (137.8 to 188.8)	37.7 (33.4 to 42.0)	0.5 (-0.5 to 0.6)	3.4 (2.2 to 4.9)	4.8 (3.0 to 7.0)	38.6 (18.8 to 63.1)	1.5 (-12.3 to 17.9)
Other drug use disorders	-	-	-	-	54.4 (31.7 to 85.2)	68.7 (39.9 to 104.9)	27.1 (-14.8 to 89.0)	-8.9 (-38.3 to 33.0)
Depressive disorders	-	-	-	-	361.2 (239.8 to 512.4)	629.2 (411.9 to 890.9)	74.0 (61.1 to 87.1)	2.9 (-3.4 to 10.3)
Major depressive disorder	1,461.0 (1,148.7 to 1,781.9)	2,449.0 (1,935.2 to 3,024.5)	67.5 (52.8 to 80.1)	-0.7 (-8.2 to 6.4)	290.2 (186.6 to 425.6)	500.0 (321.1 to 738.7)	72.3 (55.9 to 87.5)	3.0 (-4.9 to 12.3)
Dysthymia	757.9 (648.9 to 862.9)	1,346.6 (1,167.6 to 1,523.5)	77.6 (72.0 to 84.3)	-0.4 (-0.5 to -0.3)	71.0 (46.7 to 101.6)	129.3 (85.2 to 186.8)	82.0 (73.3 to 91.6)	2.5 (-0.4 to 6.9)
Bipolar disorder	382.3 (316.2 to 447.3)	635.7 (532.7 to 735.6)	66.2 (56.1 to 76.3)	-0.6 (-5.6 to 4.8)	75.9 (45.3 to 113.5)	129.7 (79.5 to 196.4)	70.7 (58.7 to 86.7)	2.9 (-3.5 to 11.7)
Anxiety disorders	899.5 (887.6 to 1,113.6)	1,369.6 (1,064.4 to 1,683.1)	51.9 (42.7 to 62.4)	51.9 (-0.9 to -0.5)	91.0 (51.6 to 117.5)	126.0 (79.2 to 187.9)	54.4 (43.4 to 68.6)	2.5 (-1.8 to 7.6)
Eating disorders	-	-	-	-	7.7 (4.8 to 11.3)	10.1 (6.3 to 15.2)	31.3 (13.5 to 53.7)	0.9 (-12.9 to 17.2)
Anorexia nervosa	19.4 (14.9 to 24.7)	24.2 (18.3 to 31.4)	24.5 (9.5 to 38.8)	-2.2 (-12.9 to 9.4)	4.1 (2.5 to 6.2)	5.2 (3.2 to 8.0)	27.2 (2.6 to 57.5)	0.3 (-18.6 to 23.9)
Bulimia nervosa	17.3 (11.3 to 25.0)	23.0 (14.8 to 33.7)	33.1 (26.3 to 39.1)	-0.9 (-1.0 to -0.8)	3.6 (2.0 to 5.9)	4.9 (2.7 to 8.2)	36.5 (10.2 to 66.5)	1.9 (-16.1 to 23.4)
Autistic spectrum disorders	-	-	-	-	81.0 (56.0 to 110.0)	108.6 (75.5 to 148.1)	34.0 (29.1 to 39.3)	3.3 (-0.2 to 7.1)
Autism	210.5 (199.5 to 221.4)	279.2 (264.4 to 294.0)	32.5 (31.5 to 33.7)	0.8 (0.8 to 0.9)	51.2 (34.6 to 70.0)	68.9 (45.8 to 94.6)	34.6 (27.4 to 42.0)	3.5 (-1.4 to 8.9)
Asperger syndrome	301.0 (282.2 to 318.7)	397.2 (371.9 to 421.8)	31.9 (30.5 to 33.4)	1.1 (1.0 to 1.1)	29.8 (20.7 to 41.3)	39.7 (27.4 to 54.8)	33.1 (27.5 to 39.0)	2.9 (-1.1 to 7.3)
Attention-deficit/hyperactivity disorder	497.6 (458.6 to 530.5)	485.3 (445.2 to 518.4)	-2.5 (-3.3 to 0.2)	0.8 (0.8 to 0.9)	6.0 (3.5 to 9.1)	5.9 (3.5 to 9.1)	-1.7 (-4.8 to 6.5)	1.8 (-5.4 to 10.6)
Conduct disorder	562.2 (475.8 to 534.6)	481.0 (451.7 to 510.0)	-14.8 (-5.7 to -3.9)	4.8 (0.6 to 9.7)	6.7 (3.7 to 87.4)	58.2 (36.3 to 84.8)	-3.4 (-4.5 to 1.8)	2.3 (-3.0 to 7.6)
Idiopathic intellectual disability	140.9 (87.3 to 247.8)	119.1 (84.6 to 185.8)	-10.5 (-46.6 to 23.9)	-30.2 (-58.4 to -3.2)	6.8 (3.6 to 12.5)	8.8 (3.5 to 9.5)	9.2 (46.6 to 27.3)	-29.0 (-58.4 to -10.1)
Other mental and substance use disorders	953.9 (890.1 to 1,015.8)	1,686.8 (1,584.5 to 1,783.4)	76.8 (73.9 to 79.9)	0.5 (0.4 to 0.7)	69.6 (47.8 to 92.9)	126.1 (85.7 to 170.1)	81.2 (72.9 to 90.5)	3.6 (-0.7 to 8.5)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	389.9 (276.8 to 539.4)	652.8 (452.5 to 899.0)	67.4 (52.9 to 82.1)	9.5 (-0.3 to 19.6)
Diabetes mellitus	979.9 (794.4 to 1,183.9)	3,584.6 (2,975.3 to 4,180.8)	265.7 (186.5 to 378.0)	98.3 (51.7 to 164.8)	64.9 (42.7 to 94.8)	228.5 (148.4 to 328.8)	249.9 (171.3 to 365.0)	86.3 (43.6 to 152.6)
Acute glomerulonephritis	6.3 (0.2 to 0.3)	0.2 (0.1 to 0.2)	-42.1 (-46.3 to -37.8)	-45.6 (-49.5 to -42.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-42.1 (-46.3 to -37.8)	-45.6 (-49.5 to -42.2)
Chronic kidney disease	-	-	-	-	63.4 (41.8 to 88.2)	98.5 (64.3 to 141.3)	54.8 (34.7 to 78.7)	-3.2 (-14.6 to 7.3)
Chronic kidney disease due to diabetes mellitus	149.1 (98.0 to 225.1)	362.6 (243.7 to 608.7)	139.1 (71.1 to 245.8)	37.7 (-3.3 to 108.0)	6.4 (4.0 to 9.8)	18.8 (11.3 to 30.8)	189.3 (103.4 to 326.6)	61.3 (-11.6 to 142.7)
Chronic kidney disease due to hypertension	287.9 (181.3 to 426.4)	161.9 (120.2 to 250.6)	44.0 (-59.2 to -18.0)	-58.6 (-70.5 to -42.6)	13.5 (8.3 to 20.5)	22.9 (13.0 to 37.4)	65.3 (19.0 to 136.2)	-0.6 (-27.2 to 35.0)
Chronic kidney disease due to glomerulonephritis	232.0 (206.6 to 555.0)	419.0 (247.4 to 876.9)	25.8 (-9.8 to 96.4)	51.9 (-43.9 to 19.3)	10.3 (6.4 to 14.4)	10.3 (2.3 to 6.3)	45.1 (-73.3 to -40.7)	72.7 (-80.9 to -58.8)
Chronic kidney disease due to other causes	908.6 (618.1 to 1,361.2)	1,249.6 (858.2 to 1,855.2)	40.4 (0.3 to 77.3)	-8.4 (-32.5 to 18.4)	33.2 (21.9 to 45.5)	52.8 (34.7 to 76.1)	59.3 (23.0 to 95.5)	-1.6 (-24.7 to 21.5)
Ur								

Appendix Table G.4 - Vietnam prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	12.0 (11.3 to 12.6)	22.4 (21.0 to 23.6)	86.8 (71.9 to 103.8)	86.8 (16.7 to 36.3)	0.4 (0.2 to 0.6)	0.7 (0.5 to 1.1)	89.8 (51.0 to 137.7)	89.8 (5.9 to 56.2)
Urolithiasis	328.7 (252.2 to 435.1)	634.6 (442.3 to 812.7)	93.5 (44.6 to 121.8)	6.5 (-21.3 to 20.4)	3.8 (2.6 to 5.1)	7.0 (4.7 to 9.7)	85.7 (63.3 to 107.5)	4.6 (-8.3 to 16.5)
Benign prostatic hyperplasia	564.7 (516.8 to 615.3)	970.9 (890.9 to 1,053.5)	71.4 (52.1 to 94.6)	0.7 (-10.8 to 15.0)	19.5 (12.8 to 28.0)	34.3 (22.5 to 48.6)	76.1 (55.9 to 100.5)	3.7 (-8.1 to 18.3)
Male infertility due to other causes	159.6 (88.6 to 239.6)	279.6 (150.7 to 411.6)	79.1 (-26.4 to 239.9)	7.2 (-54.6 to 106.5)	1.0 (0.4 to 2.4)	1.9 (0.7 to 4.1)	83.4 (-29.1 to 266.0)	11.3 (-55.3 to 121.0)
Other urinary diseases	-	-	-	-	3.4 (1.9 to 5.8)	7.3 (3.9 to 13.0)	117.1 (48.6 to 207.7)	23.7 (-15.3 to 74.3)
Gynecological diseases	-	-	-	-	78.9 (51.1 to 117.0)	122.7 (78.0 to 180.4)	55.6 (31.2 to 83.0)	-14.9 (-26.8 to -1.2)
Uterine fibroids	1,067.1 (967.6 to 1,174.0)	2,308.0 (2,112.1 to 2,522.9)	116.2 (112.7 to 120.1)	-3.5 (-3.6 to -3.4)	21.9 (13.6 to 34.1)	30.8 (17.8 to 51.3)	39.4 (23.9 to 57.4)	-33.1 (-39.8 to -25.1)
Polycystic ovarian syndrome	909.0 (747.1 to 1,065.0)	1,516.9 (1,272.8 to 1,766.3)	66.9 (32.0 to 110.2)	-7.4 (-25.5 to 14.5)	8.7 (3.9 to 16.8)	14.7 (6.9 to 27.8)	69.6 (33.8 to 112.8)	-4.8 (-23.4 to 17.7)
Female infertility due to other causes	88.4 (15.4 to 143.4)	152.7 (49.0 to 285.8)	72.5 (-40.1 to 927.6)	31.5 (-67.3 to 35.0)	0.4 (0.1 to 1.0)	0.8 (0.2 to 2.1)	117.7 (-36.7 to 873.3)	33.5 (-64.1 to 508.3)
Endometriosis	109.0 (91.8 to 125.3)	193.5 (164.5 to 223.7)	78.5 (40.2 to 123.2)	-2.9 (-22.5 to 20.1)	9.9 (6.4 to 13.9)	18.0 (11.6 to 25.2)	82.0 (40.2 to 133.3)	-0.2 (-22.1 to 27.2)
Genital prolapse	2,754.6 (2,383.2 to 3,137.4)	5,078.4 (4,461.1 to 5,690.0)	84.6 (53.6 to 123.4)	-2.8 (-17.8 to 14.9)	8.6 (4.1 to 16.0)	16.2 (7.8 to 30.3)	87.7 (55.1 to 129.8)	-1.0 (-16.9 to 18.7)
Premenstrual syndrome	2,345.8 (1,418.9 to 3,165.0)	4,104.6 (2,691.0 to 5,403.1)	74.2 (3.2 to 195.0)	7.4 (-35.7 to 76.4)	19.4 (10.1 to 31.7)	34.7 (18.3 to 56.0)	78.5 (3.6 to 201.9)	10.5 (-34.4 to 86.4)
Other gynecological diseases	298.7 (204.6 to 385.0)	254.7 (207.8 to 300.0)	-14.7 (-34.6 to 24.2)	-48.5 (-60.5 to -25.3)	10.0 (5.6 to 14.6)	7.5 (4.6 to 10.8)	-26.1 (-49.7 to -29.2)	-55.2 (-69.8 to -23.2)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	110.3 (74.3 to 159.4)	118.3 (78.7 to 173.9)	6.5 (-2.9 to 22.8)	-12.5 (-20.3 to 1.9)
Thalassemias	47.2 (42.7 to 52.7)	47.2 (42.9 to 51.9)	-0.1 (-6.0 to 6.1)	2.1 (-3.6 to 8.2)	3.4 (2.2 to 5.0)	3.2 (2.0 to 4.9)	-6.6 (-26.3 to 15.5)	-7.8 (-27.7 to 12.5)
Thalassemia trait	5,073.3 (4,693.9 to 5,444.8)	6,752.2 (6,372.9 to 7,185.8)	33.0 (28.9 to 38.8)	-0.0 (-3.1 to 4.5)	69.0 (46.5 to 99.4)	95.0 (62.6 to 139.5)	36.9 (21.9 to 59.1)	14.8 (1.1 to 32.6)
Sickle cell disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	2.3 (-17.8 to 15.0)	-6.9 (-24.8 to 4.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-1.8 to 2.4)	0.0 (-18.8 to 45.2)
Sickle cell trait	115.2 (91.4 to 138.7)	139.4 (108.1 to 145.3)	15.1 (-13.6 to 33.0)	-15.5 (-34.6 to 0.0)	1.0 (0.6 to 1.4)	0.7 (0.3 to 1.2)	23.3 (-65.2 to 15.6)	37.6 (-71.1 to 45.5)
G6PD deficiency	2,502.4 (2,258.8 to 2,734.8)	2,926.8 (2,662.2 to 3,180.0)	17.2 (1.7 to 33.2)	-11.9 (-23.7 to 0.2)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	30.4 (24.6 to 35.7)	3.7 (-0.3 to 8.1)
G6PD trait	10,682.9 (10,325.2 to 11,046.9)	14,341.6 (13,814.7 to 14,805.4)	34.2 (27.2 to 40.1)	-0.4 (-5.6 to 4.0)	0.6 (0.3 to 0.8)	0.5 (0.1 to 0.8)	-10.9 (-90.3 to 55.6)	-30.6 (-92.0 to 16.0)
Other hemoglobinopathies and hemolytic anemias	1,234.7 (1,123.7 to 1,332.2)	792.0 (704.2 to 884.9)	-35.9 (-44.0 to -26.7)	-53.0 (-59.1 to -46.2)	36.1 (23.4 to 52.7)	18.5 (11.2 to 27.1)	-8.6 (-61.3 to -36.3)	-58.6 (-69.8 to -48.8)
Endocrine, metabolic, blood, and immune disorders	1,281.4 (1,121.7 to 1,419.8)	1,048.8 (961.6 to 1,121.8)	-18.0 (-27.2 to -6.3)	-35.2 (-42.5 to -26.7)	44.2 (29.8 to 62.3)	34.4 (22.9 to 47.4)	-24.7 (-34.8 to -8.8)	-36.6 (-45.5 to -24.3)
Musculoskeletal disorders	-	-	-	-	654.2 (466.3 to 874.3)	1,226.4 (862.7 to 1,641.9)	87.0 (78.8 to 95.2)	5.5 (-3.7 to 17.0)
Rheumatoid arthritis	59.7 (55.1 to 64.2)	129.3 (121.1 to 137.5)	116.3 (96.7 to 138.7)	25.5 (13.7 to 39.3)	13.5 (9.5 to 17.8)	30.2 (20.9 to 40.1)	123.3 (95.7 to 153.2)	31.3 (16.0 to 48.5)
Osteoarthritis	994.5 (942.2 to 1,049.5)	1,987.8 (1,895.1 to 2,088.6)	99.9 (86.2 to 113.9)	3.1 (-3.8 to 10.7)	57.7 (41.7 to 77.4)	120.4 (84.2 to 163.0)	108.5 (93.1 to 127.5)	7.7 (-0.3 to 17.6)
Low back and neck pain	-	-	-	-	542.7 (379.8 to 736.4)	973.9 (667.5 to 1,312.3)	78.8 (60.7 to 103.9)	2.4 (-7.6 to 16.4)
Low back pain	3,535.6 (3,315.1 to 3,750.9)	6,179.0 (5,843.7 to 6,538.0)	74.2 (61.9 to 89.8)	-0.5 (-7.2 to 7.8)	382.5 (264.7 to 524.8)	687.2 (463.3 to 952.6)	79.1 (65.3 to 97.3)	3.0 (-4.3 to 12.7)
Neck pain	1,667.4 (1,322.9 to 2,005.4)	2,913.6 (2,189.4 to 3,606.1)	73.4 (26.2 to 147.3)	-2.5 (-29.7 to 38.0)	160.2 (102.6 to 233.2)	286.7 (175.2 to 415.7)	77.4 (28.7 to 154.9)	0.7 (-27.3 to 42.7)
Gout	29.9 (26.2 to 33.7)	58.1 (51.6 to 63.9)	93.8 (63.4 to 131.7)	-0.3 (-16.3 to 19.9)	0.9 (0.6 to 1.3)	1.9 (1.2 to 2.6)	99.7 (49.5 to 158.5)	2.5 (-22.9 to 30.7)
Other musculoskeletal disorders	452.7 (357.2 to 595.1)	1,097.5 (736.7 to 1,620.7)	136.2 (99.7 to 206.7)	18.9 (3.2 to 51.1)	39.4 (26.0 to 57.2)	100.1 (59.0 to 164.0)	147.5 (105.2 to 219.3)	25.4 (6.9 to 57.7)
Other non-communicable diseases	-	-	-	-	978.1 (670.8 to 1,373.6)	1,425.1 (978.6 to 2,016.0)	45.6 (40.4 to 51.3)	-4.9 (-8.0 to -1.3)
Congenital anomalies	-	-	-	-	60.6 (43.5 to 78.6)	91.4 (68.2 to 116.7)	50.4 (31.1 to 79.6)	24.0 (9.0 to 47.1)
Neural tube defects	12.4 (10.6 to 14.5)	19.9 (18.0 to 22.4)	60.7 (33.9 to 97.9)	37.7 (14.9 to 69.9)	3.9 (2.6 to 5.5)	6.5 (4.4 to 8.8)	68.9 (24.8 to 134.9)	46.3 (8.2 to 102.7)
Congenital heart anomalies	169.8 (141.0 to 206.4)	390.3 (316.1 to 490.3)	128.1 (72.4 to 208.2)	87.9 (41.8 to 153.7)	6.2 (2.9 to 10.2)	14.3 (6.3 to 25.6)	128.8 (75.7 to 211.8)	91.2 (48.8 to 160.0)
Orofacial clefts	36.8 (29.9 to 48.4)	88.2 (75.3 to 111.0)	138.9 (88.1 to 220.0)	108.8 (64.3 to 181.1)	0.6 (0.3 to 0.9)	1.1 (0.7 to 1.6)	8.7 (32.8 to 171.7)	61.2 (16.4 to 133.2)
Down syndrome	59.4 (48.5 to 72.9)	103.3 (87.7 to 127.7)	72.8 (31.8 to 134.0)	33.5 (2.3 to 80.9)	7.2 (5.1 to 9.7)	14.0 (10.0 to 18.7)	92.8 (45.8 to 162.0)	43.4 (9.3 to 94.4)
Turner syndrome	2.1 (1.5 to 2.9)	3.1 (2.1 to 4.3)	50.1 (-9.4 to 124.6)	16.5 (-29.6 to 74.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	52.7 (-8.1 to 142.8)	15.5 (-30.6 to 81.3)
Klinefelter syndrome	2.2 (1.7 to 2.9)	3.0 (1.9 to 4.1)	37.8 (-16.7 to 97.9)	6.3 (-35.4 to 52.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	60.4 (-14.6 to 167.7)	6.4 (-41.7 to 77.2)
Chromosomal unbalanced rearrangements	80.3 (67.3 to 95.4)	141.5 (114.4 to 171.0)	76.4 (36.9 to 129.4)	9.7 (5.5 to 77.8)	9.7 (7.0 to 13.0)	36.4 (13.0 to 26.0)	46.7 (36.2 to 55.0)	46.7 (12.6 to 92.1)
Other congenital anomalies	270.4 (216.8 to 318.3)	300.9 (245.5 to 357.4)	11.0 (-22.3 to -4.2)	-14.8 (78.2 to -4.2)	33.0 (21.0 to 45.9)	36.4 (24.3 to 49.9)	10.2 (-58.2 to 37.0)	-5.0 (-20.5 to 17.8)
Skin and subcutaneous diseases	-	-	-	-	333.3 (214.9 to 503.0)	474.9 (302.9 to 731.3)	42.5 (34.0 to 52.6)	2.6 (-2.5 to 9.3)
Dermatitis	3,199.9 (2,717.3 to 3,749.2)	4,674.6 (3,935.9 to 5,467.6)	46.2 (40.5 to 51.5)	-0.0 (-0.1 to 0.0)	95.8 (60.5 to 137.6)	132.7 (84.7 to 191.5)	38.7 (30.0 to 46.4)	1.8 (-0.9 to 5.1)
Psoriasis	402.6 (392.5 to 598.8)	798.8 (611.8 to 968.3)	96.6 (53.8 to 68.2)	60.0 (-0.1 to 0.1)	60.0 (25.8 to 56.9)	64.2 (41.1 to 95.3)	61.0 (51.8 to 76.6)	3.0 (-2.4 to 9.6)
Cellulitis	15.4 (12.1 to 19.4)	22.7 (18.2 to 27.7)	47.4 (18.7 to 80.0)	3.8 (-19.0 to 26.9)	1.1 (0.7 to 1.6)	1.6 (1.0 to 2.3)	48.9 (10.3 to 94.9)	6.2 (-21.2 to 38.3)
Pyoderma	106.2 (78.0 to 136.5)	55.0 (43.8 to 71.1)	-48.2 (-58.4 to -36.1)	0.6 (-59.0 to -42.9)	0.3 (0.2 to 1.4)	0.3 (0.1 to 0.7)	-48.3 (-59.5 to -34.7)	-51.8 (-59.8 to -41.8)
Scabies	799.1 (717.7 to 892.7)	901.0 (780.2 to 1,065.9)	12.0 (-7.7 to 39.4)	-17.2 (-30.3 to 1.0)	20.4 (11.6 to 32.7)	23.2 (13.2 to 38.0)	23.2 (-7.0 to 41.1)	12.8 (-29.5 to 3.4)
Fungal skin diseases	7,757.3 (6,067.0 to 9,500.1)	11,163.1 (8,897.7 to 13,343.3)	43.3 (35.2 to 53.2)	43.3 (0.1 to 0.4)	43.2 (17.2 to 92.8)	62.7 (25.3 to 133.8)	43.2 (36.2 to 55.0)	43.2 (0.6 to 3.4)
Viral skin diseases	1,570.4 (1,181.9 to 1,958.7)	1,699.2 (1,222.4 to 2,206.2)	8.4 (-0.9 to 16.3)	8.4 (-1.9 to 2.4)	0.1 (-1.9 to 2.4)	0.1 (-1.9 to 2.4)	52.7 (27.6 to 76.7)	9.0 (-2.3 to 15.9)
Acne vulgaris	2,183.2 (1,654.4 to 2,791.3)	3,152.2 (2,304.8 to 4,330.6)	45.3 (-10.6 to 118.8)	20.4 (-25.3 to 79.3)	23.5 (10.8 to 44.1)	34.3 (14.5 to 66.8)	46.7 (-9.9 to 121.4)	21.5 (-24.8 to 79.5)
Alopecia areata	84.9 (75.6 to 94.5)	133.6 (117.0 to 150.1)	57.6 (32.7 to 88.4)	1.4 (-14.2 to 21.5)	2.8 (1.8 to 4.2)	4.4 (2.8 to 6.8)	58.9 (31.7 to 93.6)	3.8 (-13.9 to 26.2)
Pruritus	11.2 (9.5 to 13.0)	18.3 (14.9 to 22.3)	64.3 (27.0 to 109.9)	0.3 (-21.6 to 28.5)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	65.1 (22.3 to 125.1)	2.2 (-23.8 to 37.3)
Urticaria	565.7 (392.6 to 729.8)	932.1 (686.3 to 1,196.5)	60.4 (14.4 to 161.9)	1.0 (-26.5 to 69.3)	33.1 (18.6 to 50.5)	55.2 (33.2 to 84.8)	63.0 (15.1 to 169.0)	3.6 (-25.2 to 77.9)
Decubitus ulcer	10.7 (8.5 to 13.1)	19.3 (15.5 to 24.0)	79.1 (35.6 to 154.6)	1.2 (-25.6 to 46.2)	1.5 (1.0 to 2.1)	2.7 (1.8 to 4.0)	82.6 (36.4 to 161.6)	5.6 (-22.5 to 56.6)
Other skin and subcutaneous diseases	4,100.4 (2,736.0 to 6,127.7)	6,934.9 (4,602.9 to 10,357.5)	69.0 (54.5 to 88.0)	0.4 (-2.3 to 3.7)	23.6 (10.4 to 48.1)	40.6 (17.6 to 63.6)	71.6 (56.3 to 91.1)	2.7 (-0.5 to 6.7)
Sense organ diseases	-	-	-	-	500.0 (350.8 to 680.5)	731.7 (506.8 to 1,016.5)	46.3 (31.1 to 125.8)	-10.5 (-14.4 to -6.3)
Glaucoma	84.9 (69.1 to 103.7)	128.0 (97.1 to 161.3)	51.6 (11.1 to 93.3)	-16.6 (-39.6 to 8.8)	5.8 (3.9 to 8.0)	9.5 (6.0 to 13.7)	62.2 (48.3 to 81.3)	-10.1 (-38.2 to 28.4)
Cataract	621.6 (500.8 to 758.9)	892.4 (717.2 to 1,061.5)	44.2 (20.3 to 67.2)	-20.1 (-33.5 to -7.4)	39.8 (27.5 to 54.5)	61.1 (41.6 to 84.0)	53.4 (35.1 to 77.4)	-16.0 (-26.0 to -4.1)
Macular degeneration	45.3 (29.9 to 73.0)	101.8 (74.8 to 135.8)	128.1 (37.7 to 266.7)	17.8 (-29.3 to 93.1)	2.7 (1.7 to 4.2)	5.8 (3.7 to 8.7)	117.2 (51.8 to 207.6)	9.0 (-21.6 to 55.8)
Uncorrected refractive error	3,628.4 (3,200.9 to 4,016.8)	5,420.6 (4,869.4 to 5,889.1)	49.0 (36.0 to 65.6)	-11.7 (-18.7 to -2.6)	77.8 (52.0 to 114.0)	109.8 (71.9 to 163.6)	40.9 (32.2 to 50.6)	-13.6 (-18.3 to -8.0)
Age-related and other hearing loss	9,403.7 (8,957.8 to 9,871.1)	15,234.5 (14,563.4 to 16,187.1)	62.1 (55.7 to 68.5)	-9.2 (-12.4 to -6.6)	62.1 (210.7 to 412.6)	300.4 (312.5 to 635.0)	45.1 (39.7 to 62.2)	8.5 (-13.8 to 37.5)
Other vision loss	511.9 (441.6 to 608.0)	585.2 (497.3 to 681.2)	13.3 (2.3 to 30.6)	-28.7 (-36.3 to -15.2)	31.2 (21.8 to 43.4)	37.0 (24.8 to 51.8)	18.1 (5.3 to 33.4)	-3.3 (-16.5 to -17.1)

Appendix Table G.4 - Vietnam prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	643.0 (581.2 to 705.9)	751.9 (690.9 to 818.2)	17.2 (2.9 to 32.8)	-35.3 (-43.4 to -26.6)	16.7 (11.2 to 23.3)	20.3 (13.8 to 27.8)	21.9 (6.4 to 40.0)	-32.4 (-41.0 to -22.0)
Other oral disorders	1,080.2 (1,011.9 to 1,142.7)	1,685.6 (1,599.1 to 1,778.8)	55.8 (45.0 to 68.7)	-0.3 (-6.9 to 7.4)	31.3 (19.4 to 46.7)	49.4 (31.0 to 74.2)	57.7 (46.1 to 71.4)	1.6 (-5.3 to 10.0)
Injuries	-	-	-	-	2,704.2 (1,290.8 to 5,200.4)	1,187.7 (714.0 to 1,917.6)	-54.6 (-66.9 to -36.7)	-73.0 (-80.3 to -62.2)
Transport injuries	-	-	-	-	157.6 (119.0 to 201.7)	222.7 (161.7 to 297.4)	40.5 (27.0 to 57.2)	-18.7 (-26.2 to -9.8)
Road injuries	-	-	-	-	146.6 (110.7 to 187.8)	210.7 (153.1 to 281.7)	43.0 (28.9 to 60.2)	-47.1 (-24.9 to -8.0)
Pedestrian road injuries	-	-	-	-	21.0 (15.7 to 26.8)	29.7 (21.6 to 39.4)	41.6 (25.2 to 60.4)	-14.6 (-23.8 to -4.3)
Cyclist road injuries	-	-	-	-	10.1 (7.7 to 13.0)	13.8 (10.0 to 18.7)	37.0 (24.1 to 49.6)	-19.4 (-27.1 to -11.8)
Motorcyclist road injuries	-	-	-	-	66.2 (49.9 to 84.9)	90.9 (65.2 to 122.1)	36.9 (22.2 to 53.9)	-21.8 (-29.9 to -12.7)
Motor vehicle road injuries	-	-	-	-	48.6 (36.7 to 62.5)	75.3 (55.0 to 99.2)	54.8 (35.3 to 75.8)	-10.3 (-21.1 to 1.2)
Other road injuries	-	-	-	-	0.8 (0.6 to 1.0)	1.0 (0.7 to 1.3)	20.5 (7.8 to 35.0)	-32.5 (-39.4 to -24.8)
Other transport injuries	-	-	-	-	11.0 (8.3 to 14.2)	12.0 (8.7 to 16.2)	8.5 (2.3 to 20.7)	-38.5 (-44.4 to -31.7)
Unintentional injuries	-	-	-	-	187.0 (143.0 to 240.1)	251.6 (185.6 to 333.0)	34.1 (24.6 to 45.0)	-19.3 (-24.8 to -13.6)
Falls	-	-	-	-	60.1 (45.8 to 77.3)	92.4 (67.2 to 123.7)	53.3 (39.0 to 68.2)	-13.0 (-20.8 to -4.6)
Drowning	-	-	-	-	13.3 (9.8 to 17.4)	6.7 (4.8 to 8.9)	-49.8 (-56.2 to -41.7)	67.2 (-71.3 to -62.6)
Fire, heat, and hot substances	-	-	-	-	9.1 (6.9 to 11.7)	6.9 (4.9 to 9.3)	-24.7 (-35.5 to -12.3)	-49.4 (-56.2 to -41.8)
Poisonings	-	-	-	-	0.5 (0.3 to 0.6)	0.3 (0.2 to 0.4)	-40.7 (-50.5 to -29.2)	-61.6 (-67.2 to -54.5)
Exposure to mechanical forces	-	-	-	-	64.9 (49.5 to 85.2)	82.8 (60.3 to 109.5)	27.6 (17.7 to 38.3)	-21.2 (-26.4 to -15.8)
Unintentional firearm injuries	-	-	-	-	4.2 (3.2 to 5.3)	4.1 (3.1 to 5.5)	-1.4 (-10.3 to 9.4)	-41.6 (-46.5 to -35.5)
Unintentional suffocation	-	-	-	-	1.5 (1.2 to 2.0)	2.0 (1.4 to 2.6)	26.9 (13.9 to 40.3)	-18.2 (-26.0 to -10.2)
Other exposure to mechanical forces	-	-	-	-	59.1 (44.8 to 77.9)	76.7 (55.6 to 101.5)	29.7 (19.4 to 40.8)	-19.8 (-25.1 to -14.4)
Adverse effects of medical treatment	-	-	-	-	1.2 (0.8 to 1.8)	2.1 (1.3 to 3.0)	65.3 (55.7 to 75.8)	2.3 (-3.8 to 9.2)
Animal contact	-	-	-	-	2.2 (1.7 to 2.9)	2.8 (2.0 to 3.7)	23.9 (12.1 to 37.0)	-21.7 (-28.6 to -14.5)
Venomous animal contact	-	-	-	-	1.0 (0.7 to 1.3)	1.3 (0.9 to 1.8)	28.8 (12.5 to 47.0)	-19.3 (-28.5 to -8.9)
Non-venomous animal contact	-	-	-	-	1.2 (0.9 to 1.6)	1.4 (1.0 to 2.0)	19.8 (7.4 to 33.5)	-23.9 (-30.8 to -16.4)
Foreign body	-	-	-	-	1.3 (1.0 to 1.6)	1.8 (1.3 to 2.3)	40.0 (28.7 to 54.4)	-12.8 (-19.1 to -5.0)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.4 (0.3 to 0.5)	0.4 (0.3 to 0.5)	3.9 (-11.3 to 23.3)	-29.5 (-38.7 to -18.2)
Foreign body in eyes	-	-	-	-	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.8)	45.0 (35.4 to 55.9)	-5.4 (-12.5 to 0.1)
Foreign body in other body part	-	-	-	-	0.5 (0.4 to 0.7)	0.8 (0.6 to 1.1)	64.3 (48.4 to 82.0)	-6.0 (-14.6 to 3.4)
Other unintentional injuries	-	-	-	-	34.6 (26.3 to 44.7)	55.9 (41.1 to 74.3)	61.5 (49.1 to 74.6)	-5.7 (-12.6 to 1.3)
Self-harm and interpersonal violence	-	-	-	-	9.6 (7.4 to 12.3)	7.2 (5.2 to 9.5)	-26.1 (-33.6 to -16.8)	-66.3 (-60.4 to -51.0)
Self-harm	-	-	-	-	1.7 (1.3 to 2.2)	1.3 (1.0 to 1.8)	-20.7 (-27.7 to -12.6)	-56.9 (-60.5 to -52.6)
Interpersonal violence	-	-	-	-	8.0 (6.1 to 10.1)	5.8 (4.2 to 7.8)	-27.2 (-35.3 to -17.7)	-56.0 (-60.6 to -50.6)
Assault by firearm	-	-	-	-	0.8 (0.6 to 1.0)	0.6 (0.4 to 0.8)	-25.3 (-32.4 to -16.7)	-53.6 (-57.8 to -48.9)
Assault by sharp object	-	-	-	-	1.8 (1.3 to 2.3)	1.4 (1.0 to 2.0)	-19.5 (-28.5 to -6.8)	-52.1 (-57.2 to -45.1)
Assault by other means	-	-	-	-	5.4 (4.1 to 6.9)	3.8 (2.8 to 5.1)	-30.0 (-38.3 to -19.8)	-57.6 (-62.5 to -51.8)
Forces of nature, war, and legal intervention	-	-	-	-	2,349.8 (966.2 to 4,844.2)	706.3 (313.9 to 1,356.6)	-69.6 (-76.5 to -59.9)	-81.4 (-85.6 to -75.0)
Exposure to forces of nature	-	-	-	-	7.0 (3.6 to 14.3)	8.6 (4.0 to 16.5)	25.1 (-25.6 to 79.1)	-20.4 (-51.7 to 16.3)
Collective violence and legal intervention	-	-	-	-	2,342.8 (960.9 to 4,834.7)	697.7 (308.5 to 1,341.4)	-69.9 (-76.7 to -60.4)	-81.6 (-85.7 to -75.3)

Appendix Table G.4 - Yemen prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,024.0 (735.2 to 1,354.8)	2,244.3 (1,623.5 to 2,965.9)	119.3 (110.3 to 129.1)	119.3 (5.0 to 1.5)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	309.1 (212.0 to 441.9)	590.6 (410.0 to 823.0)	90.9 (74.7 to 111.8)	-1.6 (-9.7 to 7.0)
HIV/AIDS and tuberculosis	-	-	-	-	1.8 (1.2 to 2.6)	4.7 (2.7 to 11.8)	128.2 (84.3 to 433.3)	-4.5 (-21.1 to 117.2)
Tuberculosis	5.6 (5.4 to 5.8)	10.4 (10.0 to 10.8)	86.3 (79.6 to 92.4)	-21.3 (-23.6 to -18.9)	1.7 (1.2 to 2.3)	3.2 (2.1 to 4.3)	86.1 (64.2 to 111.8)	-21.2 (-28.2 to -12.9)
HIV/AIDS	-	-	-	-	0.1 (0.0 to 0.4)	1.5 (0.2 to 8.6)	2,968.3 (220.9 to 25,314.0)	1,034.0 (19.6 to 10,038.1)
HIV/AIDS resulting in mycobacterial infection	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.2)	2,110.6 (143.2 to 16,725.9)	778.2 (-5.8 to 7,087.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	2,110.6 (142.3 to 16,787.8)	778.2 (-7.2 to 1,100.4)
HIV/AIDS resulting in other diseases	0.9 (0.0 to 3.8)	12.6 (2.0 to 63.9)	2,814.9 (316.3 to 19,903.2)	1,034.0 (61.9 to 7,987.8)	0.1 (0.0 to 0.4)	1.5 (0.2 to 8.6)	2,832.3 (214.4 to 32,879.1)	1,071.8 (18.2 to 14,251.2)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	40.9 (28.8 to 55.1)	62.8 (44.0 to 85.6)	53.9 (39.5 to 69.4)	-8.6 (-15.9 to -0.4)
Diarrheal diseases	160.6 (143.1 to 178.8)	261.8 (244.0 to 279.1)	63.2 (42.2 to 86.0)	4.6 (-7.2 to 17.9)	26.1 (17.4 to 36.5)	42.4 (28.5 to 59.0)	62.8 (41.7 to 85.8)	4.8 (-7.9 to 18.5)
Intestinal infectious diseases	-	-	-	-	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.8)	41.2 (32.1 to 85.6)	-22.7 (-42.6 to -1.1)
Typhoid fever	2.0 (1.7 to 2.3)	3.1 (2.5 to 3.6)	54.5 (18.3 to 92.8)	-15.8 (-37.0 to 5.3)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	55.0 (12.4 to 109.4)	-15.4 (-36.9 to 10.7)
Paratyphoid fever	1.0 (0.8 to 1.2)	1.7 (1.3 to 2.0)	58.8 (22.6 to 107.8)	-12.7 (-33.8 to 14.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	59.4 (13.9 to 118.7)	-12.7 (-35.2 to 17.3)
Other intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-25.4 (-59.2 to 36.1)	-95.5 (-77.4 to -26.4)
Lower respiratory infections	20.9 (17.6 to 24.0)	35.9 (29.7 to 41.8)	71.1 (35.7 to 114.7)	22.3 (-1.4 to 49.9)	2.2 (1.4 to 3.2)	3.7 (2.4 to 5.5)	69.6 (52.0 to 115.4)	21.0 (-4.4 to 48.5)
Upper respiratory infections	217.8 (201.0 to 238.4)	389.6 (362.2 to 414.0)	78.9 (57.6 to 97.4)	-9.0 (-19.3 to 0.7)	2.6 (1.4 to 4.4)	4.6 (2.6 to 7.7)	78.4 (56.1 to 100.0)	-9.2 (-19.6 to 1.4)
Otitis media	161.3 (148.4 to 174.7)	281.3 (256.9 to 307.9)	73.2 (58.0 to 93.0)	-8.0 (-17.3 to 3.1)	3.0 (1.7 to 4.9)	5.1 (3.0 to 8.2)	71.5 (56.0 to 89.6)	-9.0 (-17.8 to 1.0)
Meningitis	-	-	-	-	4.4 (2.9 to 6.4)	4.3 (2.9 to 6.1)	-2.4 (-24.6 to 23.6)	-49.9 (-60.1 to -39.8)
Pneumococcal meningitis	15.9 (9.5 to 23.9)	17.7 (10.7 to 26.6)	9.8 (-13.9 to 41.5)	-47.0 (-57.8 to -30.0)	1.5 (1.0 to 2.0)	1.7 (1.1 to 2.4)	13.0 (-16.8 to 53.7)	-44.1 (-57.0 to -27.7)
H influenzae type B meningitis	10.4 (3.9 to 19.2)	8.6 (3.0 to 15.9)	-16.6 (-45.4 to 11.5)	-60.0 (-72.4 to -47.4)	1.2 (0.7 to 2.0)	1.0 (0.6 to 1.6)	-15.7 (-56.0 to 38.5)	-57.7 (-77.2 to -32.8)
Meningococcal meningitis	6.4 (1.9 to 13.5)	5.7 (1.6 to 12.1)	-10.8 (-30.8 to 15.0)	-56.8 (-66.6 to -43.3)	0.8 (0.4 to 1.4)	0.7 (0.4 to 1.2)	-13.1 (-33.9 to 14.8)	-57.0 (-66.6 to -44.7)
Other meningitis	7.7 (4.3 to 12.5)	7.9 (4.3 to 13.3)	0.8 (-25.0 to 32.9)	-46.4 (-59.1 to -30.0)	1.0 (0.6 to 1.4)	1.0 (0.6 to 1.4)	1.5 (-22.5 to 40.5)	-45.3 (-57.8 to -26.6)
Encephalitis	0.2 (1.4 to 7.0)	5.1 (2.2 to 11.1)	24.1 (8.0 to 76.5)	-94.7 (-32.3 to -45.9)	0.4 (0.3 to 0.6)	0.7 (0.4 to 0.9)	69.8 (36.2 to 90.7)	-21.4 (-32.1 to -8.9)
Diphtheria	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-41.9 (-96.6 to 728.7)	-60.2 (-96.5 to 287.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-41.9 (-96.7 to 736.7)	-60.2 (-96.6 to 288.2)
Whooping cough	18.3 (14.2 to 23.5)	22.0 (17.1 to 28.2)	19.8 (18.9 to 20.8)	-11.4 (-12.1 to -10.7)	0.9 (0.5 to 1.5)	1.1 (0.6 to 1.7)	19.8 (9.5 to 31.5)	-11.4 (-19.3 to -2.7)
Tetanus	0.7 (0.4 to 1.3)	0.2 (0.1 to 0.4)	-66.3 (-87.5 to -19.2)	-82.6 (-93.5 to -56.0)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.0)	-59.0 (-85.6 to 8.1)	-76.2 (-91.2 to -38.1)
Measles	7.5 (5.4 to 10.0)	0.6 (0.4 to 0.9)	-92.5 (-94.7 to -89.4)	-94.7 (-96.2 to -92.4)	0.7 (0.4 to 1.1)	0.1 (0.0 to 0.1)	92.6 (-96.3 to -87.1)	-94.7 (-97.4 to -90.8)
Varicella and herpes zoster	11.0 (10.1 to 11.7)	18.7 (17.2 to 20.5)	67.8 (53.1 to 91.6)	2.8 (-14.6 to 26.9)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	122.6 (65.5 to 224.1)	4.9 (-25.8 to 51.5)
Neglected tropical diseases and malaria	-	-	-	-	45.4 (26.1 to 79.4)	57.2 (35.3 to 95.6)	26.5 (4.0 to 55.6)	-43.9 (-53.9 to -29.4)
Malaria	539.2 (425.5 to 664.2)	1,048.2 (817.7 to 1,302.0)	92.9 (61.2 to 132.4)	1.9 (-17.1 to 20.4)	5.8 (3.7 to 9.0)	9.1 (5.9 to 13.6)	-9.4 (39.1 to 76.4)	-9.4 (-19.8 to 3.6)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Leishmaniasis	-	-	-	-	0.5 (0.2 to 1.0)	1.2 (0.5 to 2.4)	136.2 (87.9 to 194.0)	0.8 (-16.9 to 22.9)
Visceral leishmaniasis	0.4 (0.2 to 0.7)	0.6 (0.3 to 1.0)	47.4 (-13.0 to 178.0)	-13.7 (-44.3 to 60.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	47.0 (-11.7 to 177.6)	-13.7 (-44.4 to 59.8)
Cutaneous and mucocutaneous leishmaniasis	45.5 (31.6 to 66.4)	109.9 (75.5 to 158.9)	140.1 (93.7 to 198.4)	0.9 (-17.1 to 23.3)	0.5 (0.2 to 1.0)	1.2 (0.5 to 2.3)	140.8 (93.4 to 200.7)	1.1 (-17.1 to 23.3)
African trypanosomiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Schistosomiasis	1,744.9 (733.1 to 3,271.7)	1,913.4 (731.3 to 4,260.7)	1.6 (-16.5 to 90.1)	-56.4 (-64.1 to -38.6)	14.2 (5.6 to 31.5)	16.3 (6.2 to 38.1)	10.3 (-11.0 to 72.2)	-52.3 (-61.1 to -25.6)
Cysticercosis	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-59.6 (-92.6 to 74.0)	-81.6 (-96.6 to -1.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-57.6 (-92.3 to 84.6)	-81.0 (-96.5 to 2.2)
Cystic echinococcosis	0.6 (0.5 to 0.8)	1.9 (1.6 to 2.1)	183.7 (158.6 to 231.6)	29.5 (19.0 to 50.8)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	182.8 (125.4 to 273.1)	28.0 (2.9 to 66.9)
Lymphatic filariasis	3.6 (2.9 to 4.4)	0.5 (0.3 to 0.7)	-86.9 (-91.4 to -81.9)	-93.0 (-95.4 to -90.4)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.1)	-64.9 (-81.9 to -46.5)	-84.6 (-91.8 to -76.9)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Trachoma	30.0 (20.0 to 42.9)	21.0 (14.8 to 28.3)	-29.6 (-48.6 to -3.8)	-70.2 (-79.5 to -59.1)	2.6 (1.6 to 4.0)	1.8 (1.1 to 2.6)	-31.7 (-51.3 to -9.5)	-70.7 (-80.4 to -59.7)
Dengue	0.6 (0.2 to 1.6)	6.5 (2.2 to 15.9)	904.9 (892.7 to 919.0)	379.3 (373.5 to 386.1)	0.1 (0.0 to 0.3)	1.0 (0.3 to 2.9)	853.0 (695.6 to 1,028.8)	348.1 (286.5 to 420.2)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-15.2 (-62.8 to 81.3)	52.7 (-76.7 to -8.3)
Intestinal nematode infections	-	-	-	-	7.4 (3.2 to 15.2)	5.2 (2.2 to 11.6)	-30.3 (-67.5 to 52.6)	-57.9 (-81.7 to 5.7)
Ascariasis	2,299.8 (1,816.8 to 2,908.8)	4,721.3 (3,576.8 to 6,257.6)	105.0 (40.2 to 184.3)	-4.6 (-35.4 to 46.3)	6.8 (2.9 to 14.3)	4.0 (1.4 to 10.1)	-43.1 (-77.5 to 44.6)	-63.7 (-86.5 to 8.1)
Trichuriasis	625.7 (486.8 to 807.1)	1,370.9 (1,036.0 to 1,868.9)	117.1 (47.7 to 222.0)	-0.9 (-37.6 to 58.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.3)	129.6 (-61.6 to 1,300.1)	2.3 (-86.9 to 674.4)
Hookworm disease	192.2 (155.8 to 235.2)	423.6 (328.0 to 541.1)	119.0 (60.7 to 201.1)	119.0 (30.4 to 47.9)	0.4 (0.3 to 1.0)	1.1 (0.5 to 1.9)	99.6 (7.8 to 275.3)	-2.8 (-52.2 to 96.0)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other neglected tropical diseases	286.5 (219.7 to 354.9)	531.4 (503.4 to 574.5)	84.8 (48.6 to 138.5)	4.9 (-12.9 to 30.4)	14.6 (8.1 to 25.1)	22.4 (14.0 to 34.0)	57.5 (11.7 to 118.2)	-20.3 (-51.8 to 12.3)
Maternal disorders	-	-	-	-	5.5 (3.9 to 7.5)	10.8 (7.4 to 14.7)	96.1 (72.6 to 124.7)	-24.6 (-33.3 to -15.1)
Maternal hemorrhage	3.4 (2.6 to 4.3)	3.8 (1.5 to 8.0)	11.7 (-57.0 to 87.9)	-56.9 (-83.1 to -26.5)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	8.3 (-58.3 to 95.4)	-97.5 (-83.2 to -26.0)
Maternal sepsis and other maternal infections	13.5 (8.3 to 17.6)	9.1 (6.3 to 12.4)	-32.9 (-45.4 to -12.9)	-74.1 (-78.6 to -66.5)	0.2 (0.1 to 0.3)	0.1 (0.0 to 0.2)	-33.1 (-65.3 to 5.9)	-74.1 (-85.1 to -61.8)
Maternal hypertensive disorders	9.2 (4.8 to 14.6)	10.5 (5.6 to 16.9)	15.1 (-1.6 to 26.7)	-57.2 (-62.3 to -53.1)	0.5 (0.2 to 0.8)	0.5 (0.2 to 0.9)	13.4 (-5.0 to 31.6)	-57.7 (-63.8 to -51.6)
Obstructed labor	11.9 (10.9 to 13.2)	25.3 (22.9 to 27.9)	111.7 (97.0 to 126.4)	-18.9 (-23.8 to -14.0)	3.9 (2.6 to 5.4)	8.3 (5.6 to 11.4)	112.5 (91.0 to 136.2)	-18.7 (-25.8 to -10.9)
Complications of abortion	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	25.7 (-34.7 to 119.1)	-54.3 (-74.8 to -25.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-52.1 (-34.3 to 204.1)	-52.1 (-76.5 to 11.5)
Other maternal disorders	-	-	-	-	0.8 (0.4 to 1.3)	1.7 (0.9 to 2.6)	113.8 (26.4 to 282.0)	-18.6 (-52.1 to 42.7)
Neonatal disorders	-	-	-	-	10.1 (6.0 to 16.0)	60.9 (36.4 to 95.3)	496.0 (243.0 to 912.1)	238.9 (97.7 to 465.2)
Preterm birth complications	43.9 (23.5 to 86.4)	225.5 (137.1 to 380.2)	421.3 (273.5 to 646.3)	152.8 (85.3 to 262.9)	4.1 (2.3 to 7.2)	26.9 (15.9 to 41.3)	570.9 (265.2 to 1,012.9)	250.7 (97.2 to 491.9)
Neonatal encephalopathy due to birth asphyxia and trauma	15.8 (5.5 to 44.2)	51.2 (27.0 to 92.5)	251.3 (57.2 to 823.3)	80.7 (-24.3 to 463.9)	1.1 (1.4 to 3.9)	10.7 (6.0 to 19.0)	413.7 (151.6 to 980.5)	235.3 (57.9 to 655.2)
Neonatal sepsis and other neonatal infections	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	163.7 (137.6 to 210.8)	114.5 (93.3 to 152.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	114.5 (104.1 to 273.4)	164.1 (66.0 to 203.8)
Hemolytic disease and other neonatal jaundice	6.9 (2.6 to 16.4)	49.7 (16.3 to 113.2)	643.5 (97.2 to 2,190.1)	334.9 (17.3 to 1,230.4)	2.2 (0.8 to 5.0)	12.8 (4.6 to 28.3)	484.3 (78.4 to 1,530.6)	231.3 (0.4 to 810.8)
Other neonatal disorders	-	-	-	-	1.7 (0.5 to 3.8)	10.4 (2.4 to 27.0)	481.9 (194.0 to 1,297.3)	231.3 (66.7 to 692.4)
Nutritional deficiencies	-	-	-	-	194.7 (130.0 to 283.9)	373.3 (248.9 to 559.3)	92.4 (69.2 to 115.9)	2.6 (-6.8 to 12.1)
Protein-energy malnutrition	158.9 (86.9 to 269.5)	202.0 (74.4 to 435.8)	20.6 (-59.9 to 241.1)	-10.3 (-70.1 to 154.2)	19.8 (9.1 to 35.2)	25.1 (8.6 to 58.7)	20.1 (-60.2 to 245.1)	-10.8 (-70.2 to 157.0)
Iodine deficiency	391.4 (121.1 to 725.3)	588.3 (364.3 to 1,002.6)	54.0 (-41.7 to 414.4)	-37.7 (-77.7 to 160.1)	7.1 (1.9 to 15.6)	10.6 (5.3 to 20.5)	52.5 (-41.4 to 398.4)	-37.8 (-77.5 to 159.7)
Vitamin A deficiency	17.8 (12.5 to 22.9)	21.4 (14.1 to 28.8)	18.7 (2.7 to 42.3)	-38.7 (-48.3 to -28.6)	1.1 (0.7 to 1.7)	1.3 (0.7 to 2.1)	12.3 (-11.7 to 38.9)	-43.0 (-56.6 to -30.9)

Appendix Table G.4 - Yemen prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	4,364.0 (4,302.4 to 4,427.0)	9,314.3 (9,238.8 to 9,391.1)	112.7 (109.4 to 115.9)	-5.6 (-4.3 to 6.8)	159.8 (107.0 to 229.8)	328.4 (220.5 to 472.5)	105.9 (100.8 to 109.3)	105.9 (4.0 to 8.2)
Other nutritional deficiencies	-	-	-	-	6.9 (1.5 to 19.1)	7.8 (1.7 to 22.2)	14.2 (-73.4 to 325.4)	-15.3 (-80.2 to 214.7)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	10.6 (6.8 to 15.4)	20.9 (13.7 to 30.5)	95.9 (72.9 to 129.1)	-2.3 (-13.3 to 13.1)
Sexually transmitted diseases excluding HIV	-	-	-	-	1.6 (0.9 to 2.8)	4.3 (2.2 to 7.5)	156.2 (80.4 to 332.4)	-3.4 (-29.0 to 48.6)
Syphilis	0.3 (0.2 to 0.3)	0.4 (0.3 to 0.4)	50.0 (28.8 to 74.9)	38.4 (-45.8 to -29.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	35.6 (16.4 to 106.3)	-96.5 (-52.4 to -15.5)
Chlamydial infection	156.0 (96.1 to 231.7)	457.0 (335.2 to 635.1)	197.2 (58.0 to 394.4)	11.3 (-38.9 to 79.1)	0.8 (0.4 to 1.4)	2.2 (0.9 to 4.2)	161.7 (25.9 to 620.1)	0.3 (-49.7 to 144.7)
Gonococcal infection	58.6 (41.1 to 80.4)	153.7 (118.1 to 197.6)	158.0 (79.6 to 321.6)	-3.3 (-28.4 to 53.0)	0.4 (0.2 to 0.6)	1.0 (0.5 to 1.6)	174.5 (82.1 to 312.1)	2.3 (-28.9 to 47.1)
Trichomoniasis	43.2 (22.9 to 69.8)	97.3 (41.5 to 174.2)	129.8 (-9.2 to 327.5)	-10.3 (-57.7 to 47.0)	0.1 (0.0 to 0.2)	0.2 (0.0 to 0.4)	122.0 (-23.2 to 374.0)	-13.2 (-64.1 to 65.4)
Genital herpes	1,188.1 (1,124.2 to 1,255.5)	2,875.1 (2,717.0 to 3,015.2)	1,411.1 (122.7 to 159.7)	-5.5 (-13.0 to 2.4)	0.8 (0.1 to 0.8)	0.8 (0.2 to 1.9)	141.4 (119.3 to 166.5)	0.7 (-13.5 to 4.1)
Other sexually transmitted diseases	2.0 (1.5 to 2.8)	3.9 (2.9 to 5.2)	93.8 (70.2 to 133.8)	-27.6 (-36.2 to -13.3)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	149.5 (61.2 to 302.0)	9.2 (-37.3 to 38.3)
Hepatitis	-	-	-	-	1.1 (0.7 to 1.6)	2.0 (1.3 to 2.9)	79.2 (53.5 to 104.3)	-26.1 (-41.0 to -13.2)
Hepatitis A	22.3 (21.0 to 23.7)	39.5 (37.7 to 41.2)	76.4 (73.5 to 79.1)	-1.0 (-1.0 to -0.9)	0.4 (0.2 to 0.6)	0.9 (0.5 to 1.2)	116.0 (92.0 to 143.0)	0.7 (-9.5 to 12.5)
Hepatitis B	1,936.2 (1,682.0 to 2,185.1)	2,440.5 (2,182.0 to 2,682.2)	25.3 (7.7 to 48.7)	-41.8 (-48.9 to -33.6)	0.7 (0.4 to 1.0)	0.9 (0.6 to 1.4)	43.1 (11.0 to 80.8)	-39.7 (-56.1 to -22.4)
Hepatitis C	170.0 (153.4 to 187.8)	295.1 (266.5 to 323.7)	72.9 (50.9 to 98.4)	-25.8 (-34.8 to -15.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	52.4 (23.7 to 94.6)	-24.9 (-44.0 to 3.4)
Hepatitis E	1.3 (0.9 to 1.6)	5.6 (3.6 to 9.4)	332.7 (156.0 to 631.2)	75.0 (14.5 to 185.6)	0.0 (0.0 to 0.1)	0.2 (0.1 to 0.3)	341.6 (151.0 to 706.3)	73.9 (8.9 to 201.7)
Leprosy	0.7 (0.5 to 0.9)	1.2 (1.0 to 1.3)	68.2 (41.6 to 110.0)	-23.6 (-34.6 to -7.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	72.9 (34.2 to 131.8)	-22.1 (-37.7 to 2.0)
Other infectious diseases	207.1 (163.1 to 251.6)	400.4 (367.5 to 444.4)	92.9 (67.9 to 117.8)	5.3 (-7.0 to 18.6)	7.8 (4.9 to 11.5)	14.6 (9.7 to 21.0)	86.2 (59.8 to 122.6)	5.0 (-10.9 to 23.5)
Non-communicable diseases	-	-	-	-	156.2 (85.5 to 268.3)	1,566.6 (1,143.5 to 2,032.9)	134.5 (124.8 to 144.6)	0.7 (-4.3 to 3.2)
Neoplasms	-	-	-	-	2.1 (1.2 to 3.5)	5.9 (3.2 to 9.8)	173.3 (75.6 to 332.5)	20.8 (-21.1 to 88.1)
Esophageal cancer	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.5)	55.2 (-16.3 to 186.7)	-32.9 (-61.9 to 18.4)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	59.5 (-7.6 to 182.8)	-30.5 (-59.3 to 19.8)
Stomach cancer	1.3 (0.8 to 2.0)	2.8 (1.6 to 4.5)	109.6 (29.3 to 254.1)	-9.6 (-41.9 to 49.2)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	105.0 (27.5 to 246.0)	-11.1 (-42.7 to 45.2)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	293.8 (136.2 to 570.5)	75.6 (6.0 to 189.0)
Liver cancer due to hepatitis B	0.1 (0.0 to 0.1)	0.3 (0.1 to 0.5)	294.1 (89.7 to 762.7)	72.4 (-18.0 to 272.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	283.5 (100.7 to 651.9)	67.5 (-13.1 to 239.6)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.1)	0.3 (0.2 to 0.6)	943.4 (367.3 to 1,968.1)	368.9 (122.6 to 821.2)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	871.5 (383.6 to 1,744.4)	333.0 (122.8 to 687.5)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-45.8 (-75.6 to 17.8)	-75.0 (-88.8 to -48.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-46.6 (-74.1 to 7.3)	-75.4 (-87.8 to -50.3)
Liver cancer due to other causes	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	93.4 (-21.0 to 375.6)	-17.5 (-67.0 to 109.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	83.0 (-17.9 to 309.6)	20.5 (-65.8 to 75.9)
Larynx cancer	0.5 (0.3 to 0.8)	1.0 (0.5 to 1.7)	96.1 (15.0 to 239.8)	-12.8 (-47.2 to 45.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	95.6 (16.1 to 241.3)	-13.4 (-48.1 to 44.9)
Tracheal, bronchus and lung cancer	0.9 (0.5 to 1.5)	2.1 (1.1 to 3.4)	123.3 (38.9 to 268.0)	-1.9 (-36.7 to 56.4)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.7)	123.2 (37.4 to 268.4)	-1.4 (-37.3 to 56.9)
Breast cancer	3.1 (1.8 to 5.4)	12.3 (6.1 to 26.6)	281.3 (111.5 to 660.3)	59.3 (-10.1 to 214.7)	0.3 (0.2 to 0.5)	1.1 (0.5 to 2.4)	246.5 (95.1 to 595.6)	45.5 (-16.7 to 195.2)
Cervical cancer	2.4 (1.3 to 4.5)	5.0 (2.7 to 9.0)	99.3 (12.7 to 287.7)	-8.3 (-52.2 to 58.0)	0.4 (0.1 to 0.4)	0.4 (0.2 to 0.7)	89.2 (13.3 to 295.2)	-15.4 (-52.2 to 62.3)
Uterine cancer	1.0 (0.4 to 1.8)	2.5 (1.0 to 5.0)	160.8 (18.7 to 421.3)	11.1 (-49.6 to 116.0)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	157.0 (19.0 to 424.5)	8.7 (-49.6 to 118.7)
Prostate cancer	0.7 (0.3 to 1.1)	3.7 (1.8 to 6.2)	471.1 (209.2 to 920.8)	140.4 (34.1 to 317.3)	0.1 (0.0 to 0.1)	0.4 (0.2 to 0.7)	362.8 (171.3 to 667.0)	96.3 (15.2 to 223.9)
Colon and rectum cancer	1.1 (0.7 to 1.7)	4.0 (2.4 to 6.3)	253.0 (119.3 to 492.8)	46.0 (-6.3 to 130.8)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.6)	224.9 (101.7 to 449.0)	34.3 (-12.1 to 118.2)
Lip and oral cavity cancer	0.6 (0.3 to 1.0)	1.4 (0.7 to 2.5)	139.5 (39.6 to 303.3)	4.0 (-38.3 to 68.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	134.2 (39.8 to 291.7)	1.3 (-38.1 to 62.4)
Nasopharynx cancer	0.4 (0.2 to 0.6)	0.7 (0.4 to 1.3)	85.9 (-0.4 to 269.1)	-21.7 (-57.6 to 55.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	80.9 (-1.3 to 251.3)	20.0 (-57.5 to 49.7)
Other pharynx cancer	0.1 (0.1 to 0.2)	0.3 (0.1 to 0.5)	86.0 (1.8 to 272.0)	-20.7 (-56.1 to 55.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	84.0 (3.3 to 250.6)	-21.4 (-54.7 to 45.2)
Gallbladder and biliary tract cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	173.1 (57.0 to 374.9)	15.2 (-32.0 to 95.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	154.5 (52.6 to 327.3)	6.5 (-35.1 to 74.8)
Pancreatic cancer	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	156.0 (54.9 to 332.7)	9.3 (-31.7 to 77.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	152.3 (60.1 to 310.8)	8.0 (-28.5 to 66.4)
Malignant skin melanoma	0.3 (0.1 to 0.7)	0.8 (0.4 to 1.7)	158.4 (47.4 to 390.8)	4.5 (-39.2 to 100.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	150.0 (30.1 to 370.2)	1.9 (-42.8 to 87.7)
Non-melanoma skin cancer	0.8 (0.4 to 1.2)	2.2 (1.3 to 3.3)	163.2 (52.6 to 365.2)	4.1 (-43.4 to 110.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	251.8 (128.4 to 460.6)	47.3 (-7.7 to 142.5)
Ovarian cancer	0.2 (0.1 to 0.4)	0.7 (0.2 to 1.4)	222.8 (56.8 to 640.0)	0.7 (-34.9 to 202.2)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	220.1 (41.9 to 627.5)	31.1 (-43.2 to 209.1)
Testicular cancer	0.2 (0.1 to 0.3)	0.3 (0.2 to 1.3)	301.1 (92.3 to 758.9)	54.6 (-21.3 to 231.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	282.6 (69.5 to 744.5)	46.4 (-26.5 to 220.4)
Kidney cancer	0.5 (0.1 to 0.5)	0.5 (0.3 to 0.9)	114.0 (20.0 to 289.2)	17.7 (-31.5 to 106.3)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	123.4 (32.1 to 318.8)	15.3 (-32.9 to 105.0)
Bladder cancer	0.8 (0.5 to 1.2)	1.6 (1.0 to 2.5)	106.8 (27.3 to 236.2)	-4.9 (-40.8 to 47.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	109.1 (32.3 to 230.6)	-6.3 (-39.3 to 46.1)
Brain and nervous system cancer	1.1 (0.5 to 3.0)	2.6 (1.4 to 4.7)	172.2 (15.2 to 377.5)	38.0 (-21.0 to 131.8)	0.1 (0.0 to 0.3)	0.3 (0.1 to 0.5)	177.8 (33.6 to 369.1)	32.4 (-21.1 to 121.9)
Thyroid cancer	0.8 (0.3 to 1.8)	2.6 (1.2 to 5.5)	228.7 (86.8 to 507.1)	25.2 (-28.8 to 124.5)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.4)	213.4 (72.9 to 489.2)	19.0 (-30.9 to 105.6)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	67.4 (-1.1 to 200.5)	-29.3 (-57.5 to 21.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	69.2 (1.1 to 197.0)	27.9 (-56.8 to 21.1)
Hodgkin lymphoma	0.9 (0.3 to 1.7)	2.0 (0.8 to 3.7)	124.2 (11.2 to 358.3)	11.2 (-39.7 to 110.7)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	125.7 (16.4 to 344.1)	7.4 (-40.5 to 74.4)
Non-Hodgkin lymphoma	0.7 (0.4 to 1.9)	2.8 (1.5 to 5.3)	293.7 (103.3 to 687.1)	78.5 (-8.1 to 287.9)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.4)	276.6 (101.7 to 662.1)	66.8 (-11.7 to 270.4)
Multiple myeloma	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.5)	204.9 (76.7 to 493.1)	31.2 (-22.5 to 145.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	191.9 (64.1 to 434.0)	24.7 (-29.5 to 128.6)
Leukemia	1.5 (0.8 to 2.6)	3.8 (2.4 to 5.9)	161.9 (39.3 to 394.3)	50.3 (-7.7 to 148.6)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.8)	174.9 (61.5 to 367.3)	39.9 (-13.6 to 132.2)
Other neoplasms	1.8 (0.8 to 5.3)	5.0 (2.8 to 9.9)	207.4 (43.0 to 415.6)	38.6 (-14.7 to 119.2)	0.1 (0.1 to 0.3)	0.4 (0.2 to 0.7)	198.4 (55.7 to 412.3)	29.1 (-19.5 to 106.8)
Cardiovascular diseases	-	-	-	-	14.3 (9.7 to 19.7)	32.1 (21.5 to 44.4)	125.4 (76.1 to 179.0)	0.5 (-18.4 to 22.7)
Rheumatic heart disease	46.8 (41.0 to 52.3)	96.0 (83.5 to 109.0)	104.8 (68.0 to 143.0)	-11.0 (-26.5 to 5.1)	2.3 (1.5 to 3.5)	5.0 (3.1 to 7.2)	111.8 (74.2 to 155.9)	-4.6 (-21.5 to 16.5)
Ischemic heart disease	56.8 (46.8 to 68.9)	109.1 (94.6 to 129.7)	90.8 (49.6 to 149.4)	-10.9 (-28.3 to 11.6)	3.3 (2.0 to 4.7)	6.1 (4.0 to 8.8)	90.7 (44.1 to 162.4)	-9.6 (-30.4 to 23.2)
Cerebrovascular disease	-	-	-	-	0.4 (0.3 to 0.6)	1.1 (0.7 to 1.5)	137.5 (92.1 to 195.9)	-0.8 (-21.5 to 24.3)
Ischemic stroke	2.4 (2.1 to 2.8)	5.9 (5.1 to 6.7)	138.9 (91.8 to 193.4)	-0.4 (-21.3 to 23.9)	0.4 (0.3 to 0.5)	0.9 (0.6 to 1.2)	139.1 (89.8 to 203.8)	0.0 (-21.5 to 27.7)
Hemorrhagic stroke	0.4 (0.3 to 0.5)	0.9 (0.7 to 1.2)	126.7 (57.7 to 226.1)	-5.1 (-34.4 to 33.5)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	126.5 (59.1 to 224.5)	-4.6 (-33.9 to 33.7)
Hypertensive heart disease	5.4 (4.0 to 7.2)	16.9 (13.1 to 22.4)	208.9 (106.5 to 369.4)	46.2 (-4.0 to 124.3)	0.6 (0.4 to 0.9)	1.9 (1.2 to 2.9)	208.2 (104.1 to 371.7)	45.4 (-4.9 to 123.8)
Cardiomyopathy and myocarditis	4.9 (3.2 to 9.1)	12.6 (8.2 to 18.9)	169.7 (7.3 to 410.9)	19.2 (-51.9 to 114.8)	0.4 (0.2 to 0.8)	1.0 (0.5 to 1.7)	171.9 (64.4 to 418.8)	20.2 (-52.8 to 117.2)
Atrial fibrillation and flutter	101.2 (65.7 to 137.8)	239.8 (161.9 to 322.2)	132.0 (39.0 to 342.3)	2.9 (-31.8 to 67.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	113.4 (14.6 to 311.6)	-7.9 (-52.5 to 73.4)
Endocarditis	0.3 (0.2 to 0.4)	0.7 (0.5 to 1.0)	139.8 (62.8 to 225.8)	22.6 (-20.6 to 86.5)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	171.0 (74.8 to 293.9)	27.1 (-23.3 to 99.4)
Other cardiovascular and circulatory diseases	93.5 (65.7 to 129.3)	215.7 (135.4 to 285.7)	131.1 (42.7 to 247.2)	-8.8 (-39.7 to 44.4)	6.6 (4.0 to 10.0)	15.2 (8.6 to 23.1)	132.2 (78.3 to 245.0)	-0.9 (-39.8 to 45.4)
Chronic respiratory diseases	-	-	-	-	27.5 (18.5 to 38.0)	64.8 (42.8 to 89.3)	137.5 (91.1 to 188.5)	-1.8 (-20.6 to 18.7)
Chronic obstructive pulmonary disease	283.7 (267.2 to 300.9)	6						

Appendix Table G.4 - Yemen prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0	0.1	133.7	-2.0
Silicosis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	116.6 (105.7 to 127.3)	-7.9 (-12.8 to -2.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	116.6 (126.1 to 143.0)	-7.8 (-5.3 to 1.6)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	441.5 (132.6 to 152.3)	0.5 (-2.9 to 4.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	142.5 (133.3 to 153.5)	1.5 (-2.1 to 5.7)
Asthma	128.2 (90.9 to 170.5)	272.8 (185.8 to 353.1)	108.2 (38.8 to 237.5)	-12.3 (36.0 to 39.5)	5.5 (3.3 to 8.7)	11.8 (6.7 to 18.3)	108.8 (35.4 to 235.7)	-12.2 (-36.4 to 40.2)
Interstitial lung disease and pulmonary sarcoidosis	0.6 (0.4 to 0.7)	1.4 (1.1 to 1.7)	150.5 (91.5 to 241.5)	3.9 (-22.2 to 46.4)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	151.3 (92.6 to 242.8)	4.5 (-22.7 to 45.7)
Other chronic respiratory diseases	-	-	-	-	3.0 (1.4 to 5.9)	4.6 (2.4 to 7.7)	53.7 (5.5 to 131.5)	-36.4 (-60.3 to -4.6)
Cirrhosis	-	-	-	-	0.7 (0.5 to 1.0)	1.1 (0.8 to 1.6)	58.6 (34.0 to 76.1)	-18.4 (-27.2 to -9.0)
Cirrhosis due to hepatitis B	1.4 (0.9 to 2.1)	2.6 (1.7 to 3.3)	93.0 (3.4 to 219.2)	-6.6 (50.7 to 55.9)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.7)	93.3 (4.5 to 230.6)	-7.3 (-51.9 to 59.4)
Cirrhosis due to hepatitis C	1.5 (0.9 to 2.1)	2.3 (1.6 to 2.9)	45.2 (-8.5 to 210.7)	-23.4 (52.0 to 80.8)	0.3 (0.1 to 0.4)	0.4 (0.2 to 0.6)	45.4 (-10.9 to 205.8)	-23.9 (-52.9 to 82.6)
Cirrhosis due to alcohol use	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	34.4 (-16.9 to 111.7)	0.0 (-60.8 to -5.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	33.7 (-21.7 to 129.3)	-37.1 (-64.4 to 6.3)
Cirrhosis due to other causes	1.2 (1.0 to 1.6)	1.6 (1.3 to 2.1)	34.0 (-5.6 to 76.8)	-15.6 (-40.7 to 18.2)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	31.9 (-19.4 to 102.7)	-16.4 (-45.8 to 24.7)
Digestive diseases	-	-	-	-	6.9 (4.8 to 9.3)	14.0 (9.8 to 18.8)	103.4 (79.5 to 131.8)	-10.8 (-21.4 to -0.5)
Peptic ulcer disease	33.1 (27.9 to 37.7)	45.2 (35.9 to 55.0)	35.6 (9.6 to 71.2)	-34.8 (-46.9 to -19.5)	1.3 (0.9 to 1.9)	2.1 (1.4 to 3.0)	58.6 (12.1 to 95.9)	-27.9 (-45.8 to -15.1)
Gastritis and duodenitis	33.0 (28.3 to 37.2)	34.7 (29.0 to 40.5)	4.9 (-16.6 to 28.7)	-46.9 (-55.7 to -36.9)	1.5 (1.0 to 2.3)	1.6 (1.0 to 2.4)	3.3 (-23.0 to 47.2)	-42.6 (-54.2 to -26.8)
Appendicitis	0.7 (0.5 to 0.9)	1.5 (1.1 to 2.0)	106.5 (36.3 to 194.8)	-17.4 (-4.1 to 14.0)	0.2 (0.1 to 0.3)	0.5 (0.2 to 0.8)	103.9 (22.0 to 226.4)	-16.7 (-46.3 to 27.0)
Paralytic ileus and intestinal obstruction	0.2 (0.1 to 0.4)	0.3 (0.2 to 0.5)	128.2 (-43.2 to 284.9)	10.9 (-39.3 to 46.9)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	128.9 (-45.2 to 339.1)	10.2 (-43.9 to 59.6)
Inguinal, femoral, and abdominal hernia	54.3 (45.9 to 68.6)	97.2 (82.2 to 115.8)	81.9 (31.2 to 131.7)	-11.1 (-32.0 to 12.3)	0.6 (0.3 to 1.1)	1.0 (0.5 to 2.0)	81.4 (29.3 to 132.4)	-11.0 (-32.0 to 12.0)
Inflammatory bowel disease	6.5 (6.1 to 7.0)	24.3 (22.2 to 26.4)	270.5 (230.6 to 314.2)	48.7 (33.0 to 65.3)	1.4 (0.9 to 1.9)	5.2 (3.5 to 7.2)	271.4 (220.8 to 329.1)	49.0 (31.5 to 69.7)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	133.3 (71.3 to 209.5)	1.0 (-31.7 to 38.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	132.6 (69.3 to 213.3)	-0.0 (-33.4 to 43.8)
Gallbladder and biliary diseases	3.0 (2.6 to 3.5)	6.6 (5.5 to 7.7)	119.1 (72.5 to 175.6)	0.3 (-24.5 to 23.5)	0.3 (0.2 to 0.4)	0.7 (0.4 to 1.0)	119.3 (67.7 to 187.2)	3.3 (-25.7 to 24.2)
Pancreatitis	1.6 (1.5 to 1.7)	3.7 (3.4 to 4.0)	124.1 (105.1 to 146.0)	-6.6 (-13.5 to 2.3)	0.2 (0.3 to 0.7)	1.1 (0.7 to 1.5)	123.9 (62.9 to 170.6)	-6.8 (-21.2 to 9.3)
Other digestive diseases	-	-	-	-	0.9 (0.5 to 1.4)	1.7 (1.0 to 2.7)	78.5 (33.1 to 191.0)	-22.1 (-42.3 to 26.8)
Neurological disorders	-	-	-	-	69.7 (45.3 to 96.3)	177.4 (117.3 to 247.5)	155.8 (103.8 to 214.6)	3.7 (-13.4 to 20.2)
Alzheimer disease and other dementias	32.1 (28.1 to 36.9)	72.3 (62.4 to 82.1)	124.7 (86.8 to 172.0)	-1.8 (-21.0 to 18.0)	4.4 (3.2 to 5.7)	9.9 (7.0 to 13.1)	156.0 (85.3 to 172.9)	-1.6 (-21.6 to 18.6)
Parkinson disease	3.1 (1.7 to 4.3)	7.1 (3.8 to 10.2)	130.0 (115.5 to 145.6)	0.9 (-5.0 to 8.2)	0.4 (0.2 to 0.6)	0.8 (0.4 to 1.3)	131.2 (104.1 to 160.2)	1.2 (-9.9 to 13.7)
Epilepsy	54.4 (45.6 to 62.0)	112.7 (94.0 to 130.8)	106.2 (65.7 to 152.9)	-1.1 (-19.8 to 21.0)	14.9 (9.7 to 20.9)	32.3 (21.4 to 45.3)	116.4 (70.3 to 176.3)	4.1 (-16.7 to 29.1)
Multiple sclerosis	0.7 (0.4 to 0.9)	2.9 (1.9 to 3.9)	335.9 (165.6 to 656.9)	0.2 (-10.0 to 179.6)	0.2 (0.1 to 0.4)	1.0 (0.6 to 1.5)	334.0 (160.1 to 627.3)	66.7 (6.0 to 175.1)
Migraine	1,018.5 (707.1 to 1,299.2)	2,427.6 (1,870.3 to 3,086.8)	142.3 (56.0 to 238.1)	8.0 (-37.9 to 32.2)	34.9 (18.2 to 54.3)	83.0 (45.6 to 129.9)	142.3 (58.9 to 243.6)	-4.6 (-37.6 to 31.1)
Tension-type headache	1,634.4 (1,489.5 to 1,765.5)	3,880.3 (2,883.5 to 5,269.8)	140.0 (57.0 to 214.8)	-1.9 (-31.2 to 22.4)	2.5 (1.2 to 4.4)	5.9 (2.5 to 11.5)	139.6 (56.9 to 216.7)	-1.8 (-23.0 to 23.0)
Medication overuse headache	67.7 (45.0 to 93.5)	265.9 (177.0 to 352.7)	291.1 (207.8 to 415.4)	53.6 (23.6 to 98.7)	10.6 (5.9 to 16.8)	41.9 (23.3 to 64.4)	294.0 (208.8 to 416.4)	54.1 (22.7 to 98.7)
Other neurological disorders	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	103.6 (36.0 to 209.3)	-0.7 (-28.3 to 46.7)	1.7 (0.8 to 3.6)	2.5 (1.5 to 3.8)	54.4 (-23.0 to 171.0)	-34.3 (-67.2 to 14.3)
Mental and substance use disorders	-	-	-	-	217.5 (148.3 to 305.6)	511.8 (346.5 to 734.0)	135.8 (122.6 to 148.8)	-1.9 (-5.7 to 0.3)
Schizophrenia	20.7 (18.8 to 22.5)	53.3 (48.5 to 57.7)	156.6 (146.6 to 169.4)	0.1 (-3.4 to 4.1)	0.1 (0.8 to 16.1)	0.1 (25.0 to 41.5)	156.6 (142.8 to 175.5)	0.3 (-5.0 to 6.3)
Alcohol use disorders	47.6 (42.2 to 53.9)	118.9 (103.8 to 135.0)	148.9 (130.7 to 165.2)	-2.3 (-8.6 to 3.8)	4.7 (3.1 to 6.8)	11.8 (7.8 to 16.8)	150.2 (128.3 to 172.4)	-2.3 (-10.1 to 5.6)
Drug use disorders	-	-	-	-	19.9 (11.0 to 34.9)	51.3 (27.8 to 94.1)	157.0 (126.6 to 188.5)	-3.0 (-12.4 to 7.6)
Opioid use disorders	32.2 (14.5 to 62.7)	84.3 (34.1 to 170.9)	156.2 (114.9 to 189.3)	-2.7 (-16.8 to 9.0)	13.4 (5.5 to 27.6)	34.9 (13.1 to 77.3)	158.3 (115.7 to 193.5)	-2.3 (-16.9 to 9.6)
Cocaine use disorders	6.1 (6.7 to 9.9)	21.2 (16.6 to 25.8)	161.1 (97.1 to 260.4)	1.1 (-2.3 to 29.9)	1.1 (0.7 to 1.7)	2.9 (1.7 to 4.3)	159.9 (87.4 to 268.6)	-0.9 (-25.9 to 34.3)
Amphetamine use disorders	14.6 (10.8 to 18.7)	35.5 (28.7 to 42.7)	142.1 (66.0 to 251.9)	-7.8 (-34.3 to 26.2)	1.9 (1.1 to 3.0)	4.6 (2.8 to 7.0)	143.6 (62.4 to 258.8)	-7.5 (-35.9 to 31.0)
Cannabis use disorders	15.4 (11.6 to 18.9)	40.6 (30.9 to 49.6)	163.1 (159.9 to 166.9)	0.6 (0.5 to 0.8)	0.4 (0.3 to 0.7)	1.2 (0.7 to 1.8)	163.3 (118.9 to 211.6)	0.7 (-15.2 to 17.4)
Other drug use disorders	-	-	-	-	3.1 (1.8 to 4.6)	7.6 (4.6 to 11.0)	148.0 (69.0 to 273.6)	-5.3 (-34.2 to 37.5)
Depressive disorders	-	-	-	-	13.6 (33.5 to 107.5)	152.1 (78.6 to 261.9)	140.4 (97.9 to 156.0)	2.2 (-14.5 to 2.1)
Major depressive disorder	268.6 (148.9 to 424.1)	636.3 (322.5 to 1,019.2)	138.1 (89.1 to 154.7)	-2.8 (-19.2 to 2.0)	55.2 (26.1 to 98.0)	130.8 (59.5 to 234.2)	138.8 (88.8 to 157.0)	-2.4 (-18.8 to 2.7)
Dysthymia	87.8 (71.7 to 104.0)	220.9 (178.4 to 264.0)	150.7 (145.3 to 155.0)	-1.4 (-1.7 to -1.1)	8.5 (5.4 to 12.4)	21.3 (13.5 to 31.2)	151.5 (142.0 to 160.4)	-1.2 (-3.6 to 1.4)
Bipolar disorder	59.0 (50.7 to 67.7)	151.5 (127.5 to 173.9)	156.1 (140.3 to 171.0)	-1.3 (-6.0 to 3.0)	12.0 (7.2 to 18.2)	30.9 (18.7 to 46.6)	156.8 (138.6 to 176.9)	-1.2 (-7.2 to 4.6)
Anxiety disorders	411.5 (176.9 to 609.3)	994.4 (429.0 to 1,452.8)	241.3 (125.8 to 156.3)	-1.5 (-1.9 to -1.1)	38.1 (1.4 to 3.7)	91.9 (36.8 to 151.3)	141.7 (124.8 to 158.8)	-1.3 (-3.6 to 1.0)
Eating disorders	-	-	-	-	1.4 (0.8 to 2.2)	1.4 (2.2 to 5.9)	167.3 (135.7 to 199.6)	1.7 (-10.1 to 13.1)
Anorexia nervosa	1.2 (0.8 to 1.8)	3.6 (2.2 to 5.3)	191.4 (159.1 to 223.7)	15.7 (2.1 to 28.0)	0.3 (0.1 to 0.4)	0.8 (0.4 to 1.3)	191.0 (111.0 to 285.2)	15.3 (-14.7 to 54.8)
Bulimia nervosa	5.4 (3.7 to 7.6)	14.2 (9.5 to 20.2)	162.4 (157.2 to 166.7)	-1.4 (-2.0 to -1.1)	1.1 (0.6 to 1.8)	3.0 (1.7 to 4.8)	161.9 (128.4 to 198.9)	-1.5 (-13.3 to 10.8)
Autistic spectrum disorders	-	-	-	-	13.6 (9.5 to 18.4)	29.0 (20.2 to 39.4)	112.9 (105.0 to 121.8)	2.2 (-1.1 to 5.8)
Autism	34.1 (32.3 to 36.1)	73.1 (69.3 to 77.3)	113.5 (112.1 to 115.0)	1.7 (1.6 to 1.8)	8.5 (5.7 to 11.6)	18.1 (12.2 to 24.9)	113.8 (102.2 to 127.2)	2.1 (-2.7 to 7.0)
Asperger syndrome	51.6 (48.4 to 54.6)	109.6 (102.7 to 116.2)	111.7 (109.8 to 113.7)	2.3 (2.1 to 2.4)	5.2 (3.6 to 7.3)	11.0 (7.5 to 15.3)	111.2 (101.0 to 122.0)	2.3 (-1.4 to 6.3)
Attention-deficit/hyperactivity disorder	88.6 (78.5 to 99.1)	182.9 (161.9 to 204.9)	105.8 (105.0 to 106.2)	0.4 (0.3 to 0.4)	1.1 (0.6 to 1.7)	2.2 (1.3 to 3.4)	106.1 (91.5 to 122.0)	0.5 (-6.6 to 8.0)
Conduct disorder	170.0 (143.7 to 195.2)	361.0 (303.9 to 417.2)	111.7 (107.2 to 115.8)	0.3 (0.3 to 0.3)	20.4 (12.3 to 30.0)	48.2 (25.9 to 63.5)	111.8 (102.7 to 121.7)	0.5 (-3.3 to 4.5)
Idiopathic intellectual disability	410.9 (342.9 to 489.8)	753.6 (615.7 to 925.9)	85.1 (67.7 to 103.9)	-10.1 (-18.6 to -0.8)	20.2 (13.3 to 28.5)	37.3 (21.4 to 52.8)	85.1 (66.9 to 104.7)	-10.1 (-18.9 to -0.6)
Other mental and substance use disorders	121.6 (113.2 to 129.6)	322.9 (300.1 to 345.3)	164.5 (162.8 to 166.3)	1.5 (1.2 to 1.9)	9.1 (6.2 to 12.3)	24.2 (16.6 to 32.5)	165.5 (154.9 to 178.5)	1.8 (-1.8 to 5.8)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	64.8 (45.2 to 90.6)	149.5 (104.8 to 206.8)	130.4 (112.9 to 151.4)	3.2 (-5.9 to 15.1)
Diabetes mellitus	148.5 (114.5 to 187.0)	364.6 (277.5 to 455.2)	142.8 (79.7 to 231.8)	0.1 (-26.5 to 41.7)	13.3 (8.5 to 19.5)	31.9 (20.8 to 46.8)	138.2 (75.1 to 234.8)	-0.6 (-26.9 to 39.8)
Acute glomerulonephritis	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	43.5 (36.0 to 52.9)	0.0 (-19.5 to -12.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.5 (35.9 to 52.9)	-16.2 (-19.6 to -12.1)
Chronic kidney disease	-	-	-	-	10.0 (7.1 to 13.7)	22.4 (15.8 to 30.6)	123.2 (101.8 to 143.7)	-0.5 (-7.0 to 6.1)
Chronic kidney disease due to diabetes mellitus	66.0 (42.7 to 101.1)	167.2 (106.0 to 248.5)	149.3 (95.6 to 231.2)	1.8 (-17.3 to 49.2)	1.8 (1.2 to 2.5)	4.5 (3.1 to 6.3)	151.0 (98.3 to 231.4)	11.3 (-24.3 to 48.3)
Chronic kidney disease due to hypertension	58.2 (40.6 to 83.5)	97.1 (69.2 to 137.3)	67.6 (22.1 to 116.3)	-23.6 (-41.2 to -3.7)	2.9 (1.9 to 4.2)	5.5 (3.5 to 7.9)	91.5 (47.0 to 149.2)	-2.3 (-38.9 to 2.9)
Chronic kidney disease due to glomerulonephritis	95.6 (67.6 to 135.5)	175.1 (118.3 to 250.4)	78.5 (35.3 to 161.0)	1.7 (-44.9 to 40.4)	1.7 (1.1 to 2.4)	2.7 (1.8 to 4.0)	62.7 (48.0 to 116.8)	-2.6 (-42.3 to 4.5)
Chronic kidney disease due to other causes	129.4 (89.7 to 192.9)	342.9 (243.2 to 465.6)	169.7 (104.9 to 244.3)	23.2 (-14.4 to 65.9)	3.7 (2.6 to 5.1)	9.6 (6.5 to 13.4)	159.6 (110.3 to 230.4)	21.1 (-5.1 to 57.7)
Urinary diseases and male infertility	-	-	-	-	3.0 (1.9 to 4.4)	8.0 (5.0 to 12.0)	170.2 (135.0 to 213.1)	17.3 (3.9 to 30.7)

Appendix Table G.4 - Yemen prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013	
Interstitial nephritis and urinary tract infections	2.1 (2.0 to 2.3)	5.0 (4.7 to 5.3)	134.4 (112.5 to 157.9)	0.1 (-5.9 to 11.2)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	136.7 (81.5 to 205.8)	2.7 (-15.9 to 24.4)	
Urolithiasis	67.7 (42.9 to 120.8)	166.5 (90.7 to 308.8)	152.5 (87.0 to 183.0)	7.0 (-16.1 to 20.8)	0.3 (0.2 to 0.5)	0.9 (0.5 to 1.6)	209.0 (153.3 to 249.0)	33.1 (12.7 to 47.5)	
Benign prostatic hyperplasia	53.4 (48.5 to 57.8)	140.2 (129.1 to 152.2)	161.0 (133.7 to 194.8)	1.9 (3.9 to 29.5)	5.0 (1.2 to 2.7)	5.0 (3.2 to 7.1)	162.7 (133.9 to 194.7)	16.5 (4.0 to 30.3)	
Male infertility due to other causes	78.1 (54.8 to 102.9)	204.0 (131.7 to 302.7)	155.4 (49.1 to 332.8)	-4.6 (42.2 to 53.7)	0.5 (0.2 to 1.1)	0.5 (0.5 to 3.1)	155.6 (41.1 to 365.6)	-4.9 (-46.6 to 63.5)	
Other urinary diseases	-	-	-	-	-	0.6 (0.3 to 1.0)	0.6 (72.6 to 354.3)	65.3 (-22.7 to 186.8)	
Gynecological diseases	-	-	-	-	-	12.7 (8.0 to 18.8)	37.3 (23.9 to 55.4)	191.3 (147.8 to 258.0)	8.4 (-6.7 to 29.4)
Uterine fibroids	152.8 (138.5 to 166.0)	351.3 (316.2 to 383.3)	129.1 (126.4 to 131.9)	-5.0 (-5.1 to -4.9)	3.3 (2.0 to 5.0)	8.1 (5.1 to 12.3)	147.6 (126.0 to 165.8)	-0.7 (-10.0 to 5.9)	
Polycystic ovarian syndrome	188.8 (171.8 to 206.0)	461.4 (414.0 to 511.3)	142.9 (110.2 to 178.8)	-6.6 (-18.6 to 5.3)	1.9 (0.9 to 3.4)	4.6 (2.1 to 8.3)	144.4 (110.9 to 181.2)	-6.4 (-18.7 to 6.1)	
Female infertility due to other causes	46.9 (31.1 to 70.6)	140.8 (94.3 to 195.5)	199.0 (87.7 to 399.5)	16.2 (-30.6 to 102.8)	0.3 (0.1 to 0.6)	0.8 (0.3 to 1.8)	267.3 (81.8 to 395.3)	13.2 (-31.1 to 92.6)	
Endometriosis	15.1 (12.7 to 17.3)	39.2 (33.6 to 45.2)	158.2 (107.4 to 221.0)	-1.5 (20.5 to 22.6)	1.4 (0.9 to 2.0)	3.6 (2.4 to 5.2)	158.6 (105.3 to 224.6)	-1.4 (-21.4 to 23.2)	
Genital prolapse	415.9 (331.6 to 501.8)	1,039.7 (837.6 to 1,274.5)	146.4 (84.7 to 243.4)	-3.8 (-25.9 to 27.6)	1.3 (0.6 to 2.5)	3.3 (1.6 to 6.3)	146.7 (84.0 to 245.7)	-3.6 (-26.6 to 27.8)	
Premenstrual syndrome	359.2 (199.3 to 521.0)	1,486.3 (856.0 to 2,072.7)	303.4 (132.7 to 706.3)	45.0 (-22.8 to 183.5)	3.0 (1.4 to 5.2)	12.5 (6.1 to 21.2)	302.6 (132.1 to 704.8)	46.0 (-21.4 to 190.8)	
Other gynecological diseases	44.3 (36.3 to 52.4)	122.4 (110.4 to 134.7)	175.0 (131.4 to 235.4)	4.4 (-12.0 to 26.2)	1.6 (1.0 to 2.3)	4.4 (2.9 to 6.5)	178.9 (137.2 to 280.6)	5.6 (-11.2 to 41.3)	
Hemoglobinopathies and hemolytic anemias	-	-	-	-	-	17.4 (11.7 to 25.0)	34.0 (22.4 to 49.9)	1.6 (-7.2 to 16.1)	
Thalassemias	2.5 (1.8 to 3.5)	4.7 (3.4 to 6.4)	86.5 (69.4 to 111.7)	0.6 (-10.0 to 14.0)	0.2 (0.2 to 0.3)	0.4 (0.2 to 0.7)	100.1 (49.3 to 176.3)	3.1 (-21.2 to 40.3)	
Thalassemia trait	437.4 (353.7 to 531.7)	900.5 (731.6 to 1,094.3)	105.0 (97.4 to 114.0)	-0.8 (-4.4 to 3.3)	8.6 (5.7 to 12.4)	16.0 (10.6 to 22.9)	84.5 (61.2 to 116.8)	-1.5 (-15.2 to 14.6)	
Sickle cell disorders	1.0 (0.8 to 1.1)	2.0 (1.8 to 2.3)	105.2 (76.5 to 148.7)	9.7 (-3.6 to 26.6)	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	135.2 (94.3 to 195.6)	17.2 (0.3 to 37.8)	
Sickle cell trait	357.7 (331.5 to 381.2)	714.6 (660.3 to 759.8)	99.1 (92.3 to 107.1)	1.6 (-6.9 to 0.2)	2.8 (1.0 to 2.4)	2.8 (1.7 to 4.1)	69.8 (17.0 to 121.9)	8.0 (-33.1 to 21.5)	
G6PD deficiency	797.0 (590.2 to 1,049.9)	1,562.1 (1,083.1 to 2,090.0)	96.3 (29.0 to 185.0)	-6.1 (-38.6 to 37.3)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	80.1 (46.2 to 116.8)	-7.2 (-17.0 to 2.3)	
G6PD trait	2,377.4 (2,059.6 to 2,667.1)	4,935.1 (4,252.3 to 5,417.9)	105.8 (73.1 to 150.6)	-2.7 (-18.1 to 18.5)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	94.2 (-27.0 to 634.9)	1.2 (-60.9 to 246.1)	
Other hemoglobinopathies and hemolytic anemias	203.3 (167.7 to 229.6)	460.1 (422.6 to 497.8)	125.3 (96.3 to 174.8)	7.1 (-4.0 to 21.1)	6.6 (4.1 to 9.6)	14.2 (8.8 to 22.0)	111.4 (68.9 to 213.1)	6.7 (-8.2 to 45.7)	
Endocrine, metabolic, blood, and immune disorders	225.5 (211.3 to 244.1)	459.7 (409.5 to 502.8)	100.5 (76.0 to 123.8)	9.8 (-1.1 to 13.5)	8.4 (5.6 to 11.9)	16.0 (10.6 to 23.1)	91.6 (58.4 to 123.7)	0.6 (-11.4 to 15.1)	
Musculoskeletal disorders	-	-	-	-	-	121.6 (83.4 to 165.3)	296.2 (205.1 to 397.2)	141.8 (106.6 to 200.7)	0.4 (-11.4 to 19.2)
Rheumatoid arthritis	15.1 (14.1 to 16.2)	32.5 (30.7 to 34.4)	113.7 (96.5 to 134.4)	-12.0 (-19.8 to -2.4)	3.6 (2.5 to 4.8)	7.8 (5.5 to 10.4)	114.3 (89.6 to 143.1)	-11.6 (-20.9 to -1.1)	
Osteoarthritis	175.8 (166.4 to 185.9)	402.6 (375.8 to 427.3)	127.8 (108.5 to 148.3)	-2.3 (-10.1 to 5.9)	10.7 (7.4 to 14.7)	24.6 (17.0 to 33.7)	128.7 (108.0 to 149.2)	-1.9 (-10.1 to 5.9)	
Low back and neck pain	-	-	-	-	-	95.1 (63.2 to 132.1)	229.4 (154.6 to 318.5)	138.7 (95.5 to 218.1)	-0.6 (-15.9 to 25.9)
Low back pain	592.0 (467.6 to 712.2)	1,398.3 (1,086.0 to 1,727.9)	132.9 (72.6 to 241.7)	-1.5 (-23.0 to 34.9)	66.2 (42.3 to 95.8)	155.9 (98.5 to 227.2)	133.5 (71.9 to 243.2)	-1.5 (-23.3 to 36.3)	
Neck pain	294.6 (243.4 to 340.3)	748.9 (635.6 to 862.5)	153.7 (105.2 to 213.3)	2.7 (-16.9 to 27.5)	28.9 (18.8 to 41.8)	73.4 (49.0 to 102.2)	154.8 (105.3 to 212.8)	3.0 (-17.1 to 28.0)	
Gout	2.9 (2.5 to 3.3)	7.3 (6.2 to 8.4)	145.6 (101.3 to 207.4)	3.8 (-14.7 to 28.9)	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	148.2 (88.1 to 228.4)	4.3 (-20.4 to 37.2)	
Other musculoskeletal disorders	132.3 (100.0 to 167.0)	376.2 (284.8 to 468.5)	183.1 (159.5 to 214.5)	13.3 (4.4 to 24.6)	13.0 (7.6 to 17.6)	34.2 (21.6 to 49.7)	184.5 (158.2 to 217.8)	13.2 (4.4 to 25.8)	
Other non-communicable diseases	-	-	-	-	-	143.2 (96.3 to 207.2)	313.7 (211.7 to 454.0)	119.0 (109.4 to 130.2)	-3.7 (-6.9 to -0.5)
Congenital anomalies	-	-	-	-	-	6.0 (4.4 to 8.0)	20.4 (14.7 to 27.3)	239.4 (184.9 to 306.2)	70.5 (42.2 to 103.9)
Neural tube defects	1.3 (1.1 to 1.7)	6.5 (5.4 to 7.6)	393.6 (260.2 to 547.0)	183.6 (104.8 to 275.2)	0.3 (0.2 to 0.5)	1.8 (1.2 to 2.7)	462.0 (271.4 to 760.6)	235.3 (121.9 to 409.3)	
Congenital heart anomalies	14.6 (10.8 to 19.0)	87.5 (68.8 to 108.8)	498.5 (305.0 to 775.8)	244.1 (129.0 to 417.5)	0.6 (0.3 to 1.0)	3.0 (1.3 to 5.2)	396.2 (231.6 to 637.6)	202.0 (104.5 to 353.9)	
Orofacial clefts	2.3 (1.5 to 3.5)	17.9 (13.3 to 24.4)	690.2 (320.3 to 1,181.0)	0.0 (166.1 to 716.5)	0.0 (0.0 to 0.1)	0.3 (0.2 to 0.5)	311.0 (220.2 to 1,051.9)	330.0 (104.5 to 623.2)	
Down syndrome	10.2 (8.2 to 12.8)	34.3 (26.6 to 50.9)	229.9 (133.5 to 413.4)	76.0 (24.6 to 177.8)	1.2 (0.8 to 1.6)	4.1 (2.7 to 6.4)	240.5 (133.9 to 441.7)	82.8 (27.4 to 189.2)	
Turner syndrome	0.3 (0.2 to 0.4)	0.8 (0.7 to 1.0)	179.2 (98.5 to 299.2)	38.3 (-2.1 to 97.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	188.1 (99.3 to 320.8)	36.5 (-5.9 to 98.2)	
Klinefelter syndrome	0.3 (0.3 to 0.4)	0.7 (0.6 to 0.8)	109.4 (56.7 to 181.0)	4.4 (-22.1 to 39.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	140.3 (80.9 to 221.7)	4.7 (-21.7 to 40.2)	
Chromosomal unbalanced rearrangements	10.4 (8.0 to 13.6)	30.5 (24.2 to 41.6)	191.9 (108.8 to 317.7)	65.9 (11.5 to 122.0)	1.2 (0.8 to 1.7)	3.6 (2.4 to 5.1)	209.1 (111.2 to 332.7)	62.7 (14.5 to 136.1)	
Other congenital anomalies	28.6 (23.0 to 34.7)	59.0 (48.3 to 70.1)	105.9 (73.8 to 143.5)	-6.6 (-21.3 to 10.8)	2.7 (1.8 to 4.0)	7.6 (5.0 to 11.1)	185.3 (118.9 to 285.3)	30.1 (16.7 to 75.4)	
Skin and subcutaneous diseases	-	-	-	-	-	60.3 (37.6 to 93.1)	136.8 (85.6 to 210.3)	126.3 (107.6 to 150.9)	1.2 (-4.9 to 8.9)
Dermatitis	597.2 (478.3 to 730.7)	1,359.1 (1,055.2 to 1,658.7)	126.9 (117.8 to 134.2)	0.1 (-0.2 to 0.4)	21.0 (12.4 to 31.7)	45.7 (26.7 to 68.5)	118.0 (100.9 to 130.5)	0.1 (-2.3 to 2.6)	
Psoriasis	53.2 (42.6 to 65.6)	129.4 (102.6 to 161.2)	129.4 (137.6 to 146.4)	0.0 (-0.3 to 0.4)	4.4 (2.9 to 6.3)	10.6 (6.9 to 15.4)	162.3 (123.4 to 162.2)	0.2 (-5.6 to 7.0)	
Cellulitis	2.4 (1.9 to 3.1)	4.0 (3.1 to 5.1)	64.9 (43.8 to 94.7)	-14.4 (-22.8 to -2.5)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	68.3 (27.1 to 123.5)	-13.4 (-29.4 to 6.4)	
Pyoderma	11.0 (8.5 to 14.1)	17.4 (13.9 to 22.1)	58.3 (44.7 to 73.6)	-7.2 (-12.8 to -0.6)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	57.9 (35.6 to 82.7)	-7.2 (-17.4 to 4.2)	
Scabies	49.8 (39.4 to 64.0)	113.2 (84.8 to 151.6)	127.3 (44.6 to 228.6)	7.7 (-21.1 to 54.7)	1.3 (0.7 to 2.1)	2.9 (1.5 to 5.0)	127.0 (43.8 to 229.5)	8.2 (-29.8 to 54.0)	
Fungal skin diseases	592.0 (434.8 to 741.2)	1,379.8 (1,030.2 to 1,755.7)	135.9 (129.8 to 143.8)	6.8 (0.4 to 12.2)	3.3 (1.3 to 7.0)	7.7 (3.1 to 16.6)	186.2 (129.2 to 144.8)	0.9 (-0.3 to 2.4)	
Viral skin diseases	292.6 (225.3 to 355.8)	577.9 (439.1 to 705.6)	96.6 (84.1 to 109.8)	0.2 (-1.7 to 2.2)	9.1 (5.4 to 14.1)	17.9 (10.4 to 27.9)	96.5 (81.7 to 111.0)	0.3 (-2.9 to 3.6)	
Acne vulgaris	1,220.8 (845.5 to 1,610.1)	3,052.6 (2,354.3 to 3,858.7)	148.6 (78.6 to 257.7)	4.3 (-24.0 to 48.3)	13.3 (5.7 to 26.5)	33.0 (14.8 to 63.1)	148.7 (78.4 to 258.3)	4.4 (-23.9 to 48.2)	
Alopecia areata	13.7 (11.7 to 15.5)	30.4 (26.3 to 34.4)	120.7 (82.0 to 174.0)	1.5 (-15.9 to 23.4)	0.5 (0.3 to 0.7)	1.0 (0.6 to 1.6)	120.2 (77.3 to 174.0)	1.7 (-16.7 to 26.3)	
Pruritus	2.0 (1.3 to 2.7)	5.1 (2.9 to 7.3)	158.4 (36.0 to 387.4)	0.0 (-34.4 to 146.6)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	158.0 (32.4 to 375.9)	12.8 (-37.4 to 142.7)	
Urticaria	77.2 (56.8 to 107.1)	188.0 (142.5 to 236.3)	145.4 (54.6 to 256.4)	5.3 (-27.9 to 48.2)	4.6 (2.7 to 7.4)	11.2 (6.8 to 16.6)	146.3 (54.3 to 256.9)	5.1 (-27.9 to 48.5)	
Decubitus ulcer	1.2 (1.0 to 1.4)	2.0 (1.6 to 2.4)	70.2 (33.2 to 122.8)	-30.5 (-50.4 to 5.4)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	72.0 (33.2 to 124.1)	-29.7 (-50.3 to 3.9)	
Other skin and subcutaneous diseases	428.2 (298.2 to 612.1)	1,012.2 (700.2 to 1,432.2)	135.6 (123.4 to 147.8)	0.9 (-2.0 to 4.5)	2.5 (1.1 to 5.2)	6.0 (2.6 to 12.2)	135.7 (123.3 to 148.9)	1.1 (-2.1 to 4.8)	
Sense organ diseases	-	-	-	-	-	57.8 (39.9 to 80.0)	113.4 (77.8 to 157.7)	96.0 (66.8 to 105.8)	-9.3 (-43.0 to -4.5)
Glaucoma	19.5 (15.1 to 24.2)	43.3 (34.8 to 54.5)	123.8 (66.0 to 182.0)	-5.1 (-31.0 to 23.6)	1.7 (1.1 to 2.5)	3.8 (2.5 to 5.5)	119.2 (80.4 to 186.9)	-4.0 (-26.4 to 21.8)	
Cataract	58.4 (44.2 to 72.9)	131.5 (109.3 to 156.5)	121.2 (74.3 to 196.4)	-4.0 (-22.7 to 27.8)	4.9 (3.1 to 7.1)	11.0 (7.2 to 15.5)	125.1 (81.6 to 191.7)	-2.5 (-19.8 to 34.3)	
Macular degeneration	10.0 (7.2 to 13.9)	21.0 (15.2 to 28.8)	108.8 (47.2 to 210.7)	-8.4 (-37.6 to 30.8)	0.6 (0.4 to 0.9)	1.3 (0.9 to 2.0)	111.7 (48.5 to 197.1)	-6.3 (-36.1 to 25.1)	
Uncorrected refractive error	846.6 (746.4 to 958.0)	1,781.4 (1,538.7 to 2,034.7)	109.9 (72.9 to 150.9)	6.0 (-20.0 to 44.4)	19.5 (12.9 to 28.5)	37.5 (24.7 to 55.5)	91.3 (75.5 to 113.0)	-13.4 (-20.4 to -2.5)	
Age-related and other hearing loss	663.6 (616.6 to 717.0)	1,397.3 (1,293.5 to 1,511.1)	110.3 (98.0 to 119.8)	-9.1 (-12.4 to -6.1)	17.8 (11.8 to 25.4)	35.2 (23.2 to 50.3)	98.2 (80.5 to 114.8)	-9.8 (-14.7 to -5.1)	
Other vision loss	60.7 (51.8 to 69.5)	113.9 (97.8 to 129.3)	87.2 (69.0 to 104.9)	-14.4 (-24.3 to -5.4)	5.4 (3.6 to 7.7)	9.7 (6.5 to 13.6)	78.8 (60.4 to 101.7)	-17.2 (-26.8 to -6.4)	
Other sense organ diseases	292.5 (277.7 to 308.3)	555.7 (527.9 to 583.8)	89.3 (76.3 to 104.3)	-1.0 (-6.7 to 5.9)	7.8 (4.9 to 11.6)	14.8 (9.1 to 22.0)	88.6 (73.6 to 105.6)	-1.1 (-7.4 to 6.1)	
Oral disorders	-	-	-	-	-				

Appendix Table G.4 - Yemen prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	299.4 (275.1 to 325.2)	650.9 (596.3 to 708.6)	116.3 (92.1 to 145.1)	-6.7 (-16.5 to 5.2)	8.2 (5.5 to 11.5)	117.2 (12.0 to 25.5)	117.2 (92.3 to 147.2)	-6.4 (-16.6 to 5.7)
Other oral disorders	155.3 (145.7 to 163.8)	370.8 (348.7 to 395.0)	138.4 (118.0 to 159.8)	-0.7 (-8.2 to 6.9)	4.6 (2.8 to 6.8)	10.9 (6.7 to 16.2)	138.4 (118.2 to 160.6)	-0.6 (-8.2 to 7.6)
Injuries	-	-	-	-	46.7 (33.8 to 65.1)	87.1 (65.0 to 113.7)	88.6 (69.8 to 100.3)	-16.3 (-24.6 to -10.8)
Transport injuries	-	-	-	-	17.7 (13.4 to 22.9)	34.6 (25.9 to 44.4)	96.3 (87.7 to 104.2)	-12.5 (-16.0 to -9.7)
Road injuries	-	-	-	-	16.0 (12.1 to 20.7)	30.5 (22.6 to 38.6)	88.7 (79.6 to 97.2)	-16.0 (-19.5 to -13.0)
Pedestrian road injuries	-	-	-	-	4.1 (3.1 to 5.3)	6.8 (5.1 to 8.8)	64.3 (51.3 to 80.0)	-22.4 (-27.1 to -16.8)
Cyclist road injuries	-	-	-	-	1.5 (1.1 to 2.0)	3.0 (2.2 to 3.9)	100.5 (89.6 to 112.3)	-7.5 (-12.3 to -2.5)
Motorcyclist road injuries	-	-	-	-	2.0 (1.5 to 2.6)	3.0 (2.2 to 3.9)	47.6 (37.3 to 60.4)	-34.0 (-38.7 to -29.1)
Motor vehicle road injuries	-	-	-	-	8.2 (6.2 to 10.6)	17.2 (12.9 to 22.1)	110.3 (94.5 to 126.9)	-9.6 (-15.9 to -4.0)
Other road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	14.6 (6.5 to 24.0)	51.5 (-54.4 to -48.0)
Other transport injuries	-	-	-	-	1.7 (1.3 to 2.2)	4.5 (3.3 to 5.8)	167.2 (150.3 to 182.7)	17.9 (10.7 to 24.5)
Unintentional injuries	-	-	-	-	17.3 (13.3 to 22.0)	36.6 (27.7 to 47.2)	110.9 (103.7 to 118.4)	-6.4 (-9.4 to -3.7)
Falls	-	-	-	-	5.3 (4.0 to 6.9)	13.0 (9.8 to 16.9)	146.1 (130.4 to 161.1)	8.2 (2.1 to 13.7)
Drowning	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.8)	55.7 (39.5 to 74.0)	-30.2 (-36.2 to -23.3)
Fire, heat, and hot substances	-	-	-	-	2.3 (1.8 to 2.9)	3.2 (2.4 to 4.0)	37.2 (25.5 to 49.9)	-37.7 (-41.9 to -32.8)
Poisonings	-	-	-	-	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	36.3 (10.6 to 65.7)	-39.2 (-48.5 to -28.4)
Exposure to mechanical forces	-	-	-	-	5.3 (4.0 to 6.9)	11.5 (8.6 to 15.0)	117.7 (104.9 to 131.6)	-6.9 (-11.0 to -2.0)
Unintentional firearm injuries	-	-	-	-	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.6)	103.2 (87.0 to 122.0)	-16.7 (-22.9 to -9.4)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	204.6 (171.5 to 243.5)	33.0 (20.6 to 45.8)
Other exposure to mechanical forces	-	-	-	-	5.0 (3.8 to 6.5)	10.9 (8.1 to 14.3)	117.6 (104.3 to 131.7)	-6.6 (-10.9 to -1.5)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	144.6 (128.4 to 163.0)	14.6 (7.5 to 23.2)
Animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.6 (0.5 to 0.8)	116.0 (98.2 to 134.8)	-3.2 (-9.1 to 3.5)
Venomous animal contact	-	-	-	-	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	116.6 (89.0 to 147.3)	-6.3 (-16.3 to 4.0)
Non-venomous animal contact	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.3 to 0.5)	116.9 (95.9 to 134.3)	-0.5 (-6.6 to 5.5)
Foreign body	-	-	-	-	0.3 (0.3 to 0.4)	0.8 (0.6 to 1.0)	126.2 (112.0 to 139.9)	1.3 (-3.4 to 6.4)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	87.9 (60.5 to 118.1)	-8.1 (-17.4 to 2.5)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	126.2 (99.4 to 152.5)	2.3 (-7.1 to 12.6)
Foreign body in other body part	-	-	-	-	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	144.1 (128.6 to 162.1)	4.1 (-1.8 to 11.3)
Other unintentional injuries	-	-	-	-	3.1 (2.4 to 4.0)	6.4 (4.8 to 8.3)	103.6 (89.0 to 120.6)	-14.3 (-20.2 to -7.7)
Self-harm and interpersonal violence	-	-	-	-	1.5 (1.1 to 1.9)	3.4 (2.6 to 4.3)	129.9 (117.5 to 144.2)	-0.2 (-5.0 to 4.9)
Self-harm	-	-	-	-	0.2 (0.1 to 0.2)	0.6 (0.5 to 0.8)	236.3 (203.1 to 268.5)	39.0 (27.2 to 50.4)
Interpersonal violence	-	-	-	-	1.3 (1.0 to 1.6)	2.8 (2.1 to 3.5)	114.8 (101.8 to 129.3)	-7.4 (-12.5 to -1.9)
Assault by firearm	-	-	-	-	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.7)	113.8 (96.1 to 133.0)	-5.1 (-12.1 to 2.8)
Assault by sharp object	-	-	-	-	0.3 (0.2 to 0.3)	0.6 (0.5 to 0.8)	138.2 (118.5 to 156.5)	2.0 (-6.0 to 10.0)
Assault by other means	-	-	-	-	0.8 (0.6 to 1.0)	1.6 (1.2 to 2.1)	107.4 (91.2 to 126.9)	-11.3 (-17.3 to -3.7)
Forces of nature, war, and legal intervention	-	-	-	-	10.2 (3.7 to 24.6)	12.5 (4.9 to 30.3)	24.0 (6.1 to 49.4)	-41.0 (-50.6 to -27.5)
Exposure to forces of nature	-	-	-	-	0.4 (0.2 to 0.8)	0.3 (0.1 to 0.5)	-35.2 (-42.3 to -26.5)	-63.2 (-68.4 to -57.1)
Collective violence and legal intervention	-	-	-	-	9.8 (3.4 to 23.9)	12.3 (4.7 to 29.9)	27.0 (7.7 to 54.1)	-40.0 (-50.1 to -25.2)

Appendix Table G.4 - Zambia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	808.3 (601.9 to 1,041.4)	1,396.7 (1,031.1 to 1,808.5)	73.8 (67.4 to 77.9)	73.8 (-9.1 to -2.4)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	277.3 (200.2 to 368.0)	449.5 (322.6 to 603.0)	62.2 (49.8 to 74.6)	-15.1 (-24.2 to -6.1)
HIV/AIDS and tuberculosis	-	-	-	-	96.3 (64.5 to 134.9)	143.9 (97.4 to 198.5)	48.8 (24.6 to 81.2)	-22.9 (-36.4 to -4.0)
Tuberculosis	59.1 (54.2 to 63.9)	95.0 (87.7 to 102.6)	60.5 (51.4 to 71.0)	-12.2 (-17.4 to -6.7)	17.8 (12.1 to 24.2)	28.8 (19.9 to 39.5)	61.5 (51.4 to 71.9)	-11.9 (-17.4 to -6.1)
HIV/AIDS	-	-	-	-	190.0 (149.9 to 232.4)	115.1 (76.4 to 162.2)	48.8 (16.6 to 85.9)	-25.4 (-41.1 to -2.1)
HIV/AIDS resulting in mycobacterial infection	22.1 (17.1 to 26.5)	26.8 (17.9 to 35.2)	21.3 (-1.3 to 40.1)	-35.7 (-49.2 to -24.4)	8.1 (5.2 to 11.2)	9.9 (5.8 to 14.4)	22.1 (0.1 to 43.0)	-35.2 (-48.5 to -23.4)
HIV/AIDS resulting in other diseases	479.2 (413.2 to 541.5)	940.9 (854.0 to 1,014.1)	95.2 (76.6 to 122.4)	12.2 (-0.4 to 29.9)	70.4 (43.0 to 103.4)	105.2 (69.5 to 150.2)	48.6 (16.7 to 99.2)	-24.2 (-41.6 to 3.9)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	38.7 (27.3 to 52.9)	57.6 (40.9 to 77.8)	49.0 (38.1 to 60.2)	-19.2 (-25.1 to -13.7)
Diarrheal diseases	116.9 (109.0 to 125.0)	176.9 (164.9 to 189.5)	51.2 (37.7 to 67.6)	-38.1 (-24.5 to -10.6)	19.0 (12.7 to 26.4)	28.7 (19.6 to 39.8)	50.9 (37.1 to 67.6)	-18.2 (-24.7 to -10.6)
Intestinal infectious diseases	-	-	-	-	0.3 (0.2 to 0.5)	0.4 (0.2 to 0.5)	0.2 (-18.8 to 41.3)	42.1 (-55.4 to -26.8)
Typhoid fever	1.8 (1.6 to 2.0)	2.0 (1.8 to 2.3)	14.2 (4.9 to 36.2)	-39.0 (-49.8 to -27.0)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	16.3 (-12.1 to 55.7)	-37.5 (-51.2 to -19.8)
Paratyphoid fever	0.7 (0.6 to 0.8)	0.9 (0.8 to 1.1)	39.3 (8.6 to 76.8)	-26.8 (-43.9 to -6.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (1.5 to 91.3)	27.6 (-45.8 to -3.8)
Other intestinal infectious diseases	-	-	-	-	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	13.9 (-70.8 to 2.2)	-70.1 (-84.2 to -45.7)
Lower respiratory infections	4.1 (3.7 to 4.7)	6.4 (5.2 to 7.9)	52.5 (23.1 to 93.4)	-3.2 (-16.9 to 14.0)	0.4 (0.3 to 0.6)	0.7 (0.4 to 1.0)	53.6 (15.6 to 100.6)	-3.9 (-20.6 to 17.2)
Upper respiratory infections	654.9 (625.0 to 685.9)	1,212.3 (1,163.5 to 1,266.5)	85.0 (72.8 to 96.1)	-0.2 (-6.3 to 6.0)	7.7 (4.3 to 12.9)	14.2 (7.9 to 23.4)	85.6 (72.7 to 97.0)	-0.1 (-6.5 to 6.3)
Otitis media	136.4 (124.0 to 148.7)	231.3 (211.8 to 255.2)	69.4 (51.3 to 91.3)	-11.0 (-20.2 to 2.2)	2.8 (1.7 to 4.5)	4.7 (2.8 to 7.4)	67.8 (48.8 to 92.6)	-11.4 (-21.3 to 2.0)
Meningitis	-	-	-	-	7.8 (5.3 to 11.0)	8.1 (5.5 to 11.0)	3.8 (-17.7 to 31.7)	-43.2 (-54.4 to -27.9)
Pneumococcal meningitis	28.8 (17.5 to 43.7)	26.2 (16.2 to 38.1)	-9.8 (-28.0 to 18.3)	-48.6 (-58.0 to -33.1)	2.6 (1.7 to 3.8)	2.6 (1.8 to 3.6)	0.7 (-28.7 to 33.5)	-44.7 (-60.0 to -28.5)
H influenzae type B meningitis	17.7 (8.0 to 33.2)	13.7 (6.0 to 24.3)	-23.9 (-43.8 to 15.6)	-58.3 (-68.7 to -38.0)	2.1 (1.2 to 3.3)	1.7 (1.1 to 2.5)	1.7 (-53.3 to 36.5)	-53.7 (-74.0 to -27.6)
Meningococcal meningitis	4.0 (1.8 to 8.3)	3.3 (1.5 to 7.2)	-16.4 (-36.9 to 15.7)	-50.6 (-61.7 to -35.0)	0.5 (0.3 to 0.8)	0.5 (0.3 to 0.7)	0.5 (-40.9 to 31.5)	-50.9 (-63.4 to -30.1)
Other meningitis	22.3 (11.9 to 40.4)	23.6 (13.9 to 39.0)	6.2 (-20.7 to 51.9)	-41.9 (-56.1 to -17.2)	2.7 (1.7 to 4.0)	3.4 (2.1 to 5.1)	25.2 (-14.9 to 103.3)	-32.1 (-52.5 to 9.5)
Encephalitis	1.3 (0.6 to 2.7)	2.1 (1.0 to 4.4)	65.3 (46.6 to 90.2)	-0.2 (-17.7 to 1.2)	0.2 (0.0 to 0.2)	0.3 (0.2 to 0.4)	73.6 (39.9 to 111.6)	-7.7 (-21.3 to 11.1)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.7 (-95.5 to 2,203.4)	-42.8 (-95.8 to 657.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-11.7 (-95.5 to 2,289.5)	-42.8 (-95.8 to 657.7)
Whooping cough	4.3 (3.4 to 5.5)	8.0 (6.3 to 10.3)	85.1 (85.0 to 85.2)	-2.6 (-2.6 to 2.5)	0.2 (0.1 to 0.4)	0.4 (0.2 to 0.6)	85.5 (61.6 to 108.2)	-2.5 (-15.2 to 10.3)
Tetanus	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-25.0 (-74.4 to 53.5)	-58.7 (-86.7 to -13.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-12.7 (-54.0 to 43.7)	-51.9 (-75.6 to -22.5)
Measles	1.4 (1.1 to 1.8)	0.1 (0.1 to 0.2)	-91.2 (-94.4 to -86.4)	-95.4 (-97.0 to -92.9)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.0)	90.9 (-94.5 to 85.8)	-95.2 (-97.1 to -92.6)
Varicella and herpes zoster	4.9 (4.5 to 5.4)	9.6 (8.8 to 10.5)	95.5 (71.0 to 122.5)	2.7 (-20.2 to 28.6)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	80.9 (28.4 to 167.0)	1.6 (-32.6 to 46.8)
Neglected tropical diseases and malaria	-	-	-	-	91.0 (59.0 to 135.4)	138.9 (89.0 to 208.1)	52.1 (43.3 to 62.7)	-13.9 (-22.6 to -1.4)
Malaria	3,126.2 (2,967.0 to 3,286.0)	3,073.4 (2,928.2 to 3,226.3)	-1.8 (-5.9 to 2.6)	-46.4 (-49.0 to -43.9)	34.2 (22.7 to 49.6)	36.2 (24.1 to 51.9)	5.6 (-1.1 to 15.4)	44.0 (-47.5 to -40.1)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	105.8 (141.1 to 336.7)	28.5 (-29.0 to 137.2)
Visceral leishmaniasis	0.6 (0.3 to 1.1)	1.2 (0.4 to 2.4)	76.2 (-7.3 to 284.5)	1.8 (-49.9 to 105.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.2)	78.9 (-12.0 to 308.2)	2.2 (-52.1 to 111.2)
Cutaneous and mucocutaneous leishmaniasis	0.1 (0.0 to 0.1)	1.1 (0.6 to 1.8)	1,663.4 (1,027.6 to 2,762.6)	1,318.2 (750.7 to 2,160.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,610.2 (952.8 to 2,718.0)	1,249.9 (696.2 to 2,103.9)
African trypanosomiasis	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	6.0 (-16.0 to 38.6)	-42.3 (-54.3 to -34.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	6.6 (-18.0 to 41.0)	-41.9 (-54.9 to -22.7)
Schistosomiasis	2,796.2 (2,009.2 to 3,699.8)	4,957.2 (3,562.1 to 6,584.7)	76.9 (74.7 to 80.1)	4.1 (-5.1 to 2.5)	27.1 (13.6 to 49.1)	49.2 (25.3 to 88.6)	82.0 (72.9 to 90.6)	-2.0 (-6.2 to 1.1)
Cysticercosis	3.4 (1.6 to 6.2)	2.4 (1.2 to 4.2)	-25.7 (-77.4 to 129.0)	-53.1 (-83.2 to 34.1)	0.9 (0.4 to 1.9)	0.7 (0.3 to 1.3)	24.9 (-78.2 to 140.0)	-52.0 (-83.7 to 37.5)
Cystic echinococcosis	2.7 (2.4 to 3.0)	3.3 (2.9 to 3.6)	20.4 (-0.1 to 51.0)	-20.8 (-33.4 to -5.2)	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.4)	20.4 (8.7 to 60.5)	-21.9 (-38.1 to -0.3)
Lymphatic filariasis	571.5 (429.5 to 708.2)	973.0 (734.8 to 1,233.4)	65.8 (24.8 to 155.3)	-9.2 (-26.4 to 32.5)	14.4 (7.9 to 24.4)	24.9 (13.0 to 43.3)	69.4 (27.9 to 142.1)	-3.9 (-29.7 to 43.5)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-	-
Trachoma	2.3 (0.9 to 4.0)	1.1 (0.5 to 2.1)	-50.5 (-72.1 to -13.4)	-72.0 (-84.8 to -50.8)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.1)	-46.3 (-69.0 to -10.5)	-69.4 (-82.2 to -46.8)
Dengue	0.3 (0.1 to 0.8)	2.5 (0.7 to 2.0)	804.0 (793.0 to 816.7)	387.4 (381.5 to 394.3)	0.0 (0.0 to 0.1)	0.4 (0.1 to 1.2)	755.1 (577.8 to 960.6)	353.8 (276.8 to 439.0)
Yellow fever	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-49.8 (-64.0 to -28.2)	-73.1 (-79.2 to -63.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-49.8 (-64.0 to -27.7)	-73.1 (-79.2 to -63.3)
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-12.9 to 102.3)	-
Intestinal nematode infections	-	-	-	-	11.2 (7.0 to 17.3)	21.6 (13.4 to 33.2)	93.7 (75.1 to 111.9)	2.5 (-7.9 to 12.8)
Ascariasis	316.1 (205.0 to 468.6)	578.5 (370.0 to 876.2)	81.5 (0.8 to 237.5)	-1.5 (-54.4 to 106.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	88.6 (36.6 to 156.0)	0.6 (-27.8 to 41.9)
Trichuriasis	438.2 (277.5 to 709.4)	826.7 (517.1 to 1,297.8)	89.9 (0.4 to 241.2)	4.0 (-53.3 to 114.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	86.4 (20.7 to 172.6)	0.1 (-36.4 to 52.8)
Hookworm disease	1,178.8 (1,607.0 to 2,832.3)	865.9 (3,050.7 to 5,415.7)	-26.6 (-26.6 to 184.5)	0.7 (-37.6 to 69.2)	11.1 (6.9 to 17.2)	21.5 (13.3 to 33.1)	93.7 (75.1 to 112.2)	2.5 (-8.0 to 12.8)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other neglected tropical diseases	69.2 (54.2 to 84.8)	144.7 (131.2 to 159.8)	109.2 (70.4 to 169.3)	7.7 (-11.1 to 35.4)	2.7 (1.6 to 4.0)	5.4 (3.6 to 8.1)	98.8 (66.8 to 172.7)	1.9 (-17.0 to 37.1)
Maternal disorders	-	-	-	-	2.8 (1.8 to 3.9)	4.1 (2.7 to 5.7)	47.3 (24.3 to 71.6)	-22.8 (-34.4 to -10.3)
Maternal hemorrhage	1.8 (1.5 to 2.0)	4.6 (3.2 to 6.0)	159.0 (75.9 to 258.6)	16.4 (-19.4 to 61.7)	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.3)	140.6 (19.2 to 289.4)	10.9 (-44.6 to 76.4)
Maternal sepsis and other maternal infections	4.0 (2.7 to 5.2)	5.2 (3.4 to 7.0)	28.4 (12.7 to 47.3)	-34.7 (-42.4 to -25.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	28.3 (-18.4 to 102.9)	-34.2 (-56.4 to -2.4)
Maternal hypertensive disorders	3.4 (1.7 to 5.6)	5.8 (2.9 to 9.5)	70.4 (48.0 to 89.5)	-14.5 (-27.4 to -5.6)	0.2 (0.1 to 0.3)	0.3 (0.1 to 0.5)	69.5 (41.2 to 102.7)	-14.5 (-29.8 to 1.0)
Obstructed labor	5.7 (4.6 to 6.9)	8.0 (6.5 to 9.6)	39.6 (26.2 to 55.7)	-25.4 (-32.7 to -16.8)	1.9 (1.2 to 2.7)	2.6 (1.7 to 3.8)	39.1 (18.9 to 60.7)	-25.5 (-35.7 to -14.3)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	81.1 (3.0 to 227.1)	-13.5 (-47.7 to 41.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (2.6 to 227.8)	-13.5 (-47.8 to 41.7)
Other maternal disorders	-	-	-	-	0.6 (0.4 to 0.9)	0.9 (0.6 to 1.4)	54.8 (28.5 to 144.9)	-19.5 (-46.5 to 25.7)
Neonatal disorders	-	-	-	-	3.6 (2.0 to 6.5)	19.8 (12.0 to 29.5)	456.0 (215.8 to 833.8)	204.7 (65.7 to 417.3)
Preterm birth complications	23.9 (11.1 to 46.9)	104.2 (57.1 to 180.7)	342.2 (242.9 to 523.8)	128.2 (77.7 to 214.4)	1.4 (0.8 to 2.2)	10.7 (5.7 to 17.3)	688.3 (361.7 to 1,264.6)	322.4 (153.6 to 639.1)
Neonatal encephalopathy due to birth asphyxia and trauma	0.1 (3.3 to 134.2)	0.3 (9.2 to 176.4)	0.3 (5.7 to 212.0)	0.3 (-46.0 to 53.2)	0.0 (0.5 to 3.2)	0.0 (1.5 to 6.8)	0.0 (61.4 to 596.8)	0.0 (-19.9 to 312.4)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.6)	159.6 (139.3 to 193.1)	42.4 (31.2 to 60.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	0.0 (132.7 to 201.1)	0.0 (27.6 to 65.1)
Hemolytic disease and other neonatal jaundice	0.9 (0.3 to 1.9)	5.4 (2.5 to 9.3)	582.3 (59.8 to 1,644.7)	314.1 (-4.0 to 985.4)	0.3 (0.1 to 0.8)	2.1 (0.9 to 3.7)	575.1 (54.6 to 1,687.1)	311.1 (5.0 to 1,008.2)
Other neonatal disorders	-	-	-	-	0.6 (0.2 to 1.4)	3.4 (1.4 to 6.3)	454.0 (128.9 to 1,172.5)	200.4 (16.6 to 606.5)
Nutritional deficiencies	-	-	-	-	40.0 (26.7 to 57.7)	76.3 (50.8 to 110.0)	90.8 (68.2 to 114.4)	-1.8 (-14.1 to 13.5)
Protein-energy malnutrition	36.8 (22.7 to 57.7)	58.8 (30.2 to 106.1)	53.4 (-27.1 to 232.2)	-10.0 (-50.7 to 67.4)	4.5 (2.3 to 7.7)	7.2 (3.1 to 14.4)	54.9 (-27.3 to 232.8)	9.8 (-51.8 to 68.4)
Iodine deficiency	202.1 (70.0 to 336.3)	309.0 (178.7 to 461.2)	47.1 (-18.8 to 354.2)	-18.6 (-57.0 to 149.7)	3.6 (1.2 to 7.2)	5.6 (2.7 to 10.2)	47.7 (-18.1 to 340.9)	-18.4 (-57.5 to 150.7)
Vitamin A deficiency	9.7 (6.4 to 12.8)	12.5 (7.2 to 17.6)	26.1 (-1.0 to 74.7)	-32.9 (-46.5 to -5.5)	0.4 (0.3 to 0.7)	0.5 (0.3 to 0.8)	12.5 (-13.3 to 53.3)	-38.2 (-50.4 to -15.5)

Appendix Table G.4 - Zambia prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Iron-deficiency anemia	903.4 (878.3 to 929.9)	1,832.6 (1,787.8 to 1,878.2)	102.6 (93.1 to 113.1)	2.4 (-1.4 to 6.8)	31.5 (21.0 to 45.5)	63.0 (41.9 to 90.2)	100.4 (82.1 to 115.0)	100.4 (3.8 to 10.5)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	4.9 (3.0 to 7.8)	9.0 (5.6 to 14.0)	86.0 (57.3 to 116.1)	-5.4 (20.0 to 10.0)
Sexually transmitted diseases excluding HIV	-	-	-	-	2.2 (1.2 to 4.1)	4.1 (2.3 to 7.2)	85.6 (37.3 to 147.2)	-4.2 (-24.7 to 21.1)
Syphilis	0.9 (0.8 to 1.1)	1.0 (0.9 to 1.2)	8.7 (-8.4 to 30.9)	-39.2 (-47.6 to -28.4)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	8.9 (-17.2 to 43.6)	49.1 (-51.4 to -22.4)
Chlamydial infection	134.3 (91.9 to 199.2)	275.6 (172.9 to 361.2)	112.8 (14.6 to 238.6)	11.4 (-37.1 to 71.2)	0.7 (0.3 to 1.5)	1.6 (0.8 to 2.8)	131.0 (61.1 to 340.2)	20.9 (-40.7 to 125.1)
Gonococcal infection	71.3 (43.9 to 95.0)	135.5 (89.2 to 187.7)	94.6 (9.3 to 191.0)	2.6 (-39.9 to 50.5)	0.4 (0.2 to 0.7)	0.7 (0.4 to 1.2)	94.7 (17.4 to 256.1)	4.2 (-36.1 to 84.3)
Trichomoniasis	204.5 (140.0 to 270.6)	355.9 (221.6 to 500.8)	75.9 (-4.2 to 197.3)	-5.9 (-45.7 to 47.1)	0.4 (0.1 to 0.8)	0.6 (0.2 to 1.3)	67.3 (-15.7 to 217.9)	-9.4 (-51.0 to 52.3)
Genital herpes	1,974.0 (1,790.1 to 2,150.6)	3,291.3 (2,946.3 to 3,641.5)	67.0 (43.9 to 89.9)	8.0 (-18.3 to 31.0)	0.6 (0.2 to 1.3)	0.9 (0.3 to 2.2)	65.9 (40.0 to 93.5)	86.5 (-22.9 to 3.7)
Other sexually transmitted diseases	3.0 (2.2 to 4.1)	4.3 (3.0 to 5.6)	42.7 (19.4 to 63.2)	-27.1 (-38.9 to -16.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	0.0 (3.5 to 124.1)	-
Hepatitis	-	-	-	-	0.7 (0.4 to 1.1)	1.1 (0.7 to 1.7)	55.3 (29.9 to 91.5)	-20.3 (-36.4 to 2.6)
Hepatitis A	14.1 (13.3 to 14.8)	25.8 (24.4 to 27.2)	83.4 (83.4 to 83.5)	-1.2 (-1.3 to -1.1)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	86.1 (63.3 to 110.6)	1.4 (-9.8 to 13.8)
Hepatitis B	836.7 (620.3 to 1,083.2)	1,195.4 (963.3 to 1,483.0)	43.8 (3.5 to 96.4)	-23.1 (-41.5 to 15.7)	0.4 (0.2 to 0.6)	0.5 (0.3 to 0.8)	36.3 (-2.0 to 103.6)	27.5 (-50.7 to 7.6)
Hepatitis C	238.7 (215.1 to 262.9)	296.5 (262.4 to 331.8)	24.0 (7.9 to 43.1)	-30.5 (-38.4 to -21.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	25.4 (-3.0 to 65.1)	-30.6 (-48.9 to -6.9)
Hepatitis E	1.5 (1.1 to 1.8)	2.2 (1.7 to 2.9)	51.7 (6.6 to 135.8)	-21.4 (-42.5 to 33.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	52.0 (-4.6 to 151.3)	-20.9 (-47.7 to 38.2)
Leprosy	0.6 (0.4 to 0.8)	0.7 (0.6 to 0.8)	21.6 (-6.3 to 66.1)	-25.5 (-40.5 to -1.6)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	22.1 (-10.1 to 80.0)	-25.3 (-42.4 to 3.5)
Other infectious diseases	48.0 (40.0 to 58.1)	99.1 (87.6 to 111.8)	106.9 (74.0 to 145.1)	5.8 (-10.2 to 23.4)	1.9 (1.2 to 2.9)	3.7 (2.4 to 5.5)	98.9 (60.3 to 154.5)	3.7 (-21.7 to 33.0)
Non-communicable diseases	-	-	-	-	511.0 (378.4 to 660.9)	911.7 (670.1 to 1,183.1)	78.4 (73.5 to 84.0)	2.5 (-5.1 to 0.7)
Neoplasms	-	-	-	-	1.7 (1.2 to 2.3)	4.2 (2.9 to 5.8)	153.0 (102.9 to 220.5)	61.8 (29.1 to 106.6)
Esophageal cancer	0.5 (0.3 to 0.7)	0.9 (0.5 to 1.3)	76.9 (13.6 to 175.3)	10.3 (-30.0 to 70.1)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	78.6 (23.2 to 160.0)	12.1 (-23.9 to 62.2)
Stomach cancer	0.3 (0.2 to 0.4)	0.7 (0.5 to 0.9)	127.0 (61.3 to 225.1)	44.5 (3.0 to 110.4)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	129.9 (65.4 to 223.2)	48.6 (5.1 to 110.5)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	115.1 (54.7 to 196.3)	33.6 (5.6 to 90.8)
Liver cancer due to hepatitis B	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	104.2 (-20.9 to 445.9)	30.2 (-53.3 to 284.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	101.5 (-16.4 to 407.9)	28.3 (-49.7 to 254.5)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.1)	0.3 (0.1 to 0.4)	483.8 (174.8 to 1,220.8)	226.6 (58.2 to 618.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	461.5 (199.0 to 1,108.3)	215.7 (70.8 to 541.7)
Liver cancer due to alcohol use	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	7.8 (-40.1 to 99.2)	-30.7 (-62.5 to 28.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	8.3 (-34.8 to 82.2)	-29.6 (-57.8 to 21.3)
Liver cancer due to other causes	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	32.5 (-34.3 to 143.3)	-18.9 (-60.8 to 59.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	27.5 (-27.4 to 119.8)	21.7 (-57.2 to 48.0)
Larynx cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	159.0 (62.2 to 286.6)	68.5 (4.8 to 153.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	165.2 (65.9 to 294.2)	74.2 (8.8 to 164.0)
Tracheal, bronchus and lung cancer	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.5)	167.8 (86.1 to 261.8)	73.4 (20.7 to 133.4)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	169.9 (86.2 to 271.1)	76.0 (19.6 to 145.3)
Breast cancer	3.3 (2.6 to 4.1)	8.1 (5.8 to 11.1)	144.6 (73.2 to 258.9)	42.4 (1.8 to 110.4)	0.3 (0.2 to 0.4)	0.7 (0.4 to 1.1)	136.4 (65.8 to 249.9)	38.6 (-1.1 to 104.9)
Cervical cancer	3.2 (2.1 to 4.2)	6.8 (4.6 to 9.5)	115.7 (43.4 to 227.0)	25.4 (-16.2 to 86.9)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	113.1 (45.2 to 232.1)	28.2 (-12.6 to 90.3)
Uterine cancer	0.6 (0.3 to 0.9)	1.0 (0.6 to 1.6)	76.9 (-7.3 to 206.8)	13.7 (-37.2 to 99.8)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	79.8 (-3.9 to 222.0)	16.0 (-36.5 to 105.3)
Prostate cancer	1.0 (0.4 to 1.7)	7.3 (4.4 to 11.5)	633.5 (282.6 to 1,790.4)	310.1 (123.8 to 929.2)	0.1 (0.0 to 0.2)	0.7 (0.4 to 1.1)	594.7 (287.5 to 1,658.4)	300.8 (127.9 to 882.8)
Colon and rectum cancer	1.0 (0.9 to 1.2)	2.5 (2.0 to 3.0)	136.2 (84.3 to 207.2)	41.5 (9.9 to 83.1)	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	137.2 (77.1 to 208.3)	43.0 (8.6 to 87.6)
Lip and oral cavity cancer	0.5 (0.3 to 0.6)	1.1 (0.7 to 1.5)	133.4 (55.5 to 240.1)	48.3 (-2.4 to 115.8)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.2)	134.5 (59.7 to 235.9)	50.3 (0.4 to 117.3)
Nasopharynx cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	63.8 (-4.1 to 182.0)	6.4 (-44.5 to 61.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	64.0 (-0.9 to 193.1)	5.6 (-42.2 to 64.5)
Other pharynx cancer	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	109.5 (21.2 to 288.4)	31.7 (-25.9 to 158.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	118.6 (35.7 to 279.8)	38.8 (-16.6 to 150.7)
Gallbladder and biliary tract cancer	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	97.0 (31.5 to 204.6)	17.1 (-22.7 to 81.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	92.2 (32.2 to 186.7)	13.5 (-23.0 to 68.0)
Pancreatic cancer	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	98.2 (39.9 to 175.4)	17.0 (-16.5 to 64.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	99.3 (50.0 to 165.6)	18.5 (-11.0 to 57.6)
Malignant skin melanoma	0.4 (0.3 to 0.5)	0.9 (0.6 to 1.2)	149.5 (81.8 to 248.9)	45.9 (3.4 to 108.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	148.8 (72.0 to 249.1)	48.9 (1.9 to 112.8)
Non-melanoma skin cancer	0.4 (0.3 to 0.5)	1.1 (0.8 to 1.4)	173.6 (101.7 to 250.8)	60.5 (16.1 to 108.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	240.4 (123.8 to 389.7)	103.9 (17.7 to 207.6)
Ovarian cancer	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	48.3 (-3.3 to 119.4)	-11.7 (-42.6 to 33.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	52.9 (-3.2 to 133.1)	-9.9 (-45.1 to 46.2)
Testicular cancer	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.5)	237.7 (91.0 to 475.7)	79.0 (3.8 to 204.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	217.1 (80.1 to 461.5)	72.4 (-6.0 to 200.8)
Kidney cancer	0.3 (0.3 to 1.0)	0.8 (0.5 to 1.4)	146.7 (-30.9 to 227.6)	29.9 (-24.2 to 82.5)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	62.0 (-20.2 to 252.8)	34.8 (-10.2 to 99.3)
Bladder cancer	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	126.9 (53.4 to 234.5)	45.5 (-1.3 to 109.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	131.7 (57.1 to 241.5)	50.4 (1.0 to 118.0)
Brain and nervous system cancer	0.3 (0.2 to 0.4)	0.7 (0.5 to 1.0)	177.0 (82.3 to 332.1)	53.3 (16.0 to 104.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	172.7 (95.6 to 284.4)	53.6 (17.8 to 101.5)
Thyroid cancer	0.4 (0.2 to 0.6)	0.6 (0.4 to 1.0)	73.5 (-8.6 to 223.4)	6.5 (-45.8 to 100.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	76.5 (-4.2 to 252.0)	10.1 (-41.7 to 108.2)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	149.5 (68.0 to 295.8)	52.7 (1.4 to 153.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	161.2 (75.8 to 314.5)	63.3 (5.0 to 167.8)
Hodgkin lymphoma	0.4 (0.3 to 0.6)	0.9 (0.7 to 1.3)	139.4 (51.9 to 281.2)	61.3 (3.5 to 143.5)	0.0 (0.0 to 0.1)	0.0 (0.1 to 0.1)	146.8 (59.1 to 281.4)	61.5 (4.0 to 145.8)
Non-Hodgkin lymphoma	1.3 (0.8 to 2.0)	2.2 (1.5 to 3.1)	67.6 (-7.1 to 164.9)	8.8 (-23.9 to 65.0)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	72.9 (3.0 to 170.6)	15.3 (-18.2 to 70.8)
Multiple myeloma	0.1 (0.0 to 0.1)	0.2 (0.1 to 0.2)	142.8 (47.6 to 277.9)	45.8 (-9.8 to 124.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	137.0 (42.4 to 261.7)	43.0 (-15.1 to 125.7)
Leukemia	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.9)	114.5 (21.8 to 258.2)	25.1 (-13.7 to 78.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	109.6 (38.4 to 193.5)	25.8 (-12.3 to 74.3)
Other neoplasms	3.1 (2.0 to 5.8)	9.1 (6.4 to 13.0)	208.8 (63.1 to 407.3)	64.5 (19.2 to 128.8)	0.2 (0.1 to 0.4)	0.6 (0.4 to 0.9)	198.5 (71.2 to 359.2)	61.0 (16.0 to 122.1)
Cardiovascular diseases	-	-	-	-	14.9 (10.1 to 20.6)	23.4 (15.9 to 32.3)	57.3 (29.4 to 90.8)	-11.2 (-27.9 to 9.1)
Rheumatic heart disease	113.3 (100.9 to 126.4)	193.2 (164.7 to 221.4)	70.8 (39.3 to 105.3)	-5.4 (-20.5 to 11.8)	5.6 (3.5 to 8.1)	9.3 (5.9 to 13.7)	66.4 (36.5 to 102.6)	-10.1 (-35.0 to 7.7)
Ischemic heart disease	70.5 (53.5 to 88.4)	78.4 (63.3 to 96.9)	9.6 (-16.4 to 53.1)	-31.2 (-45.8 to -4.8)	3.8 (2.3 to 5.8)	3.9 (2.3 to 5.7)	4.0 (-2.5 to 57.8)	-94.8 (-52.3 to -3.2)
Cerebrovascular disease	-	-	-	-	0.3 (0.3 to 0.6)	0.5 (0.5 to 0.9)	73.0 (33.6 to 126.3)	2.4 (-26.1 to 29.2)
Ischemic stroke	1.9 (1.5 to 2.3)	3.2 (2.6 to 3.9)	72.6 (32.4 to 125.7)	-2.0 (-25.2 to 30.9)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.7)	73.9 (33.6 to 126.9)	-1.3 (-25.8 to 32.6)
Hemorrhagic stroke	0.6 (0.5 to 0.8)	1.0 (0.8 to 1.3)	70.8 (25.4 to 133.5)	-7.6 (-33.8 to 22.0)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	69.9 (25.8 to 132.9)	-7.0 (-33.1 to 23.9)
Hypertensive heart disease	10.0 (6.8 to 13.3)	17.6 (11.3 to 23.2)	75.5 (-2.2 to 195.4)	1.1 (-41.5 to 74.8)	1.1 (0.6 to 1.6)	1.9 (1.1 to 2.9)	74.9 (-0.9 to 196.6)	3.4 (-42.1 to 75.1)
Cardiomyopathy and myocarditis	7.7 (6.3 to 9.4)	14.6 (10.5 to 19.8)	91.4 (27.5 to 169.6)	10.3 (-37.1 to 73.3)	0.8 (0.5 to 1.2)	1.6 (0.9 to 2.4)	91.8 (29.5 to 171.6)	11.0 (-35.9 to 73.9)
Atrial fibrillation and flutter	3.3 (2.4 to 4.3)	9.1 (6.4 to 12.3)	174.3 (85.1 to 302.2)	60.6 (8.8 to 158.4)	0.3 (0.2 to 0.4)	0.7 (0.4 to 1.0)	171.7 (83.5 to 300.5)	59.4 (6.8 to 155.8)
Peripheral vascular disease	116.8 (88.2 to 147.7)	150.0 (110.2 to 200.4)	28.9 (-14.6 to 90.4)	-17.5 (-41.1 to 24.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	59.1 (-23.0 to 204.8)	-10.4 (-58.6 to 85.8)
Endocarditis	0.3 (0.2 to 0.4)	0.3 (0.2 to 0.5)	23.5 (-21.2 to 84.1)	-29.6 (-59.8 to 22.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	23.8 (-26.7 to 100.8)	-29.3 (-64.1 to 29.7)
Other cardiovascular and circulatory diseases	41.4 (21.5 to 71.9)	75.0 (38.5 to 111.7)	83.7 (-16.1 to 270.3)	2.9 (-57.6 to 110.3)	2.9 (1.4 to 5.2)	5.2 (2.4 to 8.6)	84.7 (-15.7 to 276.4)	-2.0 (-58.7 to 113.6)
Chronic respiratory diseases	-	-	-	-	37.0 (24.7 to 53.0)	52.8 (33.9 to 74.8)	42.1 (20.5 to 70.9)	-17.0 (-30.3 to 0.4)
Chronic obstructive pulmonary disease								

Appendix Table G.4 - Zambia prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	VLDs 1990 (thousands)	VLDs 2013 (thousands)	% change VLDs, 1990 to 2013	% change age-standardized VLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	67.8 (62.4 to 74.3)	-4.0 (-7.0 to -0.8)
Silicosis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	58.2 (51.2 to 66.2)	-8.1 (-11.8 to -3.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	57.9 (50.9 to 66.2)	-8.1 (-12.0 to -3.5)
Asbestosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Coal workers pneumoconiosis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Other pneumoconiosis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	77.7 (70.6 to 85.0)	0.7 (-3.0 to 4.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	76.4 (66.6 to 84.7)	0.3 (-3.7 to 4.0)
Asthma	86.3 (69.8 to 106.7)	105.2 (80.0 to 137.6)	20.0 (-17.7 to 85.8)	-19.8 (-38.5 to 5.6)	3.8 (2.4 to 5.7)	4.6 (2.7 to 7.4)	19.2 (-18.2 to 86.1)	-20.2 (-39.2 to 5.5)
Interstitial lung disease and pulmonary sarcoidosis	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	95.4 (36.3 to 226.7)	6.8 (-20.6 to 59.2)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	94.9 (37.1 to 222.3)	7.1 (-20.0 to 57.5)
Other chronic respiratory diseases	-	-	-	-	13.5 (7.5 to 22.4)	12.9 (6.9 to 22.0)	-4.6 (-33.3 to 43.6)	-45.1 (-62.1 to -17.5)
Cirrhosis	-	-	-	-	0.6 (0.4 to 0.9)	1.0 (0.7 to 1.3)	56.4 (36.3 to 78.2)	5.9 (-15.5 to 4.4)
Cirrhosis due to hepatitis B	1.0 (0.5 to 1.4)	1.4 (1.0 to 1.9)	37.4 (-16.3 to 166.6)	-16.6 (50.7 to 71.9)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	38.0 (-22.6 to 172.3)	-15.6 (51.2 to 72.7)
Cirrhosis due to hepatitis C	0.6 (0.4 to 0.9)	1.2 (0.7 to 1.7)	101.2 (1.8 to 260.6)	16.6 (-41.5 to 103.5)	0.1 (0.0 to 0.2)	0.2 (0.1 to 0.3)	100.0 (-0.3 to 286.9)	17.3 (-41.3 to 111.1)
Cirrhosis due to alcohol use	1.0 (0.8 to 1.2)	1.2 (0.9 to 1.5)	23.3 (-17.1 to 77.8)	-22.8 (-46.9 to 10.2)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	23.6 (-22.2 to 84.2)	-23.8 (-49.2 to 14.0)
Cirrhosis due to other causes	1.2 (0.9 to 1.4)	2.1 (1.7 to 2.5)	76.6 (40.1 to 123.7)	12.6 (-14.2 to 47.9)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.5)	76.4 (22.4 to 153.4)	13.1 (-20.5 to 58.7)
Digestive diseases	-	-	-	-	9.9 (6.8 to 13.6)	17.5 (12.2 to 23.7)	76.1 (59.3 to 95.1)	-1.5 (-10.4 to 9.3)
Peptic ulcer disease	46.8 (39.9 to 52.9)	61.7 (56.0 to 67.3)	31.8 (14.1 to 54.2)	-21.5 (-31.6 to -8.6)	1.7 (1.1 to 2.4)	2.3 (1.5 to 3.3)	38.5 (14.1 to 70.3)	-20.4 (-32.3 to -5.3)
Gastritis and duodenitis	100.4 (89.9 to 111.5)	161.1 (151.1 to 171.0)	60.2 (41.3 to 80.6)	-8.2 (-21.8 to 8.1)	4.5 (3.0 to 6.4)	7.6 (5.1 to 11.0)	71.0 (45.0 to 95.4)	-4.6 (-18.4 to 10.6)
Appendicitis	1.0 (0.7 to 1.3)	1.8 (1.3 to 2.3)	86.3 (20.8 to 194.9)	-0.3 (-30.0 to 51.4)	0.3 (0.2 to 0.4)	0.6 (0.3 to 0.9)	89.7 (13.6 to 220.3)	0.6 (-34.6 to 60.4)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.4)	85.0 (29.9 to 210.4)	-2.0 (-13.6 to 18.9)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	89.8 (14.6 to 232.9)	-0.6 (-23.7 to 30.9)
Inguinal, femoral, and abdominal hernia	11.6 (10.1 to 14.2)	35.5 (30.6 to 40.9)	207.6 (144.1 to 274.7)	199.1 (144.4 to 281.7)	0.1 (0.1 to 0.2)	0.4 (0.2 to 0.7)	199.7 (137.9 to 266.0)	194.6 (137.8 to 274.4)
Inflammatory bowel disease	6.9 (6.6 to 7.2)	15.5 (14.8 to 16.2)	125.6 (112.9 to 140.5)	25.5 (18.7 to 32.5)	1.4 (1.0 to 2.0)	3.3 (2.3 to 4.5)	126.4 (105.5 to 151.0)	25.7 (16.0 to 36.8)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	72.1 (15.5 to 128.7)	-6.2 (-45.1 to 33.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	71.5 (15.9 to 130.1)	-8.0 (-48.3 to 44.4)
Gallbladder and biliary diseases	2.4 (2.1 to 2.6)	4.7 (4.1 to 5.2)	96.3 (68.0 to 131.6)	13.3 (-2.8 to 33.5)	0.2 (0.2 to 0.3)	0.5 (0.3 to 0.7)	96.4 (60.4 to 140.7)	13.5 (-4.6 to 35.8)
Pancreatitis	1.2 (1.1 to 1.3)	2.4 (2.2 to 2.5)	95.5 (80.5 to 114.8)	4.0 (-3.5 to 14.4)	0.4 (0.2 to 0.5)	0.7 (0.5 to 1.0)	97.3 (68.0 to 140.0)	5.0 (-9.1 to 23.9)
Other digestive diseases	-	-	-	-	1.3 (0.7 to 2.0)	2.1 (1.3 to 3.0)	60.9 (19.0 to 125.2)	-9.4 (-32.2 to 27.0)
Neurological disorders	-	-	-	-	51.1 (33.5 to 72.7)	99.3 (65.4 to 142.2)	94.8 (69.1 to 123.5)	3.2 (-8.2 to 15.5)
Alzheimer disease and other dementias	11.0 (9.8 to 12.3)	19.3 (17.0 to 21.3)	76.6 (49.0 to 105.5)	-3.0 (-16.9 to 15.3)	1.5 (1.1 to 2.0)	2.7 (1.9 to 3.5)	78.8 (50.1 to 109.2)	-1.9 (-17.5 to 15.5)
Parkinson disease	0.6 (0.3 to 0.8)	1.0 (0.6 to 1.4)	66.5 (50.0 to 88.5)	-2.2 (-11.2 to 7.7)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	66.9 (36.6 to 101.2)	-1.9 (-18.2 to 17.3)
Epilepsy	18.5 (10.6 to 29.0)	33.3 (18.9 to 52.8)	76.8 (-15.2 to 292.6)	-5.5 (-54.5 to 109.5)	5.6 (2.8 to 9.9)	10.4 (5.2 to 18.1)	83.9 (-13.2 to 310.5)	-2.8 (-53.2 to 116.4)
Multiple sclerosis	0.5 (0.4 to 0.5)	1.0 (0.9 to 1.2)	113.6 (81.1 to 149.9)	15.7 (-0.9 to 33.9)	0.2 (0.1 to 0.2)	0.4 (0.2 to 0.5)	115.1 (67.9 to 167.8)	15.8 (-9.5 to 43.7)
Migraine	1,031.1 (905.5 to 1,153.9)	1,956.3 (1,761.7 to 2,160.6)	89.3 (64.3 to 119.8)	35.1 (-9.9 to 17.6)	35.1 (20.7 to 52.4)	66.7 (40.4 to 92.7)	89.8 (64.2 to 120.0)	1.9 (-10.0 to 18.2)
Tension-type headache	946.9 (879.9 to 1,008.7)	1,792.9 (1,641.7 to 1,942.2)	89.2 (70.0 to 111.3)	-1.3 (-9.2 to 8.1)	1.4 (0.7 to 2.5)	2.7 (1.3 to 4.7)	89.6 (68.4 to 113.2)	-1.2 (-9.9 to 8.6)
Medication overuse headache	34.8 (22.4 to 47.7)	90.0 (59.0 to 127.1)	157.6 (93.4 to 246.2)	44.7 (7.2 to 85.9)	5.4 (3.0 to 8.4)	14.1 (7.7 to 22.4)	158.8 (92.3 to 252.2)	44.8 (7.0 to 87.2)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.0 (30.1 to 139.4)	-6.8 (-30.0 to 26.7)	1.7 (1.1 to 2.9)	2.3 (1.4 to 3.4)	34.8 (-16.7 to 98.2)	-26.6 (-54.9 to 8.5)
Mental and substance use disorders	-	-	-	-	174.3 (121.1 to 240.4)	318.4 (219.9 to 436.6)	82.6 (76.9 to 89.2)	-0.8 (-3.3 to 2.8)
Schizophrenia	15.3 (14.0 to 16.5)	28.8 (26.1 to 31.2)	87.6 (79.7 to 96.2)	2.0 (-2.1 to 6.5)	2.0 (7.1 to 11.7)	2.7 (13.3 to 22.1)	81.3 (76.2 to 102.8)	2.6 (-3.5 to 9.4)
Alcohol use disorders	80.9 (74.7 to 86.8)	135.4 (125.8 to 145.5)	67.2 (59.0 to 76.1)	-10.1 (-14.1 to -5.8)	7.9 (5.4 to 11.1)	13.2 (8.8 to 18.5)	67.4 (56.9 to 78.7)	-9.9 (-15.1 to -4.5)
Drug use disorders	-	-	-	-	9.2 (6.1 to 12.7)	17.6 (11.7 to 24.0)	90.9 (69.3 to 117.8)	2.3 (-8.5 to 15.7)
Opioid use disorders	11.3 (7.3 to 16.8)	22.1 (14.2 to 32.5)	95.7 (70.8 to 125.3)	2.9 (-9.1 to 17.0)	4.6 (2.6 to 7.3)	8.9 (5.2 to 13.6)	97.2 (70.4 to 128.3)	3.4 (-9.4 to 17.9)
Cocaine use disorders	2.7 (2.7 to 4.3)	3.5 (6.0 to 8.3)	99.8 (53.7 to 158.2)	0.5 (-13.5 to 31.4)	0.5 (0.3 to 0.7)	1.0 (0.6 to 1.4)	98.4 (46.3 to 173.8)	7.1 (-18.6 to 41.3)
Amphetamine use disorders	12.8 (11.8 to 13.9)	23.4 (21.4 to 25.5)	82.9 (61.0 to 103.1)	-0.8 (-11.7 to 9.5)	1.7 (1.0 to 2.5)	3.1 (1.9 to 4.5)	83.0 (53.9 to 116.7)	-0.4 (-15.6 to 15.6)
Cannabis use disorders	11.8 (9.3 to 14.1)	21.9 (17.4 to 26.1)	85.2 (84.0 to 86.8)	0.0 (0.0 to 0.1)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	84.8 (58.0 to 117.8)	-0.0 (-13.6 to 16.6)
Other drug use disorders	-	-	-	-	2.2 (1.4 to 3.2)	4.0 (2.5 to 6.0)	84.2 (36.5 to 157.7)	0.5 (-24.9 to 37.8)
Depressive disorders	-	-	-	-	9.4 (5.3 to 12.6)	82.7 (93.5 to 218.8)	78.1 (65.7 to 90.9)	2.4 (-7.0 to 4.2)
Major depressive disorder	369.5 (282.3 to 463.9)	656.1 (482.8 to 824.9)	77.0 (64.6 to 90.6)	-3.0 (-7.7 to 4.5)	75.7 (48.0 to 114.4)	134.7 (83.8 to 202.2)	77.6 (61.1 to 91.4)	-2.7 (-7.7 to 4.7)
Dysthymia	73.9 (60.7 to 88.3)	134.4 (110.1 to 161.7)	81.6 (78.4 to 84.4)	-0.4 (-0.5 to -0.3)	7.1 (4.5 to 10.2)	12.9 (8.2 to 18.8)	82.2 (75.8 to 88.0)	-0.3 (-2.6 to 2.2)
Bipolar disorder	41.6 (35.2 to 47.5)	76.8 (65.3 to 87.7)	84.3 (75.1 to 96.1)	-0.9 (-4.9 to 4.5)	8.4 (5.2 to 12.7)	15.5 (9.5 to 23.4)	85.2 (72.1 to 100.6)	-0.6 (-6.0 to 6.0)
Anxiety disorders	230.3 (91.3 to 386.2)	425.5 (164.9 to 721.6)	84.2 (78.1 to 87.9)	0.5 (-0.7 to -0.2)	84.2 (7.5 to 38.4)	21.1 (13.5 to 71.4)	84.5 (72.8 to 90.9)	-0.4 (-3.0 to 2.0)
Eating disorders	-	-	-	-	1.9 (1.2 to 3.1)	3.7 (2.2 to 5.7)	88.7 (72.9 to 105.4)	0.5 (-7.6 to 9.0)
Anorexia nervosa	1.3 (1.0 to 1.7)	2.6 (1.9 to 3.4)	95.1 (76.0 to 116.2)	3.9 (-6.3 to 15.5)	0.3 (0.2 to 0.4)	0.5 (0.3 to 0.9)	94.8 (51.3 to 148.6)	4.1 (-18.9 to 30.7)
Bulimia nervosa	7.9 (5.4 to 11.6)	14.9 (10.2 to 21.7)	87.5 (85.6 to 90.9)	-0.1 (-0.3 to 0.1)	1.7 (1.0 to 2.7)	3.1 (1.8 to 5.0)	87.8 (70.6 to 106.7)	0.1 (-8.7 to 9.2)
Autistic spectrum disorders	-	-	-	-	9.4 (6.5 to 12.7)	17.5 (12.1 to 23.7)	86.7 (79.4 to 94.2)	1.8 (-2.5 to 4.2)
Autism	24.0 (22.8 to 25.3)	44.8 (42.5 to 47.2)	86.1 (86.0 to 86.3)	0.4 (0.4 to 0.4)	5.9 (4.0 to 8.1)	11.0 (7.4 to 15.2)	86.5 (77.1 to 96.9)	0.7 (-3.8 to 5.6)
Asperger syndrome	34.6 (32.4 to 36.6)	64.5 (60.5 to 68.3)	86.3 (86.1 to 86.5)	0.5 (0.5 to 0.6)	3.4 (2.4 to 4.8)	6.4 (4.4 to 9.0)	87.2 (78.2 to 96.2)	0.9 (-2.9 to 5.4)
Attention-deficit/hyperactivity disorder	59.7 (55.1 to 64.6)	110.3 (101.8 to 119.2)	84.4 (84.3 to 84.4)	-0.1 (-0.1 to -0.1)	0.7 (0.4 to 1.1)	1.3 (0.8 to 2.0)	84.5 (71.4 to 99.6)	-0.0 (-6.9 to 7.9)
Conduct disorder	88.1 (83.0 to 93.3)	161.6 (152.4 to 171.3)	83.3 (83.2 to 83.5)	0.1 (-0.1 to -0.1)	10.6 (6.6 to 15.4)	19.9 (12.3 to 28.2)	85.5 (75.6 to 92.4)	0.1 (-4.4 to 4.7)
Idiopathic intellectual disability	121.4 (53.3 to 169.1)	252.7 (161.6 to 347.2)	114.6 (76.0 to 228.3)	19.6 (-4.3 to 87.2)	19.6 (2.4 to 9.3)	12.8 (2.9 to 19.0)	115.3 (76.7 to 230.5)	19.8 (-3.6 to 89.0)
Other mental and substance use disorders	92.5 (86.1 to 98.4)	169.9 (158.2 to 181.3)	83.5 (82.5 to 84.6)	0.4 (0.3 to 0.5)	6.8 (4.7 to 9.2)	12.6 (8.6 to 17.0)	84.4 (77.0 to 92.6)	0.7 (-2.7 to 4.5)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	36.8 (25.9 to 49.6)	71.1 (49.8 to 95.0)	94.1 (77.7 to 107.7)	6.2 (-4.3 to 16.6)
Diabetes mellitus	73.4 (59.5 to 90.9)	164.3 (128.2 to 199.5)	127.5 (61.4 to 189.7)	27.1 (-13.5 to 71.3)	5.4 (3.5 to 7.7)	12.0 (7.9 to 17.2)	123.5 (57.4 to 197.1)	27.8 (-12.5 to 80.5)
Acute glomerulonephritis	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	54.2 (42.1 to 67.0)	-12.3 (-17.1 to -6.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	54.2 (42.1 to 67.1)	-12.3 (-17.1 to -6.3)
Chronic kidney disease	-	-	-	-	12.0 (8.6 to 16.0)	22.1 (16.0 to 29.2)	84.6 (64.1 to 104.5)	0.7 (-8.1 to 10.9)
Chronic kidney disease due to diabetes mellitus	98.5 (62.7 to 156.9)	160.7 (106.0 to 249.7)	64.8 (16.1 to 139.5)	-4.6 (-33.8 to 53.1)	1.5 (1.0 to 2.1)	2.4 (1.6 to 3.4)	65.8 (18.7 to 125.8)	-3.8 (-34.7 to 41.4)
Chronic kidney disease due to hypertension	307.4 (188.0 to 499.5)	572.3 (348.1 to 914.0)	87.9 (40.9 to 141.9)	3.6 (-17.0 to 30.1)	3.7 (2.4 to 4.8)	6.8 (4.8 to 9.1)	91.9 (59.6 to 132.3)	4.6 (-11.4 to 23.1)
Chronic kidney disease due to glomerulonephritis	280.0 (183.6 to 373.9)	499.9 (317.4 to 789.4)	90.8 (49.5 to 145.6)	5.5 (-16.7 to 33.4)	4.3 (2.9 to 5.8)	8.0 (5.6 to 10.9)	91.1 (51.3 to 138.2)	6.1 (-13.7 to 30.4)
Chronic kidney disease due to other causes	210.3 (132.7 to 343.3)	371.1 (239.8 to 626.3)	75.9 (28.4 to 142.2)	-10.9 (-31.9 to 20.2)	2.7 (1.8 to 3.8)	4.8 (3.3 to 6.5)	77.5 (32.6 to 126.1)	-9.0 (-31.2 to 18.0)
Urinary diseases and male infertility	-	-	-	-	2.1 (1.4 to 3.0)	3.6 (2.3 to 5.2)	68.9 (50.4 to 92.1)	0.9 (-9.4 to 12.4)

Appendix Table G.4 - Zambia prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.5 (1.4 to 1.6)	2.9 (2.7 to 3.1)	97.6 (80.7 to 117.3)	0.0 (-1.4 to 15.4)	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	100.7 (57.2 to 152.9)	100.7 (-10.9 to 27.6)
Urolithiasis	17.0 (12.8 to 21.8)	22.5 (17.6 to 28.5)	32.9 (17.5 to 50.9)	-20.5 (-29.1 to -11.2)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	67.5 (46.1 to 93.0)	-7.0 (-16.7 to 3.9)
Benign prostatic hyperplasia	42.8 (39.4 to 46.7)	72.9 (66.6 to 78.8)	70.0 (50.4 to 91.0)	3.1 (-8.3 to 15.1)	1.5 (1.0 to 2.1)	2.6 (1.7 to 3.7)	70.3 (50.3 to 91.1)	3.7 (-8.2 to 15.8)
Male infertility due to other causes	41.3 (25.5 to 61.1)	73.6 (43.4 to 107.2)	79.2 (46.6 to 225.6)	-8.7 (-51.2 to 70.9)	0.3 (0.1 to 0.6)	0.4 (0.2 to 0.9)	79.2 (9.1 to 228.1)	-8.5 (-26.6 to 9.5)
Other urinary diseases	-	-	-	-	-	-	-	-
Gynecological diseases	-	-	-	-	6.5 (4.1 to 9.8)	11.5 (7.1 to 17.7)	75.7 (44.5 to 109.5)	-7.5 (-22.7 to 6.8)
Uterine fibroids	110.3 (99.6 to 120.1)	197.6 (177.1 to 216.4)	79.0 (77.3 to 80.4)	-2.7 (-2.8 to -2.6)	1.2 (0.6 to 2.1)	2.1 (1.1 to 3.5)	74.8 (58.9 to 103.2)	-6.7 (-15.1 to 6.2)
Polycystic ovarian syndrome	105.4 (93.9 to 116.3)	212.6 (184.3 to 237.9)	101.7 (67.9 to 138.1)	2.9 (-12.3 to 19.2)	1.0 (0.5 to 1.9)	2.1 (0.9 to 3.8)	102.1 (68.0 to 137.6)	3.3 (-12.3 to 19.0)
Female infertility due to other causes	49.4 (34.2 to 67.2)	85.8 (54.9 to 119.4)	71.5 (0.6 to 190.2)	-11.9 (-49.2 to 47.7)	0.3 (0.1 to 0.5)	0.4 (0.2 to 1.0)	69.3 (-0.7 to 185.6)	-12.7 (-49.3 to 45.7)
Endometriosis	10.7 (9.0 to 12.3)	18.5 (16.1 to 21.4)	73.5 (40.8 to 111.8)	-9.7 (-26.4 to 10.3)	1.0 (0.7 to 1.4)	1.7 (1.1 to 2.4)	72.8 (37.4 to 118.8)	-10.0 (-27.7 to 12.7)
Genital prolapse	184.2 (160.3 to 211.7)	354.2 (296.5 to 414.0)	91.5 (53.6 to 143.2)	4.8 (-13.2 to 26.8)	0.6 (0.3 to 1.1)	1.1 (0.5 to 2.1)	91.3 (53.9 to 144.1)	4.8 (-13.3 to 27.4)
Premenstrual syndrome	277.4 (177.9 to 376.9)	449.6 (273.7 to 637.4)	61.4 (-5.9 to 156.4)	-16.0 (-50.4 to 29.3)	2.3 (1.3 to 3.8)	3.7 (1.9 to 6.6)	61.5 (5.8 to 159.2)	-16.1 (-50.4 to 29.7)
Other gynecological diseases	8.2 (5.9 to 10.6)	15.3 (10.9 to 19.7)	87.9 (29.3 to 173.3)	-4.7 (-31.4 to 31.1)	0.2 (0.1 to 0.3)	0.4 (0.2 to 0.6)	79.7 (-19.0 to 131.0)	-8.9 (-50.7 to 74.6)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	8.5 (5.7 to 12.2)	17.8 (12.0 to 25.6)	109.8 (86.0 to 131.3)	9.5 (-0.6 to 24.8)
Thalassemias	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	66.9 (31.4 to 90.0)	-12.5 (-31.1 to -0.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	66.3 (31.9 to 87.3)	-12.9 (-31.4 to -1.9)
Thalassemia trait	41.5 (36.1 to 46.7)	77.5 (67.5 to 87.5)	87.0 (68.1 to 98.8)	0.5 (-10.5 to 7.1)	0.9 (0.6 to 1.3)	1.8 (1.2 to 2.6)	99.6 (70.9 to 130.9)	7.6 (-6.3 to 21.3)
Sickle cell disorders	9.6 (7.7 to 10.9)	22.1 (19.7 to 24.2)	128.7 (93.2 to 187.5)	23.1 (3.9 to 53.3)	1.0 (0.7 to 1.5)	2.3 (1.6 to 3.3)	128.9 (82.1 to 177.3)	24.0 (6.0 to 47.6)
Sickle cell trait	984.6 (913.9 to 1,046.0)	1,912.1 (1,792.2 to 2,023.3)	94.1 (85.8 to 102.4)	4.5 (0.1 to 9.0)	5.3 (3.4 to 7.8)	11.1 (7.2 to 16.2)	109.8 (68.9 to 147.2)	9.8 (-10.5 to 32.3)
G6PD deficiency	420.2 (294.0 to 568.4)	782.3 (336.2 to 1,131.3)	94.8 (-33.5 to 220.8)	4.8 (-63.9 to 72.8)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	96.4 (47.0 to 169.9)	5.0 (-14.7 to 31.2)
G6PD trait	1,648.3 (1,463.3 to 1,786.2)	3,058.7 (2,656.9 to 3,324.4)	86.1 (58.4 to 115.0)	-0.2 (-15.1 to 15.3)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.2)	109.1 (-66.6 to 760.7)	15.1 (-78.8 to 375.1)
Other hemoglobinopathies and hemolytic anemias	35.5 (27.3 to 42.2)	69.0 (57.4 to 79.4)	93.9 (56.0 to 165.5)	-3.5 (-19.4 to 20.2)	1.1 (0.6 to 1.7)	2.3 (1.4 to 3.5)	97.0 (43.6 to 228.4)	1.5 (-25.9 to 53.1)
Endocrine, metabolic, blood, and immune disorders	61.6 (52.7 to 70.0)	117.2 (97.1 to 137.1)	90.4 (52.1 to 144.6)	-2.4 (-18.0 to 15.1)	2.3 (1.4 to 3.2)	4.1 (2.6 to 6.0)	90.2 (25.1 to 158.2)	2.3 (-25.2 to 20.1)
Musculoskeletal disorders	-	-	-	-	80.0 (56.6 to 105.8)	146.5 (102.9 to 191.0)	83.3 (65.8 to 101.3)	0.9 (-6.2 to 8.3)
Rheumatoid arthritis	17.1 (16.3 to 17.9)	27.3 (26.2 to 28.4)	59.5 (50.3 to 69.6)	-11.3 (-16.8 to -5.5)	4.0 (2.9 to 5.3)	6.5 (4.6 to 8.6)	60.2 (47.1 to 74.9)	-11.1 (-17.8 to -4.0)
Osteoarthritis	131.8 (126.6 to 137.8)	221.9 (213.0 to 229.7)	68.1 (58.6 to 78.1)	1.2 (-4.1 to 6.9)	8.0 (5.6 to 10.8)	13.5 (9.4 to 18.3)	68.2 (58.5 to 77.6)	1.4 (-1.4 to 6.9)
Low back and neck pain	-	-	-	-	55.0 (37.0 to 74.4)	106.4 (74.0 to 141.8)	94.2 (67.3 to 121.3)	5.2 (-6.0 to 17.0)
Low back pain	281.8 (260.2 to 300.1)	507.4 (472.0 to 541.6)	79.7 (64.4 to 98.8)	0.9 (-6.7 to 10.7)	31.0 (20.8 to 43.2)	56.1 (37.6 to 77.7)	80.4 (64.6 to 100.7)	1.2 (-6.7 to 11.6)
Neck pain	246.5 (187.3 to 309.0)	514.0 (441.5 to 594.5)	109.4 (54.1 to 185.3)	9.8 (-13.7 to 38.4)	24.0 (15.6 to 34.5)	50.2 (33.7 to 69.2)	110.6 (54.6 to 191.3)	10.0 (-13.5 to 39.7)
Gout	0.9 (0.8 to 1.1)	1.6 (1.4 to 1.8)	70.8 (40.1 to 100.6)	-1.9 (-18.8 to 16.1)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	72.2 (31.0 to 124.8)	-1.1 (-25.7 to 29.1)
Other musculoskeletal disorders	143.7 (109.9 to 176.1)	224.4 (170.1 to 278.0)	55.6 (45.2 to 68.2)	-10.0 (-16.9 to -4.3)	12.9 (8.3 to 18.8)	20.2 (12.9 to 29.5)	94.2 (45.4 to 69.4)	-9.1 (-16.8 to -3.8)
Other non-communicable diseases	-	-	-	-	104.7 (68.2 to 155.0)	177.5 (116.0 to 260.4)	69.6 (60.0 to 78.8)	-6.8 (-10.5 to -3.2)
Congenital anomalies	-	-	-	-	6.8 (4.4 to 9.8)	14.8 (9.8 to 21.0)	117.8 (87.4 to 155.8)	12.7 (-2.6 to 31.5)
Neural tube defects	0.5 (0.4 to 0.7)	3.3 (2.8 to 3.8)	546.9 (357.7 to 828.9)	286.8 (170.5 to 475.3)	0.1 (0.1 to 0.2)	0.9 (0.6 to 1.3)	664.2 (350.7 to 1,167.6)	370.0 (172.7 to 679.3)
Congenital heart anomalies	4.7 (3.1 to 6.8)	33.9 (25.6 to 44.2)	625.6 (365.5 to 1,018.4)	333.3 (172.9 to 583.5)	0.2 (0.1 to 0.3)	1.2 (0.5 to 2.1)	488.2 (277.1 to 844.0)	247.6 (123.8 to 459.8)
Orofacial clefts	0.4 (0.3 to 0.6)	10.1 (3.6 to 6.1)	1,001.3 (603.2 to 1,952.8)	0.0 (340.0 to 1,295.0)	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	902.9 (490.4 to 1,393.3)	553.5 (280.1 to 1,242.4)
Down syndrome	3.1 (2.2 to 3.9)	10.1 (8.3 to 12.5)	226.9 (151.6 to 345.4)	87.2 (43.0 to 156.8)	0.4 (0.2 to 0.5)	1.1 (0.8 to 1.6)	226.8 (138.3 to 358.0)	88.4 (36.9 to 162.2)
Turner syndrome	0.1 (0.1 to 0.2)	0.4 (0.3 to 0.6)	196.7 (81.0 to 412.2)	63.0 (-1.9 to 181.6)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	195.3 (78.0 to 410.4)	62.2 (-3.5 to 182.6)
Klinefelter syndrome	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.5)	82.6 (35.1 to 142.4)	-1.6 (-27.5 to 30.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	86.6 (37.4 to 147.6)	-0.5 (-26.6 to 32.1)
Chromosomal unbalanced rearrangements	5.1 (4.1 to 6.7)	17.3 (14.1 to 21.4)	238.3 (142.5 to 362.1)	35.9 (36.8 to 169.5)	0.6 (0.4 to 0.8)	1.9 (1.3 to 2.7)	237.1 (135.2 to 364.1)	94.8 (34.7 to 174.3)
Other congenital anomalies	56.8 (40.6 to 70.7)	93.5 (64.9 to 122.3)	62.6 (38.2 to 97.2)	-11.2 (-24.3 to 6.8)	5.6 (3.3 to 8.4)	9.6 (5.6 to 14.8)	72.1 (43.2 to 108.5)	-8.9 (-24.0 to 10.8)
Skin and subcutaneous diseases	-	-	-	-	39.0 (24.5 to 62.5)	69.7 (44.1 to 110.3)	79.2 (66.2 to 93.8)	-2.2 (-9.2 to 5.5)
Dermatitis	302.4 (233.0 to 388.5)	562.6 (432.5 to 726.6)	85.7 (84.5 to 87.2)	-0.1 (-0.2 to 0.0)	10.9 (6.7 to 16.0)	20.3 (12.5 to 29.9)	86.3 (78.9 to 93.3)	0.1 (-2.7 to 3.2)
Psoriasis	46.1 (39.8 to 52.7)	94.3 (72.6 to 96.9)	82.8 (81.0 to 84.2)	0.0 (-0.1 to 0.1)	3.7 (2.5 to 5.3)	6.8 (4.6 to 9.8)	83.3 (70.3 to 96.9)	0.3 (-5.1 to 5.6)
Cellulitis	1.6 (1.2 to 2.0)	3.0 (2.4 to 3.8)	92.4 (70.3 to 120.2)	5.5 (-6.1 to 23.1)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	93.3 (48.0 to 151.3)	5.3 (-15.1 to 33.6)
Pyoderma	13.5 (10.0 to 17.4)	23.6 (17.6 to 30.3)	74.6 (64.4 to 87.7)	-4.2 (-10.6 to 3.0)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.3)	74.7 (58.3 to 93.6)	-4.2 (-13.1 to 5.9)
Scabies	130.0 (98.3 to 169.0)	198.5 (152.1 to 257.3)	52.8 (4.4 to 127.8)	-20.0 (-47.5 to 19.4)	3.3 (1.8 to 5.7)	5.1 (2.7 to 8.8)	52.8 (3.9 to 130.6)	-19.7 (-47.2 to 19.6)
Fungal skin diseases	878.2 (628.5 to 1,245.9)	1,621.3 (1,155.6 to 2,310.5)	84.3 (82.5 to 86.1)	0.1 (0.0 to 0.0)	9.1 (1.9 to 11.1)	9.1 (3.5 to 20.6)	84.7 (82.2 to 86.9)	0.3 (-0.4 to 0.9)
Viral skin diseases	191.2 (140.7 to 241.6)	357.4 (266.3 to 451.3)	86.5 (79.1 to 93.9)	-0.2 (-3.3 to 3.2)	5.9 (3.4 to 9.5)	11.1 (6.3 to 17.8)	86.8 (77.8 to 96.7)	0.0 (-4.0 to 4.7)
Acne vulgaris	516.1 (336.9 to 714.1)	702.5 (457.3 to 1,017.6)	36.0 (-14.7 to 103.0)	-27.4 (-52.5 to 6.3)	5.4 (2.4 to 11.1)	7.6 (3.2 to 15.6)	36.1 (-15.4 to 102.4)	-27.3 (-52.7 to 6.9)
Alopecia areata	6.9 (6.1 to 7.7)	12.5 (11.2 to 14.0)	82.7 (55.0 to 114.4)	0.7 (-15.2 to 14.5)	0.2 (0.1 to 0.3)	0.4 (0.3 to 0.6)	82.6 (46.8 to 128.0)	-0.6 (-17.7 to 18.9)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.4 (43.1 to 125.7)	-1.4 (-21.3 to 28.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	78.4 (43.0 to 126.2)	-1.4 (-21.3 to 28.2)
Urticaria	29.4 (18.6 to 41.4)	80.0 (54.1 to 107.7)	172.0 (68.4 to 343.4)	37.5 (-11.5 to 125.9)	1.7 (0.9 to 2.7)	4.7 (2.9 to 7.2)	174.6 (68.1 to 344.5)	38.2 (-11.1 to 129.9)
Decubitus ulcer	0.8 (0.7 to 1.0)	1.5 (1.2 to 1.8)	90.6 (40.3 to 143.9)	4.7 (-34.6 to 49.2)	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	90.3 (39.2 to 150.6)	5.1 (-34.6 to 53.1)
Other skin and subcutaneous diseases	389.4 (263.9 to 558.0)	667.8 (446.8 to 955.2)	71.4 (62.0 to 80.3)	-4.4 (-9.5 to -0.7)	2.3 (1.0 to 4.7)	3.9 (1.8 to 8.0)	71.7 (61.7 to 81.5)	-4.4 (-9.0 to -0.3)
Sense organ diseases	-	-	-	-	45.8 (28.9 to 68.9)	70.3 (43.8 to 105.6)	51.1 (38.9 to 68.1)	-12.0 (-17.6 to -6.3)
Glaucoma	5.3 (4.1 to 6.6)	8.2 (6.3 to 10.9)	55.1 (27.9 to 93.2)	-10.1 (-25.0 to 6.9)	0.4 (0.3 to 0.6)	0.7 (0.4 to 1.0)	58.0 (28.1 to 89.1)	-4.3 (-25.9 to 18.1)
Cataract	14.5 (9.7 to 19.5)	20.3 (13.7 to 27.0)	40.5 (14.8 to 69.3)	-16.0 (-29.8 to -1.2)	0.8 (0.5 to 1.3)	1.2 (0.7 to 1.7)	39.1 (17.2 to 62.7)	-18.2 (-29.7 to -5.8)
Macular degeneration	3.5 (2.2 to 5.1)	4.3 (2.9 to 6.4)	21.7 (-13.6 to 71.7)	-23.2 (-43.4 to 11.3)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	21.1 (-15.0 to 70.0)	-24.2 (-44.6 to 8.4)
Uncorrected refractive error	455.4 (419.4 to 489.2)	794.5 (731.0 to 863.0)	74.1 (57.0 to 94.3)	-0.6 (-8.2 to 9.0)	6.5 (3.7 to 10.7)	10.8 (6.1 to 18.0)	65.6 (51.1 to 82.6)	-6.6 (-12.8 to 1.7)
Age-related and other hearing loss	993.7 (841.4 to 1,124.5)	1,559.7 (1,272.4 to 1,793.7)	56.1 (47.7 to 68.7)	-7.6 (-11.0 to -3.4)	32.5 (19.6 to 50.0)	47.6 (28.1 to 73.4)	46.3 (26.9 to 67.6)	-13.6 (-21.1 to -6.3)
Other vision loss	6.4 (4.9 to 8.0)	9.0 (6.9 to 11.9)	42.3 (21.3 to 64.9)	-20.3 (-29.7 to -8.9)	0.5 (0.3 to 0.8)	0.7 (0.4 to 1.0)	24.9 (-1.1 to 56.4)	-23.7 (-36.0 to -4.7)
Other sense organ diseases	185.3 (175.4 to 196.0)	343.9 (326.7 to 362.6)	85.6 (70.7 to 100.2)	-0.4 (-6.6 to 5.9)	4.9 (3.0 to 7.4)	9.2 (5.6 to 13.6)	86.0 (69.5 to 102.9)	-0.2 (-7.0 to 7.0)

Appendix Table G.4 - Zambia prevalence and VLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	121.0 (112.1 to 130.0)	192.1 (180.2 to 205.3)	58.1 (44.4 to 75.6)	-6.7 (-13.9 to 2.8)	3.3 (2.2 to 4.6)	5.2 (3.5 to 7.3)	58.0 (44.6 to 76.0)	-6.6 (-13.8 to 3.4)
Other oral disorders	111.9 (104.9 to 119.3)	203.3 (191.6 to 214.2)	81.1 (68.1 to 97.0)	-1.0 (-7.8 to 6.7)	3.3 (2.0 to 4.9)	5.9 (3.7 to 8.9)	81.6 (67.0 to 98.2)	-0.9 (-8.1 to 7.3)
Injuries	-	-	-	-	20.1 (15.5 to 25.5)	35.5 (26.6 to 46.5)	77.7 (63.3 to 87.8)	7.8 (0.6 to 13.5)
Transport injuries	-	-	-	-	6.7 (5.1 to 8.5)	11.5 (8.7 to 15.0)	72.6 (62.4 to 83.4)	10.4 (4.1 to 16.8)
Road injuries	-	-	-	-	5.6 (4.3 to 7.2)	9.8 (7.3 to 12.8)	73.6 (62.1 to 84.5)	11.6 (4.8 to 18.2)
Pedestrian road injuries	-	-	-	-	2.3 (1.6 to 2.7)	3.2 (2.4 to 4.1)	50.7 (38.2 to 63.0)	-1.2 (-7.6 to 5.1)
Cyclist road injuries	-	-	-	-	0.5 (0.4 to 0.6)	0.9 (0.7 to 1.2)	80.7 (66.8 to 95.9)	20.6 (11.5 to 29.5)
Motorcyclist road injuries	-	-	-	-	0.7 (0.5 to 0.9)	0.9 (0.7 to 1.2)	36.9 (27.2 to 47.4)	-17.1 (-23.0 to -10.4)
Motor vehicle road injuries	-	-	-	-	2.3 (1.7 to 2.9)	4.7 (3.6 to 6.1)	106.6 (88.1 to 126.7)	31.7 (21.1 to 43.1)
Other road injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	4.7 (3.5 to 13.4)	-35.9 (-40.6 to -31.2)
Other transport injuries	-	-	-	-	1.0 (0.8 to 1.3)	1.7 (1.3 to 2.3)	67.6 (55.2 to 81.3)	4.2 (-3.7 to 13.1)
Unintentional injuries	-	-	-	-	11.2 (8.7 to 14.3)	21.9 (16.5 to 28.7)	94.7 (83.8 to 104.2)	12.6 (6.9 to 18.1)
Falls	-	-	-	-	5.1 (3.9 to 6.6)	10.8 (8.0 to 14.2)	111.8 (96.4 to 126.2)	17.3 (9.7 to 26.9)
Drowning	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	96.2 (86.3 to 106.1)	11.0 (-35.1 to -22.7)
Fire, heat, and hot substances	-	-	-	-	1.5 (1.2 to 1.9)	2.3 (1.7 to 3.1)	54.7 (40.6 to 70.6)	-11.1 (-17.4 to -4.0)
Poisonings	-	-	-	-	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	31.7 (11.4 to 55.2)	-25.7 (-34.9 to -15.5)
Exposure to mechanical forces	-	-	-	-	2.2 (1.7 to 2.9)	4.7 (3.5 to 6.3)	111.6 (93.1 to 128.2)	24.9 (15.1 to 33.5)
Unintentional firearm injuries	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	96.2 (77.2 to 115.7)	11.0 (0.3 to 21.0)
Unintentional suffocation	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	193.8 (152.2 to 236.0)	70.7 (50.3 to 91.4)
Other exposure to mechanical forces	-	-	-	-	2.1 (1.6 to 2.8)	4.5 (3.3 to 6.0)	111.5 (92.3 to 128.6)	25.1 (15.0 to 34.0)
Adverse effects of medical treatment	-	-	-	-	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	88.7 (78.5 to 100.3)	9.8 (3.0 to 16.7)
Animal contact	-	-	-	-	0.8 (0.6 to 1.1)	1.1 (0.8 to 1.5)	32.0 (22.4 to 42.7)	23.7 (-2.3 to 18.7)
Venomous animal contact	-	-	-	-	0.4 (0.3 to 0.5)	0.5 (0.4 to 0.7)	32.2 (16.8 to 49.7)	-25.0 (-32.4 to -16.5)
Non-venomous animal contact	-	-	-	-	0.5 (0.3 to 0.6)	0.6 (0.4 to 0.8)	32.2 (21.8 to 44.6)	-22.6 (-28.3 to -16.9)
Foreign body	-	-	-	-	0.2 (0.2 to 0.3)	0.4 (0.3 to 0.6)	109.6 (93.7 to 126.0)	29.0 (18.6 to 39.8)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	46.3 (29.4 to 66.2)	-11.8 (-19.5 to -4.0)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	100.2 (75.9 to 127.3)	12.4 (0.4 to 26.3)
Foreign body in other body part	-	-	-	-	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.3)	152.5 (121.3 to 185.1)	52.6 (34.0 to 71.9)
Other unintentional injuries	-	-	-	-	0.9 (0.6 to 1.1)	1.8 (1.3 to 2.3)	109.4 (81.5 to 138.7)	31.9 (17.1 to 47.4)
Self-harm and interpersonal violence	-	-	-	-	1.1 (0.8 to 1.4)	1.7 (1.3 to 2.3)	62.4 (52.4 to 72.7)	-0.1 (-5.8 to 5.3)
Self-harm	-	-	-	-	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	84.8 (69.5 to 101.8)	4.1 (-3.8 to 13.0)
Interpersonal violence	-	-	-	-	1.0 (0.7 to 1.2)	1.5 (1.1 to 2.0)	59.9 (49.2 to 70.4)	-0.7 (-6.6 to 4.8)
Assault by firearm	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	76.2 (62.9 to 90.9)	10.3 (2.1 to 18.8)
Assault by sharp object	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	74.0 (60.0 to 89.4)	4.1 (-4.1 to 13.0)
Assault by other means	-	-	-	-	0.6 (0.5 to 0.8)	1.0 (0.7 to 1.2)	52.1 (40.1 to 64.3)	-5.1 (-11.8 to 1.6)
Forces of nature, war, and legal intervention	-	-	-	-	1.1 (0.4 to 2.8)	0.4 (0.1 to 0.9)	-65.5 (-78.5 to -47.8)	-68.0 (-79.2 to -53.3)
Exposure to forces of nature	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	105.6 (36.3 to 246.5)	-0.2 (-28.4 to 53.8)
Collective violence and legal intervention	-	-	-	-	1.1 (0.4 to 2.7)	0.4 (0.1 to 0.9)	-66.6 (-79.4 to -49.1)	-68.7 (-79.9 to -53.7)

Appendix Table G.4 - Zimbabwe prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
All causes	-	-	-	-	1,115.1 (809.9 to 1,483.4)	1,500.4 (1,114.4 to 1,942.0)	35.7 (21.1 to 44.0)	35.7 (15.0 to 3.9)
Communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	317.1 (224.5 to 451.0)	496.8 (364.2 to 659.3)	57.1 (40.5 to 75.3)	29.8 (12.4 to 52.4)
HIV/AIDS and tuberculosis	-	-	-	-	72.8 (51.1 to 95.9)	203.0 (140.5 to 272.9)	176.8 (142.6 to 227.0)	118.8 (84.7 to 174.1)
Tuberculosis	99.6 (91.9 to 107.1)	150.1 (139.9 to 160.0)	51.2 (41.0 to 61.3)	0.3 (-5.3 to 6.4)	29.8 (20.2 to 39.9)	45.5 (31.1 to 60.9)	53.1 (42.2 to 64.7)	1.3 (-5.0 to 8.3)
HIV/AIDS	-	-	-	-	43.0 (30.7 to 56.1)	157.5 (107.7 to 215.2)	211.0 (208.5 to 348.0)	211.0 (153.4 to 310.7)
HIV/AIDS resulting in mycobacterial infection	26.4 (19.0 to 33.7)	51.3 (37.4 to 63.4)	94.4 (75.2 to 118.9)	41.5 (26.6 to 63.5)	9.6 (5.9 to 13.9)	18.9 (11.9 to 26.9)	96.2 (75.5 to 121.1)	42.5 (27.5 to 64.5)
HIV/AIDS resulting in other diseases	434.1 (388.8 to 466.6)	1,000.6 (891.0 to 1,075.3)	130.3 (115.9 to 150.8)	94.2 (77.3 to 119.0)	33.4 (23.2 to 44.6)	138.6 (92.6 to 191.6)	309.5 (238.2 to 431.4)	265.9 (187.7 to 409.8)
Diarrhea, lower respiratory, and other common infectious diseases	-	-	-	-	192.2 (132.2 to 256.6)	39.2 (27.8 to 52.9)	15.9 (8.4 to 23.3)	-6.4 (-12.0 to -0.9)
Diarrheal diseases	118.5 (112.1 to 125.0)	130.8 (123.3 to 138.8)	10.7 (1.9 to 19.7)	-6.2 (-12.9 to 0.8)	19.2 (13.2 to 26.6)	21.5 (14.1 to 29.6)	10.3 (1.0 to 20.0)	-16.0 (-35.7 to 1.7)
Intestinal infectious diseases	-	-	-	-	0.3 (0.2 to 0.4)	0.2 (0.1 to 0.3)	0.2 (-38.7 to 11.5)	-35.2 (-53.1 to -16.0)
Typhoid fever	1.5 (1.3 to 1.8)	1.3 (1.0 to 1.5)	-16.9 (-36.7 to 3.9)	-36.3 (-52.4 to -19.7)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	0.2 (-39.1 to 12.3)	-15.8 (-53.2 to -15.4)
Paratyphoid fever	0.7 (0.6 to 0.9)	0.8 (0.6 to 0.9)	1.3 (-23.4 to 41.7)	-21.1 (-41.1 to 10.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	2.2 (-25.0 to 49.4)	20.7 (-41.1 to 15.4)
Other intestinal infectious diseases	-	-	-	-	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-4.6 (-73.4 to 10.5)	-57.6 (-79.8 to -14.1)
Lower respiratory infections	5.3 (4.4 to 6.2)	7.6 (6.5 to 8.6)	45.1 (15.8 to 77.4)	21.9 (5.1 to 41.7)	0.6 (0.3 to 0.8)	0.8 (0.5 to 1.2)	43.7 (10.4 to 84.5)	21.2 (8.4 to 45.9)
Upper respiratory infections	308.4 (288.3 to 328.3)	428.0 (396.8 to 457.6)	39.1 (25.7 to 55.5)	4.4 (-5.5 to 16.1)	3.6 (2.0 to 6.1)	5.0 (2.8 to 8.5)	39.2 (25.1 to 56.4)	4.6 (-6.0 to 17.0)
Otitis media	197.2 (181.2 to 215.5)	244.6 (226.1 to 268.1)	24.6 (14.5 to 34.9)	-5.9 (-14.0 to 1.3)	3.6 (2.1 to 5.8)	4.5 (2.6 to 7.3)	24.7 (14.0 to 37.8)	-5.6 (-13.8 to 4.0)
Meningitis	-	-	-	-	5.8 (4.0 to 8.1)	6.4 (4.4 to 8.7)	9.9 (-10.4 to 33.0)	-16.8 (-31.7 to -1.6)
Pneumococcal meningitis	13.0 (8.1 to 19.0)	15.3 (9.6 to 22.0)	17.6 (-4.5 to 47.3)	-12.8 (-29.0 to 10.1)	1.4 (0.8 to 1.6)	1.4 (0.9 to 2.0)	20.1 (8.6 to 70.6)	-10.5 (-29.1 to 22.0)
H influenzae type B meningitis	17.9 (7.5 to 31.8)	18.0 (8.2 to 31.4)	1.6 (-22.3 to 33.7)	-24.9 (-41.0 to -1.6)	2.0 (1.2 to 3.1)	1.9 (1.2 to 2.9)	-2.3 (-35.8 to 41.6)	-26.8 (-50.8 to 3.9)
Meningococcal meningitis	9.9 (3.9 to 20.9)	10.8 (4.3 to 22.4)	9.5 (-13.0 to 38.4)	-17.9 (-34.3 to 3.2)	1.1 (0.7 to 1.7)	1.2 (0.8 to 1.8)	7.2 (-25.7 to 44.1)	-19.9 (-42.5 to 4.0)
Other meningitis	13.7 (7.6 to 22.4)	16.3 (9.8 to 26.7)	20.0 (-4.0 to 45.8)	-7.9 (-25.3 to 11.3)	1.6 (1.1 to 2.2)	1.9 (1.3 to 2.6)	19.8 (-10.7 to 60.4)	-8.2 (-29.5 to 21.5)
Encephalitis	1.9 (1.0 to 3.9)	3.0 (1.5 to 6.1)	59.2 (45.3 to 78.6)	17.8 (8.3 to 30.4)	0.4 (0.2 to 0.3)	0.4 (0.3 to 0.5)	19.0 (38.3 to 83.6)	14.6 (1.1 to 32.2)
Diphtheria	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-83.9 to 3,427.1)	0.0 (82.7 to 1,860.5)	0.0 (-84.0 to 3,577.5)	89.0 (-82.7 to 1,877.9)
Whooping cough	4.3 (3.4 to 5.5)	9.1 (7.1 to 11.7)	112.8 (104.4 to 121.8)	87.6 (80.1 to 95.5)	0.2 (0.1 to 0.3)	0.5 (0.3 to 0.7)	113.3 (86.2 to 142.3)	88.0 (64.0 to 113.5)
Tetanus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-68.1 (-84.4 to -15.3)	-76.8 (-87.6 to -27.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-69.0 (-81.3 to 7.1)	-77.2 (-85.8 to -5.6)
Measles	1.6 (1.3 to 2.0)	0.1 (0.0 to 0.1)	-96.1 (-97.5 to -93.8)	-96.6 (-97.8 to -94.5)	0.1 (0.1 to 0.2)	0.0 (0.0 to 0.0)	-96.0 (-97.6 to -93.2)	-96.5 (-97.9 to -94.0)
Varicella and herpes zoster	6.5 (5.9 to 7.1)	9.4 (8.5 to 10.3)	47.0 (25.7 to 65.3)	5.6 (-16.3 to 28.3)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	51.4 (63.3 to 113.4)	6.8 (-28.6 to 52.3)
Neglected tropical diseases and malaria	-	-	-	-	107.3 (60.6 to 185.1)	111.4 (63.1 to 188.9)	4.0 (-11.9 to 21.6)	-24.7 (-36.9 to -10.8)
Malaria	1,078.0 (913.3 to 1,300.7)	868.1 (649.2 to 1,146.6)	-19.7 (-35.0 to -0.2)	-39.8 (-51.7 to -25.9)	11.7 (7.6 to 17.1)	8.2 (5.5 to 12.0)	-30.2 (-35.5 to -22.3)	-43.8 (-48.1 to -38.0)
Chagas disease	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-
Leishmaniasis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.0 (-10.0 to 130.3)	12.1 (-26.9 to 70.1)
Visceral leishmaniasis	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	42.9 (-9.8 to 130.1)	11.9 (-27.0 to 69.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.9 (-10.1 to 130.2)	11.9 (-27.0 to 69.9)
Cutaneous and mucocutaneous leishmaniasis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,554.6 (1,053.9 to 2,329.7)	1,575.2 (1,139.8 to 2,340.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	1,554.6 (1,051.6 to 2,332.4)	1,575.2 (1,138.2 to 2,341.5)
African trypanosomiasis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	507.5 (469.4 to 546.5)	308.1 (282.4 to 334.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	506.0 (467.5 to 545.1)	307.1 (281.4 to 333.3)
Schistosomiasis	4,380.2 (2,425.3 to 6,836.9)	3,699.4 (2,007.8 to 6,016.7)	-16.8 (-25.8 to -4.2)	-41.3 (-47.6 to -26.3)	43.4 (19.0 to 89.1)	37.0 (15.0 to 78.7)	37.0 (-28.9 to 6.4)	-39.9 (-47.8 to -24.3)
Cysticercosis	10.2 (5.3 to 17.2)	11.2 (4.5 to 20.8)	9.5 (-57.2 to 126.7)	-25.6 (-66.0 to 45.8)	2.8 (1.3 to 5.0)	3.1 (1.1 to 6.2)	8.4 (-57.7 to 131.3)	-27.1 (-67.2 to 43.9)
Cystic echinococcosis	1.7 (1.6 to 2.0)	6.3 (5.3 to 7.6)	277.3 (180.2 to 370.9)	143.5 (73.9 to 210.1)	0.2 (0.1 to 0.2)	0.6 (0.4 to 0.8)	266.4 (159.1 to 426.5)	141.6 (69.9 to 237.3)
Lymphatic filariasis	395.2 (326.3 to 477.3)	490.8 (400.9 to 579.2)	25.5 (-2.5 to 53.9)	-14.5 (-28.8 to 1.4)	10.6 (5.4 to 17.8)	13.3 (7.0 to 22.4)	27.0 (-0.3 to 56.9)	-17.5 (-36.1 to 5.4)
Onchocerciasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-
Trachoma	33.0 (23.0 to 42.2)	21.4 (14.4 to 29.5)	-34.7 (-53.6 to -12.4)	-60.4 (-71.6 to -47.7)	1.7 (1.0 to 2.5)	1.0 (0.6 to 1.6)	-37.1 (-54.2 to -16.8)	-62.4 (-72.8 to -51.1)
Dengue	0.4 (0.1 to 1.1)	2.5 (0.7 to 7.0)	557.6 (549.6 to 566.6)	386.7 (380.7 to 393.6)	0.1 (0.0 to 0.2)	0.4 (0.1 to 1.2)	524.5 (401.6 to 664.3)	353.3 (277.0 to 441.5)
Yellow fever	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-	-
Rabies	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	0.0 (-39.4 to 29.3)	0.0 (-48.9 to 7.0)	0.0 (-39.8 to 29.3)	-
Intestinal nematode infections	-	-	-	-	14.4 (8.6 to 22.6)	18.7 (11.2 to 29.4)	30.1 (15.3 to 46.2)	-0.3 (-11.1 to 12.2)
Ascariasis	571.0 (419.2 to 767.1)	764.2 (548.1 to 1,081.1)	32.4 (-12.6 to 109.1)	-0.4 (-41.8 to 68.2)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	25.9 (-12.6 to 86.1)	-0.9 (-33.6 to 49.3)
Trichuriasis	2,611.1 (2,004.7 to 3,377.7)	3,471.2 (2,597.2 to 4,556.5)	33.4 (-9.7 to 93.2)	-1.5 (-38.1 to 54.6)	3.6 (2.0 to 6.2)	4.7 (2.6 to 7.8)	30.5 (8.6 to 58.2)	-0.5 (-21.0 to 25.1)
Hookworm disease	1,931.1 (1,532.2 to 2,455.8)	2,675.9 (2,134.0 to 3,386.9)	39.1 (-0.2 to 92.6)	39.4 (-32.0 to 48.5)	10.8 (6.4 to 16.8)	14.0 (8.4 to 21.7)	29.8 (11.5 to 50.0)	-0.0 (-13.1 to 14.6)
Food-borne trematodiasis	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-	-	-
Other neglected tropical diseases	147.5 (114.8 to 182.3)	197.0 (184.7 to 214.6)	34.3 (8.3 to 71.8)	15.7 (-5.1 to 43.7)	22.5 (9.4 to 46.9)	29.0 (13.0 to 60.8)	32.8 (-25.1 to 109.7)	-1.2 (-48.4 to 67.1)
Maternal disorders	-	-	-	-	3.7 (2.6 to 5.0)	3.7 (2.6 to 5.1)	2.5 (-10.7 to 16.2)	-33.3 (-40.8 to -25.6)
Maternal hemorrhage	12.4 (11.4 to 13.8)	15.6 (10.1 to 20.1)	25.7 (-17.7 to 61.5)	-38.9 (-52.1 to -8.8)	0.5 (0.3 to 0.7)	0.6 (0.3 to 0.9)	27.5 (-28.7 to 79.8)	-28.1 (-59.0 to -0.2)
Maternal sepsis and other maternal infections	2.4 (1.6 to 3.6)	2.1 (1.4 to 3.1)	-11.6 (-22.6 to 1.8)	-39.7 (-48.0 to -30.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-6.3 (-45.3 to 68.4)	-39.1 (-60.1 to -1.6)
Maternal hypertensive disorders	2.2 (1.1 to 3.8)	2.5 (1.2 to 4.2)	9.9 (0.5 to 19.8)	-33.1 (-37.3 to -28.1)	0.1 (0.0 to 0.2)	0.1 (0.1 to 0.2)	9.7 (-12.1 to 36.1)	-33.2 (-45.3 to -18.7)
Obstructed labor	8.5 (7.7 to 9.4)	8.2 (7.5 to 9.0)	-2.9 (-9.1 to 3.9)	-34.3 (-38.3 to -30.4)	2.8 (1.9 to 3.8)	2.7 (1.8 to 3.7)	-2.5 (-14.6 to 11.7)	-34.2 (-40.9 to -26.3)
Complications of abortion	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	29.8 (-42.3 to 163.4)	-24.8 (-60.5 to 41.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	29.8 (-42.3 to 163.7)	-24.8 (-60.5 to 41.4)
Other maternal disorders	-	-	-	-	0.3 (0.2 to 0.4)	0.3 (0.1 to 0.4)	4.7 (-47.2 to 68.3)	-33.0 (-65.7 to 8.0)
Neonatal disorders	-	-	-	-	16.8 (10.8 to 24.6)	24.3 (16.8 to 32.0)	43.1 (6.0 to 113.0)	5.7 (-20.5 to 56.1)
Preterm birth complications	64.2 (46.4 to 86.4)	162.1 (118.9 to 213.4)	152.7 (121.8 to 195.7)	86.9 (64.6 to 118.1)	6.6 (4.5 to 9.1)	15.6 (10.6 to 21.9)	137.3 (82.3 to 207.3)	72.3 (33.5 to 120.3)
Neonatal encephalopathy due to birth asphyxia and trauma	42.5 (8.9 to 123.9)	57.6 (11.3 to 158.9)	35.9 (-3.4 to 76.8)	1.1 (-26.0 to 28.6)	3.7 (2.0 to 6.4)	4.7 (2.4 to 7.8)	26.6 (-36.2 to 128.2)	-4.7 (-51.7 to 74.7)
Neonatal sepsis and other neonatal infections	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.3)	110.5 (98.0 to 121.9)	82.9 (72.0 to 92.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (82.4 to 136.5)	108.4 (58.5 to 105.5)
Hemolytic disease and other neonatal jaundice	6.3 (2.5 to 11.4)	6.4 (1.8 to 13.9)	4.4 (-76.7 to 126.0)	-25.9 (83.6 to 60.6)	2.4 (0.9 to 4.6)	2.4 (0.7 to 5.6)	4.9 (-77.7 to 129.8)	-24.5 (-83.6 to 64.5)
Other neonatal disorders	-	-	-	-	4.1 (0.8 to 8.6)	1.5 (0.5 to 5.0)	-80.3 (-91.1 to 334.3)	85.4 (93.4 to 220.5)
Nutritional deficiencies	-	-	-	-	74.9 (49.9 to 107.1)	105.1 (70.2 to 153.0)	40.0 (33.7 to 48.6)	15.6 (10.8 to 22.8)
Protein-energy malnutrition	22.2 (12.0 to 38.2)	31.7 (14.5 to 61.4)	36.7 (-45.9 to 258.7)	23.8 (-36.8 to 157.1)	2.7 (1.2 to 5.2)	3.9 (1.6 to 8.3)	22.0 (-49.1 to 258.9)	22.0 (-41.2 to 165.7)
Iodine deficiency	176.3 (162.3 to 191.0)	140.1 (122.3 to 161.2)	-20.5 (-32.7 to -5.7)	-45.6 (-54.6 to -35.3)	3.2 (1.9 to 5.0)	2.5 (1.6 to 4.0)	-20.3 (-33.5 to -5.2)	-45.4 (-54.5 to -34.7)
Vitamin A deficiency	12.9 (9.8 to 15.6)	10.2 (7.6 to 13.1)	-21.0 (-32.0 to -6.8)	-38.8 (-47.6 to -27.7)	0.5 (0.3 to 0.8)	0.4 (0.2 to 0.6)	-24.1 (-36.7 to -7.8)	-41.4 (-51.9 to -29.7)

Appendix Table G.4 - Zimbabwe prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Iron-deficiency anemia	1,980.9 (1,937.4 to 2,018.6)	2,907.5 (2,800.5 to 3,002.3)	47.3 (41.5 to 52.4)	20.8 (15.8 to 25.4)	68.5 (45.7 to 98.9)	98.3 (65.4 to 143.1)	43.5 (38.6 to 50.7)	43.5 (16.2 to 27.6)
Other nutritional deficiencies	-	-	-	-	0.0 (0.0 to 0.1)	14.4 (0.0 to 0.3)	14.4 (-20.7 to 642.1)	121.9 (-11.9 to 444.1)
Other communicable, maternal, neonatal, and nutritional diseases	-	-	-	-	7.8 (4.9 to 11.9)	10.1 (6.5 to 15.6)	29.2 (17.7 to 43.1)	-7.6 (-15.2 to 0.4)
Sexually transmitted diseases excluding HIV	-	-	-	-	2.8 (1.6 to 4.2)	3.8 (2.1 to 6.7)	34.1 (13.6 to 57.8)	-11.4 (-23.4 to 0.0)
Syphilis	0.9 (0.7 to 1.0)	0.8 (0.7 to 1.0)	-0.8 (-17.3 to 22.5)	-33.0 (-43.0 to -30.3)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	0.1 (-27.5 to 31.1)	32.5 (-48.8 to -14.6)
Chlamydial infection	141.2 (116.5 to 164.1)	209.6 (179.5 to 237.8)	49.0 (20.1 to 87.1)	-3.6 (-20.7 to 20.2)	0.7 (0.4 to 1.1)	1.0 (0.5 to 1.7)	44.2 (16.6 to 94.6)	-5.6 (-32.6 to 6.1)
Gonococcal infection	86.9 (68.6 to 105.4)	104.7 (75.8 to 132.8)	21.2 (-16.0 to 75.7)	-22.2 (-44.1 to 8.0)	0.7 (0.4 to 1.2)	0.8 (0.4 to 1.4)	5.9 (-31.5 to 82.8)	-30.8 (53.1 to 12.2)
Trichomoniasis	281.1 (187.9 to 372.1)	428.7 (250.3 to 593.1)	53.8 (-16.5 to 154.9)	0.5 (-38.5 to 52.1)	0.7 (0.2 to 1.1)	1.1 (0.2 to 1.7)	11 (-20.9 to 161.7)	0.3 (-40.9 to 57.0)
Genital herpes	2,534.9 (2,420.3 to 2,650.8)	3,756.8 (3,573.7 to 3,913.9)	48.5 (39.2 to 58.3)	-0.1 (-6.3 to 6.1)	0.7 (0.2 to 1.7)	1.1 (0.4 to 2.5)	49.8 (37.7 to 62.1)	29.3 (-6.7 to 7.3)
Other sexually transmitted diseases	3.6 (2.5 to 5.0)	4.0 (2.9 to 5.4)	11.0 (-6.5 to 31.4)	-24.1 (-35.9 to -10.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	25.4 (-24.3 to 110.5)	-17.6 (-43.3 to 26.8)
Hepatitis	-	-	-	-	1.3 (0.8 to 1.9)	1.3 (0.8 to 1.9)	-1.4 (-22.2 to 19.6)	-32.9 (-50.7 to -15.4)
Hepatitis A	18.8 (17.8 to 19.8)	23.8 (22.7 to 24.9)	27.5 (26.3 to 28.6)	1.0 (0.9 to 1.1)	0.4 (0.2 to 0.5)	0.5 (0.3 to 0.7)	36.1 (20.2 to 54.2)	-1.1 (-11.7 to 11.4)
Hepatitis B	2,146.7 (1,770.3 to 2,478.2)	1,551.6 (1,283.9 to 1,815.7)	-27.2 (-43.3 to -6.8)	-46.7 (-56.1 to -33.8)	0.9 (0.5 to 1.3)	0.7 (0.4 to 1.1)	-19.9 (-45.3 to 12.1)	-42.1 (-62.9 to -19.3)
Hepatitis C	308.9 (278.8 to 336.8)	315.2 (280.3 to 350.3)	1.8 (-11.2 to 19.1)	-27.9 (-36.4 to -16.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	1.6 (-20.6 to 36.7)	-22.6 (-42.5 to 2.4)
Hepatitis E	1.6 (1.4 to 1.8)	2.1 (1.9 to 2.4)	38.2 (12.4 to 61.7)	-9.4 (-22.9 to 5.6)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	40.0 (1.5 to 89.7)	-7.9 (-29.8 to 19.7)
Leprosy	0.8 (0.6 to 1.1)	0.6 (0.5 to 0.7)	-27.9 (-34.7 to -15.9)	-46.6 (-51.5 to -39.3)	0.1 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-27.9 (-42.1 to -9.3)	-46.7 (-66.5 to -34.5)
Other infectious diseases	101.8 (80.0 to 123.4)	138.8 (128.5 to 151.2)	36.8 (22.7 to 57.4)	16.7 (5.7 to 29.5)	3.7 (2.3 to 5.4)	5.0 (3.3 to 7.3)	36.8 (15.3 to 68.4)	18.1 (3.2 to 40.2)
Non-communicable diseases	-	-	-	-	624.7 (460.8 to 813.4)	908.7 (667.4 to 1,164.7)	45.9 (41.2 to 49.8)	0.8 (-1.8 to 3.5)
Neoplasms	-	-	-	-	3.0 (2.1 to 4.0)	3.9 (2.6 to 5.6)	29.0 (-6.3 to 88.9)	-18.4 (-41.9 to 24.9)
Esophageal cancer	0.9 (0.6 to 1.2)	1.2 (0.7 to 1.9)	31.1 (-24.6 to 134.7)	-18.1 (-52.0 to 40.8)	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.3)	38.8 (-14.3 to 136.5)	-13.6 (-44.9 to 43.3)
Stomach cancer	0.9 (0.7 to 1.1)	0.6 (0.4 to 0.8)	-35.2 (-56.1 to -5.7)	-61.0 (-73.4 to -42.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-31.6 (-54.8 to 0.3)	-58.7 (-73.1 to -38.2)
Liver cancer	-	-	-	-	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	0.1 (-71.6 to 57.9)
Liver cancer due to hepatitis B	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.2)	679.1 (304.1 to 1,396.3)	484.7 (185.0 to 1,109.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (362.2 to 1,293.8)	510.3 (224.1 to 1,049.6)
Liver cancer due to hepatitis C	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.3)	2,406.7 (1,138.1 to 4,655.1)	1,736.4 (810.5 to 3,389.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	2,407.6 (1,258.2 to 4,323.2)	1,738.9 (880.5 to 3,112.9)
Liver cancer due to alcohol use	0.0 (0.0 to 0.0)	0.2 (0.1 to 0.2)	578.5 (249.0 to 1,103.8)	407.4 (161.7 to 807.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	586.3 (299.3 to 966.8)	407.7 (192.4 to 690.3)
Liver cancer due to other causes	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	304.5 (102.7 to 680.0)	235.5 (60.5 to 585.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	311.1 (136.2 to 657.1)	254.4 (89.0 to 553.6)
Larynx cancer	0.4 (0.2 to 0.5)	0.3 (0.2 to 0.5)	-41.7 (-63.9 to 86.1)	-60.8 (-76.0 to 20.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	0.0 (-60.0 to 111.4)	-55.5 (-73.5 to 35.2)
Tracheal, bronchus and lung cancer	0.8 (0.6 to 0.9)	0.3 (0.2 to 0.4)	-64.8 (-74.7 to -46.1)	-78.5 (-84.8 to -66.3)	0.1 (0.1 to 0.2)	0.1 (0.0 to 0.1)	-61.2 (-73.2 to -41.0)	-76.2 (-83.7 to -64.1)
Breast cancer	3.6 (2.7 to 4.5)	4.3 (2.8 to 6.1)	16.1 (-25.2 to 25.1)	-26.1 (-52.6 to 25.1)	0.4 (0.2 to 0.5)	0.6 (0.3 to 0.6)	12.9 (-26.5 to 84.5)	-29.1 (-53.8 to 19.5)
Cervical cancer	5.6 (4.3 to 7.4)	8.3 (4.7 to 12.6)	44.5 (-16.7 to 141.8)	5.9 (-41.2 to 61.2)	0.5 (0.3 to 0.7)	0.8 (0.4 to 1.2)	13.6 (-9.5 to 160.9)	56.3 (-38.3 to 95.8)
Uterine cancer	0.8 (0.4 to 1.1)	0.7 (0.4 to 1.2)	-16.1 (-56.4 to 74.0)	-43.9 (-70.1 to 12.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-8.4 (-54.8 to 96.5)	-39.4 (-69.4 to 24.4)
Prostate cancer	3.8 (1.5 to 5.9)	9.1 (5.0 to 17.5)	112.0 (3.9 to 784.9)	24.2 (-39.0 to 395.3)	0.4 (0.2 to 0.7)	1.0 (0.5 to 1.8)	93.0 (1.8 to 728.1)	9.6 (-41.5 to 379.1)
Colon and rectum cancer	1.9 (1.6 to 2.1)	1.9 (1.5 to 2.5)	3.3 (-24.4 to 42.7)	-39.5 (-57.1 to -16.1)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	6.7 (-22.8 to 47.1)	-38.3 (-56.6 to -12.2)
Lip and oral cavity cancer	0.6 (0.4 to 0.8)	0.6 (0.4 to 0.9)	4.9 (-33.2 to 99.7)	-35.5 (-59.7 to 27.4)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	12.0 (-29.8 to 108.5)	-31.2 (-58.0 to 33.0)
Nasopharynx cancer	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	9.6 (-43.4 to 47.3)	-46.9 (-67.0 to -10.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-41.4 to 46.0)	-46.5 (-66.1 to -10.6)
Other pharynx cancer	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-17.8 (-57.4 to 69.1)	-46.0 (-72.5 to 10.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-10.5 (-47.2 to 70.7)	-41.1 (-65.7 to 12.2)
Gallbladder and biliary tract cancer	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	-79.9 (-87.4 to 31.2)	-88.2 (-92.7 to -17.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	-78.3 (-86.2 to 47.7)	-86.8 (-91.8 to -3.5)
Pancreatic cancer	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.2)	-35.5 (-58.0 to -4.3)	-62.2 (-75.7 to -43.8)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-30.3 (-53.4 to 0.4)	-58.5 (-73.0 to -40.3)
Malignant skin melanoma	1.4 (1.1 to 1.8)	1.0 (0.7 to 1.5)	-29.3 (-53.2 to 12.9)	-57.1 (-72.5 to -29.0)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	0.1 (-52.1 to 21.6)	0.1 (-72.0 to -25.2)
Non-melanoma skin cancer	1.1 (0.3 to 3.0)	0.8 (0.5 to 1.6)	-34.4 (-79.6 to 265.6)	-55.0 (-82.7 to 73.6)	0.1 (0.0 to 0.2)	0.0 (0.0 to 0.1)	47.6 (-86.2 to 414.9)	-68.8 (-79.0 to 152.8)
Ovarian cancer	0.6 (0.5 to 0.8)	0.6 (0.4 to 0.9)	-5.3 (-40.7 to 42.8)	-44.8 (-65.4 to -12.8)	0.1 (0.1 to 0.1)	0.1 (0.0 to 0.1)	-1.1 (-40.8 to 54.6)	-42.8 (-66.3 to -5.8)
Testicular cancer	0.1 (0.1 to 0.2)	0.2 (0.1 to 0.4)	70.4 (-9.9 to 222.0)	1.6 (-4.2 to 71.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	73.9 (-9.2 to 222.8)	5.2 (-40.9 to 70.0)
Kidney cancer	1.4 (0.2 to 0.3)	0.3 (0.2 to 0.4)	-39.7 (-30.6 to 61.7)	-64.7 (-63.5 to -18.9)	0.1 (0.0 to 0.0)	0.1 (0.0 to 0.0)	-37.2 (-34.4 to 46.3)	-63.6 (-64.6 to -20.3)
Bladder cancer	1.4 (0.7 to 1.8)	0.9 (0.6 to 1.5)	-39.7 (-61.9 to 92.0)	-64.7 (-77.8 to 16.4)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.1)	-37.2 (-60.1 to 97.4)	-63.6 (-76.9 to 21.8)
Brain and nervous system cancer	0.7 (0.4 to 1.0)	0.4 (0.3 to 0.7)	-45.7 (-63.5 to 47.8)	-59.3 (-71.2 to 5.8)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	-44.7 (-62.5 to 47.5)	-59.4 (-71.2 to 4.7)
Thyroid cancer	0.6 (0.3 to 0.8)	0.5 (0.3 to 0.9)	-14.4 (-48.7 to 74.4)	-47.0 (-69.0 to 13.1)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-8.7 (-45.9 to 91.0)	-44.4 (-68.4 to 18.2)
Mesothelioma	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-58.5 to -7.3)	-65.7 (-77.6 to -45.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	0.0 (-56.7 to 4.6)	0.0 (-76.5 to -44.2)
Hodgkin lymphoma	0.5 (0.2 to 0.8)	0.4 (0.2 to 0.4)	-28.0 (-63.1 to 277.8)	-43.7 (-66.2 to 162.9)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	-24.9 (-59.7 to 268.7)	-42.0 (-64.6 to 146.1)
Non-Hodgkin lymphoma	0.9 (0.6 to 1.2)	1.1 (0.7 to 1.5)	20.6 (-16.3 to 125.2)	-24.2 (-49.2 to 44.5)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	25.4 (-13.5 to 129.9)	-22.3 (-46.3 to 49.8)
Multiple myeloma	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.4)	4.2 (-51.7 to 136.3)	-32.2 (-69.8 to 53.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	10.9 (-50.7 to 139.3)	-28.2 (-69.3 to 57.2)
Leukemia	0.8 (0.5 to 1.1)	0.4 (0.2 to 0.5)	-54.1 (-70.4 to -19.4)	-67.9 (-78.3 to -46.4)	0.1 (0.1 to 0.1)	0.0 (0.0 to 0.1)	-51.4 (-66.6 to -23.2)	-67.9 (-77.8 to -49.6)
Other neoplasms	1.7 (1.3 to 2.3)	4.6 (2.7 to 6.5)	161.6 (53.8 to 303.4)	68.8 (-10.6 to 160.5)	0.3 (0.1 to 0.2)	0.3 (0.2 to 0.5)	164.1 (47.5 to 287.4)	64.1 (-12.7 to 152.5)
Cardiovascular diseases	-	-	-	-	10.3 (7.0 to 14.4)	16.1 (10.5 to 23.0)	56.6 (10.4 to 108.5)	-4.1 (-30.1 to 25.4)
Rheumatic heart disease	7.2 (6.8 to 7.6)	10.0 (9.4 to 10.7)	40.4 (28.8 to 53.3)	-0.0 (-7.1 to 7.7)	0.5 (0.3 to 0.7)	0.6 (0.4 to 0.9)	32.1 (6.3 to 63.8)	-5.7 (-27.0 to 16.2)
Ischemic heart disease	72.2 (57.7 to 94.8)	86.9 (71.8 to 109.6)	20.3 (8.8 to 63.6)	-24.7 (-43.2 to 0.7)	4.0 (2.6 to 6.1)	5.1 (3.4 to 7.3)	26.1 (9.2 to 75.4)	-21.3 (-42.9 to 8.5)
Cerebrovascular disease	-	-	-	-	1.0 (0.7 to 1.3)	1.5 (1.0 to 2.0)	49.4 (23.7 to 93.3)	0.3 (-18.3 to 33.3)
Ischemic stroke	5.2 (4.5 to 6.0)	7.9 (6.5 to 9.4)	51.9 (25.1 to 101.1)	0.7 (-18.2 to 35.1)	0.5 (0.2 to 1.0)	1.2 (0.8 to 1.6)	51.2 (23.6 to 99.7)	0.4 (-19.2 to 36.4)
Hemorrhagic stroke	1.5 (1.2 to 1.8)	2.2 (1.8 to 2.6)	45.1 (14.3 to 87.2)	-1.9 (-22.7 to 32.6)	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.5)	43.8 (12.2 to 91.6)	-1.5 (-24.9 to 34.5)
Hypertensive heart disease	5.3 (3.9 to 6.7)	9.7 (6.8 to 12.9)	85.2 (18.4 to 167.1)	9.5 (-31.2 to 56.6)	0.6 (0.4 to 0.8)	1.0 (0.6 to 1.5)	83.6 (16.5 to 168.6)	9.1 (-31.4 to 58.4)
Cardiomyopathy and myocarditis	11.1 (8.8 to 13.2)	11.3 (9.3 to 13.1)	1.8 (-21.7 to 32.9)	-33.7 (-51.6 to -10.0)	1.2 (0.8 to 1.7)	1.2 (0.8 to 1.7)	0.6 (-23.5 to 32.8)	33.9 (-51.7 to -10.3)
Atrial fibrillation and flutter	0.4 (0.3 to 0.7)	0.3 (0.2 to 0.5)	-20.8 (-54.3 to 21.8)	-48.3 (-70.8 to -22.2)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-21.8 (-55.9 to 36.7)	-48.2 (-71.5 to 12.1)
Peripheral vascular disease	208.4 (145.5 to 269.1)	384.4 (297.0 to 453.0)	85.2 (38.4 to 171.9)	13.8 (-13.2 to 60.5)	0.1 (0.0 to 0.2)	0.3 (0.1 to 0.5)	122.0 (19.6 to 315.6)	15.1 (-38.1 to 118.0)
Endocarditis	0.2 (0.1 to 0.2)	0.2 (0.2 to 0.3)	29.3 (-11.0 to 93.4)	-14.0 (-40.0 to 26.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.8 (-12.3 to 111.4)	-4.2 (-37.2 to 37.7)
Other cardiovascular and circulatory diseases	42.0 (22.8 to 73.3)	91.1 (37.6 to 143.4)	121.4 (-19.7 to 370.7)	37.8 (-51.6 to 200.3)	2.9 (1.4 to 5.3)	6.3 (2.4 to 10.8)	123.7 (-19.3 to 362.8)	38.2 (-51.4 to 202.9)
Chronic respiratory diseases	-	-	-	-	43.8 (30.2 to 60.1)	56.5 (38.4 to 80.6)	28.2 (12.2 to 49.4)	-4.6 (-1

Appendix Table G.4 - Zimbabwe prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Pneumoconiosis	-	-	-	-	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	43.4 (40.2 to 46.9)	43.4 (-8.0 to -3.4)
Silicosis	0.0 (0.0 to 0.0)	0.1 (0.1 to 0.1)	32.0 (26.6 to 38.7)	-14.2 (-17.7 to -9.4)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	32.7 (27.1 to 39.5)	-13.8 (-17.3 to -8.9)
Asbestosis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.1 (37.9 to 48.8)	-7.8 (-11.0 to -4.0)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.7 (39.4 to 50.7)	-6.8 (-10.0 to -2.9)
Coal workers pneumoconiosis	0.0 (0.0 to 0.0)	0.1 (0.0 to 0.1)	41.6 (36.2 to 47.7)	-5.6 (-8.8 to -1.9)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	44.1 (38.5 to 50.7)	-3.9 (-7.2 to -0.2)
Other pneumoconiosis	0.0 (0.0 to 0.1)	0.1 (0.1 to 0.1)	47.2 (42.1 to 53.6)	-1.2 (-5.0 to 2.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	43.9 (46.1 to 52.2)	1.3 (-2.0 to 5.5)
Asthma	188.2 (137.1 to 235.4)	122.6 (93.0 to 157.1)	-35.0 (-53.2 to -6.3)	-36.1 (-49.5 to -16.0)	8.2 (4.7 to 13.0)	5.3 (3.2 to 8.1)	-36.2 (-54.5 to -7.3)	-37.2 (-50.5 to -17.0)
Interstitial lung disease and pulmonary sarcoidosis	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	52.9 (8.2 to 135.5)	3.0 (-24.2 to 51.3)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.1)	52.8 (9.1 to 132.2)	3.0 (23.7 to 50.4)
Other chronic respiratory diseases	-	-	-	-	6.3 (3.8 to 9.8)	9.6 (5.3 to 15.8)	50.2 (4.4 to 121.7)	5.2 (-26.5 to 56.3)
Cirrhosis	-	-	-	-	0.6 (0.4 to 0.9)	0.8 (0.5 to 1.1)	19.6 (3.3 to 37.6)	-20.1 (-29.1 to -9.8)
Cirrhosis due to hepatitis B	0.6 (0.4 to 0.9)	0.9 (0.6 to 1.2)	39.2 (-23.1 to 146.7)	-4.3 (41.7 to 65.9)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	37.6 (-28.6 to 162.7)	-4.2 (-46.1 to 80.4)
Cirrhosis due to hepatitis C	0.6 (0.4 to 0.8)	0.8 (0.6 to 1.1)	28.4 (-16.1 to 101.4)	-22.3 (-47.2 to 30.2)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	31.4 (-21.4 to 107.4)	-21.0 (-51.1 to 38.4)
Cirrhosis due to alcohol use	1.3 (1.1 to 1.6)	1.2 (0.9 to 1.5)	-7.4 (-32.2 to 26.6)	-37.8 (-54.4 to -17.5)	0.2 (0.1 to 0.3)	0.2 (0.1 to 0.3)	-6.9 (-35.2 to 38.6)	-37.3 (-56.3 to -10.1)
Cirrhosis due to other causes	1.2 (1.1 to 1.4)	1.6 (1.4 to 1.9)	32.2 (3.7 to 70.9)	3.0 (-20.8 to 49.1)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	31.1 (9.7 to 52.7)	3.4 (-27.8 to 57.7)
Digestive diseases	-	-	-	-	9.1 (6.4 to 12.4)	15.2 (10.7 to 20.8)	66.9 (53.5 to 82.5)	15.9 (7.4 to 24.8)
Peptic ulcer disease	36.5 (32.3 to 40.5)	46.9 (40.6 to 52.7)	28.6 (11.3 to 49.9)	-26.6 (-35.5 to -15.5)	1.3 (0.9 to 1.9)	1.9 (1.3 to 2.7)	41.8 (17.8 to 70.8)	-14.1 (-26.0 to 1.4)
Gastritis and duodenitis	90.5 (82.5 to 97.4)	136.8 (124.9 to 147.6)	51.3 (37.7 to 68.1)	6.6 (-1.7 to 17.9)	4.0 (2.7 to 5.7)	5.8 (3.9 to 8.3)	42.4 (24.1 to 64.7)	9.2 (0.8 to 22.4)
Appendicitis	1.1 (0.8 to 1.5)	2.0 (1.4 to 2.6)	81.0 (19.3 to 184.5)	19.2 (-17.7 to 80.1)	0.3 (0.2 to 0.5)	0.6 (0.3 to 0.9)	81.6 (9.9 to 199.8)	19.4 (-23.2 to 86.8)
Paralytic ileus and intestinal obstruction	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	30.5 (3.1 to 53.7)	-7.1 (-16.3 to 2.5)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.1)	26.7 (-9.1 to 67.0)	7.1 (-28.6 to 18.2)
Inguinal, femoral, and abdominal hernia	23.6 (19.7 to 28.7)	32.4 (26.9 to 40.4)	37.3 (8.9 to 74.8)	-8.7 (-29.0 to 17.6)	0.2 (0.1 to 0.5)	0.3 (0.2 to 0.6)	36.8 (8.0 to 77.0)	-8.6 (-28.9 to 18.2)
Inflammatory bowel disease	9.1 (8.7 to 9.5)	16.6 (15.9 to 17.4)	82.9 (72.3 to 94.0)	25.1 (19.2 to 31.6)	1.9 (1.3 to 2.6)	3.5 (2.4 to 4.8)	84.7 (65.6 to 104.2)	26.2 (16.3 to 36.3)
Vascular intestinal disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	41.7 (-13.0 to 97.6)	-6.5 (-50.9 to 33.8)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	38.9 (-15.8 to 105.3)	-9.3 (-54.5 to 52.6)
Gallbladder and biliary diseases	2.6 (2.3 to 2.9)	5.4 (4.7 to 6.0)	106.8 (72.7 to 138.7)	0.3 (-5.0 to 47.1)	0.3 (0.2 to 0.4)	0.6 (0.4 to 0.8)	196.8 (70.1 to 148.7)	25.7 (4.6 to 50.6)
Pancreatitis	1.6 (1.5 to 1.7)	2.5 (2.4 to 2.7)	57.9 (45.9 to 70.9)	5.6 (-2.5 to 13.7)	0.7 (0.3 to 0.6)	0.7 (0.5 to 1.0)	59.0 (33.6 to 87.9)	6.3 (-8.7 to 23.3)
Other digestive diseases	-	-	-	-	0.4 (0.3 to 0.7)	1.7 (1.0 to 2.7)	324.4 (126.0 to 512.3)	192.9 (56.4 to 326.1)
Neurological disorders	-	-	-	-	40.6 (27.1 to 56.2)	63.4 (43.5 to 87.5)	56.2 (37.6 to 80.3)	7.0 (-4.4 to 21.0)
Alzheimer disease and other dementias	16.2 (14.2 to 18.3)	31.7 (27.9 to 35.7)	95.8 (66.9 to 134.8)	4.5 (-10.3 to 26.0)	2.2 (1.6 to 2.9)	4.4 (3.2 to 5.6)	98.7 (69.8 to 140.8)	4.2 (-11.2 to 26.2)
Parkinson disease	0.6 (0.5 to 0.8)	1.1 (0.9 to 1.3)	67.0 (57.8 to 75.9)	-0.3 (-5.4 to 5.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	67.0 (39.8 to 97.7)	0.7 (-15.0 to 18.9)
Epilepsy	15.4 (9.2 to 24.2)	22.5 (12.7 to 35.5)	44.7 (-28.8 to 189.3)	5.4 (-47.9 to 111.6)	4.8 (2.4 to 8.0)	6.9 (3.5 to 11.6)	42.7 (-31.0 to 193.6)	5.2 (-49.0 to 114.8)
Multiple sclerosis	0.8 (0.7 to 0.9)	1.3 (1.2 to 1.4)	62.4 (41.1 to 86.4)	12.5 (-2.3 to 28.4)	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.6)	61.8 (29.1 to 102.6)	12.1 (-10.3 to 39.4)
Migraine	702.8 (638.0 to 772.9)	1,002.6 (904.1 to 1,093.3)	43.1 (23.6 to 63.3)	23.7 (-11.7 to 13.5)	4.1 (1.9 to 3.7)	4.1 (2.7 to 5.0)	49.9 (32.7 to 65.1)	7.1 (-12.2 to 15.2)
Tension-type headache	1,240.6 (1,128.0 to 1,353.2)	1,896.2 (1,728.3 to 2,061.2)	53.2 (34.4 to 73.1)	3.1 (-7.6 to 14.7)	1.9 (0.9 to 3.2)	2.9 (1.4 to 5.0)	54.0 (33.4 to 75.3)	3.7 (-7.3 to 16.3)
Medication overuse headache	46.4 (30.3 to 64.0)	91.8 (58.1 to 130.2)	96.2 (43.7 to 199.6)	42.3 (4.2 to 111.7)	7.2 (4.0 to 11.5)	14.3 (7.7 to 23.2)	97.0 (43.5 to 201.9)	42.5 (4.3 to 113.5)
Other neurological disorders	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.5 (8.6 to 68.4)	-7.1 (-31.3 to 26.1)	0.5 (0.3 to 0.7)	0.3 (0.2 to 0.5)	-41.8 (-61.8 to -13.1)	-68.8 (-79.6 to -52.7)
Mental and substance use disorders	-	-	-	-	234.1 (166.5 to 307.5)	336.5 (238.3 to 446.4)	43.7 (35.3 to 48.6)	-0.1 (-3.2 to 2.7)
Schizophrenia	19.8 (18.1 to 21.6)	28.8 (26.2 to 31.4)	45.7 (38.9 to 53.9)	-1.4 (-5.6 to 3.5)	1.4 (0.9 to 15.0)	4.4 (13.3 to 22.1)	18.2 (37.4 to 60.4)	0.7 (-6.7 to 6.8)
Alcohol use disorders	100.7 (87.8 to 115.6)	173.8 (147.8 to 203.1)	73.3 (57.1 to 89.5)	12.2 (3.5 to 21.4)	9.8 (6.4 to 14.1)	17.2 (11.1 to 25.2)	75.8 (57.8 to 93.9)	13.5 (3.6 to 23.7)
Drug use disorders	-	-	-	-	12.4 (8.2 to 17.3)	19.1 (12.3 to 26.9)	53.2 (34.8 to 73.1)	1.7 (-8.9 to 11.9)
Opioid use disorders	15.7 (10.5 to 22.5)	22.5 (14.2 to 34.5)	42.2 (25.0 to 61.8)	-0.3 (-10.7 to 9.2)	6.3 (3.8 to 9.6)	9.1 (5.3 to 15.0)	44.8 (23.8 to 67.4)	0.9 (-11.2 to 12.8)
Cocaine use disorders	5.0 (4.3 to 5.7)	7.5 (6.1 to 9.2)	52.6 (16.0 to 98.8)	0.7 (-18.3 to 25.9)	0.7 (0.4 to 1.0)	1.9 (0.6 to 1.5)	54.4 (11.8 to 108.0)	1.9 (-21.6 to 33.3)
Amphetamine use disorders	17.0 (15.6 to 18.2)	27.4 (24.9 to 30.1)	62.0 (43.4 to 84.1)	1.3 (-9.5 to 14.2)	2.2 (1.4 to 3.3)	3.6 (2.2 to 5.3)	63.0 (37.0 to 96.4)	2.1 (-13.0 to 21.2)
Cannabis use disorders	15.0 (13.5 to 16.5)	22.9 (20.6 to 25.3)	53.1 (51.9 to 54.3)	-0.2 (-0.3 to -0.1)	0.4 (0.3 to 0.6)	0.7 (0.4 to 1.0)	55.0 (31.2 to 82.8)	1.0 (-13.0 to 17.0)
Other drug use disorders	-	-	-	-	2.9 (1.8 to 4.2)	4.7 (2.8 to 6.9)	62.6 (16.2 to 118.1)	3.0 (-25.0 to 38.1)
Depressive disorders	-	-	-	-	86.6 (55.2 to 130.3)	123.7 (76.7 to 186.0)	42.3 (33.0 to 53.0)	0.5 (-6.2 to 5.2)
Major depressive disorder	381.2 (280.4 to 488.8)	538.0 (379.8 to 702.5)	40.9 (31.4 to 51.9)	-1.0 (-7.7 to 4.9)	77.4 (48.4 to 118.5)	109.9 (67.0 to 168.6)	41.5 (31.1 to 53.1)	-0.6 (-7.2 to 5.6)
Dysthymia	96.6 (79.2 to 114.0)	143.5 (115.9 to 171.4)	49.1 (44.8 to 52.5)	0.5 (0.3 to 0.8)	9.2 (6.0 to 13.2)	13.7 (8.9 to 20.0)	49.5 (43.5 to 55.3)	0.9 (-1.6 to 3.4)
Bipolar disorder	55.5 (47.5 to 63.2)	84.8 (70.5 to 98.5)	53.2 (41.4 to 65.0)	-0.1 (-6.0 to 5.2)	11.1 (6.9 to 16.6)	17.1 (10.4 to 26.2)	54.2 (40.8 to 69.9)	0.5 (-6.5 to 7.7)
Anxiety disorders	320.4 (237.3 to 415.2)	476.1 (355.8 to 608.4)	49.6 (34.9 to 61.1)	2.8 (-4.5 to 10.2)	96.6 (18.4 to 43.3)	123.7 (27.3 to 65.2)	42.3 (35.3 to 63.2)	0.5 (-4.2 to 11.7)
Eating disorders	-	-	-	-	2.6 (1.6 to 4.2)	4.1 (2.4 to 6.5)	56.4 (42.3 to 70.5)	0.6 (-7.5 to 9.0)
Anorexia nervosa	1.9 (1.4 to 2.5)	2.8 (2.1 to 3.7)	50.1 (34.7 to 68.1)	0.6 (-9.6 to 11.2)	0.4 (0.2 to 0.6)	0.6 (0.4 to 0.9)	50.9 (14.9 to 92.6)	0.4 (-21.9 to 26.8)
Bulimia nervosa	10.7 (7.3 to 15.6)	16.7 (11.2 to 24.6)	56.3 (51.6 to 61.4)	0.1 (-0.4 to 0.4)	2.2 (1.3 to 3.6)	3.5 (2.0 to 5.8)	57.4 (42.5 to 73.8)	0.7 (-7.8 to 9.5)
Autistic spectrum disorders	-	-	-	-	12.5 (8.7 to 17.0)	17.0 (11.8 to 23.0)	55.3 (29.9 to 40.7)	-0.0 (-3.5 to 3.3)
Autism	32.3 (30.6 to 34.0)	43.5 (41.2 to 45.8)	35.2 (34.9 to 35.6)	-0.6 (-0.6 to -0.5)	7.9 (5.3 to 10.9)	10.7 (7.2 to 14.8)	35.0 (28.0 to 43.0)	0.0 (-4.9 to 4.8)
Asperger syndrome	46.4 (43.5 to 49.1)	62.3 (58.3 to 66.0)	34.7 (34.2 to 35.2)	-0.7 (-0.8 to -0.7)	4.6 (3.2 to 6.4)	6.2 (4.3 to 8.7)	34.8 (28.4 to 41.8)	-0.3 (-4.1 to 3.9)
Attention-deficit/hyperactivity disorder	81.1 (74.9 to 87.7)	105.0 (96.7 to 113.3)	29.9 (29.3 to 30.2)	-0.1 (-0.1 to -0.1)	1.0 (0.6 to 1.5)	1.3 (0.8 to 1.9)	30.0 (21.6 to 40.0)	0.2 (-6.4 to 7.7)
Conduct disorder	119.1 (112.3 to 126.2)	153.7 (144.8 to 162.9)	29.4 (28.6 to 30.3)	14.3 (-0.1 to -0.0)	14.3 (9.0 to 20.6)	18.5 (11.8 to 26.7)	29.6 (23.9 to 35.7)	0.1 (-4.2 to 4.8)
Idiopathic intellectual disability	681.2 (560.5 to 830.5)	871.1 (702.8 to 1,078.4)	28.1 (14.8 to 42.7)	-9.1 (-18.9 to 1.0)	33.1 (22.4 to 47.5)	42.7 (28.6 to 60.0)	28.8 (35.3 to 63.2)	8.5 (-18.3 to 1.9)
Other mental and substance use disorders	123.2 (115.0 to 131.3)	188.1 (174.3 to 201.5)	53.1 (51.7 to 54.5)	-0.6 (-0.9 to -0.2)	9.0 (6.2 to 12.2)	14.0 (9.7 to 18.9)	54.7 (47.5 to 62.0)	0.7 (-3.7 to 4.1)
Diabetes, urogenital, blood, and endocrine diseases	-	-	-	-	46.9 (33.1 to 63.0)	69.7 (49.1 to 93.4)	48.1 (38.0 to 59.9)	5.7 (-2.3 to 14.6)
Diabetes mellitus	141.0 (114.6 to 167.0)	240.4 (203.1 to 284.9)	69.8 (37.6 to 116.6)	20.2 (-4.4 to 55.0)	9.2 (6.0 to 13.0)	15.5 (10.2 to 22.2)	68.8 (36.6 to 110.6)	19.2 (-6.9 to 51.7)
Acute glomerulonephritis	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.0 (54.2 to 96.9)	0.0 (-25.9 to 57.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	74.0 (54.2 to 96.9)	0.0 (-25.8 to 57.7)
Chronic kidney disease	-	-	-	-	16.3 (11.5 to 21.3)	22.6 (16.1 to 29.8)	38.8 (24.3 to 53.7)	-1.2 (-10.2 to 8.1)
Chronic kidney disease due to diabetes mellitus	127.7 (87.5 to 192.2)	179.8 (117.2 to 289.9)	39.8 (10.9 to 86.2)	-1.1 (-23.9 to 36.3)	1.9 (1.3 to 2.6)	2.7 (1.8 to 3.8)	38.0 (8.7 to 86.7)	-2.8 (-23.9 to 35.2)
Chronic kidney disease due to hypertension	398.2 (258.9 to 666.7)	580.3 (344.2 to 954.2)	47.3 (16.7 to 75.1)	7.7 (-11.5 to 32.1)	5.3 (3.7 to 7.1)	7.2 (5.1 to 9.8)	37.1 (14.7 to 66.6)	-5.2 (-18.7 to 13.3)
Chronic kidney disease due to glomerulonephritis	379.5 (249.1 to 576.9)	525.5 (351.2 to 727.9)	38.3 (14.8 to 77.0)	4.0 (-19.7 to 19.4)	2.8 (3.8 to 7.3)	4.0 (5.6 to 10.8)	45.5 (20.2 to 74.6)	7.3 (-10.4 to 30.2)
Chronic kidney disease due to other causes	275.7 (168.8 to 444.2)	364.5 (245.3 to 633.7)	32.6 (3.4 to 77.9)	-7.2 (-30.4 to 21.6)	3.6 (3.0 to 4.5)	4.7 (3.3 to 6.5)	32.1 (-1.1 to 73.4)	-9.2 (-32.3 to 21.7)
Urinary diseases and male infertility	-	-	-	-	3.1 (2.0 to 4.4)	4.9 (3.3 to 7.0)	58.0 (40.3 to 78.9)	-2.2 (-12.3 to 8.8)

Appendix Table G.4 - Zimbabwe prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Interstitial nephritis and urinary tract infections	1.9 (1.8 to 2.1)	2.9 (2.7 to 3.2)	52.9 (37.9 to 70.9)	0.1 (-1.9 to 17.4)	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.1)	53.8 (16.0 to 97.5)	7.5 (-12.9 to 32.2)
Urolithiasis	17.6 (13.2 to 22.2)	24.8 (18.7 to 31.1)	40.9 (25.6 to 64.0)	-1.3 (-20.8 to 2.6)	0.2 (0.1 to 0.3)	0.3 (0.2 to 0.4)	46.5 (28.6 to 68.0)	-3.5 (-12.5 to 8.0)
Benign prostatic hyperplasia	59.6 (54.5 to 64.2)	94.9 (86.8 to 103.3)	59.8 (42.6 to 79.6)	-4.4 (-14.2 to 6.9)	2.1 (1.3 to 2.9)	3.3 (2.1 to 4.6)	60.1 (42.1 to 79.4)	-3.8 (-14.5 to 7.1)
Male infertility due to other causes	27.6 (18.8 to 37.6)	39.3 (28.8 to 52.3)	42.2 (9.3 to 129.0)	-9.7 (-39.6 to 48.3)	0.2 (0.1 to 0.4)	0.2 (0.1 to 0.5)	43.3 (12.6 to 137.0)	-10.8 (-42.5 to 48.7)
Other urinary diseases	-	-	-	-	-	1.0 (0.6 to 1.6)	6.5 (10.8 to 147.8)	7.6 (25.9 to 63.5)
Gynecological diseases	-	-	-	-	8.6 (5.6 to 12.9)	13.8 (8.7 to 20.5)	60.0 (36.0 to 86.7)	6.2 (-7.4 to 19.8)
Uterine fibroids	140.2 (126.0 to 153.1)	178.7 (159.1 to 196.4)	27.8 (25.5 to 30.1)	-1.1 (-1.4 to -0.9)	1.8 (1.0 to 3.0)	2.7 (1.6 to 4.5)	51.9 (36.0 to 82.8)	8.5 (-3.2 to 28.4)
Polycystic ovarian syndrome	141.2 (126.1 to 156.9)	214.9 (186.3 to 246.8)	52.6 (29.2 to 80.1)	-0.6 (-13.3 to 14.8)	1.3 (0.6 to 2.5)	2.1 (1.0 to 4.0)	53.0 (30.1 to 81.6)	-0.7 (-13.6 to 15.0)
Female infertility due to other causes	56.3 (44.4 to 69.8)	63.0 (45.4 to 81.0)	12.1 (-23.8 to 55.9)	-25.3 (-49.9 to 7.0)	0.3 (0.1 to 0.6)	0.3 (0.1 to 0.7)	11.9 (-23.7 to 58.0)	-25.5 (-49.1 to 6.5)
Endometriosis	14.2 (12.0 to 16.3)	18.8 (15.2 to 22.0)	33.3 (1.8 to 67.9)	-1.3 (-30.4 to 8.5)	1.3 (0.8 to 1.8)	1.7 (1.1 to 2.5)	33.5 (1.9 to 71.7)	-1.7 (-30.4 to 10.5)
Genital prolapse	286.7 (239.5 to 330.7)	431.7 (336.9 to 516.3)	51.0 (13.3 to 96.2)	5.4 (-15.4 to 31.5)	0.9 (0.4 to 1.7)	1.4 (0.6 to 2.6)	52.0 (13.7 to 97.2)	5.2 (-15.4 to 31.9)
Premenstrual syndrome	307.2 (212.3 to 397.9)	564.3 (383.2 to 773.0)	84.1 (13.2 to 185.9)	18.8 (-24.6 to 78.5)	2.5 (1.4 to 4.1)	4.7 (2.6 to 7.7)	83.8 (12.7 to 185.9)	19.2 (-24.9 to 77.0)
Other gynecological diseases	18.0 (13.5 to 22.6)	33.6 (23.8 to 44.0)	87.5 (30.4 to 155.0)	25.1 (-7.6 to 63.1)	0.5 (0.3 to 0.7)	0.9 (0.5 to 1.4)	100.0 (-3.4 to 272.4)	32.9 (-28.8 to 122.7)
Hemoglobinopathies and hemolytic anemias	-	-	-	-	5.8 (3.7 to 8.4)	7.4 (4.8 to 10.9)	28.3 (13.5 to 51.4)	5.1 (-6.1 to 22.3)
Thalassemias	0.2 (0.1 to 0.4)	0.1 (0.0 to 0.1)	-60.6 (-76.8 to -44.5)	-75.3 (-86.3 to -63.0)	0.0 (0.0 to 0.1)	0.0 (0.0 to 0.0)	-60.9 (-76.5 to -45.6)	-75.4 (-86.3 to -64.5)
Thalassemia trait	60.3 (46.3 to 75.8)	77.6 (57.1 to 99.6)	33.3 (0.6 to 36.0)	-0.6 (-26.8 to 1.0)	1.4 (0.9 to 1.9)	1.5 (1.0 to 2.3)	12.7 (-3.9 to 32.2)	-8.9 (-21.9 to 5.4)
Sickle cell disorders	0.8 (0.6 to 0.9)	1.0 (0.8 to 1.2)	27.2 (-3.7 to 83.6)	-3.9 (-25.9 to 34.7)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	40.2 (35.0 to 82.1)	-0.0 (-21.7 to 25.3)
Sickle cell trait	314.0 (290.4 to 337.5)	427.9 (396.1 to 457.0)	36.8 (30.4 to 42.4)	1.5 (-3.2 to 5.7)	1.7 (1.0 to 2.5)	2.0 (1.3 to 3.0)	19.9 (-6.4 to 76.7)	-1.9 (-24.3 to 45.1)
G6PD deficiency	349.8 (329.7 to 367.5)	482.9 (460.7 to 505.3)	38.6 (28.8 to 48.7)	2.6 (-4.6 to 10.1)	0.0 (0.0 to 0.1)	0.1 (0.0 to 0.1)	25.3 (-1.6 to 59.6)	2.2 (-13.5 to 19.5)
G6PD trait	1,305.4 (1,288.9 to 1,320.7)	1,726.8 (1,709.1 to 1,746.2)	32.7 (30.4 to 35.2)	-0.9 (-2.6 to 0.9)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	36.9 (-59.2 to 286.5)	6.4 (-66.0 to 174.5)
Other hemoglobinopathies and hemolytic anemias	80.8 (68.1 to 91.0)	122.0 (110.3 to 132.7)	51.2 (33.4 to 81.4)	2.5 (-11.2 to 41.0)	3.6 (1.5 to 3.8)	3.6 (2.3 to 5.7)	43.4 (13.5 to 90.4)	20.9 (-3.9 to 59.8)
Endocrine, metabolic, blood, and immune disorders	114.1 (106.1 to 123.2)	157.7 (136.6 to 176.9)	38.3 (12.6 to 71.8)	11.5 (-3.3 to 30.3)	4.0 (-3.3 to 30.3)	5.4 (3.6 to 7.6)	9.9 (4.2 to 72.2)	9.9 (-11.1 to 34.1)
Musculoskeletal disorders	-	-	-	-	113.7 (81.1 to 151.3)	179.2 (126.8 to 236.1)	57.5 (44.2 to 72.5)	5.3 (-1.4 to 13.5)
Rheumatoid arthritis	29.6 (27.9 to 31.4)	48.5 (45.8 to 51.6)	64.3 (51.4 to 77.9)	0.3 (-7.0 to 8.2)	6.8 (4.8 to 9.1)	11.4 (7.9 to 15.2)	66.6 (50.9 to 83.0)	1.3 (-6.9 to 10.4)
Osteoarthritis	174.7 (167.5 to 182.3)	270.9 (261.4 to 281.3)	55.4 (46.9 to 64.6)	2.8 (-2.5 to 8.8)	10.4 (7.3 to 14.1)	16.1 (11.4 to 21.8)	55.0 (45.9 to 64.3)	3.2 (-2.5 to 9.1)
Low back and neck pain	-	-	-	-	98.5 (62.6 to 120.8)	137.3 (96.0 to 183.7)	39.8 (36.9 to 71.4)	2.5 (-5.6 to 12.8)
Low back pain	472.5 (447.3 to 499.2)	685.8 (649.5 to 725.4)	45.5 (34.1 to 58.3)	-1.2 (-8.6 to 6.6)	51.4 (34.5 to 70.7)	75.2 (50.8 to 103.4)	46.1 (34.4 to 59.7)	-0.6 (-8.0 to 7.6)
Neck pain	394.7 (320.6 to 462.0)	636.5 (541.8 to 725.4)	62.4 (26.2 to 105.5)	6.3 (-10.1 to 30.8)	38.1 (25.1 to 53.7)	62.2 (42.1 to 86.4)	63.0 (26.9 to 107.3)	7.2 (-10.1 to 31.9)
Gout	1.7 (1.5 to 1.8)	2.3 (2.1 to 2.5)	38.9 (22.3 to 58.3)	-6.6 (-18.0 to 5.7)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	38.6 (11.0 to 73.1)	-6.8 (-26.4 to 18.7)
Other musculoskeletal disorders	78.4 (53.0 to 130.0)	160.2 (104.3 to 214.5)	113.9 (55.2 to 158.3)	6.9 (9.2 to 74.2)	4.1 (3.9 to 12.6)	4.1 (8.5 to 21.6)	45.3 (53.6 to 160.8)	4.3 (9.0 to 77.6)
Other non-communicable diseases	-	-	-	-	122.5 (80.4 to 179.3)	167.6 (110.2 to 246.3)	36.9 (29.3 to 42.9)	4.4 (-8.4 to -1.5)
Congenital anomalies	-	-	-	-	8.7 (6.2 to 11.3)	9.9 (7.2 to 13.2)	14.0 (-1.3 to 33.3)	-19.8 (-29.5 to -7.6)
Neural tube defects	2.2 (1.9 to 2.6)	2.6 (2.2 to 3.0)	16.8 (5.9 to 44.2)	-16.4 (-32.7 to 3.0)	0.6 (0.4 to 0.9)	0.7 (0.5 to 1.0)	14.6 (-17.1 to 68.3)	-17.2 (-38.7 to 19.8)
Congenital heart anomalies	29.8 (22.4 to 38.4)	33.3 (26.4 to 41.0)	11.6 (-21.0 to 67.7)	-21.6 (-45.2 to 16.9)	1.0 (0.4 to 1.9)	1.1 (0.5 to 2.0)	10.3 (-2.5 to 61.5)	-21.2 (-44.9 to 16.3)
Orofacial clefts	4.1 (3.1 to 5.7)	4.4 (3.4 to 5.5)	7.9 (-28.1 to 56.0)	-21.7 (-47.9 to 14.1)	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	8.7 (-30.9 to 69.0)	-21.2 (-49.1 to 21.3)
Down syndrome	7.8 (7.1 to 8.7)	9.5 (7.8 to 11.6)	21.2 (-3.8 to 54.3)	-18.2 (-35.8 to 2.5)	0.9 (0.7 to 1.2)	1.1 (0.7 to 1.5)	19.9 (-9.5 to 54.6)	-21.6 (-40.7 to 1.1)
Turner syndrome	0.3 (0.3 to 0.4)	0.4 (0.3 to 0.5)	23.1 (9.0 to 76.6)	-15.6 (-38.1 to 22.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	26.0 (-11.5 to 86.0)	-15.3 (-41.0 to 23.9)
Klinefelter syndrome	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	20.2 (-16.5 to 74.9)	-12.8 (-39.3 to 27.7)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	30.5 (-13.6 to 104.3)	-10.9 (-40.4 to 38.3)
Chromosomal unbalanced rearrangements	13.6 (11.2 to 16.5)	16.5 (13.5 to 20.2)	20.3 (-6.8 to 63.5)	18.8 (-37.1 to 9.3)	1.6 (1.1 to 2.2)	1.9 (1.3 to 2.6)	22.6 (-10.3 to 62.2)	22.6 (-40.6 to 5.9)
Other congenital anomalies	30.5 (23.5 to 36.9)	35.7 (28.4 to 41.8)	17.5 (5.5 to 36.7)	-15.3 (-24.2 to -0.0)	4.5 (2.9 to 6.4)	5.1 (3.3 to 7.1)	11.8 (-7.8 to 37.7)	-18.5 (-31.3 to -1.6)
Skin and subcutaneous diseases	-	-	-	-	49.8 (30.9 to 77.6)	71.1 (44.3 to 113.0)	44.2 (27.2 to 56.4)	2.9 (-7.0 to 10.4)
Dermatitis	427.7 (356.3 to 506.6)	600.1 (494.1 to 711.8)	40.7 (38.3 to 42.8)	0.1 (0.0 to 0.2)	12.9 (8.1 to 18.3)	17.9 (11.5 to 25.5)	38.7 (32.7 to 44.6)	0.5 (-2.7 to 3.7)
Psoriasis	65.2 (56.1 to 75.1)	94.0 (80.5 to 108.4)	44.6 (42.1 to 46.9)	-4.0 (-0.2 to 0.1)	5.2 (3.6 to 7.5)	7.6 (5.2 to 10.8)	45.3 (35.2 to 55.9)	0.6 (-4.9 to 6.2)
Cellulitis	2.2 (1.7 to 2.7)	3.0 (2.4 to 3.7)	37.3 (21.0 to 52.3)	-3.5 (-15.0 to 8.8)	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.3)	37.4 (7.2 to 74.8)	-2.6 (-22.5 to 21.0)
Pyoderma	18.0 (13.3 to 23.2)	20.8 (15.8 to 26.8)	16.1 (8.0 to 26.9)	-4.3 (-10.6 to 2.9)	0.1 (0.0 to 0.2)	0.1 (0.0 to 0.3)	15.8 (3.7 to 30.9)	-4.4 (-13.2 to 5.7)
Scabies	104.0 (92.4 to 115.7)	122.3 (110.6 to 136.3)	18.4 (1.4 to 37.9)	-13.7 (-26.0 to -0.0)	2.7 (1.5 to 4.3)	3.2 (1.8 to 5.1)	18.3 (0.5 to 38.5)	-13.3 (-26.2 to 0.6)
Fungal skin diseases	1,168.9 (876.4 to 1,534.8)	1,620.4 (1,213.7 to 2,141.5)	38.8 (35.9 to 42.8)	38.8 (-0.2 to 77.0)	6.6 (2.5 to 14.3)	9.1 (5.3 to 20.2)	39.1 (35.8 to 43.5)	0.2 (-0.6 to 1.1)
Viral skin diseases	211.5 (163.4 to 256.9)	276.0 (204.7 to 341.3)	30.8 (23.7 to 37.5)	-0.3 (-2.5 to 2.3)	6.5 (3.8 to 10.2)	8.5 (4.9 to 13.4)	30.9 (22.4 to 38.6)	-0.1 (-3.6 to 3.7)
Acne vulgaris	923.0 (607.1 to 1,238.5)	1,331.2 (1,060.6 to 1,614.8)	44.5 (-3.1 to 130.4)	-1.5 (-33.2 to 54.2)	10.0 (4.0 to 19.8)	14.4 (6.5 to 27.0)	44.9 (-3.2 to 131.9)	-1.2 (-32.9 to 55.6)
Alopecia areata	9.2 (8.0 to 10.4)	12.4 (10.9 to 13.9)	36.1 (17.1 to 61.1)	-0.8 (-14.9 to 15.3)	0.3 (0.2 to 0.5)	0.3 (0.3 to 0.6)	36.4 (10.9 to 69.1)	-0.3 (-16.9 to 18.6)
Pruritus	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.6 (9.7 to 81.2)	-0.2 (-23.8 to 27.5)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)	42.6 (9.7 to 81.3)	-0.2 (-23.8 to 27.7)
Urticaria	38.8 (27.0 to 56.6)	86.8 (50.9 to 126.9)	127.2 (11.2 to 269.6)	46.2 (-21.0 to 136.2)	2.3 (1.3 to 3.6)	5.1 (2.7 to 8.2)	129.3 (11.0 to 275.2)	47.4 (-21.0 to 137.8)
Decubitus ulcer	1.0 (0.9 to 1.2)	1.9 (1.6 to 2.2)	79.7 (41.1 to 122.9)	12.4 (-16.0 to 51.8)	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	12.2 (37.0 to 120.2)	12.2 (-17.8 to 52.5)
Other skin and subcutaneous diseases	498.6 (346.0 to 706.1)	717.5 (485.8 to 1,039.1)	43.9 (35.3 to 53.7)	2.9 (-2.1 to 3.5)	4.2 (1.3 to 6.0)	4.2 (1.9 to 8.7)	44.2 (35.0 to 54.4)	1.0 (-2.0 to 4.2)
Sense organ diseases	-	-	-	-	48.3 (32.5 to 70.1)	64.6 (43.7 to 92.2)	33.7 (26.2 to 40.5)	-6.6 (-10.7 to -1.9)
Glaucoma	17.6 (15.0 to 20.4)	20.3 (17.3 to 23.6)	15.7 (-1.9 to 38.5)	-18.6 (-33.0 to -0.6)	1.0 (0.7 to 1.3)	1.2 (0.8 to 1.6)	21.0 (1.6 to 41.7)	-16.1 (-30.5 to -1.6)
Cataract	23.8 (18.3 to 28.8)	39.0 (32.0 to 46.3)	66.5 (32.1 to 102.6)	-3.0 (-21.1 to 18.7)	2.0 (1.3 to 2.8)	3.0 (1.9 to 4.2)	51.9 (27.5 to 77.0)	-12.0 (-25.2 to 3.1)
Macular degeneration	6.8 (5.1 to 9.3)	13.5 (10.6 to 17.0)	105.0 (40.0 to 170.1)	36.1 (-3.8 to 80.8)	0.3 (0.2 to 0.5)	0.6 (0.4 to 0.9)	98.6 (38.4 to 156.6)	27.5 (-6.0 to 65.8)
Uncorrected refractive error	842.8 (783.8 to 896.0)	1,183.2 (1,096.5 to 1,271.4)	40.8 (28.2 to 55.3)	-1.6 (-8.8 to 6.0)	13.3 (8.2 to 21.1)	17.3 (10.2 to 28.5)	29.5 (26.5 to 40.1)	-10.3 (-15.9 to -3.9)
Age-related and other hearing loss	1,027.3 (924.5 to 1,132.1)	1,371.9 (1,227.5 to 1,506.0)	34.0 (28.6 to 39.4)	-7.3 (-10.1 to -4.3)	23.8 (16.0 to 34.8)	32.6 (21.6 to 46.2)	38.8 (22.4 to 49.5)	-4.8 (-11.5 to 2.9)
Other vision loss	23.1 (20.0 to 26.9)	28.2 (24.5 to 33.2)	22.3 (10.5 to 35.2)	-9.2 (-19.6 to 2.8)	1.3 (0.9 to 1.8)	1.4 (1.0 to 2.0)	13.4 (-1.0 to 29.0)	1.4 (-27.7 to -5.1)
Other sense organ diseases	249.4 (236.5 to 263.1)	321.3 (304.6 to 339.3)	29.3 (19.7 to 38.9)	-0.1 (-6.1 to 6.2)	6.6 (4.1 to 9.8)	8.5 (5.3 to 12.7)	28.8 (18.6 to 40.4)	-0.1 (-6.9 to 7.3)
Oral disorders	-	-	-	-	15.7 (9.8 to 23.6)	21.9 (13.4 to 32.6)	39.4 (31.7 to 47.9)	-7.2 (-13.5 to 0.0)
Deciduous caries	878.9 (841.3 to 916.2)	975.5 (935.0 to 1,019.2)	11.5 (5.3 to 18.1)	-1.9 (-7.4 to 3.9)	0.3 (0.2 to 0.7)	0.4 (0.2 to 0.7)	0.4 (1.8 to 21.8)	-1.8 (-10.5 to 7.2)
Permanent caries	3,210.5 (3,059.5 to 3,369.8)	4,475.0 (4,194.9 to 4,721.8)	39.9 (28.8 to 50.5)	-2.				

Appendix Table G.4 - Zimbabwe prevalence and YLDs numbers with percent change between 1990 and 2013 for all causes.

	Prevalent cases 1990 (thousands)	Prevalent cases 2013 (thousands)	% change prevalence, 1990 to 2013	% change age-standardized prevalence, 1990 to 2013	YLDs 1990 (thousands)	YLDs 2013 (thousands)	% change YLDs, 1990 to 2013	% change age-standardized YLDs, 1990 to 2013
Edentulism and severe tooth loss	245.4 (224.2 to 268.5)	336.7 (306.5 to 366.9)	37.1 (22.9 to 55.0)	-11.4 (-20.4 to 0.5)	6.6 (4.4 to 9.1)	9.1 (6.1 to 12.5)	36.6 (22.4 to 55.0)	-11.2 (-20.5 to 0.7)
Other oral disorders	149.9 (141.4 to 158.8)	212.4 (200.2 to 225.4)	42.4 (29.9 to 55.2)	-0.9 (-9.0 to 7.1)	4.4 (2.7 to 6.5)	6.2 (3.9 to 9.4)	42.6 (23.7 to 57.0)	-0.6 (-9.0 to 8.1)
Injuries	-	-	-	-	173.3 (84.9 to 346.0)	94.9 (61.8 to 148.9)	42.6 (-59.1 to -19.1)	-54.2 (-64.7 to -39.2)
Transport injuries	-	-	-	-	10.8 (8.2 to 14.0)	15.2 (11.4 to 19.9)	40.2 (31.9 to 48.7)	-2.4 (-7.3 to 2.8)
Road injuries	-	-	-	-	9.4 (7.1 to 12.0)	11.5 (8.9 to 15.6)	27.0 (18.8 to 35.1)	-0.7 (-16.6 to -6.7)
Pedestrian road injuries	-	-	-	-	2.2 (1.7 to 2.8)	2.7 (2.0 to 3.5)	22.6 (10.4 to 33.9)	-13.0 (-19.9 to -6.4)
Cyclist road injuries	-	-	-	-	1.0 (0.8 to 1.3)	1.2 (0.9 to 1.6)	20.0 (11.0 to 29.1)	-14.8 (-21.3 to -8.5)
Motorcyclist road injuries	-	-	-	-	1.6 (1.2 to 2.0)	1.5 (1.1 to 1.9)	-5.5 (-13.0 to 2.9)	-34.5 (-39.7 to -28.7)
Motor vehicle road injuries	-	-	-	-	4.4 (3.4 to 5.6)	6.3 (4.8 to 8.3)	44.2 (33.0 to 56.3)	-0.9 (-7.2 to 7.0)
Other road injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.2 (0.1 to 0.2)	-17.8 (-24.0 to -10.9)	-46.4 (-50.2 to -42.4)
Other transport injuries	-	-	-	-	1.5 (1.1 to 1.9)	3.3 (2.5 to 4.4)	123.8 (109.8 to 139.8)	54.4 (44.4 to 65.8)
Unintentional injuries	-	-	-	-	27.5 (20.8 to 35.3)	35.4 (26.8 to 46.1)	28.8 (23.8 to 34.3)	-14.4 (-18.0 to -10.5)
Falls	-	-	-	-	15.5 (11.7 to 20.0)	18.2 (13.6 to 23.7)	16.9 (10.4 to 23.0)	-23.7 (-27.7 to -19.5)
Drowning	-	-	-	-	0.5 (0.4 to 0.7)	0.4 (0.3 to 0.6)	-13.7 (-22.1 to -3.3)	-36.1 (-41.2 to -29.6)
Fire, heat, and hot substances	-	-	-	-	2.0 (1.5 to 2.5)	2.8 (2.1 to 3.6)	41.3 (29.1 to 55.7)	3.1 (-4.3 to 11.7)
Poisonings	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.0 to 0.1)	2.5 (-12.8 to 21.5)	-26.0 (-35.2 to -15.0)
Exposure to mechanical forces	-	-	-	-	5.8 (4.4 to 7.6)	8.9 (6.6 to 11.7)	53.0 (46.2 to 60.1)	10.3 (5.7 to 15.2)
Unintentional firearm injuries	-	-	-	-	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	115.9 (94.1 to 137.7)	54.9 (39.7 to 70.5)
Unintentional suffocation	-	-	-	-	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	73.3 (59.4 to 92.0)	24.5 (15.1 to 36.0)
Other exposure to mechanical forces	-	-	-	-	5.5 (4.2 to 7.2)	8.3 (6.2 to 11.0)	50.6 (43.8 to 57.8)	8.4 (3.8 to 13.3)
Adverse effects of medical treatment	-	-	-	-	0.2 (0.1 to 0.2)	0.3 (0.2 to 0.4)	80.9 (68.9 to 91.7)	25.4 (17.2 to 33.4)
Animal contact	-	-	-	-	0.6 (0.4 to 0.7)	0.7 (0.5 to 0.9)	15.3 (10.8 to 20.0)	-13.3 (-18.5 to -7.4)
Venomous animal contact	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.2 to 0.4)	23.0 (8.5 to 38.3)	-10.4 (-19.2 to -1.2)
Non-venomous animal contact	-	-	-	-	0.3 (0.2 to 0.4)	0.4 (0.3 to 0.5)	16.7 (9.3 to 25.4)	-15.2 (-20.3 to -9.7)
Foreign body	-	-	-	-	0.4 (0.3 to 0.6)	0.6 (0.4 to 0.8)	32.8 (25.6 to 40.8)	-6.1 (-11.3 to -0.7)
Pulmonary aspiration and foreign body in airway	-	-	-	-	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	16.0 (2.9 to 29.1)	-13.2 (-20.5 to -5.4)
Foreign body in eyes	-	-	-	-	0.1 (0.0 to 0.1)	0.1 (0.1 to 0.2)	35.4 (20.8 to 52.3)	-4.8 (-12.3 to 4.7)
Foreign body in other body part	-	-	-	-	0.2 (0.2 to 0.3)	0.3 (0.3 to 0.4)	40.7 (30.2 to 52.2)	-3.6 (-10.6 to 4.4)
Other unintentional injuries	-	-	-	-	2.4 (1.8 to 3.1)	3.6 (2.7 to 4.7)	45.9 (37.4 to 56.0)	-1.2 (-6.5 to 4.5)
Self-harm and interpersonal violence	-	-	-	-	2.8 (2.2 to 3.6)	5.2 (3.9 to 6.7)	82.0 (71.0 to 94.2)	31.0 (23.4 to 40.2)
Self-harm	-	-	-	-	0.3 (0.2 to 0.3)	0.5 (0.3 to 0.6)	86.4 (71.2 to 103.0)	26.6 (17.6 to 36.9)
Interpersonal violence	-	-	-	-	2.6 (2.0 to 3.3)	4.7 (3.6 to 6.1)	81.6 (70.9 to 94.5)	31.6 (23.6 to 41.2)
Assault by firearm	-	-	-	-	0.4 (0.3 to 0.5)	0.7 (0.5 to 0.9)	93.0 (80.6 to 104.8)	40.4 (31.6 to 49.2)
Assault by sharp object	-	-	-	-	0.5 (0.4 to 0.6)	1.0 (0.8 to 1.4)	116.9 (99.8 to 135.2)	53.5 (40.9 to 67.3)
Assault by other means	-	-	-	-	1.7 (1.3 to 2.2)	3.0 (2.3 to 3.8)	69.8 (57.9 to 83.2)	23.4 (14.9 to 33.2)
Forces of nature, war, and legal intervention	-	-	-	-	132.2 (45.4 to 302.5)	39.1 (14.2 to 86.2)	-70.1 (-72.8 to -67.0)	-70.3 (-73.0 to -67.0)
Exposure to forces of nature	-	-	-	-	-	0.4 (0.2 to 0.9)	-	-
Collective violence and legal intervention	-	-	-	-	132.2 (45.4 to 302.5)	38.7 (13.8 to 85.7)	-70.5 (-73.1 to -67.4)	-70.5 (-73.2 to -67.2)